id|nct_id|intervention_type|name|description
219367337|NCT06438822|COMBINATION_PRODUCT|Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil|cadonilimab at a dosage of 6 mg/kg on day 1 combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 2400 mg/m2 for 46 h every 2 weeks.
219367338|NCT06201910|OTHER|Observation of Blood loss|Retrospetive observation of bloodloss and RBC transfusions.
219367339|NCT05992467|BEHAVIORAL|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
219367340|NCT06401863|OTHER|Shared Decision Making Tool|EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
219367341|NCT06090071|DEVICE|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
219367342|NCT06090071|DEVICE|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
219178743|NCT06801808|DIETARY_SUPPLEMENT|Myosave|Nutritional supplementation with Myosave
219178744|NCT06477406|DRUG|Cannabidiol|Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
219367343|NCT06090071|DRUG|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
219367344|NCT05632354|DRUG|Osivelotor|Osivelotor
219367345|NCT04610658|DRUG|Nivolumab|Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
219367346|NCT04610658|DRUG|Ipilimumab|Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
219367347|NCT04610658|DRUG|Lurbinectedin|Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)
219367348|NCT01097772|DEVICE|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
219367349|NCT02644226|OTHER|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
219367350|NCT02644226|OTHER|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
219367351|NCT01542645|DRUG|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
219367352|NCT01542645|DRUG|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
219367353|NCT01559909|DEVICE|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
219367354|NCT02384811|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
219367355|NCT04644848|DIAGNOSTIC_TEST|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~* Round shape.~* Cortical thickness \> 3 mm~* Eccentric cortical thickness.~* Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
219367356|NCT04644848|PROCEDURE|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
219556279|NCT05135273|BIOLOGICAL|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
219745697|NCT02546232|DRUG|Carboplatin|Chemotherapy
219367357|NCT04644848|DIAGNOSTIC_TEST|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
219577501|NCT03114696|DIETARY_SUPPLEMENT|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
219745698|NCT02546232|DRUG|Paclitaxel|Chemotherapy
219178745|NCT06477406|DRUG|Placebo|An active placebo containing supplemental terpenes matched to the high-CBD product.
219178746|NCT06954662|DRUG|Amino acid supplement|a targeted amino acid supplement designed to provide dietary nutrients that are commonly deficient in people with PD while minimizing interference with L-Dopa medication
219556280|NCT05135273|BIOLOGICAL|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
219556281|NCT01485471|DEVICE|Diffuse optical spectroscopy imaging|ear exam imaging
219178747|NCT06954662|DIETARY_SUPPLEMENT|Whey Protein Supplement|Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. We will use a 20 gram dose.
219367358|NCT04644848|PROCEDURE|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
219367359|NCT03702725|DRUG|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
219367360|NCT03702725|DRUG|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
219367361|NCT03702725|DRUG|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
219367362|NCT01475734|BIOLOGICAL|albiglutide|subcutaneous injection
219367363|NCT01475734|BIOLOGICAL|placebo|subcutaneous injection
219367364|NCT02842931|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
219367365|NCT02842931|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
219367366|NCT02842931|DRUG|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
219367367|NCT02842931|DRUG|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
219367368|NCT03148730|DEVICE|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
219367369|NCT05589142|BEHAVIORAL|Time Restricted Eating|Eating calories only during a specific feeding window.
219367370|NCT01878630|DEVICE|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~\- electronic patient record (eHealth connect 2.0, T-Systems International)"
219367371|NCT01878630|OTHER|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
219367372|NCT04091893|BEHAVIORAL|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
219367373|NCT04091893|BEHAVIORAL|Art Rx|Individuals in this group participate in a specialized tour of an art museum
219367374|NCT04091893|BEHAVIORAL|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
219367375|NCT01224548|OTHER|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
219367376|NCT01224548|OTHER|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
219367377|NCT02714179|DRUG|Paracetamol was given intravenously in both group at different times|
219367378|NCT00486486|DRUG|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
219367379|NCT00486486|DRUG|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
219367380|NCT00439855|DRUG|Enoxaparin i.v.|
219367381|NCT00439855|DRUG|unfractionated heparin|
219367382|NCT03906825|DIETARY_SUPPLEMENT|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
219367383|NCT03906825|DIETARY_SUPPLEMENT|placebo|placebo
219367384|NCT05693584|OTHER|distraction|diverting the patient's attention with virtual reality glasses
219367385|NCT02265913|DRUG|Acyclovir 5 percent (Perrigo)|
219577502|NCT03114696|DIETARY_SUPPLEMENT|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
219745699|NCT04464733|DRUG|HRS9950|HRS9950
219367386|NCT02265913|DRUG|Acyclovir 5 percent (Reference)|
219367387|NCT02265913|DRUG|Placebo cream|
219367388|NCT01930786|DRUG|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
219367389|NCT00030082|DRUG|isolated perfusion|
219367390|NCT00030082|DRUG|melphalan|
219367391|NCT04824378|OTHER|No Intervention.|No Intervention.Only learn ICG image features of different label groups
219367392|NCT06386328|DRUG|CKD-378, QD, PO|CKD-378, QD, PO
219367393|NCT06055634|GENETIC|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
219367394|NCT00376961|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 for cycles 1-6.
219367395|NCT00376961|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
219367396|NCT00376961|DRUG|cyclophosphamide|750 mg/m\^2 on day 1 of cycles 1-6.
219367397|NCT00376961|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 1 of cycles 1-6.
219367398|NCT00376961|DRUG|prednisone|100 mg on days 1-5 of cycles 1-6.
219367399|NCT00376961|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 1 of cycles 1-6.
219367400|NCT03990129|DRUG|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
219745700|NCT04464733|DRUG|Placebo|Placebo
219178748|NCT06954662|DIETARY_SUPPLEMENT|Isonitrogenous Placebo Supplement|The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the whey protein and the targeted amino acid supplement (16.2 grams).
219178749|NCT06228846|DRUG|YY001|Oral
219556282|NCT02868723|OTHER|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
219556283|NCT04711317|DEVICE|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
219556284|NCT03031834|DRUG|Quinapril|
219556285|NCT01345734|DRUG|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
219556286|NCT03084458|BEHAVIORAL|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
219556287|NCT02497235|DRUG|TAK-935|TAK-935 oral solution.
219556288|NCT02497235|DRUG|[18F]MNI-792 (tracer)|\[18F\]MNI-792 injection.
219556289|NCT03712202|DRUG|Bleomycin|Given IV
219556290|NCT03712202|DRUG|Brentuximab Vedotin|Given IV
219556291|NCT03712202|DRUG|Dacarbazine|Given IV
219556292|NCT03712202|DRUG|Doxorubicin|Given IV
219556293|NCT03712202|BIOLOGICAL|Nivolumab|Given IV
219556294|NCT03712202|OTHER|Quality-of-Life Assessment|Ancillary studies
219556295|NCT03712202|DRUG|Vinblastine|Given IV
219556296|NCT00290264|DRUG|Budesonide/formoterol|
219556297|NCT00377572|BIOLOGICAL|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
219556298|NCT00377572|BIOLOGICAL|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
219556299|NCT03977168|PROCEDURE|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
219556300|NCT00769314|DRUG|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
219556301|NCT00769314|DRUG|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
219556302|NCT06381687|BEHAVIORAL|A multi-component, multi-level programme (MoviMusi)|"The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution."
219556303|NCT04157452|PROCEDURE|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
219556304|NCT03908528|DIETARY_SUPPLEMENT|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
219556305|NCT03908528|OTHER|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
219556306|NCT06148662|OTHER|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
219556307|NCT06148662|OTHER|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
219556308|NCT06148662|DRUG|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
219556309|NCT06148662|DRUG|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
219556310|NCT06148662|DRUG|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
219556311|NCT03217526|OTHER|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
219760770|NCT06465784|PROCEDURE|Retrograde and Antegrade Ureteroscopic Laser Lithotripsy|Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
219556312|NCT03701126|PROCEDURE|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
219367401|NCT00006417|PROCEDURE|Stem cell transplantation|
219367402|NCT02614846|DRUG|Hetrombopag Olamine|
219556313|NCT03701126|PROCEDURE|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
218990734|NCT03619486|DEVICE|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
219178750|NCT06016712|DEVICE|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
219367403|NCT03109431|BEHAVIORAL|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
219178751|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
219367404|NCT03109431|BEHAVIORAL|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
219556314|NCT03701126|DRUG|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
219556315|NCT03701126|DEVICE|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
219556316|NCT05535660|DIAGNOSTIC_TEST|Lipid panel|fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
219556317|NCT05316389|PROCEDURE|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
218990735|NCT03619486|DEVICE|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
219178752|NCT06010004|DRUG|Orforglipron|Administered orally
219367405|NCT03109431|BEHAVIORAL|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
219367406|NCT02456584|DRUG|DMPA 150|injectable contraceptive
219367407|NCT02456584|DRUG|DMPA 300|injectable contraceptive
219556318|NCT00704496|DRUG|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
218990736|NCT05219214|OTHER|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
218990737|NCT05286788|DRUG|Binimetinib Oral Tablet [Mektovi]|Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
218990738|NCT03591471|DRUG|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
218990739|NCT03591471|DRUG|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
218990740|NCT03591471|DRUG|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
218990741|NCT03591471|DRUG|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
218990742|NCT03591471|DRUG|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
218990743|NCT03591471|DRUG|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
218990744|NCT03591471|DRUG|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
219556319|NCT01069796|DRUG|Paclitaxel|80 mg/m² weekly
219556320|NCT01069796|DRUG|Bevacizumab|10 mg/kg d1 d15
219556321|NCT01069796|DRUG|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
219577503|NCT01936519|DRUG|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
219577504|NCT01936519|DRUG|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
219367408|NCT02456584|DRUG|DMPA 104|injectable contraceptive
219367409|NCT03652909|DEVICE|Ascending Hearing Technologies device|Personal Sound Amplification Device
219367410|NCT04924127|DIAGNOSTIC_TEST|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
219367411|NCT01059448|DRUG|AMG 827|AMG 827 210 mg
219367412|NCT02267486|OTHER|Standard therapy of Alzheimer Dementia (AD)|
219367413|NCT02267486|OTHER|Observation|
219367414|NCT03282747|BEHAVIORAL|no intervention|no intervention
219367415|NCT05424172|BEHAVIORAL|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
219367416|NCT05424172|BEHAVIORAL|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
219367417|NCT05424172|BEHAVIORAL|Stage-II, Groups 1a/2a: E-Coaching 1x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
219367418|NCT05424172|BEHAVIORAL|Stage-II, Groups 1b/2b: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
219367419|NCT06377566|DRUG|Brentuximab vedotin|Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle
219367420|NCT06377566|DRUG|Doxorubicin|Doxorubicin 25 mg/m\^2 IV
219367421|NCT06377566|DRUG|Vinblastine|Vinblastine 6 mg/m\^2 IV
219367422|NCT06377566|DRUG|Dacarbazine|Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle
219367423|NCT06377566|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV (flat) on day 1
219367424|NCT06377566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV (days 1 an
219367425|NCT06377566|DRUG|Vinorelbine|Vinblastine 6 mg/m\^2 IV
219367426|NCT06377566|DIAGNOSTIC_TEST|FDG-PET/CT scan|After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
218990745|NCT03591471|DRUG|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
219367427|NCT04188197|OTHER|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
219367428|NCT02107703|DRUG|Abemaciclib|Administered Orally
219367429|NCT02107703|DRUG|Fulvestrant|Administered IM
219367430|NCT02107703|DRUG|Placebo|Administered Orally
219367431|NCT00699179|DRUG|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
219367432|NCT04614792|DEVICE|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
219367433|NCT02179632|BEHAVIORAL|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
218990746|NCT00892853|PROCEDURE|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
219367434|NCT05956457|BEHAVIORAL|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
219367435|NCT05956457|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
219367436|NCT02911688|DRUG|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
219367437|NCT02911688|DRUG|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
219367438|NCT00809328|DRUG|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
219367439|NCT04201717|PROCEDURE|laparoscopic assisted left colectomy (extracorporeal anastomosis group)|For patients in the control group, the surgeon uses wound edge protectors to exteriorize the colon through a small incision in the midline of the abdomen. A ruler and methylene blue solution are employed to mark the area for colon resection. This guarantees a 10-cm margin from the tumor. Guided by these markers, the marginal vessels and mesentery are divided outside the body. The method of anastomosis is at the surgeon's discretion. A side-to-side anastomosis (including antiperistaltic, isoperistaltic, or overlapping anastomosis) is recommended. Side-to-end or end-to-end anastomosis (sewn by hand or by inserting a circular stapler through the anus or proximal colon) is also allowed. After completing the anastomosis, the incision is sutured. An abdominal drainage tube is inserted at the end of the operation.
219577505|NCT05043623|DEVICE|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
219577506|NCT05043623|DEVICE|Combined nose and throat swab|Combined nose and throat swab (standard of care)
219367440|NCT04201717|PROCEDURE|total laparoscopic left colectomy (intracorporeal anastomosis group)|In the experimental group, the surgeon will use a 10-cm medical suture and methylene blue solution to mark the resection margin. The marginal vessels and mesentery will be divided inside the body. The proximal and distal colons are resected using a 60mm linear laparoscopic stapler. Side-to-side intracorporeal anastomotic techniques like anti-peristaltic, iso-peristaltic, or overlap methods will be applied. Once the anastomosis is completed, the specimen is retrieved. The surgeon can place the specimen in a sterile plastic bag for retrieval. Alternatively, the surgeon can use a disposable incision retraction fixator to protect the wound. An abdominal drainage tube is inserted.
219367441|NCT01327755|DIETARY_SUPPLEMENT|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
219367442|NCT01327755|OTHER|Placebo|Same number of pills, frequency, and duration as selenium intervention.
219367443|NCT03286972|DEVICE|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
219367444|NCT00856310|BIOLOGICAL|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
219367445|NCT01678976|DRUG|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
219367446|NCT01678976|DRUG|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
219367447|NCT04020744|OTHER|real-time fMRI based neurofeedback from the hippocampus|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
219367448|NCT04020744|OTHER|real-time fMRI based neurofeedback from another brain area|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
219367449|NCT01711242|DRUG|Capecitabine|
219367450|NCT01711242|DRUG|Oxaliplatin|
219367451|NCT01711242|RADIATION|Radiotherapy|
219367452|NCT00907075|BEHAVIORAL|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
219367453|NCT00907075|BEHAVIORAL|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
219367454|NCT04116021|OTHER|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
218990747|NCT03749447|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules
219367455|NCT04116021|OTHER|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
219367456|NCT06490861|DEVICE|Paragit|Sleeve to quantify symptoms
219367457|NCT04782791|DRUG|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
219367458|NCT04782791|DRUG|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
219367459|NCT04782791|PROCEDURE|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
219367460|NCT04068857|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
219367461|NCT06441877|OTHER|No intervention|There is no intervention, this is an observationnal study.
219367462|NCT00066690|DRUG|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
219367463|NCT00066690|OTHER|Laboratory Biomarker Analysis|Correlative studies
219367464|NCT00066690|PROCEDURE|Oophorectomy|Undergo bilateral surgical oophorectomy
219367465|NCT00066690|OTHER|Quality-of-Life Assessment|Ancillary studies
219367466|NCT00066690|RADIATION|Radiation Therapy|Undergo ovarian irradiation
219367467|NCT00066690|DRUG|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
219577507|NCT05043623|DEVICE|Saliva swab|Saliva swab
218990748|NCT04930653|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
219367468|NCT00066690|DRUG|Triptorelin|3.75 mg by im injection q28 days for 5 years
219367469|NCT05337735|DRUG|XmAb20717|Given by vein (IV)
219367470|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
219367471|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
219367472|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
219367473|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
219367474|NCT01323205|DRUG|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
219367475|NCT01323205|DRUG|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
219367476|NCT04953871|DRUG|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
219367477|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
219367478|NCT03580616|DRUG|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
219367479|NCT03706365|DRUG|Abemaciclib|Administered orally.
219367480|NCT03706365|DRUG|Placebo|Administered orally.
219367481|NCT03706365|DRUG|Abiraterone acetate|Administered orally.
219367482|NCT03706365|DRUG|Prednisone|Administered orally.
219556322|NCT04920045|OTHER|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
219556323|NCT04622124|DRUG|Placebo|
219556324|NCT04622124|DIETARY_SUPPLEMENT|fasted vs. high-fat meal|
219556325|NCT04622124|DRUG|Placebo|
219556326|NCT00804024|DEVICE|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
219556327|NCT01662024|DEVICE|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
219556328|NCT05127135|BIOLOGICAL|ThisCART7 cells|0.5-6 x 10\^6 CAR T cells per kg body weight
219556329|NCT00304434|DRUG|Oseltamivir|
219556330|NCT00304434|DRUG|Probenecid|
219556331|NCT05105659|DIAGNOSTIC_TEST|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
219556332|NCT05105659|DIAGNOSTIC_TEST|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
219556333|NCT05105659|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
219367483|NCT06428890|DIETARY_SUPPLEMENT|Grape Seed Extract|dietary supplements that rich in polyphenolic compounds
219367484|NCT06428890|DIETARY_SUPPLEMENT|Placebo|Starch
219556334|NCT05105659|DIAGNOSTIC_TEST|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
218990749|NCT04930653|BIOLOGICAL|Mogamulizumab|Given IV
219367485|NCT02594488|DEVICE|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
219367486|NCT03116113|BIOLOGICAL|BIIB112|Administered as specified in the treatment arm.
219367487|NCT06286423|DRUG|Colchicine 0.6 mg|Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
219367488|NCT06286423|DRUG|Control/Placebo group|Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
219367489|NCT01286584|DRUG|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
219367490|NCT01286584|DRUG|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
219367491|NCT06358014|DRUG|Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs|In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
219367492|NCT06358014|DRUG|SSRIs|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
219367493|NCT02200484|BEHAVIORAL|Combined parent training and obesity prevention program|
219367494|NCT02200484|BEHAVIORAL|Wellness program (active contact control)|
219367495|NCT02159807|DRUG|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
219556335|NCT05105659|DIAGNOSTIC_TEST|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
219556336|NCT04888949|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
219556337|NCT04888949|BIOLOGICAL|Placebo|Commercially available saline.
219556338|NCT03616002|OTHER|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
219556339|NCT05700396|BEHAVIORAL|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
219556340|NCT04980456|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
219556341|NCT04980456|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
219556342|NCT04980456|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
219556343|NCT01324856|PROCEDURE|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
219556344|NCT01324856|PROCEDURE|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
219556345|NCT03296813|DRUG|Torsemide|Loop diuretic
219556346|NCT03296813|DRUG|Furosemide|Loop diuretic
219556347|NCT04832971|DRUG|ARO-ANG3|ARO-ANG3 Injection
219556348|NCT04832971|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
219556349|NCT04648007|DIAGNOSTIC_TEST|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
219556350|NCT05582109|DRUG|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
219556351|NCT02413528|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
219556352|NCT02413528|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
219556353|NCT00030407|DRUG|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
219556354|NCT00030407|DRUG|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
219556355|NCT00000745|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
219556356|NCT00000745|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219556357|NCT03395015|OTHER|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
219556358|NCT05808166|BIOLOGICAL|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
219556359|NCT05808166|OTHER|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
219556360|NCT01185860|DRUG|danoprevir|oral doses
219556361|NCT01185860|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
219556362|NCT01185860|DRUG|placebo|oral doses
219556363|NCT01185860|DRUG|ribavirin|1000-1200mg/day po
219556364|NCT01185860|DRUG|ritonavir|oral doses
219556365|NCT05656690|OTHER|Exposure to disability|Disability status assessed by functional measures
219556366|NCT01427881|DRUG|cyclophosphamide|Given IV
219556367|NCT01427881|DRUG|cyclosporine|Given IV
219556368|NCT01427881|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
219556369|NCT01427881|RADIATION|total-body irradiation|Undergo TBI
219556370|NCT01427881|DRUG|fludarabine phosphate|Given IV
219556371|NCT01427881|DRUG|busulfan|Given IV
219556372|NCT01427881|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
219556373|NCT01062334|PROCEDURE|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
219556374|NCT06617624|OTHER|MRI|Healthy volunteer will have a non-injected cardiovascular MRI
219556375|NCT06617624|OTHER|MRI Contrast|Patients will have the gadolinium injected cardiovascular MRI
219556376|NCT00500318|DRUG|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
219556377|NCT00500318|DRUG|Placebo|Dose matched placebo, once daily oral inhalation.
219556378|NCT05196100|DEVICE|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
219556379|NCT03574337|DRUG|Sugammadex|No additional information
219556380|NCT03574337|DRUG|neostigmine/glycopyrolate|No additional information
219556381|NCT05567887|DRUG|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
219367496|NCT02159807|DRUG|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
219367497|NCT00006227|DRUG|Paclitaxel|Given IV
219367498|NCT04426305|OTHER|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
219367499|NCT04426305|OTHER|care as usual|care as usual is provided by professional primary care provider
219367500|NCT03857789|OTHER|Questionnaire|A 40 question frailty questionnaire.
219367501|NCT05495048|PROCEDURE|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
219367502|NCT05495048|PROCEDURE|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
219367503|NCT01485978|DRUG|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
219367504|NCT01485978|DRUG|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
219367505|NCT01485978|DRUG|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
219367506|NCT02319902|DEVICE|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
219367507|NCT02319902|DEVICE|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
219367508|NCT03892837|PROCEDURE|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
219367509|NCT03892837|PROCEDURE|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
219367510|NCT05195528|DRUG|Vonoprazan|Orally via capsule
219367511|NCT05195528|DRUG|Placebo|Orally via capsule
219367512|NCT04856592|DEVICE|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
219367513|NCT04856592|DEVICE|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
219367514|NCT01552902|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
219367515|NCT01552902|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
219367516|NCT01552902|DRUG|Placebo|Daily oral dosing in the AM for 6 weeks
219367517|NCT00930202|DRUG|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
219367518|NCT01100489|RADIATION|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
219367519|NCT01100489|OTHER|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
219367520|NCT01100489|PROCEDURE|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
219367521|NCT05312957|OTHER|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
219367522|NCT00878124|DIETARY_SUPPLEMENT|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
218990750|NCT04930653|OTHER|Quality-of-Life Assessment|Ancillary studies
218990751|NCT04930653|OTHER|Questionnaire Administration|Ancillary studies
218990752|NCT04819646|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
219367523|NCT00878124|OTHER|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
219367524|NCT06411093|COMBINATION_PRODUCT|Kinesiology tape wrapping|Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months
219367525|NCT06411093|DRUG|Conventional treatment including silver nitrate cauterization|Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
219367526|NCT00722293|DRUG|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
219367527|NCT00722293|DRUG|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
219367528|NCT00722293|DRUG|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
219556382|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 subcutaneously.
219556383|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 intravenously.
219556384|NCT05848440|DRUG|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
219556385|NCT00098891|DRUG|entinostat|Given orally
219556386|NCT00098891|DRUG|isotretinoin|Given orally
219556387|NCT02676245|BEHAVIORAL|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
219367529|NCT00452803|DRUG|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
219367530|NCT00452803|DRUG|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
219556388|NCT02676245|BEHAVIORAL|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
219556389|NCT06615778|BEHAVIORAL|Motivated Social Emotional Learning|"MSEL arm consists of three intervention components: 1) CSEL, 2) the meaningful role tasks, and 3) the Secret Angel activity. First, participants in the MSEL arm will receive the same 6-session SEL as participants in the Curriculum-based Social-Emotional Learning arm.~Second, other than the CSEL, the second component is the Class Diploma tasks adopted from the pupil responsibilities intervention developed by Ellies et al. (2016). Participants will be provided with a list of meaningful roles and select the role they are willing to take based on their talents and interests. Each participant will take the role for two weeks, fulfilling the related duties and responsibilities. The third component is the Secret Angel, in which participants will anonymously recognize each other via the appraisal notes on Shout Out for Your Board."
219556390|NCT06615778|BEHAVIORAL|Curriculum-based Social Emotional Learning|"In the CSEL arm, 6-session SEL training will be delivered as the experimental component. The primary goal of the SEL training is to reduce traditional bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors.~Each session lasts 40 minutes and is delivered by the headteacher in each class weekly as an after-school workshop. The SEL curriculum is tailored to the social-emotional needs of primary school students, as suggested by CASEL (2013). Also, building on past literature highlighting the lack of SEC as a risk factor linked to bullying behaviors both in the physical and cyber world, specific topics such as self-appreciation (self-awareness), stress management (self-management), respect and acceptance (social awareness), and conflict resolution (relationship skills) incorporated into the curriculum design."
219556391|NCT04502498|DIAGNOSTIC_TEST|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
219556392|NCT00159835|DRUG|atorvastatin|
219556393|NCT00159835|DRUG|simvastatin|
219556394|NCT00814606|DRUG|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
219556395|NCT00814606|DRUG|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
219556396|NCT00814606|DRUG|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
219556397|NCT03084809|DRUG|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
219556398|NCT03084809|DRUG|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
219556399|NCT06532409|DRUG|Amoxicillin/CA|Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
219556400|NCT06532409|DRUG|IV ceftriaxone|Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
219556401|NCT03243396|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
218990753|NCT04819646|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
218990754|NCT02106091|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
219367531|NCT00452803|RADIATION|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
219556402|NCT03687242|DRUG|SPR001|Open label SPR001
219556403|NCT04111705|DRUG|Lorlatinib|100 mg once daily
219556404|NCT04489225|OTHER|Observational|Observational only without any intervention
219556405|NCT03759028|DRUG|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
219556406|NCT03759028|DRUG|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
219556407|NCT03759028|DRUG|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
219556408|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
219556409|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
219556410|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
219556411|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
219556412|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
219577508|NCT05043623|DIAGNOSTIC_TEST|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
218990755|NCT01533389|DRUG|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
219556413|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
219367532|NCT02828176|PROCEDURE|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
219367533|NCT02828176|PROCEDURE|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
219367534|NCT02828176|PROCEDURE|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
219745701|NCT05845580|OTHER|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
219745702|NCT05845580|OTHER|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
219745703|NCT06319053|DEVICE|Turbine-based insufflator|The use of a turbine-based insufflator instead of a conventional insufflator
218990756|NCT01533389|DRUG|Placebo|dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
218990757|NCT00995826|DRUG|CS-8958|Inhaled CS-8958
219367535|NCT02828176|PROCEDURE|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
219745704|NCT06209372|PROCEDURE|Group PENG|Pericapsular Nerve Group Block (PENG)
219745705|NCT06209372|DRUG|Group C|Tramadol infusion
218990758|NCT00995826|OTHER|Placebo|Inhaled placebo
218990759|NCT05996718|BEHAVIORAL|Training program pilot|This intervention for informal caregivers consists of training that will introduce participants to improvisational (improv) theatre and teach its core communication skills.
218990760|NCT05316688|PROCEDURE|Near Infrared Imaging|Undergo NIR imaging
218990761|NCT05316688|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218990762|NCT05316688|DRUG|Tozuleristide|Given IV
218990763|NCT05035862|DRUG|Albuterol Sulfate|Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
218990764|NCT05035862|DRUG|Interferon gamma-primed mesenchymal stromal cells (MSCs)|IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
218990765|NCT05035862|DRUG|Prednisone|Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
218990766|NCT00196755|DRUG|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
218990767|NCT00196755|DRUG|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
218990768|NCT01218113|BIOLOGICAL|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
218990769|NCT01218113|DRUG|Placebo|1 or 3 doses according to protocol schedule
218990770|NCT01713686|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
218990771|NCT04897308|PROCEDURE|Local injection of shoulder joint|Under ultrasound guidance , local shoulder joint injection will be done
218990772|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
218990773|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
219006576|NCT05993468|OTHER|TMC Treatment Approach|The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
219006577|NCT03532334|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
219006578|NCT00000938|DRUG|ceftriaxone|
219006579|NCT00000938|DRUG|doxycycline|
219006580|NCT03534557|DIAGNOSTIC_TEST|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
219006581|NCT01259908|PROCEDURE|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
219006582|NCT03952104|OTHER|Strength training|Strength training
219006583|NCT05710536|OTHER|Formulation X|This formulation containing stem cell secretome and liquorice root extract
219006584|NCT03057431|DRUG|Placebo oral capsule|Once daily for 3 years
219556414|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
219556415|NCT04857593|BEHAVIORAL|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
219556416|NCT02148744|BIOLOGICAL|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
219556417|NCT02148744|BIOLOGICAL|Placebo|
219556418|NCT02957760|DRUG|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
219556419|NCT05001698|BIOLOGICAL|Anifrolumab|intravenous infusion (IV)
219556420|NCT00735319|DEVICE|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
219006585|NCT03057431|DRUG|12.5 mg hydrochlorothiazide|Once daily for 3 years
219367536|NCT05130008|OTHER|Digitally-enabled CHW Care|Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
219556421|NCT04282694|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
219556422|NCT03772756|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
219556423|NCT03772756|RADIATION|chemoradiotherapy|Receive chemoradiotherapy
219556424|NCT05490095|DRUG|SVG101 (T)|5mg of SVG101
219556425|NCT05490095|DRUG|Afinitor (R)|5mg of Afinitor
219556426|NCT05811819|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
219556427|NCT06137781|BEHAVIORAL|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
219556428|NCT04327336|DEVICE|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
219745706|NCT06534723|DRUG|Wujia Yizhi granules|Drug: Wujia Yizhi granuless
219006586|NCT03057431|DRUG|25.0 mg hydrochlorothiazide|Once daily for 3 years
219556429|NCT04327336|DEVICE|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
219556430|NCT01536249|DRUG|Dexpramipexole|Single Oral Dose
219556431|NCT01536249|DRUG|Cimetidine plus Dexpramipexole|Multiple Oral Doses
219556432|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
219556433|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
219556434|NCT02937207|DRUG|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
219556435|NCT02937207|DRUG|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
219556436|NCT02937207|DRUG|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
219556437|NCT02937207|DRUG|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
219556438|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
219556439|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
219745707|NCT06534723|DRUG|Placebo|Placebo
219745708|NCT02041793|PROCEDURE|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
219745709|NCT02041793|PROCEDURE|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
219367537|NCT05130008|BEHAVIORAL|Usual CHW Care|Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
219367538|NCT03742778|BEHAVIORAL|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
219367539|NCT03742778|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
219367540|NCT02588456|BIOLOGICAL|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
219367541|NCT03006783|PROCEDURE|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
219367542|NCT02064764|DEVICE|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
219367543|NCT02064764|DEVICE|Arctic Front Advance™ Cardiac Cryoablation System|
219367544|NCT06473636|BEHAVIORAL|Mindfulness training|The mindfulness training program consisted of four 45-minute lessons, conducted once a week. After each lesson, participants were required to complete daily homework, which included the mindfulness exercises learned during that week for at least 30 minutes. The mindfulness training program was based on Kabat-Zinn's Mindfulness-Based Stress Reduction and Williams' Mindfulness-Based Cognitive Therapy. Additionally, specific contents of cancer-related mindfulness training were incorporated into this program, such as Anti-cancer Self-healing Power: 8 Lessons in Mindfulness-based Stress Reduction.
219367545|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
219367546|NCT05136833|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
219367547|NCT05136833|BIOLOGICAL|Placebo|Normal saline will be used as a placebo.
219367548|NCT02487108|DRUG|TV-46763|TV-46763 will be administered per dose and schedule specified in the arm description.
219556440|NCT02937207|DRUG|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
219556441|NCT02937207|DRUG|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
219006587|NCT03057431|DRUG|50.0 mg hydrochlorothiazide|Once daily for 3 years
219367549|NCT02487108|DRUG|Placebo|Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
219556442|NCT02937207|DRUG|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
219556443|NCT02937207|DRUG|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
219006588|NCT00847860|DRUG|Cilostazol|Cilostazol 100 mg bid for 12 months
219367550|NCT04848077|BEHAVIORAL|Step count increase with the use of a motivational smartphone application|All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
219367551|NCT05812911|PROCEDURE|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
219006589|NCT00847860|DRUG|Aspirin|Aspirin 100 mg qd for 12 months
219006590|NCT02848651|DRUG|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
219367552|NCT05812911|PROCEDURE|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
219367553|NCT05812911|PROCEDURE|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
219367554|NCT06960148|DRUG|CSPR Toothpaste|a commercially available 8% arginine toothpaste
219367555|NCT06960148|DRUG|Colgate Dental Cream Toothpaste|a commercially available fluoride toothpaste
219556444|NCT04172545|PROCEDURE|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
219556445|NCT06030856|DEVICE|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
219556446|NCT06030856|BEHAVIORAL|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
219556447|NCT04933240|DRUG|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
219556448|NCT04933240|DRUG|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
219556449|NCT04933240|DRUG|Placebo|A sugar tablet that does not contain any active medicine
219556450|NCT01504711|DRUG|fosaprepitant dimeglumine|Given IV
219556451|NCT05830682|DEVICE|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
219556452|NCT00416468|DRUG|Aliskiren|
219745710|NCT03296982|OTHER|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
219745711|NCT03296982|DRUG|edoxaban|
219745712|NCT03296982|DRUG|Enoxaparin|
219745713|NCT03296982|DRUG|Saline sham|
219745714|NCT01888016|OTHER|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
219745715|NCT01888016|OTHER|standard physiotherapies treatment|"10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror"
219556453|NCT00416468|DRUG|Valsartan|
219556454|NCT04487288|DIAGNOSTIC_TEST|SONAZOID|CEUS using SONAZOID with fusion technique
219556455|NCT02690051|DEVICE|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
219556456|NCT03558035|DRUG|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
219556457|NCT03558035|RADIATION|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
219556458|NCT04661449|OTHER|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
219556459|NCT02900053|DEVICE|tDCS|tDCS for transcranial Direct-Current Stimulation
219556460|NCT02900053|DEVICE|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
219556461|NCT03448276|OTHER|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
219556462|NCT03448276|OTHER|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
219556463|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
219556464|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
219556465|NCT02246764|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
219556466|NCT02246764|OTHER|Placebo|1 drop QD, AM, OU
219556467|NCT06838026|OTHER|External Intercostal Nerve Block|External ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space from outside the chest wall.
219556468|NCT06838026|OTHER|Internal Intercostal Nerve Block|Internal ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space inside the chest wall under direct thoracoscopic vision.
219556469|NCT06838026|OTHER|Intercostal Catheter|Intercostal Catheter: it will be put 1-2 intercostal spaces above the VATS incision, and the participant will receive the 15 cc of the previously mentioned mixture every 8 hours for two to three days.
219556470|NCT01767753|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
219556471|NCT02104817|DRUG|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
219556472|NCT02104817|DRUG|corn oil control|corn oil control arm
219556473|NCT01225055|DRUG|Teriparatide|20 ug daily over 12 months
219556474|NCT01225055|DEVICE|vibration|10 min/day for 12 months
219556475|NCT02587312|OTHER|Very low nicotine content cigarettes|
219745716|NCT01990690|DRUG|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
219745717|NCT05697640|DRUG|Vericiguat Oral Tablet|The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
219745718|NCT05544695|DEVICE|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
219760771|NCT05046392|BEHAVIORAL|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
219556476|NCT02587312|OTHER|Standard nicotine content cigarettes|
219556477|NCT00717782|PROCEDURE|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
219556478|NCT00717782|PROCEDURE|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
219556479|NCT00111566|DRUG|eptifibatide|
219556480|NCT03968926|OTHER|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
219556481|NCT03211039|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
219556482|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
219556483|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
219367556|NCT06960005|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|Participants will engage in one-hour exercise sessions twice weekly for 26 weeks: one day of RYMA training and one day of ADL-based training
219367557|NCT06960278|PROCEDURE|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.
219367558|NCT06960278|PROCEDURE|Control|The dimensions of the lesion were measured by oral medicine specialists using a flexible ruler
219367559|NCT06960278|DEVICE|ALUMSTONE|alum administration via adhesive patches on the healing process of aphthous ulcers
219367560|NCT06960876|PROCEDURE|Therapeutic Ultrasound|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This Group will additionally receive a therapeutic Ultrasound over the maxillary sinus.
219556484|NCT00021216|DRUG|bortezomib|Given IV
219556485|NCT00021216|OTHER|laboratory biomarker analysis|Correlative studies
219556486|NCT00021216|OTHER|pharmacological study|Correlative studies
219556487|NCT06001827|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
219556488|NCT06001827|PROCEDURE|Untreated AVF Control|AVF creation surgery without any intervention
219556489|NCT00799942|DRUG|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
219556490|NCT04915911|OTHER|cross-sectional study|cross-sectional study
219556491|NCT02575339|DRUG|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
219556492|NCT02575339|DRUG|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
219556493|NCT02575339|DRUG|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
219556494|NCT04633642|PROCEDURE|Ultrasound group|Every week during a six-week treatment period
219556495|NCT04633642|PROCEDURE|Surgical group|Every week during a six-week treatment period
219556496|NCT04675775|OTHER|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
219556497|NCT04675775|DIETARY_SUPPLEMENT|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
219556498|NCT04675775|BEHAVIORAL|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
219556499|NCT04438850|DRUG|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
219556500|NCT04438850|OTHER|Placebo|Patients should take placebo orally on an empty stomach with water
219556501|NCT06183450|DIAGNOSTIC_TEST|auditory level|"* Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality."
219556502|NCT06183450|DIAGNOSTIC_TEST|cognitive level|"* Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test."
219556503|NCT06183450|DIAGNOSTIC_TEST|quality of life level|\- Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
219745719|NCT05937243|BEHAVIORAL|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
219367561|NCT06960876|PROCEDURE|Sinus Massage|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will additionally receive, sinus massage (pressure \& milking)
219367562|NCT06960876|PROCEDURE|Control group|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will not receive any other adjunct physical therapy treatment (control group)
219367563|NCT06960304|OTHER|Physical exercise program|Evaluation of AVF maturation using clinical and ultrasound criteria, after applying a structured physical exercise program.
219367564|NCT06959719|PROCEDURE|Air Entrainment - intentional introduction of the atmospheric air into the pleural space.|This intervention is distinct in that it uses a standard 3-way tap, already present in routine pleural drainage procedures, to intentionally introduce atmospheric air into the pleural space in a controlled and repeatable manner. Unlike other studies where air entrainment may occur incidentally or as part of more invasive procedures, this method specifically utilises precise manipulation of the tap handle to allow intermittent air entry, aiming to reduce negative intrapleural pressure and associated pain during fluid drainage. Air entry is carefully controlled, can be repeated up to five times per procedure, and does not interfere with fluid drainage or introduce additional equipment or complexity.
219367565|NCT06960343|PROCEDURE|magnetic resonance imaging (MRI)|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and an MRI of the operated shoulder will also be performed.
219745720|NCT05937243|BEHAVIORAL|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
219745721|NCT05937243|BEHAVIORAL|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
219745722|NCT03375437|GENETIC|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)"
219745723|NCT04847687|DRUG|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
219745724|NCT01357681|DRUG|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
219745725|NCT01357681|DRUG|Placebo|Placebo
219745726|NCT00410579|OTHER|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
219745727|NCT01781988|DRUG|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
219745728|NCT02875535|BEHAVIORAL|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
219745729|NCT03637816|DRUG|Anamorelin Hydrochloride|Given PO
219745730|NCT03637816|OTHER|Placebo|Given PO
219745731|NCT03637816|OTHER|Questionnaire Administration|Ancillary studies
219745732|NCT04280783|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
219745733|NCT04280783|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
219745734|NCT05703126|DIAGNOSTIC_TEST|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
219745735|NCT05703126|DIAGNOSTIC_TEST|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
219745736|NCT05703126|DIAGNOSTIC_TEST|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
219745737|NCT05703126|DIAGNOSTIC_TEST|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
219745738|NCT05703126|DIAGNOSTIC_TEST|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
219745739|NCT05703126|DIAGNOSTIC_TEST|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
219745740|NCT05703126|DIAGNOSTIC_TEST|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
219745741|NCT05703126|DIAGNOSTIC_TEST|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
219745742|NCT05703126|DIAGNOSTIC_TEST|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
219745743|NCT05703126|DIAGNOSTIC_TEST|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
219367566|NCT06960343|OTHER|VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and a clinical evaluation will be performed using the following measurements and scores: VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction.
219367567|NCT06960356|OTHER|detect post-traumatic stress disorder|recommendation for follow-up by a professional specializing in child development and/or a complementary medical consultation
219367568|NCT06960200|DEVICE|Phototherapy|Non-surgical laser therapy (phototherapy)
219367569|NCT06960733|DEVICE|Winged plastic stent|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention winged stents were used.
219367570|NCT06960733|DEVICE|Standard plastic stents|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention standard plastic stents were used.
219367571|NCT06960798|OTHER|Bio-specimen Collection|Tissue samples will be taken from existing archived collections and sent for further analysis.
219367572|NCT06960798|OTHER|Blood Draw|Blood samples will be collected within the first year of enrollment.
219367573|NCT06960551|OTHER|ınfertility group|"Before starting the project, the couples in the experimental group will be informed about the mobile application. The women will use the mobile application weekly for 3 months.~4 times for at least 15 minutes each. To create motivation for use, women in the experimental group will be asked to motivational notification will be sent via the mobile application."
219367574|NCT06960551|OTHER|control group|Women in the control group will not receive any intervention. After collecting the post-test data in the project, the principle of benefit and equality Taking this into account, women and their husbands participating in the control group will be given the opportunity to use the mobile application free of charge for three months.
219367575|NCT06961045|PROCEDURE|Guided Inferior Alveolar Nerve Lateralization with Simultaneous Implant Placement|All patients will be operated on under general anesthesia. A para-crestal incision will be done and a mucoperiosteal flap will be reflected exposing the alveolar ridge and the buccal cortex. The surgical guide will be fitted and fixed in place and the outline of the window will be drawn by the aid of the surgical guide using the piezotome then the guide will be removed. Once the osteotomy is completed the bone window will be mobilized for exposure of the neurovascular bundle. The diamond tips will be used for removal of any remaining bone around the nerve. The neurovascular bundle will be dissected and retracted properly. a surgical guide will be inserted for implant osteotomy. The bone block which was removed for the buccal window will be crushed to be particulates and will be mixed with autologous fibrin glue for preparation of sticky bone, the sticky bone will be packed gently in the window area around the neurovascular bundle then will be covered by platelet rich fibrin.
219367576|NCT05926219|BEHAVIORAL|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
219367577|NCT01571063|DRUG|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
219367578|NCT01571063|DRUG|Placebo|Placebo Tbl. p.o.
219367579|NCT02367521|COMBINATION_PRODUCT|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
219367580|NCT02367521|DEVICE|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
219367581|NCT00600171|DRUG|GW642444M|GW642444M
219367582|NCT00600171|DRUG|Placebo|Placebo mulit-dose dry powder inhaler
219367583|NCT02104414|DRUG|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
219367584|NCT02104414|DRUG|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
219556504|NCT03836924|DRUG|Perampanel|Perampanel tablets.
219367585|NCT02104414|DRUG|Normal Saline|30mL Normal Saline
219367586|NCT00542191|DRUG|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
219367587|NCT00542191|PROCEDURE|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
219367588|NCT00542191|RADIATION|Radiotherapy|Standard of care RADIATION THERAPY as indicated
219367589|NCT00469612|DEVICE|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
219367590|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
219367591|NCT03258892|OTHER|Educational Intervention|Receive STG
219367592|NCT03258892|OTHER|Quality-of-Life Assessment|Ancillary studies
219367593|NCT03258892|OTHER|Survey Administration|Ancillary studies
219556505|NCT01888341|DRUG|Isotretinoin|Isotretinoin Capsules,20 mg
219556506|NCT06807541|BEHAVIORAL|Exercise intervention|45 minute exercise classes. Twice per week for 12 weeks.
219556507|NCT05357079|DRUG|Tranexamic Acid|Topical application
219556508|NCT05357079|DRUG|Normal saline|Topical application
219556509|NCT03859128|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
219556510|NCT05824494|DRUG|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
219556511|NCT05824494|DRUG|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
219556512|NCT04862962|DRUG|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
219556513|NCT00346892|BIOLOGICAL|Rotavirus (vaccine)|
219556514|NCT05255952|PROCEDURE|Electrical stimulation|Electrical stimulation of the cardiac plexus
219745744|NCT05703126|DIAGNOSTIC_TEST|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
219556515|NCT05727449|PROCEDURE|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
219556516|NCT05727449|PROCEDURE|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
219556517|NCT05424133|OTHER|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
219556518|NCT05424133|OTHER|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
219556519|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
219556520|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
219556521|NCT04815694|RADIATION|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
219556522|NCT05431777|DRUG|Avelumab|As provided in real world setting
219556523|NCT04811183|BEHAVIORAL|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
219556524|NCT03203239|DEVICE|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
219556525|NCT03203239|DRUG|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
219556526|NCT02161549|DEVICE|Motus Gl CleanUp System|
219556527|NCT05629923|DRUG|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
219556528|NCT02288351|OTHER|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
219556529|NCT02288351|OTHER|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
219556530|NCT02288351|OTHER|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
219556531|NCT02288351|OTHER|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
219556532|NCT02288351|OTHER|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
219556533|NCT02288351|DEVICE|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
219556534|NCT04440709|DEVICE|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
219556535|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
219556536|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
219556537|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
219556538|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
219556539|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
219556540|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
219556541|NCT03223909|DRUG|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
219556542|NCT03223909|DRUG|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
219556543|NCT03223909|DRUG|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
219556544|NCT06434324|PROCEDURE|Saline Irrigation|250 cc waves of warmed saline irrigation (up to 2000 cc) through thoracostomy tube on a daily basis
219556545|NCT05932810|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219367594|NCT00847327|BEHAVIORAL|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
219367595|NCT00847327|BEHAVIORAL|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
219367596|NCT05276661|DIETARY_SUPPLEMENT|TAC/Collagen gel|Apply it twice per day for 4 weeks
219367597|NCT05276661|DIETARY_SUPPLEMENT|placebo lotion|Apply it twice per day for 4 weeks
219556546|NCT05932810|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
219556547|NCT02046317|DRUG|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
219556548|NCT02046317|DEVICE|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
219745745|NCT05703126|DIAGNOSTIC_TEST|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
219745746|NCT05703126|DIAGNOSTIC_TEST|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
219745747|NCT05703126|DIAGNOSTIC_TEST|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
219745748|NCT05703126|DIAGNOSTIC_TEST|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
219745749|NCT04605276|OTHER|No intervention|No intervention
219745750|NCT01696565|DRUG|PG2|Injectable
219745751|NCT05284617|DRUG|HU6|HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
219367598|NCT00250510|BEHAVIORAL|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
219745752|NCT05284617|DRUG|Placebo|Placebo
219367599|NCT01721499|BEHAVIORAL|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
219556549|NCT02046317|DEVICE|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
219556550|NCT02046317|DEVICE|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
219556551|NCT03622359|DIAGNOSTIC_TEST|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
219556552|NCT03622359|DIAGNOSTIC_TEST|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
219556553|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
219556554|NCT03681028|DRUG|Individualized therapy|"1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
219745753|NCT01802346|DIETARY_SUPPLEMENT|dietary intervention|Consume a low-calorie diet
219745754|NCT01802346|PROCEDURE|nutritional support|Receive dietary advice
219745755|NCT01802346|OTHER|laboratory biomarker analysis|Correlative studies
219745756|NCT05253196|DEVICE|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
219367600|NCT01721499|BEHAVIORAL|Mindfulness Intervention|
219556555|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
219367601|NCT00789633|DRUG|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
219556556|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
219556557|NCT02414464|OTHER|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
219556558|NCT05771051|DEVICE|Headpulse measurements|Placement of headset on subject
219556559|NCT05212038|PROCEDURE|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
219556560|NCT05212038|PROCEDURE|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
219556561|NCT01628549|DRUG|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
219745757|NCT03037749|DRUG|Alcohol beverage|Alcohol beverage measured to have participant achieve a BAC of 0.08%
219745758|NCT03037749|DRUG|Placebo beverage|Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
219745759|NCT01953159|OTHER|Blood Collection|
219745760|NCT01953159|OTHER|Patient Questionnaires|
219745761|NCT03314428|BEHAVIORAL|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
219745762|NCT05421494|BEHAVIORAL|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
219745763|NCT05421494|BEHAVIORAL|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
219745764|NCT05550727|OTHER|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
219745765|NCT06535100|BEHAVIORAL|Art therapy|artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
219745766|NCT05053555|DEVICE|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
219745767|NCT05053555|DEVICE|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
219745768|NCT06451497|BIOLOGICAL|ZM008|Intravenous delivery
219556562|NCT01628549|DRUG|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
219745769|NCT05654181|DRUG|PF-07328948|investigational drug administered orally
219367602|NCT00789633|DRUG|Placebo|Matching placebo given orally twice daily
219367603|NCT00789633|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
219367604|NCT06130332|DRUG|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
219367605|NCT06130332|PROCEDURE|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
219556563|NCT01628549|DRUG|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
219745770|NCT05654181|DRUG|Placebo|Placebo matching active drug administered orally
219745771|NCT05918029|DRUG|Potassium Citrate Extended Release Oral Tablet|Oral potassium citrate extended-release tablet
219745772|NCT05918029|OTHER|Placebo|Placebo capsule identical to active ingredient
219367606|NCT03949907|OTHER|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
219367607|NCT03949907|OTHER|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
219367608|NCT02750059|DRUG|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
219367609|NCT02750059|DRUG|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
219367610|NCT05140057|COMBINATION_PRODUCT|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
219367611|NCT03644628|PROCEDURE|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
219367612|NCT01362582|DRUG|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
219367613|NCT02508155|BIOLOGICAL|MEDI7352 for IV infusion|MEDI7352 for IV infusion
219367614|NCT02508155|BIOLOGICAL|Placebo for IV infusion|IV Placebo infusion
219367615|NCT02508155|BIOLOGICAL|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
219367616|NCT02508155|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
219367617|NCT01935895|BEHAVIORAL|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
219367618|NCT01068444|DRUG|Pioglitazone|"1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months"
219367619|NCT01068444|DRUG|placebo|placebo 30 mg/d for 6 months
219367620|NCT01835184|DRUG|cabozantinib-s-malate|Given PO
219367621|NCT01835184|DRUG|vemurafenib|Given PO
219367622|NCT01835184|OTHER|laboratory biomarker analysis|Correlative studies
219367623|NCT01835184|OTHER|pharmacological study|Correlative studies
219367624|NCT04232826|BIOLOGICAL|single dose of CNCT19|"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
219367625|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
219556564|NCT04311944|OTHER|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
219367626|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
219367627|NCT03445702|DRUG|Metformin|Metformin 1000mg once
219367628|NCT03445702|DRUG|Placebo|Sugar pill manufactured to mimic metformin 1000mg
219367629|NCT00002113|DRUG|Flucytosine|
219367630|NCT00002113|DRUG|Fluconazole|
219367631|NCT03374280|DRUG|pemetrexed/cisplatin intercalating gefitinib|
219367632|NCT03374280|DRUG|pemetrexed/cisplatin|
219429034|NCT04183946|BEHAVIORAL|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
219367633|NCT05464017|DEVICE|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
219367634|NCT04030078|OTHER|Survey|Questionnaire-based survey
219367635|NCT04681092|BIOLOGICAL|AKS-452|s.c. or i.m. vaccination
219367636|NCT00849017|BIOLOGICAL|albiglutide|albiglutide weekly injection
219367637|NCT00849017|BIOLOGICAL|albiglutide uptitration|albiglutide uptitration at week 12
219367638|NCT00849017|BIOLOGICAL|placebo|matching albiglutide placebo weekly injection
219367639|NCT02022605|DEVICE|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
219556565|NCT04311944|OTHER|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
219556566|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
219556567|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake and withdraw|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
219367640|NCT02022605|OTHER|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
219367641|NCT01941589|DRUG|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
219367642|NCT01941589|DRUG|corticosteroids only|IV corticosteroids only
219367643|NCT01767402|BIOLOGICAL|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
219367644|NCT01767402|BIOLOGICAL|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
219367645|NCT01767402|BIOLOGICAL|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
219367646|NCT05905796|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
219367647|NCT02571348|PROCEDURE|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
219367648|NCT05655117|OTHER|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
219367649|NCT02844855|BEHAVIORAL|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
219367650|NCT04279197|DRUG|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
219367651|NCT04279197|DRUG|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
219367652|NCT04279197|DRUG|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
219367653|NCT04279197|OTHER|respiratory function rehabilitation training|Health exercise, once a day
219556568|NCT06012578|DRUG|ISM5411|Investigational Drug
219556569|NCT06012578|DRUG|Placebo|ISM5411 Matching Placebo
219556570|NCT01405469|OTHER|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
219556571|NCT06009796|DEVICE|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
219367654|NCT05327699|DRUG|Ketamine|A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
219367655|NCT05327699|OTHER|Placebo|A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
219367656|NCT01841619|DRUG|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
219367657|NCT04807894|DRUG|Vaginal Cream with Applicator|Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
219367658|NCT06960122|PROCEDURE|Fecal Microbiota Transplant (FMT)|One course of fecal microbiota transplantation (FMT) was administered in addition to standard therapy.
219367659|NCT06960122|OTHER|Standard Therapy|Standard Therapy Alone
219367660|NCT06959784|DRUG|semaglutide|The semaglutide intervention group received semaglutide (0.25 mg qw initially, increased to 0.5 mg qw after four weeks) for 24 weeks (6 months).
219367661|NCT06959784|DRUG|Metformin|The metformin control group was treated with metformin (gradually increasing to 1g bid) for 24 weeks (6 months)
219556572|NCT06009796|DEVICE|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
219556573|NCT06404463|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
219556574|NCT06404463|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
219556575|NCT06404463|DRUG|Doxorubicin|Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
219367662|NCT03962309|OTHER|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
219367663|NCT01695421|PROCEDURE|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
219367664|NCT01695421|PROCEDURE|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
219367665|NCT01695421|PROCEDURE|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
219429035|NCT00448760|DRUG|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
219556576|NCT06404463|DRUG|Cyclophosphamide|Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
219745773|NCT05918029|DRUG|Potassium Citrate and Citric Acid Oral Solution|Oral potassium citrate and citric acid
219556577|NCT06404463|DRUG|Epirubicin|Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
219556578|NCT00177164|DRUG|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
219745774|NCT05714748|BIOLOGICAL|EBV mRNA vaccine|With 25ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
219745775|NCT05763849|BEHAVIORAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
219006591|NCT05245370|BEHAVIORAL|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
219367666|NCT01695421|PROCEDURE|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
219367667|NCT04119570|BEHAVIORAL|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
219367668|NCT00511043|DRUG|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
219367669|NCT03625388|DRUG|Dasatinib|Film coated tablet contains dasatinib monohydrate
219367670|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219367671|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
219367672|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
219367673|NCT00544830|DRUG|Bicalutamide|Given PO
219367674|NCT00544830|DRUG|Goserelin Acetate|Given SC
219367675|NCT00544830|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219367676|NCT00544830|OTHER|Laboratory Biomarker Analysis|Correlative studies
219367677|NCT00544830|DRUG|Leuprolide Acetate|Given via injection
219367678|NCT04933123|DEVICE|indirect restorative treatment with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
219367679|NCT01548261|PROCEDURE|Donating oral mucosal cells|Donating oral mucosal cells
219367680|NCT05242822|DRUG|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
219367681|NCT05536375|OTHER|Exhaled breath condensate collection and blood draw|"Venepuncture- 10mls of blood to be collected~and~Exhaled breath condensate (EBC) collection method- this involved breathing in and out through a disposable device (akin to breathing onto cold glass to produce condensate) with an external cooler device. The R Tube starter kit is a complete disposable EBC collection kit and It has been used in many research clinical investigations."
219367682|NCT06542640|DEVICE|Mb-rt-fMRI-NFB|The MRI and TMS interventions described below will yield measures of change in the targeted brain regions in post- relative to pre- intervention comparisons. These change measures will be compared relative to changes in the sham/control group and the HC group. Furthermore, they will be compared to HC to assess improvement or normalization of brain function in the targeted brain regions. In addition, the investigators will examine treatment effects on traditional biomarkers that are likely to be impacted by such interventions: ERP, NP and NLP measures. Here, mindfulness meditation practiced during a real-time fMRI NFB session will be used to bring connectivity changes to brain structures involved in positive psychiatric symptoms (e.g. attenuated psychotic symptoms) in order to to reduce them.
219367683|NCT06542640|DEVICE|Sham mb-rt-fMRI-NFB|Individuals with CHR who are randomly assigned to this arm will receive mb-rt-fMRI-NFB, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
219429036|NCT00448760|DRUG|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
219429037|NCT00448760|DRUG|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
219367684|NCT06542640|DEVICE|rTMS|In previous work, the investigators used a multivariate pattern analysis to identify functional connectivity correlates of negative symptom severity in a schizophrenia (SZ) group. DLPFC-cerebellum hypo-connectivity was strongly correlated with negative symptoms. In a separate SZ cohort, the investigators used rTMS targeting the cerebellum to manipulate this circuit. The rTMS-induced increase in functional connectivity in a cerebellar-midbrain-DLPFC circuit was strongly linked to negative symptom severity reduction. Furthermore, individuals varied in the degree of change in functional connectivity in response to rTMS. This variation strongly predicted variation in post-rTMS symptom severity. The investigators predict that rTMS based intervention, but not sham rTMS, will similarly impact the cerebellar-midbrain-dorsolateral prefrontal cortex (DLPFC) network in the CHR group receiving real but not sham rTMS.
219367685|NCT06542640|DEVICE|Sham rTMS|Individuals with CHR who are randomly assigned to this arm will receive rTMS, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
219367686|NCT05254418|DRUG|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
219367687|NCT05579717|BEHAVIORAL|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
219367688|NCT01320605|BIOLOGICAL|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
219367689|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
219367690|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
219367691|NCT06213909|OTHER|This is a retrospective analysis of health data from inpatient record, no intervention was designed|This is a retrospective analysis of health data from inpatient record, no intervention was designed
219367692|NCT05547698|PROCEDURE|Off-pump lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
219367693|NCT05547698|PROCEDURE|Venoarterial ECMO lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
219367694|NCT03247634|BEHAVIORAL|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
219367695|NCT01538485|DRUG|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
219178753|NCT05623202|BEHAVIORAL|Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults|The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
219178754|NCT04469842|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
219367696|NCT00983411|OTHER|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
219367697|NCT06499922|PROCEDURE|SURGICAL EXCISION|surgical excision of low grade glioma
219367698|NCT00955773|DRUG|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
219367699|NCT03931304|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
219367700|NCT02940067|OTHER|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
219367701|NCT01111305|DRUG|Reslizumab|
219367702|NCT01111305|DRUG|Diethylcarbamazine|
219367703|NCT01111305|OTHER|Placebo|
219429038|NCT00448760|DRUG|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
219429039|NCT00448760|GENETIC|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
219429040|NCT00448760|GENETIC|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
219178755|NCT04469842|DRUG|Tacrolimus|Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
219745776|NCT05763849|BEHAVIORAL|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
219367704|NCT02909894|OTHER|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
219367705|NCT02909894|OTHER|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
219367706|NCT03624946|BIOLOGICAL|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
219367707|NCT03624946|OTHER|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
219367708|NCT00379951|DRUG|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
219367709|NCT00818376|OTHER|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
219367710|NCT06075381|COMBINATION_PRODUCT|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
219367711|NCT06075381|PROCEDURE|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
219367712|NCT04856657|DEVICE|Transcranial alternating current stimulation|The tACS will be applied with a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (25 cm²) applied to the back of the head. The anode will be located at Oz and the cathode will be located at Cz.
219367713|NCT03992144|DRUG|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
219367714|NCT03992144|DRUG|metronidazole 400mg|400mg of metronidazole an hour before extraction
219367715|NCT03992144|DRUG|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
219367716|NCT03711604|DRUG|Tenalisib|BID Orally
219367717|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
219745777|NCT06429332|OTHER|Reversal of Oral anticoagulation within 30 minutes|In situations of either an elevated INR with the use of warfarin - treatment with either 3- or 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) within 30 minutes of ICH diagnosis on NCCT to reach and maintain an INR target \<1.3; or where there has been recent use (\<48 hours) of a direct oral anticoagulant (DOAC), use of an appropriate reversal agent within 30 minutes, where available, and according to local approvals.
219178756|NCT04469842|DRUG|Mycophenolate Mofetil Hydrochloride|Standard immunosuppression of the anti-proliferative class.
219178757|NCT04469842|DRUG|Prednisone|Standard immunosuppression (corticosteroid class).
219178758|NCT04469842|DRUG|Azathioprine|Standard immunosuppression of the anti-proliferative class.
219367718|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
219367719|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
219367720|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
219367721|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
219367722|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt|Intake of yoghurt during 4 weeks
219367723|NCT01869348|BEHAVIORAL|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
219367724|NCT00130715|DEVICE|Seprafilm Bioresorbable Membrane|
219178759|NCT05691270|BEHAVIORAL|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
219556579|NCT03314376|DEVICE|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
219556580|NCT03776344|DEVICE|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
219556581|NCT03946462|DRUG|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
219556582|NCT03946462|OTHER|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
219556583|NCT00965757|DRUG|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
219556584|NCT00965757|DRUG|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
219556585|NCT01572857|BIOLOGICAL|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
219556586|NCT02689817|DEVICE|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
219556587|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
219556588|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
219556589|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
219556590|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
219556591|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
219556592|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
219556593|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
219556594|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
219556595|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
219556596|NCT01140438|DRUG|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
219556597|NCT01140438|DRUG|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
219556598|NCT00296270|BEHAVIORAL|Memory for truth|
219556599|NCT03074799|OTHER|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
219556600|NCT03074799|OTHER|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
219556601|NCT01859637|BIOLOGICAL|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
219556602|NCT05673707|DIAGNOSTIC_TEST|Thyromental Height|its measure between thyroid and mentum
219745778|NCT06429332|OTHER|Early intensive blood pressure lowering|A systolic blood pressure (BP) target of 130-140 mmHg within 30 minutes of ICH diagnosis on NCCT is strived for, and to maintain this BP level for the first 7 days (for patients presenting with blood pressure \<200 mmHg). If blood pressure ≥200 and \<220, a target BP of 160 mmHg should be targeted at 30 minutes, and 130-140 mmHg should be achieved in 60 minutes. If BP ≥220, target BP of 160 mmHg and should be achieved in 60 minutes.
219745779|NCT06429332|OTHER|Treatment of pyrexia|To achieve a body temperature target \<37.5 °C within the first 24h following ICH diagnosis on NCCT
219178760|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
219367725|NCT00624520|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
219367726|NCT00624520|OTHER|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
219367727|NCT02688348|OTHER|Quality-of-Life Assessment|Ancillary studies
219556603|NCT05539937|OTHER|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
219556604|NCT01662011|DEVICE|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
219745780|NCT06429332|OTHER|Hyperglycemia treatment|To maintain a blood glucose level 7-10 mmol/L within the first 24h following ICH diagnosis on NCCT
219367728|NCT02688348|OTHER|Questionnaire Administration|Ancillary studies
219367729|NCT00216723|DRUG|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
219367730|NCT00370201|DRUG|colchicine|
219367731|NCT04905667|DRUG|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
219367732|NCT04905667|DRUG|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
219367733|NCT05460039|OTHER|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
219367734|NCT01925209|DRUG|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
219367735|NCT01925209|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
219367736|NCT05774327|OTHER|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
219367737|NCT05774327|OTHER|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
219367738|NCT02865382|PROCEDURE|white light was used for colonoscopy withdrawal|
219556605|NCT01662011|DEVICE|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
219745781|NCT06429332|OTHER|Do-not-resuscitate (DNR) or withdrawal of care|Refrain from the use of DNR or withdrawal of care orders for 48 hours
219367739|NCT02865382|PROCEDURE|OE mode was used for colonoscopy withdrawal|
219367740|NCT03075163|PROCEDURE|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
219367741|NCT03075163|DRUG|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
219367742|NCT02796755|DRUG|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
219367743|NCT02796755|DRUG|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
219367744|NCT00397332|DRUG|Alefacept|IM Alefacept
219367745|NCT05014477|PROCEDURE|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
219367746|NCT02318758|DRUG|UT-15C|sustained release oral treprostinil
219367747|NCT02318758|OTHER|ethanol|Absolut 100 vodka
219367748|NCT05119803|DEVICE|Spinal Mouse (IDIAG M360 )|This device is an electronic computer-aided measuring december that measures the range of motion of the spine, evaluates the angle and shape of the spine in the sagittal and frontal planes. The device provides data to the computer via Bluetooth, and the measured curvatures are displayed on the computer screen. The method has no medical risks or dangers. The device has two rotating wheels that follow the spinous protrusions of the spine, and the distance and angle measurements are transferred from the device to the computer.
219367749|NCT05119803|OTHER|Nine Hole Peg Test|The nine-hole peg test is a simple, fast and manual skill test that has been proven to be valid and reliable in measuring upper limb function in Parkinson's patients. While the patient is sitting, he is asked to insert nine sticks into the holes of the test box with nine holes one by one as fast as possible and remove them back when he is finished
219367750|NCT01487369|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
219367751|NCT04704622|DRUG|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
219367752|NCT04704622|DRUG|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
219745782|NCT06429332|OTHER|Referral to Intensive Care|Immediate (\<30 min) referral to intensive care if airway, breathing and/or circulation are compromized
219745783|NCT06429332|OTHER|Referral to Neurosurgery|"Immediate (\<30 min) referral to neurosurgery if any of the following criteria are fulfilled:~* Large and/or rapidly evolving supratentorial ICH (\>20 ml volume)~* Any intraventricular extension~* Posterior fossa bleed, irrespective of volume~* Suspicion of a vascular malformation, independent of volume or location~* Reduction in reaction to sensory stimulation or drowsiness"
219429041|NCT00448760|PROCEDURE|Conventional surgery|Surgical removal of tumor for correlative studies
219556606|NCT03701451|DRUG|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
219556607|NCT02429583|DRUG|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
219745784|NCT06429332|DIAGNOSTIC_TEST|Repeat brain imaging|Repeat 6-12-hour brain imaging with the physicians choice of modality, preferably computed tomography (CT), if clinical deterioration or the patient received OAC reversal treatment
219745785|NCT06429332|OTHER|Standard care|For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
219745786|NCT04101331|DRUG|AFM13|weekly intravenous infusions of 200mg
219745787|NCT04943757|DRUG|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
219745788|NCT04943757|DRUG|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
219745789|NCT00214669|BEHAVIORAL|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
219745790|NCT00214669|BEHAVIORAL|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
219745791|NCT00214669|BEHAVIORAL|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
219745792|NCT04762368|DEVICE|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
219745793|NCT04762368|DEVICE|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
219745794|NCT05811949|DRUG|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
219745795|NCT01189851|DEVICE|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
219745796|NCT03889015|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
219745797|NCT03889015|DIETARY_SUPPLEMENT|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
219745798|NCT00195728|DRUG|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
219745799|NCT03208179|DRUG|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
219745800|NCT03208179|DRUG|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
219745801|NCT03208179|DRUG|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
219745802|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
219745803|NCT05521178|DIAGNOSTIC_TEST|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
219745804|NCT05521178|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 6 months
219745805|NCT05521178|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
219745806|NCT05521178|DEVICE|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
219745807|NCT05521178|DIAGNOSTIC_TEST|Blood pressure monitoring|Home blood pressure monitoring three times per week
219745808|NCT05521178|DIAGNOSTIC_TEST|Blood draw|Blood draw at baseline, 3 and 6 months
219745809|NCT05494619|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
219745810|NCT05494619|DRUG|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
219745811|NCT05494619|DRUG|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
219745812|NCT06342609|DRUG|Colchicine 0.5 MG|0.5mg per day of Colchicine orally administered
219745813|NCT00499447|PROCEDURE|radiofrequency ablation|
219367753|NCT04704622|DRUG|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
219745814|NCT00499447|RADIATION|radiation therapy|
219178761|NCT05549713|PROCEDURE|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
219745815|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
219745816|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."
219745817|NCT06558773|DRUG|Regorafenib+Immune checkpoint inhibitor|"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
219745818|NCT04110145|DRUG|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
219745819|NCT04110145|DRUG|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
219745820|NCT05205837|DRUG|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
219367754|NCT05640401|DEVICE|Endoscopy guided by mixed reality (HoloLens2TM) (HXtend™ software)|"Included expert gastrointestinal endoscopists performing diagnostic procedures with mixed reality guidance. All the procedures will be performed by using the HoloLens2TM (Microsoft, Redmond, WA, USA), an ergonomic self-contained holographic device.~HoloLens2TM (Microsoft, Redmond, WA, USA) uses HXtend™ developed software (mdconsgroup, Guayaquil, Ecuador) installed and running on Windows holographic OS. The monitors signals are replicated into holograms by an app developed with the unity Software package (Version 2022.1.22, Unity Technologies, San Francisco, CA, USA).~After each procedure, the researchers will evaluate the device performance along with the acceptance and experience of the endoscopists using this technology."
219367755|NCT05764148|BEHAVIORAL|behavioral activation|"Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions."
219367756|NCT01361841|DRUG|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
219367757|NCT01361841|DRUG|travoprost, latanoprost and bimatoprost|one drop once a day for life
219367758|NCT01561651|OTHER|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
219367759|NCT00110994|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
219367760|NCT00110994|DRUG|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
219367761|NCT00110994|DRUG|Dacarbazine|Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
219367762|NCT00150098|BEHAVIORAL|Enhanced HIV risk reduction and HIV vaccine education|
219367763|NCT02002702|DRUG|Serelaxin|Intravenous infusion
219367764|NCT02002702|DRUG|Placebo|Placebo
219367765|NCT06420310|OTHER|exposure to pesticides|based on work exposures to pesticides
219367766|NCT06160401|DRUG|Singletine|Singletine orally administered
219367767|NCT06160401|DRUG|Placebo|Placebo orally administered
219367768|NCT01316393|OTHER|XER2020|mucoprotective product
219367769|NCT00556426|DEVICE|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
219367770|NCT01964404|DRUG|Marijuana|Smoked plant with THC
219367771|NCT01964404|DRUG|Dronabinol|Capsule with THC
219367772|NCT01964404|DRUG|Placebo|Capsule with no active ingredient
219367773|NCT00932516|BEHAVIORAL|South Beach Diet™ with South Beach Diet™ Products|
219367774|NCT00932516|BEHAVIORAL|South Beach Diet™|
219556608|NCT00960414|BEHAVIORAL|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
219556609|NCT03303781|OTHER|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
219556610|NCT00314834|DRUG|Intradialytic parenteral nutrition|
219367775|NCT00932516|BEHAVIORAL|Calorie restricted diet with South Beach Diet™ Products|
219367776|NCT00932516|BEHAVIORAL|Calorie Restricted Diet|
219367777|NCT01570244|DRUG|levonorgestrel|multiple doses
219367778|NCT01570244|DRUG|Ethinylestradiol|multiple doses
219367779|NCT01570244|DRUG|levonorgestrel|multiple doses
219556611|NCT01185158|DRUG|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
219556612|NCT00067327|DRUG|Inosine|
219556613|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
219367780|NCT01570244|DRUG|BI 201335|multiple doses
219367781|NCT01570244|DRUG|Ethinylestradiol|multiple doses
219367782|NCT02714478|DEVICE|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
219367783|NCT02714478|DEVICE|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
219367784|NCT06201052|OTHER|Exercise test|Beep Test for measuring aerobic power
219367785|NCT02876692|DEVICE|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
219367786|NCT01523483|DRUG|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
219367787|NCT01523483|DRUG|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
219367788|NCT02266108|BEHAVIORAL|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
219367789|NCT00826735|BEHAVIORAL|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
219367790|NCT03623789|DRUG|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
219367791|NCT03623789|DRUG|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
219367792|NCT03623789|DRUG|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
219367793|NCT01598376|PROCEDURE|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
219367794|NCT01598376|PROCEDURE|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
219556614|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
219556615|NCT00974350|DRUG|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
219556616|NCT01214980|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
219556617|NCT01214980|OTHER|Standard of care|Standard of care provided per site-specific protocol
219556618|NCT02933892|PROCEDURE|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
219556619|NCT01344018|PROCEDURE|therapeutic conventional surgery|
219556620|NCT01344018|RADIATION|3-dimensional conformal radiation therapy|
219556621|NCT02044939|OTHER|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
219556622|NCT05070754|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
219556623|NCT05070754|DEVICE|Cryotherapy|Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
219556624|NCT05070754|DRUG|Canthardin Collodion|Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
219556625|NCT03127241|DEVICE|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
219556626|NCT03127241|DEVICE|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
219556627|NCT00789464|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10\^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
219556628|NCT00789464|DRUG|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
219556629|NCT00307723|DRUG|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
219556630|NCT00307723|DRUG|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
219556631|NCT00307723|DRUG|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
219556632|NCT00307723|DRUG|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
219556633|NCT00307723|PROCEDURE|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
219556634|NCT02349854|PROCEDURE|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
219556635|NCT06627374|DIAGNOSTIC_TEST|Patent Ductus Arteriosus in neonates|Neonates admitted to Neonatal care Unit after birth, undergoing hsPDA (hemodynamically significant Patent Ductus Arteriosus) closure according to standard clinical practice, will be included.
219556636|NCT01398787|DEVICE|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
219556637|NCT01398787|DEVICE|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
219556638|NCT03289260|DRUG|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
219556639|NCT03289260|DRUG|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
219745821|NCT05205837|DRUG|Placebo|Drug - Placebo Intramuscular injektion - placebo
219745822|NCT01657981|DRUG|YM150|14C-labeled YM150, oral solution
219745823|NCT00861887|DRUG|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
219745824|NCT00861887|DRUG|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
219745825|NCT06959537|DRUG|Cyclophosphamide|Given by mouth
219745826|NCT06959537|DRUG|Axatilimab (SNDX-6352)|Given by IV
219745827|NCT06959537|DRUG|Retifanlimab|Given by IV
219745828|NCT05967754|DIAGNOSTIC_TEST|polysomnography|polysomnography and serum uric acid measurement
219745829|NCT01128478|PROCEDURE|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
219745830|NCT02172729|DRUG|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
219745831|NCT02254291|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
219745832|NCT02254291|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
219745833|NCT02254291|DRUG|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
219745834|NCT02078869|DRUG|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
219745835|NCT02078869|DRUG|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
219745836|NCT05576064|DIAGNOSTIC_TEST|Gait analysis|Analysis of gait profile and measures by gait laboratory on patients with suspected lower limb rotational deformities and anterior knee pain
219745837|NCT04518501|DRUG|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
218990774|NCT06834867|BEHAVIORAL|MILAP intervention|The MILAP intervention, developed through participatory research, includes 9 sessions over 9 weeks, totaling 11 hours. It begins with the MilDil component, consisting of two sessions (4 hours) for MIL-DIL dyads, focusing on discussing cultural gender norms, raising awareness about the negative impact of IPV, establishing allyship between MIL and DIL, and empowering DILs while enhancing MILs' support for DILs' freedom of movement. This is followed by two one-hour sessions on Brief Behavioral Activation (BA) to address and prevent depression, involving MILs for necessary family support. Lastly, the husband-wife dyad will engage in four weekly sessions (4 hours) of Behavioral Couples Therapy (BCT), aimed at improving communication, coping strategies, and fostering caring behaviors between partners.
219745838|NCT06298058|DRUG|SIBP-A13 formulation for injection|"SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks."
219745839|NCT04717258|OTHER|Fire and Rescue Service Safe and Well Visit|Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
219745840|NCT04717258|OTHER|Self-Determination Theory informed trial invitation letter|Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
219367795|NCT05617521|DEVICE|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
219367796|NCT05617521|DEVICE|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
219367797|NCT05146141|OTHER|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
219367798|NCT04917770|DRUG|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
219367799|NCT01672931|OTHER|Oocyte Measurement|
219367800|NCT00455117|DRUG|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
219745841|NCT04717258|OTHER|Pen included with reminder questionaire|A pen will be included with the four-month reminder questionnaire.
219745842|NCT03988933|DRUG|Rifampin double dose|Double dose of rifampin for 2 months.
219745843|NCT03988933|DRUG|Rifampin triple dose|Triple dose of rifampin for 2 months.
219745844|NCT03988933|DRUG|Rifampin standard dose|Standard dose of rifampin for 4 months.
219745845|NCT04636073|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
219745846|NCT03705234|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
219745847|NCT03705234|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
219745848|NCT06277115|DEVICE|Continuous positive airway pressure (CPAP)|Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
219745849|NCT04878718|BIOLOGICAL|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
219745850|NCT03448835|DRUG|Atezolizumab|atezolizumab 1200 mg 5 cycles
219745851|NCT03448835|DRUG|Capecitabine|capecitabine 850 mg /m2 4 cycles
219745852|NCT03448835|DRUG|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
219745853|NCT03448835|DRUG|Docetaxel|docetaxel 50 mg/m2 4 cycles
218990775|NCT01622504|DRUG|MVP005|2 mg single dose administered intranasally
219367801|NCT02840331|DRUG|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
219367802|NCT02840331|DEVICE|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
219367803|NCT03241446|DRUG|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
219556640|NCT03289260|PROCEDURE|Fulguration|Surgical Excision and Fulguration of condyloma
219745854|NCT04804345|OTHER|standard of care|retrospective study: standard of care
219745855|NCT05030389|BEHAVIORAL|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
219745856|NCT05030389|BEHAVIORAL|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
219745857|NCT05030389|BEHAVIORAL|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
219367804|NCT03860948|DRUG|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
219367805|NCT03860948|DRUG|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
219367806|NCT06373874|BEHAVIORAL|Heel blood collection in a newborn simulation model|"The person who will take heel blood in the newborn simulation model can prepare the materials.~Firstly, the blood sample can fill in all the information on the filter paper. Knows where the baby's face should be. It can determine the area where a heel blood sample can be taken.It can gently warm the heel area for a few minutes. The area can be cleaned with alcoholic preparation (cotton/swab, etc.). He can squeeze the heel with his thumb and index finger in front. The other 3 fingers can be rubbed at the back. May stroke the heel three times. The heel can be pierced once with a lancet at a suitable location. He can relax his hand. He can wipe away the first drop of blood. It can create a large thick drop of blood to be collected on filter paper. It can make the drop fill the entire ring on the filter paper with one touch. After the procedure is completed, the heel can be pressed."
219367807|NCT02673333|DRUG|Pembrolizumab|
219367808|NCT00131807|PROCEDURE|Blood Pressure Measurement|
219367809|NCT00131807|PROCEDURE|Questionnaire|
219367810|NCT05003557|OTHER|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~* concerning the current health situation~* the SF 36~* the IPQ-R questionnaire"
219367811|NCT04142645|DEVICE|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
219367812|NCT00766792|PROCEDURE|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
219367813|NCT00766792|PROCEDURE|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
219367814|NCT00792298|DRUG|Suvorexant|oral tablet taken before bedtime
219745858|NCT05030389|BEHAVIORAL|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
219745859|NCT04179084|DRUG|fruquintinib|5mg qd, 2weeks on, 1week off
219745860|NCT04179084|DRUG|Sintilimab|200mg q3w
219745861|NCT00488293|PROCEDURE|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
219745862|NCT02093273|BIOLOGICAL|tOPV pilot batch|the tOPV vaccine is given orally
219745863|NCT02093273|BIOLOGICAL|tOPV commercial batch|tOPV vaccine is given orally
219745864|NCT03919019|OTHER|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
219745865|NCT03919019|OTHER|Placebo Group|oral placebo 2 capsules per day for 6 months
219367815|NCT00792298|DRUG|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
219367816|NCT02091180|DRUG|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
219367817|NCT02091180|DRUG|Control|Saline infusion
219367818|NCT01590342|DRUG|Diclofenac|Diclofenac 75 mg, two doses
219367819|NCT01590342|DRUG|Placebo|Placebo, two doses
219367820|NCT03649152|DRUG|Propagermanium|Immediate release capsule
219367821|NCT03649152|DRUG|Placebo|Placebo capsule
219367822|NCT03872492|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively."
219367823|NCT04354428|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
219367824|NCT04354428|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
219745866|NCT03436732|DRUG|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
219745867|NCT03436732|DRUG|SEL-110|administered on day 1 of each cycle for up to 4 cycles
219745868|NCT00233168|BEHAVIORAL|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
219745869|NCT00233168|BEHAVIORAL|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
219745870|NCT06405529|OTHER|Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge|"During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto."
219745871|NCT03345550|DRUG|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
218990776|NCT01622504|DRUG|MVP005|4 mg single dose administered intranasally
219556641|NCT01067794|DRUG|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
219556642|NCT01658358|DRUG|Lapatinib|"* dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily"
219556643|NCT01658358|DRUG|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
219556644|NCT02351167|DRUG|Combination NRT (Nicotine patch, Nicotine lozenge)|
219556645|NCT02351167|DRUG|Varenicline|
219556646|NCT02351167|DRUG|Placebo|
219556647|NCT02351167|BEHAVIORAL|Intensive smoking counseling|
219556648|NCT02608424|DEVICE|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
219556649|NCT03521362|DEVICE|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
218990777|NCT01622504|DRUG|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
218990778|NCT04238598|PROCEDURE|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
219178762|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
218990779|NCT04238598|PROCEDURE|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
218990780|NCT04238598|PROCEDURE|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
218990781|NCT04840615|BIOLOGICAL|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
218990782|NCT04840615|DRUG|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
218990783|NCT04840615|DRUG|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
218990784|NCT04840615|DRUG|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
218990785|NCT04840615|DRUG|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
218990786|NCT04840615|DRUG|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
218990787|NCT04840615|PROCEDURE|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
218990788|NCT04840615|DIAGNOSTIC_TEST|FDG-PET|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
218990789|NCT04840615|DIAGNOSTIC_TEST|CT CAP|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
219367825|NCT04354428|DRUG|Azithromycin|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
218990790|NCT04840615|DIAGNOSTIC_TEST|MRI|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
218990791|NCT04840615|DIAGNOSTIC_TEST|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
218990792|NCT04840615|DIAGNOSTIC_TEST|Echocardiogram|At screening.
218990793|NCT00634894|DRUG|Femara|2.5 mg by mouth daily x 12 weeks
218990794|NCT00634894|DRUG|Placebo|Placebo capsule by mouth daily x 12 weeks
219367826|NCT04354428|DRUG|Folic Acid|Eligible participants in a household will receive folic acid and an additional intervention drug
219367827|NCT04354428|DRUG|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]|Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
219556650|NCT03521362|DEVICE|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
219556651|NCT04933357|RADIATION|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
219556652|NCT04933357|RADIATION|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
219556653|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
219556654|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
218990795|NCT04353518|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
219556655|NCT01954030|DRUG|CTO and Bevacizumab|
219556656|NCT01954030|DRUG|CTO alone|
219556657|NCT03714373|DRUG|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
219367828|NCT04093648|GENETIC|TEGAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10\^7/m2 DL2: 3x10\^7/m2 DL3: 1x10\^8/m2 DL4: 3x10\^8/m2 DL5: 1x10\^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219367829|NCT04093648|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
219367830|NCT04093648|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
219367831|NCT01564706|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
219367832|NCT00224666|DEVICE|Cortex stimulation|
219367833|NCT00460980|BEHAVIORAL|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
219367834|NCT03670459|OTHER|Cawthorne Cooksey exercises|Eye movements and head movements
219367835|NCT03670459|OTHER|Vestibular habituation exercises|Move from a sitting position to flat on the back
219367836|NCT03670459|OTHER|Balance exercises|Weight Shift Forward and Back
219367837|NCT04258579|BEHAVIORAL|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
219367838|NCT03746691|DRUG|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
219367839|NCT03746691|DRUG|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
219367840|NCT05432531|DRUG|Anti JAK1,2|Induction of remission of active lupus nephritis
219367841|NCT05432531|DRUG|Cyclophosphamid|Induction of remission of active lupus nephritis
219367842|NCT05916872|OTHER|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
219745872|NCT03345550|DRUG|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
219367843|NCT05916872|OTHER|control group|Patients will receive conventional therapy.
219556658|NCT03714373|DRUG|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
219745873|NCT04200963|DRUG|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
219367844|NCT01510327|DEVICE|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
219367845|NCT01510327|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
219367846|NCT01510327|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
219367847|NCT04924426|PROCEDURE|TTC immersion|TTC immersion
219367848|NCT00131846|DRUG|Thiazide diuretics|Any dosage, frequency, and duration
219367849|NCT00131846|DRUG|No diuretics|Any antihypertensive regimen other than diuretics
219367850|NCT05835869|DIAGNOSTIC_TEST|Optical coherence tomography angiography and pattern electroretinogram|Optical coherence tomography angiography is an infrared eye scan that analyzes retinal vascularization and anatomy
219367851|NCT05606926|OTHER|physical therapy program|Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
219367852|NCT05606926|OTHER|whole body vibration (without extra weight vest)|9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.
219367853|NCT05606926|OTHER|whole body vibration (with weight vest)|The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
219367854|NCT02456246|PROCEDURE|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
219367855|NCT00252330|DRUG|SR58611A|
219556659|NCT03714373|DRUG|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
219429042|NCT01226706|DRUG|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
219556660|NCT06561581|BEHAVIORAL|Acuity|Enhancement to Motivity product for clinical decision support
219745874|NCT04200963|DRUG|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
219745875|NCT05380700|DEVICE|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
219556661|NCT01341678|DRUG|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
219367856|NCT03893045|DRUG|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
219367857|NCT03893045|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
219367858|NCT03844009|OTHER|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
219367859|NCT00859859|DEVICE|Vagus Nerve Stimulation|"1. Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~2. Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
219367860|NCT02816957|DRUG|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
219367861|NCT04578002|OTHER|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
219367862|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
219367863|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PG)|5.0 grams of PGX
219367864|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX|7.5 grams of PGX
219367865|NCT00801814|DIETARY_SUPPLEMENT|Control|0g of PGX
219556662|NCT01341678|DIETARY_SUPPLEMENT|NeutraPhos|Diet will be supplemented with NeutraPhos
219556663|NCT01341678|OTHER|Diet Only|Diet containing 1500mg of phosphorus
219556664|NCT04744467|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
219556665|NCT04908540|PROCEDURE|Mini-screw Assissted Rapid Palatal Expansion|Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
219745876|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
219745877|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
219367866|NCT00801814|DIETARY_SUPPLEMENT|Second Control|0g of PGX
219367867|NCT04387097|DRUG|remifentanil|postoperative drip-infusion of remifentanil
219367868|NCT00834054|PROCEDURE|Double-lung transplantation|Double-lung transplanted patients
219367869|NCT01242644|DEVICE|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
219367870|NCT01242644|DEVICE|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
219367871|NCT01242644|DRUG|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
219556666|NCT03334045|RADIATION|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
219367872|NCT04025593|DRUG|Cyclophosphamide|750mg/m2 day 1
219367873|NCT04025593|DRUG|Rituximab|375mg/m2 day 0
219367874|NCT04025593|DRUG|Doxorubicin|50mg/m2 day 1
219367875|NCT04025593|DRUG|Vincristine|1.4mg/m2, max 2mg day 1
219367876|NCT04025593|DRUG|Prednisone|60mg/m2, max 100mg day 1-5
219367877|NCT04025593|DRUG|Ibrutinib|420mg/day qd
219556667|NCT05489497|PROCEDURE|Primary closure with or without omental grafting|Primary closure with or without omental grafting
219556668|NCT03638063|DIAGNOSTIC_TEST|Adenosine Triphosphate|Adenosine Triphosphate aerosol
219556669|NCT03638063|DIAGNOSTIC_TEST|capsaicin|capsaicin aerosol
219556670|NCT05655429|PROCEDURE|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
219367878|NCT04025593|DRUG|Lenalidomide|25mg day1-10
219367879|NCT04025593|DRUG|chidamide|20mg day 1,4,8,11
219367880|NCT04025593|DRUG|decitabine|decitabine 10mg/m2 day-5 to day-1
219367881|NCT00345670|BIOLOGICAL|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
219556671|NCT05655429|PROCEDURE|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
219556672|NCT00133367|DRUG|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
219556673|NCT00133367|DRUG|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
219745878|NCT06055283|OTHER|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
219745879|NCT00203606|DRUG|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
219745880|NCT05274477|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
219745881|NCT05274477|DRUG|Placebo|no active component
219745882|NCT06564090|OTHER|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
219745883|NCT06564090|OTHER|conventional gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
219745884|NCT04120987|DRUG|Lifitegrast 5% Ophthalmic Solution|BID OU
219745885|NCT04078867|PROCEDURE|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
219745886|NCT05797623|DRUG|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
219745887|NCT05797623|DRUG|Placebo ; ciclosporin|Placebo combined with ciclosporin
219745888|NCT02595515|OTHER|Chiropractic treatment|Procedure: chiropractic treatment.
219745889|NCT02595515|OTHER|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
219367882|NCT00345670|BIOLOGICAL|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
219367883|NCT00345670|BIOLOGICAL|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
219745890|NCT05930639|OTHER|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
219745891|NCT01280669|DRUG|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
219745892|NCT01280669|DRUG|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
219745893|NCT02415114|DIETARY_SUPPLEMENT|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
219745894|NCT03409809|BEHAVIORAL|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
219745895|NCT03409809|BEHAVIORAL|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
219745896|NCT03409809|BEHAVIORAL|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
219745897|NCT02568319|DRUG|LIPO-202|
219745898|NCT02568319|DRUG|Placebo|
219745899|NCT02407119|DRUG|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
219745900|NCT02407119|DRUG|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
219745901|NCT00337168|DRUG|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
219367884|NCT05699655|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
219367885|NCT05699655|DRUG|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
219367886|NCT05699655|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
219367887|NCT05699655|DRUG|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
219745902|NCT00337168|DRUG|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
219367888|NCT03290339|PROCEDURE|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
219367889|NCT03631576|BIOLOGICAL|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
219367890|NCT01187992|DRUG|Atorvastatin|80 mg/day
219367891|NCT00157833|DRUG|Artekin / Coartemther|
219367892|NCT02867397|DRUG|Teysuno (S1) in combination with epirubicin and oxaliplatin|
219367893|NCT00240760|DRUG|Memantine Hydrochloride|
219367894|NCT03026582|DEVICE|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
219556674|NCT00133367|DRUG|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
219556675|NCT00133367|DRUG|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
218990796|NCT04353518|OTHER|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
218990797|NCT00075010|DRUG|Decitabine|15 mg/m\^2 by vein over 1 hour times 10 days
218990798|NCT00075010|DRUG|Valproic acid|20 mg/kg given orally daily for 10 days
218990799|NCT04943315|PROCEDURE|Monolithic zirconia|posterior crowns
218990800|NCT04943315|PROCEDURE|Metal-ceramic|posterior crowns
218990801|NCT04441606|RADIATION|68Ga-FAPI-04 PET/CT|"* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
218990802|NCT00967668|BEHAVIORAL|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
218990803|NCT00967668|BEHAVIORAL|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
218990804|NCT06109441|BIOLOGICAL|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
218990805|NCT01793649|DRUG|GS-5737|A single dose of GS-5737 in 2.8% saline
219178763|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
219367895|NCT05423405|OTHER|Acupressure|selected acupoint pressure
218990806|NCT04613063|OTHER|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
218990807|NCT04096963|DEVICE|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
218990808|NCT04057612|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
218990809|NCT04057612|OTHER|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
218990810|NCT03150017|OTHER|SPIRE|Online pain management programme.
218990811|NCT00115739|DRUG|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
218990812|NCT04108793|OTHER|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
218990813|NCT05678933|DRUG|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
218990814|NCT05678933|DRUG|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
218990815|NCT05678933|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
218990816|NCT05678933|DRUG|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
218990817|NCT05678933|DRUG|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
219367896|NCT02543138|DEVICE|Trocar|Closed thoracostomy using the new trocar
219556676|NCT00133367|DRUG|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
219556677|NCT00133367|DRUG|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
219556678|NCT00133367|DRUG|Melphalan|Given intravenously on day 2 before transplant.
219556679|NCT04791956|DIETARY_SUPPLEMENT|Prebiotic|Daily intake of Inulin-type fructans from chicory
219556680|NCT04791956|DIETARY_SUPPLEMENT|Placebo|Daily intake of maltodextrin
219556681|NCT00006467|DRUG|ISIS 2503|
219556682|NCT00006467|DRUG|gemcitabine hydrochloride|
219556683|NCT06193187|DRUG|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
219556684|NCT06193187|DRUG|Entresto 50 mg|Reference (R)
219556685|NCT00412204|DRUG|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
219556686|NCT00412204|OTHER|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
219745903|NCT00421564|DRUG|DBT-Danggui Buxue Tang|
218990818|NCT05678933|DRUG|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
219367897|NCT03466892|OTHER|Questionnaires and computer paradigm|Patients will complete different scales and also the visual probe task. First, we hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, we hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).
219745904|NCT05903703|DRUG|Canagliflozin and Gemcitabine|"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"
218990819|NCT04608929|BEHAVIORAL|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
218990820|NCT04608929|OTHER|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
218990821|NCT01637935|DRUG|Pioglitazone|Pioglitazone tablets.
218990822|NCT05965492|DRUG|Acetaminophen|"Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg."
218990823|NCT05965492|DRUG|Celebrex|"Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7."
218990824|NCT05965492|DRUG|Gabapentin|"Day 1 and Day 2: 300 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 900 mg.~Day 3: 200 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 600 mg.~Day 4: 200 mg two times a day and 100mg once a day administered via tablet by mouth for a total cumulative daily dose of 500 mg.~Day 5: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 6: 100 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 7: 100 mg once a day administered via tablet by mouth for a total cumulative daily dose of 100 mg."
218990825|NCT05965492|DRUG|Famotidine|Day 1- Day 7: 20 mg once a day administered via tablet by mouth for a total cumulative daily dose of 20 mg.
218990826|NCT05965492|DRUG|Decadron|"Day 1: 4 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 12 mg.~Day 2: 4 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 8 mg.~Day 3: 2 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 4 mg.~Not prescribed on Days 4 through 7."
218990827|NCT05965492|DRUG|Oxycodone|A prescription of oxycodone as per standard of care will be provided to participants in case of breakthrough pain.
219178764|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
219178765|NCT03985839|DEVICE|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
219178766|NCT03985839|DEVICE|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
219178767|NCT03985839|DEVICE|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
219178768|NCT05452408|DRUG|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
219178769|NCT01396278|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
219367898|NCT04688203|DRUG|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
219745905|NCT05903703|DRUG|Gemcitabine|on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
218990828|NCT03164135|GENETIC|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
218990829|NCT01361152|DEVICE|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
218990830|NCT01361152|DEVICE|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
218990831|NCT03037775|OTHER|Baseline|measurement of baseline hemodynamic parameters
218990832|NCT03037775|DEVICE|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
218990833|NCT03037775|DEVICE|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
218990834|NCT03037775|DEVICE|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
218990835|NCT04027062|BEHAVIORAL|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
218990836|NCT03308201|DRUG|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
218990837|NCT03308201|DRUG|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
218990838|NCT03308201|DRUG|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
218990839|NCT03240484|DIAGNOSTIC_TEST|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
218990840|NCT03240484|OTHER|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
218990841|NCT03543475|DEVICE|arabin pessary|arabin pessary: silicon device
218990842|NCT03543475|DEVICE|no pessary|control group
218990843|NCT04234750|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
218990844|NCT03982407|DRUG|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
218990845|NCT00951223|DRUG|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
218990846|NCT03725930|DRUG|Clonidine|clonidine intranasal premedication in preschool infants
218990847|NCT03725930|OTHER|Placebo|Placebo intranasal premedication
218990848|NCT04342156|DRUG|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
218990849|NCT04847011|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
218990850|NCT00313157|DRUG|Metoprolol|
218990851|NCT00313157|DRUG|Diltiazem|
218990852|NCT00313157|DRUG|Verapamil|
218990853|NCT00313157|DRUG|Carvedilol|
218990854|NCT00417469|DEVICE|NADGL|
218990855|NCT00709761|DRUG|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
218990856|NCT01372267|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
218990857|NCT01372267|BEHAVIORAL|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
218990858|NCT04984330|DRUG|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
218990859|NCT04984330|DRUG|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
218990860|NCT03859752|BIOLOGICAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
219367899|NCT04688203|DRUG|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
219367900|NCT00865215|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
219367901|NCT00865215|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
219006592|NCT05245370|BEHAVIORAL|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
219556687|NCT03525340|BEHAVIORAL|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
219556688|NCT00668395|DRUG|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
219556689|NCT05663255|DRUG|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
219367902|NCT01767584|DRUG|Cephalexin 1g tablets|Reference product
219556690|NCT00091195|DRUG|romidepsin|
219556691|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
219556692|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
219556693|NCT03769636|DEVICE|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
219556694|NCT00306306|DEVICE|Reprieve Endovascular Temperature Therapy System|
219556695|NCT05396417|PROCEDURE|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
219556696|NCT01325038|PROCEDURE|Isometric exercise|Isometric exercise several times/week for three months
219556697|NCT01249014|OTHER|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
219556698|NCT01249014|OTHER|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
219556699|NCT01249014|DEVICE|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
219556700|NCT01249014|DEVICE|Bair hugger warming blanket|Bair hugger warming blanket laid on body
219556701|NCT02858037|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
219556702|NCT04404907|OTHER|no intervention|This is a secondary analysis of registry data.
219556703|NCT01909115|DRUG|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
219556704|NCT01909115|DRUG|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
219556705|NCT02970188|BEHAVIORAL|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
219556706|NCT00624351|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
219556707|NCT00624351|OTHER|Placebo|Phosphate-buffered Saline (PBS) infusion.
219556708|NCT01206751|OTHER|Chest imaging technique and case presentation|
219556709|NCT02249117|DRUG|BIWH 3|
219556710|NCT02249117|DRUG|Placebo|
219006593|NCT05245370|BEHAVIORAL|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
219006594|NCT05245370|BEHAVIORAL|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
219367903|NCT01767584|DRUG|Cephalexin 1g tablets|Test product
219556711|NCT03993587|OTHER|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
219556712|NCT04184206|BEHAVIORAL|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
219556713|NCT04184206|BEHAVIORAL|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
219556714|NCT04184206|BEHAVIORAL|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
219556715|NCT00143273|DRUG|lasofoxifene|0.05 mg tablets
219556716|NCT00143273|DRUG|Placebo|0 mg
219556717|NCT00143273|DRUG|Lasofoxifene|0.25 mg tablets
219367904|NCT01567644|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
219556718|NCT00143273|DRUG|Lasofoxifene|0.5 mg tablets
219556719|NCT00301327|DRUG|Summers 5% L.A.|
219556720|NCT01424020|OTHER|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
219556721|NCT00377039|DRUG|AD 337|
219556722|NCT03550196|OTHER|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
219556723|NCT01847950|DIETARY_SUPPLEMENT|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
219556724|NCT01847950|DIETARY_SUPPLEMENT|Maltodextrin|
219429043|NCT01226706|DRUG|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
219556725|NCT01915641|DEVICE|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
219556726|NCT01652638|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
219556727|NCT00283842|DRUG|DVS SR|
219556728|NCT00283842|DRUG|Placebo|
219556729|NCT06040606|PROCEDURE|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
219556730|NCT05068661|DRUG|Ropivacaine 0.1% Injectable Solution|DPE
219556731|NCT05068661|DRUG|Bupivacaine 0.25% Injectable Solution|CSE
219556732|NCT03732833|DRUG|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
219556733|NCT03732833|DRUG|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
219556734|NCT05665387|DRUG|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
219556735|NCT05665387|DRUG|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
219556736|NCT05665387|DRUG|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
219556737|NCT03493633|DEVICE|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
219556738|NCT04124354|BEHAVIORAL|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
219556739|NCT03151954|PROCEDURE|functional endonasal sinus surgery|collect nasal polyps from patients
219556740|NCT03151954|PROCEDURE|nasal septal construction|collect inferior turbinates from patients as control arm
219556741|NCT04262245|PROCEDURE|Traditional Irrigation|irrigation with syringe
219556742|NCT04262245|DEVICE|Xp-endo Finisher (XPF)|irrigation activation file
219556743|NCT04262245|DEVICE|Passive Ultrasonic Irrigation|irrigation activation method
219556744|NCT04262245|DEVICE|EndoActivator|irrigation activation method
219556745|NCT00231582|DRUG|epirubicin|epirubicin
219556746|NCT00231582|PROCEDURE|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
219556747|NCT00231582|DRUG|paclitaxel|paclitaxel
219556748|NCT00231582|DRUG|etoposide|etoposide
219556749|NCT00231582|DRUG|ifosfamide|ifosfamide
219556750|NCT00231582|DRUG|carboplatin|carboplatin
219556751|NCT01220960|OTHER|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
219556752|NCT00221520|DRUG|midazolam with 2 different levels of sedation scores|
219556753|NCT06476782|OTHER|Motor Relearning Program(MRP) and aerobic exercise|Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.
219556754|NCT06476782|OTHER|Motor Relearning Program(MRP)|the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
219556755|NCT00000562|PROCEDURE|extracorporeal membrane oxygenation|
219178770|NCT01396278|DRUG|Fluticasone propionate|Fluticasone propionate HFA MDI
219556756|NCT00325780|DRUG|Pitavastatin|Pitavastatin 4 mg once daily
219556757|NCT02966860|DRUG|Oral solution OC/APAP|
219556758|NCT01919827|BIOLOGICAL|Endobronchial infusion of adult mesenchymal stem cells|
219556759|NCT01919827|BIOLOGICAL|Autologous mesenchymal stem cells derived from bone marrow|
219556760|NCT01577173|DRUG|MEHD7945A|1100 mg iv every 2 weeks
219556761|NCT01577173|DRUG|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
219556762|NCT04285073|DEVICE|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
219556763|NCT04221048|OTHER|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
219556764|NCT03792139|DRUG|LY3200882|Administered orally.
219556765|NCT03792139|DRUG|Itraconazole|Administered orally.
219556766|NCT00617825|OTHER|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
219556767|NCT00005958|BIOLOGICAL|filgrastim|
219556768|NCT00005958|DRUG|docetaxel|
219556769|NCT00005958|DRUG|gemcitabine hydrochloride|
219556770|NCT02472639|DEVICE|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
219556771|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not use device
219556772|NCT03634735|DRUG|Thiamine|Vitamine B1
219556773|NCT03634735|OTHER|Placebo|Placebo tablets
219556774|NCT02918058|OTHER|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
219178771|NCT01396278|DRUG|BI 54903|BI 54903 via Respimat inhaler
219429044|NCT03844503|DIETARY_SUPPLEMENT|Cereal Bar no fiber|Cereal Bar no fiber
219556775|NCT03797196|DRUG|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
219556776|NCT03797196|DRUG|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
219556777|NCT03542734|OTHER|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
219556778|NCT01426334|DRUG|dasatinib|Given PO
219556779|NCT01426334|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219556780|NCT01426334|OTHER|pharmacological study|Correlative studies
219556781|NCT01426334|DRUG|cyclosporine|Given PO
219556782|NCT00269386|DRUG|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
219556783|NCT00269386|DRUG|Placebo|
219556784|NCT03867916|BEHAVIORAL|Patient Navigation Program|Use patient navigation program
219556785|NCT03867916|OTHER|Quality-of-Life Assessment|Ancillary studies
219556786|NCT03867916|OTHER|Survey Administration|Ancillary studies
219556787|NCT00751023|DRUG|Modafinil|400 mg daily for four weeks
219556788|NCT00751023|DRUG|Placebo|Placebo 2 tablets daily for 4 weeks
219367905|NCT01854346|BEHAVIORAL|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
219367906|NCT00640094|DRUG|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
219367907|NCT00728065|DIETARY_SUPPLEMENT|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
219556789|NCT04685681|BEHAVIORAL|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
219556790|NCT04685681|OTHER|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
219556791|NCT03548155|DRUG|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
219556792|NCT03548155|DRUG|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
219556793|NCT03548155|DRUG|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
219556794|NCT03617419|DEVICE|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
219556795|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
219556796|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
219556797|NCT02339038|DRUG|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
219367908|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
219367909|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
219556798|NCT00999115|DRUG|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
219556799|NCT04848207|DEVICE|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
219556800|NCT04848207|OTHER|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
219556801|NCT01213407|DRUG|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
219745906|NCT02179034|DRUG|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
219367910|NCT00728065|DIETARY_SUPPLEMENT|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
219556802|NCT01213407|DRUG|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
218990861|NCT01220375|DRUG|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
219367911|NCT00728065|DIETARY_SUPPLEMENT|Rice milk|Rice milk containing 50g of available carbohydrates
219367912|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
219367913|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
219367914|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
219367915|NCT05835414|DEVICE|Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)|Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
219367916|NCT05527990|DEVICE|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
219367917|NCT05394038|OTHER|None，observational study.|observational study
219367918|NCT00914381|BEHAVIORAL|Behavioral therapy|
219367919|NCT00544934|DRUG|GLY-230|125, 250 0r 375 mg bid for 14 days
219367920|NCT00544934|OTHER|Placebo|No drug administered
219367921|NCT04977206|OTHER|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
219367922|NCT01950819|BIOLOGICAL|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
219367923|NCT01950819|DRUG|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
219367924|NCT01950819|DRUG|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
219367925|NCT01950819|DRUG|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
219367926|NCT04340050|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
219367927|NCT04134494|DEVICE|Ablative Fractional 2940 nm Laser|"* Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
219367928|NCT03541421|OTHER|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
219367929|NCT01152606|DRUG|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
219367930|NCT01710930|OTHER|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
219367931|NCT02495727|BEHAVIORAL|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
219367932|NCT02495727|BEHAVIORAL|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
219367933|NCT02495727|BEHAVIORAL|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
219367934|NCT00183846|DRUG|irinotecan|
219367935|NCT00183846|PROCEDURE|radiation therapy|
219429045|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
219556803|NCT03599583|BEHAVIORAL|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
219556804|NCT01534754|DRUG|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
219556805|NCT01534754|DRUG|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
219556806|NCT01534754|DRUG|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
219556807|NCT01534754|DRUG|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
219556808|NCT01199653|PROCEDURE|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
219556809|NCT01199653|PROCEDURE|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
219556810|NCT04385511|DEVICE|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
219556811|NCT01176981|DRUG|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
219556812|NCT05390255|DRUG|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
219556813|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
219556814|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
219556815|NCT00082160|BEHAVIORAL|Meditation|
219556816|NCT00082160|PROCEDURE|Functional Magnetic Resonance Imaging|
218990862|NCT01220375|DRUG|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
219556817|NCT02308696|BEHAVIORAL|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
219429046|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
219556818|NCT02308696|BEHAVIORAL|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
219429047|NCT01165099|PROCEDURE|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
219556819|NCT02201316|DRUG|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
219556820|NCT02201316|DRUG|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
219556821|NCT02201316|DRUG|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
219556822|NCT06533215|OTHER|antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.|"The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml)."
219556823|NCT02805517|DEVICE|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
219556824|NCT03969108|DRUG|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
219556825|NCT04806763|DEVICE|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
219429048|NCT02162121|PROCEDURE|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
219556826|NCT04806763|DEVICE|Control|Distance, single-vision glasses were used as control
219556827|NCT06352762|OTHER|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.
218990863|NCT01220375|DRUG|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
219556828|NCT06352762|OTHER|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
219556829|NCT05529576|DRUG|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
219556830|NCT01211262|DRUG|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
219556831|NCT04965233|BEHAVIORAL|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
219556832|NCT04965233|BEHAVIORAL|Information reports|Reports containing general information on eczema
219556833|NCT03350191|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219556834|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219556835|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219556836|NCT06486389|DEVICE|reading fairy tales|Reading fairy tales during inhaler medication administration.
219556837|NCT06486389|DEVICE|painting|painting during inhaler medication administration
219556838|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
219556839|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
219556840|NCT02346825|BEHAVIORAL|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
219556841|NCT05456022|DRUG|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % \_ Purity (HPLC) \> 95 %"
219556842|NCT05456022|DRUG|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
219556843|NCT05456022|DRUG|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
219556844|NCT03619330|DRUG|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
219367936|NCT01096914|PROCEDURE|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
219429049|NCT02162121|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
219556845|NCT03619330|DRUG|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
219556846|NCT00461669|PROCEDURE|ultrasound examination of the hip|
219556847|NCT01476904|DRUG|Placebo|0 mcg/inhalation, 2 inhalations QID
219556848|NCT01476904|DRUG|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
219556849|NCT01476904|DRUG|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
219556850|NCT04768114|BEHAVIORAL|Genetically-Informed RiskProfile|"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."
219556851|NCT04768114|OTHER|Brief Cessation Advice|"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."
219556852|NCT01194908|DRUG|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
219556853|NCT02070523|DRUG|VDCLD regimen|
219745907|NCT02179034|OTHER|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
219367937|NCT01096914|PROCEDURE|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
219367938|NCT02976155|OTHER|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
219367939|NCT00781365|OTHER|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
219367940|NCT01086436|BIOLOGICAL|Rotarix ™|Oral, single dose
219367941|NCT01086436|BIOLOGICAL|Placebo|Oral, single dose
219367942|NCT00456690|OTHER|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
219367943|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
219367944|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
219367945|NCT04586985|DRUG|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
219367946|NCT04586985|DRUG|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
219367947|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
219367948|NCT05734729|DEVICE|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
219367949|NCT05734729|DEVICE|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
219367950|NCT05554120|OTHER|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
219556854|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
219556855|NCT01742208|DRUG|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
219367951|NCT00102089|BIOLOGICAL|VRC-HIVADV014-00-VP booster|
219367952|NCT00102089|DRUG|VRC-HIVADV014-00-VP|
219367953|NCT01879410|DRUG|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
219367954|NCT01879410|DRUG|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
219367955|NCT01879410|DRUG|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
219367956|NCT01879410|DRUG|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
219556856|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
219556857|NCT01525680|OTHER|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
219556858|NCT01525680|OTHER|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
219367957|NCT02505529|OTHER|Resistance Exercise Training|Behavioral interventions of resistance exercise
219367958|NCT02505529|OTHER|Mental Imagery|Behavioral intervention of mental imagery
219367959|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
219367960|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
219556859|NCT00715676|DRUG|Placebo|oral, once daily
219556860|NCT00715676|DRUG|DP001|oral, once daily
219556861|NCT04595591|DRUG|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
219556862|NCT04595591|DRUG|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
219556863|NCT04595591|DRUG|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
219367961|NCT02803073|DRUG|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
219367962|NCT02803073|DRUG|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
219556864|NCT00660491|OTHER|exercise training|moderate intensity exercise group, and high intensity exercise group
219745908|NCT02179034|OTHER|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
219556865|NCT03577561|OTHER|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
219556866|NCT05003882|OTHER|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
219556867|NCT05475392|OTHER|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
219556868|NCT05475392|OTHER|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
219556869|NCT03807830|PROCEDURE|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
219556870|NCT06024148|OTHER|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
219745909|NCT03253237|DEVICE|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
219556871|NCT02992548|DRUG|Pravastatin|
219556872|NCT04470739|DIAGNOSTIC_TEST|chest x-ray|First Chest X-ray in the first 6 hours of infants
219745910|NCT03901040|DEVICE|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
219745911|NCT01490021|PROCEDURE|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
219745912|NCT01490021|PROCEDURE|rTMS/Placebo TBS|rTMS/Placebo TBS
219745913|NCT01347814|DRUG|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
219745914|NCT01347814|DRUG|Placebo|Homeopathic (Sugar) pill-Placebo
219745915|NCT03283241|DEVICE|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
219745916|NCT03283241|DEVICE|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
219178772|NCT04786106|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
219556873|NCT02441322|DEVICE|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
219556874|NCT02403973|OTHER|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
219556875|NCT02629640|OTHER|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
219556876|NCT02629640|OTHER|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
219556877|NCT02629640|OTHER|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
219556878|NCT02629640|OTHER|Blood or buccal sample|Codon-129 genotyping; storage for future research.
219556879|NCT02629640|OTHER|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
219745917|NCT00760760|DRUG|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
219745918|NCT00760760|DRUG|control|equivalent amount of fat as butter
219745919|NCT00666263|BIOLOGICAL|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
219745920|NCT00666263|BIOLOGICAL|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
219745921|NCT03091855|OTHER|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
219745922|NCT03091855|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
219745923|NCT04908644|DRUG|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
219745924|NCT04908644|OTHER|Placebo|Placebo
219745925|NCT00273884|DRUG|Amonafide L-Malate|
219556880|NCT01256996|PROCEDURE|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
219745926|NCT00273884|DRUG|Cytarabine|
219745927|NCT02691156|DIAGNOSTIC_TEST|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
219745928|NCT02691156|DIAGNOSTIC_TEST|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
219556881|NCT00131716|DRUG|sulfadoxine-pyrimethamine|
219556882|NCT01091363|BEHAVIORAL|Standard|10 minute brief cessation counseling
219556883|NCT01091363|BEHAVIORAL|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
219556884|NCT04302935|OTHER|Global pain-assessment|Global pain-assessment, based on the ICF framework
219556885|NCT00397735|PROCEDURE|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
219556886|NCT00397735|DRUG|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
219556887|NCT04576936|OTHER|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
219556888|NCT04096547|DRUG|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
219556889|NCT03960762|OTHER|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
219556890|NCT03960762|OTHER|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
219556891|NCT00216060|DRUG|Risedronate|Daily oral risedronate combined with androgen deprivation
219556892|NCT00216060|DRUG|Placebo|Daily oral placebo combined with androgen deprivation
219556893|NCT00604916|OTHER|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
219745929|NCT02691156|DIAGNOSTIC_TEST|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
219745930|NCT00586157|DRUG|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
219745931|NCT00586157|DRUG|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
219745932|NCT00212004|DRUG|pioglitazone|
219745933|NCT00212004|OTHER|control|
219745934|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
219367963|NCT00874198|PROCEDURE|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system \[pressure settings: 30 - 200 mmH20\]
219367964|NCT01200745|DRUG|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
219367965|NCT01676285|DRUG|Metoprolol succinate|
219367966|NCT01676285|DRUG|placebo|
219429050|NCT02162121|PROCEDURE|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
219556894|NCT00604916|OTHER|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
219556895|NCT05900323|COMBINATION_PRODUCT|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
219556896|NCT03837405|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
219745935|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
219745936|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
219745937|NCT01067807|DRUG|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
219745938|NCT05149729|PROCEDURE|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
219745939|NCT02288130|DRUG|GnRHa|
219745940|NCT02288130|DRUG|Ulipristal|
219745941|NCT04191226|DIAGNOSTIC_TEST|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
219745942|NCT00062764|DRUG|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
219745943|NCT01225952|DEVICE|Crystalens AO|Bausch \& Lomb model silicone multi-piece accommodating IOL.
219556897|NCT03837405|BEHAVIORAL|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
219556898|NCT00465660|BEHAVIORAL|Progressive resistance training|
219556899|NCT00530660|BIOLOGICAL|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
219556900|NCT05767762|OTHER|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
219556901|NCT05380726|BEHAVIORAL|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
219556902|NCT00776867|DRUG|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
219556903|NCT01489930|BEHAVIORAL|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
219556904|NCT01489930|BEHAVIORAL|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
219556905|NCT01489930|BEHAVIORAL|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
219556906|NCT04841967|BEHAVIORAL|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
219556907|NCT04841967|BEHAVIORAL|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
219556908|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gelatin capsule|Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
219556909|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene free form (PT)|Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
219556910|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule|Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
219556911|NCT01896492|DRUG|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
219556912|NCT05603858|PROCEDURE|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
219556913|NCT00006124|DRUG|celecoxib|Given orally
219556914|NCT00006124|DRUG|placebo|Given orally
219556915|NCT00000516|DRUG|enalapril|
219556916|NCT03201341|OTHER|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
219556917|NCT03201341|OTHER|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
219556918|NCT03201341|OTHER|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
219556919|NCT03201341|OTHER|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
219556920|NCT03201341|OTHER|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
219556921|NCT03201341|OTHER|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
219556922|NCT03201341|OTHER|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
219556923|NCT03201341|OTHER|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
219556924|NCT00360490|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
219556925|NCT00360490|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
219556926|NCT00451490|DRUG|Agomelatine|
219556927|NCT00451490|DRUG|Fluoxentine|
219556928|NCT02672761|BEHAVIORAL|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
219556929|NCT02672761|BEHAVIORAL|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
219556930|NCT02672761|BEHAVIORAL|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
219367967|NCT05460585|DEVICE|Cerebral oximetry using Rheopatch|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
219367968|NCT05460585|DEVICE|Cerebral oximetry using NIRO-200NX|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
219367969|NCT02009241|OTHER|Pulmonary Rehabilitation|
219367970|NCT05859477|DRUG|Nivolumab|360 mg, i.v., every 3 weeks
219367971|NCT05859477|DRUG|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
219367972|NCT05859477|DRUG|Oxaliplatin|130 mg/m², i.v., day 1, every 3 weeks
219367973|NCT01361516|OTHER|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
219367974|NCT02153762|DRUG|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
219367975|NCT02153762|DRUG|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
219367976|NCT03603041|DIETARY_SUPPLEMENT|Whey protein|Participants in the protein arms will receive whey protein daily for 16 weeks.
219367977|NCT03603041|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
219556931|NCT02672761|BEHAVIORAL|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
219556932|NCT01611415|DRUG|Ipragliflozin|Oral
219556933|NCT01611415|DRUG|Furosemide|Oral
219556934|NCT04130685|DIAGNOSTIC_TEST|Allosure Test|Venous Blood Draw
219556935|NCT03211351|DRUG|Liposic|one eye of the participant recieved Lipoic
219556936|NCT03211351|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
219556937|NCT03117205|OTHER|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
219367978|NCT02337803|BEHAVIORAL|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
219367979|NCT02337803|BEHAVIORAL|Usual Care|Will continue daily physical activity and complete surveys online
219367980|NCT04525963|OTHER|Preoperative visit of the operating room nurse and patient education|The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
219367981|NCT02419027|DIETARY_SUPPLEMENT|GI Flora|
219367982|NCT02419027|DIETARY_SUPPLEMENT|Placebo|
219367983|NCT04069663|OTHER|No interventional study|Retrospective data analysis
219556938|NCT03117205|OTHER|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
219429051|NCT02162121|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times a day
219429052|NCT02162121|PROCEDURE|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS\>4
219429053|NCT02162121|DRUG|Mepivacaine 1%|
219429054|NCT02162121|DRUG|Levobupivacaine 0,5%|
219556939|NCT02999698|OTHER|Observational|Observational
219556940|NCT00508898|DRUG|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
219745944|NCT01225952|DEVICE|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
219745945|NCT01225952|DEVICE|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
219367984|NCT05708391|DRUG|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
219745946|NCT01318681|DRUG|cetirizine 10 mg|cetirizine 10 mg over encapsulated
218990864|NCT01220375|DRUG|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
219367985|NCT05708391|RADIATION|Radiotherapy|Radiotherapy
219367986|NCT00481845|DRUG|Vandetanib|300 mg daily
219367987|NCT00481845|DRUG|Anastrozole|1 mg daily
219367988|NCT04625777|BEHAVIORAL|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
219367989|NCT04625777|BEHAVIORAL|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
219367990|NCT04625777|BEHAVIORAL|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
219367991|NCT00031031|DRUG|Kanglaite Injection (KLT)|
219367992|NCT01006070|PROCEDURE|kyphoplasty|surgical kyphoplasty
219367993|NCT05039060|DIETARY_SUPPLEMENT|Modified MAC diet (3-weeks)|"* Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis"
219745947|NCT01318681|DRUG|fluticasone furoate|nasal spray 25ug per dose
219745948|NCT01318681|DRUG|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
218990865|NCT01113567|DIETARY_SUPPLEMENT|Lactose-free milk|3.5 g of lactose
218990866|NCT01113567|DIETARY_SUPPLEMENT|Whole milk|Whole milk with 24 g lactose
219367994|NCT00363792|DRUG|Glyceryl trinitrate, azetazolamide|
219367995|NCT00000655|DRUG|Atovaquone|
219367996|NCT00000655|DRUG|Sulfamethoxazole-Trimethoprim|
219367997|NCT01756456|DRUG|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
219367998|NCT01756456|DRUG|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
219367999|NCT01756456|OTHER|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
219368000|NCT01618760|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
219368001|NCT01618760|DRUG|Risperidone|1 mg tablet once a day
219368002|NCT02153502|DRUG|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
219368003|NCT02153502|DRUG|Placebo|Placebo capsules administered twice a day over a 10-week period
219368004|NCT03604315|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219368005|NCT03604315|PROCEDURE|Computed Tomography|Undergo \[18F\]FTT PET/CT
219368006|NCT03604315|RADIATION|Fludeoxyglucose F-18|Given IV
219368007|NCT03604315|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
219429055|NCT02162121|DRUG|Ropivacaine 0,2%|
218990867|NCT00779714|DRUG|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
218990868|NCT00779714|DRUG|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
218990869|NCT00779714|DRUG|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
218990870|NCT03234933|OTHER|Mobility Tracker|Tracking Patient's movements and calories
218990871|NCT04335461|PROCEDURE|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
219368008|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219368009|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET/CT
219368010|NCT00198692|BEHAVIORAL|self-management|
219368011|NCT00030069|DRUG|Calcitriol|
219368012|NCT00030069|DRUG|Dexamethasone|
219556941|NCT00508898|DRUG|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
219556942|NCT03518723|OTHER|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
219556943|NCT03518723|OTHER|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
219556944|NCT01257191|DRUG|Carbon Black|source: commercial
219556945|NCT01257191|DRUG|Diesel Exhaust Particles|source: diesel engine
219556946|NCT01257191|DRUG|Fine Concentrated Ambient Particles|source: concentrated ambient air
219556947|NCT01257191|DRUG|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
219556948|NCT01257191|DRUG|Saline|Saline solution
219556949|NCT03432273|DRUG|Nicotine lozenge|Nicotine mint lozenge, 2 mg
219556950|NCT03432273|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
219556951|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
219556952|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
219556953|NCT05777694|PROCEDURE|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
219745949|NCT01183351|BEHAVIORAL|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
218990872|NCT04335461|DEVICE|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
218990873|NCT04335461|DRUG|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
219368013|NCT03221218|OTHER|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
219368014|NCT06435702|DRUG|Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
219368015|NCT06435702|DRUG|androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
219368016|NCT04810702|OTHER|no intervention|no intervention
219368017|NCT06545357|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
219368018|NCT04266535|DEVICE|Target controlled infusion|Target controlled infusion vs manually controlled infusion
219368019|NCT04187235|PROCEDURE|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
219429056|NCT02162121|DRUG|Ketorolac 30mg|
219429057|NCT02162121|DRUG|Buprenorphine 0,2mg|
219556954|NCT04228627|DRUG|Parentral Iron|Correction of Iron stores without anaemia
219556955|NCT01517867|BEHAVIORAL|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
219556956|NCT01517867|BEHAVIORAL|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
219556957|NCT02613286|PROCEDURE|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
219556958|NCT02613286|PROCEDURE|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
219556959|NCT02033317|DRUG|patiromer|15 grams/day (5 grams 3 times daily) administered orally
219556960|NCT03294317|DEVICE|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
219556961|NCT06454214|DEVICE|Multi-photon microscopy|To conduct 3D structural imaging on human breast tissues
219556962|NCT01266603|DRUG|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
219556963|NCT01266603|BIOLOGICAL|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
219556964|NCT03901690|DRUG|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
219556965|NCT03901690|DRUG|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
219556966|NCT02310503|PROCEDURE|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
219556967|NCT04621656|COMBINATION_PRODUCT|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
219556968|NCT04731493|OTHER|Therapeutic Education Program|"* needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire"
219556969|NCT03385954|OTHER|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
219556970|NCT03385954|OTHER|Control|will receive a lecture of 30 minutes.
219556971|NCT03819920|BEHAVIORAL|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
219556972|NCT03819920|BEHAVIORAL|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
219556973|NCT00076531|DRUG|Leuprolide Acetate for Injectable Suspension 22.5 mg|
219556974|NCT00054834|DRUG|hLL2 (epratuzumab)|
219556975|NCT00004241|DRUG|tanespimycin|Given IV
219556976|NCT00004241|OTHER|pharmacological study|Correlative studies
219556977|NCT00011063|DRUG|Ginkgo Biloba|
219556978|NCT04055545|OTHER|HIIT|"* 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down"
219556979|NCT04055545|OTHER|MICT|"* 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down"
219556980|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
219556981|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
219556982|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
219556983|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
219556984|NCT04789187|PROCEDURE|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
219556985|NCT04789187|PROCEDURE|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
219556986|NCT05072821|DRUG|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
219556987|NCT05072821|DRUG|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
219556988|NCT04496518|DEVICE|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
219556989|NCT01961245|DEVICE|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
219556990|NCT00574769|DRUG|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
218990874|NCT01472302|DEVICE|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
218990875|NCT01472302|DEVICE|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
218990876|NCT02781831|PROCEDURE|Standard rehab|Standard hospital based rehabilitation for patients with stroke
218990877|NCT02781831|DEVICE|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
218990878|NCT01260636|DRUG|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
218990879|NCT01260636|DRUG|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
218990880|NCT00043914|DRUG|lamotrigine|
219556991|NCT05307562|OTHER|Interval training + analytical strength|Patients will receive a training program
219556992|NCT05307562|OTHER|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
219556993|NCT02387762|DRUG|acalabrutinib|
219556994|NCT02387762|DRUG|Placebo|
219556995|NCT00608634|DRUG|perillyl alcohol|Applied as topical cream
219556996|NCT00608634|OTHER|placebo|Applied as topical cream
219556997|NCT02641873|DRUG|BBI608|240 mg twice daily (480 mg total daily dose)
219556998|NCT02641873|DRUG|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
219556999|NCT02641873|DRUG|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
219557000|NCT02641873|DRUG|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
219557001|NCT02641873|DRUG|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
219557002|NCT00914654|DRUG|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
219745950|NCT00286286|DEVICE|Intraperitoneal Aerosolization System, IntraMyst|
219745951|NCT02573064|DRUG|Colistin|
219557003|NCT02698345|DEVICE|drug-eluting balloon (In.PACT Admiral, Medtronic)|
219557004|NCT03061903|DEVICE|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
219557005|NCT03061903|DEVICE|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
219557006|NCT04315272|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
219557007|NCT04315272|DRUG|Placebo|Placebo
219557008|NCT00272272|BEHAVIORAL|Music Therapy|Listening to Music while standing
219557009|NCT04175860|BEHAVIORAL|The intervention with the patient (Chronic Patient Care Group and his family.)|"* Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
219557010|NCT01598896|DRUG|Dronabinol|Dronabinol titrated to 5 mg three times daily
219557011|NCT01598896|DRUG|Clonidine|Clonidine 0.1 mg twice daily
219557012|NCT01598896|DRUG|Placebo|One placebo capsule by mouth twice daily
219557013|NCT06382896|OTHER|No intervention|This was an observational study
219557014|NCT03534531|PROCEDURE|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
219557015|NCT03005366|DRUG|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
219557016|NCT03005366|DRUG|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
219557017|NCT02833181|DEVICE|BIS monitor|Monitoring circadian variation of EEG
219557018|NCT02450058|DRUG|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
219557019|NCT02450058|DRUG|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
218990881|NCT01685281|DRUG|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
219557020|NCT02450058|DRUG|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
218990882|NCT01685281|DRUG|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
219557021|NCT02450058|DRUG|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
219557022|NCT02450058|DRUG|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
219557023|NCT05564845|DIAGNOSTIC_TEST|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
219557024|NCT05564845|DIAGNOSTIC_TEST|Blood work|Lab work for current lab values and biobanking
219557025|NCT05564845|DIAGNOSTIC_TEST|Neurological examination|Classical neurological examination
219577509|NCT06165666|OTHER|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
219745952|NCT02573064|DRUG|Tigecycline|
219745953|NCT02573064|DRUG|Vancomycin|
219745954|NCT01916031|BEHAVIORAL|Education|
219745955|NCT02378480|DRUG|Omadacycline|Injection for IV dosing; Tablets for oral dosing
219745956|NCT02378480|DRUG|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
219745957|NCT02302287|DIETARY_SUPPLEMENT|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
219745958|NCT02302287|OTHER|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
219745959|NCT02302287|OTHER|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
218990883|NCT02550990|BEHAVIORAL|Cognitive training|
219745960|NCT05825040|BEHAVIORAL|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
219745961|NCT05825040|BEHAVIORAL|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
219745962|NCT05825040|BEHAVIORAL|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
219745963|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
219745964|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
219745965|NCT01189760|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
219745966|NCT00003794|PROCEDURE|psychosocial assessment and care|
219745967|NCT00003794|PROCEDURE|quality-of-life assessment|
219745968|NCT00269581|OTHER|Educational CD-rom|Educational CD-Rom
219745969|NCT00269581|OTHER|Headstrong CD-rom|Headstrong CD-rom
219745970|NCT00916487|DIETARY_SUPPLEMENT|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
219745971|NCT04373200|BIOLOGICAL|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
219745972|NCT04373200|OTHER|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
219745973|NCT01230060|DEVICE|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
219745974|NCT05963126|OTHER|No intervention.|No intervention.
219745975|NCT05006248|DEVICE|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
219745976|NCT05006248|DEVICE|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
219745977|NCT05006248|DEVICE|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
219577510|NCT06165666|OTHER|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
219745978|NCT06312215|OTHER|Closed-system catheter|Closed-system catheters was applied
219745979|NCT03901586|OTHER|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
219745980|NCT03901586|OTHER|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
219745981|NCT03901586|OTHER|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
219745982|NCT00931281|DRUG|ABT-450|capsules, QD or BID, 14 days, ascending doses
219745983|NCT00931281|DRUG|ritonavir|capsules, QD or BID, 14 days, ascending doses
219745984|NCT00931281|DRUG|Placebo for ABT-450|capsule, QD or BID, 14 days
219577511|NCT03826498|BIOLOGICAL|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
219577512|NCT03826498|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training etc.
219745985|NCT00931281|DRUG|Placebo for ritonavir|capsule, QD or BID, 14 days
219745986|NCT04642976|DEVICE|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
219745987|NCT01217892|DRUG|dapagliflozin|2.5 mg tablet, taken orally, twice daily
219745988|NCT01217892|DRUG|dapagliflozin|5 mg tablet taken orally, twice daily
219745989|NCT01217892|DRUG|dapagliflozin|10 mg tablet taken orally, once daily
219745990|NCT01217892|DRUG|metformin|\>/= 1500 mg total daily dose, tablets taken orally, twice daily
219745991|NCT01217892|DRUG|placebo|placebo
219745992|NCT00839501|DIETARY_SUPPLEMENT|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
219745993|NCT00839501|DRUG|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
219745994|NCT03226691|DRUG|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
219745995|NCT00900614|DRUG|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
219745996|NCT02059447|OTHER|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
219745997|NCT02059447|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
219745998|NCT02059447|BEHAVIORAL|Relaxation Therapy|
219745999|NCT01052779|DRUG|Ferumoxytol|IV Ferumoxytol
219746000|NCT01052779|DRUG|Iron Sucrose|IV Iron Sucrose
219557026|NCT05564845|DIAGNOSTIC_TEST|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
219746001|NCT03594708|DIETARY_SUPPLEMENT|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
219557027|NCT04202484|DRUG|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
219557028|NCT05198973|BEHAVIORAL|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
219746002|NCT03594708|DIETARY_SUPPLEMENT|Placebo supplement|rice starch, light olive oil, vegetable oil
219746003|NCT00243035|DRUG|bortezomib|Given IV
219746004|NCT00243035|DRUG|tipifarnib|Given orally
219746005|NCT00243035|OTHER|laboratory biomarker analysis|Correlative studies
219746006|NCT05385107|DIAGNOSTIC_TEST|Serum procalcitonin concentration|
219746007|NCT01205516|DRUG|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
219746008|NCT01205516|DRUG|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
219746009|NCT01401673|DRUG|Indantadol|Titration
219746010|NCT04125602|OTHER|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
219746011|NCT04125602|OTHER|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
219746012|NCT04932148|OTHER|Incremental HD|Starting haemodialysis at twice weekly frequency
219746013|NCT04932148|OTHER|Conventional HD|Starting haemodialysis at thrice weekly frequency
219746014|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
219746015|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
219746016|NCT01459120|OTHER|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
219746017|NCT01459120|OTHER|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
219746018|NCT00088946|DIETARY_SUPPLEMENT|Polyphenon E|4-200mg capsules PO daily for 12 months
219746019|NCT00088946|DRUG|erlotinib hydrochloride|100 mg PO daily for 12 months
219746020|NCT00088946|OTHER|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
219746021|NCT00088946|OTHER|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
219746022|NCT03663582|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
219746023|NCT03663582|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
219746024|NCT03663582|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
219746025|NCT03663582|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
219746026|NCT04388228|OTHER|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
219746027|NCT05326295|DIAGNOSTIC_TEST|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
219746028|NCT03694028|OTHER|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
219368020|NCT05833802|OTHER|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
219557029|NCT05717673|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
219557030|NCT05215873|DRUG|Misoprostol|a synthetic prostaglandin E1 analogue
219557031|NCT05215873|DRUG|Syntocinon|synthetic oxytocin
219557032|NCT04231292|DRUG|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
219557033|NCT04231292|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
219557034|NCT04231292|DRUG|placebo|placebo
219557035|NCT01120691|DRUG|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
219557036|NCT01120691|DRUG|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
219557037|NCT01120691|DRUG|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
219557038|NCT01120691|DRUG|Salbutamol/albuterol|As needed throughout the study
219557039|NCT06265038|DEVICE|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
219368021|NCT04687319|BIOLOGICAL|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
219368022|NCT01201213|DRUG|local anaesthetic injection|Single bolus of drug for pain relief in early labour
219368023|NCT03557021|DIAGNOSTIC_TEST|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
219557040|NCT01715779|DRUG|Eltrombopag|Eltrombopag exposure
219557041|NCT03828435|DEVICE|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
219557042|NCT06071338|DIAGNOSTIC_TEST|Clinical Periodontal Examination|No details will be published from the clinical assessment.
219557043|NCT04380233|DRUG|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
219557044|NCT04380233|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
219557045|NCT03370510|DRUG|Oxytocin|Oxytocin nasal spray.
219557046|NCT03370510|BEHAVIORAL|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
219557047|NCT03370510|DRUG|Placebo|Placebo nasal spray.
219577513|NCT03832699|DRUG|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
219577514|NCT03832699|DRUG|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
219577515|NCT03082170|DEVICE|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
219577516|NCT03082170|DIAGNOSTIC_TEST|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
219746029|NCT03694028|OTHER|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
219746030|NCT02648360|BEHAVIORAL|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
219746031|NCT03505060|BIOLOGICAL|DNA CON-S env|Administered by intramuscular injection in the deltoid.
219746032|NCT03505060|BIOLOGICAL|IHV01|Administered by intramuscular injection in the deltoid.
219746033|NCT03505060|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
219746034|NCT04931576|PROCEDURE|no drainage tube applied|No drainage tube implacement after TOETVA
219746035|NCT04118101|DRUG|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
219746036|NCT04118101|OTHER|control|no ESPB will be given.
219746037|NCT00336206|DRUG|Alemtuzumab|
219746038|NCT06467188|OTHER|Validity and reliability|"In order to evaluate the content validity of the Turkish version of the scale, 12 expert researchers in the field of gynecology and obstetrics were consulted. The experts were asked to evaluate the items as 1-Not Appropriate, 2-Somewhat Appropriate, 3-Reasonably Appropriate, and 4-Very Appropriate. Experts were asked to suggest items not evaluated as very appropriate. In the Davis technique, the content validity index which is calculated by dividing the number of experts who marked the options a (The item is appropriate) and b (The item needs minor revision) for each item by the total number of experts providing opinions is expected to be over 0.80 \[30\]. Based on expert opinions, the content validity index (CVI) value of the scale was calculated to be 96%, meaning that content validity was ensured. The items were reorganized by considering the experts' suggestions. The scale was administered to 252 women over 18 who were included in the study sample after scoring."
219746039|NCT05280054|DRUG|AV-101|360 mg capsules
218990884|NCT02550990|BEHAVIORAL|Aerobic exercise training|
218990885|NCT02550990|BEHAVIORAL|Sequential combination of aerobic exercise and cognitive training|
218990886|NCT04952493|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
218990887|NCT04952493|DRUG|Sodium Iodide I 131|RAI treatment may shrink the tumor
218990888|NCT04952493|DRUG|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
219178773|NCT04786106|PROCEDURE|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
219178774|NCT04786106|PROCEDURE|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
219178775|NCT04786106|DEVICE|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
219178776|NCT02143726|DRUG|sorafenib|Given PO
219178777|NCT02143726|DRUG|everolimus|Given PO
219178778|NCT04175119|DEVICE|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
219178779|NCT02322060|PROCEDURE|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
219368024|NCT00190060|DRUG|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
219368025|NCT00190060|DRUG|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
219368026|NCT02109237|PROCEDURE|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
219746040|NCT05280054|DRUG|Probenecid|1000 mg oral
219746041|NCT04628806|DIAGNOSTIC_TEST|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
219746042|NCT01285102|COMBINATION_PRODUCT|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
218990889|NCT01606800|DRUG|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
219368027|NCT06384092|OTHER|Test Sun Protection Cream|Apply directly on the designated site till absorbed.
219368028|NCT06384092|OTHER|Benchmark Sun Protection Cream|Apply directly on the designated site till absorbed.
219368029|NCT02859909|BIOLOGICAL|BT595|
219368030|NCT00168961|DIETARY_SUPPLEMENT|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
219368031|NCT03417050|OTHER|No intervention will take place for this retrospective and observational study.|No intervention will take place for this retrospective and observational study.
219368032|NCT01501279|PROCEDURE|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
219368033|NCT03246633|OTHER|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
219368034|NCT03601286|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
219368035|NCT04058327|DIAGNOSTIC_TEST|neurophysiological tests, blood biomarkers.|Let the patients do neuropsychological tests and detect blood biomarkers.
219368036|NCT00854828|PROCEDURE|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
219368037|NCT00854828|OTHER|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
219368038|NCT00004899|BIOLOGICAL|filgrastim|
219368039|NCT00004899|DRUG|busulfan|
219368040|NCT00004899|DRUG|etoposide|
219368041|NCT00004899|PROCEDURE|autologous bone marrow transplantation|
219368042|NCT04957290|DRUG|NOX66|NOX66 800 mg daily (400 mg suppository twice daily \[BID\]).
219368043|NCT04957290|DRUG|NOX66|NOX66 1200 mg daily (600 mg suppository BID).
219368044|NCT04957290|DRUG|NOX66|NOX66 1600 mg daily (800 mg suppository BID).
219368045|NCT04957290|DRUG|NOX66|NOX66 2400 mg daily (1200 mg suppository BID).
219368046|NCT04957290|DRUG|NOX66|NOX66 RP2D
219368047|NCT04957290|RADIATION|EBRT|The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.
219368048|NCT02000947|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
219368049|NCT02000947|DRUG|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
219368050|NCT02000947|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
219368051|NCT03215563|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
219368052|NCT03215563|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
219368053|NCT00287625|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation
219368054|NCT01526083|OTHER|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
219577517|NCT03082170|BEHAVIORAL|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
219577518|NCT02564081|OTHER|Static Stretching lower limb|
219368055|NCT01526083|OTHER|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
219368056|NCT01538238|DRUG|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
219368057|NCT02254031|DRUG|bivatuzumab mertansine|
219368058|NCT00384787|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
219368059|NCT00384787|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
219368060|NCT01034995|DRUG|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
219368061|NCT01034995|DRUG|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
219368062|NCT01034995|DRUG|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
219368063|NCT03440593|OTHER|Caloric delivery will target results of IC measurement.|The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
219577519|NCT02564081|OTHER|Static stretching Cervical|
219577520|NCT02944370|BEHAVIORAL|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
219577521|NCT02148861|DRUG|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
219368064|NCT01459614|DRUG|Gemcitabine|IV on Days 4 and 11
219368065|NCT01459614|DRUG|Taxotere|IV on Days 4 and 11
219368066|NCT01459614|DRUG|Xeloda|orally, twice a day Days 1-14
219368067|NCT01459614|DRUG|Cisplatin|IV Days 4 and 11
219368068|NCT04451707|OTHER|non-cholera Vibrio infection|Epidemiology of patients diagnosed with non-cholera Vibrio infection
219368069|NCT02587338|DEVICE|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anodal, right cathodal
219368070|NCT02587338|DEVICE|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
219368071|NCT01506882|DRUG|Levetiracetam (LEV)|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use"
219429058|NCT02162121|DEVICE|Stimulong, Pajunk, Germany.|
219429059|NCT02162121|PROCEDURE|Continuous lumbar plexus: non-stimulating catheter|
219557048|NCT01234961|BEHAVIORAL|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
219557049|NCT01234961|OTHER|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
219557050|NCT05276986|OTHER|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
219557051|NCT04884022|PROCEDURE|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
219557052|NCT04884022|PROCEDURE|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
219557053|NCT00804999|DRUG|Clear Care|neutralized Clear Care
219557054|NCT00804999|DRUG|ReNu|overnight soak in solution
219557055|NCT00804999|DRUG|OPTI-FREE|overnight soak in solution
219557056|NCT00749658|DRUG|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
219557057|NCT00749658|DRUG|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
219557058|NCT02766257|PROCEDURE|Anesthesia for ambulatory paediatric surgery|
219557059|NCT05723796|PROCEDURE|nasal endoscopy|nasal endoscopy and mucosal biopsy
219557060|NCT01525628|DRUG|midazolam|CYP3A probe drug
219557061|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
219557062|NCT01525628|DRUG|tenofovir|nucleoside analogue
219557063|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
219557064|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
219557065|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
219557066|NCT01525628|DRUG|midazolam|CYP3A probe drug
219178780|NCT02322060|PROCEDURE|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
219557067|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
219557068|NCT01525628|DRUG|pegylated interferon|HCV treatment
219557069|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
219557070|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
219557071|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
219178781|NCT02322060|PROCEDURE|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
219557072|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
219557073|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
219557074|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
219557075|NCT01525628|DRUG|ribavirin|HCV treatment
219557076|NCT01525628|DRUG|ribavirin|HCV treatment
219557077|NCT01525628|DRUG|ribavirin|HCV treatment
219557078|NCT01525628|DRUG|pegylated interferon|HCV treatment
219557079|NCT01525628|DRUG|ribavirin|HCV treatment
219557080|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
219557081|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
219557082|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
219557083|NCT01525628|DRUG|midazolam|CYP3A probe drug
219557084|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
219557085|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
219557086|NCT01525628|DRUG|ribavirin|HCV treatment
219557087|NCT00957762|OTHER|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
219557088|NCT03959150|DRUG|Capecitabine|Oral fluorouracil
219557089|NCT00239005|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219557090|NCT00239005|DRUG|Mycophenolate Mofetil (MMF)|
219557091|NCT02614898|OTHER|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
219557092|NCT04202757|BIOLOGICAL|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
219557093|NCT04202757|OTHER|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
219557094|NCT02075385|PROCEDURE|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
219557095|NCT00787605|DRUG|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
219746043|NCT01285102|PROCEDURE|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
219746044|NCT06183970|DEVICE|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
219746045|NCT06183970|DEVICE|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
219746046|NCT06465238|DRUG|SHR-A2009|Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
219746047|NCT06465238|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
219746048|NCT05860985|DEVICE|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
219746049|NCT01040247|OTHER|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
219746050|NCT02988908|DRUG|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
219746051|NCT02988908|DRUG|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
219746052|NCT02972645|DRUG|LY3305677|Administered SC
219557096|NCT00787605|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
219557097|NCT00787605|DRUG|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
219557098|NCT03382041|DEVICE|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
219557099|NCT03382041|DEVICE|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
219746053|NCT02972645|DRUG|Placebo|Administered SC
218990890|NCT01606800|DRUG|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
219557100|NCT06468904|PROCEDURE|cervical stabilization exercises and integrated neuromuscular technique.|"Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain."
219557101|NCT04107064|BEHAVIORAL|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
219557102|NCT04107064|BEHAVIORAL|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
219557103|NCT00606658|PROCEDURE|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
219557104|NCT02127216|BEHAVIORAL|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
219557105|NCT02299869|DEVICE|Verde (Competitor-control)|contact lens
219557106|NCT02299869|DEVICE|Green (CVI-test)|contact lens
219557107|NCT02299869|DEVICE|Cinza (Competitor-control)|contact lens
219557108|NCT02299869|DEVICE|Grey (CVI-test)|contact lens
219746054|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 21 mg administered SC
219746055|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 35 mg administered SC
219746056|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 70 mg administered SC
219746057|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 140 mg administered SC
219746058|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 15 mg administered SC
219746059|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 25 mg administered SC
219746060|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 50 mg administered SC
219746061|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 100 mg administered SC
219557109|NCT02299869|DEVICE|Esmeralda (Competitor-control)|contact lens
219557110|NCT02299869|DEVICE|Jade (CVI-test)|contact lens
219557111|NCT02299869|DEVICE|Azul (Competitor-control)|contact lens
219557112|NCT02299869|DEVICE|Blue (CVI-test)|contact lens
219557113|NCT03345615|DIAGNOSTIC_TEST|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
219557114|NCT02144805|PROCEDURE|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
219557115|NCT02144805|PROCEDURE|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
219557116|NCT06126939|BEHAVIORAL|Educational training based on the Denver model|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
219557117|NCT04485819|OTHER|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
219557118|NCT04485819|OTHER|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
219557119|NCT02484508|DRUG|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
219557120|NCT02484508|DRUG|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
219557121|NCT01859936|DEVICE|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
219557122|NCT03297541|BEHAVIORAL|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
219557123|NCT02926755|PROCEDURE|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
219557124|NCT00080795|BIOLOGICAL|filgrastim|
219557125|NCT00080795|DRUG|cisplatin|
219557126|NCT00080795|DRUG|doxorubicin hydrochloride|
219557127|NCT00080795|DRUG|gemcitabine hydrochloride|
219557128|NCT00080795|DRUG|ifosfamide|
219557129|NCT00080795|PROCEDURE|conventional surgery|
219557130|NCT00080795|PROCEDURE|neoadjuvant therapy|
218990891|NCT04189159|BEHAVIORAL|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
218990892|NCT02963792|OTHER|Preventing Professionals burnout|
219368072|NCT01187537|PROCEDURE|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
219557131|NCT03794245|BEHAVIORAL|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
219557132|NCT03794245|BEHAVIORAL|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
219557133|NCT03794245|BEHAVIORAL|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
219557134|NCT03794245|BEHAVIORAL|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
219557135|NCT01394133|DRUG|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
219557136|NCT03867773|BEHAVIORAL|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
219557137|NCT04894409|DEVICE|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
219557138|NCT04894409|DEVICE|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
219577522|NCT02148861|DRUG|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
219577523|NCT02148861|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
219577524|NCT00345059|DRUG|docetaxel|
219577525|NCT00345059|DRUG|vinorelbine|
219577526|NCT00345059|DRUG|gemcitabine|
219746062|NCT04189484|BIOLOGICAL|Placebo|Placebo administered SC
219746063|NCT06495606|DIAGNOSTIC_TEST|Voice sample; Recording with microphone + Questionnaire|Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
219746064|NCT06187389|OTHER|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
219746065|NCT05241366|DEVICE|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
219746066|NCT05241366|DEVICE|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
219746067|NCT02169596|DRUG|Ticagrelor|Blood tests taken for flow cytometry
219368073|NCT06536738|PROCEDURE|esophageal repair|The surgery confirmed a secondary esophageal fistula following the anterior cervical surgery. The procedure involved trimming the esophageal tissue around the fistula and repairing the fistula.
219557139|NCT04428645|DEVICE|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
219557140|NCT06273709|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
219557141|NCT04341337|OTHER|interview|questionnaire about ethics in surgery
219557142|NCT01889758|DRUG|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
219557143|NCT01889758|DRUG|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
219557144|NCT01889758|DRUG|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
219557145|NCT03646162|DRUG|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
219557146|NCT03646162|DRUG|Placebo|Placebo
219557147|NCT03945916|DIETARY_SUPPLEMENT|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
219368074|NCT01448200|DRUG|PPI-668|capsules
219557148|NCT03945916|DIETARY_SUPPLEMENT|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
219557149|NCT01461785|BIOLOGICAL|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
219557150|NCT01461785|PROCEDURE|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
219557151|NCT00497588|PROCEDURE|surgery|
219557152|NCT00497588|RADIATION|radiotherapy|
219577527|NCT00345059|DRUG|capecitabine|
219746068|NCT02169596|OTHER|EndoPAT - endothelial assessment|
219746069|NCT04477616|DRUG|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
219557153|NCT05845957|OTHER|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
219557154|NCT04916613|DRUG|Darolutamide 300 mg|600 mg po, b.i.d.
219557155|NCT04916613|DRUG|Placebo|po, b.i.d.
219557156|NCT04916613|DRUG|Androgen deprivation therapy|Use according to local standard of care
219557157|NCT00535041|DRUG|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
219557158|NCT03497819|BIOLOGICAL|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
219557159|NCT06678685|DRUG|.spironolactone|In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
219557160|NCT05955469|DEVICE|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
219557161|NCT05955469|DEVICE|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
219557162|NCT03965624|DRUG|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
219557163|NCT02583191|DRUG|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
219557164|NCT02583191|DRUG|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"
219557165|NCT01257581|DRUG|creatine|creatine monohydrate powder
219557166|NCT01257581|DRUG|tamoxifen|Tamoxifen citrate capsules
219557167|NCT02394288|PROCEDURE|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
219557168|NCT02824640|BEHAVIORAL|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
219557169|NCT02824640|BEHAVIORAL|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
219557170|NCT01728740|DRUG|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
219557171|NCT01728740|DRUG|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
219557172|NCT01728740|DRUG|Metformin|Metformin 500mg, oral, single dose
219557173|NCT00057967|BIOLOGICAL|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
219557174|NCT05008562|OTHER|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
219557175|NCT00523289|DRUG|Bupivacaine|Dosage: 150mg at once for anesthesia induction
219557176|NCT00523289|DRUG|Ropivacaine|Single dose of ropivacaine, 150mg
219557177|NCT02964650|DEVICE|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
219557178|NCT04767958|DIAGNOSTIC_TEST|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
219557179|NCT01559558|PROCEDURE|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
219557180|NCT02128152|DEVICE|Ekso exoskeleton|
219557181|NCT05693831|OTHER|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
219557182|NCT05719831|DRUG|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
219557183|NCT05719831|DRUG|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
219557184|NCT05719831|DRUG|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
219557185|NCT06615804|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
219557186|NCT00217334|BEHAVIORAL|Volunteer-led pharmacy sessions with feedback to physicians|
219557187|NCT02001155|PROCEDURE|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
219577528|NCT04823962|DRUG|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
219577529|NCT04823962|DRUG|Placebo hydrogel|Placebo hydrogel
219577530|NCT04823962|OTHER|Standard care|Compression therapy and neutral dressings
219368075|NCT01448200|DRUG|Placebo|capsules
219746070|NCT04477616|DRUG|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
219746071|NCT02714348|OTHER|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
219746072|NCT01907282|BEHAVIORAL|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
219557188|NCT04871009|BEHAVIORAL|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
219557189|NCT04871009|BEHAVIORAL|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
219557190|NCT05505760|BEHAVIORAL|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
219557191|NCT04684680|DIETARY_SUPPLEMENT|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
219557192|NCT04684680|DIETARY_SUPPLEMENT|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
219557193|NCT01333202|OTHER|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
219557194|NCT03405857|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
219557195|NCT06093789|OTHER|PBQ-S1|All patients will fill out Personality Belief Scale-Short Form (PBQ-S1) and Beck Anxiety Scale one day before the procedure and they will be registered.
219557196|NCT06176612|PROCEDURE|total hip arthroplasty|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
219557197|NCT05223725|BIOLOGICAL|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
219557198|NCT06850103|RADIATION|short-course radiotherapy|Neoadjuvant short-course radiotherapy (SCRT) will be administered at a total dose of 25 Gy, delivered in 5 fractions of 5 Gy each.
219557199|NCT06850103|DRUG|CAPEOX/XELOX|Capecitabine: 1000 mg/m² BID, D1-14, Q3W × 4 cycles Oxaliplatin: 130 mg/m² IV, D1, Q3W × 4 cycles
219557200|NCT06850103|DRUG|Serplulimab|Serplulimab: 300 mg IV, D1, Q3W × 4 cycles
219557201|NCT06850103|PROCEDURE|surgery|Primary tumor: Total Mesorectal Excision (TME) Metastatic lesions: Local therapeutic intervention
219557202|NCT06247241|DRUG|VMB-100|VMB-100 is administered as intrasphincteric injection in the urethra sphincter
219557203|NCT05753007|DRUG|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
219557204|NCT05753007|DRUG|Placebo|Placebo solution
219557205|NCT03945695|PROCEDURE|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
219557206|NCT05851898|DRUG|Duloxetine 30 mg|Duloxetine 30mg daily prescribed at discharge
219557207|NCT01491464|DEVICE|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
219746073|NCT01907282|BEHAVIORAL|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
219746074|NCT02119273|DRUG|Prednisone|See arm description
219557208|NCT01491464|DEVICE|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
219746075|NCT02119273|DRUG|Placebo|See arm description
219746076|NCT00876941|BEHAVIORAL|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
219746077|NCT00876941|BEHAVIORAL|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
219746078|NCT00876941|BEHAVIORAL|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
219746079|NCT04946214|BEHAVIORAL|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
219746080|NCT03629704|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
219746081|NCT04936555|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
219746082|NCT01066845|DRUG|tadalafil|prescribed in accordance with usual clinical practice
219746083|NCT04020640|OTHER|no intervention|Measure human intake using stable isotope technique
219746084|NCT00659022|PROCEDURE|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
219746085|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
219746086|NCT00659022|DRUG|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
219557209|NCT05714787|OTHER|Chest CT Scan examination|Double examination of chest CT scan on sagittal section after multiplanar reconstruction
219368076|NCT02402855|OTHER|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
219368077|NCT02402855|OTHER|Interview with a sociologist|For a sub-group of 40 womens
218990893|NCT03435861|DRUG|VX-745|active drug capsules
218990894|NCT03435861|DRUG|placebo|placebo capsules
219178782|NCT02322060|PROCEDURE|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
219178783|NCT05256394|BEHAVIORAL|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
219368078|NCT02402855|OTHER|No intervention|
219368079|NCT01602588|DRUG|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
219557210|NCT05884957|DIAGNOSTIC_TEST|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
219557211|NCT01707316|DRUG|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
219557212|NCT01707316|DRUG|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
219557213|NCT01707316|OTHER|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
219557214|NCT01021657|PROCEDURE|trabeculectomies, non penetrating deep sclerectomies|
219577531|NCT03798665|DRUG|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
219577532|NCT05712525|DIAGNOSTIC_TEST|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
219577533|NCT01075841|DRUG|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
219577534|NCT00225121|DRUG|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
219368080|NCT01602588|RADIATION|Radiotherapy|Short Course radiotherapy
219368081|NCT01758510|GENETIC|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.
219557215|NCT00397696|DRUG|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
219746087|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
219557216|NCT00555893|DRUG|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
219557217|NCT00555893|DRUG|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
219557218|NCT04875585|DRUG|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
219557219|NCT04875585|PROCEDURE|Surgery|surgical resection of primary tumor and lymph-node-dissection.
219557220|NCT04875585|DRUG|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
219557221|NCT03914898|OTHER|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
219557222|NCT02015351|DRUG|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
219557223|NCT00260026|DRUG|Docetaxel|
219557224|NCT00260026|DRUG|Jin Fu Kang|
219557225|NCT06399445|PROCEDURE|conventional cold tonsillectomy and curettage adenoidectomy|After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
219557226|NCT06399445|DRUG|Rocuronium Bromide|After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
219557227|NCT00326326|DRUG|CP-778,875|
219557228|NCT02336906|DRUG|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
219577535|NCT01626521|OTHER|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
219368082|NCT05079360|DRUG|Sabizabulin|32mg each day by mouth
219368083|NCT05079360|DRUG|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
219577536|NCT02002000|DRUG|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
219577537|NCT02002000|DRUG|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
219577538|NCT04859842|OTHER|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
219577539|NCT04859842|OTHER|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
219746088|NCT05321602|DRUG|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
219557229|NCT02336906|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
219368084|NCT02436603|BEHAVIORAL|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
219368085|NCT04800731|OTHER|observation no intervention|no intervention
219557230|NCT02336906|BEHAVIORAL|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
219746089|NCT05321602|DRUG|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
219746090|NCT05321602|DRUG|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
219746091|NCT05321602|DRUG|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
219746092|NCT01554709|DEVICE|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
219746093|NCT02348021|PROCEDURE|Percutaneous coronary intervention (PCI)|
219746094|NCT02348021|DRUG|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
219746095|NCT01101776|DRUG|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
219746096|NCT02190500|OTHER|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
219746097|NCT04120870|DRUG|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
219746098|NCT04120870|DRUG|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
219368086|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (8 mg/m^2)|
219368087|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2)|
219368088|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
219368089|NCT01302808|COMBINATION_PRODUCT|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
219557231|NCT02881359|DEVICE|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
219557232|NCT02563249|OTHER|Parabolic flight|
219557233|NCT02563249|OTHER|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
219746099|NCT00004103|DRUG|cisplatin|
219746100|NCT00004103|DRUG|floxuridine|
219746101|NCT00004103|DRUG|irinotecan hydrochloride|
219746102|NCT00004103|PROCEDURE|adjuvant therapy|
219746103|NCT00004103|PROCEDURE|conventional surgery|
219746104|NCT00004103|PROCEDURE|neoadjuvant therapy|
219368090|NCT00488787|DRUG|intranasal ketamine|low dose
219368091|NCT00488787|DRUG|intranasal ketamine|medium dose
219368092|NCT00488787|DRUG|intranasal ketamine|high dose
219368093|NCT00488787|DRUG|placebo|placebo
219368094|NCT00273000|DRUG|GLP-2|
219746105|NCT01716637|BIOLOGICAL|Etanercept|
219746106|NCT01716637|DIETARY_SUPPLEMENT|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
219746107|NCT00000307|DRUG|Naltrexone|
219746108|NCT01259531|DRUG|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
219746109|NCT00744614|PROCEDURE|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
219746110|NCT06488833|BEHAVIORAL|Komtü Programme (Komtü)|"Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully."
219746111|NCT06488833|BEHAVIORAL|Komtü Training and Reflective Practice|"This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group."
219746112|NCT00451737|DEVICE|Isokinetic test|
219746113|NCT04824677|OTHER|Hospital treatment of COVID disease|Hospital treatment of COVID disease
219746114|NCT01355666|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
219746115|NCT03574363|DRUG|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
219746116|NCT03574363|DRUG|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
219746117|NCT04023045|DEVICE|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
219746118|NCT04023045|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
219746119|NCT01968278|OTHER|Baked milk|
219746120|NCT03277599|DRUG|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
219746121|NCT03277599|DRUG|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
219746122|NCT03277599|DRUG|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
219746123|NCT06641596|DIETARY_SUPPLEMENT|Placebo|2 capsules of Placebo, once daily after breakfast for 12 weeks
219746124|NCT06641596|DIETARY_SUPPLEMENT|Cr-400|1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks
219746125|NCT06641596|DIETARY_SUPPLEMENT|Cr-800|2 capsules of Cr-400, once a day after breakfast for 12 weeks
219746126|NCT06641596|DIETARY_SUPPLEMENT|PE-500|1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks
219746127|NCT06641596|DIETARY_SUPPLEMENT|PE-1000|2 capsules of PE-500, once a day after breakfast for 12 weeks
219746128|NCT05236023|BEHAVIORAL|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
219746129|NCT06642259|RADIATION|Echocardiography|ECHO
219178784|NCT04774965|DEVICE|Slumber Curve sleep aid|Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
219577540|NCT04859842|OTHER|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
219746130|NCT06439810|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
219746131|NCT06642740|OTHER|Platelet count|divide into two groups based on platelet count
219746132|NCT06563570|OTHER|yoga (online)|8-week online yoga practices, 2 days a week
219746133|NCT06642272|DRUG|Empagliflozin 10 MG|Once daily
219746134|NCT06642272|DRUG|Dapagliflozin 10 MG|Once daily
219746135|NCT03729609|DRUG|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
219746136|NCT06216288|OTHER|Repeated back extension exercise (McKenzie)|repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
219746137|NCT06216288|DEVICE|Mechanical traction|The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
219746138|NCT06639776|DIAGNOSTIC_TEST|Questionnaire|"All erection prosthesis placements in post-phalloplasty transgender and gender non-conforming individuals at Ghent University Hospital from start of the gender clinic until June 2023 will be evaluated. All patients that are at least 6 months after erection prosthesis placement and currently have a functioning prosthesis in place are eligible and will be contacted. Upon inclusion and informed consent, the patient's medical files will be used to gather all necessary underlying medical information that is relevant to this study. will receive an email asking them to complete a questionnaire for themselves. At the end of this questionnaire the patient will be asked if they have a sexual partner and if this partner is willing to participate as well. After affirmation, the partner will be contacted in the same way.~Patients will receive a series of questionnaires reviewing recent sexual activity, sexual preference, satisfaction with the erectile prosthesis and quality partner relationship."
219178785|NCT06239402|OTHER|Observation|Observation of mortality, haemorrhagic and ischemic events in the studied population
219577541|NCT00728442|DEVICE|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
219746139|NCT05264454|DEVICE|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
219746140|NCT06641700|DIAGNOSTIC_TEST|diagnosed with gastric cancer|Pathological biopsy confirmed the diagnosis of gastric cancer.
219746141|NCT06638697|OTHER|Free walking|The free walking training program will last 32 weeks. The intensity of the training will be controlled by the scale of perceived exertion (Borg). The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746142|NCT06638697|OTHER|Nordic walking|The Nordic walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
219746143|NCT06638697|OTHER|Dance|The Dance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
219746144|NCT06638697|OTHER|Physical exercise for cognition|The Physical exercise for cognition training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
219746145|NCT06638697|OTHER|Balance|The Balance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
219746146|NCT06638697|OTHER|Aquatic physiotherapy|The Aquatic Physiotherapy training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746147|NCT06638697|OTHER|Multicomponent gymnastics|The Multicomponent Gymnastics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746148|NCT06638697|OTHER|Water aerobics|The Water Aerobics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746149|NCT06638697|OTHER|Hydroposture|The Hydroposture training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746150|NCT06638697|OTHER|deep water walking|The deep water walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746151|NCT06638697|OTHER|Weight training|The weight training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746152|NCT06638697|OTHER|Mat pilates|The MAt pilates program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
219746153|NCT06160245|OTHER|exercise therapy|core stabilization exercises
219746154|NCT03421353|DRUG|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
219746155|NCT03421353|DRUG|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
219746156|NCT03421353|DRUG|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
219746157|NCT03421353|DRUG|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
219746158|NCT03421353|DRUG|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
219746159|NCT03421353|DRUG|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
219746160|NCT03421353|DRUG|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
219746161|NCT03794947|PROCEDURE|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
219746162|NCT03794947|PROCEDURE|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
219746163|NCT04869384|OTHER|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
219746164|NCT04869384|OTHER|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
219746165|NCT05789251|DIAGNOSTIC_TEST|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
219746166|NCT02754297|DRUG|177Lu-Octreotate|"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
219368095|NCT03281980|OTHER|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
219368096|NCT03281980|OTHER|Government Intervention (UCT+HE)|fgbfgjhgykghilk
219557234|NCT01003951|PROCEDURE|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
219557235|NCT01092169|OTHER|No intervention|
219557236|NCT02179151|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
219557237|NCT02179151|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
219557238|NCT01956565|OTHER|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
219557239|NCT02754492|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
219746167|NCT06268847|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
219746168|NCT06268847|DIETARY_SUPPLEMENT|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
219746169|NCT06268847|DIETARY_SUPPLEMENT|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
219746170|NCT06040255|DRUG|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
219557240|NCT01671592|BIOLOGICAL|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
219368097|NCT06053008|OTHER|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
219577542|NCT05767606|BIOLOGICAL|NVX|Administration of NVX
219577543|NCT05767606|BIOLOGICAL|PCV20|Administration of PCV20
219577544|NCT05767606|BIOLOGICAL|Placebo|No intervention
219577545|NCT05387707|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
219577546|NCT05387707|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
219577547|NCT05387707|DRUG|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
219577548|NCT05387707|DRUG|Placebo|Oral Placebo tablets administered twice daily
219577549|NCT05387707|DRUG|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
219577550|NCT02470793|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
219577551|NCT02470793|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
219577552|NCT01314378|BEHAVIORAL|Mindfulness Training|Eight session intensive behavioral training program for smokers
219577553|NCT01314378|BEHAVIORAL|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
219577554|NCT00605735|DRUG|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
219577555|NCT00605735|DRUG|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
219577556|NCT01916746|PROCEDURE|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
219577557|NCT04171271|BEHAVIORAL|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
219746171|NCT02997085|DEVICE|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
219746172|NCT02997085|DEVICE|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
219746173|NCT01809769|BIOLOGICAL|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
219746174|NCT01809769|BIOLOGICAL|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
219746175|NCT01809769|BIOLOGICAL|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
219746176|NCT03528733|DEVICE|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
219746177|NCT02510586|DRUG|Sevoflurane|administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
219746178|NCT01829451|OTHER|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~\--------------------------------------------------------------------------------"
219746179|NCT00784615|PROCEDURE|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
219746180|NCT01533987|DIETARY_SUPPLEMENT|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
219746181|NCT01869673|DEVICE|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
219746182|NCT01869673|DEVICE|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
219746183|NCT03982173|DRUG|Tremelimumab|tremelimumab 75mg
219746184|NCT03982173|DRUG|Durvalumab|Durvalumab 1500mg
219746185|NCT04998630|DEVICE|Extracorporeal shockwave therapy|Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
219178786|NCT06492031|DRUG|Icodextrin Peritoneal Dialysis Solution|The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
219178787|NCT06492031|DRUG|Glucose Peritoneal Dialysis Solution|The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
219746186|NCT06192563|DRUG|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
219746187|NCT04311307|BIOLOGICAL|[6,6-2H2]glucose|Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
219746188|NCT04687930|DRUG|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
219746189|NCT04687930|DRUG|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
219746190|NCT01704157|DEVICE|Cryo-Touch III|Study treatment at Day 0.
219746191|NCT06042816|PROCEDURE|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
219746192|NCT06042816|PROCEDURE|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
219746193|NCT04853121|PROCEDURE|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
219746194|NCT04853121|PROCEDURE|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
219746195|NCT01683812|DEVICE|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
219746196|NCT06094738|DRUG|Relacorilant under fasted conditions|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
219178788|NCT04515576|DRUG|LY3493269|Administered SC
219178789|NCT04515576|DRUG|Dulaglutide|Administered SC
219178790|NCT04515576|DRUG|Placebo|Administered SC
219178791|NCT06166654|DRUG|Acetazolamide|1\. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
219368098|NCT05873985|OTHER|Dynamic tape on experimental group|"The dynamic taping application was carried out in 2 stages. Three I-shaped tapes were cut. In the first stage, the person was asked to perform scapular retraction, and in this position, the tape was placed by applying medium tension to the anterior part of the other deltoid muscle, passing from the anterior part of the deltoid muscle to the upper thoracic region. In the second stage, the participant was asked to do scapular retraction and depression, and while maintaining this position, medium tension was applied to the lower thoracic vertebra starting from the anterior part of the deltoid muscle and the acromion and tape was applied. Afterward, this process was applied on the other side"
219557241|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
219577558|NCT04171271|BEHAVIORAL|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
219577559|NCT01280409|DRUG|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
219577560|NCT01280409|DRUG|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
219577561|NCT04397445|DRUG|Ranitidine|Ranitidine 300 mg
219577562|NCT04397445|DRUG|Placebo|Oral placebo tablet
219577563|NCT04397445|OTHER|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
219577564|NCT04397445|OTHER|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
219178792|NCT06166654|DRUG|Metolazone 2.5 MG|2\. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
219178793|NCT06166654|OTHER|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
219577565|NCT04666415|OTHER|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
219577566|NCT02214368|OTHER|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
219577567|NCT02214368|DEVICE|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
219577568|NCT02214368|DRUG|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
219577569|NCT02214368|OTHER|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
219577570|NCT01207648|DRUG|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
219577571|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
219577572|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
219577573|NCT00548938|DRUG|Gliadel wafer|Implanted at surgery
219577574|NCT00548938|DRUG|Temozolomide|During External Beam Radiation
219577575|NCT00548938|RADIATION|External Beam Radiation Therapy|60 Gy
219577576|NCT04309318|PROCEDURE|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
219577577|NCT04309318|PROCEDURE|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
219577578|NCT00003144|DRUG|amifostine trihydrate|
219577579|NCT00003144|DRUG|cisplatin|
219577580|NCT00003144|DRUG|gemcitabine hydrochloride|
219577581|NCT00941057|DRUG|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
219577582|NCT00941057|DRUG|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
219577583|NCT00941057|DRUG|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
219577584|NCT06271720|OTHER|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
219368099|NCT05873985|OTHER|Sham tape on placebo group|"Sham taping was performed in 2 stages. Three I-shaped tapes were cut. Participants were asked to stand in the comfortable position they used during the day. The first tape was adhered from the starting point of the spine of the scapula with the acromion to the junction of the spine of the scapula and the acromion on the other side without any tension. The other two tapes, starting from the beginning and ending points of the first tape, were adhered to the lower thoracic region without any tension"
219368100|NCT00821678|OTHER|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
219368101|NCT04863274|DRUG|atorvastatin|"Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre."
219368102|NCT02225548|DRUG|Selegiline|
219368103|NCT02225548|DRUG|Tadalafil|
219368104|NCT02676830|DRUG|K-312 100 mg|Single oral dose
219368105|NCT02676830|DRUG|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
219368106|NCT01439438|DRUG|Topiramate coated tablet|Test formulation
219368107|NCT01439438|DRUG|Topamax® coated tablet|Reference formulation
219368108|NCT02243501|BEHAVIORAL|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
219368109|NCT02091609|OTHER|dental interproximal brush|use of this to maintain oral hygiene
219368110|NCT02091609|OTHER|dental floss|use of this to maintain oral hygiene
219746197|NCT06094738|DRUG|Relacorilant after a high-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
219368111|NCT02808104|DRUG|mazindol|
219368112|NCT00544921|DRUG|GLY-230|
219368113|NCT00544921|OTHER|Placebo|No drug administered
219368114|NCT02159300|BEHAVIORAL|experience brain activity recording|Intervention: experience brain activity recording
219746198|NCT06094738|DRUG|Relacorilant after a low-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
219746199|NCT00141011|DRUG|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
219746200|NCT00141011|DRUG|Placebo|0.6 mL/kg/hr
219577585|NCT06271720|OTHER|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
219368115|NCT06930833|DEVICE|Corsano CardioWatch 287-2|Eligible patients are asked to wear the Corsano CardioWatch 287-2 for 6 days, of which 3 days approximately 2 weeks before the procedure and 3 days approximately 2 months after the procedure.
219368116|NCT06911996|BEHAVIORAL|Virtual Reality|"After obtaining written consent, participants will be asked to complete a brief demographic survey and pre-intervention surveys (content knowledge, and wellbeing surveys). They will then be equipped with a VR headset, Quest 3 (Meta, Inc., Menlo Park, CA) displaying the educational field trip. After the VR field trip, participants will participate in a complementary hands-on science experiment. At the conclusion of the experiment, patients will be asked to complete the post intervention surveys (i.e awe, content knowledge, and wellbeing surveys).~Additionally, for the first 20 participants, 15 participants will be randomly selected and asked to participate in a 5 open-ended question qualitative interview regarding engagement of the lesson. Audio will be recorded via zoom."
219577586|NCT03390348|DEVICE|LENA Recorder|Use of the LENA recorder to document crying and fussing
219577587|NCT03501914|BEHAVIORAL|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
219577588|NCT04188314|DRUG|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
219577589|NCT04188314|DRUG|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
219577590|NCT02302664|PROCEDURE|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
219746201|NCT04357470|OTHER|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
219746202|NCT01623947|DIETARY_SUPPLEMENT|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
219746203|NCT01623947|DIETARY_SUPPLEMENT|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
219746204|NCT01623947|DIETARY_SUPPLEMENT|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
219746205|NCT01505855|DRUG|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
219746206|NCT00270556|DRUG|tenofovir disoproxil fumarate|
219746207|NCT00270556|DRUG|Abacavir|
219746208|NCT00605189|DEVICE|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
219746209|NCT00605189|DEVICE|Powered Suction Pump|continuous gauze based negative pressure wound therapy
219746210|NCT00605189|DEVICE|MWT|moist wound therapy
219746211|NCT05516875|DRUG|JM-010|JM-010
219746212|NCT04758988|OTHER|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
219746213|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
219746214|NCT02129972|DEVICE|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
219746215|NCT06640790|OTHER|Case Group|Root canal treated were categorized based on the AAE case difficulty assessment form. Endodontic mishaps investigated included over-instrumentation, working length loss, underfilling, overfilling, apical transportation, instrument fracture, and perforation.
219746216|NCT06539442|DEVICE|Versius Surgical System|Urological minimal access surgery performed with Versius Surgical System
219746217|NCT05546307|OTHER|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
219746218|NCT05546307|OTHER|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
219746219|NCT04427670|OTHER|Group intervention|Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.
219746220|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
219746221|NCT06487936|DEVICE|TransLoc 3D SI Joint Fusion System|Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
219746222|NCT02697448|DRUG|propofol|Participant receives propofol as anesthetic for cardiac ablation.
219746223|NCT02697448|DRUG|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
219746224|NCT05473715|DRUG|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
219746225|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Active Treatment questionnaire|Electronic questionnaire to be administered to patients in active treatment.
219746226|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Survivors questionnaire|Electronic questionnaire to be administered to cancer survivors.
219746227|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Palliative Care questionnaire|Electronic questionnaire to be administered to patients in palliative care.
219746228|NCT06511024|OTHER|Blood sample|Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
219746229|NCT02886962|BIOLOGICAL|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
219746230|NCT02886962|DRUG|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
219746231|NCT04381806|DRUG|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
219746232|NCT06043011|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
219746233|NCT06078930|DIAGNOSTIC_TEST|Tongue imaging, tougue coating, saliva, gastric juice, and feces|Tongue images, coating, saliva, gastric juice, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
219746234|NCT05277532|BEHAVIORAL|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
219368117|NCT06915415|BEHAVIORAL|Animal-assisted therapy|One group had a live therapy canine included in therapy sessions who was trained to provide comfort measures and promote interaction with autistic children. He is a certified therapy and service dog and knows over 50 commands and is certified in 10 autism service dog tasks. Participants played with him at the beginning of the session. They could choose to play fetch or hide and seek. Participants could say commands to make him do tricks and give him a treat as a reward. The canine would lay at participants' feet while the therapist was working on a skill in the clinic room. The canine would alert to the onset of anxiety and provide comfort measures. Participants could also cue the canine to provide comfort measures or could brush his fur and give him water as a prosocial behavior. Participants ended sessions with either fetch, soccer, or hide and seek.
219746235|NCT05544760|OTHER|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
219746236|NCT03577470|DRUG|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
219746237|NCT04965064|DRUG|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
219746238|NCT05498870|DRUG|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
219746239|NCT05498870|DRUG|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
219577591|NCT02302664|PROCEDURE|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
219577592|NCT02293330|DRUG|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
219577593|NCT02293330|DRUG|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
219577594|NCT00977730|DIETARY_SUPPLEMENT|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
219577595|NCT00977730|DIETARY_SUPPLEMENT|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
219577596|NCT00574925|DRUG|Esomeprazole|
219577597|NCT03121430|DEVICE|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
219577598|NCT03121430|DEVICE|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
219577599|NCT01246622|DRUG|cytarabine|Given IV
219577600|NCT01246622|DRUG|lenalidomide|Given PO
219577601|NCT05214963|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
219577602|NCT05214963|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
219577603|NCT02955017|BEHAVIORAL|traditional follow_up|"* Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months"
219577604|NCT02955017|BEHAVIORAL|"distance follow-up new technologies"|"* Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months"
219577605|NCT02963441|DEVICE|LumineticsCore (formerly IDX-DR)|Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
219577606|NCT02399735|BIOLOGICAL|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
219577607|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
219577608|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
219577609|NCT01530763|DRUG|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
219577610|NCT01530763|DRUG|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
219577611|NCT01530763|DRUG|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
219577612|NCT01338649|DEVICE|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
219577613|NCT01338649|DEVICE|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
219577614|NCT06219590|PROCEDURE|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
219577615|NCT06219590|PROCEDURE|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
219577616|NCT00361335|DRUG|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
219746240|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
219746241|NCT01690533|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
219746242|NCT02919618|RADIATION|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
219746243|NCT02592863|DRUG|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
219746244|NCT02592863|DRUG|Placebo|Patients will take placebo 3 times per day for 12 weeks
219746245|NCT02743221|DRUG|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
219746246|NCT02743221|DRUG|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
219746247|NCT04962113|OTHER|TUBE BATH|Wrap Tube Baht (immersion)
219746248|NCT04503616|DRUG|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
219557242|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
219557243|NCT05006560|OTHER|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
219557244|NCT05701124|DRUG|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
219557245|NCT04423003|PROCEDURE|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
219557246|NCT01702415|DRUG|Zoledronic acid|Single dose, intravenous solution 5mg
219557247|NCT01702415|DRUG|Placebo|
219557248|NCT05746819|OTHER|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
219557249|NCT02672540|DRUG|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
219557250|NCT02672540|DRUG|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
219368118|NCT06915415|BEHAVIORAL|Behavioral therapy|One group had a toy plush dog included in therapy sessions. The therapist would incorporate the toy plush dog in the seated portion of the session to practice social skills. Participants could brush the toy plush dog, pet it, and hold it during sessions.
219557251|NCT02866240|DEVICE|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
219557252|NCT00611884|DRUG|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
219557253|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
219557254|NCT00611884|DRUG|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
219557255|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
219557256|NCT00611884|DRUG|metformin|Tablets, 1500-2000 mg/day
219557257|NCT00981799|DRUG|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
219746249|NCT04100993|OTHER|No intervention used|No intervention used
219746250|NCT03411044|DEVICE|Fitmore Hip Stem|
219746251|NCT05325242|DEVICE|Embozene particles|Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
219746252|NCT04726527|DRUG|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
219746253|NCT04726527|DEVICE|Positron Emission Tomography|PET Scan for brain imaging
219746254|NCT05665751|DRUG|TLC-3595 Dose 1|Tablets administered orally
219746255|NCT05665751|DRUG|TLC-3595 Dose 2|Tablets administered orally
219746256|NCT05665751|DRUG|Placebo|Tablets administered orally
219746257|NCT04458766|BEHAVIORAL|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
219746258|NCT06639646|DIETARY_SUPPLEMENT|Probiotics supplements|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
219746259|NCT06639646|DIETARY_SUPPLEMENT|Health diet|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
219746260|NCT06639867|DEVICE|VR-based home physiotherapy|VR-based home physiotherapy
219746261|NCT06639867|OTHER|Standard physiotherapy care|Standard physiotherapy care as prescribed by the treating physiotherapist
219746262|NCT06639191|DRUG|[177Lu]Lu-AKIR001|"Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq."
219746263|NCT06642285|PROCEDURE|Non Invasive Respiratory Support bundle|premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning
219746264|NCT06638437|BEHAVIORAL|Cognitive-behavioral therapy|"The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process"
219746265|NCT06638788|OTHER|Knee extension|Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
219746266|NCT06637397|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
219746267|NCT06637397|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
219746268|NCT06637579|OTHER|universal exercise unit therapy with task oriented strength training|Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.
219368119|NCT06917638|PROCEDURE|implant placment|"* Crestal incision followed by full thickness mucoperiosteal flap elevation.~* Drilling of the implant according to the manufacturer's instructions to reach the final drill corresponding to the implant size.~* Allocation concealment will be broken at this point to assign the patient into one of two groups:~Control Group: osteotomy preparation the same diameter of the implant. Intervention: oversized drilling:Osteotomy preparations will include an extra drill,(0.2mm) wider than the diameter of the implant.~* A smart peg will then be attached to the implant, to measure its stability using Ostell and three readings will be recorded:occlusal buccal and lingual reading.~* A healing collar will then be place over the implant, then simple intrerupted suture~* A standardized digital periapical radiograph will be taken using a radiographic holder and a custom-made radiographic stent to determine the initial crestal bone level."
219368120|NCT06916871|OTHER|The control group will benefit from awareness|During hospitalization in rehabilitation, doctors and nursing staff will transmit information in a linear manner, i.e. explain, possibly argue and answer the patient's questions on topics such as interpreting blood sugar levels, explaining treatment, good practices in terms of diet, physical activity, etc. at the patient's bedside in an unstructured manner based on interactions between patient and caregivers. There is therefore no standard frequency, number of specific sessions, or topics addressed systematically.
219368121|NCT06916871|OTHER|The experimental group will benefit from structured education which will be carried out by the diabetes nurse|During hospitalization in rehabilitation, the experimental group will benefit from structured education which will be carried out by the diabetes nurse at a rate of 3 sessions for patients on oral anti-diabetics and 5 sessions for patients on insulin.
219368122|NCT06916273|DRUG|PA9159 Inhalation aerosol, 60 μg one day treatment|single dose of PA9159 (60 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 2 puffs.
219368123|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg one day treatment|single dose of PA9159 (120 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 4 puffs.
219368124|NCT06916273|DRUG|PA9159 Inhalation aerosol, 240 μg one day treatment|single dose of PA9159 (240 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 8 puffs.
219746269|NCT06637579|OTHER|Task-oriented training for gross motor functioning|Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
219746270|NCT06641960|DRUG|Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
219746271|NCT06641960|PROCEDURE|Traditional treatment|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
219368125|NCT06916273|DRUG|PA9159 Inhalation aerosol, 300 μg one day treatment|single dose of PA9159 (300 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 10 puffs.
219746272|NCT06639022|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219746273|NCT06639022|PROCEDURE|Erector spinae plane block|"Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219746274|NCT06639022|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
219746275|NCT06641648|DRUG|NK cell|Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
219746276|NCT06637696|OTHER|Blood Culture Bundle|In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
219746277|NCT06640270|DEVICE|Diabetes Treatment|Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
219746278|NCT06641583|BEHAVIORAL|LEGO|"The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models."
219746279|NCT06641583|OTHER|Controllo|This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
219746280|NCT06637683|COMBINATION_PRODUCT|LiveSpo COLON|LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
219746281|NCT06637683|OTHER|Routine treatment|The standard internal medicine treatment protocol of the hospital
219746282|NCT06644508|OTHER|Strict adherence to European guidelines|"The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met."
219368126|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg 7-day treatment|Repeated doses of PA9159 (120 μg/inhaler spray) i is administered by inhalation through an inhaler via the mouth, with 4 puffs, twice a day.
219368127|NCT06916273|DRUG|Placebo, the same Inhalation aerosol solution without PA9159 active ingredient|Placebo is delivered via the mouth through an inhaler with the same volume as the corresponding PA9159 dose group
219368128|NCT06912672|DIAGNOSTIC_TEST|Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer|The study aims to evaluate the diagnostic performance of the EPIPROBE TAGMe DNA Methylation Detection Kit for the detection of urothelial cancer. This assay utilizes targeted DNA methylation analysis to identify specific epigenetic alterations associated with urothelial malignancies. The performance of the kit will be assessed in terms of sensitivity, specificity, and overall diagnostic accuracy using clinical urine samples from a patient population with hematuria.
219557258|NCT00981799|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
219557259|NCT00981799|DRUG|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
219557260|NCT00981799|DRUG|Methotrexate|"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"
219178794|NCT05777889|OTHER|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
219746283|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of nano-crystalline putty hydroxyapatite.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
219746284|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade without vertical releasing incision.~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of nano-crystalline putty hydroxyapatite..~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
219746285|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
219746286|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and ALB-PRF membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing"
219746287|NCT06644339|DEVICE|Voice assistant|"Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease.~Follow-up and management of disease provided by specialists at participating institutions."
219746288|NCT05935150|PROCEDURE|Omit SLNB|All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
219746289|NCT06643949|DIAGNOSTIC_TEST|Echocardiography|The registry will focus on the diagnostic and prognostic value of of echocardiographic features of patients with takotsubo syndrome
219557261|NCT00981799|DRUG|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
219557262|NCT00687739|DRUG|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
219557263|NCT00687739|DRUG|Estradiol Transdermal|0.075 mg patch per day for 5 months
219557264|NCT00687739|BEHAVIORAL|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
219557265|NCT05728645|DRUG|Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg|Intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before induction of general anesthesia
219557266|NCT05728645|DRUG|Multiple Electrolytes injection of 5 ml/kg|Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
219557267|NCT01190930|DRUG|Cyclophosphamide|Given IV
219557268|NCT01190930|DRUG|Cytarabine|Given IT, IV, or SC
219557269|NCT01190930|DRUG|Dexamethasone|Given orally (PO) or IV
219557270|NCT01190930|DRUG|Doxorubicin Hydrochloride|Given IV
219557271|NCT01190930|OTHER|Laboratory Biomarker Analysis|Correlative studies
219178795|NCT05834257|PROCEDURE|Normal Saline for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).
219368129|NCT06917391|BEHAVIORAL|Wendyverse VR food marketing experience|"In the Wendyverse VR application (app) participants can order from a Wendy's restaurant, play games, meet with others who may be visiting the Wendyverse, and access codes that can be used to obtain free food at physical restaurants."
219557272|NCT01190930|DRUG|Leucovorin Calcium|Given PO
219557273|NCT01190930|DRUG|Mercaptopurine|Given PO
219557274|NCT01190930|DRUG|Methotrexate|Given IT, PO, or IV
219557275|NCT01190930|DRUG|Pegaspargase|Given IV
219557276|NCT01190930|OTHER|Quality-of-Life Assessment|Ancillary studies
219557277|NCT01190930|OTHER|Questionnaire Administration|Ancillary studies
219557278|NCT01190930|DRUG|Thioguanine|Given PO
219557279|NCT01190930|DRUG|Vincristine Sulfate|Given IV
219557280|NCT02095808|PROCEDURE|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
219557281|NCT04650243|DRUG|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 10mg/Kg and 5mg/Kg everyday respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be at least one year.
218990895|NCT05044390|PROCEDURE|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
218990896|NCT02272595|OTHER|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
219746290|NCT06645301|BIOLOGICAL|Group A|BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
219368130|NCT06917391|BEHAVIORAL|Nikeland VR non-food marketing experience|In Nikeland VR app, participants can play sports, try on apparel, and engage with celebrity athletes.
219368131|NCT06912880|PROCEDURE|trans obturator tape surgery|Trans-obturator technique is a more beneficial and a less invasive procedure in treatment of SUI when compared with other techiniques. In this technique, a synthetic mesh tape, which is passing bilaterally through the obturator foramen, is placed underneath the mid part of the urethra.
219368132|NCT06917729|OTHER|CardioBreath|Twice a day for ten minutes,5 days during the week CardioBreath app will be based on Prescription section , using breathing technique Ujjayi Pranayama, based on spontaneous respiratory rate of users, gamified to induce the user to improve performance of the exercises reducing the exercises respiratory exercises
219557282|NCT05479448|OTHER|Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness)|Biological material will be sampled at three time-points. The first time-point will be when patients have been treated with 15 mg of prednisone per day for at least 5 days. A second time-point will be after prednisone was successfully tapered and maintained at 5 mg per day for at least 5 days, a third time point will be 4 weeks after the stop of prednisone. Biosampling is done for cellular analyses, pharmacokinetics and hormone measurements.
219557283|NCT05479448|OTHER|Data collection for exploratory analyses of endogenous steroid hormones|Concentrations of GC, MC, androgens and progestins will be determined and the suppression of cortisol and cortisone upon prednisone treatment will be analyzed.
218990897|NCT02272595|OTHER|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
218990898|NCT03267706|OTHER|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
218990899|NCT05407402|BEHAVIORAL|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
218990900|NCT05407402|BEHAVIORAL|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
218990901|NCT02479178|DRUG|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
218990902|NCT03311724|DRUG|Tirzepatide|Administered SC
218990903|NCT03311724|DRUG|Placebo|Administered SC
218990904|NCT02519036|DRUG|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218990905|NCT02519036|DRUG|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218990906|NCT02519036|DRUG|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218990907|NCT02519036|DRUG|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218990908|NCT02519036|DRUG|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
219178796|NCT05834257|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
219178797|NCT05834257|PROCEDURE|Ringer's Lacatate for fluid resusciation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
219178798|NCT01085253|OTHER|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
219178799|NCT04637620|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of MDD
219368133|NCT06916234|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
219368134|NCT06916234|DRUG|Naproxen Sodium + Codeine Phosphate|Naproxen Sodium + Codeine Phosphate (550mg + 30mg) is a NSAID. It was given to the patients twice a day.
219577617|NCT00361335|DRUG|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
219746291|NCT06645301|BIOLOGICAL|Group B|BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
218990909|NCT02519036|OTHER|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218990910|NCT03636932|DRUG|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
219178800|NCT04637620|DRUG|Sertraline|Use of SSRI as an active comparator
219178801|NCT04637620|DRUG|Placebo Cap|Use of placebo as a comparator
219178802|NCT04648878|OTHER|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
219178803|NCT04648878|OTHER|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
219178804|NCT04648878|OTHER|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
219178805|NCT05116527|DRUG|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
219178806|NCT05116527|DRUG|Placebo|Placebo THC - marijuana flower with no THC content
219178807|NCT05670067|PROCEDURE|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
219557284|NCT05479448|OTHER|Data collection for correlation between clinical defined and lab defined GC responsivness|The time to first relapse, the cumulative steroid dose at 1 year after diagnosis, the need for treatment with steroid sparing agents and the GTI after 1 year will be correlated to the percentage of in vitro inhibition of cytokine concentration by dexamethasone treatment, to the prednisone/prednisolone ratio in plasma, to the percentage of endogenous GC suppression (plasma and urinary cortisol and cortisone) by prednisone treatment. Furthermore, correlations of steroid sensitivity with Mineralocorticoid (MC) and androgens will be investigated.
219557285|NCT05479448|OTHER|Data collection for Prednisone metabolism|Plasma concentrations of prednisone and its active metabolite prednisolone will be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). If changes on prednisone/prednisolone are observed, the quantification of the 6-hydroxylated prednisone/prednisolone metabolites in 24 h urine samples will be performed to estimate their metabolism as well as the ratio of inactive to active GC.
219557286|NCT03145688|BEHAVIORAL|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed \& then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
219577618|NCT00361335|DRUG|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
219577619|NCT04969718|OTHER|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
219368135|NCT06915064|DEVICE|Low- level laser- photobiomodulation therapy|Three patients (30%) received treatment on the left side and seven (70%) on the right side. The treatment was carried out using the EPIC X laser (BIOLASE®), which uses a solid-state diode as a semiconductor source of invisible infrared radiation. The therapy was applied to the masticatory muscles (temporal, masseter, internal pterygoid), to trigger points discovered on palpation and to the intra-articular area of the TMJ (posterior portion through the external ear, superior portion and anterior portion). All patients included in the study underwent four sessions of PBMT-LLL for four consecutive weeks. T
219368136|NCT06916884|DRUG|Desloratadine / Betamethasone in fixed dose|1 tablet, once a day of 5 mg / 0.25 mg
219368137|NCT06916884|DRUG|Desloratadine|1 tablet, once a day of 5 mg
219368138|NCT00260520|DRUG|Dalteparin|
219368139|NCT06917157|DRUG|Administration of antibiotics prophylactically at the time of membrane rupture|"Participants will receive the antibiotic regimen:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
219368140|NCT06917157|DRUG|Administration of antibiotics non-prophylactically at 22 weeks|"Participants will receive latency antibiotics starting 22 weeks 0 days:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
219368141|NCT06916663|BEHAVIORAL|Upper Body Exercise Protocol (UBE)|"Participants randomized to the Upper Body Exercise Group will perform a structured, supervised exercise regimen focused exclusively on the upper extremities and core muscles, while rigorously maintaining foot offloading prescribed for diabetic foot ulcers (DFU). This intervention is delivered face-to-face in hospital-based outpatient rehabilitation centers. Sessions are held three times per week for 12 consecutive weeks (total 36 sessions), with each session lasting 45-60 minutes.~Each UBE session comprises a 10-minute warm-up on an arm ergometer at 40-50% of the participant's heart rate reserve (HRR), followed by a circuit of eight upper body and core exercises."
219368142|NCT06916663|BEHAVIORAL|Combined Non-Weight Bearing Exercise Protocol (CE)|"Participants in the Combined Exercise Group will engage in a structured exercise regimen that integrates upper body, core, and modified lower extremity exercises-all performed in a non-weight bearing or seated position to ensure complete offloading of the affected foot. Sessions are conducted face-to-face in hospital-based rehabilitation centers. Participants attend three sessions per week for 12 weeks (36 sessions total), each lasting 45-60 minutes.~Each session begins with a 10-minute warm-up on an arm ergometer at 40-50% HRR."
219368143|NCT06916663|BEHAVIORAL|Standard Diabetic Foot Ulcer Wound Care (SC)|Participants assigned to the Standard Care Control Group will receive comprehensive DFU wound management in accordance with International Working Group on the Diabetic Foot (IWGDF) guidelines. This includes standard offloading strategies (using Total Contact Cast or removable cast walker), regular weekly wound assessments, and debridement if necessary. Diabetes management education is provided along with routine adjustments and monitoring of the offloading device to ensure proper healing support. No structured exercise intervention is added; however, all aspects of care such as continuous glucose monitoring and vascular assessments will be uniformly applied to allow comparison with the exercise groups.
219368144|NCT06916351|OTHER|Acupressure|Acupressure will be applied to a total of three points: the 4th point of the Large Intestine Meridian (LI4-Hegu point) and the 6th point of the pericardial meridian (PC6- Nei Guan point), located three fingers above the wrist.
219368145|NCT06916351|OTHER|Sham acupressure|Sham acupressure will be applied to three points parallel to HT7, LI4 and PC6, approximately 1-1.5 cm away from the meridians.
219368146|NCT06917430|OTHER|No intervention|No intervention.
219557287|NCT03145688|BEHAVIORAL|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
219746292|NCT06644859|DEVICE|Daily Activity Patterns Using Wearable Tri-Axial Sensors|This intervention uniquely focuses on the prediction of injurious falls by combining daily life gait (DLG) measures (e.g., gait speed, cadence, variability) with daily life physical activity (DLPA) measures (e.g., activity levels, activity fragmentation). Unlike other studies, this analysis leverages data from a large cohort of older women (n=17,466) enrolled in the Women's Health Study (WHS), where participants wore a tri-axial accelerometer for 1 week. Additionally, the study links accelerometer data to long-term health outcomes, specifically fall-related injuries from Centers for Medicare \&amp; Medicaid Services (CMS) records. This is the first study to explore whether combining DLG and DLPA measures, derived from wearable technology, can predict fall-related injuries in an aging population, applying advanced machine learning techniques to this large, anonymized dataset.
219746293|NCT02873052|DEVICE|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
219746294|NCT04886856|BEHAVIORAL|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
219746295|NCT04886856|BEHAVIORAL|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
219746296|NCT06232993|OTHER|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
219746297|NCT06232993|OTHER|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
219746298|NCT06232993|OTHER|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
219746299|NCT04318938|DRUG|Brigatinib|Treatment with Brigatinib
219746300|NCT04318938|DRUG|Tyrosine kinase inhibitor|Treatment with any TKI
219746301|NCT02609503|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
219746302|NCT02609503|RADIATION|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
219178808|NCT05670067|PROCEDURE|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
219178809|NCT05028634|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
219557288|NCT01207856|BEHAVIORAL|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
219746303|NCT06162507|BIOLOGICAL|CM310|CM310 injection
219746304|NCT02808611|DRUG|propranolol|Reduction of the ANS response
219178810|NCT05028634|BIOLOGICAL|Pneumococcal polysaccharide vaccine|PPSV23
219746305|NCT02808611|DRUG|Placebo|
219746306|NCT01810172|DEVICE|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
219746307|NCT01810172|DEVICE|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
219746308|NCT01555424|DIETARY_SUPPLEMENT|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
219178811|NCT05028634|BIOLOGICAL|Seasonal influenza vaccine|Seasonal influenza vaccine
219178812|NCT05653427|DRUG|Amivantamab|Amivantamab will be administered intravenously.
219178813|NCT05398484|DRUG|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
219178814|NCT05398484|DRUG|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
219557289|NCT01207856|BEHAVIORAL|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
219557290|NCT01207856|OTHER|no intervention|no intervention
219557291|NCT02404558|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
219557292|NCT02404558|DRUG|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
219557293|NCT01069614|DEVICE|TopClosure 3S System|
219557294|NCT03186716|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
219557295|NCT03186716|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
219557296|NCT03397004|DRUG|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
219557297|NCT03397004|DRUG|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
219557298|NCT05689333|DEVICE|Vista Vitrectomy Probe|Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector
219557299|NCT02988882|DRUG|Dexamethasone|
219557300|NCT02988882|OTHER|Placebo Vehicle|
219557301|NCT00514150|DRUG|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
219557302|NCT00514150|DRUG|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
219557303|NCT02564016|DRUG|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
219557304|NCT02564016|OTHER|Capped Epidural|epidural will be capped with no saline infusion.
219557305|NCT06094764|DEVICE|Group A|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
219557306|NCT06094764|DEVICE|Group B|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
219557307|NCT03031951|BEHAVIORAL|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
219557308|NCT01653405|OTHER|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
219178815|NCT05398484|BEHAVIORAL|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
219178816|NCT06445985|OTHER|Hydrotherapy|Physiotherapy led pool session
219191533|NCT04907669|OTHER|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
219557309|NCT00213005|DRUG|Carraguard (PC-515)|
219557310|NCT05793645|DEVICE|personalized care plan|Algorithm that defines personalized care plan
219557311|NCT03298516|DRUG|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
219557312|NCT03298516|DRUG|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
219557313|NCT01917227|BEHAVIORAL|Video|
219557314|NCT03240991|OTHER|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
219557315|NCT03174158|DRUG|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
219557316|NCT03174158|BEHAVIORAL|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
219557317|NCT03174158|BEHAVIORAL|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
219746309|NCT01555424|DIETARY_SUPPLEMENT|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
219746310|NCT05713838|DRUG|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
219746311|NCT05713838|DRUG|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
219746312|NCT05713838|DRUG|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
219746313|NCT05713838|RADIATION|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
219746314|NCT01787747|DRUG|AVP-786 Dose 1|
219746315|NCT01787747|DRUG|AVP-786 Dose 2|
219746316|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 1|
219746317|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 2|
219746318|NCT01787747|DRUG|AVP-786 Dose 2/Q Dose 2|
219746319|NCT01787747|DRUG|AVP-923|
219746320|NCT02306252|OTHER|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
219746321|NCT02671292|BEHAVIORAL|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
219746322|NCT02671292|OTHER|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
219746323|NCT05994300|RADIATION|Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy|"Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2"
219746324|NCT02262663|DRUG|Vilaprisan (BAY1002670)|
219746325|NCT04148209|DRUG|PF-07081532|Participants will receive single ascending doses PF-07081532
219746326|NCT04148209|DRUG|Placebo|Participants will receive placebo
219178817|NCT06470568|BEHAVIORAL|Progressive Resistance exercise training|"The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions)."
219178818|NCT06188949|DIETARY_SUPPLEMENT|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
219746327|NCT01344655|DRUG|Atimos®|Formoterol 12 μg pMDI
219746328|NCT01344655|DRUG|Serevent™|Salmeterol 25 µg pMDI
219746329|NCT01344655|DRUG|Placebo|placebo
219746330|NCT04363892|OTHER|Optical and infrared imaging|Acquiring images (photographs) of the skin
219746331|NCT05258292|DEVICE|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
219746332|NCT05258292|DRUG|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
218990911|NCT03636932|DRUG|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
218990912|NCT03636932|BIOLOGICAL|Blood sample|Circulating tissue factor assay
218990913|NCT03636932|BIOLOGICAL|Blood sample|The test of pro-coagulant activity of the tissue factor
219178819|NCT06188949|DIETARY_SUPPLEMENT|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
219178820|NCT06188949|DIETARY_SUPPLEMENT|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
219746333|NCT05258292|OTHER|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
219746334|NCT05258292|OTHER|Ovulation kits|Ovulation testing will be done using ovulation kits
219746335|NCT05258292|DEVICE|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
219746336|NCT05258292|OTHER|Keenoa|Food intake will be assessed using the Keenoa phone application
219746337|NCT05258292|OTHER|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
219746338|NCT01969409|DRUG|Rituximab|i.v. rituximab given on two occasions 14 days apart.
219746339|NCT01969409|DRUG|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
219746340|NCT01446523|DRUG|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
219746341|NCT01446523|DRUG|Lactulose|Syrup 30 ml BD for 12 weeks
219746342|NCT06564935|DRUG|Heptaminol Hydrochloride|heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
219746343|NCT06564935|DRUG|Placebo|Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
219746344|NCT02226653|DRUG|Evacetrapib|Administered orally
219746345|NCT05844319|OTHER|tele-education|The treatment of the patients will be carried out by tele-education method.
219746346|NCT01522274|BEHAVIORAL|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
219746347|NCT01522274|BEHAVIORAL|Health education|Videos
219746348|NCT05007639|OTHER|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
219746349|NCT05007639|OTHER|No public Health intervention programme|
219746350|NCT03078868|DEVICE|Magnetic Resonance Scanner|MRI
219746351|NCT05208437|BEHAVIORAL|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
219746352|NCT05208437|BEHAVIORAL|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
219746353|NCT00767208|OTHER|oral glucose load|oral ingestion of 13C labeled glucose
219746354|NCT03314896|PROCEDURE|Laparoscopic surgery|
219746355|NCT04007549|BEHAVIORAL|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
219746356|NCT05781685|DRUG|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
219746357|NCT05781685|OTHER|Placebo Syrup|Oil-based sublingual product.
219746358|NCT05949892|BEHAVIORAL|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
219746359|NCT03327129|PROCEDURE|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
219178821|NCT03461354|OTHER|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
219178822|NCT03461354|OTHER|Sodium Bicarbonate|Sodium bicarbonate oral rinse
219178823|NCT05426265|DEVICE|MEL-T01|A 12 week intervention with MEL-T01.
219178824|NCT05426265|DEVICE|MEL-S01|A 12 week intervention with MEL-S01.
219557318|NCT00403806|DRUG|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
219557319|NCT00403806|DRUG|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
219557320|NCT00403806|DRUG|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
219178825|NCT03820687|OTHER|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
219178826|NCT03820687|OTHER|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
219178827|NCT03820687|OTHER|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
219191534|NCT05266001|DRUG|GM-CSF|same as arm/group description
219191535|NCT05266001|OTHER|Placebo|same as arm/group description
219191536|NCT06618092|DEVICE|Relisten|Patients will be attended using Relisten
219557321|NCT00403806|DRUG|Saline|Intravenous saline
219557322|NCT04777552|OTHER|diazepam (or equivalence if other benzodiazepine)|
219557323|NCT05063591|OTHER|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
219557324|NCT01380522|DRUG|Metronidazole|Capsules, single-dose, fed
218990914|NCT05479084|OTHER|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
219557325|NCT01380522|DRUG|Flagyl|Capsules, single-dose, fed
219557326|NCT00046839|DRUG|celecoxib|
219557327|NCT00046839|RADIATION|radiation therapy|
219557328|NCT03092167|OTHER|Physical exercises|Physical exercises
219557329|NCT05157750|OTHER|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
219746360|NCT04519567|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
219746361|NCT04519567|BIOLOGICAL|Placebo|Placebo Comparator
219746362|NCT02071732|DEVICE|real repetitive Transcranial Magnetic Stimulation|
219746363|NCT02071732|DEVICE|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
219746364|NCT01648933|RADIATION|Rubidium PET|Myocardial Perfusion Imaging
219746365|NCT03196479|DRUG|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
219557330|NCT05770804|BEHAVIORAL|Face to face education|Face-to-face training was provided and supported by booklets.
219557331|NCT02771392|DRUG|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
219557332|NCT02771392|OTHER|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
219557333|NCT01101386|DRUG|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
219557334|NCT02018796|DRUG|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
219557335|NCT06650189|OTHER|Music intervention|Recorded music created by a certified music therapist
219557336|NCT01546363|OTHER|Blood draw|phlebotomy
219557337|NCT02569281|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
219557338|NCT02569281|OTHER|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
219557339|NCT04898816|PROCEDURE|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
219557340|NCT04898816|PROCEDURE|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
219557341|NCT02099318|OTHER|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
219557342|NCT02099318|OTHER|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
219557343|NCT06257979|OTHER|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~* Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~* The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~* Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
219557344|NCT02417428|DIETARY_SUPPLEMENT|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
219557345|NCT02417428|OTHER|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
219557346|NCT02417428|BEHAVIORAL|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
219178828|NCT03820687|OTHER|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
219557347|NCT02417428|OTHER|without exercise|No exercise program will be assigned to participants.
219557348|NCT05909696|DRUG|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
219557349|NCT03117244|OTHER|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
219557350|NCT03117244|OTHER|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
219557351|NCT03486496|DRUG|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
219557352|NCT03486496|DRUG|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
219557353|NCT00113919|DRUG|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
219557354|NCT05810636|DEVICE|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
219557355|NCT02121717|DRUG|Chiglitazar|Take orally
219557356|NCT02121717|DRUG|Placebo|Take orally
219557357|NCT04985149|OTHER|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude \> 10 Mv, and conduction velocity \> 36 m/sec in sensory response of the sural nerve."
219577620|NCT04969718|OTHER|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
219746366|NCT03196479|DRUG|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
219746367|NCT06205693|PROCEDURE|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
219746368|NCT00205985|DEVICE|Scaphoid screw|Conservative treatment versus application of scaphoid screw
219746369|NCT03270228|OTHER|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
219746370|NCT02318433|DRUG|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
219746371|NCT02318433|DRUG|Saline|
219746372|NCT00437073|DRUG|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
219746373|NCT00437073|DRUG|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
219746374|NCT00437073|DRUG|lapatinib|lapatinib administered 1250mg once daily orally
219746375|NCT03123679|RADIATION|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"1. Patient referred to radiotherapy treatment are evaluated with a baseline PFT \[Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)\].~2. RT simulation at the radiotherapy department and treatment planning.~3. Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~4. Radiotherapy."
219746376|NCT05321745|OTHER|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
218990915|NCT01393496|OTHER|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
218990916|NCT01393496|OTHER|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
218990917|NCT04084665|DRUG|Guselkumab|Guselkumab
218990918|NCT05466162|OTHER|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
219557358|NCT04985149|OTHER|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
219557359|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
219557360|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
219557361|NCT01633307|OTHER|Education|Teaching program
219557362|NCT05633251|BEHAVIORAL|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
219557363|NCT05633251|BEHAVIORAL|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
219557364|NCT05633251|BEHAVIORAL|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
219746377|NCT01275300|DRUG|Aspirin|
219746378|NCT01275300|DRUG|Placebo|
219746379|NCT01275300|DRUG|Niacin|
219746380|NCT03227549|PROCEDURE|Direct Superior Approach|Total hip arthroplasty using direct superior approach
219746381|NCT03227549|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
219746382|NCT03227549|PROCEDURE|Posterior Approach|Total Hip Arthroplasty using posterior approach
219746383|NCT05226195|OTHER|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
219746384|NCT00146822|DEVICE|ENDOTAK RELIANCE G lead|
219746385|NCT03074669|BEHAVIORAL|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
219746386|NCT02522273|DEVICE|EKF Diagnostics 'SensPoint' Lactate Meter|
219746387|NCT01422577|DEVICE|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
219746388|NCT01422577|DEVICE|White light Endoscopy|White light Endoscopy
219557365|NCT05633251|BEHAVIORAL|Control|No intervention
219746389|NCT05706350|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
219746390|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
219746391|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
219746392|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
219746393|NCT05706350|DIETARY_SUPPLEMENT|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
219746394|NCT05611164|DEVICE|Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection|Half of the oocytes will be injected with a sperm selected with SiD's assistance
219557366|NCT06361654|OTHER|The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer|"The measurements will be taken during different climbing sessions, after the warm-up.~The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer."
219746395|NCT05562856|COMBINATION_PRODUCT|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
219746396|NCT04221438|DRUG|Binimetinib|Given PO
219746397|NCT04221438|PROCEDURE|Conventional Surgery|Undergo surgery
219746398|NCT04221438|DRUG|Encorafenib|Given PO
219746399|NCT04221438|OTHER|Fluorothymidine F-18|Given IV
219746400|NCT06325410|PROCEDURE|resection of colorectal cancer|resection of bowel segment and re-anastmosis or stoma formation
219746401|NCT00855101|DRUG|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
219746402|NCT05007704|BEHAVIORAL|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
219746403|NCT06459778|DEVICE|Piezo-ICSI|Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
219557367|NCT04283851|DIAGNOSTIC_TEST|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
219557368|NCT04417959|PROCEDURE|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
219557369|NCT04417959|PROCEDURE|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
219557370|NCT03386461|BEHAVIORAL|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
219557371|NCT03386461|DIETARY_SUPPLEMENT|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
219557372|NCT03386461|DIETARY_SUPPLEMENT|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
219557373|NCT02565836|DRUG|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
219557374|NCT02565836|DRUG|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
219746404|NCT01441492|PROCEDURE|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
219746405|NCT01441492|PROCEDURE|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
219746406|NCT03510533|OTHER|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
219746407|NCT01019915|DEVICE|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
219746408|NCT06250257|DRUG|Bromocriptine mesylate plus standard GDMT|The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
219746409|NCT05049824|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
219746410|NCT05427201|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
219746411|NCT05427201|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
219746412|NCT04147286|DRUG|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
219746413|NCT04147286|DRUG|Placebo oral tablet|Identical placebo
219746414|NCT04275518|DRUG|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
219746415|NCT04275518|DRUG|Azacitidine|75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
219746416|NCT04275518|DRUG|Cytarabine|1g/m\^2 IV QD on Days 3-7 (28-day cycle)
219746417|NCT04581083|DIAGNOSTIC_TEST|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
219746418|NCT04581083|DIAGNOSTIC_TEST|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
219746419|NCT04581083|DIAGNOSTIC_TEST|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
219746420|NCT04581083|DIAGNOSTIC_TEST|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
219746421|NCT05431556|OTHER|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
219746422|NCT05431556|OTHER|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
219746423|NCT05069740|DRUG|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
219746424|NCT05069740|DRUG|Placebo|Placebo for the salsalate intervention
219746425|NCT03206450|PROCEDURE|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
219746426|NCT03206450|OTHER|Laboratory Biomarker Analysis|Correlative studies
219746427|NCT03206450|OTHER|Questionnaire Administration|Ancillary studies
219746428|NCT04414930|DRUG|d-amphetamine|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
219557375|NCT00032227|PROCEDURE|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
219557376|NCT00032227|OTHER|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
219557377|NCT00002976|DRUG|conjugated estrogens|
219557378|NCT05100680|OTHER|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
219557379|NCT05100680|OTHER|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
219746429|NCT04414930|DRUG|Placebo|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
219746430|NCT03865355|OTHER|Non- interventional|Translational, observational study
219746431|NCT05229705|BEHAVIORAL|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
219746432|NCT04869514|PROCEDURE|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
219746433|NCT01681875|OTHER|very low nicotine content cigarettes|
219746434|NCT05335057|BEHAVIORAL|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
219746435|NCT05335057|BEHAVIORAL|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
219746436|NCT05335057|BEHAVIORAL|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
219746437|NCT05335057|BEHAVIORAL|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
219746438|NCT06096363|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
219746439|NCT05923099|DRUG|LEO 138559|LEO 138559 given by injection just under the skin
219746440|NCT05923099|DRUG|Placebo|Placebo given by injection just under the skin
219746441|NCT03947385|DRUG|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
219746442|NCT03947385|DRUG|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
219746443|NCT03947385|DRUG|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
219746444|NCT00272246|PROCEDURE|deep brain stimulation of the internal globus pallidus|
219557380|NCT03087162|DRUG|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
219557381|NCT06677762|PROCEDURE|Irreversible electroporation|Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
219557382|NCT05257694|PROCEDURE|Surgery|hepatectomy
219557383|NCT05257694|PROCEDURE|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
219557384|NCT02571530|DRUG|Intra-arterial Cerebral Infusion of Trastuzumab|
219557385|NCT00356096|DRUG|pramipexole|
219557386|NCT02818296|BEHAVIORAL|Active IU CBM-I|
219557387|NCT02818296|BEHAVIORAL|Control CBM-I|
219557388|NCT00372996|DRUG|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
219557389|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day.
219557390|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
219557391|NCT00372996|DRUG|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
219557392|NCT04440358|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
219746445|NCT03340779|DRUG|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
219557393|NCT04440358|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
219557394|NCT03485716|OTHER|running on a treadmill under normoxia or hypoxia|"* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
219557395|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1"
219557396|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
219557397|NCT04305535|DIETARY_SUPPLEMENT|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
219557398|NCT00890916|DEVICE|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
219557399|NCT05421195|DRUG|corticosteroids therapy|Oral corticosteroids
219557400|NCT05421195|OTHER|Olfactory training|repeat and deliberate sniffing of a set of odorants
219557401|NCT04204590|OTHER|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
219557402|NCT05013723|OTHER|Surveys|Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
219557403|NCT03405064|DRUG|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
219557404|NCT03405064|DRUG|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
219557405|NCT05534113|DRUG|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
219557406|NCT00268164|DRUG|lactobacilus acidophilus & bifidobacterium animalis/lactis|
219557407|NCT01923818|DRUG|rivaroxaban|orally active direct factor Xa inhibitor
219557408|NCT01923818|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
219557409|NCT01923818|DRUG|placebo|
219557410|NCT04429113|DEVICE|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
219557411|NCT00252447|PROCEDURE|Pre-Operative Conformal Radiotherapy|
219557412|NCT01135940|DEVICE|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
219746446|NCT06484881|DIETARY_SUPPLEMENT|Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Probiotic
219746447|NCT06484881|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
219746448|NCT03213951|OTHER|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
219746449|NCT03213951|DIAGNOSTIC_TEST|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
219746450|NCT06043154|OTHER|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
219746451|NCT02344927|OTHER|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
219746452|NCT02344927|OTHER|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
219746453|NCT06674707|OTHER|Agility Training with Foot mobilization.|Agility training with foot mobilization with the frequency of 3 sets of 10 repetitions thrice per week for a total six weeks. Pre and post intervention values will be taken on 1st day and after six weeks. Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. TJM is a grade III Maitland technique and is applied with a high amplitude from the end range and 1s of vibration in the middle range of the joint through a linear motion to where tissue resistance is felt in the prone position, the patient is supported by a towel placed under the foot. Two sets of 5 min total were performed for 6weeks.
219746454|NCT06674707|OTHER|Agility Training without Foot mobilization|Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. Comprising of Hot pack and TENS for 10 minutes and Ultrasound for 5 minutes . Comprising of conventional exercises were given for 3 sessions per week for 6 weeks. It includes semi squat, quadriceps isometric, terminal knee extension with elastic band, terminal knee extension in supine position, and adductor squeeze in crook lying (squeeze the ball).
219368147|NCT06917144|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stimulation sessions were performed using a YINGCHI M-100 Ultimate device with liquid-cooled figure-8 coils.~Patients attended 10-minute sessions daily for 10 consecutive working days. For rTMS, stimulation was delivered at an excitatory frequency of 10 Hz, targeting the M1, contralateral to the side of pain in the facial region.~Each session consisted of the following steps.~* 10 series: 60 pulses per series (600 pulses in total).~* Rest intervals: 60 seconds between series.~* Intensity: 70% of the resting motor threshold (RMT). RMT was determined using single-pulse stimulation over the M1 region controlling the abductor pollicis brevis muscle, localized via neuronavigation. The threshold was de-fined as the lowest stimulator intensity producing a motor-evoked potential amplitude \>50 µV in at least 5 of 10 trials."
219557413|NCT01135940|DEVICE|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
219557414|NCT01181830|DRUG|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
219557415|NCT01181830|DRUG|placebo|administration of 8.1 mmol bid of placebo
219557416|NCT02151149|DRUG|nab-paclitaxel|
219557417|NCT02151149|DRUG|Carboplatin|
219557418|NCT02760433|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
219557419|NCT02760433|DRUG|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
219557420|NCT04647825|OTHER|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
219557421|NCT04531969|OTHER|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
219557422|NCT00296530|DRUG|fluticasone propionate/salmeterol|
219557423|NCT00296530|DRUG|fluticasone propionate|
219557424|NCT00296530|DRUG|montelukast|
219557425|NCT05586724|DRUG|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
219557426|NCT05586724|DRUG|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
219557427|NCT01485718|DIETARY_SUPPLEMENT|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
219746455|NCT06674187|PROCEDURE|Regular|"The stoma surgery will be performed using conventional non-molding suturing techniques. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Perform routine suturing around the stoma without additional mesentery shaping.~3. Form the stoma, ensuring a tight fit of the surrounding tissues."
219746456|NCT06674187|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery will be shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Separate the mesentery around the stoma and shape it into a sturdy support structure.~3. Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~4. Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
219746457|NCT07011225|DIETARY_SUPPLEMENT|Verisol Collagen 2,5 g/day|Patients allocated to this group will consume Verisol Collagen 2,5 g/day for 90 days.
219557428|NCT01485718|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
219746458|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 2,5 g/day|Patients allocated to this group will consume Peptech Collagen 2,5 g/day for 90 days.
219746459|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 10 g/day|Patients allocated to this group will consume Peptech Collagen 10 g/day for 90 days.
219746460|NCT07011225|OTHER|Pulmonary rehabilitation with aerobic and resistance training.|Patients enroled in this group will be submitted to Pulmonary rehabilitation with aerobic and resistance training.
219746461|NCT07011225|DIAGNOSTIC_TEST|Cardiorespiratory test|The patients allocated to this group will be submitted to initial and final evaluations only.
219746462|NCT07009808|DRUG|Nalbuphine 0.20mg/ml(total 30 mg)|In this group, participants will receive an intravenous infusion of Nalbuphine at a concentration of 0.20 mg/ml, which delivers a total of 30 mg over the course of 48 hours. Additionally, 10 mg of Metoclopramide will be administered to manage potential postoperative nausea. This intervention aims to assess the analgesic efficacy and its subsequent effect on psychological outcomes, specifically anxiety and depression, in patients undergoing surgery for ectopic pregnancy.
219746463|NCT07009808|DRUG|Nalbuphine 0.27mg/ml(total 40 mg)|Participants assigned to this group will be treated with an intravenous infusion of Nalbuphine at a concentration of 0.27 mg/ml, resulting in a total dosage of 40 mg administered during the 48-hour postoperative period. They will also receive 10 mg of Metoclopramide to mitigate nausea and vomiting. This intervention is designed to evaluate the effectiveness of this dose in pain management and its influence on anxiety and depression levels post-surgery.
219746464|NCT07009808|DRUG|Nalbuphine 0.33mg/ml(total 50 mg)|In this group, subjects will receive Nalbuphine at a concentration of 0.33 mg/ml, totaling 50 mg, delivered through intravenous infusion for 48 hours. Along with this, 10 mg of Metoclopramide will be included to address potential postoperative discomfort. This intervention seeks to explore how this higher concentration impacts pain relief and subsequent psychological effects, specifically targeting anxiety and depression following ectopic pregnancy surgery.
219746465|NCT06675773|OTHER|Conscious Awareness Development Psychoeducation Program|The Conscious Awareness Development Psychoeducation Program consists of nine sessions. The sessions will be applied once a week and last 90 minutes. The psychoeducation program is prepared based on conscious awareness. Conscious awareness and self-compassion techniques will be used in the sessions. Homework will be given to the participants in each session.
219746466|NCT06673589|BEHAVIORAL|Transcendental Meditation|meditation practice
219746467|NCT06673485|PROCEDURE|Patients received vitamin D and calcium supplementation during the healing period|"The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill, maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paralling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement.~During the healing period, the patients recieved Vitamin D and Calcium Supplements."
219746468|NCT06673485|PROCEDURE|Patients have not received any nutritional supplementation during the healing period.|The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill while maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paraling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement. During the healing period, the patients did not receive vitamin or calcium supplements.
219746469|NCT07010666|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate|25 grams of BHB
219746470|NCT07010666|DIETARY_SUPPLEMENT|Carbohydrate|25 grams of carbohydrate
219746471|NCT07010666|DIETARY_SUPPLEMENT|Caffeine|4 mg/kg of caffeine
219746472|NCT07010900|PROCEDURE|Injection|patients randomized in intervention group will use also penile extender
219746473|NCT06685770|OTHER|Mini mental state assessment test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
218990919|NCT05466162|OTHER|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
218990920|NCT02073760|OTHER|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
218990921|NCT01539850|DEVICE|OMS102|Subjects will receive implanted OMS102 System.
218990922|NCT04177160|BEHAVIORAL|Music|Subjects sit still and listen to preferred music for 5 minutes.
218990923|NCT04177160|BEHAVIORAL|White noise|Subjects sit still and listen to white noise for 5 minutes.
218990924|NCT01309594|PROCEDURE|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
218990925|NCT00844831|DRUG|Lubiprostone|24 mcg bid for 28 days
218990926|NCT01379040|OTHER|Cystic Fibrosis patients|
218990927|NCT03468153|BIOLOGICAL|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
218990928|NCT02076698|PROCEDURE|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
219557429|NCT04993118|OTHER|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
219557430|NCT04993118|OTHER|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
219557431|NCT03310593|DRUG|Cannabidiol|Cannabidiol as active intervention.
219557432|NCT03310593|DRUG|Placebo|Placebo intervention.
219557433|NCT01640041|DEVICE|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
219557434|NCT04021160|DEVICE|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
219557435|NCT04021160|DEVICE|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
219746474|NCT06685770|OTHER|Mini-cog test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
219746475|NCT07009743|DIAGNOSTIC_TEST|MRI contrast-enhancing agents|All patients underwent standard pelvic MRI examinations (1.5T or 3T) with the following sequences: T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) with and without fat suppression; axial, sagittal, and coronal post-contrast T1WI following intravenous administration of gadolinium-based contrast agents (GBCA); functional sequences including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging MRI (DWI-MRI). Enhancement sequences may be omitted if no adnexal masses were identified on T2WI, T1WI, or DWI sequences.
219557436|NCT02183376|DRUG|BI 1356|
219557437|NCT00752076|OTHER|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
219746476|NCT06691438|DEVICE|prostate biopsy|prostate biopsies with virtual reality hypnosis headset
219746477|NCT06690840|DRUG|Atezolizumab in combination with Cyclophosphamide and Vinorelbine|Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
219746478|NCT06686641|DRUG|Local and systemical treatment|Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.
219746479|NCT06689761|DIETARY_SUPPLEMENT|ColCT|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
219746480|NCT06689761|DIETARY_SUPPLEMENT|ColET|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
219746481|NCT06689761|DIETARY_SUPPLEMENT|PlaCT|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
219746482|NCT06689761|DIETARY_SUPPLEMENT|PlaET|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
219746483|NCT04857528|RADIATION|Radiation Treatment With or Without Chemotherapy|Standard care radiation treatment.
219746484|NCT04857528|OTHER|Blood Sample Collection|Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.
219746485|NCT04857528|DIAGNOSTIC_TEST|HPV Genotyping (HPV DNA Test)|A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.
219746486|NCT04857528|DIAGNOSTIC_TEST|Testing Archival Tumor Tissue|Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.
219746487|NCT04857528|OTHER|Physical Exam|A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).
219746488|NCT04857528|DIAGNOSTIC_TEST|Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)|Tests that use computers and/or rotating x-rays to scan/create images of the body.
219746489|NCT07010198|DIAGNOSTIC_TEST|Quantitative HBeAg Testing|Quantitative HBeAg Testing in Population-Based Primary Screening
219746490|NCT07010198|BIOLOGICAL|Measurement Indicators Required for Risk Scoring in HCC Screening Strategies|REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.
219746491|NCT07010198|BIOLOGICAL|Follow-Up Monitoring Parameters|AFP, Liver Ultrasound
219746492|NCT07010549|DEVICE|Hyaluronic Acid injections|Among treatments today available, bio-revitalization is a process which triggers the skin's own, natural collagen production and cell rejuvenation through the injection of hyaluronic acid serums. This substance is hydrophilic, drawing many times its weight in water. As we age, we have less naturally produced HA in our tissues and skin dehydration becomes a telltale sign of aging. The HA owns a great hydrating power, due to this property is widely used in the biorevitalization treatments. Its use results in supple, younger-looking skin with reduced wrinkles and improved elasticity.In bio-revitalization procedures that involve intradermal micro-injections of natural HA, with a molecular weight close to the endogenous one, carried out in correspondence with the imperfections, the viscoelastic properties of HA allow to rehydrate the tissues, allowing to prevent and contrast the aging process skin and promote their remodeling.
219746493|NCT06690229|DRUG|glass ionomer cement|A cement used for crown cementation
219746494|NCT06690229|DRUG|self-adhesive resin cement|A cement used for crown cementation
219746495|NCT06690229|DRUG|resin modified glass ionomer cement|A cement used for crown cementation
219746496|NCT01647256|DRUG|Nikkomycin Z|Capsule, 500 mg, single-dose
219746497|NCT04732468|BIOLOGICAL|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
219746498|NCT04732468|DRUG|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
219746499|NCT04657068|DRUG|ART0380|Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
219746500|NCT04657068|DRUG|Gemcitabine|Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
219746501|NCT04657068|DRUG|Irinotecan|Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
219746502|NCT06694051|PROCEDURE|marking|axis marking
219746503|NCT06694077|DRUG|Bupivacaine with Dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
219746504|NCT06694077|DRUG|Bupivacaine only|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
219746505|NCT06695585|DRUG|Lidocaine 2% without vessel constrictor|different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
219746506|NCT06689774|BEHAVIORAL|Cognitive-Motivational Feedback|Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.
219746507|NCT06689774|BEHAVIORAL|Staff Tobacco Quit Line Referral Implementation Support|Salvation Army personnel will receive training and will be engaged in efforts to plan, evaluate, adapt, and sustain tobacco treatment referral as part of the social services they provide to adult Salvation Army service consumers who use tobacco. Implementation support will take the form of ongoing engagement of an outreach specialist with a team of Salvation Army personnel and consumers who lead Quit Line referral efforts in the Salvation Army.
219746508|NCT06689774|BEHAVIORAL|Consumer Incentives for Immediate Referral to a Tobacco Quit Line|Salvation Army personnel will offer an incentive to adult consumers who use tobacco to encourage immediate acceptance of a live call with the Wisconsin Tobacco Quit Line. The incentive will be designed by Salvation Army personnel to fit the local context and to be sustainable over time, such as extra access to existing support or resources.
219746509|NCT06688188|DRUG|68Ga-JH12|The dose will be 148-222 MBq given intravenously.
219746510|NCT06690125|DIAGNOSTIC_TEST|Classical and computerized assessment|"Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)"
219746511|NCT06686628|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
219746512|NCT06686628|DRUG|Midazolam|Pharmaceutical form: Solution Route of administration: Oral
218990929|NCT02076698|DRUG|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
219746513|NCT06686628|DRUG|Caffeine|Pharmaceutical form: Tablet Route of administration: Oral
219746514|NCT06686628|DRUG|Metoprolol|Pharmaceutical form: Tablet Route of administration: Oral
219746515|NCT06686628|DRUG|Omeprazole|Pharmaceutical form: Capsule Route of administration: Oral
219746516|NCT06686628|DRUG|Warfarin|Pharmaceutical form: Tablet Route of administration: Oral
219746517|NCT05868655|OTHER|Exercise with Video-Based|A program of stability and balance exercises will be provided
219746518|NCT05868655|OTHER|Standart exercise-Home-Based|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
219746519|NCT06695338|PROCEDURE|Guided Bone Regeneration (Submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (submerged approach)
219746520|NCT06695338|PROCEDURE|Guided Bone Regeneration (Non-submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (Non submerged Approach)
219746521|NCT06695611|OTHER|Increase systolic blood pressure|"To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic"
219557438|NCT05653362|DEVICE|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
219557439|NCT05653362|DEVICE|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
219557440|NCT03023189|DRUG|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
219746522|NCT06695611|OTHER|Decrease systolic blood pressure|"To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight"
219746523|NCT06695741|DRUG|Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
219746524|NCT02434614|DRUG|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
219746525|NCT02434614|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
219746526|NCT02434614|DRUG|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
219746527|NCT02471677|DRUG|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
219746528|NCT02471677|DRUG|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
219746529|NCT05952323|OTHER|Teach-back|According to the prepared educational materials for medical devices, students will be trained using the teach-back method.
219746530|NCT05952323|OTHER|Video-assisted teaching|Students will be sent educational videos related to medical devices and asked to watch them.
219746531|NCT04340258|DEVICE|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
219557441|NCT03023189|DRUG|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
219557442|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (25 mg/100 kcal )|
219557443|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (34 mg/100 kcal)|
219557444|NCT02092857|DIETARY_SUPPLEMENT|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
219557445|NCT06116396|GENETIC|Genetic analysis on isolated cells|Isolation of cells from blood and urine
219557446|NCT05122858|PROCEDURE|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
219557447|NCT05122858|PROCEDURE|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
219557448|NCT03099590|DIETARY_SUPPLEMENT|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
219557449|NCT03099590|DIETARY_SUPPLEMENT|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
219557450|NCT01236495|DRUG|spinal morphine 0.3 mg|spinal morphine 0.3 mg
219557451|NCT01236495|DRUG|spinal morphine 0.2 mg|spinal morphine 0.2 mg
219557452|NCT06679595|OTHER|Pilot project paediatric transmural care|The implementation of pilot projects for transmural care for chronically ill children
219557453|NCT02199379|DRUG|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
219557454|NCT01872507|OTHER|Biofeedback training|usual treatment +12 biofeedback training
219746532|NCT04340258|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
219557455|NCT04674228|OTHER|Electronic Health Record Review|Review of medical records
219557456|NCT01292837|DRUG|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
219557457|NCT04162327|DRUG|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
219557458|NCT04162327|DRUG|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
219557459|NCT05332691|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
219557460|NCT04189120|PROCEDURE|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
219557461|NCT04370444|DEVICE|Phallus Length Reducer|Phallus Length Reducer
219557462|NCT04370444|OTHER|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
219557463|NCT01456260|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
219557464|NCT01456260|DRUG|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
219746533|NCT06742762|DRUG|AZD5004|Dose 1
219746534|NCT05995665|DEVICE|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
219746535|NCT05995665|OTHER|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
219746536|NCT00177632|BEHAVIORAL|behavioral weight loss|
219746537|NCT03094273|PROCEDURE|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
219557465|NCT01456260|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
219746538|NCT01423890|GENETIC|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
219746539|NCT03780322|DEVICE|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
219557466|NCT01456260|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
219746540|NCT03780322|OTHER|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
219746541|NCT02541201|DIETARY_SUPPLEMENT|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
219746542|NCT02541201|DIETARY_SUPPLEMENT|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
219557467|NCT01456260|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
219557468|NCT01456260|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
219557469|NCT03949062|DRUG|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
219557470|NCT03949062|DRUG|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
219557471|NCT03949062|DRUG|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
219746543|NCT04279093|OTHER|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
219557472|NCT02834962|PROCEDURE|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
219746544|NCT06905340|PROCEDURE|NOL (Nociception Level Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by NOL during general anesthesia in the experimental arm.
219746545|NCT06905340|OTHER|Control (Standard treatment)|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist
219746546|NCT04945681|BIOLOGICAL|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 5 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
219746547|NCT05690464|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
219746548|NCT05690464|DIETARY_SUPPLEMENT|placebo|placebo
219746549|NCT05855044|OTHER|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
219557473|NCT02834962|PROCEDURE|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
219746550|NCT06336213|DRUG|Ampicillin-sulbactam|If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
219746551|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
219746552|NCT04188548|DRUG|LY3484356|Administered orally
219746553|NCT04188548|DRUG|Abemaciclib|Administered orally
219746554|NCT04188548|DRUG|Everolimus|Administered orally
219746555|NCT04188548|DRUG|Alpelisib|Administered orally
219746556|NCT04188548|DRUG|Trastuzumab|Administered intravenously
219746557|NCT04188548|DRUG|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
219746558|NCT04188548|DRUG|Pertuzumab|Administered intravenously
219746559|NCT05583890|DEVICE|Continuous glucose monitors|Participants will wear continuous glucose monitors for a 7 day period.
219746560|NCT05583890|DEVICE|Activity tracker|Participants will wear the activity tracker for a 7 day period.
219746561|NCT05583890|BEHAVIORAL|Food Diary|Participants will complete a food diary of everything they eat for 7 days.
219746562|NCT05583890|BEHAVIORAL|Questionnaires|Participants will complete FACT-Hep, DiPcare-Q and health inequality related questions.
219557474|NCT03755739|DRUG|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
219746563|NCT05753683|BEHAVIORAL|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
219746564|NCT05753683|BEHAVIORAL|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
219746565|NCT05496972|BEHAVIORAL|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
219746566|NCT05851417|DEVICE|Fast Field-Cycling (FFC) imaging|FFC scan
219746567|NCT00468247|DEVICE|Navigator|Navigator circulatory mgt system
219557475|NCT05889039|DEVICE|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
219557476|NCT05889039|PROCEDURE|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
219557477|NCT05889039|PROCEDURE|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
219557478|NCT03680716|DRUG|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
219746568|NCT00468247|OTHER|Conventional care|Conventional haemodynamic care
219746569|NCT05354219|OTHER|Imaging|Imaging with 3 iris cameras
219746570|NCT06040788|PROCEDURE|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
219746571|NCT02115087|PROCEDURE|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
219746572|NCT02115087|DRUG|Morphine|
219746573|NCT02323711|DEVICE|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
219746574|NCT03514134|BEHAVIORAL|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
219557479|NCT03680716|DRUG|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
219746575|NCT03514134|BEHAVIORAL|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
219746576|NCT02471144|BIOLOGICAL|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
219746577|NCT02471144|BIOLOGICAL|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
219746578|NCT02471144|BIOLOGICAL|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
219557480|NCT04440696|DRUG|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
219557481|NCT04440696|DRUG|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
219746579|NCT02471144|BIOLOGICAL|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
219746580|NCT04271800|BIOLOGICAL|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
219746581|NCT02311803|PROCEDURE|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
219746582|NCT02311803|PROCEDURE|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
219557482|NCT04440696|DRUG|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
219746583|NCT02572531|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
219746584|NCT02572531|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
219746585|NCT05880212|OTHER|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
219746586|NCT05880212|OTHER|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
219746587|NCT04883476|OTHER|Observation study only|
219746588|NCT01809665|DEVICE|ICD/CRT-P therapy|
219746589|NCT01809665|OTHER|MRI|
219746590|NCT03199183|RADIATION|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
219746591|NCT03199183|OTHER|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
219746592|NCT03199183|GENETIC|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
219746593|NCT00003645|DRUG|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
219746594|NCT00003645|DRUG|Leuprolide Acetate|50 mg tablet orally daily for 12 months
219746595|NCT02574793|DEVICE|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
219746596|NCT04402307|OTHER|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
219746597|NCT01888861|DIETARY_SUPPLEMENT|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
219746598|NCT01888861|DRUG|placebo|the patients in this arm were received 900mg placebo through NG tube.
219557483|NCT04681586|DEVICE|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
219557484|NCT04681586|DEVICE|dim red light|using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
219746599|NCT06800209|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain.
219746600|NCT06800209|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
219746601|NCT02199912|PROCEDURE|Biopsy of adipose and muscular tissue|
219746602|NCT02199912|OTHER|Blood sampling|
219746603|NCT02199912|OTHER|Calorimetry|
219746604|NCT02199912|OTHER|Impedance measure|Evaluation of physical composition (non-invasive method)
219557485|NCT05378308|OTHER|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
219368148|NCT06917144|DEVICE|Sham Stimulation|"Sham Stimulation:~The same device and protocol used for intervention protocol with Repetitive Transcranial Magnetic Stimulation were used for sham stimulation, but no active stimulation was delivered. The equipment produced identical sounds and appearances, thereby ensuring blinding."
219557486|NCT01462578|DRUG|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
219746605|NCT02199912|OTHER|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
219746606|NCT02199912|OTHER|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
219746607|NCT02199912|OTHER|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
219557487|NCT06163937|OTHER|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219557488|NCT06163937|OTHER|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219368149|NCT06917625|DIAGNOSTIC_TEST|Imaging|The participants will be assessed with a brain MRI and will performed a neurophysiological test to evaluate executive functions
219557489|NCT06163937|OTHER|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219557490|NCT01138345|GENETIC|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
219557491|NCT01138345|GENETIC|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
219557492|NCT01138345|OTHER|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
219557493|NCT01138345|OTHER|medical chart review|perform medical chart review for all subjects
219178829|NCT03584945|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
219178830|NCT03584945|OTHER|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
219178831|NCT05675969|OTHER|Blood sample|Collection of 2 additional tubes of 4.5mL of citrate blood
219178832|NCT06442592|OTHER|Blood sampling|An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.
219368150|NCT06916403|DRUG|Intravenous Ketamine Infusions|Ketamine will be slowly infused with the routine target dose 1.5-2 mg/kg over 3-4 hours.
219368151|NCT06917209|OTHER|CBT-CD psychotherapy|9 weekly sessions of CBT-CD psychotherapy
219368152|NCT06935526|OTHER|The mobile training program and telephone follow-ups|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. All sections were shared with the intervention group. After the pre-test, intervention group patients could log in to M-ICDEP anytime using their email and password, accessing content repeatedly during the three-month follow-up. The researcher conducted telephone follow-ups in the second, fifth, and eighth weeks, evaluating patients using the Telephone Calls Monitoring Form. The information given to the patients during the telephone conversation was continued within the limited of the training program prepared within the scope of M-ICDEP.
219557494|NCT01138345|OTHER|questionnaire administration|each cohort will be given the same questionnaire
219557495|NCT04531527|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
219178833|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (CA)|The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.
219557496|NCT06277076|PROCEDURE|Computer Implant guided Surgery|Dental implant placed using printed guide after a digital planification on a superimposed 3D surface scan and a 3D Cone Beam imaging of the jaw.
219746608|NCT02199912|OTHER|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
219746609|NCT02199912|OTHER|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
219746610|NCT00943137|DRUG|5-Fluorouracil|"Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
219557497|NCT04736862|DEVICE|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
219557498|NCT04736862|DEVICE|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
219557499|NCT00411268|DRUG|OROS hydromorphone HCI SR (slow release)|
219557500|NCT04346862|DRUG|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
219557501|NCT04346862|DRUG|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
219557502|NCT02445846|DEVICE|dual HIV/syphilis rapid diagnostics tests|
219557503|NCT02180230|DEVICE|Shorty implants|Dental implant insertion to maxilla or mandible
219557504|NCT00142116|DRUG|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
219557505|NCT00142116|DRUG|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
219557506|NCT03514355|BEHAVIORAL|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
219557507|NCT05491850|OTHER|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
219557508|NCT00061464|DRUG|pemetrexed|
219557509|NCT00061464|DRUG|gemcitabine|
219557510|NCT02797379|OTHER|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
219557511|NCT05717387|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
219557512|NCT05717387|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
219557513|NCT00362687|DRUG|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
219557514|NCT00362687|DRUG|FTC alone|emtricitabine 200 mg
219178834|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (Nantes)|The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.
219178835|NCT06442592|OTHER|Assessment of the parental stress|Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.
219557515|NCT00362687|PROCEDURE|No HAART|No HAART
219557516|NCT04629170|DRUG|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
219557517|NCT04629170|DRUG|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
219557518|NCT02287636|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
219557519|NCT02287636|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
219557520|NCT02287636|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
219557521|NCT02287636|PROCEDURE|positron emission tomography|Undergo PET/MRI
219557522|NCT02287636|PROCEDURE|magnetic resonance imaging|Undergo PET/MRI
219557523|NCT05086770|DEVICE|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
219557524|NCT05086770|DEVICE|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
219557525|NCT04162587|OTHER|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
219557526|NCT04162587|OTHER|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
219557527|NCT04162587|OTHER|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
219557528|NCT04162587|OTHER|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
219557529|NCT02876133|DEVICE|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
219557530|NCT02876133|DEVICE|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
219557531|NCT03045133|DRUG|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
219557532|NCT03045133|DRUG|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
219557533|NCT01881737|DRUG|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
219557534|NCT02102932|DRUG|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
219557535|NCT02102932|DRUG|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
219178836|NCT05122325|DEVICE|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
219368153|NCT06935526|OTHER|Only a two-page summary section of M-ICDEP|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. Only a two-page summary section were shared with the control group. After the pre-test, control group patients could log in to M-ICDEP anytime using their email and password, accessing the summary section repeatedly during the three-month follow-up. Routine outpatient follow-up was continued for the control group without any other intervention.
219557536|NCT02102932|DRUG|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
219557537|NCT02102932|DRUG|850 mg metformin|850mg metformin tablet
219557538|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
219557539|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
219557540|NCT02102932|DRUG|850 mg metformin|850 mg metformin
219557541|NCT02102932|DRUG|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
219557542|NCT02102932|DRUG|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
219557543|NCT02102932|DRUG|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
219557544|NCT02102932|DRUG|500 mg metformin|500 mg metformin
219557545|NCT02102932|DRUG|500 mg metformin|500 mg metformin
219557546|NCT01562132|DRUG|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
219557547|NCT01562132|DRUG|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
219746611|NCT01927614|RADIATION|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
219746612|NCT04725838|DEVICE|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
219557548|NCT00982228|DRUG|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
219557549|NCT00982228|DRUG|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
219746613|NCT03929679|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219557550|NCT00982228|DRUG|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
219557551|NCT04518553|DRUG|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
219557552|NCT04518553|DEVICE|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
219557553|NCT06016153|OTHER|Software based feedback|Feedback is given by the data of a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary).
219557554|NCT06016153|OTHER|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
219557555|NCT02250651|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
219557556|NCT02250651|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
219557557|NCT02250651|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
219557558|NCT02250651|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
219557559|NCT06458751|OTHER|electrophysiological study|Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
219557560|NCT06458751|DEVICE|electromyograph|surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
219557561|NCT00850447|OTHER|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
219557562|NCT00850447|OTHER|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
219368154|NCT04876352|OTHER|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
219557563|NCT05207605|OTHER|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
219368155|NCT04876352|OTHER|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
219557564|NCT05207605|OTHER|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
219746614|NCT01788878|BEHAVIORAL|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
219368156|NCT04876352|OTHER|No intervention|Only baseline evaluations, without longitudinal assessment
219557565|NCT04913545|DIAGNOSTIC_TEST|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
219746615|NCT04284111|DEVICE|Orthokeratology lenses|Orthokeratology lenses
219746616|NCT00107575|BEHAVIORAL|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
219746617|NCT00107575|OTHER|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
219746618|NCT05024344|PROCEDURE|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
219746619|NCT05024344|DRUG|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
219746620|NCT05024344|DRUG|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
219557566|NCT03496298|DRUG|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
219557567|NCT03496298|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
219557568|NCT01792453|OTHER|Spring water|
219746621|NCT05725031|DRUG|Ephedrine|70 μg/kg as pretreatment
219746622|NCT05725031|DRUG|Rocuronium 0.6|0.6 mg/kg
219557569|NCT01658995|DRUG|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
219746623|NCT05725031|DRUG|Rocuronium 0.8|0.8 mg/kg
219557570|NCT01658995|DRUG|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
219746624|NCT05725031|DRUG|Rocuronium 1.2|1.2 mg/kg
219746625|NCT03768336|OTHER|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
219746626|NCT03768336|OTHER|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
219746627|NCT06263816|DRUG|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
219746628|NCT06263816|OTHER|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
219746629|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
219557571|NCT05798637|OTHER|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
219368157|NCT05145465|OTHER|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
219368158|NCT05539014|OTHER|Data collection|Prospectif data collection
219368159|NCT02299193|BEHAVIORAL|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
219368160|NCT02299193|BEHAVIORAL|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
219368161|NCT05237557|BEHAVIORAL|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
219368162|NCT04920409|OTHER|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
219368163|NCT04920409|OTHER|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
219368164|NCT03728088|OTHER|Rating scales concerning non-technical attributes|
219368165|NCT04256967|OTHER|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
219368166|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
219368167|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
219368168|NCT02591615|DRUG|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
219368169|NCT02591615|DRUG|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
219368170|NCT02591615|DRUG|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
219746630|NCT01697371|RADIATION|Proton Radiation|
219746631|NCT04551495|DRUG|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
219746632|NCT04551495|DRUG|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
219746633|NCT04551495|DRUG|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
219746634|NCT05894629|BEHAVIORAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
219746635|NCT05894629|BEHAVIORAL|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
219746636|NCT01224288|PROCEDURE|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
219746637|NCT05109325|BEHAVIORAL|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing \[MI\] + cognitive behavioral therapy \[CBT\] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
219557572|NCT00875082|DRUG|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
219557573|NCT00875082|DRUG|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
219557574|NCT01438476|PROCEDURE|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
219368171|NCT02591615|DRUG|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
219368172|NCT04306874|DIETARY_SUPPLEMENT|Ensure Max Protein|Liquid shake with 30 g protein per serving
219368173|NCT01091350|DEVICE|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
219368174|NCT01091350|DEVICE|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
219368175|NCT03429478|OTHER|Preoperative application of a bluetooth enabled Headphones.|A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
219368176|NCT03706703|DRUG|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
219368177|NCT03706703|DRUG|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
219368178|NCT03706703|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
219746638|NCT05125172|OTHER|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
219746639|NCT04245098|PROCEDURE|Carpal tunnel syndrome surgery|Biopsy
219746640|NCT03977155|DRUG|BOS-589|oral tablets
219746641|NCT03977155|DRUG|Placebo|oral tablets
219368179|NCT03706703|DRUG|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
219746642|NCT06252584|DRUG|Vaccines, Peptide|Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
219746643|NCT03620396|PROCEDURE|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
219746644|NCT00010478|PROCEDURE|Acupuncture|
219746645|NCT02829372|DRUG|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
219746646|NCT03943277|OTHER|No intervention, observational study|No intervention observational study
219368180|NCT00102310|DRUG|YM443|
219746647|NCT04667689|BEHAVIORAL|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
219746648|NCT06959342|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS sessions on five consecutive days for 20 minutes.
219746649|NCT06959342|BEHAVIORAL|Inhibition Training|Computerized Training of inhibitory control (Go-/No-Go task with pictures of preferred alcohol) on five consecutive days.
219746650|NCT00775658|DRUG|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
219368181|NCT01239407|BEHAVIORAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2\. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3\. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
219368182|NCT04828863|BEHAVIORAL|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
219368183|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
219557575|NCT01438476|PROCEDURE|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
219557576|NCT01438476|BEHAVIORAL|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
219557577|NCT01438476|BEHAVIORAL|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
219557578|NCT04832776|DRUG|Cetuximab|one group plus cetuximab
219746651|NCT00775658|DRUG|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
219746652|NCT03502681|DRUG|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"
219746653|NCT03502681|DRUG|Avelumab|Days 1, 15 Avelumab (10mg/kg)
219746654|NCT03720366|DRUG|enasidenib|enasidenib
219746655|NCT03720366|DRUG|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
219746656|NCT03720366|DRUG|Arm 2 Probes|digoxin and rosuvastatin
219746657|NCT03720366|DRUG|Arm 3 probes|pioglitazone
219746658|NCT05495438|OTHER|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
219746659|NCT04371055|OTHER|7-day Holter ECG|7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
219746660|NCT04371055|OTHER|Implantable cardiac monitor|Continuous rhythm monitoring using an implantable cardiac monitor
219746661|NCT04371055|OTHER|Standard of care|Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
219746662|NCT06790303|DRUG|Feladilimab|Feladilimab will be administered.
219746663|NCT06790303|DRUG|Ipilimumab|Ipilimumab will be administered
219746664|NCT05311397|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
219746665|NCT06497140|DRUG|Ethiodized Oil-based emulsion|Embolization of genicular arteries
219746666|NCT06497140|PROCEDURE|Sham-operation|Mimicked catheterization and embolization of genicular arteries
219746667|NCT03413995|DRUG|Rucaparib|Continuous dosing
219746668|NCT06481423|BEHAVIORAL|dCBT-I|A digital cognitive behavioral intervention course that addresses multiple aspects such as basic sleep knowledge, sleep hygiene, sleep behaviors, improving negative cognition, and improving emotions. The intervention is delivered through video, audio, and text formats.
219746669|NCT06481423|BEHAVIORAL|Relaxing music|Participants can freely listen relaxing music
219746670|NCT05845307|DRUG|Control Group|Given by PO
219746671|NCT05845307|DRUG|TTI-101|Given by PO
219746672|NCT04721691|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
219746673|NCT04721691|OTHER|Placebo|Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.
219746674|NCT02007161|DRUG|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
219178837|NCT05122325|DEVICE|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
219368184|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
219368185|NCT05288582|DEVICE|NovaTears|Over-the-counter eye drop
219368186|NCT02379325|BEHAVIORAL|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
219368187|NCT02379325|BEHAVIORAL|pamphlets material|Given pamphlets material on smoking and complication
219368188|NCT05277974|DRUG|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
219368189|NCT03339492|DEVICE|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
219368190|NCT01922921|BIOLOGICAL|HER-2/neu Intracellular Domain Protein|Given ID
219368191|NCT01922921|OTHER|Laboratory Biomarker Analysis|Correlative studies
219368192|NCT01922921|BIOLOGICAL|Pertuzumab|Given per standard of care
219368193|NCT01922921|OTHER|Placebo|Given PO
219368194|NCT01922921|BIOLOGICAL|Polysaccharide-K|Given PO
219368195|NCT01922921|BIOLOGICAL|Trastuzumab|Given per standard of care
219368196|NCT01332708|BEHAVIORAL|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
219368197|NCT04574999|DRUG|Estriol|Gel for vaginal application
219368198|NCT04574999|OTHER|Placebo|Gel for vaginal application
219368199|NCT02862314|BIOLOGICAL|Blood sample|
219557579|NCT04832776|DRUG|Bevacizumab|one group plus bevacizumab
219746675|NCT05268861|BEHAVIORAL|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
219746676|NCT05268861|BEHAVIORAL|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
219368200|NCT02933918|OTHER|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
219368201|NCT01258920|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
219368202|NCT00000979|DRUG|Zidovudine|
219368203|NCT00000979|DRUG|Didanosine|
219368204|NCT00770848|DRUG|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
219368205|NCT00770848|DRUG|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
219368206|NCT00770848|DRUG|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
219368207|NCT00770848|DRUG|Placebo|Placebo
219368208|NCT00770848|DRUG|Prednisone|5 mg orally BID
219368209|NCT00709826|DRUG|gemcitabine|Gemcitabine: per package insert.
219368210|NCT00709826|DRUG|placebo|placebo: 100 mg tablets, 400 mg/day
219368211|NCT00709826|DRUG|Erlotinib|Erlotinib - per package insert.
219368212|NCT00709826|DRUG|apricoxib|apricoxib: 100mg tablets, given orally
219368213|NCT03320655|OTHER|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
219368214|NCT03320655|OTHER|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
219368215|NCT00192374|BIOLOGICAL|CAIV-T, Liquid|
219557580|NCT04832776|DRUG|FOLFOXIRI|FOLFOXIRI
219557581|NCT03316976|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
219557582|NCT01165476|DRUG|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
219557583|NCT01186562|DRUG|Sitagliptin|100 mg PO daily
219557584|NCT01186562|DRUG|Placebo|Placebo
219368216|NCT05395676|DEVICE|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
219746677|NCT03907202|DRUG|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
219746678|NCT06549777|BEHAVIORAL|SE-group|Psychoeducation and information about treatment possibilities + SE-treatment
219368217|NCT06075225|DRUG|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
219368218|NCT03631927|OTHER|Observation|Observation
219368219|NCT00746174|DRUG|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
219746679|NCT06549777|BEHAVIORAL|Control|Psychoeducation and information about treatment possibilities + Phone
219746680|NCT06518928|OTHER|Artificial Intelligence assisted sperm selection|SiD software for sperm selection
219746681|NCT00991640|BEHAVIORAL|2-day preceptorship on obesity management|
219746682|NCT02144532|DEVICE|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
219746683|NCT04744116|OTHER|Cellular Therapy|Given ds-MSCs IV
219746684|NCT04744116|DRUG|Ruxolitinib|Given PO
219746685|NCT02098603|BEHAVIORAL|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
219746686|NCT02759510|DRUG|Norepinephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
219746687|NCT02759510|DRUG|Phenylephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
219746688|NCT02593214|DEVICE|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
219746689|NCT05061823|DRUG|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
219746690|NCT04661488|DEVICE|AI driven triage-system|AI driven triage-system
219746691|NCT05328622|BEHAVIORAL|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
219746692|NCT04999267|OTHER|INVEST|The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.
219746693|NCT06572774|BEHAVIORAL|C3Link Strategies|Education sessions and community liaison support to link to services
219746694|NCT03981510|DIAGNOSTIC_TEST|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
219746695|NCT00303407|DRUG|nadroparin|
219746696|NCT03723473|DEVICE|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
219368220|NCT00746174|DRUG|Placebo|Placebo 1 tablet PO daily for 16 weeks
219368221|NCT03717376|OTHER|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
219368222|NCT01898156|DRUG|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
219368223|NCT03411395|DIETARY_SUPPLEMENT|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
219368224|NCT03411395|OTHER|Placebo drink|Placebo water with carbonation and aroma
219368225|NCT01554787|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
219368226|NCT01554787|OTHER|Placebo|at a rate of 2.8g three times per day
219368227|NCT04646148|BEHAVIORAL|Yoga classes|All participants are invited to attend weekly yoga classes.
219368228|NCT00352703|DRUG|Kepivance (Palifermin)|
219368229|NCT04689230|PROCEDURE|upper eyelid blepharoplasty|upper eyelid blepharoplasty
219368230|NCT05779085|OTHER|Dermocosmetic|Use of daily cleanser to treat facial acne
219368231|NCT02566720|DRUG|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
219368232|NCT02566720|PROCEDURE|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
219368233|NCT00193830|PROCEDURE|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
219368234|NCT03346330|DRUG|TRK-750|TRK-750 capsule
219368235|NCT03346330|DRUG|Placebo|Placebo capsule
219368236|NCT03502512|OTHER|Questionnaire Administration|Ancillary studies
219368237|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
219368238|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
219368239|NCT04899635|OTHER|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
219368240|NCT05739773|OTHER|five-element music therapy|music therapy
219368241|NCT02681666|DIETARY_SUPPLEMENT|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
219368242|NCT02681666|BEHAVIORAL|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
219368243|NCT02427282|DEVICE|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
219368244|NCT02427282|DEVICE|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
219368245|NCT05494307|DRUG|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
219368246|NCT05494307|DRUG|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
219368247|NCT04092842|DEVICE|Silicone prosthesis|Silicone prosthesis
219368248|NCT04092842|PROCEDURE|Usual practice|Usual surgery
219368249|NCT02948361|OTHER|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
219368250|NCT00008385|OTHER|placebo|Given orally
219368251|NCT00008385|DRUG|selenium|Given orally
219368252|NCT00398112|DRUG|sunitinib malate|Given orally
219368253|NCT00398112|OTHER|pharmacological study|Correlative studies
219368254|NCT00398112|OTHER|laboratory biomarker analysis|Correlative studies
219368255|NCT02103140|BEHAVIORAL|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
219368256|NCT02103140|BEHAVIORAL|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
219368257|NCT05148884|DRUG|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
219368258|NCT05148884|DRUG|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
219368259|NCT00595231|DRUG|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
219368260|NCT00595231|DRUG|Placebo|0 mg tablets
219368261|NCT01993888|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|
219368262|NCT01993888|OTHER|Standard of Care (SoC)|
219368263|NCT02519114|PROCEDURE|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
219368264|NCT01823809|DEVICE|adenosine stress Cardiac Magnetic Resonance Imaging|
219368265|NCT00365989|DEVICE|ExAblate Enhanced Sonication|
219368266|NCT00806221|DRUG|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
219368267|NCT00832819|DRUG|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
219368268|NCT00832819|DRUG|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
219368269|NCT00832819|DRUG|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
219368270|NCT00832819|DRUG|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
219368271|NCT03993717|BIOLOGICAL|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
219368272|NCT05028803|DRUG|sodium phenylbutyrate|same as arm/group
219368273|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg twice daily
219368274|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg once daily
219368275|NCT00317044|DRUG|Placebo|Placebo twice daily
219557585|NCT01274962|DRUG|FOLFOX|"* Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
219557586|NCT01274962|RADIATION|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
219557587|NCT04016194|DIAGNOSTIC_TEST|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
219557588|NCT04099680|PROCEDURE|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
219557589|NCT04099680|PROCEDURE|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
219557590|NCT04099680|DEVICE|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
219557591|NCT04099680|PROCEDURE|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
219557592|NCT04099680|PROCEDURE|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
219557593|NCT04099680|PROCEDURE|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
219557594|NCT02522780|DRUG|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
219557595|NCT02522780|DRUG|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
219746697|NCT01468064|GENETIC|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
219746698|NCT01468064|GENETIC|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
219746699|NCT01468064|GENETIC|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
219746700|NCT00800826|DRUG|dexmedetomidine|
219368276|NCT00320970|DRUG|Candesartan|
219368277|NCT02426814|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
219368278|NCT02426814|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
219368279|NCT04792866|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis
219368280|NCT02318095|DRUG|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
219368281|NCT02318095|RADIATION|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
219368282|NCT02318095|OTHER|Sugical resection|Surgical resection of the pancreas post radiation therapy
219368283|NCT02318095|DRUG|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
219368284|NCT03817671|OTHER|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
219368285|NCT03817671|OTHER|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
219368286|NCT00686127|DRUG|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
219368287|NCT00686127|DRUG|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
219368288|NCT04852640|PROCEDURE|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
219746701|NCT03984279|OTHER|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
219368289|NCT04852640|PROCEDURE|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
219368290|NCT04275700|PROCEDURE|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
219368291|NCT05421611|BIOLOGICAL|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
219368292|NCT05421611|BIOLOGICAL|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
219368293|NCT05742984|DRUG|linaprazan glurate 25 mg QD|"The subjects will receive 25 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
219368294|NCT05742984|DRUG|linaprazan glurate 50 mg QD|"The subjects will receive 50 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
219368295|NCT05742984|DRUG|linaprazan glurate 75 mg QD|"The subjects will receive 75 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
219368296|NCT05742984|DRUG|linaprazan glurate 25 mg BID|The subjects will receive 25 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
219557596|NCT04309994|OTHER|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
219557597|NCT04309994|OTHER|Cardioplexol|cardioplegia solution
219557598|NCT03563560|DRUG|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
219557599|NCT03563560|DRUG|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
219557600|NCT03563560|DRUG|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
219557601|NCT03563560|DRUG|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
219557602|NCT03563560|DRUG|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
219557603|NCT02058160|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
219746702|NCT02321475|DRUG|EGb761®|
219746703|NCT00213070|DRUG|Miglitol|
219746704|NCT02896205|DRUG|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
219746705|NCT02896205|DRUG|Placebo|Subjects will be given matching placebo for 6 months
219746706|NCT02104934|PROCEDURE|Adductor Canal Block|
219746707|NCT06541119|OTHER|Selective Peroneus longus excercise|Weight bearing peroneus longus exercise
219746708|NCT06541119|OTHER|Conventional physical therapy programme|"* Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs"
219557604|NCT02058160|DRUG|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
219746709|NCT02398019|DEVICE|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
219746710|NCT01668680|DRUG|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
219746711|NCT04076332|OTHER|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
219746712|NCT06489366|DEVICE|Thulium Fiber laser (TFL) lithotripsy|Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
219746713|NCT06489366|DEVICE|Ho: YAG lithotripsy|Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
219746714|NCT01905540|DRUG|SSP-004184AQ|Magnesium salt
219178838|NCT05122325|DEVICE|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
219746715|NCT01905540|DRUG|SSP-004184SS|Disodium salt
219746716|NCT00000395|DRUG|Methotrexate|
219178839|NCT06005454|DIETARY_SUPPLEMENT|Fish oil (Omega)|We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
219178840|NCT04671446|DIAGNOSTIC_TEST|Autoantibody ELISA|Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
219178841|NCT04671446|DIAGNOSTIC_TEST|Granulocyte Immunofluorescence|The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
219178842|NCT05166343|DRUG|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
219178843|NCT04119791|OTHER|wild rice|30 grams of wild rice in the form salad, snack bar and soup
219178844|NCT04256941|DRUG|Abemaciclib|Given PO
219178845|NCT04256941|DRUG|Anastrozole|Given PO
219178846|NCT04256941|DRUG|Fulvestrant|Given IM
219178847|NCT04256941|DRUG|Letrozole|Given PO
219178848|NCT04256941|DRUG|Palbociclib|Given PO
219178849|NCT04256941|DRUG|Ribociclib|Given PO
219178850|NCT06257303|OTHER|Frontal Plane Projection Angle|Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.
219178851|NCT02933970|OTHER|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
219178852|NCT05914363|OTHER|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
219178853|NCT05914363|BEHAVIORAL|Behaviour change intervention|Support for behaviour change through 'floor clubs' and the provision of printed guides
219746717|NCT00000395|DIETARY_SUPPLEMENT|Folinic acid|
219746718|NCT00000395|DIETARY_SUPPLEMENT|Folic acid|
219746719|NCT02367885|DRUG|TAK-850 0.5 mL injection|TAK-850 injection
219178854|NCT05914363|DRUG|Routine deworming|Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
219178855|NCT05914363|PROCEDURE|treatment for tungiasis|Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
219178856|NCT03300648|OTHER|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
219178857|NCT03300648|DRUG|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
219178858|NCT02674295|DRUG|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
219178859|NCT02674295|DRUG|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
219178860|NCT05447741|DIAGNOSTIC_TEST|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
219557605|NCT02058160|DRUG|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
219746720|NCT02367885|DRUG|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
219746721|NCT01602484|DEVICE|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
219746722|NCT01602484|DEVICE|Bulk splint supplies|Applying splint by using the bulk splint supplies
219368297|NCT05742984|DRUG|linaprazan glurate 50 mg BID|The subjects will receive 50 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
219368298|NCT05742984|DRUG|linaprazan glurate 75 mg BID|The subjects will receive 75 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
219368299|NCT00379340|RADIATION|3-Dimensional Conformal Radiation Therapy|
219368300|NCT00379340|PROCEDURE|Conventional Surgery|
219368301|NCT00379340|DRUG|Cyclophosphamide|Given IV
219368302|NCT00379340|BIOLOGICAL|Dactinomycin|Given IV
219368303|NCT00379340|DRUG|Doxorubicin Hydrochloride|Given IV
219746723|NCT06059950|BEHAVIORAL|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
219746724|NCT03842280|DEVICE|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
219746725|NCT04326738|DRUG|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
219746726|NCT04326738|DRUG|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
219746727|NCT03910595|OTHER|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
219746728|NCT00011635|DRUG|Silymarin (milk thistle)|
219746729|NCT00498628|DRUG|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
219746730|NCT00498628|OTHER|Placebo|Placebo
219746731|NCT01322152|DRUG|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
219746732|NCT00967252|DRUG|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
219746733|NCT00967252|DRUG|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
219746734|NCT00967252|DRUG|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
219746735|NCT00967252|DRUG|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
219746736|NCT00967252|OTHER|Control|No statin being taken
219746737|NCT06230146|DRUG|Insulin group|"Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas."
219368304|NCT00379340|DRUG|Etoposide|Given IV
219368305|NCT00379340|DRUG|Vincristine Sulfate Liposome|Given IV
219368306|NCT06351293|DEVICE|Defyne Treatment in Nasolabial Fold|Defyne will be injected into left or right nasolabial fold, per randomization.
219368307|NCT06351293|DEVICE|RHA3 Treatment in Nasolabial Fold|RHA3 will be injected into left or right nasolabial fold, per randomization.
219368308|NCT04801758|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
219368309|NCT05356767|PROCEDURE|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
219368310|NCT05046028|DIETARY_SUPPLEMENT|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
219368311|NCT05046028|DIETARY_SUPPLEMENT|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
219368312|NCT05046028|DIETARY_SUPPLEMENT|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
219368313|NCT02162862|BEHAVIORAL|Behavioral Counseling|
219368314|NCT02162862|DRUG|bupropion-SR|
219368315|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
219368316|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
219368317|NCT05587881|BIOLOGICAL|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
219368318|NCT05587881|BIOLOGICAL|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
219368319|NCT06079502|DEVICE|Neuromuscular Electrical Stimulation|A supervised program of intradialytic NMES of the quadriceps and calf muscles of both lower limbs with different phases, types and current intensity. The electrical stimulation program will included (total time, intensity, contraction-relaxation phase time): a toning program in the first two weeks.
219746738|NCT06230146|DRUG|Botulinum toxin group|Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
219746739|NCT06230146|DRUG|Triamcinolone acetonide group|Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
219368320|NCT06079502|OTHER|resistive training program|"Part one: Warming up for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~Part two: The main part is the resistive training for quadriceps and calf muscles from supine position using weights in the form of sand bags for 20 min.~Part three: Cooling down for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~The training parameters:~The exercise training will be done during the first 2 hours of HD session using free leg weights. The patient will assume a supine lying position on the treatment plinth and perform the exercises for every lower limb separately while the other limb will be supported on the plinth by therapist or the patient himself. Resistance will be placed at the malleoli level in the distal third of the leg."
219368321|NCT03089567|DRUG|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
219746740|NCT02137343|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
218990930|NCT00911118|RADIATION|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
219368322|NCT03089567|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
219368323|NCT06960226|OTHER|Music Listening|Participants listen to selected instrumental music excerpts presented via headphones during designated experimental trials.
219368324|NCT06960226|OTHER|Silence Control|Participants experience periods of silence with no music presented via headphones during designated control trials. This serves as the auditory control condition compared to Music Listening.
219368325|NCT06960226|OTHER|Active Sensorimotor Synchronization|Participants actively synchronize movements (such as foot tapping and/or head nodding) by timing them with the rhythm of the presented music or with a pacing stimulus provided during silent trials.
219368326|NCT06960226|OTHER|Passive Control Task|Participants remain still and do not perform specific instructed synchronized movements during designated control trials. This serves as the motor task control condition compared to Active Sensorimotor Synchronization.
219368327|NCT06960889|OTHER|radiotherapy|Definitive radiotherapy or radiotherapy-based combined modality therapy
219368328|NCT06960889|DRUG|Immunotherapy|Immune checkpoint inhibitors as monotherapy or in combination with other therapies
219368329|NCT06960889|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Radical esophagectomy with or without neoadjuvant/adjuvant therapy
219368330|NCT06960512|BEHAVIORAL|Precision Lifestyle Intervention (PLI) group|"1. Device Application: Participants in the intervention group will wear the GX-01S continuous glucose monitoring system, with data transmitted in real-time to a secure cloud platform.~2. Multidisciplinary Management: A specialized team (health managers, nutritionists, endocrinologists, and Counselor) will analyze glucose fluctuations, dietary patterns, sleep health, physical activity and to formulate personalized adjustment plans. Modifications may include meal timing optimization, sleep duration regulation, and exercise frequency adaptations.~3. Telehealth Follow-up: Participants will receive structured guidance via telephone/telemedicine consultations throughout the 28-day intervention period. Type 2 Diabetes Mellitus (T2DM) patient compliance will be systematically monitored and documented.~4. Tailored Recommendations: Evidence-based lifestyle recommendations will be provided post-intervention, informed by quantitative biomarker data and adherence metrics collected."
219368331|NCT06960785|DEVICE|MEL90 excimer laser - PRESBYOND|"Participants will undergo laser eye surgery in both eyes using the PRESBYOND method. First, a thin flap is created on the surface of the eye using a femtosecond laser. Then, a second laser (excimer laser) reshapes the cornea to improve vision at near, intermediate, and far distances.~The treatment is similar to monovision techniques, where one eye is mainly corrected for distance and the other for near vision. However, PRESBYOND differs by adjusting the depth of focus in each eye individually, allowing the brain to better combine the two images in the intermediate range-this area is called the Blend Zone. This approach helps preserve natural binocular (3D) vision, contrast sensitivity, and depth perception. Most patients adapt well and quickly to this type of correction. The procedure is customized based on each patient's age and eye characteristics."
219368332|NCT06960161|DEVICE|Phototherapy|Phototherapy
218990931|NCT03303924|DRUG|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
219368333|NCT06959797|DEVICE|Closed loop|Ypsomed pump (Ypsomed), CamAPS HX application activated, Android smartphone. Freestyle 3 sensors (Abbott)
219368334|NCT06959797|DEVICE|Open loop|Ypsomed pump (Ypsomed). Android smartphone. Freestyle 3 sensors (Abbott)
219368335|NCT01808352|OTHER|Observational|HPTN 073 is an observational study in MSM in the United States
219746741|NCT02137343|DRUG|Placebo|Placebo
218990932|NCT06327347|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
218990933|NCT04635943|DRUG|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
218990934|NCT04635943|DRUG|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
219178861|NCT06202651|DEVICE|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
218990935|NCT03630627|DRUG|SB26|SB26 administered intravenously
219178862|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
219178863|NCT05969080|BEHAVIORAL|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
219178864|NCT05969080|OTHER|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
219178865|NCT05688956|DIETARY_SUPPLEMENT|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
219178866|NCT05688956|OTHER|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
219178867|NCT05688956|OTHER|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
219178868|NCT06295328|DRUG|Terbinafine|terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
219178869|NCT06295328|DRUG|Placebo|Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
219178870|NCT06295328|DRUG|Tenofovir|Tenofovir 245mg standard of care
219178871|NCT02722525|PROCEDURE|Magnetic Resonance Imaging|Undergo treadmill stress CMR
219178872|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete treadmill exercise
219178873|NCT02722525|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
219178874|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete resistive lower extremity exercise
219178875|NCT02722525|PROCEDURE|Spectroscopy|Undergo skeletal muscle PMRS
219178876|NCT02722525|OTHER|Laboratory Biomarker Analysis|Correlative studies
219178877|NCT02908477|RADIATION|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
219178878|NCT02908477|DRUG|Docetaxel|15 mg/m2. Experimental arm only.
219178879|NCT02908477|DRUG|Cisplatin|40 mg/m2. Standard arm only.
219178880|NCT03160794|DIAGNOSTIC_TEST|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
219178881|NCT03160794|RADIATION|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
219368336|NCT01596179|BEHAVIORAL|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
219746742|NCT02137343|DRUG|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
218990936|NCT03630627|DRUG|Placebo|Placebo administered intravenously
218990937|NCT05163444|DEVICE|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
218990938|NCT05163444|DEVICE|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
218990939|NCT01523860|DRUG|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
218990940|NCT04044612|OTHER|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
219178882|NCT02140554|GENETIC|lovo-cel|lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
219178883|NCT05659537|DRUG|Dulaglutide|Administered SC
219178884|NCT05720546|OTHER|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
219178885|NCT05720546|OTHER|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
219178886|NCT05720546|OTHER|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
219178887|NCT04871191|DRUG|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
219178888|NCT04871191|DRUG|Tocilizumab|Subcutaneous injection of 162 mg per week
219178889|NCT04871191|DRUG|Tofacitinib|\- Tofacitinib, administered orally at a dose of 5 mg twice a day. Tofacitinib will start at week 0. Treatment will be continued until week 52
219368337|NCT01596179|BEHAVIORAL|Internet access|a netbook computer with internet access is provided to participants on the control arm.
218990941|NCT05149196|OTHER|Targeted hemodynamic management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
218990942|NCT05149196|OTHER|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
218990943|NCT01793896|BEHAVIORAL|Control period|Analysis at recruitment and after a month without any intervention
219368338|NCT04888481|DRUG|68Ga-HA-DOTATATE|Tracer injection
218990944|NCT01793896|BEHAVIORAL|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
219368339|NCT00970606|DRUG|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
219368340|NCT00970606|DRUG|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
219368341|NCT00103012|DRUG|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
219368342|NCT00103012|DRUG|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
219368343|NCT00103012|DRUG|Panax ginseng|Panax ginseng 500 mg twice daily
219368344|NCT00430755|DEVICE|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
218990945|NCT01793896|BEHAVIORAL|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
219368345|NCT00430755|PROCEDURE|physician taken history|Convential history taking by physicians
219368346|NCT00430755|OTHER|Computer-assisted history taking|
219368347|NCT01790490|DRUG|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
219368348|NCT01790490|DRUG|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
219368349|NCT01790490|DRUG|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
219368350|NCT05470127|DEVICE|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
218990946|NCT01793896|BEHAVIORAL|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
219368351|NCT05261269|DRUG|DAN-222|Administered IV every week to subjects
219368352|NCT05261269|DRUG|Niraparib|Administered orally once daily
219368353|NCT05167786|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
219557606|NCT03113357|OTHER|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
219368354|NCT05167786|DEVICE|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
219368355|NCT05167786|OTHER|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
219368356|NCT05019131|BEHAVIORAL|Training|trainings to reduce conscious bias and stress
219368357|NCT05019131|BEHAVIORAL|Peer support and mentorship|facilitated peer and mentorship opportunities
219368358|NCT05019131|BEHAVIORAL|Leadership engagement|Engaged leadership at the county and facility levels
219368359|NCT05019131|BEHAVIORAL|Embedded champions|Facilitate local champions to promote intervention
219368360|NCT05791292|OTHER|Evaluation|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
219368361|NCT05723432|DRUG|KD6001|KD6001 will be administered intravenously.
219368362|NCT05723432|DRUG|Toripalimab|Toripalimab will be administered intravenously.
219368363|NCT05220839|PROCEDURE|Type of cerclage procedure Mc Donald|Patients who underwent Mc Donald cervical cerclage will be calculated the area of cervical cerclage area
219368364|NCT01621685|BIOLOGICAL|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
219557607|NCT03113357|OTHER|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
219557608|NCT03033030|DIAGNOSTIC_TEST|Ultrasound|Ultrasound examination
219557609|NCT01376544|DEVICE|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
219557610|NCT03316040|BEHAVIORAL|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
219746743|NCT02137343|DRUG|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
219557611|NCT02260635|DRUG|Evacetrapib|Administered orally
219557612|NCT02260635|DRUG|Placebo|Administered orally
219557613|NCT04106817|BIOLOGICAL|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
219746744|NCT01224314|OTHER|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
218990947|NCT02957305|DRUG|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
218990948|NCT02957305|DRUG|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
219746745|NCT03526666|OTHER|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
219746746|NCT02743962|DEVICE|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
219557614|NCT03793296|DEVICE|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
219557615|NCT03848858|BEHAVIORAL|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
219557616|NCT02798419|DRUG|DFD05 Cream|
219557617|NCT02798419|DRUG|Active01 Cream|
219557618|NCT05167617|DRUG|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
219746747|NCT02743962|OTHER|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
219746748|NCT04656912|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
219746749|NCT02132260|DRUG|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
218990949|NCT02498184|OTHER|acupuncture|
218990950|NCT00870441|DRUG|ASP2151|Oral
219178890|NCT05187351|PROCEDURE|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-100% de novo SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
219746750|NCT02132260|DRUG|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
219557619|NCT00152516|DRUG|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
218990951|NCT00870441|DRUG|Valacyclovir|Oral
218990952|NCT00870441|DRUG|Placebo|Oral
218990953|NCT02695901|DRUG|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
219178891|NCT02664337|OTHER|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
219557620|NCT06471179|DEVICE|Functional MRI|Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
219557621|NCT03011879|OTHER|clinical pathway|
219557622|NCT00630903|DRUG|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
219746751|NCT02132260|DRUG|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
219368365|NCT03904797|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|"Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team."
219368366|NCT04684420|DRUG|Glucophage® XR RM Test|Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
219368367|NCT04684420|DRUG|Glucophage® XR Reference|Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
219368368|NCT00008190|BIOLOGICAL|aldesleukin|
219557623|NCT00630903|DRUG|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
219557624|NCT03563885|PROCEDURE|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
219557625|NCT05761587|OTHER|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
218990954|NCT02695901|DRUG|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
218990955|NCT00952978|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
218990956|NCT00952978|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
219368369|NCT00008190|BIOLOGICAL|filgrastim|
219368370|NCT00008190|DRUG|busulfan|
219368371|NCT00008190|DRUG|cyclophosphamide|
219557626|NCT02476305|DEVICE|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
218990957|NCT03414060|DEVICE|Menstrual Cup|
219178892|NCT02664337|OTHER|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
219178893|NCT04728347|BIOLOGICAL|ARCT-021|ARCT-021 single dose
219557627|NCT04763447|OTHER|Attempt to withdrawal OMA treatment|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
219557628|NCT04763447|DRUG|Continuation of OMA treatment|"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."
219557629|NCT03562845|OTHER|NA-Observational only|NA-Observational only
219557630|NCT01459198|BIOLOGICAL|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
219557631|NCT01459198|BIOLOGICAL|Placebo vaccine|Given intranasally once at a baseline study visit
219557632|NCT01422486|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
219557633|NCT00008398|BIOLOGICAL|sargramostim|
219557634|NCT00008398|PROCEDURE|quality-of-life assessment|
219557635|NCT00008398|RADIATION|radiation therapy|
218990958|NCT00842608|BEHAVIORAL|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol"
219178894|NCT02289209|RADIATION|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
219368372|NCT00008190|DRUG|etoposide|
219368373|NCT00008190|DRUG|melphalan|
219368374|NCT00008190|PROCEDURE|peripheral blood stem cell transplantation|
219368375|NCT04329221|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
219368376|NCT04329221|DRUG|Vaseline|Placebo
219557636|NCT05129189|DRUG|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
219178895|NCT02289209|DRUG|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
219178896|NCT04971395|DRUG|Placebo|Single dose of 2 or 4 mg/kg
219368377|NCT04329221|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
219368378|NCT00166855|PROCEDURE|dynamic MRI and bone marrow sampling|
219368379|NCT03480802|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
219178897|NCT04971395|DRUG|XTMAB-16 2 mg/kg|Single dose of 2 mg/kg
219368380|NCT03480802|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
219368381|NCT03480802|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
219368382|NCT03015103|DEVICE|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
219368383|NCT01703000|DEVICE|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
219368384|NCT02243228|DRUG|GM-CSF|
219368385|NCT03358914|OTHER|No intervention|Completion of surveys
219368386|NCT03822884|DRUG|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
219368387|NCT02633371|DRUG|Oxybutynin 3% gel|
219368388|NCT02620904|DRUG|Mifepristone|
219368389|NCT02620904|DRUG|placebo|
219368390|NCT02557178|BEHAVIORAL|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
219368391|NCT05222321|OTHER|Sensory-Play Based (SenPlay) Intervention|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
219368392|NCT05222321|OTHER|Spontaneous, Free Play|Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
219368393|NCT03420560|BEHAVIORAL|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
219368394|NCT00126165|PROCEDURE|radiotherapy|
219368395|NCT05850845|DEVICE|Microscopic hyperspectral imaging system|CTX for idiopathic membranous nephropathy
219368396|NCT03454373|BEHAVIORAL|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
219368397|NCT00976144|DRUG|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
219368398|NCT06001567|DRUG|Avatrombopag|Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
219368399|NCT06391645|DRUG|Nerve Growth Factor|intravenously injection
219368400|NCT03168516|DEVICE|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
219368401|NCT01113320|DRUG|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
219368402|NCT01113320|DRUG|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
219557637|NCT01096745|DRUG|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
219557638|NCT01096745|DRUG|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
219746752|NCT01232140|OTHER|CRP-guided antibiotic treatment|If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
219178898|NCT04971395|DRUG|XTMAB-16 4mg/kg|Single dose of 4 mg/kg
219368403|NCT02480530|BEHAVIORAL|Individual Feedback|Patient gets feedback reports on adherence weekly.
219368404|NCT02480530|BEHAVIORAL|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
219368405|NCT05401747|OTHER|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
219368406|NCT05543590|DRUG|Plasmapheresis|5 sessions of plasma exchanges
219368407|NCT05543590|OTHER|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
219368408|NCT05543590|OTHER|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
219368409|NCT05543590|OTHER|PET scan|PET scan at baseline and M6
219557639|NCT05713227|DIETARY_SUPPLEMENT|White rice|185 g Jasmine (white) rice boiled in 356 g water
219368410|NCT05543590|OTHER|Cycle ergometer stress test|Cycle ergometer stress test at M6
219368411|NCT05543590|OTHER|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
219368412|NCT05543590|OTHER|Medical consultations|Medical consultations
219368413|NCT03377920|DEVICE|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"* pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
219368414|NCT00191854|DRUG|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
219368415|NCT00191854|DRUG|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
219368416|NCT00191854|DRUG|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
219368417|NCT00191854|DRUG|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
219368418|NCT00928811|DRUG|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
219368419|NCT00928811|DRUG|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
219368420|NCT06183008|DRUG|Intravenous immunoglobulin|Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
219368421|NCT06183008|DRUG|Placebo|Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
219368422|NCT02415309|DRUG|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
219368423|NCT02415309|DRUG|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
219368424|NCT02415309|OTHER|Placebo|40 patients will randomly receive a placebo/sugar pill
219368425|NCT05973370|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219368426|NCT05973370|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
219368427|NCT00566787|DEVICE|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
219368428|NCT01604746|BIOLOGICAL|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
219368429|NCT02941367|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219368430|NCT02941367|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
219368431|NCT02941367|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219368432|NCT02941367|DRUG|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219557640|NCT05713227|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
219557641|NCT04461340|DRUG|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
219178899|NCT06581237|OTHER|Eat2Win App|Voluntary use of the app will occur throughout the sport season.
219368433|NCT00021983|BIOLOGICAL|BL22 immunotoxin|
219368434|NCT06960265|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"Targeting: The left dorsolateral prefrontal cortex (DLPFC) will be the target for treatment.~Equipment: rTMS will be delivered using a Magstim super rapid magnetic stimulator with a 70-mm air-cooled figure-eight-shaped coil. Resting Motor Threshold (rMT) Measurement: rMT is determined through visual twitch responses in the contralateral hand, identifying the minimal intensity needed to elicit thumb movement in 50% of trials.~rTMS will be administered at a frequency of 15Hz, with each pulse at 100% rMT intensity. Sessions include 60 pulses per train, with a 26-second inter-train pause, across 40 trains, totaling 2400 pulses over a 20-minute session."
219178900|NCT04968210|DRUG|Hyperpolarized 13C-pyruvate|Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
219368435|NCT06960265|DEVICE|sham for repetitive Transcranial Magnetic Stimulation|The sham group will undergo a placebo procedure using the same rTMS parameters but with a figure-of-eight sham coil, following precedents set by studies on cocaine use disorder treatment (Terraneo et al., 2016).
219368436|NCT02348099|OTHER|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
219368437|NCT05413811|DRUG|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
219368438|NCT05413811|DRUG|Placebo|Intravaginal topical placebo cream
219368439|NCT06325007|DIETARY_SUPPLEMENT|Induction of labor|The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
219557642|NCT05998291|OTHER|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
219557643|NCT04536792|DRUG|AG-946|AG-946, oral encapsulated coated-granules or tablets.
219557644|NCT04536792|DRUG|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
219557645|NCT04318431|DIAGNOSTIC_TEST|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
219746753|NCT06642766|DIETARY_SUPPLEMENT|Fiber supplement|"Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary."
219746754|NCT04993196|DIAGNOSTIC_TEST|T1rho imaging|Magnetic Resonance Imaging using T1rho
219557646|NCT02289820|BIOLOGICAL|MEDI7510|RSV sF antigen plus adjuvant
219557647|NCT02289820|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
219557648|NCT01812473|OTHER|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
219557649|NCT00684944|DRUG|TRx0014|Gelatin capsule, tid
219368440|NCT06509841|OTHER|Electro-acupuncture at the Jiaji points|Adopting treatments for the group that received electro-acupuncture at the Jiaji points, including: ① electro-acupuncture at the Jiaji points with continuous treatment for 8 weeks.
219557650|NCT00926367|DRUG|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
219557651|NCT00926367|DRUG|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
218990959|NCT00842608|PROCEDURE|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
219368441|NCT06509841|OTHER|Electro-acupuncture at the scalp points|Adopting treatments for the group that received electro-acupuncture at the Scalp points, including: ① electro-acupuncture at the Scalp points with continuous treatment for 8 weeks.
219368442|NCT05163886|DRUG|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
219368443|NCT05163886|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
219368444|NCT05049538|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219557652|NCT04511572|PROCEDURE|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
219557653|NCT06163417|PROCEDURE|laparoscopic|laparoscopic
219368445|NCT05049538|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
219368446|NCT05049538|OTHER|Pap Smear|Undergo Pap smear
219368447|NCT06118385|DRUG|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
219368448|NCT06118385|DRUG|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
219368449|NCT05317221|OTHER|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
219557654|NCT01022255|BIOLOGICAL|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
219557655|NCT05740215|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
219557656|NCT05740215|DRUG|Lenvatinib|Lenvatinib capsules
218990960|NCT00842608|DRUG|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
218990961|NCT00842608|PROCEDURE|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
219557657|NCT02725411|DRUG|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
219557658|NCT02725411|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
219557659|NCT02725411|BIOLOGICAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
219557660|NCT02725411|DRUG|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
219557661|NCT02725411|BIOLOGICAL|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
219557662|NCT02054754|DRUG|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
219557663|NCT02054754|DRUG|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
218990962|NCT00903396|DRUG|palonosetron hydrochloride|Given IV
218990963|NCT00903396|OTHER|placebo|Given IV
219368450|NCT05815498|BIOLOGICAL|mRNA-1283.222|Sterile liquid for injection
219368451|NCT05815498|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
219368452|NCT05815498|BIOLOGICAL|mRNA-1283.815|Sterile liquid for injection
219368453|NCT05815498|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
219368454|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
219368455|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
219368456|NCT01323478|DRUG|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
219557664|NCT02054754|DRUG|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
219557665|NCT02054754|DRUG|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
219746755|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
219368457|NCT06386510|PROCEDURE|Strength training|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.
219368458|NCT06386510|PROCEDURE|Cranial nerve non-invasive neuromodulation|For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
219368459|NCT02411448|DRUG|Ramucirumab|Administered IV.
219368460|NCT02411448|DRUG|Placebo|Administered IV.
219368461|NCT02411448|DRUG|Erlotinib|Administered orally.
219368462|NCT02411448|DRUG|Gefitinib|Administered orally.
219368463|NCT02411448|DRUG|Osimertinib|Administered orally.
219368464|NCT05052268|DRUG|XTX202|XTX202 Monotherapy
219368465|NCT02689323|DEVICE|repeated transcranial magnetic stimulation|
219368466|NCT06325501|DRUG|Misoprostol 200mcg Tab|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
219368467|NCT06325501|DRUG|Oxytocin|after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
219368468|NCT05873218|DRUG|Ephedrine|The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
219368469|NCT05873218|DRUG|Normal Saline Placebo|Placebo will be administered at matching rate.
219746756|NCT06563934|DRUG|Lenvatinib + PD-1 monoclonal antibody|"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."
219746757|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules placebo|Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
219746758|NCT03578315|DEVICE|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
219746759|NCT06642129|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
219746760|NCT06640660|DEVICE|Mindlenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
219368470|NCT05728879|COMBINATION_PRODUCT|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
219368471|NCT02735629|DRUG|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
219368472|NCT02735629|DRUG|CX1739 - 600 mg|CX1739 - 600 mg
219368473|NCT02735629|DRUG|CX1739 - 900 mg|CX1739 - 900 mg
219368474|NCT02735629|DRUG|Placebo|Placebo to 300 mg CX1739
219368475|NCT05056844|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CESM
219368476|NCT05056844|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
219368477|NCT05056844|DRUG|Iodinated Contrast Agent|Given iodine-based contrast agent IV
219368478|NCT05056844|OTHER|Questionnaire Administration|Ancillary studies
219368479|NCT03399266|DEVICE|Double Balloon catheter for induction of labor|With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
219368480|NCT01451801|BIOLOGICAL|Twinrix|"A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin."
219368481|NCT02686294|DRUG|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
219368482|NCT02686294|DRUG|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
219557666|NCT02054754|DRUG|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
219746761|NCT06640660|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
219557667|NCT02054754|DRUG|Placebo|
219557668|NCT06325124|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
219746762|NCT01980264|DEVICE|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
219746763|NCT06034340|DEVICE|LET Gel after STAR Particle Application (Right or Left Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.
219746764|NCT06034340|OTHER|LET Gel Application without STAR Particle Application (Contralateral Arm)|Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
219746765|NCT06639685|DIAGNOSTIC_TEST|MRI|MR Fingerprinting and ASL
219746766|NCT06049160|DRUG|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
219746767|NCT06639178|OTHER|DECLARAN cream|Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
219746768|NCT04692922|DIAGNOSTIC_TEST|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
219746769|NCT04692922|DIAGNOSTIC_TEST|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
219746770|NCT06642597|OTHER|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
219746771|NCT06642597|OTHER|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
219746772|NCT06564363|DIAGNOSTIC_TEST|IUrisure test|Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
219746773|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy with use of Emdogain|Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
219178901|NCT05858944|DRUG|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
219368483|NCT01551979|DEVICE|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
219368484|NCT05249946|OTHER|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
219368485|NCT04233515|DRUG|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
219746774|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy without the use of Emdogain|Scaling of root with assisted use of the Videoscope.
219746775|NCT04998513|DRUG|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
219746776|NCT04998513|PROCEDURE|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
219178902|NCT05858944|DRUG|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
219746777|NCT06455033|OTHER|Manual Diaphragm Release Technique|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.
219746778|NCT06455033|OTHER|Breathing Exercise|"Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards."
219746779|NCT03544463|DEVICE|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
219746780|NCT06033560|DEVICE|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
219746781|NCT03003663|DEVICE|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
219178903|NCT06063499|BEHAVIORAL|Healthy Minds Program for Addictions|The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has \>100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
219746782|NCT03592355|OTHER|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
219746783|NCT01661283|DRUG|everolimus|10 mg tablet once daily
219746784|NCT01661283|DRUG|bevacizumab|10 mg/kg dose every 14 days
219746785|NCT01656122|DRUG|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
219746786|NCT01656122|DRUG|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
219746787|NCT02327169|DRUG|MLN2480|MLN2480 tablets.
219746788|NCT02327169|DRUG|MLN0128|MLN0128 capsules.
219746789|NCT02327169|DRUG|Alisertib|Alisertib tablets.
219746790|NCT02327169|DRUG|Paclitaxel|Paclitaxel IV infusion.
219746791|NCT02327169|DRUG|Cetuximab|Cetuximab IV infusion.
219746792|NCT02327169|DRUG|Irinotecan|Irinotecan IV infusion.
219746793|NCT02626884|DRUG|Ibrutinib|
219746794|NCT05575102|OTHER|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
219746795|NCT00492544|BIOLOGICAL|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
219746796|NCT05206370|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
219746797|NCT05206370|DRUG|Placebo|film-coated oral tablets containing matched placebo
219178904|NCT06388109|OTHER|Positive Peers mobile app|Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
219178905|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
219746798|NCT05206370|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
219746799|NCT02947971|DEVICE|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
219178906|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
219746800|NCT03132142|DRUG|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
219746801|NCT03132142|DRUG|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
219746802|NCT03132142|DRUG|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
219746803|NCT03132142|DRUG|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
219746804|NCT05910346|BEHAVIORAL|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
219746805|NCT00952692|BIOLOGICAL|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~* One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~* One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
219368486|NCT03720132|PROCEDURE|Extensive flushing of the port catheter|The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
219368487|NCT01826708|BIOLOGICAL|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
219368488|NCT05306132|DRUG|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
219368489|NCT05302687|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
219368490|NCT05302687|DIETARY_SUPPLEMENT|placebo|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
219368491|NCT04041115|DIETARY_SUPPLEMENT|Non-alcoholic beer|Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
219368492|NCT04041115|OTHER|control|Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
219746806|NCT00952692|DRUG|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
219368493|NCT02780193|DRUG|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
219746807|NCT02878863|DRUG|Paeoniflorin + phosphatidylcholine or silymarin|
219746808|NCT02878863|DRUG|Phosphatidylcholine or silymarin|
219746809|NCT04548960|OTHER|cancer patients|Blood sample RNA\_seq at time of diagnostic, best response and relapse ; Biopsy Exom\_seq and RNA\_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
219746810|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
219178907|NCT05547750|DRUG|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
219368494|NCT01590173|DRUG|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
219368495|NCT01590173|DRUG|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
219368496|NCT01016379|GENETIC|DNA analysis|
219368497|NCT01016379|OTHER|biologic sample preservation procedure|
219368498|NCT01016379|OTHER|laboratory biomarker analysis|
219368499|NCT02701673|DRUG|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
219368500|NCT02701673|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
219368501|NCT02701673|DRUG|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
219368502|NCT02701673|DRUG|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
219746811|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
219368503|NCT02701673|DRUG|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
219368504|NCT02701673|DRUG|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
219368505|NCT02701673|DRUG|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
219368506|NCT02701673|DRUG|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
219368507|NCT02701673|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
219368508|NCT06182735|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
219368509|NCT03118193|OTHER|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
219368510|NCT03118193|BIOLOGICAL|blood test|one sample of 4mL
219368511|NCT03118193|BIOLOGICAL|Collection of faeces|Collection of faeces by patient at home - optional
219368512|NCT03118193|DEVICE|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
219368513|NCT02483741|BIOLOGICAL|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
219368514|NCT02771522|DEVICE|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black \& white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
219368515|NCT01419132|DRUG|Furosemide|125-250 mg furosemide bid
219368516|NCT01419132|DRUG|Furosemide|125-250 mf furosemide bid
219368517|NCT06549010|DIAGNOSTIC_TEST|Perimetric test|This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.
219368518|NCT01555229|DEVICE|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
219368519|NCT01555229|DEVICE|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
219178908|NCT05547750|DRUG|Placebo|Similar-looking placebo tablets
219178909|NCT06127784|OTHER|Motivational interviewing counselling session|Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
219368520|NCT00995254|BEHAVIORAL|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
219760772|NCT05046392|BEHAVIORAL|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
219368521|NCT03281785|OTHER|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
219368522|NCT03281785|OTHER|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
219368523|NCT03281785|OTHER|Pressure support mode (PS)|Pressure support mode (PS)
219368524|NCT01577238|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
219368525|NCT01577238|DRUG|Placebo|Vaginal gel, daily for 7 days
219368526|NCT03539445|DRUG|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
219368527|NCT03539445|DRUG|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
219368528|NCT05083455|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
219368529|NCT05083455|DRUG|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
219368530|NCT05655377|DEVICE|FitMi PD|Exercise using the motion sensing devices and a tablet computer
219368531|NCT01256177|DRUG|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
219746812|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
219746813|NCT05389072|DEVICE|control contact lens|control CRT lens
219746814|NCT02002325|DRUG|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
219178910|NCT03771417|BEHAVIORAL|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
219178911|NCT05480761|BIOLOGICAL|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
219368532|NCT01256177|DRUG|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
219368533|NCT05845346|OTHER|Electrotherapy-Transcutaneous Electrical Stimulation (TENS)|Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
219368534|NCT05845346|OTHER|Massage therapy|Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.
219368535|NCT05845346|OTHER|Stretching exercises|Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.
219368536|NCT05845346|OTHER|Ischaemic Compression Technique|Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
219368537|NCT00000855|DRUG|Zidovudine|
219368538|NCT01110395|DIAGNOSTIC_TEST|MR Spectroscopy|MR spectroscopy of myocardial
219368539|NCT00113594|DRUG|Olanzapine|
219368540|NCT00442403|DRUG|chloroquine|
219368541|NCT00442403|DRUG|dehydroepiandrosterone sulphate|
219368542|NCT02493569|PROCEDURE|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
219368543|NCT01933841|DEVICE|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
219368544|NCT01933841|PROCEDURE|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
219368545|NCT00793767|DRUG|erythropoietin|bolus of 400 IU/kg
219746815|NCT02002325|OTHER|Standard care|Standard treatment for acute stroke without intravenous alteplase.
219746816|NCT05106556|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
219178912|NCT01605565|PROCEDURE|A nasal brushing|A nasal brushing in every nostril
219178913|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
219368546|NCT00793767|DRUG|placebo (saline)|i.v
219368547|NCT01743833|OTHER|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
219368548|NCT01743833|OTHER|Scapular High Velocity, Low Amplitude Thrust Maneuver|
219368549|NCT03966326|DRUG|sevoflurane and fentanil|Patients will receive standard general anesthesia
219368550|NCT03966326|DRUG|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
219368551|NCT00505947|DRUG|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
219368552|NCT00505947|DRUG|placebo|placebo 5 mg/Kg body weight by intravenous infusion
219368553|NCT00001676|DRUG|SQ Fludarabine|
219368554|NCT02024984|DRUG|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
219746817|NCT05106556|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
219746818|NCT03715907|BEHAVIORAL|Financial Incentives|Incentives for gap closure.
219746819|NCT03715907|BEHAVIORAL|Information|Information on care gap and closure process.
219746820|NCT03470025|OTHER|Psychological Intervention|"1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
219746821|NCT04879407|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
219746822|NCT04879407|DRUG|Warfarin|Any warfarin dispensing claim is used as the reference group
219746823|NCT00849992|DRUG|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
219746824|NCT00849992|PROCEDURE|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
219746825|NCT02294864|DEVICE|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
219746826|NCT02294864|PROCEDURE|Physical Therapy|
219746827|NCT05399173|DEVICE|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
219178914|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
219178915|NCT06484686|BIOLOGICAL|Live Attenuated Varicella Vaccine|lyophilized powder, subcutaneous injection
219368555|NCT04909528|DEVICE|Low-level tragus stimulation|Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
219368556|NCT04909528|DEVICE|Sham stimulation|Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
219368557|NCT02451787|DIETARY_SUPPLEMENT|Vitamin D|2400 units per day for 3 months
219368558|NCT00553462|DRUG|carboplatin|
219368559|NCT00553462|DRUG|erlotinib hydrochloride|
219368560|NCT00553462|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219368561|NCT00553462|RADIATION|radiation therapy|
219368562|NCT03871894|OTHER|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
219368563|NCT03871894|OTHER|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
219368564|NCT02700178|OTHER|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
219368565|NCT00983567|OTHER|teen web|Min web
219368566|NCT01728779|DRUG|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
219368567|NCT01728779|RADIATION|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
219368568|NCT01781455|DRUG|BBI503|
219368569|NCT03981159|OTHER|Physical training|Physical training for three months, twice per week (60 minutes per session).
219746828|NCT05399173|DRUG|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
219746829|NCT03755193|DRUG|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
219746830|NCT03755193|DRUG|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
219746831|NCT03755193|DRUG|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
219746832|NCT00187109|DRUG|Recombinant Human Thrombopoietin|
219746833|NCT02094235|DRUG|E6005 0.05%|
219746834|NCT02094235|DRUG|Placebo|0.5 g placebo ointment
219746835|NCT02094235|DRUG|E6005 0.2%|
219746836|NCT06365463|BEHAVIORAL|Telerehabilitation|The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
219746837|NCT04330859|OTHER|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
219746838|NCT04330859|OTHER|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
219746839|NCT05480007|DRUG|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
219746840|NCT05480007|DRUG|Sitagliptin|sitagliptin treatment (100mg per day)
219746841|NCT05480007|DRUG|Metformin|metformin group who received metformin (500mg three times per day)
219746842|NCT01381679|DRUG|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
219746843|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 100 and 150
219746844|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
219746845|NCT00420537|DRUG|Mycophenolate mofetil|mycophenolate with low doses
219746846|NCT00420537|DRUG|Everolimus|
219746847|NCT03982810|DRUG|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
219746848|NCT02106806|DIETARY_SUPPLEMENT|Zinc|35 mg of elemental zinc twice daily for 16 weeks
219746849|NCT02106806|OTHER|Placebo|One capsule, twice daily for 16 weeks
219746850|NCT03129906|DIETARY_SUPPLEMENT|Gluten|
219746851|NCT03129906|DIETARY_SUPPLEMENT|Rice protein|
219368570|NCT05730595|PROCEDURE|lymph node dissection|The extent of lymph node dissection varies between groups
219746852|NCT06564987|DRUG|4% Articaine with 1:200,000 epinephrine|Inferior Alveolar Nerve Block with 4% articaine
219746853|NCT06564987|DRUG|2% lidocaine with 1:100,000 epinephrine|Inferior Alveolar Nerve Block with 2% lidocaine
219746854|NCT04023487|BEHAVIORAL|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
219746855|NCT00361712|PROCEDURE|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
219746856|NCT00361712|DRUG|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
219746857|NCT06134401|DEVICE|saline|nebulised
219746858|NCT04770285|DEVICE|CT-152 - Digital Therapeutic|CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
219746859|NCT04770285|DEVICE|Sham|Sham mobile app was used by the participants as per the schedule specified in the respective arm.
219746860|NCT05943496|DRUG|Acalabrutinib|Given PO
219746861|NCT05943496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219746862|NCT05943496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
219368571|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
219368572|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
219368573|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
219368574|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
219746863|NCT05943496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
219746864|NCT05943496|PROCEDURE|Computed Tomography|Undergo CT scan
219746865|NCT05943496|PROCEDURE|Echocardiography|Undergo ECHO
219746866|NCT05943496|BIOLOGICAL|Obinutuzumab|Given IV
219746867|NCT05943496|OTHER|Questionnaire Administration|Ancillary studies
219746868|NCT05943496|BIOLOGICAL|Tafasitamab|Given IV
219746869|NCT03766399|DRUG|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
219746870|NCT03766399|DRUG|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
219746871|NCT05809583|DRUG|Ozanimod|Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
219746872|NCT06445439|DEVICE|Pacing rate of 80 bpm|Pacing rate of 80 bpm
219746873|NCT06445439|DEVICE|Pacing rate of 60 bpm|Pacing rate of 60 bpm
219746874|NCT03981055|DEVICE|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
219760773|NCT05962021|DRUG|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
219760774|NCT03906643|DRUG|HS-201|HS-201 will be administered intravenously as a single dose
219760775|NCT03759990|DEVICE|lean|Videolaryngoscope used in intubation
219760776|NCT03759990|DEVICE|obese|Videolaryngoscope used in intubation
219368575|NCT00814385|BIOLOGICAL|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
219368576|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
219368577|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
219368578|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
219368579|NCT00814385|BIOLOGICAL|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
219368580|NCT04822545|OTHER|referral to comprehensive weight management clinic|"Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience."
219368581|NCT05759884|DRUG|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
219368582|NCT05759884|RADIATION|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
219368583|NCT06416163|OTHER|Prospective|Collection of prospective data all ready available for participant
219368584|NCT00241332|DRUG|fentanyl|
219368585|NCT02492633|BEHAVIORAL|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
219368586|NCT02492633|BEHAVIORAL|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~1. A web-based smoking cessation intervention via Facebook~2. Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~3. A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
219368587|NCT04106154|BEHAVIORAL|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
219368588|NCT02698098|DRUG|Methadone|
219368589|NCT00065143|DRUG|clofarabine|
219368590|NCT00065143|DRUG|Ara-C|
219368591|NCT00675025|DRUG|Donepezil hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
219368592|NCT00294944|DRUG|Idazoxan|
219368593|NCT01845545|OTHER|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
219368594|NCT00166790|DRUG|chemotherapy agents|
219368595|NCT00166790|PROCEDURE|suction curettage|
219368596|NCT01845714|PROCEDURE|Corneal Cross Linking|
219368597|NCT01845714|PROCEDURE|Corneal Cross Linking combined with topoguided PRK|
219368598|NCT04398732|DRUG|Enbrel|As provided in real world practice
219368599|NCT02113670|OTHER|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
219368600|NCT00002623|DRUG|carboplatin|
219368601|NCT00002623|DRUG|cisplatin|
219368602|NCT00002623|PROCEDURE|conventional surgery|
219368603|NCT00002623|RADIATION|radiation therapy|
219368604|NCT02395991|DRUG|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
219368605|NCT02395991|OTHER|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
219368606|NCT01724957|PROCEDURE|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
219368607|NCT01596257|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
219368608|NCT01596257|DEVICE|CliniMACS|
219368609|NCT00936988|DRUG|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
219368610|NCT05501626|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
219368611|NCT05501626|DEVICE|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
219746875|NCT03981055|DEVICE|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
219746876|NCT03981055|OTHER|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
219746877|NCT03276273|DEVICE|recording of Bispectral Index|recording of Bispectral Index
219746878|NCT03453541|DRUG|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
219746879|NCT03453541|DRUG|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
219746880|NCT04978467|DEVICE|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
219746881|NCT06264596|DRUG|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
219746882|NCT06264596|PROCEDURE|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
219746883|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
219746884|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
219746885|NCT06269406|OTHER|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
219746886|NCT00523107|DRUG|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
219746887|NCT00523107|DRUG|Placebo|500 ml normal saline t.i.w. per week
219746888|NCT05811832|OTHER|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
219178916|NCT05087667|DEVICE|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
219178917|NCT05087667|DEVICE|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
219178918|NCT05239299|OTHER|No intervention, observational study|Focus Group
219178919|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
219178920|NCT02853851|OTHER|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
219178921|NCT06108596|DRUG|Sintilimab with Interleukin-2+CAPOX|Sintilimab with Interleukin-2+CAPOX
219178922|NCT03762915|DRUG|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
219557669|NCT06325124|OTHER|Conventional PT|"They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
219746889|NCT06291987|DRUG|Ivosidenib|Ivosidenib will be given at assigned dose once daily.
219746890|NCT06291987|DRUG|Ruxolitinib|Ruxolitinib will be given at assigned dose twice daily.
219746891|NCT06637748|PROCEDURE|Echocardiography|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)"
219746892|NCT06637748|PROCEDURE|Electrocardiography|"Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval"
219746893|NCT06639295|DRUG|611|611 subcutaneous (SC) injection.
219746894|NCT06639295|DRUG|Placebo|Placebo subcutaneous (SC) injection.
219746895|NCT06640127|PROCEDURE|Sinus lifting and implant placement with osteotomes|Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion
219746896|NCT06640127|PROCEDURE|Sinus lifting and implant placement with specifically designed drills|Sequential drills were used for sinus membrane elevation and implant insertion
219746897|NCT06641024|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
219746898|NCT06640218|DEVICE|sealer activation with Eddy sonic and AF max|activation of sealer after cleaning and shaping, before the obturation
219746899|NCT06640218|OTHER|without AF max or Eddy sonic sealer activation|sealer without activation
219746900|NCT02003313|BIOLOGICAL|Group T|0.5ml, Intramuscular
219746901|NCT02003313|BIOLOGICAL|Group C|0.5ml, Intramuscular
219746902|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
219746903|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
219746904|NCT06505395|DRUG|SYHX2008 injection|The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
219746905|NCT06505395|DRUG|Sandostatin LAR@|The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
219746906|NCT05176665|DRUG|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
219746907|NCT04904913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219746908|NCT04904913|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
219746909|NCT00803855|DRUG|AZD1446|oral, single dose
218990964|NCT03305575|DRUG|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
218990965|NCT03305575|DRUG|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
218990966|NCT02034201|DRUG|Lisdexamfetamine|
218990967|NCT02034201|DRUG|Placebo|
218990968|NCT05956496|OTHER|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
218990969|NCT05956496|OTHER|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
218990970|NCT00315172|PROCEDURE|Non-Exercise Activity Thermogenesis (NEAT)|
219557670|NCT00678327|BIOLOGICAL|bleomycin sulfate|Given IV
219557671|NCT00678327|BIOLOGICAL|filgrastim|Given subcutaneously
218990971|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
219746910|NCT00979758|DRUG|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
219746911|NCT04506437|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
219746912|NCT04506437|BEHAVIORAL|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
219746913|NCT00938080|BIOLOGICAL|AG013|Mouth rinse once a day for 14 days
219746914|NCT00938080|BIOLOGICAL|AG013|Mouth rinse three times a day for 14 days
219746915|NCT00938080|BIOLOGICAL|AG013|Mouth rinse six times a day for 14 days
218990972|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
218990973|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
218990974|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
218990975|NCT02705469|DRUG|ZEN003694|
219557672|NCT00678327|BIOLOGICAL|pegfilgrastim|Given subcutaneously
219746916|NCT00938080|OTHER|Placebo|Mouth rinse once a day for 14 days
219557673|NCT00678327|DRUG|cyclophosphamide|Given IV
218990976|NCT04002713|OTHER|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
218990977|NCT04002713|OTHER|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
218990978|NCT02577978|DEVICE|Medacta GMK posterior stabilized prosthesis|
218990979|NCT02577978|DEVICE|Medacta GMK Sphere prosthesis|
218990980|NCT02792881|PROCEDURE|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
219557674|NCT00678327|DRUG|dacarbazine|Given IV
219557675|NCT00678327|DRUG|doxorubicin hydrochloride|Given IV
219746917|NCT00938080|OTHER|Placebo|Mouth rinse three times a day for 14 days
219746918|NCT00938080|OTHER|Placebo|Mouth rinse six times a day for 14 days
219746919|NCT02014376|DRUG|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
219746920|NCT02014376|DRUG|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
219746921|NCT02014376|DRUG|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
219746922|NCT01531335|DIETARY_SUPPLEMENT|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
219746923|NCT01531335|DIETARY_SUPPLEMENT|Standard care|25 kcal per kg of body weight
219746924|NCT06563869|DRUG|PEG-rhG-GSF|Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
219746925|NCT04656561|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT
219746926|NCT04656561|OTHER|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
219746927|NCT06195007|BEHAVIORAL|Motivational Interview|"The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior."
219746928|NCT06172023|DRUG|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
219746929|NCT06172023|DRUG|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
219746930|NCT05727501|OTHER|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
219746931|NCT05727501|OTHER|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
219746932|NCT01929694|DIETARY_SUPPLEMENT|Berocca Boost|
219746933|NCT01929694|DIETARY_SUPPLEMENT|Placebo|
219746934|NCT03000881|OTHER|standard adhesive|This is a standard adhesive (hydrocolloid)
218990981|NCT03794297|DRUG|Dabrafenib Mesylate|Given PO
219557676|NCT00678327|DRUG|etoposide|Given IV
219557677|NCT00678327|DRUG|prednisolone|Given orally
218990982|NCT03794297|OTHER|Quality-of-Life Assessment|Ancillary studies
218990983|NCT03794297|OTHER|Questionnaire Administration|Ancillary studies
219557678|NCT00678327|DRUG|procarbazine hydrochloride|Given orally
219557679|NCT00678327|DRUG|vinblastine sulfate|Given IV
219746935|NCT03000881|OTHER|New adhesive strip|This is a newly developed adhesive strip
219746936|NCT00718185|PROCEDURE|Obtain blood specimens|Obtain blood samples at multiple timepoints.
219746937|NCT04873557|OTHER|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
219746938|NCT00001854|DRUG|Ribavirin|
219746939|NCT01833078|DRUG|ghrelin|ghrelin administration subcutaneously for 7 days
219746940|NCT05623605|DRUG|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
219746941|NCT05623605|DRUG|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
218990984|NCT03794297|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
218990985|NCT04660877|DIETARY_SUPPLEMENT|Cheddar Cheese|20g of protein from cheddar cheese
218990986|NCT04660877|DIETARY_SUPPLEMENT|Milk|20g of protein from milk
219557680|NCT00678327|DRUG|vincristine sulfate|Given IV
219557681|NCT01269476|DRUG|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
219557682|NCT01269476|DRUG|Placebo|Same volumes and frequency as active.
219746942|NCT05623605|DRUG|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
219746943|NCT05532800|DRUG|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
219746944|NCT05532800|DRUG|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
219746945|NCT02531256|DEVICE|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
219746946|NCT00854737|DIETARY_SUPPLEMENT|cytidine|cytidine (2g po daily for 4 months)
219746947|NCT00854737|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
219746948|NCT00854737|DRUG|placebo|sugar pill
219746949|NCT01840072|OTHER|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
219746950|NCT02946983|OTHER|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
219746951|NCT02946983|OTHER|Control|Intragastric administration of distilled water
219760777|NCT01865487|BIOLOGICAL|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
219760778|NCT01865487|BIOLOGICAL|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
218990987|NCT01335191|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
218990988|NCT01335191|OTHER|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
218990989|NCT03340688|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
218990990|NCT00441714|PROCEDURE|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
219368612|NCT04019366|OTHER|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
219368613|NCT04019366|OTHER|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
219368614|NCT02274337|DRUG|AC0010|patients take avitinib orally once per day at different dose
219368615|NCT06487546|DIETARY_SUPPLEMENT|Ergothioneine|This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.
219368616|NCT06454084|DRUG|Acetylcholine Chloride|Vasodilator solution
219368617|NCT03599180|DEVICE|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
219368618|NCT00237133|DRUG|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
219368619|NCT06526780|PROCEDURE|Bronchscopy|Bronchscopy in critical ill children with airway diseases
219368620|NCT02427113|OTHER|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
219368621|NCT02427113|OTHER|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
219368622|NCT01912755|DRUG|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
219368623|NCT01912755|DRUG|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
219368624|NCT02054182|DRUG|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
219746952|NCT04077320|BEHAVIORAL|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
219746953|NCT04077320|BEHAVIORAL|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
218990991|NCT06506656|DEVICE|Hyadrol®|Sterile single-use Medical Device for intra-articular injections
218990992|NCT04269447|DIAGNOSTIC_TEST|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
218990993|NCT03486223|DRUG|GSK2256294|Drug will be taken daily by mouth for 7 days.
218990994|NCT03486223|DRUG|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
218990995|NCT02126020|DRUG|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
218990996|NCT01819831|RADIATION|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
219368625|NCT05779709|OTHER|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
219368626|NCT05779709|OTHER|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
219368627|NCT01526525|DRUG|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
219368628|NCT01526525|DRUG|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
219368629|NCT01526525|DRUG|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
219746954|NCT01832194|DRUG|Botox|
219746955|NCT03170986|BEHAVIORAL|Multisectoral agriculture and Microfinance Intervention|
219746956|NCT03285360|COMBINATION_PRODUCT|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
219746957|NCT03285360|COMBINATION_PRODUCT|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
219746958|NCT01706315|DRUG|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
219746959|NCT01706315|DRUG|Placebo|Matching placebo will be available
219746960|NCT00099905|DRUG|vildagliptin|
219746961|NCT00421967|DRUG|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
219746962|NCT00421967|DRUG|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
219746963|NCT01652404|BEHAVIORAL|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
219746964|NCT01652404|BEHAVIORAL|Conventional treatment|The antibiotics duration will be determined by treating physician.
219746965|NCT01758120|DRUG|prednisone plus cyclophosphamide|"1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
219746966|NCT01758120|DRUG|Prednisone alone|"1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
218990997|NCT01819831|PROCEDURE|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
218990998|NCT04800354|BEHAVIORAL|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
218990999|NCT04800354|BEHAVIORAL|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
218991000|NCT01749137|DRUG|Setmelanotide|Daily subcutaneous infusion
218991001|NCT01749137|DRUG|Placebo|Daily subcutaneous infusion
218991002|NCT00388960|DRUG|Amrubicin|"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
218991003|NCT00388960|DRUG|Cisplatin|"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
218991004|NCT00388960|DRUG|Etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
218991005|NCT05812196|DIAGNOSTIC_TEST|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
218991006|NCT05812196|BIOLOGICAL|COVID infection|Verified COVID-19 infection.
219368630|NCT01526525|DRUG|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
219746967|NCT02311504|DEVICE|OCT examination|
219746968|NCT05536115|DEVICE|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
219746969|NCT00265499|PROCEDURE|Skeletonization of the internal thoracic artery|
219746970|NCT01435356|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
219746971|NCT01435356|BIOLOGICAL|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
219746972|NCT03236545|OTHER|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
219746973|NCT03236545|OTHER|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
219746974|NCT01481610|DRUG|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
219746975|NCT01481610|DRUG|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
219746976|NCT03855540|DIAGNOSTIC_TEST|ECHOcardiography|"ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease"
219746977|NCT03855540|DIAGNOSTIC_TEST|Peripheral blood samples for plasmatic biomarkers|"1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499"
219746978|NCT03855540|DIAGNOSTIC_TEST|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
219746979|NCT03855540|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
219368631|NCT01526525|PROCEDURE|sedation|If the patient had sedation score \>2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
219746980|NCT03855540|DIAGNOSTIC_TEST|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
219746981|NCT02386956|OTHER|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
219746982|NCT02386956|OTHER|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
219746983|NCT02386956|OTHER|Control|10 minutes with the patient lying on a machine off of magnetotherapy
218991007|NCT03627143|OTHER|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance"
218991008|NCT01758432|COMBINATION_PRODUCT|PRT064445/Apixaban|
218991009|NCT01758432|COMBINATION_PRODUCT|Placebo/Apixaban|
218991010|NCT01758432|DRUG|Placebo|
218991011|NCT01101984|DRUG|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
218991012|NCT01101984|DRUG|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
219368632|NCT01526525|PROCEDURE|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
219368633|NCT01526525|DRUG|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
219368634|NCT01526525|DRUG|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
219368635|NCT02928952|BEHAVIORAL|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
219368636|NCT05655585|OTHER|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
219368637|NCT05655585|OTHER|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
218991013|NCT01572558|PROCEDURE|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
218991014|NCT01572558|DRUG|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
218991015|NCT04188847|DRUG|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
218991016|NCT06364098|DRUG|Misoprostol|400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
218991017|NCT00232609|DEVICE|GameCycle Exercise System|
219746984|NCT00860496|DRUG|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
219746985|NCT00860496|DRUG|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
219746986|NCT00020683|DRUG|incyclinide|High dose given orally
219746987|NCT00020683|DRUG|incyclinide|Low dose given orally
218991018|NCT05166824|DEVICE|TempSure|Radiofrequency platform
218991019|NCT05166824|DEVICE|Scalpel|Cold knife
218991020|NCT05166824|DEVICE|Bovie|Electrosurgery and electrocautery platform
218991021|NCT05166824|DEVICE|Pelleve|Radiofrequency platform
218991022|NCT02647203|DRUG|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
218991023|NCT01803204|OTHER|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
219368638|NCT02553837|BIOLOGICAL|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
219368639|NCT03406533|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
219368640|NCT03406533|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
219368641|NCT03406533|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
219746988|NCT00020683|OTHER|laboratory biomarker analysis|Correlative studies
219746989|NCT03774381|DIETARY_SUPPLEMENT|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
219746990|NCT03774381|DIETARY_SUPPLEMENT|Control group|160 mg of placebo is orally administered per day for 12 weeks.
218991024|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils|4 months consumption
218991025|NCT01611649|DIETARY_SUPPLEMENT|Formula containing plant oils|4 months consumption
219368642|NCT03406533|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
219368643|NCT03406533|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
219368644|NCT03325179|OTHER|Thread-embedding Therapy|
219368645|NCT01905475|DRUG|POL6326|
219368646|NCT01905475|DRUG|Placebo|
219368647|NCT00612599|DRUG|biphasic insulin aspart|
219368648|NCT01998542|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
219368649|NCT01998542|BIOLOGICAL|CRCL|autologous tumor-derived chaperone protein mixture
219368650|NCT01998542|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
219368651|NCT01850615|DRUG|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
219368652|NCT01850615|DRUG|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
219368653|NCT04920240|BEHAVIORAL|cleaning and disinfection mode for surfaces with high frequency contact|According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
219368654|NCT04920240|BEHAVIORAL|Routine procedure|clean the high frequency contact surface like other surfaces
219368655|NCT02829879|DRUG|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
219368656|NCT02829879|DRUG|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
219368657|NCT04522492|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
219368658|NCT04522492|OTHER|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
219368659|NCT00004373|DRUG|alprazolam|
219368660|NCT01275014|DRUG|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
219368661|NCT01275014|DRUG|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
219368662|NCT00998439|DEVICE|SeQuent® Please|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
219368663|NCT00998439|DEVICE|SeQuent® II|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
218991026|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
218991027|NCT02698839|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
219368664|NCT05383690|DEVICE|LED bright light treatment device|Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
219368665|NCT06199167|BEHAVIORAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
219368666|NCT06199167|BEHAVIORAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
219368667|NCT04727541|DRUG|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
219368668|NCT06218927|OTHER|QoL monitoring|QoL questionnaire
218991028|NCT02698839|DEVICE|BuMA™|Stent platform: stainless steel
218991029|NCT03130257|DIAGNOSTIC_TEST|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
219368669|NCT05740774|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
218991030|NCT03130257|DIAGNOSTIC_TEST|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
218991031|NCT03130257|DIAGNOSTIC_TEST|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
219368670|NCT02266433|DRUG|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
219368671|NCT02266433|DRUG|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
219368672|NCT03709563|DIETARY_SUPPLEMENT|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
219746991|NCT06473714|DEVICE|tDCS|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will be made at 1,5mA
219368673|NCT03709563|DIETARY_SUPPLEMENT|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
219368674|NCT01745757|DRUG|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
219368675|NCT01745757|DRUG|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
219368676|NCT04525703|BEHAVIORAL|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
219746992|NCT06473714|DEVICE|SHAM|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will not be made. The electrodes are placed on the skull and a slight but non-continuous intensity is applied.
219746993|NCT03731572|OTHER|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
219368677|NCT06231017|DRUG|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
219746994|NCT03731572|OTHER|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
219746995|NCT04875533|BIOLOGICAL|20vPnC|20vPnC
219746996|NCT04875533|OTHER|Saline|Saline
219746997|NCT04875533|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
219746998|NCT04875533|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
219746999|NCT04981912|DRUG|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"* Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
219747000|NCT02657343|DRUG|Ribociclib|
219747001|NCT02657343|DRUG|T-DM1|
219747002|NCT02657343|DRUG|Trastuzumab|
219747003|NCT02657343|DRUG|Fulvestrant|
219747004|NCT04751357|DIAGNOSTIC_TEST|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
219747005|NCT00811850|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
219747006|NCT00811850|DRUG|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
219747007|NCT03416387|DEVICE|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
218991032|NCT03130257|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
218991033|NCT02131194|DIETARY_SUPPLEMENT|Lenstatin|Dietary Supplement Lenstatin
218991034|NCT02131194|DRUG|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
219747008|NCT00044733|DRUG|Mylotarg (gemtuzumab ozogamicin) Injection|
219747009|NCT01333787|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
219747010|NCT02011542|DRUG|VSL#3|This is a probiotic mixture
219747011|NCT02011542|DRUG|Placebo|This is a pill with inactive ingredients.
219747012|NCT05713292|DRUG|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
219747013|NCT05713292|DRUG|Pirfenidone placebo|Pirfenidone placebo
218991035|NCT03903848|OTHER|Exercise|Single session of treadmill walking and resistance exercise
219747014|NCT06312059|OTHER|Advance Infant Formula Powder|Sole source infant nutrition for the control arm.
219747015|NCT06312059|OTHER|"Kendamil Cow milk test product"|Sole source infant nutrition for the cow milk test arm.
218991036|NCT04079101|DRUG|BIIB104|Administered as specified in the treatment arm.
219747016|NCT06312059|OTHER|"Kendamil goat milk test product"|Sole source infant nutrition for the goat milk test arm.
219747017|NCT03988205|BEHAVIORAL|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
219747018|NCT03988205|DRUG|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
219747019|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
218991037|NCT04079101|DRUG|Placebo|Administered as specified in the treatment arm.
219747020|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
219747021|NCT05338736|DIAGNOSTIC_TEST|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
219747022|NCT00951639|DIETARY_SUPPLEMENT|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
219747023|NCT00951639|PROCEDURE|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
219747024|NCT00951639|DIETARY_SUPPLEMENT|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
219368678|NCT04304456|OTHER|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
219747025|NCT04412746|DRUG|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
219747026|NCT06549231|DRUG|Rituximab|one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
219747027|NCT06549231|DRUG|Placebo|one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
219747028|NCT00072995|BEHAVIORAL|Four Diets Differing in Macronutrient Composition|
219747029|NCT00072995|BEHAVIORAL|Diets Low in Saturated Fat|
219747030|NCT00330733|DRUG|Salsalate|Participants were randomized to 12-week treatment with up to 4 g/day.
219747031|NCT00330733|DRUG|Placebo|Participants were randomized to 12-week treatment matching the active salsalate arm.
218991038|NCT06502496|BEHAVIORAL|art-therapy|Over the 6 sessions, different artistic techniques will be explored, depending on the artist leading the workshop: stencil, graffiti, spray paint, collage, oil pastel, calligraphy and acrylic doodling. A collective work may also be proposed.
218991039|NCT06502496|BEHAVIORAL|relaxation|relaxation sessions with the referent psychologist
218991040|NCT01824641|DEVICE|Eliminate aspiration catheter|Eliminate aspiration catheter
218991041|NCT01824641|PROCEDURE|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
218991042|NCT00080808|DRUG|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
219747032|NCT03358173|PROCEDURE|Conservative Treatment|Conservative Treatment
219747033|NCT03358173|PROCEDURE|Operative Plate Fixation|Operative Plate Fixation
219747034|NCT01836354|BEHAVIORAL|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
219747035|NCT03531541|DEVICE|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
219747036|NCT03531541|DEVICE|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
218991043|NCT00080808|DRUG|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
218991044|NCT00080808|DRUG|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
218991045|NCT00080808|DRUG|Sildenafil citrate|Oral sildenafil as needed
219368679|NCT00712348|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
219368680|NCT02820961|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDAC)
219368681|NCT02820961|DRUG|exemestane|Aromatase inhibitor
219368682|NCT02848196|RADIATION|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
218991046|NCT00080808|PROCEDURE|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
219747037|NCT03531541|DEVICE|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
218991047|NCT04979468|DRUG|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
219368683|NCT00002909|DRUG|chemotherapy|
219368684|NCT00002909|DRUG|oral sodium phenylbutyrate|
218991048|NCT05205330|DRUG|CR6086|oral CR6086, twice a day for 14 days
218991049|NCT05205330|BIOLOGICAL|AGEN2034|AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
218991050|NCT03673852|BEHAVIORAL|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
218991051|NCT03673852|BEHAVIORAL|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
219368685|NCT02788864|DRUG|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
219368686|NCT02788864|DRUG|Placebo|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
219368687|NCT05272865|DRUG|Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator|Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
219368688|NCT00047658|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
219368689|NCT01920360|OTHER|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
219368690|NCT01920360|OTHER|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
219368691|NCT01920360|OTHER|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
219747038|NCT03531541|DEVICE|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
219747039|NCT03014115|DIETARY_SUPPLEMENT|combination ARA + DHA|combination ARA + DHA supplemented infant formula
219747040|NCT03014115|DIETARY_SUPPLEMENT|DHA|DHA supplemented infant formula
219747041|NCT00751985|OTHER|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
218991052|NCT05310461|PROCEDURE|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
218991053|NCT05310461|PROCEDURE|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
218991054|NCT05469035|OTHER|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
219747042|NCT00751985|OTHER|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
219747043|NCT00751985|OTHER|Control|The participant is being informed about their allocation to the control group.
219747044|NCT00660231|DRUG|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
219747045|NCT00660231|DRUG|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
219747046|NCT00982280|DRUG|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
219747047|NCT01979185|DRUG|Simvastatin|
219747048|NCT01979185|DRUG|SSP-004184SS|
219747049|NCT02941029|OTHER|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
219747050|NCT00980798|DRUG|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
218991055|NCT05469035|OTHER|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
218991056|NCT03736733|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
218991057|NCT03736733|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
218991058|NCT03944421|OTHER|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
218991059|NCT03944421|OTHER|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
218991060|NCT01847274|DRUG|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
218991061|NCT01847274|DRUG|placebo|
218991062|NCT05210335|OTHER|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
218991063|NCT06055101|DRUG|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
219368692|NCT02745561|DRUG|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
219747051|NCT00980798|DRUG|Placebo|placebo tablet once daily for 16 weeks
219747052|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
219747053|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
218991064|NCT06055101|DRUG|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
218991065|NCT06055101|DRUG|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
218991066|NCT03398785|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
218991067|NCT00860483|OTHER|observational|PET Scan
218991068|NCT03582878|DRUG|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
218991069|NCT03582878|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
218991070|NCT03692247|OTHER|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
219368693|NCT02745561|DRUG|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
219368694|NCT02745561|RADIATION|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
219368695|NCT05623293|DIAGNOSTIC_TEST|eye - Optcial coherence tomography|pre and postoperative
219747054|NCT03283956|DEVICE|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
218991071|NCT05119517|OTHER|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
218991072|NCT03443375|OTHER|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
218991073|NCT03367221|DEVICE|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
219368696|NCT02602223|DEVICE|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
219747055|NCT03749239|DIETARY_SUPPLEMENT|Collagen protein|Collagen protein
219747056|NCT04724837|DRUG|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
218991074|NCT02179242|OTHER|Cardiac rehab|
219368697|NCT02602223|DEVICE|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
219368698|NCT01375764|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219368699|NCT01375764|DRUG|Ezetimibe|Administered orally once a day
219368700|NCT01375764|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
219368701|NCT04070482|OTHER|Tenofovir exposure in utero and during breastfeeding|Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
219747057|NCT04724837|DRUG|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
219747058|NCT04724837|DRUG|Placebo|Participants will receive placebo as per the arms they are randomized to.
219747059|NCT05962736|DEVICE|Mirror therapy|The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
219747060|NCT05018728|DRUG|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
219747061|NCT04375358|BIOLOGICAL|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
219747062|NCT00522379|DRUG|Rotigotine|2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
219747063|NCT00522379|DRUG|Rotigotine|4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
219747064|NCT00522379|OTHER|Placebo|Placebo transdermal patch applied daily
219747065|NCT00522379|DRUG|Rotigotine|6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
219747066|NCT00522379|DRUG|Rotigotine|8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
218991075|NCT02057679|DRUG|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
218991076|NCT02057679|DRUG|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
219368702|NCT04213755|DIAGNOSTIC_TEST|ROTEM|ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
219368703|NCT05286606|BEHAVIORAL|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
219368704|NCT03436784|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
219368705|NCT03595280|BEHAVIORAL|Hookah tobacco risk messages|Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
219368706|NCT05042739|DIAGNOSTIC_TEST|CAARMS;SIPS; BSABS;|Comprehensive Assessment of At Risk Mental State (CAARMS); Structured Interview for Psychosis-Risk Syndrome (SIPS); Bonn Scale for the Assessment of Basic Symptoms (BSABS);
219368707|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation in Whole Course of Treatment with ATDs|Moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken from ATDs treatment starting until 1 year after ATDs withdrawal.
219747067|NCT03901365|OTHER|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
219747068|NCT03901365|OTHER|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
219747069|NCT03901365|OTHER|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
219747070|NCT01613586|DRUG|ASP3652|Oral
219747071|NCT01613586|DRUG|Placebo|Oral
219747072|NCT05196620|OTHER|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
219747073|NCT04198402|BIOLOGICAL|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
219747074|NCT03135067|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
219747075|NCT02100826|DRUG|Cephalexin|Administered orally.
219747076|NCT05348421|PROCEDURE|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
219747077|NCT05348421|PROCEDURE|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
219747078|NCT00877656|BIOLOGICAL|HuMax-CD4|Active treatment
219747079|NCT01676870|BEHAVIORAL|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
219747080|NCT01676870|BEHAVIORAL|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
219747081|NCT01676870|BEHAVIORAL|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
219747082|NCT00894881|PROCEDURE|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
219747083|NCT03429088|BEHAVIORAL|Motivational interviewing telephone counseling|
219747084|NCT06466642|BEHAVIORAL|Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©|The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
219747085|NCT05189678|OTHER|No intervention|No intervention
219747086|NCT05105724|BIOLOGICAL|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
219747087|NCT00019448|DRUG|gp100 antigen|
219747088|NCT00019448|DRUG|interleukin-2|
219747089|NCT06048042|BIOLOGICAL|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
219747090|NCT06048042|BIOLOGICAL|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
219747091|NCT03316430|OTHER|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
219747092|NCT00967499|DRUG|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
218991077|NCT04784377|OTHER|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
219747093|NCT00967499|DRUG|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
219747094|NCT00091975|DRUG|Zemplar Capsule|
219747095|NCT05920252|BEHAVIORAL|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
219747096|NCT05920252|BEHAVIORAL|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
219747097|NCT05697224|DIAGNOSTIC_TEST|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis
219747098|NCT05846893|DEVICE|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
219747099|NCT05846893|DEVICE|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
219747100|NCT05838248|OTHER|antibiotic duration|Duration of antibiotic treatment post appendectomy
219747101|NCT06468176|OTHER|Cognitive Behavioral Therapy (CBT) neuropsychologist|"* CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week"
219747102|NCT03763370|DRUG|Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)|"Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles"
219747103|NCT03763370|DRUG|Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)|"Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information"
219747104|NCT06548971|DRUG|Aspirin|Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
219747105|NCT06548971|DRUG|Placebo|Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
219747106|NCT06548971|OTHER|Best medical management|Patients in both groups will receive the best medical management according to the guidelines.
219747107|NCT02954562|OTHER|fMRI|Participants will undergo two to three fMRI scans
219747108|NCT05189860|DEVICE|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
219747109|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
219747110|NCT06036368|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
219747111|NCT06117540|DRUG|WX390|WX390 tablet, 1.1 mg once a day
219747112|NCT05766254|DEVICE|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
219747113|NCT05766254|DEVICE|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219747114|NCT03673072|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
219747115|NCT03673072|DRUG|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
219191537|NCT04014166|OTHER|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
219747116|NCT03673072|PROCEDURE|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
219747117|NCT03673072|DRUG|Adjuvant chemotherapy|Can be selected by Investigator's Choice
219747118|NCT05789290|DEVICE|Hilotherm cryocompression device|An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
219747119|NCT05422482|BIOLOGICAL|GC1123|ICV-administered Hunterase, Idursulfase-ß
219747120|NCT04344912|OTHER|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
219747121|NCT04498767|RADIATION|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
219747122|NCT04498767|RADIATION|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
219747123|NCT05855993|OTHER|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
219747124|NCT05855993|OTHER|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
219747125|NCT03377322|DRUG|Probiotic Capsule|Probiotic - one capsule a day for four weeks
219747126|NCT03377322|DRUG|Placebo Capsule|Placebo - one capsule a day for four weeks
219747127|NCT00022854|PROCEDURE|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
219747128|NCT00022854|PROCEDURE|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
219747129|NCT00022854|PROCEDURE|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
219747130|NCT06637566|OTHER|Brandt Daroff exercises along with Cawthorne Cooksey exercises|"Brandt Daroff exercises along with Cawthorne Cooksey exercises. The Cawthorne Cooksey exercises include eye and head movements, coordination of eye and head movements (visual-vestibular interaction), postural control exercises, and progressively more difficult balance tasks (eyes open, eyes closed, large base support, uneven base support, while walking, in high visual or noisy environments). Exercises should be done three times a day, with 5 repetitions of each. The exercises will be performed in three sessions per week with 60 minutes each session for eight weeks. The cawthorne Cooksey exercises includes the following:~A: Eye and head movement~B: Head and body movement, sitting down:~C: Standing up exercises:"
219747131|NCT06637566|OTHER|Brandt Daroff exercises|brandt daroff exercises without cawthorne Cooksey exercises. To begin the Brandt-daroff exercise, the patient will sit and swivel the head 45 degrees to one side (left), then instantly lie down on the other shoulder (right). The patient should be instructed to maintain this posture for 30 seconds or until the vertigo subsides. The patient then gradually returns to the starting position, maintaining the left ear rotation until sat upright. Following the same 30 second time limits, the patient turns his head in the opposite way (right) and rests down on the opposite shoulder (left). These exercises will be instructed to perform at home for 3 sets (morning, afternoon and evening) with 5 repetitions approximately for 30 minutes in each session for five weeks
219747132|NCT06638775|OTHER|Fesia Grasp|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
219747133|NCT06638775|OTHER|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
219747134|NCT06637670|OTHER|Kinesiology taping|'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
219191538|NCT05756686|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
219747135|NCT06637670|OTHER|Placebo taping|A tape without tension was applied perpendicular on the quadriceps femoris muscle.
219747136|NCT06638762|PROCEDURE|surgery|We recruited patients diagnosed with oral squamous cell carcinoma who had received surgical treatment, collected patient follow-up information and postoperative pathological images, enhanced and standardized pathological images, and extracted pathological features through visual transformation model.
219747137|NCT06638723|BEHAVIORAL|Balance and fall recovery training|Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
219747138|NCT06639880|OTHER|usual care exercise|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
219191539|NCT05756686|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
219191540|NCT04410328|DRUG|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
219747139|NCT06639880|OTHER|triple attack protocol|a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
219747140|NCT06642051|DEVICE|High Intensity focused ultrasound|Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
219747141|NCT06641453|BIOLOGICAL|GPC3-CART cells|"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."
219747142|NCT06641453|DRUG|Fludarabine Phosphate for Injection|Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
219747143|NCT06641453|DRUG|Cyclophosphamide for Injection|Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
219747144|NCT04562090|DRUG|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
219747145|NCT06643247|DRUG|Drug|1\) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
219747146|NCT06643247|PROCEDURE|Electroacupuncture|Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
219747147|NCT06639009|OTHER|940nm diode laser photobiomodulation|"The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes"
219747148|NCT06639009|OTHER|Conventional non -Invasive management in Oral Submucous fibrosis|"Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation"
219747149|NCT06253767|PROCEDURE|Endodontic Treatment|Conventional endodontic treatment will be performed equally on all participants.
219747150|NCT06253767|DEVICE|Low Level Laser Therapy|Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
219747151|NCT06253767|DEVICE|Simulation Low Level Laser therapy|A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
219747152|NCT04782180|DRUG|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
219747153|NCT04782180|BEHAVIORAL|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
218991078|NCT04784377|OTHER|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
219747154|NCT05949385|DRUG|ZX-7101A|Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
219747155|NCT06125405|DRUG|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
219747156|NCT06320782|BEHAVIORAL|Calorie restriction and balanced distribution of macronutrients|Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats
219747157|NCT06320782|BEHAVIORAL|Calorie restriction and low-carbohydrate diet|Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate
219747158|NCT06320782|BEHAVIORAL|Calorie restriction and low-fat diet|Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate
219747159|NCT06320782|BEHAVIORAL|Collective nutritional guidance|Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
218991079|NCT04784377|OTHER|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
219368708|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation During Maintenance Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded at the early course of ATDs treatment, and moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken when the ATDs dose is titrated down to a maintenance level until 1 year after ATDs withdrawal.
219368709|NCT06540469|DIETARY_SUPPLEMENT|Iodine Restriction in Whole Course of Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded from ATDs treatment starting until 1 year after ATDs withdrawal.
219368710|NCT06540469|DRUG|anti-Thyroid Drugs|Individualized methimazole (MMI)
219368711|NCT06095739|COMBINATION_PRODUCT|DA-OTC-002|"The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject"
219368712|NCT01194440|DRUG|letrozole|Given orally
219368713|NCT01194440|DRUG|zoledronic acid|Given IV
219368714|NCT03299803|BEHAVIORAL|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
219368715|NCT01239355|DRUG|Akt Inhibitor MK2206|Given PO
219368716|NCT01239355|OTHER|Laboratory Biomarker Analysis|Correlative studies
219368717|NCT03418012|DEVICE|cervical pessary|Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
219368718|NCT03418012|OTHER|Control-Group|Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
218991080|NCT06450821|PROCEDURE|PRIOR [Proactive Intensive Oral Review & Treatment]|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
219747160|NCT04672681|BEHAVIORAL|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
219747161|NCT04662879|OTHER|Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score|ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
218991081|NCT00420693|DRUG|sevoflurane|
218991082|NCT03859778|OTHER|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
218991083|NCT05289791|OTHER|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
218991084|NCT03333447|OTHER|MRI|
218991085|NCT01830478|DRUG|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
218991086|NCT01830478|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
218991087|NCT02497339|BEHAVIORAL|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
218991088|NCT02144623|DRUG|Valproate|
218991089|NCT05473390|OTHER|functional electrical stimulation|functional electrical stimulation on back muscles
218991090|NCT05473390|OTHER|kinesotaping|no intervention
218991091|NCT01483755|PROCEDURE|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
218991092|NCT01483755|PROCEDURE|Percutaneaous intervention|Conventional primary percutaneaous intervention
218991093|NCT06278701|OTHER|late-evening snacks|have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
219368719|NCT03410511|OTHER|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
219368720|NCT03410511|OTHER|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
219368721|NCT03410511|OTHER|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
219368722|NCT02409238|DRUG|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
219747162|NCT04662879|OTHER|Abdominal imaging|Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
219747163|NCT06161493|DRUG|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
219747164|NCT06161493|DRUG|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
219747165|NCT03886636|OTHER|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
218991094|NCT00288054|BIOLOGICAL|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
219747166|NCT03886636|OTHER|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
218991095|NCT00288054|DRUG|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
219747167|NCT03886636|OTHER|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
219178923|NCT05516836|OTHER|Multicomponent exercise program|"Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
219747168|NCT05706740|OTHER|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
219747169|NCT00684580|OTHER|Data Collection|Continuing review of outcomes and late toxicities
219747170|NCT05253131|DRUG|Selumetinib|"* Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
219747171|NCT06064318|PROCEDURE|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
219747172|NCT04625660|DEVICE|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
219178924|NCT05516836|OTHER|Tele-health primary care rehabilitation program|A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
219178925|NCT06557434|DEVICE|MIRIA|The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
219178926|NCT06453902|DRUG|TGRX-678|All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
219747173|NCT03633058|DRUG|Ketamine|oral ketamine dosed twice daily for 5 days
218991096|NCT00288054|RADIATION|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
218991097|NCT04565470|OTHER|online questionnaire|Web-based questionnaire about use of self-management strategies
219747174|NCT04859075|OTHER|Bifidobacterium longum 35624|1 capsule daily
219178927|NCT05534802|DRUG|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
219178928|NCT05534802|OTHER|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
219747175|NCT05474859|DRUG|XT-0528|Once Daily
219747176|NCT03312543|DEVICE|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
219747177|NCT03312543|DEVICE|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
219747178|NCT05535972|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
219747179|NCT05790031|DEVICE|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
219368723|NCT02409238|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
219368724|NCT02409238|BEHAVIORAL|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
219747180|NCT05362305|BEHAVIORAL|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
219747181|NCT06265415|DRUG|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
219747182|NCT06265415|DRUG|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
218991098|NCT02040571|DEVICE|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
219178929|NCT04966247|OTHER|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
219178930|NCT05369533|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
219178931|NCT05369533|DRUG|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
219178932|NCT05369533|DRUG|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
219178933|NCT04799704|DIAGNOSTIC_TEST|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
219178934|NCT06476275|BIOLOGICAL|Influenza A/Texas/71/2017 (H3N2)|Virus will be administered intranasally
219178935|NCT06476275|BIOLOGICAL|Sham placebo|Placebo will be administered intranasally
219191541|NCT04410328|OTHER|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days.
219191542|NCT02902055|DRUG|Neuromuscular Blocking Agents|Neuromuscular blockae
219191543|NCT02902055|DRUG|Isotonic saline|Placebo
219191544|NCT05517811|DIAGNOSTIC_TEST|TEG indices|Blood samples
219191545|NCT04299581|DRUG|Camrelizumab|a PD-1 immune check inhibitor
219191546|NCT04299581|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
219747183|NCT06265415|DRUG|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
219747184|NCT02614248|OTHER|Organic, Unrefined Coconut Oil|
219747185|NCT02614248|OTHER|Medline Remedy Phytoplex Z-Guard Skin Protectant|
219747186|NCT02694263|DRUG|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
219747187|NCT02694263|DRUG|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
219747188|NCT02694263|DRUG|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
219747189|NCT02694263|DRUG|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
219747190|NCT02694263|DRUG|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
219747191|NCT02402647|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
219747192|NCT02402647|BEHAVIORAL|Exposure Therapy (ET)|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
219747193|NCT05724771|DRUG|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
219747194|NCT06258382|OTHER|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
219747195|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
219747196|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
219747197|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
219178936|NCT03715738|OTHER|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
219747198|NCT01374854|BIOLOGICAL|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
219747199|NCT01374854|DRUG|traditional therapy|exogenous insulin injection daily
219747200|NCT04197583|DEVICE|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
219747201|NCT01568879|OTHER|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
219747202|NCT01568879|OTHER|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
219747203|NCT06355297|BEHAVIORAL|Education about pelvic floor|The three educational sessions will last 60 minutes, as follows: session1, anatomy of pelvic floor; session2, function and dysfunction of pelvic floor; session3, risk factor for pelvic floor dysfunctions.
219747204|NCT06564597|OTHER|Patient education|Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
219747205|NCT03637348|DEVICE|TrueTear|Ues of TrueTear neurostimulator
219747206|NCT03754361|PROCEDURE|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
219747207|NCT03754361|PROCEDURE|IHD|HD 4hour 2-3times per week
219747208|NCT04134936|DRUG|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
219747209|NCT04134936|DRUG|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
219747210|NCT06124313|DIETARY_SUPPLEMENT|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
219747211|NCT06446648|DRUG|ICG|Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
219747212|NCT01381887|DRUG|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
219747213|NCT01381887|DRUG|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
219747214|NCT01381887|DRUG|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
219747215|NCT01381887|DRUG|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
219747216|NCT03345225|DEVICE|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
219747217|NCT03345225|DEVICE|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
219747218|NCT01717274|PROCEDURE|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
219747219|NCT01040026|OTHER|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
219747220|NCT00242892|PROCEDURE|Intra coronary measures of pressure|Intra coronary measures of pressure
219747221|NCT02170519|DRUG|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
219747222|NCT05498909|OTHER|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
219747223|NCT01430715|OTHER|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
219747224|NCT02793050|DRUG|Trabectedin|Collection of data on the clinical use of Trabectedin
219747225|NCT04600089|DRUG|Saline|Saline infusion
219747226|NCT04600089|DRUG|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
219747227|NCT05938946|DRUG|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
219747228|NCT05938946|DRUG|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
219747229|NCT05294523|PROCEDURE|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
219747230|NCT00323622|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
218991099|NCT02040571|DEVICE|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
218991100|NCT04882618|DRUG|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
219747231|NCT00323622|BIOLOGICAL|Engerix™-B|IM injection in the deltoid muscle
219747232|NCT00323622|BIOLOGICAL|Hiberix®|IM injection in the deltoid muscle
219747233|NCT00323622|BIOLOGICAL|Prevnar™|IM injection in the deltoid muscle
219747234|NCT00323622|DRUG|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
219747235|NCT00323622|DRUG|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
219747236|NCT04954989|BIOLOGICAL|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
219747237|NCT04954989|BIOLOGICAL|Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
219747238|NCT00622206|DRUG|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
219747239|NCT06016244|OTHER|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
219747240|NCT06567392|DRUG|[14C] HRS-5965|Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
219747241|NCT05280145|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
219747242|NCT05280145|DEVICE|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
219747243|NCT05280145|PROCEDURE|Ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
219747244|NCT04977349|OTHER|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
219747245|NCT04977349|OTHER|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
219747246|NCT05430321|OTHER|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
219747247|NCT05430321|OTHER|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
219747248|NCT05430321|OTHER|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
219747249|NCT06265441|PROCEDURE|Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected|The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
219747250|NCT06265441|PROCEDURE|Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%|The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
219747251|NCT02420717|DRUG|Cyclophosphamide|Given IV
219747252|NCT02420717|DRUG|Cytarabine|Given IV
219747253|NCT02420717|DRUG|Dasatinib|Given PO
219747254|NCT02420717|DRUG|Dexamethasone|Given PO or IV
219747255|NCT02420717|DRUG|Doxorubicin|Given IV
219747256|NCT02420717|OTHER|Laboratory Biomarker Analysis|Correlative studies
219747257|NCT02420717|DRUG|Leucovorin|Given IV or PO
219747258|NCT02420717|DRUG|Mercaptopurine|Given PO
218991101|NCT02624609|OTHER|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
218991102|NCT02624609|OTHER|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
218991103|NCT00289991|DRUG|Itraconazole|Prophylaxis
218991104|NCT00289991|DRUG|Vfend - voriconazole|Prophylaxis
218991105|NCT05969145|PROCEDURE|application of thermophor|The experimental group will be given hot and cold application to the bladder
218991106|NCT04130620|DIAGNOSTIC_TEST|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
218991107|NCT02249585|DEVICE|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
218991108|NCT02249585|DEVICE|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
218991109|NCT02249585|DRUG|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
218991110|NCT02249585|DRUG|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
218991111|NCT02607150|OTHER|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
218991112|NCT02062021|OTHER|No intervention|
218991113|NCT02814578|OTHER|Optical coherent tomography|comparative method for BVS
218991114|NCT02814578|OTHER|IntraVascular UltraSound|The method of goldstandard for decision stent choice
218991115|NCT03203616|DRUG|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
219747259|NCT02420717|DRUG|Methotrexate|Given IV and PO
219747260|NCT02420717|DRUG|Prednisone|Given PO
219747261|NCT02420717|BIOLOGICAL|Rituximab|Given IV
219747262|NCT02420717|DRUG|Ruxolitinib Phosphate|Given PO
219747263|NCT02420717|DRUG|Vincristine|Given IV
219747264|NCT00009542|DRUG|kava (Piper methysticum)|
219747265|NCT01123187|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
219747266|NCT06644963|DEVICE|Impella (5, 5.5 or CP)|Impella (5, 5.5 or CP) as an isolated circulatory support or combined with others Temporary Mechanical Circulatory Support
219747267|NCT06637553|COMBINATION_PRODUCT|Adlay formula|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
219747268|NCT06637553|COMBINATION_PRODUCT|Placebo|Same weight as the adlay formula but did not include the active compound
219747269|NCT03133377|BEHAVIORAL|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
219747270|NCT05328167|DRUG|Perflutren Protein-Type A Microspheres|Given IV
219747271|NCT05328167|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
218991116|NCT05373745|BEHAVIORAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
218991117|NCT05373745|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
219747272|NCT06238856|DRUG|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
219747273|NCT06238856|DRUG|Placebo|Nebulized saline.
219747274|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
218991118|NCT04420442|PROCEDURE|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
218991119|NCT00261222|DRUG|Amodiaquine|
218991120|NCT02084693|DEVICE|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
218991121|NCT01158157|BIOLOGICAL|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
218991122|NCT04159571|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
218991123|NCT04159571|DEVICE|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
218991124|NCT03118635|BEHAVIORAL|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
218991125|NCT00839891|DRUG|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
218991126|NCT01155271|OTHER|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
218991127|NCT01776112|OTHER|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
218991128|NCT01776112|OTHER|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
218991129|NCT03903068|DEVICE|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
218991130|NCT03903068|DEVICE|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
219747275|NCT06658249|OTHER|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
219760779|NCT01441388|DRUG|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
219760780|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
219760781|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
219747276|NCT06658249|OTHER|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
219747277|NCT05248009|DEVICE|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
219747278|NCT06665555|DRUG|ledaborbactam etzadroxil|Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours
219747279|NCT06665555|DRUG|ceftibuten|Five doses of ceftibuten will be administered orally every 12 hours
219747280|NCT06675045|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
219747281|NCT03255395|DEVICE|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
219747282|NCT05319197|OTHER|No Interventions|No Interventions
219747283|NCT07003841|DEVICE|Surgical navigation system with stereotactic guidance|This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery
219747284|NCT07003841|DEVICE|General ultrasound imaging system|A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.
219747285|NCT02397720|DRUG|Azacitidine|Given SC or IV
219747286|NCT02397720|DRUG|Ipilimumab|
219747287|NCT02397720|DRUG|Venetoclax|Given Orally
219747288|NCT02397720|DRUG|Nivolumab|Given IV
219747289|NCT07006883|OTHER|Therapeutic exercise|Therapeutic exercise focused on muscle strengthening, balance, and functional performance.
219747290|NCT07006883|OTHER|Yoga therapeutic exercise|Yoga is a mind-body practice that integrates physical postures, breathing techniques, and mindfulness with the aim of improving physical function, balance, strength, mobility, and psychological well-being. I
219747291|NCT03646357|OTHER|Non-betablocker|No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
219747292|NCT03646357|DRUG|Betablocker|"A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care."
219747293|NCT04420923|OTHER|Observe and Plan|First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.
219747294|NCT04420923|OTHER|Treat-and-Extend|"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."
219747295|NCT02323620|PROCEDURE|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
219747296|NCT07010874|OTHER|REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL|"The duration of the intervention is determined as 10 weeks. Distance nursing interventions based on the model will be carried out through a web page called Take Care of Yourself. Each participant will have a unique username and password while using the website, so that login information and the frequency of visiting the website will be recorded. During the 10-week intervention period, caregivers will be provided with 8 modules of training content. In the first session of the intervention, the website will be introduced, personal goals will be set and the session will be completed with the planning of the next week. personal goals will be set, and in the last session of the intervention, feedback will be given to the individuals by the researcher regarding the achievement of their personal goals and their ability to cope with future difficulties."
218991131|NCT01606007|DRUG|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
218991132|NCT01606007|DRUG|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
218991133|NCT01606007|DRUG|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
218991134|NCT01606007|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
218991135|NCT01606007|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
218991136|NCT01815801|OTHER|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
218991137|NCT01815801|OTHER|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
218991138|NCT01060813|DIETARY_SUPPLEMENT|Leucine supplements|leucine supplements
218991139|NCT00000789|DRUG|Stavudine|
218991140|NCT00000789|DRUG|Zidovudine|
218991141|NCT01826188|DRUG|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
218991142|NCT01826188|DRUG|Placebo|olive oil without cannabis
218991143|NCT00332163|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
218991144|NCT00332163|DRUG|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
218991145|NCT00332163|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
218991146|NCT00332163|DRUG|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
218991147|NCT00332163|DRUG|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
219747297|NCT07010042|OTHER|The Beck Anxiety Inventory (BAI) of adult patients|Postoperative 0,5,10,15 minutes , RSAS and NRS values
219747298|NCT07010991|OTHER|AI based clinical problem solving education|This direct involvement of AI and educators aims to improve learning outcomes by leveraging the scalability of AI and the expertise of educators. The question sets created by students and the answers obtained from ChatGPT are discussed within the group and prepared for class presentation, and the instructor provides feedback on accuracy, timeliness, and scientific relevance. This process aims to support students' participation as active questioners and analyzers, rather than passive consumers of information. Intervention will last for 2 weeks, 2 hours of courses each week, in total 4 hours of education will be given. First 2 hours will be the usage parameters and the knowledge about the ChatGPT system and the 2nd week's 2 hours of education will include the presentations and interactive discussion about the case.
219760782|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
218991148|NCT02519257|PROCEDURE|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
218991149|NCT02519257|PROCEDURE|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
218991150|NCT01292811|DEVICE|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
218991151|NCT01292811|OTHER|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
218991152|NCT00001190|DRUG|Deslorelin|
218991153|NCT02895230|OTHER|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
218991154|NCT02621060|DRUG|Placebo|Placebo: 1200 mg per day for three months
218991155|NCT02621060|DRUG|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
218991156|NCT00573612|BEHAVIORAL|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
218991157|NCT00573612|BEHAVIORAL|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
218991158|NCT03495219|PROCEDURE|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
218991159|NCT03733470|DRUG|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
218991160|NCT03787732|DRUG|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
218991161|NCT03787732|OTHER|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
218991162|NCT05830968|DEVICE|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.
218991163|NCT05722782|DRUG|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
219747299|NCT07010991|OTHER|Traditional Low Back Pain Education|The first session will be given by an independent/different instructor about the definition, reasons, evaluation and the treatment of low back pain for 2 hours. Afterwards the students will be informed about the content of the next week's interactive course and supplied with the study sources like book, articles by the other lecturer. A week will be given to the students to study and the other week they will meet with the lecturer to discuss over a specific case. At the beginning and end of the courses, outcome measures will taken from the both groups.
219747300|NCT07010263|DRUG|AK112|AK112 20mg/kg, intravenous \[IV\]),Q3W
219747301|NCT07010263|OTHER|Placebo|Placebo, intravenous \[IV\]),Q3W
218991164|NCT05722782|DRUG|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
219747302|NCT07009925|DRUG|Ivonescimab 20mg/kg intravenous every 3 weeks|Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.If patient assessment is of clinical benefit, maintenance therapy with ivonescimab or plus polymeric micelles paclitaxel(≤230mg/m\^2) can be continued based on investigator's evaluation and patient's own choice until disease progression or unacceptable toxicity. Ivonescimab is administered first, followed by paclitaxel polymeric micelles and platinum.The maximum treatment duration of ivonescimab and polymeric micelles paclitaxel is 24 months.
219747303|NCT07010523|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.
219747304|NCT07010523|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
219747305|NCT07010523|DRUG|Cyclophosphamide|D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.
219747306|NCT07010419|DRUG|Firmonertinib|Firmonertinib: 240 mg, QD, orally
219747307|NCT07010419|DRUG|Placebo|Placebo: 240 mg, QD, orally
219747308|NCT06679907|DEVICE|WaveLinQ® device|The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.
219747309|NCT06679907|DEVICE|Ellipsys® device|The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
219747310|NCT06679907|DEVICE|No device|Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
219747311|NCT07009977|BEHAVIORAL|self-guided mHealth app only|Mindfulness based stress reduction
219747312|NCT07009977|BEHAVIORAL|self-guided mHealth app + 'real-time' feedback|Mindfulness based stress reduction with mobile app feedback
219747313|NCT07011160|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|Force-steadiness training will be performance either without (sham) or paired with TENS.
219747314|NCT07011160|BEHAVIORAL|Familiarization|Participants will perform 25 trials of the Grooved Pegboard Test
219747315|NCT07011199|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|Intraoperative trans-portal vein injection of 20 million mesenchymal stem cells derived from umbilical cord tissue, suspended in 5 mL autologous plasma.
218991165|NCT05722782|DRUG|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
218991166|NCT03396185|DRUG|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
218991167|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
218991168|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
218991169|NCT02711397|OTHER|Observational study|Comparison excretion levels of gluten immunogenic peptides
218991170|NCT00695877|BIOLOGICAL|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
218991171|NCT04329897|BEHAVIORAL|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
218991172|NCT04379024|DRUG|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
219747316|NCT07011199|PROCEDURE|Kasai Portoenterostomy|Surgical procedure to create a portoenterostomy for biliary drainage in infants with biliary atresia.
219747317|NCT04581577|OTHER|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
219747318|NCT05064540|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
219747319|NCT05064540|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
219760783|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
219760784|NCT01441388|DRUG|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
219760785|NCT01441388|DRUG|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
219760786|NCT02821325|OTHER|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
219368725|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
219368726|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
219368727|NCT00896532|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
219368728|NCT00896532|DRUG|Alendronate|Administered orally once a week
219368729|NCT00896532|DRUG|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
219368730|NCT00896532|DRUG|Romosozumab|Administered by subcutaneous injection
219368731|NCT00896532|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
219368732|NCT00896532|DRUG|Placebo to Denosumab|Administered by subcutaneous injection Q6M
219368733|NCT00896532|DRUG|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
219368734|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
219368735|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
219368736|NCT04758962|BIOLOGICAL|1 µg CoV2 SAM (LNP)|2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
219368737|NCT04399083|DIETARY_SUPPLEMENT|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
219368738|NCT02149810|BEHAVIORAL|Automatic Self Transcending Meditation|as above
218991173|NCT06143644|OTHER|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
219368739|NCT02035826|BEHAVIORAL|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
219368740|NCT05351658|DEVICE|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
219368741|NCT01176916|DRUG|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
219368742|NCT03587532|DIAGNOSTIC_TEST|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
219368743|NCT03587532|DIAGNOSTIC_TEST|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
219368744|NCT03587532|DIAGNOSTIC_TEST|Biological and pathological markers of ischemia|"* Systemic and local capillary lactate on blood samples~* Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~* Pathological analyses of the biopsies at 3 ROI"
219368745|NCT02714166|OTHER|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
219368746|NCT02714166|OTHER|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
219577621|NCT04969718|OTHER|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
219178937|NCT06142630|OTHER|Alteration of patients' position after erector spinae plane block|After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
219178938|NCT06425068|DEVICE|Exposure of the patient to a novel air mattress.|"see information provided in the Arms section (experimental)"
219747320|NCT06694142|BEHAVIORAL|Rosy app|Participants will be provided a six-month membership subscription to the mobile application ROSY. ROSY will recommend pathways for addressing issues through 1) coaching by board certified coaches or 2) joining a completely anonymous community with other people where they can share experiences and get help as new members of the community to overcome sexual health challenges .Users will work towards their health goals each day using tools from medical and mental health experts . Tools used include 1) virtual workshops and 2) coaching sessions which will provide the opportunity to a) Have an authentic and relatable conversation with an expert b) Explore new pathways to better health experience c) Improve their relationship with themselves, partner, and healthcare providers d) Learn fun ways to improve their everyday wellness e) Access live events from anywhere.
219747321|NCT06691555|DEVICE|Suprachoroidal silicone tube (SST) shunt|This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.
219747322|NCT06687096|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
219747323|NCT06687096|OTHER|standart diet list|patients prepared with a routine colonoscopy preparation scheme
219747324|NCT06691178|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
219747325|NCT06690567|DEVICE|Impella implantation|To implante Impella
219747326|NCT06368193|DEVICE|Neuralert Monitor|Device to identify upper extremity asymmetry in patients who are high risk for stroke.
219747327|NCT06694363|BIOLOGICAL|Blood samples|A maximum of 27 ml of blood collected at each visit for metabolic markers analysis
219747328|NCT06694363|BIOLOGICAL|Urine samples|One urine sample collected at each visit for enteric virus infection research
219747329|NCT06694363|BIOLOGICAL|Stool samples|One stool sample collected at each visit for enteric virus infection research
219747330|NCT05461326|PROCEDURE|Quad tendon|quadriceps tendon autograft
219747331|NCT05461326|PROCEDURE|BTB|patellar tendon autograft
219747332|NCT04614272|BEHAVIORAL|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
219747333|NCT04614272|BEHAVIORAL|Reading a poem|Reading is a distraction tool for pain management
219747334|NCT00736151|DRUG|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
219747335|NCT03780712|OTHER|Non applicable|No intervention as it is an observational study
219747336|NCT05345314|PROCEDURE|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
219747337|NCT04849507|DEVICE|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
219747338|NCT06769750|OTHER|leg-lift maneuver|"Patients will be monitored as usual using an SpO2 sensor placed on the index finger of the limb contralateral to the pressure cuff, giving the PI value, a tensiometer taking blood pressure (systolic, diastolic and mean) every 2 minutes, and an ECG.~A transthoracic cardiac echocardiogram will be performed with measurement of the sub-aortic time-velocity integral, and the same measurement will be performed 1 min after a passive leg-lift to see if this maneuver significantly increases systolic ejection volume. The PI value and blood pressure will be measured at each of these maneuvers."
219747339|NCT06769750|OTHER|leg-lift maneuver|The perfusion index (PI) value and arterial pressure will be measured at each of manoeuvre
219747340|NCT04376008|PROCEDURE|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
219429060|NCT03296865|DEVICE|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
219747341|NCT04376008|PROCEDURE|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
219747342|NCT03193385|PROCEDURE|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
219747343|NCT00543127|DRUG|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
219747344|NCT00543127|DRUG|Anastrozole|1 mg oral Anastrozole per day during 5 years.
219747345|NCT02513641|DEVICE|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of \~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
219747346|NCT02853084|DRUG|HL2351|The dose will be adjusted based on disease activities
219747347|NCT02235688|DRUG|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
219747348|NCT02235688|DRUG|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
218991174|NCT00249756|BEHAVIORAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
219747349|NCT02235688|DRUG|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
219747350|NCT02235688|DRUG|gemcitabine|
219747351|NCT03807648|OTHER|Data Inclusion|Patients in this group will be included in the project
219747352|NCT02122185|DRUG|metformin hydrochloride|Given PO
219747353|NCT02122185|DRUG|placebo|Given PO
219747354|NCT02122185|DRUG|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
219747355|NCT00131885|DIETARY_SUPPLEMENT|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
219747356|NCT00131885|DIETARY_SUPPLEMENT|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
219747357|NCT00131885|DRUG|Levonorgestrel|Levonorgestrel in a single oral dose
219747358|NCT04266912|DRUG|Avelumab|Given IV
219747359|NCT04266912|DRUG|Berzosertib|Given IV
219747360|NCT06858683|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16pm) followed by a 16 h fasting period.
219747361|NCT06858683|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period.
219747362|NCT06667869|DRUG|Sedative|Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
219747363|NCT02953457|BIOLOGICAL|Durvalumab|Given IV
219747364|NCT02953457|OTHER|Laboratory Biomarker Analysis|Correlative studies
219747365|NCT02953457|DRUG|Olaparib|Given PO
218991175|NCT00249756|BEHAVIORAL|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
219747366|NCT02953457|BIOLOGICAL|Tremelimumab|Given IV
219747367|NCT06905223|DIETARY_SUPPLEMENT|MQU10|MQU10 consists of a blend of food-grade probiotic strains (20 billion CFU daily) and prebiotic compounds.
219747368|NCT05134883|OTHER|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
218991176|NCT01010061|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
218991177|NCT01010061|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
219747369|NCT05134883|OTHER|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
218991178|NCT01010061|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
218991179|NCT03012438|DEVICE|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
218991180|NCT06177743|DEVICE|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
219577622|NCT04969718|OTHER|educational posters|Six educational posters will be displayed in all schools in this cluster.
219577623|NCT04969718|OTHER|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
219577624|NCT04493320|DRUG|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
219577625|NCT04493320|DRUG|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
219577626|NCT03205930|BIOLOGICAL|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
219747370|NCT05690204|DRUG|SAP-001|Test the efficacy and safety of SAP-001 versus placebo
219747371|NCT04003402|DRUG|ASP8062|oral
219747372|NCT04003402|DRUG|Alcohol|oral
219577627|NCT05676086|BEHAVIORAL|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
219747373|NCT04003402|DRUG|ASP8062 Placebo|oral
219747374|NCT04003402|DRUG|Alcohol Placebo|oral
219747375|NCT04191135|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
218991181|NCT03470441|DRUG|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
218991182|NCT03470441|OTHER|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
219747376|NCT04191135|DRUG|Olaparib|oral tablets
219747377|NCT04191135|DRUG|Carboplatin|IV infusion
219747378|NCT04191135|DRUG|Gemcitabine|IV infusion
219747379|NCT06921499|BEHAVIORAL|Va Meh Du (Mental Health Education)|Participants randomized to Va Meh Du (mental health education) will receive 20-30 minutes of mental health education each week for roughly 5 weeks. Mental health education will be evidence-based, using sports psychology practices, and culturally targeted toward Karenni refugees.
219747380|NCT06921499|BEHAVIORAL|Active Compartor|Participants randomized to comparison will receive 20-30 minutes of team-building activities each week for roughly 5 weeks.
219747381|NCT06931639|BEHAVIORAL|Safe Alternatives for Teens and Youth (SAFETY)|Please see description of experimental arm (arm one)
219747382|NCT06931639|BEHAVIORAL|Enhanced Treatment As Usual|Please see description of active comparator arm (arm two).
219747383|NCT05884528|BIOLOGICAL|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
219747384|NCT05884528|BIOLOGICAL|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
219747385|NCT05884528|BIOLOGICAL|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
219747386|NCT05884528|BIOLOGICAL|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
219747387|NCT06933043|DRUG|NAV-240|Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.
219747388|NCT06933043|DRUG|Placebo|Three doses of matching placebo will be administered to participants.
219747389|NCT06688890|OTHER|Surgical hand rub with the reference product; n-propanol 60%.|Propanol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
219747390|NCT06688890|OTHER|Surgical hand rub with the product P1; Sorbectol for 1 min.|Sorbectol hand rub for 1 min. The applied volume of product is sufficient to keep the hand moist for a total time of 1 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
219747391|NCT06688890|OTHER|Surgical hand rub with the product P2; Sorbectol for 3 min.|Sorbectol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
219747392|NCT06688890|OTHER|Surgical hand rub with the product P3; Sorbectol for 5 min.|Sorbectol hand rub for 5 min. The applied volume of product is sufficient to keep the hand moist for a total time of 5 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
218991183|NCT05109156|OTHER|This is an observational study|This is an observational study
218991184|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
218991185|NCT04029948|PROCEDURE|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
218991186|NCT04029948|PROCEDURE|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
218991187|NCT03559660|DRUG|Certolizumab Pegol|
218991188|NCT02433405|BIOLOGICAL|Fetuin-A|Acute phase protein
218991189|NCT02433405|BIOLOGICAL|Serum Amyloid A|Acute phase protein
218991190|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
218991191|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
219747393|NCT06943378|BIOLOGICAL|Monoclonal antibody JST-010|Active study drug
219747394|NCT06943378|DRUG|Placebo|Placebo
219747395|NCT06951620|OTHER|HIIT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to High intensity training (HIIT)
219747396|NCT06951620|OTHER|MICT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to Moderate intensity training
219747397|NCT04060238|DIAGNOSTIC_TEST|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
219747398|NCT03830437|OTHER|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
219747399|NCT03830437|OTHER|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
219747400|NCT02882347|DRUG|Somatostatin|
218991192|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
218991193|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
219747401|NCT03769350|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
219747402|NCT04596722|DIETARY_SUPPLEMENT|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
219747403|NCT04596722|OTHER|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
219747404|NCT03525262|RADIATION|30Gy (Gray) planning target volume (PTV)|PTV1\_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
219747405|NCT05634174|DRUG|Mirabegron|Single dose, 100mg oral mirabegron
219747406|NCT06004232|BEHAVIORAL|Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention|The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.
219747407|NCT06004232|BEHAVIORAL|Treatment as Usual (TAU)|TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
219747408|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
219747409|NCT06429930|DRUG|L608 Liposomal inhalation solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
219747410|NCT06429930|DRUG|Placebo Solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
219747411|NCT04531579|DRUG|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
219368747|NCT01469559|DRUG|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
219747412|NCT04531579|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
219747413|NCT06477770|PROCEDURE|Clorhexidine soap|surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap
219747414|NCT06477770|OTHER|Sucrose|75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
219747415|NCT04974476|OTHER|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
219747416|NCT05604586|DIETARY_SUPPLEMENT|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
218991194|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
219429061|NCT03792451|DRUG|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
219747417|NCT05604586|DIETARY_SUPPLEMENT|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
218991195|NCT01355757|DEVICE|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
219747418|NCT06565312|DIETARY_SUPPLEMENT|Flora Power Probiotic Vaginal Suppository|The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
219747419|NCT04185779|DIAGNOSTIC_TEST|Colonoscopy|Diagnostic colonoscopy
219747420|NCT02733094|DRUG|Secukinumab|
219747421|NCT02771301|BIOLOGICAL|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
219747422|NCT03262961|DRUG|Sildenafil 20 MG|
219747423|NCT03262961|DRUG|Placebo Oral Tablet|
219747424|NCT05791344|DEVICE|ECG monitoring|Intra-procedural ECG changes during TAVR
218991196|NCT01355757|DRUG|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
218991197|NCT06317727|DEVICE|Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)|The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
218991198|NCT05749965|PROCEDURE|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
218991199|NCT00169546|DRUG|Salmeterol/fluticasone propionate|
218991200|NCT00169546|DRUG|Fluticasone propionate|
218991201|NCT06546007|DIAGNOSTIC_TEST|CTC-DNA|ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
219368748|NCT01469559|DRUG|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
219368749|NCT00134628|PROCEDURE|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
219747425|NCT05334238|DRUG|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
219747426|NCT02804620|BEHAVIORAL|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
219747427|NCT00621283|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
219747428|NCT01395134|DEVICE|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
219747429|NCT02433964|OTHER|Grupo LED|
219747430|NCT02433964|OTHER|Placebo|ledterapia off + price
219747431|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
219747432|NCT01444781|BIOLOGICAL|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
219747433|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
219747434|NCT06333106|OTHER|POCUS diagnostic value|Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room
219747435|NCT01331759|DEVICE|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
219368750|NCT00134628|PROCEDURE|Sham treatment|Normal air under pressure (1.1 ATA)
219368751|NCT00832897|PROCEDURE|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
219178939|NCT06425068|DEVICE|Exposure of the patient to a conventional foam mattress.|"see information provided in the Arms section (active comparator)"
219368752|NCT00759070|DRUG|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~\+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
219368753|NCT00759070|DRUG|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
219368754|NCT01014403|DRUG|enoxaparin|Enoxaparin 30 mg sq q 12 hours
219368755|NCT01014403|DRUG|placebo|vehicle
219368756|NCT02500186|DRUG|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
219747436|NCT02724241|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
219747437|NCT02724241|OTHER|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
219747438|NCT02724241|OTHER|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
219747439|NCT06318676|DRUG|Mezigdomide|Specified dose on specified days
219747440|NCT06579508|OTHER|Cycle ergometer|"The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh."
219747441|NCT04523519|BEHAVIORAL|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
219747442|NCT04523519|BEHAVIORAL|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
219368757|NCT02500186|OTHER|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
219368758|NCT03668574|OTHER|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
219368759|NCT03668574|OTHER|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
219368760|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
219747443|NCT04336566|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg
218991202|NCT05647460|PROCEDURE|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
218991203|NCT05647460|PROCEDURE|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
218991204|NCT05315544|DEVICE|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
218991205|NCT04258865|DRUG|CKD-348 F1|QD, PO
218991206|NCT04258865|DRUG|CKD-348 F2|QD, PO
218991207|NCT04258865|DRUG|CKD-828, D097, D337|QD, PO
218991208|NCT04994600|OTHER|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA\_2nd\_phase group.
218991209|NCT05975892|BIOLOGICAL|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
218991210|NCT05022082|OTHER|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
218991211|NCT00884871|PROCEDURE|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
218991212|NCT04743739|DRUG|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
218991213|NCT04743739|DRUG|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
218991214|NCT01004705|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
218991215|NCT01004705|DRUG|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
218991216|NCT04374721|DIAGNOSTIC_TEST|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
218991217|NCT01781754|PROCEDURE|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
218991218|NCT02225561|PROCEDURE|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
218991219|NCT02225561|PROCEDURE|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
218991220|NCT00785265|BEHAVIORAL|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
219368761|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
219368762|NCT06548139|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
219368763|NCT06548139|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
219368764|NCT03137615|PROCEDURE|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
219368765|NCT03137615|DRUG|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
219368766|NCT01629745|GENETIC|gene expression analysis|
219747444|NCT04336566|DIETARY_SUPPLEMENT|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
219747445|NCT00889330|DRUG|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
219747446|NCT00889330|DRUG|Placebo|Vehicle without active, one drop in each eye at each of two visits.
219368767|NCT01629745|OTHER|flow cytometry|
219368768|NCT01629745|OTHER|laboratory biomarker analysis|
219368769|NCT03158220|BIOLOGICAL|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
219368770|NCT00364299|DEVICE|Automatic control of tracheal tube cuff pressure|
219368771|NCT00591695|PROCEDURE|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
219368772|NCT00591695|PROCEDURE|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
219368773|NCT03847285|OTHER|solid organ transplantation|solid organ transplantation: kidney, heart, pancreas, lung and liver transplantation
219368774|NCT01015833|DRUG|Doxorubicin Hydrochloride|Given IV
219368775|NCT01015833|OTHER|Laboratory Biomarker Analysis|Correlative studies
219747447|NCT05537389|DEVICE|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
218991221|NCT00785265|BEHAVIORAL|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
218991222|NCT02941991|BIOLOGICAL|hESC-RPE|sub-retinal injection
218991223|NCT00678093|OTHER|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
218991224|NCT02998983|DRUG|Racotumomab|
218991225|NCT02027519|OTHER|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
218991226|NCT00229593|DRUG|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
218991227|NCT00229593|DRUG|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
218991228|NCT02217878|DRUG|Morphine|IV bolus injection
218991229|NCT02217878|DRUG|Placebo|IV bolus injection
218991230|NCT02217878|DRUG|Ticagrelor|180 mg loading dose
218991231|NCT02771431|OTHER|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
219368776|NCT01015833|OTHER|Pharmacogenomic Study|Correlative studies
219368777|NCT01015833|DRUG|Sorafenib Tosylate|Given PO
219368778|NCT02276586|PROCEDURE|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
219368779|NCT02276586|PROCEDURE|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
219368780|NCT01671280|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
219368781|NCT03897543|DRUG|ABX196|ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
219368782|NCT01419431|PROCEDURE|Laparoscopic resection|Inflammatory response in laparoscopic surgery
219368783|NCT02299960|DEVICE|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
219368784|NCT02299960|DEVICE|NICOM|Non-invasive measurement of cardiac output
219368785|NCT01959165|DRUG|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
219368786|NCT01959165|DRUG|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
219368787|NCT01959165|DRUG|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
219368788|NCT01959165|DRUG|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
219368789|NCT04500704|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
218991232|NCT02809612|BEHAVIORAL|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
218991233|NCT00557128|DRUG|COREG CR and lisinopril (FDC)|
219747448|NCT02346279|OTHER|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
219747449|NCT02075060|PROCEDURE|IPOI (pre-operative)|
218991234|NCT05210907|BIOLOGICAL|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
219747450|NCT02075060|PROCEDURE|IPOP (post-operative)|
218991235|NCT01338103|DRUG|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
219747451|NCT05750784|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
219747452|NCT02956473|DEVICE|Supine MRI|
219368790|NCT04500704|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
219368791|NCT03174145|BEHAVIORAL|Positive behaviour|Information about T4P1010 treatment
219368792|NCT03174145|DRUG|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
219368793|NCT03174145|GENETIC|Pharmacogenetic|Blood sample of 10 millilitres maximum
219368794|NCT03174145|OTHER|Questionnaires and diary completion|Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
219747453|NCT02956473|OTHER|Neoadjuvant Therapy (NAT)|
219747454|NCT02956473|DEVICE|Ultrasound|
219747455|NCT02956473|DEVICE|Mammography|
219747456|NCT02956473|PROCEDURE|Standard of Care|
219747457|NCT02956473|DEVICE|Standard MRI|
219747458|NCT05175157|OTHER|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
219368795|NCT05815355|DIETARY_SUPPLEMENT|exclusive enteral nutrition treatment group|
219747459|NCT03898011|DRUG|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
219747460|NCT03898011|DRUG|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
219747461|NCT06100120|PROCEDURE|Implant placement|Placement of osteointegrated implants
219747462|NCT02494115|PROCEDURE|subcutaneous drainage|
219747463|NCT03033784|DRUG|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
218991236|NCT00133913|PROCEDURE|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
218991237|NCT03513458|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
218991238|NCT03513458|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
218991239|NCT03513458|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
219368796|NCT03052803|DEVICE|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
219368797|NCT00180973|DRUG|Hydroxyurea|
219368798|NCT03497845|BIOLOGICAL|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368799|NCT03497845|BIOLOGICAL|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368800|NCT03497845|BIOLOGICAL|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368801|NCT03497845|BIOLOGICAL|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368802|NCT03497845|BIOLOGICAL|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368803|NCT03497845|BIOLOGICAL|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219368804|NCT03497845|BIOLOGICAL|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
219747464|NCT03033784|DRUG|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
219747465|NCT03033784|DRUG|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
219747466|NCT03033784|DRUG|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
219747467|NCT00568009|DRUG|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
219747468|NCT01058746|OTHER|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
219747469|NCT01058746|OTHER|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
219747470|NCT05786326|DEVICE|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
219368805|NCT06960486|PROCEDURE|Bedside ultrasound-guided real-time biliary drainage|Bedside ultrasound-guided real-time biliary drainage by emergency surgeon in the frail and high risk elderly patients with severe acute suppurative infection of biliary tract
219368806|NCT06960486|PROCEDURE|traditional appointment ultrasound|Traditional appointment ultrasound
219368807|NCT01817816|PROCEDURE|Botox_A|
219368808|NCT01817816|PROCEDURE|Botox_B|
219747471|NCT05786326|DEVICE|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
219747472|NCT05786326|DEVICE|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
219747473|NCT02085980|DEVICE|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
219747474|NCT02465008|DRUG|Levobupivacaine|
219747475|NCT02465008|DRUG|Placebo|
219747476|NCT02424162|DEVICE|+2.75 diopters multifocal intraocular lens|
219747477|NCT02424162|DEVICE|+3.25 diopters multifocal intraocular lens|
218991240|NCT02938312|BEHAVIORAL|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
218991241|NCT02938312|BEHAVIORAL|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
218991242|NCT02736838|DEVICE|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
219747478|NCT02485184|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
219747479|NCT02485184|DRUG|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
218991243|NCT02736838|DEVICE|Laser Doppler|
218991244|NCT05136287|DRUG|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
219747480|NCT02485184|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
219178940|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
219368809|NCT00927563|DRUG|Tolcapone|pill, 100-300mg/day for 8 weeks
219368810|NCT03016780|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
219368811|NCT03016780|OTHER|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
219368812|NCT02737865|DRUG|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
219368813|NCT02737865|DEVICE|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
219368814|NCT04208425|BEHAVIORAL|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
219747481|NCT02485184|DRUG|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
219747482|NCT02987140|BEHAVIORAL|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
219747483|NCT03129997|DIETARY_SUPPLEMENT|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
219747484|NCT03295942|DRUG|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
219747485|NCT00684385|DRUG|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
219747486|NCT02374255|BEHAVIORAL|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
219747487|NCT03332056|DRUG|Belladonna and Opium|
219747488|NCT03332056|OTHER|Placebo suppository|
218991245|NCT01389388|DRUG|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
218991246|NCT06424574|BEHAVIORAL|motivational interview|"The sample of the second phase of the study consisted of 74 parents with Type 1 diabetes children, 37 of which were in the study group and 37 in the control group. İn the collection of data process, Descriptive Information Form, University of Virginia Parent Low Blood Sugar Scale, BAKAS Care-Giving Impact Scale, Fatigue Severity Scale, Parental Version Of The Diabetes-Specific Self-Compassion Scale SCS-(Dp) was used. The scales were applied at the beginning of the study and 10 weeks after the first data. After the first test data were obtained from each parent in our research group, four face-to-face motivational interviews were conducted at two-week intervals. In the xvii interviews, attempts were made to change and improve the behaviors and skills that parents felt inadequate within the scope of fear of hypoglycemia, caregiving, fatigue and self-compassion."
219368815|NCT04208425|BEHAVIORAL|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
219368816|NCT04112680|BEHAVIORAL|Debunking Misinformation through Audio Dramas|The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
219368817|NCT04112680|BEHAVIORAL|Control group audio jingles|The control group will receive audio jingles about exclusive breastfeeding
219368818|NCT04392960|DRUG|[18F]Florbetaben|"Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
219368819|NCT02730260|BEHAVIORAL|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
219368820|NCT02730260|BEHAVIORAL|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
219368821|NCT00412776|DRUG|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
219368822|NCT04524845|DEVICE|Unloading brace|"Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain."
218991247|NCT01443208|DRUG|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
219368823|NCT04524845|DEVICE|Rebel Reliever (RR)|Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
219368824|NCT04524845|DEVICE|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France)
219368825|NCT06087757|DRUG|Open Label Clemastine with a blinded randomize withdrawal|Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
219368826|NCT02787772|PROCEDURE|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
219368827|NCT05231083|DEVICE|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
219368828|NCT00177515|BEHAVIORAL|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
219368829|NCT01468987|DRUG|LY2605541|
219368830|NCT01468987|DRUG|Insulin Glargine|
219368831|NCT01468987|DRUG|Insulin Lispro|
219368832|NCT04920773|OTHER|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
219368833|NCT04920773|OTHER|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
219368834|NCT02834949|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
219429062|NCT03810001|BEHAVIORAL|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
219429063|NCT02489006|DRUG|Olaparib|
219429064|NCT02489006|DRUG|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
219429065|NCT01916993|DRUG|NBI-98854 50 mg capsule|
219429066|NCT06435182|DRUG|OT202 conc 0.5%|Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
219429067|NCT06435182|DRUG|OT202 conc 0.1%|Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
219368835|NCT02834949|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
219368836|NCT02834949|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
219368837|NCT04234737|BEHAVIORAL|Hypnotherapy|Hypnotherapy
219368838|NCT03247621|BEHAVIORAL|Whatsapp|
219368839|NCT03247621|BEHAVIORAL|Article|
219368840|NCT03247621|BEHAVIORAL|No Phone|
219368841|NCT03132402|DIAGNOSTIC_TEST|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
219368842|NCT05112796|PROCEDURE|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
219368843|NCT05112796|PROCEDURE|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
219747489|NCT01817400|OTHER|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
219760787|NCT04008914|OTHER|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
219368844|NCT05032950|DRUG|Midazolam|Midazolam administered as a single dose on Day 1
219368845|NCT05032950|DRUG|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
219368846|NCT05032950|DRUG|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
219368847|NCT03257189|DEVICE|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
219368848|NCT03257189|DEVICE|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
219368849|NCT03257189|DEVICE|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
219368850|NCT03257189|OTHER|Activity classification|Visual annotation of subject posture and other activities used for reference
219368851|NCT00299988|DRUG|Intravenous Immunoglobulin|
219368852|NCT00299988|OTHER|Placebo|
219368853|NCT02959814|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
219368854|NCT06296121|DRUG|BCD-264|IV, 16 mg/kg
219368855|NCT06296121|DRUG|Darzalex|IV, 16 mg/kg
219368856|NCT01428466|DRUG|GSK2585823|CLDM1%/BPO3%
219368857|NCT01428466|DRUG|Benzoyl peroxide 3%|Benzoyl peroxide 3%
219368858|NCT01428466|DRUG|Benzoyl peroxide 5%|Benzoyl peroxide 5%
219368859|NCT01428466|OTHER|Vehicle|placebo
219368860|NCT02116621|BEHAVIORAL|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
219368861|NCT02116621|DEVICE|smartphone|
219368862|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
219368863|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
219368864|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
219368865|NCT02972320|DRUG|temozolomide|temozolomide maintain therapeutic
219368866|NCT00005724|BEHAVIORAL|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
219368867|NCT00005724|OTHER|Minimal Intervention Group|Dietary Information pamphlets.
219368868|NCT00005724|BEHAVIORAL|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
219429068|NCT06435182|DRUG|Placebo|Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
219429069|NCT01789346|DEVICE|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
219429070|NCT01789346|DEVICE|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
219747490|NCT01817400|DIETARY_SUPPLEMENT|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
219747491|NCT01817400|DRUG|Aspirin|
219747492|NCT01817400|DRUG|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
219747493|NCT03106714|DIAGNOSTIC_TEST|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
219747494|NCT04132297|BEHAVIORAL|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
219747495|NCT04132297|BEHAVIORAL|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
219747496|NCT02093520|PROCEDURE|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
219747497|NCT02093520|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
219747498|NCT00525863|DRUG|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to \~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
219747499|NCT03014089|BIOLOGICAL|mRNA-1325|Escalating dose levels
219747500|NCT03014089|OTHER|Placebo|
219747501|NCT01520441|DRUG|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
219747502|NCT02792322|DEVICE|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
219747503|NCT02995200|BEHAVIORAL|Accelerometer Based Feedback|
219747504|NCT00434941|DRUG|Capecitabine|
219747505|NCT00434941|RADIATION|Radiotherapy|
219747506|NCT01342055|DRUG|Apetrol ES|sequences of administered drugs
219747507|NCT03618069|DIAGNOSTIC_TEST|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
219747508|NCT03182855|DRUG|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
219747509|NCT03182855|DRUG|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
219747510|NCT01969929|PROCEDURE|20G Vitrectomy|
219747511|NCT01969929|PROCEDURE|23G vitrectomy|
219747512|NCT00797303|DRUG|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
219747513|NCT00321932|DIETARY_SUPPLEMENT|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
219429071|NCT05003063|DRUG|Donepzil|Test
219747514|NCT00321932|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
219747515|NCT00321932|DRUG|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
219747516|NCT06402305|DIAGNOSTIC_TEST|Lipid profile|Abdominal ultrasound and lipid profile will be done
219747517|NCT02310269|DRUG|Pasireotide|
219747518|NCT03487133|DRUG|bortezomib/dexamethasone|"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
219747519|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
219747520|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
218991248|NCT01443208|DRUG|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
219429072|NCT05003063|DRUG|Placebo oral tablet|Test
219429073|NCT02890043|PROCEDURE|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
219429074|NCT02890043|PROCEDURE|free-hand surgery|traditional free-hand surgery
219429075|NCT02890043|DEVICE|TiRobot system|a robot-assisted spine surgery system
219429076|NCT01770899|DRUG|Montelukast|
219747521|NCT00157872|DRUG|MK0966; rofecoxib|
219747522|NCT00157872|DRUG|Comparator: naproxen tablet 500 mg|
219747523|NCT05787041|OTHER|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
219747524|NCT05787041|OTHER|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
219747525|NCT06559319|DIAGNOSTIC_TEST|blood sampling|Venous blood is collected, and sIgE and BAT will be detected using whole blood and serum, respectively.
219747526|NCT06563648|OTHER|shotblocker|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
219747527|NCT06563648|OTHER|local cold application|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.
219747528|NCT06563648|OTHER|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
219747529|NCT06247748|DRUG|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
219747530|NCT06247748|DRUG|Metformin Hydrochloride tablet|D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
219747531|NCT06247748|DRUG|Rosuvastatin calcium tablets|D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
219747532|NCT06247748|DRUG|Digoxin tablet|D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
219747533|NCT05495568|BIOLOGICAL|CT-P17|CT-P17 40mg will be subcutaneous administered
219747534|NCT05495568|BIOLOGICAL|EU-approved Humira|subcutaneous administration
219747535|NCT03809000|RADIATION|Radiation Therapy|daily fractions
219747536|NCT03809000|DRUG|Enzalutamide|tablet
219747537|NCT03809000|DRUG|Bicalutamide|tablet
219747538|NCT03809000|DRUG|GnRH analog|Injection
219747539|NCT03360344|DEVICE|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
219747540|NCT03360344|DEVICE|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
219747541|NCT03360344|DEVICE|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
219747542|NCT04196621|DEVICE|High viscous artificial tears|Instillation of one drop high viscous artificial tears
219747543|NCT04196621|DEVICE|Low viscous artificial tears|Instillation of one drop low viscous artificial tears
219747544|NCT01145183|DRUG|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
219429077|NCT01770899|DRUG|Placebo|Gelatin capsule given every 24 hours
219747545|NCT01145183|DRUG|Placebo|Matched placebo daily dosing
219747546|NCT04576754|DEVICE|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
219747547|NCT04576754|DEVICE|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
219747548|NCT03388827|DEVICE|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
219747549|NCT03388827|DRUG|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
219747550|NCT01418105|PROCEDURE|Videofluroscopic swallow study (VFSS)|Barium, radiation
219747551|NCT01418105|PROCEDURE|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
219747552|NCT01418105|PROCEDURE|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
219747553|NCT02331758|BEHAVIORAL|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
219747554|NCT01993732|PROCEDURE|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
218991249|NCT01443208|DRUG|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
218991250|NCT01146834|DRUG|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
218991251|NCT01146834|DRUG|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
219368869|NCT03056105|OTHER|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
219368870|NCT04928183|OTHER|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to \~10%
219368871|NCT04928183|DRUG|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
219368872|NCT04928183|DRUG|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
219368873|NCT00708370|OTHER|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
219368874|NCT00708370|OTHER|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
219368875|NCT01983644|DEVICE|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
219747555|NCT03840967|DRUG|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
219747556|NCT04023058|PROCEDURE|Mitral surgery|Guidelines approved mitral surgery
219747557|NCT03257657|BEHAVIORAL|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
219747558|NCT03257657|BEHAVIORAL|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
219747559|NCT03906409|OTHER|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
219747560|NCT03906409|OTHER|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
219747561|NCT04260958|OTHER|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
219747562|NCT05410314|DRUG|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
219747563|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
219747564|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement|(List No- P968/Z0)
219747565|NCT02523027|OTHER|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
219747566|NCT04809337|OTHER|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
219747567|NCT02014987|BEHAVIORAL|Training programmes|"Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
219747568|NCT01855984|DIETARY_SUPPLEMENT|Oral mixed tocotrienols|200mg per day
219747569|NCT01855984|DIETARY_SUPPLEMENT|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
219747570|NCT01828060|DIETARY_SUPPLEMENT|Jobelyn™|Sorghum bicolor leaf sheath extract
219747571|NCT01828060|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
219747572|NCT01085903|DRUG|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
219747573|NCT01085903|DRUG|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
219747574|NCT01085903|BEHAVIORAL|Baseline|Observations made at baseline before any intervention
219747575|NCT01085903|BEHAVIORAL|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
218991252|NCT01146834|DRUG|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
218991253|NCT01146834|DRUG|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
219368876|NCT01983644|DEVICE|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
219368877|NCT05996484|DRUG|Toripalimab|Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
219747576|NCT01085903|BEHAVIORAL|Post CPS|20 minutes following the CPS condition.
219747577|NCT01085903|BEHAVIORAL|Follow up|Follow up testing occurred at 3 months
219747578|NCT03220633|DRUG|ATB-346|
219747579|NCT03220633|DRUG|Placebo|
219747580|NCT04945837|OTHER|self administered questionnaire|longitunidal descriptive study
218991254|NCT01234441|DIETARY_SUPPLEMENT|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
219368878|NCT05996484|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
219368879|NCT05996484|DRUG|Albumin paclitaxel|Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
218991255|NCT01234441|DIETARY_SUPPLEMENT|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
218991256|NCT01234441|BEHAVIORAL|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
218991257|NCT05046899|DEVICE|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
218991258|NCT05046899|DEVICE|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
218991259|NCT01263977|DEVICE|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
218991260|NCT06385600|DRUG|Labetalol|Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
218991261|NCT06385600|DRUG|Phentolamine|Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
218991262|NCT03751696|BEHAVIORAL|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
218991263|NCT03751696|BEHAVIORAL|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
218991264|NCT04916821|DIETARY_SUPPLEMENT|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
218991265|NCT00282984|DRUG|placebo|1 mg placebo twice daily by mouth for 12 weeks
218991266|NCT00282984|DRUG|Varenicline|1 mg twice daily by mouth for 12 weeks
218991267|NCT05846971|OTHER|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
218991268|NCT05808114|BEHAVIORAL|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
219760788|NCT03218839|DEVICE|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
218991269|NCT05808114|BEHAVIORAL|TAU|Individually tailored and delivered specialized child psychiatric care
218991270|NCT00941005|DEVICE|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
218991271|NCT04749277|OTHER|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
218991272|NCT02087735|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
218991273|NCT02327689|DRUG|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
218991274|NCT02859311|DRUG|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
218991275|NCT01807975|OTHER|Forced oscillation|
218991276|NCT01738542|DRUG|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
218991277|NCT01738542|DRUG|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
218991278|NCT01738542|DRUG|Statins|
218991279|NCT01738542|DRUG|Antihypertensive therapy|
218991280|NCT01742702|DRUG|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
218991281|NCT01742702|DRUG|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
219368880|NCT05996484|DRUG|Cisplatin|Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
219368881|NCT02312973|DRUG|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
219368882|NCT02312973|DRUG|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
219368883|NCT05986942|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
219368884|NCT05986942|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
219429078|NCT01899677|OTHER|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
219429079|NCT01899677|DRUG|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
219368885|NCT03132584|DRUG|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~\- Via IV Day 3"
219368886|NCT03132584|DRUG|Alemtuzumab|"* The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4"
219368887|NCT04159883|OTHER|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
219368888|NCT04159883|OTHER|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
219368889|NCT04086732|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
219368890|NCT03844867|DIETARY_SUPPLEMENT|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
219747581|NCT01678742|DIETARY_SUPPLEMENT|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
219368891|NCT00961961|DRUG|Lithium / Fluoxetine|Individualized Daily Dosage
219368892|NCT00961961|DRUG|Lithium / Placebo|Individualized Daily Dosage
219368893|NCT00652184|DRUG|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
219368894|NCT00652184|DRUG|placebo|placebo cream and placebo valaciclovir
219368895|NCT00652184|DRUG|valaciclovir|active valaciclovir
219747582|NCT01678742|DIETARY_SUPPLEMENT|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
219747583|NCT02296099|DRUG|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
219747584|NCT02296099|DRUG|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
219747585|NCT02971839|DRUG|VX-561|
219747586|NCT02971839|DRUG|Placebo|
219747587|NCT02971839|DRUG|IVA|
219760789|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
219760790|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
219368896|NCT01699256|BEHAVIORAL|Guideline implementation as usual|Newsletters and Invitation to Meetings
219368897|NCT01699256|BEHAVIORAL|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
219368898|NCT04965740|DRUG|Cannabis|Recreational Cannabis
219368899|NCT02298114|DEVICE|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
219368900|NCT02298114|OTHER|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
219368901|NCT00525577|DRUG|Placebo|Placebo tablet, once daily
219368902|NCT00525577|DRUG|AGI-1067|75 mg AGI-1067 tablet, once daily
219368903|NCT00525577|DRUG|AGI-1067|150 mg AGI-1067 Tablet, once daily
219368904|NCT02334150|DRUG|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
219368905|NCT00796588|OTHER|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
219760791|NCT04945486|OTHER|Peer-mentor intervention|Peer-mentor support for up to 6 months
219760792|NCT01213082|DRUG|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
219368906|NCT00354302|DIETARY_SUPPLEMENT|calcium carbonate|
219368907|NCT00354302|DIETARY_SUPPLEMENT|calcium citrate|
218991282|NCT01742702|DRUG|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
218991283|NCT01742702|DIETARY_SUPPLEMENT|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
219368908|NCT00354302|DIETARY_SUPPLEMENT|cholecalciferol|
219368909|NCT00354302|DRUG|alendronate sodium|
219368910|NCT00354302|DRUG|calcium gluconate|
219368911|NCT00354302|DRUG|risedronate sodium|
219368912|NCT00354302|OTHER|laboratory biomarker analysis|
219368913|NCT00354302|PROCEDURE|dual x-ray absorptometry|
219368914|NCT01105390|BIOLOGICAL|rilotumumab|Given IV
219368915|NCT01105390|DRUG|cisplatin|Given IV
219368916|NCT01105390|DRUG|pemetrexed disodium|Given IV
219368917|NCT01105390|OTHER|laboratory biomarker analysis|Correlative studies
219368918|NCT04452890|DIAGNOSTIC_TEST|Sonourethrography|Ultrasound of the urethra.
219368919|NCT04941196|DRUG|Anplag (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
219368920|NCT04941196|DRUG|Brilinta (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
219747588|NCT04707209|DRUG|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."
219368921|NCT05204043|OTHER|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
219747589|NCT06240286|BEHAVIORAL|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
219747590|NCT06240286|BEHAVIORAL|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
218991284|NCT01742702|DIETARY_SUPPLEMENT|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
218991285|NCT01742702|DRUG|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
218991286|NCT03108677|OTHER|Blood samples|15 ml peripheral blood
218991287|NCT01919606|DRUG|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
218991288|NCT02184481|BEHAVIORAL|Working memory training|
218991289|NCT02184481|BEHAVIORAL|Placebo training|
218991290|NCT01128842|DRUG|Neratinib|240 mg once daily by mouth.
219368922|NCT05204043|OTHER|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
219368923|NCT05204043|OTHER|Questionnaires|"* State Trait Anxiety Inventory (STAI)~* Pain assessment - Visual Analogic Scale (from 0 to 10)."
219368924|NCT05533892|DRUG|Nocardia rubra cell wall skeleton|Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
218991291|NCT01128842|DRUG|Capecitabine|1500 mg/m\^2 twice daily by mouth.
218991292|NCT00210483|DRUG|almotriptan malate|
219368925|NCT05533892|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
219368926|NCT05533892|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
219368927|NCT05533892|DRUG|Tislelizumab|200mg intravenously every 3 weeks
219368928|NCT06120530|DRUG|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
219368929|NCT06120530|OTHER|Saline|Placebo
219368930|NCT02425098|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
219368931|NCT02425098|BIOLOGICAL|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
219368932|NCT01929135|DRUG|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
219368933|NCT01929135|DRUG|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
219368934|NCT02887443|DRUG|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
219368935|NCT02887443|DRUG|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
219368936|NCT02078219|DRUG|RDEA3170|Oral Treatment
219368937|NCT02078219|DRUG|Allopurinol|Oral Treatment
219368938|NCT02078219|DRUG|Placebo|Oral Treatment
219368939|NCT05074108|BEHAVIORAL|Pilot study|Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
219368940|NCT04421690|BEHAVIORAL|Cognitive Training|Participants (n=15) will complete computerized cognitive training games and activities online 3 times/week for 8 weeks.
219368941|NCT04421690|BEHAVIORAL|Trivia Training|Participants (n=15) will receive computerized trivia questions to answer and submit 3 times/week for 8 weeks.
219368942|NCT01111266|DEVICE|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
219368943|NCT00376467|DRUG|Imatinib|
219368944|NCT03962985|OTHER|Guided tour at the Montreal Museum of Fine Arts|"* The duration of the participation -3 months~* The duration of the guided tour-45 minutes, each week~* All participants will be asked to fill out some specific online questionnaires during their participations in the study"
219368945|NCT03036527|PROCEDURE|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
219368946|NCT03036527|PROCEDURE|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
219368947|NCT03036527|PROCEDURE|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
219368948|NCT03036527|PROCEDURE|Activity-based training + spinal epidural stimulation|combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
219747591|NCT06240286|BEHAVIORAL|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
219747592|NCT06240286|BEHAVIORAL|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
218991293|NCT06052085|OTHER|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
218991294|NCT06052085|OTHER|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
218991295|NCT06052085|OTHER|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
218991296|NCT04489433|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
218991297|NCT04489433|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
218991298|NCT04489433|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
218991299|NCT02066142|DEVICE|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
218991300|NCT02066142|DEVICE|Ultrasound|
219747593|NCT00375232|DRUG|Administration of montelukast or placebo|
218991301|NCT05394961|PROCEDURE|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
218991302|NCT01478477|DIETARY_SUPPLEMENT|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
218991303|NCT01478477|OTHER|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
219747594|NCT04744792|OTHER|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
218991304|NCT01478477|OTHER|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
218991305|NCT01478477|OTHER|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
218991306|NCT01478477|PROCEDURE|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
218991307|NCT01478477|PROCEDURE|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
218991308|NCT03408483|DRUG|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
218991309|NCT03408483|DRUG|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
218991310|NCT00654017|DRUG|placebo|Placebo comparator to be given per protocol.
219368949|NCT02469571|DIETARY_SUPPLEMENT|Winclove 607|multispecies probiotic
219368950|NCT02469571|DIETARY_SUPPLEMENT|Placebo|Placebo
219368951|NCT03135405|BEHAVIORAL|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
219368952|NCT03135405|BEHAVIORAL|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
219747595|NCT04744792|OTHER|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
219178941|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
219747596|NCT02194179|DRUG|NVP XR 400 mg (KCR 25%)|
219747597|NCT02194179|DRUG|NVP XR 400 mg (KCR 20%)|
219747598|NCT02194179|DRUG|NVP XR 300 mg (KCR 25%)|
219747599|NCT02194179|DRUG|NVP XR 300 mg (KCR 20%)|
219747600|NCT02194179|OTHER|high-fat breakfast|
219747601|NCT02194179|DRUG|NVP IR 200 mg (Viramune®)|
219747602|NCT05012579|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
219747603|NCT00002035|DRUG|Zidovudine|
219747604|NCT00002035|DRUG|Didanosine|
219747605|NCT05425121|PROCEDURE|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
219747606|NCT05425121|DEVICE|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
219747607|NCT04033640|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
219747608|NCT04033640|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
219747609|NCT04033640|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
219747610|NCT04033640|DIAGNOSTIC_TEST|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
219178942|NCT06800131|DEVICE|Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)|A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).
219178943|NCT06800131|BIOLOGICAL|Active comparator vaccine via intramuscular injection|10 subjects administered with active comparator vaccine via intramuscular injection.
219178944|NCT04265625|DEVICE|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
219747611|NCT06254833|OTHER|micro dosing of ICG|smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
219747612|NCT05334797|OTHER|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
219747613|NCT04622930|DEVICE|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
219747614|NCT04904302|BIOLOGICAL|Nivolumab|Given IV
219747615|NCT04904302|OTHER|Quality-of-Life Assessment|Ancillary studies
219747616|NCT04904302|OTHER|Questionnaire Administration|Ancillary studies
219747617|NCT04904302|DRUG|Sitravatinib|Given PO
219747618|NCT06563921|BEHAVIORAL|physical exercise programme|resistance/hypertrophy-oriented resistance programme
219747619|NCT06563921|DIETARY_SUPPLEMENT|probiotics supplementation|probiotics supplementation
219747620|NCT06563921|DIETARY_SUPPLEMENT|placebo|placebo
219747621|NCT06560190|OTHER|Orthopaedic Manual Physical Therapy|Individualized Treatment
219747622|NCT04225767|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
219747623|NCT02811887|BEHAVIORAL|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
219747624|NCT02811887|OTHER|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
219747625|NCT02811887|BEHAVIORAL|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
219760793|NCT01213082|DRUG|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
219368953|NCT03135405|BEHAVIORAL|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
219368954|NCT03791333|OTHER|injury severity score|injury severity score of multi trauma patients
219368955|NCT06333873|OTHER|patient-reported outcome|Performance of real-life tests and tasks
219368956|NCT05352542|BIOLOGICAL|GPC3 Targeting CART Cells|before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen
219368957|NCT01130987|OTHER|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
219368958|NCT01130987|BEHAVIORAL|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
219368959|NCT02761967|BEHAVIORAL|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
219178945|NCT05114616|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
219178946|NCT05114616|DEVICE|Ellcie Healthy Glasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
219178947|NCT02694809|DRUG|Conjugated Estrogens/Bazedoxifene|Given PO
219368960|NCT04095767|DEVICE|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters \[DACs\]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
219368961|NCT06617754|BIOLOGICAL|Biologic drugs|Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies
219178948|NCT02694809|OTHER|Laboratory Biomarker Analysis|Correlative studies
219368962|NCT06214260|DIAGNOSTIC_TEST|Peripheral blood sample|Peripheral blood will be collected with a 10 ml Ethylenediaminetetra acetic acid (EDTA) tube before surgery during menstrual phase. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
219368963|NCT06214260|DIAGNOSTIC_TEST|Menstrual Blood sample|5ml menstrual blood will be collected before surgery by the women herself. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
219368964|NCT02108925|DRUG|Oxygen|supplementary oxygen during exercise
219368965|NCT00004160|DRUG|cisplatin|
219368966|NCT00004160|DRUG|gemcitabine hydrochloride|
219368967|NCT00004160|DRUG|paclitaxel|
219368968|NCT00004160|RADIATION|radiation therapy|
219368969|NCT03283085|DRUG|25 mg Ontamalimab|Ontamalimab SC solution for injection
219178949|NCT02694809|OTHER|Pharmacological Study|Correlative studies
219178950|NCT02694809|OTHER|Placebo|Given PO
219368970|NCT03283085|DRUG|75 mg Ontamalimab|Ontamalimab SC solution for injection
219368971|NCT03136107|OTHER|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
219368972|NCT03136107|OTHER|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
219368973|NCT03291561|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
219368974|NCT03291561|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
219368975|NCT06613633|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
219368976|NCT04201080|DRUG|Part A: TRV250-20mg/ml|TRV250 SC Injections
219760794|NCT01213082|DRUG|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
219760795|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
219178951|NCT02694809|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219178952|NCT02694809|OTHER|Questionnaire Administration|Ancillary studies
219178953|NCT03085316|DEVICE|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
219178954|NCT06244810|DEVICE|Lingual retainer from Fiber|lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
219368977|NCT04201080|DRUG|Placebo|Placebo SC injections
219368978|NCT04201080|DRUG|Part B: TRV250 Dose 1|Dose 1of3 TRV250
219368979|NCT04201080|DRUG|Part B: TRV250 Dose 2|Dose 2of3 TRV250 SC injections
219760796|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
218991311|NCT00654017|DRUG|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
218991312|NCT05890508|DEVICE|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
218991313|NCT05890508|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
218991314|NCT01374997|OTHER|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
218991315|NCT01209611|PROCEDURE|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
218991316|NCT01209611|PROCEDURE|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
218991317|NCT03277664|BEHAVIORAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
218991318|NCT02516046|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
218991319|NCT02516046|PROCEDURE|PET Scan|positron emission tomography (PET) scan
218991320|NCT02185092|DIETARY_SUPPLEMENT|Lactobacillus GG|probiotic supplement
218991321|NCT02185092|OTHER|Sugar pill|placebo
218991322|NCT04216238|BEHAVIORAL|quasi-experimental Pre-test/Post-test design|surveys to document progress
218991323|NCT00114530|BIOLOGICAL|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
218991324|NCT00114530|DRUG|cyclophosphamide|An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
218991325|NCT03503175|DEVICE|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
218991326|NCT03503175|DEVICE|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
218991327|NCT06270810|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
218991328|NCT06270810|BEHAVIORAL|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
218991329|NCT04051528|PROCEDURE|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
219178955|NCT06244810|DEVICE|Lingual retainer from metal|lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
219178956|NCT06244810|DEVICE|Traditional retianer from braided|lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
219178957|NCT06638567|OTHER|Basal bolus insulin regimen|Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
219178958|NCT06640101|OTHER|sham IMT|with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted on a stable surface
219178959|NCT06640101|OTHER|IMT-stable group (sitting on a stable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on a stable surface
219760797|NCT00129285|DRUG|Placebo|placebo 400 mg/day
219006595|NCT06012825|BEHAVIORAL|Physical Activity|"The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min)."
219178960|NCT06640101|OTHER|IMT-unstable group (sitting on an unstable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on an unstable surface
219178961|NCT06640101|OTHER|Conventional treatment|Participants in all groups will receive a standardised conventional rehabilitation protocol. It includes limb range of motion, muscle tone reduction, strengthening and endurance of limb muscles, transfer skills, task-directed movements, general gait training, and activities of daily living training.
219368980|NCT04201080|DRUG|Part B: TRV250 Dose 3|Dose 3of3 TRV250 SC injections
219178962|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
219178963|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
219178964|NCT06488365|DEVICE|Cytophone|"The Cytophone clinical prototype incorporates two pulse lasers, optical system for delivery of laser light to the skin, ultrasound transducer array and detection electronics for acquisition of acoustic waves from CTCs.~Parameters of lasers:~C-Wedge 1064 (Bright Solutions, Cura Carpignano (PV), Italy): Wavelength,1064 nm; pulse width, 0.6 ns; pulse rate: 1 kHz; pulse energy, 240 μJ.~C-Wedge 18901 (Bright Solutions, Cura Carpignano (PV), Italy):~Wavelength, 770 nm; pulse width 3 ns; pulse rate, 1 kHz; pulse energy, 240 μJ. Detection of acoustic waves from CTCs is performing by a focused ultrasound transducer array placed in an acoustic contact with the skin of the subject with ultrasound gel. The signals from the transducers are amplified with a 16 channel amplifier, then digitized by a 12-bit, 500 MSPS high speed board digitizer (ATS9350, AlazarTech, Canada). This information is then transferred to a data recording system using a secure computer."
219178965|NCT06022302|DRUG|Diet + laxative|The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.
219178966|NCT06022302|OTHER|Diet only|This is only a control and participants will not receive Movicol.
219178967|NCT02869074|GENETIC|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
219178968|NCT06181006|DRUG|Pirtobrutinib|Administered orally.
219178969|NCT06640959|PROCEDURE|Procedure - blood, urine and stool sample collection|Samples will be collected (blood, urine, stool and optional rectal swab) at baseline (prior to the start of radiotherapy), weekly during radiotherapy for 4 weeks, 6-8 weeks and 12 weeks from start of radiotherapy, and at 6-month and 12-month follow-up appointments
219178970|NCT02105766|DRUG|Alemtuzumab|Immunosuppressant
219178971|NCT02105766|DRUG|Sirolimus|Immunosuppressant
219178972|NCT02105766|DRUG|Cyclophosphamide|Immunosuppressant
219178973|NCT02105766|DRUG|Pentostatin|Immunosuppressant
219178974|NCT02105766|PROCEDURE|Radiotherapy|Immunosuppressant and myelosuppressant
219178975|NCT02105766|DRUG|Filgrastim|mobilize peripheral blood stem cells for apheresis collection
219368981|NCT04201080|DRUG|Placebo|Placebo SC injections
219178976|NCT06264141|DRUG|Nitric Oxide Releasing Solution|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
219178977|NCT06264141|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
219178978|NCT02427698|PROCEDURE|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
219178979|NCT02427698|PROCEDURE|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
219178980|NCT06643676|PROCEDURE|Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data|Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment
219178981|NCT06643676|PROCEDURE|Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis|A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
219178982|NCT06644066|PROCEDURE|Partial pressure of Oxygen Control method|During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
219178983|NCT05586997|DEVICE|Bonded-Hyrax|The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
219178984|NCT05586997|COMBINATION_PRODUCT|Bonded Rapid Maxillary Expansion and low-Level Laser therapy|Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
219368982|NCT01891071|PROCEDURE|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
219368983|NCT02038348|DEVICE|PET with 18F-FDOPA|
219178985|NCT06157749|OTHER|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
219368984|NCT00403221|GENETIC|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp~One dose only followed by a radical prostatectomy 4 weeks later."
219178986|NCT03850756|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
219368985|NCT01178645|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
219368986|NCT00565331|DRUG|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
219368987|NCT00565331|DRUG|Placebo|saline solution
219178987|NCT03850756|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
219178988|NCT03850756|DIAGNOSTIC_TEST|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
219178989|NCT03866525|BIOLOGICAL|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
219178990|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
219178991|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
219178992|NCT03905005|PROCEDURE|Mandibular reconstruction with free tissue transfer.|Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
219178993|NCT05347693|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."
219178994|NCT05347693|DRUG|Local standard of care|Local SoC in the country to be used as per local label
219178995|NCT04895631|DRUG|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
219178996|NCT04895631|PROCEDURE|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
219178997|NCT05557812|DRUG|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
219178998|NCT05557812|DRUG|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
219178999|NCT06150326|DEVICE|medical honey Activon® 25g Tube|no blinding procedures will be set up for the adminisration of the treatement
219368988|NCT00477789|DRUG|allopurinol|
219368989|NCT00109148|DRUG|MK0364|
219368990|NCT05070338|BEHAVIORAL|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]"
219429080|NCT03999112|OTHER|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
219429081|NCT01925391|DRUG|Tono-pen XL Applanation tonometer + Ocu-film +|
219429082|NCT01213264|OTHER|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
219179000|NCT06150326|DEVICE|standard of care|no blinding procedures will be set up for the adminisration of the treatement
219179001|NCT05781347|PROCEDURE|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is an endoscopic treatment performed under general anesthesia. It utilizes radiofrequency (RF) energy delivered to the lower esophageal sphincter (LES) and the gastric cardia to enhance the antireflux barrier.
219179002|NCT05781347|DEVICE|Stretta|Stretta is a FDA approved device for the management of GERD.
219179003|NCT06345898|DRUG|JWK002|Subretinal administration of gene therapy vector JWK002 to one eye.
219179004|NCT05119023|BEHAVIORAL|SRT Observational Learning|All participants completed a computer-based serial response time (SRT) task intended to measure observational (implicit) learning ability. The SRT Observational learning task is a classic paradigm, which has been integral to the understanding of implicit learning (see Schwarb \& Schumacher, 2012). The current task is a replication of classic SRT tasks first described by Nissen and Bullemer (1987), adapted for eye-tracking by Kinder et al. (2008). In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
219747626|NCT02399293|BEHAVIORAL|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
219368991|NCT05070338|BEHAVIORAL|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
219368992|NCT05111587|OTHER|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
219368993|NCT03596346|OTHER|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
219368994|NCT03596346|OTHER|Control product without added RI|2 snack bars daily containing 0 g of RI.
219368995|NCT04440462|OTHER|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
219747627|NCT02399293|BEHAVIORAL|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
219747628|NCT02485886|DRUG|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
219747629|NCT01688804|BEHAVIORAL|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
219747630|NCT00690339|DEVICE|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
218991330|NCT04051528|PROCEDURE|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
219006596|NCT02435784|OTHER|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
219368996|NCT04440462|OTHER|Sterile water|2 ml of sterile water
219368997|NCT02232256|DRUG|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
219368998|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
219368999|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
219369000|NCT05873712|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219006597|NCT02435784|OTHER|Treatment as usual|Patients will attend a psychiatric consultation as usual.
219369001|NCT05873712|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
219369002|NCT05873712|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219369003|NCT05873712|DRUG|Cyclophosphamide|Given IV
219369004|NCT05873712|DRUG|Fludarabine|Given IV
219369005|NCT05873712|PROCEDURE|Leukapheresis|Given IV
219760798|NCT03758261|DRUG|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
219760799|NCT03758261|DRUG|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
219369006|NCT05873712|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219760800|NCT01883024|OTHER|A decision support software|
219760801|NCT01883024|OTHER|Insulin Pump|
219760802|NCT01883024|OTHER|Continuous glucose monitoring|
219760803|NCT03848416|BIOLOGICAL|Ixekizumab|Administered SC
219369007|NCT05873712|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
219369008|NCT05873712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219369009|NCT05873712|DRUG|Zanubrutinib|Given PO
219369010|NCT00863577|DRUG|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
219369011|NCT02292771|DRUG|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
219747631|NCT04503369|BEHAVIORAL|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
219747632|NCT06396559|BEHAVIORAL|pre test-post test|The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
219747633|NCT04921267|BEHAVIORAL|training|training with filtered speech
219747634|NCT03412955|DRUG|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
219747635|NCT04057157|DEVICE|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
219747636|NCT04978415|PROCEDURE|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
219747637|NCT04085250|OTHER|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
219747638|NCT04085250|OTHER|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
219747639|NCT04085250|RADIATION|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
219747640|NCT04085250|DRUG|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
219747641|NCT04085250|OTHER|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
219747642|NCT02427490|BEHAVIORAL|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
219747643|NCT02427490|OTHER|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
219747644|NCT02000102|DRUG|Intravitreal Injection of Aflibercept|
219747645|NCT05393492|BEHAVIORAL|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
219747646|NCT05688085|DRUG|Irbesartan High/Amlodipine FDC|Irbesartan High/Amlodipine FDC
219747647|NCT05688085|DRUG|Irbesartan High|Co-administration of Irbesartan High and Amlodipine
219747648|NCT05688085|DRUG|Amlodipine|Co-administration of Irbesartan High and Amlodipine
219747649|NCT03713450|DEVICE|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
219369012|NCT02292771|DRUG|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
219369013|NCT02292771|DRUG|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
219369014|NCT02292771|DRUG|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
219369015|NCT01631305|DRUG|Levothyroxine|3 mcg/kg/day
219369016|NCT01631305|OTHER|Calcium magnesia|Placebo.
219760804|NCT00988793|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
219760805|NCT00988793|PROCEDURE|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
219369017|NCT00715975|DRUG|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
219369018|NCT00715975|DRUG|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
219369019|NCT00003788|DRUG|carmustine|
219369020|NCT00003788|DRUG|lomustine|
219369021|NCT00003788|DRUG|porfimer sodium|
219006598|NCT03806998|DIETARY_SUPPLEMENT|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
219006599|NCT03806998|DIETARY_SUPPLEMENT|Placebo|Provision of placebo capsules similar to active supplement
219369022|NCT00003788|DRUG|procarbazine hydrochloride|
219369023|NCT00003788|PROCEDURE|neoadjuvant therapy|
219369024|NCT00003788|PROCEDURE|surgical procedure|
219369025|NCT00003788|RADIATION|radiation therapy|
219179005|NCT05119023|BEHAVIORAL|AGL Observational Learning|All participants completed a computer-based observational artificial grammar learning (AGL) task. The AGL Observational learning task is another classic test of implicit learning involving learning of ordered items through exposure (Schuchard \& Thompson, 2017). Artificial grammars contain hierarchal dependencies, similar to the rules that govern word-order and syntax in natural language. In this task, participants look at sequences of geometric shapes on a computer screen. Participants judged if two sequences matched or did not match. After training, participants are shown sequences and must judge if sequences adhere to the pattern or not.
218991331|NCT04051528|PROCEDURE|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
219179006|NCT05119023|BEHAVIORAL|AGL Rule-based Learning|All participants completed a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability of an artificial grammar expressed in nonlinguistic form (sequences of shapes). In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
219179007|NCT05119023|BEHAVIORAL|Standardized cognitive-linguistic assessment|Participants completed standardized cognitive-linguistic assessments that evaluate their ability to produce and understand language and evaluate cognitive skills of attention, executive function and working memory important for learning. Tests involve paper and pencil, looking at pictures, listening to words, indicating responses on a keyboard and talking.
219179008|NCT05119023|OTHER|Brain imaging|Enrolled participants who were safe to scan via magnetic resonance imaging (MRI) completed a structural MRI scan between one-month and five months from behavioral testing of learning.
219179009|NCT05944289|BEHAVIORAL|Acceptance and Commitment Therapy|a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy
219179010|NCT05944289|BEHAVIORAL|Caregiver Support Group|Caregiver support group to run parallel to the ACT intervention group.
219179011|NCT04816851|PROCEDURE|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
219179012|NCT06156163|OTHER|Perturbation training|The exercise program will be applied 2 days/week for 8 weeks, with the addition of progressive perturbation conditions.
219179013|NCT06156163|OTHER|Exercise|The exercise program will be applied 2 days/week for 8 weeks.
219179014|NCT06785961|PROCEDURE|Regeneration of traumatic tooth|Revascularization is a new treatment method for immature necrotic , pulp revascularization allows also the stimulation of the apical development and the root maturation of immature teeth ( growth and thickening of dentinal walls ).
219179015|NCT02284919|DRUG|[18F]ISO-1|\[18F\]ISO-1 PET/CT scan
219369026|NCT00067652|BEHAVIORAL|Education and awareness about body image issues.|
219369027|NCT06929182|OTHER|"non-high risk thrombotic APS patients treated with DOAC"|There is no specific intervention in this study. Routine care data will be collected from patients with a 'non-high-risk' APS profile who are currently being treated with DOACs or have been in the past.
218991332|NCT05250882|OTHER|Enhanced perioperative care protocol|See arm/group description
218991333|NCT00365508|DRUG|nicotine lozenge|nicotine lozenge
218991334|NCT00365508|DRUG|nicotine patch|transdermal nicotine patch
218991335|NCT01577108|DIETARY_SUPPLEMENT|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
218991336|NCT01577108|DIETARY_SUPPLEMENT|Placebo|oral taking 2 capsules before sleeping per day for 14 days
218991337|NCT02753114|DRUG|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
218991338|NCT02753114|DRUG|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
218991339|NCT00783237|DRUG|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
218991340|NCT00783237|DRUG|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
218991341|NCT04939116|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
218991342|NCT04939116|DRUG|Placebo|Orally administered placebo capsule
218991343|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
218991344|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
218991345|NCT00751933|DIETARY_SUPPLEMENT|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
218991346|NCT00751933|OTHER|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
218991347|NCT05806411|DIAGNOSTIC_TEST|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
218991348|NCT04600557|BEHAVIORAL|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
218991349|NCT04600557|BEHAVIORAL|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
219747650|NCT03713450|DEVICE|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
219747651|NCT00688740|DRUG|Docetaxel|intravenous
218991350|NCT04600557|BEHAVIORAL|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
219369028|NCT06917131|DIETARY_SUPPLEMENT|Royal Jelly|Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
219369029|NCT06917131|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
219747652|NCT00688740|DRUG|5-fluorouracil|intravenous
219747653|NCT00688740|DRUG|Doxorubicin|intravenous
219747654|NCT00688740|DRUG|Cyclophosphamide|intravenous
219747655|NCT04505800|DIETARY_SUPPLEMENT|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
219747656|NCT04505800|DIETARY_SUPPLEMENT|Maltose|Maltose
219747657|NCT05994287|DRUG|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
219747658|NCT05994287|DRUG|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
219747659|NCT05994287|DRUG|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
219747660|NCT05416814|DIETARY_SUPPLEMENT|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
219747661|NCT00057148|PROCEDURE|massage treatment|
219747662|NCT01943227|OTHER|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
219747663|NCT01943227|OTHER|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
219747664|NCT02499614|DRUG|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
219747665|NCT03999476|DEVICE|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
219747666|NCT03999476|DEVICE|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
219747667|NCT02676180|OTHER|Group|
219747668|NCT01096004|DRUG|AZD4017|oral suspension, 1200mg, once daily, for 10 days
218991351|NCT04600557|BEHAVIORAL|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
219369030|NCT06915116|PROCEDURE|Acupuncture|Acupuncture will be delivered by licensed experienced acupuncturists at MSK. The intervention includes 12 treatments of acupuncture over 12 weeks (i.e. one treatment a week) with a +/- 14-day window. When patients experience menses recovery during the treatment period, they have the option to discontinue treatment or continue receiving up to 12 acupuncture sessions for symptom management over 12 weeks.
219369031|NCT06915116|OTHER|No Acupuncture|Will have the option to receive the same acupuncture treatment as the acupuncture group after a 16-week waiting period
219369032|NCT06915935|RADIATION|dualenergy X-ray absorptiometry|Dual-energy X-ray Absorptiometry (DXA) is an accurate, safe, and rapid bone mineral density measurement method that is widely used in the diagnosis of osteoporosis and the assessment of fracture risk. The principle is based on the difference in absorption of different energy X-rays in bone and soft tissue, and bone mineral content (BMC) and bone mineral density (BMD) are obtained through mathematical calculations. DXA is commonly used to measure bone mineral density in the lumbar spine, femoral neck, and forearm, and to assess the degree of osteoporosis using a T score, where T ≤ -2.5 is defined as osteoporosis. Due to the advantages of high precision, low radiation dose and convenient operation, DXA is considered as the gold standard for clinical bone mineral density detection.
219369033|NCT06917118|DRUG|Oxycodone 5mg taken first|10 pills of 5mg oxycodone Q4hrs as needed
219369034|NCT06917118|DRUG|Acetaminophen|30 pills of 500mg acetaminophen Q4hrs
219369035|NCT06917118|DRUG|Naproxen Tablets, 500 mg|30 pills of 500mg naproxen Q4hrs
219369036|NCT06917118|DRUG|OxyCODONE 5 mg Oral Tablet|Only used for breakthrough pain
219747669|NCT01096004|DRUG|Placebo|
219747670|NCT03463655|DIAGNOSTIC_TEST|cirrhotic albumin|Ascites puncture
219747671|NCT03463655|DIAGNOSTIC_TEST|serum albumin|blood punctures
219747672|NCT03796104|OTHER|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
219747673|NCT03859219|DRUG|Rozanolixizumab|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
219747674|NCT03859219|DRUG|Placebo|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
219747675|NCT03372616|DIAGNOSTIC_TEST|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
219747676|NCT03372616|DIAGNOSTIC_TEST|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
219747677|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
219747678|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
218991352|NCT04301037|PROCEDURE|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
219369037|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
219369038|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
219369039|NCT06911359|DRUG|Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given a placebo when they receive their dextrose prolotherapy (DPT) injection
219369040|NCT06911359|DRUG|Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given Ibuprofen when they receive their dextrose prolotherapy (DPT) injection
219369041|NCT06915558|PROCEDURE|Opioid-Free Anesthesia (OFA)|Opioid-free anesthesia using a multimodal approach, including dexmedetomidine, lidocaine, ketamine, and magnesium sulfate. No intraoperative opioids are administered.
218991353|NCT04301037|PROCEDURE|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
219369042|NCT06915558|PROCEDURE|Opioid-Based Intravenous Anesthesia (OBA-IV)|Standard opioid-based intravenous anesthesia using propofol, remifentanil, and neuromuscular blockade.
219369043|NCT06915558|PROCEDURE|Opioid-Based Inhalational Anesthesia (OBA-Inh)|Standard opioid-based inhalational anesthesia using sevoflurane, remifentanil, and neuromuscular blockade.
219747679|NCT05370092|OTHER|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
219747680|NCT05370092|OTHER|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
219747681|NCT05370092|OTHER|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
219747682|NCT00392574|DRUG|Prulifloxacin|Tablet
219747683|NCT00392574|DRUG|Placebo|Tablet
219747684|NCT02341274|DRUG|Tacrolimus|Bioequivalence study
219747685|NCT04746755|DEVICE|Orthotic Insole: Lower Back|This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
218991354|NCT06555497|DRUG|topical 1% methotrexate gel|topical 1% methotrexate gel
219369044|NCT06916949|DIAGNOSTIC_TEST|Electrocardiogram|two leads ECG
218991355|NCT06555497|DRUG|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment
218991356|NCT02450591|DRUG|Erlotinib|
218991357|NCT02450591|OTHER|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
219369045|NCT06916949|DIAGNOSTIC_TEST|Pupillometry|During the simulation, automatic pupillometry will be performed on all team members at the following time points: Baseline (T0) During the simulation (T1) End of the simulation (T2) End of the debriefing (T3)
219369046|NCT06916949|DIAGNOSTIC_TEST|Electroencephalogram|EEG monitoring throughout the entire simulation. The EEG recordings will be sampled at: Baseline (T0) During the simulation (T1) End of the debriefing (T2)
219369047|NCT06917443|OTHER|Abdominally targeted exercises|The interventional exercise regimen will include specific abdominally targeted exercises postulated to increase blood flow to the intestine and decrease inflammation.
219369048|NCT06917443|OTHER|General exercises|Generally recommended exercises, without particular attention to the abdomen
219369049|NCT05648474|DIAGNOSTIC_TEST|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
219369050|NCT03684655|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
219369051|NCT06533592|PROCEDURE|Continous suture technique|Duct-to-duct anastomosis will be performed using continuous suture technique for study group
218991358|NCT02623023|DRUG|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
218991359|NCT02623023|OTHER|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
218991360|NCT04782661|DRUG|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
218991361|NCT04782661|DRUG|Placebo|Placebo solution will be administered orally.
218991362|NCT01044875|PROCEDURE|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
219747686|NCT04746755|DEVICE|Orthotic Insole: Heel|This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
219747687|NCT04746755|DEVICE|Orthotic Insole: Knee to Heel|This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
219747688|NCT04746755|DEVICE|Orthotic Insole: Arch|"This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes."
219747689|NCT01434940|OTHER|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
218991363|NCT00777114|DRUG|bortezomib, tositumomab|"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
219747690|NCT06376955|OTHER|High intensity interval exercise|HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.
219747691|NCT06376955|OTHER|Focused ultrasound|Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
219747692|NCT00856557|BEHAVIORAL|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
219747693|NCT00239915|DRUG|Pagoclone|
218991364|NCT02656537|DEVICE|EnSite™ HD Grid Catheter mapping system|
218991365|NCT04219007|DRUG|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
218991366|NCT00371280|PROCEDURE|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
218991367|NCT02538029|BEHAVIORAL|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
218991368|NCT02538029|BEHAVIORAL|Single Task Group|Performing motor or cognitive tasks alone.
218991369|NCT00077961|DRUG|CAMPATH (alemtuzumab)|
218991370|NCT00716534|DRUG|ABT-869|12.5 mg ABT-869
218991371|NCT00716534|DRUG|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
219369052|NCT06533592|PROCEDURE|Interrupted suture technique|Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
219747694|NCT06101420|DRUG|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
219747695|NCT01502527|DIETARY_SUPPLEMENT|Femarelle|Twice daily oral treatment with Femarelle
219747696|NCT01432444|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
219747697|NCT03673176|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
219747698|NCT02301897|DRUG|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
219747699|NCT02301897|DRUG|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
219747700|NCT02015130|OTHER|Individual treatment|See detailed description
219747701|NCT02518529|BIOLOGICAL|G17DT|
219747702|NCT01353729|DRUG|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
219747703|NCT01353729|DRUG|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
219747704|NCT01353729|DRUG|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
219747705|NCT01353729|DRUG|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
219747706|NCT02675400|DRUG|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
218991372|NCT00716534|DRUG|ABT-869|7.5 mg ABT-869
218991373|NCT00716534|DRUG|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
218991374|NCT00716534|DRUG|Paclitaxel|Paclitaxel (200 mg/m2)
218991375|NCT05146895|DRUG|Imiquimod treatment|As an control arm, for patients with flat warts
218991376|NCT05146895|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
218991377|NCT00072566|BIOLOGICAL|Bevacizumab|Given IV
218991378|NCT00072566|DRUG|Cyclophosphamide|Given PO
218991379|NCT00072566|OTHER|Laboratory Biomarker Analysis|Correlative studies
218991380|NCT05884996|OTHER|PNF training|Resistance training with elastic bands in diagonals of PNF
218991381|NCT05248867|DRUG|Placebo|Placebo solution for injection
218991382|NCT05248867|DRUG|AGN-151586|AGN-151586 solution for injection
218991383|NCT02545556|PROCEDURE|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
219747707|NCT02675400|BEHAVIORAL|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
219747708|NCT02675400|DRUG|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
219747709|NCT02439957|DRUG|Brincidofovir|
219747710|NCT02439957|DRUG|Valganciclovir|
219369053|NCT05799261|PROCEDURE|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
219747711|NCT03532347|DEVICE|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
219747712|NCT03770702|DRUG|Angiotensin receptor blockers|Candesartan
219747713|NCT03770702|DRUG|Statins|Atorvastatin
219369054|NCT05799261|PROCEDURE|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
219369055|NCT04558593|PROCEDURE|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
219369056|NCT04558593|PROCEDURE|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
219369057|NCT06550362|DRUG|iron sulfate|Oral iron administration
219369058|NCT04531722|PROCEDURE|Intraoperative brain microdialysis|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
219369059|NCT05639569|DEVICE|Ankura™ TAA Stent Graft System|All patients will be implanted with Ankura™ TAA Stent Graft System in accordance with the instructions for use (IFU).
219369060|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
219369061|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
219369062|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219747714|NCT03497377|DRUG|18F-DCFPyL Injection|
219747715|NCT03497377|DRUG|18F-NaF|
219747716|NCT01831908|OTHER|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
219747717|NCT05606107|DRUG|Tofacitinib|Tofacitinib combined with other csDMARDs, but no glucocorticoids.
219747718|NCT05606107|DRUG|Glucocorticoid|Glucocorticoid
219747719|NCT05879029|DRUG|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
219747720|NCT05879029|DRUG|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
219369063|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
219369064|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219369065|NCT06320405|DRUG|Paclitaxel|Given IV
219369066|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219369067|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
219369068|NCT05646056|DEVICE|Software|Observation only
219747721|NCT03377751|PROCEDURE|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
219369069|NCT06957392|BEHAVIORAL|Systematic self-help training program for enhancing social reward|"Based on previous research, this study has made significant innovations and optimizations within the traditional framework of Acceptance and Commitment Therapy (ACT). We have specifically developed a systematic self-help training module aimed at enhancing social reward, which includes components such as social scenario experience, social skills training, and the improvement of social reward sensitivity.~A single-blind randomized controlled trial will be conducted, dividing IGD participants into two groups. The SRI group (Social Reward Intervention group) will receive a psychological self-help training program designed to improve social reward, while the other (Control group) will receive a course introducing general knowledge about Internet Gaming Disorder. Both groups will have identical learning durations and modalities. The self-help training consists of 8 sessions, delivered twice weekly through a blended online and offline learning format, lasting approximately one month."
219369070|NCT06957392|BEHAVIORAL|general knowledge about Internet Gaming Disorder .|"A single-blind randomized controlled trial is conducted. 30 people, assigned to Control group, was provided with standard educational courses introducing general knowledge about Internet Gaming Disorder. Assessments including standardized scales, behavioral tests, and neuroimaging are conducted once before and once after the intervention.~During the course, participants will receive twice-weekly online guidance sessions totaling eight sessions. The entire intervention lasts approximately one month, with follow-up assessments conducted at 3, 6, and 12 months post-intervention."
219369071|NCT03069651|OTHER|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
219369072|NCT04025632|DRUG|zilucoplan|Daily subcutaneous (SC) inection
219747722|NCT03377751|PROCEDURE|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
219747723|NCT03377751|PROCEDURE|PVI only group|PVI will be performed in this arm.
219747724|NCT04143776|PROCEDURE|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
219747725|NCT02666053|DRUG|BMS-663068|BMS-663068
219747726|NCT04608058|BEHAVIORAL|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
219747727|NCT04608058|BEHAVIORAL|Routine training|The control group received the clinics' routine training include face to face class education.
219747728|NCT01734044|DRUG|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
219747729|NCT01734044|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
218991384|NCT06042504|OTHER|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
218991385|NCT05995483|OTHER|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
219369073|NCT04025632|OTHER|Placebo|Daily subcutaneous (SC) inection
219369074|NCT03592459|DEVICE|Macy Catheter|Undergo placement of Macy catheter
219369075|NCT03592459|PROCEDURE|Pain Therapy|Receive opioids via Macy catheter
219369076|NCT03592459|OTHER|Questionnaire Administration|Ancillary studies
219369077|NCT03592459|OTHER|Survey Administration|Ancillary studies
219747730|NCT02246491|OTHER|A-T iPS cell line|Reprogramming A-T patients iPS cell line
219747731|NCT02246491|OTHER|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
218991386|NCT01861860|DEVICE|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
218991387|NCT01673217|DRUG|decitabine|Given IV
218991388|NCT01673217|BIOLOGICAL|NY-ESO-1 peptide vaccine|Given SC
218991389|NCT01673217|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
218991390|NCT01673217|BIOLOGICAL|sargramostim|Given SC
218991391|NCT01673217|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
218991392|NCT01673217|OTHER|immunohistochemistry staining method|Correlative studies
218991393|NCT01673217|OTHER|liquid chromatography|Correlative studies
218991394|NCT01673217|OTHER|mass spectrometry|Correlative studies
219369078|NCT00127127|DRUG|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
219369079|NCT00482963|DRUG|levonorgestrel, efavirenz|
219369080|NCT05896345|DEVICE|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
219369081|NCT05896345|COMBINATION_PRODUCT|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
219369082|NCT00565630|DEVICE|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
219369083|NCT04693871|DEVICE|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
219369084|NCT01136551|DRUG|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
219369085|NCT01401569|BEHAVIORAL|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
219369086|NCT05651646|OTHER|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
219747732|NCT00890500|DRUG|Fludarabine|30mg/m2/day IV x 6 days
219747733|NCT00890500|DRUG|Melphalan|100 mg/m2/day IV x 1 day
219747734|NCT00890500|DRUG|Antithymocyte Globulin|1mg/kg/day x 4 days
219747735|NCT00890500|DRUG|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
219747736|NCT00890500|DRUG|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
218991395|NCT01673217|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
218991396|NCT01673217|OTHER|laboratory biomarker analysis|Correlative studies
218991397|NCT01673217|GENETIC|DNA methylation analysis|Correlative studies
218991398|NCT01673217|OTHER|enzyme-linked immunosorbent assay|Correlative studies
218991399|NCT02384486|BEHAVIORAL|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
218991400|NCT02384486|OTHER|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
218991401|NCT01995474|OTHER|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
218991402|NCT01995474|OTHER|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
219369087|NCT05217914|DRUG|Copanlisib (BAY80-6946)|Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
219369088|NCT01413269|RADIATION|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
219369089|NCT04575948|DRUG|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
219369090|NCT04575948|DRUG|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
219369091|NCT04575948|DRUG|Base formula|Base formula is a negative control
219369092|NCT00585234|OTHER|Digital Photography|Digital Photography
219369093|NCT04363333|DIAGNOSTIC_TEST|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
219369094|NCT06518629|OTHER|Photobiomodulation with low power laser|All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
219369095|NCT03442803|DEVICE|Target-Controlled Infusion|Propofol Target-Controlled Infusion
219369096|NCT01827891|PROCEDURE|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
219369097|NCT05798052|BEHAVIORAL|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
219369098|NCT02780076|OTHER|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
219369099|NCT05486403|BEHAVIORAL|Appetite Toolbox Programme|Preschool educators are trained to deliver a bio-behavioural classroom-based programme focusing on building skills in i) appetite awareness, ii) attention/attention control and iii) sensing body cues. The programme is delivered using a combination of interactive story books, classroom props and activities, and mealtime transitions/routines.
219369100|NCT04239846|DRUG|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
218991403|NCT03634657|RADIATION|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
218991404|NCT03634657|RADIATION|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield \& X-ray protective strips
218991405|NCT03634657|RADIATION|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
218991406|NCT04427371|OTHER|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
218991407|NCT01064310|DRUG|pazopanib|oral anti-angiogenic treatment
218991408|NCT01064310|DRUG|sunitinib|oral anti-angiogenic treatment
218991409|NCT00272012|DRUG|Insulin glulisine|
218991410|NCT02011971|DRUG|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
218991411|NCT01558232|DEVICE|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
218991412|NCT01408927|OTHER|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
218991413|NCT01408927|OTHER|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
218991414|NCT01408927|OTHER|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
219369101|NCT04239846|OTHER|Placebo Gel|Placebo Gel, BID
218991415|NCT04096664|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
218991416|NCT06204601|OTHER|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
218991417|NCT05315401|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
218991418|NCT05315401|DIETARY_SUPPLEMENT|Placebo|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
218991419|NCT05315401|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
218991420|NCT03305341|BIOLOGICAL|COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix"
218991421|NCT01980940|DRUG|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
218991422|NCT01980940|DRUG|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
218991423|NCT01980940|DRUG|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
218991424|NCT01980940|DRUG|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
218991425|NCT01980940|DRUG|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
218991426|NCT01980940|DRUG|Placebo|Placebo gel applied topically.
218991427|NCT01980940|DRUG|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
218991428|NCT01980940|DRUG|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
218991429|NCT04242719|DEVICE|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
218991430|NCT04242719|BIOLOGICAL|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
218991431|NCT02939430|DRUG|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
218991432|NCT02939430|DRUG|Intravenous neostigmine and atropine|
218991433|NCT00180050|DRUG|Budesonide|
218991434|NCT03033004|DEVICE|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
218991435|NCT03033004|DEVICE|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
218991436|NCT03033004|DEVICE|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
218991437|NCT00496652|RADIATION|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
218991438|NCT00496652|DRUG|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
218991439|NCT03000283|DRUG|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
218991440|NCT05556330|PROCEDURE|computer guided autogenous cortical shell technique|computer guided autogenous cortical shell technique
218991441|NCT02476383|PROCEDURE|spinal manipulative therapy|refer to arm descriptions
218991442|NCT04050579|DEVICE|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
218991443|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 1|In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
219747737|NCT06272604|BEHAVIORAL|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
218991444|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 2|In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
219747738|NCT02354521|OTHER|NO INTERVENTIONS|
219747739|NCT02884453|DRUG|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
219747740|NCT06375148|OTHER|Enteral nutrition|prone position ventilation
219747741|NCT06062303|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
218991445|NCT04724980|DRUG|PRGN-2012 - Phase II; Dose Level 2|The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
218991446|NCT04685317|DEVICE|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
218991447|NCT04685317|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
219369102|NCT02274688|BEHAVIORAL|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
219369103|NCT00219115|DRUG|aliskiren|
219369104|NCT03009604|DRUG|Simethicone|Simethicone 40mg oral tablets
219369105|NCT03009604|DRUG|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
219369106|NCT04047888|OTHER|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
219369107|NCT04047888|OTHER|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
219747742|NCT04243486|DRUG|UHE-105|Topical shampoo containing active drug
219747743|NCT04243486|DRUG|Vehicle|Topical shampoo containing no active drug
219747744|NCT03716596|RADIATION|SBRT|SBRT radiation dose is 40-50 Gy in total.
219747745|NCT03716596|DRUG|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
219747746|NCT04999410|BEHAVIORAL|High Intensity Interval Training|Interventions will contrast alternative training protocols
219747747|NCT04923997|BEHAVIORAL|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
218991448|NCT05192941|DRUG|Inclisiran Sodium|Subcutaneously injected on Day 1, Day 90, and Day 270
218991449|NCT05192941|DRUG|Placebo|Placebo to inclisiran 300 mg subcutaneously
218991450|NCT04543838|DIAGNOSTIC_TEST|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
218991451|NCT04543838|OTHER|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
219369108|NCT03656965|DRUG|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
219369109|NCT03656965|COMBINATION_PRODUCT|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
219369110|NCT02684071|DRUG|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
219369111|NCT02684071|DRUG|topotecan|To be administered in conjunction with methotrexate
219369112|NCT02684071|DRUG|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
219369113|NCT01524991|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
219369114|NCT01524991|DRUG|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
219369115|NCT01524991|DRUG|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
219369116|NCT02221089|DRUG|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
219747748|NCT06549335|DRUG|Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
219747749|NCT00850330|OTHER|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
219747750|NCT00478257|DEVICE|bright white light|Intervention: Bright white light administered for 30 minutes each morning
219747751|NCT00478257|DEVICE|comparator red light treatment|dim red light administered for 30 minutes every morning
219747752|NCT01920113|DRUG|Dexmedetomidine - remifentanil group|
219747753|NCT01920113|DRUG|Propofol - remifentanil group|
219747754|NCT06419881|BEHAVIORAL|Tele-drama therapy|A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy
218991452|NCT04177914|PROCEDURE|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
218991453|NCT04177914|DEVICE|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
218991454|NCT05955001|DRUG|Tadalafil 5mg / Placebo|Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
218991455|NCT06330051|BEHAVIORAL|improvement acute reperfusion treatment quality for stroke through spatiotemporal computing|"1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS"
219747755|NCT06419881|OTHER|Usual Care|This arm continued to receive the routine activities provided by Uniper Care
219747756|NCT05503277|DEVICE|LTSD|measuring seal pressure
219747757|NCT05503277|DEVICE|i-gel|measuring seal pressure
219747758|NCT00809822|DRUG|NPB-01|Intravenous immunoglobulin
219747759|NCT00809822|DRUG|Placebo|Physiological saline
219747760|NCT03931330|DEVICE|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
219747761|NCT03412929|DEVICE|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
219747762|NCT03962647|DIETARY_SUPPLEMENT|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
219747763|NCT03962647|DRUG|Letrozole|2.5 mg taken once daily by mouth
219747764|NCT00818194|DRUG|extended release tacrolimus|oral
218991456|NCT04518072|OTHER|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
218991457|NCT05343052|OTHER|Patient Reported Outcomes Surveys|"* Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)"
218991458|NCT05343052|OTHER|Clinical Assessments|"* Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS"
219747765|NCT00818194|DRUG|cyclosporine A microemulsion|oral
219747766|NCT06052553|DEVICE|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
219747767|NCT04897568|OTHER|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
219747768|NCT06186518|OTHER|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
219747769|NCT06186518|OTHER|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
219747770|NCT02878395|PROCEDURE|Ileocolic resection|
219747771|NCT05718739|DEVICE|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
219747772|NCT02474173|OTHER|Laboratory Biomarker Analysis|Correlative studies
219747773|NCT02474173|DRUG|Onalespib|Given IV
219747774|NCT02474173|DRUG|Paclitaxel|Given IV
219747775|NCT02474173|OTHER|Pharmacological Study|Correlative studies
219747776|NCT03947619|DEVICE|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
219747777|NCT05076110|DRUG|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
219747778|NCT05076110|DRUG|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
219747779|NCT05076110|DRUG|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
219747780|NCT05076110|DRUG|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
219747781|NCT05076110|DRUG|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
219747782|NCT06527430|PROCEDURE|4 mg bupivacaine|Spinal anesthesia was applied to the patients with 4 mg bupivacaine in the lateral decubitus position.
219747783|NCT06527430|PROCEDURE|6 mg bupivacaine|Spinal anesthesia was applied to the patients with 6 mg bupivacaine in the lateral decubitus position.
219747784|NCT05141149|DRUG|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
219747785|NCT05141149|DRUG|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
219747786|NCT03157128|DRUG|LOXO-292|Oral LOXO-292
219747787|NCT06165107|OTHER|No intervention|No intervention
219747788|NCT06257277|DRUG|GBCAs|GBCAs are given per routine clinical practice.
218991459|NCT05343052|OTHER|Biomechanical and Neuromuscular Assessments|"* Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS"
219747789|NCT06067516|OTHER|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
219747790|NCT01179880|DRUG|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
219747791|NCT01179880|DRUG|Placebo|Matching placebo for each step
219747792|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
219747793|NCT05026723|BEHAVIORAL|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
219747794|NCT05026723|BEHAVIORAL|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
219747795|NCT06129877|DEVICE|CHAMP App|CHAMP App software platform will have been used in other research studies to be included in the Feeding difficulties repository
219747796|NCT06639581|DEVICE|20 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
219747797|NCT06639581|DEVICE|30 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
219747798|NCT06639581|DEVICE|40 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
219747799|NCT06638034|DRUG|68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
219747800|NCT06640309|DRUG|Nicotinamide Tablet|Nicotinamide is anti-inflammatory and antioxidant.
218991460|NCT05343052|DEVICE|Conventional MRI|at baseline, within 7 days of injury, and within 7 days of RTS
218991461|NCT00895232|DRUG|Cohort I|
219747801|NCT06640309|DRUG|conventional synthetic antirheumatic drugs|methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
219747802|NCT06638515|OTHER|Walking apnea at Low Lung Volume|Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
219747803|NCT06638515|OTHER|Walking at normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
219747804|NCT06638528|OTHER|Walking apnea at High Lung Volume|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
219747805|NCT06638528|OTHER|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
218991462|NCT00895232|DRUG|Cohort II|
219747806|NCT05653999|DEVICE|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
219747807|NCT01467856|PROCEDURE|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
219747808|NCT01066299|DRUG|Syntocinon®|single dose of OXT (24 IU)
219747809|NCT01066299|DRUG|inactive nasal spray|single dose (24 IU)
219747810|NCT04258631|DRUG|Hydromorphone|Given IT
219747811|NCT04258631|PROCEDURE|Laparotomy|Undergo laparotomy
219747812|NCT04258631|DRUG|Liposomal Bupivacaine|Drug
219747813|NCT04258631|OTHER|Questionnaire Administration|Ancillary studies
218991463|NCT00895232|DRUG|Cohort III|
218991464|NCT06067061|COMBINATION_PRODUCT|Atezolizumab + RP1|Patients will be treated in a window period (ie 3 treatment cycles). After evaluation, patients that had no increase in ctDNA after 3 cycles (see Definition of ctDNA status) will continue on the same treatment (intratumoral injections of RP1 in combination with Atezolizumab) for a total of 10 treatment cycles prior to surgery.
218991465|NCT02044445|PROCEDURE|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
218991466|NCT03120312|PROCEDURE|total hip replacement|primary hip replacement patients during past 5 years．
219747814|NCT03895372|DRUG|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
218991467|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
219747815|NCT03895372|DRUG|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
219747816|NCT01179555|BEHAVIORAL|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
219747817|NCT01179555|BEHAVIORAL|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
219747818|NCT04466839|OTHER|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
219747819|NCT06441305|BEHAVIORAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
219747820|NCT03119220|DEVICE|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
219747821|NCT04316416|PROCEDURE|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
219747822|NCT04316416|PROCEDURE|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
219747823|NCT04316416|DRUG|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
219747824|NCT06089993|OTHER|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
218991468|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
218991469|NCT01857856|DRUG|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
218991470|NCT05983757|DEVICE|Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion|"The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA)."
218991471|NCT05983757|OTHER|Standard medical management|All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
218991472|NCT01422174|PROCEDURE|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
218991473|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
219747825|NCT06089993|OTHER|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
219747826|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
219747827|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
219747828|NCT06634784|OTHER|Bone Conduction Implant (BCI)|Improvement in hearing using BCI.
219747829|NCT03896633|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
219747830|NCT03896633|DRUG|Azopt 1%|Azopt 1%, RLD
219747831|NCT06271057|DRUG|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
219747832|NCT05687578|DIAGNOSTIC_TEST|Measurements Only|This is an observational study only using biospecimen and imaging-based measurements only
219747833|NCT01722643|BEHAVIORAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
218991474|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
219747834|NCT01722643|BEHAVIORAL|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
219747835|NCT05423613|PROCEDURE|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
219747836|NCT04639726|DIETARY_SUPPLEMENT|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
219747837|NCT04639726|OTHER|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
219747838|NCT01472185|DRUG|Ranolazine|Ranolazine tablets administered orally twice daily.
219747839|NCT01472185|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily.
219747840|NCT01472185|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
219747841|NCT01472185|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
218991475|NCT06681805|DRUG|Placebo + Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
218991476|NCT06681805|DRUG|Placebo+ Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
218991477|NCT07015879|BEHAVIORAL|Continuous Care Counseling Based on the Roy Adaptation Model|Patients in the control group will receive the clinic's routine treatment and nursing care. This care includes preoperative and postoperative information, prevention of leg flexion, monitoring of vital signs, pain management, discharge education, and discharge of patients without complications three days after surgery. In addition, patients' overall comfort and quality of life will be assessed face-to-face five days before surgery and on the second postoperative day, and by telephone at the first and third months after discharge.
218991478|NCT07015021|DRUG|Daratumumab|Daratumumab: 16mg/Kg, IV or 1800mg Sc; C1-2 d1,8,15,22; C3-6 d1,15; C7-12 d1
218991479|NCT07015021|DRUG|Cafizomide|Cafizomide: 20mg/m2; C1-8 d1,2,8,9,15,16； C9-12 d1,2,15,16；After tolerance to 20mg/m2, the dose of C1D1 and C1D2 can be adjusted to 27g/m2.
218991480|NCT07015021|DRUG|Pomalidomide|Pomalidomide: 4mg, PO,d1-21
218991481|NCT07015021|DRUG|Dexamethasone|Dexamethasone: 20mg, po,d1, 2,8,9,15,16,22,23.
218991482|NCT03835780|OTHER|No intervention|A observation of outcomes in usual practice
218991483|NCT07054125|BEHAVIORAL|Education, lifestyle counseling, and peer support|"This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes.~People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit)."
219747842|NCT03941561|DRUG|S-1 for 9 months|S-1 for 9 months after D2 resection
218991484|NCT07053930|DRUG|Intraumbilical oxytocin|Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.
218991485|NCT07053930|DRUG|Intravenous oxytocin|Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.
219747843|NCT03941561|DRUG|S-1 for 1 year|S-1 for 1 year after D2 resection
219747844|NCT06337214|BEHAVIORAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
219747845|NCT04240509|DRUG|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
219747846|NCT00823797|DRUG|Bendamustine Hydrochloride|Given IV
219747847|NCT00823797|OTHER|Quality-of-Life Assessment|Ancillary studies
219747848|NCT06315998|DEVICE|Magnetocardiography|Magnetocardiography
219747849|NCT00748774|BEHAVIORAL|Questionnaire|Two questionnaires taking about 10 minutes to complete.
219747850|NCT04017312|DEVICE|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
219747851|NCT04017312|DEVICE|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
219747852|NCT05681949|OTHER|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
219747853|NCT05417906|OTHER|Standard care|Oral prednisolone for 5 days
219747854|NCT05417906|OTHER|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
219747855|NCT06252415|BIOLOGICAL|foetal amniotic fluid sample|At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
219747856|NCT06252415|BIOLOGICAL|blood samples|2 x 5ml blood EDTA tubes for both parents
219747857|NCT06252415|OTHER|semi-structured online interviews|25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
219747858|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|MG-K10 Humanized Monoclonal Antibody Injection
219747859|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection（Penicillin bottle）|MG-K10 humanized monoclonal antibody injection (single injection)
219747860|NCT06563817|DRUG|Rapamycin|All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
219747861|NCT06519526|DRUG|SHR-0302|SHR-0302 will be administered orally as tablets.
219747862|NCT06519526|DRUG|SHR-2554|SHR-2554 will be administered orally as tablets.
219747863|NCT00843960|BEHAVIORAL|behavioral adaptation and symptom management|behavioral adaptation and symptom management
219747864|NCT06563687|DEVICE|Dexcom ONE+|In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
219747865|NCT04541927|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
218991486|NCT07053644|BEHAVIORAL|FRESH-EATS|"1. Six weekly Cooking Matters® for Families sessions. Each session is designed to take 90 minutes including hands-on cooking or other activities.~2. Two 90-minute family workshop sessions will be implemented.~3. Food delivery budget (i.e., the Walmart+ annual membership with free shipping and gift cards to purchase ingredients) will be provided up during the intervention period and local food pantry information will be distributed to families.~4. Community garden at the Cornerstone Family Ministries will be utilized by incorporating garden activities, harvesting, and cooking with the produce from the garden."
218991487|NCT07053644|BEHAVIORAL|Lagged Intervention Control Group|Nutrition education materials that address nutrition in school-age children and families Cooking Matters® for Families will be implemented. Each of six sessions will take about 90 minutes. All lessons will be delivered by qualified nutrition educators along with student assistants at the Cornerstone Family Ministries classrooms. After completing the post-intervention assessment, participants will then receive the other FRESH-EATS intervention components.
219747866|NCT03049644|PROCEDURE|Mechanical Diagnosis and Therapy|Identification of directional preference.
219747867|NCT03049644|PROCEDURE|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
219747868|NCT04539288|OTHER||There is no intervention in this study.
219747869|NCT06059898|DEVICE|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
219747870|NCT06059898|PROCEDURE|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
219747871|NCT00356187|DRUG|Propranolol|
219747872|NCT06003504|OTHER|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
219747873|NCT06003504|OTHER|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
219747874|NCT05226338|DRUG|D-0502|Formulation 1 Formulation 2 Formulation 3
219747875|NCT03104920|PROCEDURE|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
219747876|NCT03104920|PROCEDURE|Traditional treatment|A traditional perioperative management for HCC.
219747877|NCT02264366|BEHAVIORAL|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
219747878|NCT02266771|DEVICE|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
219747879|NCT02266771|DEVICE|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
219747880|NCT05177380|PROCEDURE|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
219747881|NCT05177380|OTHER|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
219747882|NCT02951481|BEHAVIORAL|Systematic evaluation by an ID expert.|"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
219747883|NCT01459627|OTHER|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
219747884|NCT01459627|OTHER|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
219747885|NCT00007774|DRUG|Haloperidol|
219747886|NCT00007774|DRUG|Olanzapine|
219747887|NCT05504434|DEVICE|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
219747888|NCT02699411|DEVICE|Dry needling|dry needling Travell and Simons
219369117|NCT02221089|DIETARY_SUPPLEMENT|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
219369118|NCT02221089|OTHER|Placebo|Placebo capsules identical in appearance to Retaron capsules
219747889|NCT02699411|OTHER|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
219747890|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
219747891|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
219747892|NCT01051661|BIOLOGICAL|Placebo|Intramuscular injection, one dose
219747893|NCT04962516|DEVICE|single-use precision filtered infusion sets|single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
219747894|NCT04962516|DEVICE|single-use precision filter infusion set with needle|single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
219747895|NCT05929313|DEVICE|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
219747896|NCT05929313|DEVICE|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
219747897|NCT03809533|DRUG|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
219747898|NCT04642079|BIOLOGICAL|20vPnC|20-valent pneumococcal conjugate vaccine
219747899|NCT02881827|RADIATION|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
219747900|NCT02881827|OTHER|Placebo|Simulation of treatment with the device switched off
219747901|NCT02881827|OTHER|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
219747902|NCT05632393|DRUG|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
219747903|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
219747904|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
219747905|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
219747906|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)
219747907|NCT05931822|OTHER|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
219747908|NCT05931822|OTHER|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
219747909|NCT03517605|OTHER|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
219747910|NCT01146821|DIETARY_SUPPLEMENT|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care
219747911|NCT01146821|DIETARY_SUPPLEMENT|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
219747912|NCT05272280|OTHER|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
219747913|NCT05272280|OTHER|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
218991488|NCT07053696|DRUG|Technetium-99m Diethylenetriaminepentaacetic Acid|Technetium-99m Diethylenetriaminepentaacetic Acid A single inhaled dose of 99mTc-DTPA in 0.9% sodium chloride solution, total volume 2 ml, with radioactivity of 500-800 µCi. The solution is radiolabeled only in the aqueous phase to allow gamma scintigraphic imaging of pulmonary deposition. Delivered via breath-actuated EDDIS system. The formulation includes a non-labeled microdose of perfluorocarbon emulsion to simulate clinical aerodynamic behavior.
218991489|NCT07053696|DEVICE|EDDIS-IDDS (Enhanced Digital Dose Inhalation Delivery System)|Portable, maintenance-free breath-actuated inhalation delivery system with integrated digital sensors. Records real-time data including inspiratory volume, flow rate, duration, and breath-hold time. Provides controlled aerosol delivery and secure transmission of inhalation parameters to the clinical monitoring platform.
218991490|NCT07054086|DRUG|Neoadjuvant Chemotherapy (NACT)|"The planned regimen for neoadjuvant therapy may include one or more of the following agents:~1. Paclitaxel Injection~2. Albumin-bound paclitaxel Injection (Abraxane® equivalent formulation)~3. Cisplatin Injection~4. Carboplatin Injection~5. Nivolumab~6. Pembrolizumab~7. Toripalimab~8. Tirilibumab~9. Camrelizumab The specific agent(s) and their combination will be selected based on the patient's clinical treatment protocol. The final regimen must be approved jointly by the principal investigator and the attending physician according to established clinical guidelines and individualized patient factors."
218991491|NCT07054697|DRUG|Homoeopathic medicines|
218991492|NCT07054697|DRUG|Placebo|
218991493|NCT07054697|BEHAVIORAL|THERAPY|SPEECH THERAPY / OCCUPATIONAL THERAPY
219369119|NCT05876351|DRUG|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
219747914|NCT02412982|DRUG|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
219747915|NCT02412982|DRUG|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
219747916|NCT03097978|DEVICE|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
219747917|NCT03097978|DEVICE|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
219747918|NCT03097978|OTHER|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
219747919|NCT03097978|OTHER|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
219747920|NCT01172392|DRUG|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
219747921|NCT01172392|DRUG|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
219747922|NCT03986892|BEHAVIORAL|Physical Activity|Physical Activity
218991494|NCT07054645|DIETARY_SUPPLEMENT|Elderberry Anthocyanin Chewing Gum|Participants receive a functional chewing gum containing encapsulated elderberry (Sambucus nigra L.) anthocyanins standardized for cyanidin-3-glucoside and cyanidin-3-sambubioside. The gum is formulated to be geriatric-friendly (soft, low-elasticity) and is administered twice daily for 6 weeks. It enables transmucosal polyphenol delivery through buccal absorption.
218991495|NCT07054645|DIETARY_SUPPLEMENT|Placebo Chewing Gum|Participants receive a placebo chewing gum identical in appearance, taste, and texture to the active gum but containing no elderberry anthocyanins or bioactive compounds. The gum is administered twice daily for 6 weeks to match the intervention group.
218991496|NCT07053228|BEHAVIORAL|Nature-based virtual reality|"Participants in this group will receive standard pain management care plus one session of immersive virtual reality (VR) using Oculus Go headsets. The session consists of viewing a nature-themed 360º video (e.g., beach, waterfall, songbirds) for approximately 8 minutes, accompanied by synchronized natural sounds.~The VR experience is designed to promote distraction, relaxation, and emotional engagement with nature to support pain relief and emotional regulation. The equipment is sanitized between uses according to hospital infection control protocols."
218991497|NCT07053228|DRUG|Standard Pain Management|"Participants in this group will receive the institution's standard pharmacological pain management, monitored and adjusted by the Pain Control Team using the hospital's electronic medical record system. This may include opioid and non-opioid analgesics according to clinical evaluation.~No complementary interventions will be provided during the study period."
218991498|NCT07053332|DRUG|PD-1/CTLA-4 combination antibody with low-dose radiotherapy|"* PD-1/CTLA-4 combination antibody: Iparomlimab and Tuvonralimab， 5mg/kg on day 1, day 22, and day 43, administered via intravenous infusion, for a total of three cycles before surgery and maintained for up to 1 year after surgery.~* Radiotherapy: To be conducted within one week of the start of immunotherapy, with a total dose of DT: 30Gy, 2.5Gy × 12 fractions, once daily, five times per week. The preoperative radiotherapy target area will be delineated by the radiation oncologist in accordance with the NCCN Guidelines for Gastric/Esophagogastric Junction Cancers 2022 and in consultation with the opinions of the general surgeon.~* Surgery: Surgical treatment will be completed within 3-5 weeks after the completion of neoadjuvant therapy.~* Adjuvant therapy: Postoperative immunotherapy will be maintained for up to 1 year."
218991499|NCT07054229|DRUG|Contrast enhanced Ultrasound|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
218991500|NCT07054229|GENETIC|88-gene panel for thyroid cancer|"88-gene panel refers to a testing combination that includes 88 genes, which are typically associated with the onset, progression, and prognosis of thyroid cancer."
218991501|NCT07054151|OTHER|No clinical intervention (observational study only)|This is an observational study. No experimental or clinical intervention was applied. Only non-invasive data collection such as capillary refill time and vital sign measurements was performed.
218991502|NCT07053436|DRUG|Bispecific Monoclonal Antibody and Triplet Therapy|Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy
219747923|NCT03032809|OTHER|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
219747924|NCT06341335|DRUG|cadonilimab|iv, q3w
219747925|NCT06341335|DRUG|pulocimab|iv, q3w
219747926|NCT06341335|DRUG|paclitaxel|iv, q3w
219747927|NCT06341335|DRUG|placebo|iv, q3w
219747928|NCT03030534|COMBINATION_PRODUCT|Educational package and software package|Using Information and communication technology to deliver health promoting activities
219747929|NCT03030534|OTHER|Health promotion tips|Give general information on health promotion
219747930|NCT04486677|BEHAVIORAL|Caring Cards Group|Group of Veteran card-makers.
219747931|NCT04486677|BEHAVIORAL|Caring Cards Recipients|Group of Veteran card-recipients.
219747932|NCT04270019|DRUG|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
219747933|NCT04270019|DRUG|Normal Saline|Standard solution of sterile normal saline.
219747934|NCT02668757|BEHAVIORAL|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
219747935|NCT01526200|PROCEDURE|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
219747936|NCT04547387|DEVICE|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
219747937|NCT04584723|OTHER|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
219747938|NCT00635050|DRUG|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
219747939|NCT06116097|BEHAVIORAL|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
219747940|NCT05699057|BEHAVIORAL|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
219747941|NCT06489509|DEVICE|Positive End Expiratory Pressure 5 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
219747942|NCT06489509|DEVICE|Positive End Expiratory Pressure 10 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
219747943|NCT00725855|DRUG|MEM 3454|1 mg dose
219747944|NCT00725855|DRUG|MEM 3454|5 mg dose
219747945|NCT00725855|DRUG|MEM 3454|15 mg dose
219747946|NCT00725855|DRUG|MEM 3454|50 mg dose
219747947|NCT00725855|DRUG|Placebo for MEM 3454|Placebo dose
219747948|NCT04913116|DIAGNOSTIC_TEST|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
219747949|NCT03038620|DRUG|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
219747950|NCT03038620|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
219747951|NCT00386581|DRUG|atomoxetine|
219747952|NCT00386581|DRUG|placebo|
219747953|NCT00473174|DRUG|Ramipril|Dosing on awakening versus bedtime
219747954|NCT00473174|DEVICE|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
219747955|NCT00176748|DRUG|AG 6013736|5 mg po bid
219747956|NCT03653819|OTHER|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
219747957|NCT03653819|OTHER|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
219747958|NCT01156350|DRUG|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
219747959|NCT01871922|DRUG|Placebo|Saline
219747960|NCT01871922|DRUG|Atropine|Atropine
219747961|NCT01711099|DEVICE|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
219747962|NCT04011241|DRUG|BI 1323495|Tablet
219747963|NCT04011241|DRUG|Itraconazole|Oral solution
219747964|NCT00672035|BIOLOGICAL|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
219747965|NCT00759395|DRUG|AZD2327|Tablet, Oral, Daily
219369120|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
219369121|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
219369122|NCT00391599|PROCEDURE|enema|
219369123|NCT03455673|DIAGNOSTIC_TEST|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1"
219369124|NCT04159090|DIAGNOSTIC_TEST|F18-PSMA|Patients with moderate or high risk of prostate cancer
219369125|NCT04963478|OTHER|exercise|exercise testing
219369126|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
219369127|NCT00582556|DRUG|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
219369128|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
219369129|NCT01501903|PROCEDURE|Standard|FNA in a single plane
219369130|NCT01501903|PROCEDURE|Fanning|FNA in multiple planes
219747966|NCT00759395|DRUG|Placebo|Tablet, Oral, Daily
219747967|NCT01648322|DRUG|F-627|subcutaneous injection given 1 per chemotherapy.
219747968|NCT01648322|DRUG|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
219747969|NCT04150445|BEHAVIORAL|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
219747970|NCT03063645|DRUG|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
219747971|NCT03063645|DRUG|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
219747972|NCT03063645|DRUG|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
219747973|NCT02304185|BIOLOGICAL|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
219747974|NCT02304185|BIOLOGICAL|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
219747975|NCT02304185|BIOLOGICAL|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
219747976|NCT02304185|BIOLOGICAL|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
219747977|NCT02304185|DRUG|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
219747978|NCT00157261|DRUG|tenecteplase|
218991503|NCT07053436|DRUG|Monoclonal Antibody with Stem Cell Transplant|Isatuximab-KRd with Autologous Stem Cell Transplant
219369131|NCT03606382|DIAGNOSTIC_TEST|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
219369132|NCT03606382|DIAGNOSTIC_TEST|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
218991504|NCT07054580|BEHAVIORAL|knowledge and awareness|Focus on the level of knowledge and awareness regarding instrument sterilization protocols among healthcare workers in the operation theater.
218991505|NCT07054008|PROCEDURE|Microsurgical approach with Digital Microscope|The incision will be sutured with the use of a digital microscope (30 X) (Group 1). The microsurgical approach is a research only procedure that may add time to the total surgical time (\< 6%).
219369133|NCT03276741|DIETARY_SUPPLEMENT|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
219369134|NCT06329934|BEHAVIORAL|Establishment of a hierarchical monitoring and management team|To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
219369135|NCT06329934|BEHAVIORAL|Assessment of pressure injury|Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
219369136|NCT06329934|BEHAVIORAL|Communication|Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
219747979|NCT05612945|OTHER|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
219747980|NCT05612945|OTHER|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
219747981|NCT03983239|DRUG|Fedratinib|Fedratinib
219747982|NCT03983239|DRUG|Rifampin|Rifampin
219747983|NCT03983239|DRUG|Efavirenz|Efavirenz
219747984|NCT00165607|DRUG|MENATETRANONE|
219747985|NCT03728686|OTHER|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
219747986|NCT01233947|DRUG|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
219747987|NCT01233947|DRUG|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
219747988|NCT02290912|BEHAVIORAL|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
219747989|NCT06268106|BEHAVIORAL|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
219747990|NCT04233892|DRUG|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
219747991|NCT04233892|DRUG|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
219747992|NCT04233892|DRUG|Estrogen|Patients will receive regular estrogen therapy
219747993|NCT00086515|DRUG|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
219747994|NCT00086515|DRUG|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
219747995|NCT00086515|DRUG|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
219747996|NCT00086515|DRUG|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
219006600|NCT06058676|PROCEDURE|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
219747997|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
219747998|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
219747999|NCT02041273|DRUG|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
219748000|NCT00506766|BEHAVIORAL|Bladder Health Class consisting of 6 weekly group sessions|1 time
219748001|NCT00506766|BEHAVIORAL|Practice PFMT and BT|As needed for 4 years
219748002|NCT00506766|BEHAVIORAL|Clinic examination for pelvic muscle function|1/year for 4 years
219748003|NCT00506766|BEHAVIORAL|Record keeping in 3-day voiding diary|Every 6 months for 4 years
219748004|NCT03185026|BEHAVIORAL|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~1. Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~2. Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~3. and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5\) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
219748005|NCT03185026|OTHER|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
219748006|NCT04986150|OTHER|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
218991506|NCT07053098|OTHER|Implementation Facilitation|Implementation facilitation is a multi-faceted process of enabling and supporting the adoption and integration of best practices into routine clinical care. It involves collaboration to understand a setting's challenges and barriers and working together to identify the best activities to address them. IF will incorporate External Facilitation, a problem-solving implementation strategy that builds supportive interpersonal relationships between an External Facilitator who is outside of the clinic who works with clinics and their identified internal champions to learn their unique barriers to implementation, use strategies to address these barriers, and plan for sustainability by integrating the practice into routine processes and workflows. Other implementation activities that will be used IF include staff training, patient education, audit and feedback, and care coordination.
219748007|NCT02009787|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
219748008|NCT02009787|DRUG|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
219748009|NCT00382226|DRUG|Azopt|
219748010|NCT01331655|DRUG|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
219748011|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
219748012|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
219748013|NCT00400140|DEVICE|Hyperopic lens|+3 D glasses
219748014|NCT00049543|DRUG|gefitinib|Given PO
219748015|NCT00049543|OTHER|placebo|Given PO
219748016|NCT00049543|OTHER|laboratory biomarker analysis|Correlative studies
219748017|NCT02714751|BEHAVIORAL|Daily asynchronies information|
219748018|NCT02480049|DRUG|Asmakast|1 tablet contains 10 mg of montelukast
219748019|NCT02480049|DRUG|Singulair|1 tablet contains 10 mg of montelukast
219748020|NCT01489137|DRUG|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
219748021|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
219748022|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
219748023|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
218991507|NCT07054047|OTHER|mrTDV|The training of radiologists to implement specialised MRI reporting using the TDV staging system
219748024|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
219748025|NCT02053155|BEHAVIORAL|Computer based patient education|
219748026|NCT04192708|PROCEDURE|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
219748027|NCT04192708|PROCEDURE|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
219748028|NCT04192708|PROCEDURE|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
219748029|NCT06332157|DRUG|Remimazolam besylate|In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
218991508|NCT07054255|DRUG|Test formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
218991509|NCT07054255|DRUG|Reference formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
218991510|NCT07055308|DEVICE|SEAPatch|Daily measurement with multisensory patch from day 1 post-surgery maximally up to the day of discharge from hospital.
218991511|NCT07053150|DRUG|Sintilimab|Dosage Form: Intravenous (IV) infusion Dosage: 200 mg Frequency: Every 3 weeks (Q3W) Duration: Until disease progression, unacceptable toxicity, or up to 2 years
218991512|NCT07053150|DRUG|Pyrotinib|Dosage Form: Oral tablet Dosage: 400 mg once daily (QD) Frequency: Continuous daily dosing Duration: Until disease progression or intolerable toxicity
219006601|NCT01353326|DEVICE|Cormet|Cementless hip resurfacing system
219006602|NCT01353326|DEVICE|Conserve|Cemented hip resurfacing system
219748030|NCT06332157|DRUG|Propofol Injection Emulsion|In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
219748031|NCT00767780|DEVICE|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
219748032|NCT05325684|DRUG|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
219748033|NCT06083454|DRUG|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
218991513|NCT07053150|DRUG|Optional Chemotherapy|"1. FOLFOX:~   Oxaliplatin 85 mg/m² IV Day 1, leucovorin 400 mg/m² IV Day 1, 5-FU 400 mg/m² IV bolus + 2400 mg/m² continuous infusion over 46h (Days 2-3)~2. GEMOX:~   Gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² IV Day 1~3. GC:~   Gemcitabine 1000 mg/m² and cisplatin 25 mg/m² IV on Days 1 and 8~4. XELOX (CapeOX) Oxaliplatin 130 mg/m² IV Day 1, capecitabine 1000 mg/m² PO BID Days 1-14~5. SOX:~   Oxaliplatin 130 mg/m² IV Day 1, S-1 PO BID Days 1-14 (dose based on BSA: \<1.25 m² = 40 mg, 1.25-\<1.5 m² = 50 mg, ≥1.5 m² = 60 mg)~6. TS:~   Paclitaxel 80 mg/m² IV Days 1 and 8, S-1 as above~7. mFOLFOX6: Same as FOLFOX; used primarily in colorectal cancer~8. FOLFIRINOX:~   Leucovorin 400 mg/m², 5-FU (bolus + continuous), irinotecan 180 mg/m², oxaliplatin 85 mg/m² IV Day 1~9. AG:~Nab-paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² IV on Days 1 and 8"
218991514|NCT07054996|OTHER|body awareness therapy|Basic body awareness training will be applied to preschool children in terms of motor development and body perception
218991515|NCT07054996|OTHER|play-based exercise|Play-based exercise training will be implemented for preschool children by designing games that they enjoy playing, in order to support motor development and body perception.
218991516|NCT07055360|BEHAVIORAL|Resilience-Based Intervention for Stress Reduction and HIV-Related Efficacy (RISE)|RISE is based on Cognitive-Behavior Therapy (CBT) and the Information-Motivation-Behavioral Skills (IMB) Model. RISE will consist of six, weekly sessions, followed by a booster session in week 8, including resilience-building and health-promoting activities of RISE. Sessions will emphasize the participants' strengths, including positive thoughts, beliefs, and behaviors that work for the client and existing assets and supports in the participant's life. Tailored, health-promotion text messages will be sent weekly after each session.
218991517|NCT07055360|BEHAVIORAL|Waitlist control: Text messaging-reminder comparison condition|This control condition will involve reminder text messages for adherence to HIV treatment and engaging in HIV care. As this condition is a waitlist control, participants in this condition will ultimately receive the RISE intervention.
218991518|NCT07054268|OTHER|Nurse-Led ABCDEF Bundle Implementation|This intervention is distinguished by its structured, nurse-led delivery of all six components of the ABCDEF bundle, with nurses serving as primary implementers rather than multidisciplinary teams. Unlike other studies that may focus on select elements of the bundle or physician-led application, this study emphasizes standardized nursing protocols and daily documentation to ensure consistent implementation and evaluation across all components specifically targeting delirium prevention and management in ICU patients.
218991519|NCT07053813|BEHAVIORAL|Web resources|Mailed educational resources through portal and USPS mail
218991520|NCT07053813|BEHAVIORAL|Personalized outreach|Phone call to discuss due and overdue screening and other personalized risk management recommendations
218991521|NCT05166083|OTHER|Testosterone Hormon Therapy|Testosterone isocaproate, ... ml, 8 doses, once per 21 days
218991522|NCT06756451|DRUG|RJK-RT2831 dose-escalation phase Ia|there are seven doses(1mg-160mg) in this part. The subjects will receive RJK-RT2831 injection twice a week by intravenous push or intravenous infusion for 4 weeks until the end of one dosing cycle (28 days). After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
218991523|NCT06756451|DRUG|RJK-RT2831 Dose Expansion Phase Ib|there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
219748034|NCT06083454|DRUG|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
218991525|NCT06843044|DRUG|Ranquilon|1 mg tablets
218991526|NCT06843044|DRUG|Afobazole|10 mg tablets
218991527|NCT06540638|BEHAVIORAL|Web based education program|In a pre-operative assessment, 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The content of our e-module included: introduction to brain health, surgery, and delirium, causes and risk factors, modifiable risk factors, and delirium prevention. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.
218991528|NCT06897527|DRUG|Dostarlimab|Dostarlimab will be administered.
218991529|NCT06541548|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
218991530|NCT06541548|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
218991531|NCT06541548|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
219748035|NCT06083454|PROCEDURE|Surgery (SOC)|Surgery SOC
219748036|NCT03088033|DEVICE|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
219748037|NCT03088033|OTHER|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
219748038|NCT06218602|DRUG|Fecal Microbiota Transplantation|Given by PO
219748039|NCT06218602|PROCEDURE|Chemotherapy|Given by Infusion
219748040|NCT06218602|PROCEDURE|CAR-T Therapy|Given by Infusion
219748041|NCT03485157|BIOLOGICAL|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
219748042|NCT03485157|DRUG|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
219748043|NCT05871060|DIETARY_SUPPLEMENT|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
219748044|NCT05871060|DIETARY_SUPPLEMENT|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
219748045|NCT05871060|DIETARY_SUPPLEMENT|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
219748046|NCT02115529|DRUG|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
219748047|NCT02115529|DRUG|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
219748048|NCT00422487|DRUG|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
219748049|NCT00422487|DRUG|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
219748050|NCT00422487|DRUG|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
219748051|NCT00422487|DRUG|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
219748052|NCT00422487|DRUG|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
219748053|NCT00422487|DRUG|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
219748054|NCT00422487|DRUG|Placebo for MBX-2044|Placebo Intervention
219748055|NCT00265122|DRUG|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
219748056|NCT00265122|DRUG|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
219748057|NCT00265122|DRUG|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
219748058|NCT00265122|DRUG|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
219748059|NCT01429688|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
219748060|NCT01146145|DRUG|Ketamine|intravenous morphine titration combined to ketamine
219748061|NCT04744584|OTHER|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
219748062|NCT04744584|OTHER|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
219748063|NCT00770393|PROCEDURE|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
219748064|NCT00770393|PROCEDURE|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~\- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
219748065|NCT03198403|DRUG|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
219748066|NCT04349683|DRUG|Jinshuibao|6 capsules at a time, 3 times a day (tid).
218991532|NCT05347238|DRUG|Dopamine|Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
219748067|NCT04349683|DRUG|Placebo|6 capsules at a time, 3 times a day (tid).
219748068|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
219748069|NCT05205616|DEVICE|Reciprocating saw|See above description
219748070|NCT03757494|DEVICE|Alpha Stim|Use of Alpha Stim Device
219748071|NCT04492384|OTHER|non-interventional|Interview on health conditions
219748072|NCT02033941|DRUG|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
219748073|NCT02033941|DRUG|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
219748074|NCT01324973|BEHAVIORAL|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
219748075|NCT04813120|BEHAVIORAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
219748076|NCT04813120|BEHAVIORAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
219748077|NCT04813120|BEHAVIORAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
219748078|NCT04813120|BEHAVIORAL|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
219748079|NCT02333474|BIOLOGICAL|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
219748080|NCT02333474|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
219748081|NCT01003327|DEVICE|I-gel|intubation with I-gel airway
219748082|NCT01003327|DEVICE|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
219748083|NCT04014192|DRUG|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
219748084|NCT04014192|DRUG|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
219748085|NCT04014192|DRUG|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
219748086|NCT04855890|PROCEDURE|Ablation|The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
219748087|NCT03648892|DRUG|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
219748088|NCT03648892|DRUG|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
219748089|NCT03391791|GENETIC|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219748090|NCT01955863|PROCEDURE|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
219748091|NCT01955863|PROCEDURE|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
219369137|NCT06329934|BEHAVIORAL|Intervention for pressure ulcer|For patients with a Braden score of \>14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
219748092|NCT01955863|PROCEDURE|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
219748093|NCT03338920|DRUG|sumatriptan nasal powder|nasal powder administered via nosepiece
218991533|NCT05347238|DRUG|Norepinephrine|Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
218991534|NCT04914923|DEVICE|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
218991535|NCT04914923|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
219179016|NCT03153410|DRUG|Cyclophosphamide|"200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
219748094|NCT03338920|DRUG|Placebo|lactose monohydrate powder administered via nosepiece
219748095|NCT05368935|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
218991536|NCT04914923|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
218991537|NCT06618027|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D was adapted from Learning to BREATHE, a group mindfulness-based intervention for teens. It teaches mindfulness strategies adapted to be specific and relatable to, teens with T1D to improves symptoms of depression and anxiety as well as diabetes self-management.
218991538|NCT06618027|BEHAVIORAL|HealthEd-T1D|HealthEd-T1D is a 6 week, virtual, group based diabetes education group.
218991539|NCT05613361|DRUG|Colistin|added for infection with multi drug resistant bacteria
218991540|NCT05613361|DRUG|Curcumin|added for the possible nephroprotective effect
218991541|NCT05092022|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cells for screening purposes.
218991542|NCT06912776|OTHER|Participant will view a visual aid picture (appendix A) first|Participant will view a visual aid picture (appendix A) of a post delivery complication first
218991543|NCT06912776|OTHER|Participant will view a visual aid picture (appendix B) first|Participant will view a visual aid picture (appendix B) of a post delivery complication first
219748096|NCT04573738|PROCEDURE|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
219748097|NCT04573738|PROCEDURE|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
219748098|NCT00802906|DEVICE|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
219748099|NCT00802906|DRUG|bevacizumab|1.5 mg initial intravitreal injection
218991544|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
218991545|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218991546|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
218991547|NCT06917677|BEHAVIORAL|2000-meter maximal effort test on rowing ergometer|Participants will perform a 2000-meter maximal effort test on a Concept II rowing ergometer, aiming to complete the distance in the shortest possible time. The test simulates a competitive race and serves as a qualification trial. It will be conducted under medical supervision and is intended to induce a high level of physiological and psychological stress representative of elite competition.
218991548|NCT06929871|DEVICE|Mako cementless TKA|Mako robotic-arm assisted total knee arthroplasty using cementless implants
218991549|NCT06929871|DEVICE|Mako cemented TKA|Mako robotic-arm assisted total knee arthroplasty using cemented implants
218991550|NCT05605704|DRUG|Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
218991551|NCT05605704|DRUG|Placebo Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.
218991552|NCT06941077|DRUG|INCB057643|Tablet
218991553|NCT06942377|DRUG|Amlodipine|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine
218991554|NCT06950060|BEHAVIORAL|Moderate-to-high intensity cycling|Participants cycle on a stationary ergometer at an intensity prescribed to reach their lactate threshold, guided by VO2 max results and lactate sampling. The session lasts approximately 20 minutes and is preceded and followed by TMS assessments and a structured motor learning task. This condition is designed to evaluate the effect of exercise-induced metabolic stress on cortical inhibition and motor learning.
218991555|NCT06950060|BEHAVIORAL|Low-intensity cycling|Participants perform 20 minutes of cycling at a light workload below their lactate threshold. Exercise intensity is individualized using heart rate and perceived exertion (Borg RPE scale), avoiding significant metabolic activation. TMS and motor learning are assessed pre- and post-exercise. This condition serves as an active comparator to assess the impact of exercise intensity.
219369138|NCT06329934|BEHAVIORAL|Rehabilitation training|After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
218991556|NCT06950060|BEHAVIORAL|Health education session|Participants receive a 20-minute session of health education content (e.g., wellness, healthy aging). No exercise is performed. Participants undergo TMS and motor learning testing before and after the session. This condition is used to control for attention and cognitive engagement without physical activity.
219369139|NCT06329934|BEHAVIORAL|introduction of the current patient's condition to family members|timely introduction of the current patient's condition to family members to alleviate their concerns
219748100|NCT02011529|OTHER|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
219748101|NCT04798820|OTHER|Dietary education(nutritional counselling)|Dietary education provided to gastrectomy patients by dietitian.
219748102|NCT02816112|DRUG|Ciprofloxacin|Antibiotic
219748103|NCT02816112|DRUG|Neupogen|Granulocyte-colony stimulating factor
219748104|NCT03843073|DEVICE|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
219748105|NCT03889535|DEVICE|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
219748106|NCT03889535|DEVICE|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
219748107|NCT06537687|OTHER|Control|A standardized handout on HPV and vaccine education will be given
219748108|NCT06537687|OTHER|Intervention|A video about HPV and vaccines on a tablet provided by a research assistant
219748109|NCT03085953|BEHAVIORAL|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
219748110|NCT03085953|OTHER|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
219748111|NCT05823441|DRUG|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
219748112|NCT05823441|DRUG|Placebo|Volunteers inhale 24 units of placebo spray
219748113|NCT05823441|BEHAVIORAL|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
219748114|NCT05823441|BEHAVIORAL|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
219748115|NCT01399645|DRUG|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
219748116|NCT01799135|OTHER|DCE-MRI scan|
219748117|NCT01799135|RADIATION|Stereotactic Body Radiation Therapy|
219748118|NCT01799135|OTHER|4D-CT scan|
219748119|NCT02766855|DRUG|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
219006603|NCT03149198|OTHER|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
219369140|NCT06329934|BEHAVIORAL|maintaining appropriate temperature and humidity in the ward|maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
219369141|NCT06329934|BEHAVIORAL|careful observation of vital signs in patients|careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients
219369142|NCT00851903|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
219369143|NCT00851903|DRUG|Sitagliptin|Oral administration. 100mg film-coated tablets.
219369144|NCT00851903|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
219369145|NCT03642184|DRUG|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
219369146|NCT03642184|DRUG|Linagliptin|Dosage adjustment based on glucose targets. Once daily
219369147|NCT03960528|PROCEDURE|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
219369148|NCT03960528|PROCEDURE|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
219369149|NCT04271462|OTHER|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
219369150|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
219369151|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
219369152|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
219369153|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
219369154|NCT06553833|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
219369155|NCT06553833|OTHER|Patient Blood Management|PBM is a strategy to manage the participants own blood. Its focus is on anemia, bleeding and coagulation management (using predominantly pharmaceutical and technological means).
219369156|NCT05304962|DRUG|RGT-419B|oral capsules
219369157|NCT05304962|DRUG|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
219369158|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
219369159|NCT05632237|BEHAVIORAL|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
219369160|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
219369161|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
219006604|NCT03149198|OTHER|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
219369162|NCT00006981|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
219369163|NCT02208960|DEVICE|Neonatal Kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
219369164|NCT02208960|BEHAVIORAL|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch"
219748120|NCT01890031|OTHER|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
218991557|NCT06954636|DIAGNOSTIC_TEST|olfactory testing (threshold and identification test)|"In the identification test, 12 sniffin sticks are presented, which the patient has to name using a selection card with four terms each. Both nostrils are tested individually at each visit during the identification test. A correct answer scores one point. A maximum of 12 points is possible.~The threshold test consists of 16 dilution levels. Each level contains one sniffin stick with odor and two blanks. All three sniffin sticks of a dilution level are presented to the patient one after the other with eyes closed. The patient must indicate which of the three sticks contains an odor. Depending on whether the patient gives the correct answer, the three sniffin sticks in the next higher or next lower level are presented next. A maximum of 16 points is possible."
219429083|NCT01213264|DRUG|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
219748121|NCT01890031|OTHER|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
218991560|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
218991561|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
218991562|NCT06290336|OTHER|Pre-operative exercise therapy and education|Pre-operative supervised exercise therapy consisting of individualized strength, mobility and balance exercises and continuous education through individual discussions of expectations of post-operative recovery, pain and swelling, course of rehabilitation, long term function and activity level etc. Twice a week, approximately one hour/session.
218991563|NCT06290336|OTHER|Standardized pre-operative information session|As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.
218991564|NCT06106035|BEHAVIORAL|low-fat vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
218991565|NCT00688753|DRUG|RAD001|
218991566|NCT05467280|OTHER|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
218991567|NCT03744611|DIETARY_SUPPLEMENT|CE|550mg capsule (Eucommia ulmoides Oliver extract)
218991568|NCT03744611|DIETARY_SUPPLEMENT|Placebo|550mg capsule (Placebo)
218991569|NCT02256904|PROCEDURE|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
219748122|NCT05851547|RADIATION|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
218991570|NCT02256904|PROCEDURE|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
218991571|NCT03968484|BIOLOGICAL|platelet transfusion|Transfusion of platelets
218991572|NCT05619081|BEHAVIORAL|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
218991573|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
218991574|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
218991575|NCT06257082|OTHER|Online Survey|Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
218991576|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
219748123|NCT05851547|DRUG|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
219748124|NCT01940419|DRUG|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
219748125|NCT01940419|DRUG|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
219748126|NCT05021848|OTHER|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
219748127|NCT00003670|DRUG|arzoxifene hydrochloride|
218991577|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
219748128|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
219748129|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
219748130|NCT02233569|DEVICE|Ventralight ST implant|
219748131|NCT02233569|DEVICE|ETHICON PHYSIOMESH®|
219748132|NCT04942847|DEVICE|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
219748133|NCT04942847|DEVICE|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
219748134|NCT04785638|COMBINATION_PRODUCT|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
219748135|NCT02979990|OTHER|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
218991578|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
219748136|NCT02979990|OTHER|Control Video|The control group will have access to a video about the IVF process
219748137|NCT04586257|PROCEDURE|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
219748138|NCT04586257|PROCEDURE|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
219748139|NCT05810480|DIAGNOSTIC_TEST|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
219748140|NCT04996745|BEHAVIORAL|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
219748141|NCT03620981|DRUG|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
219748142|NCT03620981|DRUG|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
219748143|NCT06264570|DIETARY_SUPPLEMENT|B-TMG supplementation|B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
218991579|NCT06137664|BIOLOGICAL|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
218991580|NCT04147130|OTHER|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
218991581|NCT04147130|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
218991582|NCT02945683|DIETARY_SUPPLEMENT|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
218991583|NCT02945683|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
218991584|NCT04674930|OTHER|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
218991585|NCT01535547|DRUG|isavuconazole|oral
218991586|NCT01535547|DRUG|tacrolimus|oral
218991587|NCT01119612|DIETARY_SUPPLEMENT|Iron|Daily oral dose of 60 mg from enrollment until delivery
219748144|NCT06264570|DIETARY_SUPPLEMENT|B-SAM supplementation|B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
219748145|NCT06264570|OTHER|B-TMG placebo|B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
219748146|NCT06264570|OTHER|B-SAM placebo|B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
219748147|NCT05642858|BEHAVIORAL|Digital Educational Messaging|Education via mobile phone text messages for up to 6 months.
219748148|NCT06005324|DRUG|Paclitaxel|Given as part of induction chemotherapy.
219748149|NCT06005324|DRUG|Carboplatin|Given as part of induction chemotherapy.
219748150|NCT06005324|DRUG|Cetuximab|Given as part of induction chemotherapy.
219748151|NCT06005324|RADIATION|Standard Dose Radiation|Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
219748152|NCT06005324|RADIATION|Low Dose Radiation|Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
219748153|NCT06005324|DRUG|Cisplatin|Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
219748154|NCT06005324|DRUG|TFHX Regimen|Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
219748155|NCT03775837|DIETARY_SUPPLEMENT|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
219748156|NCT03775837|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
219748157|NCT02607722|DRUG|Nintedanib|
219748158|NCT03238196|DRUG|Erdafitinib|4mg - 8mg
219748159|NCT03238196|DRUG|Palbociclib|125 mg
219748160|NCT03238196|DRUG|Fulvestrant|500 mg
219748161|NCT05442879|BEHAVIORAL|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
219748162|NCT05442879|BEHAVIORAL|Educational handout|Educational handout describing a commonly cited ACL-IPP.
219748163|NCT01969578|DRUG|bicalutamide + triptorelin|
219748164|NCT01969578|DRUG|Cisplatin + Doxorubicin|
218991588|NCT01119612|OTHER|Placebo|Daily oral dose from enrollment until delivery
219748165|NCT01969578|DRUG|Carboplatin + Paclitaxel|
219748166|NCT03551119|BEHAVIORAL|Exercise|See previous description
219748167|NCT03551119|OTHER|Enhanced usual care|See previous description
219748168|NCT06638970|DRUG|Secretome|3 ml Injection of secretome for 4 times two weeks apart
219748169|NCT06636760|OTHER|Placebo|The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
219748170|NCT06636760|DIETARY_SUPPLEMENT|herbal compound|The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
219748171|NCT06644950|OTHER|Efficacy and safety of administering 1 or two cartridges of anesthesia|"The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block."
218991589|NCT03812094|DEVICE|Enurad 400|Alarm treatment
218991590|NCT03812094|BEHAVIORAL|Basic Bladder advice|Pre-specified Basic bladder advice
218991591|NCT02881437|DRUG|IgHy10|Sub Cutaneous IgHy10 administration
218991592|NCT03187197|DRUG|Pradaxa®|Dabigatran etexilate
218991593|NCT03478020|DRUG|AQX-1125|Investigational Drug
218991594|NCT03478020|DRUG|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
218991595|NCT05412745|DEVICE|Kaloidon Plus|topical application; twice daily
218991596|NCT05412745|DEVICE|silicone gel|topical application; twice daily
218991597|NCT02860013|DEVICE|Telemedicine|
218991598|NCT04588948|DRUG|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
219748172|NCT06643650|DIETARY_SUPPLEMENT|CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML|Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
219748173|NCT04938427|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
219748174|NCT04938427|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
219748175|NCT00745667|PROCEDURE|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
219748176|NCT00745667|PROCEDURE|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
219748177|NCT05407766|BIOLOGICAL|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
219748178|NCT05407766|OTHER|Placebo|Single injection of placebo (saline)
219748179|NCT05620134|DRUG|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
219748180|NCT05620134|DRUG|Pembrolizumab|Immune checkpoint inhibitor
219748181|NCT05620134|DRUG|Lenvatinib Pill|Multi-kinase inhibitor
219748182|NCT06114368|PROCEDURE|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
219748183|NCT00417287|DRUG|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
219748184|NCT02513251|OTHER|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
219748185|NCT05881291|DRUG|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
219748186|NCT05881291|DRUG|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
219748187|NCT06387953|DEVICE|Bridge Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
219748188|NCT06387953|DEVICE|Sham Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
219748189|NCT06569485|DRUG|Trilaciclib+R-CHOP|This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
219748190|NCT06471673|BIOLOGICAL|BC1 cell line|BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
219748191|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab)|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
219748192|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab) expansion cohort|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
219748193|NCT02245659|DEVICE|CPAP|Continuous Positive Airway Pressure
219748194|NCT02245659|OTHER|Nasal dilator strip|Nasal dilator strip to be worn nightly
219748195|NCT06674343|DRUG|Furmonertinib|Furmonertinib 160mg, once daily, orally. Other Names: AST2818
219748196|NCT03006315|DEVICE|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
219748197|NCT03006315|BEHAVIORAL|Mobile Health quality of life assessements|
219748198|NCT04767048|PROCEDURE|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
219748199|NCT04767048|PROCEDURE|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
219748200|NCT06675214|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
219748201|NCT06675214|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
219748202|NCT06675214|RADIATION|Standard-dose IMRT|GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy
219748203|NCT06675214|RADIATION|Gradient Fractionated IMRT|GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy
219748204|NCT06675214|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
219748205|NCT07011134|DRUG|Group (E): receive aminophylline early intraoperatively,|Group E (n=20): patients received aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1)
219748206|NCT07011134|DRUG|Group (L) received aminophylline late intraoperatively|Group L (n=20): patients received aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).
219748207|NCT07011134|DRUG|Group (C) will receive normal saline post-anesthetic discontinuation.|Group (C) (n=20): patients received normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).
219748208|NCT07010055|PROCEDURE|Semi-structured interview|A semi-structured interview will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
219748209|NCT07009691|DIETARY_SUPPLEMENT|Hydrogen water which is prepared from an OTC supplement.|The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.
219748210|NCT07009912|DEVICE|Total Knee Arthroplasty|Robotic-assisted primary total knee arthroplasty, evaluating updated features for the Zimmer Biomet ROSA® Knee System, v1.5.
219748211|NCT07010731|OTHER|Social support|After adopting the questioner from Oslo-3 -item social support scale, it was translated in to local language (Amharic) and then back to English by another language expert. The data was collected through face-to-face interviews with three BSc nurses. It was supervised by one MSc nurse
219748212|NCT07011290|OTHER|Self-paced Walking (W) training sessions|Participants will partake in 2 sessions of self-paced walking (W), each composed by 3x14 min periods interspersed by 2 min breaks, in which the participants will walk at a self-selected speed (without running) along a 38x18 m course.
219748213|NCT07011290|OTHER|Brisk walking (BW) training sessions|Participants will partake in 2 sessions of brisk walking (BW), each composed by 3x14 min periods, interspersed by 2 min breaks, in which the participants will follow a designated instructor who will dictate the walking speed along a 38x18 m course, thus ensuring that the speed of the walking corresponds to a brisk walking speed.
219748214|NCT07011290|OTHER|Recreational running team handball (RTH) training sessions|"Recreational running team handball (RTH):~Participants will partake in 2 sessions of recreational team handball matches (RTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
219748215|NCT07011290|OTHER|Recreational walking team handball (WTH) training sessions|"Recreational walking team handball (WTH):~Participants will partake in 2 sessions of recreational walking team handball matches (WTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
219748216|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
219748217|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
219748218|NCT06682000|DRUG|DWC202404, DWC202314|\- 2 tablet, Oral, Once a day
219748219|NCT06682000|DRUG|DWC202404, DWC202314P|\- 2 tablet, Oral, Once a day
219748220|NCT06683248|OTHER|Investigate sleep deprivation|"Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor"
219748221|NCT06682598|OTHER|Multicomponent physical exercise training|The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
219748222|NCT06689527|DRUG|Vamorolone|Days 3 to 14: 6 mg/kg vamorolone once daily.
219748223|NCT06689527|DRUG|Midazolam|Day 1 and 14: Single doses of 2.5 mg midazolam
219748224|NCT06692764|DRUG|Placebo|"0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets.~Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose."
219748225|NCT06692764|DRUG|AZD0780|"Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose."
219748226|NCT03968042|DRUG|Nerve Growth Factor|Intramuscular injection for 2 weeks
219748227|NCT03968042|DRUG|Edaravone|Intravenous injection for 2 weeks
219748228|NCT03968042|DRUG|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
219748229|NCT06695689|DRUG|LM303|Treatment with LM303 injection
218991599|NCT05650216|DRUG|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
218991600|NCT04565106|DEVICE|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
218991601|NCT01748084|DRUG|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
219748230|NCT06695208|DRUG|Biodentine|biodentine used in socket preservation
219748231|NCT06695975|BEHAVIORAL|Occupational self-analysis|"Occupational self analysis program is delivered in group sessions, each session lasting 45 minutes, twice a week. Also Individual sessions are held throughout the program with each participant, with the intention of clarifying certain concepts and resolving specific difficulties that were occurring.The thematic modules worked are 5; occupation-health and difficulty, occupational balance, adaptation strategies to difficulties, social relationships and knowing other realities.~The methodological strategies used to structure the program were the Model of Human Occupation (MOHO) and the See-Judge-Act methodology"
219748232|NCT06631534|DRUG|Dexmedetomidine|Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
218991602|NCT01748084|DRUG|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
218991603|NCT03773991|DIAGNOSTIC_TEST|Lung MRI|Proton Lung Magnetic Resonance Imaging
219748233|NCT06631534|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline (placebo)
219748234|NCT06688253|DRUG|IV efgartigimod|IV efgartigimod
219748235|NCT06687850|BEHAVIORAL|animal assisted therapy|The canine was included in therapy sessions to determine the effect of the canine on prosocial behavior and emotional regulation in autistic children with varying verbality.
219748236|NCT06690450|DRUG|Venofer® 200 mg|A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
218991604|NCT03773991|DIAGNOSTIC_TEST|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
219748237|NCT06690450|DRUG|Venofer® 100 mg|A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
219748238|NCT06132789|BIOLOGICAL|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
219748239|NCT03436667|DIAGNOSTIC_TEST|Spirometry|Lung volumes will be measured using spirometry.
219748240|NCT03436667|DIAGNOSTIC_TEST|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
219748241|NCT01263210|BIOLOGICAL|Prevenar|
219748242|NCT04361500|DEVICE|Seraph 100|Seraph 100 therapy during a COVID-19 infection
219748243|NCT02953431|DEVICE|CPAP|CPAP will be administered with a CPAP machine
219748244|NCT00936936|DRUG|Gemcitabine|1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
219748245|NCT00936936|DRUG|Docetaxel|Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
219748246|NCT00936936|DRUG|Melphalan|50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
218991605|NCT03773991|DIAGNOSTIC_TEST|Chest CT|High-resolution Quantitative Chest CT
218991606|NCT03773991|DIAGNOSTIC_TEST|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
219748247|NCT00936936|DRUG|Carboplatin|"Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3."
218991607|NCT03773991|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
218991608|NCT03773991|DIAGNOSTIC_TEST|Pulmonary Function Tests|Spirometry and Plethysmography
218991609|NCT03773991|DIAGNOSTIC_TEST|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
218991610|NCT03773991|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test
219748248|NCT00936936|DRUG|Mesna|3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
218991611|NCT03773991|DIAGNOSTIC_TEST|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
219748249|NCT00936936|DRUG|Ifosfamide|3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
218991612|NCT02975518|BIOLOGICAL|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
219748250|NCT00936936|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
219748251|NCT00936936|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
218991613|NCT00259649|DRUG|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
218991614|NCT03118115|DEVICE|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
219748252|NCT03670472|OTHER|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
219748253|NCT00931541|DRUG|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
219748254|NCT00931541|DRUG|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
219748255|NCT01714674|DIETARY_SUPPLEMENT|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
219748256|NCT01714674|DIETARY_SUPPLEMENT|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
219748257|NCT06140225|BEHAVIORAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
219748258|NCT06140225|BEHAVIORAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
219748259|NCT06140225|BEHAVIORAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
219748260|NCT06140225|BEHAVIORAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
218991615|NCT00000445|DRUG|naltrexone (Revia)|
219748261|NCT06140225|BEHAVIORAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
219748262|NCT06140225|BEHAVIORAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
219748263|NCT06140225|BEHAVIORAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
219748264|NCT00913822|DRUG|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
219748265|NCT00913822|DRUG|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
219748266|NCT03733548|BEHAVIORAL|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
219748267|NCT01373281|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
219748268|NCT01373281|BIOLOGICAL|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
219179017|NCT03153410|DRUG|GVAX Pancreas Vaccine (GVAX)|"5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
219748269|NCT02101463|DEVICE|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
219748270|NCT04432779|OTHER|no intervention|no intervention
219748271|NCT06571864|DRUG|Anti-CD38 Monoclonal Antibody|Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
219748272|NCT06571539|DEVICE|AR-assisted EVD placement|Cfr. arm description
219748273|NCT06571539|PROCEDURE|Freehand EVD placement|External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
219748274|NCT01300637|DRUG|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
219748275|NCT01300637|DRUG|placebo|identical-appearing pill of placebo
219748276|NCT04197232|OTHER|clinical evaluation|\- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
219748277|NCT04277130|BEHAVIORAL|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
219748278|NCT02167776|BEHAVIORAL|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
219748279|NCT04253600|BEHAVIORAL|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
219748280|NCT04253600|PROCEDURE|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
219748281|NCT04253600|BEHAVIORAL|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
219748282|NCT04253600|BEHAVIORAL|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
219748283|NCT04253600|BEHAVIORAL|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
218991616|NCT05713175|DEVICE|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
218991617|NCT05713175|DEVICE|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
218991618|NCT05713175|DEVICE|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
219179018|NCT03153410|DRUG|Pembrolizumab|"200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
218991619|NCT03435484|OTHER|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
218991620|NCT03435484|OTHER|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
218991621|NCT04487392|DRUG|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
219179019|NCT03153410|DRUG|IMC-CS4|"75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
219179020|NCT04976660|DRUG|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
219179021|NCT04817735|PROCEDURE|TAVI|TAVI sizing with dedicated algorithm
219179022|NCT03408340|PROCEDURE|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
219179023|NCT03408340|DRUG|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
219179024|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
219179025|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
219179026|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
219179027|NCT04728932|DRUG|Levosimendan|A continuous infusion of Levosimendan over 24h
219179028|NCT04728932|DRUG|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
219577628|NCT05676086|BEHAVIORAL|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
219577629|NCT02745886|DRUG|metformin 0.85 twice daily for 6 months|
219369165|NCT04665557|BEHAVIORAL|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
219369166|NCT04396977|PROCEDURE|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
219369167|NCT04396977|PROCEDURE|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
219369168|NCT00522392|DRUG|bortezomib|Given IV
219369169|NCT00522392|DRUG|lenalidomide|Given PO
219369170|NCT00522392|DRUG|dexamethasone|Given PO
219369171|NCT06337201|DEVICE|Test of the application Min Memoria|Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
219369172|NCT02479789|DRUG|Lidocaine|
219369173|NCT02479789|DRUG|Placebo|
219369174|NCT04755829|DEVICE|BreathX test for breath VOCs|Breath samples are collected into an ultra-clean bag and breath VOCs are analyzed with GC-SAW.
219369175|NCT01910792|DEVICE|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
219369176|NCT00006449|DRUG|naltrexone (Revia)|
219369177|NCT00006449|BEHAVIORAL|broad spectrum treatment|
219369178|NCT00006449|BEHAVIORAL|motivational enhancement therapy|
219369179|NCT00140803|DRUG|Visudyne|
219369180|NCT00140803|DRUG|Kenalog|
219369181|NCT04891237|BIOLOGICAL|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
219369182|NCT04891237|BIOLOGICAL|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
219369183|NCT04891237|OTHER|Placebo|The same solution and presentation as the active treatment, but without active ingredients
219369184|NCT02154594|DRUG|Acacia catechu|
219369185|NCT02154594|DRUG|Chlorhexidine gluconate|
219369186|NCT02154594|OTHER|Distilled water|
219369187|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
219369188|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
219369189|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
219369190|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
219369191|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
219369192|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
219369193|NCT06959940|OTHER|experimental group (gum group)|"After the pregnant woman in the experimental group was admitted to the delivery room, the data collection tools Personal Information Form and Pregnant Follow-up Form were applied. Pregnant women who agreed to participate in the study were given information about chewing gum. Pain, anxiety, fatigue and thirst scales were administered to the pregnant woman before she started chewing gum. The pregnant woman was allowed to chew gum for 15 minutes. At the end of 15 minutes, the measurements were repeated. Applications were repeated as stated above every two hours until the pregnant woman's dilation reached 5 cm. Routine medical treatment of pregnant women continued."
219369194|NCT06961019|OTHER|Sugar support effervescent Tablets|"Dissolve one effervescent tablet in a full glass of water (approximately 200 mL). Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation.~Frequency: Twice a day before the meal Route of Administration: Oral"
219369195|NCT06960369|COMBINATION_PRODUCT|rTMS combined with Live Probiotic tablet|rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week.
219369196|NCT06960369|DEVICE|rTMS combined placebo|rTMS group received 1 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
219369197|NCT06960369|DRUG|shamrTMS combined with Live Probiotic tablet|Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week.
219369198|NCT06960369|OTHER|shamrTMS combined placebo group|shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
219369199|NCT06960850|DRUG|Propranolol|A set of 154 numbers will receive oxytocin and propranolol once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
219369200|NCT06960850|OTHER|Placebo|A set of 154 numbers will receive oxytocin and placebo once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
219577630|NCT02745886|BEHAVIORAL|Calorie restriction|
219577631|NCT01727986|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
219748284|NCT02722785|BEHAVIORAL|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
219748285|NCT03934294|OTHER|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
219748286|NCT03934294|DRUG|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
219369201|NCT06960408|OTHER|sleep hygiene education and progressive relaxation exercise|The study will be conducted with diabetic individuals who come to the endocrine clinic. The study will be conducted for 6 months. Intervention group Individuals who accept the study will be given face-to-face Progressive Relaxation Exercise training by the researcher in the first week of the first month of the study and will be applied. The Progressive Relaxation Exercise application will also be sent to the patient via WhatsApp and will be applied with the researcher via online interviews in the 2nd, 3rd and 4th weeks for 30 minutes 3 days a week (Monday-Wednesday-Friday). From the 2nd month of the study to the end of the 6th month, the patient will be asked to do the Progressive Relaxation Exercise on their own for 30 minutes 3 days a week (Monday, Wednesday, Friday). No intervention will be made to the control group.
219369202|NCT06959732|DRUG|zanubrutinib, obinutuzumab,combined with CVP|Zanubrutinib (160 mg, twice daily \[bid\]), obinutuzumab (1000 mg on cycle 1 \[C1\], days 1, 8, and 15; on cycle 2 - 6 \[C 2-6\], day 1), cyclophosphamide (750 mg/㎡ on day 1), vincristine (1.4 mg/㎡, maximum dose 2 mg on day 1), and prednisone tablets (40 mg/㎡ once daily \[qd\] orally on days 1-5) were used every 21 days as a treatment cycle. Six cycles of treatment were completed, and the efficacy was reviewed every two cycles. Patients with PD were excluded from the group. MRD was detected after six cycles. If MRD was negative, routine maintenance therapy was performed (obinutuzumab 1000 mg once every 8 weeks, a total of 12 times). If MRD was positive, Zanubrutinib (160 mg, continuous bid) was added to the conventional maintenance therapy for 12 months.
219369203|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219369204|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219369205|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219369206|NCT06960499|OTHER|Surveys|No intervention will be carried out in this study; the recruited patients will only complete the questionnaires provided below
219369207|NCT06960109|BEHAVIORAL|A Mindfulness-Based Stress Reduction Program for Pregnant Women with Gestational Diabetes|The Gestational diabetes mellitus(GDM) pregnant women in the intervention group who agreed to participate in the study and completed the pre-test were invited to the WhatsApp group created by the researcher. 3 separate groups were created with a maximum of 11 participants in each group. The days (for example; Group 1: Tuesday, Saturday) on which the program, which will continue for 4 weeks, will be implemented were determined, considering the participants in each group and the times they were available. For each group, the conscious awareness-based stress reduction program for pregnant women with GDM; For 4 weeks, there were 8 sessions, 2 sessions per week, with each session varying in duration, for an average of 45-60 minutes. The program was carried out using the Google Meet application created online by the researcher, and the connection details were shared with the participants via WhatsApp groups. In the implementation of the mindfulness-based stress reduction program for pregnant
219369208|NCT06961188|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension + Standard Therapy Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 12 weeks (maximum treatment duration: 12 weeks), whichever occurred first.
219369209|NCT06961188|OTHER|Standard Therapy|Standard Therapy
219748287|NCT03934294|OTHER|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
219748288|NCT06420700|PROCEDURE|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
219748289|NCT06378840|RADIATION|Nab-paclitaxel/Platinum, Sintilimab|Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy
219748290|NCT05701826|DRUG|HRS3797|HRS3797 for injection, low dose
219369210|NCT06961383|BIOLOGICAL|NG01 - Autologous bone marrow derived human stromal cells|NG01 is a cellular therapy product of autologous stromal cells derived from the bone marrow of multiple sclerosis (MS) patients. NG01 is provided as a cell suspension for intrathecal injection.
219748291|NCT05701826|DRUG|HRS3797|HRS3797 for injection, medium dose
219748292|NCT05701826|DRUG|HRS3797|HRS3797 for injection, high dose
219748293|NCT03842397|DEVICE|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
219748294|NCT01302886|DRUG|BHQ880|
219748295|NCT04370886|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
219748296|NCT01312298|PROCEDURE|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
219748297|NCT01312298|PROCEDURE|Regional anesthesia|Patients will receive intrathecal anesthesia
219748298|NCT06344247|DRUG|RAS inhibitors：Losartan®️/Valsartan®️|Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
218991622|NCT04487392|RADIATION|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
218991623|NCT01301352|OTHER|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
218991624|NCT01565512|DRUG|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
218991625|NCT01565512|DRUG|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
218991626|NCT01055171|DRUG|Propranolol|40 mg; Single Administration.
219369211|NCT06961383|OTHER|Sodium Chloride 0.9%|The placebo for use in the NG01 clinical trial is 0.9% Sodium Chloride Solution for Injection
219748299|NCT06344247|DRUG|dapagliflozin：Forxiga®️|Forxiga®️ : titrated to the target dose (10 mg qd).
219369212|NCT06961396|DEVICE|Relaxation Technique|utilizing virtual reality and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
219369213|NCT06961396|DEVICE|Pain treatment|utilizing cold laser and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
219369214|NCT06960824|DRUG|Life-Cycle Pharma Tacrolimus|Patients receiving LCPT Envarsus® \[Life-Cycle Pharma Tacrolimus\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics (SmPC).
219748300|NCT06344247|DRUG|simagliptin：Forxiga®️|Semaglutide®️ : titrated to the target dose (1 mg qw).
219748301|NCT00851084|DRUG|aflibercept|administration: IV infusion
219748302|NCT00851084|DRUG|oxaliplatin|administration: IV infusion
219748303|NCT00851084|DRUG|5-FU|administration: IV infusion
219748304|NCT00851084|DRUG|Folinic Acid|administration: IV infusion
219369215|NCT06960824|PROCEDURE|Kidney transplantation|Kidney transplant patients using the iBox prognostic system (risk prediction system for kidney transplants)
219369216|NCT06961201|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication.
219369217|NCT06961201|DRUG|standard treatment|standard treatment
219577632|NCT03399318|DRUG|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
219577633|NCT03399318|DRUG|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
219577634|NCT03399318|DRUG|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
219577635|NCT03399318|DRUG|placebo for ibuprofen|placebo for ibuprofen
219577636|NCT00531349|PROCEDURE|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
219577637|NCT00531349|DRUG|Sevoflurane|General anesthesia
219748305|NCT05310357|DIAGNOSTIC_TEST|Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.
219748306|NCT02997007|DEVICE|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
219748307|NCT02997007|DEVICE|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
219748308|NCT03236883|DRUG|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
219748309|NCT03236883|OTHER|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
219748310|NCT05516173|DIAGNOSTIC_TEST|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
219748311|NCT03650023|DIETARY_SUPPLEMENT|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
219748312|NCT03650023|DIETARY_SUPPLEMENT|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
219748313|NCT04973319|DRUG|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
219748314|NCT04973319|DRUG|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
219748315|NCT00734032|DRUG|SB480848 40mg EC Tablet|1 tablet once a day
219748316|NCT00734032|DRUG|SB480848 80mg EC Tablet|1 tablet once a day
219748317|NCT00734032|DRUG|SB480848 160mg EC Tablet|1 tablet once a day
219748318|NCT00734032|DRUG|SB480848 Placebo Tablet|1 tablet once a day
219748319|NCT05903235|BEHAVIORAL|Virtual Reality-based Mirror Therapy (VR+MT)|In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
219748320|NCT05903235|BEHAVIORAL|Mixed Reality-based Mirror Therapy (MR+MT)|In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
219748321|NCT05903235|BEHAVIORAL|Traditional Mirror Therapy (MT)|In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
219748322|NCT03828604|BEHAVIORAL|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
218991627|NCT01055171|DRUG|Placebo|40 mg; Single Dose.
218991628|NCT02414997|PROCEDURE|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
218991629|NCT02414997|PROCEDURE|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
218991630|NCT02200211|DEVICE|iPad®|Binocular therapy on iPad®
219748323|NCT03828604|BEHAVIORAL|Placebo Trier Social Stress Task|Active control version of the TSST
219748324|NCT05379530|DIAGNOSTIC_TEST|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
219748325|NCT05379530|OTHER|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
218991631|NCT02200211|OTHER|Patching 2 hours per day, 7 days per week|
218991632|NCT02584816|BIOLOGICAL|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
218991633|NCT02584816|BIOLOGICAL|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
219748326|NCT04669067|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
219748327|NCT04669067|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
219748328|NCT04144920|BEHAVIORAL|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
219748329|NCT04144920|BEHAVIORAL|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
219748330|NCT04144920|BEHAVIORAL|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
219748331|NCT01798225|DRUG|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
219748332|NCT01798225|DRUG|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
218991634|NCT02584816|BIOLOGICAL|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
218991635|NCT02584816|BIOLOGICAL|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
219748333|NCT00751231|DRUG|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
219748334|NCT00751231|DRUG|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
219748335|NCT04446052|DRUG|GM-CSF priming|
219748336|NCT04446052|DRUG|Placebo|Placebo
219748337|NCT02753972|BEHAVIORAL|Mindful Eating and Living|8 week mindfulness skills intervention
219748338|NCT02753972|BEHAVIORAL|Active Weight Loss Control|8 week active weight loss control group
219748339|NCT00133705|DRUG|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
219748340|NCT00133705|DRUG|Inert Capsule|sugar pill
219748341|NCT04164719|DRUG|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
219748342|NCT00400101|BIOLOGICAL|Virosome-formulated synthetic peptides (malaria vaccine)|
219748343|NCT00824954|PROCEDURE|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
219748344|NCT00246103|DRUG|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
219748345|NCT00246103|DRUG|Epirubicin|Beginning Dose, Level 1: 75 mg/m\^2.
219748346|NCT00246103|DRUG|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
219748347|NCT00246103|DRUG|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
219748348|NCT03320005|OTHER|Resistance training group|Resistive exercises for legs and arms
219748349|NCT04881058|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
219748350|NCT05077423|DRUG|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
219748351|NCT01795157|DEVICE|CCADSS|Questionnaire is transferred wireless to the physician's PC
219748352|NCT01795157|DEVICE|pen-paper|Questionnaire completed and transferred to the physician using standard methods
219748353|NCT01342666|DIETARY_SUPPLEMENT|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
219748354|NCT01342666|DIETARY_SUPPLEMENT|Cucumber consumption|Daily consumption of 300g of cucumber.
219748355|NCT00175500|DEVICE|Large Diameter Femoral Head|
219748356|NCT05481684|OTHER|Normal Progesterone group|No progesterone supplementation
219748357|NCT05481684|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, vaginal pills (Lutinus 2\*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
219748358|NCT04114825|BIOLOGICAL|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
219748359|NCT04114825|OTHER|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
219748360|NCT05938686|OTHER|Home_Based Digital Mindful Dance Program|Home\_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
218991636|NCT01918774|BEHAVIORAL|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
218991637|NCT05955105|DRUG|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
218991638|NCT05955105|DRUG|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
218991639|NCT06120998|PROCEDURE|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
219179029|NCT06565819|DIAGNOSTIC_TEST|The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)|DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
219748361|NCT01651988|DRUG|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
219748362|NCT01110512|DRUG|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
219748363|NCT01110512|DRUG|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
219748364|NCT03960736|OTHER|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
219748365|NCT03960736|OTHER|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
219748366|NCT00808873|OTHER|socio-educational intervention|brief mental health education and 6 follow-up visits
219748367|NCT03362671|DEVICE|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
218991640|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
218991641|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
218991642|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
218991643|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
218991644|NCT04717609|PROCEDURE|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
218991645|NCT04717609|DRUG|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
218991646|NCT06053294|OTHER|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
218991647|NCT06053294|OTHER|CS+Fast|(CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
218991648|NCT06053294|OTHER|CS+Slow|(CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
218991649|NCT00378820|BEHAVIORAL|Whey without milk minerals|
218991650|NCT00378820|BEHAVIORAL|Whey with milk minerals|
218991651|NCT00378820|BEHAVIORAL|Casein without milk minerals|
218991652|NCT00378820|BEHAVIORAL|Casein with milk minerals|
218991653|NCT03613545|PROCEDURE|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
218991654|NCT03613545|PROCEDURE|Infusion of sham|Infusion of sham
219369218|NCT06961240|DIAGNOSTIC_TEST|AI-Based Difficult Airway Prediction Model|"The AI-Based Difficult Airway Prediction Model is an artificial intelligence system designed to predict difficult intubation in patients undergoing general anesthesia. It combines clinical data (age, BMI, Mallampati score, mouth opening, thyromental distance, sternomental distance, neck circumference) and anatomical image data. Machine learning (Random Forests, SVM, Gradient Boosting) and deep learning (ANN, CNN) algorithms are used to classify airway difficulty. The model's predictions are compared with clinical assessments by anesthesiologists using Cormack-Lehane grading. The goal is to improve prediction accuracy, enhance airway management, and support clinical decision-making."
219369219|NCT06959979|DRUG|CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)|Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).
218991655|NCT03613545|DRUG|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
218991656|NCT01337739|DRUG|Placebo Comparator|Placebo administration (.9 normal saline sterile)
219748368|NCT03362671|DEVICE|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
219748369|NCT05737979|OTHER|Study chart review|Evaluation of the IVF cycle using the prescribed medication
218991657|NCT01337739|DRUG|Active Comparator|Administration of Dexmedetomidine
218991658|NCT05777577|DIETARY_SUPPLEMENT|probiotic therapy|probiotic including bifidobacterium
218991659|NCT03711812|PROCEDURE|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
218991660|NCT03711812|PROCEDURE|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
218991661|NCT01182675|DRUG|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
219369220|NCT01388400|OTHER|conventional occupational therapy|upper limb exercises
219369221|NCT01388400|DEVICE|video capture virtual reality|virtual reality delivered uppe limb exercises
219369222|NCT03713190|COMBINATION_PRODUCT|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
219748370|NCT00691626|BEHAVIORAL|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
219748371|NCT00691626|BEHAVIORAL|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
219748372|NCT02793960|DRUG|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
219748373|NCT04992273|DRUG|casirivimab+imdevimab|Single dose administered based on weight
219748374|NCT03440411|DRUG|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
219748375|NCT03440411|DRUG|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
219748376|NCT03440411|DRUG|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
219748377|NCT02167711|DRUG|SIRT Yttrium-90|
219748378|NCT01519479|OTHER|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
219748379|NCT01519479|OTHER|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
219748380|NCT02101255|DEVICE|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
219748381|NCT02101255|DEVICE|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
219748382|NCT04480866|DEVICE|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
219748383|NCT01093131|OTHER|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
219748384|NCT01093131|DRUG|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
219748385|NCT01093131|OTHER|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
219748386|NCT01093131|DRUG|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
219748387|NCT04419246|OTHER|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
219748388|NCT04419246|DRUG|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
219748389|NCT04419246|OTHER|general anesthesia|general anesthesia will be applied in accordance with standard procedures
219748390|NCT05892107|PROCEDURE|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
219748391|NCT05892107|PROCEDURE|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
219748392|NCT05892107|PROCEDURE|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
219748393|NCT03974061|BEHAVIORAL|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
219748394|NCT03974061|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
219748395|NCT06188195|DRUG|Dexamethasone|ACS intervention were used in the experimental group
219748396|NCT03641287|OTHER|Exercise Counseling|Meet with exercise physiology
219748397|NCT03641287|OTHER|Aerobic Exercise|Receive prescription for moderate aerobic exercise
219748398|NCT03641287|OTHER|Physiological Support|Receive motivational support via telephone care
219748399|NCT03641287|OTHER|Quality-of-Life Assessment|Ancillary studies
219748400|NCT03641287|OTHER|Questionnaire Administration|Ancillary studies
219748401|NCT03641287|OTHER|Best Practice|Undergo habitual level of physical activity
219748402|NCT05104060|PROCEDURE|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
218991662|NCT01182675|DRUG|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
218991663|NCT05500105|OTHER|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
218991664|NCT03677531|OTHER|Quality-of-Life Assessment|Ancillary studies
218991665|NCT03677531|OTHER|Questionnaire Administration|Ancillary studies
218991666|NCT03677531|RADIATION|Radiation Therapy|Undergo RT
218991667|NCT03677531|OTHER|Video|Watch video of choice during RT
218991668|NCT05135117|OTHER|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
218991669|NCT05135117|OTHER|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
218991670|NCT01135420|BEHAVIORAL|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
218991671|NCT01135420|OTHER|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
218991672|NCT06284746|DRUG|Tirolizumab+SOX/XELOX|Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
218991673|NCT06284746|DRUG|SOX/XELOX|Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
218991674|NCT01658462|DRUG|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
218991675|NCT01658462|DRUG|Nintedanib|"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"
219369223|NCT03713190|DRUG|Placebo|A substance without specific pharmacology principles
219369224|NCT06108102|OTHER|Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)|Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
219577638|NCT05990842|DRUG|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
219577639|NCT05990842|OTHER|placebo|the individual will receive 10 ml of saline during anesthetic induction
219577640|NCT02408328|DRUG|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
219577641|NCT02408328|DEVICE|Home monitor|Use of home monitor until 44 weeks postmenstrual age
219577642|NCT02408328|OTHER|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
218991676|NCT01658462|DRUG|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
218991677|NCT05453656|BEHAVIORAL|exercise|physical activity promotion and engagement following kidney transplantation
218991678|NCT03986502|OTHER|Media Intervention|Watch web-based financial literacy video
218991679|NCT03986502|OTHER|Informational Intervention|Receive information on financial counseling and medical cost assistance
218991680|NCT03986502|OTHER|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
218991681|NCT03986502|OTHER|Questionnaire Administration|Ancillary studies
218991682|NCT03986502|OTHER|Quality-of-Life Assessment|Ancillary studies
219577643|NCT02749292|DRUG|Rituximab|re-dosing dependent on interventional arm parameter.
219577644|NCT05116748|BIOLOGICAL|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
219577645|NCT02458092|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
219577646|NCT02458092|BIOLOGICAL|Rabipur|Rabipur is a licensed rabies vaccine.
219577647|NCT01825122|DRUG|Nadolol|
219577648|NCT01825122|DRUG|Placebo|
219577649|NCT03022474|BEHAVIORAL|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
219577650|NCT03595163|DRUG|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
219577651|NCT03595163|DRUG|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
219577652|NCT00251641|DRUG|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
218991683|NCT00717197|DRUG|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
218991684|NCT03464305|DRUG|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
218991685|NCT03464305|DRUG|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
218991686|NCT04276792|BEHAVIORAL|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
218991687|NCT03326102|DRUG|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
218991688|NCT03326102|DRUG|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
218991689|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
218991690|NCT00982137|BIOLOGICAL|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
218991691|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
218991692|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
218991693|NCT00566371|DRUG|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
218991694|NCT00566371|DRUG|placebo|placebo
218991695|NCT06223178|DEVICE|thumb-tack needle|Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
218991696|NCT06223178|DEVICE|sham thumb-tack needle|Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
219179030|NCT03884946|OTHER|Getting Off App|"A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included."
219179031|NCT06801106|DEVICE|Acapella|is an airway clearance device that combines the resistive features of a positive expiratory pressure device with oscillations, which diminishes the mucus adhesiveness and decrease the collapsibility of airways
219179032|NCT06801106|DEVICE|Lung flute|is a new oscillatory positive expiratory pressure (OPEP) device that produces a low frequency acoustic wave with vigorous exhalation that increases mucociliary clearance
219179033|NCT06796296|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide involves administering Loperamide orally, with a daily dosage of 2mg. This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate sysmptoms associated with LARS
219748403|NCT05104060|PROCEDURE|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
218991697|NCT06223178|OTHER|Basic gynecological treatment|Gynecological health care guidance will be provided as patients needed.
218991698|NCT01811654|DEVICE|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
218991699|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
218991700|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
218991701|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
218991702|NCT03394326|BEHAVIORAL|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
218991703|NCT05924620|DRUG|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
218991704|NCT02575495|DRUG|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
218991705|NCT02575495|DRUG|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
218991706|NCT02379871|OTHER|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
218991707|NCT02379871|OTHER|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
218991708|NCT02537197|DRUG|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
218991709|NCT06115213|BEHAVIORAL|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
218991710|NCT03870698|PROCEDURE|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
219369225|NCT05434884|PROCEDURE|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
219748404|NCT06487520|OTHER|group watching hot environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
219748405|NCT06487520|OTHER|group watching cold environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
219748406|NCT00841139|DRUG|Perhexiline|100mg o bd
219748407|NCT00841139|DRUG|Placebo|1 tablet bd
219748408|NCT01569412|BIOLOGICAL|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
219748409|NCT01252680|BIOLOGICAL|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
219748410|NCT01252680|BIOLOGICAL|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
219748411|NCT01252680|BIOLOGICAL|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
219748412|NCT01252680|BIOLOGICAL|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
219748413|NCT05187234|OTHER|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
219748414|NCT05375630|DIETARY_SUPPLEMENT|Placebo|Placebo
219748415|NCT05375630|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
219748416|NCT05809700|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
219748417|NCT01370148|DRUG|conivaptan hydrochloride|Intravenous
219748418|NCT06329219|DEVICE|water-filtered Infrared-A radiation|The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
219748419|NCT00600340|BIOLOGICAL|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
219748420|NCT00600340|BIOLOGICAL|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
219748421|NCT05872412|DRUG|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
219748422|NCT05872412|DRUG|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
219748423|NCT05872412|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
219748424|NCT05872412|DRUG|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
219748425|NCT05754125|DIETARY_SUPPLEMENT|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
219748426|NCT05754125|DIETARY_SUPPLEMENT|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
219748427|NCT05754125|DIETARY_SUPPLEMENT|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
219748428|NCT00722670|BEHAVIORAL|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
219748429|NCT00722670|BEHAVIORAL|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
219748430|NCT05530304|DEVICE|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
219748431|NCT00181246|DRUG|Transdermal Fentanyl|
219748432|NCT03847519|DRUG|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
219748433|NCT03847519|DRUG|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
218991711|NCT00003128|BIOLOGICAL|filgrastim|
218991712|NCT00003128|DRUG|ifosfamide|
218991713|NCT00003128|DRUG|paclitaxel|
218991714|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
219748434|NCT04403776|DRUG|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
219748435|NCT04403776|DRUG|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
218991715|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
218991716|NCT04828252|DEVICE|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
218991717|NCT05077722|DEVICE|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
218991718|NCT02728609|DEVICE|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
218991719|NCT02728609|DEVICE|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
218991720|NCT04869644|BEHAVIORAL|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
218991721|NCT04869644|BEHAVIORAL|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.
218991722|NCT04869644|BEHAVIORAL|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
218991723|NCT04869644|BEHAVIORAL|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
219179034|NCT06801184|BIOLOGICAL|Plasma Sample|A peripheral venous blood sample will be collected on the day of the inclusion consultation and during the follow-up consultation at V2. These samples will be collected in a single2 tubes (4 mL and 5 mL)l tube and will be taken simultaneously with routine blood samples, which require 2 tubes (10 3 mL and 4 mLl).
219369226|NCT05434884|PROCEDURE|endocrown restorations|endocrown restorations
219369227|NCT03268356|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
219369228|NCT02005822|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
219369229|NCT02472457|OTHER|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
219369230|NCT02472457|OTHER|Free Diet|This diet contains no restrictions.
219369231|NCT00956826|DEVICE|Agit Vacuum|With an electrode and a regular vacuum device
219748436|NCT05827341|OTHER|No intervention|No intervention needed
219748437|NCT00376558|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
219748438|NCT01228032|OTHER|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
219748439|NCT03787147|DEVICE|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
219748440|NCT03787147|DEVICE|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
219748441|NCT03787147|DRUG|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
218991724|NCT04869644|BEHAVIORAL|Habit Formation|Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
218991725|NCT04374032|DRUG|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
218991726|NCT04374032|DRUG|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
218991727|NCT06499155|DEVICE|Use of periacryl in gingival recession closure procedures|Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.
218991728|NCT06499155|PROCEDURE|Use of sutures in gingival recession closure procedures|Both recipient and donor areas will be closed with traditional suturing techniques.
218991729|NCT04988178|OTHER|Data extraction from medical files|Data extraction from medical files
218991730|NCT04736836|DRUG|Rifaximin|locally absorbed antibiotic
218991731|NCT04448483|DEVICE|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
218991732|NCT04448483|DEVICE|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
219369232|NCT00631878|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
219748442|NCT03787147|DRUG|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
219748443|NCT01652157|BIOLOGICAL|ULTRESA|pancreatic enzyme replacement therapy
219748444|NCT01652157|BIOLOGICAL|PANCREAZE|pancreatic enzyme replacement therapy
219748445|NCT01652157|BIOLOGICAL|CREON|pancreatic enzyme replacement therapy
219748446|NCT01652157|BIOLOGICAL|ZENPEP|pancreatic enzyme replacement therapy
219748447|NCT01652157|BIOLOGICAL|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
219748448|NCT01652157|BIOLOGICAL|PERTZYE|pancreatic enzyme replacement therapy
219748449|NCT01652157|OTHER|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
219748450|NCT02712203|BIOLOGICAL|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
219748451|NCT06334796|DIAGNOSTIC_TEST|Virtual Assistant|Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
219748452|NCT06443853|DIAGNOSTIC_TEST|Dental plaque scoring and dental plaque coated tooth surface measuring|"The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination.~Intraoral photographs of the volunteers were taken by using a digital camera and 3D images were recorded by an intraoral scanner. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the Image J program and the areas were measured in square pixels. The correlation between clinical visual scoring, dental plaque areas on images were compared."
219748453|NCT04547556|DIAGNOSTIC_TEST|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)"
219748454|NCT03528902|DRUG|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
219748455|NCT03528902|DRUG|Placebo Oral Tablet|Placebo
219748456|NCT06367413|DIETARY_SUPPLEMENT|Placebo|Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).
219748457|NCT06367413|DIETARY_SUPPLEMENT|NAC|Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
219748458|NCT06367413|DIETARY_SUPPLEMENT|NAC + Whey Protein|Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
219748459|NCT00645658|DRUG|Testim, 1% testosterone gel|Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
219748460|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
219369233|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
219748461|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
219748462|NCT04483778|DRUG|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
218991733|NCT00787891|DRUG|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
218991734|NCT00787891|DRUG|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
218991735|NCT03210168|OTHER|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
218991736|NCT02415660|PROCEDURE|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
219369234|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
219369235|NCT02507804|OTHER|Patient diary PROMs|
219369236|NCT02507804|OTHER|Counselling|
219748463|NCT06252077|DIETARY_SUPPLEMENT|very low ketogenic diet|1 month of active phase of very low ketogenic diet
219748464|NCT06004063|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|Given by Nasogastric Tube
219748465|NCT06004063|OTHER|Standard care parenteral nutrition (PN)|Given by PO or Given by IV (vein)
219748466|NCT06636955|OTHER|biobank|"* nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any"
218991737|NCT02415660|PROCEDURE|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
219748467|NCT06636955|OTHER|follow up|\- one year follow up: after 1 month, 3 months, 6 months et 12 months
219369237|NCT06303622|PROCEDURE|MRI-USG fusion approach|MRI-USG fusion approach prostate biopsy
219748468|NCT06637046|DIAGNOSTIC_TEST|Diagnostic procedures|A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
219748469|NCT06637046|DIAGNOSTIC_TEST|Lidocaine HCl|This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
219748470|NCT06644703|OTHER|Cryotherapy|The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
219748471|NCT03605693|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
219748472|NCT06289764|OTHER|Bergamot Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
219748473|NCT06289764|OTHER|Grapefruit Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
219748474|NCT06289764|OTHER|Sweet almond oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
219748475|NCT03093415|DRUG|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
219748476|NCT05805189|PROCEDURE|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
219748477|NCT00304161|DRUG|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
219748478|NCT00304161|DRUG|Placebo|40 to 80 mg orally once daily for 8 weeks
219748479|NCT06296225|DEVICE|Vibration|"Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol."
219748480|NCT05593289|OTHER|telerehabilitation|Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
219748481|NCT05342168|DIAGNOSTIC_TEST|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
219748482|NCT01655277|PROCEDURE|Ultrasound Guided Adductor Canal Block|
219748483|NCT01655277|PROCEDURE|Ultrasound Guided Femoral Nerve Block|
219748484|NCT00796458|DRUG|docetaxel|Given IV
219748485|NCT00796458|DRUG|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
219748486|NCT04552054|DEVICE|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
219748487|NCT04552054|DEVICE|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
219748488|NCT04331275|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
219748489|NCT05071326|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
218991738|NCT02415660|BEHAVIORAL|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
219748490|NCT05150678|PROCEDURE|removal of ceserean section scar|we will remove the previous scar in group A
219748491|NCT05150678|PROCEDURE|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
219748492|NCT06635122|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.
219748493|NCT06635122|PROCEDURE|Endoscopic treatment|Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
219748494|NCT06632171|BEHAVIORAL|Cognitive Behavioral Therapy- Based and Motivational Interviewing-Supported Psychoeducation|The aim of this study is to examine the effects of cognitive-behavioral-based and motivational interview-supported psychoeducation on emotional eating and psychological resilience in obese individuals. The study will be conducted in a randomized controlled experimental design. The sample of the study will consist of 102 obese individuals in total, 51 in the experimental group and 51 in the control group, who meet the inclusion criteria. A cognitive-behavioral and motivational interview-supported psychoeducation program will be applied to the experimental group. All patients will be evaluated at three time points: pretest (baseline), posttest (8 weeks), and follow-up test (3 months after the posttest). No intervention will be applied to the control group.
219748495|NCT06632080|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
219748496|NCT06632080|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
219748497|NCT06519565|DRUG|PRG-1801|PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
219748498|NCT02420509|DRUG|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
219748499|NCT04047355|DRUG|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
219748500|NCT04315922|DIAGNOSTIC_TEST|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
219748501|NCT04320199|DIETARY_SUPPLEMENT|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
219748502|NCT04320199|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
219748503|NCT05617326|OTHER|AAA screening by a GP|The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
219748504|NCT05617326|OTHER|AAA screening by a radiologist|General practitioners in the control group will refer their patients to the radiologist for AAA screening.
219748505|NCT06680661|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
219748506|NCT06680661|DRUG|Fludarabine|Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)
219748507|NCT06680661|DRUG|Thiotepa|Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)
219748508|NCT06680661|RADIATION|Total Body Irradiation|400 cGy (200 cGy per day on days -2 and -1).
219748509|NCT06680661|BIOLOGICAL|Double Umbilical Cord Transplant|Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.
219748510|NCT06680661|DRUG|Tacrolimus|Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.
218991739|NCT02415660|BEHAVIORAL|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
219748511|NCT06680661|DRUG|Mycophenolate Mofetil|MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.
219748512|NCT06680661|DRUG|Abatacept|Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
219369238|NCT06303622|PROCEDURE|Cognitive-guided approach|Cognitive-guided approach prostate biopsy
219748513|NCT06235801|DRUG|Gilteritinib|Given by PO
219748514|NCT06235801|DRUG|Momelotinib|Given by PO
219748515|NCT03090165|DRUG|ribociclib|400mg PO
219748516|NCT03090165|DRUG|ribociclib|600mg PO
219748517|NCT03090165|DRUG|Bicalutamide|150mg PO
219748518|NCT05269082|OTHER|No intervention|This is a non-interventional study.
219748519|NCT01405664|OTHER|Weight-Bearing as Tolerated|WBAT immediately after surgery
219748520|NCT04289493|OTHER|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
219369239|NCT01834235|DRUG|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
219369240|NCT01834235|DRUG|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
219369241|NCT01834235|DRUG|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
219748521|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
219748522|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
219748523|NCT03008408|DRUG|Everolimus|Given PO
219748524|NCT03008408|DRUG|Letrozole|Given PO
219748525|NCT03008408|DRUG|Ribociclib|Given PO
219748526|NCT03044054|DEVICE|ECHOPULSE|HIFU Under ultrasound guidance
219748527|NCT05805800|DRUG|5HT3RA+Olanzapine|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner."
219748528|NCT05805800|DRUG|5HT3RA+Olanzapine+Dexamethasone|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered."
219748529|NCT06138782|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
219748530|NCT00023595|PROCEDURE|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
219748531|NCT00023595|DRUG|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
219748532|NCT00023595|PROCEDURE|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
219748533|NCT01277185|DIETARY_SUPPLEMENT|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
219748534|NCT01277185|DIETARY_SUPPLEMENT|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
219369242|NCT05191043|OTHER|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
219577653|NCT00251641|DRUG|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
219577654|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
219748535|NCT06501105|DEVICE|WOUNDCHEK Bacterial Status|Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
219748536|NCT01443312|GENETIC|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
219748537|NCT04817436|OTHER|physical activity program (APA)|adapted physical activity program (APA)
219748538|NCT05870072|OTHER|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
219577655|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
219577656|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
219577657|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
219577658|NCT01387763|DRUG|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
219577659|NCT03329534|OTHER|Gluten free diet|A month long gluten free diet
219577660|NCT01797484|DRUG|Ranolazine|Improvement of myocardial microcirculation
219577661|NCT05681312|DRUG|systemic proteolytic enzyme (Tibrolin)|Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
219577662|NCT05681312|DRUG|Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg|Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
219577663|NCT02093221|BIOLOGICAL|180 mg/kg Alpha1-PI|
219577664|NCT02093221|BIOLOGICAL|90 mg/kg Alpha1-PI|
219577665|NCT02093221|BIOLOGICAL|Placebo|
219577666|NCT02147249|DRUG|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
219577667|NCT03516136|DEVICE|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
219748539|NCT05870072|OTHER|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
219748540|NCT05870072|OTHER|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
219748541|NCT05889468|DRUG|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
219748542|NCT05889468|DRUG|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
219748543|NCT01309230|BIOLOGICAL|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
219748544|NCT05985135|PROCEDURE|Muscle Biopsy|Needle muscle biopsy of the outer thigh muscle
219748545|NCT05985135|OTHER|Jell-O with Amino acids|An amino acid mixture containing 13C6 Lysine isotope label
219748546|NCT05985135|DIETARY_SUPPLEMENT|Dextrose|Intravenous form of sugar
219748547|NCT05468918|DEVICE|Phonak Audeo previous generation hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
219748548|NCT05468918|DEVICE|Phonak Audeo Lumity hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
219748549|NCT00796263|DRUG|HAART|"1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily~plus~dolutegravir(DTG) 50 mg orally once daily"
219748550|NCT04481685|DRUG|ATI-450|50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.
219748551|NCT04481685|DRUG|Placebo|Placebo pill will be taken twice daily preferably spaced 12 hours apart.
219748552|NCT02565394|OTHER|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
219748553|NCT04611243|BIOLOGICAL|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
219748554|NCT04611243|BIOLOGICAL|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
219748555|NCT04611243|BIOLOGICAL|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
219748556|NCT04611243|BIOLOGICAL|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
219748557|NCT06006286|DRUG|Atezolizumab|Given by IV (vein)
219748558|NCT06006286|DRUG|Bevacizumab|Given by IV (vein)
219748559|NCT06006286|DRUG|ADI-PEG 20|Given by Injection (inj)
219748560|NCT06570746|DRUG|Sedative|Sedation is applied before the procedure
219748561|NCT06570174|DIETARY_SUPPLEMENT|oral protein supplements|Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
219748562|NCT06570174|GENETIC|placebo|Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
219748563|NCT06569459|DRUG|Trilaciclib Injection [Cosela]|Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
219748564|NCT06569459|DRUG|Placebo|Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
219748565|NCT06557811|DRUG|Semaglutide|After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
219748566|NCT05513365|DRUG|Goserelin 10.8 mg|Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
218991740|NCT02415660|PROCEDURE|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
218991741|NCT02415660|DEVICE|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
218991742|NCT02824874|DRUG|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
218991743|NCT02824874|DRUG|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
219577668|NCT01421121|BIOLOGICAL|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
219577669|NCT01421121|BIOLOGICAL|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
219577670|NCT01421121|BIOLOGICAL|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
219577671|NCT01421121|BIOLOGICAL|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
219577672|NCT01421121|BIOLOGICAL|Placebo|0.5ml placebo, two doses, 28 days interval
219577673|NCT05099484|DRUG|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
219577674|NCT05466279|DRUG|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
219577675|NCT05466279|DRUG|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
219577676|NCT05466279|DRUG|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
219577677|NCT02172352|DRUG|Ba 679 BR low dose|
219577678|NCT02172352|DRUG|Ba 679 BR middle dose|
219577679|NCT02172352|DRUG|Ba 679 BR high dose|
219577680|NCT02172352|DRUG|Placebo inhalation powder|
219577681|NCT06098287|DEVICE|Residential mechanical ventilation system (Exhaust)|Exhaust-only ventilation system
219577682|NCT06098287|DEVICE|Residential mechanical ventilation system (CFIS) and air filtration upgrades|Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
219577683|NCT06098287|DEVICE|Residential mechanical ventilation system (ERV) and air filtration upgrades|Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
219577684|NCT00000607|DEVICE|Left ventricular assist device|A type of implantable heart pump
219577685|NCT00000607|DEVICE|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
219577686|NCT00384878|DRUG|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
219577687|NCT02387593|DEVICE|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
219577688|NCT01312311|DRUG|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
219577689|NCT04923711|BEHAVIORAL|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
219577690|NCT04923711|BEHAVIORAL|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
219577691|NCT02514161|OTHER|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
219577692|NCT02514161|OTHER|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
219577693|NCT03356028|BEHAVIORAL|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
219577694|NCT03356028|OTHER|salivary biological collection|Saliva sampling will be done using a specific kit
219577695|NCT03356028|BEHAVIORAL|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
219577696|NCT03356028|BEHAVIORAL|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
219577697|NCT03356028|BEHAVIORAL|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
219577698|NCT03356028|BEHAVIORAL|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
219577699|NCT03356028|BEHAVIORAL|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
219577700|NCT00701974|BIOLOGICAL|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
219577701|NCT00701974|BIOLOGICAL|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
219577702|NCT00188227|DRUG|Midazolam (sedative)|
219577703|NCT00188227|DRUG|Piritramid (analgetic)|
219577704|NCT00188227|BEHAVIORAL|Cognitive exercises|
219748567|NCT05513365|DRUG|Bicalutamide 50 mg|Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
219748568|NCT05513365|DRUG|Dutasteride 0.5 mg|Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
219369243|NCT05191043|OTHER|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
219748569|NCT04535297|OTHER|exposure|Exposure to social distancing due to COVID-19
219748570|NCT01074346|DRUG|Interferon-β-1a|Interferon-β-1a according to the standard practice
219748571|NCT03900650|BEHAVIORAL|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
219748572|NCT03900650|BEHAVIORAL|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
219748573|NCT03900650|BEHAVIORAL|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
219748574|NCT03900650|BEHAVIORAL|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
219748575|NCT02891356|DEVICE|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
219748576|NCT02835105|DRUG|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
219748577|NCT02835105|DRUG|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
219748578|NCT05919498|OTHER|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
219748579|NCT05919498|OTHER|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
219748580|NCT02577809|DRUG|Morphine100|100mcg added to the spinal anaesthetic
219748581|NCT02577809|DRUG|Morphine50|50mcg added to the spinal anaesthetic
218991744|NCT05209958|DIAGNOSTIC_TEST|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
219748582|NCT02577809|DRUG|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
219748583|NCT02577809|DRUG|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
219748584|NCT02577809|DRUG|Indomethacin|100mg Indomethacin suppository
218991745|NCT04388800|OTHER|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
218991746|NCT06049940|BIOLOGICAL|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
218991747|NCT06049940|BIOLOGICAL|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
218991748|NCT01258582|PROCEDURE|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
218991749|NCT01258582|PROCEDURE|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
218991750|NCT03216889|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
218991751|NCT03216889|BEHAVIORAL|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
219748585|NCT06017557|DIAGNOSTIC_TEST|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
219748586|NCT02507726|DEVICE|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
219748587|NCT03508583|OTHER|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
219748588|NCT02899403|OTHER|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
218991752|NCT00653055|DRUG|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
219748589|NCT03403179|OTHER|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
219748590|NCT04279587|BEHAVIORAL|Residential camp|Intensive education at a residential camp.
219748591|NCT00370578|DEVICE|repeated thrombus aspiration during primary PCI|
219748592|NCT00427700|DRUG|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
219748593|NCT00427700|DRUG|raloxifene|100mg PO on days 5-9 of the menstrual cycle
219748594|NCT05664529|DIAGNOSTIC_TEST|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
219748595|NCT05444387|OTHER|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
219748596|NCT03477422|DRUG|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
219748597|NCT03477422|DRUG|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
219748598|NCT01379690|OTHER|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
219748599|NCT02423694|DEVICE|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA"
219748600|NCT02423694|DRUG|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
219748601|NCT06388629|DEVICE|Rook Epicardial Access Kit|Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
219748602|NCT04581395|OTHER|non-pretreated Succinylcholine|no pretreatment
219748603|NCT04581395|DRUG|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
219748604|NCT04581395|DRUG|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
219748605|NCT06119217|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
219748606|NCT06119217|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
219748607|NCT06119217|COMBINATION_PRODUCT|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
219748608|NCT05945225|DEVICE|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
219748609|NCT05945225|DEVICE|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
219748610|NCT05945225|DEVICE|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
219748611|NCT05945225|DEVICE|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
219748612|NCT03560388|OTHER|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
219748613|NCT06564688|DIAGNOSTIC_TEST|Swallowing function test|"The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants."
219748614|NCT06272578|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
219748615|NCT04452916|OTHER|Buchinger fasting|Caloric intake of \< 250 kcal/d for 5 days
219748616|NCT05634343|OTHER|experimental group 1|Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.
219369244|NCT04697966|BEHAVIORAL|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
219748617|NCT05634343|OTHER|experimantal group 2|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
219748618|NCT05500521|DIAGNOSTIC_TEST|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
219748619|NCT05500521|DIAGNOSTIC_TEST|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
219748620|NCT05500521|DIAGNOSTIC_TEST|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
219748621|NCT04049513|BIOLOGICAL|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
219748622|NCT04049513|DRUG|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
219748623|NCT06417060|DRUG|Caudal block anesthesia|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
219748624|NCT06417060|DRUG|Dorsal penile block anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
219748625|NCT01296204|DRUG|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
219748626|NCT05313490|DIETARY_SUPPLEMENT|Beetroot Juice|7 days of 140 mL per day of beetroot juice
219429084|NCT01213264|DRUG|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
219748627|NCT05313490|OTHER|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
219748628|NCT04597801|DRUG|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
219748629|NCT04794504|DRUG|Botox 100 UNT Injection|Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
219748630|NCT04794504|OTHER|0.9% Saline Injection|As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
219748631|NCT02731482|OTHER|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~* Aerobic training in stepping training.~* Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~* Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
219748632|NCT02731482|OTHER|Control Group|"* The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~* Participants will not receive any supervised physical training.~* Once a week, patients will receive a phone call to provide support and general advice."
219748633|NCT03898427|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
219748634|NCT03898427|DEVICE|Polysomnography|Sleep Monitor
219748635|NCT03898427|DEVICE|Videography|Thermal Camera
219748636|NCT03960944|OTHER|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
219748637|NCT04190472|DIAGNOSTIC_TEST|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
219748638|NCT05358223|OTHER|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
219748639|NCT05358223|DEVICE|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
219748640|NCT00815633|DRUG|Alefacept|15mg intramuscular injection weekly for 12 weeks
219748641|NCT02978495|DRUG|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
219748642|NCT02978495|DRUG|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
219748643|NCT02978495|DRUG|Paclitaxel|80mg/m2 weekly for 12 weeks
219748644|NCT02978495|DRUG|Cyclophosphamide|600mg/m2 4 cycles each 21 days
219748645|NCT00721110|DRUG|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
219748646|NCT00721110|DRUG|Placebo|Placebo boluses and infusions will be substituted
219748647|NCT00721110|DRUG|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
219748648|NCT00721110|DRUG|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
219748649|NCT00416507|DRUG|fluorouracil|
219748650|NCT00416507|DRUG|gemcitabine hydrochloride|
219748651|NCT00416507|DRUG|liposomal cisplatin|
219748652|NCT00000222|DRUG|Buprenorphine|
219748653|NCT01554904|DEVICE|Facial-Flex|Oral exercise device
219748654|NCT00517790|DRUG|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
219748655|NCT00517790|DRUG|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
219748656|NCT06131190|BEHAVIORAL|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
219748657|NCT01940055|BEHAVIORAL|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
219748658|NCT01940055|BEHAVIORAL|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
219748659|NCT05417178|OTHER|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
219748660|NCT02162173|PROCEDURE|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
219748661|NCT03965117|DRUG|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
219748662|NCT02553096|DEVICE|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
219748663|NCT01605097|RADIATION|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
219748664|NCT02554955|DRUG|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
219748665|NCT02554955|DRUG|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
219748666|NCT02554955|DRUG|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
219748667|NCT00924274|DIETARY_SUPPLEMENT|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
219748668|NCT00924274|DIETARY_SUPPLEMENT|sunflower oil|sunflower oil
219748669|NCT04250701|OTHER|Body Posture Assessment|Application of three evaluations above at a one time.
219748670|NCT03531580|DEVICE|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
219748671|NCT02305992|PROCEDURE|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
219748672|NCT02305992|PROCEDURE|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
219748673|NCT02305992|PROCEDURE|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
219748674|NCT04190264|DEVICE|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
219748675|NCT04190264|OTHER|Cold Water Immersion|Whole-body immersion in cold water.
219748676|NCT04831229|OTHER|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
219748677|NCT04831229|OTHER|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
219748678|NCT04179617|OTHER|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
219748679|NCT04179617|OTHER|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
219748680|NCT02786329|DRUG|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
219748681|NCT02786329|DRUG|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
219748682|NCT02786329|DRUG|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
219748683|NCT02786329|DRUG|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
218991753|NCT00653055|DRUG|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
219429085|NCT03049995|PROCEDURE|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
219748684|NCT06486220|DRUG|Intestinal bacteria freeze-dried powder capsules|Oral healthy intestinal bacteria freeze-dried powder capsules, tid
219748685|NCT03256487|DRUG|Buprenorphine|buprenorphine 0.3mg IV
219748686|NCT03256487|DRUG|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
219748687|NCT03107845|BEHAVIORAL|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
219748688|NCT03107845|BEHAVIORAL|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
219748689|NCT03107845|BEHAVIORAL|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
219748690|NCT01715116|DEVICE|Enhanced ICD programming|"* VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices."
219748691|NCT02038647|DRUG|Alisertib|Alisertib tablets
219748692|NCT02038647|DRUG|Placebo|Placebo matching tablets
219748693|NCT02038647|DRUG|Paclitaxel|Paclitaxel intravenous injection
219748694|NCT02259803|DRUG|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
219748695|NCT02259803|DRUG|Telmisartan|
219748696|NCT02259803|DRUG|Amlodipine|
219748697|NCT02962661|OTHER|Best Practice|Given standard of care
219748698|NCT02962661|OTHER|Laboratory Biomarker Analysis|Correlative studies
219748699|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given IV
219748700|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given transendocardially
219748701|NCT05576649|OTHER|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
219748702|NCT05576649|OTHER|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
219748703|NCT05576649|OTHER|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
219748704|NCT02757430|PROCEDURE|Cardiac Ablation|
219748705|NCT06570265|DEVICE|GBR membrane|GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
218991754|NCT03164902|DEVICE|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
219748706|NCT01809431|BEHAVIORAL|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
219429086|NCT03049995|PROCEDURE|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
219748707|NCT05755750|DRUG|Genipin|Intratendinous genipin injection
219748708|NCT02130037|BEHAVIORAL|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
219748709|NCT02130037|OTHER|psychotherapy|standard psychotherapy for eating disorders
219748710|NCT06013852|DIAGNOSTIC_TEST|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
219748711|NCT04544631|OTHER|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
219748712|NCT05454865|DIETARY_SUPPLEMENT|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
219748713|NCT05454865|DIETARY_SUPPLEMENT|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
219748714|NCT03469895|DRUG|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
219748715|NCT05910424|OTHER|collection of saliva, gum fluid and/or dental plaque samples|Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
219748716|NCT04817956|DRUG|Atezolizumab|drugs used outside indication, based on biomarker
219748717|NCT03196778|RADIATION|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
219748718|NCT00892866|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219748719|NCT00892866|OTHER|Laboratory Biomarker Analysis|Correlative studies
219748720|NCT01256047|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
219748721|NCT06040398|BEHAVIORAL|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
219748722|NCT01842347|OTHER|Fecal microbiota|
219748723|NCT01516372|DRUG|GEn 1200mg|1200 mg of Gen administered as a single dose
219748724|NCT01516372|DRUG|Gen 6000 mg|6000 mg of Gen administered as a single dose
219748725|NCT01516372|DRUG|GEn Placebo|Placebo to match GEn Tablets
219748726|NCT01516372|DRUG|Moxifloxacin Placebo|Placebo to match Moxifloxacin
218991755|NCT05450731|OTHER|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
218991756|NCT02980601|DEVICE|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
218991757|NCT02980601|PROCEDURE|STSG|0.012mm STSG
219748727|NCT01516372|DRUG|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
219748728|NCT04244734|OTHER|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
218991758|NCT01575769|DRUG|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
218991759|NCT04569266|OTHER|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
218991760|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
219748729|NCT04244734|OTHER|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
219748730|NCT01933763|DRUG|REGN1193|
219748731|NCT01933763|OTHER|Placebo|
219748732|NCT02082977|DRUG|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
219748733|NCT01535482|BEHAVIORAL|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
219748734|NCT01535482|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
219748735|NCT00001382|BIOLOGICAL|PROSTVAC|
219748736|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
219748737|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
219748738|NCT01188187|DRUG|Custirsen|
219748739|NCT01188187|DRUG|Docetaxel|
219429087|NCT03049995|PROCEDURE|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
219429088|NCT03049995|PROCEDURE|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
219748740|NCT01188187|DRUG|Prednisone|
219748741|NCT01188187|DRUG|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
219748742|NCT00945087|OTHER|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
219748743|NCT00236041|DRUG|ACTIQ®|
219748744|NCT03045952|PROCEDURE|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
219748745|NCT06565182|OTHER|Exercise|The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
219748746|NCT04637061|COMBINATION_PRODUCT|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
218991761|NCT01080534|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
219748747|NCT04637061|DIAGNOSTIC_TEST|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
219748748|NCT04637061|DIAGNOSTIC_TEST|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
219748749|NCT04839640|OTHER|Bredent denture teeth|composite resin denture teeth
219748750|NCT03321942|DRUG|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
219748751|NCT03321942|DRUG|Control group|Conventional treatment were used to treat patients with chronic renal failure.
219748752|NCT00541424|PROCEDURE|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
219748753|NCT00741377|DRUG|BHQ880|
219748754|NCT00741377|DRUG|Zoledronic acid|
219748755|NCT00706173|DRUG|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
219748756|NCT00706173|DRUG|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
218991762|NCT01574131|DRUG|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
218991763|NCT01574131|DRUG|Sugar Pill|pill every day for 6 months
218991764|NCT01619982|DRUG|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
218991765|NCT01619982|DRUG|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
219748757|NCT03464201|DRUG|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
219748758|NCT04434183|DEVICE|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
219748759|NCT00219414|DEVICE|Adacolumn Apheresis System|
219748760|NCT00375258|DRUG|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
218991766|NCT02948972|PROCEDURE|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
219748761|NCT00375258|DRUG|Sodium Chloride 0.9%|Visual matched placebo
219748762|NCT02692027|OTHER|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
219748763|NCT02692027|OTHER|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
219748764|NCT00319007|DRUG|Sulindac (drug)|
219748765|NCT00319007|DRUG|VSL#3 (probiotic)|
219369245|NCT04697966|BEHAVIORAL|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
219748766|NCT00319007|DRUG|Inulin (probiotic)|
219748767|NCT05764928|DRUG|BLEX 404|BLEX 404 Oral Liquid, PO, BID
219748768|NCT01048957|BEHAVIORAL|Real Time Feedback Training|
219748769|NCT05808712|OTHER|validation|Translation and validation design
219748770|NCT02394574|OTHER|Clean Cookstove|Ethanol
219748771|NCT02394574|OTHER|Traditional Cookstove|Firewood / Kerosene
219748772|NCT04892589|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
219748773|NCT02710032|BEHAVIORAL|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
219748774|NCT02710032|BEHAVIORAL|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
219748775|NCT02386241|OTHER|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
219748776|NCT04582591|DRUG|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
219748777|NCT02873728|PROCEDURE|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
219748778|NCT02873728|OTHER|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
219748779|NCT05509660|BEHAVIORAL|PUMA+|Transdiagnostic CBT
219748780|NCT05509660|BEHAVIORAL|PUMA|Transdiagnostic CBT
219748781|NCT00608062|DRUG|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
219748782|NCT00608062|DRUG|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
219748783|NCT00608062|DRUG|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
219748784|NCT02695277|DEVICE|AtriCure Bipolar System|
218991767|NCT02948972|PROCEDURE|In vitro fertilization without surgery|IVF without endometriosis surgery
218991768|NCT02539121|DEVICE|Acupuncture|Acupuncture needles
218991769|NCT01821521|DRUG|AGSPT_L20|
218991770|NCT01821521|DRUG|Pantoloc 40mg|
218991771|NCT00000883|DRUG|Azithromycin|
218991772|NCT01455259|BIOLOGICAL|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
219748785|NCT02695277|DEVICE|Standard Endocardial Ablation with Catheter|
219748786|NCT02695277|DEVICE|AtriClip® PRO LAA Exclusion System|
219748787|NCT02695277|DEVICE|Endocardial Ablation with Catheter|
219748788|NCT02695277|DEVICE|Repeated Endocardial ablation(s)|
219748789|NCT01728103|DEVICE|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
219748790|NCT05430438|OTHER|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
219748791|NCT05430438|OTHER|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
219748792|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
219748793|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
219748794|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
219748795|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
219748796|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
219748797|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
219748798|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
219748799|NCT04720001|DRUG|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
219748800|NCT04720001|DEVICE|PET|PET Scan for brain imaging
219748801|NCT02040909|DRUG|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
219748802|NCT02215473|DRUG|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
219748803|NCT02215473|PROCEDURE|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
219748805|NCT01889446|DIETARY_SUPPLEMENT|Calcium propionate|
219748806|NCT06551727|OTHER|Intervention group|"After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database."
219748807|NCT06551727|OTHER|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
219748808|NCT01460615|DRUG|Hydrocortisone|
219748809|NCT00087035|DRUG|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
219748810|NCT00087035|DRUG|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
219748811|NCT04708847|DRUG|GYM329|GYM329 subcutaneous injection
219748812|NCT04708847|DRUG|Placebo|Placebo subcutaneous injection
219748813|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
219748814|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
219748815|NCT00663260|DRUG|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
219748816|NCT03361631|DRUG|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
219748817|NCT06199752|DIETARY_SUPPLEMENT|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
219748818|NCT05781451|DRUG|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
219748819|NCT02678377|DRUG|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
219748820|NCT02678377|DRUG|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
219748821|NCT05497687|OTHER|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
219748822|NCT03246880|DRUG|Tamsulosin 0.2mg|per oral for 12weeks after 2\~4weeks run-in period
219748823|NCT03246880|DRUG|Tadalafil 5mg|per oral for 12weeks after 2\~4weeks run-in period
219748824|NCT04429763|BIOLOGICAL|Umbilical cord derived mesenchymal stem cells|One dosis of 1\*10\^6 cells/Kg
219748825|NCT04429763|BIOLOGICAL|Placebo|Placebo
219748826|NCT03109457|OTHER|oral squamous cell carcinoma|Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
219748827|NCT06010979|PROCEDURE|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
219748828|NCT06010979|PROCEDURE|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
219748829|NCT06010979|PROCEDURE|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
219748830|NCT06010979|PROCEDURE|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
219748831|NCT02362763|PROCEDURE|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
219748832|NCT05061836|DRUG|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
219748833|NCT05061836|DRUG|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
219748834|NCT05061836|DRUG|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
219369246|NCT00720928|DRUG|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
219369247|NCT00332709|DRUG|Letrozole|2.5 mg/day for 3 years
219369248|NCT00332709|DRUG|Zoledronic acid|4 mg every 6 months
219369249|NCT06549361|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
219748835|NCT05061836|DRUG|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
219369250|NCT05944536|OTHER|Balance Exercises (BE)|Each exercise was performed with 10 repetitions for both lower limbs.
219748836|NCT05050669|OTHER|No Intervention for this observational study|No Intervention for this observational study
219748837|NCT02884479|DRUG|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
219748838|NCT02884479|DRUG|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
219748839|NCT03292029|DIAGNOSTIC_TEST|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
219748840|NCT00538447|OTHER|Database|data base for CML
219748841|NCT04379830|DIETARY_SUPPLEMENT|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
219748842|NCT01522872|DRUG|TH-302|
219748843|NCT01522872|DRUG|TH-302 and Dexamethasone|
219748844|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
219748845|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
219748846|NCT04021745|BEHAVIORAL|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
219748847|NCT04412239|BEHAVIORAL|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
219748848|NCT02231580|DRUG|BN82451B|BN82451B capsule
219748849|NCT02231580|DRUG|Placebo|Placebo capsule
219748850|NCT05787015|BEHAVIORAL|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
219748851|NCT05787015|BEHAVIORAL|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
219748852|NCT04573985|BEHAVIORAL|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
219748853|NCT01533415|DEVICE|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
219748854|NCT01533415|DEVICE|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
219748855|NCT02843633|DEVICE|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
219748856|NCT02843633|DRUG|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
219369251|NCT05944536|OTHER|BE + Dual Task|Cognitive and motor secondary tasks were given
219369252|NCT05997355|DRUG|Gabapentin 600Mg Tab|A single preoperative dose of gabapentin 600mg
219748857|NCT05295472|BEHAVIORAL|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
219748858|NCT05295472|BEHAVIORAL|Vector|A computer game focusing on children's development of mathematic skills
219748859|NCT05295472|BEHAVIORAL|Usual schooling|No GL or Math computer games, only the usual schooling
219748860|NCT05006755|COMBINATION_PRODUCT|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
219748861|NCT05006755|COMBINATION_PRODUCT|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
219748862|NCT00997659|DIETARY_SUPPLEMENT|chromium picolinate|1000 mg per day
219748863|NCT05199844|DEVICE|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
219748864|NCT00480727|PROCEDURE|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
219748865|NCT00480727|PROCEDURE|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
219748866|NCT04980209|DEVICE|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
219748867|NCT02129621|PROCEDURE|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
219748868|NCT02129621|DRUG|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
219748869|NCT01793389|PROCEDURE|Subepithelial connective tissue graft|
219748870|NCT01793389|PROCEDURE|Platelet Rich Fibrin|
218991773|NCT05157984|PROCEDURE|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
218991774|NCT05120128|DEVICE|Acuvue® Oasys 1-Day|TEST Lens
218991775|NCT00674700|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
218991776|NCT00674700|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
218991777|NCT00674700|DRUG|Placebo tablet|One sublingual tablet daily for one year
218991778|NCT00684099|DRUG|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
218991779|NCT00684099|DRUG|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
218991780|NCT00395304|DRUG|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
218991781|NCT00395304|DRUG|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
218991782|NCT00395304|DRUG|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
219748871|NCT03286361|DEVICE|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
219748872|NCT04554836|DRUG|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
219748873|NCT04554836|OTHER|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
219748874|NCT05238740|OTHER|ViviGen®|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
219748875|NCT05238740|OTHER|rhBMP-2|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
219748876|NCT04355832|DRUG|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
219748877|NCT04355832|DRUG|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
219179035|NCT06801184|BIOLOGICAL|Stool Sample|Approximately 1 gram of stool will be collected by the patient at home within 72 hours following the inclusion consultation and the follow-up consultation at V2, using the kits provided along with the instructions. The stools will be immediately collected into two tubes: one tube with nucleic acid preservative and one tube conservative to ensure for future metabolomic analyses. The patient will then send the sample using the pre-paid envelope included in the kit to the HCL microbiota biobank (CRB GHN) for aliquoting and storage at -80°C.
219748878|NCT06507722|DIAGNOSTIC_TEST|Timing of OGTT|In Aim 1, timing of oral glucose tolerance test will be altered.
219748879|NCT06507722|BEHAVIORAL|Timing of Standardized Meal|In Aim 2, timing of a standardized meal will be altered.
219748880|NCT06212687|BEHAVIORAL|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
219748881|NCT06212687|BEHAVIORAL|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
219748882|NCT00471393|DRUG|1.5% diclofenac in 45.5% DMSO (topical treatment)|
219748883|NCT00471393|DRUG|45.5% DMSO (topical placebo)|
219748884|NCT04923672|BEHAVIORAL|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
219748885|NCT04923672|BEHAVIORAL|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
219748886|NCT05826626|DEVICE|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
219748887|NCT05826626|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
219748888|NCT05106062|DEVICE|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
219748889|NCT05080478|DRUG|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
219748890|NCT03989284|BEHAVIORAL|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
219748891|NCT00708981|OTHER|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
219748892|NCT02624479|DRUG|Sodium thiosulfate|oral administration of thiosulfate
219748893|NCT02689557|OTHER|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
219748894|NCT05026801|DRUG|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
219748895|NCT05852340|DRUG|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
219748896|NCT05694611|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
219748897|NCT05694611|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
219748898|NCT01955356|PROCEDURE|Scratching|Endometrial biopsy
219748899|NCT01765387|BEHAVIORAL|Spa session|
219748900|NCT02210676|OTHER|PROMIS Upper Extremity|
219748901|NCT02210676|OTHER|Likert Pain Scale|
219748902|NCT02210676|OTHER|Mallet Finger Extensor Lag Measurement|
219748903|NCT02236013|DRUG|Gilteritinib|Oral
219179036|NCT06802042|OTHER|Intervention with probiotic bacteria|The intervention group (n=20) received free intervention with probiotic bacteria (Lactobacillus reuteri DSM 8 +) for 4 weeks (1 bag bid)
219748904|NCT02236013|DRUG|Idarubicin|lyophilized powder administered intravenously
219748905|NCT02236013|DRUG|Cytarabine|solution administered intravenously
219748906|NCT02236013|DRUG|Daunorubicin|solution administered intravenously
219748907|NCT05363683|PROCEDURE|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
219748908|NCT05363683|PROCEDURE|Standard Care|The intervention group will receive standard care post-operative physical therapy.
219748909|NCT05852470|DEVICE|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
219748910|NCT05852470|DEVICE|Clareon Monofocal/Clareon Toric IOL|Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
219748911|NCT04665895|DRUG|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
219748912|NCT04665895|DRUG|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
219748913|NCT04665895|DRUG|Placebo|twice daily inhalation throughout the study
219748914|NCT06350110|BIOLOGICAL|CD19- BCMA CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
219748915|NCT04212923|BEHAVIORAL|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
219748916|NCT05942040|OTHER|Tailored Palliative Care Information|This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
219748917|NCT00123942|DRUG|MEDI-507|
219748918|NCT02542215|DRUG|Cobiprostone|Cobiprostone 30 mcg oral spray
219748919|NCT02542215|DRUG|Placebo|Matching placebo oral spray
219748920|NCT02542215|DRUG|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
219748921|NCT02542215|RADIATION|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
219748922|NCT01903863|BIOLOGICAL|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
219748923|NCT00403052|DRUG|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
219748924|NCT05951101|DEVICE|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
219748925|NCT04261985|BEHAVIORAL|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
219748926|NCT04906512|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
219748927|NCT04906512|DEVICE|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
219748928|NCT06570850|DRUG|Colistin Sodium Methanesulfonate|Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
219179037|NCT06802042|DRUG|Lactulose oral solution treatment|The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)
219179038|NCT06800378|DRUG|Zolpidem 10 mg|Zolpidem tartrate 10 mg tablet (taken before bedtime)
218991783|NCT01723488|RADIATION|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
218991784|NCT05246683|OTHER|observational|registry
218991785|NCT02938104|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
218991786|NCT02938104|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
218991787|NCT02938104|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
218991788|NCT06359392|OTHER|No message|Participants will not be exposed to a message in this arm of the intervention.
218991789|NCT06359392|OTHER|Culture-centric message|Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.
218991790|NCT06359392|OTHER|General messge|Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
218991791|NCT05391698|BEHAVIORAL|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
218991792|NCT05391698|COMBINATION_PRODUCT|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
218991793|NCT03432702|PROCEDURE|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
218991794|NCT00386048|BEHAVIORAL|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
218991795|NCT06011057|DIAGNOSTIC_TEST|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
219369253|NCT05726357|PROCEDURE|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
219369254|NCT00254410|DRUG|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
219748929|NCT06570850|DRUG|Colistin Sodium Methanesulfonate plus Fosfomycin|Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
218991796|NCT06011057|DIAGNOSTIC_TEST|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
218991797|NCT01272674|OTHER|exercise training|4 weeks supervised physical exercise training
218991798|NCT02543437|DEVICE|Trident Acetabular X3 Insert|
219179039|NCT06800378|OTHER|Placebo|Starch 10 mg tablet (taken before bedtime)
219179040|NCT06801951|OTHER|acute resistance exercise with oral nutrition supplementation|acute bout of resistance exercise on an isokinetic exercise machine of each limb (i.e., right and left arm and right and left leg) allowing control of velocity and force. Immediately upon completion, 1 serving of liquid nutrition supplement will be consumed. An additional serving of the liquid nutrition supplement will be sent home for consumption in the evening.
219369255|NCT00254410|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
219369256|NCT00254410|DRUG|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
219369257|NCT00254410|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
219369258|NCT00254410|DRUG|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
219369259|NCT06300515|BEHAVIORAL|Control Group (Active Comparator)|During the intervention phase (hospitalization for HSCT and subsequent 8-week outpatient phase following discharge), the control group will participate in a Health Counseling Program (1 time/week) on aspects related to a healthy lifestyle such as reducing sedentary lifestyle, acquiring healthy nutritional habits, the importance sleep, screen use, and how to address barriers related to clinical status. We will adapt the program to the needs and timing of the patient's treatment, providing the content in one session/week orally (e.g. using presentations) and in writing (e.g. through brochures).
219429089|NCT03049995|PROCEDURE|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
219429090|NCT03049995|PROCEDURE|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
219748930|NCT00220077|PROCEDURE|Endoscopy|
219748931|NCT03537508|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
219748932|NCT03537508|BIOLOGICAL|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
219748933|NCT03537508|BIOLOGICAL|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
219748934|NCT03537508|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
219748935|NCT03537508|BIOLOGICAL|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
219748936|NCT03537508|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
219748937|NCT03537508|BIOLOGICAL|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
219748938|NCT03537508|BIOLOGICAL|Varicella vaccine|Varicella vaccine at 12 months of age
219748939|NCT03537508|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
219748940|NCT04280588|DRUG|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
219748941|NCT01972659|DRUG|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
219748942|NCT01972659|DRUG|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
219748943|NCT01972659|DRUG|sugammadex|4 mg/kg iv bolus at the end of the surgery
219748944|NCT02399228|DRUG|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
219748945|NCT04983979|DRUG|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
218991799|NCT03797014|DRUG|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
219748946|NCT04983979|DRUG|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
219748947|NCT04144517|DRUG|Nemvaleukin Alfa|Nemvaleukin alfa IV infusion.
219748948|NCT04144517|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
219748949|NCT06811285|OTHER|Kinesiological Taping|The Kinesiological Taping group will receive two parallel I-shaped kinesiological taping applications.
219748950|NCT06811285|OTHER|Foot Massage Group|The Foot Massage Group will receive foot massage for 20 minutes.
219748951|NCT03292978|DIETARY_SUPPLEMENT|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
219748952|NCT03292978|DIETARY_SUPPLEMENT|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
219748953|NCT04928638|BEHAVIORAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
218991800|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
219748954|NCT04928638|BEHAVIORAL|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
219748955|NCT01003964|DRUG|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
219748956|NCT01003964|DRUG|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
219748957|NCT05307094|BEHAVIORAL|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
219748958|NCT03067636|BEHAVIORAL|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
219748959|NCT03067636|BEHAVIORAL|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
219748960|NCT03067636|BEHAVIORAL|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
219748961|NCT03664544|DRUG|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
219748962|NCT05147142|DEVICE|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
219748963|NCT06267417|DEVICE|Laser therapy|\- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
219748964|NCT06267417|DEVICE|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
218991801|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
219748965|NCT06656572|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
219748966|NCT06656572|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
219761812|NCT02414269|GENETIC|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
219748967|NCT06658236|OTHER|Proprioceptive Neuromuscular Facilitation|Group A will follow a PNF-based training protocol to enhance strength, flexibility, and coordination. The exercises include two main movement patterns: flexion-abduction-external rotation with the elbow extended and extension-adduction-internal rotation with the elbow extended. These patterns target the muscles around the shoulder and upper chest. A yellow Thera-Band adds light resistance, increasing muscle engagement. The protocol also employs the reversal of antagonists technique, alternating between opposing muscle groups for balanced development and improved coordination. Participants will complete three sets of ten repetitions per session, with a 60-second rest between sets. The program spans 12 weeks, with three weekly sessions, allowing for consistent progress and muscle recovery. This structured approach aims to improve functional mobility and the performance of activities involving similar movements, offering a comprehensive training strategy through PNF and resistance.
219748968|NCT06658236|OTHER|Chest Expansion Exercises|Group B participants followed a breathing-coordinated exercise protocol using a yellow Thera-Band to improve upper extremity function. The protocol began with subjects breathing generally at rest. They were then instructed to synchronize their movements with their breathing: performing upper extremity flexion, abduction, and external rotation during inhalation, followed by extension, adduction, and internal rotation during exhalation. This coordination between breathing and movement aimed to enhance muscle activation and control. Each session included three trials of ten repetitions for each exercise, with a 1-minute rest between trials. The protocol was conducted three times per week over 12 weeks. This approach was designed to promote strength, flexibility, and coordination in the upper body while integrating breath control, which may also support relaxation and better movement efficiency. The structured schedule ensures consistent practice and gradual improvement over the 12 weeks
219748969|NCT05472818|DRUG|[11C]APP311|For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
219748970|NCT06824493|OTHER|no interventions|no intervention as this is an observational studies
219748971|NCT06824493|OTHER|None-placebo|Observational study with no interventions
219748972|NCT06824493|OTHER|No Intervention: Observational Cohort|no intervention because of observational studies
219748973|NCT06605820|OTHER|None - Interview Only|None - Interview Only
219748974|NCT05336357|DEVICE|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
219748975|NCT01622478|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
219748976|NCT01622478|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
219748977|NCT01622478|PROCEDURE|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
219748978|NCT01622478|PROCEDURE|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
219748979|NCT05293314|DIAGNOSTIC_TEST|An exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
219748980|NCT06248710|DRUG|Oxytocin nasal spray|Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
219748981|NCT06248710|OTHER|Animal-Assisted Intervention|The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
219748982|NCT06248710|DRUG|Placebo|The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
219748983|NCT06611306|RADIATION|DE-iPTV|Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
219761813|NCT02414269|DRUG|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
219761814|NCT02414269|DRUG|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
219761815|NCT05606289|BEHAVIORAL|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
219761816|NCT06310213|DEVICE|Non-Invasive Pressure Monitor|Modified smart soft contact lens and cap with reader coil
219761817|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
219761818|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
219748984|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
219761819|NCT04047030|OTHER|None- Observational Study|No Intervention
219761820|NCT06136624|DRUG|Opevesostat|Administered orally
219761821|NCT06136624|DRUG|Abiraterone acetate|Administered orally
218991802|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
219761822|NCT06136624|DRUG|Enzalutamide|Administered orally
218991803|NCT01234285|DRUG|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
218991804|NCT01326143|DEVICE|ORM Narval MRD|
218991805|NCT05515081|PROCEDURE|blood sample collection|blood sample colletion at regular intervals
218991806|NCT02544399|OTHER|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
218991807|NCT04925362|OTHER|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
218991808|NCT04925362|OTHER|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
219006605|NCT02141243|PROCEDURE|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
219006606|NCT02141243|PROCEDURE|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
219179041|NCT06801951|OTHER|stable tracer infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
219179042|NCT05721560|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
219179043|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
219179044|NCT03496402|OTHER|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
219179045|NCT06778811|DRUG|Intraoperative infusion of dexmedetomidine|Intraoperative infusion of 0.3ug/kg/h dexmedetomidine
219429091|NCT03049995|PROCEDURE|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
219577705|NCT04576182|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
219179046|NCT06778811|DRUG|Intraoperative infusion of esketamine|Intraoperative infusion of 0.3mg/kg/h esketamine
219179047|NCT06778811|DRUG|Saline control|Intraoperative infusion of equal volumes of saline
219179048|NCT04855786|PROCEDURE|Thoracic duct drainage|drain placement into the thoracic duct
219179049|NCT05879211|BEHAVIORAL|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
219179050|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
219179051|NCT02359825|DRUG|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
219179052|NCT03676764|DRUG|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
219179053|NCT03676764|DRUG|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
219748985|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
219748986|NCT00835367|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
219748987|NCT00835367|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
218991809|NCT06069882|BEHAVIORAL|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
219748988|NCT04111601|DEVICE|Blue light imaging|Advanced virtual chromoendoscopy
219748989|NCT06606275|DRUG|Apixaban|Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
219748990|NCT06606275|DRUG|Warfarin|Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
219748991|NCT06606158|OTHER|Exercises program|Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.
218991810|NCT01090843|PROCEDURE|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
218991811|NCT01090843|DEVICE|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
219006607|NCT02141243|PROCEDURE|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
219577706|NCT04576182|BEHAVIORAL|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
219577707|NCT05758220|DEVICE|MRI|Structural MRI volumetry, resting functional MRI \& MR spectroscopy
219577708|NCT03647631|PROCEDURE|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
219748992|NCT06606158|OTHER|App exercises program|A strength, mobility, and balance exercise program delivered through a mobile app.
219748993|NCT06121856|DEVICE|VerioVue Enhancements BGMS|Blood glucose monitoring system
219748994|NCT06497946|BEHAVIORAL|SlimTrack Plataform|SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
219748995|NCT06497946|BEHAVIORAL|Diet prescription|Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
219748996|NCT05145816|DRUG|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
219748997|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
219748998|NCT05145816|DRUG|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
219748999|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
219749000|NCT05145816|DRUG|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
219749001|NCT05145816|DRUG|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
219761823|NCT06136624|DRUG|Hydrocortisone|Administered orally or IM as a rescue medication
219761824|NCT06136624|DRUG|Fludrocortisone acetate|Administered orally
219761825|NCT06136624|DRUG|Prednisone|Administered orally
219761826|NCT06136624|DRUG|Dexamethasone|Administered orally as rescue medication
218991812|NCT01090843|DEVICE|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
218991813|NCT01970397|DEVICE|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
218991814|NCT01970397|DEVICE|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
218991815|NCT05542160|DIETARY_SUPPLEMENT|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
218991816|NCT04246450|DEVICE|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
218991817|NCT02782637|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
219369260|NCT06300515|BEHAVIORAL|Intervention Group|"Same as Control Group + exercise program as described below:~Same as Control Group + exercise program as described below:~Hospital ward (during HSCT); and Hospital Gym or online (patients' home) during the outpatient phase. Frequency: 3-5 days/week. Session duration: 30 to 55-60 minutes Aerobic training (5-25 minutes): bicycling, crank-ergometry, circuit-style exercises, and games. Muscle strength training (10-20 minutes): large muscle group exercises (upper/lower limb + trunk exercises) performed as a circuit using body weight or against resistance (against gravity and with body weight, elastic bands, dumbbells, weighted vests, machines), with a wide range of joint mobility and at submaximal/maximum voluntary speed. Inspiratory muscle training will also be performed (5 min daily, using a specific device that creates resistance against inspiration)."
219369261|NCT03584763|DIAGNOSTIC_TEST|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
219369262|NCT04226469|PROCEDURE|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
219761827|NCT03033303|BIOLOGICAL|Hu3F8|Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
218991818|NCT03716037|OTHER|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
218991819|NCT01850875|BEHAVIORAL|Eye-Movement-Desensitization-Reprocessing|
218991820|NCT00681083|DEVICE|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
218991821|NCT00681083|DEVICE|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
218991822|NCT01524471|PROCEDURE|Per Oral Endoscopic Myotomy|
218991823|NCT06431087|OTHER|Mindfulness course|Online or in presence Information on Mindfulness, healthy diet and exercise.
218991824|NCT04614597|BIOLOGICAL|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
219006608|NCT01635946|DRUG|Isavuconazole|oral
219006609|NCT01635946|DRUG|atorvastatin|oral
219006610|NCT04614740|DRUG|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
219006611|NCT00118365|OTHER|placebo|Given orally
219006612|NCT00118365|DRUG|eflornithine|Given orally
219006613|NCT00118365|DRUG|sulindac|Given orally
219006614|NCT00118365|OTHER|laboratory biomarker analysis|Correlative studies
219006615|NCT02637453|PROCEDURE|PVI|Pulmonary vein isolation
219006616|NCT02637453|PROCEDURE|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
219006617|NCT00547092|DRUG|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
219006618|NCT00547092|DRUG|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
219006619|NCT04480437|DEVICE|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
219006620|NCT05156853|DIETARY_SUPPLEMENT|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
219006621|NCT05156853|DIETARY_SUPPLEMENT|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
219006622|NCT00003170|DIETARY_SUPPLEMENT|glutamine|
219006623|NCT00003170|OTHER|placebo|
219006624|NCT01432353|DRUG|DFRF4539A|multiple ascending doses
219006625|NCT03829150|DRUG|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
219006626|NCT03829150|DRUG|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
219749002|NCT06617806|OTHER|Follow-up by the Advanced Practice Nurse|"At each follow-up (FU), the recommendations of an APN may include :~* Referral to a specialized memory assessment in case of cognitive impairment~* Psychological FU in the event that APN detects any mood complaints~* Ophthalmological and/or ear, nose, and throat consultation if any auditory or visual difficulties is observed~* Compression stockings use if orthostatic hypotension is present~* Nutritional counseling, with particular emphasis on the intake of protein, in combination with long-term assessment of weight~* Supplementation with vitamin D and calcium based to prevent osteoporosis in older adults, especially those at risk of recurrent falls~* Proposal of a standardized and personalized physical activity program~* Evaluation of medication therapies, especially antipsychotics, blood pressure medication or broad anticholinergics. The STOPPFall tool will be also proposed and coordinated by APN in accordance with the patient's physician~* A comprehensive social evaluative approach"
218991825|NCT04433377|PROCEDURE|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
219749003|NCT06675409|OTHER|Education|The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
219749004|NCT06674317|BEHAVIORAL|Internet Delivered Cognitive Behavioral Therapy for Insomnia in Persons with Inflammatory Rheumatic Diseass|"Cognitive behavioral therapy for insomnia (CBTi) is considered a first-line treatment for insomnia. Access to this treatment option is limited therefore we have been developing an internet delivered cognitive behavioral therapy for insomnia (I-CBTi) to help overcome accessibility barriers.~The purpose of this study is to pilot test a tailored internet-delivered cognitive behavioral therapy for insomnia (I-CBTi) intervention for persons with Inflammatory Rheumatic Diseases showing symptoms of insomnia."
219749005|NCT06674005|OTHER|Cucurbita pepo L. Flowers Extract|2 mg twice per day for 1 month
219749006|NCT06674005|OTHER|Placebo|2 mg twice per day for 1 month
219749007|NCT03790956|PROCEDURE|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
219749008|NCT04112368|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
218991826|NCT04433377|PROCEDURE|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
218991827|NCT01389817|DEVICE|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
218991828|NCT02251184|DRUG|Aggrenox|
218991829|NCT02251184|DRUG|Dipyridamole|
219369263|NCT00689247|DRUG|AZD1305|oral solution, single dose
219749009|NCT04112368|DRUG|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
219749010|NCT04112368|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
219749011|NCT04112368|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
219749012|NCT04501718|DRUG|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
219761828|NCT03033303|DRUG|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
218991830|NCT02251184|DRUG|Aspirin|
218991831|NCT02251184|DRUG|Lansoprazole|
218991832|NCT01023620|DRUG|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
218991833|NCT01023620|OTHER|Observation|Participants will be observed for 16 weeks but will not receive drug
218991834|NCT05902455|PROCEDURE|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
219761829|NCT03033303|DRUG|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
219369264|NCT00689247|DRUG|AZD1305|iv infusion, single dose
219369265|NCT01035190|DRUG|Budesonide|Inhalation, 200 µg/puff
219369266|NCT01409928|DEVICE|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
219369267|NCT05378009|BEHAVIORAL|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
218991835|NCT05535699|OTHER|exercises|scapular exercise
218991836|NCT00970567|BEHAVIORAL|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
218991837|NCT02613975|DEVICE|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
218991838|NCT03346278|BEHAVIORAL|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
218991839|NCT02298920|DRUG|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
219749013|NCT06598761|COMBINATION_PRODUCT|Immunotherapy+radiotherapy|"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
219749014|NCT06598761|OTHER|surveillance alone|Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
218991840|NCT05878145|BEHAVIORAL|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
218991841|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
218991842|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
218991843|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
218991844|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
218991845|NCT05389397|BEHAVIORAL|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
218991846|NCT02050191|BEHAVIORAL|www.princetonlivingwell.com|
218991847|NCT02871297|DRUG|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
219369268|NCT05378009|BEHAVIORAL|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
219577709|NCT05311761|OTHER|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
219577710|NCT05449509|DIAGNOSTIC_TEST|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
219577711|NCT00631852|DRUG|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
219577712|NCT04629859|PROCEDURE|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
219577713|NCT04629859|PROCEDURE|mandibular setback|12 patients will undergo mandibular setback
219577714|NCT05859399|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
219577715|NCT00621036|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219577716|NCT00621036|BIOLOGICAL|sargramostim|
219577717|NCT00621036|DRUG|methotrexate|
219577718|NCT00621036|DRUG|thiotepa|
219577719|NCT00621036|RADIATION|radiation therapy|
219577720|NCT06537804|RADIATION|Screening by low-dose CT scan|Screening for lung cancer by low-dose CT scan
219577721|NCT06172855|DEVICE|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
219577722|NCT04571892|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
219577723|NCT03380559|DRUG|Injection, botulinum toxin + corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
219577724|NCT03380559|DRUG|Injection, placebo of toxin + corticoid|"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
219577725|NCT03380559|DRUG|Injection, botulinum toxin + placebo corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
219577726|NCT04121650|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
219577727|NCT02836834|BIOLOGICAL|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
219577728|NCT04683237|DRUG|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
219577729|NCT04683237|DRUG|Megestrol Acetate 160 MG|160mg po qd
218991848|NCT01559597|BIOLOGICAL|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
218991849|NCT03700775|OTHER|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
218991850|NCT01740193|PROCEDURE|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
218991851|NCT01740193|PROCEDURE|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
218991852|NCT05279183|DIETARY_SUPPLEMENT|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
219749015|NCT02549820|DEVICE|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
218991853|NCT05279183|DIETARY_SUPPLEMENT|Sucrose|30 g sucrose dissolved in 300 mL tap water.
218991854|NCT05279183|DIETARY_SUPPLEMENT|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
218991855|NCT00933972|DRUG|RO4998452|20mg po single dose
218991856|NCT03439553|BEHAVIORAL|Ads display with target websites|Ads are shown, but users are referred to control websites.
218991857|NCT03439553|BEHAVIORAL|Ads display with control websites|Ads are shown, but users are referred to control websites.
218991858|NCT00277147|DRUG|BB IND 6989|
218991859|NCT03918122|OTHER|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
218991860|NCT00838396|DRUG|XP19986 CR|
218991861|NCT00838396|DRUG|Placebo for XP19986 CR|
219749016|NCT06266351|DEVICE|This is observational IOP measurement|IOP measurement of patients having LASIK with both CATS and GAT
218991862|NCT02417831|DRUG|tamsulosin capsules|
218991863|NCT02417831|DRUG|tamsulosin HCl|
218991864|NCT04922775|PROCEDURE|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
219557683|NCT06024343|PROCEDURE|MPD Exposure, Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
219749017|NCT06676085|DRUG|Nafamostat|Nafamostat combined with unfractionated heparin for anticoagulation
219749018|NCT06676085|DRUG|Heparin|unfractionated heparin for anticoagulation
219749019|NCT06609304|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel at 2.0×10\^6/Kg
219749020|NCT06279130|DRUG|botensilimab|Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
219749021|NCT06279130|DRUG|balstilimab|Anti programmed cell death protein-1 (anti-PD1)
219749022|NCT07004296|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
219749023|NCT03592264|DRUG|OBI-3424|liquid formulation for Intravenous infusion
219749024|NCT07004608|BEHAVIORAL|Aalana Palana|Alan Palana is a facilitated video viewing intervention which promotes responsive and sensitive parenting, early learning opportunities and desired nutritional practices for young children and pregnant women. The content not only describes 'WHAT' behaviours caregiver should adopt, 'HOW' they could include these behaviours in their routines but also 'WHY' a particular behaviour is important for their child's development.
219749025|NCT06919471|OTHER|Fitbit|Wear it on wrist
218991865|NCT04922775|PROCEDURE|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
218991866|NCT00209469|DRUG|alendronate sodium|
219749026|NCT06919471|OTHER|MySnackTracker App|App to track your dietary intake
219749027|NCT06679478|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol|The intervention is applied from the first day after surgery until discharge. (including the day of discharge).
219749028|NCT07006025|DRUG|Decitabine|Oral tetrahydrouridine and oral decitabine capsule
219749029|NCT06675266|DIAGNOSTIC_TEST|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester screening scan|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester of pregnancy
219761830|NCT02585323|BEHAVIORAL|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
219761831|NCT02585323|BEHAVIORAL|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
219761832|NCT06072482|DRUG|Avacopan|Administered orally.
219749030|NCT06675032|BIOLOGICAL|PCV24 formulation 1|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
218991867|NCT00813306|DRUG|AZD2066|13 mg oral solution, 1 single dose
219761833|NCT06072482|DRUG|Placebo|Administered orally.
218991868|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
218991869|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
218991870|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
218991871|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
218991872|NCT02587234|DEVICE|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
218991873|NCT04036344|BEHAVIORAL|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
218991874|NCT00523016|PROCEDURE|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
218991875|NCT00523016|PROCEDURE|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
218991876|NCT01367210|DRUG|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
218991877|NCT01367210|DRUG|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
218991878|NCT00030810|RADIATION|Hyperfractionated|Hyperfractionated radiotherapy
218991879|NCT00030810|DRUG|Taxotere/Cisplatin|Taxotere/Cisplatin
218991880|NCT00030810|PROCEDURE|conventional surgery|conventional surgery
218991881|NCT01415284|DRUG|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
218991882|NCT04381403|OTHER|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
218991883|NCT04381403|OTHER|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
218991884|NCT03180723|DRUG|Rituximab|Intravenous injection
218991885|NCT03180723|DRUG|Cyclosporin|Oral tablets
219761834|NCT06072482|DRUG|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
218991886|NCT03780855|DEVICE|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
218991887|NCT01228760|DRUG|ASG-5ME|IV
218991888|NCT03068130|DRUG|Bardoxolone methyl|Capsules of Bardoxolone methyl
218991889|NCT01144286|DRUG|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
218991890|NCT01144286|DRUG|placebo|placebo, single dose
219557684|NCT04937647|OTHER|collection of endoscopic images and videos|collection of endoscopic images and videos
219557685|NCT03847974|DRUG|LIB003|300 mg SC Q4W
219557686|NCT06679673|DRUG|SHR-1701|SHR-1701
218991891|NCT03779802|OTHER|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
218991892|NCT02380781|BEHAVIORAL|Information in the form of a video|see intervention description
218991893|NCT04314336|DRUG|Public procurement|Cost minimisation study through public procurement
218991894|NCT04314336|DRUG|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
218991895|NCT02835820|DIETARY_SUPPLEMENT|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
218991896|NCT02272491|DEVICE|ZrO2 (Straumann CARES)|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
218991897|NCT02272491|DEVICE|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
219006627|NCT03829150|DRUG|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
219006628|NCT03829150|DRUG|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
219006629|NCT03221400|DRUG|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
219006630|NCT03221400|DRUG|fluorouracil|Fluorouracil 2400 mg/m2 IV
219557687|NCT06679673|DRUG|BP102|BP102
219557688|NCT06679673|DRUG|SHR2554|SHR2554
219749031|NCT06675032|BIOLOGICAL|PCV24 formulation 2|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
219749032|NCT06675032|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine:Dosage form: Injection Specification:0.5 mL/strip Dosage: The preferred site for infants is the anterolateral thigh (lateral femoral muscle), and for toddlers and children, the deltoid muscle of the upper arm.~Dosing schedule:6 weeks months: 4 doses, one dose each of basic immunization at 2, 4, and 6 months of age, and one dose of booster immunization at 12-15 months of age, with the earliest of the first dose being given at 6 weeks of age. The first dose should be given at 6 weeks of age at the earliest."
219761835|NCT04578834|DRUG|Placebo|Placebo to LNP023 200mg b.i.d
219761836|NCT04578834|DRUG|LNP023|LNP023 200mg b.i.d
219761837|NCT03997370|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219761838|NCT03997370|DRUG|Carboplatin|Given IV
218991898|NCT03554746|OTHER|GC group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation"
218991899|NCT03554746|OTHER|CG group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps"
218991900|NCT05066113|DEVICE|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
218991901|NCT02478996|OTHER|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
218991902|NCT02367183|DRUG|GED-0301|
218991903|NCT02367183|DRUG|Placebo|
218991904|NCT06145061|DEVICE|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
218991905|NCT01925053|OTHER|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
218991906|NCT01925053|OTHER|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
218991907|NCT04985097|PROCEDURE|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
218991908|NCT00286403|DRUG|Fenoldopam Mesylate and/or MESNA|
218991909|NCT00332007|DRUG|Tonabersat|two tablets once daily
218991910|NCT00332007|DRUG|Placebo|two tablets once daily
218991911|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
218991912|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
219761839|NCT03997370|DRUG|Iohexol|Given IV
219761840|NCT06580314|BIOLOGICAL|Bevacizumab|Given IV
218991913|NCT04568070|DIAGNOSTIC_TEST|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
218991914|NCT04568070|DIAGNOSTIC_TEST|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
218991915|NCT04568070|DIAGNOSTIC_TEST|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
219006631|NCT03221400|DRUG|Folinic acid|Folinic acid 400 mg/m2 IV
219006632|NCT03221400|DRUG|Niraparib|Niraparib
219761841|NCT06580314|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761842|NCT06580314|PROCEDURE|Computed Tomography|Undergo CT
219749033|NCT06675032|BIOLOGICAL|Sodium Chloride Injection|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
219749034|NCT06675318|OTHER|Cross training for quadriceps muscle of contralateral lower limb|An isokinetic exercise program consisting of 20 sessions conducted five days a week. The program begins with five repetitions at a speed of 60°/s, followed by sets of 5-15 repetitions with incremental increases of 30°/s. Rest periods of 30 seconds were included between sets.
219749035|NCT06675318|OTHER|Quadriceps isometric exercises, along with hot pack and TENS for painful knee|10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee
218991916|NCT04568070|DIAGNOSTIC_TEST|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
218991917|NCT01876797|DRUG|ticagrelor/prasugrel|
218991918|NCT02268344|DEVICE|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
218991919|NCT03039283|DEVICE|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
218991920|NCT01207791|BEHAVIORAL|screening|Brief screening to assess eligibility and collect minimal baseline data
218991921|NCT01207791|BEHAVIORAL|assessment|comprehensive substance use assessment
218991922|NCT01207791|BEHAVIORAL|referral|referral to treatment if indicated or requested
219749036|NCT06673719|RADIATION|99mTc-pertechnetate SPECT/CT|This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.
219749037|NCT06673719|PROCEDURE|Combined High-Resolution Manometry-Nutrient Drink Test|Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
219749038|NCT06674239|BEHAVIORAL|Patient Follow-up and Evaluation Form, Patient Information Form Healthy Lifestyle Behaviors Scale Education Booklet|"In the experimental phase of the study, an informed consent form, patient information form, healthy lifestyle behaviors scale, patient follow-up and evaluation form and education booklet were used.~Patient Information Form: This form was developed by the researchers. Healthy Lifestyle Behaviors Scale: The scale, which measures the health-promoting behaviors associated with the individual's healthy lifestyle, consists of a total of 52 items.~Patient Follow-up and Evaluation Form: Metabolic value tests are routinely requested in the institution.~Education Booklet: An education booklet was created based on the literature and the opinions of three experts.~Data collection method: Individualized education was given to the experimental group. Then, the Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
218991923|NCT01207791|BEHAVIORAL|Brief intervention|30-minute brief intervention session in ED
218991924|NCT01207791|BEHAVIORAL|booster sessions|two 15-minute booster counseling sessions conducted by telephone
218991925|NCT01867424|DRUG|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
219761843|NCT06580314|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761844|NCT06580314|DRUG|Olaparib|Given PO
219761845|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
219761846|NCT05511363|DRUG|Placebo|Placebo Capsules
218991926|NCT00189982|DRUG|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
218991927|NCT01056653|BEHAVIORAL|Standard Dose|Two intevention home visits
218991928|NCT01056653|BEHAVIORAL|High Dose|Four intervention home visits
218991929|NCT01056653|BEHAVIORAL|Comparison Group|One home visit, information only
218991930|NCT06081205|OTHER|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
218991931|NCT05614830|OTHER|Dry needling ,|The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
218991932|NCT05614830|OTHER|usual physical therapy program|Therapeutic exercise
218991933|NCT05634720|DRUG|HA Chemotherapy|Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).
218991934|NCT04260256|DRUG|[18F]F-AraG|\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
218991935|NCT00905411|BEHAVIORAL|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
218991936|NCT06485765|OTHER|Diet planning|Healthy eating planning
218991937|NCT04907656|BEHAVIORAL|dCBT|As per arm of the same name
218991938|NCT06383819|DRUG|Longidaza®|dose 3000 IU intramuscularly once every 5 days, 15 injections
218991939|NCT06383819|DRUG|Placebo|intramuscularly once every 5 days, 15 injections
218991940|NCT02980497|OTHER|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
218991941|NCT02980497|OTHER|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
218991942|NCT05386680|GENETIC|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
218991943|NCT03197454|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
219749039|NCT06674252|OTHER|Jiawei Bufei Tang granules|"Jiawei Bufei Tang is a traditional Chinese medicine formula applied by Professor Li Pingping to patients with lung cancer and qi yin deficiency syndrome. It consists of Huangqi, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Ziyuan, Mulberry bark, Snake berry, Half branch Lotus, White Hedyotis diffusa, etc. Bu Fei Tang is derived from the Yuan Dynasty's Yong Lei Ling Fang and consists of six ingredients: ginseng, astragalus, schisandra, Radix Rehmanniae, Ziyuan, and mulberry bark. It is mainly used to treat cough caused by lung qi deficiency. Jiawei Bufei Tang adds white Hedyotis diffusa, Scutellaria barbata, and snake berry to the original formula. White Hedyotis diffusa is more effective in dispelling carbuncles and detoxifying, Scutellaria barbata is more effective in dispelling phlegm and diuresis, and snake berry is more effective in dispelling scrofula and dispersing nodules, increasing the effect of clearing heat and detoxifying. This formula is particularly e"
219749040|NCT06674252|DRUG|Placebo|placebo
218991944|NCT03197454|OTHER|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
218991945|NCT05167929|BEHAVIORAL|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
218991946|NCT05167929|BEHAVIORAL|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
218991947|NCT05167929|BEHAVIORAL|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
219761847|NCT05008848|BEHAVIORAL|Smoking Cessation Intervention|Participate in schedule gradual reduction program
218991948|NCT06354309|OTHER|Virtual reality game|Pre and post control study after use virtual reality game
218991949|NCT04868214|DEVICE|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
218991950|NCT05276531|DRUG|subcutaneous progesterone|clinical pregnancy rates
218991951|NCT05276531|DRUG|vaginal progesterone|clinical pregnancy rates
218991952|NCT03727230|OTHER|Blood transfusion|Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
218991953|NCT03471520|BEHAVIORAL|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
218991954|NCT01373242|DRUG|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
218991955|NCT02699814|BEHAVIORAL|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
218991956|NCT02393183|DRUG|ASTED|A tablet of ASTED will be taken twice a day
218991957|NCT02393183|DIETARY_SUPPLEMENT|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
219761848|NCT05008848|OTHER|Health Promotion and Education|Receive cessation support messages
219761849|NCT05008848|OTHER|Informational Intervention|Receive NCI's Clearing the Air booklet
219761850|NCT05008848|OTHER|Questionnaire Administration|Ancillary studies
218991958|NCT02393183|OTHER|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
218991959|NCT05876975|PROCEDURE|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
218991960|NCT01186965|BEHAVIORAL|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
218991961|NCT02616081|OTHER|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
218991962|NCT02616081|OTHER|Indwelling Catheter|Indwelling catheterization is a standard of care.
218991963|NCT02616081|OTHER|Surgery|Bladder surgery is a standard of care.
218991964|NCT02616081|OTHER|Voiding|Voiding spontaneously is a standard of care.
218991965|NCT06643286|DEVICE|Digizorg Melanoma app|The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.
218991966|NCT04377620|DRUG|Placebo|Placebo administered BID approximately 12 hours apart
218991967|NCT04377620|DRUG|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
218991968|NCT02966262|DEVICE|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
219006633|NCT01759667|OTHER|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
219006634|NCT05976750|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
219006635|NCT05976750|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
219761851|NCT05702853|DRUG|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
219761852|NCT05702853|DRUG|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
219749041|NCT06673732|OTHER|Muscle Energy Technique with Stationary Bi-Cyclying|"MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition.~For PFS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times. Stationary cycling complements the routine."
219749042|NCT06673732|OTHER|Muscle Energy Technique without Stationary Cycling|MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition. Post FS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times without Stationary Cycling
219749043|NCT06674434|OTHER|Mobilization with Movement|Mobilization with Movement (MWM) is a manual therapy technique that combines active, patient-directed movements with passive joint mobilization to treat tennis elbow. To find joint restrictions or dysfunctions, a comprehensive patient assessment is the first step in the process. While the patient was in a supine position with the elbow fully extended and the forearm pronated, the therapist applied a sustained lateral glide of the forearm and stabilized the distal portion of the arm. While the patient asked to make a fist, the therapist kept up the lateral glide. Each session included three sets of movement-based mobilizations, each with ten repetitions. The entire course of treatment consists of twelve sessions.
218991969|NCT05199181|PROCEDURE|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
218991970|NCT00199680|PROCEDURE|PET|
218991971|NCT01236482|DRUG|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
218991972|NCT03452423|PROCEDURE|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
218991973|NCT03738683|DRUG|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
218991974|NCT05731895|DRUG|BI 425809 (iclepertin)|BI 425809 (iclepertin)
218991975|NCT03379805|DIAGNOSTIC_TEST|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
218991976|NCT03379805|DIAGNOSTIC_TEST|Non-contrast MRI|The anatomy is described using non-contrast MRI.
218991977|NCT03379805|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
219557689|NCT06464874|PROCEDURE|Conventional ESD|Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
218991978|NCT01885403|DEVICE|non-invasive respiratory parameter measurements|
218991979|NCT02324296|DRUG|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
218991980|NCT03768414|DRUG|Cisplatin|Given IV
218991981|NCT03768414|DRUG|Gemcitabine Hydrochloride|Given IV
218991982|NCT03768414|DRUG|Nab-paclitaxel|Given IV
218991983|NCT06181331|BEHAVIORAL|eConquerFear|The key goals of this e-intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
218991984|NCT06181331|BEHAVIORAL|eHealthMaintenance|eHealthMaintenance is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
218991985|NCT06181331|BEHAVIORAL|ConquerFear|ConquerFear is an intensive version of eConquerFear, which consists of 6 face-to-face therapist-led sessions.
218991986|NCT06181331|BEHAVIORAL|eConquerFear+eHealthMaintenance|The combination of eConquerFear and eHealthMaintenance interventions, that consists of 10 weekly online modules.
218991987|NCT06249165|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
218991988|NCT03566888|DEVICE|Blood pressure assessment|Validation of an automated blood pressure device
219749044|NCT06674434|OTHER|Sustained Stretch|The basic concept of stretching involves lengthening the tendon during a state of relaxation. To stretch the Extensor Carpi Radialis Brevis tendon, the following position should be adopted: the elbow should be extended, the forearm in a pronated position, the wrist flexed, and the wrist should also be ulnar deviated, based on the patient's comfort level. This position should be maintained for 30 to 45 seconds and repeated three times before and after exercises in each treatment session, with a 30-second rest period in between.
219749045|NCT06673576|DIAGNOSTIC_TEST|Complete crown technique for superimposition|the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.
219749046|NCT06673576|DIAGNOSTIC_TEST|Gold standard technique for superimposition|the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
219749047|NCT06675851|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
218991989|NCT04454294|OTHER|Control|"Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
218991990|NCT04454294|OTHER|Experimental Group (Absorption Group)|"1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
218991991|NCT04454294|OTHER|Experimental Group (Milking Group)|"1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
218991992|NCT03633656|DEVICE|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
219749048|NCT06675851|DRUG|Cipralex (escitalopram)|Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
218991993|NCT03633656|DEVICE|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
218991994|NCT03628820|BEHAVIORAL|Dog Therapy|5 minutes spent with therapy dog during shift
219749049|NCT07011394|DIAGNOSTIC_TEST|FeNO|FeNO will be measured before the bronchial provocation test using a FeNO VIOX device
219749050|NCT07011394|DIAGNOSTIC_TEST|Blood eosinophil count|a blood test will be performed om the day of bronchial provocation test
219557690|NCT06464874|PROCEDURE|Hybrid ESD|Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
219557691|NCT02879773|RADIATION|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
219749051|NCT07010172|DEVICE|cognitive rehabilitation with computer software|3-5 sessions per week, 4 weeks cognitive rehabilitation with computer software
219749052|NCT07010640|OTHER|Video Instrctions|Video instructions of rehabilitation techniques and movements to help with adherence and compliance to treatment.
219749053|NCT07011069|PROCEDURE|ESP block group|ESP blocks are performed for patients undergoing VATS.
219749054|NCT07011069|PROCEDURE|RISS block group|RISS blocks are performed for patients undergoing VATS.
219749055|NCT06674044|GENETIC|Atorvastatin|Atorvastatin 10mg once a day for 1 month
219749056|NCT07010445|OTHER|Naïve: epilepsy first diagnosis, anti-epileptic drugs; DRE-surgery: resective surgery; DRE-VNS: vagal nerve stimulation; DRE-KD: ketogenic diet.|Anti-epileptic drugs, resective surgery, vagal nerve stimulation or ketogenic diet.
219749057|NCT07010510|DIAGNOSTIC_TEST|CMR, stress ECG, Holter, BnP|"This study involves no experimental intervention. All data were collected retrospectively from patients with repaired Tetralogy of Fallot (TOF) who underwent standard clinical follow-up. As part of routine care, patients received comprehensive multimodal functional assessment, including:~Cardiac Magnetic Resonance Imaging (CMR) with feature-tracking strain analysis~Transthoracic Echocardiography~Exercise stress testing (treadmill ECG using Bruce protocol)~12-lead ECG and 24-hour Holter monitoring~Laboratory evaluation including NT-proBNP levels~NYHA functional class assessment"
219749058|NCT07011355|OTHER|Stress Ball|"Targeted Sensory Stimulus Type - Proprioceptive Input Based Mechanism:~Stress ball application is aimed at regulating the nervous system, especially through proprioceptive and tactile (tactile) stimuli. In this respect, it differs from methods such as aromatherapy, music therapy or breathing exercises, which are more effective through the sensory, emotional or autonomic nervous system."
219749059|NCT06678581|DRUG|SAP-001|Solid Oral Tablet
219749060|NCT06678581|DRUG|Placebo|Solid Oral Tablet
219749061|NCT06678568|OTHER|telemedicine follow-up in 3rd week|Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
218991995|NCT03628820|BEHAVIORAL|Coloring|5 minutes spend coloring mandalas during shift
218991996|NCT05743582|PROCEDURE|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
218991997|NCT05743582|PROCEDURE|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
218991998|NCT05375734|DRUG|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
218991999|NCT06463613|DEVICE|STR Skin Tag Removal device with diary and follow-up|The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.
218992000|NCT05774236|DEVICE|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
218992001|NCT05774236|DRUG|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
218992002|NCT06394310|DEVICE|Dry needling|The dry needling technique will employ in the current proposed study follows the standard technique for needling patients with spasticity
218992003|NCT06394310|DEVICE|Sham dry needling|In the control group, The investigators will use the methods proposed by Cushman et al. to apply sham dry needling (DN) to our participants
218992004|NCT03947450|BIOLOGICAL|Autologous Skin Fibroblasts|The site or whole stump will be injected with autologous fibroblasts
218992005|NCT03947450|BIOLOGICAL|Placebo|The site or whole stump will be injected medium only without autologous skin fibroblasts
219749062|NCT03267849|OTHER|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
219749063|NCT05156528|BIOLOGICAL|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
219749064|NCT05156528|BIOLOGICAL|Placebo|Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
219749065|NCT06687447|OTHER|Oxycotin Massage Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. At this stage, the patient will receive an oxytocin massage for 10 minutes while in a sitting position. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
219749066|NCT06687447|OTHER|Reflexology Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed women who want to participate in the study, and pre-test data will be collected. The pre-test data of the research were it will be collectedapproximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured. In practice; The foot is first relaxed and warmed up with passive movements, then the sole of the foot is scanned with the thumb walking crawling technique. The application will be applied first to the right foot for 10 minutes and then to the left foot for a total of 20 minutes. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again and uterine involution and physiological parameters will be evaluated.
218992006|NCT06253572|OTHER|Education|"Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time."
218992007|NCT03044678|BEHAVIORAL|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
218992008|NCT03044678|BEHAVIORAL|Self-Study|Books for youth about anxiety management
218992009|NCT03851705|DRUG|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
218992010|NCT03851705|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
218992011|NCT03851705|DRUG|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
218992012|NCT05188911|DRUG|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
218992013|NCT05188911|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
218992014|NCT05188911|DRUG|Androgen deprivation therapy|Patients would get medical or surgical castration.
219557692|NCT01288924|DRUG|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
219749067|NCT06687447|OTHER|Control Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. Patients in the control group will not undergo any intervention and will receive their routine care. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
219749068|NCT03035214|DRUG|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
219749069|NCT05950438|PROCEDURE|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
218992015|NCT05369637|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
218992016|NCT05369637|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
218992017|NCT05369637|BEHAVIORAL|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
218992018|NCT05369637|BEHAVIORAL|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
218992019|NCT05369637|OTHER|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
218992020|NCT06506708|OTHER|Hydrotherapy + massage|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
218992021|NCT01755078|DRUG|Sevelamer HCl|Non-metal phosphate binder
218992022|NCT01755078|DRUG|Calcium-based phosphate binder|
218992023|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
218992024|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
218992025|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
218992026|NCT06340373|DEVICE|DCB Angioplasty|Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
218992027|NCT05249374|DRUG|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
218992028|NCT05249374|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
218992029|NCT04273204|DIAGNOSTIC_TEST|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
218992030|NCT03031314|DEVICE|barbed suture|
219557693|NCT01288924|OTHER|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
219749070|NCT05898594|PROCEDURE|Low-dose Computed Tomography|Per standard care
219749071|NCT04030650|OTHER|Functional analyses|2-minute walking test 200-metre walking test
219749072|NCT04030650|OTHER|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
218992031|NCT03031314|DEVICE|standard suture|
218992032|NCT00864383|DRUG|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
218992033|NCT02197520|DRUG|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
218992034|NCT02197520|DRUG|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
218992035|NCT02197520|DRUG|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
218992036|NCT00158158|DRUG|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
218992037|NCT00158158|OTHER|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
218992038|NCT01306942|DRUG|Dasatinib|
218992039|NCT01306942|DRUG|Trastuzumab|
218992040|NCT01306942|DRUG|Paclitaxel|
218992041|NCT05827510|DEVICE|BTL-585F|BTL-585F device with BTL-585-4 applicator
218992042|NCT05641324|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
218992043|NCT05641324|DRUG|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
218992044|NCT05641324|DRUG|Daratumumab|Daratumumab administered by subcutaneous injection
218992045|NCT03676010|OTHER|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
218992046|NCT03676010|OTHER|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
219749073|NCT04030650|OTHER|Functional analyses|400-metre walking test 200-metre walking test
219749074|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
219749075|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
218992047|NCT03676010|OTHER|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
218992048|NCT03676010|OTHER|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
218992049|NCT03676010|OTHER|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
218992050|NCT03676010|OTHER|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
218992051|NCT02880059|DEVICE|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
218992052|NCT01271062|PROCEDURE|gastric bypass surgery|
218992053|NCT01271062|PROCEDURE|abdominal surgery|
218992054|NCT01271062|BEHAVIORAL|very low caloric diet|
218992055|NCT02574468|DRUG|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
218992056|NCT02574468|PROCEDURE|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
218992057|NCT03240302|DEVICE|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
218992058|NCT03240302|DEVICE|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
218992059|NCT01422018|DRUG|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
218992060|NCT04411654|GENETIC|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
218992061|NCT04411654|DRUG|Methylprednisolone|Single IV pulse administered as concomitant medication.
218992062|NCT04411654|DRUG|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
218992063|NCT04411654|DRUG|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
218992064|NCT00369824|BIOLOGICAL|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
218992065|NCT00369824|BIOLOGICAL|Menactra TM|One dose of vaccine administered intramuscularly
218992066|NCT00369824|BIOLOGICAL|Boostrix TM|One dose of vaccine administered intramuscularly
218992067|NCT01831648|OTHER|Blood sample|
219179054|NCT05831345|DRUG|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
219749076|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219749077|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219749078|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
219749079|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
219749080|NCT04227587|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
219749081|NCT04227587|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
219749082|NCT01397253|OTHER|Automated communication tools|"Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries"
219749083|NCT06141928|OTHER|Functional recovery analysis|Functional recovery analysis with force evaluator \& tester
219749084|NCT00137592|BEHAVIORAL|small media, group education (multicomponent)|
218992068|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
219749085|NCT02550002|DRUG|Aflibercept|Intravitreal injection
219749086|NCT06839053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219749087|NCT06839053|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219749088|NCT06839053|PROCEDURE|Computed Tomography|Undergo CT
219749089|NCT06839053|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
219749090|NCT06839053|BIOLOGICAL|Rituximab|Given IV
219749091|NCT06839053|DRUG|Sonrotoclax|Given PO
219749092|NCT06839053|DRUG|Zanubrutinib|Given orally (PO)
218992069|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
218992070|NCT04394975|COMBINATION_PRODUCT|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
218992071|NCT04394975|DRUG|sunitinib|Drug: Sunitinib, oral capsule
218992072|NCT05371431|OTHER|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
218992073|NCT05371431|OTHER|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
218992074|NCT04874584|BEHAVIORAL|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
218992075|NCT04874584|BEHAVIORAL|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
218992076|NCT00334958|DRUG|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
219179055|NCT05831345|DRUG|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
219749093|NCT01871649|DRUG|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
219749094|NCT01871649|DRUG|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
219749095|NCT03130049|PROCEDURE|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
219749096|NCT04523025|DIAGNOSTIC_TEST|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
219749097|NCT06500507|DRUG|QLS4131 Injection|Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
219749098|NCT05640557|OTHER|Physical Exercises|An original, noninvasive exercise program
219749099|NCT00404911|BEHAVIORAL|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
219749100|NCT00404911|BEHAVIORAL|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
219749101|NCT03290521|PROCEDURE|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
219749102|NCT03290521|PROCEDURE|No washing|no washing
219749103|NCT01937702|OTHER|0.9% NaCl (sodium chloride)|
218992077|NCT00334958|DRUG|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
218992078|NCT03802760|DEVICE|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
218992079|NCT04873115|OTHER|Placebo|Sialanar placebo
218992080|NCT04873115|DRUG|Sialanar|Sialanar - a licensed glycopyrronium bromide product
218992081|NCT04873115|OTHER|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
218992082|NCT01332643|GENETIC|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
218992083|NCT00105417|DRUG|IL-7|
218992084|NCT04397601|DRUG|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
218992085|NCT04397601|DRUG|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
219749104|NCT05585294|BEHAVIORAL|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
219749105|NCT02295865|DRUG|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
219749106|NCT02295865|DRUG|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
219749107|NCT02295865|DRUG|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
219749108|NCT02295865|DRUG|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
219749109|NCT01892189|DRUG|Ketamine|Ketamine intravenous administration.
219749110|NCT01892189|DRUG|TAK-063|TAK-063 tablets
219749111|NCT01892189|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
219749112|NCT05975424|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
218992086|NCT00133471|BIOLOGICAL|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
218992087|NCT00133471|DRUG|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
218992088|NCT03363958|PROCEDURE|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
218992089|NCT03363958|PROCEDURE|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
218992090|NCT03773263|DRUG|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
218992091|NCT03773263|PROCEDURE|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
218992092|NCT03773263|PROCEDURE|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
218992093|NCT03773263|DRUG|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
218992094|NCT04937231|OTHER|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
218992095|NCT04937231|OTHER|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
219749113|NCT03622606|DIAGNOSTIC_TEST|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
219749114|NCT03247101|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
219749115|NCT03247101|DRUG|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
219749116|NCT03247101|DRUG|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
219749117|NCT03378960|DRUG|Omeprazole 20mg|
219749118|NCT05549544|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
219749119|NCT05549544|DEVICE|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
218992096|NCT04937231|OTHER|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
218992097|NCT03385564|DRUG|BI 655064|subcutaneous injection
218992098|NCT03385564|DRUG|Placebo|subcutaneous injection
218992099|NCT00622401|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
219749120|NCT00932607|DRUG|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
219749121|NCT04461886|DRUG|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
218992100|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 30ng/kg
218992101|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 100ng/kg
218992102|NCT01514071|BEHAVIORAL|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
218992103|NCT00844675|DRUG|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
218992104|NCT00844675|DRUG|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
218992105|NCT05574738|OTHER|Observational|
218992106|NCT01194466|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
218992107|NCT03582189|OTHER|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
218992108|NCT04153669|BEHAVIORAL|Exercise-NMES|Exercise-NMES
218992109|NCT04153669|BEHAVIORAL|Exercise-No NMES|Exercise-No NMES
218992110|NCT04525846|OTHER|PFMT|"* program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
218992111|NCT04525846|OTHER|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
218992112|NCT05400109|BIOLOGICAL|UF-KURE19 CAR-T cells|UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved
219749122|NCT02957838|DIETARY_SUPPLEMENT|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
219749123|NCT02957838|DIETARY_SUPPLEMENT|mock|Low fat banana milkshake without C18:0 supplement.
219749124|NCT04910620|DRUG|Placebo|Placebo only
219749125|NCT04910620|DRUG|TCI378|TCI378 (Lactobacillus plantarum TCI378)
219749126|NCT04910620|DRUG|TCI507|TCI507 (Lactobacillus plantarum TCI507)
218992113|NCT05400109|DRUG|Fludarabine|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
218992114|NCT05400109|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA
218992115|NCT01957930|DRUG|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
218992116|NCT01957930|DRUG|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
218992117|NCT01605162|DRUG|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
218992118|NCT01605162|DRUG|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
218992119|NCT05626985|DIAGNOSTIC_TEST|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
218992120|NCT00179556|DRUG|Isoflavone supplement|
218992121|NCT00129428|PROCEDURE|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
218992122|NCT04945122|DRUG|Pitavastatin|Pitavastatin 4mg Qn
218992123|NCT04945122|DRUG|Atorvastatin|Atorvastatin 20mg Qn
218992124|NCT03892096|DIAGNOSTIC_TEST|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
218992125|NCT00679666|DRUG|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
218992126|NCT00679666|DRUG|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
219749127|NCT03716648|DIAGNOSTIC_TEST|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
219749128|NCT03716648|DIAGNOSTIC_TEST|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
219749129|NCT03716648|DEVICE|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
219749130|NCT03859011|OTHER|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
219749131|NCT03859011|OTHER|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
219749132|NCT05136716|OTHER|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
219749133|NCT05136716|DEVICE|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
219749134|NCT02903485|OTHER|nurses perform presurgical assessement and surveillance during surgery|
219749135|NCT02903485|OTHER|the anesthetic team performs presurgical assessement and surveillance during surgery|
219749136|NCT04778202|DIAGNOSTIC_TEST|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
219749137|NCT05349604|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
219749138|NCT05349604|DIETARY_SUPPLEMENT|Placebo|One intake in total
218992127|NCT00837057|PROCEDURE|crrt|early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
219749139|NCT01659294|BEHAVIORAL|Nurse Case Management|
219749140|NCT01659294|BEHAVIORAL|standard diabetologist care|routine care by diabetologist \& team
219749141|NCT00569179|DEVICE|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
219749142|NCT03146260|PROCEDURE|Conventional TESE|usual procedure for sperm extraction
219749143|NCT03146260|PROCEDURE|Microdissection TESE|Procedure of extraction is performed under the operating microscope
219749144|NCT02834364|DRUG|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
219749145|NCT02834364|DRUG|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
219749146|NCT00005835|DRUG|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
219749147|NCT00005835|DRUG|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
219749148|NCT00005835|PROCEDURE|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
219749149|NCT00005835|OTHER|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
219749150|NCT00358878|DRUG|Satavaptan|oral administration once daily
219749151|NCT00358878|DRUG|placebo|oral administration once daily
219749152|NCT03022721|OTHER|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
219749153|NCT02323048|DRUG|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
218992128|NCT04080375|DRUG|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
218992129|NCT04080375|DRUG|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
219749154|NCT02323048|DRUG|placebo|Placebo (sugar pill)
218992130|NCT00603174|DEVICE|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
218992131|NCT03907228|DIETARY_SUPPLEMENT|RHT-3201|PROBIOTIC
218992132|NCT00454896|DRUG|VESIcare®|Oral
218992133|NCT00454896|DRUG|placebo|Oral
219749155|NCT03906214|OTHER|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
219749156|NCT01447992|DEVICE|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
219749157|NCT03359161|COMBINATION_PRODUCT|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
219749158|NCT04101773|PROCEDURE|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
218992134|NCT01803061|BEHAVIORAL|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
218992135|NCT03556072|OTHER|Routine ERCP|
218992136|NCT05624593|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
218992137|NCT05624593|DEVICE|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
218992138|NCT03996733|OTHER|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
218992139|NCT03996733|OTHER|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
218992140|NCT03996733|OTHER|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
218992141|NCT03996733|OTHER|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
218992142|NCT02464020|DRUG|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
218992143|NCT02244112|DRUG|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
218992144|NCT02244112|DRUG|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
218992145|NCT05495620|DRUG|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
218992146|NCT05495620|DRUG|Lenalidomide|Oral
218992147|NCT05495620|DRUG|Dexamethasone|Oral or intravenous
218992148|NCT04905758|PROCEDURE|platform switching|reduced implant abutment interface
218992149|NCT04905758|PROCEDURE|platform amtching|matched implant abutment interface
218992150|NCT02107170|DRUG|Sevoflurane|sevoflurane-based general anesthesia
219749159|NCT00757016|DRUG|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
218992151|NCT02107170|DRUG|Propofol|total intravenous anesthesia
218992152|NCT02107170|DRUG|Remifentanil|
218992153|NCT00255112|BEHAVIORAL|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
218992154|NCT02883270|DEVICE|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
218992155|NCT02883270|OTHER|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
219749160|NCT00757016|DRUG|Saline solution|Saline solution
218992156|NCT04981548|OTHER|no intervention|no intervention
218992157|NCT03978000|DRUG|IBP-9414|Oral suspension
219749161|NCT00738127|PROCEDURE|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
218992158|NCT03978000|DRUG|Placebo|Sterile water
218992159|NCT00811759|DRUG|sorafenib tosylate|
218992160|NCT00811759|DRUG|temozolomide|
218992161|NCT00811759|GENETIC|gene expression analysis|
218992162|NCT00811759|GENETIC|mutation analysis|
218992163|NCT00811759|OTHER|laboratory biomarker analysis|
218992164|NCT00811759|OTHER|pharmacological study|
218992165|NCT00811759|PROCEDURE|biopsy|
218992166|NCT04942899|DRUG|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
218992167|NCT01887665|BEHAVIORAL|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
218992168|NCT00478231|DRUG|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
218992169|NCT04092400|DEVICE|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
218992170|NCT00511446|DRUG|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
218992171|NCT00436384|PROCEDURE|Monitoring-blood samples drawn for CMV testing|
218992172|NCT04226872|BEHAVIORAL|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
218992173|NCT05021601|PROCEDURE|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
218992174|NCT05021601|PROCEDURE|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
218992175|NCT04688957|PROCEDURE|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
219179056|NCT05393193|DIAGNOSTIC_TEST|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
218992176|NCT04688957|PROCEDURE|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
218992177|NCT04633018|DEVICE|AsthmaMD mobile application|asthma management app with Spanish-language user interface
218992178|NCT04633018|OTHER|Usual care|Asthma management without the app
218992179|NCT04054505|DIETARY_SUPPLEMENT|EZPAK|One packet with breakfast for three months
218992180|NCT04054505|DIETARY_SUPPLEMENT|Placebo|One packet with breakfast for three months
218992181|NCT05622175|DRUG|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
218992182|NCT02599714|DRUG|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
218992183|NCT02599714|DRUG|Palbociclib|cyclin dependent kinase inhibitor
218992184|NCT02599714|DRUG|Fulvestrant|Fulvestrant hormonal therapy as background
218992185|NCT01133873|DRUG|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
218992186|NCT01133873|DRUG|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
218992187|NCT01423318|DRUG|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
218992188|NCT01423318|DRUG|placebo|single dose subcutaneously
219749162|NCT05858814|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
219749163|NCT01892566|OTHER|mHealth Intervention|See arm description
219749164|NCT06397092|PROCEDURE|transapical beating-heart septal myectomy|The patients with hypertrophic cardiomyopathy undergoing TA-BSM
219749165|NCT00732888|DRUG|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
218992189|NCT01785264|PROCEDURE|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
218992190|NCT01785264|PROCEDURE|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
219369269|NCT05195788|BEHAVIORAL|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
219749166|NCT00732888|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
218992191|NCT01785264|PROCEDURE|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
219749167|NCT01195597|DEVICE|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
219761853|NCT05702853|BIOLOGICAL|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
218992192|NCT00372671|BEHAVIORAL|Survey|
218992193|NCT00372671|BEHAVIORAL|Survey and videotape|
218992194|NCT06438458|PROCEDURE|Postural change from supine to sitting|Patients go from supine to sitting position in bed (passive)
218992195|NCT06438458|PROCEDURE|Mobilization to a chair|Patients go from the bed to sitting in a chair (active)
218992196|NCT00824720|DRUG|High Dose Device|inserted for 14 days
218992197|NCT00824720|DRUG|Low Dose Device|inserted for 14 days
218992198|NCT00824720|DEVICE|Placebo Device|inserted for 14 days
218992199|NCT05593926|DIETARY_SUPPLEMENT|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
219749168|NCT06228950|BEHAVIORAL|Mindfulness-Based Stress Reduction|A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
219749169|NCT03322566|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
219749170|NCT03322566|DRUG|Epacadostat|Epacadostat administered orally twice daily.
219749171|NCT03322566|DRUG|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
218992200|NCT03298165|DEVICE|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
218992201|NCT03752983|DIAGNOSTIC_TEST|blood samples|blood samples
219749172|NCT03322566|DRUG|Placebo|Matching placebo administered orally twice daily.
219749173|NCT00603681|DRUG|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
219749174|NCT00603681|DRUG|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
219749175|NCT00986882|DRUG|SAF312A|
219749176|NCT00986882|DRUG|Placebo|
219749177|NCT00986882|DRUG|Ibuprofen|
219749178|NCT02736071|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
219749179|NCT02736071|DRUG|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
219749180|NCT02736071|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
219749181|NCT02736071|DRUG|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
219749182|NCT00164580|BEHAVIORAL|Community-Level Intervention|
219749183|NCT03656354|DEVICE|Seismocardiography|Seismocardiography recording
219749184|NCT00679614|DRUG|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
219749185|NCT00679614|DRUG|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
219749186|NCT00679614|DRUG|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
218992202|NCT01070498|DRUG|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
219749187|NCT03884673|DRUG|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
219749188|NCT01524406|DRUG|HPP593|Oral, twice a day.
219749189|NCT01524406|DRUG|Placebo|Oral, twice a day.
219749190|NCT03347669|DEVICE|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
219749191|NCT01687062|OTHER|FeSO4|
219749192|NCT01687062|OTHER|reduction of phytate|
219749193|NCT01687062|OTHER|NaFeEDTA|
219749194|NCT00798408|DIETARY_SUPPLEMENT|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
219749195|NCT00798408|DIETARY_SUPPLEMENT|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
219749196|NCT01928056|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
218992203|NCT00873015|DRUG|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
218992204|NCT00873015|DRUG|Saline|14 day continuous infusion of a vehicle control infusion
219369270|NCT06413004|OTHER|Elimination and re-introduction of CLE or COLAP positive food item(s)|Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
219749197|NCT01238887|DIETARY_SUPPLEMENT|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
219749198|NCT01238887|DIETARY_SUPPLEMENT|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
218992205|NCT01988688|DEVICE|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
218992206|NCT03364933|BEHAVIORAL|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
219749199|NCT01238887|DIETARY_SUPPLEMENT|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
218992207|NCT00110838|PROCEDURE|Supplementation with fish oil versus placebo|
218992208|NCT02745444|DIETARY_SUPPLEMENT|low-calorie formula diet|
218992209|NCT02745444|DIETARY_SUPPLEMENT|protein-restricted diet|
218992210|NCT02368015|OTHER|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
218992211|NCT02368015|DRUG|cefazolin|
218992212|NCT06506149|DEVICE|Microwave ablation(MWA) device|The device for USG-guided MWA treatment would be performed under USG guidance, aiming to ablate the entire thyroid gland, i.e. the right lobe, left lobe, isthmus and pyramidal lobe.
218992213|NCT02487667|DEVICE|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
218992214|NCT00448981|BEHAVIORAL|Hand hygiene and educational material|
218992215|NCT00448981|DEVICE|Mask, alcohol and hand sanitizer|
218992216|NCT03152071|PROCEDURE|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
218992217|NCT03152071|PROCEDURE|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
218992218|NCT03918785|DIETARY_SUPPLEMENT|Rice germ|25 g twice a day.
219749200|NCT05255666|DRUG|Pembrolizumab|400 mg intravenously
219749201|NCT05255666|DRUG|Liposomal Irinotecan|Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
218992219|NCT03918785|DIETARY_SUPPLEMENT|Wheat-based supplement|25g twice a day.
218992220|NCT01382212|DRUG|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
218992221|NCT02416401|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
218992222|NCT02416401|OTHER|Commercially available computerized training|
218992223|NCT00272740|DRUG|Fulvestrant|
218992224|NCT04148053|DIAGNOSTIC_TEST|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
218992225|NCT00506480|PROCEDURE|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
218992226|NCT03329573|DRUG|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
218992227|NCT03329573|DRUG|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
218992228|NCT05902780|DRUG|Caudal Bupivacaine injection|\- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
218992229|NCT05902780|DRUG|Caudal Dexmedetomidine Injection|\- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
219179057|NCT05393193|DRUG|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
218992230|NCT05000463|DRUG|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
218992231|NCT05000463|DRUG|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
218992232|NCT01423058|DRUG|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
218992233|NCT03535116|DRUG|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
218992234|NCT03535116|DRUG|Saline|injectable normal saline
218992235|NCT05085652|PROCEDURE|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
218992236|NCT00650260|DEVICE|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
218992237|NCT00650260|DEVICE|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
218992238|NCT02777333|BEHAVIORAL|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
218992239|NCT02564549|PROCEDURE|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
218992240|NCT02564549|PROCEDURE|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
218992241|NCT05165836|PROCEDURE|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
219749202|NCT01738412|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
219749203|NCT02314923|BIOLOGICAL|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
219749204|NCT02314923|OTHER|Placebo|0.9% Saline
218992242|NCT05165836|PROCEDURE|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
218992243|NCT00479726|DRUG|duloxetine hydrochloride|
218992244|NCT04490343|DIAGNOSTIC_TEST|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
218992245|NCT03477097|OTHER|Nutrition, exercise and social network intervention|
219369271|NCT04918563|DRUG|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
219749205|NCT03419819|DIETARY_SUPPLEMENT|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
219369272|NCT04918563|DRUG|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
219749206|NCT00725985|DRUG|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
219749207|NCT00725985|DRUG|Placebo|Placebo matched to cladribine tablets were administered.
219749208|NCT00725985|DRUG|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
219749209|NCT03765931|DRUG|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
219749210|NCT03765931|DRUG|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
219749211|NCT02546323|DRUG|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
219749212|NCT02546323|DRUG|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
219749213|NCT03548129|DRUG|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
219749214|NCT03548129|DRUG|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
219749215|NCT03548129|DIAGNOSTIC_TEST|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
219749216|NCT03548129|DIAGNOSTIC_TEST|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
219749217|NCT03548129|DIAGNOSTIC_TEST|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
219749218|NCT04476784|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
219749219|NCT04476784|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
219749220|NCT04476784|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
219749221|NCT02020226|DRUG|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
219369273|NCT04349137|DEVICE|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
219749222|NCT04087642|DIAGNOSTIC_TEST|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
219749223|NCT04087642|DIAGNOSTIC_TEST|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
219749224|NCT02551783|PROCEDURE|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
219749225|NCT02551783|PROCEDURE|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
219749226|NCT02578082|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
219749227|NCT00195780|DRUG|Divalproex Sodium (Depakote ER)|
219749228|NCT03323255|DEVICE|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
219749229|NCT03323255|DEVICE|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
219749230|NCT04957589|DIETARY_SUPPLEMENT|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
219749231|NCT04957589|OTHER|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
219749232|NCT04621578|DEVICE|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
219761854|NCT06134167|DEVICE|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
219369274|NCT04349137|DEVICE|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
219369275|NCT03115996|DRUG|REGN3918|Intravenous (IV) or Subcutaneous (SC)
218992246|NCT01063452|DEVICE|Truvalve|Atkinson Product Design urinary slide valve
218992247|NCT01063452|OTHER|Control (catheter drainage bag)|urinary catheter drainage bag
218992248|NCT00837811|BIOLOGICAL|LY2127399|60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
218992249|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
218992250|NCT05637606|DRUG|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
218992251|NCT05637606|DRUG|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
219749233|NCT06637189|DRUG|Ganirelix|Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
219749234|NCT06637189|DRUG|Medroxyprogesterone Acetate 10 MG|Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
219749235|NCT01515371|DRUG|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
219749236|NCT01515371|DRUG|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
219749237|NCT00054262|DRUG|T900607|
219749238|NCT03748550|BEHAVIORAL|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
218992252|NCT05637606|DRUG|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
218992253|NCT05637606|DIAGNOSTIC_TEST|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini\_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
218992254|NCT06046794|OTHER|Analyze of GemCore status|Genomic analyze of GemCore status
218992255|NCT05552001|DRUG|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
218992256|NCT04443010|DRUG|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
218992257|NCT04443010|DRUG|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
218992258|NCT06678243|BEHAVIORAL|Smiling instead of Smoking|"Participants randomized to the treatment condition will use the Smiling instead of Smoking (SiS) smartphone app. This app delivers and guides participants through two types of content to help them during their quit attempt: (1) positive psychology content (i.e., happiness habit-building exercises, happiness boost activity, and science-based information on the relevance of positive psychology activities) designed to help nondaily smokers maintain positive affect while they go through the process of smoking cessation; and (2) traditional behavioral smoking cessation content to guide their quit process based on US Clinical Practice Guidelines."
218992259|NCT06678243|BEHAVIORAL|QuitGuide|"Participants randomized to the control condition will use the National Cancer Institute (NCI)'s QuitGuide (QG) smartphone app. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
218992260|NCT07009535|DIAGNOSTIC_TEST|Polysomnography|Assessment of AHI index and pO2 in pediatric patients
218992261|NCT07008001|DEVICE|Novel spectacle lens design|Use of spectacle lenses may reduce the rate of progression of juvenile myopia
218992262|NCT06681584|DIAGNOSTIC_TEST|CTCA|CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
218992263|NCT06681831|DEVICE|DaVinci SP|robotic single-port hysterectomy (R-SPH) with DaVinci SP
219749239|NCT06637410|DEVICE|High intensity laser therapy|HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
218992264|NCT06680518|OTHER|tourniquet|peroperation tourniquet
218992265|NCT06680518|OTHER|No tourniquet|no tourniquet during surgery
218992266|NCT07014410|DRUG|pyrotinib dalpiciclib letrozole|ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole
218992267|NCT07015450|DRUG|self-manufactured 40% dextrose gel|The self-manufactured 40% dextrose gel was applied in buccal mucosa region
218992268|NCT07015450|DRUG|Standard therapy|standard therapy for asymptomatic transient neonatal hypoglycemia
218992269|NCT07016568|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
218992270|NCT07015112|OTHER|Patient-centered multidisciplinary treatment review|Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)
218992271|NCT07016113|DRUG|0.005% latanoprost gel|\- Apply 0.005% latanoprost gel to the predetermined skin lesions twice daily (morning and evening) every day for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
218992272|NCT07016113|DRUG|0.1% mometasone furoate cream|\- Apply 0.1% mometasone furoate cream to the predetermined skin lesions twice daily (morning and evening) for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
218992273|NCT07015736|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|Standard treatment (50-90 mg/kg/day for 10 days)
218992274|NCT07015736|DIETARY_SUPPLEMENT|Saccharomyces boulardii CNCM I-745|Probiotic sachet, twice daily for 10 or 21 days depending on group assignment
218992275|NCT07016477|DIAGNOSTIC_TEST|Ultra-High Resolution Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Ultra-High Resolution Photon-Counting Detector Coronary Computed Tomography Angiography (UHR PCD-CT CCTA) for the pre-procedural evaluation of patients scheduled to undergo transcatheter aortic valve implantation.
218992276|NCT07014332|DEVICE|Steel ligature|Steel ligatures that are used to ligate wire with bracket
218992277|NCT07014332|DEVICE|Elastomeric ligature|Elastomeric ligature that is used to ligate wire to bracket
218992278|NCT07014371|DRUG|Ferrous Fumarate Oral Tablet|Ferrous fumarate oral tablet 200 mg is an iron supplement used for the treatment of iron deficiency anemia (IDA). In this study, it is administered as either one tablet daily (OD group) or two tablets on alternate days (AD group), with a treatment duration of 8 weeks. The goal is to compare the efficacy and tolerability of alternate-day dosing versus standard once-daily dosing.
218992279|NCT07015827|OTHER|Mango (langra)|Participants will consume mango variety A . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
218992280|NCT07015827|OTHER|mango (chaunsa)|Participants will consume mango variety B . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
219179058|NCT04090086|DRUG|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
219179059|NCT04090086|DRUG|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
219369276|NCT03115996|DRUG|Placebo|Matching Placebo
219369277|NCT01742260|PROCEDURE|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
218992281|NCT07015827|OTHER|MANGO (SINDHRI)|Participants will consume mango variety C . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
218992282|NCT07014709|DRUG|GLP1 receptor agonist|Patients must be under GLP1-RA treatment for ether diabetes or obesity
218992283|NCT07016464|DRUG|REM0045392|Liquid formulation
218992284|NCT07016464|DRUG|Placebo|Liquid formulation
219179060|NCT06109181|GENETIC|LX2020|LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
219369278|NCT03122626|BEHAVIORAL|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
218992285|NCT07016555|DIETARY_SUPPLEMENT|Oral cooling spray|Use oral spray 3 times per day for 2 weeks
219749240|NCT06637410|DEVICE|Ultrasound therapy|US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
219749241|NCT06637410|OTHER|Therapeutic Exercise|ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
219369279|NCT05051956|DRUG|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
219749242|NCT01943760|DRUG|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
219749243|NCT01943760|DRUG|0.9% saline|
219749244|NCT03963284|PROCEDURE|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
218992286|NCT04774913|PROCEDURE|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
218992287|NCT04522388|DIETARY_SUPPLEMENT|Ensure Enlive|Ensure Enlive shake twice a day
218992288|NCT06681571|OTHER|TAP Block|TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
218992289|NCT06681571|OTHER|RSB|Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
218992290|NCT00607815|BEHAVIORAL|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
218992291|NCT00607815|BEHAVIORAL|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
219179061|NCT06559124|OTHER|Traditional Physiotherapy + Sham Kinesiotape|"As exercise training, joint range of motion, flexion and abduction external cycle will be practiced with the gymnasts.~Circumference measurements will be taken for shoulder bone swelling and for atrophy.~Shoulder joint mobilizations will be applied (posterior cutting for flexion limitation, downward shifting and scapular mobilizations for abduction limitation).~Flexion and abduction will be stretched externally. Friction massage will be applied. Strengthening exercises for flexion, abduction and external rotation in the lower and upper segments of the shoulder with dumbbells and theraband, shoulder wheel and finger ladder will be practiced.~Codman exercises and staff exercises will be practiced."
219179062|NCT06559124|OTHER|Kinesiotape with Facilitation Method + Traditional Physiotherapy|Kinesio tape will be applied with 0 tension at the starting point when the arm is in a relaxed position and will be slightly heated. Since the deltoid muscle is a three-headed muscle, it will be applied with 0 tension in the flexed position at the elbow, for the front part, the arm with the elbow in full extension, and for the middle part of the deltoid, the I tape will be applied along the muscle without applying tension.
219179063|NCT06559124|OTHER|Kinesiotape with Inhibition Method + Traditional Physiotherapy|The Y-shaped kinesio tape will be placed on the deltoid muscle with inhibition and mechanical correction technique, and the Y-shaped kinesio tape will be placed on the supraspinatus muscle with inhibition technique, 3 cm below the humerus tuberculum deltoidea without tension. The Y tape will be applied along the outer edge of the anterior deltoid of the forearm with 15-25% light tension, and the posterior arm will be applied along the outer edge of the posterior deltoid with 15-25% light tension up to the lateral acromion. The last 3-5 cm of the tails will be applied to their permanent locations without tension. The shoulder will be held in maximum transverse extension and external rotation for the forearm of the Y support, and in 45 degrees transverse flexion and horizontal adduction for the posterior arm of the Y support. In addition, ultrasound, electrotherapy and cold application will be applied to the participants depending on their tolerance.
219179064|NCT04426968|DRUG|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
219179065|NCT04426968|DRUG|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
219369280|NCT02582996|DRUG|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
219369281|NCT02582996|DRUG|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
219749245|NCT03963284|DEVICE|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
219369282|NCT02649257|PROCEDURE|cataract surgery|
219369283|NCT02649257|DEVICE|intraocular lens (MC 6125 AS)|
219369284|NCT02649257|DEVICE|capsular tension ring (CTR 13/11)|
219369285|NCT04315467|DRUG|SGM-101|A one-time infusion of SGM-101
219369286|NCT04315467|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
218992292|NCT04262570|DEVICE|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
218992293|NCT03676283|OTHER|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
218992294|NCT06711614|OTHER|Intervention Diet|Designed to increase Omega-3 Fatty Acids (Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)), fruit, and vegetable intake, participants will receive grocery and meal deliveries for approximately 4-weeks via online ordering with dietician counselling.
219179066|NCT04426968|DRUG|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
219179067|NCT04426968|DRUG|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
219179068|NCT04426968|DRUG|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
219179069|NCT04426968|DRUG|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
219179070|NCT04426968|DRUG|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
219749246|NCT06638489|OTHER|High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)|The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
219749247|NCT06638489|OTHER|Pelvic-Floor-Muscle-Training (PFMT)|The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
219749248|NCT02589288|PROCEDURE|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
219749249|NCT02589288|PROCEDURE|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
219749250|NCT06641531|OTHER|Screening pap smear test|"The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain"
219749251|NCT06640673|DIAGNOSTIC_TEST|Hd-EEG|Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
219749252|NCT04789941|DRUG|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
219749253|NCT06015516|DRUG|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
219749254|NCT06015516|DRUG|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
219749255|NCT06639230|DEVICE|laser therapy|Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
219749256|NCT06639230|DRUG|Sclerotherapy|Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
219749257|NCT05812690|OTHER|This is a non intervention - observation only study|This is non intervention study
219749258|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
219179071|NCT06427005|DRUG|Fruquintinib|Fruquintinib 5 mg daily for 14 days followed by a 7-day break
219179072|NCT06427005|DRUG|S-1|S-1 80-120 mg daily for 14 days, followed by a 7-day break
219761855|NCT05013307|OTHER|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
219179073|NCT06427005|DRUG|raltitrexed|raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
219179074|NCT03208868|DIETARY_SUPPLEMENT|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
219179075|NCT03208868|DIETARY_SUPPLEMENT|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
219179076|NCT00875277|DRUG|LEO 29102 cream|
219179077|NCT00875277|DRUG|LEO 29102 Cream Vehicle|
219179078|NCT00875277|DRUG|Betamethasone Dipropionate Cream|
219179079|NCT00875277|DRUG|LEO 29102 Plus Calcipotriol Cream|
219179080|NCT00875277|DRUG|LEO 29102 Plus Betamethasone Dipropionate|
219179081|NCT00875277|DRUG|Daivobet® Ointment|
219179082|NCT03800108|PROCEDURE|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
219179083|NCT03696784|BIOLOGICAL|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
219179084|NCT03696784|DRUG|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
219749259|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
219749260|NCT05332704|DRUG|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
219749261|NCT05332704|DRUG|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
219179085|NCT03696784|DRUG|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
219179086|NCT03696784|DRUG|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
219179087|NCT03696784|DRUG|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
219179088|NCT01293526|DEVICE|Control|Patients who respond will have leads will be placed using standard procedures.
219179089|NCT01293526|DEVICE|Experimental|Patients who respond will have their leads placed based on study measurements.
219179090|NCT01293526|DEVICE|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
219749262|NCT05332704|DRUG|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
219179091|NCT03443388|DEVICE|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
219179092|NCT06343649|OTHER|Visual|Delivery of images to conduct several exercises of Explicit Motor Imagery
219179093|NCT06343649|OTHER|Auditory|Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
219179094|NCT03463785|OTHER|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
219179095|NCT06516705|BEHAVIORAL|Hypoglycemia education|Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
219179096|NCT04507178|DRUG|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
219369287|NCT03908944|DRUG|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
219749263|NCT05332704|DRUG|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
219749264|NCT05332704|DRUG|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
219749265|NCT05332704|DRUG|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
219749266|NCT06462404|DRUG|E2086|E2086 oral tablets.
219749267|NCT06462404|DRUG|E2086 Placebo|E2086 matching placebo tablet.
219749268|NCT06462404|DRUG|Active Comparator|Active comparator oral tablets.
219749269|NCT06462404|DRUG|Active Comparator Placebo|Active comparator matching placebo tablet.
219179097|NCT05400252|BEHAVIORAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
219179098|NCT05400252|BEHAVIORAL|Health and Wellness|Health \& Wellness is an educational wellness intervention
219179099|NCT03651349|DRUG|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
219179100|NCT03651349|DRUG|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
219179101|NCT06519305|OTHER|Survey completion|Participants will be asked to fill out the survey via email.
219179102|NCT05936658|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
219749270|NCT06563986|DRUG|Systemic treatment (FTD-TPI and bevacizumab)|"Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice."
219749271|NCT06563986|DEVICE|Radioembolization with 166-Ho microspheres|"Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated."
219749272|NCT03413800|DRUG|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
219749273|NCT06561802|DIAGNOSTIC_TEST|GCF and saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
219749274|NCT06424639|DRUG|Luspatercept|Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)
219749275|NCT06424639|DRUG|cyclosporine|Cyclosporine (3-5mg/kg/day)
219749276|NCT00006167|DRUG|oxandrolone|
219749277|NCT00006167|BEHAVIORAL|Progressive Resistance Training|
219749278|NCT00863304|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
219179103|NCT05332756|OTHER|Conservative management|Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
219179104|NCT06544707|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
219179105|NCT06615518|PROCEDURE|transforaminal endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
219179106|NCT06615518|PROCEDURE|Interlaminar endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
219369288|NCT03908944|DRUG|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
219749279|NCT00863304|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
219749280|NCT00863304|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
219749281|NCT00863304|OTHER|placebo|placebo to match tanezumab and naproxen dosing
219749282|NCT01008826|DIETARY_SUPPLEMENT|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
219749283|NCT03921567|DRUG|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
219749284|NCT03921567|DRUG|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
219749285|NCT03921567|DRUG|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
219749286|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
219749287|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
219749288|NCT03578055|DRUG|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
219749289|NCT03578055|DRUG|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
219749290|NCT05819957|OTHER|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
219749291|NCT00453492|DRUG|risedronate sodium|
219749292|NCT01505088|DRUG|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
219749293|NCT01505088|DRUG|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
219749294|NCT01505088|DRUG|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
219749295|NCT01505088|DRUG|Placebo Eyedrops|Placebo Eyedrops
219749296|NCT01055028|DRUG|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
219749297|NCT01055028|DRUG|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
219749298|NCT01349478|DEVICE|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
219749299|NCT05181345|OTHER|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
219191547|NCT06580600|DIAGNOSTIC_TEST|Point of care respiratory virus testing|"Patients to be randomised to receive OCS based on the the result of the RSV results within their respiratory virus test. This test will be performed as a point of care (POC) test in ED.~This intervention will stratify the randomisation in a 1:1 ratio, to receive OCS or not.~NB) Whilst the respiratory pathogen test is not routine care to determine the OCS prescription, it is frequently used within this setting. Additionally both the receipt (or not the receipt) of OCS is within standard care pathway. For the purpose of the trial OCS = Dexamethasone, which is delivered as oral suspension 300mcg/kg as per standard practice within the local Trust."
219749300|NCT05181345|OTHER|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
219749301|NCT05181345|OTHER|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
219749302|NCT05181345|OTHER|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
219749303|NCT04871620|DIAGNOSTIC_TEST|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
219749304|NCT01868412|DEVICE|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
219749305|NCT01868412|DEVICE|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
219749306|NCT00285051|DRUG|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
219749307|NCT02806661|PROCEDURE|Vagus nerve-preserving Robot-assisted Gastrectomy|
219191548|NCT05750589|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
219191549|NCT05750589|DRUG|Providone-Iodine|5% Providone-Iodine
219749308|NCT02806661|PROCEDURE|Conventional Robot-assisted Gastrectomy|
219749309|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 12|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
219749310|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 3|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
219749311|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 6|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
219749312|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 24|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
219749313|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 21|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
219749314|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 18|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
219749315|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 15|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
219749316|NCT04670809|DRUG|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
219761856|NCT06634810|BEHAVIORAL|Self-Management Support|The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
219369289|NCT02051907|DEVICE|KAM1403 Gel|
219179107|NCT06615518|PROCEDURE|Microdiscectomy|"Microdiscectomy is a conventional surgical technique for treating lumbar disc herniation, involving a small open incision. In this procedure, the surgeon makes an incision typically between 2-3 cm in length, then uses an operating microscope to gain magnified visualization of the herniated disc. The surgeon removes part of the lamina (laminotomy) to access the disc and nerves. Special instruments are used to remove the herniated portion of the disc that is compressing the spinal nerves, relieving symptoms such as pain, numbness, and weakness.~What distinguishes this intervention:~* Larger incision (2-3 cm) compared to FELD, but still smaller than traditional open discectomy, allowing better visualization.~* Microscopic magnification allows precise removal of disc material while minimizing trauma to surrounding neural structures.~* Direct access to the affected area via the removal of part of the lamina (laminotomy), offering a well-established and highly effective approach to reli"
219179108|NCT04292223|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
219179109|NCT06300372|PROCEDURE|M-TAPA plane block|As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
219179110|NCT06300372|PROCEDURE|Postoperative pain management|For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
219179111|NCT02531607|OTHER|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
219179112|NCT04244214|OTHER|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
219179113|NCT06410287|OTHER|ArtSpective|ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
219179114|NCT06791252|BEHAVIORAL|genital hygiene education|"The pregnant women in the experimental group were given genital hygiene training individually and in their own homes by the researcher. During the training, the privacy of the client was observed and the researcher and the pregnant women were left alone in the room where the training would be given. Care was taken to ensure that the environment was quiet and calm while the training was given. It was preferred that the pregnant women be in the most comfortable position during the training.~The training was completed by explaining each topic in the training booklet in an average of 20-25 minutes.~Genital hygiene training content:~Session 1 (Day 1): After the introduction phase, information was given about the method to be followed in the study to the pregnant women who agreed to participate in the study. Then, the Minimum Informed Consent Form was given to these women, and the pregnant women who approved the form after reading it were included in the study. Pre-test data were collecte"
219179115|NCT06799299|OTHER|No Intervention|No intervention
219179116|NCT05144763|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
219179117|NCT06475846|DRUG|HRS5580|HRS5580; low dose
219179118|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
219749317|NCT04670809|DRUG|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
219179119|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
219179120|NCT06475846|DRUG|Ondansetron|Ondansetron
219749318|NCT06121752|PROCEDURE|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
219761857|NCT06634810|BEHAVIORAL|COPD Education|The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
219179121|NCT06475846|DRUG|blank preparation|blank preparation.
219191550|NCT04301765|DRUG|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
219369290|NCT02051907|DEVICE|aloevera gel|
219369291|NCT00972465|DRUG|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
219369292|NCT00893516|BIOLOGICAL|CHOP + CD4|
219369293|NCT00893516|DRUG|CHOP|
219191551|NCT04301765|OTHER|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
219191552|NCT03805477|DRUG|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
219191553|NCT06210802|OTHER|Korean version of Defense and Veterans Pain Rating Scale|Defense and Veterans Pain Rating Scale translated into Korean
218992295|NCT06711614|OTHER|Control Diet|Participants will receive weekly food subsidies for their groceries for 4-weeks (\~equivalent to the subsidies to provide groceries in the Intervention arm) but are free to purchase whatever they wish. The participants will continue to have dietician counseling during this time.
219006636|NCT04945551|BEHAVIORAL|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
219006637|NCT02632474|DRUG|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
219006638|NCT00271050|OTHER|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
219006639|NCT01656785|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
219369294|NCT00732173|BEHAVIORAL|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
219749319|NCT06121752|DEVICE|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
219749320|NCT06464770|DRUG|Chlorhexidine Gluconate|Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
219749321|NCT05882370|DRUG|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
219749322|NCT05882370|PROCEDURE|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
219749323|NCT03763630|DRUG|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
219749324|NCT03763630|DRUG|Normal saline|Normal saline administered in same frequency and manner as intervention
219749325|NCT05987137|OTHER|No intervention is being administered.|No intervention is being administered.
219006640|NCT01057654|DRUG|Pravastatin|Pravastatin 40 mg
219006641|NCT01057654|DRUG|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
219006642|NCT01138033|DRUG|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
219006643|NCT03724955|DRUG|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
219006644|NCT03724955|OTHER|Placebo|The placebo group will receive placebo oral daily for 6 months
219006645|NCT02159014|BEHAVIORAL|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
219006646|NCT02159014|BEHAVIORAL|Online, video prompted, individual aerobic dance|Supported online activity intervention
219006647|NCT02159014|BEHAVIORAL|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
219006648|NCT02159014|BEHAVIORAL|Self-paced online aerobic dance activity|Self paced physical activity
219006649|NCT02159014|BEHAVIORAL|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
219006650|NCT02482623|BEHAVIORAL|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
219006651|NCT00296894|DRUG|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
219006652|NCT00296894|DRUG|Placebo|Placebo
219006653|NCT03423095|BEHAVIORAL|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
219006654|NCT03423095|BEHAVIORAL|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
219006655|NCT03423095|BEHAVIORAL|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
219006656|NCT03423095|BEHAVIORAL|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
219179122|NCT04184375|BEHAVIORAL|cognitive stimulation|"Patients participate in one session per week according to the following schedule:~* 2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~* 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~* 2 voluntary attention sessions: improve daily attention.~* 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~* 2 sessions of structuring through language: impact on social life.~* 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips."
219179123|NCT03017755|OTHER|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
219179124|NCT00454467|PROCEDURE|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
219179125|NCT00454467|PROCEDURE|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
219179126|NCT00454467|PROCEDURE|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
219179127|NCT00454467|PROCEDURE|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
219179128|NCT00454467|PROCEDURE|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
219179129|NCT00454467|PROCEDURE|Cost Data|Cost Data will be collected via hospital billing databases.
219179130|NCT00454467|PROCEDURE|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
219179131|NCT06634797|BIOLOGICAL|mRNA-1273.712|Intramuscular (IM) injection.
219179132|NCT06634797|BIOLOGICAL|Placebo|Sodium chloride for IM injection.
219749326|NCT06130540|DRUG|Secukinumab|Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
219749327|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
219749328|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
219749329|NCT02507934|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
219749330|NCT02507934|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
219749331|NCT03298737|BEHAVIORAL|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
219749332|NCT05393180|DEVICE|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
219749333|NCT05992909|PROCEDURE|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
219179133|NCT03570632|DRUG|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
219179134|NCT06634654|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty is performed using conventional surgical techniques.
219179135|NCT06634654|DIAGNOSTIC_TEST|Multifaceted diagnostic assessments|Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.
219179136|NCT06634654|BEHAVIORAL|Follow-ups|Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.
219179137|NCT06634654|GENETIC|Genetic screening|Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
219179138|NCT03023410|PROCEDURE|VERASENSE|Sensor-Assisted Revision TKA
219179139|NCT06324721|OTHER|Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)|"Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis~Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography"
219179140|NCT06324721|OTHER|Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)|Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)
219179141|NCT06324721|OTHER|Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer|Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer
219179142|NCT06542484|DRUG|Gefapixant Citrate|An additional treatment of gefapixiant will be performed for 12 weeks.
219749334|NCT01930500|BEHAVIORAL|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
219749335|NCT01930500|BEHAVIORAL|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
219749336|NCT02848131|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
219749337|NCT02848131|DRUG|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
219749338|NCT06847256|PROCEDURE|Heat Challenge|Participants will be asked to arrive well-hydrated and to refrain from exercise, alcohol, caffeine, and smoking for 24 hours prior to the visit. Height, weight, blood pressure, and body fat percentage will be measured. Blood (15.5 ml) and urine will be collected. Participants will wear a heart rate monitor and sit in a heat chamber at 62-63 degrees Celsius for 45 minutes. Heart rate will be measured continuously. Body temperature and a self-report of their comfort (1-4 scale) and thermosensation (1-7 scale) will be measured before the challenge, every 15 minutes during the challenge, and after the challenge. During the challenge, a sample of sweat will be collected to measure electrolyte loss. Participants will consume 16 ounces of water at their own pace during the 45 minutes. If they become too uncomfortable to continue or their body temperature rises above 39 degrees Celsius, the challenge will be stopped. All baseline measures except body fat percentage will be measured again.
219749339|NCT06494995|DRUG|Cadonilimab|a PD-1/CTLA-4 dual antibody
219749340|NCT06494995|RADIATION|Low-dose radiotherapy|Low-dose radiation
219749341|NCT06494995|RADIATION|SBRT|selected leisions to treat with stereotactic radiotherapy
219749342|NCT06494995|DRUG|Capecitabine|Capecitabine metronomic chemotherapy
219749343|NCT04511494|DIETARY_SUPPLEMENT|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
219749344|NCT06469021|OTHER|Conservative Approach|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
219749345|NCT06469021|OTHER|Rehabilitative Game Therapy|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
219749346|NCT06035562|BEHAVIORAL|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
219179143|NCT04799899|BEHAVIORAL|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
219179144|NCT04799899|BEHAVIORAL|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
219179145|NCT04153032|DRUG|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
219749347|NCT05463133|DRUG|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
219749348|NCT05463133|DRUG|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
219749349|NCT05463133|DRUG|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
219749350|NCT05463133|DRUG|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
219749351|NCT05463133|BIOLOGICAL|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
219749352|NCT05463133|DRUG|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
219179146|NCT04153032|DRUG|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
219179147|NCT04019873|DRUG|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
219179148|NCT04019873|DRUG|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
219179149|NCT04019873|DRUG|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
219179150|NCT06629168|DIAGNOSTIC_TEST|lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.
219369295|NCT00732173|BEHAVIORAL|exercise intervention|Undergo SUCCEED lifestyle intervention
219179151|NCT06629168|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
219179152|NCT06629168|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
219179153|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #1|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
218992296|NCT06722248|BEHAVIORAL|high fidelity simulation-based training|"The intervention is a two-hour high-fidelity simulation training session focusing on newborn assessment, care practices, skin-to-skin contact, and breastfeeding. It uses SimBaby mannequins and breastfeeding models to mimic the hospital environment. Scenarios are tailored to nursing students' learning levels and reviewed by experienced midwives.~The training includes:~Prebriefing: Introduction of learning objectives, scenario background, simulation familiarization, confidentiality discussions, and ground rules.~Intervention: Scenario-based training on baby care and breastfeeding. Debriefing: Plus-delta debriefing model reviewed by simulation educators. The training will be conducted in the nursing simulation laboratory."
219179154|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #2|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
219179155|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #3|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
219179156|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #4|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
219179157|NCT06629168|DIAGNOSTIC_TEST|Telemetric prechamber reading|Non-invasive reading of telemetric prechamber made during each follow-up control.
219179158|NCT06629168|OTHER|Valve setting change|Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
219179159|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
219179160|NCT04118608|OTHER|No intervention|No intervention
219179161|NCT02305277|DRUG|BIA 9-1067 (clinical micronized, CM)|
219179162|NCT02305277|DRUG|BIA 9-1067 (to-be-marketed, TBM)|
218992297|NCT06722248|BEHAVIORAL|conventional training|Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.
219179163|NCT06798688|DEVICE|A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations|"This Study aims to pilot software algorithms based on respiratory features and hemodynamics for predicting exacerbations on a total of 20 participants with COPD. The end-points of this Study includes the following:~1. To validate respiratory-based biomarkers in models to predict exacerbations - benchmarking to be done versus physician assess exacerbations, emergency department visits, hospitalizations and any other visit.~2. To validate level of compliance, drop-out rate and if additional measures are required to get participants to follow-on"
219179164|NCT06629597|DRUG|YL201|YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
219179165|NCT06629597|DRUG|Docetaxel|Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
219179166|NCT06629597|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
219179167|NCT06629597|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
219179168|NCT06151834|PROCEDURE|KeriFuse implant implantation|The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
219179169|NCT04815720|DRUG|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
219179170|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
219179171|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
219179172|NCT06789705|DRUG|MDMA|MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
219179173|NCT06789705|OTHER|Placebo|Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
218992298|NCT06157918|DRUG|SYHA1813 oral solution (2.0g:25mg)|SYHA1813 oral solution, 25mg, oral
218992299|NCT06157918|DRUG|SYHA1813 oral solution (20ml:200mg)|SYHA1813 oral solution, 25mg, oral
218992300|NCT06447688|DRUG|Verapamil|Prevent
219179174|NCT06086418|DRUG|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
219179175|NCT06086418|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
219179176|NCT06086418|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
219179177|NCT04309188|DEVICE|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
218992301|NCT04460482|DEVICE|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
218992302|NCT04460482|DEVICE|Angiography|Angiography guided PCI
218992303|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
219749353|NCT05463133|DRUG|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
219749354|NCT05463133|DRUG|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
219749355|NCT05719246|BEHAVIORAL|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
218992304|NCT04731363|DIETARY_SUPPLEMENT|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
218992305|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
218992306|NCT04731363|DIETARY_SUPPLEMENT|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
218992307|NCT06893315|RADIATION|Photobiomodulation Therapy|Photobiomodulation (PBM) is a non-invasive therapy that uses low-level light, typically from lasers or Light Emission Diodes (LEDs), to stimulate cellular function and promote healing. It works by delivering specific wavelengths of light to target tissues, which enhances mitochondrial activity and increases adenosine triphosphate (ATP) production. PBM is commonly used for pain relief, reducing inflammation, and accelerating tissue repair in conditions like muscle injuries, arthritis, and skin disorders.
218992308|NCT06893315|OTHER|Hospital Standard Protocol of treatment for pain and healing|Medical team evaluations are conducted daily throughout the hospitalization period, and anti-inflammatory medications (ketoprofen ), analgesics (dipyrone), and, in cases where vulvar edema is observed, ice packs are prescribed. In addition to the standard treatment described, the health care team routinely offers patients the use of laser therapy (photobiomodulation) once a day during hospitalization. Patients who agree to the laser therapy receive both treatments.Patients who do not accept receiving PBM receive exactly only the same standard routine care described. These protocols are standardized at the hospital, and this observational study did not interfere with any care practices.
218992309|NCT06815237|DIETARY_SUPPLEMENT|Kenetik|Ketone supplement is randomly given once.
218992310|NCT06815237|OTHER|Alcohol beverage|Alcohol beverage is randomly given once. Participants will receive the alcohol beverage that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.050%
218992311|NCT06778447|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
218992312|NCT06778447|OTHER|Sham|A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
218992313|NCT06621719|PROCEDURE|Alveolar Cleft Reconstruction|Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
218992314|NCT06826612|GENETIC|SPK-10001|Specified dose on specified days
218992315|NCT06826612|OTHER|Placebo Surgery Control|Placebo Surgery procedure for SPK-10001
218992316|NCT06669247|DRUG|Linvoseltamab|Administered per protocol
218992317|NCT06669247|DRUG|REGN7945+Linvoseltamab|Administered per protocol
218992318|NCT06866379|OTHER|Brain imaging|fMRI session with the ALCUE paradigme.
218992319|NCT02513394|DRUG|Palbociclib|
218992320|NCT02513394|DRUG|Standard Adjuvant Endocrine Therapy|
218992321|NCT06822231|DEVICE|High-tech rehabilitative treatment|"Robotic Verticalization System (e.g., Erigo): Assists in regaining upright posture and mobility.~Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises.~Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training.~Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback"
219179178|NCT04309188|OTHER|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
219369296|NCT00732173|OTHER|counseling intervention|Undergo SUCCEED lifestyle intervention
219749356|NCT05499702|BEHAVIORAL|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
218992322|NCT06822231|OTHER|Rehabilitation|Traditional rehabilitative treatment
219369297|NCT00732173|OTHER|educational intervention|Receive information
219369298|NCT00732173|OTHER|survey administration|Undergo SUCCEED lifestyle intervention
218992323|NCT06491654|OTHER|12-week supervised exercise|During the study period (1 week for acute effects, 12 weeks for chronic effects), there will be 8 sessions per month, lasting 40-60 minutes each, with 2 sessions per week on alternate days, totaling 24 sessions. Each session includes: (1) warm-up (mobility exercises); (2) training: 5-min warm-up, followed by 15-min moderate-to-high intensity circuit of 7 functional global exercises with 10 reps each at a perceived exertion effort (RPE) of 5-7 on a scale of 1 to 10; (3) Aerobic exercise: starting at 15 mins, increasing by 5 mins biweekly to 30 mins by week 7; (4) Cool-down (general mobility); (5) Application of cohesive compressive bandage on the affected upper limb, worn for 2 hours post-session, removed at home. Participants may add a cotton bandage and finger bandage if needed.
219369299|NCT05521737|PROCEDURE|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
219369300|NCT05521737|PROCEDURE|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
219749357|NCT05499702|DRUG|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
219749358|NCT05030766|DRUG|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
219749359|NCT05030766|BEHAVIORAL|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
219749360|NCT05030766|BEHAVIORAL|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
219749361|NCT05059327|DRUG|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
219179179|NCT04021498|DRUG|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
219749362|NCT05059327|DRUG|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
219749363|NCT01419730|DRUG|Vitamin D3|Vitamin D3 50,000 IU
219179180|NCT04021498|OTHER|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
219179181|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
219179182|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
219179183|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
219179184|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
219179185|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
219179186|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
219179187|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
219179188|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
219179189|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
219179190|NCT05449132|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
219179191|NCT05449132|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
219749364|NCT01419730|BEHAVIORAL|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
219749365|NCT02947048|DRUG|L1-79|
219749366|NCT02947048|DRUG|Placebo|
219749367|NCT00518869|DRUG|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
219179192|NCT04048993|OTHER|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
219179193|NCT05720949|DRUG|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
219179194|NCT03830762|DRUG|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
219179195|NCT03830762|DRUG|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
219179196|NCT03344250|DRUG|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
219179197|NCT03344250|DRUG|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
219369301|NCT04484350|DRUG|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
219369302|NCT04484350|DRUG|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
219369303|NCT04484350|DRUG|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
219369304|NCT01356381|DRUG|Vildagliptin|Dosage 50mg b.i.d.
219369305|NCT01356381|DRUG|Placebo|50mg bid
219369306|NCT00432237|DRUG|MK0974 50 mg|
219369307|NCT00432237|DRUG|MK0974 150 mg|
219369308|NCT00432237|DRUG|MK0974 300 mg|
219749368|NCT06642025|BIOLOGICAL|CAR-T Cell Injection|"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."
219749369|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
219749370|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
219749371|NCT06637956|DRUG|Nitroglycerin (NTG)|Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
219749372|NCT06642883|DIETARY_SUPPLEMENT|Prolife|randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
219369309|NCT00432237|DRUG|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
219369310|NCT06395493|PROCEDURE|Pilates Group|In this study, the participants in the Pilates group will undergo 2 sessions per week, for 12 consecutive weeks.
219369311|NCT06395493|PROCEDURE|Exercise Group|In this study, the participants in the Exercise group will undergo 2 sessions per week, for 12 consecutive weeks.
219369312|NCT06395493|PROCEDURE|Control Group|The participants in the control group, are those who either opt not to do the exercises or are on the waiting list for physiotherapy intervention. Therefore, they will not undergo any intervention for 12 consecutive weeks.
219749373|NCT06642883|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 vial/day for 60 days.
219749374|NCT06643325|DIAGNOSTIC_TEST|Gastric ultrasound|Serial, gastric sonography
219749375|NCT06413914|BEHAVIORAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~."
219749376|NCT06567782|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219749377|NCT06567782|DRUG|CAPEOX|CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
219749378|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
219749379|NCT06800846|PROCEDURE|Intraosseous Morphine|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation
219749380|NCT06800846|PROCEDURE|Periarticular Injection|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.
219749381|NCT02063256|DIETARY_SUPPLEMENT|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
219749382|NCT02063256|OTHER|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
219749383|NCT04753619|DRUG|Niclosamide Oral Tablet|"* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding."
219749384|NCT03047044|OTHER|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
219749385|NCT03047044|OTHER|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
219749386|NCT01851798|OTHER|Home sleep test administered to all enrolled subjects|
219749387|NCT05793086|DIAGNOSTIC_TEST|Ultrasound|Using shear wave elastography and gray scale analysis of ultrasound.
219749388|NCT05793086|DIAGNOSTIC_TEST|Electrical impedance myography|Measurement of localized bioimpedance of muscle
219749389|NCT05793086|DIAGNOSTIC_TEST|Excitability testing|Electrical studies of myofiber excitability
219749390|NCT05731245|DRUG|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
219006657|NCT05647954|DRUG|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
219006658|NCT05647954|DRUG|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
219006659|NCT05647954|DRUG|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
219006660|NCT00662363|DRUG|Lubiprostone|24 µg po BID given with meals for 6 days
219006661|NCT00662363|DRUG|Senna|2 tabs daily for 6 days
219006662|NCT01379547|BEHAVIORAL|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
219006663|NCT01379547|BEHAVIORAL|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
219006664|NCT05495256|DEVICE|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
219369313|NCT03320499|PROCEDURE|echo doppler at the bed|we practise the echo doppler at the patient 's bed
219179198|NCT05467345|DEVICE|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
219179199|NCT04701645|COMBINATION_PRODUCT|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
219179200|NCT05210608|BEHAVIORAL|Working Memory Training + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
219179201|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Three-Dimensional Printer|Band and loop space maintainer produced with three-dimensional printer using micro laser sinterisation method
219179202|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Conventional Technique|Band and loop space maintainer produced with conventional methods
219179203|NCT06245187|OTHER|GWTG Atrial Fibrillation program|Evidence based recommended therapies and counseling prior to hospital discharge.
219179204|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in EFT
219749391|NCT03112928|DEVICE|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
219749392|NCT03112928|DEVICE|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
219749393|NCT05689099|DRUG|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
219749394|NCT05689099|DRUG|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
219749395|NCT05883709|DRUG|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
219179205|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in ERT
219179206|NCT05012176|OTHER|Quality-of-Life Assessment|Ancillary studies
219749396|NCT05589025|PROCEDURE|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
219179207|NCT05012176|OTHER|Questionnaire Administration|Ancillary studies
219179208|NCT06494943|DRUG|Sintilimab|PD-1 inhibitor
219179209|NCT06494943|DRUG|IBI110|LAG-3 inhibitor
219179210|NCT06494943|DRUG|Paclitaxel|Chemotherapy
219179211|NCT06494943|DRUG|Cis Platinum|Chemotherapy
219179212|NCT06494943|PROCEDURE|Surgery|Definitive surgery
219179213|NCT06494943|RADIATION|Adjuvant radiation|Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
219179214|NCT02912897|BIOLOGICAL|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
219179215|NCT05653661|PROCEDURE|Biopsy|Undergo tissue biopsies
219179216|NCT05653661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219179217|NCT05653661|PROCEDURE|Computed Tomography|Undergo CT scans
219179218|NCT05653661|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
219179219|NCT05653661|DRUG|Nab-paclitaxel/Danburstotug Complex AP160|Given IV
219179220|NCT04613947|BEHAVIORAL|Informed consent|The style of informing patients about the procedure they will undergo
219179221|NCT04613947|PROCEDURE|Third molar surgery|Surgical extraction of the third molar tooth
219179222|NCT05851573|BEHAVIORAL|Psychosocial intervention|an SLP-administered 5-week treatment focused on psychological well-being
219179223|NCT00832325|BEHAVIORAL|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
219369314|NCT03320499|PROCEDURE|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
219749397|NCT05589025|PROCEDURE|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
218992324|NCT06772675|BEHAVIORAL|External Facilitation|Designated external facilitators will conduct monthly meetings with local champions at each site. Designated facilitators will follow the developed facilitation guide, that includes content area to cover in each meeting, case scenarios as examples, and tips on how to communicate and support the internal facilitators. The goal is to enable problem-solving and support the local champion in implementing VRP with fidelity
218992325|NCT03677921|DIETARY_SUPPLEMENT|Investigational Product (Bio-Germanium)|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
218992326|NCT03677921|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
218992327|NCT04292743|BIOLOGICAL|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
218992328|NCT04292743|DRUG|FOLFIRINOX|intravenous administration of FOLFIRINOX
218992329|NCT03595267|OTHER|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations."
218992330|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
218992331|NCT05888831|DRUG|BMS-986449|Specified dose on specified days
218992332|NCT05888831|DRUG|Nivolumab|Specified dose on specified days
219369315|NCT03426176|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
219369316|NCT03426176|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
218992333|NCT06455345|DEVICE|Self-Guided Online ACT Program|Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.
218992334|NCT06455345|OTHER|Treatment As Usual|Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
218992335|NCT05766423|BEHAVIORAL|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond."
218992336|NCT06915545|DEVICE|Aortic Arch Single Branch Covered Stent System|to Evaluate the Safety and Efficacy of the Aortic Arch Single Branch Covered Stent System for Aortic Dissection Involving the Aortic Arch
218992337|NCT06937710|DIAGNOSTIC_TEST|Measure of symmetry between the inferior limbs|Hip force moments will be analyzed in the 3 planes (in Nm/Kg) and compared between the two legs.
218992338|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
218992339|NCT02385045|DEVICE|i-scan|i-scan function is located on the head of the Pentax endoscopes
219369317|NCT03426176|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
219369318|NCT03426176|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
219369319|NCT05981066|DRUG|Neoantigen vaccine, I.M injection|Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
219369320|NCT04847388|DRUG|Substance like alcohol, marijuana, etc.|Cohort study
219369321|NCT04122599|DRUG|Melatonin|Melatonin for prevent post stroke delirium
219179224|NCT00832325|BEHAVIORAL|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
219749398|NCT06109324|OTHER|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
219179225|NCT00832325|BEHAVIORAL|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
219179226|NCT06040320|DRUG|Polatuzumab vedotin|Given at 1.8 mg/kg
219179227|NCT06040320|DRUG|Rituximab|Given at 375 mg/m\^2
219179228|NCT06040320|DRUG|CHP|Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
219179229|NCT04045184|OTHER|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
219179230|NCT06493422|BEHAVIORAL|Reaching Movements|participants will perform a perceptual decision making task while moving their hand.
219179231|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
219179232|NCT05302193|OTHER|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
219749399|NCT06109324|OTHER|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
219749400|NCT03559530|DRUG|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
218992340|NCT02385045|DEVICE|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
218992341|NCT00042289|DRUG|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
218992342|NCT00042289|DRUG|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
218992343|NCT00042289|DRUG|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
218992344|NCT00042289|DRUG|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
218992345|NCT00042289|DRUG|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
218992346|NCT00042289|DRUG|dolutegravir|dolutegravir 50 mg q.d.
218992347|NCT00042289|DRUG|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
218992348|NCT00042289|DRUG|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
218992349|NCT00042289|DRUG|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
218992350|NCT00042289|DRUG|efavirenz|efavirenz 600 mg q.d.
218992351|NCT00042289|DRUG|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
218992352|NCT00042289|DRUG|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
218992353|NCT00042289|DRUG|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
218992354|NCT00042289|DRUG|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
218992355|NCT00042289|DRUG|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
218992356|NCT00042289|DRUG|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
218992357|NCT00042289|DRUG|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
218992358|NCT00042289|DRUG|kanamycin|kanamycin (2nd line TB drug)
218992359|NCT00042289|DRUG|amikacin|amikacin (2nd line TB drug)
218992360|NCT00042289|DRUG|capreomycin|capreomycin (2nd line TB drug)
218992361|NCT00042289|DRUG|moxifloxacin|moxifloxacin (2nd line TB drug)
218992362|NCT00042289|DRUG|levoflaxacin|levofloxacin (2nd line TB drug)
218992363|NCT00042289|DRUG|ofloxacin|ofloxacin (2nd line TB drug)
218992364|NCT00042289|DRUG|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
218992365|NCT00042289|DRUG|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
218992366|NCT00042289|DRUG|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
218992367|NCT00042289|DRUG|high dose INH|high dose INH (2nd line TB drug)
218992368|NCT00042289|DRUG|bedaquiline|bedaquiline (2nd line TB drug)
218992369|NCT00042289|DRUG|clofazamine|clofazamine (2nd TB drug)
218992370|NCT00042289|DRUG|delamanid|delamanid (2nd line TB drug)
218992371|NCT00042289|DRUG|linezolid|linezolid (2nd line TB drug)
218992372|NCT00042289|DRUG|pretomanid|pretomanid (2nd line TB drug)
218992373|NCT00042289|DRUG|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
218992374|NCT00042289|DRUG|etonogestrel implant|etonogestrel implant contraceptive
218992375|NCT00042289|DRUG|nevirapine|nevirapine 200 mg twice a day
218992376|NCT00042289|DRUG|amprenavir|amprenavir 1200mg twice a day
218992377|NCT00042289|DRUG|abacavir|abacavir 300mg twice a day
219749401|NCT03058874|DEVICE|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
219749402|NCT03058874|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
219749403|NCT06565117|DRUG|White yu green skin lotion|Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
219749404|NCT03331354|BEHAVIORAL|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
219749405|NCT03331354|OTHER|Basic vocational services|self-help manual
219749406|NCT06469242|DEVICE|Serafilcon A multifocal contact lenses|Investigational multifocal soft contact lenses
219749407|NCT06469242|DEVICE|Senofilcon A multifocal contact lenses|Commercially available multifocal soft contact lenses
219749408|NCT06469242|DEVICE|CLEAR CARE® Cleaning & Disinfecting Solution|Hydrogen peroxide-based contact lens cleaning and disinfection system
219749409|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
219749410|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
219749411|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
219749412|NCT01370044|DRUG|Carbogen|3 minutes administration of carbogen
219749413|NCT01370044|DRUG|Placebo|3 minutes administration of oxygen
219749414|NCT02816814|OTHER|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
219749415|NCT02816814|OTHER|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
219749416|NCT04626726|DRUG|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
219749417|NCT04626726|DRUG|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
219749418|NCT04626726|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
219749419|NCT04626726|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
219749420|NCT04626726|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
219749421|NCT04618276|OTHER|Photodynamic Therapy|PDT with two different photosensitizers
219749422|NCT05941429|DRUG|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
219749423|NCT05941429|DRUG|Silver diamine fluoride|38% silver diamine fluoride
219749424|NCT02992730|BEHAVIORAL|No Intervention|No Intervention
219749425|NCT01208766|DRUG|Bortezomib, Melphalan, Prednisone (VMP)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11,22,25,29,32~* Melphalan \_ 9 mg/m² \_ p.o. \_ days 1-4~* Prednisone \_ 60 mg/m² \_ p.o. \_ days 1-4"
219749426|NCT01208766|DRUG|1 or 2 cycle(s) HDM (High Dose Melphalan)|"\- Melphalan \_ 100 mg/m² \_ i.v. rapid infusion \_ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
219749427|NCT01208766|DRUG|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11~* Lenalidomide \_ 25 mg \_ p.o. \_ days 1-21~* Dexamethasone \_ 20 mg \_ p.o. \_ days 1,2,4,5,8,9,11,12"
219749428|NCT03885700|BEHAVIORAL|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation."
219749429|NCT01968122|DEVICE|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
219749430|NCT06636578|DRUG|dexmedetomidine|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
219749431|NCT06636578|DRUG|ropivacaine|will receive 30 ml of 0.25% of plain ropivacaine for each side.
219749432|NCT06636578|DRUG|fentanyl|will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
219749433|NCT06576687|OTHER|Physical Rehabilitation|Exercises include (1) single-limb hops to stabilization, (2) hop to stabilization and reach, (3) unanticipated hop to stabilization, (4) single-limb stance activities, and (5) continuous choice-reaction hopping.
219749434|NCT01928537|DRUG|rigosertib sodium|
219749435|NCT01657331|DRUG|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
218992378|NCT00042289|DRUG|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
218992379|NCT00042289|DRUG|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
218992380|NCT00042289|DRUG|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
219749436|NCT01657331|DRUG|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
219749437|NCT01657331|DRUG|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
219749438|NCT01664715|BEHAVIORAL|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
219749439|NCT01664715|BEHAVIORAL|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
219749440|NCT01664715|BEHAVIORAL|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
219749441|NCT04924933|DIAGNOSTIC_TEST|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
219749442|NCT06802809|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247 (Crispact®)|Crispact® is a probiotic food supplement containing Lactobacillus crispatus M247.
219749443|NCT06802809|OTHER|Placebo|The placebo does not contain the active probiotic strain and consists of inactive excipients.
219749444|NCT05530655|DRUG|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
219749445|NCT03275831|DEVICE|PluroGel|Surfactant based gel
219749446|NCT03275831|DEVICE|Intrasite gel|Hydrogel
219749447|NCT00997763|DEVICE|XIENCE V|everolimus-eluting stent
219749448|NCT00997763|DEVICE|CYPHER|sirolimus-eluting stent
219749449|NCT03801590|DEVICE|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
219749450|NCT05793502|DEVICE|Solia S and Selectra 3D Developed by BIOTRONIK|LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
219749451|NCT02652247|PROCEDURE|molecular analysis of exhaled breath condensate|
219749452|NCT02652247|PROCEDURE|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
219749453|NCT02652247|PROCEDURE|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
219749454|NCT03380273|BEHAVIORAL|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes"
219749455|NCT03452930|RADIATION|Radiation Therapy|Undergo RT
219749456|NCT03452930|DRUG|Tinostamustine|Given IV
219749457|NCT04830085|PROCEDURE|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
219749458|NCT01362790|DRUG|Pentostatin|Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
219749459|NCT01362790|DRUG|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
219749460|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
219749461|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
219749462|NCT02457065|BEHAVIORAL|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
219749463|NCT05896241|OTHER|non-interventional study|non-interventional study
219749464|NCT01969214|DEVICE|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
219749465|NCT05044767|DEVICE|total hip arthroplasty|hip replacement surgery
218992381|NCT00042289|DRUG|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
218992382|NCT00042289|DRUG|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
218992383|NCT00042289|DRUG|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
218992384|NCT00042289|DRUG|emtricitabine|emtricitabine 200 mg once a day
218992385|NCT00042289|DRUG|tenofovir|tenofovir 300 mg once a day
218992386|NCT00042289|DRUG|nelfinavir dosage #1|nelfinavir \[625 mg tablets\] 1250 mg twice a day
218992387|NCT00042289|DRUG|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
219749466|NCT00279695|PROCEDURE|high frequency ultrasound examination|high frequency ultrasound examination of the eye
219749467|NCT03429140|DRUG|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
219749468|NCT03429140|OTHER|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
219749469|NCT00763828|DEVICE|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
219749470|NCT05887336|DEVICE|Walther System|Walther System providing INMEST treatment
219749471|NCT05887336|DEVICE|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
219749472|NCT05887336|DRUG|Non preserved ocular lubricants|"* Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)"
219749473|NCT05887336|PROCEDURE|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
219179233|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
219179234|NCT04380545|DRUG|Fluorouracil|Given IV
219179235|NCT04380545|BIOLOGICAL|Nivolumab|Given IV
219179236|NCT04380545|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Given SC
219179237|NCT04927364|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
219179238|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
219179239|NCT03547323|DEVICE|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
219179240|NCT03547323|DEVICE|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
219179241|NCT04583293|OTHER|No intervention|This study does not involve any intervention or new treatment.
219179242|NCT05478564|OTHER|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
219179243|NCT05219123|OTHER|ERCP with no PD cannulation|ERCP with no PD cannulation
219179244|NCT05219123|OTHER|ERCP with single PD cannulation|ERCP with single PD cannulation
219179245|NCT03483610|BEHAVIORAL|Provider Referral|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
219179246|NCT03483610|BEHAVIORAL|Text Messaging|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
219179247|NCT03523975|DRUG|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
219749474|NCT03510689|DIAGNOSTIC_TEST|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
218992388|NCT00042289|DRUG|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
218992389|NCT00042289|DRUG|raltegravir|raltegravir 400 mg twice a day
218992390|NCT00042289|DRUG|etravirine|etravirine 200 mg twice a day
218992391|NCT00042289|DRUG|maraviroc|maraviroc 150 mg or 300 mg twice a day
218992392|NCT00042289|DRUG|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
218992393|NCT00042289|DRUG|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
218992394|NCT00042289|DRUG|nelfinavir dosage #2|nelfinavir \[625 mg tablets\] 1875 mg twice a day
218992395|NCT00042289|DRUG|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
218992396|NCT00042289|DRUG|rilpivirine|rilpivirine (25 mg q.d.)
218992397|NCT00042289|DRUG|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
218992398|NCT04653129|PROCEDURE|Autologous Fat Grafting|"* The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
218992399|NCT04653129|PROCEDURE|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
218992400|NCT01687998|DRUG|Evacetrapib|Administered Orally
218992401|NCT01687998|DRUG|Placebo|Administered Orally
218992402|NCT00745823|DRUG|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
218992403|NCT00745823|DRUG|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
218992404|NCT00745823|DRUG|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
218992405|NCT03143439|BEHAVIORAL|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
218992406|NCT05364125|OTHER|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
218992407|NCT05364125|OTHER|Control|Normal Saline will be used
218992408|NCT04011267|OTHER|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
219179248|NCT03523975|DRUG|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
219179249|NCT03523975|DRUG|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
219179250|NCT04221945|BIOLOGICAL|Pembrolizumab|IV infusion
219179251|NCT04221945|DRUG|Placebo for pembrolizumab|IV infusion
219179252|NCT04221945|DRUG|Cisplatin|IV infusion
219179253|NCT04221945|RADIATION|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
219179254|NCT04221945|RADIATION|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
219179255|NCT06158139|BIOLOGICAL|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
219179256|NCT04899310|BIOLOGICAL|mRNA-3705|A sterile liquid for injection
219179257|NCT00858312|OTHER|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
219179258|NCT00858312|OTHER|Low Dairy|less than 1 serving of dairy foods per day.
219179259|NCT05552014|BEHAVIORAL|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
219179260|NCT05552014|BEHAVIORAL|Mental Health Education|Mental Health Education Seminar
219179261|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
219179262|NCT00621894|DRUG|Placebo|Placebo
219179263|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
219179264|NCT05307133|OTHER|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
219749475|NCT03510689|OTHER|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
219749476|NCT03510689|OTHER|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
219749477|NCT01173744|DEVICE|Gamma-3 Nail|Gamma-3 Nail (stryker)
219179265|NCT04118088|BIOLOGICAL|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
219179266|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
219179267|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
219179268|NCT04169906|DRUG|Placebo|Participants will receive placebo once daily for 7 consective days
219179269|NCT04169906|DRUG|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
219179270|NCT04169906|DRUG|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
219179271|NCT04169906|DRUG|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
219179272|NCT05148507|DEVICE|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2003.
219179273|NCT03539822|DRUG|Cabozantinib|by mouth
219179274|NCT03539822|DRUG|Durvalumab|infusion
219749478|NCT01173744|DEVICE|DHS|DHS (Zimmer)
219749479|NCT06007157|BEHAVIORAL|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
219749480|NCT00219726|DRUG|Imatinib mesylate|
219749481|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
219179275|NCT03539822|DRUG|Tremelimumab|infusion
219179276|NCT04867122|BEHAVIORAL|Problem-Solving Therapy|Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.
219179277|NCT04867122|OTHER|Attention-matched Control|"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."
219749482|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
219749483|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
219179278|NCT04867122|OTHER|In-depth interviews|The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.
219179279|NCT04091750|DRUG|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
219179280|NCT04091750|DRUG|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
219749484|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
219179281|NCT04091750|DRUG|Cabozantinib|Induction and Maintenance: 40mg PO daily
219179282|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
219179283|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
219179284|NCT06242119|DIAGNOSTIC_TEST|J-PET scan|Diagnostic Test: Positron-Emission Tomography Imaging Examination of radiation distribution in the patient body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA, \[18F\]choline or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
219179285|NCT05921357|OTHER|Questionnaire|Questionnaire and examine
219179286|NCT05342064|OTHER|patient-centered TB preventive therapy|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
219179287|NCT05342064|OTHER|TB preventive therapy adherence support|As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
219179288|NCT02584244|DRUG|LUM015|
219179289|NCT02584244|DEVICE|LUM 2.6 Imaging Device|
219179290|NCT04106466|DEVICE|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
219179291|NCT06770231|OTHER|Single drill system|New system for drilling
219179292|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
219179293|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
219179294|NCT05388916|OTHER|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
219179295|NCT03844074|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
219179296|NCT03844074|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
219179297|NCT03033446|RADIATION|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
219179298|NCT03033446|DRUG|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
219179299|NCT05700123|PROCEDURE|In-Office Hysteroscopy|In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
219749485|NCT02659085|DRUG|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
219749486|NCT02659085|PROCEDURE|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
219749487|NCT01666366|PROCEDURE|Coronary artery bypass grafting|
219749488|NCT02124980|BEHAVIORAL|Recovery Line|
219749489|NCT02260232|OTHER|exercise training|
219749490|NCT06179537|DRUG|BLU-5937|Single and multiple doses assessment
219179300|NCT03016533|DRUG|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 50 mg tablets.
219179301|NCT03016533|DRUG|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
219179302|NCT03016533|DRUG|ABC/DTG/3TC immediate release tablets|ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
219179303|NCT03016533|DRUG|ABC/DTG/3TC film-coated dispersible tablets|ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
219191554|NCT03387761|DRUG|Ipilimumab|"For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg"
219191555|NCT03387761|DRUG|Nivolumab|"For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~\- Days 1, 22 and 43: Nivolumab 3 mg/kg"
219191556|NCT06482268|COMBINATION_PRODUCT|Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)|"Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain."
219191557|NCT06799312|DEVICE|Ipsilesional high frequency rTMS combined with physiotherapy|As mentioned in details in arms description.
219749491|NCT00516308|DEVICE|NightHawk|
219179304|NCT06797557|DIAGNOSTIC_TEST|2D Ultrasound|"* Crow- rump length (CRL) measurement using 2D ultrasound. Proper measurement of the CRL was done according to obtaining a true, unflexed, longitudinal section of the embryo or fetus, with the end-points of the crown (the top of the head) and rump (the end of the trunk) clearly defined, and then placing the calipers correctly on these defined end-points.~* Yolk sac diameter (largest outer to outer measure).~* Mean gestational sac diameter (arithmetic mean of 3 diameters).~* Embryonic heart rate. the heart rate was determined from M-mode tracings using electronic calipers .The sweep speed was set at 4 s and the calculation of the heart rate was made by measuring the time interval of two cardiac cycles, using clearly identified points in the M-mode tracing"
219179305|NCT06797557|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound rotational VOCAL method was used. YSV measurement (axial, sagittal and coronal). The sagittal plane was chosen as the reference plane and 'scanned' to obtain the longest axis of the yolk sac. Then a magnification of image was used and the yolk sac moved to the center of the plane. The VOCAL switch was then activated using a 30° rotation angle and the manual setting. Calipers were positioned on the superior and inferior extremities of the structure and after obtaining six sequential planes, the equipment automatically displayed the yolk sac as a 3D image with its volume in cm3
219179306|NCT04457687|DRUG|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
219179307|NCT04473222|BEHAVIORAL|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
218992409|NCT00612690|BEHAVIORAL|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
219179308|NCT04473222|BEHAVIORAL|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
219179309|NCT02919306|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
219179310|NCT02919306|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
219179311|NCT02919306|DRUG|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
219179312|NCT06774937|DIAGNOSTIC_TEST|All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his|"Thorough clinical examination:~1\. General examination including general look, vital signs and anthropometric measurements.~2\. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
219179313|NCT06774937|DIAGNOSTIC_TEST|EMG ,rNST,Ach R antibodies & thyroid function|"C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
218992410|NCT00612690|BEHAVIORAL|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
219179314|NCT06271278|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
219179315|NCT04293055|BEHAVIORAL|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
218992411|NCT03548103|DIETARY_SUPPLEMENT|Green tea extract|Green tea extract 500 mg tid for 16 weeks
218992412|NCT03548103|DIETARY_SUPPLEMENT|Placebo|Placebo tid for 16 weeks
218992413|NCT04232384|PROCEDURE|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
218992414|NCT04232384|PROCEDURE|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
218992415|NCT02955602|DRUG|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
219179316|NCT04293055|BEHAVIORAL|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
219179317|NCT03560609|DEVICE|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
219749492|NCT01061788|DRUG|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
219179318|NCT03560609|DEVICE|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
218992416|NCT02955602|DRUG|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
218992417|NCT02955602|DRUG|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
219179319|NCT03560609|DEVICE|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
219179320|NCT03560609|DEVICE|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
219179321|NCT03560609|DEVICE|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
219179322|NCT02839161|BIOLOGICAL|Na-GST-1/Alhydrogel|
219179323|NCT02839161|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
219179324|NCT02839161|BIOLOGICAL|Hepatitis B Vaccine|
219179325|NCT04636528|DEVICE|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
219179326|NCT04636528|DEVICE|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, physical therapists will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
219179327|NCT06519487|BEHAVIORAL|Cyberball|"Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars."
219179328|NCT06192329|BEHAVIORAL|Hot water therapy|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
219179329|NCT06192329|BEHAVIORAL|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
219179330|NCT06561477|OTHER|Intensive care cirrhosis outcome (ICCO) score|ICCO score will be calculated for the participants to use it as a predictor for mortality and ICU outcome The ICCO score is 0.3707 + (0.0773 x bilirubin (mg/dl)) - (0.00849 x cholesterol (mg/dl)) -(0.0155 x creatinine clearance (ml/min)) + (0.1351 x lactate (mmol/l))
219179331|NCT06293950|BIOLOGICAL|WJMSC|\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
219179332|NCT04195698|DRUG|Upadacitinib|Upadacitinib will be administered oral as tablet
219179333|NCT05165524|DEVICE|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
219369322|NCT04139083|PROCEDURE|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
218992418|NCT03647397|DEVICE|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
218992419|NCT01523990|DRUG|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
219369323|NCT04139083|PROCEDURE|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
219369324|NCT02393911|DIETARY_SUPPLEMENT|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
219749493|NCT04116684|DEVICE|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
219749494|NCT00834782|PROCEDURE|IOP measurement|Measuring IOP
219749495|NCT00261339|DRUG|Pantoprazole|
219749496|NCT00044785|DRUG|triacetyluridine|
219749497|NCT00044785|DRUG|fluorouracil|
219749498|NCT00044785|DRUG|leucovorin|
219749499|NCT00044785|DRUG|camptosar|
219749500|NCT01862354|PROCEDURE|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
219749501|NCT01862354|PROCEDURE|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
219749502|NCT06052592|OTHER|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
219749503|NCT00670644|OTHER|questionnaire administration|Completed self-report form
219179334|NCT05165524|DRUG|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
219191558|NCT06799312|DEVICE|Contralesional Continuous Burst Theta rTMS (cTBS) + Physiotherapy|As mentioned in details in arms description.
219191559|NCT06799312|DEVICE|Sham rTMS + Physiotherapy|As mentioned in details in arms description.
219191560|NCT06798779|DEVICE|Glasses|The patients will have had their vision corrected with glasses that may contain both spherical and cylindrical corrections. The glasses prescription that offers the best subjective correction of vision are being recorded.
219749504|NCT00670644|OTHER|survey administration|Completed self-report form-other
219749505|NCT00670644|PROCEDURE|quality-of-life assessment|Completed self-report form qol
218992420|NCT01523990|DRUG|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
218992421|NCT02557620|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
219191561|NCT06798779|DIAGNOSTIC_TEST|Corneal topography|This is a scan of the cornea (front of the eye). This gives us information on how the cornea is refracting light for the patient.
219369325|NCT03514082|DEVICE|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
219369326|NCT00267527|DRUG|CJC 1295|
219749506|NCT03598348|DRUG|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
219749507|NCT03598348|DRUG|Apatinib|Apatinib 250mg po Qd
219749508|NCT05006664|DRUG|Adcetris 50 MG Injection|Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
219749509|NCT05006664|DRUG|Endoxan|Treatment by study drug Cyclophosphamide (Endoxan) in combination.
219749510|NCT05006664|DRUG|Doxorubicin|Treatment by study drug Doxorubicin in combination.
219749511|NCT05006664|DRUG|Etoposide|Treatment by study drug Etoposide in combination.
219749512|NCT05006664|DRUG|Prednisone tablet|Treatment by study drug Prednisone in combination.
219179335|NCT05507684|OTHER|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
219179336|NCT06269484|DRUG|Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
219179337|NCT06269484|DRUG|Zibotentan + placebo (placebo matching dapagliflozin tablet)|"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"
219179338|NCT06269484|DRUG|Zibotentan + dapagliflozin|"zibotentan capsule~dapagliflozin 10 mg tablet"
219179339|NCT05740813|DRUG|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
219179340|NCT05740813|DRUG|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
219179341|NCT05740813|DRUG|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
219179342|NCT02103361|DRUG|Ustekinumab|
219179343|NCT02103361|DRUG|Guselkumab|
218992422|NCT02557620|DRUG|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
219179344|NCT05966961|DEVICE|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
219179345|NCT05966961|DEVICE|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
218992423|NCT03748797|OTHER|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
218992424|NCT04908878|PROCEDURE|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
218992425|NCT04908878|PROCEDURE|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
218992426|NCT06040372|DRUG|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
218992427|NCT06040372|DRUG|Placebo|Placebo is provided as a matching placebo
219179346|NCT06410950|DIAGNOSTIC_TEST|MyotonPRO Assessment of Muscle Biomechanical Properties|"Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements."
219179347|NCT06087536|DRUG|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
219179348|NCT06087536|DRUG|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
219179349|NCT06806501|BEHAVIORAL|Unilateral Resistance Exercise|Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.
219179350|NCT04201457|DRUG|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
219179351|NCT04201457|DRUG|Trametinib|Tablet; Powder for Oral Solution
219179352|NCT04201457|DRUG|Hydroxychloroquine|Tablet
219749513|NCT00002930|PROCEDURE|positron emission tomography|
218992428|NCT03156543|DEVICE|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
218992429|NCT03156543|OTHER|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
218992430|NCT00413452|DRUG|Etanercept|50 mg once weekly
218992431|NCT03256565|DIAGNOSTIC_TEST|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
218992432|NCT03583489|DRUG|APD421|10 mg IV
219179353|NCT03123848|DRUG|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
219179354|NCT01369355|DRUG|Placebo SC|Placebo will be administered subcutaneously.
219179355|NCT01369355|DRUG|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
219179356|NCT01369355|DRUG|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
219179357|NCT01369355|DRUG|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
219179358|NCT01369355|DRUG|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
219749514|NCT00002930|RADIATION|fludeoxyglucose F 18|
219749515|NCT06571435|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test|"The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm."
218992433|NCT03583489|DRUG|Placebo|IV
218992434|NCT03583489|DRUG|Ondansetron|4 mg IV
218992435|NCT04214054|OTHER|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
218992436|NCT04214054|PROCEDURE|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
218992437|NCT05292898|BIOLOGICAL|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
219179359|NCT06296459|OTHER|3D R100 scanner|A cone beam computed tomography used for planning of implant surgery
218992438|NCT05062434|OTHER|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
219179360|NCT06296459|OTHER|Conventional Radiograph|Imaging used as standard of care to plan for implant surgery
219179361|NCT03183570|DRUG|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
219749516|NCT03903783|OTHER|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
219179362|NCT06425211|BEHAVIORAL|Therapeutic exercises|Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.
219179363|NCT06425211|DEVICE|Perineal electromyographic biofeedback|Free muscle work and gross motor coordination:
219179364|NCT06425211|DEVICE|Electrical stimulation|Muscular proprioceptive work: 50 Hz 300 µs
218992439|NCT00643227|DRUG|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
218992440|NCT00643227|DRUG|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
218992441|NCT00297375|DRUG|tramadol HCl/acetaminophen|
219179365|NCT05553860|OTHER|Speech positioning technique|Speech positioning technique
219179366|NCT01902173|PROCEDURE|Biopsy|Undergo a biopsy
219179367|NCT01902173|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219179368|NCT01902173|PROCEDURE|Computed Tomography|Undergo a CT scan
219179369|NCT01902173|DRUG|Dabrafenib Mesylate|Given PO
219179370|NCT01902173|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219179371|NCT01902173|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219179372|NCT01902173|DRUG|Uprosertib|Given PO
219179373|NCT02649842|DEVICE|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
219179374|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
219179375|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
219179376|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
219179377|NCT04625270|DRUG|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
219179378|NCT04625270|DRUG|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
219179379|NCT04014088|DEVICE|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
219179380|NCT06495216|DEVICE|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
219179381|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
219179382|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
219179383|NCT05540665|DRUG|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
219179384|NCT04207723|OTHER|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
219179385|NCT04207723|DRUG|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
219179386|NCT06422936|DRUG|BO-112|Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
219191562|NCT05580991|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
219749517|NCT03903783|OTHER|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
219749518|NCT03935347|DRUG|Cyclophosphamide|Given IV
219749519|NCT03935347|DRUG|Fludarabine|Given IV
219749520|NCT03935347|DRUG|Fludarabine Phosphate|Given IV
219749521|NCT03935347|BIOLOGICAL|Pembrolizumab|Given IV
219749522|NCT03935347|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
218992442|NCT06769854|DEVICE|Urgent PC|PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
218992443|NCT05575986|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
218992444|NCT02568800|DRUG|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
218992445|NCT02568800|DRUG|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
218992446|NCT06032442|DIETARY_SUPPLEMENT|ARTNEO|"Dietary Supplement: undenatured collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
218992447|NCT06032442|DRUG|Artra|"Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months."
218992448|NCT06789861|DRUG|TT5|Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients
218992449|NCT06789861|DRUG|Placebo - TT5 vehicle|Intravenous administration of vehicule, according to the same drug regimen than TT5
218992450|NCT06547528|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
218992451|NCT02687633|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
218992452|NCT00101595|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
218992453|NCT04462445|DRUG|Pazopanib|
218992454|NCT02183194|DEVICE|Lutonix Paclitaxel Drug Coated Balloon|
218992455|NCT01509950|PROCEDURE|Staples|Staples for closure of cesarean section skin incision
218992456|NCT01509950|PROCEDURE|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
218992457|NCT01509950|PROCEDURE|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
218992458|NCT00959231|DRUG|cyclophosphamide|
218992459|NCT00959231|DRUG|cyclosporine|
218992460|NCT00959231|DRUG|fludarabine phosphate|
218992461|NCT00959231|DRUG|mycophenolate mofetil|
218992462|NCT00959231|OTHER|laboratory biomarker analysis|
218992463|NCT00959231|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
218992464|NCT00959231|PROCEDURE|umbilical cord blood transplantation|
218992465|NCT00959231|RADIATION|total-body irradiation|
218992466|NCT01434667|BEHAVIORAL|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
218992467|NCT01434667|BEHAVIORAL|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
218992468|NCT06374901|DRUG|Tislelizumab|Preoperative treatment with Tislelizumab
219749523|NCT03935347|BIOLOGICAL|Aldesleukin|Given IV
219749524|NCT00693147|PROCEDURE|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
219749525|NCT03817580|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219749526|NCT03817580|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219749527|NCT03817580|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219749528|NCT02852707|BEHAVIORAL|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
219749529|NCT02852707|BEHAVIORAL|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
219749530|NCT02852707|BEHAVIORAL|Not exposed|People not engaged in regular sports competition/exercise training.
219749531|NCT06322901|PROCEDURE|Flap|Different flap designs for implant placement
219749532|NCT03880357|DRUG|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
219749533|NCT03880357|DRUG|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
219749534|NCT03880357|DRUG|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
219749535|NCT00184392|PROCEDURE|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
219749536|NCT02320656|OTHER|Blood sampling|Longitudinal (3 stages of the disease)
219749537|NCT02320656|OTHER|Bone marrow aspirate|Longitudinal (3 stages of the disease)
219749538|NCT02320656|OTHER|Skin biopsy|Single biopsy (optional)
219749539|NCT02320656|OTHER|Buccal swab|Single sampling.
219749540|NCT03430999|DRUG|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
219749541|NCT03430999|DRUG|Placebo|Placebo
219749542|NCT06254625|OTHER|Fecal Microbiome|Fecal microbiome transplantation from a healthy donor.
219749543|NCT06254625|OTHER|Placebo|Place capsules
219749544|NCT03254810|BIOLOGICAL|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
219749545|NCT03254810|BIOLOGICAL|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
219749546|NCT03254810|BIOLOGICAL|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
219749547|NCT06310486|OTHER|Drowning-related OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
219749548|NCT06310486|OTHER|Drowning-related non-OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
219749549|NCT04715126|OTHER|Oxyjun|One capsule to be taken after breakfast with water.
219749550|NCT04715126|OTHER|Placebo|One capsule to be taken after breakfast with water.
218992469|NCT06374901|DRUG|SOX/XELOX|Preoperative treatment with SOX/XELOX
218992470|NCT02743169|OTHER|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
218992471|NCT02991248|DEVICE|robotic training|robotic training by applying pelvis force perturbation
218992472|NCT02991248|DEVICE|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
218992473|NCT02991248|DEVICE|treadmill|conventional treadmill training only
219749551|NCT03156114|DRUG|BI 754111|Day 1 of 3 week cycle
219749552|NCT03156114|DRUG|BI 754091|Day 1 of 3 week cycle
219749553|NCT00822380|DIETARY_SUPPLEMENT|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
219749554|NCT00822380|DIETARY_SUPPLEMENT|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
219749555|NCT00822380|DIETARY_SUPPLEMENT|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
219749556|NCT00822380|DIETARY_SUPPLEMENT|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
219749557|NCT00822380|DIETARY_SUPPLEMENT|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
219749558|NCT05271006|BEHAVIORAL|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
219749559|NCT04172220|DRUG|Midazolam|1-2 mg of Midazolam as premedication.
219749560|NCT04172220|PROCEDURE|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
219749561|NCT04172220|PROCEDURE|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
219179387|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
219179388|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
219179389|NCT06807762|DRUG|Cannabis oil|"Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages:~Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg.~Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days."
219179390|NCT05781893|OTHER|Digital intervention (DiLCoS)|The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.
219179391|NCT05781893|OTHER|Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
219179392|NCT04821440|DEVICE|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
219179393|NCT04821440|DEVICE|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
219179394|NCT04022850|BEHAVIORAL|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
219179395|NCT04022850|BEHAVIORAL|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
219749562|NCT04172220|PROCEDURE|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
219749563|NCT04172220|PROCEDURE|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
219749564|NCT05202782|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given IV
219749565|NCT05202782|OTHER|Quality-of-Life Assessment|Ancillary studies
219179396|NCT04022850|BEHAVIORAL|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
219179397|NCT05181540|BIOLOGICAL|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
219179398|NCT05181540|OTHER|Placebo|Placebo
219179399|NCT06060782|DRUG|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
219179400|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
219749566|NCT05202782|OTHER|Questionnaire Administration|Ancillary studies
219749567|NCT05202782|DRUG|Zanubrutinib|Given PO
219749568|NCT03719859|OTHER|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
219749569|NCT03719859|OTHER|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
219179401|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
219179402|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
219749570|NCT03157895|BEHAVIORAL|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
219179403|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
219749571|NCT02895555|PROCEDURE|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
219749572|NCT02895555|PROCEDURE|Allograft|Approx 50 g of allograft bone in the fused site
219749573|NCT05642338|DIAGNOSTIC_TEST|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
219749574|NCT01272258|DRUG|PRO 140|SC injection
219749575|NCT01272258|DRUG|Placebo|SC injection
219749576|NCT01506726|DRUG|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
219749577|NCT01506726|DRUG|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
219749578|NCT01825863|DRUG|Ropivacaine|
219749579|NCT01825863|DRUG|Saline 9%|
219749580|NCT02009826|RADIATION|[18F]-PBR111 Positron Emission Tomography (PET)|\[18F\]-PBR111 radioligand to assess binding to TSPO
219749581|NCT02009826|BEHAVIORAL|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
219179404|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
219179405|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
219179406|NCT06413810|OTHER|Calmarell|Food ingredient
219749582|NCT02009826|BIOLOGICAL|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
219749583|NCT02001519|DRUG|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
219749584|NCT01468155|DRUG|dabigatran|30 days pre ablation and 90 days post ablation
219749585|NCT00616720|BIOLOGICAL|aldesleukin|
219749586|NCT00616720|BIOLOGICAL|idiotype-pulsed autologous dendritic cell vaccine APC8020|
219749587|NCT00616720|BIOLOGICAL|recombinant interferon gamma|
219749588|NCT00616720|GENETIC|polymerase chain reaction|
219749589|NCT00616720|GENETIC|reverse transcriptase-polymerase chain reaction|
219749590|NCT00616720|OTHER|flow cytometry|
219749591|NCT00616720|OTHER|laboratory biomarker analysis|
219749592|NCT05279560|BIOLOGICAL|autologous PRP (platelet rich plasma)|The required volume of PRP will be extracted from 60 ml of the patient's peripheral blood. Injecting PRP into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. After centrifugation of the whole blood, 5ml PRP will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
219749593|NCT05279560|OTHER|Saline solution (NaCL) Injection|Injecting NaCL into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. NaCL will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
219749594|NCT06563557|OTHER|Hemodynamic changes between epidural and paravertebral during esophagectomy|The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
219749595|NCT01413815|DIETARY_SUPPLEMENT|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
219179407|NCT06413810|OTHER|Placebo|Blinded placebo
219179408|NCT02359890|DEVICE|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
219749596|NCT01413815|OTHER|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
219749597|NCT06052891|DEVICE|CHAMP Application|Children's Mercy Kansas City's CHAMP application was developed for data transfer of pediatric cardiac population vitals from home to the healthcare team in March 2014. CHAMP provides families and the clinical team with a new model of care leveraged by a remote patient monitoring (RPM) platform. CHAMP has been used in over 1000 patients, 28 states, and across 12 pediatric hospitals in pediatric cardiology. The CHAMP application is available in 11 languages for families to use on mobile devices (Apple and Android).
219749598|NCT03271775|OTHER|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
219749599|NCT03271775|OTHER|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
219749600|NCT03863574|DRUG|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
219749601|NCT03863574|DRUG|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
219749602|NCT03863574|DRUG|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
219749603|NCT05443321|OTHER|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
219749604|NCT05712681|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
219749605|NCT05712681|DRUG|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
219749606|NCT03884257|DEVICE|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
219749607|NCT03884257|DEVICE|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
219749608|NCT06162351|DRUG|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
219749609|NCT06065046|DRUG|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
219179409|NCT01762462|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219749610|NCT06065046|OTHER|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
219749611|NCT04347538|OTHER|Saline Nasal Irrigation|Saline nasal irrigation BID
219749612|NCT04347538|OTHER|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
219749613|NCT02135133|DRUG|Idelalisib|150 mg BID Oral Daily
219179410|NCT02356653|DEVICE|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
219179411|NCT05968937|DRUG|20 mg baclofen vaginal suppository daily per vagina|20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
219179412|NCT05968937|DRUG|Placebo|Vaginal suppository composed of Supposibase F daily per vagina
219179413|NCT04066244|DRUG|BLZ945|Investigational drug capsules taken orally or via enteral infusion
219179414|NCT05974254|DEVICE|Acupuncture|Electroacupuncture
219179415|NCT06765993|DRUG|Isosorbide oral solution|30 mL, TID
219179416|NCT06765993|DRUG|Placebo|30 mL, TID
219179417|NCT05188092|OTHER|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
219179418|NCT05073666|OTHER|NO INTERVENTION|NO INTERVENTION
219179419|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
219749614|NCT02135133|DRUG|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
219749615|NCT06614543|DIETARY_SUPPLEMENT|Meal Replacement|These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.
219749616|NCT04891198|DRUG|Envafolimab|Subcutaneous injection
219749617|NCT06077357|OTHER|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
219749618|NCT06077357|OTHER|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
219749619|NCT06077357|OTHER|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
219749620|NCT06077357|OTHER|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
219749621|NCT06077357|OTHER|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
219749622|NCT06077357|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
219749623|NCT06393738|DRUG|ARV-393|Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
219749624|NCT06634303|DEVICE|Brain cooling|Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
219749625|NCT05081843|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
219749626|NCT05081843|BEHAVIORAL|Usual health education curriculum|The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
219749627|NCT05918354|DEVICE|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
218992474|NCT02966028|DRUG|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
218992475|NCT02966028|DRUG|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
219179420|NCT03167177|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219179421|NCT03167177|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
218992476|NCT04115839|DRUG|Filgotinib|Tablets will be administered orally once daily with or without food.
218992477|NCT04115839|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
219179422|NCT03167177|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
218992478|NCT04946006|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
218992479|NCT02664844|BEHAVIORAL|Physical activity|
218992480|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
218992481|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
218992482|NCT04072497|BIOLOGICAL|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)
219179423|NCT03167177|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219179424|NCT03167177|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219179425|NCT03167177|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219179426|NCT03167177|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219749628|NCT03985527|DEVICE|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
219749629|NCT04281940|DEVICE|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
219749630|NCT02531191|DRUG|peficitinib|oral
219749631|NCT02303821|DRUG|Carfilzomib|
219179427|NCT03167177|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219179428|NCT03167177|BIOLOGICAL|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
219179429|NCT03167177|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
219179430|NCT03167177|RADIATION|Stereotactic Body Radiation Therapy|radiation
219179431|NCT03167177|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219179432|NCT03167177|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219179433|NCT03167177|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219179434|NCT03167177|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
219179435|NCT03167177|BIOLOGICAL|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
219179436|NCT03167177|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
219179437|NCT03167177|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
219179438|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
219179439|NCT06803381|OTHER|Salivary test|"In order to determine the quantity and quality of patients saliva before food tasting a saliva test will be performed using a Saliva-Check BUFFER kit. A small quantity of saliva will be collected and discarded immediately after the test result obtained.~The test will be done only once for each patient."
219179440|NCT06803381|OTHER|Food tasting|Patients will be invited to taste four different food samples, 2 sweet and 2 salty samples, and to evaluate them using a visual analog scale (0 : I don't like at all to 100 : I like a lot). The intervention will be done once for each patient during one of their standard of care treatment visit.
219179441|NCT06803381|OTHER|Questionnaires|Patients will be invited to answer to some questionnaires : socio-demographics, appreciation of food samples, self-assessment of oral symptoms and sensory perceptions, QLQ-C30 quality of life and food quality of life questionnaire. They will answer to all questionnaires only once during participation to the study.
219179442|NCT06803381|OTHER|sensory capacity evaluation|"For the sensory capacity the test 6-n-propylthiouracil (PROP) taste strip will be used. One tasting strip will be placed on the tongue and patients will be asked to assess the intensity of bitterness.~The test will be done only once for each patient."
219179443|NCT03964571|DIAGNOSTIC_TEST|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
219179444|NCT06802627|OTHER|Education session|"The information that will be delivery is going to be focused on:~* Lifestyle changes regarding nutrition and daily physical activity.~* Abstinence of the additive behaviors smoking, alcohol, and drug consumption.~* Personal hygiene care and hospital routines.~* Importance of postoperative physiotherapy. A booklet summarizing the information provided at the education session will be delivered for all participants."
219179445|NCT06802627|OTHER|Inspiratory muscle training group|"Education Session (described in the control group) Inspiratory muscle training (IMT) After the education session, patients will start the IMT program that will last two weeks.~The IMT will be 5 days/ week, lasting 20 minutes, using the PowerBreath KH2 device. In the first week, the intensity of the PowerBreath KH2 will be set at 50% of the maximal inspiratory pressure (with 12 breaths per minute), and it will be increasing by 10% in the second week (with 15 breaths per minute). Patients will be continuously monitored by an oximeter and modified Borg scale"
219179446|NCT06802627|OTHER|Expiratory muscle training group|"Education Session (described in the control group) Expiratory muscle training (EMT)~After the education session, patients will start the EMT that will last two weeks, 5 days a week. The sessions will last 20 minutes and will be structured as follows:~4 minutes of total body stretching exercises 8 minutes of abdominal resistance exercises:~1. First week: 2 exercises, 4 sets of 8 repetitions~2. Second week: 2 exercises, 4 sets of 10 repetitions 8 minutes of specific EMT using the Philips Respironics Threshold PEP device (Load: 20 cmH2O; 10 expirations for minute) Patients will be continuously monitored by an oximeter and modified Borg scale."
219179447|NCT06802627|OTHER|Global exercise training group|"The GET-G will be submitted to an education session (equal to the CG) plus 2-weeks of physical exercise, 3 sessions per week, 45-60 minutes.~The structure is:~Warm-up: 5 minutes of whole-body stretching exercises~Main workout:~-Aerobic: Week 1: 20 min of treadmill walking at 70% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate. Week 2: 20 min of treadmill walking at 80% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate.~-Resistance Week 1: 8 exercises, 2 sets of 8-10 repetitions, using body weight and elastic bands. Week 2: 8 exercises, 2 sets of 10-12 repetitions, using body weight and elastic bands Coll-down: 5 min of whole-body stretching exercises, holding the point of feeling lightness discomfort for 15 seconds.~Patients will be continuously monitored by an oximeter and modified Borg scale."
219749632|NCT02303821|DRUG|Dexamethasone|
219749633|NCT02303821|DRUG|Mitoxantrone|
219749634|NCT02303821|DRUG|PEG-asparaginase|
219749635|NCT02303821|DRUG|Vincristine|
219749636|NCT02303821|DRUG|Intrathecal (IT) Methotrexate|
219749637|NCT02303821|DRUG|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
219749638|NCT02303821|DRUG|6-Mercaptopurine|
219749639|NCT02303821|DRUG|Cyclophosphamide|
219749640|NCT02303821|DRUG|Cytarabine|
219749641|NCT02303821|DRUG|Daunorubicin|
219749642|NCT05087342|DRUG|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
219749643|NCT05087342|DRUG|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
219749644|NCT06644248|DIAGNOSTIC_TEST|Colposcopy|The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
219749645|NCT05191485|OTHER|Qualitative interviews|We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA\_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
219749646|NCT06845436|BEHAVIORAL|Exercise|Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax.
219749647|NCT06845436|OTHER|routine physical activity|The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period.
219749648|NCT05736471|DIAGNOSTIC_TEST|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
219749649|NCT04341012|DIAGNOSTIC_TEST|Collection of breath sample|Analysis of volatile organic compounds in breath
219749650|NCT03408262|BIOLOGICAL|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
219749651|NCT03408262|BIOLOGICAL|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
219749652|NCT03408262|BIOLOGICAL|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
219749653|NCT05625802|PROCEDURE|Erector Spinae Plane Block (ESPB)|Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
219749654|NCT05625802|DRUG|Ropivacaine|0.5% ropivacaine
219749655|NCT05974787|BEHAVIORAL|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
219749656|NCT04606849|OTHER|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
219749657|NCT04606849|DEVICE|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
219749658|NCT05499819|OTHER|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
219749659|NCT05499819|OTHER|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
219749660|NCT05499819|OTHER|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
219749661|NCT01456403|OTHER|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
219749662|NCT06506513|OTHER|High-intensity interval training|High-intensity interval training
219749663|NCT06506513|OTHER|Moderate intensity exercise training|Moderate intensity exercise training
219749664|NCT06506513|OTHER|Low intensity exercise training|Low intensity exercise training
218992483|NCT04072497|BIOLOGICAL|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)
218992484|NCT04072497|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
219749665|NCT00091897|DRUG|Rituximab|
219749666|NCT00091897|DRUG|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
218992485|NCT00732017|DEVICE|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
218992486|NCT00732017|DEVICE|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
219006665|NCT03273374|DEVICE|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
219749667|NCT04858997|DRUG|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219749668|NCT04858997|DRUG|AI|AI, orally once daily (continuously)
219749669|NCT05795764|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
218992487|NCT00732017|OTHER|standard physical therapy treatment|"* Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
218992488|NCT04077827|DRUG|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
218992489|NCT02034110|DRUG|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
218992490|NCT02034110|DRUG|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
218992491|NCT04758169|OTHER|Enhanced Homestead Food Production|Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
218992492|NCT04758169|OTHER|Control|Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
218992493|NCT01842074|DRUG|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
218992494|NCT00621985|DRUG|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
218992495|NCT00621985|DRUG|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
218992496|NCT02720991|DRUG|Mifepristone|200 mg of oral mifepristone
218992497|NCT02720991|DRUG|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
218992498|NCT03162991|OTHER|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for \~30-55 minutes per exercise session.
218992499|NCT05382624|PROCEDURE|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
218992500|NCT01244724|DRUG|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
218992501|NCT01251601|OTHER|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
218992502|NCT04763304|OTHER|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
218992503|NCT04763304|OTHER|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
218992504|NCT00971594|BEHAVIORAL|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
218992505|NCT00971594|BEHAVIORAL|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
218992506|NCT02577510|DRUG|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
218992507|NCT02577510|DRUG|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
218992508|NCT02223091|BEHAVIORAL|Consultation by a trained physician|
218992509|NCT02223091|BEHAVIORAL|Consultation by an untrained physician|
218992510|NCT00205582|DEVICE|Positron Emission Tomography|
219006666|NCT02496650|DRUG|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
219006667|NCT01737151|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219006668|NCT01737151|RADIATION|four fraction split-course SBRT|four fraction split-course SBRT
219749670|NCT05795764|BEHAVIORAL|Treatment as Usual|Standard care provided for patients at risk for suicide
219749671|NCT06475820|DRUG|Baricitinib|"GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day."
219749672|NCT03701334|DRUG|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
219749673|NCT03701334|OTHER|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
219749674|NCT05132491|OTHER|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
219179448|NCT04903899|COMBINATION_PRODUCT|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
219749675|NCT00005626|DRUG|Irinotecan|Irinotecan as outlined in treatment arm
219749676|NCT02070211|DIETARY_SUPPLEMENT|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
219179449|NCT03032107|DRUG|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
219179450|NCT03032107|DRUG|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
219179451|NCT05562297|DRUG|sintilimab|Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
219749677|NCT02070211|OTHER|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
219749678|NCT02070211|DIETARY_SUPPLEMENT|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
219749679|NCT04507269|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
219749680|NCT04507269|DRUG|Placebo|Saline given by subcutaneous injection
219749681|NCT01080235|OTHER|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
219749682|NCT01080235|OTHER|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
219749683|NCT06463730|BEHAVIORAL|Serious games|Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
219749684|NCT06129955|DRUG|Pucotenlimab Combined With Lenvatinib|Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
219749685|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
219749686|NCT05410223|DRUG|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
219749687|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
219749688|NCT05410223|DRUG|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
219179452|NCT05562297|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
219749689|NCT03662451|PROCEDURE|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
219749690|NCT03246412|DIAGNOSTIC_TEST|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
219749691|NCT05051228|DEVICE|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
219749692|NCT02120261|DRUG|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
219749693|NCT02120261|DRUG|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
219749694|NCT02120261|DRUG|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
219749695|NCT06570070|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
219749696|NCT06570070|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
219749697|NCT06570070|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
219749698|NCT06570070|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
219749699|NCT06570070|BEHAVIORAL|Counselor individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
219749700|NCT02071589|DRUG|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
219749701|NCT02071589|DRUG|Nifedipine oral solution|6 mL of Nife Par solution
219749702|NCT05143814|DEVICE|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
219749703|NCT04245189|OTHER|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
219749704|NCT04103931|BEHAVIORAL|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
218992511|NCT06177327|OTHER|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
218992512|NCT00669227|OTHER|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
218992513|NCT00669227|OTHER|placebo suspension|intracoronary administration at the same day as cell aspiration
218992514|NCT01162512|BEHAVIORAL|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
218992515|NCT00786149|OTHER|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
218992516|NCT00786149|OTHER|Varenicline without counseling|Brief advice, one time during initial session
218992517|NCT02364739|OTHER|Written information|Brochure
218992518|NCT02364739|OTHER|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
219749705|NCT01013571|DRUG|insulin glargine|pre-filled disposable pen, in package of 5.
219749706|NCT01013571|DRUG|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
219761858|NCT04456920|OTHER|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
218992519|NCT06119945|DRUG|DWJ1568|One tablet of DWJ1568
218992520|NCT06119945|DRUG|DWC202215|One tablet of DWC202215
218992521|NCT05541770|OTHER|Survey|Healthcare workers/Physicians involved in cancer diagnosis \& management in the Arab countries should respond to a survey
218992522|NCT02887885|DRUG|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
219006669|NCT00298545|DRUG|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
219006670|NCT00298545|DRUG|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
219006671|NCT02178202|BEHAVIORAL|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
219749707|NCT02784587|PROCEDURE|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
219749708|NCT00071032|BIOLOGICAL|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
219749709|NCT00071032|BIOLOGICAL|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
219749710|NCT03070665|DRUG|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
219749711|NCT02903147|BEHAVIORAL|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
219749712|NCT02903147|BEHAVIORAL|The employer's training|
219749713|NCT06064617|DEVICE|Contact Lens|Coopervision Biofinity Multifocal Lens
219749714|NCT05752032|GENETIC|ICM-203|Long term follow-up
219749715|NCT05752032|DRUG|Placebo|Long term follow-up
219749716|NCT05580705|OTHER|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
219749717|NCT05580705|OTHER|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
219749718|NCT03381326|PROCEDURE|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
219749719|NCT01907893|BEHAVIORAL|Trauma Collaborative Care Plus Treatment as Usual|
219749720|NCT05974540|DIAGNOSTIC_TEST|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
219749721|NCT05947838|PROCEDURE|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
219749722|NCT05878795|BEHAVIORAL|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 40 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
219749723|NCT05878795|BEHAVIORAL|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
219749724|NCT05720104|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
219749725|NCT05720104|OTHER|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
219749726|NCT05136495|OTHER|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
219749727|NCT04104789|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
219749728|NCT04104789|DRUG|Articaine Injection|Local anesthetic
219749729|NCT05561387|DRUG|Bortezomib|Given SC
219006672|NCT02178202|DEVICE|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
219749730|NCT05561387|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
219749731|NCT05561387|DRUG|Dexamethasone|Given PO
219749732|NCT05561387|DRUG|Lenalidomide|Given PO
219749733|NCT05561387|OTHER|Quality-of-Life Assessment|Ancillary studies
219749734|NCT05561387|OTHER|Questionnaire Administration|Ancillary studies
219749735|NCT06196138|OTHER|Gum|In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.
219749736|NCT06196138|OTHER|Hot Compress|Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
219749737|NCT06071104|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
219749738|NCT06071104|DEVICE|UNITY VCS|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
219749739|NCT05866081|DEVICE|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
219749740|NCT05866081|OTHER|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
219749741|NCT05866081|OTHER|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
219749742|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
219749743|NCT03518060|DRUG|JULUCA|JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
219749744|NCT05078112|DEVICE|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
219749745|NCT05136846|DRUG|Carboplatin|Given IV
219749746|NCT05136846|BIOLOGICAL|Durvalumab|Given IV
219749747|NCT05136846|DRUG|Paclitaxel|Given IV
219749748|NCT05136846|DRUG|Papaverine|Given IV or SC
219749749|NCT05136846|RADIATION|Radiation Therapy|Undergo RT
219749750|NCT05136846|DRUG|Pemetrexed|Given IV
219749751|NCT05136846|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
219749752|NCT05136846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219749753|NCT05136846|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219749754|NCT05136846|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219749755|NCT05136846|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
219749756|NCT05136846|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219749757|NCT03241615|OTHER|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
219749758|NCT04766567|PROCEDURE|Cesarean section with cesarean myomectomy (serosal)|Serosal or endometrial myomectomy performed during cesarean section
219749759|NCT04766567|PROCEDURE|Cesarean section without myomectomy|Cesarean delivery without performing myoemctomy
219749760|NCT06113367|OTHER|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
218992523|NCT03856892|OTHER|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
219006673|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
219006674|NCT01536847|OTHER|Dietary Intervention|300 mL of liquid food product
219006675|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
219006676|NCT01428453|DRUG|250mg rilapladib|Experimental Drug
219006677|NCT01428453|DRUG|placebo|Placebo comparator
219006678|NCT02412423|DRUG|post-transplantation cyclophosphamide|
219006679|NCT04028843|BEHAVIORAL|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
219006680|NCT02607033|OTHER|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
219006681|NCT02607033|OTHER|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
219006682|NCT05090007|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
219006683|NCT05090007|OTHER|gut microbiota|gut microbiota
219006684|NCT05343351|OTHER|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
219749761|NCT00553969|DRUG|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
219749762|NCT00553969|DRUG|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
218992524|NCT03856892|OTHER|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
218992525|NCT04271137|COMBINATION_PRODUCT|3D printed PEEK onlay|3d computer-designed Orbital onlay
218992526|NCT04271137|COMBINATION_PRODUCT|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
218992527|NCT04412369|DIAGNOSTIC_TEST|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
218992528|NCT06052605|BEHAVIORAL|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
218992529|NCT01628575|PROCEDURE|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
218992530|NCT00003594|DRUG|irinotecan|
218992531|NCT00003594|DRUG|fluorouracil|
218992532|NCT00003594|DRUG|leucovorin calcium|
218992533|NCT00003594|DRUG|oxaliplatin|
218992534|NCT03465306|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
218992535|NCT03465306|DEVICE|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
218992536|NCT00490360|DRUG|Gemcitabine / Cisplatin|
218992537|NCT05083572|DRUG|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
218992538|NCT05083572|DIETARY_SUPPLEMENT|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
218992539|NCT05083572|DRUG|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
218992540|NCT01877265|DRUG|LY2605541|
218992541|NCT00691015|BIOLOGICAL|rituximab|Given IV
218992542|NCT00691015|DRUG|busulfan|Given IV
218992543|NCT00691015|DRUG|carmustine|Given IV
218992544|NCT00691015|DRUG|cyclophosphamide|Given IV
218992545|NCT00691015|DRUG|cytarabine|Given IV
218992546|NCT00691015|DRUG|etoposide|Given IV
218992547|NCT00691015|DRUG|fludarabine phosphate|Given IV
218992548|NCT00691015|DRUG|melphalan|Given IV
218992549|NCT00691015|RADIATION|total body irradiation (TBI)|Given once or twice daily
218992550|NCT00691015|DRUG|anti-thymocyte globulin IV|Given IV
218992551|NCT01738321|OTHER|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
218992552|NCT02161367|DRUG|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
218992553|NCT02161367|DRUG|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
218992554|NCT03112395|DEVICE|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
218992555|NCT03729089|OTHER|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
218992556|NCT06352801|BEHAVIORAL|Self-Compassion Intervention|Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
218992557|NCT06229340|DRUG|Leflunomide|100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
218992558|NCT06229340|DRUG|The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab|"Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously."
218992559|NCT01826630|OTHER|CLn BodyWash|Comparing two washes to determine change in bacterial load.
218992560|NCT01826630|OTHER|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
218992561|NCT05416502|PROCEDURE|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
218992562|NCT00950105|DRUG|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
218992563|NCT04160195|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0
219749763|NCT00553969|DRUG|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
219749764|NCT00553969|DRUG|placebo and placebo|capsule once daily for 9 months; dosage unknown
219749765|NCT04614532|DIAGNOSTIC_TEST|cognitive assessment|"global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery"
219761859|NCT04456920|OTHER|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
219749766|NCT04614532|OTHER|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
219749767|NCT04614532|OTHER|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
219749768|NCT00220792|BEHAVIORAL|Brief supportive-expressive group therapy|
218992564|NCT04160195|DRUG|Cyclophosphamide|500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
218992565|NCT04160195|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
218992566|NCT00349440|DRUG|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
218992567|NCT00232232|DRUG|Fish oil|
218992568|NCT04167644|DIAGNOSTIC_TEST|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
218992569|NCT00589251|OTHER|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
218992570|NCT04585386|OTHER|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
218992571|NCT04585386|OTHER|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
218992572|NCT04585386|OTHER|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
218992573|NCT04585386|OTHER|Quebec questionnaire|To access the patient's perception of incapacity
218992574|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
218992575|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
218992576|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
218992577|NCT01581814|DRUG|Metformin|500 mg of Metformin per 3/die
218992578|NCT01581814|DRUG|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
218992579|NCT01581814|DRUG|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
218992580|NCT01540240|DRUG|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
218992581|NCT01540240|DRUG|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
218992582|NCT00684593|DRUG|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
218992583|NCT00684593|OTHER|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
218992584|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
218992585|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
218992586|NCT00709683|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218992587|NCT00121602|DRUG|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
219749769|NCT05242367|DEVICE|Modius Spero active device|Battery powered non-invasive neurostimulation device
219749770|NCT05242367|DEVICE|Sham device|Placebo comparator sham device (no active stimulation)
219749771|NCT03458572|DEVICE|Seirin Pyonex press needle acupuncture|Acupuncture
219749772|NCT06063876|PROCEDURE|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
218992588|NCT05258175|OTHER|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
218992589|NCT05258175|OTHER|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
218992590|NCT04949048|DEVICE|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
218992591|NCT04325581|DRUG|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
219369327|NCT05699148|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
219749773|NCT06063876|PROCEDURE|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
219749774|NCT04219020|OTHER|Co-created intervention|
219749775|NCT00582296|BEHAVIORAL|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
219749776|NCT00582296|BEHAVIORAL|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
219749777|NCT02475993|OTHER|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
219749778|NCT04116489|OTHER|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
219749779|NCT04116489|OTHER|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
219749780|NCT04116489|OTHER|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
219749781|NCT04116489|OTHER|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
219749782|NCT04231019|OTHER|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
219749783|NCT02370147|BEHAVIORAL|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
218992592|NCT04325581|DRUG|Placebos|Normal Saline SC daily
218992593|NCT05577260|DRUG|magnesuim sulphate|magnesuim sulphate
219369328|NCT04668508|DRUG|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
219749784|NCT02370147|BEHAVIORAL|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
219749785|NCT03734536|DEVICE|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
219749786|NCT03734536|DEVICE|Arthroscopic repair of the high-grade (>50%) partial-thickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
218992594|NCT05577260|DRUG|Dexmedetomidine|Dexmedetomidine
218992595|NCT05577260|DRUG|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
218992596|NCT00560976|DRUG|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
218992597|NCT02926365|BEHAVIORAL|ICBT|
218992598|NCT00309569|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
218992599|NCT00309569|DRUG|Methotrexate|Methotrexate 40mg/m2
218992600|NCT00309569|DRUG|Fluorouracil|Fluorouracil 600mg/m2
218992601|NCT00309569|DRUG|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
218992602|NCT00309569|OTHER|Surgery|Surgery
218992603|NCT06304376|PROCEDURE|Alveolar ridge grafting|Alveolar ridge grafting was carried out using anterior iliac crest bone graft. Khoury shell technique was the method of ridge reconstruction via a cortical bone shell was fixed away from alveolar ridge using two micro-screws and the gap created was filled by cancellous bone
218992604|NCT03535844|OTHER|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
218992605|NCT03535844|OTHER|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
218992606|NCT03445715|GENETIC|ART-I02|Single Intra-articular injection in the wrist joint
218992607|NCT01303107|DRUG|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
219369329|NCT00352248|PROCEDURE|Tongue Acupuncture (Procedure)|
219369330|NCT05444712|PROCEDURE|Chemotherapy + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
219369331|NCT05444712|PROCEDURE|Chemotherapy + ASCT + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
219749787|NCT05064618|DRUG|Am80|medicine taken internally
219749788|NCT05064618|DRUG|Gemcitabine|Administered intravenously at a dose of 1000mg/m2
219749789|NCT05064618|DRUG|nab-Paclitaxel|Administered intravenously at a dose of 125mg/m2
219749790|NCT02248493|DRUG|Paracetamol|
219749791|NCT02248493|DRUG|Placebo (for paracetamol)|
218992608|NCT05009121|DIAGNOSTIC_TEST|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
218992609|NCT05930912|DIAGNOSTIC_TEST|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
218992610|NCT05930912|DRUG|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
218992611|NCT05930912|DRUG|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
218992612|NCT05930912|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
218992613|NCT06959602|PROCEDURE|Final Irrigation with 2.5% Sodium Hypochlorite|After supragingival scaling and removal of caries or defective restorations, the tooth will be isolated and disinfected with 3% H202 and 2.5% NaOCl. Access preparation will be done using a sterile high-speed bur under sterile saline irrigation, followed by re-disinfection. NaOCl will be neutralized with 5% sodium thiosulphate, and sterility will be confirmed via paper point sampling. Only teeth with negative sterility samples will proceed. Sample S1 will be collected after saline irrigation and mild instrumentation with a sterile K-file #15, using an apex locator. Paper points will absorb canal fluid and be frozen in Tris-EDTA buffer at -20°C. Complete chemomechanical preparation will follow, with irrigation after each instrument change. Cervical and mid-thirds will be enlarged with Gates-Glidden burs and the apical third with NiTi RaCe files (40/04). Sample S2 will be taken after preparation. Group A will receive final irrigation with 2.5% NaOCl before collection of sample S3.
218992614|NCT06959602|PROCEDURE|Passive Ultrasonic Irrigation (PUI) with Sodium Hypochlorite|Activation of 2.5% sodium hypochlorite solution inside the root canal system using Passive Ultrasonic Irrigation (PUI) after chemomechanical preparation. Group B, sample (S3).
218992615|NCT06959602|PROCEDURE|XP-Endo Finisher Activation with Sodium Hypochlorite|Mechanical activation of 2.5% sodium hypochlorite solution using the XP-Endo Finisher instrument following chemomechanical preparation.Group C, sample (S3).
218992616|NCT05951673|OTHER|Safe Space based life skills training program|This is a Safe Space based life skills training program given to adolescent girls. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change.
218992617|NCT05951673|OTHER|Safe Space based life skills training program + Digital Skills|This is a Safe Space based life skills training program given to adolescent girls complemented with a digital literacy training program. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change. The adolescent girls in this group also receive a digital literacy training program that covers content on word processing. database management and analysis, online marketing, online safety and programming.
218992618|NCT05758051|PROCEDURE|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
218992619|NCT02208557|PROCEDURE|Reinforcement with Absorbable Mesh|
218992620|NCT02208557|RADIATION|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
218992621|NCT02208557|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
218992622|NCT02102906|PROCEDURE|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
218992623|NCT04851834|DRUG|NTX-301|Oral hypomethylating agent
218992624|NCT04851834|DRUG|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
218992625|NCT04851834|DRUG|Temozolomide|Standard of care for high-grade glioma
218992626|NCT05226663|PROCEDURE|Computed Tomography|Undergo \[18F\]FFT PET/CT
219749792|NCT02248493|DRUG|Ketoprofen|
219749793|NCT02248493|DRUG|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
219749794|NCT02248493|DRUG|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
219749795|NCT04727151|BIOLOGICAL|TAC01-HER2|"TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
219179453|NCT05562297|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
219179454|NCT02728284|PROCEDURE|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
219179455|NCT02728284|PROCEDURE|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
219179456|NCT05396586|BEHAVIORAL|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
219179457|NCT05396586|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
219179458|NCT05396586|BEHAVIORAL|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
219179459|NCT03940690|DRUG|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
219179460|NCT03940690|DEVICE|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
219179461|NCT05758376|BEHAVIORAL|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
219179462|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
219179463|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
219179464|NCT06499896|BIOLOGICAL|MTP-101-C|MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
219179465|NCT06141720|BEHAVIORAL|pain education|Pain education
219179466|NCT06141720|BEHAVIORAL|mindfulness of pain introduction and intervention|Brief mindfulness of pain introduction and intervention
219179467|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
219179468|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
219179469|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
219179470|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
219179471|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
219369332|NCT00603239|DRUG|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
219749796|NCT04727151|BIOLOGICAL|TAC01-HER2 plus pembrolizumab|"TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
219179472|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
219179473|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
219179474|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
219179475|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
219179476|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
219179477|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
219179478|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
219191563|NCT05076513|DRUG|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
219191564|NCT05076513|RADIATION|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
219749797|NCT05025605|DRUG|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
219191565|NCT05983770|DRUG|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
219369333|NCT00603239|DRUG|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
219369334|NCT01354132|DRUG|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
219369335|NCT01354132|DRUG|Placebo|Placebo tablets are placed in water or juice in the AM and PM
219749798|NCT05025605|DRUG|Placebo Film|Matching Sublingual Placebo film
219369336|NCT05858190|PROCEDURE|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
219369337|NCT03601871|DRUG|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
219369338|NCT03601871|DRUG|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
219369339|NCT03601871|DRUG|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
219369340|NCT00701493|DRUG|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
219369341|NCT02357420|DRUG|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
219369342|NCT02357420|DRUG|Placebo|Placebo given subcutaneously for 12 weeks.
219369343|NCT05650034|RADIATION|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
219369344|NCT00929955|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
219369345|NCT00929955|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
219369346|NCT00929955|DRUG|Placebo|Placebo added to TAU
219369347|NCT01774214|PROCEDURE|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
219369348|NCT01774214|PROCEDURE|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
219369349|NCT04233489|BEHAVIORAL|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
219369350|NCT03669978|PROCEDURE|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
219369351|NCT00582517|DEVICE|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
219369352|NCT00582517|PROCEDURE|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
219369353|NCT04726332|DRUG|XL102|oral doses of XL102
219369354|NCT04726332|DRUG|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
219369355|NCT04726332|DRUG|Abiraterone|abiraterone 1000 mg administered orally once daily.
219749799|NCT05025605|DRUG|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
219749800|NCT05025605|DRUG|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
219749801|NCT01969058|DRUG|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
219749802|NCT05478876|RADIATION|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
219369356|NCT04726332|DRUG|Prednisone|prednisone 5 mg administered orally twice daily.
218992627|NCT05226663|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
218992628|NCT05226663|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FFT PET/CT
219179479|NCT06036849|PROCEDURE|Spinal manipulation|The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
219749803|NCT03886857|DEVICE|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
219749804|NCT05803772|DRUG|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
219749805|NCT05803772|DRUG|APH-012P|Distal jejunal-release placebo beads
219749806|NCT03797807|PROCEDURE|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
219179480|NCT06036849|PROCEDURE|Spinal mobilization|The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
219179481|NCT04844073|DRUG|TAK-186|TAK-186 IV infusion.
219179482|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
219179483|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
219179484|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
219179485|NCT05823116|DRUG|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
219179486|NCT05823116|DRUG|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
219179487|NCT04844463|DRUG|JNJ-68179280|JNJ-68179280 will be administered as an oral capsule.
219179488|NCT04844463|OTHER|Placebo|Matching placebo will be administered as an oral capsule.
219749807|NCT03797807|PROCEDURE|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
219749808|NCT03797807|DIAGNOSTIC_TEST|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
219749809|NCT04862403|PROCEDURE|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
219749810|NCT04796805|OTHER|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
219749811|NCT04089696|DEVICE|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
219749812|NCT04305756|DRUG|Enoxaparin|Low molecular weight heparin
219179489|NCT05696132|DRUG|Betadine|Nasal decolonization with betadine gel
219179490|NCT04561947|PROCEDURE|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
219179491|NCT04561947|PROCEDURE|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
219191566|NCT05983770|DRUG|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
219749813|NCT03924284|DIAGNOSTIC_TEST|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
219749814|NCT00723632|BIOLOGICAL|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
219749815|NCT00723632|DRUG|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
219749816|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
219761860|NCT04456920|OTHER|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
219749817|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
219749818|NCT03910972|BIOLOGICAL|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
219749819|NCT02756585|RADIATION|ct perfusion|computed tomography perfusion of the head
219749820|NCT01678365|DRUG|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
219749821|NCT00311831|BEHAVIORAL|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
219749822|NCT00311831|BEHAVIORAL|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
219749823|NCT03078231|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
219749824|NCT03078231|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
219749825|NCT03092193|DRUG|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
219749826|NCT03092193|DRUG|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
219749827|NCT01346592|BIOLOGICAL|Trivalent split influenza vaccine (TIV)|
219749828|NCT01346592|BIOLOGICAL|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
219749829|NCT01346592|BIOLOGICAL|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
219749830|NCT04964752|DEVICE|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
219749831|NCT05686980|DRUG|ABBV-552|Oral Capsule
219749832|NCT02679274|DRUG|Placebo|Intermittent intramuscular injections of saline (males and females).
219749833|NCT02679274|DRUG|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
219749834|NCT03694730|OTHER|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
219749835|NCT03694730|OTHER|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
219749836|NCT06810440|BEHAVIORAL|Sumadhur|Sumadhur is a 4-month intervention with weekly sessions that last about 1.5 hours. Newly married women, their husbands and mothers-in-law gather with other household triads (5 households per group for a total of 15 people per group).
219749837|NCT06810440|DIETARY_SUPPLEMENT|Multiple micronutrient supplement MMS|Multiple micronutrient supplement MMS provided in 180 pill bottles
219191567|NCT06770283|DIETARY_SUPPLEMENT|Spirulina tablet|In the Spirulina tablet intervention group, patients will receive oral Spirulina tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
219191568|NCT06770283|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|In the control group, patients will receive oral maltodextrin tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
219749838|NCT06570356|DIAGNOSTIC_TEST|Geriatric Depression Scale - 15|a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
219749839|NCT06570980|DRUG|sulfonylurease with metformin, DPP4 inhibitors with Metformin|Oral hypoglycemic agents
219749840|NCT03207347|DRUG|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
219749841|NCT03596554|OTHER|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
219749842|NCT04154163|DIAGNOSTIC_TEST|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
219749843|NCT04154163|DIAGNOSTIC_TEST|Venous blood sampling|Venous blood
219749844|NCT02208765|DEVICE|Stress Single Photon Emission Computed Tomography|
219749845|NCT00974272|DRUG|Exenatide|Single subcutaneous injection (10 μg)
219749846|NCT00974272|OTHER|Normal Saline|Single subcutaneous injection
219749847|NCT03272321|DRUG|Oxytocin|Syntocinon nasal spray
219749848|NCT03272321|DRUG|Placebo|Placebo nasal spray
219749849|NCT03290677|PROCEDURE|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
219749850|NCT03290677|PROCEDURE|Biopsy|Removing a small piece of the affected area to confirm cancer
219749851|NCT05594186|DRUG|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
219749852|NCT05905198|DEVICE|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
219369357|NCT02852525|DEVICE|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
219369358|NCT04000646|OTHER|standard care|standard care non-pharmacologic interventions during anesthesia induction
219369359|NCT04000646|OTHER|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
219369360|NCT00928070|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg
219369361|NCT00928070|DRUG|Placebo|Placebo sham 4 mg and 8 mg
219749853|NCT05605197|DRUG|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
219369362|NCT05173129|DIAGNOSTIC_TEST|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
219369363|NCT00004255|BIOLOGICAL|anti-thymocyte globulin|
219369364|NCT00004255|BIOLOGICAL|filgrastim|
219369365|NCT00004255|DRUG|cyclophosphamide|
219749854|NCT05119868|OTHER|Nutritional intervention based on Mediterranean Diet|A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
219369366|NCT00004255|DRUG|fludarabine phosphate|
219369367|NCT00004255|DRUG|methylprednisolone|
219369368|NCT00004255|DRUG|tacrolimus|
219369369|NCT00004255|PROCEDURE|allogeneic bone marrow transplantation|
219369370|NCT00004255|PROCEDURE|in vitro-treated bone marrow transplantation|
219369371|NCT00004255|RADIATION|radiation therapy|
219369372|NCT06960473|DEVICE|Intravascular Ultrasound|In the IVUS group, the diameter of the reference vessel (the normal segment of the artery distal to the occlusion) is measured using Intravascular Ultrasound (IVUS). Based on the IVUS measurements, an appropriate balloon is selected to dilate the occluded segment.
219369373|NCT06960473|DEVICE|Digital Subtraction Angiography|The DSA group patients will have the appropriate balloon dilation selected for the occluded segment based on the DSA measurement results.
219369374|NCT06555627|BEHAVIORAL|High Protein Breakfast|For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
219369375|NCT06555627|BEHAVIORAL|Morning Exercise|Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.
219369376|NCT06555627|BEHAVIORAL|High Carb Breakfast|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
219369377|NCT05215184|DEVICE|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
219369378|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
219369379|NCT05567562|DRUG|Placebo|Placebo
219369380|NCT06293703|PROCEDURE|Surgery|Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
219369381|NCT06130085|DIETARY_SUPPLEMENT|Partially hydrolyzed formula|Partially hydrolyzed formula given as the milk supplement for cow milk allergy patients after 6 months of strict elimination diet
219369382|NCT04526106|DRUG|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
219369383|NCT06498921|OTHER|Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel|No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.
219369384|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
219369385|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
219369386|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
218992629|NCT04957901|DRUG|Pediatric lymphoma protocol|The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
218992630|NCT04442867|OTHER|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
218992631|NCT04442867|OTHER|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
218992632|NCT02132091|OTHER|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
218992633|NCT02132091|DIETARY_SUPPLEMENT|400 IU Vitamin E|once each day in morning; oral pill form
218992634|NCT02132091|DIETARY_SUPPLEMENT|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
219179492|NCT04561947|OTHER|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
219179493|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
219179494|NCT04923984|PROCEDURE|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
219179495|NCT06519877|DIETARY_SUPPLEMENT|Soluble corn fiber|Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
219179496|NCT06419075|DRUG|Tranexamic acid|The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
219179497|NCT06419075|DRUG|Vasopressin|The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
219179498|NCT06419075|OTHER|NaCl 0.9%|The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
219179499|NCT03070106|DIETARY_SUPPLEMENT|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
219179500|NCT05622006|BEHAVIORAL|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
219179501|NCT05030675|DRUG|Fostamatinib|Given PO
219179502|NCT04605081|DRUG|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
219179503|NCT04605081|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
219369387|NCT06157385|BEHAVIORAL|Culinary Medicine|The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.
219369388|NCT06157385|BEHAVIORAL|Control|The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
219369389|NCT04067518|BIOLOGICAL|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days
219369390|NCT00010231|DIETARY_SUPPLEMENT|calcitriol|
219369391|NCT00010231|DRUG|dexamethasone|
219369392|NCT00275431|DRUG|AT-101|Oral
219369393|NCT04508387|PROCEDURE|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
219369394|NCT00862251|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
219369395|NCT00862251|DRUG|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
219179504|NCT04448301|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
218992635|NCT00160693|BIOLOGICAL|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
218992636|NCT01966159|DEVICE|SYNERGY Investigational Device|percutaneous coronary intervention
218992637|NCT01966159|DEVICE|PE Plus Investigational Device|percutaneous coronary intervention
218992638|NCT03698149|DEVICE|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
219179505|NCT02962557|DEVICE|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
219179506|NCT05956067|DEVICE|Green Light stimulation|A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.
219179507|NCT05956067|DEVICE|Equal Energy White stimulation|A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.
219179508|NCT05956067|DEVICE|S-cone modulating white light|A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
219749855|NCT04431284|OTHER|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
219749856|NCT03519880|DEVICE|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
219179509|NCT06074536|PROCEDURE|patient-centered approach training|face to face training of general practitioner of interventional arm
219179510|NCT06530355|OTHER|The same evaluation methods were used for both groups. No intervention was applied to individuals in two groups..|No intervention was applied to individuals in this group.
219179511|NCT02547233|DRUG|LEO 43204 gel|
219749857|NCT02330003|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
219749858|NCT02330003|BIOLOGICAL|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
219749859|NCT02731560|DRUG|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
219749860|NCT04463355|BEHAVIORAL|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
219749861|NCT05544409|DEVICE|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
219749862|NCT02659371|DIETARY_SUPPLEMENT|Low energy diet|
219749863|NCT01260779|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
219749864|NCT06205069|DEVICE|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
219749865|NCT04977232|DRUG|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
219749866|NCT04977232|BEHAVIORAL|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
219749867|NCT03249649|BEHAVIORAL|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
219179512|NCT02547233|DRUG|Vehicle gel|
219749868|NCT06398184|OTHER|Exercise + motor imagery and action observation|A total of 8 sessions of 4 sets of knee extension exercises will be performed. During the breaks between each series, participants will perform a progressive protocol of action observation and motor imagery.
219749869|NCT06398184|OTHER|Exercise|A total of 8 sessions of 4 sets of knee extension exercises will be performed.
219179513|NCT02638116|DRUG|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
219179514|NCT02638116|DRUG|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
219179515|NCT05620433|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
219179516|NCT05620433|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
219179517|NCT03603600|DEVICE|enVista MX60E|enVista MX60E monofocal IOL
219179518|NCT03603600|DEVICE|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
219179519|NCT05373823|OTHER|MySmartSkin enhancement|Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
219179520|NCT05373823|OTHER|Educational webpage on Skin Self-Examination|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
219179521|NCT05373823|OTHER|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
219179522|NCT06488508|BEHAVIORAL|MoveEarly|"The intervention has two levels: the kindergarten level and the child level.~1. Staff will receive approximately 60 hours of professional development, including 6 full-day physical seminars, 2 full-day kindergarten visits, 6 written tasks with follow-up webinars and an online resource. The focus will be how to promote movement, play and exploration among children aged 1-6 years.~2. Staff is supposed to promote children's movement, play and exploration through 7 pedagogical principles: 1. Value, understand and promote movement, 2. Value, understand and promote play, 3. Value, understand and promote exploration, 4. Create rich physical environments, 5. Create opportunities for meaningful participation, 6. Create good balance between challenge and support, and 7. Create good dialogue through action and words."
219179523|NCT05028972|OTHER|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
219179524|NCT05028972|OTHER|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
219179525|NCT01497184|PROCEDURE|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
219179526|NCT01497184|GENETIC|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
219179527|NCT05170009|DRUG|Baloxavir Marboxil|Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
219179528|NCT05170009|DRUG|Placebo|Placebo at baseline, day 4, and day 7.
219179529|NCT05170009|DRUG|Oseltamivir|Oseltamivir 75 mg twice daily for 10 days.
219179530|NCT00243464|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
219179531|NCT05285683|DRUG|Methylphenidate|0.5 mg/kg
219179532|NCT05285683|DRUG|carbidopa-levodopa|25 mg/100 mg
219179533|NCT05285683|DRUG|Placebo|oral pill
219179534|NCT04304625|DRUG|Tranexamic Acid / Sodium chloride|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
219179535|NCT03203603|OTHER|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
219179536|NCT01836497|DEVICE|SD01 ICD lead|
219179537|NCT03807310|DIETARY_SUPPLEMENT|Targeted nutrient supplementation (Long-drink)|Once daily for at least 12 months
219179538|NCT03807310|DIETARY_SUPPLEMENT|Placebo supplement|Once daily for at least 12 months
219179539|NCT03807310|BEHAVIORAL|Counselling|Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
219749870|NCT02085720|DEVICE|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
219749871|NCT03661099|DIAGNOSTIC_TEST|colonoscopy|endoscopists' performance outcome
219749872|NCT05382130|DIAGNOSTIC_TEST|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
219749873|NCT01737723|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
219749874|NCT06053372|DEVICE|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
219179540|NCT06645574|OTHER|The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.|"Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires"
219179541|NCT05444751|DRUG|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
219369396|NCT00862251|DRUG|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
219369397|NCT00862251|DRUG|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
219179542|NCT05444751|DRUG|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
219179543|NCT01363388|DRUG|Placebo|BID for 84 days
219179544|NCT01363388|DRUG|CCX168|BID for 84 days
219179545|NCT06238609|DEVICE|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
219179546|NCT06238609|DEVICE|Control Group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
219179547|NCT03524612|DRUG|eltrombopag|12.5, 25, 50 and 75 mg tablets for oral use once daily
219179548|NCT06077513|PROCEDURE|CAD-CAM designed and preprinted Ti-Mesh frame|CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.
219179549|NCT06077513|PROCEDURE|Conventional chairside fabrication of Ti-Mesh frame|A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
219749875|NCT06564740|DRUG|Stem Cell|UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
219749876|NCT06564740|OTHER|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
219749877|NCT04976855|DRUG|INDV-2000|Capsule for oral administration
219749878|NCT04976855|DRUG|Placebo|Capsule for oral administration
219749879|NCT04976855|DRUG|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
219749880|NCT06565299|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
219749881|NCT03275337|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
219749882|NCT01295047|DRUG|Atenolol|
219749883|NCT01295047|DRUG|VERAPAMIL|240 MG SR
219749884|NCT01295047|DRUG|Perindopril|4 MG
219749885|NCT04648085|DEVICE|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
219749886|NCT00689884|DRUG|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
219749887|NCT04029779|BIOLOGICAL|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
219179550|NCT05919290|OTHER|MRI|Non-invasive imaging technique that is used to take pictures of organs within the body.
219749888|NCT02038036|DRUG|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
219749889|NCT02038036|DRUG|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
219749890|NCT05591365|OTHER|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
219749891|NCT05591365|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
219749892|NCT03005886|PROCEDURE|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
219749893|NCT03005886|PROCEDURE|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
219749894|NCT03005886|PROCEDURE|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
219749895|NCT03352947|DRUG|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
219749896|NCT03352947|DRUG|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
219749897|NCT03463187|BIOLOGICAL|SHR-1314|Administered subcutaneously
219749898|NCT03463187|DRUG|Placebo|Administered subcutaneously
219749899|NCT03265184|DIETARY_SUPPLEMENT|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
219749900|NCT02476448|DRUG|Normal saline|Used to distend the bladder for cystoscopic evaluation
219179551|NCT04470453|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
219179552|NCT04470453|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
219749901|NCT02476448|DRUG|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
219749902|NCT02476448|DRUG|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
219749903|NCT02476448|DRUG|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
219749904|NCT05609825|DRUG|LY3875383|Administered SC.
219749905|NCT05609825|DRUG|Placebo|Administered SC.
219749906|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
219749907|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
219749908|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
219749909|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
219749910|NCT06637241|BEHAVIORAL|Risk stratification care|In this group, Taiwanese adolescent baseball players are categorized into high-risk, medium-risk, and low-risk groups based on injury risk from a previous study. High-risk players receive sports protection education and physician referrals for shoulder and elbow assessments, with further imaging if necessary. Common issues like Little League shoulder and elbow are managed with conservative treatments. The sports protection education includes the Modified Yokohama Baseball-9 (mYKB-9), a program that significantly reduces injuries with exercises targeting shoulder and elbow health. Medium-risk players receive mYKB-9 education only, while low-risk players are observed without changes to their training methods.
219749911|NCT06641739|DEVICE|laser assisted SPPF|A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
219749912|NCT06641739|PROCEDURE|Platelet Rich Plasma|In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
219179553|NCT04404088|DRUG|Acalabrutinib|Given PO
219179554|NCT04404088|DRUG|Lenalidomide|Given PO
219749913|NCT04174586|BIOLOGICAL|microtransplantation|HLA mismatched donor cord blood infusion
219179555|NCT04404088|BIOLOGICAL|Rituximab|Given IV
219749914|NCT00937105|DEVICE|lotrafilcon A contact lenses|FDA approved soft contact lenses
219749915|NCT00937105|DEVICE|Renu Multiplus|
219749916|NCT00937105|DEVICE|Clear Care|
219179556|NCT06047353|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
219749917|NCT04952714|DEVICE|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
219749918|NCT00000354|DRUG|Lofexidine|
219749919|NCT00002256|DRUG|Zalcitabine|
219749920|NCT02682251|OTHER|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
219749921|NCT02394067|OTHER|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
219179557|NCT06047353|DEVICE|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
219179558|NCT01414400|OTHER|Blood draw for culture|Blood will be drawn and sent for culture.
219179559|NCT05964998|DEVICE|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
219179560|NCT05964998|DEVICE|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
219179561|NCT05933135|DRUG|Factor XIII Injection|Patients could have had an Factor XIII Injection in clinical routine
219191569|NCT02951130|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
219191570|NCT02951130|DRUG|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
219191571|NCT00429364|DRUG|Losartan Potassium|Losartan .3 - 1.4 mg/kg
219191572|NCT00429364|DRUG|Atenolol|Atenolol .5 - 4 mg/kg
219191573|NCT04871529|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219191574|NCT04871529|DRUG|Avelumab|Given IV
219191575|NCT04871529|DRUG|Gemcitabine Hydrochloride|Given IV
219191576|NCT04871529|DRUG|Carboplatin|Given IV
219191577|NCT05584553|DEVICE|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
219191578|NCT05584553|DEVICE|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
219191579|NCT05766332|OTHER|Clinical Evaluation|Undergo clinical evaluation
219191580|NCT05766332|OTHER|Electronic Health Record Review|Medical records reviewed
219749922|NCT05315752|PROCEDURE|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~* Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~* Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~* for patients with a BMI \>40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss \>7%) or~* for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
219749923|NCT02516813|DRUG|M3814 100 mg|Participants received 100 mg of M3814 as capsule or tablet orally once daily.
219749924|NCT02516813|DRUG|M3814 200 mg|Participants received 200 mg of M3814 as capsule or tablet orally once daily.
219749925|NCT02516813|DRUG|M3814 300 mg|Participants received 300 mg of M3814 as capsule or tablet orally once daily.
219749926|NCT02516813|DRUG|M3814 400 mg|Participants received 400 mg of M3814 as capsule or tablet orally once daily.
219749927|NCT02516813|DRUG|M3814 50 mg|Participants received 100 mg of M3814 as capsule orally once daily.
219749928|NCT02516813|RADIATION|Fractionated RT|Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
219749929|NCT02516813|DRUG|Cisplatin|Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
219749930|NCT06597513|DRUG|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."
219749931|NCT01200134|OTHER|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
219749932|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread mixed with fermented brown seaweed|5-day intake period
219749933|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread|5-day intake period
219749934|NCT05639725|PROCEDURE|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
219749935|NCT05639725|PROCEDURE|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
219749936|NCT04497155|DRUG|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
219749937|NCT05434468|OTHER|Sustained neutral apophyseal glides|gong mobilization
219749938|NCT02755350|DRUG|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
219749939|NCT05361798|DRUG|M9241|In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
219749940|NCT05361798|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
219749941|NCT06001723|BEHAVIORAL|Forest Therapy|Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
219749942|NCT04556045|BEHAVIORAL|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
219749943|NCT06183593|OTHER|Radiofrequency application|Radiofrequency stimuli will be applied at pain threshold intensity. Arm and leg will be stimulated.
219749944|NCT06183593|OTHER|Pinprick stimuli|Pinprick stimuli will be administered at varying speeds and forces using an automated device
219749945|NCT05697380|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
219749946|NCT06675747|OTHER|Ultrasound imaging|To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
219749947|NCT04175015|OTHER|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
219749948|NCT06032390|OTHER|AI assisted mammography screening interpretation|Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
219749949|NCT06032390|OTHER|Standard mammography screening interpretation|Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
219749950|NCT06262659|OTHER|Doppler Ultrasonography Assessment|"Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF."
219749951|NCT04070209|DRUG|Darolutamide (BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
219749952|NCT04070209|RADIATION|SBRT|SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.
219749953|NCT05040776|DRUG|EP-7041 Injection|EP-7041 infusion
219749954|NCT05176587|OTHER|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
219749955|NCT02639689|DEVICE|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
219749956|NCT05785208|DRUG|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
219749957|NCT06193707|OTHER|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
219749958|NCT06193707|OTHER|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
219749959|NCT04410861|PROCEDURE|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
219749960|NCT05928988|DRUG|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
219749961|NCT02185183|DRUG|Alequel|Alequel
219749962|NCT04164381|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
219749963|NCT05702307|OTHER|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219006685|NCT06092710|DIAGNOSTIC_TEST|neuro-sensorial subjective evaluation of the airways collapsibility|verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility
219006686|NCT02744014|BEHAVIORAL|Add-on Therapy for Axial Spondyloarthritis|
219006687|NCT03789318|DRUG|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
219006688|NCT03789318|DRUG|Placebo|Each cohort will use placebo reconstituted in saline.
219006689|NCT03789318|DRUG|Bupivacaine Hydrochloride|0.25% administered pre-surgery
219006690|NCT03789318|DRUG|Hydromorphone|0.02 mg/kg IV administered intraoperatively
219006691|NCT03789318|DRUG|Fentanyl|100 mcg IV administered intraoperatively
219006692|NCT03789318|DRUG|Acetaminophen|1000 mg IV administered intraoperatively
219006693|NCT03789318|DRUG|Oxycodone|5-10 mg PO administered post-surgery
219006694|NCT03789318|DRUG|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
219006695|NCT03789318|DRUG|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
219006696|NCT02127879|DEVICE|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
219179562|NCT05457647|DEVICE|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure is performed using the C4V CHROMO4VIS™ medical device equipped with theranostic software module in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop is done for 15 minutes for the epi-off CXL treatment and 20 minutes for the epi-on CXL treatment. Estimates of riboflavin concentration into the cornea are monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the pre-set dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A light irradiation of the cornea with 5.4 J/cm2 total energy dose (10 mW/cm2 for 9 min.) and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score are performed by the C4V CHROMO4VIS™ system during UV-A light irradiation.
219179563|NCT06304610|BEHAVIORAL|Questionnaire|Questionnaire to probe socio-demographic data and information regarding sexual and reproductive health.
219179564|NCT06304610|PROCEDURE|HPV self-sample|Collection of HPV self-sample. The study nurse will explain step by step how the participant should take the test. The participant will also be given written instructions and the study nurse will always be around if the participant has any questions. The participant will be asked to take the self-sample in a private room with toilet. After collection the sample is handed back to the study nurse, who will then take the samples to the laboratory for analysis.
219179565|NCT06304610|PROCEDURE|Endocervical sample|Endocervical sample taken by the gynaecologist. This procedure can be somewhat uncomfortable but not painful. The participant may always ask questions if she has any doubts or questions. The gynaecologist will perform the standard colposcopy examination after collection (for which the woman sits in the colposcopy waiting room)
219179566|NCT03333616|DRUG|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
219179567|NCT03333616|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
219179568|NCT06528704|DEVICE|Ventilation feedback device|Device showing delivered ventilation frequency and volume.
219749964|NCT05702307|OTHER|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219749965|NCT05702307|OTHER|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219749966|NCT05702307|OTHER|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219749967|NCT05702307|OTHER|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219179569|NCT02489903|DRUG|RRx-001|
219179570|NCT02489903|DRUG|Cisplatin|
219179571|NCT02489903|DRUG|Etoposide|
219179572|NCT02489903|DRUG|Carboplatin|
219179573|NCT02489903|DRUG|Irinotecan|
219179574|NCT02489903|DRUG|Vinorelbine|
219179575|NCT02489903|DRUG|Doxil|
219179576|NCT02489903|DRUG|Gemcitabine|
219179577|NCT02489903|DRUG|Taxane|
219179578|NCT02489903|DRUG|Paclitaxel|
219749968|NCT05702307|OTHER|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219749969|NCT03589274|BEHAVIORAL|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
219749970|NCT03589274|BEHAVIORAL|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
219749971|NCT00791648|DRUG|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
219006697|NCT02127879|DEVICE|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
219179579|NCT02489903|DRUG|Nab-Paclitaxel|
219179580|NCT02489903|DRUG|Pemetrexed|
219179581|NCT05855083|DRUG|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
219179582|NCT04828681|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
219006698|NCT02454998|OTHER|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
219006699|NCT01369797|OTHER|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
219006700|NCT01414907|BEHAVIORAL|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
219006701|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
219006702|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
219749972|NCT00791648|DRUG|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
219749973|NCT05209035|DRUG|Trazodone|Trazodone 50mg daily
219749974|NCT05209035|OTHER|Placebo|Starch 50mg
219749975|NCT00317265|PROCEDURE|Coronary bypass surgery|
219749976|NCT03944395|OTHER|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
219749977|NCT04976777|DEVICE|Updated DEX PS DDS Applicator|Intravitreal Administration
219749978|NCT04976777|DEVICE|Approved DEX PS DDS Applicator|Intravitreal administration
219749979|NCT04976777|DRUG|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
219749980|NCT00462826|BIOLOGICAL|ziv-aflibercept|
219749981|NCT05114928|PROCEDURE|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
219749982|NCT05114928|DIAGNOSTIC_TEST|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
219749983|NCT03983330|BEHAVIORAL|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
219749984|NCT03983330|BEHAVIORAL|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
219749985|NCT04319757|DRUG|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
219749986|NCT04319757|DRUG|Cyclophosphamide|Lympho-conditioning agent
219749987|NCT04319757|DRUG|Fludarabine|Lympho-conditioning agent
219749988|NCT05291650|DRUG|Glucocorticoids|The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
219749989|NCT05291650|DRUG|Saline|A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
219749990|NCT05291650|DRUG|Hyaluronic acid|After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
219749991|NCT06789588|DRUG|pharmacogenetic algorithm|The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
219749992|NCT06789588|DRUG|Clinical treatment|Patients with AF indicated for OAC therapy guided by institutional protocol.
219749993|NCT05975242|BEHAVIORAL|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
219749994|NCT06441162|DRUG|Nebulized 3% sodium chloride solution|Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.
219749995|NCT06441162|DEVICE|Chest percussion cups|The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.
219749996|NCT05939141|DEVICE|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
219749997|NCT01701388|DEVICE|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
219749998|NCT05503082|DRUG|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG \[Ubrelvy\]
219749999|NCT05503082|DRUG|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG \[Ubrelvy\]
219750000|NCT06177431|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
219750001|NCT05264727|DRUG|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
219750002|NCT05264727|DRUG|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
219750003|NCT04996667|DRUG|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
219750004|NCT05153772|DRUG|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
219750005|NCT06627049|OTHER|Focus group|Focus group to evaluate the facilitators and barriers to the use of virtual reality.
219750006|NCT06627049|OTHER|Implementing facilitating strategies|Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.
219750007|NCT06627049|OTHER|Focus group|Evaluate the strategies used to facilitate VR implementation.
219750008|NCT06627049|OTHER|Interviews|Interviews to evaluate the facilitators and barriers to the use of virtual reality.
218992639|NCT04261777|DRUG|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
218992640|NCT02285803|DEVICE|transcranial direct current stimulation (tDCS)|
218992641|NCT02353104|DIETARY_SUPPLEMENT|Onion-Pumpkin Extract|
218992642|NCT06365398|DRUG|Heparin|As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
218992643|NCT06365398|DRUG|Heparin Sodium Injection|In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
218992644|NCT06365398|OTHER|No heparinization|No additional heparin was administered via the sheath or arterial route in the no heparinization group.
218992645|NCT05789810|OTHER|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
218992646|NCT05789810|OTHER|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
218992647|NCT05789810|OTHER|Control|No intervention was performed to reduce pain and fear.
218992648|NCT04915430|OTHER|Training|
218992649|NCT03665805|OTHER|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
218992650|NCT01129817|OTHER|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
218992651|NCT01129817|OTHER|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
218992652|NCT02643381|DRUG|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
218992653|NCT02643381|DRUG|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
219179583|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
219179584|NCT04542317|BEHAVIORAL|REACH VN|4-6 sessions delivered over the course of 2-3 months.
219750009|NCT06627049|OTHER|Interviews|Evaluate the strategies used to facilitate VR implementation.
219750010|NCT06571682|DEVICE|Target Controlled Infusion|TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
219750011|NCT06571682|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
219750012|NCT05861843|DIAGNOSTIC_TEST|Virtual Reality-based cue exposure paradigm|Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)
219750013|NCT03495414|OTHER|Brain Imaging|"* Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
219750014|NCT03495414|OTHER|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task)."
219750015|NCT03495414|OTHER|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
219750016|NCT03495414|OTHER|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
219750017|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
219750018|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
219750019|NCT02458729|DRUG|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
219750020|NCT02458729|DRUG|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
219750021|NCT02458729|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
219750022|NCT04555759|OTHER|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
219750023|NCT03731429|DRUG|Lidocaine|prior to extubation
219750024|NCT03731429|DRUG|Saline Solution|Prior to extubation
219750025|NCT02278003|OTHER|memory test|
219750026|NCT02278003|DRUG|Propofol|
219750027|NCT06116123|DEVICE|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
219750028|NCT06263803|OTHER|Music listening, classic physical therapy|Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
219750029|NCT05425160|OTHER|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
219750030|NCT05425160|OTHER|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
219750031|NCT00152126|PROCEDURE|Stem Cell Transplantation|Autologous stem cell transplantation
219750032|NCT00152126|DRUG|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
219750033|NCT04242680|DEVICE|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
219750034|NCT04242680|DEVICE|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
219750035|NCT04242680|DEVICE|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
219750036|NCT04242680|BEHAVIORAL|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
219750037|NCT06062693|DEVICE|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
219750038|NCT06268470|DRUG|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
219750039|NCT06268470|DRUG|Desloratadine|Desloratadine 20 mg/day
219179585|NCT04542317|BEHAVIORAL|Enhanced control|A single session providing education about dementia
219179586|NCT05760274|DIAGNOSTIC_TEST|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
219750040|NCT02947984|RADIATION|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
219750041|NCT02947984|RADIATION|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
219750042|NCT03369158|PROCEDURE|patient specific pedicle screw positioning guide|
219750043|NCT03369158|PROCEDURE|Free hand technique pedicle screw positioning|
219750044|NCT03369158|DEVICE|MUST pedicle screw|
219750045|NCT04924348|PROCEDURE|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
219750046|NCT04924348|PROCEDURE|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
219750047|NCT04924348|PROCEDURE|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
219750048|NCT03738917|DRUG|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
219750049|NCT03738917|DRUG|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
219750050|NCT03738917|DIETARY_SUPPLEMENT|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
219750051|NCT03738917|OTHER|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
219750052|NCT04636632|DRUG|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
219750053|NCT00247546|BEHAVIORAL|Multifactorial prevention|
219750054|NCT03764969|BEHAVIORAL|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
219750055|NCT03764969|BEHAVIORAL|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
219750056|NCT03764969|BEHAVIORAL|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
219750057|NCT02141321|DRUG|Misoprostol|
219750058|NCT02141321|DRUG|Placebo|
219750059|NCT01872884|DRUG|Sevorane Remifentanil|Sevorane Remifentanil
219750060|NCT01872884|DRUG|Remifentanil|Remifentanil
219750061|NCT03174327|DIAGNOSTIC_TEST|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
219750062|NCT03980639|DRUG|patient treated with DMARD|Case report of cancer overall
219750063|NCT02649764|DRUG|Cytarabine|Given IV
219750064|NCT02649764|DRUG|Fludarabine Phosphate|Given IV
219750065|NCT02649764|OTHER|Laboratory Biomarker Analysis|Correlative studies
219750066|NCT02649764|DRUG|Prexasertib|Given IV
219750067|NCT00148356|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219750068|NCT00148356|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219750069|NCT03253081|BEHAVIORAL|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
219750070|NCT03253081|BEHAVIORAL|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
219750071|NCT05594875|DRUG|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
219750072|NCT05260242|OTHER|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
219750073|NCT02985138|PROCEDURE|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
219750074|NCT02985138|PROCEDURE|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
219750075|NCT02985138|DEVICE|Pedicle screw and cage|Pedicle screw and cage
219750076|NCT04161482|DRUG|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
219750077|NCT05773040|DRUG|JV-213|Given by (IV) vein
219750078|NCT05773040|PROCEDURE|Leukapheresis|Given by IV (vein)
219750079|NCT05569317|OTHER|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
219750080|NCT00939185|DRUG|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
219369398|NCT02958943|BEHAVIORAL|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
219369399|NCT03843476|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
219369400|NCT02204631|OTHER|Head and Neck Educational Handbook|
219369401|NCT04082208|DEVICE|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
219369402|NCT04082208|DEVICE|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
219369403|NCT05265767|BIOLOGICAL|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
219369404|NCT01545960|OTHER|not applicable in this study|No actual interventions will be administered for this study.
219750081|NCT05870631|BIOLOGICAL|vaccinate with DTaP|vaccinate with DTaP
219750082|NCT05870631|BIOLOGICAL|vaccinate with DT|vaccinate with DT
219750083|NCT02104193|DRUG|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
219750084|NCT02104193|RADIATION|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
219750085|NCT01160185|DRUG|paclitaxel|paclitacel
219369405|NCT00968422|DRUG|ABT-384|3 escalating doses will be administered daily for 21 days
219369406|NCT00968422|DRUG|Matching placebo to ABT-384|Doses will be administered daily for 21 days
219369407|NCT01727089|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
219369408|NCT01727089|BIOLOGICAL|Bevacizumab|Given IV
219369409|NCT01727089|OTHER|Laboratory Biomarker Analysis|Correlative studies
219369410|NCT01727089|OTHER|Pharmacological Study|Correlative studies
219750086|NCT01160185|DRUG|cisplatin|cisplatin monotherapy
219750087|NCT01160185|DRUG|topotecan|topotecan
219750088|NCT00004419|DRUG|insulin-like growth factor I|
219750089|NCT00789711|DRUG|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
219750090|NCT00789711|DRUG|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
219750091|NCT01596920|OTHER|Tissue|Allograft Tissue Cellular Repair Matrix
219750092|NCT01596920|OTHER|Control|Non-adherent Dressing
219750093|NCT00363298|DRUG|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
219750094|NCT00363298|DRUG|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
219750095|NCT05713487|OTHER|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
219750096|NCT02852915|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
219750097|NCT04218981|DRUG|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
219750098|NCT04218981|DRUG|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
219750099|NCT04218981|DRUG|Paroxetine|Patients with major depressive disorder are treated with paroxetine
219750100|NCT05482451|DRUG|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
219750101|NCT05482451|DRUG|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
219750102|NCT05234216|OTHER|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
219750103|NCT05234216|PROCEDURE|Surgery|The patient will undergo surgery in accordance with standard care
219750104|NCT05234216|BEHAVIORAL|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
219750105|NCT05234216|BEHAVIORAL|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
219750106|NCT05234216|OTHER|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
219750107|NCT02943161|DIETARY_SUPPLEMENT|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
219750108|NCT02534922|BIOLOGICAL|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
219750109|NCT00864279|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
219750110|NCT00864279|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
219750111|NCT02116023|OTHER|Orange flavored beverage|
219750112|NCT02798757|DRUG|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
219750113|NCT01657188|DEVICE|Cheyne-Stokes respiration by adaptive servoventilation|
219750114|NCT00836706|DRUG|clarithromycin|500 mg Tablet
219750115|NCT00836706|DRUG|BIAXIN®|500 mg Tablet
219750116|NCT03275987|BEHAVIORAL|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
219750117|NCT03275987|BEHAVIORAL|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
219750118|NCT03275987|BEHAVIORAL|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
219750119|NCT01055340|DRUG|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
219750120|NCT01055340|DRUG|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
219750121|NCT01055340|DRUG|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
219369411|NCT00050102|DRUG|MDX-010 (CTLA-4)|
219179587|NCT05831241|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
219750122|NCT02898688|BEHAVIORAL|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
219750123|NCT02898688|BEHAVIORAL|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
219750124|NCT02898688|BEHAVIORAL|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
219750125|NCT02898688|BEHAVIORAL|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
219750126|NCT01329133|PROCEDURE|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
219750127|NCT00864357|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
219179588|NCT05831241|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
219179589|NCT02859961|DRUG|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
219179590|NCT02859961|DRUG|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
219369412|NCT02371850|DRUG|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
219369413|NCT01296048|DEVICE|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
219369414|NCT04225325|COMBINATION_PRODUCT|SYMTUZA|DESCOVY+REZOLSTA
219369415|NCT04225325|COMBINATION_PRODUCT|DESCOVY+DOLUTEGRAVIR|DESCOVY+DOLUTEGRAVIR
219369416|NCT04225325|COMBINATION_PRODUCT|SYMTUZA+DOLUTEGRAVIR|DESCOVY+REZOLSTA+DTG
219750128|NCT00864357|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
219179591|NCT02859961|DRUG|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
219179592|NCT05739643|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
219750129|NCT01599286|DRUG|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
219750130|NCT01599286|DRUG|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
219179593|NCT05590962|OTHER|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
219750131|NCT02429960|DEVICE|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
219750132|NCT02429960|DEVICE|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
219750133|NCT02429960|DEVICE|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
219750134|NCT02429960|DRUG|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
219750135|NCT02729415|PROCEDURE|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
219750136|NCT02729415|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
219750137|NCT02729415|OTHER|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
219750138|NCT01291589|BEHAVIORAL|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
219179594|NCT03976362|BIOLOGICAL|Pembrolizumab|IV infusion
219179595|NCT03976362|DRUG|Carboplatin|IV infusion
219179596|NCT03976362|DRUG|Paclitaxel|IV infusion
219179597|NCT03976362|DRUG|Nab-paclitaxel|IV infusion
219179598|NCT03976362|DRUG|Olaparib|Tablets
219750139|NCT04348474|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
219750140|NCT04348474|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
219179599|NCT03976362|DRUG|Placebo|Placebo to olaparib, tablets
219179600|NCT05575440|PROCEDURE|Computed Tomography|Undergo a PET/CT scan
219369417|NCT02033356|PROCEDURE|Adductor canal block with lidocaine 1%|US-guided adductor canal block
219750141|NCT02356237|OTHER|No episiotomy|Avoidance of episiotomy
219750142|NCT01139515|DRUG|Eletriptan commercial tablet|20 mg tablet, single dose
219750143|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
219750144|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
219750145|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
219750146|NCT02541591|OTHER|Neuroprotective goal directed hemodynamic optimization|
219179601|NCT05575440|RADIATION|Fluorine F 18 Tetrafluoroborate|Given IV
219179602|NCT05575440|PROCEDURE|Positron Emission Tomography|Undergo a PET/CT scan
219179603|NCT05575440|OTHER|Survey Administration|Ancillary studies
219179604|NCT04118673|BEHAVIORAL|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
219179605|NCT05949645|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
219179606|NCT03593018|DRUG|Oral azacitidine|Azacitidine tablets
219179607|NCT03593018|DRUG|Romidepsin|Romidepsin injection
219179608|NCT03593018|DRUG|Bendamustine|Bendamustine injection
219179609|NCT03593018|DRUG|Gemcitabine|Gemcitabine injection
219179610|NCT04672863|BEHAVIORAL|Dietary Intervention|Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
219179611|NCT06164002|OTHER|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
219750147|NCT02541591|OTHER|MAP > 65mmHg|MAP \> 65mmHg
219750148|NCT03134040|BEHAVIORAL|Incentives (Rebate)|
219750149|NCT03134040|BEHAVIORAL|Incentives (Donation)|
219750150|NCT03134040|BEHAVIORAL|Feedback|
219750151|NCT03890211|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
219750152|NCT01512576|OTHER|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
219750153|NCT01512576|BEHAVIORAL|relaxation|1 treatment session of 30 minutes
219179612|NCT02124239|DRUG|Ingenol mebutate|
219179613|NCT04164069|BIOLOGICAL|Bevacizumab|Given IV
219179614|NCT04164069|DRUG|Dasatinib|Given PO
219750154|NCT03747692|PROCEDURE|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
219750155|NCT03747692|PROCEDURE|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
219750156|NCT04803565|DEVICE|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
219750157|NCT04803565|DEVICE|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
219750158|NCT01966627|OTHER|ogtt|oral glucose tolerance test
219750159|NCT01966627|OTHER|genotyping|genotyping to look for risk alleles
219750160|NCT01966627|OTHER|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
219750161|NCT01966627|OTHER|stool sample|stool sample taken to investigate metabolites
219750162|NCT01966627|OTHER|liver biopsy|liver biopsy to examine for cellular change and steatosis
219750163|NCT03904485|RADIATION|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
219750164|NCT03100526|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
219750165|NCT01444105|DEVICE|iStent|Implantation of two iStent devices
219750166|NCT01444105|OTHER|SLT|Laser treatment
219750167|NCT04243265|PROCEDURE|MPFL reconstruction with fascia lata allograft|Reconstruction of MPFL using a fascia lata allograft. The rationale for this technique is to stabilize the patella and limit medium to long-term patellofemoral arthritic degeneration by restoring the MPFL in the most anatomical way possible, not using a tubular graft but an aponeurosis with biomechanical characteristics similar to the native MPFL. The MPFL reconstruction can be used alone or in association with the realignment of the extensor apparatus by transposition of the anterior tibial tuberosity, managing to correct most of the recurrent patellofemoral instabilities. Only in very serious particular cases is it necessary to perform more invasive additional procedures with a more uncertain clinical result (such as Trocleoplasty).
219750168|NCT02332928|DRUG|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
219750169|NCT02332928|DRUG|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
219750170|NCT02491879|DRUG|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
219750171|NCT02491879|OTHER|Placebo|Placebo gel with a 2 g local use
219750172|NCT03474276|DRUG|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
219750173|NCT03474276|DIETARY_SUPPLEMENT|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
219750174|NCT03474276|DRUG|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
219750175|NCT03474276|DIETARY_SUPPLEMENT|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
219179615|NCT04164069|DRUG|Fluorouracil|Given IV
219179616|NCT04164069|DRUG|Leucovorin|Given IV
219179617|NCT04164069|DRUG|Leucovorin Calcium|Given IV
219179618|NCT04164069|DRUG|Oxaliplatin|Given IV
219179619|NCT04164069|OTHER|Quality-of-Life Assessment|Ancillary studies
219179620|NCT05241392|BIOLOGICAL|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
219179621|NCT06004479|OTHER|Carotenoid Intake|Carotenoid intake assess by 24 hour dietary recalls
219179622|NCT06004479|OTHER|Serum carotenoid concentration|Serum total carotenoid concentration
219369418|NCT02033356|DRUG|Lidocaine|
219750176|NCT04484857|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
219750177|NCT05586295|OTHER|Placebo|Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.
219750178|NCT05586295|OTHER|EX plus|Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
219750179|NCT00614224|BEHAVIORAL|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
219750180|NCT03855904|DEVICE|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
219750181|NCT04570202|BEHAVIORAL|EMDR|The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
219750182|NCT02390076|DEVICE|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
219750183|NCT02390076|OTHER|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
219750184|NCT02390076|DEVICE|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
219750185|NCT02390076|DEVICE|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
219750186|NCT01418456|DRUG|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
219750187|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
219179623|NCT04028947|PROCEDURE|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
219179624|NCT01565109|DRUG|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
219179625|NCT01565109|RADIATION|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
219179626|NCT05938478|DRUG|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
219179627|NCT06543381|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219179628|NCT06543381|DRUG|Olutasidenib|Given PO
219179629|NCT05703074|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
219179630|NCT05703074|BEHAVIORAL|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
219179631|NCT05703074|BEHAVIORAL|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
219179632|NCT05703074|DIETARY_SUPPLEMENT|Placebo|4 capsules (empty) 2 times daily for 84 days.
219179633|NCT06068530|DRUG|DHA/piperaquine and a SLD-PQ|Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
219191581|NCT06665113|DEVICE|taVNS real stimulation|For the real stimulation group, two modified point electrodes will deliver stimulation near the auricular branch of the vagus nerve in the left concha cymba. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
219750188|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
219750189|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
219750190|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
219750191|NCT06634498|OTHER|real rTMS on the dlPFC|During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
219750192|NCT06634498|OTHER|Sham (No Treatment)|During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
219750193|NCT01358734|DRUG|Azacitidine|Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
219750194|NCT01358734|DRUG|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
219750195|NCT01358734|OTHER|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
219750196|NCT02012517|DRUG|Prolonged antibiotic treatment|
219750197|NCT02012517|DRUG|Short antibiotic course (standard of care)|
219750198|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
219750199|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
219750200|NCT03404882|BEHAVIORAL|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
219750201|NCT01822925|DRUG|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
219191582|NCT06665113|DEVICE|taVNS sham stimulation|For the sham stimulation group, two modified point electrodes will deliver stimulation to the earlobes.Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
219750202|NCT01822925|DRUG|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
219750203|NCT01822925|DRUG|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
219750204|NCT01822925|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
219750205|NCT02300545|DRUG|Pazopanib|
219750206|NCT01731782|DRUG|bupivacaine|
219750207|NCT01731782|DRUG|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
219750208|NCT02295462|OTHER|Person-centered Care|Medication Review + Person-centered Care
219750209|NCT02295462|OTHER|Optimised Treatment|Medication Review only
219750210|NCT05890209|DEVICE|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
218992654|NCT02643381|PROCEDURE|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
218992655|NCT02643381|DEVICE|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
218992656|NCT02193867|DRUG|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
219750211|NCT04542681|DRUG|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
219750212|NCT04542681|DRUG|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
219750213|NCT04542681|DRUG|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
219750214|NCT02476227|PROCEDURE|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
219750215|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(RESTORE DEB）|
219750216|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(SeQuent® Please）|
219750217|NCT06412887|DEVICE|Virtual reality headset|Meta-Quest 2 virtual reality headset was used in this study
219750218|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
219750219|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
219750220|NCT03044145|BEHAVIORAL|Treatment as usual|Standard mental health treatment at FHMC
219750221|NCT02196532|DEVICE|Device: Optical coherence tomography|
219750222|NCT05870345|DEVICE|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
219750223|NCT04585178|DEVICE|Biobeat patch|"The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)"
219750224|NCT05291910|DRUG|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
219750225|NCT05291910|DRUG|Toripalimab|240mg intravenously every 3 weeks
219750226|NCT05291910|DRUG|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
219750227|NCT03551093|DEVICE|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
219750228|NCT02089204|RADIATION|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
219750229|NCT02089204|RADIATION|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
219750230|NCT02089204|RADIATION|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
219750231|NCT02937571|DRUG|Carfilzomib|
219750232|NCT02937571|DRUG|Lenalidomide|
219750233|NCT02937571|DRUG|Dexamethasone|
219750234|NCT06236646|OTHER|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
219750235|NCT06236646|OTHER|Control (CON)|The CON group did not have any intervention but usual care.
219750236|NCT05384483|DRUG|Cariprazine|Cariprazine 1.5 to 3 mg per day
219750237|NCT05384483|DRUG|Placebo|Matching placebo
219750238|NCT04617860|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
219750239|NCT00009178|DRUG|Fluoxetine|
219750240|NCT00009178|BEHAVIORAL|Guided Self-Help|
219750241|NCT02800733|DIETARY_SUPPLEMENT|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
219750242|NCT02800733|DIETARY_SUPPLEMENT|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
219750243|NCT01182350|DRUG|Bevacizumab|
219750244|NCT01182350|DRUG|Erlotinib|
219750245|NCT01182350|DRUG|Temozolomide|
219750246|NCT01182350|RADIATION|Radiation|
219761861|NCT04456920|OTHER|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
219761862|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
219369419|NCT01403909|DEVICE|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
219369420|NCT01403909|PROCEDURE|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
219369421|NCT00891995|DEVICE|Closed loop|Closed loop therapy for up to 4 to 6 days
219750247|NCT04002375|OTHER|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
219750248|NCT03898180|BIOLOGICAL|Pembrolizumab|IV infusion
219750249|NCT03898180|DRUG|Lenvatinib|oral capsule
219750250|NCT03898180|DRUG|Placebo for lenvatinib|oral capsule
219750251|NCT02472249|RADIATION|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
219750252|NCT02472249|DRUG|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
219750253|NCT02423486|DEVICE|Electromagnetic stimulation therapy (BIOCON-2000)|
219750254|NCT02423486|DEVICE|Electromagnetic stimulation therapy with biofeedback|
219750255|NCT05147220|DRUG|Remibrutinib|tablet taken orally
219750256|NCT05147220|DRUG|Teriflunomide|capsule taken orally
219750257|NCT05368883|OTHER|Exercise- One-Legged|The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly
219750258|NCT05368883|OTHER|Exercise-Two-Legged|The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
219750259|NCT06637930|OTHER|Edentulous Alveolar Ridge In Mandible|"implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray"
219750260|NCT06640140|BEHAVIORAL|Supervised aerobic plus strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
219750261|NCT06644053|BEHAVIORAL|Quantified analysis of walking during a crossing task through different horizontal openings|Functional test that reproduce a task of daily living
219750262|NCT05406401|BIOLOGICAL|Zilovertamab Vedotin|IV infusion
219750263|NCT05406401|DRUG|Cyclophosphamide|IV infusion
219750264|NCT05406401|DRUG|Doxorubicin|IV infusion
219750265|NCT05406401|BIOLOGICAL|Rituximab|IV infusion
219750266|NCT05406401|BIOLOGICAL|Rituximab Biosimilar|IV infusion
219369422|NCT00891995|DEVICE|Home glucose monitoring|Standard diabetes management using a home glucose meter.
219750267|NCT05406401|DRUG|Prednisone|IV or oral administration (per local guidelines)
219369423|NCT00891995|DEVICE|Insulin pump|Insulin pump use for 2 years
219369424|NCT00891995|DEVICE|Continuous glucose monitor|Continuous glucose monitor use for 2 years
219750268|NCT05406401|DRUG|Prednisolone|IV or oral administration (per local guidelines)
219750269|NCT01646827|DRUG|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
219750270|NCT00928668|DRUG|Placebo|Placebo device for comparison
219750271|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
219750272|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
218992657|NCT05808972|DRUG|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
218992658|NCT05808972|DRUG|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
218992659|NCT06259019|DEVICE|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
218992660|NCT05889195|DIAGNOSTIC_TEST|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
218992661|NCT00454883|DRUG|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
219750273|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
219750274|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
219750275|NCT05000710|DRUG|Durvalumab|Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks
219750276|NCT05000710|DRUG|Tremelimumab|Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1
219750277|NCT05000710|RADIATION|Low dose irradiation|21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
219750278|NCT00186459|BEHAVIORAL|Hypocaloric diet of varying macronutrient composition|
219750279|NCT01838226|BEHAVIORAL|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
219750280|NCT05078437|BEHAVIORAL|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
219750281|NCT01923038|PROCEDURE|First arm: patients ventilated with zero end expiratory pressure|
219750282|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure|
219750283|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
219750284|NCT02261792|PROCEDURE|24 hours Trendelenburg position|Trendelenburg position
219750285|NCT02261792|PROCEDURE|24 hours bed rest|24 hours bed rest after EBP
219750286|NCT02261792|PROCEDURE|EBP|Autologous Epidural Blood Patch
219750287|NCT06149182|BEHAVIORAL|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
219750288|NCT06149182|BEHAVIORAL|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
219750289|NCT01416337|DRUG|GSK1120212|2 mg single dose tablet on Day 1 of study
219750290|NCT01416337|DRUG|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
219750291|NCT05368519|DEVICE|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
219750292|NCT03089294|DEVICE|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
219750293|NCT01767987|DRUG|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
219750294|NCT01767987|DRUG|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
219750295|NCT03232567|BIOLOGICAL|NasoVAX|Single ascending dose study
219750296|NCT05837481|BEHAVIORAL|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
219750297|NCT05361616|DEVICE|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
219750298|NCT06564857|DRUG|Remifentanil|Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
219750299|NCT06564857|DRUG|Rocuronium|Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
219750300|NCT00514189|BIOLOGICAL|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
219750301|NCT00103844|DRUG|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
219750302|NCT00103844|DRUG|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
219750303|NCT03271333|OTHER|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
219750304|NCT02474498|DRUG|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
219750305|NCT02474498|DEVICE|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
219750306|NCT02474498|PROCEDURE|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
219750307|NCT01469247|RADIATION|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
219750308|NCT04544280|DRUG|Xeomin Injectable Product|Intramuscular injection
219750309|NCT04942145|DEVICE|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
219750310|NCT02164110|BIOLOGICAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
219750311|NCT02164110|BIOLOGICAL|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
219750312|NCT04179344|OTHER|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
219750313|NCT05032378|BEHAVIORAL|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
219750314|NCT05032378|BEHAVIORAL|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
219750315|NCT01771497|DEVICE|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
219750316|NCT06467409|DRUG|Placebo|patient-controlled analgesia(PCA) administration
219750317|NCT06467409|DRUG|morphine hydrochloride injection|patient-controlled analgesia(PCA) administration
219369425|NCT04755556|OTHER|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
219750318|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
219750319|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
219750320|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
219750321|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
219750322|NCT03038087|DEVICE|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
219750323|NCT02600650|DIETARY_SUPPLEMENT|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
219750324|NCT02600650|DIETARY_SUPPLEMENT|Placebo Comparator|Daily administration of Placebo Comparator
219750325|NCT02160431|BEHAVIORAL|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
219750326|NCT00654355|DRUG|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
219750327|NCT01202162|DRUG|Desflurane|Administratino of Desflurane
219750328|NCT01202162|DRUG|Administration of Sevoflurane|Administration of Sevoflurane
219750329|NCT02725684|OTHER|Observational study, no intervention|Observational study, no intervention
219750330|NCT06209866|DEVICE|PTA|Percutaneous Trans lumenal Angioplasty
218992662|NCT04673838|OTHER|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
218992663|NCT04673838|OTHER|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
218992664|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
218992665|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
218992666|NCT04724018|DRUG|Pembrolizumab|Intravenous infusion
218992667|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
218992668|NCT02453178|BEHAVIORAL|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
218992669|NCT03880734|DRUG|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
218992670|NCT03880734|OTHER|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
218992671|NCT05512767|OTHER|Best Practice|Undergo self-manual lymphatic drainage
218992672|NCT05512767|OTHER|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
218992673|NCT05512767|PROCEDURE|Diagnostic Imaging|Undergo photographs of face and neck
218992674|NCT05512767|OTHER|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
219369426|NCT04755556|OTHER|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
219750331|NCT05022719|DEVICE|PillCam Colon2 procedure with MB-MMX|Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
219750332|NCT01117246|DEVICE|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
219750333|NCT03324841|DIAGNOSTIC_TEST|Caris MI Profiling|Customized comprehensive biomarker testing
219750334|NCT02501447|BEHAVIORAL|Guided audio-visual relaxation|
219750335|NCT06544720|BIOLOGICAL|SCG142 TCR-T cells|Monotherapy of SCG142
219750336|NCT05006495|PROCEDURE|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
219750337|NCT05006495|PROCEDURE|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
219750338|NCT03137823|DIAGNOSTIC_TEST|throat culture|throat culture - from the tonsills and from the bucal surface
219750339|NCT03161873|DEVICE|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
219750340|NCT04661527|DRUG|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
219750341|NCT05501899|DRUG|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
219750342|NCT02786407|DRUG|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
219750343|NCT02786407|DRUG|Placebo|In these studies,patients received placebo administered to 20 injection sites
219750344|NCT05805150|DEVICE|Control Lens (stenfilcon A)|One week wear
219750345|NCT05805150|DEVICE|Test Lens (senofilcon A)|One week wear
219750346|NCT05885750|BEHAVIORAL|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
219750347|NCT05885750|BEHAVIORAL|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
219750348|NCT05885750|BEHAVIORAL|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
219750349|NCT01530958|BEHAVIORAL|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials"
219750350|NCT01530958|BEHAVIORAL|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
219750351|NCT01530958|BEHAVIORAL|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
219750352|NCT02114645|DRUG|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
219750353|NCT02114645|DRUG|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
219750354|NCT02114645|DRUG|4 mg oral estradiol valerate|estrofem is given twice a day
219750355|NCT02284893|DRUG|Saxagliptin|administered orally once daily
219750356|NCT02284893|DRUG|Dapagliflozin|administered orally once daily
219750357|NCT02284893|DRUG|Sitagliptin|administered orally once daily
219750358|NCT02284893|DRUG|Placebo matching with Saxagliptin|administered orally once daily
219750359|NCT02284893|DRUG|Placebo matching with Dapagliflozin|administered orally once daily
218992675|NCT05512767|PROCEDURE|Modified Barium Swallow|Undergo swallow study
218992676|NCT05512767|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
219369427|NCT02054702|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
219750360|NCT02284893|DRUG|Placebo matching with Sitagliptin|administered orally once daily
219750361|NCT03139721|DEVICE|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
218992677|NCT05512767|DEVICE|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
218992678|NCT05512767|OTHER|Quality-of-Life Assessment|Ancillary studies
218992679|NCT05512767|OTHER|Questionnaire Administration|Ancillary studies
218992680|NCT05512767|OTHER|Voice Handicap Index-10|Ancillary studies
219369428|NCT02054702|DRUG|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
219750362|NCT06222021|GENETIC|Genetic analysis of polymorphism of membrane receptors involved in lactate transport|The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
219750363|NCT04560530|RADIATION|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
219750364|NCT02688439|OTHER|Sciatic Nerve block|
219750365|NCT02688439|OTHER|Leg raised 30°|
219750366|NCT02688439|OTHER|Distal tourniquet placed on the lower part of the leg|
219750367|NCT02688439|OTHER|Leg in a neutral position|
219750368|NCT04814914|OTHER|KB109 + Self Supportive Care|KB109 is a novel glycan
219750369|NCT04814914|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
219750370|NCT04576559|OTHER|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
219750371|NCT04576559|OTHER|Regular dental visual aids|Regular dental visual aids
219750372|NCT04769284|OTHER|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~* Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~* International Physical Activity Questionnaire (IPAQ)~* Abbreviated Goldberg Anxiety Scale EADG~* Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
219750373|NCT05093608|DRUG|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
219750374|NCT05093608|DRUG|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
219750375|NCT05093608|DRUG|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
219750376|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
219750377|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
219750378|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
219750379|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
219750380|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
219750381|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
219750382|NCT02444754|OTHER|Medical Chart Review|Obtain medical data
219750383|NCT02444754|OTHER|Questionnaire Administration|Complete demographics questionnaires
219750384|NCT02444754|OTHER|Survey Administration|Complete surveys
219750385|NCT03455686|OTHER|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
219750386|NCT05126303|DRUG|RMC-035|Concentrate for Solution for Infusion
219750387|NCT05126303|DRUG|Placebo|Concentrate for Solution for Infusion
219750388|NCT04502914|PROCEDURE|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
219750389|NCT04502914|PROCEDURE|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
219750390|NCT05405270|DRUG|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
219750391|NCT05405270|DIAGNOSTIC_TEST|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
219750392|NCT05405270|OTHER|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
219750393|NCT05405270|DIAGNOSTIC_TEST|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
219750394|NCT00105066|DRUG|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
219750395|NCT00105066|DRUG|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
218992681|NCT04779125|PROCEDURE|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
219750396|NCT05577741|BEHAVIORAL|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
219750397|NCT05577741|BEHAVIORAL|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
219750398|NCT05577741|OTHER|Standard treatment|Standard of care treatment
219750399|NCT03270995|BEHAVIORAL|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
219750400|NCT03270995|BEHAVIORAL|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
219750401|NCT03802019|OTHER|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
218992682|NCT05683964|DRUG|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
218992683|NCT05683964|DIAGNOSTIC_TEST|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
218992684|NCT00489346|DRUG|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
218992685|NCT00489346|DRUG|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
218992686|NCT02164825|DRUG|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
218992687|NCT02164825|DRUG|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
218992688|NCT03600818|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219750402|NCT03802019|OTHER|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
219750403|NCT04417985|DEVICE|18F-FDG PET/CT, MRI|
219750404|NCT02886364|BEHAVIORAL|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
219750405|NCT05036343|DEVICE|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
219750406|NCT00105898|PROCEDURE|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
219750407|NCT00105898|PROCEDURE|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
219750408|NCT00105898|PROCEDURE|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
219750409|NCT01771354|BIOLOGICAL|Engerix B Vaccine|
219750410|NCT01771354|BIOLOGICAL|Placebo|
219750411|NCT00031733|BIOLOGICAL|MART-1 antigen|
219750412|NCT00031733|BIOLOGICAL|gp100 antigen|
219750413|NCT00031733|BIOLOGICAL|incomplete Freund's adjuvant|
219750414|NCT00031733|BIOLOGICAL|recombinant interleukin-12|
219750415|NCT00031733|BIOLOGICAL|sargramostim|
219750416|NCT00031733|BIOLOGICAL|tyrosinase peptide|
219750417|NCT00031733|DRUG|alum adjuvant|
219750418|NCT00031733|PROCEDURE|adjuvant therapy|
219750419|NCT03473587|BEHAVIORAL|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
219750420|NCT03473587|BEHAVIORAL|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
219750421|NCT01416350|DRUG|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
219750422|NCT01416350|DRUG|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
219750423|NCT01416350|DRUG|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
219750424|NCT02733757|DRUG|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
219750425|NCT03815344|DRUG|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
219750426|NCT03815344|DRUG|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
219750427|NCT03577457|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
219750428|NCT03577457|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
219750429|NCT03577457|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
219750430|NCT03577457|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
219750431|NCT05233839|OTHER|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
219750432|NCT05233839|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
219750433|NCT05990686|DRUG|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
219761863|NCT02178410|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
218992689|NCT03600818|DRUG|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
218992690|NCT03600818|DRUG|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
218992691|NCT03600818|DRUG|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
218992692|NCT03600818|DRUG|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
218992693|NCT03429686|OTHER|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
218992694|NCT06044610|OTHER|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
218992695|NCT06044610|OTHER|GENPOP Ad lib fluid intake|Over 24 hours
218992696|NCT06044610|OTHER|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
218992697|NCT06044610|OTHER|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
219006703|NCT01317160|DEVICE|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
219750434|NCT05990686|DRUG|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
219750435|NCT03346837|DRUG|BMS-986205|BMS-986205
219179634|NCT06068530|BIOLOGICAL|Study vaccine R21/Matrix-M™|The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
219750436|NCT03346837|DRUG|Itraconazole|Oral solution
219750437|NCT03346837|DRUG|Rifampin|Tablet
219750438|NCT01912573|DRUG|Intranasal (IN) naloxone|
219750439|NCT01912573|DRUG|Intravenous (IV) naloxone|
219750440|NCT01912573|DRUG|Intramuscular (IM) naloxone|
219750441|NCT01912573|DRUG|Intraosseus (IO) naloxone|
219750442|NCT03145220|DRUG|EA-230|Active intervention
219750443|NCT03145220|OTHER|Placebo (NaCl)|Placebo intervention
219750444|NCT02421094|DRUG|GR-MD-02|GM-MD-02 active
219750445|NCT02421094|DRUG|Placebo|Placebo
219750446|NCT01139151|DRUG|3 Day Thiarabine|Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
219750447|NCT01139151|DRUG|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
219750448|NCT05356715|PROCEDURE|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
219750449|NCT02774694|DEVICE|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
219750450|NCT06408376|PROCEDURE|Physiological cord clamping|Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
219750451|NCT02878785|DRUG|Decitabine|DNA methyltransferase inhibitor
219750452|NCT02878785|DRUG|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
219750453|NCT05759403|DIAGNOSTIC_TEST|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
219750454|NCT03820076|OTHER|AZT-04|Staphylococcus epidermidis
219750455|NCT01483560|DRUG|Metformin|3 years treatment duration
219750456|NCT01483560|DRUG|Placebo|3 years duration
219750457|NCT00895804|DRUG|MDMA|capsule, 1.6 mg/kg body weight, single dose
219750458|NCT00895804|DRUG|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
219750459|NCT00749346|DEVICE|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
219750460|NCT00460213|DRUG|Valsartan 80mg daily|
219750461|NCT00460213|DRUG|Valsartan 160mg daily|
219750462|NCT04870047|DEVICE|Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device|Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
219750463|NCT00874601|DRUG|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
219750464|NCT06513247|DIAGNOSTIC_TEST|screening for Islet autoantibody|IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
219750465|NCT06513247|DIAGNOSTIC_TEST|HLA phenotype and genetic risk score|using DBS filter paper
219750466|NCT01219257|BIOLOGICAL|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
219750467|NCT03549962|PROCEDURE|TKA|Total Knee Arthroplasty
219750468|NCT04716894|DRUG|BI 474121|BI 474121 oral solution
219750469|NCT04716894|DRUG|Itraconazole|Itraconazole oral solution
219750470|NCT03701243|PROCEDURE|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
219750471|NCT03701243|PROCEDURE|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
219750472|NCT01413438|PROCEDURE|Craniotomy|
219761864|NCT02178410|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219006704|NCT03601689|PROCEDURE|rectal resection|total mesorectal excision
219006705|NCT03898050|PROCEDURE|transcutaneous cardiac pacing|transcutaneous cardiac pacing
219006706|NCT01086722|DRUG|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
219750473|NCT01378143|DRUG|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
219750474|NCT00000884|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
219750475|NCT00000884|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
219750476|NCT00000884|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
219750477|NCT04881084|OTHER|Digital storytelling group|Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
219750478|NCT04881084|OTHER|Social marketing/fundraising group|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
219750479|NCT06377319|DIAGNOSTIC_TEST|Cardiac Output Response to Stress (CORS) test|Cardiac Output Response to Stress (CORS) is a novel, non-invasive, easy-to-use test developed by the Newcastle and Coventry Universities. CORS test measures heart function (cardiac output) at rest and in response to short step-exercise using validated electrical signal processing bioreactance technology, similar to an ECG.
219750480|NCT05977998|DRUG|Paclitaxel|Given by IP (Intraperitoneal injection)
219750481|NCT05977998|DRUG|Dexamethasone|Given by IV (vein)
219750482|NCT05977998|DRUG|Diphenhydramine|Given by IV (vein)
219750483|NCT05977998|DRUG|Famotidine|Given by IV (vein)
219750484|NCT03610698|BEHAVIORAL|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
219750485|NCT03610698|OTHER|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
219750486|NCT05713266|DEVICE|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
219750487|NCT01720550|DRUG|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
219750488|NCT01720550|DRUG|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
219750489|NCT04205786|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
219750490|NCT04205786|OTHER|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA"
219750491|NCT04205786|OTHER|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
219750492|NCT04205786|OTHER|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
219750493|NCT04205786|OTHER|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
219750494|NCT04205786|OTHER|Demographics Questionnaire|Demographics Questionnaire
219750495|NCT02928835|DEVICE|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
219750496|NCT05292703|OTHER|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
219750497|NCT05292703|OTHER|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
219750498|NCT02205320|BIOLOGICAL|DRL_PG|
219750499|NCT02205320|BIOLOGICAL|Pegfilgrastim Form A|
219750500|NCT02205320|BIOLOGICAL|Pegfilgrastim Form B|
219750501|NCT06494046|OTHER|Non-Interventional Study|Non-Interventional Study
219750502|NCT00037882|DRUG|PEG-Intron|Once weekly injection.
219750503|NCT03014258|BIOLOGICAL|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
219750504|NCT04943679|DRUG|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
219750505|NCT04943679|DRUG|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
219750506|NCT01280331|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
219750507|NCT01280331|DRUG|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
219750508|NCT01280331|DRUG|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
219750509|NCT00005830|DRUG|Doxorubicin Hydrochloride|Given IV
219750510|NCT00005830|DRUG|Cisplatin|Given IV
219750511|NCT00005830|RADIATION|Radiation Therapy|Undergo radiation therapy
219750512|NCT04778566|DIAGNOSTIC_TEST|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
219750513|NCT06099002|OTHER|Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale|"All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls."
219750514|NCT00572819|DRUG|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
219750515|NCT00572819|DRUG|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
219750516|NCT03483701|BEHAVIORAL|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
219750517|NCT01957384|DEVICE|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
219750518|NCT01957384|DEVICE|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
219750519|NCT01957384|DEVICE|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
219750520|NCT03248752|BEHAVIORAL|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
219369429|NCT05510960|OTHER|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
219369430|NCT02898480|PROCEDURE|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
219750521|NCT03248752|BEHAVIORAL|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
219750522|NCT02006511|DEVICE|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
219750523|NCT02006511|OTHER|Standard of Care wound therapy|Gauze type dressing.
219750524|NCT01283672|OTHER|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
219750525|NCT04017858|BEHAVIORAL|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
219761865|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
219761866|NCT06447675|OTHER|Hyperthermic Baths|The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
219369431|NCT01884792|OTHER|Sitting OGTT|
219369432|NCT01884792|OTHER|Standing OGTT|
219750526|NCT04017858|BEHAVIORAL|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
219750527|NCT05176067|RADIATION|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
219750528|NCT00661856|DIETARY_SUPPLEMENT|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
219750529|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (25 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
219750530|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (40 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
219750531|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
219750532|NCT06473246|DIETARY_SUPPLEMENT|CBD Broad Extract (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
219750533|NCT06473246|DIETARY_SUPPLEMENT|Placebo|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
219750534|NCT05743309|BEHAVIORAL|Video call sessions|Investigators made video call sessions with the participants.
219750535|NCT04883138|DRUG|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
219750536|NCT04017208|DRUG|ASP2713|Administered intravenously
219750537|NCT04017208|DRUG|placebo|Administered intravenously
219750538|NCT00099814|PROCEDURE|Two different loop designs which deliver distinctive forces|
219750539|NCT05492045|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
219179635|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
219179636|NCT03194685|DRUG|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
219179637|NCT04473430|DEVICE|Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance.~Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).~Diagnostic Test: Real-time CGM will be used to collect outcomes variables"
219750540|NCT05492045|DRUG|Other|Standard treatment of NSCLC.
219750541|NCT04748237|DIAGNOSTIC_TEST|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
219750542|NCT02259231|DRUG|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
219750543|NCT02259231|DRUG|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
219750544|NCT02259231|DRUG|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
218992698|NCT04486911|DRUG|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
218992699|NCT00486200|DRUG|ASP2151|Oral administration.
218992700|NCT00486200|DRUG|valacyclovir|Oral administration of active comparator.
219369433|NCT01884792|OTHER|Sitting CGM|
219369434|NCT01884792|OTHER|Standing CGM|
219750545|NCT02259231|DRUG|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
219750546|NCT02259231|DRUG|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
219750547|NCT06293898|DRUG|BL-M07D1|"Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks.~Other Names:~BL-M07D1"
219750548|NCT06821841|BEHAVIORAL|Online Physical Activity Group|The online physical activity group will consist of four 45-60-minute sessions, which participants allocated to this group will be asked to commit to. These sessions will be delivered online and occur for 4 weeks. Discussions within the sessions will incorporate motivational interviewing, focussing on the benefits of physical activity, current physical activity levels, barriers to physical activity and overcoming these, motivation to complete physical activity, and goal setting. Participants allocated to this group will receive weekly reminders to promote attendance. Participants will also be asked to complete a weekly physical activity log that includes detail about the type of physical activity they completed, the duration, intensity, context and comments.
219750549|NCT06821841|BEHAVIORAL|Information Leaflet|Participants will receive an information leaflet that includes information about menopause (e.g. definition, symptoms), the benefits of physical activity for menopause, recommended weekly physical activity levels (based on CMO guidelines), examples of physical activity, and signposting to online resources. Participants will be able to use the information leaflet as they wish, and complete a weekly physical activity log that includes detail about the type of physical activity completed, the duration, intensity, context and comments.
219750550|NCT05079334|BEHAVIORAL|MeTree Questionnaire|"MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature."
219750551|NCT00496119|RADIATION|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
219750552|NCT00496119|RADIATION|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
219750553|NCT05164653|DRUG|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
219750554|NCT05164653|DRUG|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
219750555|NCT03979001|OTHER|complete ophthalmological examination|"collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography"
219750556|NCT03815552|DEVICE|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
219750557|NCT05826665|OTHER|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
219179638|NCT04473430|DEVICE|POC Glucose Testing|"POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.~Diagnostic Test: Professional CGM will be used to collect outcomes variables (including during the POC BG testing)."
219750558|NCT06638736|OTHER|Wound Closure with sutures vs staples|Closure of the wound with either sutures or staples depending upon the study arm
219750559|NCT06639334|OTHER|Fasttrack pathway for THA/HE prosthesis reduction|"The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol."
219750560|NCT06639334|OTHER|Standard pathway for THA/HE prosthesis reduction|Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
219750561|NCT06637150|DRUG|Dalpicilib|Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
219750562|NCT06637150|DRUG|endocrine therapy|standard endocrine therapy
219750563|NCT06210893|OTHER|The cricoid cartilage is located.|The cricoid cartilage is located.
219750564|NCT05371379|BIOLOGICAL|CM338 Injection|A humanized monoclonal antibody.
219179639|NCT02535338|DRUG|Erlotinib Hydrochloride|Given PO
219179640|NCT02535338|OTHER|Laboratory Biomarker Analysis|Correlative studies
219179641|NCT02535338|DRUG|Onalespib Lactate|Given IV
219369435|NCT05448118|DIAGNOSTIC_TEST|Virtual POC Toxicology Test|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
219179642|NCT02535338|OTHER|Pharmacological Study|Correlative studies
219179643|NCT03761446|BEHAVIORAL|Bed rest|The participant will remain in bed rest for 10 complete days.
219179644|NCT04454788|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
219179645|NCT04454788|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
219179646|NCT05126433|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
219369436|NCT00887458|DRUG|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
219369437|NCT00887458|DRUG|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
219750565|NCT06643572|DEVICE|Virtual reality simulator|This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
219750566|NCT03126630|BIOLOGICAL|Anetumab Ravtansine|Given IV
219750567|NCT03126630|OTHER|Laboratory Biomarker Analysis|Correlative studies
219750568|NCT03126630|BIOLOGICAL|Pembrolizumab|Given IV
219750569|NCT03126630|OTHER|Pharmacological Study|Correlative studies
219750570|NCT00847730|DEVICE|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
219750571|NCT05908500|BEHAVIORAL|CPR Training|Various durations and frequencies of CPR training
219750572|NCT05908500|DEVICE|CPR Manikin Type|Various types of CPR manikins are compared
219750573|NCT06171802|DRUG|Empagliflozin|10 mg empagliflozin daily for six months
219750574|NCT06171802|DRUG|Placebo|Placebo capsule once daily for six months
219750575|NCT06852898|OTHER|Chiropractic Care|Chiropractic Care is the active comparator arm / intervention. All subjects will receive chiropractic care.
219750576|NCT06852898|OTHER|Radial Extracorporeal Shockwave Therapy (ESWT) - Radial Pulse Therapy|This intervention is answering the question: Does on radial ESWT have additive therapeutic effects on the recovery of acute lower back pain symptoms - better or earlier reduction in pain intensity or improvement in physical function - than chiropractic care / manual therapy alone? Subjects will be randomly assigned to receive chiropractic care and ESWT or only chiropractic care.
219750577|NCT03607500|BEHAVIORAL|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
219750578|NCT01427478|DRUG|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
219750579|NCT01427478|DRUG|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
219750580|NCT05185622|DRUG|Vamorolone|Oral administration of vamorolone for 12 weeks.
219750581|NCT06560307|DEVICE|Enterra Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
219750582|NCT06499961|BEHAVIORAL|Digital version of Holistic Healthy Life Education|Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
219750583|NCT06499961|OTHER|Waitlist control|usual care first, then switch to receive the intervention
219750584|NCT02496000|DRUG|ORMD-0801|Oral Insulin
218992701|NCT00486200|DRUG|Placebo|Oral administration of placebo.
218992702|NCT05581862|BEHAVIORAL|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
219750585|NCT02496000|DRUG|Placebo Comparator|Placebo
219750586|NCT05040932|DRUG|YH004|IV infusion once every 3 weeks (Q3W).
219750587|NCT01150370|DEVICE|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
219750588|NCT02255656|DRUG|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
219750589|NCT02898038|DIETARY_SUPPLEMENT|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
219750590|NCT05806528|OTHER|Ultrasound|Use ultrasound to make placental invasion index
219750591|NCT06461507|OTHER|Janda's Approach|For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
219750592|NCT03852420|DEVICE|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
219750593|NCT02422108|DRUG|Denosumab|
219750594|NCT05100095|DRUG|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
219750595|NCT05446207|OTHER|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
219750596|NCT05446207|OTHER|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
219750597|NCT04269863|DRUG|Aspirin|control - 81mg. treatment - 81-325mg.
219750598|NCT04736355|DRUG|DAOIB|oral, for 24 weeks
218992703|NCT05581862|BEHAVIORAL|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
218992704|NCT05111171|DEVICE|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
219750599|NCT04736355|DRUG|Placebo|oral, for 24 weeks
219750600|NCT06316570|DRUG|Early Dual Antiplatelet Therapy|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
219750601|NCT06316570|DRUG|Placebo|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
219750602|NCT05565118|PROCEDURE|Standard Surgical Treatment|During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
219750603|NCT05565118|PROCEDURE|Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
219750604|NCT01877278|DEVICE|Wearable pulsed electromagnetic fields|
219179647|NCT04768257|BEHAVIORAL|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
219179648|NCT05658874|DRUG|Multimodal Bundle Drugs|multimodal pain therapy
219179649|NCT05658874|PROCEDURE|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
219179650|NCT05658874|BEHAVIORAL|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
219179651|NCT05658874|OTHER|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
219179652|NCT05658874|OTHER|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
219179653|NCT05658874|DRUG|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
219179654|NCT05658874|DRUG|Vaginal estrogen|Topical vaginal estradiol application
219179655|NCT05658874|DRUG|Methenamine|UTI prevention/bladder therapeutic
219179656|NCT05658874|DRUG|Amitriptyline/Gabapentin|Part of multimodal pain therapy
219179657|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
219179658|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
219179659|NCT04775381|DRUG|Vitamin D|Patients will receive a cholecalciferol supplementation added to a fruit juice.
219179660|NCT05226806|OTHER|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
219750605|NCT06381960|DRUG|Fuzheng Quxie Recipe|Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
219750606|NCT06381960|DRUG|Fuzhengquye Fang Recipe simulant|Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
219750607|NCT01480830|DEVICE|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
219750608|NCT03014505|BIOLOGICAL|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
219750609|NCT03014505|OTHER|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
219750610|NCT04619628|BIOLOGICAL|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
219750611|NCT04619628|OTHER|Placebo|normal saline
219750612|NCT05535569|DRUG|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
219750613|NCT01757496|DEVICE|Cough Assist|
219750614|NCT04731597|DRUG|drug interaction|when two drugs are taken together
219750615|NCT06460532|OTHER|Baseline treatment|Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
219750616|NCT06431581|BEHAVIORAL|m-Health intervention (educational video, SMS and reminder phone call)|Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
219750617|NCT05678465|PROCEDURE|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
219750618|NCT05678465|PROCEDURE|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
219750619|NCT04317742|DEVICE|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
219750620|NCT04317742|DEVICE|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
219750621|NCT06428188|BIOLOGICAL|BCMA/CD19 CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
219750622|NCT06640699|OTHER|exercise|exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
219750623|NCT06642116|DEVICE|OCEAN|Biodegradable nasal dressing
219750624|NCT06637059|OTHER|observational study|observation alone
219750625|NCT06645275|GENETIC|POCT test|Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
219750626|NCT06638918|DEVICE|Virtual Reality|The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
219750627|NCT06187714|PROCEDURE|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
219750628|NCT01716702|BEHAVIORAL|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
219750629|NCT03716973|DEVICE|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
219750630|NCT06358508|DEVICE|Sapphire 3 Coronary Dilatation Catheter|To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
219750631|NCT05289544|BEHAVIORAL|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
219750632|NCT00883311|DEVICE|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
219750633|NCT02314195|DRUG|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
219750634|NCT02314195|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
219750635|NCT02314195|OTHER|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
219750636|NCT01527955|OTHER|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
219750637|NCT05024162|DIAGNOSTIC_TEST|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
219750638|NCT05024162|DIAGNOSTIC_TEST|MRT Stability|MRT's predicted GG at second MRI-P.
219750639|NCT04416711|BEHAVIORAL|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
219750640|NCT04416711|BEHAVIORAL|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
219179661|NCT05226806|OTHER|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
219179662|NCT05521269|DRUG|ANX1502|ANX1502 is a prodrug of ANX1439.
219750641|NCT04416711|OTHER|Services As Usual|These participants will receive services as usual
219750642|NCT05972785|DRUG|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
219750643|NCT05972785|DRUG|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
219750644|NCT05972785|DRUG|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
219750645|NCT05972785|DRUG|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
219750646|NCT05972785|DRUG|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
219750647|NCT05972785|DRUG|None AHT|None AHT
219750648|NCT06565091|DEVICE|Measurements of physiological parameters of the anterior chamber|Acquisition by the investigational device
219750649|NCT06565091|DEVICE|Measurements of the Axial biometry|Acquisition by the investigational device
219179663|NCT05521269|DRUG|Placebo|Placebo comparator.
219179664|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
219179665|NCT06074055|OTHER|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
219179666|NCT04137289|DRUG|BI 905711|BI 905711
219750650|NCT00291837|DRUG|CT-2106|
219750651|NCT01558167|DRUG|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose"
219750652|NCT00060125|DRUG|tipifarnib|Given orally
219750653|NCT00060125|OTHER|laboratory biomarker analysis|Correlative studies
219750654|NCT05386966|OTHER|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (\<20 day or \>20 day ).Expectance for permanent infirmity
218992705|NCT06438068|OTHER|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy separated by 48 hours. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
218992706|NCT02124083|DRUG|Vorinostat|Histone deactylase inhibitor
218992707|NCT05055063|DRUG|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
218992708|NCT05546502|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
218992709|NCT05546502|BIOLOGICAL|Active Comparator|Covovax
218992710|NCT05264935|PROCEDURE|Ultrasound-Guided Puncture and Lavage (UGPL)|After local anaesthesia with rapidocain the calcific deposit of the rotator cuff will be punctured and washed out with saline solution.
219179667|NCT06199453|DRUG|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
219179668|NCT06500598|DRUG|Evinacumab|
219179669|NCT04322279|DIAGNOSTIC_TEST|Serology|SARS-CoV-2 serology
219179670|NCT04322279|GENETIC|Sequencing|Whole exome sequencing
219179671|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
219179672|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
219179673|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
219179674|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
219179675|NCT02361827|PROCEDURE|Embryo transfer|For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
219179676|NCT06017544|PROCEDURE|PCI|The T2DM affected by AMI will be referred for receiving PCI.
219179677|NCT04410341|DRUG|Vildagliptin 50 MG|Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.
219179678|NCT04410341|DRUG|Escitalopram 20 mg|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
219179679|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
219179680|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
219179681|NCT06843954|DRUG|Bevacizumab|bevacizumab (7.5mg/kg every 21 days) for minimum of 3 cycles
219179682|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
219179683|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
219179684|NCT06846918|BEHAVIORAL|High-Intensity Interval Training|"The high-intensity interval training (HIIT) protocol will run for 12 weeks, with two weekly sessions, totaling 24 sessions. Each 20-minute session will follow a group-based circuit format with functional exercises (e.g., jogging, jumping jacks, step-ups). High-intensity phases will be performed at maximum effort, while moderate-intensity phases will be maintained at a Borg scale rating of 4-6.~Training will amount to 40 minutes per week. The intensity ratio will progress over time:~* Weeks 1-4: 15 sec high / 60 sec moderate (1:4)~* Weeks 5-8: 15 sec high / 45 sec moderate (1:3)~* Weeks 9-12: 15 sec high / 30 sec moderate (1:2)~* Weeks 13-16: 15 sec high / 15 sec moderate (1:1)~This progressive structure ensures gradual adaptation while maximizing effectiveness."
219179685|NCT06846918|BEHAVIORAL|Exercise Snacks Protocol|The exercise snack protocol will last for 12 weeks, with sessions held twice a week, totaling 24 sessions. The exercise snacks will amount to 40 minutes per week, divided across the five weekdays. Participants will be required to perform 4 minutes of functional exercises (e.g., jogging in place, jumping jacks in place, modified burpees in place, etc.) in both the morning (AM) and evening (PM), completing a total of 8 minutes per day. The exercises must be performed at high intensity, with a score of \>8 on a modified Borg scale.
219179686|NCT06486636|PROCEDURE|Left Posterior Pericardiotomy|The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass. A soft channel drain will be put into place at an angle directed toward the posterior pericardium. The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm. The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
219179687|NCT04617496|BEHAVIORAL|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
219750655|NCT02946697|BEHAVIORAL|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
219750656|NCT04652765|DRUG|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
219750657|NCT04652765|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
219750658|NCT06570005|OTHER|Water Quality Assurance Fund|"* At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions."
219179688|NCT04617496|BEHAVIORAL|Health education|Provision of general information about a variety of topics
219179689|NCT06177990|OTHER|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
219179690|NCT06177990|OTHER|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
219179691|NCT06151015|OTHER|Nitrate-rich beetroot juice plus calorie-restricted diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).
219750659|NCT06183021|PROCEDURE|Vital pulp cryotherapy|Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
219750660|NCT06183021|PROCEDURE|Intracanal cryotherapy|After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
219750661|NCT04470037|DRUG|DAAOI-P|DAAOI-P 250-1500mg
219750662|NCT04470037|DRUG|Placebo|starch pill
219750663|NCT03657485|DIETARY_SUPPLEMENT|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
219750664|NCT05607849|OTHER|The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool.|"The leaflet will include a link to access the discutons-mammo.fr DA aid tool, and will inform women about shared decision-making.~The GPs of women who are sent the leaflet will also be sent a letter encouraging shared decision-making. This material will be sent 3 months after women have received their breast cancer screening invitation letter.~Data related to primary and secondary objectives will be collected by questionnaire from the 2 groups. The questionnaire will be sent 2 months after participants are informed about the tool."
219750665|NCT02757768|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
219750666|NCT02757768|DRUG|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
219750667|NCT02757768|DRUG|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
219750668|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
219750669|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
219750670|NCT06662513|OTHER|No Intervention: Observational Cohort|No intervention - retrospective observational study
219750671|NCT06674148|DRUG|Qifangfeixian granules|The experimental group was treated with Qifangfixian granules
219750672|NCT06674148|OTHER|Placebo|The control group was treated with placebo
218992711|NCT05239247|OTHER|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
218992712|NCT05239247|OTHER|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
218992713|NCT00168896|DRUG|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
218992714|NCT02059395|OTHER|Mastery based learning|Participants are allowed to follow the course content at their own speed
218992715|NCT02059395|OTHER|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
218992716|NCT04728399|DIETARY_SUPPLEMENT|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
219750673|NCT06673654|DRUG|Ruxolitinib Topical Cream 1.5%|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
219750674|NCT06673654|DRUG|OPZELURA (Ruxolitinib) Cream|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
219750675|NCT06673654|DRUG|Placebo|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
219750676|NCT06674551|PROCEDURE|Suprascapular nerve block and Axillary nerve block|A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic
219750677|NCT06674551|PROCEDURE|Interscalene Nerve Block|The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
218992717|NCT04728399|DIETARY_SUPPLEMENT|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
219179692|NCT06151015|OTHER|Nitrate-rich beetroot juice plus weight-maintenance diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
219750678|NCT06681012|DEVICE|Gelsectan®|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
218992718|NCT03167190|PROCEDURE|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
218992719|NCT03167190|PROCEDURE|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
218992720|NCT03416946|DEVICE|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
218992721|NCT03416946|OTHER|Traditional|Traditional cutting method
218992722|NCT04571879|DRUG|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
218992723|NCT04571879|DRUG|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
218992724|NCT04571879|OTHER|Placebo|Nebulized normal saline and intranasal normal sline
218992725|NCT01488370|DEVICE|Endotracheal intubation|Endotracheal intubation
218992726|NCT00372762|DRUG|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
218992727|NCT00372762|DRUG|Bumetanide|Equivalent dose to pre-existing furosemide will be used
219750679|NCT06681012|DRUG|Placebo|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
219750680|NCT06680648|PROCEDURE|addition of oxygeninsufflation via working channel of flexible scope|addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope
219750681|NCT06680648|PROCEDURE|no-oxygen insufflation|no-oxygen insufflation added to the flexible scope while advancing it
219750682|NCT03598829|DIAGNOSTIC_TEST|Tryptase, Serum test|Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
219750683|NCT04180722|DEVICE|aTouchAway™ platform|Participants will receive multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
219750684|NCT07011212|DIAGNOSTIC_TEST|BL-Predicter|To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial
219750685|NCT06674291|DRUG|No intervention (observational study)|This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
219369438|NCT02844127|PROCEDURE|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
219369439|NCT03180892|OTHER|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
219369440|NCT01453881|DEVICE|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
219369441|NCT01453881|DEVICE|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
219369442|NCT00129064|BEHAVIORAL|Electronic referral system|
219369443|NCT00393419|BEHAVIORAL|Comprehensive pharmacy care program|
219369444|NCT03448640|DRUG|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
219750686|NCT07009795|BEHAVIORAL|Rise & Renew Hybrid Grief Support Program|"The Rise \& Renew Hybrid Grief Support Program is a culturally responsive, multi-component behavioral intervention designed specifically for Black women aged 40 and older who have experienced the loss of a spouse, parent, or child. It integrates wellness practices, grief support, spiritual care, and community healing in a hybrid format that includes both an in-person and virtual component.~This intervention is distinguished by its cultural tailoring for middle-aged and older Black women, co-facilitation by both a trained facilitator and a faith-based leader, and its combination of expressive arts, spiritual guidance, and practical wellness strategies delivered in a hybrid format. It addresses grief holistically through emotional, physical, spiritual, and social dimensions, and emphasizes culturally relevant healing practices often overlooked in conventional grief programs."
219750687|NCT06675669|OTHER|Reflective thinking method|It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
218992728|NCT00372762|DRUG|furosemide|20mg to 80mg orally once or twice daily
218992729|NCT00372762|DRUG|bumetanide|0.5mg to 2mg orally once or twice daily
218992730|NCT05042154|DEVICE|WatchPAT|The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
218992731|NCT04229420|DEVICE|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
218992732|NCT03355820|PROCEDURE|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
218992733|NCT04580069|PROCEDURE|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
218992734|NCT04189081|DEVICE|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
218992735|NCT04189081|OTHER|Water Control|negative control
218992736|NCT00910026|PROCEDURE|low tidal volume ventilation|6 ml/kg tidal volume ventilation
218992737|NCT00910026|PROCEDURE|high tidal volume ventilation|12 ml/kg tidal volume ventilation
218992738|NCT05304273|DRUG|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
218992739|NCT05304273|DRUG|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
218992740|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
218992741|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
218992742|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
218992743|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
218992744|NCT02656732|BIOLOGICAL|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
218992745|NCT02656732|PROCEDURE|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
218992746|NCT03441308|BEHAVIORAL|Educational method of group treatment|
219750688|NCT07010588|DEVICE|non-contrast abbreviated MRI (NC-AMRI)|Non-contrast abbreviated MRI (NC-AMRI) examination include T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), which takes 10 minutes approximately.
219369445|NCT01509625|DRUG|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
219750689|NCT07010588|DEVICE|enhanced abbreviated MRI (E-AMRI)|E-AMRI examination (using gadoxetic acid disodium) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)and hepatobiliary phase (HBP) images, which takes 15 minutes approximately.
219750690|NCT07010211|OTHER|Gait Video Recording and Analysis|Participants undergo a 6-minute walk test (6MWT) while being recorded on video. The footage is later analyzed using artificial intelligence algorithms to assess gait parameters.
219750691|NCT07010237|DRUG|Dose-attenuated IST and Hetrombopag|Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily for 24weeks.
219750692|NCT07010185|BEHAVIORAL|home based exercise|warm-up Exercises (5 minutes), dynamic Stretching (5 to 10 repetitions), strengthening exercises focused on lower limb muscles, such as bridging, clamshells, and various leg exercises (5-10 repetitions across 2-3 sets, based on patient tolerance)
219750693|NCT06681974|BEHAVIORAL|CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.|"* Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances."
219750694|NCT06681974|BIOLOGICAL|EXPERIMENTAL: program of exercises that will be composed of 4 blocks|the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
219750695|NCT06690879|DEVICE|Smartphone application AI Posture Evaluation and Correction System (APECS)|Mobile application APECS v. 6.2.0. is used to assess upper body posture during standing from back side and right side.
219750696|NCT06690320|BEHAVIORAL|IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER|Description: By examining the parameters of the health belief model and fatalism scales, 6 targets were determined for these scale parameters. The targets were prepared to gain early diagnosis behaviors in breast cancer. By using the breast model, the behavior will be demonstrated in practice
219750697|NCT06626126|OTHER|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
219750698|NCT06626126|OTHER|LDL-C-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
219750699|NCT06418282|DEVICE|Dayspring|NPCD
219750700|NCT06630767|PROCEDURE|ERAS|Enhanced recovery after surgery (ERAS) programs are a combination of evidenced-based perioperative care approaches that work synergistically to improve recovery after surgery. The core elements of ERAS protocols are preoperative advice, optimization of diet, systematic analgesic and anesthetic regimes, and early mobilization.
219750701|NCT06630767|PROCEDURE|Conventional|Conventional care for patients subjected for laparoscopic common bile duct exploration
219750702|NCT06686472|DRUG|TL-925|TL-925 is an eye drop.
219750703|NCT06686472|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
219750704|NCT06690671|DRUG|Golidocitinib in combination with anti-PD-1|Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
219750705|NCT06691737|OTHER|Whole Body Vibration|"Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm."
218992747|NCT02385500|DRUG|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
218992748|NCT02385500|DRUG|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
218992749|NCT04745130|DRUG|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
218992750|NCT04745130|DRUG|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
218992751|NCT04191720|OTHER|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
219369446|NCT00934102|DEVICE|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
219369447|NCT00934102|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
219369448|NCT00934102|DEVICE|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
219369449|NCT02318784|DRUG|Carfilzomib|
219750706|NCT06691815|DIAGNOSTIC_TEST|Triptorelin (GnRH agonists)|"1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"
219750707|NCT04275284|BIOLOGICAL|PCV10|0.5 ml injection
219750708|NCT04275284|BIOLOGICAL|PCV13|0.5 ml injection
219750709|NCT00863590|DRUG|odanacatib|\[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
219750710|NCT00863590|DRUG|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
219750711|NCT00863590|DRUG|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
219750712|NCT00863590|DRUG|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
219750713|NCT02495883|OTHER|Ethanol|50ml of 40% Ethanol
219750714|NCT02495883|DRUG|Propranolol|Beta blocker
219750715|NCT00470223|DRUG|cisplatin|
219750716|NCT00470223|DRUG|doxorubicin hydrochloride|
219750717|NCT00470223|DRUG|etoposide|
219750718|NCT00470223|DRUG|ifosfamide|
219750719|NCT00470223|DRUG|methotrexate|
219750720|NCT00470223|DRUG|zoledronic acid|
219750721|NCT00470223|PROCEDURE|conventional surgery|
219750722|NCT05039307|BEHAVIORAL|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
219750723|NCT06257420|DRUG|Rapamycin|Once weekly oral rapamycin
219750724|NCT06691568|DEVICE|Air purifier|Purifiers were turned on for the active group and off for the placebo
219369450|NCT05931783|PROCEDURE|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
219369451|NCT05931783|PROCEDURE|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
219750725|NCT06690632|OTHER|water preparation|ingestion of 1.5L of water 30min prior MRE acquisition
219750726|NCT06690632|OTHER|polyethylene glycol preparation|ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
219369452|NCT00421876|BEHAVIORAL|multifactorial continued educational - behavioural programme|
219750727|NCT00420706|DRUG|SCA-136|
219750728|NCT00217802|BEHAVIORAL|six-session telephone counseling program|
219750729|NCT00666042|DRUG|Vigamox - administration in spray form|Vigamox will be administered in a spray form
219750730|NCT00666042|DRUG|Vigamox eye drops|Vigamox eye drops
219750731|NCT05505500|BEHAVIORAL|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
219750732|NCT04293432|DRUG|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
219750733|NCT03085290|OTHER|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
219750734|NCT03085290|OTHER|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
219750735|NCT00069550|DRUG|dextromethorphan|
219750736|NCT00069550|DRUG|donepezil hydrochloride|
219750737|NCT04809805|DRUG|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
219750738|NCT03268278|DRUG|Buprenorphine|Buprenorphine plus local anesthetic
219750739|NCT03268278|DRUG|Sterile saline|Placebo 1,8 ml
219750740|NCT03268278|DRUG|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
219369453|NCT04375657|COMBINATION_PRODUCT|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
219369454|NCT04375657|COMBINATION_PRODUCT|Active Control|Metformin and DHEA
219369455|NCT03812406|PROCEDURE|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
219369456|NCT03812406|PROCEDURE|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
219750741|NCT01442571|DEVICE|Hyaluronic Acid Injection|
219750742|NCT01442571|DRUG|Saline Injection|
219750743|NCT01554358|BEHAVIORAL|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~\--------------------------------------------------------------------------------"
219750744|NCT02477033|DIETARY_SUPPLEMENT|Butyricicoccus pullicaecorum 25-3T|
219750745|NCT02477033|OTHER|Maltodextrin|
219750746|NCT04847037|PROCEDURE|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
219750747|NCT04528186|DIAGNOSTIC_TEST|Maternal thyroid volume|Maternal thyroid volume measurement
219750748|NCT05046730|DEVICE|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
219750749|NCT04848506|DRUG|Aficamten (5 - 20 mg)|Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
219750750|NCT06308315|OTHER|Rhythmic balance visual auditory exercise + Routine physical therapy|"5 minute warm-up activities.~Bal-A-Vis-X training includes:~1. Ball Rectangle; A and B hold one ball in each hand, simultaneously bounce right balls to patient left hand; while balls bounce, clap left balls on right hand; catch patient ball with left hand; continue pattern. Bounces must be simultaneous. (10 minutes)~2. Ball rectangle in which one hand has to toss a ball to a partner and the other hand catch an incoming bag from the partner and 2 ball drop/pass/catch, two-foot jumping forward, tandem walking on ground. (10 minutes)~Routine Physical therapy treatment includes:~Range of Motion exercises, Stretching, Strength, balance training for 15 minutes~5 minute cool-down activities."
219750751|NCT06308315|OTHER|Strength Training + Routine Physical Therapy|"The expert managed sessions based on:~5 minute warm-up activities. 5 minute cool-down activities. Strength training includes 5 tasks for 20 minutes~1. core strengthening,~2. upper and lower limbs strength in both static positions as well as with dynamic movements~3. standing long jump,~4. knee push-ups,~5. sit-ups~Routine Physical therapy treatment will be given for 15 minutes.~It includes:~Range of Motion exercises, Stretching, Strength, balance training."
219750752|NCT04699877|DRUG|Gilteritinib|Oral
219750753|NCT02776735|DRUG|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
219750754|NCT05395338|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
219750755|NCT03533569|PROCEDURE|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
219750756|NCT03449472|DRUG|Quetiapine|Patients are tested for their normal prescription quetiapine medication
219750757|NCT03224845|BEHAVIORAL|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
219750758|NCT02229357|BIOLOGICAL|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
219750759|NCT05589909|DIAGNOSTIC_TEST|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
219750760|NCT06956391|DRUG|18F-FDG|Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner
219750761|NCT01926860|BIOLOGICAL|Prevenar13|
219750762|NCT01926860|BIOLOGICAL|Hepatitis A vaccine|
219750763|NCT04692506|OTHER|Probiotic|The study product is probiotic
219750764|NCT00003486|DRUG|antineoplaston A10|
219750765|NCT00003486|DRUG|antineoplaston AS2-1|
219750766|NCT00003486|PROCEDURE|alternative product therapy|
219369457|NCT00000981|DRUG|Fiacitabine|
219369458|NCT02304926|DRUG|Simvastatin|simvastatin (40 mg/day) for 4 weeks
219369459|NCT02304926|DRUG|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
219369460|NCT02304926|DRUG|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
219750767|NCT00003486|PROCEDURE|biological therapy|
219369461|NCT01361347|DIETARY_SUPPLEMENT|milk|milk for milk allergic children (1:25 dilution, whole milk)
219369462|NCT04737148|OTHER|Mortality scores|Revised Baux, BOBI and FLAMES scores
219750768|NCT00003486|PROCEDURE|biologically based therapies|
219750769|NCT00003486|PROCEDURE|cancer prevention intervention|
219750770|NCT00003486|PROCEDURE|complementary and alternative therapy|
219750771|NCT00003486|PROCEDURE|differentiation therapy|
219750772|NCT04630483|OTHER|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
219750773|NCT04630483|OTHER|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
219750774|NCT04670796|DRUG|HLX02|subject receive one dose of HLX02
219750775|NCT04670796|DRUG|EU-sourced Trastuzumab (Herceptin®)|subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
219750776|NCT04670796|DRUG|US-licensed Trastuzumab (Herceptin®)|subject receive one dose of US-licensed Trastuzumab (Herceptin®)
219750777|NCT01689948|BEHAVIORAL|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
219750778|NCT01296308|OTHER|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
219750779|NCT04893863|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
219750780|NCT04893863|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
219750781|NCT01595477|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
219750782|NCT01312480|OTHER|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up."
219750783|NCT01312480|OTHER|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
219750784|NCT06285799|DRUG|Low Dose IHAT|Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)
219750785|NCT06285799|DRUG|High Dose IHAT|Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)
219750786|NCT06285799|DRUG|Carob Flour|Twice daily dose of 1 placebo capsule (carob flour)
219750787|NCT03744637|DRUG|Frespaciguat|Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization
219750788|NCT03744637|DRUG|Placebo|Single inhaled dose of placebo to match frespaciguat
219750789|NCT04123704|DRUG|Sitravatinib|sitravatinib capsule
219750790|NCT03440385|DRUG|Ozanimod|Specified dose on specified days
219750791|NCT03440385|OTHER|Placebo|Specified dose on specified days
219750792|NCT04103242|OTHER|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
219750793|NCT05915377|OTHER|READI-SET GO UB-CAM delirium screening into EHR|UB-CAM Delirium screening tool integrated into EHR with education on best practices for delirium management
219750794|NCT01497730|DEVICE|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
219750795|NCT04682847|DRUG|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
219179693|NCT05787379|BEHAVIORAL|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
219750796|NCT06288568|OTHER|No intervention|No intervention
219750797|NCT06571942|DRUG|Vilanterol / Umeclidinium (25/62.5 mcg)|One inhalation daily from Ellipta device for three months
219750798|NCT06571942|DRUG|Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)|One inhalation daily from Ellipta device for three months
219750799|NCT06571942|DRUG|Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg|Two inhalations twice daily form pMDI device for three months
219750800|NCT06571942|DRUG|Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg|Two inhalations twice daily form pMDI device for three months
219750801|NCT04389463|OTHER|No intervention|No description
219750802|NCT06168773|DRUG|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
219750803|NCT02695836|OTHER|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
219750804|NCT02695836|OTHER|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
219750805|NCT02695836|OTHER|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
219750806|NCT02695836|OTHER|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
219750807|NCT02695836|OTHER|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
219750808|NCT00190957|DRUG|Atomoxetine|
219750809|NCT00190957|DRUG|placebo|
219750810|NCT06213480|DIETARY_SUPPLEMENT|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
219750811|NCT06213480|OTHER|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
219750812|NCT05627921|DEVICE|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
219750813|NCT05627921|DRUG|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
219750814|NCT05755984|DIAGNOSTIC_TEST|3D printed model|scan
219750815|NCT00410683|OTHER|clinical observation|
218992752|NCT02829528|BEHAVIORAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
218992753|NCT00028405|DRUG|LS 11(Taporfin Sodium)|
218992754|NCT00028405|DEVICE|Lumaflex Light Delivery Catheter|
219179694|NCT05787379|BEHAVIORAL|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
218992755|NCT05223244|DRUG|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
218992756|NCT05223244|DRUG|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
218992757|NCT04660669|OTHER|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
219179695|NCT05286970|DRUG|AK115|Abdominal subcutaneous injection
219750816|NCT00410683|PROCEDURE|adjuvant therapy|
219750817|NCT00410683|RADIATION|3-dimensional conformal radiation therapy|
219750818|NCT02647502|OTHER|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
219179696|NCT05286970|DRUG|Placebo|Abdominal subcutaneous injection
219750819|NCT02354573|DRUG|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
219750820|NCT00663078|BEHAVIORAL|Brief CBT Group therapy|CBT based therapy also expert patient programme
219750821|NCT02845414|DRUG|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
219750822|NCT00692328|BEHAVIORAL|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
219750823|NCT03552029|DRUG|Quizartinib|20 or 30 mg tablets for oral administration
219750824|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
219750825|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
219750826|NCT03134209|DEVICE|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
219750827|NCT03134209|OTHER|Monocryl + Dermabond|conventional sutures and skin adhesive glue
218992758|NCT04660669|OTHER|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
218992759|NCT01991691|DEVICE|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
218992760|NCT02505204|OTHER|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
218992761|NCT02505204|OTHER|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
219750828|NCT03134209|OTHER|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
219750829|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
219750830|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
219750831|NCT01462331|OTHER|Sucrose|12g/dose, three times a day
219750832|NCT01198691|DEVICE|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
219750833|NCT01198691|DEVICE|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
219750834|NCT04367389|BEHAVIORAL|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
219750835|NCT04367389|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
219750836|NCT03537794|DIAGNOSTIC_TEST|PET scans|PET scans and PHNO scans
219750837|NCT02299245|DRUG|rosuvastatin|different dose of rosuvastatin treatment
219750838|NCT04918082|OTHER|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
219750839|NCT03336229|BEHAVIORAL|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
218992762|NCT00972868|DEVICE|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
219179697|NCT04421066|PROCEDURE|Gingival and bone sample collection|Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
219179698|NCT04421066|PROCEDURE|Healthy individuals|Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
219750840|NCT03325322|DIETARY_SUPPLEMENT|Fisetin|Flavonoid family
219750841|NCT03325322|DRUG|Placebo oral capsule|Placebo
219750842|NCT02499926|DIETARY_SUPPLEMENT|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
219750843|NCT03148002|DRUG|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
219750844|NCT03148002|DRUG|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
218992763|NCT02765295|DEVICE|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
219179699|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
219750845|NCT01282398|DRUG|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
219750846|NCT01282398|DRUG|placebo|the control group wiil take placebo pills for at least two years.
219179700|NCT01461655|DRUG|marketed topical NSAID|once daily application, 4 weeks
219179701|NCT01461655|DRUG|vehicle gel|once daily application, 4 weeks
219179702|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
219179703|NCT03812679|DEVICE|AMIA APD Solution Generation System|The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
219750847|NCT03468998|DEVICE|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
219179704|NCT06215560|OTHER|PDMP Check CDS|Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
219750848|NCT03468998|DEVICE|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
219750849|NCT03468998|DEVICE|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
219750850|NCT03468998|DEVICE|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
219750851|NCT06305403|DIAGNOSTIC_TEST|serum creatinin level|Serum creatinine and urine amounts will be checked for five days.
219750852|NCT01765400|DRUG|Prasugrel 10 mg daily x 2 weeks|
219750853|NCT01765400|DRUG|Clopidogrel 75 mg daily x 2 weeks|
219750854|NCT04236076|DEVICE|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
219750855|NCT04236076|DEVICE|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
219750856|NCT00091156|DRUG|gefitinib|
219750857|NCT00091156|PROCEDURE|adjuvant therapy|
219750858|NCT02085863|DRUG|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
219750859|NCT02085863|DRUG|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
219750860|NCT02989857|DRUG|AG-120|Tablet administered orally
219750861|NCT02989857|DRUG|Placebo|Tablet administered orally
219750862|NCT01467557|DEVICE|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
219750863|NCT01467557|DEVICE|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
219750864|NCT05271357|PROCEDURE|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
219750865|NCT05271357|PROCEDURE|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
219750866|NCT02853292|BIOLOGICAL|urine collection|
219750867|NCT00149357|OTHER|Thrombophilia Testing|TP testing in Group 1 and 3 only
219750868|NCT00633126|DRUG|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
219750869|NCT04329884|PROCEDURE|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
219750870|NCT04329884|DRUG|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
219750871|NCT04991948|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
219750872|NCT04991948|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
219750873|NCT04991948|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
219750874|NCT03314090|DRUG|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
219750875|NCT05577156|BEHAVIORAL|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
219750876|NCT05892900|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
219750877|NCT05892900|DEVICE|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
219750878|NCT02700438|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
219750879|NCT02700438|PROCEDURE|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
219750880|NCT06424002|BIOLOGICAL|Mosquirixs|RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
219750881|NCT06424002|DRUG|artemether-lumefantrine|A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
219750882|NCT03243721|DIAGNOSTIC_TEST|7T MRI|A high field MRI that will take approximately one hour.
219750883|NCT03243721|DIAGNOSTIC_TEST|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
219750884|NCT03926455|BIOLOGICAL|Typhax (investigational typhoid fever candidate vaccine)|
219750885|NCT03926455|BIOLOGICAL|Placebo|Placebo is administered to the control group on Day 0 and 28
219750886|NCT03926455|BIOLOGICAL|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
219750887|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
219750888|NCT03978598|DEVICE|Nexplanon|Implant.
219750889|NCT04451798|DEVICE|Impella CP microaxial pump|ramp test
219750890|NCT05795907|DRUG|SAR443820|Capsule / Oral
219750891|NCT05795907|DRUG|Placebo|Matching Capsule / Oral
219750892|NCT00203190|DRUG|Topiramate|
219750893|NCT00853853|DEVICE|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
219750894|NCT00853853|PROCEDURE|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
219750895|NCT06527885|DRUG|Lurasidone|Patients treated with Lurasidone in according to routine clinical practice, in Italy
219750896|NCT02538614|DRUG|Idelalisib|Tablets administered orally twice daily
219750897|NCT02538614|DRUG|BI 836826|Intravenous administration as a rate-controlled infusion
219750898|NCT03835078|DEVICE|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
219179705|NCT06470191|DRUG|B007|B007： Subcutaneous injection was administered on days 1 and 15
219750899|NCT03835078|DEVICE|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
219750900|NCT01605994|DRUG|BMS-933043|
219750901|NCT01605994|DRUG|Placebo matching with BMS-933043|
219750902|NCT01605994|DRUG|Antacid Buffer Predose Solution|
219750903|NCT01145950|DRUG|LBEC0101|Etanercept 25mg, single dose
219750904|NCT01145950|DRUG|Enbrel|Etanercept 25mg, single dose
219750905|NCT02383160|DEVICE|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
219750906|NCT02383160|DEVICE|Sham device|Placebo device with no active therapy
219750907|NCT01203007|DIETARY_SUPPLEMENT|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
219750908|NCT01203007|DIETARY_SUPPLEMENT|Low antigen content diet|Low-antigen content diet for one month
219750909|NCT00726908|DIETARY_SUPPLEMENT|Low carbohydrate|43% CHO
219179706|NCT06470191|DRUG|Cyclosporin Capsules|Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
219179707|NCT05607381|BEHAVIORAL|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
219369463|NCT04940234|BEHAVIORAL|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
219750910|NCT04955548|PROCEDURE|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
219750911|NCT04955548|PROCEDURE|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
219750912|NCT01638507|DEVICE|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
219179708|NCT05607381|OTHER|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
219179709|NCT04791371|BEHAVIORAL|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
219179710|NCT04435054|DIAGNOSTIC_TEST|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~\- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
219179711|NCT05006963|OTHER|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
219179712|NCT06329141|DRUG|Vutiglabridin|Once-daily oral administration
219179713|NCT06329141|DRUG|Placebo|Once-daily oral administration
219179714|NCT02637505|PROCEDURE|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
219179715|NCT02637505|PROCEDURE|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
219750913|NCT03302767|OTHER|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
219750914|NCT04256850|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
219750915|NCT04256850|BEHAVIORAL|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
219750916|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
219750917|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
219179716|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
219179717|NCT05818423|BEHAVIORAL|Brain Health Academy|The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
219369464|NCT02732067|OTHER|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
219750918|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
219750919|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
219750920|NCT01425814|DRUG|Reference|Dry powder inhalation (capsule),single dose
219750921|NCT01425814|DRUG|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
219750922|NCT01190319|OTHER|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
219750923|NCT01190319|OTHER|Placebo|Placebo beverage, 8 weeks
219750924|NCT00629928|DRUG|Esomeprazole|20mg oral capsule daily
219750925|NCT00629928|DRUG|Esomeprazole|40mg oral capsule daily
219750926|NCT00629928|DRUG|Placebo|
219750927|NCT00144326|DRUG|Tiotropium Bromide|
219750928|NCT00144326|DRUG|Placebo|
219750929|NCT05617261|OTHER|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
219750930|NCT03889652|DIAGNOSTIC_TEST|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
219750931|NCT01179230|OTHER|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
219750932|NCT01179230|OTHER|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
219750933|NCT03386162|DRUG|Alpelisib|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
219750934|NCT03386162|DRUG|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
219750935|NCT06204783|OTHER|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
219750936|NCT00995787|DRUG|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
219750937|NCT00995787|DRUG|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
219750938|NCT04768153|BIOLOGICAL|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
219750939|NCT00064857|DRUG|Pycnogenol|
219750940|NCT04445103|DIAGNOSTIC_TEST|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
219750941|NCT01999530|DRUG|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
219750942|NCT06164054|DEVICE|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
219750943|NCT06164054|BEHAVIORAL|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
219750944|NCT03580954|DEVICE|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
219750945|NCT00565747|DEVICE|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
219750946|NCT00565747|DEVICE|Control culture|The same standard culture medium, but without any additions (ready-to-use)
219750947|NCT00800644|PROCEDURE|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
219750948|NCT05547035|BEHAVIORAL|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
219369465|NCT04752202|BEHAVIORAL|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
219750949|NCT01697709|DRUG|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
219750950|NCT01697709|DRUG|Placebo|placebo capsules
219750951|NCT02545439|DRUG|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
219750952|NCT04077502|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
219750953|NCT05849558|DRUG|Ursoplus|Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
219750954|NCT05849558|DRUG|UDCA 250mg|UDCA 250mg alone
219750955|NCT05849558|OTHER|Placebo|Placebo alone
219750956|NCT05192278|OTHER|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
219750957|NCT02940548|DRUG|Nifedipine GITS|Nifedipine GITS 30\~60mg/day for 8 weeks
219750958|NCT02940548|DRUG|Amlodipine besylate|Amlodipine besylate 5\~10mg/day for 8 weeks
219750959|NCT06140693|OTHER|Continuous exercise at an intensity below the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
219750960|NCT06140693|OTHER|Continuous exercise at an intensity at the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
219750961|NCT06140693|OTHER|Continuous exercise at an intensity above the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
219750962|NCT06140693|OTHER|Sprint interval training|22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
219750963|NCT06140693|OTHER|Reduced-exertion high-intensity interval training|10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
219750964|NCT02684461|DRUG|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
219750965|NCT05170802|OTHER|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
219750966|NCT02138825|DRUG|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
219750967|NCT02138825|DRUG|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
219750968|NCT03914690|DRUG|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
219750969|NCT03914690|DRUG|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
219750970|NCT00693758|DRUG|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
219750971|NCT00693758|OTHER|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
219750972|NCT00693758|OTHER|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
219750973|NCT00693758|DEVICE|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
219750974|NCT00693758|DEVICE|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
219750975|NCT05640427|DRUG|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
219750976|NCT05640427|DRUG|normal saline|The same capacity of 0.9% normal saline was used in group C
219750977|NCT01229566|DRUG|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
219750978|NCT05539547|DEVICE|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
219750979|NCT05539547|OTHER|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
219750980|NCT03714516|BEHAVIORAL|Psychological internet intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
219750981|NCT04028258|DIETARY_SUPPLEMENT|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
219750982|NCT04028258|DIETARY_SUPPLEMENT|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
219369466|NCT04752202|BEHAVIORAL|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
219750983|NCT03367104|DEVICE|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
219750984|NCT00004128|BIOLOGICAL|aldesleukin|
219369467|NCT01405092|DEVICE|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
219750985|NCT00004128|BIOLOGICAL|filgrastim|
219750986|NCT00004128|DRUG|busulfan|
219750987|NCT00004128|DRUG|cyclophosphamide|
219750988|NCT00004128|DRUG|cytarabine|
219750989|NCT00004128|DRUG|daunorubicin hydrochloride|
219750990|NCT00004128|DRUG|etoposide|
219750991|NCT00004128|PROCEDURE|autologous bone marrow transplantation|
219750992|NCT00004128|PROCEDURE|peripheral blood stem cell transplantation|
219750993|NCT00004128|RADIATION|radiation therapy|
219750994|NCT00909701|DIETARY_SUPPLEMENT|PreOP Booster|1 serving of 400 ml per study arm
219750995|NCT00909701|DIETARY_SUPPLEMENT|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
219750996|NCT00151021|BEHAVIORAL|Tailored web-based walking program|
219750997|NCT02769793|DRUG|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
219750998|NCT02769793|DRUG|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
219750999|NCT03060837|DIAGNOSTIC_TEST|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
219751000|NCT03060837|OTHER|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
219751001|NCT03060837|OTHER|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
219751002|NCT03060837|OTHER|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
219751003|NCT03060837|PROCEDURE|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
219751004|NCT03060837|PROCEDURE|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
219751005|NCT02755961|BEHAVIORAL|Dietary education|
219751006|NCT02755961|BEHAVIORAL|Education on phosphate binder use|
219751007|NCT03319641|DIAGNOSTIC_TEST|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
219751008|NCT02229617|DRUG|Subcutaneous testosterone|
219751009|NCT00781547|DRUG|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
219751010|NCT05656157|DEVICE|Medical device|Clinical decision support system
219751011|NCT02969070|DIETARY_SUPPLEMENT|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
219751012|NCT02969070|DIETARY_SUPPLEMENT|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
219751013|NCT05242289|DEVICE|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
219751014|NCT04968483|OTHER|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
219751015|NCT02350452|PROCEDURE|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
219751016|NCT02350452|PROCEDURE|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
218992764|NCT02765295|DEVICE|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
219179718|NCT05818423|BEHAVIORAL|Brain Health Together|The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
219751017|NCT01527565|DRUG|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
219751018|NCT04816032|OTHER|Pennebaker's expressive writing intervention|It focuses on the emotional aspect of the written event
219751019|NCT04816032|OTHER|Neutral writing|Description of neutral topics with less emotional involvement
219751020|NCT06004622|OTHER|Calgary Family Intervention Model|under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
219751021|NCT06235502|OTHER|Home-based cycle-exercise for COPD patients|Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app
219751022|NCT06235502|OTHER|Standard of Care|Exercise at Fitness Center, home based exercise according to a programme
219751023|NCT02749747|DRUG|Sulpiride use|50mg sulpiride once a day use for 60 days
219751024|NCT02749747|DRUG|Placebo|50mg placebo once a day use for 60 days
219751025|NCT02646410|OTHER|FPD+NDOT|
219751026|NCT02646410|OTHER|FPD+DOT|
218992765|NCT05673889|DRUG|ARV-471|Experimental
219751027|NCT02646410|OTHER|DDD+NDOT|Door to door delivery + non directly observed treatment
219751028|NCT02646410|OTHER|DDD+DOT|Door to door delivery + directly observed treatment
219751029|NCT01192074|DEVICE|Ultrasound|Preprocedure ultrasound examination of the spine
218992766|NCT05673889|DRUG|Dabigatran etexilate|Probe substrate
218992767|NCT02560571|DEVICE|ultrasound|
218992768|NCT02560571|OTHER|blood test|
218992769|NCT04668625|BEHAVIORAL|Participate in a massive musical event|Participate in a massive musical event
218992770|NCT06392620|OTHER|Study Group|n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
219179719|NCT05818423|BEHAVIORAL|Maintain Brain Health Together|The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
219179720|NCT05789524|DRUG|SerpinPC|Administered as SC injection.
219179721|NCT03079999|DRUG|Aspirin|Twice daily aspirin
219179722|NCT03079999|DRUG|Placebo|Twice daily placebo
219751030|NCT03981874|OTHER|telephonic interview|Telephonic interview
219751031|NCT03515421|DEVICE|Frazier 3 Verio|In vitro diagnostic device (IVDD)
219751032|NCT03515421|DEVICE|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
219751033|NCT06544460|PROCEDURE|Secondary cytoreduction|Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
219751034|NCT06544460|DRUG|Hyperthermic intraperitoneal chemotherapy|Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
219751035|NCT00895921|DRUG|Olanzapine|Single intramuscular 10-mg dose
219751036|NCT00895921|DRUG|Aripiprazole|Single intramuscular 9.75-mg dose
219751037|NCT01451021|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
219751038|NCT00002673|PROCEDURE|infection prophylaxis and management|
219751039|NCT03401866|DIAGNOSTIC_TEST|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
219751040|NCT04602845|DRUG|Fentanyl|50ug Fentanyl intravenously
219751041|NCT04602845|DRUG|Flurbiprofen|50mg Fentanyl intravenously
219751042|NCT04602845|DRUG|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
219751043|NCT04602845|DRUG|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
219751044|NCT00030264|DRUG|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
219751045|NCT00030264|DRUG|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
219751046|NCT02873156|DRUG|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
219751047|NCT02873156|DRUG|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
219751048|NCT05835648|DIETARY_SUPPLEMENT|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
219751049|NCT00757068|BEHAVIORAL|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
219751050|NCT00757068|BEHAVIORAL|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
219751051|NCT00950521|PROCEDURE|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
219369468|NCT01405092|DEVICE|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
219369469|NCT01812642|DRUG|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
219751052|NCT00950521|DRUG|convention therapy|antiplatelet
219751053|NCT00240877|BIOLOGICAL|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
219751054|NCT00240877|OTHER|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
219751055|NCT04513236|OTHER|Pre-survey incentive|An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
219751056|NCT04513236|OTHER|Post-survey incentive|An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
219751057|NCT00355043|DRUG|Zinc sulphate 20 mg|
219751058|NCT01202695|DRUG|AVP-21D9|intravenously, single dose
219751059|NCT01202695|DRUG|Placebo|Placebo comparator
219751060|NCT01421056|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
219751061|NCT01421056|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
219751062|NCT01421056|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
219751063|NCT06489015|DRUG|Recombinant Human Serum Albumin|Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
219751064|NCT03823989|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
219751065|NCT03823989|RADIATION|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
218992771|NCT01346449|BEHAVIORAL|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
218992772|NCT01346449|BEHAVIORAL|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
219751066|NCT06211699|PROCEDURE|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.
219751067|NCT06211699|PROCEDURE|Clips with Laparoscopic Sleeve Gastrectomy|Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
219751068|NCT05299515|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
219751069|NCT04223271|DIAGNOSTIC_TEST|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
219751070|NCT00108381|BEHAVIORAL|tailored cognitive behavior therapy|tailored psychological treatment
219751071|NCT00108381|BEHAVIORAL|standard care|standard psychological treatment
219751072|NCT05242939|OTHER|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
219751073|NCT05242939|OTHER|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
219751074|NCT05477888|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
219751075|NCT01818778|OTHER|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
219751076|NCT01818778|OTHER|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
219751077|NCT01142180|PROCEDURE|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
219369470|NCT01812642|OTHER|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
219751078|NCT01142180|PROCEDURE|No TAE|No TAE procedure will be performed after endoscopic treatment
219751079|NCT00687076|DRUG|Ezetimibe|Daily dose of 10 mg of Ezetimibe
219751080|NCT00687076|DRUG|Niaspan|Daily dose of 1500 mg of Niaspan
219751081|NCT00687076|DRUG|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
219751082|NCT00687076|BEHAVIORAL|Standard care|Standard of medical care for PAD
219751083|NCT00687076|DRUG|Aspirin|Daily dose of 325 mg of aspirin
219751084|NCT00687076|DRUG|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
219751085|NCT00687076|DRUG|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
219751086|NCT00687076|DRUG|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
219751087|NCT00687076|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
219369471|NCT05447702|DRUG|Camrelizumab|Intravenous (IV) infusion
219369472|NCT05447702|DRUG|Apatinib|po.
219369473|NCT05447702|DRUG|Nab-paclitaxel|IV infusion.
218992773|NCT01346449|BEHAVIORAL|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
218992774|NCT01346449|BEHAVIORAL|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
219369474|NCT05447702|DRUG|Epirubicin|IV infusion.
219369475|NCT05447702|DRUG|Cyclophosphamide|IV infusion.
219751088|NCT02663362|OTHER|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
219751089|NCT00575224|DRUG|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
219751090|NCT05375422|OTHER|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
219751091|NCT05375422|OTHER|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
219751092|NCT00378092|DRUG|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
219751093|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
219751094|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
219179723|NCT05257070|DIAGNOSTIC_TEST|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
219179724|NCT04508543|OTHER|Non-verbal communication score|1\. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
219179725|NCT01972347|DRUG|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
219179726|NCT01972347|DRUG|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
219179727|NCT05290766|PROCEDURE|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
219179728|NCT05290766|PROCEDURE|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
219179729|NCT05290766|DEVICE|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
219179730|NCT03060421|DEVICE|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
219751095|NCT05821946|OTHER|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
219751096|NCT01203345|DRUG|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
219751097|NCT01203345|DRUG|Placebo|An equal volume of 5 percent albumin solution
219751098|NCT05313581|BEHAVIORAL|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
219751099|NCT00647647|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
219751100|NCT00647647|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fasting
219751101|NCT02243358|DRUG|Folfox6|
219751102|NCT02243358|DRUG|Gemcitabine|
219751103|NCT02243358|RADIATION|Radiation Therapy|
219751104|NCT02243358|PROCEDURE|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
219179731|NCT05486078|DEVICE|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
219179732|NCT05590403|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
219179733|NCT05590403|DRUG|Placebo|One dose administered intramuscularly at Day 1.
219179734|NCT04838418|PROCEDURE|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
219369476|NCT03855501|OTHER|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
219751105|NCT05665283|DRUG|Ensartinib Hydrochloride|oral ALK inhibitor
219751106|NCT03808935|DRUG|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
219369477|NCT03855501|OTHER|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
219369478|NCT01639430|OTHER|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
219369479|NCT05987748|BEHAVIORAL|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
219751107|NCT03808935|DRUG|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
219751108|NCT00968409|RADIATION|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
219751109|NCT00968409|OTHER|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
219751110|NCT00968409|OTHER|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
219751111|NCT00968409|DRUG|F18-FFNP|injection of F18-FFNP
219751112|NCT06156150|BIOLOGICAL|tumor vaccine|DC vaccine produced by the Team
219751113|NCT00710099|DRUG|sildenafil|systemic absorption of sildenafil
219751114|NCT00710099|DRUG|nitroprussiate iontophoresis|nitroprussiate iontophoresis
219751115|NCT01323608|DRUG|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
219751116|NCT01323608|DRUG|Placebo|Placebo
219751117|NCT04989361|PROCEDURE|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
219751118|NCT04989361|PROCEDURE|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
219751119|NCT03278561|PROCEDURE|Sputum induction|Sputum induction according to the ERS protocol
219751120|NCT03278561|PROCEDURE|Blood sample|A blood sample of 100ml will be taken.
219751121|NCT04154722|DRUG|Meropenem Injection|inj meropenum for 10 days
219751122|NCT04154722|DRUG|Azithromycin Powder|syp azithromycin for10days
219751123|NCT03243084|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
219369480|NCT05688462|OTHER|Data Collection|This is an observational prospective cohort study. Children admitted to ten identified PICUs in the UK with severe TBI with a clinical need for ICP and ABP monitoring will be included for data collection. The database will contain routinely monitored physiological parameters during management of PTBI in PICU. Without disturbing the routine care and management of these patients, investigators aim to collect this data continuously in a bedside laptop equipped with the study software (ICM+, Cambridge Enterprise Ltd, Cambridge, UK). Alongside these physiological parameters, investigators will also collect relevant clinical and demographic data (details below) and follow these patients for up to 12 months post ictus to assess neuro-psychological outcome.
219369481|NCT01393977|PROCEDURE|rehabilitation of limb function|only receive rehabilitation of limb function
219751124|NCT03243084|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
219751125|NCT04958603|PROCEDURE|"L type release surgery"|Lateral release of the lateral support belt
219751126|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
219751127|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
219751128|NCT01807884|PROCEDURE|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
219751129|NCT01807884|OTHER|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
219751130|NCT06637943|DIAGNOSTIC_TEST|POC viscoelastic test|applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
219751131|NCT06637943|DIAGNOSTIC_TEST|standard central laboratory test|applying central laboratory test to arterial blood sample
219751132|NCT05148338|OTHER|Comprehensive risk factor treatment|"1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform"
219751133|NCT05148338|OTHER|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
219751134|NCT06564129|DEVICE|electroencephalography|Fifty-nine EEG electrodes conforming to international standard points were placed using a saline electrode EEG cap (Gelfree, Prysmian, China), and an accompanying portable multimodal EEG acquisition system (Neurohub, Prysmian, China) was used. EEG data were collected using collect software (Brycon, China).
219751135|NCT00737789|DRUG|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
219751136|NCT00737789|DRUG|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
219751137|NCT05072379|DEVICE|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
219751138|NCT04755647|DRUG|Nitric Oxide-Releasing Solution|Active antimicrobial
219751139|NCT04755647|DRUG|Saline solution, hypotonic|Placebo
219751140|NCT03060889|DRUG|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
219751141|NCT00000628|DRUG|L-697,661|
219751142|NCT00000628|DRUG|Zidovudine|
219751143|NCT00182143|DRUG|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
219751144|NCT00182143|DRUG|Unfractionated Heparin|5000 IU BID
219751145|NCT02300233|DRUG|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
219751146|NCT02300233|DRUG|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
219751147|NCT03567694|DRUG|HA115|Test Drug
219751148|NCT03567694|DRUG|Placebo|Placebo
219751149|NCT06275867|OTHER|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
219751150|NCT06275867|OTHER|Close distance|The network of contracted providers is located close to where participants live.
219751151|NCT06275867|OTHER|Far distance|The network of contracted providers is located far to where participants live.
219751152|NCT03896646|PROCEDURE|Computed Tomography|Undergo SPECT/CT HIDA scan
219751153|NCT03896646|OTHER|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
219751154|NCT03896646|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
219751155|NCT03896646|RADIATION|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
219751156|NCT03896646|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
219751157|NCT05763771|BEHAVIORAL|Smart Phone App|Collection of data
219751158|NCT05763771|OTHER|NIcotine Patches|Place on the skin
219751159|NCT02588014|OTHER|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
219751160|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
219751161|NCT04474873|PROCEDURE|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
219751162|NCT05054101|OTHER|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
219751163|NCT03470051|DIAGNOSTIC_TEST|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
219751164|NCT05836909|DIETARY_SUPPLEMENT|Swisse plus cholesterol capsule|Swisse plus cholesterol capsule per day orally for 12 weeks
219751165|NCT05836909|DIETARY_SUPPLEMENT|Placebo|Placebo
219751166|NCT02583841|PROCEDURE|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
219751167|NCT03178682|DIAGNOSTIC_TEST|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
219751168|NCT06264154|OTHER|E-cigarettes|All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
219751169|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
219751170|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
219751171|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL."
219751172|NCT00509288|DRUG|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
219751173|NCT00509288|DRUG|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
219751174|NCT00509288|BIOLOGICAL|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
219751175|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
219751176|NCT03127930|BEHAVIORAL|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
219751177|NCT03102086|PROCEDURE|Scaling|Scaling of dental calculus
219751178|NCT01334879|DRUG|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
219751179|NCT03795142|BIOLOGICAL|BGB149|Single Ascending Dose
219751180|NCT03795142|BIOLOGICAL|Placebo|Matching placebo
219751181|NCT02870426|PROCEDURE|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
219751182|NCT02870426|PROCEDURE|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
219751183|NCT02903862|BEHAVIORAL|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
219751184|NCT02903862|DEVICE|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
219751185|NCT00875446|DRUG|PLACEBO|Placebo
219751186|NCT00875446|DRUG|GSK1223249|I.V Infusion
219751187|NCT04139291|OTHER|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
219751188|NCT00938574|DRUG|Atu027|
219751189|NCT05809089|DEVICE|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
219751190|NCT05809089|DEVICE|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
219751191|NCT01731145|DEVICE|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
219751192|NCT01350076|DRUG|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
219751193|NCT01350076|DRUG|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
219751194|NCT04972279|BEHAVIORAL|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
219751195|NCT04380142|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
219179735|NCT06315855|BEHAVIORAL|Telehealth Intervention (THI)|The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
219179736|NCT05988684|DRUG|Metformin|Patients randomized to metformin group will be instructed to take 500 mg metformin daily for 1 week before titrating up to twice a day
219751196|NCT04380142|DRUG|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
219751197|NCT04380142|DRUG|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
219751198|NCT04380142|DRUG|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
219751199|NCT02908178|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
219751200|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
219751201|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
219751202|NCT02395276|DEVICE|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
219751203|NCT05766605|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
219751204|NCT05766605|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
219179737|NCT04503551|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
219369482|NCT01393977|PROCEDURE|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
219751205|NCT05766605|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
219751206|NCT05766605|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
219751207|NCT05766605|DRUG|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
219751208|NCT05766605|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
219751209|NCT04115306|DRUG|PMD-026|Investigational Drug
219751210|NCT04115306|DRUG|fulvestrant|SERDs
219751211|NCT03464266|COMBINATION_PRODUCT|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
219751212|NCT03464266|DRUG|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
219179738|NCT04503551|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
219179739|NCT05636514|DRUG|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
219751213|NCT03464266|DRUG|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
219751214|NCT03464266|OTHER|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
219751215|NCT05007132|BIOLOGICAL|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
219751216|NCT05007132|BIOLOGICAL|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
219751217|NCT05007132|DRUG|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
219751218|NCT06186310|OTHER|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
219751219|NCT06186310|OTHER|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
219751220|NCT03773484|BEHAVIORAL|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
219751221|NCT03773484|BEHAVIORAL|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
219751222|NCT03773484|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
219751223|NCT02578251|DRUG|Paracetamol|
219751224|NCT02578251|DRUG|Pethidine|
219751225|NCT05229016|BEHAVIORAL|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
219179740|NCT05636514|DRUG|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
219369483|NCT01770327|BEHAVIORAL|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
219179741|NCT03298542|DRUG|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
219179742|NCT03298542|DRUG|Placebo|Matching placebo to golimumab.
219179743|NCT06574425|OTHER|long-term, high blood flow hemoadsorption therapy|Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
219179744|NCT04998682|PROCEDURE|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
219751226|NCT05460286|OTHER|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
219369484|NCT04239326|DIAGNOSTIC_TEST|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
219369485|NCT03240926|DEVICE|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
219369486|NCT01963481|DRUG|Exemestane|
219369487|NCT01963481|DRUG|Cyclophosphamide|
219751227|NCT05460286|OTHER|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
219751228|NCT01889251|DRUG|Ocriplasmin|
219751229|NCT01889251|DRUG|Sham injection|
219751230|NCT01533623|DEVICE|Mandibular Advancement Device|Nightly wearing time
219369488|NCT02388295|DRUG|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
219751231|NCT01006148|BIOLOGICAL|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
219369489|NCT02388295|DRUG|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
219751232|NCT02740985|DRUG|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
219751233|NCT02740985|DRUG|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
219751234|NCT02740985|DRUG|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
218992775|NCT06259747|OTHER|Acutaping|Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
218992776|NCT06259747|DRUG|Doxylamine and Pyridoxine|traditional medical treatment for nausea and vomiting during pregnancy
218992777|NCT02228460|DRUG|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
218992778|NCT01243892|DEVICE|NuSpin|Device for administration of doses of somatropin.
218992779|NCT01243892|DRUG|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
218992780|NCT00007865|BIOLOGICAL|rituximab|
218992781|NCT00007865|DRUG|carboplatin|
218992782|NCT00007865|DRUG|etoposide|
218992783|NCT00007865|DRUG|ifosfamide|
218992784|NCT05496062|DEVICE|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
218992785|NCT04911881|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
218992786|NCT04476069|DRUG|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
218992787|NCT01247909|DRUG|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
218992788|NCT00740831|DRUG|PGL4001|tablets
218992789|NCT00740831|DRUG|leuprorelin|solution for injection
218992790|NCT03421665|DEVICE|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
219751235|NCT02740985|DRUG|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
219751236|NCT02740985|DRUG|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
219751237|NCT02740985|DRUG|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
219751238|NCT01530516|DEVICE|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
219751239|NCT01530516|DEVICE|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
219751240|NCT06379100|DEVICE|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
219751241|NCT00085839|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
219751242|NCT00085839|DRUG|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
219751243|NCT03682484|DRUG|MA-0211|oral
219751244|NCT03682484|DRUG|Placebo|oral
219751245|NCT03342222|DEVICE|Interference Screws|tibial fixation for ACL reconstruction
219369490|NCT03718247|OTHER|Modified Atkins diet|High fat low carbohydrate diet.
219369491|NCT04007159|OTHER|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
219751246|NCT04653376|PROCEDURE|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
219751247|NCT00409656|DRUG|Basiliximab|
218992791|NCT06172322|DRUG|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
218992792|NCT02207296|DEVICE|Plethysmographic variability index|
218992793|NCT02667054|DRUG|RX0041 4%|Anesthetic
218992794|NCT02667054|DRUG|Placebo|Placebo Comparator
218992795|NCT02667054|DRUG|RX0041 8%|Anesthetic
218992796|NCT05528354|DRUG|VEN and DEC based conditioning regimen|"Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
218992797|NCT05528354|DRUG|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed."
218992798|NCT04466735|DIETARY_SUPPLEMENT|Active group|2 x 12 g of EKS/day
219369492|NCT04007159|OTHER|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
219369493|NCT04007159|OTHER|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
219751248|NCT05136027|OTHER|Combined training|Low-intensity interval training and resistance exercise
219751249|NCT01172782|DRUG|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
218992799|NCT04466735|DIETARY_SUPPLEMENT|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
218992800|NCT04289675|DRUG|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
218992801|NCT01796561|DIETARY_SUPPLEMENT|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
218992802|NCT03706079|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218992803|NCT03706079|OTHER|Placebo|Placebo subcutaneous injection
218992804|NCT00986557|BIOLOGICAL|adoptive immunotherapy|
218992805|NCT00986557|BIOLOGICAL|alemtuzumab|
218992806|NCT00986557|BIOLOGICAL|in vitro-treated peripheral blood lymphocyte therapy|
218992807|NCT00986557|DRUG|foscarnet sodium|
218992808|NCT00986557|DRUG|ganciclovir|
218992809|NCT00986557|GENETIC|polymerase chain reaction|
218992810|NCT00986557|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218992811|NCT00986557|PROCEDURE|infection prophylaxis and management|
218992812|NCT00986557|PROCEDURE|peripheral blood stem cell transplantation|
218992813|NCT00986557|PROCEDURE|standard follow-up care|
218992814|NCT00986557|RADIATION|radiation therapy|
219751250|NCT06107699|OTHER|Patient Navigation|Assigned a Patient Navigator to provide information on transitional care and community resources.
219751251|NCT05880355|DRUG|Dapansutrile|Oral inhibitor of NLRP3
219751252|NCT05880355|OTHER|Placebo|Non-active placebo
219751253|NCT06529237|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
219751254|NCT06529237|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|Routine malaria rapid diagnostic tests
219751255|NCT05216380|BEHAVIORAL|ActivityLink|"ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
219751256|NCT02628535|BIOLOGICAL|MGD009|B7-H3 x CD3 DART protein
219751257|NCT04312022|DIETARY_SUPPLEMENT|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
219751258|NCT04312022|OTHER|Placebo|Placebo (flour capsule)
219751259|NCT01344226|DRUG|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
219751260|NCT05335434|DEVICE|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
219751261|NCT02914938|DRUG|ME-401|60 mg
219751262|NCT02914938|DRUG|Rituximab|IV infusion 375 mg/m2
219751263|NCT02914938|DRUG|Zanubrutinib|80 and 160 mg bid
219751264|NCT00201279|DRUG|13-cis Retino Acid|
219751265|NCT04825600|DIAGNOSTIC_TEST|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
219751266|NCT04825600|DIAGNOSTIC_TEST|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
219751267|NCT04118764|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
219751268|NCT04118764|DRUG|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
219751269|NCT04118764|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
219751270|NCT04118764|OTHER|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
219751271|NCT04118764|OTHER|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
219751272|NCT06239376|PROCEDURE|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
219751273|NCT06239376|PROCEDURE|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
219751274|NCT03211416|OTHER|Laboratory Biomarker Analysis|Correlative studies
219751275|NCT03211416|BIOLOGICAL|Pembrolizumab|Given IV
219751276|NCT03211416|DRUG|Sorafenib Tosylate|Given PO
219751277|NCT04716725|DRUG|68Ga-PSMA-11|Given IV
219751278|NCT04716725|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET
219751279|NCT03888027|BEHAVIORAL|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
219751280|NCT05008614|PROCEDURE|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
219751281|NCT05008614|PROCEDURE|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
219751282|NCT06413212|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.|Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
219751283|NCT02302222|DEVICE|Customizable Dressing with ActiV.A.C. Therapy Unit|
219751284|NCT02302222|DEVICE|Standard of Care Dressing|
219751285|NCT05974800|BEHAVIORAL|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
219751286|NCT01950520|DRUG|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
219751287|NCT01950520|DRUG|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
219751288|NCT01950520|DRUG|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
219751289|NCT01950520|DRUG|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
219751290|NCT01950520|DRUG|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
219751291|NCT01950520|DRUG|Qsymia|Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
219751292|NCT01950520|DRUG|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
219751293|NCT01950520|BEHAVIORAL|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
219751294|NCT01950520|DRUG|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
219751295|NCT01950520|DRUG|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
219751296|NCT01950520|DRUG|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
219751297|NCT01950520|DRUG|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
219751298|NCT01950520|DRUG|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
219751299|NCT01950520|DRUG|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
219751300|NCT04908046|DRUG|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
219751301|NCT04212442|BEHAVIORAL|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
219751302|NCT04809064|PROCEDURE|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
219179745|NCT04552223|DRUG|Nivolumab|Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
219179746|NCT04552223|DRUG|Relatlimab|Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
219751303|NCT04809064|PROCEDURE|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
219751304|NCT04809064|PROCEDURE|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
219751305|NCT04809064|OTHER|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
219751306|NCT03858777|DIAGNOSTIC_TEST|cell free DNA|All groups will have blood draws and cfDNA measured
219751307|NCT04623593|PROCEDURE|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
219179747|NCT04790396|DEVICE|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
219179748|NCT04784832|DEVICE|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
219179749|NCT04784832|DEVICE|Peripheral Nerve Stimulation|Electric stimulation of the nerves
219751308|NCT04623593|PROCEDURE|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
219179750|NCT04784832|DEVICE|Transcranial direct current stimulation|Electric stimulation of the cortex
219179751|NCT04784832|DEVICE|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
219179752|NCT04784832|DEVICE|Wrist|Short-term immobilization of the arm
219179753|NCT04784832|DEVICE|Robotic arm|External perturbation of force field induced by robotic arm
219179754|NCT04784832|DEVICE|Cervicomedullar stimulation|Electric stimulation of the muscle
219751309|NCT03592017|DEVICE|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
219751310|NCT06645171|DIETARY_SUPPLEMENT|Fibre drink|One drink will be tested
219751311|NCT04429919|DRUG|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
219751312|NCT04429919|DRUG|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
219751313|NCT03781570|BEHAVIORAL|Placebo Cream|"In the Placebo intervention, participants are given an inert cream with instructions that it is Prodicaine, an effective pain-relieving drug. The cream is applied to two fingers on the left hand."
219751314|NCT03781570|BEHAVIORAL|Control Cream|"In the Control intervention, participants are given an inert cream with instructions that it is a control cream with no effects . The cream is applied to two fingers on the left hand."
219751315|NCT01107496|DRUG|IR Viloxazine|"One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6."
219751316|NCT01107496|DRUG|Placebo|Placebo capsules administered orally 3 times a day
219751317|NCT06063551|PROCEDURE|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
219751318|NCT03732794|DEVICE|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
219751319|NCT03709472|BEHAVIORAL|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
219751320|NCT03709472|BEHAVIORAL|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
219751321|NCT05644301|DRUG|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
219751322|NCT05644301|DRUG|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
219751323|NCT05644301|DRUG|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
219751324|NCT03030755|OTHER|Optical coherence tomography|
219751325|NCT03559556|OTHER|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
219751326|NCT05826054|DIETARY_SUPPLEMENT|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
219751327|NCT02056769|RADIATION|CT Perfusion|Quantitative CT Perfusion imaging
219751328|NCT06479707|BEHAVIORAL|Digital Literacy Intervention|This intervention consists of 4-6 home visits with 3-4 interim phone calls based on the participant's individual digital literacy needs and goals. Each participant will receive internet connectivity (if not already available), a tablet (if not already available) and tailored action plans co-developed by the participant and the interventionist.
219751329|NCT06621589|BEHAVIORAL|Nutritional Counseling|The intervention involves nutritional counseling aimed at improving dietary habits and overall health to participants. During the 2-month period, participants will receive guidance on nutrition, diet planning, and lifestyle changes tailored to their needs. Assessments of knowledge, attitudes, and health metrics will be conducted before and after the counseling sessions to measure the effectiveness of the intervention
219751330|NCT05498090|DRUG|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
218992815|NCT01941875|DRUG|Progesterone Effervescent Vaginal Tablets|Experimental
218992816|NCT03839901|OTHER|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
218992817|NCT04068714|PROCEDURE|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
218992818|NCT01346228|BEHAVIORAL|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
218992819|NCT00647881|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
218992820|NCT00647881|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fed
218992821|NCT05710861|DEVICE|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
218992822|NCT05710861|PROCEDURE|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
219751331|NCT06464640|DEVICE|"Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up"|The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
218992823|NCT05817461|DRUG|AZD0780 tablet|oral, fasted
219751332|NCT06464640|DEVICE|E-book|Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
219751333|NCT03366259|DRUG|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
219751334|NCT03366259|PROCEDURE|elective cesarean section|elective cesarean section for full term patients
219751335|NCT03141970|DRUG|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
219751336|NCT04464538|BEHAVIORAL|WALC-R|Initial group education session and individualized coaching (remote)
219751337|NCT04464538|OTHER|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
219751338|NCT03659721|BEHAVIORAL|FACAM|Support person
219751339|NCT03659721|BEHAVIORAL|Care as Usual|Usual care
219751340|NCT03659721|BEHAVIORAL|COS-P|Attachment based therapy
219751341|NCT03506360|DRUG|Dexamethasone|Given PO
219751342|NCT03506360|DRUG|Ixazomib Citrate|Given PO
219751343|NCT03506360|OTHER|Laboratory Biomarker Analysis|Correlative studies
219751344|NCT03506360|BIOLOGICAL|Pembrolizumab|Given IV
219751345|NCT02025218|DRUG|Gefitinib standard dose|
219751346|NCT02927964|DRUG|Ibrutinib|Given PO
219751347|NCT02927964|RADIATION|Radiation Therapy|Undergo radiation therapy
219751348|NCT02927964|DRUG|TLR9 Agonist SD-101|Given IT
219751349|NCT02229682|RADIATION|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
219751350|NCT03543423|OTHER|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
219751351|NCT03543423|OTHER|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
219751352|NCT01555580|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
219751353|NCT06973876|BEHAVIORAL|Pain-Sensitive Teleyoga Primer|The 5-session Pain-Sensitive Teleyoga Primer will be delivered synchronously to participants who will practice from their home. The purpose of the 5-session primer is two-fold: (1) it allows trained yoga instructors to determine physical abilities and limitations of patient participants so that pose modifications may be taught and (2) it provides education to participants on pain neuroscience, breathwork, relaxation, mindfulness, and interoception so that they may apply this knowledge to maximize the benefits of whichever yoga condition they are randomized to. Each session will last approximately 75 minutes. Participants will be provided with a supplementary handout to reinforce content from the sessions.
219751354|NCT06973876|BEHAVIORAL|Synchronous Teleyoga|Participants randomized to receive synchronous teleyoga will be provided information so that they can attend VAPORHCS virtual yoga offerings. They will be encouraged to attend one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked via a signed note in the medical record. Each session will last approximately 30-60 minutes.
219751355|NCT06973876|BEHAVIORAL|Asynchronous Teleyoga|Participants randomized to receive asynchronous teleyoga will be provided information so that they can access to the digital library of yoga videos on Ompractice, an existing partner with VA Medical Centers. Ompractice contains a suite of yoga video content, and participants will be encouraged to complete one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked by Ompractice and shared with VAPORHCS.
219751356|NCT06269315|OTHER|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
219751357|NCT06575894|BEHAVIORAL|Adapted Facilitation|Home visiting supervisor trained in adapted facilitation will employ interactive problem-solving focused on supporting the home visitors to implement Mothers and Babies - working with pregnant people, challenges with resources, additional training needs, etc. - based on understanding the individual communities, contexts, and recipients' and home visitors' needs over the course of the project.
219751358|NCT06575894|BEHAVIORAL|Standard Implementation|Standard Mothers and Babies training includes ongoing implementation support from the Mothers and Babies training team
218992824|NCT05817461|DRUG|[14C]AZD0780 Solution for Infusion|intravenous
219751359|NCT06637813|OTHER|Blood sampling for evaluation of biomarkers|Non-routine diagnostic test evaluations
218992825|NCT05817461|DRUG|[14C]AZD0780 Oral Solution|oral, fasted
219179755|NCT04784832|OTHER|Physical training|Training to perform the task by actually doing the task
219179756|NCT04784832|OTHER|Mental training|Training to perform the task by imaging doing the task
219751360|NCT06641518|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
219751361|NCT04953026|DIAGNOSTIC_TEST|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
219751362|NCT05493410|OTHER|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
219751363|NCT05493410|OTHER|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
219751364|NCT00287560|DRUG|propofol (drug)|
219751365|NCT05095467|PROCEDURE|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
219751366|NCT05095467|DRUG|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
219751367|NCT05095467|DRUG|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.
219751368|NCT05095467|PROCEDURE|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
219751369|NCT01606241|DRUG|Cyclophosphamide|Given PO
219751370|NCT01606241|OTHER|Laboratory Biomarker Analysis|Correlative studies
219751371|NCT01606241|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
219751372|NCT03100279|BEHAVIORAL|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
219751373|NCT03100279|BEHAVIORAL|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
219751374|NCT06195956|OTHER|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
219751375|NCT05318287|BEHAVIORAL|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
219751376|NCT05185453|BEHAVIORAL|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
219751377|NCT05185453|BEHAVIORAL|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
219751378|NCT06596525|OTHER|Conventional physical therapy|"Conventional physical therapy program will include:~1. Stretching exercises (forearm pronators, ulnar deviators, shoulder internal rotators, hip flexors and adductors, and hamstring muscle groups)~2. Strengthening exercises (ankle dorsiflexors, knee extensors, and hip flexor muscle groups)~3. Posture exercises~4. Balance and proprioception exercises~5. Walking training, obstacle crossing training, stair climbing and descending exercises"
218992826|NCT00968513|BEHAVIORAL|Brief Intervention|(N=416) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
219179757|NCT06221800|DIAGNOSTIC_TEST|Microbiome|Stool and saliva samples will be collected
219751379|NCT06596525|OTHER|Barefoot Whole Body Vibration Training (WBVTb)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will be barefoot. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
219179758|NCT04526704|DRUG|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
219751380|NCT06596525|OTHER|Shod Whole Body Vibration Training (WBVTs)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will wear everyday sports shoes. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
219751381|NCT06596525|OTHER|Sham Whole Body Vibration Training (WBVTsh)|"During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated."
219751382|NCT06983665|DRUG|Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 2.0 mg/kg in each period.
219751383|NCT06983665|DRUG|Reference product (AmBisome®, Astellas Pharma US Inc.)|Single intravenous administration of 2.0 mg/kg in each period.
219751384|NCT03403738|BEHAVIORAL|Bounce Back Now|web/smartphone-based intervention for disaster victims
219751385|NCT03403738|BEHAVIORAL|enhanced usual care|enhanced usual care with list of resources
219751386|NCT00391716|DRUG|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
219751387|NCT00391716|BEHAVIORAL|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
219751388|NCT00391716|DRUG|placebo|lactose capsule compounded to mimic gabapentin capsules
218992827|NCT00968513|BEHAVIORAL|Extended Treatment|(N=408) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
218992828|NCT00968513|BEHAVIORAL|Usual Care|(N=132) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
218992829|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
218992830|NCT06803524|BIOLOGICAL|Pertagen® vaccine|Pertagen® vaccine, manufactured by BioNet-Asia Co., Ltd., Bangkok, Thailand. The vaccine is presented in pre-filled syringe, each containing one human dose (0.5 mL) of aP vaccine.
219369494|NCT04007159|OTHER|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
219751389|NCT00391716|DRUG|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
219751390|NCT02410187|RADIATION|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
219751391|NCT02410187|DRUG|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
219751392|NCT02410187|RADIATION|palliative RT|fraction size of RT = \< 3 Gy
219751393|NCT00349986|DRUG|Insuline glargine|
219751394|NCT01045733|DEVICE|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
218992831|NCT06803524|BIOLOGICAL|Adacel® vaccine|Adacel® vaccine, manufactured by Sanofi Pasteur, Ltd, Toronto, Ontario, Canada. The vaccine is presented in a single-dose vial, each containing one human dose (0.5 mL) of Tdap vaccine.
219751395|NCT01045733|DEVICE|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
218992832|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
218992833|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
218992834|NCT05379231|DEVICE|Hearing aid fitting|A participant will wear a hearing aid with and without a CROS device on the unaidable ear.
219179759|NCT02737436|DRUG|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
219179760|NCT02737436|DRUG|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
219179761|NCT02737436|PROCEDURE|Functional MRI scanning|All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
219369495|NCT01650090|DRUG|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
219369496|NCT02076165|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
219751396|NCT01045733|PROCEDURE|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
219751397|NCT03331887|PROCEDURE|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
219751398|NCT03331887|PROCEDURE|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
219751399|NCT00414154|BEHAVIORAL|Group based multidisciplinary patient education programme|
219751400|NCT06599320|OTHER|Oral rehabilitation with dental implants|Patients rehabilitated with implant-supported fixed partial dental prostheses
219751401|NCT06816823|BIOLOGICAL|CL-NK-001|Dose level 1 (5 × 10\^8 cells); dose level 2 (15 × 10\^8 cells); dose level 3 (30 × 10\^8 cells); additional dose levels (investigator's discretion).
219751402|NCT06303453|OTHER|Balance exercises|Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.
219751403|NCT06303453|OTHER|Resisted exercises|"The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week."
219751404|NCT02457793|DRUG|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
219751405|NCT02457793|DRUG|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
219751406|NCT03997500|DRUG|normal saline|a bolus of normal saline was given followed by normal saline infusion
219751407|NCT03997500|DRUG|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
219751408|NCT04316143|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat
219751409|NCT06239649|PROCEDURE|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
219751410|NCT05849844|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
219751411|NCT06658067|DEVICE|Continuous Glucose Monitor (CGM)|The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
219751412|NCT05218434|DRUG|AX-158|Oral administrations of AX-158
219751413|NCT06669039|DEVICE|Computer-controlled Local Anesthetic delivery system|Local anesthesia will be delivered using Computer-controlled Local Anesthetic delivery system.
219751414|NCT06669039|PROCEDURE|Inferior Alveolar Nerve Block|Local anesthesia will be delivered using the conventional syringe
219751415|NCT06503510|OTHER|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
219751416|NCT06503510|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
219751417|NCT06503510|OTHER|bovine adrenal medulla (BAM8-22)|A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
219751418|NCT06990555|OTHER|Neutral White Cast|This intervention consists of receiving a cast of neutral white color.
219751419|NCT06990555|OTHER|Color Wrapped Cast|This intervention consists of receiving a cast of color that is the choice of the participant.
219751420|NCT06990555|OTHER|Cast with Cast Art|This intervention consists of receiving a cast with art at the request of the participant, to include drawing, multiple colors, glitter, and any artwork.
219751421|NCT06078189|DEVICE|HORUS|"The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal head."
219751422|NCT02322840|DEVICE|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
219751423|NCT02322840|DEVICE|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
219751424|NCT00934180|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
219751425|NCT00934180|DRUG|Zofran®|1 x 8 mg ODT
219751426|NCT05497934|DRUG|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
219751427|NCT00835172|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
218992835|NCT03046758|DRUG|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
218992836|NCT00509444|BEHAVIORAL|Educational materials|
218992837|NCT00509444|BEHAVIORAL|educational materials, plus patient navigation|
219751428|NCT00835172|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
219751429|NCT04890509|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
219751430|NCT04890509|OTHER|SoC|The SoC will be administered based on local guidelines.
219751431|NCT06541197|OTHER|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.
219751432|NCT06541197|OTHER|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
219751433|NCT06672341|DIAGNOSTIC_TEST|Endometrial Cytology Testing|Endometrial Cytology Examination Liquid-based endometrial cytology is an emerging minimally invasive screening technique. This method involves collecting endometrial cells and tissues from the uterus and its downstream anatomical structures. The samples are preserved and analyzed using either liquid-based cytology techniques or tissue smear methods to reach a pathological diagnosis. Compared to invasive procedures such as fractional curettage, liquid-based cytology offers advantages in the screening of endometrial cancer, including being minimally invasive, convenient, and low-risk.
219751434|NCT06672341|DIAGNOSTIC_TEST|Cervical Methylation Testing|Cervical Cell Methylation Testing Cervical cell methylation testing is another promising method for methylation-based screening of endometrial cancer. This approach targets specific genes that undergo methylation in the early stages of endometrial cancer. The combined methylation analysis of four genes (CD01, BHLHE22, ACTB, and SEPTIN9) uses menstrual blood or vaginal secretions as samples, offering advantages such as safety, non-invasiveness, and self-collection. This method has shown high sensitivity and specificity for the early detection of endometrial cancer. Ongoing research suggests that the sensitivity and specificity of cervical cell methylation testing can reach 93.2% and 96%, respectively, although this data is yet to be published.
219751435|NCT06671119|DEVICE|Gastric Mucosal Ablation (GMA)|Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
219751436|NCT06516198|OTHER|Auricular Acupressure|Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
219751437|NCT06675786|DEVICE|I.V. House UltraDressing|I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. It is intended to prevent complications such as catheter-related displacement, phlebitis, infiltration, extravasation, catheter occlusion, and folding of PVCs.
219751438|NCT06675916|PROCEDURE|PENG Block with lidocaine hydrochloride|Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride
219751439|NCT06675916|PROCEDURE|Intra-articular infiltration with lidocaine hydrochloride|Intervention is intra-articular analgesia with lidocaine hydrochloride
219751440|NCT06673888|OTHER|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.
219751441|NCT06673888|OTHER|alkasite based restorative material|Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
219751442|NCT06674564|DIETARY_SUPPLEMENT|Zinc Acetate 50 Mg Oral Capsule|zinc suppose to improve immunity and wound healing after laryngectomy
219751443|NCT06674564|DIETARY_SUPPLEMENT|Probiotic|probiotics lowering infections rates and improving outcomes after surgery
219751444|NCT06673992|OTHER|This study does not involve any interventions|This study does not involve any interventions
219751445|NCT06675422|DRUG|JY231 injection|Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
219751446|NCT06673875|PROCEDURE|conservative treatment of stress urinary incontinence - pelvic floor muscle training|evaluation of pelvic floor muscle rehabilitation to change the clinical severity of urinary incontinence
219751447|NCT06673875|DEVICE|vaginal device Aniball INCO|"the firt group - the pelvic floor muscle training with vaginal device Aniball INCO according manual after education by the urogynecologist, who is educated in pelvic floor dysfunction.~the second group - the pelvic floor muscle training without vaginal device, the education was performed by certified physiotherapist trained in pelvic floor disorder."
219751448|NCT06997926|PROCEDURE|blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
219751449|NCT06999278|DRUG|Levothyroxin|Levothyroxin 50ug/d from randomization until delivery
219751450|NCT06999278|DRUG|Placebo|Placebo to levothyroxin
219751451|NCT07004439|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
218992838|NCT04090424|DEVICE|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
219751452|NCT07004049|DRUG|Colistin/Polymyxin B + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand and Singapore
219751453|NCT07004049|DRUG|Colistin/Polymyxin B + Tigecycline/Eravacycline|For carbapenem-resistant Acintobacter, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand and Singapore
219751454|NCT07004049|DRUG|Colistin/Polymyxin B + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia and Singapore
219179762|NCT06331182|DRUG|Ketamine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
219751455|NCT07004049|DRUG|Ceftazidime-avibactam + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand, Singapore and Australia.
219751456|NCT07004049|DRUG|Ceftazidime-avibactam + Fosfomycin|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Malaysia, Thailand and Singapore
219751457|NCT07004049|DRUG|Ceftazidime-avibactam|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
219751458|NCT07004049|DRUG|Ceftazidime-avibactam + Aztreonam|For carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
219751459|NCT07004049|DRUG|Ceftazidime-avibactam + Colistin/Polymyxin B|For carbapenem-resistant Pseudomonas aeruginosa in China, Malaysia, Thailand, Singapore and Europe.
219751460|NCT07004049|DRUG|High-dose meropenem|For carbapenem-resistant Enterobacterales infection in Europe
219751461|NCT07004049|DRUG|Meropenem + Fosfomycin|For carbapenem-resistant Enterobacterales in Europe
219751462|NCT07004049|DRUG|Meropenem-vaborbactam|For carbapenem-resistant Enterobacterales infection in Europe
219751463|NCT07004049|DRUG|Cefiderocol|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Europe and Australia.
219751464|NCT07004049|DRUG|Ceftolozane-tazobactam|For carbapenem-resistant Pseudomonas aeruginosa in Europe and Australia.
219751465|NCT07004049|DRUG|Ceftolozane-tazobactam + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa in Europe.
219751466|NCT07005375|BEHAVIORAL|thermal mineral water bath|One group will bathe in a pool filled with 36°C thermal mineral water of the Palatinus Spa for 3 weeks, 5 days a week, for a total of 15 sessions, 20 minutes per session. Bathing in the thermal mineral water takes place in the medicinal water pool. The control group does not receive balneotherapy. Both groups can continue their usual training plan.
219751467|NCT06675838|BEHAVIORAL|Time Management and Procrastination Behavior Management Training|"Intervention Content~Training Program Name: Time Management and Procrastination Behavior Management Training Duration: 3 sessions of 1 hour each, 5-day program Target Audience: Intern Nurses~Training Content:~Fundamentals of Time Management:~Definition and importance of time management. Key principles for effective use of time (prioritization, time blocking, planning).~Understanding Procrastination Behavior:~Definition and reasons for procrastination behavior. Effects of procrastination on student success.~Time Management Strategies:~Task Prioritization: Differentiating between urgent and important tasks. Time Blocking: Completing specific tasks in designated time slots. Daily Planning: Organizing daily tasks and activities.~Managing Procrastination Behavior:~Identification and analysis of procrastination habits. Coping strategies for procrastination (e.g., goal setting, increasing motivation, self-rewarding).~Effective Teaching Techniques:~Presentations and Information Sharing"
219751468|NCT06674590|PROCEDURE|Proprioceptive Neuromuscular Facilitation|PNF of 30 minutes duration will given in a single session. Pelvic anterior elevation and posterior depression of the hemiplegic side. rhythmic initiation slow reversal agonistic reversals Pelvic anterior depression and posterior elevation of the hemiplegic side. The first diagonal (D1): Flexion and extension The second diagonal (D2): Flexion and extension 4 session per week
219751469|NCT06674590|PROCEDURE|Motor Relearning Program|Motor Relearning Programme (MRP) This is a task-oriented approach to help the control of movement, focusing on the relearning of daily activities.
219751470|NCT06675734|DRUG|diclofenac sodium solution|The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
219751471|NCT06673784|DIAGNOSTIC_TEST|ophthalmic saline eye drops|for optical examination
219751472|NCT06673784|DRUG|Saline|Most one natural and not effects on study
219751473|NCT03077061|PROCEDURE|Open flap debridement|Open flap debridement using saline as irrigation
219751474|NCT03077061|DEVICE|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
219751475|NCT05317858|DEVICE|Blood Brain Barrier Opening - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of ICI infusion to treat brain metastases.
219751476|NCT05317858|DRUG|Pembrolizumab|Pembrolizumab infusion
219751477|NCT05317858|DRUG|Atezolizumab|Atezolizumab infusion
219751478|NCT05317858|DRUG|Cemiplimab|Cemiplimab infusion
219751479|NCT05317858|DRUG|Nivolumab|Nivolumab infusion
219751480|NCT05317858|DRUG|Iptilimumab|Iptilimumab infusion
219751481|NCT07010029|DEVICE|Coronary Sinus Reducer|Patients will undergo implantation of Coronary Sinus Reducer
219751482|NCT07009730|PROCEDURE|Bypassing Agents|Cardiopulmonary bypass surgery, pulsatile flow
219751483|NCT06674330|OTHER|concentration of teicoplanin|post analysis of concentration of teicoplanin
219179763|NCT06331182|DRUG|Dexmedetomidine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
219179764|NCT06331182|DRUG|Bupivacaine|29 ml bupivacaine 0.25%
219179765|NCT05289414|DEVICE|Radiofrequency on mid cervical medial branches|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on mid cervical medial branches
219179766|NCT05289414|DEVICE|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on Greater occipital nerve
219751484|NCT07010861|OTHER|Expressive Art Therapy|As a strategy for coping with trauma, art production creates therapeutic effects on the individual with its sensory and physical aspects (Chapman, 2013; King-West and Hass-Cohen, 2008). When verbal expression is insufficient or carries the risk of re-traumatization, expressive art therapy offers a safe space through non-verbal expression (Talwar, 2007). It is stated that art production is effective in repairing self-integrity ruptures that occur in traumatic experiences (Harris, 2009). Through creative processes, the individual can restructure both internally and externally. Expressive art therapy, especially when applied in a group environment, creates a psychotherapeutic effect by providing participants with the opportunity to express their emotions, imagination and unconscious processes (Malchiodi, 2012; Kim et al., 2021). The commitment and reflective understanding that occur in group psychotherapy are among the factors that give hope and strength (Robb, 2017).
219751485|NCT07010653|DEVICE|Higroscopic Cervical ripening|Participants assigned to the Dilapan-S group will have 3 to 5 rods inserted under aseptic conditions. Placement will follow manufacturer instructions, and rods will remain in place for up to 12 hours unless spontaneous labor or device expulsion occurs earlier. Upon removal, cervical status will be assessed, and induction will continue with prostaglandins or oxytocin based on standard care.
219751486|NCT07010653|DEVICE|Cervical ripening via CRB|Double Balloon Catheter (CRB) Participants randomized to CRB will undergo insertion of a double balloon catheter with inflation of each balloon (approximately 80 mL saline each) according to established protocols. The catheter will remain for up to 12 hours or until spontaneous labor or expulsion. Post-removal management will mirror that of the Dilapan-S group.
219751487|NCT07010848|OTHER|Core stability training|Core stability Training consists in the activation of trunk.
219751488|NCT07010718|DRUG|Scented Oil|inpatient-safe aromatherapy (scented oil)
219751489|NCT07010718|DEVICE|Ear Plugs|ingestible-safe ear plugs (noise blocking)
219751490|NCT07010718|DEVICE|Eye Mask|inpatient-safe eye mask (light blocking).
219751491|NCT07010718|BEHAVIORAL|Video based safety check|video based safety checks will be conducted as long as participants are in bed and asleep
219751492|NCT07010718|BEHAVIORAL|In person safety check|In person safety checks will be conducted every 30 minutes
219751493|NCT06624995|OTHER|chatbot education|elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
219751494|NCT07011407|OTHER|Maximal Exercise Test|"Healthy participants will be situated on a cycle ergometer fitted with a 12-lead ECG or chest-strap heart rate monitor. Data from the questionnaire will be stored in a study site file in a locked cabinet in an office. Baseline readings will be obtained whilst on the bike for 3 minutes before the subject embarks on a 3-minute warm-up at 50 Watts (W). The workload (watts) on the bike is then increased to a workload that corresponds to a heart rate of 120 bpm (gentle exercise). The workload will then be increased by 25-50W every three minutes until volitional exhaustion. Between each stage, there will be a 30s rest period where the participant will be cycling with minimal resistance (freewheeling) but will be otherwise stationary on the cycle ergometer. Still images of the face and facial video recordings will be taken during a 30s rest period between increases in exercise intensity. A finger-prick blood sample (glucose \& lactate) will be taken at the beginning and every 3 minutes."
219751495|NCT07010614|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive electrical brain stimulation.
219751496|NCT07010614|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation
219751497|NCT07010614|DEVICE|TMS sham|Sham TMS will be used as a comparator for noninvasive brain stimulation
218992839|NCT04090424|PROCEDURE|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
218992840|NCT05002452|OTHER|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
218992841|NCT04178486|BEHAVIORAL|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
218992842|NCT04178486|BEHAVIORAL|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
218992843|NCT04178486|BEHAVIORAL|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
218992844|NCT04178486|BEHAVIORAL|Hypnosis with induction only|Participants received only hypnotic induction.
218992845|NCT06044883|PROCEDURE|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
218992846|NCT06044883|DIAGNOSTIC_TEST|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
218992847|NCT04907903|OTHER|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
219179767|NCT05607732|DIAGNOSTIC_TEST|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
219179768|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
219179769|NCT06016920|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
219179770|NCT06016920|DRUG|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
219179771|NCT06795282|DRUG|MTA|MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.
219751498|NCT07010068|DIETARY_SUPPLEMENT|TGF-β2-enriched food for special medical purposes|"The experimental treatment is Modulen-IBD®, a food for special medical purpose, polymeric, enriched with TGF-beta. If the patient refuses the experimental supplementation, NGT will be proposed to ensure the correct intake of Modulen-IBD® supplementation.~If the patient refuses, not tolerates, or there are contraindications to NGT placement, best supportive therapy will be warranted as reported below (BST)."
219751499|NCT07010068|DIETARY_SUPPLEMENT|BST|Best Nutritional Supportive Treatment as per center's policy according to EBMT Handbook 2024
219179772|NCT04674462|BIOLOGICAL|CpG-adjuvanted HBV Vaccine|Subjects receiving CpG-adjuvanted HBV vaccine will require two doses at 0 and 1 month after initiation. The second dose will be considered the same as the one month time point following the first dose.
219179773|NCT04674462|BIOLOGICAL|Traditional HBV Vaccine|Subjects receiving traditional HBV vaccine series will require three doses at 0, 1, and 6 months after initiation. The second dose will be considered the same as the one month time point following the first dose.
219179774|NCT05605587|DRUG|Leflunomide 20 mg|once daily for 6 months
219751500|NCT07011433|DIAGNOSTIC_TEST|Inflammatory Biomarker Evaluation|Venous blood samples are collected from subjects and analyzed for inflammatory biomarkers, including CD64, presepsin, IL-6, and IL-8, using a Luminex multiplex assay. Results are used for research purposes only and do not affect clinical management.
219751501|NCT06683677|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to extremely preterm infants immediately after birth.
219751502|NCT07011108|OTHER|No intervention (observational study)|no intervention
219751503|NCT06691360|DRUG|AK137|IV infusion, specified dose on specified days.
219751504|NCT06687733|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
219751505|NCT04255563|DEVICE|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
219751506|NCT07010393|DRUG|Dabrafenib|150 mg orally twice daily; ≤4 × 28-day cycles
219751507|NCT07010393|DRUG|Trametinib|2 mg orally once daily; same duration
219751508|NCT07010393|DRUG|Selpercatinib|160 mg orally twice daily; ≤4 cycles
219179775|NCT03984201|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
219751509|NCT07010393|DRUG|Pralsetinib|retrospective, 400 mg orally once daily; ≤4 cycles
219751510|NCT07010393|DRUG|Lenvatinib|24 mg orally once daily; ≤4 cycles
219751511|NCT07010393|DRUG|Larotrectinib|Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.
219751512|NCT07010393|DRUG|Anlotinib|12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)
219751513|NCT07010393|DRUG|Pembrolizumab|200 mg IV infusion every 3 weeks; ≤4 cycles
219751514|NCT07010393|DRUG|Sintilimab|200 mg IV infusion every 3 weeks; ≤4 cycles
219751515|NCT07010393|DRUG|Cabozantinib|Cabozantinib 60 mg orally once daily, continuous 28-day cycles.
219751516|NCT07010393|DRUG|Bemosuzumab|China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).
219751517|NCT07010393|PROCEDURE|Conversion Surgery|Conversion Surgery if resectable
219751518|NCT06607770|DRUG|Karelizumab+Apatinib|Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
219751519|NCT06625710|DRUG|GV1001|Lyophilized peptide from hTERT
219751520|NCT06625710|DRUG|Placebo|0.9 % Normal Saline
219751521|NCT03274466|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
219751522|NCT03274466|DEVICE|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
219751523|NCT02371187|DRUG|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
219751524|NCT02371187|DRUG|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
219751525|NCT03462121|DRUG|RPh201|RPh201 is a well-defined extract from a botanical source
219751526|NCT03462121|OTHER|Placebo|Inactive placebo consisting of the therapeutic vehicle
219751527|NCT02117076|DRUG|Gabapentin immediate release|up to 1200 mg per day
219751528|NCT02117076|DRUG|Gabapentin enacarbil extended release|up to 1200 mg per day
219751529|NCT05918146|DRUG|Dextrose|Dextrose injection plus physical therapy
219751530|NCT05918146|DRUG|Normal saline|Normal saline injection plus physical therapy
219751531|NCT06022887|BEHAVIORAL|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
219179776|NCT06641895|GENETIC|BBM-D101|BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
219751532|NCT06022887|BEHAVIORAL|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
219751533|NCT04701710|DRUG|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
219751534|NCT05406531|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219751535|NCT05406531|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219751536|NCT05406531|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219751537|NCT03057340|BIOLOGICAL|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
219751538|NCT00005819|DRUG|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
218992848|NCT03292562|DEVICE|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
218992849|NCT03292562|DEVICE|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
219179777|NCT04205968|DRUG|Fluorouracil|Given IV bolus or IV
219751539|NCT00005819|DRUG|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
219751540|NCT00005819|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
219751541|NCT03864705|DIAGNOSTIC_TEST|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
219751542|NCT00414557|PROCEDURE|Quadriceps strengthening|
219751543|NCT00657683|BIOLOGICAL|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
219751544|NCT00657683|BIOLOGICAL|Placebo|1 dose of placebo
219751545|NCT03420820|BIOLOGICAL|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
219751546|NCT01564329|DRUG|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
219751547|NCT00618787|DEVICE|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
219179778|NCT04205968|DRUG|Irinotecan|Given IV
219179779|NCT04205968|DRUG|Irinotecan Hydrochloride|Given IV
219179780|NCT04205968|DRUG|Leucovorin|Given IV
219179781|NCT04205968|DRUG|Leucovorin Calcium|Given IV
219179782|NCT04205968|DRUG|Paclitaxel|Given IV
219179783|NCT04205968|BIOLOGICAL|Ramucirumab|Given IV
219369497|NCT02076165|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
219369498|NCT01755988|OTHER|Educational website (in addition to usual care).|
219751548|NCT00618787|DEVICE|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
219751549|NCT03334955|PROCEDURE|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
219751550|NCT06301113|DIETARY_SUPPLEMENT|CBD infused candy|300 Nano mg CBD Candy cherry flavor
219751551|NCT06301113|DIETARY_SUPPLEMENT|Sugar free Candy|Raspberry flavored sugar free candy
219751552|NCT01096251|BEHAVIORAL|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
219751553|NCT04514835|DRUG|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
219751554|NCT01107886|DRUG|Saxagliptin|5 mg or 2.5 mg once daily
219751555|NCT01107886|DRUG|Placebo|
219751556|NCT03761550|COMBINATION_PRODUCT|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
219751557|NCT02007460|BEHAVIORAL|Exercise|multidirectional unilateral hopping exercise
219751558|NCT05512338|OTHER|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
219751559|NCT05512338|OTHER|Active control group|Standard physiotherapy methods.
219179784|NCT06308497|OTHER|Probiotic Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
219751560|NCT04392076|PROCEDURE|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
219751561|NCT03027596|PROCEDURE|Remote ischemic conditioning|
219751562|NCT03772925|DRUG|Belinostat|Given IV
219179785|NCT06308497|OTHER|Standard Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
219179786|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
219751563|NCT03772925|DRUG|Pevonedistat|Given IV
219751564|NCT06896903|DIAGNOSTIC_TEST|Coronary reactivity testing with and without nitrates|CRT will be performed in the left and right coronary arteries. Measurements will be obtained in each of the coronaries first without intracoronary nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat measurements.
219751565|NCT06835959|BEHAVIORAL|Moms@Home|Participants will use a storytelling mobile health app for daily home-based blood pressure monitoring and symptom/medication adherence tracking.
219751566|NCT06835959|BEHAVIORAL|Enhanced Standard of Care|Participants will use a paper journal daily to track home-based blood pressure values
219751567|NCT03272932|OTHER|No intervention|No intervention
219751568|NCT05301764|COMBINATION_PRODUCT|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
219179787|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
219179788|NCT03667599|OTHER|home care|This is the interventional arm where patients receive the transplant care in their homes.
219179789|NCT05682885|PROCEDURE|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
219179790|NCT06639724|COMBINATION_PRODUCT|Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)|Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
219179791|NCT06642649|PROCEDURE|General Anesthesia (control group)|Only General Anestesia
219179792|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and no fentanyl)|General anesthesia + spinal anesthesia with local anesthetic and morfine
219179793|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and 20 mcg fentanyl)|General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
219369499|NCT01755988|OTHER|Website and interactive platform with telemonitoring.|
219751569|NCT06089317|DRUG|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
219751570|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
219751571|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
219751572|NCT06089317|DRUG|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
219751573|NCT06089317|DRUG|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
219179794|NCT06642675|DEVICE|Intermittent theta burst stimulation(iTBS)|By using the TMS Navigation System, the iTBS will be targeted at the left Supramarginal Gyrus.iTBS will be performed using Magstim Rapid² stimulator, parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, intensity of 90% resting motor threshold(RMT), total duration of 10 minutes.
219751574|NCT06510621|PROCEDURE|Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
219751575|NCT02445911|DRUG|KQ-791|Capsules administered orally
219751576|NCT02445911|DRUG|Placebo|Capsules administered orally
219751577|NCT06919887|OTHER|EMMII|The tool/app, consists of educational components designed to enable women to more effectively identify menopause symptoms and feel confident in seeking treatment to address their symptoms. The tool/app also produces a tailored menopause discussion guide for patients to bring to their primary care appointment.
219751578|NCT06919887|OTHER|Comparison Group|Receive educational menopause pamphlet describing menopause symptoms and evidence-based treatment options.
219751579|NCT04309682|PROCEDURE|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
219751580|NCT04309682|PROCEDURE|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
219751581|NCT06054542|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
219751582|NCT00583583|DEVICE|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
219751583|NCT01649869|OTHER|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
219751584|NCT01649869|DRUG|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
219751585|NCT06146062|DRUG|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
219751586|NCT06146062|DRUG|placebo|3 injections one week apart
219751587|NCT05894655|BEHAVIORAL|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
219751588|NCT05894655|BEHAVIORAL|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
219751589|NCT05894655|BEHAVIORAL|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
219751590|NCT05459753|RADIATION|(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET|Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
219751591|NCT05459753|RADIATION|Dihydrotetrabenazine (DTBZ) PET|Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
219751592|NCT06439771|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
219179795|NCT06642675|DEVICE|Sham stimulation|Patients in sham group would receive the same intervention procedure as the active ITBS group, but the coil will be replaced with sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
219179796|NCT06640049|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219751593|NCT02333799|DRUG|Bedaquiline|100mg tablets
219751594|NCT02333799|DRUG|PA-824|200mg tablets
219751595|NCT02333799|DRUG|Linezolid|Scored 600mg tablets
219751596|NCT06834321|DRUG|Homoharringtonine combined with androgen deprivation therapy|Homoharringtonine 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, repeated administration after three weeks of intermittent treatment, lasting two cycles + continuous androgen deprivation therapy.
219751597|NCT06834321|DRUG|Placebo combined with androgen deprivation treatment group|Placebo 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, and repeated administration after a break of three weeks for two cycles + continuous androgen deprivation therapy,placebo is 5% glucose injection.
219179797|NCT06257485|DIAGNOSTIC_TEST|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
219179798|NCT06568367|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
219751598|NCT06834321|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle.
219751599|NCT05411718|DRUG|Naproxen|Given by PO
219751600|NCT05411718|DRUG|Aspirin|Given by PO
219751601|NCT04565509|BEHAVIORAL|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
219751602|NCT04565509|BEHAVIORAL|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
219751603|NCT04565509|BEHAVIORAL|Best Message Alone|The best message will be either the general or focused/targeted message described above.
219751604|NCT04565509|BEHAVIORAL|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
219751605|NCT00710944|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
219751606|NCT06471712|DRUG|18F-LNC1007 Injection|Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
219751607|NCT05612230|OTHER|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
219751608|NCT05613556|DEVICE|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
219751609|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 4 weeks
219751610|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 24 weeks
219751611|NCT03048370|PROCEDURE|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219751612|NCT03048370|PROCEDURE|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219751613|NCT03048370|PROCEDURE|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219751614|NCT03048370|PROCEDURE|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219751615|NCT03048370|PROCEDURE|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219751616|NCT03048370|PROCEDURE|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
219179799|NCT06568367|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
219179800|NCT06568367|DRUG|Placebo|Placebo tablets, taken once daily
219179801|NCT03701399|DRUG|troriluzole|Administered orally
219179802|NCT03701399|DRUG|Placebo|Administered orally
219179803|NCT06644157|DEVICE|Laser Néo Élite|One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
219179804|NCT06644378|DRUG|[14C]-LY3866288|Administered orally.
219751617|NCT00314613|DRUG|Antipsychotic/Risperidone Consta|
219751618|NCT06218459|OTHER|Oldpain2go®|OldPain2Go® is a non-medical intervention for the treatment of chronic pain conditions including, but not limited to Chronic Low Back Pain. The underlying premise is rooted in the biopsychosocial model of pain, where the cause of ongoing pain and the development of chronicity, is believed to lie beyond simple tissue damage, injury or malfunction. The intervention draws upon subconscious communication as a means to help patients to re-frame their pain as less threatening and remove old, out of date, pain messages that no longer serve a purpose.
219751619|NCT06218459|OTHER|Jacobson's progressive relaxation|Jacobson's progressive relaxation is a technique commonly used for eliciting the relaxation response and relieving muscular tension. It involves sequentially relaxing various muscle groups, often starting at the head and moving down the body to the feet.
219751620|NCT00674921|DRUG|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
219751621|NCT00674921|DRUG|Placebo|starch, magnesium stearate, sodium lauryl sulphate
219751622|NCT02840630|OTHER|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
219179805|NCT06644378|DRUG|LY3866288|Administered orally.
219751623|NCT01657370|DRUG|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
219751624|NCT01657370|DRUG|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
219751625|NCT01657370|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
219751626|NCT02648581|DRUG|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
219751627|NCT05973903|DRUG|Lenvatinib|Oral Lenvatinib 20 mg once daily
219751628|NCT05973903|DRUG|Pembrolizumab|intravenous pembrolizumab 200 mg every three weeks
219751629|NCT05973903|DEVICE|Tumor Treating Fields (TTFields)|TTF extra-dermal scalp electrodes
219179806|NCT06644378|DRUG|[14C]-LY3866288|Administered IV.
219751630|NCT06788132|COMBINATION_PRODUCT|Cranberry products|One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days
219751631|NCT06788132|OTHER|Placebo|Starch one capsule per day for 10 days
219751632|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
219751633|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
219751634|NCT05215145|BEHAVIORAL|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
219179807|NCT05384496|DRUG|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
219179808|NCT05384496|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
219369500|NCT02509559|DRUG|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
219369501|NCT02509559|DRUG|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
219751635|NCT05215145|BEHAVIORAL|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
219751636|NCT06535854|DEVICE|Prevail DCB|The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
219751637|NCT06535854|DEVICE|Agent DCB|The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
219751638|NCT06548711|OTHER|Transcutaneous Acupoint Electrical Stimulation (TAES)|Transcutaneous acupoint electrical stimulation (TAES) is a non-invasive treatment method that delivers gentle electrical pulses through the skin to specific acupuncture points on the body. This technique aims to mimic the effects of traditional acupuncture, providing a convenient and painless method of treatment.
219751639|NCT00925275|DRUG|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
218992850|NCT02485197|OTHER|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
219751640|NCT05465304|DRUG|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
219751641|NCT01893086|PROCEDURE|LH alone|LH, laparoscopic hysterectomy
219751642|NCT01893086|PROCEDURE|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
219751643|NCT04423432|OTHER|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
219751644|NCT04423432|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
219751645|NCT04423432|DEVICE|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
219751646|NCT04423432|PROCEDURE|Joint Mobilization|"1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization"
219751647|NCT04423432|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
219751648|NCT04423432|DIETARY_SUPPLEMENT|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
219751649|NCT01163942|DRUG|G-CSF|Yes/no addition of G-CSF
219751650|NCT01163942|DRUG|Early retreatment with ATG|Yes/no early retreatment with ATG
219751651|NCT00043602|BEHAVIORAL|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
219751652|NCT00043602|BEHAVIORAL|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
219751653|NCT01880463|DRUG|Omega-3 fatty acids (fish oil)|
219751654|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3|
219751655|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
219179809|NCT05384496|DRUG|axitinib|5mg twice daily
219179810|NCT05494723|DRUG|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
219751656|NCT01880463|DRUG|Fish oil placebo|
219751657|NCT02682056|DEVICE|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
219751658|NCT02682056|DEVICE|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
219751659|NCT02682056|DEVICE|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
219751660|NCT02746315|DRUG|HS-20004|
219751661|NCT02746315|DRUG|Placebo|
219751662|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
219751663|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
219179811|NCT06645145|BEHAVIORAL|Orthographic facilitation|Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.
219179812|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
219179813|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
219179814|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
219179815|NCT00554788|DRUG|Carboplatin|Given IV
219179816|NCT00554788|DRUG|Cisplatin|Given IV
219179817|NCT00554788|DRUG|Cyclophosphamide|Given IV
219179818|NCT00554788|DRUG|Etoposide|Given IV
219179819|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
219179820|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
219751664|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
219751665|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
219751666|NCT00664950|DEVICE|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
219751667|NCT00664950|DEVICE|IntertAn IM nail|interTAN IM nail
219751668|NCT04942002|DRUG|Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]|Retrobulbar injection performed by care provider
219751669|NCT04942002|DRUG|Placebo Comparator: Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
219751670|NCT03873545|PROCEDURE|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
219751671|NCT02749916|OTHER|Methods of carotid wall imaging|
219751672|NCT01882816|RADIATION|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
219751673|NCT01882816|DEVICE|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
219751674|NCT01882816|DRUG|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
219751675|NCT01882816|OTHER|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
219751676|NCT04548908|DIAGNOSTIC_TEST|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
219751677|NCT03735355|PROCEDURE|Surgery|Surgical resection of fibrostenotic area
219179821|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
219369502|NCT02509559|DEVICE|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
219751678|NCT03735355|PROCEDURE|TTS balloon dilation|Dilation of a stricture using TTS balloon
219751679|NCT01680211|DIETARY_SUPPLEMENT|Salacia bark extract|
219751680|NCT01680211|DIETARY_SUPPLEMENT|Salacia leaf extract|
219751681|NCT01680211|DIETARY_SUPPLEMENT|Sesame seed extract|
219751682|NCT01680211|BEHAVIORAL|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
219751683|NCT01680211|OTHER|Placebo|
219751684|NCT03361449|OTHER|Flamingo exercise|Flamingo exercise
219751685|NCT03361449|OTHER|training with kinesthetic ability trainer|training with kinesthetic ability trainer
219751686|NCT06253650|DRUG|Experimental|6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
219751687|NCT06253650|DRUG|Control|4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
219751688|NCT00002325|DRUG|Fluconazole|
219751689|NCT01400711|OTHER|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
219751690|NCT01400711|OTHER|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
219751691|NCT00066040|DRUG|Cervitec chlorhexidine varnish|
219751692|NCT00066040|DRUG|Duraphat fluoride varnish|
219751693|NCT00066040|DRUG|xylitol gum from Fennobon, Finland|
219751694|NCT01090596|DRUG|Naproxen|500mg naproxen, twice daily for 7 days
219751695|NCT01090596|DRUG|Placebo|1 tab,twice a day for a seven days
219751696|NCT01212900|DRUG|Statins, HMG CoA|Statin therapy
219751697|NCT01480687|DIETARY_SUPPLEMENT|DHA-EPA|1800 mg/day
219179822|NCT00554788|DRUG|Thiotepa|Given IV
219179823|NCT00554788|DRUG|Vincristine Sulfate|Given IV
219751698|NCT01480687|DRUG|Ciprofibrate|100 mg/day
219179824|NCT06578182|DRUG|Colchicine|Colchicine 0.5mg tablets once a day for 3 to 4.5 years
219751699|NCT01511133|PROCEDURE|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
219751700|NCT01511133|PROCEDURE|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
219751701|NCT02260037|DRUG|Epinastine nasal|
219751702|NCT02260037|DRUG|Placebo|
219751703|NCT04120467|OTHER|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
219179825|NCT06578182|DRUG|Placebo|Placebo tablets once a day for 3 to 4.5 years
219179826|NCT02702102|DRUG|11C-PBR28|Up to 20 millicuries
219179827|NCT05244486|DEVICE|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
219179828|NCT05244486|DEVICE|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
219179829|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
219751704|NCT04120467|OTHER|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
219751705|NCT01676233|DRUG|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
219751706|NCT01676233|DRUG|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
219751707|NCT00649584|DRUG|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
219751708|NCT00649584|DRUG|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
219751709|NCT05157360|DRUG|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
219751710|NCT05157360|DRUG|Placebo|normal saline solution
219751711|NCT06529432|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
219179830|NCT03272698|DRUG|Ketamine|IV Ketamine 0.50 mg/kg
219179831|NCT03272698|PROCEDURE|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
219179832|NCT04532047|DRUG|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
219179833|NCT05511909|DRUG|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
219751712|NCT06529432|DRUG|Bupivacaine Hydrochloride Injection|Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
219751713|NCT01168596|DRUG|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
219751714|NCT01168596|DRUG|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
219751715|NCT00794430|DRUG|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
219751716|NCT00794430|DRUG|Placebo|Capsule, bid, for 13 weeks
219751717|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
219751718|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
219751719|NCT00004200|DRUG|prinomastat|
219751720|NCT00004200|DRUG|temozolomide|
219751721|NCT00123630|DRUG|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
219751722|NCT00123630|DRUG|Placebo|Placebo given IV once every 2-4 weeks based on weight
219179834|NCT05511909|DRUG|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
219179835|NCT05511909|DRUG|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
219179836|NCT05829265|BEHAVIORAL|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
219751723|NCT06406933|DRUG|Carbomer Gel/Jelly|The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
219751724|NCT00318682|DEVICE|FIBROSCAN|diagnostic examination of the hepato fibrosis
219751725|NCT06247137|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal"
219751726|NCT06247137|OTHER|Placebo|"Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal."
219179837|NCT05852184|OTHER|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
219751727|NCT02297516|DRUG|Azzalure or Dysport|Glabellar lines
219751728|NCT02297516|DEVICE|Restylane or Emervel filler|Facial tissue augmentation
219751729|NCT02297516|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
219751730|NCT04781179|BEHAVIORAL|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
219751731|NCT04781179|BEHAVIORAL|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
219751732|NCT00371124|DRUG|Atropine Eye drops|
219751733|NCT06300775|DEVICE|modified hyrax|Appliance used for rapid maxillary expansion
219751734|NCT06300775|DEVICE|quad helix|device use for slow maxillary expansion
219751735|NCT01900366|PROCEDURE|Fat Biopsy|Fat biopsy
219751736|NCT01969734|DEVICE|Zephyr endobronchial valve placement|
219751737|NCT02965781|DRUG|SADBE|Topical solution
219751738|NCT02965781|OTHER|Placebo|Topical solution
219751739|NCT06486909|DIAGNOSTIC_TEST|Cerebrospinal Fluid (CSF) Sample|Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
219751740|NCT06486909|DIAGNOSTIC_TEST|Blood Serum Sample|Samples for glucose in blood serum will be completed every day, for the first 14 days.
219751741|NCT01175122|BIOLOGICAL|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
219751742|NCT00366457|DRUG|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
219751743|NCT00366457|DRUG|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
219751744|NCT00366457|DRUG|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
219751745|NCT01098747|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
219751746|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
219751747|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
219751748|NCT01098747|DRUG|Placebo|Single-dose of placebo
219751749|NCT06469983|DEVICE|ErigoBasic or ErigoPro®|Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
219751750|NCT06469983|BEHAVIORAL|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
219751751|NCT01876498|PROCEDURE|Xiaflex surgery|Xiaflex surgery
219751752|NCT02692196|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
219751753|NCT04868292|DRUG|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
219751754|NCT04983784|BEHAVIORAL|walking|walking for 12 weeks at home
219179838|NCT04818255|BEHAVIORAL|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
219751755|NCT04983784|OTHER|Routine care|Routine care
219751756|NCT00189423|DEVICE|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
219751757|NCT00189423|PROCEDURE|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
219751758|NCT01502384|OTHER|neurological examination|motor and cognitive functions
219751759|NCT04622592|BIOLOGICAL|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
219751760|NCT05026164|DIETARY_SUPPLEMENT|CHI-202|Blend of cannabinoids \& other ingredients
219751761|NCT05026164|DIETARY_SUPPLEMENT|CHI-101|Placebo
219751762|NCT06032130|OTHER|Clinical measurements|Optometric measurements
219751763|NCT06032130|OTHER|Oculomotor or perceptual therapy|Oculomotor or perceptual visual learning exercices
219751764|NCT00641693|DRUG|Budesonide|16mg Nasal Spray
219751765|NCT00641693|DRUG|Budesonide|32mg Nasal Spray
219751766|NCT00641693|DRUG|Budesonide|64mg Nasal Spray
219751767|NCT00641693|DRUG|Placebo|
219751768|NCT03901430|BEHAVIORAL|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
219751769|NCT02798887|PROCEDURE|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
219751770|NCT05542888|PROCEDURE|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
219751771|NCT05542888|PROCEDURE|Standard therapy|Postural education, Hot pack, Antenatal exercises
219751772|NCT00003249|DRUG|carboxyamidotriazole|
219179839|NCT05850546|DRUG|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
219179840|NCT05850546|DRUG|Corticosteroid|guideline-recommended corticosteroid therapy
219179841|NCT05915988|DEVICE|UNEEG EpiSight solution|Implantation subcutis under local anesthetics
219179842|NCT05463432|DRUG|HR19024|Intravenous infusion
219369503|NCT02509559|DEVICE|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
219751773|NCT00003249|DRUG|chemotherapy|
219751774|NCT00003249|DRUG|ketoconazole|
219751775|NCT03028701|DRUG|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
219751776|NCT05552404|OTHER|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
219751777|NCT05552404|DRUG|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
219751778|NCT05552404|PROCEDURE|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
219751779|NCT01518413|DRUG|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
219751780|NCT01518413|DRUG|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
219751781|NCT01871376|DRUG|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
219751782|NCT01681147|BEHAVIORAL|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
219751783|NCT01681147|BEHAVIORAL|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
219751784|NCT00183248|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
219751785|NCT00183248|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
219751786|NCT00183248|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
219751787|NCT00183248|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
219751788|NCT00183248|PROCEDURE|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
219751789|NCT00183248|PROCEDURE|Kidney transplant|Occurs at study entry
219751790|NCT01144650|DRUG|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
219751791|NCT01144650|DRUG|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
219751792|NCT03224884|PROCEDURE|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
219751793|NCT03224884|PROCEDURE|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
219751794|NCT03309202|DRUG|PF-05221304|25 mg dose
219751795|NCT05294887|DRUG|Bisoprolol|beta-adrenergic receptor blocker
219751796|NCT05294887|DRUG|Diltiazem|calcium channel blocker
219751797|NCT05294887|DRUG|Placebo|Placebo
219751798|NCT05228418|DRUG|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
219751799|NCT03970031|DRUG|MSDC-0602K|MSDC-0602K tablet
219751800|NCT03970031|DRUG|Placebo|Matching tablet
219751801|NCT00415636|DRUG|IC83/LY2603618|40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
219751802|NCT00415636|DRUG|IC83/LY2603618|70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
219179843|NCT06328647|DEVICE|POC Quantra QPlus System|The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
219751803|NCT00415636|DRUG|IC83/LY2603618|105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
219751804|NCT00415636|DRUG|IC83/LY2603618|150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
219751805|NCT00415636|DRUG|IC83/LY2603618|195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
219369504|NCT02509559|DEVICE|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
219751806|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
219751807|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
219751808|NCT04734210|DRUG|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
219751809|NCT04734210|DRUG|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
219369505|NCT02509559|DEVICE|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
219369506|NCT02509559|DEVICE|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
219751810|NCT04734210|DRUG|Placebo|topical vehicle solution
219751811|NCT00331721|DRUG|Enecadin|Dose escalating
219751812|NCT00331721|DRUG|Placebo|Placebo comparator
219751813|NCT03699202|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
219751814|NCT03699202|DRUG|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
219751815|NCT06458569|OTHER|Rehabilitation|3-weeks rehabilitation in hospital
219751816|NCT03369808|BIOLOGICAL|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
219751817|NCT03369808|BIOLOGICAL|Phosphate Buffer Solution|0.5ml phosphate buffer solution
219751818|NCT03369808|BIOLOGICAL|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
219751819|NCT03369808|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
219751820|NCT03369808|BIOLOGICAL|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
219751821|NCT01910454|BEHAVIORAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
219751822|NCT01910454|BEHAVIORAL|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
219751823|NCT01335607|DRUG|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
219751824|NCT01335607|DRUG|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
219751825|NCT01690273|OTHER|mobility exercise|30 minutes, twice a week
219751826|NCT01690273|OTHER|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
219751827|NCT05201807|DEVICE|Dailies Total 1 (DT1)|TEST Lens
219751828|NCT02683902|DEVICE|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
219751829|NCT02683902|BEHAVIORAL|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
219751830|NCT02683902|DEVICE|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
219751831|NCT00005978|BIOLOGICAL|filgrastim|
219751832|NCT00005978|DRUG|carboplatin|
219751833|NCT00005978|DRUG|etoposide|
219369507|NCT02509559|PROCEDURE|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
219369508|NCT04477226|DIAGNOSTIC_TEST|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
219369509|NCT03157531|DEVICE|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
219369510|NCT04024592|DEVICE|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
219751834|NCT00005978|DRUG|melphalan|
219751835|NCT00005978|PROCEDURE|autologous bone marrow transplantation|
219751836|NCT00005978|PROCEDURE|peripheral blood stem cell transplantation|
219751837|NCT00005978|RADIATION|iobenguane I 131|
219751838|NCT00005978|RADIATION|radiation therapy|
219751839|NCT04695990|DRUG|Wenyang Huoxue Decoction|Wenyang Huoxue granules
219751840|NCT04695990|DRUG|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
219751841|NCT01209767|DEVICE|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
219751842|NCT01209767|PROCEDURE|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
219751843|NCT01209767|OTHER|Control|
218992851|NCT04861389|PROCEDURE|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
218992852|NCT05125757|OTHER|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
218992853|NCT05125757|OTHER|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
218992854|NCT01369095|DRUG|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
218992855|NCT01369095|DRUG|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
218992856|NCT01369095|DRUG|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
218992857|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
218992858|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
218992859|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
218992860|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
218992861|NCT03504657|DEVICE|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
218992862|NCT03504657|DEVICE|stenting angioplasty|Angioplasty with a stenting
218992863|NCT02347280|PROCEDURE|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
219751844|NCT01702298|DRUG|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
219751845|NCT01702298|DRUG|Metformin|Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
219751846|NCT00400686|BIOLOGICAL|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
219751847|NCT05511948|DRUG|DBI-102|Topical application on dorsal hand and upper volar arm
219751848|NCT05511948|DRUG|Vehicle gel|Inactive comparator
219751849|NCT05511948|DRUG|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
219179844|NCT06328647|OTHER|Routine care|Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
219179845|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
219751850|NCT01141530|OTHER|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
219751851|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled|Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.
219751852|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous|Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
219751853|NCT04574336|PROCEDURE|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
219751854|NCT04574336|DEVICE|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
219751855|NCT01010464|PROCEDURE|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
219751856|NCT05619393|DEVICE|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
219751857|NCT01241630|PROCEDURE|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
219751858|NCT06186609|DRUG|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
219751859|NCT01912014|BEHAVIORAL|Psychosocial support and counselling|
219751860|NCT05749471|DIAGNOSTIC_TEST|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
219751861|NCT05439733|OTHER|Questionnaire completion|Women will be asked to complete questionnaires 6 weeks after delivery
219751862|NCT01775527|OTHER|blood test|
219751863|NCT00577369|OTHER|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
219369511|NCT05264350|DEVICE|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
219751864|NCT01041261|DIETARY_SUPPLEMENT|BariatrX Essentials 360 Treatment|Medical food
219751865|NCT01029535|DEVICE|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
219751866|NCT05168761|PROCEDURE|partial nephrectomy|
219751867|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
219751868|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
219751869|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
219751870|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
219751871|NCT04442009|OTHER|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219751872|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
219751873|NCT00573768|DRUG|Placebo|Vehicle 2 times daily
219751874|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
219751875|NCT01785030|DRUG|50% Nitrous oxide|
219751876|NCT04587492|DRUG|Nusinersen|Treatment with nusinersen
219751877|NCT04624984|DRUG|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
219751878|NCT04624984|DRUG|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
219179846|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
219179847|NCT06801509|BIOLOGICAL|Placebo control: Saline|The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;
219179848|NCT06801509|BIOLOGICAL|Shingrix®|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart
219751879|NCT04470414|DIAGNOSTIC_TEST|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
219751880|NCT05383261|OTHER|exercise|aerobic and resisted ex
219751881|NCT04541615|PROCEDURE|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
219751882|NCT04541615|PROCEDURE|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
219751883|NCT04541615|PROCEDURE|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
219751884|NCT04541615|PROCEDURE|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
219751885|NCT04703140|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
219751886|NCT01239940|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
219751887|NCT01239940|DEVICE|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
219751888|NCT06489002|OTHER|Implementation Support|Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
219751889|NCT03839914|DRUG|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
219179849|NCT06801509|BIOLOGICAL|Ganwei®|Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60；
219369512|NCT05264350|DEVICE|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
219369513|NCT02718859|BIOLOGICAL|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
219751890|NCT00735150|BEHAVIORAL|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
219751891|NCT06227949|DRUG|Luveris|Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
219751892|NCT06157034|OTHER|Placebo|Inert Material
219751893|NCT06157034|DIETARY_SUPPLEMENT|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
219751894|NCT06157034|DIETARY_SUPPLEMENT|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
219751895|NCT06157034|DIETARY_SUPPLEMENT|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
219751896|NCT03181191|OTHER|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
219179850|NCT04824235|OTHER|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
219179851|NCT04824235|OTHER|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
219179852|NCT06554093|DEVICE|Medical Device - PKS|The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
219179853|NCT06242028|DRUG|Group P|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
219369514|NCT02718859|PROCEDURE|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
219179854|NCT06242028|DRUG|Group S|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
219179855|NCT05805865|DRUG|Toothpaste Tablet|Colgate Anywhere Toothpaste Tablets
219179856|NCT05805865|DRUG|Conventional Toothpaste|Colgate Cavity Protection
219369515|NCT00109473|DRUG|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
219369516|NCT00109473|DRUG|cortecosteroid|As prescribed by the referring gastroenterologist
219369517|NCT02937805|DEVICE|Moisturizing vaginal and vulvar sea buckthorn oil cream|
219369518|NCT02937805|DEVICE|Moisturizing vaginal and vulvar cream|
219751897|NCT05109741|BEHAVIORAL|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
219751898|NCT05109741|BEHAVIORAL|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
219751899|NCT02862093|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
219751900|NCT04037215|OTHER|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
219751901|NCT00970398|OTHER|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
219751902|NCT00970398|OTHER|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
219751903|NCT01508364|DRUG|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
219751904|NCT01018602|DRUG|vildagliptin|100 mg per day over 24 months
219751905|NCT01018602|DRUG|inactive pill|1 pill per day over 24 months
219751906|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
219751907|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
219751908|NCT04722666|DRUG|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
219751909|NCT04722666|DRUG|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
219751910|NCT06456840|DIAGNOSTIC_TEST|ULTRASOUND|Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
219751911|NCT01006733|GENETIC|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
219751912|NCT01006733|DRUG|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
219751913|NCT01741129|DEVICE|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
219751914|NCT01741129|DEVICE|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
219751915|NCT01137890|DRUG|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
219751916|NCT01137890|DRUG|Placebo|capsules administered in split doses at 22:00 and 09:00.
219751917|NCT01137890|DRUG|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
219751918|NCT01137890|BEHAVIORAL|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
219751919|NCT01137890|BEHAVIORAL|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
219751920|NCT00583219|DRUG|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
219751921|NCT00583219|DRUG|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
219751922|NCT04046640|DEVICE|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
219751923|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
219369519|NCT03870841|DRUG|PC945|PC945, nebulized
218992864|NCT02347280|PROCEDURE|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
218992865|NCT00459628|RADIATION|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
218992866|NCT00459628|RADIATION|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
219751924|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
219179857|NCT05393882|RADIATION|Computed tomography coronary angiogram|"Preparation~* Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~* Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~* 18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~* Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~* Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~* Scanning coverage: From the thoracic inlet to diaphragm"
219179858|NCT02719314|DRUG|Glucocorticoid treatment|Glucocorticoid treatment
219179859|NCT05978180|DEVICE|Medical Device : HO-1|The injection will be performed at Day 1.
219179860|NCT05978180|DEVICE|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
219179861|NCT05978180|DEVICE|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
219179862|NCT04742205|DRUG|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
219179863|NCT06801925|PROCEDURE|GPT-4o and RAG Voice Chatbot for PHQ-9 Screening|"This study involves the use of a voice-based chatbot powered by GPT-4o and Retrieval-Augmented Generation (RAG) to conduct depression screening using the Patient Health Questionnaire-9 (PHQ-9).~The chatbot aims to evaluate the feasibility and acceptability of using AI-powered conversational tools for mental health screening.~Participants interact with the chatbot in a single session, answering PHQ-9 questions and receiving responses generated using GPT-4o and RAG technologies."
219179864|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
219179865|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
219179866|NCT06224725|OTHER|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
219179867|NCT06800417|DEVICE|Percutaneous fixation by internal cemented screw (InnoFix®)|Percutaneous fixation by internal cemented screw
219179868|NCT03274310|BEHAVIORAL|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
219179869|NCT05664477|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
219179870|NCT05664477|DRUG|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
219751925|NCT06642012|OTHER|Cash only|Households received 1 mobile cash transfer per month for 6 months.
219179871|NCT00817219|DRUG|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
219179872|NCT04289870|DEVICE|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
219179873|NCT03197571|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219179874|NCT03197571|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
219751926|NCT06642012|OTHER|Cash + Social Behavior Change Communication|Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
219179875|NCT03197571|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219179876|NCT03197571|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219179877|NCT03197571|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219179878|NCT03197571|DRUG|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219179879|NCT03197571|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
219179880|NCT03197571|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219179881|NCT03197571|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219179882|NCT03197571|DRUG|Lovaza|Omega-3-acid ethyl esters
219179883|NCT03197571|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
219179884|NCT03197571|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
219179885|NCT03197571|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
219179886|NCT03197571|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
219179887|NCT03197571|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219179888|NCT03197571|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
219179889|NCT03197571|BIOLOGICAL|GI-4000|RAS yeast vaccine
219179890|NCT03197571|BIOLOGICAL|GI-6207|CEA yeast vaccine
219751927|NCT06642012|OTHER|Cash + top-up cash|Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
219751928|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
219751929|NCT02090764|DRUG|Ozenoxacin|
219751930|NCT02090764|DRUG|Placebo|
219751931|NCT01598155|PROCEDURE|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
219751932|NCT01598155|PROCEDURE|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
219751933|NCT02384421|DEVICE|Adaptive DBS (Activa PC+S Neurostimulator)|
219751934|NCT02384421|DEVICE|Continuous DBS (Activa PC+S Neurostimulator)|
219751935|NCT05533840|DIAGNOSTIC_TEST|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
219751936|NCT02146157|DIETARY_SUPPLEMENT|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
219179891|NCT03197571|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219751937|NCT02146157|DIETARY_SUPPLEMENT|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
219751938|NCT02264314|BEHAVIORAL|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
219179892|NCT03197571|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
219179893|NCT06800703|BEHAVIORAL|follow up interviews for 12 months to determine opioid use|Follow-up
219179894|NCT06801483|OTHER|Strengthening|All subjects will recieve an ankle muscle strenghening training program twice a week for six weeks.
219179895|NCT05191472|BIOLOGICAL|Pembrolizumab|Given IV
219751939|NCT02264314|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
219179896|NCT02132936|DRUG|LEO 90100 aerosol foam|
219751940|NCT05769114|PROCEDURE|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
219751941|NCT00173719|DEVICE|Standard cane|
219751942|NCT03586531|PROCEDURE|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
219751943|NCT00998010|DRUG|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
219751944|NCT04485702|DRUG|Midazolam injection|2mg IV
219751945|NCT04485702|DRUG|Ketamine Injectable Product|6mg IV
219751946|NCT04485702|DRUG|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
219751947|NCT06387381|DRUG|68Ga-PSFA|Each subject receives a single intravenous injection of 68Ga-PSFA.
219751948|NCT04259593|OTHER|exercise training|
219751949|NCT01707537|BIOLOGICAL|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
219751950|NCT03274765|DIAGNOSTIC_TEST|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
219751951|NCT00982384|OTHER|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
219751952|NCT00982384|OTHER|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
219751953|NCT00529048|OTHER|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
219751954|NCT00529048|OTHER|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
219179897|NCT02132936|DRUG|Aerosol foam vehicle|
219179898|NCT02132936|DRUG|Calcipotriol BDP gel|
219179899|NCT02132936|DRUG|Gel vehicle|
219179900|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
219179901|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
219179902|NCT05538338|OTHER|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
219179903|NCT05538338|OTHER|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
219179904|NCT02561585|DRUG|LEO 124249|
219179905|NCT02561585|OTHER|Vehicle|
219179906|NCT06523595|DRUG|VX-993|Suspension for Oral Administration.
219179907|NCT06523595|DRUG|Metformin|Tablets for Oral Administration.
219179908|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
219179909|NCT03622749|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
219179910|NCT04947449|DEVICE|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
219179911|NCT06524310|DEVICE|Stimulation with low frequency rTMS at 1 Hz|Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
219179912|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
219179913|NCT05910164|DEVICE|PELGRAZ prefilled syringe or PELGRAZ prefilled pen|PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
219179914|NCT06009458|DEVICE|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
219179915|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
219179916|NCT05976139|DEVICE|subthreshold treatment with micropulsed laser|"The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~* Power: 5% Duty Cycle~* Power 250 mw~* Pulse duration 200 ms~* Spot size 100 micron~* Pattern spacing 0.0 confluente, griglie 7x7"
219179917|NCT03134196|DRUG|Masked Placebo|Oral Placebo
219179918|NCT03134196|DRUG|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
219179919|NCT06531421|OTHER|Equity Report Cards|At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
219179920|NCT06416111|DEVICE|NIRS|Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
219179921|NCT06416111|OTHER|Pinprick Test|"With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling"
219179922|NCT06416111|OTHER|Modified Bromage Scale|"Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers."
219179923|NCT06416111|DRUG|Bupivacaine|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
219179924|NCT06416111|DRUG|Prilocaine|Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
219179925|NCT05564611|DRUG|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
219179926|NCT02648997|DRUG|Nivolumab - 240 mg|240 mg every 2 weeks
219179927|NCT02648997|DRUG|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
219179928|NCT02648997|DRUG|Nivolumab - 480 mg|480 mg once every 4 weeks
219179929|NCT02648997|DRUG|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
219179930|NCT02648997|RADIATION|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
219179931|NCT05513716|OTHER|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
219179932|NCT06206291|DRUG|Placebo|Matching placebo twice daily for first 4 weeks
219179933|NCT06206291|DRUG|Cannabidiol (CBD) 200mg|First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
219179934|NCT06206291|DRUG|Cannabidiol (CBD) 400mg|Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
219179935|NCT05456360|DEVICE|ViSi Mobile device|Participants will wear the device on your wrist like a watch, and it will continuously (non-stop) monitor your pulse, blood pressure, temperature, breathing rate, heart rate, and pulse rate
219751955|NCT00529048|OTHER|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
219179936|NCT05456360|DRUG|Sleep enhancement intervention|Participants will receive a medication administration will be limited to before bedtime.
219179937|NCT05857384|DRUG|IHL42X|IHL-42X consists of acetazolamide and dronabinol.
219179938|NCT05857384|DRUG|Acetazolamide 250 MG|A solid tablet containing 250 mg acetazolamide
219179939|NCT05857384|DRUG|Dronabinol 2.5 MG|A soft gelatin capsules containing 2.5mg dronabinol
219179940|NCT00819546|DRUG|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
219179941|NCT00819546|DRUG|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
219179942|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
219179943|NCT05660798|BEHAVIORAL|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
219751956|NCT03758807|OTHER|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
219751957|NCT03758807|OTHER|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
219751958|NCT00833690|DRUG|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
219751959|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
219751960|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
219751961|NCT01220661|DRUG|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
219751962|NCT06250829|OTHER|Observational|Observational study of body composition, cytokine profile, immune status, ctDNA, serial radiology.
219179944|NCT05888870|DRUG|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
219179945|NCT05888870|DRUG|SCT800|SCT800 50IU/kg TIW alone
219179946|NCT03992755|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
219751963|NCT04679454|RADIATION|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
219179947|NCT04719390|BEHAVIORAL|Text Message|"Maternal-Focused Message: When randomized to receive a maternal-focused message, participants will receive a message that is focused on the transition to motherhood and the joys and challenges of caring for a newborn.~Drinking-Focused Message:~When randomized to receive a drinking-focused message, participants will receive a message that is focused on reducing alcohol use.~All messages of both types are designed to map onto behavior change techniques that are empirically supported for alcohol use."
219179948|NCT05715463|OTHER|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
219179949|NCT05715463|OTHER|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
219751964|NCT04679454|RADIATION|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
219751965|NCT01486303|PROCEDURE|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
219751966|NCT02236910|OTHER|Lu-DOTA-TATE|
219751967|NCT04128748|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219751968|NCT04128748|DRUG|Quizartinib|Given PO
219751969|NCT04306926|DRUG|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
219751970|NCT04306926|RADIATION|SBRT|Give according to the location of the lesion and clinical condition.
219751971|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
219751972|NCT06197243|OTHER|Acupuncture|Patients will receive acupuncture for 12 weeks.
219751973|NCT06197243|OTHER|Yoga|Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.
219751974|NCT06197243|OTHER|Deprescribing|Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
219751975|NCT06353906|DRUG|Carboplatin/Paclitaxel|Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
219179950|NCT05715463|OTHER|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
219179951|NCT00753545|DRUG|AZD2281|Tablets Oral BID
219179952|NCT00753545|DRUG|matching placebo|matching placebo bid
219179953|NCT06799442|PROCEDURE|Erector Spinae Plane Block|Patients will be placed in lateral position with the surgical site upward. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. An echogenic needle needle will be inserted using an in-plane approach and craniocaudally direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.
219179954|NCT06799442|DRUG|Dexmedetomidine|50 mic dexmedetomidine which is diluted to 2ml.
219179955|NCT06799442|DRUG|fentanyl|100 mic fentanylwhich is also diluted to 2 ml.
219179956|NCT06190691|DRUG|Pirtobrutinib|Administered orally
219179957|NCT06382155|DRUG|Vosoritide Injection|Experimental Drug Lyophilized powder for reconstitution
219179958|NCT06382155|DRUG|Human Growth Hormone|Commercial product containing somatotropin
219179959|NCT06382155|DRUG|Placebo|Lyophilized powder for reconstitution
219179960|NCT06793137|DRUG|Metronidazole|This intervention involves administering the oral antibiotic metronidazole during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma who are undergoing total neoadjuvant treatment. Metronidazole is considered a safe medication, with a very low risk of adverse effects. It is commonly used to treat infections caused by anaerobic bacteria that are part of the intestinal microbiota. Additionally, it is well established that certain genera of anaerobic bacteria are linked to a poorer response to treatment.
219179961|NCT04290546|DRUG|Interleukin-15 Superagonist (N-803)|"\-- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight."
219179962|NCT04290546|BIOLOGICAL|CIML NK cell Infusion|(Dose 0 or -1) infused on Day 0
219179963|NCT04290546|DRUG|Ipilimumab|single dose of lead-in ipilimumab via iv per protocol determined dose
219179964|NCT04290546|DRUG|Cetuximab|Starting day +15, every 14 days for 8 total doses via IV per protocol
219179965|NCT05746455|BEHAVIORAL|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
219179966|NCT05822414|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
219179967|NCT04840797|DEVICE|HeartStart HS1|Automated External Defibrillator
219751976|NCT06353906|DRUG|Pembrolizumab|"Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery"
219751977|NCT06353906|PROCEDURE|Partial or total penectomy with inguinal and/or pelvic lymph node dissection|Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
219751978|NCT05490225|DEVICE|VenaSure|The device will be surgically implanted at the access site in subjects undergoing routine hemodialysis. The device is expected to provide a target to aid in long-term cannulation success.
219751979|NCT06848413|OTHER|Arabic education video intervention based on the Positive Education about Aging and Contact Experiences (PEACE)|This video is designed based on the Positive Education about Aging and Contact Experiences (PEACE), which is suitable for professional medical that is Arabic speaker only.
219751980|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
219751981|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
219179968|NCT04869449|DRUG|Ketoconazole|400 mg (two 200 mg tablets) orally
219751982|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
219751983|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
219751984|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
219751985|NCT05700643|DIETARY_SUPPLEMENT|Montmorency cherry supplement|Montmorency cherry supplement
219751986|NCT05700643|DIETARY_SUPPLEMENT|Control|Placebo
219751987|NCT06067854|PROCEDURE|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
219751988|NCT06067854|PROCEDURE|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
219751989|NCT05448950|DEVICE|VIG Continued Access Study|Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
219751990|NCT04533750|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219751991|NCT04533750|OTHER|Fludeoxyglucose F-18|Given IV
219751992|NCT04533750|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219751993|NCT04533750|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219751994|NCT04533750|DRUG|Peposertib|Given PO
219751995|NCT04533750|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219751996|NCT05327257|DEVICE|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
219751997|NCT06640738|DRUG|arm 2|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
219751998|NCT06640738|DRUG|arm 1|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
219751999|NCT06096337|DEVICE|FARAPULSE™ Pulsed Field Ablation (PFA) System|Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.
219752000|NCT06096337|DRUG|Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone|Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
219752001|NCT06645314|BIOLOGICAL|Group A|3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
219752002|NCT06645314|BIOLOGICAL|Group B|3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
219752003|NCT06645431|BEHAVIORAL|Water Intake|Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
219752004|NCT04914845|DRUG|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
219752005|NCT02836249|DRUG|TAF|TAF 25 mg tablet administered orally once daily
219179969|NCT05231187|DIAGNOSTIC_TEST|T2Resistance Panel|"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)"
219752006|NCT02836249|DRUG|TDF|TDF 300 mg tablet administered orally once daily
219752007|NCT02836249|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
219752008|NCT02836249|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
219752009|NCT06245863|DEVICE|Negative pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
219752010|NCT06245863|DEVICE|Positive Pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
219752011|NCT06245863|DEVICE|Ultrasound and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
219179970|NCT05575505|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
219179971|NCT05130762|DEVICE|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
219179972|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
219752012|NCT06245863|DEVICE|Laser|Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
219179973|NCT05640115|DEVICE|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
219752013|NCT06245863|DEVICE|Placebo Laser|Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
219752014|NCT03681145|BEHAVIORAL|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
219752015|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
219752016|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
219752017|NCT00750399|DRUG|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
219752018|NCT00750399|DRUG|ranibizumab|intravitreal ranibizumab 0.5 mg
219752019|NCT05921786|DEVICE|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
219752020|NCT05921786|DEVICE|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
219752021|NCT00283166|BEHAVIORAL|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
219752022|NCT05933811|PROCEDURE|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
219752023|NCT05878704|DRUG|GBT021601|Oral
219752024|NCT01786122|OTHER|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
219752025|NCT01786122|BEHAVIORAL|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
219752026|NCT05443828|OTHER|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
219752027|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
219752028|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
219752029|NCT05291533|OTHER|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
219752030|NCT04157335|BIOLOGICAL|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).~For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE."
219752031|NCT04157335|BIOLOGICAL|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
219752032|NCT05971407|DEVICE|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
219752033|NCT05971407|DEVICE|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
219179974|NCT05640115|DEVICE|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
219752034|NCT03465774|DRUG|Doxycycline|Receive via IPC
219752035|NCT03465774|DEVICE|Indwelling Catheter|Receive IPC
219752036|NCT03465774|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219752037|NCT03465774|OTHER|Questionnaire Administration|Ancillary studies
219752038|NCT03465774|OTHER|Survey Administration|Ancillary studies
219752039|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
219752040|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
219752041|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
219179975|NCT02485938|DRUG|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
219179976|NCT05571865|DIETARY_SUPPLEMENT|Probiotic|Oral administration of a probiotic
219752042|NCT05610163|DRUG|Capecitabine|Given PO
219752043|NCT05610163|DRUG|5-fluorouracil|Given IV
219179977|NCT05979974|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
219179978|NCT05979974|OTHER|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
219752044|NCT05610163|DRUG|Leucovorin calcium|Given IV
219752045|NCT05610163|DRUG|Irinotecan|Given IV
219752046|NCT05610163|DRUG|Oxaliplatin|Given IV
219752047|NCT05610163|RADIATION|Long Course Chemoradiotherapy|Receive LCRT
219752048|NCT05610163|PROCEDURE|Computed Tomography|undergo CT
219752049|NCT05610163|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
219752050|NCT05610163|PROCEDURE|Sigmoidoscopy|undergo sigmoidoscopy
219752051|NCT05610163|PROCEDURE|biopsy|undergo biopsy
219752052|NCT06412120|DRUG|Niraparib|Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
219752053|NCT05867251|DRUG|AVZO-021|AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
219752054|NCT05867251|DRUG|Palbociclib|Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
219752055|NCT05867251|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
219752056|NCT05867251|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
219752057|NCT05867251|DRUG|Ribociclib|Antineoplastic CDK4/6 inhibitor
219179979|NCT05979974|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
219179980|NCT05743868|BEHAVIORAL|Standardized Dinner|De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
219752058|NCT05867251|DRUG|Abemaciclib|Antineoplastic CDK4/6 inhibitor
219752059|NCT05867251|DRUG|Carboplatin|Alkylating agent
219752060|NCT05867251|DRUG|Sacituzumab Govitecan-hziy|Trop-2 antibody and topoisomerase inhibitor
219179981|NCT05743868|BEHAVIORAL|Premeal exercise|DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
219179982|NCT06799182|PROCEDURE|periodontal treatment|Based on the results of the dental examination and the diagnosis of the periodontal tissue condition according to the new classification of periodontal disease, we performed appropriate non-surgical treatment of periodontal disease, provided oral hygiene instruction, and took a biofilm sample from the deep periodontal pocket. We then collected a sample of the altered mucosa during bowel surgery for colorectal cancer and conducted a microbiological investigation using quantitative culture to compare the presence of Fusobacterium nucleatum and Porphyromonas gingivalis in the pariodontal pocket and altered intestinal mucosa.
219752063|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
219752064|NCT04983394|OTHER|conventional exercises|aerobic, strength, stretching, and neuromuscular exercises
219752065|NCT03270982|DEVICE|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
219752066|NCT02958865|DRUG|PF-06651600 or Placebo|Delivered orally for 8 weeks.
219752067|NCT02958865|DRUG|PF-06700841 or Placebo|Delivered orally for 8 weeks.
219752068|NCT02958865|DRUG|PF-06700841|Delivered orally for 24 weeks.
219752069|NCT02958865|DRUG|PF-06651600|Delivered orally for 24 weeks.
219752070|NCT02661815|DRUG|Paclitaxel|Please see arm/group description.
219752071|NCT02661815|DRUG|Ricolinostat|Please see arm/group description.
219752072|NCT02661815|DRUG|Bevacizumab|Please see arm/group description.
219752073|NCT00989495|DEVICE|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
219752074|NCT03591159|OTHER|Membran Sweeping|Cervical Membrane Sweeping by digital examination
219752075|NCT00374179|DRUG|CT-322|IV solution, weekly or bi-weekly
219752076|NCT02247921|OTHER|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
219752077|NCT03209258|OTHER|Care bundle of active management|"1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
219752078|NCT03209258|OTHER|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
219179983|NCT04585594|BEHAVIORAL|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
219179984|NCT04585594|BEHAVIORAL|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
219179985|NCT02807129|BIOLOGICAL|blood withdrawn|
219179986|NCT02807129|BIOLOGICAL|urine collection|
219179987|NCT06259227|OTHER|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
219179988|NCT06635538|DRUG|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
219179989|NCT06635538|DRUG|Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
219179990|NCT06635538|DIAGNOSTIC_TEST|Monitoring cycle|Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
219179991|NCT03477968|DIAGNOSTIC_TEST|DDimer test|Measuring the level of DDimer in blood sample
219179992|NCT04961619|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
219179993|NCT04961619|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
219179994|NCT06636344|OTHER|Pseudoxanthoma Elasticum|Answer to the PSQ-18, patient care confidence score (likert scale) and SF-12 questionaries at each visit, for an estimated duration of 15 minutes.
219179995|NCT04704648|PROCEDURE|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
219179996|NCT06635226|DRUG|ID110521156|ID110521156 capsules taken orally once daily
219179997|NCT06635226|DRUG|Placebo of 110521156|ID110521156 placebo capsules taken orally once daily
219179998|NCT05697302|BEHAVIORAL|Education|Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
219179999|NCT05697302|BEHAVIORAL|Follow-up|Among the data collection forms, LATCH-Breastfeeding Diagnostic Scale and IMDAT-The Baby's Breastmilk Scoring System will be applied at each interview, and the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale will be applied at the first interview, at the end of the 1st month and at the end of the 2nd month. Mother interviews will be held in their homes or at the Family Health Center (whichever they prefer). At each meeting, an appointment schedule will be made for the next meeting and this information will be shared with the mothers in writing.
219180000|NCT05697302|BEHAVIORAL|Referral to Lactation and Relactation Polyclinic|Due to the nature of the research, mothers in the control group will not be given any training, and they will be referred to the Lactation and Relaxation Polyclinic in Erzincan Mengücek Gazi Training and Research Hospital.
219369520|NCT04236544|BEHAVIORAL|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
219369521|NCT04236544|BEHAVIORAL|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
219369522|NCT05679414|DIAGNOSTIC_TEST|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
219369523|NCT00047346|DRUG|erlotinib hydrochloride|Given PO
219369524|NCT00047346|OTHER|pharmacological study|Correlative studies
219369525|NCT00047346|OTHER|laboratory biomarker analysis|Correlative studies
219369526|NCT00379327|PROCEDURE|Acupuncture|Acupuncture administered in last three weeks of pregnancy
219369527|NCT00379327|DEVICE|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
219369528|NCT02544555|PROCEDURE|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
219577730|NCT04952532|OTHER|Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)|The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
219577731|NCT00534794|DRUG|Elestat|Elestat BID for 2 days
219577732|NCT00534794|DRUG|Pataday|Pataday QD for 2 days
219577733|NCT03922074|PROCEDURE|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
219577734|NCT03922074|PROCEDURE|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
219577735|NCT01401257|DRUG|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
219577736|NCT01401257|DRUG|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
219577737|NCT01401257|DRUG|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
219577738|NCT01401257|OTHER|Placebo|Liquid,5 ml, twice a day, 12-month treatment
219577739|NCT04323020|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
219577740|NCT06105320|OTHER|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
219577741|NCT06105320|OTHER|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
219577742|NCT02217631|DRUG|BI 653048 BS H3PO4|
219577743|NCT02217631|DRUG|Prednisolone low dose|
219577744|NCT02217631|DRUG|Prednisolone high dose|
219577745|NCT02217631|DRUG|Placebo|
219577746|NCT02413931|OTHER|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
219577747|NCT01918631|DRUG|tenofovir disoproxil fumarate|
219577748|NCT01918631|DRUG|Entecavir|
219577749|NCT04873531|DRUG|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
219577750|NCT04873531|DRUG|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
219577751|NCT00112346|DRUG|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
219577752|NCT00112346|DRUG|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
219752079|NCT04198012|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
219752080|NCT04869397|BIOLOGICAL|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
219752081|NCT04869397|OTHER|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
219752082|NCT01417767|DRUG|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
219752083|NCT01417767|DRUG|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
219752084|NCT04743232|OTHER|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
219180001|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
219180002|NCT05882292|DRUG|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
219180003|NCT06334965|OTHER|Simultaneous 18F-Choline PET-MRI|before first TARE administration (after work-up procedure) and one month after TARE administration
219180004|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
219369529|NCT02544555|PROCEDURE|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
219369530|NCT02649101|DRUG|Thalidomide|Thalidomide tablet 100mg qn po.
219369531|NCT02649101|DRUG|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
219369532|NCT01371461|DRUG|Paroxetine|
219752085|NCT05112640|DEVICE|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
219752086|NCT05112640|DEVICE|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
219752087|NCT06412666|DRUG|Aficamten|Oral Tablet
219752088|NCT06412666|DRUG|Placebo|Oral Tablet
219752089|NCT05068583|OTHER|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
219752090|NCT02102945|PROCEDURE|Computed tomography perfusion|Computed tomography perfusion of the head
219752091|NCT02527512|DRUG|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
219752092|NCT02527512|OTHER|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
219752093|NCT02340195|DRUG|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
219752094|NCT05005533|OTHER|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
219752095|NCT06206590|OTHER|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
219752096|NCT00189475|DRUG|Montelukast|
219752097|NCT00189475|DRUG|Placebo|
219752098|NCT00244985|BIOLOGICAL|rituximab|IV
219752099|NCT00244985|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
219752100|NCT02329587|OTHER|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
219752101|NCT02329587|OTHER|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
219752102|NCT03005002|BIOLOGICAL|Durvalumab|Given IV
219752103|NCT03005002|OTHER|Laboratory Biomarker Analysis|Correlative studies
219752104|NCT03005002|BIOLOGICAL|Tremelimumab|Given IV
219752105|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement with a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
219752106|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement without a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
219752107|NCT05293262|PROCEDURE|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
219752108|NCT02010268|OTHER|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
219752109|NCT04078243|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
219752110|NCT01728246|DRUG|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
219752111|NCT01728246|DRUG|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
219752112|NCT00773188|DRUG|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
219752113|NCT00773188|DRUG|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
219752114|NCT00773188|DRUG|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
219752115|NCT00502918|DEVICE|CLM - HA Continuous Monitoring System Heart Application|
219752116|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
219752117|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
219752118|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
219752119|NCT04747041|COMBINATION_PRODUCT|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
219180005|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 1 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
219752120|NCT05708859|DRUG|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
219752121|NCT05708859|DRUG|Placebo|Volume matched Subcutaneous Solution
219752122|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
219752123|NCT06317935|OTHER|Traditional Rehabilitation|It includes traditional occupational therapy and physiotherapy approaches.
219752124|NCT04440774|BIOLOGICAL|CHIK low dose|A single dose of 5x10\^9 vp ChAdOx1 Chik
219752125|NCT04440774|BIOLOGICAL|CHIK mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Chik
219752126|NCT04440774|BIOLOGICAL|CHIK high dose|A single dose of 5x10\^10 vp ChAdOx1 Chik
218992867|NCT00764738|DEVICE|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
218992868|NCT00764738|DRUG|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
218992869|NCT02968771|OTHER|Non intervention|
219180006|NCT06451159|DRUG|Chemotherapy: cyclophosphamide (CYC)|Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
219752127|NCT04440774|BIOLOGICAL|ZIKA low dose|A single dose of 5x10\^9 vp ChAdOx1 Zika
219752128|NCT04440774|BIOLOGICAL|ZIKA mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Zika
219752129|NCT04440774|BIOLOGICAL|ZIKA high dose|A single dose of 5x10\^10 vp ChAdOx1 Zika
219752130|NCT04440774|BIOLOGICAL|Saline placebo|A single dose of isotonic saline solution (0.9%)
219752131|NCT02918448|OTHER|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
219752132|NCT05703230|OTHER|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
219752133|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
219752134|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
219752135|NCT06570122|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
219752136|NCT06570122|OTHER|Health warning leaflet|The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
219752137|NCT06570122|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
219752138|NCT02244515|DRUG|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
219752139|NCT01983111|DRUG|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
219752140|NCT01983111|DRUG|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
219752141|NCT01985789|DRUG|Diphenhydramine|
219752142|NCT01985789|DRUG|cetirizine|
219752143|NCT01985789|DRUG|desloratadine|
219752144|NCT01985789|DRUG|placebo|
219752145|NCT01777061|DRUG|[11C]Acetate|intravenous injection of an average of 40 mCi of \[11C\]Acetate
219752146|NCT00855335|DRUG|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
219752147|NCT00855335|DRUG|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
219752148|NCT00855335|DRUG|Etravirine|200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
219752149|NCT00855335|DRUG|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
219752150|NCT00855335|DRUG|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
219752151|NCT03502200|DEVICE|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
219752152|NCT03502200|OTHER|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
219752153|NCT06048029|PROCEDURE|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
218992870|NCT04466020|OTHER|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
218992871|NCT04188782|DRUG|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
219369533|NCT02673229|DRUG|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
219752154|NCT04627714|OTHER|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
219752155|NCT05903534|OTHER|Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
219752156|NCT05903534|OTHER|Lower Limb Strength Training Group|Lower Limb Strength Training Group
219752157|NCT05284578|OTHER|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
219752158|NCT05284578|OTHER|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
219752159|NCT05284578|OTHER|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
219752160|NCT02661750|DRUG|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
219752161|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
219752162|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
219752163|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
219752164|NCT05095922|DRUG|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
219752165|NCT05095922|DRUG|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
219752166|NCT05095922|DRUG|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
219752167|NCT00823173|BIOLOGICAL|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
219752168|NCT05132972|BIOLOGICAL|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
219752169|NCT05132972|OTHER|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
219752170|NCT02259595|DRUG|HPN-07|500-1,500 mg oral capsules administered in a single dose
219752171|NCT02259595|DRUG|NAC|1,200mg NAC administered via oral capsule in single dose
219752172|NCT02259595|DRUG|Placebo|placebo oral capsule
219180007|NCT06451159|DRUG|Chemotherapy: fludarabine (FLU)|Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
219180008|NCT03524183|BEHAVIORAL|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
219180009|NCT05335850|BEHAVIORAL|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
219752173|NCT04264000|DRUG|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
219752174|NCT04264000|DRUG|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
219180010|NCT05335850|BEHAVIORAL|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
219180011|NCT05335850|BEHAVIORAL|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
219180012|NCT05335850|OTHER|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
219180013|NCT03016754|DEVICE|Wearable Cardioverter Defibrillator|LifeVest is the brand of Wearable Cardioverter Defibrillator used in this study.
219180014|NCT03671629|OTHER|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
219180015|NCT03839940|DRUG|Dexamethasone|Given as mouthwash
219180016|NCT03839940|OTHER|Placebo|Given as mouthwash
219180017|NCT03839940|OTHER|Questionnaire|Ancillary studies
219752175|NCT04928378|OTHER|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
219180018|NCT03839940|OTHER|Quality-of-Life Assessment|Ancillary studies
219180019|NCT03839940|DRUG|Everolimus|Standard of care
219752176|NCT00831883|BEHAVIORAL|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
219752177|NCT00831883|BEHAVIORAL|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
219752178|NCT03624075|OTHER|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
219180020|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
219180021|NCT06086886|OTHER|Placebo|Specified dose on specified days
219180022|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
219180023|NCT02103725|DRUG|Vehicle cream|
219180024|NCT04599192|OTHER|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
219180025|NCT04340596|BIOLOGICAL|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
219180026|NCT04340596|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
219180027|NCT04340596|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
219180028|NCT03241745|DRUG|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
219752179|NCT00925574|DRUG|CNTO 1959; Placebo|
219752180|NCT00918619|DEVICE|Sangustop|Application of Sangustop haemostatic agent on resection area
218992872|NCT01203098|DRUG|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
218992873|NCT01203098|DRUG|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
218992874|NCT01203098|DRUG|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
218992875|NCT02650856|DRUG|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
219180029|NCT03180216|BIOLOGICAL|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
219180030|NCT03367299|DRUG|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
219180031|NCT06502717|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219369534|NCT02673229|DRUG|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
219752181|NCT00918619|DRUG|Tachosil|Application of Tachosil fibrin sealant on resection area
219369535|NCT04212000|DRUG|Levoketoconazole|Levoketoconazole tablet
219752182|NCT03464825|OTHER|Specific and progressive balance training|Specific and progressive balance training for the intervention group
219752183|NCT00179686|DRUG|CC-5013|
219752184|NCT04247438|OTHER|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
219752185|NCT05321290|OTHER|Robotic Therapy Program|
219752186|NCT03860987|DRUG|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
219752187|NCT03860987|DRUG|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
219752188|NCT03860987|DRUG|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
219752189|NCT03860987|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
219752190|NCT03860987|DRUG|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
219752191|NCT03860987|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
219752192|NCT02109276|DEVICE|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
219752193|NCT02109276|DEVICE|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
219752194|NCT02706392|OTHER|Laboratory Biomarker Analysis|Correlative studies
219752195|NCT02706392|BIOLOGICAL|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
219752196|NCT02897336|PROCEDURE|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
219752197|NCT02897336|PROCEDURE|interlaminar|interlaminar epidural corticosteroid injection
219752198|NCT05452473|OTHER|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
219752199|NCT05452473|OTHER|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
219752200|NCT05840913|DRUG|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
219752201|NCT01283984|DRUG|AZD2115|Single dose, oral inhalation (nebuliser solution)
219752202|NCT01283984|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
219752203|NCT01194596|BEHAVIORAL|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
219752204|NCT01194596|BEHAVIORAL|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
219752205|NCT00399087|DRUG|Perifosine|Perifosine oral administration
219752206|NCT00399087|DRUG|Docetaxel|IV administration
219752207|NCT00399087|DRUG|Prednisone|Oral administration
219752208|NCT00963872|DRUG|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
219752209|NCT00963872|DRUG|fludarabine phosphate|40 mg/m\^2 over 1 hour on Days -6 through -2.
219752210|NCT00963872|RADIATION|Total body irradiation|200 cGy on Day -1
219752211|NCT00963872|BIOLOGICAL|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
219752212|NCT00963872|BIOLOGICAL|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
219752213|NCT01968980|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
219752214|NCT01968980|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
219752215|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel|
219752216|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
219752217|NCT00567554|DRUG|paclitaxel|
219369536|NCT04212000|DRUG|Ketoconazole|Ketoconazole tablet
219752218|NCT00567554|DRUG|paclitaxel + everolimus (RAD001)|
219752219|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
219752220|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + lapatinib|
219752221|NCT00283192|DRUG|Sertraline|
219752222|NCT03212729|RADIATION|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
219752223|NCT03212729|PROCEDURE|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
219752224|NCT03464773|OTHER|PIUO Pathway|See arm descriptions
219752225|NCT03018873|OTHER|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
219752226|NCT00314457|DRUG|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
219752227|NCT03124186|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
219752228|NCT05626660|OTHER|Coronary angiography and percutaneous coronary intervention|Coronary angiography and percutaneous coronary intervention via radial approach
219752229|NCT05074914|PROCEDURE|oesophagectomy|removal of oesophagus
219752230|NCT03306550|DRUG|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
219752231|NCT03306550|DRUG|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
219752232|NCT05636839|RADIATION|UVB treatment|UVB treatment 3 times per week for 10 weeks
219752233|NCT02128035|PROCEDURE|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
219752234|NCT03075228|DEVICE|IntelliCap|Sampling of the small intestine using a samling capsule.
219752235|NCT01527032|DRUG|melphalan, thalidomide and dexamethasone|
219752236|NCT00101348|DRUG|erlotinib hydrochloride|Given orally
219752237|NCT00101348|BIOLOGICAL|cetuximab|Given IV
219752238|NCT00101348|BIOLOGICAL|bevacizumab|Given IV
219752239|NCT00101348|OTHER|laboratory biomarker analysis|Correlative studies
219752240|NCT05164471|GENETIC|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
219752241|NCT02890875|OTHER|Ethanol lock|
219752242|NCT02890875|OTHER|Heparin lock|
219752243|NCT04005300|DIETARY_SUPPLEMENT|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
219752244|NCT04005300|DIETARY_SUPPLEMENT|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
219752245|NCT02532101|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
219752246|NCT04857060|BEHAVIORAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
219752247|NCT02184533|DRUG|sodium selenite|Given PO
219752248|NCT02184533|RADIATION|radiation therapy|Undergo radiation therapy
219752249|NCT02184533|OTHER|laboratory biomarker analysis|Correlative studies
219752250|NCT02184533|OTHER|pharmacological study|Correlative studies
219752251|NCT02184533|OTHER|questionnaire administration|Ancillary studies
219752252|NCT04335968|DRUG|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
219752253|NCT04335968|DRUG|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
219752254|NCT05446064|BEHAVIORAL|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
219752255|NCT00787150|DRUG|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
219752256|NCT00787150|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
219752257|NCT00787150|DRUG|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
219752258|NCT01772654|DEVICE|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
219752259|NCT04537650|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
219752260|NCT01849276|DRUG|metformin hydrochloride|Given orally
219752261|NCT01849276|DRUG|cytarabine|Given IV
219752262|NCT01849276|OTHER|laboratory biomarker analysis|Correlative studies
219752263|NCT04998942|BEHAVIORAL|virtual cardiac wellness program|Participants assigned to this arm will participate in the experimental intervention.
219752264|NCT04998942|BEHAVIORAL|Placebo comparator|Participants assigned to this arm will participate in a placebo intervention.
219752265|NCT04695665|OTHER|Cervical pain|Exercise program for cervical spine according to McGill's approach.
219752266|NCT04695665|OTHER|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
219752267|NCT04695665|OTHER|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
219752268|NCT04269954|DRUG|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
219752269|NCT02699307|BEHAVIORAL|Counseling|OT led counseling
219752270|NCT03477812|DEVICE|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
218992876|NCT02650856|BIOLOGICAL|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
218992877|NCT04640285|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
219180032|NCT03956407|DEVICE|Suprathreshold repetitive peripheral sensory stimulation|Suprathreshold repetitive peripheral sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For suprathreshold stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
219180033|NCT03956407|DEVICE|Subthreshold repetitive sensory stimulation|Subthreshold repetitive sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For subthreshold stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
219180034|NCT05141695|DEVICE|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
219180035|NCT05141695|DEVICE|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
219180036|NCT02693223|OTHER|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
219180037|NCT06469138|DRUG|Bemcentinib|Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
219180038|NCT05084235|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
219180039|NCT05084235|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling
219180040|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
219180041|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
219180042|NCT03437057|OTHER|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
219180043|NCT05051761|DRUG|Jaktinib|Administered orally.
219180044|NCT05051761|DRUG|placebo|Administered orally.
219180045|NCT00470704|DRUG|Lapatinib|
219180046|NCT00470704|DRUG|Herceptin|
219180047|NCT03838549|PROCEDURE|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
219752271|NCT01262105|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
219752272|NCT00879398|DRUG|Toviaz treatment|4 mg starting then can be followed by 8 mg
219752273|NCT06501313|DEVICE|Photobiomodulation|Soft laser therapy
219180048|NCT06631508|OTHER|Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge|Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
219180049|NCT04634513|BIOLOGICAL|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
219180050|NCT04634513|OTHER|Placebo|Sodium bicarbonate buffer
219752274|NCT02347410|DEVICE|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
219752275|NCT01716000|OTHER|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
219180051|NCT06628258|OTHER|Moiz Cleansing Lotion|"Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
219180052|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
219180053|NCT01120223|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
219180054|NCT05375643|BEHAVIORAL|SURGE|Video with or without person to person guidance to support decision making around genetic testing
219180055|NCT04295798|DEVICE|Conventional tDCS|The anode will be placed over F3 and the cathode over the contralateral supraorbital margin. At the beginning of stimulation, the current will be increased from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
219752276|NCT01716000|BEHAVIORAL|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
219752277|NCT02382146|DRUG|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
219752278|NCT02382146|DRUG|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
219752279|NCT02609594|OTHER|Weekly application of Amnioband|Weekly application of Amnioband.
219752280|NCT02609594|OTHER|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
219180056|NCT04295798|DEVICE|Optimized tDCS|This intervention will utilize eight gel electrodes with placement and current parameters optimized to the cohort, with the goal of generating an average nE over the left dlPFC of the same size as the one delivered by a conventional montage using sponges. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
219752281|NCT02609594|OTHER|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
219180057|NCT04295798|DEVICE|Conventional Sham|Conventional sham will be used to maximize blinding of conventional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration described above will be used; however, current will be automatically ramped down 60 seconds after ramp-up.
219752282|NCT04743648|BEHAVIORAL|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
219752283|NCT04252079|PROCEDURE|Endovascular Repair of Juxtarenal Aortic Aneurysm|"1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b\_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
219752284|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
219752285|NCT04959331|DRUG|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
219752286|NCT04959331|DRUG|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
219752287|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
219180058|NCT04295798|DEVICE|Optimized Sham|An active sham will be used in which very low-level currents (0.5 mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. We have shown that this active sham effectively blinds participants and operators to stimulation condition and does not affect functional outcomes.
219752288|NCT05662670|DRUG|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
219752289|NCT03526172|PROCEDURE|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
219752290|NCT03526172|DEVICE|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
219752291|NCT03526172|DEVICE|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
219752292|NCT03526172|OTHER|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
219752293|NCT01380080|DRUG|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
219752294|NCT01380080|DRUG|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
219752295|NCT01380080|DRUG|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
219752296|NCT01380080|DRUG|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
219752297|NCT01380080|DRUG|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
219752298|NCT01380080|DRUG|Isoniazid|INH 300 mg orally once daily
219752299|NCT06414902|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV
219752300|NCT06270056|DRUG|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
219752301|NCT05962775|PROCEDURE|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
219752302|NCT02002715|DRUG|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
219752303|NCT06038175|DEVICE|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
218992878|NCT04640285|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
218992879|NCT04640285|OTHER|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
218992880|NCT04640285|OTHER|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
219752304|NCT06038175|OTHER|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
219752305|NCT02009267|DEVICE|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
219180059|NCT06772831|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Patients meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique.
219180060|NCT06772831|BEHAVIORAL|Downregulate condition|Patients either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
219180061|NCT04872413|PROCEDURE|Biospecimen Collection|Undergo blood, saliva or tissue sample collection
219180062|NCT04872413|OTHER|Follow-Up|Undergo follow-up
219180063|NCT04611022|BEHAVIORAL|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
219180064|NCT04063501|OTHER|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
219180065|NCT04063501|OTHER|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
219180066|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
219180067|NCT06771167|BEHAVIORAL|Building Community Resilience Program (BCR)|To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).
219180068|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
219752306|NCT02009267|PROCEDURE|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
219752307|NCT02009267|PROCEDURE|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
219180069|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
219180070|NCT05601440|OTHER|Observation|Monitoring arm
219180071|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
219180072|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
219180073|NCT05601440|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
219180074|NCT06293339|BIOLOGICAL|CHMI with 3D7 malaria|Controlled human malaria infection with 3D7 malaria through mosquito bites
219752308|NCT03584490|OTHER|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
219752309|NCT03584490|OTHER|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
219752310|NCT00375713|DRUG|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
219180075|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
219180076|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
219180077|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
219180078|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
219180079|NCT05968586|OTHER|Body positioning|Body positioning of infants prone vs supine.
219180080|NCT05378035|DIAGNOSTIC_TEST|Blood Tests|Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
219752311|NCT00375713|DRUG|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
219752312|NCT00375713|DRUG|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
219752313|NCT00375713|DRUG|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
219752314|NCT00375713|DRUG|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
219752315|NCT02756052|DEVICE|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
219752316|NCT02756052|DEVICE|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
219752317|NCT05726968|DRUG|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
219752318|NCT03755427|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
219752319|NCT03755427|BIOLOGICAL|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
219752320|NCT04598425|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
219752321|NCT05759767|DRUG|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
219752322|NCT05759767|DRUG|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
219752323|NCT01342315|DRUG|33525|Daily dosing
219752324|NCT01342315|DRUG|Placebo|Daily dosing
219752325|NCT06291779|DEVICE|Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio|"* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample."
219752326|NCT06098573|BEHAVIORAL|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
219752327|NCT06098573|BEHAVIORAL|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
219752328|NCT06098573|BEHAVIORAL|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
219752329|NCT00867152|DRUG|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
219752330|NCT00867152|DRUG|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
219752331|NCT00867152|DRUG|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
219752332|NCT00867152|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
219180081|NCT05792176|BEHAVIORAL|Music Training Intervention|The Music Training Intervention (MTI) entails 12-weeks of online instruction to learn to play the ukulele. Participants will be taught the basic information on how to handle and hold the ukulele, musical chords, and popular songs. They will be instructed to play at least 30-minutes a day, five days a week.
219180082|NCT05792176|BEHAVIORAL|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
219180083|NCT06800235|OTHER|Computer-Assisted Simulation|Nursing students in the experimental group were informed about computer-based simulation. They were also informed about the aspiration skill form and general competency scale.
219369537|NCT05239845|DIETARY_SUPPLEMENT|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
219369538|NCT05239845|OTHER|Control|Maltodextrin
219369539|NCT00499109|DRUG|Docetaxel|"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
218992881|NCT00730405|DRUG|Albaconazole 100mg|Albaconazole for 36 weeks
219369540|NCT00499109|DRUG|Vinorelbine|DV Group: 35 mg/m\^2 on days 1 and 15
219752333|NCT00867152|DRUG|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
219752334|NCT01722669|DRUG|isoquercetin or quercetin|Single dose PK/PD study
219752335|NCT06644326|DRUG|100mg IkT-148009 Wet|100mg wet tablet formulation
219752336|NCT06644326|DRUG|200 mg Itraconazole|2 100mg capsules
219752337|NCT06644326|DRUG|100mg IkT-148009 Dry|100mg dry tablet formulation
219752338|NCT06644326|DRUG|50mg IkT-148009 Wet|50mg wet tablet formulation
219752339|NCT03140969|DRUG|QR-110|RNA antisense oligonucleotide for intravitreal injection
219752340|NCT04604431|OTHER|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
219752341|NCT00552136|PROCEDURE|Ankle Arthroplasty|
219752342|NCT00552136|PROCEDURE|Ankle Arthrodesis|Ankle fusion surgery
219752343|NCT00285194|DRUG|Allogeneic Islets of Langerhans|
219752344|NCT00285194|DRUG|hOKT3γ1 (Ala-Ala)|
219752345|NCT02888340|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
219752346|NCT04603560|BEHAVIORAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
219752347|NCT04603560|BEHAVIORAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
219752348|NCT00643279|DEVICE|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
219752349|NCT00643279|OTHER|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
219752350|NCT05614882|BEHAVIORAL|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
219752351|NCT05614882|BEHAVIORAL|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
219752352|NCT03940248|RADIATION|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
219752353|NCT03257501|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
219752354|NCT00301860|BIOLOGICAL|anti-thymocyte globulin|
219752355|NCT00301860|BIOLOGICAL|filgrastim|
219752356|NCT00301860|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219752357|NCT00301860|DRUG|cyclosporine|
219752358|NCT00301860|DRUG|fludarabine phosphate|
219752359|NCT00301860|DRUG|melphalan|
219752360|NCT00301860|DRUG|methotrexate|
219752361|NCT00301860|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219752362|NCT00301860|PROCEDURE|peripheral blood stem cell transplantation|
219752363|NCT02334657|OTHER|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
219752364|NCT01766687|DIETARY_SUPPLEMENT|Hydration|
219752365|NCT06652490|PROCEDURE|Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.|"In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial."
219752366|NCT04573504|DRUG|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
219752367|NCT04573504|DRUG|Placebo|Placebo
219752368|NCT04701554|OTHER|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
219752369|NCT04701554|OTHER|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
219752370|NCT03183947|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
219752371|NCT03183947|BEHAVIORAL|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
219180084|NCT06800235|OTHER|Control grup|Nursing students in the control group were informed about the standard procedure/traditional method. They were also informed about the aspiration skill form and general competency scale.
219752372|NCT03183947|OTHER|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
219752373|NCT03183947|OTHER|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
219180085|NCT03509012|DRUG|Durvalumab|IV (intravenous)
219180086|NCT03509012|DRUG|Tremelimumab|IV
219180087|NCT03509012|DRUG|Cisplatin (dose level 4)|IV
219180088|NCT03509012|DRUG|Cisplatin (dose level 3)|IV
219180089|NCT03509012|DRUG|Carboplatin (dose level 1)|IV
219180090|NCT03509012|DRUG|Carboplatin (dose level 2)|IV
219180091|NCT03509012|DRUG|Etoposide (dose level 1)|IV
219180092|NCT03509012|DRUG|Etoposide (dose level 2)|IV
219752374|NCT03183947|OTHER|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
219752375|NCT03777605|DRUG|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
219180093|NCT03509012|DRUG|Paclitaxel|IV
219180094|NCT03509012|DRUG|Pemetrexed|IV
219180095|NCT03509012|RADIATION|External beam radiation (dose level 1)|radiation therapy
219180096|NCT03509012|RADIATION|External beam radiation (dose level 2)|radiation therapy
219180097|NCT03509012|RADIATION|External beam radiation (hyperfractionated)|radiation therapy
219180098|NCT03509012|DRUG|Cisplatin (dose level 1)|IV
219180099|NCT03509012|DRUG|Cisplatin (dose level 2)|IV
219752376|NCT03643237|BEHAVIORAL|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
219752377|NCT03643237|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
219752378|NCT05715827|DEVICE|RAS prostatectomy and RAS cholecystectomy|"There are two types of interventions in the study.~Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.~Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system."
219752379|NCT06159309|OTHER|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
218992882|NCT00730405|DRUG|Albaconazole 200mg|Albaconazole for 36 weeks
218992883|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 36 weeks
219180100|NCT03509012|RADIATION|External beam radiation (standard)|radiation therapy
219180101|NCT06798246|DRUG|Chemotherapy|Gemicitabin and cisplatin
219180102|NCT06798246|DRUG|Immunotherapy|PD-1/PD-L1
219180103|NCT06798246|DRUG|ADC|ADC drug like RC48
219180104|NCT06798246|DRUG|Chemotherapy combined with immunotherapy|Chemotherapy combined with immunotherapy
219180105|NCT06772818|DRUG|Nemtabrutinib|Oral Tablet
219180106|NCT06581003|DRUG|Oxygen 99.7 %|The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
219180107|NCT06581003|DRUG|Oxygen 21 %|The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
219180108|NCT04872738|OTHER|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
219180109|NCT05578300|DIAGNOSTIC_TEST|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
219180110|NCT05578300|DIAGNOSTIC_TEST|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
219180111|NCT03122847|DRUG|Methylprednisolone|Intravenous methylprednisolone
219180112|NCT04971889|BEHAVIORAL|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
219180113|NCT04971889|BEHAVIORAL|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
219180114|NCT03624608|DEVICE|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
219180115|NCT06063083|BEHAVIORAL|"Tell Me More (Dime Mas)"|Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
219752380|NCT06985927|BEHAVIORAL|psychotherapeutic sessions|Analysis of effect of psychotherapeutic sessions based on self-concept and autobiographical memory on alcohol addiction
219752381|NCT06640764|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty with SMS Femoral Stem (Medacta)
219752382|NCT05481697|DIAGNOSTIC_TEST|GRAIL Galleri|A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.
219752383|NCT06660420|DRUG|Cyclophosphamide|Given by IV
219752384|NCT06660420|DRUG|Fludarabine|Given by IV
219752385|NCT06305429|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
219752386|NCT05576337|OTHER|16 weeks of strength training protocol|16 weeks of strength training protocol
219180116|NCT06063083|BEHAVIORAL|"Peer Ambassador Stories [Listen Miami (Oye Miami)]"|Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
219180117|NCT06063083|BEHAVIORAL|Standard Community Outreach|Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
219180118|NCT04219280|DRUG|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
219180119|NCT04219280|DRUG|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
219180120|NCT03916510|BIOLOGICAL|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
219369541|NCT00499109|DRUG|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
219369542|NCT00499109|DRUG|Gemcitabine|"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
219369543|NCT06110052|OTHER|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
219752387|NCT06602011|COMBINATION_PRODUCT|TACE, Lenvatinib, combined with Tislelizumab group|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
219752388|NCT06601179|DEVICE|HIFU|high-intensity focused ultrasound treatment of benign prostatic hyperplasia
219752389|NCT04327817|DEVICE|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
219752390|NCT03632044|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
219752391|NCT03632044|OTHER|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
219752392|NCT04950439|OTHER|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
219752393|NCT00281385|BEHAVIORAL|traditional vs. lifestyle exercise|
219752394|NCT05618925|DRUG|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
219752395|NCT05618925|BIOLOGICAL|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
219752396|NCT05618925|DRUG|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
219752397|NCT05618925|DRUG|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
219752398|NCT05618925|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
219752399|NCT03814044|DEVICE|PEEK Suture Anchors|"Subjects who have undergone hip joint repair using PEEK Suture Anchors:~BIORAPTOR™ Knotless Suture Anchor and SpeedLock Hip Suture Anchor"
219369544|NCT00119340|DRUG|cyclosporine|
219369545|NCT00119340|DRUG|fludarabine phosphate|
219369546|NCT00119340|DRUG|mycophenolate mofetil|
219752400|NCT06268249|DRUG|Ulinastatin|Ulinastatin was pumped continuously during the operation
219752401|NCT05929326|DIAGNOSTIC_TEST|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
219752402|NCT06615219|OTHER|Intergroup contact training|The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
219752403|NCT06615219|OTHER|Regular course training only|The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
219752404|NCT06670417|DEVICE|Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light|"Low level laser therapy watch:~The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light. It provides 18 individual laser beams used for extravascular blood irradiation (transcutaneous) through radial and ulnar vessels at the wrist site."
219752405|NCT06670417|OTHER|Buerger Allen exercise|Procedure-Keep the Buerger Allen exercise board on the cot. Elevate the lower extremities to an angle of 45 to 90 degree with the help of exercise board. Provided support to the lower extremities to maintain the position. Make the subject to maintain the same position in the same manner until the skin blanches (appears dead white). Lower the feet and the legs below the level of the rest of the body until redness appears (care should be taken that there is no pressure against the back of the knees). Place the legs flat on the bed for a few minutes. Ask the subjects to sit in a relaxed position while each foot is flexed and extended then inverted and everted for 3 minutes till the feet turns entirely pink. Ask the subject to rotate the feet in all the direction. Make the subject to lie quietly for 5 minutes, keeping legs warm with a blanket
219752406|NCT06670417|OTHER|Regular wound care|Regular wound care and dressing to the wound and ulcer
219752407|NCT06996314|DEVICE|TVNS + Slow-Paced Breathing (TVNS+SDB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
218992884|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
218992885|NCT00730405|DRUG|Placebo 400 mg|Placebo for 36 weeks
218992886|NCT03677362|BEHAVIORAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
218992887|NCT04821947|OTHER|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
218992888|NCT00394732|DEVICE|Total Disc Prosthesis|
218992889|NCT00394732|BEHAVIORAL|Multidisciplinary rehabilitation program|
218992890|NCT02478775|DRUG|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
218992891|NCT02478775|DRUG|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
218992892|NCT02478775|DRUG|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
219369547|NCT00119340|PROCEDURE|peripheral blood stem cell transplantation|
219369548|NCT00119340|RADIATION|radiation therapy|
219752408|NCT06996314|DEVICE|TVNS without Breathing Training (TVNS+NB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
219752409|NCT06996314|DEVICE|Sham TVNS + SDB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
219752410|NCT06996314|DEVICE|Sham TVNS + NB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
219752411|NCT06669702|BEHAVIORAL|12-week home based exercise|"Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an rating of perceived exertion in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.~Participants can break down the exercise time in a way that suits their time, i.e., they can do 3 × 10 minutes, 2 × 15 minutes, etc."
219752412|NCT06669702|BEHAVIORAL|Routine care|Participants in this group will continue with their current routine care and will be given a diary of exercises that they can do, which are usually given to them as part of their health care routine by physiotherapists or consultants. The diary has information about yoga-like stretching practices.
219752413|NCT06221449|PROCEDURE|Positive end expiratory pressure|"The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O."
219752414|NCT02625428|DRUG|Optison|
219752415|NCT02625428|DIAGNOSTIC_TEST|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
219752416|NCT02625428|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
219752417|NCT05766280|BEHAVIORAL|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
219752418|NCT04093453|OTHER|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
219752419|NCT04093453|OTHER|Exercise|1 hour exercise
219752420|NCT04093453|DIETARY_SUPPLEMENT|Sodium Propionate|Participant receive Sodium Propionate
219752421|NCT06668220|DRUG|Dexmedetomidine|Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
219752422|NCT06668220|DRUG|Bupivacain|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
219752423|NCT06520553|DRUG|BI 1569912 (C-14)|unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
219752424|NCT06520553|DRUG|BI 1569912 (C-13)|\[13C\]- labelled BI 1569912
219752425|NCT06673823|DEVICE|Mirror therapy|Mirror Therapy (MT) is a non-invasive treatment method aimed at addressing unilateral conditions impacting either the upper or lower limbs. This technique involves placing a mirror along the patient's sagittal plane, allowing the reflection of the unaffected limb to visually overlay the affected limb.
219752426|NCT06673823|OTHER|conventional therapy|conventional therapy
219369549|NCT05936762|DEVICE|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
219180121|NCT03916510|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
219180122|NCT03916510|RADIATION|Radiotherapy|50 Gy/25#
219180123|NCT06486584|BEHAVIORAL|Contingency Management|Contingency management payment for no disruptive behaviors each week.
219180124|NCT00300859|BEHAVIORAL|brief motivational intervention|
219180125|NCT04650269|DRUG|Biktarvy 50Mg-200Mg-25Mg Tablet|Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
219369550|NCT03417440|OTHER|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
219752427|NCT06674746|BEHAVIORAL|SOLUTION FOCUSED APPROACH|The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
219180126|NCT04650269|OTHER|HIV care|HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
219180127|NCT06236620|DIETARY_SUPPLEMENT|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
219180128|NCT05398679|DRUG|Cefaclor|cefaclor intravenous 2 gr/day
219180129|NCT05398679|DRUG|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
219180130|NCT05398679|DRUG|Ciprofloxacin Injection|1200 mg/day maximum dose IV
219180131|NCT05398679|DRUG|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
219180132|NCT05398679|DRUG|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
219180133|NCT05398679|DRUG|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
219180134|NCT05398679|DRUG|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
219180135|NCT05398679|DRUG|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
219180136|NCT05398679|DRUG|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
219180137|NCT05398679|DRUG|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
219180138|NCT05398679|DRUG|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
219180139|NCT05398679|DRUG|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
219180140|NCT05398679|DRUG|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
219180141|NCT05398679|DRUG|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
219180142|NCT05398679|DRUG|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
219180143|NCT05398679|DRUG|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
219180144|NCT05398679|DRUG|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
219180145|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
219180146|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
219180147|NCT05398679|DRUG|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
219752428|NCT06675292|OTHER|Survey-based study|The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
219180148|NCT05398679|DRUG|Tedizolid Injection|200 mg (maximum x day)
219752429|NCT06675656|OTHER|DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.|DNA extraction from urine, stool and biopsy for microbiome analysis. Isolation of peripheral blood mononuclear cells from peripheral blood for immunophenotypic analysis, and isolation of serum for analysis of cytokines and bacterial metabolites.
219752430|NCT07000331|OTHER|Thoracic expansion exercises|Individuals placed their hands on their lower ribs and then took 3 deep breaths under their hands in a row. After this cycle, individuals rested by taking 3-4 calm breaths. The cycle was repeated 10 times. The individual did this session 4 times a day.
219752431|NCT07000331|OTHER|Physical activity counseling|Individuals were given weekly group phone calls and meetings. Individuals were gradually accustomed to regular walking to increase their daily step count. In the first week, individuals were asked to walk a total of 30-45 minutes per day, at least 4-5 days per week, and to increase the number of steps measured at the beginning by approximately 1000-2000 steps per day to reach at least 6500 steps. In the second week, the expected goal was at least 7500 steps. In the third and fourth weeks, they were asked to reach at least 10000 steps.
219752432|NCT07004335|DRUG|Iparomlimab and Tuvonralimab Injection plus Bevacizumab|The experimental group will receive intravenous infusion of anti PD-1/CTLA-4 (Iparomlimab/Tuvonralimab) Injection (5 mg/kg) and Bevacizumab (dose 7.5mg/kg) once every 3 weeks up to 35 cycles (105 weeks).
219752433|NCT06998277|OTHER|Dietary therapy|"Participants with quiescent UC will undergo a 10-day observational period followed by 15-days of the UC-TREAT dietary intervention. Disease activity, quality of life, and gastrointestinal symptoms will be assessed throughout"
219752434|NCT06998277|OTHER|Dietary therapy|"Healthy participants will undergo a 10-day observational period, followed by 15-days of the UC-TREAT dietary intervention. Gastrointestinal symptoms will be assessed throughout."
219752435|NCT07003464|DRUG|Zanubrutinib|160 mg (2 tablets) BID. Each 4-week period constitutes one treatment cycle.
219752436|NCT07003464|DRUG|Obinutuzumab|1000 mg IV (Days 1, 8, 15 of Cycle 1; Day 1 thereafter).Each 4-week period constitutes one treatment cycle.
219752437|NCT07003464|DRUG|Bendamustine|70 mg/m² (Days 1-2 per cycle) for induction only (Cycles 1-4).Each 4-week period constitutes one treatment cycle.
219752438|NCT07002905|DRUG|ASC30 tablets or ASC30 tablets A1 or placebo|Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily
219752439|NCT07005687|OTHER|Stem Cells|MSCs Derived
219752444|NCT06689423|DEVICE|Credo POCT Device|Testing Credo's POCT device for respiratory viruses detection.
219752445|NCT07003698|PROCEDURE|The group without the rectointercostal nerve block|Patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period. These patients will not receive the rectointercostal nerve block.
219180149|NCT05398679|DRUG|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
219180150|NCT05398679|DRUG|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
219180151|NCT05398679|DRUG|Cefaclor Capsules|2 gr/day
219180152|NCT01437709|BIOLOGICAL|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
219180153|NCT01437709|OTHER|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
219752446|NCT07003698|PROCEDURE|The rectointercostal plane block|The rectointercostal plane block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position. Additionally, patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period.
219752447|NCT06729866|PROCEDURE|electrogram guided pulse field ablation|In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.
219752448|NCT03557502|OTHER|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
219752449|NCT03557502|OTHER|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
219752450|NCT05972850|BEHAVIORAL|Vivo Heart|Vivo is an online, live, small group fitness program developed for older adults that uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session for 45 min, 2-3 times/week.
219752451|NCT01822379|PROCEDURE|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
219752452|NCT04070846|DRUG|[14C] LC350189|Carbon-14 labelded LC350189
219752453|NCT02411851|DRUG|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
219752454|NCT02411851|OTHER|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
219752455|NCT03683082|DRUG|Oxygen supplementation|40% FiO2 via Venturi mask
219180154|NCT06542588|COMBINATION_PRODUCT|HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)|Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
219180155|NCT05858424|OTHER|Multidisciplinary day hospitalization|"This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment."
219180156|NCT06408181|DRUG|Aspirin 162 mg|Aspirin is a nonsteroidal anti-inflammatory drug.
219180157|NCT06408181|DRUG|Aspirin 81mg|Aspirin is a nonsteroidal anti-inflammatory drug.
219180158|NCT06353191|OTHER|Non-Interventional Study|Non-interventional study
219180159|NCT03227146|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
219180160|NCT03227146|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
219180161|NCT04807192|RADIATION|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
219752456|NCT03683082|DRUG|Sham O2 (medical air)|Medical air supplementation via Venturi mask
219752457|NCT00174629|DRUG|Docetaxel/DDP|
219752458|NCT00174629|DRUG|docetaxel/gemcitabine|
219752459|NCT05715762|BEHAVIORAL|prone postion|ventilation at prone positioning
219752460|NCT05715762|DRUG|NO inhalation|NO inhalation at 20 ppm
219752461|NCT02337556|OTHER|Peptamen Bariatric|Commercially available enteral diet
219752462|NCT02337556|OTHER|Replete|Commercially available enteral diet
219180162|NCT04807192|DRUG|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
219752463|NCT00270387|DRUG|Natrecor (nesiritide)|
219752464|NCT01516476|DRUG|Placebo|Placebo for 12 weeks
219752465|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
219752466|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
219752467|NCT01516476|DRUG|liraglutide|liraglutide for 12 weeks
219752468|NCT01447537|OTHER|Exercise + relaxation|Exercise + relaxation
219752469|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
219752470|NCT05604703|DIAGNOSTIC_TEST|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
219752471|NCT07136038|BEHAVIORAL|Low Energy Availability Screening and Nutrition Support|Athletes will receive screening for low energy availability, strength and body composition assessments and receive nutrition support from a sports dietitian over the competitive season.
219752472|NCT07146555|OTHER|No Interventions|
219752473|NCT07145905|DEVICE|TCRM|N=128
219752474|NCT05913687|DIAGNOSTIC_TEST|AIDP|Machine learning algorithm of imaging data
219752475|NCT06524180|DEVICE|Telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
219752476|NCT06524180|OTHER|Usual care|Participants will be followed up as usual by face-to-face consultation with the doctors
219752477|NCT05684965|DRUG|XTX301|XTX301 monotherapy
219752478|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
219180163|NCT05634967|OTHER|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
219180164|NCT06468280|PROCEDURE|Local treatment (Surgical)|Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
219752479|NCT06316947|RADIATION|CHW-delivered intervention|WellShare CHWs will then deliver the brief, approximately 15-minute intervention to the participating parent. The new intervention components will build off existing tobacco education outreach using verbal instruction and images developed by WellShare CHWs and layer in home smoke-free rules, potential biomarker feedback about smoke exposure, and other educational intervention components that align. Additionally there will be pre and post-intervention surveys and urine samples collection for cotinine levels.
219752480|NCT06569758|DRUG|GenSci098|subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
219752481|NCT06569758|DRUG|GenSci098 Placebo|In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.
219752482|NCT03042143|BIOLOGICAL|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
219752483|NCT03042143|BIOLOGICAL|Placebo (Plasma-Lyte 148)|Infusion of placebo
219752484|NCT06406842|OTHER|Cerebral oxygenation index guided hemodynamics management|In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
219752485|NCT05288751|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
219752486|NCT05965310|BEHAVIORAL|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
219752487|NCT04985630|DIETARY_SUPPLEMENT|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
219752488|NCT04985630|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice
219752489|NCT03021486|DRUG|Chlorpromazine|Given IV
219752490|NCT03021486|DRUG|Haloperidol|Given IV
219180165|NCT06468280|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
219180166|NCT06468280|DRUG|XELOX Chemotherapy Regimen|"Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle."
219180167|NCT06468280|PROCEDURE|Local Treatment (Non-surgical)|"Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team."
219752491|NCT03021486|OTHER|Quality-of-Life Assessment|Ancillary studies
219752492|NCT03021486|OTHER|Questionnaire Administration|Ancillary studies
219752493|NCT05984849|BEHAVIORAL|vaccination game|A health game to promote HPV vaccination among youth
219752494|NCT06183723|OTHER|Combination of social-behavior model and eHealth|"The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects."
219752495|NCT04887831|DRUG|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
219752496|NCT04887831|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
219752497|NCT04887831|DRUG|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
219752498|NCT04887831|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
219752499|NCT04887831|DRUG|Avelumab|Avelumab administered IV on Day 1 of each 14-day maintenance cycle
219752500|NCT06628908|DRUG|Suzetrigine|Tablets for oral administration.
219752501|NCT06628908|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
219752502|NCT06628908|DRUG|Pregabalin|Capsules for oral administration.
219752503|NCT06628908|DRUG|Placebo (matched to Pregabalin)|Placebo matched to Pregabalin for oral administration.
219752504|NCT04760873|DEVICE|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
219752505|NCT02931097|DEVICE|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
219752506|NCT02931097|DEVICE|Sham stimulation|
219752507|NCT04017767|PROCEDURE|Induced Acute Intermittent Hypoxia (AIH)|AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).
218992893|NCT06014268|OTHER|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
218992894|NCT03078660|BEHAVIORAL|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
218992895|NCT03078660|BEHAVIORAL|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
218992896|NCT03304548|OTHER|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
218992897|NCT05277324|OTHER|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
218992898|NCT00476697|DEVICE|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
218992899|NCT00944905|BIOLOGICAL|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
218992900|NCT01496807|DRUG|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
218992901|NCT01496807|DRUG|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
218992902|NCT00603616|DRUG|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
218992903|NCT00603616|DRUG|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
218992904|NCT00959764|DRUG|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
218992905|NCT00959764|DRUG|Intranasal Calcitonin|Intranasal Calcitonin Spray
218992906|NCT00959764|DRUG|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
218992907|NCT03007160|DRUG|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
218992908|NCT01695265|OTHER|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
218992909|NCT01695265|DEVICE|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
218992910|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
218992911|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
218992912|NCT04240769|DEVICE|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
218992913|NCT05043506|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
218992914|NCT05043506|DRUG|Aromatase inhibitor|Aromatase inhibitor monotherapy
218992915|NCT05087108|DEVICE|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
218992916|NCT05087108|DEVICE|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
218992917|NCT05087108|DEVICE|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
218992918|NCT04535648|OTHER|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
219180168|NCT03589339|DRUG|NBTXR3|Single intra Tumoral injection
219180169|NCT03589339|RADIATION|SABR|Radiotherapy given as a definite number of fractions at the dose defined for each radiation field
219180170|NCT03589339|DRUG|Nivolumab|Anti-PD-1 monotherapy
219180171|NCT03589339|DRUG|Pembrolizumab|Anti-PD-1 monotherapy
219180172|NCT05006859|OTHER|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
219180173|NCT02657486|DRUG|BGJ398|
219180175|NCT02857777|DRUG|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
219180176|NCT06186401|BIOLOGICAL|E-SYNC T Cells|Given IV
219180177|NCT06186401|DRUG|Cyclophosphamide (non-investigational)|Given IV
219180178|NCT06186401|DRUG|Fludarabine (non-investigational)|Given IV
219180179|NCT06186401|PROCEDURE|Leukapheresis|Undergo leukapheresis
219180180|NCT06186401|PROCEDURE|Surgical resection|Undergo surgical resection of tumor tissue
219180181|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
219180182|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
219180183|NCT06806358|DEVICE|IUD insertion|"* Perform a bimanual examination~* Insert a warm, moistened speculum.~* Cleanse the cervix with an antiseptic solution.~* Open the sterile insertion instruments without touching~* Remove the tenaculum by its handle and grasp the anterior or posterior lip of the cervix.~* Apply gentle traction with the tenaculum to straighten the canal.~* Remove the sound by its handle and gently insert it to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed~* Open the IUD pack without touching its contents.~* Put on sterile gloves.~* Load the IUD and insert it into the uterine cavity according to the manufacturer instructions.~* Gently remove the tenaculum.~* Trim the strings of the IUD to 3-4 cm in length~* Remove the speculum and assess the woman."
219180184|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
219180185|NCT06577584|OTHER|Follow-up in the Diabetes Care Trajectory|Being followed-up in the Diabetes Care Trajectory in Belgium
219180186|NCT06577584|OTHER|Follow-up in the Diabetes Convention|Being followed-up in the Diabetes Convention in Belgium
219180187|NCT04478890|DIAGNOSTIC_TEST|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
219180188|NCT04680403|OTHER|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
219180189|NCT06313866|DIETARY_SUPPLEMENT|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
219180190|NCT06313866|OTHER|Electronuchal acupuncture group treatment|Electronuchal acupuncture
219180191|NCT06313866|OTHER|Smell therapy group treatment|nasal suction intervention with volatile oil of Acorus calamus
219180192|NCT06313866|OTHER|Electronuchal acupuncture combined with smell and inhalation therapy group treatment|On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.
219180193|NCT06313866|OTHER|Sham stimulation|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
219180194|NCT04908722|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
219180195|NCT06807385|OTHER|Reaction Training|"* The exercise list consists of 15 different exercises that aim to both shorten reaction time and improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks (tasks related to the color of the light to be touched, giving the command to read lights that are lit in different directions) and a second cognitive task.~* Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes.~  * Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points) according to the Borg scale."
219180196|NCT06807385|OTHER|Conventional Exercises|"The exercises used in reaction training will be applied as in conventional training without reaction training system. The difficulty of the exercise will be increased by changing the support surface and ground properties, taking the difficulty perceived by the individual as the criterion, as in reaction training.~The exercise list consists of 15 different exercises that aim to improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks and a second cognitive task. Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes. Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points for Borg Scale)."
219180197|NCT04863222|DEVICE|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
219180198|NCT04863222|BIOLOGICAL|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
219180199|NCT05827718|BEHAVIORAL|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
219180200|NCT05827718|BEHAVIORAL|Source of Contact|Behavioral Intervention studied here is source of contact (personal clinic vs. research team)
219752508|NCT04017767|DEVICE|AIH mask|Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
219752509|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
219752510|NCT03519269|DEVICE|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
218992919|NCT03323710|DRUG|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
218992920|NCT03323710|DRUG|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
218992921|NCT06287008|PROCEDURE|robot-assisted kidney transplantation|The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
218992922|NCT02893670|PROCEDURE|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
218992923|NCT00836485|DRUG|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
218992924|NCT00836485|DRUG|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
218992925|NCT00836485|DRUG|Olopatadine 0.2%|1 gtt/eye on two separate occasions
218992926|NCT00836485|DRUG|Artificial tears|1 gtt/eye on two separate occasions
218992927|NCT02591290|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
218992928|NCT04590222|OTHER|blood sample|One blood sample of 60 mL (EDTA)
218992929|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.
218992930|NCT06197971|OTHER|Therapeutic Cupping Technique|Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
218992931|NCT06428669|DRUG|Nitro-Bid 2 % Topical Ointment|Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
218992932|NCT00913497|DRUG|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
218992933|NCT00913497|DRUG|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
218992934|NCT03765905|DIAGNOSTIC_TEST|study|Scube-1 scube-2 scube-3
218992935|NCT04193332|DEVICE|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
218992936|NCT04284670|OTHER|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
218992937|NCT02087397|OTHER|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
218992938|NCT02087397|BIOLOGICAL|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
218992939|NCT03197597|OTHER|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
219752511|NCT06546787|OTHER|PSYCHOTHERAPY|IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
219752512|NCT02496208|PROCEDURE|Biopsy Procedure|Undergo biopsies
219752513|NCT02496208|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219752514|NCT02496208|DRUG|Cabozantinib S-malate|Given PO
219752515|NCT02496208|PROCEDURE|Computed Tomography|Undergo CT scan
219752516|NCT02496208|PROCEDURE|Echocardiography Test|Undergo echocardiography
219752517|NCT02496208|BIOLOGICAL|Ipilimumab|Given IV
219752518|NCT02496208|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219752519|NCT02496208|BIOLOGICAL|Nivolumab|Given IV
219752520|NCT05267587|RADIATION|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
219752521|NCT03977207|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
219752522|NCT03977207|DRUG|Placebos|Placebo oral capsule
219752523|NCT05150470|OTHER|prevention|dental digital fingerprinting
219752524|NCT02499237|DRUG|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
219752525|NCT02499237|DRUG|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
219752526|NCT00730327|DEVICE|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
219752527|NCT00730327|OTHER|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
219752528|NCT02705963|DRUG|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
219752529|NCT02705963|DRUG|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
219752530|NCT02705963|DRUG|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
219752531|NCT06153264|OTHER|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
219752532|NCT06153264|OTHER|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
219752533|NCT04448951|OTHER|transcriptomics|transcriptomics
219752534|NCT04448951|OTHER|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
219752535|NCT04448951|OTHER|cytokines|peripheral blood cytokine analysis
219752536|NCT04394494|OTHER|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
219752537|NCT04394494|OTHER|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
219752538|NCT03773419|BEHAVIORAL|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
219752539|NCT03773419|BEHAVIORAL|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
219752540|NCT04868422|DEVICE|Telemonitoring via wireless internet-based system|
219752541|NCT02552225|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
219752542|NCT02552225|OTHER|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
219752543|NCT03035747|PROCEDURE|conventional surgery|high ligation and stripping of incompetent saphenous veins
219752544|NCT03035747|PROCEDURE|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
219752545|NCT03035747|PROCEDURE|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
219752546|NCT03035747|PROCEDURE|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
219752547|NCT03035747|PROCEDURE|phlebectomy|hooks phlebectomy of varicose veins
219752548|NCT00003287|DRUG|FOLFOX regimen|
219752549|NCT00003287|DRUG|fluorouracil|
219752550|NCT00003287|DRUG|leucovorin calcium|
219752551|NCT00003287|DRUG|oxaliplatin|
219752552|NCT02970565|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
219752553|NCT02970565|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
219752554|NCT00893802|OTHER|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
219752555|NCT02329808|PROCEDURE|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
219752556|NCT05685784|DEVICE|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
219180201|NCT05827718|BEHAVIORAL|Framing Method (Appeal to Altruism or Social Proof|"Behavioral Intervention studied here is the framing methods appeal to altruism and social proof"
219180202|NCT05827718|BEHAVIORAL|Incentive Structure|Behavioral Interventions studied here are guaranteed vs. lottery incentives
219180203|NCT04931810|BEHAVIORAL|All Nations Breath of Life|Same.
219180204|NCT02319759|DRUG|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
219180205|NCT02319759|DRUG|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
219752557|NCT01497197|DRUG|GONAL-f®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
219752558|NCT01497197|DRUG|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
219752559|NCT01497197|BIOLOGICAL|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
219752560|NCT02996396|DEVICE|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
219752561|NCT03388372|BIOLOGICAL|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
219180206|NCT02319759|DRUG|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
219180207|NCT02187848|DRUG|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
219180208|NCT03131154|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
219180209|NCT03131154|DRUG|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
219180210|NCT06550219|DEVICE|Nasal humidified heated high flow cannula (NHHHC)|Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.
219180211|NCT06550219|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV)|Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.
219180212|NCT06550219|DEVICE|Nasal continuous positive airway pressure NCPAP|Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
219180213|NCT06550219|DEVICE|lung ultrasound|Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
219180214|NCT06424236|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks, at escalating doses; at target, dosing was every 2 weeks
219180215|NCT05206929|OTHER|Self Managed Care|Self Managed Care
219180216|NCT04501536|BEHAVIORAL|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
219180217|NCT04213872|BEHAVIORAL|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
219180218|NCT06806826|DRUG|Omalizumab|The patients in the study group were started on omalizumab and intranasal fluticasone propionate. Omalizumab was administered subcutaneously to these patients at a dose of 300 mg once a month. . Twenty-five patients in the control group were started on intranasal fluticasone propionate spray and a tablet containing 5 mg desloratadine+10 mg montelukast sodium at the same dose and in the same manner as the patients in the study group. The patients were asked to use 100 mg of suspension equivalent to 50 micrograms of fluticasone propionate as two sprays into each nostril once daily and to use the tablet once daily. Patients in both groups were asked to fill out the visual analog scale and their total Ig E levels were checked. Patients who were called for a check-up after eight to ten weeks were evaluated again with the visual analog scale.
218992940|NCT05387031|DRUG|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
219180219|NCT05292625|BIOLOGICAL|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
219180220|NCT05292625|BIOLOGICAL|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
219180221|NCT05292625|OTHER|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
218992941|NCT03111602|OTHER|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
218992942|NCT06023459|DRUG|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
219180222|NCT04734626|DIAGNOSTIC_TEST|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
219752562|NCT03388372|DRUG|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
219752563|NCT03388372|RADIATION|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
219752564|NCT01511302|DRUG|RNS60|RNS60, 2ml, nebulized twice daily.
219752565|NCT01511302|DRUG|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
219752566|NCT01511302|DRUG|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
219752567|NCT03014635|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
219752568|NCT03014635|BIOLOGICAL|Placebos|Intramuscular injection
218992943|NCT06023459|DRUG|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
218992944|NCT03769766|DRUG|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
219369551|NCT03417440|OTHER|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
219752569|NCT05738538|DRUG|ziftomenib|
219752570|NCT04507204|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
219752571|NCT04507204|DRUG|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
219752572|NCT02769104|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
219752573|NCT02769104|DRUG|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
219752574|NCT00220090|DRUG|dexloxiglumide|
219752575|NCT01752049|DRUG|Topical timolol maleate|"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"
219752576|NCT01752049|DRUG|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
219752577|NCT04781491|BEHAVIORAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
219752578|NCT01744015|BEHAVIORAL|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
219752579|NCT01744015|OTHER|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
219752580|NCT01779960|OTHER|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
219752581|NCT01779960|OTHER|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
219752582|NCT04015388|DEVICE|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
218992945|NCT03769766|DRUG|Placebo|Take medication one 500mg pill twice daily
218992946|NCT06012669|DIETARY_SUPPLEMENT|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
218992947|NCT06012669|DIETARY_SUPPLEMENT|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
218992948|NCT06012669|DIETARY_SUPPLEMENT|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
218992949|NCT00611208|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
219752583|NCT05809388|BEHAVIORAL|Parent training|"Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing."
219752584|NCT05809388|BEHAVIORAL|Virtual Reality-assisted PT sessions|"The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies."
219752585|NCT05093621|DRUG|Furosemide|Standard of care diuretic
219752586|NCT05093621|DRUG|Torsemide|Standard of care diuretic
219752587|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
219752588|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
219180223|NCT04016142|DRUG|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
219180224|NCT03339713|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.
219180225|NCT03339713|BIOLOGICAL|Fluarix|Fluarix will be administered as intramuscular injection.
218992950|NCT05152914|DRUG|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
219369552|NCT03417440|OTHER|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
219752589|NCT04219410|PROCEDURE|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
219752590|NCT02672995|RADIATION|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
219752591|NCT02672995|DRUG|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
219752592|NCT04925141|DRUG|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
219752593|NCT03690778|DRUG|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
219752594|NCT03690778|DRUG|JLP-1310|administration of JLP-1310
219752595|NCT05253040|OTHER|KEEP Intervention|Educational intervention
219752596|NCT05253040|OTHER|control|booklet from Parkinson's UK
219752597|NCT01941602|DRUG|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
219752598|NCT01941602|PROCEDURE|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
219752599|NCT01206517|DRUG|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
219752600|NCT01206517|DRUG|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
219752601|NCT01206517|DRUG|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
219752602|NCT00865748|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
219752603|NCT00865748|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
219752604|NCT04426747|OTHER|No intervention|No intervention
219752605|NCT01846026|DRUG|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
219752606|NCT01846026|DRUG|placebo|
219752607|NCT03493958|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
219752608|NCT01854684|DRUG|Temoporfin|Given IV
219752609|NCT01854684|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219752610|NCT01854684|DRUG|Photodynamic Therapy|Undergo intraoperative PDT
219752611|NCT01854684|OTHER|Laboratory Biomarker Analysis|Correlative studies
219752612|NCT01854684|OTHER|Pharmacological Study|Correlative studies
219752613|NCT06255353|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219752614|NCT06255353|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
219180226|NCT03339713|BIOLOGICAL|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
219180227|NCT02162563|DRUG|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
219180228|NCT02162563|DRUG|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
219180229|NCT02162563|DRUG|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
219180230|NCT05917171|BEHAVIORAL|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
219180231|NCT06143293|DEVICE|Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters|Duty cycle: At Visit 1, while the frequencies are being changed over Period 1, 2, and 3, duty cycle will be held constant at the participant's randomly assigned first duty cycle setting. At Visit 2, duty cycle will be held constant at the participant's randomly assigned second duty cycle setting. At Visit 2 the participant will receive whichever duty cycle they were not randomly assigned at Visit 1. Therefore, by completing the combination of three frequencies at two duty cycles, each participant will have received all six possible VNS parameter combinations over the two study visits. Chronic period: The VNS setting for the Chronic Period in between Visit 1 and Visit 2 will be the same settings as tested during Visit 1 Period 3. Since Visit 1 Period 3 settings were already randomly assigned to each participant, another randomization for the chronic period is not needed.
219752615|NCT06255353|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219752616|NCT04047446|DRUG|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
219752617|NCT04047446|DRUG|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
219752618|NCT05788445|DEVICE|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
219752619|NCT05788445|DEVICE|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
219752620|NCT02367456|DRUG|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
219752621|NCT02367456|DRUG|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
219752622|NCT04089410|DEVICE|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
219752623|NCT04089410|DEVICE|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
219752624|NCT04089410|OTHER|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
219752625|NCT04089410|OTHER|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
219752626|NCT04089410|OTHER|Autonomic Balance, Orthostatic and Hypoxic tolerance|"1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
219752627|NCT04089410|OTHER|Psychological Testing|"1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
219752628|NCT04089410|OTHER|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
219752629|NCT03230214|DIAGNOSTIC_TEST|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
219752630|NCT02458235|DRUG|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
219752631|NCT02458235|BIOLOGICAL|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
219752632|NCT00845702|DRUG|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
219752633|NCT00845702|OTHER|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
219752634|NCT00548886|DRUG|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
219752635|NCT05950321|PROCEDURE|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
219752636|NCT05950321|PROCEDURE|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
219752637|NCT03379974|DRUG|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
219752638|NCT03379974|BEHAVIORAL|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
219369553|NCT03417440|OTHER|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
219369554|NCT01114789|OTHER|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
219006707|NCT07132047|OTHER|Mulligan Mobilization SNAG with Home Exercise|This intervention combines manual mobilization and self-exercise. The therapist applies sustained postero-anterior glides to the second cervical vertebra for 10-30 seconds, up to six repetitions if pain decreases. The home program involves C1-C2 self-SNAG with a towel, maintaining end-range rotation for 10 seconds before returning to neutral. Exercises are completed twice daily for 10 repetitions each session. Participants receive illustrated instructions to promote correct execution and compliance.
219369555|NCT05479903|PROCEDURE|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
219752639|NCT01489904|BIOLOGICAL|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
218992951|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screen Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
218992952|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
219006708|NCT07132047|OTHER|Active Release Technique with Home Exercise|This approach integrates manual soft tissue release with targeted exercise. ART is applied to the neck and shoulder region, focusing on pectoralis major, upper trapezius, and levator scapulae. Exercises include wall angles, doorway stretches, Brugger's stretch, and head/neck retractions. Strengthening activities target rhomboids, deep neck flexors, and serratus anterior. The home routine consists of neck stretches, chin tucks, and postural drills, performed regularly to enhance muscle balance, posture, and headache relief.
219180232|NCT06213857|DIETARY_SUPPLEMENT|Silymarin|Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
219180233|NCT06213857|DRUG|Mesalamine|A 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.
219180234|NCT06213857|DRUG|Azathioprine|An immunosuppressive medication that is used for the treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis). It works by decreasing the activity of the body's immune system so it will not attack itself.
219180235|NCT01959425|OTHER|Off OAT Group (Test)|Discontinuation of OAT Therapy
219180236|NCT01959425|OTHER|On OAT Group (Control)|Continuation of OAT Therapy
219369556|NCT05479903|BEHAVIORAL|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
219180237|NCT06162728|DRUG|Briquilimab|Subcutaneous Administration
219180238|NCT06162728|OTHER|Placebo|Placebo Comparator
219369557|NCT05479903|BEHAVIORAL|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
219752640|NCT00842621|PROCEDURE|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
219180239|NCT06216808|DEVICE|HyperQure Renal Denervation System|"The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA."
219180240|NCT04619745|OTHER|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
219180241|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
219180242|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
219180243|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
219369558|NCT05479903|BEHAVIORAL|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
219369559|NCT05479903|OTHER|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
219369560|NCT00756548|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
219752641|NCT00842621|OTHER|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
219752642|NCT01427491|DEVICE|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
219752643|NCT01427491|DEVICE|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
219752644|NCT02418091|BEHAVIORAL|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
219752645|NCT04817150|PROCEDURE|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
219752646|NCT06034626|PROCEDURE|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
219752647|NCT06034626|DRUG|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
219752648|NCT01164826|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
219180244|NCT06821958|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
219180245|NCT02835222|DRUG|Cytarabine|Given IV
219180246|NCT02835222|DRUG|Daunorubicin Hydrochloride|Given IV
219180247|NCT02835222|DRUG|Selinexor|Given PO
219180248|NCT03881098|PROCEDURE|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
219180249|NCT03881098|PROCEDURE|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
219369561|NCT00756548|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
219369562|NCT00238264|RADIATION|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
219369563|NCT05484193|DRUG|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
219369564|NCT05484193|DRUG|Progesterone|vaginal progesterone for luteal phase support
219752649|NCT01164826|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
219752650|NCT05119816|OTHER|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
219752651|NCT04987372|DRUG|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
219752652|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
219752653|NCT01198587|DRUG|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
219752654|NCT01198587|DRUG|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
219752655|NCT01263327|BIOLOGICAL|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
219180250|NCT03881098|PROCEDURE|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
219369565|NCT00065026|BEHAVIORAL|Physical activity opportunities for low-income women|
219369566|NCT02706938|OTHER|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
219180251|NCT06384183|DEVICE|Kerecis Fish Skin Graft|Patients already treated with a Kerecis device
219180252|NCT02619838|DEVICE|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
219180253|NCT03715478|DRUG|GSK2857916 with Pomalidomide and Dexamethasone|Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
219180254|NCT01715285|DRUG|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
219180255|NCT01715285|DRUG|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
219180256|NCT01715285|OTHER|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
219180257|NCT01715285|DRUG|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
219180258|NCT01715285|DRUG|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
219180259|NCT05397912|DIAGNOSTIC_TEST|Uterine Elastography|Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
219180260|NCT02876510|DRUG|Fludarabine|Fludarabine infusion
219180261|NCT02876510|DRUG|Cyclophosphamide|Cyclophosphamide infusion
219180262|NCT02876510|BIOLOGICAL|IMA101 product|i.v. infusion of IMA101 product(s).
219180263|NCT02876510|BIOLOGICAL|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
219180264|NCT02876510|DIAGNOSTIC_TEST|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
219752656|NCT03425916|OTHER|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
219180265|NCT02876510|DRUG|Atezolizumab|Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
218992953|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
219180266|NCT05505292|DRUG|Lifitegrast 5% Ophthalmic Solution|Dosed twice a day for 8 weeks
219180267|NCT05505292|OTHER|Lifitegrast Ophthalmic Solution Vehicle|Dosed twice a day for 8 weeks
219180268|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
219180269|NCT06771466|PROCEDURE|Bilateral Ultrasound-Guided Erector Spinae Plane Block (group E)|The curvilinear ultrasound transducer should be placed in a cephalocaudal orientation over the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level. The transverse process will be more superficial and wider, while the rib will be deeper and thinner. Upon verification of the transverse process, the trapezius muscle, rhomboid major muscle (if performing at T5 level or higher), and erector spinae muscle should be identified superficial to the transverse process. The Tuohy needle should be inserted superior to the ultrasound probe using an in-plane approach in the cephalad to caudal direction.
219180270|NCT06771466|PROCEDURE|Bilateral Ultrasound-guided Quadratus Lumborum, Lateral approach (group Q)|With the patient positioned in the lateral position, scanning is usually started at the mid-axillary line between the iliac crest and subcostal margin, moving the probe posteriorly until tapering of the three abdominal muscle layers and appearance of fascia transversalis and QL muscle are observed. The fascia transversalis usually appears as a hyperechoic layer, which forms a safe landmark to separate the muscle layers from the peri-nephric fat and the abdominal contents
219180271|NCT06252285|BIOLOGICAL|RSVt Vaccine|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
219180272|NCT06252285|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
219180273|NCT05140200|BIOLOGICAL|GSK3511294|GSK3511294 will be administered.
219180274|NCT06616454|BEHAVIORAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
219180275|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
219180276|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
219180277|NCT06125132|PROCEDURE|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
219369567|NCT02706938|OTHER|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
219752657|NCT06006104|DRUG|HRS-4357 injection|HRS-4357 injection
219752658|NCT00930124|PROCEDURE|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
219752659|NCT00930124|PROCEDURE|Distraction osteogenesis|
219752660|NCT01758029|DRUG|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
219752661|NCT02822664|BEHAVIORAL|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
219752662|NCT02822664|BEHAVIORAL|Healthy subjects|cerebral MRI and/or cerebral PET imaging
219752663|NCT02822664|DEVICE|PET/MRI|
219752664|NCT05420571|PROCEDURE|digital impression|3D printed models after digital impressions
219752665|NCT05420571|PROCEDURE|alginate impression|Alginate impressions after plaster model infusion to make models
219752666|NCT04556253|DRUG|AK104|Subjects will receive AK104 by intravenous administration.
219752667|NCT01603654|DRUG|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
219752668|NCT01603654|DRUG|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
219752669|NCT04252014|BEHAVIORAL|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
219752670|NCT04009980|OTHER|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
219752671|NCT04009980|OTHER|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
219752672|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
219752673|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
219752674|NCT00151840|DRUG|IVIG-L|
219752675|NCT04798677|DIETARY_SUPPLEMENT|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
218992954|NCT05111925|OTHER|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
218992955|NCT06454019|BEHAVIORAL|Phone Outreach|Phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
219180278|NCT06648811|DEVICE|Pain management after surgery|Kinesio tapes will be applied to the patients in the study group after gynecological laparoscopic operations. The routine pain management will also be provided in these patients in addition to the kinesio tapes. Only postoperative pain management will be provided to the patients in the control group. The patients will be consisted of only the patients who will be operated laparoscopically for gynecological diseases.
219752676|NCT04798677|DIETARY_SUPPLEMENT|Placebo|Powder for dissolution in water, excipents. Lemon flavor
219752677|NCT04422496|DRUG|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
219752678|NCT03448211|DRUG|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
219752679|NCT02697357|BEHAVIORAL|Psychosocial Instruments|
219752680|NCT02697357|BEHAVIORAL|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
219752681|NCT00104702|PROCEDURE|adjuvant therapy|
219752682|NCT00104702|PROCEDURE|conventional surgery|
219752683|NCT00104702|RADIATION|radiation therapy|
219752684|NCT01113684|DEVICE|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
219752685|NCT01952977|DIETARY_SUPPLEMENT|Test breakfast|
219752686|NCT04076033|OTHER|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
219752687|NCT02095106|DEVICE|Waterproof Cast|
219752688|NCT02095106|DEVICE|Traditional cast|
219752689|NCT04992130|BEHAVIORAL|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
219752690|NCT03373435|DRUG|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
219369568|NCT04713943|DIETARY_SUPPLEMENT|>Your< Iron Syrup|Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
219180279|NCT06771557|OTHER|656 Online Platform|The 656 Platform provides valuable information regarding three common ailments among the elderly, namely stroke, dementia, and fall-related fractures. Serving as an online platform, the 656 Platform incorporates a Chatbot feature that facilitates connections between local caregivers, social workers, and community members to various services. Serving as an online platform, the 656 Platform incorporates an AI Chatbot and a Live Chat feature that facilitates connections between local caregivers, social workers, and community members to various services. Apart from this, the 656 Platform offers several features that enhance its functionality and user experience, including problem-based elderly resource database, interim care solutions, exchange forum, data analytics and research, and professional knowledge and resources.
219180280|NCT01073566|DEVICE|Finesse|Finesse Insulin Delivery Patch
219180281|NCT01073566|DEVICE|Pen/Syringe (Usual injection device)|Pen/Syringe
219180282|NCT02936102|DRUG|FAZ053|Anti-PD-L1 Antibody
219180283|NCT02936102|DRUG|PDR001|Anti-PD-1 Antibody
219180284|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
219180285|NCT05057845|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
219180286|NCT05057845|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219180287|NCT05057845|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
219180288|NCT05082181|BEHAVIORAL|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
219752691|NCT03373435|OTHER|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
219180289|NCT05082181|BEHAVIORAL|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
219180290|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
219180291|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
219180292|NCT04218708|OTHER|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
219180293|NCT04218708|BEHAVIORAL|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
219180294|NCT04218708|BEHAVIORAL|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
219180295|NCT04218708|BEHAVIORAL|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
219180296|NCT04218708|OTHER|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver \>300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
219180297|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923 cell suspension
219180298|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
219180299|NCT01579409|OTHER|PNNS guidelines|Application of PNNS guidelines
219369569|NCT04713943|OTHER|Placebo|Once daily dose of placebo syrup for 12 weeks
219752692|NCT00553254|DRUG|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
218992956|NCT06454019|BEHAVIORAL|Standard Notice|Standard notification letter without phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
218992957|NCT01172262|PROCEDURE|MRI|This is an observational study, no intervention will occur.
218992958|NCT02002091|OTHER|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
218992959|NCT00003870|DRUG|cyclophosphamide|
218992960|NCT00003870|DRUG|methotrexate|
218992961|NCT00003870|PROCEDURE|allogeneic bone marrow transplantation|
218992962|NCT00003870|RADIATION|iodine I 131 monoclonal antibody BC8|
218992963|NCT00003870|RADIATION|radiation therapy|
218992964|NCT04862455|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
218992965|NCT04862455|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
218992966|NCT04862455|BIOLOGICAL|Pembrolizumab|Given IV
218992967|NCT04862455|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218992968|NCT01390649|BIOLOGICAL|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
218992969|NCT06245031|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
218992970|NCT02846714|BEHAVIORAL|FLARE|
218992971|NCT02528396|DRUG|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
218992972|NCT02528396|DRUG|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
218992973|NCT04470323|DIAGNOSTIC_TEST|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
218992974|NCT00169026|DRUG|Clozapine versus typical (conventional) and atypical antipsychotic medications|
218992975|NCT00917397|DRUG|Sertraline|varies
218992976|NCT00917397|BEHAVIORAL|trauma-focused cognitive behavioural therapy|once a week
218992977|NCT03087643|OTHER|Passive mobilization - PM|
218992978|NCT01822171|OTHER|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
218992979|NCT01822171|OTHER|Home medication if needed|Patient will be provided with medication to take home, when needed.
218992980|NCT01822171|OTHER|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
218992981|NCT00000557|BEHAVIORAL|social support|
218992982|NCT02740556|OTHER|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
218992983|NCT02740556|DEVICE|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
218992984|NCT02740556|OTHER|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
218992985|NCT00183677|DRUG|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
218992986|NCT04563611|OTHER|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
218992987|NCT04563611|OTHER|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
218992988|NCT04563611|OTHER|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
218992989|NCT04563611|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
218992990|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of original formulation.
218992991|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of new formulation.
219180300|NCT03168971|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
218992992|NCT00113022|DRUG|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
218992993|NCT00113022|DRUG|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
218992994|NCT00882063|DRUG|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
218992995|NCT03366038|PROCEDURE|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
218992996|NCT05683769|GENETIC|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
218992997|NCT00536562|BEHAVIORAL|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
218992998|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218992999|NCT06438588|OTHER|Dietary Intervention|Given FMD
218993000|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
218993001|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
218993002|NCT06438588|OTHER|Interview|Ancillary studies
218993003|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
218993004|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
218993005|NCT02083783|DRUG|TRI102|formulation containing active moiety (amphetamine)
218993006|NCT02083783|OTHER|Placebo|formulation without active moiety
218993007|NCT00149201|DRUG|5-FU continuous infusion|
218993008|NCT00149201|DRUG|MTX + 5-FU sequential therapy|
218993009|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
219180301|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
219180302|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
219180303|NCT06807671|OTHER|Experimental Group|Patients in the intervention group received HBM based training for a period of 6 months. During the training, one-on-one interviews were provided with each patient. Patients were shown a power point presentation, a brochure, and 3 training videos. Any questions patients had were answered one-on-one.
219180304|NCT04326673|OTHER|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
219180305|NCT04326673|OTHER|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
219752693|NCT00189137|DRUG|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
218993010|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
218993011|NCT02287857|DRUG|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
218993012|NCT02287857|DRUG|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
218993013|NCT01762878|DRUG|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
218993014|NCT01762878|DRUG|Placebo|Dry powder for oral inhalation once daily using DIKUS device
218993015|NCT00223262|DRUG|Lamotrigine (Drug)|
218993016|NCT01546883|DRUG|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
219180306|NCT03903562|BIOLOGICAL|V503|0.5 mL 9vHPV VLP Vaccine
219180307|NCT03916042|DRUG|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
219180308|NCT03916042|DRUG|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
219180309|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
219180310|NCT05916456|DIAGNOSTIC_TEST|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
219180311|NCT05916456|DIAGNOSTIC_TEST|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
219180312|NCT05916456|DIAGNOSTIC_TEST|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
219752694|NCT05437991|DIAGNOSTIC_TEST|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
219752695|NCT00140686|BIOLOGICAL|Rotavirus (vaccine)|
219752696|NCT02008617|DRUG|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
219752697|NCT02008617|DRUG|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
219752698|NCT01641575|DRUG|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
219752699|NCT02134184|BIOLOGICAL|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
219752700|NCT03569189|OTHER|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
219752701|NCT00073125|DRUG|ABT-510/Thrombospondin-1 mimetic|
219752702|NCT00754572|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
219752703|NCT00754572|DRUG|methotrexate|10-25mg oral or parenteral weekly.
219752704|NCT01864434|DEVICE|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
219752705|NCT01864434|DEVICE|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
219752706|NCT02071615|DRUG|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
219752707|NCT02071615|DRUG|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
219752708|NCT02071615|DRUG|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
219752709|NCT02071615|DRUG|placebo|
219752710|NCT05751759|DRUG|Mitiperstat|Participants receive mitiperstat orally.
219752711|NCT05835154|BEHAVIORAL|Assessment|Complete checklist
219752712|NCT05835154|OTHER|Questionnaire Administration|Complete questionnaires
219752713|NCT05835154|OTHER|Interview|Undergo semi-structured feedback interview
219752714|NCT05835154|OTHER|Electronic Health Record Review|Review of medical records
219752715|NCT04484818|DRUG|Darolutamide|Given PO
219752716|NCT04484818|DRUG|Goserelin Acetate|Given via injection
219752717|NCT04484818|DRUG|Leuprolide Acetate|Given IV
219752718|NCT04484818|DRUG|Placebo Administration|Given PO
219752719|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
219752720|NCT04484818|DRUG|Triptorelin|Given via injection
219752721|NCT06467240|PROCEDURE|hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)|patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
219752722|NCT06388564|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
219752723|NCT06388564|DRUG|Ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
219752724|NCT06388564|DRUG|Corticosteroids|Corticosteroids will be administered at protocol defined dose.
219752725|NCT03746015|BIOLOGICAL|TDV|TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
219752726|NCT04710264|OTHER|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
219752727|NCT05948540|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily at least 2 hours after the last meal and within 30 minutes of going to bed.
219752728|NCT05948540|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
219752729|NCT03890094|DRUG|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
219752730|NCT05134649|DRUG|OnabotulinumtoxinA|Intramuscular Injection
219752731|NCT06295809|BIOLOGICAL|Pembrolizumab|IV Infusion
219752732|NCT06295809|BIOLOGICAL|Intismeran autogene|IM injection
219752733|NCT06295809|PROCEDURE|Surgery|Local resection of cancerous lesions of the skin
219752734|NCT05723640|DRUG|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219180313|NCT04855032|BEHAVIORAL|Reactive Perturbations|A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.
219180314|NCT04855032|BEHAVIORAL|Proactive Perturbations|A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
219180315|NCT04893434|DRUG|Gadobutrol|Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
219180316|NCT04893434|DIAGNOSTIC_TEST|MRI|All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations. For SA1, subjects will undergo a single research DCE-MRI exam. Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
219180317|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
219180318|NCT05039151|BIOLOGICAL|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
219180319|NCT05039151|BIOLOGICAL|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
219180320|NCT05062187|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
219180321|NCT05604508|OTHER|Many posters with prices|No poster number or price restrictions
219180322|NCT05604508|OTHER|Many posters, no prices|No poster number restrictions, but price restrictions
219180323|NCT05604508|OTHER|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
219180324|NCT05702138|OTHER|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
219752735|NCT05723640|DRUG|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219752736|NCT05723640|DRUG|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219752737|NCT05723640|DRUG|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219752738|NCT03162536|DRUG|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
219752739|NCT05050162|DRUG|Cisplatin|Given cisplatin IV every 3 weeks
219180325|NCT03420547|BEHAVIORAL|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
219180326|NCT06485609|PROCEDURE|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
219752740|NCT05050162|DRUG|Cisplatin|Given cisplatin IV weekly
219752741|NCT05050162|PROCEDURE|Computed Tomography|Undergo CT scan
219752742|NCT05050162|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219752743|NCT05050162|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219752744|NCT05050162|OTHER|Quality-of-Life Assessment|Ancillary studies
219752745|NCT05050162|OTHER|Questionnaire Administration|Ancillary studies
219752746|NCT05050162|RADIATION|Radiation Therapy|Undergo radiation therapy
219752747|NCT06103838|DRUG|18F-fluciclovine injection|370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
219752748|NCT06103838|PROCEDURE|18F-FDG PET/CT|All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
218993017|NCT04179708|OTHER|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
219180327|NCT05972005|OTHER|The Intervention (Stronger at Home Intervention)|The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.
219180328|NCT05972005|OTHER|Usual care (Control)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
219180329|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
219180330|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
219180331|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
219180332|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
219180333|NCT06802237|OTHER|Other|Assess and Evaluate hair growth and scalp health
219180334|NCT05856552|BEHAVIORAL|CBT|Cognitive behavioral therapy delivered by community resource persons via home visits.
219180335|NCT05856552|BEHAVIORAL|Group Activities|Weekly hour-long group activities delivered by community resource persons in community spaces.
219180336|NCT06802432|DRUG|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)
219180337|NCT06802302|BEHAVIORAL|Planet Nutrition Program|"The intervention in this study will be the same for both intervention groups, both based on the previously designed and tested Planet Nutrition Program (PNP). The program components include: nutrition education lessons (one 1-hour session per week), physical activity classes (two 1-hour sessions per week), and nutrition information for parents. The intervention will be implemented from February to June 2025."
219180338|NCT06803264|OTHER|Activity Oriented therapy (N.A.P.)|"The following six exercises were used, each of which was performed 10 times. Their progression was introduced by changing positions, individually adjusted to the patient's capabilities.~1. Eccentric infrahyoid muscle work during breathing activity and phonation of the lsound.~2. Reciprocal innervation of suboccipital muscles in gaze activity.~3. Stimulation of the diaphragm in the activity of breathing and phonation.~4. Repeated eccentric activity of the sternocleidomastoid (SCM) muscles during body transfer activity.~5. Repeated eccentric activity of scalene muscles in blanket pulling activity.~6. Eccentric work of suboccipital muscles in the activity of biting a snack."
219180339|NCT06803264|OTHER|Traditional therapy|"Traditional therapy included:~1. Isometric work of the neck muscles.~2. Self-assisted active exercises for the shoulder girdle muscles.~3. Active exercises in relief for the muscles of the shoulder girdle performed in the sitting position in the transverse plane.~4. TENS current treatment performed in the cervical spine and shoulder girdle in the forward lying position.~5. The local cryotherapy treatment with carbon dioxide."
219180340|NCT04590664|DRUG|Verteporfin|Given IV
219180341|NCT06451250|OTHER|Adult Day Service use for family member with dementia|Self-collection of salivary biomarkers 4 times daily for 5 days, two of those days the family member with dementia has to use adult day services
219180342|NCT05006872|DEVICE|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
219180343|NCT06802718|DRUG|Interferon|Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.
219180344|NCT05917067|DIAGNOSTIC_TEST|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
219180345|NCT03424018|DRUG|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
219180346|NCT06314399|DIAGNOSTIC_TEST|Bile culture and phenotypic antibiogram resistance test|Extraction of 3-5ml of bile from surgical specimen (gallbladder) to be taken for bacterial culture testing and phenotypical antibiogram resistance if positive
219180347|NCT04991324|DRUG|Vitamin D3|24,000 IU cholecalciferol
219180348|NCT05756777|DRUG|Gilteritinib|Dose level (-1) 80mg, (1) 120mg, (2) 120mg
219180349|NCT05756777|DRUG|Ivosidenib|Dose level (-1) 250mg, (1) 250mg, (2) 500mg
219180350|NCT05756777|DRUG|Enasidenib|Dose level (-1) 50mg, (1) 50mg, (2) 100mg
219180351|NCT06542939|BEHAVIORAL|Integrated CHW Intervention|Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
219180352|NCT06542939|BEHAVIORAL|CHW Session 1 Only|Participants will attend only the first group-based health education session on hypertension and diabetes management.
219180353|NCT06007274|OTHER|No intervention|No intervention
219180354|NCT06489106|DEVICE|Activity based upper extremity training with and without stimulation|Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
218993018|NCT04179708|OTHER|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
218993019|NCT03746457|BEHAVIORAL|Behavioral intervention|Individual counseling, group intervention, collective advocacy
218993020|NCT04746963|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
219180355|NCT04687631|DRUG|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
219180356|NCT04687631|DRUG|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
219180357|NCT06800105|OTHER|High fat smoothie|Participants will consume a standardized 490 kcal high-fat smoothie, consisting of 57% fat, 23% carbohydrate, and 20% protein.
219180358|NCT06432647|DRUG|ATH-1105|ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
219180359|NCT06432647|DRUG|Placebo|Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
219180360|NCT06802783|OTHER|Photo consent|The first group was shown photographs of the devices alongside the written consent form, while the second group received only the written consent. The study compared the pain, depression and anxiety scores between the two groups.
219180361|NCT03291028|BIOLOGICAL|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
219180362|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
219180363|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
219180364|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
219180365|NCT06803277|PROCEDURE|endodontic retreatment|Root canal retreatment is recommended when endodontic disease persists or develops after root canal treatment. Root canal retreatment is believed to be the elimination of the main causes of treatment failure.
219180366|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
219180367|NCT05209997|OTHER|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
219180368|NCT02598219|DRUG|Pre-operative SN mapping with radionucleide|"1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
218993021|NCT04746963|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
218993022|NCT04746963|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
219180369|NCT02598219|DRUG|Intra-operative SN mapping with patent V blue dye|"1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~3. SN are detected by direct visualization of blue colored lymphatics and node"
218993023|NCT04154735|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
218993024|NCT04154735|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
218993025|NCT04154735|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
219752749|NCT05623722|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
218993026|NCT04154735|DRUG|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
219752750|NCT03728478|DRUG|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
219752751|NCT03728478|DRUG|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
219752752|NCT03728478|DRUG|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
219752753|NCT03308474|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
219752754|NCT01385826|DRUG|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
219752755|NCT01385826|DRUG|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
219752756|NCT06100172|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
219752757|NCT06100172|DEVICE|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
218993027|NCT04154735|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
218993028|NCT04154735|DRUG|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
218993029|NCT04154735|DRUG|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
219752758|NCT01559935|DRUG|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
219752759|NCT01559935|DRUG|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
219752760|NCT01559935|DRUG|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
219752761|NCT01559935|DRUG|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
219752762|NCT01559935|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
219752763|NCT01559935|DRUG|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
218993030|NCT02256631|BIOLOGICAL|VRC01|Administered by subcutaneous injection in the thigh
218993031|NCT02256631|BIOLOGICAL|VRC01LS|Administered by subcutaneous injection in the thigh
218993032|NCT02256631|BIOLOGICAL|VRC07-523LS|Administered by subcutaneous injection in the thigh
218993033|NCT01646307|DRUG|Atorvastatin|
218993034|NCT01646307|DRUG|Rosuvastatin|
218993035|NCT03711461|DEVICE|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
218993036|NCT03711461|DEVICE|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
218993037|NCT03851757|DEVICE|waist-shaped interdental brush|use four times each per interdental space
218993038|NCT03851757|DEVICE|cylindric interdental brush|use four times each per interdental space
218993039|NCT02641808|OTHER|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
219752764|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
218993040|NCT02641808|OTHER|no follicular flushing|
218993041|NCT02159417|OTHER|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics"
218993042|NCT02206542|DEVICE|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
218993043|NCT02206542|OTHER|Physical therapy|
218993044|NCT02206542|DEVICE|Electroacupuncture|
218993045|NCT02647814|BEHAVIORAL|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
218993046|NCT04802317|DIAGNOSTIC_TEST|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
218993047|NCT00457301|BEHAVIORAL|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
218993048|NCT03217812|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
218993049|NCT03217812|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
218993050|NCT03217812|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
218993051|NCT03217812|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
218993052|NCT03208712|DRUG|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
218993053|NCT03208712|DRUG|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
218993054|NCT00285805|DRUG|Rosiglitazone versus placebo|
218993055|NCT00285805|DRUG|response (sodium excretion) to amiloride infusion|
219752765|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
219752766|NCT04873362|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
219752767|NCT04873362|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
219752768|NCT04873362|DRUG|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
219752769|NCT04873362|DRUG|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
219752770|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
219752771|NCT06493318|PROCEDURE|Dorsal ligamentoplasty reinforced with an internal brace|After a longitudinal dorsal incision of the wrist, an ECRB (extensor carpi radialis brevis) or palmaris longus hemi-tendon is harvested. The scapholunate positioning is adjusted using joystick pins. A 2.5 mm blind tunnel is made in the lunate and two 2.5 mm blind tunnels are made in the proximal and distal poles of the scaphoid. The tendon graft is threaded using a fiberloop and reinforced with suture tape. The graft is fixed in the proximal pole of the scaphoid with a swive-lock anchor (Arthrex®), then in the lunate, and finally fixed in the distal pole of the scaphoid by the same method. An anti-rotation scapho-capitate pin is then placed. This is maintained for 6 weeks during post-operative immobilization with a wrist orthosis. Rehabilitation begins after the pin is removed.
218993056|NCT00285805|DRUG|response (sodium excretion) to furosemide infusion|
218993057|NCT04817631|OTHER|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
218993058|NCT03750617|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
218993059|NCT05269043|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
218993060|NCT02563743|BEHAVIORAL|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
218993061|NCT02563743|BEHAVIORAL|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
219752772|NCT01431430|DRUG|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
218993062|NCT02367443|RADIATION|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
218993063|NCT05257655|PROCEDURE|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
218993064|NCT04405414|OTHER|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
218993065|NCT03954236|DRUG|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
218993066|NCT03954236|OTHER|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
219752773|NCT01431430|DRUG|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
219752774|NCT04416724|PROCEDURE|Phacoemulsification|Lens removal by Phacoemulsification
219752775|NCT04416724|DEVICE|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
219752776|NCT05379153|DEVICE|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
219752777|NCT05379153|DEVICE|Sham Intervention|Undergo placebo procedure
219752778|NCT05379153|OTHER|Questionnaire Administration|Ancillary studies
219752779|NCT05379153|OTHER|Quality of Life Assessment|Ancillary studies
219752780|NCT03186898|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219752781|NCT03186898|PROCEDURE|Computed Tomography|Undergo CT scan
219752782|NCT03186898|OTHER|Laboratory Biomarker Analysis|Correlative studies
218993067|NCT01202812|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
218993068|NCT01202812|OTHER|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
218993069|NCT02304718|BEHAVIORAL|Stationary bike|
218993070|NCT03734276|OTHER|High intensity activity|Cyclo-ergometer session in high intensity setting
218993071|NCT03734276|OTHER|control arm|Usual care
218993072|NCT05717946|DIETARY_SUPPLEMENT|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
218993073|NCT05717946|OTHER|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
218993074|NCT03599999|DRUG|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
218993075|NCT00672243|DRUG|Erlotinib + sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
219369570|NCT05533749|DEVICE|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
219369571|NCT01838044|DRUG|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
218993076|NCT04925583|RADIATION|Stereotactic body radiotherapy (SBRT)|"* level 0 (de-escalation): 10 x 5.0Gy~* level 1 (start): 10 x 5.5Gy~* level 2: 10 x 6.0Gy~* level 3: 10 x 6.5Gy"
218993077|NCT00004730|DRUG|magnesium sulfate|
218993078|NCT06049238|OTHER|Maitland Mobilization|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
218993079|NCT06049238|OTHER|Post facilitation stretch|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
218993080|NCT01223430|DRUG|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
218993081|NCT01323283|DIETARY_SUPPLEMENT|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
218993082|NCT01323283|DIETARY_SUPPLEMENT|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
218993083|NCT05649397|OTHER|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
218993084|NCT05649397|OTHER|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
218993085|NCT01102517|PROCEDURE|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
218993086|NCT01102517|PROCEDURE|axillary thoracotomy|axillary thoracotomy lobectomy
219752783|NCT03186898|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219752784|NCT03186898|OTHER|Quality-of-Life Assessment|Ancillary studies
219752785|NCT03186898|RADIATION|Radiation Therapy|Undergo proton therapy
219752786|NCT03186898|RADIATION|Radiation Therapy|Undergo photon therapy
219752787|NCT05335031|DRUG|Ozanimod|As per product label
219752788|NCT05255900|DRUG|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
219752789|NCT00694590|DRUG|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
219752790|NCT01929603|PROCEDURE|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
219752791|NCT01929603|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
219752792|NCT01929603|DRUG|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
218993087|NCT04617171|DRUG|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
219180370|NCT02598219|DRUG|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
219180371|NCT02598219|PROCEDURE|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"* Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~* Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~* Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
219180372|NCT02598219|PROCEDURE|Current initial staging protocols|Current French initial staging protocols
219180373|NCT05925985|OTHER|NA-Observational Registry|NA Observational Registry
219180374|NCT06030700|OTHER|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
219752793|NCT06343623|PROCEDURE|myomucosal resection and direct closure|myomucosal resection and direct closure
218993088|NCT04617171|DRUG|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
218993089|NCT05509114|DEVICE|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
218993090|NCT00001880|DRUG|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
218993091|NCT00001880|DRUG|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
218993092|NCT02425020|DIETARY_SUPPLEMENT|Meat Protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
218993093|NCT02425020|DIETARY_SUPPLEMENT|Whey protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
218993094|NCT02425020|DIETARY_SUPPLEMENT|Carbohydrate|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
219180375|NCT06118905|DRUG|Denosumab 60 MG/ML|Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
219180376|NCT06118905|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Infusion|Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
219180377|NCT05027841|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
219180378|NCT04111536|DRUG|liothyronine|Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
219180379|NCT04111536|OTHER|Placebo|Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
219180380|NCT06487650|BEHAVIORAL|sleep intervention|At the beginning of the intervention, participants will have an orientation and overview of the program. Then, participants will follow the curriculum of modules, and professional feedback to complete the intervention.
219180381|NCT06487650|BEHAVIORAL|Control group|Participants in control group will follow standardized usual care and a perinatal health booklet
219180382|NCT04350463|DRUG|CC-90011|CC-90011
219180383|NCT04350463|DRUG|Nivolumab|Nivolumab
219180384|NCT03689842|PROCEDURE|Uterine transplantation|Uterine transplantation from living donor
219180385|NCT05275439|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
219180386|NCT05275439|DRUG|Azacitidine (AZA)|Chemotherapy drug approved for use in MDS and AML.
219180387|NCT05275439|DRUG|Venetoclax|Drug approved for use in AML.
219180388|NCT06430437|DRUG|SHR-A1811|Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
219752794|NCT06343623|PROCEDURE|superiorly based flap|superiorly based pharyngeal flap
219752795|NCT01596270|DRUG|SAR245409|Pharmaceutical form: tablet Route of administration: oral
219752796|NCT02969577|BEHAVIORAL|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
219752797|NCT02969577|BEHAVIORAL|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
219752798|NCT02969577|OTHER|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
219180389|NCT06430437|DRUG|Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin|"Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)"
219180390|NCT05289063|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
219180391|NCT05289063|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
219180392|NCT05289063|OTHER|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
219180393|NCT05339425|OTHER|No additional intervention will be administered.|No additional intervention will be administered.
219180394|NCT06098833|DRUG|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
219180395|NCT06098833|DRUG|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
219180396|NCT04402216|BEHAVIORAL|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
219180397|NCT04402216|BEHAVIORAL|MRI preparation video|A descriptive video about what to expect when undergoing MRI
219180398|NCT04402216|BEHAVIORAL|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
219180399|NCT05257967|DIAGNOSTIC_TEST|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
219180400|NCT02674100|OTHER|Registry|
219752799|NCT03812848|OTHER|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
219752800|NCT01017900|PROCEDURE|local excision|surgical excision by orthopaedic surgeon under local anesthesia
219752801|NCT05227157|OTHER|swab with iron sulfate solution|measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
219752802|NCT06035731|OTHER|SOCIO-AESTHETICS care|SOCIO-AESTHETICS well being care performed by qualify person
219752803|NCT06314347|DIAGNOSTIC_TEST|Figure of 8 walk test|clinical measurement
219752804|NCT05657847|DEVICE|Photon-counting detector-CT|CT scan
219752805|NCT00318617|DRUG|GW510516X|
219180401|NCT03870633|OTHER|Medical Chart Review|Undergo medical chart abstraction
219180402|NCT03870633|OTHER|Interview|Complete telephone interview
219180403|NCT03870633|OTHER|Questionnaire|Ancillary studies
219180404|NCT03870633|OTHER|Quality-of-Life Assessment|Ancillary studies
219180405|NCT05068232|RADIATION|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
219180406|NCT05068232|DRUG|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
219180407|NCT05068232|DRUG|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
219180408|NCT05068232|DRUG|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
219180409|NCT05866640|DEVICE|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
219180410|NCT04103879|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
219369572|NCT01838044|DRUG|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
219752806|NCT01245608|DRUG|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
219752807|NCT05162846|OTHER|Publicly available genetic testing resources|Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
219752808|NCT05162846|BEHAVIORAL|Virtual genetics navigator|A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
219180411|NCT06332378|OTHER|Experimental group 1 :Ball training|Ball training Training in sitting position (the participants sat on the ball and did the exercises): holding balance position on the ball, active movements (flexion, extension, abduction, adduction) of one upper extremity, active movement of two upper extremities, trunk movements (bending forward and rotation), raising heel, raising toes, raising heel and toes simultaneously, resistance against perturbation, and weight shifting on ball and 2-Training in standing position: moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand, throwing the ball against the wall with foot
219752809|NCT05162846|BEHAVIORAL|Motivational interviewing (MI)|At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
218993095|NCT06478485|DIAGNOSTIC_TEST|No Intervention: MCSM|No Intervention: MCSM
218993096|NCT02657369|DRUG|Lenvatinib 24 mg|
218993097|NCT02727361|RADIATION|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
218993098|NCT02727361|OTHER|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
218993099|NCT00361569|DRUG|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
218993100|NCT00361569|DRUG|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
218993101|NCT00361569|OTHER|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
218993102|NCT00361569|OTHER|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
218993103|NCT04546815|DRUG|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
218993104|NCT02624752|DIETARY_SUPPLEMENT|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
218993105|NCT02033109|DRUG|PC-1005|Intravaginal use
218993106|NCT02033109|DRUG|HEC gel|
218993107|NCT03449797|PROCEDURE|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
218993108|NCT03449797|PROCEDURE|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
218993109|NCT05548816|OTHER|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
218993110|NCT04778930|OTHER|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
219180412|NCT06332378|OTHER|Experimental group 2 :Frenkel Exercises|"Frenkel Exercises Supine position~1. Flex and extend one leg, heel sliding down a straight line on table.~2. Abduct and adduct leg with knee and hip extended, leg sliding on table. Sitting position~1\. Place foot on therapist's hand, which will change position. 2. Raise leg and put foot on traced footprint on the wall. 3. Rise and sit with knees together. Standing position~1. Place foot forward and backward on a straight line.~2. Walk along a winding strip.~3. Walk between two parallel lines"
218993111|NCT04778930|OTHER|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
218993112|NCT02339935|BEHAVIORAL|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
218993113|NCT02339935|OTHER|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
218993114|NCT02863952|OTHER|Single photon emission computed tomography myocardial perfusion imaging|
218993115|NCT02863952|DEVICE|novel cadmium-zinc-telluride (CZT) SPECT cameras|
218993116|NCT04355520|DRUG|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
218993117|NCT04355520|DRUG|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
218993118|NCT02779829|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
218993119|NCT01480752|DRUG|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
218993120|NCT01480752|DRUG|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
218993121|NCT01480752|DRUG|no injection|inject nothing after inferior alveolar injection and before root canal therapy
218993122|NCT03282643|DRUG|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
218993123|NCT03282643|DRUG|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
218993124|NCT03282643|DRUG|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
218993125|NCT06504784|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides
219752810|NCT01189721|DRUG|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
219752811|NCT05534867|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
219752812|NCT06199479|PROCEDURE|MRI Scan|Performed by MRI Scan
219752813|NCT06199479|PROCEDURE|CT Scan|Performed by CT Scan
219752814|NCT06199479|PROCEDURE|Biopsy|Standard of Care Biopsy
219752815|NCT06335212|DEVICE|Single vision and multifocal contact lenses|Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
219752816|NCT02825667|OTHER|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
219752817|NCT01461460|DRUG|TR-701 FA 1200 mg|6 tablet of T-701 FA
219752818|NCT01461460|DRUG|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
218993126|NCT06504784|OTHER|Placebo|10g/day of placebo (glucose)
218993127|NCT02095093|DEVICE|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
218993128|NCT02095093|DEVICE|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
219006709|NCT06877169|OTHER|Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.|During combined heart and kidney transplantation, heart and kidney allografts may be implanted during a single operative event, or with delayed kidney implantation in a second operative event. Timing of the delay is often determined by recipient stability and kidney availability; however, clinicians must balance recipient factors with accumulating cold ischemic time of the kidney allograft. This study uses hypothermic oxygenated machine perfusion to reduce ischemic injury to the kidney allograft and allow for improved recipient stability with planned delayed implantation of the kidney graft. Delays will allow for at least 6 hours of hypothermic oxygenated machine perfusion prior to implantation.
219180413|NCT06332378|OTHER|Control Group|By using random allocation, the participants will divided into three groups: an intervention group (N=30) that receive ball training exercise, another intervention group (N=30) that receive Frenkel training exercise and a control group (N=30
219180414|NCT05780723|DRUG|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
219180415|NCT05780723|DRUG|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
219180416|NCT03758989|DRUG|Rituximab Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
219180417|NCT03758989|DRUG|Cyclophosphamide|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
219180418|NCT03758989|DRUG|Doxorubicin|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
219180419|NCT03758989|DRUG|Vincristine|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
219180420|NCT03758989|DRUG|Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
219180421|NCT06623253|OTHER|not aplicable|no intervention
219180422|NCT05362487|DEVICE|Spiriva® Respimat®|Spiriva® Respimat®
219180423|NCT05362487|DEVICE|Spiriva® HandiHaler®|Spiriva® HandiHaler®
219180424|NCT05362487|DRUG|Tiotropium bromide|Tiotropium bromide
219180425|NCT04274127|DIAGNOSTIC_TEST|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
219180426|NCT06350279|DRUG|HSK39297|50-600mg
219180427|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
219180428|NCT04096040|DEVICE|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
219180429|NCT03333590|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
219180430|NCT04973254|OTHER|CAB-RPV LA|Monthly administration of injectable HIV medication
219369573|NCT00495157|BEHAVIORAL|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
219180431|NCT04973254|OTHER|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
219180432|NCT06355622|DIAGNOSTIC_TEST|Characterization of pain|Standardized scales and questionnaires to detect and characterize pain, blood sample for pain biomarkers, neurophysiological tests
219180433|NCT06360796|DRUG|[(14)C]ADC189|Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
219752819|NCT01461460|DRUG|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
218993129|NCT04352816|DEVICE|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
218993130|NCT04026997|DRUG|CIN-102 Dose 1|CIN-102 Dose 1
218993131|NCT04026997|DRUG|CIN-102 Dose 2|CIN-102 Dose 2
218993132|NCT04026997|DRUG|CIN-102 Dose 3|CIN-102 Dose 3
218993133|NCT04026997|DRUG|Placebo|Placebo
219180434|NCT05920824|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound scan of the heart
219752820|NCT01461460|DRUG|Placebo|6 placebo tablets
219752821|NCT04635852|DRUG|Fentanyl|
219752822|NCT04635852|DRUG|Immediate release morphine|
219752823|NCT01140204|DEVICE|Implantation of a bare metal stent|Bare Metal Stent
219752824|NCT06448013|DRUG|Venetoclax|Given by PO
219752825|NCT06448013|DRUG|Gemtuzumab|Given by IV
219752826|NCT06448013|DRUG|Ziftomenib|Given by PO
219752827|NCT05189665|PROCEDURE|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
219752828|NCT05189665|PROCEDURE|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
219752829|NCT02553733|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
219752830|NCT02553733|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
219752831|NCT01014871|DRUG|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
219752832|NCT01014871|DRUG|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
219752833|NCT03057704|DRUG|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
219752834|NCT03057704|DRUG|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
219752835|NCT04012450|PROCEDURE|Epidural anesthesia|Performing an epidural anesthesia
219752836|NCT04012450|PROCEDURE|spina-epidural anesthesia|Performing a spina-epidural anesthesia
219752837|NCT01542892|OTHER|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
219752838|NCT01542892|DIETARY_SUPPLEMENT|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
219752839|NCT04856280|BEHAVIORAL|Kinesiological taping|In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.
219752840|NCT04856280|BEHAVIORAL|Aerobic exercise|In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
219752841|NCT06042946|PROCEDURE|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
219752842|NCT03788044|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
219752843|NCT05842551|COMBINATION_PRODUCT|Prismatic adaptation and electric stimulation|Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group
219752844|NCT02602652|BIOLOGICAL|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
219752845|NCT04047485|DIAGNOSTIC_TEST|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
219752846|NCT04047485|DIAGNOSTIC_TEST|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
219752847|NCT04047485|DIAGNOSTIC_TEST|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
219752848|NCT04047485|DIAGNOSTIC_TEST|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
218993134|NCT04094883|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
219180435|NCT05457465|DRUG|Cannabidiol|Custom formulation of a hemp-derived, high-CBD product that contains no THC.
219180436|NCT06068985|DRUG|PHESGO|Subcutaneous formulation with pertuzumab and trastuzumab.
218993135|NCT02211937|DRUG|BI 44847 solution, low dose|
219180437|NCT04629716|OTHER|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
219180438|NCT04251117|BIOLOGICAL|GNOS-PV02|GNOS-PV02 delivered by intradermal injection and electroporation
219180439|NCT04251117|BIOLOGICAL|INO-9012|INO-9012 delivered by intradermal injection and electroporation
219180440|NCT04251117|DRUG|Pembrolizumab|Pembrolizumab administered as an intravenous (IV) infusion
218993136|NCT02211937|DRUG|BI 44847 suspension, high dose|
219752849|NCT04047485|DIAGNOSTIC_TEST|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
219752850|NCT04047485|DIAGNOSTIC_TEST|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
218993137|NCT02211937|DRUG|BI 44847 tablet, low dose|
218993138|NCT02211937|DRUG|BI 44847 tablet, high dose|
218993139|NCT02211937|OTHER|high fat breakfast|
218993140|NCT04747509|OTHER|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
218993141|NCT04747509|OTHER|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
218993142|NCT05492344|OTHER|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver"
219752851|NCT04047485|DIAGNOSTIC_TEST|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
219752852|NCT00455702|DRUG|d-cycloserine|50mg dose d-cycloserine v placebo
219180441|NCT04251117|DEVICE|CELLECTRA®2000 EP Device|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
219180442|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
219180443|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
219180444|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
219752853|NCT04378868|DRUG|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
219752854|NCT04378868|DRUG|No antibiotics|No antibiotics are given while waiting surgery.
219752855|NCT04378868|OTHER|urgent schedule|Patients can wait up to 8 hours for surgery.
219752856|NCT04378868|OTHER|less urgent schedule|Patients can wait up to 24 hours for surgery.
219752857|NCT06449118|BEHAVIORAL|Mindfulness Stress Reduction Program|Mindfulness based-Stress Reduction Program an 8-week program
219752858|NCT00062257|DRUG|irofulven|
218993143|NCT05492344|OTHER|Standard care|"Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg"
219752859|NCT02908217|DRUG|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
219180445|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
219180446|NCT04266418|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
219180447|NCT04266418|DIETARY_SUPPLEMENT|Banana flower stamens extract|consume 1 sachet per day for 2 months
219369574|NCT00495157|BEHAVIORAL|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
219752860|NCT02908217|DRUG|Placebo|6 Intravenous infusions of placebo every 4 weeks.
219752861|NCT00288145|BEHAVIORAL|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
218993144|NCT03440268|DRUG|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
218993145|NCT03440268|DRUG|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
218993146|NCT01063868|DRUG|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
218993147|NCT01063868|DRUG|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
218993148|NCT05654337|OTHER|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
218993149|NCT03830424|PROCEDURE|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
218993150|NCT03830424|DIETARY_SUPPLEMENT|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
219752862|NCT03261804|BEHAVIORAL|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
218993151|NCT03009981|DRUG|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
218993152|NCT03009981|DRUG|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
218993153|NCT03009981|DRUG|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
218993154|NCT03009981|DRUG|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
218993155|NCT03565744|BEHAVIORAL|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
218993156|NCT04690998|OTHER|Blood Samples|Genetic, proteomic, neurofilament analysis
218993157|NCT04690998|OTHER|MRI|Spinal and muscular MRI
218993158|NCT01009632|BEHAVIORAL|Resonant voice|4-hr of resonant voice exercise
218993159|NCT01009632|BEHAVIORAL|Voice rest|4-hr of complete refrain from any voice use
218993160|NCT01009632|BEHAVIORAL|Spontaneous speech|
218993161|NCT04080245|BIOLOGICAL|Treatment Group Live Attenuated Flu Vaccine (LAIV)|We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.
218993162|NCT04904328|DEVICE|Lumishade® Active Lens|"Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
219006710|NCT06736418|DRUG|225Ac-ABD147|A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
219006711|NCT04777994|DRUG|ABBV-CLS-484|Oral Capsule
219006712|NCT04777994|DRUG|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
219006713|NCT04777994|DRUG|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
219006714|NCT06590987|DEVICE|Strolll AR|Strolll AR is an augmented-reality (AR) neurorehabilitation platform for delivering gait and balance exercises (assisted with cues when deemed beneficial) for Parkinson's disease onto state-of-the-art AR glasses.
219006715|NCT05084638|DRUG|Ofatumumab|20mg subcutaneous injection
219006716|NCT06152133|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
219006717|NCT06791356|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|8 sessions of therapy that focus on psychoeducation about sleep hygiene, cognitive restructuring of dysfunctional beliefs that reinforce insomnia, stimulus control to eliminate the association between the bed and wakefulness, sleep restriction in order to establish a consistent sleep schedule, and relaxation training to reduce anxiety that interferes with sleep
219006718|NCT06791356|BEHAVIORAL|Sleep hygiene education|One session of education about behavioral strategies to optimize sleep quality
219180448|NCT04061967|OTHER|Sending of screening summon.|"2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent."
219752863|NCT04164927|OTHER|Manual Lymphatic Drainage|"1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment."
219752864|NCT04164927|OTHER|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
219752865|NCT04164927|OTHER|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
219180449|NCT05477420|OTHER|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
219180450|NCT05467657|DEVICE|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
219180451|NCT04948749|DEVICE|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
219180452|NCT04948749|DRUG|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
219180453|NCT04948749|BEHAVIORAL|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
219180454|NCT04948749|DRUG|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
219180455|NCT02903290|OTHER|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait
219180456|NCT02903290|OTHER|walking track GAITRite,manual dynamometer, and treadmill|walking track GAITRite,manual dynamometer, and treadmill
219180457|NCT06628557|OTHER|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients
219180458|NCT03461276|BIOLOGICAL|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.
219180459|NCT03461276|BIOLOGICAL|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.
219180460|NCT05770284|OTHER|12 weeks exercise|12 weeks exercise
219180461|NCT05770284|OTHER|Standard Medical Treatment|Standard Medical Treatment
219180462|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
219180463|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
219180464|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
219180465|NCT02679352|DEVICE|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
219180466|NCT06112275|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
219180467|NCT06190613|BEHAVIORAL|Combination Peer navigation and mHealth intervention|Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
219180468|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
219180469|NCT06778577|OTHER|intra-articular corticosteroid injection (IACI) group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
219180470|NCT06778577|PROCEDURE|suprascapular nerve radiofrequency group (SCNRFT)|"SCNRFT is a new choice for treatment of frozen shoulder. The suprascapular nerve is the nerve that is most commonly affected in the condition of a frozen shoulder and it is for this reason that the suprascapular nerve is directly targeted by pulsed radiofrequency treatment. As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to tag the nerve accurately without injury to the nerves or vessels."
219180471|NCT06210477|DRUG|medical treatment for lower urinary tract symptoms|The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
219180472|NCT04663737|DRUG|Silmitasertib|Capsules
219180473|NCT04663737|DRUG|SOC|Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
219752866|NCT01038323|OTHER|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
219180474|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
219180475|NCT03954522|OTHER|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
219180476|NCT04960735|OTHER|VOICE intervention|"The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Best practice sharing: Identifying what lessons could be learned from the best-performing sites, according to the results of the VOICE community benchmarking and following qualitative techniques."
219180477|NCT05066412|OTHER|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
219180478|NCT05353348|DRUG|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
219180479|NCT05353348|PROCEDURE|conventional treatment|Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team
218993163|NCT04904328|DEVICE|Lumishade® Sham Lens|"Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
219180480|NCT06318143|BEHAVIORAL|TASSH|Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
219180481|NCT04700163|BIOLOGICAL|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
219180482|NCT05610644|OTHER|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
219180483|NCT03865498|BEHAVIORAL|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
219180484|NCT03865498|BEHAVIORAL|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
219180485|NCT02619994|DRUG|Linezolid|
219180486|NCT02619994|DRUG|Delamanid|
219180487|NCT02619994|DRUG|Levofloxacin|
219752867|NCT01038323|BEHAVIORAL|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
219180488|NCT02619994|DRUG|Pyrazinamide|
219180489|NCT02619994|DRUG|Locally-used WHO-approved MDR-TB regimen in Korea|
218993164|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants|As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
219006719|NCT06470373|DRUG|RBS-001 Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
219006720|NCT06470373|DRUG|Eylea® Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
219006721|NCT04203238|OTHER|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
219006722|NCT04203238|OTHER|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
219006723|NCT01955733|DRUG|BI 695500|
219006724|NCT03232047|DEVICE|Combined executive function and memory training|Computerized combined executive function and memory training
219006725|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 50mg|
219752868|NCT01038323|DRUG|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
218993165|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants|As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
218993166|NCT00147446|BEHAVIORAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
218993167|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
218993168|NCT06394817|OTHER|No intervention|No intervention
218993169|NCT00382577|DRUG|Itopride|
218993170|NCT00382577|DRUG|Placebo|
218993171|NCT01031355|DRUG|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
218993172|NCT01031355|DRUG|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
218993173|NCT01031355|DRUG|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
218993174|NCT02914470|DRUG|carbplatin, cyclophophamide, atezolizumab|
218993175|NCT00786734|DRUG|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
218993176|NCT00786734|DRUG|Pitavastatin|4mg daily for 28 days after PCI
218993177|NCT03307967|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
218993178|NCT02578316|DRUG|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
218993179|NCT05372419|DRUG|Lebrikizumab|Administered SC
218993180|NCT00254761|DRUG|Cannabis|
218993181|NCT02008630|OTHER|Animal-assisted activity|
218993182|NCT02008630|OTHER|Animal-assisted therapy|
218993183|NCT02761252|DRUG|Bilastine 20mg|
218993184|NCT02761252|DRUG|Montelukast 10mg|
218993185|NCT02761252|DRUG|Placebo Bilastine 20mg|
219752869|NCT01143402|DRUG|Dacarbazine|Given IV
219752870|NCT01143402|OTHER|Laboratory Biomarker Analysis|Correlative studies
219752871|NCT01143402|OTHER|Quality-of-Life Assessment|Ancillary studies
218993186|NCT02761252|DRUG|Placebo Montelukast 10mg|
218993187|NCT00035997|DRUG|Zometa|
218993188|NCT04758104|RADIATION|Yttrium90|Intracystic implantation of 90yttrium colloid
218993189|NCT03974191|OTHER|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
218993190|NCT01423370|DRUG|YHD1023|5g oral once daily
218993191|NCT01423370|DRUG|YHD1023|5g oral twice a day
218993192|NCT01423370|DRUG|YHD1023|10g oral once daily
218993193|NCT01423370|DRUG|Cialis|5mg oral once daily
218993194|NCT01423370|DRUG|Placebo|Oral
218993195|NCT06128044|DRUG|CB-012|CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
218993196|NCT00808626|DRUG|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
218993197|NCT04362072|DRUG|Lorlatinib|25 milligram (mg) tablet
218993198|NCT06816108|DRUG|ONO-7428|Specified dose on specified days
218993199|NCT06670794|BEHAVIORAL|Web-based intervention for concerned partners|The web-based intervention will comprise sessions focusing on community reinforcement and family therapy principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to their partner (PPR; i.e., actively listening, showing understanding, expressing interest in what their partner is thinking and feeling, and trying to see where their partner is coming from), (3) understanding their partner's drinking reinforcers, and (4) supporting their partner if they want help and engaging in positive, healthy activities with their partner.
218993200|NCT06670794|BEHAVIORAL|Psychoeducation control|This is a psychoeducation control condition.
219006726|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 25mg|
219006727|NCT04782024|DIETARY_SUPPLEMENT|Placebo|
219006728|NCT00733408|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219006729|NCT00733408|BIOLOGICAL|bevacizumab|Given IV
219006730|NCT00733408|DRUG|erlotinib hydrochloride|Given PO
219006731|NCT02965547|DEVICE|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
219180490|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
219180491|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
219180492|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
219180493|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
219180494|NCT05947357|OTHER|Nutrition Assistance Program|Patients will receive in the intervention group a $40.00 per month voucher for 6 months for use in the produce section of a local grocery store.
219180495|NCT04923945|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest. Or patient will receive Savolitinib \[Savolitinib 300 mg, po, twice per day (BID) continuously in patients with baseline weight ≥50 kg, and Savolitinib 200 mg, po, BID in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
219180496|NCT01048281|PROCEDURE|Blood draw|
219180497|NCT01048281|PROCEDURE|Tissue tumor biopsy|
219180498|NCT04552756|DIAGNOSTIC_TEST|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
219180499|NCT05703932|OTHER|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
219180500|NCT06417944|DIAGNOSTIC_TEST|Scoliosis study form|Scoliosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in detail.
219180501|NCT06417944|DIAGNOSTIC_TEST|Scoliosis X-ray (orthorontgenogram)|Patients whose Adam's forward bending test and clinical evaluation results are compatible with scoliosis, scoliosis graphy are requested. (Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 5 degrees in those with BMI (Body Mass Index) above 85%. If it is below 85% and above 7 degrees, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis film will be requested.).Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
219369575|NCT00495157|BEHAVIORAL|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
219752872|NCT01143402|DRUG|Selumetinib|Given PO
219752873|NCT01143402|DRUG|Temozolomide|Given PO
219752874|NCT04369326|OTHER|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
219752875|NCT00441025|DRUG|Alemtuzumab|
219752876|NCT02686944|BIOLOGICAL|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
219752877|NCT02842385|OTHER|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
219752878|NCT00384943|BEHAVIORAL|Moderate-intensity Exercise|
219752879|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
219752880|NCT00665834|DRUG|placebo|placebo 20 mg from day 0 to (maximum) day 6
219752881|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
219752882|NCT00665834|DRUG|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
219752883|NCT02526290|DEVICE|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
219752884|NCT02895217|OTHER|ergocycle|
219752885|NCT06560892|DRUG|Bupivacaine injection|patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
219752886|NCT06560892|DRUG|Dexmedetomidine injection|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
219752887|NCT02048540|BIOLOGICAL|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
219752888|NCT02048540|DRUG|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
219752889|NCT02048540|PROCEDURE|Gastrectomy|
219752890|NCT05603637|PROCEDURE|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
219752891|NCT05603637|PROCEDURE|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
219752892|NCT00737360|DRUG|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
219369576|NCT05601245|OTHER|High voltage pulsed current|The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
219752893|NCT06493526|DRUG|Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.|Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
219752894|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
218993201|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
218993202|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
218993203|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
218993204|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
218993205|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
218993206|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
218993207|NCT01133522|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
218993208|NCT01133522|BIOLOGICAL|Placebo|Administered by subcutaneous injection
218993209|NCT06991049|DEVICE|Fully covered self-expandable metal esophageal stent|Esophageal stent placement for patients with benign esophageal strictures not responding to endoscopic dilations.
218993210|NCT06995326|DRUG|SGB-3383|SGB-3383 for sc injection, single dose
218993211|NCT06995326|DRUG|SGB-3383-Matching placebo|SC injection, single dose
218993212|NCT06008249|DRUG|Lithium Carbonate 400 MG|Lithium carbonate vs placebo (2:1)
218993213|NCT07005739|BEHAVIORAL|Turkish Folk Dance-Based Exercise Program|Participants in the intervention group received a structured Turkish folk dance-based exercise program in addition to their regular football training. The dance-based intervention consisted of two 45-minute sessions per week for 8 weeks, including traditional Turkish folk dance movements aimed at improving balance, agility, and core stability.
218993214|NCT07010796|DEVICE|Alma Prime X|Alma Prime x is a platform that provides applicators for radiofrequency and ultrasound.
218993215|NCT07016204|BEHAVIORAL|Cognitive-Behavioral Therapy|A structured 12-week psychotherapy protocol targeting maladaptive appearance-related beliefs and behaviors in individuals with Body Dysmorphic Disorder (BDD). The intervention involves individual sessions once per week (60 minutes) and incorporates techniques such as psychoeducation, cognitive restructuring, exposure and response prevention (ERP), mindfulness, and attentional retraining.
218993216|NCT07014930|DRUG|Control session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling.
218993217|NCT07014930|DRUG|Inhibition session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 50 mg of fluvoxamine for 7 consecutive days (CYP2C19 inhibitor).
218993218|NCT07014930|DRUG|Induction session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 600 mg of rifampicin for 10 consecutive days (CYP2C19 inducer).
218993219|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein with the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation with the additional use of the FARAVIEW mapping system (The additional mapping approach)
218993220|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein without the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation without the use of the FARAVIEW mapping system.
218993221|NCT07014384|DEVICE|Anodal and cathodal ctDCS|CtDCS will be delivered using an DC-stimulator and two saline-soaked sponge electrodes: one electrode placed 3 cm lateral to the right of the inion, the other electrode on the right buccinator muscle. A 2 mA current will be delivered through these electrodes for a duration of 20 minutes with a 8-second fade-in and fade-out.
218993222|NCT07014384|DEVICE|Sham stimulation|The tDCS procedure will be identical to the active (anodal and cathodal) stimulation condition, but stimulation will cease after 30 seconds.
218993223|NCT06627751|BIOLOGICAL|Mezigdomide|Given PO
218993224|NCT06627751|DRUG|Carfilzomib|Given IV
218993225|NCT06627751|DRUG|Dexamethasone|Given PO
218993226|NCT06627751|PROCEDURE|Echocardiography|Undergo ECHO
218993227|NCT06627751|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218993228|NCT06627751|PROCEDURE|Computed Tomography|Undergo PET/CT
219369577|NCT05601245|OTHER|Microcurrent therapy|The treatment session duration is 40 minutes.
219369578|NCT04707638|OTHER|No intervention used|No intervention used
219369579|NCT05191160|OTHER|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
219369580|NCT05191160|OTHER|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
219369581|NCT05191160|OTHER|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
219752895|NCT04379570|OTHER|Educational Intervention|Receive online educational information about ET medication
219752896|NCT04379570|OTHER|Text Message-based Navigation Intervention|Receive text messages
218993229|NCT06627751|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT guided tumor Biopsy
218993230|NCT06627751|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration biopsy
218993231|NCT06627751|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218993232|NCT06627751|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
218993233|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
218993234|NCT03598751|DRUG|Placebo|2 mL
218993235|NCT05237687|DRUG|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
218993236|NCT00009997|BIOLOGICAL|trastuzumab|
218993237|NCT00009997|DRUG|cyclophosphamide|
218993238|NCT00009997|DRUG|doxorubicin hydrochloride|
218993239|NCT00009997|DRUG|paclitaxel|
219180502|NCT06417944|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. We will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
219180503|NCT06417944|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter- cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
218993240|NCT00009997|DRUG|tamoxifen citrate|
219369582|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
219369583|NCT03824301|DEVICE|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
219369584|NCT03824301|DEVICE|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
219369585|NCT01982591|OTHER|laboratory biomarker analysis|Correlative studies
219752897|NCT04379570|BEHAVIORAL|Motivational Interviewing|Receive motivational interviewing counseling sessions
219752898|NCT04379570|OTHER|Best Practice|Attend usual care clinic visits
218993241|NCT00009997|PROCEDURE|conventional surgery|
218993242|NCT05869422|DIETARY_SUPPLEMENT|Iron|60 ± 5 days of daily oral iron supplementation.
218993243|NCT05869422|OTHER|Placebo|60 ± 5 days of daily oral placebo intake.
218993244|NCT06507046|PROCEDURE|Total knee replacement|Mechanical or Personalized alignment
218993245|NCT03834961|DRUG|Larotrectinib Sulfate|Given PO or via NG or G tube
218993246|NCT01700725|OTHER|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
219752899|NCT04379570|OTHER|Questionnaire Administration|Ancillary studies
219752900|NCT04379570|OTHER|Quality-of-Life Assessment|Ancillary studies
218993247|NCT01700725|DRUG|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
218993248|NCT03092154|DRUG|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
218993249|NCT03578861|OTHER|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
218993250|NCT00809276|DRUG|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
218993251|NCT05621785|DEVICE|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
218993252|NCT00595530|DRUG|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
218993253|NCT02176499|DRUG|Telmisartan, low dose|
218993254|NCT02176499|DRUG|Telmisartan, high dose|
218993255|NCT02176499|DRUG|Placebo|
218993256|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
219180504|NCT06417944|PROCEDURE|Three-dimensional Exercise (BSPTS Schroth Exercise)|"It only provides outpatient treatment, but it has different practices, intensive or regular, depending on local and external patients. For local patients, it is applied once a week, accompanied by a therapist, and the treatment duration is determined according to the patient's condition. In patients coming from outside; It can be continued as 2 hours a day for 10 days, then as additional treatment for 1-2 weeks for 3-6 months depending on the patient's condition. I In regular treatment; 30 sessions of 90 minutes group treatment, the first 8 sessions are carried out under the supervision of a therapist for a shorter period of time.~We will give 10 sessions of BSPTS Schroth exercises, either outpatient or inpatient. After 10 sessions of the Schroth exercise program, the home program will continue two months after outpatient/inpatient schroth exercise(Home program: 5 days/week, 45-60 minutes for all patients)."
219369586|NCT01982591|OTHER|questionnaire administration|Ancillary studies
219752901|NCT05213741|DEVICE|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
219752902|NCT04490681|DRUG|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
219752903|NCT04490681|DRUG|Placebo|Placebo group
219752904|NCT01965847|BEHAVIORAL|Medication therapy management|
219752905|NCT03622151|OTHER|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
219752906|NCT05073588|OTHER|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
219752907|NCT05073588|OTHER|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
219752908|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
219752909|NCT01447784|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
219752910|NCT01447784|BIOLOGICAL|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
219752911|NCT03290027|DRUG|DFD-03|DFD-03 Lotion
219752912|NCT03290027|OTHER|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
219752913|NCT00238394|DRUG|cediranib maleate|Given orally
219752914|NCT00238394|OTHER|laboratory biomarker analysis|Correlative studies
219752915|NCT05408845|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219752916|NCT05408845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219752917|NCT05408845|PROCEDURE|Computed Tomography|Undergo a CT scan
219752918|NCT05408845|DRUG|Docetaxel|Given IV
219752919|NCT05408845|PROCEDURE|Echocardiography Test|Undergo ECHO
219752920|NCT05408845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219752921|NCT05408845|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219752922|NCT05408845|OTHER|Questionnaire Administration|Ancillary studies
219752923|NCT05408845|BIOLOGICAL|Trastuzumab|Given IV
219752924|NCT05408845|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219752925|NCT05408845|BIOLOGICAL|Trastuzumab Emtansine|Given IV
219752926|NCT01891955|BEHAVIORAL|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
219752927|NCT01891955|BEHAVIORAL|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
219752928|NCT00619866|DRUG|Elagolix|Elagolix tablets administered orally
219752929|NCT00619866|DRUG|placebo|Placebo tablet administered orally
219752930|NCT04570371|BEHAVIORAL|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
219752931|NCT05940428|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
219752932|NCT01098422|DEVICE|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
219752933|NCT01135966|BEHAVIORAL|Conventional resistance training program|Conventional resistance training program is followed.
219752934|NCT01135966|BEHAVIORAL|Whole body vibration resistance training program|WBV training on FITVIBE
219752935|NCT03949517|DRUG|68-Ga RM2|Radioactive agent
219752936|NCT03949517|DRUG|68-Ga PSMA11|Radioactive agent
219752937|NCT03949517|DEVICE|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
219752938|NCT03949517|PROCEDURE|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
219752939|NCT03558217|DEVICE|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
219752940|NCT03558217|DEVICE|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
219752941|NCT04473560|DEVICE|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
219752942|NCT01923376|DRUG|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
219752943|NCT01923376|DRUG|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
219752944|NCT02665377|DRUG|ANP|
219752945|NCT02665377|DRUG|Placebo|
219752946|NCT01474109|DRUG|macitentan 3mg|macitentan 3mg tablet once daily
219752947|NCT01474109|DRUG|macitentan 10mg|macitentan 10mg tablet once daily
219752948|NCT01474109|DRUG|placebo|matching placebo once daily
219752949|NCT02589938|OTHER|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
219752950|NCT02589938|OTHER|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
219752951|NCT02589938|OTHER|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
219752952|NCT05512624|BEHAVIORAL|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
219752953|NCT00778427|DRUG|metformin hydrochloride 1000 mg tablets|
219752954|NCT00129857|DRUG|Dexanabinol|
219752955|NCT05997329|OTHER|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
219752956|NCT01814982|DRUG|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
219752957|NCT05056766|BEHAVIORAL|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
219752958|NCT03050190|GENETIC|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
219752959|NCT02521285|DRUG|Aspirin|Given PO
219752960|NCT02521285|OTHER|Laboratory Biomarker Analysis|Correlative studies
219752961|NCT02521285|OTHER|Placebo Administration|Given PO
219752962|NCT02521285|OTHER|Questionnaire Administration|Ancillary studies
219752963|NCT05235204|PROCEDURE|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
219752964|NCT01424553|OTHER|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
219752965|NCT00317122|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
219752966|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with propofol|Incremental administration of propofol up to a cummulative full therapeutic dose (2mg/kg) in POH patients investigated for propofol. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.02mg/kg-0.2 mg/kg -0.6 mg/kg -1.2mg/kg).
219752967|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with ketamine|Incremental administration of ketamine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for ketamine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mg/kg -0.1 mg/kg -0.3 mg/kg -0.6mg/kg).
219752968|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with etomidate|Incremental administration of etomidate up to a cummulative full therapeutic dose (0.2mg/kg) in POH patients investigated for etomidate. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.002 mg/kg -0.02 mg/kg -0.06 mg/kg -1.2mg/kg).
219752969|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with midazolam|Incremental administration of midazolam up to a cummulative full therapeutic dose (0.05mg/kg) in POH patients investigated for midazolam. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.0005 mg/kg -0.005 mg/kg -0.015 mg/kg -0.03mg/kg).
219752970|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with fentanyl|Incremental administration of fentanyl up to a cummulative full therapeutic dose (1mcg/kg) in POH patients investigated for fentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mcg/kg -0.1 mcg/kg -0.3 mcg/kg -0.6mcg/kg).
219752971|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with sufentanyl|Incremental administration of sufentanyl up to a cummulative full therapeutic dose (0.1mcg/kg) in POH patients investigated for sufentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.001 mcg/kg -0.01 mcg/kg -0.03 mcg/kg -0.06µg/kg).
219752972|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with alfentanil|Incremental administration of alfentanil up to a cummulative full therapeutic dose (10mcg/kg) in POH patients investigated for alfentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.1 mcg/kg -1 mcg/kg -3 mcg/kg -6µg/kg).
219752973|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with remifentanil|Incremental administration of remifentanil up to a cummulative full therapeutic dose (0.5mcg/kg) in POH patients investigated for remifentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.005 mcg/kg -0.05 mcg/kg -0.15 mcg/kg -0.3µg/kg).
219752974|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with rocuronium|Incremental administration of rocuronium up to a cummulative full therapeutic dose (0.6mg/kg) in POH patients investigated for rocuronium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.006 mg/kg -0.06 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.18 mg/kg -0.42mg/kg) are administerd under general anesthesia.
219752975|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with atracurium|Incremental administration of atracurium up to a cummulative full therapeutic dose (0.5mg/kg) in POH patients investigated for atracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.005 mg/kg -0.05 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.15 mg/kg -0.35mg/kg) are administered under general anesthesia .
219752976|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with cisatracurium|Incremental administration of cisatracurium up to a cummulative full therapeutic dose (0.15mg/kg) in POH patients investigated for cisatracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.0015 mg/kg -0.015 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.045 mg/kg -0.105mg/kg) are administered under general anesthesia .
219752977|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with succinylcholine|Incremental administration of succinylcholine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for succinylcholine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.01 mg/kg -0.1 mg/kg). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.3 mg/kg -0.7mg/kg) are administered under general anesthesia.
219752978|NCT05677048|BEHAVIORAL|Free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing
219180505|NCT06417944|PROCEDURE|Home Exercise|In the home exercise program; daily living activities, neutral pelvis exercises, coronal balance exercises, rotational angular breathing exercises and axial elongation exercises were taught by the physiotherapist in one session. A total of 10-week home exercise program was planned, with exercises to be performed twice a week for the first two weeks, once every 15 days for 1 month (twice in one month), and then once a month.
219180506|NCT06042803|OTHER|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
219752979|NCT05677048|BEHAVIORAL|IGNITE-TX Group|Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
219752980|NCT05677048|BEHAVIORAL|IGNITE-TX and free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
219752981|NCT06555419|DRUG|Nusinersen|Administered as specified in the treatment arm.
219752982|NCT06555419|DEVICE|ThecaFlex DRx System|Implanted as specified in the treatment arm.
219752983|NCT06430346|BEHAVIORAL|Exercise|Physical activity and resistance training
219752984|NCT02688959|BEHAVIORAL|Tai Chi|
219752985|NCT02688959|BEHAVIORAL|Exercise|
219752986|NCT03655782|BEHAVIORAL|PATH + DigitMemory (DM) neurotraining|Improve visual timing and sensitivity in the dorsal stream. The mTBI subject will sit 57 cm in front of a computer monitor. During the presentation, the bars in the 'fish-shaped' window in the center of the screen formed by a sinusoidal grating, move left or right very briefly. When the screen goes blank, the subject reports which way the center pattern moved by pushing the left or right arrow key. A brief tone is presented after incorrect responses. The program adaptively changes the contrast of the test pattern so that the subject detects motion at lowest contrast possible. A sequence of patterns in each training cycle that are designed to optimally activate magnocellular neurons are shown to the subject. There are two programs, the first measures the contrast needed to see one direction of movement, and the second program measures the contrast needed to see two directions of movement, requiring memory. Both are followed by digit memory exercises.
219752987|NCT05273268|OTHER|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
219752988|NCT05273268|OTHER|Generalized nutrition|General nutrition guidelines currently used by USDA.
219752989|NCT04369105|OTHER|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
219752990|NCT05432973|PROCEDURE|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
219180507|NCT06042803|OTHER|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
219180508|NCT06042803|OTHER|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
219180509|NCT05760144|DRUG|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
219180510|NCT05760144|DRUG|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
219180511|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
219180512|NCT03270501|DRUG|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
219180513|NCT06513832|BEHAVIORAL|The asthma navigator|The asthma navigator is a Registered Respiratory Therapist and Certified Asthma Educator who will review the care plan at discharge and provide asthma education; assist with follow-up clinic appointment scheduling, medication access, and transportation; and daily as-needed telephone support.
219180514|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
219180515|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
219180516|NCT04696042|DRUG|Lanreotide autogel|Lanreotide autogel 90-120 mcg, every 4 weeks
219180517|NCT05329090|DRUG|Rituximab Injection|anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
219180518|NCT05329090|DRUG|placebo|placebo experimental treatment
219180519|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
219180520|NCT03991130|DRUG|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
219369587|NCT03465033|OTHER|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
218993257|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
218993258|NCT00381485|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
218993259|NCT02495298|PROCEDURE|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
218993260|NCT02495298|PROCEDURE|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
218993261|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
218993262|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
218993263|NCT04243967|OTHER|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
218993264|NCT04243967|OTHER|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
218993265|NCT03330730|OTHER|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
218993266|NCT05979350|DIAGNOSTIC_TEST|Metagenomic next-generation sequencing|Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
218993267|NCT05979350|DIAGNOSTIC_TEST|Standard work-up for pneumonia|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
218993268|NCT01511315|DRUG|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
218993269|NCT02697825|PROCEDURE|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
218993270|NCT04767932|BEHAVIORAL|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
218993271|NCT05478785|DRUG|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
219369588|NCT05596214|COMBINATION_PRODUCT|Curcumin-Berberine (coptis)|dietary supplement
219752991|NCT05432973|PROCEDURE|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
219752992|NCT04425239|DRUG|Panitumumab|Continuous administation
219752993|NCT04425239|DRUG|Panitumumab|Intermittent administation
219752994|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
219752995|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
219752996|NCT04548648|DRUG|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
219752997|NCT05151640|DRUG|Nintedanib|Nintedanib
219752998|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
219752999|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
219753000|NCT01684904|RADIATION|Proton radiation|
219753001|NCT02268656|DRUG|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
219753002|NCT00748605|DRUG|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
219753003|NCT00748605|DRUG|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
219753004|NCT00748605|DRUG|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
219369589|NCT05596214|COMBINATION_PRODUCT|Placebo|Placebo
219753005|NCT00748605|OTHER|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
219753006|NCT00748605|OTHER|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
219753007|NCT04806152|OTHER|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
219753008|NCT04806152|OTHER|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
219753009|NCT06548048|DIETARY_SUPPLEMENT|Dietary supplement containing plant derived phenolics|Dietary supplement containing plant derived phenolics
219753010|NCT06548048|DIETARY_SUPPLEMENT|Microcrystaline cellulose|Microcrystaline cellulose (MCC)
219753011|NCT06548724|OTHER|assessment of quality of life before and after anal surgery|"Preoperatively, the state of continence will be assessed using Wexner Incontinence Score (WIS) . Also, the basal state of quality of life (QoL) will be assessed using a validated disease-specific tool known as Quality of Life in patients with Anal Fistula Questionnaire (QoLAFQ) (Ferrer-Márquez et al., , faecal incontinence quality of life (FIQL)~Surgical Techniques:~The selection of surgical technique depends on the type of fistula , patient choice and commitment to guidelines . Follow-up Patients will be followed-up in the outpatient clinic weekly in the first month, then every two weeks in the second month, then at 3, and 6 months postoperatively. The continence state and QoL change will be assessed using QoLAF-Q and GIQLI 3 months and6 months postoperatively."
219753012|NCT00895505|DRUG|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
219753013|NCT00895505|DRUG|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
219753014|NCT04862312|BEHAVIORAL|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
219753015|NCT06201845|OTHER|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
219369590|NCT04060615|PROCEDURE|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
218993272|NCT01206660|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
219369591|NCT00860470|DIETARY_SUPPLEMENT|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
218993273|NCT01206660|DRUG|placebo|Placebo administered to affected area twice a day for 28 days
218993274|NCT02967744|DRUG|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
218993275|NCT03922503|PROCEDURE|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
218993276|NCT03922503|PROCEDURE|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
218993277|NCT03387332|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
218993278|NCT05328193|BEHAVIORAL|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
218993279|NCT05328193|BEHAVIORAL|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
218993280|NCT01898806|DRUG|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
218993281|NCT01898806|DRUG|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
218993282|NCT01898806|DRUG|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
218993283|NCT01898806|DRUG|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
218993284|NCT00674544|BEHAVIORAL|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
218993285|NCT00126191|DRUG|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
218993286|NCT00126191|DRUG|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
218993287|NCT00126191|DRUG|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
219180521|NCT06324318|BEHAVIORAL|Parenting in 2 Worlds (P2W)|P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
219180522|NCT06324318|BEHAVIORAL|Healthy Families in 2 Worlds (HF2W)|HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
219753016|NCT06201845|OTHER|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
219753017|NCT02824679|DRUG|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
219753018|NCT02824679|DRUG|saline|0.9%normal saline
218993288|NCT00126191|DRUG|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
219753019|NCT05231980|DIETARY_SUPPLEMENT|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
219753020|NCT05231980|DRUG|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
219753021|NCT05231980|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
219753022|NCT02758821|OTHER|No CRP will be measured onsite|No CRP will be measured onsite
219753023|NCT02758821|OTHER|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
219753024|NCT02758821|OTHER|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
219753025|NCT04772794|OTHER|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
218993289|NCT00126191|DRUG|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
219180523|NCT06180954|DRUG|[14C]-LOXO-305|Administered orally
219180524|NCT06180954|DRUG|LOXO-305|Administered orally
219180525|NCT06180954|DRUG|[14C]-LOXO-305|Administered IV
219753026|NCT00249626|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
219753027|NCT01435343|DRUG|fludarabine|30 mg/m2/day intravenously on days 1 to 4
219753028|NCT01435343|DRUG|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
219753029|NCT01435343|DRUG|cytarabine|2 g/m2/day intravenously on days 1 to 4
219753030|NCT01435343|DRUG|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
219753031|NCT01435343|DRUG|plerixafor|intravenously from days 1 to 4
218993290|NCT00126191|DRUG|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
218993291|NCT00126191|DRUG|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
218993292|NCT00126191|DRUG|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
218993293|NCT00126191|DRUG|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
218993294|NCT00126191|DRUG|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
218993295|NCT01648101|DRUG|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
218993296|NCT01648101|DRUG|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
218993297|NCT01648101|OTHER|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
218993298|NCT03003390|DRUG|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
218993299|NCT03178877|OTHER|No intervention|
219369592|NCT00860470|DIETARY_SUPPLEMENT|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
219753032|NCT04940169|PROCEDURE|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
219753033|NCT01121757|DRUG|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
218993300|NCT01340885|DRUG|Strattera|10-30 mg b.i.d. for 6 weeks
218993301|NCT01340885|DRUG|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
218993302|NCT01340885|OTHER|Placebo|2-6 pills for 6 weeks
218993303|NCT00940225|DRUG|Cabozantinib|
218993304|NCT00940225|DRUG|Placebo|
218993305|NCT02007694|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
218993306|NCT04352647|BEHAVIORAL|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
218993307|NCT00500669|DRUG|Betadine|Topically
218993308|NCT03283852|GENETIC|blood sample|search for genetic mutations
218993309|NCT00649324|DRUG|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
219753034|NCT01121757|DRUG|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
219753035|NCT06422455|OTHER|Best Practice|Receive provider-based genetic counseling
219753036|NCT06422455|OTHER|Educational Intervention|Receive genetics education
219753037|NCT06422455|OTHER|Electronic Health Record Review|Ancillary studies
219753038|NCT06422455|OTHER|Genetic Counseling|Receive provider-based genetic counseling
219753039|NCT06422455|OTHER|Interview|Ancillary studies
219753040|NCT06422455|OTHER|Survey Administration|Ancillary studies
219753041|NCT00319761|DRUG|Calcitriol|
219180526|NCT05329220|BIOLOGICAL|ABNCoV2|ABNCoV2 100μg single dose
219369593|NCT03689192|BIOLOGICAL|ARG1-18,19,20|300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
219753042|NCT03611712|DRUG|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
218993310|NCT00649324|DRUG|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
219180527|NCT05329220|BIOLOGICAL|Comirnaty|Comirnaty
219753043|NCT06032182|BEHAVIORAL|CRESTR Intervention|15 1-hour sessions of CRT + SRT
219753044|NCT06032182|BEHAVIORAL|CRESTR Control|15 1-hour sessions of SRT alone
219753045|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
218993311|NCT00307294|DRUG|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
218993312|NCT00307294|DRUG|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
218993313|NCT00869154|BEHAVIORAL|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
218993314|NCT00869154|BEHAVIORAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
218993315|NCT00475358|DRUG|Duloxetine|
218993316|NCT00475358|DRUG|Placebo|
218993317|NCT02704117|DEVICE|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
218993318|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
218993319|NCT04616378|OTHER|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
218993320|NCT04616378|OTHER|Phase 3 No Prosthesis|No prosthetic device is attached.
218993321|NCT04616378|OTHER|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
218993322|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
218993323|NCT03269864|PROCEDURE|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
218993324|NCT02052583|PROCEDURE|therapeutic hypothermia at 32 ° C|
218993325|NCT02052583|PROCEDURE|therapeutic hypothermia at 34 ° C|
218993326|NCT00871702|GENETIC|CD34-TK75 transduced donor lymphocytes|
218993327|NCT00871702|RADIATION|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
218993328|NCT02032121|PROCEDURE|Blood specimen|
218993329|NCT02032121|PROCEDURE|Echocardiography|
218993330|NCT02243332|DEVICE|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
218993331|NCT01282892|PROCEDURE|excess of visceral fat|excess of visceral fat
218993332|NCT01282892|PROCEDURE|patients with NAFLD|patients with NAFLD
218993333|NCT00943059|DRUG|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
218993334|NCT00943059|DRUG|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
218993335|NCT06508424|OTHER|PulseOn|PulseOn - 1 week washout period between interventions 75g crackers
218993336|NCT06508424|OTHER|Wheat flour control|Control -1 week washout period between interventions 75g crackers
218993337|NCT04244331|DIAGNOSTIC_TEST|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
218993338|NCT05890846|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
218993339|NCT05890846|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
218993340|NCT05890846|BEHAVIORAL|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
219369594|NCT05851469|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
218993341|NCT03777878|DRUG|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
218993342|NCT03777878|DRUG|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
218993343|NCT03777878|DRUG|TA|2 ampoules of TA in 100 ml saline by slow infusion
218993344|NCT03777878|DRUG|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
218993345|NCT03777878|DRUG|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
218993346|NCT03777878|DRUG|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
218993347|NCT04010708|DIAGNOSTIC_TEST|Urinary Iodine Concentration Measurement|UIC
219753046|NCT01207037|PROCEDURE|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
218993348|NCT03043131|DRUG|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
218993349|NCT03043131|DRUG|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
218993350|NCT03775811|OTHER|AUTOMATED POLYP CLASSIFICATION|COLONIC POLYP HISTOLOGY PREDICTION IN WHITE LIGHT IMAGES COMBINING ARTIFICIAL INTELLIGENCE AND CLINICAL INFORMATION
218993351|NCT02122393|DRUG|Sertraline|
218993352|NCT02122393|BEHAVIORAL|Cognitive Behavioural Therapy|
218993353|NCT00656110|DRUG|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
218993354|NCT00656110|DRUG|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
218993355|NCT01953198|OTHER|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
218993356|NCT00634166|DRUG|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
218993357|NCT00634166|DRUG|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
218993358|NCT01308060|DRUG|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
218993359|NCT01308060|OTHER|Placebo|
218993360|NCT06485882|BEHAVIORAL|Self-Care Training|Animation films are watched children about self-care and social competence
219753047|NCT02935764|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
218993361|NCT06219512|BEHAVIORAL|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
218993362|NCT06219512|BEHAVIORAL|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
218993363|NCT06219512|BEHAVIORAL|Regular exercise|Regular exercise
218993364|NCT06131034|OTHER|Music|Participant in the intervention group will receive music interventions perioperatively.
218993365|NCT02292979|DRUG|Doxorubicin|25mg/m2
218993366|NCT02292979|DRUG|Bleomycin|10mg/m2
218993367|NCT02292979|DRUG|Vinblastine|6mg/m2
218993368|NCT02292979|DRUG|Dacarbazine|375mg/m2
219753048|NCT02935764|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
219753049|NCT02935764|DRUG|Leucovorin|400mg/m2 iv gtt,d1
218993369|NCT02292979|DRUG|Brentuximab Vedotin|1.2 mg/kg
218993370|NCT00111345|DRUG|Anthracyclines|3x12 mg/qm
218993371|NCT00111345|DRUG|liposomal daunorubicin|3x80 mg/qm
218993372|NCT00111345|DRUG|2-CDA|2x6 mg/qm
218993373|NCT00111345|DRUG|AI|AI
218993374|NCT04818398|DRUG|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
218993375|NCT04818398|DRUG|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
218993376|NCT01581931|DRUG|Linagliptin/metformin|FDC
219753050|NCT02461186|DRUG|Arterolane maleate-piperaquine phosphate (Synriam)|
218993377|NCT01581931|DRUG|Metformin|single tablet Metformin
218993378|NCT01581931|DRUG|Linagliptin|single tablet Linagliptin
218993379|NCT02185833|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
218993380|NCT02185833|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
218993381|NCT06374160|BEHAVIORAL|Exercise intervention|Exercise
218993382|NCT02316808|DIETARY_SUPPLEMENT|Plant stanol ester|Smoothie that contains plant stanol ester
218993383|NCT02316808|DIETARY_SUPPLEMENT|placebo|Smoothie that contains placebo
218993384|NCT04803825|OTHER|Heavy Slow Exercises|"* Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
218993385|NCT04803825|DEVICE|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
218993386|NCT04803825|OTHER|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
218993387|NCT04488484|OTHER|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
219006732|NCT02965547|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
219753051|NCT02461186|DRUG|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
219180528|NCT05714683|DRUG|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
219753052|NCT04834921|DEVICE|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
218993388|NCT02954237|DEVICE|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
218993389|NCT04455113|DIAGNOSTIC_TEST|Phosphorus level|infusion
218993390|NCT05448183|DRUG|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
218993391|NCT00706823|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
218993392|NCT00706823|DEVICE|Laryngeal Mask Airway-Unique|supra-glottic airway device
218993393|NCT00009698|BIOLOGICAL|aldesleukin|Given SQ and IV
218993394|NCT03719885|DEVICE|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
218993395|NCT01761890|BEHAVIORAL|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
218993396|NCT03239288|OTHER|Control digestible carbohydrate|Single serving of control product
218993397|NCT03239288|OTHER|Test resistant starch type 4|Single serving of test product
218993398|NCT03087669|DEVICE|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
218993399|NCT03087669|DRUG|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
218993400|NCT04443725|DRUG|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
218993401|NCT04443725|DRUG|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
218993402|NCT04030611|DIAGNOSTIC_TEST|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
218993403|NCT03644212|DRUG|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
219180529|NCT05854550|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
219180530|NCT03327805|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
219180531|NCT03327805|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
219753053|NCT04168931|DRUG|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
219753054|NCT06118866|DRUG|placebo-Q2W|placebo, 0mg，SC，Q2W，12 cycles
219753055|NCT06118866|DRUG|HMI-115-120mg-Q4W|HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
219753056|NCT06118866|DRUG|HMI-115-240mg-Q4W|HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
219753057|NCT06118866|DRUG|HMI-115, 240mg-Q2W|HMI-115, 240mg，SC，Q2W，12 cycles
219180532|NCT04036682|DRUG|CLN-081|CLN-081 tablets
219180533|NCT06251180|DRUG|Rocbrutinib|orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
219180534|NCT06251180|BIOLOGICAL|Rituximab|375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
219180535|NCT06251180|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
219180536|NCT06251180|DRUG|doxorubicin|50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
219180537|NCT06251180|DRUG|Vincristin|1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
219180538|NCT06251180|DRUG|Prednisone|100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
219180539|NCT02561936|DRUG|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
219180540|NCT02561936|DRUG|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10\*2.5 mg tablets.
219180541|NCT02561936|DRUG|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10\*2.5 mg tablets.
219180542|NCT02561936|DRUG|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
219180543|NCT02561936|DIETARY_SUPPLEMENT|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter \[mL\]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) \[189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins\]).
219180544|NCT06273293|DIAGNOSTIC_TEST|Fractional Flow Reserve|"Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center."
219180545|NCT05775471|PROCEDURE|Biopsy|Undergo tissue biopsy
219180546|NCT05775471|PROCEDURE|Biospecimen Collection|Undergo blood and urine collection
219180547|NCT05775471|DRUG|Enfortumab Vedotin|Given IV
219180548|NCT05775471|PROCEDURE|MR Urography|Undergo MRU
219180549|NCT05775471|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy
219180550|NCT05775471|BIOLOGICAL|Pembrolizumab|Given IV
219180551|NCT04835506|DRUG|Infliximab|infliximab
219180552|NCT05687084|DEVICE|Uterine manipulator use|The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
219180553|NCT06312436|PROCEDURE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
219180554|NCT05503927|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
219180555|NCT05206500|DRUG|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC \>0 and \<10,000
219180556|NCT05206500|DEVICE|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
219180557|NCT06600022|DRUG|SCTB41|SCTB41 of different doses,IV,every 3 weeks
219180558|NCT02601313|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
219180559|NCT02601313|DRUG|Cyclophosphamide|Administered intravenously
219180560|NCT02601313|DRUG|Fludarabine|Administered intravenously
219180561|NCT02601313|DRUG|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
219180562|NCT06798064|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stem cells|
219180563|NCT06001749|DRUG|Psilocybin|A tryptamine derivative, capsule, taken orally.
219180564|NCT04523493|COMBINATION_PRODUCT|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
219180565|NCT04523493|COMBINATION_PRODUCT|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
219753058|NCT01193452|DRUG|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
219753059|NCT01193452|DRUG|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
218993404|NCT00878423|DRUG|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
218993405|NCT00878423|DRUG|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
218993406|NCT01432080|DRUG|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
218993407|NCT01432080|DRUG|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
219180566|NCT06956300|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
218993408|NCT01432080|DRUG|Montelukast|Montelukast 10 mg PO qhs for 3 months
219180567|NCT06956300|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
219180568|NCT04989686|OTHER|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
219180569|NCT06405607|DRUG|Psilocybin|30 mg single dose
219180570|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
219180571|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
219180572|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
219180573|NCT06101745|DRUG|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0 or 2.5 mg depending on trial phase.
219180574|NCT06101745|DRUG|Placebo Comparator|In Phase 3A only, \~50 subjects will be randomly allocated to receive sugar placebo
219180575|NCT04511845|DRUG|SPYK04|SPYK04 capsule
219180576|NCT06130501|DEVICE|Sparrow Ascent tAN|The Sparrow Ascent device from Spark Biomedical (Dallas, TX), applies stimulation frequencies of 15 Hz at the cymba concha (vagal innervation) and 100 Hz anterior to the tragus (trigeminal innervation). Both tAN and active sham conditions have square biphasic waveforms with identical pulse widths of 250 µs separated by a 125 µs interval between pulses. Stimulation is applied using a duty cycle of 5-minutes ON and 10 seconds OFF. The stimulation intensities (mA) will be programmed for each individual based on the highest amplitude for each channel that is both comfortable and perceptible. Patients using the device may alter the intensity of stimulation at these sites using the Patient Controller to achieve the desired effect.
219180577|NCT06130501|DEVICE|Sparrow Ascent Active Sham|The Sparrow Ascent Active Sham is a modified version of the Sparrow Ascent tAN System that has been designed to provide sub-therapeutic stimulation to the trigeminal nerve only and no stimulation to the vagus nerve. The trigeminal nerve will receive 1 Hz stimulation at the temporomandibular region at an amplitude that is comfortable and perceptual. The pulse duration will be set to a value that does not exceed 250 μs in a square biphasic waveform. The patient controller device for the active sham will give the appearance that stimulation is being applied at both vagal and trigeminal electrode sites.
219180578|NCT05909137|RADIATION|IMRT+adjuvant immunotherapy|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.
219180579|NCT05147844|DRUG|Toripalimab|"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
219180580|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
219180581|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
219369595|NCT01348802|BEHAVIORAL|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
218993409|NCT01432080|DRUG|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
218993410|NCT04934397|OTHER|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
218993411|NCT02332278|PROCEDURE|Early feeding|Fluid diet four hours after cesarean section
218993412|NCT02332278|PROCEDURE|Late feeding|Fluid diet 12 hours after cesarean section
218993413|NCT01797653|OTHER|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
218993414|NCT01797653|PROCEDURE|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
218993415|NCT02139332|BEHAVIORAL|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
218993416|NCT02139332|BEHAVIORAL|Resource & Referral Group|The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
218993417|NCT05130398|BIOLOGICAL|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
218993418|NCT05130398|DIETARY_SUPPLEMENT|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
218993419|NCT05130398|DIAGNOSTIC_TEST|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
218993420|NCT05130398|COMBINATION_PRODUCT|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
218993421|NCT05130398|BIOLOGICAL|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
218993422|NCT05130398|OTHER|Placebo|About 30 children do not receive diet, nor active pathogen detection
218993423|NCT02563223|OTHER|Parabolic flight|
218993424|NCT02563223|DEVICE|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
218993425|NCT00043771|DRUG|Tolvaptan|
218993426|NCT01223001|DRUG|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
218993427|NCT01223001|DRUG|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
218993428|NCT04592315|DRUG|Lipovirtide Injection|Single dosage of Lipovirtide Injection
218993429|NCT04454268|PROCEDURE|cyst extirpation|complete removal of the cyst without rupture
218993430|NCT00590720|BIOLOGICAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
218993431|NCT00590720|OTHER|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
219180582|NCT05837533|OTHER|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
219180583|NCT05925582|OTHER|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
218993432|NCT04023851|DEVICE|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
219180584|NCT05925582|OTHER|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
219180585|NCT06086821|DIAGNOSTIC_TEST|Periodontal Re-Evaluation|Recording of the periodontal charting
219180586|NCT06505863|PROCEDURE|Transanal total mesorectal excision|Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
219180587|NCT06505863|PROCEDURE|Abdominal total mesorectal excision|Patients who underwent laparoscopic, robotic, or open total mesorectal excision with anastomosis for primary rectal cancer UICC stage I to III
218993433|NCT01240720|DRUG|131I-F16SIP Radioimmunotherapy (RIT)|"* Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
218993434|NCT02957422|DIETARY_SUPPLEMENT|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
218993435|NCT02957422|DIETARY_SUPPLEMENT|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
218993436|NCT01001377|DRUG|Cetuximab|Administered by intravenous infusion
218993437|NCT01001377|DRUG|Panitumumab|Administered by intravenous infusion
218993438|NCT03495362|DIETARY_SUPPLEMENT|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219180588|NCT06413537|DRUG|SPG601|synthetic small molecule
219180589|NCT06413537|DRUG|Placebo|Placebo
219180590|NCT04864080|BEHAVIORAL|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
219180591|NCT04864080|BEHAVIORAL|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
219180592|NCT06460948|DRUG|Norethindrone Acetate-Ethinyl Estradiol|Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
219180593|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
219180594|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
219180595|NCT04061382|PROCEDURE|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
219180596|NCT04061382|PROCEDURE|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
219180597|NCT03766009|OTHER|Usual Care|Usual Care
219180598|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
219753060|NCT05794646|OTHER|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
219753061|NCT05712187|DRUG|ALTO-100|ALTO-100 tablet BID
219753062|NCT05712187|DRUG|Placebo|Placebo tablet BID
219753063|NCT05053152|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219753064|NCT05053152|PROCEDURE|Bone Scan|Undergo bone scan
219753065|NCT05053152|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219753066|NCT05053152|OTHER|Fluciclovine F18|Given fluciclovine F18
219753067|NCT05053152|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET/MRI
219753068|NCT05053152|DRUG|Placebo Administration|Given PO
219753069|NCT05053152|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and/or PET/MRI
219753070|NCT05053152|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT or PET/MRI
219753071|NCT05053152|DRUG|Relugolix|Given PO
219753072|NCT05053152|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
219753073|NCT05573308|DEVICE|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
219753074|NCT05573308|DEVICE|Clear Aligners|Removabale orthodontics appliances
219753075|NCT06226376|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
219753076|NCT06140017|BEHAVIORAL|Msingi Bora responsive parenting and family wellbeing program|Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.
219753077|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 1 - Gluteal|Dose level 1
219753078|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 2 - Gluteal|Dose level 2
219753079|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Gluteal|Dose level 3
219753080|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Deltoids|Dose level 3
219753081|NCT03123458|BIOLOGICAL|clonal fetal MSCs|clonal fetal MSCs
219753082|NCT06225817|DIETARY_SUPPLEMENT|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
219753083|NCT04980326|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
219753084|NCT04980326|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
219753085|NCT04980326|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
219753086|NCT06383338|DRUG|Omeprazole|Sub-therapeutic probe drug administration to measure phenoconversion.
218993439|NCT03495362|OTHER|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
218993440|NCT05928039|BIOLOGICAL|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
218993441|NCT05928039|BIOLOGICAL|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
218993442|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
219180599|NCT00169806|OTHER|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
219180600|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
219180601|NCT03869866|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
219180602|NCT04563507|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
219180603|NCT04563507|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
219180604|NCT04563507|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
219180605|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
219180606|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
219180607|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
219180608|NCT06019949|DEVICE|Transcutaneous spinal cord stimulator|Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
219180609|NCT06019949|DEVICE|Respiratory Training|Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
219180610|NCT02566668|OTHER|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
219180611|NCT06220019|DRUG|TCM|We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
219180612|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
219180613|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
219180614|NCT05629858|OTHER|6-h Time restricted eating (TRE)|Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
219180615|NCT05629858|OTHER|Calorie restriction (CR)|25% energy restriction every day
219180616|NCT05629858|OTHER|Control|Usual diet, eating over \>10 h per day
219753087|NCT06383338|DRUG|Dextromethorphan|Sub-therapeutic probe drug administration to measure phenoconversion.
218993443|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
218993444|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
218993445|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
218993446|NCT01430390|BIOLOGICAL|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
218993447|NCT01430390|DRUG|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
218993448|NCT06846489|DRUG|Acalabrutinib|100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment.
218993449|NCT06846489|DRUG|Rituximab|375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months
218993450|NCT03950115|DEVICE|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
218993451|NCT06497621|PROCEDURE|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
218993452|NCT06497621|PROCEDURE|Conventional two-step PVS impression|Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
218993453|NCT04472702|PROCEDURE|cRFA|cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
218993454|NCT04535700|DRUG|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
218993455|NCT04535700|OTHER|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
218993456|NCT00766311|OTHER|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
218993457|NCT00766311|OTHER|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
218993458|NCT00766311|OTHER|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
218993459|NCT00766311|OTHER|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
219180617|NCT06643754|DRUG|SHR-3276|"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."
219180618|NCT06547099|DIAGNOSTIC_TEST|Clinical tau PET|Tau PET (flortaucipir)
219180619|NCT06547099|DIAGNOSTIC_TEST|Clinical amyloid test|Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
218993460|NCT00766311|OTHER|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
219180620|NCT06547099|OTHER|Research blood collection|Research blood assays for amyloid, tau, and neurodegeneration
219180621|NCT06547099|OTHER|Cognitive assessments|Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
219180622|NCT06216483|OTHER|PDM Alert|passive digital marker (PDM) for postoperative delirium risk
219180623|NCT02985957|BIOLOGICAL|Nivolumab|Specified dose on specified days
219180624|NCT02985957|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219180625|NCT02985957|DRUG|Cabazitaxel|Specified dose on specified days
219180626|NCT02985957|DRUG|Prednisone|Specified dose on specified days
219180627|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
219180628|NCT04148352|DRUG|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
219180629|NCT04148352|OTHER|Placebo|Placebo injected every 2 weeks for 18 weeks
219180630|NCT06393998|DEVICE|Breathing with CO2 during daytime and night at high altitude|Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.
219369596|NCT01348802|BEHAVIORAL|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
219369597|NCT00220220|DRUG|olmesartan medoxomil|
219369598|NCT00220220|DRUG|amlodipine|
219369599|NCT05394415|DRUG|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
219180631|NCT06393998|DEVICE|Sleep and doing exercise test under inhalation of air|Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
219180632|NCT04583514|BEHAVIORAL|Control|Weight-stable Control group
219180633|NCT04583514|BEHAVIORAL|Overfeeding|30% Overfeeding group
219180634|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
219180635|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
219180636|NCT04887558|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
219180637|NCT03266302|DEVICE|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
219753088|NCT04584008|DRUG|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
219753089|NCT04584008|DRUG|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
219753090|NCT05194436|DEVICE|AeviceMD|The AeviceMD will be placed on the patient to detect wheeze and perform auscultation.
219753091|NCT05204485|PROCEDURE|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
219753092|NCT05204485|PROCEDURE|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
218993461|NCT00766311|OTHER|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
218993462|NCT00766311|OTHER|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
218993463|NCT02109380|BEHAVIORAL|Bed rest|
218993464|NCT06280170|OTHER|Artificial Intelligence platform for case managers|Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
219180638|NCT06062082|PROCEDURE|adrenalectomy|laparoscopic exeresis of the adrenal gland
219180639|NCT04447651|OTHER|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
219180640|NCT04711447|DEVICE|kinesio-tape|Twenty-two individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
219180641|NCT05626153|OTHER|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
219753097|NCT05845749|DRUG|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
219753098|NCT05459402|DRUG|Methadone (100% dose)|Methadone for the treatment of opioid use disorder
218993465|NCT06218641|DEVICE|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
219180642|NCT05626153|OTHER|Improved anesthesia care|"* Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery."
219369600|NCT05394415|DRUG|Paclitaxel|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
219753099|NCT05459402|DRUG|Methadone (50% dose)|Methadone for the treatment of opioid use disorder
219753100|NCT05214573|DRUG|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
219753101|NCT05214573|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
219753102|NCT05214573|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
219753103|NCT05214573|DRUG|Sulfonylurea|Patients in the data who filled a sulfonylurea
219753104|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
219753105|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
219753106|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
219753107|NCT05634538|DEVICE|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
219753108|NCT05634538|PROCEDURE|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
219753109|NCT05383482|DRUG|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
219753110|NCT05383482|DRUG|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
219753111|NCT05383482|DRUG|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
219753112|NCT05383482|DRUG|Sintilimab|Sintilimab 200 mg Q3W
219753113|NCT04619797|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
219753114|NCT04619797|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219753115|NCT04619797|DRUG|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219753116|NCT04619797|DRUG|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
219753117|NCT04619797|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
219753118|NCT04619797|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219753119|NCT04619797|DRUG|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
219753120|NCT06378008|DRUG|CSPS toothpaste|Toothpaste containing 5.0% weight/weight (w/w) CSPS.
218993466|NCT06218641|DEVICE|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
218993467|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
219191583|NCT06565481|OTHER|Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia|"This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices."
219753121|NCT06378008|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
219753122|NCT04047576|DRUG|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
219753123|NCT04047576|DRUG|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
219753124|NCT06028412|PROCEDURE|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
219753125|NCT06028412|PROCEDURE|Lobectomy|lobectomy+system lymph node dissection
219753126|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
219753127|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
219753128|NCT06637124|DEVICE|Blood Flow Restriction Therapy Device|"Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group)."
219753129|NCT06637124|DEVICE|45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.|Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
219753130|NCT06638346|OTHER|Shortened FIFA 11+ warm-up exercise program|"The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines."
218993468|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
218993469|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
218993470|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
218993471|NCT04229394|DRUG|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
218993472|NCT04229394|DRUG|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
218993473|NCT02617745|OTHER|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
218993474|NCT05531760|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
218993475|NCT01828957|BIOLOGICAL|Pneumostem®|
219191584|NCT04786119|DEVICE|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
219191585|NCT06772506|PROCEDURE|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|non-surgical technique plus splint and ultrasonic device with 200 mg Tetracycline
218993476|NCT01828957|OTHER|Normal Saline|
218993477|NCT00822783|DRUG|Omalizumab|
218993478|NCT00822783|DRUG|Placebo|
218993479|NCT06533787|DEVICE|Echocardiography|Functional echocardiography assessment
218993480|NCT00548223|DRUG|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid\*1year
218993481|NCT00548223|DRUG|placebo|Capsule, 0.18g, 2#, Bid\*1year
218993482|NCT05787275|OTHER|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
218993483|NCT05787275|OTHER|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
218993484|NCT05787275|OTHER|Control|Traditional medical treatment
218993485|NCT03616600|OTHER|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
218993486|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
218993487|NCT03317327|DRUG|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
218993488|NCT03317327|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
218993489|NCT06962956|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Brush two times a day for 1 minute with manual toothbrush
218993490|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 1 minute with manual toothbrush
218993491|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 2 minutes with electric toothbrush
219369601|NCT05394415|DRUG|Carboplatin|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
218993492|NCT01651039|DRUG|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
218993493|NCT01651039|DRUG|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
218993494|NCT01651039|DRUG|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
219753131|NCT06638346|OTHER|Brazilian warm-up exercise program|"The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf."
218993495|NCT00915122|RADIATION|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
218993496|NCT04693988|BEHAVIORAL|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
219180643|NCT06794333|PROCEDURE|Transperineal laser Ablation|Treatments are performed with the combined EchoLaser EVO system (Elesta SpA - Calenzano, FI). The EchoLaser EVO consists of the Echolaser X4, a multi-source laser system with a wavelength of 1064 nm, and the Echolaser Smart Interface (ESI). The procedure are performed with the patient in the lithotomy position. Local anesthesia of the perineal region and periprostatic block with lidocaine is administered under ultrasound guidance. A catheter is placed during the irradiation to allow continuous irrigation of the urethra with saline solution, protecting the urethra from temperature rise. The Echolaser Smart Interface, defines: the number and positioning of fibers, the optimal dose, and the need for multiple pullbacks. 2 to 4 21G needles are inserted simultaneously (1 or 2 per lobe) in the peri-urethral area via transperineal ultrasound guidance. A 300-micron optical fiber will be placed in each needle. Each treatment delivers a maximum energy of 1800 J per fiber with a power of 3-5 W.
219753132|NCT06638905|DRUG|Babor Ultimate ECM Repair Serum|The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
219753133|NCT06638905|DRUG|Babor Cure Cream|Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
219753134|NCT06641609|DRUG|Dose-Escalation (Phase Ia) CFT8919 capsule|Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
219753135|NCT06641609|DRUG|Dose-Expansion (Phase Ib) CFT8919 capsule|Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
219753136|NCT06641609|DRUG|Cohort-Expansion (Phase Ic) CFT8919 capsule|Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
219753137|NCT04106778|DRUG|DMT310|Topical Powder
219753138|NCT04106778|DRUG|Placebo|Placebo Topical Powder
219753139|NCT06642909|DRUG|Zuberitamab 600mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
219753140|NCT06642909|DRUG|Zuberitamab 1000mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
218993497|NCT06072157|DRUG|AK006-IV|Intravenous infusion
218993498|NCT06072157|DRUG|Placebo-IV|Intravenous infusion
218993499|NCT06072157|DRUG|AK006-SC|Subcutaneous
218993500|NCT06072157|DRUG|Placebo-SC|Subcutaneous
218993501|NCT05018975|DRUG|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
218993502|NCT01002222|DRUG|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
218993503|NCT02147470|DRUG|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
218993504|NCT02837328|DRUG|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
218993505|NCT02837328|DRUG|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
219577753|NCT03776292|OTHER|monitoring|Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
219577754|NCT01591889|DRUG|Tinidazole|500 mg tablet
219577755|NCT01591889|DRUG|Tinidazole|500 mg tablet
219753141|NCT06642909|DRUG|cyclosporine|Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
219753142|NCT06643923|OTHER|Exercise|"F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance."
218993506|NCT04930965|BEHAVIORAL|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
218993507|NCT00788567|DRUG|mycophenolate mofetil|1
218993508|NCT03730571|DEVICE|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
219180644|NCT06794333|PROCEDURE|Rezum Vapor Therapy|The treatment involves the insertion of a radiofrequency needle into the prostate tissue and the emission of water vapor. Treatment under local anesthesia/sedation. Treatment planning using the REZUM device, with the number of injections proportional to the recommended therapeutic scheme based on prostate volume (1 injection every centimeter starting 1 cm below the bladder neck and 1 cm in front of the verumontanum). Water vapor emission for 9-second intervals with a maximum of 9 applications per patient. Three-way bladder catheter to decrease local temperature. The bladder catheter will be removed 15 days after patient discharge. Regarding the REZUM, it is a system that uses sterile single-use handpieces available within the company, where a special optics is inserted for direct visualization. The handpiece features a device that allows the manual insertion of a needle into the prostate, from which water vapor is emitted for the described treatment.
219180645|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
219180646|NCT03003572|OTHER|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
219180647|NCT05473767|BEHAVIORAL|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
219180648|NCT05473767|BEHAVIORAL|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
219180649|NCT06799624|OTHER|Observation only|Only observation following standard of care (histological diagnosis, molecular classification, progestine therapy)
219180650|NCT06417255|OTHER|kinesiotape application|The strips used for kinesiological taping can be applied by giving different shapes. These shapes are I, Y, X, ring (donut), rake and net
219180651|NCT06417255|OTHER|foam roller application|"In the foam roller group, Actifoam brand non-serrated foam rollers with a size of 15x90 cm were used."
219180652|NCT04647240|BIOLOGICAL|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
219180653|NCT04718805|DRUG|Darunavir|Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
219180654|NCT04718805|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
219180655|NCT04718805|DRUG|Darunavir/Cobicistat FDC|Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
219180656|NCT05263037|DEVICE|EaseVRx|VR software with interactive content
219180657|NCT05263037|DEVICE|Sham VR|VR with neutral non-interactive content
219180658|NCT06168461|DRUG|Aspirin|162mg aspirin capsule
219753143|NCT06643923|BEHAVIORAL|Urotherapy|The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
219753144|NCT00210132|DRUG|Ropivacaine|"ropivacaine at 7.5 mg/ml: 4 ml + 4 ml of saline solution to obtain 8 ml of a ropivacaine solution at 3.75 mg/ml injected into the intrapleural catheter every 6 hours.~Treatment administration = every 6 hours for 48 hours."
219753145|NCT00210132|DRUG|Reference|8 ml of saline solution will be injected into the intrapleural catheter. Treatment administration = every 6 hours for 48 hours.
219180659|NCT06168461|DRUG|Placebo|placebo capsule
219180660|NCT04902352|PROCEDURE|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
219180661|NCT04902352|PROCEDURE|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
219180662|NCT02813135|DRUG|Ribociclib|
219180663|NCT02813135|DRUG|Topotecan|
219180664|NCT02813135|DRUG|Temozolomide|
219180665|NCT02813135|DRUG|Everolimus|
219180666|NCT02813135|DRUG|Adavosertib|
219180667|NCT02813135|DRUG|Carboplatin|
219180668|NCT02813135|DRUG|Olaparib|
219180669|NCT02813135|DRUG|Irinotecan|
219180670|NCT02813135|DRUG|Vistusertib|
219180671|NCT02813135|DRUG|Nivolumab|
219180672|NCT02813135|DRUG|Cyclophosphamide|
219180673|NCT02813135|DRUG|Selumetinib|
219180674|NCT02813135|DRUG|Enasidenib|
219180675|NCT02813135|DRUG|Lirilumab|
219180676|NCT02813135|DRUG|Fadraciclib|
219180677|NCT02813135|DRUG|Cytarabine|
219180678|NCT02813135|DRUG|Dexamethasone|
219180679|NCT02813135|DRUG|Ceralasertib|
219180680|NCT02813135|DRUG|Futibatinib|
219180681|NCT02813135|DRUG|Capmatinib|
219180682|NCT02813135|DRUG|Avelumab|
219180683|NCT02813135|DRUG|Peposertib|
219180684|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
219180685|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
219180686|NCT02918253|RADIATION|targeted focal HDR brachytherapy|
219180687|NCT02918253|RADIATION|Whole-gland HDR Brachytherapy|Control/Standard of Care
219180688|NCT05438823|OTHER|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
219180689|NCT06245421|DEVICE|DM934|1 drop in each eye, 4 to 6 times per day
219180690|NCT06245421|DEVICE|Théalose|1 drop in each eye, 4 to 6 times per day
219180691|NCT04802967|DRUG|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
219180692|NCT04802967|DRUG|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
219753146|NCT06206265|DRUG|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
219753147|NCT06206265|BEHAVIORAL|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
219753148|NCT03809351|DRUG|[F-18]AV-1451-PET|All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
219180693|NCT04802967|DRUG|Gabapentin|300 mg
219180694|NCT04802967|OTHER|Placebo|2 capsules to maintain the blind
219180695|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
219180696|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
219180697|NCT02708810|DEVICE|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
219180698|NCT02708810|RADIATION|80 Gy Radiation|
219180699|NCT04114877|BEHAVIORAL|Attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.
219753149|NCT06094803|BEHAVIORAL|Mindfulness-based Zentangle Program|"Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection."
219753150|NCT04028999|DEVICE|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
218993509|NCT05561699|DRUG|Penpulimab Combined With CRT|"1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
218993510|NCT02710474|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
218993511|NCT02710474|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
218993512|NCT02252913|DRUG|Volitinib|oral administration
218993513|NCT02252913|DRUG|Docetaxel|intravenous injection
218993514|NCT03045185|PROCEDURE|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
218993515|NCT00757497|BEHAVIORAL|Electrical Polarization|
218993516|NCT03068260|DRUG|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
218993517|NCT03068260|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
218993518|NCT03068260|DRUG|Acetaminophen|1 g orally administered postoperatively
218993519|NCT03068260|DRUG|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
218993520|NCT03068260|DEVICE|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
218993521|NCT03068260|DRUG|Morphine|intravenously administered morphine via PCA-pump
218993522|NCT03068260|DEVICE|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
219180700|NCT04114877|BEHAVIORAL|Visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
219180701|NCT05896228|DRUG|Iberdomide|"Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy"
219180702|NCT05896228|DRUG|Carfilzomib|"Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15."
219753151|NCT05934123|BEHAVIORAL|EMNODN NEC Care Bundle|A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born \<32 weeks' gestational age.
218993523|NCT01671800|DRUG|Botulinum Type B|
218993524|NCT01671800|DRUG|Placebo|
218993525|NCT00134082|BIOLOGICAL|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
218993526|NCT00134082|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.
218993527|NCT00134082|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
218993528|NCT00134082|DRUG|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
218993529|NCT01695590|DRUG|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
218993530|NCT05346770|BEHAVIORAL|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
218993531|NCT05346770|DIAGNOSTIC_TEST|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
218993532|NCT05346770|OTHER|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
218993533|NCT00182286|BEHAVIORAL|Assessment of continuity of care from the patient perspective|
218993534|NCT00182286|BEHAVIORAL|Relationship between continuity of care, patient outcomes, and costs|
219753152|NCT06484166|OTHER|Fullerene cream|Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
219753153|NCT06484166|DRUG|Trolamine (Biafine)|Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
219753154|NCT03737292|DRUG|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
219753155|NCT03737292|DRUG|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
219753156|NCT05207670|DRUG|Mosunetuzumab (Cohorts A-C)|Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
219753157|NCT05207670|DRUG|Mosunetuzumab (Cohorts D-E)|Participants will receive SC mosunetuzumab for up to 34 cycles
219753158|NCT05207670|DRUG|Tocilizumab|Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
219753159|NCT04317105|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
219753160|NCT04317105|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219753161|NCT04317105|PROCEDURE|Computed Tomography|Undergo a CT scan
219753162|NCT04317105|DRUG|Copanlisib Hydrochloride|Given IV
219753163|NCT04317105|PROCEDURE|Echocardiography Test|Undergo ECHO
219753164|NCT04317105|BIOLOGICAL|Ipilimumab|Given IV
219753165|NCT04317105|BIOLOGICAL|Nivolumab|Given IV
219753166|NCT04317105|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219753167|NCT06303310|OTHER|Gaze Stability Exercises|Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
219753168|NCT06303310|OTHER|Optokinetic Exercises|Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
219753169|NCT06303310|OTHER|Routine Physical Therapy|Routine Physical Therapy
219753170|NCT05524012|DIAGNOSTIC_TEST|Blood sample|longitudinal blood samples for CTC monitoring
219753171|NCT05524012|DEVICE|MRI scan|longitudinal MRI scans (non-contrast enhanced)
219753172|NCT04005833|DIAGNOSTIC_TEST|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
219753173|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
219753174|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
219753175|NCT01890330|OTHER|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
219753176|NCT01890330|OTHER|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
219753177|NCT01965249|DEVICE|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
219753178|NCT01965249|DEVICE|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
219753179|NCT05834881|BEHAVIORAL|Contingency Management (CM) combined with vocational/educational coaching|Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.
219753180|NCT06969807|DRUG|Amimestrocel|In the first month (day 1, 14, 28): 1×10E6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16, 20, 24): 1.5×10E6 cells per kilogram.
219753181|NCT06967987|DRUG|Bemarituzumab + Flot regimen|"Bemarituzumab (IV administration) over 30 min (+/- 10min) at C1D1 to C8D1 + 15 mg/kg of bodyweight + single additional dose of 7,5 mg/kg at C1D8~\+ FLOT regimen~* Fluorouracil for solution for infusion (IV administration) as a continuous IV infusion approximately 24 hours 2600 mg/m²~* Leucovorin (folinic acid) solution for infusion (IV administration) over 120 min on the first day, 200 mg/m²~* Oxaliplatin concentrate for solution for infusion (IV administration) over 120 min on the first day, 85 mg/m²~* Docetaxel concentrated for solution for infusion (IV administration) over 60 min on the first day, 50 mg/m²"
219753182|NCT04902807|BIOLOGICAL|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
219753183|NCT05400564|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
219753184|NCT05817942|DRUG|Filgotinib|Jyseleca
219753185|NCT04085172|DRUG|Guanfacine hydrochloride (TAK-503)|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.
219753186|NCT04085172|DRUG|Atomoxetine hydrochloride|Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.
219753187|NCT04085172|OTHER|Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
219753188|NCT06157801|BEHAVIORAL|Interview Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
219753189|NCT06157801|BEHAVIORAL|Survey Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
219753190|NCT06161831|BEHAVIORAL|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
219753191|NCT06364540|DRUG|Ketamine|Nebulized ketamine administered at 0.75 mg/kg via BAN
219753192|NCT06364540|DRUG|Fentanyl|Nebulized fentanyl administered at 3 mcg/kg via BAN
219753193|NCT05990543|DRUG|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
219753194|NCT02390752|DRUG|TURALIO(R)|take oral drug daily for a 28 day cycle
219753195|NCT06326060|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219753196|NCT06326060|DRUG|Placebo|Placebo will be administered subcutaneously.
219753197|NCT06326060|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
219753198|NCT06136208|DRUG|s.c 25 mg estradiol pellet|Subcutaneous insertion of 25 mg estradiol pellet.
219753199|NCT00340054|OTHER|questionnaire administration|
219753200|NCT00340054|PROCEDURE|study of high risk factors|
219753201|NCT01803633|OTHER|Cheddar cheese|Tillamook medium cheddar cheese brand
219753202|NCT01803633|OTHER|Vegan cheese|Daiya brand vegan cheese
219753203|NCT06122948|DRUG|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
219753204|NCT06122948|DRUG|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
219753205|NCT06973720|DRUG|MET097|For subcutaneous administration.
219753206|NCT06973720|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
219753207|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 1|Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753208|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 2|Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753209|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 3|Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753210|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 1|Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753211|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 1|Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753212|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 1|Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753213|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 2|Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753214|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 2|Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753215|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 2|Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
219753216|NCT05298254|DRUG|Placebo|Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
218993535|NCT05045248|DRUG|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
218993536|NCT00006161|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
218993537|NCT00006161|PROCEDURE|Distal Splenorenal Shunt|
218993538|NCT04901936|DRUG|Pegcetacoplan|Complement (C3) inhibitor
218993539|NCT01439269|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
218993540|NCT05069532|RADIATION|MSCT chest|CORAD 4-5 MSCT chest
219753217|NCT05298254|BIOLOGICAL|HSVTI_F1|Two doses of the formulation of the HSVTI\_F1 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
219753218|NCT05298254|BIOLOGICAL|HSVTI_F2|Two doses of the formulation of the HSVTI\_F2 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
219753219|NCT06515106|BEHAVIORAL|Remote cognitive rehabilitation program|Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
219753220|NCT06082453|DIAGNOSTIC_TEST|Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum|A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.
219753221|NCT06082453|DIAGNOSTIC_TEST|Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum|The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.
219753222|NCT06082453|OTHER|Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis|Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
219753223|NCT01561469|DRUG|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
219753224|NCT01561469|DRUG|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
218993541|NCT05069532|DIAGNOSTIC_TEST|PCR|PCR positive for COVID-19
218993542|NCT03713359|BIOLOGICAL|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
218993543|NCT03713359|BIOLOGICAL|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
218993544|NCT02849678|DRUG|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
219753225|NCT05002959|DEVICE|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
219753226|NCT05002959|DEVICE|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
219753227|NCT06151197|BIOLOGICAL|EN3835|Biologic: EN3835 injection
219753228|NCT06151197|OTHER|Placebo|Placebo injection
219753229|NCT06395935|OTHER|Wecare (website)|support feedback of qutionaire \& supply educational contents
219753230|NCT02274675|DEVICE|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
219753231|NCT02274675|OTHER|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
219753232|NCT04031508|COMBINATION_PRODUCT|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
219753233|NCT05871437|DRUG|Huaier granule|On the basis of routine clinical treatment/follow-up, take Huaier Granules orally, 10g each time, three times a day, for one year continuously or until disease progression, intolerable toxicity, withdrawal from the study for any reason or death occurs, whichever occurs first.
219753234|NCT06149442|OTHER|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
218993545|NCT02849678|DRUG|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
219753235|NCT06149442|OTHER|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
219753236|NCT06149442|OTHER|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
219753237|NCT05991427|BIOLOGICAL|Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
219753238|NCT05991427|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted (Shingrix)|2 doses of Shingrix vaccine on Day 0 and Month 4
219753239|NCT05991427|BIOLOGICAL|ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
219753240|NCT05991427|BIOLOGICAL|Shingrix|2 doses of Shingrix vaccine on Day 0 and Month 4
219753241|NCT05991427|BIOLOGICAL|IH ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
219753242|NCT05991427|BIOLOGICAL|IH saline|2 doses of saline on Day 0 and Month 4
219753243|NCT05510908|OTHER|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
219753244|NCT05510908|OTHER|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
219753245|NCT06271915|OTHER|SNAGs - eccentric exercise|intervention done 2 times per week, 45 minutes each session for 4 weeks
219753246|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 1|Investigational RSV vaccine 1 administered intramuscularly on Day 1 and Day 30.
219753247|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 2|Investigational RSV vaccine 2 administered intramuscularly on Day 1 and Day 30.
219753248|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 3|Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.
219753249|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 4|Investigational RSV vaccine 4 administered intramuscularly on Day 1 and Day 30.
219753250|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 5|Investigational RSV vaccine 5 administered intramuscularly on Day 1 and Day 30.
219753251|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 6|Investigational RSV vaccine 6 administered intramuscularly on Day 1.
219753252|NCT06573281|DRUG|Placebo|Placebo administered intramuscularly on Day 1 and Day 30 and for RSV\_Group F placebo administered only on Day 30.
219753253|NCT06088667|OTHER|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
219753254|NCT05624528|DRUG|Tolcapone|catechol-O-methyl transferase inhibitor
218993546|NCT06298591|PROCEDURE|co2 laser|laser
219753255|NCT05624528|DRUG|Placebo|Pill that contains no medicine
219753256|NCT06643871|OTHER|Adapted physical activity program involving connected bikes|The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
219753257|NCT03636022|OTHER|VR System|Use of virtual reality to deliver exposure therapy
219753258|NCT03636022|OTHER|Control|Use of conventional delivery of exposure therapy
218993547|NCT03129165|OTHER|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
218993548|NCT00424983|DRUG|Zoledronic acid|
218993549|NCT03204903|PROCEDURE|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
218993550|NCT03204903|PROCEDURE|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
218993551|NCT01471171|DRUG|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
218993552|NCT01471171|DRUG|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
219180703|NCT05896228|DRUG|Daratumumab|"Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1."
219180704|NCT05896228|DRUG|Dexamethasone|"Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15."
219180705|NCT05896228|DRUG|Acetaminophen|"Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1."
218993553|NCT00966329|DRUG|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
218993554|NCT00966329|DRUG|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz)."
218993555|NCT01320904|PROCEDURE|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
218993556|NCT01320904|PROCEDURE|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
218993557|NCT02204878|DRUG|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
219180706|NCT05896228|DRUG|Diphenhydramine|"Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1."
219180707|NCT05896228|DRUG|Montelukast|"Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D)."
219180708|NCT06386094|DIAGNOSTIC_TEST|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
219180709|NCT06298227|OTHER|Postoperative analgesia management with Paracerol® and IV PCA with Talinat®|In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
219180710|NCT06298227|OTHER|Erector spinae plane block|The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
219191586|NCT06772506|PROCEDURE|Minimally invasive non-surgical technique with mini five and after five minimally invasive instrument plus splint|minimally invasive instruments, with mini five and after five minimally invasive instrument ultrasonic scaler device, conventional radiographic device and periodontal instruments with post-operative 1 gram penicillin for 3 days regulatory Statement: This study does not include an FDA-regulated device intervention, as the tools utilized are not the subject of investigation but are instead employed as part of routine clinical
218993558|NCT03727529|OTHER|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
218993559|NCT03727529|OTHER|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
218993560|NCT05081141|DIAGNOSTIC_TEST|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
219753259|NCT04950153|BEHAVIORAL|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
219753260|NCT04950153|BEHAVIORAL|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
219753261|NCT04950153|BEHAVIORAL|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
219753262|NCT04950153|BEHAVIORAL|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
219753263|NCT06367855|DRUG|Dexamethasone|long-acting corticosteroid IV route
219753264|NCT06367855|DRUG|Normal saline|normal saline
219753265|NCT05360888|BEHAVIORAL|Tools for Life|Tools for Life focuses on empowering youth to learn more about their culture and their identity.
219753266|NCT05360888|BEHAVIORAL|Tools for Life + MISN|Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
219753267|NCT05301127|DEVICE|spinal-epidural device|received combined spinal-epidural-general anesthesia.
219753268|NCT06420063|BIOLOGICAL|CD123/CD33 CART|"The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
219753269|NCT05172726|DRUG|tapinarof cream, 1%|applied topically once daily
219753270|NCT04918407|DRUG|Empagliflozin 25 MG|25 mg
219753271|NCT04918407|DRUG|Insulin|Insulin
219753272|NCT03189719|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
219753273|NCT03189719|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
219753274|NCT03189719|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
218993561|NCT05386810|BIOLOGICAL|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
219191587|NCT03546361|BIOLOGICAL|Autologous Dendritic Cell-Adenovirus CCL21 Vaccine|Given via CT-guided or bronchoscopic IT injection
219753275|NCT03189719|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
219753276|NCT05853718|DRUG|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
219753277|NCT02684162|BIOLOGICAL|Donor Lymphocytes|Given IV
219753278|NCT02684162|DRUG|Guadecitabine|Given SC
219191588|NCT03546361|BIOLOGICAL|Pembrolizumab|Given IV
219191589|NCT04118023|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
219753279|NCT02684162|OTHER|Laboratory Biomarker Analysis|Correlative studies
219753280|NCT03340116|PROCEDURE|Burn surgery|Burn surgery including wound debridement, skin grafting
219753281|NCT03340116|DIAGNOSTIC_TEST|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
219753282|NCT05310435|DEVICE|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
219753283|NCT05310435|DEVICE|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
219753284|NCT05310435|DEVICE|Single circumference measurement with tape measure|Single circumference measurement with tape measure
219753285|NCT05310435|DEVICE|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
219753286|NCT03762018|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
219753287|NCT03762018|DRUG|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
219753288|NCT03762018|DRUG|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
219753289|NCT03762018|DRUG|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
219753290|NCT05023018|DRUG|NEO100|NEO100 is a purified form of perillyl alcohol.
219753291|NCT03448393|BIOLOGICAL|CD19/CD22 CAR T-Cells|Cluster of differentiation 19 (CD19)/cluster of differentiation 22 (CD22) chimeric antigen receptor (CAR) T-cells will be infused on Day 0 after lymphodepleting chemotherapy regimen.
219180711|NCT06298227|OTHER|Quadratus lumborum plane block|QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
219180712|NCT05344469|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
219180713|NCT05344469|OTHER|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
219180714|NCT05344469|OTHER|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
219180715|NCT03804944|RADIATION|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
219180716|NCT03804944|DRUG|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
219180717|NCT03804944|BIOLOGICAL|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
219180718|NCT05536531|DEVICE|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
218993562|NCT05386810|BIOLOGICAL|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
218993563|NCT05386810|BIOLOGICAL|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
218993564|NCT03746652|DRUG|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
218993565|NCT06084663|DRUG|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
218993566|NCT06084663|DRUG|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
218993567|NCT05993130|OTHER|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
218993568|NCT04959903|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
219753292|NCT03448393|DRUG|Fludarabine|Fludarabine is administered as an intravenous (IV) infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on body surface area (BSA) (25-30 mg/m\^2/dose) on Days -4, -3, -2 or Days -5, -4, -3, -2.
219753293|NCT03448393|DRUG|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the body surface area (BSA), at 900 mg/m\^2/dose after fludarabine infusion on Day -2 or 600 mg/m\^2/dose on Days -3 \& -2.
219753294|NCT03448393|PROCEDURE|Apheresis|According to institutional standards.
219753295|NCT03448393|OTHER|Anti-emetic|Prophylaxis and treatment.
219753296|NCT03448393|DRUG|Diphenhydramine|Pre-medication: 0.5-1 mg/kg/dose (maximum 50 mg/dose) by mouth or intravenous over 10-15 minutes.
219753297|NCT03448393|DRUG|Acetaminophen|Pre-medication: 15 mg/kg/dose (maximum 650 mg/dose by mouth).
219753298|NCT03448393|DIAGNOSTIC_TEST|ECG|Pre-cell infusion.
219753299|NCT03448393|DIAGNOSTIC_TEST|ECHO|Pre-cell infusion.
218993569|NCT04059783|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
218993570|NCT04343469|PROCEDURE|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
218993571|NCT03879278|DRUG|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
218993572|NCT02658903|DEVICE|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
218993573|NCT02658903|DEVICE|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
218993574|NCT00707720|DEVICE|TERIS procedure|The implantation of the restrictive implant
218993575|NCT03478930|DRUG|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
218993576|NCT03478930|DRUG|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
218993577|NCT01416064|DRUG|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
219753300|NCT03448393|DIAGNOSTIC_TEST|MRI Brain|Pre-cell infusion.
219753301|NCT03448393|PROCEDURE|Bone marrow biopsy|Pre-cell infusion.
219753302|NCT03448393|DIAGNOSTIC_TEST|Cardiac MRI|Screening
219753303|NCT06488846|OTHER|INVITE-Home|Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
219753304|NCT06488846|OTHER|Clinic-Administered LAI-ART|People with HIV who continue to receive LAI-ART in clinic
219180719|NCT06429319|DEVICE|"Hydrous biopolymer with silver ions Argiform (HBISA) endoprosthesis of synovial fluid NOLTREX™"|If clinically indicated patients received a repeat course of NOLTREX™ (one or two weekly intra-articular injections of 4.0 NOLTREX™ at the investigator's discretion depending on the stage of OA and clinical response to treatment).
219180720|NCT04434664|DRUG|Amlodipine Besylate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
219180721|NCT04434664|DRUG|Metoprolol Succinate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
219753305|NCT06488846|OTHER|Oral ART|Oral ART
218993578|NCT04073654|PROCEDURE|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
218993579|NCT00037596|DRUG|Gemtuzumab Ozogamicin|
218993580|NCT00037596|DRUG|cytarabine.|
218993581|NCT05517044|OTHER|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
218993582|NCT03045315|OTHER|IVF Procedure|
218993583|NCT01211002|RADIATION|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
218993584|NCT01211002|DRUG|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
218993585|NCT05405374|OTHER|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
218993586|NCT05405374|DEVICE|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
218993587|NCT02713347|BEHAVIORAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
218993588|NCT00365911|PROCEDURE|Taking blood sample|A blood sample will be taken.
218993589|NCT05866172|PROCEDURE|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
218993590|NCT05866172|DRUG|Zoledronic acid|Zoledronic acid 4mg iv.drip
218993591|NCT03799081|PROCEDURE|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
218993592|NCT00247975|DRUG|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
218993593|NCT04991909|DRUG|HRS4800|HRS4800
218993594|NCT04991909|DRUG|Placebo|Placebo
218993595|NCT04556162|DIAGNOSTIC_TEST|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
218993596|NCT04556162|OTHER|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
218993597|NCT00968214|GENETIC|polymorphism analysis|
218993598|NCT00968214|OTHER|laboratory biomarker analysis|
218993599|NCT00001535|DRUG|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
218993600|NCT05438394|DRUG|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
219753315|NCT03816891|DRUG|Vixarelimab|solution for injection
219753316|NCT03816891|DRUG|Placebo|solution for injection
219180722|NCT05935761|DRUG|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
219180723|NCT05935761|DRUG|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
219180724|NCT05935761|DRUG|Placebo|Same as active comparator arms, except placebo dispensed
219180725|NCT06046742|BIOLOGICAL|M1-c6v1|Intravenous drip administration
219753317|NCT05262426|BEHAVIORAL|Behavioral: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
219753318|NCT05262426|BEHAVIORAL|Enhanced YaCool|Enhanced YaCool is mobile application developed to support transgender women self-management of their gender and sexual health, including PrEP use. YaCool is a passcode-protected app that allows users to personalized text messaged reminders to take PrEP and/or clinic appointments, record PrEP adherence and sexual activity, and track lab tests. The application is set up to provide personalized recommendations for PrEP regimen, confirmed by clinic healthcare staff. Participants will be asked to download Enhanced YaCool to support PrEP use and gender/sexual health self-management between MES-PrEP sessions for 30 days, and thereafter until the end of Month 12 (if desired).
219753319|NCT05262426|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3, 6, 9 and 12. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
219753320|NCT03012880|BIOLOGICAL|Daratumumab|Given IV
219753321|NCT03012880|DRUG|Dexamethasone|Given PO
219753322|NCT03012880|DRUG|Ixazomib Citrate|Given PO
219753323|NCT03012880|OTHER|Laboratory Biomarker Analysis|Correlative studies
219753324|NCT03012880|DRUG|Lenalidomide|Given PO
219753325|NCT03012880|OTHER|Questionnaire Administration|Ancillary studies
219753326|NCT05702450|BIOLOGICAL|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
219753327|NCT01587196|DRUG|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
219753328|NCT01589640|OTHER|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
219753329|NCT01589640|OTHER|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
219753330|NCT01589640|OTHER|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
218993601|NCT00705484|BIOLOGICAL|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
219180726|NCT00085735|DRUG|Cisplatin|Given IV
219180727|NCT00085735|RADIATION|Craniospinal Irradiation|Undergo craniospinal Irradiation
219180728|NCT00085735|DRUG|Cyclophosphamide|Given IV
219180729|NCT00085735|RADIATION|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
219180730|NCT00085735|OTHER|Laboratory Biomarker Analysis|Correlative studies
219753331|NCT05329831|BEHAVIORAL|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
219753332|NCT04614714|DRUG|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
219753333|NCT04614714|DRUG|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
219753334|NCT01933152|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
219753335|NCT01075672|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
219753336|NCT03161262|BEHAVIORAL|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
219753337|NCT02430714|DRUG|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
219753338|NCT02769481|DRUG|Bexagliflozin|20 mg, tablet
218993602|NCT00705484|DRUG|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
218993603|NCT02687997|OTHER|poligraphy|Sleep study
218993604|NCT00585143|DRUG|ABT-335|45 mg once daily for 10 consecutive days
219180731|NCT00085735|DRUG|Lomustine|Given orally
219180732|NCT00085735|OTHER|Quality-of-Life Assessment|Ancillary studies
219180733|NCT00085735|RADIATION|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
219180734|NCT00085735|DRUG|Vincristine Sulfate|Given IV
219180735|NCT05582668|PROCEDURE|Bariatric surgery|Bariatric surgery
219180736|NCT04436835|BEHAVIORAL|Psychotherapy|Undergo ART
219180737|NCT04436835|OTHER|Questionnaire Administration|Ancillary studies
219180738|NCT01973179|RADIATION|Radiation therapy|Radiation therapy with protons
219180739|NCT06068543|DRUG|Epigallocatechin-3-Gallate (EGCG)|800mg Epigallocatechin-3-Gallate (EGCG)
219180740|NCT06068543|DRUG|Microcrystalline cellulose (MCC)|800mg microcrystalline cellulose (MCC)
219180741|NCT06068543|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C)|250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
219180742|NCT06806566|OTHER|Carvacrol|"1-absorbable gelatine sponge soaked in carvacrol oil placed in the palatal donor site.~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a carvacrol loaded absorbable gelatin sponge (test group)"
219180743|NCT06806566|OTHER|Gelatin Sponge Sheet|"Absorbable gelatin sponge placed in the palatal donor site~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a absorbable gelatin sponge(control group)."
219180744|NCT04625283|DRUG|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
219180745|NCT04625283|DRUG|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
219180746|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
219180747|NCT06770179|OTHER|recruitment maneuver|in the group 2, in addition to the fixed PEEP of 5 cm H₂O, a recruitment maneuver is planned at the end of the surgery. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, before extubation.
219180748|NCT06770179|OTHER|positional recruitment maneuver|In the third group, in addition to the fixed PEEP, a recruitment maneuver will be performed at the end of the surgery before extubation. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, with 3 breaths in the right lateral decubitus position and 3 breaths in the left lateral decubitus position
219180749|NCT02598388|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
219753339|NCT02769481|DRUG|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
218993605|NCT00585143|DRUG|Rosuvastatin|10 mg once daily for 10 days
218993606|NCT01577056|DIETARY_SUPPLEMENT|Fish oil capsule|4g Omega capsule for 12 weeks
218993607|NCT01577056|DRUG|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
218993608|NCT04664712|DIETARY_SUPPLEMENT|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
219180750|NCT02598388|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units).
219180751|NCT02598388|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
219180752|NCT04920175|OTHER|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
218993609|NCT04664712|DEVICE|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
218993610|NCT00303784|DRUG|Goserelin|3.6mg implant, in pre-filled syringe
218993611|NCT00303784|DRUG|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
219180753|NCT05298358|BIOLOGICAL|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines."
219180754|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
219180755|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
219753340|NCT02769481|DRUG|Glimepiride|2, 4 or 6 mg, capsule
219753341|NCT02769481|DRUG|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
219753342|NCT01046994|PROCEDURE|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
219753343|NCT01046994|DRUG|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
219180756|NCT03309306|OTHER|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
219753344|NCT06265818|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
219753345|NCT06265818|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219753346|NCT06548438|PROCEDURE|Transurethral resection of the bladder performed with PDD tecnique and Hexvix|For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
219753347|NCT01629888|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
219753348|NCT01629888|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
219753349|NCT03510715|DRUG|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
219753350|NCT03510715|DRUG|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
219753351|NCT03510715|DRUG|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
219753352|NCT03510715|DRUG|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
219753353|NCT03510715|DRUG|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
219753354|NCT03510715|DRUG|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
219753355|NCT03510715|DRUG|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
219753356|NCT03510715|DRUG|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
219753357|NCT03510715|DRUG|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
218993612|NCT00287885|DRUG|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
218993613|NCT06313814|DIETARY_SUPPLEMENT|Swanson ginger capsule|"Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond."
219753358|NCT03510715|DRUG|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
219753359|NCT03510715|DRUG|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
219753360|NCT03510715|DRUG|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
219753361|NCT02184286|DRUG|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
219753362|NCT02184286|DRUG|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
219753363|NCT04527744|PROCEDURE|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
219753364|NCT05405608|DRUG|Ondansetron|hemodynamic stability in orthopedic surgeries
219753365|NCT03826472|OTHER|Almond Butter|Natural almond butter
219753366|NCT00385112|PROCEDURE|Echocardiogram|2D echocardiogram with Doppler flow
219753367|NCT04310657|DIAGNOSTIC_TEST|mNGS|Metagenomics second generation sequencing technology
219753368|NCT04994613|OTHER|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
219753369|NCT05748769|BEHAVIORAL|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
219753370|NCT05748769|BEHAVIORAL|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
218993614|NCT05892471|DRUG|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
218993615|NCT05892471|DRUG|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
218993616|NCT01530061|OTHER|Egg Breakfast|Egg, Toast and Jelly
218993617|NCT01530061|OTHER|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
218993618|NCT01979445|DRUG|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
218993619|NCT01979445|DRUG|Clopidogrel|Clopidogrel 600 mg single oral dose
218993620|NCT01979445|DRUG|Prasugrel|Prasugrel 60 mg single oral dose
218993621|NCT03982368|DRUG|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
218993622|NCT03982368|DRUG|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
218993623|NCT03982368|OTHER|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
219753371|NCT05748769|BEHAVIORAL|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
219753372|NCT02225535|OTHER|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
219753373|NCT02225535|OTHER|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
219753374|NCT02225535|OTHER|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
219753375|NCT03639402|BEHAVIORAL|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
219753376|NCT01498861|DRUG|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
219753377|NCT01498861|DRUG|Dolutegravir|Dolutegravir is an experimental HIV drug
219753378|NCT01498861|DRUG|Placebo|Placebo is a tablet with no drug in it
219753379|NCT04471311|PROCEDURE|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies \>20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
219753380|NCT04471311|DEVICE|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
219753381|NCT01942109|DRUG|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
219753382|NCT01942109|DRUG|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
219753383|NCT06671210|DEVICE|Urine and vaginal swab self-control|Each participant provided urine and vaginal swabs for HPV testing.
219753384|NCT07004153|DEVICE|Smart Coaching Insulin Pen|Subjects randomized to the intervention group will use the DIA:CONN P8 smart insulin pen with full functionality, including Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. During the 12-week application period, including the baseline visit, participants will visit the hospital up to 5 times. At the start of the period, initial basal and bolus doses will be determined using the Setup Wizard and reviewed by investigators. Throughout the study, subjects will receive real-time insulin dose recommendations and coaching via the DIA:CONN app based on CGM data, carbohydrate input, and insulin dosing history.
219753385|NCT07004647|DRUG|Fludarabine|D-10 to D-2: Fludarabine (25 mg/m2/day) will be administered intravenously for 3 days;D-10 to D-2: Cyclophosphamide (250 mg/m2/day) will be administered intravenously for 3 days.
219753386|NCT07002723|DRUG|Esketamine combined with dexmedetomidine|After successful neuraxial anesthesia, 0.125mg/kg esketamine and 0.3ug/kg dexmedetomidine are diluted into 30ml of normal saline and continuously pumped for 20 minutes, then connected to a micropump: 15ug/kg/h esketamine 0.02ug/kg/h dexmedetomidine to 96ml saline, continuous amount: 2ml/h, continuous pumping for 48h.
219753387|NCT07002723|DRUG|Normal saline|After successful neuraxial anesthesia, 30ml of normal saline was continuously pumped for 20 minutes, followed by a micropump: 96ml of saline, continuous amount: 2ml/h for 48h.
219753388|NCT06680479|BIOLOGICAL|CH505 TF chTrimer|Stabilized CH505 TF chTrimer, 300 mcg
219753389|NCT06680479|BIOLOGICAL|3M-052-AF|3 mcg
219753390|NCT06680479|BIOLOGICAL|Aluminum Hydroxide Suspension|500 mcg
219753391|NCT06680479|OTHER|Sodium Chloride for Injection|Sodium chloride for injection, 0.9% USP volume-matched placebo injection.
219753392|NCT07004595|OTHER|Evaluation of patient frailty|Quality of Life questionnaire
219753393|NCT06624345|PROCEDURE|Inspiratory muscle training|Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
219753394|NCT06624345|PROCEDURE|Control Group|Subjects received routine care.
219753395|NCT07142083|DEVICE|Bioelectrical Impedance Analysis (BCM)|The Body Composition Monitor (BCM) device will be used to perform daily bioelectrical impedance measurements to guide fluid resuscitation in critically ill patients after major surgery. Measurements include extracellular water, intracellular water, total body water, and phase angle. The results will be used to tailor fluid therapy.
219753396|NCT07142083|PROCEDURE|Conventional Fluid Management|Patients in this group will receive fluid therapy based on standard clinical parameters including blood pressure, heart rate, urine output, laboratory values, and physical examination. No bioelectrical impedance measurement will be performed.
219753397|NCT07161323|OTHER|Sustained Natural Apophyseal Glide (SNAG)|In this intervention, participants will initially receive the SNAG technique targeting the L5-S1 lumbar segment. Participants will be seated on a treatment table with feet flat and knees at 90°. The therapist will position a specialized Mulligan belt around the L5-S1 segment and anchor it around their pelvis to generate a gentle traction force via controlled hip movement. While this force is applied, participants will perform active trunk flexion, holding the end-range position for 30 seconds. This movement will be repeated six times, constituting a 3-minute set. A total of 4 sets will be administered, with 2-minute rest periods between sets.
218993624|NCT03776552|OTHER|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
219753398|NCT07161323|OTHER|Sciatic Nerve Mobilization Exercises (SNME)|Participants will sit with hips and knees at 90° flexion, feet flat on the floor. The involved leg will be fully extended at the knee. In this position, the participant will be asked to perform ankle dorsiflexion and neck extension simultaneously (applying tension to the distal part of the sciatic nerve while relaxing the proximal part) and hold for 3 seconds. Next, the participant will plantarflex the ankle and flex the neck (tensioning the proximal end while relaxing the distal), again holding for 3 seconds. This 6-second sequence will be repeated 10 times per set. The exercise will be performed in 3 sets per leg, with 3-minute rests between sets.
219753399|NCT07159737|PROCEDURE|Two-stent strategy|DES from LMCA to LAD and DES to LCx using a recognised bifurcation technique such as double kissing crush (DK crush), Culotte, T-stenting or T and small protrusion (TAP).
219753400|NCT07159737|PROCEDURE|Hybrid Strategy|DES from LMCA to LAD and DCB to LCx. No LCx DES unless bail-out needed.
219753401|NCT07158645|OTHER|Medical Food Tri-betahydroxybutyrin|Medical Food Containing Tri-betahydroxybutyrin
219753402|NCT07158775|BIOLOGICAL|BS01|a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)
219753403|NCT07158775|OTHER|Sham procedure control|Sham procedure without needle
219753404|NCT07159009|DRUG|Biological: GB261|GB261 will be dosed according to the protocol
219753405|NCT07159646|OTHER|exercise interventions|athletic/physical protocol
218993625|NCT03776552|OTHER|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
218993626|NCT05283213|DIAGNOSTIC_TEST|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\],~* urinary CCL-14 \[H6\],~* plasma angiopoietin-2 \[H6\],~* plasma PENK-A \[H6\]~These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."
218993627|NCT00687466|DRUG|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
218993628|NCT04899869|OTHER|Faecal microbiota transplantation with active study microbiota first|2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
218993629|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota first|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota
218993630|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota only|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
218993631|NCT00329238|DRUG|Dabigatran|Dabigatran 150 mg BID (twice daily)
218993632|NCT00329238|DRUG|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
218993633|NCT02257008|DRUG|BILR 355 BS|
218993634|NCT02257008|OTHER|Grapefruit juice|
218993635|NCT02257008|DRUG|Nelfinavir|
218993636|NCT02257008|DRUG|Atazanavir|
218993637|NCT02257008|DRUG|Ritonavir|
218993638|NCT05845151|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
218993639|NCT02528929|DIETARY_SUPPLEMENT|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
218993640|NCT06204146|BEHAVIORAL|massage|stressn level and preterm growth
219753406|NCT07161570|DEVICE|Virtual Reality (VR) Intervention|10-min VR intervention, once a day, everyday for 14 days.
219753407|NCT07161570|DEVICE|Light Box (LB) intervention|30-min LB intervention once a day, everyday for 14 days.
219753408|NCT07159711|DIAGNOSTIC_TEST|Seismofit|"Seismofit® is a 3 x 5 x 1.5 cm Class I medical device manufactured by Ventriject, which utilizes SCG principles and machine learning to estimate an individual's fitness. It is afixed to a patient's sternum with an adhesive patch. It measures the amplitude and timing of vibrations on the chest using accelerometers. The device then averages the data collected over 45 seconds to create the SCG. From the SCG, several maxima and minima (fiducial points) are identified, which correlate to the opening and closing of the mitral and aortic valves. Features of the SCG, including the timing, frequency, amplitude, and variability of these points, are then incorporated into an algorithm that also considers patient height, weight, age, and sex to calculate the VO2 peak.~Data is transmitted via Bluetooth to an allocated smartphone app."
219753409|NCT07160855|DRUG|Misoprostol (given vaginally)|800 micrograms of a single dose of vaginal misoprostol will be given
219753410|NCT07160855|DRUG|Letrozole 5 mg|10 mg oral letrozole for 3 days will be given
219753411|NCT07160855|DRUG|Placebo|oral placebo for three days will be given
219753412|NCT07161193|BIOLOGICAL|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
219753413|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Active (focused) ultrasound
219753414|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Sham (unfocused) ultrasound
219180757|NCT03309306|BEHAVIORAL|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns"
219369602|NCT05394415|RADIATION|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
218993641|NCT05732688|DIAGNOSTIC_TEST|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
218993642|NCT03558698|OTHER|Good ventilation|Good ventilation with a low concentration of CO2
218993643|NCT03558698|OTHER|Ventilation CO2|CO2 High and Good ventilation
218993644|NCT03558698|OTHER|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
218993645|NCT03385005|DEVICE|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
218993646|NCT04085276|DRUG|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
218993647|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
218993648|NCT04085276|DRUG|Placebo|Placebo, i.v., q3w;
218993649|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
219180758|NCT05685615|DRUG|BV100 plus Polymyxin B|Rifabutin for Infusion plus Polymyxin B for Injection
219180759|NCT05685615|DRUG|BAT|The best avaialble antibiotic therapy to treat CRAB
219369603|NCT00934076|DRUG|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
218993650|NCT04924322|DRUG|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
218993651|NCT05370170|BEHAVIORAL|Acupressure and nutritional advices|Teaching using booklets and application of acupressure
218993652|NCT03652012|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
218993653|NCT02199366|PROCEDURE|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
218993654|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection30mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
218993655|NCT05941585|DRUG|HomoharringtonineD1-D7(2mg/m2/day)|Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
218993656|NCT05941585|DRUG|Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)|Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
218993657|NCT05941585|DRUG|Cytarabine(standard-dose:d1-d7100mg/m2/day)|Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
218993658|NCT05941585|DRUG|Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)|d1-d4100mg/m2/day, d5-d7 1g/m2
218993659|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection24mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
218993660|NCT05298709|OTHER|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
218993661|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) as usual|Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
218993662|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) + Smart Parents|"Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session."
218993663|NCT05393895|DRUG|CSF-1|One drop bilaterally twice daily for at least 6 weeks
218993664|NCT05393895|DRUG|Vehicle|One drop bilaterally twice daily for at least 6 weeks
219180760|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
219753415|NCT07161518|DRUG|Propofol|Intravenous propofol administration
219753416|NCT00221858|PROCEDURE|Ultrasound guided blocks|
219753417|NCT07158697|BEHAVIORAL|HcELP_CMM|The intervention consists of two phases. Phase 1 is an initial individualized, face-to-face meeting to collaboratively set goals and develop action plan (week 1) and Phase 2 is an ongoing, personalized online support delivered by WeChat platform utilizing the official account, chat function, and synchronized online videos to integrate and sustain healthy lifestyle (weekly, week 2-12). Phase 1 covers 4 core steps: 1) assess symptom burden and lifestyle behaviors; 2) generate and analysis symptom burden and lifestyle report; 3) empowerment-based therapeutic person-centered health communication; and 4) behavior commitment. Phase 2 covers two modules: 1) integrate healthy behaviors to long-term lifestyle, and 2) sustain healthy lifestyle behaviors.
218993665|NCT06132386|OTHER|biopsy|colorectal biopsy for tissue acquisition
218993666|NCT04740190|DRUG|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
218993667|NCT04124757|OTHER|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
218993668|NCT05537883|DRUG|Liposomal bupivacaine|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
218993669|NCT05537883|DRUG|Bupivacaine Injection|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
218993670|NCT04034446|BIOLOGICAL|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
218993671|NCT04530773|BEHAVIORAL|Watch VR movies/ Play VR games|The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
218993672|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
218993673|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
218993674|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
218993675|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing high dose of the drug substance.
218993676|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing low dose of the drug substance.
218993677|NCT05039515|DRUG|Placebo|Placebo will be supplied as powder filled hard capsules
218993678|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
218993679|NCT03665051|PROCEDURE|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
218993680|NCT03665051|OTHER|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
218993681|NCT05427461|OTHER|Blood samples will be collected at different times.|"For patients with localized leiomyosarcoma, samples will be collected:~* At Baseline.~* Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).~* After surgery.~* At each control visit.~* At local or metastatic recurrence (or at 24 months post inclusion if no progression).~For patients with metastatic leiomyosarcoma, samples will be collected:~* At Baseline.~* At each therapeutic line.~* At progression (or at 24 months post inclusion if no progression)."
218993682|NCT02903680|DRUG|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
218993683|NCT02903680|DRUG|Placebo group|Normal Saline 0,9% same volume
218993684|NCT05154396|DRUG|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
218993685|NCT03217357|DEVICE|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
218993686|NCT06072898|DRUG|Psilocybin|Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
218993687|NCT06072898|OTHER|Microcrystalline cellulose|MCC (excipient), 25mg PO.
218993688|NCT06072898|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.
219180761|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
218993689|NCT01594671|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
218993690|NCT01594671|DRUG|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
218993691|NCT01594671|OTHER|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
218993692|NCT01328431|OTHER|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
218993693|NCT02796469|DRUG|Pentoxifylline|
218993694|NCT02796469|DRUG|Corticosteroid|
218993695|NCT02796469|DRUG|Placebo|
218993696|NCT02975687|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
218993697|NCT00018031|DRUG|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
218993698|NCT00018031|DRUG|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
218993699|NCT01644539|DIETARY_SUPPLEMENT|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
218993700|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
218993701|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
218993702|NCT00769392|DRUG|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
218993703|NCT00769392|DRUG|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
218993704|NCT00769392|DRUG|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
218993705|NCT00769392|DRUG|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
218993706|NCT01463488|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
218993707|NCT01463488|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
218993708|NCT01521546|DRUG|eplerenone|25mg tablet, once daily by mouth for 12 months
218993709|NCT01521546|DRUG|placebo|one tablet by mouth daily for 12 months
218993710|NCT00286312|DRUG|Atorvastatin|
218993711|NCT02296320|DRUG|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
218993712|NCT02296320|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
218993713|NCT06185283|DIAGNOSTIC_TEST|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
218993714|NCT01667029|DRUG|Sulfasalazine|
218993715|NCT01667029|DRUG|placebo|
218993716|NCT02609269|OTHER|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
218993717|NCT01341145|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
218993718|NCT01341145|BEHAVIORAL|Relaxation|12-week progressive muscle relaxation program (active control)
218993719|NCT03244215|DIAGNOSTIC_TEST|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
219369604|NCT00723957|DRUG|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
218993720|NCT03244215|DIAGNOSTIC_TEST|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
218993721|NCT03244215|OTHER|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
218993722|NCT00820690|DRUG|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
218993723|NCT00820690|DRUG|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
218993724|NCT00820690|DRUG|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
218993725|NCT00820690|PROCEDURE|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
218993726|NCT02899793|DRUG|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
218993727|NCT03310021|BIOLOGICAL|Andexanet alfa|fXa inhibitor antidote
218993728|NCT03310021|DRUG|Apixaban|factor Xa inhibitor
218993729|NCT03310021|DRUG|Rivaroxaban|factor Xa inhibitor
218993730|NCT03310021|DRUG|Edoxaban|factor Xa inhibitor
218993731|NCT03310021|DRUG|Placebo|Placebo
219180762|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
219369605|NCT00723957|DRUG|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m\^2
219180763|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
218993732|NCT04999176|DRUG|Rivaroxaban|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
218993733|NCT04999176|DRUG|Enoxaparin|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
218993734|NCT01822795|PROCEDURE|Lung volume reduction coïl treatment|
218993735|NCT01822795|OTHER|Regular medical treatment|
219753418|NCT07158697|BEHAVIORAL|Usual care-maintain daily lifestyle|"Participants in this group will continue with their normal daily lifestyle. WeChat-based follow-up will be performed weekly in the first 4 weeks and bi-weekly in the next 8 weeks. Each follow-up will last for 20 minutes. Follow-up communications will include: (1) general well-being assessments using brief, non-intrusive inquiries (e.g., How have participants felt overall in the past week/two weeks?); (2) disease management monitoring through standardized question tracking significant changes in their underlying diseases, intentionally avoiding exploration of intervention-targeted lifestyle behaviors (e.g., Have participants experienced notable changes in their health status or disease management approach since last contact?); and (3) addressing disease-related inquiries. For any questions inquired by participants in the control group, general advice will be given for ethical consideration."
218993736|NCT02158234|DRUG|Cisplatin|Cisplatin 15 mg/m\^2 prior to each fraction
218993737|NCT02158234|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
218993738|NCT02331342|DEVICE|NICOM cardiac output measurement|
218993739|NCT02331342|DEVICE|Innocor cardiac output measurement|
218993740|NCT03158896|BIOLOGICAL|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
218993741|NCT03638609|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
218993742|NCT05235555|DEVICE|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
218993743|NCT02221687|DIETARY_SUPPLEMENT|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
218993744|NCT02221687|DIETARY_SUPPLEMENT|Control formula|Standard milk formula without pre and probiotic
218993745|NCT01193595|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
218993746|NCT01193595|DRUG|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
218993747|NCT01061411|DRUG|Dalteparin|Given SC
218993748|NCT01061411|OTHER|Pharmacological Study|Correlative studies
218993749|NCT01061411|DRUG|Sunitinib Malate|Given PO
218993750|NCT04259567|DEVICE|Cytokine absorption|Use of CytoSorb absorber
218993751|NCT04746339|DRUG|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
218993752|NCT04746339|DRUG|Placebo|placebo twice daily for 30 days
219180764|NCT05533359|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
219180765|NCT05533359|BEHAVIORAL|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
219180766|NCT05533359|BEHAVIORAL|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
219180767|NCT06800118|DEVICE|Music intervention|Music will be played for patients undergoing coronary angiography, and vasospasm and pain levels will be evaluated.
219180768|NCT06800196|DRUG|KNT-0916|• KNT-0916 is an oral inhibitor of FGFR2.
219180769|NCT04309474|DRUG|Elezanumab|Intravenous (IV) infusion
218993753|NCT00592215|DRUG|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
218993754|NCT04511104|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
218993755|NCT04511104|OTHER|Standard of Care|Standard of care rehabilitation
218993756|NCT03312101|OTHER|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
218993757|NCT06310538|BEHAVIORAL|kou sha|Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
218993758|NCT06310538|DRUG|Hongjin Xiaojie Capsules|The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
218993759|NCT02871414|BEHAVIORAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
218993760|NCT02871414|BEHAVIORAL|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
218993761|NCT01427972|DRUG|LY2623091|Administered orally
218993762|NCT01427972|DRUG|Eplerenone|Administered orally
219180770|NCT04309474|DRUG|Placebo|Intravenous (IV) infusion
219180771|NCT06798519|DRUG|HNC364 Injectable Suspension|Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.
219180772|NCT06798519|DRUG|Rasagiline Tablets|Subjects in rasagiline tablets cohort will receive 1 mg of rasagiline tablets orally once daily for 20 days, followed by 2 mg once daily for 5 days. Subjects will remain domiciled at the clinic stay until Day 26 and have a follow-up visit on Day 29 due to PK and PD blood sample collections
219180773|NCT06611592|DRUG|Pramipexole 0.088mg/tid|Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).
219180774|NCT06611592|DRUG|Pramipexole 0.18 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt)."
219180775|NCT06611592|DRUG|Pramipexole 0.35 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt)."
219180776|NCT06800469|DIAGNOSTIC_TEST|Microbiota analysis|Upon acquisition of informed consent, fecal, digiunal mucosa, biliary and pancreatic fluid samples will be collected for microbiota analysis
218993763|NCT01015209|DEVICE|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
218993764|NCT03047057|DRUG|Lidocaine|IV Lidocaine infusion
218993765|NCT03047057|DRUG|IV normal saline|IV normal saline infusion
219180777|NCT06800729|DRUG|TIX100, an orally available inhibitor of thioredoxin-interacting protein|TIX100, an orally available inhibitor of thioredoxin-interacting protein
219180778|NCT06800729|DRUG|Placebo|placebo
219369606|NCT00723957|DRUG|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
219369607|NCT01007526|OTHER|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
218993766|NCT05160103|OTHER|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
218993767|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
218993768|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
218993769|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
218993770|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
218993771|NCT02946528|DEVICE|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
218993772|NCT02946528|DEVICE|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
218993773|NCT05679583|RADIATION|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
218993774|NCT04764279|DIETARY_SUPPLEMENT|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
218993775|NCT00622284|DRUG|Placebo identical to BI 1356 5mg|Placebo tablet once daily
219180779|NCT06801782|BEHAVIORAL|Experimental Cognitive training in Immersive Virtual Reality and Telemedicine approach|The cognitive training involved a 4-week immersive virtual reality program to improve planning, cognitive flexibility, and information updating in patients with mild cognitive impairment related to Parkinson's disease. Over 12 sessions of 30 minutes each, participants trained in a virtual supermarket to strengthen attentional and executive skills. The planning task required creating and following a route to collect items while following rules, with increasing complexity. The cognitive flexibility task involved alternating between selecting items from different categories, with difficulty rising due to more categories and distractors. The updating task, set at a virtual checkout, challenged participants to memorize and recall items on a conveyor belt, with difficulty increasing based on sequence length and item count. Progression to higher levels required three successful trials, with feedback provided to support performance improvement
219180780|NCT06801782|BEHAVIORAL|Active Comparator #1|The active placebo used the same virtual environment, Oculus Go system, and telemedicine setup as the training group, but engaged in tasks with low cognitive demands, mimicking everyday activities. The placebo-planning task involved following a fixed shopping list order in a modified version of the Zoo Map Test. The placebo-shifting task required selecting items from shelves without alternating between categories, while the placebo-updating task involved recalling only the last item from a conveyor belt sequence. The sessions mirrored the training group's structure, with 12 sessions over 4 weeks (3 per week, 30 minutes each), maintaining the same frequency, duration, and levels than Training.
219180781|NCT01753414|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Daily fractions
219180782|NCT01753414|PROCEDURE|Surgery|Radical resection
218993776|NCT00622284|DRUG|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
218993777|NCT00622284|DRUG|BI 1356|5mg, once daily in the morning for 104 weeks
218993778|NCT00622284|DRUG|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
218993779|NCT03965039|DEVICE|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
218993780|NCT03965039|DRUG|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
218993781|NCT03965039|DRUG|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
218993782|NCT03965039|DRUG|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
219180783|NCT06803992|DRUG|Dinoprostone vaginal insert|Described in the arm descriptions
219180784|NCT06803992|COMBINATION_PRODUCT|Dinoprostone gel and Foley catheter balloon|Described in the arm descriptions
219180785|NCT06802458|OTHER|Motivational interviewing|A total of 9 sessions were conducted, including 1 preparation session, 6 motivational interviews, 1 initial follow-up interview one week after the intervention, and 2 follow-up interviews 4 weeks after the initial follow-up. Considering the interactive training method, the motivational interviewing sessions were conducted in the training room of the Health Center in groups of 10 at three different days (Monday, Thursday, Friday) once a week, through face-to-face sessions each lasting 50-60 minutes. During the interviews, the women were provided with counseling to activate their own sources of motivation, develop healthy lifestyle behaviors and improve their quality of life specific to menopause
218993783|NCT00880009|DRUG|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
218993784|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
218993785|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
218993786|NCT01099553|OTHER|Educational video|Instructions to view an educational video about preparing for a colonoscopy
219180786|NCT06803329|BEHAVIORAL|Qnnections|A novel group-based suicide prevention intervention that augments standard VA mental health services for LGBTQ+ Veterans with current suicidal thoughts or recent suicidal behavior. Informed by the empirically-supported theoretical framework of the interpersonal theory of suicide and prior work tailoring interventions for minority stress, Qnnections is a structured 10-week group that uses a cognitive behavioral framework to target perceived burdensomeness and thwarted belongingness. Veterans will also receive safety planning and referrals.
219180787|NCT06803329|BEHAVIORAL|Enhanced Usual Care|The active control condition includes: 1) VA Safety Planning Intervention and 2) referrals to VA and non-VA services relevant to the individual. The safety plan will be conducted by Dr. Chang, a licensed psychologist. Therefore, EUC only differs from the Qnnections condition as it does not have the 10-session Qnnections intervention. EUC is intended to include elements of VA suicide prevention standard practice. The control condition is considered enhanced as all participants will receive these elements, whereas Veterans are not guaranteed to receive all of these services if not enrolled in this study.
218993787|NCT01099553|OTHER|Written instructions|Written instructions on preparing for a colonoscopy
218993788|NCT02469922|DEVICE|Positron emission tomography|
218993789|NCT02469922|RADIATION|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
218993790|NCT01481597|DRUG|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
218993791|NCT01481597|DRUG|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
218993792|NCT01481597|DRUG|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
218993793|NCT01481597|DRUG|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
218993794|NCT01481597|DRUG|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
218993795|NCT03958851|DIAGNOSTIC_TEST|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
218993796|NCT03958851|DIAGNOSTIC_TEST|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
218993797|NCT03958851|DIAGNOSTIC_TEST|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
218993798|NCT03958851|DIAGNOSTIC_TEST|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
218993799|NCT03958851|DIAGNOSTIC_TEST|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
218993800|NCT02771093|DRUG|Trelagliptin|Trelagliptin 100 mg tablet
218993801|NCT02771093|DRUG|Alogliptin|Alogliptin 25 mg tablet
218993802|NCT02398760|OTHER|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
218993803|NCT01268969|PROCEDURE|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
218993804|NCT01268969|PROCEDURE|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
218993805|NCT03322631|DRUG|Tirzepatide|Administered SC.
218993806|NCT03322631|DRUG|Placebo|Administered SC.
219180788|NCT06803550|OTHER|Enhanced recovery after surgery protocol|"ERAS pathway was developed based on the available guidelines and protocols it includes 14 items:~1. Preoperative patient education using an information sheet which includes instructions on postoperative wound care, pain management, and preventing and managing constipation.~2. Single preoperative enema 2 hours prior to surgery.~3. Solid or semisolid food stopped 6 hours before surgery.~4. Clear liquids may be continued up to 2 hours before surgery.~5. Preoperative carbohydrate loading in non-diabetic patients for up to 2 hours prior to surgery in the form of a single 330 ml high-carbohydrate clear drink (apple juice).~6. Saddle anesthesia.~7. Single dose of intravenous 500 mg metronidazole at the time of the anaesthesi induction.~8. Restriction of intraoperative intravenous fluids to less than 500 ml.~9. Balanced chloride-restricted crystalloid solutions should be used for maintenance infusions and fluid boluses.~10. A bundle measures to reduce surgical site infection which includes"
219180789|NCT06803550|OTHER|Routine pathway|This is the routine preoperative preparation at our institute
219180790|NCT03913702|DRUG|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
218993807|NCT02289339|DEVICE|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
218993808|NCT01646762|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
218993809|NCT01646762|OTHER|Laboratory Biomarker Analysis|Correlative studies
218993810|NCT02378961|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
218993811|NCT02378961|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
218993812|NCT02412618|DRUG|Mifepristone|Progesterone antagonist
218993813|NCT02412618|DRUG|Misoprostol|Prostaglandin E1
218993814|NCT02412618|DIETARY_SUPPLEMENT|Placebo|Tasteless, odorless, sugar based pill
218993815|NCT02840955|DEVICE|Staphefekt SA.100|
218993816|NCT02840955|OTHER|Placebo|
218993817|NCT01253408|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
218993818|NCT01253408|DRUG|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
218993819|NCT01217801|DRUG|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
218993820|NCT01217801|DRUG|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
218993821|NCT05239208|OTHER|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
218993822|NCT05239208|OTHER|Control Group|Dietary counseling
218993823|NCT02957669|BEHAVIORAL|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
218993824|NCT02957669|BEHAVIORAL|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
218993825|NCT04456959|DRUG|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
218993826|NCT01844128|DIETARY_SUPPLEMENT|weight loss|
218993827|NCT04682028|OTHER|professional care|The trained nurses provide professional care for the patients.
218993828|NCT04682028|OTHER|coventional care|nurses provide coventional care for the patients.
219180791|NCT03913702|DRUG|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
219180792|NCT06803212|OTHER|Conventional Physiotherapy Program|The patients' conventional physiotherapy program included stretching, strengthening, balance, and coordination exercises according to their individual needs
219180793|NCT06803212|OTHER|Dual-Task Interference|This intervention consisted of counting backward, reading words backward, and remembering word exercises.
219180794|NCT06803108|BEHAVIORAL|pyramidal activity program|the participating subjects of this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In this group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. this form form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned, the this group will follow low clorie diet
219753419|NCT07160517|BEHAVIORAL|Visual Pedagogy and Manual Toothbrushing|Participants in this arm will use a manual toothbrush with caregiver support. Visual pedagogy resources will include printed PECS cards illustrating each step of toothbrushing and tactile sensory panels simulating toothbrush bristles, toothpaste texture, and dental floss. Caregivers will be instructed to use these materials daily at home for 3 weeks to improve comprehension, adherence, and cooperation in children with ASD.
219753420|NCT06215118|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219753421|NCT06215118|DRUG|Iberdomide|cereblon-modulating agent
219753422|NCT04972838|BEHAVIORAL|Remaking Recess (RR)|Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
218993829|NCT03081533|OTHER|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
218993830|NCT05026255|PROCEDURE|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
218993831|NCT04505189|DRUG|Psilocybin|Psilocybin assisted psychotherapy
219753423|NCT05272384|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218993832|NCT05944757|DRUG|PRP plasma rich platelets|Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
218993833|NCT05944757|DRUG|Autologous serum|Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
218993834|NCT01595607|OTHER|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
218993835|NCT03035409|DRUG|Anamorelin Hydrochloride|Given PO
218993836|NCT03035409|BEHAVIORAL|Exercise Intervention|Undergo physical activity
219180795|NCT06803108|BEHAVIORAL|aerobic activity program|the participating subjects of the this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in this group with moderate intensity. the form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned , this group will follow low clorie diet
219180796|NCT06435039|DRUG|APL-1202|APL-1202 IR tablets.
219180797|NCT06435039|DRUG|APL-1501|APL-1501 ER capsules.
219180798|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
219753424|NCT05272384|PROCEDURE|Computed Tomography|Undergo PET/CT
219753425|NCT05272384|DRUG|Decitabine and Cedazuridine|Given PO
219753426|NCT05272384|BIOLOGICAL|Nivolumab|Given IV
219753427|NCT05272384|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218993837|NCT03035409|OTHER|Laboratory Biomarker Analysis|Correlative studies
218993838|NCT03035409|OTHER|Nutritional Assessment|Undergo nutritional counseling
218993839|NCT03035409|OTHER|Quality-of-Life Assessment|Ancillary studies
218993840|NCT03035409|OTHER|Questionnaire Administration|Ancillary studies
219180799|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
218993841|NCT04338074|DRUG|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
218993842|NCT04338074|DRUG|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
218993843|NCT06053996|RADIATION|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
218993844|NCT01430000|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
218993845|NCT01577680|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
218993846|NCT01577680|DRUG|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
219180800|NCT04925505|PROCEDURE|Interscalene brachial plexus blocks with ultrasound guidance under general anesthesia|Ultrasound-guidance, interscalene brachial plexus blocks, in-plane technique, perineural injection, 0.5% ropivacaine 12.5ml and 0.2% lidocaine 12.5ml
219180801|NCT01972919|RADIATION|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
219180802|NCT01972919|DRUG|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
219180803|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
219180804|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
219180805|NCT05018481|DRUG|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
219180806|NCT05018481|DRUG|Placebo|A placebo will be given in capsule form to study participants
219180807|NCT04971681|DEVICE|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
219180808|NCT04971681|DEVICE|Sham|The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
219180809|NCT06020716|DRUG|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
219180810|NCT06020716|DRUG|Placebo|Three times daily
219753428|NCT06399536|PROCEDURE|Individualized ANH|Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
219753429|NCT05772546|DRUG|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
219753430|NCT05772546|DRUG|Matching Placebo|Lactose monohydrate, tablet taken orally.
219753431|NCT03283007|DRUG|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
219753432|NCT03283007|DRUG|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
219753433|NCT05938699|DRUG|NCX 470|NCX 470 0.1% vs Placebo
218993847|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 1|milk supplement with probiotics
219753434|NCT05938699|DRUG|Placebo|NCX 0.1% vs Placebo
218993848|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 2|milk supplement without probiotics
218993849|NCT01607242|OTHER|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
218993850|NCT01607242|OTHER|Voice Handicap Index|Subjective Evaluation of Voice disorders
218993851|NCT01607242|OTHER|Swallowing Assesment|Swallowing function questionnaire
218993852|NCT01552694|DRUG|Sitagliptin|Oral, 100 mg/day for 2 months
218993853|NCT01552694|DRUG|Placebo|oral, matching placebo daily for 2 months
218993854|NCT01918436|BEHAVIORAL|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
218993855|NCT01918436|OTHER|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
218993856|NCT02004119|DRUG|KHK4577|
218993857|NCT02004119|DRUG|Placebo|
218993858|NCT02303366|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
219180811|NCT04191655|DEVICE|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
219180812|NCT04191655|DEVICE|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
219753435|NCT06127199|DEVICE|Ovaprene|Non-hormonal intravaginal ring
219753436|NCT02466919|DRUG|Pantoprazole|H. pylori eradication therapy
219753437|NCT02466919|DRUG|Amoxicillin|H. pylori eradication therapy
219753438|NCT02466919|DRUG|Metronidazole|H. pylori eradication therapy
219753439|NCT02466919|DRUG|Levofloxacin|H. pylori eradication therapy
219753440|NCT02466919|DRUG|Clarithromycin|H. pylori eradication therapy
219753441|NCT06483802|GENETIC|ASP2016|Intravenous (IV) infusion
219753442|NCT06483802|DRUG|Prednisolone|Oral
219753443|NCT04606914|DRUG|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
219753444|NCT05916040|DEVICE|Radiotherapy with MRIdian with simultaneous integrated boost|radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost
218993859|NCT02303366|DRUG|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
219180813|NCT00686335|DRUG|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
218993860|NCT02349529|BEHAVIORAL|Psychosocial Intervention Group|6 group sessions
218993861|NCT02349529|OTHER|Waiting list control|Treatment as usual
218993862|NCT01007266|BEHAVIORAL|Assignment of a Lay Patient Partner|
218993863|NCT01944696|OTHER|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
218993864|NCT03724032|DEVICE|HD-tDCS*|Non-invasive brain stimulation (active protocol)
218993865|NCT03724032|DEVICE|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
218993866|NCT02267083|DRUG|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
219180814|NCT00686335|DRUG|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
219180815|NCT04767906|DRUG|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
219180816|NCT06446661|OTHER|High Intensity|Daily texts
219180817|NCT06446661|OTHER|No Text Messagings|Standard Care
218993867|NCT00970970|OTHER|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
218993868|NCT05292508|DIAGNOSTIC_TEST|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
218993869|NCT00727428|BIOLOGICAL|FluLaval® TF|One IM injection.
218993870|NCT04335097|DEVICE|Biosensors|Sensor that detect vital signs
218993871|NCT02929667|DRUG|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
218993872|NCT02929667|DRUG|Placebo|Standard 6 weeks titration.
218993873|NCT03940222|DEVICE|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
218993874|NCT03940222|PROCEDURE|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
218993875|NCT05152030|DIAGNOSTIC_TEST|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
218993876|NCT05152030|DIAGNOSTIC_TEST|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
218993877|NCT01378637|DEVICE|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
218993878|NCT06193291|PROCEDURE|Feet heating|Feet placed in hot water
218993879|NCT06193291|PROCEDURE|Calf heating|Feet to calves placed in hot water
218993880|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
218993881|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
218993882|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
219180818|NCT06446661|OTHER|Low Intensity Text Messaging|Weekly Texts
219180819|NCT06403020|PROCEDURE|Block|qadratus lumboroum (QL) block
219180820|NCT06532591|DRUG|cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin|PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
219180821|NCT03375892|OTHER|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
219180822|NCT03375892|OTHER|Free breathing during radiation|The patient will be instructed to breathe freely.
219180823|NCT04169386|DRUG|AK102|AK102 single dose administered subcutaneously
219180824|NCT04169386|DRUG|Placebo|Placebo single dose administered subcutaneously
218993883|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
218993884|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
218993885|NCT03673215|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
218993886|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
218993887|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
218993888|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
218993889|NCT02201485|DEVICE|Stent|
218993890|NCT02201485|DEVICE|Balloon|
218993891|NCT02639065|DRUG|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
218993892|NCT02094183|OTHER|GLP-1|GLP-1
218993893|NCT02094183|DIETARY_SUPPLEMENT|low calorie diet|low calorie diet
219180825|NCT05714306|BIOLOGICAL|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
219180826|NCT05714306|BIOLOGICAL|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
219180827|NCT05714306|BIOLOGICAL|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
219180828|NCT05714306|DRUG|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
219180829|NCT04149704|BEHAVIORAL|ACP video decision aid|10 minute video decision aid describing the goals-of-care options
219180830|NCT04149704|OTHER|Usual Care-|Verbal description of the three types of care
219180831|NCT05071963|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
219180832|NCT03629678|OTHER|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
219180833|NCT00528268|DRUG|Sodium phenylbutyrate|Sodium phenylbutyrate is dispensed as a powder, 450-600 mg/kg/day, divided into four doses. For cohort 1, treatment and monitoring continues for 18 months. For cohort 2, treatment and monitoring continues for 24 months.
219180834|NCT06470672|DRUG|SHR-A1921|Anti-TROP-2 ADC
219180835|NCT06470672|DRUG|Adebrelimab|PD-L1 inhibitor
219180836|NCT06077903|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
218993894|NCT06556537|DEVICE|Face-to-face and video-assisted training|"During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes."
218993895|NCT00481078|DRUG|vorinostat|Given PO
218993896|NCT00481078|DRUG|paclitaxel|Given IV
218993897|NCT00481078|DRUG|carboplatin|Given IV
218993898|NCT00481078|OTHER|placebo|Given PO
218993899|NCT00481078|OTHER|laboratory biomarker analysis|Correlative studies
218993900|NCT01558271|DRUG|LY2189265|
218993901|NCT01558271|DRUG|Placebo|
218993902|NCT01558271|DRUG|Liraglutide|
218993903|NCT01845831|DRUG|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
218993904|NCT01845831|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
218993905|NCT01845831|DRUG|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
219180837|NCT06621641|BEHAVIORAL|The new HFNC weaning protocol|Patients will be randomly assigned to two groups: one following the new HFNC weaning protocol and another using the standard care protocol. The new protocol includes stepwise flow reduction based on the patient's clinical stability and uses the Respiratory Assessment Scale (RAS) to monitor weaning progress. The protocol emphasizes a multidisciplinary approach involving pediatricians, nurses, and respiratory therapists, with consistent training and application of weaning criteria
219180838|NCT06030141|OTHER|sesame oil application|sesame oil application
219180839|NCT06030141|OTHER|nigella sativa oil application|nigella sativa oil application
219180840|NCT06192940|BEHAVIORAL|Counseling home caregivers|Advice on the proper use of insulin therapy will be given, if necessary, to caregivers. Patients are reviewed at 1 month of this first visit with a collection of the same data
219180841|NCT02615730|DRUG|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
219180842|NCT02615730|DRUG|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
219180843|NCT04691817|DRUG|Atezolizumab|1200mg infusion
219180844|NCT04691817|DRUG|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
219180845|NCT06500130|DEVICE|Body Surface Gastric Mapping|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
219180846|NCT05562752|DIETARY_SUPPLEMENT|Probiotic|multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.
219180847|NCT05562752|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 12 weeks.
219180848|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
219753445|NCT05916040|OTHER|Questionnaires before, during and after radiotherapy|"Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~* EORTC QLQ-C30~* EORTC QLQ-CR29~* Low Anterior Resection Syndrome Score (LARS) questionnaire~* Hospital Anxiety and Depression Scale (HADS) questionnaire"
219753446|NCT03737136|DRUG|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
219753447|NCT04333537|PROCEDURE|Chest Radiography|Undergo chest x-ray
219753448|NCT04333537|PROCEDURE|Computed Tomography|Undergo SPECT/CT scan and FDG PET/CT or CT
219753449|NCT04333537|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
219753450|NCT04333537|DRUG|Imaging Agent|Receive imaging agent via injection
219753451|NCT04333537|PROCEDURE|Neck Dissection|Undergo standard elective neck dissection
219753452|NCT04333537|PROCEDURE|Planar Imaging|Undergo planar imaging
219753453|NCT04333537|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219753454|NCT04333537|OTHER|Questionnaire Administration|Ancillary studies
219753455|NCT04333537|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
219753456|NCT04333537|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT scan
219753457|NCT05553249|BEHAVIORAL|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
219753458|NCT03467243|BEHAVIORAL|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
219753459|NCT03467243|BEHAVIORAL|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
218993906|NCT01845831|DRUG|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
219753460|NCT03467243|BEHAVIORAL|Treatment as usual|TAU is when Veterans continue to receive their usual care.
219753461|NCT06011187|PROCEDURE|Routine care|Fluid administration will be given per routine care MAP between 65 - 70 mmHg
219753462|NCT06011187|DEVICE|AFM|AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg
218993907|NCT01845831|DRUG|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
218993908|NCT01845831|DRUG|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
218993909|NCT00760097|DEVICE|Transcranial direct stimulation|sessions of 20 minutes each
219180849|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
219180850|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
219180851|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
219180852|NCT03409614|DRUG|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
219180853|NCT03409614|DRUG|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
219180854|NCT03409614|OTHER|Chemotherapy|Platinum-based doublet chemotherapy Part 1
219753463|NCT04795531|DRUG|Insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
219753464|NCT04795531|DRUG|Placebo insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
219753465|NCT04795531|DRUG|Insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
219753466|NCT04795531|DRUG|Placebo insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
219753467|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
219753468|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
219753469|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
219753470|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
219753471|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
219753472|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
219753473|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
219753474|NCT05041985|DRUG|Diazepam Tablets|Diazepam 5 mg tablet once per day (bedtime) for 7 days
219753475|NCT05272878|DRUG|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
218993910|NCT04959916|BEHAVIORAL|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
218993911|NCT02172768|OTHER|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
218993912|NCT02172768|OTHER|daily dosing|micafungin daily for 8 days
218993913|NCT02172768|DRUG|micafungin|
219180855|NCT03409614|DRUG|Placebo|Matching placebo Part 2
219180856|NCT02291302|OTHER|integrated pest management|integrated pest management and environmental strategy
219180857|NCT02291302|OTHER|air purifier|air purifiers
219180858|NCT02291302|OTHER|No intervention (control)|no integrated pest management and sham air purifier
219180859|NCT04234022|DRUG|Zn-DDC|Zn-DDC added to myeloma samples for culturing
219180860|NCT04234022|DRUG|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
219180861|NCT04234022|DRUG|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
219180862|NCT05609786|BEHAVIORAL|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
219180863|NCT06315920|DRUG|Parecoxib|Single dose of 40mg of IV Parecoxib.
219180864|NCT06315920|DRUG|Morphine|Single dose of 5 mg of IV Morphine.
219180865|NCT05022316|OTHER|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
219180866|NCT02268253|DRUG|Tagraxofusp Injection|Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
219180867|NCT05369975|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
219180868|NCT05369975|OTHER|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
219180869|NCT03810196|DEVICE|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
219180870|NCT04364256|DEVICE|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
219180871|NCT05714761|DEVICE|Dexcom glucose sensor|Use of a Dexcom G6 Pro
219180872|NCT05119842|DEVICE|APrevent® VOIS-Implant|To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
219180873|NCT05632107|DEVICE|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
219180874|NCT03674424|DRUG|Avelumab|Chemotherapy with or without avelumab followed by surgery
219180875|NCT03674424|PROCEDURE|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
219180876|NCT03674424|COMBINATION_PRODUCT|CG|Chemotherapy 4 cycles of 3 weeks
218993914|NCT05532761|OTHER|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
218993915|NCT00415831|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
218993916|NCT03501459|DRUG|Rituximab|
218993917|NCT04566679|DIETARY_SUPPLEMENT|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
218993918|NCT04566679|DIETARY_SUPPLEMENT|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
218993919|NCT00967590|DRUG|RO5036505|380mg iv infusion once weekly for 8 weeks
218993920|NCT00967590|DRUG|placebo|iv infusion once weekly for 8 weeks
219180877|NCT03674424|COMBINATION_PRODUCT|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
219180878|NCT03674424|COMBINATION_PRODUCT|PG|Chemotherapy 2 cycles of 4 weeks
219180879|NCT05857761|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.
219753476|NCT05272878|DRUG|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
218993921|NCT00067665|OTHER|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
218993922|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
218993923|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
219180880|NCT05857761|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Five sessions of sham rTMS therapy will be distributed over 2 weeks
218993924|NCT02610725|OTHER|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
218993925|NCT04048928|BEHAVIORAL|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
219180881|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
219180882|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
219180883|NCT06580899|DEVICE|Intra-articular catheter|Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period
219180884|NCT06580899|OTHER|Routine Standard of Care Treatment|No changes to what would occur outside of the study.
219180885|NCT06580067|BEHAVIORAL|Pray Until Something Happens (PUSH)|Self-monitoring of outcomes + alerts/reminders + use of PUSH
219180886|NCT06580067|BEHAVIORAL|Self-monitoring|Self-monitoring of outcomes + alerts/reminder
219180887|NCT04518280|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
219180888|NCT04518280|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
219180889|NCT04518280|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219180890|NCT04518280|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
219180891|NCT05986422|DRUG|Methylprednisolone|The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
218993926|NCT00003105|BIOLOGICAL|filgrastim|
218993927|NCT00003105|DRUG|cisplatin|
218993928|NCT00003105|DRUG|doxorubicin hydrochloride|
218993929|NCT00003105|DRUG|gemcitabine hydrochloride|
218993930|NCT00003105|DRUG|ifosfamide|
218993931|NCT00003105|DRUG|paclitaxel|
218993932|NCT04075760|PROCEDURE|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
218993933|NCT04075760|DRUG|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
218993934|NCT01297660|OTHER|Video-urodynamic examination|
218993935|NCT00826943|DRUG|Cetirizine|Cetirizine 10 mg tab daily x 7 days
219180892|NCT01453127|DRUG|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
219180893|NCT01453127|DEVICE|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
219180894|NCT05932992|OTHER|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
219180895|NCT04547920|DEVICE|Wearable Bladder Modulation System|Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation Device
219180896|NCT04390009|DIAGNOSTIC_TEST|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
219180897|NCT04390009|DRUG|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
219180898|NCT04881630|BEHAVIORAL|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
219180899|NCT04881630|OTHER|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
218993936|NCT00826943|DRUG|Levocetirizine|5 mg tab daily x 7 days
218993937|NCT00826943|DRUG|Placebo|Placebo tablet daily x 7 days
218993938|NCT01348165|DRUG|BI 137882|Powder for oral solution
218993939|NCT01348165|DRUG|Placebo|Powder for oral solution
218993940|NCT04191031|DEVICE|ioveraº|Cryoneurolysis
218993941|NCT04191031|DEVICE|ioveraº sham|ioveraº sham
218993942|NCT01595997|DRUG|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
218993943|NCT01696825|DRUG|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
218993944|NCT01696825|DRUG|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
218993945|NCT01696825|DRUG|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
218993946|NCT00705198|DRUG|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
218993947|NCT00705198|DRUG|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
218993948|NCT00705198|RADIATION|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
218993949|NCT00133497|BIOLOGICAL|MF-59|Microfluoridized adjuvant 59 (MF59).
219180900|NCT06503692|DEVICE|DKutting PTA Scoring Balloon Dilatation Catheter|The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.
219180901|NCT06503692|DEVICE|Peripheral Balloon Catheter|The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.
219180902|NCT06127550|DEVICE|active taVNS|low level stimulation to the auricular branch of the vagus nerve
219753477|NCT04043286|DEVICE|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
219753478|NCT00280202|PROCEDURE|Biopsy of the major carinal area|Biopsy performed intraoperatively
218993950|NCT00133497|DRUG|Placebo|0.5 mL of saline placebo.
218993951|NCT00133497|BIOLOGICAL|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
218993952|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
218993953|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
218993954|NCT03873974|DIAGNOSTIC_TEST|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
218993955|NCT03873974|DIAGNOSTIC_TEST|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
218993956|NCT03873974|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
218993957|NCT03873974|DIAGNOSTIC_TEST|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
218993958|NCT02271568|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
218993959|NCT02271568|OTHER|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
218993960|NCT05723978|PROCEDURE|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
218993961|NCT02517983|OTHER|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
219180903|NCT06127550|DEVICE|sham taVNS|device placed with no current administered
219180904|NCT05655091|DRUG|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
218993962|NCT03810560|DEVICE|laser device Er,Cr:YSGG laser|laser device with open flap debridement
218993963|NCT06208683|BIOLOGICAL|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
218993964|NCT06208683|BIOLOGICAL|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
218993965|NCT01594762|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
218993966|NCT01594762|DRUG|Topical placebo cream|14 days of treatment
218993967|NCT01594762|OTHER|Standard wound care|14 days of treatment
218993968|NCT01645345|DEVICE|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
218993969|NCT05937542|BEHAVIORAL|Qualitative Investigation of Participant Experiences|There is no intervention. This is a retrospective qualitative study.
218993970|NCT04568733|BEHAVIORAL|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
219180905|NCT05655091|DRUG|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
219180906|NCT03958838|BEHAVIORAL|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
219753479|NCT00280202|PROCEDURE|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
219753480|NCT00280202|PROCEDURE|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
218993971|NCT04568733|BEHAVIORAL|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
218993972|NCT04568733|BEHAVIORAL|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
219753481|NCT00280202|PROCEDURE|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
219753482|NCT00280202|PROCEDURE|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
219753483|NCT00280202|PROCEDURE|Analysis of lymph nodes|Tissues banked for future analysis
219753484|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
219753485|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
219753486|NCT06334497|DRUG|Letermovir|"480mg (2X240mg- tablets) of Letermovir given orally once a day until the treatment success or the treatment failure, up to 12 weeks. In case of co-administration with cyclosporine A, the dosage of Letermovir will be reduced."
219753487|NCT06334497|DRUG|Valganciclovir|"Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced."
219753488|NCT06334497|DRUG|Letermovir placebo|"480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks"
219753489|NCT03604978|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219753490|NCT03604978|PROCEDURE|Echocardiography Test|Undergo ECHO
219753491|NCT03604978|BIOLOGICAL|Ipilimumab|Given IV
219753492|NCT03604978|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
219753493|NCT03604978|BIOLOGICAL|Nivolumab|Given IV
219753494|NCT03604978|RADIATION|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
219753495|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenate|200 µg selenium as selenate
219753496|NCT00271245|DIETARY_SUPPLEMENT|400 µg selenium as selenate|400 µg selenium as selenate
219753497|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
219753498|NCT00271245|DIETARY_SUPPLEMENT|Placebo|Placebo
219753499|NCT05842031|BEHAVIORAL|Quality of Life Questionnaires|Identify what interventions may be helpful in improving quality of life.
219753500|NCT05842031|BEHAVIORAL|Patient Educational Needs|Identify what interventions may be helpful in improving patient educational needs
219753501|NCT05842031|BEHAVIORAL|Symptom Management|Identify what interventions may be helpful in improving symptom management Improve symptom management
219753502|NCT05568862|DIAGNOSTIC_TEST|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
219753503|NCT05568862|DIAGNOSTIC_TEST|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
219753504|NCT01323192|DRUG|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
219753505|NCT01323192|DRUG|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
219753506|NCT01019265|DRUG|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
219753507|NCT00867607|DRUG|MRX-6|b.i.d treatment for 21 days
219753508|NCT00867607|DRUG|Steroid|b.i.d. 21 days
219753509|NCT02398331|OTHER|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
219753510|NCT06835036|OTHER|Exercise Treatment|In this study, a functional exercise programme will be performed 3 days a week for 8 weeks in three cycles as previously recommended. This programme consisted of a 5-minute warm-up and a 45-minute exercise phase.
219753511|NCT02390895|PROCEDURE|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
219753512|NCT04019002|DRUG|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
219753513|NCT06958237|DEVICE|salicylic acid wart patches|"The wart patches contain the auxiliary therapeutic substance salicylic acid at a concentration of 40%, which causes chemical exfoliation, removing the exfoliated skin. Salicylic acid softens the keratinised skin, making it easier to remove. The remedial process leads to the removal of the wart by exfoliation. The wart should disappear after about 7 days of using the patch. The treatment can be prolonged up to 21 days.~The wart patch is intended for the treatment of common warts and plantar warts. The mechanism of action of the product is the barrier and protective action of the patch, reducing the possibility of spreading viral infection and, as an auxiliary, to exfoliate keratinised epidermis, accelerating the skin renewal process."
219180907|NCT04884724|OTHER|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
219180908|NCT05776563|BEHAVIORAL|Nutrition visits|Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee
219180909|NCT05776563|OTHER|Intensification of diabetes regimen|Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
219180910|NCT05776563|OTHER|Continuous glucose monitor (CGM)|Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
219180911|NCT01451502|BIOLOGICAL|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
219180912|NCT04752826|DRUG|BI-1808|BI-1808 administered as a flat-dose IV infusion once every 3 weeks
219180913|NCT04752826|DRUG|Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection|Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.
219180914|NCT04830137|DRUG|NX-2127|Oral NX-2127
219180915|NCT06462625|OTHER|High tibial osteotomy|Correction of lower limb malalignement with tibial bone wedge insertion/removal
219180916|NCT05412381|PROCEDURE|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
219180917|NCT05412381|PROCEDURE|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
219180918|NCT05797753|DRUG|SAR443820|Tablet by oral administration
219753514|NCT02296476|DRUG|Birabresib|Administered orally in a fasted state once daily.
219753515|NCT06796101|DEVICE|Vagus Nerve Stimulation|In the study, CE certified vagus nerve stimulation device Vagustim will be used. Transcutaneous auricular vagus nerve stimulation will be applied bilaterally. The stimulation pulse width is 300 microseconds, frequency is 10 Hz and will be applied biphasically for 20 minutes.
219753516|NCT06796101|OTHER|Controlled breathing exercises|"A controlled breathing exercise group will continue for a total of 2 weeks and will receive 10 sessions of 20 minutes per day.~The thoracic expansion exercise will be performed in 10 repetitions. In each intervention session, 2 sets of nadi shodhana pranayama consisting of 8 respiratory cycles will be applied to the patients, with a 2-minute rest period between the sets. Kapalabhati will be practised for 3 minutes, with 15 quick breaths in 10 seconds followed by a 20-second break (a total of 30 breaths per minute). In each session, 2 sets of bhramari pranayama consisting of 10 breathing cycles will be performed at a low respiratory rate, with a 1-minute rest period between sets. The physiological sigh exercise involves the first inspiration phase being 1 second, the second phase 0.25 seconds, and the exhalation 2 seconds for 3 minutes."
219753517|NCT00442702|DRUG|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
219753518|NCT00442702|DRUG|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
219753519|NCT01746524|DEVICE|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
219753520|NCT05068349|DRUG|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
219753521|NCT01248325|DRUG|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
219753522|NCT01248325|DRUG|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
218993973|NCT01297712|DEVICE|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
218993974|NCT01703039|DRUG|Riluzole|
218993975|NCT01703039|DRUG|Sertraline|
218993976|NCT01703039|OTHER|placebo|
218993977|NCT01205711|DRUG|FOLFIRI regimen|
218993978|NCT01205711|DRUG|fluorouracil|
218993979|NCT01205711|DRUG|irinotecan hydrochloride|
218993980|NCT01205711|DRUG|leucovorin calcium|
218993981|NCT01205711|DRUG|zibotentan|
218993982|NCT01205711|OTHER|laboratory biomarker analysis|
218993983|NCT01205711|OTHER|pharmacogenomic studies|
218993984|NCT05570500|BEHAVIORAL|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
218993985|NCT02091934|PROCEDURE|Wavefront-guided PRK|Wavefront-guided PRK
218993986|NCT02091934|PROCEDURE|Wavefront-optimized PRK|Wavefront-optimized PRK
218993987|NCT04554979|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
218993988|NCT04706091|DRUG|Suvorexant|10-mg or 20-mg suvorexant capsules
218993989|NCT04706091|OTHER|Placebo|Matching placebo capsules
218993990|NCT00580021|OTHER|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
218993991|NCT04527705|PROCEDURE|Non-surgical root canal retreatment|Non-surgical root canal retreatment
219180919|NCT05797753|DRUG|SAR443820|Capsule by oral administration
218993992|NCT01419691|DRUG|auranofin|6 mg twice a day for a total of 12 mg total daily dose
218993993|NCT00150202|DRUG|pegaptanib sodium|
218993994|NCT05465434|DRUG|Zinc Supplement|Zinc sulphate 50 mg
218993995|NCT03609905|BIOLOGICAL|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline
219180920|NCT05797753|DRUG|Erythromycin ethyl succinate|Tablet by oral administration
219180921|NCT05797753|DRUG|Itraconazole|Capsule by oral administration
218993996|NCT03609905|OTHER|Conventional drugs|5-amino-salicylic acid or glucocorticoid
218993997|NCT04711044|OTHER|Papain|Papain will be applied using cowhage spicules inactivated by heat
218993998|NCT04711044|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
218993999|NCT04711044|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
218994000|NCT04711044|OTHER|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
219180922|NCT06331858|DEVICE|hip device-assisted concentric abductor strengthening (HDACAS)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
219180923|NCT06331858|DEVICE|knee device-assisted concentric flexor-extensor strengthening (KDACFES)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
219180924|NCT05183464|BIOLOGICAL|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
219180925|NCT05183464|BEHAVIORAL|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
219180926|NCT05183464|BEHAVIORAL|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
218994001|NCT00953901|DRUG|Fresh Frozen Plasma Transfusion|
218994002|NCT04007978|GENETIC|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
218994003|NCT05547685|DIAGNOSTIC_TEST|Methylene blue intradermal injection|Methylene blue intradermal injection
218994004|NCT02612727|DEVICE|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
218994005|NCT02612727|DEVICE|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
218994006|NCT01446289|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
218994007|NCT01446289|BIOLOGICAL|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
218994008|NCT02302807|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
218994009|NCT02302807|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
218994010|NCT02302807|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
218994011|NCT02302807|DRUG|Vinflunine|Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
218994012|NCT01809483|DEVICE|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
218994013|NCT01809483|DEVICE|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
218994014|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple|Active juice with added fibre and ginseng
218994015|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple control|Control products without active ingredients
218994016|NCT00376727|BIOLOGICAL|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
218994017|NCT00376727|GENETIC|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
218994018|NCT00376727|OTHER|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
218994019|NCT00376727|OTHER|laboratory biomarker analysis|Cetuximab Pharmacodynamics
218994020|NCT00539136|DRUG|GSK561679 tablet or solution|
218994021|NCT02947685|DRUG|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
218994022|NCT02947685|DRUG|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
218994023|NCT02947685|DRUG|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
218994024|NCT02947685|DRUG|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
218994025|NCT02947685|DRUG|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
218994026|NCT02947685|DRUG|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
218994027|NCT02947685|DRUG|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
218994028|NCT05465460|DRUG|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
218994029|NCT05465460|DRUG|Placebo|Placebo tablet orally four times per day for 14 days
219180927|NCT05183464|BEHAVIORAL|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
219180928|NCT05183464|BEHAVIORAL|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
219180929|NCT04417530|DRUG|AU-011|AU-011 Via Suprachoroidal Administration
219180930|NCT04417530|DEVICE|Suprachoroidal Microinjector|Suprachoroidal Injection Device
218994030|NCT00096798|DRUG|Ethyl-eicosapentanoic acid (ethyl-EPA)|
219180931|NCT04417530|DEVICE|PDT Laser|Laser Administration
219180932|NCT05949788|OTHER|No intervention|Retrospect study, no direct intervention
219180933|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
219180934|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
219180935|NCT06565078|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|CUVITRU 20% Solution
219180936|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
219753523|NCT05604261|DRUG|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
219180937|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
219753524|NCT05604261|DRUG|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
219753525|NCT05604261|DRUG|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
219180938|NCT05213390|OTHER|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
219753526|NCT00313560|DRUG|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
219753527|NCT04257019|OTHER|Lavender oil|Inhalation of Lavender oil
219753528|NCT04257019|OTHER|Almond oil|Inhalation of Almond oil
219753529|NCT04257019|OTHER|Water|Inhalation of water
219753530|NCT06628570|DIAGNOSTIC_TEST|HRA + Biopsy|High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
219753531|NCT06628570|DIAGNOSTIC_TEST|Anal Cytology|Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
219753532|NCT06628570|DIAGNOSTIC_TEST|Genotyping of anal hrHPV infection|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
219180939|NCT04868903|DIETARY_SUPPLEMENT|Vitamin D3|Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
219753533|NCT06628570|DIAGNOSTIC_TEST|CINtec®PLUS|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, \>50).
218994031|NCT04254497|DIAGNOSTIC_TEST|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with \> 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (\> 8000 pores/mm\^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
218994032|NCT06408610|OTHER|moderate intensity continuous training|exercise and diet
218994033|NCT05001737|DRUG|Emapalumab|Emapalumab iv infusion
218994034|NCT04610944|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
218994035|NCT04993742|BEHAVIORAL|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
218994036|NCT05243641|DRUG|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
218994037|NCT05243641|DRUG|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
218994038|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
219180942|NCT01824537|BIOLOGICAL|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
219180943|NCT01824537|BIOLOGICAL|Hepatitis A vaccine|Provided by Sanofi Pasteur.
219180944|NCT06618989|OTHER|Blood sampling and follow-up call|An additional 1.5 mL of blood will be collected at the time of the child care in the pediatric emergency department. In addition, a telephone call for patient follow-up (unless still hospitalized) will be done.
219753534|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 4-7 days per week
219753535|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 1 day per week
219753536|NCT02194387|OTHER|Internet-Based Intervention|Receive email coaching
219753537|NCT02194387|OTHER|Internet-Based Intervention|Participate in social networking
218994039|NCT04457193|DEVICE|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
218994040|NCT04125836|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
218994041|NCT06666907|DEVICE|Smilefy|AI based DSD
219180945|NCT04179448|PROCEDURE|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
219180946|NCT04179448|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
219753538|NCT02194387|OTHER|Laboratory Biomarker Analysis|Correlative studies
219753539|NCT02194387|OTHER|Questionnaire Administration|Ancillary studies
219753540|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
219753541|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
219753542|NCT06775860|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
218994042|NCT06666907|DEVICE|EXOCAD|Conventional DSD software
218994043|NCT04067752|OTHER|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
218994044|NCT04067752|OTHER|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
218994045|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
219180947|NCT06066346|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression
219180948|NCT03374085|DRUG|CC-92480|CC-92480
219180949|NCT03374085|DRUG|Dexamethasone|Dexamethasone
219180950|NCT05127187|DIAGNOSTIC_TEST|Rapid diagnosis test against HIV and hepatitis C and B|combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
219180951|NCT04922229|PROCEDURE|RCT|This is the standard of care for this diagnosis
219180952|NCT04922229|PROCEDURE|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
219180953|NCT02725463|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
219180954|NCT01743807|DRUG|GNKG168|"GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168."
219180955|NCT01935869|DRUG|LEO 90100|
218994046|NCT04107506|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
218994047|NCT04107506|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
218994048|NCT06420375|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
218994049|NCT06420375|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
218994050|NCT03386500|DRUG|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
218994051|NCT04518306|DRUG|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
218994052|NCT04518306|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
218994053|NCT04518306|DRUG|Placebo|Placebo
218994054|NCT06731348|DRUG|restricted opioid prescribing|Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
218994055|NCT06731348|DRUG|standard opioid prescribing|Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
218994056|NCT02137161|DRUG|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
218994057|NCT02137161|DRUG|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
218994058|NCT05966792|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
219180956|NCT01935869|DRUG|Vehicle|
218994059|NCT05966792|DRUG|metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
219180957|NCT01935869|DRUG|Petrolatum ointment|
219180958|NCT06093477|DIETARY_SUPPLEMENT|Fast-Dissolve Melatonin Pill|Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.
218994060|NCT03904043|RADIATION|Radiation therapy|-Monday-Friday treatment is strongly recommended
218994061|NCT03904043|DRUG|FOLFOX regimen|-CAPOX can be given as alternative
218994062|NCT03904043|DRUG|CAPOX regimen|Given as an alternative to FOLFOX
218994063|NCT05315609|BEHAVIORAL|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
218994064|NCT04340778|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
218994065|NCT04340778|DRUG|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
219180959|NCT06093477|OTHER|Fast-Dissolve Placebo Pill|Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
219180960|NCT03892265|OTHER|Observational Study|No intervention is included in this observational study.
219753543|NCT06775860|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
219753544|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
219753545|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as specified in the treatment arm.
219753546|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
219753547|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
218994066|NCT04340778|DRUG|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
218994067|NCT06209996|BEHAVIORAL|L4 weight management intervention|he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.
219180961|NCT05967364|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
218994068|NCT06209996|BEHAVIORAL|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
219180962|NCT05967364|BEHAVIORAL|Stress Management|Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
219180963|NCT04390308|PROCEDURE|Ovarian puncture|Egg collection
219180964|NCT04390308|OTHER|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
219180965|NCT04390308|DIAGNOSTIC_TEST|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
219180966|NCT04835129|DRUG|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
219180967|NCT04835129|DRUG|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
219180968|NCT04835129|DRUG|Pomalidomide|4 mg PO days 1-21 of each cycle.
219180969|NCT04835129|DRUG|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
219180970|NCT04835129|DRUG|Dexamethasone|40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
219180971|NCT03344094|DRUG|ocrelizumab|FDA-approved MS drugs
219180972|NCT05292118|DEVICE|Navitian|Patients in whom treatment with (Navitian) has been attempted
219753548|NCT05728658|DRUG|ICP-248 +Rituximab|Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.
219180973|NCT06016959|OTHER|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition \& also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
219180974|NCT06016959|OTHER|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton \& Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
219180975|NCT05134922|DRUG|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
219180976|NCT05838313|BEHAVIORAL|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
219180977|NCT04704986|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
219753549|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
219753550|NCT05728658|DRUG|ICP-248+Orelabrutinib+Rituximab|Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.
219753551|NCT03887455|DRUG|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
219753552|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
219753553|NCT03887455|DRUG|Lecanemab|Dose 1 administered as a subcutaneous injection.
219753554|NCT03887455|DRUG|Lecanemab|Dose 3 administered as a subcutaneous injection.
219753555|NCT03887455|DRUG|Lecanemab|Dose 2 administered as a subcutaneous injection.
219753556|NCT03887455|DRUG|Lecanemab|10 mg/kg once every 4 weeks administered as intravenous infusion.
219753557|NCT03887455|DRUG|Drug: Lecanemab|Dose 4 administered as a subcutaneous injection.
218994069|NCT05087459|DRUG|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
218994070|NCT06115746|BEHAVIORAL|iDECIDE|iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
218994071|NCT07008664|OTHER|Epigenetic Signature Assay|Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.
218994072|NCT03352349|DRUG|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
218994073|NCT07011329|RADIATION|Changes in the brain MTP parameters after radiotherapy|Our study explores the changes in brain MTP parameters and their correlation with clinical cognitive scores before and after chemotherapy and/or radiotherapy in patients with NPC. We investigates MRI-derived multiparametric imaging biomarkers (MTP) as predictive biomarkers for chemotherapy/radiotherapy-induced cognitive decline in nasopharyngeal carcinoma, aiming to optimize neurotoxicity risk stratification and guide personalized neuroprotective interventions in precision oncology.
218994074|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
218994075|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
218994076|NCT06680349|DRUG|Anti-CD20 antibodies|comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
218994077|NCT06759389|DEVICE|Resuscitation (Ventor)|Resuscitation with the Ventor device
218994078|NCT07012603|OTHER|External oblique and rectus abdominis plane (EXORA) block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20 mL of bupivacaine 0.25%.
218994079|NCT07012603|OTHER|Sham block|Patients will receive a sham block using 20 mL of normal saline as a control group.
219180978|NCT04704986|DRUG|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
219180979|NCT05415722|DRUG|TERN-501|Investigational drug
219180980|NCT05415722|DRUG|TERN-101|Investigational drug
219180981|NCT05415722|OTHER|Placebo|Matching placebo
219753558|NCT05850416|OTHER|mGlide-Care|Mhealth mediated model of HTN care with self-monitoring and medication management
219753559|NCT05850416|OTHER|Usual Care +|Usual Care with self-monitoring support
218994080|NCT06869278|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
218994081|NCT07015801|BIOLOGICAL|CMV-VST|30-40 x 10\^3 viable CD3+ cells/kg
218994082|NCT07014527|PROCEDURE|Patient specific subperiosteal implants|Patient specific subperiosteal implants
218994083|NCT07015372|BEHAVIORAL|Laughter Yoga|Laughter yoga intervention including clapping, breathing, childlike play, and laughter exercises, delivered in 8 sessions over 4 weeks to reduce stress and burnout and improve general health among psychiatric nurses.
218994084|NCT07014501|OTHER|High altitude|Altitude above 3500 meters.
218994085|NCT07014501|OTHER|Medium altitude|Altitude between 3500 meters and 1500 meters.
218994086|NCT07014501|OTHER|Low altitude group|Altitude below 1500 meters.
219180982|NCT04023110|DRUG|Carvedilol|Individually dosed carvedilol
219180983|NCT06155838|OTHER|"Early Adolescent Skills for Emotions (EASE)"|"Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care"
219180984|NCT05028738|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
219180985|NCT02650505|DRUG|LEO 43204|
219753560|NCT06523504|DEVICE|DIMS|wear DIMS ,and use placebo,once nightly, both eye
218994087|NCT07016048|PROCEDURE|Try-in of one crown test with a digital wax-up (per group)|"In a CAD/CAM software, we will integrate IOS, CBCT, and FS data into the virtual environment, and it will be possible the articulation of virtual models.~The digital wax-up for the preparation of the crown will be designed by the prosthodontist and then adjusted based on the occlusion obtained in each of the groups.~The steps of clinical procedure are:~1. \- In the first appointment, the patients mention their smile concerns, and the dentist evaluate and diagnoses.~2. \- Digital impressions, and a model of the teeth will be done.~3. \- Diagnostic wax-up, where dentist and dental laboratory plan the wax-up on the study models.~4. \- Diagnostic mock-up, where dentist transfers the diagnostic wax-up to the patient's mouth.~We will evaluate the volumetric difference between the diagnostic wax-ups obtained in each group.~After each mock-up, a questionnaire will be delivered to the patients in order to assess patients's aesthetics and comfort self-perception, using a numeric scale."
218994088|NCT07014696|PROCEDURE|PNF application Group|PNF Application; in the application method, the subjects will be in a sitting position. The application will be made to the fingers, wrist and forearm in both D1 and D2 directions in flexion and extension patterns. The techniques will start using rhythmic initiation, then the combination of isotonics, dynamic-opposite, rhythmic stabilization and muscle-relaxation are determined. The movements will be made in 10 repetitions with rest in between (Saklecha et al., 2023).
218994089|NCT07014696|PROCEDURE|KB application Group|KB Application; In the taping treatment to be applied, taping will be applied starting from the fingers and up to the elbow with kinesiology taping (Huang et al., 2019). Taping will be done 3 days a week and the tape will remain on the patient for 2 days.
218994090|NCT07014696|PROCEDURE|PNF+KB application Group|PNF+ KB Application; In this application, both PNF and taping will be applied. After each application, conventional treatment will be applied to all three groups at the end of each session. When all treatments are completed, re-evaluations will be made by the blind physiotherapist
218994091|NCT07014449|DRUG|WBC100 QD|WBC100 will be administered orally as capsules once daily in 28-day cycles. The dose-escalation phase follows an accelerated titration combined with the traditional '3+3' design.
218994092|NCT07014592|DEVICE|stimulating probes and electrodes|Subdural electrodes and/or ball tip probes will be used intraoperatively to provide electrical stimulation to the brain.
218994093|NCT06714929|BEHAVIORAL|Hydration|Clusters of schools will sequentially be exposed to the intervention in a stepped-wedge fashion. The intervention is a 4-month community participatory school-based hydration intervention that includes provision of refillable water bottles in schools with hydration stations in addition to: 1) social marketing, 2) behavioral reinforcement, and 3) education and outreach.
218994094|NCT05232110|DRUG|Pozelimab|
218994095|NCT06774872|DRUG|Doravirine 100Mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 1 will receive the DORAVIRINE/LAMIVUDINE combination: doravirine (PIFELTRO®) 100 mg 1 pill a day + lamivudine 300 mg 1 pill a day"
218994096|NCT06774872|DRUG|Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 2 will receive the DTG/3TC combination: dolutegravir 50 mg/lamivudine 300 mg (DOVATO®) 1 pill a day"
218994097|NCT04147221|DRUG|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
218994098|NCT04086147|DRUG|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
218994099|NCT04086147|DRUG|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
218994100|NCT01730391|OTHER|Data collection|Collection of demographic data and vaccination history
219753561|NCT06523504|DRUG|The 0.02% ATP Group|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
218994101|NCT01730391|OTHER|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
218994102|NCT02625272|PROCEDURE|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
218994103|NCT06298110|BIOLOGICAL|Platelets Rich plasma of the same patient|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
218994104|NCT01174303|DRUG|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
218994105|NCT01174303|DRUG|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
218994106|NCT02529345|DEVICE|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
218994107|NCT02290561|PROCEDURE|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
219753562|NCT06523504|DRUG|The 0.04% ATP Group|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
219753563|NCT06523504|COMBINATION_PRODUCT|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
218994108|NCT02290561|DEVICE|MRI|
218994109|NCT02290561|DEVICE|high intensity focused ultrasound (HIFU)|
218994110|NCT02894918|DRUG|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
218994111|NCT00438698|OTHER|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
219753564|NCT06523504|COMBINATION_PRODUCT|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
219753565|NCT02964377|DRUG|(+)- Epicatechin|
219753566|NCT03184753|BIOLOGICAL|OC-IgT cells|Autologous human OC-IgT cells.
219180986|NCT02650505|DRUG|LEO 43204 Vehicle|
219180987|NCT06156592|PROCEDURE|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
219180988|NCT05418010|DRUG|Tysabri Injectable Product|Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
219180989|NCT05418010|DRUG|Placebo|Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
219180990|NCT06458868|OTHER|salt water or tap water before UVA|Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
219180991|NCT06646523|OTHER|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
219180992|NCT06646523|OTHER|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
219180993|NCT06581523|BEHAVIORAL|SKY Breath and Meditation|SKY Breath and Meditation is a unique breath-based technique that uses cyclical, rhythmic patterns of breath to bring the mind and body effortlessly into meditation. It has been empirically validated and holds distinct advantages over other forms of meditation.
219180994|NCT04968808|PROCEDURE|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
219180995|NCT04968808|PROCEDURE|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
219180996|NCT04361331|DRUG|Lenvatinib combined with gemox|Arm2: Lenvatinib + gemox
219180997|NCT04361331|DRUG|Toripalimab combined with lenvatinib|Toripalimab combined with lenvatinib
219180998|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
219180999|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
219181000|NCT06349837|DRUG|Tislelizumab|Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
219181001|NCT06349837|RADIATION|Low Dose Radiotherapy|LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.
219181002|NCT06349837|RADIATION|Stereotactic Ablative Radiotherapy|Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
219181003|NCT04182204|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
218994112|NCT00438698|OTHER|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
218994113|NCT05412654|DIETARY_SUPPLEMENT|High potassium water|High potassium water Potassium 6.2 mg/100ml
218994114|NCT05412654|DIETARY_SUPPLEMENT|Control low potassium water|Control water Potassium 0.2 mg/100ml
218994115|NCT01883830|DEVICE|gaming therapy (Xbox)|
218994116|NCT01883830|DEVICE|Dynamic balance platform (Biodex)|
218994117|NCT01664533|DRUG|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
218994118|NCT04910802|BIOLOGICAL|Gardasil9|Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
218994119|NCT04070274|PROCEDURE|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
218994120|NCT04911530|OTHER|no intervention|no intervention
218994121|NCT06094569|PROCEDURE|Endovascular Therapy|Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
218994122|NCT03961581|BEHAVIORAL|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
218994123|NCT02708160|DRUG|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
218994124|NCT02708160|DRUG|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
218994125|NCT02708160|DRUG|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
218994126|NCT00804791|OTHER|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
218994127|NCT00804791|OTHER|Unisol 4 Saline Solution|saline solution for irrigating the cornea
218994128|NCT02932670|OTHER|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
218994129|NCT02264197|DRUG|BIBX 245 CL - fed|
218994130|NCT02264197|DRUG|BIBX 245 CL- fasted|
218994131|NCT01804621|BEHAVIORAL|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
219181004|NCT04182204|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
218994132|NCT05604118|DRUG|Aspirin|1 week of aspirin supplementation prior to sampling
218994133|NCT06962384|PROCEDURE|Posterior release sclerotomy|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~Posterior Release Sclerotomy Group (PRS Group)~* A posterior sclerotomy (2-3 mm) was created at the posterior pole of the scleral shell using a crescent blade.~* This sclerotomy expanded the intraocular space, reducing intraoperative resistance during implant insertion.~* The spherical implant was gently placed within the expanded scleral shell, ensuring minimal stress on the tissue."
218994134|NCT06962384|PROCEDURE|Conventional Ball Implantation|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~* No posterior sclerotomy was performed.~* The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space."
218994135|NCT00493324|DRUG|alefacept|Intramuscular
218994136|NCT00493324|DRUG|polyvalent pneumococcal vaccine|Injection
218994137|NCT01068132|DRUG|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
219181005|NCT04182204|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
219753567|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
219753568|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
218994138|NCT01068132|DRUG|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
218994139|NCT02950532|OTHER|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
218994140|NCT02747095|DEVICE|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
218994141|NCT00290888|PROCEDURE|Acromioplasty|
218994142|NCT04009382|OTHER|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
218994143|NCT04009382|OTHER|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
218994144|NCT05265689|BEHAVIORAL|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
218994145|NCT05265689|BEHAVIORAL|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
219181006|NCT04182204|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
219181007|NCT05477095|BIOLOGICAL|UB-313|A synthetic peptide-based immunotherapy
218994146|NCT01801891|DEVICE|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
218994147|NCT01801891|OTHER|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
218994148|NCT03000439|DRUG|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
218994149|NCT03000439|DRUG|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
218994150|NCT00926276|PROCEDURE|Fundoplication|Fundoplication
218994151|NCT02786446|DRUG|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
218994152|NCT02786446|DRUG|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
218994153|NCT02786446|DRUG|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
218994154|NCT00594438|DEVICE|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
218994155|NCT00594438|DEVICE|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
218994156|NCT03036046|DRUG|F901318 with fluconazole low dose|adverse events
218994157|NCT03036046|DRUG|F901318 with fluconazole high dose|adverse events
218994158|NCT03036046|DRUG|F901318 with posaconazole|adverse events
218994159|NCT01983436|OTHER|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
218994160|NCT00823368|DRUG|STX209|
218994161|NCT05104164|OTHER|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
218994162|NCT02634229|GENETIC|blood sample|
218994163|NCT00748501|DRUG|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
218994164|NCT05307419|PROCEDURE|Rectal suction biopsy.|Suction biopsy performed
219181008|NCT05477095|BIOLOGICAL|Placebo|Normal saline
218994165|NCT05307419|PROCEDURE|Full-thickness rectal biopsy.|Full-thickness biopsy performed
218994166|NCT03766633|DIAGNOSTIC_TEST|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
218994167|NCT05238441|BIOLOGICAL|SCTV01E|D0; intramuscular injection
218994168|NCT05238441|BIOLOGICAL|Comirnaty|D0; intramuscular injection
219181009|NCT04213547|BEHAVIORAL|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
219181010|NCT03906708|OTHER|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
219181011|NCT04518917|BEHAVIORAL|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
218994169|NCT05238441|BIOLOGICAL|SCTV01E|D180; intramuscular injection
218994170|NCT05238441|BIOLOGICAL|Comirnaty|D180; intramuscular injection
219181012|NCT04518917|BEHAVIORAL|Listening to music|Participants listen to their song and match their footfalls to the beat.
219181013|NCT03937609|DRUG|Infliximab|infliximab iv 5mg/kg
219181014|NCT03895359|RADIATION|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
219753569|NCT04534075|BIOLOGICAL|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
219753570|NCT06579664|DEVICE|iTBS|Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.
219753571|NCT06579664|DEVICE|sham iTBS|Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.
219753575|NCT05169346|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
219753576|NCT05169346|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
219753577|NCT05548647|BEHAVIORAL|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
219753578|NCT05548647|DRUG|Placebo|An inactive saline solution administered via subcutaneous injection
219181015|NCT03895359|DRUG|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
219181016|NCT05731609|OTHER|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
219753579|NCT05548647|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
219753580|NCT05581485|DRUG|Dexmetedomedine infusion|Patients received a loading dose of dexmedetomidine at 1 µg/kg over 10 minutes, followed by a continuous infusion at 1 µg/kg/h throughout the procedure. This regimen was combined with TIVA (propofol) and THRIVE to support spontaneous breathing during endoscopic laryngeal surgery.
219753581|NCT05581485|PROCEDURE|Ultrasound-Guided Superior Laryngeal Nerve Block (SLNB)|Following anesthesia induction, patients received bilateral ultrasound-guided superior laryngeal nerve blocks using 5 mL of 1% lidocaine per side. This intervention was combined with total intravenous anesthesia (TIVA) using propofol and high-flow nasal oxygenation (THRIVE) to maintain spontaneous respiration during endoscopic laryngeal surgery.
219753582|NCT06490718|DRUG|USG ESPB|"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."
219753583|NCT06490718|DRUG|Intravenous Infusion|"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."
219753584|NCT06304857|DRUG|Dapagliflozin|10 mg tablet q.d
219753585|NCT06304857|DRUG|Placebo|tablet matching dapagliflozin 10 mg q.d
219753586|NCT03558126|DEVICE|silicone tube|
219753587|NCT06466395|DRUG|Venetoclax|Given by PO
219753588|NCT06466395|DRUG|Hyper-CVAD|Given by IV
219753589|NCT05494086|PROCEDURE|DPLDG|Dual-port laparoscopic distal gastrectomy
219753590|NCT05494086|PROCEDURE|LDG|Laparoscopic distal gastrectomy
219753591|NCT06021600|DRUG|Cladribine|Given by PO and Given by IV (vein)
219753592|NCT01813383|OTHER|There is not any intervention|
219753593|NCT06523803|DRUG|ZW171|Administered per protocol requirements
219753594|NCT01644591|OTHER|Quality-of-Life Assessment|Ancillary studies
219753595|NCT01644591|OTHER|Questionnaire Administration|Ancillary studies
219753596|NCT01644591|RADIATION|Stereotactic Radiosurgery|Undergo SRS
218994171|NCT04750148|DIAGNOSTIC_TEST|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
218994172|NCT04750148|DIAGNOSTIC_TEST|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
218994173|NCT04750148|DIAGNOSTIC_TEST|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
218994174|NCT04750148|DIAGNOSTIC_TEST|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
219753597|NCT04746898|OTHER|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
219753598|NCT04746898|OTHER|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
219753599|NCT04746898|OTHER|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
219753600|NCT05473065|DEVICE|Multiaxial Prosthetic Foot Emulator|Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.
219753601|NCT05473065|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet."
219753602|NCT04134260|DRUG|Apalutamide|Given PO
219753603|NCT04134260|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219753604|NCT04134260|PROCEDURE|Bone Scan|Undergo bone scan
219753605|NCT04134260|PROCEDURE|Computed Tomography|Undergo CT
219753606|NCT04134260|DRUG|Hormone Therapy|Receive hormone therapy
219753607|NCT04134260|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219753608|NCT04134260|PROCEDURE|Positron Emission Tomography|Undergo PET
219753609|NCT04134260|OTHER|Quality-of-Life Assessment|Ancillary studies
219753610|NCT04134260|OTHER|Questionnaire Administration|Ancillary studies
219753611|NCT04134260|RADIATION|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
219753612|NCT05470478|DEVICE|Mobile neural decoding platform (mobile iBCI)|An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
219753613|NCT03122184|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
219753614|NCT03122184|BEHAVIORAL|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
219753615|NCT05248594|DRUG|HEMLIBRA|Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
219753616|NCT00830531|DRUG|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
219753617|NCT00830531|DRUG|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
219753618|NCT04697849|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
218994175|NCT05533021|OTHER|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
218994176|NCT00592384|DRUG|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
218994177|NCT00592384|DRUG|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
218994178|NCT05872841|DRUG|Recombinant human adenovirus type 5 + TACE|"1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles."
219181017|NCT02191618|DEVICE|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
218994179|NCT02151591|DRUG|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
218994180|NCT06507891|DRUG|TQ-A3334 tablets|TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
218994181|NCT06507891|DRUG|TQ-A3334 tablets + Anlotinib capsules|"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
219181018|NCT02316002|DRUG|Pembrolizumab|
218994182|NCT03120416|BEHAVIORAL|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
218994183|NCT04812691|BIOLOGICAL|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
218994184|NCT01468012|DRUG|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
219181019|NCT04818268|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
219181020|NCT04818268|OTHER|cTBS|continuous theta-burst stimulation
219181021|NCT05109494|RADIATION|Conventional Fractionated|50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive \> 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
219181022|NCT05109494|RADIATION|Hypofractionated|27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive \> 97% of the prescribed dose
219181023|NCT03031470|DRUG|Reparixin|"Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours).~Reparixin was provided as 33 mg/ml concentrated solution to be diluted for i.v. infusion, packaged into 250 mL clear glass vials. To give a final concentration of 11 mg/mL, the content of a vial (250 ml) was diluted with 500 ml of 0.9% sterile saline to a total volume of 750 ml. The dosing solution was placed in a 1000 ml sterile empty Infusion Bag. Dosing solutions were to be used within 72 h from preparation, unless more restrictive rules.~Reparixin infusion started approximately 60-90 minutes before the anticipated time of OLT. Infusion interruption was allowed for no more than 60 min.~All patients received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.~Patients and allograft survival were monitored up to 1 year after OLT."
219181024|NCT03031470|OTHER|Control|The patients who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.
219181025|NCT05841797|BEHAVIORAL|In-Person Program Management Plus (PM+)|PM+ sessions conducted in-person by mentor mothers
219181026|NCT05841797|BEHAVIORAL|Mobile Program Management Plus (mHealth PM+)|PM+ sessions conducted via phone
219181027|NCT04974099|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
219753619|NCT04697849|BEHAVIORAL|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
218994185|NCT01468012|DRUG|Placebo|matched placebo for LCE condition dosed twice daily
218994186|NCT06404216|OTHER|Nordic walking group training|"16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged."
218994187|NCT02888886|OTHER|Questionnaires about food habits and tobacco|
218994188|NCT02888886|OTHER|Spirometry|
218994189|NCT02888886|OTHER|Carotid echography|
218994190|NCT02888886|OTHER|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
218994191|NCT04082312|OTHER|No intervention|No intervention
219181028|NCT04974099|DRUG|Precision dosing with a dashboard|The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
219181029|NCT04927299|DRUG|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
219181030|NCT04927299|DRUG|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
219181031|NCT06487078|DRUG|Lorlatinib|ALK-positive NSCL treatment
219181032|NCT05817786|DEVICE|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
219181033|NCT05817786|OTHER|sham stimulation|treated by sham stimulation
219753620|NCT00846157|BIOLOGICAL|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
219753621|NCT00435448|DRUG|Lonidamine|
219753622|NCT02835690|BIOLOGICAL|Pembrolizumab|IV infusion
218994192|NCT04819568|DRUG|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
218994193|NCT04819568|OTHER|Standard of Care|Standard of Care
218994194|NCT05868200|DRUG|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
218994195|NCT05868200|DRUG|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
218994196|NCT05448053|PROCEDURE|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
218994197|NCT04688853|BIOLOGICAL|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
218994198|NCT02198274|DRUG|BIBH 1|100 mg/week
218994199|NCT04506021|DRUG|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
218994200|NCT04506021|DRUG|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
218994201|NCT01029626|PROCEDURE|Endoscopy|Realization of an upper GI endoscopy
219181034|NCT05641402|OTHER|Text messages|Text messages based on behaviour change techniques
219181035|NCT03364803|OTHER|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
219181036|NCT03364803|OTHER|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
218994202|NCT01167894|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
218994203|NCT03902821|OTHER|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
218994204|NCT06033794|DEVICE|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
218994205|NCT03769454|DRUG|PP-001|PP-001 eye drops
219181037|NCT03364803|OTHER|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
219181038|NCT03364803|OTHER|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
219181039|NCT03364803|OTHER|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
219181040|NCT03364803|OTHER|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
219181041|NCT03364803|OTHER|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
218994206|NCT03769454|OTHER|Placebo|Placebo eye drops
218994207|NCT06476561|OTHER|- Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D|"The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance."
219181042|NCT03364803|OTHER|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
219753623|NCT03674281|DEVICE|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
218994208|NCT01659775|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
219753624|NCT03674281|DEVICE|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
219753625|NCT05761821|DEVICE|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
218994209|NCT01659775|DRUG|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
218994210|NCT04932096|DRUG|melatonin|melatonin supplementation
218994211|NCT04932096|OTHER|placebo|microcrystalline cellulose filled capsule
218994212|NCT01121237|DRUG|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
218994213|NCT03571815|DRUG|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
218994214|NCT03571815|OTHER|WATER ON TEETH|control group
218994215|NCT02039492|PROCEDURE|Sympathetic Renal Denervation|
218994216|NCT02039492|DRUG|Treatment with aldactone|
218994217|NCT00528788|DRUG|doxercalciferol|
218994218|NCT05593120|DIAGNOSTIC_TEST|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
218994219|NCT05593120|DIAGNOSTIC_TEST|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
218994220|NCT02164500|DRUG|Ruxolitinib|
218994221|NCT00652405|DIETARY_SUPPLEMENT|alcohol|250 ml of white wine (13% vol; \~25 gram of alcohol per day)
218994222|NCT00652405|DIETARY_SUPPLEMENT|Placebo|250 ml of mineral water (Brand name: Vittel)
218994223|NCT01189903|DRUG|Regorafenib|
218994224|NCT03719521|OTHER|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
218994225|NCT00144053|DRUG|Cisplatin+Vindesine+MMC/ concurrent radiation|
218994226|NCT00144053|DRUG|Irinotecan+Carboplatin/concurrent radiation|
218994227|NCT00144053|DRUG|Paclitaxel+Carboplatin/concurrent radiation|
218994228|NCT04869332|DEVICE|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
218994229|NCT04869332|DEVICE|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
218994230|NCT05771376|OTHER|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
218994231|NCT05771376|OTHER|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
218994232|NCT02254187|DRUG|Salmeterol capsule - low|
218994233|NCT02254187|DRUG|Salmeterol capsule - high|
218994234|NCT02254187|DRUG|Salmeterol via Serevent® Diskus®|
218994235|NCT00964860|DEVICE|Glide dental floss|Glide waxed dental floss
218994236|NCT05251090|DRUG|ADVATE|50 international units (IU)/kg, a single dose.
218994237|NCT05251090|DRUG|FRSW107|50 IU/kg, a single dose.
218994238|NCT03025477|DRUG|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
218994239|NCT03025477|DRUG|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
218994240|NCT03025477|DRUG|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
218994241|NCT03025477|DRUG|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
218994242|NCT05408949|BEHAVIORAL|Single exercise into pain (SEP) program|"* Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program"
218994243|NCT05408949|BEHAVIORAL|Shoulder Symptom Modification Procedure (SSMP)|\[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
219753626|NCT00710593|BIOLOGICAL|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
218994244|NCT05408949|BEHAVIORAL|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
218994245|NCT05408949|BEHAVIORAL|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
218994246|NCT05408949|BEHAVIORAL|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
218994247|NCT04885361|BIOLOGICAL|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
218994248|NCT03053544|DRUG|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
218994249|NCT03716024|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
218994250|NCT03716024|DRUG|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
219181043|NCT03364803|OTHER|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
218994251|NCT04425694|DEVICE|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
218994252|NCT04346602|OTHER|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
219181044|NCT03364803|OTHER|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
219181045|NCT03364803|OTHER|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
219181046|NCT04446481|DEVICE|Neurofeedback|Neurofeedback will be tested in both groups of Vets
219181047|NCT04623671|BIOLOGICAL|CAP-1002|Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)
219181048|NCT04623671|BIOLOGICAL|Placebo|Matching placebo solution
219753627|NCT06551220|DRUG|Trastuzumab Deruxtecan|The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
219753628|NCT03279653|PROCEDURE|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
218994253|NCT01523353|BEHAVIORAL|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
218994254|NCT00867568|DRUG|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
218994255|NCT02923934|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
218994256|NCT02923934|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
218994257|NCT02221193|OTHER|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
218994258|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
218994259|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
218994260|NCT01434069|DRUG|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
218994261|NCT01434069|DRUG|FOLFIRI Infusion|Standard therapy of FOLFIRI
218994262|NCT04343261|BIOLOGICAL|Convalescent Plasma|treatment with 2 Units of convalescent plasma
218994263|NCT01803373|DRUG|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
218994264|NCT01803373|DRUG|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
218994265|NCT01803373|DRUG|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
218994266|NCT04278638|RADIATION|IORT|IORT in surgery of laryngocarcinoma
218994267|NCT04278638|PROCEDURE|surgery|total laryngectomy or hemilaryngectomy
218994268|NCT04278638|RADIATION|External radiotherapy|External radiotherapy
218994269|NCT02123121|DRUG|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
218994270|NCT02123121|DRUG|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
218994271|NCT02123121|OTHER|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
218994272|NCT02123121|OTHER|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
218994273|NCT01751425|DRUG|Dasatinib|Given PO
218994274|NCT01751425|DRUG|Imatinib Mesylate|Given PO
219181049|NCT06349408|DRUG|IBI3001|"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"
219181050|NCT04621279|PROCEDURE|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
219181051|NCT04621279|PROCEDURE|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
219181052|NCT05151926|PROCEDURE|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
219181053|NCT05151926|PROCEDURE|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
219753629|NCT00525421|DRUG|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
219753630|NCT00525421|DRUG|Placebo|
219181054|NCT05151926|PROCEDURE|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
219181055|NCT04742452|PROCEDURE|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
218994275|NCT01751425|DRUG|Nilotinib|Given PO
218994276|NCT01751425|DRUG|Ruxolitinib|Given PO
219181056|NCT04742452|PROCEDURE|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
219753631|NCT01695603|DEVICE|Intellivent|
218994277|NCT01007773|DRUG|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
218994278|NCT01007773|DRUG|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
218994279|NCT01007773|DRUG|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
218994280|NCT01007773|DRUG|Propofol|Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
218994281|NCT03878628|DRUG|Adipose tissue-derived mesenchymal stem cells|CSCC\_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
218994282|NCT03000140|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
218994283|NCT03000140|BEHAVIORAL|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
218994284|NCT01154855|PROCEDURE|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
219753632|NCT00822302|DRUG|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
219181057|NCT04855799|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
219181058|NCT06455917|DRUG|Combination of TIL Transfer and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses)."
219181059|NCT05652699|OTHER|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
219753633|NCT00822302|DRUG|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
219753634|NCT05201131|PROCEDURE|Rezum|Rezum
219753635|NCT03690908|OTHER|no intervention (descriptive study)|no intervention (descriptive study)
218994285|NCT02753868|BEHAVIORAL|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
218994286|NCT02753868|PROCEDURE|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
219753636|NCT01310972|OTHER|Registry|Registry
218994287|NCT00596284|BEHAVIORAL|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
218994288|NCT00596284|BEHAVIORAL|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
218994289|NCT00975650|DRUG|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
218994290|NCT00975650|DRUG|Androderm® (Positive Control)|QD administration
218994291|NCT00763672|OTHER|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
218994292|NCT00763672|OTHER|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
218994293|NCT02250170|DRUG|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
218994294|NCT05275400|DRUG|Insulin Efsitora Alfa|Administered SC
218994295|NCT05275400|DRUG|Insulin Degludec|Administered SC
218994296|NCT04000490|OTHER|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
218994297|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
218994298|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Standard treatment
219181060|NCT05652699|OTHER|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
219753637|NCT02684968|PROCEDURE|Colorectal surgery|
219753638|NCT00158678|PROCEDURE|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
219753639|NCT00158678|PROCEDURE|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
218994299|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Intensified treatment
218994300|NCT02783625|DRUG|Romidepsin|
218994301|NCT02783625|DRUG|Bortezomib|
218994302|NCT02783625|DRUG|duvelisib|
218994303|NCT03639935|DRUG|Rucaparib|Rucaparib 600 mg PO BID days 1-28
218994304|NCT03639935|DRUG|Nivolumab|Nivolumab 240 mg IV days 1 and 15
218994305|NCT01050712|DRUG|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
218994306|NCT01050712|DRUG|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
219181061|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
219181062|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
219753640|NCT00158678|DRUG|concomitant cisplatin|100 mg/m2 D1, D22, D43
219753641|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
219753642|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
219181063|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
219181064|NCT05095935|OTHER|N/A observational registry|N/A observational registry
218994307|NCT06333613|DEVICE|ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY (AO1D)|Test Lens
218994308|NCT04251169|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute intravenous (IV) infusion every 3 weeks beginning in Cycle 1
218994309|NCT04251169|DRUG|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
218994310|NCT03576560|OTHER|Retrospective Chart Review|Retrospective Chart Review
218994311|NCT03648541|DRUG|Spesolimab|Solution
218994312|NCT01903187|DEVICE|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
218994313|NCT01903187|PROCEDURE|Sham|Renal artery angiogram
218994314|NCT06837740|OTHER|Aromatherapy group|Effects of Aromatherapy Interventions
218994315|NCT06837740|OTHER|Aromatherapy with music therapy group|Effects of Music Therapy and Aromatherapy Interventions
218994316|NCT02153619|BEHAVIORAL|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
218994317|NCT02153619|BEHAVIORAL|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
219181065|NCT04215146|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
219181066|NCT04215146|BIOLOGICAL|Pelareorep|Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
219181067|NCT04215146|DRUG|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
218994318|NCT02153619|BEHAVIORAL|questionnaires assessments|
218994319|NCT06279234|DRUG|Placebo|Oral tablet
218994320|NCT06279234|DRUG|Rosuvastatin|Oral tablet
218994321|NCT06279234|DRUG|Midazolam|Oral suspension
219181068|NCT06585241|BIOLOGICAL|mRNA-1273 Variant-containing Formulation|Sterile liquid for injection
219181069|NCT01943409|DRUG|Intralipid|soybean oil-based lipid emulsion
219181070|NCT01943409|DRUG|ClinOleic|olive oil-based lipid emulsion
219181071|NCT03281798|DEVICE|Fetoscopes|Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.
219181072|NCT03281798|PROCEDURE|Fetal Cystoscopy|A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.
218994322|NCT06279234|DRUG|Omeprazole|Oral tablet
218994323|NCT06279234|DRUG|PF-06954522|Oral tablet
218994324|NCT06297928|PROCEDURE|baratric surgery|Participants in this study will undergo bariatric surgery, either gastric bypass or sleeve gastrectomy, based on clinical criteria and consensus from a multidisciplinary team.
218994325|NCT06848790|PROCEDURE|Calibrated interdental brush|participants will use calibrated interdental brushes
218994326|NCT06541665|DRUG|ONO-4059|Specified dose, once daily
218994327|NCT06541665|DRUG|Rituximab|Specified dose on specified days
218994328|NCT06541665|DRUG|Methotrexate|Specified dose on specified days
218994329|NCT06541665|DRUG|Procarbazine|Specified dose on specified days
218994330|NCT06541665|DRUG|Vincristine|Specified dose on specified days
218994331|NCT04623216|BIOLOGICAL|Sabatolimab|Sabatolimab is a solution in vial for IV infusion
218994332|NCT04623216|DRUG|Azacitidine|Azacitidine comes in Vial for IV infusion or subcutaneous administration
218994333|NCT04960644|DRUG|MTX|MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
218994334|NCT04960644|DRUG|Corticosteroid|corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
218994335|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
218994336|NCT04177004|DRUG|Cyclophosphamide|Given IV
218994337|NCT04177004|DRUG|Etoposide|Given IV
218994338|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
218994339|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
218994340|NCT04177004|BIOLOGICAL|Palifermin|Given IV
218994341|NCT04177004|DRUG|Sirolimus|Given PO
218994342|NCT04177004|DRUG|Tacrolimus|Given IV and PO
219181073|NCT03480594|DRUG|MRI Tracer|Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
219181074|NCT06158386|DRUG|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
219181075|NCT02310646|DRUG|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
219181076|NCT02310646|DRUG|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
219181077|NCT04983043|DRUG|Low dose QiShen YiQi Dripping Pills 3 bags|Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
218994343|NCT01433705|OTHER|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
218994344|NCT01433705|OTHER|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
218994345|NCT01433705|OTHER|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
218994346|NCT01433705|DRUG|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
218994347|NCT00463112|DRUG|Sibutramine|
218994348|NCT00044083|OTHER|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
218994349|NCT00044083|DRUG|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
219181078|NCT04983043|DRUG|High dose QiShen YiQi Dripping Pills 3 bags|High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
219181079|NCT04983043|DRUG|QiShen YiQi Dripping Pills placebo 3 bags|QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
219181080|NCT06397846|OTHER|Biological sample|blood sample will be collected at baseline
219181081|NCT04115163|DRUG|Gemcitabine|Given IV
219181082|NCT04115163|DRUG|Nab-paclitaxel|Given IV
219181083|NCT03848065|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
219181084|NCT03848065|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
219181085|NCT03848065|BIOLOGICAL|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
219181086|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
219181087|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
219181088|NCT02659735|DRUG|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
219181089|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
219181090|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
219753643|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
219181091|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
218994350|NCT05075122|BIOLOGICAL|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
218994351|NCT05075122|DRUG|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
218994352|NCT05075122|DRUG|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
218994353|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
218994354|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
218994355|NCT01830270|DRUG|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
218994356|NCT01830270|DRUG|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
218994357|NCT01830270|DRUG|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
218994358|NCT01830270|PROCEDURE|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
218994359|NCT04762784|DRUG|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
218994360|NCT04762784|DRUG|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
219181092|NCT05721209|DEVICE|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
219181093|NCT05721209|DEVICE|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
219181094|NCT05721209|DEVICE|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
219181095|NCT05721209|DEVICE|Hunova|Used to conduct fall-risk assessment.
219181096|NCT03908099|BEHAVIORAL|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
219181097|NCT03908099|OTHER|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
219181098|NCT00670358|BIOLOGICAL|pegfilgrastim|
219181099|NCT00670358|BIOLOGICAL|rituximab|
219753644|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
218994361|NCT06085378|DRUG|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
219181100|NCT00670358|DRUG|cyclophosphamide|
219181101|NCT00670358|DRUG|doxorubicin hydrochloride|
219181102|NCT00670358|DRUG|lenalidomide|
219181103|NCT00670358|DRUG|prednisone|
218994362|NCT06085378|OTHER|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
218994363|NCT02587260|DRUG|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
218994364|NCT02587260|DRUG|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
218994365|NCT02587260|DRUG|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
218994366|NCT02126917|DRUG|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
218994367|NCT02126917|DRUG|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
218994368|NCT02126917|DRUG|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
219181104|NCT00670358|DRUG|vincristine sulfate|
219181105|NCT00670358|GENETIC|polymorphism analysis|
219181106|NCT00670358|OTHER|laboratory biomarker analysis|
219181107|NCT03847480|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
219181108|NCT05029635|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
219181109|NCT05029635|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
219181110|NCT06625892|BEHAVIORAL|the multidimensional interventions|The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
218994369|NCT03727269|OTHER|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
218994370|NCT03727269|OTHER|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities"
218994371|NCT00166478|DRUG|Exisulind Therapy|
218994372|NCT02031354|DIETARY_SUPPLEMENT|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
218994373|NCT04077268|OTHER|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
218994374|NCT03680690|PROCEDURE|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
218994375|NCT06124560|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
218994376|NCT02179866|DRUG|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
218994377|NCT02168634|DRUG|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
218994378|NCT02168634|DRUG|Placebo|1cc normal saline, local injection
218994379|NCT01393691|BEHAVIORAL|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
219181111|NCT00185744|RADIATION|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
219181112|NCT00185744|PROCEDURE|Lumpectomy|
219181113|NCT00185744|RADIATION|Whole Breast Radiotherapy|six and a half week treatment
219181114|NCT00185744|RADIATION|Intracavitary Brachytherapy|5 day treatment
219753645|NCT05775445|PROCEDURE|Blood draw|2 6ml blood tubes will be collected from patient
219753646|NCT02665910|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
219753647|NCT02665910|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
219753648|NCT02408744|DRUG|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
218994380|NCT01393691|BEHAVIORAL|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
218994381|NCT03060538|DRUG|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
218994382|NCT03060538|OTHER|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
218994383|NCT05248048|BIOLOGICAL|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
218994384|NCT04218422|PROCEDURE|Battlefield Acupuncture|Acupuncture at 5 points on the ears
218994385|NCT04218422|PROCEDURE|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
218994386|NCT04220320|DIAGNOSTIC_TEST|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
218994387|NCT04220320|DIAGNOSTIC_TEST|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
218994388|NCT01619423|DRUG|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
219181115|NCT00185744|RADIATION|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
219181116|NCT00185744|RADIATION|Stereotactic APBI|4 day treatment
219181117|NCT03496168|DRUG|mavacamten|mavacamten capsules
218994389|NCT01619423|DRUG|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
218994390|NCT01619423|DRUG|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
219181118|NCT02379793|DRUG|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
219181119|NCT05256576|OTHER|Implementation of an innovative multi-modal peri-operative care pathway|The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
219181120|NCT05445167|DRUG|KLH-2109|Oral administration
219181121|NCT05445167|DRUG|Placebo|Oral administration
219181122|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
219181123|NCT05183854|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
219181124|NCT05183854|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
219181125|NCT05183854|OTHER|Questionnaire Administration|Ancillary studies
219181126|NCT06168383|DRUG|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
218994391|NCT01619423|DRUG|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
218994392|NCT06169384|DEVICE|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
218994393|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod.
218994394|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod.
218994395|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
218994396|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
218994397|NCT00961233|DRUG|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
218994398|NCT00961233|DRUG|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
218994399|NCT03928496|DRUG|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
218994400|NCT03928496|DRUG|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
218994401|NCT03172442|DEVICE|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
218994402|NCT03172442|DEVICE|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
219181127|NCT06168383|DRUG|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
219753649|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Workshop|2 day workshop
218994403|NCT03172442|DEVICE|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
218994404|NCT05269498|DEVICE|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
218994405|NCT04452682|OTHER|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
218994406|NCT04360668|OTHER|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
218994407|NCT04360668|OTHER|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
218994408|NCT04360668|OTHER|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
219181128|NCT06168383|DRUG|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
219181129|NCT04767282|OTHER|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
218994409|NCT04384146|RADIATION|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
218994410|NCT04384146|BEHAVIORAL|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
218994411|NCT04974840|BEHAVIORAL|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
218994412|NCT00138580|DRUG|vildagliptin|
219181130|NCT05869383|DRUG|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
219181131|NCT05869383|DRUG|Placebo|Placebo 2x5 grams
219181132|NCT06494891|DRUG|Intravenous Alcohol|Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an alcohol challenge. During the challenge, participants will be administered alcohol designed to reach target BrACs of 20, 40, and 60 mg%, each over 15 min. After reaching the last target BrAC (0.06 g/dl) participants will complete a self-administration (SA) paradigm. Participants will be invited to work (button press) for alcohol according to a log-linear progressive ratio schedule.
219753650|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Online|Online curriculum
219753651|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Group|3 in person group sessions
219753652|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Individual|3 sessions in person one on one
219753653|NCT00089492|DRUG|Optimized Background ARVs|As prescribed
219753654|NCT00089492|DRUG|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
218994413|NCT04700761|PROCEDURE|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
218994414|NCT04700761|PROCEDURE|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
218994415|NCT03140943|DRUG|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
218994416|NCT01468363|DEVICE|Dry weight adjustment|Dry weight adjustment according to BCM results
218994417|NCT04993248|OTHER|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
218994418|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
218994419|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
218994420|NCT02340975|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion.
218994421|NCT02340975|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion.
218994422|NCT02340975|BIOLOGICAL|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
218994423|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
218994424|NCT04003012|DRUG|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
218994425|NCT04003012|DRUG|Lidocaine|lidocaine 1%
218994426|NCT02034383|OTHER|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
218994427|NCT02034383|OTHER|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
218994428|NCT02034383|OTHER|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
218994429|NCT02034383|OTHER|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
218994430|NCT02034383|OTHER|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
218994431|NCT03564314|OTHER|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
218994432|NCT02601391|BEHAVIORAL|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
218994433|NCT00120835|DRUG|valopicitabine|
218994434|NCT00120835|DRUG|pegylated interferon|
218994435|NCT02482506|BEHAVIORAL|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
218994436|NCT02482506|BEHAVIORAL|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
218994437|NCT00816764|BIOLOGICAL|AGS-8M4|IV Infusion
218994438|NCT06044428|DEVICE|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
218994439|NCT00720538|DRUG|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
218994440|NCT00720538|DRUG|placebo|placebo capsules
218994441|NCT01591759|DRUG|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
218994442|NCT01591759|DRUG|Placebo|Placebo arm of single-blind study
218994443|NCT00309114|PROCEDURE|bacterial interference|
218994444|NCT06798233|DIAGNOSTIC_TEST|Non-Ambulatory Hip Pain questionnaire|a new questionnaire for care givers to identify hip pain in pediatric patients with quadriplegia
218994445|NCT04388878|DRUG|PF-07054894|Participants will receive oral ascending doses
218994446|NCT04388878|DRUG|Placebo|Participants will receive matching placebo
218994447|NCT06491940|DRUG|Losartan|Patients will receives Losartan (LS) 50 mg per day.
218994448|NCT06491940|DRUG|Losartan + Hydrochlorothiazide|Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
218994449|NCT04219657|BIOLOGICAL|mesenchymal stem cell application|
219753655|NCT00089492|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
219753656|NCT02004158|BEHAVIORAL|Positive psychology intervention|
218994450|NCT02054091|DIETARY_SUPPLEMENT|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
218994451|NCT04353271|DRUG|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
218994452|NCT04353271|OTHER|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
218994453|NCT00003097|OTHER|preventative dietary intervention|
218994454|NCT00284583|DRUG|Injection of Steroid into Foot|
218994455|NCT00284583|DRUG|Injection of Alcohol into Foot|
218994456|NCT00284583|DRUG|Injection of Lidocaine into Foot|
218994457|NCT00848874|BEHAVIORAL|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
218994458|NCT03923712|BEHAVIORAL|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
218994459|NCT02284984|DRUG|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
219753657|NCT03766984|DRUG|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
218994460|NCT03675477|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
218994461|NCT03675477|DRUG|Placebo|Placebo Oral Tablet
218994462|NCT00404261|DRUG|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
218994463|NCT02936830|DRUG|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
219181133|NCT06251609|DRUG|Naloxone 2 MG|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
219753658|NCT03766984|DRUG|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
219753659|NCT03766984|DRUG|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
219753660|NCT05511402|OTHER|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
219753661|NCT02986074|DEVICE|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
219753662|NCT02986074|DEVICE|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
219753663|NCT00360945|DRUG|cisplatin|
219753664|NCT00360945|DRUG|temozolomide|
219753665|NCT00360945|GENETIC|fluorescence in situ hybridization|
219753666|NCT00360945|GENETIC|loss of heterozygosity analysis|
218994464|NCT02936830|DRUG|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
218994465|NCT02936830|DRUG|Glycerol|Glycerol with water in a 1: 1 ratio
218994466|NCT02591069|DEVICE|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
218994467|NCT01163175|OTHER|Ruminant trans fats|"Consumption of the 4 experimental diets:~1. a diet rich in ruminant TFA (8 g/day);~2. a diet moderately rich in ruminant TFA (4 g/day);~3. a diet rich in industrial TFA (8 g/d);~4. a control diet (minimal dietary TFA of industrial and ruminant sources)."
219753667|NCT00360945|OTHER|immunohistochemistry staining method|
219753668|NCT00360945|OTHER|laboratory biomarker analysis|
219753669|NCT00360945|RADIATION|radiation therapy|
219753670|NCT00071955|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219753671|NCT00071955|BIOLOGICAL|sargramostim|
219753672|NCT02004626|DRUG|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
218994468|NCT02523248|PROCEDURE|tonsillectomy|Tonsillectomy with cold steel
218994469|NCT02523248|PROCEDURE|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
218994470|NCT04473391|DEVICE|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
218994471|NCT00119106|DRUG|Tenofovir disoproxil|Antiretroviral
218994472|NCT00119106|DRUG|Placebo|Placebo
218994473|NCT02370745|DRUG|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
218994474|NCT02370745|DRUG|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
218994475|NCT02370745|DIETARY_SUPPLEMENT|Oral amino acids|Oral amino acids containing 15 g of amino acids
218994476|NCT02370745|DRUG|GIP|This will be co infused with GLP-1 and intravenous amino acids
218994477|NCT02370745|DRUG|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
218994478|NCT03066804|DRUG|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
218994479|NCT03066804|DRUG|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
218994480|NCT03066804|DRUG|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
218994481|NCT03066804|DRUG|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
218994482|NCT03066804|DRUG|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
218994483|NCT03066804|DRUG|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
218994484|NCT04468854|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
218994485|NCT04468854|OTHER|Placebo|mannitol formulated for oral administration (capsules)
219181134|NCT06251609|DRUG|Saline 2ml|Placebo
219181135|NCT03625349|DRUG|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
218994486|NCT02777801|DRUG|Entecavir|anti-HBV
218994487|NCT06229990|DRUG|Furosemide Injection|After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
218994488|NCT00524862|DRUG|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
218994489|NCT00524862|DEVICE|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
218994490|NCT00000430|DRUG|Alendronate|
218994491|NCT00000430|DRUG|Estrogen/progestin therapy|
218994492|NCT02746146|OTHER|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
218994493|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
218994494|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
218994495|NCT00816530|DEVICE|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
218994496|NCT00096070|RADIATION|radiation therapy|Undergo radiation therapy
219181136|NCT06308861|DRUG|Single administration Amg dose Group|Orally, Amg tablet single administration
219181137|NCT06308861|DRUG|Single administration Bmg dose Group|Orally, Bmg tablet single administration
218994497|NCT00096070|DRUG|oxaliplatin|Given IV
218994498|NCT00096070|DRUG|fluorouracil|Given IV
218994499|NCT00096070|DRUG|gemcitabine hydrochloride|Given IV
218994500|NCT00696722|DRUG|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
218994501|NCT00696722|DRUG|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
218994502|NCT05759728|BIOLOGICAL|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10\^7 cells - intravenous infusion
218994503|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10\^8 cells - intravenous infusion
218994504|NCT05759728|BIOLOGICAL|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10\^8 cells - intravenous infusion
218994505|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10\^9 cells - intravenous infusion
218994506|NCT05759728|BIOLOGICAL|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10\^7 cells - intravenous infusion
218994507|NCT01288235|RADIATION|Proton radiotherapy|5 days a week
219181138|NCT06308861|DRUG|Single administration Cmg dose Group|Orally, Cmg tablet single administration
218994508|NCT03984240|DRUG|Midazolam|Participant will be sedated by midazolam.
218994509|NCT03984240|DRUG|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
218994510|NCT02696603|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
218994511|NCT02696603|BEHAVIORAL|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
218994512|NCT02696603|BEHAVIORAL|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
218994513|NCT02696603|BEHAVIORAL|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
218994514|NCT02696603|BEHAVIORAL|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
218994515|NCT02696603|BEHAVIORAL|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
218994516|NCT02696603|OTHER|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
218994517|NCT05051722|DIAGNOSTIC_TEST|Vaginal Fluid Collection|A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
218994518|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
218994519|NCT04213729|BEHAVIORAL|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
219753673|NCT02004626|DRUG|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
218994520|NCT04213729|OTHER|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
218994521|NCT04213729|BEHAVIORAL|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
218994522|NCT03985904|OTHER|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
218994523|NCT02158273|DRUG|Sugar Pill|145 mg/day, oral pill, 9 days
219753674|NCT02457026|DRUG|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
218994524|NCT02158273|DRUG|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
218994525|NCT06282146|PROCEDURE|transcranial magnetic stimulation|non-invasive form of brain stimulation
218994526|NCT05468931|DEVICE|Prostate stimulator|Prostate stimulation device for sexual dysfunction
218994527|NCT01874054|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
218994528|NCT01874054|DRUG|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
218994529|NCT03563976|OTHER|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
219181139|NCT06308861|DRUG|Single administration Dmg dose Group|Orally, Dmg tablet single administration
218994530|NCT00003331|DRUG|fluorouracil|
218994531|NCT00003331|DRUG|leucovorin calcium|
219181140|NCT06308861|DRUG|Single administration Emg dose Group|Orally, Emg tablet single administration
219181141|NCT06308861|DRUG|Single administration Amg dose Group-Placebo|Orally, Placebo Amg tablet, single administration
218994532|NCT00003331|DRUG|topotecan hydrochloride|
219181142|NCT06308861|DRUG|Single administration Bmg dose Group-Placebo|Orally, Placebo Bmg tablet, single administration
219181143|NCT06308861|DRUG|Single administration Cmg dose Group-Placebo|Orally, Placebo Cmg tablet, single administration
218994533|NCT01769989|PROCEDURE|Electrodermabrasion|
219181144|NCT06308861|DRUG|Single administration Dmg dose Group-Placebo|Orally, Placebo Dmg tablet, single administration
219181145|NCT06308861|DRUG|Single administration Emg dose Group-Placebo|Orally, Placebo Emg tablet, single administration
218994534|NCT01769989|PROCEDURE|Dermabrasion|
218994535|NCT05409326|DRUG|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
219181146|NCT06308861|DRUG|Multiple administration Amg dose group|Orally, Amg 1 tablet, once a day for 3 days, multiple administration
219181147|NCT06308861|DRUG|Multiple administration Bmg dose group|Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
218994536|NCT05409326|DRUG|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
218994537|NCT00702923|DRUG|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
218994538|NCT00702923|DRUG|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
218994539|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
218994540|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
218994541|NCT00702923|DRUG|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
218994542|NCT04312048|DRUG|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
218994543|NCT04312048|DRUG|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
219181148|NCT06308861|DRUG|Multiple administration Cmg dose group|Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
219181149|NCT06308861|DRUG|Multiple administration Dmg dose group|Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
219181150|NCT06308861|DRUG|Multiple administration Emg dose group|Orally, Emg 1 tablet, once a day for 3 days, multiple administration
219181151|NCT06308861|DRUG|Multiple administration Amg dose group - Placebo|Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
218994544|NCT05092646|BIOLOGICAL|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
218994545|NCT05092646|DRUG|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
218994546|NCT05737732|DEVICE|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
218994547|NCT05737732|DEVICE|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
218994548|NCT01275040|OTHER|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
218994549|NCT01275040|OTHER|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
218994550|NCT00719108|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
218994551|NCT00719108|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
218994552|NCT02334358|DEVICE|YVOIRE Classic s|
218994553|NCT06376149|BEHAVIORAL|M3 Intervention group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
219181152|NCT06308861|DRUG|Multiple administration Bmg dose group - Placebo|Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
219181153|NCT06308861|DRUG|Multiple administration Cmg dose group - Placebo|Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
219181154|NCT06308861|DRUG|Multiple administration Dmg dose group - Placebo|Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
219181155|NCT06308861|DRUG|Multiple administration Emg dose group - Placebo|Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
219181156|NCT04137367|BEHAVIORAL|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
218994554|NCT06376149|BEHAVIORAL|M3 Waitlist Group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
218994555|NCT06324370|DIETARY_SUPPLEMENT|Virgin Coconut Oil|"Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study."
218994556|NCT02423993|BEHAVIORAL|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
218994557|NCT02423993|DEVICE|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
218994558|NCT02423993|DEVICE|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
219753675|NCT02457026|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
218994559|NCT02423993|PROCEDURE|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
218994560|NCT02423993|PROCEDURE|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
219181157|NCT04137367|BEHAVIORAL|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
219181158|NCT03907878|BIOLOGICAL|Ligelizumab|Liquid in vial
219181159|NCT04858230|DEVICE|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
219181160|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
219181161|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
219181162|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
219181163|NCT04499924|DRUG|tucatinib|300 mg given twice daily orally
219181164|NCT04499924|DRUG|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
219181165|NCT04499924|DRUG|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
219181166|NCT04499924|DRUG|paclitaxel|60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
219181167|NCT04499924|OTHER|tucatinib placebo|Given twice daily orally
219181168|NCT04499924|OTHER|trastuzumab placebo|IV on Days 1 and 15 of each cycle
219181169|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
219753676|NCT02457026|DRUG|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
219181170|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
219181171|NCT05144009|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
219753677|NCT01006161|DRUG|SCH 527123|Low dose
219753678|NCT01006161|DRUG|SCH 527123|Medium dose
219753679|NCT01006161|DRUG|SCH 527123|High dose
219753680|NCT01006161|DRUG|SCH 527123|Placebo to match SCH 527123
219753681|NCT03581175|PROCEDURE|Colonoscopy|
219753682|NCT03581175|DRUG|Bowel cleansing regimen|
218994561|NCT02423993|PROCEDURE|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
218994562|NCT02423993|PROCEDURE|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
218994563|NCT04292483|DRUG|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
218994564|NCT02178735|PROCEDURE|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
218994565|NCT02178735|PROCEDURE|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
218994566|NCT05073211|PROCEDURE|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
218994567|NCT03953820|DRUG|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
218994568|NCT03953820|DRUG|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
218994569|NCT01847378|PROCEDURE|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
218994570|NCT02974283|OTHER|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
218994571|NCT00001071|DRUG|Filgrastim|
218994572|NCT04372082|OTHER|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration
219753683|NCT05804929|OTHER|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
218994573|NCT04372082|DRUG|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
218994574|NCT04372082|DRUG|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
218994575|NCT00025363|DRUG|vincristine sulfate|Given IV
218994576|NCT00025363|DRUG|irinotecan hydrochloride|Given IV
218994577|NCT00025363|DRUG|cyclophosphamide|Given IV
218994578|NCT00025363|DRUG|doxorubicin hydrochloride|Given IV
218994579|NCT00025363|DRUG|ifosfamide|Given IV
218994580|NCT00025363|DRUG|etoposide|Given IV
218994581|NCT00025363|DRUG|tirapazamine|Given IV
218994582|NCT00025363|BIOLOGICAL|filgrastim|Given SC
219181172|NCT05144009|DRUG|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
219753684|NCT01968343|BEHAVIORAL|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
219753685|NCT01968343|OTHER|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
219753686|NCT04270643|DIETARY_SUPPLEMENT|Vitamin D3|ATC code A11CC05 (cholecalciferol)
219753687|NCT04270643|DIETARY_SUPPLEMENT|Placebo|Ethyl oleate
219753688|NCT06351618|OTHER|No intervention will be conducted.|No intervention will be conducted.
219753689|NCT04750421|DEVICE|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
219753690|NCT02117011|OTHER|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
219753691|NCT05090618|GENETIC|DNA analysis|GWAS
218994583|NCT00025363|BIOLOGICAL|sargramostim|Given SC
218994584|NCT00025363|OTHER|pharmacological study|Correlative studies
218994585|NCT00025363|OTHER|pharmacogenomic studies|Correlative studies
218994586|NCT00025363|OTHER|laboratory biomarker analysis|Correlative studies
218994587|NCT01128556|DRUG|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
218994588|NCT01128556|DRUG|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
218994589|NCT01100671|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
218994590|NCT06556589|BEHAVIORAL|Collaborative Care|Collaborative care components include patient-centered team care, population-based care, measurement-based treatment to target, evidence-based care, and accountable care.
218994591|NCT02046161|PROCEDURE|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
218994592|NCT02933606|DRUG|BNC210|
218994593|NCT02933606|DRUG|Placebo|
219753692|NCT05101720|PROCEDURE|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
219753693|NCT05101720|PROCEDURE|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
218994594|NCT02385942|DEVICE|Smart phone|"* measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation"
218994595|NCT01344785|PROCEDURE|Intramedullary nailing|All patients will be treated with Intramedullary nailing
218994596|NCT00916942|DRUG|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
218994597|NCT00916942|DRUG|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
218994598|NCT03209661|DRUG|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
218994599|NCT03209661|DRUG|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
218994600|NCT03209661|DRUG|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
218994601|NCT03962842|OTHER|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
218994602|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
218994603|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
218994604|NCT06447740|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
218994605|NCT06447740|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
218994606|NCT06447740|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
218994607|NCT00827333|OTHER|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
218994608|NCT00827333|OTHER|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
218994609|NCT00827333|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
218994610|NCT00827333|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
218994611|NCT00827333|PROCEDURE|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
218994612|NCT02285842|DEVICE|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
218994613|NCT04282642|BEHAVIORAL|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
218994614|NCT04282642|BEHAVIORAL|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
218994615|NCT02137265|DRUG|Clomiphene|Clomiphene citrate 50 mg orally daily
218994616|NCT02137265|DRUG|Placebo|One pill every other day
218994617|NCT00687960|DIETARY_SUPPLEMENT|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
218994618|NCT00687960|DIETARY_SUPPLEMENT|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
218994619|NCT00687960|DIETARY_SUPPLEMENT|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
218994620|NCT00687960|DIETARY_SUPPLEMENT|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
218994621|NCT04977193|BIOLOGICAL|LY011|CAR-T
218994622|NCT00291577|DRUG|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
218994623|NCT00291577|DRUG|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
218994624|NCT02051686|DRUG|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
218994625|NCT02051686|DRUG|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
218994626|NCT04967443|DRUG|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
218994627|NCT04967443|DRUG|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
218994628|NCT04967443|DRUG|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
218994629|NCT00335478|DRUG|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
218994630|NCT02405780|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
218994631|NCT02405780|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
218994632|NCT03801460|OTHER|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
218994633|NCT01654536|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
218994634|NCT01654536|DRUG|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
218994635|NCT05047835|DIAGNOSTIC_TEST|electrocardiogram|Prone position electrocardiogram
218994636|NCT06409715|OTHER|Enhanced Care with PMRT and Acupressure|Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established
218994637|NCT06409715|OTHER|standard care|vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
219753694|NCT06102395|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
218994638|NCT03464071|DEVICE|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
218994639|NCT03464071|DEVICE|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
218994640|NCT00726869|DRUG|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
218994641|NCT01837108|DRUG|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
218994642|NCT01837108|DRUG|Placebo|
218994643|NCT06341751|BEHAVIORAL|Psychological treatment for persistent fatigue|The treatment consists of three main phases: 1) goal-setting; stabilizing sleep-wake patterns and even distribution of activities over the day (pacing). Attention-shifting and cognitive reappraisal 2. Gradual increase in physical activity followed by gradual increase in mental and social activity 3. Individual work to reach treatment goals.
218994644|NCT06361160|DEVICE|Active Transcranial Magnetic Stimulation (TMS)|Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
218994645|NCT06361160|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|"Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).~An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation."
218994646|NCT05209425|DIETARY_SUPPLEMENT|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
218994647|NCT04843020|DRUG|ION 682884|Subcutaneous injection every month
219181173|NCT04469296|DIETARY_SUPPLEMENT|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
219181174|NCT04469296|DIETARY_SUPPLEMENT|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
219181175|NCT04772937|PROCEDURE|LLETZ|LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
219181176|NCT04772937|PROCEDURE|LEEP|LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
219181177|NCT03966313|DEVICE|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~* After anesthetic induction~* Before starting the device~* 2h, 6h and 48h after starting the device"
219181178|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
219181179|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
219753695|NCT06102395|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
218994648|NCT02140086|BEHAVIORAL|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
218994649|NCT01560793|BIOLOGICAL|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
218994650|NCT03473977|BIOLOGICAL|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
218994651|NCT03473977|BIOLOGICAL|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
218994652|NCT01893164|PROCEDURE|simple decompression|decompression of the ulnar nerve
218994653|NCT01893164|PROCEDURE|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
218994654|NCT01893164|PROCEDURE|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
218994655|NCT04502693|COMBINATION_PRODUCT|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine was administered intramuscularly.
219181180|NCT04358874|OTHER|Medication reconciliation|Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
219181181|NCT04358874|OTHER|Blood Pressure Management|Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (\>160/100)
219181182|NCT05759754|DRUG|TCM+ Routine Therapy|"The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued."
219181183|NCT05759754|DRUG|Routine Therapy|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
219753696|NCT06102395|DRUG|Carboplatin|Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
219753697|NCT06102395|DRUG|Nedaplatin|Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
218994656|NCT04502693|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine was administered intramuscularly.
218994657|NCT04502693|COMBINATION_PRODUCT|Placebo|Placebo was administered intramuscularly.
218994658|NCT04502693|COMBINATION_PRODUCT|MenABCWY-1|Lot 1 of the MenABCWY vaccine was administered intramuscularly.
218994659|NCT04502693|COMBINATION_PRODUCT|MenABCWY-2|Lot 2 of the MenABCWY vaccine was administered intramuscularly.
218994660|NCT04502693|COMBINATION_PRODUCT|MenABCWY-3|Lot 3 of the MenABCWY vaccine was administered intramuscularly.
218994661|NCT00602797|DRUG|Paclitaxel|Given IV
218994662|NCT00602797|OTHER|Quality-of-Life Assessment|Ancillary studies
218994663|NCT00602797|OTHER|Questionnaire Administration|Ancillary studies
218994664|NCT00602797|DRUG|Vinorelbine Tartrate|Given IV
218994665|NCT04312880|DRUG|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
218994666|NCT01954719|PROCEDURE|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
218994667|NCT01954719|PROCEDURE|control group|surgeon not dilated cervix after surgery
218994668|NCT06086470|DEVICE|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
218994669|NCT01450995|DRUG|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
218994670|NCT01450995|DRUG|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
218994671|NCT00834171|DRUG|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
218994672|NCT00834171|DRUG|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
218994673|NCT04490850|PROCEDURE|Blood sample|Blood sample
218994674|NCT00749645|DRUG|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
218994675|NCT00749645|DRUG|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
218994676|NCT02416921|BEHAVIORAL|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
218994677|NCT02416921|BEHAVIORAL|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
218994678|NCT03159221|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
218994679|NCT03943147|DRUG|BMS-986165|Specified dose on specified days
218994680|NCT03943147|DRUG|Placebo|Specified dose on specified days
218994681|NCT03943147|DRUG|Mycophenolate Mofetil|Specified dose on specified days
218994682|NCT00502047|DRUG|Plantago ovata husk|
218994683|NCT00991718|DRUG|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
218994684|NCT00991718|DRUG|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
218994685|NCT00991718|DRUG|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
218994686|NCT00171392|DRUG|Enteric-coated mycophenolate sodium|
218994687|NCT02758990|DIETARY_SUPPLEMENT|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
218994688|NCT02758990|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
218994689|NCT02758990|DIETARY_SUPPLEMENT|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
218994690|NCT02758990|DIETARY_SUPPLEMENT|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
218994691|NCT02758990|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
218994692|NCT02758990|DIETARY_SUPPLEMENT|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
218994693|NCT02758990|OTHER|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
218994694|NCT02758990|OTHER|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
218994695|NCT02758990|DIETARY_SUPPLEMENT|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
218994696|NCT02758990|OTHER|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
218994697|NCT02758990|DEVICE|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
218994698|NCT02758990|OTHER|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
218994699|NCT03674671|DRUG|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
218994700|NCT03674671|PROCEDURE|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
218994701|NCT02527005|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
218994702|NCT02527005|DRUG|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
218994703|NCT01446978|BIOLOGICAL|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
219753698|NCT06102395|DRUG|Nab paclitaxel|Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
219753699|NCT06102395|DRUG|Docetaxel|Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
219753700|NCT06102395|DRUG|Liposomal paclitaxel|Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
219753701|NCT06102395|DRUG|Fluorouracil|Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
218994704|NCT01446978|BIOLOGICAL|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
218994705|NCT01318993|DRUG|GSK1605786A|500 milligrams twice daily
218994706|NCT02548780|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
218994707|NCT02548780|OTHER|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
218994708|NCT00439478|DRUG|Radioiodine|
218994709|NCT04563351|OTHER|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
218994710|NCT00004983|BEHAVIORAL|diabetes self-management education|
218994711|NCT05122832|DIAGNOSTIC_TEST|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
218994712|NCT05122832|DIAGNOSTIC_TEST|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
218994713|NCT05122832|DIAGNOSTIC_TEST|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
218994714|NCT03668860|DRUG|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
218994715|NCT03668860|DRUG|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
218994716|NCT03668860|DRUG|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
218994717|NCT03668860|DRUG|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
218994718|NCT03668860|DRUG|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
218994719|NCT00864331|RADIATION|radiation|39 Gy in 13 daily fractions of 3 Gy
218994720|NCT00864331|OTHER|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
218994721|NCT00864331|DRUG|Chemotherapy|Chemotherapy given alone
218994722|NCT00864331|OTHER|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
218994723|NCT03218514|DRUG|Dalteparin|
218994724|NCT00714883|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
218994725|NCT00629707|OTHER|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
218994726|NCT02845934|OTHER|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
218994727|NCT00418457|DRUG|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
218994728|NCT00418457|DRUG|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
218994729|NCT04317469|DIAGNOSTIC_TEST|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
218994730|NCT01552941|DEVICE|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
218994731|NCT00934492|DRUG|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
219753702|NCT05058326|DIAGNOSTIC_TEST|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
219753703|NCT05058326|DIAGNOSTIC_TEST|Endoanal ultrasound|To assess the integrity of the anal canal.
219753704|NCT05058326|OTHER|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
219753705|NCT00002529|DRUG|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
219753706|NCT00002529|DRUG|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
219753707|NCT00002529|DRUG|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
219753708|NCT00002529|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily.
219753709|NCT00002529|DRUG|toremifene|Toremifene 60 mg daily.
219753710|NCT03766061|PROCEDURE|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
218994732|NCT00934492|DRUG|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
218994733|NCT06234917|OTHER|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
218994734|NCT03460730|BIOLOGICAL|Pneumovax|23-valent pneumococcal polysaccharide vaccine
219181184|NCT06494722|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
219181185|NCT06494722|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
219181186|NCT05777460|DEVICE|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
219181187|NCT04625686|BEHAVIORAL|Mental Health Treatment|Treatment of suicidal ideation
219181188|NCT06105918|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219181189|NCT06105918|PROCEDURE|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
219181190|NCT06105918|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219181191|NCT06105918|OTHER|Flotufolastat F-18|Given IV
219181192|NCT06105918|DRUG|Lutetium Lu 177 PSMA-10.1|Given IV
219181193|NCT06105918|PROCEDURE|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
219181194|NCT06105918|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
219181195|NCT04600466|OTHER|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
219181196|NCT04600466|OTHER|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
219181197|NCT04600466|OTHER|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
219181198|NCT05355766|DRUG|CN128 Tablets|Iron chelator, oral tablets
219181199|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
218994735|NCT00207350|DEVICE|Interstitial Laser Therapy|Device
218994736|NCT04563702|BIOLOGICAL|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
218994737|NCT01317485|PROCEDURE|Laparoscopic lavage and drainage|"\[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
218994738|NCT01317485|PROCEDURE|Sigmoidectomy with primary anastomosis|\[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
218994739|NCT01317485|PROCEDURE|Sigmoidectomy with end-colostomy|\[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
218994740|NCT04449926|BIOLOGICAL|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
219181200|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
219181201|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
218994741|NCT00002307|DRUG|Stavudine|
218994742|NCT00002307|DRUG|Zidovudine|
218994743|NCT02420171|OTHER|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
219181202|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
219181203|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
219181204|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
219181205|NCT05988255|DEVICE|Static progressive stretching|A stretching technique applies a mechanical progressive stretch
219181206|NCT05988255|OTHER|Cyclic manual stretching|A stretching technique applies an intermittent manual stretch
219181207|NCT05643846|PROCEDURE|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
219181208|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
219181209|NCT04141956|OTHER|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
219181210|NCT04316013|DRUG|Sevoflurane|Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
219181211|NCT04316013|DRUG|Propofol|Intravenous anaesthetic used for induction and maintenance of anaesthesia
219181212|NCT04316013|DRUG|Lidocaine IV|1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
219181213|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
219181214|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
219181215|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
219181216|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
219181217|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
219181218|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
219181219|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
219181220|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
219181221|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
219181222|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
219181223|NCT05827094|OTHER|Mobile app|The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
219181224|NCT05827094|OTHER|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
219753711|NCT03766061|PROCEDURE|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
219753712|NCT00948350|PROCEDURE|awake intubation|two anesthesia techniques
219753713|NCT00660803|DRUG|Fulvestrant|
219753714|NCT01055145|DRUG|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
219753715|NCT05178186|PROCEDURE|Thyroidectomy|Surgery for thyroid carcinoma
219753716|NCT06173089|DEVICE|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
219753717|NCT02902614|PROCEDURE|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
219753718|NCT02902614|PROCEDURE|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
219753719|NCT01478425|DEVICE|Lipidic Microemulsion|Topical nasal, twice a day
219753720|NCT01478425|DEVICE|Saline|Topical Nasal, twice a day
219753721|NCT00000720|DRUG|Globulin, Immune|
219753722|NCT00000720|DRUG|Zidovudine|
219753723|NCT02748447|DEVICE|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
219753724|NCT02482311|DRUG|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
218994744|NCT00727493|DRUG|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
218994745|NCT00727493|DRUG|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
218994746|NCT06184932|BEHAVIORAL|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
219753725|NCT02589821|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
219753726|NCT02589821|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
219753727|NCT00221767|DEVICE|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
219753728|NCT03787654|DEVICE|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
218994747|NCT06184932|BEHAVIORAL|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
218994748|NCT00358683|DRUG|Certolizumab pegol|
218994749|NCT03736447|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
218994750|NCT03736447|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
218994751|NCT02619175|DEVICE|Stroke Subjects Perturbation-Based Balance Training|
218994752|NCT02619175|DEVICE|Stroke Subjects Weight Shifting and Gait training|
218994753|NCT00004779|GENETIC|Ad5-CB-CFTR|
218994754|NCT06177730|OTHER|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
218994755|NCT00925093|DRUG|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
218994756|NCT00925093|DRUG|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
218994757|NCT00925093|DRUG|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
219753729|NCT03787654|DEVICE|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
219753730|NCT03787654|DRUG|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
219753731|NCT03484104|DIAGNOSTIC_TEST|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
219753732|NCT05971095|DEVICE|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
219753733|NCT03790189|BIOLOGICAL|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
219753734|NCT03944850|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
219753735|NCT01263119|DRUG|Warfarin|10-mg warfarin oral dose
219753736|NCT01263119|DRUG|LY2216684|18-mg LY2216684 oral dose
219753737|NCT01895192|OTHER|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
219753738|NCT02385071|DRUG|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
219753739|NCT02385071|DRUG|Treatment B|Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
219753740|NCT02385071|DRUG|Treatment C|Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
218994758|NCT04036890|DRUG|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
218994759|NCT04036890|DRUG|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
219753741|NCT02385071|DRUG|Treatment D|\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
219753742|NCT02385071|DRUG|Treatment E|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
219753743|NCT02385071|DRUG|Treatment F|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
219753744|NCT03101800|DRUG|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
219753745|NCT03101800|DRUG|Azathioprine|Standard weight based azathioprine dosage
218994760|NCT03054441|OTHER|Actigraph|Actigraphs worn on wrists
218994761|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
218994762|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
218994763|NCT02124330|DIETARY_SUPPLEMENT|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
218994764|NCT03253497|DRUG|Chlorobenzene Liquid|before induction will be used for oropharynx
218994765|NCT00514111|DRUG|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
218994766|NCT01714011|DRUG|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
218994767|NCT01714011|DRUG|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
218994768|NCT00074152|DRUG|chemotherapy|Given within 10 weeks after surgery.
218994769|NCT00074152|RADIATION|radiation therapy|Given within 6 months after surgery
218994770|NCT02989714|DRUG|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
218994771|NCT02989714|DRUG|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
218994772|NCT03547583|DRUG|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
218994773|NCT03547583|DRUG|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
218994774|NCT04933994|DEVICE|computed Tomography|All cases were detected with computed Tomography
218994775|NCT00382252|PROCEDURE|computed tomography|
218994776|NCT00382252|PROCEDURE|positron emission tomography|
218994777|NCT00382252|PROCEDURE|radiofrequency ablation|
219181225|NCT03735472|DEVICE|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
219753746|NCT02328495|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
218994778|NCT05270343|DRUG|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
218994779|NCT03884491|DRUG|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
218994780|NCT03884491|DRUG|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
218994781|NCT03884491|DRUG|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
218994782|NCT03884491|DRUG|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
218994783|NCT04848597|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
218994784|NCT04959422|OTHER|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
218994785|NCT04303832|OTHER|eye exercises|Eye exercises for correcting eye deviation
218994786|NCT04303832|DEVICE|eye glasses|Eye glasses for correcting eye deviation
218994787|NCT04741282|OTHER|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
218994788|NCT04741282|OTHER|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
218994789|NCT00484432|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
218994790|NCT00484432|DRUG|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
218994791|NCT03896386|OTHER|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
218994792|NCT01136603|DEVICE|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
218994793|NCT02657915|DRUG|Placebo|Administered as specified in the treatment arm.
218994794|NCT02657915|DRUG|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
219181226|NCT03287453|OTHER|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
219181227|NCT03287453|OTHER|Survey Administration|Ancillary studies
219181228|NCT02610361|DRUG|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
218994795|NCT02221791|DIETARY_SUPPLEMENT|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
218994796|NCT02221791|DIETARY_SUPPLEMENT|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
218994797|NCT02221791|DIETARY_SUPPLEMENT|Placebo|Participants will consume 70g white chocolate + placebo capsules
218994798|NCT01371175|BIOLOGICAL|DNA.HIVA|0.5mg DNA.HIVA or placebo
218994799|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^6 pfu MVA or placebo
218994800|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^7 pfu MVA or placebo
218994801|NCT01371175|BIOLOGICAL|MVA.HIVA|2.5x10\^8 pfu MVA or placebo
218994802|NCT01695902|DRUG|Levosert-20|
218994803|NCT01695902|DRUG|Mirena|
218994804|NCT03384212|DRUG|Cladribine|
218994805|NCT03384212|DRUG|Fludarabine|
218994806|NCT03384212|DRUG|Busulfan|
218994807|NCT03384212|DRUG|Cytarabine|
218994808|NCT02512588|DRUG|BTD-001|
218994809|NCT02512588|DRUG|Placebo|
218994810|NCT05006196|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
218994811|NCT02639143|DRUG|ticagrelor|
219181229|NCT05577702|DRUG|Tislelizumab|Administered as an intravenous infusion
219181230|NCT05577702|DRUG|Ociperlimab|Administered as an intravenous infusion
219181231|NCT05577702|DRUG|LBL-007|Administered as an intravenous infusion
218994812|NCT02639143|DRUG|Clopidogrel|
218994813|NCT01433614|DRUG|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
218994814|NCT01433614|DRUG|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
218994815|NCT01433614|DRUG|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
218994816|NCT03119584|DRUG|linaclotide or placebo|
218994817|NCT01149226|DRUG|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
218994818|NCT04274413|COMBINATION_PRODUCT|Beta Adrenergic Sweat Test|"In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded."
218994819|NCT02021240|DRUG|Ketamine|
218994820|NCT02021240|DRUG|Dexamethasone|
218994821|NCT02021240|DRUG|Normal Saline|
218994822|NCT00225550|DRUG|ADH -1 (Exherin™)|
218994823|NCT05953311|OTHER|Blood analysis|Blood analysis for neurological biomarkers measurements
218994824|NCT05953311|OTHER|Cognitive tests|Questionnaires assessing cognitive function
218994825|NCT01686529|PROCEDURE|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
218994826|NCT01686529|DRUG|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
218994827|NCT05041205|DIETARY_SUPPLEMENT|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
218994828|NCT05041205|DEVICE|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
218994829|NCT01725178|BEHAVIORAL|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
218994830|NCT02166905|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
218994831|NCT02166905|DRUG|Epacadostat|Given PO
218994832|NCT02166905|OTHER|Laboratory Biomarker Analysis|Correlative studies
218994833|NCT02166905|OTHER|Pharmacological Study|Correlative studies
218994834|NCT02166905|DRUG|Poly ICLC|Given SC
219181232|NCT05577702|DRUG|Cisplatin|Administered as an intravenous infusion
219181233|NCT05577702|DRUG|Carboplatin|Administered as an intravenous infusion
219181234|NCT05577702|DRUG|Pemetrexed|Administered as an intravenous infusion
219181235|NCT05577702|DRUG|Paclitaxel|Administered as an intravenous infusion
218994835|NCT02617628|DRUG|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
218994836|NCT02065375|DRUG|Omaveloxolone Ophthalmic Suspension 1.0%|
218994837|NCT02065375|DRUG|Omaveloxolone Opthalmic Suspension 0.5%|
218994838|NCT02065375|DRUG|Placebo|
218994839|NCT03278873|BIOLOGICAL|Prior exposure to AAV-CNGA3 or AAV-CNGB3|Participants previously received AAV-CNGA3 or AAV-CNGB3 in an open-label, Phase 1/2 dose escalation trial for adults and children with achromatopsia owing to defects in CNGA3 or CNGB3, respectively.
218994840|NCT01652209|BIOLOGICAL|Hearticellgram-AMI|
218994841|NCT02035098|OTHER|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
219181236|NCT04082689|BEHAVIORAL|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
219181237|NCT05885880|OTHER|Blue-button screening|Patients will be screened for clinical trial matches using the Blue-button tool
219181238|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
219181239|NCT06426381|BEHAVIORAL|Therapeutic Touch|Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
218994842|NCT05326165|DEVICE|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
218994843|NCT05326165|DEVICE|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
218994844|NCT05775458|DIAGNOSTIC_TEST|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
218994845|NCT03847649|DRUG|Durvalumab|1500 mg IV, 60 min, Day 1 every 4 weeks
218994846|NCT03847649|DRUG|Prednisone|0.5mg/kg; PO, Daily cycles 1 \& 2
218994847|NCT03847649|DRUG|Prednisone|10mg, PO, Daily cycles 1 \& 2
219181240|NCT06306586|BEHAVIORAL|Digital Treatment for Adolescents With Eating Disorders|"The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media."
219181241|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
219181242|NCT04641221|BEHAVIORAL|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
219181243|NCT05913388|DRUG|GB1211|Administered orally twice daily at 100mg.
219181244|NCT05913388|DRUG|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
219181245|NCT05913388|DRUG|Placebo|Administered orally twice daily at 100mg.
219181246|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Sanger technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
218994848|NCT03847649|DRUG|Tremelimumab|Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
218994849|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
218994850|NCT05621369|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
218994851|NCT05621369|BEHAVIORAL|Psoriasis Draw|Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
219181247|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
219181248|NCT05074303|BIOLOGICAL|Influenza Vaccine|All subjects will receive the influenza vaccine.
219181249|NCT05074303|DIETARY_SUPPLEMENT|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
218994852|NCT05621369|BEHAVIORAL|Psoriasis Area Photo|Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
218994853|NCT05621369|BEHAVIORAL|Finger and Toe Photos|Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
218994854|NCT05621369|BEHAVIORAL|Digital Jar Open|Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
218994855|NCT05621369|BEHAVIORAL|30 Second Walk|Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
218994856|NCT05621369|OTHER|Psorcast mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
218994857|NCT06573359|OTHER|questionnaire|Turkish translation of the scale will be made by a native English speaker and the back translation will be made into English, and the consistency of the original and Turkish translation will be evaluated by a three-person expert committee. The psychometric properties of the scale will be investigated according to the methods used for the validity of the original scale. The validity of the scale was validated by analyzing the correlations between the rcs-e-tr score obtained at admission (both for each partial item and the total score) and other suitability indicators used in Turkey (FIM Motor and Barthel) using Spearman's rank correlation coefficient r (rho). will be evaluated. Additionally, to check the ability of rcs-e-tr to capture case complexity, it will be correlated with other scores usually recorded in our rehabilitation services on admission, using Spearman's rank correlation coefficient r(rho).
218994858|NCT04109716|BEHAVIORAL|Interpersonal Psychotherapy - Adolescent Skills Training|This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.
218994859|NCT04109716|BEHAVIORAL|Services as usual|Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
218994860|NCT03410043|DRUG|Osimertinib|Given PO
218994861|NCT03410043|RADIATION|Radiation Therapy|Undergo radiation therapy
218994862|NCT03410043|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218994863|NCT06367959|BEHAVIORAL|Esays|Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
218994864|NCT06367959|BEHAVIORAL|Questionnaires|"Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay."
218994865|NCT02801331|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
218994866|NCT06505447|OTHER|Daytime light exposure|Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
218994867|NCT06505447|OTHER|Daytime restricted feeding|Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
218994868|NCT05212428|PROCEDURE|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
218994869|NCT05212428|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
218994870|NCT05212428|OTHER|Genetic Counseling|Receive genetic counseling
218994871|NCT05212428|OTHER|Questionnaire Administration|Complete family history
218994872|NCT05212428|OTHER|Questionnaire Administration|Ancillary studies
218994873|NCT05240534|BEHAVIORAL|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
219181250|NCT05074303|DIETARY_SUPPLEMENT|Placebo|2 - 250 mg capsules/day of cellulose
219181251|NCT04094298|DRUG|FX006 Injection|One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
219181252|NCT03888950|DIAGNOSTIC_TEST|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
219753747|NCT02328495|OTHER|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
219753748|NCT01179373|DEVICE|TMS, H coil|TMS, H Coil, High/ Low Frequency
219753749|NCT04653792|DRUG|Pregabalin 75mg|75 mg capsule
219753750|NCT04653792|DEVICE|Placebo|75 mg
219753751|NCT02857972|DEVICE|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
219753752|NCT01162759|BEHAVIORAL|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
219753753|NCT06295419|OTHER|dual task|cerebral palsy and healthy controls will be evaluated dual task conditions
219753754|NCT06295419|OTHER|single task|cerebral palsy and healthy controls will be evaluated single task conditions
218994874|NCT05240534|BEHAVIORAL|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
218994875|NCT01352546|BIOLOGICAL|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
218994880|NCT00946478|DRUG|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
218994881|NCT00946478|OTHER|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
219181253|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
219181254|NCT03815825|DRUG|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
219181255|NCT03815825|DRUG|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
219181256|NCT06344143|DIAGNOSTIC_TEST|Various labs and imaging tests|Dexamethasone Suppression Test, Adrenocorticotropic Hormone (ACTH), Salivary Cortisol Levels, Vasopressin Stimulation test, Fasting Glucose, Fasting Insulin, Complete Metabolic Panel (CMP), Gamma-glutamyl transferase (GGT), Sex Hormone Binding Globulin, Cat scan of abdomen/Pelvis, Whole body dual energy x-ray absorptiometry (DXA) scan, Ultrasound Fibroscan Transient Elastography
219181257|NCT06256432|DRUG|Ambrisentan|Endothelin receptor antagonist
218994882|NCT02214407|DRUG|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
218994883|NCT02214407|DRUG|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
218994884|NCT02043275|OTHER|Leg training|Lower body resistance training twice per week for one hour each time.
218994885|NCT02043275|OTHER|Arm training|Upper body resistance training twice per week for one hour each time.
219181258|NCT06256432|DRUG|Terlipressin|Terlipressin
219181259|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
219181260|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
219181261|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
219181262|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
219181263|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
219181264|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
219181265|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
218994886|NCT05510531|BEHAVIORAL|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
218994887|NCT00593008|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
218994888|NCT00593008|DRUG|Gemcitabine|Given intravenously every other week of each 28-day cycle.
218994889|NCT00887653|DRUG|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
218994890|NCT05438888|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
218994891|NCT05438888|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
218994892|NCT06128473|DEVICE|Soft Contact Lens|Vision Correction
218994893|NCT04180358|BEHAVIORAL|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
218994894|NCT04180358|BEHAVIORAL|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
218994895|NCT03246893|DEVICE|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
218994896|NCT03246893|DEVICE|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
218994897|NCT01848860|PROCEDURE|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
218994898|NCT01848860|BIOLOGICAL|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
218994899|NCT04698187|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
218994900|NCT04698187|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
218994901|NCT03179696|BEHAVIORAL|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
218994902|NCT06657716|DEVICE|ANTERION investigational|"Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)"
218994903|NCT02537106|PROCEDURE|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
218994904|NCT02537106|PROCEDURE|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
218994905|NCT01355926|OTHER|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
218994906|NCT01355926|OTHER|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
218994907|NCT02633605|DEVICE|First Sense Medical®|
218994908|NCT03814317|DRUG|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
218994909|NCT01504620|OTHER|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
218994910|NCT01504620|DRUG|insulin infusion|i.v. infusion of insulin
218994911|NCT07008352|PROCEDURE|Blood sample collection for amino acid profiling|Blood samples (5 mL) will be collected from participants in both groups. In the bariatric surgery group, samples will be collected at three time points: preoperatively, and at 1 and 3 months postoperatively. For the control group, a single sample will be obtained. Serum will be separated, stored at -80°C, and analyzed for free amino acid profiles using LC-MS/MS.
218994912|NCT06680713|BEHAVIORAL|Exercise|Progressive exercise testing on a cyclo ergometer
218994913|NCT04529434|OTHER|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
218994914|NCT04529434|OTHER|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
218994915|NCT06861101|DRUG|JT002 Nasal spray|200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD, 64 patients per cohort, total 256 patients for treatment 14 days
218994916|NCT06861101|DRUG|Placebo|Total 64 patients for treatment 14 days
218994917|NCT07014566|OTHER|Digital Combined Decongestive Therapy|The intervention consisted of a digitally delivered combined decongestive therapy (CDT) program for patients with unilateral or bilateral lower extremity lymphedema. Patients attended a single face-to-face session where a physiotherapist provided training on skin care, self-bandaging, self-manual lymphatic drainage, and therapeutic exercises (breathing, gluteal sets, knee sets, and toe movements). Caregivers recorded the demonstrations for home use. Following this session, a 4-week remote physiotherapy program was implemented using telecommunication technologies. Patients continued self-management with guidance via digital platforms. Compression stockings replaced self-bandaging during the 12-week follow-up phase.
218994918|NCT07015008|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
218994919|NCT07015008|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
218994920|NCT07014605|BEHAVIORAL|Smoking Cessation Self Help Guide|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help guide in this study. Attached to the guide is an information sheet regarding NRT (e.g., patches and lozenges), where to buy them, and how to use them."
218994921|NCT07014605|BEHAVIORAL|Smartphone-delivered Automated Messaging|The MAP includes text messages, images, and videos with content designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The MAP will begin immediately after enrollment and continue for a 26-week period. The MAP approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
218994922|NCT07016607|DEVICE|GPIV|The investigational device is a peripheral intravenous catheter with a passive fully automatic needlestick protection, with a glide-on-contact design of the plastic cannula tip featuring asymmetry, with the negative, convex slope in the plane perpendicular to the longitudinal axis of the tip resulting in bottom part of the cannula being shorter.
218994923|NCT07014956|PROCEDURE|Labour epidural analgesia|Prenatal exposure to labour epidural analgesia during delivery
218994924|NCT07016256|DEVICE|intraoral devices|Intraoral devices not registed with a patent
218994925|NCT07015684|DRUG|131I-apamistmab|131I-apamistamab is a drug construct consisting of the apamistamab monoclonal antibody (mAb) and radioactive isotope iodine 131 (131I). The study drug will be patient-specific and will be manufactured for dosing on a specific date. The antibody dose will be at least 0.5mg/kg, however the final antibody amount may be higher if necessary based on the target radioactivity level. The 131I-apamistamab study drug requires patient details such as height, weight, a calculation to determine weight for use in calculating antibody amount for the dose. 131I-apamistmab will be given via intravenous (IV) infusion.
218994926|NCT07015684|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is an immunosuppressant agent. Sirolimus is to be given orally either as tablet or solution form. Dosage will be adjusted to a therapeutic target of 10-15 ng/mL in first 6 months post-transplant and 5-10 ng/mL after 6 months.
218994927|NCT07015684|DRUG|Campath|Campath is a recombinant DNA-derived humanized monoclonal antibody that is directed against the 21-28 kD cell surface glycoprotein, CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and tissues of the male reproductive system. Campath will be given via IV at a total dose of 1 mg per kilogram of body weight.
218994928|NCT07015684|DRUG|Total Body Irradiation|Radiation dose is 3Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
219181266|NCT05332522|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
219181271|NCT05319639|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
219181272|NCT05319639|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
218994929|NCT07015684|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell (RBC) exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
218994930|NCT07015684|RADIATION|Planar gamma imaging|Dosimetric imaging will be performed using quantitative planar gamma camera acquisition. Planar gamma imaging is a technique used in medical imaging to take pictures of the inside of the body, particularly to look at how certain organs or tissues are functioning. This allows the study doctor to evaluate how the study drugs are absorbed into the body.
218994931|NCT06679894|PROCEDURE|Implant site preparation with osteotomes and electrified mallet|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
218994932|NCT06679894|PROCEDURE|Implant site preparation with osseodensification drills|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
218994933|NCT05814783|BEHAVIORAL|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
218994934|NCT05814783|DEVICE|digital CBTI|CBTI app
218994935|NCT07016451|PROCEDURE|Li-ESWT|The intervention treatment uses Li-ESWT. (Dornier Aries® devices, Power 0.29mj/m² and 3000 shocks per week for 4 weeks)
218994936|NCT07016451|DRUG|Medication|"The medication treatment of Radiation cystitis and relevant symptoms such as Antimuscarinics, Beta3 agonist, and pain control, as listed. Antimuscarinic Agents~* Oxybutynin~* Tolterodine~* Solifenacin~* Darifenacin~* Trospium~* Fesoterodine β3-Adrenergic Agonists~* Mirabegron Pain Control Medications~* Paracetamol~* NSAIDs (e.g., Ibuprofen, Diclofenac)~* Phenazopyridine~* Amitriptyline~* Gabapentin / Pregabalin"
218994937|NCT07015658|PROCEDURE|Baduanjin|The Baduanjin protocol, based on China's 2003 General Administration of Sport standard, was modified by professional physiotherapists for targeted adaptations, with nurses receiving specialized training. Patients viewed step-by-step instructional clips upon admission alongside a full-length routine video. Standard postoperative rehabilitation was maintained during Weeks 1-2. At Week 3, patients demonstrating adequate wound healing and unimpaired static lumbar muscle contraction performed Baduanjin exercises wearing a lumbar brace, supervised by trained nurses for movement correction. The brace was discontinued after 8 weeks. Modified professional videos with background music were distributed via WeChat/official accounts twice daily (30min/session, 5 days/week) for 13 weeks (total ≥2000min). Duration/frequency adjustments were permitted based on individual recovery and physician recommendations post-intervention.
218994938|NCT07015658|PROCEDURE|Moxibustion|Moxibustion was performed at acupoints including Yaoyangguan (GV3), Shenshu (BL23), Dachangshu (BL25, affected side), Chengfu (BL36), Mingmen (GV4), Weizhong (BL40, affected side), Taixi (KI3), Fuliu (KI7), Zhishi (BL52), Zusanli (ST36), and Ashi points. Using five-year-aged Qizhou mugwort, the patient's treatment areas were fully exposed in a comfortable position. The moxa stick was held 3-4 cm from the skin with intensity adjusted to patient tolerance to prevent burns. The circular moxibustion technique was applied for 3-5 minutes per acupoint until the skin exhibited erythema, perspiration, or mottling, or until the patient experienced warmth, distension, itchiness, or perceived moxa-heat propagation. Treatment commenced at postoperative Week 3 following evaluation of satisfactory wound healing, administered three times weekly for four consecutive weeks.
218994939|NCT07015658|PROCEDURE|Conventional intervention|Postoperative Rehabilitation Exercises: Week 1: Ankle Pump Exercises: Start after anesthesia. Slowly rotate/invert, dorsiflex/plantarflex ankles. Hold each position 10-15s. 30 min/set, 6 sets/day, until ambulation. Straight Leg Raising (SLR): Start Day 2, supine. Elevate leg \>30°. Progress from passive to active hold. Hold 5-10s/rep, 10-20 reps/set. 3 sets (morning/noon/night) daily for 15 days. Week 2: Supine hip/knee flexion exercises in bed. Hold each flexion 3-5s. 30-50 reps/set. 2 sets/day. Weeks 3-4: Start back muscle training (e.g., bridge/bird-dog poses). Months 1-3: Gradually increase back exercise frequency/difficulty. Perform flexion, extension, lateral flexion, and rotation wearing a lumbar brace. Intensity/reps based on tolerance.
219181273|NCT05319639|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
219181274|NCT05319639|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
219181275|NCT05319639|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
219181276|NCT05319639|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
219181277|NCT05745246|BEHAVIORAL|e-health training program|"1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
219181278|NCT06158724|OTHER|Personal Protective Equipment|Simplified PPE for use in COVID-19 departments.
219181279|NCT05246280|DRUG|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219181280|NCT06549608|DRUG|Mavacamten|As per product label
218994940|NCT07015411|DIETARY_SUPPLEMENT|Neuro-Complex and Multi|"Participants will orally consume 2 caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).~Participants will take 1 cap of each product simultaneously twice a day directly in their mouth."
218994941|NCT07014761|OTHER|No Intervention: Observational Cohort|No Intervention
218994942|NCT07015775|PROCEDURE|Neurostimulation|Procedure guided by neurostimulation
218994943|NCT07015775|PROCEDURE|Ultrasound|Procedure guided by ultrasound
218994944|NCT07014657|BEHAVIORAL|Digital Combined Decongestive Therapy|Participants received digital combined decongestive therapy, which included an initial face-to-face session where skin care and risk reduction training were provided. Self-bandaging and self-manual lymphatic drainage techniques were demonstrated and practiced under supervision. Additionally, decongestive and breathing exercises were taught to both patients and caregivers. Following this, the intensive treatment phase was conducted remotely using electronic communication technologies over a period of 4 weeks to monitor and guide the therapy. After the intensive phase, participants continued with maintenance therapy, which involved the use of compression stockings. The therapy aimed to reduce limb volume and improve symptoms related to breast cancer-related lymphedema.
218994945|NCT07014644|DRUG|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo
218994946|NCT07014644|DRUG|1.5g Naltrexone Implant|1.5g Naltrexone Implant
218994947|NCT06205316|DRUG|Antiandrogen Therapy|Receive ADT
218994948|NCT06205316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218994949|NCT06205316|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219181281|NCT06412055|DEVICE|NEURO SWING AFO (Fior& Gentz, Lüneburg, Germany)|stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
219181282|NCT06412055|DEVICE|WalkOn Reaction® (Ottobock, Duderstadt)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
218994950|NCT06205316|PROCEDURE|Positron Emission Tomography|Undergo PET scan
218994951|NCT06205316|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218994952|NCT06205316|OTHER|Survey Administration|Ancillary study
218994953|NCT06205316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218994954|NCT06629207|DEVICE|PET/CT with 18-FDG|FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.
219181283|NCT06412055|DEVICE|Matrix Max2® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
219181284|NCT06412055|DEVICE|Matrix® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)
219181285|NCT01909245|BIOLOGICAL|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
218994955|NCT06629207|DEVICE|SPECT : 123 I-FP-CIT (DATSCAN)|DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
218994956|NCT06629207|DEVICE|MRI|MRI examination to exclude structural brain anomalies.
218994957|NCT06881979|DEVICE|High-tech rehabilitative treatment|Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises. Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training. Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback
218994958|NCT06881979|OTHER|Rehabilitation|Traditional rehabilitative treatment
219181286|NCT01909245|DRUG|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
219181287|NCT01909245|DRUG|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
219181288|NCT06318117|OTHER|Rice infant formula|Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
219181289|NCT05967195|BEHAVIORAL|Financial Incentive and Text-Messages|"Patient-participants will receive modest financial incentive for attending therapy or medication management appointments combined with text messages to encourage attendance at these appointments. Text messages will be informed by principles of behavioral economics. Maximum incentive = $50/month if all appointments attended. Incentives will be pro-rated by percentage of appointments attended. Pro-rating strategies (e.g., uniform amount per appointment, escalating \[aka, 'back-loaded'\], or decreasing \[aka 'frontloaded'\] will be sequentially changed based on acceptability and other intervention-related data gathered from participants during the trial.~Clinician-participants will not receive any intervention, but will receive surveys and interviews to assess their perceptions about the optimization, acceptability, scalability, and other implementation barriers/facilitators for the intervention."
219181290|NCT06058663|PROCEDURE|Angiography|Undergo mapping angiography
219181291|NCT06058663|PROCEDURE|Biopsy|Undergo biopsy
219181292|NCT06058663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218994959|NCT06723834|OTHER|Psychiatric Service Dog|Partnership with a trained service dog for PTSD.
218994960|NCT06723834|BEHAVIORAL|Prolonged Exposure Therapy|12 weeks of Prolonged Exposure once per week.
219181293|NCT06058663|PROCEDURE|Computed Tomography|Undergo CT
219181294|NCT06058663|BIOLOGICAL|Durvalumab|Given IV
219181295|NCT06058663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219181296|NCT06058663|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219181297|NCT06058663|BIOLOGICAL|Tremelimumab|Given IV
219181298|NCT06058663|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
219181299|NCT05432427|RADIATION|64Cu-DOTATATE and 18F-FDG|All participants will get a 64Cu-DOTATATE-PET and 18F-FDG-PET/CT.
219181300|NCT06434480|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given."
219181301|NCT04599062|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
219181302|NCT04599062|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
219181303|NCT04441034|DRUG|Anti-convulsant medications|Anti-convulsants are very commonly used to treat patients with chronic pain.
219181304|NCT04441034|DRUG|Anti-depressant medications|Anti-depressants are very commonly used to treat patients with chronic pain.
219181305|NCT04527315|OTHER|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
219181306|NCT03374787|DEVICE|Fusion Sound Processor|Sound Processor
219181307|NCT06376734|DEVICE|Transcranial magnetic stimulation|Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
219181308|NCT04074759|BIOLOGICAL|FPT155|A soluble CD80 fusion protein
219181309|NCT04074759|BIOLOGICAL|pembrolizumab|An anti-PD1 antibody
219181310|NCT06049329|DRUG|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
219181311|NCT06049329|DRUG|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
219753755|NCT02285881|BEHAVIORAL|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
219181312|NCT03521830|DRUG|Nivolumab|480mg IV every 4 weeks
219181313|NCT03521830|DRUG|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
219181314|NCT03521830|DRUG|Relatlimab|480 mg IV q4wks
219181315|NCT03197584|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219753756|NCT03301584|OTHER|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
219753757|NCT03301584|OTHER|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
219753758|NCT04902040|BIOLOGICAL|Atezolizumab|Given IV
219753759|NCT04902040|DRUG|Avelumab|Given IV
219753760|NCT04902040|BIOLOGICAL|Durvalumab|Given IV
219753761|NCT04902040|BIOLOGICAL|Nivolumab|Given IV
219753762|NCT04902040|BIOLOGICAL|Pembrolizumab|Given IV
219753763|NCT04902040|DRUG|Plinabulin|Given IV
219753764|NCT04902040|RADIATION|Radiation Therapy|Undergo radiation therapy
219181316|NCT03197584|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
219181317|NCT03197584|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219181318|NCT03197584|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219181319|NCT03197584|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219181320|NCT03197584|DRUG|Fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
219181321|NCT03197584|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219181322|NCT03197584|DRUG|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219181323|NCT03197584|DRUG|omega-3 acid ethyl esters|omega-3 acid ethyl esters
219181324|NCT03197584|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219181325|NCT03197584|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
219181326|NCT03197584|BIOLOGICAL|ALT-803|Recombinant human super agonist IL-15 complex
219181327|NCT03197584|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2 vaccine
219181328|NCT03197584|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219181329|NCT03197584|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1 vaccine
219181330|NCT03197584|BIOLOGICAL|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
219181331|NCT03197584|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
219181332|NCT03197584|BIOLOGICAL|haNK®|NK-92 \[CD16.158V, ER IL-2\]
219181333|NCT04623944|BIOLOGICAL|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
218994961|NCT06743295|DEVICE|DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction|"Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise."
218994962|NCT03275376|DRUG|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
218994963|NCT03275376|DRUG|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
218994964|NCT06830369|DEVICE|HypnoVR|In the intervention group, after extubation, patients will receive IVR with HypnoVR®, twice-a-day over two to five days. The product consists of HypnoVR® virtual reality software and HypnoVR® Compagnon remote control software. HypnoVR® is a CE-marked class 1 medical device, developed and marketed by HypnoVR SAS, an ISO 13484:2016 and ISO 27001:2017 certified company. The device works with a virtual reality headset, a personal audio device and a mobile terminal. The investigators will only use sessions of 10 to 20 minutes. For each type of session, a visual universe, a musical atmosphere and a male or female voice are defined. Typically, the scenarios include 3 phases: preparation, hypnosis and return. We will use the following sessions: anxiety, pain, rehabilitation.
218994965|NCT06830369|OTHER|usual health care|usual health care
218994966|NCT01354977|DRUG|Resveratrol|1,000mg twice daily for 28 days
218994967|NCT05798832|OTHER|Virtually reality training group|BLS Training with VR
218994968|NCT05798832|OTHER|Traditional training group|BLS Training with Traditional
218994969|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
218994970|NCT03478358|DRUG|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
218994971|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
218994972|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
218994973|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
218994974|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
218994975|NCT02644733|PROCEDURE|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
218994976|NCT02644733|PROCEDURE|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
218994977|NCT03600545|OTHER|Brain Fitness App|Brain exercises using an iPAD
218994978|NCT05715034|BEHAVIORAL|Compassionate Care|Single-session web-based program
218994979|NCT05715034|BEHAVIORAL|Relaxing with Nature|Single-session web-based program
218994980|NCT03718585|OTHER|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
218994981|NCT04638933|OTHER|No intervention|No intervention
218994982|NCT01495117|DRUG|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
218994983|NCT01495117|DRUG|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
218994984|NCT03724760|OTHER|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
218994985|NCT02140372|DRUG|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
218994986|NCT03973996|DIETARY_SUPPLEMENT|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
218994987|NCT03973996|DIETARY_SUPPLEMENT|Placebo|A matched gummy confection formulated without green tea extract
218994988|NCT02469298|DRUG|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
218994989|NCT02469298|DRUG|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
218994990|NCT02469298|DRUG|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
218994991|NCT02469298|DRUG|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
218994992|NCT04249583|BIOLOGICAL|botulinum toxin|neuromodulator to be injected in the GL region
219181334|NCT06528626|DIAGNOSTIC_TEST|rapid HIV and HCV serological tests|In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
219181335|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
219181336|NCT06581952|BEHAVIORAL|Poem writing|"The poem themes will focus on accomplishment moments, joyful moments, and gratitude. Participants will be motivated to write at least one poem in each session. The instructor will lead the participants to improve the poem after the participants complete the first draft. The participants will be encouraged to perform in reading their completed poem, sharing their feelings and expressing the meaning of the poems during the session.~In the second session, participants will be invited to do a poem reading performance using one of their newly written poems."
218994993|NCT04249583|BIOLOGICAL|Placebo|Placebo to be injected in the GL area
218994994|NCT04388618|OTHER|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
218994995|NCT06058481|DEVICE|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
218994996|NCT06058481|DEVICE|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
218994997|NCT01661296|OTHER|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
218994998|NCT01661296|DRUG|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
218994999|NCT01230944|PROCEDURE|Laparoscopic Nissen fundoplication|
218995000|NCT01230944|PROCEDURE|Open Nissen fundoplication|
218995001|NCT03667261|DEVICE|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
218995002|NCT03667261|DEVICE|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
218995003|NCT01779401|DRUG|Clopidogrel 75mg|
218995004|NCT01779401|DRUG|Clopidogrel 150mg|
219181337|NCT05500443|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone-7)|Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
219181338|NCT04580446|RADIATION|Hypofractionated intensity modulated radiotherapy|Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
219181339|NCT04430179|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
219181340|NCT04430179|OTHER|Placebo|No active drug
219753765|NCT01151267|OTHER|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
218995005|NCT01779401|DRUG|Aspirin 100mg|
218995006|NCT01779401|DRUG|Cilostazol 100mg|
218995007|NCT05192681|DRUG|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
218995008|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
218995009|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
218995010|NCT02671396|BEHAVIORAL|Virtual reality based intervention|Virtual reality based balance training
219181341|NCT05415904|OTHER|HANTA-NE|Observational cohort study
219181342|NCT05506449|DEVICE|Impella CP®|"Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm."
219753766|NCT01151267|DEVICE|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
218995011|NCT02671396|BEHAVIORAL|Conventional intervention|Conventional balance training
218995012|NCT04235478|DRUG|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
218995013|NCT02566434|DIETARY_SUPPLEMENT|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
218995014|NCT00977899|BIOLOGICAL|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
218995015|NCT05246501|OTHER|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
218995016|NCT05246501|OTHER|No simulation|The students in the control group did not receive simulation training.
218995017|NCT02370160|BIOLOGICAL|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
218995018|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
219181343|NCT05506449|OTHER|Standard of Care|This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
219181344|NCT06417918|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
218995019|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
218995020|NCT03055793|OTHER|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
218995021|NCT05738668|OTHER|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
218995022|NCT01456468|DRUG|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
218995023|NCT01502059|OTHER|Pilates|Pilates training - twice a week (one hour per class) during 90 days
218995024|NCT03296241|DEVICE|laser|
218995025|NCT03296241|DEVICE|sham control|
218995026|NCT04010487|GENETIC|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
218995027|NCT02505997|DRUG|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
218995028|NCT02505997|DRUG|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
218995029|NCT02917304|BIOLOGICAL|GC3110A vaccine|0.5mL, Intramuscular
218995030|NCT01314573|BEHAVIORAL|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
219753767|NCT03580044|COMBINATION_PRODUCT|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
218995031|NCT01314573|BEHAVIORAL|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
218995032|NCT04487730|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
218995033|NCT04487730|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
218995034|NCT01954550|BEHAVIORAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
218995035|NCT01954550|BEHAVIORAL|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
218995036|NCT00468325|PROCEDURE|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
218995037|NCT00468325|PROCEDURE|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
218995038|NCT00468325|PROCEDURE|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
218995039|NCT01458652|DRUG|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
218995040|NCT02551757|DEVICE|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
219181345|NCT03208686|BEHAVIORAL|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
219181346|NCT05092386|BIOLOGICAL|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
218995041|NCT02551757|DEVICE|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
218995042|NCT06293807|DRUG|Xylocaine 2 % with 1:100,000 epinephrine|Local anesthetic used during dental procedures
218995043|NCT06293807|DRUG|Bupivicaine 0.5% with 1:200,000 epinephrine|Local anesthetic used during dental procedures
218995044|NCT06293807|OTHER|Placebo|0.9% Normal Saline solution used in place of local anesthetic
218995045|NCT02734940|DRUG|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
218995046|NCT02734940|DRUG|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
218995047|NCT02734940|DRUG|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
218995048|NCT02734940|DRUG|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
218995049|NCT02734940|DRUG|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
218995050|NCT04221841|OTHER|descriptive|correlation
218995051|NCT02252094|DEVICE|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
218995052|NCT02252094|OTHER|Ultra-protective ventilation|Ventilation with \</= 3ml/kg predicted body weight
218995053|NCT02252094|OTHER|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
218995054|NCT03232957|PROCEDURE|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
219181347|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
219181348|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
218995055|NCT03232957|PROCEDURE|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
218995056|NCT03232957|PROCEDURE|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
218995057|NCT03232957|DRUG|Morphine|intrathecal morphine
218995058|NCT03232957|DRUG|Bupivacaine|0.5 isobaric bupivacaine
219369608|NCT05249049|DEVICE|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
218995059|NCT05695443|BEHAVIORAL|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
218995060|NCT05884723|DIETARY_SUPPLEMENT|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
218995061|NCT05124964|OTHER|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
219181349|NCT04204265|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
219181350|NCT04325334|BEHAVIORAL|Running volume increase|"Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the 10% rule advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run."
219181351|NCT05523999|OTHER|Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA|Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.
219181352|NCT02165007|DRUG|peripheral blood stem cell graft that are CD34+ selected|The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
219181353|NCT05086497|DIAGNOSTIC_TEST|Whole Brain Spectroscopy Imaging Array Mapping Layout|All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
219181354|NCT04908423|DRUG|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
219181355|NCT06137482|DRUG|REGN13335|Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
219181356|NCT06137482|DRUG|Matching Placebo|Administered IV or SC, sequential ascending single dose
219181357|NCT04983368|DRUG|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
219181358|NCT04983368|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
219753768|NCT03580044|DRUG|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
219753769|NCT01365754|PROCEDURE|standard|fusion
219753770|NCT01365754|PROCEDURE|new|dynamic stabilization
218995062|NCT05124964|OTHER|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
218995063|NCT05124964|OTHER|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
218995064|NCT05894928|DRUG|LOXO-783|Administered orally.
218995065|NCT05894928|DRUG|Cholestyramine|Administered orally.
218995066|NCT04047498|DEVICE|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
218995067|NCT01785550|OTHER|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
218995068|NCT02524795|DIETARY_SUPPLEMENT|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
218995069|NCT04593225|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
218995070|NCT04593225|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
218995071|NCT04287244|DEVICE|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
218995072|NCT01894191|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
218995073|NCT01894191|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
218995074|NCT01894191|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
218995075|NCT02710565|OTHER|Cohort|Obtaining additional EBUS TBNA samples for cell culture
218995076|NCT02206568|DRUG|URAL|
218995077|NCT00902408|DIETARY_SUPPLEMENT|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
219181359|NCT04983368|DRUG|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
219181360|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
218995078|NCT03291808|BEHAVIORAL|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
219181361|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
218995079|NCT03875885|BEHAVIORAL|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
219181362|NCT04324164|DRUG|Third-generation EGFR-TKI|Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
219181363|NCT04324164|DRUG|EGFR-TKI|All EGFR-TKI
219181364|NCT06490276|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
219181365|NCT06490276|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
219181366|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
219181367|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
219369609|NCT00706628|DRUG|BIBF 1120|
219369610|NCT00706628|DRUG|BIBW 2992|
219369611|NCT00706628|DRUG|Sequential BIBF 1120 + BIBW 2992|
219369612|NCT02235649|BEHAVIORAL|Social Cognition therapy ( Psychological Therapy)|
218995080|NCT03875885|BEHAVIORAL|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
218995081|NCT05814978|OTHER|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
218995082|NCT00056524|DRUG|AVP-923|
218995083|NCT01265732|DRUG|PF-04191834|single dose, 100mg, dispersion
218995084|NCT01265732|DRUG|PF-04191834|single dose, 100mg, suspension
218995085|NCT01265732|DRUG|PF-04191834|single dose, 300mg, suspension
218995086|NCT00205738|DRUG|Risperidone, Olanzapine|
218995087|NCT02924779|OTHER|No intervention|Retrospective observational study
218995088|NCT01120301|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
218995089|NCT05014763|PROCEDURE|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
218995090|NCT02821182|RADIATION|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."
218995091|NCT03269942|PROCEDURE|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
218995092|NCT03269942|PROCEDURE|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
218995093|NCT02837094|DRUG|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
218995094|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
218995095|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
219181368|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
219181369|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
218995096|NCT02300584|OTHER|iPad|a tablet computer with an internet connection
218995097|NCT00299455|DRUG|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
218995098|NCT00299455|DRUG|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
218995099|NCT02702505|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
218995100|NCT02702505|OTHER|ProRoot MTA|Control group
218995101|NCT01892293|DRUG|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
218995102|NCT00005045|DRUG|carboxyamidotriazole|
218995103|NCT00569569|DRUG|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
218995104|NCT03506178|DRUG|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
219369613|NCT01574534|DEVICE|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
218995105|NCT03506178|DRUG|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
218995106|NCT03506178|DRUG|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
219369614|NCT01574534|DEVICE|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
219369615|NCT00443508|DRUG|adding Certican to therapy|
219369616|NCT00443508|DRUG|reducing Tacrolimus|
219369617|NCT05106530|DIAGNOSTIC_TEST|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
218995107|NCT03506178|DEVICE|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
218995108|NCT03660267|OTHER|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
218995109|NCT03660267|OTHER|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
218995110|NCT03660267|OTHER|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
218995111|NCT02297477|DRUG|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
218995112|NCT02297477|DRUG|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
218995113|NCT03740061|DIAGNOSTIC_TEST|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
218995114|NCT03999372|BIOLOGICAL|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
218995115|NCT03999372|OTHER|ICSI|Normal ICSI procedure
219181370|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
219181371|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
219181372|NCT05038878|DRUG|Elagolix|Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
219181373|NCT04985487|OTHER|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
219181374|NCT01783288|OTHER|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
219181375|NCT01783288|OTHER|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
219181376|NCT01783288|PROCEDURE|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
218995116|NCT03490097|DRUG|Simvastatin 10mg|tablets
218995117|NCT03490097|DRUG|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
218995118|NCT03602482|BEHAVIORAL|Standing|Participants will stand and complete cognitive tests.
218995119|NCT03602482|BEHAVIORAL|Supine|Participants will complete cognitive tests while supine.
218995120|NCT01445262|DRUG|Levocetirizine|
218995121|NCT02397278|DRUG|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
218995122|NCT05403281|DRUG|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
218995123|NCT05541120|DEVICE|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
218995124|NCT02720471|DRUG|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
218995125|NCT02720471|DRUG|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
218995126|NCT02467868|BIOLOGICAL|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
218995127|NCT02467868|BIOLOGICAL|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
218995128|NCT04344509|OTHER|Bacterial species isolated|in the respiratory specimen
218995129|NCT00192556|BEHAVIORAL|food|
218995130|NCT00164775|DRUG|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
218995131|NCT00164775|DRUG|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
218995132|NCT02222974|DRUG|BIIR 561 CL|
218995133|NCT02222974|DRUG|Placebo|
218995134|NCT04503902|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
218995135|NCT04503902|DRUG|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
218995136|NCT01180946|DIETARY_SUPPLEMENT|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
218995137|NCT01180946|OTHER|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
218995138|NCT03744091|DRUG|P1|10 mg or 20 mg of THC:THCa
218995139|NCT06293404|DRUG|Bupivacain|7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)
218995140|NCT01991210|DRUG|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
218995141|NCT01991210|DRUG|PLD|PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
218995142|NCT01158300|DRUG|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
218995143|NCT02381288|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
218995144|NCT02381288|DRUG|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
218995145|NCT01578460|DEVICE|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
218995146|NCT01578460|DEVICE|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
218995147|NCT00657527|DRUG|Rosuvastatin|
218995148|NCT00657527|BEHAVIORAL|Cholesterol lowering diet|
218995149|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
218995150|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
218995151|NCT01397084|DRUG|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
218995152|NCT00869674|PROCEDURE|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
218995153|NCT03202498|DEVICE|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
218995154|NCT03202498|OTHER|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
218995155|NCT03202498|DEVICE|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
218995156|NCT03202498|OTHER|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
218995157|NCT00542854|DEVICE|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
218995158|NCT02139228|BIOLOGICAL|Hib-CRM197|No vaccine administered in V37\_07E2 study
218995159|NCT02139228|BIOLOGICAL|Hib-TT|No vaccine administered in V37\_07E2 study
218995160|NCT01108302|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
218995161|NCT04670848|DEVICE|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
218995162|NCT03185767|OTHER|blood sampling|blood sampling
218995163|NCT02301052|DRUG|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
218995164|NCT02301052|DRUG|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
218995165|NCT02301052|DRUG|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
218995166|NCT02471430|DRUG|Panobinostat|Panobinostat will be administered orally.
218995167|NCT02471430|DRUG|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
218995168|NCT03555201|OTHER|Manual therapy|protocol of soft tissues techniques
218995169|NCT03555201|OTHER|Regular treatment control.|Regular treatment control.
218995170|NCT00618072|DRUG|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
219181377|NCT01783288|OTHER|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
218995171|NCT03292588|BIOLOGICAL|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
218995172|NCT03292588|DRUG|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
218995173|NCT01264497|DRUG|TH9507|1 and 2 mg, sc daily for 12 weeks
218995174|NCT02395380|OTHER|C-reactive protein dosage|
218995175|NCT04479423|PROCEDURE|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
218995176|NCT00062374|DRUG|Cisplatin|Given IV
218995177|NCT00062374|PROCEDURE|Computed Tomography|Undergo FDG and FLT PET/CT
218995178|NCT00062374|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
218995179|NCT00062374|OTHER|Fluorothymidine F-18|Undergo FLT-PET/CT
218995180|NCT00062374|DRUG|Irinotecan Hydrochloride|Given IV
218995181|NCT00062374|PROCEDURE|Positron Emission Tomography|Undergo FDG and FLT PET/CT
218995182|NCT00062374|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
218995183|NCT04083053|PROCEDURE|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
218995184|NCT04083053|PROCEDURE|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
218995185|NCT05512845|PROCEDURE|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
218995186|NCT02870582|DRUG|Donafenib|treatment drug
218995187|NCT02870582|DRUG|Placebo|Best support treatment
218995188|NCT05339568|OTHER|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
218995189|NCT01211327|DRUG|Cyclosporine A|Cyclosporine 2% eye drops
218995190|NCT01211327|DRUG|Dexamethasone|Dexamethasone 0,1% eye drops
218995191|NCT05593393|DEVICE|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
218995192|NCT01613404|OTHER|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
218995193|NCT06140784|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
218995194|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
218995195|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
218995196|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
218995197|NCT04817865|DIAGNOSTIC_TEST|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
218995198|NCT04817865|DIAGNOSTIC_TEST|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
218995199|NCT05887726|DRUG|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
218995200|NCT05887726|DRUG|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
218995201|NCT05887726|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
218995202|NCT05887726|DRUG|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
218995203|NCT05887726|DRUG|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
218995204|NCT05887726|DRUG|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
218995205|NCT03710538|DIETARY_SUPPLEMENT|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
218995206|NCT03710538|BEHAVIORAL|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
218995207|NCT02266121|DEVICE|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
218995208|NCT04072302|DRUG|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
218995209|NCT04072302|DRUG|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
218995210|NCT00869349|BEHAVIORAL|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
218995211|NCT00869349|OTHER|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
218995212|NCT03633695|DEVICE|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
218995213|NCT03633695|DEVICE|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
218995214|NCT06446700|OTHER|neck disability index and visual functional questionnaire|participants complete the 2 questionnaire by an online form and paper
218995215|NCT00487773|DRUG|budesonide|budesonide
218995216|NCT00487773|DRUG|D3 vitamin|D3 vitamin
218995217|NCT00487773|DRUG|montelukast sodium|montelukast sodium
218995218|NCT00487773|DRUG|salbutamol|salbutamol
218995219|NCT00436683|DRUG|Fermagate|Film coated tablet 500mg
218995220|NCT00436683|DRUG|Sevelamer HCl|tablet 800mg
218995221|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
218995222|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
218995223|NCT01087398|DRUG|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
218995224|NCT01087398|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
218995225|NCT01087398|DRUG|Cyclosporin, Methotrexate (GVHD prophylaxis)|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
218995226|NCT01882491|DRUG|Placebo|Solution for subcutaneous injection
218995227|NCT01882491|DRUG|gevokizumab|Solution for subcutaneous injection
218995228|NCT03876444|DRUG|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
218995229|NCT03876444|DRUG|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
218995230|NCT02728050|DRUG|Cladribine|Given IV
218995231|NCT02728050|DRUG|Cytarabine|Given IV
219181378|NCT06454812|DEVICE|Mechanical vibration|The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The same procedure was repeated for DTaP-IPV-Hib vaccine administered to the the right extremity. The baby will be swaddled and placed in the mother's lap.
218995232|NCT02728050|BIOLOGICAL|Filgrastim|Given SC
218995233|NCT02728050|OTHER|Laboratory Biomarker Analysis|Correlative studies
218995234|NCT02728050|OTHER|Quality-of-Life Assessment|Ancillary studies
218995235|NCT02728050|DRUG|Mitoxantrone|Given IV
218995236|NCT02728050|DRUG|Sorafenib|Given PO
218995237|NCT00798499|OTHER|Laboratory variables|1 visit
218995238|NCT02380677|DRUG|CRLX301|
218995239|NCT00983021|DRUG|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
218995240|NCT00983021|DRUG|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
218995241|NCT00983021|DRUG|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
218995242|NCT00983021|DRUG|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
218995243|NCT06217055|DRUG|remimazolam based MAC|The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
219191590|NCT05840354|DEVICE|Magstim Rapid2|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
219753771|NCT00251433|DRUG|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
218995244|NCT06217055|DRUG|general anesthesia with sevoflurane|The surgery will be performed under mechanical ventilation with inhalation general anesthesia
218995245|NCT02968953|DRUG|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
218995246|NCT01512277|BIOLOGICAL|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
218995247|NCT02673437|OTHER|This is a non-interventional study|This is a non-interventional study
218995248|NCT03629132|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
218995249|NCT03629132|PROCEDURE|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
218995250|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
218995251|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
218995252|NCT05295511|OTHER|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
218995253|NCT04522362|OTHER|Control task and Trier Social Stress Task|Same as Arm
218995254|NCT02322034|OTHER|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
218995255|NCT00189254|DRUG|Imiquimod|No defined treatments were given during this study.
218995256|NCT03519425|OTHER|Optimised HIV screening and linkage to care|As described in group descriptions
218995257|NCT03519425|OTHER|Optimised tuberculosis screening and linkage to care|As described in group descriptions
219753772|NCT00481936|DRUG|VB6-845|Intravenous infusion once weekly for 4 weeks
219753773|NCT06446570|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
218995258|NCT05371743|DIAGNOSTIC_TEST|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆\_Ct) method
218995259|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
218995260|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
218995261|NCT02799511|BIOLOGICAL|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
218995262|NCT03041597|PROCEDURE|placement of implants|surgical procedure and placement of implants
219753774|NCT01664624|DRUG|Roflumilast|Roflumilast tablets
218995263|NCT03041597|PROCEDURE|immediate loading|cone-anchored implant supported removable dental prostheses placement
218995264|NCT03041597|PROCEDURE|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
219753775|NCT01664624|DRUG|Alogliptin|Alogliptin tablets
219753776|NCT01664624|DRUG|Exenatide|Exenatide solution
219753777|NCT01664624|DRUG|Placebo to roflumilast|Placebo-matching roflumilast tablets
219753778|NCT01664624|DRUG|Placebo to alogliptin|Placebo-matching alogliptin tablets
219753779|NCT03481439|OTHER|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
218995265|NCT03041597|DEVICE|Ankylos implant|
218995266|NCT04950309|DEVICE|SQUID MEG|MEG recordings acquired on a standard whole brain SQUID MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
218995267|NCT04950309|DEVICE|OPM MEG|MEG recordings acquired on an investigational OPM MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
218995268|NCT04187014|DRUG|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
218995269|NCT04187014|DRUG|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
218995270|NCT02891759|OTHER|Alloderm RTU|-Most commonly used acellular dermal matrices
219191591|NCT05840354|DEVICE|Placebo D70mm Air Film Coil|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
219753780|NCT06310382|DRUG|GH55|GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
219753781|NCT01195974|DRUG|YASMIN|YASMIN for 21 days
219753782|NCT01195974|DRUG|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
219753783|NCT01195974|OTHER|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
219753784|NCT00360139|DEVICE|Sculptra Injection|
219753785|NCT04506684|DEVICE|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
219753786|NCT01662206|DIETARY_SUPPLEMENT|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
219753787|NCT01662206|DIETARY_SUPPLEMENT|Placebo|2 capsules daily containing 348.25 mg of potato starch
219753788|NCT04542928|BEHAVIORAL|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
219753789|NCT05623020|DRUG|Elranatamab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
219753790|NCT05623020|DRUG|Daratumumab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
219753791|NCT05623020|DRUG|Lenalidomide|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
219753792|NCT05623020|DRUG|Dexamethasone|Randomized
219753793|NCT01336348|DRUG|Prasugrel|60 mg loading dose given orally at presentation
219753794|NCT01336348|DRUG|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
219753795|NCT01593540|DEVICE|metal-free interdental brush|one time per day
219753796|NCT01593540|DEVICE|metal-core interdental brush|one time per day
219753797|NCT06416813|PROCEDURE|GDMT+DCB|Preventive Intervention on Eligible Vulnerable Plaques Using DCB
219753798|NCT06418958|DEVICE|Red Light|Light Curing with Red Light
219753799|NCT06418958|DEVICE|Blue Light|Light Curing with Blue Light
219753800|NCT03186547|DRUG|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
219753801|NCT03186547|PROCEDURE|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
219753802|NCT06467682|OTHER|tele-exercise|The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
218995271|NCT02891759|OTHER|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
218995272|NCT02891759|PROCEDURE|Skin or nipple-sparing mastectomy|-Standard of care
219753803|NCT02234193|DEVICE|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
219753804|NCT02234193|PROCEDURE|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
219753805|NCT00844506|DRUG|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
219753806|NCT00844506|DRUG|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
219753807|NCT01727934|DRUG|Miravirsen sodium|Subcutaneous injection
218995273|NCT02891759|OTHER|Breast Q|"* 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
218995274|NCT02891759|PROCEDURE|Surgery|"* To address the tissue expander~* Standard of care"
218995275|NCT00889460|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
219753808|NCT00127439|PROCEDURE|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
219753809|NCT00127439|OTHER|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
218995276|NCT00889460|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
218995277|NCT06457321|PROCEDURE|Sequence in receiving the fabricated dentures made using the conventional and partial digital method|Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
218995278|NCT00688974|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
219369618|NCT04928014|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
219369619|NCT02618369|DEVICE|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
219369620|NCT02924701|OTHER|Blood samples, fibroscan and questionaires|
219369621|NCT00295269|DRUG|Mythylprednisolone|
219753810|NCT04782921|DEVICE|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
219753811|NCT03364504|OTHER|urine collection|3 urine collections during 24 hours
219753812|NCT02456129|DRUG|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
219753813|NCT02456129|DRUG|[14C] Vilaprisan|an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
219753814|NCT02456129|OTHER|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
219753815|NCT00751478|DRUG|ALO-01|ALO-01 capsules
219753816|NCT00751478|DRUG|MSIR|immediate release morphine sulfate
219753817|NCT00751478|DRUG|Placebo|Placebo
219753818|NCT04252209|OTHER|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
219753819|NCT04252209|OTHER|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
219753820|NCT03483948|DRUG|HMPL-523|HMPL-523 tablet
219753821|NCT03483948|DRUG|Azacitidine|Azacitidine Injection
219753822|NCT03344484|OTHER|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
219753823|NCT02398214|BEHAVIORAL|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to \< 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
218995279|NCT00688974|PROCEDURE|Adjustable gastric band|Laparoscopic adjustable gastric band
218995280|NCT00007969|BIOLOGICAL|Detox-B adjuvant|
218995281|NCT00007969|DRUG|verteporfin|
218995282|NCT03552653|DIETARY_SUPPLEMENT|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
218995283|NCT05779293|DEVICE|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
219753824|NCT00619775|DEVICE|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
219753825|NCT03326908|DEVICE|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
219753826|NCT02927444|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
219753827|NCT02927444|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
218995284|NCT05779293|OTHER|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
218995285|NCT04039815|DRUG|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
218995286|NCT04039815|DRUG|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
218995287|NCT01344005|OTHER|caregiver-related intervention or procedure|
218995288|NCT01344005|OTHER|questionnaire administration|
218995289|NCT01344005|PROCEDURE|quality-of-life assessment|
218995290|NCT01344005|PROCEDURE|radiography|
218995291|NCT03102372|DIETARY_SUPPLEMENT|Whey protein supplementation|
218995292|NCT03102372|OTHER|walking program|
218995293|NCT03102372|OTHER|Very Low Calorie Diet|
218995294|NCT05349916|OTHER|Control|300 g rice porridge + 150 ml drinking water
218995295|NCT05349916|OTHER|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
218995296|NCT05349916|OTHER|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
218995297|NCT05349916|OTHER|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
218995298|NCT05349916|OTHER|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
218995299|NCT06201377|OTHER|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
219181379|NCT06454812|BEHAVIORAL|Helfer skin tap technique (HSTT)|In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4).
219181380|NCT02141919|RADIATION|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
219753828|NCT04513925|DRUG|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
219753829|NCT04513925|DRUG|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
218995300|NCT06201377|OTHER|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
218995301|NCT00284271|DRUG|Cyclophosphamide|
218995302|NCT00284271|DRUG|Adramycin|
218995303|NCT00284271|DRUG|Procarbacine|
218995304|NCT00284271|DRUG|Prednisone|
218995305|NCT00284271|DRUG|Vincristine|
218995306|NCT00284271|DRUG|Bleomycin|
218995307|NCT00284271|DRUG|Erythropoietin beta|
218995308|NCT05234151|OTHER|NEWS|Newborn Early Warning Score
218995309|NCT03598621|DRUG|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
218995310|NCT03598621|DRUG|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
218995311|NCT03598621|DRUG|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
218995312|NCT03598621|DRUG|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
218995313|NCT03598621|DEVICE|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
218995314|NCT03598621|DEVICE|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
218995315|NCT03598621|DEVICE|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
218995316|NCT03598621|DEVICE|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
218995317|NCT06131177|DIETARY_SUPPLEMENT|Nutritional supplement|Protein supplement
218995318|NCT01752127|PROCEDURE|percutaneous coronary intervention using drug eluting stent|"1\. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
218995319|NCT02759432|OTHER|High-intensity interval exercise training|
218995320|NCT04970797|DRUG|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
218995321|NCT03351803|OTHER|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
218995322|NCT02314416|BIOLOGICAL|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
218995323|NCT05572450|OTHER|Infectious Titre 1|Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
218995324|NCT05572450|OTHER|Infectious Titre 2|Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
218995325|NCT05572450|OTHER|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
218995326|NCT05572450|OTHER|Infectious Titre 4|TBD, depending on outcome of Part A
218995327|NCT05155059|DEVICE|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
218995328|NCT05155059|OTHER|Sham Comparator|Sham TMS stimulation using a sham coil
218995329|NCT04525417|DIAGNOSTIC_TEST|AAZ Covid-19 rapid test|To assess the immune status
218995330|NCT05117437|OTHER|Physiological test|This test was conducted to determine the endurance levels of the participants.
218995331|NCT05117437|OTHER|Physical test|Height, weight, and BMI were determined
218995332|NCT05117437|OTHER|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
218995333|NCT05217147|OTHER|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
218995334|NCT03939260|OTHER|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).
218995335|NCT03004456|OTHER|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
218995336|NCT04020965|BEHAVIORAL|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
218995337|NCT04020965|BEHAVIORAL|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
218995338|NCT04020965|BEHAVIORAL|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
219181381|NCT06493227|OTHER|No routine fibrinolysis inhibitors after surgery|Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.
219753830|NCT04513925|DRUG|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
219753831|NCT04943848|BIOLOGICAL|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
219753832|NCT04943848|DRUG|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
219753833|NCT04943848|DRUG|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
219181382|NCT06493227|OTHER|Routine fibrinolysis inhibitors after surgery|During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
219181383|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
219753834|NCT04565457|DEVICE|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
219753835|NCT06308978|DRUG|FT819|FT819 will be administered as intravenous (IV) infusion at planned dose levels.
219753836|NCT06308978|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
219753837|NCT06308978|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
219181384|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
219181385|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
219181386|NCT04099394|BEHAVIORAL|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
219181387|NCT04099394|BEHAVIORAL|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
219181388|NCT06426940|OTHER|anesthesia-related critical events|anesthesia-related critical events
219181389|NCT03931174|BEHAVIORAL|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
219181390|NCT03931174|BEHAVIORAL|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
219181391|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
219181392|NCT03322267|DRUG|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
219181393|NCT06177912|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219181394|NCT06177912|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219181395|NCT05513443|PROCEDURE|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
219181396|NCT05513443|PROCEDURE|Radical prostatectomy|Radical prostatectomy
219181397|NCT05513443|RADIATION|Radiation therapy|Radiation therapy for prostate cancer
219181398|NCT06005168|DRUG|Cefazolin for Injection|2 grams or 3 grams based on standard of care or morphomic-based decision
219181399|NCT06036914|DRUG|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
219181400|NCT06036914|DRUG|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
219181401|NCT05898529|DIAGNOSTIC_TEST|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
219181402|NCT03046251|DRUG|Natalizumab|
219181403|NCT05119387|OTHER|Observation|Observation of genetic characteristics
219181404|NCT05757453|DEVICE|mHealth|Mobile platform
219753838|NCT06308978|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
218995339|NCT04020965|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
218995340|NCT02442518|PROCEDURE|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
218995341|NCT03254836|OTHER|Standard of care|Elective radical surgery for adenocarcinoma.
218995342|NCT04294576|DRUG|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
218995343|NCT04294576|DRUG|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
218995344|NCT02786797|BEHAVIORAL|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
218995345|NCT02786797|BEHAVIORAL|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
218995346|NCT05473702|DEVICE|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
218995347|NCT01354990|DRUG|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
218995348|NCT02807532|OTHER|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
218995349|NCT02807532|OTHER|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
218995350|NCT02067338|DRUG|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
218995351|NCT02067338|DRUG|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
219181405|NCT05251129|DRUG|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
219181406|NCT05251129|DRUG|Pravastatin 40 Mg Oral Tablet|Lower intensity statin
219181407|NCT06742593|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
218995352|NCT06499597|OTHER|Observation|All individuals included in the study will be included in this group and evaluations will be made.
218995353|NCT02170298|DRUG|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
218995354|NCT04366102|OTHER|Multisensory stimulation with soft tissue therapy|Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week
218995355|NCT04366102|OTHER|Routine hospital care|Routine hospital care will be given to the preterm neonates
218995356|NCT00027898|DRUG|bortezomib|Given IV
219181408|NCT05564104|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
219181409|NCT03705416|PROCEDURE|Endoscopy|endoscopic suturing of stomach
219181410|NCT03705416|PROCEDURE|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
219181411|NCT06075615|DRUG|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
219753839|NCT06434636|DRUG|Transamine 10% IV/IM Solution for Injection|10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
219753840|NCT06434636|DRUG|%0.9 Saline|100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
219753841|NCT05985954|DRUG|Cetuximab|Given by IV (vein)
219753842|NCT05985954|DRUG|Ulixertinib|Given by PO
218995357|NCT00027898|DRUG|carboplatin|Given IV
218995358|NCT00027898|DRUG|etoposide|Given IV
218995359|NCT00027898|OTHER|laboratory biomarker analysis|Correlative studies
219753843|NCT05985954|DRUG|Encorafenib|Given by PO
218995360|NCT00027898|OTHER|pharmacological study|Correlative studies
218995361|NCT01461603|DIETARY_SUPPLEMENT|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
218995362|NCT01461603|DIETARY_SUPPLEMENT|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
218995363|NCT03508479|BIOLOGICAL|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
218995364|NCT01976338|DRUG|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
218995365|NCT01976338|OTHER|Sham injection|Sham intravitreal injection
218995366|NCT00040573|DRUG|131I-TM-601|
218995367|NCT00987675|OTHER|pharmacological study|
218995368|NCT00987675|OTHER|questionnaire administration|
218995369|NCT00987675|PROCEDURE|assessment of therapy complications|
218995370|NCT00987675|PROCEDURE|high-intensity focused ultrasound ablation|
218995371|NCT00987675|PROCEDURE|quality-of-life assessment|
219181412|NCT03097536|OTHER|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
219753844|NCT06262321|RADIATION|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
218995372|NCT03530878|PROCEDURE|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
218995373|NCT01655914|DRUG|Flumazenil|
218995374|NCT00777608|DRUG|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
219369622|NCT02866864|OTHER|Animal allergy +|Allergic symptom occurs when subject contact animal
219753845|NCT04373369|DRUG|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
219753846|NCT04373369|DRUG|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
219753847|NCT04961957|DEVICE|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
219753848|NCT04961957|DEVICE|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
219753849|NCT04067011|DRUG|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
219753850|NCT04067011|DRUG|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
219753851|NCT04067011|BIOLOGICAL|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
218995375|NCT00777608|DRUG|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
218995376|NCT00777608|DRUG|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
218995377|NCT00777608|DRUG|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
218995378|NCT03148132|DRUG|Bevacizumab Injection|0.5mg/0.02 mL
218995379|NCT03148132|DRUG|Ranibizumab Ophthalmic|0.25mg/0.025 mL
218995380|NCT00158990|DRUG|triiodothyronine|
218995381|NCT00158990|DRUG|sertraline|
218995382|NCT01754701|DIETARY_SUPPLEMENT|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
218995383|NCT01754701|DIETARY_SUPPLEMENT|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
218995384|NCT05278767|OTHER|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
218995385|NCT02853604|DRUG|ADXS11-001|
218995386|NCT02853604|DRUG|Placebo|
218995387|NCT02688205|OTHER|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
218995388|NCT02688205|DEVICE|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
218995389|NCT04213079|DEVICE|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
218995390|NCT04213079|DEVICE|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
218995391|NCT04592601|PROCEDURE|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
219369623|NCT02866864|OTHER|Animal allergy -|Allergic symptom does not occur when subject contact animal
219369624|NCT00540891|DRUG|ALFUZOSIN|
219369625|NCT05241158|BEHAVIORAL|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
219369626|NCT05241158|BEHAVIORAL|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
219753852|NCT05664191|DRUG|Levosimendan|Infusion at 0.1 µg/kg/min at day 1 and day 8
218995392|NCT01145443|OTHER|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
219753853|NCT05664191|OTHER|Placebo|Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
219753854|NCT06100562|BEHAVIORAL|Adapted Dance Program|"* Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~* Each class will start with a 10 min warm-up that will include stretching and motor games.~* Learn a section of choreography every session using action-based intervention for 30 minutes.~* Break for 5 min.~* Improvisation part of class for 10 min.~* Cool-down for 5 min."
218995393|NCT02115893|DIETARY_SUPPLEMENT|Sodium Nitrate|
218995394|NCT02115893|DIETARY_SUPPLEMENT|Sodium Chloride|
218995395|NCT04786015|OTHER|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
218995396|NCT03910023|OTHER|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
218995397|NCT03910023|OTHER|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
218995398|NCT00844714|DRUG|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
218995399|NCT02469753|DRUG|NSAIDs|continuous daily
218995400|NCT02469753|DRUG|NSAIDs|on demand
218995401|NCT02469753|DRUG|anti-TNF|
219181413|NCT03360591|DEVICE|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
219181414|NCT06036836|BIOLOGICAL|favezelimab/pembrolizumab|IV infusion
219181415|NCT06036836|BIOLOGICAL|pembrolizumab|IV infusion
219369627|NCT04929990|BEHAVIORAL|Respiratory muscle training|Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
219753855|NCT04115631|DRUG|Acalabrutinib|Given PO
218995402|NCT03766581|DRUG|BMS-986177|Oral administration
219753856|NCT04115631|DRUG|Bendamustine|Given IV
219753857|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
218995403|NCT03766581|OTHER|Placebo|Oral Administration
218995404|NCT03766581|DRUG|Clopidogrel|Oral administration
218995405|NCT03766581|DRUG|Aspirin|Oral administration
218995406|NCT03501316|DEVICE|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
218995407|NCT03501316|DEVICE|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
218995408|NCT00477243|BEHAVIORAL|Questionnaire|8 questionnaires will take about 40 minutes to complete.
218995409|NCT06436365|PROCEDURE|Locking expert intramedullary nail fixation|"the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement."
219181416|NCT06036836|DRUG|lenvatinib|Oral administration of capsule
219181417|NCT05746299|BEHAVIORAL|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
219181418|NCT05746299|BEHAVIORAL|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
219753858|NCT04115631|DRUG|Cytarabine|Given IV
219753859|NCT04115631|BIOLOGICAL|Rituximab|Given IV
219181419|NCT05746299|BEHAVIORAL|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
219181420|NCT04786067|DRUG|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
219181421|NCT04392193|RADIATION|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
219181422|NCT05086250|DRUG|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
219181423|NCT05086250|DRUG|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
219181424|NCT05086250|DRUG|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
219181425|NCT05086250|DRUG|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
219181426|NCT06314724|BIOLOGICAL|Varicella Vaccine|lyophilized powder,subcutaneous injection
219181427|NCT06314724|BIOLOGICAL|Varivax|lyophilized powder,subcutaneous injection
219181428|NCT06332469|BEHAVIORAL|Internet based education and support program for patients awaiting kidney transplantation|"A guided internet based support an education program consisting of 9 modules running over 9 weeks. First, an introductory module is given that involves goal setting, followed by two educational modules with information regarding kidney disease, treatment and self-care in severe renal failure and while waiting for kidney transplantation, and kidney transplant-specific areas. Supportive content consist of three behavioral components spread over five modules/weeks and are based on cognitive behavioural therapy principles. The last module is a summation focusing on consolidating the knowledge learned during the program.~Each module consists of texts, illustrations, short films, reminders to practice physical activity and weekly homework for which the participants receive feedback from a contact person."
219181429|NCT05440630|DIETARY_SUPPLEMENT|Probiotics|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
219369628|NCT01264939|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
219369629|NCT01264939|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
219753860|NCT05763121|DRUG|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
218995410|NCT06436365|PROCEDURE|Distal locked plate|Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
218995411|NCT02732119|DRUG|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
218995412|NCT02732119|DRUG|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
218995413|NCT02732119|DRUG|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
218995414|NCT05818397|BEHAVIORAL|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and and up to two experienced SCCC facilitators. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
218995415|NCT04538261|DEVICE|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
218995416|NCT03701347|DEVICE|Reeve's model|Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
218995417|NCT03701347|DEVICE|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
218995418|NCT03701347|DEVICE|Ida's model|Reusable, portable and modular 3D printed simulator
218995419|NCT05802511|DEVICE|Exablate treatment|Exablate treatment for Neuropathic Pain
218995420|NCT06960421|BEHAVIORAL|XFIT|XFIT is an 8-week telehealth-delivered, home-based exercise/behavior modification intervention. It integrates theoretical frameworks of behavior change to engage frail lung transplant candidates in program of pre-habilitation.
218995421|NCT00571545|BEHAVIORAL|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
218995422|NCT00571545|BEHAVIORAL|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
218995423|NCT05184985|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
218995424|NCT05184985|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
218995425|NCT04446000|BIOLOGICAL|CSL730|solution for injection and infusion
219753861|NCT05763121|DRUG|Placebo|oral administration of placebo tablet
219753862|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
218995426|NCT04446000|DRUG|Placebo|A solution matching the excipient profile of CSL730 without the active substance
218995427|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
219753863|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
219753864|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
218995428|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
218995429|NCT01529502|DRUG|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
218995430|NCT03397537|DRUG|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
218995431|NCT03397537|DRUG|GnRH analogue|3.75 mg triptorelin im. q28d
218995432|NCT05598541|PROCEDURE|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
218995433|NCT01552200|PROCEDURE|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
218995434|NCT01552200|PROCEDURE|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
218995435|NCT02019693|DRUG|INC280|Supplied by Novartis as film-coated tablet for oral use.
218995436|NCT02611219|OTHER|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"* 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time"
218995437|NCT02611219|OTHER|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"* 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
218995438|NCT02611219|OTHER|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
218995439|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
219753865|NCT04153292|DEVICE|SAPIEN M3 valve and dock|During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
219753866|NCT05209386|BEHAVIORAL|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
218995440|NCT02611219|OTHER|General Health Module-Baseline Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
218995441|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
218995442|NCT02611219|OTHER|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
218995443|NCT02611219|OTHER|SCT Daily Activity Log|"* Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
218995444|NCT02611219|OTHER|The Functional Independence Measure for Children|"* 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
218995445|NCT02611219|OTHER|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
218995446|NCT02611219|OTHER|3-Minute Step Test|"* Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
218995447|NCT02611219|OTHER|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"* 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
218995448|NCT02611219|OTHER|HSCT Module-Follow Child-Self Report (5-12 years)|"* 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
218995449|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
218995450|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
218995451|NCT03146013|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
219181430|NCT05440630|DIETARY_SUPPLEMENT|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
219181431|NCT05440630|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
219181432|NCT06127914|BEHAVIORAL|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
219181433|NCT03267758|DIETARY_SUPPLEMENT|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
219181434|NCT03267758|DIETARY_SUPPLEMENT|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
219753867|NCT05837676|BEHAVIORAL|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
218995452|NCT04876924|DRUG|BBP-711|BBP-711, oral suspension
218995453|NCT04876924|DRUG|Placebo|Placebo matching BBP-711
218995454|NCT04343547|DRUG|DWP16001|Tablets, Oral, once daily single dose
219181435|NCT03852472|DRUG|Avacopan|Active treatment
219181436|NCT03852472|OTHER|Placebo|Placebo
218995455|NCT04343547|DRUG|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
218995456|NCT04343547|DRUG|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
218995457|NCT00251784|DRUG|Sildenafil|
218995458|NCT02099708|DRUG|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
218995459|NCT00082251|DRUG|Niacin extended release and simvastatin tablets|
218995460|NCT04802291|BEHAVIORAL|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
218995461|NCT01184391|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
218995462|NCT01184391|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
218995463|NCT03282682|PROCEDURE|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
218995464|NCT03655509|PROCEDURE|Dynamic test ACTH stimulation|
218995465|NCT00549081|DIETARY_SUPPLEMENT|DHEA|oral DHEA tablets 75 mg daily
218995466|NCT01284829|OTHER|FDG-PET scan|
219181437|NCT05017766|OTHER|analysis of antimicrobial resistance|"In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data."
219181438|NCT06214312|DIAGNOSTIC_TEST|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
219181439|NCT06104839|DRUG|NXC736|oral administration
219181440|NCT06104839|DRUG|Placebo|oral administration
219181441|NCT04029337|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
219181442|NCT05627167|OTHER|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
219181443|NCT05627167|OTHER|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
219181444|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
219181445|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
219181446|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
219181447|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
219181448|NCT06125860|DIETARY_SUPPLEMENT|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
219181449|NCT06648642|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues
219181450|NCT06649552|DIAGNOSTIC_TEST|Psychiatric and psychological diagnostic tests|French validation of the SPI-CY
219181451|NCT04060082|OTHER|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
219181452|NCT05533216|OTHER|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
219181453|NCT05022485|DEVICE|ZNN Bactiguard tibia|Tibia fracture fixation
219181454|NCT06457802|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
219181455|NCT06380114|BEHAVIORAL|Communication|Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.
219181456|NCT06380114|BEHAVIORAL|Standing Orders|Practice personnel (providers and nurses) receive training in the implementation of standing orders for HPV vaccination via an online learning module and meetings with the study team.
219181457|NCT04870177|DRUG|AK112|AK112 infusion biweekly
219181458|NCT01467427|DRUG|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
219181459|NCT03161028|DRUG|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
219181460|NCT03161028|DRUG|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
219181461|NCT03497962|PROCEDURE|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
219181462|NCT03497962|PROCEDURE|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
218995467|NCT02723214|PROCEDURE|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
218995468|NCT03008603|DEVICE|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
218995469|NCT03064997|DIETARY_SUPPLEMENT|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
218995470|NCT03064997|DIETARY_SUPPLEMENT|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
218995471|NCT01609374|DEVICE|M6-C Artificial Cervical Disc|Total disc replacement
218995472|NCT01609374|DEVICE|Anterior plate system with corticocancellous allograft bone|Cervical fusion
218995473|NCT03182478|BEHAVIORAL|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
218995474|NCT03182478|BEHAVIORAL|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
218995475|NCT05517915|OTHER|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
218995476|NCT05517915|OTHER|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
218995477|NCT05466682|BEHAVIORAL|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
218995478|NCT05466682|BEHAVIORAL|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
218995479|NCT01697566|DRUG|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
218995480|NCT01697566|OTHER|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
218995481|NCT01697566|PROCEDURE|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
218995482|NCT01697566|BEHAVIORAL|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
218995483|NCT01697566|BEHAVIORAL|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
218995484|NCT06620146|OTHER|mechanical bathing|Providing mechanical bathing (MB) is a commonly used strategy to maintain cleanness and comfort in patients with terminally illness. The electric medical bathtub (ARJO, Rhapsody) provides functions such as showering, bathing, and water massage. The MB will be operated by 2-3 nursing staff, trained hospice volunteers, or researchers. Each patient\&amp;#39;s MB process lasts about 20 minutes, including washing the hair and body with a handheld showerhead, followed by soaking in warm water for about 5-10 minutes. Based on the patient preference, the water temperature is adjusted between 38 to 40 degrees Celsius.
218995485|NCT01930123|DRUG|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
218995486|NCT01930123|OTHER|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
218995487|NCT04171050|DRUG|Local anaesthetic|Local anesthesia injections
218995488|NCT04171050|DRUG|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
219181463|NCT03492216|BEHAVIORAL|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
219181464|NCT03492216|BEHAVIORAL|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
218995489|NCT01447433|DRUG|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
218995490|NCT01447433|BEHAVIORAL|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
218995491|NCT00036270|DRUG|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
218995492|NCT00036270|DRUG|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
218995493|NCT00593502|DRUG|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
218995494|NCT00593502|DRUG|placebo|The dosage of placebo will be similar to the active drug
218995495|NCT03689348|DIETARY_SUPPLEMENT|Avena sativa|A supplement derived from wild green oat
218995496|NCT03689348|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
218995497|NCT01964430|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
219753868|NCT05837676|OTHER|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
219753869|NCT04732260|DRUG|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
218995498|NCT01964430|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
218995499|NCT00561808|OTHER|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
218995500|NCT00321308|DRUG|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
218995501|NCT00321308|DRUG|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
218995502|NCT04589078|DEVICE|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
218995503|NCT02516163|DEVICE|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
218995504|NCT01832974|DRUG|IL-13-PE|IL-13-PE intravenous infusion
218995505|NCT03723941|DRUG|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
218995506|NCT03723941|OTHER|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
218995507|NCT02801396|DEVICE|Etafilcon A Design 1 (Test 1)|
218995508|NCT02801396|DEVICE|Etafilcon A Design 2 (Test 2)|
218995509|NCT02801396|DEVICE|Etafilcon A (Control)|
218995510|NCT05214456|OTHER|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
218995511|NCT05214456|OTHER|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
218995512|NCT00993083|BIOLOGICAL|MVA-NP+M1|Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
218995513|NCT05343845|OTHER|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
218995514|NCT02446483|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
218995515|NCT02446483|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
218995516|NCT04968301|DEVICE|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
218995517|NCT03802669|OTHER|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
218995518|NCT01658072|PROCEDURE|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
218995519|NCT01658072|PROCEDURE|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
218995520|NCT03910062|PROCEDURE|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
218995521|NCT05758298|OTHER|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
218995522|NCT05758298|DRUG|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
218995523|NCT05758298|DRUG|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
218995524|NCT06163729|DRUG|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
218995525|NCT00888862|DRUG|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
218995526|NCT01805154|DEVICE|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
218995527|NCT00969696|DRUG|Placebo|8Mg a day of a sugar pill
218995528|NCT00969696|DRUG|Galantamine|8mg of Galantamine
218995529|NCT04688970|OTHER|no intervention|no intervention
219753870|NCT05456139|BEHAVIORAL|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
219753871|NCT05456139|BEHAVIORAL|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
219753872|NCT02254863|BIOLOGICAL|DUOC-01|Intrathecal administration of DUOC-01
219753873|NCT06050122|DRUG|Patidegib Topical Gel|Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.
219753874|NCT06050122|DRUG|Patidegib Topical Gel with no active patidegib|Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
219753875|NCT06143189|OTHER|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
219753876|NCT06143189|OTHER|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
219753877|NCT02105129|DRUG|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
219753878|NCT02105129|DRUG|Placebo|Oral administration
219753879|NCT02143882|DRUG|Fluenz|Live attenuated influenza vaccine
219753880|NCT04462471|DIAGNOSTIC_TEST|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
219753881|NCT04462471|DRUG|Vemurafenib|Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
219753882|NCT04462471|DRUG|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
219753883|NCT00724763|DEVICE|acupuncture|to Liv 3 and PE 9.
219753884|NCT00724763|DEVICE|sham needle treatment|needle not in meridian area
219753885|NCT04921982|DRUG|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
219753886|NCT04921982|DRUG|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
219753887|NCT01734525|DRUG|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
219753888|NCT05584098|OTHER|qSOFA, MEWS and physiological parameters combination|qSOFA ,MEWS and physiological parameters combination used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
219753889|NCT05666830|DEVICE|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
219753890|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered during skin closure (end of operation).
219753891|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
219753892|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered 6 hours after the first administration.
219753893|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
219753894|NCT03078452|DEVICE|Power drill|Undergo bone marrow biopsy using power drill
219753895|NCT03078452|DEVICE|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
219753896|NCT04502082|BIOLOGICAL|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
219753897|NCT02781363|OTHER|Thoracic ultrasound|
219753898|NCT02781363|OTHER|CXR|
219753899|NCT02343185|OTHER|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
219753900|NCT02343185|OTHER|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
219181465|NCT05966870|OTHER|Unsweetened flavored sparkling water|Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
219753901|NCT00922857|PROCEDURE|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
219753902|NCT06500455|PROCEDURE|Computed Tomography|Undergo CT
219753903|NCT06500455|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRS
219753904|NCT06500455|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219753905|NCT06500455|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219753906|NCT02065284|OTHER|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
219753907|NCT03489694|PROCEDURE|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
219753908|NCT06104644|DRUG|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
219753909|NCT02239237|DRUG|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
219753910|NCT06120790|OTHER|3 Oz water screen|Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
219753911|NCT04876911|BEHAVIORAL|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
219753912|NCT05657158|OTHER|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
219753913|NCT04644952|OTHER|Electronic Health Record Review|Review of medical records
219753914|NCT03558789|BIOLOGICAL|bovine lactoferrin|mouthwash
219753915|NCT04358237|DRUG|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
219753916|NCT04358237|DRUG|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
219753917|NCT06325514|DIAGNOSTIC_TEST|Artificial intelligence based program|the AI based program is based on image analysis
219753918|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
219753919|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
219753920|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
219753921|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
219753922|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
219753923|NCT06077994|BEHAVIORAL|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
219753924|NCT06077994|BEHAVIORAL|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
219753925|NCT06425120|DRUG|Xuesaitong Soft Capsule|Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
219753926|NCT06425120|DRUG|Placebo|Each participant in the placebo group will take matching placebo.
219753927|NCT06529692|BEHAVIORAL|Placebo Split-Belt Training|Walking on a split-belt treadmill in which the belt under the ACL leg will move at a speed that is minimally slower than the other belt.
219753928|NCT06529692|BEHAVIORAL|Split-Belt Training|Walking on a split-belt treadmill in which the treadmill belt under the ACL leg will move at a speed faster or slower than the belt under the Non-ACL leg.
219753929|NCT06364072|DRUG|CT001|Intranasal
219753930|NCT06390579|OTHER|Deep learning algorithm applied on retrospectively collected color fundus photographs|Deep learning algorithm applied on retrospectively collected color fundus photographs
219753931|NCT03032029|DEVICE|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
219753932|NCT06641804|PROCEDURE|Pessary care, change of pessary|Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
219753933|NCT04385290|DRUG|MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO|"Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7"
218995530|NCT05328063|OTHER|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
218995531|NCT05328063|OTHER|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
218995532|NCT00057889|BIOLOGICAL|ipilimumab|
218995533|NCT05086848|DRUG|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
218995534|NCT04790422|DIETARY_SUPPLEMENT|Dietary fiber supplement|Dietary fiber
218995535|NCT04790422|DIETARY_SUPPLEMENT|Caseine protein hydrolisate|Dietary supplement
218995536|NCT04790422|DIETARY_SUPPLEMENT|Maltrodextrine|Placebo comparator
218995537|NCT04279457|DEVICE|DyeVert Plus System|The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
218995538|NCT04279457|OTHER|Standardized hydration protocol|hydration protocol based up on the Poseidon protocol
218995539|NCT00820846|BIOLOGICAL|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
218995540|NCT00820846|BIOLOGICAL|Placebo|1 mL of sodium chloride for injection
218995541|NCT00820846|BIOLOGICAL|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
218995542|NCT05751265|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
218995543|NCT05751265|DRUG|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
218995544|NCT05751265|DRUG|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
218995545|NCT06199817|BEHAVIORAL|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
218995546|NCT02920385|DRUG|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
219369630|NCT01264939|DRUG|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
218995547|NCT02920385|DRUG|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
218995548|NCT02920385|DRUG|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
218995549|NCT02920385|DRUG|Placebo|Oral administration once daily together with semaglutide
218995550|NCT03834441|OTHER|Oral HRSN screening|Verbal screening delivered by an RA
218995551|NCT03834441|OTHER|Written HRSN screening|Patient completes written screen on iPad.
218995552|NCT01930266|DIETARY_SUPPLEMENT|Experimental|
218995553|NCT01930266|BEHAVIORAL|Active comparator|
218995554|NCT05869266|DEVICE|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
218995555|NCT06557447|DIAGNOSTIC_TEST|Immunological and microbiological sample of peri-implant crevicular fluid; clinical evaluation|"Immunological sample collection involves placing a Periopaper strip in the peri-implantar sulcus for 30 seconds. If sample is contaminated with blood, sample will be discarded and another sample will be collected (a different surface of the same implant/tooth can be used).~Microbiological sample collection involves collecting subgingival dental plaque by sliding the end of the STERILE curette (Gracey) inside the peri-implant sulcus. In case of slight bleeding following the first sample, dry the site again before collection. In case of profuse bleeding, collect a sample from another site (by site mean mesial/buccal/distal/lingual) of the same implant.~Both immunological and microbiological samples will be sent for respective laboratories for the analysis.~Clinical evaluation will assess presence of dental plaque, bleeding on probing and gingival status."
219181466|NCT05955729|BEHAVIORAL|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
218995556|NCT01245621|BEHAVIORAL|Later entry group|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
218995557|NCT01245621|BEHAVIORAL|Early palliative care intervention|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
218995558|NCT04926428|DRUG|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
218995559|NCT02859168|BEHAVIORAL|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
218995560|NCT02859168|DEVICE|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
218995561|NCT01264757|BEHAVIORAL|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
218995562|NCT01264757|BEHAVIORAL|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
218995563|NCT06468566|DIAGNOSTIC_TEST|Ultrasound light scattering imaging equipment|Radiologists use ultrasound light scattering imaging to evaluate the benign and malignant nature of breast nodules
218995564|NCT06059794|OTHER|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
218995565|NCT06059794|OTHER|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
218995566|NCT03685968|DEVICE|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
218995567|NCT04614220|BEHAVIORAL|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
218995568|NCT00799422|DEVICE|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
218995569|NCT00799422|DEVICE|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
218995570|NCT00799422|DEVICE|Clear Care|Commercially marketed contact lens solution for contact lens care
218995571|NCT00799422|DEVICE|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
218995572|NCT03493074|DIAGNOSTIC_TEST|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
218995573|NCT00457925|DRUG|GSK221149A|
218995574|NCT00830362|DRUG|Propranolol|40 mg administered once
218995575|NCT00830362|DRUG|Placebo|administered once
218995576|NCT01930864|DRUG|metformin|metformin up to 2500mg/d
219181467|NCT05955729|BEHAVIORAL|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
219181468|NCT05955729|DEVICE|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
218995577|NCT01930864|DRUG|irinotecan|Irinotecan 350 mg/m² IV q21d
218995578|NCT00277498|DRUG|Xalacom|
218995579|NCT00277498|DRUG|Xalatan|
218995580|NCT00277498|DRUG|Timolol|
218995581|NCT06009705|DRUG|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
218995582|NCT01996852|BEHAVIORAL|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
218995583|NCT01996852|DRUG|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
219181469|NCT05955729|DEVICE|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
219369631|NCT01264939|DRUG|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
218995584|NCT01996852|DEVICE|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
218995585|NCT00067600|BEHAVIORAL|Diet with increased fruits, vegetables, and calcium|
218995586|NCT00067600|BEHAVIORAL|Increased high impact activity and resistance training|
218995587|NCT01587001|DIETARY_SUPPLEMENT|N-acetyl-cysteine|900mg three times daily for 8 weeks
219181470|NCT05955729|DEVICE|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
218995588|NCT01587001|DRUG|Placebo|Matching placebo three times daily for 8 weeks.
218995589|NCT01458938|OTHER|treatment plan|Data Collection Study
218995590|NCT01781143|DEVICE|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
218995591|NCT05729646|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
218995592|NCT05729646|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
218995593|NCT05729646|DRUG|S1|S-1 orally intake as perioperative chemotherapy
218995594|NCT00828659|DRUG|Placebo|
218995595|NCT00828659|DRUG|Active Comparator #1|
218995596|NCT00828659|DRUG|Active Comparator #2|
218995597|NCT00828659|DRUG|Active Comparator #3|
218995598|NCT00828659|DRUG|Lorcaserin Dose #1|
218995599|NCT00828659|DRUG|Lorcaserin Dose #2|
218995600|NCT00828659|DRUG|Lorcaserin Dose #3|
218995601|NCT04833543|OTHER|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
218995602|NCT04833543|OTHER|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
218995603|NCT01186471|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
218995604|NCT01186471|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
218995605|NCT01186471|DRUG|placebo|placebo - three times daily during each treatment period
218995606|NCT04931407|OTHER|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
219181471|NCT05955729|DEVICE|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
219753934|NCT04385290|DRUG|MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
219753935|NCT04385290|DRUG|MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO|"GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
219753936|NCT04385290|DRUG|MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
218995607|NCT00730769|DRUG|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
218995608|NCT00133328|DRUG|valsartan|
218995609|NCT02337660|PROCEDURE|Liver biopsy|One ultrasound guided liver biopsy
218995610|NCT02337660|OTHER|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
218995611|NCT02756013|DRUG|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
218995612|NCT02756013|DRUG|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
218995613|NCT04597723|DRUG|oxygen|Patients will be given different concentrations of oxygen.
218995614|NCT04836572|OTHER|3M 1529 Adhesive Tape|5-12 hour adhesive wear
218995615|NCT06515743|OTHER|Delayed surgical obturator|Prosthetic rehabilitation after surgical treatment of mucormycosis is essential for the early restoration of oral function and facial esthetics which is performed by using the surgical obturator.
218995616|NCT03989271|DRUG|Quercetin|Placebo
218995617|NCT05663190|OTHER|mental foramen location|location of mental foramen in relation to primary molars
218995618|NCT06376396|DRUG|albendazole and praziquantel|Combination of albendazole plus praziquantel
218995619|NCT06376396|DRUG|Albendazole|Albendazole alone
218995620|NCT04014816|OTHER|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
218995621|NCT04014816|OTHER|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
218995622|NCT06297161|DRUG|Bosulif|chronic myelogenous leukemia patients
218995623|NCT03600571|PROCEDURE|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
218995624|NCT03600571|PROCEDURE|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
218995625|NCT01749397|DRUG|Floxuridine|Given IP
218995626|NCT01749397|OTHER|Laboratory Biomarker Analysis|Correlative studies
218995627|NCT01749397|OTHER|Pharmacological Study|Correlative studies
218995628|NCT01749397|DRUG|Veliparib|Given IV
218995629|NCT00118677|PROCEDURE|Treatment interruption|
218995630|NCT02381145|DIETARY_SUPPLEMENT|EGCG+RSV-supplementation|Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
218995631|NCT02381145|DIETARY_SUPPLEMENT|Placebo|
218995632|NCT03334539|BIOLOGICAL|HL036 ophthalmic solution|HL036 ophthalmic solution
218995633|NCT03334539|OTHER|Placebo vehicle solution|Placebo vehicle solution
218995634|NCT04399317|DEVICE|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
218995635|NCT06492317|DRUG|Disitamab Vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
218995636|NCT06492317|DRUG|Cadonilimab|Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
218995637|NCT01162460|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
218995638|NCT00515346|DEVICE|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
218995639|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
218995640|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
218995641|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
218995642|NCT05232396|BIOLOGICAL|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
219753937|NCT04385290|DRUG|MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
219753938|NCT00158587|DRUG|primaquine|
218995643|NCT03533543|DEVICE|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
218995644|NCT03706456|BIOLOGICAL|Darvadstrocel|Darvadstrocel cell suspension for intralesional injection.
218995645|NCT00547482|DEVICE|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
218995646|NCT02771912|DRUG|Propofol|Propofol and excipients
218995647|NCT02771912|DRUG|Placebo|Qualitative composition of Propofol lipuro 2% excipients
218995648|NCT03589560|DRUG|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
218995649|NCT03589560|DRUG|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
218995650|NCT02829697|DRUG|Ropivacaine|Perineural injection.
218995651|NCT02228200|BEHAVIORAL|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
218995652|NCT02228200|BEHAVIORAL|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
218995653|NCT05176730|BEHAVIORAL|Mindfulness meditation|Similar to the information included in arm/group descriptions
218995654|NCT04903990|OTHER|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
218995655|NCT02784431|DEVICE|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
218995656|NCT00866385|DRUG|AZD8566|Single 6 mg oral solution dose
218995657|NCT00866385|DRUG|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
218995658|NCT04123600|DEVICE|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
218995659|NCT02644135|DRUG|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
218995660|NCT02644135|DRUG|Halo Placebo|Three sprays per use, total = 9 sprays per day
218995661|NCT00598988|PROCEDURE|traditional Chinese acupuncture|10 treatments over 6 weeks
218995662|NCT00598988|OTHER|standard medical care|standard care as provided by primary physician
218995663|NCT01901120|DRUG|Betanis|oral
218995664|NCT03302234|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
218995665|NCT03302234|BIOLOGICAL|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
218995666|NCT03302234|OTHER|Placebo|Normal saline solution administered as an IV infusion Q6W
218995667|NCT06199596|DIETARY_SUPPLEMENT|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
218995668|NCT06199596|DIETARY_SUPPLEMENT|Maltodextrin|150mg of Maltodextrin per capsule
218995669|NCT05687383|DEVICE|Safe breastfeeding pillow|A randomized controlled trial
218995670|NCT00873574|BIOLOGICAL|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
218995671|NCT04145557|DEVICE|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
218995672|NCT04145557|DEVICE|scaling root planing|scaling and root planing
219753939|NCT06645223|DRUG|No Interventions|no interventions
218995673|NCT00200616|PROCEDURE|Antimicrobial prophylaxis|
218995674|NCT05163236|DIAGNOSTIC_TEST|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
218995675|NCT05163236|DIAGNOSTIC_TEST|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
218995676|NCT05163236|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
218995677|NCT05488730|DIAGNOSTIC_TEST|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
218995678|NCT05979558|DRUG|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
219753940|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
219753941|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
219753942|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
219753943|NCT04583618|BIOLOGICAL|Pneumococcal 13 - valent conjugate vaccine-Prevnar 13|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
218995679|NCT05979558|DRUG|Ropivacaine with placebo|this group received with ropivacaine with normal saline
218995680|NCT05353166|DRUG|REGN5381|Single dose administered via IV infusion
219753944|NCT04583618|BIOLOGICAL|Pneumococcal Vaccine Polyvalent-Pneumovax 23|Pharmaceutical form:Solution for injection Route of administration: intramuscular
218995681|NCT05353166|DRUG|Matching Placebo|Single dose administered via IV infusion
218995682|NCT04774315|DRUG|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
218995683|NCT02795832|DRUG|ZPL-5212372 1% w/w Ointment BID|
218995684|NCT02795832|DRUG|Placebo Ointment BID|
218995685|NCT04523220|DRUG|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
218995686|NCT04523220|DRUG|Placebo|Subcutaneous administration in the same manner as Osocimab.
218995687|NCT06075862|PROCEDURE|Decompressive surgery|Decompressive lumbar spinal surgery
218995688|NCT02592252|BEHAVIORAL|Participatory gender training|10 sessions of participatory gender training
218995689|NCT02592252|OTHER|Microfinance|Microfinance loan
218995690|NCT04528108|DRUG|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
218995691|NCT04528108|DRUG|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
218995692|NCT03207230|DEVICE|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
218995693|NCT03207230|DEVICE|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
218995694|NCT03207230|DEVICE|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
218995695|NCT04889079|BEHAVIORAL|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
218995696|NCT05888766|DRUG|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
218995697|NCT05947825|DRUG|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
218995698|NCT05332665|DEVICE|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
218995699|NCT05332665|PROCEDURE|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
218995700|NCT06382259|OTHER|Movement breaks|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
218995701|NCT05367622|BEHAVIORAL|Self-regulation health education|"1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days"
219181472|NCT05955729|BIOLOGICAL|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
218995702|NCT05367622|BEHAVIORAL|Usual diabetes health education|"1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education"
218995703|NCT00221403|DRUG|Risperidone oral solution|liquid, BID dosing.
218995704|NCT00221403|DRUG|Valproate Oral Solution|liquid, BID dosing.
218995705|NCT00221403|OTHER|Placebo|liquid, BID dosing.
218995706|NCT05045131|PROCEDURE|Left atrial combined pulmonary vein isolation and posterior wall isolation|
218995707|NCT02272062|OTHER|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
218995708|NCT03925883|BEHAVIORAL|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
219181473|NCT05955729|OTHER|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
219753945|NCT04548999|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W.~During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)"
219181474|NCT05955729|OTHER|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
218995709|NCT06248632|OTHER|Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)|Expression of inflammatory markers obtained from circulating monocytic cells of XLH
218995710|NCT03067961|OTHER|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
218995711|NCT05840991|DEVICE|elastic bandage|3M™ Coban™ elastic bandage
218995712|NCT05840991|DEVICE|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
218995713|NCT04790890|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
218995714|NCT02010775|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
218995715|NCT02010775|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
218995716|NCT01324908|PROCEDURE|extracorporeal photopheresis|Undergo ECP
219181475|NCT05955729|OTHER|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
219181476|NCT05955729|OTHER|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
219181477|NCT05955729|OTHER|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
218995717|NCT01324908|OTHER|laboratory biomarker analysis|Correlative studies
218995718|NCT02389361|DRUG|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
218995719|NCT02389361|DRUG|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
218995720|NCT00256750|DRUG|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
218995721|NCT00256750|DRUG|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
218995722|NCT00256750|DRUG|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
218995723|NCT01475994|OTHER|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
218995724|NCT01475994|OTHER|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
219181478|NCT05955729|OTHER|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
219181479|NCT05955729|DEVICE|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
219181480|NCT06779058|DEVICE|MRE|All imaging studies were performed by using a 1.5T/3.0-T MRI system
219181481|NCT06779058|DEVICE|Liver biopsy|Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.
219181482|NCT06207877|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
219181483|NCT06207877|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
218995725|NCT03072147|DRUG|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
218995726|NCT03072147|DRUG|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
218995727|NCT02887638|OTHER|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
218995728|NCT02030041|DRUG|Vitamin D|Vitamin D will be given to achieve normal serum levels
218995729|NCT02030041|DRUG|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
218995730|NCT02030041|DRUG|Placebo|Placebo will be provided to the study participants
219181484|NCT06207877|DRUG|Placebo|Placebo will be administered subcutaneously.
219181485|NCT06778915|PROCEDURE|surgery|surgery
219181486|NCT07062978|DRUG|QL1206|QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
218995731|NCT01916720|DRUG|SB-480848 40 mg|Study Drug
218995732|NCT01916720|DRUG|SB-480848 80 mg|Study Drug
218995733|NCT01916720|DRUG|Placebo|Study Drug
218995734|NCT03621397|DEVICE|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
218995735|NCT05907512|DRUG|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
218995736|NCT05907512|DRUG|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
219181487|NCT07062978|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
219181488|NCT06634823|DRUG|Triamcinolone Acetonide Injectable Suspension|Triamcinolone injection into deltoid muscle (arm)
219181489|NCT06634823|DRUG|Saline injection|Saline injection into deltoid muscle (arm)
219181490|NCT02013583|OTHER|No intervention|This is an observational registry. No interventions are required or provided.
219181491|NCT04682587|DRUG|Axitinib|Inlyta, axitinib
219181492|NCT04682587|DRUG|Avelumab|Avelumab, Bavencio
219181493|NCT04682587|DRUG|Pembrolizumab|Pembrolizumab, Keytruda
219181494|NCT06116682|BIOLOGICAL|Amivantamab|Given amivantamab-SC
218995737|NCT05512572|DEVICE|IPL|intense pulsed light
219181495|NCT06116682|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219181496|NCT06116682|PROCEDURE|Computed Tomography|Undergo CT scan
219181497|NCT06116682|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218995738|NCT05512572|PROCEDURE|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
218995739|NCT02788812|PROCEDURE|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
218995740|NCT02788812|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
218995741|NCT01704378|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
218995742|NCT02154178|OTHER|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
218995743|NCT02277145|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
218995744|NCT02077920|DRUG|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
218995745|NCT02077920|DRUG|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
218995746|NCT02077920|DEVICE|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
218995747|NCT02077920|DEVICE|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
218995748|NCT04736030|BEHAVIORAL|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
218995749|NCT01197560|DRUG|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
218995750|NCT01197560|DRUG|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
218995751|NCT01197560|DRUG|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
218995752|NCT01197560|DRUG|Rituximab|Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
218995753|NCT01197560|DRUG|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
218995754|NCT05201703|DRUG|Fycompa|Fycompa 4 mg daily
218995755|NCT05201703|DRUG|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
218995756|NCT03472183|OTHER|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
218995757|NCT01132430|BEHAVIORAL|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
219181498|NCT06171828|DEVICE|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
219181499|NCT04913012|COMBINATION_PRODUCT|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
219181500|NCT04913012|COMBINATION_PRODUCT|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
219181501|NCT04913012|COMBINATION_PRODUCT|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
219181502|NCT04913012|COMBINATION_PRODUCT|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
219181503|NCT00506519|DRUG|Antithrombin alfa (INN name)|
219181504|NCT00506519|DRUG|Control (Standard treatment)|
219181505|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
219181506|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
219753946|NCT04548999|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
218995758|NCT01132430|BEHAVIORAL|Usual care|Standard medical care within 4-6 week period
218995759|NCT04635462|OTHER|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
218995760|NCT04635462|OTHER|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
218995761|NCT03280498|PROCEDURE|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
218995762|NCT02412605|PROCEDURE|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
218995763|NCT05374369|DIAGNOSTIC_TEST|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
218995764|NCT05374369|PROCEDURE|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
218995765|NCT02927730|OTHER|no interventions|no interventions
218995766|NCT01600638|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
218995767|NCT00386438|PROCEDURE|Honan balloon application|
219181507|NCT06403111|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment (lung adenocarcinoma) / albumin-bound paclitaxel + platinum-based treatment (lung squamous cell carcinoma) for 4-6 cycles. If there is no progression of the disease after 4-6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. Patients will receive tislelizumab maintenance treatment (lung squamous cell carcinoma), or tislelizumab + pemetrexed maintenance treatment (lung adenocarcinoma).
219181508|NCT01186367|BEHAVIORAL|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
219181509|NCT01186367|BEHAVIORAL|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
219181510|NCT01186367|BEHAVIORAL|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
219181511|NCT01186367|OTHER|Cardiopulmonary exercise test (CPET)|
219181512|NCT01186367|OTHER|Blood draws|Complete blood count
219181513|NCT06114108|OTHER|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
219181514|NCT06114108|OTHER|Surgery|Surgery
219181515|NCT06114108|RADIATION|Radiotherapy|Radiotherapy
219181516|NCT06075368|DEVICE|GENOSS Sirolimus Eluting Coronary Stent System|The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.
218995768|NCT03129178|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
218995769|NCT01125267|BEHAVIORAL|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
218995770|NCT01125267|BEHAVIORAL|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
218995771|NCT04460404|BEHAVIORAL|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~1. Basic information~2. Digestive tract symptoms:~   A constipation-related symptoms B abnormal symptoms~3. Fecal traits~4. Lifestyle habits~5. Others"
218995772|NCT01682109|DRUG|Valacyclovir|
218995773|NCT04176666|DEVICE|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
218995774|NCT00601211|DRUG|Pilocarpine|
219181517|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
219181518|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
219181519|NCT02975882|OTHER|Pharmacological Study|Correlative studies
219181520|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
219181521|NCT02975882|DRUG|Temozolomide|Given PO
219181522|NCT05419479|DRUG|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
219181523|NCT05419479|DRUG|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
219181524|NCT05419479|DRUG|APX005M|Via IV on two days per cycle, dosage per protocol
218995775|NCT04648553|BEHAVIORAL|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
218995776|NCT04648553|BEHAVIORAL|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
218995777|NCT00558558|DRUG|Haelan|4 oz orally twice daily for 8 Weeks
218995778|NCT05190159|DEVICE|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
218995779|NCT05222737|DEVICE|medency diode laser|intra pocket application of diode laser
218995780|NCT05222737|DRUG|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
218995781|NCT02014025|PROCEDURE|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
218995782|NCT02014025|PROCEDURE|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
218995783|NCT02460627|DRUG|Lidocaine adhesive tape|700 mg for 12 hours
219181525|NCT05419479|DRUG|FOLFIRI|every two weeks through an infusion at a dose determined by physician
218995784|NCT02460627|OTHER|Adhesive tape|For 12 hours
219181526|NCT05264480|PROCEDURE|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
219181527|NCT05264480|PROCEDURE|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
219753947|NCT04548999|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
219753948|NCT04548999|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
218995785|NCT02217267|DRUG|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
218995786|NCT02217267|DRUG|Placebo|
218995787|NCT05858762|DIAGNOSTIC_TEST|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
218995788|NCT04771039|OTHER|reason for consultation|search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
218995789|NCT01265368|BIOLOGICAL|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
218995790|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
218995791|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
219181528|NCT06378138|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
219181529|NCT06378138|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
219181530|NCT05844436|DRUG|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
219181531|NCT06275724|OTHER|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
219181532|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily|(2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
219181533|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily|(2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
219753949|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
218995792|NCT04263220|DEVICE|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
218995793|NCT04263220|OTHER|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
218995794|NCT01095731|DRUG|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
218995795|NCT01095731|DRUG|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
219181534|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
219181535|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
219181536|NCT06460454|DEVICE|PET scan of 18F-FDG|VEREOS PET scanner. Philips VEREOS digital PET-CT scanners are installed in the nuclear medicine department.
219181537|NCT06643793|DRUG|Irinotecan liposome (ll) + 5-FU/LV + bevacizumab|"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."
219753950|NCT02711202|DRUG|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
219753951|NCT02711202|DRUG|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
219753952|NCT02711202|DRUG|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
219753953|NCT02711202|DRUG|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
219753954|NCT05844527|DRUG|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
219753955|NCT05844527|DRUG|Saline|Sterile saline will serve as placebo treatment.
219753956|NCT04331249|PROCEDURE|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
219753957|NCT04436731|OTHER|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
219753958|NCT04436731|DRUG|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
219753959|NCT04436731|DRUG|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
219753960|NCT04436731|DRUG|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
219753961|NCT04436731|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
219753962|NCT05812170|BEHAVIORAL|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
218995796|NCT01423305|DRUG|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
218995797|NCT01423305|DRUG|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
218995798|NCT03641274|OTHER|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
218995799|NCT03293290|DRUG|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
218995800|NCT01411202|DRUG|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
218995801|NCT01411202|OTHER|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
219181538|NCT06257706|BIOLOGICAL|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
219181539|NCT05957432|DRUG|Black Seed Oil Cap/Tab|possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
219181540|NCT05957432|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|H pylori vonoprazan based treatment
219181541|NCT06057909|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Test that looks at the structure of the brain.
219181542|NCT06057909|DIAGNOSTIC_TEST|Electroencephalography|Non-invasive technique to measure brain waves
219181543|NCT06057909|DIAGNOSTIC_TEST|Electromyography|Technique to evaluate muscle activity
219753963|NCT03925246|DRUG|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
219753964|NCT00432965|DEVICE|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
219753965|NCT00432965|DEVICE|VAC Therapy|VAC Therapy
219753966|NCT02381587|OTHER|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
219753967|NCT05804045|DRUG|Pimicotinib(ABSK021)|capsule
219753968|NCT05804045|DRUG|Placebo|capsule
219753969|NCT05168293|OTHER|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
219753970|NCT04046237|OTHER|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
219753971|NCT00159016|DRUG|Glivec|
219753972|NCT03798210|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
219753973|NCT03798210|DIETARY_SUPPLEMENT|Placebo|Placebo
219753974|NCT05680818|DRUG|Encaleret|Administered as film-coated tablet for oral use
219753975|NCT05680818|DIETARY_SUPPLEMENT|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
219753976|NCT03180268|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219753977|NCT03180268|OTHER|Clinical Observation|Undergo observation
219753978|NCT03180268|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219753979|NCT03180268|OTHER|Laboratory Biomarker Analysis|Correlative studies
219753980|NCT03180268|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219753981|NCT03180268|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219753982|NCT03180268|OTHER|Quality-of-Life Assessment|Ancillary studies
219753983|NCT06963021|DRUG|NBI-1065845|NBI-1065845 tablets
219753984|NCT06963021|DRUG|Placebo|Matching placebo tablets
219753985|NCT05624996|DRUG|Carboplatin|Given IV
219753986|NCT05624996|DRUG|Cisplatin|Given IV
219753987|NCT05624996|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219753988|NCT05624996|BIOLOGICAL|Durvalumab|Given IV
219753989|NCT05624996|DRUG|Etoposide|Given IV
219753990|NCT05624996|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
219753991|NCT05624996|DRUG|Nab-paclitaxel|Given IV
219753992|NCT05624996|DRUG|Paclitaxel|Given IV
219753993|NCT05624996|DRUG|Pemetrexed|Given IV
219753994|NCT05624996|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219753995|NCT05624996|OTHER|Questionnaire Administration|Ancillary studies
219753996|NCT05624996|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219753997|NCT04595201|DEVICE|NIPT|Non-invasive pregnancy testing
219753998|NCT06498479|DRUG|HS-20093|HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
219753999|NCT06498479|DRUG|Topotecan|Topotecan will be administered per drug label.
219754000|NCT03255473|DRUG|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
219754001|NCT03255473|DRUG|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
219754002|NCT01732185|GENETIC|Patient|Blood and histological samples will be done at day of the inclusion.
219754003|NCT06057532|DIETARY_SUPPLEMENT|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
219754004|NCT06057532|DIETARY_SUPPLEMENT|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
219754005|NCT06305234|DRUG|Pegvaliase|Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
218995802|NCT04284410|BEHAVIORAL|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
218995803|NCT03330821|DRUG|Cytarabine|Given IV
218995804|NCT03330821|DRUG|Idarubicin|Given IV
218995805|NCT03330821|OTHER|Laboratory Biomarker Analysis|Correlative studies
218995806|NCT03330821|DRUG|Pevonedistat|Given IV
218995807|NCT03330821|OTHER|Pharmacological Study|Correlative studies
218995808|NCT06709248|BEHAVIORAL|Life Coping Program|The Life Coping Program is built around a coordinated 5-day Life Coping Course. Participants included are grouped by their primary condition, meaning the diagnosis or illness reasoning the referral. Each family is assigned a dedicated Primary Contact throughout the program, and the program consists of three phases: Phase 1: Preparation - Written/visual materials and questionnaires are provided to motivate and inform. A digital consultation occurs 3-5 weeks before the Life Coping Course, covering goals, commitment, and follow-up. Materials are offered in paper or digital formats. Phase 2: Life Coping Course - The 5-day course includes individual consultations, group activities, education, and medical follow-ups, focusing on coping strategies and well-being. Phase 3: Implementation - A summary meeting is conducted, including key persons for further implementation in own local area. Digital follow-ups at 3-4 weeks and 6 months post course assess progress and guide goal achievement.
218995809|NCT04034836|DRUG|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
218995810|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
219181544|NCT05177146|DRUG|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
219181545|NCT05985018|OTHER|Traditional Diet|Provided as an educational leaflet
219181546|NCT05985018|OTHER|Mediterranean Diet|Provided as an educational leaflet
219181547|NCT03853395|DIAGNOSTIC_TEST|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
219181548|NCT06799676|DRUG|a combination treatment of Linperlisib and the VRD regimen|Subjects will be administered Linperlisib orally at doses of 40 mg, 60 mg, or 80 mg once daily for 4 consecutive weeks, combined with the VRD regimen at standard doses. Subsequently, during the expansion phase, at least four cycles of Linperlisib at the recommended Phase II dose (RP2D) will be combined with the VRD regimen for induction therapy.
219181549|NCT03945292|DRUG|Fazisiran Injection|solution for subcutaneous (sc) injection
219181550|NCT03945292|OTHER|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
219181551|NCT04374175|BIOLOGICAL|Blood sample|Blood sample will be performed
219181552|NCT06004973|DEVICE|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
219181553|NCT02750826|OTHER|Health Education Program|
219181554|NCT02750826|OTHER|Weight Loss Intervention|
219181555|NCT01857245|OTHER|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
219754006|NCT05246566|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
218995811|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
218995812|NCT06511037|DRUG|Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging|Given IV
218995813|NCT03481036|DRUG|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
218995814|NCT03481036|DRUG|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
218995815|NCT03481036|DRUG|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
218995816|NCT02342327|OTHER|switch to non-menthol cigarettes prior to cessation attempt|
218995817|NCT02342327|OTHER|continue smoking menthol cigarettes prior to cessation attempt|
218995818|NCT00758212|BIOLOGICAL|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
218995819|NCT02885012|DRUG|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
218995820|NCT05489510|COMBINATION_PRODUCT|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
218995821|NCT00651794|BEHAVIORAL|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
219181556|NCT05281809|DRUG|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
219181557|NCT04321395|DRUG|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
219181558|NCT03524118|DRUG|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
219181559|NCT03524118|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
219181560|NCT02716116|DRUG|TAK-788|TAK-788 capsules.
219181561|NCT04987320|DRUG|Olpasiran|Subcutaneous injection
219754007|NCT06803030|DRUG|Tamsulosin Hydrochloride 0.4 mg|placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
219754008|NCT06803030|DRUG|Solifenacin Succinate 5 mg|placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
219754009|NCT06803030|DRUG|Mirabegron 25 mg|placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
218995822|NCT00651794|BEHAVIORAL|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
218995823|NCT00651794|BEHAVIORAL|Skills practice with low-fidelity mannequin|
218995824|NCT00651794|BEHAVIORAL|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
218995825|NCT00949520|OTHER|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
218995826|NCT00949520|OTHER|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
218995827|NCT05433792|DEVICE|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
218995828|NCT05433792|DEVICE|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
219754010|NCT05462262|DRUG|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
219754011|NCT05462262|DRUG|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
219754012|NCT00537797|OTHER|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
219754013|NCT04653012|DEVICE|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
219754014|NCT06558578|DIAGNOSTIC_TEST|Helicobacter pylori antigen in stool|"H pylori antigen in stool: for all patients suffering from migraine and control group.~Upper GIT endoscopy: for children with positive H Pylori antigen in stool."
219754015|NCT06503913|BEHAVIORAL|Cognitive Muscular Therapy|Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.
218995829|NCT03182088|DRUG|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
218995830|NCT03182088|DRUG|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
218995831|NCT03182088|DRUG|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
218995832|NCT03182088|DRUG|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
218995833|NCT01655615|BEHAVIORAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
218995834|NCT06158789|PROCEDURE|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
218995835|NCT02562053|DRUG|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
218995836|NCT02562053|DRUG|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
219181562|NCT04200547|OTHER|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
218995837|NCT02562053|DRUG|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
218995838|NCT02562053|DRUG|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
218995839|NCT03576976|BEHAVIORAL|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
218995840|NCT06241534|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
218995841|NCT06241534|BEHAVIORAL|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
219181563|NCT04200547|OTHER|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI \> 220 together with an increase of 70 points) and biological relapse (CRP \> 10mg/mL and fecal calprotectin \> 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
219181564|NCT00579072|BEHAVIORAL|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
219181565|NCT00579072|BEHAVIORAL|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
219369632|NCT01972321|OTHER|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
218995842|NCT06241534|DEVICE|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
218995843|NCT06241534|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
218995844|NCT02835924|DRUG|Regorafenib|
218995845|NCT00275990|DEVICE|rheolytic thrombectomy with direct stenting|
218995846|NCT00275990|DEVICE|direct stenting|
218995847|NCT04448288|OTHER|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
218995848|NCT06301685|BEHAVIORAL|Routine therapy|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
219181566|NCT00579072|DEVICE|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
219181567|NCT01824875|DRUG|temozolomide|Given PO
219181568|NCT01824875|DRUG|capecitabine|Given PO
219181569|NCT06021782|OTHER|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
219181570|NCT06555562|DEVICE|Ultrasound Stimulation|Ultrasound therapy will be administered to the appropriate target.
219181571|NCT06555562|DEVICE|Non-active ultrasound stimulation|Non-active ultrasound therapy will be administered to the appropriate target
219754016|NCT06503913|BEHAVIORAL|Breathing visualisation|Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
219754017|NCT06563375|DRUG|NP-101|Given by mouth
219181572|NCT02014649|DRUG|20 mg laninamivir octanoate|
219181573|NCT02014649|DRUG|Placebo|
219181574|NCT02014649|DRUG|40 mg laninamivir octanoate|
219181575|NCT06807229|DEVICE|Transcutaneous electrical nerve stimulation|We will apply high frequency TENS for low back pain relief as it showed effectiveness more than low frequency TENS in pain relief (21). The recommendation is to apply the TENS at the highest tolerable intensity (22). While adjusting the current amplitude in a continuous manner so that its presence will be noticeable throughout the treatment. We applied a TENS device (ENRAF NONIUS Model, four electrodes) with a frequency of 0- 100/HZ and 90-100 pulse /seconds was applied for 20 minutes, to increase circulation and to have pain relief at the first day of menstrual complaints without taking any analgesics. Patients lied in prone position with a thin pillow placed under their abdomen. Two electrodes were placed to the proximal margin of low back area, and two others were placed to the proximal of gluteal region laterally. The intensity of stimulation was increased up to the tolerated level without causing any contraction
219754018|NCT05580042|DRUG|AC-1101|For each patient, once daily (QD)
219754019|NCT05548283|DRUG|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
219754020|NCT05548283|DRUG|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
218995849|NCT06301685|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218995850|NCT06301685|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
218995851|NCT04477902|OTHER|none - observational|online survey
219754021|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
219754022|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
218995852|NCT01485237|OTHER|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
218995853|NCT01504035|DEVICE|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
218995854|NCT01504035|DEVICE|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
218995855|NCT04625309|OTHER|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
218995856|NCT00003746|DRUG|2-chlorodeoxyadenosine (CDA) daily|Daily administration
218995857|NCT00003746|DRUG|2-chlorodeoxyadenosine weekly|Weekly administration
218995858|NCT00003325|PROCEDURE|Sentinel lymph node mapping|Sentinel lymph node mapping
218995859|NCT02898337|DEVICE|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
219181576|NCT06807229|OTHER|stretching exercises|"The first stretching exercise: The subjects will be asked to stand and bend trunk forward from the hip joint so that the shoulders and back were positioned on a straight line and the upper body was placed parallel to the floor for 5 seconds repetition; 10 times.~The second stretching exercise: The subjects will be requested to stand then raise 1 heel off the floor, then repeat the exercise with the other heel alternatively. The exercise will be performed 20 times.~The third stretching exercise: The subjects will be asked to spread their feet shoulder width, place trunk and hands in forward stretching.~The fourth stretching exercise: The subjects will be asked to spread her feet wider than shoulder width. Then the subject was asked to bend and touch left ankle with her right hand while putting her left hand in a stretched position above her head so that the head was in the middle and her head was turned and looked for her left hand, this exercise was repeated for the opposite foot with"
218995860|NCT02615366|DRUG|Tranexamic Acid|
218995861|NCT02615366|DRUG|Placebo|
218995862|NCT06337331|DRUG|Venetoclax|400mg/day PO Days -8 to -2
218995863|NCT06337331|DRUG|Decitabine|20mg/m2/day IV Days -7 to -3
219181577|NCT06506721|DEVICE|Double ballon device, Cook|"Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
219181578|NCT06506721|DEVICE|Hygroscopic cervix dilators, Dilapan-S|"A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
218995864|NCT06337331|DRUG|Fludarabine|30mg/m2/day IV Days -7 to -3
219181579|NCT04255784|DEVICE|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
219181580|NCT04255784|DEVICE|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
219754023|NCT03615638|OTHER|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
219754024|NCT01292031|DRUG|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
219754025|NCT01292031|DRUG|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
218995865|NCT06337331|DRUG|Busulfan|3.2mg/kg/day IV Days -5 to -4
218995866|NCT06337331|RADIATION|Total Body Irradiation|200cGy Day -2
218995867|NCT05673278|DIAGNOSTIC_TEST|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~\+ Image quality"
218995868|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
218995869|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
218995870|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
218995871|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
218995872|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
218995873|NCT02301884|BIOLOGICAL|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
218995874|NCT05137106|OTHER|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
218995875|NCT05137106|OTHER|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
218995876|NCT01995240|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
218995877|NCT01675414|OTHER|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
219181581|NCT05840263|BEHAVIORAL|Qualitative interview|Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
219181582|NCT05840263|BEHAVIORAL|Cognitive Interviews|The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
218995878|NCT01473836|DRUG|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
218995879|NCT01473836|DRUG|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
218995880|NCT00878774|BIOLOGICAL|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
218995881|NCT00878774|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
219181583|NCT05739149|DIAGNOSTIC_TEST|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
219181584|NCT05739149|PROCEDURE|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
218995882|NCT01993654|PROCEDURE|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
218995883|NCT05261360|DRUG|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
218995884|NCT05261360|DRUG|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
219181585|NCT05916170|BEHAVIORAL|Health Warnings|Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
219181586|NCT05916170|BEHAVIORAL|No Warnings|No warnings posted in the hookah café
219754026|NCT03344887|OTHER|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
218995885|NCT01166113|DRUG|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
218995886|NCT00208611|DIETARY_SUPPLEMENT|Vitamin B12 Supplementation|1000 micrograms daily
218995887|NCT05450341|DEVICE|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
219181587|NCT01098812|DEVICE|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
219181588|NCT01098812|DEVICE|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
219181589|NCT05180526|DRUG|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
219181590|NCT05360459|RADIATION|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
219181591|NCT06294769|OTHER|essencial oil of lavandula angustifolia|The intervention will consist of the application of aromatherapy with 2% lavender essential oil cutaneously and inhalation via by a nurse, associated with usual care, in the immediate postoperative period
219181592|NCT06294769|OTHER|grape seed vegetable oil|The placebo group will only receive the application of grape seed vegetable oil associated with usual care in the immediate postoperative period.
219754027|NCT03344887|OTHER|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
219754028|NCT06506747|DEVICE|Navigated Photogrammetry|Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
218995888|NCT05450341|DEVICE|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
218995889|NCT03364023|DEVICE|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
218995890|NCT04068662|BEHAVIORAL|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
218995891|NCT04068662|BEHAVIORAL|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
219754029|NCT06506747|DEVICE|Standard Photogrammetry|The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
219754030|NCT02484274|BIOLOGICAL|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
219754031|NCT03925480|DRUG|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
219754032|NCT03925480|DRUG|Matching Placebo|Matching Placebo
219754033|NCT04565665|OTHER|Best Practice|Receive standard of care
219754034|NCT04565665|BIOLOGICAL|Mesenchymal Stem Cell|Given IV
219754035|NCT05662202|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
219754036|NCT05662202|COMBINATION_PRODUCT|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
219754037|NCT05949099|DRUG|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
219754038|NCT05949099|PROCEDURE|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
219754039|NCT02464748|OTHER|TiM telehealth arm|
219754040|NCT05677347|DRUG|GSK3923868|GSK3923868 will be administered
219754041|NCT05677347|DRUG|Placebo|Placebo will be administered
219754042|NCT04728113|OTHER|Supportive care visit with questionnaires|5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
219754043|NCT04728113|OTHER|Oncological standard visit|Oncological standard visit
219754044|NCT06530615|PROCEDURE|Bronchoalveolar Lavage (BAL) during Bronchoscopy|Bronchoalveolar Lavage (BAL) is a standard diagnostic tool for the evaluation of lower respiratory tract pathology including respiratory infections and unexplained radiographic pulmonary lesions including lung neoplasia. It is a minimally invasive procedure that involves introduction of the bronchoscope, installation of sterile normal saline into a subsegment of the lung, and suction and collection of the recovered saline for diagnostic evaluation.
219754045|NCT04179981|DEVICE|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
219754046|NCT04179981|OTHER|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
219754047|NCT06971796|DEVICE|Inspire UAS System|Participants will be implanted with the Inspire UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
219754048|NCT00611663|BIOLOGICAL|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
219754049|NCT00611663|BIOLOGICAL|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
219754050|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
218995892|NCT04998461|BIOLOGICAL|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
218995893|NCT05439161|DEVICE|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
219181593|NCT04663724|BEHAVIORAL|Computer-Based Treatment|A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
219181594|NCT02732834|BEHAVIORAL|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
219369633|NCT01972321|BEHAVIORAL|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
219754051|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
219754052|NCT06569797|DIETARY_SUPPLEMENT|oligosaccharides and multiple nutrients|The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
219754053|NCT06569797|DIETARY_SUPPLEMENT|no oligosaccharides and optimizing multiple nutrients|The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
219754054|NCT06569797|DIETARY_SUPPLEMENT|breastfeeding|The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
219754055|NCT06110910|DRUG|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
219754056|NCT06053892|DIAGNOSTIC_TEST|Puncture|Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
219754057|NCT02796911|DRUG|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
219754058|NCT02796911|DRUG|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
219754059|NCT05825716|OTHER|Ifaa Basic|"* PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~* Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~* Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~* Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
219754060|NCT05825716|BEHAVIORAL|Ifaa Enhanced|"* PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~* Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~* Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~* Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
219754061|NCT05825716|OTHER|Ifaa Enhanced + Livelihoods|"* Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~* Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
219754062|NCT01715870|BEHAVIORAL|Life style and food habits questionnaire|
219754063|NCT02065986|DRUG|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
219181595|NCT02732834|BEHAVIORAL|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
218995894|NCT04669639|OTHER|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia"
218995895|NCT02753023|OTHER|no intervention|No intervention related
218995896|NCT06037434|DRUG|Captopril Tablets|0.3mg/kg, tid
218995897|NCT06037434|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
218995898|NCT06037434|DRUG|Spironolactone Tablets|2-4mg/kg, bid
218995899|NCT06037434|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
218995900|NCT06037434|DRUG|Potassium citrate powder|0.06g/kg, tid
218995901|NCT05872646|DIAGNOSTIC_TEST|clinical assessment|clinical staging
218995902|NCT04666051|BIOLOGICAL|Application of fibrin glue sealant|
218995903|NCT04519125|DRUG|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
219181596|NCT02732834|BEHAVIORAL|Audio recordings of clinical consultations|
219181597|NCT02732834|BEHAVIORAL|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
219181598|NCT02732834|BEHAVIORAL|2-hour empathic communication skills training|2-hour empathic communication skills training
218995904|NCT04519125|OTHER|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
219754064|NCT06535373|OTHER|Blood flow restriction|Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
218995905|NCT03684395|DRUG|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
218995906|NCT03684395|DRUG|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
218995907|NCT05627154|DRUG|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
218995908|NCT05627154|BEHAVIORAL|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
219181599|NCT02732834|BEHAVIORAL|Standardized Patient Assessments|pre-training SPA, post-training SPA
219754065|NCT06576648|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.
218995909|NCT05627154|DRUG|Placebo|A lactose-based tablet.
218995910|NCT00719251|DEVICE|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
218995911|NCT00719251|DEVICE|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
218995912|NCT00719251|OTHER|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
218995913|NCT03566394|DRUG|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
218995914|NCT02348827|BEHAVIORAL|Family psychoeducation|
218995915|NCT02348827|BEHAVIORAL|Social support group|
218995916|NCT01651195|DIETARY_SUPPLEMENT|Probiotic|
219181600|NCT02732834|BEHAVIORAL|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
219181601|NCT02732834|BEHAVIORAL|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
219181602|NCT04475679|DEVICE|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth surface
218995917|NCT01651195|OTHER|Placebo|
218995918|NCT01029574|OTHER|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
218995919|NCT02417974|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
218995920|NCT00963196|DIETARY_SUPPLEMENT|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
218995921|NCT00963196|DRUG|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
218995922|NCT00000443|DRUG|ondansetron (Zofran)|
218995923|NCT04988646|DRUG|Acyclovir 200 MG|Administered with 240 mL of water
218995924|NCT04988646|DRUG|Acyclovir 400 MG|Administered with 240 mL of water
218995925|NCT04988646|DRUG|Zovirax 200 MG Tablet|Administered with 240 mL of water
218995926|NCT04988646|DRUG|Zovirax 400 MG Tablet|Administered with 240 mL of water
218995927|NCT00164554|BEHAVIORAL|Parent-child Interaction Therapy (PCIT)|
218995928|NCT02697864|DRUG|tafamidis|
218995929|NCT00811369|DRUG|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
218995930|NCT00811369|DRUG|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
218995931|NCT03715881|DRUG|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
218995932|NCT03715881|DRUG|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
219369634|NCT01972321|OTHER|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
219754066|NCT06576648|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.
219754067|NCT06576648|BEHAVIORAL|Standard PrEP Counseling|All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.
219754068|NCT06647589|BEHAVIORAL|Acceptance and Commitment Therapy|participants will then receive ACT-based individual therapy weekly for twelve weeks.
219754069|NCT05946213|PROCEDURE|Computed Tomography|Undergo CT
218995933|NCT01140243|DIETARY_SUPPLEMENT|LCPUFA|premature infant formula supplemented with LCPUFA
218995934|NCT02356575|OTHER|Acupuncture|
219181603|NCT04475679|DEVICE|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth
219181604|NCT06086431|DRUG|0.9% sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
219181605|NCT06086431|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
219181606|NCT06086431|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
219369635|NCT01099228|OTHER|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
219369636|NCT01099228|OTHER|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
219369637|NCT01199666|OTHER|Text message|text message appointment and immunization reminders
219369638|NCT01488006|DEVICE|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
219754070|NCT05946213|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219754071|NCT05946213|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219754072|NCT05946213|OTHER|Quality-of-Life Assessment|Ancillary studies
219754073|NCT05946213|OTHER|Questionnaire Administration|Ancillary studies
219754074|NCT05946213|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219754075|NCT05363527|BIOLOGICAL|Endotoxin|Endotoxin
219754076|NCT05363527|BIOLOGICAL|Placebo|Placebo
219754077|NCT03834363|DRUG|Fentanyl|Fentanylpatch 12 mcg/hr, change patch every three days.
219754078|NCT03834363|DRUG|Morphine Retard|Morphine retard capsules 10 mg bid.
219754079|NCT03834363|DRUG|Placebo patch|Placebo patch, change patch every three days.
219754080|NCT03834363|DRUG|Placebo oral capsule|Placebo oral capsule bid
219754081|NCT05860673|PROCEDURE|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
218995935|NCT02356575|OTHER|Cognitive Behavior Therapy|
218995936|NCT00000688|DRUG|Ganciclovir|
218995937|NCT00844389|DEVICE|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
218995938|NCT00844389|DEVICE|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
218995939|NCT00105469|DRUG|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
218995940|NCT00105469|DRUG|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
218995941|NCT05577442|DRUG|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
218995942|NCT00380952|DEVICE|Dune Device|
219181607|NCT05597085|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
219181608|NCT05931432|OTHER|Comprehensive Well-Being Intervention|The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
218995943|NCT03444961|DEVICE|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
218995944|NCT04254471|DRUG|AL3810|5mgQD, 7.5mgQD, 10mgQD
218995945|NCT04254471|DRUG|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
218995946|NCT04254471|DRUG|Placebo|Placebo
218995947|NCT03205033|DRUG|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
218995948|NCT03205033|DRUG|Placebo oral capsule|1 capsule/day 1 hour before go to bed
218995949|NCT02598544|OTHER|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
218995950|NCT01437722|DRUG|1% SPL7013 Gel|vaginal gel
218995951|NCT01437722|DRUG|3% SPL7013 Gel|vaginal gel
218995952|NCT01437722|DRUG|placebo gel|vaginal gel
218995953|NCT03558854|DRUG|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
218995954|NCT03558854|DRUG|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
218995955|NCT01270412|BIOLOGICAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
218995956|NCT01270412|DRUG|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
218995957|NCT02417597|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
218995958|NCT02787668|OTHER|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
218995959|NCT02787668|OTHER|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
219181609|NCT04418037|DEVICE|Digital Health Feedback System(DHFS)|We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
219181610|NCT06773286|OTHER|Active Stimulation|Participants will receive activity-based training (ABT) while receiving concomitant, active spinal stimulation (scTS) applied at the cervical and thoracic spinal segments over the dorsal skin with optimized and customized stimulation parameters. Round self-adhesive electrodes will be placed over the skin at the midline of spinous processes as cathodes and a pair of rectangular anodes electrodes will be placed over the anterior iliac crests of the pelvis. The stimulation waveform is rectangular pulse with 1-ms duration filled with a carrier frequency of 5kHz. Target simulation will be sub-threshold for UE muscle activation and verified by the absence of visible muscle contraction. The stimulation parameters will be adjusted as needed throughout the intervention course based on the participant's performance and comfort level. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
219369639|NCT05878028|COMBINATION_PRODUCT|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
218995960|NCT03023475|DEVICE|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
218995961|NCT03023475|DEVICE|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
218995962|NCT03517098|PROCEDURE|The ERAS group|"ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
218995963|NCT03517098|PROCEDURE|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
218995964|NCT00501670|PROCEDURE|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
218995965|NCT00501670|PROCEDURE|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
218995966|NCT06247020|DIETARY_SUPPLEMENT|Supplementation with sodium- butyrrate|Oral supplementation with sodium butyrrate capsules
218995967|NCT06247020|DIETARY_SUPPLEMENT|Placebo|Oral supplementation with placebo capsules
218995968|NCT00552721|OTHER|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
218995969|NCT00552721|OTHER|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
218995970|NCT03736616|DRUG|Carboplatin|Chemotherapy
218995971|NCT03736616|DRUG|Ifosfamide|Chemotherapy
218995972|NCT03736616|DRUG|Etoposide|Chemotherapy
218995973|NCT03736616|BIOLOGICAL|Rituximab|Anti-CD20 mAb
218995974|NCT03736616|DRUG|Carmustine|Chemotherapy
218995975|NCT03736616|DRUG|Cytarabine|Chemotherapy
218995976|NCT03736616|DRUG|Melphalan|Chemotherapy
218995977|NCT03736616|OTHER|Autologous HSCT|Cellular Therapy
218995978|NCT03736616|DRUG|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
218995979|NCT04678271|BEHAVIORAL|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
218995980|NCT04658498|OTHER|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
219181611|NCT06773286|OTHER|Sham|The sham-control group will go through ABT paired with sham stimulation to control for placebo effects associated with the perception of scTS. Stimulation will be delivered at one cervical location. No stimulation mapping procedure will be performed. During the training session, the stimulation intensity will be briefly ramped up to a level at which the participants report perceiving the stimulation, and then ramped down to 0mA at both the start and the end of session. The stimulator and electrodes will remain attached to the participant while receiving ABT training. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
219181612|NCT06773286|OTHER|Training only|articipants in ABT group will receive ABT only. ABT will concentrate on activities of gross UE movement, grasping, pinching, gross and fine motor skill. The hand grasp task will focus on grasping objects with different shapes and weights (i.e. weighted container and tennis ball) and placing/removing them from small storage container; the pinch task involves picking up, translating, and releasing small objects with varied sizes (i.e. blocks, dices, marble balls, nuts, etc.). The training therapist selects tasks based on participant's level of impairment and individual goals. The dosage of ABT will be 30 minutes/session, with approximately 15 minutes allocated on each side.
219181613|NCT06788015|DIETARY_SUPPLEMENT|Hydrogen-infused water|Water containing molecular hydrogen
219181614|NCT06788015|DIETARY_SUPPLEMENT|Placebo|Water containing no molecular hydrogen
219369640|NCT03181113|DRUG|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
219369641|NCT03181113|DRUG|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
219369642|NCT03384329|DRUG|Resveratrol Pill|Resveratrol 500 mg
218995981|NCT04658498|OTHER|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
218995982|NCT04658498|OTHER|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
218995983|NCT05581420|DRUG|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
218995984|NCT05581420|DRUG|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
218995985|NCT00517998|DRUG|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
218995986|NCT00630981|BEHAVIORAL|Psychotherapy|Specific psychotherapy for dissociative disorders
218995987|NCT00630981|DRUG|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
218995988|NCT03129698|DRUG|Apatinib|Apatinib 250mg daily
218995989|NCT06376279|GENETIC|IEM-EP|Data from IEM-inborn error of metabolism cohort of individuals
218995990|NCT01941121|BEHAVIORAL|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
218995991|NCT01236599|OTHER|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
219181615|NCT06822608|DRUG|dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
218995992|NCT02452489|DEVICE|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
218995993|NCT02452489|DEVICE|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
218995994|NCT02452489|DEVICE|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
218995995|NCT03504475|DRUG|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
218995996|NCT03504475|DRUG|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
218995997|NCT00041990|DRUG|decitabine (5-aza-2'deoxycytidine)|
218995998|NCT05002062|DEVICE|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
218995999|NCT05002062|OTHER|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
218996000|NCT02820753|BEHAVIORAL|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
218996001|NCT01308554|DRUG|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
218996002|NCT01308554|DRUG|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
218996003|NCT01332474|DRUG|BOTOX|BOTOX
218996004|NCT01722084|BEHAVIORAL|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
218996005|NCT05588232|PROCEDURE|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
218996006|NCT02878746|DEVICE|Robotic mirror therapy|2-dimensional
218996007|NCT02878746|DEVICE|Conventional mirror therapy|2- and 3-dimensional
218996008|NCT01874132|BEHAVIORAL|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
218996009|NCT01286298|PROCEDURE|Laser gingivectomy|Gingivectomy by diode laser
218996010|NCT01286298|PROCEDURE|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
218996011|NCT02161731|DRUG|Evacetrapib|Oral administration
218996012|NCT02161731|DRUG|Warfarin|Oral administration
218996013|NCT00002169|DRUG|Nelfinavir mesylate|
218996014|NCT05742594|DRUG|Lazertinib|Lazertinib will be administered orally.
218996015|NCT00646009|DRUG|budesonide/formoterol|
218996016|NCT00646009|DRUG|fluticasone/salmeterol|
218996017|NCT00646009|DRUG|albuterol|
218996018|NCT01408485|DEVICE|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator"
219181616|NCT06822608|DRUG|Placebo|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
219369643|NCT03384329|DRUG|Placebos|Placebo Pills
218996019|NCT00465374|PROCEDURE|Change ventilatory parameters with stress index monitoring|
218996020|NCT03935100|PROCEDURE|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
218996021|NCT03935100|OTHER|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
218996022|NCT05755048|BIOLOGICAL|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
219181617|NCT01134653|OTHER|Jump Stretch|distraction with early mobilization
219181618|NCT06807866|DRUG|Duloxetine|Participants will come in person and receive a one time 60 mg dose by mouth.
219181619|NCT06807866|OTHER|Placebo|Participants will come in person and receive a one time 60 mg placebo pill dose by mouth.
219181620|NCT06441630|DRUG|AD-227A|Per Oral, 1 Tablet, Once a day for 8 weeks
219369644|NCT01167608|OTHER|No Intervention. This is a cross-sectional survey study.|No intervention.
218996023|NCT05755048|BIOLOGICAL|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
218996024|NCT04884477|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
218996025|NCT06281990|BEHAVIORAL|Education|"1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded."
218996026|NCT01738373|DRUG|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
218996027|NCT02052284|OTHER|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
218996028|NCT05025761|OTHER|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
218996029|NCT00692081|BEHAVIORAL|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
218996030|NCT00692081|BEHAVIORAL|Special vocational training|as provided in German special centres for vocational training
218996031|NCT00617773|BIOLOGICAL|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
218996032|NCT02283697|BEHAVIORAL|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
218996033|NCT02283697|OTHER|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
218996034|NCT02554669|BEHAVIORAL|postprandial and postabsorptive physical activity on treadmill|
218996035|NCT03732235|DEVICE|TACE+ systemic Bevacizumab|PEG embolics
218996036|NCT03732235|DRUG|FOLFIRI+Bevacizumab|antiangiogenic factor
218996037|NCT03732235|DEVICE|TACE|PEG embolics
218996038|NCT03582540|PROCEDURE|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
218996039|NCT05443789|BEHAVIORAL|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
218996040|NCT05443789|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
218996041|NCT02837016|DEVICE|Wearable biofeedback|
218996042|NCT02837016|BEHAVIORAL|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
218996043|NCT03568760|BEHAVIORAL|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
218996044|NCT03568760|BEHAVIORAL|Comprehension training|Reading and hearing comprehension
218996045|NCT03074591|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
218996046|NCT03074591|DRUG|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
218996047|NCT02174120|DRUG|propofol|
218996048|NCT02174120|DRUG|etomidate|
218996049|NCT00957775|BEHAVIORAL|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
218996050|NCT00957775|BEHAVIORAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
218996051|NCT00036738|DRUG|Cyclosporine|Given IV or PO
218996052|NCT00036738|DRUG|Dasatinib|Given PO
218996053|NCT00036738|DRUG|Fludarabine Phosphate|Given IV
218996054|NCT00036738|DRUG|Imatinib Mesylate|Given PO
218996055|NCT00036738|DRUG|Mycophenolate Mofetil|Given PO
218996056|NCT00036738|DRUG|Nilotinib|Given PO
218996057|NCT00036738|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
218996058|NCT00036738|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
218996059|NCT00036738|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
218996060|NCT00036738|RADIATION|Total-Body Irradiation|Undergo TBI
218996061|NCT03773081|DEVICE|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
218996062|NCT02902419|OTHER|Wound dressing removal.|
218996063|NCT04650360|BEHAVIORAL|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
218996064|NCT00134095|DRUG|irinotecan hydrochloride|
218996065|NCT00134095|DRUG|tegafur-gimeracil-oteracil potassium|
218996066|NCT00134095|PROCEDURE|adjuvant therapy|
218996067|NCT00134095|PROCEDURE|conventional surgery|
218996068|NCT00134095|PROCEDURE|neoadjuvant therapy|
218996069|NCT06957912|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. All conscious patients will be told they may or may not feel any sensation from the stimulation.~The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery."
218996070|NCT06957912|DEVICE|Sham stimulation|Sham stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. And the current will be automatically switched off after 15 s. All conscious patients will be told they may or may not feel any sensation from the stimulation. The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery.
218996071|NCT02706470|DRUG|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
218996072|NCT02706470|DRUG|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
218996073|NCT03398967|BIOLOGICAL|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~3. Other: Laboratory Biomarker Analysis"
218996074|NCT01023750|DRUG|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
218996075|NCT01127074|BIOLOGICAL|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
218996076|NCT00314665|DRUG|Thalidomide|
219181621|NCT06441630|DRUG|AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
219181622|NCT06441630|DRUG|AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
219181623|NCT06441630|DRUG|Placebo of AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
219181624|NCT06441630|DRUG|Placebo of AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
219181625|NCT04502888|DRUG|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
219181626|NCT05964868|DRUG|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
219181627|NCT05964868|DRUG|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
219181628|NCT05964868|OTHER|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
219181629|NCT05915013|DRUG|Ketamine|Intravenous ketamine
219181630|NCT05915013|DRUG|Perampanel|Oral perampanel (6 mg)
219181631|NCT05915013|DRUG|Placebo|Oral placebo
219181632|NCT05472558|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
218996077|NCT05004766|OTHER|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
218996078|NCT04792164|PROCEDURE|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
218996079|NCT04792164|PROCEDURE|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
218996080|NCT01888679|PROCEDURE|Head movement|Head movement in extension, flexion, right and left rotation
218996081|NCT01221883|DRUG|Diazepam|Single dose 10mg Diazepam tablet
218996082|NCT03998033|BIOLOGICAL|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
218996083|NCT02224040|DRUG|ceftriaxone|
218996084|NCT02224040|DRUG|ceftriaxone and azithromycin|
218996085|NCT02224040|DRUG|azithromycin|
218996086|NCT02224040|DRUG|azithromycin and cefixime|
218996087|NCT05168488|BEHAVIORAL|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
218996088|NCT05168488|BEHAVIORAL|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
219181633|NCT06228924|GENETIC|TN-401|TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
219181634|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
219181635|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
219181636|NCT03506308|DEVICE|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
219181637|NCT03543852|BEHAVIORAL|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
219181638|NCT01480440|DEVICE|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
219181639|NCT04072198|DRUG|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
219181640|NCT04072198|DRUG|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
218996089|NCT00617565|DRUG|biphasic insulin aspart|
218996090|NCT00617565|DRUG|biphasic human insulin|
218996091|NCT03906123|DRUG|NBP|NBP soft capsules
218996092|NCT03906123|DRUG|Placebos|Soft capsules manufactured to mimic NBP
218996093|NCT01735682|DEVICE|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
218996094|NCT01735682|BEHAVIORAL|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
218996095|NCT01735682|BEHAVIORAL|Control|The control treatment involves exercises of the upper limbs.
218996096|NCT03015389|PROCEDURE|Diagnostic Test|WATS3D brush biopsy
218996097|NCT01235247|BEHAVIORAL|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
218996098|NCT02047890|DRUG|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
218996099|NCT02047890|DRUG|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
218996100|NCT04847505|DIAGNOSTIC_TEST|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
218996101|NCT04340401|DRUG|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
218996102|NCT04340401|DRUG|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
218996103|NCT04340401|DRUG|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
218996104|NCT04340401|RADIATION|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
218996105|NCT04340401|PROCEDURE|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
218996106|NCT02552199|OTHER|gravimetric|
218996107|NCT03837106|OTHER|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
218996108|NCT03487276|DRUG|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
218996109|NCT03487276|DRUG|Placebo|Placebo
218996110|NCT03174236|DRUG|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
218996111|NCT03174236|DRUG|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
218996112|NCT03174236|DRUG|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
218996113|NCT03174236|OTHER|Placebo|Suspension manufactured to match metronidazole
218996114|NCT03174236|DRUG|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
218996115|NCT05035550|BEHAVIORAL|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
218996116|NCT01179854|DRUG|Remegal|Drug/ placebo
218996117|NCT01751867|DRUG|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
218996118|NCT01751867|DRUG|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
218996119|NCT04920604|OTHER|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
218996120|NCT04920604|OTHER|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
218996121|NCT04769440|DRUG|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
218996122|NCT01464489|DRUG|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
218996123|NCT01464489|DRUG|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
218996124|NCT00754819|DRUG|Colchicine|1mg once daily
219181641|NCT04072198|DRUG|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
219181642|NCT04072198|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
219181643|NCT04072198|DRUG|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
219181644|NCT04072198|DRUG|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
219181645|NCT03462030|DRUG|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
219181646|NCT03462030|DRUG|Placebo: Tapioca Powder|Placebo control.
219181647|NCT06128343|OTHER|collection of biological samples|Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
218996125|NCT00754819|DRUG|Placebo|1 capsule daily
218996126|NCT00002531|DRUG|asparaginase|
218996127|NCT00002531|DRUG|cyclophosphamide|
218996128|NCT00002531|DRUG|cytarabine|
218996129|NCT00002531|DRUG|daunorubicin hydrochloride|
218996130|NCT00002531|DRUG|dexamethasone|
218996131|NCT00002531|DRUG|doxorubicin hydrochloride|
218996132|NCT00002531|DRUG|etoposide|
218996133|NCT00002531|DRUG|ifosfamide|
218996134|NCT00002531|DRUG|leucovorin calcium|
218996135|NCT00002531|DRUG|mercaptopurine|
218996136|NCT00002531|DRUG|methotrexate|
218996137|NCT00002531|DRUG|mitoxantrone hydrochloride|
218996138|NCT00002531|DRUG|prednisolone|
218996139|NCT00002531|DRUG|teniposide|
218996140|NCT00002531|DRUG|thioguanine|
218996141|NCT00002531|DRUG|vincristine sulfate|
218996142|NCT00002531|DRUG|vindesine|
218996143|NCT00002531|PROCEDURE|allogeneic bone marrow transplantation|
218996144|NCT00002531|PROCEDURE|peripheral blood stem cell transplantation|
218996145|NCT00002531|RADIATION|radiation therapy|
218996146|NCT03354611|RADIATION|Contrast Enhanced Cone Beam Breast CT Scan|"* Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
218996147|NCT03354611|DRUG|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement."
218996148|NCT04610840|PROCEDURE|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
218996149|NCT01806545|BIOLOGICAL|SRM003|One time implant (2 SRM003 pieces) on surgery day.
218996150|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
219181648|NCT05832216|DRUG|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
219181649|NCT06316778|BEHAVIORAL|Pelvic floor muscle training|12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
219181650|NCT06218303|BIOLOGICAL|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
218996151|NCT03006991|OTHER|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
218996152|NCT00295841|DRUG|clofarabine|
218996153|NCT00295841|DRUG|cytarabine|
218996154|NCT01325415|DRUG|NKTR-118|25 mg tablet
218996155|NCT01325415|DRUG|moxifloxacin|400 mg tablet
218996156|NCT01325415|DRUG|Placebo|tablet
218996157|NCT02116907|DRUG|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
218996158|NCT01267734|DEVICE|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
218996159|NCT01267734|DEVICE|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
218996160|NCT01267734|DRUG|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
218996161|NCT01267734|DRUG|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
218996162|NCT00001995|DRUG|Rifabutin|
218996163|NCT05432414|DRUG|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
218996164|NCT05432414|DRUG|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
218996165|NCT05432414|DRUG|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
218996166|NCT03793231|COMBINATION_PRODUCT|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
218996167|NCT03910842|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
218996168|NCT01089062|DRUG|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
218996169|NCT01089062|DRUG|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
219181651|NCT06218303|DRUG|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
219181652|NCT06218303|DRUG|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
219369645|NCT04186611|OTHER|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
219369646|NCT03251326|DRUG|Nabilone|Nabilone capsules (4 mg)
218996170|NCT01089062|DRUG|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
218996171|NCT01089062|DRUG|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
218996172|NCT04058145|DRUG|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
218996173|NCT04058145|DRUG|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
218996174|NCT04635215|DEVICE|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
218996175|NCT03214965|BEHAVIORAL|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
218996176|NCT00840450|DRUG|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
218996177|NCT03513731|DEVICE|Adipose-derived stem cell injection|ADRC injection into the facet joint
218996178|NCT03513731|DRUG|Corticosteroid injection|Corticosteroid injection into the facet joint
218996179|NCT04404374|PROCEDURE|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
218996180|NCT03323112|BIOLOGICAL|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
218996181|NCT04566328|DRUG|Bortezomib|Given SC
218996182|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
218996183|NCT04566328|DRUG|Dexamethasone|Given PO
218996184|NCT04566328|DRUG|Lenalidomide|Given PO
218996185|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
218996186|NCT00617123|DRUG|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
218996187|NCT00617123|DRUG|Placebo|matching placebo oral tablet
218996188|NCT00461045|DRUG|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
218996189|NCT00133952|DRUG|Ruboxistaurin|Administered orally
218996190|NCT00133952|DRUG|Placebo|Administered orally
218996191|NCT00314093|DRUG|RFT5pdgA|
218996192|NCT04293120|OTHER|Training with weighted ball|Participants will stop or catch a weighted ball
218996193|NCT06378255|DEVICE|Polycation-based new dentinal desensitizer|Dental desensitization treatment
218996194|NCT06378255|DEVICE|GLUMA desensitizer|Dental desensitization treatment
218996195|NCT04303819|DRUG|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
219369647|NCT03251326|DRUG|Cannabis|Cigarettes (0.0 and 5.6% THC)
219369648|NCT03251326|DRUG|Propranolol|Propranolol capsules (40mg)
218996196|NCT00682162|DEVICE|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
218996197|NCT00682162|DEVICE|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
218996198|NCT01482000|OTHER|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
218996199|NCT01482000|OTHER|usual care|The control group will get the usual care with some additional tests for the study.
218996200|NCT04277416|DEVICE|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
218996201|NCT01142349|BEHAVIORAL|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
218996202|NCT01142349|BEHAVIORAL|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
218996203|NCT01142349|BEHAVIORAL|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
218996204|NCT02556814|DRUG|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
218996205|NCT02556814|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
218996206|NCT02556814|DRUG|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
218996207|NCT04810312|OTHER|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
218996208|NCT00728871|PROCEDURE|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
218996209|NCT02648776|DRUG|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
218996210|NCT00520936|DRUG|pemetrexed|1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
218996211|NCT04522960|DIAGNOSTIC_TEST|MEG+hdEEG+MRI|"We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
218996212|NCT00783003|DRUG|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
218996213|NCT00783003|DRUG|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
218996214|NCT00783003|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
218996215|NCT00783003|DRUG|Placebo|Matching placebo.
218996216|NCT03481322|DIETARY_SUPPLEMENT|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
218996217|NCT03258021|DEVICE|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
218996218|NCT05062382|BEHAVIORAL|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
218996219|NCT04579705|OTHER|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
218996220|NCT02554357|DRUG|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
218996221|NCT02554357|DRUG|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
218996222|NCT02460302|DRUG|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
218996223|NCT02460302|DRUG|Placebo|Placebo suppository inserted vaginally
218996224|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
218996225|NCT05777876|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
219369649|NCT03251326|DRUG|Placebo|Placebo capsules
218996226|NCT05777876|DEVICE|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
218996227|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
218996228|NCT02759328|BEHAVIORAL|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
218996229|NCT02759328|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
218996230|NCT03369405|OTHER|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
218996231|NCT04561193|OTHER|Observational|Observational
218996232|NCT06352203|DIETARY_SUPPLEMENT|Probiotic|1 dose of the probiotic every 24 hours, for 6-months.
218996233|NCT06352203|DIETARY_SUPPLEMENT|Placebo|1 dose of the placebo every 24 hours, for 6-months.
218996234|NCT02612662|DRUG|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
218996235|NCT02612662|DRUG|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
218996236|NCT02683161|DRUG|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
219181653|NCT06771596|DRUG|Nimotuzumab Injection|Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
219181654|NCT03810807|DRUG|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
218996237|NCT02683161|BEHAVIORAL|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
218996238|NCT02683161|BEHAVIORAL|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
218996239|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
218996240|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
218996241|NCT03781115|DRUG|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
219181655|NCT03810807|DRUG|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
219181656|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
219369650|NCT06543771|DIAGNOSTIC_TEST|Safety Test ABO and ABTest Card®|Pre transfusional control with the Safety Test ABO device (reference device) and the ABTest Card® device (comparator).
219369651|NCT03670030|DRUG|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
219369652|NCT00003490|BIOLOGICAL|sargramostim|
218996242|NCT03781115|DRUG|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
218996243|NCT03781115|DRUG|Placebo Comparator|A non drug oral placebo capsule will be given as a control
219369653|NCT00003490|DRUG|cyclophosphamide|
219369654|NCT00003490|DRUG|prednisone|
219369655|NCT00003490|DRUG|vincristine sulfate|
218996244|NCT03674749|OTHER|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
218996245|NCT06193252|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
218996246|NCT05525208|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
218996247|NCT05525208|BIOLOGICAL|Active Comparator|The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
218996248|NCT02228629|DEVICE|CrocsRx Medical Silver cloud clogs|
218996249|NCT06636786|DRUG|Cyclobenzaprine HCl|TNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
218996250|NCT06636786|DRUG|Placebo|Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
218996251|NCT03502239|OTHER|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
218996252|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
218996253|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
218996254|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
218996255|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
219181657|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
219181658|NCT06807931|OTHER|Interactive film|An interactive film, co-produced with young people, that aims to provide young people with a virtual experience of making choices and facing consequences in various life scenarios. At key moments the action is paused and the user decides the outcome. The particular film series that was commissioned and included in the trial was 'Jessica's story', which focused on perinatal mental health, as well as many other public health issues relevant to young people, including mental wellbeing, domestic violence, and help-seeking behaviour.
219181659|NCT06553989|OTHER|osteopatic visceral mobilization|a combination of breathing and visceral mobilizations
219181660|NCT05987410|OTHER|Nordic Walking (NW)|The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
219181661|NCT05987410|OTHER|Standard Rehabilitation (SR)|The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
219181662|NCT05987410|OTHER|Cardiological Counselling (CC)|The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
219369656|NCT01722461|DEVICE|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
219369657|NCT01722461|DEVICE|Sham treatment|Ulthera System delivering no ultrasound energy
219369658|NCT04113811|DEVICE|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
218996256|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
218996257|NCT06642571|DRUG|NNC0519-0130 B|NNC0519-0130 B will be administered subcutaneously.
218996258|NCT06642571|DRUG|NNC0519-0130 C|NNC0519-0130 C will be administered subcutaneously.
218996259|NCT00003479|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
218996260|NCT06125145|BEHAVIORAL|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
218996261|NCT03102255|PROCEDURE|Sniffing position|All procedure is done under sniffing position.
218996262|NCT03102255|PROCEDURE|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
218996263|NCT01293175|DIETARY_SUPPLEMENT|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
218996264|NCT02128113|DRUG|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
218996265|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
218996266|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
218996267|NCT03195998|DIAGNOSTIC_TEST|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
218996268|NCT01061177|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
218996269|NCT00307411|DRUG|Growth hormone|
218996270|NCT03375775|DRUG|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
218996271|NCT03375775|OTHER|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
218996272|NCT00299104|DRUG|folate|Intravenous repeating dose
218996273|NCT00299104|DRUG|methotrexate|Oral or parenteral repeating dose
218996274|NCT00299104|DRUG|methylprednisolone|Intravenous repeating dose
218996275|NCT00299104|DRUG|placebo|Intravenous repeating dose
218996276|NCT00299104|DRUG|rituximab|Intravenous repeating dose
218996277|NCT03680105|DRUG|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
218996278|NCT03680105|DRUG|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
218996279|NCT02454400|OTHER|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active"
218996280|NCT02454400|OTHER|Waiting-list|"Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active"
218996281|NCT00587054|DRUG|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
218996282|NCT03888456|OTHER|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
218996283|NCT03888456|OTHER|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
218996284|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
218996285|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
218996286|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
218996287|NCT05873257|DEVICE|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
218996288|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
218996289|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
218996290|NCT06831175|DRUG|Camrelizumab|Camrelizumab was administered 200mg IV every 3 weeks.
218996291|NCT06831175|DRUG|Apatinib|Apatinib was administered 250 mg PO QD.
218996292|NCT06831175|DRUG|mitotane|Mitotane is administered orally and plasma concentration was measured. The target steady-state plasma concentration is 14-20 mg/L.
218996293|NCT06836349|OTHER|Early active motion training after operated FPL injury|Early active motion training after operated FPL injury
219369659|NCT05548478|PROCEDURE|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
219369660|NCT05548478|PROCEDURE|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
218996294|NCT06836349|OTHER|Immobilisation in plaster cast 4 weeks after operated FPL injury|Immobilisation in plaster cast 4 weeks after operated FPL injury
218996295|NCT05194358|DRUG|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
218996296|NCT06390306|DRUG|Ponatinib|Ponatinib is recommended orally (PO) daily continuously on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
218996297|NCT06390306|DRUG|Azacitidine|Azacitidine is recommended 75mg/m2 subcutaneously on days 1-7 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
219369661|NCT03065829|BEHAVIORAL|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
218996298|NCT06390306|DRUG|Venetoclax|Venetoclax is recommended orally (PO) daily on days 1-14 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
218996299|NCT06390306|DRUG|Olverembatinib|Olverembatinib is recommended orally (PO) every other day on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
218996300|NCT06294145|BEHAVIORAL|Savoring Intervention|The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
218996301|NCT05847842|PROCEDURE|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
218996302|NCT05847842|PROCEDURE|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
218996303|NCT05847842|PROCEDURE|Local infiltration|20 mL of 0.25% bupivacaine will be given
218996304|NCT02060123|BEHAVIORAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
218996305|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
218996306|NCT05988970|OTHER|Blood samples will be collected at two times before the treatment initiation:|"* at 4:00 a.m.~* at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
218996307|NCT03222960|DRUG|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
218996308|NCT03222960|DRUG|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
218996309|NCT03636984|DRUG|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
218996310|NCT06047483|DRUG|HRF2105 patch|HRF2105 patch ，external use，once a day
218996311|NCT06047483|DRUG|Loxoprofen patch|Loxoprofen patch ，external use，once a day
218996312|NCT06047483|DRUG|placebo|placebo ，external use，once a day
218996313|NCT03739593|DRUG|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
218996314|NCT03739593|DRUG|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
218996315|NCT03210571|DEVICE|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
218996316|NCT00109083|DRUG|RWJ-333369|
218996317|NCT02759783|RADIATION|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
218996318|NCT02759783|OTHER|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
218996319|NCT06065943|OTHER|Palpation and Fluoroscopy|Vessel puncture guided palpation and fluoroscopy only
218996320|NCT06065943|PROCEDURE|Ultrasound guidance|Vessel puncture guided by Ultrasound
218996321|NCT01435369|DRUG|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
218996322|NCT00454012|PROCEDURE|biophysical profile|
218996323|NCT06313775|PROCEDURE|bilateral orchiectomy|Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
218996324|NCT05528185|OTHER|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
218996325|NCT05801874|DIAGNOSTIC_TEST|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
218996326|NCT01294631|DRUG|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
218996327|NCT03699657|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
218996328|NCT03699657|DEVICE|SSM|Monopolar RFA using single switching mode (SSM)
219369662|NCT03065829|BEHAVIORAL|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
219369663|NCT00257634|DRUG|dexamethasone to injury site|
219369664|NCT04957563|BEHAVIORAL|olfactory rehabilitation|treatment for improve olfactory function
219369665|NCT00268814|DRUG|Diacetylmorphine|Diacetylmorphine (i.v.), daily
219369666|NCT00268814|BEHAVIORAL|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
219369667|NCT00268814|DRUG|Methadone|Methadone (p.o.), daily
218996329|NCT03699657|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
218996330|NCT01561170|DEVICE|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
218996331|NCT01561170|DEVICE|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
218996332|NCT00001006|DRUG|AS-101|
218996333|NCT05199129|DRUG|HCP1904-3|Take once daily for 8 weeks orally
218996334|NCT05199129|DRUG|RLD2001-1|Take once daily for 8 weeks orally
218996335|NCT01970215|DRUG|TA-8995|
218996336|NCT01970215|DRUG|Atorvastatin|
218996337|NCT01970215|DRUG|Rosuvastatin|
218996338|NCT01970215|DRUG|TA-8995 0mg (placebo)|
218996339|NCT01970215|DRUG|Placebo Statin|
218996340|NCT03622944|PROCEDURE|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
218996341|NCT03622944|PROCEDURE|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
218996342|NCT03622944|PROCEDURE|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
218996343|NCT03493594|OTHER|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
218996344|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
218996345|NCT02197247|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
218996346|NCT02197247|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
218996347|NCT02197247|PROCEDURE|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
218996348|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
218996349|NCT03857958|PROCEDURE|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
218996350|NCT05417139|OTHER|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
218996351|NCT03266965|DRUG|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
218996352|NCT03266965|DIETARY_SUPPLEMENT|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
219369668|NCT00268814|BEHAVIORAL|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
218996353|NCT01538043|OTHER|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
218996354|NCT03822078|DRUG|Placebo|Administered by subcutaneous injection
218996355|NCT03822078|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
218996356|NCT06014203|DIAGNOSTIC_TEST|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel"
219369669|NCT01285349|BEHAVIORAL|Couple HIV/STI prevention intervention|
219369670|NCT01285349|BEHAVIORAL|Couple-based HIV/STI prevention|
219369671|NCT01285349|BEHAVIORAL|Individual HIV/STI prevention|
218996357|NCT04344392|DIAGNOSTIC_TEST|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
218996358|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
218996359|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
218996360|NCT01854710|DRUG|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
218996361|NCT01854710|DRUG|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
218996362|NCT01854710|DRUG|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
218996363|NCT01854710|DRUG|Oral placebo|Oral capsule identical in appearance to moxifloxacin
218996364|NCT02908360|GENETIC|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
218996365|NCT03273114|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
219369672|NCT01285349|BEHAVIORAL|Couple Wellness Promotion|
219369673|NCT03609255|BEHAVIORAL|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
219369674|NCT03609255|BEHAVIORAL|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
219369675|NCT03609255|BEHAVIORAL|Control|An educational handout for sedentary behavior and weekly neutral topic videos
218996366|NCT03273114|OTHER|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
218996367|NCT01929798|DEVICE|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
218996368|NCT04286243|OTHER|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
218996369|NCT04286243|OTHER|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
218996370|NCT01949558|BEHAVIORAL|Dietary Intervention|
218996371|NCT00373152|PROCEDURE|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
218996372|NCT00373152|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
218996373|NCT00373152|PROCEDURE|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
218996374|NCT00373152|RADIATION|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
218996375|NCT05065632|DIAGNOSTIC_TEST|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
219181663|NCT06465524|DEVICE|High-intensity laser therapy|High-intensity laser therapy (HILT), also referred to as Class IV laser therapy, involves the administration of collimated and monochromatic electromagnetic radiation within the infrared or red spectrum. It operates at power levels exceeding 500 milliwatts (0.5 W), leveraging both photobiomodulation and thermal effects. This distinguishes HILT from Class III lasers (low-level laser therapy, or LLLT), which lack photothermal effects when operating below 500 mW.
219181664|NCT06675435|DEVICE|Nitric oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
218996376|NCT00790985|DIETARY_SUPPLEMENT|flavocoxid|medical food
218996377|NCT00790985|DRUG|Naproxen|antiinflammatory drug
218996378|NCT00370032|DRUG|alosetron|
218996379|NCT06120296|DEVICE|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
218996380|NCT01452828|DRUG|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
219181665|NCT04780971|DIAGNOSTIC_TEST|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) and subsequent OCT of the CTO vessel will be performed. OCT may also be performed during a staged procedure when clinically indicated.
219369676|NCT06217250|PROCEDURE|Traditional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
218996381|NCT01452828|DRUG|TR-701 FA|Two separate infusions of 200 mg
218996382|NCT01452828|DRUG|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
218996383|NCT03026400|PROCEDURE|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
218996384|NCT03026400|PROCEDURE|Subumbilical incision|Considered here as the ''control'' intervention.
218996385|NCT05129215|OTHER|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
218996386|NCT02052531|DRUG|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
218996387|NCT02052531|OTHER|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
218996388|NCT00158834|DRUG|Salmeterol/Fluticasone propionate combination product|
218996389|NCT00158834|DRUG|Fluticasone propionate|
218996390|NCT05801250|BEHAVIORAL|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
218996391|NCT03036007|OTHER|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
218996392|NCT03036007|OTHER|Exercises with Internet support|Neck-specific exercise with Internet support
218996393|NCT04774796|OTHER|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
218996394|NCT01578187|DEVICE|Hair2Go|Treatment with the device once under observation
218996395|NCT04837261|DRUG|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
218996396|NCT04837261|DRUG|Flecainide|80 mg/m2/d
218996397|NCT04837261|DRUG|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
218996398|NCT05043129|BIOLOGICAL|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
218996399|NCT05012332|PROCEDURE|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
218996400|NCT02672878|DEVICE|Bioresorbable vascular scaffold|
218996401|NCT05581628|DIAGNOSTIC_TEST|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
218996402|NCT05581628|DIAGNOSTIC_TEST|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
218996403|NCT05581628|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
218996404|NCT01022632|DIETARY_SUPPLEMENT|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
218996405|NCT01022632|DRUG|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
218996406|NCT01022632|DIETARY_SUPPLEMENT|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
218996407|NCT03208244|DRUG|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
218996408|NCT02398175|OTHER|reanimation/intubation|
218996409|NCT01221792|DRUG|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
218996410|NCT01221792|DRUG|Placebo|Non active comparator
218996411|NCT00894660|DRUG|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
218996412|NCT00894660|DRUG|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
218996413|NCT01709162|BIOLOGICAL|Ipilimumab|
218996414|NCT01709162|DRUG|Chemotherapy|
218996415|NCT02856035|OTHER|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
218996416|NCT05540457|DEVICE|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
218996417|NCT04733404|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
218996418|NCT05482412|DEVICE|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
218996419|NCT03845985|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
218996420|NCT04800744|OTHER|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
218996421|NCT04800744|OTHER|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
218996422|NCT02701400|BIOLOGICAL|Durvalumab|Given IV
218996423|NCT02701400|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218996424|NCT02701400|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218996425|NCT02701400|BIOLOGICAL|Tremelimumab|Given IV
218996426|NCT00608686|DIETARY_SUPPLEMENT|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
218996427|NCT00592930|DRUG|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
218996428|NCT00592930|DRUG|placebo|
218996429|NCT04459533|DEVICE|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
218996430|NCT00317512|PROCEDURE|Percutaneous Coronary Revascularization|
218996431|NCT00317512|DRUG|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
218996432|NCT00317512|DRUG|Voluven|
218996433|NCT06265246|OTHER|Habitual Diet + Milk|1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
218996434|NCT06265246|OTHER|Habitual Diet + Yogurt|2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
218996435|NCT03434093|DEVICE|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
218996436|NCT03434093|BEHAVIORAL|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
218996437|NCT00194571|BEHAVIORAL|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
219181666|NCT05971147|DIETARY_SUPPLEMENT|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
219181667|NCT06589518|DRUG|Tenofovir Alafenamide Citrate|Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
219181668|NCT03897374|DIAGNOSTIC_TEST|Genetic Testing|Buccal swab
219181669|NCT03647124|DRUG|Lenalidomide|Specified dose on specified days
219181670|NCT04087759|DRUG|Bedaquiline (Test formulation)|Participants will receive bedaquiline orally.
218996438|NCT00552565|DRUG|Rezular 15mg|Oral Tablets
218996439|NCT00552565|DRUG|Placebo|placebo
218996440|NCT00552565|DRUG|Rezular|Rezular 37.5mg 3xday up to 12 weeks
218996441|NCT00552565|DRUG|Rezular|Rezular 75mg 3xday up to 12 weeks
218996442|NCT00002588|DRUG|etoposide|
218996443|NCT00002588|DRUG|topotecan hydrochloride|
218996444|NCT04642443|DEVICE|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
218996445|NCT00967057|DRUG|asparaginase|Given intramuscularly
218996446|NCT00967057|DRUG|dexamethasone|Given orally
218996447|NCT00967057|DRUG|idarubicin|Given IV
218996448|NCT00967057|DRUG|methotrexate|Given intrathecally
218996449|NCT00967057|DRUG|mitoxantrone hydrochloride|Given IV
218996450|NCT00967057|DRUG|pegaspargase|Given intramuscularly
218996451|NCT00967057|DRUG|vincristine sulfate|Given IV
218996452|NCT00851370|DRUG|Omalizumab (Xolair)|Bi-weekly
218996453|NCT00851370|DRUG|Placebo|Bi-Weekly
219181671|NCT04087759|DRUG|Bedaquiline (Reference formulation)|Participants will receive bedaquiline orally.
219181672|NCT05896137|DRUG|CS0159|Oral QD
219181673|NCT05561478|DEVICE|Implantation of Synthesis Plus IOL (control device)|Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.
219181674|NCT05561478|DEVICE|Implantation of Synthesis Plus Toric IOL (investigational device)|Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
218996454|NCT00363883|DRUG|vorinostat|Given orally
218996455|NCT00363883|OTHER|laboratory biomarker analysis|Correlative studies
218996456|NCT00968201|DRUG|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
218996457|NCT00968201|DRUG|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
218996458|NCT06393829|BEHAVIORAL|Applying the Early Mobilization Program|A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
218996459|NCT02521545|DRUG|BIIB061|Capsule
218996460|NCT02818400|PROCEDURE|composite tissue allotransplantation|
218996461|NCT05501301|OTHER|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
218996462|NCT04141488|OTHER|experimantal group|Control Group
218996463|NCT00492141|DRUG|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
218996464|NCT00492141|DRUG|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
218996465|NCT00684346|OTHER|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
218996466|NCT03256643|BEHAVIORAL|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
219181675|NCT01867554|GENETIC|gene analysis|gene analysis
219181676|NCT06276205|DRUG|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
219181677|NCT06276205|DRUG|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
219181678|NCT02979327|DRUG|Adderall capsule|25 mg orally one time
219181679|NCT02979327|DRUG|Placebo capsule|Looks exactly like the study drug, but it contains no active ingredient. Taken one time.
219181680|NCT05020249|DRUG|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
218996467|NCT03256643|BEHAVIORAL|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
218996468|NCT03256643|BEHAVIORAL|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
218996469|NCT00230204|PROCEDURE|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
218996470|NCT06116760|DEVICE|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
218996471|NCT06116760|BEHAVIORAL|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
219369677|NCT06217250|PROCEDURE|"the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms"|"The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR."
219369678|NCT01145560|DRUG|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
218996472|NCT06147804|PROCEDURE|Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation|How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
218996473|NCT06310317|BEHAVIORAL|Applied Behavior Analysis protocol|"The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. The use of Applied Behavior Analysis procedures, with the help of technological tools such as a tablet or robot can facilitate the increase of new knowledge and skills.~The criterion is acquired if the subject emits 8 out of 10 independent correct responses (90%) for 3 consecutive sessions.~The objective is to test whether the technological tool used (tablet or robot) can make the proposed learning procedure more effective. The experimental group carries out the procedure by means of stimuli presented on tablets or robots."
218996474|NCT06310317|BEHAVIORAL|Traditional intervention|The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. In this group the materials are traditional, such as image printed. The criterion is acquired if the subject emits 9 out of 10 independent correct responses (90%) for 3 consecutive sessions. The control group performs the procedure with images printed on A4 laminated sheets.
218996475|NCT05113017|OTHER|NO Intervention|NO Intervention
218996476|NCT02223832|DRUG|ACT-128800|
218996477|NCT05536050|OTHER|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
218996478|NCT03217331|DRUG|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
218996479|NCT04974697|DEVICE|JJVC Investigational Multifocal Toric Contact Lens|TEST
218996480|NCT03085381|BIOLOGICAL|HPV vaccine|
218996481|NCT03085381|BIOLOGICAL|Placebo|
218996482|NCT05206578|DRUG|AGT2, AGZ|Tablet, q.d.
219181681|NCT05020249|OTHER|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
219181682|NCT04841434|DRUG|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
219181683|NCT05465629|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219181684|NCT05465629|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219181685|NCT06129188|DRUG|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
219369679|NCT01145560|DRUG|Placebo|Placebo
218996483|NCT05206578|DRUG|AGT2|Tablet, q.d.
218996484|NCT05206578|DRUG|AGT4, AGZ|Tablet, q.d.
218996485|NCT05206578|DRUG|AGT4|Tablet, q.d.
218996486|NCT02250378|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
219369680|NCT04292600|DIAGNOSTIC_TEST|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
218996487|NCT02250378|PROCEDURE|therapeutic conventional surgery|Undergo wedge resection
218996488|NCT02250378|OTHER|laboratory biomarker analysis|Correlative studies
218996489|NCT02250378|OTHER|quality-of-life assessment|Ancillary studies
218996490|NCT01434030|BEHAVIORAL|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
218996491|NCT01016197|PROCEDURE|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
218996492|NCT01016197|PROCEDURE|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
218996493|NCT01332955|DRUG|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
218996494|NCT01332955|BIOLOGICAL|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
218996495|NCT01332955|DRUG|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
218996496|NCT01219569|DRUG|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
218996497|NCT01219569|DRUG|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
218996498|NCT05699031|DEVICE|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
218996499|NCT05699031|OTHER|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
218996500|NCT00571948|OTHER|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
218996501|NCT00571948|OTHER|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
218996502|NCT01102959|DEVICE|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
218996503|NCT03692130|BEHAVIORAL|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
218996504|NCT03692130|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson
218996505|NCT04112784|DEVICE|INVSENSOR00039|Noninvasive pulse oximeter sensor
218996506|NCT05334966|OTHER|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
218996507|NCT01938456|DRUG|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
218996508|NCT01938456|DRUG|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
219369681|NCT06041555|OTHER|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
219369682|NCT04187027|DEVICE|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
218996509|NCT01938456|DRUG|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
218996510|NCT00000297|DRUG|Labetalol|
218996511|NCT04427566|RADIATION|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
218996512|NCT01048177|DRUG|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
218996513|NCT03017495|DRUG|Midazolam|2 mg/mL oral solution
218996514|NCT03017495|DRUG|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
218996515|NCT05013684|OTHER|Particle Repositioning Maneuver|treatment with Particle Repositioning Maneuver
218996516|NCT05682898|PROCEDURE|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
218996517|NCT02006719|BIOLOGICAL|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
219369683|NCT03656913|DIAGNOSTIC_TEST|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
218996518|NCT02006719|OTHER|Placebo|Placebo injection
218996519|NCT03255798|DEVICE|G2 and G3|Two iStent inject devices and one iStent supra device
218996520|NCT04497831|DRUG|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
218996521|NCT04497831|DRUG|Placebo|Inhalation use
218996522|NCT01965587|PROCEDURE|novasure mirena IUS combined|novasure mirena IUS combined
218996523|NCT02554500|PROCEDURE|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
218996524|NCT01352910|DEVICE|rTMS|120 pulses 0.2 Hz
218996525|NCT01352910|DEVICE|Sham rTMS|120 pulses 0.2 Hz
218996526|NCT05019352|DEVICE|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
218996527|NCT05019352|DEVICE|CRRT|continuous renal replacement therapy
218996528|NCT01699906|OTHER|Diet regimen to induce weight loss|Diet regimen to induce weight loss
218996529|NCT04637230|DIAGNOSTIC_TEST|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
218996530|NCT05496530|DRUG|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
218996531|NCT02900196|OTHER|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
218996532|NCT02900196|OTHER|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
218996533|NCT01872377|RADIATION|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
218996534|NCT00393029|BIOLOGICAL|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
218996535|NCT00393029|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
218996536|NCT00393029|BIOLOGICAL|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
219181686|NCT06129188|DRUG|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
219181687|NCT06803719|OTHER|Observations on main concerns and attracting factors when choosing the surgical approach for thyroid disease|Size of incision, cost, operation duration, postoperative recovery, postoperative hospitalization, absence of the anterior incision
219181688|NCT06104384|BEHAVIORAL|Behavioral and supportive therapy|Behavioral and supportive therapy
218996537|NCT00393029|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
218996538|NCT00393029|DRUG|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
219181689|NCT05775965|DRUG|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
219181690|NCT05775965|DRUG|acetylsalicylic acid (ASA) 81mg Oral Tablet|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
219181691|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
219181692|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
219181693|NCT06635889|DRUG|Bupivacaine|The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
219181694|NCT06635889|OTHER|Normal saline|Placebo of 50 ml of Normal Saline
219369684|NCT04819906|DRUG|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
219369685|NCT04819906|DRUG|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
218996539|NCT03355716|DRUG|bupivacaine|Bupivacaine 25 ml (0.25%)
218996540|NCT03355716|DRUG|morphine|Morphine (3.0 mg)
218996541|NCT03355716|DRUG|fentanyl|fentanyl (30.0 Mc)
218996542|NCT03355716|DRUG|Ketamine:|ketamine (0.5 mg/kg).
218996543|NCT00640991|DRUG|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
218996544|NCT06293001|OTHER|No intervention|No intervention
219181695|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
219181696|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
219181697|NCT05559983|OTHER|Placebo Cohort A|Sterile 0.9% sodium chloride
219181698|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
219181699|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
219181700|NCT05559983|OTHER|Placebo Cohort B|Sterile 0.9% sodium chloride
219181701|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
219181702|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
219181703|NCT05559983|OTHER|Placebo Cohort C|Sterile 0.9% sodium chloride
219369686|NCT04819906|DRUG|Placebo|Five placebo tablets orally once
219369687|NCT04819906|DRUG|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
218996545|NCT04152278|DIAGNOSTIC_TEST|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
218996546|NCT05436093|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
218996547|NCT04659161|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
218996548|NCT04659161|DRUG|Placebo|Placebo Capsules twice a day (BID)
218996549|NCT03155568|PROCEDURE|sciatic nerve block|sciatic nerve block at popliteal fossa
218996550|NCT03155568|PROCEDURE|ankle block|block of major nerves supplying the foot at the level of the ankle
219181704|NCT02014675|DEVICE|SD01 ICD lead|
219181705|NCT06770296|DRUG|Pyrotinib low dose group|Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
219181706|NCT06770296|DRUG|Pyrotinib normal dose group|Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
219181707|NCT03069924|BEHAVIORAL|Gain-framed messaging|Gain-framed messaging materials
219181708|NCT03069924|COMBINATION_PRODUCT|Unframed messaging materials|Unframed smoking cessation materials
219181709|NCT05030545|DRUG|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
219181710|NCT04098263|BIOLOGICAL|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
219181711|NCT05998785|DEVICE|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
219181712|NCT05420324|DRUG|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
219181713|NCT05420324|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
219181714|NCT05420324|DRUG|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
219181715|NCT06770218|OTHER|pelvic girdle stability training and therapeutic tapping|pelvic girdle stability training performed along with therapeutic taping in experimental group tapping involves applying strips one and two over the paraspinal region from l4 to t1 in a caudo cephalic directions. strips 3 and 4 along the lower portion of trapezius with a medially directed force from the acromion process to T12 obliquely. total session time 45 minutes to 60 minutes
219181716|NCT06770218|OTHER|pelvic girdle stability training only|participates engaged in pelvic girdle stability training focusing on exercises therapeutics taping was not be administrated during these stability exercises. excercise include pelvic brigde, one leg bridge, calm exercise for gluteus medius, leg lift 4 point kneelig arm lift
219181717|NCT03710902|DIAGNOSTIC_TEST|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
219181718|NCT03710902|OTHER|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
219181719|NCT06266403|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
219181720|NCT06266403|BEHAVIORAL|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the \_\_\_ this time. Participations will be instructed to overenunciate the critical words."
219181721|NCT06266403|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
218996551|NCT03155568|DRUG|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
219181722|NCT06266403|BEHAVIORAL|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
219181723|NCT06480864|DRUG|Adebrelimab Injection|Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
219181724|NCT06480864|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
219181725|NCT06480864|DRUG|Carboplatin|Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
219181726|NCT06480864|DRUG|Cisplatin|Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
219181727|NCT06480864|DRUG|Etoposide|Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
219181728|NCT02872259|DRUG|BGB324+pembrolizumab|Combination
219181729|NCT02872259|DRUG|BGB324+dabrafenib and trametinib|Combination
219181730|NCT02872259|DRUG|pembrolizumab|Monotherapy
219181731|NCT02872259|DRUG|dabrafenib and trametinib|Combination
219181732|NCT03959696|BEHAVIORAL|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
219181733|NCT03959696|BEHAVIORAL|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
219181734|NCT03474679|DRUG|Ibrutinib|Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
219754082|NCT05860673|PROCEDURE|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
218996552|NCT01929343|DRUG|lidocaine following cue-induced craving|as described in Arm Description
219754083|NCT04695080|DRUG|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
219754084|NCT04695080|DRUG|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
219754085|NCT05815134|BIOLOGICAL|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
219754086|NCT02077621|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
219754087|NCT02077621|DRUG|Placebo|500 mL normal saline
219754088|NCT05713565|DEVICE|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
219754089|NCT05713565|OTHER|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
219754090|NCT00780299|DEVICE|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
219754091|NCT00780299|PROCEDURE|CVVH|hemofiltration intermittent dialysis
219754092|NCT03330847|DRUG|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
219754093|NCT03330847|DRUG|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
219754094|NCT03330847|DRUG|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
219754095|NCT06232044|DRUG|Iberdomide|Receive PO
218996553|NCT01929343|DRUG|lidocaine following neutral stimulus|as described in Arm Description
218996554|NCT01929343|DRUG|saline|as described in Arm Description
218996555|NCT00901316|PROCEDURE|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
219754096|NCT06232044|BIOLOGICAL|Belantamab Mafodotin|Receive IV
219754097|NCT06232044|DRUG|Dexamethasone|Receive PO
219754098|NCT06232044|PROCEDURE|Echocardiography|Undergo ECHO
219754099|NCT06232044|PROCEDURE|Computed Tomography|Undergo CT
218996556|NCT00901316|PROCEDURE|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
218996557|NCT05820178|DEVICE|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
218996558|NCT05820178|DEVICE|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
218996559|NCT06055010|OTHER|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
218996560|NCT02197130|DRUG|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
219754100|NCT06232044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219754101|NCT06232044|PROCEDURE|Positron Emission Tomography|Undergo PET
219754102|NCT06232044|PROCEDURE|Bone Marrow Biopsy|Undergo Bone Marrow Biopsy
219754103|NCT06232044|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspirate
219754104|NCT06232044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219754105|NCT06646679|OTHER|Ultrasonic imaging|Ultrasonic imaging
219754106|NCT01355627|PROCEDURE|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
219754107|NCT01355627|PROCEDURE|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
218996561|NCT02197130|DRUG|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
218996562|NCT02197130|OTHER|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
218996563|NCT04812145|RADIATION|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
218996564|NCT04257981|DEVICE|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
218996565|NCT04257981|OTHER|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
219754108|NCT03532256|BEHAVIORAL|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
219754109|NCT03532256|BEHAVIORAL|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
219754110|NCT03532256|BEHAVIORAL|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
219754111|NCT02293551|DRUG|Lispro|Administered SC
219754112|NCT05967299|OTHER|Placebo Cohort 1 (1.5 mg/kg/dose) only|30mg/ml Sucrose
219754113|NCT05967299|DRUG|ZMA001 (BC-NKA-20008)|ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
219754114|NCT02748798|DRUG|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
218996566|NCT02320669|DRUG|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
219754115|NCT02748798|DRUG|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
219754116|NCT02748798|DRUG|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
219754117|NCT02748798|DRUG|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
219754118|NCT02748798|DEVICE|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
219754119|NCT02748798|DEVICE|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
219754120|NCT02748798|DEVICE|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
219754121|NCT02992210|GENETIC|4SCAR-GD2|GD2-specific 4th Generation CART
219754122|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
219754123|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
219754124|NCT02439463|PROCEDURE|Below-knee amputation|Patients with traumatic below-knee amputation.
219754125|NCT02496312|BEHAVIORAL|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
219754126|NCT01838733|OTHER|Observational study|
219754127|NCT00121966|DRUG|Insulin Aspart|
219754128|NCT00121966|DRUG|Insulin NPH|
219754129|NCT00121966|DRUG|Metformin|
219754130|NCT00121966|DRUG|Rosiglitazone|
219754131|NCT01653314|DRUG|Megavec|
219754132|NCT01653314|DRUG|Glivec|
219754133|NCT00642759|DRUG|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
219754134|NCT00642759|DRUG|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
219754135|NCT00642759|DRUG|Bevacizumab|IV infusion
219754136|NCT04614337|DRUG|LUM-201|Administered orally once daily
219754137|NCT04614337|DRUG|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
219754138|NCT03742726|DEVICE|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
219754139|NCT02834741|DRUG|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
219754140|NCT01092650|DRUG|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
219754141|NCT01505985|DIETARY_SUPPLEMENT|Oral nutritional Supplement|Specialized nutritional supplement for seniors
219754142|NCT01505985|DIETARY_SUPPLEMENT|Placebo|placebo product with no specific nutrients
218996567|NCT02320669|DRUG|Placebo|Bolus of Placebo followed by infusion for 48 hours
218996568|NCT04948710|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
218996569|NCT00211510|DEVICE|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
218996570|NCT00211510|DEVICE|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
218996571|NCT00000329|DRUG|Opioid-Related Disorders|
218996572|NCT02937883|OTHER|Empowerment intervention|Empowerment intervention for persons with young onset dementia
218996573|NCT01996501|DRUG|Olanzapine Orally Disintegrating 5mg Tablets|
219754143|NCT04632173|OTHER|non interventional study|There is no intervention
219754144|NCT01613651|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
219754145|NCT01613651|OTHER|questionnaire administration|Ancillary studies
219754146|NCT01613651|OTHER|intraoperative complication management/prevention|Undergo placement of pelvic drain
219754147|NCT00032812|DRUG|Raclopride|
219754148|NCT03720808|OTHER|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
219754149|NCT03720808|OTHER|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
219754150|NCT03720808|OTHER|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
219181735|NCT06191653|BEHAVIORAL|Mindfulness and Self-Compassion for Caregivers working in Youth Detention Centres|The adapted form of the MSC is a 12-session structured program, delivered on a weekly basis in group. It intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind and courageous way. Each session lasts about 2 hours. Each session has the following structure: Grounding exercise; sharing individual insights about the weekly practice; Reviewing the previous session and link for the session theme; coffee break; soft landing exercise; Formal/Informal practice(s); Session summary and challenges to be applied during the week; Session evaluation and take-off. Each participant receives a manual with the contents shared in each session as well as some space for individual reflections. On the day after each session, a summary email is sent to the participants, resuming the contents and with records of the (in)formal practices delivered. All the sessions will be delivered in a space on each YDC.
218996574|NCT00541710|DIETARY_SUPPLEMENT|genistein|pills of 27 mg, twice per day for 12 months
218996575|NCT00541710|DIETARY_SUPPLEMENT|placebo|sugar pills twice per day for 12 months
218996576|NCT05466656|OTHER|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
218996577|NCT04841460|DIETARY_SUPPLEMENT|Low-fat ground beef|5% fat ground beef
218996578|NCT04841460|DIETARY_SUPPLEMENT|High-fat ground beef|25% fat ground beef
218996579|NCT00565045|DEVICE|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
219369688|NCT03204344|DIETARY_SUPPLEMENT|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
218996580|NCT04575116|DRUG|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
218996581|NCT04575116|DRUG|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
218996582|NCT03335098|DRUG|Bortezomib|Six 4-week cycles
218996583|NCT02400632|DEVICE|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
218996584|NCT04561830|PROCEDURE|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
218996585|NCT03645798|BEHAVIORAL|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
218996586|NCT03645798|BEHAVIORAL|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
218996587|NCT03153969|DEVICE|SHOFU Beautifil II LS|Placed under manufacturer's instructions
218996588|NCT03153969|DEVICE|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
218996589|NCT05089942|DRUG|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
218996590|NCT05089942|DRUG|Placebo|health subjects receive placebo patch
218996591|NCT04584151|PROCEDURE|regional analgesia|Insertion of bilateral ESP catheters
219181736|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
219181737|NCT04684966|DEVICE|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
219754151|NCT03720808|OTHER|Control|No intervention was performed to reduce pain and fear in the control group.
219754152|NCT00726583|DRUG|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
219754153|NCT01931410|DRUG|Misoprostol|
219754154|NCT01230411|OTHER|saline placebo|250 cc of placebo administered IV
218996592|NCT01737697|DRUG|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
218996593|NCT01737697|DRUG|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
218996594|NCT01737697|DRUG|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
219181738|NCT04684966|DEVICE|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
219181739|NCT03298386|OTHER|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
219181740|NCT03057964|DEVICE|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
219181741|NCT03057964|DEVICE|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
219181742|NCT05337306|OTHER|GogyUp Reader|Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
219181743|NCT06064136|PROCEDURE|Psoas tenotomy under ultrasound|Tenotomy of the ilio-psoas tendon under ultrasound is performed using an ultrasound machine, a 3 mm Acufex hook blade and a specific kit usually used for guided vertebroplasty and which allows the introduction of the Acufex hook blade atraumatically (foam end). The patient, under general anesthesia, is placed in supine position with the hip extending from 15 to 20°.
219181744|NCT06803706|BEHAVIORAL|6-weeks CBT smoking cessation programme|Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.
219181745|NCT06803706|BEHAVIORAL|Long-term drug therapy within a therapeutic community|The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.
219181746|NCT06293261|DRUG|Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg|Experimental only, not included active and placebo comparator
219181747|NCT06803472|DEVICE|pulsed high intensity laser therapy|The high-intensity laser therapy (HILT), which involves laser radiation with high-intensity, is a kind of novel and powerful . The HILT possesses its own photomechanical, photothermal, and the photo-chemical properties.
219754155|NCT01230411|DRUG|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
219754156|NCT00238329|BIOLOGICAL|PEG-interferon alfa-2b|
219754157|NCT00238329|DRUG|thalidomide|
219754158|NCT00427830|BIOLOGICAL|MVA85A|
218996595|NCT01737697|DRUG|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
218996596|NCT04367428|BIOLOGICAL|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
218996597|NCT05038436|DEVICE|Polyglucosamine L112|Two tablets once daily per os
218996598|NCT04729868|DRUG|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
218996599|NCT06131567|PROCEDURE|Implantoplasty|Implantoplasty as surface decontamination method
218996600|NCT04992676|DIAGNOSTIC_TEST|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
218996601|NCT04992676|DIAGNOSTIC_TEST|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
218996602|NCT00858130|DEVICE|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
218996603|NCT02131207|DEVICE|magnetic resonance imaging|Undergo pelvic MRI
218996604|NCT02131207|PROCEDURE|prostate biopsy|Undergo prostate biopsy
218996605|NCT01362205|DRUG|Dexmedetomidine|
218996606|NCT01362205|DRUG|Placebos|Inactive placebo (normal saline)
218996607|NCT01925937|DRUG|Atorvastatin|
218996608|NCT01925937|DRUG|Coenzyme Q10|
218996609|NCT01925937|DRUG|placebo for coenzyme Q10|
218996610|NCT03338998|DRUG|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
218996611|NCT03338998|DRUG|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
218996612|NCT03338998|DRUG|BAF312 tablet|2 mg film-coated tablet
218996613|NCT03338998|DRUG|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
218996614|NCT01372462|DEVICE|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
218996615|NCT01372462|DEVICE|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
219181748|NCT06803472|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy is an acoustic wave that mechanically disrupts tissue by cavitation.Shock waves develop microscopic injuries in scar tissue and break down collagen fibers which lead to scar remodelin .The patient is positioned in a comfortable position. The scar site is prepared with contact gel to conduct the shock waves, 30-50 shocks/cm2 , with an energy flux density of 0.25mJ/mm2 and a frequency of 6Hz. Each treatment region is covered with 2500 to 3000 impulses with an average session time of 10-15min .
219181749|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
219181750|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
219181751|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
218996616|NCT01372462|DEVICE|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
218996617|NCT05728905|OTHER|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
218996618|NCT05728905|OTHER|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
218996619|NCT00653120|DRUG|Propranolol|ER capsules, 160 mg, single-dose
218996620|NCT00653120|DRUG|Inderal-LA|ER capsules, 160 mg, single-dose
218996621|NCT03288129|DRUG|Perampanel|film-coated tablets
219181752|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
219181753|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
219181754|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
219181755|NCT06800664|BEHAVIORAL|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
219181756|NCT06800664|BEHAVIORAL|Control Group|Providers in the control group will not receive ISS support
219369689|NCT03204344|OTHER|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
219369690|NCT00126971|DRUG|chlorproguanil-dapsone|
218996622|NCT05776615|OTHER|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
218996623|NCT02579239|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
218996624|NCT02579239|BIOLOGICAL|Placebo|Concentrate for solution for infusion
218996625|NCT02194244|DRUG|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
218996626|NCT02194244|DRUG|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
218996627|NCT04805424|PROCEDURE|Lipo-abdominoplasty|Abdominoplasty plus liposuction
218996628|NCT04805424|PROCEDURE|Abdominoplasty|Abdominoplasty
218996629|NCT06464848|OTHER|Narrative identity task|All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).
218996630|NCT06978270|BEHAVIORAL|Healthy Eating: Provider and Parent Components|Healthy Eating intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's tableware and food toys; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, healthy eating encoragement and communication from childcare providers including via the Classtag App, newsletters, videos and tableware/food toys focused on child diet at home.
218996631|NCT06978270|BEHAVIORAL|Healthy Start: Reading Readiness Childcare Proiver and Parent Materials|Reading readiness intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's books; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, reading readiness encoragement and communication from childcare providers including via the Classtag App, newsletters, books focused for use at home.
218996632|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
218996633|NCT03782961|DEVICE|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
219181757|NCT06800521|BEHAVIORAL|Mixed Reality Breastfeeding Education|"Mixed Reality Breastfeeding Education:~This intervention includes an innovative mixed reality-based educational strategy combined with traditional breastfeeding counseling. Participants use mixed reality goggles to experience immersive breastfeeding scenarios, interact with audio-visual materials tailored for breastfeeding education, and engage with realistic breastfeeding simulations. The session is delivered once during the third trimester of pregnancy and lasts approximately 90 minutes. This intervention is designed to improve maternal confidence, satisfaction, and adherence to exclusive breastfeeding through an engaging and practical learning environment."
219181758|NCT06800521|BEHAVIORAL|Traditional Breastfeeding Counseling|This intervention involves standard prenatal breastfeeding education provided by trained healthcare professionals. Participants receive verbal and visual explanations of breastfeeding techniques, benefits, and solutions to common challenges. Delivered in a single session during the third trimester of pregnancy, the session lasts approximately 60 minutes and represents the current standard of care in breastfeeding education.
219181759|NCT05139121|DRUG|MR-100A-01|Transdermal contraceptive delivery system
219181760|NCT05176509|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
219181761|NCT05176509|DRUG|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
219181762|NCT05176509|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
218996634|NCT06046365|DIAGNOSTIC_TEST|lymphoscintigraphy|lymphoscintigraphy
218996635|NCT06046365|DIAGNOSTIC_TEST|circumference measurement|circumference measurement
219181763|NCT06802770|DIAGNOSTIC_TEST|Anxiety, Depression levels|Parents of children with spina bifida will be filled out symptom scores regarding depression and anxiety levels.
219181764|NCT06759805|OTHER|eCardiacRehab|Interdisciplinary supervised home-based digital secondary prevention programme (12-week programme) based on the European Society of Cardiology guidelines for cardiac rehabilitation for patients after percutaneous coronary intervention.
219181765|NCT04105777|DEVICE|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
218996636|NCT06046365|DIAGNOSTIC_TEST|sonography|B-mode sono and elastography
218996637|NCT06046365|DIAGNOSTIC_TEST|DXA body composition analysis|DXA body composition analysis
218996638|NCT06997601|OTHER|Serratus posterior superior intercostal plane block|Patients will receive a serratus posterior superior intercostal plane block.
218996639|NCT06997601|OTHER|Suprascapular nerve block + Axillary nerve block|Patients will receive suprascapular nerve block + axillary nerve block.
219181766|NCT04105777|DEVICE|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
219181767|NCT05549349|PROCEDURE|Cholecystectomy|Gallbladder removal
219181768|NCT06045663|PROCEDURE|laminectomy without lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
218996640|NCT04329533|OTHER|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
218996641|NCT07001345|PROCEDURE|Alveolar Ridge Reconstruction|Alveolar ridge preservation with either xenograft of allograft material
218996642|NCT06546267|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT for Prostate cancer will be evaluated
219181769|NCT06045663|PROCEDURE|laminectomy with lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
218996643|NCT06546267|RADIATION|Intensity Modulated Radiotherapy|Patients treated with IMRT for Prostate cancer will be evaluated
218996644|NCT06546267|RADIATION|Stereotactic Body Radiotherapy|Patients treated with SBRT for Prostate cancer will be evaluated
218996645|NCT06621472|PROCEDURE|Retrolaminar block group|patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
218996646|NCT06621472|OTHER|subcostal TAP technique|The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
219181770|NCT06803953|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
219181771|NCT06803953|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
218996647|NCT06621472|OTHER|thoracic Epidural|Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
218996648|NCT07132463|RADIATION|Long-course chemoradiotherapy|45-50.4 Gy in 25-28 fractions to the pelvis on Days 1-5 each week. Capecitabine at a dose of 825 mg/m², taken orally twice daily (bid), 5 days per week during radiotherapy.
218996649|NCT07132463|DRUG|Tislelizumab combined with the CAPOX regimen|"Tislelizumab 200 mg IV on Day 1 of each 21-day cycle. Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
218996650|NCT07132463|DRUG|CAPOX regimen|"Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
218996651|NCT03557099|DRUG|Hetrombopag Olamine|once daily
219181772|NCT06803953|DIAGNOSTIC_TEST|Nasal Allergen Challenge|nasal allergen challenge with either house dust mite allergens or birch pollen allergens
219181773|NCT06802133|OTHER|Post Market Study|Prospective case series without a concurrent comparator group.
219181774|NCT05347667|OTHER|Unilateral Resistance Exercise Leg|One leg will perform unilateral resistance exercise
219181775|NCT05347667|OTHER|Control Leg|One leg will serve as a non-exercise control
219369691|NCT03282032|OTHER|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
218996652|NCT06681753|OTHER|Experimental|No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
219181776|NCT05499377|DEVICE|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
219181777|NCT04279236|OTHER|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
219181778|NCT04279236|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
219181779|NCT04279236|OTHER|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
219181780|NCT04034706|OTHER|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
218996653|NCT07016373|DEVICE|Palatal Plate without Manuka Honey|A Palatal plate without Manuka Honey will be inserted by a blinded investigator on the donor site for post-operative procedures.
218996654|NCT07016373|DEVICE|Palatal plate with Manuka Honey|A Palatal plate with Manuka Honey will be inserted by a blinded researcher on the donor site.
218996655|NCT07015814|OTHER|Golden sugarcane jaggery|Participants will consume a standardized portion of jaggery Type A providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
218996656|NCT07015814|OTHER|Dark brown sugarcane jaggery|Participants will consume a standardized portion of jaggery Type B providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
218996657|NCT07016126|COMBINATION_PRODUCT|D-BACE in combination with chemotherapy and karelizumab|3 cycles of D-BACE (DCB-loaded microspheres loaded with epirubicin 50 mg) in combination with chemotherapy and karelizumab (the specific regimen of chemotherapy is determined by the investigator, and platinum-containing two-agent chemotherapy is generally used).
218996658|NCT07015034|OTHER|focus on vision impairment in older patients in general practice|GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.
218996659|NCT07014813|PROCEDURE|Sub pectoral fixation|Subpectoral biceps tenodesis via mini-open incision. Biceps tendon prepared with Krackow sutures, press-fit into bony tunnel using harvested bone plug. Stability checked post-fixation.
218996660|NCT07016087|OTHER|Cosmetic formulation experimental|Cosmetic formulation containing emollients and a butyrate releaser: the postbiotic N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA)
218996661|NCT07016087|OTHER|Cosmetic formulation usual|Cosmetic formulation containing emollients
218996662|NCT07015645|PROCEDURE|Gamma Knife Radiosurgery|Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
218996663|NCT07014839|PROCEDURE|Endovascular Aortic Intervention|This intervention involves EVAR or TEVAR for the treatment of abdominal or thoracic aortic aneurysms, respectively. The procedures were performed using commercially available stent-grafts via a transfemoral approach under standard perioperative protocols. The study specifically focuses on the systemic inflammatory response following these interventions, with close monitoring of laboratory parameters including IL-6, neutrophil-to-lymphocyte ratio (NLR), CRP, leukocyte count, and procalcitonin during the early postoperative period. No adjunctive anti-inflammatory or immunomodulatory therapies were administered.
218996664|NCT07014397|DRUG|Valacyclovir|valacyclovir group received 2 g (two 1 g tablets) one hour prior to treatment, followed by 2 g 12 hours later, and 1 g at both 24 and 36 hours post-treatment
218996665|NCT07014397|DRUG|Placebo|The control group received a placebo identical in appearance and administration schedule
218996666|NCT03053193|DIAGNOSTIC_TEST|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
218996667|NCT06361342|BEHAVIORAL|General decrease in smartphone use|Subjects will decrease their time on smartphone in general.
218996668|NCT06361342|BEHAVIORAL|Avoiding Social Media Apps|Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
218996669|NCT03355521|OTHER|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
219181781|NCT04034706|OTHER|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
219181782|NCT04034706|OTHER|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
219181783|NCT04034706|PROCEDURE|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
219181784|NCT04034706|OTHER|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
219181785|NCT05944016|DRUG|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
219181786|NCT05944016|DRUG|Placebo|Placebo (standard dose p.o. once daily)
219181787|NCT02573493|DRUG|nab-Paclitaxel|
219181788|NCT02573493|DRUG|Cisplatin|
219181789|NCT02573493|BIOLOGICAL|Cetuximab|
219181790|NCT02573493|RADIATION|Intensity-Modulated Radiation Therapy|
219181791|NCT06425133|PROCEDURE|Blood sample|Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection
218996670|NCT03355521|OTHER|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
218996671|NCT03985631|OTHER|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
218996672|NCT01114425|DRUG|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
218996673|NCT01114425|DRUG|Truvada®|
219181792|NCT06425133|OTHER|Quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
219181793|NCT06425133|PROCEDURE|Biopsy|Fresh tumor biopsy at baseline and week 8
218996674|NCT06243991|DEVICE|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
219181794|NCT06425133|DRUG|Regorafenib|"For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
219181795|NCT06425133|COMBINATION_PRODUCT|Regorafenib + metronomic chemotherapy|"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression."
219181796|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
219181797|NCT06494436|DEVICE|All Microvention Class III implantable device CE marked|Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
219181798|NCT03017911|PROCEDURE|Piccline|
219181799|NCT04332926|OTHER|Tobacco product administration and assessment, own brand cigarettes|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
219181800|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
219181801|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
218996675|NCT06243991|DIAGNOSTIC_TEST|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
218996676|NCT06243991|DEVICE|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
218996677|NCT06243991|DIAGNOSTIC_TEST|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].
218996678|NCT06243991|DEVICE|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
218996679|NCT00671697|DRUG|Arsenic Trioxide|
218996680|NCT00671697|DRUG|Decitabine|
218996681|NCT02857543|OTHER|Plant-Based Diet|
218996682|NCT02857543|OTHER|American Heart Association Diet|
218996683|NCT02857543|OTHER|Mediterranean Diet|
218996684|NCT05255068|BEHAVIORAL|OPTIMAL|A person-centered mealtime care intervention
218996685|NCT04624568|DEVICE|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
218996686|NCT04121377|OTHER|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
218996687|NCT04388189|DRUG|Duloxetine|FDA approved antidepressant
218996688|NCT04388189|DRUG|Bupropion|FDA approved antidepressant
218996689|NCT05300620|DEVICE|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
218996690|NCT05300620|DEVICE|Original Liner|these are original shoe liners
218996691|NCT05300620|DEVICE|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
218996692|NCT05300620|DEVICE|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
218996693|NCT01561365|BEHAVIORAL|Ottawa ankle rules|Ottawa ankle rules implementation
219181802|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
219181803|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
219369692|NCT02321969|DIETARY_SUPPLEMENT|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
219369693|NCT03284190|PROCEDURE|Surgery|Surgery
218996694|NCT05815940|BEHAVIORAL|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
218996695|NCT05033860|OTHER|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
218996696|NCT05759676|DEVICE|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
218996697|NCT03919214|OTHER|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
218996698|NCT01548521|DRUG|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
218996699|NCT03709160|DRUG|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
218996700|NCT02076880|OTHER|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
218996701|NCT02076880|OTHER|No caloric restriction|No change in eating habits to patients in this arm
218996702|NCT00872534|DRUG|acetylsalicylic acid|325mg once a day for 7 days
218996703|NCT04440202|BEHAVIORAL|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
218996704|NCT04440202|BEHAVIORAL|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
218996705|NCT03275662|BEHAVIORAL|Dietary Fiber|
218996706|NCT03275662|BEHAVIORAL|Fermented Foods|
218996707|NCT00540514|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
218996708|NCT00540514|DRUG|Paclitaxel|Administered by intravenous infusion.
218996709|NCT00540514|DRUG|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
218996710|NCT02501473|DRUG|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
218996711|NCT02501473|DRUG|Pembrolizumab|PD-1 Inhibitor
219369694|NCT00628186|DEVICE|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
218996712|NCT02501473|DRUG|Rituximab|Rituximab (anti-CD20 antibody)
218996713|NCT00000105|BIOLOGICAL|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
218996714|NCT00000105|BIOLOGICAL|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
218996715|NCT00000105|DRUG|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
218996716|NCT00000105|BIOLOGICAL|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
218996717|NCT03846596|BIOLOGICAL|Additional blood tube|Additional blood tube during care
218996718|NCT05348070|PROCEDURE|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
218996719|NCT03281486|DEVICE|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
218996720|NCT03281486|DEVICE|Placebo|Placebo formulation without the active ingredients
218996721|NCT04922008|DRUG|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
218996722|NCT04922008|DRUG|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
218996723|NCT05592964|DIETARY_SUPPLEMENT|Fasting|Standard fasting
218996724|NCT05592964|DIETARY_SUPPLEMENT|Water|In Group S, water was given 1 hour before the operation.
218996725|NCT05592964|DIETARY_SUPPLEMENT|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
218996726|NCT02313181|OTHER|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
218996727|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
218996728|NCT06463210|DEVICE|Virtual reality as a distraction technique|A 360º relaxing video with music was displayed through a VR headset
218996729|NCT06060288|DIAGNOSTIC_TEST|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
218996730|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
219181804|NCT06143917|BEHAVIORAL|parent-child sleep intervention|The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
218996731|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
218996732|NCT05186064|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
218996733|NCT06397014|PROCEDURE|D-type stoma lateral hernia repair|underwent D-type stoma lateral hernia repair
218996734|NCT01974583|PROCEDURE|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
218996735|NCT01974583|PROCEDURE|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
219181805|NCT05832996|DRUG|Refresh Plus Preservative-free Lubricant Eye Drops|Refresh Plus Preservative-free Lubricant Eye Drops at either 4 or 25 degree Celsius
218996736|NCT01974583|PROCEDURE|covered with paraffin gauze|Group C covered with paraffin gauze
218996737|NCT04445922|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
218996738|NCT04445922|DRUG|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
218996739|NCT02049281|DRUG|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
219181806|NCT05641103|OTHER|Patient with splenomegaly or splenectomy|No interventional study
218996740|NCT02129725|DRUG|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
218996741|NCT02129725|DRUG|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
218996742|NCT03440710|PROCEDURE|BET|Balloon Eustachian Tuboplasty
218996743|NCT04441021|OTHER|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
218996744|NCT04546438|DEVICE|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
218996745|NCT01191229|DEVICE|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
218996746|NCT01191229|DEVICE|Crystalens AO|25 patients that are previously implanted
218996747|NCT04506372|DRUG|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
218996748|NCT04506372|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
218996749|NCT04506372|BEHAVIORAL|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
218996750|NCT04506372|BEHAVIORAL|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
218996751|NCT04506372|BEHAVIORAL|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
218996752|NCT06211166|DIAGNOSTIC_TEST|Digital PCR|digital Polymerase Chain Reaction (dPCR)
218996753|NCT06211166|DIAGNOSTIC_TEST|Quantitative PCR|Real-time Polymerase Chain Reaction (real-time PCR)
218996754|NCT06211166|DIAGNOSTIC_TEST|MFC|Multicolor Flow Cytometry
218996755|NCT02370134|DEVICE|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
218996756|NCT02370134|DEVICE|sham glove|
218996757|NCT01104506|PROCEDURE|fMRI|
218996758|NCT01104506|PROCEDURE|mTMS|
218996759|NCT00215332|DEVICE|CHARITE|Lumbar Total Disc Replacement
218996760|NCT01095445|DRUG|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
218996761|NCT03947372|PROCEDURE|Appendectomy|removal of acutely inflamed appendix
218996762|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
218996763|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
218996764|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
218996765|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
218996766|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
218996767|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
218996768|NCT00599924|DRUG|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
218996769|NCT02601469|DRUG|DSXS|twice daily for 28 days
218996770|NCT01806298|DRUG|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
218996771|NCT02638545|DRUG|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
218996772|NCT04356950|OTHER|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].
218996773|NCT04356950|OTHER|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
218996774|NCT05503394|BEHAVIORAL|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
218996775|NCT05503394|BEHAVIORAL|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
218996776|NCT03588039|DRUG|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
218996777|NCT03588039|BIOLOGICAL|Pembrolizumab|Intravenously administered
218996778|NCT00301665|BIOLOGICAL|Botulinum toxin type A|
218996779|NCT01497691|DEVICE|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
218996780|NCT01497691|DEVICE|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
218996781|NCT01497691|DEVICE|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
218996782|NCT03619954|BIOLOGICAL|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
219369695|NCT00628186|DEVICE|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
219369696|NCT02057133|DRUG|LY2835219|Administered orally.
218996783|NCT03808545|BEHAVIORAL|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
218996784|NCT03808545|BEHAVIORAL|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
218996785|NCT04062175|DRUG|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
218996786|NCT04062175|DRUG|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
218996787|NCT05557981|BEHAVIORAL|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
218996788|NCT03229278|DRUG|Enzyme Inhibitor Therapy|Given trigriluzole PO
218996789|NCT03229278|OTHER|Laboratory Biomarker Analysis|Correlative studies
218996790|NCT03229278|BIOLOGICAL|Nivolumab|Given IV
218996791|NCT03229278|BIOLOGICAL|Pembrolizumab|Given IV
218996792|NCT03792581|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
218996793|NCT02292277|DRUG|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
218996794|NCT02646072|DRUG|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
218996795|NCT00718835|BEHAVIORAL|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
218996796|NCT03797599|BEHAVIORAL|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
218996797|NCT03797599|BEHAVIORAL|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
218996798|NCT03797599|OTHER|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
218996799|NCT03797599|OTHER|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
218996800|NCT03797599|OTHER|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
218996801|NCT03313791|DIETARY_SUPPLEMENT|Whey protein concentrate|see arm description
218996802|NCT03313791|DIETARY_SUPPLEMENT|Yoghurt|see arm description
218996803|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Standard)|see arm description
218996804|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Alternative)|see arm description
218996805|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate- WPH|see arm description
218996806|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate - Na-caseinate|see arm description
218996807|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate|see arm description
218996808|NCT03313791|DIETARY_SUPPLEMENT|UHT milk|see arm description
218996809|NCT03313791|DIETARY_SUPPLEMENT|Recombined milk|see arm description
218996810|NCT03313791|DIETARY_SUPPLEMENT|Recombined 50%whey milk|see arm description
218996811|NCT03313791|DIETARY_SUPPLEMENT|Ca-caseinate|see arm description
218996812|NCT03313791|DIETARY_SUPPLEMENT|Milk protein isolate|see arm description
218996813|NCT01502098|PROCEDURE|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
218996814|NCT01502098|OTHER|Sling|Sling for 4 weeks
218996815|NCT00980057|DEVICE|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
218996816|NCT00980057|DEVICE|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
218996817|NCT05104320|PROCEDURE|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
218996818|NCT05104320|PROCEDURE|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
218996819|NCT04249674|DIAGNOSTIC_TEST|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
218996820|NCT04249674|GENETIC|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
218996821|NCT00174278|DRUG|Somatropin|
218996822|NCT04980040|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
218996823|NCT02075710|OTHER|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
218996824|NCT02075710|OTHER|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
218996825|NCT02075710|OTHER|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
218996826|NCT02075710|OTHER|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
218996827|NCT02075710|OTHER|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
218996828|NCT02075710|OTHER|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
218996829|NCT01235143|DRUG|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
218996830|NCT01235143|DRUG|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
219369697|NCT02057133|DRUG|Letrozole|Administered orally.
219369698|NCT02057133|DRUG|Anastrozole|Administered orally.
219181807|NCT05815030|OTHER|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
219181808|NCT04530799|OTHER|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
219181809|NCT06274970|OTHER|Enhanced recovery protocols|Aforementioned in the detailed description
219181810|NCT06274970|OTHER|Conventional Protocols|Conventional protocols for non-ERASP group Eg: No preoperative vitamin D and calcium supplementation etc.
219181811|NCT05743049|OTHER|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
219181812|NCT05937438|DRUG|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
219181813|NCT05707975|OTHER|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
219181814|NCT03556839|DRUG|Atezolizumab|Intravenous Infusion
219181815|NCT03556839|DRUG|Bevacizumab|Intravenous Infusion
219181816|NCT03556839|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
219181817|NCT03556839|DRUG|Paclitaxel|Intravenous Infusion
219181818|NCT02951325|OTHER|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
219181819|NCT01251406|DRUG|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
219181820|NCT01251406|DRUG|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
219181821|NCT01251406|DRUG|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
219181822|NCT03495973|DRUG|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
219181823|NCT05337163|DIAGNOSTIC_TEST|Diagnostic Test: Sputum DNA methylation analysis|Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
218996831|NCT05230771|COMBINATION_PRODUCT|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
218996832|NCT05230771|DRUG|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
218996833|NCT01315678|DRUG|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
218996834|NCT01315678|DRUG|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
219181824|NCT05337163|PROCEDURE|chest CT or pathological examination|Subjects will undergo chest CT or pathological examination.
219181825|NCT06156371|OTHER|lymphatic drainage massage|"Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated."
219369699|NCT02057133|DRUG|Tamoxifen|Administered orally.
218996835|NCT01738360|DRUG|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
218996836|NCT01516697|PROCEDURE|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
218996837|NCT01516697|PROCEDURE|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
218996838|NCT03676257|OTHER|Endocrine therapies|No intervention
219181826|NCT06156371|OTHER|classic massage|The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.
219181827|NCT05507099|BIOLOGICAL|Bone Marrow Aspirate, Lipoaspirate Concentrate|Autologous Cell Therapy.
219181828|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
219181829|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
219181830|NCT05845086|BEHAVIORAL|Preoperative patient education|In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
219181831|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
219181832|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
219181833|NCT05710744|BEHAVIORAL|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
219181834|NCT05535933|DRUG|HMPL-523(300mg PO QD)|HMPL-523(300mg PO QD)
219181835|NCT05535933|DRUG|Placebo|Placebo(300mg PO QD)
219181836|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
219181837|NCT06166381|DRUG|Parenteral Antibacterial Agents|Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
219181838|NCT06166381|DRUG|Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft|in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
219181839|NCT05672069|PROCEDURE|Osteosynthesis|Foot pathologies
219181840|NCT05915286|DRUG|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
219181841|NCT05915286|DRUG|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
219181842|NCT03674567|DRUG|FLX475|tablet
219181843|NCT03674567|DRUG|pembrolizumab (KEYTRUDA®)|IV infusion
219181844|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
219181845|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 200 mg|Participants in this Arm will take 200 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
219369700|NCT02057133|DRUG|Exemestane|Administered orally.
219181846|NCT06575751|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
219181847|NCT05318222|DIAGNOSTIC_TEST|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
219181848|NCT05731791|RADIATION|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
218996839|NCT01720121|OTHER|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
218996840|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
218996841|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
218996842|NCT03040102|OTHER|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
218996843|NCT03040102|OTHER|Standard of Care|Standard of Care practice is used
218996844|NCT05182138|OTHER|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
218996845|NCT05182138|OTHER|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
218996846|NCT05182138|OTHER|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
218996847|NCT04953377|BEHAVIORAL|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
218996848|NCT02916108|OTHER|Reading EEG|EEG recording for 5 minutes (not an intervention)
218996849|NCT00573469|DRUG|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
218996850|NCT00573469|DRUG|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
218996851|NCT00573469|DRUG|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
218996852|NCT04782427|OTHER|COVID-19 infection|Case of nosocomial infection within the long-term care facility
218996853|NCT01294657|BEHAVIORAL|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
218996854|NCT01294657|BEHAVIORAL|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
218996855|NCT05832359|RADIATION|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
218996856|NCT02376088|DRUG|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
218996857|NCT01532414|DRUG|Androxal|oral, capsules, taken one time daily, for 3 months
218996858|NCT01532414|DRUG|Placebo|Oral capsule taken one time daily for 3 months
218996859|NCT00253045|BEHAVIORAL|Motivational groups|Motivational interviewing in group format
218996860|NCT01192854|DRUG|Clevudine|Clevudine flexible dosages of 30 mg/day
218996861|NCT01192854|DRUG|Adefovir|Adefovir flexible dosages of 10 mg/day
218996862|NCT05013073|OTHER|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
219181849|NCT02882425|DRUG|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
218996863|NCT00187486|DRUG|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
219181850|NCT02882425|DRUG|Selexipag for oral use|Tablet containing 200 µg of selexipag
218996864|NCT00187486|DRUG|Temodar|Temodar 200 mg/m\^2/day x 5 days every 28 days
218996865|NCT00187486|PROCEDURE|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
218996866|NCT01606514|BEHAVIORAL|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
218996867|NCT00314392|BEHAVIORAL|Information (behavior)|
218996868|NCT01765088|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
218996869|NCT01765088|DRUG|α-IFN|3mIU (3million) D1，3，5
219369701|NCT02057133|DRUG|Everolimus|Administered orally.
219369702|NCT02057133|DRUG|Trastuzumab|Administered IV infusion.
219369703|NCT02057133|DRUG|LY3023414|Administered orally.
219369704|NCT02057133|DRUG|Fulvestrant|Administered IM.
219181851|NCT05793866|BEHAVIORAL|BUTEYKO RESPIRATORY TECHNIQUE|Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
219181852|NCT05285878|DRUG|Fingolimod|0.5 mg daily
219181853|NCT05285878|DRUG|Placebo|0.5 mg daily
219181854|NCT03001713|BEHAVIORAL|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
219181855|NCT06488183|PROCEDURE|preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q|preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
219181856|NCT05723588|DEVICE|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
219181857|NCT05723588|DEVICE|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
219181858|NCT05723588|BEHAVIORAL|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
219181859|NCT05723588|DRUG|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
219181860|NCT03997162|OTHER|Best Practice|Complete standard of care enhanced recovery after surgery protocol
219181861|NCT03997162|OTHER|Quality-of-Life Assessment|Ancillary studies
219181862|NCT03997162|OTHER|Questionnaire Administration|Ancillary studies
219181863|NCT01803477|DRUG|once daily for two consecutive days (Picato)|
219181864|NCT05215353|OTHER|Music Therapy|Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.
219181865|NCT05215353|OTHER|Cognitive Behavioral Therapy|Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.
219181866|NCT05215353|OTHER|assessments|Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
219181867|NCT05613153|DIETARY_SUPPLEMENT|Peppermint Oil|Participants weighing more than 40 kg will receive 2 peppermint oil capsules 3 times a day. Smaller children who weigh between 30 kg and 40 kg will receive 1 capsule of peppermint oil 3 times a day. All subjects will receive 8 weeks of treatment.
219181868|NCT05095701|BIOLOGICAL|Investigational Live Attenuated Varicella Vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
219181869|NCT05095701|BIOLOGICAL|Placebo (Freeze Dired Dilution)|The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
219181870|NCT05847166|RADIATION|[99mTc]Tc-PSMA-T4|\[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
219181871|NCT05296356|DRUG|OSU6162|OSU6162
219181872|NCT04855695|DRUG|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
219181873|NCT04855695|DRUG|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
219181874|NCT04855695|DRUG|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
219181875|NCT04251585|DRUG|Regular Novolin R|Intranasal insulin
219181876|NCT04251585|DRUG|Placebo|Intranasal placebo (0.9% saline)
218996870|NCT04657120|PROCEDURE|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
218996871|NCT04657120|PROCEDURE|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
218996872|NCT05426902|BEHAVIORAL|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
218996873|NCT01837615|DEVICE|Photopill treatment|
218996874|NCT00004814|DRUG|copolymer 1|
218996875|NCT01186510|PROCEDURE|lung perfusion|see literature of proceeding
218996876|NCT01186510|PROCEDURE|no lung perfusion|see literature of proceeding
218996877|NCT04233151|DRUG|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
218996878|NCT04233151|DRUG|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
219181877|NCT06350851|BIOLOGICAL|Biological samples collection (blood drawing + feces)|Blood and feces samples will be collected from each volunteer.
219181878|NCT04562194|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
218996879|NCT04233151|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
218996880|NCT05205044|DIAGNOSTIC_TEST|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
219181879|NCT04162938|OTHER|Patient-Centered Electronic App|The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
219181880|NCT05670730|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
219181881|NCT05670730|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion.
218996881|NCT00952679|DEVICE|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
218996882|NCT01508650|BEHAVIORAL|Usual care|Usual care control group
218996883|NCT01508650|BEHAVIORAL|Rehabilitation intervention|Multi-domain rehabilitation intervention
218996884|NCT06628791|DIETARY_SUPPLEMENT|BK329|Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks
219181882|NCT06044025|DRUG|Metformin|Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
219369705|NCT02057133|DRUG|Pertuzumab|Administered IV infusion.
218996885|NCT06628791|DIETARY_SUPPLEMENT|Placebo|Placebo 400 mg/day for 12 weeks
218996886|NCT02064894|DRUG|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
218996887|NCT02064894|DRUG|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
218996888|NCT02064894|DRUG|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
218996889|NCT01682057|DEVICE|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
218996890|NCT01682057|DEVICE|ROX Anastomotic Coupler System (ACS)|
218996891|NCT01396148|DRUG|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
218996892|NCT01396148|DRUG|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
218996893|NCT05830292|DEVICE|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
218996894|NCT02536040|DRUG|38% diammine silver fluoride|treatment of cavity with study agent
218996895|NCT02536040|OTHER|Water|Fluoride free, distilled water
218996896|NCT03472404|PROCEDURE|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
218996897|NCT03472404|PROCEDURE|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
218996898|NCT01851616|DIETARY_SUPPLEMENT|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
218996899|NCT01851616|DIETARY_SUPPLEMENT|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
218996900|NCT00884312|DRUG|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
218996901|NCT06280937|OTHER|Wearing a tie|Individuals in the study group will be asked to wear a tie during one office working day.
218996902|NCT00777712|OTHER|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
218996903|NCT00224042|DRUG|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
218996904|NCT00224042|DRUG|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
218996905|NCT04051762|DEVICE|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
218996906|NCT04561661|PROCEDURE|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
218996907|NCT04561661|PROCEDURE|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
219181883|NCT06044025|DRUG|Turmeric|Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
219181884|NCT06532734|DEVICE|EsoGuard|device used to collect esophageal cell samples to test for the presence of abnormal cells which may indicate a dx of Barrett's esophagitis.
219181885|NCT06486103|OTHER|MetSheFlora - Vaginal Health|Take one slow-release capsule twice a day, after meal.
219181886|NCT03808818|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
218996908|NCT01113281|BIOLOGICAL|VPM1002 live vaccine|
218996909|NCT01113281|BIOLOGICAL|commercially available live vaccine BCG|
218996910|NCT03052725|DRUG|reslizumab|Reslizumab was provided in a pre-filled syringe.
219181887|NCT03808818|DRUG|Nicotine Replacement|Given NRT patch or lozenge (or both)
218996911|NCT03809117|DIAGNOSTIC_TEST|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
219181888|NCT03808818|OTHER|Quality-of-Life Assessment|Ancillary studies
219181889|NCT03808818|OTHER|Survey Administration|Ancillary studies
218996912|NCT00404846|PROCEDURE|Hyperbaric Oxygenation Therapy|
218996913|NCT01448486|DRUG|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
218996914|NCT00415662|DEVICE|Pulsed Signal Therapy (PST)|
218996915|NCT04390178|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
218996916|NCT03047694|OTHER|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
218996917|NCT03047694|OTHER|usual care|speech therapy
219181890|NCT03808818|OTHER|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
219181891|NCT05943509|BEHAVIORAL|Alternative rehabilitation strategies|Counseling intervention.
218996918|NCT03645369|DEVICE|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
218996919|NCT03645369|DEVICE|Ice pack|Ice pack containing gel
218996920|NCT05447715|DRUG|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
218996921|NCT06258356|DRUG|Remimazolam|novel ultra-short-acting benzodiazepine-like anesthetic.
218996922|NCT06258356|DRUG|placebo|normal saline (compared to Remimazolam)
218996923|NCT00812864|DRUG|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
218996924|NCT05935293|DRUG|Dexmedetomidine|iv administration dexmedetomidine
218996925|NCT01996293|DRUG|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
218996926|NCT05392010|OTHER|no intervention|no intervention
218996927|NCT02098759|DEVICE|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
218996928|NCT01186354|BEHAVIORAL|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
218996929|NCT04028700|BIOLOGICAL|G6PD Deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
219181892|NCT05943509|BEHAVIORAL|Usual Care|Usual care audiology pathway.
218996930|NCT04028700|BIOLOGICAL|Non-G6PD deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
218996931|NCT00873197|DRUG|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
219181893|NCT04410536|DRUG|Symptomatic drugs|indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
219181894|NCT04410536|DRUG|Bridge therapy|prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
219181895|NCT04410536|BEHAVIORAL|Mindfulness program|home based withdrawal program
219181896|NCT05295927|DRUG|EPI-7386|EPI-7386 will be administered orally once daily.
219181897|NCT05295927|DRUG|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
219181898|NCT05295927|DRUG|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
219181899|NCT05295927|DRUG|Apalutamide|Apalutamide will be administered orally once daily.
219181900|NCT06324604|DRUG|Placebo|Placebo
219181901|NCT06324604|DRUG|MTX-101|MTX-101 (bispecific CD8 Treg modulator)
219369706|NCT02057133|DRUG|Loperamide|Administered orally.
218996932|NCT01657669|DRUG|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
218996933|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
218996934|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
218996935|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
218996936|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
218996937|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
218996938|NCT05588908|DRUG|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
218996939|NCT05588908|OTHER|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
218996940|NCT03974425|DRUG|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
219181902|NCT06407791|DEVICE|LymphaVibe|The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
219181903|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
219181904|NCT02000050|DRUG|FOLFOX4|FOLFOX4
219181905|NCT02000050|RADIATION|Tomotherapy|Tomotherapy
219181906|NCT02000050|PROCEDURE|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
219181907|NCT03691857|PROCEDURE|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
218996941|NCT00847379|DRUG|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
219181908|NCT06362668|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
219181909|NCT06362668|DRUG|Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
219181910|NCT05086380|BEHAVIORAL|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
218996942|NCT02672865|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
218996943|NCT05154591|GENETIC|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
218996944|NCT03895385|DRUG|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
218996945|NCT05094583|BEHAVIORAL|Use of SmokeFree app|Intervention Arm
218996946|NCT00531323|DRUG|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
218996947|NCT00531323|DRUG|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
218996948|NCT02969369|DRUG|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
218996949|NCT02969369|DRUG|Placebo capsule|Placebo once daily
218996950|NCT00521014|BIOLOGICAL|filgrastim|
218996951|NCT00521014|BIOLOGICAL|rituximab|
218996952|NCT00521014|BIOLOGICAL|sargramostim|
218996953|NCT00521014|DRUG|carmustine|
218996954|NCT00521014|DRUG|cytarabine|
218996955|NCT00521014|DRUG|etoposide|
218996956|NCT00521014|DRUG|melphalan|
218996957|NCT00521014|PROCEDURE|autologous hematopoietic stem cell transplantation|
218996958|NCT04645927|DIETARY_SUPPLEMENT|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
218996959|NCT04645927|DIETARY_SUPPLEMENT|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
218996960|NCT00120731|DRUG|Potassium Citrate|
218996961|NCT00120731|DRUG|Acetazolamide|
218996962|NCT00120731|BEHAVIORAL|Diet low in oxalate and purines|
218996963|NCT01780077|DRUG|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
218996964|NCT01780077|DRUG|Placebo|Multiple intradermal injections of placebo at incision sites
218996965|NCT02279563|DRUG|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
218996966|NCT02279563|DRUG|Dymista™ Nasal Spray|
218996967|NCT02279563|DRUG|Placebo|
218996968|NCT04027426|BEHAVIORAL|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
218996969|NCT04027426|BEHAVIORAL|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
218996970|NCT05214885|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
219181911|NCT05086380|DEVICE|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
218996971|NCT02794883|BIOLOGICAL|Durvalumab|Given IV
218996972|NCT02794883|OTHER|Laboratory Biomarker Analysis|Correlative Studies
218996973|NCT02794883|PROCEDURE|Surgical Procedure|Undergo surgical tumor resection
218996974|NCT02794883|BIOLOGICAL|Tremelimumab|Given IV
218996975|NCT05063487|OTHER|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
218996976|NCT05063487|OTHER|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
218996977|NCT01023932|DEVICE|Cochlear Implants|
218996978|NCT00003499|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218996979|NCT03859193|BEHAVIORAL|Nutritional Video|A 10 - 15 minute video
218996980|NCT04449900|OTHER|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
218996981|NCT05199012|DIETARY_SUPPLEMENT|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
218996982|NCT06505668|DRUG|Atenolol 25 mg|Patients will be receiving Atenolol 25mg OD for 2 months.
218996983|NCT06505668|DRUG|Ivabradine 10mg|Patients will be receiving Ivabradine 5mg BD for 2 months.
218996984|NCT03184831|PROCEDURE|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
218996985|NCT03184831|PROCEDURE|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
218996986|NCT02864498|DRUG|DS107|
218996987|NCT02864498|DRUG|Placebo|
218996988|NCT04309539|PROCEDURE|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
218996989|NCT04309539|PROCEDURE|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
218996990|NCT06506383|OTHER|No Intervention as this is an ecological study|No Intervention as this is an ecological study
219181912|NCT05086380|BEHAVIORAL|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
219369707|NCT02057133|DRUG|Endocrine therapy|Endocrine therapy administered orally.
218996991|NCT03425877|DEVICE|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
218996992|NCT03425877|BEHAVIORAL|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
219181913|NCT05086380|DEVICE|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
218996993|NCT03425877|BEHAVIORAL|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
218996994|NCT03425877|BEHAVIORAL|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
219181914|NCT05086380|DEVICE|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
219181915|NCT05086380|DEVICE|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
219181916|NCT05086380|BEHAVIORAL|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
219181917|NCT06448247|DRUG|SPY001-001|Experimental
219181918|NCT06448247|OTHER|Placebo|Placebo
219181919|NCT02667873|DRUG|SL-801|SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
219181920|NCT04615104|PROCEDURE|Operative|surgical treatment
219181921|NCT04615104|PROCEDURE|Nonoperative|nonsurgical treatment
219181922|NCT02724449|DEVICE|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
219181923|NCT04052061|BIOLOGICAL|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
219181924|NCT06640725|DRUG|Avelumab administration at 10mg/kg|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"
219181925|NCT06640725|DRUG|Cetuximab (Erbitux)|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"
219181926|NCT03611686|DRUG|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
219181927|NCT06539936|DEVICE|Glide|Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
219181928|NCT06539936|DEVICE|Direct Control|Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
219181929|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
219369708|NCT02278783|DRUG|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
219369709|NCT02678429|DEVICE|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
219369710|NCT05462184|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
219369711|NCT05462184|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|
218996995|NCT03425877|BEHAVIORAL|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
218996996|NCT01595932|DIETARY_SUPPLEMENT|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
218996997|NCT01595932|DIETARY_SUPPLEMENT|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
218996998|NCT02027896|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
218996999|NCT00246155|BIOLOGICAL|Botulinum toxin type A|
218997000|NCT01292616|DRUG|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
218997001|NCT05698030|OTHER|Food allergy|Oral immunotherapy to pistachio
218997002|NCT03485339|DIAGNOSTIC_TEST|genome testing|blood sampling via venipuncture
218997003|NCT05884905|PROCEDURE|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
218997004|NCT05884905|PROCEDURE|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
218997005|NCT02509273|DRUG|Clonidine|
218997006|NCT02509273|DRUG|Midazolam|
218997007|NCT03803397|BIOLOGICAL|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
218997008|NCT00865696|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
218997009|NCT00865696|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
218997010|NCT04481932|DRUG|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
218997011|NCT00016185|DRUG|alvocidib|
218997012|NCT00016185|DRUG|docetaxel|
218997013|NCT04950998|BEHAVIORAL|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
218997014|NCT00428311|DRUG|Metformin|
218997015|NCT00428311|DRUG|Ethynyl-estradiol plus cyproterone acetate|
218997016|NCT03370601|DRUG|Infliximab|Infliximab 10mg/kg every 8 weeks
218997017|NCT03370601|DRUG|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
218997018|NCT03370601|DRUG|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
218997019|NCT03370601|DRUG|Infliximab|Infliximab 5mg/kg every 8 weeks
219369712|NCT04640714|BEHAVIORAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
218997020|NCT03198117|DRUG|Huaier Granule|a Chinese traditional medicine
218997021|NCT03198117|OTHER|placebo|placebo
218997022|NCT00169598|PROCEDURE|positron emission tomography|
218997023|NCT01783301|DRUG|FSH|
218997024|NCT04478539|DEVICE|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
218997025|NCT04987346|OTHER|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
218997026|NCT04987346|OTHER|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
218997027|NCT01980368|OTHER|Educational Intervention|Receive readings and attend book club
218997028|NCT01980368|BEHAVIORAL|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
218997029|NCT01980368|OTHER|Questionnaire Administration|Ancillary studies
218997030|NCT01795209|DRUG|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
218997031|NCT01795209|DEVICE|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
219369713|NCT03904680|DRUG|Methotrexate|Methotrexate 2.5 mg tablet
219369714|NCT03904680|DRUG|Vitamin D|Vitamin D 200,000 IU ampules
219369715|NCT01541293|DRUG|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
218997032|NCT01795209|PROCEDURE|Rescue laser|"In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3"
218997033|NCT04849598|OTHER|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
219181930|NCT06538142|PROCEDURE|Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
219181931|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
219181932|NCT04770571|DEVICE|observational study|observational
219181933|NCT04390347|DIETARY_SUPPLEMENT|Yakult|A fermented milk product with live microorganisms.
218997034|NCT03105895|PROCEDURE|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
218997035|NCT03346915|BEHAVIORAL|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
218997036|NCT00807378|OTHER|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
218997037|NCT02837601|DEVICE|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
218997038|NCT03948711|DEVICE|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
218997039|NCT00257543|PROCEDURE|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
218997040|NCT05288920|PROCEDURE|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
218997041|NCT05288920|DRUG|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
218997042|NCT00977860|RADIATION|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
218997043|NCT04269096|OTHER|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
218997044|NCT00851747|DRUG|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
218997045|NCT00851747|DRUG|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
218997046|NCT03431428|PROCEDURE|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
218997047|NCT03431428|PROCEDURE|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
218997048|NCT03431428|DRUG|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
218997049|NCT04176757|DRUG|ZN-c5|ZN-c5 study drug to be administered orally daily
218997050|NCT02215512|DRUG|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
218997051|NCT02798133|PROCEDURE|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
218997052|NCT02798133|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
218997053|NCT01385215|DRUG|Fluzone|0.5 ml/15 micrograms
218997054|NCT01385215|DRUG|Fluzone|0.5 ml/60 micrograms
218997055|NCT05863832|DRUG|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
218997056|NCT05863832|DRUG|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
218997057|NCT05601284|BEHAVIORAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
218997058|NCT05601284|BEHAVIORAL|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
218997059|NCT00038220|DRUG|Lopinavir/ritonavir|
218997060|NCT00038220|DRUG|Efavirenz|
218997061|NCT00038220|DRUG|Lamivudine|
218997062|NCT00038220|DRUG|Tenofovir DF|
218997063|NCT00702611|DEVICE|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
218997064|NCT03365830|DIAGNOSTIC_TEST|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
218997065|NCT03548259|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma injection
218997066|NCT03548259|PROCEDURE|Platelet-poor plasma|Platelet-poor plasma injection
218997067|NCT02024815|RADIATION|External Beam radiotherapy|External Beam radiotherapy
218997068|NCT06498492|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
219181934|NCT04390347|DIETARY_SUPPLEMENT|Placebo|A milk product with no live microorganisms.
218997069|NCT01111097|DRUG|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
218997070|NCT03187106|DRUG|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
218997071|NCT03187106|DRUG|Placebo|Placebo representing standard of care
218997072|NCT03187106|DRUG|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
218997073|NCT02581514|OTHER|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
218997074|NCT02533739|BEHAVIORAL|Cognitive and neuropsychological assesment|
218997075|NCT03203304|DRUG|Nivolumab|240mg every two weeks by IV infusion
218997076|NCT03203304|DRUG|Ipilimumab|1mg/kg every six weeks by IV infusion
218997077|NCT02809937|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
218997078|NCT02809937|DRUG|placebo|normal saline infusion
218997079|NCT02004210|PROCEDURE|transarterial radioembolization (TARE)|transarterial radioembolization
218997080|NCT02004210|PROCEDURE|transarterial chemoembolization (TACE)|transarterial chemoembolization
218997081|NCT00895167|DIETARY_SUPPLEMENT|curcumin|one oral dose of 12 caplets = 12 g curcumin
218997082|NCT00601458|DRUG|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
218997083|NCT00601458|DRUG|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
219181935|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
218997084|NCT00601458|DRUG|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
218997085|NCT03445208|DRUG|BMS-986036|Crossover administration to abdomen then upper arm
218997086|NCT04211623|OTHER|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
219181936|NCT06193174|DRUG|C134 Re-Administration|Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
219369716|NCT01541293|DRUG|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
218997087|NCT04211623|OTHER|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
218997088|NCT03453008|OTHER|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
218997089|NCT02187497|DRUG|Low dose of BIBR 277|
218997090|NCT02187497|DRUG|Medium dose of BIBR 277|
218997091|NCT02187497|DRUG|High dose of BIBR 277|
218997092|NCT04624646|DEVICE|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
218997093|NCT04624646|DEVICE|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
218997094|NCT04624646|DEVICE|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
218997095|NCT03166384|DEVICE|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
218997096|NCT03166384|PROCEDURE|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
218997097|NCT02230800|DRUG|Tocovid SupraBio plus pentoxifylline|
218997098|NCT02230800|DRUG|Matching placebos|
218997099|NCT00033020|BEHAVIORAL|Behavior Therapy|
218997100|NCT04101877|DRUG|Bevacizumab Injection|25 mg/ml
218997101|NCT04101877|DRUG|Aflibercept Injection|40 mg/ml
218997102|NCT03737942|DEVICE|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
218997103|NCT04486105|DIETARY_SUPPLEMENT|sucrose|pure sucrose in water in addition to habitual diet
218997104|NCT01844518|BIOLOGICAL|Abatacept|
218997105|NCT00008372|DRUG|chloroquinoxaline sulfonamide|
218997106|NCT01575587|DRUG|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
218997107|NCT01575587|DRUG|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
218997108|NCT01575587|DRUG|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
218997109|NCT01575587|DRUG|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
219369717|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
218997110|NCT02557555|OTHER|educational information|patients will receive pamphlet on labor analgesia options.
218997111|NCT00012311|BIOLOGICAL|filgrastim|
218997112|NCT00012311|DRUG|CMF regimen|
218997113|NCT00012311|DRUG|carboplatin|
218997114|NCT00012311|DRUG|cyclophosphamide|
218997115|NCT00012311|DRUG|docetaxel|
218997116|NCT00012311|DRUG|doxorubicin hydrochloride|
218997117|NCT00012311|DRUG|etoposide|
218997118|NCT00012311|DRUG|fluorouracil|
218997119|NCT00012311|DRUG|ifosfamide|
219369718|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
218997120|NCT00012311|DRUG|methotrexate|
218997121|NCT00012311|DRUG|thiotepa|
218997122|NCT00012311|PROCEDURE|peripheral blood stem cell transplantation|
218997123|NCT01945528|DRUG|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
218997124|NCT01945528|DRUG|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
218997125|NCT04739904|OTHER|Normoxia|48 hours experimental protocol conducted at sea level
218997126|NCT04739904|OTHER|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
218997127|NCT04739904|OTHER|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
218997128|NCT02144415|DRUG|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
218997129|NCT02144415|DRUG|EB-1020 800 mg|8 x EB-1020 100-mg capsules
218997130|NCT02144415|DRUG|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
218997131|NCT02144415|DRUG|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
218997132|NCT02144415|DRUG|Placebo|8 x matching placebo capsules
218997133|NCT06524284|DEVICE|Releaf|10 days/35 minutes per day EVNS (non-invasive electrostimulation) treatment on lower legs and feet by the subject or its caregiver after instruction by the podiatrist.
218997134|NCT00143637|OTHER|Office dust|airborne office dust spiked with glucan
219181937|NCT05825547|PROCEDURE|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
219181938|NCT06128382|BIOLOGICAL|OVX033|One single administration intramuscularly on Day 1
219181939|NCT06128382|BIOLOGICAL|Saline solution|One single administration intramuscularly on Day 1
219181940|NCT05674578|BEHAVIORAL|Patient Navigation|Assigned a patient navigator and receive coaching
219181941|NCT05674578|OTHER|Quality-of-Life Assessment|Ancillary studies
219181942|NCT05674578|OTHER|Questionnaire Administration|Ancillary studies
219181943|NCT06515990|DRUG|DM005|An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
218997135|NCT00143637|OTHER|clean air|Clean air
218997136|NCT06301334|DRUG|Bupivacaine 0.25% Injectable Solution|Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
218997137|NCT03268369|RADIATION|MRI of the brain|to eliminate a structural intra-cerebral lesion
218997138|NCT03268369|RADIATION|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq \[18F\]F-A-85380
218997139|NCT03268369|RADIATION|PET scan [18F]FDG|exam performed after iv injection of 200 MBq \[18F\]FDG
218997140|NCT05430932|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
218997141|NCT02445092|OTHER|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
218997142|NCT04584645|OTHER|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
219181944|NCT04543357|OTHER|Blood Draw|Blood Samples for NAb and ADA to AAV9
219181945|NCT06352359|DRUG|ONC-841|ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
219181946|NCT06566534|BEHAVIORAL|Reminder|Flu shot messages via SMS
219181947|NCT05337189|DIAGNOSTIC_TEST|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
219181948|NCT05337189|PROCEDURE|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
219181949|NCT03800693|DRUG|Fluorouracil|Given IV
219181950|NCT03800693|DRUG|Leucovorin|Given IV
219181951|NCT03800693|DRUG|Oxaliplatin|Given IV
218997143|NCT02554448|OTHER|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
218997144|NCT00390468|DRUG|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
219181952|NCT06108336|PROCEDURE|TMS during sequence-demanding task|TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
219181953|NCT06108336|PROCEDURE|No TMS during sequence-demanding task|TMS is not administered during the execution of sequence-demanding task.
219181954|NCT06108336|PROCEDURE|TMS during non-sequence-demanding task|TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
219181955|NCT06108336|PROCEDURE|No TMS during non-sequence-demanding task|TMS is not administered during the execution of non-sequence-demanding task
219181956|NCT06167317|DRUG|GS-0201|Pill administered orally
219181957|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
219181958|NCT02706704|DRUG|Adalimumab|
219181959|NCT05237648|OTHER|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
219181960|NCT05237648|OTHER|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
219181961|NCT05606731|BEHAVIORAL|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
219181962|NCT05657691|DRUG|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
219181963|NCT05657691|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
218997145|NCT02564237|BIOLOGICAL|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
218997146|NCT02564237|BIOLOGICAL|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
218997147|NCT02564237|BIOLOGICAL|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
218997148|NCT02564237|BIOLOGICAL|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
218997149|NCT03205332|BEHAVIORAL|Concreteness Training|
218997150|NCT06083285|OTHER|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
218997151|NCT00797030|DRUG|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
218997152|NCT00797030|DRUG|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
218997153|NCT06056713|BEHAVIORAL|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
218997154|NCT03129100|DRUG|Ixekizumab|Administered SC
218997155|NCT03129100|DRUG|Placebo|Administered SC
218997156|NCT02868775|PROCEDURE|cystoscopy, bladder hydrodistention and bladder biopsy|
218997157|NCT01486667|DRUG|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
218997158|NCT01486667|DRUG|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
218997159|NCT05191771|DEVICE|Neovis Total Multi|1 drop in each eye, 4 times per day
219181964|NCT03616496|DRUG|Neuraceq PET/CT imaging|PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
219181965|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
219181966|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
218997160|NCT05191771|DEVICE|Systane Balance|1 drop in each eye, 4 times per day
219181967|NCT06126588|DRUG|Everolimus|Patient will be treat during 7 months of Everolimus
219181968|NCT05214729|DIAGNOSTIC_TEST|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
219754159|NCT01146197|DRUG|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
218997161|NCT01117831|OTHER|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
218997162|NCT01499056|BIOLOGICAL|stem cell injection|intra articular inection of mesenchymal stem cell
218997163|NCT03789474|DEVICE|HUNTLEIGH FLOWTRON ACS900|
218997164|NCT02171520|DRUG|Dabigatran etexilate generation I|
218997165|NCT02171520|DRUG|Dabigatran etexilate generation II|
218997166|NCT02457260|DRUG|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
218997167|NCT01332903|DRUG|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
218997168|NCT02544360|BEHAVIORAL|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
219754160|NCT05470686|BIOLOGICAL|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
218997169|NCT05344170|DRUG|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
218997170|NCT05344170|DRUG|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
218997171|NCT05344170|DRUG|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
218997172|NCT01475357|OTHER|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
218997173|NCT01475357|OTHER|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
218997174|NCT03889444|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
218997175|NCT03708328|DRUG|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
218997176|NCT00753467|DRUG|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
218997177|NCT00753467|DRUG|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
218997178|NCT00753467|DRUG|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
218997179|NCT05016999|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
218997180|NCT00483730|DRUG|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
218997181|NCT02605824|DRUG|n-acetylcystine|NAC is a mucolytic drug.
218997182|NCT02605824|DRUG|0.9% saline|Normal saline is a placebo agent.
218997183|NCT06292520|OTHER|Portage Guide Protocol|Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL
218997184|NCT06292520|OTHER|ABLLS-R protocol|ABLLS-R protocol will be given to this group
218997185|NCT01989897|DRUG|saline with 1mg/ml Histamine base|
219754161|NCT01587560|DEVICE|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
219754162|NCT01587560|DEVICE|TITAN, Ascension Orthopedics, Inc.|
218997186|NCT01989897|DRUG|diluent, saline with HSA--phenol|
218997187|NCT01796080|OTHER|Mueller manoeuvre|
218997188|NCT01796080|OTHER|Inspiratory threshold|
219754163|NCT06526234|DEVICE|MRI|MR enterography
218997189|NCT01796080|OTHER|Expiratory apnoea|
218997190|NCT01796080|OTHER|Steady state normal breathing|
218997191|NCT05824793|COMBINATION_PRODUCT|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
218997192|NCT01944592|BEHAVIORAL|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
218997193|NCT01944592|BEHAVIORAL|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
218997194|NCT00496808|DRUG|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
218997195|NCT06233617|DRUG|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
219754164|NCT02124408|BEHAVIORAL|Personalized Behavioral Intervention|
218997196|NCT06233617|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
218997197|NCT06233617|DRUG|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
218997198|NCT04963335|BEHAVIORAL|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
218997199|NCT01691209|DEVICE|Phoenix (BAY81-2996)|Topical formulation applied to the skin
218997200|NCT01691209|DRUG|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
218997201|NCT01256801|BIOLOGICAL|cytokine|interleukin 2 2 million unit every week
218997202|NCT04528381|PROCEDURE|Laparoscopy|Laparoscopic orchiopexy
218997203|NCT00453622|DEVICE|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
218997204|NCT00065403|DEVICE|Acupuncture|
218997205|NCT01347944|DRUG|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
218997206|NCT06237998|DEVICE|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
218997207|NCT00160628|DRUG|Levetiracetam|
218997208|NCT06467474|BEHAVIORAL|PEG-D program|PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
218997209|NCT06467474|DRUG|TAU|The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
219181969|NCT05214729|DIAGNOSTIC_TEST|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
218997210|NCT01390805|DRUG|Valaciclovir Hydrochloride.|
218997211|NCT03123718|DRUG|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
218997212|NCT03123718|DRUG|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years."
218997213|NCT01425996|DRUG|Lipotecan® (TLC388)|"* Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
218997214|NCT00978198|DRUG|ASP1517|oral
218997215|NCT00978198|DRUG|Placebo|oral
218997216|NCT05781854|DRUG|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
218997217|NCT04786145|PROCEDURE|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
218997218|NCT04786145|PROCEDURE|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
218997219|NCT04786145|PROCEDURE|Placebo|No active treatment is given.
218997220|NCT05637866|OTHER|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
218997221|NCT06085612|DIAGNOSTIC_TEST|Automated retinal oximetry|Non invasive standard examination on automated retinal oximetry.
218997222|NCT06270667|BEHAVIORAL|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
218997223|NCT06270667|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
218997224|NCT05366946|OTHER|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
218997225|NCT02023606|DRUG|SPN-810M|
218997226|NCT03715530|DEVICE|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
218997227|NCT06037447|PROCEDURE|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
218997228|NCT02805010|DRUG|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
218997229|NCT02805010|OTHER|Placebo|On Day 1, subjects will receive a single SC dose of placebo
218997230|NCT00052481|PROCEDURE|quality-of-life assessment|
218997231|NCT01072331|DRUG|MP-513|MP-513 10 mg, once a day, for 4 weeks
218997232|NCT01072331|DRUG|MP-513|MP-513 20 mg, once a day, for 4 weeks
218997233|NCT01072331|DRUG|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
218997234|NCT00607009|BEHAVIORAL|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
218997235|NCT02301000|BIOLOGICAL|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
218997236|NCT02301000|DRUG|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
218997237|NCT01962896|DRUG|Erlotinib|
218997238|NCT01962896|DRUG|Sirolimus|
218997239|NCT02792725|DRUG|Abemaciclib|Administered orally
218997240|NCT06504940|DRUG|Orelabrutinib combined with bendamustine and rituximab|they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
218997241|NCT06504940|DRUG|Orelabrutinib combined with obinutuzumab|they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
218997242|NCT00637338|BIOLOGICAL|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
218997243|NCT00637338|BIOLOGICAL|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
219754165|NCT01508767|OTHER|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
218997244|NCT03781869|DRUG|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
218997245|NCT03781869|DRUG|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
219006733|NCT02965547|PROCEDURE|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
219006734|NCT01035515|DRUG|Placebo|Single dose oral capsule placebo comparator
219754166|NCT02893891|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
218997246|NCT04874298|OTHER|Ginger|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
218997247|NCT04874298|OTHER|Peppermint|Peppermint
218997248|NCT02871700|BEHAVIORAL|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
218997249|NCT02871700|BEHAVIORAL|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
218997250|NCT02871700|BEHAVIORAL|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
218997251|NCT02385513|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|
218997252|NCT02901405|DEVICE|Negative Pressure Wound Therapy (ActivVAC, KCI)|
218997253|NCT02901405|DEVICE|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
218997254|NCT00099008|DIETARY_SUPPLEMENT|Genistein|oral Genistein twice daily on days 1-84
218997255|NCT00099008|DIETARY_SUPPLEMENT|Placebo|oral Placebo twice daily on days 1-84
218997256|NCT02726152|PROCEDURE|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
218997257|NCT02726152|PROCEDURE|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
218997258|NCT04645082|DIAGNOSTIC_TEST|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
218997259|NCT01172431|DRUG|Indapamide|Indapamide SR 1.5mg qd
218997260|NCT01172431|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
218997261|NCT00074204|DRUG|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
218997262|NCT00074204|DRUG|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
218997263|NCT00074204|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
218997264|NCT03648983|PROCEDURE|arm circumference measurement|Undergo arm circumference measurement
218997265|NCT03648983|DEVICE|Bioimpedance spectroscopy|bioimpedance spectroscopy
218997266|NCT05892120|BEHAVIORAL|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
218997267|NCT05119452|OTHER|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
218997268|NCT01269463|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
218997269|NCT01269463|DRUG|Placebo|Capsule without active drug
218997270|NCT05677581|OTHER|iodine nutrition status|iodine nutrition status
218997271|NCT04972695|DIAGNOSTIC_TEST|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
218997272|NCT01435200|DRUG|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
218997273|NCT02803632|BEHAVIORAL|questionnaires|
218997274|NCT02803632|DEVICE|actigraphic recording|
218997275|NCT02288897|DRUG|PV-10 (10% rose bengal disodium)|
218997276|NCT02288897|DRUG|Dacarbazine, temozolomide or talimogene laherparepvec|
218997277|NCT00270868|PROCEDURE|Double guide wire technique|
218997278|NCT00270868|PROCEDURE|Standard bile duct cannulation|
218997279|NCT05745571|OTHER|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
218997280|NCT03428724|DRUG|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
218997281|NCT03428724|DRUG|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
218997282|NCT02499822|DRUG|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
218997283|NCT02499822|DRUG|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
219006735|NCT01035515|DRUG|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
218997284|NCT00456014|DRUG|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
218997285|NCT00456014|DRUG|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
218997286|NCT03121638|BIOLOGICAL|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
218997287|NCT03121638|BIOLOGICAL|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
218997288|NCT03121638|BIOLOGICAL|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
218997289|NCT03121638|BIOLOGICAL|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
218997290|NCT03121638|BIOLOGICAL|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
218997291|NCT03886805|OTHER|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
218997292|NCT03886805|OTHER|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
218997293|NCT04008576|BEHAVIORAL|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
218997294|NCT04404361|DRUG|Pacritinib|100 mg capsules
218997295|NCT04404361|DRUG|Placebo|Placebo capsules matching pacritinib 100 mg capsules
218997296|NCT03534960|DEVICE|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
218997297|NCT03534960|DEVICE|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
218997298|NCT02862171|DRUG|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
218997299|NCT03324308|DIAGNOSTIC_TEST|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
218997300|NCT02657291|DRUG|Ropivacaine|Local anesthetic
218997301|NCT02657291|DEVICE|Ultrasound|Ultrasound guided block
218997302|NCT02849431|BEHAVIORAL|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
218997303|NCT04132258|OTHER|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
218997304|NCT00245115|BIOLOGICAL|filgrastim|
218997305|NCT00245115|DRUG|busulfan|
218997306|NCT00245115|DRUG|cyclophosphamide|
218997307|NCT00245115|PROCEDURE|in vitro-treated bone marrow transplantation|
218997308|NCT00245115|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
218997309|NCT05282862|PROCEDURE|Horizontal bone augmentation|Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
218997310|NCT02549937|DRUG|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
218997311|NCT02798601|OTHER|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
218997312|NCT03930797|BEHAVIORAL|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
218997313|NCT03930797|BEHAVIORAL|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
219006736|NCT01035515|DRUG|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
219006737|NCT02762266|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218997314|NCT00662012|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
218997315|NCT01322139|DRUG|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
218997316|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
218997317|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
218997318|NCT01322139|DRUG|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
218997319|NCT03594721|OTHER|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
218997320|NCT06451094|DEVICE|US therapy|3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
218997321|NCT06451094|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
218997322|NCT01205906|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
218997323|NCT01205906|BEHAVIORAL|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
218997324|NCT01205906|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
218997325|NCT00216632|DRUG|risperidone|
218997326|NCT01893632|DRUG|gabapentin|
218997327|NCT01893632|DRUG|Placebo|
218997328|NCT04269252|OTHER|CHI-907|CHI-907 is a high CBD extract.
218997329|NCT04269252|OTHER|CHI-804|CHI-804 is the placebo formulation.
218997330|NCT00567294|BEHAVIORAL|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
218997331|NCT00567294|BEHAVIORAL|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
218997332|NCT00567294|BEHAVIORAL|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
218997333|NCT02640014|DIETARY_SUPPLEMENT|Milk|Milk Oral immunotherapy
218997334|NCT03224715|OTHER|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
218997335|NCT01523535|BEHAVIORAL|repeated cycles of short sleep|\- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
218997336|NCT02144012|DRUG|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
218997337|NCT02144012|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
218997338|NCT02144012|DRUG|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
218997339|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
218997340|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
218997341|NCT02567916|DRUG|Fresofol|
218997342|NCT02567916|DRUG|Propofol|
219006738|NCT02762266|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
219006739|NCT02762266|DRUG|embolic agent|". Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads"
219006740|NCT02762266|DRUG|lipiodol|
219006741|NCT00950547|DEVICE|CARDIOPAT|Cell Saver System at bedside for ICU stay
219006742|NCT00950547|DEVICE|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
219006743|NCT00195182|BEHAVIORAL|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
218997343|NCT06464068|DRUG|Durvalumab|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
218997344|NCT04433221|BIOLOGICAL|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
218997345|NCT01949506|RADIATION|SBRT|Stereotactic Body Radiation Therapy
218997346|NCT05457764|DEVICE|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
218997347|NCT06197750|OTHER|Vestibular stimulation|Vestibular stimulation by swing
218997348|NCT06197750|OTHER|General strengthening exercises|General strengthening exercises
218997349|NCT00130598|DRUG|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
218997350|NCT01175252|OTHER|Database analysis|Review and collect data from database
218997351|NCT04812171|PROCEDURE|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
218997352|NCT03628794|DEVICE|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
218997353|NCT02915016|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
218997354|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
218997355|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
218997356|NCT02915016|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
218997357|NCT05332197|BIOLOGICAL|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
218997358|NCT03973710|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
218997359|NCT03973710|DIETARY_SUPPLEMENT|Placebo controls|placebo with a similar appearance to probiotics supplement
218997360|NCT00440713|DRUG|Aripiprazole|
218997361|NCT00440713|BEHAVIORAL|Interpersonal Therapy|
218997362|NCT03570021|PROCEDURE|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~\- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\]."
219369719|NCT06374758|OTHER|The Accelerate model of care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
219369720|NCT06374758|DRUG|bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg|Same as above, it is the same intervetion
218997363|NCT03570021|PROCEDURE|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
218997364|NCT05405309|DRUG|RP-3500|RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.
218997365|NCT05405309|DRUG|Olaparib|Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.
218997366|NCT06975878|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
218997367|NCT06975878|BIOLOGICAL|Vaxneuvance vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
218997368|NCT06975878|BIOLOGICAL|Hexyon vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
218997369|NCT06975878|BIOLOGICAL|M-M-RvaxPro vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
218997370|NCT06975878|BIOLOGICAL|Varivax vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
218997371|NCT05930483|BEHAVIORAL|¡Vida! program|Participate in ¡Vida! program
218997372|NCT05930483|BEHAVIORAL|¡Vida! Plus [¡Vida! + Experiential Learning (EL)]|Participate in ¡Vida! Plus program
218997373|NCT05930483|BEHAVIORAL|Health Coaching|Receive health coaching
218997374|NCT05930483|BEHAVIORAL|Mailed Toolkits|Receive a mailed toolkit of health items
218997375|NCT05913843|DEVICE|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
218997376|NCT06272695|BIOLOGICAL|Volagidemab|Administered by SC injection once weekly for 6 weeks
218997377|NCT04519879|OTHER|Clinical Observation|Undergo clinical observation
218997378|NCT04519879|OTHER|Patient Observation|Undergo active surveillance
219369721|NCT02298101|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
218997379|NCT04519879|OTHER|Questionnaire Administration|Ancillary studies
218997380|NCT04519879|DRUG|White Button Mushroom Extract|Given PO
218997381|NCT05735431|DRUG|Administration of investigation drug|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
218997382|NCT05735431|DRUG|Administration of comparator|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
218997383|NCT05792709|OTHER|Oral Motor Therapy|In Traditional therapy we will give cognitive and articulation therapy to the patients.
219369722|NCT02298101|DEVICE|Aeroneb Solo Adapter|Nebulizer
218997384|NCT02592356|PROCEDURE|Computed Tomography|Correlative studies
218997385|NCT02592356|PROCEDURE|Dual X-ray Absorptiometry|Correlative studies
218997386|NCT02592356|PROCEDURE|Physical Examination|Correlative studies
218997387|NCT02592356|OTHER|Quality-of-Life Assessment|Ancillary studies
218997388|NCT02592356|OTHER|Questionnaire Administration|Ancillary studies
218997389|NCT02592356|DRUG|Cabozantinib|
218997390|NCT02592356|DRUG|Lenvatinib|
218997391|NCT01087138|BEHAVIORAL|exercise|exercise class 3x's/week
218997392|NCT01087138|BEHAVIORAL|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
218997393|NCT01670240|DRUG|Adalimumab|
218997394|NCT01670240|DRUG|Placebo|
219369723|NCT02298101|DEVICE|Opti-Mist Plus Nebulizer|Standard jet nebulizer
219369724|NCT02298101|OTHER|Planar scintigraphy|Imaging technique to investigate whole lung deposition
219369725|NCT02298101|OTHER|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
219369726|NCT02298101|OTHER|Spirometry|FEV1, FVC assessment
218997395|NCT00580684|BIOLOGICAL|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
218997396|NCT03261050|BEHAVIORAL|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
218997397|NCT03261050|BEHAVIORAL|Interpersonal Therapy|8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
218997398|NCT06667544|DRUG|RNK08954-01|Once daily oral treatment for a 3 week cycle
218997399|NCT06651437|OTHER|Experimental dietary educational intervention|At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
218997400|NCT06650800|DRUG|Psilocybin|Single-dose psilocybin administration: oral ingestion of one 25 mg capsule
218997401|NCT06650800|OTHER|MRI|1.5 hour brain MRI before and after psilocybin administration
218997402|NCT06170970|DRUG|Solriamfetol|solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
218997403|NCT06170970|DRUG|Placebo|Four weeks of oral placebo
218997404|NCT06979141|DRUG|Dexmedetomidine|Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
218997405|NCT06979141|DRUG|Magnesium sulfate|Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
218997406|NCT06979141|DRUG|Lidocaine|Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
218997407|NCT06979141|DRUG|normal saline|Patients will receive 10 ml normal saline 10 min before the end of surgery.
219369727|NCT01870635|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
218997408|NCT06977256|OTHER|Sensory-Based Exercises|Participants in the Sensory-Based Intervention Group received weekly 40-minute face-to-face sessions for 8 weeks, involving structured exercise and sensory-based activities tailored to individual needs, with caregiver feedback and home programs provided after each session.
218997409|NCT06977256|OTHER|Telerehabilitation and Based Sensory Intervention|Participants in the Telerehabilitation-Based Sensory Intervention Group received 8 weeks of in-person sessions followed by 8 weeks of weekly 30-minute telerehabilitation sessions, combining individualized sensory-based activities with caregiver coaching and home-based implementation via Zoom. Sessions were personalized, progressively structured, and conducted in a stable virtual environment to support continuity and engagement.
218997410|NCT07133165|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
218997411|NCT07132515|DRUG|Enoxaparin, warfarrin, or apixaban|Enoxaparin, warfarrin, or apixaban
218997412|NCT07131306|DRUG|ucMSC and Standard medical treatment|umbilical cord Mesenchymal stem cell1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. All patients will receive the standard medical treatment.
218997413|NCT07131306|OTHER|Standard medical treatment|Standard medical treatment
218997414|NCT06599996|DEVICE|Testing artificial intelligence algorithms for interpreting gestures|The effectiveness of artificial intelligence algorithms for detecting and interpreting body-based gestures by individuals who have motor/visual impairments will be evaluated.
218997415|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
218997416|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
218997417|NCT04921189|DRUG|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
218997418|NCT04921189|DRUG|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
218997419|NCT06577727|OTHER|Gold standard blood test|Blood test will measure haemoglobin and other parameters
218997420|NCT06577727|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected for AI to estimate iron status
218997421|NCT06535945|DRUG|Albumin administration|when albumin serum concentration is at 30 g/L or below
218997422|NCT06630728|DRUG|Reduced Nicotine Content Cigars|Participants will smoke a very low nicotine content filtered little cigar containing 0.50mg nicotine per gram of tobacco
218997423|NCT06630728|DRUG|Normal nicotine content cigar|Participants will smoke a normal nicotine content filtered little cigar containing 5.17mg nicotine per gram of tobacco
218997424|NCT06630728|DRUG|Usual brand cigar|Participants will smoke their usual brand filtered little cigar
218997425|NCT05977647|DRUG|Tamsulosin Oral Capsule|Patient will be enrolled in one of study arm through randomization.
218997426|NCT06820021|OTHER|Strength-based Tailored-Exercise Program at Home (STEP@Home)|The 20-week STEP@Home is a multi-component exercise training program designed to recondition the functional status of older adults in the post-discharge period and to develop long-term exercise engagement. The content is developed based on the recommendations from a scope review and the Vivifrail exercise guideline on home-based exercise for older adults , with expert input from the research team including geriatricians in frailty management, exercise physiologist, nursing academicians in aged care research. Three design characteristics, including an empowerment approach (Funnell \& Anderson, 2004), lifestyle-integrated functional exercises (Weber et al., 2018), and an optimized tele-platform, are incorporated into the exercise program to enhance such therapeutic benefit.
218997427|NCT06820021|OTHER|Usual Care|The control group will receive the usual post-discharge care provided in the hospital setting, including general education on medication, basic knowledge of disease-related self-care, and/or attending regular medical follow-ups in the specialist outpatient clinics. The RA will review the client's post-discharge planning and record social and healthcare service referral information. The RA will only make home visits for data collection, and the controls will receive a HK$100 supermarket coupon as an incentive, which will be applied to the intervention group.
218997428|NCT05795439|BEHAVIORAL|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
218997429|NCT04415008|DRUG|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
218997430|NCT06596655|DEVICE|Single use bronchoscope|Use of single use bronchoscopes for interventional pulmonology procedures instead of reusable bronchoscopes.
218997431|NCT06827418|OTHER|simulation|Students will practice the psychomotor steps of blood pressure measurement using a simulator.
218997432|NCT06827418|OTHER|peer teaching|Students will practice the psychomotor steps of blood pressure measurement through peer teaching. Third- and fourth-year nursing students will serve as peer educators. Students will apply the skill steps under the guidance of an upper-class peer instructor.
218997433|NCT05284656|DRUG|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
218997434|NCT05284656|DRUG|folic acid|drugs used to delay progression of chronic kidney disease
219181970|NCT05997875|BEHAVIORAL|Educational Materials|"Participants are provided with the Getting Ready: Your Vascular Access Journey video and brochure about hemodialysis vascular access. The video is available for viewing via smartphone or computer. Both the brochure and video were created with input from patients with chronic kidney disease."
218997435|NCT05284656|DRUG|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
218997436|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
219181971|NCT05997875|BEHAVIORAL|Motivational Interviewing|Participants receive coaching with telehealth-based motivational interviewing designed to prepare participants to move forward with vascular access creation. Motivational interviewing will consist of a minimum of 3 and maximum of 8 telehealth sessions with a coach. The coach will use patient-centered communication skills to work though the stages of pre-contemplative, contemplative, preparation, action, and maintenance of an arteriovenous vascular access.
219181972|NCT05997875|BEHAVIORAL|Usual Care|Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
219181973|NCT05997875|OTHER|Patient Lists for Clinicians: System-Level Intervention|Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
219181974|NCT04024761|BIOLOGICAL|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
218997437|NCT04779554|DRUG|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
219181975|NCT04024761|DRUG|Fludarabine|Fludarabine is a chemotherapy agent
219369728|NCT01870635|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
218997438|NCT04779554|DRUG|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
218997439|NCT06992063|PROCEDURE|Spinal anesthesia|In both groups patients will undergo spinal anesthesia and be followed intra- and postoperatively in the context of postdural puncture headache
218997440|NCT07000630|DRUG|Deucravacitinib|25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.
218997441|NCT06081036|OTHER|Questionnaire|Questionnaire about children development
218997442|NCT07001592|BIOLOGICAL|vvDD-hIL-2-RG-1|"A single dose of the investigational agent will be injected intratumorally at one of the following three dose levels.~Level 1: 3 x 108 p.f.u. Level 2: 1 x 109 p.f.u. Level 3: 3 x 109 p.f.u. p.f.u = Plaque-forming unit(s)~Dose will be escalated in cohorts of 3, according to a standard 3+3 design."
218997443|NCT07002190|OTHER|Watching an animation video|education
218997444|NCT07001033|BEHAVIORAL|Dance Movement Therapy (DMT)|All participants will be invited to five group meetings at weekly intervals. Each of these therapy sessions will take place with a specific theme. In weeks 1 and 5, data important for the study will be collected once before the short-term DMT and once again at the end of the study. This includes different assessments, laboratory blood tests as well as immunophenotyping. Additionally, patients are requested to complete a questionnaire that addresses QoL. Specific examinations, such as testing the maximal handgrip strength, a BIA and recording Eastern Cooperative Oncology Group (ECOG) performance status are implemented in each of the five meetings.
218997445|NCT07002177|DRUG|FWD1802|orally QD with 28 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
218997446|NCT07002177|DRUG|Palbociclib 125mg|Dose: 125 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break (3-weeks-on/1-week-off), constituting a 28-day cycle
218997447|NCT07002177|DRUG|Ribociclib 200Mg Oral Tablet|Dose: 600 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break, constituting a 28-day cycle
218997448|NCT07002177|DRUG|Abemaciclib 150 MG|Dose: 150 mg Route: Orally Frequency: BID Schedule: Everyday
218997449|NCT07002177|DRUG|Everolimus 10 mg|Dose: 10 mg Route: Orally Frequency: QD Schedule: Everyday
218997450|NCT06679270|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
218997451|NCT06547918|DEVICE|Omnipod 5 SA2.0 System|The Omnipod 5 SA2.0 System provides automated insulin delivery based on Continuous Glucose Monitoring (CGM) values.
219181976|NCT04024761|DRUG|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
219181977|NCT04520672|OTHER|Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
219181978|NCT04520672|OTHER|Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
219181979|NCT04117295|DEVICE|Carmat Total Artificial Heart|Heart replacement therapy
219181980|NCT03051282|DRUG|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
219181981|NCT06029062|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
219181982|NCT06029062|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
219181983|NCT06029062|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
219181984|NCT05890976|DRUG|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
219181985|NCT05890976|DRUG|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
219181986|NCT04476160|DIETARY_SUPPLEMENT|Cinnamon|children recipe 3 grams by day of cinnamon
219369729|NCT06274567|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
218997452|NCT07131930|OTHER|Caregiver Burden, Psychological Resilience, Sleep Quality|Informal caregivers who provide daily care for bedridden patients are evaluated in this study. The exposure involves physical, emotional, and financial caregiving responsibilities such as assistance with feeding, mobility, and emotional support. The impact of caregiving on sleep quality and psychological resilience is assessed using validated questionnaires (Zarit Burden Interview, Pittsburgh Sleep Quality Index, Resilience Scale).
218997453|NCT06246578|DEVICE|Continuos glucose monitoring and blood glucose measurement|The individuals who use Dexcom G 7 sensors for continous glucose monitoring is in addition applied a Libre 2 sensor and asked to wear both sensors for 14 days. In case of a Dexcom glucose value \< 5 mmol/l, the participants is aked to measure a blood glucose as well uising fingerprick and Contour Next One
218997454|NCT04710056|DRUG|REGN4461|
218997455|NCT04316676|DIAGNOSTIC_TEST|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
218997456|NCT04316676|DIAGNOSTIC_TEST|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s. The CT examinations are scheduled within 90 days of the standard clinical PET examination."
218997457|NCT04316676|DIAGNOSTIC_TEST|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml. The CT examinations are scheduled within 90 days of the standard clinical PET examination.
218997458|NCT04316676|DRUG|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
218997459|NCT03734055|BEHAVIORAL|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
218997460|NCT03734055|BEHAVIORAL|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
218997461|NCT06526052|BEHAVIORAL|Mindfulness Program|Online, coached mindfulness training program
218997462|NCT06526052|BEHAVIORAL|Active Comparator|Remote meetings with a supportive coach
218997463|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
218997464|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
218997465|NCT06259175|DRUG|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
218997466|NCT02821013|DRUG|Intermittent PD-1 inhibitor therapy|
218997467|NCT02821013|DRUG|Continuous PD-1 inhibitor therapy|
218997468|NCT03997110|RADIATION|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
218997469|NCT03997110|RADIATION|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
219369730|NCT06274567|DEVICE|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
218997470|NCT06318871|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells|Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
218997471|NCT06318871|DRUG|Interleukin-2 (IL-2)|Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
218997472|NCT05425745|DRUG|Obicetrapib|10 mg Obicetrapib tablet
218997473|NCT05425745|DRUG|Placebo|placebo tablet made to resemble active
219181987|NCT04210102|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
219181988|NCT04210102|DIAGNOSTIC_TEST|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
219181989|NCT05718479|BEHAVIORAL|Trauma Informed Prenatal Intervention (TPI)|TPI is designed to foster behavior change and health coping by enhancing knowledge, beliefs, regulation skills and abilities. In the experimental group, a research staff member will meet with participants and help them to identify a health behavior they want to change, explore the pros and cons of making a change, create a behavior change plan, and learn several mindfulness meditation techniques. The facilitator will check-in with the participants about their behavior change plan in the subsequent sessions regarding progress made, barriers encountered, and changes in the plan and/or goal going forward. Participants will be instructed to implement an at-home mental wellness skills and provided with a tracking log to report the frequency and dose of daily/weekly practice.
219181990|NCT05718479|OTHER|Prenatal Education Topics|In the control group, a research staff member will provide participants with four different weekly prenatal education topics, including information on prenatal care, labor and delivery, postpartum care, and newborn care.
219181991|NCT03026127|BEHAVIORAL|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
219181992|NCT03026127|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
219181993|NCT05799105|DRUG|Omeprazole 40 milligrams|Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
219181994|NCT05160272|DRUG|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
219181995|NCT05160272|DRUG|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
219181996|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
219181997|NCT06007521|OTHER|interview with neurologist|interview with neurologist
219181998|NCT05098613|DRUG|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
219181999|NCT05208164|BEHAVIORAL|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
219182000|NCT04937179|PROCEDURE|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
219182001|NCT04937179|PROCEDURE|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
219182002|NCT02637479|DEVICE|GammaKnife®|
219182003|NCT02637479|DEVICE|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
219182004|NCT02637479|DEVICE|MRI|
219182005|NCT03692065|DRUG|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
218997474|NCT05263206|DRUG|Dupilumab|Injection solution subcutaneous
219182006|NCT05459857|OTHER|Product A|Heated tobacco (HT) device with Intense HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
218997475|NCT05263206|DRUG|Placebo|Injection solution SC
218997476|NCT05263206|DRUG|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
218997477|NCT05048979|OTHER|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
218997478|NCT05992311|DRUG|Montelukast|This group will receive the montelukast treatment.
218997479|NCT05992311|OTHER|Placebo|This group will receive a placebo pill instead of montelukast
218997480|NCT05231954|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
218997481|NCT01479673|DIETARY_SUPPLEMENT|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
218997482|NCT01002703|DRUG|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
218997483|NCT02976428|PROCEDURE|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
218997484|NCT02976428|PROCEDURE|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
218997485|NCT06001424|OTHER|physical therapy|Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
218997486|NCT06001424|OTHER|life kinetic exercises|A multimodal training that combines coordinative, cognitive and visual tasks.
219182007|NCT05459857|OTHER|Product B|Heated tobacco (HT) device with Regular HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
219182008|NCT05459857|OTHER|Product C|Heated tobacco (HT) device with Menthol HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
219182009|NCT05459857|OTHER|Product D|Subject's own brand combustible cigarette, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
219182010|NCT06394167|DRUG|VX-993|Solution for IV administration.
219182011|NCT06394167|DRUG|Placebo|Solution for IV administration.
219182012|NCT05589389|OTHER|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
219182013|NCT05589389|OTHER|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
219182014|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
219182015|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
219182016|NCT04432532|OTHER|No intervention|There are no interventions
219182017|NCT06185790|OTHER|LCHF diet|Low-carb high-fat (LCHF) diet
219182018|NCT04732533|OTHER|tES (transcranial electrical stimulation)|"Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tES. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tES sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 52 weeks.~Phase 4: The participant will receive up to 780, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 156 weeks."
219182019|NCT06117579|OTHER|Inspiratory muscle training|"Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device."
219182020|NCT06296537|PROCEDURE|Dynamic Neuromuscular Stabilization Training (DNS)|Dynamic neuromuscular stabilization training has been developed, which optimizes the movement system based on the scientific principles of developmental kinesiology. DNS training aims to stimulate the natural movement control system in the brain to activate the body's stabilization system. Supine, prone, oblique sitting, tripod, high kneeling, hanging stance-midstance faze, hanging stance- propulsion, bear, squat exercises will be applied.
218997487|NCT02891850|DRUG|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
218997488|NCT02891850|DRUG|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
218997489|NCT02891850|DRUG|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
218997490|NCT02674529|DRUG|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
218997491|NCT02674529|DRUG|Placebo|Placebo
218997492|NCT02674529|BEHAVIORAL|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
218997493|NCT06069245|DIETARY_SUPPLEMENT|MitoQ|80mg of MitoQ taken in one dose on one occasion.
218997494|NCT06069245|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
218997495|NCT04349670|PROCEDURE|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
218997496|NCT06141590|DRUG|administration of UI068|Test
218997497|NCT06141590|DRUG|administration of UIC202205, UIC202206|Reference
218997498|NCT06111300|DRUG|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
218997499|NCT02532491|DRUG|Aripiprazole|Initial dose: 10 mg.
218997500|NCT02532491|DRUG|Risperidone|Initial dose: 2 mg.
218997501|NCT04773483|DIETARY_SUPPLEMENT|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
218997502|NCT04773483|DIETARY_SUPPLEMENT|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
218997503|NCT00331682|DRUG|alvocidib|Given IV
219182021|NCT06296537|PROCEDURE|Balance Training|Multi-plane single limb challenges, jumping and landing exercises, proprioceptive exercises, and perturbation exercises
219182022|NCT06296537|PROCEDURE|Conventional Training|Education, electrotherapy, soft tissue fascia massage, stretching, range of motion, strengthening and postural control exercises
218997504|NCT00331682|DRUG|docetaxel|Given IV
218997505|NCT02732704|DEVICE|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
218997506|NCT00004978|DRUG|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
218997507|NCT03761277|DEVICE|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
218997508|NCT03761277|DRUG|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
218997509|NCT05288231|DIAGNOSTIC_TEST|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
218997510|NCT00003211|BIOLOGICAL|filgrastim|
218997511|NCT00003211|DRUG|amifostine trihydrate|
218997512|NCT00003211|DRUG|cisplatin|
218997513|NCT00003211|DRUG|cyclophosphamide|
218997514|NCT00003211|DRUG|vincristine sulfate|
218997515|NCT00003211|PROCEDURE|peripheral blood stem cell transplantation|
218997516|NCT00003211|RADIATION|radiation therapy|
218997517|NCT01384253|OTHER|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
218997518|NCT01384253|BIOLOGICAL|trastuzumab|4 mg/kg.
218997519|NCT05973500|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet for 42 Days
218997520|NCT00109798|DRUG|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
218997521|NCT00109798|DRUG|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
218997522|NCT00302250|DRUG|ALT-711 (alagebrium chloride)|
218997523|NCT03555591|DRUG|Trelagliptin|Trelagliptin tablets
218997524|NCT05002010|DEVICE|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
218997525|NCT00081484|DRUG|epoetin alfa or beta|iv or sc, as prescribed
218997526|NCT00081484|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
218997527|NCT03210818|DEVICE|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
219182023|NCT04159259|OTHER|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
219182024|NCT04159259|OTHER|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
219182025|NCT04159259|OTHER|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
219182026|NCT05806593|BEHAVIORAL|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
219182027|NCT05448443|DRUG|AD981|Oral administration of AD981 in the morning and before sleep for 14 days
219182028|NCT05448443|OTHER|Placebo|Oral administration of placebo in the morning and before sleep for 14 days
219369731|NCT00125034|BIOLOGICAL|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
218997528|NCT01184794|DRUG|levobupivacaine|40 ml over 48 hours
218997529|NCT05420077|BIOLOGICAL|RVM-V001 10 µg|Low Dose
218997530|NCT05420077|BIOLOGICAL|RVM-V001 30 µg|Mid Dose
218997531|NCT05420077|BIOLOGICAL|RVM-V001 60 µg|High Dose
218997532|NCT01938677|RADIATION|Initial Gamma knife radiosurgery|
218997533|NCT05846191|DIAGNOSTIC_TEST|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
218997534|NCT02414750|DRUG|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
218997535|NCT02414750|DEVICE|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
218997536|NCT02414750|PROCEDURE|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
218997537|NCT02414750|PROCEDURE|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
218997538|NCT01598051|DRUG|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
218997539|NCT00578812|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
218997540|NCT00578812|DEVICE|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
218997541|NCT02768012|BEHAVIORAL|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
218997542|NCT04069611|OTHER|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
218997543|NCT04069611|OTHER|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
218997544|NCT04069611|PROCEDURE|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
218997545|NCT04978740|OTHER|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
218997546|NCT01088945|BEHAVIORAL|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
218997547|NCT01541124|DRUG|Opioid|10 mg/pill, po, each 6h, during 6m
218997548|NCT06243263|DRUG|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
218997549|NCT03808493|DRUG|TAK-438 OD|TAK-438 OD tablet
218997550|NCT03808493|DRUG|TAK-438|TAK-438 tablet
218997551|NCT01125865|DEVICE|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
219182029|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
219182030|NCT05443347|BEHAVIORAL|Aerobic exercise|Supervised aerobic exercise
219182031|NCT05443347|BEHAVIORAL|Newsletter|Biweekly newsletter
219369732|NCT00125034|DRUG|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
219369733|NCT00113243|DRUG|adult stem cells|
218997552|NCT01125865|DEVICE|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
218997553|NCT06146452|OTHER|Not|Not
218997554|NCT02743559|DEVICE|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
218997555|NCT04167202|PROCEDURE|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
218997556|NCT04167202|PROCEDURE|RICE|RICE protocol
218997557|NCT02464462|DIETARY_SUPPLEMENT|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
218997558|NCT02464462|OTHER|Placebo|Rice powder pills
218997559|NCT00846430|DRUG|Peg-Interferon alpha-2b|age and weight dependant
218997560|NCT00846430|DRUG|Celecoxib (Celebrex)|age and weight dependant
218997561|NCT00846430|DRUG|Temozolomide (temodar)|age and weight dependant
218997562|NCT00846430|DRUG|Vincristine Sulfate (Oncovin)|age and weight dependant
218997563|NCT01029795|DRUG|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
218997564|NCT01029795|DRUG|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
218997565|NCT01029795|DRUG|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
218997566|NCT00115050|DRUG|TMC114|
218997567|NCT00861432|OTHER|additive homeopathic treatment|These patients receive additive homeopathic treatment
218997568|NCT02113592|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
218997569|NCT03217175|DEVICE|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
218997570|NCT03217175|DEVICE|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
218997571|NCT03217175|DRUG|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
218997572|NCT03217175|DRUG|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
218997573|NCT03445338|DRUG|K0706|Study
218997574|NCT03445338|DRUG|K0706|Study
218997575|NCT03445338|DRUG|K0706|Study
218997576|NCT02190357|DRUG|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
218997577|NCT03178864|DRUG|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
218997578|NCT03178864|DRUG|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
218997579|NCT02177305|DRUG|0.02 mcg tiotropium solution|
218997580|NCT02177305|DRUG|0.04 mcg tiotropium solution|
218997581|NCT02177305|DRUG|0.08 mcg tiotropium solution|
218997582|NCT02177305|DRUG|0.16 mcg tiotropium solution|
218997583|NCT02177305|DRUG|0.28 mcg tiotropium solution|
218997584|NCT02177305|DRUG|0.40 mcg tiotropium solution|
218997585|NCT02177305|DRUG|Placebo solution|
218997586|NCT06026761|DEVICE|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
218997587|NCT05864001|BEHAVIORAL|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
218997588|NCT01118702|DRUG|Ritalin-SR|3-20mg tablets, once
218997589|NCT01118702|DRUG|Concerta|one 54mg tablet, once
218997590|NCT01118702|DRUG|Novo-Methylphenidate ER-C|one 54mg tablet, once
218997591|NCT05770791|DIETARY_SUPPLEMENT|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
218997592|NCT05770791|DIETARY_SUPPLEMENT|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
218997593|NCT05500586|DRUG|Glucagon response study|Please see information in group descriptions
218997594|NCT02254993|DRUG|C16G2|antimicrobial peptide
218997595|NCT01331915|BIOLOGICAL|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
219754167|NCT02893891|PROCEDURE|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
218997596|NCT05604092|DIAGNOSTIC_TEST|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
218997597|NCT05604092|OTHER|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
218997598|NCT01896544|DIETARY_SUPPLEMENT|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
218997599|NCT01896544|DIETARY_SUPPLEMENT|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
218997600|NCT04044235|BEHAVIORAL|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
218997601|NCT03062683|OTHER|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
218997602|NCT06959472|BEHAVIORAL|Hyperarch Fascia Training|A 12-week behavioral intervention involving Hyperarch Fascia Training (HFT), which includes one weekly 1-hour virtual session with a certified coach and two 1-hour independent training sessions. The protocol combines meditation, mental imagery, foot and toe strengthening exercises, myofascial rolling, balance drills, and low-impact plyometrics.
218997603|NCT01823523|DRUG|Cefazolin, Cephalexin, Clindamycin|
219006744|NCT05542927|DIAGNOSTIC_TEST|urine chloride|Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
219006745|NCT01438424|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily
219006746|NCT01438424|DRUG|Lamivudine|Oral, 100 mg, daily
219006747|NCT05508581|PROCEDURE|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
219006748|NCT03038191|DEVICE|Neuroelectrics Enobio 8(R)|Monitoring
219006749|NCT00118963|DRUG|Metformin|Tablets of 500 mg; 1000 mg two times daily.
219006750|NCT00118963|DRUG|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
219006751|NCT00118963|DRUG|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
219006752|NCT00118963|DRUG|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
219006753|NCT00118963|DRUG|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
219006754|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
218997604|NCT02618889|BEHAVIORAL|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
218997605|NCT00429273|DRUG|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
218997606|NCT00429273|DRUG|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
218997607|NCT04165434|OTHER|Concurrent Training|Strength training and interval aerobic training in the same training session
218997608|NCT01186679|PROCEDURE|laminectomy|surgical laminectomy with glial scar resection
218997609|NCT01186679|PROCEDURE|Intrathecal|direct into the CSF through lumbar puncture
218997610|NCT00374790|DRUG|Ferrous sulfate|
218997611|NCT01438957|DRUG|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
218997612|NCT01438957|DRUG|Placebo|
218997613|NCT02760199|DRUG|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
218997614|NCT02760199|DEVICE|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
218997615|NCT06055647|GENETIC|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
218997616|NCT02854735|OTHER|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
218997617|NCT05240053|OTHER|enhanced recovery programe|Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
218997618|NCT02603614|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
218997619|NCT02603614|DRUG|Placebo|Placebo control
218997620|NCT04752150|OTHER|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
218997621|NCT02632955|DRUG|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
218997622|NCT02632955|PROCEDURE|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
218997623|NCT01793675|PROCEDURE|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
218997624|NCT00398892|DRUG|Lipoic acid|Lipoic acid capsules
218997625|NCT02150096|OTHER|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
218997626|NCT02150096|OTHER|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
218997627|NCT02150096|OTHER|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
218997628|NCT01074866|DEVICE|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
218997629|NCT05921305|DRUG|MTX|MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
218997630|NCT05921305|DRUG|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
218997631|NCT00289965|BEHAVIORAL|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
218997632|NCT00289965|BEHAVIORAL|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
218997633|NCT00289965|BEHAVIORAL|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
218997634|NCT00934830|DRUG|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
218997635|NCT00934830|OTHER|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
218997636|NCT00751270|BIOLOGICAL|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
218997637|NCT00751270|DRUG|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
218997638|NCT04976751|DRUG|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
218997639|NCT04305262|DEVICE|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
218997640|NCT00136656|DRUG|antibiotic|cephalosporine by oral route : cefixime
218997641|NCT00136656|DRUG|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
218997642|NCT02302001|DEVICE|Silicone Implant|
218997643|NCT03018821|DRUG|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
218997644|NCT03018821|DRUG|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
218997645|NCT03018821|DRUG|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
218997646|NCT03018821|DRUG|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
218997647|NCT03018821|DRUG|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
218997648|NCT03018821|DRUG|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
219754168|NCT02893891|PROCEDURE|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
218997649|NCT03018821|DRUG|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
218997650|NCT03018821|DRUG|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
218997651|NCT03018821|DRUG|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
218997652|NCT03018821|DRUG|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
218997653|NCT03018821|DRUG|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
218997654|NCT03018821|DRUG|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
218997655|NCT03018821|DRUG|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
218997656|NCT01694030|OTHER|Attachment security priming|
218997657|NCT01125683|DRUG|AZD1446|Capsule, oral single and multiple dose
218997658|NCT01125683|DRUG|Donepezil|Capsule, oral and single dose
218997659|NCT01125683|DRUG|Placebo|Capsule, oral and single dose
218997660|NCT00292266|DRUG|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
218997661|NCT00292266|DRUG|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
218997662|NCT05261074|OTHER|No intervention|No intervention (retrospective study)
218997663|NCT00859053|DRUG|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
218997664|NCT01679860|PROCEDURE|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
219754169|NCT02893891|DEVICE|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
219754170|NCT07104513|DEVICE|Red Light|use red light twice per day, both eyes. use red light for one year in The RLRL-1year Group. use red light for two year in The RLRL-2years Group. red light for three years in The RLRL-3years Group.red light for more than three years in The RLRL- more than 3years Group.
219754171|NCT03923335|OTHER|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
218997665|NCT01679860|DRUG|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
218997666|NCT02130973|DRUG|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
218997667|NCT02130973|DRUG|Experimental Cyclic Regimen|Experimental Cyclic Regimen
219182032|NCT06246045|DIAGNOSTIC_TEST|Walking test|"PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy."
218997668|NCT02302820|OTHER|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
218997669|NCT02823301|BEHAVIORAL|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
218997670|NCT01176084|BEHAVIORAL|low carbohydrate diet|
218997671|NCT01176084|BEHAVIORAL|low carbohydrate diet and exercise|
218997672|NCT02548650|DRUG|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
218997673|NCT02548650|DRUG|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
218997674|NCT02548650|DRUG|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
218997675|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
218997676|NCT06122896|OTHER|Screening Blood Tests|Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.
218997677|NCT06122896|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
218997678|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Imaging|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
218997679|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Cholangiopancreatography|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
218997680|NCT05091749|BIOLOGICAL|blood samples|troponin measurement
218997681|NCT03264261|DEVICE|robotic training|robotic training, 3 times/week for 6 weeks
218997682|NCT03264261|DEVICE|treadmill training|treadmill training only, 3 times/week for 6 weeks
219182033|NCT06802640|COMBINATION_PRODUCT|Transcutaneous spinal cord electrical stimulation and Kunming Locomotor Training|Patients will undergo Kunming Locomotor Training along with transcutaneous spinal cord stimulation. . The training is at least 1 hour per day, 5 hours per week, for 6 consecutive months.
219182034|NCT06802705|BEHAVIORAL|Psychosocial Stress on Quality of Life|Psychosocial Stress on Quality of Life in Saudi Arabian Patients with Alopecia Areata
219182035|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
218997683|NCT06120387|PROCEDURE|Radical surgery|Radical nephroureterectomy
218997684|NCT06120387|RADIATION|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
218997685|NCT02983474|PROCEDURE|cholecystectomy|"Laparoscopic surgery~1. Reverse Trendelenburg position~2. Skin incision and trocar insertion~3. CO2 gas insufflation~4. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction~6. Calot triangle exposure~7. Cystic artery and cystic duct isolation~8. Gallbladder bed dissection~9. Bleeding control~10. Gallbladder extraction~11. Trocar removal and wound closure~Open surgery~1. Supine position~2. Skin incision~3. Intra-abdominal inspection and gallbladder exposure~5\. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
218997686|NCT01539538|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
218997687|NCT01539538|DRUG|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
218997688|NCT05947396|DIETARY_SUPPLEMENT|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
218997689|NCT05947396|OTHER|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
218997690|NCT02654743|DIETARY_SUPPLEMENT|Sulforaphane|Children with ASD will receive Sulforaphane in this study
218997691|NCT00598104|DRUG|QAX576|
218997692|NCT00598104|DRUG|Placebo|
218997693|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
218997694|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
218997695|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
218997696|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
218997697|NCT04496271|DEVICE|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
218997698|NCT03909841|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
218997699|NCT03909841|OTHER|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
218997700|NCT00003931|GENETIC|reverse transcriptase-polymerase chain reaction|
218997701|NCT01909674|DEVICE|Switch CPAP mask type|
218997702|NCT04604223|DRUG|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
218997703|NCT04858243|OTHER|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
218997704|NCT04858243|OTHER|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
218997705|NCT05862480|OTHER|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
218997706|NCT05862480|OTHER|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
218997707|NCT01695187|DRUG|NB-001 (0.3%)|Topical administration at least five times throughout the day
218997708|NCT01695187|DRUG|Placebo|
218997709|NCT04890769|DEVICE|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
218997710|NCT03641859|DEVICE|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
218997711|NCT04390191|DEVICE|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
218997712|NCT02321878|DRUG|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
218997713|NCT00735410|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
218997714|NCT00942253|OTHER|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
218997715|NCT01867437|DRUG|Placebo|Sterile solution (vehicle) for subcutaneous infusion
218997716|NCT01867437|DRUG|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
218997717|NCT05576870|OTHER|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
218997718|NCT05576870|DIETARY_SUPPLEMENT|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
219182036|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
219182037|NCT02231164|DRUG|placebo|oral placebo
219182038|NCT02231164|DRUG|nintedanib|oral experimental therapy
219182039|NCT05919810|OTHER|Probiotic|Oral probiotic
219182040|NCT05919810|DIETARY_SUPPLEMENT|Oral herbal powder supplement|oral herbal powder
219182041|NCT05914246|DEVICE|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
219182042|NCT05700903|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH)|8 weeks of GnRH agonist
219182043|NCT05700903|DRUG|Androgen receptor (AR) inhibitor|2 weeks of AR Inhibitor
219182044|NCT05700903|DRUG|Placebo|Placebo tablet and injection
219182045|NCT06195319|DRUG|Simufilam|100 mg of \[14C\]-simufilam
219182046|NCT02547363|DRUG|LEO 43204 gel|
219182047|NCT02547363|DRUG|Vehicle gel|
218997719|NCT03336671|PROCEDURE|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
218997720|NCT03336671|PROCEDURE|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
218997721|NCT05566912|OTHER|filling out a survey|This research is a descriptive study
218997722|NCT05700097|DRUG|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
218997723|NCT05700097|DRUG|Placebo injection|placebo control arm for the standard protocol
218997724|NCT02781597|DRUG|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
218997725|NCT02781597|DRUG|Placebo|Patients will receive 0.9% normal saline
218997726|NCT02954731|BEHAVIORAL|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
218997727|NCT02954731|BEHAVIORAL|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
219182048|NCT05634993|OTHER|Assessment|Assessment of disability level and trunk control
219182049|NCT03569631|DRUG|BPN14770|25 mg BPN14770 capsules
219182050|NCT03569631|DRUG|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
219182051|NCT04226313|DIAGNOSTIC_TEST|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
219182052|NCT04226313|DIAGNOSTIC_TEST|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
219182053|NCT04895761|BIOLOGICAL|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
219182054|NCT04895761|DRUG|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
219182055|NCT04895761|DRUG|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
219182056|NCT04895761|RADIATION|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
219182057|NCT05412433|BEHAVIORAL|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
219182058|NCT05412433|BEHAVIORAL|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
219182059|NCT05412433|BEHAVIORAL|Control|Standard of care
219182060|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
219182061|NCT06539520|OTHER|Aerobic training program|Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
219182062|NCT06539520|OTHER|Selected physical therapy program for post stroke patients|Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
219182063|NCT04436276|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
219182064|NCT04436276|BIOLOGICAL|Placebo|Participants will receive Placebo.
219182065|NCT05281562|DRUG|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
218997728|NCT02034214|BEHAVIORAL|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
218997729|NCT02034214|OTHER|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
218997730|NCT02034214|BEHAVIORAL|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
218997731|NCT03978832|DRUG|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
218997732|NCT03978832|DRUG|Risperidone|Oral risperidone
218997733|NCT04281810|DEVICE|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
218997734|NCT01752998|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|
218997735|NCT01752998|BEHAVIORAL|Health Education|
218997736|NCT02563405|DRUG|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
218997737|NCT02563405|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
218997738|NCT05772000|DIAGNOSTIC_TEST|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
218997739|NCT01744574|OTHER|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
218997740|NCT01744574|DRUG|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
218997741|NCT01744574|OTHER|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
218997742|NCT00002098|DRUG|Lentinan|
218997743|NCT00002098|DRUG|Didanosine|
218997744|NCT01727297|DEVICE|REVEAL Implantable Cardiac Monitor|
218997745|NCT02042183|DRUG|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
218997746|NCT02042183|DRUG|Placebo|0 mcg soft capsules of placebo for oral administration
218997747|NCT02084654|DRUG|Exenatide 5 and 10 mcg 2 times a day|
218997748|NCT02084654|DRUG|placebo|
218997749|NCT05823129|BEHAVIORAL|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
218997750|NCT04080401|DEVICE|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
218997751|NCT04080401|OTHER|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
218997752|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
218997753|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
218997754|NCT00318630|DRUG|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
218997755|NCT00318630|DRUG|Placebo|Subjects will also receive placebo oral tablet.
218997756|NCT02244606|DRUG|SCY-078|
218997757|NCT02244606|DRUG|Fluconazole|
218997758|NCT02244606|DRUG|Micafungin|
218997759|NCT02256189|DRUG|Sitagliptin|Sitagliptin 100 mg daily
218997760|NCT02256189|DRUG|Placebo|Placebo one tablet daily
218997761|NCT04483271|DIETARY_SUPPLEMENT|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
218997762|NCT00285454|PROCEDURE|Retrograde coronary venous delivery of cells.|
218997763|NCT02824952|DRUG|Tagrisso|taking orally everyday for 6 or 12 weeks.
218997764|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
218997765|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
219182066|NCT05281562|DRUG|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
219182067|NCT05281562|DRUG|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
219182068|NCT05573126|DRUG|Vosilasarm|Vosilasarm is an orally administered investigational selective androgen receptor modulator (SARM)
219182069|NCT05573126|DRUG|Elacestrant|Oral SERD
219182070|NCT05573126|DRUG|Everolimus|mTOR Inhibitor
219182071|NCT04052971|DRUG|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
219182072|NCT04052971|DRUG|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
218997766|NCT01292434|BEHAVIORAL|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
218997767|NCT00378378|DRUG|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
218997768|NCT00378378|DRUG|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
218997769|NCT05948020|BIOLOGICAL|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10\^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10\^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10\^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10\^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10\^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
218997770|NCT05948020|OTHER|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
218997771|NCT04902794|DEVICE|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
218997772|NCT04902794|DEVICE|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
218997773|NCT00263601|BIOLOGICAL|Allergovit 6-grasses|Subcutaneous injections
218997774|NCT00263601|OTHER|Placebo|Subcutaneous injections
218997775|NCT03312270|BEHAVIORAL|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
218997776|NCT02295488|PROCEDURE|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
218997777|NCT02295488|BIOLOGICAL|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
218997778|NCT01013376|DRUG|MC-1101|MC-1101 1.0%
218997779|NCT01013376|DRUG|Vehicle|Vehicle
219182073|NCT05313620|DRUG|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
219182074|NCT05313620|DRUG|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
219182075|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
219182076|NCT06326099|BEHAVIORAL|Brief Online Binge Eating and Drinking Intervention|The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
219754172|NCT03167060|DEVICE|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
218997780|NCT00407797|DRUG|Pregabalin|150 to 600 mg/day during 21 weeks
218997781|NCT01084369|DRUG|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
218997782|NCT01812174|DEVICE|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
218997783|NCT01812174|DEVICE|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
218997784|NCT03612505|BEHAVIORAL|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
218997785|NCT02535117|PROCEDURE|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
218997786|NCT02535117|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
218997787|NCT01437072|OTHER|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
218997788|NCT04332562|OTHER|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
218997789|NCT05823961|DEVICE|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
218997790|NCT00553644|DRUG|Bortezomib|Given IV
218997791|NCT00553644|OTHER|Laboratory Biomarker Analysis|Correlative studies
218997792|NCT00553644|DRUG|Lenalidomide|Given PO
218997793|NCT02073552|DRUG|Polyethylene glycol 4000|\- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
218997794|NCT02073552|DRUG|Macrogol 3350 plus ascorbic acid|\- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
218997795|NCT03782792|DRUG|Spesolimab|Solution for infusion
218997796|NCT03782792|DRUG|Placebo|Solution for infusion
218997797|NCT01829373|BIOLOGICAL|vaccine 1650-G|
219754173|NCT03167060|DEVICE|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
219754174|NCT03226041|DEVICE|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
219754175|NCT02096107|DRUG|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
219754176|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
219754177|NCT05023109|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
219754178|NCT01811420|PROCEDURE|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
219182077|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
219182078|NCT04380831|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219182079|NCT04380831|DRUG|Cyclophosphamide|Undergo HSCT
218997798|NCT06354595|DEVICE|Multidimensional Rehabilitation in the Metaverse|Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
218997799|NCT05273918|OTHER|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
218997800|NCT05273918|OTHER|body mediation|15 workshops once a week during 90 minutes
218997801|NCT00919919|DRUG|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
218997802|NCT00919919|DRUG|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
218997803|NCT01333254|PROCEDURE|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
218997804|NCT05776498|PROCEDURE|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
218997805|NCT05776498|PROCEDURE|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
218997806|NCT03137290|DRUG|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
218997807|NCT03137290|DRUG|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
218997808|NCT04964375|DRUG|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
218997809|NCT04883931|DRUG|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
218997810|NCT04883931|BIOLOGICAL|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
218997811|NCT04866225|DRUG|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
218997812|NCT04866225|DRUG|Oral PF-06865571|Oral PF-06865571
218997813|NCT04866225|DRUG|IV [14C]PF-06865571|IV radiolabeled PF-06865571
218997814|NCT05509920|OTHER|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
219182080|NCT04380831|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
219182081|NCT04380831|PROCEDURE|Total-Body Irradiation|Undergo TBI using IMRT
219182082|NCT06185491|OTHER|HGI|Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
219182083|NCT03709680|DRUG|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
219182084|NCT03709680|DRUG|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
219182085|NCT03709680|DRUG|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
219182086|NCT03709680|DRUG|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
219182087|NCT03709680|DRUG|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
219182088|NCT06777446|PROCEDURE|Elective Adhesionlysis|See descriptions in study arms
219182089|NCT06777446|DEVICE|Adhesion barrier|At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).
219182090|NCT05802056|BIOLOGICAL|Aldesleukin|Given IP
219182091|NCT05802056|PROCEDURE|Biopsy|Undergo biopsy
219182092|NCT05802056|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219182093|NCT05802056|PROCEDURE|Computed Tomography|Undergo PET/CT
219182094|NCT05802056|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
219182095|NCT05802056|DRUG|Fluorouracil|Given IV
219182096|NCT05802056|DRUG|Leucovorin Calcium|Given IV
219182097|NCT05802056|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219182098|NCT05802056|BIOLOGICAL|Nivolumab|Given IV
219182099|NCT05802056|DRUG|Oxaliplatin|Given IV
219369734|NCT04364919|BEHAVIORAL|aerobic exercise program|"The program incorporated modified yoga movements suitable for pregnant women. The DVD provides an illustration with the written caption, Please take enough water before exercise, and wear loose and comfortable clothes in a suitable environment. If you feel tired, stop exercising immediately. The DVD's narrator then says, Now you are ready to prepare a comfortable, solid chair with a chair back. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercises were developed as a progressive program in order to achieve the goals of strength-conditioning, moderate-intensity exercise (ACOG, 2015)."
219754179|NCT01811420|PROCEDURE|Conventional method|Dental caries removal using rotatory instrument
219754180|NCT01415947|DEVICE|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
219182100|NCT05802056|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
219182101|NCT05280548|DRUG|Venglustat (GZ402671)|Tablet; Oral
219182102|NCT05280548|DRUG|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
219182103|NCT05280548|DRUG|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
219182104|NCT05280548|DRUG|Migalastat|Hard capsules; Oral
219182105|NCT01767636|DRUG|Pazopanib Hydrochloride|Given PO
219182106|NCT04881838|DRUG|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
219182107|NCT04881838|DRUG|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
219182108|NCT04881838|DRUG|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
219182109|NCT04881838|DRUG|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
219182110|NCT04881838|DRUG|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
219182111|NCT04881838|DRUG|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
219182112|NCT04881838|DRUG|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
219182113|NCT04881838|DRUG|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
219182114|NCT06647810|DRUG|BI 690517 formulation 1|BI 690517 formulation 1
219182115|NCT06647810|DRUG|BI 690517 formulation 2|BI 690517 formulation 2
219182116|NCT06647810|DRUG|Probenecid|Probenecid
219754181|NCT07115667|DRUG|BCMA/CD3 bispecific antibody (CM336)|Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA/CD3 bispecific antibody (CM336)
219754182|NCT06416475|DIETARY_SUPPLEMENT|Mankai supplementation|The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
219754183|NCT06416475|OTHER|Water consumption|Water consumption
219754184|NCT03612570|DEVICE|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
219754185|NCT03144401|DRUG|Misoprostol|mesotac
219754186|NCT03144401|OTHER|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
219754187|NCT01844596|BEHAVIORAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
219754188|NCT01844596|BEHAVIORAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
219754189|NCT02087852|OTHER|salvia for germline DNA|
219754190|NCT02087852|BEHAVIORAL|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
219754191|NCT02087852|BEHAVIORAL|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
219754192|NCT02087852|OTHER|Blood draw|
219182117|NCT06546592|DEVICE|AI assisted contouring|Initial are generated automatically using software powered by artificial intelligence
218997815|NCT00425295|BEHAVIORAL|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
218997816|NCT02396485|OTHER|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
219182118|NCT06107231|OTHER|Honey|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)
219182119|NCT06107231|OTHER|Sucrose|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)
219557694|NCT06650124|DRUG|Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.|Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
218997817|NCT06413563|DIAGNOSTIC_TEST|Complete blood count|"Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker"
218997818|NCT05336812|DRUG|Acalabrutinib|Given PO
218997819|NCT05336812|BIOLOGICAL|Obinutuzumab|Given IV
218997820|NCT05336812|DRUG|Venetoclax|Given PO
218997821|NCT06199895|DRUG|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
218997822|NCT05084378|DRUG|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
218997823|NCT05084378|DRUG|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
218997824|NCT05084378|DRUG|Topical Antibiotic|2 grams Vancomycin powder
218997825|NCT05084378|DRUG|Saline Lavage Solution|1 litre of sterile isotonic saline
218997826|NCT06113809|DRUG|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
218997827|NCT06113809|DRUG|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
218997828|NCT02321800|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
218997829|NCT02321800|DRUG|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
218997830|NCT00543504|DRUG|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
218997831|NCT00543504|DRUG|Sorafenib|200 mg By Mouth Daily for 28 Days
218997832|NCT00543504|DRUG|Erlotinib|50 mg By Mouth Daily for 28 Days.
218997833|NCT00543504|DRUG|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
218997834|NCT00543504|DRUG|Lapatinib|250 mg By Mouth Daily for 21 Days.
218997835|NCT00543504|DRUG|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
218997836|NCT00543504|DRUG|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
218997837|NCT06558032|DRUG|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)|One tablet of the test drug was given orally under fasting condition
218997838|NCT06558032|DRUG|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)|One tablet of the test drug was given orally under fasting condition
218997839|NCT02407353|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
218997840|NCT02407353|DRUG|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
218997841|NCT03132220|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
219182120|NCT06107231|OTHER|Honey plus almonds|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
219182121|NCT06107231|OTHER|Sucrose plus almonds|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
219182122|NCT03547336|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
219182123|NCT03547336|DEVICE|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
219182124|NCT06647888|DRUG|Envlo Tablet|Envlo Tab. 0.3mg
218997842|NCT03132220|BEHAVIORAL|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
218997843|NCT03837197|DEVICE|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
218997844|NCT03837197|DEVICE|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
218997845|NCT03824613|DIAGNOSTIC_TEST|Urinary miRNA|MiRNA detection in urine
218997846|NCT00935571|DRUG|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
218997847|NCT04884854|DEVICE|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
218997848|NCT06506786|OTHER|Garden-fresh Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
218997849|NCT06506786|OTHER|Supermarket Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
218997850|NCT01969968|OTHER|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
218997851|NCT05251974|DIAGNOSTIC_TEST|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
218997852|NCT02458040|DRUG|Drug selected in the study|
218997853|NCT00039975|DRUG|Indinavir sulfate|
218997854|NCT00039975|DRUG|Ritonavir|
218997855|NCT00039975|DRUG|Amlodipine|
218997856|NCT00039975|DRUG|Diltiazem HCl|
219182125|NCT06647888|DRUG|Envlomet SR Tablet|Envlomet SR Tablet 0.3/ Metformin1,000mg
219182126|NCT06648239|OTHER|Usual Care|In the usual care group, patients will proceed directly to ICA following referral from community cardiology, as is the current standard of care. Research staff will screen participants in this group for significant CAD using the decision support tool; however, the tool's recommendations will not affect their care, as all patients in this group will invariably receive ICA.
218997857|NCT00903591|OTHER|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
218997858|NCT01051323|DRUG|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
218997859|NCT00888368|PROCEDURE|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
218997860|NCT00888368|PROCEDURE|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
218997861|NCT02596308|BIOLOGICAL|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
218997862|NCT03181334|BEHAVIORAL|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
219369735|NCT02094144|OTHER|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
219182127|NCT06648239|OTHER|Centralized triage with risk score-based screening for obstructive CAD|Patients randomized to the intervention will have selected features of their medical history, recorded on their referral form, entered into a decision support tool by research personnel to generate a recommendation of whether they should proceed directly to ICA or whether they should receive CCTA. Patients with recommendations for ICA will proceed directly to ICA. Patients with recommendations for CCTA will be referred to CCTA. Based on the results of the CCTA, recommendations for medical management versus referral for ICA will be made.
219182128|NCT04421547|DRUG|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
218997863|NCT03181334|BEHAVIORAL|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
218997864|NCT03181334|BEHAVIORAL|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
218997865|NCT03181334|BEHAVIORAL|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
218997866|NCT03181334|BEHAVIORAL|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
218997867|NCT05477810|DRUG|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
218997868|NCT05477810|DRUG|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
218997869|NCT04564937|DRUG|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
218997870|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
218997871|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
219182129|NCT04421547|DRUG|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
219182130|NCT06648824|DRUG|Mitapivat|Oral tablets
219182131|NCT06648824|DRUG|Midazolam|Oral syrup
218997872|NCT01109043|DRUG|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
218997873|NCT04905485|BEHAVIORAL|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
218997874|NCT05890872|DEVICE|Aliya Pulsed Electric Fields (PEF)|Percutaneous or Endobronchial PEF
218997875|NCT04873804|OTHER|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
218997876|NCT02627105|BEHAVIORAL|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
218997877|NCT02627105|BEHAVIORAL|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
218997878|NCT04770662|OTHER|Questionnaires|"Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
219182132|NCT06283251|BEHAVIORAL|PediRISE Resource Program|A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
219182133|NCT05200260|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
219369736|NCT02094144|OTHER|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
219182134|NCT05200260|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
219182135|NCT05200260|DRUG|PARP inhibitor|For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy. In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.
218997879|NCT02978430|DEVICE|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
218997880|NCT02978430|OTHER|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
218997881|NCT02146898|OTHER|Position|
218997882|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
218997883|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
218997884|NCT05202652|DIETARY_SUPPLEMENT|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
218997885|NCT05202652|DIETARY_SUPPLEMENT|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
218997886|NCT01778218|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
218997887|NCT02655796|DEVICE|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
218997888|NCT05805410|BEHAVIORAL|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
218997889|NCT05805410|BEHAVIORAL|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
218997890|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
218997891|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Single pill
218997892|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg|oral tablet
219182136|NCT05200260|DRUG|Bevacizumab|For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy. In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.
219182137|NCT06257771|DRUG|Alcohol (Ethanol)|Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
219182138|NCT02431845|DRUG|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
219182139|NCT05429476|DRUG|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
219182140|NCT04413955|DEVICE|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
218997893|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg|oral tablet
218997894|NCT04518293|DRUG|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
218997895|NCT04518293|DRUG|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
218997896|NCT04518293|DRUG|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
218997897|NCT04518293|DRUG|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
218997898|NCT01278979|DEVICE|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus."
218997899|NCT01278979|OTHER|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
218997900|NCT01369758|DEVICE|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
218997901|NCT06504706|PROCEDURE|Matcha Tea|Japanese tea rich in antioxidants and Catechins
218997902|NCT06504706|PROCEDURE|Green Tea|Green tea rich in catechins
218997903|NCT02066246|DEVICE|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
218997904|NCT02066246|DEVICE|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
218997905|NCT01974804|PROCEDURE|MRI|
219182141|NCT05977530|BEHAVIORAL|self-rescue training|children will receive training for self-rescue if they are alone in water
218997906|NCT05057182|BIOLOGICAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
218997907|NCT03385512|BEHAVIORAL|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
218997908|NCT03385512|BEHAVIORAL|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
218997909|NCT03385512|BEHAVIORAL|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
218997910|NCT05451225|BEHAVIORAL|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
218997911|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
218997912|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
218997913|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
218997914|NCT00823095|DRUG|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
218997915|NCT04173585|DRUG|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
218997916|NCT04173585|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
218997917|NCT01764672|DRUG|Methylphenidate|Oral dose 40mg (2 x 20mg)
218997918|NCT01764672|OTHER|Placebo|Oral intake of 2 placebo tablets
219182142|NCT04416984|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
219182143|NCT04416984|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
219182144|NCT04416984|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219182145|NCT04416984|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219182146|NCT04102150|DRUG|Valemetostat Tosylate|Once a day, 200 mg, oral administration
219182147|NCT04427384|DEVICE|GammaTile|Surgically Targeted Radiation Therapy
219182148|NCT06148194|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
218997919|NCT04789135|DRUG|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
218997920|NCT05123820|DRUG|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
218997921|NCT05123820|DRUG|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
218997922|NCT01185756|RADIATION|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
218997923|NCT00436839|DRUG|Docetaxel|75mg/m² intravenously (day 1) every 21 days
218997924|NCT00436839|DRUG|Mitoxantrone|12mg/m² intravenously every 21 days
218997925|NCT00436839|DRUG|Prednisone|10mg orally given daily
218997926|NCT05027100|DRUG|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
218997927|NCT04904562|DRUG|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
218997928|NCT04904562|DRUG|Placebo|Placebo
218997929|NCT00016887|BIOLOGICAL|filgrastim|
218997930|NCT00016887|BIOLOGICAL|recombinant interferon alfa|
218997931|NCT00016887|DRUG|carmustine|
218997932|NCT00016887|DRUG|cyclophosphamide|
218997933|NCT00016887|DRUG|cytarabine|
218997934|NCT00016887|DRUG|dexamethasone|
218997935|NCT00016887|DRUG|etoposide|
218997936|NCT00016887|DRUG|melphalan|
218997937|NCT00016887|PROCEDURE|bone marrow ablation with stem cell support|
218997938|NCT00016887|PROCEDURE|peripheral blood stem cell transplantation|
218997939|NCT00016887|RADIATION|radiation therapy|
218997940|NCT03571425|OTHER|Oral Placebo|A placebo beverage will be consumed orally
218997941|NCT03571425|OTHER|Oral Protein|A protein beverage will be consumed orally
218997942|NCT03571425|OTHER|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
218997943|NCT05964205|OTHER|Electronic clinical decision support tool|Electronic clinical decision support tool
218997944|NCT03972332|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
218997945|NCT05196204|OTHER|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
218997946|NCT05196204|OTHER|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
218997947|NCT01637272|DRUG|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
218997948|NCT04141592|PROCEDURE|Bariatric Surgery|Already clinically indicated surgical procedures
218997949|NCT02493140|DIETARY_SUPPLEMENT|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
218997950|NCT02493140|DIETARY_SUPPLEMENT|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
218997951|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
218997952|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
218997953|NCT03024060|DRUG|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
219182149|NCT06148194|COMBINATION_PRODUCT|Probiotic 1|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device (Product declaration: No. 210001337/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.
218997954|NCT03024060|DRUG|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
219182150|NCT06148194|COMBINATION_PRODUCT|Probiotic 2|In Vietnam, LiveSpo Navax Kid is manufactured as a Class-A medical device (Product declaration: No. 220002534/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.
219369737|NCT05419895|BEHAVIORAL|Early Diagnostic Response Model (EDRM)|Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
218997955|NCT03024060|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
218997956|NCT03024060|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
218997957|NCT06487585|DRUG|Angiotensin II|Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
218997958|NCT02968797|DEVICE|SafeSed|Monitor respiratory parameters
218997959|NCT01399515|DRUG|Valproic Acid|One 500mg tablet by mouth daily
218997960|NCT00681005|DRUG|rabeprazole|20 mg bid for 14 days
218997961|NCT00681005|DRUG|pantoprazole|pantoprazole 40 mg bid
218997962|NCT05866796|DIAGNOSTIC_TEST|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
218997963|NCT04534361|OTHER|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
218997964|NCT01350297|PROCEDURE|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
218997965|NCT02600572|OTHER|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
218997966|NCT02600572|OTHER|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
218997967|NCT01496612|DRUG|Buspirone|
218997968|NCT01496612|DRUG|Placebo|
218997969|NCT05032560|DRUG|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
218997970|NCT05032560|DRUG|Placebo|Drug: Matching Placebo placebo matching with ABX464
218997971|NCT00358371|DRUG|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
218997972|NCT00358371|DRUG|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
218997973|NCT06557005|OTHER|Facilitated Transition to Primary Care|The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
218997974|NCT04235985|COMBINATION_PRODUCT|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
218997975|NCT04194034|BIOLOGICAL|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
218997976|NCT04194034|DRUG|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
218997977|NCT05658146|DRUG|Mavacamten Capsule 1|Specified dose on specified days
218997978|NCT05658146|DRUG|Mavacamten Capsule 2|Specified dose on specified days
218997979|NCT05658146|DRUG|Mavacamten Capsule 3|Specified dose on specified days
218997980|NCT03675100|PROCEDURE|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
218997981|NCT01146418|BIOLOGICAL|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
218997982|NCT01146418|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
218997983|NCT06201741|RADIATION|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
218997984|NCT02885103|DEVICE|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
218997985|NCT02885103|DEVICE|Nebulizer|Inhalation will be done will Nebulizer and via mouth
218997986|NCT00358852|OTHER|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
218997987|NCT00356291|BEHAVIORAL|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
219182151|NCT04594057|BEHAVIORAL|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
219182152|NCT02688140|DRUG|Arsenic trioxide|
219182153|NCT02688140|DRUG|Idarubicin|
218997988|NCT00356291|BEHAVIORAL|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
218997989|NCT04489563|DEVICE|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
218997990|NCT05856032|DEVICE|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
218997991|NCT05856032|OTHER|Conventional Treatment|Conventional chest physiotherapy techniques
218997992|NCT05106283|PROCEDURE|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
218997993|NCT02828696|DEVICE|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
218997994|NCT05865067|OTHER|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
218997995|NCT05865067|OTHER|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
218997996|NCT02955160|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
218997997|NCT02955160|BIOLOGICAL|Tdap|Tetanus, diphtheria, and pertussis vaccine
218997998|NCT00066885|DRUG|calcitriol + docetaxel|
218997999|NCT00283452|BEHAVIORAL|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
218998000|NCT04345809|PROCEDURE|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
218998001|NCT04345809|PROCEDURE|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
218998002|NCT05780229|PROCEDURE|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
218998003|NCT05780229|PROCEDURE|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
218998004|NCT05780229|PROCEDURE|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
218998005|NCT05780229|DRUG|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
218998006|NCT05780229|DEVICE|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
218998007|NCT01802931|DRUG|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
219182154|NCT02688140|DRUG|Cytarabine|
219182155|NCT02688140|DRUG|Tretinoin|
219182156|NCT02688140|DRUG|Mitoxantrone|
219182157|NCT02688140|DRUG|Mercaptopurine|
219182158|NCT02688140|DRUG|Methotrexate|
218998008|NCT01802931|DRUG|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
218998009|NCT02716428|DRUG|Faldaprevir|
218998010|NCT02716428|DRUG|TD-6450|
218998011|NCT02716428|DRUG|Ribavirin|
219182159|NCT05692960|OTHER|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
219182160|NCT05692960|DEVICE|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
219182161|NCT04992767|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
219182162|NCT04992767|BEHAVIORAL|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
218998012|NCT00779285|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
218998013|NCT03209596|DIETARY_SUPPLEMENT|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
218998014|NCT03209596|DIETARY_SUPPLEMENT|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
218998015|NCT01623583|OTHER|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
218998016|NCT01623583|OTHER|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
218998017|NCT04891952|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
218998018|NCT03036696|OTHER|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
218998019|NCT03036696|OTHER|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
218998020|NCT04729270|PROCEDURE|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
218998021|NCT04729270|PROCEDURE|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
218998022|NCT01666496|BEHAVIORAL|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
218998023|NCT01666496|BEHAVIORAL|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
218998024|NCT02695329|DEVICE|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
218998025|NCT04324775|OTHER|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
218998026|NCT04324775|OTHER|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
218998027|NCT03721744|DRUG|GB201|GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
218998028|NCT03721744|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
218998029|NCT03721744|DRUG|Gemcitabine|Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
218998030|NCT03721744|OTHER|Standard of care treatment options|Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
218998031|NCT00384566|DRUG|Carvedilol|anit hypertensive medication
218998032|NCT00384566|DRUG|Metoprolol|Anti hypertensive medication
218998033|NCT02213367|DRUG|Bilastine|20mg (8 weeks)
218998034|NCT02213367|DRUG|Bilastine|40mg
218998035|NCT02213367|DRUG|Bilastin|80mg
218998036|NCT02366052|BEHAVIORAL|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
218998037|NCT02366052|DIETARY_SUPPLEMENT|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
218998038|NCT02366052|OTHER|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
218998039|NCT04425915|BIOLOGICAL|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
218998040|NCT04425915|OTHER|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
218998041|NCT03198247|OTHER|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
218998042|NCT03198247|OTHER|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
218998043|NCT06505876|BEHAVIORAL|Basic treatment|including anti-infection therapy, blood pressure and blood glucose control
218998044|NCT06505876|DEVICE|Oral Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
218998045|NCT06505876|DEVICE|Nasogastric Tube Feeding|The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
218998046|NCT06242158|PROCEDURE|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
218998047|NCT01201005|DIETARY_SUPPLEMENT|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
218998048|NCT01201005|DIETARY_SUPPLEMENT|Sham injection|needle injection without any substance given
218998049|NCT01316796|DRUG|Sodium Nitrite Cream|
218998050|NCT02275468|DRUG|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
219182163|NCT05230043|OTHER|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
219369738|NCT01647607|BEHAVIORAL|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
218998051|NCT06237829|BEHAVIORAL|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
218998052|NCT06237829|BEHAVIORAL|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
218998053|NCT06237829|BEHAVIORAL|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
218998054|NCT00563498|DRUG|Glutamine|
218998055|NCT01184300|GENETIC|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
218998056|NCT02256020|OTHER|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
218998057|NCT02256020|OTHER|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
218998058|NCT00745836|DRUG|statin|
218998059|NCT01866930|BIOLOGICAL|Pegylated Interferon Lambda-1a|
218998060|NCT01866930|DRUG|Daclatasvir (DCV)|
218998061|NCT01866930|DRUG|Ribasphere (RBV)|
218998062|NCT03834597|DEVICE|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
218998063|NCT03834597|DEVICE|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
218998064|NCT00279305|DRUG|Anti-CD20 (rituximab)|
218998065|NCT00279305|DRUG|Placebo Comparator|Placebo intravenous infusion
218998066|NCT03081988|OTHER|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
218998067|NCT01212315|DEVICE|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
218998068|NCT04380415|DIAGNOSTIC_TEST|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
218998069|NCT05173805|DRUG|YL-15293|After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
218998070|NCT04481854|PROCEDURE|cricoid pressure|cricoid pressure during laryngoscopy
218998071|NCT04481854|PROCEDURE|left paratracheal pressure|left paratracheal pressure during laryngoscopy
218998072|NCT03303365|RADIATION|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
218998073|NCT04956367|PROCEDURE|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
218998074|NCT04956367|DEVICE|CO2 laser with PRP|CO2 laser with PRP
218998075|NCT04956367|DEVICE|CO2 laser with placebo|CO2 laser with placebo
218998076|NCT00171353|DRUG|valsartan|
218998077|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
218998078|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
218998079|NCT06074367|DRUG|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
218998080|NCT04813198|BEHAVIORAL|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
218998081|NCT03046004|OTHER|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
218998082|NCT03046004|OTHER|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
218998083|NCT00078442|DRUG|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
218998084|NCT05894083|PROCEDURE|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
218998085|NCT05894083|COMBINATION_PRODUCT|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV\_High and PTV\_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV\_High in 2 Gy per fraction.
218998086|NCT05894083|OTHER|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
218998087|NCT05894083|RADIATION|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
218998088|NCT00232024|DRUG|Tegaserod|
218998089|NCT05853185|DRUG|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
219182164|NCT05230043|OTHER|functional MRI|"* Two 8s sequences of spin echo field map with phase encoding AP and PA~* A 12:00min bold sequence for resting-state~* A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~* A 6:38min T1w MPR sequence~* A 7:40min T1w MPR sequence~* A 5:57min T2w SPC sequence~* A 8:24min T2w SPC sequence~* A 8:32min FLAIR T2w sequence~* Two 8:26min Multi-echo GRE sequence~* A 8:29min high resolution multi-echo GRE sequence~* Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~* Two 6:03min diffusion weighted images with phase encoding AP and PA"
219182165|NCT05633303|OTHER|Substrate guided ablation|Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
219182166|NCT04203303|OTHER|Observational|Observational
219182167|NCT04382664|BIOLOGICAL|UV1|UV1 vaccine (300 μg) will be injected intradermally.
218998090|NCT05853185|DRUG|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
218998091|NCT01156870|DRUG|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
218998092|NCT05450952|DIETARY_SUPPLEMENT|Theanine Formulation|Theanine Formulation Tablet
218998093|NCT05450952|DIETARY_SUPPLEMENT|Placebo|Placebo Tablet
219182168|NCT04382664|BIOLOGICAL|Sargramostim|Sargramostim (75 μg) is used as a vaccine adjuvant.
219182169|NCT04382664|BIOLOGICAL|Ipilimumab|Ipilimumab is dosed according to label.
219182170|NCT04382664|BIOLOGICAL|Nivolumab|Nivolumab is dosed according to label.
219182171|NCT04763577|OTHER|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
218998094|NCT05190237|DIETARY_SUPPLEMENT|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
218998095|NCT05190237|DIETARY_SUPPLEMENT|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
218998096|NCT05190237|DIETARY_SUPPLEMENT|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
218998097|NCT00477256|BEHAVIORAL|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
218998098|NCT04186728|DIETARY_SUPPLEMENT|Magnesium glycinate|Daily magnesium capsule.
218998099|NCT04186728|OTHER|Placebo|Daily placebo capsule.
218998100|NCT01965301|DRUG|BP1.5375 suspension|single oral dose
218998101|NCT01965301|DRUG|Diphenhydramine|single oral dose of Diphenhydramine 50mg
218998102|NCT01965301|DRUG|Placebo|Single oral dose
218998103|NCT01261910|BEHAVIORAL|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
218998104|NCT04644081|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
218998105|NCT04644081|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
218998106|NCT04644081|DRUG|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
218998107|NCT01939652|PROCEDURE|Restrictive VS Standard Fluid Regime|
218998108|NCT01939652|DRUG|Drag: Crystalloids and Colloids|
218998109|NCT03602144|OTHER|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
218998110|NCT03602144|OTHER|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
218998111|NCT04193098|BIOLOGICAL|CTL|CTL injection
218998112|NCT04193098|BIOLOGICAL|Toripalimab|Toripalimab injection
218998113|NCT02019329|OTHER|Placebo|Oral daily administration from Days 1-12
218998114|NCT02019329|DRUG|RO5545965|Oral daily administration from Days 1-12
218998115|NCT02019329|DRUG|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
218998116|NCT06266910|OTHER|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
218998117|NCT03331367|PROCEDURE|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
218998118|NCT03331367|PROCEDURE|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
218998119|NCT01375556|DRUG|Ethanol|
218998120|NCT00317356|DRUG|OPC-6535(Tetomilast)|
219182172|NCT06122701|DIETARY_SUPPLEMENT|Thiamin p.o.|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
219182173|NCT06122701|DIETARY_SUPPLEMENT|Thiamin i.v.|"A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
219369739|NCT01647607|BEHAVIORAL|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
218998121|NCT06504849|BEHAVIORAL|Receiving LSM messages.|"* LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications"
218998122|NCT06504849|BEHAVIORAL|Receiving brief pre-HTN messages.|"* A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications"
218998123|NCT00870792|BEHAVIORAL|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
218998124|NCT03844646|DEVICE|CGM|Intermittent use of a continuous glucose monitor (CGM)
218998125|NCT03844646|OTHER|Dietitian|Monthly meetings with a dietitian
218998126|NCT02154243|DRUG|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
218998127|NCT02154243|OTHER|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
218998128|NCT00176228|DRUG|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
218998129|NCT01833013|OTHER|live birth date and quality of life assessment|
218998130|NCT01378949|DRUG|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
218998131|NCT01378949|DRUG|Morphine|Morphine 1 mg/cc
218998132|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
218998133|NCT00621153|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
218998134|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
218998135|NCT00694174|DRUG|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
218998136|NCT00694174|DRUG|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
218998137|NCT00753415|BIOLOGICAL|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).
218998138|NCT00753415|BIOLOGICAL|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
218998139|NCT00653575|BEHAVIORAL|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
218998140|NCT00653575|BEHAVIORAL|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
218998141|NCT02784808|DRUG|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
218998142|NCT02784808|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
218998143|NCT06341842|DRUG|Dapagliflozin 10mg Tab|Dapaglifloziin 10 mg 1 tab daily
218998144|NCT04212650|DRUG|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
218998145|NCT04212650|OTHER|Placebo|Appearance-matched microcrystalline cellulose placebo
218998146|NCT00003993|BIOLOGICAL|aldesleukin|
218998147|NCT00003993|DRUG|bryostatin 1|
218998148|NCT04235114|DRUG|50 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
218998149|NCT04235114|DRUG|1 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
218998150|NCT00634374|DEVICE|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
218998151|NCT02099994|BIOLOGICAL|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo
218998152|NCT02099994|BIOLOGICAL|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo
218998153|NCT02099994|BIOLOGICAL|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
219182174|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
219182175|NCT05891587|DRUG|Semaglutide|Semaglutide pen injector
219182176|NCT05891587|DRUG|Placebo|Saline solution
218998154|NCT02099994|BIOLOGICAL|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
218998155|NCT01530568|OTHER|Xpert|This arm receives the GeneXpert test
218998156|NCT01530568|OTHER|Smear|This arm receives smear microscopy
218998157|NCT00241215|DRUG|Botulinum toxin serotype A|
218998158|NCT04804475|OTHER|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
218998159|NCT06001840|BEHAVIORAL|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
218998160|NCT06001840|BEHAVIORAL|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
219182177|NCT04528173|DRUG|Ketorolac|Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
219182178|NCT04528173|DRUG|Dexmedetomidine|Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
219182179|NCT04528173|DRUG|Morphine|Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
219182180|NCT04528173|DRUG|Fentanyl|Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
218998161|NCT06992791|BEHAVIORAL|Prenatal Education on Childbirth|"Starting at 30 weeks, participants will be given access to Tinyhood, an online educational service aimed at perinatal education. Text reminders will be sent periodically throughout the third trimester to encourage interaction with educational videos and written materials, which will be tracked for number of interactions via the Tinyhyood interface. The videos include: Pregnancy Milestones, Physically and Mentally Preparing for Labor, Finding Support During Labor, Deciding Birth Preferences and Self-Advocacy, Signs Labor Is Approaching, Contractions, Signs of Preterm Labor, Going to the Hospital, Baby's Positioning, Stages of Labor, Induction of Labor, Managing Pain, Pain Options in Labor, Relaxation Techniques for Labor,  Breathing Techniques, Labor Positions and several handouts highlighting common obstetrical emergencies and possible interventions."
218998162|NCT06992310|DEVICE|Hearing Aid with standard noise reduction (NR_1)|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The active comparator condition is the state of the art Noise Reduction principle to mimic the natural directivity of the outer ear."
218998163|NCT06992310|DEVICE|Hearing Aid with NR_2|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
218998164|NCT06992310|DEVICE|Hearing Aid with NR_3|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
218998165|NCT06856915|OTHER|Inspiratory muscle training|Participants will engage in inspiratory muscle training programme at home using an inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
218998166|NCT06856915|OTHER|Combined inspiratory and expiratory muscle training|Participants will engage in inspiratory+expiratory muscle training programme at home using an inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
218998167|NCT06856915|OTHER|Sham inspiratory muscle training|Participants will engage in sham inspiratory muscle training programme at home using a sham inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
218998168|NCT06856915|OTHER|Sham combined inspiratory and expiratory muscle training|Participants will engage in sham inspiratory+expiratory muscle training programme at home using a sham inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
218998169|NCT06856915|OTHER|Conventional cardiac rehabilitation programme|Following the respiratory muscle training programme, participants will transition to a center-based cardiovascular exercise programme conducted twice weekly for eight weeks.
218998170|NCT06994962|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the mobile technologies as they choose while drinking for a four-week period.
218998171|NCT06994962|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
218998172|NCT06994962|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
218998173|NCT06994962|BEHAVIORAL|Higher tech facilitation|Participants will use an app developed during the study, SmartSip, that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
218998174|NCT06994962|BEHAVIORAL|Alcohol Education|Brief 25/30-minute psychoeducation on generalized alcohol use providing information about alcohol and its effects, adapted from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Rethinking Drinking resources
218998175|NCT06994962|DEVICE|Alcohol Education Technology|Participants will be able to prompt text messages which will provide them one-off trivia facts using information provided during the attention control psychoeducation session
218998176|NCT06996431|BEHAVIORAL|EMA-based weight management intervention|"Participants will complete four 7-day EMA sessions, reporting their diet for 3 days and physical activity for 4 days by completing ﬁve brief daily mobile app surveys (under 2 minutes each), using a 5-digit case number for privacy. The app automatically retrieves Fitbit data-such as step count, moderate-to-vigorous physical activity (MVPA), sedentary behavior, and heart rate- and sends timely reminders if surveys are missed.~Within one week after the ﬁrst EMA session, participants will attend a nurse- led counseling session using the 5A Model (Assess, Advise, Agree, Assist, Arrange), providing tailored feedback based on EMA and Fitbit data, and addressing barriers to change. This is followed by risk-based coaching from a dietitian and ﬁtness instructor, with individualized diet and exercise plans. Between sessions, participants receive ongoing support, including instant reminder messaging and weekly motivational messages to encourage healthy behaviors."
218998177|NCT06996431|BEHAVIORAL|Minimal Intervention|Participants will not receive risk-stratified services but will be provided with informational leaflets offering general advice on maintaining a healthy diet, regular exercise, smoking cessation, and alcohol cessation.
219182181|NCT05118295|DEVICE|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
219182182|NCT04978623|OTHER|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
219182183|NCT06206876|PROCEDURE|Biopsy|Undergo biopsy
218998178|NCT06674499|OTHER|Self-help rehabilitation model|The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.
218998179|NCT06674499|OTHER|Conventional rehabilitation model|The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
218998180|NCT07000474|OTHER|Omics|Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
218998181|NCT07002372|BEHAVIORAL|Procedure video viewing|Patients who have never had an intravitreal injection before will be randomly assigned to watch an educational video about the procedure prior to treatment.
218998182|NCT06993545|BEHAVIORAL|Video-based educational program on physical activity for migraine management|The intervention consisted of a series of seven short, pre-recorded educational videos delivered over a 3-month period. The videos focused on the benefits of regular physical activity for individuals with migraine and included practical strategies to increase daily activity levels. The content was evidence-based, developed with input from healthcare professionals, and tailored to migraine management. Participants received access to one video approximately every two weeks via email or online platform. The videos aimed to improve awareness, motivation, and self-efficacy regarding physical activity without prescribing a specific exercise program. No direct interaction with healthcare providers occurred during the intervention period.
218998183|NCT07001436|DRUG|Azvudine tablets|On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach.
218998184|NCT06997263|DRUG|Melatonin 3 mg Sublingual|A single 3 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the Low-Dose Melatonin Group.
218998185|NCT06997263|DRUG|Melatonin 6 mg Sublingual|A single 6 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the High-Dose Melatonin Group.
218998186|NCT07000786|PROCEDURE|Endometrial biopsy or menstrual cup and blood sample|Enrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw.
218998187|NCT07000877|DRUG|Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))|Decongestant nasal spray containing active ingredient.
219182184|NCT06206876|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218998188|NCT07000877|DRUG|PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%|Control nasal spray containing no active ingredient.
218998189|NCT07004010|DEVICE|Deoxycholic Acid Injection|The intervention include Deoxycholic acid, SC, 0.15 ml each injection, up to 2-4 ml in each site (2 ml at visit 1 for everyone, and 2 ml at visit 2 unless the patient does not agree)
218998190|NCT07001566|OTHER|There was no intervention. Only assessment procedure will be performed.|There was no intervention. Only assessment procedure will be performed.
218998191|NCT04118114|DRUG|PRL3-zumab|IV administration every 2 weeks
218998192|NCT05342467|DRUG|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
218998193|NCT05342467|DRUG|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
218998194|NCT07007832|PROCEDURE|Endoscopic retrograde cholangiopancreatography|Since patients with biliary strictures almost universally require endoscopic biliary interventions for both diagnostic and drainage purposes, bile aspiration can be readily obtained during these procedures, facilitating subsequent analyses. However, proteomic and metabolomic profiling of bile in malignant biliary strictures remains unreported to date. This study aims to evaluate the diagnostic value of combining bile proteomics/metabolomics with biliary brush cytology/biopsy for malignant biliary strictures, while also providing evidence for identifying potential biomarkers.
218998195|NCT06681480|DEVICE|figure-of-eight active rTMS coil device|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
218998196|NCT06681480|DEVICE|figure-of-eight sham rTMS coil device|rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
218998197|NCT06865560|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|A validated, 8-week, group-based telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, emotion-focused expressive writing, in-vivo emotional expression practices, self-compassion and forgiveness exercises, and assertive communication strategies. Participants will also be provided handouts and pre-recorded guided imagery and cognitive exercises that they can use to facilitate between-session practices.
219182185|NCT06206876|PROCEDURE|Computed Tomography|Undergo CT
219182186|NCT06206876|DRUG|DDX5 Degrader FL118|Given PO
219182187|NCT06206876|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218998198|NCT07010302|DRUG|Rituximab (R)|1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months
218998199|NCT07010302|DRUG|Eculizumab (Soliris®)|900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks
218998200|NCT07010302|DRUG|Ravulizumab|"* 40 to \< 60 kg: 2400 mg~* 60 to \< 100 kg: 2700 mg~* 100 kg: 3000 mg as an induction dose, followed by~* 40 to \< 60 kg: 3000 mg~* 60 to \< 100 kg: 3300 mg~* 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose"
218998201|NCT07010302|DRUG|Satralizumab|120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks
218998202|NCT07010302|DRUG|Inebilizumab|300 mg on Day 1 and Day 15, followed by 300 mg every 6 months
218998203|NCT07016191|OTHER|Ingestion of Water|Ingestion of Super-Oxygenated or Normal water
218998204|NCT07015294|DIETARY_SUPPLEMENT|Fruits and chaya infusion|Increased fruit consumption and daily intake of chaya infusion (prepared from Cnidoscolus chayamansa leaves),
218998205|NCT07015294|DIETARY_SUPPLEMENT|Conventional diet|Usual dietary habits, with no specific modifications
218998206|NCT07015710|PROCEDURE|Gamma Knife Radiosurgery|Patients underwent gamma knife radiosurgery (GKRS) for tectal plate gliomas (TPGs).
219182188|NCT05572957|DRUG|Guideline-Directed Medical Therapy(GDMT)|"Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~\*Criteria for \<3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest."
219182189|NCT05572957|COMBINATION_PRODUCT|left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)|"GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by \>10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique."
219182190|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
219182191|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
219182192|NCT05186753|DRUG|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
219182193|NCT06291428|DIAGNOSTIC_TEST|Raman spectroscopy|Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
218998207|NCT07016438|PROCEDURE|Transplant surgery|One piece of PAL-222 is implanted into the ulcer area through the surgical procedure.
218998208|NCT07014917|DRUG|Venetoclax|intermittent venetoclax (7days administration per cycle) + acalabrutinib
218998209|NCT07014917|DRUG|Acalabrutinib|intermittent venetoclax (7days administration per cycle) + acalabrutinib
218998210|NCT07014917|DRUG|Venetoclax|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
218998211|NCT07014917|DRUG|Acalabrutinib|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
218998212|NCT07015333|DRUG|pembrolizumab and cetuximab|Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab
218998213|NCT07014878|BIOLOGICAL|TCR-T cells|"Dose escalation will follow the standard 3+3 design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially."
218998214|NCT07015060|PROCEDURE|cutaneous biospy|cutaneous biospy
218998215|NCT07014774|DEVICE|Laser acupuncture|"Laser acupuncture is a modern, non-invasive approach to acupuncture that uses low-level laser therapy (LLLT) instead of traditional needles to stimulate acupuncture points. This technique combines the principles of traditional Chinese medicine with modern technology to provide pain relief and promote healing (Chon et al., 2019).~* Device: UNIPHY PHYACTION 740, made in EEC device.~* Laser type: Gallium aluminum arsenide laser.~* Wavelength: 808 nm.~* Power Output: 200 mW.~* Dose/energy density: 4J/point.~* Frequency of treatment: Three times weekly for 8 weeks.~* Duration: 12 min.~* Cumulative dose: 48J/point.~* Target Acupuncture Points: Key points for CTS: PC4 (Ximen), PC6 (Neiguan), PC7 (Daling), PC8 (Laogong), LI4 (Hegu), LI10 (Shousanli), LI11 (Quchi), HT-2 (Qingling), HT7 (Shenmen), HT-8 (Shaofu), LU9 (Taiyuan) and LU10 (Yuji)"
218998216|NCT07014774|OTHER|Traditional Therapy|"* Splinting/Bracing: Patients in the two groups will advised to wear a static wrist splint locked at 0\_ wrist flexion for at least 8 h at night throughout the entire length of the study as the primary management which reduce pressure on the median nerve.~* Physical Therapy: Engaging in specific exercises, such as nerve glide exercises and wrist stretches, can improve mobility and reduce symptoms. These exercises aim to restore normal movement of the median nerve and alleviate compression"
218998217|NCT07015320|BEHAVIORAL|urotherapy|prompted and scheduled voiding, regular sleep timing, fluid and caffeine restriction and avoiding the cellular phones 2 hours before bedtime. If the child had constipation, it should be treated. In addition, alarm therapy was performed in the form of awaking the child every night by his parents after 1-2 hours from deep sleep to void then continue the sleep. The parents should be informed about the importance of their psychological support to their child by avoiding any punishment or embarrassment. Furthermore, the parents were asked to monitor their child's response by documenting the number of wet nights within the last month
218998218|NCT07015320|BEHAVIORAL|no intervention|no intervention
218998219|NCT07015788|OTHER|EARLY GRAND|Participants will consume a standardized portion of peach variety A containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
218998220|NCT07015788|OTHER|SPRING CREST PEACH|Participants will consume a standardized portion of peach variety B containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
218998221|NCT07015788|OTHER|INDIAN BLOOD|Participants will consume a standardized portion of peach variety C containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
218998222|NCT06235203|PROCEDURE|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
218998223|NCT06235203|DRUG|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
218998224|NCT06235203|DRUG|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
218998225|NCT06235203|DRUG|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
218998226|NCT07015502|OTHER|Questionnaires|Patients will undergo socio-demographic and history of violence suffered interview, passation of the Montgomery-Asberg Depression Rating Scale (MADRS),Childhood Trauma Questionnaire, Deshumanization Measure within Romantic Relationships scale, self-esteem scale, violentometer and an implicit association test (IAT).
218998227|NCT07014540|DRUG|Irinotecan Hydrochloride Liposome Injection|Liposome irinotecan (70/50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
218998228|NCT07014540|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by continuous infusion for 46 hours in a 2-week
218998229|NCT07014540|DRUG|LV|LV (400mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
218998230|NCT07014475|DEVICE|drug-coated balloon|Drug-coated balloon was used during the index procedure.
218998231|NCT07014683|BEHAVIORAL|INCREM|This is a specifically designed program to improve psychosocial functioning which targets cognitive symptoms.
218998232|NCT07014683|BEHAVIORAL|Psychoeducation|This is a 12-session psychoeducation program designed as an active comparator for the current trial
218998233|NCT07015489|DRUG|induction chemotherapy and immunotherapy|"All patients will first receive 2 cycles of induction chemoimmunotherapy, followed by radiotherapy. During radiotherapy, 2 concurrent cycles of chemoimmunotherapy will be administered. Afterward, maintenance immunotherapy will continue for up to one year.~Chemotherapy regimen: Paclitaxel: 135 mg/m², Day 1, every 3 weeks (Q3W); Carboplatin: area under the curve (AUC) = 5, intravenous infusion over more than 30 minutes, Day 2, Q3W; Alternatively, Nedaplatin: 75 mg/m², Day 2, Q3W.~Immunotherapy regimen: programmed death-1 (PD-1) inhibitor (e.g., Camrelizumab): Day 0, intravenous infusion, Q3W; Continued until disease progression (PD) or unacceptable toxicity, for a maximum duration of one year.~Radiotherapy: Prescribed dose: 95% of the planning target volume (PTV) and planning target volume for nodal disease (PTV-nd) should receive 50-50.4 Gy over 25-28 fractions; Fraction dose range: 1.8-2.0 Gy per fraction, 5 days per week; External beam radiotherapy to the chest."
218998234|NCT07014943|DRUG|High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy|Gemcitabine (2.5 g/m²) (Days -9 and -3), Busulfan (3.2 mg/kg) (Days -9 to -7), and Thiotepa (5 mg/kg) (Days -5, -4, and -3) were all administered intravenously. Peripheral stem cells were infused on Day 0.
218998235|NCT07015567|BEHAVIORAL|Emotion regulation module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about emotion regulation. This module contains exercises for emotional awareness and emotion regulation with different focuses (on body, thoughts and behaviour).
218998236|NCT07015567|BEHAVIORAL|Negative self-concept module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about negative self-concept. In this module, we tackle topics such as what is the self, thinking about the self through cognitive restructuring, criticism and compassion and the self in relation to others.
218998237|NCT07015567|BEHAVIORAL|Interpersonal relationships module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about interpersonal relationships. This module includes exercises to understand relationship patterns, increasing assertiveness, practicing assertiveness, and managing power.
219006755|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
219006756|NCT02346630|DRUG|Placebo|Placebo capsules daily for 3 weeks.
219006757|NCT02346630|DRUG|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
219006758|NCT02346630|DEVICE|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
218998238|NCT07015567|BEHAVIORAL|Narrative exposure therapy module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|"ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. It contains 24 sessions which are organised in four modules. The manual was adapted to our target population. In this context, the module modified prolonged exposure was replaced with Narrative Exposure Therapy (NET). NET is a standardised approach for the treatment of PTSD that has been tested across diverse social and cultural contexts. In this intervention, patients and therapists elaborate together a chronological timeline (called the lifeline) of patient's life and the traumatic events, using a rope, stones for traumatic events, and flowers for positive events. Thereafter, the traumatic events are discussed in detail, one in each session. At the end of each session, patients receive a written form of these narrations, co-signed by patient and the therapist."
218998239|NCT07016217|BEHAVIORAL|Early Plain Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The plain Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median). Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
218998240|NCT07016217|BEHAVIORAL|Early Complete Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The complete Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median) and a series of self-reflection questions. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
218998241|NCT07016217|BEHAVIORAL|No intervention|To measure the impact of the interventions, Arm C (Group 3) will receive no intervention in the Early mailing and Arm B (Group 2) will receive no intervention in the Delayed mailing.
218998242|NCT07016217|BEHAVIORAL|Delayed Plain Portrait and Letter|"Delayed plain Portrait and Letter (as described)"
218998243|NCT07016217|BEHAVIORAL|Delayed Complete Portrait|"Delayed complete Portrait and Letter (as described)"
218998244|NCT06622941|DRUG|ONO-4538|every 2 weeks
218998245|NCT05761561|BEHAVIORAL|Exercise and medical nutrition|"The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight)."
218998246|NCT03793127|OTHER|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
218998247|NCT03793127|OTHER|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
218998248|NCT03793127|OTHER|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
218998249|NCT06548581|DEVICE|SpeedPlate™ Rapid Compression Implants|MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
218998250|NCT06762561|PROCEDURE|Prophylactic retromuscular mesh reinforcement|Prophylactic retromuscular mesh placement involves reinforcing the abdominal wall during closure after open abdominal aortic aneurysm (AAA) repair to prevent incisional hernias. This technique creates a retro-muscular space by carefully dissecting the rectus abdominis muscles from the posterior rectus sheath. A self-gripping polyester mesh or composite mesh is placed in this space, extending 4 cm beyond the midline on each side, ensuring tension-free coverage. The mesh is secured at key points, and the rectus sheaths are closed with continuous sutures. This approach leverages the anatomical integrity of the abdominal wall to reduce hernia risk without increasing postoperative complications.
218998251|NCT06752980|OTHER|Eye mask|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
219006759|NCT03192254|BEHAVIORAL|self-monitoring|recording fruit and vegetable consumption
219006760|NCT03192254|BEHAVIORAL|daily monetary incentives|daily payments for consuming fruits and vegetables
219006761|NCT03192254|BEHAVIORAL|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
219006762|NCT00022308|DRUG|cisplatin|
219006763|NCT00022308|DRUG|irinotecan hydrochloride|
219006764|NCT00022308|RADIATION|radiation therapy|
219006765|NCT01709591|BEHAVIORAL|Prenatal education|
219006766|NCT06106516|DEVICE|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
219006767|NCT03284827|DRUG|NOAC|edoxaban (60 mg once daily \[OD\]) for at least 6 months
219006768|NCT03284827|DRUG|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
219006769|NCT04508244|DRUG|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
218998252|NCT06752980|OTHER|Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
218998253|NCT06752980|OTHER|Eye Mask and Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
218998254|NCT06826989|DRUG|[14C]MK-8527|Oral Dose
218998255|NCT06895538|DRUG|Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)|Patients in the ATLG arm receive ATLG instead of ATG as part of the routine conditioning regimen before allo-HSCT; ATLG is given intravenously by infusion for 4 consecutive days, after which they undergo routine transplantation.
218998256|NCT03989999|PROCEDURE|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 12 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
218998257|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
218998258|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
218998259|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
218998260|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
218998261|NCT06618586|BEHAVIORAL|TodaysBaby|The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .
218998262|NCT03618186|COMBINATION_PRODUCT|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
218998263|NCT06916533|BEHAVIORAL|ENBORTH-TR Intervention|This intervention program is structured with a multifaceted and holistic approach, starting with the definition of pain and covering topics such as basic body anatomy, functions and pain mechanisms, ergonomics training, environmental regulations, psychosocial factors such as stress, relaxation techniques, sleep and time management.
218998264|NCT06916533|BEHAVIORAL|Client-centred Occupational Therapy Intervention Group|Client-centered occupational therapy intervention consists of 5 stages: (1) Client-centered goal setting, (2) creation of the therapy plan, (3) implementation of interventions, (4) evaluation of results, and (5) obtaining feedback.
218998265|NCT07111858|OTHER|Watchful waiting with supportive care|Usual care is Pavlik Harness Treatment. Watchful waiting with ongoing ultrasound scans is the intervention in this study to determine whether the hip matures without the use of the Pavlik Harness
218998266|NCT06918795|BEHAVIORAL|Digital Exercise Intervention|Subjects randomized to the intervention arm will receive the same as the enhanced usual care arm but will be additionally exposed to: (1) personalized plans for aerobic-based PA, (2) personalized resistance exercise sessions, and (3) financial and non-financial engagement strategies. These intervention components will be delivered continuously using an advanced digital health informatics platform during the 6 months of the intervention. The intervention will be overseen and supplemented by the exercise physiologist, who will meet with participants on a weekly, then biweekly and finally monthly basis over 6 months.
218998267|NCT07125976|BEHAVIORAL|peer support|This intervention is a one-week, structured peer support program for patients in the first six months of hemodialysis treatment.
218998268|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
218998269|NCT07127211|BEHAVIORAL|Suspension and Stable Push-Up Training at Multiple Angles|"Participants will perform push-ups under three suspension conditions: (1) no suspension (hands and feet on a stable surface), (2) hands suspended using TRX straps, and (3) feet suspended using TRX straps. Each condition will be performed at five different body angles relative to the floor: +30°, +15°, 0°, -15°, and -30° (0° defined as shoulder joints aligned with ankle joints when arms are extended).~For each angle, participants will complete five repetitions, with 3-5 minutes of rest between angles and at least 48 hours of rest between suspension conditions to minimize fatigue effects. All exercises will be conducted under supervision to ensure correct form and safety.~Surface electromyography (EMG) will record muscle activity from the pectoralis major, anterior deltoid, triceps brachii, upper trapezius, and serratus anterior. EMG data will be processed as root mean square (RMS) and normalized to maximal voluntary isometric contraction (%MVIC).~This intervention is designed to dete"
218998270|NCT07131904|OTHER|non-alcoholic, fiber-enriched beer (FEB)|500 ml FEB consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
219182194|NCT05810064|OTHER|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
219182195|NCT06269549|OTHER|Non-training Real Dietary Supplement (G1)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen.
219182196|NCT06269549|OTHER|Training Placebo Dietary Supplement (G2)|One capsule of placebo glucosamine three times daily, and one packet containing placebo collagen + physical exercise (60 minutes per session twice a week)
219182197|NCT06269549|OTHER|Training Real Dietary Supplement (G3)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen + physical exercise (60 minutes per session twice a week)
218998271|NCT07131904|OTHER|conventional, non-alcoholic beer|500 ml conventional non-alcoholic beer consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
218998272|NCT07131904|OTHER|glucose solution|Glucose solution containing 12.5 g glucose in 500 ml water, consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
218998273|NCT07132008|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
218998274|NCT07132008|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
218998275|NCT07132008|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
218998276|NCT07132931|BEHAVIORAL|Mindful Leadership Intervention|Mindful leadership training program focusing on contemplative practices, mindfulness exercises, and leadership skill development.
218998277|NCT07132931|BEHAVIORAL|Management Skills Training|Standard management skills training including organizational techniques, communication skills, and leadership fundamentals.
218998278|NCT07132944|OTHER|CTraC-FIT|"The intervention is designed to support Veterans at high risk of readmission with comprehensive transitional care that includes:~Structured Follow-Ups: Regularly scheduled follow-up calls to monitor the patient's progress, address any issues, and provide ongoing support.~Health Coaching: Personalized coaching to help Veterans manage their health conditions, adhere to treatment plans, and make lifestyle changes that can improve their overall health.~Care Coordination: Assistance with navigating the healthcare system, facilitating appointments, and ensuring that the Veteran receives all necessary post-discharge services.~The intervention arm aims to improve functional abilities and reduce hospital readmissions by providing tailored support based on the unique needs of each participant. The CTraC NCM will follow a standardized protocol to ensure consistent and effective delivery of the intervention across all participants in this group."
218998279|NCT07132944|OTHER|Enhanced Usual Care|"The Enhanced Usual Care (EUC) arm involves participants receiving the standard care provided by their assigned Veterans Affairs Boston Healthcare System (VABHS) inpatient and outpatient teams. This includes routine medical evaluations, treatments, and follow-up appointments as typically recommended by their healthcare providers. In addition to receiving standard care, participants in the EUC group will undergo baseline, endpoint, and 3-month follow-up assessments as part of the study protocol.~For participants with intermediate functional ability (SPPB score of 7-9), no additional intervention will be provided after randomization to the control group. However, for participants with low functional ability (SPPB score of 0-6), a safety protocol will be activated to notify their assigned inpatient medical team (e.g., hospitalist, social worker) about the participant's risk of functional decline, ensuring that appropriate support and referrals are provided if needed."
218998280|NCT07132125|BEHAVIORAL|Default-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination, using the model's default style with longer, structured responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
218998281|NCT07132125|BEHAVIORAL|Conversational-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination in a conversational style, with short responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
218998282|NCT07132125|BEHAVIORAL|Public health informational materials|Official public health informational materials on HPV vaccination from the Centers for Disease Control and Prevention (U.S.), National Health Service (U.K.), or Public Health Agency of Canada, matched to the participant's country of residence. Materials are 589-680 words in length, cover HPV risks and benefits of vaccination, and are presented for three minutes before participants proceed.
218998283|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
218998284|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
218998285|NCT06932757|DRUG|Quisinostat|Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.
218998286|NCT06935227|OTHER|Use Steri-Strip in post-surgery + standard care|Steri-strip will be maintained for 8 days postoperatively.
218998287|NCT06935227|OTHER|Standard care|Postoperative care recommendations.
219182198|NCT05146973|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
219182199|NCT05680363|DEVICE|HyperSperm|Multi-step sperm preparation
218998288|NCT05179798|DEVICE|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
218998289|NCT06943820|DRUG|AK129(dose 1)|IV infusion
218998290|NCT06943820|DRUG|Pemetrexed|IV infusion;500mg/m2
219182200|NCT05680363|DEVICE|Standard Sperm Preparation|Standard sperm preparation
219182201|NCT03639701|DRUG|Thymidine|Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
219182202|NCT03847714|DIETARY_SUPPLEMENT|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
218998291|NCT06943820|DRUG|Paclitaxel|IV infusion;175mg/m2
218998292|NCT06943820|DRUG|Carboplatin|IV infusion;AUC 5
219182203|NCT03847714|DIETARY_SUPPLEMENT|placebo|similar looking and tasting powder
219182204|NCT05700877|OTHER|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
219182205|NCT05700877|OTHER|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
219182206|NCT04797897|DEVICE|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
219182207|NCT04797897|DEVICE|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
218998293|NCT06943820|DRUG|AK129(dose 2)|IV infusion
218998294|NCT06943820|DRUG|Docetaxel|IV infusion;75mg/m2
218998295|NCT06943820|DRUG|Cis-platinum|IV infusion;100 mg/m2
218998296|NCT06943820|DRUG|5-FU (5-fluorouracil)|IV infusion;1000 mg/m2
219182208|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
219182209|NCT06113289|DRUG|ASTX727|Given by PO
218998297|NCT06943820|DRUG|Cetuximab|IV infusion;400mg/m2/ 250mg/m2
218998298|NCT06943820|DRUG|Paclitaxel|IV infusion;80mg/m2
218998299|NCT06943820|DRUG|Docetaxel|IV infusion;35mg/m2
218998300|NCT06943820|DRUG|Chemotherapy|IV infusion
218998301|NCT06943820|DRUG|AK129(RP2D)|IV infusion
218998302|NCT06943820|DRUG|Penpulimab|IV infusion;200mg
218998303|NCT01466647|DRUG|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
218998304|NCT03320954|BEHAVIORAL|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
218998305|NCT01839851|DRUG|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
218998306|NCT01839851|DRUG|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
218998307|NCT06955494|OTHER|Empowerment Network for Auditory-Cognitive Training (ENACT) Program|The ENACT Program is an overall 12-week training and comprises of three phases as follows: 1. Goal-oriented health counseling phase (1st - 2nd week) - A nurse consultation will be conducted in the center with the aim to identify the participants' experience of living with the hearing and cognitive impairment. 2. Peer-assisted group-based auditory-cognitive training phase (3rd-8th week) - This phase is led and conducted by the nurse with the focus to provide combined group-based auditory and cognitive training (group size = 6) with support from the trained peers. 3. Family engaged active-communication training phase (9th - 12th week) - This phase is to empower the PLwMCI and their primary caregivers on active communication strategies in the presence of hearing loss. In the 2nd and 3rd phase, the nurse will continue to monitor the goal attainment of the PLwMCI and make additional health counseling and goal adjustment accordingly.
218998308|NCT06955494|OTHER|Usual Care|Usual care will be provided to the control group which mainly covers the social activities offered by the affiliated center. The participants are requested not to join any activities relating to cognitive training or auditory training before the post-test data collection.
219182210|NCT06113289|DRUG|ASTX029-01|Given by PO
219182211|NCT06437574|DRUG|Vytorin|Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
219182212|NCT06437574|DRUG|Ezetimibe|Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
219182213|NCT06823882|BEHAVIORAL|Floor-Rise Training|Practicing getting up from the floor using the Backward Chaining Method (BCM) for 20 minutes per week for 5 weeks
219182214|NCT06823882|BEHAVIORAL|Video Demonstration|Watching a 20-min video on floor-rise technique and over 5 weeks, with discussions. This video explains how to get up safely from the floor and how to practice.
219182215|NCT06823219|OTHER|endurance training program|Groupe 2: 52 weeks of out-of-hospital physical activity Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity
218998309|NCT06132191|DRUG|Cemiplimab|
218998310|NCT03395743|BIOLOGICAL|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
218998311|NCT05102006|DRUG|LBL-007 Injection|LBL-007 Injection; dose A or dose B; Q3W
218998312|NCT05102006|DRUG|Toripalimab Injection|Toripalimab Injection; dose C; Q3W
218998313|NCT00318110|PROCEDURE|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
218998314|NCT00630396|DRUG|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
218998315|NCT04467060|DRUG|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
218998316|NCT04467060|DRUG|Placebo|single dose, fasting oral administration
218998317|NCT01087190|DRUG|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
218998318|NCT01748032|BEHAVIORAL|Cognitive training|20 minutes/day for 5 sequential working days
218998319|NCT02741024|DRUG|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
218998320|NCT02741024|DRUG|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
218998321|NCT05000060|OTHER|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
218998322|NCT05000060|OTHER|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
218998323|NCT00635596|BIOLOGICAL|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
218998324|NCT04143321|DRUG|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
218998325|NCT01446900|DRUG|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
218998326|NCT01446900|DRUG|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
218998327|NCT00413127|DRUG|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
218998328|NCT00413127|DRUG|NaCl 0,9%|Administration of placebo i.v.
218998329|NCT04489680|OTHER|Educational|Teaching session
218998330|NCT01513161|DRUG|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
218998331|NCT01513161|DRUG|Placebo|
218998332|NCT02287272|DRUG|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
219006770|NCT04508244|DRUG|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
219006771|NCT06501066|BIOLOGICAL|umbilical cord mesenchymal stem cells|Patients assigned to UC-MSC administration groups will receive one administrations
219006772|NCT06240975|OTHER|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
219006773|NCT06240975|OTHER|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
219006774|NCT00763477|BIOLOGICAL|ghrelin|subcutaneous injection
219006775|NCT00360789|BEHAVIORAL|Conventional UK physical therapy|
219006776|NCT00360789|BEHAVIORAL|Increased intensity of UK conventional physical therapy (PT)|
219006777|NCT00360789|BEHAVIORAL|UK conventional PT plus functional strength training|
219006778|NCT05973383|BEHAVIORAL|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
219006779|NCT05973383|BEHAVIORAL|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
219006780|NCT05973383|BEHAVIORAL|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
219006781|NCT04284618|DIAGNOSTIC_TEST|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
219006782|NCT05847231|BEHAVIORAL|Perceived Stress, Mandala application|Mandala
219006783|NCT05670392|DEVICE|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
218998333|NCT02287272|DRUG|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
218998334|NCT03006497|OTHER|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
218998335|NCT00059982|DRUG|perifosine|
218998336|NCT00090480|BIOLOGICAL|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
219182216|NCT04224779|BIOLOGICAL|Biological collection|The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
218998337|NCT02716454|PROCEDURE|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
218998338|NCT04822454|OTHER|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
218998339|NCT04617509|DRUG|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
218998340|NCT04617509|DRUG|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
218998341|NCT05136768|DRUG|Sintilimab|Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
219006784|NCT05670392|DEVICE|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
219006785|NCT01743131|DRUG|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
219006786|NCT01743131|DRUG|placebo|
219006787|NCT05503641|OTHER|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
219006788|NCT04273646|BIOLOGICAL|UC-MSCs|4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
219006789|NCT04273646|DRUG|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
219006790|NCT03695679|BEHAVIORAL|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
219006791|NCT06475482|OTHER|Lip hydrant|lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.
219006792|NCT06475482|OTHER|Petroleum gel|Vaseline
219006793|NCT04840238|DRUG|Cholecalciferol|30,000IU cholecalciferol
219006794|NCT04840238|DRUG|Placebo|Placebo tablets
219006795|NCT00224055|DRUG|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
219006796|NCT00224055|DRUG|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
219006797|NCT02983331|PROCEDURE|complications during procedure|patients may have anesthesia related complications during procedure
219006798|NCT02391740|OTHER|Questionnaire|
219006799|NCT02699528|DRUG|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
219006800|NCT01940679|DIETARY_SUPPLEMENT|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
219006801|NCT04317066|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle.
219006802|NCT01864447|BEHAVIORAL|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
219006803|NCT06052007|BEHAVIORAL|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
219006804|NCT06052007|BEHAVIORAL|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
218998342|NCT05136768|RADIATION|SBRT|"At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2."
218998343|NCT05136768|DRUG|Platinum based chemotherapy|Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
218998344|NCT01053884|DRUG|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
218998345|NCT00790023|DRUG|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
218998346|NCT00790023|DRUG|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
218998347|NCT00790023|DRUG|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
218998348|NCT03880071|BEHAVIORAL|DBT+ACT|\- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
218998349|NCT03880071|BEHAVIORAL|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
218998350|NCT05708287|DEVICE|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
218998351|NCT01338792|DRUG|oxaliplatin|Given IV
218998352|NCT01338792|DRUG|pemetrexed disodium|Given IV
218998353|NCT01338792|OTHER|questionnaire administration|Ancillary studies
218998354|NCT01338792|OTHER|laboratory biomarker analysis|Correlative studies
218998355|NCT01338792|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
218998356|NCT01338792|GENETIC|polymorphism analysis|Correlative studies
219182217|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
219182218|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
219182219|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
219369740|NCT05788939|OTHER|Planned Visual Education Based on Health Belief Model|"The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~."
218998357|NCT01975753|DRUG|Morphine|
218998358|NCT01975753|DRUG|Fentanyl|
218998359|NCT02503553|BEHAVIORAL|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
218998360|NCT02503553|BEHAVIORAL|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
218998361|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
218998362|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
218998363|NCT03269383|DRUG|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
218998364|NCT03269383|OTHER|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
218998365|NCT04201002|PROCEDURE|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
218998366|NCT05739097|DIAGNOSTIC_TEST|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
218998367|NCT03517956|DRUG|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
218998368|NCT03517956|DRUG|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
218998369|NCT04286321|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
218998370|NCT04286321|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
218998371|NCT04286321|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
218998372|NCT04286321|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
218998373|NCT04286321|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
218998374|NCT04286321|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
218998375|NCT04286321|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
218998376|NCT04286321|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
218998377|NCT00336063|DRUG|Azacitidine|Given SC
218998378|NCT00336063|OTHER|Laboratory Biomarker Analysis|Correlative studies
218998379|NCT00336063|OTHER|Pharmacological Study|Correlative studies
218998380|NCT00336063|DRUG|Vorinostat|Given PO
218998381|NCT04512404|DRUG|HMG-CoA Reductase Inhibitor|
218998382|NCT01652703|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
218998383|NCT01652703|OTHER|Placebo|Administered by subcutaneous injection
218998384|NCT01044862|DRUG|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
218998385|NCT01044862|DRUG|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
218998386|NCT01044862|DRUG|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
218998387|NCT02521636|OTHER|Antibiotic therapy randomization|
218998388|NCT02521636|OTHER|Serum PCT dosage|
218998389|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
218998390|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
218998391|NCT04775459|DRUG|Surfactant administration until 2020|Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
218998392|NCT04775459|DRUG|Surfactant administration since 2021|Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
218998393|NCT04078113|OTHER|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
218998394|NCT04051723|DRUG|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
218998395|NCT04051723|DRUG|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
218998396|NCT05832385|RADIATION|IMRT|anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
218998397|NCT02790528|DRUG|Atorvastatin|20mg QD
218998398|NCT02790528|DRUG|Placebo|Placebo drug will be administered.
218998399|NCT03167840|BEHAVIORAL|Physical and Cognitive Training|Physical Exercise and Cognitive Training
218998400|NCT03167840|BEHAVIORAL|Physical Training|Physical training alone
218998401|NCT03167840|BEHAVIORAL|Cognitive training|Cognitive training alone
218998402|NCT05769881|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
218998403|NCT05769881|PROCEDURE|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
218998404|NCT05123768|DIAGNOSTIC_TEST|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
218998405|NCT02314897|DEVICE|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
218998406|NCT02314897|DEVICE|RV pacing|Conventional right ventricular pacing.
218998407|NCT04497688|DRUG|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
218998408|NCT06127277|BEHAVIORAL|Next4You|Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
218998409|NCT01786798|DEVICE|Transvaginal sonography|"Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern"
218998410|NCT04153240|DEVICE|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
218998411|NCT01525537|DRUG|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
218998412|NCT01525537|DRUG|sufentanil|sufentanil was given at standard practise
218998413|NCT02927522|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
218998414|NCT02927522|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
218998415|NCT01604174|OTHER|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
218998416|NCT01604174|OTHER|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
218998417|NCT02155608|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
218998418|NCT02155608|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
218998419|NCT03346785|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
218998420|NCT03346785|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
218998421|NCT03346785|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
218998422|NCT02329353|DRUG|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
218998423|NCT02338440|DRUG|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
218998424|NCT06159530|PROCEDURE|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
218998425|NCT06159530|PROCEDURE|peek framework|peek framework screwed to multi-unit abutments of 4-implants
218998426|NCT06159530|PROCEDURE|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
218998427|NCT06159530|PROCEDURE|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
218998428|NCT00903695|DRUG|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
219182220|NCT06821984|PROCEDURE|FGG secured using cyanoacrylate tissue adhesive without sutures.|The intervention involved securing the free gingival graft (FGG) using cyanoacrylate adhesive instead of conventional sutures. After harvesting the graft from the hard palate, hemostasis at the donor site was achieved with gauze compression. The recipient site was prepared with a partial-thickness dissection to ensure a stable graft bed. In the intervention group, cyanoacrylate adhesive was applied along the margins of the graft and underlying periosteal bed, ensuring complete coverage without the use of sutures. The adhesive polymerized within seconds, creating an immediate bond between the graft and recipient site, minimizing micro-movements and reducing the need for additional fixation.
219182221|NCT05814666|DRUG|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
219182222|NCT05814666|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
219182223|NCT06823544|DRUG|Alvogyl|this is standard treatment drug
219182224|NCT06823544|DRUG|Eugenol|this not standard drug for the treatment of Alveolar Osteitis but an antiseptic agent
219182225|NCT06823544|DRUG|Nigella Sativa Oil|it not standard medicine for Alveolar Osteitis. it is a herbal medicine
219182226|NCT04438304|DRUG|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
219182227|NCT04990141|PROCEDURE|Peripheral blood collection in cases group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group
219182228|NCT04990141|PROCEDURE|Peripheral blood collection in control group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
219182229|NCT06823232|DRUG|[14C]XY0206|On the morning of the day of medication (D1), the subject took \[14C\] XY0206 suspension orally on an empty stomach (containing approximately 37.5 mg/100 µ Ci \[14C\] XY0206).
219182230|NCT06366711|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device for pregnancy care
219182231|NCT06366711|DRUG|Pulsenmore device|Remote ultrasound device for pregnancy care
219182232|NCT05787821|DEVICE|Total Knee Arthroplasty|Total knee replacement.
218998429|NCT00903695|DRUG|placebo|placebo comparator
218998430|NCT00573911|PROCEDURE|Endoscopy and pH study|endoscopy and PH study done one time
218998431|NCT03633682|BEHAVIORAL|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
218998432|NCT03633682|BEHAVIORAL|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
218998433|NCT03983291|BEHAVIORAL|FaReWell Depression|Facial massage and force exercise
218998434|NCT04882540|DRUG|brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use"
218998435|NCT01082120|DRUG|AZD1656|Tablets orally, twice daily for 10 days
218998436|NCT01082120|DRUG|Pioglitazone|Tablet oral single dose for 10 days
219369741|NCT00476580|BEHAVIORAL|Questionnaire|Questions to collect health information specific to Sri Lankans.
218998437|NCT06840366|OTHER|Lokomat intervention|The intervention will consist of an 8-week motor rehabilitation program, with 3 weekly sessions of 60 minutes each. In the first weeks, joint mobilization and postural control in a sitting position will be worked on, followed by muscle strengthening and balance re-education in a standing position. Subsequently, coordination exercises and assisted walking on different surfaces will be incorporated. In the final phase, independent walking and the integration of functional movements in daily life activities will be encouraged. The program will be adapted to the individual needs of each patient to optimize recovery and improve quality of life.
218998438|NCT02817191|DRUG|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
218998439|NCT02817191|DRUG|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
218998440|NCT01785732|PROCEDURE|Renal Denervation|Sympathetic renal denervation via renal arteries
218998441|NCT02466360|BEHAVIORAL|Back Belief questionnaire|
218998442|NCT02466360|BEHAVIORAL|QUEBEC scale|
218998443|NCT02466360|BEHAVIORAL|Fear Avoidance beliefs questionnaire|
218998444|NCT02466360|BEHAVIORAL|Visual analog scale|
218998445|NCT02466360|BEHAVIORAL|individual interviews|
218998446|NCT02466360|BEHAVIORAL|Focus groups|
218998447|NCT02108353|DRUG|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
218998448|NCT02108353|DRUG|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
218998449|NCT01285674|DRUG|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
218998450|NCT02662296|DRUG|Ibrutinib|Given PO
218998451|NCT02662296|DRUG|Idelalisib|Given PO
218998452|NCT05404295|OTHER|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
219182233|NCT06377371|DIAGNOSTIC_TEST|Brain Imaging with [Cu64]DOTATATE|Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
219182234|NCT06377371|PROCEDURE|Radio-guided Surgery With Neoprobe Utilization|After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
218998453|NCT00543140|DEVICE|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
218998454|NCT01906502|DEVICE|Sensimed Triggerfish|
218998455|NCT02663323|DEVICE|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
218998456|NCT02584673|DEVICE|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
218998457|NCT00873223|DRUG|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
218998458|NCT00873223|DRUG|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
218998459|NCT02097576|OTHER|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
218998460|NCT02097576|OTHER|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
218998461|NCT06000098|OTHER|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
218998462|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
219182235|NCT06244511|OTHER|Early Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.
219182236|NCT06244511|OTHER|Late Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
219369742|NCT03324360|DRUG|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
218998463|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
218998464|NCT02599129|DRUG|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
218998465|NCT02599129|DRUG|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
218998466|NCT04353076|OTHER|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
218998467|NCT04353076|OTHER|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
218998468|NCT02487693|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
218998469|NCT02487693|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
218998470|NCT02515058|DEVICE|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
218998471|NCT02515058|DEVICE|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
218998472|NCT01975545|DRUG|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
218998473|NCT01975545|DRUG|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
218998474|NCT05711940|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
218998475|NCT05571540|BIOLOGICAL|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
218998476|NCT00661882|OTHER|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
219182237|NCT04696289|DIAGNOSTIC_TEST|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
219182238|NCT03868618|DEVICE|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
218998477|NCT00661882|OTHER|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
218998478|NCT00661882|OTHER|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
218998479|NCT00661882|PROCEDURE|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
218998480|NCT03591198|BEHAVIORAL|Qigong Training|Eight-Section Brocades
219182239|NCT06070870|BEHAVIORAL|Patient Navigation|"Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening"
219182240|NCT05533918|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
219182241|NCT05533918|BEHAVIORAL|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
218998481|NCT03591198|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
218998482|NCT03425123|OTHER|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
218998483|NCT03095014|PROCEDURE|Cesarean Myomectomy|Myomectomy was done during Cesarean section
218998484|NCT03095014|PROCEDURE|Cesarean section|Cesarean delivery
218998485|NCT02115789|BEHAVIORAL|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
218998486|NCT01506167|DRUG|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
218998487|NCT01506167|DRUG|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
218998488|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
218998489|NCT01506167|DRUG|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
218998490|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
218998491|NCT01506167|DRUG|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
218998492|NCT00144963|DRUG|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
218998493|NCT00144963|DRUG|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
218998494|NCT04897932|DEVICE|RS - WP06|Ad hoc use of handheld urinal
218998495|NCT02615587|DRUG|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
218998496|NCT01892202|OTHER|Cohort|
218998497|NCT03294902|DEVICE|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
218998498|NCT03192111|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
218998499|NCT00727025|DEVICE|wound closure device (Steri-Strip™)|wound closure with steri-strip S
219182242|NCT06007352|DRUG|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
219182243|NCT06007352|OTHER|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
218998500|NCT04231864|BIOLOGICAL|Durvalumab|Given intravenously (IV)
218998501|NCT04231864|DRUG|Epacadostat|Given orally (PO)
218998502|NCT04144205|OTHER|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
218998503|NCT06433869|DRUG|serplulimab|Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
218998504|NCT06433869|DRUG|Bevacizumab|Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
218998505|NCT06433869|DRUG|rmhTNF-NC|Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
218998506|NCT01785927|OTHER|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
218998507|NCT06178939|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
218998508|NCT06178939|PROCEDURE|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
218998509|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
218998510|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
218998511|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
218998512|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
218998513|NCT02352402|DRUG|Ticagrelor|
218998514|NCT02352402|DRUG|Placebo|
218998515|NCT03651921|BEHAVIORAL|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
218998516|NCT04106960|OTHER|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
218998517|NCT04013334|DRUG|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
218998518|NCT04013334|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
218998519|NCT06102759|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
218998520|NCT00679315|DRUG|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
218998521|NCT00679315|DRUG|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
218998522|NCT02468115|DRUG|VIS410|Single fixed IV dose of VIS410
219369743|NCT05490420|OTHER|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
218998523|NCT02468115|DRUG|Placebo|Single IV dose of placebo
218998524|NCT02269241|DRUG|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
218998525|NCT01487551|DRUG|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
218998526|NCT03556150|OTHER|Manual Therapy protocol|"This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching."
218998527|NCT03556150|OTHER|Effleurage|"The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
218998528|NCT02270957|BIOLOGICAL|Abatacept|
218998529|NCT02270957|OTHER|Placebo|
218998530|NCT03604380|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
218998531|NCT03604380|OTHER|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
218998532|NCT01880398|OTHER|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
218998533|NCT05033353|DIAGNOSTIC_TEST|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
218998534|NCT00859404|DRUG|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
218998535|NCT03291054|DRUG|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
218998536|NCT03291054|DRUG|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
218998537|NCT05325554|BEHAVIORAL|Multimodal rehabilitation|Multimodal rehabilitation
218998538|NCT04246008|OTHER|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
218998539|NCT04246008|OTHER|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
218998540|NCT01246401|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
218998541|NCT02931487|BEHAVIORAL|Attentional Bias Modification|Computerized
218998542|NCT02931487|BEHAVIORAL|Sham Comparator|Computerized
218998543|NCT02031107|DEVICE|cTBS|
218998544|NCT02031107|DEVICE|cathodal tDCS|
218998545|NCT02031107|DEVICE|sham stimulation|
218998546|NCT00637481|DRUG|atorvastatin calcium|Given orally
218998547|NCT00637481|OTHER|laboratory biomarker analysis|Correlative studies
218998548|NCT04077983|DRUG|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
218998549|NCT03466697|OTHER|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
218998550|NCT04380168|PROCEDURE|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
218998551|NCT00925912|PROCEDURE|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
218998552|NCT00925912|PROCEDURE|Perianal block|0.25% bupivacaine injected at perianal region
218998553|NCT00166114|DRUG|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
218998554|NCT00166114|DRUG|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
218998555|NCT02093832|OTHER|There are no specific Intervention|are no specific Intervention
218998556|NCT02335294|DRUG|TRV130|Rescue: Ibuprofen, oxycodone
218998557|NCT02335294|DRUG|Morphine|Rescue: Ibuprofen, oxycodone
218998558|NCT02335294|DRUG|Placebo|Rescue: Ibuprofen, oxycodone
218998559|NCT05496257|OTHER|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
218998560|NCT00545168|DRUG|Spinosad|10 minute topical application of product, followed by a complete rinse off.
218998561|NCT00545168|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
218998562|NCT00545168|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
218998563|NCT01218204|DRUG|10mg atorvastatin|10mg
218998564|NCT01218204|DRUG|80mg atorvastatin|80mg
218998565|NCT01218204|DRUG|GSK1292263 Placebo|Placebo
218998566|NCT01218204|DRUG|100mg GSK1292263|100mg
218998567|NCT01218204|DRUG|300mg GSK1292263|300mg
218998568|NCT01218204|DRUG|800mg GSK1292263|800mg
218998569|NCT01218204|DRUG|10mg ezetimibe|10mg
218998570|NCT01218204|OTHER|Washout|No interventions - washout period
218998571|NCT05615272|BIOLOGICAL|Bio-PRF|Intervention group
218998572|NCT05615272|DRUG|Alveogyl|Control group
218998573|NCT03516994|BEHAVIORAL|Respecting Choices First Steps|Advance Care Planning Approach
219182244|NCT06709963|DEVICE|ITBS|"We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold."
219369744|NCT05952700|DEVICE|inContAlert|InContAlert is a non-invasive sensor technology to measure the bladder filling level for incontinence patients. The device is fixed about 2cm above the pubic bone using a patch or strap and does not require surgery. The data collected from the patient is analyzed using deep learning algorithms. The bladder filling level determined in this way is then displayed on an app.
218998574|NCT03516994|BEHAVIORAL|Five Wishes Form|Advance Care Planning Approach
218998575|NCT06436482|DEVICE|Optical Coherence Tomography|Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
219369745|NCT03180775|OTHER|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
218998576|NCT02122250|BEHAVIORAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
218998577|NCT02122250|BEHAVIORAL|Static web-based materials|Static web-based materials
218998578|NCT02216188|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
218998579|NCT02216188|OTHER|Control|Untreated control group
218998580|NCT04554667|BEHAVIORAL|Exercise Intervention|Heavy Lifting Strength Training
218998581|NCT03251768|DRUG|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
218998582|NCT03251768|DRUG|GCSF|GCSF 5 mcg/kg/day
218998583|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing=no|
218998584|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing = yes|
218998585|NCT00127660|BEHAVIORAL|Menu: calories=no, value pricing = no|
218998586|NCT01221571|DRUG|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
218998587|NCT02685085|DRUG|Misoprostol ( Prostaglandin E2)|
218998588|NCT02685085|DEVICE|Foley's catheter|
218998589|NCT00775424|BIOLOGICAL|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
218998590|NCT00775424|BIOLOGICAL|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
218998591|NCT00775424|BIOLOGICAL|PLACEBO|PLACEBO
218998592|NCT00775424|BIOLOGICAL|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
218998593|NCT01919125|DRUG|IDX719|IDX719 supplied as 50 mg tablets.
218998594|NCT02427893|DRUG|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
218998595|NCT02427893|DRUG|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
218998596|NCT03763214|DEVICE|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
218998597|NCT01987505|DRUG|Rituximab|1400 mg will be injected subcutaneously (SC).
218998598|NCT00035334|DRUG|NC-503 (Anti-amyloidotic (AA) Agent)|
218998599|NCT04829396|OTHER|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
218998600|NCT04829396|DIETARY_SUPPLEMENT|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
218998601|NCT05506891|BEHAVIORAL|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
218998602|NCT05506891|DRUG|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
218998603|NCT04224649|DEVICE|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
218998604|NCT04224649|DEVICE|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
218998605|NCT05735015|DRUG|encaleret|Oral administration, twice a day
218998606|NCT04617002|DRUG|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
218998607|NCT02459353|DRUG|Dapagliflozin|
218998608|NCT02459353|DRUG|Placebo|
218998609|NCT04930016|BEHAVIORAL|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
219182245|NCT05585814|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles
219182246|NCT05585814|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 3cycles
219182247|NCT05585814|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 3 cycles
219182248|NCT05585814|DRUG|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
219182249|NCT03717142|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
219182250|NCT06193577|DIETARY_SUPPLEMENT|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
219369746|NCT03180775|DIETARY_SUPPLEMENT|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219557695|NCT06650124|DRUG|Azathioprine + Prednisolone|In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
218998610|NCT00157534|DRUG|Celgosivir|
218998611|NCT00489541|DEVICE|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
218998612|NCT05131646|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
218998613|NCT03132207|OTHER|Non interventionel study|Only one questionnaire will be done for women and professional
218998614|NCT06299826|DRUG|AZD5462|Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.
218998615|NCT06299826|DRUG|Placebo|Participants will receive matching doses of film-coated tablets of Placebo OD orally.
218998616|NCT03266107|DEVICE|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
218998617|NCT01503151|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
218998618|NCT01503151|BEHAVIORAL|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
218998619|NCT01503151|BEHAVIORAL|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
218998620|NCT01503151|BEHAVIORAL|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
218998621|NCT01898611|DRUG|Ghrelin|Ghrelin
218998622|NCT01898611|DRUG|Placebo|Saline will be used as a placebo
218998623|NCT06089291|DEVICE|Persona IQ|"Persona IQ is a system comprised of the following subsystems:~1. RTM utilizing mymobility® patient application and care team dashboard,~2. PPK System with~3. CTE Extension Implant and Instrumentation,~   1. Surgical Base Station System,~  2. Home Base Station System,~  3. Canary CDMP,~  4. Canary CMGP software module, and~4. The ZBEdgeTM Connected Artificial Intelligence data platform.~The system combines physical components, electronics, software, and user interfaces to collect, store, analyze, transmit, and display patient data for use by both physicians and patients."
219182251|NCT06193577|DIETARY_SUPPLEMENT|Placebo|The placebo control does not contain active ingredients.
219182252|NCT03024437|DRUG|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
219182253|NCT03024437|DRUG|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
218998624|NCT01708733|DRUG|KSY|Chinese herbal formula
218998625|NCT03784729|OTHER|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
218998626|NCT03784729|OTHER|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
218998627|NCT01191801|DRUG|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
218998628|NCT01191801|DRUG|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
218998629|NCT02506140|DRUG|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
218998630|NCT02506140|DRUG|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
218998631|NCT00740805|DRUG|Cyclophosphamide|Given IV
218998632|NCT00740805|DRUG|Doxorubicin Hydrochloride|Given IV
218998633|NCT00740805|OTHER|Laboratory Biomarker Analysis|Correlative studies
218998634|NCT00740805|OTHER|Pharmacological Study|Correlative studies
218998635|NCT00740805|DRUG|Veliparib|Given PO
218998636|NCT03348956|DIAGNOSTIC_TEST|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
218998637|NCT03731780|OTHER|Personalized Treatment|Targeting individual caries risk factors
218998638|NCT03731780|OTHER|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
218998639|NCT03731780|OTHER|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
218998640|NCT00934973|DRUG|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
218998641|NCT00934973|DRUG|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
218998642|NCT00934973|DRUG|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
218998643|NCT00934973|BEHAVIORAL|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
218998644|NCT00934973|BEHAVIORAL|No website|No CBT website
218998645|NCT00934973|BEHAVIORAL|CBT website with minimal support|
218998646|NCT00328757|BEHAVIORAL|Regular diet as the first postoperative meal|
218998647|NCT02221947|DRUG|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
218998648|NCT02221947|DRUG|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
218998649|NCT03017547|DRUG|IC14|Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
218998650|NCT03017547|OTHER|Placebo|sterile normal saline for infusion
218998651|NCT00114101|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
218998652|NCT00114101|OTHER|Laboratory Biomarker Analysis|Correlative studies
218998653|NCT00114101|DRUG|Lenalidomide|Given PO
218998654|NCT00114101|DRUG|Melphalan|Given IV
218998655|NCT00114101|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
218998656|NCT00114101|OTHER|Placebo Administration|Given PO
218998657|NCT06517693|DRUG|PGT121.414.LS|Administered SC in the thigh
218998658|NCT06517693|DRUG|VRC07-523LS|Administered SC in the thigh
218998659|NCT03210376|DRUG|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
218998660|NCT03210376|DRUG|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
218998661|NCT03210376|DRUG|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
218998662|NCT03210376|DRUG|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
218998663|NCT03210376|BEHAVIORAL|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
218998664|NCT06421428|OTHER|LEI Interview|"In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the scientific literature and with reference to the Theoretical Domains Framework (TDF), created and validated by Michie et al. (2005) and later updated by Cane et al. (2012). The interview questions will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women."
218998665|NCT06421428|OTHER|LEI Survey|Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
219557696|NCT05690035|DRUG|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
218998666|NCT05802121|DRUG|Apple Cider Vinegar|"Each patient will be instructed to take 1 caplet (equivalent of 143 mg/caplet containing 36% acetic acid) per day for 3 months (NPN: 80078433)~https://www.jamiesonvitamins.com/products/apple-cider-vinegar-chromium?srsltid=AfmBOoqdVBFe83\_5JM9BmkomQM1LqsJYSFTiP\_78cnmehfzVg-4T4Z6o"
218998667|NCT03569514|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
218998668|NCT05147350|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
218998669|NCT06298500|DEVICE|hernia repair surgery|In recent years, atraumatic mesh fixation with tissue adhesive has increasingly become the method of choice. It is the recommended mesh fixation method by the International Hernia Society Guidelines. In this study patients with inguinal hernia are treated by placing a prosthetic mesh in one of the layers of the abdominal wall to cover the weakness, the mesh is fixed by Histoacryl LapFix,
218998670|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
218998671|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
218998672|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
218998673|NCT02359760|PROCEDURE|Piezocision|Flapless corticotomies
218998674|NCT04105101|DEVICE|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
218998675|NCT00723983|DRUG|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
218998676|NCT00723983|DRUG|NP101 Study Patch|NP101 study patch 4 hour application
218998677|NCT04673422|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
218998678|NCT04673422|DRUG|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
218998679|NCT04669652|DEVICE|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
218998680|NCT04927260|DRUG|Patient treated by Avapritinib in real life|"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."
218998681|NCT00923338|DEVICE|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
218998682|NCT00577681|DRUG|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
218998683|NCT04955197|DIAGNOSTIC_TEST|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
218998684|NCT01616667|PROCEDURE|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
218998685|NCT01774604|DRUG|Indomethacin|100 mg Indomethacin PR x 1
218998686|NCT01774604|DRUG|Placebo|
219182254|NCT03024437|DRUG|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
219182255|NCT05858125|OTHER|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to \>65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
218998687|NCT00509015|DRUG|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S\&25mg P/20 kg, 1 day, single dose
218998688|NCT00509015|DRUG|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
218998689|NCT00509015|DRUG|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
218998690|NCT00509015|DRUG|placebo tablets|3 days of lactose tablets (160mg) albochin
218998691|NCT04052347|BEHAVIORAL|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
218998692|NCT04052347|BEHAVIORAL|routine shared decision-making|control group
218998693|NCT03384095|DRUG|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
218998694|NCT03384095|OTHER|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
218998695|NCT00564772|DRUG|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
218998696|NCT01312272|DRUG|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
218998697|NCT01312272|DRUG|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
219557697|NCT01041235|DRUG|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
218998698|NCT05806281|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
218998699|NCT05927506|BEHAVIORAL|Other|Observational study of behavior cognitive and motor control
218998700|NCT01615185|DRUG|full-dose amisulpride|amisulpride 800mg/d
218998701|NCT03609632|OTHER|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
218998702|NCT05574790|OTHER|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
218998703|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
218998704|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
218998705|NCT01192516|BEHAVIORAL|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
218998706|NCT01192516|BEHAVIORAL|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
218998707|NCT03874247|DRUG|pelubiprofen 45mg|bid for 3 days after meal
218998708|NCT03874247|DRUG|pelubiprofen placebo|bid for 3 days after meal
218998709|NCT01256008|BEHAVIORAL|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
218998710|NCT01256008|BEHAVIORAL|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
218998711|NCT03641430|OTHER|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
218998712|NCT02846311|DEVICE|Flu Test|
218998713|NCT05458843|PROCEDURE|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
218998714|NCT05458843|PROCEDURE|No fluid replacement|Participants will not be permitted to drink.
218998715|NCT00119626|DRUG|NXY-059|
218998716|NCT02248103|PROCEDURE|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
218998717|NCT02248103|BIOLOGICAL|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
218998718|NCT00036712|PROCEDURE|management of therapy complications|
218998719|NCT00036712|PROCEDURE|pain therapy|
218998720|NCT01685034|BIOLOGICAL|"Allergy immunotherapy (allergy shots)"|
218998721|NCT05527340|DRUG|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
218998722|NCT05527340|DRUG|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
218998723|NCT05527340|DRUG|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
219182256|NCT05681923|OTHER|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
219182257|NCT05681923|OTHER|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
219557698|NCT04615312|DRUG|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
218998724|NCT05722483|OTHER|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
218998725|NCT02205112|DRUG|Nemonoxacin|
218998726|NCT02205112|DRUG|Levofloxacin|
218998727|NCT05521789|DRUG|ESB Thoracic|Erector spinae thoracic block with bupivacaine
218998728|NCT05536986|OTHER|Stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
218998729|NCT05228132|DEVICE|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
218998730|NCT02362061|RADIATION|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
218998731|NCT05499312|DRUG|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
218998732|NCT05499312|DRUG|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
218998733|NCT02770560|DEVICE|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
218998734|NCT01753271|OTHER|thoracic mobilization & shoulder mobilization & exercise|
218998735|NCT01753271|OTHER|shoulder mobilization & exercise|
218998736|NCT02277756|DEVICE|thermode|thermal stimulation with test thermode
218998737|NCT05230303|DIETARY_SUPPLEMENT|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
218998738|NCT05230303|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
218998739|NCT01336764|BEHAVIORAL|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
218998740|NCT01336764|BEHAVIORAL|Control|Unguided listening to radio/music.
218998741|NCT01131754|OTHER|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
218998742|NCT01357733|OTHER|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
218998743|NCT02294591|DRUG|N-acetylcysteine|Add-on treatment of NAC
218998744|NCT02294591|DRUG|Placebo|Add-on treatment of placebo
218998745|NCT01264900|BEHAVIORAL|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
218998746|NCT04873505|DIETARY_SUPPLEMENT|troches|Take one troche after each meal.
218998747|NCT00094744|DEVICE|Eye patch|adhesive eye patch used to cover the sound eye
218998748|NCT01888237|DRUG|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
218998749|NCT01888237|DRUG|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
218998750|NCT01033968|PROCEDURE|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
218998751|NCT06133205|OTHER|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
218998752|NCT00730132|DRUG|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
218998753|NCT00730132|DRUG|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
218998754|NCT05168527|DRUG|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
218998755|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
218998756|NCT03956732|DIETARY_SUPPLEMENT|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
218998757|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
218998758|NCT01626391|DRUG|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
218998759|NCT01626391|DRUG|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
218998760|NCT03059602|OTHER|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
218998761|NCT02624908|DRUG|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
218998762|NCT02624908|DRUG|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
218998763|NCT05820685|DRUG|Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)|Participants will receive acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, and gabapentin 300 mg every eight hours. Participants will also receive Oxycodone 5 mg or Tramadol 50 mg every six hours as needed for breakthrough pain. Providers will have the ability to adjust this pain regimen based on clinical judgement.
218998764|NCT05820685|DRUG|Dronabinol|Participants will receive Dronabinol 10 mg every 12 hours scheduled. Providers will have the ability to adjust this pain regimen based on clinical judgement.
218998765|NCT00772343|BIOLOGICAL|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
218998766|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
218998767|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
218998768|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
218998769|NCT01218568|DRUG|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
218998770|NCT01218568|DRUG|Lactulose|Lactulose 30-60 ml in two or three divided doses.
219006805|NCT01593488|DRUG|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
219006806|NCT02771990|DEVICE|Sham transcranial direct current stimulation|sham stimulation
219006807|NCT02771990|DEVICE|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
219006808|NCT02691299|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
219006809|NCT02691299|DRUG|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
219006810|NCT00002007|DRUG|Zidovudine|
219006811|NCT00002007|DRUG|Sargramostim|
219006812|NCT00848081|DRUG|Tadalafil|5 mg taken by mouth once daily for 12 weeks
219006813|NCT00848081|DRUG|Placebo|By mouth once daily for 12 weeks
219006814|NCT03032731|BEHAVIORAL|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
219006815|NCT03032731|OTHER|Control|Standard, publicly available NHS resources for healthy lifestyles.
219006816|NCT02355353|OTHER|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
219006817|NCT02753101|DRUG|[18F]-FTC-146|10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
219006818|NCT01739478|OTHER|Packing of abscess cavity|
219006819|NCT01739478|OTHER|External dressing|Application of external dressing whilst abscess cavity heals
219006820|NCT03590587|DRUG|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
219006821|NCT03590587|DEVICE|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
219006822|NCT02136186|DEVICE|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
219006823|NCT01199523|DRUG|Placebo|oral
219006824|NCT01199523|DRUG|mirabegron|oral
219006825|NCT01199523|DRUG|moxifloxacin|oral
219006826|NCT00310128|DRUG|cisplatin|
219006827|NCT00310128|DRUG|cytarabine|
219006828|NCT00310128|DRUG|etoposide|
219006829|NCT00310128|DRUG|methylprednisolone|
219006830|NCT00310128|DRUG|rituximab|
219006831|NCT00310128|DRUG|yttrium Y 90 ibritumomab tiuxetan|
219006832|NCT00310128|PROCEDURE|antibody therapy|
219006833|NCT00310128|PROCEDURE|biological therapy|
219006834|NCT00310128|PROCEDURE|chemotherapy|
219006835|NCT00310128|PROCEDURE|monoclonal antibody therapy|
219006836|NCT00310128|PROCEDURE|radiation therapy|
219006837|NCT00310128|PROCEDURE|radioimmunotherapy|
219006838|NCT00310128|PROCEDURE|radioisotope therapy|
219006839|NCT03114228|DRUG|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
219006840|NCT05264077|DRUG|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
219006841|NCT03415191|DRUG|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
219006842|NCT03415191|DRUG|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
219006843|NCT00660998|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
219006844|NCT00660998|DRUG|Placebo|Matching placebo
219006845|NCT02534870|DRUG|ABT-450/r/ABT-267|Tablet
219006846|NCT02534870|DRUG|ABT-333|Tablet
219006847|NCT01817998|OTHER|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
219006848|NCT06295770|DRUG|Obinutuzumab|Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
219006849|NCT06066554|DEVICE|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
219006850|NCT05237154|OTHER|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
219006851|NCT05237154|OTHER|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
219006852|NCT06409572|DIAGNOSTIC_TEST|GeneXpert MTB/RIF|Rapid and accurate method for detection of tuberculosis.
219557699|NCT03268096|DEVICE|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
219557700|NCT02721550|DRUG|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
219557701|NCT01652508|OTHER|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
218998771|NCT01804283|PROCEDURE|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
218998772|NCT01804283|PROCEDURE|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
218998773|NCT01804283|DEVICE|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
218998774|NCT01804283|DEVICE|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
218998775|NCT05229406|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
219006853|NCT03608501|DRUG|Ixazomib|Ixazomib capsules.
219006854|NCT03608501|DRUG|Thalidomide|Thalidomide capsules.
219006855|NCT03608501|DRUG|Dexamethasone|Dexamethasone tablets.
219006856|NCT01876030|DEVICE|FES|
219006857|NCT02322918|GENETIC|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
219006858|NCT00002904|DRUG|trabectedin|
219006859|NCT03331419|BEHAVIORAL|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
219006860|NCT02064868|DRUG|Serelaxin|30 µg/kg/day IV infusion
219006861|NCT02064868|DRUG|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
219006862|NCT02014597|DEVICE|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
219006863|NCT04525664|DRUG|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
219006864|NCT04525664|DRUG|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
219006865|NCT04525664|DRUG|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
219006866|NCT04525664|DRUG|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
219006867|NCT00020475|DRUG|gp100 antigen|
219006868|NCT00020475|DRUG|interleukin-2|
219006869|NCT00020475|DRUG|MART-1 antigen|
219006870|NCT00020475|DRUG|Montanide ISA-51|
219006871|NCT00711711|OTHER|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
219006872|NCT00711711|OTHER|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
219006873|NCT03025503|OTHER|nipple stimulation|
219006874|NCT02028624|BEHAVIORAL|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
219006875|NCT03858114|OTHER|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
219006876|NCT03858114|OTHER|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
219006877|NCT03500627|DRUG|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
219006878|NCT01938378|BIOLOGICAL|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
219006879|NCT00754624|DRUG|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
218998776|NCT04512716|DRUG|131-I Apamistamab|Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
218998777|NCT04512716|BIOLOGICAL|CAR T-cell|19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10\^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
218998778|NCT06251648|DRUG|Lenalidomide|Patients exposed to LEN
219182258|NCT05681923|OTHER|Neurodevelopmental assessment visit|"High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals."
218998779|NCT02054260|DRUG|Surgicel|
219182259|NCT05681923|OTHER|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
219182260|NCT05969392|DEVICE|Intradiscal Gelified Ethanol (Discogel)|Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
219182261|NCT03536052|DEVICE|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
219182262|NCT03498612|OTHER|Laboratory Biomarker Analysis|Correlative studies
219182263|NCT03498612|BIOLOGICAL|Pembrolizumab|Given IV
219182264|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
219182265|NCT06367296|OTHER|Prolonged resistance exercise training|"Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm."
219182266|NCT03967795|DRUG|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
219182267|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
219182268|NCT06572813|DRUG|Sintilimab|PD-1 antibody
219182269|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
219182270|NCT01799265|DEVICE|Somnetics Transcend Auto|
219182271|NCT01799265|DEVICE|Respironics REMstar Auto with C-Flex|
219182272|NCT06448182|DIETARY_SUPPLEMENT|Postbiotic|1 capsule of postbiotic daily in the morning
219182273|NCT06448182|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo daily in the morning
219182274|NCT03459729|DRUG|Antitumor B|Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
219182275|NCT02364557|RADIATION|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~* For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~* For a single liver metastases, patients receive a single fraction of 30 Gy.~* For metastases in the abdominal-pelvic or liver (\>1), patients receive 3 fractions for a total of 45 Gy.~* For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~* For spinal metastases, patients receive 1 fraction of 20 Gy.~* For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~* For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
219182276|NCT02364557|PROCEDURE|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
219182277|NCT03134092|OTHER|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
219557702|NCT01652508|BEHAVIORAL|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
218998780|NCT04556695|OTHER|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
218998781|NCT04556695|DEVICE|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
218998782|NCT04556695|OTHER|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
218998783|NCT05446805|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
218998784|NCT05446805|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
218998785|NCT01351922|OTHER|No treatment given|Patients will fill out a questionaire by interview.
218998786|NCT00674245|DRUG|Pantoprazole|40 mg once daily for 4 weeks
218998787|NCT00674245|DRUG|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
218998788|NCT00674245|DRUG|placebo|40 mg once daily for 4 weeks
218998789|NCT01032837|DRUG|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
218998790|NCT01032837|DRUG|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
218998791|NCT01032837|DRUG|Placebo|Matching placebo provided as capsules and as a suspension.
218998792|NCT00843024|DRUG|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
218998793|NCT00843024|DRUG|Placebo|Placebo to match
218998794|NCT01741597|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
218998795|NCT01741597|OTHER|pharmacological study|Correlative studies
218998796|NCT01741597|BIOLOGICAL|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
218998797|NCT05948397|DIAGNOSTIC_TEST|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
218998798|NCT05948397|DIAGNOSTIC_TEST|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
218998799|NCT05948397|DIAGNOSTIC_TEST|Pad test|"One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence"
218998800|NCT04113005|DRUG|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
218998801|NCT02840500|OTHER|No intervention|No intervention
218998802|NCT02643680|DEVICE|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
218998803|NCT02643680|DEVICE|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
218998804|NCT03839979|DIAGNOSTIC_TEST|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
218998805|NCT03839979|DIAGNOSTIC_TEST|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
218998806|NCT03839979|DIAGNOSTIC_TEST|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
218998807|NCT01008488|DRUG|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
218998808|NCT03265769|OTHER|radial access site|radial route
218998809|NCT03265769|OTHER|femoral access site|femoral route
219557703|NCT06674421|OTHER|Reliability Analyses|For the reliability analysis test-retest method will use. There will be a one-week break between the first test and the retest.
218998810|NCT02216734|BEHAVIORAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
218998811|NCT00804544|DEVICE|SPECT/CT|SPECT/Low-Dose MultiSclice CT
218998812|NCT02801383|DRUG|Yallaferon®， the recombinant human interferon α-2b gel|
218998813|NCT02801383|OTHER|gel without active ingredient|
218998814|NCT03123913|DRUG|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
218998815|NCT03123913|DRUG|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
219182278|NCT03134092|OTHER|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
219754193|NCT02087852|BEHAVIORAL|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
218998816|NCT03108183|DIAGNOSTIC_TEST|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
218998817|NCT01523262|PROCEDURE|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
218998818|NCT01523262|PROCEDURE|Normal surgery, with sham intervention without inflating arm cuff|
218998819|NCT02439138|DRUG|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
218998820|NCT00394368|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|
218998821|NCT00394368|DRUG|fluticasone propionate plus salmeterol xinafoate combination|
218998822|NCT02517567|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218998823|NCT02517567|DEVICE|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218998824|NCT02517567|DEVICE|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218998825|NCT00837642|DIAGNOSTIC_TEST|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
218998826|NCT05108155|PROCEDURE|Cemented THA|THA with cement fixation
218998827|NCT05108155|PROCEDURE|Unemented THA|THA with uncemented / pressfit fixation
218998828|NCT00615511|DIETARY_SUPPLEMENT|placebo pregnenolone|Sugar pill, taken twice a day
218998829|NCT00615511|DIETARY_SUPPLEMENT|pregnenolone|500mg in tablet form taken orally twice a day
218998830|NCT05097989|DRUG|ALXN2050|Oral tablets
218998831|NCT05097989|DRUG|Placebo|Oral tablets
219754194|NCT05391776|DRUG|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
218998832|NCT00002105|DRUG|Doxorubicin hydrochloride (liposomal)|
218998833|NCT00002105|DRUG|Bleomycin sulfate|
218998834|NCT00002105|DRUG|Vincristine sulfate|
218998835|NCT06968195|BIOLOGICAL|Anti-GPC3-CAR Autologous T Lymphocytes|Given IV
218998836|NCT06968195|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
218998837|NCT06968195|PROCEDURE|Computed Tomography|Undergo CT
218998838|NCT06968195|DRUG|Cyclophosphamide|Given IV
218998839|NCT06968195|PROCEDURE|Echocardiography Test|Undergo ECHO
218998840|NCT06968195|DRUG|Fludarabine|Given IV
218998841|NCT06968195|PROCEDURE|Leukapheresis|Undergo leukapheresis
218998842|NCT06968195|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218998843|NCT06968195|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218998844|NCT05096897|OTHER|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
218998845|NCT00006237|BIOLOGICAL|interleukin-2|Given IV
218998846|NCT00006237|BIOLOGICAL|filgrastim|Given subcutaneously
218998847|NCT00006237|BIOLOGICAL|interferon alfa|Given IV and subcutaneously
218998848|NCT00006237|DRUG|cisplatin|Given IV
218998849|NCT00006237|DRUG|dacarbazine|Given IV
218998850|NCT00006237|DRUG|vinblastine|Given IV
218998851|NCT00820560|DRUG|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
218998852|NCT02920372|DRUG|EPOETIN ALFA|
218998853|NCT05829304|OTHER|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
218998854|NCT05829304|OTHER|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
218998855|NCT00585247|DRUG|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
218998856|NCT00585247|OTHER|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
218998857|NCT01846416|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
218998858|NCT01257087|DRUG|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
219182279|NCT05844137|BEHAVIORAL|NAFLD Education|NAFLD Education
218998859|NCT04821115|DEVICE|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
219754195|NCT05391776|DRUG|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
218998860|NCT04821115|DEVICE|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
218998861|NCT04835532|PROCEDURE|guided bone gereration|"guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation."
218998862|NCT01065285|BIOLOGICAL|Evaluation of vaccines against flu|evaluate efficacy and tolerance
218998863|NCT03290092|DRUG|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
218998864|NCT03290092|DRUG|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
218998865|NCT03794271|PROCEDURE|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
218998866|NCT03794271|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
218998867|NCT00533598|DRUG|MK0557|
218998868|NCT05654220|BEHAVIORAL|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
218998869|NCT06268002|DIETARY_SUPPLEMENT|Vernonia cinerea|Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
218998870|NCT06268002|DIETARY_SUPPLEMENT|Placebo|Sweetener
218998871|NCT02837783|DRUG|Linaclotide|Oral, once daily
218998872|NCT02837783|DRUG|Placebo|Oral, one daily
218998873|NCT03409835|DRUG|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
218998874|NCT03409835|DRUG|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
218998875|NCT05309642|BEHAVIORAL|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
218998876|NCT05309642|BEHAVIORAL|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
218998877|NCT06306781|DRUG|HCL001 cell (homologous allogeneic hepatocytes) injection|The patient will undergo a DSA procedure in the hospital's operating room before infusion. A catheter will be inserted into the femoral artery and guided to the hepatic artery. Upon confirmation through imaging, HCL001 cell injection will be slowly infused through the catheter. During the infusion, the cells should be continuously agitated to prevent clumping. The infusion can be administered as a single dose or multiple doses, and after infusion, the patient will be closely monitored for at least one week.
218998878|NCT01487200|DRUG|FX006 10 mg|single 3 mL IA injection
218998879|NCT01487200|DRUG|FX006 40 mg|single 3 mL IA injection
218998880|NCT01487200|DRUG|FX006 60 mg|single 3 mL IA injection
218998881|NCT01487200|DRUG|TCA IR 40|single 1 mL IA injection
218998882|NCT05759247|DEVICE|BORA Band (wristband)|Wristband collecting patient vital signs and activity
218998883|NCT03638297|DRUG|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
218998884|NCT00115102|DRUG|fentanyl|
218998885|NCT00115102|DRUG|S-ketamine|
218998886|NCT02158403|OTHER|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
219754196|NCT05739448|OTHER|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
218998887|NCT05173662|PROCEDURE|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
218998888|NCT00920712|DRUG|Weiqi decotion|Decoction ,two times a day
219754197|NCT05739448|OTHER|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
219182280|NCT05844137|BEHAVIORAL|diet/lifestyle support|diet/lifestyle support
219182281|NCT05844137|DRUG|T2D medication management|T2D medication management
219182282|NCT05844137|DIAGNOSTIC_TEST|clinically-indicated liver testing and care|clinically-indicated liver testing and care
218998889|NCT00040482|DRUG|Cyclophosphamide|
218998890|NCT00040482|DRUG|ATG|
218998891|NCT00040482|DRUG|MESNA|
218998892|NCT00040482|PROCEDURE|Radiation therapy|
218998893|NCT04013204|OTHER|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
218998894|NCT03641443|DEVICE|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
218998895|NCT03072992|DRUG|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
219182283|NCT04196413|DRUG|GD2 CAR T cells|Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
219182284|NCT04196413|DRUG|Fludarabine|Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
219182285|NCT04196413|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
218998896|NCT03072992|DRUG|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
218998897|NCT03072992|DRUG|Placebo|Placebo i.v. solution, once weekly for 12 weeks
218998898|NCT05325671|PROCEDURE|transarticular multimodal drug infiltration|as described previously
218998899|NCT03258268|DEVICE|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
218998900|NCT03258268|OTHER|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
218998901|NCT02634671|OTHER|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
218998902|NCT02634671|OTHER|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
218998903|NCT02634671|OTHER|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
218998904|NCT03980002|DRUG|FCR and Ibrutinib|"Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d"
218998905|NCT03980002|DRUG|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
218998906|NCT03980002|DRUG|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
218998907|NCT00867724|DEVICE|Aer-O-Scope Colonoscopy|Screening Colonoscopy
218998908|NCT05375370|OTHER|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
218998909|NCT03601975|DRUG|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
218998910|NCT01190345|DRUG|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
218998911|NCT01190345|DRUG|no bevacizumab|no bevacizumab
218998912|NCT02313792|DRUG|Palifermin|
218998913|NCT01239004|DRUG|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
218998914|NCT01239004|DRUG|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
218998915|NCT01910025|DRUG|ADI-PEG 20|
218998916|NCT00843947|PROCEDURE|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
219182286|NCT05775406|DRUG|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
219182287|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
219182288|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
219182289|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
219182290|NCT03666000|DRUG|IL-2|Specified dose on specified days
219182291|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
219182292|NCT06126900|OTHER|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
218998917|NCT02714582|BEHAVIORAL|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
218998918|NCT00003997|DRUG|irofulven|
218998919|NCT04933877|PROCEDURE|Fascial plane block|Serratus anterior plane block
218998920|NCT04356391|PROCEDURE|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
218998921|NCT04356391|PROCEDURE|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
218998922|NCT02207244|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
218998923|NCT02207244|DRUG|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
218998924|NCT02207244|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
219557704|NCT01924364|DEVICE|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
218998925|NCT02207244|DRUG|Placebo for adalimumab|Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
218998926|NCT02216591|DEVICE|Active Cognitive Training (ACT)|
218998927|NCT02216591|DEVICE|Control (CON)|
218998928|NCT04298801|PROCEDURE|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
218998929|NCT04298801|OTHER|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
218998930|NCT02406716|OTHER|Biospecimen retention|
218998931|NCT00039130|BIOLOGICAL|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII
218998932|NCT00039130|BIOLOGICAL|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
218998933|NCT00039130|DRUG|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
218998934|NCT00039130|DRUG|cytarabine|1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
218998935|NCT00039130|DRUG|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
218998936|NCT00039130|DRUG|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
218998937|NCT00039130|DRUG|etoposide|80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
218998938|NCT00039130|DRUG|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
218998939|NCT00039130|DRUG|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
218998940|NCT00039130|DRUG|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
218998941|NCT00039130|DRUG|prednisone|60 mg/sq m PO/day Days 1-7 course I
218998942|NCT00039130|DRUG|vincristine sulfate|2 mg IV push Day 1 courses II-VII
218998943|NCT00039130|DRUG|Allopurinol|300 mg/day PO Days 1-14, course I
219754198|NCT05128747|OTHER|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
218998944|NCT04920019|PROCEDURE|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
218998945|NCT00908713|DRUG|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
218998946|NCT00908713|DRUG|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
218998947|NCT00139698|DRUG|olmesartan alone or in combination with hydrochlorothiazide|
218998948|NCT06505434|PROCEDURE|Cataract surgery|Phaco + IOL Implantation
218998949|NCT03147560|BIOLOGICAL|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
218998950|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
218998951|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
218998952|NCT05651997|PROCEDURE|MACT|"* A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site."
218998953|NCT05651997|PROCEDURE|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
218998954|NCT00750815|DRUG|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
218998955|NCT00750815|DRUG|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
218998956|NCT05165901|DEVICE|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
218998957|NCT05106686|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
218998958|NCT05106686|DIETARY_SUPPLEMENT|placebo group|Placebo 300 mg/day for 12 weeks
218998959|NCT03378232|DIETARY_SUPPLEMENT|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
218998960|NCT03378232|DIETARY_SUPPLEMENT|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
218998961|NCT03378232|DIETARY_SUPPLEMENT|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
218998962|NCT03533764|BEHAVIORAL|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
218998963|NCT04158115|OTHER|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
218998964|NCT04158115|OTHER|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~\- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
218998965|NCT00701675|DRUG|sertraline 50 mg daily|50 mg daily
218998966|NCT00701675|DRUG|sertraline 100 mg daily|100 mg daily
218998967|NCT00701675|DRUG|Placebo 50 or 100 mg|50mg or 100mg matching placebo
218998968|NCT06049862|BEHAVIORAL|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
218998969|NCT02817256|DIETARY_SUPPLEMENT|Vitamins and Minerals|Multivitamins and Minerals supplementation
218998970|NCT03258437|DIETARY_SUPPLEMENT|DA-9401|
218998971|NCT03258437|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
218998972|NCT01412515|DRUG|everolimus|everolimus per os 10mg per day
218998973|NCT02412475|DRUG|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
218998974|NCT02412475|DRUG|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
218998975|NCT02412475|DRUG|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
218998976|NCT02412475|DRUG|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
218998977|NCT02412475|DRUG|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
218998978|NCT02412475|DRUG|Cytarabine|"Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1"
218998979|NCT02412475|DRUG|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
218998980|NCT00273871|DRUG|Cyclosporin or tacrolimus|
218998981|NCT00079898|PROCEDURE|Acupuncture|
218998982|NCT05665478|OTHER|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
219754199|NCT02645864|DRUG|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
218998983|NCT03931538|DIAGNOSTIC_TEST|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
218998984|NCT03931538|DIAGNOSTIC_TEST|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
218998985|NCT00323921|DEVICE|dermatological infrared laser|
218998986|NCT03919799|DRUG|Belumosudil (KD025)|ROCK-2 Inhibitor
218998987|NCT03919799|DRUG|Placebo|Inactive substance
218998988|NCT04936256|DEVICE|Clareon|Clareon monofocal intraocular lens (IOL)
218998989|NCT04255602|DRUG|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
218998990|NCT04255602|DRUG|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
218998991|NCT03004027|OTHER|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
218998992|NCT05948696|BEHAVIORAL|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
219182293|NCT05094908|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
219182294|NCT02950987|DEVICE|Whole Body MRI|
218998993|NCT03548909|DIAGNOSTIC_TEST|VITROS Immunodiagnostic Products|NT-proBNP II assay
218998994|NCT04239144|PROCEDURE|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
218998995|NCT04239144|PROCEDURE|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
218998996|NCT00042900|DRUG|pyroxamide|
218998997|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
218998998|NCT00330746|DRUG|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
218998999|NCT00330746|DRUG|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
218999000|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
218999001|NCT01503918|DRUG|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
218999002|NCT01503918|DRUG|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
218999003|NCT02717585|DEVICE|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
218999004|NCT06584552|DIETARY_SUPPLEMENT|Lactobacillus Paracasei LPB27|Probiotic
218999005|NCT06584552|OTHER|Maltodextrin|Placebo
218999006|NCT01787487|DRUG|Azacitidine|Given SC or IV
218999007|NCT01787487|OTHER|Laboratory Biomarker Analysis|Correlative studies
218999008|NCT01787487|DRUG|Ruxolitinib Phosphate|Given PO
218999011|NCT03076697|DIAGNOSTIC_TEST|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
219182295|NCT06153420|DRUG|CIN-103|CIN-103 BID
219182296|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
219557705|NCT01924364|PROCEDURE|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
219754200|NCT02645864|DRUG|Irinotecan|150mg/m\^2 i.v. q2w
219754201|NCT02039830|BEHAVIORAL|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
219754202|NCT02039830|BEHAVIORAL|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
219754203|NCT07125742|OTHER|Chewing gum|The chewing gum group was asked to chew sugar-free gum for 15 minutes at each time point.
218999012|NCT05226117|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 7.5 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
218999013|NCT03752827|DEVICE|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
218999014|NCT03752827|DRUG|Corticosteroid|Corticosteroid injection into subacrominal space
218999015|NCT03385993|DEVICE|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
218999016|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
218999017|NCT05491109|DEVICE|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
218999018|NCT03996252|DRUG|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
218999019|NCT03996252|DRUG|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
218999020|NCT07131410|OTHER|Group hialuronyc|Patients will receive the container with cream for application on both feet after thoroughly washing and drying them. It is recommended to use an amount the size of a hazelnut for each foot, spreading it in a thin layer over the entire foot, excluding the interdigital area. The application will be done every night for twelve months. The product will be massaged into the foot for 15 seconds. During the study, participants will not be allowed to use any other topical product (cream, emulsion, gel, lotion, or oil) on their feet and/or nails.
218999021|NCT07133126|DEVICE|Acumen monitoring|Patient undergoing a thoracic surgery or an aortic surgery will be monitored as usual using the CE marked medical device ACUMEN with the intelligent HPI system.
218999022|NCT07131631|DIAGNOSTIC_TEST|Cardiac MRI|Clinically indicated baseline CMR study with contrast up to 90 days before TEER procedure, including KCCQ questionnaire. At 6 months, participants will return for repeat of KCCQ, CMR study and a transthoracic echocardiogram. Blood samples, done as standard clinical care for hemotocrit for ECV calculation, will be obtained.
219369747|NCT03180775|DIETARY_SUPPLEMENT|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
218999023|NCT05475236|BEHAVIORAL|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
219182297|NCT03466294|DRUG|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
219182298|NCT04200456|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
219182299|NCT04200456|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
219182300|NCT06145386|BEHAVIORAL|Aerobic Exercise and Strength Training|Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
219182301|NCT03778996|DRUG|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
219182302|NCT06554405|OTHER|Unilateral Intervention|Treatment plan will be applied to the symptomatic side.
219182303|NCT06554405|OTHER|Bilateral Intervention|Treatment plan will be applied to the symptomatic and nonsymptomatic sides.
219182304|NCT05176080|DRUG|Famitinib|Famitinib orally, daily or every other day
219182305|NCT05176080|DRUG|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
219182306|NCT05176080|DRUG|Fulvestrant|Fulvestrant
219557706|NCT00152906|PROCEDURE|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
219557707|NCT00051818|BEHAVIORAL|Treatment interruption/reinitiation schedule|
219557708|NCT02874196|PROCEDURE|Standard arthrography|
218999024|NCT07131319|OTHER|Spatially Fractionated Radiotherapy (SFRT)|Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.
218999025|NCT07131319|DRUG|Tislelizumab, Carboplatin, Pemetrexed|For adenocarcinoma, pemetrexed (500 mg/m², day 1) + carboplatin (AUC 5, day 1) is used.
218999026|NCT07131319|DRUG|Tislelizumab, paclitaxel, Carboplatin|For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg/m² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.
218999027|NCT07131683|BIOLOGICAL|Human umbilical cord mesenchymal stem cell derived exosomes|Nasal spray of hUC-MSC-Exo (low dose: 2.5×10\^10 particles, mid-dose: 5.0×10\^10 particles, high-dose: 1.0×10\^11 particles), once per day for 7 days, then once per week for 3 weeks
218999028|NCT07131683|OTHER|Placebo Control|Nasal spray of placebo control, once per day for 7 days, then once per week for 3 weeks
218999029|NCT07131059|DRUG|Ivosidenib|500mg d1-28
218999030|NCT07131059|DRUG|Gilteritinib|120mg d1-28
218999031|NCT07131059|DRUG|Venetoclax|400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21
218999032|NCT07131059|DRUG|Avapritinib|200mg d1-28.
218999033|NCT07131059|DRUG|Daunorubicin|45mg/m2/d d1-2;
218999034|NCT07131059|DRUG|Cytarabine|100mg/m2/d d1-5
218999035|NCT07131059|DRUG|Idarubicin|10mg/m2/d d1-2
218999036|NCT07131059|DRUG|MTZ|8mg/m2/d d1-2
218999037|NCT07131059|DRUG|HHT|2mg/m2/d d1-5
218999038|NCT07131059|DRUG|Azacitidine|75mgd/m2 d1-7.
218999039|NCT04841590|OTHER|Intervention of the experimental group (EG)|Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
218999040|NCT04841590|OTHER|Control Group (CG)|Subjects in the control group (CG) will not receive any treatment
218999041|NCT06443359|RADIATION|hypofractionated radiation|All patients will receive a dose of 42.56 Gy in 16 daily fractions to the whole breast or chest wall and regional lymph nodes. A boost dose of 10 or 12.5 Gy in 4 or 5 daily fractions of 2.5 Gy, respectively, will be administered to either the lumpectomy cavity or mastectomy scar, as appropriate.
218999042|NCT06985446|OTHER|Study Group:Black stain-positive|In children with black stains (BS+), we evaluated DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
218999043|NCT06985446|OTHER|Control Group: Black stain-negative|In healthy children without black stains (BS-), we assessed DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
218999044|NCT06089473|OTHER|Intervention Group: Exercise and education.|"* Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session.~* Education: Prior to each zoom session with the kinesiologist (starting on week 2), participants will watch short educational videos. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress."
218999045|NCT06089473|OTHER|Usual Care Only|Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
218999046|NCT06997120|BEHAVIORAL|Bodhi AIM (intervention group)|"AIM (Action In Mindfulness) is a smartphone app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations."
218999047|NCT06997120|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone app that is matched to AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in AIM. Like AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
218999048|NCT06587399|OTHER|Manual therapy treatment|"Joint mobilization techniques will be applied to the shoulder joint complex, adapted to the subjects' degree of irritability.~The muscular trigger points of the shoulder muscles will be treated using a pressure release technique applied for 60 seconds.~In addition, the subjects will carry out a 12-week home-based therapeutic exercise program."
218999049|NCT06587399|OTHER|Radial shock wave treatment|"The treatment will be carried out with 1 session per week for 6 weeks. For this purpose, a radial shock wave generator will be used, at a frequency of 8 to 12 Hz, 2000 pulses/session and with a pressure of 2.5 to 4.0 bar.~Between 3 and 5 points will be treated per session: insertion of the supraspinatus muscle, dorsolateral area under the acromion and a maximum of 3 trigger points of the rotator cuff muscles.~In addition, the subjects will carry out a 12-week home therapeutic exercise program."
218999050|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
219182307|NCT02098629|DRUG|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
218999051|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days."
218999052|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
218999053|NCT07002281|DRUG|[14C]Azvudine suspension|A single oral dose of 3 mg/100 μCi of \[14C\]Azvudine suspension is given orally on an empty stomach.
218999054|NCT07002463|DEVICE|Luna EMG|Participants receive additional upper limb rehabilitation using the Luna EMG robotic system. Each session includes 4 EMG-triggered exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
218999055|NCT07002463|BEHAVIORAL|Therapist-assisted upper limb training|Participants receive additional upper limb rehabilitation with a physiotherapist performing assisted movements equivalent to the robotic training protocol. Each session includes 4 assisted exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
218999056|NCT07001202|BEHAVIORAL|Indicated Prevention for suicidality|The Reframe-IT+U program is an individualized preventive intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, delivered within the University with psychologists and supervision. The program consists of six weekly sessions of 60-90 minutes each.
218999057|NCT07000903|OTHER|Exposure and immune profiles|The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.
218999058|NCT07001254|DRUG|Romiplostim|The investigational drug, Romiplostim, is a thrombopoietin receptor agonist (TPO-RA) that has been granted orphan drug designation by the FDA.
218999059|NCT07001254|DRUG|Immunosuppressive therapy (IST)|Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)
218999060|NCT07001787|DRUG|Drug：HS-10510；|Drug：HS-10510 Description：Subjects will receive HS-10510 orally as a single and multiple ascending dose.
218999061|NCT07001787|DRUG|Drug：Placebo|Drug：Placebo Description：Subjects will receive placebo matching the HS-10510 dose orally as a single and multiple ascending dose.
218999062|NCT07001787|DRUG|Drug： Rosuvastatin|Drug：Rosuvastatin Description：Subjects will receive rosuvastatin orally.
218999063|NCT07000292|DRUG|Injection of MSC303|Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.
219182308|NCT02098629|DRUG|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
219182309|NCT02098629|DRUG|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
219182310|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
219182311|NCT05085067|OTHER|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
219182312|NCT04593810|PROCEDURE|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
219182313|NCT04593810|PROCEDURE|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
219557709|NCT02874196|PROCEDURE|Dual energy arthrography|
218999064|NCT07002099|DRUG|Selinexor + High-dose Methotrexate + Rituximab + WBRT|"Rituximab 375 mg/m² intravenously on Day 0 of each 21-day cycle~High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle~Selinexor 80 mg orally once weekly (on Days 1, 8, and 15) during each cycle~Treatment is administered every 21 days for up to 6 cycles. Tumor response will be evaluated every 3 cycles.~Patients who achieve a partial response (PR) or better will undergo consolidative low-dose whole-brain radiotherapy (WBRT) at 23.4 Gy in 13 fractions."
218999065|NCT07000942|OTHER|Electrical cardioversion (ECV)|Electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure
218999066|NCT07001007|DIAGNOSTIC_TEST|Coronary Computer Tomography (CCTA)|Use of standard equipment for usual care
218999067|NCT07001007|OTHER|Laser Doppler Vibrometry and single-lead ECG|Physiological data acquisition equipment
218999068|NCT07001007|DEVICE|Echocardiography|GE Vivid E95
218999069|NCT07001007|DEVICE|Pulse Wave Velocity|Arteriograph, Tensiomed, Hungary
218999070|NCT07000461|PROCEDURE|Group Non-pulsatile perfusion|Non-pulsatile group in pump blood flow
218999071|NCT07002619|PROCEDURE|Routine cholangiography|Intraoperative cholangiography attempted regardless of indication and anatomy
218999072|NCT07002619|PROCEDURE|Selective cholangiograpy|Intraoperative cholangiography only attempted in case of uncertainty regarding anatomy
218999073|NCT07002424|BEHAVIORAL|Therapeutic - Psychological|The intervention uses a transdiagnostic model that incorporates aspects of peer support, psychoeducation, trauma-informed cognitive behavioural therapy (CBT), Compassion focused therapy (CFT) models of distress. It also aligns itself to the Dual Processing Model of coping with bereavement (Stroebe \& Schut, 2010) and Tonkin's model of grief (Tonkin, 1996).
218999074|NCT07001839|DRUG|QLS4131 for Injection.|Eligible participants will be assigned to 1 of the 9 dose groups ranging from 0.06 μg/kg to 600 μg/kg.
218999075|NCT07002151|OTHER|educational kinesiology training program intervention for study group|The Educational kinesiology program were included : (Cross crawl) Sit or stand and with the right-hand elbow touch the left knee and vice versa. (The owl) Bring one hand up to the opposite shoulder and hold a pinch around the trapezius muscle between the neck and shoulder. the thumb should be on one side of the muscle and the other fingers clasping around the other side. Turn the head to the same side as thehand is gripping and take a deep breath. Slowly exhale as bringing the head gently around to the other side. Repeat this movement one more time. (The arm activation) Hold one arm next to the ear. Exhale gently while activating the muscles by pushing the arm against the other hand in four directions (front, back, in and away). (The Energizer) Place the head on the desk in front exhale and inhale while coming up and try to hyperextend the neck carefully. (cook's hook-up) put the left ankle over your right knee. Next, hook the right hand around the left ankle.
218999076|NCT07002151|OTHER|conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups|Bimanual coordination,Hand-arm coordination ,Drinking \& Strength training
218999077|NCT07001085|DIAGNOSTIC_TEST|Tumor Tissue Collection and NGS|Tumor tissue is collected during surgery and used for DNA extraction. Next-Generation Sequencing (NGS) is performed to identify oncogenic mutations.
218999078|NCT07001085|OTHER|Blood Collection for Plasma ctDNA|Blood is collected at three time points: one day before surgery, one month, and six months after surgery. Plasma is separated and used for further molecular analysis or storage.
218999079|NCT07001085|DIAGNOSTIC_TEST|ctDNA Mutation Analysis via ddPCR|Circulating tumor DNA (ctDNA) is isolated from plasma samples. Mutations previously identified by NGS are quantitatively analyzed using droplet digital PCR (ddPCR).
218999080|NCT07004426|PROCEDURE|Surgical treatment of renal lesions|Surgical treatment of renal lesions
218999081|NCT06603844|DRUG|CRB-601 monoclonal antibody|CRB-601
218999082|NCT06603844|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD(L)-1 used as per label
218999083|NCT05782361|DRUG|Tepotinib|Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
218999084|NCT05782361|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
218999085|NCT07133152|OTHER|Adverse events|During patient follow-up (hospitalisation + 6 months post-hospitalisation), adverse events will be collected from the patient's computerised medical record (available at the hospital) and by means of a questionnaire carried out by telephone with the patient at 3- and 6-months post-hospitalisation.
218999086|NCT07016360|DRUG|Topical Adapalene Gel 0.1%|Topical adapalene is a retinoid that helps in epidermal changes. Cryotherapy is a liquid nitrogen applied to affected parts for 6 months
218999087|NCT07016360|PROCEDURE|Topical Liquid Nitrogen application|Liquid Nitrogen will be applied to affected parts.
218999088|NCT07015073|DEVICE|Pulsed dye laser (PDL)|Treatment with a pulsed dye laser (PDL) at 595 nm using the VBeam Prima® system (Candela Medical). Parameters: 10 mm spot size, 7-9 J/cm² fluence, 0.5-3 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to one of the three defined regions of each participant's port-wine stain.
218999089|NCT07015073|DEVICE|Potassium titanyl phosphate (KTP) laser|Treatment with a KTP laser at 532 nm using the DermaV® system (Lutronic Medical Systems). Parameters: 10 mm spot size, 8-11 J/cm² fluence, 10 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to a second anatomically comparable region of the port-wine stain.
219557710|NCT02874196|PROCEDURE|Arthro-tomosynthesis|
218999090|NCT07015073|DEVICE|Sequential KTP + PDL laser treatment|Sequential treatment of the same region with two lasers: first with KTP (532 nm, DermaV® system), then with PDL (595 nm, VBeam Prima® system). Each laser will be applied using its standard parameters: KTP (10 mm spot, 8-11 J/cm², 10 ms), followed by PDL (10 mm spot, 7-9 J/cm², 0.5-3 ms). Cryogen spray cooling is used before each pass. No anesthesia is applied. This treatment is administered to a third region of the port-wine stain.
218999091|NCT07015931|DRUG|retinoic acid cream 0.025%|half finger tip unit
218999092|NCT07015931|DRUG|adapalene cream 0.1%|half finger tip unit
218999093|NCT07016503|OTHER|Professional values education|At this stage, a comprehensive literature review was conducted and professional values education was prepared. The prepared education content was transferred to a website for which a domain was purchased within the scope of the research. The developed website was presented to the opinion of a group of 7 experts in terms of content: Child Health and Diseases Nursing Department Faculty Members (4), Nursing Fundamentals Department Faculty Members (1), Public Health Nursing Department Faculty Members (2). Expert opinions were evaluated with the measurement tool prepared by the researchers in line with the literature.
218999094|NCT06680765|BEHAVIORAL|Intervention group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
219182314|NCT07063394|DEVICE|Group 1|Patients in Group 1 will receive standard anesthesia protocol combined with interactive and immersive Virtual Reality (VR) therapy. This includes both engaging in interactive games that require cognitive and motor tasks, such as slicing objects or solving puzzles, and watching immersive 360-degree videos featuring calming environments like natural landscapes. The VR sessions are designed to distract patients from pain perception and reduce anxiety. The intervention will be administered for 3 sessions per day, each lasting 30-45 minutes, over 5 consecutive postoperative days.
219182315|NCT07063394|DEVICE|Group 2|Patients in Group 2 will receive standard anesthesia protocol combined with passive Virtual Reality (VR) therapy. This involves the use of a VR headset to watch immersive 360-degree videos, such as tranquil natural landscapes or underwater scenes, designed to promote relaxation and reduce anxiety. The VR sessions do not require active participation, allowing patients to passively observe calming environments. The intervention will be administered for 3 sessions per day, lasting 30-45 minutes each, over 5 consecutive postoperative days.
218999095|NCT06680765|BEHAVIORAL|Comparison group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
219182316|NCT07062744|DEVICE|Swan-Ganz IQ Pulmonary Arterial catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂).~These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
219369748|NCT03180775|DIETARY_SUPPLEMENT|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219557711|NCT02874196|PROCEDURE|Arthro-tomography|
218999096|NCT06680050|DRUG|Durvalumab (MEDI4736)|Durvalumab will be administered via IV infusion at a dose of 1500 mg on day 8 Q4W until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
218999097|NCT06680050|DRUG|Ceralasertib|Ceralasertib dose will be administered orally, 240mg BID, approximately 12 ± 2 hours apart, days 1 to 7 q28 (Q4W), up to progression or unacceptable toxicity.
218999098|NCT06680050|RADIATION|radiotherapy|Loco-regional recurrences of the primary tumor and regional lymph node metastases will be treated with a total dose of 36 to 50 Gy in daily fractions with a dose of 2 to 3 Gy per fraction. Two weeks from the last dose of radiotherapy, a systemic treatment with durvalumab and ceralasertib will be started.
218999099|NCT02971254|DRUG|Sevoflurane|
218999100|NCT02971254|DRUG|Desflurane|
218999101|NCT07015892|RADIATION|Thoracic Radiotherapy 45 Gy BID|45 Gy delivered in 30 fractions of 1.5 Gy twice daily over three weeks, with 95% of the planning target volume (PTV) receiving at least 95% of the prescribed dose.
218999102|NCT07015892|RADIATION|Thoracic Radiotherapy 60 Gy BID|60 Gy delivered in 40 fractions of 1.5 Gy BID. A minimum dose of 54 Gy will be accepted if organ-at-risk tolerance is exceeded.
218999103|NCT07015892|RADIATION|Thoracic Radiotherapy SIB 45-54 Gy BID|45 Gy in 30 fractions (1.5 Gy BID) to PTV and 54 Gy in 30 fractions (1.8 Gy BID) to high-risk CTV. Both delivered simultaneously using 3D conformal planning.
218999104|NCT07014748|DIAGNOSTIC_TEST|Handheld brain hematoma detector|Near Infrared based handheld traumatic brain hematoma detector
218999105|NCT07016061|OTHER|Motor İmagery Group|Participants will engage in a motor imagery exercise program consisting of 5 minutes of warm-up, 20 minutes of motor imagery, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
218999106|NCT07016061|OTHER|Action Observation Group|Participants will receive an action observation training program delivered by researchers, including 5 minutes of warm-up, 20 minutes of action observation, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
218999107|NCT07016061|OTHER|Exercise Group|Participants will perform a standard physical exercise program. The session will last 30 minutes, including warm-up, exercise, and cool-down phases. The intervention will be administered in three sessions per week for one week.
218999108|NCT07016061|OTHER|Combined Group (Motor Imagery + Action Observation+Exercise)|articipants will engage in a combined motor imagery and action observation program for a total of 30 minutes, incorporating elements of both interventions. The intervention will be administered in three sessions per week for one week.
218999109|NCT00534430|DRUG|busulfan|
218999110|NCT00534430|DRUG|cyclosporine|
218999111|NCT00534430|DRUG|etoposide|
218999112|NCT00534430|DRUG|mycophenolate mofetil|
218999113|NCT00534430|PROCEDURE|allogeneic bone marrow transplantation|
218999114|NCT00534430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218999115|NCT00534430|PROCEDURE|peripheral blood stem cell transplantation|
218999116|NCT00534430|RADIATION|total-body irradiation|
218999117|NCT07016490|DRUG|SSGJ-709|A bispecific antibody targeting PD-1 and LAG-3.
218999118|NCT07015580|OTHER|16S rRNA sequencing|Clinical data including medical history, clinical symptoms, imaging examination, laboratory examination will be collected. 3-5ml saliva sample of every patients will be collected for 16S rRNA sequencing of oral microbiota.
218999119|NCT07014358|DEVICE|Fastening systems by placing two steel pins|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of two steel pins.
218999120|NCT07014358|DEVICE|Fastening systems by a wire in an obenque configuration|Fixation of the osteotomized bone with a stable fixation system, in this case, an obenque configuration
218999121|NCT07014358|DEVICE|Fastening systems by the placement of a bolted plate or the placement of a compression screw|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of a bolted plate or the placement of a compression screw.
218999122|NCT07014735|DRUG|glucose|Participants will receive treatments with glucose or matching placebo (please see study design section).
218999123|NCT07014735|DRUG|moxifloxacin|Participants will receive moxifloxacin or matching placebo (please see study design section).
218999124|NCT06396741|OTHER|The quadriceps muscle will be punctured with ultrasound control|With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
218999125|NCT03921047|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218999126|NCT03921047|OTHER|Laboratory Biomarker Analysis|Correlative studies
218999127|NCT06693687|BEHAVIORAL|Metastatic Cancer|Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
218999128|NCT02155790|DEVICE|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
218999129|NCT06701617|BEHAVIORAL|restorative visual rehabitation|black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
218999130|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
218999131|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
218999132|NCT04109183|DRUG|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
218999133|NCT02041078|PROCEDURE|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
218999134|NCT02041078|PROCEDURE|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
218999135|NCT02856178|DRUG|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
218999136|NCT02856178|DRUG|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
218999137|NCT06634095|BEHAVIORAL|Moulage group|The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
218999138|NCT06895096|DEVICE|Pit Fissure Sealant|Flowable composite is being used for the purpose of sealing pits and fissures which require etching and bonding before application whereas self etch sealants are self adhesive and do not require etching and sealing.
218999139|NCT06760949|PROCEDURE|Direct anterior approach hemiarthroplasty|Direct anterior approach hemiarthroplasty
218999140|NCT06760949|PROCEDURE|Posterior lateral approach hemiarthroplasty|Posterior lateral approach hemiarthroplasty
218999141|NCT05618704|DIETARY_SUPPLEMENT|Hydrolyzed protein infant formula|The subjects will take the formula for 16 weeks
219557712|NCT02874196|PROCEDURE|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
219557713|NCT01685216|BIOLOGICAL|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
219182317|NCT07062744|DEVICE|Swan-Ganz IQ catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂). These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
219182318|NCT07062900|BEHAVIORAL|Low-Intensity Physical Activity|"This includes a structured and progressive 8-week physical activity program involving:~Gentle walking~Portable pedal exerciser~Low-intensity resistance exercises (e.g., resistance bands, seated leg press, hip circles)~Supervised sessions with warm-up and cool-down components"
219182319|NCT07062900|BEHAVIORAL|usual care|Standard Medical Management: Participants continued with their prescribed medications and routine clinical follow-ups for congestive heart failure as directed by their healthcare providers.
219182320|NCT07064252|PROCEDURE|Educational Informed Consent Video|Individualized procedure-specific educational video. Videos are developed by a multidisciplinary collaboration of neurosurgeons, medical educators, and patient advocates. Each video is tailored based on location of the pathology, surgical approach, positioning, anticoagulation intake, and intraoperative adjuncts such as electrophysiology. Each video followes a standardized format covering anatomical considerations, preoperative care, the surgical procedure, and postoperative care including potential complications, expected recovery process, and post-surgery instructions.
218999142|NCT07073365|OTHER|Local Therapy (Surgery or Radiotherapy)|Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.
218999143|NCT07014969|PROCEDURE|En-bloc HoLEP|Removal of the whole adenoma in one piece using laser energy
219182321|NCT07064252|PROCEDURE|Standard informed consent|Standard informed consent, consisting of an in-person verbal consultation with the responsible neurosurgeon supplemented by written documentation and cranial models when applicable
219182322|NCT07062770|DEVICE|Continuous positive airway pressure (CPAP)|Subjects will be administered either 0, 5 or 10 cmH2O
219182323|NCT07062770|OTHER|Mask exhaust port flow|Subjects will be administered varying levels of exhaust flow: 35, 23, 18, 13 and 8 L/s
219182324|NCT07062913|PROCEDURE|Conventional Rehabilitation|A standard rehabilitation program including positioning, range of motion exercises, stretching, strengthening, and conventional transcutaneous electrical nerve stimulation.
219182325|NCT07062913|DEVICE|Contrast Compression Therapy|Contrast compression therapy using a Game Ready® MED4 ELITE device applied to the affected upper extremity with sequential hot and cold phases and pneumatic compression.
219182326|NCT07062913|PROCEDURE|Conventional Rehabilitation|Same standard rehabilitation program as in the control group.
218999144|NCT06780319|PROCEDURE|Standard rehabilitation|rehabilitation with a private physiotherapist. Patients usually undergo 15 rehabilitation sessions, in line with HAS recommendations; the number of sessions can go up to 25, depending on the patient's profile and needs.
218999145|NCT06780319|PROCEDURE|Tele-rehabilitation|Tele-education is a digital home-based intervention involving exercises and education. Patients are monitored remotely by a physiotherapist via a secure messaging system. The system consists of a mobile application for the patient and a web portal enabling the physiotherapist to review patient data (physical activity, pain levels, medication use, exercise adherence, patient-reported results, images, videos) on a daily basis and tailor the protocol accordingly.
218999146|NCT06879639|OTHER|Exercise|The workout routine for the Land Exercise (LE) group will be segmented as follows: A cardio segment (15-20 minutes) involving treadmill walking/running or cycling on the stationary bike; A strength training segment (35 minutes) comprising bench press, seated row, leg extension, squats, pull down, peck-deck, hamstring curls, curl-ups, and back extensions; and a cool-down phase (5-10 minutes) featuring stretching exercises.
218999147|NCT06879639|OTHER|Control|The control group will not receive any formal indication or support to perform structured exercise training but will be allowed to engage in physical activity ad libitum.
218999148|NCT06879639|OTHER|Exercise|The activities for the Water Exercise (WE) group will be divided into segments: An aerobic portion (15-20 minutes) involving water walking and jogging combined with arm movements; A resistance portion (35 minutes) including chest/upper back guidance, chest back press, behind-the-back press, pivoted shoulder press (upper body), and calf lifts, supported squats, outer/inner thigh scissors, and forward and back leg glide (lower body), and finally, a cool-down period (5-10 minutes) comprising stretching exercises.
219182327|NCT07062237|OTHER|Ultrashort abstinence|Ultrashort abstinence: producing a sperm sample after 1 hour of abstinence.
219182328|NCT07062237|OTHER|Standard abstinence|Standard abstinence: producing a sperm sample after 2-5 days of abstinence.
219182329|NCT07064278|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Flexible bronchoscopy to assess airway patency, remove mucous plugs, and collect bronchoalveolar lavage (BAL) fluid for microbiological and cytological analysis.
219182330|NCT07064278|PROCEDURE|Chest CT with Scoring|Chest CT scans at baseline and day 14 to quantitatively assess lesion range, lesion type, pleural effusion, and lymphadenectasis (Total score: 0-13).
219182331|NCT07064278|DIAGNOSTIC_TEST|Monocyte Subpopulation Analysis|Flow cytometry analysis of peripheral blood to phenotype monocyte subsets (Classical, Intermediate, Non-classical) at baseline and day 14 to guide immunomodulatory therapy.
218999149|NCT06872671|OTHER|Experimental: Breathing Exercise Group|Eyes will be closed first. Head and neck will be relaxed. Breathing will be taken through the nose for three seconds. Then the breath will be held for three seconds. In the last step, breath will be exhaled through the mouth for three seconds. The patient will be instructed to take five normal breaths between each breathing exercise. The patient will be asked to count to three and will be told that he/she can count by using his/her fingers. The exercise will be started two minutes before the catheterisation procedure and the patient will be instructed to perform the breathing exercise twice. The patient will be asked to continue doing the breathing exercise until the PIC application process is completed.
218999150|NCT06872671|OTHER|Valsalva Manoeuvre Group|The valsalva manoeuvre will be performed by blowing into a plastic tube connected through a sphygmomanometer. Patients will be allowed to raise the manometer by 30 mmHg for at least 20 seconds. Care will be taken to ensure that the PIC procedure is performed by the same nurse for the patients in the Valsalva manoeuvre group. The nurses performing the PIC procedure will be informed about the research subject and will be told that the patients will start the valsalva manoeuvre before the PIC procedure. Patients who can perform the valsalva manoeuvre by the researcher will be included in the study. Haemodynamic variables (blood pressure, pulse, saturation) of the patients will be recorded before the valsalva manoeuvre. Afterwards, the researcher will instruct the patients to blow into the plastic tube for 20 seconds after a deep breath to create 30 mmHg pressure.
218999151|NCT06751927|BEHAVIORAL|Educational Video|Education video on smoking, nicotine receptor involvement in addiction, craving, withdrawal and mechanisms of action for nicotine replacement and varenicline.
218999152|NCT05610072|DRUG|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
218999153|NCT05610072|DRUG|Hydromorphone|Subjects will receive up to 192 mg oral hydromorphone daily.
218999154|NCT05610072|DRUG|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
218999155|NCT05610072|DRUG|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
218999156|NCT06930534|DEVICE|Swoop Plus Mk2.0|portable brain MRI scanner
218999157|NCT06781255|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
218999158|NCT04419714|DEVICE|TatchSleep|Wearable measurement device
218999159|NCT07133204|OTHER|Investigator developed cream infused with HuangQin extract|A water in oil emulsion with consistency similar to cold cream. Infused with organic extract of scutellaria baicalensis.
218999160|NCT07133009|OTHER|Intentional Relationship Model (IRM) Training|"1 Theory: Brief introduction to the Intentional Relationship Model, therapeutic self-awareness, and explanation of therapeutic styles.~1. Practice: Students share their existing knowledge and thoughts about therapeutic styles, and discuss the practical implications of therapeutic styles that may be relevant to them.~2. Theory: Information about defining interpersonal characteristics and getting to know our clients~2 Practice: Sources of differences in client profiles in the client-therapist relationship, structuring questions appropriately, and practices for getting to know our clients better 3 Theory: Information about potential difficulties that may arise in the therapeutic process 3 Practice: Scenarios are played out about what can be done to address difficulties that may arise in the client-therapist relationship 4 Theory: Information about interpersonal reasoning skills and coping with difficulties 4 Practice: Strategies that can be used to create an appropriat"
218999161|NCT05799729|DRUG|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
218999162|NCT06347484|BEHAVIORAL|EHR-informed Recruitment Method of Contact|The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR
218999163|NCT06347484|BEHAVIORAL|Educational Text-Messages and Connection to Cardiovascular Research Opportunities|All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
218999164|NCT04312126|DEVICE|MRI system|MRI system - GE Discovery MR750 3T
218999165|NCT04312126|DEVICE|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
218999166|NCT06362733|BEHAVIORAL|Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth|This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and parent-mediated intervention with the child.
218999167|NCT05947643|DRUG|theophylline|capsules dissolved in intranasal irrigation
218999168|NCT05947643|DRUG|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
218999169|NCT04023526|DRUG|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
218999170|NCT04023526|DRUG|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
218999171|NCT02940977|OTHER|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
218999172|NCT05857735|OTHER|Observational registry with no intervention.|No intervention
218999173|NCT01373437|DEVICE|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
218999174|NCT02371551|OTHER|Blood/urine sampling|Routine chemistry profile
218999175|NCT02371551|OTHER|Conventional routine CT examination|Standard diagnostic examination
218999176|NCT02371551|OTHER|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
218999177|NCT02371551|OTHER|Functional MRI|Study-specific diagnostic examination
218999178|NCT00015301|DRUG|Methylphenidate|
218999179|NCT05346471|DEVICE|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
218999180|NCT03631472|DEVICE|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
218999181|NCT05952063|DIAGNOSTIC_TEST|Digital Psychological Test: Schema Scale|Thirty-five questionnaire, 5-point likert scale
218999182|NCT02197715|BEHAVIORAL|Computer-adaptive SAFE|
218999183|NCT02197715|BEHAVIORAL|Face-to-face SAFE|
218999184|NCT02197715|BEHAVIORAL|Usual Care|
219182332|NCT07064278|DRUG|Azithromycin, Doxycycline, Prednisone|Sequential azithromycin as baseline therapy. Doxycycline (4 mg/kg/day) was used if BAL results confirmed azithromycin resistance. Oral prednisone (1 mg/kg/day for 5 days) was added if intermediate monocytes were \>15%.
218999185|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
218999186|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
218999187|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
219182333|NCT07064278|OTHER|Supportive Care|Management of cough, wheezing, and fever based on clinical symptoms.
219182334|NCT07062107|PROCEDURE|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery adopts the traditional perfusion system and uses intraoperative optical coherence tomography to assist in observation.
219182335|NCT07062107|PROCEDURE|Phacoemulsification using adaptive fluidics technology|Phacoemulsification surgery adopts the adaptive fluidics system to precisely and dynamically control the pressure and flow rate of the perfusion fluid. During the operation, optical coherence tomography is used to assist in observing the stability of the anterior chamber.
219182336|NCT07063888|RADIATION|Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost|Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative.
219182337|NCT06773325|BEHAVIORAL|Buzzy application|Buzzy application during heel prick blood collection
219182338|NCT06801522|DRUG|0.1% xylometazoline nasal drops|Xylometazoline is direct acting, non selective, adrenergic agonist binding with alpha 1\&2 receptors, used for vasoconstriction to decrease nasal bleeding.
219182339|NCT06801522|DRUG|Adrenaline nasal pack|Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
219182340|NCT05335096|BEHAVIORAL|An AI-chatbot-based mHealth intervention|The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
219182341|NCT05335096|BEHAVIORAL|An attention-chatbot-based mHealth intervention|The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
219182342|NCT05335096|BEHAVIORAL|Educational materials|the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
219182343|NCT05022173|DEVICE|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
219182344|NCT05022173|DEVICE|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
219182345|NCT06806943|DEVICE|avatar-based interactions|SUD patients were investigated using the Autobiographical Memory Test in two conditions: face-to-face and avatar-based interactions. Patients had to recall 6 neutral cue words and 6 substance-related cue words for each condition.
218999188|NCT03217487|PROCEDURE|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
218999189|NCT03217487|PROCEDURE|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
218999190|NCT03217487|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
218999191|NCT03217487|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
219182346|NCT05391230|OTHER|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
219182347|NCT05391230|OTHER|Untreated lesu|Water soaked baby wraps (lesus)
219182348|NCT07062497|DRUG|Rectus Sheath Block|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1%, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
218999192|NCT03019822|DRUG|LSD|100ug per os, single dose
219182349|NCT07062497|DRUG|Rectus Sheath Block with Clonidine|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1% + clonidine 75 mcg, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
219182350|NCT07062172|DIAGNOSTIC_TEST|Low Dose CT Scan|Completed once after screening and eligibility is confirmed.
219182351|NCT06852469|DRUG|Lorazepam 1 mg tablet|Lorazepam is an oral medication which is FDA approved to treat anxiety.
219182352|NCT06852469|DRUG|Placebo tablet|Placebo will match the study drug in mode of administration, color, size, and taste.
218999193|NCT03019822|DRUG|MDMA|125mg per os, single dose
219182353|NCT06234176|BEHAVIORAL|Personalised psychomotor therapy|"The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.~The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.~Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.~The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.~During each session, the participant will be required to complete the Duke health profile."
219182354|NCT06234176|OTHER|Usual treatment|Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
219182355|NCT06864234|DRUG|Saline (NaCl)|IV 0.9% NaCl (5 ml)
219182356|NCT06864234|DRUG|Metoprolol Tartrate|Metoprolol Tartrate (5 ml of 1 mg/ml solution for injection)
219182357|NCT02110212|PROCEDURE|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
219182358|NCT02110212|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
219182359|NCT05388149|DRUG|Neratinib|Neratinib administered as 40mg tablets
219182360|NCT06807112|OTHER|Intravenously administered secretin|16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.
219182361|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
219182362|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
219182363|NCT06913855|DRUG|EMLA Cream|EMLA cream is applied once, 3 hours before the tube is removed. EMLA cream will be applied by the researcher in a thin layer to an area of 7-10 cm2, with the chest tube entrance to the skin remaining in the center. It will be covered with a Tegaderm transparent film dressing.
219182364|NCT06913855|PROCEDURE|Cold application|Cold application will be made with an ice cube pack immediately before the chest tube removal procedure. Cold application will be applied to a 7 cm diameter area, with the chest tube entrance to the skin being considered as the center. Skin temperature will be measured with an infrared thermometer and will be ensured to reach 13.0 degrees. Ice pack application is expected to last approximately 9-10 minutes.
219182365|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
219182366|NCT06279351|DRUG|Thalidomide+cetuximab+FOLFOX/FOLFIRI|Thalidomide+cetuximab+FOLFOX/FOLFIRI
219182367|NCT05013957|DIAGNOSTIC_TEST|Methylation analysis|Methylation analysis
219182368|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
219182369|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
219182370|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
219182371|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
219182372|NCT06325657|BIOLOGICAL|Placebp|Placebo
219182373|NCT04527185|DRUG|Endotoxin|Endotoxin 0.4ng/kg i.v.
219182374|NCT06783452|OTHER|Exercise|"Clinical Pilates Session:~Each clinical Pilates movement will have three difficulty levels: beginner, intermediate, and advanced. The progression criteria for increasing difficulty will be determined by the prevention of compensatory movements, the ability to activate target muscles, achieving more controlled movements during exercise, and maintaining a more stable posture. This program will include standard hip-focused as well as full-body clinical Pilates movements."
219182375|NCT06783452|OTHER|Exercise|"Conventional Therapeutic Exercise Program:~The Conventional Therapeutic Physiotherapy Exercise Program will consist of strengthening exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors. Additionally, stretching exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors, will be included. Stretching exercises will be performed at a pain-free point where tension is felt, holding for 10-30 seconds to achieve a total duration of 60 seconds per muscle group. These exercises will represent standard hip-targeted exercises.~During the exercises, patients will be asked to rate their perceived exertion using the BORG scale (0-10). When the difficulty level reaches 5-6 points, progression will first be achieved by increasing the number of sets, followed by the use of resistance bands."
219182376|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
219182377|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
219182378|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
219182380|NCT06325332|OTHER|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
219557714|NCT02911935|DRUG|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
219557715|NCT02911935|DRUG|Placebo|Placebo suspension
219557716|NCT00645827|OTHER|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
218999194|NCT03019822|DRUG|Amphetamine|40.3mg per os, single dose
218999195|NCT03019822|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs
218999196|NCT00147810|PROCEDURE|Telephone outreach to enhance asthma care|
218999197|NCT05035953|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
218999198|NCT05035953|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
218999199|NCT00000383|BEHAVIORAL|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
218999200|NCT00000383|BEHAVIORAL|Child-Centered Therapy|Client-directed supportive interventions
218999201|NCT00122668|DRUG|non-nucleoside reverse transcriptase inhibitors|
218999202|NCT00122668|DRUG|nucleoside reverse transcriptase inhibitors|
218999203|NCT00122668|DRUG|protease inhibitor|
218999204|NCT05554705|BEHAVIORAL|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
218999205|NCT02194205|DRUG|COMBIVENT HFA|
218999206|NCT02194205|DRUG|Placebo HFA|
218999207|NCT02194205|DRUG|COMBIVENT CFC|
218999208|NCT02194205|DRUG|Placebo CFC|
218999209|NCT04719754|DIAGNOSTIC_TEST|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
218999210|NCT04492202|OTHER|Survey|The survey will be sent to health professionals via online link.
218999211|NCT05659095|OTHER|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
218999212|NCT05871294|DEVICE|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
218999213|NCT05871294|DEVICE|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
218999214|NCT04182360|DRUG|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
218999215|NCT05605314|OTHER|Cyclosporine|eye drop
218999216|NCT05990972|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
218999217|NCT04723745|BEHAVIORAL|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
218999218|NCT04723745|BEHAVIORAL|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
218999219|NCT04723745|BEHAVIORAL|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
219182381|NCT06095817|BEHAVIORAL|Internet Delivered Brief Intervention (IDBI)|The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
219182382|NCT06646432|PROCEDURE|Tunnel with connective tissue graft and injectable platelet rich fibrin|Tunnel with connective tissue graft and injectable platelet rich fibrin
219182383|NCT06646432|PROCEDURE|Tunnel with connective tissue graft only|Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
219182384|NCT05789134|OTHER|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
219182385|NCT04472091|DEVICE|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
219182386|NCT01881048|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Given PO
219182387|NCT01881048|DRUG|Celecoxib|Given PO
219182388|NCT06181344|BEHAVIORAL|FCR screening and referral program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
219182389|NCT06551246|DRUG|Solifenacin|According to randomization.
219182390|NCT06551246|DRUG|Mirabegron|According to randomization.
219182391|NCT06073665|DRUG|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
219182392|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
219182393|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
219182394|NCT06358274|OTHER|Thru-hiking|planning to embark on the Colorado Trail
219182395|NCT06181929|DIAGNOSTIC_TEST|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
219182396|NCT02342249|DRUG|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
219182397|NCT02342249|DRUG|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
219182398|NCT02342249|DRUG|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
219182399|NCT02342249|DRUG|Placebo|Subjects will receive matching placebo of Oseltamivir
219182400|NCT03484078|DEVICE|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
219182401|NCT03484078|DEVICE|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
219182402|NCT06616857|BEHAVIORAL|NUDGE|Individuals in this condition will receive intervention content to promote physical activity.
219182403|NCT06616857|OTHER|Education|Individuals will receive educational materials about how to increase physical activity
219182404|NCT05962606|DRUG|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
219182405|NCT05962606|DRUG|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
219182406|NCT01129102|DRUG|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
219182407|NCT01129102|DRUG|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
219182408|NCT01129102|DRUG|Placebo|Placebo for NPC-01
219182409|NCT06450210|DRUG|psilocybin trihydrate|Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
219182410|NCT06450210|DRUG|Placebo|Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
219182411|NCT05501379|OTHER|No intervention - observational study only|No intervention - observational study only
219182412|NCT06437314|BEHAVIORAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
219182413|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
219182414|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
219182415|NCT05403827|DRUG|Placebo|Vehicle Solution
219182416|NCT03479671|DRUG|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
219182417|NCT00310830|DRUG|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
219182418|NCT04569435|DRUG|ANX005|IV Infusion
219182419|NCT05681962|DIAGNOSTIC_TEST|Bronchoscopy|Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
219182420|NCT03379675|DRUG|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
219182421|NCT03379675|DRUG|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
219182422|NCT03379675|DRUG|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
219182423|NCT05402293|DIAGNOSTIC_TEST|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
219182424|NCT04735653|BEHAVIORAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
219182425|NCT04735653|BEHAVIORAL|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
219182426|NCT05180435|BEHAVIORAL|Family Meals|A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.
219182427|NCT05180435|BEHAVIORAL|Standard|A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
219182428|NCT04638946|BEHAVIORAL|Titration to high intensity exercise (T-HIE)|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate \[220-age\] - resting heart rate)\*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.
219182429|NCT04638946|BEHAVIORAL|Low intensity exercise prescription|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate \[220-age\] - resting heart rate)\*30-39% (lower/upper limit of zone) - resting heart rate.
219182430|NCT03371381|BIOLOGICAL|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
219182431|NCT03371381|DRUG|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
219182432|NCT05961982|PROCEDURE|Chemical Ablation|Undergo EUS-guided chemoablation
219182433|NCT05961982|PROCEDURE|Computed Tomography|Undergo CT
219182434|NCT05961982|OTHER|Electronic Health Record Review|Ancillary studies
219182435|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
219182436|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
219182437|NCT05961982|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
219182438|NCT05961982|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/MRCP
219182439|NCT03628924|DRUG|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
219182440|NCT03628924|DRUG|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
219182441|NCT03628924|DRUG|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
219182442|NCT03628924|DRUG|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
219182443|NCT04305548|DRUG|Trabectedin|Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
219182444|NCT05058560|DRUG|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
219182445|NCT05435014|DRUG|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
219182446|NCT05435014|DRUG|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
219182447|NCT01539083|DRUG|Thalidomide|Thalidomide 100 mg tablet, orally.
219182448|NCT01539083|DRUG|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
219182449|NCT01539083|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 orally.
219182450|NCT01539083|DRUG|Dexamethasone|Dexamethasone 20 mg orally.
219182451|NCT01539083|DRUG|Prednisolone|Prednisolone 50 mg orally.
219182452|NCT06802744|DEVICE|Addition of an artificial air-pocket device during simulated avalanche burial|In contrast to the control group, the subjects in this arm are provided with a functioning device that directs the exhaled air away from the area of the respiratory cavity.
219182453|NCT06802744|DEVICE|Addition of a non-functioning artificial air-pocket device during simulated avalanche burial|In contrast to the intervention arm, the subjects in this arm are provided with a non-functioning artificial air-pocket device which does not redirect the exhaled air away from the breathing-cavity.
219182454|NCT05254262|PROCEDURE|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
219182455|NCT06802107|BEHAVIORAL|Backward-treadmill Walking|A backward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
219182456|NCT06802107|BEHAVIORAL|Forward-treadmill Walking|A forward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
219182457|NCT06802107|OTHER|Traditional physiotherapy|"Traditional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.~To be done 3 times a week / 8 weeks. 20 min hotpack + 7 min ultrasound + 20 min TENS and knee osteoarthritis exercises (hip knee flexion extension, knee extension while sitting on a chair, quadriceps isometric exercise in the supine position, straight leg raise exercises) are planned to be applied in the clinic with the physiotherapist. The exercises are planned to be started with 5 repetitions in the first week and the intensity of the exercise is planned to be increased with 10 repetitions, 15 repetitions and 20 repetitions depending on the patient's tolerance."
219182458|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
219182459|NCT06042309|OTHER|SLS|Exposure to SLS on a randomized arm
219182460|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
219182461|NCT06042309|OTHER|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
219182462|NCT02318654|OTHER|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
219182463|NCT02318654|DRUG|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
219182464|NCT04439019|OTHER|Lifestyle and dietary modification program|"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown."
219182465|NCT06464510|DRUG|Early Vasopressin|Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
219182466|NCT06464510|DRUG|Norepinephrine and Vasopressin for Rescue|Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
219182467|NCT06324071|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
219182468|NCT06324071|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
219182469|NCT06415773|DRUG|HTD1801|HTD1801 1000 mg BID administered orally BID as four capsules
219182470|NCT06415773|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablet administered orally QD
219182471|NCT06284213|OTHER|No interventions|This is an observational study with no interventions.
219182472|NCT03340519|DEVICE|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
219182473|NCT05177692|DEVICE|Vguard|VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
219182474|NCT04847843|BEHAVIORAL|Mindfulness Orientated Recovery Enhancement|The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.
219182475|NCT04847843|BEHAVIORAL|Control Intervention|The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
219182476|NCT05652179|DRUG|Stellate ganglion block|After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.
219182477|NCT05554211|DRUG|Tranexamic acid|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
219182478|NCT05554211|DRUG|Normal saline|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
219182479|NCT04463576|OTHER|Discharge Prescription|All hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions of the Bordeaux and Rennes University Hospital and Georges Pompidou European Hospital will be recorded between June 1, 2018 and June 1, 2019.
219182480|NCT05833542|BEHAVIORAL|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
219182481|NCT05833542|BEHAVIORAL|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
219182482|NCT06258564|BIOLOGICAL|vaccination against human papillomavirus infection (HPV vaccination)|Women with or without HPV vaccination before or after excision
219182483|NCT02175342|DRUG|Tiotropium 0.625 mcg/puff|
219182484|NCT02175342|DRUG|Tiotropium 1.25 mcg/puff|
219182485|NCT02175342|DRUG|Tiotropium 2.5 mcg/puff|
219182486|NCT02175342|DRUG|Tiotropium 5 mcg/puff|
219182487|NCT02175342|DRUG|Placebo solution|
219182488|NCT02175342|DRUG|Tiotropium-18 lactose powder|
219182489|NCT02175342|DRUG|Placebo lactose powder|
219182490|NCT02175342|DRUG|Tiotropium 10 mcg/puff|
219182491|NCT02175342|DEVICE|Respimat|
219182492|NCT02175342|DEVICE|Handihaler|
218999220|NCT04723745|BEHAVIORAL|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
218999221|NCT04723745|BEHAVIORAL|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
219182493|NCT05373719|OTHER|No intervention; observational|No intervention; observational
219182494|NCT06019559|DRUG|K-757 120 mg BID and K-833 100 mg BID|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally."
219182495|NCT06019559|DRUG|K-757 120 mg BID and matching placebo to K-833|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally."
219182496|NCT06019559|DRUG|Matching placebo to K-757 and matching placebo to K-833|Both administered orally.
219182497|NCT04094844|OTHER|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
219182498|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets
219182499|NCT04094844|OTHER|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
219754204|NCT07125742|OTHER|Fennel Tea|Fennel Tea: The fennel tea group received 2 g of fennel steeped in 150 ml boiling water for 10 minutes.
219754205|NCT07125742|OTHER|Ginger Tea|Ginger Tea: The ginger tea group received 2 g of fresh ginger steeped in 150 ml boiling water for 10 minutes.
219754206|NCT04756531|DRUG|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
219754207|NCT04756531|DRUG|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
218999222|NCT04723745|BEHAVIORAL|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
218999223|NCT00785668|DRUG|AER 001|10 mg dry powder administered using a handheld device
218999224|NCT01652898|DRUG|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
218999225|NCT01652898|DRUG|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
219754208|NCT04756531|DRUG|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
219754209|NCT04756531|DRUG|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
219754210|NCT04756531|DRUG|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
219754211|NCT04756531|DRUG|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
218999226|NCT01652898|DRUG|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
218999227|NCT00638378|DRUG|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
218999228|NCT00023634|BIOLOGICAL|KLH|100 mcg w/EGFRvIII
218999229|NCT00023634|BIOLOGICAL|GMCSF|arm 1: 100 mcg w/EGFRvIII
219754212|NCT02375828|DRUG|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
218999230|NCT01929278|DRUG|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
218999231|NCT01929278|OTHER|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
218999232|NCT01929278|OTHER|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
218999233|NCT02559245|OTHER|Descurainia Sophia|
218999234|NCT02559245|OTHER|Ficus carica|
218999235|NCT06289608|OTHER|No intervention|No dental intervention was made. Only a clinical examination
219754213|NCT06854016|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
218999236|NCT05519540|DRUG|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese) received a single oral dose of 200mg xevinapant (Debio 1143) on Day 1 under fasted condition.
218999237|NCT06259266|OTHER|Anti-reflux valve for dialysis catheter|
218999238|NCT00079118|DRUG|docetaxel|
218999239|NCT00079118|DRUG|irinotecan hydrochloride|
218999240|NCT02114814|BEHAVIORAL|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
218999241|NCT02114814|BEHAVIORAL|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
218999242|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
218999243|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
218999244|NCT00766337|DRUG|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
218999245|NCT05385731|OTHER|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218999246|NCT05385731|OTHER|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218999247|NCT05385731|OTHER|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
218999248|NCT00819611|BEHAVIORAL|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
218999249|NCT00819611|BEHAVIORAL|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
218999250|NCT00125294|DRUG|Methadone|
218999251|NCT00319865|DRUG|Velcade|
218999252|NCT00319865|DRUG|Thalidomide|
218999253|NCT00319865|DRUG|Adriamycin|
218999254|NCT00319865|DRUG|Dexamethasone|
218999255|NCT00854477|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
218999256|NCT04654130|OTHER|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
218999257|NCT04758780|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
219754214|NCT06854016|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
218999258|NCT01693653|DRUG|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
218999259|NCT04540601|OTHER|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
218999260|NCT04655391|DRUG|Bosutinib Monohydrate|Given PO
218999261|NCT04655391|DRUG|Decitabine|Given IV
218999262|NCT04655391|DRUG|Enasidenib Mesylate|Given IV
218999263|NCT04655391|DRUG|Gilteritinib Fumarate|Given PO
218999264|NCT04655391|DRUG|Glasdegib Maleate|Given PO
218999265|NCT04655391|DRUG|Ivosidenib|Given PO
218999266|NCT04655391|DRUG|Venetoclax|Given PO
218999267|NCT04388709|DRUG|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
218999268|NCT05131698|COMBINATION_PRODUCT|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
218999269|NCT05433805|OTHER|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
218999270|NCT01204853|DRUG|Sitaxentan|sitaxentan sodium 100 mg
218999271|NCT03304743|DIAGNOSTIC_TEST|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
218999272|NCT01304316|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
218999273|NCT05524038|DRUG|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
218999274|NCT05524038|DEVICE|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
218999275|NCT05524038|DRUG|Dexamethasone|injection of 4mg dexamethasone in each block
218999276|NCT05524038|DEVICE|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
218999277|NCT01213745|OTHER|Intervention|
219369749|NCT03180775|DIETARY_SUPPLEMENT|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
218999278|NCT01213745|OTHER|Attention|
218999279|NCT01213745|OTHER|Control|
218999280|NCT02937909|OTHER|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
218999281|NCT04700371|DEVICE|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
218999282|NCT04700371|DEVICE|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
218999283|NCT04397107|DRUG|IL-2|Patients were received low dose recombinant human Interleukin-2
218999284|NCT05625087|DRUG|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
218999285|NCT05625087|DRUG|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
218999286|NCT02563444|DEVICE|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
218999287|NCT02936570|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
218999288|NCT04109794|PROCEDURE|E-CTG|Envelope connective tissue graft
218999289|NCT03284944|DEVICE|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
218999290|NCT03284944|DEVICE|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
218999291|NCT05276401|DRUG|5% Bisphosphocin Topical Gel|Topical Gel
218999292|NCT05276401|DRUG|Placebo Topical Gel|Topical Gel
218999293|NCT05276401|DRUG|10% Bisphosphocin Topical Gel|Topical Gel
219754215|NCT06854016|OTHER|RICE and physiotherapy/exercise protocol|RICE plus physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes: for the first 2 weeks RICE protocol performed daily at home by the patient, for the following 4 weeks a physiotherapy/exercise protocol will be performed at site with 2 sessions per week.
218999294|NCT04334031|GENETIC|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
218999295|NCT04334031|OTHER|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
218999296|NCT00607971|DRUG|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
218999297|NCT05607277|PROCEDURE|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
218999298|NCT02050529|DRUG|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
218999299|NCT02050529|DRUG|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
218999300|NCT04184869|DRUG|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
218999301|NCT04184869|DRUG|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
218999302|NCT02255604|DRUG|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
218999303|NCT02255604|DRUG|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
218999304|NCT02255604|DRUG|0.1 ml Isoton saline|4 injection into a lymphnode
218999305|NCT05415839|DEVICE|Laser|Laser
218999306|NCT04410211|DRUG|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
218999307|NCT04410211|DRUG|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
218999308|NCT05954013|BEHAVIORAL|PD_Pal intervention|The PD\_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD\_Pal intervention, i.e. the PD\_Pal nurse. In the PD\_Pal intervention, the patient, family caregiver and PD\_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD\_Pal nurse.
218999309|NCT01411774|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
218999310|NCT01411774|DRUG|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
218999311|NCT01411774|DRUG|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
218999312|NCT02466178|DEVICE|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
218999313|NCT02531906|DRUG|Gabapentin|Given PO
218999314|NCT02531906|DRUG|Methadone Hydrochloride|Given PO
218999315|NCT02531906|DRUG|Oxycodone Hydrochloride|Given PO
218999316|NCT02531906|OTHER|Quality-of-Life Assessment|Ancillary studies
218999317|NCT02531906|OTHER|Questionnaire Administration|Ancillary studies
218999318|NCT02403492|DEVICE|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
218999319|NCT02403492|DEVICE|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
218999320|NCT02403492|DEVICE|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
218999321|NCT00279591|DEVICE|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
218999322|NCT00279591|DEVICE|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
219182500|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system with Positive Activities|Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
219182501|NCT06166433|BEHAVIORAL|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
219182502|NCT06458959|BEHAVIORAL|PEM+|The Young Children's Participation in Environment Measure (YC-PEM), an evidence-based and promising electronic patient-reported outcome (e-PRO) when combined with the Participation and Environment Measure Plus (PEM+) care planning application that yields a summary report and is paired with a program-specific decision-support tool, may support family engaged Early Intervention (EI) service plan development. Intervention group caregivers will complete the YC-PEM e-PRO and PEM+ intervention before their child's annual review of progress. The online summary report will be combined with a program-specific decision-support tool to guide EI service plan development.
219182503|NCT04551040|DRUG|Terazosin|Terazosin 1 mg oral capsule
219182504|NCT03476655|DRUG|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
219182505|NCT04629469|DIAGNOSTIC_TEST|Hyperfine MRI|• Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
219182506|NCT06533566|PROCEDURE|Erector spinae plane block|patients will be placed in the lateral decubitus position. The ESP block is usually performed at the level of fourth transvers process. The ultrasound probe should be placed in a cephalo-caudal orientation over the midline of the back at the desired level.Under aseptic conditions, the block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T4 transverse process at erector spinae plane. After hydro-dissection with 2-3 mL of isotonic saline solution to confirm the correct needle tip position and after negative aspiration to prevent intra vascular injection or position, (20 ml) of plain bupivacaine 0.25% will be injected deep to the erector spinae muscle.
219182507|NCT06533566|PROCEDURE|local wound infiltration|after the surgeon complete the surgery and insert the surgical drains (pectoral and axillary drains) we will inject 20ml of plain bupivacaine 0.25% in each surgical drain, the drains will be clamped for 20 minutes then declamped.
219182508|NCT04711733|OTHER|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
218999323|NCT06102239|DIAGNOSTIC_TEST|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium \&c-reactive protein as indicator of complicated appendicitis
218999324|NCT00056316|BEHAVIORAL|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
218999325|NCT00056316|BEHAVIORAL|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
218999326|NCT05813951|DRUG|Linezolid|linezolid either continues infusion or standard intermittent dose
218999327|NCT04766580|BEHAVIORAL|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
218999328|NCT00231075|DRUG|Paraplatin|
218999329|NCT00231075|DRUG|Paclitaxel|
218999330|NCT02038023|DRUG|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
218999331|NCT04847362|BEHAVIORAL|Experimental|education group
218999332|NCT04413396|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
219182509|NCT04711733|OTHER|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~* Pediatric Quality of Life Inventory Cancer module~* Screen for Child Anxiety Related Emotional Disorders Revised~* Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~* 36-Item Short Form Health Survey~* Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
219182510|NCT04711733|OTHER|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~\- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
219182511|NCT06505499|OTHER|Gait Profile Score|Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009).
219182512|NCT06505499|OTHER|Gait Visual Score|Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009)
219182513|NCT05695924|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
219182514|NCT05695924|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
219182515|NCT05378100|DRUG|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
219182516|NCT05378100|DRUG|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
219182517|NCT06215521|DRUG|Pirtobrutinib|Administered orally
219182518|NCT06215521|DRUG|Placebo|Administered orally
219182519|NCT06215521|DRUG|Moxifloxacin|Administered orally
219182520|NCT06113068|DEVICE|Fistura® procedure|The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
219182521|NCT04165330|DRUG|AL3818|"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."
219182522|NCT04165330|DRUG|Nivolumab Injection|Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
219182523|NCT05504317|DRUG|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
219182524|NCT05504317|DRUG|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
219182525|NCT01814813|BIOLOGICAL|HSPPC-96|intradermal infusion
219182526|NCT01814813|DRUG|bevacizumab|intravenous
219182527|NCT05810129|OTHER|concentric-eccentric strength training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
219182528|NCT05810129|OTHER|eccentric strength training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
219182529|NCT05810129|OTHER|standard physical therapy|Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
219182530|NCT06232109|DRUG|Fluvoxamine|Oral
219182531|NCT06232109|DRUG|Itraconazole|Oral
219182532|NCT06232109|DRUG|Paroxetine|Oral
219182533|NCT06232109|DRUG|ASN51|Oral
219182534|NCT06233578|DEVICE|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
219182535|NCT03821779|BEHAVIORAL|In vivo social exposure|Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.
219182536|NCT03821779|BEHAVIORAL|Social exposure in a virtual reality setting|Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.
219182537|NCT03821779|OTHER|EEG recording|EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control
218999333|NCT03150615|OTHER|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
218999334|NCT03150615|OTHER|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
218999335|NCT03150615|DEVICE|nasojejunal tube insertion|
218999336|NCT03150615|OTHER|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
218999337|NCT05611398|PROCEDURE|Orthopedic Surgery|A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
218999338|NCT05798650|BEHAVIORAL|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
218999339|NCT01456247|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
218999340|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
218999341|NCT01456247|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
218999342|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
218999343|NCT01456247|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
218999344|NCT01456247|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
218999345|NCT00712127|OTHER|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
218999346|NCT00712127|OTHER|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
218999347|NCT06334510|BIOLOGICAL|One dose of quadrivalent influenza virus split vaccine was administered|"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
218999348|NCT06081257|DIETARY_SUPPLEMENT|"KB-120 small molecular nutrient and vitamin E"|"The experimental group was given oral KB-120 small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles"
218999349|NCT06081257|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
218999350|NCT03021122|DEVICE|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
218999351|NCT03021122|DEVICE|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
218999352|NCT00585728|PROCEDURE|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
218999353|NCT04673162|DRUG|Methylprednisolone, Placebo|iv administration
218999354|NCT05377983|OTHER|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
218999355|NCT04370405|DRUG|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
218999356|NCT04014712|DRUG|Tetrahydrobiopterin|Oral, Single dose
218999357|NCT04014712|DRUG|Placebo oral tablet|Single dose
218999358|NCT02990910|DRUG|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
218999359|NCT02990910|DEVICE|conventional opioid analgesia|(b) all received 25μg/kg morphine
218999360|NCT02893514|OTHER|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
219182538|NCT03821779|DIAGNOSTIC_TEST|Psychometric evaluation|"Subjects will be evaluated prior to inclusion using the following assessment tools~* Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire~* Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses)~* Liebowitz Social Anxiety Scale (LSAS)~* Montgomery Asberg Depression Rating Scale (MADRS)~* Brief Anxiety Scale of Tyrer (BAS)~* State-Trait Anxiety Inventory (STAI A-B)~* Global Assessment of Functioning (GAF)"
219182539|NCT03821779|DIAGNOSTIC_TEST|Visual Analogue Scale of anxiety|"Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)"
219182540|NCT03109210|BEHAVIORAL|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
219182541|NCT03109210|BEHAVIORAL|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
219182542|NCT03858634|DRUG|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
219182543|NCT03858634|DRUG|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
219182544|NCT04676763|DRUG|Substance P|Participants will receive Substance P
219182545|NCT04676763|DRUG|Normal Saline|Participants will receive normal saline as Negative control
219182546|NCT04676763|DRUG|Histamine|Participants will receive histamine as Positive control
219182547|NCT03150173|BEHAVIORAL|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
219182548|NCT03150173|BEHAVIORAL|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
219182549|NCT03150173|DRUG|Buprenorphine|all participants will receive buprenorphine
219182550|NCT06384560|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.
219182551|NCT06384560|DRUG|Folfirinox|FOLFIRINOX is a combination of systemic chemotherapy agents. FOLFIRINOX consists of oxaliplatin at a dose of 85 mg/m2, given as a 2-hour intravenous infusion, immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector. This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks. (The FOLFIRINOX given in the trial is the modified scheme, whereby the fluorouracil bolus at a dose of 400 mg/m2 is omitted and the irinotecan dose reduced to 150 mg/m2).
219182552|NCT06384560|RADIATION|SABR|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on five non-consecutive days.
219182553|NCT06453512|DEVICE|Doublebase Once|Emollient
219182554|NCT05135390|DRUG|HSK21542|three times per week
219182555|NCT05135390|DRUG|Placebo|three times per week
219182556|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
219182557|NCT05366465|OTHER|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
219182558|NCT06646562|DRUG|Cabotegravir LA + Rilpivirine LA|Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
219182559|NCT03443128|DRUG|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
219182560|NCT05322031|DRUG|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
219182561|NCT05424276|DRUG|IkT-148009|Oral administration gelatin capsule
219182562|NCT05424276|DRUG|Placebo|Oral administration gelatin capsule
219182563|NCT06184568|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
219182564|NCT06184568|DRUG|Semaglutide|Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
219182565|NCT05556655|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
219557717|NCT00645827|OTHER|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
219182566|NCT06141850|BEHAVIORAL|COVID-19 Test Reporting|Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.
219182567|NCT06141850|BEHAVIORAL|Personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.
219182568|NCT06141850|BEHAVIORAL|Non-personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
219182569|NCT06180902|DIAGNOSTIC_TEST|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'."
219182570|NCT06180902|DIAGNOSTIC_TEST|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP \> 12 mmHg (16.3 cm H2O) indicates a non-responder."
219182571|NCT06180902|DIAGNOSTIC_TEST|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP \> 12 mmHg (16.3 cm H2O)."
219182572|NCT06180902|DIAGNOSTIC_TEST|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase \> 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement \> 12 mmHg (16.3 cm H2O)."
219182573|NCT06180902|PROCEDURE|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
219182574|NCT02852330|DEVICE|SA16 research software|Software for measurement of voltage tomography intraoperatively.
219182575|NCT02852330|DEVICE|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
219182576|NCT03507842|DRUG|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
219182577|NCT03507842|DRUG|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
219182578|NCT03507842|DRUG|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
219182579|NCT06725602|DEVICE|"TQ - Proximal Application (high and tight)"|"Tourniquet application: proximal (high and tight) on arms and thighs."
219182580|NCT06725602|DEVICE|TQ - Controlled application (2-3 inches)|TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.
219182581|NCT04482140|DEVICE|Genta-Foil resorb®|Use of Genta-Foil resorb® to prevent adhesions in patients undergoing hand surgery
219182582|NCT04950075|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
219182583|NCT04950075|DRUG|Placebo|Placebo
219182584|NCT05967247|OTHER|The experimental group used App for MBSR intervention|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
219182585|NCT05967247|OTHER|"the Heart Care Life app"|"Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app."
219182586|NCT05967247|OTHER|APP|APP
219182587|NCT06018233|OTHER|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
219182588|NCT05659654|DRUG|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
219182589|NCT04016662|DEVICE|Tandem t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
219182590|NCT04467723|DRUG|Atezolizumab|Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
219182591|NCT01802788|DEVICE|St Jude Medical Portico replacement aortic valve|
219182592|NCT01802788|PROCEDURE|Transcatheter Aortic Valve Implant|
219182593|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
219182594|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
219182595|NCT05170386|OTHER|Cognitive training Therapy|"Cognitive training Therapy include: Writing the reminiscences~• Solving a table• Writing a letter making a calendar and writing a note about the daily activities on it Facing patients' fears instead of avoiding them.Using role-playing to prepare for potentially problematic interactions with others.Learning to calm one's mind and relax one's body."
219182596|NCT05170386|OTHER|instructive conventional treatment|instructive conventional treatment breathing relaxation exercise inform of diaphragmatic breathing Practice sleep hygiene such as keeping a regular sleep schedule. Get regular exercise. Minimize noise. Minimize light. Manage the temperature so that you're comfortable.
219182597|NCT06335043|GENETIC|Pharmacogenetics Testing|Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
219182598|NCT06201156|DEVICE|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
219182599|NCT05268809|OTHER|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
219182600|NCT03021096|OTHER|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
219182601|NCT01192048|OTHER|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
219182602|NCT04322864|OTHER|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
219182603|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
219182604|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
219182605|NCT05988788|OTHER|Epigallocatechin-3-gallate|to be used as a root canal irrigant
219182606|NCT05988788|OTHER|sodium hypochlorite|to be used as a root canal irrigant
219182607|NCT05082116|DRUG|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
219182608|NCT03478553|OTHER|Blood draw|Blood draw
219182609|NCT03478553|OTHER|Questionnaire|Pulmonary Fibrosis Questionnaire
219182610|NCT04379596|DRUG|Fluorouracil (5-FU)|5-FU: administered as an IV infusion
219182611|NCT04379596|DRUG|Capecitabine|Capecitabine: administered orally
219182612|NCT04379596|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
219182613|NCT04379596|DRUG|Oxaliplatin|Oxaliplatin: administered as an IV infusion
219182614|NCT04379596|BIOLOGICAL|Trastuzumab|Trastuzumab: administered as an IV infusion
219182615|NCT04379596|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
219182616|NCT04379596|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
219182617|NCT04379596|BIOLOGICAL|Pembrolizumab|Pembrolizumab: administered as an IV infusion
219182618|NCT04379596|BIOLOGICAL|Volrustomig|Volrustomig: administered as an IV infusion
219182619|NCT04379596|BIOLOGICAL|Rilvegostomig|Rilvegostomig: administered as an IV infusion
219182620|NCT06055842|OTHER|over-denture|implant retained overdenture prosthesis.
219182621|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
219182622|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
219182623|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
219182624|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
219182625|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
219182626|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
219182627|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
219182628|NCT03192280|DEVICE|iPhone 7|Smart phone
219182629|NCT05382650|BIOLOGICAL|Human rabies immune globulin 300 IU/mL|All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
219182630|NCT04573517|PROCEDURE|Amniotomy|Artificial rupture of amniotic membranes
219182631|NCT04573517|DEVICE|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
219182632|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
219182633|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
219182634|NCT03586414|DIETARY_SUPPLEMENT|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
219182635|NCT03586414|DIETARY_SUPPLEMENT|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
219182636|NCT03604302|DEVICE|fMRI Paradigms|T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
219182637|NCT03655886|PROCEDURE|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
219182638|NCT03655886|RADIATION|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
219182639|NCT04821817|DRUG|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
219182640|NCT04821817|DRUG|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
219006880|NCT04762433|DEVICE|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
219182641|NCT03904147|DEVICE|TriClipTM Device|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
219182642|NCT06074497|DRUG|KGX101- Cohort -1|Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
219182643|NCT06074497|DRUG|KGX101- Cohort 1|Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
219182644|NCT06074497|DRUG|KGX101- Cohort 2|Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
219182645|NCT06074497|DRUG|KGX101- Cohort 3|Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
219182646|NCT06074497|DRUG|KGX101- Cohort 4|Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
219182647|NCT06074497|DRUG|KGX101- Cohort 5|Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
219182648|NCT06074497|DRUG|KGX101 and Envafolimab|Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
219182649|NCT03583866|DRUG|Candesartan|7 days of Candesartan (16mg/day)
219182650|NCT03583866|DRUG|Placebo|7 days of Placebo
219182651|NCT00769223|OTHER|medical chart review|
219182652|NCT00769223|OTHER|questionnaire administration|
219182653|NCT00769223|PROCEDURE|quality-of-life assessment|
219182654|NCT00769223|RADIATION|brachytherapy|
219182655|NCT00769223|RADIATION|radiation therapy|
219182656|NCT01037881|DRUG|LEO 29102|comparison of different dosages of drug
219182657|NCT01037881|DRUG|Elidel®|comparison
219182658|NCT05775497|BEHAVIORAL|Behavioral weight loss intervention (Online; Rx Weight Loss)|Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
219182659|NCT05775497|BEHAVIORAL|Minority stress intervention|The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
219182660|NCT05775497|BEHAVIORAL|Social support intervention|The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
219182661|NCT05775497|BEHAVIORAL|Negative body image intervention|The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
219182662|NCT04477460|DIETARY_SUPPLEMENT|Thickened feeds|Thickened feeds directed by medical team
219182663|NCT04477460|DIETARY_SUPPLEMENT|Non-thickened feeds|Non-thickened feeds directed by medical team
219182664|NCT00764751|DRUG|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
219182665|NCT00764751|DRUG|Dovonex® cream|Twice daily application
219182666|NCT00764751|DRUG|Cream vehicle|Twice daily application
219182667|NCT04563546|OTHER|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
219369750|NCT03180775|DIETARY_SUPPLEMENT|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219369751|NCT03180775|DIETARY_SUPPLEMENT|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219006881|NCT00418314|DEVICE|Control|Empiric programming or one-time optimization using a non-IEGM method.
219006882|NCT00418314|DEVICE|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
219006883|NCT00193154|DRUG|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
219006884|NCT00193154|DRUG|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
219006885|NCT02272920|PROCEDURE|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
219006886|NCT00507962|DRUG|Cisplatin|100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
219006887|NCT00507962|DRUG|Liposomal Doxorubicin|Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
219006888|NCT00931762|DRUG|Panobinostat|Panobinostat oral capsules
219006889|NCT04049396|OTHER|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
219182668|NCT05243680|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
219182669|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
219182670|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
219182671|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
219182672|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
219182673|NCT02775500|DRUG|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
219182674|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
219182675|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
219182676|NCT03011333|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
219182677|NCT03011333|DRUG|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
219182678|NCT03011333|DRUG|Saline Placebo|Saline placebo via nerve block.
219182679|NCT05008042|DRUG|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
219182680|NCT05008042|OTHER|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
219182681|NCT04876053|BEHAVIORAL|Healthy Food Delivery Intervention|Each weekly food box will include \~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
219182682|NCT04831580|DEVICE|da Vinci|Minimally invasive robotic-assisted radical or simple hysterectomy
219182683|NCT04831580|OTHER|open surgery|open radical or simple hysterectomy
219182684|NCT04089943|PROCEDURE|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
219182685|NCT04089943|OTHER|Control group|Healthy non-PAD participants will be recruited for the study.
219182686|NCT04844931|PROCEDURE|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
219182687|NCT04844931|PROCEDURE|Standard PCI|Standard PCI
219182688|NCT05554848|DRUG|Dexmedetomidine|dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
219182689|NCT05554848|DRUG|Magnesium sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
219182690|NCT06382402|RADIATION|CCTA scan|• CCTA will be performed per the standard clinical protocol using a Cannon Aquilion ONE scanner with 16 cm z-axis coverage at 0.5 mm resolution, low contrast, and reduced radiation dose requirements.
219182691|NCT03739853|DRUG|Methotrexate|Used in all three arms of study
219182692|NCT03739853|DRUG|Sulfasalazine|Used in arm 2 of study
219182693|NCT03739853|DRUG|Leflunomide|Used in arm 2 of study
219182694|NCT03739853|DRUG|Adalimumab|Used in arm 3 of the study only
219182695|NCT03977662|COMBINATION_PRODUCT|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
219369752|NCT03180775|DIETARY_SUPPLEMENT|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219182696|NCT04039347|DRUG|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
219182697|NCT04039347|DRUG|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
219182698|NCT04100174|RADIATION|focal brachytherapy boost to SBRT|As above
219182699|NCT05504850|OTHER|Multicultural Health Diet|The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
219182700|NCT04817891|DEVICE|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
219182701|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
219182702|NCT03298477|DEVICE|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
219182703|NCT06412315|DRUG|Citalopram|Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
219182704|NCT06412315|DRUG|Placebo|Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
219182705|NCT02171650|DRUG|BIBW 2992|
219182706|NCT05440708|DRUG|TTI-101|Oral tablet
219182707|NCT05440708|DRUG|Pembrolizumab|Intravenous (IV) infusion
219182708|NCT05440708|DRUG|Atezolizumab|Intravenous (IV) infusion
219182709|NCT05440708|DRUG|Bevacizumab|Intravenous (IV) infusion
219182710|NCT04198454|OTHER|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
219182711|NCT04198454|OTHER|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
219182712|NCT04198454|DEVICE|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
219182713|NCT02809443|BIOLOGICAL|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
219182714|NCT02802618|OTHER|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
219182715|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume \~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
219182716|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
219182717|NCT00082745|OTHER|Laboratory Biomarker Analysis|Correlative studies
219182718|NCT00082745|OTHER|Questionnaire Administration|Ancillary studies
219182719|NCT02998268|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219182720|NCT02998268|DRUG|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
219182721|NCT02998268|DRUG|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
219182722|NCT05950191|OTHER|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
219182723|NCT05950191|OTHER|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
219182724|NCT05950191|BEHAVIORAL|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
219182725|NCT06458400|DRUG|Tegileridine|single dose+PCA dose
219182726|NCT06458400|DRUG|Oliceridine|single dose+PCA dose
219182727|NCT06458400|DRUG|Morphine|single dose+PCA dose
219182728|NCT06393790|BEHAVIORAL|FMG (Fibromyalgia group)|This intervention will report results of a strength training programme in people with fibromyalgia
219182729|NCT06393790|BEHAVIORAL|HG (Healthy group)|This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
219182730|NCT06407089|OTHER|Spinertial Group|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
219182731|NCT04433351|DEVICE|Enriched rehabilitation|"The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter."
219182732|NCT04433351|DEVICE|Simple rehabilitation|The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
219182733|NCT04880590|OTHER|Sex intercourse|A heterosexual sexual relationship
219182734|NCT05269667|DRUG|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
219182735|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks."
219182736|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed on the vertex target location."
219182737|NCT05215548|PROCEDURE|therapeutic thoracic surgery|The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
219182738|NCT05215548|DRUG|Afatinib|The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
219182739|NCT06249945|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
219182740|NCT06249945|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
219182741|NCT04794868|DIAGNOSTIC_TEST|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
219182742|NCT04794868|DIAGNOSTIC_TEST|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
219182743|NCT06584071|DRUG|PM8002|PM8002 via IV infusion, Q3W
219182744|NCT06584071|DRUG|PM1009|PM8002 via IV infusion, Q3W
219182745|NCT06584071|DRUG|atezolizumab|atezolizumab,1200mg, via IV infusion, Q3W
219182746|NCT06584071|DRUG|bevacizumab|bevacizumab,15mg/kg, via IV infusion, Q3W
219182747|NCT06310018|DEVICE|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (treated with a total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours for first 10 patients followed by 50 patients treated with total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
219182748|NCT05495269|DRUG|QLS-101 ophthalmic solution, 2.0 %|ophthalmic solution in a single use dropper vial
219182749|NCT05355753|DRUG|CFT8634|Oral dose of CFT8634
219182750|NCT05133973|DEVICE|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
219182751|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
219369753|NCT03180775|DIETARY_SUPPLEMENT|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219369754|NCT03180775|DIETARY_SUPPLEMENT|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219182752|NCT04165694|PROCEDURE|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
219182753|NCT06053580|DRUG|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
219182754|NCT06053580|DRUG|Placebo|Placebo twice daily for 24 weeks.
219182755|NCT04413708|BEHAVIORAL|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
219182756|NCT00179946|PROCEDURE|HLA typing|
219182757|NCT04989413|DRUG|Placebo oral drops|use of placebo for 12 weeks
219182758|NCT04989413|DRUG|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|use of cannabidiol + canabigerol + thc for 12 weeks
219182759|NCT05939830|PROCEDURE|Stained region Lymph Node Biopsy (SrLNB)|Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
219182760|NCT05939830|RADIATION|Regional lymph node radiotherapy (RNI) including the axilla|RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
219182761|NCT04824053|DIETARY_SUPPLEMENT|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
219182762|NCT04824053|DIETARY_SUPPLEMENT|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
219182763|NCT04824053|DIETARY_SUPPLEMENT|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
219182764|NCT04824053|DIETARY_SUPPLEMENT|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
219182765|NCT04824053|DIETARY_SUPPLEMENT|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
219182766|NCT04824053|DIETARY_SUPPLEMENT|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
219182767|NCT06328439|DRUG|ANS014004|Specification: 7.5mg; 30mg QD/BID Oral
219182768|NCT05376488|OTHER|One meal|One meal given to assess impact on ammonia levels serially
219182769|NCT06367556|BEHAVIORAL|Emotion and Symptom-Focused Engagement (EASE)|EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.
219182770|NCT02392130|DRUG|Clobetasol propionate 0.05% ointment|
219182771|NCT02392130|DRUG|LEO 130852A gel 1%|
219182772|NCT02392130|DRUG|LEO 130852A placebo gel|
219182773|NCT04349371|DRUG|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
219182774|NCT04349371|DRUG|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
219182775|NCT06030219|DRUG|Omadacycline|10-day course
219182776|NCT06030219|DRUG|Vancomycin Pill|10-day course
219182777|NCT06030219|DRUG|Moxifloxacin|10-day course
219182778|NCT05022329|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|This arm receives Pfizer-BioNTech COVID-19 Vaccine
219182779|NCT05022329|BIOLOGICAL|MODERNA SARS-CoV-2 Vaccine|This arm receives MODERNA SARS-CoV-2 Vaccine
219182780|NCT02216240|OTHER|Paramedic|
219182781|NCT02216240|OTHER|Standard care|
219182782|NCT05714891|DRUG|JDQ443|Dose will be assigned at enrollment
219182783|NCT06449196|DRUG|Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.
219182784|NCT06449196|DRUG|: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
219182785|NCT05615974|DRUG|LM101|Administered intravenously
219182786|NCT05615974|DRUG|Toripalimab|Administered intravenously
219182787|NCT05615974|DRUG|Rituximab|Administered intravenously
219182788|NCT06269120|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
219182789|NCT05256199|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
219182790|NCT05358717|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
219182791|NCT05358717|DRUG|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
219182792|NCT05662423|BEHAVIORAL|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
219182793|NCT05662423|BEHAVIORAL|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
219182794|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
218999361|NCT02893514|OTHER|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
218999362|NCT05272020|DIAGNOSTIC_TEST|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
218999363|NCT00851500|DRUG|K-604|K-604 is given for 26 weeks
218999364|NCT00851500|OTHER|Placebo|placebo tablets are given for 26 weeks
219182795|NCT05849090|DRUG|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
219182796|NCT05849090|DRUG|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
219182797|NCT06010563|DEVICE|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
219182798|NCT06010563|DEVICE|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
219182799|NCT04546958|DIETARY_SUPPLEMENT|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
219182800|NCT04546958|OTHER|Nutritional counseling|Nutritional counseling by dietitians for 3 months
219182801|NCT05536752|DRUG|QA102/Placebo|Capsules
219182802|NCT05536752|DRUG|QA102|Capsules
219182803|NCT05536752|DRUG|Placebo|Capsules
219182804|NCT04870515|OTHER|Best Practice|Receive standard lifestyle recommendations
219182805|NCT04870515|OTHER|Dietary Intervention|Receive dietary instructions
219182806|NCT04870515|OTHER|Exercise Intervention|Complete aerobic and strength/resistance exercises
219182807|NCT04870515|OTHER|Quality-of-Life Assessment|Ancillary studies
219182808|NCT04870515|OTHER|Questionnaire Administration|Ancillary studies
218999365|NCT00179114|DRUG|Botulinum Toxin Type A|
218999366|NCT00179114|DRUG|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
218999367|NCT00583778|DRUG|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
219754216|NCT04788693|OTHER|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
218999368|NCT01937728|DRUG|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
218999369|NCT01937728|DRUG|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
218999370|NCT01937728|DRUG|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
218999371|NCT01937728|DRUG|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
218999372|NCT01937728|DRUG|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
218999373|NCT01937728|DRUG|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
218999374|NCT03775655|DRUG|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
218999375|NCT06498999|BEHAVIORAL|4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)|"4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions"
218999376|NCT05622084|DEVICE|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
218999377|NCT03410550|DEVICE|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
218999378|NCT02314611|DEVICE|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
218999379|NCT00114036|BEHAVIORAL|Quality improvement strategies|
218999380|NCT01916213|PROCEDURE|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
218999381|NCT01672697|BEHAVIORAL|Physical Therapy (PT) and Behavioral Therapy (BT)|"1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
218999382|NCT00848705|BEHAVIORAL|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
218999383|NCT04949477|DRUG|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
218999384|NCT04949477|DRUG|paracetamol|the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
218999385|NCT00369616|BIOLOGICAL|CYT002-NicQb|
218999386|NCT03937310|DIAGNOSTIC_TEST|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
218999387|NCT03733795|OTHER|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
219754217|NCT04788693|OTHER|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
219754218|NCT06588101|OTHER|Written informed consent with infographic|Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
219754219|NCT06588101|OTHER|Compensation|Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
218999388|NCT01499745|BEHAVIORAL|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
218999389|NCT05329974|OTHER|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
218999390|NCT03912155|OTHER|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
218999391|NCT05544357|OTHER|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
218999392|NCT05544357|OTHER|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
218999393|NCT01011634|DRUG|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
218999394|NCT03147014|BIOLOGICAL|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
218999395|NCT00309387|DIETARY_SUPPLEMENT|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
218999396|NCT00309387|OTHER|Placebo|placebo tablets manufactured to mimic Centrum tablets.
218999397|NCT01357187|OTHER|Scheduled removal of posterior instrumentation with AmnioFix|
218999398|NCT01357187|OTHER|Scheduled removal of posterior instrumentation without AmnioFix|
218999399|NCT04498013|DRUG|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
218999400|NCT04498013|BEHAVIORAL|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
218999401|NCT05360381|DRUG|HLX35|A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody, HLX35 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
218999402|NCT02483520|BEHAVIORAL|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
218999403|NCT00070278|DRUG|cyclophosphamide|
218999404|NCT00070278|DRUG|epirubicin hydrochloride|
218999405|NCT00070278|DRUG|gemcitabine hydrochloride|
218999406|NCT00070278|DRUG|paclitaxel|
218999407|NCT00070278|GENETIC|comparative genomic hybridization|
218999408|NCT00070278|GENETIC|microarray analysis|
218999409|NCT00070278|GENETIC|mutation analysis|
218999410|NCT00070278|PROCEDURE|conventional surgery|
218999411|NCT00070278|PROCEDURE|neoadjuvant therapy|
218999412|NCT03258489|DEVICE|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
218999413|NCT03258489|DEVICE|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
218999414|NCT03258489|DEVICE|TENS and IES Placebo|Same protocol without electrical output.
218999415|NCT00084721|DRUG|celecoxib|
218999416|NCT00084721|DRUG|irinotecan hydrochloride|
218999417|NCT03141476|DRUG|Cefuroxime 1,5g|Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
218999418|NCT03141476|DRUG|Cefuroxime 3g|Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
218999419|NCT03141476|DRUG|Cefuroxime 4,5g|Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
218999420|NCT04847492|PROCEDURE|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
218999421|NCT04847492|PROCEDURE|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
218999422|NCT01827397|BIOLOGICAL|EN41-UGR7C HIV vaccine|
218999423|NCT01827397|BIOLOGICAL|NaCl|
218999424|NCT01036841|DRUG|desmopressin tablet|Administration of desmopressine tablet
218999425|NCT01036841|DRUG|desmopressin MELT formulation|Administration of desmopressine MELT formulation
219182809|NCT06193213|PROCEDURE|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference \> 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
219182810|NCT06456762|BEHAVIORAL|iPEACE: Intervention for Parent Education about Care after the ED|Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
219182811|NCT06456762|BEHAVIORAL|Text Messaging Reminders Only|Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
219182812|NCT03264352|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
219182813|NCT03264352|DRUG|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
219182814|NCT03264352|OTHER|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
219182815|NCT05524922|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
219182816|NCT04895137|DRUG|mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
219182817|NCT04509791|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
219182818|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
219182819|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
219182820|NCT05831891|DRUG|Fruquintinib combined with Serplulimab|Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
219182821|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
219182822|NCT05456789|DEVICE|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
219182823|NCT05456789|OTHER|conventional treatment|conventional treatment of pulmonary embolism
219182824|NCT04315064|DRUG|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
219182825|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
219182826|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
219182827|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
219182828|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
219182829|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
219182830|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
219182831|NCT04982757|DEVICE|MagVenture MagPro System with Brainsight neuronavigation device|10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
219182832|NCT05475808|DEVICE|Static wrist splint treatment|Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
219369755|NCT03180775|DIETARY_SUPPLEMENT|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
219369756|NCT02452762|DRUG|Vitamin D3|
219369757|NCT02452762|DRUG|Placebo|
219369758|NCT02890680|PROCEDURE|Platelet-rich fibrin|
219369759|NCT02890680|PROCEDURE|Control group|
219369760|NCT01739751|DEVICE|pedometers|portable device that estimate the number of steps walked daily
219369761|NCT04506983|BIOLOGICAL|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.
219369762|NCT00584870|DRUG|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
219369763|NCT00584870|DRUG|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
219754220|NCT06654232|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at collecting a complete overview of different aspects of quality of life, including:~* Florida patient acceptance score (FPAS)~* Short Form Health Survey (SF-12)~* Kansas City Cardiomyopathy Questionnaire (KCCQ-12)~* Hospital Anxiety and Depression Scale (HADS)~* Florida Shock Acceptance score (FSAS)~* Steinke Sexual Concerns Inventory~* the Good Death questionnaire"
219754221|NCT06987656|DRUG|Standard Pharmacologic Treatment|Standard pharmacologic management including nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants (e.g., thiocolchicoside), and analgesics (e.g., paracetamol, tramadol) for acute lumbar spasm.
219754222|NCT06987656|OTHER|Physiotherapy Intervention|Physiotherapy interventions included spinal mobilization (Maitland techniques), myofascial release, transcutaneous electrical nerve stimulation (TENS), and personalized exercise programs, as documented in patient medical records.
219760806|NCT05257928|BEHAVIORAL|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
218999426|NCT03684811|DRUG|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
218999427|NCT03684811|DRUG|Azacitidine|Azacitidine will be administered per the site's standard of care.
218999428|NCT03684811|BIOLOGICAL|Nivolumab|Nivolumab will be administered per the site's standard of care.
218999429|NCT03684811|DRUG|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
218999430|NCT06231160|PROCEDURE|Systematic Therapy Combined With Microwave Ablation|Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
218999431|NCT00613249|DRUG|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
218999432|NCT00613249|DRUG|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
218999433|NCT00613249|DRUG|HEC-based Placebo Gel|intravaginal gel, dosed daily
218999434|NCT03902574|DRUG|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
218999435|NCT03902574|DRUG|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
218999436|NCT03902574|DRUG|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
218999437|NCT06243809|DRUG|Linagliptin 5 mg Oral Tablet|Linagliptin 5 mg Oral Tablet
218999438|NCT06243809|DRUG|Trajenta 5 MG Oral Tablet|Linagliptin 5 mg Oral Tablet (Trajenta )
218999439|NCT06436508|BEHAVIORAL|Early mobilization protocol|"* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
218999440|NCT06436508|BEHAVIORAL|Standard care|During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
218999441|NCT01945957|DRUG|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
218999442|NCT00786682|DRUG|docetaxel|
218999443|NCT00786682|DRUG|hydroxychloroquine|
218999444|NCT04492618|DRUG|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
218999445|NCT03152851|PROCEDURE|Pressure stimulus group|
218999446|NCT00789139|DEVICE|ICM Implantation|Sub cutaneous implantation of the ICM
218999447|NCT01114178|OTHER|questionnaire|self completed questionnaire supervised by a technician
218999448|NCT05551559|PROCEDURE|bariatric surgery|bariatric surgery
218999449|NCT03398681|DRUG|Ferric carboymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
218999450|NCT03398681|DRUG|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
218999451|NCT03398681|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance including T2\* and T1-mapping sequences
218999452|NCT02689388|PROCEDURE|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
218999453|NCT03862820|DIAGNOSTIC_TEST|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
219006890|NCT01432886|DRUG|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
219182833|NCT05475808|OTHER|Tendon and nerve gliding exercises|"Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding)."
219182834|NCT05475808|DRUG|Wrist local steroid injection|"Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance."
219182835|NCT06254261|DRUG|RAY1225|Administered SC
219182836|NCT06254261|DRUG|Placebo|Placebo
219182837|NCT04690972|PROCEDURE|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
219182838|NCT04690972|PROCEDURE|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
219182839|NCT04690972|DIAGNOSTIC_TEST|Blood sample during diagnostic test|Blood sample as part of the care
219182840|NCT05787405|OTHER|Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.
219182841|NCT05512793|DIAGNOSTIC_TEST|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
219182842|NCT05512793|DIAGNOSTIC_TEST|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
219182843|NCT03286686|BEHAVIORAL|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
219182844|NCT03286686|BEHAVIORAL|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
219182845|NCT03286686|BEHAVIORAL|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
219182846|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
219182847|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
219182848|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
219182849|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
219182850|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Condoms & Contraception)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them."
219182851|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
219182852|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Gender & Partner Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
219182853|NCT06223165|BEHAVIORAL|Floreciendo (Foundations)|• Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.
219369764|NCT00584870|DRUG|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
219182854|NCT06148324|BEHAVIORAL|MENTOR Program|"MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week."
219182855|NCT05781100|BEHAVIORAL|Technology Use during Feeding Conditions|At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
219182856|NCT05302648|DRUG|Human Derived anti-BCMA CAR-T Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
219182857|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
219182858|NCT05144776|DIAGNOSTIC_TEST|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
219182859|NCT05144776|DIAGNOSTIC_TEST|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
219760807|NCT02639390|DEVICE|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
218999454|NCT03489720|BEHAVIORAL|Prescribed Exercise Program|"Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing"
218999455|NCT03489720|BEHAVIORAL|Usual Exercise Program|Usual exercise activity for 8 weeks
218999456|NCT04183595|DRUG|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
218999457|NCT04183595|OTHER|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
218999458|NCT01288495|DIETARY_SUPPLEMENT|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
218999459|NCT01288495|DIETARY_SUPPLEMENT|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
218999460|NCT01829334|OTHER|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
218999461|NCT01829334|OTHER|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
218999462|NCT01829334|OTHER|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
218999463|NCT01829334|OTHER|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
218999464|NCT02396433|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle.
218999465|NCT02396433|DRUG|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
218999466|NCT02396433|DRUG|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
218999467|NCT02322567|OTHER|medical records|review of medical records
218999468|NCT02111772|BIOLOGICAL|Rhinovirus|
218999469|NCT06831812|BIOLOGICAL|AV-1959R (Abeta vaccine)|AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ) to support the primary prevention of Alzheimer's disease and the treatment of asymptomatic preclinical Alzheimer's disease. It is administered intramuscularly (IM) at doses of 100 µg or 300 µg on Weeks 0, 4, and 14, in combination with the adjuvant.
218999470|NCT00372125|DRUG|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
218999471|NCT04648956|OTHER|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
218999472|NCT06164223|DEVICE|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
218999473|NCT03723759|DRUG|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
218999474|NCT03723759|DRUG|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
218999475|NCT01352689|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
218999476|NCT01352689|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
218999477|NCT00799240|DRUG|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
219182860|NCT05618756|DIETARY_SUPPLEMENT|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
219182861|NCT05618756|DIETARY_SUPPLEMENT|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
219182862|NCT00664014|DRUG|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
219182863|NCT00664014|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
219182864|NCT04458272|DRUG|DS-1001b|250 mg, twice daily, continuous oral administration
219182865|NCT06117046|DRUG|Cardiopeptidin|Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
219182866|NCT06117046|DRUG|50 ml of normal saline intravenous infusion|50 ml of normal saline intravenous infusion
219182867|NCT06502639|OTHER|theraplay program|"A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing."
219182868|NCT06502639|OTHER|conventional physical therapy|conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
219182869|NCT05678179|BEHAVIORAL|Telehealth|Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
219182870|NCT05678179|BEHAVIORAL|In Person (Face-2-Face)|Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
219182871|NCT06138418|PROCEDURE|Neurotomy|Surgical treatment of spastic foot
219182872|NCT04837222|OTHER|No Intervention|This is a non-interventional study.
219182873|NCT03133546|DRUG|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
219182874|NCT03133546|DRUG|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
219182875|NCT06532877|BEHAVIORAL|Acceptance and Commitment Therapy|Patients and caregivers in the acceptance and commitment therapy arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
219182876|NCT06532877|BEHAVIORAL|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
219182877|NCT03468868|BEHAVIORAL|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
219182878|NCT06164392|DRUG|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
219182879|NCT06075836|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~\- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
219182880|NCT06075836|OTHER|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
219182881|NCT05356104|DRUG|Exenatide extended release|2mg once weekly via subcutaneous injection
219182882|NCT05985356|DEVICE|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
219182883|NCT04696965|OTHER|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
219182884|NCT04696965|OTHER|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
219182885|NCT06802679|DRUG|Urokinase|In the higher dose group: 30,000unit (1.5ml) per catheter lumen is instilled per catheter lumen (in both arterial and venous ports respectively). This allows utilization of the entire vial of Urokinase to prevent wastage and to assess if this increase in dose improves catheter patency and survival, thus reducing the need for a TDC exchange in our HD patients. The urokinase lock is dwelled for at least 2 hours, after which aspiration and catheter testing will be done by a trained HD nurse.
219182886|NCT06802679|DRUG|Urokinase|20,000unit (1ml) is instilled per catheter lumen (in both arterial and venous ports respectively); and the remaining 1ml is discarded.
219182887|NCT05399459|DRUG|Rimegepant 25 MG|Single dose of 25 mg orally disintegrating tablet of rimegepant
219182888|NCT05399459|DRUG|Rimegepant 75 MG|Single dose of 75 mg orally disintegrating tablet of rimegepant
219182889|NCT05399459|DRUG|Placebo|Matching placebo tablet
219182890|NCT02152046|PROCEDURE|ROP exam with spring loaded retractor|
219182891|NCT02152046|PROCEDURE|ROP exam with screw retractor|
219182892|NCT06802354|DRUG|Ozone|In Ozone group, ozone will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar, according to the manufacturer's recommendation for wound treatment following tooth extraction.
219182893|NCT06802354|DRUG|Placebo|In the control group, a sham ozone therapy will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar .
219182894|NCT03221517|OTHER|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
219182895|NCT05712057|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|high frequency rTMS over the right dlPFC
219182896|NCT05712057|DEVICE|electrical scalp stimulation|electrical scalp stimulation over the right dlPFC
219182897|NCT05712057|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal.
219182898|NCT05712057|BEHAVIORAL|Emotional Awareness Training|Emotional awareness training is a behavioral intervention through which participants learn how to identify and evaluate their emotions and the components that make up each emotion.
219182899|NCT04442646|BEHAVIORAL|multidisciplinary lessons|the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
219182900|NCT05642182|DRUG|SFA002|Study drug formula without excipient
219182901|NCT05642182|DRUG|SFA002|Study Drug SFA002 with excipient (Propionate)
219182902|NCT05729438|DIETARY_SUPPLEMENT|BCAA|status of nutrition evaluation after 3 months of BCAA
219182903|NCT05574270|DEVICE|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
219182904|NCT01642641|PROCEDURE|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
219182905|NCT01642641|PROCEDURE|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
219182906|NCT01642641|PROCEDURE|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
219182907|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training|"The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure."
219182908|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage|"Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
219182909|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise|"Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
219182910|NCT02733003|BEHAVIORAL|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
219182911|NCT06694259|PROCEDURE|Pneumatic retinopexy with transscleral cryopexy|"Pneumatic retinopexy with transscleral cryopexy is a procedure used to treat certain types of rhegmatogenous retinal detachments.~Procedure steps:~Transscleral cryopexy: in this first step, the surgeon uses a cryoprobe applied to the sclera directly over the retinal tear. The cryoprobe emits extreme cold, creating a small, localized freeze that reaches the retina and seals the tear by causing a controlled scar to form. This scar tissue holds the retina in place and prevents further fluid from passing through the tear.~Gas bubble injection: after the cryopexy, a small gas bubble (usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8)) is injected into the vitreous cavity. This bubble applies upward pressure on the retina, gently pressing it against the back wall of the eye, which aids in reattaching the retina.~Head positioning: for several days following the procedure, the patient must keep their head in a specific position so the gas bubble remains aligned with the retinal tear."
219182912|NCT06694259|PROCEDURE|Pneumatic retinopexy with laser photocoagulation|"Pneumatic retinopexy with laser photocoagulation is a minimally invasive procedure used to repair certain types of rhegmatogenous retinal detachments.~Procedure steps:~Gas bubble injection: a small gas bubble, usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8), is injected into the vitreous cavity which rises and applies pressure to the detached retina, pressing it back against the eye wall and helping to reapproximate the retinal layers.~Laser photocoagulation: once the retina is positioned correctly, laser is used to create small burns around the retinal tear. This laser application causes a mild inflammatory response, creating a scar around the tear and effectively welding the retina to the underlying tissue. This seal prevents fluid from reaccumulating beneath the retina.~Head positioning: following the procedure, the patient must keep their head in a specific position for several days. This positioning ensures that the gas bubble stays aligned with the retinal tear."
219369765|NCT03365193|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.
219182913|NCT05719493|OTHER|multicomponent treatment|The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
219182914|NCT03630211|DRUG|Cyclophosphamide|Stem Cell Mobilization
219182915|NCT03630211|DRUG|Mesna|Stem Cell Mobilization
219182916|NCT03630211|DRUG|Rituximab|Transplantation Conditioning
219182917|NCT03630211|DRUG|Alemtuzumab|Transplantation Conditioning
219182918|NCT03630211|DRUG|Thiotepa|Transplantation Conditioning
219182919|NCT03630211|DRUG|GM-CSF|Transplantation Conditioning
219182920|NCT03630211|DRUG|Intravenous immunoglobulin|Transplantation Conditioning
219182921|NCT03630211|RADIATION|Total Body Irradiation|Transplantation Conditioning
219182922|NCT03630211|DRUG|Anti Thymocyte Globulin|Transplantation Conditioning
219182923|NCT06103188|DRUG|Placebo|The placebo pill will be given to the patients 1 hour prior to their planned surgery.
219182924|NCT06103188|DRUG|Diazepam|Diazepam will be given to the patients 1 hour prior to their planned surgery.
219182925|NCT06103188|DRUG|Melatonin|Melatonin will be given to the patients 1 hour prior to their planned surgery.
219182926|NCT05411159|PROCEDURE|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
219182927|NCT05411159|PROCEDURE|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
219182928|NCT05703971|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
219182929|NCT05703971|BIOLOGICAL|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
219182930|NCT05813080|DEVICE|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
219182931|NCT05813080|OTHER|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
219182932|NCT03358719|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
219182933|NCT03358719|DRUG|Decitabine|Given IV
219182934|NCT03358719|OTHER|Laboratory Biomarker Analysis|Correlative studies
219182935|NCT03358719|BIOLOGICAL|Nivolumab|Given IV
219182936|NCT03358719|DRUG|Poly ICLC|Given SC
219182937|NCT00986856|DRUG|Fucidin® cream|
219182938|NCT06331598|DRUG|Atezolizumab|A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
219182939|NCT06331598|DRUG|Tiragolumab|A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
219182940|NCT04594447|DEVICE|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
219182941|NCT04594447|DEVICE|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
219182942|NCT01541553|PROCEDURE|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
219182943|NCT01541553|DRUG|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
219182944|NCT01541553|DRUG|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
219182945|NCT06158646|DEVICE|kinematic knee prosthesis|Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.
219182946|NCT06158646|DEVICE|biomechanic knee prosthesis|A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
219182947|NCT05887583|BEHAVIORAL|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
219182948|NCT05523700|OTHER|Mobile Application|Intervention is a mobile application than combines patient data via EMR with PROMIS outcome measures.
219182949|NCT01175356|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
219182950|NCT01175356|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
219182951|NCT01175356|DRUG|Busulfan|Given IV
219182952|NCT01175356|DRUG|Cisplatin|Given IV
219182953|NCT01175356|DRUG|Cyclophosphamide|Given IV
219182954|NCT01175356|DRUG|Doxorubicin Hydrochloride|Given IV
219182955|NCT01175356|DRUG|Etoposide Phosphate|Given IV
219182956|NCT01175356|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
219182957|NCT01175356|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
219182958|NCT01175356|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
218999478|NCT00799240|DRUG|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
218999479|NCT02801292|DRUG|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
218999480|NCT05219084|DRUG|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
218999481|NCT05219084|DRUG|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
218999482|NCT05219084|DRUG|Combined group|hip denervation and intra-articular hydration were conducted together
218999483|NCT05219084|DRUG|Control group|Normal; saline was injected subcutaneously
218999484|NCT04190615|DIAGNOSTIC_TEST|thromboelastometry test (TEM test)|TEM test from the whole blood sample
218999485|NCT02845544|OTHER|Pilates-based exercises|
218999486|NCT01366690|BEHAVIORAL|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
218999487|NCT05790629|PROCEDURE|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
218999488|NCT05790629|PROCEDURE|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
218999489|NCT03505762|DRUG|Cyclophosphamide|Given IV
218999490|NCT03505762|DRUG|Doxorubicin Hydrochloride|Given IV
218999491|NCT03505762|OTHER|Laboratory Biomarker Analysis|Correlative studies
218999492|NCT03505762|DRUG|Prednisone|Given PO
218999493|NCT03505762|OTHER|Quality-of-Life Assessment|Ancillary correlative
218999494|NCT03505762|OTHER|Questionnaire Administration|Ancillary studies
218999495|NCT03505762|BIOLOGICAL|Rituximab|Given IV
218999496|NCT03505762|DRUG|Vincristine Sulfate|Given IV
218999497|NCT05773430|BEHAVIORAL|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
218999498|NCT04777500|DEVICE|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
218999499|NCT02495168|DRUG|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
218999500|NCT02495168|DRUG|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
218999501|NCT02495168|DRUG|Placebo|Oral inhalation, no active ingredient.
218999502|NCT01410786|PROCEDURE|Conventional Instrumentation|Standard Oxford surgical instruments
218999503|NCT01410786|PROCEDURE|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
218999504|NCT05090137|OTHER|Diuretics|As per group descriptions
218999505|NCT05590013|DRUG|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
218999506|NCT04613960|DRUG|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
218999507|NCT04613960|DRUG|normal saline|Placebo treatment
218999508|NCT06497933|PROCEDURE|Atrial fibrillation ablation|Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
218999509|NCT05867745|OTHER|Interview|As previously specified
218999510|NCT05867745|OTHER|Survey|As previously specified
218999511|NCT05867745|OTHER|Letter to a friend (autoethnography)|As previously specified
218999512|NCT05225766|OTHER|bupivacaine|used for peripheral block
218999513|NCT06054698|DRUG|HRS9531 injection|HRS9531 injection , QW，36 weeks
218999514|NCT06054698|DRUG|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
218999515|NCT05163600|OTHER|Blod flow restriction training|includes one strength and one endurance training
218999516|NCT06281600|DIETARY_SUPPLEMENT|Human milk oligosaccharide|5g daily dose of HMOs.
218999517|NCT06281600|DIETARY_SUPPLEMENT|Maltodextrin placebo|5g daily dose of maltodextrin.
218999518|NCT01484847|DRUG|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
218999519|NCT01437462|DRUG|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
218999520|NCT01437462|DRUG|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
218999521|NCT01603056|BIOLOGICAL|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
218999522|NCT01603056|BIOLOGICAL|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
218999523|NCT02198066|OTHER|Dry Sterile Dressing|Described in Arm Description.
218999524|NCT02198066|OTHER|Metallic Silver Dressing|Described in Arm Description.
218999525|NCT02198066|OTHER|Ionic Silver Dressing|Described in Arm Description.
219182959|NCT01175356|RADIATION|Iobenguane I-131|Given IV
219182960|NCT01175356|DRUG|Isotretinoin|Given PO
219182961|NCT01175356|OTHER|Laboratory Biomarker Analysis|Correlative studies
219182962|NCT01175356|DRUG|Melphalan|Given IV
219182963|NCT01175356|OTHER|Pharmacological Study|Correlative studies
219182964|NCT01175356|OTHER|Questionnaire Administration|Ancillary studies
219760808|NCT02639390|OTHER|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
219760809|NCT01908140|DRUG|Aclidinium Bromide / Formoterol Fumarate|
219760810|NCT01908140|DRUG|Salmeterol / Fluticasone|
218999526|NCT04339439|DEVICE|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
218999527|NCT00786500|DIETARY_SUPPLEMENT|Gynostemma pentaphyllum tea|3 grams twice daily, orally
218999528|NCT00786500|DIETARY_SUPPLEMENT|Placebo tea|3 grams twice daily, orally
218999529|NCT00549965|DRUG|Risedronate Sodium|
218999530|NCT01024634|BEHAVIORAL|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
218999531|NCT04517812|OTHER|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
218999532|NCT01705639|DRUG|Melatonin|All subjects receive the same dose of melatonin
218999533|NCT06513949|BIOLOGICAL|Atibuclimab|monoclonal antibody against human CD14
218999534|NCT06513949|OTHER|Placebo|Sterile normal saline for injection
218999535|NCT00645060|OTHER|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
218999536|NCT00645060|OTHER|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
218999537|NCT00645060|PROCEDURE|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
218999538|NCT00645060|PROCEDURE|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
218999539|NCT00645060|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
218999540|NCT01250275|OTHER|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
218999541|NCT01250275|OTHER|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
218999542|NCT01250275|OTHER|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
218999543|NCT01250275|OTHER|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
218999544|NCT01250275|OTHER|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
218999545|NCT01250275|OTHER|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
218999546|NCT01250275|OTHER|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
218999547|NCT01201018|DRUG|Oshadi D, Oshadi R|Oral administration
218999548|NCT01095783|PROCEDURE|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
218999549|NCT01095783|PROCEDURE|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
218999550|NCT04004715|DIETARY_SUPPLEMENT|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
218999551|NCT04004715|DIETARY_SUPPLEMENT|Whey Protein|commercially available whey protein isolate
219182965|NCT01175356|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218999552|NCT04004715|DIETARY_SUPPLEMENT|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
218999553|NCT00772291|DRUG|pregabalin|pregabalin 150-600mg/day during 8 weeks
218999554|NCT00772291|DRUG|placebo|placebo drug during 8 weeks
218999555|NCT04022993|DRUG|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
218999556|NCT04022993|DRUG|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
218999557|NCT00113984|BIOLOGICAL|PROSTVAC-V/TRICOM|
218999558|NCT00113984|BIOLOGICAL|PROSTVAC-F/TRICOM|
218999559|NCT00113984|DRUG|MDX-010|
218999560|NCT00113984|DRUG|Sargramostim|
218999561|NCT04639375|BIOLOGICAL|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
219182966|NCT01175356|DRUG|Topotecan Hydrochloride|Given IV
219182967|NCT01175356|DRUG|Vincristine Sulfate|Given IV
219182968|NCT04565743|BEHAVIORAL|Support on dentification and treatment of patients with high risk of osteoporotic fractures|Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
219182969|NCT05583578|DEVICE|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
219182970|NCT05583578|DEVICE|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
219182971|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
219182972|NCT05598372|BEHAVIORAL|shotblocker|infant pain during vaccination and mother anxiety
219182973|NCT05598372|BEHAVIORAL|lullaby|infant pain during vaccination and mother anxiety
219182974|NCT02172690|PROCEDURE|Laparoscopic Staging|Laparoscopic Staging
219182975|NCT04447469|DRUG|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
219182976|NCT04447469|OTHER|Placebo|matching placebo
219182977|NCT06529978|DEVICE|CoreMap EP Mapping System Mapping|Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
219182978|NCT06529978|DEVICE|CoreMap EP Mapping System Map-Guided Ablation|Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
219182979|NCT06090734|OTHER|My Voice|The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
219182980|NCT05201079|BIOLOGICAL|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
219182981|NCT05201079|DRUG|Fidaxomicin|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
219182982|NCT04849572|BEHAVIORAL|Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
219182983|NCT04849572|BEHAVIORAL|Delayed Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
219182984|NCT00267137|DEVICE|Pacing Algorithms|
219182985|NCT06592144|DRUG|Testosterone cypionate (200mg/3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
219182986|NCT06592144|OTHER|Sesame oil (3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
219182987|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
219182988|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
219182989|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
219182990|NCT04907851|BIOLOGICAL|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
219182991|NCT04907851|BIOLOGICAL|pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
219182992|NCT04752709|DEVICE|ELITONE UUI|External electrical stimulation
219182993|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
219182994|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
219182995|NCT06076512|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
219182996|NCT06417021|OTHER|Frontal Ultrasound Machine|Ultrasound machine will be placed in a frontal position
219182997|NCT06417021|OTHER|Lateral Ultrasound Machine|Ultrasound machine will be placed in a lateral position
219182998|NCT06071429|DEVICE|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
219182999|NCT06071429|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
219183000|NCT06069661|DEVICE|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
219369766|NCT02292212|DEVICE|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
218999562|NCT03533868|DIAGNOSTIC_TEST|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
218999563|NCT00814164|DRUG|clofarabine|IV
218999564|NCT00814164|DRUG|daunorubicin hydrochloride|IV
218999565|NCT00814164|GENETIC|cytogenetic analysis|Correlative study
218999566|NCT00814164|GENETIC|protein expression analysis|Correlative Study
218999567|NCT00814164|OTHER|immunologic technique|Correlative Study
218999568|NCT00814164|OTHER|pharmacological study|Correlative Study
218999569|NCT03537105|PROCEDURE|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
218999570|NCT03338374|DEVICE|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
218999571|NCT04395443|OTHER|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
218999572|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
218999573|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
218999574|NCT03012165|DRUG|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
218999575|NCT02454491|DRUG|Heparin|intraradial administration of heparin 5000 ui
218999576|NCT02454491|DRUG|Verapamil|intraradial administration of verapamil 5 mg
218999577|NCT00064116|BIOLOGICAL|rituximab|Rituximab 375 mg/m² i.v. day 1
218999578|NCT00064116|DRUG|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
218999579|NCT01746745|DRUG|[^14C]-LY2940680|Administered as solution by mouth
218999580|NCT03722966|DRUG|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
218999581|NCT03722966|DRUG|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
218999582|NCT03722966|BEHAVIORAL|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
218999583|NCT03722966|BEHAVIORAL|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
218999584|NCT01169493|DEVICE|VVI-40|Pacing mode set to VVI-40, RV only pacing
218999585|NCT01169493|DEVICE|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
218999586|NCT01169493|DEVICE|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
218999587|NCT00791856|DRUG|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
218999588|NCT00791856|DRUG|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
218999589|NCT06127953|PROCEDURE|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
218999590|NCT02744690|DRUG|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
218999591|NCT04144244|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
218999592|NCT04144244|OTHER|Gradient-Density Centrifugation|sperm selection of IUI treatment
219369767|NCT01946815|DRUG|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
219369768|NCT00080197|DRUG|E7070|
218999593|NCT02837445|DEVICE|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
218999594|NCT02837445|DEVICE|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
218999595|NCT04019574|DRUG|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
218999596|NCT04019574|DRUG|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
218999597|NCT04019574|DRUG|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
218999598|NCT04019574|OTHER|Placebo|IV Placebo as a bolus injection
219183001|NCT04116398|DRUG|Dexamethasone with 2 loading doses followed by PRN regimen.|"* Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~* Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®/Topcon; and/or increase of CSMT \> 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~* Minimal time limit between two IVI : 12 weeks~* Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
219183002|NCT05801380|DRUG|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
219183003|NCT05801380|DRUG|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
219183004|NCT06475638|DEVICE|brachial artery doppler|brachial artery doppler evaluation before and after supraclavicular block
219183005|NCT06481280|DIETARY_SUPPLEMENT|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
219183006|NCT06481280|DIETARY_SUPPLEMENT|Placebo Formula|Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
219183007|NCT05472961|BEHAVIORAL|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
219183008|NCT05711758|PROCEDURE|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
219183009|NCT05562401|DEVICE|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
219183010|NCT05562401|DRUG|Oral Electrolytes|Is be considered a drug that not require medical prescrption and containing water, carbohydrates and electrolytes.
219183011|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
219183012|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
219183013|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
219183014|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
219183015|NCT04081701|DIAGNOSTIC_TEST|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
219183016|NCT05452902|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
219183017|NCT05452902|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
219183018|NCT06505980|BEHAVIORAL|Brief Behavioral Parenting Program|The brief behavioral parenting program is a 6 session, group-based behavioral parent training program. The components include support-building, parenting strategy education, and actively practicing parenting strategies. It is delivered through telehealth.
219183019|NCT03849443|DRUG|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
219183020|NCT03849443|DRUG|Vitamin C 250 MG Oral Tablet|Oral method of placebo
219183021|NCT03849443|DRUG|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
219183022|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
219183023|NCT05810220|DEVICE|Electrode-Neural Interface|Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
219183024|NCT05486156|OTHER|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
219183025|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
219183026|NCT01529983|DEVICE|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
219183027|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
219183028|NCT01210807|DEVICE|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
219183029|NCT01210807|DEVICE|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
219183030|NCT04996017|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
219183031|NCT04996017|DRUG|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
219183032|NCT06447987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
219183033|NCT06447987|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219183034|NCT06447987|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219183035|NCT06447987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219183036|NCT06447987|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
219183037|NCT06447987|BIOLOGICAL|Cetuximab|Given IV
219183038|NCT06447987|PROCEDURE|Computed Tomography|Undergo CT and PET
219183039|NCT06447987|DRUG|Cyclophosphamide|Given IV
219183040|NCT06447987|PROCEDURE|Echocardiography|Undergo ECHO
219183041|NCT06447987|DRUG|Fludarabine|Given IV
219183042|NCT06447987|PROCEDURE|Leukapheresis|Undergo leukapheresis
219183043|NCT06447987|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219183044|NCT06447987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219183045|NCT06447987|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219183046|NCT06539416|PROCEDURE|MitraClip implantation|The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
219183047|NCT03566940|BIOLOGICAL|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
219183048|NCT03566940|BIOLOGICAL|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
219183049|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
219183050|NCT06449287|OTHER|Diet|The diet intervention will start after all baseline testing is complete
219183051|NCT06449287|BIOLOGICAL|Blood Draw|Blood samples will be collected biweekly.
219183052|NCT06449287|BIOLOGICAL|Ketone/Glucose Monitoring|Hand-held glucometer will be used daily to monitor dietary intervention adherence.
219183053|NCT06449287|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
219183054|NCT06449287|BIOLOGICAL|Urine Analysis|24 hour urine collection will be done biweekly.
219183055|NCT06449287|BEHAVIORAL|Neuropsychological Measures - ANAM|The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
219183056|NCT00704262|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
219183057|NCT03029884|DEVICE|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
219183058|NCT03029884|DEVICE|Sham Stimulation|No Active Stimulation
219183059|NCT03029884|DEVICE|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
219183060|NCT03189498|DRUG|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
219183061|NCT03490240|BEHAVIORAL|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
219183062|NCT03490240|BEHAVIORAL|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
219183063|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
219183064|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
219183065|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
219183066|NCT05405426|OTHER|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
219183067|NCT05322044|BEHAVIORAL|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
219183068|NCT06501859|OTHER|Standard of care physical therapy|Standard rehabilitation protocol for 3 months.
219183069|NCT06501859|DEVICE|Shoulder pacemaker with physical therapy|Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
219183070|NCT04573387|PROCEDURE|Operation|All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
219183071|NCT04573387|PROCEDURE|Fixed-time drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
219183072|NCT04573387|PROCEDURE|Exhaustive drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
219183073|NCT04573387|PROCEDURE|Postoperative computed tomography|All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
219183074|NCT05477186|BIOLOGICAL|CV0501 (3 μg)|Study vaccine was administered as a single intramuscular injection.
219183075|NCT05477186|BIOLOGICAL|CV0501 (6 μg)|Study vaccine was administered as a single intramuscular injection.
219183076|NCT05477186|BIOLOGICAL|CV0501 (12 μg)|Study vaccine was administered as a single intramuscular injection.
219183077|NCT05477186|BIOLOGICAL|CV0501 (25 μg)|Study vaccine was administered as a single intramuscular injection.
219183078|NCT05477186|BIOLOGICAL|CV0501 (50 μg)|Study vaccine was administered as a single intramuscular injection.
219183079|NCT05477186|BIOLOGICAL|CV0501 (100 μg)|Study vaccine was administered as a single intramuscular injection.
219183080|NCT05477186|BIOLOGICAL|CV0501 (200 μg)|Study vaccine was administered as a single intramuscular injection.
219183081|NCT04164641|DEVICE|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
219183082|NCT05813236|DEVICE|Novosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
219183083|NCT05813236|DEVICE|Monosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
219183084|NCT06449638|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219183085|NCT06449638|OTHER|Revita|Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219183086|NCT06449638|OTHER|Relese|Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219183087|NCT06449638|OTHER|Cogenex|Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219183088|NCT06449638|OTHER|Enverse|Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219183089|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with metal/Bio-Tenodesis screws|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by\~10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Metal/Bio-Tenodesis screw(MBS). The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with an MBS in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
219183090|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with Shark Screws®|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by approx.10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Shark Screw®. The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with the Shark Screw® in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
219183091|NCT04137107|DRUG|Oxaliplatin|Given standard of care oxaliplatin
219183092|NCT04137107|DRUG|Duloxetine Hydrochloride|Given PO
219183093|NCT04137107|DRUG|Duloxetine|Given PO
219183094|NCT04137107|OTHER|Quality-of-Life Assessment|Ancillary studies
219183095|NCT04137107|OTHER|Questionnaire Administration|Ancillary studies
219183096|NCT04137107|OTHER|Placebo|Given PO
219183097|NCT06078085|OTHER|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
219183098|NCT05158166|DRUG|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
219183099|NCT02747303|PROCEDURE|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
219183100|NCT06307600|DRUG|RD06-03 cell injection|The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
219183101|NCT04550182|PROCEDURE|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
219183102|NCT06295744|RADIATION|Radiation Therapy|WBI with SIB delivered over 5 fractions
219183103|NCT00324805|BIOLOGICAL|Bevacizumab|Given IV
219183104|NCT00324805|DRUG|Cisplatin|Given IV
219183105|NCT00324805|DRUG|Docetaxel|Given IV
219183106|NCT00324805|DRUG|Gemcitabine Hydrochloride|Given IV
219183107|NCT00324805|OTHER|Laboratory Biomarker Analysis|Correlative studies
219183108|NCT00324805|DRUG|Pemetrexed Disodium|Given IV
219183109|NCT00324805|OTHER|Questionnaire Administration|Ancillary studies
219183110|NCT00324805|DRUG|Vinorelbine Tartrate|Given IV
219183111|NCT04364048|DRUG|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
219183112|NCT04364048|DRUG|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
219183113|NCT04364048|RADIATION|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
219183114|NCT04364048|DRUG|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
219183115|NCT03687814|OTHER|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
219183116|NCT03687814|OTHER|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
219183117|NCT06558123|PROCEDURE|block|Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
219183118|NCT05792085|BEHAVIORAL|EHR-based GDMT Optimization|Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
219183119|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
219183120|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
219183121|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
219183122|NCT06189365|DEVICE|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
219183123|NCT06318455|OTHER|Breathing exercise|For 12 weeks they will do kumbaka breathing exercise for 5 minutes twice a day in the morning and evening
219183124|NCT05543733|BEHAVIORAL|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
219183125|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
219183126|NCT05742178|BEHAVIORAL|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
219183127|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
219183128|NCT05096364|BIOLOGICAL|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
219183129|NCT03206814|OTHER|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
219183130|NCT03206814|OTHER|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
219183131|NCT05743270|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
219183132|NCT05743270|OTHER|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
219183133|NCT05743270|OTHER|carboplatin and paclitaxel|chemotherapeutic agents
219183134|NCT05743270|BIOLOGICAL|nivolumab|anti-PD1 monoclonal antibody
219183135|NCT03173703|DEVICE|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
219183136|NCT03173703|PROCEDURE|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
219183137|NCT03173703|DEVICE|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
219183138|NCT06020235|DRUG|5% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
219183139|NCT06020235|DRUG|10% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
219183140|NCT06020235|DRUG|Placebo|Placebo gel is either applied once per day or twice per day to the infected ulcer.
219183141|NCT01919554|BIOLOGICAL|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 10 days
219183142|NCT01919554|BIOLOGICAL|1000 IR house dust mites allergen extract tablet|Two sublingual tablets daily during 10 days
219183143|NCT01919554|BIOLOGICAL|1500 IR house dust mites allergen extract tablet|Three sublingual tablets daily during 10 days
219183144|NCT01919554|BIOLOGICAL|Placebo tablet|One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets
219183145|NCT05095571|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
219183146|NCT06648759|DEVICE|Vagal Nerve Stimulator|The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.
219183147|NCT06648759|DEVICE|Placebo Vagal Nerve Stimulator|The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
219183148|NCT03906253|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
219183149|NCT05336214|OTHER|Virtual CGM initiation service|Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.
219183150|NCT05336214|OTHER|Online educational module on CGM|Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.
219183151|NCT05336214|OTHER|Practice facilitation|A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
219183152|NCT05919602|OTHER|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
219183153|NCT06151392|DRUG|Probiotic Formula|probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
219183154|NCT06151392|DRUG|Zinc|Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
219183155|NCT05299658|DRUG|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
219183156|NCT06356168|BEHAVIORAL|Social Virtual Reality|Participants interact using virtual reality during dialysis.
219183157|NCT06356168|BEHAVIORAL|Individual Virtual Reality|Participants use virtual reality alone during dialysis.
219183158|NCT06085183|OTHER|Saline Injection 0.9%|Placebo
219183159|NCT06085183|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
219183160|NCT04866888|PROCEDURE|closure of the uterine wall defect|Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
219183161|NCT04866888|DIAGNOSTIC_TEST|ultrasound|"Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded."
219183162|NCT04866888|DIAGNOSTIC_TEST|outpatient hysteroscopy|Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
219183163|NCT05648591|DRUG|Iloperidone|oral tablet
219183164|NCT04974138|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
219183165|NCT04974138|DRUG|Amlodipine besylate and folic acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
219183166|NCT04974138|DRUG|Amlodipine placebos|An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
219183167|NCT04974138|DRUG|Amlodipine-folic acid placebos|An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
219183168|NCT05778695|DIETARY_SUPPLEMENT|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
219183169|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
219183170|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
219183171|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
219183172|NCT04649476|DRUG|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
219183173|NCT04649476|DRUG|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
219183174|NCT04517487|BIOLOGICAL|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
219183175|NCT04517487|BIOLOGICAL|Placebo|Placebo
219183176|NCT05741372|DRUG|Rosuvastatin|Rosuvastatin
219183177|NCT05741372|DRUG|Digoxin|Digoxin
219183178|NCT05741372|DRUG|Metformin hydrochlorid|Metformin hydrochloride
219183179|NCT05741372|DRUG|Furosemide|Furosemide
219183180|NCT06591026|BEHAVIORAL|Standard Helpline (SH)|One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
219183181|NCT06591026|BEHAVIORAL|Motivational Interviewing (MI)|One digital helpline session that includes a structured motivational interviewing brief intervention.
219183182|NCT06591026|BEHAVIORAL|Coping Skills Training (CST)|One digital helpline session that includes a structured cognitive coping skills brief intervention.
219183183|NCT06591026|BEHAVIORAL|Automated Text Messaging (ATM)|Automated text messages are sent daily for 4 weeks.
219183184|NCT04601987|BEHAVIORAL|Breastfeeding|Counseling about the maternal health benefits of lactation.
219183185|NCT04601987|BEHAVIORAL|Smokefree Homes|Counseling about the importance of smoke-free homes.
219183186|NCT06225310|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
219183187|NCT06225310|DRUG|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
219183188|NCT06225310|DRUG|Methylprednisolone|Glucocorticoid, steroid
219183189|NCT06823674|OTHER|core endurance test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
219183190|NCT06823674|OTHER|cervical stabilization test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
219183191|NCT06823674|OTHER|cervical proprioception test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
219183192|NCT06608394|OTHER|no intervention|no intervention
219183193|NCT06823986|DEVICE|Retraction of anterior teeth by putting miniscrews and power arm|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolar on miniscrews and power arm
219183194|NCT06823986|DEVICE|Retraction of upper anterior teeth by putting miniscrews and welded hooks in main wire arch|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolars on miniscrews and welded hooks in main wire arch
219183195|NCT06696924|OTHER|Reciprocal inhibition|First Subjects will start doing baseline warmup exercises which are mentioned then they will perform reciprocal inhibition of the serratus muscle in supine or side-lying. After identifying the antagonist muscles of the serratus anterior, which are typically the rhomboids or the middle and lower trapezius. Athletes will perform a gentle contraction of the antagonist's muscles by retracting or squeezing their shoulder blades together. While the antagonist muscles are contracting, we will ask the athlete to simultaneously relax and lengthen the serratus anterior muscle. The patient can achieve this by protracting or pushing their shoulder blades forward and away from each other.
219183196|NCT06696924|OTHER|Static stretching|"Subjects will perform 2 stretches~1. Standing Wall Stretch: Stand facing a wall with your feet about hip-width apart. Place their palms on the wall at shoulder height, slightly wider than shoulder-width apart. will Lean their body forward, keeping their arms straight, until feel a stretch in their serratus anterior. Hold the stretch for 15 to 30 seconds, then slowly release. Instead of using a wall or object, the athlete will use their opposite hand to hold the stretched arm in position.~2. Seated Cross-Body Stretch: Sit on the edge of a chair or bench. Cross one arm over your chest, placing your hand on the opposite shoulder. The athlete will use the other hand to gently pull the crossed arm closer to your body, feeling a stretch in the serratus anterior. Hold the stretch for 15 to 30 seconds or more, and then switch sides and repeat."
219183197|NCT06540911|OTHER|Personalized physical back training program|The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
219183198|NCT06540911|OTHER|Non-personalized physical back training program|The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
219183199|NCT06238076|DEVICE|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
219183200|NCT04223505|DIAGNOSTIC_TEST|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
219183201|NCT04223505|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
219183202|NCT05698849|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
219183203|NCT00063063|OTHER|No Intervention|
219183204|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
219183205|NCT06822894|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine
219183206|NCT06116526|DRUG|Dupilumab - Discontinuation|Drug injections are discontinued.
219183207|NCT06116526|DRUG|Dupilumab - Dose Reduction|The drug is given as a subcutaneous injection.
219183208|NCT06116526|DRUG|Dupilumab - Standard Dose|The drug is given as a subcutaneous injection.
219183209|NCT05943639|OTHER|The Cultural Marginality Theory-Based Education|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
219183210|NCT01733316|DRUG|RP103|
219183211|NCT01733316|DRUG|Cystagon®|
219183212|NCT03096028|OTHER|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
219183213|NCT06370000|DRUG|Oral Azacitidine|Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.
219183214|NCT05674786|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
219183215|NCT05213936|DEVICE|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
219183216|NCT05213936|DEVICE|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
219183217|NCT03260023|BIOLOGICAL|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
219183218|NCT03260023|DRUG|Avelumab|Anti PD-L1
219183219|NCT06822088|DRUG|Esketamine|A total of 126 patients undergoing thoracoscopic surgery under elective general anesthesia were randomly divided into three groups: normal saline group (group C), dexmedetomidine group (group D), eschloroacetone group (group E) and dexmedetomidine group (group D), with 42 cases in each group. Group C was continuously injected with the same amount of normal saline, group D was given dextrometin 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery. Group E was given esketamine 0.2 mg/kg 10min before surgery, and maintained at 0.15 mg/kg\*h after intubation until 30min before surgery. Other anesthetic induction and maintenance drugs were consistent among the three groups.
219760811|NCT06271824|BEHAVIORAL|Self-Compassion Based Resilient Caregiving Course|The Resilience Habits for Caregivers Course is a live, online, weekly 6 session program lasting 1.5 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
219183220|NCT06822088|DRUG|Dexmedetomidine|group D was given Dexmedetomidine 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery.
219183221|NCT06822088|DRUG|Normal Saline|Group C was continuously injected with the same amount of normal saline,
219183222|NCT06513793|BEHAVIORAL|Roots and Shoots|Four-week intervention involving a self-help guidebook to improve mental wellbeing.
219183223|NCT06513793|BEHAVIORAL|Waiting list|Four-week waiting list period involving treatment as usual.
219183224|NCT06413524|DEVICE|Whole-body Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles.
219183225|NCT06413524|DEVICE|Local Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. During the vibration, participants will hold onto the handle to ensure balance stability.
219183226|NCT06823609|DRUG|QLS1304 tablet|QLS1304 monotherapy dose escalation and expansion
219183227|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
219183228|NCT06122662|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
219183229|NCT06122662|OTHER|Placebo|Matching Placebo Comparator
219183230|NCT05535894|PROCEDURE|Ablation of Celiac Ganglion|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
219183231|NCT06555822|DRUG|AZD5004|Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
219183232|NCT06555822|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
219183233|NCT05713110|DRUG|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
219183234|NCT05713110|DRUG|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
219183235|NCT03589846|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
219183236|NCT05286151|BEHAVIORAL|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
219183237|NCT05482698|DRUG|MC2-25 cream|Topical application
219183238|NCT05482698|DRUG|MC2-25 vehicle|Topical application
219183239|NCT06379685|DRUG|PRO-190|Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
219183240|NCT06379685|DRUG|Systane Ultra®|Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
219183241|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
219183242|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
219183243|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
219183244|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
219183245|NCT02639897|OTHER|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
219183246|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
219183247|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
219183248|NCT06330922|OTHER|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
219183249|NCT04214561|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
219183250|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
219183251|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
219183252|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
219183253|NCT06778369|PROCEDURE|traingular exclusion technique in mitral valve repair|The prolapsed part of the posterior leaflet is inverted and excluded, not resected toward the left ventricle, and the margins of the prolapsed part are sutured to each other's using proline 5/0, extending from the posterior leaflet edge to the posterior annulus. Then the posterior annulus is reinforced with an annuloplasty band using a treated strip of pericardium. The determination of suitable ring size is subsequently predicated upon the assessment of inter-commissural distance surface area and the anterior leaflet, utilizing sizers that are correlated with typical mitral geometry.
219183254|NCT04034862|DRUG|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
219183255|NCT06536140|OTHER|Home observations and interview|"If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth."
219183256|NCT05294042|OTHER|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
219183257|NCT03058289|DRUG|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."
219183258|NCT03058289|BIOLOGICAL|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
219183259|NCT03058289|BIOLOGICAL|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
219183260|NCT05436314|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
219183261|NCT05436314|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
219183262|NCT05436314|OTHER|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
219183263|NCT02240862|DEVICE|Carotid Artery Stent|Placement of a stent within the carotid artery
219183264|NCT00855036|OTHER|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
219183265|NCT01674140|DRUG|anastrozole|Given orally
219183266|NCT01674140|DRUG|everolimus|Given PO
219183267|NCT01674140|DRUG|exemestane|Given orally
219183268|NCT01674140|DRUG|goserelin acetate|Given subcutaneously or intramuscularly
219183269|NCT01674140|DRUG|letrozole|Given orally
219183270|NCT01674140|DRUG|leuprolide acetate|Given subcutaneously or intramuscularly
219183271|NCT01674140|DRUG|tamoxifen citrate|Given PO
219183272|NCT01674140|OTHER|placebo|Given PO
219183273|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject's comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
219183274|NCT06667739|BEHAVIORAL|IMPACT-L3|The intervention is a physical activity behaviour change intervention: IMproving Physical Activity through Coaching and Technology following Lower Limb Loss (IMPACT-L3). Two theories provide a framework for IMPACT-L3. One is social cognitive theory and the other is self-determination theory. As mHealth solutions have the potential to increase access and improve health outcomes, IMPACT-L3 will be delivered entirely virtually.
219183275|NCT05694871|DRUG|Palbociclib|Given PO
219183276|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
219183277|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
219183278|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
219760812|NCT05822154|OTHER|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
219183279|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
219183280|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
219183281|NCT06233903|DRUG|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
219183282|NCT04697095|OTHER|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
219183283|NCT06066996|DRUG|Transdermal Nicotine Patch|Blinded Nicotine Patch
219183284|NCT06066996|DRUG|Placebo Nicotine Patch|Blinded Patch with No Nicotine
219183285|NCT06004453|OTHER|Heart Failure medications|There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
219183286|NCT06273436|OTHER|H.E.A.R. for Mamas|H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
219183287|NCT06777888|BEHAVIORAL|Family Healthy Living Program weekly group sessions|Children aged 8-12 and at least one caregiver will meet for 9 weekly virtual group intervention sessions (2 hours per session) with program facilitators and will also have access to a virtual Q and A session and up to 3 virtual cooking classes with a Registered Dietician. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions.
219183288|NCT06777888|BEHAVIORAL|Self-guided Web Portal Resources Only|Children aged 8-12 and at least one caregiver will be offered access to digital educational content and downloadable resources on topics such as physical activity, healthy eating, and positive mental well-being.
219760813|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
219760814|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
219183289|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
219183290|NCT07063875|DRUG|Aldesleukin|IL-2 in combination with Tebentafusp
219183291|NCT06089278|DRUG|300mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
219183292|NCT06089278|DRUG|600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
219183293|NCT06089278|DRUG|TQH2722 injection matching placebo|Placebo without active substance.
219183294|NCT06389565|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.
219183295|NCT06389565|OTHER|Change My Story|Change My Story is a narrative game with a choose-your-own-adventure format in which players navigate emotionally difficult experiences along with the character(s) and interact with the virtual environment to choose a narrative path toward the story's conclusion. It will used to address important obstacles in the mental health treatment gap for Y-PLWH.
219183296|NCT04068246|DRUG|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
219183297|NCT04068246|DRUG|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
219183298|NCT04116320|DEVICE|Echopulse|The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
219183299|NCT04116320|DRUG|Poly ICLC|Poly-ICLC is a TLR3 agonist.
219183300|NCT04116320|DRUG|Standard of Care PD-1 Therapy|PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
219183301|NCT06492746|DEVICE|HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring|The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
219183302|NCT06964633|BEHAVIORAL|Kūkākūkā Discussion Sessions|Participants attend a single 2-hour, flip-chart-guided module that integrates a focused health topic (e.g., colorectal cancer screening) with Hawaiian cultural teachings-beginning with an 'ōlelo no'eau (proverb) and guided by trained facilitators-to foster peer discussion, deliver key health information, and assess knowledge via pre- and post-test surveys.
219183303|NCT05678673|DRUG|XL092|Specified doses on specified days
219183304|NCT05678673|DRUG|Nivolumab|Specified doses on specified days
219183305|NCT05678673|DRUG|Sunitinib Malate|Specified doses on specified days
219754223|NCT06862622|BEHAVIORAL|Computer-based visuomotor sequence learning and interference|The behavioral sequence learning and interference paradigm allows the experimental manipulation of sequence memory after long-term consolidation achieved through individualized longitudinal practice and serves the extraction of the primary behavioral outcome. The learning task requires participants to respond with keypresses on a standard computer keyboard of visual targets. Participants will implicitly (without being made aware) learn sequential regularities provided through the recurring order of cued keys contrasted with random keys. Participants will practice the learning task remotely over consecutive days until a stable performance plateau is reached. During this phase, data will be collected online, and behavioral change will be monitored in real time. Then participants will undergo the behavioral interference intervention, in which the initially learned sequence memory will be perturbed through (implicit) exposure to new sequential information (i.e., interference).
219754224|NCT07004842|OTHER|48 hr Respite Service|Caregivers will be provided with 48 hours of respite service within 6 months. Trained alternative caregivers will provide elderly-sitting service at their home, allowing the caregivers to have their personal time.
219183312|NCT05211180|BEHAVIORAL|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
219183313|NCT05211180|BEHAVIORAL|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
219183314|NCT05637320|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
219183315|NCT06772220|DIETARY_SUPPLEMENT|Folic Acid 1 MG|Folic Acid 1mg per day
219183316|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B6 25 MG|Vitamin B6, 25mg per day
219183317|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, 1,000 ug per day
219183318|NCT03792763|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
219183319|NCT03792763|DRUG|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
219183320|NCT06487182|OTHER|reiki|reiki
219183321|NCT06487182|OTHER|placebo reiki|placebo reiki
219183322|NCT05756985|PROCEDURE|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
219183323|NCT00433329|DRUG|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
219183324|NCT00433329|DRUG|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
219183325|NCT06070012|DRUG|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
219183326|NCT03381196|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
219183327|NCT03381196|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
219183328|NCT03381196|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
219183329|NCT06803186|DEVICE|High-power laser therapy|"High power laser therapy (HPLT) with a neodymium-yttrium aluminum garnet laser with a pulsating waveform produced by a ( Hilterapia device , ASA, Arcugnano, Vicenza, Italy). It will be set at the following parameters: Nd:YAG laser with pulsed emission (1064 nm), very high peak powers with average power 6 W, high levels of fluency (760 mJ/cm energy density), short pulse duration (250 μs), low frequency (10-40 Hz), and 5-cm probe diameter for 15 minutes.~The scanning will be performed longitudinally \&transversely from the C3 to C7 posterior neck in the paraspinal region, upper back, inter-scapular area, trapezius, sternocleidomastoid muscles, and posterior \& lateral shoulder areas"
219183330|NCT06803186|DEVICE|Placebo (PL) high power laser|laser probe scanning will be applied to the same areas as that applied in the HPLT procedure. PL will be applied while the lights of the device will be on, with no current flowing through the device. Placebo therapy will be applied at the same frequency as HPLT (Three sessions a week for six weeks for a total of 18 sessions; one session will be lasted 15 minutes).
219183331|NCT06803186|OTHER|Conventional physical therapy program|A specific program of 45-min exercise of three sessions a week for six weeks for a total of 18 sessions. Corrective exercises will be performed initially by stretching exercises for(suboccipital, upper trapezeius, scalene, levator scapulae, sternocleidomastoid, pectoralis major/minor muscles) will be given four repetitions with 30 second hold. each with 3 seconds rest between each stretch Then, strengthening exercises will be performed initially in an isometric manner for weak muscles (deep cervical flexors, rhomboidus, and lower trapezeius muscles) will be done initially without weight and afterward by using Theraband and dumbells. All patients will be instructed to achieve three sets of 12 repetitions of the strengthening exercises (isometrics exercises) with 1 to 2 minutes rest in between each set. Contraction will be held for 5 seconds/repetitions. 10-20 repetitions for strengthening exercises and 3 sets of 30 repetitions for endurance exercise
219183332|NCT05333016|BEHAVIORAL|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
219183333|NCT06807125|PROCEDURE|Resin matrix ceramic block|Milled resin composite block for fabrication of permanent, indirect restorations using a CAD/CAM grinding process. shock absorbing affect due to the dentin- like modulus of elasticity makes BRILLIANT Crios will suited or indirect restoration.
219183334|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
219183335|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
219183336|NCT06401512|BEHAVIORAL|Guided self-determination (GSD) follow-up approach by primary care nurses.|The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
219183337|NCT05907798|PROCEDURE|LIMA Blood flow|30 minutes after induction
219183338|NCT06804083|DRUG|oral combination of colostrum and Serenoa repens extracts (PROSTYM®)|"The composition of PROSTYM® (per capsule) includes bovine colostrum (30 mg), Serenoa extracts (320 mg), glutathione (30 mg), N-acetyl cysteine (20 mg), Ribes nigrum extracts (50 mg), willow extracts (50 mg), zinc (5 mg), selenium (27.5 micrograms), and vitamin E (6 mg).~Drug administration (1 capsule per day) for 6 months."
219183339|NCT04140903|DRUG|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
219183340|NCT04140903|DRUG|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
219183341|NCT05385237|DIAGNOSTIC_TEST|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
219183342|NCT04972669|DEVICE|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
219754225|NCT07004400|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
219754226|NCT07004400|PROCEDURE|Nissen fundoplication|Standard surgical technique for Nissen fundoplication
219183343|NCT04972669|DEVICE|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
219183344|NCT05258071|DRUG|Pirepemat|Oral use
219183345|NCT05258071|DRUG|Placebo|Oral use
219183346|NCT03388944|BEHAVIORAL|PCT group|In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
219183347|NCT05868343|OTHER|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
219183348|NCT05868343|OTHER|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
219183349|NCT06460389|DIAGNOSTIC_TEST|Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
219183350|NCT05986682|DRUG|Blenrep|Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
219183351|NCT04044768|GENETIC|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
219183352|NCT06265922|DEVICE|High frequency repetitive transcranial magnetic stimulation|High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.
219183353|NCT06265922|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
219183354|NCT06052865|BEHAVIORAL|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
219183355|NCT06052865|BEHAVIORAL|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
219183356|NCT06052865|OTHER|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
219754227|NCT04810091|DRUG|Placebo Administration|Given PO
219183357|NCT04468659|DRUG|Lecanemab|IV infusion.
219183358|NCT04468659|DRUG|Placebo|IV infusion.
219183359|NCT06225063|OTHER|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
219183360|NCT06225063|OTHER|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
219183361|NCT01574274|DRUG|SC-PEG|11 doses Intravenously over one hour
219183362|NCT01574274|DRUG|Oncaspar|16 doses Intravenously over one hour
219183363|NCT06307951|OTHER|No intervention|No intervention
219754228|NCT04810091|OTHER|Questionnaire Administration|Ancillary studies
219754229|NCT04810091|DRUG|Telotristat Ethyl|Given PO
219183364|NCT05089019|DRUG|Selpercatinib|Administered orally
219183365|NCT06279416|PROCEDURE|fiberoptic intubation|awake nasal fiberoptic intubation
219183366|NCT06279416|PROCEDURE|laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
219183367|NCT06279416|PROCEDURE|videolaryngoscopy|awake intubation with videolaryngoscopy
218999599|NCT01044771|DRUG|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
218999600|NCT05780658|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
218999601|NCT02088710|BEHAVIORAL|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
218999602|NCT03118258|BEHAVIORAL|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
218999603|NCT03118258|BEHAVIORAL|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
218999604|NCT04357132|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
218999605|NCT04357132|OTHER|VR-Distraction|Participants will be instructed to use one of four applications
218999606|NCT01230632|DIETARY_SUPPLEMENT|high fat overfeeding|Dietary Supplement:3 days overfeeding
218999607|NCT03332654|OTHER|Determine prevalence of stress urinary incontinence|
218999608|NCT04775875|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
218999609|NCT06379412|OTHER|observational study, no intervention|observational study, no intervention
218999610|NCT05817825|BEHAVIORAL|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
218999611|NCT05817825|BEHAVIORAL|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
218999612|NCT04007718|BEHAVIORAL|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
218999613|NCT02285790|DEVICE|Reflectance confocal microscopy|
218999614|NCT02285790|PROCEDURE|Punch biopsy|
218999615|NCT02285790|PROCEDURE|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
218999616|NCT05786820|DIETARY_SUPPLEMENT|Pycnogenol|daily consumption of a pycnogenol-containing capsule
218999617|NCT05786820|DIETARY_SUPPLEMENT|Placebo|Daily consumption of a placebo capsule
218999618|NCT00420927|BIOLOGICAL|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
218999619|NCT00420927|DRUG|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
218999620|NCT00420927|BIOLOGICAL|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
218999621|NCT02246660|DRUG|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
218999622|NCT02246660|DRUG|Placebo|Placebo will be taken orally for 6 months.
218999623|NCT03032146|PROCEDURE|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
218999624|NCT03018704|DRUG|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
218999625|NCT03018704|DRUG|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
219183368|NCT03626766|BEHAVIORAL|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
219183369|NCT03626766|BEHAVIORAL|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
219183370|NCT03626766|BEHAVIORAL|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
219183371|NCT05720416|DIETARY_SUPPLEMENT|protein supplementation|protein supplementation for 16 weeks
219183372|NCT05720416|BEHAVIORAL|muscle strength training|muscle strength training for 16 weeks
219183373|NCT05720416|OTHER|usual care|no intervention
219183374|NCT01593917|DEVICE|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
219183375|NCT04978506|DRUG|BI 1569912|BI 1569912
219183376|NCT04978506|DRUG|Placebo|Placebo
219183377|NCT05553145|DIAGNOSTIC_TEST|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
219183378|NCT05006157|DEVICE|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
219183379|NCT05856344|DEVICE|Spherical tip noncompliant balloon|The main difference of this experimental balloon is the spherical tip, other parameters are consistent with regular noncompliant balloons.
219183380|NCT05856344|DEVICE|Regular noncompliant balloon|The balloon is designed as tapered-tip.
219183381|NCT06029075|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
219183382|NCT06029075|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
219183383|NCT06029075|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
219183384|NCT05713383|BEHAVIORAL|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
219183385|NCT04043156|RADIATION|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
219183386|NCT04068623|OTHER|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
219183387|NCT05673772|RADIATION|short-course radiotherapy|25 Gy in 5 fractions for 5 days
219183388|NCT05673772|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
219183389|NCT05673772|RADIATION|Chemoradiotherapy|45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
219183390|NCT05673772|PROCEDURE|TME surgery|TME surgery
219183391|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
219183392|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
219183393|NCT04070443|DRUG|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
219183394|NCT04070443|DRUG|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
219183395|NCT06283511|OTHER|educational workshops|patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme
219183396|NCT05921344|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
219183397|NCT04588064|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
219754230|NCT06920238|DEVICE|Therabot-CALM|Therabot is a generative-AI-driven mobile app designed to provide mental health treatment. The feasibility of Therabot-CALM, an adapted Therabot application, is being tested for the future use of treating co-occurring substance use disorders and anxiety and/or depression. The primary purpose of this study is application feasibility.
219183398|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
219183399|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
219183400|NCT05099302|OTHER|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
219183401|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
219183402|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
219183403|NCT04457596|BIOLOGICAL|Trastuzumab Emtansine|Given IV
219183404|NCT04457596|DRUG|Placebo Administration|Given PO
219183405|NCT04457596|DRUG|Tucatinib|Given PO
219183406|NCT04457596|OTHER|Questionnaire Administration|Ancillary studies
219183407|NCT04457596|OTHER|Quality-of-Life Assessment|Ancillary studies
219183408|NCT03538899|DRUG|AProArt-CD34|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
219183409|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
219183410|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
219183411|NCT05378113|DRUG|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
219183412|NCT05378113|DRUG|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
219183413|NCT06546891|BEHAVIORAL|Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
219183414|NCT05304104|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
219183415|NCT05895838|DRUG|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
219183416|NCT05895838|PROCEDURE|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
219183417|NCT05895838|PROCEDURE|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
219183418|NCT05895838|DRUG|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
219183419|NCT03127007|DRUG|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
219183420|NCT03127007|DRUG|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
219183421|NCT06485687|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
219183422|NCT05530603|BEHAVIORAL|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
219183423|NCT05423444|BEHAVIORAL|TF-CBT|evidence-based psychotherapy for trauma in youth
219183424|NCT05423444|BEHAVIORAL|TAU|treatment as usual
219183425|NCT02043678|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
219183426|NCT02043678|DRUG|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
219183427|NCT02043678|DRUG|Abiraterone|1000 mg once daily, oral, with best supportive care
219183428|NCT02043678|DRUG|Prednisone/Prednisolone|5 mg twice daily, oral, with best supportive care
219183429|NCT06499389|PROCEDURE|Systematic and early intensive instrumental respiratory physiotherapy for patients undergoing difficult ventilatory weaning|Patients randomized to this group will receive 3 sessions per day of intensive early respiratory physiotherapy with instrumental techniques from randomization to day 7, before and after any extubation. The strategy will be applied until day 7 of randomization, regardless of the patient's status (intubated or not).
219183430|NCT06499389|PROCEDURE|Protocolized standard-of-care respiratory physiotherapy|Patients in this group will receive standardized and protocolized respiratory physiotherapy to reproduce the usual practices of non-expert centers,1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary
219183431|NCT06431997|BEHAVIORAL|Time-limited eating|All participants will be instructed to follow a diet of 1800-2200 kcal/d (45-50% of energy from carbohydrate, 15-20% from protein, 25-30% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
219183432|NCT05522075|BEHAVIORAL|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
219183433|NCT05522075|BEHAVIORAL|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
219183434|NCT04855175|DEVICE|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
219183435|NCT04855175|OTHER|Autograft|Patients in this arm will use patient's own bone
219183436|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
219183437|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
219183438|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
219183439|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
219183440|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
219183441|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
219183442|NCT03216057|DIETARY_SUPPLEMENT|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
219760815|NCT03256721|DRUG|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
219183443|NCT03216057|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
219183444|NCT05275725|DRUG|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
219183445|NCT04568603|DRUG|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
219183446|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
219183447|NCT06151119|DIAGNOSTIC_TEST|68Ga FAPI PET/CT|68Ga FAPI PET/CT
219183448|NCT04564742|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
219183449|NCT04564742|DRUG|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
219183450|NCT05194540|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
219183451|NCT03313076|DRUG|Omega-3 fatty acids (fish oil)|4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
219183452|NCT03313076|DRUG|Vitamin D3 (cholecalciferol)|1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
219183453|NCT03313076|DRUG|Vitamin D3 (cholecalciferol) placebo|1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
219183454|NCT03313076|DRUG|Omega-3 fatty acid placebo|4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
219183455|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
219183456|NCT06073301|DEVICE|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
219183457|NCT06073301|OTHER|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
219183458|NCT05946070|OTHER|ONKOSIS|ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
219183459|NCT05644028|BEHAVIORAL|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
219183460|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
219183461|NCT05044689|BEHAVIORAL|Questionnaire|Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
219183462|NCT05044689|DEVICE|Bioimpedance/Body Composition Unit|Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
219183463|NCT04243356|BEHAVIORAL|Nurse Encounter Group|Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
219183464|NCT04243356|OTHER|Nurse control group|This group will complete surveys.
219183465|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
219183466|NCT05659381|DRUG|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
219183467|NCT05659381|OTHER|No treatment|No treatment with Cisplatin
219183468|NCT04484727|OTHER|PEEP-step method|By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
219183469|NCT06813469|GENETIC|LRS analysis|Long Read Sequencing (LRS) and High-throughput chromosome conformation capture (Hi-C) analysis to explore and functionally characterize the r(14) event and its impact on the three-dimensional (3D) genomic architecture inside the cells of r(14)S patients
219183470|NCT04406623|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
219183471|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
219754231|NCT06921707|DEVICE|Clinical Decision Support Tool|WounDx is a clinical decision support tool that will help augment the clinicians' judgment regarding the wounds readiness to close.
219754232|NCT06921707|PROCEDURE|Standard of Care (SOC)|The standard of care consists of serial wound irrigation, negative pressure wound therapy, and surgical debridement
219183472|NCT05320250|OTHER|Single saliva collection|1 ml of saliva will be collected with Salivette swabs.
219183473|NCT05320250|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects diagnosed with PD will undergo assessments and saliva sampling before starting rehabilitation treatment (T0), at the end of treatment (T1) and 3 months after the end of treatment (T2).
219183474|NCT04094246|PROCEDURE|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
219183475|NCT04094246|PROCEDURE|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
219183476|NCT03965338|DIAGNOSTIC_TEST|fMRI|Screening
219183477|NCT02298504|DRUG|Mineral Trioxide Aggregate|Vital pulp therapy
219183478|NCT02298504|DRUG|Biodentin|Vital pulp therapy
219183479|NCT02298504|DEVICE|Vitrebond|Vital pulp therapy
219183480|NCT04307355|DEVICE|Transcu O2®|Breasts randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
219183481|NCT04307355|OTHER|Tegaderm|A 10 cm × 12 cm Tegaderm TM Film adhesive (3M Healthcare, Minnesota).
219183482|NCT04307355|OTHER|Silagen|A 10 cm × 12 cm silicon sheet (Silagen, New Medical Technology, Inc, Illinois).
219183483|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
219183484|NCT05309551|DEVICE|IMT- Intervention group|The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
219183485|NCT05309551|DEVICE|IMT- Placebo group|The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
219183486|NCT05543655|OTHER|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
219183487|NCT06008730|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219183488|NCT06008730|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219183489|NCT06008730|OTHER|Radiology, Treatment Planning|Undergo radiation treatment planning
219183490|NCT05843799|DRUG|ILB-202|Single i.v. infusion
219183491|NCT05843799|DRUG|Placebo|Single i.v. infusion
219183492|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 1|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 short hairpin (sh)RNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 1 in the dose escalation phase of the study will receive a fixed number of intramuscular (IM) injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 1.2e13 vg/subject."
219183493|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 2|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 2 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 3.6e13 vg/subject."
219183494|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 3|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject."
219183495|NCT06185673|GENETIC|BB-301: Dose expansion phase 2a|Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
219183496|NCT03039751|DRUG|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
219183497|NCT03039751|DRUG|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
219183498|NCT02690558|DRUG|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
219183499|NCT04225273|DEVICE|Sculptra Aesthetic, Lidocaine HCL|No intervention was administered during this extension study.
219183500|NCT04888832|OTHER|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
219183501|NCT04599504|DRUG|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
219183502|NCT04599504|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
219183503|NCT06285357|DIETARY_SUPPLEMENT|EGCG + folic acid + B12|EGCG + folic acid + B12
219183504|NCT05686395|PROCEDURE|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
219183505|NCT05686395|PROCEDURE|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
219183506|NCT05686395|DRUG|Bupivacaine|bupivacaine 0.25%.
219183507|NCT04016155|DEVICE|Abbott FreeStyle Libre|Flash CGMS
219183508|NCT04016155|DEVICE|Patient Own SMBG|Market SMBG
219760816|NCT03256721|DRUG|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
219183509|NCT06332859|OTHER|Resilience training|The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
219183510|NCT05448105|OTHER|My Diabetes Care (MDC)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate diabetes self-care information. In this study, the MDC user-interface was expanded to display additional diabetes health-data, including urine microalbumin and weight/body mass index (BMI) and a Spanish-language version of MDC was available to Spanish-speaking patients with limited English proficiency.
219183511|NCT06382675|DEVICE|Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2|230 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
219183512|NCT00313222|DRUG|bosentan|
219183513|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
219183514|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
219183515|NCT05270408|DEVICE|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
219183516|NCT05688280|DRUG|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
219183517|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
219183518|NCT05646524|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
219183519|NCT06119464|OTHER|Multimodal Intervention: Education|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
219183520|NCT06119464|OTHER|Multimodal Intervention: Audit and Feedback|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
219183521|NCT06119464|OTHER|Multimodal Intervention: Patient Engagement|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
219183522|NCT06119464|OTHER|Multimodal Intervention: System Changes|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
219183523|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (active)|Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
219183524|NCT05842473|BEHAVIORAL|Language therapy|Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
219183525|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (sham)|Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
219183526|NCT05195840|BEHAVIORAL|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
219183527|NCT05195840|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
219183528|NCT03767621|OTHER|Indication of revascularization|Device: iFR/FFR
219183529|NCT06522256|PROCEDURE|High-resolution anoscopy|"The study includes 2 visits:~* a medical consultation for inclusion~* a proctology consultation including the performance of an AHR associated or not with biopsy sampling"
219183530|NCT05774639|DRUG|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
219183531|NCT05774639|DRUG|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
219183532|NCT02465268|BIOLOGICAL|pp65-shLAMP DC with GM-CSF|
219183533|NCT02465268|BIOLOGICAL|unpulsed PBMC and saline|
219754233|NCT06680583|OTHER|physical indicators such as shock index relatives|shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
219183534|NCT02465268|DRUG|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
219183535|NCT02465268|DRUG|Saline|
219183536|NCT02465268|BIOLOGICAL|pp65-flLAMP DC with GM-CSF|
219183537|NCT06166420|OTHER|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
219183538|NCT06166420|OTHER|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
219183539|NCT06803758|DIAGNOSTIC_TEST|Teicoplanin Allergy Testing using autologous serum|"In addition to performing teicoplanin allergy skin testing using standard recommended Teicoplanin concentration, we will perform skin testing using autologous serum, the supernatant which is obtained via centrifugation. Skin testing ( skin prick test and intradermal test) will be performed with these additional samples:~1. STpre: Teicoplanin added to blood sample pre-centrigufation.~2. STpost: Teicoplanin added to supernatant post-centrigufation.~3. ST0: Supernatant with no additives ( serum negative control)"
219183540|NCT06027086|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
219183541|NCT06027086|DRUG|DRP-104|"Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration."
219183542|NCT06802419|OTHER|Continuous adductor canal block|Patients will receive continuous adductor canal block.
219183543|NCT06802419|OTHER|Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule|Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee
219183544|NCT06798896|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
219183545|NCT06798896|DRUG|Placebo|Placebo, bid
219183546|NCT06803017|BEHAVIORAL|combination of exercise and sport with fast-tempo music|Fast-tempo music selected by the researcher with exercise training and sports training
219183547|NCT06803017|BEHAVIORAL|combination of exercise and sport with slow-temp music|Slow-tempo music selected by the researcher with exercise training and sports training
219183548|NCT06803017|BEHAVIORAL|combination of exercise and sport with no music|Exercise training and sports training without music
219183549|NCT04701671|BEHAVIORAL|Observational (not including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
219183550|NCT04701671|BEHAVIORAL|Observational (including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
219183551|NCT06803784|GENETIC|Genetic: whole genome sequencing|Genetic: whole genome sequencing PD Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
219183552|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~AD Partecipants will be assessed for disease progression:~* assessment of cognitive disorders (MMSE, MOCA test, clock test);~* assessment of language disorders;~* current drug therapy (and possible start date of treatment);~* date of onset of cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate AD genes"
219183553|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~ALS/FTD Partecipants will be assessed for disease progression:~* clinical classification according to El Escorial - revised;~* assessment of cognitive disorders (and classification according to Strong criteria, 2017);~* assessment of language disorders;~* ongoing pharmacological therapy (and possible start date of treatment);~* date of onset of motor and cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate ALS/FTD genes"
219183554|NCT02596802|DEVICE|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
219183555|NCT04333745|OTHER|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
219183556|NCT04333745|DIETARY_SUPPLEMENT|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
219183557|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation
219183558|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation + training with WBVE|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation + 24 sessions (2 sessions per day) of 30 minutes each of training on a vibration platform (WBVE)
219183559|NCT06111027|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
219183560|NCT06799104|OTHER|Pyramidal training|"Pyramidal training prescription:Mode of exercise: aerobic interval training. Intensity: ranging from 20-80% from THR. Duration: 40 minutes per session.Frequency: Three sessions per week for 12 weeks.~The course of the program will be 2 sets of pyramidal training with 10 minutes for rest between them. Each set will be 5 levels of incremental and 5 levels of decremental aerobic exercise and each level 2 minutes on a treadmill.~1. Level one: will be set as a 20% walking of Karvonen formula.~2. Level two: will be set as a 30% running of Karvonen formula.~3. Level three: will be set as a 50%running of Karvonen formula.~4. Level four: will be set as a 70% running of Karvonen formula.~5. Level five: will be set as a 80% running of Karvonen formula."
219183561|NCT06799104|OTHER|Mediterranean diet|"Mediterranean diet:~Meal Composition Main meals consumed daily should be a combination of three elements: cereals, vegetables and fruits, and a small quantity of legumes, beans or other (though not in every meal). Cereals in the form of bread, pasta, rice, couscous or bulgur (cracked wheat) should be consumed as one-two servings per meal. Vegetable consumption should amount to two or more servings per day, in raw form for at least one of the two main meals (lunch and dinner). Fruit should be considered as the primary form of dessert, with one-two servings per meal."
219183562|NCT06803173|OTHER|No intervention|No intervention
219183563|NCT05798845|RADIATION|SBRT+LDRT|primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/2Fx, d1-2, d22-23 (2 cycles)
219183564|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d4, d24 (2 cycles)
219183565|NCT05798845|DRUG|Chemotherapy drug|Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
219183566|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d1, d22 (2 cycles)
219183567|NCT05148299|DRUG|Pegcetacoplan|20-cc glass vials-1080 mg
219183568|NCT06011174|OTHER|survey application|Participants will only be asked to fill out the questionnaires.
219183569|NCT05445375|OTHER|PAD education video|20-min online multi-media video
219183570|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
219183571|NCT05135650|OTHER|Questionnaire Administration|Ancillary studies
219183572|NCT05135650|BIOLOGICAL|Sotrovimab|Given IV
219183573|NCT05135650|PROCEDURE|Biospecimen Collection|Undergo blood and nasal swab sample collection
219183574|NCT04326010|DEVICE|Surgery|THA surgery
219183575|NCT03259360|BEHAVIORAL|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
219183576|NCT03259360|BEHAVIORAL|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
219183577|NCT05245682|DRUG|Tolinapant|Given PO
219183578|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
219183579|NCT06365970|DRUG|Niraparib|An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
219183580|NCT06365970|DRUG|Dostarlimab|An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
219183581|NCT06333561|PROCEDURE|Hepatic arterial infusion chemotherapy|Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
219183582|NCT06333561|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
219183583|NCT06333561|DRUG|Tislelizumab|200mg intravenously every 3 weeks
219183584|NCT06333561|DRUG|Toripalimab|240mg intravenously every 3 weeks
219183585|NCT06333561|DRUG|Sintilimab|200mg intravenously every 3 weeks
219183586|NCT06333561|DRUG|Camrelizumab|200mg intravenously every 3 weeks
219183587|NCT03838263|DRUG|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
219183588|NCT03838263|RADIATION|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
219183589|NCT05724823|OTHER|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
219183590|NCT06501729|OTHER|Kiss|Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.
219183591|NCT04571255|BEHAVIORAL|Music-Assisted Relaxation|The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
219183592|NCT04880785|DRUG|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
219183593|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
219183594|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
219183595|NCT05582681|DIAGNOSTIC_TEST|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
219183596|NCT05582681|OTHER|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
219183597|NCT05582681|DRUG|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
219183598|NCT04632238|BEHAVIORAL|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
219183599|NCT04486833|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
219183600|NCT04486833|DRUG|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
219183601|NCT04486833|DRUG|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
219183602|NCT05894954|DIETARY_SUPPLEMENT|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
219183603|NCT05894954|COMBINATION_PRODUCT|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
219183604|NCT05894954|BEHAVIORAL|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
219183605|NCT05894954|BEHAVIORAL|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
219183606|NCT03623074|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
219183607|NCT03623074|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
219183608|NCT03947814|DRUG|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
219183609|NCT05642780|DRUG|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
219183610|NCT05642780|DRUG|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
219183611|NCT02268461|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
219183612|NCT02268461|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
219183613|NCT04686175|DRUG|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
219183614|NCT06407063|PROCEDURE|Micro-decompression alone|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
219183615|NCT06407063|PROCEDURE|Decompression and instrumented fusion|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
219183616|NCT03559569|BIOLOGICAL|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
219183617|NCT05212090|DIAGNOSTIC_TEST|EOS X-Ray|Repeated Anteroposterior (AP) Pelvis x-ray and Lateral Lumbar EOS x-ray
219183618|NCT06074172|DRUG|Cannabidiol (246mg press pill)|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
219183619|NCT06074172|DRUG|Placebo (246mg press pill)|Placebo press pills were provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
219183620|NCT01571700|PROCEDURE|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension \>5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
219183621|NCT03020199|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
219754242|NCT07004231|OTHER|GOUT Buddy, an AI chatbot|"AI Chatbot (GOUT Buddy) offers personalized gout education and awareness tailored to individual needs"
219754243|NCT07002853|OTHER|Nature-based Intervention|Combination of activities in nature such as walking, exercises (strengthening, mobility, balance), mindfulness, guided meditation, forest bathing or Shinrin-Yoku, interpretation of nature, gardening and pain education.
219183622|NCT03020199|RADIATION|nb-UVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
219183623|NCT05496751|BEHAVIORAL|Low amount, low intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
219183624|NCT05496751|BEHAVIORAL|Low amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
219183625|NCT05496751|BEHAVIORAL|High amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
219183626|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
219183627|NCT05372029|BEHAVIORAL|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
219183628|NCT05372029|BEHAVIORAL|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
219183629|NCT04005794|BEHAVIORAL|social VR (virtual reality) training|Social skills game that we developed in the R21 phase will be used across 8 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 4-5 weeks.
219183630|NCT04005794|BEHAVIORAL|Cognitive training (control game)|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
219183631|NCT04547309|RADIATION|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
219183632|NCT05216315|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus HDC stimulator (Newronika TM)
219183633|NCT05216315|DEVICE|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.10 sessions
219183634|NCT05677113|DRUG|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
219183635|NCT05677113|DRUG|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
219183636|NCT04855188|DEVICE|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
219183637|NCT04855188|DEVICE|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
219183638|NCT02859727|DRUG|CDZ173|140 mg/day
219183639|NCT05563038|DEVICE|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
219183640|NCT05563038|DRUG|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
219183641|NCT06041971|DEVICE|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
219183642|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
219183643|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
219183644|NCT05180240|DRUG|CardiolRx|Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
219183645|NCT03245489|DRUG|Pembrolizumab|200mg intravenous (IV) over 30 minutes
219183646|NCT03245489|DRUG|Clopidogrel|75mg/day oral
219183647|NCT03245489|DRUG|acetylsalicylic acid|81mg/day oral
219183648|NCT06580054|PROCEDURE|Computed Tomography|Undergo CT
219183649|NCT06580054|OTHER|Digital Photography|Undergo photographs of tumor
219183650|NCT06580054|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219183651|NCT06580054|BIOLOGICAL|Pembrolizumab|Given IV
219183652|NCT04313972|DRUG|low-dose naltrexone|2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
219183653|NCT04313972|DRUG|Placebo oral tablet|1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
219183654|NCT05557838|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219183655|NCT05557838|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
219183656|NCT03482349|PROCEDURE|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
219183657|NCT06195514|DRUG|TAK-113|Description: TAK-113 5 mg capsules, orally, once daily, in a 3 weeks on/1 week off schedule for each 4-week cycle per treatment guidelines.
219183658|NCT06194773|PROCEDURE|Totalfil|Root canal treatment using TotalFil sealer
219183659|NCT06194773|PROCEDURE|NeoSealer|Root canal treatment using NeoSealer
219183660|NCT06194773|PROCEDURE|AH-Plus sealer|Root canal treatment using AH-Plus sealer
219183661|NCT06428214|DEVICE|Restylane Shaype|Injection
219183662|NCT06428214|DEVICE|Restylane Defyne|Injection
219183663|NCT06428214|DEVICE|Restylane Lyft lidocaine|Injection
219183664|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
219183665|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
219183666|NCT05131581|OTHER|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
219183667|NCT05131581|BEHAVIORAL|Extra time allotted|Extra time allotted for each visit for CST
219183668|NCT05131581|BEHAVIORAL|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
219183669|NCT05354544|BIOLOGICAL|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
219183670|NCT05814653|BEHAVIORAL|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
219183671|NCT05814653|BEHAVIORAL|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
219183672|NCT03649633|DRUG|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
219183673|NCT03649633|DRUG|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
219183674|NCT03550950|DRUG|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
219183675|NCT03550950|DRUG|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
219183676|NCT03550950|DRUG|Placebo|Matching placebo will be administered as IV infusion or SC injection.
219183677|NCT05228158|DRUG|Tazemetostat|Tazemetostat oral tablets.
219183678|NCT06288503|OTHER|Hydrolysed Rice Protein Formula|Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
219183679|NCT06288503|OTHER|Cow's Milk Based Extensively Hydrolysed Formula|Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
219183680|NCT06132581|DEVICE|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
219183681|NCT06132581|DEVICE|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
219183682|NCT06132581|DEVICE|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
219183683|NCT05121545|RADIATION|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
219183684|NCT05151653|DRUG|BI 765250|BI 765250
219183685|NCT05151653|DRUG|Placebo|Placebo
219183686|NCT01652196|BIOLOGICAL|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
219183687|NCT01652196|DRUG|oxaliplatin|85 mg/m2 IV infused over 2 hours
219183688|NCT01652196|DRUG|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
219183689|NCT01652196|DRUG|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
219183690|NCT01652196|OTHER|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
219183691|NCT01652196|PROCEDURE|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
219183692|NCT01652196|RADIATION|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
219183693|NCT01652196|PROCEDURE|PET (positron emission tomography)|Correlative studies
219183694|NCT06286930|DEVICE|anodal trans cranial direct current stimulation (tDCS)|1 20-minute anodal tDCS stimulation
219183695|NCT06286930|DEVICE|cathodal trans cranial direct current stimulation (tDCS)|1 20-minute cathodal tDCS stimulation
219183696|NCT05252520|DRUG|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
219183697|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
219183698|NCT02419976|OTHER|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
219183699|NCT02419976|DEVICE|Aeonose|
219183700|NCT04399941|DIAGNOSTIC_TEST|Venography|The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.
219183701|NCT04399941|DIAGNOSTIC_TEST|Intravascular ultrasound (IVUS)|IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.
219183702|NCT04399941|OTHER|Image processing|Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
219183703|NCT03543683|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
219183704|NCT03543683|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
219183705|NCT06124079|OTHER|OPY interactive messaging service|2 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The two versions differ in the motivational techniques interspersed throughout the OPY experience.
219183706|NCT06124079|OTHER|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
219183707|NCT05386030|COMBINATION_PRODUCT|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
219183708|NCT05386030|COMBINATION_PRODUCT|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
219183709|NCT05219396|DEVICE|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
219183710|NCT06375343|DRUG|PRO-240|-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
219183711|NCT06375343|DRUG|Optive®|\- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.
219183712|NCT04048551|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
219183713|NCT04048551|BEHAVIORAL|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
219183714|NCT04208984|DEVICE|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
219754244|NCT03081390|OTHER|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
219183715|NCT04208984|OTHER|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
219183716|NCT05699239|DRUG|TS-172 10mg bid|oral administration of TS-172 10 mg bid
219183717|NCT05699239|DRUG|TS-172 30mg bid|oral administration of TS-172 30 mg bid
219183718|NCT05699239|DRUG|TS-172 60mg bid|oral administration of TS-172 60 mg bid
219183719|NCT05699239|DRUG|TS-172 20mg tid|oral administration of TS-172 20 mg tid
219183720|NCT05699239|DRUG|Placebo|oral administration of placebo
219183721|NCT01953588|DRUG|fulvestrant|Fulvestrant 500 mg IM
219183722|NCT01953588|DRUG|anastrozole|Anastrozole 1 mg oral tablet
219183723|NCT06241872|OTHER|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
219183724|NCT04524442|DRUG|arginine/lysine|1000 milliliters (mL) administered at a constant rate of 250 mL per hour
219183725|NCT04719832|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
219183726|NCT04719832|DRUG|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
219183727|NCT04469569|BEHAVIORAL|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
219183728|NCT05819346|BEHAVIORAL|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
219183729|NCT05024760|DRUG|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
219183730|NCT05024760|DRUG|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
219183731|NCT03355274|DIAGNOSTIC_TEST|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up)."
219183732|NCT03355274|DIAGNOSTIC_TEST|Photopletysmography|Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
219183733|NCT03355274|OTHER|Questionnaires of Quality of Life (QoL)|Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
219183734|NCT05304364|COMBINATION_PRODUCT|Combination Product: Naltrexone|Naltrexone Implant
219183735|NCT06335095|OTHER|Kinematic sensors|Comparative analysis of kinematic data acquired in supervised and unsupervised environment
219183736|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
219183737|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
219183738|NCT06380868|PROCEDURE|Intravascular imaging-guided PCI|Intravascular imaging including intravascular ultrasound or optical coherence tomography.
219183739|NCT06380868|PROCEDURE|Angiography-guided PCI group|Deployment of a drug-eluting stent under angiography.
219183740|NCT05456880|BIOLOGICAL|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
219183741|NCT03883945|DRUG|AIV001|intradermal injection
219183742|NCT03883945|DRUG|Vehicle|intradermal injection
219183743|NCT04774445|BEHAVIORAL|MyCancerGene|Interactive Health Communication Application
219183744|NCT05228457|DEVICE|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
219183745|NCT06130345|BIOLOGICAL|SPIKEVAX|Intramuscular injection
219183746|NCT05109351|BEHAVIORAL|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
219183747|NCT04826588|DRUG|Methylprednisolone sodium succinate 10 mg/kg intravenously|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
219183748|NCT04826588|BIOLOGICAL|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
219183749|NCT00167674|DRUG|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
219183750|NCT00167674|DRUG|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
219183751|NCT05017545|BIOLOGICAL|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
219183752|NCT05017545|BIOLOGICAL|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
219183753|NCT05017545|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
219183754|NCT05993442|BEHAVIORAL|Optimised kangaroo care|The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,
219183755|NCT04696263|DEVICE|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
219183756|NCT04696263|DEVICE|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
219183757|NCT05669599|BIOLOGICAL|Maridebart Cafraglutide|Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
219183758|NCT05669599|DRUG|Placebo|Participants will receive placebo by SC injection.
219183759|NCT05283915|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: oral
219183760|NCT05308108|PROCEDURE|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
219183761|NCT06135792|OTHER|Arginine|See arm description
219183762|NCT06135792|OTHER|Placebo|See arm description
219183763|NCT03850600|OTHER|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
219183764|NCT05052125|DRUG|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
219183765|NCT04535349|DIAGNOSTIC_TEST|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
219183766|NCT02789956|DEVICE|Internal vs. external cad cam co/cr framework|
219183767|NCT04006951|OTHER|Biological collection|"Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)"
219183768|NCT03948139|DEVICE|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
219183769|NCT03948139|DEVICE|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
219183770|NCT05971381|DEVICE|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
219183771|NCT05906095|BEHAVIORAL|LOCK Falls Program|The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
219183772|NCT06685211|DEVICE|Eyetronic rtACS|The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.
219183773|NCT06685211|DEVICE|Sham rtACS|Participants will wear the Eyetronic system but there will be no active stimulations applied.
219183774|NCT04591275|DRUG|CMAB807 Injection|mAb targeting RANKL, human monoclonal antibody targeting RANKL
219183775|NCT04591275|DRUG|Prolia®|mAb targeting RANKL, human monoclonal antibody targeting RANKL
219183776|NCT03987399|OTHER|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
219183777|NCT04680468|DRUG|Belantamab mafodotin|2.5 mg/kg IV
219183778|NCT06779526|OTHER|Heartfulness Meditation|Receiving an orientation session regarding the study, attending once weekly didactic sessions on Zoom for Heartfulness Meditation, and participating in morning and evening meditation for ten to fifteen minutes daily either by themselves or along with the trainer.
219369769|NCT00675597|DRUG|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
219183779|NCT05590351|BEHAVIORAL|First diet: m-health coaching application|Intervention for the study would comprise of a culturally appropriate m-health application called first diet. This application will be developed considering the perceptions, barriers and facilitators identified through formative research. Content of the messages would focus on breastfeeding, its importance and early initiation within one hour of birth, significance of first feed i.e. colostrum, importance of EBF from birth till 6 months, introduction of complementary feeding to 6-8 months old infants and appropriate YCFP. These messages would be drafted in the local preferable language assessed during formative research. The content of the messages would be translated and then back translated to ensure validity. These messages will be short, contextual and tailored according to the women's stage of gestation, delivery and infant's age
219183780|NCT05590351|BEHAVIORAL|Face to Face counselling|Women randomly enrolled in the non-interventional group will receive face-face nutritional counseling instead of mobile application. Once enrolled in the group, Research Assistant (RA) will collect relevant details on the baseline questionnaire like intervention group but on a paper-based questionnaire. Women will be given first face-face counseling on the day of enrollment. The counseling sessions will coincide with the routine vaccination and growth monitoring schedule of the infant after women deliver
219183781|NCT00070590|DRUG|Bosentan|
219183782|NCT02416258|DRUG|LP0113 aerosol spray|
219183783|NCT02416258|DRUG|Aerosol spray vehicle|
219183784|NCT02416258|DRUG|LEO 90100 aerosol foam|
219183785|NCT02416258|DRUG|Betamethasone dipropionate aerosol spray|
219183786|NCT02416258|DRUG|Calcipotriol aerosol spray|
219183787|NCT02416258|DRUG|Daivobet® gel|
219183788|NCT05631223|BEHAVIORAL|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
219183789|NCT04880863|DRUG|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that are linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP is administered at a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg is administered on Day 1.
219183790|NCT04880863|DRUG|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel is administered in combination with the study drug, NAP, on Day 2.
219183791|NCT04880863|DRUG|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
219183792|NCT04539587|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
219183793|NCT04822363|DRUG|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
219183794|NCT04822363|DRUG|Clopidogrel|Arms C and E
219183795|NCT01006239|OTHER|No study intervention|The is no study related intervention.
219183796|NCT03213691|OTHER|Laboratory Biomarker Analysis|Correlative studies
219183797|NCT03213691|DRUG|Selumetinib|Given PO
219183798|NCT03213691|DRUG|Selumetinib Sulfate|Given PO
219183799|NCT04757363|DRUG|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
219183800|NCT04757363|DRUG|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
219183801|NCT04757363|DRUG|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
219183802|NCT04144023|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
219183803|NCT04144023|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
219183804|NCT04144023|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219183805|NCT04144023|PROCEDURE|Echocardiography|Undergo ECHO
219183806|NCT04144023|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219183807|NCT04144023|PROCEDURE|Biopsy|Undergo biopsy
219183808|NCT04898673|DEVICE|CP1110|Sound Processor
219183809|NCT04898673|DEVICE|CP1000|Sound Processor
219183810|NCT02862210|DRUG|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
219183811|NCT02862210|DRUG|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
219183812|NCT04437264|DIETARY_SUPPLEMENT|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
219183813|NCT04437264|DIETARY_SUPPLEMENT|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
219183814|NCT02587403|DEVICE|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
219183815|NCT02587403|DEVICE|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
219183816|NCT01152450|DRUG|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
219183817|NCT01152450|DRUG|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
219183818|NCT01152450|DRUG|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
219183819|NCT06419621|DRUG|PM8002|PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
219183820|NCT06419621|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
219183821|NCT06419621|DRUG|Placebo|Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
219183822|NCT06361056|BEHAVIORAL|Survey|All participants will complete a brief questionnaire.
219183823|NCT06361056|BEHAVIORAL|mHealth app|Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
219369770|NCT06192173|PROCEDURE|Percutaneous PFO closure|Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.
219183824|NCT06407037|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
219183825|NCT06407037|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Serratus Posterior Superior Intercostal Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
219183826|NCT06066125|DRUG|AK111|AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
219183827|NCT06066125|DRUG|AK111|AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
219183828|NCT06066125|DRUG|Placebo|Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
219183829|NCT06518122|DRUG|HCP1306|Take it once a day per period.
219183830|NCT06518122|DRUG|RLD2302|Take it once a day per period.
219183831|NCT06518122|DRUG|RLD2102|Take it once a day per period
219183832|NCT06779344|OTHER|MxA and CRP tests|A whole blood sample will be collected on the day of randomization for MxA and CRP testing.
219183833|NCT06779344|OTHER|MxA and CRP feedback|MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.
219183834|NCT06779344|OTHER|Follow up|"Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death."
219183835|NCT06704204|DRUG|The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks|To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
219183836|NCT06182527|DEVICE|Free Style Libre Pro IQ|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
219183837|NCT06344026|BIOLOGICAL|ANPD001|Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
219183838|NCT06344026|DEVICE|Custom Device|A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
219183839|NCT06261671|DRUG|antioxidants-enriched culture medium (Gx)|Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
219183840|NCT04455750|DRUG|Enzalutamide|Given PO
219183841|NCT04455750|DRUG|Rucaparib camsylate|Given PO
219183842|NCT04455750|DRUG|Placebo|Given PO
219183843|NCT04455750|DRUG|Leuprolide Acetate|Given IM
219183844|NCT04455750|DRUG|Goserelin Acetate|Given SC
219183845|NCT04455750|DRUG|Degarelix|Given SC
219183846|NCT04455750|OTHER|Quality-of-Life Assessment|Ancillary studies
219183847|NCT04455750|OTHER|Questionnaire Administration|Ancillary studies
219183848|NCT05546411|DRUG|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
219183849|NCT05546411|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219183850|NCT05546411|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219183851|NCT05546411|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219183852|NCT05546411|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219183853|NCT05546411|DRUG|NIS793|Given by intravenous infusion
219183854|NCT05546411|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
219183855|NCT05546411|PROCEDURE|Surgery|Surgical removal of tumor
219183856|NCT02606422|DEVICE|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
219183857|NCT02606422|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
219183858|NCT03257462|DRUG|SPR001|SPR001 Capsules
219183859|NCT04625465|BEHAVIORAL|CBT Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
219369771|NCT00631137|DRUG|testosterone gel applied to skin|Application of testosterone gel
219369772|NCT00631137|DIETARY_SUPPLEMENT|whey powder protein|
219183860|NCT04625465|BEHAVIORAL|Attention Control Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
219183861|NCT03828513|DEVICE|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
219183862|NCT03828513|DEVICE|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
219183863|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
219183864|NCT05986240|DRUG|Danvatirsen|Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
219183865|NCT05986240|COMBINATION_PRODUCT|Danvatirsen + Venetoclax|"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
219183866|NCT04221451|DRUG|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
219183867|NCT04221451|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219183868|NCT05881278|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
219183869|NCT04547595|OTHER|Hypnosis|given by Expert in this method
219183870|NCT06777537|DRUG|Talniflumate|Talniflumate was administered
219183871|NCT04597541|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
219183872|NCT06571994|BEHAVIORAL|Low Plastic Intervention|Participants will be provided with food that contain no or low plastic and PAC. This is defined as minimally processed (according to NOVA Classification) fresh produce where the supply chain is either known to be free, or likely to be free of plastic contamination. Foods that are canned, pickled, use plastic storage containers will be either avoided or substituted where possible with glass. Participants will also follow guidance concerning the preparation of their food. Plastic utensils used in the preparation of food will be substituted for non-plastic. Commonly used personal care products, e.g., shampoo and soaps, and cleaning products will be replaced with no/low PAC alternatives. Participants will be supplied with a comprehensive schedule, and instructions for the 4-week intervention.
219183873|NCT05369429|BEHAVIORAL|My Wellbeing Guide|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
219183874|NCT05985148|RADIATION|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
219183875|NCT04708145|DRUG|Aflibercept Injection|Intravitreal 2mg aflibercept injection
219183876|NCT05566639|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219183877|NCT05566639|BIOLOGICAL|Fluarix Quadrivalent|Sterile suspension for injection.
219183878|NCT06702722|BEHAVIORAL|Enhanced Friendship Bench|Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
219183879|NCT06702722|BEHAVIORAL|Enhanced usual care|Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
219183880|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number."
219183881|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2"
219183882|NCT06283589|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
219183883|NCT03206047|DRUG|Atezolizumab|Given IV
219183884|NCT03206047|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
219183885|NCT03206047|DRUG|Guadecitabine|Given SC
219183886|NCT03206047|OTHER|Laboratory Biomarker Analysis|Correlative studies
219183887|NCT03206047|DRUG|Poly ICLC|Given SC
219183888|NCT04818645|DEVICE|ASSERT Insertable Cardiac Monitor|Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
219183889|NCT04818645|OTHER|Conventional Management and monitoring|Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
219183890|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
219183891|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
219183892|NCT05776810|DIAGNOSTIC_TEST|Diagnostic Test: Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
219183893|NCT05776810|DEVICE|Device: Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
219183894|NCT03819933|BEHAVIORAL|Educational intervention|Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
219183895|NCT04731818|BIOLOGICAL|ZB-06|ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
219183896|NCT03609021|PROCEDURE|Screening Mammography|Provide bilateral mammogram
219183897|NCT03609021|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219183898|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
219183899|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
219369773|NCT04455711|DRUG|Lidocaine Iv|Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
219183900|NCT01705899|DRUG|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
219183901|NCT04990323|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)
219183902|NCT03329157|OTHER|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
219183903|NCT03576365|BEHAVIORAL|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
219183904|NCT03576365|BEHAVIORAL|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
219183905|NCT06277388|DEVICE|Impedance cardiography|The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).
219369774|NCT04455711|DRUG|Remifentanil|Continuous infusion of remifentanil 1.5 ng/ml until extubation
219369775|NCT04385173|DRUG|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
219369776|NCT04385173|DRUG|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
219369777|NCT01805947|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
219369778|NCT03682120|BIOLOGICAL|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
219369779|NCT03682120|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
219369780|NCT03682120|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
219183906|NCT04735458|OTHER|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
219183907|NCT04114669|BEHAVIORAL|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
219183908|NCT04114669|BEHAVIORAL|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
219183909|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
219183910|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
219183911|NCT03593317|DRUG|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
219183912|NCT03593317|DRUG|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
219183913|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
219183914|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
219183915|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
219183920|NCT04593732|DEVICE|STERN FIX (Sternal Stabilization System)|Sternotomy closure with STERN FIX and supplemented with wires
219183921|NCT03800654|BEHAVIORAL|Mindful Action for Pain|MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.
219183922|NCT03800654|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
219183923|NCT04159415|DRUG|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
219183924|NCT04159415|DRUG|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
219183925|NCT04159415|DRUG|High-dose REGN4461|IV infusion loading dose or SC injection QW.
219183926|NCT05859204|BEHAVIORAL|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
219183927|NCT05859204|BEHAVIORAL|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
219183928|NCT06581094|DIETARY_SUPPLEMENT|UCII, glucosamine and curcumin|compound capsules twice daily.
219369781|NCT03470181|DIETARY_SUPPLEMENT|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
219369782|NCT05488860|DRUG|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
219183929|NCT06581094|DIETARY_SUPPLEMENT|Placebo|Placebo capsules twice daily.
219183930|NCT04900701|OTHER|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
219183931|NCT03439449|DEVICE|CLEOS software program|Computer-assisted history taking program
219183932|NCT03439449|PROCEDURE|Physician taken history|Conventional history taking by physicians
219183933|NCT06176300|BEHAVIORAL|PAR - the SEED Method|The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
219183934|NCT06176300|BEHAVIORAL|PAR-Youth Voices|Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
219183935|NCT06176300|BEHAVIORAL|Emerging Leaders hospital-based intervention|Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
219183936|NCT04269200|DRUG|olaparib|Olaparib tablets
219183937|NCT04269200|BIOLOGICAL|durvalumab|Durvalumab by intravenous infusion
219183938|NCT04269200|DRUG|durvalumab placebo|Matching placebo for intravenous infusion
219183939|NCT04269200|DRUG|olaparib placebo|Placebo tablets to match olaparib
219183940|NCT04269200|DRUG|Carboplatin|Standard of care chemotherapy
219183941|NCT04269200|DRUG|Paclitaxel|Standard of care chemotherapy
219183942|NCT06512805|BEHAVIORAL|Routine transport|"1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record."
219183943|NCT06512805|BEHAVIORAL|Post-guideline transfer|"In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0."
219183944|NCT01856478|DRUG|methotrexate|intravenous bolus injection, once weekly
219183945|NCT01856478|DRUG|afatinib|oral intake, once daily
219183946|NCT06827197|DIAGNOSTIC_TEST|Blood test|Blood samples were withdrawn from all the neonates under strict aseptic conditions and stored at -80°C for detecting PGE2 and IL-1β levels. PGE2 and IL-1β concentrations were measured using ELISA.
219183947|NCT05261204|DEVICE|Transcatheter Aortic Valve Implantation|Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
219183948|NCT05261204|PROCEDURE|Bioprothesis|The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
219183949|NCT05261204|PROCEDURE|Sutureless|The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
219183950|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
219183951|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
219183952|NCT04430725|PROCEDURE|Computed Tomography with Contrast|Undergo contrast-enhanced CT
219183953|NCT04430725|PROCEDURE|Microwave Ablation|Undergo microwave ablation
219183954|NCT04430725|OTHER|Questionnaire Administration|Ancillary studies
219183955|NCT04430725|PROCEDURE|Wedge Excision|Undergo wedge resection
219183956|NCT06838780|OTHER|No intervention|No intervention for this retrospective study
219183957|NCT06335823|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
219183958|NCT06335823|DEVICE|Placebo Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
219183959|NCT03850418|DRUG|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
219183960|NCT04737941|PROCEDURE|Endothermal Ablation|Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
219183961|NCT04737941|PROCEDURE|Foam Sclerotherapy|Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
219183962|NCT05759637|DIAGNOSTIC_TEST|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
219183963|NCT04748601|DRUG|Qudexy XR|Extended-Release Capsule
219183964|NCT04748601|DRUG|Placebo|Qudexy XR Matching capsules
219183965|NCT04703179|OTHER|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
219183966|NCT06833424|PROCEDURE|Dural venous sinus stenting|40 patients with idiopathic intracranial hypertension according to Modified Dandy Criteria will subjected to Dural venous stenting
219183967|NCT06820138|DEVICE|Brainsonix Ultrasound Device|This device delivers low intensity focused ultrasound and delivers either active or sham sonication depending upon the transducer pad used.
219183968|NCT06839729|BEHAVIORAL|CEASE+|The intervention will be delivered by the clinician to smoking parents who attend the office visit and to smoking parents not present at the visit via resources sent home with a non-smoking parent. If the smoking parent is present in clinic, the intervention consists of a brief, clinician- delivered motivational intervention that includes messaging around the risks of household smoking, verbal recommendation for establishing home/car smoke-free rules, a printed prescription for nicotine replacement therapy and quitline information, and messaging on the benefits of cessation and a quitline referral. If the smoking parent is not present in clinic, the intervention will include clinician-delivered messaging to the non-smoking parent to share CEASE+ resources with the parent who smokes and an invitation for the parent who smokes to participate in a single call delivered by a culturally-/linguistically-congruent community health worker to connect them to CEASE+ resources.
219183969|NCT05576155|DRUG|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
219183970|NCT05576155|DRUG|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
219183971|NCT02323867|DEVICE|Alpha Beta T cell depletion|
219183972|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
219183973|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
219183974|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
219183975|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
219183976|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
219183977|NCT05012683|DEVICE|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
219183978|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
219183979|NCT04767841|DRUG|Metformin|Metformin 1000mg tablet plus celecoxib 200 mg capsule
219183980|NCT04767841|DRUG|Placebo|Placebo tablet plus celecoxib 200 mg capsule
219183981|NCT06198426|DRUG|IBI3004|IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
219183982|NCT05416658|OTHER|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
219183983|NCT06849219|DRUG|Oxcarbazepine|Oxcarbazepine will be started at a dose of 150 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1800 mg per day.
219183984|NCT06849219|DRUG|Carbamazepine|Carbamazepine will be started at a dose of 100 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1200 mg per day.
219183985|NCT06393608|DRUG|Epsom salt|Epsom salt solution in water, 25% concentration
219183986|NCT06393608|OTHER|Water|Water
219183987|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
219183988|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
219183989|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
219183990|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
219183991|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
219183992|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
219183993|NCT05655702|OTHER|Community based TB intervention|"* 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts."
219183994|NCT04818021|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
219183995|NCT04818021|BEHAVIORAL|Facial Skin Stretch|Facial skin stretch
219183996|NCT04532346|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
219184000|NCT06465381|BEHAVIORAL|Safety Planning Intervention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
219184001|NCT06465381|BEHAVIORAL|Enhanced Usual Care|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
219184002|NCT06465381|BEHAVIORAL|Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
219184003|NCT04732065|DRUG|ONC206|Given orally (PO)
219184004|NCT04732065|RADIATION|Standard of Care Radiation Therapy|Undergo RT
219369783|NCT05488860|PROCEDURE|Piezoelectric drived microneedling|Piezoelectric drived microneedling
219369784|NCT05488860|DRUG|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
219369785|NCT03092050|BEHAVIORAL|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
219184005|NCT04732065|PROCEDURE|Optional Proton (1H) MR spectroscopy (MRS)|Optional imaging procedure
219184006|NCT06975436|DIAGNOSTIC_TEST|cobas® BV/CV test|The cobas® BV/CV test is an automated, qualitative in vitro real-time PCR diagnostic test that detects bacteria and yeast associated with bacterial vaginosis (BV) and candida vaginitis (CV), respectively. The test does not distinguish among the pathogens but can give an overall qualitative result indicating the presence or absence of pathogen(s) associated with BV and/or CV.
219184007|NCT06975436|DIAGNOSTIC_TEST|BD Max™ Vaginal Panel|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
219369786|NCT03092050|BEHAVIORAL|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
219369787|NCT01970163|OTHER|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
219184008|NCT06975436|DIAGNOSTIC_TEST|Cepheid Xpert Xpress MVP|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
219184009|NCT06975436|DIAGNOSTIC_TEST|Hologic Aptima BV Assay|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
219184010|NCT05754203|RADIATION|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
219184011|NCT06429657|DRUG|Ketamine with propofol|Propofol at a rate of 300 mcg/kg/hr (5 mcg/kg/min) with the addition of ketamine at a rate of 1000-5000 mcg/kg/hr (16.67 - 83.33 mcg/kg/min) (using weight at time of admission) with an additional 2 mg/kg (2000 mcg/kg) bolus of ketamine
219184012|NCT06429657|OTHER|Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam|Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the institutional SOC guidelines.
219184013|NCT06609356|PROCEDURE|Study Visit 1|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
219184014|NCT06609356|DRUG|Placebo|"* T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies."
219184015|NCT06609356|PROCEDURE|Study Visit 2|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
219184016|NCT06609356|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
219184017|NCT04046562|BEHAVIORAL|PAW|Pain and Weight Treatment plus standard of care
219184018|NCT04046562|BEHAVIORAL|Pain Education|Pain Education plus standard of care
219184019|NCT05973890|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
219184020|NCT05973890|BEHAVIORAL|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
219184021|NCT05528536|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
219184022|NCT05528536|OTHER|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
219184023|NCT05528536|OTHER|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
219184024|NCT05528536|OTHER|Treatment as usual|treatment as usual within their community centres
219184025|NCT06469723|OTHER|INFA Program|"Participants will be screened using the INFA Screening tool, comprising of assessments for multiple domains that are part of existing routine admission nursing assessments, including functional decline, delirium, recurrent falls, self-reported hearing and visual impairment questionnaires, malnutrition risk, oral health, and dysphagia screening. Nurse-led protocols will be done to address each identified geriatric syndrome.~Participants with complex cases (defined as delirium and/or high-risk falls) will be referred to the GeriCARE service, with capabilities for performing comprehensive geriatric assessment (CGA) guiding discharge planning. Referrals to geriatricians can be initiated whenever necessary, facilitating access to specialised geriatric medical expertise.~Participants will also receive comprehensive discharge planning and systematic follow-up procedures, done by ward resource nurses."
219184026|NCT06978647|DRUG|YTS109 cell|Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.
219184027|NCT06408350|BEHAVIORAL|Text Me, Alexis!|Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
219184028|NCT06655064|OTHER|None- Observational|None- Observational
219184029|NCT05332067|DRUG|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
219184030|NCT05332067|DRUG|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
219184031|NCT05183828|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples
219184032|NCT05183828|DRUG|Letrozole|Given PO
219184033|NCT05183828|OTHER|Questionnaire Administration|Ancillary studies
219184034|NCT06856174|DRUG|Transdermal estradiol gel|All participants: Estradiol gel 0.1%, 0.75 grams (corresponding to estradiol 0.75 mg) applied to the skin of the upper thigh once daily for 12 weeks.
219184035|NCT06856174|DRUG|Micronized Progesterone|Participants with intact uterus: Encapsulated micronized progesterone 100 mg orally once daily for 12 weeks.
219184036|NCT06856174|DRUG|Placebo for estradiol gel|All participants: Placebo for estradiol gel 0.1%, 0.75 grams applied to the skin of the upper thigh once daily for 12 weeks.
219184037|NCT06856174|DRUG|Placebo for micronized progesterone|• Participants with intact uterus: Encapsulated placebo for micronized progesterone 100 mg orally once daily for 12 weeks.
219184038|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
219184039|NCT05840172|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
219184040|NCT05840172|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
219184041|NCT05840172|DEVICE|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
219184042|NCT04581564|BEHAVIORAL|Rhythm-based speech therapy app (i.e., Speech Hero)|Participants will be issued a tablet device pre-installed with a rhythm-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
219184043|NCT04581564|BEHAVIORAL|Non-rhythm based (singing) application (conventional speech therapy)|Participants will be issued a tablet device pre-installed with a singing-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
219184044|NCT05098704|DRUG|clopidogrel treatment|75 mg daily during 24 months
219369788|NCT01970163|OTHER|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
219184045|NCT05098704|DRUG|Placebo|75 mg daily during 24 months
219184046|NCT02992704|DRUG|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
219184047|NCT06595862|BEHAVIORAL|EA-Avatar|The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
219184048|NCT05209152|DRUG|AMG 176|Administered as an intravenous (IV) infusion.
219184049|NCT05209152|DRUG|Azacitidine|Administered as an IV infusion or subcutaneous (SC) injection.
219184050|NCT04700072|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219184051|NCT04700072|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
219184052|NCT04700072|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
219184053|NCT06842498|DRUG|FG-3246|FG-3246 will be administered per schedule specified in the arm description.
219184054|NCT04242199|DRUG|INCB099280|INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
219184055|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
219184056|NCT05547542|DRUG|CVL-354|Oral solution/capsule
219184057|NCT05547542|DRUG|[11C]-LY2795050|IV injection
219184058|NCT05547542|DRUG|[11C]-carfentanil|IV injection
219184059|NCT06171698|DEVICE|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
219184060|NCT05673187|DRUG|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
219184061|NCT06345755|DRUG|VX-407|Solution or Suspension for oral administration.
219184062|NCT06345755|DRUG|Placebo|Solution or Suspension for oral administration.
219184063|NCT06345755|DRUG|Midazolam|Syrup for oral administration.
219184064|NCT06345755|DRUG|VX-407|Suspension or Tablets for oral administration.
219184065|NCT06867185|DEVICE|Brief Electrical Stimulation Therapy|10-minutes of electrical stimulation to repaired nerve
219184066|NCT06867185|PROCEDURE|Digital Nerve Repair|Standard of care surgical repair of digital nerve injury as determined by health care provider.
219184067|NCT06867835|DRUG|Vyleesi (Bremelanotide Injection)|Single dose of BMT 1.75 mg SC on Day 1
219184068|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
219184069|NCT06872944|DRUG|Melatonin|"Melatonin, or N-acetylmethoxytryptamine, is a hormone secreted by the pineal gland in the brain. Light is the main factor that regulates melatonin production. Melatonin has important biological effects on the body and plays an important role in regulating the sleep wake cycle. Besides circadian rhythm stabilizing, exogenous melatonin has been investigated for other effects such as modulation of blood pressure, body temperature and cortisol control, immune function, and anti-oxidative defense.~Recent studies showed some benefits of perioperative short-acting melatonin in different groups of patients such as quality of recovery after surgery, diminished depressive symptoms and pain score reduction"
219184070|NCT06872944|DRUG|Sugar Coated Tablet|sugar coated tablets will be given to the patients at the night (8 PM) before the procedure and another dose 2 hours before surgery
219184071|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
219184072|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
219184073|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
219184074|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
219184075|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
219184076|NCT02568566|OTHER|Laboratory Biomarker Analysis|Correlative studies
219184077|NCT02568566|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219184078|NCT07040761|OTHER|Two medical questionnaires|Medical questionnaires delivered by hand and completed the same day
219184079|NCT07050745|BEHAVIORAL|DADA LINK|"Intervention facilities will receive the DADA-LINK intervention, comprised of:~1. HPV self-sampling: We will provide clinics with HPV self-sampling kits to administer to eligible patients.~2. Care Navigation: One study-supported non-physician care navigator will be assigned to each clinic to support the clinic staff. These trained individuals will be responsible for managing data collection through the mHealth platform to aid the coordination of services and for motivating the clinic staff to adhere to cervical cancer care guidelines.~3. mHealth support for cervical cancer screening and treatment linkage: The WEMA application is a low-cost and highly adaptable open-source application designed for cervical cancer data monitoring and evaluation. Relevant patient information and data on uptake of cervical cancer screening and triage/treatment will be entered in the WEMA platform. The platform will additionally be used to send text messages to patients to facilitate clinic attendance."
219184080|NCT07049497|OTHER|Evaluation of the T cell response in terms of IFN-γ measured by ELISpot|The evaluation of the T cell response will be performed by quantifying the frequencies of SARS-CoV-2-specific T cells producing IFN-γ using an enzyme-linked immunospot assay (ELISpot), with cryopreserved PBMC collected at the designated timepoints (T0, T1, T2, T3, and T4)
219184081|NCT07052006|DRUG|HT-6184|Oral HT-6184
219184082|NCT07057232|OTHER|Usual care provided from pain specialist or within a dedicated pain unit|Adult non-cancer chronic pain patients receiving care in outpatient settings from a pain specialist or within a dedicated pain unit
219754245|NCT03081390|OTHER|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
219184083|NCT04168580|OTHER|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
219184084|NCT07056764|OTHER|Standard treatment|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
219184085|NCT07056764|DEVICE|Standard treatment + Lung vibration device|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
219184086|NCT07058987|BEHAVIORAL|Cardiac Rehabilitation Combined With EECP|This intervention consists of a comprehensive cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support, and lifestyle counseling, combined with enhanced external counterpulsation (EECP) therapy administered according to standard cardiovascular protocols. The combined intervention is designed to improve cardiac function, exercise tolerance, and quality of life in patients with atrial fibrillation.
219184087|NCT07058987|OTHER|Routine Medical Care|Participants in the control group will receive standard medical treatment for atrial fibrillation as prescribed by their attending physicians, without enhanced external counterpulsation or structured cardiac rehabilitation. This may include pharmacological therapy, routine clinical monitoring, and general lifestyle advice.
219184088|NCT07057947|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Injection of local anesthetic between deltoid muscle and subcapsularis tendon
219184089|NCT07057947|PROCEDURE|Interscalene Nerve Block|Injection of local anesthetic between anterior and middle scalene muscles around the roots of brachial plexus
219184090|NCT07057947|DEVICE|Acuson X300 ultrasound,Siemens medical solution INC, Germany|high frequency linear probe
219184091|NCT07059572|DRUG|Group A- 0.15% Guava leaf extract mouthwash group|Participants will be instructed to rinse with 10 ml of 0.15% Guava Leaf Extract Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing.
219184092|NCT07059572|DRUG|Group B- 0.2% Chlorhexidine mouthwash|"Participants will be instructed to rinse with 10 ml of 0.2% Chlorhexidine Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing."
219184093|NCT07059208|PROCEDURE|Atrioventricular nodal ablation|Patients randomised to this arm would undergo physiological pacing followed by atrioventricular nodal ablation
219184094|NCT07059208|PROCEDURE|Pulmonary vein isolation|Patients randomised to this arm would undergo catheter ablation targeted at achieving pulmonary vein isolation
219184095|NCT07062029|OTHER|Laughter Yoga|"The laughter yoga intervention consists of four sessions conducted once a week for four weeks. Each session lasts approximately 30 minutes and includes four components:~* Warm-up exercises with clapping and rhythmic movements~* Deep breathing exercises~* Childlike playful activities and laughter exercises~* Laughter meditation and relaxation Sessions are led by a certified laughter yoga leader in a quiet classroom setting that allows participants to move freely and comfortably. The intervention is designed to improve spiritual well-being and perception of spiritual care among nursing students."
219184096|NCT07063940|OTHER|Home-based exercise and theory-based motivation support programme|"1. A remotely-monitored personalised home-based exercise programme (HBEP) and~2. An autonomous motivation enhancement programme, known as Empowering Physio, delivered to physiotherapists to support them in delivering the HBEP."
219184097|NCT07063940|OTHER|Patient exercise advice leaflet before and after LT.|Control
219184098|NCT07062562|OTHER|Sham (No Treatment)|A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.
219184099|NCT07062562|OTHER|NMES|Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.
219184100|NCT07062562|DIETARY_SUPPLEMENT|Protein bolus (20g)|A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.
219184101|NCT07062562|OTHER|Standard nutrition|Provision of a normal Western standardized diet.
219184102|NCT07063004|OTHER|Bruegger's Exercise and Upper Thoracic Mobilization|"Bruegger's Exercise: The position will be held for 10 second at first session and then there will be an increment of 2 seconds during each session.~Upper Thoracic Mobilization: Upper thoracic (T1-T6) mobilization (Maitland mobilization (Grade I, II and III; PA glide) applied in prone lying position from via spinous process. Amount of treatment will be 3-4 mobilizations for a vertebra for 30 seconds approximately."
219184103|NCT07063004|OTHER|Standard Physical Therapy|"Isometric exercises will be done for flexors, extensors, rotators, and lateral flexors of the neck. Isometrically contracting working muscle for 5 seconds against patients own hand, which was placed in compliance with the working muscles, with a total of 10 repetitions.~Passive stretching will apply to Upper trapezius, Levator scapulae, Sternocleidomastoid, Scalene, Pectoralis major and minor muscle for 3-5 repetition 10 with 20-30 second hold. Intensity of exercise will be prescribed according to patient's tolerance level. Duration of stretch will 15 to 30 seconds, 3-5repetition and for 10 minutes.~Postero-anterior Maitland mobilization (Grade I \& II) for C1-C2, Maitland lateral PA glide (Grade-III \& IV) for C3-C6. Time of oscillations will be two or three oscillations in a second for one to two minutes."
219184104|NCT07062601|DRUG|Etomidate and fentanyl group|In the etomidate-fentanyl group (group A), 0.3 mg/kg etomidate and 4 µg/kg fentanyl were given at the induction of anesthesia, followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the surgery, respectively.
219184105|NCT07062601|DRUG|Etomidate and esketamine group|In the etomidate-esketamine group (group B), induction of anesthesia with 0.3 mg/kg etomidate and 0.5 mg/kg esketamine , followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the operation
219184106|NCT07063992|OTHER|thoracic facet manipulations|"Group A will receive thoracic facet manipulations of the restricted segments between T3 to T9, in the prone position and cephalic direction. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre- and post-intervention observations will be recorded.~Bilateral hypothenar Cross bilateral hypothenar manipulationThese flexibility exercises will be targeted for~* Rhomboid and middle trapezius stretching (2-3 times daily; 3 sets for 30 seconds))~* Pectoralis muscle stretch in a corner (2-3 times daily; 3 sets for 30 seconds)~* Prone on the elbow with upper thoracic extension exercise (2-3 times daily; 3 sets for 30 seconds) .~The postural exercises will be the following~* Postural strengthening/ stabilization with back to a wall. The participant will press their arms into the wall while retracting scapulae.~* Trunk rotation stretching in the sitting position"
219184107|NCT07063992|OTHER|thoracic facet and costovertebral manipulations|"Group B will receive thoracic facet and costovertebral manipulations of the restricted segments between T3 to T9 and ribs 3 to 9 (costovertebral joints), in the prone position. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre and post-intervention observations will be recorded.~Hypothenar Costal Manipulative technique Ilial Hypothenar costal manipulation between T3-T9"
219184108|NCT07062289|PROCEDURE|endoscopic ultrasound-guided portal pressure gradient|This study employs an integrated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG+) protocol uniquely designed for cirrhotic patients with portal vein thrombosis (PVT). Under general anesthesia in the left lateral decubitus position (novel positioning), a linear echoendoscope directs 22G needle puncture of the portal vein and inferior vena cava for direct pressure measurement, with real-time Doppler confirmation to avoid thrombosed vessels. Crucially, this intervention synchronizes diagnostic and therapeutic actions: if high-risk esophageal/gastric varices are identified during EUS, immediate endoscopic therapy (e.g., glue injection) is delivered in the same session. All participants additionally undergo standard hepatic venous pressure gradient (HVPG) measurement via transjugular access within 24 hours, enabling within-patient correlation analysis.
219184109|NCT07062731|BEHAVIORAL|Supervised pelvic floor muscle exercises|4 months of supervised physiotherapy by a women's health physiotherapists (3 sessions in total)
219184110|NCT07064031|OTHER|Neck Isometrics , TENS and Hot pack|Hot apck and TENS applied for 10min each. Using the same amount of light pressure, gently push your head into your hand as you did before. This time, allow the head to move slowly toward the shoulder against the pressure of the hand. This too can be repeated on the opposite side, forwards, backward, and into left and right rotation
219184111|NCT07064291|OTHER|The Lexical Association Technique (LAT)|"The Lexical Association Technique (LAT) was developed by Niveau, New, and Beaudoin in 2021 (Niveau et al., 2022). It is grounded in principles of memory functioning described in the cognitive psychology literature, particularly the theoretical framework of the Self-Memory System proposed by Conway (2000, 2005).~The technique aims to enhance self-esteem by strengthening associative links between the self and positively valenced concepts stored in memory. To achieve this, it relies on the repeated mental visualization of positive autobiographical episodes paired with positive self-referential linguistic statements.~The effectiveness of this technique in increasing self-esteem has been demonstrated and replicated across three studies, conducted with distinct samples: two involving healthy participants and one involving a clinical sample of individuals with a chronic illness (Niveau et al., 2022, 2023)."
219184112|NCT07064291|OTHER|Placebo of the Lexical Association Technique|"The active control condition is based on the same procedural structure as the Lexical Association Technique (LAT), but without the core therapeutic component - the self-referential content. Participants in the control group are exposed to a series of positive statements, similar in form and valence to those used in the LAT, but referring to others (e.g., generic social roles or entities such as teachers, pharmacists, or animals) rather than the self.~Like in the LAT condition, participants are asked to generate mental imagery based on each statement, visualizing a corresponding positive episodic event. This ensures that the control task involves the same cognitive mechanisms (episodic memory retrieval, positive visualization, and sustained attention), while excluding the specific associative link to the self that constitutes the active ingredient of the intervention.~This control condition was designed to match the LAT in terms of structure, cognitive demand, and duration, and has be"
219184113|NCT07061990|DIAGNOSTIC_TEST|Polysomnography (PSG)|Participants underwent overnight polysomnography for a minimum of 7 hours using an E series polysomnography monitor. The monitoring included electroencephalogram (EEG), eye movement, Holter monitoring, airflow, chest and abdominal respiratory movements, and fingertip oxygen saturation. The results were used to diagnose Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) and calculate the Apnea-Hypopnea Index (AHI) for severity classification.
219184114|NCT07061990|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|A whole-brain scan was performed on all participants using a Philips Ingenia 3.0T MRI scanner. The scanning sequences included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), and Fluid-Attenuated Inversion Recovery (FLAIR). The images were analyzed by two neurologists to identify asymptomatic lacunar infarction and to assess the severity of white matter lesions using the Age-Related White Matter Change (ARWMC) scoring system.
219184115|NCT07061990|DIAGNOSTIC_TEST|Serum Inflammatory Marker Measurement|Fasting venous blood (3mL) was collected from all participants on the day of their brain MRI scan. Serum was separated by centrifugation. Levels of Serum Amyloid A (SAA), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-6 (IL-6) were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) method according to the manufacturer's protocols.
219369789|NCT01970163|OTHER|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~* If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~* Hydrogels can also be used if the wound is in need of moisture.~* For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion."
219369790|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
219369791|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
219369792|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
219369793|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
219184116|NCT07062432|BEHAVIORAL|Continuous Comprehensive Nursing System|A multi-faceted nursing plan delivered by trained cardiac nurses, extending from the preoperative phase to 3 months post-discharge. In addition to routine inpatient care, the intervention included: preoperative education and psychological support; postoperative individualized rehabilitation guidance; and a continuous post-discharge program. The post-discharge phase involved structured follow-up (monthly phone calls, one 6-week outpatient visit), ongoing psychological support, reinforcement of education on medication adherence, diet, and activity progression, and guidance on a structured home-based exercise program.
219184117|NCT07062432|OTHER|Routine Postoperative Care|Standard institutional postoperative care for patients after Coronary Artery Bypass Graft (CABG) surgery. This care was primarily focused on the inpatient period and included monitoring of vital signs, wound and drainage tube management, respiratory and circulatory support, and progressive diet guidance. The care concluded with standard discharge instructions and did not include the structured, continuous, or extended follow-up provided to the intervention group.
219184118|NCT07063407|DRUG|HS-20093 in combination with Adebrelimab|HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until disease progression or other criteria for termination of treatment are met.
219184119|NCT07062185|DRUG|ENC1018 capsule administration group|ENC1018 capsules were taken orally once a day for 14 days.
219184120|NCT07063537|DEVICE|Virtual Reality Visual Field (VR-VF)|Both devices administer a standard visual field test. The Humphrey is the gold standard desk top model and the VR-VF is a virtual reality headset designed to deliver visual field testing
219184121|NCT06765681|OTHER|Diagnosis of both VTE and sepsis|Both diagnoses need to present during ICU stay for case inclusion into this retrospective study
219184122|NCT07063641|DEVICE|Percutaneous Electrical Nerve Stimulation (PENS)|Ultrasound-guided percutaneous electrical nerve stimulation applied to the suprascapular nerve using a monophasic or biphasic current at 10 Hz frequency and 250 μs pulse width. Intensity is progressively increased to patient tolerance, aiming to induce visible muscle contractions of the supraspinatus and infraspinatus. Duration of the session is 30 minutes.
219184123|NCT07062575|DEVICE|ABLE Daily|The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks
219184124|NCT07064096|OTHER|cawthorne cooksey exercise|Cawthorne Cooksey exercises -Start with low to moderate intensity. Cawthorne Cooksey exercise Training Phase1-In bed exerercises:- Eye movements: 1)Up and down 2)Side to side 3)Moving finger away from face -Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed -bending forward and backward -turning from side to side. --Shoulder shrugging and circling -Bending forward and picking up objects from the ground - Phase 3 - Standing: -Eye, Head, Shoulder movements -Throwing ball from hand to hand, hand under knee -Switch to sitting to standing and turning around in between. -Phase 4 - Walk: with eyes closed and open: -Across room -Slope and Stairs
219184125|NCT07064096|OTHER|mental imagery|The mental imagery intervention in this study is a structured, guided cognitive training program designed to enhance the effects of vestibular rehabilitation in young adults with unilateral vestibular hypofunction. Mental imagery (MI) involves the internal visualization and mental rehearsal of physical movements without actual motor output, engaging similar neural pathways as actual execution.
219184126|NCT07062224|DIETARY_SUPPLEMENT|Probiotic/Prebiotic Supplement|Oral dietary supplement in gel form (10 mL per day) containing 4000 mg of inulin and 1000 mg of tyndallized probiotics. Administered once daily for approximately 98 consecutive days. Produced by Martínez Nieto S.A. (MARNYS®). Intended to modulate gut microbiota and improve glycemic and inflammatory markers.
219184127|NCT07062224|DIETARY_SUPPLEMENT|Placebo Gel|Oral placebo in gel form (10 mL per day), identical in appearance, texture, and taste to the active supplement, but without probiotic or prebiotic components. Administered once daily for 98 days to maintain blinding and control effects.
219184128|NCT07062666|DRUG|SSRIs|take SSRIs for 2 weeks
219184129|NCT07062666|DEVICE|fNIRS|All subjects receive fNIRS examination.
219184130|NCT07062952|DIETARY_SUPPLEMENT|Salt substitute|Patient consume salt substitutes daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.Salt substitutes (potassium-enriched low-sodium salt, primarily NaCl and KCl) reduce sodium content versus regular salt
219184131|NCT07062341|BEHAVIORAL|Self-Help Plus (SH+)|SH+ is a low-intensity, scalable stress management intervention developed by the World Health Organization. It is designed for delivery in humanitarian settings by non-specialist facilitators. The intervention consists of five 2-hour group sessions delivered via pre-recorded audio, supported by an illustrated guidebook adapted to the local cultural and linguistic context (Juba Arabic). Sessions teach mindfulness, acceptance, and value-driven behavior based on principles from Acceptance and Commitment Therapy. In this study, SH+ is delivered to 12 groups of up to 30 South Sudanese refugee mothers in Rhino Camp, Uganda, by trained lay peers from the refugee community. The intervention is paired with Enhanced Usual Care.
219184132|NCT07062341|BEHAVIORAL|Enhanced Usual Care (EUC)|"EUC consists of a one-time, brief psychoeducation session lasting approximately 15 minutes, delivered individually by a trained lay provider under clinical supervision. The session focuses on helping participants understand and manage common symptoms of psychological distress-particularly local expressions such as overthinking-and introduces simple self-management strategies. Participants are also provided with information about available mental health and psychosocial support services within Rhino Camp, including referral pathways to professional care and community-based resources. This intervention serves as a minimal yet contextually relevant comparator that controls for attention and information exposure while remaining distinct from structured therapeutic interventions like SH+."
219184133|NCT07063771|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
219184134|NCT07062653|OTHER|Supervised group|A progressive core stability exercise program based on motor control principles will be applied on an online platform through videos under the control of a physiotherapist.
219184135|NCT07062653|OTHER|Non-Supervised group|A core stability exercise program with detailed exercise videos will be implemented at home.
219184136|NCT07062354|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Carboplatin + Paclitaxel + Amivantamab hyaluronidase
219184137|NCT07063160|BEHAVIORAL|Pain|Injection was used to determine the level of pain
219184138|NCT07063160|BEHAVIORAL|Fear of injection|The scale developed determines the fear levels of individuals towards the injection procedure. The scale consists of 14 items. It was developed on a 5-point Likert type, 1-I am not afraid at all, 5- I am very afraid. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of fear increases. Stated in their research that the Cronbach Alpha value for the entire scale was 0.92.
219184139|NCT07063160|BEHAVIORAL|Post-injection satisfaction|The scale developed to determine the satisfaction levels of patients regarding the injection process. The scale was developed in a 5-point Likert type, 1-I am not satisfied at all, 5-I am very satisfied. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of satisfaction increases. Post-injection satisfaction Scale consists of 9 items. In the study conducted, it was determined that the Cronbach Alpha value of the entire scale was 0.895.
219184140|NCT07064525|DRUG|SPC1001 Low|low-dose combination therapy
219184141|NCT07064525|DRUG|SPC5002|low-dose combination therapy
219184142|NCT07064525|DRUG|SPC5003|low-dose combination therapy
219184143|NCT07064525|DRUG|SPC5004|low-dose combination therapy
219184144|NCT07063173|DIETARY_SUPPLEMENT|Fruit Bar|Tart Cherry N185
219184145|NCT07063173|DIETARY_SUPPLEMENT|Powdered Drink|Vita Cherry Sport N1244 (FutureCeuticals, Momence, IL)
219184146|NCT07063173|DIETARY_SUPPLEMENT|Commercially available 100% tart cherry juice|100% concentrated Montmorency cherry juice (CherryActive, Sunbury, UK)
219184147|NCT07063173|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
219184148|NCT07064460|DEVICE|Physician Modified Endovascular Graft|The participant's surgeon will modify a commercially available graft tailored to their anatomy for their surgery. All components used to create the final device (PMEG), made specifically for each participant and tailored to their individual anatomy, are FDA-approved, although the final graft itself (the PMEG) is considered investigational.
219184149|NCT07062718|OTHER|Median nerve flossing technique and conventional physical therapy|"Median nerve flossing technique and conventional physical therapy Nerve flossing will be started from root along brachial plexus,median nerve root.~Before starting the procedure ,subjects will be shown the flossing technique as it will be performed actively by the subjects. Each flossing will be performed with 10 repetitions starting from neck,arm,elbow,wrist and whole nerve flossing (12).~It will be a 3 week treatment with 4 session per week (12 sessions)"
219184150|NCT07062718|OTHER|Conventional physical therapy|"The subjects in this group will be treated with TENS and hot pack. All the subjects will be screened according to the inclusion and exclusion criteria .Written informed consent will be taken from all the subjects before the treatment. The subjects will be allowed to withdraw the treatment any time.The subjects will be divided into 2 groups through convenience sampling.All the subjects from both group will be given trancutaneous electric nerve stimulation TENS ,hot pack, isometrics and stretching as a conventional physical therapy followed by respective group techniques~The session will last for 20 -25 minutes , TENS pad will be placed in the suboccipital region and the trapezius unilaterally with hot pack simultaneously for 10 minutes"
219184151|NCT07064590|DEVICE|Transcranial Magnetic Stimulation (TMS)|Patients will receive continuous theta burst stimulation, a five minute treatment protocol with inhibitory effects over the respective brain region 3 times daily. A total of 15 treatments, but will be performed in an accelerated design. Treatment site localization will be based on each patient's individual MRI. Following cortical parcellation using FreeSurfer 7.4.1, the centroid coordinates of the frontal pole will be extracted. For frontopolar stimulation, neuronavigation will be employed to guide coil placement to each patient's frontal pole centroid using Localite Neuronavigator. Stimulation will be performed at 110% resting motor threshold. Pulses will be administered in a burst-firing pattern (3 pulse burst, 50 Hz; 5 Hz \[200-ms\] interburst intervals; 1800 pulses/train with a 60-seconds intertrain interval). To enhance tolerability of frontopolar FP1 TBS, stimulation intensity is gradually escalated from 30% to 110% of resting motor threshold over the first 30 sec of each train.
219184152|NCT05619913|DRUG|Eribulin Mesylate|Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
219184153|NCT05619913|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
219184154|NCT06830239|DRUG|Dostarlimab|"Dostarlimab \[Jemperli GlaxoSmithKline (GSK)\] is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.~Dostarlimab is in clinical development for the treatment of subjects with solid tumors, including those with recurrent/advanced dMMR/MSI-H solid tumors who have progressed on standard of care chemotherapy, as monotherapy or in combination with other agents."
219184155|NCT05925972|PROCEDURE|Plane block|Plane block application in laparoscopic hysterectomies
219184156|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression, the patient will receive the treatment of 6-10Gy\*3-6F plus Benmelstobart.
219184157|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression and the largest lesion measures between 3 cm and 5 cm, the patient will receive the treatment of 3 Gy \* 15 fractions plus Benmelstobart.
219184158|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression and the largest lesion is larger than 5 cm, the patient will receive treatment with Spatial Fractionated Radiotherapy Technique (SFRT) plus Benmelstobart.
219184159|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression, and when the largest lesion is ≤ 3 cm and the patient can maintain the radiotherapy position for 50 minutes, the patient will receive treatment with the hyperfractionated pulsed radiotherapy technique (0.5 Gy \* 16 \* 6 fractions) plus Benmelstobart.
219184160|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, Benmelstobart is continued for maintenance treatment.
219184161|NCT06953843|DRUG|Benmelstobart combined with Bevacizumab and chemotherapy|For eligible subjects who have developed resistance to EGFR-TKI, after 4 cycles of treatment with Benmelstobart combined with Bevacizumab and chemotherapy, if there is no disease progression, they will receive the treatment of 6-10Gy \* 3-6 fractions plus Benmelstobart.
219184162|NCT04531709|OTHER|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
219184163|NCT04531709|OTHER|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
219184164|NCT04531709|OTHER|EORTC QLQ C-30|Assess quality of life in cancer patients
219184165|NCT04531709|OTHER|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
219184166|NCT06955923|DRUG|Trigger point injection (lidocaine)|A trigger point injection utilizing lidocaine 1% without epinephrine will be injected into several muscles bellies immediately following surgery to halt a trigger point from forming. One group will receive this type of intervention and the sham group will not receive any type of injection.
219184167|NCT06955923|OTHER|Sham Comparator|This arm of the study will not receive any injection.
219184168|NCT06067750|DIAGNOSTIC_TEST|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
219184169|NCT06377111|DIETARY_SUPPLEMENT|C-PAN|C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
219184170|NCT06377111|BIOLOGICAL|Nivolumab|Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
219184171|NCT06377111|BIOLOGICAL|Ipilimumab|Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
219184172|NCT03491969|DRUG|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
219184173|NCT03491969|DRUG|Placebos|200 mg, po, tid
219184174|NCT03807128|OTHER|Prélèvement sanguin (2*4mL) ou médullaire (2mL)|Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
219184175|NCT03807128|OTHER|Data collection through questionnaires|Collection of quality of life and occupational exposure data via questionnaires
219184177|NCT05968170|DEVICE|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
219184178|NCT02696707|PROCEDURE|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
219184179|NCT02696707|PROCEDURE|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
219184180|NCT06181227|DRUG|AVD-104|An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
219184181|NCT05882734|DRUG|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
219184182|NCT05882734|DRUG|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
219184183|NCT04867681|BEHAVIORAL|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
219184184|NCT03457402|BEHAVIORAL|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
219184185|NCT06806397|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
219184186|NCT06530511|DRUG|Polatuzumab vedotin|Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;
219184187|NCT06530511|DRUG|Rituximab|Rituximab: 375 mg/m2, IV Drip infusion, D1
219184188|NCT06530511|DRUG|Orelabrutinib|Orelabrutinib: 150 mg/time, qd, po, D1-21
219184189|NCT06211413|OTHER|no intervention|no intervention
219184190|NCT05667857|BEHAVIORAL|Integrative neurocognitive remediation therapy|Integrative Neurocognitive Remediation Therapy is a clinical program of 12 weeks (1 day/week) that combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of adapted physiotherapy, acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and information sessions on cognition, fatigue, nutrition and physical exercise.
219184191|NCT05839080|BEHAVIORAL|Gardens to Bellis|In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
219184192|NCT05839080|BEHAVIORAL|No intervention|Pupils are not receiving any intervention
219184193|NCT06801197|COMBINATION_PRODUCT|MI-Coach: ED Mobile App|The MI-Coach: ED mobile app is a self-guided intervention designed to enhance motivation and readiness for treatment in adults with eating disorders. The app includes seven sequential modules based on motivational interviewing (MI) principles, addressing ambivalence, self-acceptance, compassionate motivation, behavior change goals, sustain and change talk, commitment language, and relapse prevention. Each module incorporates interactive content, including educational videos, articles, and exercises, tailored to support motivation across a range of eating disorder diagnoses. The app is designed to be user-friendly and scalable, providing an accessible, cost-effective solution for individuals on waitlists for formal eating disorder treatment.
219184194|NCT06801977|GENETIC|Genome-wide genotyping|Whole blood from the participants was used to extract DNA for genotyping.
219184195|NCT05560971|DIETARY_SUPPLEMENT|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
219184196|NCT05560971|OTHER|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
219184197|NCT06798168|BIOLOGICAL|Combining bacteriophage therapy with antibiotics for a case with hip PJI|The treatment plan is to treat the patient with weekly intra-articular injections of a personalized phage therapy cocktail (QDP-PSA-011) for 3 consecutive weeks. This will be associated with antibiotics for 6 weeks.
219184198|NCT06800560|OTHER|MenoScale|Menopause symptom questionnaire
219184199|NCT06800560|OTHER|Greene Climacteric Scale|Menopause symptom questionnaire
219184200|NCT06800560|OTHER|RAND 36-Item Health Survey 1.0|Quality of life questionnaire
219184201|NCT06800560|OTHER|PREDICT-FFQ-v1|Food frequency questionnaire
219184202|NCT05260112|OTHER|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
219184203|NCT06803420|DEVICE|Portable, ultra-low-field MRI scanner|"This study evaluates a portable, ultra-low-field MRI scanner (the Hyperfine Swoop) combined with artificial intelligence (AI) to detect brain abnormalities.~Patients undergoing a standard brain MRI scan will be invited to have an additional portable MRI scan within 30 days of their clinical scan. The portable MRI scan will take approximately 60 minutes, using multiple imaging sequences, including T2-weighted scans.~The AI system will then analyse the portable MRI images and categorise them as normal or abnormal. The results will be compared with expert neuroradiologist reports from standard MRI scans to validate accuracy.~This intervention aims to assess whether portable MRI with AI can provide a low-cost, accessible alternative to standard MRI, potentially improving triage and reducing waiting times for patients requiring urgent brain imaging."
219184204|NCT06301412|DEVICE|hypothermia|hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
219184205|NCT06798935|PROCEDURE|autologous platelet-rich stroma|Autologous platelet-rich stroma, which is the combined product of stromal vascular fraction and platelet-rich plasma
219184206|NCT06803290|DRUG|VHX-896|Oral tablet
219184207|NCT06802926|DRUG|Colchicine|Oral Colchicine 0.5mg qd for 1 year
219184208|NCT06802848|DRUG|Xeligekimab injection|This is a real-world study. All treatment regimens are developed and implemented through detailed communication between patients and their treating clinicians. Treatment recommendations are consistent with the medication's prescribing information and treatment guidelines. The recommended dosing for xeligekimab is 200 mg at weeks 0, 2, 4, 6, 8, 10, and 12, followed by every 4 weeks thereafter. Each 200 mg dose is given in 2 separate 100 mg subcutaneous injections. The preferred injection site is the abdomen. Upper arms or thighs are recommended as alternative sites.
219184209|NCT06803433|DEVICE|Aligners|Lower arch in office aligners.
219184210|NCT06803433|DEVICE|Lingual braces|Lingual braces bonded to the lower anterior teeth
219184211|NCT06803433|DEVICE|Active fixed lingual wire|A customized 14 Niti lingual wire customized to the lingual surface of the lower anterior teeth and secured with ligature wires.
219184212|NCT03400826|DRUG|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
219184213|NCT03400826|DRUG|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
219184214|NCT03994367|OTHER|High animal protein isolate|Increased dietary protein content from animal protein isolates
219184215|NCT03994367|OTHER|High animal protein whole food|Increased dietary protein content from animal protein whole food
219184216|NCT03994367|OTHER|High plant protein isolate|Increased dietary protein content from plant protein isolates
219184217|NCT03994367|OTHER|High plant protein whole food|Increased dietary protein content from animal protein whole food
219184218|NCT03854227|DRUG|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
219184219|NCT03854227|DRUG|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
219184220|NCT03854227|DRUG|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
219184221|NCT06268535|DRUG|Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023|Disproportionality analysis studying the association between cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.
219184222|NCT03668236|DRUG|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
219184223|NCT06447480|DRUG|ISOtretinoin 5 MG|"The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended."
219184224|NCT06447480|DRUG|Topical cream|Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
219184225|NCT05374681|OTHER|Medical treatment|Medical treatment alone
219184226|NCT05374681|OTHER|Surgical treatment|Surgical treatment alone
219184227|NCT05374681|OTHER|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
219184228|NCT05295030|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
219184229|NCT05295030|OTHER|Kieember Infant formula, Ruibuen®|Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited
219184230|NCT05295030|OTHER|Yashili Infant formula, Ruibuen®|Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
219184231|NCT04863378|BEHAVIORAL|Walking conversational reminiscence|Triadic walking with prompted conversational reminiscence
219184232|NCT03798093|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
219184233|NCT03798093|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
219184234|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
219184235|NCT05330351|DIAGNOSTIC_TEST|Gastric Ultrasound|The investigators will compare gastric fluid volume as determined by ultrasound pre-induction vs. gastric volume aspirated via an orogastric tube post-intubation. The results will be stratified into low risk, moderate risk and high risk for aspiration based on ultrasound exam by an investigator off-line.
219184236|NCT03818880|DEVICE|Novel spectacle lens design|Spectacle lens to control progression of myopia
219184237|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
219184238|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
219184239|NCT06134336|OTHER|Interview|No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
219184240|NCT06132282|BEHAVIORAL|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
219184241|NCT03132506|OTHER|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
219184242|NCT03850964|DRUG|Pazopanib|gel capsule, with 25mg-similar fills
218999626|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
218999627|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
218999628|NCT06150313|OTHER|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
218999629|NCT00327249|DRUG|imexon|
218999630|NCT04383795|DRUG|Antithyroid Drug|Administration of antithyroid Drug for 6 months
218999631|NCT00320411|DRUG|lapatinib|Lapatinib 1500mg QD
218999632|NCT04580953|DEVICE|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
218999633|NCT01110434|DRUG|Topiramate|Topiramate (200 mg daily)
218999634|NCT01110434|DRUG|Placebo|Placebo (daily)
219184243|NCT03850964|DRUG|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
219184244|NCT03397303|OTHER|elastography measurements|elastography measurements
219184245|NCT06557330|DRUG|Bendamustine|Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
219184246|NCT06557330|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
219184247|NCT06771934|BIOLOGICAL|Allergen-specific immunotherapy(AIT)|"Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks."
219184248|NCT06771934|BIOLOGICAL|omalizumab|Omalizumab Treatment Protocol: The dosage and administration frequency (once every 2 weeks or once every 4 weeks) of omalizumab were determined based on the patients' pretreatment serum total IgE (kU/L), age, and body weight (kg). Each dosage ranged from 15 to 600 mg and was administered subcutaneously. If the dosage was ≤ 150 mg, it was injected subcutaneously at 1 site; otherwise, it was injected subcutaneously at 1 to 4 sites respectively. After the first 3 injections, patients were observed in the hospital for at least 2 hours, and after the 4th and subsequent injections, they were observed for at least 30 minutes. During the treatment period, the background medications for asthma control were adjusted according to the patient's condition.
219184249|NCT06548022|BEHAVIORAL|Rare Group Problem Management Plus|The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.
219184250|NCT05138822|DRUG|GSK3882347|GSK3882347 will be administered on each dosing day.
219184251|NCT05138822|DRUG|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
219184252|NCT05138822|DRUG|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
218999635|NCT03233503|DIAGNOSTIC_TEST|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
218999636|NCT00081640|DRUG|PRO 2000/5 Gel (P)|
218999637|NCT06072729|OTHER|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
218999638|NCT02557646|BIOLOGICAL|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
218999639|NCT02557646|DRUG|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
218999640|NCT04013139|DIAGNOSTIC_TEST|CPET|CPET
218999641|NCT01094223|BEHAVIORAL|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
218999642|NCT01094223|BEHAVIORAL|Health Education|Psychoeducation group focused on various topics pertaining to physical health
218999643|NCT05484622|DRUG|Vorasidenib|Administered orally as tablets.
218999644|NCT05484622|DRUG|Pembrolizumab|Administered as IV infusion.
218999645|NCT01220622|DRUG|Nimodipine|Administration of nimodipine 30mg tid for 6 months
218999646|NCT01220622|DRUG|Placebo|Administration of placebo 30mg tid for 6 months
219184253|NCT05641441|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery
219184254|NCT04527029|OTHER|No interventions|It is an observational study. No interventions.
219184255|NCT05880966|BEHAVIORAL|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
219184256|NCT03936959|DRUG|LY3434172|Administered IV
219184257|NCT05984433|DEVICE|Auricular acupuncture|Electro auricular acupuncture
219184258|NCT06027567|DRUG|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
219184259|NCT06027567|DIETARY_SUPPLEMENT|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
219184260|NCT06027567|BEHAVIORAL|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
219184261|NCT06507735|DIETARY_SUPPLEMENT|Mannose|Mannose is a sugar monomer that is important in the glycosylation of many proteins. The concentration of mannose in mammalian plasma is \~50-100 μM, which is primarily derived from N-glycan processing. Taking dietary mannose supplements can raise the levels of plasma mannose by 3- to 5-fold. There are currently no known adverse effects of mannose supplementation in humans.
219184262|NCT05345015|DEVICE|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
219184263|NCT05345015|DEVICE|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
218999647|NCT00089154|BIOLOGICAL|apolizumab|Given IV
218999648|NCT00089154|OTHER|laboratory biomarker analysis|Correlative studies
218999649|NCT00089154|OTHER|pharmacological study|Correlative studies
218999650|NCT00518986|DRUG|armodafinil|200 mg/day
218999651|NCT00518986|DRUG|placebo|placebo
218999652|NCT04448171|DEVICE|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
218999653|NCT04448171|DEVICE|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
218999654|NCT01021046|PROCEDURE|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
218999655|NCT01021046|PROCEDURE|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
218999656|NCT04287816|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
218999657|NCT04287816|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
218999658|NCT04287816|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
219184264|NCT06360328|DEVICE|video laryngoscopy|The residents used video laryngoscopy for endotracheal intubation
219184265|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
219369794|NCT01881646|RADIATION|Positron emission tomography (PET) using [11C]PBR28|
219369795|NCT05300945|COMBINATION_PRODUCT|HIPEC|HIPEC after gastrectomy with D2 local lymph node dissection.
219369796|NCT03163420|DRUG|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
218999659|NCT04287816|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
218999660|NCT04287816|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
218999661|NCT04287816|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
218999662|NCT04287816|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
218999663|NCT04287816|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
218999664|NCT00002916|BIOLOGICAL|human papillomavirus 16 E7 peptide|
218999665|NCT00002916|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
218999666|NCT00002916|PROCEDURE|adjuvant therapy|
218999667|NCT00002916|PROCEDURE|surgical procedure|
218999668|NCT00002916|RADIATION|radiation therapy|
218999669|NCT03647033|DEVICE|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
218999670|NCT00660309|DRUG|Aliskiren|Aliskiren 300 mg tablets
218999671|NCT00660309|DRUG|Irbesartan|Irbesartan 300 mg tablets
218999672|NCT00660309|DRUG|Captopril|Captopril 25 mg tablet
218999673|NCT03005314|PROCEDURE|chemotherapy|chemotherapy before surgery
218999674|NCT03005314|PROCEDURE|Surgery|chemotherapy after surgery
218999675|NCT01010490|PROCEDURE|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
218999676|NCT01010490|PROCEDURE|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
218999677|NCT01010490|PROCEDURE|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
218999678|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
218999679|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
218999680|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
218999681|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
219369797|NCT03163420|OTHER|Placebo|Fructose
219369798|NCT01779284|DRUG|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
219369799|NCT01779284|DRUG|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
219369800|NCT02567526|BEHAVIORAL|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
219184266|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
219184267|NCT06215430|DRUG|Caffeine Tablet|Administered orally.
219184268|NCT06215430|DRUG|Omeprazole capsule|Administered orally.
219184269|NCT06215430|DRUG|Warfarin tablet|Administered orally.
219184270|NCT06215430|DRUG|Pirtobrutinib|Administered orally.
219184271|NCT06408220|PROCEDURE|Biopsy|Undergo tissue biopsy
219184272|NCT06408220|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219184273|NCT06408220|PROCEDURE|Breath Test|Undergo H. pylori breath test
219184274|NCT06408220|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
219184275|NCT06408220|OTHER|Questionnaire Administration|Complete questionnaires
219184276|NCT04600713|OTHER|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
219369801|NCT04113967|OTHER|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
219369802|NCT03863314|DEVICE|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
219184277|NCT06564948|OTHER|Treatment as usual (TAU)|"TAU patients will be identified using targeted limited chart review methods used in our prior studies, scraping clinical notes in the EHR for criminal justice involvement. Initial Identification terms, police, arrest, court, summons, jail, and crime will be used to identify candidates for police involvement, downloading the sentence in which the keyword appeared and the sentence before and after. Next, an iterative process of editing of the search terms will be conducted to remove patients with negation of the keyword (did not commit a crime), and other sentence characteristics that generate false positives (cardiac arrest). Samples of the resulting dataset will be taken, accuracy assessed by examining the surrounding sentences, leading to further iterations and repetition of the process until a high level of accuracy is achieved."
219184278|NCT06564948|OTHER|Family and Social Justice|Documentation and follow-up by the Cambridge Police Department (CPD) for all mental health-related police calls, including involuntary and voluntary Emergency Department admissions; Established partnerships with city departments, healthcare systems, clergy, courts, businesses, and mental health advocates to ensure timely engagement in mental health treatment and community-based services; Required 40 hours of officer crisis intervention training (CIT), and additional sessions on trauma- informed policing, mental health, procedural justice, race, and crisis negotiation; and Staffing of sworn and civilian staff including specially-trained officers designated to work with individuals living with mental illness, homelessness, and substance abuse.
219184279|NCT06564948|OTHER|Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention|"The FSJS+Navigator intervention adds an Emergency Department (ED)-based Systems Navigator, a community health worker with lived experience (as family member or patient) with criminal justice and mental health systems, to the FSJS. This navigator will enhance communication between Cambridge Police Department (CPD), Cambridge Health Alliance (CHA), and community agencies by being the needed point person within the healthcare system (the FSJS intervention only has a CPD-based social worker) to maintain communication to improve mental health services and prevent deeper justice involvement. The Navigator engages with the FSJS process in step i) of the above sequence, engaging the patient in the CHA ED and obtaining consent. The Navigator then discusses the case with the presenting CPD officer, and relays critical information about the context of the service call to ED staff. Next, the Navigator will administer the baseline CAT-MH/SS and assess additional needs (employment, housing, food)."
219184280|NCT04376502|RADIATION|Radiation Therapy|Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (Gy) in 5 fractions), and after a 1-week interval during which ICI is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).
219184281|NCT06527339|OTHER|Dry Needling with Vibration|In the PS+V technique, no movements will be performed with the needle once it is correctly inserted. Instead, only vibratory stimulus will be applied for 10 minutes. Since this is a completely novel technique, the optimal duration of application is not yet known; however, it is considered that 10 minutes may be sufficient to demonstrate an effect.
219369803|NCT03863314|OTHER|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
219369804|NCT03437447|DRUG|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
219184282|NCT06527339|OTHER|Conventional Dry Needling|"In the conventional PS technique, the needle will be inserted into the MTrP using the fast-in and fast-out technique described by Hong (1994) at an approximate frequency of 1 insertion per second (1 Hz) without completely withdrawing the needle from the skin. This technique will be maintained for 30 seconds in an attempt to elicit a local twitch response. After the procedure, the treated area will be firmly compressed with a cotton pad for three seconds."
219184283|NCT00912041|DEVICE|Placement of the BrainGate2 sensor(s) into the motor-related cortex|Up to six 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one, two, or three percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
219184284|NCT06689722|OTHER|chiropractic|Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.
219184285|NCT06689722|OTHER|sham|The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.
219184286|NCT06689722|OTHER|ergonomics|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
218999682|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
218999683|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
218999684|NCT03103568|DRUG|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
218999685|NCT03103568|DRUG|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
218999686|NCT03103568|DRUG|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
218999687|NCT03103568|DRUG|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
218999688|NCT03103568|DRUG|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
218999689|NCT03103568|DRUG|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
218999690|NCT00160290|DRUG|Lactulose|15 mL / 12 hours
218999691|NCT00160290|DRUG|Plantago ovata|3,5 g / 12 hours
218999692|NCT02782975|DRUG|aducanumab|
218999693|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg）|
218999694|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg）|
218999695|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg）|
219184287|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
219184288|NCT06521645|OTHER|electroacupuncture|electrical stimulation is given through needles inserted into the skin
219184289|NCT06521645|OTHER|sham needle|needles are inserted shallowly into the skin
219184290|NCT01423656|DRUG|LEO 29102|
219184291|NCT01423656|DRUG|Placebo|Placebo Comparator: LEO 29102 vehicle
219184292|NCT03748953|DRUG|Ixazomib|Ixazomib Capsules
219184293|NCT06026241|OTHER|Collecting data from the medical record|Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
219184294|NCT04746105|DRUG|TS-142|Subjects received single-dose of 10 mg of TS-142 (oral tablet)
219184295|NCT04746105|DRUG|Dose-matched Placebo to TS-142|Subjects received single-dose matched placebo to TS-142 (oral tablet)
219184296|NCT05427812|DRUG|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
219184297|NCT05427812|DRUG|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
219184298|NCT06377982|BIOLOGICAL|hUCB|hUCB
219184299|NCT05662189|DRUG|68Ga-exendin-4|68Ga-exendin4 PET-CT scan
219184300|NCT05662189|OTHER|mixed meal test|before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
218999696|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg） and vaccine|
218999697|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg） and vaccine|
218999698|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg） and vaccine|
218999699|NCT02559921|BIOLOGICAL|placebo and vaccine|
218999700|NCT03712072|DEVICE|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
218999701|NCT03712072|DEVICE|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
219184301|NCT04890171|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
219184302|NCT04890171|PROCEDURE|Surgery|Gastrectomy with lymph node dissection by a surgeon
219184303|NCT06532370|BEHAVIORAL|Contingency Managment|"If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. great job!). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
219184304|NCT05204797|PROCEDURE|Robot-assisted UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
219184305|NCT05204797|PROCEDURE|Standard technique UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
219184306|NCT03769155|BIOLOGICAL|Ipilimumab|Given IV
219184307|NCT03769155|BIOLOGICAL|Nivolumab|Given IV
219184308|NCT03769155|BIOLOGICAL|VX15/2503|Given IV
219184309|NCT03769155|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
219184310|NCT06076187|OTHER|Dual isotope protein digestibility method|Dual isotope method
219184311|NCT04174391|BEHAVIORAL|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
219184312|NCT04174391|BEHAVIORAL|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
219184313|NCT01269593|DRUG|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
219184314|NCT03833206|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
219184315|NCT04408313|DRUG|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
219184316|NCT04408313|DRUG|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
219184317|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
219184318|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
219184319|NCT06194305|OTHER|CBIT|Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
219184320|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging
219184321|NCT06402955|DRUG|ketamine hydrochloride|There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.
219184322|NCT06264635|BIOLOGICAL|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
219184323|NCT06264635|OTHER|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
219184324|NCT05580419|BEHAVIORAL|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
218999702|NCT03712072|DEVICE|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on \>50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
218999703|NCT04258384|OTHER|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
218999704|NCT01116011|DRUG|AZD7268|Capsule, Oral, BID
218999705|NCT01116011|DRUG|Placebo|Capsule, Oral, BID
218999706|NCT02573311|DRUG|tamsulosin hydrochloride|
218999707|NCT06485167|DEVICE|HIFEM- chair|The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
218999708|NCT05660551|OTHER|Demostration|This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
218999709|NCT05660551|OTHER|Telesimulation|After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
218999710|NCT05660551|OTHER|Kahoot Game|Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
218999711|NCT00603889|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
218999712|NCT00005589|BIOLOGICAL|filgrastim|
218999713|NCT00005589|BIOLOGICAL|rituximab|
218999714|NCT00005589|DRUG|carmustine|
218999715|NCT00005589|DRUG|cyclophosphamide|
218999716|NCT00005589|DRUG|cytarabine|
218999717|NCT00005589|DRUG|etoposide|
218999718|NCT00005589|DRUG|melphalan|
218999719|NCT00005589|PROCEDURE|bone marrow ablation with stem cell support|
218999720|NCT00005589|PROCEDURE|peripheral blood stem cell transplantation|
218999721|NCT05494333|OTHER|no intervention|NO intervention
218999722|NCT05022108|BIOLOGICAL|Alpha bisabolol gel|Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
218999723|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
218999724|NCT04089384|OTHER|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
218999725|NCT04089384|OTHER|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
218999726|NCT04774640|DEVICE|MaterniT GENOME|
219184325|NCT04510025|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
218999727|NCT04661384|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
218999728|NCT04171531|DRUG|Botox® injection|Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
218999729|NCT04171531|DEVICE|Mid-urethral sling|"Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate."
219369805|NCT03437447|DRUG|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
219369806|NCT06424496|OTHER|Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression|Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
218999730|NCT06629818|DRUG|Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)|qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
218999731|NCT06629818|DRUG|Venetoclax|400mg po qd for 1 year
218999732|NCT06629818|DRUG|Dexamethasone|Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
218999733|NCT06069102|DRUG|Usual care|The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
218999734|NCT06069102|DRUG|Tight blood pressure control|The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
218999735|NCT04947319|DRUG|Tirabrutinib|Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.
218999736|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
219184326|NCT03209102|OTHER|Clinical assessment|"* Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~* and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
219184327|NCT03209102|BEHAVIORAL|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
219184328|NCT03209102|OTHER|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
219184329|NCT03209102|BIOLOGICAL|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
219184330|NCT04119843|DRUG|Mangoral|800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
219184331|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
219184332|NCT06360263|COMBINATION_PRODUCT|Densah bur in combination with activated plasma albumin gel|Simultaneous implant placement after transcrestal maxillary sinus lifting using densah burs in combination with activated plasma albumin gel.(APAG). A full mucoperiosteal flap will be elevated, and then reflected with periosteal elevator application of first densah bur (the narrowest) with densifying mood (reverse) counterclockwise, 800-1500 revolutions per minute with copious irrigation until the sinus is reached confirm bur position with a radiograph. Then a wider densah bur (3.0) is used with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.The sequential densah bur will be used with the same mode and bouncing motion to elevate the the sinus floor 3 mm maximum. After achieving the final planned osteotomy diameter, the osteotomy will be filled with APAG. Then, the desired implant length is inserted.
219184333|NCT04929743|DEVICE|BTI Implant|Placement of dental implants of 5.5 vs \>6.5 mm length
219184334|NCT05992870|RADIATION|Neoadjuvant radiotherapy|"In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment."
219184335|NCT04601857|DRUG|futibatinib and pembrolizumab (KEYTRUDA®))|Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
219184336|NCT04794777|COMBINATION_PRODUCT|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
219184337|NCT04794777|RADIATION|Standard salvage therapy|Standard salvage radiotherapy
219184338|NCT05929430|BEHAVIORAL|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
219184339|NCT05929430|BEHAVIORAL|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
219184340|NCT05043870|DRUG|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
219184341|NCT05043870|DRUG|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
219184342|NCT06061627|PROCEDURE|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of\>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
219184343|NCT06061627|PROCEDURE|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
219184344|NCT04817644|DRUG|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
218999737|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
218999738|NCT05540652|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
219184345|NCT04878549|DIAGNOSTIC_TEST|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
219184346|NCT06165367|DRUG|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
219184347|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
219184348|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
219184349|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
219184350|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
219184351|NCT05608083|BEHAVIORAL|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
219184352|NCT05608083|BEHAVIORAL|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
219184353|NCT05712512|BEHAVIORAL|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
219184354|NCT05712512|OTHER|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
219184355|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
219184356|NCT05317897|DIAGNOSTIC_TEST|Lung ultrasound examination|45 pediatric patients who will go elective repair of congenital acyanotic heart diseases will be included and will be examined with Lung ultrasound together with arterial blood gases preoperative and postoperative and given a score range from 0-3 according to number of B lines in each region and sensitivity of post-operative lung ultrasound score to extubation within 6 hours was examined.
219184357|NCT04885855|DRUG|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
219184358|NCT04885855|DRUG|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
219184359|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
219184360|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
219184361|NCT04828733|PROCEDURE|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
219184362|NCT04096170|DRUG|IV lidocaine|Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
219184363|NCT04096170|DRUG|Placebo|o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
219184364|NCT05380752|DRUG|TPOXX IV (Tecovirimat Injection, 10 mg/mL)|IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
219184365|NCT05898711|DEVICE|Fish skin graft|Kerecis Fish Skin Graft - SurgiBind
219184366|NCT05694013|DEVICE|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
219184367|NCT05694013|DRUG|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
219184368|NCT05694013|OTHER|Local SOC support|Participants will receive local SOC support
219184369|NCT06055075|DRUG|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
219184370|NCT06055075|DRUG|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
219184371|NCT06055075|DRUG|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
219184372|NCT04373031|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
219184373|NCT04373031|DRUG|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
219184374|NCT06530030|DRUG|efanesoctocog alfa|All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
219184375|NCT05113160|BEHAVIORAL|Conversation Treatment for Aphasia|Conversation treatment is a theoretically motivated approach in which a speech language pathologist facilitates discourse about topics of interest to the client using individualized, multi-modal supports. Treatment occurs either in groups of 6-8 people with aphasia or 2 people with aphasia. Individual communication goals are targeted for each group member within the context of naturalistic conversations.
219184376|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
219184377|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
219184378|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
219184379|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
219184380|NCT04478643|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus Reuteri|Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
219184381|NCT04478643|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
219184382|NCT05447312|OTHER|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
219184383|NCT05447312|OTHER|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
219184384|NCT06771908|DIAGNOSTIC_TEST|Conjunctival Swab|CFU/ml by bacterial species before and after prophylaxis.
219184385|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
219184386|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
219184387|NCT05613036|DRUG|BI 907828|BI 907828
219184388|NCT05188222|DRUG|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
219184389|NCT05188222|DRUG|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
219184390|NCT03358810|DEVICE|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
219184391|NCT06465641|DRUG|Methylphenidate Hydrochloride|Methylphenidate hydrochloride in capsules
219184392|NCT06465641|DRUG|Placebo|Microcrystalline cellulose in capsules
219184393|NCT03965468|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
219184394|NCT03965468|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
219184395|NCT03965468|DRUG|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
219184396|NCT03965468|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
219184397|NCT03965468|PROCEDURE|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
219184398|NCT03965468|RADIATION|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
219184399|NCT03965468|DRUG|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
219184400|NCT04893733|DRUG|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
219369807|NCT01352481|OTHER|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
219369808|NCT00145444|DRUG|olanzapine|
219369809|NCT00145444|DRUG|ziprasidone|
219754246|NCT03081390|OTHER|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
219184401|NCT04893733|OTHER|STOP AKI protocol|"STOP AKI protocols includes:~S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration"
219184402|NCT06224283|PROCEDURE|Cryoablation|Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
219184403|NCT06159153|DIAGNOSTIC_TEST|Dynamic Ultrasonography assessment|Ultrasound evaluation that will be compared with an MRI.
219184404|NCT03945552|BEHAVIORAL|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
219184405|NCT04454489|DRUG|Pembrolizumab (immunotherapy)|Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.
219184406|NCT04454489|RADIATION|Quad-shot palliative radiotherapy|"* Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles"
219184407|NCT05341726|BEHAVIORAL|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
219184408|NCT05341726|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
219184409|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
219184410|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
219184411|NCT04174157|OTHER|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
219184412|NCT04174157|DRUG|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
219184413|NCT03768505|DRUG|Zandelisib (ME-401)|Zandelisib (ME-401) 60 mg
219184414|NCT05240755|DRUG|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
219184415|NCT04886726|DRUG|uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
219184416|NCT04331639|DIETARY_SUPPLEMENT|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
219184417|NCT05966727|DRUG|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
219184418|NCT02905188|GENETIC|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219184419|NCT02905188|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
219184420|NCT02905188|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
219184421|NCT05419193|DRUG|Propranolol Hydrochloride|"Day of randomization:~propranolol IV vp for 7 days after randomization"
219184422|NCT05419193|OTHER|control group|Patients will receive usual care and drug use in hospital
219184423|NCT02815566|DRUG|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
219184424|NCT02815566|DRUG|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
219184425|NCT05179993|OTHER|Microplastics|Detection of microplastics as a yes/no value
219754247|NCT03766672|DIAGNOSTIC_TEST|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
219754248|NCT06684769|DEVICE|Emdogain® FL|Enamel Matrix Derivatives
219754249|NCT06684769|DEVICE|Labrida BioClean®|Oscillating Chitosan Brush
219754250|NCT04569084|DRUG|MT-1186|Oral edaravone
219754251|NCT04569084|DRUG|Placebo|Oral
219754252|NCT06690151|BEHAVIORAL|Neurodevelopmental assessment (Bayley-IV)|Assessment of developmental delays through administration of the Bayley-4 test by a neuropsychologist
219184426|NCT06178549|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling. Participants will be provided with education regarding cervical cancer prevention and Aptima kit and instructions for self-sampling. Patient navigators will assist participants with positive HPV test results to connect with healthcare providers for follow-up screening and care.
219184427|NCT05078970|BEHAVIORAL|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
219184428|NCT05078970|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
219184429|NCT05078970|BEHAVIORAL|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
219184430|NCT04187183|OTHER|Fresh Platelet Rich Plasma with leukocyte|autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
219184431|NCT04187183|OTHER|Fresh Platelet Rich Plasma without leukocyte|autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
219184432|NCT03994653|OTHER|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
219184433|NCT03994653|OTHER|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
219184434|NCT05928572|OTHER|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
219184435|NCT06441890|DRUG|Paclitaxel|80mg/m2 IV D1, 8, 15
219184436|NCT06441890|DRUG|Nab-paclitaxel|125mg/m2 IV D1, 8, 15
219184437|NCT06441890|DRUG|Docetaxel|75mg/m2 IV D1
219184438|NCT06441890|DRUG|Trastuzumab|8mg/kg loading, then 6mg/kg IV/SQ D1
219184439|NCT06441890|DRUG|Pertuzumab|840 mg loading, then 420mg IV/SQ D1
219557718|NCT06270095|DIAGNOSTIC_TEST|Neurocognitive, neuromuscular and neurosensitive tests.|"At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated."
219184440|NCT04032704|DRUG|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
219184441|NCT04032704|DRUG|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
219184442|NCT03647852|DRUG|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
219184443|NCT03647852|DRUG|IVIG|1\. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
219184444|NCT03647852|DRUG|other basic supportive treatment|"1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d"
219184445|NCT05718700|DRUG|Bulevirtide|Administered via subcutaneous (SC) injections
219184446|NCT02861300|DRUG|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
219184447|NCT02861300|DRUG|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
219184448|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
219184449|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
219184450|NCT02867865|DRUG|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
219184451|NCT02867865|DRUG|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
219184452|NCT02867865|RADIATION|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
219184453|NCT02867865|PROCEDURE|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
219184454|NCT02867865|PROCEDURE|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
219184455|NCT06491030|DEVICE|Align PJK™ TLSO brace|Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.
219184456|NCT06491030|OTHER|Standard of Care|Patients will receive the standard of care postoperative instructions without a brace
219184457|NCT04072458|DRUG|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
219184458|NCT06179498|BEHAVIORAL|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
219184459|NCT04344678|DRUG|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
219184460|NCT04344678|DRUG|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
219184461|NCT06062745|DRUG|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
218999739|NCT05707910|BIOLOGICAL|EBV immunological agent|Low-dose group:2\*10\^7 Medium-dose group:5\*10\^7 High-dose group:2\*10\^8
218999740|NCT05683249|DRUG|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
218999741|NCT05683249|DRUG|Placebo|Matching placebo
218999742|NCT05833152|PROCEDURE|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
218999743|NCT05727215|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
218999744|NCT06398574|OTHER|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
218999745|NCT06398574|OTHER|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
218999746|NCT06249126|PROCEDURE|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Definitive fixation by joint fusion
218999747|NCT06249126|PROCEDURE|Open Reduction Internal Fixation (ORIF) only|Definitive fixation with plates and screws
218999748|NCT05148052|DEVICE|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
218999749|NCT05148052|BEHAVIORAL|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
218999750|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
218999751|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
218999752|NCT06133270|DRUG|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
218999753|NCT06133270|DRUG|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
218999754|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
218999755|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
218999756|NCT04704921|BIOLOGICAL|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
218999757|NCT06647407|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
218999758|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
218999759|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
218999760|NCT06647407|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
218999761|NCT06647407|DRUG|Paracetamol|Pharmaceutical form:Suspension-Route of administration:oral
218999762|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
218999763|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
218999764|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Oral solution in tube Route of administration: oral
218999765|NCT06647407|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
218999766|NCT06647407|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
219184462|NCT06062745|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
219184463|NCT03252847|GENETIC|AAV5-RPGR|Single, subretinal administration of AAV5-RPGR
219184464|NCT04035434|BIOLOGICAL|CTX110|CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
219184465|NCT01501955|DEVICE|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
219184466|NCT01501955|DEVICE|Stanmore|Stanmore hip prosthesis
219184467|NCT06136728|DRUG|Dalfampridine 10 MG [Ampyra]|Dalfampridine (10 mg) every 12 hours for 6 weeks.
219184468|NCT06136728|BEHAVIORAL|Physical therapy|Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
219184469|NCT06136728|OTHER|Dalfampridine plus physical therapy|Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
219184470|NCT05947760|DRUG|IV Magnesium Sulfate|Participants will receive IV Magnesium Sulfate intraoperatively.
219184471|NCT05387954|PROCEDURE|Transcatheter PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
219184472|NCT05387954|DRUG|Oral Anticoagulant, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
219184473|NCT05387954|DRUG|Antiplatelet therapy|Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
219184474|NCT04240054|DRUG|Bortezomib|Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
219184475|NCT04240054|DRUG|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
219184476|NCT04240054|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
218999767|NCT04741828|DRUG|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
218999768|NCT06091748|DRUG|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
218999769|NCT00265798|DRUG|Sorafenib Tosylate|
218999770|NCT05517083|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
218999771|NCT03569553|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
218999772|NCT03503305|DEVICE|adipose-derived stem cell injection|5 ml injection of adipose derived stem cells
218999773|NCT03503305|DRUG|Corticosteroid injection|5 ml injection of corticosteroid
218999774|NCT05854069|BEHAVIORAL|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
218999775|NCT05854069|BEHAVIORAL|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
218999776|NCT04545502|DEVICE|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
218999777|NCT04545502|DEVICE|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
218999778|NCT04545502|DEVICE|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
218999779|NCT04545502|DEVICE|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
218999780|NCT04545502|DEVICE|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
218999781|NCT01401582|OTHER|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
219184477|NCT04240054|DRUG|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
219184478|NCT05633615|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
219184479|NCT05633615|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219184480|NCT05633615|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
219184481|NCT05633615|DRUG|Cyclophosphamide|Given IV
219184482|NCT05633615|DRUG|Fludarabine|Given IV
219184483|NCT05633615|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219184484|NCT05633615|BIOLOGICAL|Mosunetuzumab|Given IV
219184485|NCT05633615|OTHER|Patient Observation|Undergo observation
219184486|NCT05633615|DRUG|Polatuzumab Vedotin|Given IV
218999782|NCT05798897|DRUG|MT-601|Multi-antigen specific CD4+ andCD8+ T cells
218999783|NCT05637710|DRUG|Administration of investigation of Eurofarma drug|Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.
218999784|NCT05637710|DRUG|Administration of Comparator|Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.
218999785|NCT04015622|DRUG|Enzalutamide|Enzalutamide 160 mg PO OD
218999786|NCT04015622|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
218999787|NCT03959839|PROCEDURE|ESD|Rectal Endoscopic Submucosal Dissection
218999788|NCT03959839|PROCEDURE|TAMIS|Transanal Minimally Invasive Surgery
218999789|NCT03959839|PROCEDURE|TEO|Transanal Endoscopic Operation
218999790|NCT05127265|OTHER|Video Monitoring|continuous video monitoring
218999791|NCT05127265|OTHER|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
218999792|NCT05127265|OTHER|Noise Level Monitoring|continuous environmental noise monitoring
218999793|NCT05127265|OTHER|Light Level Monitoring|continuous environmental light monitoring
218999794|NCT05127265|OTHER|Air Quality Monitoring|continuous environmental air quality monitoring
218999795|NCT05127265|OTHER|EKG Monitoring|continuous EKG monitoring
218999796|NCT05127265|OTHER|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
218999797|NCT05127265|OTHER|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
218999798|NCT05127265|OTHER|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
218999799|NCT03366337|DRUG|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
218999800|NCT04603183|DRUG|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
218999801|NCT04603183|DRUG|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
218999802|NCT04603183|DRUG|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
218999803|NCT04603183|DRUG|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
218999804|NCT05860647|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
218999805|NCT06278779|DRUG|Esketamine group|"The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly"
218999806|NCT06278779|DRUG|Racemic ketamine|"Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg"
218999807|NCT06274918|DEVICE|Personalized Body-Worn Alcohol Dispenser|This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
218999808|NCT04774393|DRUG|Decitabine and Cedazuridine|Given PO
218999809|NCT04774393|DRUG|Enasidenib|Given PO
218999810|NCT04774393|DRUG|Ivosidenib|Given PO
218999811|NCT04774393|DRUG|Venetoclax|Given PO
218999812|NCT05618652|BEHAVIORAL|Equity Focused and Trauma-Informed Communication Intervention|Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.
218999813|NCT05288062|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
218999814|NCT05288062|DRUG|Dexamethasone|Given orally
218999815|NCT05288062|DRUG|Lenalidomide|Given orally
218999816|NCT05288062|DRUG|Pomalidomide|Given orally
218999817|NCT06384209|DRUG|Fluoxetine|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 40mg Fluoxetine.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 60mg, reassured and encouraged that the goals they set can be achieved.
218999818|NCT06384209|DRUG|Sertraline Pill|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 100mg Sertraline if breastfeeding.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 150mg.
219184487|NCT05633615|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219184488|NCT05633615|BIOLOGICAL|Tisagenlecleucel|Given IV
219184489|NCT04440982|DRUG|LUM015|LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
219184490|NCT04440982|DEVICE|Lum Imaging System|UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
219184491|NCT03482557|DEVICE|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
219184492|NCT03482557|DEVICE|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
219184493|NCT06798441|OTHER|Brush Only|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. Subjects will record their twice daily product usage on a subject diary.
219184494|NCT06798441|OTHER|Brush / Rinse (Jolly Rancher Prototype)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
219184495|NCT06798441|OTHER|Brush / Rinse (LISTERINE® Total Care Zero Alcohol)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
219184496|NCT06803589|DRUG|Growth Hormone|"Subjects will receive growth hormone, Sogroya (Somapacitan-beco injections) via weekly injections for 12 weeks.~For males, the fixed dose will be 0.2 mg/day, 1.5 mg per week~For females, the fixed dose will be 0.3 mg/day, 2.1 mg per week"
219184497|NCT05553301|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
219184498|NCT05553301|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
219184499|NCT05553301|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
219184500|NCT05553301|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
219184501|NCT06799663|OTHER|activity questionnaire|Physical activity questionnaire will be applied on children and adolescents to compare the effect of smart phone on physical fitness
219184502|NCT06799663|OTHER|Raven's Progressive Matrices test (RPM)|Raven's Progressive Matrices test will be applied on children and adolescents to compare the effect of smart phone on intelligence
219184503|NCT06799663|OTHER|Postural assessment software|Postural assessment software will be applied on children and adolescents to compare the effect of smart phone on posture
219184504|NCT06536452|OTHER|Non-Interventional Study|Non-interventional study
219184505|NCT06229951|DIETARY_SUPPLEMENT|Collagen|Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day
219184506|NCT06229951|OTHER|Placebo|Control patients will take placebo 2 tabs a day.
219184507|NCT02474160|OTHER|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
219184508|NCT04631926|BEHAVIORAL|Hip Muscle Exercise|Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
219184509|NCT06446960|DRUG|Lidocaine 20mg/ml|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
219184510|NCT06446960|DRUG|Levobupivacaine Hydrochloride 1.25 MG/ML|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
219184511|NCT06446960|DRUG|Sodium Chloride 0.9% Inj|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
219184512|NCT04992520|BIOLOGICAL|Shigella sonnei 53G|Shigella sonnei (S. sonnei) strain 53G (Lot 1794); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
219184513|NCT04992520|BIOLOGICAL|Shigella flexneri 2a 2457T|Shigella flexneri (S. flexneri) strain 2457T (Lot 1617); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
219184514|NCT05627375|DRUG|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
219557719|NCT02932917|DEVICE|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
219184515|NCT05627375|DRUG|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
219184516|NCT03841357|DRUG|Abatacept Injection|Supplied as a weekly injection via a pre-filled syringe
219184517|NCT03841357|OTHER|Usual Care|Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
219557720|NCT00685750|PROCEDURE|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
219184518|NCT06801561|PROCEDURE|Laser therapy|This group will be subjected to laser therapy. Er,Cr:YSGG will be used (Waterlase®, Biolase, USA) of a wavelength of 2780 nm at a power of 0.75 W using a frequency of 20 Hz and pulse duration of 140 µs. (33) Irradiation will be performed on the entire occlusal and at the hypomineralized areas. (34) The laser tip will pass in a uniform scanning motion steadily for 20 sec with relative isolation with 11% air and no water-cooling system. During the laser treatment, all safety measures will be followed.
219184519|NCT06801561|PROCEDURE|Glass ionomer sealant|This group will receive glass ionomer sealant. Conditioning of the surface will be done using polyacrylic acid (10%) conditioner for 20 seconds, then rinsed and dried. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
219184520|NCT00188539|PROCEDURE|Pre-treatment tumour oxygen measurements (under anesthesia)|
219184521|NCT05651308|BEHAVIORAL|Care coordination delivered based on perceived need|If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
219184522|NCT05651308|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
219184523|NCT05942287|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
219184524|NCT02532244|OTHER|sample collection|collection of blood
219184525|NCT05227222|DEVICE|PEP-device|PEP-device
219184526|NCT05642442|DRUG|Placebo|Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
219184527|NCT05642442|DRUG|Suvecaltamide|Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
219184528|NCT04778046|DRUG|Hyperpolarized 129Xe|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
219184529|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
219184530|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
219184531|NCT04701853|OTHER|Usual care|Care according to each center.
219184532|NCT04949100|DEVICE|Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
219184533|NCT04949100|DEVICE|PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
219184534|NCT02714257|BEHAVIORAL|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
219184535|NCT05846685|OTHER|Patient Phone Interviews|Collecting perceptions about automated falls-risk screening and referral tool
219184536|NCT05846685|OTHER|Patient In Person Interviews|Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
219184537|NCT05401578|DRUG|Canakinumab|Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
219184538|NCT05401578|DRUG|Placebo (0.9% NaCl)|1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
219184539|NCT05201248|DRUG|Epcoritamab|Subcutaneous Injection (SC)
219184540|NCT05201248|DRUG|Cyclophosphamide|IV Injection
219184541|NCT05201248|DRUG|Rituximab|Intravenous (IV) Infusion
219184542|NCT05201248|DRUG|Doxorubicin|IV Infusion
219184543|NCT05201248|DRUG|Vincristine|IV Infusion
219184544|NCT05201248|DRUG|Prednisone|Oral; Tablet
219184545|NCT05201248|DRUG|Lenalidomide|Oral; Capsule
219184546|NCT05825755|OTHER|vitalera telemonitoring platform|Patients will be followed-up with measurements from medical devices and health questionnaires delivered through the app
219184547|NCT04103580|BEHAVIORAL|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
219184548|NCT04145440|DRUG|MOR202|Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
219184549|NCT00104676|BIOLOGICAL|bleomycin sulfate|At least one course administered
219184550|NCT00104676|DRUG|cisplatin|At least one course administered
219184551|NCT00104676|DRUG|etoposide|At least one course administered
219184552|NCT00104676|DRUG|ifosfamide|Given in a dose-dense sequential fashion
219184553|NCT00104676|DRUG|oxaliplatin|Given in a dose-dense sequential fashion
219184554|NCT00104676|DRUG|paclitaxel|Given in a dose-dense sequential fashion
219184555|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
219184556|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
219184557|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
219184558|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
219184559|NCT04662489|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy
219184560|NCT04662489|PROCEDURE|Radial ablation|Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.
219184561|NCT01837576|DRUG|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
219184562|NCT03838536|DIETARY_SUPPLEMENT|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
219184563|NCT03838536|DIETARY_SUPPLEMENT|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
219184564|NCT05859737|BEHAVIORAL|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
219184565|NCT05859737|OTHER|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
219184566|NCT06436378|BEHAVIORAL|Music intervention in person|The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
219184567|NCT06081452|BEHAVIORAL|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
219184568|NCT05923216|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
219184569|NCT05923216|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
219184570|NCT05808257|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
219184571|NCT05808257|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
219184572|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
219184573|NCT03726398|DRUG|Opsumit 10 Mg Tablet|Oral tablet taken once daily
219184574|NCT04042233|DRUG|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
219184575|NCT04042233|DRUG|Standard IV administration of vancomycin|IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
219184576|NCT05918380|BEHAVIORAL|PAL2|"Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
219184577|NCT05918380|OTHER|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
219184578|NCT03986931|OTHER|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
219184579|NCT03986931|OTHER|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
219184580|NCT03728790|DEVICE|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
219184581|NCT05895175|OTHER|Questionnaires|Questionnaires
219184582|NCT03481530|DEVICE|Continuing Glucose Monitor System|glucose monitoring
219184583|NCT06416800|DRUG|Digoxin|Oral; Tablet
219184584|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
219184585|NCT06416800|DRUG|Metformin|Oral; Tablet
219184586|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
219184587|NCT06416800|DRUG|Probenecid|Oral; Tablet
219184588|NCT06114082|PROCEDURE|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
219184589|NCT06114082|PROCEDURE|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
219184590|NCT05932836|OTHER|No interventions.|No interventions to be administered.
219184591|NCT06217393|DRUG|Itopride Hydrochloride 150 mg extended release tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
219184592|NCT06217393|DRUG|Itopride Hydrochloride 50 mg film coated tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
219184593|NCT03760575|DRUG|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
219184594|NCT03760575|PROCEDURE|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
219184595|NCT03760575|DRUG|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
219184596|NCT03760575|DRUG|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
219184597|NCT04525729|DRUG|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
219184598|NCT04525729|DRUG|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
219184599|NCT05597371|OTHER|the use of the platform|the use of the platform
219184600|NCT03387475|DRUG|Deferasirox|iron chelation
219184601|NCT05158374|DRUG|Aspirin tablet|75mg Aspirin once per day
219184602|NCT05158374|DRUG|Metformin|500mg Metformin once per day
219184603|NCT05158374|DRUG|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
219184604|NCT05581017|PROCEDURE|Preoperative biliary drainage|Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
219184605|NCT05056714|OTHER|Questionaries|The patient will answer several questionaries
219184606|NCT05605756|DRUG|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
219184607|NCT05925608|COMBINATION_PRODUCT|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
219184608|NCT05925608|DIAGNOSTIC_TEST|Diagnostic Catheterization|Left ventricular catheterization with no active therapy
219184609|NCT06069791|DRUG|Bupivacaine Injection|subcutaneous injection around bilateral greater occipital nerves
219184610|NCT05458518|PROCEDURE|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
219184611|NCT04324359|DRUG|SURF-201|One drop twice daily (BID) in the study eye for 16 days.
219184612|NCT04324359|DRUG|Placebo|One drop twice daily (BID) in the study eye for 16 days.
219184613|NCT05586334|BIOLOGICAL|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
219184614|NCT05586334|BIOLOGICAL|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
219184615|NCT05586334|OTHER|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
219184616|NCT06777797|DEVICE|PU condoms (Test PU Condom A, Test PU Condom B, Test PU Condom C, Test PU Condom D)|Participants will be provided with PU condoms (2 condoms per variant) to use during masturbation.
219184617|NCT06777797|DEVICE|NRL condoms (Test NRL Condom A, Test NRL Condom B, Test NRL Condom C, Test NRL Condom D)|Participants will be provided with NRL condoms (2 condoms per variant) to use during masturbation.
219184618|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
219184619|NCT06319430|OTHER|robots|LEGO robots with adaptation according to child's age and developmental skills.
219184620|NCT06319430|OTHER|conventional|A pack of conventional play tools consists of dolls, teddy bears, miniature wild animals, and small cars. All are available, and the child can choose to play with them.
219184621|NCT06075979|OTHER|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
219184622|NCT06075979|OTHER|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
219184623|NCT03899259|DRUG|Baricitinib|Administered orally
219184624|NCT03899259|DRUG|Placebo|Administered orally
219184625|NCT02617758|DRUG|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
219184626|NCT02617758|DRUG|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
219184627|NCT05918744|BEHAVIORAL|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
219184628|NCT06120972|DRUG|Olaparib tablet|Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
219184629|NCT05115942|DRUG|Hydronidone capsules|After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.
219184630|NCT05115942|DRUG|The placebo capsules|After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
219184631|NCT04888702|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219184632|NCT02947750|DRUG|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
219184633|NCT02947750|OTHER|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
219184634|NCT02947750|DIETARY_SUPPLEMENT|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
219184635|NCT02947750|OTHER|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
219184636|NCT02947750|OTHER|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
219184637|NCT02947750|DIETARY_SUPPLEMENT|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
219184638|NCT02947750|OTHER|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
219184639|NCT04998006|DRUG|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
219184640|NCT06582355|OTHER|Neurofeedback|The participants will be instructed to use cognitive strategies to upregulate (increase) their brain activity in the selected brain region, with the suggestion that motor imagery may be particularly effective, for example, mental imagery of swimming or playing a musical instrument. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner, and the brain activity of the putamen will be displayed in real-time using a thermometer bar for visualization.
219369810|NCT03778437|PROCEDURE|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
219184641|NCT06582355|OTHER|Kinesthetic imagery|The participants will be instructed to imagine movements during the active blocks. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner. No feedback is provided regarding brain activity.
219184642|NCT05815953|DEVICE|Polarstem|Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
219184643|NCT05815953|DEVICE|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
219184644|NCT05670587|DEVICE|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
219184645|NCT04760652|BEHAVIORAL|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
219184646|NCT06394206|OTHER|Specialized Unit|The participant will be visited every three months for one year
219184647|NCT06394206|OTHER|Usual Follow-Up|The participant will be visited as usual, it means they will be visited at Digestive Consultation
219184648|NCT05795959|BEHAVIORAL|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
219184649|NCT06067009|BEHAVIORAL|ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease|ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
219184650|NCT05296109|DIAGNOSTIC_TEST|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
219184651|NCT01197378|DRUG|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
219184652|NCT04458792|OTHER|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
219184653|NCT04458792|OTHER|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
219184654|NCT06259981|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily
219184655|NCT06259981|DRUG|Placebo|4 placebo capsules orally twice daily
219184656|NCT05873413|BEHAVIORAL|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
219184657|NCT05873413|BEHAVIORAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
219184658|NCT05873413|BEHAVIORAL|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
219184659|NCT05139810|DRUG|Donidalorsen|Donidalorsen was administered by SC injection.
219184660|NCT05139810|DRUG|Placebo|Donidalorsen-matching placebo was administered by SC injection.
219184661|NCT04476303|DRUG|BEY2153|Capsule
219184662|NCT05767541|OTHER|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
219184663|NCT05767541|OTHER|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
219184664|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
219184665|NCT05241860|OTHER|Follow-Up|Undergo follow-up
219184666|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
219184667|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
219184668|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
219184669|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
219184670|NCT06177652|OTHER|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
219184671|NCT06177652|OTHER|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
219184672|NCT03239808|PROCEDURE|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
219184673|NCT03239808|PROCEDURE|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
219184674|NCT04763174|BEHAVIORAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
219184675|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
219184676|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
219184677|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
219184678|NCT04268199|DRUG|Bortezomib Injection|Subcutaneous injection
219184679|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
219184680|NCT05787834|OTHER|Best Practice|Receive usual care
219184681|NCT05787834|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
219184682|NCT05787834|PROCEDURE|Respiratory Muscle Training|Undergo RMT
219184683|NCT05787834|OTHER|Survey Administration|Ancillary studies
219184684|NCT05437172|PROCEDURE|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
219184685|NCT05437172|PROCEDURE|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
219184686|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
219184687|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
219184688|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
219184689|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
219184690|NCT04568746|PROCEDURE|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
219184691|NCT04568746|PROCEDURE|box|patient with score \< 2 will be supported in box
219184692|NCT05433298|BIOLOGICAL|Mesenchymal stem cell|Administration of advanced cell product
219184693|NCT05433298|OTHER|Placebo|Ringer's lactate, albumin and heparin solution
219184694|NCT05571670|DRUG|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
219184695|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
219184696|NCT06182033|BEHAVIORAL|Peer-mediated pivotal response training|Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
219184697|NCT06142253|BEHAVIORAL|WATER+CT|This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
219184698|NCT06142253|BEHAVIORAL|Usual Care|This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
219184699|NCT05704543|DRUG|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
219184700|NCT06681909|BEHAVIORAL|UB Campus Veggie Van|The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
219184701|NCT06524492|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
219184702|NCT03704415|PROCEDURE|Extended endoscopic sinus surgery|ESS of all sinuses
219184703|NCT03704415|PROCEDURE|Limited endoscopic sinus surgery|Partial ethmoidectomy
219184704|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
219184705|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
219184706|NCT05576792|OTHER|Ranibizumab|Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
219184707|NCT06270680|DRUG|Vision Edge Pro|Each dose will consist of one supplement capsule containing 10 mg lutein, 2 mg zeaxanthin, 10 mg mesozeaxanthin, 50mg EPA, 250mg DHA. Capsules are to be taken orally, once daily with a meal. Duration of supplementation will last approximately 2 - 5 months, depending on the length of the athletic seasons for the sports recruited.
219184708|NCT06270680|OTHER|Placebo|A sunflower oil placebo containing 380 mg of sunflower oil
219184709|NCT03653676|OTHER|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
219184710|NCT06248567|DRUG|ZSP1273|Oral
219184711|NCT04736823|DRUG|AK112|IV infusion
219184712|NCT04736823|DRUG|Pemetrexed|IV infusion
219184713|NCT04736823|DRUG|Paclitaxel|IV infusion
219184714|NCT04736823|DRUG|Carboplatin|IV infusion
219184715|NCT04736823|DRUG|Docetaxel|IV infusion
219184716|NCT06642636|DEVICE|Intensive Care Unit-specific Virtual Reality|The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
219184717|NCT04947527|DRUG|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
219184718|NCT04947527|DRUG|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
219184719|NCT02723591|DRUG|Tacrolimus|Oral Capsule
219184720|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
219184721|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
219184722|NCT06158490|DRUG|JYP0061 15 mg|Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
219184723|NCT06158490|DRUG|JYP0061 30 mg|articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
219184724|NCT06158490|DRUG|Placebo|Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
219184725|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
219369811|NCT03778437|PROCEDURE|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
219184726|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
219184727|NCT04768426|DRUG|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
219184728|NCT02888327|DRUG|AL-794|
219184729|NCT02888327|DRUG|Oseltamivir|
219184730|NCT02888327|DRUG|Digoxin|
219184731|NCT02888327|DRUG|Midazolam|
219184732|NCT02888327|DRUG|Pitavastatin|
219184733|NCT02888327|DRUG|JNJ-63623872|
219184734|NCT06789978|OTHER|Extracorporeal cardiopulmonary resuscitation (ECPR)|Prehospital extracorporeal cardiopulmonary resuscitation (ECPR)
219184735|NCT03012971|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
219184736|NCT03012971|DRUG|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
219184737|NCT05124704|DRUG|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
219184738|NCT05124704|OTHER|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
219184739|NCT06847373|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 4000 IU daily orally
219184740|NCT03080987|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
219184741|NCT03080987|DRUG|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
219184742|NCT03080987|DRUG|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
219184743|NCT03080987|OTHER|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
219184744|NCT03080987|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
219184745|NCT06851351|DIAGNOSTIC_TEST|Spirometry and optoelectronic plethysmography|Spirometry for respiratory function and optoelectronic plethysmography for respiratory pattern during wakefulness
219184746|NCT06847295|PROCEDURE|Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program.|The intervention consists of surgical implantation of an epidural electrical stimulator using a paddle lead (Medtronic Specify 5-6-5) placed in the lumbar epidural space and a subcutaneously implanted pulse generator (Medtronic Intellis). After a one-month recovery and device calibration period, the stimulator is activated during a 12-month intensive rehabilitation program. Patients receive electrical stimulation during five supervised physiotherapy sessions per week. Stimulation parameters-including pulse width, frequency, and amplitude-are individually optimized based on intraoperative neurophysiological monitoring and ongoing clinical assessments, with the goal of enhancing gait recovery, reducing spasticity, and improving overall motor function and quality of life.
219184747|NCT06849531|OTHER|Foot Biomechanics and Lower Extremity Muscle Analysis|Focus on Foot Biomechanics
219184748|NCT06849622|DIAGNOSTIC_TEST|Test on blood sample|The blood sample will be drawn by venipuncture during clinical routine. The serum will be tested for coeliac or diabetes 1 auto-antibodies, using Elisa test.
219184749|NCT06849622|DIAGNOSTIC_TEST|Test on dried blood sample|A finger prick will be used to collect Dried blood Spot (DBS) on a special card. The eluted blood spot will be tested, for coeliac and diabetes 1 auto-antibodies, using the same method used for serum, and the same cut-offs for positivity and negativity (Elisa tests)
219184750|NCT06850272|BEHAVIORAL|Brisk walking|Participants in the brisk walking training group receive an eight-week instructor-led interval brisk walking training (40 minutes/session, three sessions/week).
219184751|NCT06850272|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|Participants in the CBT-I group receive standard-of-care group-based eight-session CBT-I (one session/week).
219184752|NCT02424305|DRUG|LEO 43204 gel 0.018%|
219184753|NCT02424305|DRUG|LEO 43204 gel 0.1%|
219184754|NCT02424305|DRUG|LEO 43204 gel 0.037%|
219184755|NCT06849973|DRUG|Drug: Bionetide|NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
219184756|NCT06849973|DRUG|Placebo|NA-921 (Bionetide) placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
219184757|NCT03064529|BEHAVIORAL|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
219184758|NCT06852092|DRUG|Carbon-14 labeled HSK39297|Dose A
219184759|NCT06853262|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
219184760|NCT06853262|OTHER|Sham Manual Protocol|The Sham techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The Sham techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
219184761|NCT06853080|DRUG|Bortezomib|4 cycles of Bortezomib treatment, with each cycle include 8 doses of Bortezomib at 1.3 mg/m2
219184762|NCT06852404|OTHER|Photovoice|Photovoice is a participant-driven research method that enables individuals to communicate their experiences through visual data. It is especially useful for exploring social issues and the challenges people encounter. In this approach, participants capture images that they find meaningful in relation to the research topic, using these photographs to express their emotions, thoughts, and personal experiences.
219184763|NCT06852924|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
219184764|NCT06851026|OTHER|Pilates Exercise|Pilates exercises were applied for 8 weeks
219184765|NCT06852001|DEVICE|X-ray stereotactic radiotherapy for brain metastasis|X-ray stereotactic radiotherapy for brain metastasis
219184766|NCT06851949|DEVICE|Vsling|Implantable ventricular repair device
219184767|NCT06851143|DIAGNOSTIC_TEST|18F-DPA-714 PET/MR scan|Saline intravenous solution of 18F-DPA-714 administered at 0.1 mCi/kg by bodyweight
219184768|NCT06852625|BIOLOGICAL|Autologous Tolerogenic Dendritic Cells|• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.
219184769|NCT06851338|DEVICE|Hypoglossal Nerve Stimulation|Implant of Inspire Upper Airway Stimulation (UAS) system for treatment of obstructive sleep apnea (OSA) in the pediatric down syndrome population
219184770|NCT06851403|DRUG|Dupilumab|initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
219184771|NCT06852690|OTHER|exercise with virtual reality goggles|Exercise and smartwatch tracking for type 2 diabetics with virtual reality glasses
219184772|NCT06851988|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times. And record of physical activities at home. According to the record set goal to acheive.
219184773|NCT06851988|OTHER|HIIT only|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times.
219184774|NCT05497440|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
219184775|NCT05991700|DRUG|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
219184776|NCT05991700|DRUG|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
219184777|NCT04455308|OTHER|Biological sample collection|10mL blood sample
219184778|NCT02618577|DRUG|Edoxaban|Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF
219184779|NCT02618577|DRUG|ASA|ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.
219184780|NCT02151981|DRUG|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
219184781|NCT02151981|DRUG|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
219184782|NCT06842212|DEVICE|Balance Training|balance training exercises performed on the biodex balance system 3 sessions every week for 12 weeks
219184783|NCT06426550|PROCEDURE|Periodontal treatment|Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed.
219184784|NCT05406362|DRUG|VAD044 Part I|capsules to be taken once daily for 12 weeks
219184785|NCT05406362|DRUG|VAD044 Part II|capsules to be taken once daily for 12 months
219184786|NCT05560893|BEHAVIORAL|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
219184787|NCT05658471|OTHER|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
219184788|NCT05658471|OTHER|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
219184789|NCT05658471|BEHAVIORAL|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
219369812|NCT03778437|PROCEDURE|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
219184790|NCT05658471|OTHER|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
219184791|NCT03847311|DRUG|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
219184792|NCT03847311|DRUG|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
219184793|NCT05493072|OTHER|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
219184794|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
219184795|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
219184796|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
219184797|NCT06203093|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
219184798|NCT01946789|BIOLOGICAL|ALT-803|N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.
219184799|NCT04935359|DRUG|NIS793|Concentrate for solution infusion (Liquid in Vial)
219184800|NCT04935359|DRUG|Nab-paclitaxel|Per locally approved formulation
219184801|NCT04935359|DRUG|Gemcitabine|Per locally approved formulation
219184802|NCT04935359|DRUG|Placebo|Dextrose 5% in water (D5W) solution for infusion
219184803|NCT05997030|DEVICE|low intensity focused ultrasound (LIFU)|Subjects will undergo undergo a single LIFU of the target brain region
219184804|NCT06489405|OTHER|Horticultural practices|The first week of the program was 'Getting to know horticultural practices', the second week was 'Painting pots', the third week was 'Planting vegetable seedlings', the fourth week was 'Preparing compost', the fifth week was 'Making pressed flowers' and the sixth week was 'Harvesting vegetables'.
219184805|NCT05374798|DEVICE|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
219184806|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
219184807|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
219184808|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
219184809|NCT06840340|DEVICE|Customised mouthguards|Wore customised mouthguards and measurement athletic performance of baseball and softball performance.
219184810|NCT04861077|DRUG|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
219369813|NCT01322906|OTHER|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
219369814|NCT01322906|OTHER|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
219369815|NCT01322906|OTHER|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
219184811|NCT06833944|OTHER|HIIT intervention program|"The HIIT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 36 minutes). The program will be divided into two phases: phase 1 (adaptation to HIIT training: during the first 4 weeks, the intensity will be progressively increased to ensure the safety and progressive physical conditioning of the patients.~The high-intensity intervals will follow the Norwegian 4 x 4-minute HIIT model: 4 bouts of 4 minutes of high intensity corresponding to a rating of perceived exertion (RPE) 15 to 18 on the Borg 6 to 20 Scale33 and an 85-95%HRmax, interspersed with 3-minute active recovery intervals (RPE of 11 to 13 and 54-69%HRmax). This protocol has been widely applied and is safe in general and in clinical populations. Additionally, this protocol includes the training parameters recently proposed in a recent meta-analysis to maximize the training effects of HIIT on cardiorespiratory fitness (primary outcome)."
219184812|NCT06833944|OTHER|MICT intervention program|"The MICT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 44 minutes). The workout will be performed at RPE 11 to 13 (54-69%HRmax) to provide an isoenergetic workload (same energy expenditure) as the HIIT group.~Each session will include 3 parts: warm-up (5 min), main MICT workout (34 min), and a cool-down (5 min). Warm-up will include mobility, core, and aerobic exercise involving major muscle groups. The main workout (MICT) will include exercises involving major muscle groups using the same materials and rationale as commented on in the HIIT group. The cool-down phase will include aerobic exercise at a lower intensity, stretching, and relaxation exercises (RPE\<11). The highest and average HR and RPE for each session will be registered."
219184813|NCT06840613|OTHER|Myo-Inositol|"Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment"
219184814|NCT06840613|OTHER|Glucophage|"Intervention: Patients in this group will receive 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment."
219184815|NCT06837896|DRUG|QLG1080|Oral administration
219184816|NCT03683277|DRUG|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
219184817|NCT02188264|DRUG|Cyclosporine|Given PO
219184818|NCT02188264|OTHER|Laboratory Biomarker Analysis|Correlative studies
219184819|NCT02188264|OTHER|Pharmacological Study|Correlative studies
219184820|NCT02188264|DRUG|Selumetinib|Given PO
219184821|NCT06840964|DIETARY_SUPPLEMENT|omega 3 ethyl esters at 90%|2 grams/day of omega 3 capsules will be administered orally, for 12 weeks
219184822|NCT06840964|DIETARY_SUPPLEMENT|Placebo|Mygliol 812
219184823|NCT06840561|DRUG|Local triamcinolone injection combined with fibrin glue spray|TA injection and fibrin glue spray are used in two sessions after ESD immediately (D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity is diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points (0.5ml/point) depending on the defective area. But TA injection should avoid muscular injury place. We check the wound to make sure there is no bleeding or perforation after the TA injection, then spray 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage is depending on the wound area. The key point is that the glue could cover all the injection wound. Seven days later, the protocol is carried out again.
219184824|NCT03502590|DEVICE|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
219184825|NCT05887401|BEHAVIORAL|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
219184826|NCT05887401|BEHAVIORAL|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
219184827|NCT05887401|BEHAVIORAL|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
219184828|NCT05887401|BEHAVIORAL|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
219184829|NCT05887401|BEHAVIORAL|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
219184830|NCT05887401|BEHAVIORAL|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
219184831|NCT05887401|BEHAVIORAL|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
219184832|NCT05887401|BEHAVIORAL|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
219184833|NCT05887401|BEHAVIORAL|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
219184834|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
219184835|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
219184836|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
219184837|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
219184838|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
219184839|NCT00194285|PROCEDURE|FDG-PET Imaging|
219184840|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
219184841|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
219184842|NCT05690711|DRUG|HRS8179|HRS8179 injection
219184843|NCT05690711|DRUG|Placebo|physiological saline
219184844|NCT05922722|OTHER|Decision-making tool|The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
219184845|NCT05922722|OTHER|Questionnaire|Questionnaire to assess participant's understanding of the decision-making tool
219184846|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
219184847|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
219184848|NCT01271465|PROCEDURE|Kidney Biopsy|biopsy of transplant kidney
219184849|NCT05033067|BEHAVIORAL|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
219184850|NCT02677961|OTHER|Observation|
219184851|NCT01471236|DEVICE|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
219184852|NCT01471236|PROCEDURE|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
219184853|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
219184854|NCT06540586|PROCEDURE|M-TAPA BLOCK|In the M-TAPA block group, with the patient in the supine position, a linear high-frequency linear ultrasound (USG) probe is angled to visualize the inferior surface of the costochondral junction at the level of the 10th costochondral cartilage. Under sterile conditions, using the in-plane technique with a 22G 80 mm peripheral block needle, the needle is advanced posterior to the 10th costal cartilage by taking the lower edge of the cartilage in the sagittal plane as the midline. After hydrodissection with 2-3 ml isotonic saline to confirm the site, 20 ml of 0.25% Bupivacaine is administered under USG guidance. The same procedure is performed on the contralateral side as well.
219184855|NCT06278350|DRUG|D-2570|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
219184856|NCT06278350|DRUG|Placebo|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
219184857|NCT06368466|DEVICE|iStatis HBsAg Test|capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples are tested on the iStatis HBsAg Test
219184858|NCT05306028|DRUG|Metformin or insulin treatment|"1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."
219184859|NCT05814055|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
219184860|NCT05814055|DRUG|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
219184861|NCT04089137|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
219184862|NCT04633889|DRUG|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
219184863|NCT04633889|DRUG|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
219184864|NCT04383496|BEHAVIORAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
219184865|NCT04078191|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219184866|NCT06540456|DRUG|Qutenza® 8% Capsaicin Topical System|Treatment of patients with neuropathic LBP and painful lumbosacral radiculopathy using the Qutenza 8% capsaicin topical system.
219184867|NCT05864560|DEVICE|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
219184868|NCT03478215|BIOLOGICAL|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
219184869|NCT03478215|OTHER|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
219184870|NCT06781268|BEHAVIORAL|Life Kinetic Training|Combination of cognitive and physical exercises aimed at improving neuroplasticity, agility, balance, and cognitive functions.
219184871|NCT06007664|BEHAVIORAL|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
219184872|NCT04965090|DRUG|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
219184873|NCT04965090|DRUG|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
219184874|NCT04972552|DIETARY_SUPPLEMENT|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
219184875|NCT04972552|OTHER|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
218999819|NCT06384209|BEHAVIORAL|Friendship Bench Intervention- Problem Solving Therapy|The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart
219184876|NCT04972552|OTHER|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
219184877|NCT04972552|OTHER|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
219184878|NCT01275677|DRUG|Cyclophosphamide|Given IV
219184879|NCT01275677|DRUG|Docetaxel|Given IV
219184880|NCT01275677|DRUG|Doxorubicin|Given IV
219184881|NCT01275677|DRUG|Doxorubicin Hydrochloride|Given IV
219184882|NCT01275677|OTHER|Laboratory Biomarker Analysis|Correlative studies
219184883|NCT01275677|DRUG|Paclitaxel|Given IV
219184884|NCT01275677|OTHER|Quality-of-Life Assessment|Ancillary studies
219184885|NCT01275677|BIOLOGICAL|Trastuzumab|Given IV
219184886|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1\) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
219184887|NCT00207636|BEHAVIORAL|Computer Assisted Decision making tool|The intervention consisted of access to a computer tailored decision aid designed to promote informed decision making.
219184888|NCT00335816|DRUG|fluorouracil|Given IV
218999820|NCT06628128|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
218999821|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
218999822|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
218999823|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
218999824|NCT04038502|DRUG|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
218999825|NCT04038502|DRUG|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
218999826|NCT05765266|DEVICE|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
218999827|NCT05765266|DEVICE|Depo-Medrol®|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
219184889|NCT00335816|DRUG|leucovorin calcium|Given IV
219184890|NCT00335816|DRUG|oxaliplatin|Given IV
219184891|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
219184892|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
218999828|NCT03350581|PROCEDURE|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
218999829|NCT03350581|PROCEDURE|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
218999830|NCT06459245|BEHAVIORAL|Resistance training|Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.
218999831|NCT03286335|RADIATION|Proton Radiation|Radiation treatment
218999832|NCT00390065|DRUG|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
219184893|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
219184894|NCT00335816|GENETIC|DNA analysis|Correlative studies
219184895|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
219184896|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
219184897|NCT00409435|DRUG|pyridostigmine|one 180 mg capsule per day for 3 days
219184898|NCT00409435|DRUG|Placebo|one capsule per day for 3 days
219184899|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
219184900|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
219184901|NCT06518941|DRUG|Donepezil|Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
219184902|NCT05002608|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
219184903|NCT06529094|BEHAVIORAL|Provider training|Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.
219184904|NCT06529094|BEHAVIORAL|CAPP-FIT intervention with RA facilitation|After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.
219184905|NCT06529094|BEHAVIORAL|CAPP-FIT implementation during maintenance phase|Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
219184906|NCT06545188|OTHER|Mortality Attitudes Personality Survey|Two open questions about death and mortality will bei administered to trigger mortality salience
219184907|NCT06545188|OTHER|Dental treatment questions (control condition)|Two open questions about a dental treatment (control condition)
219184908|NCT04164888|DRUG|CIVI 007|hypercholesterolemia agent
219184909|NCT06852352|PROCEDURE|Modified deep cervical Lymphatic-Venous Anastomosis|Deep cervical lymph-vein anastomosis surgery, connecting deep cervical lymph input vein vessels to enhance glymphatic-mediated protein clearance
219184910|NCT03372317|DRUG|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
219184911|NCT06852417|BEHAVIORAL|Health qigong training|Participants will receive two 60-minute Baduanjin qigong training sessions every week under the instruction and supervision of qualified qigong instructors over 12 weeks (i.e., 24 sessions in total). Baduanjin qigong consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. Instructions on each movement, voice-guide audios, and demonstration videos will be provided for participants' daily self-practice. They will be advised to practice Baduanjin for at least 10 minutes every day.
219184912|NCT06850974|DEVICE|Foley Balloon Catheter|18 French Foley Balloon placed trans-cervically and inflated with 30-60ml of Normal Saline.
219184913|NCT06850974|DRUG|Misoprostol|400 mcg of buccal misoprostol sublingual
219184914|NCT06850974|DEVICE|Laminaria|Laminaria will be placed in the cervix according to the following standard formula: Estimated gestational age -10 = number of 5mm laminaria.
219184915|NCT03252834|DIAGNOSTIC_TEST|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
219184916|NCT04409353|DEVICE|Distraction-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Distraction software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
219184917|NCT04409353|DEVICE|Sham VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Sham software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
219184918|NCT04409353|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
219184919|NCT04409353|DEVICE|Activity Tracker|Participants among all arms will be provided the option to passively wear a Fitbit Charge 4 throughout their 90-day study enrollment period. The Fitbit collects biometric data such as daily steps, heart rate, hours of sleep, stages of sleep, and sleep efficiency.
219184920|NCT06774820|PROCEDURE|self-blocking tenodesis|the LHB tendon is detached from its origin in the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate later localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
219184921|NCT06774820|PROCEDURE|arthroscopic tenodesis|LHB tendon is detached from its origin, and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-lasso loop tenodesis technique. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
219184922|NCT05341557|DRUG|BPI-371153|Subjects will receive BPI-371153 until disease progression
219184923|NCT06336863|DIAGNOSTIC_TEST|Allosure and TruGraf|Precision medicine will be employed to withdraw immunosuppression in kidney transplant recipients.
219184924|NCT06336863|OTHER|Immunosuppression Taper|An immunosuppression taper will be employed over a 12-month period for those that are deemed immune quiescent.
219184925|NCT05936905|OTHER|Acupuncture|Acupuncture 1 time per month
219184926|NCT05936905|OTHER|Chiropractic|Chiropractic 1 time per month
219184927|NCT04081103|DRUG|Nexagon® (lufepirsen) High Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
219184928|NCT04081103|DRUG|Nexagon® (lufepirsen) Low Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
219184929|NCT04081103|DRUG|Vehicle|Vehicle is administered topically in the affected eye three (3) times over 28 days.
219184930|NCT04081103|DRUG|Open-label Nexagon® (lufepirsen)|Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
219184931|NCT03833154|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
219184932|NCT03833154|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
219184933|NCT03833154|DRUG|(Osimertinib cohort, single-arm, open-label separate cohort)|Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
219184934|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
219184935|NCT06559553|DRUG|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
219184936|NCT06169527|DRUG|Dupilumab|Dupilumab cohort
218999833|NCT04755569|DEVICE|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
218999834|NCT03886480|DEVICE|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
218999835|NCT06558565|PROCEDURE|stromal vascular fraction or platelet rich plasma|stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
218999836|NCT00356473|DRUG|Atorvastatin|
218999837|NCT01217359|DRUG|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
218999838|NCT00896571|DRUG|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
218999839|NCT00247897|DRUG|Skin antisepsis|See Detailed Description
218999840|NCT03342183|OTHER|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
218999841|NCT03342183|OTHER|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
218999842|NCT04505462|OTHER|Therapeutic diet|A special healthy diet for dialysis patients
218999843|NCT04578431|DIETARY_SUPPLEMENT|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
218999844|NCT04696315|DIAGNOSTIC_TEST|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
218999845|NCT01581645|DEVICE|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
218999846|NCT03201835|DRUG|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
218999847|NCT03201835|DRUG|Sativex|spray X 4 actuations
218999848|NCT03201835|DRUG|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
218999849|NCT03201835|DRUG|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
218999850|NCT03201835|DRUG|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
219184937|NCT04675515|BEHAVIORAL|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
219184938|NCT06197178|BIOLOGICAL|LCAR-G08 cells|Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219184939|NCT03034356|DRUG|Levetiracetam|Anticonvulsant drug
219184940|NCT03034356|DRUG|Placebo|Placebo
219184941|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
219184942|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
219184943|NCT05270213|DRUG|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
219184944|NCT05270213|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
219184945|NCT05270213|DRUG|Other approved anti-cancer therapy|Standard of care (SOC) therapy
219184946|NCT05701657|OTHER|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, nuts/seeds, and olive oil, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
219184947|NCT05701657|OTHER|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
219184948|NCT05701657|OTHER|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, nuts/seeds, dairy and fats/oils, low amounts of fruits, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
219557721|NCT05352438|OTHER|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
219184949|NCT05701657|OTHER|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
219184950|NCT05701657|OTHER|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
219184951|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
219184952|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
219184953|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
219184954|NCT06274034|OTHER|Survey Administration|Ancillary studies
219184955|NCT06128148|DRUG|JYP0322 50 mg qd|JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184956|NCT06128148|DRUG|JYP0322 100 mg qd|JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184957|NCT06128148|DRUG|JYP0322 200 mg qd|JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184958|NCT06128148|DRUG|JYP0322 100 mg bid|JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184959|NCT06128148|DRUG|JYP0322 150 mg bid|JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184960|NCT06128148|DRUG|JYP0322 200 mg bid|JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184961|NCT06128148|DRUG|JYP0322 150mg tid|JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.
219184962|NCT06160388|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
219184963|NCT05111509|DRUG|[203Pb]VMT-α-NET|3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.
219184964|NCT05111509|DEVICE|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
219184965|NCT06651099|OTHER|mhealth application|Individuals enrolled in the mhealth intervention will receive tailored content will include exercises focused on mobility, flexibility, core stabilization, and strengthening. Additionally, the mobile application will provide educational material on pain and health, covering topics such as the neurophysiology of pain, the multidimensional nature of low back pain, myths and facts about the condition, the importance of sleep, and stress management, which will include relaxation techniques and mindfulness. All content will be evidence-based, using clinical guidelines, systematic reviews and other high-quality studies to support inclusion in the mobile application. The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
219184966|NCT06651099|OTHER|Conventional exercise therapy|Participants in this intervention will receive a printed booklet containing a description and recommendations for carrying out an exercise program at home, which will be characterized by general exercises (such as strengthening, mobilization). The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
219184967|NCT05309291|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode.
219184968|NCT05309291|DEVICE|FX 800 Dialyzer|Dialysis performed in HDF mode.
219184969|NCT06982846|DRUG|Retatrutide|Administered SC
219184970|NCT06982846|DRUG|Placebo|Administered SC
219184971|NCT05944458|DRUG|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
219184972|NCT05944458|DRUG|Placebo|20 ml normal saline iv every 12 hours
219184973|NCT03876626|OTHER|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
219184974|NCT03876626|OTHER|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
219184975|NCT07062705|OTHER|Progressive Inhibition of Neuromuscular Structure|The index fingers of both hands were used to palpate two connected locations, referred to as main and endpoints. The locations were located along a neuromuscular structure and were the most and least sensitive sections, respectively. Once an endpoint (region of least sensitivity) was identified, the index finger of one hand was used to provide a moderate ischemia compression; the pressure was kept constant until the course of therapy was finished. After identifying the primary point-the area of greatest sensitivity-a moderate ischemic compression was also applied for 30 seconds using the index finger of the other hand.
219184976|NCT07062705|OTHER|Neural Tissue Mobilization.|The patient sat well back on the end of a plinth with thighs fully supported. The patient was asked to slump. Overpressure was applied to the lumbar and thoracic flexion in attempt to bow the spine rather than the hips. With spinal flexion position maintained, the patient was asked to bend his chin to chest and then overpressure in the same direction was added. The patient was asked to extend his knee actively. The patient was asked to dorsiflex his ankle. The therapist was maintaining the ankle dorsiflexion as a progression for technique. The number of these sequences was repeated several times,through which the amplitude of the technique was increased according to the patient response. The technique was progressed to a point where symptoms reproduced, or it was taken to a point where resistance of the movement was encountered.
219184977|NCT07063225|DRUG|Romiplostim N01|The subjects will receive ropivacaine N01 treatment, with an initial dose of (2-3) µg/kg. When the dose is less than 250 µg, 250 µg (1 vial) can be administered (subcutaneously), once a week. The dose will be increased by (1) µg/kg each week, up to a maximum of 10 µg/kg, until the platelet count reaches ≥ 50 × 10\^9/L. If the platelet count returns to normal, the dose can be reduced according to the platelet level as appropriate.
218999851|NCT05379738|OTHER|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary"
218999852|NCT02590081|DRUG|Dextrose 5%|
219184978|NCT07064239|DEVICE|cooling vest|"Cooling vest :~It is one of cooling methods proposed to improve exercise performance in MS by reducing one's core and/or skin temperature before taking on physical work"
219184979|NCT07064239|OTHER|Aerobic exercises|aerobic exercise as any activity that uses large muscle groups, can be maintained continuously and is rhythmic in nature. As the name implies, muscle groups activated by this type of exercise rely on aerobic metabolism to extract energy in the form of adenosine triphosphate (ATP) from amino acids, carbohydrates and fatty acids. Examples of aerobic exercise include cycling, dancing, hiking, jogging/long distance running, swimming and walking
218999853|NCT02590081|DRUG|normal saline|
218999854|NCT03849196|DRUG|2L PEG-Asc|PEG-Asc powder
218999855|NCT03849196|DRUG|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
218999856|NCT03849196|DRUG|1L PEG-Asc|PEG-Asc powder
218999857|NCT02973698|OTHER|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
218999858|NCT02973698|OTHER|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
218999859|NCT02973698|OTHER|Control|No intervention will do
218999860|NCT00689234|PROCEDURE|diaphragm plication 6 months after inclusion|thoracotomy
218999861|NCT00689234|PROCEDURE|diaphragm plication at time of inclusion|thoracotomy
218999862|NCT00880828|OTHER|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
219184980|NCT07063849|BIOLOGICAL|A/Texas|Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1
218999863|NCT00880828|OTHER|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
219184981|NCT07062848|DIAGNOSTIC_TEST|AI Toolkit for ATTR-CM Diagnosis|An artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE)
219369816|NCT06353776|PROCEDURE|conjunctival biopsy after micropulse transscleral laser therapy|"During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed."
219369817|NCT01253603|DRUG|QAW039 capsules once daily for 28 days|
218999864|NCT00880828|DRUG|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
218999865|NCT02742610|BEHAVIORAL|Mindfulness with Contingency Management|
218999866|NCT02742610|BEHAVIORAL|Active Control|
218999867|NCT06498401|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
218999868|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
218999869|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
218999870|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
218999871|NCT03785808|BEHAVIORAL|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
218999872|NCT01486732|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
218999873|NCT01486732|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
218999874|NCT01486732|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
218999875|NCT05015244|PROCEDURE|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
218999876|NCT00574132|DRUG|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
218999877|NCT00574132|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
218999878|NCT00574132|DRUG|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
218999879|NCT00821353|PROCEDURE|RF catheter ablation|RF catheter ablation
218999880|NCT00821353|DRUG|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
218999881|NCT05292846|DRUG|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
218999882|NCT04318795|PROCEDURE|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
218999883|NCT04318795|PROCEDURE|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
218999884|NCT03863249|PROCEDURE|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
218999885|NCT03863249|DRUG|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
218999886|NCT03863249|DIAGNOSTIC_TEST|MICROBIAL SAMPLING|"1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
219184982|NCT07061925|DRUG|ALC-2203-1|This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
219184983|NCT07061925|DRUG|ALC-2203-2|This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
219184984|NCT07061925|DRUG|ALC-2203-AC|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.
219184985|NCT07061925|DRUG|Placabo|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
219184986|NCT06339710|DRUG|benznidazole 300 mg daily 8 weeks|672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)
218999887|NCT04443270|DRUG|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
219184987|NCT05891600|DEVICE|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
219184988|NCT07063810|DEVICE|Mixed Reality Rehabilitation|"The mixed reality protocol will be based on 5 perceptual-motor activities (i.e., games specifically developed for the purposes of this study). The activities consist in walking to collect objects, avoid obstacles, or move the upper limbs to catch virtual balls or fit in narrow shapes.~Three games will be performed per session, for a duration of 15 minutes each over 1h sessions with rest times.~The level of the activities will be adapted to the performance of the participants during the course of the protocol, by manipulating game settings: necessary speed, accuracy and movement frequency."
219184989|NCT03221426|BIOLOGICAL|Pembrolizumab|IV infusion
219184990|NCT03221426|DRUG|Placebo|IV infusion
219184991|NCT03221426|DRUG|Cisplatin|IV infusion
219184992|NCT03221426|DRUG|Capecitabine|Oral tablets
219184993|NCT03221426|DRUG|5-fluorouracil|IV infusion
219184994|NCT03221426|DRUG|Docetaxel|IV infusion
219184995|NCT03221426|DRUG|Oxaliplatin|IV infusion
219184996|NCT03221426|DRUG|Leucovorin|IV infusion
219184997|NCT06441760|OTHER|Video teleconsultation|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while PEM physicians will provide medical direction remotely using video to communicate with EMS personnel via tablet devices.
219184998|NCT06441760|OTHER|Audio support|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while EM physicians will provide medical direction remotely using audio to communicate with EMS personnel via tablet devices.
219184999|NCT06934980|DEVICE|Microneedle Device|Microneedle device will be used for collecting dermal interstitial skin fluid samples as defined by the protocol.
219185000|NCT06952387|OTHER|Personalized blood pressure management|"In patients assigned to personalized blood pressure management, clinicians were asked to maintain intraoperative MAP at least at the preoperative mean 24-hour MAP (with a maximum MAP target of 110 mmHg) from anesthesia induction to 2 hors after completion of surgery. If the preoperative mean 24-hour MAP was below 65mmHg, intraoperative MAP was maintained at least at 65mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger fluid challenge (FC) administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
219185001|NCT06952387|OTHER|Routine blood pressure management|"In patients assigned to routine blood pressure management, clinicians were blinded to the results of preoperative automated 24-hour blood pressure monitoring, and thus managed blood pressure per institutional routine which generally is to maintain MAP above 60 mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger FC administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
219185002|NCT04543617|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
218999888|NCT02912910|OTHER|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
219185003|NCT04543617|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219185004|NCT04543617|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219185005|NCT04543617|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219185006|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snack with original level of sugar
219185007|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 2|Fruit snack with reduced level of sugar
219185008|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 3|Fruit snack with 0 added sugar - formulation 1
219185009|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 4|Fruit snack with 0 added sugar - formulation 2
219185010|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 5|Fruit snack from raisins
219185011|NCT06458946|DIETARY_SUPPLEMENT|Confection control|confection
219185012|NCT06443775|DRUG|Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)|Eye Drops
218999889|NCT02912910|OTHER|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
218999890|NCT04103853|DRUG|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
218999891|NCT00905697|PROCEDURE|Living donor lung transplantation|Living donor lung transplantation
219185013|NCT06533761|DRUG|Eganelisib|eganelisib will be administered as monotherapy
219185014|NCT06533761|DRUG|Eganelisib in combination with cytarabine|eganelisib will be administered in combination with cytarabine
219185015|NCT05000294|DRUG|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
219185016|NCT05000294|DRUG|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
219185017|NCT06834100|DRUG|polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y|"Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site.~Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site."
219185018|NCT05453916|DRUG|Nitazoxanide 500Mg Oral Tablet|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
219369818|NCT01253603|DRUG|Placebo to QAW039 capsules once daily for 28 days|
219185019|NCT05453916|DRUG|Rifaximin 550Mg Tab|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
219185020|NCT05455034|GENETIC|single-cell sequencing|Treatment is given according to the results of single-cell sequencing.
219185021|NCT06956014|DRUG|VER-01|Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product
219185022|NCT06956014|OTHER|Placebo|Comparator without active ingredient
219185023|NCT06041581|BEHAVIORAL|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
219185024|NCT06041581|BEHAVIORAL|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
219185025|NCT06041581|BEHAVIORAL|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
219185026|NCT06041581|OTHER|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
219185027|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
219185028|NCT06212804|BIOLOGICAL|VIS954|A humanized IgG4 monoclonal antibody.
219185029|NCT06212804|OTHER|Placebo|VIS954 Placebo
219185030|NCT03856515|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
219185031|NCT03856515|OTHER|Questionnaire Administration|Ancillary studies
219185032|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette - with Nicotine
219185033|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette -without Nicotine
219369819|NCT01253603|DRUG|Fluticasone propionate inhaler twice daily for 28 days|
219369820|NCT02532348|OTHER|Blood samples|Blood samples
219369821|NCT05253456|PROCEDURE|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
218999892|NCT06407167|DIAGNOSTIC_TEST|DN4 (Douleur Neuropathique 4 Questions) questionnaire|DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination
218999893|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
218999894|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
218999895|NCT00725569|DRUG|Bellis perennis and Staphysagria (C6)|homeopathic remedy
218999896|NCT00725569|DRUG|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
218999897|NCT00725569|DRUG|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
218999898|NCT05812898|OTHER|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
219369822|NCT02764541|DRUG|Letrozole|
219369823|NCT02764541|DRUG|Tamoxifen|
219369824|NCT02764541|DRUG|Palbociclib|
219185034|NCT06959290|PROCEDURE|Multiple nonpharmacological methods|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. The nurse will then give the baby 25% dextrose solution orally (0.5ml for those \<32 weeks gestation, 1ml for those \>32 weeks gestation). The nurse then places a pacifier soaked in 25% dextrose solution in the preterm infant's mouth. After these three non-pharmacological methods, the doctor will perform the ROP examination.
219185035|NCT06959290|OTHER|Routine Treatment|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. After these three non-pharmacological methods, the doctor will perform the ROP examination.
219185036|NCT05378841|PROCEDURE|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
219185037|NCT06845904|DEVICE|WaveWriter Alpha™ neurostimulation system|Two Boston Scientific WaveWriter Alpha™ Implantable Pulse Generators (IPGs) will be implanted and connected to CoverEdge™ or CoverEdge™ X 32 Surgical Paddle Leads. The leads are positioned to enable targeted stimulation of the spinal cord to optimize control of urinary functions.
219185038|NCT05421065|DRUG|Psilocybin|1 oral dose
219185039|NCT05421065|DRUG|Ketamine|1 oral dose
219185040|NCT05728229|DRUG|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
219185041|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
219185042|NCT05310773|BEHAVIORAL|Community Stigma Awareness and Education Workshop|Key aspects of the workshop include community stigma awareness of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. The workshop adapts a stigma-reduction curriculum based on a stigma-reduction toolkit and community HIV prevention project with community peers with skits to address stigmatizing attitudes and behaviors toward young women and men who use AODs and who may need health services, including HIV treatment and prevention. Selected modules were modified from the existing clinic-based training to fit community stigma awareness and attitudes to focus on aspects of stigma specific to young women and men who engage in syndemic-related behaviors who live in their communities. The stigma awareness and education workshop will be delivered in communities randomized to receive workshops (N=12 communities).
219185043|NCT05310773|BEHAVIORAL|Couples Health CoOp Plus (CHC+)|The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, violence, and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporates antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; estimated N=240 couples).
219185044|NCT06259526|DRUG|Placebo group|(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
219185045|NCT06259526|DRUG|JS1-1-01 low-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
219185046|NCT06259526|DRUG|JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules|(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
219185047|NCT06259526|DRUG|JS1-1-01 high-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
219185048|NCT06259526|DRUG|Active drug group|(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.
219185049|NCT06347822|BEHAVIORAL|Therapy Session|Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
219185050|NCT05809453|DRUG|Cocaine|Cocaine (cocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
219185051|NCT05809453|DRUG|Lidocaine|Lidocaine (lidocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
219185052|NCT05030623|DRUG|Tadalafil 5Mg Tab|Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule
219185053|NCT05030623|DRUG|Placebo|Placebo Tab plus Fluoxetine 20 mg capsule
219185054|NCT05734833|DIETARY_SUPPLEMENT|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
219185055|NCT05734833|OTHER|Placebo|The Placebo comparator arm will receive placebo sachets
219185056|NCT06355453|DEVICE|Goldcrest Patch and Three Patch Coupons|Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
219185057|NCT06355453|DEVICE|Goldcrest Patch and Novii Patch|Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
219185058|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
219185059|NCT05159050|DRUG|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose"
218999899|NCT05812898|OTHER|myofascial release|myofascial release using instrument assisted soft tissue mobilization
218999900|NCT03624894|OTHER|impression|common polyvinylsiloxane oral impression
218999901|NCT06384768|OTHER|Video training|A 4 week support program consist of videos for fear of childbirth
218999902|NCT05292040|DRUG|LY3857210|Administered orally.
218999903|NCT02337257|DRUG|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
218999904|NCT02337257|DRUG|Placebo|subjects will receive placebo one pill per day for 16 weeks
218999905|NCT01057342|DRUG|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
218999906|NCT01057342|DRUG|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
218999907|NCT01057342|DRUG|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
218999908|NCT02579044|DRUG|Everolimus and lonafarnib|
218999909|NCT00459953|DRUG|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
218999910|NCT06076265|PROCEDURE|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
218999911|NCT04006574|OTHER|Exercises|Core stabilization
218999912|NCT03875651|DEVICE|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
218999913|NCT00437307|DRUG|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
218999914|NCT05806073|PROCEDURE|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
218999915|NCT05806073|PROCEDURE|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
218999916|NCT00386178|DRUG|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
218999917|NCT05978804|OTHER|Computerized Cognitive Training|Computerized Cognitive training (BrainHQ or Constant Therapy)
218999918|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
218999919|NCT00810030|DRUG|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
218999920|NCT00810030|DRUG|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
218999921|NCT02250781|DRUG|Oral ONC201|Given PO
218999922|NCT04658953|OTHER|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
218999923|NCT04658953|OTHER|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
218999924|NCT03725098|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
218999925|NCT03725098|DEVICE|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
218999926|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
218999927|NCT01087645|DRUG|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
218999928|NCT01087645|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
218999929|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
218999930|NCT01087645|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo
219369825|NCT02764541|DRUG|Endocrine Therapy|
219369826|NCT00749190|DRUG|BI 10773|
219369827|NCT00749190|DRUG|placebo|
219369828|NCT00749190|DRUG|sitagliptin|
219185060|NCT05867472|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
219185061|NCT05867472|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
219185062|NCT00963417|OTHER|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
219185063|NCT00963417|PROCEDURE|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
219185064|NCT06787703|BEHAVIORAL|Psychological First Aid Intervention|"Psychological first aid is a compassionate and supportive presence designed to mitigate acute distress and asses the need for continued mental health care. The intervention aims to enhance the compassionate presence, assist with needs and promote adaptive functioning. The intervention encompasses seven main themes (RAPID model, emotion stabilization, self-compassion, reframing, instillation of hope and empowerment) that will be covered through a series of five training exercises conducted on 6 sessions. Each session ranged in duration from 30 to 45 minutes.~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition).~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition). The"
219185065|NCT04404881|DRUG|Bevacizumab (Avastin®)|"* Induction Period (first 3 months of bevacizumab treatment):~  \-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
219185066|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
219185067|NCT03287817|BIOLOGICAL|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells with limited duration of anti-PD1 antibody (pembrolizumab).
219185068|NCT00636077|DEVICE|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
219185069|NCT00636077|DEVICE|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
219185070|NCT00636077|DEVICE|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
219185071|NCT00636077|DEVICE|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
219185072|NCT05251909|BIOLOGICAL|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
219185073|NCT05251909|BIOLOGICAL|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
219185077|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219185078|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
219185079|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
219185080|NCT04659616|DRUG|Cytarabine|Given IV
219185081|NCT04659616|DRUG|Daunorubicin|Given IV
219185082|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
219185083|NCT04659616|DRUG|Pemigatinib|Given PO
219185084|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
219185085|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
219185086|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
219185087|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 2|Participants will use their Radicle Energy Placebo Control Form 2 as directed for a period of 6 weeks.
219185088|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 2.1 Usage|Participants will use their Radicle Energy Active Study Product 2.1 as directed for a period of 6 weeks.
219185089|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 3|Participants will use their Radicle Energy Placebo Control Form 3 as directed for a period of 6 weeks.
219185090|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 3.1 Usage|Participants will use their Radicle Energy Active Study Product 3.1 as directed for a period of 6 weeks.
219185091|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 4|Participants will use their Radicle Energy Placebo Control Form 4 as directed for a period of 6 weeks.
219185092|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.1 Usage|Participants will use their Radicle Energy Active Study Product 4.1 as directed for a period of 6 weeks.
219185093|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.2 Usage|Participants will use their Radicle Energy Active Study Product 4.2 as directed for a period of 6 weeks.
219185094|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.3 Usage|Participants will use their Radicle Energy Active Study Product 4.3 as directed for a period of 6 weeks.
219185095|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.1.0|Participants will use their Radicle Energy Placebo Control Form 5.0 as directed for a period of 6 weeks.
219185096|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.1.1 Usage|Participants will use their Radicle Energy Active Study Product 5.1.1 as directed for a period of 6 weeks.
219185097|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.3.0|Participants will use their Radicle Energy Placebo Control Form 5.3 as directed for a period of 6 weeks.
219185098|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.1 Usage|Participants will use their Radicle Energy Active Study Product 5.3.1 as directed for a period of 6 weeks.
219185099|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.2 Usage|Participants will use their Radicle Energy Active Study Product 5.3.2 as directed for a period of 6 weeks.
219185100|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.2.0|Participants will use their Radicle Energy Placebo Control Form 5.2 as directed for a period of 6 weeks.
219185101|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.2.1 Usage|Participants will use their Radicle Energy Active Study Product 5.2.1 as directed for a period of 6 weeks.
219185102|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
219185103|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
219185104|NCT05543915|DEVICE|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
219185105|NCT05880472|DEVICE|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
219185106|NCT06643897|OTHER|Qualitative Interview|40-50 minute-qualitative interview.
219185107|NCT06359223|DIETARY_SUPPLEMENT|coffee consumption|After cesarean section, patients will be allowed to drink coffee.
219185108|NCT06359223|OTHER|control group|Patients will undergo a routine surgical procedure.
219185109|NCT05915806|DIETARY_SUPPLEMENT|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
219185110|NCT05915806|DIETARY_SUPPLEMENT|Control|Control with no or low-dose DHA.
219185111|NCT05689515|BEHAVIORAL|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
219185112|NCT05131425|BEHAVIORAL|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
219185113|NCT05131425|OTHER|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
219185114|NCT06348992|BEHAVIORAL|Acceptance commitment therapy and yoga|The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.
219185115|NCT06348992|BEHAVIORAL|Active Comparator: Mental Health Education Group|The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
219185116|NCT06393595|DIAGNOSTIC_TEST|surface enhanced Raman Spectroscopy|"Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation."
219185117|NCT05282277|DRUG|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
219185118|NCT05282277|DRUG|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
219185119|NCT05282277|DRUG|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
219185120|NCT05282277|DRUG|Raclopride C11|All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
219185121|NCT04873050|DRUG|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
219185122|NCT04873050|DRUG|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
219185123|NCT03533985|BEHAVIORAL|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
219185124|NCT03533985|OTHER|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
219185125|NCT03533985|OTHER|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
219185126|NCT03533985|OTHER|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
219185127|NCT03533985|OTHER|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
219185128|NCT03533985|OTHER|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
219185129|NCT06215027|OTHER|Dance|Dance protocol
219185130|NCT04714476|DEVICE|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
219185131|NCT06014983|DIETARY_SUPPLEMENT|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
219185132|NCT06014983|DIETARY_SUPPLEMENT|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
219185133|NCT03956446|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
219185134|NCT03956446|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
219185135|NCT03956446|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
219185136|NCT05469347|DRUG|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
219185137|NCT05469347|DRUG|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
219185138|NCT06442982|DEVICE|insole-type gait analyzer|Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
219185139|NCT06494787|COMBINATION_PRODUCT|Aliya Pulse Electric Field sysem and pembrolizumab|This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
219185140|NCT05222971|DRUG|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
219185141|NCT05222971|DRUG|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
219185142|NCT02955290|OTHER|Laboratory Biomarker Analysis|Correlative studies
219185143|NCT02955290|BIOLOGICAL|Nivolumab|Given IV
219185144|NCT02955290|BIOLOGICAL|Pembrolizumab|Given IV
219185145|NCT02955290|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
219185146|NCT04974554|BEHAVIORAL|FIT|FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
219185147|NCT04974554|BEHAVIORAL|Home-Based Family Support|Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
219185148|NCT04251429|OTHER|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
219185149|NCT02974998|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
219185150|NCT02974998|BEHAVIORAL|Standard HTC|Participants received the standard HTC available in South Africa for this population.
219185151|NCT04014335|DRUG|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
219185152|NCT06149429|BEHAVIORAL|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
219185153|NCT05356286|DEVICE|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
219185154|NCT03532282|BEHAVIORAL|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
219185155|NCT03532282|BEHAVIORAL|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm (checklist). Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
219185156|NCT05793541|BEHAVIORAL|Phone call|A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call. This intervention occurs at High Risk only.
219185157|NCT05793541|BEHAVIORAL|Text messaging|A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction. This intervention occurs at High Risk only.
219185158|NCT05793541|BEHAVIORAL|Automated interactive smartphone-based tool|An automated interactive, smartphone-based tool that will (a) (at High Risk only) guide the participant through a risk assessment and (b) (at High and Medium/Low Risk) present recommendation to use and a review of the safety plan.
219369829|NCT04713761|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
219185159|NCT05793541|BEHAVIORAL|Non-interactive pop-up messages|Automated non-interactive, static pop-up messages that recommend use of the safety plan or its components (Medium/Low Risk only).
219185160|NCT02378350|DEVICE|Hemodialysis treatment (no specific device is defined)|
219185161|NCT02378350|DRUG|Peritoneal Dialysis treatment (no specific drug is defined)|
219185162|NCT05058287|DRUG|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
219185163|NCT05058287|DRUG|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
219185164|NCT02744677|DEVICE|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position
219185165|NCT02744677|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
219185166|NCT02744677|DEVICE|SAPIEN 3 Ultra RESILIA THV|SAPIEN 3 Ultra RESILIA THV in the pulmonic position
219185167|NCT05802615|BEHAVIORAL|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
219185168|NCT05802615|OTHER|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
219185169|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
219185170|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
219185171|NCT03705715|DRUG|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|\[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
219185172|NCT03705715|OTHER|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
218999931|NCT03937011|DEVICE|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;"
219185173|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
218999932|NCT00545662|DRUG|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
218999933|NCT00545662|DRUG|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
218999934|NCT04664166|OTHER|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
218999935|NCT01600469|DRUG|DAOI-B|250-1500 mg/day, oral, for 24 weeks
218999936|NCT01600469|OTHER|Placebo|placebo, oral, for 24 weeks
218999937|NCT01734356|OTHER|Skin biopsies|
218999938|NCT05751902|OTHER|Arabic version of OHIP questionnaire|Translated Arabic version of Oral Health Impact Profile questionnaire
218999939|NCT05050604|DRUG|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
219185174|NCT05348993|DRUG|Placebo|placebo
219185175|NCT05259085|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
219185176|NCT04075864|BEHAVIORAL|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
219185177|NCT02993159|DRUG|Afimoxifene|Applied to the breast
219185178|NCT02993159|OTHER|Laboratory Biomarker Analysis|Correlative studies
219185179|NCT02993159|OTHER|Placebo|Given PO
219185180|NCT02993159|OTHER|Placebo|Applied to the breast
219185181|NCT02993159|DRUG|Tamoxifen Citrate|Given PO
219185182|NCT05034328|DEVICE|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
219185183|NCT05034328|OTHER|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
219185184|NCT02473536|RADIATION|Stereotactic ablative radiation therapy|SABR
219185186|NCT02895464|OTHER|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
219185187|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
219185188|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
219185189|NCT05357430|DRUG|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
219185190|NCT05039788|OTHER|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
219185191|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
219185192|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
219185193|NCT06097910|PROCEDURE|Watchful waiting|Conduct thoracic computed tomography scans every 12 months. The decision regarding surgery is based on the surgeon's evaluation of radiologic follow-up. The reference resection criteria encompass: a) Any lesion that progresses to a tumor diameter larger than 2cm or has CTR greater than 0.25. b) Clinical Tumor, node, metastasis (TNM) stage upstaging.
219185194|NCT05653453|DEVICE|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
219185195|NCT05653453|DRUG|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
219185196|NCT05172999|DEVICE|levonorgestrel-releasing intrauterine system|Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
218999940|NCT05050604|DRUG|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
218999941|NCT03474770|DRUG|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
218999942|NCT03926169|DRUG|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
218999943|NCT03926169|DRUG|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
218999944|NCT03556774|BEHAVIORAL|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
218999945|NCT02392143|OTHER|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
219185197|NCT05172999|DRUG|Polyethylene Glycol Loxenatide|Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
219185198|NCT06208514|BEHAVIORAL|Brief pain exposure therapy (BPET)|"Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol (fibromyalgia participants only will complete the daily logs), and 7 for days post-treatment.~Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study."
219185199|NCT06802822|DRUG|Prevention of Allosensitization|This study evaluates the impact of two different durations of immunosuppressive therapy on kidney transplant patients who return to dialysis after a failed transplant. One group will continue immunosuppressive therapy for two years, while the other will stop the therapy six months after starting dialysis. The goal is to determine if continuing immunosuppression can reduce the risk of allosensitization and improve outcomes, compared to stopping the therapy earlier.
219185200|NCT06801158|DRUG|use of anticancer drugs in monotherapy or in combination therapy|ICSRs involving antineoplastic or immunomodulating agents were included.
219185201|NCT06802692|BEHAVIORAL|VR glasses and meditation music group|Starting 15 minutes before the ET procedure, participants in the VR glasses and meditation music group will be shown a video of the sea, underwater and forest with VR glasses and will be made to listen to meditation music. At the same time, meditation music will be played. When the ET procedure is completed, the video and meditation music will be stopped. After the procedure, the VR glasses will be disinfected with antiseptic spray before being used on another patient, and disposable ear pads will be placed on the headphones after each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be evaluated 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure, the application of VR glasses and listening to meditation music will be evaluated.
219185202|NCT06802692|BEHAVIORAL|Meditation music group|Meditation music group participants will listen to meditation music through headphones starting from 15 minutes before the ET procedure until the procedure is completed. When the ET procedure is completed, the meditation music will be stopped. After the procedure, disposable ear pads will be placed on the headphones for each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be assessed 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure and listening to meditation music will be assessed.
219185203|NCT03625167|OTHER|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
219185204|NCT04743167|PROCEDURE|Surgery|Laparoscopic treatment of endometriotic lesions
219185205|NCT04743167|PROCEDURE|IVF|Up to three completed cycles of IVF
219185206|NCT05825677|DEVICE|tDCS actif|Active brain stimulation
219185207|NCT05825677|DEVICE|tDCS Sham|Sham brain stimulation
219185208|NCT05919979|BEHAVIORAL|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
219185209|NCT05919979|BEHAVIORAL|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
219185210|NCT06102733|BEHAVIORAL|Rehabilitation therapy|Chronic pain rehabilitation therapy
219185211|NCT05445427|DEVICE|vagal nerve stimulator|Non-invasive vagus nerve stimulator
219185212|NCT04602091|OTHER|no intervention|no intervention
219185213|NCT02969707|DEVICE|MagPro TMS system (MagVenture, Denmark)|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
219185214|NCT02969707|BEHAVIORAL|Hypnosis|Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
219185215|NCT06031623|DEVICE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
219185216|NCT04986995|DRUG|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
219185217|NCT06346678|OTHER|Accuhaler tester|Patients will perform testing with Accuhaler tester, Ellipta tester and Turbutester.
219185218|NCT06223867|DEVICE|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
219185219|NCT06223867|BEHAVIORAL|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
219185220|NCT04488497|BEHAVIORAL|Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis|This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.
219185221|NCT04488497|BEHAVIORAL|Standard of care|Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
219185222|NCT05572047|DEVICE|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
219185223|NCT04722185|DIAGNOSTIC_TEST|Veriton SPECT/CT|The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
219185224|NCT05639348|OTHER|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
219185225|NCT06348342|OTHER|Pelvic Floor Muscle Exercise|Training for PFME will be given orally and will cover the importance of FME and how to do the exercises, as well as the conditions and frequency of doing the exercises. You will be told that the exercise should be done when the bladder is empty, three times a day (morning, noon and evening) and repeated 10 times in each set. In the first week of exercise, the pelvic floor muscles will be contracted for 3 seconds and relaxed for 3 seconds, and will be increased by 1 second each week. It will be explained that from the 8th week onwards, it will be done by contracting for 10 seconds and relaxing for 10 seconds and will continue. It will be stated that the learning process of pelvic floor muscle exercise may take 6 weeks to 6 months. It will be stated that this exercise should be applied throughout their lives for the sustainability of PFM strength. The training is planned to last approximately 20 minutes. PFME will last for two months. Women in menopause will be given an exercise chart.
219185226|NCT06348342|OTHER|Core Exercise|Activating the contraction of the deep core muscles TrA and mutifidus without disrupting breathing forms the basis of core stabilization exercises. To teach the \&#34;abdominal hallowing\&#34; maneuver, which enables the activation of these muscles, patients will be shown a picture of the TrA muscle and asked to contract their lower abdominal muscles while lying on their back in the hook position. During the maneuver, care will be taken to ensure that no movement occurs in the trunk and pelvis and that diaphragmatic breathing continues. After the abdominal hallowing maneuver is taught, the exercises will be progressed gradually. A home exercise program will be given for this. The 7-level exercise program recommended by Hagins et al. will be used as a home exercise program. The movements in this program load more moments on the muscles that stabilize the lumbar spine as the levels progress. The stages of the exercise program are shared in the brochure to be given to the patients.
219185227|NCT01224184|BEHAVIORAL|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
219185228|NCT01224184|BEHAVIORAL|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
219185229|NCT06074952|OTHER|Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)|Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
219185230|NCT06690411|OTHER|Mulligan Concept|The participants of the Mulligan SNAG group will undergo the Mulligan SNAG technique. Mulligan's SNAG technique is a gentle manual therapy method. This technique is based on the correction of the joint position. There are 3 techniques specified for headache; Headache SNAG, Reverse Headache SNAG, and C1-C2 SNAG.
219185231|NCT06690411|OTHER|Myofascial Release Technique|Myofascial therapy can be described as massage-type manual therapy. The participants of the Myofascial Release Group will undergo the myofascial release technique.
219369830|NCT01652924|DEVICE|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
219185232|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
219185233|NCT04314713|DRUG|Scopolamine Hydrobromide Trihydrate|Scopolamine Hydrobromide Trihydrate Intramuscular Injection
219185234|NCT03287336|DRUG|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
219369831|NCT01652924|DEVICE|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
219369832|NCT03064464|OTHER|None Intervention|It is observational study, no interventios to any of the three study arms
219369833|NCT04957459|OTHER|No intervention|No intervention
219369834|NCT04706910|DRUG|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
219185235|NCT06250153|BEHAVIORAL|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|M-SBIRT is a mobile phone-based program designed to enhance delivery of Screening, Brief Intervention, and Referral to Treatment (SBIRT), an evidence-based approach for mental health and substance use screening and treatment. The program utilizes mobile phone text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder treatment services.
219185236|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
219185237|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
219185238|NCT06040866|OTHER|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
219185239|NCT06040866|OTHER|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
219185240|NCT06040866|OTHER|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
219185241|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
219185242|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
219185243|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
219185244|NCT05351801|DRUG|Placebo|Placebo
219185245|NCT05410496|DRUG|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
219185246|NCT03222999|OTHER|No intervention planned|No intervention planned
219185247|NCT00248287|DRUG|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
219185248|NCT00248287|DRUG|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
219185249|NCT05384431|DIETARY_SUPPLEMENT|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
219185250|NCT05384431|OTHER|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
219185251|NCT04338776|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
219185252|NCT04338776|DEVICE|Rezum|"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
219185253|NCT05289648|DRUG|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
219369835|NCT04706910|DRUG|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
219185254|NCT05579951|PROCEDURE|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
219185255|NCT05579951|PROCEDURE|Conventional|Total knee replacement with conventional instrumentation
219185256|NCT05579951|DEVICE|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
219185257|NCT05312164|DEVICE|HF-OCT Imaging|Subjects undergo HF-OCT imaging of stenosed coronary arteries
219185258|NCT05312164|DEVICE|FFR Pressure Wire|Subjects undergo FFR physiology assessment of stenosed coronary arteries
219185259|NCT05312164|DEVICE|Angiography|Subjects undergo angiography imaging of stenosed coronary arteries
219185260|NCT06220006|PROCEDURE|Pulmonary vein isolation|Catheter ablation
219369836|NCT00570245|DRUG|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
219369837|NCT00570245|DRUG|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
219369838|NCT01245673|BIOLOGICAL|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
219369839|NCT01245673|OTHER|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.
219369840|NCT01245673|DRUG|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
219185261|NCT05202964|OTHER|Tolerance and adherence to oral antibiotics in patients managed for BJI|"Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire).~Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3.~Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse."
219185262|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
219185263|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
219185264|NCT04504721|OTHER|light therapy|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
219185265|NCT01529593|DRUG|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
219185266|NCT01529593|DRUG|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
219185267|NCT04700176|DRUG|Daratumumab|During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
219185268|NCT04700176|DRUG|Pomalidomide|Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
219185269|NCT04700176|DRUG|All-trans retinoic acid|ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
219185270|NCT04700176|DRUG|Dexamethasone|Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
219185271|NCT04948398|DRUG|Guselkumab|Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
219185272|NCT05599711|BEHAVIORAL|Transitioning Together (TT) / Juntos en la Transicion (JET)|"1. One individual family joining session when each family dyad meets with group therapists to establish rapport and share their own unique family's background, goals, and supports.~2. A series of four 2.5-hour multi-family group psychoeducation intervention sessions focused on problem-solving education and psychoeducational autism transition-to-adulthood content which can include independence in adulthood, community involvement, guardianship and legal issues, employment and education, health and well-being."
219185273|NCT05599711|BEHAVIORAL|Usual autism transition care|An expedited referral will be made for participants to establish care with a BMC Autism Program Transition/Resource Specialist. Data will be abstracted from the electronic medical record on how many visits each family completes with a BMC Autism Program Transition/Resource Specialist or other BMC Developmental and Behavioral Pediatrics provider throughout the study period.
219185274|NCT05007067|DEVICE|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
219185275|NCT05531747|OTHER|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
219185276|NCT05531747|OTHER|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
219185277|NCT00576979|DRUG|cyclophosphamide|Given IV
219185278|NCT00576979|DRUG|etoposide|Given IV
219185279|NCT00576979|PROCEDURE|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
219185280|NCT00576979|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
219185281|NCT00576979|PROCEDURE|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
219185282|NCT00576979|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219185283|NCT00576979|RADIATION|tomotherapy|Undergo IMRT using helical tomotherapy
219185284|NCT05032040|BIOLOGICAL|vudalimab|Monoclonal bispecific antibody
219185285|NCT03697096|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
219185286|NCT03697096|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
219185287|NCT03924661|DEVICE|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
219185288|NCT06454331|DEVICE|Transcranial direct current stimulation|The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.
219185289|NCT06454331|DEVICE|Sham transcranial direct current stimulation|it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days
219185290|NCT05759299|PROCEDURE|Advanced airway management|Advanced airway management with either tracheal intubation or supraglottic airways performed after induction with hypnotic and/or opioid drugs
219185291|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1|Components of LMN-201
219185292|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-2|Components of LMN-201
219185293|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-3|Components of LMN-201
219185294|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3|Components of LMN-201
219185295|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
219185296|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
219185297|NCT04031820|PROCEDURE|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
219185298|NCT04031820|PROCEDURE|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
219185299|NCT06289517|DRUG|68Ga-Her2-affibody|68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
219185300|NCT03766685|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219185301|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
219185302|NCT05099679|BEHAVIORAL|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
219185303|NCT05099679|BEHAVIORAL|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
219185304|NCT04241250|DEVICE|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
219185305|NCT04241250|DEVICE|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
219369841|NCT01245673|BIOLOGICAL|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
219185306|NCT04226547|DEVICE|Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)|Implantation of an Amplatzer Amulet left atrial appendage occluder
219185307|NCT04226547|DRUG|Non-Vitamin K Oral Antagonists|Initiation or continuation of a NOAC drug
219185308|NCT05266365|OTHER|The video-based exercise (VBE) group|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video."
219185309|NCT05266365|OTHER|The standard exercise group (SE)|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic."
219185310|NCT05601700|DRUG|Letrozole tablets|ATC: L02BG04
219185311|NCT05601700|DRUG|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
219185312|NCT06526117|DRUG|Hydroxyurea|The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
219185313|NCT01019564|DEVICE|Complete Easy Rub Formula MPS|Multi-purpose solution
219185314|NCT01019564|DEVICE|Aquify MPS|Multi-purpose solution
219185315|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
219185316|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
219185317|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
219185318|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
219185319|NCT06201247|DRUG|JD123 injection|JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
219185320|NCT05766462|OTHER|Pacemaker lower rate setting|Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
219185321|NCT04930874|OTHER|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
219185322|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
218999946|NCT02392143|OTHER|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
218999947|NCT02392143|OTHER|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
218999948|NCT06153329|DRUG|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
218999949|NCT06153329|DRUG|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
218999950|NCT06153329|DRUG|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
218999951|NCT00316849|OTHER|pharmacological study|
218999952|NCT00316849|PROCEDURE|adjuvant therapy|
218999953|NCT00316849|RADIATION|3-dimensional conformal radiation therapy|
218999954|NCT00316849|RADIATION|intensity-modulated radiation therapy|
218999955|NCT00316849|DRUG|temsirolimus|Given IV
218999956|NCT00316849|DRUG|temozolomide|Given orally
218999957|NCT01862900|BIOLOGICAL|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
218999958|NCT05810883|DIAGNOSTIC_TEST|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4"
218999959|NCT05680896|BIOLOGICAL|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
218999960|NCT01218711|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
218999961|NCT04234178|DRUG|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
218999962|NCT04234178|DRUG|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
218999963|NCT01003288|BIOLOGICAL|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~\* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
218999964|NCT06321783|OTHER|Assessment|Evaluation of cervical proprioception, hand-eye coordination, postural control and endurance of cervical muscles
218999965|NCT02941198|DEVICE|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
218999966|NCT02941198|DEVICE|Cu T380 A|Cu T380 A will be inserted into the uterus
218999967|NCT01926236|OTHER|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
218999968|NCT01926236|DRUG|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
218999969|NCT01926236|DRUG|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
218999970|NCT01926236|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
218999971|NCT05262127|BEHAVIORAL|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
218999972|NCT02147236|BEHAVIORAL|Social Skills Training|
218999973|NCT00450281|GENETIC|chromogenic in situ hybridization|
218999974|NCT00450281|GENETIC|gene expression analysis|
218999975|NCT00450281|GENETIC|mutation analysis|
218999976|NCT00450281|GENETIC|polymerase chain reaction|
218999977|NCT00450281|GENETIC|polymorphism analysis|
218999978|NCT00450281|OTHER|fluorescent antibody technique|
218999979|NCT00450281|OTHER|immunohistochemistry staining method|
218999980|NCT00450281|OTHER|laboratory biomarker analysis|
218999981|NCT00450281|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
218999982|NCT00450281|OTHER|study of socioeconomic and demographic variables|
218999983|NCT00450281|PROCEDURE|study of high risk factors|
218999984|NCT03295812|OTHER|standard therapy|standard therapy,non-interventional study
218999985|NCT03727347|DEVICE|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
219185323|NCT05565417|DRUG|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
218999986|NCT02200562|DRUG|ipilimumab and dabrafenib|
218999987|NCT02186990|DRUG|propofol|2,5 mg/kg
218999988|NCT02186990|DRUG|etomidate|0,3 mg/kg
218999989|NCT02186990|DRUG|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
218999990|NCT03615378|DIETARY_SUPPLEMENT|5000 IU D3|Daily
218999991|NCT03615378|DIETARY_SUPPLEMENT|1000 IU D3|Daily
218999992|NCT03615378|DIETARY_SUPPLEMENT|Placebo|lactose/sugar tablet
218999993|NCT01421004|DRUG|TKI258|
218999994|NCT03200860|DRUG|Empagliflozin 10 MG|10 mg daily, oral, 30 days
218999995|NCT03200860|DRUG|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
218999996|NCT04063930|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
218999997|NCT04063930|DRUG|Placebos|Matching placebo
218999998|NCT02418364|OTHER|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
218999999|NCT02418364|OTHER|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
219000000|NCT04199910|OTHER|There is no intervention, only research blood samples are collected|Research blood samples collected
219000001|NCT00980382|DRUG|S-1, Docetaxel|"* Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8"
219000002|NCT00000208|DRUG|Buprenorphine|
219000003|NCT00217594|DRUG|Alemtuzumab (Campath)|
219000004|NCT02764060|DEVICE|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
219000005|NCT02764060|DEVICE|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
219000006|NCT01744197|DRUG|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
219000007|NCT02872194|DRUG|BAY987516, Y55-170|10 uL in one eye
219000008|NCT02872194|DRUG|BAY987516, X72-151|10 uL in one eye
219000009|NCT02872194|DRUG|BAY987516, Y49-034|10 uL in one eye
219000010|NCT02872194|DRUG|Standard shampoo mixture (control)|10 uL in one eye
219000011|NCT03863054|DEVICE|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
219000012|NCT05686811|OTHER|Myofascial release therapy therapy|Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side
219000013|NCT05686811|OTHER|Post isometric relaxation technique|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
219000014|NCT05482724|BEHAVIORAL|Super Skills for Life|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children"
219000015|NCT01031927|DRUG|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
219000016|NCT06988566|OTHER|Intervention Group|The intervention were connected to the ECM response and coordination centre (RCC) which provided the participants with 24/7/365 access to assistance from certified RCC staff who were supported by eDoctors. Patients self-tracking activities (saturation, pulse, lung function, temperature and report on increased sputum, coughing, and shortness of breath) were monitored dayly by the RCC whoom would contact them in the event of signs of deterioration. The RCC staff together with the participant would make informed decisions, via phone or video call, on how to best manage the change in condition guided by the previous measures evaluated with graphs, including plotted trends. If there was a need for medical treatment, a treatment plan was drawn up with fixed follow-ups and a course plan.
219000017|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 9 mg/kg/day
219000018|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 18 mg/kg/day
219000019|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 27 mg/kg/day
219000020|NCT07001072|DEVICE|Smartshoes with haptic vibration feedback|wearable smartshoe with capability‬ to deliver haptic/vibration feedback to assess effect on freezing of gait
219000021|NCT07001774|BEHAVIORAL|Vitalis Cardio|Participants receive five free health coaching sessions with a trained student health coach, access to two health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
219000022|NCT07132827|DRUG|SHR-1905 Injection|SHR-1905 Injection
219000023|NCT07132827|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
219185324|NCT05565417|COMBINATION_PRODUCT|Fruquintinib|Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
219185325|NCT04275713|DRUG|Metformin|Metformin is an oral antidiabetic drug
219000024|NCT07133113|OTHER|We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).|"The patients will be identified via the French Nationwide Multidisciplinary Team Meetings for Autoimmune encephalitis, which are conducted on a bi-monthly basis. All patients with newly diagnosed NMDAR, LGI1, CASPR2, IgLON5, GFAP or GAD65 encephalitis and treated for less than 8 weeks will be included. Treatment protocols at the initiation of therapy will be stratified into: 1) first-line only; 2) rituximab without cyclophosphamide; 3) rituximab combined with cyclophosphamide; 4) others.~The referral clinicians will be contacted by email and the data will be collected using standardized questionnaires, which will be sent at baseline (visit 1, V1) and 4 months after the initiation of therapy (visit 2, V2). The questionnaires will be structured into 7 sections:~* 1 Demographics~* 2 Symptoms~* 3 Cognitive screening tests (MMSE, MoCA, and/or others)~* 4 Level of dependence (ADL, I-ADL, mRS, CASE) and impact on social life~* 5 Diagnostic tests (brain MRI, brain PET, CSF, and EEG findings)"
219000025|NCT06618313|DRUG|JCXH-213,an mRNA-LNP based in vivo CAR therapy|JCXH-213 infusion
219000026|NCT07131254|BIOLOGICAL|GT719 Injection|GT719 Injection
219000027|NCT07133061|DIAGNOSTIC_TEST|Wingate test|During the test, 1s power, 5s power, 30s power, speed, heart rate, the value of lactate and other parameters are determined.
219000028|NCT07133061|DIAGNOSTIC_TEST|Dynamometry|The test determines the strength of the handshake by right and left hand separately.
219000029|NCT07133061|DIAGNOSTIC_TEST|Rebound plate|The test determines the height of the jump from the right lower limb and from the left lower limb separately.
219000030|NCT07133061|DIAGNOSTIC_TEST|Blood lactate test|Measurement of volume of lactate in the blood.
219000031|NCT07131124|BEHAVIORAL|Mindful Self-Compassion program|"The MSC self-compassion program will be delivered by instructors trained by the LBCM Organization, certified Qualiopi and affiliated to the ADM (accredited training organization).~The MSC program consists of 8 weekly sessions, each 2.5 hours long, plus an additional half-day of supplementary practice ."
219000032|NCT07131124|BEHAVIORAL|Treatment As Usual (TAU) program|"Current treatment strategies for Alcohol Use Disorders (AUD) rely on a combination of pharmacological and psychotherapeutic treatments (Schuckit, 2009). The three specialized outpatient centers participating in our study provide comprehensive and up-to-date addiction care that meets international and national recommendations (HAS, 2023; SFA, 2023).~The services offered, in addition to standard care, include:~Brief interventions, Psychoeducation sessions, Motivational interview, Individual and group therapies for patients (cognitive-behavioral therapies, cognitive remediation, relaxation techniques), Individual and group therapies for families, Psychosocial interventions, including social support and strengthening of psychosocial skills, Peer support groups (peer helpers, expert patients, former user groups)"
219000033|NCT07001631|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The Dutch version of the standard EMDR protocol with age-specific adaptations for children and adolescents will be used. The eight phases consist of history taking, preparation, assessment, desensitization, installation, body scan, closure, and re-evaluation. During an EMDR session, the child focuses on emotionally disturbing memories (images, thoughts, emotions, and sensations) while simultaneously focusing on an external distracting stimulus (e.g., eye movements). This process facilitates accessing and desensitizing the traumatic memory network, so information processing is enhanced, and new associations can be made between the traumatic memory and more adaptive memories and information. As a result, the traumatic memory representation will be less intense and emotionally disturbing. After the intake session (week 1), including case conceptualization and treatment plan, a maximum of 6 weekly EMDR sessions with a duration of 1 hour per session will be offered.
219000034|NCT06870812|PROCEDURE|Surgical management|"Following randomization into the surgical arm, a competency-trained neurosurgeon will perform the MIPS for clot evacuation with strict adherence to the Surgical Manual of the CSG. Image interpretation, patient position, anesthetic plan, stereotactic navigation registration, exoscopic positioning, access, optics, resection, and hemostasis are detailed in the Surgical Manual of the CSG.~The OR arrival time should occur \<24 hours from the last known normal (LKN) with a goal of arrival in less than 8 hours from the last known normal."
219185326|NCT04275713|DRUG|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
219185327|NCT06201234|DRUG|Olaparib + Elacestrant|Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
219185328|NCT06201234|DRUG|Olaparib|Olaparib 600 mg orally daily
219185329|NCT06503471|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
219185330|NCT06503471|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
219185331|NCT03878589|DRUG|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
219185332|NCT03878589|DRUG|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
219185333|NCT03214796|DRUG|Human albumin|Infusion of human albumin
219185334|NCT05909150|DRUG|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
219185335|NCT05909150|DRUG|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
219185336|NCT04521712|DIAGNOSTIC_TEST|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
219185337|NCT01476839|BIOLOGICAL|basiliximab|Given IV
219185338|NCT01476839|DRUG|carmustine|Given IV
219185339|NCT01476839|DRUG|etoposide|Given IV
219185340|NCT01476839|DRUG|cytarabine|Given IV
219185341|NCT01476839|DRUG|melphalan|Given IV
219185342|NCT01476839|OTHER|pharmacological study|Correlative studies
219185343|NCT01476839|OTHER|laboratory biomarker analysis|Correlative studies
219185344|NCT01476839|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
219185345|NCT01476839|BIOLOGICAL|yttrium Y 90-labeled basiliximab|Given IV
219185346|NCT06352424|DRUG|BI 456906|BI 456906
219185347|NCT06352424|DRUG|BI 1820237|BI 1820237
219185348|NCT06352424|DRUG|Placebo for BI 1820237|Placebo for BI 1820237
219185349|NCT06352424|DRUG|Placebo for BI 456906|Placebo for BI 456906
219185350|NCT03623464|OTHER|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
219185351|NCT03623464|OTHER|Standard of care|Post-operative standard of care information
219185352|NCT05010421|DRUG|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
219185353|NCT05010421|DEVICE|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
219185354|NCT06349057|DRUG|reducing anticholinergic burden|In the intraoperative and postoperative periods instead of drugs with high anticholinergic burden; drugs with low burden will be preferred.
219185355|NCT05260411|BIOLOGICAL|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219185356|NCT05260411|BIOLOGICAL|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219185357|NCT05260411|DRUG|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219185358|NCT03572374|OTHER|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
219185359|NCT03572374|OTHER|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
219185360|NCT05297565|BIOLOGICAL|Nivolumab/rHuPH20|Specified dose on specified days
219185361|NCT05297565|BIOLOGICAL|Nivolumab|Specified dose on specified days
219185362|NCT05972187|OTHER|Temperature and Humidity|Temperature and Humidity of room changed
219185363|NCT05907564|DEVICE|Thrombectomy|Use of Aventus Thrombectomy System to treat pulmonary embolism
219185364|NCT00223171|DRUG|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
219185365|NCT05516485|OTHER|Assessment|Undergo grading and recording of tumor consistency/stiffness
219185366|NCT05516485|DEVICE|Magnetic Resonance Elastography|Undergo MRE
219185367|NCT04835103|BEHAVIORAL|CM|Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation
219185368|NCT04835103|BEHAVIORAL|P/T|Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
219185369|NCT02675777|OTHER|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
219185370|NCT05994625|DEVICE|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
219185371|NCT05994625|DEVICE|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
219185372|NCT05664633|DRUG|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
219185373|NCT02307058|RADIATION|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
219185374|NCT02307058|RADIATION|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
219185375|NCT03171129|DEVICE|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
219185376|NCT03171129|DEVICE|High flow Nasal Canula|Oxygen will be administered via nasal canula
219185377|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
219185378|NCT03531073|DRUG|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
219185379|NCT04646096|DEVICE|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
219185380|NCT01420783|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219185381|NCT06101056|BEHAVIORAL|Junior Enlisted Component|"Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7."
219191592|NCT05506878|DEVICE|NSS-2 BRIDGE|"NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose."
219185382|NCT06101056|BEHAVIORAL|Leadership Component|"Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7."
219185383|NCT06101056|BEHAVIORAL|Social Marketing Campaign|"All participating Airmen (including Junior Enlisted Airmen and Leaders) will be exposed to X-CoRe's social marketing campaign, which includes posters, flyers, postcards, and digital content for social media. Messages are designed to increase awareness of consent and foster Wing-wide norms that are supportive of healthy relationships. Resources for Service members to receive support if they have experienced SH or SA will also be provided through the social marketing materials. Social marketing materials, such as posters, will be distributed at hot spots for SA (e.g., dorms)."
219185384|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
219185385|NCT00691002|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
219185386|NCT00691002|DRUG|LEO 80190 Vehicle|
219185387|NCT00691002|DRUG|Hydrocortisone|
219185388|NCT00691002|DRUG|Calcipotriol|
219185389|NCT06345664|OTHER|Diagnostics and intervention recommendations|All families get the same diagnostics and receive individual treatment recommendations.
219185390|NCT05431010|DEVICE|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
219185391|NCT05431010|BEHAVIORAL|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
219185392|NCT04036695|DEVICE|Reveal LINQ insertable cardiac monitoring system|A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
219185393|NCT06256458|DEVICE|NanoBone® Bone Graft|The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.
219185394|NCT05974150|OTHER|Web based survey|online weekly survey
219185395|NCT04282122|RADIATION|Radiotherapy|curative-intent radiotherapy
219185396|NCT04186689|OTHER|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
219185397|NCT05930418|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance provides more sensitive measure of ventricular volume and ejection fraction as well as novel markers of tissue characterization and edema assessment.
219185398|NCT06033508|OTHER|exercise with whole body vibration device|exercise with whole body vibration device
219185399|NCT06033508|OTHER|placebo exercise|exercise without vibration on land
219185400|NCT01205828|DRUG|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
219185401|NCT01205828|DRUG|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
219185402|NCT05851963|DEVICE|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
219185403|NCT05851963|DEVICE|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
219185404|NCT05851963|DEVICE|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
219185405|NCT05851963|DEVICE|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
219185406|NCT03186729|DRUG|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
219185407|NCT05524181|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
219185408|NCT06823817|DIAGNOSTIC_TEST|colpscope|Colposcopic cervical biopsy
219185409|NCT06823245|DRUG|HS-10241|HS-10241 administered orally once at D1
219185410|NCT06714656|OTHER|Food Swap|Personalised food swaps and dietary advice on how to incorporate these swaps into their usual diet
219185411|NCT06582043|OTHER|SCARCr tester 1|Twice daily
219006891|NCT03709771|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
219185412|NCT06582043|OTHER|Placebo|Twice daily
219185413|NCT05603910|DRUG|Lenvatinib|Lenvatinib capsules taken daily by mouth
219185414|NCT05603910|DRUG|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
219185415|NCT05603910|RADIATION|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
219185416|NCT06115135|DRUG|Venetoclax|All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.
219185417|NCT06777706|DIETARY_SUPPLEMENT|QD (Qing Dai)|Children age 4 years to 17.9 years with mild to moderate UC will receive QD and dosing will be stratified based on body weight at time of enrollment.
219185418|NCT04186117|OTHER|Blood sample|Blood sample before any treatment
219185419|NCT05836155|DIETARY_SUPPLEMENT|Intervention|multispecies probiotic
219185420|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
219185421|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
219185422|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
219185423|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
219185424|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
219185425|NCT04649905|PROCEDURE|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
219185426|NCT04649905|PROCEDURE|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
219185427|NCT06823726|OTHER|12-week Taekwondo training|"12-week structured Taekwondo training program under the supervision of qualified instructors following a standardized protocol.~Frequency: 3 sessions per week Session Length: 60 minutes per session"
219185428|NCT05531474|PROCEDURE|Bariatric Surgery|Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
219185429|NCT05531474|BEHAVIORAL|Medical Weight Management|The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
219185430|NCT05940194|BIOLOGICAL|COVIVAC vaccine|For prevention Covid-19
219185431|NCT06636357|DRUG|50% N2O plus 50% O2|Inhalation of 50% N2O plus 50% O2 for 45 min
219185432|NCT06636357|DRUG|Oxygen (O2)|50% O2 plus 50% air for 45 min
219185433|NCT06401577|DEVICE|Dexcom Continuous Glucose Monitor (CGM)|Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level
219185434|NCT02950766|DRUG|NeoVax|combination of Neoantigen peptides and poly-ICLC
219185435|NCT02950766|DRUG|Ipilimumab|local administration of ipilimumab
219185436|NCT04799015|DRUG|Dexamethasone|Dexamethasone 10mg IV
219185437|NCT04799015|DRUG|Metoclopramide 10mg|Metoclopramide 10mg IV
219185438|NCT02667418|DRUG|Fidaxomicin|200 mg PO twice daily for 10 days
219185439|NCT02667418|DRUG|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
219185440|NCT02667418|DRUG|Vancomycin|125 mg PO for times daily for 10 days
219185441|NCT06347549|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|"Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest."
219185442|NCT06175832|DRUG|Elonva®|Single injection
219185443|NCT06175832|DRUG|Puregon®|Multiple injections
219185444|NCT06175832|DRUG|Orgalutran®|Multiple injections
219185445|NCT06175832|DRUG|Gonapeptyl®|Double injection
219185446|NCT06175832|DRUG|Cerazette®|Oral tablet
219185447|NCT01959607|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
219185448|NCT01959607|OTHER|CC|Single use of subject's own cigarette (CC)
219185449|NCT01959607|OTHER|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
219185450|NCT01543763|DRUG|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
219185451|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
219185452|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
219006892|NCT03873233|DEVICE|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
219006893|NCT03873233|DEVICE|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
219006894|NCT00217386|BIOLOGICAL|anti-thymocyte globulin|
219006895|NCT00217386|BIOLOGICAL|etanercept|
219006896|NCT05763550|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
219006897|NCT05763550|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
219006898|NCT05763550|DRUG|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
219006899|NCT02664441|DRUG|Exenatide|Weekly injections of active drug.
219006900|NCT02664441|DRUG|placebo|Weekly placebo injections
219006901|NCT00951990|BEHAVIORAL|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
219006902|NCT00951990|BEHAVIORAL|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
219006903|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
219006904|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
219006905|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
219006906|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
219006907|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
219006908|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
219006909|NCT01529346|DRUG|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
219006910|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
219006911|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
219006912|NCT01529346|OTHER|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
219006913|NCT06160960|OTHER|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
219006914|NCT00106392|DRUG|Tacrolimus|oral
219006915|NCT00106392|DRUG|Placebo|oral
219006916|NCT01725620|DRUG|LBEC0101 (Etanercept 25mg)|
219006917|NCT01725620|DRUG|Enbrel (Etanercept 25mg)|
219006918|NCT03652844|PROCEDURE|AAM|Subcutaneous injection procedure
219006919|NCT01365234|DEVICE|Pacing Lead|Implant and follow up of Model 20066 lead
219006920|NCT05122520|OTHER|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
219006921|NCT03409406|BEHAVIORAL|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
219006922|NCT03409406|BEHAVIORAL|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
219006923|NCT03773679|PROCEDURE|Daily Exercise|Daily Exercise Programme
219006924|NCT03171792|OTHER|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
219006925|NCT05053789|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
219006926|NCT05053789|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
219006927|NCT02350725|DRUG|Furosemide injection solution for subcutaneous administration (80 mg)|
219006928|NCT02350725|DRUG|Oral Furosemide tablets (80 mg)|
219006929|NCT05642754|OTHER|Overall uncertainty language|Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
219006930|NCT05898815|DIAGNOSTIC_TEST|Medical record collection|Medical record collection
219006931|NCT03725696|DIAGNOSTIC_TEST|Semen Analysis|Sperm counts will be determined by semen analysis.
219006932|NCT03725696|DIAGNOSTIC_TEST|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
219006933|NCT03725696|PROCEDURE|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
219185453|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
219185454|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
219185455|NCT04731961|PROCEDURE|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
219185456|NCT04731961|PROCEDURE|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
219185457|NCT05124769|BEHAVIORAL|Pain Allowing Program (PAllow)|Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).
219185458|NCT05124769|BEHAVIORAL|Pain Avoiding Program (PAvoid)|"Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued."
219185459|NCT03974828|DEVICE|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
219000035|NCT06870812|OTHER|Medical Management|"Following randomization into the medical arm patients will be treated following the Medical Manual of the CSG. The Medical Manual has been adapted by the REACH Executive Committee (REC) from the current American Heart Association (AHA) and American Stroke Association (ASA) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Whenever clinically feasible, the CSG should be followed as it represents a template for the care of these subjects.~The Medical Manual details specialty level of care, including intensive care placement, blood pressure control, hemostasis and coagulopathy, anemia, deep venous thrombosis and pulmonary embolism prophylaxis/treatment, glucose management, temperature management, seizure prophylaxis, intracranial pressure monitoring and management, intraventricular hemorrhage (IVH)/obstructive hydrocephalus management, cerebral edema, decompressive hemicraniectomy, nutritional support, respiratory support, and comfort care."
219185460|NCT06203795|OTHER|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
219185461|NCT06203795|OTHER|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
219185462|NCT06203795|OTHER|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
219185463|NCT06203795|DEVICE|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
219185464|NCT03128021|DRUG|Escitalopram Pill|Double-blinded, randomly assigned
219185465|NCT03128021|OTHER|Placebo|Double-blinded, randomly assigned
219000036|NCT03905668|OTHER|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
219000037|NCT03905668|OTHER|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
219000038|NCT03905668|OTHER|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
219000039|NCT03905668|OTHER|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
219000040|NCT03905668|OTHER|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
219000041|NCT07012616|OTHER|Supraclavicular brachial plexus block|Patients will receive an ultrasound-guided supraclavicular brachial plexus block.
219000042|NCT07015593|OTHER|interview|30 for Qualitative interview and 750 for quantitative survey
219000043|NCT07015970|OTHER|No Intervention: Observational Cohort|No intervention
219000044|NCT06880354|DRUG|CLL1 and CD38 Dual-Target CAR-T Cell Injection|This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that targets both CLL1 and CD38.
219000045|NCT06719531|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
219000046|NCT01594983|DRUG|LCQ908|
219000047|NCT01594983|DRUG|Fenofibrate|Fenofibrate once daily 12 weeks
219000048|NCT01594983|DRUG|Fish Oil|Fish Oil once daily for 12 weeks
219000049|NCT01594983|DRUG|Placebo of LCQ908|Matching placebo of LCQ908
219000050|NCT01594983|DRUG|Placebo of fenofibrate|Matching placebo of fenofibrate
219000051|NCT01594983|DRUG|Placebo of fish oil|Matching placebo of fish oil capsule
219185466|NCT03128021|DRUG|Levomilnacipran Pill|Double-blinded, randomly assigned
219185467|NCT04668560|BEHAVIORAL|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
219185468|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
219185469|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
219185470|NCT05470036|BEHAVIORAL|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
219185471|NCT05166577|DRUG|Nanatinostat|Phase 1b: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, then Phase 2: Nanatinostat at the confirmed recommended Phase 2 dose
219000052|NCT07122427|PROCEDURE|Graft collection|Sampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery.
219000053|NCT07124429|OTHER|Reformer Pilates|Reformer pilates is a form of exercise that uses a specialized machine with a sliding carriage and springs to provide resistance. It is highly effective for improving core strength, flexibility, and muscle tone while also promoting better posture and balance.
219185472|NCT05166577|DRUG|Valganciclovir|Phase 1b: Valganciclovir starting at 900 mg orally daily, then Phase 2: Valganciclovir at the confirmed recommended Phase 2 dose
219185473|NCT05166577|DRUG|Pembrolizumab|Phase 2: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
219185474|NCT05347446|PROCEDURE|Hybrid ESD|Method of removing colon lesion
219185475|NCT05347446|PROCEDURE|Non-hybrid ESD|Method of removing colon lesion
219185476|NCT06437080|DRUG|Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg|01 tablet daily for 03 months, This is assigned to Group A.
219185477|NCT06437080|DRUG|Ferric Carboxymaltose|03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
219185478|NCT05995886|BEHAVIORAL|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
219185479|NCT04054193|DRUG|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
219185480|NCT04054193|DRUG|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
219185481|NCT04054193|DRUG|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
219185482|NCT02503423|DRUG|ASTX660|described above
219185483|NCT06497075|DRUG|Albendazole 400mg|Single oral dose of Albendazole 400mg tablet
219000054|NCT07124429|OTHER|conservative treatment|Conservative physiotherapy is a treatment approach that aims to manage pain and improve function using non-surgical methods. This treatment often includes methods like applying hot packs to relax muscles and increase circulation, and using a TENS (Transcutaneous Electrical Nerve Stimulation) device to help relieve pain.
219000055|NCT07132372|OTHER|Birth Memories and Recall scale|The data collection tools were applied to the participants by the researcher through face-to-face interviews. At the outset, the purpose of the study was explained to the participants. It was stated that participation in the study was completely voluntary and that they could withdraw from the study at any time. Then, their written and verbal consent was obtained.Participants who agreed to participate in the study, had no condition that would prevent communication, and had babies between the ages of 0 and 1 were included in the study.Data were collected using a personal information form, BIMF, PMBAS, and BirthMARQ.
219000056|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
219000057|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
219000058|NCT06205238|OTHER|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
219000059|NCT02751996|DRUG|SB 9200|SB 9200
219000060|NCT02751996|DRUG|Placebo|
219000061|NCT02751996|DRUG|Tenofovir|
219000062|NCT06508125|DRUG|cross-linked hyaluronic acid|cross-linked hyaluronic acid injection with physical therapy
219000063|NCT06508125|DRUG|non-cross-linked hyaluronic acid|non-cross-linked hyaluronic acid injection with physical therapy
219000064|NCT03713970|PROCEDURE|celtra duo press|celtra duo press ingot
219000065|NCT03713970|PROCEDURE|IPS e.max press|IPS e.max press ingot
219000066|NCT04122898|OTHER|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
219000067|NCT02113605|OTHER|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
219000068|NCT04541940|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
219185484|NCT06497075|DRUG|Ivermectin 3 MG|Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
219185485|NCT05816616|DIAGNOSTIC_TEST|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
219185486|NCT02966873|DRUG|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
219185487|NCT02966873|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
219185488|NCT02966873|DRUG|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
219185489|NCT02966873|OTHER|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
219185490|NCT02966873|OTHER|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
219185491|NCT03080974|DRUG|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
219185492|NCT03080974|PROCEDURE|Irreversible Electroporation|Non-thermal ablation of tumor
219185493|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
219185494|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
219185495|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
219185496|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
219185497|NCT06611319|DRUG|Prevention of Venous Thromboembolism|Direct oral anticoagulant
219185498|NCT06611319|DRUG|Placebo Oral Tablet|Placebo
219185499|NCT06417554|DRUG|SHR-A2102|SHR-A2102
219185500|NCT06417554|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 + Adebrelimab injection
219185501|NCT01792687|DRUG|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
219185502|NCT01792687|DRUG|Abiraterone acetate|1,000 mg, oral, daily
219185503|NCT01792687|DRUG|Prednisone|5 mg, oral, daily
219185504|NCT03084536|DRUG|Bupivacaine|-Given after general anesthesia
219185505|NCT03084536|DRUG|Gabapentin|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
219185506|NCT03084536|DRUG|Celecoxib|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies."
219185507|NCT03084536|DRUG|Acetaminophen|-As per routine care
219185508|NCT03084536|DRUG|Midazolam|-As per routine care
219185509|NCT03084536|DRUG|Fentanyl|-As per routine care
219185510|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
219185511|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
219185512|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
219185513|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
219185514|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
219185515|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
219185516|NCT06828783|DIETARY_SUPPLEMENT|ginger extract|Participants will receive a ginger-based capsule
219185517|NCT06828783|OTHER|Placebo|Participants will receive a placebo capsule
219185518|NCT06755983|OTHER|Endorphin massage|For Group 1 (experimental group), patients admitted to the clinic one day before surgery will complete the first two sections of the Patient Diagnosis Form (I. Individual characteristics and II. Health and illness-related data), the Surgical Fear and Anxiety Scale, and the VAS scales after the endorphin massage. The patients will be informed that the endorphin massage will last approximately 20 minutes. According to evidence-based current guidelines, it is stated that the intensity of the patient's pain should be assessed during the preoperative period for pain management planning and goals in the postoperative period. Therefore, patients' pain scores will also be recorded preoperatively using the VAS scale. On the morning of the surgery, before going to the operating room, the endorphin massage will be repeated, and the scales will be applied again. After surgery, patients will have their pain levels measured using the VAS at hours 0, 4, 8, 16, and 24, and the amount of analgesics tak
219185519|NCT05702723|BEHAVIORAL|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
219185520|NCT05702723|BEHAVIORAL|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
219185521|NCT05511246|DRUG|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
219185522|NCT05511246|PROCEDURE|Catheter ablation|Endocardial catheter ablation of VT substrate
219185523|NCT01043224|DRUG|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
219185524|NCT05145192|DEVICE|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
219185525|NCT05145192|DEVICE|ParvoMedics CPET|ParvoMedics CPET
219185526|NCT03946618|DEVICE|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
219185527|NCT04082143|DEVICE|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
219185528|NCT04082143|DEVICE|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
219185529|NCT04006782|DEVICE|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
219185530|NCT03576885|DRUG|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
219185531|NCT03576885|DRUG|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
219185532|NCT05971485|DRUG|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
219185533|NCT05971485|OTHER|Placebo|The placebo group will receive 2 ml of distilled water as a placebo 30 minutes before venous cannula insertion.
219185534|NCT04680221|DRUG|Liposomal bupivacaine|Deposition of liposomal bupivacaine
219185535|NCT04680221|PROCEDURE|TAP block|Transversus abdominis plane block performed to deposit anesthetic
219185536|NCT04680221|DRUG|Deposition of saline|Deposition of saline
219185537|NCT03337607|DEVICE|rESWT|"rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics"
219185538|NCT03337607|DRUG|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
219185539|NCT03337607|DRUG|Eperisone|3 x 50 mg per day for four weeks
219185540|NCT02938377|BEHAVIORAL|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
219185541|NCT02938377|BEHAVIORAL|CBT4CBT|9 computerized modules delivered at the participant's pace
219185542|NCT02938377|DRUG|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
219185543|NCT02780219|OTHER|stable amino acid infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
219185544|NCT02780219|OTHER|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
219185545|NCT02780219|OTHER|24-hour post exercise amino acid infusion|stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
219185546|NCT05683691|DEVICE|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
219185547|NCT03824132|BEHAVIORAL|Improvisational comedy classes|6 consecutive improvisational comedy classes
219185548|NCT03824132|BEHAVIORAL|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
219185549|NCT01897168|DEVICE|No intervention|
219185550|NCT05785741|DRUG|DB-1310|Administered I.V.
219185551|NCT05785741|DRUG|Trastuzumab|Administered I.V.
219185552|NCT05785741|DRUG|Osimertinib|Oral
219185553|NCT06340763|DEVICE|JETi Hydrodynamic Thrombectomy System|The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
219185554|NCT04704843|DRUG|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
219185555|NCT04704843|DRUG|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
219185556|NCT04053075|OTHER|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
219185557|NCT04053075|OTHER|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
219185558|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
219185559|NCT05686850|PROCEDURE|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
219185560|NCT05686850|PROCEDURE|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
219185561|NCT06538870|PROCEDURE|Placement of dental implants|Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.
219185562|NCT05873673|DRUG|Coenzyme Q10|cystic jaw defect filled with coenzyme Q10 gel
219185563|NCT05873673|DRUG|control group|cystic jaw defect filled with placebo gel
219185564|NCT03235544|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
219185565|NCT06025435|OTHER|SAIA-HIV-SSP|The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
219185566|NCT02466737|PROCEDURE|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
219185567|NCT02466737|PROCEDURE|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
219185568|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
219185569|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects. A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
219185570|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 healthy individuals (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
219185571|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 individuals with Parkinson's disease (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
219185572|NCT02671890|DRUG|Chemotherapy|
219185573|NCT02671890|DRUG|Disulfiram|Given PO
219185574|NCT02671890|DRUG|Gemcitabine Hydrochloride|Given IV
219185575|NCT02671890|OTHER|Laboratory Biomarker Analysis|Correlative studies
219185576|NCT06323707|BEHAVIORAL|Exercise|Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.
219185577|NCT06323707|BEHAVIORAL|Self-management e-module|Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
219185578|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
219185579|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
219185580|NCT05643638|BIOLOGICAL|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
219185581|NCT05643638|BIOLOGICAL|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
219185582|NCT05643638|DRUG|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
219185583|NCT06339398|BEHAVIORAL|Aerobic exercise|Standardized volume of aerobic exercise, measured as METs-minutes/week
219185584|NCT03696680|RADIATION|FSRT Stereotactic radiation therapy|For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
219185585|NCT06147791|DEVICE|External scrotal drainage|Application of external scrotal drainage during three-component penile prosthesis placement
219185586|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
219369842|NCT05853471|DRUG|[18F]MC225|All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
219369843|NCT05653375|OTHER|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
219000069|NCT04541940|OTHER|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
219000070|NCT00968994|DEVICE|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
219000071|NCT00968994|DEVICE|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
219000072|NCT05342545|OTHER|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
219000073|NCT04106856|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219000074|NCT04106856|DRUG|Losartan|Given PO
219000075|NCT04106856|DRUG|Losartan Potassium|Given PO
219000076|NCT04106856|OTHER|Quality-of-Life Assessment|Ancillary studies
219000077|NCT04106856|OTHER|Questionnaire Administration|Ancillary studies
219000078|NCT06539728|DIAGNOSTIC_TEST|Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces|Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
219000079|NCT06539728|DIAGNOSTIC_TEST|Biomechanical Measurements|Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
219000080|NCT06539728|BEHAVIORAL|Psychophysical Tasks|Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
219000081|NCT03894462|BEHAVIORAL|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
219000082|NCT03894462|BEHAVIORAL|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
219000083|NCT04998786|DRUG|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
219000084|NCT04998786|DRUG|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
219000085|NCT04998786|DRUG|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
219000086|NCT01545986|BEHAVIORAL|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
219000087|NCT04247360|DEVICE|cuff pressure|maintaining cuff pressure according the groups
219000088|NCT04761289|OTHER|Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment."
219000089|NCT00040937|BIOLOGICAL|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
219000090|NCT00040937|BIOLOGICAL|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
219000091|NCT00040937|DRUG|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
219000092|NCT00040937|DRUG|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
219185587|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
219185588|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
219185589|NCT04845503|RADIATION|MR-guided Radiotherapy|Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
219185590|NCT06260228|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
219185591|NCT06134154|OTHER|Endoscopic insufflation gas|Carbon dioxide gas versus air for endoscopic insufflation
219185592|NCT04097730|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
219185593|NCT04097730|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
219185594|NCT04097730|DRUG|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
219185595|NCT04097730|OTHER|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
219185596|NCT04983030|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
219185597|NCT04983030|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
219185598|NCT04983030|BIOLOGICAL|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
219185599|NCT04983030|BIOLOGICAL|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
219185600|NCT04983030|BIOLOGICAL|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
219185601|NCT04830800|BIOLOGICAL|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
219185602|NCT04830800|BIOLOGICAL|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
219185603|NCT04853576|GENETIC|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
219185604|NCT06559852|BEHAVIORAL|Yoga|Participants will engage in a 12-week virtual yoga course to assess impact on endometriosis-related pain
219185605|NCT04285515|DRUG|Lumateperone|Lumateperone 42mg oral capsule
219185606|NCT04285515|DRUG|Placebos|Placebo oral capsule
219185607|NCT06159075|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
219000093|NCT00040937|DRUG|melphalan|"1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1"
219000094|NCT00040937|DRUG|prednisone|maint: 50 mg/d PO every other day until progression
219000095|NCT00040937|DRUG|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
219000096|NCT00040937|PROCEDURE|peripheral blood stem cell transplantation|2-4 x 10\^6/kg IV day 0
219000097|NCT04256070|BEHAVIORAL|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
219185608|NCT06411028|DIAGNOSTIC_TEST|Polymyography|We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.
219000098|NCT04488900|DRUG|CKD-508 Capsule|Investigational drug
219000099|NCT04488900|DRUG|Placebo Capsule|Placebo
219185609|NCT06411028|DIAGNOSTIC_TEST|Muscle ultrasound|We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.
219185610|NCT06411028|DIAGNOSTIC_TEST|(Functional) magnetic resonance imaging|Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.
219185611|NCT06411028|DIAGNOSTIC_TEST|Clinical assessment|We will assess tremor and dystonia severity using clinical scales.
219185612|NCT06411028|DIAGNOSTIC_TEST|Questionnaires|We will collect patient-reported outcomes.
219000100|NCT04488900|DRUG|CKD-508 Tablet|Investigational drug
219000101|NCT04488900|DRUG|Placebo Tablet|Placebo
219000102|NCT00806390|DRUG|Metoprolol|Metroprolol tartrate titrated up
219000103|NCT02267811|OTHER|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
219000104|NCT02267811|DEVICE|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
219000105|NCT02289040|PROCEDURE|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
219000106|NCT00352560|DRUG|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
219000107|NCT00352560|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
219000108|NCT05463575|DRUG|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
219000109|NCT05463575|OTHER|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
219000110|NCT02581449|DIETARY_SUPPLEMENT|omega-3|dietary supplement
219000111|NCT02581449|OTHER|empty soft gelatin capsules|empty softgels of matched size, shape and color
219000112|NCT06083116|DRUG|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
219000113|NCT04567225|DRUG|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
219000114|NCT04567225|DRUG|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
219000115|NCT04567225|OTHER|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
219000116|NCT04567225|OTHER|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
219000117|NCT05184140|PROCEDURE|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
219000118|NCT04369521|OTHER|low free sugar diet|low free sugar diet with nutrition and exercise recommendation
219000119|NCT03157778|OTHER|Obese men|Biological measures before, just before, and after lunch, in obese men
219000120|NCT03157778|OTHER|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
219000121|NCT00345345|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
219000122|NCT01740986|DRUG|SA09012 Low dose|Tablet, b.i.d
219000123|NCT01740986|DRUG|SA09012 High dose|Tablet, b.i.d
219000124|NCT01740986|DRUG|Placebo|Tablet, b.i.d
219000125|NCT00819221|DRUG|AZD2281|capsules, oral, bd, 2 months
219000126|NCT00819221|DRUG|liposomal doxorubicin|once every 4 weeks at 40mg/m2
219000127|NCT02324569|DRUG|SYR-472|SYR-472 tablets
219000128|NCT02324569|DRUG|Placebo|Placebo tablets
219000129|NCT02016560|DRUG|florbetapir F 18|
219000130|NCT02016560|DRUG|Flortaucipir F18|
219000131|NCT02016560|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
219000132|NCT03630172|PROCEDURE|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
219000133|NCT05778747|OTHER|Heart to Heart Yoga|The Heart to Heart Yoga intervention is a therapeutic and standardized form of yoga intervention that is adapted from MediYoga designed to fit the needs of patients with HF and family caregivers who have physical limitations and depressive symptoms and to fit cultural and social norms in Kentucky. The intervention will use a gradual, physical/ psychological yoga adaptation approach, and it will be delivered two times per week (40 -60 minutes per session) via videoconference technology for 12 weeks (total 24 sessions). Real-time, face-to-face, video conferencing technology is used.
219000134|NCT01943292|DRUG|Defactinib|
219000135|NCT02559193|OTHER|Observational study, data collection only trial.|Data collection only trial design.
219000136|NCT00911820|DRUG|Bevacizumab|
219000137|NCT00911820|DRUG|Cisplatin|
219000138|NCT00911820|DRUG|Irinotecan|
219000139|NCT00911820|DEVICE|Docetaxel|
219000140|NCT06226753|PROCEDURE|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
219000141|NCT01852110|DRUG|MK-7622|MK-7622 capsule
219000142|NCT01852110|DRUG|Placebo|Matching placebo to MK-7622 capsule
219000143|NCT01852110|DRUG|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
219000144|NCT04755803|PROCEDURE|Penoplasty|"Modified penoplasty technique:~1. Degloved the penile skin and excise the inner prepuce.~2. Advanced penoscrotal skin to cover penile shaft~3. Fixed the penis base and reconstructed the penoscrotal angle"
219000145|NCT00218465|DRUG|GW468816|Pharmacotherapies for Relapse Prevention
219000146|NCT00218465|DRUG|Placebo Comparator: Placebo|
219369844|NCT05653375|OTHER|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
219000147|NCT01356472|DRUG|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
219185613|NCT06411028|DRUG|botulinum toxin injection (BTX A)|Three consequetive botulinum toxin injections of the upper extremities
219185614|NCT05204563|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
219185615|NCT05204563|DRUG|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
219185616|NCT03075748|DEVICE|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
219185617|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
219185618|NCT03816332|BIOLOGICAL|Ipilimumab|Given IV
219185619|NCT03816332|BIOLOGICAL|Nivolumab|Given IV
219185620|NCT03816332|DRUG|Prednisone|Given PO
219185621|NCT03816332|DRUG|Tacrolimus|Given PO
219185622|NCT04508907|DRUG|Mavyret|Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
219185623|NCT04865965|PROCEDURE|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
219185624|NCT01456949|DEVICE|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
219185625|NCT03710603|DRUG|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
219185626|NCT03710603|DRUG|Velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
219185627|NCT03710603|DRUG|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
219185628|NCT03710603|DRUG|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
219185629|NCT05477134|OTHER|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
219185630|NCT03802682|DRUG|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
219185631|NCT00293839|DRUG|oxybutynin chloride|
219185632|NCT05456490|DRUG|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
219185633|NCT05456490|DRUG|Bupivacaine|Injection into the Intrathecal space
219185634|NCT05456490|OTHER|Placebo|Injection into the Intrathecal space
219185635|NCT03930498|DRUG|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
219000148|NCT02181023|DRUG|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
219000149|NCT02181023|DRUG|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
219185636|NCT03930498|DRUG|Chemotherapy|Cisplatin and Gemcitabine
219185637|NCT03930498|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
219185638|NCT05557773|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
219369845|NCT03404648|DRUG|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
219000150|NCT06160154|OTHER|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
219000151|NCT03571269|PROCEDURE|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
219000152|NCT00399854|DEVICE|Dhermia® - Industra Mecânica Fina Ltda|
219000153|NCT02818686|DRUG|TD-1473|
219000154|NCT02818686|DRUG|Placebo|
219000155|NCT04734223|DIAGNOSTIC_TEST|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
219000156|NCT03991715|BEHAVIORAL|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
219000157|NCT06038084|DRUG|Bronpass Tab.|Twice a day
219000158|NCT06038084|DRUG|Placebo of Erdos capsule|Three times a day (It is for the masking.)
219000159|NCT06038084|DRUG|Erdos capsule|Three times a day
219000160|NCT06038084|DRUG|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
219000161|NCT02941978|BEHAVIORAL|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
219006934|NCT03725696|DIAGNOSTIC_TEST|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
219006935|NCT02859779|BEHAVIORAL|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
219006936|NCT05856201|PROCEDURE|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
219006937|NCT05856201|PROCEDURE|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
219006938|NCT02311010|DRUG|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
219006939|NCT05931159|OTHER|Abdominal Hypopressive Training|"Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week."
219006940|NCT05931159|OTHER|Conventional Physical therapy for DrA|"Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)"
219006941|NCT05528679|DRUG|610 100mg|100mg administered subcutaneously Q4W
219006942|NCT05528679|DRUG|610 300mg|300mg administered subcutaneously Q4W
219006943|NCT05528679|DRUG|placebo|administered subcutaneously Q4W
219006944|NCT04087694|PROCEDURE|Microdecompression|comparative surgical treatment
219006945|NCT03071627|OTHER|New items with spin|Interpretation of news items with spin
219006946|NCT03071627|OTHER|New items without spin|Interpretation of news items without spin
219006947|NCT03280914|DEVICE|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
219006948|NCT00255450|DRUG|ferumoxytol or placebo|
219006949|NCT05514691|DIAGNOSTIC_TEST|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
219006950|NCT05514691|DIAGNOSTIC_TEST|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
219006951|NCT00589914|DRUG|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
219006952|NCT00589914|DRUG|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
219369846|NCT03404648|DRUG|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
219000162|NCT02941978|BEHAVIORAL|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
219000163|NCT05285982|DRUG|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
219000164|NCT02847832|OTHER|Standardized transvaginal ultrasound examination|
219000165|NCT06499077|DIAGNOSTIC_TEST|Sampling of exhaled breath|Exhaled breath of all participants is collected following our standardized procedure
219000166|NCT02487602|DEVICE|Gelesis100|Gelesis100 capsules
219000167|NCT02487602|OTHER|Placebo|Sucrose (sugar) capsules
219000168|NCT02376361|DEVICE|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
219000169|NCT02789709|PROCEDURE|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
219000170|NCT02101060|OTHER|exercise|16-week progressive aerobic and resistance exercise training
219000171|NCT03733002|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
219000172|NCT03733002|DRUG|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
219000173|NCT03733002|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
219000174|NCT02302027|DEVICE|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
219000175|NCT00736684|DEVICE|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
219000176|NCT00736684|DEVICE|Gamma Nail 3TM (Gamma3)|intramedullary nailing
219000177|NCT00949897|DEVICE|Biofoam|Device
219000178|NCT00949897|OTHER|Iliac Crest Allograft with locked plate|
219000179|NCT03761160|OTHER|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
219000180|NCT03761160|OTHER|Usual care|Usual care per hospital guidelines
219000181|NCT03829982|BEHAVIORAL|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
219000182|NCT03829982|BEHAVIORAL|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
219000183|NCT06211478|DRUG|Vitamin E|Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
219000184|NCT03988985|OTHER|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
219000185|NCT03988985|OTHER|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
219000186|NCT02321644|DRUG|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
219000187|NCT06304194|OTHER|Analysis of biological samples|"The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS"
219000188|NCT00048555|DRUG|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
219000189|NCT03462082|OTHER|Asymmetric STN-DBS|Asymmetric deep brain stimulation
219000190|NCT04540224|DIAGNOSTIC_TEST|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
219000191|NCT00335673|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
219000192|NCT04012775|BIOLOGICAL|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
219000193|NCT04012775|BIOLOGICAL|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
219000194|NCT00799604|DRUG|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
219000195|NCT02838303|OTHER|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
219000196|NCT02838303|OTHER|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
219000197|NCT04348773|PROCEDURE|Dehydration|Dehydration of the natural tooth by tooth isolation
219000198|NCT04348773|PROCEDURE|Rehydration|Rehydration
219000199|NCT00960778|DRUG|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
219000200|NCT00960778|OTHER|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
219000201|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
219185639|NCT05557773|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
219185640|NCT02626533|PROCEDURE|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
219185641|NCT04753697|DRUG|CC-93538|Subcutaneous
219185642|NCT04753697|OTHER|Placebo|Subcutaneous
219185643|NCT03889093|OTHER|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
219185644|NCT04763330|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) consists of Collaborative Safety Planning, a VA usual care practice. It is a tool that Veterans can use when they are in an acute suicidal crisis. The condition is considered enhanced because Veterans in this condition receive 6 sessions total, Safety Planning which is delivered in 1-2 sessions and 4-5 sessions of check-ins with a brief assessment. Safety Planning involves a worksheet completed by the patient in collaboration with a health provider.
219185645|NCT04763330|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"Veterans randomized to this condition received EUC and PST. EUC is delivered in both conditions to ensure the safety of all Veterans enrolled in the study. In addition to EUC, Veterans in this condition receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by older Veterans with mental health disorders and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
219185646|NCT06280547|OTHER|Oral health education|Oral Health Education Program performed in the school.
219185647|NCT04328584|PROCEDURE|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
219185648|NCT05465031|DRUG|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
219185649|NCT05465031|DRUG|Placebo|Placebo matching the sacubitril/valsartan (Entresto®) administered in the target dose matching the dosing of 200 mg b.i.d. (97/103 mg) for the period of 24 months. In case of intolerance of target dose of placebo, the physician-in-charge will be able to reduce the dose to placebo matching the dose of 100 mg b.i.d. (49/51mg). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of placebo matching the dose of 200 mg b.i.d.
219185650|NCT06200467|DRUG|BI 456906|Solution for injection
219185651|NCT06200467|DRUG|Placebo to BI 456906|Solution for injection
219185652|NCT06200467|DRUG|Moxifloxacin|Film-coated tablet
219185653|NCT06200467|DRUG|Placebo to moxifloxacin|Film-coated tablet
219185654|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
219185655|NCT03701763|OTHER|Placebo|Placebo
219185656|NCT06640413|DRUG|[177Lu]Lu-OncoFAP-23|3.7, 7.4, or 11.1 GBq to define the RD
219185657|NCT06640413|DRUG|L19IL2|22.5 Mio IU
219185658|NCT03571321|DRUG|Ruxolitinib|"Participants will receive one of 3 doses \[taken by mouth\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~* Days 1-14 and 29-43~Interim maintenance regimen:~* Days 1-14 and 29-43~Delayed Intensification regimen:~* Days 1-14 and 29-43"
219185659|NCT03571321|DRUG|Cyclophosphamide|"Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29"
219185660|NCT03571321|DRUG|Cytarabine|"Remission consolidation regimen:~* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~* 75 mg/m2/day IV or SC on Days 29-32 and 36-39"
219185661|NCT03571321|DRUG|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84"
219185662|NCT03571321|DRUG|Vincristine|"Remission consolidation regimen:~* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
219185663|NCT03571321|DRUG|Pegaspargase|"Remission consolidation regimen:~* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~* 2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
219185664|NCT03571321|DRUG|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8"
219185665|NCT03571321|DRUG|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)"
219185666|NCT03571321|DRUG|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
219185667|NCT03571321|DRUG|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
219185668|NCT03571321|DRUG|Doxorubicin|"Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15"
219185669|NCT03571321|DRUG|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42"
219369847|NCT03404648|DEVICE|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
219000202|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
219000203|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
219000204|NCT00694993|DRUG|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
219000205|NCT00694993|DRUG|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
219000206|NCT05068102|DRUG|BI 765063|BI 765063
219000207|NCT05068102|DRUG|Ezabenlimab|Ezabenlimab
219000208|NCT05068102|DRUG|[89Zr]Zr- BI 765063|\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
219000209|NCT05068102|DRUG|BI 770371|BI 770371
219000210|NCT05068102|DRUG|[89Zr]Zr- BI 770371|\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
219000211|NCT03332797|DRUG|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219000212|NCT03332797|DRUG|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219000213|NCT03332797|DRUG|LHRH Agonist|The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
219000214|NCT05311618|DRUG|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
219000215|NCT05311618|DRUG|Pembrolizumab (KEYTRUDA ®)|Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
219000216|NCT06147739|OTHER|Temporary Anchorage Devices|intrusion
219000217|NCT06209177|DRUG|ARO-CFB|ARO-CFB for sc injection
219000218|NCT06209177|DRUG|Placebo|sterile normal saline (0.9% NaCl for sc injection)
219000219|NCT04394286|GENETIC|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
219000220|NCT06266078|DEVICE|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
219000221|NCT06266078|DEVICE|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
219000222|NCT05695352|DRUG|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
219000223|NCT05695352|DRUG|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
219000224|NCT05695352|OTHER|Placebo|Each tablet contains Calcium Carbonate 1000 mg
219000225|NCT04856371|DRUG|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
219000226|NCT04856371|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
219000227|NCT04856371|DRUG|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
219000228|NCT04856371|DRUG|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
219000229|NCT00116467|BIOLOGICAL|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
219000230|NCT00484874|DRUG|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
219000231|NCT02279537|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
219000232|NCT03374397|DRUG|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
219000233|NCT00238004|DRUG|Nicotinic acid|
219000234|NCT02530593|BEHAVIORAL|There is no intervention, only observation|
219000235|NCT01280175|PROCEDURE|charcoal block|
219000236|NCT01280175|DEVICE|Aerochamber Plus spacer|
219000237|NCT01280175|DRUG|pMDI standard actuator|
219000238|NCT04937673|DRUG|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
219000239|NCT04937673|DRUG|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
219000240|NCT01927874|PROCEDURE|Infiltration|injection of local anesthetic, associated with general anesthesia
219000241|NCT01927874|PROCEDURE|Spinal block|injection of anesthetic
219000242|NCT01927874|DRUG|Bupivacaine|10ml 0.5% bupivacaine.
219000243|NCT01927874|DRUG|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
219000244|NCT00217295|DRUG|Avonex and Topamax|
219000245|NCT05038423|BEHAVIORAL|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
219006953|NCT06186011|PROCEDURE|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
219185670|NCT03571321|DRUG|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]"
219185671|NCT06266338|DRUG|Pembrolizumab|200 mg IV q 3 weeks
219185672|NCT06266338|DRUG|Lenvatinib|20 mg PO daily
219185673|NCT03603002|DIAGNOSTIC_TEST|Post-SABR Biopsy|Post-SABR Biopsy
219185674|NCT05913037|DRUG|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
219185675|NCT05913037|DRUG|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
219185676|NCT05966532|BEHAVIORAL|Hot Cognitive Task|"1. Emotion processing:~   * Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~  * Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~  * Participant will be shown a series of emotions and asked to respond to only a specific emotion.~2. Motivation reward and processing:~   * Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~  * Participant will be shown colored circles and choose the one more likely to win money.~3. Impulsivity:~   • Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~4. Social cognition:~   * Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
219185677|NCT05966532|BEHAVIORAL|Cold cognitive tasks|"* Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~* Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~* Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~* California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~* Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
219185678|NCT05966532|OTHER|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
219185679|NCT05966532|OTHER|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
219185680|NCT05966532|BEHAVIORAL|four self-report forms per the requirement of the NIH Common Data Elements project|1\) DSM-5 Level 1 Cross Cutting Symptom Measure - Adult Report; a measure of multiple psychiatric symptoms, 2) Generalized Anxiety Disorder-7 (GAD-7; a measure of anxiety symptom severity), 3) Patient Health Questionniare-9 (PHQ-9; a measure of depression symptom severity), and 4) World Health Organization Disability Assessment Scale-2.0 (WHODAS-2.0; a measure of overall general functional status)
219185681|NCT05966532|BEHAVIORAL|Four self-report measures to assess interpersonal functioning|1\) Social Adjustment Scale - Self-report Short Form (SAS-SR: Short), 2) Inventory of Interpersonal Problems (IIP-64), 3) Social Network Index (SNI), 4) Interpersonal Support Evaluation List - 12 Items (ISEL-12).
219185682|NCT05966532|BEHAVIORAL|Clinical assessments|A Demographic and a Medical History Form will be completed. The Mini International Neuropsychiatric Interview (MINI-7.0 for DSM-5) is a structured psychiatric interview that will confirm presence of MDD and any exclusionary neuropsychiatric disorders. To measure depression symptoms/severity, primarily we will use the Clinician Rated Inventory of Depressive Symptomatology (IDS-C), Menstrual history and pregnancy tests for female participants.
219185683|NCT05966532|OTHER|ATHF|Psychotropic medication use/ treatment resistance level will be measured/documented with the Antidepressant Treatment History Form-Short-Form (ATHF-SF)
219185684|NCT05068310|DEVICE|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
219185685|NCT05068310|DEVICE|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
219185686|NCT05068310|DEVICE|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
219185687|NCT05068310|DEVICE|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
219185688|NCT05501574|DRUG|Tacrolimus Inhalation Powder|Tacrolimus powder for inhalation to prevent acute allograft rejection
219185689|NCT05501574|DEVICE|Plastiape RS00 Dry Powder inhaler device|dry powder inhaler device
219191593|NCT05506878|DEVICE|Sham NSS-2 BRIDGE|Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
219191594|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
219191595|NCT03408665|RADIATION|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
219369848|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
219000246|NCT05038423|BEHAVIORAL|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
219000247|NCT01007097|DRUG|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
219000248|NCT01007097|DRUG|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
219000249|NCT01007097|DRUG|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
219000250|NCT01007097|DRUG|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
219000251|NCT01007097|DRUG|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
219000252|NCT01007097|DRUG|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
219000253|NCT01007097|DRUG|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
219000254|NCT00136799|DRUG|Fluvastatin|
219000255|NCT00675493|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
219000256|NCT00299975|DRUG|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
219000257|NCT00299975|DRUG|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
219000258|NCT00299975|DRUG|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
219000259|NCT01815593|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
219000260|NCT00982878|DRUG|Maraviroc|150mg twice daily
219000261|NCT02590367|DRUG|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks."
219000262|NCT02590367|DRUG|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
219000263|NCT02590367|DRUG|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
219000264|NCT05374434|OTHER|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
219000265|NCT05374434|DEVICE|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
219000266|NCT04302298|DEVICE|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
219000267|NCT04071561|OTHER|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
219000268|NCT04071561|OTHER|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
219000269|NCT00113620|DRUG|Neurodex|
219000270|NCT02486497|BIOLOGICAL|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
219000271|NCT02627144|DRUG|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
219000272|NCT02627144|DRUG|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
219000273|NCT05883449|DRUG|AFM13|anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
219000274|NCT05883449|DRUG|AB-101|NK cell therapy, intravenous infusion
219000275|NCT05883449|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy, intravenous infusion
219000276|NCT05883449|DRUG|Fludarabine|Lymphodepleting chemotherapy, intravenous infusion
219000277|NCT05883449|DRUG|Interleukin-2|Immune cytokine, subcutaneously
219000278|NCT02825056|DRUG|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
219000279|NCT02825056|DRUG|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
219185690|NCT06369116|DEVICE|INSTI HCV Self Test|"Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received."
219185691|NCT06643663|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
219185692|NCT06207773|OTHER|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
219185693|NCT06644261|DRUG|Bupivacaine injection|"Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks"
219185694|NCT05857228|PROCEDURE|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
219185695|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
219185696|NCT04884789|DEVICE|COFIS 3D|Patient have to wear the COFIS 3D 20h a day for at least 6 month
219185697|NCT05294991|BEHAVIORAL|Wellness app intervention #1|This is the active intervention group.
219185698|NCT05294991|BEHAVIORAL|Wellness app intervention #2|This is the active comparator/control group.
219185699|NCT05296135|DIAGNOSTIC_TEST|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
219185700|NCT04510311|DRUG|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
219185701|NCT04510311|DRUG|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi \[123I\]MIBG
219185702|NCT04510311|DIAGNOSTIC_TEST|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
219185703|NCT04510311|DIAGNOSTIC_TEST|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
219185704|NCT04510311|DIAGNOSTIC_TEST|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
219185705|NCT03785964|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
219185706|NCT03785964|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
219185707|NCT05524337|BEHAVIORAL|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
219185708|NCT05524337|BEHAVIORAL|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
219185709|NCT05524337|BEHAVIORAL|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
219185710|NCT06010030|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
219185711|NCT06010030|BEHAVIORAL|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
219185712|NCT06031298|BIOLOGICAL|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
219185713|NCT03744182|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
219185714|NCT03744182|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
219185715|NCT05039229|OTHER|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
219185716|NCT05039229|OTHER|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
219185717|NCT05665686|DEVICE|Relaxation training with device|Relaxation training will be applied with the device.
219185718|NCT05665686|OTHER|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
219369849|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
219191596|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
219006954|NCT06186011|PROCEDURE|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
219006955|NCT06186011|PROCEDURE|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
219185719|NCT02748941|DEVICE|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
219185720|NCT06272006|PROCEDURE|Coronally Positioned Flap with Connective Tissue Graft|his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.
219185721|NCT06272006|PROCEDURE|Modified Coronally Advanced Tunnel with Connective Tissue Graft|This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
219185722|NCT06163690|COMBINATION_PRODUCT|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
219185723|NCT03896685|DRUG|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
219185724|NCT03896685|DRUG|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
219185725|NCT03896685|DRUG|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
219185726|NCT03896685|DRUG|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
219185727|NCT03896685|DRUG|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
219185728|NCT05883241|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
219185729|NCT05883241|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
219185730|NCT05110716|BEHAVIORAL|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
219185731|NCT05110716|BEHAVIORAL|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
219185732|NCT05110716|BEHAVIORAL|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
219185733|NCT05237388|DRUG|Baricitinib|One pill daily
219185734|NCT05237388|DRUG|Placebo|Baricitinib placebo pill
219185735|NCT05796388|DEVICE|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
219185736|NCT04117347|DEVICE|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
219185737|NCT04117347|DEVICE|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
219185738|NCT04117347|DEVICE|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
219185739|NCT05909891|OTHER|Patient training|"A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated."
219185740|NCT06352658|DEVICE|Conventional mandibular advancement device|With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
219185741|NCT06352658|DEVICE|CAD CAM mandibular advancement device|"3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by"
219185742|NCT06352658|PROCEDURE|Uvuloplatopharyngeoplasty UPPP|uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.
219185743|NCT04342234|OTHER|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
219185744|NCT03046992|DRUG|YH25448|"* Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448"
219185745|NCT05756036|OTHER|None Observational study|Non interventional study
219185746|NCT04817618|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
219185747|NCT04817618|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
219000280|NCT04799431|DRUG|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
219000281|NCT04799431|DRUG|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
219000282|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
219000283|NCT02300688|DRUG|Treatment A|administration of 1 time administration of the test drug (Treatment A)
219000284|NCT02300688|DRUG|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
219000285|NCT02429544|BEHAVIORAL|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
219000286|NCT02429544|BEHAVIORAL|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
219000287|NCT02429544|DEVICE|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
219000288|NCT02429544|OTHER|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
219185748|NCT03278080|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
219000289|NCT02429544|BEHAVIORAL|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
219000290|NCT04101461|DRUG|Iron|PharaFerro27; Devart Lab Company, Egypt
219000291|NCT04101461|DIAGNOSTIC_TEST|Complete blood count|to assess the anemia
219185749|NCT03278080|OTHER|Car-following test|Driving with simulator program for DCV measurement
219185750|NCT03278080|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
219185751|NCT05680012|DIETARY_SUPPLEMENT|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
219185752|NCT04766866|DIAGNOSTIC_TEST|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
219185753|NCT03687086|OTHER|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
219185754|NCT03687086|OTHER|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
219185755|NCT02505984|DRUG|Oxytocin|Study participants will be randomized to a placebo or drug group.
219185756|NCT02505984|DRUG|Placebo|Study participants will be randomized to a placebo or drug group.
219185757|NCT05194956|PROCEDURE|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
219185758|NCT05194956|PROCEDURE|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
219185759|NCT05088616|BEHAVIORAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
219185760|NCT05800457|PROCEDURE|Partial synovectomy|Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
219185761|NCT04749212|DIAGNOSTIC_TEST|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
219185762|NCT06419582|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 21 days
219000292|NCT04101461|DIAGNOSTIC_TEST|Serum ferritin|to assess the anemia
219000293|NCT04101461|DIAGNOSTIC_TEST|Serum hepcidin|to assess the iron abosrption
219000294|NCT04101461|DIAGNOSTIC_TEST|Serum Iron|to assess the anemia
219000295|NCT04101461|DIAGNOSTIC_TEST|Serum total iron binding capacity|to assess the anemia
219000296|NCT04964531|OTHER|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
219000297|NCT03469375|DRUG|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
219000298|NCT01906008|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
219000299|NCT01906008|DRUG|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
219000300|NCT01906008|BEHAVIORAL|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
219000301|NCT01906008|BEHAVIORAL|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
219000302|NCT04971122|OTHER|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
219000303|NCT04547569|BEHAVIORAL|Speech adaptation|Sensorimotor adaptation in speech
219000304|NCT04547569|BEHAVIORAL|Vibrotactile Discrimination|Vibrotactile Discrimination
219000305|NCT04547569|OTHER|fMRI|fMRI measurement of brain activity
219000306|NCT04547569|BEHAVIORAL|Speech production|Speech production task
219000307|NCT02491203|OTHER|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
219000308|NCT02008201|DIETARY_SUPPLEMENT|vitamin D|
219000309|NCT01193868|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219000310|NCT01193868|OTHER|laboratory biomarker analysis|Correlative studies
219000311|NCT01193868|OTHER|pharmacological study|Correlative studies
219000312|NCT02444520|BEHAVIORAL|Integrated GP Care|"The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
219000313|NCT05864872|PROCEDURE|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
219000314|NCT01815515|DRUG|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."
219000315|NCT04162639|BIOLOGICAL|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
219000316|NCT02220205|OTHER|PelvicSim|
219000317|NCT02220205|DEVICE|Manufacturer model|
219000318|NCT04394260|BEHAVIORAL|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
219000319|NCT04394260|BEHAVIORAL|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
219000320|NCT04620993|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
219000321|NCT04620993|OTHER|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
219000322|NCT04620993|OTHER|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
219000323|NCT06279962|OTHER|Survey questionnaire|The intervention is being assigned to one of the 8 different versions of the survey vignette.
219000324|NCT05079139|PROCEDURE|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
219000325|NCT01465997|DRUG|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
219000326|NCT01465997|DRUG|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
219000327|NCT05152589|DIAGNOSTIC_TEST|hearing test|Auditory Brainstem Response (ABR) Test
219000328|NCT04873791|DIAGNOSTIC_TEST|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
219185763|NCT06419582|DRUG|Placebo|Matching placebo taken once daily for 21 days
219185764|NCT06851741|BEHAVIORAL|Behavioural Activation for depression (BeatIt2)|"It is a structured, time limited, manualised psychological therapy, developed to treat those with learning disabilities and depressive symptoms.~There is an initial training session for carers regarding their role in the treatment, then 12 sessions with the person with a learning disability and their carer, held weekly or fortnightly, spanning approximately 6 months.~Activities are carried out with the individuals with learning disabilities at each session and elements of the intervention are delivered via carers. The three main phases are: i) assessment and socialisation into the intervention and establishing a relationship with the person with the disability, ii) working towards change, and iii) finishing therapy. The first phase includes assessment of the person's pattern of daily activity, barriers and facilitators to engaging in activity, and examining the link between activity and mood. Specific attention is given to the role of communication and how scaffolding can be provid"
219185765|NCT06140069|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
219000329|NCT00440219|DRUG|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
219000330|NCT00440219|DRUG|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
219185766|NCT06582329|DRUG|Alfa1 Antitrypsin|Participants will be treated intravenously with A1AT 120 mg/kg bodyweight once a week for 4 weeks (4 total infusions).
219185767|NCT05808140|DRUG|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
219185768|NCT05808140|DEVICE|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
219185769|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
219185770|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
219185771|NCT03709121|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
219185772|NCT06847113|OTHER|Physical function|Observe walking speed, both maximal and self-selected, over a 12-months period after knee arthroplasty
219000331|NCT04851249|PROCEDURE|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
219000332|NCT03598985|DIAGNOSTIC_TEST|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
219000333|NCT04040114|DEVICE|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
219000334|NCT00642460|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
219000335|NCT00642460|DRUG|Placebo|iv every 2 weeks for 12 weeks
219000336|NCT00642460|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
219000337|NCT00642460|DRUG|methotrexate|as prescribed
219000338|NCT00642460|DRUG|corticosteroids|orally, as prescribed
219000339|NCT02397785|DEVICE|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
219000340|NCT02397785|DEVICE|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
219000341|NCT01947205|DRUG|paracetamol|
219000342|NCT01947205|DRUG|dexketoprofen trometamol|
219000343|NCT01947205|DRUG|suction curettage|
219185773|NCT06851117|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation (PNF)|Participants in the PNF group will undergo intensive training of the affected limbs for 20 minutes per day, 5 days a week, over a 4-week period. During therapy sessions, the unaffected limb will be constrained using a mitt or cast to encourage focused activation and strengthening of the affected side. The therapy will include repetitive movement patterns designed to enhance strength, flexibility, and coordination.
219000344|NCT01947205|DRUG|suction curettage|
219000345|NCT01947205|OTHER|without drug|
219185774|NCT06851117|COMBINATION_PRODUCT|Spider Cage Therapy Group|This group will participate in therapy sessions within the Spider Cage for 20 minutes per day, 5 days a week, for 4 weeks. Interventions will involve weight-bearing exercises, movement facilitation, and balance training, utilizing the cage's elastic cords to support and stabilize posture. The goal is to improve gross motor skills, balance, and controlled movement.
219185775|NCT06851117|DIAGNOSTIC_TEST|Combined PNF and Spider Cage Therapy Group|Participants in this group will receive both PNF and Spider Cage Therapy, with integrated principles and techniques from both approaches. The intensity and duration will be consistent with the individual therapy groups, with sessions held for 20 minutes per day, 5 days a week, over 4 weeks. This combination is expected to enhance functional outcomes by targeting both strength/coordination and balance/postural control.
219185776|NCT05137574|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
219185777|NCT05137574|DRUG|propofol|propofol
219185778|NCT05137574|DRUG|ketamine|ketamine
219185779|NCT06393114|OTHER|Fermented oat-based product|Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
219185780|NCT06393114|OTHER|Unfermented oat-based product|Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
219185781|NCT06853223|DRUG|Maraviroc|Product will be administered for 300 mg immediately preceding the lung transplant surgery and then will be administered every 12 hours. There will be 7 total doses. The first 3 will be 300 mg doses and the remaining 4 will be 150 mg doses. Maraviroc will be given oral (PO) or by feeding tube (PFT) in crushed format depending on the route availability.
219185782|NCT06853223|DRUG|Placebo|Placebo in 300 and 150 mg formulations Product will be administered every 12 hours for 3 days. The placebo will be matched in appearance and taste to the Maraviroc and is available in PO and liquid (PFT) formulations.
219185783|NCT06849479|PROCEDURE|Aerobic exercise and medical treatment|Aerobic exercise training was done for 30 minutes, day after day (3 sessions weekly) for 6 weeks. Each session started by warming up phase that was walking on treadmill for 5 minutes at 20% of target heart rate. Active phase after warming up was walking on treadmill for 20 min at 50-70 % of target heart rate. And cooling down phase after the active phase of exercise was walking on treadmill for 5 minutes at 20 % of the target heart rate
219185784|NCT06849479|DIETARY_SUPPLEMENT|Medical treatment group|patient received supplement in the form of one capsule daily, that contain iron supplement (10 mg) and multi vitamins (B1=0.6 mg;, B2=0.6 mg; B6=0.6 mg; B12= 1.2 mc and C=30 mg) as well as essential trace elements (Zinc=5 mg; Copper=0.44 mg; Folic acid=200 mc and Biotin=12 mc
219185785|NCT04176601|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
219185786|NCT05145478|DEVICE|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
219185787|NCT03382106|DRUG|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
219185788|NCT03382106|DRUG|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
219185789|NCT03382106|DIAGNOSTIC_TEST|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
219185790|NCT03382106|DIAGNOSTIC_TEST|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
219185791|NCT03382106|DIAGNOSTIC_TEST|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
219185792|NCT06850961|DEVICE|Digital health intervention by using a mobile application|A digital health intervention for promoting self-management in patients with COPD by using a mobile application.
219185793|NCT06850961|OTHER|Feasibilty study and qualitative interview studies|This study is a one group feasibility study including quantitative and qualitative study designs. The investigators will use focus groups and indiviual interviews, as well as Interpersonal Process Recall (IPR) interviews.
219185794|NCT03759431|RADIATION|Vocal-cord Radiotherapy|Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.
219185795|NCT03759431|RADIATION|Complete Larynx Radiotherapy|Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
219185796|NCT06441123|BIOLOGICAL|Blood Sampling|20 ml of blood (5 tubes of 4 ml) will be collected once.
219185797|NCT04746586|OTHER|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
219185798|NCT06380361|DEVICE|BioSpy System|One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
219185799|NCT04290754|BEHAVIORAL|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
219185800|NCT04290754|BEHAVIORAL|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
219185801|NCT06851377|GENETIC|Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)|After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.
219185802|NCT06851377|OTHER|Trascriptome analysis|Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.
219185803|NCT06843369|DIAGNOSTIC_TEST|inflammatory markers|Serum amyloid A , cbc and IL-10
219369850|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
219000346|NCT00937625|BIOLOGICAL|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
219000347|NCT01348503|DRUG|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
219000348|NCT01348503|DRUG|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
219000349|NCT00439842|BEHAVIORAL|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
219000350|NCT02317185|DEVICE|genex bone graft with bone graft|
219000351|NCT02317185|OTHER|autogenous bone graft|
219000352|NCT02656979|DRUG|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
219000353|NCT03085420|DIAGNOSTIC_TEST|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
219000354|NCT00700960|DRUG|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
219000355|NCT05260788|PROCEDURE|Cystoscopy|Standard of care cystoscopy procedure
219000356|NCT06471452|DEVICE|Interaktor|"In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal."
219000357|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
219000358|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
219000359|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
219000360|NCT01786044|BEHAVIORAL|MasterMed|An online interactive educational program
219000361|NCT01786044|BEHAVIORAL|Usual Care|
219000362|NCT00856154|BIOLOGICAL|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~1. Gag150 RLLNAWVKV~2. Gag433 FLGKIWPV~3. Env 67 NIWATHACV~4. Pol606 KLGKAGYVV~5. Vpu66 ALVEMGHHV~6. Vif101 GLADQLIHL~7. Vif23 SLVKHHMYV~8. Gag298 KRWIILGLNKIVRMY~9. gp41 VWGIKQLQARVLAVERYLKD~10. Padre AKXVAAWTLKAAA"
219000363|NCT05157854|BEHAVIORAL|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
219000364|NCT02088047|DEVICE|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
219000365|NCT01115101|DRUG|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
219000366|NCT01115101|DRUG|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
219185804|NCT06850324|DRUG|ABL-101 is administered at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour).|The doses of ABL-101 is administered using an IV infusion pump in the arm at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour). Patients will undergo a 1 hour-imaging with 19F MRI, 16h-36h after end of PFC infusion.
219185805|NCT06847971|PROCEDURE|Flexor hallucis longus tendon transfer|The FHL tendon will be dissected and transected as far distally as possible. The FHL tendon will be transfixed by Krakow's suture being inserted into the distal 3 cm in the stump to ensure adequate length of the graft inserted within the bony tunnel in the calcaneus.A guide wire with eyelet will be inserted in the calcaneum just anterior to the native AT insertion by a distance 2 mm more than the half of the diameter of the transferred tendon to avoid blow up of the posterior wall of the tunnel. A tunnel will be drilled over the guide wire according to the tendon thickness, without penetrating the planter surface of the calcaneum. The threads at the end of FHL tendon suture will be passed through the eyelet of the guide wire. The tendon will be driven into the calcaneal bony tunnel by pulling the guide wire through the plantar aspect of the heel. Then the FHL tendon will be tenodesed into the bone tunnel using a interference screw of the same size or 1 mm larger than the bone tunnel.
219185806|NCT06847971|PROCEDURE|Gastrocnemius augmented Flexor hallucis longus tendon transfer|The gastrocnemius tendon will be refixed to the calcaneal tuberosity using anchors. According to the size of the defect: If the size of the gap was 4-5 cm, an additional gastrocnemius turndown or V-Y flaps will be done. Turn down flap will be achieved by creating 2 cm wide and 5-6 cm long flap from the gastrocnemius tendon. The most distal 1 cm from the proximal stump will be secured along the lateral border of the flap to prevent its separation from the original stump during tensioning and fixation to the calcaneus. V-Y flap will be achieved by having inverted V-shaped incision in the distal part of the gastrocnemius starting proximally and extending the two limbs distally leaving the lateral 1 cm from the original tendon. Then carful advancement of the proximal AT stump distally to reach the calcaneal tuberosity. then Fixation will be achieved by suture anchors. If more than 5 cm gap, tenomyodesis of FHL through the proximal stump of Gastrocnemius muscle will be done.
219185807|NCT06851676|DIETARY_SUPPLEMENT|water supplemented by calcium|Fonte Fausta® water is a natural mineral water, rich in essential minerals, such as calcium, magnesium, and bicarbonate, which are important for maintaining bone density, muscle function, and overall metabolic health.
219185808|NCT06851676|OTHER|Water (Placebo)|a natural mineral commercially available
219185809|NCT06852027|OTHER|Different Dietary Practices|The aim was to investigate the effects of Gluten-Casein-Free Diet and Feingold Diet on gastrointestinal complaints in children with Autism Spectrum Disorder.
219185810|NCT06851182|OTHER|Helfer skin tap technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25gauge sterile disposable sterile disposable needle will be used in all patients for injection administration. the procedure will be performed with helfer skin tap technique. Forms will be applied to the children by the researcher before and after IM injection.
219185811|NCT06851182|OTHER|Shotblocker technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25Gauge sterile disposable sterile disposable needle will be used in all patients. The procedure will be performed using Shotblocker method. Forms will be applied to the children by the investigator before and after IM injection.
219185812|NCT06851962|DRUG|Metformin|Metformin maximum daily dose 2000 mg
219185813|NCT06851962|DRUG|Dulaglutide|Dulaglutide
219185814|NCT06851962|DRUG|Semaglutide 1.0 mg|Semaglutide
219185815|NCT06851962|DRUG|Empagliflozin (BI 10773)|Empagliflozin
219185816|NCT06851962|DRUG|Canagliflozin|Canagliflozin
219185817|NCT06851962|DRUG|Dapagliflozin|Dapagliflozin
219185818|NCT06851962|DRUG|pioglitazone|Pioglitazone
219185819|NCT06851962|DRUG|Sitagliptin|Sitagliptin
219185820|NCT06851962|DRUG|Vildagliptin (Galvus)|vildagliptin
219185821|NCT06851962|DRUG|linagliptin|linagliptin
219185822|NCT04863924|DIAGNOSTIC_TEST|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
219185823|NCT04201262|BIOLOGICAL|Ravulizumab|Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
219185824|NCT05536388|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
219185825|NCT05446168|DRUG|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
219185826|NCT06362785|DEVICE|Virtual Reality|The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
219369851|NCT04531384|DEVICE|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
219369852|NCT04531384|OTHER|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
219369853|NCT04420130|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
219369854|NCT04420130|DRUG|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
219185827|NCT06362785|BEHAVIORAL|Therapeutic exercise|The control group will receive conventional therapeutic exercise treatment following the recommendations of the Osteoarthritis Research Society International (OARSI), similar to the exercises performed with VR.
219185828|NCT05421429|BIOLOGICAL|KN057 doseⅠ|KN057 subcutaneous (SC) injection
219185829|NCT05421429|BIOLOGICAL|KN057 dose Ⅱ|KN057 SC injection
219185830|NCT05421429|BIOLOGICAL|KN057 dose Ⅲ|KN057 SC injection
219185831|NCT03512327|OTHER|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
219185832|NCT05076396|DRUG|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
219185833|NCT03511664|DRUG|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
219185834|NCT03511664|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
219185835|NCT03548428|DRUG|Atezolizumab|1200mg IV every 3 weeks for 4 months
219185836|NCT03548428|RADIATION|SBRT|3 to 5 fractions depending on tumor size
219185837|NCT06839924|BEHAVIORAL|Cognitive Motor Interference|Dual task that uses cognitive in addition to Motor training
219185838|NCT06839924|BEHAVIORAL|traditional physical therapy|physiotherapy program including exercises in addition to physical modalities
219185839|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
219185840|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
219185841|NCT05951725|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185842|NCT05951725|BIOLOGICAL|Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185843|NCT05951725|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185844|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185845|NCT05951725|BIOLOGICAL|DTaP-IPV-Hib|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185846|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
219185847|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
219185848|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
219185849|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
219185850|NCT03210311|DEVICE|compression|a compression stocking is worn, a garment compression class 2, flat knitted
219185851|NCT04535934|OTHER|Adenine 5+ (five stable-labeled nitrogens)|taggant coencapsulated with an excipient
219185852|NCT04016675|OTHER|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
219185853|NCT04016675|OTHER|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
219185854|NCT03995043|BEHAVIORAL|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
219185855|NCT03995043|BEHAVIORAL|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
219185856|NCT03995043|BEHAVIORAL|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
219185857|NCT05020860|DRUG|Paclitaxel|80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
219185858|NCT05020860|DRUG|Carboplatin|Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
219185859|NCT05020860|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
219185860|NCT05020860|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
219185861|NCT05020860|DRUG|Doxorubicin|60 mg/m2 IV administered on Day 1 of each 14-day cycle
219185862|NCT05020860|DRUG|Cyclophosphamide|600 mg/m2 IV administered on Day 1 of each 14-day cycle
219185863|NCT05020860|DRUG|Pembrolizumab|"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."
219185864|NCT05020860|DRUG|Pertuzumab/Trastuzumab/Hyaluronidase-zzxf|Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
219185865|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
219185866|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
219185867|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
219185868|NCT04868708|BIOLOGICAL|AK104|Subjects will receive AK104 intravenously.
219185869|NCT04868708|BIOLOGICAL|Bevacizumab|Subjects will receive Bevacizumab intravenously.
219185870|NCT04868708|DRUG|Paclitaxel|Subjects will receive Paclitaxel intravenously.
219185871|NCT04868708|DRUG|Cisplatin or Carboplatin|Subjects will receive Cisplatin or Carboplatin intravenously.
219185872|NCT05823376|DRUG|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
219185873|NCT06803667|DEVICE|Radiofrequency ablation alone|Radiofrequency ablation under imaging guidance allows for heating of diseased tissues, and has been used for the treatment of benign and malignant soft tissue masses throughout the body in the United States over the last several decades. Newer radiofrequency ablation devices are smaller and allow for precision temperature regulation; these technologies allow us to safely and precisely deliver heat to diseased tissues while minimizing the heating of nearby healthy tissues. Furthermore, we are able to clearly see these devices under ultrasound, which allows us to move the device in real-time to deliver heat as safely, effectively, and efficiently as possible.
219185874|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
219185875|NCT04924803|BEHAVIORAL|No video|Weekly text messages
219185876|NCT04924803|BEHAVIORAL|Video Text|Weekly text messages including links to intervention videos
219000367|NCT03740711|PROCEDURE|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
219000368|NCT05788081|DRUG|golcadomide|BMS-986369 is an orally administered Cereblon-modulating compound
219000369|NCT05788081|DRUG|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
219000370|NCT05788081|DRUG|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
219000371|NCT06578338|OTHER|Physical height measurement|Physical height will be measured and images will be collected for AI to estimate the height
219000372|NCT05290415|DIAGNOSTIC_TEST|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
219000373|NCT00006097|DRUG|CC-1088|
219000374|NCT04605484|BIOLOGICAL|Posoleucel (formerly known as ALVR105) cells|Infusion
219000375|NCT04605484|BIOLOGICAL|Placebo (visually identical to Posoleucel)|Infusion
219000376|NCT02761278|PROCEDURE|Endometrial biopsy|
219000377|NCT04332146|BEHAVIORAL|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
219185877|NCT06288477|DRUG|A cotton pellet moistened with full-strength FC|A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
219185878|NCT06288477|DRUG|Neo-Putty|Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
219185879|NCT06058533|OTHER|Previsit Imagery Picturebook|This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
219185880|NCT06121258|OTHER|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
219185881|NCT06282510|DRUG|Povidone Iodine Topical|Topical intranasal povidone iodine (10%) twice daily for 5 days
219185882|NCT06720311|PROCEDURE|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
219185883|NCT06720311|PROCEDURE|Flexible Ureterorenoscopy|Flexible Ureterorenoscopy
219185884|NCT06720311|PROCEDURE|Shockwave Lithotripsy|Shockwave Lithotripsy
219185885|NCT04032041|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
219185886|NCT04032041|DEVICE|Caliper|Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.
219185887|NCT05551728|BEHAVIORAL|ESDM-informed caregiver coaching|The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
219185888|NCT03953196|BIOLOGICAL|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
219185889|NCT03953196|BIOLOGICAL|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
219185890|NCT03953196|BIOLOGICAL|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
219185891|NCT03953196|BIOLOGICAL|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
219185892|NCT03953196|OTHER|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
219185893|NCT03953196|OTHER|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
219185894|NCT04636814|DRUG|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
219185895|NCT04636814|DRUG|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
219185896|NCT04636814|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
219185897|NCT04636814|DRUG|Roflumilast|\- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
219185898|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
219185899|NCT05983809|DEVICE|Technological rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
219185900|NCT04082117|BEHAVIORAL|Educational video|Educational genetic counseling video
219185901|NCT04754165|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
219185902|NCT05292391|BIOLOGICAL|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
219185903|NCT05292391|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
219185904|NCT07019259|DEVICE|Anodyne Therapy System|Survivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.
219185905|NCT06925295|DRUG|Xenon MRI|MRI with Xenon used for contrast
219185906|NCT06925295|DIAGNOSTIC_TEST|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volumes, DLCO and oscillometry
219000378|NCT04332146|BEHAVIORAL|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
219185907|NCT06925295|OTHER|Quality of Life Questionnaire|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30+QLQ-LC29)
219185908|NCT06925295|OTHER|Medical Research Council Dyspnea score|modified Medical Research Council Dyspnea score (mMRC Dyspnea)
219185909|NCT06925295|OTHER|St. George's Respiratory Questionnaire|St. George's Respiratory Questionnaire (SGRQ)
219185910|NCT06925295|DIAGNOSTIC_TEST|Blood Biomarkers|blood biomarkers of inflammation and injury (e.g. Angiopoetin-2, Interleukin-6, myofibroblast activity, BPD4)
219369855|NCT04420130|PROCEDURE|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
219000379|NCT04901468|OTHER|No Intervention|This is an observational study
219000380|NCT02454296|DRUG|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
219000381|NCT02454296|DRUG|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
219000382|NCT01308775|BEHAVIORAL|SIS.NET, Routine Follow-up|"* SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
219185911|NCT07050355|DEVICE|rTMS|Subjects will undergo rTMS to the left dorsolateral prefrontal region as a treatment for depression. Treatment will be performed three times per week for 12 weeks (36 sessions) . We will use a standard resting motor threshold (rMT) determination from unaffected abductor pollicis brevis. Treatments will be delivered at the EEG coordinate for F3 (approximating the left DLPFC) and will be found using the Beam-F3 method. A total of 5000 pulses/session will be delivered at 10Hz with an intensity of 120% of rMT.
219185912|NCT07050355|BEHAVIORAL|AEx|The goal of AEx will be 20 minutes of continuous walking at an intensity of \~70% of heart rate reserve (HRR calculated via the Karvonen method). The desired intensity will be achieved by a combination of increasing treadmill speed and incline. Rest breaks will be allowed as needed during training with the goal of progressing to 20 minutes of continuous walking.
219185913|NCT06737029|DIAGNOSTIC_TEST|Enhanced diagnostic workup|"Patients will undergo review by a study physician, including a detailed history and physical examination, as well as review of additional investigations that have been performed thus far.~Based on the precise nature of the complaints, and additional findings, additional diagnostic testing may be requested, including, but not limited to: blood testing, spirometry, computed tomography of the chest, repeat chest X-ray, sputum investigations, or bronchoscopy."
219185914|NCT06891625|OTHER|SMT|In the present study, a short examination of the whole spine and pelvic area will be performed to identify those segments with the highest restricted range of motion compared to other parts. A standard HVLA manipulation of this area is applied, which refers to Maitland grade 5.
219185915|NCT06891625|OTHER|ET|In the present study, the participant will, after short warming up, perform three standard exercises aiming to increase the possibility for a person with back pain to control the full range of spinal, pelvis and hip joints (Exercise 1) to increase the motor control and coordination of the muscles controlling the low back, pelvis and hip joints in flexion and rotation (Exercise 2), and to increase the motor control of muscles controlling the low back, pelvis and hip joints in extension (Exercise 3).
219185916|NCT06891625|OTHER|OLP|"In the present study, the procedure will follow the study of Carvalho, et al. (2016).28 The researcher explains clearly in a positive way to the participants that i) a placebo effect can be powerful, ii) the body can automatically respond to taking placebo pills like Pavlov's dogs that salivated when they heard a clock, iii) that a positive attitude can be helpful, but is not necessary, and iiii) the researcher shows a short video clip (1 minute 25 seconds) of a news report, where participants in an OLP study are interviewed on the positive effects they experienced (https://www.youtube.com/watch?v=Jp14Lhl0T9). Thereafter, the participants are asked to take two pills, containing the inactive substance microcrystalline cellulose from a container clearly labeled with placebo."
219185917|NCT04857723|DEVICE|daily disposable contact lens|Daily disposable contact lens for 3 months
219185918|NCT07057960|OTHER|Group Social Work Intervention Based on Cognitive Behavioral Therapy|"The aim of the intervention is to modify children's bullying-related cognitions and enhance peer relationships through cognitive restructuring, achieved by increasing awareness of cognitions, emotions, and behaviors among children in institutional care.~The content of the intervention was developed using the core principles and techniques of cognitive behavioral therapy."
219185919|NCT07063667|OTHER|bulid primary AI model|For the collected patient data, deep learning is used to perform feature screening on the selected or collected images, and malignant risk factors are determined by combining clinical significance. A neural network classifier is trained on the training set data. Variable selection: independent variables (breast MRI images, breast ultrasound images, indicators such as CA199, CA153, CA125, AFP/CEA, etc.), dependent variables (whether suffering from breast cancer and breast cancer subtypes), and the verification accuracy standard is set as the pathological biopsy result.
219185920|NCT07063667|OTHER|verdict model and develop its function|The accuracy of a breast cancer prediction model is typically evaluated using multiple metrics that assess its performance in different aspects
219185921|NCT07062692|OTHER|dry needling trigger release therapy|The dry needling intervention involved inserting sterile filiform needles directly into active rhomboid trigger points for 1-2 sessions (1 session/week) to elicit local twitch responses and relieve tension.
219185922|NCT07062692|OTHER|MANUAL TRIGGER POINT RELEASE|The manual trigger point release intervention involved applying sustained pressure to active rhomboid trigger points followed by passive stretching to release muscle tension and improve mobility.
219185923|NCT07063680|DRUG|Argipressin|Argipressin 0.4 U.ml-1 (i.e. 40IU diluted in 100ml 0.9% NaCl bag)
219185924|NCT07063680|DRUG|Chlorure de sodium|NaCl 0.9%
219185925|NCT07063680|OTHER|Collection of clinical data|At inclusion, D0 to D7, ICU discharge, D30 and D90
219185926|NCT07062276|OTHER|Dynamic taping|The dynamic tape is a new type of treatment. The material has high resilience. Its purpose is to help muscles and tissues absorb external forces and reduce tissue energy consumption.
219185927|NCT07062276|OTHER|Kinesio ®|Kinesio ®can effectively improve pain, edema, and assist functional movements. The elasticity of the patch creates wrinkles to relax the extensor pollicis brevis and the abductor longus muscle of the thumb.
219185928|NCT07062822|OTHER|Resisted exercise|Patients in this group will be applied Kinesio taping 3 times per week over the study period of 6 weeks. Before the kinesio taping, the skin surface will be clean. Patients will positioned lying on their side, hip extended, and knee joint at 60° of flexion. The knee will be tape with an I-shaped kinesio tape starting at the origin of the rectus femoris, and a Y-shaped kinesio tape proximal to the superior patellar border. The taping will be no tension at its base, whereas the portion between the anchor and the superior patella will be stretched ≈40%.
219185929|NCT07062822|OTHER|kinesiology tapping|kinesiology tapping
219369856|NCT04942392|DEVICE|Digital dance for PD|The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
219369857|NCT01796002|DRUG|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
219369858|NCT01796002|DRUG|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
219369859|NCT03541473|DIETARY_SUPPLEMENT|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
219369860|NCT03541473|DIETARY_SUPPLEMENT|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
219185930|NCT07062510|DEVICE|Dasuit Cusion|The Dasuit cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
219185931|NCT07062510|DEVICE|Placebo|The placebo cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
219185932|NCT07062510|OTHER|Washout|A 10 min washout period is in between the two interventions. The paitent is asked to walk around at ease.
219185933|NCT07062874|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Participants received supervised exercise training 3 times per week for 6 weeks. Each session included a 10-minute warm-up (walking at 1.5 km/h), a 30-minute aerobic phase at 60-85% heart rate reserve (calculated using the Karvonen formula), and a 10-minute cool-down (walking at 1 km/h). In addition, participants performed resistance training for upper and lower extremities using TheraBands, with 8-10 sets targeting major muscle groups.
219185934|NCT07062874|BEHAVIORAL|Aerobic Exercise Only|Participants followed the same aerobic training protocol as the experimental group-3 sessions per week for 6 weeks, with 10-minute warm-up, 30-minute aerobic exercise (60-85% HRR), and 10-minute cool-down. No resistance training was provided.
219185935|NCT06899087|OTHER|not interventional|This is an observational study
219185936|NCT07063797|DRUG|Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Denosumab treatment: Administer 60 mg of denosumab via subcutaneous injection every six months for a total treatment period of one year."
219185937|NCT07063797|DRUG|Eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Eldecalcitol treatment: Eldecalcitol, 0.75 µg per capsule, taken orally once daily for a total treatment period of one year."
219185938|NCT07063732|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|0.6 g KME per kg body mass; \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate. (Delta G Ketone, TΔS, Oxford).
219185939|NCT07063732|DIETARY_SUPPLEMENT|Placebo|Inert, calorie-free placebo drink that is taste-matched to the ketone monoester supplement
219185940|NCT07063368|OTHER|Otago exercises and systematic desensitization with routine physical therapy|Warm-up (5 minutes) Marching in place (assisted), arm swings, side steps Otago Balance Exercises (7 minutes) Knee bends (with support), heel-to-toe stand (with support), side hip abduction (with support) Otago Strength Exercises (8 minutes) Ankle dorsiflexion, seated knee extensions, seated marching Routine Physical Therapy - Strength and Mobility Exercises (15 minutes) Assisted squats or sit-to-stand exercises, standing calf raises (with support), seated bicep curls, seated shoulder press Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring, quadriceps, shoulder, and neck stretches Relaxation Training (7 minutes) Review goals, PMR, deep breathing exercises Gradual Exposure and Visualization (10 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance) Discussion and Feedback (3 minutes) Share experiences, provide feedback, assign homework
219185941|NCT07063368|OTHER|Otago Exercises and Routine physical Therapy|"Warm-up (10 minutes) Marching in place, arm swings, and side steps. Otago Balance Exercises (10 minutes) Knee bends, heel-to-toe stand, side hip abduction. Otago Strength Exercises (10 minutes) Ankle dorsiflexion, seated knee extensions, seated marching. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (10 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches, seated torso twist."
219185942|NCT07063368|OTHER|Systematic desensitization and routine physical therapy|"Warm-up (5 minutes) Marching in place, arm swings, and side steps. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches. Relaxation Training (10 minutes) Review goals and expectations, PMR, deep breathing exercises. Gradual Exposure and Visualization (15 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance).~Discussion and Feedback (5 minutes) Share experiences, provide feedback, and assign homework."
219185943|NCT07064018|DRUG|Spedox-6|Given Intravenously (IV)
219185944|NCT07064018|DRUG|Pegfilgrastim|Given Subcutaneous Injection or IV
219185945|NCT07064018|DRUG|Filgrastim|Given Subcutaneous Injection or IV
219185946|NCT07064122|DRUG|AZD2962|AZD2962 will be administered orally once daily.
219185947|NCT05379101|DIAGNOSTIC_TEST|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
219185948|NCT05379101|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
219185949|NCT05379101|DIAGNOSTIC_TEST|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
219185950|NCT04761848|DRUG|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
219185951|NCT04761848|DRUG|Placebo|Placebo tablet twice daily
219185952|NCT05457959|BIOLOGICAL|Dendritic Cell Tumor Peptide Vaccine|Given ID
219185953|NCT05457959|BIOLOGICAL|Ipilimumab|Given IV
219185954|NCT05457959|PROCEDURE|Leukapheresis|Undergo leukapheresis
219185955|NCT05457959|BIOLOGICAL|Nivolumab|Given IV
219185956|NCT05457959|DRUG|Placebo Administration|Given ID
219185957|NCT05457959|DRUG|Placebo Administration|Given IV
219185958|NCT05457959|DRUG|Poly ICLC|Given IM
219185959|NCT05457959|PROCEDURE|Resection|Undergo standard of care surgical resection
219185960|NCT05050747|DRUG|HCG is introduced at day of trigger intra-uterine|hcg is introduced
219185961|NCT05050747|DEVICE|endometrial injury by pipelle|endometrial injury using pipelle on day 8-9 on the same cycle of ovulation
219185962|NCT06329492|BIOLOGICAL|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
219185963|NCT05486650|DRUG|PD-1 inhibitor|After receiving PD-1 inhibitor treatment in the first three cycles, patients with locally advanced or advanced NSCLC whose curative effect is evaluated as stable disease receive SBRT combined with PD-1 inhibitor treatment
219185964|NCT02276885|RADIATION|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
219185965|NCT02276885|RADIATION|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
219185966|NCT02891824|DRUG|atezolizumab + avastin + platinum-based chemotherapy|"* atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
219185967|NCT02891824|DRUG|placebo + avastin + platinum-based chemotherapy|"* placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
219185968|NCT04228731|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
219185969|NCT04228731|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
219185970|NCT04944706|DRUG|Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time|Take 3 times a day after meals,24 weeks
219185971|NCT04944706|DRUG|Qishen Yiqi dripping pills 4 bags/time|Take 3 times a day after meals,24 weeks
219185972|NCT04944706|DRUG|Qishen Yiqi dripping pills placebo 4 bags/time|Take 3 times a day after meals,24 weeks
219185973|NCT03847207|DRUG|HTL0030310|Solution for Subcutaneous injection
219185974|NCT03847207|DRUG|Pasireotide|Pasireotide 600 μg for subcutaneous injection
219185975|NCT03847207|DRUG|Placebo|Matching placebo Solution
219185976|NCT05680753|BEHAVIORAL|Physiotherapy|Physiotherapy
219185977|NCT06338722|OTHER|Making it Work Systemic Sclerosis|One 2 hour virtual meeting per week for 5 weeks, plus an individual meeting with an occupational therapist and a vocational counselor
219185978|NCT04808076|PROCEDURE|Shunt surgery|Shunt operation
219185979|NCT05297266|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
219185980|NCT06101706|BEHAVIORAL|Fatigue assessment|FACIT-F questionnaire and Visual Analog Scale for fatigue
219185981|NCT06101706|BEHAVIORAL|Quality of life assessment|PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
219185982|NCT06101706|OTHER|Assess severity of psoriatic arthritis|DAPSA score
219185983|NCT06101706|OTHER|Assess severity of cutaneous psoriasis|PASI score
219185984|NCT05989802|DIAGNOSTIC_TEST|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
219185985|NCT05989802|DIAGNOSTIC_TEST|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
219185986|NCT05989802|DIAGNOSTIC_TEST|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
219185987|NCT05989802|OTHER|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
219185988|NCT03325855|OTHER|None - Observational|None - Observational
219185989|NCT06505850|DEVICE|Tapered-shaped cuff tracheal tube|Tracheal intubation with a tapered-shaped cuff tube
219185990|NCT06505850|DEVICE|Cylindrical-shaped cuff tracheal tube|Tracheal intubation with a cylindrical-shaped cuff tube
219185991|NCT02714634|DRUG|Methotrexate + targeted therapy administration|"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"
219185992|NCT02714634|DRUG|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
219185993|NCT03693105|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
219185994|NCT03693105|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
219185995|NCT05168280|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
219185996|NCT05168280|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
219185997|NCT02601053|OTHER|Dull movie|A dull movie (duration approximately 90 minutes)
219185998|NCT02601053|OTHER|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
219185999|NCT02601053|OTHER|Heart rate measurement|Heart rate measurement using a actiheart device
219186000|NCT05825456|PROCEDURE|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
219186001|NCT05825456|PROCEDURE|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
219186002|NCT05825456|PROCEDURE|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
219186003|NCT04803994|DRUG|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
219186004|NCT04803994|DRUG|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
219186005|NCT04803994|PROCEDURE|TACE|Locoregional therapy will be performed as a standard-of-care procedure
219186006|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
219186007|NCT06407687|DEVICE|Electro Dry Needlig|Electro Dry Needling is a modified form of dry needling which utilises an electro-stimulation unit connected via cables to fine filament needles. The combination of dry needling with electro-stimulation often prolongs the pain relief effect by blocking nerve pathways and preventing pain signals from travelling to the brain.
219186008|NCT06407687|DEVICE|dry needling|Dry needling is a technique that acupuncturists, physical therapists and other trained healthcare providers use to treat musculoskeletal pain and movement issues.
219186009|NCT03743142|PROCEDURE|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
219186010|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with lower limb cycle ergometer
219186011|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with upper limb cycle ergometer
219186012|NCT04881903|BEHAVIORAL|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
219186013|NCT04881903|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
219186014|NCT03587272|DRUG|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
219186015|NCT06645704|DRUG|EP262|Single dose of \[14C\]-EP262 administered orally.
219186016|NCT04157101|BEHAVIORAL|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
219186017|NCT04157101|BEHAVIORAL|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
219191597|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
219186018|NCT06150430|DEVICE|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
219186019|NCT05287321|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg with Aspirin 100mg
219186020|NCT05973864|DRUG|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
219186021|NCT05973864|DRUG|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
219186022|NCT05973864|RADIATION|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
219186023|NCT06251167|DEVICE|Lateral wedge insoles (LWIs)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.
219186024|NCT06251167|DEVICE|Lateral wedge plus custom arch support (LWAS)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
219186025|NCT03435614|DRUG|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
219186026|NCT04171141|DRUG|PF-07062119|PF-07062119
219186027|NCT04171141|DRUG|Anti-PD1|Anti-PD1 PF-06801591
219186028|NCT04171141|DRUG|Anti-VEGF|Anti-VEGF IV (bevacizumab)
219186029|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
219186030|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
219186031|NCT04315701|BIOLOGICAL|Cemiplimab|Given IV
219186032|NCT04315701|PROCEDURE|Resection|Undergo surgical resection
219186033|NCT03457493|DRUG|DPA-714-PET/MRI|DPA-714-PET/MRI
219186034|NCT03457493|DRUG|5-year Follow-up DPA-714-PET/MRI|PET/MRI scan with DPA-714
219186035|NCT03457493|DRUG|DPA-714 Metabolite Analysis|Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
219186036|NCT02599480|DRUG|mirabegron|50 mg daily during 12 months
219186037|NCT02599480|PROCEDURE|Echocardiography|Echocardiography
219186038|NCT02599480|PROCEDURE|Cardiac MRI|Cardiac MRI
219186039|NCT02599480|PROCEDURE|Maximal exercise capacity|Maximal exercise capacity
219186040|NCT02599480|PROCEDURE|Blood sampling|Blood sampling for study assessments and future exploratory studies.
219186041|NCT02599480|PROCEDURE|Endothelial function measurement|EndoPAT assessment
219186042|NCT02599480|RADIATION|18FDG-PET|PET scanning for beige/brown fat activation
219186043|NCT06150261|DIETARY_SUPPLEMENT|AvailOm|5 capsules taken once daily with main meal
219186044|NCT06150261|DIETARY_SUPPLEMENT|Placebo|5 capsules taken once daily with main meal
219186045|NCT06255535|DEVICE|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
219186046|NCT06255535|DEVICE|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
219186047|NCT05647915|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
219186048|NCT05647915|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
219186049|NCT03414489|DRUG|ABC294640|
219186050|NCT06360107|OTHER|brief video|brief video about depression
219186051|NCT05805137|DEVICE|WoundWatch® wound monitoring system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
219186052|NCT04858451|DRUG|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
219186053|NCT03314454|DRUG|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
219186054|NCT03314454|DEVICE|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
219186055|NCT05341817|DRUG|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
219186056|NCT05341817|DRUG|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
219186057|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
219186058|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
219186059|NCT02673996|DRUG|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
219186060|NCT02673996|DRUG|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
219186061|NCT01803542|RADIATION|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
219186062|NCT04612933|OTHER|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
219186063|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
219186064|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
219186065|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
219186066|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
219186067|NCT05158738|OTHER|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
219186068|NCT06231342|DEVICE|Direct Laryngoscope (DL)|DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
219186069|NCT06231342|DEVICE|Video laryngoscope (VL)|VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
219186070|NCT06231342|PROCEDURE|Endotracheal Tube (ETT) 180|A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
219186071|NCT04280848|DRUG|UCPVax|"The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum."
219186072|NCT04280848|DRUG|Temozolomide|6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
219186073|NCT06302816|OTHER|TUPLER exercises|"will be conducting tupler exercises, exercises that are designed to target core muscles in order to improve posture, regain core strength and reducing discomfort.~Each exercise will be repeated 10reps for 3 times on 3 days a week for 8 weeks."
219186074|NCT06302816|OTHER|SCOOP EXERCISES|will be required to complete scoop exercises basically deals with Pilates which is deep core and hip strengthening and stability through breathing patterns with the utilization of transversus abdominis muscle majorly. In each exercise participant will be asked to hold pelvic floor muscles for 8sec, then relax the muscles and count to 10, repeat I for 10 times each day for 3 days a week for 8weeks. Basic commands about the positing, activation and engagement of core along with breathing control were given to the subjects.
219186075|NCT04451226|DRUG|Fezolinetant|Oral
219186076|NCT06485206|DEVICE|One level Mobi-C and one level fusion|"Cervical Disc Arthroplasty:~• Mobi-C~Fusion devices:~* One-level cervical plates~  o MaxAn Cervical plate system~* Interbody spacers~  * TrellOss-C - 3D printed Ti interbody~ * Vista-S - PEEK interbody~* Standalone Fixation~  * Ti-Coated ROI-C - PEEK cage w/ Ti coating~ * TrellOss-C SA - 3D printed Ti~* Bone Graft~  * Local Autograft~ * PrimaGen Advanced Allograft"
219186077|NCT06241781|BIOLOGICAL|GT101 injection|GT101 injection to treat cervical cancer
219186078|NCT06241781|DRUG|Gemcitabine injection|Gemcitabine injection to treat cervical cancer
219186079|NCT05424224|DEVICE|MagVita|rTMS system
219186080|NCT05922462|DIETARY_SUPPLEMENT|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
219186081|NCT05922462|DIETARY_SUPPLEMENT|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
219186082|NCT04620759|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
219186083|NCT04620759|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
219186084|NCT04418232|COMBINATION_PRODUCT|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
219186085|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
219186086|NCT05110924|OTHER|Standard of care|Patients in the treatment arm will receive standard care.
219186087|NCT05110924|OTHER|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
219186088|NCT06352970|OTHER|TB infection|Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
219186089|NCT05728944|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
219186090|NCT05728944|DRUG|Aceclidine|Aceclidine ophthalmic solution
219186091|NCT05728944|DRUG|Vehicle|Proprietary vehicle ophthalmic solution
219186092|NCT05980299|BEHAVIORAL|Individualized Positive Psychosocial Interaction|The intervention involves a brief positive interaction around a preferred activity or personal care routine.
219186093|NCT05826639|PROCEDURE|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
219186094|NCT05826639|OTHER|No intervention|No intervention
219186095|NCT06418854|OTHER|Questionnaire|Adapted design questionnaire to estimate the vaccine hesitancy specifically for dengue vaccine
219186096|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
219186097|NCT04233216|DRUG|ISL|ISL 0.75 mg capsule taken by mouth.
219186098|NCT04233216|DRUG|DOR|DOR 100 mg tablet taken by mouth.
219186099|NCT04233216|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
219186100|NCT04233216|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
219186101|NCT04233216|DRUG|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
219186102|NCT05772468|DEVICE|Virtual Reality ('VRelax' VR system)|The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
219186103|NCT04877717|DRUG|SHR-A1904|SHR-A1904
219186104|NCT05548322|DEVICE|Different surfaces to be touched|The participant will touch various different surfaces and textures, including ones of different temperature and including solids and liquids.
219186105|NCT05548322|BEHAVIORAL|Emotional state change|The emotional state of the participant will be modulated by listening to music.
219186106|NCT05548322|DEVICE|Electrical stimulation|The participant will receive electrical stimulation of single nerve fibers (a few microamps) to artificially excite an individual afferent.
219186107|NCT06161974|DRUG|Olutasidenib + TMZ|Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
219369861|NCT04608214|DRUG|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
219186108|NCT03199651|OTHER|Best Practice|Receive usual care
219186109|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
219186110|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
219186111|NCT03199651|OTHER|Laboratory Biomarker Analysis|Correlative studies
219186112|NCT03199651|OTHER|Medical Chart Review|Undergo medical record abstraction
219186113|NCT03199651|OTHER|Quality-of-Life Assessment|Ancillary studies
219186114|NCT03199651|OTHER|Questionnaire Administration|Ancillary studies
219186115|NCT03199651|BEHAVIORAL|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
219186116|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
219186117|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
219186118|NCT06458933|BEHAVIORAL|Sage|Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).
219186119|NCT06458933|BEHAVIORAL|Supportive Individual Psychotherapy|Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
219186120|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
219186121|NCT04521608|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
219186122|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
219186123|NCT03823209|BEHAVIORAL|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
219186124|NCT03823209|BEHAVIORAL|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
219186125|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
219186126|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & Carbohydrate|Essential amino acid plus whey beverage with added carbohydrate
219186127|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & EAA|Essential amino acid plus whey beverage with added essential amino acid
219186128|NCT06139016|DEVICE|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
219186129|NCT06272903|DRUG|20% benzocaine, topical anesthetic|"Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators)."
219186130|NCT06272903|OTHER|Children's Toothpaste|Strawberry-flavored children's toothpaste available in Dubai, UAE.
219186131|NCT03484039|BEHAVIORAL|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
219186132|NCT03484039|BEHAVIORAL|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
219186133|NCT03484039|BEHAVIORAL|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
219186134|NCT03484039|BEHAVIORAL|Stress Management|Some subjects will be enrolled in a stress management course.
219186135|NCT05819697|OTHER|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
219186136|NCT05734183|OTHER|MIME|Multisensorial IMmersive Experiences
219186137|NCT05734183|OTHER|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
219186138|NCT05503238|BEHAVIORAL|Skin-to-skin contact|Preterm infants will receive maternal-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge, and other nursing care will be same as the routine group. During skin-to-skin contact, place naked baby only with diaper on the mother's bare chest in an upright position and tilt the baby's head to one side in a slightly extended position to keeps the airway open, cover the infant with a blanket to keep them warm. A neonatal nurse will be stay with mother and infant to observe and support.
219186139|NCT05503238|OTHER|Routine care|Preterm infants will receive standard nursing care provided by neonatal nurses in accordance with hospital principles during hospitalization.
219186140|NCT02057783|OTHER|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
219186141|NCT04481555|DRUG|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
219186142|NCT04481555|DRUG|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
219186143|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
219186144|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
219186145|NCT06109818|DRUG|ICP-488 Tablets|ICP-488 will be administered as tablet
219186146|NCT06109818|DRUG|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
219186147|NCT06044090|DRUG|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
219186148|NCT06044090|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
219186149|NCT05338801|OTHER|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
219186150|NCT05338801|OTHER|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
219186151|NCT04910152|DRUG|BRD4 Inhibitor PLX51107|Given PO
219186152|NCT05563675|DRUG|Long acting muscarinic antagonists (LAMAs) in the evening|LAMAs administered at bedtime (8pm - 2am)
219186153|NCT05126082|BEHAVIORAL|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
219186154|NCT03296371|PROCEDURE|Biospecimen Collection|Undergo saliva or buccal mucosa collection
219186155|NCT03296371|OTHER|Laboratory Biomarker Analysis|Correlative studies
219186156|NCT03296371|OTHER|Questionnaire Administration|Ancillary studies
219186157|NCT02591745|PROCEDURE|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
219186158|NCT05974852|OTHER|Ocrelizumab|Non-interventional
219186159|NCT05449743|OTHER|Spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
219186160|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
219186161|NCT04611971|DRUG|Benlysta|Benlysta injection will be administered subcutaneously.
219186162|NCT04611971|DRUG|Candin|Candin will be administered intradermally along with NaCl solution.
219186163|NCT06035224|DRUG|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
219186164|NCT06171386|PROCEDURE|Microneedling|a form of collagen induction therapy
219186165|NCT06171386|PROCEDURE|Dermabrasion|a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization
219186166|NCT04871269|DRUG|Dronabinol|Dronabinol
219186167|NCT04871269|DRUG|Placebo|Placebo
219186168|NCT05982314|BIOLOGICAL|Gamma-PN3|Experimental whole-cell pneumococcal vaccine
219186169|NCT05982314|BIOLOGICAL|Pneumovax-23|Licensed pneumococcal vaccine
219186170|NCT05982314|BIOLOGICAL|Prevenar-13|Licensed pneumococcal vaccine
219186171|NCT05982314|BIOLOGICAL|Placebo|Saline placebo
219186172|NCT01427153|PROCEDURE|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
219186173|NCT01427153|PROCEDURE|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
219186174|NCT06389084|BEHAVIORAL|Parents Together parenting course|parenting course and coaching calls
219186175|NCT06492005|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
219186176|NCT06492005|DRUG|PD-1 inhibitior|Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
219186177|NCT05877261|DEVICE|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
219186178|NCT04402255|OTHER|pilates exercise|The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.
219186179|NCT05190718|DEVICE|Pharyngeal electrostimulation|"Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential."
219186180|NCT04082650|DRUG|vitamin D|4000IU per day
219186181|NCT04082650|OTHER|Placebo|The same doses with vitamin D
219186182|NCT02588651|DRUG|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
219186183|NCT03747146|DEVICE|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
219186184|NCT03747146|DEVICE|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
219186185|NCT06460038|DRUG|Tenapanor|Inhibitor of NHE3
219186186|NCT06460038|DRUG|Placebo|Placebo drug
219186187|NCT06799091|DEVICE|Low frequency TENS|Low TENS group participated in twelve sessions of electrical stimulation with low frequency (TENS, 10 Hz/200 μs) was applied with self-adhesive electrodes (size 9 × 5 cm,), in the paravertebral ganglionar region (from T1 to L2). The sessions took place at the same time of the day, lasted 30 min, in an acclimatized room (23 °C) and the intensity of the current was delivered at sensory-level intensity, adjusted every 5 min by the sensory threshold, during the 30 min as tolerated by each subject, but without motor contraction or pain reported by the subject.
219186188|NCT04662541|OTHER|Mobile Integrated Health (MIH)|MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
219186189|NCT04662541|OTHER|Transitions of care coordinator (TOCC)|The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
219186190|NCT05768763|BEHAVIORAL|Community-enhanced reach activities|We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care, working closely with community health workers, integrated in the community health system.
219186191|NCT05768763|BEHAVIORAL|Person-centered care delivery|Structured approach to provide patient-centered biomedical options for HIV prevention (dynamic choice prevention). Tailored services for HIV treatment support using structured life stage evaluation and assessment plan (LEAP) for youth, pregnant women, and persons with or at risk of HIV viral non-suppression, that includes counselling for heavy alcohol users. Structured approach to offer telehealth for severe hypertension follow up.
219186192|NCT05768763|OTHER|Data system enhancement to improve reach and person-centered delivery|Both community-enhanced reach and person-centered delivery will be strengthened through a customized in-country Ministry of Health-compatible community health worker smartphone app and two-way data system linking community health workers and clinical records.
219186193|NCT05768763|BEHAVIORAL|Standard of Care|Standard of Care in Uganda and Kenya
219186194|NCT02278744|RADIATION|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
219186195|NCT02278744|DEVICE|MRI and/or CT|
219186196|NCT05994937|DEVICE|PAC with HEPA filter intact|A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
219186197|NCT05994937|DEVICE|PAC with HEPA filter removed|Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
219186198|NCT04792931|OTHER|description of adult autoimmune myopathies|description of adult autoimmune myopathies
219186199|NCT04465708|BEHAVIORAL|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
219186200|NCT03720197|OTHER|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
219186201|NCT03720197|OTHER|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
219186202|NCT03720197|OTHER|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
219186203|NCT03720197|OTHER|Food questionnaire|24-hour food recall questionnaire
219186204|NCT03720197|OTHER|Pedometer|Participants will wear a podometer for 14 consecutives days
219186205|NCT03720197|OTHER|Waist circumference|Participants will be asked to measure their waist circumference
219186206|NCT03720197|OTHER|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
219186207|NCT03720197|OTHER|List of medications|Participants will be invited to send us their list of medications
219186208|NCT03720197|OTHER|Continuous glucose monitor|Participants will be invited to send us the latest report of their continuous glucose monitor
219186209|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
219186210|NCT05290363|OTHER|Blood sampling|A 51 mL blood sample will be collected during the study
219186211|NCT05290363|OTHER|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
219186212|NCT05188287|BEHAVIORAL|HealthyCells|Smoking cessation smartphone app
219000383|NCT02914899|BEHAVIORAL|Surveys|"Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc."
219000384|NCT02914899|BEHAVIORAL|Navigation|CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.
219000385|NCT02914899|BEHAVIORAL|Focus groups|Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).
219000386|NCT02914899|BEHAVIORAL|In-depth interviews|"Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context."
219000387|NCT04862585|DRUG|Cimetidine|Given IV and/or PO
219000388|NCT04862585|DRUG|Dexamethasone|Given IV and/or PO
219000389|NCT04862585|DRUG|Diphenhydramine|Given IV and/or PO
219000390|NCT04862585|DRUG|Famotidine|Given IV and/or PO
219000391|NCT04862585|DRUG|Paclitaxel|Weekly or every 14 day dosing
219000392|NCT04862585|OTHER|Quality-of-Life Assessment|Ancillary studies
219000393|NCT04862585|DRUG|Ranitidine|Given IV and/or PO
219000394|NCT05487989|OTHER|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
219000395|NCT00885430|DRUG|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
219000396|NCT03740945|DRUG|Placebo|Daily administration of one placebo vaginal ovule at bedtime
219000397|NCT03740945|DRUG|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
219000398|NCT06205004|OTHER|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
219000399|NCT03789344|OTHER|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
219000400|NCT03789344|OTHER|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
219000401|NCT03789344|OTHER|blank control|Blank control subjects would be observed only during this investigation.
219000402|NCT05686551|DRUG|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks (Q16W).
219000403|NCT05686551|DRUG|Placebo|Matching placebo administered intrathecally Q16W.
219000404|NCT05686551|DRUG|Tominersen 100 mg|100 mg tominersen administered intrathecally Q16W.
219000405|NCT02862444|OTHER|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
219000406|NCT02741180|OTHER|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
219000407|NCT02741180|OTHER|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
219000408|NCT00496470|DRUG|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
219000409|NCT00496470|DRUG|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
219000410|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
219000411|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
219000412|NCT05704062|PROCEDURE|Diffusion Weighted Imaging|Undergo DW-MRI
219000413|NCT05704062|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
219000414|NCT06332781|DRUG|Gentamicin|administered via bladder
219000415|NCT06332781|DRUG|Nitrofurantoin|administered PO
219000416|NCT04242303|PROCEDURE|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
219000417|NCT00262574|DRUG|Nesiritide,|PCI
219000418|NCT01217814|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219000419|NCT01217814|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219000420|NCT01217814|DRUG|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219000421|NCT01217814|DRUG|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
219000422|NCT01217814|DRUG|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
219000423|NCT02680080|DRUG|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
219000424|NCT02680080|DIETARY_SUPPLEMENT|Grapefruit group|one liter of fresh pink-grapefruit juice
219186213|NCT05254574|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
219186214|NCT05254574|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
219186215|NCT02608320|DRUG|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
219186216|NCT02608320|DRUG|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
219186217|NCT02608320|DRUG|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
219186218|NCT02608320|DRUG|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
219186219|NCT02608320|DRUG|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
219186220|NCT02608320|DRUG|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
219186221|NCT05429827|OTHER|normal saline|Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
219186222|NCT05429827|DRUG|Dextrose 5% in water|Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
219186223|NCT05429827|DRUG|Dextrose 15% in water|Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
219186224|NCT06275360|DRUG|Nivolumab|Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
219186225|NCT04990089|DEVICE|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
219186226|NCT05203523|DEVICE|transcranial alternative current stimulation (tACS)|A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.
219186227|NCT05203523|OTHER|cognitive exercises|"Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant."
219186228|NCT04457960|DRUG|JNJ-66525433|Participants will receive JNJ-66525433 oral capsules.
219186229|NCT04457960|DRUG|Placebo|Participants will receive matching placebo oral capsules.
219186230|NCT04979442|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
219186231|NCT04979442|DRUG|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
219186232|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
219186233|NCT05928091|OTHER|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
219186234|NCT02149030|OTHER|Cytological screening in A1 and A3|Cytological screening.
219186235|NCT05348174|BEHAVIORAL|Virtual Reality Assisted Guided Imagery (VRAGI)|The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
219186236|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
219186237|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
219186238|NCT05283304|DRUG|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
219186239|NCT05283304|OTHER|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
219186240|NCT06234423|DRUG|CUSP06|Antibody drug conjugate (ADC)
219186241|NCT05593250|DRUG|SHR-1905|subcutaneous
219186242|NCT05593250|DRUG|placebo|subcutaneous ,placebo
219186243|NCT06253819|OTHER|survey and physical test|6 min. walking test respiratory function test 30 second sit-stand test respiratory muscle test tıme up and go corbin posture analysis Waist/Hip Circumference Ratio Glucose and Cholesterol values Lanss Neuropathic Pain Scale
219186244|NCT04368949|OTHER|Stepping-Up|The intervention group will receive STEPPING-UP, a virtual 12-week, multicomponent intervention that includes tailored task-oriented motor learning exercise and a mobility self-management (SM) program.
219186245|NCT04368949|OTHER|Telephone-Based Coaching Walking Program|The participants assigned to this group will receive a 12-week Telephone-Based Coaching Walking Program (TELE) delivered by a PT who will help participants set short and long term walking goals.
219186246|NCT04368949|OTHER|Chair-Based Yoga Program|Participants assigned to this group will receive a virtual 12-week Chair-Based Yoga Program (YOGA), a group-based exercise control where participants will undertake a seated exercise program that includes: warm up, seated and standing yoga poses, cool down.
219186247|NCT05374304|OTHER|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
219186248|NCT02427464|BIOLOGICAL|Engensis (VM202)|gene therapy
219186249|NCT02427464|OTHER|placebo|
219186250|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
219186251|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
219186252|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
219186253|NCT05910229|OTHER|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
219186254|NCT06362967|COMBINATION_PRODUCT|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG|For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
219186255|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
219186256|NCT04508088|DIAGNOSTIC_TEST|Coronal T1 weighted spin echo images|Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
219186257|NCT04508088|DIAGNOSTIC_TEST|Spin-lattice relaxation (T1)|Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
219186258|NCT04508088|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
219186259|NCT04508088|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
219186260|NCT01696513|PROCEDURE|Suction|
219186261|NCT01696513|PROCEDURE|Subcision|
219186262|NCT04547049|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
219186263|NCT04547049|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
219186264|NCT04547049|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
219186265|NCT04547049|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
219186266|NCT04547049|DRUG|Rabbit antithymocyte globulin|Between 6mg/kg total dose administered IV day -5 through -2 AND 7.5mg/kg total dose administered IV day -5 through -2.
219186267|NCT04547049|PROCEDURE|Allogeneic HSCT|Day 0
219186268|NCT04547049|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
219186269|NCT04547049|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
219186270|NCT04547049|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
219186271|NCT06297863|PROCEDURE|HEAD DOWN TILT -10° to -15°|"Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body.~Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint.~The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time."
219186272|NCT05643014|OTHER|Sample collection|This study will involve three sample collections including buccal cells and urine samples
219186273|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation with Fusion imaging system Cydar-EV|Cydar-EV image fusion is a CE-marked medical device, which instead of a table-tacked overlay uses computer vision to fuse pre-procedural 3D images with intra-operative 2D fluoroscopy automatically and in real-time.
219186274|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation without Fusion imaging system Cydar-EV|patients will be assigned either to an endovascular repair using standard X-ray fluoroscopy imaging alone (the current reference standard)
219186275|NCT03277495|BEHAVIORAL|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
219186276|NCT06467617|DRUG|Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab|"Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle"
219186277|NCT04123821|DEVICE|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
219186278|NCT05560581|BEHAVIORAL|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
219186279|NCT05560581|BEHAVIORAL|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
219186280|NCT05729802|DEVICE|HoloSIM Software via Hololens 2|Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
219186281|NCT05729802|OTHER|Training by Mannequin Based Simulation|Participants will train a via traditional mannequin based medical crisis scenario
219186282|NCT04861818|BEHAVIORAL|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
219186283|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
219186284|NCT06247306|BEHAVIORAL|ScanSTRESS fMRI-paradigm (Streit et al., 2014)|The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
219186285|NCT06247306|BEHAVIORAL|real-time fMRI neurofeedback|"Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination."
219186286|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
219186287|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
219186288|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
219186289|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
219186290|NCT06427343|DRUG|High-dose ferric derisomaltose|"After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up."
219186291|NCT06427343|DRUG|Low-dose ferric derisomaltose|In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
219000425|NCT01370356|DRUG|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
219000426|NCT01370356|DRUG|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
219000427|NCT03748186|DRUG|STRO-002|intravenous antibody drug conjugate
219000428|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
219186292|NCT05553743|BIOLOGICAL|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
219186293|NCT05553743|DRUG|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
219186294|NCT00922571|PROCEDURE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
219186295|NCT00922571|DEVICE|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
219186296|NCT05495555|DEVICE|INTREPID® Hybrid tip|INTREPID® Hybrid tip for cataract removal
219186297|NCT06144697|DRUG|BMS-986465|Specified dose on specified days
219186298|NCT06144697|OTHER|Placebo|Specified dose on specified days
219186299|NCT06144697|DRUG|Pegasys|Specified dose on specified days
219186300|NCT06144697|DRUG|Famotidine|Specified dose on specified days
219186301|NCT02927236|DEVICE|Transcranial magnetic stimulation (TMS)|Theta burst stimulation is a type of TMS.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 active/sham coil will be used.
219186302|NCT04028479|DIAGNOSTIC_TEST|Biomarker Testing (L)|Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
219186303|NCT04028479|DRUG|Systemic Treatment (T)|Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
219186304|NCT04028479|OTHER|Patient Reported Outcomes (P)|Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
219186305|NCT06680869|DRUG|Amiodarone Hydrochloride Injection|"The use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
219186306|NCT06680869|OTHER|Usual Care Protocol|"The use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
219186307|NCT06292325|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard therapy for Obstructive Sleep Apnea. It consists of a machine that delivers a constant and steady air pressure through a mask worn over the nose or both nose and mouth during sleep. This continuous flow of air helps to keep the airway open, preventing episodes of airway collapse and obstruction characteristic of OSA. CPAP therapy is highly effective in reducing symptoms such as snoring, daytime sleepiness, and fatigue, as well as improving overall sleep quality and decreasing the risk of complications associated with untreated OSA, such as cardiovascular issues. It is considered the gold standard treatment for moderate to severe OSA and is often prescribed after a sleep study confirms the diagnosis. CPAP machines come in various designs and features to suit individual needs and preferences, and proper adjustment and compliance are essential for optimal treatment outcomes.
219186308|NCT06355752|OTHER|Dry needling of lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow"
219186309|NCT06355752|OTHER|Sham dry needling lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow"
219186310|NCT05805176|DEVICE|ADHD Therapy|investigational game-play therapy
219186311|NCT05787470|BEHAVIORAL|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
219186312|NCT05787470|DIAGNOSTIC_TEST|Blood Draw|Sample of blood will be taken.
219186313|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
219186314|NCT05772767|OTHER|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
219186315|NCT05772767|DIAGNOSTIC_TEST|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
219186316|NCT05629039|BEHAVIORAL|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
219369862|NCT04608214|OTHER|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
219369863|NCT00024232|BIOLOGICAL|monoclonal antibody huJ591|
219369864|NCT04492566|DEVICE|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
219186317|NCT01710488|DRUG|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
219186318|NCT01710488|DRUG|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
219186319|NCT06534255|BIOLOGICAL|MegaLT injection|"Three dose groups were set: 1×10\^6/kg, 5×10\^6/kg, and 1×10\^7/kg. The dose escalation was carried out in ascending order using a 3+3 design. To ensure participant safety, enrollment followed a 1+2 rule. Specifically, the first participant in each dose group received the cell infusion and was observed for 14 days. If no dose-limiting toxicity (DLT) was observed, the remaining two participants could then be enrolled and receive cell therapy at the same dose level."
219186320|NCT05626751|DRUG|HZN-825|HZN-825 will be administered BID for 52 weeks
219186321|NCT06245668|DEVICE|SaCoVLM™ video laryngeal mask|The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
219186322|NCT06245668|DEVICE|LMA Supreme|The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
219186323|NCT05698875|OTHER|Breakfast meals|Test meal 1: HGL Test meal 2: HGLP Test meal 3: MGL Control meal: usual breakfast
219186324|NCT06551935|BEHAVIORAL|Habitual sleep habits without intervention|Sleep habits maintenance
219186325|NCT06551935|BEHAVIORAL|Sleep extension and sleep hygiene|Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
219186326|NCT05487846|BEHAVIORAL|Patient Navigation|Receive peer navigation services
219186327|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
219186328|NCT05487846|OTHER|Survey Administration|Ancillary studies
219186329|NCT05487846|OTHER|Best Practice|Receive standard care
219186330|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
219186331|NCT05487846|OTHER|Survey Administration|Ancillary studies
219186332|NCT05456750|DEVICE|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
219186333|NCT06500481|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219186334|NCT06500481|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219186335|NCT06500481|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
219186336|NCT06500481|PROCEDURE|Lumbar Puncture|Undergo LP
219186337|NCT06500481|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219186338|NCT06500481|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219186339|NCT06500481|RADIATION|Proton Beam Craniospinal Irradiation|Undergo pCSI
219186340|NCT06500481|OTHER|Quality-of-Life Assessment|Ancillary studies
219186341|NCT05983367|DRUG|Ompenaclid|Ompenaclid (RGX-202-01)
219186342|NCT05983367|DRUG|Placebo|Placebo
219186343|NCT05983367|DRUG|Bevacizumab|Bevacizumab
219186344|NCT05983367|DRUG|FOLFIRI regimen|FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
219369865|NCT04751942|DEVICE|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
219369866|NCT04751942|DEVICE|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
219369867|NCT04964011|OTHER|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
219000429|NCT06317181|DEVICE|Collection of elastography data|patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
219000430|NCT06317181|DEVICE|Collection of ultrasonic raw data|Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
219000431|NCT00131118|DRUG|Zoledronic Acid|
219186345|NCT03787264|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
219186346|NCT03787264|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
219186347|NCT03787264|BIOLOGICAL|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
219186348|NCT03787264|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
219369868|NCT02102750|DRUG|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
219369869|NCT02367950|BEHAVIORAL|Exercise|10 exercise sessions with a personal trainer
219186349|NCT04991402|DEVICE|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
219186350|NCT00216892|DRUG|Calcipotriol, (calcipotriol + betamethasone)|
219186351|NCT06506591|DRUG|WD-890|Administered P.O.
219186352|NCT06506591|DRUG|WD-890 Tablets Placebo|Administered P.O.
219186353|NCT05472389|OTHER|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
219186354|NCT05472389|OTHER|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
219186355|NCT06689098|DIAGNOSTIC_TEST|Magnetocardiography scan|The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
219186356|NCT06648304|DRUG|TTYP01 tablets|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
219186357|NCT06648304|DRUG|Placebo (Simulant TTYP01 Tablets)|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
219186358|NCT04329975|DRUG|Desmopressin|Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
219186359|NCT02886312|DEVICE|Supplemental Oxygen Delivery System|
219186360|NCT05195294|BIOLOGICAL|LioCyx-M|HBV antigen specific TCR redirected T cells
219186361|NCT05195294|DRUG|Lenvatinib|12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
219000432|NCT06331416|DEVICE|Telemonitoring|Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
219000433|NCT02837575|BIOLOGICAL|VCL-HB01|Investigational Product
219000434|NCT02837575|OTHER|Phosphate-buffered saline|Placebo
219000435|NCT05012488|OTHER|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
219000436|NCT00499577|BIOLOGICAL|CMV pp65 peptide|Given intramuscularly
219000437|NCT00499577|BIOLOGICAL|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
219000438|NCT00499577|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
219000439|NCT00499577|BIOLOGICAL|survivin Sur1M2 peptide vaccine|Given subcutaneously
219000440|NCT05385952|DEVICE|GATT-Patch (currently named ETHIZIA)|"GATT-Patch (currently named ETHIZIA) is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
219186362|NCT05010681|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219186363|NCT05010681|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219186364|NCT06123312|DIAGNOSTIC_TEST|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
219186365|NCT05496231|BIOLOGICAL|HPV9 High formulation|3 doses of the high formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
219186366|NCT05496231|BIOLOGICAL|HPV9 Medium formulation|3 doses of the medium formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
219186367|NCT05496231|BIOLOGICAL|HPV9 Low formulation|3 doses of the low formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
219186368|NCT05496231|BIOLOGICAL|Gardasil 9|3 doses of the marketed HPV vaccine (Gardasil 9) were administered intramuscularly at Day 1, Month 2 and Month 6.
219186369|NCT06462443|BEHAVIORAL|RISE for Physicians Program|RISE for Physicians Program. Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
219186370|NCT03711734|OTHER|Acupuncture + Standard of Care|Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
219186371|NCT03896867|DEVICE|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
219186372|NCT03896867|DEVICE|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
219186373|NCT06048185|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
219186374|NCT04438083|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
219186375|NCT06461923|DEVICE|Insole wearing|The insole-wearing group is instructed to wear the insole gait analysis device as frequently and for as long as possible during outdoor activities. Participants receive feedback during 3rd to 4th week via telephone. Following a period of 6 weeks, an evaluation of the usability and satisfaction of the insole gait analysis device will be conducted.
219186376|NCT04571229|DRUG|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
219186377|NCT05875545|OTHER|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
219186378|NCT05875545|OTHER|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
219186379|NCT04284969|BEHAVIORAL|PROADAPT program|"* A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
219000441|NCT05385952|DRUG|TachoSil|"TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical."
219000442|NCT00040664|DRUG|ritonavir|ritonavir oral capsules or oral solution
219000443|NCT00040664|DRUG|fosamprenavir|fosamprenavir oral suspension or tablet
219000444|NCT03659812|OTHER|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
219000445|NCT00729651|DRUG|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
219000446|NCT00729651|DRUG|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
219186380|NCT06313021|OTHER|Reliability and Validity Study|Reliability and Validity Study
219186381|NCT06094153|DIETARY_SUPPLEMENT|Placebo|Consume placebo (Maltodextrin) once daily before going to bed for 28 days
219186382|NCT06094153|DIETARY_SUPPLEMENT|HMO 1|Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
219186383|NCT06094153|DIETARY_SUPPLEMENT|HMO 2|Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
219186384|NCT06482762|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
219186385|NCT05029622|DRUG|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
219186386|NCT04084288|OTHER|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
219186387|NCT04084288|DEVICE|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
219186388|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Oblique Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
219186389|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Offset Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
219186390|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
219186391|NCT05363891|DRUG|Placebo|Placebo
219186392|NCT05012696|DEVICE|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
219186393|NCT05012696|DEVICE|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
219369870|NCT05307458|DRUG|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
219000447|NCT00729651|DIETARY_SUPPLEMENT|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
219000448|NCT04418453|OTHER|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
219000449|NCT01119391|BEHAVIORAL|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
219000450|NCT02611557|PROCEDURE|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
219000451|NCT02275871|OTHER|MRI|High risk screening MRI will be performed as part of the patient's routine care.
219000452|NCT02275871|OTHER|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
219000453|NCT00313391|DRUG|Risperdal Consta|
219000454|NCT02399826|DEVICE|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
219000455|NCT02399826|PROCEDURE|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
219000456|NCT02421276|OTHER|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
219000457|NCT02925494|DRUG|Estradiol/Norethindrone Acetate|capsules
219000458|NCT02925494|DRUG|Elagolix|film-coated tablets
219000459|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
219000460|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
219000461|NCT06963736|BEHAVIORAL|Blue light|Blue light blocking glasses use and discouraged late night eating.
219000462|NCT06963736|BEHAVIORAL|Eating|Encouraged not to eat past 8pm.
219000463|NCT06963736|BEHAVIORAL|Standing|Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
219000464|NCT04210687|PROCEDURE|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
219000465|NCT04210687|PROCEDURE|Trapeziectomy|Simple trapeziectomy
219000466|NCT03256916|DRUG|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
219186394|NCT06250803|DEVICE|early pancreatic stent placement (EPSP)|In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.
219186395|NCT03995173|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
219186396|NCT06181461|OTHER|Gong's Mobilization|Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
219186397|NCT06181461|OTHER|Kaltenborn Mobilization|Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
219186398|NCT02430129|PROCEDURE|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
219186399|NCT02430129|PROCEDURE|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
219186400|NCT02430129|DEVICE|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
219186401|NCT02430129|DEVICE|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
219186402|NCT04219436|PROCEDURE|vertical mattress suturing technique|vertical mattress suturing technique used for flap closure after esthetic crown lengthening
219186403|NCT04219436|PROCEDURE|figure of eight suturing technique|figure of eight suturing technique used for flap closure after esthetic crown lengthening
219186404|NCT06023212|DRUG|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
219186405|NCT06023212|DRUG|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
219186406|NCT05745285|OTHER|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
219186407|NCT04284917|DRUG|Carglumic Acid (Carbaglu®)|"A. Study period: 36 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12).~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12.~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis and methylmalonic acid will be recorded during treatment period."
219186408|NCT06482216|BIOLOGICAL|Varicella vaccine|lyophilized powder,subcutaneous injection
219186409|NCT03974178|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
219186410|NCT03739723|OTHER|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
219186411|NCT05650788|DIAGNOSTIC_TEST|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
219186412|NCT04228419|PROCEDURE|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
219186413|NCT04228419|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
219186414|NCT04319042|PROCEDURE|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
219186415|NCT04319042|PROCEDURE|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
219186416|NCT05436444|BIOLOGICAL|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
219186417|NCT03815656|DEVICE|STN alone|DBS stimulation of STN alone
219186418|NCT03815656|DEVICE|GPi alone|DBS stimulation of GPi alone
219186419|NCT03815656|DEVICE|STN + GPi|cooperative DBS stimulation of STN and GPi sites
219186420|NCT03815656|DEVICE|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
219186421|NCT02400229|PROCEDURE|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
219186422|NCT02400229|PROCEDURE|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
219369871|NCT01569581|BIOLOGICAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
219369872|NCT01569581|BIOLOGICAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
219186423|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
219186424|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
219186425|NCT05244239|DRUG|Lurbinectedin|Given IV
219186426|NCT05244239|RADIATION|Palliative Radiation Therapy|Undergo RT
219186427|NCT06494150|DRUG|nab-Sirolimus|nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle
219186428|NCT06494150|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
219186429|NCT03467191|DRUG|Alcohol|target BAC .08%
219186430|NCT03467191|OTHER|Placebo|placebo beverage
219186431|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
219186432|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
219186433|NCT05328934|DEVICE|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
219186434|NCT05328934|DEVICE|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
219186435|NCT04829877|BEHAVIORAL|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
219186436|NCT04829877|BEHAVIORAL|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
219186437|NCT06823648|DEVICE|Arterial blood samplers with needles PICO70 and safePICO syringes|PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation. safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle.
219186438|NCT05358834|DIETARY_SUPPLEMENT|Melatonin|Oral melatonin administered as a single pill.
219186439|NCT05358834|DIETARY_SUPPLEMENT|Placebo|Oral placebo administered as a single pill.
219186440|NCT06723444|BEHAVIORAL|Learning and Memory Training|"The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions)."
219186441|NCT06723444|BEHAVIORAL|Placebo Comparator|The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
219186442|NCT06784089|OTHER|Geriatric Nutrition Risk Index|GNRI will be calculated from the formula \[1.489 X albumin (g/L)\] + \[41.7 (weight/ideal weight)\]. If the patient's weight is more than their ideal weight, the weight/ideal weight ratio will be accepted as 1. The ideal weight will be calculated for men with the formula \[(Height-100) -(Height-150/4)\], for women with the formula \[(Height-100) -(Height-150/2.5)\]. According to the results, patients will be determined as no risk (GNRI \> 98), low risk (92-98), severe/moderate risk (GNRI \< 92).
219186443|NCT06784089|OTHER|visual analog scale|During the VAS evaluation, the patient will be asked to indicate the location of the pain on a 100 cm long scale where 0: no pain, 100: maximum pain, and the value shown by the patient will be recorded.
219186444|NCT06717880|DRUG|IBI363 combined with Bevacizumab|"IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection."
219186445|NCT06717880|DRUG|IBI363 + Furuitinib|IBI363 Q2W or Q3W IV，Furuitinib po
219186446|NCT05832437|BEHAVIORAL|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
219186447|NCT05832437|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
219186448|NCT05681624|OTHER|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
219186449|NCT05681624|OTHER|Room air|Room air, no mask
219186450|NCT03828799|COMBINATION_PRODUCT|Folfirinox + regorafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
219186451|NCT06822985|DRUG|QL1706|Drug: QL1706 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
219186452|NCT06542263|DEVICE|CPAP|For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
219186453|NCT04091867|DRUG|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
219186454|NCT04091867|DRUG|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
219186455|NCT04091867|RADIATION|Radiation Therapy|6930 cGy IMRT starting D15-D18
219186456|NCT05473273|DRUG|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
219186457|NCT05473273|DRUG|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
219186458|NCT04239820|RADIATION|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
219186459|NCT06823934|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most common operations performed in oral surgery is the extraction of lower impacted wisdom teeth. The extraction of impacted third molars causes significant inflammatory changes resulting in edema, trismus and pain. Complications encountered after the extraction of lower impacted wisdom teeth can negatively affect the daily lives of patients. Some of the treatments applied for these complications can be listed as drug use, cold/hot compression, low-dose laser therapy, cryotherapy, autogenous biomaterials such as PRF.
219186460|NCT04508309|BIOLOGICAL|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
219186461|NCT04508309|BIOLOGICAL|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
219186462|NCT05526430|DRUG|Harmine Hydrochloride Capsules|capsules taken orally
219186463|NCT06518525|OTHER|pilates-based tele-exercises|pilates-based tele-exercises
219186464|NCT06778512|OTHER|Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t|Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
219186465|NCT06210308|PROCEDURE|Data collection from gastric ultrasound|observational study
219186466|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.|1\) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.
219186467|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.|2\) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.
219186468|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.|3\) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
219186469|NCT06398795|PROCEDURE|Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).|An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
219186470|NCT06398795|PROCEDURE|Conventional open thyroidectomy (COT)|open thyroidectomy with traditional collar incisions
219186471|NCT05166499|DIETARY_SUPPLEMENT|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
219186472|NCT05166499|DIETARY_SUPPLEMENT|Balanced Amino Acids|Balanced Amino Acids
219186473|NCT06251687|PROCEDURE|Transbronchial Cryobiopsy，TBLC|Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
219186474|NCT06251687|PROCEDURE|Transbronchial Lung Biopsy，TBLB|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
219186475|NCT05984446|DEVICE|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
219186476|NCT05984446|DEVICE|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
219186477|NCT05622929|BEHAVIORAL|Digitally-enabled Multifaceted Quality Improvement Intervention|"Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~* Knowledge of effective lipid lowering therapies~* Clinical decision support~* Audit and feedback on adherence to optimal clinical management~* Audit and feedback on LDL-C control"
219186478|NCT05622929|BEHAVIORAL|Usual care|Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
219369873|NCT01569581|BIOLOGICAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
219186479|NCT04864314|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
219186480|NCT04864314|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
219186481|NCT05726279|DEVICE|NIRS based personalized blood pressure management|In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
219186482|NCT06242665|OTHER|Low UPF Meals (Study Provided)|Meals provided through delivery service
219186483|NCT06242665|OTHER|Low UPF Nutritional Guidance|Self-guided instructions from study team.
219186484|NCT06242665|OTHER|Low UPF Snacks (Study Provided)|Low UPF snacks provided to participant
219186485|NCT05196919|BIOLOGICAL|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
219186486|NCT05196919|BIOLOGICAL|Placebo|Phosphate-buffered saline for injection
219186487|NCT05263440|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
219186488|NCT05546996|DEVICE|FlowSense|"Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis."
219186489|NCT02760030|DRUG|Fulvestrant|Given IM
219186490|NCT02760030|OTHER|Laboratory Biomarker Analysis|Correlative studies
219186491|NCT02760030|DRUG|Palbociclib|Given PO
219186492|NCT02760030|OTHER|Questionnaire Administration|Correlative studies
219186493|NCT02760030|DRUG|Aromatase Inhibitors|Given PO
219186494|NCT05858736|DRUG|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
219186495|NCT06184919|OTHER|Process Mapping: Observations|Direct observations of the POSH clinic visit.
219186496|NCT06184919|OTHER|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
219186497|NCT06184919|OTHER|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
219186498|NCT06184919|OTHER|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
219186499|NCT04015804|OTHER|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
219186500|NCT05710224|BIOLOGICAL|V181|0.5 mL SC dose of V181
219186501|NCT05710224|BIOLOGICAL|Butantan-DV|0.5 mL SC dose of Butantan-DV
219186502|NCT05851183|DRUG|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
219186503|NCT05851183|BEHAVIORAL|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
219186504|NCT05897944|OTHER|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
219186505|NCT05509413|DEVICE|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
219186506|NCT00540774|DEVICE|detection of oral pathology|detection of oral pathology
219369874|NCT01569581|BIOLOGICAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
219186507|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
219186508|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
219186509|NCT02259218|OTHER|laboratory biomarker analysis|Correlative studies
219186510|NCT05208697|BEHAVIORAL|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
219186511|NCT05208697|OTHER|off-site linkage|standard of care linkage to a Ryan White clinic
219186512|NCT03085810|DRUG|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
219186513|NCT06779396|DRUG|The triamcinolone acetonide plus ropivacaine group|The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
219186514|NCT06779396|DRUG|The ropivacaine group|The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
219186515|NCT05470023|OTHER|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
219186516|NCT04085510|DEVICE|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
219186517|NCT03621371|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
219186518|NCT03621371|BEHAVIORAL|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
219186519|NCT04532190|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS)
219186520|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
219186521|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
219186522|NCT02109302|PROCEDURE|Blood sample|
219186523|NCT02109302|PROCEDURE|Skin biopsy|
219186524|NCT02109302|OTHER|Questionnaire|
219186525|NCT04568902|DRUG|H3B-6545|H3B-6545 oral tablets.
219000467|NCT03256916|DRUG|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
219186526|NCT04568902|DRUG|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
219186527|NCT06159361|BEHAVIORAL|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
219186528|NCT06125808|DRUG|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
219186529|NCT06125808|DRUG|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
219186530|NCT05268887|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
219186531|NCT05268887|DEVICE|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
219186532|NCT05925218|RADIATION|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
219186533|NCT05200403|DRUG|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
219000468|NCT03256916|RADIATION|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
219000469|NCT02382393|OTHER|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
219000470|NCT02382393|OTHER|Computerized Assessment|a validated, computerized cognitive assessment tool
219000471|NCT03636061|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
219000472|NCT03636061|DRUG|Placebo (vehicle) nasal spray|Placebo
219000473|NCT06526650|OTHER|'Ai Pono|"Hands-on Cooking and Cultural Lessons These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare."
219000474|NCT06149247|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
219000475|NCT06149247|DRUG|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
219000476|NCT05594784|DRUG|Olverembatinib|a third-generation TKI
219000477|NCT05594784|DRUG|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
219000478|NCT05594784|DRUG|prednisone|Glucocorticoids
219000479|NCT05594784|DRUG|Vincristine|Anti-tumor alkaloids
219000480|NCT02018588|DIETARY_SUPPLEMENT|tryptophan|graded levels of tryptophan will be given to each subject
219000481|NCT06108739|DRUG|Cyclophosphamid|A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
219000482|NCT06108739|DRUG|ATG|A total of 10mg/kg ATG was administered.
219000483|NCT05853419|DEVICE|Robotic-assisted PCI|Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
219000484|NCT06258642|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, Q2W, iv
219000485|NCT06258642|DRUG|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
219000486|NCT06851767|GENETIC|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
219000487|NCT06851767|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
219186534|NCT05200403|DRUG|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
219186535|NCT05200403|DEVICE|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
219186536|NCT05200403|DEVICE|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
219186537|NCT06520878|DIETARY_SUPPLEMENT|NANO-PSO (pomegranate seed oil)|NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
219186538|NCT06520878|DIETARY_SUPPLEMENT|Placebo|Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
219186539|NCT06667973|DRUG|Gilteritinib|"Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients."
219186540|NCT03209583|DEVICE|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
219186541|NCT03937843|DRUG|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
219000488|NCT06851767|DRUG|Palifermin|Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
219000489|NCT06851767|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice.
219000490|NCT06851767|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose \>5(SqrRoot) 10\^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy.
219000491|NCT06182059|PROCEDURE|continuous peripheral nerve block|continuous regional anesthesia in total knee replacement
219000492|NCT05182125|BIOLOGICAL|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
219186542|NCT03937843|DRUG|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
219186543|NCT03937843|DRUG|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
219186544|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
219186545|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
219186546|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
219186547|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
219186548|NCT03584633|DRUG|Indocyanine Green|The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
219186549|NCT05037500|DRUG|Decitabine and Cedazuridine|Given PO
219186550|NCT05037500|DRUG|Enzalutamide|Given PO
219186551|NCT05049512|OTHER|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
219186552|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
219186553|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
219186554|NCT06392308|OTHER|none intervention|No interventions are administered to either group of patients.
219186555|NCT05073458|DRUG|parsaclisinib|parsaclisib will be administered QD orally
219186556|NCT05073458|DRUG|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
219186557|NCT05577390|OTHER|Intraneural Facilitation Therapy Treatment|Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
219186558|NCT05577390|OTHER|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
219186559|NCT06438133|OTHER|CIMON|The sensor assess changes in the circumference of the limb and will be applied to the lower limb before compression bandaging is applied.
219186560|NCT06438133|OTHER|Sens Motion|The sensor assess physical activity and the amount of time spent at rest, standing, walking, running and count steps.
219186561|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
219186562|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
219186563|NCT03377647|BEHAVIORAL|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
219186564|NCT03377647|BEHAVIORAL|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
219186565|NCT00950742|DRUG|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
219186566|NCT00950742|DRUG|BIBW 2992|Increased dose cohorts from low dose to MTD
219186567|NCT06254924|BEHAVIORAL|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
219186568|NCT06254924|BEHAVIORAL|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
219186569|NCT04751071|DRUG|Roflumilast 500Mcg Tab|Roflumilast 500µg tablet once daily for 6 weeks plus the standard therapy
219186570|NCT04751071|DRUG|Placebo|Placebo tablet once daily for 6 weeks plus the standard therapy
219186571|NCT03916783|BEHAVIORAL|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
219186572|NCT05476328|DEVICE|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
219186573|NCT05476328|DEVICE|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
219186574|NCT05476328|DEVICE|ACE|Advanced Combination Encoder (ACE) is the commercially available, reference sound processing strategy.
219186575|NCT05476328|DEVICE|Cochlear Device Interface (CDI) Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
219191598|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
219191599|NCT05406284|PROCEDURE|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
219191600|NCT06558825|BEHAVIORAL|Integrated Intervention to Promote PrEP Uptake|Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
219186576|NCT06444633|BEHAVIORAL|Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc|The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.
219186577|NCT06560476|OTHER|Data collection|Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.
219186578|NCT05989854|BEHAVIORAL|Exercise|8 week exercise intervention, 3x/wk
219186579|NCT06453980|DEVICE|sham tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.
219186580|NCT06453980|DEVICE|active tDCS|Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
219186581|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and placebo|Live attenuated pertussis vaccine and placebo
219000493|NCT05182125|BIOLOGICAL|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
219000494|NCT05182125|BIOLOGICAL|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
219000495|NCT05182125|BIOLOGICAL|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
219000496|NCT05182125|BIOLOGICAL|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
219000497|NCT05962697|OTHER|SA controller|Novel controller to be tested
219000498|NCT05962697|OTHER|TA controller|original controller to be tested
219000499|NCT05962697|OTHER|SA controller early testing|Novel controller to be tested early testing
219000500|NCT06430528|DRUG|Osilodrostat|Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
219000501|NCT06072313|OTHER|Monopolar electrical diathermy plus therapeutic exercise|The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
219000502|NCT06072313|OTHER|Therapeutic Exercise|The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
219000503|NCT02672826|PROCEDURE|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
219000504|NCT06174610|DIAGNOSTIC_TEST|Measurement of Renal Resistive Index|"The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card)."
219000505|NCT06562751|OTHER|Questionnaire|Online questionnaire designed by the investigatory team.
219000506|NCT06562751|OTHER|Focus group|Online focus group
219000507|NCT06562751|OTHER|Interview|Online semi-structured interview
219000508|NCT06562751|OTHER|Workshop|Online and face to face co-production workshops
219000509|NCT00017446|DRUG|CP4071|
219000510|NCT00654680|DRUG|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
219000511|NCT00654680|DRUG|Placebo|Matching placebo
219000512|NCT01086085|DRUG|Adefovir|Adefovir 10 mg po once daily for 36 weeks
219186582|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and Boostrix|Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine
219186583|NCT05116241|BIOLOGICAL|Placebo and Boostrix|Tetanus, diphtheria, and aP vaccine and placebo
219186584|NCT03352531|BIOLOGICAL|AK-105|Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
219186585|NCT05322408|DRUG|HCW9218|HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
219186586|NCT06237647|DIETARY_SUPPLEMENT|Hyaluronic acid, HA|improve tissue repair
219186587|NCT05683223|BEHAVIORAL|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
219186588|NCT05683223|DRUG|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
219186589|NCT05683223|BEHAVIORAL|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
219186590|NCT04615143|DRUG|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
219186591|NCT04615143|DRUG|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
219186592|NCT05314504|DEVICE|YVOIRE Y-Solution 360|Cross-linked sodium hyaluronate gel for injection with lidocaine
219186593|NCT05946616|OTHER|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
219186594|NCT05946616|OTHER|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
219186595|NCT06192095|DEVICE|Skin barrier film|Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
219186596|NCT01658930|PROCEDURE|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
219186597|NCT01658930|PROCEDURE|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
219186598|NCT05651139|DEVICE|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
219186599|NCT06396026|DRUG|TLL-018 tablets|Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks
219186600|NCT06396026|DRUG|Placebo tablets|Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
219186601|NCT05089227|DRUG|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
219186602|NCT05089227|DRUG|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
219000513|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
219000514|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
219000515|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
219000516|NCT03530969|BEHAVIORAL|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
219000517|NCT03530969|BEHAVIORAL|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
219186603|NCT05089227|BIOLOGICAL|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
219186604|NCT05671861|DEVICE|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
219186605|NCT05671861|OTHER|Questionnaires|Surveys will be administered to participants
219186606|NCT05671861|OTHER|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
219186607|NCT04792502|DRUG|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
219186608|NCT04792502|DRUG|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
219186609|NCT03418987|OTHER|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
219186610|NCT04979351|OTHER|Abdominal Massage|Abdominal massage will be applied twice a day.
219186611|NCT04502550|DRUG|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
219186612|NCT04469192|OTHER|Cryotherapy|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
219186613|NCT04469192|OTHER|Education|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
219186614|NCT06520657|OTHER|Community Health Worker|Participants are screened for social determinants of health and work with a community health worker for three months to connect them with community and government services to address their family's needs.
219186615|NCT06520657|BEHAVIORAL|Child weight management intervention|This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.
219186616|NCT06520657|OTHER|Standard of Care referral to resources|One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.
219186617|NCT00592852|DRUG|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
219186618|NCT06266312|BEHAVIORAL|A multimodal prehabilitation programme|"1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. \+ strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3\) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
219186619|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
219186620|NCT05002088|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
219186621|NCT04814771|DRUG|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
219186622|NCT05078255|DRUG|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
219186623|NCT05078255|DRUG|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
219186624|NCT05078255|OTHER|Semaglutide 1.34 mg/ml placebo|Saline
219186625|NCT05078255|OTHER|GIP placebo|Saline
219186626|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
219186627|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
219186628|NCT04538976|DRUG|Sildenafil|Sildenafil in standard dosage
219000518|NCT03530969|BEHAVIORAL|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
219000519|NCT03530969|BEHAVIORAL|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
219000520|NCT03530969|BEHAVIORAL|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
219000521|NCT03530969|BEHAVIORAL|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
219000522|NCT00519402|OTHER|tonsillar examination and questionnaire completion|
219006956|NCT01488539|BEHAVIORAL|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
219006957|NCT01488539|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
219006958|NCT01732250|DRUG|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
219006959|NCT01732250|DRUG|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
219006960|NCT04688762|OTHER|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
219006961|NCT03590145|DIAGNOSTIC_TEST|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
219006962|NCT02781051|BEHAVIORAL|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
219186629|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
219186630|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
219186631|NCT05149638|DIAGNOSTIC_TEST|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
219186632|NCT06104176|BEHAVIORAL|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
219186633|NCT06104176|OTHER|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
219186634|NCT06104176|BEHAVIORAL|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
219186635|NCT06378294|PROCEDURE|Mastectomy|Adjuvant postmastectomy radiotherapy
219186636|NCT05575336|OTHER|ADLIFE intervention|"The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study for a follow-up period between 3 and 12 months."
219186637|NCT05594901|OTHER|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
219186638|NCT04909801|DRUG|Abatacept|Abatacept SC (125 mg) once weekly
219186639|NCT04909801|DRUG|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
219186640|NCT04909801|DRUG|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
219186641|NCT06852118|PROCEDURE|AMM Group: Adductor Magnus Muscle Plane approach + Femoral Nerve Blocks|In the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. After performing the femoral nerve block, the adductor magnus muscle plane block will be performed using a low-frequency ultrasound probe positioned 6 cm distal to the inguinal crease to identify the sartorius muscle, femoral artery, femoral vein, and femoral nerve on the deep side of the sartorius muscle, the probe will be slide by about 2-2.5 cm distally, where we could identify the plane between the adductor magnus and the semimembranosus muscles, and after proper sterilization, the needle will be slowly advanced until the needle tip is close to the posterior surface of the AMM, 20 mL of bupivacaine 0.5% will be injected while observing fluid distribution under the posterior surface of the AMM, Then GA.
219186642|NCT06852118|PROCEDURE|SG Group: Sciatic nerve block by sub-gluteal approach + Femoral nerve blocks|While the patient is in the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify a cross-sectional view of the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. the patient will be turned on their sides with the operative side uppermost and flexed, the sub-gluteal sciatic nerve will be identified using a low-frequency probe, and then the same needle will be advanced the in-plane to inject 20 ml bupivacaine 0.5% around the nerve., then GA will be conducted as the other group
219186643|NCT04113603|DIAGNOSTIC_TEST|Urinary malignancy|Single bolus three phase CTU
219186644|NCT06031727|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
219000523|NCT01218243|DEVICE|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
219000524|NCT06297577|PROCEDURE|Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)|Albumin-PRF will be placed into intrabony defect
219000525|NCT06297577|PROCEDURE|Minimally invasive surgical technique (MIST)|MIST will be the surgical access for treatment of Intrabony defect
219000526|NCT01114256|PROCEDURE|FNA Biopsy|
219000527|NCT04966039|OTHER|No intervention.|There was no intervention.
219000528|NCT05011565|OTHER|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
219000529|NCT04600128|OTHER|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
219000530|NCT04600128|OTHER|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
219000531|NCT04600128|OTHER|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
219000532|NCT04600128|OTHER|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
219000533|NCT06136793|BEHAVIORAL|HomeStyles-China|2-arm \~10 week educational intervention
219000534|NCT03591991|DRUG|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
219000535|NCT03591991|OTHER|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
219000536|NCT05071469|OTHER|Kinesiotaping|KT was applied.
219000537|NCT05071469|OTHER|Mulligan Mobilization Technique|MMT was applied
219000538|NCT00592943|DRUG|armodafinil|tablet, taken by mouth, once each study day
219000539|NCT04971408|OTHER|passive heat stress|as above
219000540|NCT04971408|OTHER|control|participant engage in activity as usual
219000541|NCT01130012|BEHAVIORAL|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
219000542|NCT01130012|BEHAVIORAL|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
219000543|NCT00172133|DRUG|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
219000544|NCT00634530|BEHAVIORAL|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
219000545|NCT01730469|DRUG|AT1001 150 mg|AT1001 150mg is available as a capsule
219000546|NCT03918083|BEHAVIORAL|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
219000547|NCT02959931|OTHER|High Potassium Meal|Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
219000548|NCT02959931|OTHER|Low Potassium Meal|Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
219000549|NCT05004870|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
219000550|NCT01961193|DEVICE|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
219000551|NCT01961193|DEVICE|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
219000552|NCT02984709|BEHAVIORAL|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
219000553|NCT02984709|BEHAVIORAL|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
219000554|NCT00787852|DRUG|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
219006963|NCT02781051|DEVICE|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
219186645|NCT05875467|OTHER|SE3 Game|A prototype online game designed to increase environmental health literacy
219754253|NCT06690151|OTHER|Biological sampling|"The samples to be collected at delivery will include:~* A 4 ml maternal blood sample in an EDTA tube for lipidomic and metabolomic analyses at delivery~* A 6 ml maternal blood sample in an EDTA tube (2 tubes of 3 ml) for genetic analysis~* A 4 ml venous cord blood sample in an EDTA tube for transcriptomic and epigenetic analysis; and a 2 ml EDTA tube for metabolomic/lipidomic analysis~* Samples from fresh placenta for transcriptomic, epigenetic, metabolomic, and lipidomic analyses~* A meconium sample collected as soon as possible after birth in a dry tube for microbiome analysis~During hospitalization for the cardiac surgery:~* Genome analysis samples will be collected from the father and the infant. These samples will be taken in two EDTA tubes of 3 ml each.~* Perioperative neurobiomarker samples will be collected (one EDTA tube of 500 μL preoperatively and postoperatively on Day 1 and 2).~At 1 month, a stool sample will be collected from the infants for microbiome analysis."
219000555|NCT00787852|DRUG|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
219000556|NCT03758209|PROCEDURE|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
219000557|NCT03758209|PROCEDURE|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
219000558|NCT05329610|DIETARY_SUPPLEMENT|Beta-alanine|Slow-release beta-alanine.
219000559|NCT05329610|DIETARY_SUPPLEMENT|Placebo|Taste and appearance-matched placebo (tapioca starch).
219000560|NCT06461364|PROCEDURE|Assessment of cuspal deflection of bulk-fill restorations|To assess the performance of bulk-fill restorations on premolar teeth in class II cavities using some selected FDI criteria, a total sample size of 30 (10 for each group test) will be sufficient to detect: an effect size of 1.22 at a power (1-β error) of 0.8 and using a two-sided hypothesis test and a significance level (α error) 0.05 for data. Two teeth will be added to each group to compensate drop out samples.
219000561|NCT02575937|BEHAVIORAL|low glycemic diet|nutrition education-based low glycemic diet intervention
219000562|NCT04271969|DEVICE|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
219000563|NCT01337232|BEHAVIORAL|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
219000564|NCT00035516|DRUG|Epothilone|
219000565|NCT02067871|OTHER|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
219000566|NCT02067871|OTHER|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
219000567|NCT02893943|DIETARY_SUPPLEMENT|Probiotics|
219000568|NCT02893943|DIETARY_SUPPLEMENT|Placebo|
219000569|NCT04938804|DEVICE|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
219000570|NCT04039698|OTHER|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
219000571|NCT04039698|DRUG|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
219000572|NCT05388331|OTHER|No intervention|No intervention
219000573|NCT00365729|BEHAVIORAL|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
219000574|NCT01018966|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
219000575|NCT00810238|BIOLOGICAL|C-Cure|Intraventricular injection
219000576|NCT05079282|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
219000577|NCT00080470|DEVICE|bion|battery powered microstimulator
219000578|NCT06042452|GENETIC|Genetic|A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
219000579|NCT01950741|DRUG|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
219000580|NCT06266169|OTHER|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
219000581|NCT02521870|DRUG|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
219000582|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
219000583|NCT02521870|DRUG|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
219000584|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
219000585|NCT02521870|BIOLOGICAL|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
219000586|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
219754254|NCT06690151|BEHAVIORAL|ELFE dietary questionnaire|Questionnaire on diet and lifestyle during pregnancy (only for the mother)
219186646|NCT05761600|OTHER|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
219186647|NCT05761600|OTHER|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
219186648|NCT05761600|OTHER|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
219186649|NCT03392987|GENETIC|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
219186650|NCT00882895|PROCEDURE|Stem cell infusion|
219186651|NCT00882895|PROCEDURE|TLI|
219186652|NCT00882895|DRUG|Anti-thymocyte globulin|
219186653|NCT00882895|DRUG|Solumedrol|
219186654|NCT00882895|DRUG|Tacrolimus|
219186655|NCT00882895|DRUG|Mycophenolate mofetil|
219186656|NCT05427734|DEVICE|WisePath for Adults|Participants assigned to this condition will receive access to the WisePath app for 12 weeks.
219186657|NCT05427734|DEVICE|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
219186658|NCT06281678|DRUG|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
219186659|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
219186660|NCT04789837|DRUG|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
219186661|NCT04789837|DRUG|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
219186662|NCT05767242|OTHER|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
219186663|NCT05767242|BEHAVIORAL|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
219186664|NCT05027568|DRUG|IOA-289|Daily oral twice daily dosing of IOA-289
219186665|NCT05027568|DRUG|Nab paclitaxel / gemcitabine|Given in combination with IOA-289
219186666|NCT03661645|DRUG|10 mg IV dexamethasone & 6 day oral methylprednisolone taper|"Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone"
219186667|NCT03661645|OTHER|10 mg IV dexamethasone|Drug:10 mg intravenous (IV) dexamethasone
219186668|NCT04781634|BIOLOGICAL|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
219186669|NCT04745884|DEVICE|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
219186670|NCT06075004|PROCEDURE|Periarticular Local Anesthetic Infiltration|Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
219186671|NCT06075004|PROCEDURE|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle."
219186672|NCT04793867|DRUG|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
219186673|NCT04935710|BEHAVIORAL|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
219186674|NCT04935710|GENETIC|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
219186675|NCT05328115|BIOLOGICAL|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
219186676|NCT05328115|OTHER|Placebo|Intramuscular injections of adjuvanted placebo.
219186677|NCT03774758|DIAGNOSTIC_TEST|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
219186678|NCT04421989|BEHAVIORAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
219186679|NCT04421989|OTHER|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
219186680|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
219186681|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
219186682|NCT05325645|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
219186683|NCT05325645|DRUG|Placebo|Two placebo tablets will be orally administered once weekly for 7weeks.
219186684|NCT06583187|OTHER|Coloring a mandala picture|In the study, the experimental group was taken to their room on the day they came for circumcision and then had them paint mandalas. The coloring books chosen for mandala painting were determined to be appropriate for the age group of the children. The child was given a book and was given the freedom to paint the figures they wanted. Care was taken to ensure that the environment was quiet so that the child would be comfortable and calm. Care was taken to ensure that the crayons used in mandala painting did not contain carcinogenic substances and were anti-allergic.
219186685|NCT05020678|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
219186686|NCT03814759|DRUG|TS-1 + cisplatin|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
219186687|NCT03814759|RADIATION|radiation|radiation 45Gy per 5 weeks
219186688|NCT05824572|OTHER|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
219186689|NCT05824572|OTHER|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
219186690|NCT06229860|OTHER|Interview|In-person interview with the study coordinator to complete study questionnaire.
219186691|NCT04742621|PROCEDURE|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
219186692|NCT05706103|BEHAVIORAL|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
219186693|NCT05706103|BEHAVIORAL|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
219186694|NCT05516472|DRUG|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
219186695|NCT05516472|DRUG|Placebo|Participants will take placebo capsules
219186696|NCT06298331|OTHER|Aerobic Exercise|Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
219191601|NCT06558825|OTHER|Standard Treatment Condition|Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
219191602|NCT04145375|DRUG|ZEN003694|Up to 120mg
219191603|NCT04145375|DRUG|Enzalutamide|160mg
219186697|NCT06298331|OTHER|Abdominal Massage|Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
219186698|NCT06298331|OTHER|Patient Education|Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
219186699|NCT06073067|RADIATION|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
219186700|NCT05556915|OTHER|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
219186701|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
219186702|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
219186703|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
219186704|NCT05783752|BEHAVIORAL|Stair Stepping|1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal
219186705|NCT05783752|BEHAVIORAL|No exercise control|Participants avoid exercise within 1 hour of eating a meal
219186706|NCT06122441|BEHAVIORAL|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
219186707|NCT06122441|BEHAVIORAL|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
219186708|NCT06555705|OTHER|Placebo|The control group will be given placebo for 3 months
219186709|NCT06555705|DIETARY_SUPPLEMENT|Omega 3|The interventional group will be given omega 3 for 3 months
219186710|NCT03930810|PROCEDURE|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
219557722|NCT05352438|OTHER|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
219557723|NCT01776528|BIOLOGICAL|NGM282|
219186711|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
219186712|NCT03138603|DRUG|Metoprolol Tartrate|Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
219186713|NCT03138603|DRUG|Placebo|Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
219186714|NCT06269367|OTHER|NewGait|wearable limb orthotic device
219186715|NCT06269367|OTHER|Control wearable limb orthotic device|wearable limb orthotic device
219186716|NCT06011772|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
219186717|NCT06011772|DRUG|Leucovorin|Given IV
219186718|NCT06011772|DRUG|Oxaliplatin|Given IV
219186719|NCT06011772|DRUG|Fluorouracil|Given IV
219186720|NCT06011772|BIOLOGICAL|Bevacizumab|Given IV
219186721|NCT06011772|DRUG|Irinotecan|Given IV
219186722|NCT06011772|BIOLOGICAL|Cetuximab|Given IV
219186723|NCT06011772|PROCEDURE|Metastasectomy|Undergo metastasectomy
219186724|NCT06011772|PROCEDURE|Biospecimen collection|Undergo collection of blood samples
219186725|NCT06011772|PROCEDURE|Computed Tomography|Undergo CT
219557724|NCT01776528|BIOLOGICAL|Placebo|
219186726|NCT06011772|BIOLOGICAL|Panitumumbab|Given IV
219186727|NCT03779139|PROCEDURE|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
219186728|NCT03779139|PROCEDURE|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
219186729|NCT03779139|OTHER|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
219186730|NCT06838819|DEVICE|Continuous glucose monitoring system|Medtronic Simplera™
219186731|NCT06724341|BEHAVIORAL|Distraction|"Control group: inferior alveolar nerve block will be administrated with passive behavior management (displaying animated movies directly on the screen of a mobile device).~Movies group: inferior alveolar nerve block will be administrated with displaying animated movies directly on the screen of a mobile device usage of the augmented reality glasses.~Video games group: Application of active behavior management by usage video games on the screen of a mobile device connected to augmented reality glasses before administration of inferior alveolar nerve block.~Movies and Video games group: An active and passive behavior management will be applied by usage video games before administration of inferior alveolar nerve block and animated movies during administration on the screen of a mobile device connected to augmented reality glasses."
219186732|NCT06077552|OTHER|pyramidal training by treadmill|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
219186733|NCT05100654|DRUG|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
219186734|NCT05100654|DRUG|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
219186735|NCT05100654|DRUG|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
219186736|NCT05100654|DRUG|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
219186737|NCT05299242|DRUG|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
219186738|NCT05299242|DRUG|Placebo|Saline \[0.9% NaCl\]
219186739|NCT04715529|DRUG|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
219186740|NCT04715529|DRUG|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
219186741|NCT05525286|DRUG|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
219186742|NCT04777721|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
219186743|NCT04822324|OTHER|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
219186744|NCT04822324|OTHER|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
219186745|NCT06472115|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE) for insistence on sameness (IS)|This study will examine the potential effectiveness of a virtually delivered parent-mediated intervention for insistence on sameness behaviors in autism. This includes a 16 week protocol where caregivers meet weekly for one hour with a study therapist.
219186746|NCT06438302|DEVICE|EEG activity measurement|"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."
219186747|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
219186748|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
219186749|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
219186750|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
219186751|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
219186752|NCT05126290|OTHER|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
219186753|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
219754255|NCT06690151|BEHAVIORAL|Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)|The IES-R is a 22-item self-report measure (for DSM-IV) that assesses subjective distress caused by traumatic events.
219754256|NCT06690151|OTHER|Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)|"* Cardiovascular follow-up data collection~* Developmental follow-up data collection~* Collection of postoperative brain MRI data, scheduled between Day 5 post-surgery and the end of the hospital stay~* Collection of data on pregnancy exposure, obstetric events, and delivery data.~* Collection of fetal ultrasound data (T2 and T3).~* Collection of fetal echocardiography data (T2 and T3)."
219754257|NCT00978458|DRUG|temozolomide|Given orally
219754258|NCT00978458|RADIATION|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
219186754|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
219186755|NCT05178251|PROCEDURE|appendectomy|appendectomy for acute appendicitis
219186756|NCT05706493|OTHER|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
219186757|NCT06082492|DIAGNOSTIC_TEST|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
219186758|NCT06082492|DIAGNOSTIC_TEST|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
219186759|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
219186760|NCT05328856|DEVICE|Hansgrohe prototype/shower head|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
219186761|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
219186762|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
219186763|NCT05617599|DEVICE|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
219186764|NCT06383013|BIOLOGICAL|BB-101|Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
219186765|NCT03837821|DRUG|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
219186766|NCT02975375|PROCEDURE|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
219186767|NCT02975375|PROCEDURE|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
219186768|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
219186769|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
219186770|NCT04910542|OTHER|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
219186771|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
219186772|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
219186773|NCT03272217|DRUG|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
219186774|NCT03272217|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
219186775|NCT05890911|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
219186776|NCT05890911|DIAGNOSTIC_TEST|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
219186777|NCT05890911|DIAGNOSTIC_TEST|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
219186778|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
219186779|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
219186780|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
219186781|NCT04024787|BEHAVIORAL|Cognitive-Behavioural therapy for insomnia (CBT-I)|"Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks."
219186782|NCT03935295|DRUG|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
219186783|NCT03935295|DRUG|Placebos|Placebo prepared by Ipsen for use as control
219186784|NCT03935295|DEVICE|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
219186785|NCT04573231|DRUG|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
219186786|NCT04976153|BIOLOGICAL|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
219186787|NCT04976153|OTHER|Placebo|Placebo control is the vehicle solution used for the study product
219186788|NCT05268120|DRUG|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
219186789|NCT05268120|DRUG|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
219186790|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
219186791|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
219186792|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
219186793|NCT06488456|OTHER|TRSC-C|Data were collected using TRSC-C
219186794|NCT04577963|DRUG|Fruquintinib|Oral VEGFR inhibitor
219186795|NCT04577963|DRUG|Tislelizumab|PD-1 inhibitor
219186796|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract|Cocoa extract manufactured as 250 mg capsules
219186797|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
219186798|NCT07000175|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Non-invasive transcutaneous vagus nerve stimulation with special earphones placed in the ear will be applied to the participants for 20 minutes and a single session.
219186799|NCT07064343|OTHER|Aspirin|Participants are required to complete the training program includes an educational workshops and five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
219186800|NCT07062055|DRUG|Anti-VEGF|Drug: Bevacizumab (15 mg/kg, IV, every 3 weeks)
219186801|NCT07062055|DRUG|Immunotherapy|QL1706 (7.5 mg/kg, IV, every 3 weeks, administered sequentially after bevacizumab)
219186802|NCT07062055|RADIATION|Local Therapy|Stereotactic Body Radiotherapy (SBRT), total dose of 25-50 Gy in 5 fractions over 1-2 weeks, targeting intrahepatic tumors, portal vein tumor, and/or limited extrahepatic oligometastatic lesions
219186803|NCT04375800|DRUG|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
219186804|NCT04375800|DRUG|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
219186805|NCT06185452|DRUG|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
219186806|NCT06185452|DRUG|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
219186807|NCT02534168|DEVICE|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
219186808|NCT01370512|DRUG|Droxidopa|100 mg tablets by mouth three times a day
219186809|NCT01370512|DRUG|Pyridostigmine|60 mg tablets by mouth three times a day
219186810|NCT01370512|OTHER|Placebo|Looks exactly like the study drug but contains no active ingredients
219186811|NCT06792812|DRUG|ginger mouthwash|contain Sulfetal Zn® (Zinc Coco Sulphate) has a cleansing and antibacterial action and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
219186812|NCT06792812|DRUG|chlorohexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
219186813|NCT06792812|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
219186814|NCT05837091|DRUG|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
219186815|NCT05837091|DIAGNOSTIC_TEST|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
219186816|NCT05837091|DEVICE|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
219186817|NCT05837091|DEVICE|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
219186818|NCT03335670|DRUG|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
219000587|NCT04336085|PROCEDURE|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
219186819|NCT06130410|BIOLOGICAL|COMIRNATY intramuscular injection|Booster injection in the muscle, 1 dose
219186820|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
219191604|NCT04872855|DEVICE|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
219191605|NCT05996406|DRUG|Venetoclax|Venetoclax 400mg po qd for 1 year
219754259|NCT00978458|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
219186821|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
219186822|NCT04982796|DRUG|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
219186823|NCT04982796|BEHAVIORAL|Treatment-as-usual|See description of treatment-as-usual arm.
219186824|NCT05669976|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
219186825|NCT05669976|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
219186826|NCT06960941|DIETARY_SUPPLEMENT|TrioBiotix360®|Dietary supplement combining prebiotics and probiotics to promote the balance of intestinal bacterial microflora.
219186827|NCT06960941|OTHER|Booklet with a series of postural hygiene exercises|The booklet will contain a series of postural hygiene exercises to be performed at home
219186828|NCT03971799|BIOLOGICAL|CD33CART autologous|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
219186829|NCT03971799|BIOLOGICAL|CD33CART allogeneic|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
219186830|NCT06641973|DEVICE|Robotic balance rehabilitation with hunova® robotic platform|The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
219186831|NCT03257410|DEVICE|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
219186832|NCT03257410|DEVICE|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
219186833|NCT02561247|DEVICE|Prismaflex HF20 CRRT Filter|
219186834|NCT02561247|DEVICE|Prismaflex® System 7.10 and 7.20|
219186835|NCT05407025|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
219186836|NCT05407025|OTHER|Questionnaire Administration|Complete risk factor questionnaire
219186837|NCT05365230|OTHER|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
219186838|NCT05365230|OTHER|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
219186839|NCT04826003|DRUG|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
219186840|NCT04826003|DRUG|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
219186841|NCT04826003|DRUG|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~\- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
219186842|NCT05616130|OTHER|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
219186843|NCT05616130|PROCEDURE|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
219191606|NCT05996406|DRUG|Dexamethasone Oral|Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
219754260|NCT07020429|DRUG|Huanjingjian decoction|Participants will receive the traditional Chinese herbal formulation Huanjingjian decoction, administered at a dose of one vial (10 ml) twice daily, taken 30 minutes after breakfast and dinner. The intervention will commence immediately following the cessation of menstruation and will continue until the onset of the subsequent menstrual period. Upon the completion of each menstrual cycle, the treatment will be resumed. Each treatment course spans 28 days, with a total of three consecutive cycles administered.
219186844|NCT05616130|OTHER|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
219186845|NCT05616130|OTHER|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
219186846|NCT06193642|OTHER|experimental|Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
219186847|NCT04943042|DRUG|Avatrombopag|According to prescription
219186848|NCT05022134|BEHAVIORAL|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
219186849|NCT02179359|DRUG|Reduced Toxicity Ablative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0"
219186850|NCT02179359|DRUG|Reduced Intensity Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0"
219186851|NCT02179359|DRUG|Myeloablative Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0"
219186852|NCT05726045|BEHAVIORAL|Standard smoking cessation program (SCP)|Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
219186853|NCT05726045|BEHAVIORAL|Cognitive remediation treatment (CRT)|The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
219186854|NCT05726045|BEHAVIORAL|High-intensity interval training (HIIT evening)|"The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise)."
219186855|NCT03387592|DRUG|CPT-11|180 mg/m2
219186856|NCT03387592|DRUG|Calcio levofolinate|200 mg/m2
219186857|NCT03387592|DRUG|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
219186858|NCT03387592|DRUG|Capecitabine|1500 mg/m2
219186859|NCT03387592|DRUG|Temozolomide|200 mg/m2
219186860|NCT06142903|OTHER|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
219186861|NCT04636619|PROCEDURE|Colonic polypectomy|Cold snare resection of colorectal polyps
219186862|NCT04636619|BEHAVIORAL|Online training course|Polypectomy technique online course
219186863|NCT06616532|DRUG|PM8002|Following a predefined dose and date.
219186864|NCT06616532|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 Q3W
219186865|NCT06616532|DRUG|Topotecan|1.25mg/m2/day via IV infusion on Days 1-5 Q3W
219186866|NCT03705806|RADIATION|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
219186867|NCT04050436|DRUG|Cemiplimab|Cemiplimab administered intravenously
219186868|NCT04050436|BIOLOGICAL|RP1|RP1 administered intratumorally
219186869|NCT02345122|BEHAVIORAL|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
219186870|NCT02345122|OTHER|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
219186871|NCT04044794|BEHAVIORAL|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
219186872|NCT04044794|BEHAVIORAL|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
219191607|NCT04593095|OTHER|NeuroN-QI|SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
219191608|NCT04351906|DEVICE|ECCO2R|ECCO2R integrated into the multiFiltrate device
219754261|NCT07020429|DRUG|Hormone replacement therapy|Participants will begin oral administration of Utrogestan (estradiol valerate) on the 5th day of menstruation at a dose of 1 mg daily for 21 consecutive days. Starting from day 17 of treatment, medroxyprogesterone acetate will be added at a dose of 10 mg per day.
219191609|NCT04099472|BEHAVIORAL|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
219754262|NCT07020429|DRUG|Placebo|Participants will take the placebo oral solution at a dose of 10 mL twice daily (30 minutes after breakfast and dinner). The placebo intervention will commence immediately after the cessation of menstruation and will continue until the onset of the subsequent menstrual period. At the completion of each menstrual cycle, the treatment will be resumed. Each treatment course will last for 28 days, with a total of three consecutive cycles administered.
219006964|NCT02781051|BEHAVIORAL|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
219369875|NCT04011202|BEHAVIORAL|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
219369876|NCT05685940|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
219369877|NCT05685940|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
219369878|NCT02040142|PROCEDURE|HIPEC|
219369879|NCT02040142|DRUG|Mitomycin C|
219369880|NCT04190446|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219369881|NCT04190446|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219369882|NCT04190446|OTHER|Quality-of-Life Assessment|Ancillary studies
219369883|NCT04190446|OTHER|Questionnaire Administration|Ancillary studies
219369884|NCT04190446|PROCEDURE|Computed Tomography|Undergo CT scan
219369885|NCT04190446|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219369886|NCT04190446|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219369887|NCT04912960|DEVICE|Mechanical ventilation|Optimum PEEP
219369888|NCT06365619|DRUG|Ipilimumab|Two cycles of neoadjuvant ipilimumab prior to surgical resection.
219369889|NCT06365619|DRUG|Nivolumab|two cycles of neoadjuvant nivolumab prior to surgical resection.
219369890|NCT05535764|DRUG|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
219369891|NCT04172285|BEHAVIORAL|Physical activity|Home-based physical activity program
219369892|NCT04172285|DIETARY_SUPPLEMENT|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
219369893|NCT04172285|OTHER|Control|No intervention
219369894|NCT00743808|OTHER|quality improvement|3-phase quality improvement intervention
219369895|NCT05635890|OTHER|Cawthorne Cooksey exercise protocol|Cawthorne Cooksey exercise protocol
219369896|NCT05635890|OTHER|conventional vestibular rehabilitation|conventional vestibular rehabilitation
219369897|NCT01474655|PROCEDURE|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
219369898|NCT00814242|PROCEDURE|surgical resection|radical resection performed in patinets with HCC.
219369899|NCT00814242|PROCEDURE|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
219369900|NCT00974987|RADIATION|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
219369901|NCT00974987|RADIATION|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
219369902|NCT00974987|DRUG|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
219369903|NCT02846103|OTHER|Biological samples|blood and tumor tissue samples
219369904|NCT01565980|BEHAVIORAL|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
219369905|NCT01565980|BEHAVIORAL|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
219369906|NCT01416363|DRUG|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
219369907|NCT01416363|DRUG|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
219369908|NCT01416363|DRUG|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
219369909|NCT05827757|BIOLOGICAL|autologous adipose-derived mesenchymal stem cell transplantation|Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90
219369910|NCT05536323|DRUG|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years
219369911|NCT05536323|DRUG|Remimazolam continuous|Remimazolam 12 mg/kg/hr
219369912|NCT00895830|DRUG|APD405|IV
219369913|NCT00895830|DRUG|Placebo|IV
219369914|NCT05920798|PROCEDURE|Biopsy|Undergo biopsy
219369915|NCT05920798|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219369916|NCT05920798|PROCEDURE|Computed Tomography|Undergo CT
219369917|NCT05920798|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219369918|NCT05920798|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
219369919|NCT05920798|BIOLOGICAL|Pembrolizumab|Given IV
219369920|NCT05920798|PROCEDURE|Pheresis|Undergo apheresis
219369921|NCT02750670|DRUG|Obinutuzumab|Type II anti-CD20 monoclonal antibody
219369922|NCT02750670|DRUG|Gemcitabine|Antineoplastic agent
219369923|NCT02750670|DRUG|Dexamethasone|Corticosteroid
219369924|NCT02750670|DRUG|Cisplatin|Antineoplastic Agent
219369925|NCT00881660|DEVICE|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
219369926|NCT03099733|OTHER|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
219369927|NCT04714372|DRUG|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
219369928|NCT04714372|DRUG|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
219369929|NCT04714372|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
219369930|NCT04714372|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
219369931|NCT01938157|PROCEDURE|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
219369932|NCT03219164|DRUG|AZLI|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
219369933|NCT03219164|DRUG|Placebo|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
219369934|NCT04265066|DIAGNOSTIC_TEST|microcirculation|measurement of microcirculation
219369935|NCT01334398|BEHAVIORAL|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
219369936|NCT02126059|BEHAVIORAL|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
219369937|NCT02126059|BEHAVIORAL|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
219369938|NCT02126059|BEHAVIORAL|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
219369939|NCT02029976|BEHAVIORAL|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
219369940|NCT02029976|BEHAVIORAL|Mailed monthly newsletters|Newsletters
219369941|NCT04617808|OTHER|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~* Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~* Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~* If possible, patient information on the collection of their data for research and possibility of opposing~* Filling of a medical questionnaire by the regulating doctor~* Weekly collection of medical questionnaires by investigating doctors"
219369942|NCT03733912|OTHER|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
219557725|NCT04330547|DRUG|Analgesic administration|"* Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
219557726|NCT04330547|DRUG|Placebo administration|Folavit (folic acid, 0.4 mg)
219006965|NCT02781051|OTHER|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
219006966|NCT04630418|OTHER|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
219006967|NCT00255827|BIOLOGICAL|HyperAcute-Pancreatic Cancer Vaccine|
219369943|NCT01142414|BIOLOGICAL|panitumumab|
219369944|NCT01142414|DRUG|cisplatin|
219369945|NCT01142414|DRUG|fluorouracil|
219369946|NCT01142414|OTHER|laboratory biomarker analysis|
219369947|NCT01142414|PROCEDURE|adjuvant therapy|
219369948|NCT01142414|PROCEDURE|quality-of-life assessment|
219369949|NCT01142414|RADIATION|3-dimensional conformal radiation therapy|
219369950|NCT01142414|RADIATION|intensity-modulated radiation therapy|
219369951|NCT00295945|DRUG|fentanyl citrate|
219369952|NCT00295945|DRUG|hydromorphone hydrochloride|
219369953|NCT00295945|DRUG|ropivacaine hydrochloride|
219369954|NCT04643184|OTHER|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
219369955|NCT02303054|PROCEDURE|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
219369956|NCT01185847|DRUG|RO5083945|intravenously, until disease progression
219369957|NCT01185847|DRUG|cisplatin|standard treatment, up to 6 cycles
219369958|NCT01185847|DRUG|gemcitabine|standard treatment, up to 6 cycles
219369959|NCT01185847|DRUG|pemetrexed|standard treatment, up to 6 cycles
219369960|NCT00951821|BEHAVIORAL|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
219369961|NCT00951821|BEHAVIORAL|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
219369962|NCT05637255|DRUG|SYL1801|1 drop in the eligible eye
219369963|NCT01417676|RADIATION|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
219369964|NCT06146894|PROCEDURE|Single obturation technique (Bioceramic Sealer)|Root canal will be obturated using single cone technique using Bioceramic Sealer
219369965|NCT06146894|PROCEDURE|lateral condensation technique (Bioceramic Sealer)|Root canal will be obturated using lateral condensation technique using Bioceramic Sealer
219369966|NCT06146894|PROCEDURE|Warm Vertical condensation technique (Bioceramic Sealer)|Root canal will be obturated using vertical condensation technique using Bioceramic Sealer
219369967|NCT06146894|PROCEDURE|lateral condensation technique (AH Plus Sealer)|Root canal will be obturated using lateral condensation technique using AH plus Sealer
219369968|NCT06146894|PROCEDURE|Warm Vertical condensation technique (AH plus Sealer)|Root canal will be obturated using vertical condensation technique using AH plus Sealer
219369969|NCT04764435|OTHER|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
219369970|NCT04764435|OTHER|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
219369971|NCT05679206|DIAGNOSTIC_TEST|Echocardiography images|"Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient"
219369972|NCT05679206|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring|Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
219006968|NCT01737944|DRUG|Methotrexate (MTX)|Vibex MTX Device
219006969|NCT03569540|DRUG|Glibenclamide|Placebo-controlled; Double blind test
219006970|NCT03569540|OTHER|Placebo|Amylum
219006971|NCT00002925|DRUG|ara-C|
219006972|NCT00002925|DRUG|Daunorubicin|
219006973|NCT00002925|DRUG|Etoposide|
219369973|NCT05507957|DIAGNOSTIC_TEST|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
219369974|NCT00004479|DRUG|midodrine|
219369975|NCT04954482|OTHER|No Intervention|This is an observation study, with no intervention
219369976|NCT03856957|DEVICE|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
219369977|NCT03856957|DEVICE|control|colonoscopy without endocuff
219369978|NCT04006184|OTHER|Chart review|Retrospective review of medical records at a single site with six physicians
219369979|NCT03294993|DEVICE|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
219369980|NCT01341457|DRUG|LY2603618|Administered intravenously
219369981|NCT01341457|DRUG|Gemcitabine|Administered intravenously
219369982|NCT04222283|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
219369983|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
219369984|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
219369985|NCT00333216|OTHER|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
219369986|NCT05317767|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
219369987|NCT05317767|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
219369988|NCT02590029|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
219369989|NCT02590029|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
219369990|NCT02590029|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
219369991|NCT03422484|OTHER|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
219369992|NCT05555810|PROCEDURE|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
219369993|NCT00412256|DRUG|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
219369994|NCT01918254|DRUG|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
219369995|NCT01918254|DRUG|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
219369996|NCT01918254|DRUG|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
219369997|NCT02609581|DRUG|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
219369998|NCT02979756|PROCEDURE|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
219369999|NCT03124459|DRUG|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
219370000|NCT03124459|DRUG|Placebo|Recombinant fusion protein or buffer solution
219370001|NCT01116193|DRUG|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
219370002|NCT00496366|DRUG|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
219370003|NCT00496366|DRUG|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
219370004|NCT00576771|PROCEDURE|PSV|Pressure Support Ventilation
219370005|NCT00576771|PROCEDURE|NAVA|Neurally Adjusted Ventilatory Assist
219370006|NCT00576771|PROCEDURE|patient-controlled|assisted controlled MV through a button
219370007|NCT05135364|DRUG|Camrelizumab|Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
219370008|NCT05135364|DRUG|HAIC|A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
219370009|NCT05135364|DRUG|TKI|Lenvatinib or Regorafenib
219370010|NCT01475890|DIETARY_SUPPLEMENT|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
219370011|NCT01475890|DIETARY_SUPPLEMENT|Placebo|Once a day for 12 months.
219370012|NCT01740336|DRUG|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
219370013|NCT01740336|DRUG|Placebo|Placebo matching to GDC-0941
219370014|NCT01740336|DRUG|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
219370015|NCT01717638|BIOLOGICAL|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
219370016|NCT01717638|BIOLOGICAL|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
219370017|NCT02570451|OTHER|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
219370018|NCT02570451|OTHER|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
219370019|NCT02570451|OTHER|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
219370020|NCT02570451|OTHER|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
219370021|NCT02570451|OTHER|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
219370022|NCT02570451|OTHER|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
219370023|NCT02570451|OTHER|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
219370024|NCT02570451|OTHER|Grip Strength|Measured using the JAMAR dynamometer
219370025|NCT05704114|DRUG|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
219370026|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation A|
219370027|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation B|
219370028|NCT00687453|DRUG|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
219370029|NCT00687453|DRUG|NPH twice-daily|Addition of morning NPH to bedtime NPH
219557727|NCT05841693|DRUG|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
219557728|NCT05841693|DRUG|Placebo|The control group will be offered same amount of placebo fluid.
219006974|NCT00002925|DRUG|PSC-833|
219006975|NCT00002925|BIOLOGICAL|Aldesleukin|
219191610|NCT04099472|BEHAVIORAL|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
219191611|NCT04151550|DEVICE|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
219191612|NCT06141733|OTHER|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
219191613|NCT06310668|BEHAVIORAL|group cognitive behavioral therapy sessions|12 group CBT sessions based on catching and challenging cognitive errors and behavioral techniques to deal with substance use problems
219191614|NCT00661141|DRUG|Antizol|
219191615|NCT00661141|DRUG|Placebo|
219191616|NCT00661141|OTHER|Ethanol|oral dose of ethanol (0.5 g/kg)
219191617|NCT05203835|DRUG|Acebilustat|By mouth, once a day, 100 mg capsule
219191618|NCT05203835|DRUG|Placebo|Placebo to match acebilustat by mouth, once a day
219191619|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 1|Our current hearing aids which will be programmed to our standard frequency response curve.
219191620|NCT05828017|DEVICE|Hearing Aid - Variation #1 under Program 1|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
219191621|NCT05828017|OTHER|Hearing Aid - Variation #2 under Program 5 - Streaming Only|Our current hearing aids which will be programmed to our standard frequency response curve.
219191622|NCT05828017|OTHER|Hearing Aid - Variation #3 under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #3 adjusted and fit to the participant's hearing loss.
219191623|NCT05828017|OTHER|Hearing Aid - Variation #4under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #4 adjusted and fit to the participant's hearing loss.
219191624|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 2|Our current hearing aids which will be programmed to our standard frequency response curve.
219191625|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 2|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
219191626|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 3|Our current hearing aids which will be programmed to our standard frequency response curve.
219191627|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 3|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
219191628|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 4|Our current hearing aids which will be programmed to our standard frequency response curve.
219191629|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 4|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
219191630|NCT05828017|OTHER|Unaided|No hearing aids worn at all and participants tested as is.
219191631|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
219191632|NCT05005416|BEHAVIORAL|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
219191633|NCT05005416|BEHAVIORAL|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
219191634|NCT06412263|PROCEDURE|Routine root canal treatment/ retreatment|It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
219191635|NCT05012163|BEHAVIORAL|Reminder|Letter, short message service (SMS) text, phone, and/or email
219191636|NCT05012163|BEHAVIORAL|Financial incentive|Letter, SMS, phone, and/or email
219191637|NCT05012163|BEHAVIORAL|Lottery|Letter, SMS, phone, and/or email
219191638|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
219191639|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
219191640|NCT05584683|DRUG|Amoxicillin potassium clavulanate|LP-001 will be reconstituted and administered as a single dose
219191641|NCT05584683|DRUG|Amoxicillin potassium clavulanate (Augmentin ES-600)|Augmentin ES-600 will be reconstituted and administered as a single dose
219191642|NCT04104633|PROCEDURE|Blood samples|30 ml of blood collection
219191643|NCT04260867|OTHER|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
219191644|NCT04260867|OTHER|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
219191645|NCT04896580|BEHAVIORAL|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
219370030|NCT06959927|OTHER|Standard Care Group|"Patients in this group received conventional hemodialysis care, including:~Continuous monitoring of vital signs (blood pressure, respiratory rate, pulse, heart rhythm); Supplemental oxygen therapy as needed; Instruction on effective coughing techniques; Strict fluid and electrolyte management; Metabolic support therapies; Positional adjustments (upright posture with lower limb dependency); Environmental regulation (temperature: 22-24°C; humidity: 50-60%); Individualized dietary counseling."
219370031|NCT06959927|OTHER|Risk-Stratified Management Group|"Patients in this group received standard care plus targeted risk management interventions:~System Enhancement:~Standardized nursing protocols and accountability frameworks Competency-based staff training (emergency response, fluid management) Individualized care plans (e.g., intensified glycemic control for diabetics, optimized BP monitoring for hypertensives)~Risk Stratification:~Admission assessments and follow-up evaluations to identify high-risk patients Hemodynamic monitoring with alert thresholds for early deterioration detection Strict pharmacological supervision and fluid balance protocols~Environmental Modification:~Optimized dialysis unit conditions (temperature: 22-24°C; humidity: 50-60%) Dedicated cardiac care zones for HF patients~Quality Control:~Quarterly audits of critical care domains (patient education, vital signs documentation, protocol compliance, satisfaction metrics) Corrective actions for identified deficiencies"
219370032|NCT05591781|DEVICE|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
219370033|NCT05591781|DEVICE|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
219370034|NCT03051633|BEHAVIORAL|Be Under Your Own Influence|School based anti-drug use communications campaign
219370035|NCT05211336|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
219370036|NCT05211336|DRUG|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
219370037|NCT05211336|DRUG|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
219370038|NCT05211336|DRUG|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
219370039|NCT05211336|DRUG|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
219370040|NCT05211336|DRUG|Acetaminophen|650 mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
219370041|NCT05211336|DRUG|Diphenhydramine|50mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
219370042|NCT05211336|OTHER|Peg-filgrastim|6 mg subcutaneous once on day 8 only.
219370043|NCT05211336|DIAGNOSTIC_TEST|CT Scan (chest, abdomen, and pelvis)|To assess sites of disease.
219370044|NCT05211336|DIAGNOSTIC_TEST|MRI|If clinically indicated.
219370045|NCT05211336|DIAGNOSTIC_TEST|18f-FDG-PET|If clinically indicated.
219370046|NCT05211336|DIAGNOSTIC_TEST|PET|If clinically indicated.
219370047|NCT05211336|DIAGNOSTIC_TEST|Lumbar puncture/Ommaya tap|If clinically indicated.
219370048|NCT05211336|DIAGNOSTIC_TEST|Bone marrow aspiration/biopsy|If clinically indicated.
219370049|NCT05211336|COMBINATION_PRODUCT|EKG|To determine eligibility.
219370050|NCT05408689|DEVICE|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
219370051|NCT05408689|DEVICE|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
219370052|NCT05408689|DEVICE|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
219370053|NCT04271761|OTHER|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
219370054|NCT01784887|DRUG|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
219370055|NCT06203054|DEVICE|Penditure™ Left Atrial Appendage (LAA) Exclusion System|Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
219370056|NCT02733029|DRUG|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
219370057|NCT02733029|DEVICE|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
219370058|NCT03575104|DRUG|Daridorexant|Daridorexant will be administered as tablets, orally, once daily in the evening.
219370059|NCT03575104|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
219370060|NCT04988698|OTHER|none intervention|none intervention
219370061|NCT00434967|DRUG|Candesartan cilexetil|32 mg oral tablet
219370062|NCT00434967|DRUG|Hydrochlorothiazide|25 mg oral tablet
219370063|NCT00434967|DRUG|Candesartan/HCT 32/25 mg|
219370064|NCT05749835|OTHER|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
219370065|NCT05749835|OTHER|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
219370066|NCT03695029|DRUG|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
219370067|NCT03226990|OTHER|impression technique|impression technique with and without wax spacer
219370068|NCT00751413|DRUG|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
219370069|NCT04355013|DEVICE|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
219370070|NCT04200612|BEHAVIORAL|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
219370071|NCT04200612|BEHAVIORAL|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
219370072|NCT04200612|OTHER|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
219370073|NCT01838057|DEVICE|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
219370074|NCT01838057|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
219370075|NCT04274439|OTHER|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
219370076|NCT04274439|OTHER|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
219370077|NCT02972827|DEVICE|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
219370078|NCT02972827|OTHER|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
219370079|NCT00003956|DRUG|fluorouracil|
219370080|NCT00003956|DRUG|leucovorin calcium|
219370081|NCT00003956|DRUG|lonafarnib|
219370082|NCT03011229|DEVICE|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
219370083|NCT03011229|DEVICE|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
219370084|NCT02752828|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219370085|NCT02752828|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219370086|NCT02752828|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
219370087|NCT04929639|OTHER|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
219370088|NCT03224286|DEVICE|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
219370089|NCT03542838|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
219370090|NCT03542838|DRUG|Saline|Saline is a normal physiological solution
219370091|NCT02372617|PROCEDURE|periacetabular osteotomy|
219370092|NCT06959953|OTHER|Low-cost model|The primary structure of a low-cost training model fashioned from an old portable 3-drawer organizer unit repurposed to serve as the foundation for the training apparatus. This training apparatus will act as the experimental arm to compare it to the Airway Part-Task Trainer in FBTI.
219370093|NCT06959953|OTHER|Airway Part-task Trainer|Training using Airway Part-Task Trainer
219370094|NCT06959966|COMBINATION_PRODUCT|Placebo|Starch capsule, 4 grams, two capsules per day for six months.
219370095|NCT06959966|COMBINATION_PRODUCT|Oligo Fucoidan|Oligo fucoidan capsule, 4 grams, two capsules per day for six months.
219370096|NCT01586988|BEHAVIORAL|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
219370097|NCT02204904|GENETIC|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
219370098|NCT06289569|OTHER|Home telerehabilitation therapy|Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
219370099|NCT00408005|DRUG|Asparaginase|Given IM or IV
219370100|NCT00408005|DRUG|Cyclophosphamide|Given IV
219370101|NCT00408005|DRUG|Cytarabine|Given IT, IV, or SC
219370102|NCT00408005|DRUG|Daunorubicin Hydrochloride|Given IV
219370103|NCT00408005|DRUG|Dexamethasone|Given IV or PO
219370104|NCT00408005|DRUG|Doxorubicin Hydrochloride|Given IV
219370105|NCT00408005|OTHER|Laboratory Biomarker Analysis|Correlative studies
219370106|NCT00408005|DRUG|Leucovorin Calcium|Given PO
219370107|NCT00408005|DRUG|Mercaptopurine|Given PO
219370108|NCT00408005|DRUG|Methotrexate|Given IT or PO
219370109|NCT00408005|DRUG|Nelarabine|Given IV
219370110|NCT00408005|DRUG|Pegaspargase|Given IM or IV
219370111|NCT00408005|DRUG|Prednisone|Given IV or PO
219370112|NCT00408005|RADIATION|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
219370113|NCT00408005|DRUG|Thioguanine|Given PO
219370114|NCT00408005|DRUG|Vincristine Sulfate|Given IV
219370115|NCT00962845|DRUG|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
219370116|NCT06475300|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219370117|NCT06475300|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
219370118|NCT01430351|DRUG|Mefloquine|Given PO
219370119|NCT01430351|DRUG|Memantine Hydrochloride|Given PO
219370120|NCT01430351|DRUG|Metformin Hydrochloride|Given PO
219370121|NCT01430351|DRUG|Temozolomide|Given PO
219370122|NCT06462417|DRUG|Arbidol|Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
219370123|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
219370124|NCT04809766|DRUG|Cyclophosphamide|Given IV
219370125|NCT04809766|DRUG|Fludarabine|Given IV
219370126|NCT04809766|DRUG|Bendamustine|Given IV
219370127|NCT03155997|DRUG|Abemaciclib|Administered orally.
219370128|NCT03155997|DRUG|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
219370129|NCT01848145|DRUG|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of \>= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE \>= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
219370130|NCT02145494|RADIATION|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
219370131|NCT01799876|PROCEDURE|Autologous Cell|
219370132|NCT01799876|PROCEDURE|Standard microfracture arthroscopic surgery|
219370133|NCT02660125|PROCEDURE|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
219370134|NCT00773487|OTHER|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
219370135|NCT02692625|DIETARY_SUPPLEMENT|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
219370136|NCT02692625|DIETARY_SUPPLEMENT|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
219370137|NCT03803527|PROCEDURE|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
219370138|NCT02347631|DEVICE|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
219754263|NCT02438761|DRUG|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
219370139|NCT02347631|DEVICE|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
219370140|NCT01830530|DRUG|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
219370141|NCT01830530|DRUG|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
219370142|NCT01830530|DRUG|placebo|two tablets daily in the morning
219370143|NCT00501228|DRUG|Filgrastim|5 mg/kg ID Once Daily x 1 Week
219370144|NCT03982550|BEHAVIORAL|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
219370145|NCT05859035|DEVICE|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
219370146|NCT04285320|DRUG|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water"
219370147|NCT04285320|DRUG|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)"
219370148|NCT00203684|DRUG|Flunisolide-HFA|
219370149|NCT01219842|PROCEDURE|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
219370150|NCT01219842|OTHER|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
219370151|NCT02960282|PROCEDURE|Biospecimen Collection|Undergo collection of fecal specimens
219370152|NCT02960282|OTHER|Laboratory Biomarker Analysis|Correlative studies
219370153|NCT01438645|DEVICE|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
219370154|NCT00848744|DRUG|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
219370155|NCT00848744|DRUG|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
219370156|NCT02673255|BIOLOGICAL|Tetanus and Diphtheria (Td) Vaccine|
219000588|NCT04336085|PROCEDURE|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
219370157|NCT04472728|DRUG|BIO101|BIO101 capsules
219370158|NCT04472728|DRUG|Placebo|placebo capsules
219370159|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
219370160|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
219370161|NCT05024006|DRUG|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
219370162|NCT05024006|DRUG|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
219370163|NCT05024006|DRUG|Lopinavir / Ritonavir|Orally twice daily for 14 days
219370164|NCT05024006|DRUG|Interferon beta-1a|Daily injection for 6 days
219370165|NCT05024006|DRUG|Acalabrutinib|Orally twice daily for 10 days
219754264|NCT07013409|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
219000589|NCT02877381|PROCEDURE|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
219370166|NCT03585140|OTHER|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
219370167|NCT03585140|OTHER|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
219370168|NCT03585140|DRUG|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
219370169|NCT03585140|DRUG|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
219370170|NCT05448625|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
219370171|NCT03719235|OTHER|CBCT|ultra-low dose CBCT
219000590|NCT02877381|PROCEDURE|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
219000591|NCT00920998|DRUG|Z-338|oral
219186873|NCT05326451|DEVICE|active tDCS|Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
219186874|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
219186875|NCT05058417|DRUG|Empagliflozin 10 MG|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
219186876|NCT05058417|DRUG|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
219186877|NCT04231149|DEVICE|Test product 2|Test catheter 2
219186878|NCT04231149|DEVICE|Test product 3|Test catheter 3
219186879|NCT04231149|DEVICE|Comparator|SpeediCath Flex
219186880|NCT04974632|PROCEDURE|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
219186881|NCT05292157|PROCEDURE|shoulder arthroplasty|range of motion (in degrees) measured in annual postoperative follow-up
219186882|NCT05718583|DIETARY_SUPPLEMENT|Butyrate|"Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an evaluable participant will be 2 weeks of SCFA supplementation."
219186883|NCT04506307|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
219186884|NCT04298983|DRUG|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
219186885|NCT04298983|DRUG|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
219186886|NCT04298983|RADIATION|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
219186887|NCT02567669|RADIATION|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
219370172|NCT03291314|DRUG|Axitinib|1\. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
219370173|NCT03291314|DRUG|Avelumab|2\. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
219370174|NCT05085509|PROCEDURE|US guidance and MB staining|Ultrasound guidance and methylene blue staining
219370175|NCT03625531|OTHER|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
219370176|NCT03625531|DRUG|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
219370177|NCT03625531|DRUG|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
219370178|NCT06192979|DRUG|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
219370179|NCT06192979|DRUG|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
219370180|NCT06192979|DRUG|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
219370181|NCT06192979|DRUG|Venetoclax|All patients received venetoclax 400mg daily.
219370182|NCT00250692|DRUG|Nitrous Oxide|
219370183|NCT05373550|BEHAVIORAL|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
219370184|NCT00331006|DRUG|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
219000592|NCT04400591|BIOLOGICAL|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
219186888|NCT05606237|DEVICE|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
219000593|NCT00519831|BIOLOGICAL|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
219186889|NCT03121404|PROCEDURE|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
219186890|NCT06258330|DRUG|AM003|Bispecific Personalized Aptamer for intratumoral administration
219186891|NCT01526096|DRUG|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
219186892|NCT01526096|DRUG|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
219186893|NCT01526096|PROCEDURE|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
219186894|NCT01526096|DRUG|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
219186895|NCT01526096|PROCEDURE|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
219186896|NCT01526096|DRUG|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
219186897|NCT01526096|DEVICE|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
219186898|NCT04296097|DEVICE|DBS|Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
219186899|NCT06145334|BEHAVIORAL|Veterans Social|Peer-led weekly community-based social groups (16 weeks) that are current treatment at the study site.
219186900|NCT02216032|OTHER|TMW Curriculum|
219186901|NCT02216032|OTHER|Nutrition Curriculum|
219186902|NCT02116530|DRUG|Olanzapine|oral
219186903|NCT02116530|DRUG|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
219186904|NCT02116530|DRUG|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
219186905|NCT02116530|OTHER|Placebo|oral
219186906|NCT05842876|DEVICE|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
219186907|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
219186908|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
219186909|NCT05842876|OTHER|Satisfaction Survey|Survey to assess which method of monitoring is preferred
219186910|NCT06128993|OTHER|Transcoronary cooling and dilution|Transcoronary cooling and dilution
219186911|NCT06128993|OTHER|Standard of care|Routine clinical care
219186912|NCT01148849|BIOLOGICAL|margetuximab|margetuximab
219186913|NCT03656510|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
219186914|NCT03656510|DRUG|Placebo|Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
219186915|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
219186916|NCT06044311|DRUG|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
219186917|NCT06044311|DRUG|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
219370185|NCT03388593|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
219370186|NCT03388593|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
219370187|NCT05595278|DIAGNOSTIC_TEST|(CBC) ,(NT-proBNP) ,(cTnT)|complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.
219370188|NCT05131061|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
219370189|NCT03804684|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
219754265|NCT07013409|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
219000594|NCT00519831|DRUG|vinflunine|Vinflunine 320 mg/m² every 21 days
219000595|NCT02150317|PROCEDURE|TACE+Sorafenib|TACE followed by Sorafenib
219186918|NCT06044311|RADIATION|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
219186919|NCT05243888|DIAGNOSTIC_TEST|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
219186920|NCT06502561|DRUG|Aramchol meglumine|Aramchol meglumine is a salt form of Aramchol free acid
219186921|NCT06502561|DRUG|Aramchol free acid|Aramchol free acid is a fatty acid-bile acid conjugate
219186922|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
219186923|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
219186924|NCT04074135|DRUG|68-Gallium DOTATATE|68-Gallium DOTATATE, to be used in yearly PET/CT research scans
219186925|NCT03749902|DRUG|Oral misoprostol|"* An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
219186926|NCT03749902|DRUG|Oxytocin|"* Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured."
219186927|NCT05098184|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219186928|NCT06189495|DRUG|GenSci048|1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
219186929|NCT06189495|DRUG|GenSci048 placebo|"1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4\. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
219186930|NCT03617731|DRUG|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
219186931|NCT03617731|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
219186932|NCT03617731|DRUG|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
219186933|NCT03617731|DRUG|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
219186934|NCT06059014|DRUG|177Lu-PSMA-1 (radiopharmaceutical)|7.4 GBq (or 5.9 GBq in case of lower actvity) of 177Lu-PSMA-1, every 6 weeks for 4 administirations
219186935|NCT05376111|DRUG|Venetoclax, Azacitidine|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
219186936|NCT03737864|BEHAVIORAL|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
219186937|NCT03737864|BEHAVIORAL|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
219186938|NCT06441682|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
219186939|NCT06441682|OTHER|Placebo|Intravenous infusion of placebo
219186940|NCT02305888|DRUG|LEO 43204|Treatment of actinic keratosis
219186941|NCT02483312|BIOLOGICAL|IL-12|
219186942|NCT06232590|DEVICE|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
219186943|NCT06232590|DEVICE|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
219186944|NCT05573074|DEVICE|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
219186945|NCT05573074|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
219370190|NCT03804684|DIAGNOSTIC_TEST|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
219370191|NCT05722184|DIAGNOSTIC_TEST|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
219370192|NCT02542488|OTHER|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI \>35 kg/m2? A: Are you \>50 years old? N: Is your neck circumference \>40cm? G: Is your gender male?"
219370193|NCT02542488|DIAGNOSTIC_TEST|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
219370194|NCT02542488|OTHER|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
219370195|NCT03644290|BEHAVIORAL|Cognitive training|Five sessions of semantic strategy training and face-name association training
219370196|NCT03644290|BEHAVIORAL|Control Condition|Five sessions of active control information and education
219370197|NCT02310620|BEHAVIORAL|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
219370198|NCT02736903|BEHAVIORAL|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
219370199|NCT02736903|BEHAVIORAL|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
219370200|NCT02052102|RADIATION|Radiation therapy|
219370201|NCT06422182|DRUG|Bupivacain 25% (Erector Spinae Plane Block)|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
219370202|NCT06422182|DRUG|Morphine (Intravenous patient-controlled analgesia)|Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
219370203|NCT02780791|OTHER|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
219370204|NCT02780791|OTHER|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
219370205|NCT05428709|BEHAVIORAL|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
219370206|NCT05926427|DRUG|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
219370207|NCT05926427|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
219370208|NCT05926427|DRUG|Chemotherapy|Not specified, recommended regimen according to histopathologic type
219370209|NCT01290627|DEVICE|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
219370210|NCT01290627|DEVICE|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
219370211|NCT06020794|BEHAVIORAL|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
219370212|NCT06020794|BIOLOGICAL|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
219370213|NCT04004949|OTHER|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
219370214|NCT00923429|PROCEDURE|Stay-active care|No other treatment than the stay-active care
219370215|NCT00923429|PROCEDURE|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
219370216|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
219370217|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
219370218|NCT05799014|PROCEDURE|CT-guided percutaneous lung biopsy|The participants would undergo CT-guided percutaneous lung biopsy.
219370219|NCT05799014|PROCEDURE|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology|The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.
219370220|NCT03304522|DRUG|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
219000596|NCT02150317|PROCEDURE|TACE|TACE alone
219000597|NCT02854631|DRUG|Selonsertib|18 mg tablet administered orally once daily
219000598|NCT02854631|DRUG|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
219000599|NCT02854631|DRUG|Placebo|Selonsertib placebo tablet administered orally once daily
219370221|NCT03304522|DRUG|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
219370222|NCT01784835|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
219370223|NCT01784835|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
219370224|NCT02952976|DEVICE|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
219370225|NCT02952976|DEVICE|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
219370226|NCT01217502|BEHAVIORAL|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
219370227|NCT01217502|BEHAVIORAL|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
219370228|NCT02415790|DRUG|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
219370229|NCT02415790|DRUG|E2027 matching placebo|E2027 matching placebo capsule will be administered.
219370230|NCT01708031|OTHER|physiological signals|
219370231|NCT01474590|DRUG|Epiduo/Tactuo|topical to the face, once daily in the evening
219370232|NCT01474590|OTHER|vehicle gel|topical to the face, once daily in the evening
219370233|NCT01474590|DRUG|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
219370234|NCT01474590|DRUG|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
219370235|NCT03038347|BEHAVIORAL|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
219370236|NCT03038347|BEHAVIORAL|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
219370237|NCT00486603|DRUG|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
219370238|NCT00486603|DRUG|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
219370239|NCT00486603|OTHER|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
219370240|NCT00486603|RADIATION|Radiation|Radiation during the first six weeks of treatment Monday-Friday
219370241|NCT03939234|COMBINATION_PRODUCT|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
219370242|NCT01958957|DRUG|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
219370243|NCT01305512|DRUG|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
219370244|NCT04401657|DIAGNOSTIC_TEST|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
219370245|NCT05075668|DEVICE|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
219370246|NCT05075668|DEVICE|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
219000600|NCT04232995|OTHER|Balance Training|Balance enhancing exercises
219370247|NCT00367211|DRUG|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
219370248|NCT00367211|DRUG|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
219370249|NCT05069584|PROCEDURE|Biopsy|patient must have a biopsy for his prostate cancer
219370250|NCT00747487|DRUG|Idebenone|Idebenone 900 mg/day
219370251|NCT00747487|DRUG|Placebo|Placebo
219370252|NCT05340972|DIAGNOSTIC_TEST|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
219370253|NCT00331305|BEHAVIORAL|Supervised Exercise|
219370254|NCT00331305|BEHAVIORAL|Home-Based Exercise|
219370255|NCT00331305|DRUG|Sertraline (Zoloft)|
219370256|NCT00331305|DRUG|Placebo Pill|
219370257|NCT00037648|DRUG|Anakinra|anakinra
219370258|NCT00037648|DRUG|Placebo|placebo
219370259|NCT01670994|BIOLOGICAL|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
219370260|NCT01736046|RADIATION|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
219370261|NCT03696329|DRUG|Tetrabenazine Tablets 25 mg|
219370262|NCT03314506|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
219370263|NCT02013544|DRUG|Placebo|
219370264|NCT02013544|DRUG|Prasterone (DHEA)|
219370265|NCT02785809|OTHER|Pausing oral contraceptive|
219370266|NCT04741373|DIETARY_SUPPLEMENT|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
219370267|NCT04741373|BEHAVIORAL|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
219370268|NCT04741373|OTHER|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
219370269|NCT02557087|DRUG|Hyoscine|
219370270|NCT02557087|DRUG|Pethidine|
219370271|NCT05503355|DRUG|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
219370272|NCT05503355|DRUG|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
219370273|NCT00837187|DRUG|Intravenous dexmedetomidine|100 ug
219370274|NCT00837187|DRUG|Intranasal dexmedetomidine|100 ug
219370275|NCT06487013|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
219370276|NCT06487013|OTHER|Sham MRgHIFU treatment|Sham MRgHIFU treatment
219370277|NCT03110588|DRUG|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
219370278|NCT03110588|DRUG|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
219000601|NCT04232995|OTHER|General Exercises|General Exercises
219186946|NCT06818370|OTHER|Coconut Oil|The coconut oil application protocol will be explained to the patients in the experimental group and 10 milliliters of coconut oil will be applied to the hair follicles once a week. Alopecia assessment will be done every week.
219186947|NCT05174767|DEVICE|AMDS|AMDS Implantation
219186948|NCT04673032|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain
219186949|NCT04012606|DRUG|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
219186950|NCT06672809|BEHAVIORAL|Core Stability Training|Participants in this group undergo core stability training sessions targeting deep stabilizing muscles. The exercises are designed to enhance spinal support and core control by activating the transversus abdominis and other core muscles. Sessions involve the use of a Pilates reformer and other unstable surfaces, fostering proprioceptive engagement and improved muscle coordination. Training is conducted three times per week for eight weeks, with each session lasting 50 minutes.
219186951|NCT06672809|BEHAVIORAL|Aerobic Exercise|Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
219186952|NCT04914676|DRUG|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
219186953|NCT04914676|DRUG|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
219186954|NCT04610372|RADIATION|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
219186955|NCT04610372|RADIATION|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
219186956|NCT04610372|RADIATION|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
219186957|NCT04610372|RADIATION|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
219186958|NCT03518606|DRUG|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
219186959|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
219186960|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
219186961|NCT06408506|PROCEDURE|Re-Entry Surgery|Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration
219186962|NCT06408506|PROCEDURE|Probing peri-implant bone|Probing peri-implant bone with Dental Probe during surgery
219186963|NCT06408506|PROCEDURE|Scanning peri-implant bone|Scanning peri-implant bone during surgery
219186964|NCT06408506|PROCEDURE|Conventional Impressions|Conventional Impressions during surgery
219186965|NCT06408506|PROCEDURE|Implant Surgery|Placement of 6 implants in the edentulous mandible
219186966|NCT06408506|PROCEDURE|Healing procedure|"All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures"
219186967|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
219186968|NCT06096311|OTHER|Interviews|Interviews
219186969|NCT06176963|COMBINATION_PRODUCT|SB11 PFS|SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
219186970|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
219186971|NCT05343572|DRUG|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
219186972|NCT03496922|BEHAVIORAL|Experimental Tobacco Marketplace|See arm group description.
219186973|NCT02652078|DEVICE|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
219370279|NCT01295125|DEVICE|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
219370280|NCT01295125|PROCEDURE|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
219370281|NCT03182439|DEVICE|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
219370282|NCT03182439|DEVICE|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
219006976|NCT04726423|OTHER|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
219006977|NCT04387175|DEVICE|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
219006978|NCT04387175|DEVICE|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
219006979|NCT06088550|DIETARY_SUPPLEMENT|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
219006980|NCT06088550|OTHER|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
219006981|NCT05417061|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
219006982|NCT00022139|DRUG|carboplatin|
219006983|NCT00022139|DRUG|fluorouracil|
219006984|NCT00022139|DRUG|paclitaxel|
219006985|NCT00022139|PROCEDURE|conventional surgery|
219006986|NCT00022139|RADIATION|radiation therapy|
219006987|NCT01643655|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
219006988|NCT02030392|BEHAVIORAL|Intervention group|Cognitive-behavioral intervention
219006989|NCT02030392|BEHAVIORAL|Active control group|Education and information
219006990|NCT01402544|DRUG|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
219006991|NCT04158440|DRUG|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
219006992|NCT04158440|DRUG|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
219006993|NCT05133453|DRUG|Pirfenidone|drug intake three times daily for one year
219006994|NCT01324765|BEHAVIORAL|TARGET|12-session group therapy twice weekly 6 weeks
219006995|NCT01324765|BEHAVIORAL|SGT|12 sessions supportive group therapy twice weekly 6 weeks
219006996|NCT00186381|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
219006997|NCT05331274|OTHER|exercise group|"1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance"
219006998|NCT05331274|OTHER|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
219006999|NCT05060055|PROCEDURE|Immediate dental implant placement|Immediate dental implant placement
219007000|NCT04350840|BEHAVIORAL|feedback|feedback of optical diagnosis performance per 3 month
219007001|NCT02430584|OTHER|Observational - no intervention|
219007002|NCT06254586|PROCEDURE|Aerobic exercises|This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
219370283|NCT03182439|DEVICE|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
219370284|NCT03182439|DEVICE|Apple Watch|Apple Watch Heart Rate Monitoring Device
219370285|NCT05229939|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
219370286|NCT05729841|OTHER|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
219370287|NCT00003558|DRUG|carboplatin|
219370288|NCT00003558|DRUG|etoposide|
219370289|NCT00003558|DRUG|fluorouracil|
219370290|NCT00003558|DRUG|leucovorin calcium|
219370291|NCT00003558|DRUG|paclitaxel|
219370292|NCT00474916|DRUG|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
219370293|NCT00474916|DRUG|Placebo|Normal Saline given as dose escalation for placebo
219370294|NCT01247857|DRUG|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
219370295|NCT01247857|DRUG|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
219370296|NCT01247857|DRUG|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
219370297|NCT02036320|DEVICE|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
219370298|NCT00701987|DRUG|ALS-357|Topical application of ALS-357
219370299|NCT00456703|OTHER|intraoperative fluid management|fluid restriction
219370300|NCT00456703|OTHER|fluid restriction|restriction of fluids
219370301|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
219370302|NCT03013465|OTHER|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
219370303|NCT01008345|DRUG|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
219370304|NCT00723684|OTHER|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
219370305|NCT00723684|OTHER|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
219370306|NCT00885365|DRUG|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
219370307|NCT00885365|DRUG|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
219754266|NCT06689072|OTHER|rTMS|To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
219007003|NCT06254586|PROCEDURE|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
219754267|NCT06689072|BEHAVIORAL|Psychotherapy|Using psychotherapy in opioid use disorder.
219370308|NCT00417872|DRUG|Nitazoxanide|
219370309|NCT00417872|DRUG|Metronidazole|
219370310|NCT03030963|OTHER|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
219370311|NCT03030963|OTHER|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
219370312|NCT01824979|DEVICE|CPAP mask ( Pilairo)|
219370313|NCT01824979|PROCEDURE|Other CPAP mask|
219370314|NCT01982825|BEHAVIORAL|Online intervention arm|See online intervention arm
219370315|NCT01982825|BEHAVIORAL|Online control arm|See online control arm
219370316|NCT02133417|DEVICE|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
219370317|NCT03807531|DEVICE|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
219370318|NCT03102229|OTHER|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
219370319|NCT03102229|OTHER|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
219370320|NCT01625806|DRUG|RO4602522|Single oral dose
219000602|NCT04653961|DEVICE|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
219000603|NCT04662125|DRUG|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
219000604|NCT04662125|DRUG|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
219000605|NCT04662125|DRUG|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
219000606|NCT03544658|PROCEDURE|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
219000607|NCT03544658|PROCEDURE|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
219000608|NCT03544658|PROCEDURE|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
219000609|NCT03544658|PROCEDURE|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
219000610|NCT00268593|DRUG|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
219000611|NCT00268593|DRUG|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
219000612|NCT00268593|DRUG|prednisone|5 mg twice a day orally
219000613|NCT04945005|PROCEDURE|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
219000614|NCT02473432|PROCEDURE|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
219000615|NCT02473432|PROCEDURE|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
219000616|NCT02473432|PROCEDURE|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
219007004|NCT04934384|DIAGNOSTIC_TEST|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
219007005|NCT03428789|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
219007006|NCT00109889|PROCEDURE|magnetic resonance imaging|magnetic resonance imaging (MRI)
219007007|NCT00109889|PROCEDURE|positron emission tomography|positron emission tomography (PET)
219007008|NCT01314443|OTHER|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
219007009|NCT01314443|DIETARY_SUPPLEMENT|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
219007010|NCT01314443|OTHER|Placebo|Participants will take placebo for 7 days
219007011|NCT01314443|BEHAVIORAL|Smoking cessation|Participants will quit smoking without any pharmacological aids
219007012|NCT01072812|DRUG|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
219007013|NCT01980914|DEVICE|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
219007014|NCT02946645|DEVICE|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
219007015|NCT02946645|PROCEDURE|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
219007016|NCT02946645|OTHER|Placebo|No interventions.
219007017|NCT02680912|DEVICE|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
219007018|NCT02680912|DEVICE|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
219007019|NCT03097874|BEHAVIORAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
219007020|NCT03097874|BEHAVIORAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
219007021|NCT06300242|BEHAVIORAL|Reminders|Reminders
219007022|NCT06300242|BEHAVIORAL|Financial Incentive|$50 financial incentive for getting vaccinated within 1-week
219370321|NCT01625806|DRUG|ketoconazole|Multiple oral doses
219370322|NCT05196893|BEHAVIORAL|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
219370323|NCT01592994|BEHAVIORAL|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
219370324|NCT04850560|BIOLOGICAL|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
219370325|NCT06190587|DIETARY_SUPPLEMENT|Goji Berry|As a functional food goji berry contains 19 amino acids, 21 minerals, a wide range of carotenoids (β-Carotene, Neoxanthin, Cryptoxanthin, Zeaxanthin), polysaccharides, flavonoids, phytosterols, vitamin A, C and E.
219370326|NCT04281797|DIAGNOSTIC_TEST|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
219370327|NCT05503290|BEHAVIORAL|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
219370328|NCT06196502|OTHER|Gentle Human Touch (GHT)|Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.
219370329|NCT06196502|OTHER|Kangaroo Care|"Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total."
219370330|NCT06196502|OTHER|Lactation|Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
219370331|NCT01634932|OTHER|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
219370332|NCT01634932|OTHER|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
219370333|NCT01634932|OTHER|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
219370334|NCT01221857|DRUG|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
219370335|NCT06318884|DRUG|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
219370336|NCT04490889|DIAGNOSTIC_TEST|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
219370337|NCT01577862|DRUG|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
219370338|NCT01577862|DRUG|Rifampicin|600 mg every 12 hours intravenously
219754268|NCT06870916|OTHER|Multi-cancer Early Detection|Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.
219760817|NCT02234726|BEHAVIORAL|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
219760818|NCT04451759|OTHER|MRI exploration|ultra high field (7T) magnetic resonance imaging
219007023|NCT06300242|OTHER|Placebo|No special messages or incentives
219370339|NCT04430907|BIOLOGICAL|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
219370340|NCT05011487|DRUG|Osimertinib|80mg/qd oral for 60 days
219370341|NCT05011487|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
219370342|NCT05011487|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
219370343|NCT00006430|BIOLOGICAL|Autologous dendritic cells transfected with amplified tumor RNA|
219370344|NCT00135057|DRUG|insulin glulisine|
219370345|NCT00135057|DRUG|insulin glargine|
219370346|NCT00888238|DRUG|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
219370347|NCT00888238|DRUG|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
219370348|NCT05673538|DRUG|TT-00973-MS tablets treatment|The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
219370349|NCT03184844|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
219370350|NCT05265650|DRUG|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
219370351|NCT05265650|PROCEDURE|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
219370352|NCT03482869|DIAGNOSTIC_TEST|walking ability|Included patients will perform a 6 min walk test
219370353|NCT01748799|DRUG|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
219370354|NCT01748799|DRUG|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
219370355|NCT00850252|DEVICE|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
219370356|NCT01079767|DRUG|temsirolimus|
219370357|NCT03371355|DRUG|Placebo|Placebo (Matched with ISIS 703802)
219370358|NCT03371355|DRUG|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
219370359|NCT03371355|DRUG|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
219370360|NCT03371355|DRUG|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
219370361|NCT01997151|BEHAVIORAL|Healthy Pregnancy: Step by Step|
219370362|NCT01662648|DRUG|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
219370363|NCT02633540|RADIATION|IMRT Radiation|Radiation to Larynx
219370364|NCT06249750|DRUG|Immunotherapy|Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
219370365|NCT06249750|DRUG|Targeted therapy|Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
219370366|NCT06249750|DEVICE|Hyperthermia|"Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h."
219754269|NCT06874296|DEVICE|Quality Assessment with Normothermic Machine Perfusion (NMP)|"Quality assessment using NMP in the experimental arm is performed according to previously published viability criteria for initially declined liver grafts, which are mandatory for all participating study centers, with minor device-specific modifications. These criteria are based on the Birmingham criteria used in the VITTAL trial for viability assessment of DBD and DCD grafts with the OrganOx Metra device and are comparable to the Groningen criteria previously established with the LiverAssist device, with the exception of biliary viabilit~These criteria are: Lactate clearance \< 2.5 mmol/L, And two or more of the following: Evidence of bile production, maintenance of a perfusate pH \>7.30 (without correction for at least one hour), glucose metabolism (falling perfusate glucose value with consistent downward trend), maintenance of stable arterial and portal venous flows (OrganOx Metra: 150 and 500 mL/min respectively), homogeneous perfusion with soft consistency of the parenchyma."
219754270|NCT06724159|DRUG|darolutamide|Darolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice
219754271|NCT06724159|DRUG|Nivolumab monotherapy|Adjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice
219754272|NCT06724159|DRUG|enfortumab vedotin|Following the posology and administration details of its marketing authorization and standard clinical practice
219186974|NCT04004416|OTHER|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
219186975|NCT04004416|DRUG|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
219186976|NCT06192550|DEVICE|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
219186977|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
219186978|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
219186979|NCT05391243|PROCEDURE|LLETZ|Large loop excision of the transformation zone
219186980|NCT06517628|OTHER|Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.|The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.
219186981|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
219186982|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
219186983|NCT05436262|DEVICE|Real-time fMRI with neurofeedback of motor imagery|Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.
219186984|NCT05512208|DRUG|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
219186985|NCT06561321|DRUG|Tapinarof|Daily topical Tapinarof use will stop disease advancement and improve the quality of life in patients with palmoplantar keratoderma, through its AhR \& NRF2 agonism properties.
219186986|NCT04114084|PROCEDURE|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
219186987|NCT04462276|DRUG|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
219186988|NCT04462276|RADIATION|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
219186989|NCT05299073|DRUG|MB09|Single dose of 35mg SC administered
219186990|NCT05299073|DRUG|US-sourced Xgeva|Single dose of 35mg SC administered
219186991|NCT05299073|DRUG|EU-sourced Xgeva|Single dose of 35mg SC administered
219186992|NCT01763190|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219186993|NCT06547411|DEVICE|PC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).
219186994|NCT06547411|DEVICE|VC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).
219186995|NCT06547411|DEVICE|PRVC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
219186996|NCT06016608|DIAGNOSTIC_TEST|Magnetic Resonance Angiography, Ocular OCTA, CT Angiography|Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
219186997|NCT06539247|COMBINATION_PRODUCT|Motor Relearning Program with Electrical Muscle Stimulation (MRA + EMS)|This arm received a 30-minute motor relearning program focused on improving foot drop and gait patterns and Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes) with 40 mA (default) adaptive, considering both intensity and duration for safe foot lift during walking.
219186998|NCT06539247|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation Technique with Electrical Muscle Stimulation (PNF + EMS)|"This arm received a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program consisted of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) and Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS applied to the affected ankle dorsiflexors for 10 minutes with the same parameters."
219186999|NCT03441321|OTHER|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
219187000|NCT03441321|OTHER|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
219187001|NCT03441321|OTHER|Survey Administration|Ancillary studies
219187002|NCT05975359|DEVICE|Interi Manifold Drain System|The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
219754273|NCT06725706|DIAGNOSTIC_TEST|18F-92/AV45, 11C-PIB|Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
219760819|NCT02700672|OTHER|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
219370367|NCT05527002|OTHER|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
219370368|NCT02628925|DEVICE|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
219370369|NCT03751111|DRUG|Naloxone|Naloxone at an sublingual dose of 0.4 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
219370370|NCT03751111|DRUG|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
219370371|NCT05814445|OTHER|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
219370372|NCT05814445|OTHER|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
219370373|NCT00807950|DRUG|Simvastatin|
219370374|NCT03308188|BEHAVIORAL|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
219370375|NCT04935983|OTHER|High CHO|Diet with high carbohydrate content
219370376|NCT04935983|OTHER|Low CHO|Diet with low carbohydrate content
219370377|NCT02254915|DEVICE|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
219370378|NCT02254915|DRUG|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
219370379|NCT00772447|DRUG|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
219370380|NCT00772447|DRUG|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~\- 1 g every 6 hours or 2 g every 8 hours"
219370381|NCT02147873|DRUG|birinapant|
219370382|NCT02147873|DRUG|Azacitidine|
219370383|NCT02147873|DRUG|Placebo|
219370384|NCT04485585|DRUG|BR9006-1|* Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
219187003|NCT05975359|DEVICE|Jackson Pratt Drain System|The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
219370385|NCT04485585|DRUG|BR9006-2|"* Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose"
219370386|NCT01951677|DRUG|HBsAg|Standard hepatitis B vaccine antigen
219370387|NCT01951677|BIOLOGICAL|PreS HBsAg|preS hepatitis B surface antigen
219370388|NCT01951677|BIOLOGICAL|Advax-1(TM)|Adjuvant formulated with vaccine antigen
219370389|NCT01951677|BIOLOGICAL|Advax-2(TM)|Adjuvant formulated with vaccine antigen
219370390|NCT01951677|BIOLOGICAL|Advax-3(TM)|Adjuvant formulated with vaccine antigen
219187004|NCT04850898|BIOLOGICAL|SAB-176|Treatment of influenza
219187005|NCT04850898|OTHER|Placebo|Placebo Control
219370391|NCT01951677|BIOLOGICAL|Alum|Adjuvant formulated with vaccine antigen
219370392|NCT03688217|BEHAVIORAL|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
219760820|NCT00698828|DRUG|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
219370393|NCT03688217|BEHAVIORAL|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
219370394|NCT00650858|DRUG|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
219370395|NCT01957137|DEVICE|InterStim® (Device Programming)|
219370396|NCT04553107|BEHAVIORAL|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
219370397|NCT04553107|BEHAVIORAL|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
219370398|NCT03529409|BEHAVIORAL|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
219370399|NCT01497262|DRUG|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
219370400|NCT00777179|DRUG|Vandetanib|Tablet, oral, daily
219370401|NCT00777179|DRUG|Placebo|Placebo
219370402|NCT04127201|BEHAVIORAL|en_línea|This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.
219370403|NCT04127201|BEHAVIORAL|Group therapy|This is a traditional behavioral weight control program
219370404|NCT02497001|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
219370405|NCT02497001|DRUG|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
219370406|NCT02497001|DRUG|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
219370407|NCT02497001|DRUG|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
219370408|NCT05587283|DRUG|Experimental: Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.
219370409|NCT05587283|DRUG|Experimental: Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.
219370410|NCT05587283|DRUG|Experimental: High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule, 5 x 10\^9 CFU/capsule with excipients.
219370411|NCT05587283|OTHER|Placebo Comparator: Low dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
219370412|NCT05587283|OTHER|Placebo Comparator: Medium dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
219370413|NCT05587283|OTHER|Placebo Comparator: High dose Placebo capsule|High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
219370414|NCT03898063|BEHAVIORAL|90 DAYS film|the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
219370415|NCT03898063|BEHAVIORAL|HIV pamphlet on disclosure|A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
219370416|NCT05438381|PROCEDURE|Atraumatic Restorative Technique (ART)|Glass ionomer capsule (GC, USA)
219370417|NCT05438381|PROCEDURE|SMART Technique|silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
219370418|NCT05610371|DRUG|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
219370419|NCT05610371|DRUG|Saline|The control group underwent hysteroscopy using a saline distension medium.
219370420|NCT04937010|PROCEDURE|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
219007024|NCT00449540|DEVICE|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
219370421|NCT03706573|DRUG|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
219370422|NCT03684135|OTHER|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
219007025|NCT00449540|DEVICE|Sham TMS Device|Simulated Sham treatment without TMS delivery
219370423|NCT02347904|DRUG|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
219370424|NCT03711903|DRUG|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
219370425|NCT03711903|DRUG|0.9% Sodium-chloride|normal saline
219370426|NCT00054132|BIOLOGICAL|Bevacizumab|Given IV
219370427|NCT00054132|DRUG|Erlotinib Hydrochloride|Given PO
219370428|NCT00054132|OTHER|Laboratory Biomarker Analysis|Correlative studies
219370429|NCT02949830|DRUG|Givosiran|Givosiran by subcutaneous (SC) injection.
219370430|NCT03955094|DEVICE|Intubation via AMBU® AURAGAIN™|Success rate of paediatric intubation through AMBU® AURAGAIN™
219370431|NCT01290887|DRUG|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
219370432|NCT02920060|DRUG|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
219370433|NCT02920060|DRUG|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
219370434|NCT03316352|PROCEDURE|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
219370435|NCT03316352|PROCEDURE|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
219370436|NCT03316352|DEVICE|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
219370437|NCT03316352|DRUG|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
219370438|NCT05430269|OTHER|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
219370439|NCT05430269|OTHER|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
219370440|NCT01811511|DIETARY_SUPPLEMENT|Chungkookjang|
219370441|NCT01811511|DIETARY_SUPPLEMENT|Placebo|
219370442|NCT02886299|DRUG|Fenofibrate|
219370443|NCT02886299|DRUG|Simvastatin|
219370444|NCT01705015|BEHAVIORAL|direct feedback about exercise|
219370445|NCT01705015|BEHAVIORAL|PLacebo|UCFit plus encouraged exercise
219370446|NCT04058522|OTHER|Rotator cuff rehabilitation classes|
219370447|NCT04058522|OTHER|Individual Physiotherapy|
219370448|NCT04058522|DRUG|Triamcinolone Injection|Subacromial Injection 40mg/1ml
219370449|NCT01042444|DEVICE|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
219370450|NCT03436173|DRUG|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
219370451|NCT03436173|OTHER|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
219370452|NCT04725279|PROCEDURE|Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home|The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
219370453|NCT03471325|PROCEDURE|Plaque disclosed with air flow|air polishing with prior plaque disclosing
219370454|NCT03471325|PROCEDURE|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
219370455|NCT03471325|PROCEDURE|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
219370456|NCT03471325|PROCEDURE|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
219370457|NCT01795547|DRUG|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
219370458|NCT01795547|DRUG|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
219370459|NCT00578357|BEHAVIORAL|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
219370460|NCT00308451|DRUG|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
219370461|NCT06334588|DIAGNOSTIC_TEST|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist
219187006|NCT06455839|BEHAVIORAL|Guided Resipiration Mindfulness Therapy (GRMT)|GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
219370462|NCT06334588|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
219370463|NCT06334588|OTHER|Clinical Scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
219370464|NCT06334588|GENETIC|Research of genetic anomalies|For the diagnosis of autism, patients benefit from a a genetic assessment. This is carried out as part of their care
219370465|NCT04334382|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.
219370466|NCT04334382|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
219370467|NCT01551745|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
219370468|NCT01551745|DRUG|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
219370469|NCT01247311|DIETARY_SUPPLEMENT|Dietary supplement|Placebo given orally 3xweek for six months
219370470|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
219370471|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
219370472|NCT05219422|BEHAVIORAL|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
219370473|NCT05219422|BEHAVIORAL|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
219370474|NCT05690659|OTHER|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
219370475|NCT03114449|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
219370476|NCT03114449|DEVICE|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
219370477|NCT01576211|GENETIC|DNA methylation analysis|
219370478|NCT01576211|GENETIC|RNA analysis|
219370479|NCT01576211|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
219370480|NCT01576211|GENETIC|gene expression analysis|
219370481|NCT01576211|GENETIC|nucleic acid sequencing|
219370482|NCT01576211|GENETIC|polymorphism analysis|
219754274|NCT06922851|PROCEDURE|Immunoadsorption|Immunoadsorption (IA) therapy using a protein A column for four consecutive days, plus immunoglobulin supplementation after IA
219187007|NCT03882073|PROCEDURE|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
219187008|NCT03882073|PROCEDURE|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
219187009|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
219187010|NCT02701153|PROCEDURE|Conventional Surgery|Undergo surgery
219187011|NCT02701153|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219187012|NCT02701153|OTHER|Laboratory Biomarker Analysis|Correlative studies
219187013|NCT02701153|OTHER|Questionnaire Administration|Ancillary studies
219187014|NCT05795114|BEHAVIORAL|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
219187015|NCT05868876|DRUG|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
219187016|NCT05844397|DEVICE|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
219187017|NCT05844397|DEVICE|VisuMax Surgical Laser|SMILE Refractive Surgery
219187018|NCT06336083|PROCEDURE|Doppler ultrasound|Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
219187019|NCT05962541|DRUG|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA \[TM\]).
219187020|NCT05962541|DEVICE|Power Led Saphira (TM)|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
219187021|NCT06449586|DRUG|Letermovir|letermovir stops when CMI\>1.5
219187022|NCT06485232|DRUG|Universal BCMA CAR-T|Universal BCMA CAR-T
219187023|NCT06485232|DRUG|Universal CD19 CAR-T|Universal CD19 CAR-T
219187024|NCT06485232|DRUG|Universal BCMA CAR-T; Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T
219187025|NCT04158934|BIOLOGICAL|ADYNOVI/ADYNOVATE|Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
219187026|NCT03374241|BIOLOGICAL|HM15211 or Placebo|Long-acting tri-agonist
219187027|NCT00614146|DEVICE|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
219187028|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
219187029|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
219187030|NCT04770402|OTHER|Acupuncture|12 acupuncture sessions over 10 weeks
219187031|NCT04770402|OTHER|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
219187032|NCT04681339|OTHER|Antibiotic treatment|Antibiotic treatment
219187033|NCT04681339|OTHER|No antibiotic treatment|No antibiotic treatment
219187034|NCT05584930|OTHER|Collection of blood sample|"* Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)"
219187035|NCT06033950|DRUG|Finerenone|Oral finerenone.
219187036|NCT06033950|DRUG|Placebo|Matching oral placebo.
219187037|NCT02322203|DIETARY_SUPPLEMENT|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
219187038|NCT05016947|DRUG|Venetoclax|Tablet, taken by mouth
219187039|NCT05016947|DRUG|Dexamethasone|Taken orally
219187040|NCT05016947|DRUG|Inotuzumab Ozogamicin|Intravenous infusion
219187041|NCT05520268|BEHAVIORAL|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
219754275|NCT03552445|BIOLOGICAL|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
219754276|NCT03552445|BIOLOGICAL|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
219187042|NCT05520268|BEHAVIORAL|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
219187043|NCT03599661|OTHER|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
219187044|NCT03599661|OTHER|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
219187045|NCT04739839|OTHER|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
219187046|NCT06548425|OTHER|Smart Phone Based Cardiac Telerehabilitation|"Smart Phone Based Cardiac Telerehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60 % THR and modified borg scale 9 (very light- 13 (somewhat hard) Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
219187047|NCT06548425|OTHER|Center based cardiac Rehabilitation|"Center based cardiac Rehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60% THR and modified borg scale 9 (very light- 13 (somewhat hard)~Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
219187048|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
219187049|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
219187050|NCT04872543|DRUG|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
219187051|NCT06534385|DEVICE|Air purifier|Winix HEPA air purifier
219187052|NCT03725384|DRUG|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
219187053|NCT03725384|DRUG|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
219187054|NCT04550221|BEHAVIORAL|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
219187055|NCT04811040|DRUG|Oral Lenacapavir|Tablets administered without regard to food
219187056|NCT04811040|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
219187057|NCT04811040|DRUG|Teropavimab|Administered intravenously
219187058|NCT04811040|DRUG|Zinlirvimab|Administered intravenously
219187059|NCT05274074|BEHAVIORAL|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
219187060|NCT04101487|OTHER|Cash Transfer|Monthly cash transfers
219187061|NCT04101487|OTHER|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
219187062|NCT05562622|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
219187063|NCT05562622|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
219187064|NCT06398106|DRUG|Proactive TDM-based dosing of secukinumab|"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
219187065|NCT06398106|DRUG|Proactive TDM-based dosing of ixekizumab|"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
219187066|NCT06398106|DRUG|Proactive TDM-based dosing of guselkumab|"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
219370483|NCT01576211|OTHER|laboratory biomarker analysis|
219370484|NCT04752384|DRUG|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
219370485|NCT04752384|DRUG|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
219370486|NCT04752384|DEVICE|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
219370487|NCT05998395|DRUG|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
219370488|NCT03651947|DRUG|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
219370489|NCT03651947|DRUG|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
219370490|NCT00888511|DRUG|Tarceva|Tarceva 150 mg/day
219370491|NCT00888511|RADIATION|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
219370492|NCT00338507|DRUG|Erdosteine|
219370493|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
219370494|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
219370495|NCT02527356|BEHAVIORAL|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
219370496|NCT00141947|DRUG|bexarotene (Targretin)|
219370497|NCT03889587|PROCEDURE|Innervation|There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.
219370498|NCT03889587|PROCEDURE|Non-innervation|This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
219370499|NCT05733585|DEVICE|Purabond|hemostatic efficacy of PuraBond
219370500|NCT01979497|PROCEDURE|Suture with Adhesive Stripping|
219370501|NCT01979497|PROCEDURE|Suture without Adhesive Stripping|
219370502|NCT00707798|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
219370503|NCT00707798|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
219754277|NCT03552445|BIOLOGICAL|Td alone|437 Td recipients: one vaccine injection administered on Day 0
219370504|NCT02500693|BIOLOGICAL|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
219370505|NCT04653493|BIOLOGICAL|CD19 CAR engineered autologous T-cells|"Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities."
219370506|NCT04653493|DRUG|Cyclophosphamide|Given IV
219370507|NCT04653493|DRUG|Fludarabine|Given IV
219370508|NCT04653493|DRUG|Mesna|Given IV
219370509|NCT02316834|OTHER|Laboratory Biomarker Analysis|Correlative studies
219370510|NCT02316834|DRUG|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
219370511|NCT05150548|OTHER|No Intervention|Not applicable, non-interventional study
219754278|NCT06770634|OTHER|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral thigh, pretibial region and left forearm as remote site and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~Bilateral thigh: Mid-thigh anterior surface Bilateral pretibial region: Anterior proximal 1/3 of the pretibial area Bilateral forearm volar side center as control point"
219370512|NCT05359393|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
219370513|NCT03052647|DEVICE|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
219187067|NCT06565052|BEHAVIORAL|Prehabilitation Program|A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
219187068|NCT05884073|BEHAVIORAL|Circuit-based Resistance Training|Participants will engage in a 12-week circuit-based resistance training program 2-3 times/week. Each supervised session will last about 30 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
219187069|NCT05884073|BEHAVIORAL|Nature-based Walking|Participants will be asked to engage in 30 minutes of self-paced walking in nature 2-3 days/week. Participants will be provided with a list of resources that direct them to walkable nature/green spaces close to their home or workplace.
219187070|NCT06851455|OTHER|Cadaveric Workshop on Ultrasound-guided Injections|"Participant physicians will attend a structured cadaveric workshop on ultrasound-guided musculoskeletal injections.~Participants will perform hands-on procedures under expert supervision on lower extremity joints listed as hip, knee and ankle.~For the assessment participants will be asked to complete pre- and post-workshop assessments to measure skill improvement and confidence levels."
219187071|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
219187072|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
219187073|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
219187074|NCT06853002|OTHER|Breathing exercise with spirometry|Breathing exercise with spirometry
219187075|NCT06853002|OTHER|Breathing exercise with deep breathing method|Breathing exercise with deep breathing method
219370514|NCT03052647|DEVICE|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
219754279|NCT06770634|OTHER|Central Sensitization Inventory|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization.
219187076|NCT06852521|OTHER|Stimulus Properties: Target Location|The location of the target item in the display will be varied across trials (appear left, right, up, or down)
219187077|NCT06852521|OTHER|Stimulus Properties: Distractor Presence|A proportion of all trials will contain a task-irrelevant, singleton distractor defined in a non-target dimension (e.g., color target and motion distractor)
219187078|NCT06852521|OTHER|Stimulus properties: Cue Validity|Varied across trials, the validity of the cue will be determined by the match or mismatch between direction of the visual cue (an arrowhead around the fixation pointing to the right, left, up, or down) and actual target location
219187079|NCT06848621|DEVICE|40Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
219187080|NCT06848621|DEVICE|100Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
219187081|NCT05367102|BEHAVIORAL|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
219754280|NCT06770634|OTHER|Numeric Rating Scale|Leg pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
219370515|NCT02330419|DRUG|Placebo|Placebo capsules will contain microcrystalline cellulose (Medisca). Placebo and active medication will be provided in capsules that are an exact match in color, so as to make the placebo and active medication indistinguishable from each other.
219187082|NCT06668623|OTHER|Reiki Group|Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.
219187083|NCT06668623|OTHER|Sham Reiki Group|In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
219187084|NCT06712290|DRUG|celgene|"CTM Boost (CTM Biomedical, Miami, FL) is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. It is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is regulated as a minimally-manipulated biologic by the FDA and is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is administered applied into the tissue via injection.~Participant will undergo a single injection of 2.0cc of the injectable CTM allograft, administered using a 20G needle in the subacromial space. 3mL of ropivacaine will be mixed into the syringe prior to administration of the injection. Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used."
219187085|NCT06712290|DRUG|Corticosteroid|Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or intra-articular (into the joints) use. It may be used to treat many different types of inflammatory conditions. In this study, a 2.0cc dose injection of Kenalog-40 will be administered directly into the subacromial space using a 20G needle. 3mL of ropivacaine will be injected along with the steroid (as part of the same injection). Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.
219187086|NCT06827743|BEHAVIORAL|feeding behavior education|Two groups will receive personalized sensory integration training, and one group will receive feeding behavior training. Both the caregiver and the child will take part in feeding behavior training. In order for the training to be successful, the therapist, child, and parent cooperation is necessary. Before this training, the children will be evaluated with the Behavioral Pediatric Feeding Assessment Scale and a behavioral training plan will be created according to the children's attitudes and behaviors during feeding. This plan will include organizing feeding times, determining the family's approach to the child's behaviors during feeding, regulating the children's feeding behavior problems with extinguishing and desensitization methods, and organizing the feeding environment, and creating a personalized training plan.
219187087|NCT06827743|BEHAVIORAL|Sensory integration intervention|The sensory integration training given to both groups includes training that includes oral processing skills in particular, as well as training that includes tactile, vestibular, proprioception, and visual stimuli as needed. Children will be supported with sensory stimuli in order to ensure that the child focuses and remains calm. Sensory integration training will be planned by taking into account the Dunn Sensory Profile test results. In this training, different patterned fabrics, plushes, and toys with different surfaces for tactile stimulation will be provided to maintain the child's calmness and focus; swings and exercise balls for vestibular stimulation; and training to provide sensory regulation with proprioceptive approaches. In addition, within the scope of sensory integration training, stimuli will be provided in the oral region according to the children's sensory responses to the texture, taste, and content of foods.
219187088|NCT04075526|DRUG|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
219187089|NCT04075526|DRUG|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
219187090|NCT04075526|OTHER|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
219187091|NCT04730583|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion
219187092|NCT04730583|DEVICE|1064nm laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
219187093|NCT04730583|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
219187094|NCT06852378|DRUG|Iliopsoas nerve block|Patients will receive an Iliopsoas nerve block using 10 ml of bupivacaine 0.5%.
219187095|NCT06852378|DRUG|Femoral nerve block|Patients will receive femoral nerve block using 10 ml of bupivacaine 0.5%.
219187096|NCT06850909|DEVICE|Microdrop GPS dish|The µDrop GPS® micro-wells dish is specifically designed for oocyte and embryo handling and culture. The sloped concave micro-well bottoms of the µDrop GPS® dish allow oocytes and embryos to settle at a central location away from the well walls. The concave nature of the wells provides the thinnest well bottom possible, helping to reduce refraction and allow for optimal visualization. The wells may reduce droplet collapsing/mixing, offer better orientation/optics, and reduce set-up/observation time.
219370516|NCT02330419|DRUG|Naltrexone|REVIA is a white, crystalline compound. The hydrochloride salt is soluble in water to the extent of about 100 mg/mL. REVIA is available in scored film-coated tablets containing 50 mg of naltrexone hydrochloride.
219760821|NCT00698828|DRUG|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
219760822|NCT00698828|DRUG|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
219760823|NCT02013609|DRUG|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
219760824|NCT01135225|DEVICE|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
219760825|NCT01135225|DEVICE|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
219760826|NCT00358111|DEVICE|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
219760827|NCT05983094|DRUG|Utidelone|Utidelone injection 30mg/m2, on days 1-5 of each cycle
219370517|NCT02330419|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist
219370518|NCT02330419|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers:|Urine samples will be collected weekly and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours).
219370519|NCT02330419|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measure that will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection
219187097|NCT06850909|DEVICE|16 well BIRR dish|The 16-Well BIRR Dish is a high-quality 3D culture dish designed for optimal embryo handling and identification in IVF. It features well-numbering (1-16) for clear tracking, a large labeling area, and an expanded working space for better accessibility. Its 16 wells allow for increased wash drops and single embryo culture, reducing the number of dishes needed per IVF cycle. Rigorously tested (MEA+, LAL, and SMA per lot), it ensures safe and efficient embryo culture.
219187098|NCT06851611|BIOLOGICAL|COVID-19 vaccine, low dose level|Test article
219187099|NCT06851611|BIOLOGICAL|COVID-19 vaccine, high dose level|Test article
219187100|NCT06851611|OTHER|Nasal Drops|Method of administration of test article
219187101|NCT06851611|OTHER|Nasal Spray|Method of administration of test article
219187102|NCT04116671|DEVICE|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
219187103|NCT05523206|OTHER|No intervention|No intervention
219187104|NCT06846762|OTHER|This study did not include intervention between the two cohorts|The study is divided into two parts, Part A and Part B. The purpose of Part A is to reveal the proportion of NSCLC patients who are primarily resistant to first-line non-targeted therapy due to the omission of driver genes (especially fusion variations) by DNA-NGS, the median PFS of patients in the first line, and clinical characteristics through synchronous co-testing of DNA and RNA NGS. The purpose of Part B is to compare the difference in ORR between patients with driver gene positivity identified through synchronous co-testing of DNA and RNA NGS who receive and do not receive targeted therapy, with subsequent treatment regimens determined at the discretion of the patients without any intervention measures.
219187105|NCT06845241|DRUG|ICP-490|Specified dose on specified days
219187106|NCT06232915|PROCEDURE|Mechanical ventilation|Mechanical ventilation during surgery
219187107|NCT06842459|OTHER|Geriatric Assessment|"The intervention group will undergo Geriatric Assessment in addition to diabetes usual care.~Usual care for both the Control and Intervention groups will be assured by a diabetologist according to in-use guidelines.~After randomization, a geriatrician will administer a thorough CGA to all participants allocated to the intervention groups. CGA results will be used to diagnoses or drug review; to identify specific treatment goals according to the functional status of the patient and to incorporate Patient-preferred outcome in the management of diabetes and comorbidities. Using the results of the CGA the geriatricians along with the attending diabetologist and additional healthcare professional, if needed, will implement a personalized diagnostic and therapeutic plan of care. Participants in the Control group will receive no additional intervention over and above usual care."
219187108|NCT06841939|OTHER|castor oil|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of castor oil under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of castor oil.
219187109|NCT06841939|OTHER|Water|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of water under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of water.
219187110|NCT06846073|COMBINATION_PRODUCT|The combination of intravitreal anti-VEGF and dexamethasone implants injections.|Early combination of intravitreal dexamethasone implant and anti-VEGF injection for the treatment of DME.
219187111|NCT06848829|OTHER|Pre-manepausal women|Compare tear ferning structure between pre-menopause and post-menopause women.
219370520|NCT02330419|DIAGNOSTIC_TEST|Dried Blood Spot (DSB) Testing for Phosphatidylethanol|Phosphatidylethanol (PEth)-a phospholipid formed only in the presence of alcohol-is a novel, direct biochemical marker of alcohol that has shown high (\>95%) sensitivity and specificity to detect heavy drinking over a period of 2-3 weeks in several studies of dependent patients and abstainers. DSB samples will be collected at enrollment, weeks 3, 6, 9, 12, and post-treatment visits at month 1, 3, and 6.
219187112|NCT06849089|PROCEDURE|Transurethral resection of prostate (TURP)|The surgical intervention used to resect the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a hot loop shaped knife, operated by electrocautery, to cut the obstructing tissues from center towards periphery of the prostate until the prostatic capsule is reached.
219187113|NCT06849089|PROCEDURE|Holmium laser enucleation of prostate|The surgical intervention used to enucleate the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a laser fiber to dissect the obstructing adenoma from the prostatic capsule starting from the plane in-between the capsule and the adenoma, meaning removal of tissues from periphery towards the center of the prostate.
219370521|NCT02330419|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments are SMS texts to collect data on alcohol consumption, number of drinks on drinking days, and targeted medication administration prior to anticipated drinking sessions. Messages will use short-hand notations to maintain participant confidentiality
219370522|NCT06494579|DRUG|Lamivudine|Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy
219760828|NCT05983094|DRUG|Carboplatin|Carboplatin Area under curve(AUC)6, iv, was administered on day 1
219760829|NCT05983094|DRUG|Epirubicin|Epirubicin 75mg/m2 was administered on day 1
219760830|NCT05983094|DRUG|Trastuzumab|Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
219760831|NCT05983094|DRUG|Pertuzumab|Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
219187114|NCT06850584|OTHER|Observation|The study was observational and did not involve any intervention.
219187115|NCT06848959|OTHER|No intervention|Pediatric Encephalopathy Science and Prevention Decision Aid Follow-Up Q\&A
219187116|NCT06852482|OTHER|SBE Capacitation (behavioral intervention) for facilitator population|"An intervention is proposed with two training sessions for the tutors of the Pràcticum I, III, and IV courses in the Physiotherapy Degree. The first session will be on January 10, 2024 (3 hours), and the second on February 2, 2024 (2 hours), both at the FCSB facilities of UVic-UCC.~The sessions aim to:~Promote behavior that facilitates learning in Simulation-Based Education (SBE). Provide facilitators with tools and strategies for effective SBE implementation.~Highlight the differences and similarities in SBE across the Pràcticum I, III, and IV courses, based on increasing difficulty.~Training will involve clinical simulation principles, with facilitators experiencing all SBE phases. An actress, later participating in student simulations, will be involved. Scenarios from the courses will be used, supported by a PowerPoint presentation and an information dossier for participants."
219187117|NCT06852482|OTHER|SBE (behavioral intervention) for student population|"Simulation-Based Education Each student in Pràcticum I, III, and V will participate in a simulation session tailored to their course.~Simulations are conducted in groups of five students with the same UVic tutor acting as facilitator. Each simulation follows three phases (prebriefing, simulation, debriefing), with varying emphasis across courses:~Pràcticum I: The prebriefing ensures group confidence. Two volunteer students participate in the simulation. The debriefing is shorter, less focused on outcomes, and highlights learning over errors. Emphasizes guidance for student.~Pràcticum III: Prebriefing and debriefing are equally emphasized. One volunteer student performs the simulation.~Pràcticum V: Cases are more complex, requiring less prebriefing but comprehensive briefing. Students autonomously set session rules. The debriefing is in-depth and focuses on clinical application. One volunteer student performs the simulation, Focuses on autonomy and independent work."
219187118|NCT06851260|PROCEDURE|Fine-dissection of the thymus|In thyroid surgery, precise dissection and preservation of thymus tissue are used to improve the protection of the lower parathyroid gland function and increase the curative effect of the surgery.
219187119|NCT06852131|PROCEDURE|open carpal tunnel surgery|open carpal tunnel surgery
219187120|NCT06852131|PROCEDURE|Steroid Injection|triamsinolon injection
219187121|NCT06852131|PROCEDURE|PRP injection|PRP injection
219187122|NCT06852066|PROCEDURE|Computer-Assisted Local Anesthesia|"Description: Local anesthesia applied using the SleeperOne5 (Dental Hi Tec, Cholet, France) device, with controlled injection speed (60 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 35 mm, 30G dental syringe"
219187123|NCT06852066|PROCEDURE|Conventional Local Anesthesia|"Description: Local anesthesia applied using a manual dental syringe, with injection speed manually controlled (30 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 40 mm, 27G dental syringe"
219187124|NCT06851234|PROCEDURE|osteopathic manipulative medicine|OMM
219187125|NCT06851234|PROCEDURE|The sham light touch will be performed by an investigator not trained in bodywork or a first--year osteopathic medical student.|Participants will lay supine on an OMM table. After the OSE, the investigator will place their hands flat in light contact with the participants' parietal bone regions, then the shoulders, then the sides of the lower ribs, and finally over the trochanters.
219187126|NCT05992077|DRUG|Sofosbuvir/Daclatasvir|Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
219187127|NCT06852079|OTHER|Qurs e Fishar|Qurs e Fishar is a herbal remedy for Hypertension
219187128|NCT06852638|DRUG|[18F]F-RESCA-RCCB6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
219187129|NCT06852638|DRUG|[18F]F-RESCA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.
219187130|NCT06852638|DRUG|[18F]F-RESCA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RD06 injection.
219187131|NCT06852638|DRUG|[68Ga]Ga-NOTA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.
219187132|NCT06852638|DRUG|[68Ga]Ga-NOTA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]RD06 injection.
219187133|NCT06852638|DRUG|[89Zr]Zr-DFO-RB6|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RB6 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
219187134|NCT06852638|DRUG|[89Zr]Zr-DFO-R8B4|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-R8B4 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
219187135|NCT06852638|DRUG|[89Zr]Zr-DFO-RD06|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RD06 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
219187136|NCT06851364|DRUG|0.38% Sodium Hyaluronate (SH) Eye Drops|"A lubricant eye drop containing 0.38% sodium hyaluronate (SH), designed to improve tear film stability and ocular surface health in individuals with moderate to severe dry eye disease (DED).~The formulation has a higher viscosity and retention time, potentially offering better symptom relief for evaporative dry eye (EDE)."
219760832|NCT00856609|DRUG|Byetta (exenatide)|Exenatide is an injectable medication
219760833|NCT00856609|BEHAVIORAL|Weight loss|Because response to weight loss
219760834|NCT00856609|OTHER|Metabolic Chamber|The subject stays in the small room
219760835|NCT00856609|DRUG|Placebo|
219760836|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
219370523|NCT06494579|DRUG|PD-L1 Blocker|PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
219370524|NCT04535193|DRUG|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
219370525|NCT00183690|PROCEDURE|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
219187137|NCT06851364|DRUG|0.18% Sodium Hyaluronate Eye Drops|"A lubricant eye drop containing 0.18% sodium hyaluronate (SH), used to alleviate dry eye symptoms and improve tear film stability.~This formulation has a lower viscosity compared to 0.38% SH, potentially providing faster absorption but with shorter ocular surface retention."
219187138|NCT06851364|DRUG|Normal Saline Eye Drops|"A non-active control treatment consisting of sterile normal saline (0.9% NaCl) used as a placebo comparator.~It provides temporary moisture but lacks the viscoelastic and therapeutic properties of sodium hyaluronate."
219187139|NCT06852911|DIAGNOSTIC_TEST|Chemiluminescent FeNO Analyzer|A novel chemiluminescence FeNO Analyzer has been developed, capable of measuring both FeNO50 and FeNO during tidal breathing. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
219187140|NCT06852911|DIAGNOSTIC_TEST|Electrochemical FeNO Analyzer|Electrochemical FeNO analyzers are employed in clinical settings for the measurement of FeNO50. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
219187141|NCT02990819|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
219187142|NCT06216886|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
219187143|NCT06216886|DRUG|Sodium Chloride 0.9% for Injection, Preservative Free|intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
219187144|NCT06851845|OTHER|No intervention|Patients will receive medical care in accordance with the routine practice of disease treatment
219187145|NCT06851598|DRUG|25 units botox|25 units of botox injection into ischiocavernosus muscle
219187146|NCT06851598|DRUG|50 units Botox|50 Units botox injection into ischiocavernosus muscle
219187147|NCT06851598|DRUG|75 units Botox|75 units botox injection into ischiocavernosus muscle
219187148|NCT06843265|DEVICE|Vacuum- Induce Hemorrhage Control|The JADA System is designed for single use only and is composed of medical grade silicone. Its components include an intrauterine loop with protected vacuum pores, a cervical seal with a sealing valve for infusing saline and a vacuum connector port for applying suction. The intrauterine loop is located at the distal end of a tube and contains 20 protected vacuum pores oriented inward along the loop. This shielded design facilitates intracavitary suction by shielding maternal tissue from the vacuum source and prevents clogging of the vacuum pores with tissue or clot.
219187149|NCT05567328|DEVICE|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
219187150|NCT02714439|DRUG|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
219187151|NCT02714439|PROCEDURE|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
219187152|NCT05011851|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
219187153|NCT03049618|OTHER|Laboratory Biomarker Analysis|Correlative studies
219187154|NCT03049618|BIOLOGICAL|Pembrolizumab|Given IV
219187155|NCT03049618|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219187156|NCT04114981|RADIATION|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
219187157|NCT04114981|RADIATION|Fractionated Stereotactic Radiosurgery|Undergo FSRS
219187158|NCT04114981|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219187159|NCT04114981|OTHER|Questionnaire Administration|Ancillary studies
219187160|NCT06251752|DIAGNOSTIC_TEST|X-rays: load bearing inferior limbs, lateral knee, axial patella|X-rays at 5 years follow-up minimum
219370526|NCT00183690|PROCEDURE|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
219760837|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
219370527|NCT06286462|OTHER|Cancer Tracking System (CATSystem)|The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
219370528|NCT05764967|OTHER|Low Dye Taping|The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.
219370529|NCT05764967|OTHER|Temporary Felt Insoles|A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
219370530|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
219370531|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
219370532|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
219370533|NCT03710447|OTHER|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
219370534|NCT03710447|OTHER|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
219370535|NCT03710447|OTHER|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
219370536|NCT03710447|OTHER|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
219370537|NCT05187377|DRUG|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
219370538|NCT05187377|DRUG|Saline|Placebo (saline) will be administered subcutaneously once daily.
219370539|NCT03183362|DEVICE|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
219370540|NCT03183362|DEVICE|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
219370541|NCT03644160|BEHAVIORAL|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
219370542|NCT04735003|DEVICE|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
219370543|NCT02667145|OTHER|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
219370544|NCT00033865|BEHAVIORAL|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
219370545|NCT01438008|DRUG|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
219370546|NCT01438008|DRUG|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
219370547|NCT03804385|PROCEDURE|intercostal tube|surgical operation
219370548|NCT02293122|OTHER|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F\&A Specular Microscope.
219370549|NCT06250140|DEVICE|Tie up device|The recurrence rate of internal hemorrhoids in different treatment methods
219370550|NCT01813890|DRUG|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
219370551|NCT01813890|DRUG|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
219370552|NCT01813890|DRUG|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
219370553|NCT02071433|PROCEDURE|Saphenous nerve blockade|
219370554|NCT02071433|PROCEDURE|Femoral nerve blockade|
219370558|NCT01556984|OTHER|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
219370559|NCT01457183|DEVICE|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
219370560|NCT02229201|DRUG|Propofol|4-6 mg/kg/h during anaesthesia
219370561|NCT02229201|DRUG|Sevoflurane|0.8 MAC
219370562|NCT03939013|DIAGNOSTIC_TEST|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
219370563|NCT02230176|DRUG|Sunitinib|
219370564|NCT02230176|DRUG|177Lu-DOTA0-Tyr3-Octreotate|
219370565|NCT05042830|PROCEDURE|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
219370566|NCT05042830|PROCEDURE|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
219370567|NCT05042830|BIOLOGICAL|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
219370568|NCT05042830|PROCEDURE|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
219370569|NCT05042830|PROCEDURE|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
219370570|NCT05042830|PROCEDURE|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
219370571|NCT05042830|PROCEDURE|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
219370572|NCT05042830|BIOLOGICAL|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
219370573|NCT00386906|PROCEDURE|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
219370574|NCT04591392|DEVICE|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
219370575|NCT05281757|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
219370576|NCT03952559|DRUG|Baricitinib|Administered orally
219370577|NCT03952559|DRUG|Placebo|Administered orally
219370578|NCT03952559|DRUG|Topical corticosteroid|Administered as standard-of-care
219370579|NCT06199076|DRUG|Oxytocin nasal spray|The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
219370580|NCT02867306|DRUG|ASP1707|Oral
219370581|NCT02867306|DRUG|methotrexate (MTX)|Oral
219370582|NCT05327322|BEHAVIORAL|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
219370583|NCT05327322|BEHAVIORAL|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
219370584|NCT05327322|BEHAVIORAL|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
219370585|NCT05406323|BEHAVIORAL|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
219000617|NCT00844896|BEHAVIORAL|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
219000618|NCT00844896|BEHAVIORAL|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
219000619|NCT00580190|DRUG|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
219000620|NCT00580190|OTHER|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
219000621|NCT00580190|DRUG|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
219000622|NCT03955744|OTHER|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
219000623|NCT00004915|DRUG|raloxifene|
219000624|NCT05052762|OTHER|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
219000625|NCT05052762|OTHER|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
219370586|NCT05937412|OTHER|Alcohol sterilization|Sterilizing skin using alcohol
219370587|NCT05937412|OTHER|Honey sterilization|Sterilizing skin using honey
219370588|NCT04172883|OTHER|Treatment arm|All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
219370589|NCT00002120|DRUG|Trimetrexate glucuronate|
219370590|NCT00002120|DRUG|Trimethoprim|
219370591|NCT00002120|DRUG|Sulfamethoxazole|
219370592|NCT00002120|DRUG|Dapsone|
219370593|NCT00002120|DRUG|Leucovorin calcium|
219370594|NCT01997463|DRUG|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
219370595|NCT03892161|DRUG|Darunavir/ritonavir 800/100 mg tablet|Standard dose DRV/r administered
219370596|NCT03892161|DRUG|Rifampicin 600mg QD tablet and DTG 50mg BD|Rifampicin and DTG added
219370597|NCT06089447|BEHAVIORAL|A story based intervention called 'The Shadow of Tallystick Valley'|'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
219370598|NCT03426098|DEVICE|Secret RF|A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
219370599|NCT06253039|OTHER|Repeated sprint|"* The group will endure four weeks (8 sessions) of the assigned training program in addition to the regular swimming training.~* Data collection sessions: All groups will be evaluated before and after the supervised training period in three testing sessions in normoxia separated by at least 24 hours within 7 days.~* Training sessions: will be performed in the ski ergometer and consist of 4 sets of 5x6s all-out sprints with 24s and 5 min of passive rest between the sprints and sets, respectively."
219000626|NCT04774328|DRUG|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
219000627|NCT04774328|DRUG|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
219000628|NCT02233647|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
219000629|NCT02233647|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
219000630|NCT02590614|DIETARY_SUPPLEMENT|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
219000631|NCT02590614|DIETARY_SUPPLEMENT|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
219370600|NCT05624463|BEHAVIORAL|Modified intubation protocol|1\. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
219000632|NCT03129984|DEVICE|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
219000633|NCT02129400|DRUG|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
219000634|NCT02129400|DRUG|Aer medicinalis Linde 100%|
219000635|NCT05148598|DEVICE|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
219000636|NCT05148598|OTHER|Standard Care|Standard care
219000637|NCT05148598|OTHER|Placebo|Placebo visually indistinguishable from ADRCs
219000638|NCT02174250|DRUG|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
219000639|NCT02174250|DRUG|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
219000640|NCT04906291|OTHER|Toothpaste use|Brushing three times a day
219000641|NCT01652612|OTHER|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
219000642|NCT04342897|DRUG|LY3127804|Administered IV
219000643|NCT04342897|DRUG|Placebo|Administered IV
219000644|NCT02551965|OTHER|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
219000645|NCT01831050|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
219000646|NCT01831050|BIOLOGICAL|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
219000647|NCT01831050|BIOLOGICAL|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
219000648|NCT01831050|BIOLOGICAL|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
219000649|NCT01831050|BIOLOGICAL|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
219000650|NCT01831050|BIOLOGICAL|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
219000651|NCT06266000|DRUG|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
219370601|NCT05624463|BEHAVIORAL|Conventional intubation protocol|1\. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.
219370602|NCT05624463|BEHAVIORAL|Early resumption of oral intake|Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
219370603|NCT05624463|BEHAVIORAL|Delayed resumption of oral intake|Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
219000652|NCT06266000|DRUG|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
219187161|NCT02831244|DEVICE|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
219187162|NCT02425982|PROCEDURE|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
219187163|NCT02425982|PROCEDURE|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
219187164|NCT05050149|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
219187165|NCT06253013|DEVICE|Hyfe Smartwatch|Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
219187166|NCT06253013|DEVICE|FitBit Versa 2|Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
219370604|NCT03033771|DEVICE|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
219370605|NCT00851071|BEHAVIORAL|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
219370606|NCT04257760|BEHAVIORAL|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
219000653|NCT06266000|DRUG|Palm Oil capsule|Palm oil capsule
219000654|NCT04166175|PROCEDURE|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
219000655|NCT04166175|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
219000656|NCT02223897|DRUG|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
219000657|NCT02223897|DRUG|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
219000658|NCT03568734|OTHER|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
219000659|NCT00112320|PROCEDURE|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
219000660|NCT00112320|PROCEDURE|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
219000661|NCT01270776|DRUG|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
219000662|NCT01270776|DRUG|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
219000663|NCT01190774|BEHAVIORAL|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
219000664|NCT01190774|BEHAVIORAL|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
219000665|NCT05221528|DIAGNOSTIC_TEST|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
219187167|NCT06253013|DEVICE|Home Spirometer|Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
219187168|NCT06253013|BEHAVIORAL|Audio recording|Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
219187169|NCT06510842|OTHER|External drainage of intraventricular hemorrhage|An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
219187170|NCT04954573|RADIATION|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
219187171|NCT06580119|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
219370607|NCT01870739|DRUG|sacubitril/valsartan (LCZ696)|200 mg tablets
219370608|NCT01870739|DRUG|olmesartan|
219370609|NCT01870739|OTHER|placebo to sacubitril/valsartan (LCZ696)|placebo
219370610|NCT01870739|OTHER|placebo to olmesartan|placebo
219370611|NCT01870739|DRUG|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
219370612|NCT01384214|BIOLOGICAL|botulinum toxin Type A|750 U at Visit 1
219370613|NCT05664984|BEHAVIORAL|1-face-to-face|The cognitive rehabilitation intervention consists of 45-minute sessions, 2 days a week for 12 weeks. The same rehabilitation intervention program was applied to both groups by face-to-face or tele-rehabilitation method. The main purpose of the study is to see the effectiveness of cognitive rehabilitation intervention in the elderly with amnestic mild cognitive impairment and to compare the two methods.
219370614|NCT05664984|BEHAVIORAL|2-tele rehabilitation|2-tele rehabilitation
219370615|NCT00327522|BIOLOGICAL|pneumococcal vaccine|
219370616|NCT01986062|DRUG|AR11|
219370617|NCT01986062|DRUG|Placebo|
219370618|NCT03538743|DRUG|Placebo|Tablet, 0 mg, twice daily, 28 days
219370619|NCT03538743|DRUG|PF-06882961|Tablet, 15 mg twice daily, 28 days
219370620|NCT03538743|DRUG|PF-06882961|Tablet, 50 mg twice daily, 28 days
219370621|NCT03538743|DRUG|PF-06882961|Tablet, 150 mg twice daily, 28 days
219187172|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
219187173|NCT05427006|DEVICE|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
219187174|NCT05427006|DEVICE|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
219187175|NCT00769522|BIOLOGICAL|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
219187176|NCT00769522|DRUG|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
219187177|NCT00769522|DRUG|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
219187178|NCT00769522|DRUG|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
219187179|NCT03624244|DRUG|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
219187180|NCT06209632|BEHAVIORAL|mirror therapy|30 minutes of intervention, twice a week, and a total of 12 weeks
219187181|NCT06209632|DEVICE|contralaterally controlled functional electrical stimulation|30 minutes of intervention, twice a week, and a total of 12 weeks
219187182|NCT06209632|BEHAVIORAL|conventional physiotherapy|50 minutes of intervention, twice a week, and a total of 12 weeks
219187183|NCT05856890|BIOLOGICAL|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
219370622|NCT03538743|DRUG|PF-06882961|Tablet, 300 mg twice daily, 28 days
219370623|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 5, 28 days
219370624|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 6, 28 days
219370625|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 7, 28 days
219370626|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 8, 28 days
219760838|NCT05730881|PROCEDURE|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
219187184|NCT05856890|OTHER|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
219187185|NCT06559930|OTHER|Traditional Neurological Rehabilitation + Dual Task Focused Training|Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.
219370627|NCT04207047|DEVICE|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
219370628|NCT04207047|DEVICE|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
219370629|NCT04207047|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
219370630|NCT04207047|DEVICE|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
219760839|NCT02136043|DEVICE|PBASE system 1.1 (active treatment)|
219760840|NCT03346525|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
219760841|NCT01130181|DRUG|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
219370631|NCT04207047|DEVICE|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
219370632|NCT02828800|OTHER|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith \& Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
219187186|NCT06559930|OTHER|Traditional Neurological Rehabilitation|Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
219187187|NCT01828099|DRUG|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.
219187188|NCT01828099|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
219187189|NCT01828099|DRUG|Cisplatin|Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.
219187190|NCT01828099|DRUG|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
219187191|NCT06276868|DRUG|Dalcilib+letrozole+HP treatment group|"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks."
219187192|NCT03785561|OTHER|participation in a health research study|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
219187193|NCT02896348|DEVICE|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
219187194|NCT02896348|OTHER|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
219187195|NCT04162665|RADIATION|Adaptive short course radiation therapy|Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.
219187196|NCT04162665|DRUG|Standard of care chemotherapy regimen|The recommendations are CAPOX, FOLFOX, or FLT.
219187197|NCT05247502|BIOLOGICAL|Data observation|At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
219370633|NCT06357650|OTHER|No intervention. This is an observational study|This is an observational study. Hence there is no intervention
219370634|NCT03664128|OTHER|Coping with Anxiety through Living Mindfully (CALM) Pregnancy|Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
219370635|NCT00171860|DRUG|imatinib mesylate|
219370636|NCT02488122|OTHER|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
219187198|NCT06258863|PROCEDURE|incision type|Total mastectomy was performed using one of the four incision types
219187199|NCT03561961|RADIATION|Moderate Hypo-fractionation|66-68Gy in 25#
219187200|NCT03561961|RADIATION|Extreme Hypo-fractionation|35-36.25 Gy in 5#
219187201|NCT02990533|DRUG|Testosterone|
219187202|NCT02990533|DIETARY_SUPPLEMENT|Protein Supplement|
219187203|NCT02990533|OTHER|Placebo Injection|
219187204|NCT02990533|OTHER|Placebo supplement|
219187205|NCT05870319|DRUG|SKB264|intravenous (IV) infusion (Q2W)
219187206|NCT05870319|DRUG|Pemetrexed|500 mg/m2 intravenous (IV) infusion (Q3W)
219187207|NCT05870319|DRUG|Carboplatin|AUC 5 intravenous (IV) infusion (Q3W) 4cycles
219370637|NCT02488122|OTHER|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
219187208|NCT05870319|DRUG|Cisplatin|75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
219187209|NCT05743907|DRUG|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
219187210|NCT05743907|DRUG|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
219187211|NCT06208748|DRUG|Bezuclastinib in combination with sunitinib|Bezuclastinib in combination with sunitinib (sutent)
219760842|NCT01130181|DRUG|Placebo|Matching placebo
219370638|NCT03162679|BEHAVIORAL|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
219370639|NCT02369081|DRUG|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
219370640|NCT02369081|DRUG|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
219370641|NCT02369081|DRUG|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
219370642|NCT02369081|DRUG|Placebo|Placebo treatment for 12 weeks.
219370643|NCT05402826|DIETARY_SUPPLEMENT|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
219370644|NCT05402826|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
219370645|NCT00630331|BIOLOGICAL|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
219370646|NCT00630331|BIOLOGICAL|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
219370647|NCT00630331|BIOLOGICAL|Placebo|One dose (0.5 mL) of phosphate buffered solution.
219370648|NCT04640766|DEVICE|PRISM|"The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes."
219370649|NCT01827384|DRUG|Adavosertib|Given by mouth (PO)
219370650|NCT01827384|DRUG|Carboplatin|Given intravenous (IV)
219370651|NCT01827384|DRUG|Everolimus|Given by mouth (PO)
219370652|NCT01827384|DRUG|Temozolomide|Given by mouth (PO)
219370653|NCT01827384|DRUG|Trametinib|Given by mouth (PO)
219370654|NCT01827384|DRUG|Veliparib|Given by mouth (PO)
219370655|NCT00667615|DRUG|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
219370656|NCT02368327|BIOLOGICAL|Fluad|
219370657|NCT02368327|BIOLOGICAL|Fendrix|
219370658|NCT02368327|BIOLOGICAL|Placebo|
219370659|NCT00584961|OTHER|non-interventional|non-interventional
219370660|NCT00317460|OTHER|Physician Management|Standard physician care
219370661|NCT00317460|BEHAVIORAL|Counseling|Physician Management and Counseling
219370662|NCT05010460|DRUG|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
219370663|NCT05010460|DRUG|Placebo|orally 100mg every other day for 5-8 days prior to CABG
219370664|NCT05660304|DEVICE|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
219370665|NCT05660304|DEVICE|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
219370666|NCT01902979|BEHAVIORAL|Lifestyle intervention|
219370667|NCT02944019|DRUG|Edoxaban|Prescribed according to approved label
219370668|NCT01110252|DRUG|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
219370669|NCT01110252|PROCEDURE|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
219370670|NCT01110252|GENETIC|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
219370671|NCT04707755|OTHER|Motor imagery technique|"The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs."
219370672|NCT04707755|OTHER|Conventional Physical Therapy|It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
219370673|NCT00804115|DRUG|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
219370674|NCT06043440|DRUG|Oxygen|Active nocturnal oxygen concentrator
219370675|NCT03170752|BEHAVIORAL|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
219370676|NCT03720171|DEVICE|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
219370677|NCT01629615|DRUG|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
219370678|NCT03327233|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
219370679|NCT04144439|DRUG|GABA|Gamma amino butyric acid
219370680|NCT04946266|PROCEDURE|Surgical intervention|Surgical intervention with collection of tissue material
219370681|NCT01233206|DRUG|Metformin|Metformin pre-treatment and co-administration
219370682|NCT01233206|DRUG|Placebo administration|Placebo pre-treatment and co-administration
219370683|NCT00382031|DRUG|Zalutumumab|Individual dose titration weekly i.v doses
219370684|NCT00382031|OTHER|Control|Best Supportive Care
219370685|NCT03639948|DRUG|Carboplatin|Intravenous solution
219187212|NCT05215119|PROCEDURE|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
219187213|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
219187214|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
219187215|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
219187216|NCT03859635|DRUG|Liposomal Bupivacaine|20 ml
219187217|NCT03859635|DRUG|Bupivacaine, 0.25%|10 ml
219187218|NCT03859635|DRUG|Bupivacaine, 0.5%|30 ml
219187219|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
219187220|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
219370686|NCT03639948|DRUG|Docetaxel|Intravenous solution
219370687|NCT03639948|DRUG|Pembrolizumab|Intravenous solution
219370688|NCT03639948|DRUG|Pegfilgrastim|Injectable product
219370689|NCT03883737|OTHER|PNM|an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
219370690|NCT01260103|DRUG|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
219370691|NCT01260103|DRUG|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
219370692|NCT00054587|BIOLOGICAL|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
219370693|NCT00054587|DRUG|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
219370694|NCT00054587|DRUG|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
219187221|NCT06481488|DRUG|E2086|E2086 tablets.
219187222|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
219187223|NCT06852794|OTHER|Survey|The patients will receive questionnaires. The enrolled patients will be asked to provide feedback on the answers they read.
219187224|NCT06561204|DEVICE|FMET|A full-mouth electronic toothbrush
219187225|NCT03611036|OTHER|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
219187226|NCT03611036|OTHER|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
219187227|NCT00882167|OTHER|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
219187228|NCT05977192|BEHAVIORAL|Standard MI|One phone-based MI session
219187229|NCT05977192|BEHAVIORAL|Intensive MI|Four phone-based MI sessions
219187230|NCT05977192|BEHAVIORAL|MOTIVACC|mHealth-based MI
219187231|NCT05977192|BEHAVIORAL|Ecological momentary assessment (EMA) messages|EMA messages focused on vaccinations and health
219187232|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
219187233|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
219187234|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
219187235|NCT04470011|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219187236|NCT04470011|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
219187237|NCT04470778|DRUG|BMS-986256|Specified dose on specified days
219187238|NCT04470778|DRUG|Famotidine|Specified dose on specified days
219187239|NCT04908033|DEVICE|pacemaker implantation|pacemaker implantation
219370695|NCT00054587|DRUG|Epirubicin|100 mg/m², D1 and every 3 weeks
219370696|NCT00054587|DRUG|Fluorouracil|500 mg/m², D1 and every 3 weeks
219370697|NCT05617287|DIETARY_SUPPLEMENT|Semaine Menopause Supplement|Synergistic Dietary Supplement
219370698|NCT04336904|DRUG|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
219760843|NCT02731287|DRUG|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
219370699|NCT04336904|OTHER|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
219370700|NCT01955707|DRUG|natalizumab|Administered as described in the treatment arm
219370701|NCT01955707|DRUG|Placebo|Matched placebo
219370702|NCT02487875|OTHER|rehabilitation|
219000666|NCT04974385|DRUG|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
219187240|NCT03792919|DRUG|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
219187241|NCT03792919|DRUG|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
219187242|NCT05570877|DEVICE|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
219187243|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
219187244|NCT05490875|PROCEDURE|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
219187245|NCT05490875|OTHER|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
219187246|NCT05490875|OTHER|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
219187247|NCT06046001|DEVICE|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
219187248|NCT04728451|BEHAVIORAL|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
219187249|NCT04728451|DEVICE|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
219187250|NCT06096935|OTHER|bood sample|Exome measurements
219187251|NCT03753204|DRUG|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
219187252|NCT05964504|PROCEDURE|Blood Specimen|Blood will be drawn via venipuncture
219187253|NCT06550609|DRUG|Miltefosine Oral Capsule|Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
219187254|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
219187255|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
219187256|NCT02677064|OTHER|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
219187257|NCT05576077|BIOLOGICAL|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
219187258|NCT05576077|DRUG|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
219187259|NCT05648214|DRUG|ALN-PNP - Part A|Administered by subcutaneous (SC) single ascending dose (SAD)
219187260|NCT05648214|DRUG|ALN-PNP - Part B|Administered by SC parallel single dose
219187261|NCT05648214|DRUG|Placebo (PB)|Administered by SC injection
219187262|NCT04208373|DRUG|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
219187263|NCT04208373|DRUG|Itraconazole|Itraconazole capsules will be administered orally
219187264|NCT04208373|DRUG|Etravirine|etravirine tables will be administered orally.
219187265|NCT05511415|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
219187266|NCT05511415|DRUG|Dexmedetomidine|Dexmedetomidine (10-9M to 10-4M)
219187267|NCT04397679|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
219187268|NCT04397679|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
219187269|NCT04397679|DRUG|Temozolomide|Given PO
219187270|NCT04397679|DRUG|Chloroquine|Given PO
219187271|NCT04397679|PROCEDURE|Tumor Treating Fields Therapy (TTF)|Undergo TTF
219187272|NCT04362254|DRUG|Spesolimab|Spesolimab
219370703|NCT01714466|DRUG|NER1006|
219370704|NCT01714466|DRUG|MOVIPREP|
219370705|NCT03551587|DEVICE|Vibringe|The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
219370706|NCT01817790|DRUG|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
219370707|NCT01817790|DRUG|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
219370708|NCT01671345|BEHAVIORAL|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
219370709|NCT01671345|BEHAVIORAL|Control|Attention control
219370710|NCT01301989|BEHAVIORAL|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
219370711|NCT01301989|OTHER|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
219370712|NCT02065544|BEHAVIORAL|behavioral weight loss and exercise|Weight loss and exercise counseling
219370713|NCT04817501|OTHER|Taking 5 ml of venous blood at different time intervals|
219370714|NCT04817501|OTHER|Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any|
219370715|NCT04093596|GENETIC|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
219370716|NCT04093596|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
219370717|NCT04093596|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219370718|NCT04093596|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219370719|NCT04093596|DRUG|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
219370720|NCT04633590|BEHAVIORAL|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
219370721|NCT05876559|OTHER|Joyuus Self-care Mobile App|Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.
219370722|NCT05876559|OTHER|Standard Care|Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
219370723|NCT03493360|OTHER|Visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.
219370724|NCT03493360|OTHER|No visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
219370725|NCT02719340|PROCEDURE|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
219370726|NCT02617238|OTHER|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
219000667|NCT04974385|DRUG|Bupivacaine|Active comparator as standard of care.
219000668|NCT06129071|PROCEDURE|US guided block of maxillary nerve|Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
219000669|NCT00257101|BEHAVIORAL|self-medication monitoring|
219000670|NCT02426437|OTHER|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
219000671|NCT02426437|OTHER|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
219000672|NCT04374773|DRUG|Dronabinol|2.5 mg PO administered once prior to and once after 1 week of hormone therapy
219370727|NCT06625086|OTHER|Convensional exercises|Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.
219370728|NCT06625086|OTHER|Supervised exercises|Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.
219370729|NCT06625086|OTHER|Web based exercises|The exercises will be administered to participants through a web-based application.
219370730|NCT04596891|BEHAVIORAL|Psychotherapy|Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
219370731|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 180 mg/day
219370732|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 300 mg/day
219370733|NCT04838873|PROCEDURE|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
219370734|NCT04838873|PROCEDURE|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
219370735|NCT03370393|BEHAVIORAL|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
219370736|NCT06759792|OTHER|eye hand coordination exercises|exercises to improve eye hand coordination post strabismus surgery
219370737|NCT06771895|BEHAVIORAL|Combined exercise and nutritional intervention|The intervention consists of a combined exercise and nutritional intervention. All subjects will perform 20 weeks of supervised resistance and endurance type exercise training 2 to 3 days per week. The dietary intervention aims to attain a diet that comprises sufficient protein and is otherwise in line with the Dutch Healthy Diet guidelines. In support, subjects will consume a daily high protein multi-nutrient supplement which will be ingested pre-sleep. There will be an additional supplement intake moment following each training session.
219370738|NCT06900452|DIETARY_SUPPLEMENT|0.5 serving of pistachios|"The equivalent of 0.5 servings (15g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 15g pistachio, 35g muesli base, 150g full fat natural yoghurt, 15g unsalted butter (melted), 10g unflavoured whey powder"
219370739|NCT06900452|DIETARY_SUPPLEMENT|1 serving of pistachios|"The equivalent of 1 serving (30g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 30g pistachio, 35g muesli base, 150g full fat natural yoghurt, 10g unsalted butter (melted), 5g unflavoured whey powder"
219370740|NCT06900452|DIETARY_SUPPLEMENT|2 servings of pistachios|"The equivalent of 2 servings (60g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 60g pistachios, 25g muesli base, 150g low fat natural yoghurt"
219370741|NCT06900452|DIETARY_SUPPLEMENT|Placebo|Macronutrient-matched placebo breakfast meal. Ingredients: 40g muesli base, 150g full fat natural yoghurt, 25g unsalted butter (melted), 15g unflavoured whey powder
219370742|NCT06755879|BEHAVIORAL|digital game-based learning activity|learning interventions to prevent surgical site infections with a digital game-based learning activity
219370743|NCT06755879|BEHAVIORAL|traditional method|Evaluation of the effectiveness of students' learning of interventions to prevent surgical site infections in the theoretical course taught by traditional method
219370744|NCT06855082|BEHAVIORAL|stoma self-care apps|This study uses a stoma self-care app, accessed through LINE official account, a communication software commonly used by Chinese people, as an intervention measure to integrate technology acceptance and task technology adaptation models to explore the correlation of each aspect and its impact on self-care ability and quality of life. Whether the factors and task technology adaptability will affect the willingness and usage behavior of enterostomy patients, the research subjects can effectively improve their self-care ability, quality of life, usage willingness, and usage behavior after intervention.
219370745|NCT06855082|BEHAVIORAL|Traditional Education Receive colostomy health education manual with oral instruction|conventional
219370746|NCT06901284|DIAGNOSTIC_TEST|Graded Exercise Test|"Participants will perform a graded exercise test on either a cycle ergometer or treadmill. The testing protocol will begin with a 5- 10 min warm-up of either cycling or running/walking at the participants preferred pace.~If the graded exercise test is on a bike, exercise will begin at wattage that elicits \~50% of their heart rate max, HRmax = 208 - 0.7 × age and increase by either 10W, 15W, or 20W every two minutes in a stepwise fashion until symptom limitation. The step of the wattage increase will be at the discretion of the investigators.~If the graded exercise test is on a treadmill, the test will begin at a speed that elicits \~50% of predicted HRmax. Following, the speed of the treadmill will increase 0.5 mph (0.8 km/hr) every two minutes in a stepwise fashion until symptom limitation. If the participant maxes out the speed of the treadmill, we will increase the grade 2% every 2-minutes until symptom limitation."
219370747|NCT06901284|DIAGNOSTIC_TEST|Graded Hypoxia Exercise Test|"Participants will perform a single constant work rate exercise tests during graded hypoxia. They will be outfitted with either a facemask or mouthpiece connected to a uni-directional breathing valve. During inspiration, subjects will breathe from a closed-system Douglas bag balloon reservoir (\~200 L) connected to the value on the inspired side via air-tight clean-bor tubing.~The participant will complete the same mode of exercise as they did during visit 1, either bike or treadmill. The resistance on the bike or incline of the treadmill will be set to elicit an intensity equivalent to \~50% of their V̇O2max determined during visit 1. Participants will complete 5-minute stages over a range of FiO2 values. The exercise test will begin in an FiO2=0.21 (i.e. room air). Following this first 5-min stage the FiO2 will increase to 0.25, afterwards, participants will complete another stage at FiO2=0.21 and then decrease in a stepwise fashion every 5-minutes."
219370748|NCT04981223|DEVICE|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
219370749|NCT04280081|DRUG|Selpercatinib|Administered orally
219370750|NCT06621394|OTHER|nutritional intervention|nutritional intervention to mediterranean diet
219370751|NCT06621394|BEHAVIORAL|Mindful Eating|intervention regarding mindful eating, e.g. attention while eating, apprechiation of food
219370752|NCT06621394|OTHER|Attention Control|Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games
219370753|NCT06927778|OTHER|Exercise|Individualised corrective exercise protocols based on Functional Movement Screening
219370754|NCT05026905|DRUG|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
219370755|NCT05026905|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
219370756|NCT05026905|DRUG|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day"
219370757|NCT05026905|DRUG|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
219370758|NCT05026905|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
219000673|NCT03158116|DRUG|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
219000674|NCT04655898|DRUG|[14C]CC-90001|Oral
219370759|NCT00289679|DEVICE|Hip prosthesis revision|
219370760|NCT06782269|PROCEDURE|ankle fusion|fusion of ankle joint
219370761|NCT01052649|OTHER|Blood sampling|
219370762|NCT06916130|DRUG|AD-120A|Administered before the breakfast during 7 days, Oral, Tablet
219370763|NCT06916130|DRUG|AD-120|Administered before the breakfast during 7 days, Oral, Tablet
219370764|NCT06915168|OTHER|Informational Intervention|Given CIPN DecisionAid
219370765|NCT06915168|OTHER|Survey Administration|Ancillary studies
219370766|NCT06916572|OTHER|Scapular stabilization exercises|"Individuals in the Scapular Stabilization group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included scapular stabilization exercises in addition to conventional treatment. Scapular stabilization exercises were planned to be applied only on the days of the session. Each of the exercises was applied as 10 repetitions and 2 sets.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
219370767|NCT06916572|OTHER|Scapular PNF|"Physiotherapy and rehabilitation program was applied to the individuals in the PNF group for 6 weeks, 3 days a week, as in the Scapular Stabilization group. In addition to conventional treatment, scapular PNF approaches were added to the treatment of individuals in this group.~The scapular PNF patterns of anterior elevation - posterior depression and anterior depression - posterior elevation were applied with rhythmic initiation, repeated contractions (stretches) and rhythmic stabilization techniques with 10 repetitions of each technique.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
219370768|NCT06915350|OTHER|maspin ( mammary serine protease inhibitor)|Maspin is an immunohistochemical marker to detect the prognosis of colorectal carcinoma
219370769|NCT06916650|DEVICE|High-Intensity Laser Therapy (HILT)|Nd:YAG laser (1064 nm) applied to anterior, lateral, posterior glenohumeral joint aspects. Three-phase protocol per session: (1) 10 J/cm² @ 10 Hz; (2) 12 J/cm² @ 2000 Hz; (3) 10 J/cm² @ 15 Hz. Total energy \~1200 J/session. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by trained PTs.
219370770|NCT06916650|DRUG|Ultrasound-Guided Intra-articular Corticosteroid Injection|Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered at baseline by an experienced orthopedic physician.
219370771|NCT06916650|BEHAVIORAL|Manual Therapy|Skilled hands-on techniques including glenohumeral joint mobilizations (Maitland grades III-IV), posterior capsule stretching, scapular mobilization, and soft tissue techniques targeting restricted tissues. Session duration: \~30 minutes. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by PTs specialized in manual therapy.
219370772|NCT06916650|BEHAVIORAL|Standard Exercise Program|Standardized program including pendulum exercises, active-assisted range of motion exercises (e.g., wand, wall climbs), stretching (e.g., cross-body, sleeper stretch), and progressive resistive exercises using resistance bands. Includes supervised instruction/progression and a daily home exercise program component. Supervised instruction frequency: 2 sessions/week for first 6 weeks, then 1 session/week for next 6 weeks (total 18 supervised sessions over 12 weeks). Delivered by trained PTs.
219370773|NCT06916611|OTHER|Cardiac Magnetic Resonance Imaging|This study included patients who were diagnosed with HFpEF and had completed CMR.
219370774|NCT06916104|OTHER|search for respiratory allergies|analyses in terms of biotherapy and respiratory allergy
219370775|NCT06915701|DIETARY_SUPPLEMENT|Will take vitamin E 800mg/day|Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.
219370776|NCT06915701|DRUG|Will take 200mg/day magnesium oxide placebo.|Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.
219370777|NCT06917040|DEVICE|Spatial repellant emanator|Spatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).
219370778|NCT06915649|PROCEDURE|Amygdalo-Hippocampectomy|"This technique is characterized by specific hallmarks that distinguish it from other approaches, including the Yasargil technique and newer minimally invasive methods. It integrates precise anatomical targeting with optimized surgical pathways to enhance outcomes in patients with those pathologies. The approach of the choroidal fissure will be explained in the article.~By addressing limitations observed in traditional techniques, it aims to minimize neurological deficits while achieving better seizure control."
219370779|NCT01468311|PROCEDURE|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
219370780|NCT01468311|DRUG|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
219370781|NCT01468311|RADIATION|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
219370782|NCT01468311|RADIATION|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
219370783|NCT06916793|DRUG|CKD-843 dose#1|IM injection every 3 months for 12 months
219000675|NCT00886574|DRUG|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
219000676|NCT00886574|DRUG|Aspirin|100 mg once a day
219000677|NCT02634320|DRUG|Aripiprazole Lauroxil|Monthly IM injection
219000678|NCT06123845|BEHAVIORAL|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
219000679|NCT06123845|BEHAVIORAL|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
219000680|NCT01952275|PROCEDURE|Collection of biological samples|
219000681|NCT01900704|DRUG|SER120 750 ng|SER120 750 ng
219370784|NCT06916793|DRUG|CKD-843 dose#2|IM injection every 3 months for 12 months
219370785|NCT06916793|DRUG|Placebo of CKD-843 dose|IM injection every 3 months for 12 months
219370786|NCT06916793|DRUG|Dutasteride Capsules|oral, once daily, 12 months
219370787|NCT06916793|DRUG|Placebo of Dutasteride Capsule|oral, once daily, 12 months
219370788|NCT06498986|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219370789|NCT06498986|DRUG|Osimertinib Mesylate Tablets|Oral administration, 80mg daily for a cycle of 3 weeks.
219370790|NCT06935708|DRUG|Intrathecal Morphine|In Spinal group, 25 G or 27 G pencil point needle, depending on the preference of the anesthesiologist, will be inserted at L2-L3 or L3-L4 intervertebral space and 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
219370791|NCT06935708|PROCEDURE|Epidural Analgesia|Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery. Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery.
219370792|NCT06934278|DRUG|Pooled human plasma|Infusion of pooled human plasma (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
219370793|NCT06934278|DRUG|Placebo|Infusion of cryst (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
219370794|NCT03463772|PROCEDURE|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
219370795|NCT03463772|DRUG|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
219370796|NCT00168350|DRUG|memantine|
219370797|NCT02366000|OTHER|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
219370798|NCT06198686|DRUG|Nalmefene|Opioid antagonist
219370799|NCT03919240|BIOLOGICAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
219370800|NCT04533711|BEHAVIORAL|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
219370801|NCT04533711|BEHAVIORAL|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
219370802|NCT01116050|DRUG|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
219370803|NCT01116050|DRUG|Placebo|5 tablets in opque introducer
219370804|NCT00313274|DRUG|Clevudine|
219370805|NCT05390216|PROCEDURE|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
219370806|NCT03688386|BEHAVIORAL|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
219370807|NCT03688386|BEHAVIORAL|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
219370808|NCT03688386|BEHAVIORAL|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
219370809|NCT03688386|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
219370810|NCT03688386|BEHAVIORAL|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
219370811|NCT01750918|DRUG|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
219000682|NCT01900704|DRUG|SER120 1500 ng|SER120 1500 ng
219000683|NCT01900704|DRUG|Placebo|Placebo
219000684|NCT03274505|OTHER|Questionnaires|"* Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)"
219187273|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
219187274|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
219187275|NCT04005690|DRUG|Cobimetinib|Given PO
219187276|NCT04005690|DRUG|Olaparib|Given PO
219187277|NCT04005690|DRUG|Onvansertib|Given PO
219187278|NCT04005690|DRUG|Azenosertib|Given PO
219187279|NCT04005690|DRUG|Saruparib|Given PO
219187280|NCT04005690|BIOLOGICAL|Tremelimumab|Given IV
219187281|NCT06557343|DIAGNOSTIC_TEST|Single Cell Sequencing|Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
219370812|NCT01750918|DRUG|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
219000685|NCT00197132|DRUG|Avandia|
219000686|NCT00359060|BEHAVIORAL|Physical activity|
219000687|NCT01849198|DEVICE|accelerometry m. trapezius and m. adductor pollicis|
219000688|NCT04736420|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
219000689|NCT04736420|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
219000690|NCT02970422|OTHER|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
219000691|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
219000692|NCT03951402|DRUG|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
219000693|NCT03951402|DRUG|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
219000694|NCT03951402|DRUG|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
219000695|NCT03951402|DRUG|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
219000696|NCT02812160|DEVICE|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
219000697|NCT06177600|BEHAVIORAL|Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers|"Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked."
219000698|NCT00465205|DRUG|Valacyclovir|500mg oral twice daily
219000699|NCT00465205|DRUG|Matching Placebo|500 mg oral twice daily
219000700|NCT04423237|DRUG|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
219187282|NCT05116189|BIOLOGICAL|Pembrolizumab|IV infusion
219187283|NCT05116189|DRUG|Paclitaxel|IV infusion
219187284|NCT05116189|DRUG|Bevacizumab|IV infusion
219187285|NCT05116189|OTHER|Placebo for pembrolizumab|IV infusion
219187286|NCT05116189|DRUG|Docetaxel|IV infusion
219187287|NCT06108245|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
219187288|NCT06108245|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
219187289|NCT04053322|DRUG|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
219187290|NCT04053322|DRUG|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
219187291|NCT04053322|DRUG|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
219187292|NCT05592158|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
219187293|NCT03624517|DRUG|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
219187294|NCT04642820|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
219187295|NCT04642820|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
219187296|NCT04568434|DRUG|Olezarsen|Olezarsen was administered by SC injection.
219187297|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo was administered by SC injection.
219187298|NCT05469464|DRUG|Orismilast modified release tablets|"Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731"
219187299|NCT05469464|DRUG|Placebo|Placebo matching tablets
219187300|NCT01542580|DEVICE|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
219187301|NCT01542580|DEVICE|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
219187302|NCT01542580|DEVICE|Vanguard DA 360|Dual-articulation device, only cleared in EU
219760844|NCT02731287|DRUG|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
219760845|NCT00783432|DRUG|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
219370813|NCT01750918|DRUG|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
219370814|NCT01750918|DEVICE|5-fluorouracil|5-fluorouracil-based chemotherapy
219370815|NCT03805880|DIAGNOSTIC_TEST|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
219370816|NCT01509027|BEHAVIORAL|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
219370817|NCT01509027|BEHAVIORAL|Standard care|standard care
219370818|NCT01509027|BEHAVIORAL|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
219370819|NCT05426811|DRUG|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
219370820|NCT05426811|DRUG|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
219370821|NCT03226093|PROCEDURE|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
219370822|NCT03027167|DRUG|Aspirin|
219370823|NCT03027167|DEVICE|(Post- discharge) Mechanical Compression Device|
219370824|NCT00460993|DRUG|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
219370825|NCT02610309|BEHAVIORAL|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
219370826|NCT01337349|DRUG|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
219370827|NCT01337349|DRUG|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
219370828|NCT02561897|DRUG|Edoxaban|
219370829|NCT02561897|DRUG|Warfarin|
219370830|NCT03135392|PROCEDURE|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
219370831|NCT03135392|PROCEDURE|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
219370832|NCT03135392|PROCEDURE|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
219370833|NCT04177836|BEHAVIORAL|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
219370834|NCT01967043|DRUG|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
219370835|NCT00170976|DRUG|valsartan + amlodipine|
219370836|NCT03898648|OTHER|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
219370837|NCT03041727|OTHER|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
219370838|NCT03041727|OTHER|Standard exercises protocol|Stretching and strengthening exercises
219370839|NCT00622193|DRUG|anamorelin HCl|50 mg tablet
219370840|NCT00622193|DRUG|anamorelin HCl|100 mg tablet
219370841|NCT00622193|DRUG|placebo|placebo tablet
219370842|NCT03332069|DEVICE|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
219370843|NCT03332069|RADIATION|External beam radiation|
219370844|NCT03332069|DRUG|Cisplatin|
219000701|NCT04656691|DRUG|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
219000702|NCT00282594|DRUG|Novolin R (human recombinant Insulin)|
219000703|NCT03199274|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
219000704|NCT03199274|DRUG|Perflutren Protein-Type A Microspheres|Given IV.
219370845|NCT03332069|RADIATION|Brachytherapy|High Dose Rate
219370846|NCT03429218|DRUG|TP-0184|Oral dose once weekly for 4 weeks
219370847|NCT06541847|DRUG|HLX-1502|Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
219370848|NCT06378827|DRUG|Dexmedetomidine|Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
219370849|NCT00503191|BEHAVIORAL|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
219760846|NCT00783432|DRUG|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
219370850|NCT04387292|PROCEDURE|Ophthalmologic exam|"* Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)"
219370851|NCT00654927|DRUG|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
219370852|NCT05780866|OTHER|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
219370853|NCT04224363|PROCEDURE|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
219370854|NCT04224363|PROCEDURE|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
219370855|NCT05219565|DEVICE|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
219370856|NCT04847128|BEHAVIORAL|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
219370857|NCT02355301|PROCEDURE|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
219370858|NCT00129025|PROCEDURE|Hypofractionated radiotherapy|
219370859|NCT01000103|DEVICE|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
219370860|NCT01000103|DEVICE|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
219370861|NCT02592005|OTHER|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
219370862|NCT02338843|DRUG|LJPC-501|Treatment arm
219370863|NCT02338843|DRUG|Placebo|PBO
219370864|NCT04085432|OTHER|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
219370865|NCT02226484|DRUG|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
219370866|NCT00023322|DRUG|Peginterferon Alpha-2a|Treatment
219370867|NCT02828267|BEHAVIORAL|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
219370868|NCT02828267|BEHAVIORAL|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
219370869|NCT02828267|BEHAVIORAL|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
219370870|NCT06108661|PROCEDURE|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
219370871|NCT06108661|PROCEDURE|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
219370872|NCT06108661|PROCEDURE|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
219370873|NCT06123156|DRUG|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
219370874|NCT06123156|OTHER|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
219370875|NCT05168618|BIOLOGICAL|Atezolizumab|Given IV
219370876|NCT05168618|DRUG|Cabozantinib S-malate|Given PO
219370877|NCT03265587|OTHER|No intervention|No intervention
219370878|NCT05890703|DRUG|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
219370879|NCT05890703|DRUG|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
219370880|NCT03335501|DEVICE|Insulin pump|The participant's insulin pump will be used to infuse insulin
219370881|NCT03335501|DEVICE|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
219370882|NCT03335501|OTHER|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
219370883|NCT03918512|OTHER|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~* Demographical and clinical characteristics at baseline~* Consolidated version of the CSS-48 questionnaire~* Lumbar pain numeric rating scale (NRS)~* Radicular pain NRS~* Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~* Oswestry Disability Index (ODI)~* Fukushima LSS Scale 25 (FLS-25)~* 12-Item Short Form Health Survey (SF-12)~* Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
219187303|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
219187304|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
219187305|NCT05101161|BEHAVIORAL|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
219187306|NCT06044831|BEHAVIORAL|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott \& White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
219187307|NCT03905798|DRUG|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
219187308|NCT05167487|DRUG|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
219187309|NCT05167487|DRUG|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
219187310|NCT04390425|DEVICE|Experimental - Limb Occlusion pressure|This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
219187311|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
219187312|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
219187313|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 125 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
219370884|NCT02332252|DEVICE|Scalpel|Skin incision performed with a scalpel during cesarean section.
219370885|NCT02332252|DEVICE|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
219370886|NCT02332252|PROCEDURE|Skin incision|
219370887|NCT00476138|DRUG|Epigallocatechin-gallate|
219370888|NCT00419250|DRUG|lenalidomide|
219370889|NCT00419250|DRUG|lenalidomide|
219370890|NCT00419250|DRUG|lenalidomide|
219370891|NCT00419250|DRUG|lenalidomide|
219370892|NCT00419250|DRUG|lenalidomide|
219370893|NCT03522545|BIOLOGICAL|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
219370894|NCT03522545|BIOLOGICAL|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
219370895|NCT03783195|OTHER|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
219370896|NCT06472856|PROCEDURE|Acupuncture|Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
219370897|NCT03914352|DRUG|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
219370898|NCT03914352|PROCEDURE|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
219370899|NCT05452603|DEVICE|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
219370900|NCT05132166|OTHER|Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.|Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
219370901|NCT05132166|BIOLOGICAL|Decidual Stromal Cells|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
219370902|NCT03884686|OTHER|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
219370903|NCT06548321|DIAGNOSTIC_TEST|Extracorporeal Shockwave Therapy|" The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.~Once treatment is completed, patients should do their best to physical activity… higher levels of energy Shockwaves into deeper tissue locations… ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke."
219370904|NCT06252116|DRUG|Pregabalin group|Pregabalin group
219370905|NCT06252116|DRUG|Duloxetine group|Duloxetine group
219370906|NCT02863341|OTHER|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
219370907|NCT03115931|OTHER|no intervention|no intervention
219370908|NCT01793792|DEVICE|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
219370909|NCT02185521|OTHER|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
219370910|NCT00185861|DRUG|Arsenic Trioxide|
219370911|NCT00185861|PROCEDURE|Stereotactic radiosurgery|
219370912|NCT04379752|DEVICE|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
219370913|NCT05641350|BEHAVIORAL|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
219370914|NCT05766722|DEVICE|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
219370915|NCT01676831|DRUG|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
219370916|NCT01676831|DRUG|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
219000705|NCT03199274|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
219000706|NCT00766480|DRUG|cisplatin|Given IV
219370917|NCT00999830|DRUG|IPH2101|One infusion of IPH2101 every 4 weeks
219370918|NCT00003200|DRUG|Taxotere|
219000707|NCT00766480|DRUG|fluorouracil|Given IV
219000708|NCT00766480|RADIATION|radiation therapy|Patients undergo radiotherapy
219000709|NCT03779724|OTHER|exercises|
219000710|NCT00602342|DRUG|Terbinafine|
219000711|NCT00227695|BIOLOGICAL|rituximab|comparing two maintenance schedules of Rituximab
219370919|NCT00003200|RADIATION|Radiation therapy|
219370920|NCT02850848|DRUG|Entigin Film Coated Tablet 0.5mg|
219370921|NCT02850848|DRUG|(Baraclude 0.5mg Tablets|
219370922|NCT00004386|GENETIC|recombinant adenovirus containing the ornithine transcarbamylase gene|
219370923|NCT04475341|BIOLOGICAL|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
219370924|NCT04475341|PROCEDURE|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
219370925|NCT05774821|PROCEDURE|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
219187314|NCT05454306|DEVICE|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
219187315|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
219187316|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
219187317|NCT06829875|PROCEDURE|wait for outpatient appointment|this is an observational study measuring impact of pain and function at start and end of wait for those waiting for care from outpatient physiotherapy occupations therapy and podiatry
219187318|NCT02128802|PROCEDURE|Gastric Bypass|
219187319|NCT02128802|OTHER|Weight Loss Program|
219187320|NCT06058936|OTHER|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
219187321|NCT04557618|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
219187322|NCT04557618|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
219187323|NCT04949737|BIOLOGICAL|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
219370926|NCT04640727|PROCEDURE|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
219760847|NCT00373607|DRUG|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
219760848|NCT00373607|DRUG|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
219187324|NCT05828173|DEVICE|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
219187325|NCT04989595|DEVICE|MyIUS app|Data will be self-reported by participants through the MyIUS app.
219187326|NCT06563154|DIAGNOSTIC_TEST|Exercise Capacity Assessment|To examine the relationship between exercise capacity and physical fitness of dyslipidemia patients and quality of life, cognitive status and health literacy.
219191646|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
219370927|NCT04640727|PROCEDURE|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
219370928|NCT04647110|DRUG|crizotinib|as provided in real world practice
219370929|NCT04647110|DRUG|alectinib|as provided in real world practice
219370930|NCT04647110|DRUG|brigatinib|as provided in real world practice
219370931|NCT04647110|DRUG|ceritinib|as provided in real world practice
219370932|NCT04647110|DRUG|lorlatinib|as provided in real world practice
219370933|NCT03751293|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
219370934|NCT02072629|OTHER|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
219370935|NCT05723887|BEHAVIORAL|Attachment-Based Intervention Program|Attachment-Based Intervention Program
219370936|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
219370937|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
219370938|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
219370939|NCT04372095|PROCEDURE|oral smears|oral smears
219370940|NCT04305392|DRUG|SHR4640|orally SHR4640
219370941|NCT03220412|BEHAVIORAL|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
219370942|NCT04561349|OTHER|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
219370943|NCT04561349|OTHER|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
219370944|NCT03290014|DIAGNOSTIC_TEST|polysomnography|Monitoring of brain activity and respiratory variables during sleep
219370945|NCT03290014|DIAGNOSTIC_TEST|Actigraphy|monitoring daily physical activity for 7 days
219370946|NCT03290014|DIAGNOSTIC_TEST|Osler test|Evaluation of subjects´ ability to remain awake
219370947|NCT03071718|OTHER|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
219370948|NCT03071718|OTHER|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
219370949|NCT00135421|DRUG|Pexacerfont|Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
219370950|NCT00135421|DRUG|Escitalopram|Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
219370951|NCT00135421|DRUG|Placebo|Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
219370952|NCT02012010|PROCEDURE|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
219370953|NCT02012010|PROCEDURE|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
219370954|NCT01947270|OTHER|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
219370955|NCT03815890|DRUG|Nivolumab|2 courses 240 mg flat dose
219370956|NCT03815890|DRUG|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
219370957|NCT03815890|DRUG|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
219370958|NCT03638492|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
219370959|NCT03638492|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
219370960|NCT05521165|OTHER|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
219370961|NCT02651090|DRUG|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
219370962|NCT02145962|DEVICE|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
219370963|NCT02145962|DEVICE|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
219370964|NCT02312570|DEVICE|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
219370965|NCT02312570|OTHER|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
219370966|NCT00419796|DRUG|Lumiracoxib|
219187327|NCT06563154|DIAGNOSTIC_TEST|Physical Fitness Assessment|"* 1-Minute Sit-to-Stand Test: Participants will be asked to sit down and stand up for 1 minute without pausing, and the repetition number will be recorded.~* Timed Up-and-Go Test: Participants will be asked to get up, walk a distance of 3 meters, return and sit down again. The time spent during this track will be recorded.~* Peripheral muscle strength assessment: Participants will be asked to resist the resistance by producing maximum isometric force during the movement, and the maximal force will be evaluated with a dynamometer. The quadriceps femoris muscle, shoulder abductor muscles and hand grip strength will be used for the assessment.~* Flexibility assessment: Participants will be asked to reach towards the tips of their toes while sitting. During this time, the distance between the participant's fingertips and toes will be measured."
219187328|NCT06563154|OTHER|Quality of Life Assessment|Participants' quality of life will be assessed with the Turkish version of the Short Form Quality of Life Questionnaire (SF-36). The questionnaire consists of 36 questions that examine quality of life from different perspectives. It examines quality of life in the subcategories of physical function, physical role difficulty, pain, general health, vitality (energy), social function, emotional role difficulty and mental health. The score for each category varies between 0-100, with a high score indicating a good quality of life.
219187329|NCT06563154|OTHER|Physical Activity Assessment|Participants' physical activity level will be assessed with the Turkish version of the International Physical Activity Scale - Short Form (IPAQ-SF). The IPAQ-SF evaluates the physical activities of the participants in the last 7 days based on sitting time, walking time, moderate and vigorous physical activities.
219187330|NCT06563154|OTHER|Cognitive Health Assessment|Participants' cognitive health will be assessed with the with the Turkish version of the Mini Mental State Examine (MMSE). The test is scored between 0-30. Scores of 25 and above are considered normal. A total score of less than 10 indicates severe impairment. Scores between 10-19 indicate moderate dementia. Scores between 19-24 indicate early dementia.
219191647|NCT03914300|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219191648|NCT03914300|DRUG|Cabozantinib S-malate|Given PO
219191649|NCT03914300|PROCEDURE|Computed Tomography|Undergo CT
219191650|NCT03914300|BIOLOGICAL|Ipilimumab|Given IV
219191651|NCT03914300|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219191652|NCT03914300|BIOLOGICAL|Nivolumab|Given IV
219191653|NCT06170437|BEHAVIORAL|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
219191654|NCT06170437|BEHAVIORAL|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
219191655|NCT05662293|OTHER|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
219191656|NCT05662293|OTHER|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
219191657|NCT05662293|OTHER|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
219191658|NCT05662293|OTHER|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
219191659|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
219191660|NCT05076266|OTHER|Questionnaire|Complete the survey questions
219191661|NCT04070573|DRUG|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
219191662|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
219191663|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
219191664|NCT06628024|OTHER|Milk|Milk
219191665|NCT06628024|OTHER|Yoghurt|Yoghurt
219191666|NCT06804668|DEVICE|tDCS|The intervention involves a home-based, self-administered application of network-targeted, multifocal transcranial direct current stimulation (tDCS) using the Neuroelectrics® StarStim Home-tES device. Participants will apply the tDCS for 20 minutes each day over seven consecutive days. The device is specifically programmed to target a brain network associated with motor symptom improvement in Parkinson's Disease, based on recent research identifying this network through deep brain stimulation studies.
219370967|NCT03448744|DRUG|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
219370968|NCT03448744|DRUG|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
219370969|NCT03204630|DIETARY_SUPPLEMENT|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
219370970|NCT03204630|DIETARY_SUPPLEMENT|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
219370971|NCT03204630|OTHER|Control|Standard infant formula
219370972|NCT04701125|DEVICE|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
219370973|NCT02309463|DRUG|Endothelin receptor antagonist therapy|
219370974|NCT01018355|DEVICE|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
219370975|NCT03067090|DEVICE|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
219370976|NCT02159144|OTHER|cold stress|
219370977|NCT05057364|OTHER|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
219370978|NCT02221544|DEVICE|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
219370979|NCT02221544|DEVICE|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
219370980|NCT02221544|DEVICE|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
219370981|NCT02221544|DEVICE|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
219370982|NCT02537041|PROCEDURE|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
219370983|NCT02537041|PROCEDURE|MRI|
219370984|NCT04008732|DRUG|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
219370985|NCT04008732|DRUG|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
219370986|NCT04008732|DRUG|Nitro Pohl|to be dosed intravenously in Part 2 of the study
219370987|NCT01756274|DEVICE|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
219370988|NCT01756274|DEVICE|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
219370989|NCT01756274|DEVICE|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
219000712|NCT02180152|BEHAVIORAL|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
219000713|NCT00404677|OTHER|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
219370990|NCT05255003|BIOLOGICAL|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
219370991|NCT05255003|BIOLOGICAL|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"
219370992|NCT05255003|BIOLOGICAL|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
219370993|NCT01147926|DRUG|Placebo|Placebo matched to Prucalopride tablet orally once daily.
219370994|NCT01147926|DRUG|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
219370995|NCT02241473|OTHER|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
219370996|NCT00363831|DRUG|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
219370997|NCT04939857|DRUG|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
219370998|NCT02494570|DRUG|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
219370999|NCT02734173|DRUG|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
219371000|NCT01840046|DRUG|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
219371001|NCT03339804|OTHER|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
219371002|NCT04267640|BIOLOGICAL|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
219371003|NCT04267640|BIOLOGICAL|Placebo|Matching placebo
219371004|NCT01560351|DEVICE|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
219371005|NCT03514914|BEHAVIORAL|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
219371006|NCT03432728|PROCEDURE|Dental rehabilitation under general anesthesia|Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
219371007|NCT03707457|DRUG|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219371008|NCT03707457|DRUG|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219371009|NCT03707457|DRUG|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219371010|NCT03707457|DRUG|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
219371011|NCT02850419|DRUG|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
219371012|NCT02850419|RADIATION|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
219371013|NCT02850419|DEVICE|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
219371014|NCT01488253|DRUG|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
219371015|NCT01488253|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
219371016|NCT02183714|DRUG|Songha Night ®|
219371017|NCT02183714|DRUG|Placebo|
219371018|NCT01855256|DRUG|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
219371019|NCT01855256|DRUG|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
219371020|NCT01841632|DRUG|MultiStem|
219371021|NCT02575430|OTHER|No treatment: retrospective chart review|
219371022|NCT04080011|DEVICE|NP-PWD|Application of NP-PWD device.
219371023|NCT05207150|DEVICE|LINQII/Apple Watch Series 6|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
219371024|NCT05207150|DEVICE|LINQII/SkyLabs CART-I ring|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
219371025|NCT05289960|OTHER|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
219371026|NCT04514263|OTHER|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
219371027|NCT04514263|OTHER|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
219000714|NCT06968624|DRUG|Intravenous Ketamine Infusions|The patients received a single intravenous infusion of esketamine (0.2 mg/kg), which was added to 50 ml of normal saline and administered via a micro-infusion pump over 40 minutes.
219000715|NCT06968624|DRUG|Intravenous normal saline|The patients received a single intravenous infusion of 50 ml normal saline via a micro-infusion pump over 40 minutes
219371028|NCT02325544|BEHAVIORAL|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
219371029|NCT02325544|BEHAVIORAL|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
219371030|NCT00869297|OTHER|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
219371031|NCT00869297|OTHER|Control|Fluids titrated at discretion of anesthesiologist.
219371032|NCT00041314|DRUG|carboplatin|
219371033|NCT00041314|DRUG|exisulind|
219371034|NCT00041314|DRUG|gemcitabine hydrochloride|
219371035|NCT04337957|OTHER|geriatric nephrology|Collection of the geriatrician's opinion
219371036|NCT03373019|DRUG|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
219371037|NCT00292084|DRUG|Celgosivir|
219371038|NCT02506530|PROCEDURE|intensive decongestive treatment|intensive decongestive treatment
219371039|NCT02506530|DEVICE|Cellu M6|Use of Cellu M6
219371040|NCT04899648|BEHAVIORAL|Behavioral Intervention Group|Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
219371041|NCT05939297|OTHER|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
219371042|NCT05939297|OTHER|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
219371043|NCT05939297|OTHER|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
219371044|NCT01355289|DRUG|Avatrombopag|
219371045|NCT01355289|DRUG|Placebo|
219371046|NCT01355289|DRUG|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
219371047|NCT01355289|DRUG|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
219371048|NCT01355289|DRUG|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
219371049|NCT02814773|OTHER|questionnaires|
219371050|NCT01795651|PROCEDURE|identification of take-home message of lecture|
219371051|NCT06450665|BEHAVIORAL|VR Social Avoidance Intervention|The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
219371052|NCT05877131|DRUG|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
219371053|NCT05877131|DRUG|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
219371054|NCT03492593|OTHER|lycopene|A tomato oleoresin containing lycopene
219371055|NCT03492593|OTHER|beta-carotene|13C beta-carotene
219371056|NCT03492593|OTHER|control|emulsified liquid meal alone
219371057|NCT05612919|OTHER|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development."
219371058|NCT05612919|OTHER|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
219371059|NCT05782829|DIETARY_SUPPLEMENT|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
219371060|NCT05782829|DIETARY_SUPPLEMENT|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
219371061|NCT03983551|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
219371062|NCT03983551|DRUG|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
219371063|NCT04336163|DEVICE|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
219371064|NCT01880307|DRUG|Azathioprine|
219371065|NCT01880307|DRUG|Infliximab|
219371066|NCT01880307|DRUG|Prednisolon|
219000716|NCT06968624|DRUG|Oral Duloxetine 60mg|Patients received 60 mg/day of oral duloxetine as maintenance therapy for depression.
219187331|NCT06563154|OTHER|Health Literacy Assessment|Participants' health literacy will be assessed with the Turkish version of the HLS-EU-47 health literacy survey. The survey consists of 47 questions. Each item is assessed with one of the following options: Very difficult (1), difficult (2), easy (3), very easy (4) and I don't know. A high total score indicates good health literacy. A total score of 0-25 points indicates insufficient health literacy, \>25-33: problematic - limited health literacy, \>33-42: sufficient health literacy, \>42-50: excellent health literacy.
219187332|NCT06562608|DRUG|Anticholinergic Deprescription|per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
219187333|NCT06562608|DRUG|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
219187334|NCT04820764|DEVICE|CardioMech MVRS|CardioMech MVRS
219187335|NCT00937001|PROCEDURE|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
219187336|NCT06300762|DEVICE|Superabsorbent dressing application|Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
219187337|NCT04522908|DRUG|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
219187338|NCT05618574|DIETARY_SUPPLEMENT|140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 140 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
219187339|NCT05618574|DIETARY_SUPPLEMENT|210 ml of nitrate-depleted placebo|Participants randomized to the placebo arm will receive 210 ml of nitrate-depleted beverage (cranberry juice) per day for 14 days.
219187340|NCT05236660|DEVICE|Custom-made shoes: pressure-optimized|Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
219187341|NCT05236660|DEVICE|Custom-made indoor shoes: pressure optimized|Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
219187342|NCT05236660|DEVICE|Foot temperature monitoring|Personalised at-home daily foot temperature monitoring at high-risk regions.
219187343|NCT05236660|BEHAVIORAL|Education|Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
219187344|NCT05537948|DRUG|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
219187345|NCT05537948|DRUG|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
219187346|NCT06558266|OTHER|Since this was an observational study, no intervention was performed.|Since it is an observational study, only evaluation will be made. Each participant s mental imagery ability will be evaluated with the Movement Imagery Vividness Questionnaire-2 four times, follicular phase, ovulation, luteal phase and menstrual phase. In addition, the pain intensity experienced during menstruation will be evaluated with the Numerical Classification Scale-11, and the symptoms experienced due to menstruation will be evaluated with the Menstruation Symptom Scale.
219187347|NCT02920229|DRUG|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
219187348|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
219187349|NCT06050369|DEVICE|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
219371067|NCT01085682|BEHAVIORAL|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
219371068|NCT01085682|BEHAVIORAL|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
219371069|NCT03906266|DIAGNOSTIC_TEST|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
219371070|NCT03089307|DEVICE|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
219371071|NCT06140771|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
219371072|NCT06140771|DRUG|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
219371073|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
219371074|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
219371075|NCT03920969|BEHAVIORAL|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
219371076|NCT03749395|PROCEDURE|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
219371077|NCT04201743|DRUG|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
219371078|NCT04948008|BIOLOGICAL|IBI306|IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
219371079|NCT03623919|OTHER|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
219371080|NCT05410990|DIAGNOSTIC_TEST|eosinophil and other hematological parameters|
219371081|NCT02563301|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
219371082|NCT00004396|DRUG|heme arginate|
219371083|NCT00004396|DRUG|tin mesoporphyrin|
219371084|NCT05210595|DRUG|Clopidogrel 75 mg|75 mg/day as maintenance dose.
219371085|NCT05210595|DRUG|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
219371086|NCT05210595|DRUG|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
219371087|NCT03931655|DIAGNOSTIC_TEST|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
219371088|NCT02198833|BIOLOGICAL|Urine Culture|Obtain urine culture every third day
219371089|NCT02198833|DEVICE|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
219371090|NCT02198833|DEVICE|Scanning Electron Microscopy|Houston Site Only
219371091|NCT02198833|PROCEDURE|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
219371092|NCT02198833|PROCEDURE|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
219371093|NCT01911858|DEVICE|Askina Calgitrol Paste|
219371094|NCT00289822|DRUG|intracoronary infusion of progenitor cells|
219371095|NCT04919915|DEVICE|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
219371096|NCT05621356|OTHER|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
219371097|NCT01885780|DEVICE|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
219371098|NCT03268629|BEHAVIORAL|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
219371099|NCT03268629|BEHAVIORAL|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
219371100|NCT00457496|BEHAVIORAL|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
219000717|NCT02288052|BEHAVIORAL|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
219187350|NCT06050369|DEVICE|MRI|Get the anatomical shape of the brain.
219371101|NCT01923025|DRUG|RO5545965|Single dose
219371102|NCT03628157|OTHER|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
219371103|NCT04097548|BEHAVIORAL|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
219371104|NCT04513691|DIAGNOSTIC_TEST|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
219371105|NCT05266404|DRUG|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
219371106|NCT05266404|DRUG|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
219371107|NCT05266404|DRUG|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
219371108|NCT01379625|DRUG|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
219371109|NCT02324166|DRUG|Cefazolin|cephalosporin antibiotic
219371110|NCT02324166|DRUG|Lidocaine|local anesthetic
219371111|NCT03614572|BEHAVIORAL|Group MI|refer to the arm description
219371112|NCT01447394|BIOLOGICAL|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
219371113|NCT01447394|BIOLOGICAL|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
219371114|NCT01447394|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
219371115|NCT01461681|PROCEDURE|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
219371116|NCT00813995|DRUG|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
219371117|NCT00813995|DRUG|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
219371118|NCT02507349|BEHAVIORAL|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
219371119|NCT02507349|BEHAVIORAL|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
219371120|NCT05497726|PROCEDURE|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
219371121|NCT06363162|DIAGNOSTIC_TEST|Immunohistochemistry or genetic test|Perform two diagnostic methods on the same sample
219371122|NCT01614964|DRUG|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
219371123|NCT01614964|DRUG|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
219371124|NCT03618030|DRUG|PRC-063 oral capsules|Daily dose
219371125|NCT03618030|DRUG|Placebo oral capsules|Daily dose
219187351|NCT05049018|OTHER|Traditional Physical Therapy Program|"This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities."
219187352|NCT05049018|DEVICE|ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)|ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
219187353|NCT06473662|DRUG|Oral insulin|Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
219187354|NCT05725161|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
219187355|NCT05725161|BEHAVIORAL|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
219371126|NCT02082197|DRUG|ABT-SLV176|ABT-SLV176 administered daily
219371127|NCT02684305|DRUG|Administration of Propess|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
219000718|NCT02288052|BEHAVIORAL|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
219000719|NCT01794884|DRUG|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
219187356|NCT04461327|BEHAVIORAL|Painful stimulations of major depressive patients|"All three pain mechanisms will be tested in one session lasting 1h approximately.~The mechanisms are tested in the following order:~1. Aδ and C threshold~2. Wind-up~3. CPM~(more details in detailed description)"
219187357|NCT04461327|BIOLOGICAL|Blood sample|The blood test is made between 2 and 24 hours before the experimental procedure. The biological collection is made to measure medications' concentration if the patient takes antiepileptics and/or lithium, and to measure complete blood count (CBC).
219187358|NCT04461327|DIAGNOSTIC_TEST|Clinical assessment|"A clinical assessment will be made by a trained researcher.~(more details in detailed description)"
219187359|NCT04461327|BEHAVIORAL|Social touch|Stroking
219187360|NCT04592978|BEHAVIORAL|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
219187361|NCT04592978|BEHAVIORAL|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
219187362|NCT03551392|DEVICE|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
219187363|NCT03551392|DEVICE|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
219187364|NCT03551392|DEVICE|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
219187365|NCT03551392|DEVICE|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
219187366|NCT05430152|DRUG|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
219187367|NCT05430152|OTHER|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
219187368|NCT02611518|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
219187369|NCT02611518|DRUG|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
219187370|NCT02611518|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
219187371|NCT05651178|DRUG|Human CD19-CD22 Targeted T Cells Injection|Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
219187372|NCT06538207|DRUG|ONO-4578|Specified dose on specified days
219187373|NCT06538207|DRUG|ONO-4538|Specified dose on specified days
219187374|NCT06538207|DRUG|Oxaliplatin|Specified dose on specified days
219187375|NCT06538207|DRUG|Levofolinate|Specified dose on specified days
219187376|NCT06538207|DRUG|Irinotecan|Specified dose on specified days
219187377|NCT06538207|DRUG|Fluorouracil|Specified dose on specified days
219187378|NCT06538207|DRUG|Gemcitabine|Specified dose on specified days
219187379|NCT06538207|DRUG|Nab-Paclitaxel|Specified dose on specified days
219187380|NCT03449706|DRUG|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
219760849|NCT05554458|BEHAVIORAL|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
219760850|NCT00852410|DRUG|1% lidocaine with 1:100,000 adrenaline|high dose
219187381|NCT06238726|BEHAVIORAL|Reminder|Shingrix messages via SMS, patient portal, email, and/or another modality
219187382|NCT05727930|BEHAVIORAL|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
219187383|NCT05727930|BEHAVIORAL|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
219187384|NCT05727930|BEHAVIORAL|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
219187385|NCT05727930|BEHAVIORAL|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
219187386|NCT06125054|DRUG|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
219187387|NCT06125054|DRUG|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
219187388|NCT06125054|BEHAVIORAL|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.
219187389|NCT06125054|BEHAVIORAL|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.
219187390|NCT06443489|DRUG|SHR-4849|SHR-4849
219187391|NCT05485779|DRUG|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
219187392|NCT05485779|DRUG|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
219371128|NCT02684305|DEVICE|balloon|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
219371129|NCT02684305|DRUG|Intravenous oxytocin infusion|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
219371130|NCT02612870|DEVICE|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
219371131|NCT02612870|DEVICE|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
219371132|NCT02612870|DEVICE|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
219371133|NCT02612870|DEVICE|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
219371134|NCT02612870|DEVICE|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
219371135|NCT00541983|DRUG|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
219371136|NCT00541983|DRUG|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
219371137|NCT01851538|OTHER|Observational study; no intervention.|
219371138|NCT02909868|DEVICE|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
219371139|NCT06016816|PROCEDURE|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
219371140|NCT06016816|PROCEDURE|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
219371141|NCT00357773|DRUG|Azithromycin (T1225)|
219371142|NCT04972877|OTHER|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
219371143|NCT04972877|OTHER|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
219371144|NCT03023904|BIOLOGICAL|Nivolumab|Given IV
219371145|NCT03023904|OTHER|Laboratory Biomarker Analysis|Correlative studies
219371146|NCT06448793|DRUG|Approved Non-small Cell Lung Cancer (NSCLC) therapies|As prescribed by treating physician
219371147|NCT01105637|BEHAVIORAL|Augmented Exercise Program|12 week (3 x per week) exercise prescription
219371148|NCT02759042|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219371149|NCT02700984|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
219371150|NCT02700984|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
219371151|NCT00733525|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
219371152|NCT00733525|DRUG|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
219371153|NCT00733525|BEHAVIORAL|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
219371154|NCT00331435|PROCEDURE|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
219371155|NCT00619008|OTHER|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
219371156|NCT00619008|OTHER|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
219371157|NCT00619008|OTHER|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
219371158|NCT02648386|PROCEDURE|Laparoscopic surgery|Completely resected rectal tumor.
219371159|NCT02648386|DEVICE|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
219760851|NCT00852410|DRUG|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
219371160|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
219371161|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
219371162|NCT04600167|DRUG|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
219371163|NCT04600167|DRUG|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
219371164|NCT00061256|DRUG|Alendronate|
219371165|NCT00061256|DRUG|Calcium carbonate|
219371166|NCT00061256|DRUG|Vitamin D|
219371167|NCT01543347|DRUG|Temocillin|Antibiotic treatment
219371168|NCT02557061|PROCEDURE|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
219371169|NCT02557061|BIOLOGICAL|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
219371170|NCT05784207|OTHER|Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern|The aim is to evaluate the performance of AI with the performance of doctors
219371171|NCT03254173|DRUG|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
219371172|NCT03254173|DRUG|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
219371173|NCT05233358|PROCEDURE|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
219371174|NCT05233358|PROCEDURE|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
219371175|NCT05233358|DRUG|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
219371176|NCT05233358|DRUG|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
219371177|NCT03911622|DEVICE|MRI|medical device that is used as an imaging tool for soft tissues
219371178|NCT05066685|OTHER|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
219371179|NCT03705481|DEVICE|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
219371180|NCT00473876|DRUG|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
219371181|NCT00473876|DRUG|Matched Placebo (Capsules)|Similar dosing regime as active comparator
219371182|NCT01032629|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily
219371183|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
219371184|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
219371185|NCT00348140|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
219371186|NCT00348140|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
219371187|NCT00348140|OTHER|Placebo|Placebo
219371188|NCT00516919|DRUG|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
219371189|NCT00516919|BEHAVIORAL|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
219371190|NCT06064760|BEHAVIORAL|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself."
219371191|NCT04795479|DRUG|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
219371192|NCT04795479|DRUG|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
219371193|NCT04795479|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
219371194|NCT02489370|DEVICE|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
219371195|NCT02619422|OTHER|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
219371196|NCT05086679|DEVICE|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
219371197|NCT05086679|DEVICE|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
219371198|NCT05086679|BEHAVIORAL|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
219371199|NCT01392833|DRUG|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
219371200|NCT01392833|DRUG|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
219371201|NCT01392833|DRUG|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
219371202|NCT05411302|OTHER|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
219371203|NCT04629560|DRUG|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
219371204|NCT01508455|DRUG|Dexmedetomidine|
219371205|NCT01508455|DRUG|Midazolam|
219371206|NCT01508455|DRUG|Fentanyl|
219371207|NCT01508455|DRUG|Morphine|
219371208|NCT00452712|PROCEDURE|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
219371209|NCT00799526|PROCEDURE|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
219371210|NCT00799526|PROCEDURE|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
219371211|NCT01968941|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
219371212|NCT01968941|RADIATION|Conventional Radiotherapy (CRT)|
219371213|NCT02291211|DRUG|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
219371214|NCT03254056|PROCEDURE|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
219371215|NCT03254056|PROCEDURE|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
219371216|NCT04416802|COMBINATION_PRODUCT|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
219371217|NCT02086019|DRUG|Conservative Arm|crossover to angiogram only if predefined criteria met
219371218|NCT02086019|PROCEDURE|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
219371219|NCT03305640|PROCEDURE|acetabular fracture surgery|acetabular fracture surgery
219371220|NCT03499730|DRUG|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
219371221|NCT02797119|DRUG|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
219371222|NCT02797119|DRUG|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
219371223|NCT02797119|DRUG|Saline Solution (TA0)|
219371224|NCT00977470|DRUG|Erlotinib|150 mg taken orally once daily
219371225|NCT00977470|DRUG|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
219760852|NCT02546882|BIOLOGICAL|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
219760853|NCT02546882|DRUG|saline|1 ml saline was injected for 1 cm2 area.
219371226|NCT00032084|BEHAVIORAL|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
219371227|NCT00032084|DRUG|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
219371228|NCT00032084|DRUG|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
219371229|NCT00032084|PROCEDURE|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
219371230|NCT04103866|DEVICE|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
219371231|NCT02284165|OTHER|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
219371232|NCT00737529|DRUG|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
219371233|NCT01339455|PROCEDURE|AHSCT|"AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF"
219371234|NCT00134914|DRUG|Buprenorphine|single doses given by sublingual and parenteral routes
219371235|NCT03757039|DEVICE|Multifocal soft contact lenses|Commercially available contact lenses
219371236|NCT03757039|OTHER|Progressive addition lens spectacles|Per subject's habitual prescription
219371237|NCT02976415|OTHER|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
219371238|NCT03501056|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
219371239|NCT03501056|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
219371240|NCT00188084|PROCEDURE|DNA Index|
219371241|NCT00188084|PROCEDURE|S-Phase%|
219371242|NCT00188084|PROCEDURE|CD45 expression|
219371243|NCT00188084|PROCEDURE|P16 metabolic way|
219371244|NCT00096161|DRUG|Cyclosporine|Given PO
219371245|NCT00096161|DRUG|Mycophenolate Mofetil|Given PO
219371246|NCT00096161|DRUG|Pentostatin|Given IV
219000720|NCT01794884|DRUG|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
219371247|NCT00096161|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
219371248|NCT01126346|BEHAVIORAL|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
219371249|NCT01126346|BEHAVIORAL|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
219371250|NCT01126346|OTHER|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
219371251|NCT01173653|OTHER|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
219371252|NCT01173653|OTHER|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
219371253|NCT00227357|DRUG|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
219371254|NCT00227357|DRUG|Off-site - methadone or no agonist|
219371255|NCT00206570|DRUG|Estradiol|
219371256|NCT05169671|DRUG|ATH-1020|ATH-1020 in oral capsule form
219371257|NCT05169671|DRUG|Placebo|Placebo in oral capsule form
219371258|NCT02062931|BIOLOGICAL|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
219371259|NCT00326092|DRUG|Brinzolamide/Timolol|
219371260|NCT03502850|DRUG|ASK120067|patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
219371261|NCT05840939|BEHAVIORAL|Pranayama|"Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity."
219371262|NCT05840939|BEHAVIORAL|diaphragm breathing exercise|Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
219371263|NCT04468217|DIAGNOSTIC_TEST|Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples|Each patient will undergo a sample collection where two nasopharyngeal samples will be obtained, one of them with lysis buffer as the transport medium and the other with the AAA-Safe solution as the transport medium. Oropharyngeal, buccal, nasal, and salivary samples will also be obtained using AAA-Safe as the transport medium
219371264|NCT04758494|OTHER|Questionnaire|"In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population."
219371265|NCT06199245|OTHER|emotional freedom technique experimental group|Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
219371266|NCT06366243|DRUG|Emraclidine|Oral tablet
219371267|NCT06366243|DRUG|Esomeprazole|Oral delayed-release capsule
219371268|NCT00850746|DRUG|YM443|Oral
219371269|NCT00850746|DRUG|Placebo|Oral
219371270|NCT00850746|DRUG|Moxifloxacin|Oral
219371271|NCT00138086|DRUG|Zevalin plus BEAM|
219371272|NCT04502303|DIAGNOSTIC_TEST|18F-FDG and 68Ga-FAPI PET/CT|Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.
219371273|NCT02844998|BEHAVIORAL|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
219371274|NCT02844998|DRUG|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
219371275|NCT02519881|PROCEDURE|Microfracture|simple microfracture of ankle
219371276|NCT02519881|DEVICE|CartiFill|add collagen when doing microfracture
219371277|NCT04415398|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
219371278|NCT01494363|DRUG|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
219371279|NCT01494363|DRUG|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
219371280|NCT01494363|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
219371281|NCT01494363|DRUG|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
219371282|NCT01903941|BEHAVIORAL|Aerobic Exercise|
219371283|NCT01903941|BEHAVIORAL|Only Counseling|
219371284|NCT02914509|DRUG|Travoprost|
219371285|NCT02914509|OTHER|Placebo Vehicle|
219371286|NCT00242294|DRUG|Roflumilast|
219371287|NCT01656772|DEVICE|Vdrive Lasso navigation|Remote robotic Lasso navigation
219371288|NCT01656772|PROCEDURE|Manual Lasso navigation|Manually maneuver a Lasso catheter
219371289|NCT01415024|PROCEDURE|second LV lead in CRT|second LV lead in CRT
219371290|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
219371291|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
219371292|NCT01011348|DIETARY_SUPPLEMENT|Placebo|Three month period
219371293|NCT05774340|DRUG|CM326|CM326 injection
219371294|NCT05774340|OTHER|Placebo|Placebo
219371295|NCT02947867|DRUG|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
219371296|NCT01651780|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
219371297|NCT01651780|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
219371298|NCT02096094|PROCEDURE|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
219371299|NCT02096094|PROCEDURE|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
219371300|NCT02096094|PROCEDURE|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
219371301|NCT04273074|RADIATION|sonographic assessment|preoperative sonographic assessment to airway
219371302|NCT02368548|OTHER|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
219371303|NCT02368548|OTHER|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
219371304|NCT00200265|BEHAVIORAL|diet|diet
219371305|NCT04880122|DIAGNOSTIC_TEST|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
219371306|NCT00003141|BIOLOGICAL|filgrastim|Given IV
219371307|NCT00003141|DRUG|carboplatin|Given IV
219371308|NCT00003141|DRUG|cisplatin|Given IV
219371309|NCT00003141|DRUG|cyclophosphamide|Given IV
219371310|NCT00003141|DRUG|etoposide|Given IV
219371311|NCT00003141|DRUG|thiotepa|Given IV
219371312|NCT00003141|DRUG|vincristine sulfate|Given IV
219371313|NCT00003141|PROCEDURE|conventional surgery|
219371314|NCT00003141|PROCEDURE|peripheral blood stem cell transplantation|
219371315|NCT05207475|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
219371316|NCT01412229|DRUG|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
219371317|NCT01412229|DRUG|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
219371318|NCT01412229|DRUG|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
219371319|NCT05548036|DEVICE|OPEP|OPEP (Aerobika (tm)
219371320|NCT03359902|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
219371321|NCT03359902|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
219371322|NCT00323284|DEVICE|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
219371323|NCT00323284|PROCEDURE|Cataract surgery only|Cataract surgery only
219371324|NCT01051089|BEHAVIORAL|Lifestyle modification|Exercise and diet education
219371325|NCT05855161|OTHER|Rebound therapy|Participants will receive exercise-based training on a trampoline
219371326|NCT05855161|OTHER|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
219371327|NCT02930174|DEVICE|noninvasive positive pressure ventilation|Application of various levels of positive pressure
219371328|NCT02139956|DEVICE|ultrasonography|open
219371329|NCT05388747|DRUG|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
219371330|NCT01907386|OTHER|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
219371331|NCT00151892|DRUG|SPD476|2.4 g/day Once Daily (QD)
219371332|NCT00151892|DRUG|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
219371333|NCT02901431|DRUG|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
219371334|NCT02901431|DRUG|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
219371335|NCT03474055|BIOLOGICAL|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
219371336|NCT06484894|DEVICE|Pentacam and IOL master|Device used for measurement of central corneal thickness
219371337|NCT03883074|DEVICE|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
219371338|NCT03883074|DEVICE|Placebo|tablets with the same aspect of the active device
219371339|NCT01889602|DRUG|Lorazepam|Lorazepam: 2mg, po, 1x
219371340|NCT01889602|OTHER|Placebo|Non-active placebo, po, 1x
219371341|NCT01889602|DRUG|Topiramate 100mg|Topiramate: 100 mg, po, 1x
219371342|NCT01889602|DRUG|Topiramate 150mg|Topiramate: 150 mg, po, 1x
219371343|NCT01889602|DRUG|Topiramate 200mg|Topiramate: 200 mg, po, 1x
219371344|NCT00435734|BEHAVIORAL|obesity intervention|
219371345|NCT00404092|DRUG|caspofungin|i.v.
219371346|NCT01783067|OTHER|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
219371347|NCT01783067|OTHER|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
219371348|NCT01256216|DEVICE|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
219371349|NCT04453735|DRUG|Atorvastatin mylan 40 Mg Oral Tablet|Oral tablet on regular prescription
219371350|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
219187393|NCT04670900|PROCEDURE|Tension band wiring or plate fixation|Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
219187394|NCT04670900|PROCEDURE|Active non-operative treatment with optional plaster cast|Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
219187395|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
219187396|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
219371351|NCT03303989|DRUG|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
219371352|NCT03303989|DRUG|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
219371353|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
219371354|NCT01278290|DIAGNOSTIC_TEST|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
219371355|NCT01278290|DIAGNOSTIC_TEST|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
219371356|NCT02896530|OTHER|No intervention. Description study|
219371357|NCT05812391|PROCEDURE|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
219371358|NCT05812391|PROCEDURE|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
219371359|NCT01272583|DRUG|Sitagliptin|100 mg once daily for six weeks
219371360|NCT01272583|DRUG|Placebo|placebo, once daily for six weeks
219371361|NCT02674945|DEVICE|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
219371362|NCT06088927|DEVICE|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
219371363|NCT05666557|OTHER|manual erector spinae myofascial realease|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
219371364|NCT05666557|OTHER|self-myofascial release technique|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
219371365|NCT00255073|DRUG|baclofen|
219371366|NCT04223609|DRUG|Oxycodone|5 mg tablet
219371367|NCT04223609|DRUG|Placebo|Oxycodone-matched placebo tablet
219187397|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
219187398|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
219187399|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
219187400|NCT05605509|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
219187401|NCT06157580|DRUG|Compound 21|differences in vasodilation to compound 21 in the skin between groups
219187402|NCT06157580|DRUG|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
219187403|NCT05998824|BEHAVIORAL|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
219371368|NCT04223609|DEVICE|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
219371369|NCT04223609|DIAGNOSTIC_TEST|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
219371370|NCT04223609|DEVICE|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
219371371|NCT03141944|OTHER|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
219371372|NCT03871686|BEHAVIORAL|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
219371373|NCT02154399|DRUG|EF5|Given IV
219187404|NCT05819996|BEHAVIORAL|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
219187405|NCT04760899|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
219187406|NCT02464007|BIOLOGICAL|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
219187407|NCT03463044|DRUG|nangibotide|Continous i.v. infusion
219187408|NCT03463044|DRUG|Placebo|Placebo
219187409|NCT04704544|OTHER|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
219187410|NCT06838468|DIAGNOSTIC_TEST|Screening of compensated advance chronic liver disease|"The tests performed will include a general blood analysis to evaluate liver and kidney function, an assessment of the prevalence of metabolic diseases such as obesity, hypertension, or diabetes, an abdominal ultrasound, and elastography to assess liver stiffness.~Another intervention to be studied is whether the request for diagnostic tests to evaluate liver disease, as well as the visit of the hepatologist during hospitalization in the detoxification unit, influences subsequent alcohol abstinence. To this end, abstinence will be assessed six months after admission to the alcohol detoxification unit and compared with a retrospective cohort of patients admitted to the detoxification unit one year ago, in whom no liver disease evaluation was conducted neither information of potencial liver damage was offered by hepatologist and the intervention was carried out only by the psychiatrists responsible for the unit."
219187411|NCT02965755|OTHER|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
219187412|NCT05192109|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
219187413|NCT05192109|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
219187414|NCT04498390|DRUG|LY3493269|Administered orally.
219187415|NCT04498390|DRUG|Placebo|Administered orally.
219187416|NCT05106491|DEVICE|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
219187417|NCT04781153|PROCEDURE|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
219187418|NCT05095532|BIOLOGICAL|Bone marrow-derived mesenchymal stem cells|MSC transplantation
219187419|NCT05095532|OTHER|Placebo|Standard of Care
219187420|NCT06484920|DRUG|ATRA|150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
219187421|NCT06484920|DRUG|Pembrolizumab|200mg Q3W pembrolizumab
219187422|NCT03820141|DRUG|Durvalumab|programmed cell death-ligand 1 inhibitor
219187423|NCT03820141|DRUG|Trastuzumab|anti-HER2 monoclonal antibody
219187424|NCT03820141|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
219187425|NCT05681169|OTHER|School-based HPV-counselling and HPV-vaccination.|"1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV"
219187426|NCT06322940|OTHER|250 mL serving size, 3.25% fat content|Milk
219187427|NCT06322940|OTHER|175 g serving size, ≥2% fat content|Yogurt
219187428|NCT06322940|OTHER|50 g serving size, ≥28% fat content|Cheese
219187429|NCT05370040|BIOLOGICAL|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
219187430|NCT05370040|BIOLOGICAL|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
219187431|NCT05370040|BIOLOGICAL|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
219187432|NCT06802289|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females older adults.
219187433|NCT05170841|DRUG|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg|Administered as one single tablet to be taken every 8 hours
219187434|NCT05170841|DRUG|Tramadol Hydrochloride 100 mg|Administered as two capsules with 50 mg each to be taken every 8 hours
219187435|NCT05170841|DRUG|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
219187436|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
219187437|NCT04872439|DIAGNOSTIC_TEST|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
219187438|NCT05686278|DEVICE|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
219187439|NCT04865289|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
219187440|NCT04865289|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
219187441|NCT04865289|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
219187442|NCT04865289|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
219371374|NCT02154399|OTHER|Laboratory Biomarker Analysis|Correlative studies
219371375|NCT02154399|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
219371376|NCT02154399|OTHER|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
219371377|NCT02549716|DRUG|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
219371378|NCT02549716|DRUG|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
219371379|NCT02549716|DRUG|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
219371380|NCT02549716|DRUG|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
219371381|NCT02713451|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
219371382|NCT00073840|DRUG|levalbuterol|"* Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID"
219371383|NCT03440944|DEVICE|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
219371384|NCT03440944|DEVICE|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
219371385|NCT04318392|OTHER|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
219371386|NCT04318392|OTHER|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
219371387|NCT04318392|OTHER|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
219371388|NCT04318392|OTHER|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
219371389|NCT04318392|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
219371390|NCT04318392|OTHER|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
219371391|NCT04318392|OTHER|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
219371392|NCT04152382|DRUG|LY3462817 - IV|Administered IV
219371393|NCT04152382|DRUG|LY3462817 - SC|Administered SC
219371394|NCT04152382|DRUG|Placebo - IV|Administered IV
219371395|NCT04152382|DRUG|Placebo - SC|Administered SC
219371396|NCT04152382|DRUG|LY3509754|Administered orally.
219371397|NCT04152382|DRUG|Placebo|Administered orally.
219371398|NCT04790227|DEVICE|MRI|MRI
219371399|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
219371400|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
219371401|NCT04899583|DEVICE|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
219371402|NCT04899583|DEVICE|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
219371403|NCT00943683|DRUG|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
219371404|NCT00943683|DRUG|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
219371405|NCT02652039|OTHER|Questionnaires|Questionnaires
219371406|NCT03505437|OTHER|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
219371407|NCT03505437|OTHER|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
219371408|NCT01597102|OTHER|No interventions|No intervention is planned in this study
219371409|NCT01963494|BEHAVIORAL|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
219371410|NCT01963494|BEHAVIORAL|Individual planning intervention|Target persons form action plans on their own.
219371411|NCT01963494|BEHAVIORAL|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
219371412|NCT04796519|PROCEDURE|Total knee arthroplasty|Surgical procedure
219371413|NCT01646359|DEVICE|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
219371414|NCT01646359|DEVICE|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
219371415|NCT03306654|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
219371416|NCT06287879|DIAGNOSTIC_TEST|Dry eye examination|"1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images"
219371417|NCT04492904|OTHER|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
219371418|NCT00914693|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
219371419|NCT04695509|DRUG|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
219371420|NCT04695509|DRUG|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
219371421|NCT00631631|DRUG|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
219371422|NCT05360550|DRUG|LSP-5415|pregnancy prevention
219371423|NCT03152942|DRUG|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
219371424|NCT03152942|DRUG|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
219371425|NCT04738357|DRUG|HSK21542|HSK21542：1 µg/kg
219371426|NCT04738357|DRUG|Placebo|Placebo
219371427|NCT00382148|DRUG|omalizumab|SC repeating dose
219371428|NCT02870725|BEHAVIORAL|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
219371429|NCT05485207|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
219371430|NCT02536248|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
219371431|NCT02536248|DRUG|Placebo|Placebo for 6 weeks
219371432|NCT06071611|OTHER|Experimental: Oxygen-Ozone (O2-O3)|Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
219371433|NCT06071611|OTHER|Active Comparator: Oxygen (O2)|Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
219371434|NCT06071611|OTHER|Placebo Comparator: Placebo (Air)|Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
219187443|NCT05752149|DRUG|CRGD-ZW800-1|Intravenous administration of study drug at lesat 2h prior to surgery
219187444|NCT04360252|OTHER|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
219187445|NCT05052684|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
219187446|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
219187447|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
219187448|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
219187449|NCT04603443|DIETARY_SUPPLEMENT|Protein Control|Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
219187450|NCT04380311|DEVICE|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
219371435|NCT05200793|DRUG|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
219371436|NCT05200793|DRUG|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
219371437|NCT05200793|DRUG|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
219371438|NCT03035760|DRUG|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
219371439|NCT01552343|DRUG|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
219371440|NCT01552343|DRUG|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
219371441|NCT02339467|OTHER|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
219371442|NCT02339467|OTHER|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
219371443|NCT05792384|PROCEDURE|transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
219371444|NCT05792384|PROCEDURE|transbronchial lung biopsy with biopsy forceps|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps
219371445|NCT01446211|DRUG|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
219371446|NCT01446211|DRUG|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
219371447|NCT00730743|PROCEDURE|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
219371448|NCT03767569|DRUG|Myo-inositol|Myo-inositol and Folic acid daily
219371449|NCT03767569|DRUG|Folic Acid|Folic Acid daily
219371450|NCT04217564|BEHAVIORAL|Nutritional counselling|Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
219371451|NCT01132105|DEVICE|Vestibular myogenic evoked potential analyzer|
219371452|NCT05448677|DRUG|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
219371453|NCT05448677|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
219371454|NCT05448677|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219371455|NCT04360967|OTHER|Standard Formula|Standard Formula
219371456|NCT04360967|OTHER|Nutrient-enriched Formula|Nutrient-enriched Formula
219371457|NCT05302635|OTHER|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
219000721|NCT04170153|DRUG|M1774|M1774 will be administered orally throughout the study.
219000722|NCT04170153|DRUG|Niraparib|Niraparib will be administered orally throughout the study.
219187451|NCT05917119|OTHER|BLT|Bright light therapy delivered via glasses
219187452|NCT05917119|OTHER|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
219187453|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
219371458|NCT04418856|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
219371459|NCT04418856|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
219371460|NCT03198689|DRUG|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
219371461|NCT05761964|BEHAVIORAL|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
219371462|NCT05761964|BEHAVIORAL|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
219371463|NCT03542058|DRUG|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
219371464|NCT06542146|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet is consisting of fruits, vegetables , legumes, whole grains, nuts, and olive oil as the main source ofdietary fat
219371465|NCT06542146|DIETARY_SUPPLEMENT|Usual diet|Usual diet including routine diet we already eat
219371466|NCT04311658|DRUG|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
219371467|NCT04311658|DRUG|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
219371468|NCT04439123|DRUG|Capivasertib|Given PO
219371469|NCT04895306|DRUG|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
219371470|NCT04895306|DRUG|Placebo|Weekly intramuscular administration of Placebo
219371471|NCT04555941|DEVICE|intermittent theta burst stimulation|active or Sham iTBS will be given to the AD/MCI patient
219371472|NCT05943704|DIETARY_SUPPLEMENT|beef broth|It indicates if the child has allergy of Beef or not.
219371473|NCT06936059|DEVICE|Mixed Reality based analgesic therapy|"The intervention is a single 15 min MR therapy. The MR therapy is consisted of MR device and software. The model of MR device used is Pico Neo 3 Pro. The software run on the MR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.~And the placebo-group used the same non-mixed reality(Non-MR) scenario to treat patients, although the scenario is completely identical, it is not presented in a mixed reality scenario. It only presents the scene in normal display mode."
219371474|NCT02608918|DRUG|BMS-955176|
219371475|NCT02786823|DIETARY_SUPPLEMENT|Folic acid|tab. Folic acid 5 mg
219371476|NCT02786823|DIETARY_SUPPLEMENT|Vitamin B12|tab. Vitamin B12 500 mcg
219371477|NCT02786823|DRUG|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea"
219371478|NCT01404663|BIOLOGICAL|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
219371479|NCT03952260|OTHER|Fasting time for clear fluid prior to anaesthesia|"This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery."
219371480|NCT06271525|OTHER|cupping therapy|"All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~1. -Primary sucking~2. -Scarification 3- Bloodletting 4-Removal~5 -Dressing"
219371481|NCT04141176|DEVICE|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
219187454|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
219187455|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
219371482|NCT04888663|DRUG|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
219371483|NCT01370967|OTHER|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
219371484|NCT01370967|OTHER|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
219371485|NCT01370967|OTHER|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
219371486|NCT03623867|DRUG|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
219371487|NCT03623867|DRUG|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
219371488|NCT00288574|DRUG|Fluoxetine|
219371489|NCT00288574|DRUG|Placebo|
219371490|NCT04880928|DRUG|Eye injection (Mydrane)|"Mydrane 0.2 mg/ml + 3.1 mg/ml~\+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride"
219371491|NCT04880928|DRUG|eye drops (Phenylephrin)|Phenylephrine 10%
219371492|NCT04880928|DRUG|eye drops (Tropicamid)|Tropicamid 0,5%
219371493|NCT03849339|DRUG|CKD-387|Test drug
219371494|NCT03849339|DRUG|D635|Reference drug
219371495|NCT03633357|DRUG|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
219371496|NCT03633357|DRUG|Placebo|Participants will take two placebo tablets daily, for seven days.
219371497|NCT05136963|DRUG|Iohexol|5 milliliter of iohexol will be administrated.
219371498|NCT05136963|BIOLOGICAL|pharmacokinetics|10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
219371499|NCT02800187|DEVICE|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
219371500|NCT02796105|DRUG|Progevera|
219371501|NCT02796105|DRUG|Orgalutran|
219371502|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
219371503|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
219371504|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
219371505|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
219371506|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
219371507|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
219371508|NCT01951001|DRUG|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
219371509|NCT00245947|DRUG|ERB-041|
219371510|NCT02921386|DRUG|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
219371511|NCT01905956|DIETARY_SUPPLEMENT|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
219371512|NCT01905956|DIETARY_SUPPLEMENT|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
219371513|NCT03033329|DRUG|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
219371514|NCT03033329|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
219371515|NCT03033329|DRUG|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
219371516|NCT03033329|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
219371517|NCT03033329|DRUG|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
219371518|NCT03137979|BIOLOGICAL|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
219371519|NCT03137979|BIOLOGICAL|Collagen scaffolds|Patients in this group were given collagen scaffolds.
219371520|NCT03137979|PROCEDURE|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
219371521|NCT05323422|PROCEDURE|intravenous Ketamine induction|preoperatively ketamine wll administer in group 1-3
219371522|NCT05998915|OTHER|observe only|observe only
219371523|NCT04007315|DEVICE|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
219371524|NCT04007315|BEHAVIORAL|Usual care|6-weeks of usual NHS care
219371525|NCT00503256|BEHAVIORAL|Questionnaire|Questionnaires each taking 60 minutes to complete.
219371526|NCT00330707|DRUG|Bacillus Calmette Guerin and interferon alpha|
219187456|NCT01233531|BEHAVIORAL|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
219187457|NCT01233531|BEHAVIORAL|B--No cash transfers|No monthly cash transfers
219187458|NCT05346757|DIAGNOSTIC_TEST|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
219187459|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
219187460|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
219187461|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
219187462|NCT05396040|PROCEDURE|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
219187463|NCT03318601|PROCEDURE|Blood taking|"Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume"
219187464|NCT05363319|DRUG|Cemiplimab|solution for injection via intravenous (IV) infusion
219187465|NCT05363319|DRUG|Platinum-based chemotherapy|IV administration
219187466|NCT05084209|BEHAVIORAL|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
219187467|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
219187470|NCT06201559|DRUG|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
219187471|NCT06201559|DRUG|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
219187472|NCT03875287|DRUG|Decitabine|"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5~Level 4 25 mg daily days 1-5"
219187473|NCT03875287|DRUG|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5~Level 4 100mg daily days 1-5"
219187474|NCT04198181|PROCEDURE|Surgery|Resective surgery included lobectomy (partial or total brain lobe resection), tuberectomy (epileptogenic tuber resection), and tuberectomy plus (resection of epileptogenic tuber and perituberal gyri). Tuberectomy was typically performed on the epileptogenic tuber within or near an eloquent area. Lobectomy was performed in patients with large epileptogenic tubers in the brain lobes. Multiple lobectomies, tuberectomies, tuberectomies plus, and lobectomy combined with tuberectomy/tuberectomies plus were further performed in patients with multiple epileptogenic tubers.
219187475|NCT06852729|OTHER|Biering-sorenson protocol|"* Students shouldn't perform any vigorous activity a day before assessment.~* Frist, therapist will request from each participant to watch videos to understand how the test should be applied.~* The starting position will be a half prone lying on a plinth with the superior edge of the iliac crest horizontal at the edge of the plinth and the arms crossed over the chest.~* The participant should keep the unsupported upper part of the body.~* The lower limbs will strategically be stabilized with straps.~* The participant will be asked to maintain the upper body in a horizontal position and the timer started.~* The test ends if the participant can maintain the previous position for 4 minutes (240 seconds) or can no longer maintain the set position before 4 minutes elapses. The stop time is recorded.~* There is considerable range of mean fatigue times reported for the Biering-Sørensen test in the literature ranging from 84s to 180s in healthy males."
219187476|NCT06852976|DRUG|0.75% MDI-1228_mesylate gel plus Standard of Care|Approximately 40 subjects will receive 0.75% MDI-1228\_mesylate gel twice daily for 12 weeks.
219187477|NCT06852976|OTHER|Standard of Care Alone|Approximately 20 subjects will receive the standard of care alone including wound cleaning, debribement and other additional care decided by the healthcare provider.
219371527|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
219371528|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
219371529|NCT03636906|BIOLOGICAL|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
219371530|NCT03636906|BIOLOGICAL|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
219371531|NCT03636906|BIOLOGICAL|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
219371532|NCT03636906|BIOLOGICAL|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
219371533|NCT03636906|DRUG|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
219187478|NCT06852144|OTHER|clinical practice drug treatment|Observational, prospective and retrospective study, transversal, non-profit, monocentric. All data of patients affected/ afferents to theU.O. of Nuclear Medicine of the IRCCS AOU of Bologna will be collected submitted/ who will undergo a PET/ CT investigation for thyroid pathology or other indication with incidental feedback of thyroid uptake and patients who have They undergo PET/CT with known thyroid disease. Of these patients will be collected the personal data, clinical news, data related to PET/ CT (dedicated software e.g. MIM), biochemical/ laboratory and anatomopathological (for operated patients), any other imaging investigations already performed and to be performed later by normal clinical practice. The medical nuclear images will be evaluated by at least two nuclear medical experts, with qualitative, semi-quantitative and radiometric parameters as far as possible. Patients will be treated according to normal clinical practice.
219187479|NCT06851689|DEVICE|Jamar handheld dynamometer|Jamar handheld dynamometer to asses hand grip strength
219187480|NCT06851689|DEVICE|Biodex isokinetics|Biodex isokinetics to asses torque
219187481|NCT06852963|DRUG|VP-001|VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.
219187482|NCT06852846|DIAGNOSTIC_TEST|Biological sample|Biomarker test for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-inducible protein of 10 kDa (IP-10), and C-reactive protein
219187483|NCT06850246|DEVICE|treatment of radiofrequency technology|When operating, first select 470 kHz frequency, CRT resistance probe for deep fat management operation for 10 minutes, and then select CET capacitance mode 470 kHz for superficial fat operation for 6 minutes. Then, select the 940 kHz frequency CET capacitance probe for epidermal tightening operation for 4 minutes. The temperature is set by the energy value. In CRT mode, the energy value is set to 70, and it can reach above 42 ℃ within one minute. In CET mode, the energy value setting is adjusted to 75. The operation mode is to gradually raise the temperature to the midline after partially increasing the temperature at the side of the waist. The technique is mainly to move in a circle and lift to the midline.
219187484|NCT06850246|DEVICE|Placebo|Under the condition that the machine is not turned on, the treatment is performed in the same operation time, mode, and treatment area of the treatment group.
219187485|NCT03985592|BEHAVIORAL|Education|Intervention description provided in elaboration on arms of the study.
219187486|NCT06848543|BEHAVIORAL|Arm 1 Intervention|Arm 1 intervention is weight based taxes on cannabis, where participants make hypothetical purchases under weight based taxes.
219187487|NCT06848543|BEHAVIORAL|Arm 2 Intervention|Arm 2 intervention is price based taxes on cannabis, where participants make hypothetical purchases under price based taxes.
219187488|NCT04922736|DEVICE|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
219187489|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
219187490|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
219187491|NCT02733159|DRUG|pembrolizumab|anti PD-1
219187492|NCT05168306|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
219187493|NCT06113562|PROCEDURE|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
219187494|NCT06850714|DIETARY_SUPPLEMENT|Bifidobacterium breve PRL2020 (Brevicillin®)|Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) at a dose of 20 billion CFU per day (one stick in the morning and one in the evening).
219187495|NCT06850714|DRUG|Amoxicillin or Amoxicillin/Clavulanic Acid|Treatment of Amoxicillin or Amoxicillin/Clavulanic Acid as per medical prescription.
219187496|NCT06567613|DIAGNOSTIC_TEST|Speech test|The hearing screening ensures normal hearing before enrollment. The speech reception threshold for swiss german mono- and bisyllable words is determined in an adaptive procedure.
219187497|NCT06848660|DEVICE|A rigid cervical collar|The rigid cervical collar is used for spinal motion restriction for 12 weeks for the non-surgical treatment of a stable cervical spine fracture.
219187498|NCT06851065|DRUG|Luspatercept|As per product lable
219187499|NCT06851065|DRUG|Erythropoiesis-stimulating agents|As per product label
219187500|NCT06568107|BEHAVIORAL|Environmental And Sensory Experience (EASE) intervention|The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
219187501|NCT06122194|DRUG|Drug: PF-07817883|PF-07817883 tablet
219187502|NCT06536374|DRUG|Trimethoprim Tablets|Trimethoprim 150mg is administered once daily for 3 months
219187503|NCT05477056|OTHER|PrecivityAD blood test|Clinician Survey post receipt of PrecivityAD blood test result
219187504|NCT04606030|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
219187505|NCT04606030|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
219187506|NCT00291525|DEVICE|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
219371534|NCT05333094|OTHER|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
219187507|NCT00291525|DEVICE|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
219187508|NCT04376918|DEVICE|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
219187509|NCT04376918|DEVICE|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
219187510|NCT06217198|BEHAVIORAL|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
219187511|NCT05464056|BEHAVIORAL|Be Unstoppable in Life Together (BUILT)|Participants will complete weekly sleep, food, and exercise home challenges focused on creating sustainable healthy eating, sleep, and exercise routines. Parents will participate in weekly support calls by UIC and Chicago Park District staff to provide support and accountability. Children will have the opportunity to win small prizes based on completing weekly challenges. The intervention will be co-facilitated by UIC students and Chicago Park District staff and will largely take place on-line. For additional details visit: https://built.ahs.uic.edu.
219187512|NCT02470962|OTHER|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
219187513|NCT03908697|DEVICE|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
219187514|NCT05509803|BEHAVIORAL|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
219187515|NCT05987813|DEVICE|TENS Unit|Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
219187516|NCT04192435|DRUG|Tranexamic Acid|100mg/ml
219187517|NCT04192435|DRUG|Placebos|Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
219187518|NCT05263089|OTHER|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
219187519|NCT05263089|OTHER|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
219187520|NCT06175091|DEVICE|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
219187521|NCT06175091|DEVICE|restrictive alarm use strategy|more restrictive protocol for the use of alarms
219187522|NCT05553457|DEVICE|Testing of MyHand-SCI Device|Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
219187523|NCT05540288|DRUG|Nalmefene|"Week 1: 18 mg/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~2. In the presence of grade 3 ARs, 18 mg/d~3. In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
219187524|NCT05540288|DRUG|Placebo|"Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
219187526|NCT06799559|DRUG|3-6mg QLM1016|3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
219187527|NCT06799559|DRUG|10-20 mg Aripiprazole oral solution film|10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
219187528|NCT06798129|PROCEDURE|extracorporeal blood purification therpay|Extracorporeal blood purification therapy in this study includes intermittent hemodialysis (HD), continuous renal replacement therapy (CRRT), plasma exchange (PE), and hemoperfusion (HP).
219187529|NCT06798662|DEVICE|Ultrasound-Guided Pulsed Radiofrequency (PRF)|A high-frequency linear ultrasound transducer will be used for this procedure. The transducer will be placed transversely over the target rib area to obtain a clear visualization of the rib, intercostal muscles, and pleura. The entry point for needle insertion will be selected 1-2 cm inferior to the inferior border of the target rib. Using a 22G radiofrequency (RF) needle, an in-plane approach will be used for needle advancement. The needle will be advanced slowly until it reaches the inferior border of the rib. The needle will then be withdrawn 1-2 mm to ensure the needle tip is positioned adjacent to the intercostal nerve. The RF needle will then be connected to the RF generator for sensory testing. Stimulation parameters will be set at 50 Hz and 0.5-1V. The target location will be considered accurate if stimulation induces pain in the participant. Pulsed radiofrequency treatment will then be administered using the following parameters: voltage of 45V, frequency of 2 Hz, pulse width
219371535|NCT04815837|BEHAVIORAL|Intervention|"1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8."
219371536|NCT06170645|OTHER|APA program|An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
219371537|NCT06170645|OTHER|Active transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
219371538|NCT06170645|OTHER|Sham transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
219371539|NCT06100575|BEHAVIORAL|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
219371540|NCT02348515|PROCEDURE|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
219371541|NCT02348515|PROCEDURE|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
219371542|NCT02348515|PROCEDURE|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
219371543|NCT02348515|PROCEDURE|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
219371544|NCT02348515|PROCEDURE|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
219371545|NCT05238051|OTHER|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
219371546|NCT00793351|PROCEDURE|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~* Enrollment - Pre-RIST treatment - RIST~* 4 cycles of conventional chemotherapy will be given prior to RIST.~* Surgery will be done whenever possible prior to RIST.~* Local radiotherapy will be applied whenever possible prior to RIST.~* topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~* Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
219371547|NCT03275545|OTHER|No intervention|No intervention is being examined in this study
219371548|NCT06654713|OTHER|Commercial AID system|AID system that is commercially available and FDA approved for use
219371549|NCT06654713|OTHER|Open source AID system|AID system that uses unregulated open-source software to customize an insulin delivery algorithm to connect an insulin pump to a continuous glucose monitor
219371550|NCT01629147|DIETARY_SUPPLEMENT|Biogaia|5 drops containing Lactobacillus reuteri Protectis
219371551|NCT01629147|OTHER|Placebo|5 drops
219371552|NCT00508573|BEHAVIORAL|Questionnaire|Follow-up questionnaire done once a year for five years.
219371553|NCT06813404|BEHAVIORAL|Heavy resistance training|The heavy resistance training intervention will consist of twice weekly exercise sessions of 60 minutes each.
219371554|NCT06813404|BEHAVIORAL|Yoga|Twice weekly yoga sessions of 60 minutes each
219371555|NCT02631707|OTHER|High protein diet|The intervention diet is higher in protein than the control diet.
219371556|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
219371557|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
219371558|NCT06820242|BEHAVIORAL|HIPS|HIPS is a 6-session (one 30-minute session per week) mind-body intervention delivered in person by a trained physical therapist (PT). Across these six 30-minute sessions, the HIPS intervention aims to teach relaxation and coping skills (e.g., SMART goal-setting, coping thoughts, deep breathing, and progressive muscle relaxation) and provides pain education.
219371559|NCT01291017|DRUG|PD0332991|PD0332991 125 mg PO days 1 - 21
219000723|NCT06444464|OTHER|Aerobic exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
219371560|NCT02795455|BEHAVIORAL|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
219371561|NCT02795455|BEHAVIORAL|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
219000724|NCT06444464|OTHER|Isometric exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
219187530|NCT06798662|DEVICE|Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine)|The patient is positioned in either the lateral decubitus or sitting position, with the affected side facing upwards, ensuring adequate exposure of the targeted intercostal region. A high-frequency linear ultrasound transducer is placed transversely over the posterior lateral aspect of the targeted rib, using the vertebral column as a reference point. The transducer is then scanned laterally to identify the target rib, clearly visualizing the rib, intercostal muscles, and pleura. The intercostal nerve appears as a small hyperechoic structure located between the internal and innermost intercostal muscles. The needle is advanced until it contacts the inferior border of the rib. The needle is then slightly withdrawn and positioned between the internal and innermost intercostal muscles to avoid pleural puncture. After negative aspiration, 10 mL of 0.5% ropivacaine (or 133 mg of liposomal bupivacaine) combined with 10 mg of triamcinolone acetonide is injected slowly.
219187531|NCT06798662|DEVICE|Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|For the Paravertebral (PVB) block, a high-frequency linear ultrasound transducer was placed transversely, parallel to the spinous processes, approximately 2-3 cm lateral to the spinous process of the target thoracic vertebral segment. The position and angle of the transducer were adjusted to clearly visualize the transverse process (TP) and the axial view of the lamina of the target vertebra. In the ultrasound image, the transverse process appeared as a hyperechoic structure, typically with a characteristic acoustic shadow posterior to it. Subsequently, the transducer was slightly slid caudally, causing the transverse process and its acoustic shadow to gradually disappear from view. At this point, the ultrasound image revealed components of the paravertebral space (PVS), including the parietal pleura, the superior costotransverse ligament, and the intercostal fascia, which exhibited a heterogeneous mixed echogenicity. Using an in-plane technique, a puncture needle was advanced from lat
219187532|NCT06798662|DEVICE|Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|"The RISS block is a composite nerve block technique that involves two injection sites: the inter-rhomboid plane and the sub-serratus plane. The selection of block plane was determined by the patient's specific location of pain.~Rhomboid Intercostal Plane Block (RIPB):~For the Rhomboid Intercostal Plane Block (RIPB), a high-frequency linear ultrasound transducer was initially positioned in a sagittal orientation, medial to the scapular border. It was then slightly rotated to obtain an oblique sagittal view (oblique paramedian sagittal view), located 1-2 cm lateral to the scapular border. Upon obtaining the appropriate ultrasound image, the following anatomical structures were identified sequentially, from superficial to deep: the trapezius muscle, the rhomboid muscles (specifically, the major rhomboid), the intercostal muscles (located between the ribs), the pleura, and the lung. The target injection plane was the fascial plane situated between the rhomboid muscle and the intercostal"
219187533|NCT06798662|DRUG|Drug (famciclovir and gabapentin)|All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
219187534|NCT05125029|DRUG|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
219187535|NCT06972264|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
219187536|NCT06972264|DRUG|Placebo|Placebo
219187537|NCT06823375|RADIATION|Radiotherapy|\- SBRT 27.5Gy to 50Gy in 5 fractions on alternate days will be delivered between cycle 3 and 5 to the PVTT and its adjacent lesions.
219187538|NCT06823375|DRUG|Atezolizumab plus Bevacizumab|\- Atezolizumab 1200mg IV and Bevacizumab 15mg/kg IV will be given every 3 weeks, till disease progression, intolerable toxicity, death or withdrawal of consent.
219187539|NCT03824327|PROCEDURE|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
219187540|NCT03824327|DRUG|Papaverine Hydrochloride|Given IV
219371562|NCT02795455|DIETARY_SUPPLEMENT|meal replacement shake|
219000725|NCT05542576|DRUG|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
219000726|NCT05076630|OTHER|Air pollutants|Particulate matter and gaseous pollutants
219187541|NCT03824327|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219187542|NCT02112526|DRUG|Acalabrutinib|
219187543|NCT02709161|DEVICE|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219760854|NCT01738061|BEHAVIORAL|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
219371563|NCT06597032|BEHAVIORAL|Resilience Challenge|We previously have tested this online program in people facing health- and work-related stressors (e.g., dementia caregivers, healthcare workers), and in 2020 we enrolled adults in a test of the online program to support coping with the stress of the COVID pandemic. This intervention has been tailored for a widespread, public audience (e.g., we have added a few other safety measures including limits on public forum posting and have clarified wording on some of the intervention content to make it clearer and easier to understand).
219371564|NCT00462787|BIOLOGICAL|filgrastim|
219371565|NCT00462787|DRUG|clofarabine|
219371566|NCT00462787|DRUG|dexamethasone|
219371567|NCT00462787|DRUG|thiotepa|
219371568|NCT00462787|DRUG|topotecan hydrochloride|
219371569|NCT00462787|DRUG|vinorelbine tartrate|
219371570|NCT03204149|DEVICE|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
219371571|NCT03204149|DEVICE|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
219371572|NCT06671626|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
219371573|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
219371574|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
219371575|NCT04881565|OTHER|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
219371576|NCT01750892|BEHAVIORAL|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
219371577|NCT01750892|BEHAVIORAL|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
219371578|NCT01750892|OTHER|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
219371579|NCT06861582|DIAGNOSTIC_TEST|Point-of-care ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using point-of-care (POC) technology, the Atellica® VTLi Patient-side Immunoassay Analyzer (Siemens Healthineers) will be used. This high-sensitivity troponin I (hs-cTnI) test utilizes Magnotech® Technology with paramagnetic particles and external magnetic fields, providing rapid results (\~8 minutes) using whole capillary blood collected via fingertip puncture, and/or with direct withdrawal from the test tube. Additionally, venous blood samples will be collected for laboratory comparison. The assay measures hs-cTnI within a range of 0-1250 pg/mL, with values \<LoD and \>1250 pg/mL recorded accordingly. Samples will be collected at 0 and 1 hour. Reference values (99th percentile, pg/mL): Women: 18.5, Men: 27.1. This intervention enables bedside testing, reducing turnaround time compared to standard laboratory assays, facilitating early myocardial infarction diagnosis.
219371580|NCT06861582|DIAGNOSTIC_TEST|Laboratory-based ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using the local laboratory, the Alinity™ i STAT High Sensitive Troponin-I assay (Abbott) will be used. Samples will be taken at 0 and 1 hour after admission by venipuncture and collected in 5 mL serum tubes with a separator. This chemiluminescence microparticle immunoassay (CMIA) quantifies cardiac troponin I (cTnI) in serum and plasma using the Alinity™ i analyzer, with a measurement range of 10-50,000 pg/mL. Analysis will follow the manufacturer's instructions. Reference values (99th percentile, pg/mL): Women (21-75 years): 15.6, Men (21-73 years): 34.2.
219371581|NCT03454854|DEVICE|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
219371582|NCT04101149|OTHER|No intervention|No intervention.
219371583|NCT06872190|OTHER|ED-Based Clinical Decision Support for Opioid Use Disorder|"The original clinical decision support (CDS) tool, EMergency department initiated BuprenorphinE for opioid use Disorder or EMBED, was designed by researchers at Yale to support emergency department (ED) clinicians with varying levels of experience prescribing buprenorphine for patients with opioid use disorder (OUD). The tool alerts ED providers of a patient who is potentially eligible for MOUD using Epic's storyboard. The provider must then click on the notification to open the OUD evaluation tool, which has multiple components: OUD assessment, OUD diagnosis, withdrawal assessment, and readiness for treatment. These components are then paired with an orderset, ED Opioid Use Disorder Treatment that includes nursing orders, prescriptions for buprenorphine and ancillary medications, and substance use disorder discharge resources."
219371584|NCT06872190|OTHER|Social Care-Enhanced Clinical Decision Support for Opioid Use Disorder|The investigators will use human-centered design to adapt the basic CDS tool to incorporate patient social needs, involving patients, staff, and end-user ED clinicians in the iterative design process. This tool is being actively developed.
219371585|NCT03690869|DRUG|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
219371586|NCT03690869|DRUG|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
219371587|NCT03690869|RADIATION|Conventional or hypofractionated|Combined with cemiplimab IV administration
219371588|NCT03690869|RADIATION|Re-irradiation|Combined with cemiplimab IV administration
219371589|NCT02722681|PROCEDURE|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
219371590|NCT02722681|PROCEDURE|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
219371591|NCT06682442|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
219371592|NCT06682442|PROCEDURE|Radiographic Imaging|Undergo imaging procedure
219371593|NCT06682442|PROCEDURE|Biospecimen Collection|Blood samples will be collected
219371594|NCT06629610|BEHAVIORAL|DAiLY|The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
219371595|NCT06689410|OTHER|blood or saliva sample|Collection of blood or saliva
219371596|NCT02507583|DRUG|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
219371597|NCT06695221|DIETARY_SUPPLEMENT|Traditional Kefir|350 mL/day of traditional fermented/prepared kefir
219371598|NCT06695221|DIETARY_SUPPLEMENT|Milk (placebo)|350 mL/day of commercial 2% fat milk
219371599|NCT00191373|DRUG|Gemcitabine|
219371600|NCT00191373|DRUG|Trastuzumab|
219371601|NCT02229422|DRUG|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
219371602|NCT06734767|BEHAVIORAL|Mindfulness Based Stress Reduction 8-week course|The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
219371603|NCT06742411|DRUG|XELOX+Sintilimab+HBOT|"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."
219371604|NCT06889766|BIOLOGICAL|NY-ESO-1 TCR redirected autologous T cell product|Ex vivo expanded autologous CD4+/CD8+ cells expressing the transgenic TCR I53F recognizing NY-ESO-1 peptides presented on tumor cells in the context of HLA-A\*02. The LauT-1-ACT infusion contains a minimum of 3x10\^8 transduced cells (i.e. CD3+vβ13.1+) and a maximum of 1x10\^10 total cells.
219371605|NCT06889766|RADIATION|Low-dose irradiation|1Gy will be administered using tomotherapy (Accuray) to all irradiable lesions.
219371606|NCT06889766|DRUG|Non-myeloablative lymphodepleting chemotherapy|Fludarabine (30 mg/m2 x 4 days, from D-6 to D-3) and cyclophosphamide (2400 mg/ m2 x 2 days, on days -6 and -5) are administered as an IV infusion. The cyclophosphamide dose may be reduced to 1800mg/m2 on days -6 and -5, if the patient has previously been exposed to significant cumulative doses of chemotherapy)
219371607|NCT02149641|RADIATION|Intensity modulated radiotherapy with chemotherapy|
219371608|NCT00601978|DRUG|carbidopa/levodopa|
219371609|NCT00601978|DRUG|Carbidopa/Levodopa/Entacapone|
219371610|NCT06121128|PROCEDURE|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
219371611|NCT06121128|PROCEDURE|Normal Breathing|No IMT performed
219371612|NCT00150189|BEHAVIORAL|Sucrose|
219371613|NCT00909272|PROCEDURE|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
219371614|NCT00909272|PROCEDURE|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
219371615|NCT02276261|PROCEDURE|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
219371616|NCT02276261|PROCEDURE|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
219371617|NCT01542307|BIOLOGICAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
219371618|NCT01542307|BIOLOGICAL|Room air|Placebo
219371619|NCT03222271|DEVICE|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
219371620|NCT03157544|BEHAVIORAL|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
219371621|NCT04578210|BIOLOGICAL|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
219371622|NCT05917886|OTHER|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
219371623|NCT00550628|GENETIC|DNA methylation analysis|
219371624|NCT00550628|GENETIC|fluorescence in situ hybridization|
219371625|NCT00550628|GENETIC|gene expression analysis|
219371626|NCT00550628|GENETIC|polymerase chain reaction|
219371627|NCT00550628|GENETIC|protein expression analysis|
219371628|NCT00550628|GENETIC|reverse transcriptase-polymerase chain reaction|
219371629|NCT00550628|OTHER|diagnostic laboratory biomarker analysis|
219371630|NCT00550628|OTHER|immunoenzyme technique|
219371631|NCT00550628|OTHER|immunohistochemistry staining method|
219371632|NCT00550628|PROCEDURE|biopsy|
219371633|NCT00550628|PROCEDURE|therapeutic conventional surgery|
219371634|NCT00550628|RADIATION|fludeoxyglucose F 18|
219371635|NCT03616743|BEHAVIORAL|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
219371636|NCT03616743|BEHAVIORAL|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
219371637|NCT00937235|DRUG|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
219371638|NCT00937235|BEHAVIORAL|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
219371639|NCT00937235|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
219371640|NCT02948894|DEVICE|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
219371641|NCT00337389|DRUG|5- Fluorouracil (5-FU)|
219371642|NCT00337389|DRUG|bevacizumab (Avastin)|
219371643|NCT00337389|DRUG|Leucovorin|
219371644|NCT00337389|DRUG|CoFactor (ANX-510)|
219371645|NCT03414879|DRUG|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
219371646|NCT03414879|DRUG|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
219371647|NCT06096519|BEHAVIORAL|Information, motivation, behavioral skills treatment arm|Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of all adolescents.
219371648|NCT06096519|BEHAVIORAL|Information only control arm|This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
219371649|NCT03607344|PROCEDURE|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
219371650|NCT00811629|OTHER|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
219371651|NCT04363216|DRUG|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
219371652|NCT01804855|BEHAVIORAL|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
219371653|NCT01804855|DEVICE|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
219371654|NCT02923271|DEVICE|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
219371655|NCT06435507|DRUG|IM-250 (50 mg)|Single dose
219371656|NCT06435507|DRUG|IM-250 (100 mg)|Single dose
219371657|NCT06435507|DRUG|IM-250 (200 mg)|Single dose
219371658|NCT06435507|DRUG|IM-250 (400 mg)|Single dose
219371659|NCT03047538|DRUG|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
219371660|NCT01014715|OTHER|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
219187544|NCT02709161|DEVICE|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219187545|NCT05109988|BEHAVIORAL|Breastfeeding telephone support|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
219187546|NCT04761861|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
219187547|NCT04761861|DRUG|Placebo|Placebo one tablet daily
219187548|NCT05795400|DRUG|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
219187549|NCT05795400|DRUG|Placebo|tablet of placebo drug dosed once daily
219187550|NCT03507257|DRUG|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
219187551|NCT03507257|DRUG|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
219187552|NCT03507257|DRUG|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
219754281|NCT06770634|OTHER|Lower Extremity Functional Scale|The lower extremity functional scale is a valid patient-rated outcome measure for the measurement of lower extremity function. The scale consist of 4 groups with 20 questions. The questions in these group focus on activities with increasing physical demands like questions from walking between rooms to running on uneven ground. The scoring of this scale varies from 0 (extreme difficulty/unable to perform activity) to 4 (no difficulty). The total score can be obtained by summing the scores of the individual items. The maximum score of 80 indicates no functional limitations and the minimum score of 0 indicates extreme limitations.
219187553|NCT06060522|DIAGNOSTIC_TEST|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
219371661|NCT01434225|DRUG|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
219371662|NCT02528344|BEHAVIORAL|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
219371663|NCT02708823|OTHER|CogCheck application|The application is administered once to all study participants.
219371664|NCT01495819|DRUG|Saline|5cc's of saline give at least once.
219371665|NCT01495819|DRUG|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
219371666|NCT03946176|DIETARY_SUPPLEMENT|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
219371667|NCT03946176|DIETARY_SUPPLEMENT|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
219371668|NCT03946176|DEVICE|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
219371669|NCT04246554|DRUG|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
219371670|NCT04246554|DRUG|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
219371671|NCT06066879|DRUG|Ketamine Hydrochloride|Pre-Operative Ketamine infusion
219371672|NCT06793670|DRUG|Landiolol|Intravenous infusion of landiolol
219371673|NCT06793670|DRUG|Placebo|Intravenous infusion of saline solution of NaCl 0.9%
219371674|NCT06106698|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
219371675|NCT06464406|BEHAVIORAL|Virtual Reality condition|Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
219371676|NCT06464406|BEHAVIORAL|Control condition|Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
219371677|NCT04684030|DEVICE|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
219371678|NCT04684030|DEVICE|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
219371679|NCT03306537|DEVICE|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
219371680|NCT04886765|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
219371681|NCT00283829|DRUG|docetaxel|chemotherapy
219371682|NCT00283829|DRUG|IL2|immunotherapy
219371683|NCT00075517|DRUG|docetaxel|
219371684|NCT00075517|DRUG|gemcitabine hydrochloride|
219371685|NCT04323501|OTHER|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
219371686|NCT04323501|OTHER|Control group|Usual care
219371687|NCT03319628|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
219371688|NCT04934202|OTHER|Teleconsultation|"Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties"
219371689|NCT04934202|OTHER|Outpatient clinic|"During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation"
219371690|NCT03910192|BEHAVIORAL|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
219371691|NCT03910192|BEHAVIORAL|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
219371692|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
219371693|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
219371694|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
219371695|NCT02162888|DRUG|Test Product (Bendamustine)|
219371696|NCT05666089|DRUG|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
219371697|NCT05666089|DRUG|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
219371698|NCT01517880|DRUG|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
219371699|NCT01517880|DRUG|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
219371700|NCT00459030|OTHER|educational intervention via internet|additional cancer screening information via password protected internet site
219371701|NCT00459030|OTHER|educational intervention mailed|
219371702|NCT00459030|OTHER|No additional educational intervention|
219371703|NCT04507009|DEVICE|Ozone|topical gaseous ozone application
219371704|NCT04507009|OTHER|CGF|concentrated growth factor (CGF) application
219371705|NCT04507009|OTHER|Traditional treatment|Alvogyl application
219371706|NCT06322758|OTHER|Tidal volume customization in the acute respiratory distress syndrome|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
219371707|NCT03006211|OTHER|Nitrogen protoxide|
219371708|NCT03006211|OTHER|Oxygen|
219371709|NCT04490629|DEVICE|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
219371710|NCT04490629|DEVICE|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
219371711|NCT04023084|DRUG|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
219371712|NCT04255511|DEVICE|Twin Block|Functional appliance
219371713|NCT04255511|DEVICE|Fixed orthodontic appliance|Braces
219371714|NCT04720703|BEHAVIORAL|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
219371715|NCT04720703|BEHAVIORAL|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
219371716|NCT05987761|BEHAVIORAL|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
219371717|NCT01903876|BEHAVIORAL|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
219371718|NCT01903876|BEHAVIORAL|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
219371719|NCT03231514|DIETARY_SUPPLEMENT|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
219371720|NCT03231514|OTHER|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
219371721|NCT03231514|OTHER|Exercise|All groups will participate in a standardized exercise intervention.
219371722|NCT00001087|DRUG|Ritonavir|
219371723|NCT00001087|DRUG|Nelfinavir mesylate|
219371724|NCT00001087|DRUG|Efavirenz|
219371725|NCT00001087|DRUG|Levocarnitine|
219371726|NCT00001087|DRUG|Adefovir dipivoxil|
219371727|NCT00001087|DRUG|Saquinavir|
219371728|NCT00001087|DRUG|Lamivudine|
219371729|NCT00001087|DRUG|Stavudine|
219371730|NCT00001087|DRUG|Zidovudine|
219754282|NCT06770634|OTHER|Short form 12|The Short form 12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.The scoring yields two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).Utilize the norm-based scoring system to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population.Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.
219371731|NCT00001087|DRUG|Zalcitabine|
219371732|NCT00001087|DRUG|Didanosine|
219371733|NCT02427165|DRUG|RPL554|A dual PDE3 and PDE4 inhibitor
219371734|NCT02427165|DRUG|Salbutamol|a beta-2 receptor agonist
219371735|NCT02427165|DRUG|Placebo|RPL554 placebo containing no active ingredients
219371736|NCT02811744|DRUG|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
219371737|NCT04610099|DEVICE|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
219371738|NCT04610099|DEVICE|Standard SG|Standard SG
219371739|NCT05551130|OTHER|Restoration|Restorations completed with these materials.
219371740|NCT01975103|PROCEDURE|Topcon Endpoint Management|
219371741|NCT00146692|BEHAVIORAL|Free medical treatment|
219371742|NCT03780998|DRUG|Life7|Life7 will used on the perianal skin with finger tips
219371743|NCT03661684|DRUG|Prednisone|40 mg po q day of Prednisone for 3 days
219371744|NCT01771783|DRUG|ACEI-ARB-RI|
219371745|NCT01771783|DRUG|ARB-RI-ACEI|
219371746|NCT01771783|DRUG|RI-ACEI-ARB|
219371747|NCT02368470|DRUG|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
219371748|NCT02368470|DRUG|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
219371749|NCT03509506|BEHAVIORAL|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
219371750|NCT05090956|OTHER|mri|
219371751|NCT05773456|OTHER|Sushi and wakame salad|One serving of mixed sushi and wakame salad
219371752|NCT04847271|BEHAVIORAL|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
219371753|NCT00876031|DRUG|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
219371754|NCT05617170|OTHER|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
219371755|NCT01901224|DRUG|Metformin 1000 mg|
219371756|NCT01901224|DRUG|Placebo|
219371757|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
219371758|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
219371759|NCT04676477|DRUG|Osimertinib|Oral administration at 40 mg or 80 mg once daily
219187554|NCT03626220|OTHER|acupuncture|More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
219187555|NCT05387265|DRUG|CX-904|CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
219187556|NCT04363164|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
219187557|NCT04363164|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
219187558|NCT04363164|DRUG|Testosterone enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
219187559|NCT05940740|OTHER|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
219187560|NCT06397586|OTHER|Routine volleyball|MOtor imagery
219187561|NCT02201134|DRUG|sevoflurane|
219187562|NCT05957406|DEVICE|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
219187563|NCT05957406|DEVICE|The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff|Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff
219371760|NCT04676477|DRUG|Osimertinib|Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
219371761|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg Q3W
219371762|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 4.8 mg/kg Q3W
219371763|NCT04676477|DRUG|Osimertinib|Oral administration at 80 mg once daily
219371764|NCT06478862|DRUG|Promitil|The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
219371765|NCT01587066|DRUG|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
219557729|NCT01817686|OTHER|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
219371766|NCT01587066|DRUG|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
219371767|NCT06181955|OTHER|Extracorporeal Shock Wave Therapy|The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).
219371768|NCT06181955|OTHER|conventional physical therapy|Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
219371769|NCT03732547|DRUG|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
219371770|NCT03732547|DRUG|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
219371771|NCT02633449|BEHAVIORAL|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
219371772|NCT02633449|DEVICE|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
219371773|NCT02633449|DEVICE|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
219371774|NCT03804671|DRUG|BI 730357|Oral dose
219371775|NCT03804671|DRUG|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
219371776|NCT04268134|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
219371777|NCT06256848|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219371778|NCT06256848|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219371779|NCT01996787|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
219371780|NCT01996787|DEVICE|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
219371781|NCT05961748|OTHER|Multi-disciplinary assessment|Multi-disciplinary assessment
219371782|NCT03303001|PROCEDURE|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
219371783|NCT03303001|PROCEDURE|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
219371784|NCT05641883|COMBINATION_PRODUCT|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
219371785|NCT03902080|DRUG|Vibegron|oral administration
219371786|NCT03902080|DRUG|Placebo|oral administration
219371787|NCT05571683|OTHER|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
219371788|NCT04444245|PROCEDURE|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
219371789|NCT04444245|PROCEDURE|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
219371790|NCT04444245|PROCEDURE|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
219371791|NCT04444245|DEVICE|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000
219371792|NCT04444245|DRUG|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
219371793|NCT04444245|DEVICE|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
219371794|NCT03737656|DRUG|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
219371795|NCT00286052|DRUG|Low Dose Naloxone|
219371796|NCT01583426|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
219371797|NCT01583426|DRUG|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
219371798|NCT04013126|DIAGNOSTIC_TEST|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
219371799|NCT02812199|DEVICE|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
219371800|NCT02812199|DRUG|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
219371801|NCT02812199|PROCEDURE|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
219371802|NCT02902094|DEVICE|Drug eluting balloons|
219371803|NCT02902094|DEVICE|Non drug eluting balloons|
219371804|NCT04321161|DRUG|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
219371805|NCT01634373|DRUG|Torrent's Quetiapine Fumarate Tablets|
219371806|NCT00457405|DRUG|dipyridamole|dipyridamole 200mg twice daily
219371807|NCT01479348|DRUG|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
219371808|NCT01479348|DRUG|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m\^2, IV
219371809|NCT01479348|DRUG|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
219371810|NCT01479348|DIAGNOSTIC_TEST|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
219371811|NCT03766425|DRUG|Aflibercept|subconjunctival injection
219371812|NCT03766425|DRUG|Mitomycin|subconjunctival injection
219371813|NCT02220387|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
219371814|NCT02220387|OTHER|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
219371815|NCT02760251|DRUG|romiplostim|
219371816|NCT05693402|PROCEDURE|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
219371817|NCT00412529|DRUG|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
219371818|NCT00412529|DRUG|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
219371819|NCT02529527|BEHAVIORAL|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
219371820|NCT05781048|DRUG|HRS-6209|HRS-6209
219371821|NCT01769911|DRUG|carmustine|Given IV
219371822|NCT01769911|DRUG|cytarabine|Given IV
219371823|NCT01769911|DRUG|melphalan|Given IV
219557730|NCT01817686|OTHER|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
219754283|NCT06770634|OTHER|lower extremity volumetric measurement|It is calculated by converting the circumference measurements taken at 4 cm intervals from the ankle to the proximal thigh into lower extremity volume with Excel.
219000727|NCT00704054|DRUG|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
219000728|NCT06360562|BEHAVIORAL|Resilience Training|Behavioral group-based intervention delivering mindfulness, metallization, and self-compassion skills.
219000729|NCT05733221|DEVICE|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
219371824|NCT01769911|DRUG|etoposide|Given IV
219371825|NCT01769911|DRUG|O6-benzylguanine|Given IV
219371826|NCT01769911|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
219371827|NCT01769911|PROCEDURE|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
219371828|NCT01769911|OTHER|laboratory biomarker analysis|Correlative studies
219371829|NCT05654402|DIAGNOSTIC_TEST|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"* Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~* Measurement of the distance between the carotid and femoral points with a tape measure (m).~* Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~* Before induction (awake without premedication)~* During general anesthesia or loco-regional anesthesia~* Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
219371830|NCT00662961|PROCEDURE|Periosteum|Periosteum fixation
219371831|NCT00662961|PROCEDURE|Bone|Bone tunnel fixation
219371832|NCT06488118|DRUG|R848|Inhaled R848 dose ranging from 0.1 to 100 μg/mL
219371833|NCT06488118|DRUG|Saline|Inhaled Saline control
219371834|NCT02160067|DRUG|Second generation BTDS patch|
219371835|NCT02160067|DRUG|First generation BuTrans patch|
219371836|NCT01172379|DRUG|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
219371837|NCT01172379|DRUG|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
219371838|NCT01172379|DRUG|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
219371839|NCT01172379|OTHER|Placebo Comparator|Placebo 1 tablet per day
219371840|NCT00432692|PROCEDURE|Falls Prevention Program|
219371841|NCT01474577|OTHER|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
219371842|NCT03246438|BEHAVIORAL|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
219371843|NCT03246438|BEHAVIORAL|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
219371844|NCT03246438|BEHAVIORAL|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
219371845|NCT06008548|PROCEDURE|TACE|
219371846|NCT05305716|OTHER|Online Pilates Training|The group that received telerehabilitation and telerehabilitation-based pilates training.
219371847|NCT05305716|OTHER|Control group|The group who received breathing and relaxation exercises with a home program.
219371848|NCT06269523|OTHER|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
219371849|NCT06269523|OTHER|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
219371850|NCT00679861|BEHAVIORAL|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
219371851|NCT00679861|BEHAVIORAL|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
219371852|NCT00688038|PROCEDURE|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
219371853|NCT00688038|PROCEDURE|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
219371854|NCT05759052|BEHAVIORAL|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
219371855|NCT05548686|OTHER|adapted physical activity|3 sessions of adapted physical activity per week during 12 weeks for each patient
219371856|NCT01485874|DRUG|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
219371857|NCT01485874|DRUG|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
219371858|NCT05374486|DEVICE|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
219371859|NCT01919307|OTHER|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
219371860|NCT05413681|DIAGNOSTIC_TEST|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
219371861|NCT05413681|DIAGNOSTIC_TEST|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
219371862|NCT04507815|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
219371863|NCT04507815|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
219371864|NCT04408456|DRUG|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
219371865|NCT04408456|OTHER|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
219371866|NCT01346930|DRUG|Macitentan|10 mg, tablet, once daily
219371867|NCT06962696|OTHER|No intervention|no intervention provided
219371868|NCT06961227|OTHER|No investigational intervention|No investigational intervention. Patients will be observed under standard ventilation modes (SIMV and MMV) as part of routine care.
219371869|NCT06961136|DRUG|Fuzheng Yangxin prescription|Fuzheng Yangxin prescription
219371870|NCT06961136|DRUG|placebo|placebo
219371871|NCT06959745|DRUG|Magnesium-L-Threonate|Magnesium L-threonate, 1740 mg, taken orally, twice a day, for 8 weeks.
219371872|NCT06959745|DRUG|Placebo|Placebo, 1740 mg, taken orally, twice a day, for 8 weeks.
219754284|NCT06770634|OTHER|lower extremity circumference measurement|bilateral tuberosity tibia, 20 cm proximal tuberosity tibia, tuberosity tibia 10 cm distal and ankle level
219754285|NCT06770634|OTHER|Bioelectrical Impedance Analysis|With Bioelectrical Impedance Analysis, fat, muscle and water ratio and lean mass are calculated in addition to the patient's body weight.
219754286|NCT06770634|DIAGNOSTIC_TEST|Ultrasound|Measurement of subcutaneous fat tissue thickness from mid-thigh, pretibial, lateral leg and supramalleolar regions with ultrasound.The average of two measurements taken from the same area will be recorded.According to these measurements; 12-15 mm = mild lipedema or lipohyperplasia, 15-20 mm = moderate lipedema, \>20 mm = significant lipedema, \>30 mm = severe lipedema.
219754287|NCT05638113|PROCEDURE|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
219371873|NCT06838091|OTHER|Observational|"During anesthesia administration:~T0, T1, T2, T3, T4 represent the following periods:~T0: Double lumen ventilation in the supine position immediately after intubation T1: Double lumen ventilation in the lateral position T2: Single lumen ventilation in the lateral position (with the chest wall closed) T3: Single lumen ventilation in the lateral position (with the chest wall open) T4: Just before extubation~1. Airway pressure (P plateau, Ppeak) values from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (Routinely from pharyngeal temperature probe),~4. Oxygen saturation (Routinely from the patient monitor)~5. End-tidal CO₂,~6. Inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. Inspiratory and expiratory desflurane/sevoflurane concentrations,~9. Tidal volume,~10. MAC, routinely from anesthesia device data~11. Blood Gas Analysis (COHgb, Ph, PO 2 , PCO 2 , SaO 2, HCO 3 , Base deficit, glucose, lactate)"
219371874|NCT06961955|RADIATION|Radiation Therapy|Undergo hypofractionated radiation therapy
219754288|NCT04210960|RADIATION|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) \_ 9583 sec, echo time (TE) \_ 25 sec, inversion time (TI) \_ 3400 sec, IR delay \_ 325 sec, echo train length (ETL) \_ 17, 50 contiguous axial slices, thickness \_ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
219000730|NCT05980182|BEHAVIORAL|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
219000731|NCT06436547|DEVICE|Subiculum-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral subiculum.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
219000732|NCT03107780|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219000733|NCT03107780|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219000734|NCT03107780|DRUG|Navtemadlin|Given PO
219000735|NCT03107780|RADIATION|Radiation Therapy|Undergo radiation therapy
219000736|NCT03730181|DRUG|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
219000737|NCT03730181|DRUG|Isoniazid|Isoniazid. 25mg/kg
219000738|NCT05403450|DRUG|Tolinapant|Capsule for oral administration
219000739|NCT05403450|DRUG|Decitabine + Cedazuridine|Tablet for oral administration
219000740|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.
219000741|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit through Week 48.
219000742|NCT06533059|DRUG|ALTA2618|Oral ALTA2618 tablets will be administered at protocol-defined dose
219000743|NCT04566380|DRUG|ONO-4538|IV infusion over 30 minutes
219000744|NCT04566380|DRUG|oxaliplatin|IV infusion over 2 hours
219000745|NCT04566380|DRUG|S-1|Administered orally twice daily
219000746|NCT04566380|DRUG|capecitabine|Administered orally twice daily
219000747|NCT04566380|DRUG|bevacizumab|IV infusion over 30 minutes
219000748|NCT04566380|DRUG|temozolomide|Administered orally once daily for 5 days every 28 days
219000749|NCT06105554|DRUG|Belumosudil mesylate|Given by PO
219000750|NCT00659997|DRUG|Albendazole|Single oral dose of 400mg
219000751|NCT00659997|DRUG|Levamisole|Single oral dose of 2.5mg/kg
219000752|NCT03291730|BEHAVIORAL|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
219000753|NCT03291730|OTHER|Art-therapy|May help reduce anxiety of receiving chemotherapy
219000754|NCT04849143|OTHER|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
219000755|NCT04849143|OTHER|Gel dressing|Smith-Nephew's Intrasite gel
219000756|NCT03771677|DRUG|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
219000757|NCT03771677|DRUG|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
219000758|NCT05725902|DRUG|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
219000759|NCT05044546|BEHAVIORAL|Behavioral Activation Therapy|Participate in BA counseling
219000760|NCT05044546|PROCEDURE|Discussion|Participate in focus group
219000761|NCT05044546|BEHAVIORAL|Health Education|Participate in health and wellness education counseling
219000762|NCT05044546|OTHER|Questionnaire Administration|Ancillary studies
219000763|NCT05044546|OTHER|Tobacco Cessation Counseling|Participate in smoking cessation counseling
219000764|NCT05615610|DEVICE|tSCS|The participants in Group A will receive tSCS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
219371875|NCT05008328|OTHER|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
219371876|NCT05008328|PROCEDURE|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
219371877|NCT04122287|DRUG|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
219371878|NCT04122287|DRUG|tinidazole|tinidazole-tetracycline-containing quadruple regimens
219371879|NCT02736747|OTHER|Cryotherapy|
219371880|NCT02736747|OTHER|Placebo|
219371881|NCT05762198|DEVICE|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
219371882|NCT05762198|DEVICE|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
219371883|NCT05910827|DRUG|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
219371884|NCT05910827|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
219371885|NCT05910827|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
219371886|NCT05935306|DRUG|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
219371887|NCT05935306|OTHER|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
219371888|NCT05935306|DEVICE|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
219371889|NCT05935306|OTHER|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
219371890|NCT06419205|DRUG|ADX-097|Open Label
219371891|NCT06081075|OTHER|Genetic testing|Rapid whole genome sequencing
219371892|NCT05966272|DRUG|HRS9531 injection|single dose
219371893|NCT05966272|DRUG|HRS9531 injection Placebo|single dose
219371894|NCT04130646|DEVICE|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
219371895|NCT04130646|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
219371896|NCT06232512|DEVICE|Haptic Device|Provides sensory substitution by mapping pressure from the insole sensor onto a corresponding vibrating and heating patch to be worn where more sensation is present.
219371897|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
219371898|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
219371899|NCT04098315|OTHER|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
219371900|NCT04317755|BEHAVIORAL|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
219371901|NCT03903510|DEVICE|Virtual Reality (VR)|Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
219371902|NCT01072292|BEHAVIORAL|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
219371903|NCT01278576|DRUG|BOTOX-A®|200 units, single treatment only
219371904|NCT05573802|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
219371905|NCT05573802|DRUG|Lenalidomide|Lenalidomide will be administered per os.
219371906|NCT05573802|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
219371907|NCT05573802|DRUG|Nirogacestat|Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
219371908|NCT01276184|BEHAVIORAL|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
219371909|NCT00002085|DRUG|Azithromycin|
219371910|NCT03216460|DEVICE|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
219371911|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract|
219371912|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin|
219371913|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract placebo|
219371914|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin placebo|
219371915|NCT05559307|DRUG|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
219371916|NCT03496753|DEVICE|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
219371917|NCT05760716|OTHER|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
219371918|NCT04756414|BEHAVIORAL|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
219371919|NCT05154474|OTHER|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
219371920|NCT04272593|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
219371921|NCT02835170|BIOLOGICAL|Autologous immunoglobulin|Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
219371922|NCT02835170|OTHER|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
219371923|NCT03017209|DIETARY_SUPPLEMENT|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
219371924|NCT03017209|DIETARY_SUPPLEMENT|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
219371925|NCT03017209|OTHER|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
219371926|NCT00278603|BIOLOGICAL|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
219371927|NCT02429856|DEVICE|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
219371928|NCT02271165|DRUG|Immunoglobulin (Hizentra)|
219371929|NCT03471455|DRUG|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
219371930|NCT03471455|DRUG|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
219371931|NCT03471455|DRUG|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
219371932|NCT05850078|OTHER|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
219371933|NCT00978302|DRUG|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371934|NCT00978302|DRUG|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371935|NCT00978302|DRUG|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371936|NCT00978302|DRUG|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371937|NCT00978302|DRUG|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371938|NCT00978302|DRUG|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
219371939|NCT00978302|DRUG|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
219371940|NCT05243849|DEVICE|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
219371941|NCT04816240|DRUG|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90)
219371942|NCT04816240|BIOLOGICAL|Albumin|80grams/week for 2 weeks followed by 40gram/week
219371943|NCT04816240|OTHER|Standard Medical Treatment|Standard Medical Treatment
219754289|NCT04210960|RADIATION|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
219371944|NCT04816240|OTHER|Placebo|Placebo
219371945|NCT03700047|DEVICE|GAL1704|new dermal filler
219371946|NCT03700047|DEVICE|Juvederm Voluma|hyaluronic acid
219371947|NCT00035451|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
219371948|NCT00035451|DRUG|Placebo|tablets, twice daily for 6 months
219371949|NCT00035451|DRUG|Sotalol|160 mg sot twice daily for 6 months
219371950|NCT05588427|DIETARY_SUPPLEMENT|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
219371951|NCT05588427|DIETARY_SUPPLEMENT|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
219371952|NCT01797718|DRUG|Testosterone|1mg/kg every 4 weeks for 6 months
219371953|NCT01797718|DRUG|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
219371954|NCT00863551|DRUG|Trospium Chloride|Extended release, 60 mg, oral daily
219371955|NCT05146557|OTHER|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
219371956|NCT02763956|DEVICE|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
219371957|NCT02763956|OTHER|Placebo|Intradiscal saline injection
219371958|NCT04471896|DEVICE|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
219371959|NCT00680225|DRUG|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
219371960|NCT01569633|DRUG|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
219371961|NCT01569633|DRUG|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
219371962|NCT01569633|DRUG|placebo|The dose of sugar water is 1 ml per 8 hours.
219371963|NCT03837184|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
219371964|NCT06172556|PROCEDURE|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
219371965|NCT02906553|DRUG|Glyceryl Trinitrate|
219371966|NCT02906553|DRUG|Placebo|
219371967|NCT00758784|DRUG|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
219371968|NCT01055509|BEHAVIORAL|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
219371969|NCT00327938|DEVICE|Measuring of skin conductance|
219000765|NCT05615610|DEVICE|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
219000766|NCT05615610|DEVICE|Control|The participants in Group C will receive placebo tSCS and tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
219371970|NCT00327938|PROCEDURE|Tetanic stimuli|
219371971|NCT05527951|OTHER|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
219371972|NCT05527951|OTHER|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
219371973|NCT03978273|DEVICE|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
219371974|NCT03978273|OTHER|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
219371975|NCT02047006|DRUG|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
219371976|NCT00918944|OTHER|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families"
219371977|NCT00918944|OTHER|Intervention|"Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link"
219187564|NCT04350359|DEVICE|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
219187565|NCT04350359|DEVICE|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
219187566|NCT04350359|DEVICE|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
219187567|NCT06988306|BEHAVIORAL|GDM Enhanced|The GDM Enhanced intervention is comprised of HV-delivered, evidence-based modules (10-20 minutes) with facilitator guides. The content prioritizes management and prevention of diabetes through healthy eating, physical activity, and stigma-informed weight management strategies.
219187568|NCT06988306|BEHAVIORAL|Meals|The Meal intervention includes medically tailored meals being provided to participants starting after randomization and tailored to their individual dietary preferences and cultural considerations.
219371978|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade the Flexor Hallucis|
219371979|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade adductor of the thumb.|
219371980|NCT01561664|OTHER|muscle and fat biopsy|muscle and fat biopsy
219371981|NCT03226626|DRUG|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
219371982|NCT03226626|DEVICE|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
219371983|NCT02547623|DRUG|Dexamethasone|depot intracameral
219371984|NCT02547623|DRUG|Prednisolone|Prednisolone eye drops 1%
219371985|NCT00004054|DRUG|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
219371986|NCT00004054|DRUG|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
219371987|NCT00004054|DRUG|etoposide|50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
219371988|NCT00004054|DRUG|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
219371989|NCT00004054|DRUG|paclitaxel|135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
219371990|NCT00004054|DRUG|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
219371991|NCT00004054|RADIATION|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
219371992|NCT00004054|DRUG|warfarin|To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
219371993|NCT02005055|PROCEDURE|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
219371994|NCT01964248|DRUG|Placebo|Placebo cream applied 2 hours before blood sample
219371995|NCT01964248|DRUG|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
219371996|NCT01480739|DRUG|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
219371997|NCT01480739|DRUG|100 mg Placebo|Twice daily for 7 days
219371998|NCT03573167|BEHAVIORAL|In-Person Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
219371999|NCT03573167|BEHAVIORAL|Mobile Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
219372000|NCT01451645|DRUG|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
219372001|NCT01451645|DRUG|placebo|daily placebo dosing for 16 weeks
219372002|NCT01451645|DRUG|allopurinol|background therapy
219372003|NCT05065112|PROCEDURE|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
219372004|NCT05065112|PROCEDURE|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
219372005|NCT03156036|DRUG|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
219187569|NCT03100760|DEVICE|13C-urea breath test|Subjects will undergo 13C-urea breath test involving collection of baseline breath samples, nebulization of 13C-urea, and collection of post-nebulization breath samples
219187570|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
219187571|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
219187572|NCT06999811|BEHAVIORAL|Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR)|EMPWR is evidence-informed, behavioral intervention to address risk factors for fear of opioid withdrawal, craving, and stress, with an adjective mobile application among pregnant women receiving opioid agonist therapies. The goal of EMPWR is to promote medication retention and adherence.
219187573|NCT06999811|OTHER|Medication monitoring (control)|Participants will record the dose and time buprenorphine was taken for two months via REDCap daily diaries, which will be delivered via text.
219187574|NCT06676384|DRUG|Oral prednisolone and SoC|Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
219187575|NCT06676384|DRUG|Gut-directed budesonide and SoC|Gut-directed Budesonide 12 mg once daily for nine months and tapered to 9mg once daily for the next three months, 6mg once daily for the next three months and 3mg once daily for the next three months and stopped (total 18 months). All participants in this arm will receive SoC.
219187576|NCT06676384|DRUG|Mycophenolate mofetil (MMF) and SoC|Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.
219187577|NCT06676384|DRUG|Hydroxychloroquine and SoC|Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months. All participants in this arm will receive SoC.
219187578|NCT06676384|DRUG|Non-steroidal mineralocorticoid receptor antagonist and SoC|Generic drug not available currently. All participants in this arm will receive SoC.
219187579|NCT06676384|DRUG|SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).
219187580|NCT05494359|DIAGNOSTIC_TEST|The nitrogen isotope|The nitrogen mass-charge ratio abundances (NMAs) and NMA ratios (NMARs) The nitrogen components of various m/z values in oral gas were detected.
219187581|NCT06868238|DRUG|Magtrace|Participants will receive a single injection of Magtrace into the breast during their mastectomy.
219187582|NCT06874998|BEHAVIORAL|Structured group discussions|"A group-based program for immigrant parents of children aged 0-17, providing essential information on key aspects of family life in Sweden. The intervention consists of five weekly three-hour sessions, combining lectures, group discussions, and interactive exercises, led by a trained group leader and, when necessary, an interpreter.~The following topics are discussed:~* Parenting in a New Country - Adapting to cultural changes and supporting children's integration.~* Education \& Child Development - School system, parental involvement, and learning support.~* Healthcare \& Well-being - Access to healthcare, preventive care, and mental health.~* Parents' Rights \& Responsibilities - Child welfare laws, positive discipline, and social services.~* Parenting Teenagers - Navigating adolescence, peer relationships, and risk prevention."
219187583|NCT06874998|BEHAVIORAL|Unstructured group meeting|"Parents in the control group are asked to participate in a gathering where they will watch two short films from the Swedish Educational Broadcasting Company (UR), followed by a brief discussion. The films have been handpicked by representatives from BRIS and PLUS together with the researchers to create an opportunity for a meeting. The first film A way in - first meeting shows a family from Iran living in Sweden for 1,5 years and explores how one can establish a place in society. In the second film Make new friends it is illustrated how hard it can be to create a new social context. The intention with the short films is not to give a short version of PiS, but to engage parents in the study and the program so they will complete them."
219187584|NCT07027748|DRUG|Naxitamab|Recombinant humanized anti-GD2 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
219187585|NCT07027748|DRUG|Irinotecan|Topoisomerase Inhibitor, single-dose vial, via intravenous infusion per standard of care
219187586|NCT07027748|DRUG|Temozolomide|Alkylating agent, capsule, via orally (by mouth) per standard of care
219187587|NCT07027748|DRUG|Sargramostim granulocyte-macrophage colony stimulating factor|Recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF), multi-use vial, via subcutaneously (under the skin) injection per standard of care
219187588|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; high dose ；Denosumab placebo
219187589|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; low dose ；Denosumab placebo
219187590|NCT07028268|DRUG|Denosumab；SHR-2017 placebo|Denosumab；SHR-2017 placebo
219372006|NCT02562547|DEVICE|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
219372007|NCT00004029|BIOLOGICAL|recombinant viral vaccine therapy|
219372008|NCT00004029|BIOLOGICAL|sargramostim|
219372009|NCT01365156|PROCEDURE|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
219372010|NCT01365156|RADIATION|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
219372011|NCT00924157|DIETARY_SUPPLEMENT|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
219372012|NCT00924157|OTHER|Placebo|Matching placebo capsules
219372013|NCT03756090|DRUG|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
219372014|NCT03756090|DRUG|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
219372015|NCT03756090|DRUG|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
219372016|NCT03756090|DRUG|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
219372017|NCT03756090|DRUG|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
219372018|NCT05619458|BEHAVIORAL|Mindfulness Intervention|6-week mindfulness intervention
219372019|NCT01186393|BEHAVIORAL|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
219000767|NCT06526273|BEHAVIORAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
219000768|NCT06526273|OTHER|Control|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
219000769|NCT07132905|BEHAVIORAL|"Mpata Yathu (Our Space)"|Mpata Yathu is a church-based, lay counselor-delivered psychological intervention adapted from the Friendship Bench problem-solving therapy (PST) model. Designed for adolescent girls and young women in Zambia with a history of gender-based violence and elevated mental health symptoms, the intervention includes six weekly individual PST sessions delivered in private spaces within Catholic churches. Lay counselors are trained in trauma-informed, survivor-centered care and offer optional referrals to mental health, HIV, or GBV-related services. Mpata Yathu maintains the core structure of Friendship Bench but was adapted through community-partnered participatory research to meet the sociocultural needs of Zambian youth.
219000770|NCT07131605|OTHER|Before bariatric surgery, both blood and biological samples (stool and urine) will be collected. Patients will also undergo a cardiology examination|This study includes a comprehensive set of laboratory and clinical investigations to evaluate the cardiovascular and metabolic impact of obesity and its modulation after bariatric surgery. Multiple biological samples (blood, urine, stool, and omental adipose tissue) will be collected at baseline and during follow-up.
219000771|NCT06977841|DRUG|Tegoprazan|50 mg twice daily (BID), d1-14, administered 30 minutes before morning and evening meals.
219000772|NCT06977841|DRUG|Amoxicillin 250Mg Cap|750 mg four times daily (QID), d1-14, administered immediately after breakfast, lunch, dinner, and bedtime snack.
219000773|NCT06977841|DRUG|Tetracycline 500 Mg|500 mg three times daily (TID), d1-14, postprandial after breakfast, lunch, and dinner.
219000774|NCT06977841|DRUG|Bismuth|220 mg BID, d1-14, administered 2-3 hours after tetracycline doses at lunch and dinner
219000775|NCT06979297|BEHAVIORAL|Web-based physical activity and diet intervention|Participants receive access to a theory-driven, web-based intervention for 12 weeks that provides interactive information on diet and physical activity, including goal setting, diet and activity tracking, tailored information on healthy eating and increasing exercise, and videos on topics of healthy eating and physical activity.
219000776|NCT06979297|OTHER|Wait-list control arm|Participants in the wait-list control will complete all the same measures as the intervention group for the first 12 weeks, then will receive access to the Internet-based intervention for another 12 weeks.
219000777|NCT07124975|BEHAVIORAL|Comparison of the treatment data with other patients|In this group, feedback will be provided as in the routine treatment data feedback group. In addition to this information, aggregated results for all participants (proportion of days with CPAP usage ≥4 hours per day and average daily usage time) and the participant's ranking based on these aggregated data will also be provided as feedback.
219000778|NCT07124975|BEHAVIORAL|CPAP data feedback|Participants will receive monthly feedback on their CPAP therapy treatment data (usage time and the proportion of days with \>4 hours of use) via mail or email for 6 months.
219000779|NCT07132112|BIOLOGICAL|GT719 Injection|GT719 Injection
219000780|NCT07131202|DRUG|FL115+PD-1|Combined treatment
219000781|NCT07132021|DEVICE|Active taVNS|Protocol uses a 25 Hz frequency with 500 μs pulse width in biphasic configuration, operating at a 1:1 duty cycle with current intensity set to the maximum tolerable level without inducing pain. The total stimulation duration is 60 minutes. The stimulation is combined with physical therapy focused on upper extremity function.
219372020|NCT01186393|BEHAVIORAL|Low Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
219372021|NCT01186393|BEHAVIORAL|High Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
219372022|NCT06257212|DRUG|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
219372023|NCT06257212|DRUG|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
219372024|NCT06257212|DRUG|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
219372025|NCT03311672|DRUG|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
219372026|NCT03311672|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
219372027|NCT03311672|RADIATION|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
219372028|NCT05785195|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
219372029|NCT01886118|PROCEDURE|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
219372030|NCT01886118|OTHER|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
219372031|NCT01886118|OTHER|Conventional media culture|embryos are cultured in conventional media
219372032|NCT01516827|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
219372033|NCT02034487|OTHER|retrospective data collection|
219372034|NCT02978222|BIOLOGICAL|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
219372035|NCT02978222|DRUG|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
219372036|NCT01686568|DRUG|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
219372037|NCT01686568|DRUG|placebo|
219372038|NCT03972072|OTHER|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
219000782|NCT07132021|DEVICE|Sham taVNS|Physical therapy focused on upper extremity function with masking for transcutaneous vagus nerve stimulation
219372039|NCT03972072|DIAGNOSTIC_TEST|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
219372040|NCT02703857|DRUG|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
219372041|NCT01908595|DRUG|M518101|
219372042|NCT05314673|DRUG|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
219372043|NCT05314673|PROCEDURE|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
219372044|NCT03838484|DRUG|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
219372045|NCT03838484|DRUG|Placebo patch|Placebo skin patch will be applied to the skin.
219372046|NCT04675047|OTHER|no intervention for healthy control|observational study - no intervention
219372047|NCT00697957|BEHAVIORAL|Exercise|Progressive impact exercise
219372048|NCT03124225|DRUG|DMARD|
219372049|NCT03476044|DRUG|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
219372050|NCT03476044|DRUG|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
219372051|NCT03424161|DEVICE|Secret RF|Subjects will receive treatment with the Secret RF device
219372052|NCT01583348|PROCEDURE|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
219372053|NCT01053312|DRUG|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
219372054|NCT04856137|DRUG|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
219372055|NCT01755832|PROCEDURE|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
219372056|NCT01211808|DRUG|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
219372057|NCT01211808|DRUG|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
219372058|NCT04833439|OTHER|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
219372059|NCT05807009|OTHER|core exercise|the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
219372060|NCT05807009|OTHER|traditional therapy|the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
219372061|NCT00014092|BIOLOGICAL|aldesleukin|
219372062|NCT00014092|BIOLOGICAL|recombinant interferon alfa|
219372063|NCT00014092|BIOLOGICAL|sargramostim|
219372064|NCT00014092|DRUG|temozolomide|
219372065|NCT06301360|BEHAVIORAL|Internet based Emotional Awareness and Expression Therapy (I-EAET)|"In I-EAET with therapist support, the therapist and participants communicate asynchronous using written messages. The therapist gives feedback each week on home-work assignments and is available on demand for support.~In I-EAET without therapist support, the participants works with home-work assignments on their own and only have technical support."
219372066|NCT04673058|PROCEDURE|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
219372067|NCT04673058|PROCEDURE|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
219372068|NCT01872455|DIETARY_SUPPLEMENT|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
219372069|NCT01872455|DIETARY_SUPPLEMENT|Usual diet|Usual diet of the patients
219372070|NCT02059876|DRUG|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
219372071|NCT06213662|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
219372072|NCT03624816|DEVICE|Restylane Defyne|hyaluronic acid dermal filler gel
219372073|NCT03386084|DEVICE|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
219372074|NCT06546865|DEVICE|22F Sheath Size|Participants in this group will have the 22F sheath size used in their procedure.
219372075|NCT06546865|DEVICE|26F Sheath Size|Participants in this group will have the 26F sheath size used in their procedure.
219372076|NCT04751721|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
219372077|NCT02236689|PROCEDURE|Non operative|no surgical intervention
219372078|NCT02236689|PROCEDURE|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
219372079|NCT02868892|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
219372080|NCT01106924|OTHER|Probiotic|daily probiotic consumption
219372081|NCT01106924|OTHER|Placebo|daily placebo consumption
219372082|NCT04378777|PROCEDURE|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
219372083|NCT04378777|PROCEDURE|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
219372084|NCT06185855|OTHER|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
219000783|NCT07132723|OTHER|Time in minutes from admission to closed reduction|Time in minutes from admission to closed reduction measured as: From arriving time in the emergency department until the start of surgery in the operating theater.
219000784|NCT07132658|RADIATION|MR-Guided SBRT|MR-Guided SBRT
219000785|NCT06393751|BIOLOGICAL|Bevacizumab|Given IV
219372085|NCT02131844|OTHER|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
219372086|NCT02131844|OTHER|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
219372087|NCT02669979|OTHER|Intervention|Professional oral care
219372088|NCT06354933|DIAGNOSTIC_TEST|Neurological Soft Signs|Neurological Soft Signs score according to the Heidelberg Manual
219372089|NCT02704247|DEVICE|CARDIOSPACE System|"* autonomic nervous system test~* tilt test~* ultrasound exploration at rest (heart / vessels)~* laser doppler + iontophoresis test~* sub-maximal exercise test"
219372090|NCT04048512|PROCEDURE|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
219372091|NCT04048512|PROCEDURE|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
219372092|NCT02984462|PROCEDURE|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
219372093|NCT04814979|DEVICE|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
219372094|NCT04814979|OTHER|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
219372095|NCT00661583|DRUG|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
219372096|NCT00661583|DRUG|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
219372097|NCT00661583|DRUG|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
219372098|NCT05116657|DIAGNOSTIC_TEST|Nasal Lavage and Oral Wash|"* Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
219372099|NCT02393209|DRUG|Docetaxel|Docetaxel intravenous infusion
219372100|NCT02393209|DRUG|TAK-117|TAK-117 Tablets
219372101|NCT02216565|OTHER|Hospitalization in specialized neuro-vascular unit|
219372102|NCT02216565|DRUG|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
219372103|NCT02216565|OTHER|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
219372104|NCT02216565|PROCEDURE|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
219372105|NCT00348166|DRUG|cyclopentolate|
219372106|NCT00619957|DRUG|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
219000786|NCT06393751|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219000787|NCT06393751|PROCEDURE|Computed Tomography|Undergo CT
219000788|NCT06393751|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219000789|NCT06393751|DRUG|Paclitaxel|Given IV
219000790|NCT06393751|DRUG|Tolinapant|Given PO
219372107|NCT00619957|DRUG|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
219372108|NCT00755079|DRUG|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
219372109|NCT00755079|DRUG|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
219372110|NCT03545282|BEHAVIORAL|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
219372111|NCT00899652|GENETIC|Southern blotting|
219372112|NCT00899652|GENETIC|chromosomal translocation analysis|
219372113|NCT00899652|GENETIC|cytogenetic analysis|
219372114|NCT00899652|GENETIC|gene rearrangement analysis|
219372115|NCT00899652|GENETIC|mutation analysis|
219372116|NCT03393026|DRUG|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
219372117|NCT00854646|DRUG|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
219372118|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
219372119|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
219372120|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
219372121|NCT04095455|PROCEDURE|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
219372122|NCT04095455|DRUG|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
219372123|NCT04095455|DRUG|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
219372124|NCT03841552|DEVICE|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
219000791|NCT07131709|OTHER|AI Generated Summary|Summary of the doctor's appointment generated by AI (either with or without the Next Steps Plan, depending on the arm participants are allocated to).
219372125|NCT03841552|OTHER|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
219372126|NCT00751894|DRUG|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
219372127|NCT00815646|DRUG|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
219372128|NCT03545139|BIOLOGICAL|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
219372129|NCT03545139|BIOLOGICAL|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
219372130|NCT00006131|DRUG|Valacyclovir|
219372131|NCT00868790|DRUG|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
219372132|NCT00868790|DRUG|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
219372133|NCT00868790|DRUG|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
219372134|NCT00868790|DRUG|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
219372135|NCT04052841|PROCEDURE|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
219372136|NCT04052841|PROCEDURE|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
219372137|NCT04052841|PROCEDURE|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
219372138|NCT01231412|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
219372139|NCT01231412|DRUG|Cyclosporine|Given PO or IV
219372140|NCT01231412|DRUG|Fludarabine Phosphate|Given IV
219372141|NCT01231412|DRUG|Mycophenolate Mofetil|Given PO
219372142|NCT01231412|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219372143|NCT01231412|DRUG|Sirolimus|Given PO
219372144|NCT01231412|RADIATION|Total-Body Irradiation|Undergo TBI
219372145|NCT04680117|OTHER|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
219372146|NCT04680117|OTHER|Saliva sample|Saliva sample by subject at J0
219372147|NCT04680117|OTHER|Nasal|Nasal brushing by subject at J0
219372148|NCT02149225|DRUG|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
219372149|NCT02149225|DRUG|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
219372150|NCT03377634|BEHAVIORAL|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
219372151|NCT04028037|PROCEDURE|FTPGT treated patients|"The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
219372152|NCT04028037|PROCEDURE|CAF+SCTG treated patients|According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
219372153|NCT00764725|DRUG|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
219372154|NCT00764725|BIOLOGICAL|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
219372155|NCT01957956|OTHER|Laboratory Biomarker Analysis|Correlative studies
219372156|NCT01957956|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
219372157|NCT01957956|DRUG|Temozolomide|Given PO
219372158|NCT01961427|DIETARY_SUPPLEMENT|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
219372159|NCT01961427|DIETARY_SUPPLEMENT|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
219372160|NCT01306760|DRUG|Ketamine|Ketamine used as the anaesthetic during ECT.
219372161|NCT01306760|DRUG|Propofol|The standard anaesthetic used for ECT.
219372162|NCT00620061|DRUG|Lubiprostone 24|24 mcg capsules for oral administration
219372163|NCT00944827|DIETARY_SUPPLEMENT|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
219372164|NCT00944827|DIETARY_SUPPLEMENT|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
219372165|NCT05396209|PROCEDURE|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
219372166|NCT05396209|PROCEDURE|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
219372167|NCT05396209|PROCEDURE|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
219372168|NCT01717534|DIETARY_SUPPLEMENT|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
219372169|NCT04222985|BIOLOGICAL|HSV 2 Formulation 1|Route of administration: Intramuscular
219372170|NCT04222985|BIOLOGICAL|HSV 2 Formulation 2|Route of administration: Intramuscular
219372171|NCT04222985|BIOLOGICAL|HSV 2 Formulation 3|Route of administration: Intramuscular
219372172|NCT04222985|BIOLOGICAL|HSV 2 Formulation 4|Route of administration: Intramuscular
219372173|NCT04222985|BIOLOGICAL|HSV 2 Formulation 5|Route of administration: Intramuscular
219372174|NCT04222985|BIOLOGICAL|HSV 2 Formulation 6|Route of administration: Intramuscular
219372175|NCT04222985|BIOLOGICAL|Sodium Chloride 0.9%|Route of administration: Intramuscular
219372176|NCT01724892|DRUG|Dexamethasone|
219372177|NCT01724892|DRUG|Loteprednol etabonate|
219372178|NCT03040024|DRUG|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
219372179|NCT03040024|DRUG|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
219372180|NCT03040024|DEVICE|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
219372181|NCT00783627|PROCEDURE|Angiography|Angiography done at the J1 visit
219372182|NCT02910427|OTHER|Regular salt|Participants eat a regular salt diet.
219187591|NCT07035327|OTHER|Dual-task training program|"Participants in the intervention group will engage in a dual-task training program, in which resistance training will be incorporated with cognitive tasks.~\- Resistance training: Participants will be instructed to perform the following exercises with proper form: (1) squat to chair, (2) seated unilateral hip flexion, (3) seated unilateral knee extension, (4) standing unilateral knee flexion and (5) bilateral calf raise. The lower limb exercises will be followed by four upper limb exercises: (6) seated elbow flexion, (7) twisting a towel, (8) seated horizontal opening of arms and elbow, (9) seated diagonal opening of arm and elbow.~\- Cognitive task: Subjects will be asked to perform a verbal fluency task or mental arithmetic tasks simultaneously with the resistance training exercises."
219187592|NCT07035327|OTHER|Resistance exercise|Subjects in the control group will perform the resistance exercises only without receiving any cognitive training. Ten-minute warm-up and cool-down sessions will precede and follow each exercise session.
219187593|NCT06254482|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
219372183|NCT02910427|OTHER|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
219372184|NCT02910427|OTHER|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
219372185|NCT01086787|OTHER|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
219187594|NCT00636389|DEVICE|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
219187595|NCT00636389|DEVICE|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
219187596|NCT07057583|OTHER|Non-Interventional Study|Non-interventional study
219187597|NCT07057544|DEVICE|LBBAP CRT device implantation|Pacing system with a lead implanted in the left bundle branch area will be done.
219187598|NCT07057544|DEVICE|BVP-CRT|Implantation of biventricular device
219187599|NCT06749132|DIAGNOSTIC_TEST|Transthoracic echocardiogram|All study participants will undergo a clinical transthoracic echocardiogram (TTE) performed by certified echocardiography technicians. The TTE includes standard transthoracic examination with acquisition of B-mode, color and spectral Doppler images and videos in line with standard echocardiographic guidelines.
219187600|NCT07064044|OTHER|Conventional Traetment|TENS applied for 10 minutes, Therapeutic ultrasound,Hip abductors and lateral rotators strengthening, Hamstring muscle passive stretching, Isometrics for quadriceps, given thrice a week for 4 weeks .
219187601|NCT07064044|OTHER|Muscle Energy Technique and Patellar Inferior Glide|Muscle Energy Technique for Hamstrings and Quadriceps While the patient contract muscle (Hamstring / Quadriceps) the therapist applies a gentle controlled force. After the contraction patient release and the therapist reposition the leg into a new barrier. Intensity of contraction will be 20-25-% of maximum strength. Each contraction will be held for 5-7 seconds, followed by additional passive stretching maintained for 30 and the relaxation patellar inferior glide applied at patella: the examiner applied a gentle downward force on the patella with their right hand, while the left hand controlled the direction of the patella's movement. This will be applied for 3-4 minutes as tolerated by the patient.
219372186|NCT01133743|DRUG|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
219372187|NCT03366714|DEVICE|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
219372188|NCT03366714|DEVICE|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
219372189|NCT03179917|DRUG|Pembrolizumab|pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.
219372190|NCT03179917|RADIATION|Involved Site Radiation Therapy|30 Gy of ISRT
219372191|NCT04636905|OTHER|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
219372192|NCT02792140|DRUG|Naltrexone|one week
219372193|NCT02792140|OTHER|Placebo|one week
219372194|NCT00056706|PROCEDURE|Transient deafferentation|
219372195|NCT04722718|DRUG|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
219372196|NCT03056443|DEVICE|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
219372197|NCT05278390|RADIATION|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
219372198|NCT05753111|DIETARY_SUPPLEMENT|PEA|PEA supplementation
219372199|NCT05753111|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin supplementation
219372200|NCT02262403|OTHER|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
219372201|NCT04609748|DRUG|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
219372202|NCT04609748|DRUG|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
219372203|NCT06030011|BEHAVIORAL|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
219187602|NCT07062991|OTHER|Kendall Exercises|Kendall exercises which includes: Chin tuck in supine Stretching the cervical extensors Shoulder retraction with theraband Stretching of the pectoralis major muscle Every strengthening exercise will be repeated for 12 repetitions and done for 3 sets and each stretching exercise will be hold for 30 seconds and repeated 3 times. The exercises will be performed three times per week for 4 weeks
219372204|NCT06030011|BEHAVIORAL|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
219372205|NCT02916277|BIOLOGICAL|endocan|to look series Endocan level for 5 days in intubated patients
219372206|NCT01526148|DRUG|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
219372207|NCT01526148|DRUG|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
219372208|NCT03567655|DRUG|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
219372209|NCT03308851|PROCEDURE|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
219372210|NCT03308851|PROCEDURE|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
219372211|NCT06167161|DEVICE|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
219372212|NCT02107144|DRUG|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
219372213|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
219557731|NCT01817686|OTHER|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
219557732|NCT03853369|DRUG|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
219557733|NCT00358631|DRUG|SSR149415|
219372214|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
219372215|NCT02926339|BEHAVIORAL|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
219372216|NCT01334073|DRUG|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
219372217|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
219372218|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
219372219|NCT03890055|DRUG|Anlotinib Hydrochloride|Best supportive care
219372220|NCT04696497|DIAGNOSTIC_TEST|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment"
219372221|NCT04696497|DIAGNOSTIC_TEST|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
219372222|NCT04696497|DIAGNOSTIC_TEST|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
219372223|NCT03237468|OTHER|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
219372224|NCT05009758|PROCEDURE|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
219372225|NCT05009758|PROCEDURE|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
219372226|NCT05009758|PROCEDURE|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
219372227|NCT05009758|PROCEDURE|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
219372228|NCT05009758|PROCEDURE|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
219372229|NCT05009758|PROCEDURE|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
219372230|NCT05009758|PROCEDURE|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
219372231|NCT05009758|DIAGNOSTIC_TEST|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
219372232|NCT05009758|OTHER|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
219187603|NCT07062991|OTHER|Scapular stabilization exercises|Shoulder shrugs Prone arm lift Stretching of levator scapular Stretching pectoralis minor muscle Each strengthening exercise will be repeated for 15 repetitions of 3 sets and each stretching exercises will be hold for 30 seconds and repeated 3 times. The exercises will be performed three days per week for 4 weeks.
219372233|NCT05009758|DIAGNOSTIC_TEST|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
219372234|NCT05009758|PROCEDURE|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
219187604|NCT07063472|BEHAVIORAL|Tele- pilates|"Tele-Pilates for (TP) group The TP program included warm-up, main session, and cool-down phases. The session started with warm-up exercises in the form of breathing, spinal twist, cat stretch, arm circles, and abdominal stretching. Each exercise was performed for five repetitions, with each repetition held for 10-15 seconds and followed by a 5-second rest period. The warm-up phase lasted a total of 10 minutes.~Tele-Pilates was supervised by a Pilates professional trainer. Participants engaged in mat-based Pilates exercises. These exercises included roll-up, bug leg, crock leg lying, prone single leg kick, bug roll, knee/lumbar roll, and prone attitude rotation.The session ended with 10-minute cool-down that involved relaxation exercises and stretching."
219187605|NCT07063472|DEVICE|Kinesio taping application for the KT group|Kinesio taping application for the KT group The participant sat upright in a chair, and a piece of kinesiology tape (5 × 5 cm, 3NS, Korea) was used to measure the distance from just above the anus to the upper border of the pelvis. This measured length was then divided by eight, and the tape was cut accordingly. One end of the tape was anchored on the ulnar bone just above the inguinal region. With 25% stretch, the tape was applied diagonally upward and outward, following the contour of the iliac crest over the ilium. The second end was secured to overlap the base of the initial tape. A second strip was applied in a similar manner in the opposite direction over the ilium. KT was applied for over eight weeks, with the tape changed every three days
219187606|NCT07062458|DIAGNOSTIC_TEST|Nipple Sensation Assessment|"the measurement of nipple sensation preservation, will be conducted using the Semmes-Weinstein esthesiometer. The clinician will use the device to touch the nipple and the surrounding quadrants of the skin, applying filaments of increasing calibers (0.07gr, 0.4gr, 2.0gr, 4.0gr, 300gr), and the lightest caliber perceived by the patient will be recorded. This assessment will be conducted at four different times:~* Before surgery, to assess baseline sensation.~* 1 month after surgery.~* 3 months after surgery.~* 6 months after surgery."
219372235|NCT05009758|PROCEDURE|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
219372236|NCT05009758|PROCEDURE|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
219372237|NCT05095025|DRUG|Bupivacaine Hydrochloride 20ml injectate|Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
219372238|NCT00408967|DRUG|Tucotuzumab celmoleukin (EMD 273066)|
219372239|NCT01818297|DEVICE|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
219372240|NCT03280979|DRUG|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
219372241|NCT03280979|DRUG|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
219372242|NCT01798576|DRUG|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
219372243|NCT01798576|DRUG|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
219372244|NCT04582838|DIAGNOSTIC_TEST|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
219372245|NCT04582838|DIAGNOSTIC_TEST|ECG|ECG signal is used to monitor respiratory rate (RR).
219372246|NCT01857921|DRUG|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
219372247|NCT01857921|DRUG|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
219372248|NCT00140764|DRUG|Metronidazole gel versus placebo gel|
219372249|NCT03047525|BIOLOGICAL|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
219372250|NCT01422993|OTHER|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
219372251|NCT03029832|DRUG|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
219372252|NCT03029832|DRUG|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
219372253|NCT01628926|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
219372254|NCT01628926|DRUG|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
219372255|NCT01628926|DRUG|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
219372256|NCT02467998|DEVICE|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
219372257|NCT05398198|DRUG|GSK3923868|GSK3923868 dose and administration as per study intervention.
219372258|NCT05398198|DRUG|Placebo|Placebo matching GSK3923868 will be administered.
219372259|NCT02382094|DRUG|Bicalutamide|
219372260|NCT04799561|BEHAVIORAL|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
219372261|NCT02222402|BEHAVIORAL|INTRA-DIALYTIC EXERCISE TRAINING|
219372262|NCT06277973|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention is based on EMDR therapy for PTSD treatment. Participants will answer demographic questions, choose a primary distress source and watch a therapist-guided video (male or female, based on participant choice) that will instruct them through the 'Butterfly Hug' method (tapping alternately on both sides of the body) while hearing positive statements from the therapists on the chosen distress source. Before and after each video participants will rate their distress level on a scale between 0 and 10 and they can view up to 8 videos per session. The system will monitor distress levels, and if it detects a sustained deterioration, it will end the intervention. At the end of the intervention, participants will be given information about possible reactions to it and how to deal with them, they will be encouraged to use the technique whenever necessary, and they will be informed of relevant support lines that they can contact if needed.
219372263|NCT04995094|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
219372264|NCT04995094|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
219372265|NCT01275222|DRUG|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
219372266|NCT01275222|DRUG|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
219372267|NCT01275222|DRUG|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
219372268|NCT02146339|OTHER|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219372269|NCT02146339|OTHER|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219372270|NCT02146339|OTHER|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219372271|NCT02146339|OTHER|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219557734|NCT01325935|DRUG|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
219557735|NCT00156650|DRUG|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
219557736|NCT00156650|DRUG|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
219557737|NCT00156650|DRUG|Depo-Medroxyprogesterone|300 mg IM every 3 months
219557738|NCT01945619|BIOLOGICAL|Trivirus-Specific CTLs|Patients will receive up to 2 x 10\^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
219372272|NCT02146339|OTHER|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219372273|NCT02146339|OTHER|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
219372274|NCT01146925|DRUG|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
219372275|NCT01146925|DRUG|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
219372276|NCT00125047|BIOLOGICAL|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
219372277|NCT00125047|BIOLOGICAL|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
219372278|NCT00591734|DRUG|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
219372279|NCT00591734|DRUG|Everolimus|10 mg by mouth daily
219372280|NCT06200350|OTHER|Experimental group|Tailored training based on the profile of each participant.
219372281|NCT06200350|OTHER|Control group|They will continue with the traditional training.
219372282|NCT04294485|BEHAVIORAL|Physical therapy|Electrostimulation combined with exercise
219372283|NCT02407626|DRUG|Propofol|Total intravenous anesthesia is a clinical standard procedure
219372284|NCT02407626|DRUG|Sevoflurane|Volatile anesthesia is a clinical standard procedure
219372285|NCT05888350|DRUG|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
219372286|NCT05888350|DRUG|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
219372287|NCT01400256|DRUG|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
219372288|NCT03043144|OTHER|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
219372289|NCT03043144|OTHER|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
219372290|NCT03043144|OTHER|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
219372291|NCT03043144|OTHER|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
219372292|NCT03043144|OTHER|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
219372293|NCT03043144|OTHER|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
219372294|NCT04672083|DRUG|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
219372295|NCT04672083|DRUG|Placebo|matching placebo
219372296|NCT02500537|DEVICE|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
219372297|NCT03266679|OTHER|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
219372298|NCT00987844|DRUG|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
219372299|NCT05359107|BEHAVIORAL|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
219372300|NCT05359107|BEHAVIORAL|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
219372301|NCT00130338|DRUG|Rivastigmine|
219372302|NCT05451420|DRUG|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
219372303|NCT04684654|BIOLOGICAL|BMS-986325|Specified dose on specified days
219372304|NCT04684654|OTHER|Placebo for BMS-986325|Specified dose on specified days
219372305|NCT01661790|DRUG|Bevacizumab|Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
219372306|NCT01661790|DRUG|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
219372307|NCT01479608|PROCEDURE|Liver transplantation and liver resection|
219372308|NCT02048904|DRUG|Sitagliptin|Sitagliptin 100 mg/day for 3 months
219372309|NCT02048904|DRUG|Placebo|Placebo 1 pill/day for 3 months
219372310|NCT04042480|DRUG|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
219372311|NCT01449890|BEHAVIORAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
219372312|NCT04156321|DIETARY_SUPPLEMENT|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
219372313|NCT02624648|BEHAVIORAL|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
219372314|NCT02624648|BEHAVIORAL|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
219372315|NCT02624648|BEHAVIORAL|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
219372316|NCT02624648|DRUG|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
219372317|NCT02624648|DRUG|Placebo|They will receive a capsule of Placebo twice a day for 120 days
219372318|NCT00784758|DEVICE|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
219372319|NCT00784758|DEVICE|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
219372320|NCT02844361|OTHER|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
219372321|NCT02844361|OTHER|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
219372322|NCT06057311|OTHER|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
219372323|NCT06057311|OTHER|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
219372324|NCT06057311|OTHER|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
219372325|NCT00130871|DRUG|levosimendan|
219372326|NCT03877406|DRUG|Empagliflozin 10 MG|addition of empagliflozin 10 MG
219372327|NCT03877406|DRUG|Hypoglycemics Oral|dose escalation of hypoglycemics oral
219372328|NCT06852443|BEHAVIORAL|Selfhelp modules|16 web-based structured selfhelp modules, based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
219372329|NCT06852443|BEHAVIORAL|Therapist Chat Service|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
219372330|NCT00764556|DRUG|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
219372331|NCT00003454|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219372332|NCT05957705|PROCEDURE|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
219372333|NCT05957705|PROCEDURE|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
219372334|NCT01712347|DRUG|Bevacizumab|Bevacizumab will be administered as per approved label.
219372335|NCT01712347|DRUG|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
219372336|NCT06648590|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
219372337|NCT06648590|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
219372338|NCT05296304|DRUG|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
219372339|NCT05296304|RADIATION|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
219372340|NCT04742335|OTHER|Survey|Survey will be applied to the participants.
219372341|NCT04126655|DRUG|Arfolitixorin|Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
219372342|NCT01274884|PROCEDURE|Tightrope fixation|Arthroscopic repair
219372343|NCT02313831|OTHER|Interval training|Patients of this group will be submitted to an interval training program
219372344|NCT04870073|PROCEDURE|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
219372345|NCT04870073|DRUG|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
219372346|NCT04870073|PROCEDURE|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
219372347|NCT04774939|PROCEDURE|Endovenous laser ablation|The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment
219372348|NCT03604666|OTHER|Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
219372349|NCT06645886|DRUG|KQB198|Oral KQB198
219372350|NCT06645886|DRUG|Dasatinib|Oral dasatinib
219372351|NCT03148210|DRUG|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
219372352|NCT03148210|BEHAVIORAL|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
219372353|NCT03148210|BEHAVIORAL|Participant Education|Standardized education for asthma or COPD disease
219372354|NCT06807606|DRUG|Drugs Cyclophosphamide|Given as standard of care treatment through IV infusion
219372355|NCT06807606|DRUG|Fludarabine|Given as standard of care treatment through IV infusion
219372356|NCT06807606|DRUG|Thiotepa|Given as standard of care treatment through IV infusion
219372357|NCT06807606|DRUG|Tacrolimus|Given as standard of care treatment through IV infusion
219372358|NCT06807606|DRUG|Mycophenolate mofetil|Given as standard of care treatment through IV infusion
219372359|NCT06814561|DRUG|Marcaine 0.5% Solution for Injection|The study involves the administration of 0.5% Marcaine heavy for spinal anesthesia in patients undergoing vascular surgery. The aim is to assess how this anesthesia affects urine output relative to mean arterial pressure.
219372360|NCT06223698|DRUG|Letrozole|Letrozole 2.5 mg daily
219372361|NCT06223698|DRUG|Anastrozole|Anastrozole 1 mg daily
219372362|NCT06223698|DRUG|Exemestane|Exemestane 25 mg daily
219372363|NCT06223698|DRUG|Tamoxifen|Tamoxifen 20 mg daily
219372364|NCT06819488|DRUG|[14C]HRS-7535|\[14C\]HRS-7535.
219372365|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
219372366|NCT03042000|OTHER|non-NCRT|without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
219372367|NCT03042000|OTHER|NCRT|the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
219372368|NCT03042000|DRUG|capecitabine with oxaliplatin|combined chemotherapy with capecitabine with oxaliplatin
219372369|NCT03042000|DRUG|capecitabine|single-agent chemotherapy with capecitabine
219372370|NCT03042000|PROCEDURE|TEM|transanal endoscopic microsurgery (TEM) excision of the lesion
219372371|NCT03042000|PROCEDURE|radical resection|radical resection of rectal cancer
219372372|NCT02069002|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
219372373|NCT02069002|BEHAVIORAL|Applied relaxation group therapy|
219372374|NCT02069002|BEHAVIORAL|Information session (psychoeducation)|
219372375|NCT02514759|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
219372376|NCT06351033|DIETARY_SUPPLEMENT|High ozonide (HOO) ozonated oil|ozonated oil with high ozonides (HOO) administered orally (os) in gastro-resistant capsules
219372377|NCT06856252|GENETIC|Liver resection to isolate cells|Isolation and culture of organoids Isolation of hepatic stellate cells Isolation and culture of sinusoidal stellate cells Generation of assembloids
219372378|NCT05133102|OTHER|Sample collection|Collection of saliva sample
219372379|NCT02376465|DRUG|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
219372380|NCT02376465|DRUG|PEG based bowel preparation|Oral bowel preparation for colonoscopy
219372381|NCT06666829|OTHER|Multidomain intervention|"treatment plan using combination of more than one technological or robotic devices, choosing from: Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~In this way, the child will be taken care of holistically, considering their needs from a motor, cognitive, and speech therapy perspective. The treatment plan will also include a conventional multi-level rehabilitation program."
219372382|NCT06666829|DEVICE|Single domain intervention|"Treatment plan using only one of these technological or robotic device:~Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~Technological rehabilitation will focus on the main specific need for the child, it'll be chosen individually. The treatment plan will also include a conventional multi-level rehabilitation program."
219372383|NCT03396770|PROCEDURE|Standard clinical routine|Patient management is carried out according to the usual service protocol
219372384|NCT03396770|PROCEDURE|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~* If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~* If the test is negative, patient management is carried out according to the usual protocol.~* A second test is realized 6 hours after the first test whatever the result of it."
219372385|NCT01036399|DRUG|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
219372386|NCT05839535|BEHAVIORAL|BDJ|BDJ is a mind-body intervention
219372387|NCT05839535|DEVICE|tDCS|tDCS is a brain stimulation method.
219372388|NCT05839535|DEVICE|sham tDCS|sham tDCS
219372389|NCT05839535|OTHER|exercise|exercise including stretching and other activities.
219372390|NCT06299280|OTHER|dual task training|students will be given additional cognitive tasks while exercising in physical education class
219372391|NCT06299280|OTHER|single task training|students will exercise in physical education class, without additional cognitive tasks
219372392|NCT06695663|BEHAVIORAL|Referral and communication skills learning|assigned to receive a brief, live, experiential training on the referral process and communication strategies.
219372393|NCT06695663|BEHAVIORAL|Written guide to the referral process|assigned to receive only written information about the referral process
219372394|NCT06695663|BEHAVIORAL|Empowered Generations (eGen): parent training|eGen is a six-session parent training program provided by therapists via video chat online to parents with a child between the ages of 3-8 years.
219372395|NCT06695663|BEHAVIORAL|control|The control condition consists of a single scripted session, in which therapists guide the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) vetted parenting advice websites; (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools; and (d) a list of culturally tailored parenting advice websites.
219372396|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
219372397|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
219372398|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
219372399|NCT06724445|BEHAVIORAL|Thabo cartoon|The animated cartoon features Thabo, a Black South African man living with HIV. Through his narrative, viewers follow his daily experiences managing his condition and confronting societal stigma in a South African context. The story explores his interactions with family, friends, and community members, highlighting both challenges and moments of resilience. The animation concludes with Thabo delivering an anti-stigma message directly to viewers.
219372400|NCT06724445|BEHAVIORAL|Steve cartoon|The animated cartoon follows Steve, a White man living with HIV. His narrative parallels Thabo's, showing his daily experiences managing HIV and facing societal stigma. The story depicts his interactions with family, friends, and community members, presenting the same situations and challenges as in Thabo's story. The animation ends with Steve delivering the same anti-stigma message to viewers.
219372401|NCT06926049|OTHER|The Effect of The Mindfulness-Based Psycho-Educational Program Focused on Emotions|The mindfulness based psychoeducation program focusing on emotions that aims to reduce the difficulties in regulating emotions and depressive symptoms in schizophrenia patients and to increase the level of hope.
219372402|NCT06895525|DIETARY_SUPPLEMENT|HellenCare|2 g, twice daily, to be taken on an empty stomach.
219372403|NCT06895525|DIETARY_SUPPLEMENT|Placebo|2 g, twice daily, to be taken on an empty stomach.
219372404|NCT06771037|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|Transcutaneous Auricular stimulation will be delivered using the Spark Biomedical Sparrow Link pulse generator with Sparrow Ascent earpieces. The Sparrow Link generator is based on FDA-cleared predicate Sparrow Ascent.
219372405|NCT06900556|PROCEDURE|Dry cupping with suction|Dry cupping with suction applied to the biceps
219372406|NCT06900556|PROCEDURE|Dry cupping without suction|Dry cupping without suction applied to the biceps
219372407|NCT03820817|DRUG|Rifaximin|Given PO
219372408|NCT06907511|BIOLOGICAL|Pandemic flu H5 HA mRNA SD2 vaccine|"Pharmaceutical Form:~Suspension in a vial~Route of Administration:~Intramuscular injection"
219372409|NCT06907511|OTHER|Placebo|"Pharmaceutical Form:~Liquid solution in a vial~Route of Administration:~Intramuscular injection"
219372410|NCT06481137|DIAGNOSTIC_TEST|Electrophysiological study (EP study)|Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
219372411|NCT06481137|DIAGNOSTIC_TEST|ePatch (extended Holter Monitoring)|Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
219372412|NCT04577040|DRUG|Tadalafil 5mg|Drugs
219372413|NCT06915129|DIETARY_SUPPLEMENT|Prebiotic galactooligosaccharides (GOS)|Galactooligosaccharides (GOSs) are a group of nondigestible oligosaccharides consisting of galactose units linked via glycosidic bonds to galactose, terminal glucose, or sucrose. The linkages are not digested by human and animal pancreatic or intestinal enzymes. Some recent papers reported that daily supplementation with prebiotic GOS to lactose-intolerant individuals altered the gut microbiome and decreased lactose intolerance (LI) symptoms.
219372414|NCT06915337|DEVICE|Gastric-Jejunal Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: gastric-jejunal anastomosis creation in subjects undergoing surgical procedures. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into portions of the stomach and the jejunum that are intended to be anastomosed. An OTOLoc device will be deployed into the gastric wall of the stomach to provide access for the deployment of a Flexagon SFM into the stomach. The process is repeated at an intended section of jejunum. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
219372415|NCT06915974|DIAGNOSTIC_TEST|Interleukin 6|Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
219372416|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
219372417|NCT03596073|OTHER|Topical Vaseline|Placebo
219372418|NCT03510325|DRUG|Phase 1: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
219372419|NCT03510325|DRUG|Phase 1: Risperidone|Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks
219372420|NCT03510325|DRUG|Phase 1: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
219372421|NCT03510325|DRUG|Phase 1: Aripiprazole|Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks
219372422|NCT03510325|DRUG|Phase 1: Perphenazine|Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks
219372423|NCT03510325|DRUG|Phase 2: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
219372424|NCT03510325|DRUG|Phase 2: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
219372425|NCT03510325|DRUG|Phase 2: Clozapine|Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks
219372426|NCT03510325|OTHER|Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy|"Clozapine extended treatment:~dosage: 200-600 mg/d; dosage form: po.~Combined clozapine-MECT therapy:~Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month."
219372427|NCT03510325|DRUG|Phase 3B: Clozapine or another SGAs|"Clozapine:~Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks~Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2."
219372428|NCT06935565|OTHER|Trifocal IOL implantation|Patients were implanted bilaterally with Asqelio Trifocal IOL 270±90 days before study visit
219372429|NCT06936735|DRUG|HS-20108 Monotherapy|Intravenous (IV) Infusion
219372430|NCT06935318|OTHER|Exercise|The exercise group performed an 11-week high-functional resistance program in a group training format. They trained 3-4 days a week following nationally assigned workouts
219372431|NCT06935318|OTHER|Control|Did not participate in exercise related activities for the duration of the study period.
219372432|NCT06936865|BEHAVIORAL|VIVIFIL App Program|A digitally supported multicomponent exercise program delivered through the VIVIFIL mobile application. Participants followed a daily home-based routine including strength, balance, flexibility, and aerobic exercises, adapted to their functional reserve. The app provided video instructions, progression tracking, and a chat for remote communication with healthcare professionals.
219372433|NCT06936865|BEHAVIORAL|Hospital-Based Multicomponent Exercise|A supervised multicomponent exercise program delivered at a geriatric day hospital by trained professionals. Sessions lasted 45-60 minutes, 2-4 times per week for 8 weeks. Exercises included strength training, balance, flexibility, and aerobic components, adjusted to the participant's functional status.
219372434|NCT06935864|DIAGNOSTIC_TEST|KLF factor (4 and 7)|Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.
219372435|NCT06935279|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
219372436|NCT06935552|DRUG|Ketamine infusion|group A will receive ketamine intravenous infusion
219372437|NCT06935552|DRUG|Lidocaine Intravenous Infusion|group B will receive lidocaine intravenous infusion
219372438|NCT06935552|DRUG|Dextrose 5% in water|group C will only receive Dextrose 5% in water
219372439|NCT06936332|DEVICE|Omnilux Clear Light Emitting Diode Treatment|Omnilux Clear is a medical-grade, home light emitting diode (LED) treatment for acne-prone skin, using the most clinically effective LED's available, optimized for superior results. The blue light (415nm) targets and kills P. acnes bacteria living on the skin's surface. Red light (633nm) penetrates the dermis, triggering the body's own natural healing response, including the production of new collagen, the downregulation of excess oils, and the reduction of inflammation and redness.
219372440|NCT06936358|OTHER|Control|Control group received bone graft alone after extraction
219372441|NCT06936358|OTHER|A-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 1500 rpm for 14 minutes.
219372442|NCT06936358|OTHER|I-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 700 rpm for 3 minutes
219372443|NCT06935617|PROCEDURE|nissein|nissein surgery
219372444|NCT06936267|OTHER|rehabilitation : eyes closed|proprioceptive exercise with eyes closed
219372445|NCT06936267|OTHER|rehabilitation : eyes open|proprioceptive exercise with eyes open
219372446|NCT06936514|PROCEDURE|Bilateral Cervical Deep Lymphatic Trunk Decompression Combined with Mid-Cervical Deep Lymph Node-External Jugular Vein Anastomosis for Alzheimer's Disease|This intervention involves a surgical approach that combines bilateral cervical deep lymphatic trunk decompression with mid-cervical deep lymph node-external jugular vein anastomosis (LVA) to enhance lymphatic drainage in Alzheimer's Disease (AD) patients. The aim is to reduce the accumulation of neurotoxic substances in the brain, potentially improving cognitive function by facilitating waste clearance via the lymphatic system. The procedure is intended to restore normal lymphatic flow, potentially slowing disease progression in AD patients who have moderate to severe cognitive impairment.
219372447|NCT06936371|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|Participants received a removable open bite activator constructed with the mandible opened beyond the freeway space and combined with vertical intermaxillary elastics applying 150g of force, supported by mini-screws placed between the lateral and canine teeth in both the maxilla and mandible. The appliance was worn 20-22 hours daily for 12 months. This approach aimed to treat skeletal open bite without using extraoral appliances by promoting anterior mandibular rotation and inhibiting posterior vertical dentoalveolar development.
219372448|NCT06936137|DRUG|lactobacillus LS|Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients
219557739|NCT00250705|DRUG|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
219372449|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
219372450|NCT06935682|DRUG|Y-4 tables|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 tablets on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 tablets continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
219372451|NCT06935682|DRUG|Y-4 placebos|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 placebos on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 placebos continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
219372452|NCT06937008|OTHER|Whole body vibration|"All women in group (A) received whole body vibration and balance board training, three times per week for three months.~Parameters: The WBV was performed by using whole body vibration which is a side-alternating vibration device working as a teeterboard with amplitude of 0 to 5.3 mm (medial to distal) and a variable frequency of 5 to 30 Hz. The amplitude was controlled by adjusting the foot position from 1 to 3, with the larger the position, the greater the amplitude. Before the treatment, procedures of using the Galileo 900 were instructed by the research assistant and its safety issues explained.~Patient's position: The patient was asked to stand on WBV device by Hold hand support for those elderly women. the vibrating platform in a 100 to 110° squat position, the oscillating platform operating at 20Hz in bare feet at the second foot position for 15 minutes a day for 3 days a week for 3 months. All unusual or uncomfortable complaints from subjects during the WBV treatment were docu"
219372453|NCT06937008|OTHER|Balance training|Balance training exercises treatment: All women in both group (A, B) received balance training exercises on balance ball, half ball and balance board exercises three times per week for 3 months
219372454|NCT06936969|PROCEDURE|Autologous blood patch pleurodesis|The intervention in this study is distinguished by the fact that patients are randomized, the dose of both glucose and ABPP is 120 ml, the patient remains in a supine position for 2 hours after administration, the procedure can be repeated at 48-hour intervals, a maximum of 3 times.
219372455|NCT06936969|PROCEDURE|40% glucose solution pleurodesis|"After obtaining informed consent, the patient will lie supine in their room. 30 minutes before the procedure, the patient's capillary blood glucose level will be measured. The patient does not have to fast before the procedure. The nurse will be asked to collect 120 ml of peripheral venous blood from the patient. Then the doctor, assisted by the nurse, will first administer 20 ml of 1% Lignocaine through the pleural drain, and then after about 5-10 minutes, the patient's previously collected venous blood. At the moment of blood administration, the drainage system will be disconnected. Then, the drain will be injected with 20 ml of air to avoid clogging the drain. The patient will remain supine for two hours post-procedure, maintaining fasting status. After 30 minutes from the administration of the patient's own blood, the capillary blood glucose level will be measured again. After two hours, the patient, with nursing assistance, may resume normal activities."
219372456|NCT06955728|DRUG|Vaccine|The active ingredients in RSVpreF are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution.
219372457|NCT06955728|OTHER|Placebo|Placebo matched to vaccine but not containing any active ingredients
219372458|NCT04068103|DRUG|Capecitabine|Given PO
219372459|NCT04068103|DRUG|Fluorouracil|Given IV
219372460|NCT04068103|DRUG|Leucovorin|Given IV
219372461|NCT04068103|DRUG|Leucovorin Calcium|Given IV
219372462|NCT04068103|DRUG|Oxaliplatin|Give IV
219372463|NCT04068103|OTHER|Patient Observation|Undergo active surveillance
219372464|NCT06119191|DEVICE|Control Lenses (comfilcon A with current process)|Daily wear lenses for 30±2 days
219372465|NCT06119191|DEVICE|Test Lenses (comfilcon A with novel process)|Daily wear lenses for 30±2 days
219372466|NCT05135286|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
219372467|NCT05135286|DRUG|Carbachol PF|A single drop in each eye at a visit.
219372468|NCT05135286|DRUG|Vehicle|A single drop in each eye at a visit.
219372469|NCT03779178|DRUG|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
219372470|NCT03779178|DRUG|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
219372471|NCT04304820|DRUG|Eltrombopag|Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
219372472|NCT04304820|DRUG|Cyclosporine|Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
219557740|NCT06073847|DRUG|Fedratinib|According to the approved label
219187607|NCT07063199|DRUG|Daratumumab Injection|"This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
219372473|NCT04304820|DRUG|Horse-Anti-thymocyte-Globulin|h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
219372474|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
219372475|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
219372476|NCT05177796|DRUG|Carboplatin|Given IV
219372477|NCT05177796|DRUG|Cyclophosphamide|Given IV
219372478|NCT05177796|DRUG|Doxorubicin|Given IV
219372479|NCT05177796|DRUG|Paclitaxel|Given IV
219372480|NCT05177796|BIOLOGICAL|Panitumumab|Given IV
219372481|NCT05177796|BIOLOGICAL|Pembrolizumab|Given IV
219372482|NCT04815096|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
219372483|NCT06763536|OTHER|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
219372484|NCT06763536|OTHER|Nicotine Lozenge|Use nicotine lozenge
219372485|NCT06763536|OTHER|Oral Nicotine Pouch|Use oral nicotine pouch
219372486|NCT06763536|OTHER|Nicotine Patch|Use nicotine patch
219372487|NCT06763536|OTHER|Survey Administration|measurements; data gathering
219372488|NCT06763536|OTHER|Check-in Phone Calls|Check-in phone calls to study participants
219372489|NCT05995704|DRUG|Apraglutide|Peptide analogue of GLP-2
219372490|NCT05995704|DRUG|Placebo|Matching placebo to apraglutide
219372491|NCT05995704|DRUG|Acetaminophen|Acetaminophen mixed with a liquid meal
219372492|NCT04837014|OTHER|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
219372493|NCT04837014|OTHER|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
219372494|NCT04699188|DRUG|JDQ443|KRAS G12C inhibitor
219372495|NCT04699188|DRUG|TNO155|SHP2 inhibitor
219372496|NCT04699188|BIOLOGICAL|tislelizumab|Anti PD1 antibody
219372497|NCT06501443|DRUG|Usual care|Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
219372498|NCT06501443|DRUG|KJX839|Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
219372499|NCT05507216|DRUG|ABX464|Administered once daily in the morning with food
219372500|NCT05507216|DRUG|Placebo|Administered once daily in the morning with food
219372501|NCT00002285|DRUG|Zidovudine|
219372502|NCT01717248|DRUG|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
219372503|NCT01775748|OTHER|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
219372504|NCT01775748|OTHER|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
219372505|NCT03089788|OTHER|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
219372506|NCT03089788|OTHER|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
219372507|NCT03125603|OTHER|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
219372508|NCT01838135|DEVICE|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
219372509|NCT06541444|DRUG|NK520|The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
219372510|NCT02569515|DRUG|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
219372511|NCT05163665|PROCEDURE|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
219372512|NCT00042809|DRUG|paclitaxel|Given IV
219372513|NCT00042809|BIOLOGICAL|trastuzumab|Given IV
219372514|NCT00042809|DRUG|erlotinib hydrochloride|Given orally
219372515|NCT00042809|OTHER|laboratory biomarker analysis|Correlative studies
219372516|NCT00042809|OTHER|pharmacological study|Correlative studies
219372517|NCT05742321|GENETIC|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
219372518|NCT05742321|DIAGNOSTIC_TEST|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
219372519|NCT05742321|OTHER|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
219372520|NCT04844138|BEHAVIORAL|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
219372521|NCT03395678|DEVICE|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
219372522|NCT03395678|DEVICE|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
219372523|NCT02732951|DRUG|BI 1026706|
219372524|NCT02732951|DRUG|Placebo|
219372525|NCT05751525|DRUG|Sulfonylurea|Glibenlclamide / glyburide
219372526|NCT04585763|DEVICE|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
219372527|NCT04724525|OTHER|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
219372528|NCT03757598|OTHER|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
219372529|NCT03263806|DIAGNOSTIC_TEST|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
219372530|NCT03263806|DIAGNOSTIC_TEST|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
219372531|NCT00371267|BEHAVIORAL|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
219372532|NCT00371267|OTHER|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
219372533|NCT02249715|DEVICE|Brainsway Multiway deep TMS device (two channels)|
219372534|NCT01834495|DEVICE|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
219372535|NCT01834495|DEVICE|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
219372536|NCT01412879|BIOLOGICAL|rituximab|Given IV
219372537|NCT01412879|DRUG|bendamustine hydrochloride|Given IV
219372538|NCT01412879|DRUG|cyclophosphamide|Given IV
219372539|NCT01412879|DRUG|cytarabine|Given IV
219372540|NCT01412879|DRUG|dexamethasone|Given PO or IV
219372541|NCT01412879|DRUG|doxorubicin hydrochloride|Given IV
219372542|NCT01412879|DRUG|leucovorin calcium|Given PO or IV
219372543|NCT01412879|DRUG|methotrexate|Given IV
219372544|NCT01412879|DRUG|vincristine sulfate|Given IV
219372545|NCT04840667|DRUG|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
219372546|NCT01676038|PROCEDURE|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
219372547|NCT01676038|PROCEDURE|Conventional Total Knee Arthroplasty|Conventional technique.
219372548|NCT02693964|OTHER|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
219372549|NCT04544566|DEVICE|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
219372550|NCT04544566|DEVICE|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
219372551|NCT04544566|DEVICE|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
219372552|NCT02704962|DRUG|full-dose olanzapine|trifluoperazine 5mg/d
219372553|NCT01445171|DEVICE|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
219372554|NCT05109312|DRUG|Bupivacaine Hydrochloride|100 mg
219372555|NCT05109312|DRUG|Bupivacaine Hydrochloride|125 mg
219372556|NCT05109312|DRUG|HTX-011|400 mg
219372557|NCT05109312|DEVICE|Luer lock applicator|Applicator for instillation
219372558|NCT05109312|DRUG|Ibuprofen|400 mg
219372559|NCT05109312|DRUG|Acetaminophen|1 g
219372560|NCT03050125|DEVICE|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
219372561|NCT03050125|DEVICE|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
219372562|NCT03050125|DEVICE|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
219372563|NCT00787111|DRUG|Fluoxetine (prozac)|Formulation: ODT
219372564|NCT06117189|OTHER|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
219372565|NCT03195894|DEVICE|TripleA|
219372566|NCT05995444|DRUG|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
219372567|NCT05995444|DRUG|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
219372568|NCT05995444|DRUG|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
219372569|NCT05995444|DRUG|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
219372570|NCT00957541|DEVICE|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
219372571|NCT01575912|OTHER|experimental pain tests|
219557741|NCT01489605|DEVICE|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
219557742|NCT01489605|DEVICE|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
219557743|NCT03639220|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
219372572|NCT05377632|PROCEDURE|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
219372573|NCT01715844|DIETARY_SUPPLEMENT|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
219372574|NCT02493179|DRUG|Serodase 5 mg|Serodase 5mg two tablets three times per day
219372575|NCT02493179|DRUG|Placebo|Placebo two tablets three times per day
219372576|NCT00162773|DRUG|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
219372577|NCT00162773|OTHER|Placebo|150-375 milligrams depending on body weight and serum IgE.
219372578|NCT05415579|OTHER|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
219372579|NCT04412304|DRUG|Dose of Tinzaparin or Dalteparin|The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
219372580|NCT01745003|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
219372581|NCT06487377|BIOLOGICAL|IX001 TCR-T cells|IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
219372582|NCT06060301|DRUG|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
219372583|NCT06060301|DRUG|corticosteroids|The patients will use topical corticosteroids 4 times per day.
219372584|NCT05700461|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
219372585|NCT06151925|DEVICE|Laminaria|mechanical method for induction of labor
219372586|NCT06151925|DRUG|Vaginal prostaglandin|Vaginal prostaglandin for ripening
219372587|NCT02473796|OTHER|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
219372588|NCT04673994|BEHAVIORAL|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
219372589|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
219372590|NCT01991561|BIOLOGICAL|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
219372591|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
219372592|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
219372593|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
219372594|NCT01991561|BIOLOGICAL|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
219372595|NCT01724281|OTHER|No intervention, only follow up|
219372596|NCT05856864|DRUG|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
219372597|NCT05856864|DRUG|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
219372598|NCT00469937|DRUG|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
219372599|NCT00469937|PROCEDURE|cognitive assessment|cognitive assessment
219372600|NCT00469937|PROCEDURE|quality-of-life assessment|quality-of-life assessment
219187608|NCT07063082|OTHER|Erythromycin Phonophoresis|The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.
219372601|NCT00469937|RADIATION|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
219372602|NCT00896961|DRUG|EF5|
219372603|NCT00896961|OTHER|diagnostic laboratory biomarker analysis|
219372604|NCT00896961|OTHER|pharmacological study|
219372605|NCT05806242|OTHER|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
219372606|NCT03397836|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
219372607|NCT03397836|OTHER|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
219372608|NCT06006975|RADIATION|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
219372609|NCT06006975|DIAGNOSTIC_TEST|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
219372610|NCT02773797|DRUG|IN-DEX 1.0 mcg/kg, intranasal saline|
219372611|NCT02773797|DRUG|IN-DEX 1.5 mcg/kg, intranasal saline|
219372612|NCT02773797|DRUG|Placebo - Saline|
219372613|NCT01737775|PROCEDURE|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
219372614|NCT03503123|DEVICE|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
219372615|NCT04917783|BEHAVIORAL|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
219372616|NCT04917783|BEHAVIORAL|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
219372617|NCT01725139|DRUG|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
219372618|NCT01725139|DRUG|Placebo|Matching placebo will be available
219372619|NCT00390832|DRUG|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
219372620|NCT00390832|OTHER|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
219372621|NCT03415230|OTHER|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
219372622|NCT03415230|OTHER|Sham massage|Sham massage involves only light touch massage in a non systematic way
219372623|NCT03463330|BEHAVIORAL|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
219372624|NCT03463330|BEHAVIORAL|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
219372625|NCT03829761|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
219372626|NCT03829761|DEVICE|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
219372627|NCT03959436|DRUG|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
219372628|NCT02490852|OTHER|Investigational infant formula|fed ad libitum
219372629|NCT02490852|OTHER|Active Comparator: Commercially available Infant formula|fed ad libitum
219372630|NCT02490852|OTHER|Active Comparator: Human milk|fed ad libitum
219372631|NCT03645187|DRUG|FOLFERI|FOLFERI regimen
219372632|NCT03645187|DRUG|Folferi and celecoxib|Folferi regimen and celecoxib
219372633|NCT01300104|BEHAVIORAL|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
219372634|NCT01300104|BEHAVIORAL|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
219372635|NCT01300104|BEHAVIORAL|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
219372636|NCT04287530|DIETARY_SUPPLEMENT|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
219372637|NCT04287530|BEHAVIORAL|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
219372638|NCT04287530|DIETARY_SUPPLEMENT|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
219372639|NCT01888094|OTHER|Ultrasound-guided cannulation and examination|
219372640|NCT05928741|BEHAVIORAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
219372641|NCT04652362|BEHAVIORAL|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
219372642|NCT04652362|BEHAVIORAL|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
219372643|NCT04691661|DRUG|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
219372644|NCT04691661|DRUG|Placebo|Placebo
219372645|NCT02639377|DRUG|Chlorhexidine gluconate|
219372646|NCT02639377|DRUG|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
219372647|NCT02807077|DRUG|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
219372648|NCT03217162|DRUG|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
219372649|NCT03217162|DRUG|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
219372650|NCT02830425|OTHER|No intervention|
219372651|NCT04029376|DRUG|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
219372652|NCT03322800|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
219372653|NCT03322800|OTHER|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
219372654|NCT03572088|DRUG|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
219372655|NCT03572088|DRUG|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
219372656|NCT02790229|OTHER|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
219372657|NCT02790229|OTHER|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
219372658|NCT03338556|DRUG|PrEP-001|
219372659|NCT03338556|OTHER|Placebo|
219372660|NCT00961532|DRUG|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
219372661|NCT06031753|BEHAVIORAL|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
219372662|NCT02010203|BIOLOGICAL|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
219372663|NCT02010203|BIOLOGICAL|Placebo|Injection containing sterile solution but no cells
219372664|NCT02010203|BIOLOGICAL|BCG|Vaccine derived from a live bacterium
219372665|NCT01649492|DIETARY_SUPPLEMENT|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
219372666|NCT05446948|DEVICE|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
219372667|NCT05446948|DEVICE|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
219372668|NCT05047523|DRUG|ALXN1840|Administered as an oral tablet.
219372669|NCT05047523|DRUG|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
219372670|NCT00489762|PROCEDURE|Installation of an energy efficient heater|
219372671|NCT04918121|DRUG|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
219372672|NCT06136858|DEVICE|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
219372673|NCT03898570|BEHAVIORAL|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
219372674|NCT00224016|DRUG|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
219372675|NCT00224016|DRUG|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
219372676|NCT01609933|DRUG|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
219372677|NCT01609933|DRUG|ABT-267|ABT-267 (tablets)
219372678|NCT01609933|DRUG|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
219372679|NCT01609933|DRUG|Ribavirin (RBV)|Ribavirin (tablets)
219372680|NCT03947294|DEVICE|Q-NRG®|Energy expenditure measurements
219372681|NCT01252966|BEHAVIORAL|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
219372682|NCT01252966|BEHAVIORAL|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
219372683|NCT00197860|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
219372684|NCT03340350|DRUG|Minocycline|Minocycline capsule
219372685|NCT05734287|DIAGNOSTIC_TEST|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
219372686|NCT05666154|OTHER|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
219372687|NCT05666154|OTHER|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
219372688|NCT05666154|OTHER|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
219372689|NCT05666154|OTHER|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
219372690|NCT00565955|DRUG|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
219372691|NCT00565955|DRUG|Placebo|The patients will receive placebo tablets.
219372692|NCT01264315|DRUG|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
219372693|NCT03835338|DEVICE|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
219372694|NCT03835338|DEVICE|LAA Isolation|LAA Isolation by RF Ablation
219372695|NCT03835338|DEVICE|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
219372696|NCT03275870|DRUG|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
219372697|NCT04244825|DRUG|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
219372698|NCT04244825|DRUG|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
219372699|NCT04092036|DEVICE|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
219372700|NCT01364415|DRUG|Pasireotide LAR|
219372701|NCT05718102|OTHER|Population-health management|Population-health management
219372702|NCT04163198|DEVICE|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
219372703|NCT04163198|DEVICE|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
219372704|NCT03283839|DIAGNOSTIC_TEST|Posturography|Evaluation of postural control and of orientation function
219372705|NCT00919022|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
219372706|NCT01133639|DRUG|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
219372707|NCT01133639|DRUG|Placebo|Placebo plus standard of care
219372708|NCT00718133|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
219372709|NCT06527599|OTHER|Opioid Risk Monitoring (ORM)|A brief battery of self-reported screeners for risk factors associated with opioid misuse (e.g., Current Opioid Misuse Measure; Pain, Enjoyment of life, and General activities scale; Pain Catastrophizing Scale). These measures will be administered within seven days of hospital discharge (i.e., baseline), and again at 2-, 4-, 8-, and 12-weeks following discharge to assess for ongoing risk for opioid misuse. Participants will additionally complete the self-reported Opioid Risk Tool within seven days of hospital discharge.
219372710|NCT06527599|BEHAVIORAL|enhanced Trauma Care Coordination (eTCC)|An enhanced care management model with increased patient contact and embedded interventions based on clinical presentation and collaboration with the patient. eTCC is a telehealth-based care coordinating intervention where a care coordinator assesses the participant, creates a plan of care, collaborates with the eTCC team, follows up with a second virtual visit within a week, and communicates with the participant and care team at least bi-weekly for the 3 month intervention period.
219372711|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Brief (PCST-LITE)|PCST-LITE will consist of a single 55-minute videoconference session, in which participants will receive brief psychoeducation grounded in gate control theory, progressive muscle relaxation (PMR), and therapist-guided imagery. Participants will be asked to practice PMR and imagery daily and will receive four weeks of regular (4-5 times per week) text messaging as a reminder.
219372712|NCT06527599|BEHAVIORAL|Standard Trauma Care Coordination (sTCC)|Standard Trauma Care Coordination (sTCC) will functionally serve as a treatment-as-usual arm, as it will involve no study intervention.
219372713|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Plus (PCST+)|PCST+ will include two videoconferencing sessions, in addition to the first videoconferencing session they previously received. In session 1, participants will be taught an activity/rest cycle to schedule activities, so they are productive while avoiding increasing pain severity due to taking insufficient breaks. Session 2 centers around cognitive restructuring, involving brief psychoeducation and skills development surrounding how participants might recognize the influence that cognitions can have on pain intensity and coping. Participants will receive 3 weekly, 15-minute calls to review skills and problem-solve.
219372714|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Maintenance (PCST-M)|PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.
219372715|NCT06183658|DIAGNOSTIC_TEST|Fluids biomarker and neuroimaging of AD diagnosis|Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.
219372716|NCT02272192|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
219372717|NCT02272192|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
219187609|NCT07063082|DEVICE|Ultrasound (US)|"Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy.~The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions)."
219372718|NCT06657443|OTHER|First Session|Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
219372719|NCT06657443|OTHER|Second Session|Training of peer mentors on communication techniques, interview methods and empathic approach.
219372720|NCT06657443|OTHER|Third session|Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
219372721|NCT06657443|OTHER|Fourth session|Training of peer mentors on social motivation and leader-member interaction
219372722|NCT06657443|OTHER|Fifth Session|Sharing postcasts with peer mentors on social motivation and leader-member interaction.
219372723|NCT06657443|OTHER|Sixth Session|Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
219372724|NCT02315521|PROCEDURE|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
219372725|NCT04677270|BEHAVIORAL|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
219372726|NCT02240134|BEHAVIORAL|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
219372727|NCT02240134|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
219372728|NCT02240134|DEVICE|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
219372729|NCT05951179|BIOLOGICAL|TARA-002|All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
219372730|NCT06351631|DRUG|Bomedemstat|10, 15, 20, and 50 mg oral capsules
219372731|NCT05991973|DRUG|Chidamide|In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
219372732|NCT04546620|DRUG|R-CHOP|Arm A patients will receive R-CHOP alone.
219372733|NCT04546620|DRUG|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
219372734|NCT05643144|DEVICE|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
219372735|NCT06364592|DEVICE|Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period)."
219372736|NCT06364592|DEVICE|Sham Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi."
219372737|NCT01382160|BIOLOGICAL|adalimumab|40 mg every two weeks, by subcutaneous way
219372738|NCT01498133|PROCEDURE|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
219372739|NCT01956214|OTHER|FES Exercise|receive FES while exercising
219372740|NCT01956214|OTHER|Mock FES Exercise|participants will receive Mock FES
219372741|NCT04378166|DEVICE|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
219372742|NCT05756192|OTHER|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
219187610|NCT07063082|DRUG|Topical Erythromycin|Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics
219187611|NCT07063082|OTHER|Medical treatment|Saline nasal wash 3 times daily for a month.
219187612|NCT07062926|OTHER|Spencer Muscle Energy Technique|Spencer muscle energy technique participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks. Group A will undergo Spencer Muscle Energy Technique for 30 minutes
219187613|NCT07062926|OTHER|Post Facilitation Stretch|Post facilitation stretch participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks.post facilitation stretching process was repeated 5 times with 10 second interval between each stretch.
219187614|NCT07063953|OTHER|Standard Physical Therapy|Hot pack \& Transcutaneous Electric Nerve Stimulation (TENS) Myofascial Release Mulligan Mobilization with Movement Exercises
219187615|NCT07063953|OTHER|Egoscue Exercises|Warm Up Exercises (5 min) which includes Stretching ,Walking (Forward, Backward, Sideways), Arm Circles, Side bends, March on the spot, Knee lifts, Standing Gluteal Contractions , Sitting heel raises, Isolated hip flexor lifts on a towel, Supine groin stretch on towels, Static back, Sitting Knee Pillow Squeezes, Sitting floor, Progressive supine groin, Supine calf-hamstring stretch with a strap,Foot circles and point flexes, Cool Down and Breathing Exercises
219372743|NCT03871907|BEHAVIORAL|Digital technology|Lifestyle-Focused Text Messaging
219372744|NCT00206726|DRUG|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
219372745|NCT06441708|OTHER|No intervention|No intervention on patient
219372746|NCT04790942|DRUG|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
219372747|NCT04790942|BEHAVIORAL|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
219372748|NCT02369783|OTHER|Questionnaire and interview|The aim is to detect social fragility.
219372749|NCT05103150|DIAGNOSTIC_TEST|High-definition white light endoscopy (HD-WLE)|"Evaluation of the duodenal mucosa with HD-WLE (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.~There were used the following standard endoscopic findings were: a) scalloping or dented aspect of the duodenal folds; b) submucosal vascular pattern; c) mosaicism or micronodular look of the mucosa; d) grooves and fissurations of the mucosa."
219372750|NCT05103150|DIAGNOSTIC_TEST|HD-WLE plus I-Scan optical enhancement (OE) virtual chromoendoscopy with High-definition optical magnification (HD-OM)|"Evaluation of the duodenal mucosa through upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves using a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode one and mode two without HD-OM to obtain an overview of the duodenal surface and identify any changes in the mucosa, then HD-OM will be implemented.~There were used OE criteria as previously validated by Cammarota et al: brightness, Ave/peak, blue, red, surface, contrast, and tone enhancement."
219372751|NCT06246383|DIETARY_SUPPLEMENT|Q Actin|cucumber extract
219372752|NCT03083717|DIAGNOSTIC_TEST|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
219372753|NCT02285829|DRUG|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
219372754|NCT05092607|DIAGNOSTIC_TEST|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
219372755|NCT02612909|BIOLOGICAL|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
219372756|NCT02612909|BIOLOGICAL|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
219372757|NCT02071940|DRUG|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
219372758|NCT01895530|DIETARY_SUPPLEMENT|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
219372759|NCT01871883|PROCEDURE|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
219372760|NCT01871883|PROCEDURE|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
219372761|NCT04486560|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
219372762|NCT01719757|DRUG|Oxycodone/Naloxone|Twice daily
219372763|NCT02626338|DRUG|Crenolanib|
219372764|NCT02626338|DRUG|Mitoxantrone|
219372765|NCT02626338|DRUG|Cytarabine|
219372766|NCT02626338|DRUG|Etoposide|
219372767|NCT02626338|DRUG|Fludarabine|
219372768|NCT02626338|DRUG|G-CSF|
219372769|NCT02626338|DRUG|Idarubicin|
219000792|NCT07131917|DEVICE|Miniaturized Intracavitary Monitoring Probe|A sterile, miniaturized, biocompatible monitoring probe (≤1.5 mm diameter) is temporarily introduced into the cavity of an infected walled-off pancreatic necrosis (WOPN) during standard percutaneous drainage. The device is designed to measure local microenvironmental parameters in situ, such as acidity and related indicators, without interfering with fluid evacuation. Measurements are performed intermittently or continuously for up to 72 hours and are used solely for observational purposes. This intervention is distinct from standard WOPN management, as it allows real-time assessment of local physicochemical conditions, which are not accessible through systemic biomarkers or imaging alone.
219000793|NCT07131475|DRUG|PBR28 TSPO PET|Each SEAL participant will undergo brain imaging with PBR28 translocator protein (TSPO) positron emission tomography (PET) at study enrollment and at 1-year follow up.
219000794|NCT07131761|OTHER|Tai chi|Yang style of Tai Chi (24 form)
219372770|NCT04101812|DRUG|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
219372771|NCT04101812|DRUG|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
219372772|NCT04710108|OTHER|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
219372773|NCT04967690|DRUG|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
219372774|NCT00241267|DEVICE|Dedicated ultrasonographic probe during bronchoscopy|
219372775|NCT00566306|OTHER|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
219372776|NCT06372925|DRUG|atorvastatin|20mg atorvastatin PO
219372777|NCT06372925|PROCEDURE|IVUS/OCT|performed the IVUS/OCT at baseline and Day 360
219372778|NCT06372925|DRUG|inclisiran|Inclisiran 284mg SC
219372779|NCT00450580|DRUG|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
219372780|NCT02418130|DRUG|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
219372781|NCT02418130|DRUG|Placebo|
219372782|NCT03977779|DEVICE|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
219372783|NCT02268162|PROCEDURE|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
219372784|NCT03061708|DRUG|AZD2014|mTOR inhibitor
219000795|NCT07131761|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
219000796|NCT07131761|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
219000797|NCT07132242|DRUG|SHR-A1811 4.0mg/kg|SHR-A1811 4.0mg/kg, IV, Day 1, Q3W
219000798|NCT07132242|DRUG|Pyrotinib 240mg|Pyrotinib 240mg, po, QD, from Day 8 to Day 21,Q3W
219000799|NCT07132242|DRUG|SHR-A1811 4.8mg/kg|SHR-A1811 4.8mg/kg, IV, D1, Q3W
219000800|NCT07132242|DRUG|Pyrotinib 320mg|Pyrotinib 320mg, po, QD, from Day 8 to Day 21, Q3W
219000801|NCT07131670|OTHER|Electronic Patient-Reported Outcome Monitoring|Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.
219372785|NCT00393718|DRUG|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
219372786|NCT00393718|DRUG|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
219372787|NCT00393718|DRUG|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
219372788|NCT00393718|DRUG|placebo|glibenclamide placebo. Given orally once or twice daily.
219372789|NCT01015508|OTHER|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
219372790|NCT01015508|OTHER|Weight maintenance|10 months
219372791|NCT06053021|DRUG|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
219372792|NCT00627666|BIOLOGICAL|anti-thymocyte globulin|
219372793|NCT00627666|DRUG|busulfan|
219372794|NCT00627666|DRUG|fludarabine phosphate|
219372795|NCT00627666|DRUG|leucovorin calcium|
219372796|NCT00627666|DRUG|methotrexate|
219372797|NCT00627666|PROCEDURE|allogeneic bone marrow transplantation|
219372798|NCT00627666|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219372799|NCT00627666|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219372800|NCT05861505|DRUG|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
219372801|NCT05861505|OTHER|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
219372802|NCT03850821|BEHAVIORAL|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
219372803|NCT04008017|DIAGNOSTIC_TEST|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
219372804|NCT06063473|DRUG|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
219000802|NCT07132099|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|This is a brief, structured, patient-centered therapy consisting of three to four face-to-face sessions. Each session typically lasts between 60 to 90 minutes. A fourth session may be added if clinically necessary.
219187616|NCT07062068|PROCEDURE|ultrasound guided Brachiocephalic vein and internal jugular vein cannulation in mechanically ventilated ICU patients|"For Arm ( candidates for BCV cannulation ) :~by ultrasound guided we insert Central venous catheter in BCV under complete aseptic condition For Arm ( candidates for IJV cannulation ) by ultrasound guided we insert central venous catheter in IJV under complete aseptic conidtion we do comparison between the 2 arms as regard : 1st pass success rate , complications and failure rate in ventilated patient in ICU ."
219000803|NCT07132099|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"This intervention uses the ACT for Life protocol, which is designed to maximize recovery after suicidal crises. It consists of three components delivered over three to six individual sessions. The average number of sessions is four to five, with each session lasting approximately 60 minutes."
219187617|NCT07063615|OTHER|Microbiome-Powered Cream|"Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
219187618|NCT07063615|OTHER|Placebo Hair Cream|"Mode of Usage: : Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
219187619|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
219187620|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
219187621|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
219187622|NCT05673785|DRUG|Prednisone|Prednisone tablets
219187623|NCT07063927|PROCEDURE|personalized oral instruction form|The investigators will customize the POIF for participants. The POIF will be conceived to have a cover, and participants extraoral photos and intraoral photos will be covered when not conducting oral hygiene, the cover will ensure participants confidentiality. The personalized oral instruction form will be handed to the independent residents along with a hygiene kit comprising the necessary tools to conduct oral hygiene by the second investigator. For dependent residents, the personalized oral instruction form will be handed to the caregivers along with the personalized oral hygiene kit.
219187624|NCT07062484|DRUG|Control: gemcitabine, cisplatin, tirelizumab|PD-1 inhibitors combined with chemotherapy
219187625|NCT07062484|DRUG|Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy|PD-1 inhibitors combined with chemoradiotherapy
219187626|NCT07064304|PROCEDURE|Laser Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using Er,Cr:YSGG laser (2780 nm, 2.5 W, 83.3 mJ, 30 Hz, 600 μm tip) before placement in gingival recession treatment.
219187627|NCT07064304|PROCEDURE|Scalpel Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using a 15c surgical scalpel blade before placement in gingival recession treatment.
219187628|NCT07064421|DIAGNOSTIC_TEST|Magnetoencephalography plus Stereo-electroencephalography/Electrocorticography|Use Magnetoencephalography and Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
219187629|NCT07064421|DIAGNOSTIC_TEST|Stereo-electroencephalography/Electrocorticography|Use Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
219187630|NCT07062328|DRUG|Recaticimab and Adebrelimab|"Patients would receive Recaticimab (150 mg, sc., q4w) and Adebrelimab (1200 mg, iv., q3w) plus GP chemotherapy in 21day cycles.~Recaticimab and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years."
219187631|NCT07062328|DRUG|GP chemotherapy|Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle, up to 6 cycles.
219187632|NCT06808256|PROCEDURE|the acupuncture therapy|Acupuncture is performed for 3 consecutive days, using filiform needles in the chest, hands, feet area with 20 minutes retention during therapy and using press needle on the forehead which are retained for 3 days and after 3 days the stick needles will be removed. And patient continue to receive standard therapy in accordance with the clinical practice guidelines of the ICU Tangerang Hospital
219187633|NCT06808256|OTHER|Standard therapy|Pharmacological therapy provided by the doctor in charge of anesthesia science patients to the research subjects was in accordance with existing clinical practice guidelines. In the ICU of Tangerang Hospital, the standard therapy given to post-craniotomy patients with mechanical ventilation is analgesic and sedation. This standard therapy is also given according to the patient's clinical condition
219187634|NCT07062471|DEVICE|Carotid Intravascular Lithotripsy (IVL)|The Shockwave Medical Intravascular Lithotripsy (IVL) System with the Shockwave SkyRunner Carotid IVL Catheter is intended for lithotripsy- enhanced balloon dilatation of ≥ 3 mm thick calcified lesions in the carotid arteries prior to stenting. Not for use for treating massive exophytic (mushroom-like) or irregular endoluminal carotid calcification, or in the coronary or cerebral arteries.
219372805|NCT06063473|DRUG|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
219372806|NCT06063473|DRUG|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
219372807|NCT00507325|PROCEDURE|Blood Sample|Blood samples will be collected.
219372808|NCT00507325|PROCEDURE|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
219372809|NCT04502615|OTHER|Sand|sand surface
219372810|NCT04502615|OTHER|artificial grass|grass surface
219372811|NCT04502615|OTHER|firm ground|firm surface
219372812|NCT01191814|PROCEDURE|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
219372813|NCT01191814|PROCEDURE|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
219372814|NCT02834130|BEHAVIORAL|Evaluation of psychological and psychopathological|
219372815|NCT03293654|DRUG|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
219372816|NCT03293654|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
219372817|NCT03293654|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
219372818|NCT01106261|PROCEDURE|Metastasectomy|Pulmonary Metastasectomy
219372819|NCT01106261|PROCEDURE|Active monitoring|Active monitoring
219372820|NCT00391976|DRUG|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
219372821|NCT00603005|DEVICE|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
219372822|NCT01761734|BEHAVIORAL|text message|
219372823|NCT05766735|BEHAVIORAL|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
219372824|NCT05766735|OTHER|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
219372825|NCT02724033|PROCEDURE|regional nerve block|regional nerve block
219372826|NCT02724033|DRUG|Antiemetic|Antiemetic
219372827|NCT02327650|PROCEDURE|The examinations for bones in joints of OA and RA patients|
219372828|NCT03742427|DIAGNOSTIC_TEST|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
219372829|NCT04459845|BEHAVIORAL|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
219372830|NCT04459845|BEHAVIORAL|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
219372831|NCT00057707|DRUG|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
219372832|NCT00057707|PROCEDURE|Functional MRI|
219372833|NCT00057707|PROCEDURE|Neuropsychological Testing|
219372834|NCT00220376|DRUG|SPM 907|
219372835|NCT06110650|DRUG|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
219372836|NCT00318435|DEVICE|Stent or stent-graft deployment|
219372837|NCT05784389|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
219372838|NCT06637176|DEVICE|Laser speckle contrast imaging|"LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments"
219372839|NCT05521087|DRUG|JNJ-75276617|JNJ-75276617 will be administered orally.
219372840|NCT05521087|DRUG|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
219372841|NCT05521087|DRUG|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
219372842|NCT05521087|DRUG|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
219372843|NCT05521087|DRUG|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
219372844|NCT05521087|DRUG|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
219372845|NCT05521087|DRUG|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
219372846|NCT06346548|OTHER|oral photography|The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner
219372847|NCT06335082|DEVICE|Pulsed Field Ablation|Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)
219372848|NCT01091636|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
219372849|NCT03093402|DRUG|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
219372850|NCT03093402|DRUG|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
219372851|NCT00333996|DRUG|Dexamethasone|
219372852|NCT02886702|DRUG|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
219372853|NCT02886702|DRUG|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
219372854|NCT02886702|DRUG|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
219372855|NCT05533567|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
219372856|NCT05533567|DRUG|Propofol|The control group was sedated with propofol.
219372857|NCT01305447|BEHAVIORAL|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
219372858|NCT01305447|BEHAVIORAL|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
219372859|NCT01305447|BEHAVIORAL|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
219372860|NCT05947240|OTHER|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
219187635|NCT07063979|DEVICE|Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient|Use of a wearable device, which emits a low-level electric current across 2 small electrodes on the underside of the patient's wrist, stimulating the nerves and sending a signal to the center of the brain that can help suppress nausea/vomiting. A review of the medical literature found studies that found the device to be effective in reducing PONV. It has been studied in the past, but the trials had limitations, not double blinded and no true placebo. We have proposed a true double blind randomized study utilizing a placebo which specifically mimics the actual device as closely as possible to prevent bias and adversely effecting data results. Nor had this device been tested specifically in the postop bariatric surgical patient.
219187636|NCT07063979|DEVICE|A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.|The company who makes the active device created a sham wearable device that looks like the active, and buzzes (to give the feel of stimulation), but does not actual emit a low-leve electrical signal to stimulate the nerves.
219187637|NCT07063342|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
219187638|NCT07063342|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
219187639|NCT07063342|DRUG|Trospium Chloride|Specified dose on specified days
219187640|NCT07062757|OTHER|no intervention|this group patients receive any medication for edema control.
219372861|NCT05947240|OTHER|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
219372862|NCT04456829|DIETARY_SUPPLEMENT|Resveratrol drink|Subjects will consume a bottle of resveratrol drink for two months.
219187641|NCT07062757|OTHER|lymphatic drainage massage|A total of 10 sessions of lymphatic drainage massage will be applied to this group of patients, starting from the 2nd postoperative day, with 2 sessions per week.
219187642|NCT07062757|DIETARY_SUPPLEMENT|oral melatonin tablet|In this group of patients, the first dose of 10 mg oral melatonin tablet will be given one day prior to the operation, and the patients will continue taking the tablet daily for a total of 21 days.
219187643|NCT07062757|COMBINATION_PRODUCT|both melatonin and lymphatic drainage|In this group of patients, a total of 10 sessions of lymphatic drainage massage will be applied starting from the 2nd postoperative day, with 2 sessions per week, while the first dose of 10 mg oral melatonin tablet will be administered one day prior to the operation, and the patients will continue taking the tablet daily for 21 days.
219372863|NCT04456829|DIETARY_SUPPLEMENT|Placebo drink|Subjects will consume a bottle of placebo drink for two months.
219372864|NCT00188578|PROCEDURE|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
219372865|NCT05430620|DRUG|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
219372866|NCT03967821|OTHER|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
219372867|NCT03014960|OTHER|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
219372868|NCT00415220|PROCEDURE|Spinal Manipulation, Microdiscectomy|
219372869|NCT00763009|DRUG|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
219372870|NCT01096147|DEVICE|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
219372871|NCT00000312|DRUG|M-CPP|
219372872|NCT05773391|DRUG|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
219372873|NCT01802359|DRUG|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
219372874|NCT03649919|OTHER||Patients receive routine diagnostic and treatment medications.
219372875|NCT04587115|DRUG|Risperidone|Risperidone 1mg to be used in combination with other drugs
219372876|NCT04587115|DRUG|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
219372877|NCT04587115|DRUG|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
219372878|NCT02491385|PROCEDURE|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
219372879|NCT02491385|DRUG|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
219372880|NCT00891735|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
219372881|NCT04290182|BIOLOGICAL|MSC-KI-PL-204|Autologous MSC product
219372882|NCT02676258|DEVICE|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
219372883|NCT02676258|DEVICE|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
219372884|NCT02318056|OTHER|Aquacel® Ag Burn Glove|burn dressing
219372885|NCT02318056|OTHER|Mepilex® Transfer Ag|burn dressing
219372886|NCT02318056|DRUG|antibiotic|antibiotic burn dressing
219372887|NCT00673595|DRUG|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
219372888|NCT00673595|DRUG|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
219372889|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
219372890|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
219372891|NCT01743430|OTHER|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
219372892|NCT03262376|DIETARY_SUPPLEMENT|Minerals + Vitamins|A mineral and vitamin tablet
219372893|NCT03262376|DIETARY_SUPPLEMENT|Botanical A|Botanical extract administered in capsule form
219372894|NCT03262376|DIETARY_SUPPLEMENT|Botanical B|Botanical extract administered in capsule form
219372895|NCT03262376|OTHER|Placebo|Cellulose crystalline tablet
219372896|NCT03663166|RADIATION|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
219372897|NCT03663166|DRUG|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
219372898|NCT03663166|DRUG|ipilimumab|ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
219372899|NCT03663166|DRUG|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
219372900|NCT01666223|DRUG|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
219372901|NCT01666223|DRUG|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
219372902|NCT01666223|OTHER|saline|100 ml saline
219372903|NCT01666223|DRUG|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
219372904|NCT02148367|DRUG|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
219372905|NCT05733455|DRUG|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
219372906|NCT05733455|DRUG|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
219372907|NCT05733455|DEVICE|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
219000804|NCT07132099|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) is not a structured intervention within this study. It may include standard outpatient or inpatient services, pharmacotherapy, or no structured treatment, depending on individual circumstances.
219187644|NCT07063212|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate
219372908|NCT05733455|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
219372909|NCT05733455|DIETARY_SUPPLEMENT|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
219372910|NCT03244358|DRUG|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
219372911|NCT02573116|PROCEDURE|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
219372912|NCT02749214|OTHER|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
219372913|NCT02749214|OTHER|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
219372914|NCT01523080|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
219372915|NCT03108716|PROCEDURE|hamate hook removal|The patients were assigned to treat with hamate hook removal.
219372916|NCT03108716|PROCEDURE|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
219372917|NCT03108716|OTHER|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
219372918|NCT05294029|OTHER|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
219372919|NCT04727671|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
219372920|NCT04727671|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
219372921|NCT04727671|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
219372922|NCT04727671|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
219372923|NCT00291720|DRUG|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
219372924|NCT00291720|DRUG|Placebo|matching placebo
219372925|NCT03711383|DIETARY_SUPPLEMENT|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
219372926|NCT03711383|DIETARY_SUPPLEMENT|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
219000805|NCT07132359|OTHER|The Body Understanding Measure for Pregnancy Scale|During the study, the purpose of the study was explained to the pregnant women, and it was stated that participation in the study was completely voluntary and that they could leave the study at any time, and their written and verbal consent was obtained (Informed Consent Form). Pregnant women who agreed to participate in the study filled out the data collection forms individually.
219372927|NCT03711383|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before test day
219372928|NCT06117514|DRUG|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
219372929|NCT06117514|DRUG|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
219372930|NCT06117514|DRUG|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
219187645|NCT07063212|DRUG|Cetuximab|Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist
219372931|NCT06117514|DRUG|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
219372932|NCT06117514|DRUG|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
219372933|NCT06117514|OTHER|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
219372934|NCT06117514|OTHER|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
219187646|NCT07064057|OTHER|Aerobic exercise combined with the sniff maneuver technique|Aerobic exercises on a stationary bike or electric treadmill three times a week for six week. Five minutes of stretching, concentrated on the main lower limb muscle groups, were followed by a ten-minute warm-up, twenty minutes of training during the first two weeks and thirty minutes during the third to sixth week, and finally, a five-minute cooling-down phase..
219372935|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
219372936|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
219372937|NCT02794337|RADIATION|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
219372938|NCT02794337|PROCEDURE|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
219372939|NCT02794337|DRUG|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
219372940|NCT05675137|DEVICE|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
219372941|NCT05675137|OTHER|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
219372942|NCT02938182|DRUG|clopidogrel|clopidogrel troche 75 mg daily for three months
219372943|NCT01021943|DRUG|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
219372944|NCT01021943|DRUG|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
219372945|NCT06263088|OTHER|EQUITY GI|"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
219372946|NCT01511484|BEHAVIORAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
219372947|NCT01511484|BEHAVIORAL|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
219372948|NCT01511484|BEHAVIORAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
219372949|NCT05105386|DEVICE|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
219372950|NCT04151108|OTHER|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
219372951|NCT04151108|OTHER|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
219372952|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
219372953|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
219372954|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
219372955|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
219372956|NCT02639351|BIOLOGICAL|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
219372957|NCT04530162|PROCEDURE|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
219372958|NCT00158184|DRUG|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
219372959|NCT00158184|DRUG|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
219372960|NCT00158184|DRUG|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
219372961|NCT01466842|PROCEDURE|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
219372962|NCT06011135|OTHER|No intervention|No intervention - qualitative study only using semi-structured interview
219372963|NCT04828044|DEVICE|Microwave Ablation/ Coagulation Arm|An 11-gauge microwave probe from MedWaves, Inc., will be placed in the tumor. An ablation lesion will then be generated at the appropriate power (10-35 watts) to maintain up to 130C degrees at the MW applicator tip thermocouple for 10 minutes duration. Palpation and/or ultrasound may be used to place the MWA needle and monitor the progress of the microwave ablation.
219372964|NCT05340504|DRUG|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
219372965|NCT05340504|DRUG|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
219000806|NCT06853925|BEHAVIORAL|Radioactive Iodine Support (RAI Support)|RAI Support consists of multimedia content (images, videos, text, audio, and infographics across different website pages) that is written at an 8th grade reading level. RAI Support uses patient materials that are visually diverse to appeal to patients from different racial and ethnic backgrounds and inclusion of all genders. RAI Support users can access short (\~3 minutes or less) clinician-approved symptom management education videos and follow clinician-led video-guided activities such as nutrition management for dry mouth. In addition, RAI Support contains infographic pages about specific symptoms of RAI (e.g., salivary, lacrimal, and nasal symptoms with strategies for symptom management) and a resources page consisting of a printable treatment summary and survivorship plan to bring to provider appointments and access to evidence-based stress-management resources such as relaxation recordings.
219372966|NCT04911621|BIOLOGICAL|Dendritic cell vaccination + temozolomide-based chemoradiation|"1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
219000807|NCT06853925|OTHER|Treatment as Usual (TAU)|The American Cancer Society (ACS) website on Radioactive Iodine (Radioiodine)Therapy for Thyroid Cancer is the TAU comparison. This website is a reputable and trusted source of information about cancer, with relevant content and web availability. Using the ACS website allows participants in both groups to receive information (addressing ethical concerns) through a website (similar delivery mode for information).
219372967|NCT04911621|BIOLOGICAL|Dendritic cell vaccination +- conventional next-line treatment|"1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
219000808|NCT06813092|OTHER|Whole-Body Electromyostimulation|20 min of WB-EMS (bipolar, 85 Hz, 350 µs, 6s impulse - 4s impulse break)
219000809|NCT06813092|OTHER|Resistance exercise|High-intensity/high velocity multiple set resistance exercise
219000810|NCT05011422|DEVICE|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
219000811|NCT06981325|DRUG|Cemiplimab|Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).
219000812|NCT05448560|BEHAVIORAL|Multi-level Intervention of shared model of survivorship care|1\) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
219000813|NCT05448560|OTHER|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
219000814|NCT06978673|PROCEDURE|Splanchnic nerve neurolysis - 5 ml of absolute alcohol (100%)|Splanchnic neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the eleventh thoracic vertebra.
219000815|NCT06978673|PROCEDURE|Celiac Plexus Neurolysis - 5 ml of absolute alcohol (100%)|Celiac plexus neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the first lumbar vertebra.
219000816|NCT06983041|DEVICE|vaginal cooling device|medical grade polymer capsule filled with inert fluid (15 cc's)
219000817|NCT06985108|PROCEDURE|nazotracheal intubation|intubation tube will be placed from nasal orifice through nazopharyngeal pathway to place into trachea
219000818|NCT04309604|BIOLOGICAL|IC14|monoclonal antibody directed against CD14
219000819|NCT01844440|PROCEDURE|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
219000820|NCT05479474|BIOLOGICAL|Platelet rich plasma|"Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.~* On the third month after the testicular PRP procedure, a TESE will be performed~* If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done."
219000821|NCT06986785|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219000822|NCT06986785|DRUG|Lenvatinib|8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD.
219000823|NCT05923866|DRUG|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
219000824|NCT05923866|DRUG|Placebo|Oral administration of placebo once a daily for 24 weeks
219000825|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
219000826|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
219000827|NCT05304988|OTHER|Testing of the EFT|Our team will develop specific questions in EFT. Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The physiotherapists will rate the subject with the most appropriate level of physical activity.
219372968|NCT00923637|DRUG|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
219372969|NCT00650923|DRUG|ziv-aflibercept|Given IV
219372970|NCT00650923|PROCEDURE|radiation therapy|Undergo RT
219372971|NCT00650923|DRUG|temozolomide|Given PO
219372972|NCT00650923|PROCEDURE|pharmacological study|Correlative studies
219372973|NCT00650923|PROCEDURE|laboratory biomarker analysis|Correlative studies
219372974|NCT03813030|PROCEDURE|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
219372975|NCT03813030|DRUG|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
219372976|NCT03813030|DRUG|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
219372977|NCT03813030|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
219372978|NCT03813030|DEVICE|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
219372979|NCT03813030|PROCEDURE|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
219372980|NCT03813030|PROCEDURE|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
219372981|NCT05805514|OTHER|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
219372982|NCT05805514|OTHER|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
219372983|NCT05805514|OTHER|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
219372984|NCT06013774|DEVICE|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
219372985|NCT02666326|PROCEDURE|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
219372986|NCT02168595|DRUG|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
219372987|NCT02168595|DRUG|Placebo|
219372988|NCT06151652|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
219372989|NCT06151652|DRUG|Placebo|placebo
219372990|NCT04890873|DRUG|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
219372991|NCT04890873|DRUG|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
219372992|NCT03537040|OTHER|Method of Levels|Talking Therapy
219372993|NCT05965037|DEVICE|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
219372994|NCT03135366|BEHAVIORAL|Keheala|
219372995|NCT03135366|OTHER|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
219372996|NCT05642377|DRUG|HGR4113|Once-daily oral administration
219372997|NCT05642377|DRUG|Placebo|Once-daily oral administration
219372998|NCT05642377|DRUG|HGR4113|Twice-daily oral administration
219372999|NCT05642377|DRUG|Placebo|Twice-daily oral administration
219373000|NCT00558935|DIETARY_SUPPLEMENT|Red Wine|20g alcohol daily/red wine for 4 weeks
219373001|NCT02511977|OTHER|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
219373002|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
219373003|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
219373004|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
219373005|NCT00844493|BIOLOGICAL|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
219373006|NCT00208637|BEHAVIORAL|moderate carbohydrate, high protein diet (MCHP)|
219373007|NCT00208637|BEHAVIORAL|high carbohydrate-high fibre (HCHF) diet|
219373008|NCT01455974|OTHER|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
219000828|NCT06590285|BEHAVIORAL|App-based Educational Intervention|"The program's educational content is designed to engage patients in the science of sleep and recovery. Segments like The Sleep Adventure demystify complex neurobiological processes in an accessible format, aligning with emerging trends in patient education that focus on engagement and knowledge empowerment. Concurrently, the program's physical activity component is meticulously crafted, offering safe, supportive exercises that correspond with the treatment stages of alloHSCT patients. This aspect draws upon evidence highlighting the importance of sustained physical activity during intensive treatments to enhance overall recovery and quality of life. Additionally, the program comprehensively addresses sleep disturbances, prevalent in HSCT patients, through in-depth exploration and evidence-based, non-pharmacologic management strategies, reflecting the significant impact of sleep quality on patient recovery and long-term health outcomes."
219000829|NCT06074133|PROCEDURE|Blood collection|Undergo blood draw
219557744|NCT02466386|DRUG|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
219557745|NCT04330495|DRUG|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
219000830|NCT06074133|PROCEDURE|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
219000831|NCT06990464|DRUG|SIBP-A19|"SIBP-A19 formulation for injection. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
219000832|NCT04715997|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
219000833|NCT04715997|DRUG|Placebo|Normal saline
219000834|NCT06345781|BEHAVIORAL|Abdominal Functional Electrical Stimulation|Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
219000835|NCT06993142|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting moderate-to-vigorous physical activity (MVPA) relative to baseline level).
219000838|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
219000839|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
219000840|NCT06668571|DRUG|Ketamine|The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
219000841|NCT06668571|DRUG|Normal Saline|The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
219000842|NCT05766852|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
219000843|NCT04196842|DEVICE|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
219000844|NCT05513859|PROCEDURE|Craniotomy|Undergo craniotomy
219000845|NCT05513859|DEVICE|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
219000846|NCT06999226|BEHAVIORAL|RENEW-AI|AI assisted health coaching using the LLM-driven chat functionality.
219000847|NCT07001527|DEVICE|Chlorhexidine|dressing impregnated
219000848|NCT07001527|DEVICE|Chlorhexidine|COmmon dressing
219000849|NCT07000565|OTHER|Eye Care with Artificial Tears|Every 2 hours, the artificial tear solution was gently applied to the designated eye for 5 days. The artificial tear product (REFRESH®) contains 5.6 mg of polyvinyl alcohol and 2.4 mg of povidone per mL and is used to maintain ocular surface moisture and reduce irritation.
219000850|NCT07000565|OTHER|Eye Care with Normal Saline|Every 2 hours, the saline solution(Bio-Fleks brand) was gently applied to the designated eye for 5 days.
219000851|NCT07000812|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants in the intervention arm receive 12 weekly sessions of individual CBT. Therapy includes exposure and response prevention, cognitive restructuring, psychoeducation, and relapse prevention strategies.
219373009|NCT02432547|DRUG|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
219373010|NCT02432547|PROCEDURE|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
219373011|NCT00313924|DRUG|DETRUSITOL|
219373012|NCT00630045|DRUG|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
219373013|NCT00630045|PROCEDURE|resection of liver metastasis|surgery with the aim of R0 resection
219373014|NCT03494283|BEHAVIORAL|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
219373015|NCT05014854|DEVICE|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
219373016|NCT03578679|DRUG|Ivermectin Oral Product|treatment of pediculosis (head lice)
219373017|NCT05043584|DEVICE|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
219373018|NCT02582671|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
219373019|NCT02582671|DRUG|Dasabuvir|Tablet
219373020|NCT02582671|DRUG|Ribavirin|Tablet
219373021|NCT00728429|BEHAVIORAL|exercise intervention|24 week program of exercise
219373022|NCT02210156|DIETARY_SUPPLEMENT|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
219373023|NCT02210156|OTHER|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
219373024|NCT03068715|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
219373025|NCT03068715|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219373026|NCT03068715|DEVICE|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
219373027|NCT00078130|DRUG|Buprenorphine/naloxone|
219373028|NCT05174091|OTHER|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
219373029|NCT03787069|DRUG|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
219373030|NCT03462251|COMBINATION_PRODUCT|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
219373031|NCT03462251|COMBINATION_PRODUCT|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
219557746|NCT04330495|DRUG|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
219557747|NCT05317195|OTHER|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
219557748|NCT05317195|OTHER|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
219557749|NCT05317195|OTHER|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
219557750|NCT05317195|OTHER|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
219557751|NCT05317195|OTHER|Velo-NP|Velo-NP; 10 mg nicotine;
219000852|NCT07001969|PROCEDURE|Massoud-Goel Technique and Theory|Percutaneous Trans-facet Fixation Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
219373032|NCT05015309|DRUG|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
219373033|NCT01484964|DRUG|ASP015K|oral
219373034|NCT04209231|OTHER|1.25(OH)2D3|
219373035|NCT04209231|OTHER|25(OH)D|
219373036|NCT05288712|OTHER|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
219373037|NCT05288712|OTHER|Conventional training protocol|Conventional training protocol
219373038|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
219373039|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
219373040|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
219373041|NCT00971308|DRUG|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
219373042|NCT00971308|DRUG|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
219000853|NCT07001969|PROCEDURE|Percutaneous Trans-facet Fixation for Treatment of Degenerative Spine|Percutaneous Trans-facet Fixation (Developmental of Dr Atul goel technique of transfacet fixation by open surgery using Magrel technique) Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
219000854|NCT07001904|OTHER|Enzyme-linked immunosorbent assay (ELISA)|The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
219000855|NCT07001163|DIETARY_SUPPLEMENT|Probiotic|Probiotic sachets contained 1× 109 colony-forming unit of Bifidobacterium Animalis subsp.lactis BB-12), were given via orogastric tube twice daily.
219000856|NCT07001995|DRUG|limertinib|limertinib 80 mg
219000857|NCT07001995|DRUG|etoposide and carboplatin|etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV
219000858|NCT06676904|PROCEDURE|Higher Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 35 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
219000859|NCT06676904|PROCEDURE|Lower Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 20 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
219000860|NCT07000643|RADIATION|Intensity-Modulated Proton Therapy (IMPT)|"This is the experimental arm intervention. Patients receive Intensity-Modulated Proton Therapy (IMPT) for primary nasopharyngeal carcinoma.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin, reducible near organs at risk) at a dose of 69.6-70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction. The protocol notes that proton therapy does not use a PTV (Planning Target Volume).~The systemic therapy plan is formulated according to clinical guidelines."
219000861|NCT07000643|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"This is the control arm intervention. Patients receive Intensity-Modulated Radiotherapy (IMRT) for primary nasopharyngeal carcinoma; IMRT is one of the current standard and widely used treatment techniques.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin); PTV70 (CTV70 + 3-5mm margin, reducible near organs at risk) at a dose of 70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions); PTV50-54 (CTV50-54 + 3-5mm margin, reducible near organs at risk) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction.~The systemic therapy plan is formulated according to clinical guidelines."
219000862|NCT07000695|DRUG|Pelacarsen|Patients receive Pelacarsen
219373043|NCT01133964|DIETARY_SUPPLEMENT|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
219373044|NCT04911387|DEVICE|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
219373045|NCT03519048|PROCEDURE|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
219373046|NCT03519048|OTHER|Low Dose Chest CTscan|every year in patients with tobacco consumption history of \> 20 pack-year
219373047|NCT03519048|OTHER|injected CT-scan|the first performed 12 months after inclusion
219373048|NCT03519048|OTHER|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
219373049|NCT03519048|PROCEDURE|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
219373050|NCT03519048|PROCEDURE|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
219373051|NCT01495026|DRUG|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
219373052|NCT01495026|DRUG|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
219557752|NCT05317195|OTHER|Zyn-NP|Zyn-NP; 3 mg nicotine;
219557753|NCT05327712|BEHAVIORAL|Control group|No outreach during the intervention period beyond an initial eligibility notice.
219373053|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
219373054|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
219373055|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
219373056|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
219373057|NCT01495026|DRUG|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
219373058|NCT01495026|DRUG|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
219373059|NCT01495026|DRUG|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
219373060|NCT05134909|DEVICE|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
219373061|NCT00794287|OTHER|Taking blood samples|No intervention is done. Only blood samples are taken.
219373062|NCT00572884|OTHER|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
219373063|NCT06112587|BEHAVIORAL|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
219373064|NCT04970329|DRUG|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
219373065|NCT00219908|DRUG|Mitoxantrone|
219373066|NCT02610985|DEVICE|3-D laparoscopy|3-D laparoscopy
219373067|NCT02610985|DEVICE|2-D laparoscopy|2-D laparoscopy
219373068|NCT01415388|DIETARY_SUPPLEMENT|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
219373069|NCT00762346|DRUG|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
219373070|NCT01956981|DRUG|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
219373071|NCT01956981|DRUG|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
219373072|NCT04624425|OTHER|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
219373073|NCT04624425|OTHER|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
219373074|NCT01507376|DRUG|recombinant hCG|recombinant hCG(250 µg Ovitrell)
219373075|NCT01507376|DRUG|recombinant hCG|recombinant hCG(500 µg Ovitrell)
219373076|NCT01507376|DRUG|urinary hCG|10,000 IU urinary hCG
219373077|NCT04409938|OTHER|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
219373078|NCT04409938|OTHER|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
219373079|NCT00889044|DRUG|clopidogrel by chewing|600 mg clopidogrel by chewing
219373080|NCT00889044|DRUG|Placebo|Placebo p.o
219373081|NCT05295537|PROCEDURE|PERCUTANEOUS LIVER BIOPSY (PLB)|Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.
219373082|NCT05295537|PROCEDURE|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)|EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
219373083|NCT00481065|BIOLOGICAL|MF59-eH5N1|
219373084|NCT00481065|BIOLOGICAL|eTIV_a|
219373085|NCT00481065|BIOLOGICAL|MF59-eH5N1 + eTIV_a|
219373086|NCT02058901|DRUG|Sunitinib|
219373087|NCT00885079|DRUG|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
219373088|NCT00885079|DRUG|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
219373089|NCT02953041|DRUG|Glycopyrronium|long-acting muscarinic antagonist
219373090|NCT02953041|DRUG|Indacaterol|ultra long-acting beta agonist
219373091|NCT01709331|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
219373092|NCT01709331|DRUG|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
219373093|NCT03553394|DRUG|Ringer's Acetate|Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
219557754|NCT05327712|BEHAVIORAL|Email only|Email reminders in addition to an initial eligibility notice.
219557755|NCT05327712|BEHAVIORAL|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
219557756|NCT05327712|BEHAVIORAL|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
219000863|NCT07002450|DIAGNOSTIC_TEST|Cardiac computed tomography angiography|Patients will undergo CCT according to the following protocol. A non-contrast enhanced prospective ECG-triggered image will be acquired followed by a contrast-enhanced prospective ECG-triggered image using a tri-phasic contrast protocol. Delayed CT images 60 seconds after the initial contrast-enhanced CT scan will be obtained. Cardiac CT image interpretation will be performed according to routine clinical practices in a pragmatic fashion. The LA will be assessed for filling defects and characterized based upon attenuation values. If LA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. If the CCT shows no LA thrombus then the ED physician will be able to perform electrical and/or chemical cardioversion at their discretion.
219000864|NCT07002450|OTHER|Standard of care management|"Patients in the standard of care arm may undergo any combination of the following management strategies in the emergency department (ED) at the discretion of their treating physician:~1\. Transesophageal echocardiogram (TEE) facilitated cardioversion; 2. Rate control; 3. Consultation with inpatient cardiac specialist for assessment/management and consideration of hospital admission; 4. cardioversion after 3 weeks of anticoagulation; and/or 5. Outpatient referral to cardiac specialist or general practitioner for further management."
219000865|NCT07000539|DIAGNOSTIC_TEST|Indocyanine Green Angiogram|Three different doses of indocyanin green will be compared (5 mg, 7.5 mg, and 10 mg). These doses are within the range of currently recommended doses by the International Society for Fluorescence Guided Surgery (ISFGS) for bariatric surgery.
219000866|NCT07001397|DRUG|EPAG-pfos|The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved
219000867|NCT07001683|DEVICE|VR SHINECON VIRTUAL REALITY GLASES|"Unity program; It is a game engine that is used for the development of 2D, 3D, virtual reality and augmented reality applications and also has mobile support. 3D objects and animations necessary to develop the application have been prepared. These objects and animations; It was developed in the Autodesk 3ds Max program, where 3D modeling and animations are made.~The virtual reality aspect of the application is integrated into the Google VR SDK (Google Virtual Reality Software Development Kit). Interactions in the virtual environment and 360° viewing operations in the virtual world are provided through this Google VR SDK. The development process was completed by writing application codes in C#, one of the languages supported by the Unity program, using the methods included in the SDK."
219000868|NCT07001514|BEHAVIORAL|Calming digital content|Participants watch a curated selection of soothing documentaries narrated by Sir David Attenborough for 30-60 minutes each evening during one hour before bedtime.
219000869|NCT07001514|BEHAVIORAL|Exciting Digital Content|Participants engage with the interactive word-based game Ruzzle for 30-60 minutes each evening during one hour before bedtime, designed to provide mental stimulation.
219000870|NCT07001514|BEHAVIORAL|Non-digital book reading|Participants read a non-fiction book of their choice for the same duration, avoiding all digital screens during one hour before bedtime before bedtime.
219000871|NCT07002385|BEHAVIORAL|control group|The control group received standard psychiatric care, which involved physician-led management following clinical guidelines for geriatric disease treatment, including routine medication prescriptions based on diagnostic results. At diagnosis, healthcare providers informed caregivers about the confirmed disease entity, clinical status, and necessary precautionary measures. Monthly mental health lectures were conducted for all patients, covering topics such as common psychological symptoms and coping strategies. Post-discharge, monthly outpatient follow-ups included blood pressure and glucose monitoring. Medication dosages were adjusted if patients reported changes in somatic symptoms.
219000872|NCT07002385|COMBINATION_PRODUCT|Intervention group|The intervention group received a structured biopsychosocial program delivered by a multidisciplinary team. Geriatricians adjusted medications biweekly; rehabilitation therapists led Baduanjin sessions and monitored daily exercises via smart wristbands. Nurses provided CBT-I manuals, and psychologists offered weekly video support. Psychological care included biweekly mindfulness sessions and daily app-guided exercises, with monthly life review activities. Social support involved community events, volunteer roles, and weekly caregiver workshops. Adherence (≥70%) was tracked via app; non-compliance triggered reminders and tailored support. Exercise intensity was regulated by heart rate; patients with ≥5-point HAMD-17 increases were referred. Monthly reviews ensured ongoing quality improvement.
219000873|NCT07002398|DRUG|VG801|Administered as specified in the single treatment arm. Study Cohort: Low dose, medium dose and high dose cohort
219000874|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
219000875|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
219000876|NCT07001488|DRUG|Azvudine tablets (FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
219187647|NCT07064057|OTHER|Aerobic exercise|The treadmill was used for both the warm-up and cooling-down phases. Heart rate was kept between 40% and 50% of maximum heart rate for these sessions. (5) To achieve a moderate exertion (rated as 11--13 on the Borg scale) and/or a moderate dyspnea (rated as 3---4 on the modified Borg scale), the intensity of the aerobic training was progressively increased.
219373094|NCT02630953|BEHAVIORAL|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
219373095|NCT02630953|BEHAVIORAL|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
219373096|NCT05791279|OTHER|Heart age|information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
219373097|NCT06375304|DRUG|B/F/TAF|"The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements."
219373098|NCT05020561|BEHAVIORAL|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
219000877|NCT07000825|DIETARY_SUPPLEMENT|Intervention with yerba mate extract or placebo|The standardized extract of yerba mate (Ilex paraguariensis) will be supplied by Sustentec. It is a dry extract of the plant's green, powdered leaves, obtained through aqueous extraction. The extract was obtained by infusing the dried leaves of the plant and the drying process was carried out using a spray-dryer (ratio 6/1 leaves/extract). The extract will be encapsulated containing 250 mg each. Administration Intervention group: 2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals. This amount will provide approximately 980 mg of caffeoylquinic acids/day, which was defined based on the estimated usual intake of caffeoylquinic acids by individuals in a municipality in the southern region of the country, from traditional drinks made with yerba mate (chimarrão and tereré) (Gebara et al., 2017). Placebo group: 9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.
219000878|NCT07002346|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706: 5 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 2 years.
219000879|NCT07002346|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 22 cycles.
219000880|NCT07002346|DRUG|carboplatin|Carboplatin: AUC=5, intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
219000881|NCT07002346|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
219000882|NCT07132957|DRUG|14C-labeled AL8326|Oral, About 60mg (200μCi) of 14C-labeled AL8326
219000883|NCT07132255|DEVICE|R-One assisted tele-PCI|Surgeons perform operations using R-One vascular interventional navigation control system from remote control center via 5G. robotic slave executes at procedure site.
219000884|NCT07132255|DEVICE|R-One assisted on-site PCI|Surgeons perform operations by controlling robot from local console .
219000885|NCT07132203|DEVICE|Laser interstitial thermal therapy|The LITT procedure was performed using the LS1 laser ablation system and SR1 stereotactic robotic system (Sinovation, Beijing, China). The ablation system was equipped with a 980-nm laser with a maximum of 15 W of power, a core silica fiber optic with a 1.8-mm diameter cooling catheter, and a cooling pump to make saline flow into and out through the catheter. The optic and catheter approaches were planned with the preoperative simulation software (Sinovation, Beijing, China) using the preoperative T1-weighted MRI scan, and passing through important cerebral vascular and functional zones was avoided。. The catheter was implanted by neurosurgeons under stereotactic guidance, and a laser probe was inserted through the catheter. After LITT, a T1-weighted intraoperative MRI scan was performed to confirm the effect of ablation. The ablation rate was calculated by another neurosurgeon who did not participate in the study.
219000886|NCT07132164|OTHER|biobank sample collection|"At inclusion, patients will benefit from blood testing for biobank establishment, and stool sample collection for gut microbiota analysis will be organized depending on the center.~The 12-month visit (M12) will also include an additional blood sample collection as part of the biobank, as well as stool sample collection"
219000887|NCT07132190|RADIATION|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
219000888|NCT07132879|OTHER|No intervention - Prospective cohort study|No intervention - Prospective cohort study
219000889|NCT07132320|BIOLOGICAL|Pressure Ulcer Nursing AI Application Training|Clinical nurses receive training and guidance via an AI application designed for pressure ulcer nursing based on a clinical judgment model.
219000890|NCT07132320|BIOLOGICAL|Traditional Pressure Ulcer Nursing Education|Clinical nurses receive conventional pressure ulcer nursing education not involving the developed AI application.
219000891|NCT06418724|DRUG|Cetuximab|Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR). EGFR is over-expressed in many human cancers, including colorectal cancers.
219373099|NCT05020561|BEHAVIORAL|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
219373100|NCT02956811|DRUG|Dapagliflozin|SGLT2 inhibitor
219373101|NCT02956811|DRUG|Placebo|Matching Placebo
219373102|NCT02945592|BEHAVIORAL|Cueing|
219373103|NCT00433238|BEHAVIORAL|Participants will be screened for depression and cognitive impairment, then receive screening results.|
219373104|NCT05637268|DRUG|Camrelizumab|Camrelizumab 200mg iv q2w
219373105|NCT05637268|DRUG|Paclitaxel|150mg/m² iv d1 q2w
219373106|NCT05637268|DRUG|Cisplatin|50 mg/m² iv d2 q2w
219373107|NCT06386458|DEVICE|AThrough radiofrequency transseptal puncture system|Utilizing AThrough radiofrequency transseptal puncture system for left atrial access
219373108|NCT06386458|DEVICE|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
219373109|NCT04418921|BEHAVIORAL|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
219373110|NCT04418921|BEHAVIORAL|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
219373111|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
219373112|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
219373113|NCT06153862|DIAGNOSTIC_TEST|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
219373114|NCT02954315|OTHER|Almonds|
219373115|NCT05868369|DEVICE|iVR Group|"On the day of surgery, the iVR group will receive a 30-minute sessions or dose of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes."
219373116|NCT05868369|DRUG|Standard pain management regimen|In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
219373117|NCT02797470|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
219373118|NCT02797470|DRUG|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
219373119|NCT02797470|DRUG|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
219373120|NCT02797470|DRUG|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
219373121|NCT02797470|OTHER|Laboratory Biomarker Analysis|Correlative studies
219187648|NCT07062081|DIAGNOSTIC_TEST|lipid profile|The blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values.
219187649|NCT06638944|BEHAVIORAL|In-person sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
219373122|NCT02797470|BIOLOGICAL|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
219373123|NCT02797470|DRUG|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
219373124|NCT02797470|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
219373125|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
219373126|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
219373127|NCT04529967|OTHER|no interventions|it is a observational study, do not have interventions.
219187650|NCT06638944|BEHAVIORAL|Remote sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
219187651|NCT06638944|BEHAVIORAL|Standard-of-care treatment|Participants in this intervention will complete the same standardized behavioral swallowing rehabilitation protocol and in the same frequency as the sEMG biofeedback intervention groups but WITHOUT a device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week. For this intervention group, patients use a visual analog scale and a timer as feedback tools, as frequently done in clinical practice where sEMG devices are not widely available.
219187652|NCT07064408|DRUG|Esketamine|Intravenous administration of a subanesthetic dose of esketamine (0.25 mg/kg) during induction of general anesthesia. The drug was administered slowly over approximately 30 seconds after midazolam (2 mg) and sufentanil (50 µg), and prior to propofol (2 mg/kg) and rocuronium (0.6 mg/kg). The goal was to evaluate its effect on intraoperative hemodynamic stability and postoperative recovery in elderly patients undergoing thoracic surgery.
219187653|NCT07064408|DRUG|Normal Saline (0.9% Sodium Chloride)|Intravenous administration of an equivalent volume of 0.9% normal saline during anesthesia induction, matching the timing and method of the esketamine group. Used as a placebo comparator.
219187654|NCT07064408|DRUG|Midazolam|Intravenous administration of 2 mg midazolam during anesthesia induction for sedation. Administered prior to study drug.
219187655|NCT07064408|DRUG|Sufentanil|Intravenous administration of 50 µg sufentanil for analgesia during anesthesia induction. Administered prior to study drug.
219187656|NCT07064408|DRUG|propofol|Intravenous administration of 2 mg/kg propofol for loss of consciousness during anesthesia induction. Administered after study drug.
219187657|NCT07064408|DRUG|Rocuronium|Intravenous administration of 0.6 mg/kg rocuronium to facilitate neuromuscular blockade and endotracheal intubation.
219187658|NCT04382443|DRUG|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
219187659|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
219187660|NCT05586958|DRUG|Placebo|Matching placebo
219187661|NCT06076304|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
219187662|NCT06076304|DRUG|Placebo|Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days
219187663|NCT06076304|DRUG|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
219187664|NCT06076304|OTHER|C-reactive protein|Measurement of C-reactive protein level in capillary blood
219187665|NCT06368986|DRUG|VH4011499 Dose A|VH4011499 administered in fasted or fed conditions.
219187666|NCT06368986|DRUG|VH4011499 Dose B|VH4011499 Dose B administered in fasted or fed conditions.
219187667|NCT06953882|DRUG|Ribociclib 400mg|400 mg (2 x 200 mg tablets by mouth) once daily on days 1 to 21 of a 28-day cycle, followed by seven days off ribociclib (Days 22 to 28).
219187668|NCT06953882|DRUG|Letrozole 2.5mg|Letrozole will be administered as an endocrine therapy. The regimen will differ depending on the demographic of the patient. For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously.
219187669|NCT06953882|DRUG|Anastrazole 1mg|For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously.
219187670|NCT06953882|DRUG|Goserelin 3.6 MG|For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously, concurrently with goserelin 3.6 mg monthly injection.
219187671|NCT06953882|RADIATION|Adjuvant chemotherapy|Adjuvant chemotherapy dose modifications in Arm 2 will be per institutional guidelines and investigator discretion.
219187672|NCT05513833|OTHER|Standard School Screening and Referral|Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
219187673|NCT05513833|OTHER|Enhanced mHealth Screening|The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
219187674|NCT05513833|OTHER|Specialty Telemedicine Referral|The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
219187675|NCT05874154|PROCEDURE|Tibial nerve selective neurotomy|Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
219191667|NCT05674357|BEHAVIORAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea"
219754290|NCT01346176|OTHER|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
219373128|NCT06543433|DEVICE|Skincubator 2|"The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator."
219373129|NCT01984515|BEHAVIORAL|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
219373130|NCT01846780|PROCEDURE|PTA & stenting|PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
219373131|NCT05280496|DRUG|Metformin|Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
219373132|NCT05445349|DEVICE|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
219373133|NCT02356809|DRUG|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
219373134|NCT02875223|DRUG|CC-90011|Specified dose on specified days
219373135|NCT02875223|DRUG|Rifampicin|Specified dose on specified days
219373136|NCT02875223|DRUG|Itraconazole|Specified dose on specified days
219373137|NCT01608035|PROCEDURE|Sciatic catheter|presurgical sciatic catheter insertion
219373138|NCT01608035|PROCEDURE|Stump catheter|intraoperative placed stump catheter
219373139|NCT01233479|DRUG|systemic chemotherapy|
219373140|NCT01233479|OTHER|laboratory biomarker analysis|
219373141|NCT01233479|PROCEDURE|therapeutic surgical procedure|
219373142|NCT01233479|RADIATION|radiation therapy|
219373143|NCT04526184|PROCEDURE|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
219373144|NCT00000573|PROCEDURE|enteral nutrition|
219373145|NCT00448292|DRUG|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
219373146|NCT00448292|DRUG|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
219373147|NCT06134297|DEVICE|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (\> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
219373148|NCT06134297|DEVICE|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
219373149|NCT06134297|DEVICE|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
219373150|NCT03866200|DRUG|resveratrol|125 mg/day or 5 ml once per day for 90 days
219373151|NCT03866200|DRUG|Placebo|5 ml once per day for 90 days
219557757|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
219373152|NCT05222074|OTHER|Venous congestion|Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg
219373153|NCT05222074|OTHER|Introperation hypotension|Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
219557758|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
219187676|NCT05874154|DRUG|Botulinum toxin injection|Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
219187677|NCT06353204|BEHAVIORAL|Halt-intervention|The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
219187678|NCT04945590|BEHAVIORAL|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
219187679|NCT05740137|DEVICE|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
219187680|NCT05895136|DRUG|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
219187681|NCT05895136|DRUG|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
219187682|NCT05895136|DRUG|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
219187683|NCT03663569|DRUG|Spiolto® Respimat®|Drug
219187684|NCT04732598|DRUG|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
219187685|NCT04732598|DRUG|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
219187686|NCT05603741|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
219187687|NCT05603741|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
219187688|NCT03079232|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
219187689|NCT03079232|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
219187690|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
219187691|NCT05327465|OTHER|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
219187692|NCT05327465|OTHER|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
219187693|NCT06562283|OTHER|Thumb test|Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
219187694|NCT06562283|OTHER|Grip test|Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
219187695|NCT06562283|OTHER|Quadriceps Intermittent Fatigue test (QIF test))|Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
219187696|NCT06256510|DRUG|Midazolam|Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
219187697|NCT06256510|DRUG|Vepdegestrant|Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
219187698|NCT05877976|BEHAVIORAL|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
219187699|NCT05058833|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
219187700|NCT05058833|DIAGNOSTIC_TEST|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
219187701|NCT04271644|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cell therapy
219187702|NCT06436807|DEVICE|Indwelling catheter|The tunneled catheter is an implant product that enables the drainage of effusion accumulations from serous body cavities so that the symptoms caused by an effusion are relieved by draining off the accumulated fluids.
219557759|NCT04799223|OTHER|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
219754291|NCT01994876|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
219754292|NCT01994876|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
219187703|NCT03982316|BEHAVIORAL|Telehealth Behavioral Migraine Management|1\) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
219187704|NCT05134246|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
219187705|NCT05134246|PROCEDURE|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
219187706|NCT04248725|BEHAVIORAL|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
219187707|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
219187708|NCT03916978|BIOLOGICAL|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
219187709|NCT03916978|BIOLOGICAL|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
219187710|NCT05823220|BEHAVIORAL|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
219187711|NCT05823220|BEHAVIORAL|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
219187712|NCT06207136|OTHER|Mediterranean-style diet|Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
219187713|NCT05408793|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
219187714|NCT05520346|DEVICE|Electronic Device for Toilet|Device will be installed on toilet of patients will in hospital to measure all waste output.
219187715|NCT06016387|DRUG|Tucatinib 150 MG|Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
219187716|NCT06016387|DRUG|Trastuzumab|"MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations."
219187717|NCT06016387|DRUG|Capecitabine|Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
219187718|NCT06016387|RADIATION|Brain & Spinal Radiation|Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
219187719|NCT05938855|DEVICE|Electrical stimulation and biofeedback with the medical device Phenix Liberty|"The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session"
219187720|NCT05622812|DEVICE|Restylane Lyft Lidocaine|Treatment for Jawline definition
219187721|NCT04359784|BIOLOGICAL|Anakinra|Given IV (previously SC)
219187722|NCT04359784|PROCEDURE|X-Ray Imaging|Undergo x-ray
219187723|NCT04359784|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219187724|NCT04359784|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219187725|NCT04359784|PROCEDURE|Bone Marrow Aspiration|Undergo BMA
219187726|NCT04359784|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219187727|NCT04359784|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219187728|NCT04359784|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219187729|NCT04133077|BIOLOGICAL|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
219187730|NCT05314491|DEVICE|Multigen Plus CCK|Total Knee Arthroplasty
219187731|NCT05314491|DEVICE|AMF TT cones|To fill a proximal tibia or distal femur defect
219187732|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
219187733|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219754293|NCT04194242|DRUG|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
219373154|NCT05585255|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
219373155|NCT01572090|BEHAVIORAL|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
219373156|NCT01572090|OTHER|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
219373157|NCT01572090|PROCEDURE|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
219373158|NCT01572090|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
219373159|NCT01904799|OTHER|Cognitive Assessment test|
219373160|NCT01707992|DRUG|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
219373161|NCT01707992|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
219373162|NCT03700099|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
219373163|NCT03700099|DRUG|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
219373164|NCT06244459|OTHER|VR Assessment Tool|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
219373165|NCT03006614|DRUG|NVB|
219373166|NCT03006614|DRUG|EPI|
219373167|NCT03006614|DRUG|DDP|
219373168|NCT03006614|DRUG|CAP|
219373169|NCT03006614|DRUG|GEM|
219373170|NCT03006614|DRUG|H|
219373171|NCT03006614|DRUG|CTX|
219373172|NCT03006614|DRUG|T|
219373173|NCT01904981|DRUG|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
219373174|NCT01904981|DRUG|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
219373175|NCT01453504|DRUG|DHAP|Dexamethasone, Cytarabine, Cisplatin
219373176|NCT01453504|DRUG|Everolimus|
219373177|NCT04144621|PROCEDURE|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
219373178|NCT05122130|DRUG|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
219373179|NCT05122130|DRUG|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
219373180|NCT03046420|OTHER|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
219373181|NCT04551014|DEVICE|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
219373182|NCT04551014|DEVICE|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
219373183|NCT01041248|DRUG|Tocilizumab|8mg/kg every 2 weeks i.v.
219373184|NCT06206889|OTHER|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
219373185|NCT02654002|DRUG|Cilofexor|Tablets administered orally
219373186|NCT02654002|DRUG|Placebo|Tablets administered orally
219373187|NCT06398873|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300mg/2 weeks
219373188|NCT06376721|DRUG|Linperlisib|Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
219373189|NCT06376721|DRUG|Camrelizumab|Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
219373190|NCT06376721|DRUG|Pegaspargase|"Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee."
219373191|NCT06376721|DRUG|Dexamethasone|Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
219557760|NCT04799223|OTHER|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
219557761|NCT00367536|DRUG|bazedoxifene/conjugated estrogens combination tablet|
219754294|NCT04194242|DRUG|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
219754295|NCT00536289|DEVICE|Blunt needle|Blunt tipped suture needle
219373192|NCT00891202|DRUG|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
219373193|NCT00891202|DRUG|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
219373194|NCT06264609|DRUG|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
219373195|NCT06264609|DRUG|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
219373196|NCT06264609|DRUG|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
219373197|NCT02992002|OTHER|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
219373198|NCT06042673|DIETARY_SUPPLEMENT|Pomegranate seed oil|10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
219373199|NCT06042673|DIETARY_SUPPLEMENT|Mixed vegetable oil|50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
219373200|NCT04108429|BEHAVIORAL|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
219373201|NCT04947644|PROCEDURE|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
219373202|NCT04947644|PROCEDURE|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
219373203|NCT06253416|OTHER|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
219373204|NCT06253416|OTHER|Control|exercise freely and without supervision with their daily routine
219373205|NCT01216774|OTHER|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
219373206|NCT03951636|PROCEDURE|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
219373207|NCT03951636|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
219373208|NCT03951636|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
219373209|NCT04348448|DRUG|Canakinumab 150 MG/ML [Ilaris]|COVID-19
219373210|NCT00546975|DIETARY_SUPPLEMENT|Resource Support®|
219373211|NCT00546975|DIETARY_SUPPLEMENT|Resource Protein®|
219373212|NCT00546975|DIETARY_SUPPLEMENT|Placebo|
219373213|NCT02006992|OTHER|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
219373214|NCT02006992|OTHER|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
219373215|NCT02257424|DRUG|Trametinib 2 mg daily|
219373216|NCT02257424|DRUG|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
219373217|NCT02257424|DRUG|dabrafenib 150 mg orally twice a day|
219373218|NCT01668368|OTHER|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
219754296|NCT06564623|DRUG|mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.
219754297|NCT06564623|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.
219754298|NCT06564623|DRUG|Tremelimumab|Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
219754299|NCT06851585|DEVICE|CathIRU Cohort|All adult patients requiring a CVP in an emergency department can participate in the study
219191668|NCT05674357|BEHAVIORAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
219191669|NCT06039852|OTHER|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
219191670|NCT05236062|BEHAVIORAL|Exercise|aerobic and resistance exercise
219191671|NCT05236062|BEHAVIORAL|Attention control|stretching
219191672|NCT04003246|RADIATION|Thoracic RT and Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation
219191673|NCT04003246|DRUG|Consolidative Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year
219191674|NCT06804772|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
219191675|NCT06804772|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
219191676|NCT06804772|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
219191677|NCT06805708|BEHAVIORAL|Sleep hygiene training programme|"A programme focusing on cognitive-behavioural counselling. The programme will be delivered in 12 sessions of 30 minutes each (intensive phase: 1 session per week for 3 weeks; maintenance phase: 1 session every 2 weeks). After each meeting, the research group members will provide a short-written report reflecting the main discussion topics, the degree of participation, and the group's position in the participatory action research cycle. The discussion topics will be:~1. Management of sleep hygiene in schoolchildren, families and teachers:~   * Surveys (quantitative approach)~  * Focus groups (qualitative approach)~  * The study will identify the health assets~2. Educational elements"
219191678|NCT06804967|DEVICE|virtual reality relaxation headset|No headset will be used
219191679|NCT06577259|DRUG|BMS-986435|Specified dose on specified days
219191680|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1\) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
219191681|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
219191682|NCT03914742|DRUG|Temozolomide|Given PO
219191683|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
219191684|NCT06627413|DRUG|Lumateperone Capsule|Lumateperone 42 mg capsule, oral administration
219191685|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E2 IM injection
219191686|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E3 IM injection
219191687|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X2 IM injection
219191688|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X5 IM injection
219191689|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
219191690|NCT06805292|OTHER|Acacia catechu|local delivery of acacia catechu gel in patient with chronic periodontitis stage 2
219191691|NCT06805292|OTHER|Low Level Laser Therapy|low-level laser as an adjunctive therapy in patient with chronic periodontitis stage 2
219191692|NCT06805292|OTHER|phase 1 therapy chronic periodontitis|patient with chronic periodontitis stage 2 will go for phase one therapy only
219191693|NCT06805292|OTHER|local drug delivary acacia +LLL|pateient with chronic periodontitis treated with LLL +acacia catehu gel
219191694|NCT06572397|DRUG|H-1337 1.0%|ophthalmic solution
219191695|NCT05426395|DRUG|Vitamin B12 2.6 µg|There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
219191696|NCT05426395|DRUG|Vitamin B12 10 µg|There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
219191697|NCT05426395|DRUG|Vitamin B12 50 µg|The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
219191698|NCT06805357|OTHER|Chest Physiotherapy by Rib Cage Compressions (RCC)|Bimanual Rib Cage Compressions (RCC) applied to the thorax only, with patients in a standardized position (supine with the head of the bed elevated to 35 degrees). The intervention is standardized in terms of the direction of force (posterior and downward) and the characteristics of the compression (brief and vigorous compressions at the beginning of expiration).
219191699|NCT06804148|DEVICE|Myval Transcatheter Heart Valve|The Myval TAVR bioprothesis is a balloon-expandable THV developed by Meril Lifesciences, which has novel operator friendly design features to improve deliverability and aid precise deployment.
219191700|NCT06425536|OTHER|Home use|Home use twice a day
219191701|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
219191702|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
219373219|NCT01213030|DRUG|[F-18] FMISO|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
219373220|NCT01213030|DRUG|[F-18] HX4|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
219754300|NCT06758869|OTHER|Control|Participants will consume the Base DGA diet with a standardized non-pulse product snack.
219754301|NCT06758869|OTHER|Whole Chickpeas|Participants will consume an adjusted DGA diet with a standardized whole chickpea snack.
219187734|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
219000892|NCT06418724|DRUG|Cemiplimab|Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
219000893|NCT05127005|PROCEDURE|Trapeziectomy|Surgical excision of trapezoideum
219000894|NCT05127005|PROCEDURE|Sham|Skin incision only
219000895|NCT01004627|PROCEDURE|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
219191703|NCT04977869|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
219191704|NCT04977869|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
219191705|NCT05552443|DRUG|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
219191706|NCT05552443|DRUG|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
219191707|NCT05552443|DRUG|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
219191708|NCT05552443|DRUG|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
219191709|NCT05552443|DRUG|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
219191710|NCT05552443|DRUG|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
219191711|NCT05552443|DRUG|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
219191712|NCT05552443|DRUG|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
219191713|NCT05300035|DRUG|Recombinant human monoclonal antibody (bNAbs)|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
219191714|NCT05300035|DRUG|Placebo|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
219191715|NCT04572295|DRUG|E7090|E7090 oral tablet.
219191716|NCT04572295|DRUG|Fulvestrant|Fulvestrant intramuscular injection.
219191717|NCT04572295|DRUG|Exemestane|Exemestane oral tablet.
219191718|NCT04132518|DEVICE|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
219191719|NCT03092453|BIOLOGICAL|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
219191720|NCT03092453|DRUG|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
219191721|NCT03092453|DRUG|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
219191722|NCT06835062|BEHAVIORAL|Recommendations for Enhancing General Well-Being|"* Wear comfortable clothing and lie on your back. Place one hand on your abdomen. As you inhale through your nose, direct your breath towards your hand, and exhale through your mouth.~* In the same position, place one hand on your abdomen, inhale through your nose, and expand your belly under your hand. As you exhale through your mouth, purse your lips and blow out the air from your lungs.~* Engage in brisk walking at least three times a week.~* Perform stretching exercises similar to yoga; try forward bends while standing and sitting.~* Stay active throughout the month; you can dance, swim, or ride a bike.~* Reduce your intake of tea and caffeine.~* Increase your consumption of milk.~* Drink plenty of water.~* Reduce your intake of sugar-rich snacks such as chocolate.~* Prioritize foods rich in calcium, as well as vitamins A, B, and E."
219191723|NCT06835062|OTHER|Clinical Pilates|"In addition to the general well-being recommendations, the Clinical Pilates Group participated in a total of 16 face-to-face, clinically based Pilates exercise training sessions over eight weeks, with two sessions per week, each lasting 50 minutes. The exercise training started at the end of the menstrual cycle.~The clinical Pilates-based exercise program applied to the group was designed by the researcher. The number of repetitions, levels, and variations of the exercises were progressively adjusted by the researcher according to the participants' conditions.~During the first session, the principles of clinical Pilates were explained, following the BASI Pilates method as described by Isacowitz. Participants were taught alignment, breathing, and core engagement techniques."
219191724|NCT06836102|DIETARY_SUPPLEMENT|Orange|usage of orange peel extract in gel layer in treatment of epistaxis
219191725|NCT06833879|DEVICE|Activity Tracking Watch|Device includes a wristwatch that tracks physical activity and a data storage unit that transmits data to a central database.
219373221|NCT05863611|OTHER|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
219373222|NCT02486861|OTHER|optical coherence tomography|
219373223|NCT06381193|DIETARY_SUPPLEMENT|Probiotic|oral, daily
219373224|NCT06381193|DIETARY_SUPPLEMENT|Prebiotic|oral, daily
219373225|NCT06381193|DIETARY_SUPPLEMENT|Probiotic + Prebiotic|oral, daily
219373226|NCT06381193|DIETARY_SUPPLEMENT|Placebo|oral, daily
219373227|NCT02246972|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
219373228|NCT01654679|DEVICE|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
219373229|NCT01654679|OTHER|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
219373230|NCT00268645|DRUG|Insulin Glargine|
219373231|NCT06960330|OTHER|Wearable Biofeedback + Virtual Physiotherapy|Participants will use wearable devices designed to monitor physiological parameters and provide real-time feedback during exercises. The intervention includes remote guidance from physiotherapists via virtual consultations.
219373232|NCT06960330|OTHER|Standard Physiotherapy Exercises|Participants will be given printed or video instructions for standard physiotherapy exercises commonly used for arthritis and fibromyalgia management, without any digital monitoring or remote guidance.
219373233|NCT01587950|DRUG|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
219373234|NCT01587950|DRUG|Placebo|Sterile Water
219373235|NCT02059083|BEHAVIORAL|Heart rate variability biofeedback|
219373236|NCT02059083|BEHAVIORAL|CBT|
219373237|NCT01914952|DIETARY_SUPPLEMENT|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
219373238|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
219373239|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid mixed in water|0.8 g HMB free acid in water
219373240|NCT01914952|DIETARY_SUPPLEMENT|CaHMB in water|1.0 g CaHMB powder mixed in water
219373241|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid|0.8 g HMB free acid
219373242|NCT03313050|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
219373243|NCT03313050|BIOLOGICAL|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
219373244|NCT03313050|BIOLOGICAL|polysaccharide|23-valent pneumococcal polysaccharide vaccine
219373245|NCT00094614|DRUG|Atropine|
219373246|NCT02158559|DRUG|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
219373247|NCT02158559|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
219373248|NCT06599736|DEVICE|RhinAer Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810).
219754302|NCT06758869|OTHER|Puréed Chickpeas|Participants will consume an adjusted DGA diet with a standardized puréed chickpea snack.
219373249|NCT04211337|DRUG|Selpercatinib|Administered orally
219373250|NCT04211337|DRUG|Cabozantinib|Administered orally
219373251|NCT04211337|DRUG|Vandetanib|Administered orally
219373252|NCT04630379|OTHER|Palliative Therapy|Visit with palliative care team
219373253|NCT04630379|OTHER|Quality-of-Life Assessment|Ancillary studies
219373254|NCT04630379|OTHER|Supportive Care|Visit with neuro-oncologist
219373255|NCT04630379|OTHER|Survey Administration|Complete survey
219373256|NCT01722513|DRUG|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
219373257|NCT03970343|DEVICE|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~1. Optimizer Smart or Optimizer Smart Mini~2. Vesta Charger or Guardio Charger~3. Two commercially available intravascular leads"
219373258|NCT05925205|PROCEDURE|Muscle energy technique combined with the physical therapy program.|A manual therapy technique
219373259|NCT05925205|PROCEDURE|Strain counterstrain technique combined with the physical therapy program|A manual therapy technique
219373260|NCT05925205|PROCEDURE|The physical therapy program|Electrotherapy and exercise.
219373261|NCT01422005|OTHER|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
219373262|NCT01422005|OTHER|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
219373263|NCT01189383|BIOLOGICAL|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
219373264|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
219373265|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
219754303|NCT06758869|OTHER|100% Chickpea Flour Product|Participants will consume an adjusted DGA diet with a standardized 100% chickpea flour product snack.
219373266|NCT04977037|DEVICE|Active tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
219373267|NCT04977037|DEVICE|Sham tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
219373268|NCT00261235|BEHAVIORAL|Supported Employment|
219373269|NCT00261235|BEHAVIORAL|Using Strengths in Employment System (USES)|
219373270|NCT06587100|DEVICE|Fitbit|Participants will wear Fitbit device
219373271|NCT06587100|DEVICE|Apple HealthKit-based devices|Participants will wear personal device and share data with study team.
219373272|NCT06767969|DRUG|Acetaminophen|Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
219373273|NCT00875069|OTHER|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
219373274|NCT02963376|DRUG|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
219373275|NCT02963376|DRUG|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
219373276|NCT02963376|DRUG|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
219373277|NCT02963376|DRUG|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
219373278|NCT02963376|DRUG|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
219373279|NCT02963376|DRUG|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
219373280|NCT02093702|BEHAVIORAL|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
219373281|NCT02093702|BEHAVIORAL|Unstructured Physical Activity and Exercise Education|
219373282|NCT05777733|DRUG|n-acetylcystine|Single daily oral administration of N\_acetylcystein on dose 10mg /kg/day
219373283|NCT04920032|DRUG|TAS-102|Given PO
219373284|NCT04920032|DRUG|Irinotecan|Given IV
219373285|NCT04920032|COMBINATION_PRODUCT|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
219373286|NCT04920032|DIAGNOSTIC_TEST|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
219373287|NCT02847598|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
219373288|NCT02847598|DRUG|Placebo|Administered as specified in the treatment arm.
219373289|NCT02848833|DRUG|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
219373290|NCT02848833|DRUG|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
219373291|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
219373292|NCT05351476|BEHAVIORAL|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
219754304|NCT06819306|DEVICE|Hedia Diabetes Assistant|Hedia Diabetes Assistant is an insulin bolus calculator app designed to calculate an insulin bolus dose recommendation for people with type 1 or type 2 diabetes on rapid-acting insulin treatment.
219373293|NCT05351476|BEHAVIORAL|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
219373294|NCT04855773|OTHER|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
219754305|NCT06898996|OTHER|Fecal immunochemical test|Detects blood in stool
219373295|NCT04855773|DEVICE|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
219373296|NCT06856707|DEVICE|Use of the MIRA Surgical System during surgery|Use of the MIRA Surgical System to perform robotically assisted colorectal surgery.
219373297|NCT00369031|BIOLOGICAL|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
219373298|NCT00369031|BIOLOGICAL|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
219373299|NCT00369031|BIOLOGICAL|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
219373300|NCT05651516|DRUG|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
219373301|NCT04167345|DRUG|VX-814|Tablet for oral administration.
219373302|NCT04167345|DRUG|Placebo|Placebo matched to VX-814 for oral administration.
219373303|NCT03337256|DIAGNOSTIC_TEST|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~* 75 2.5 Haemoglobin(g/L)~* 10.0 0 \<9.9 2 Systolic blood pressure (mmHg)~* 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0~* 100 1.5 Creatinine (mmol/L) \<200 0~* 200 3.5 Number of blood transfusion 0 0~  1 1.5~* 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
219373304|NCT06842524|DRUG|Dihydroartemisinin|Dihydroartemisinin tablets 40mg tid po for 90 days
219373305|NCT06842524|DRUG|Placebo|Identical placebo tid for 90 days
219373306|NCT06796608|BEHAVIORAL|Behavioral Activation|Behavioral activation is an evidence-based intervention based on the idea that depression leads to withdrawal from rewarding activities, which sustains or exacerbates depression, and breaks this cycle by increasing the frequency with which people engage in rewarding activities regardless of their motivation. Like those with depression, people living with advanced cancer may reduce or stop participation in meaningful life activities resulting in decreased positive emotion and worse quality of life. The goal of this intervention is to adapt and test a fully remote technology-supported behavioral activation intervention aimed at supporting patients with advanced cancer to optimize the quality of their remaining years of life.
219373307|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin 5% cream will be given as a single application
219373308|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin Cream will be given as twice application
219373309|NCT06896929|DRUG|Ivermectin 200 µg/kg|Group C will be given Tab Ivermectin
219373310|NCT04572009|OTHER|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
219373311|NCT04572009|OTHER|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
219373312|NCT06910787|DEVICE|VR-directed BGBT|VR-directed BGBT using the Oculus Meta Quest 3 VR headset will be delivered using the Synergi application. The program includes 4-weeks of daily self-led activities using 5 virtual modules: (1) education (2) two interactive games (3) breathing exercises (4) gut-directed meditation and (5) gastroenterology-specific Cognitive behavioral therapy (CBT). Participants will also receive standard care. On day 1, intervention arm participants will undergo a brief in-person or virtual (i.e., zoom or Microsoft teams) training with study staff to learn how to use the VR headset and access intervention modules. On day 1 participants will be asked to explore each of the program modules to achieve initial familiarity. Participants will be encouraged to use the VR-BGBT program for at least 15 minutes daily, but at minimum 3-4 days each week. Additionally, study assessments will be completed at baseline, 2-weeks, 4-weeks, and 8-weeks, with an interview within 1-2 weeks of completing the program.
219373313|NCT06910787|OTHER|E-TAU|Participants will receive standard of care, as directed by the participant's gastroenterologist. Participants will also receive an educational video and fact sheet on pain in IBD. This will be 4-weeks with study assessments at baseline, 2-weeks, and 4-weeks, 8-weeks.
219373314|NCT05832918|OTHER|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
219373315|NCT03598244|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219373316|NCT03598244|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219373317|NCT03598244|DRUG|Savolitinib|Given PO
219373318|NCT03598244|PROCEDURE|X-Ray Imaging|Undergo X-ray imaging
219373319|NCT03270215|PROCEDURE|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
219373320|NCT06858709|PROCEDURE|True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment|"Participants will receive a total of 8 treatments over 6 weeks, with twice a week treatments for the first and the forth weeks and weekly treatment for the remaining weeks.The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. In the meantime, participants will receive the same standard anti-CIPN treatments."
219754306|NCT06903000|DEVICE|a percussion massage gun|Participants in this group will receive percussion-based vibration therapy applied using a percussion massage device (Compex Fix 2.0) with a soft head attachment. Therapy will target trapezius, levator scapula, and cervical paravertebral muscles along their origin-insertion lines for 3 minutes per muscle group.
219373321|NCT06858709|PROCEDURE|Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid de qi sensation. In the meantime, participants will receive the same standard anti-CIPN treatments."
219373322|NCT06935539|DEVICE|Cryoneurolysis|"The iovera° system consists of a reusable, portable Handpiece, along with single-patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study."
219373323|NCT06935539|DEVICE|Radiofrequency ablation|Radiofrequency ablation is a minimally invasive procedure that uses heat at the lumbosacral spine to destroy the target spinal nerves.
219373324|NCT06935773|OTHER|High-Fidelity Simulated Emergency Training|A high-fidelity simulation-based in-service training program focusing on emergency scenarios. The training includes simulated resuscitation cases, teamwork drills, and post-simulation debriefings conducted at Chang Bing Show Chwan Memorial Hospital.
219373325|NCT06935773|OTHER|No intervention (observational study)|Participants in this arm will not receive any training or simulation intervention during the study period.
219373326|NCT06935929|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
219373327|NCT06937021|OTHER|Art and philosophy intervention (APBI)|8 session intervention delivered during school time. Each session involves an art activity with a corresponding philosophical discussion.
219373328|NCT06937021|OTHER|Art based intervention (ABI)|A 8 session intervention delivered during school time. Each session involve a creative arts activity.
219373329|NCT06936228|DIETARY_SUPPLEMENT|Propolis spray|The product obtained from 30% pure Anatolian propolis was applied once daily.
219373330|NCT06936098|PROCEDURE|CRLM surgery|Surgical resection of colorectal cancer liver metastasis (CRLM) involves the removal of metastatic lesions from the liver. This procedure is aimed at improving survival rates and reducing tumor burden in patients diagnosed with CRLM. The resection is performed to treat liver metastasis, and clinical outcomes, such as progression-free survival (PFS) and overall survival (OS), are assessed post-surgery to determine treatment efficacy.
219373331|NCT06936397|BEHAVIORAL|Cognitive Remediation Therapy|CRT is a structured behavioral intervention consisting of weekly 60-minute sessions for 12 weeks. The therapy includes tasks to enhance cognitive skills such as attention, memory, executive function, and emotional regulation using computer-based training and therapist-guided exercises.
219373332|NCT06936644|DRUG|IBI351+AK112|The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in first-line treatment
219373333|NCT06935955|DIAGNOSTIC_TEST|upper endoscopy|"All subjects will be asked to complete a medical history questionnaire, followed by physical examination (height, body weight, waist circumference and blood pressure), and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, with assessment of chronic and acute gastritis, atrophic gastritis and metaplasia. The endoscopist will obtain five biopsies samples, two from the antrum, two from the corpus and one from incisura.~All biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two sets of tissue sections will be stained: one with hematoxylin and eosin (H\&E) and the other with Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atro"
219373334|NCT02908399|DEVICE|FLIR ONE|
219373335|NCT03690154|DRUG|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
219373336|NCT06416501|OTHER|Mode of detection|Mode of detection
219373337|NCT02536287|PROCEDURE|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
219373338|NCT02536287|PROCEDURE|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1\*1 \*1 mm,and placed into the subcutaneous of the forearm.
219373339|NCT06087835|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
219373340|NCT06087835|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized to
219373341|NCT03496506|DRUG|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
219373342|NCT03496506|DRUG|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
219373343|NCT05121415|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219373344|NCT05564767|DIETARY_SUPPLEMENT|B. adolescentis Bif-038|B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
219373345|NCT05564767|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
219373346|NCT05564767|DIETARY_SUPPLEMENT|Placebo|Placebo capsule delivered orally once daily
219187735|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
219187736|NCT04453774|DEVICE|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
219187737|NCT06308198|DRUG|AGN-151586|Intramuscular Injections
219187738|NCT06308198|DRUG|Placebo|Intramuscular Injections
219187739|NCT05483933|DRUG|Pegylated Liposomal Doxorubicin + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
219187740|NCT05483933|DRUG|Mirvetuximab + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
219187741|NCT06353022|DRUG|Teclistamab|Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
219187742|NCT06353022|DRUG|Talquetamab|Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
219187743|NCT06353022|DRUG|Lenalidomide|"Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration."
219187744|NCT06353022|DRUG|Bortezomib|Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
219187745|NCT06353022|DRUG|Daratumumab|Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
219187746|NCT06353022|DRUG|Dexamethasone|"Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22"
219187747|NCT05079698|DRUG|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
219187748|NCT05079698|PROCEDURE|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
219187749|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
219187750|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
219187751|NCT05763719|BEHAVIORAL|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
219187752|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
219187753|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
219187754|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
219187755|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
219187756|NCT05412771|PROCEDURE|Hysteroscopy|Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes
219187757|NCT05840315|DIETARY_SUPPLEMENT|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
219187758|NCT05840315|PROCEDURE|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
219187759|NCT05840315|PROCEDURE|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
219187760|NCT05840315|PROCEDURE|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trial 1, Third subtrial will perform progressive strength training for the gluteal muscles is carried out in form of hip abduction, using rubber bands, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press.~Hip abduction will be performed from a standing position with a straight arm length from a wall, supporting the wall. The participant will be instructed to abduct the hip facing the wall until the foot is in contact with the wall, and then back until it touches the standing leg.~Progression will be placing a rubber band just proximal to the knee with resistances being: yellow= light, red= moderate, blue= heavy.~further progression will be placing the rubber band around the ankles using the same progression as above."
219187761|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
219187762|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
219187763|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
219187764|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
219187765|NCT03571763|OTHER|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
219187766|NCT00513760|DIETARY_SUPPLEMENT|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
219187767|NCT00513760|DIETARY_SUPPLEMENT|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
219187768|NCT00513760|DIETARY_SUPPLEMENT|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
219187769|NCT06057454|DRUG|R-5280|Modified Superior Starch
219187770|NCT06057454|OTHER|Placebo|Food Grade Starch
219187771|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
219187772|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
219187773|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
219187774|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
219187775|NCT00120263|PROCEDURE|Plasma Exchange|
219187776|NCT02476838|PROCEDURE|Hand Transplantation|microvascular VCA transplant
219373347|NCT03751332|DRUG|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
219373348|NCT04850183|BEHAVIORAL|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
219373349|NCT05590572|DRUG|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
219373350|NCT05590572|DRUG|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
219373351|NCT05590572|DRUG|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
219373352|NCT05105243|DRUG|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
219187777|NCT03832569|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
219187778|NCT05593900|BEHAVIORAL|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
219187779|NCT05816603|DEVICE|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
219187780|NCT05816603|DEVICE|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
219187781|NCT05422638|BEHAVIORAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
219187782|NCT05422638|BEHAVIORAL|PCT|8-week health promotion group focused on providing support and facilitating problem solving
219187783|NCT05312008|DRUG|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
219187784|NCT05312008|DRUG|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
219187785|NCT05128942|DRUG|Tildacerfont|Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
219187786|NCT02844465|DEVICE|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
219187787|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
219187788|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
219187789|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
219187790|NCT06345430|DEVICE|Exopulse Molli-Suit (Wearable Technological Device)|After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
219187791|NCT06134752|OTHER|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
219373353|NCT06369779|DEVICE|TM Fill in combination with TM Flow|The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
219373354|NCT04892563|PROCEDURE|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
219373355|NCT04892563|DRUG|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
219373356|NCT05850741|DEVICE|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
219373357|NCT00960076|DRUG|Saxagliptin|5mg oral tablet once daily
219373358|NCT00960076|DRUG|Metformin XR|500mg oral tablet once daily
219373359|NCT00960076|DRUG|Metformin XR|750mg, 2 tablets once daily
219373360|NCT00500266|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
219373361|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
219373362|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
219373363|NCT01431287|DRUG|tiotropium|low dose or high dose
219373364|NCT01431287|DRUG|tiotropium|low dose or high dose
219373365|NCT01431287|DRUG|olodaterol|one dose only
219373366|NCT01431287|DEVICE|Respimat|Respimat inhaler
219373367|NCT02583984|PROCEDURE|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
219373368|NCT02583984|PROCEDURE|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
219373369|NCT00136864|PROCEDURE|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
219373370|NCT01365221|DRUG|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
219373371|NCT01365221|DRUG|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
219373372|NCT01622426|DIETARY_SUPPLEMENT|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
219373373|NCT01622426|DIETARY_SUPPLEMENT|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
219373374|NCT05809934|DRUG|AZD2693|AZD2693 solution SC once per month
219373375|NCT05809934|OTHER|Placebo|Sodium chloride 0.9% solution SC once per month
219373376|NCT01150110|DEVICE|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
219373377|NCT02271490|OTHER|Acrosome Reaction induction|
219373378|NCT02271490|OTHER|capacitation in incubation medium prior to ICSI|
219187792|NCT06134752|OTHER|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
219373379|NCT03156530|DEVICE|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
219373380|NCT03156530|OTHER|Control|Not receive stimulation.
219373381|NCT00968266|BEHAVIORAL|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
219373382|NCT04537611|DIAGNOSTIC_TEST|dHb contrast and gadolinium contrast imaging|see arm description
219373383|NCT00000264|DRUG|30% Nitrous oxide|
219373384|NCT00000264|OTHER|0.35 g/Kg ethanol|
219373385|NCT00000264|OTHER|0.7 g/Kg ethanol|
219373386|NCT00000264|OTHER|0 g/Kg ethanol|
219373387|NCT04873687|DEVICE|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
219373388|NCT00393562|DRUG|modafinil|
219373389|NCT00393562|DRUG|methylphenidate|
219373390|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT with post procedure curettage
219373391|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT without post procedure curettage
219373392|NCT04360304|DEVICE|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
219373393|NCT05973409|DEVICE|scleral lens|scleral lens with and without hydra-peg coating
219373394|NCT02714530|DRUG|Erlotinib|Tarceva daily during radiotherapy course
219373395|NCT02714530|RADIATION|Radiation|Radiotherapy
219373396|NCT02509325|DEVICE|Parkinson's Kinetigraph|
219373397|NCT05811195|DEVICE|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
219373398|NCT05811195|DEVICE|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
219373399|NCT04942548|OTHER|Ketogenic Diet|Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
219373400|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
219373401|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
219373402|NCT01322828|PROCEDURE|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
219373403|NCT02109029|DRUG|Insulin Peglispro|Administered IV
219373404|NCT02109029|DRUG|Human Insulin|Administered IV
219373405|NCT01902108|DRUG|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
219373406|NCT01902108|DRUG|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
219373407|NCT01858103|DRUG|BMN 110|
219187793|NCT03184233|PROCEDURE|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
219187794|NCT03184233|PROCEDURE|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
219187795|NCT04901988|DRUG|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
219187796|NCT04357873|DRUG|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
219187797|NCT04109027|BEHAVIORAL|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
219187798|NCT04109027|BEHAVIORAL|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
219187799|NCT03828786|PROCEDURE|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
219187800|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
219187801|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
219187802|NCT05182775|PROCEDURE|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
219187803|NCT04738812|DRUG|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
219187804|NCT04738812|DRUG|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
219187805|NCT05007470|DRUG|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
219187806|NCT05007470|OTHER|Placebo|100 mg sugar
219187807|NCT05776459|DRUG|AC102 gel|Drug: AC102 Single intratympanic injection
219187808|NCT05776459|DRUG|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
219187809|NCT05776459|OTHER|Placebo Tablets|Placebo Tablets taken daily by mouth
219187810|NCT05776459|OTHER|Placebo gel|Placebo Single intratympanic injection
219187811|NCT06528158|OTHER|sibling group|"The group will be based on a systemic model and led by two child psychiatrists trained in family and multi-family therapy, who will not subsequently be involved in the data analysis. It will consist of 4 sessions of 1h30, spread over a period of 2 months, with a maximum of 8 participants per session. The first 3 sessions will be spaced 15 days apart, and the last session will take place 3 weeks apart from the third session.~The characteristics of the group (frequency, duration, number of sessions and participants) were built on data from the literature as well as on clinical feedback from a first pilot group conducted in January and February 2024 on the Toulouse pediatric unit by the two therapists who will lead the groups during the study."
219187812|NCT03674684|OTHER|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
219187813|NCT02551068|OTHER|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
219187814|NCT02551068|OTHER|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
219187815|NCT03819153|DRUG|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
219187816|NCT03819153|DRUG|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
219373408|NCT04039139|BEHAVIORAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
219373409|NCT04039139|BEHAVIORAL|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
219373410|NCT02451956|DRUG|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
219373411|NCT02451956|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
219373412|NCT00110305|DRUG|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
219373413|NCT00110305|DRUG|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
219373414|NCT00110305|DRUG|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
219373415|NCT00110305|DRUG|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
219373416|NCT00110305|DRUG|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
219373417|NCT00142506|DRUG|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
219373418|NCT00142506|DRUG|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
219373419|NCT05290467|BEHAVIORAL|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
219373420|NCT00033735|DRUG|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
219373421|NCT00033735|DRUG|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
219373422|NCT00581503|DEVICE|diagnostic|oct imaging
219373423|NCT06131645|DIAGNOSTIC_TEST|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
219373424|NCT04128098|OTHER|Evaluation|"* Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~* 3D analysis of locomotion and posture~* Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
219373425|NCT04128098|OTHER|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
219373426|NCT04128098|OTHER|Rehabilitation care program|"* Personalized global exercises (aerobics) on ergometers~* Muscle strengthening with resistance~* Balneotherapy~* Learning health skills related to their condition (therapeutic education)~* Personal and group motivational interviews~* Nutritional advice~* Relaxation session"
219373427|NCT05617885|DRUG|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
219373428|NCT05617885|DRUG|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
219373429|NCT05617885|DRUG|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
219373430|NCT05617885|DRUG|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
219373431|NCT05617885|DRUG|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
219373432|NCT04776850|DRUG|Bortezomib|Given IV
219373433|NCT04776850|DRUG|Busulfan|Given IV
219373434|NCT04776850|DRUG|Cyclophosphamide|Given IV
219373435|NCT04776850|DRUG|Dexamethasone|Given IV
219373436|NCT04776850|DRUG|Fludarabine Phosphate|Given IV
219373437|NCT04776850|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219373438|NCT04776850|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
219373439|NCT04776850|DRUG|Mycophenolate Mofetil|Given IV or PO
219373440|NCT04776850|PROCEDURE|Plasmapheresis|Undergo plasmapheresis
219373441|NCT04776850|BIOLOGICAL|Rituximab|Given IV
219373442|NCT04776850|DRUG|Tacrolimus|Given IV or PO
219373443|NCT01673048|PROCEDURE|3-Nail-ESIN in femoral shaft fractures|
219373444|NCT03793478|DRUG|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
219373445|NCT03793478|DRUG|Fludarabine|30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
219373446|NCT03793478|DRUG|Cytarabine|"2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
219373447|NCT03793478|DRUG|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
219373448|NCT03793478|DRUG|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
219373449|NCT04385498|BEHAVIORAL|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
219373450|NCT04385498|BEHAVIORAL|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
219373451|NCT04759898|DEVICE|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
219373452|NCT04759898|DEVICE|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
219187817|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
219187818|NCT06481319|BEHAVIORAL|Infertility Patient Navigator|Assistance with infertility evaluation including scheduling appointments
219187819|NCT03397654|DRUG|Pembrolizumab|Pembrolizumab solution
219187820|NCT03397654|COMBINATION_PRODUCT|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
219187821|NCT00206791|DEVICE|MBCP-Gel (tm)|MBCPGel 5ml
219187822|NCT00206791|DEVICE|MBCP Gel|MBCPGel 5ML
219187823|NCT06469788|BEHAVIORAL|Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences|Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD
219557762|NCT04487964|DIETARY_SUPPLEMENT|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
219187824|NCT06469788|BEHAVIORAL|Video on the importance of good oral health for patients with AIRD|Participants will watch video on the importance of good oral health in AIRD patients.
219187825|NCT06469788|BEHAVIORAL|Brochure on COVID-19 vaccination in AIRD patients|Participants
219187826|NCT06469788|BEHAVIORAL|Patient Navigation|Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD
219187827|NCT06469788|BEHAVIORAL|Brochure on the importance of good oral health in AIRD patients|Participants will receive a brochure on the importance of good oral health in AIRD patients.
219373453|NCT04759898|DEVICE|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
219373454|NCT05983432|DRUG|BL-B01D1|BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
219373455|NCT04724590|RADIATION|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
219373456|NCT03215966|COMBINATION_PRODUCT|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
219373457|NCT03215966|DRUG|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
219373458|NCT03215966|DRUG|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
219373459|NCT01871506|BEHAVIORAL|Standard Care (SC)|"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
219373460|NCT01871506|BEHAVIORAL|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
219373461|NCT01973257|PROCEDURE|imaging diagnostics|
219373462|NCT04239417|OTHER|Graduated abdominal strengthening exercises|"1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing"
219373463|NCT04239417|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
219373464|NCT04239417|COMBINATION_PRODUCT|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
219373465|NCT01028352|DRUG|Duloxetine|"Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
219373466|NCT00006122|DRUG|cytarabine|
219373467|NCT00006122|DRUG|etoposide|
219373468|NCT00006122|DRUG|gemtuzumab ozogamicin|
219373469|NCT00006122|DRUG|idarubicin|
219373470|NCT00006122|DRUG|mitoxantrone hydrochloride|
219373471|NCT01393587|PROCEDURE|Taking blood samples|
219373472|NCT05381402|OTHER|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
219373473|NCT06325449|BEHAVIORAL|STREAM program|The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
219373474|NCT03389243|DRUG|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
219373475|NCT03389243|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
219373476|NCT03389243|DRUG|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
219373477|NCT02461017|OTHER|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
219373478|NCT02461017|OTHER|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
219373479|NCT01906749|DRUG|Colchicine|0.5mg once daily orally
219373480|NCT01906749|DRUG|Placebo|
219373481|NCT03323749|COMBINATION_PRODUCT|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
219373482|NCT03323749|COMBINATION_PRODUCT|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
219373483|NCT03323749|COMBINATION_PRODUCT|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
219187828|NCT05043714|BIOLOGICAL|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
219373484|NCT00312013|DRUG|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
219187829|NCT04846933|GENETIC|WGS and RNA sequencing|
219187830|NCT04846933|GENETIC|circulating tumor DNA (ctDNA)|
219187831|NCT04846933|DIAGNOSTIC_TEST|FDG PET/CT imaging|
219187832|NCT01903330|DRUG|ERC1671|Given intradermally
219187833|NCT01903330|DRUG|GM-CSF|Given intradermally
219187834|NCT01903330|DRUG|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
219373485|NCT04470895|DIAGNOSTIC_TEST|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
219373486|NCT02468193|DRUG|Osilodrostat|Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
219373487|NCT06475404|BIOLOGICAL|verenafusp alfa 6 mg/kg|Single intravenous administration of 6 mg/kg of verenafusp alfa
219373488|NCT06475404|BIOLOGICAL|verenafusp alfa 9 mg/kg|Single intravenous administration of 9 mg/kg of verenafusp alfa
219373489|NCT06475404|BIOLOGICAL|verenafusp alfa 12 mg/kg|Single intravenous administration of 12 mg/kg of verenafusp alfa
219373490|NCT01306981|DRUG|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
219373491|NCT01306981|DRUG|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
219373492|NCT04674943|OTHER|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
219373493|NCT05951582|OTHER|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone"
219187835|NCT01903330|DRUG|Oral Control (Sucrose pill)|Given PO
219187836|NCT01903330|DRUG|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
219187837|NCT01903330|DRUG|Bevacizumab/Bevacizumab Biosimilar|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
219187838|NCT06466915|DRUG|Dexmedetomidine|Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
219187839|NCT06466915|DRUG|Propofol|Group Pofol received 1 mg/kg propofol IV before the extubation.
219187840|NCT05745727|DRUG|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
219187841|NCT05745727|DRUG|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
219187842|NCT06261021|DRUG|Ruxolitinib 1.5% cream|Topical application of Ruxolitinib 1.5% cream
219187843|NCT06261021|PROCEDURE|Application without occlusion in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
219373494|NCT05951582|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills"
219373495|NCT03312218|BEHAVIORAL|Spaced educational intervention|A spaced educational intervention will be provided to participants
219373496|NCT02046330|DEVICE|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
219187844|NCT06261021|PROCEDURE|Application under occlusion at night in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
219187845|NCT06261021|PROCEDURE|Application under occlusion at night in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
219187846|NCT06261021|PROCEDURE|Application without occlusion in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
219187847|NCT04271436|DEVICE|FDG PET/CT|A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.
219187848|NCT04271436|DEVICE|FLT PET/CT|. A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
219187849|NCT04271436|DEVICE|PET/MR|MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
219187850|NCT04271436|DRUG|[F-18] flurothymidine|-Radiopharmaceutical
219373497|NCT05055908|DRUG|Pemetrexed plus Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
219373498|NCT05055908|DRUG|Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
219373499|NCT05055908|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
219373500|NCT02169076|DEVICE|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
219373501|NCT01662089|DRUG|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
219373502|NCT01662089|DRUG|Placebo drug supplement|Placebo drug instead of Zinc supplement
219373503|NCT00714142|DRUG|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
219373504|NCT00714142|DRUG|15O-water|10-20 mCi, IV
219373505|NCT00714142|PROCEDURE|Positron Emission Tomography|PET Scan
219373506|NCT01760434|OTHER|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
219373507|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
219373508|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
219373509|NCT02306278|DRUG|gabapentin|gabapentin capsules 0.3g
219373510|NCT02306278|DRUG|vitamin capsules|vitamin B
219373511|NCT01887912|BIOLOGICAL|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
219373512|NCT01887912|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
219373513|NCT05650229|DRUG|KL1333|Twice daily
219373514|NCT05650229|DRUG|Placebo|Twice daily
219373515|NCT06423885|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219373516|NCT06423885|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
219373517|NCT04611217|OTHER|Dietary fiber: 10-25g|10-25 g/day of fiber
219373518|NCT04611217|OTHER|Dietary fiber: 5g|5 g/day of fiber
219373519|NCT02924896|DIETARY_SUPPLEMENT|Palm olein|60g of palm olein will be given in a milkshake at breakfast
219373520|NCT02924896|DIETARY_SUPPLEMENT|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
219373521|NCT02924896|DIETARY_SUPPLEMENT|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
219373522|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
219373523|NCT04053387|DRUG|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
219373524|NCT04709549|BEHAVIORAL|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
219373525|NCT04709549|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
219373526|NCT05067127|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219373527|NCT05067127|OTHER|Placebo|Sterile solution of equal volume to active arm
219187851|NCT04018053|DRUG|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
219373528|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
219373529|NCT06306417|DEVICE|acupuncture|acupuncture
219373530|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
219373531|NCT03180450|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
219373532|NCT03180450|DRUG|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
219373533|NCT04462536|DRUG|Placebo|Vehicle only
219373534|NCT04462536|DRUG|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
219373535|NCT06640114|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin)."
219373536|NCT06313944|DIAGNOSTIC_TEST|Registry|Clinical data collection of patients scheduled for on-label treatment
219373537|NCT04980898|DEVICE|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
219373538|NCT04980898|OTHER|Standard cares|Cleaning and monitoring
219373539|NCT06046482|DRUG|Pembrolizumab|Given by IV (vein)
219373540|NCT06046482|DRUG|Magrolimab|Given by IV (vein)
219373541|NCT06046482|DRUG|cetuximab|Given by IV (vein)
219373542|NCT06046482|DRUG|Docetaxel|Given by IV (vein)
219373543|NCT03624738|PROCEDURE|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
219373544|NCT04846309|RADIATION|Radiation|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic. Subjects with tumors identified by imaging as hypoxic will be treated with a higher dose of radiation therapy. Tumors will be defined as being hypoxic if FMISO accumulation occurs as demonstrated by standardized uptake value (SUV) uptake in the tumor.
219373545|NCT04846309|DRUG|FMISO PET CT|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
219373546|NCT01499173|BEHAVIORAL|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
219373547|NCT02109081|DRUG|Dexamethasone|
219373548|NCT02109081|DRUG|Placebo|
219373549|NCT03312192|DEVICE|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
219373550|NCT03312192|DEVICE|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
219373551|NCT03485989|OTHER|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
219373552|NCT03234335|OTHER|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
219373553|NCT02861170|BEHAVIORAL|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
219373554|NCT03198221|DRUG|Golytely|bowel preparation
219373555|NCT03198221|DRUG|Clenpiq|bowel preparation
219373556|NCT05662644|PROCEDURE|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
219373557|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Group (EBCM-G)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
219373558|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Individual (EBCM-I)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
219373559|NCT05057390|DIETARY_SUPPLEMENT|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
219373560|NCT04670705|OTHER|patients' characteristics|There was no intervention.
219373561|NCT02119715|DRUG|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
219373562|NCT02119715|DRUG|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
219373563|NCT02119715|DRUG|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
219373564|NCT01154101|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
219373565|NCT01154101|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
219373566|NCT02114190|BEHAVIORAL|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
219373567|NCT02114190|BEHAVIORAL|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
219373568|NCT06359184|OTHER|yoga|1 hour yoga practice 2 days a week for 8 weeks
219373569|NCT06359184|OTHER|control|no intervention for 8 weeks
219373570|NCT05946967|OTHER|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
219373571|NCT05946967|OTHER|Biofeedback only|Constipation patients will be given biofeedback treatment only
219373572|NCT03158402|OTHER|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
219373573|NCT00460382|DRUG|raltegravir potassium|400 mg twice a day
219373574|NCT00460382|DRUG|darunavir/ritonavir|2 pills of 300 mg twice a day
219373575|NCT00460382|DRUG|etravirine|2 pills of 100 mg twice a day
219373576|NCT00460382|DRUG|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
219373577|NCT06211855|DIAGNOSTIC_TEST|doppler assesment|In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
219373578|NCT04697914|DIAGNOSTIC_TEST|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
219373579|NCT02988856|DEVICE|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
219373580|NCT04125680|BEHAVIORAL|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
219373581|NCT06041243|OTHER|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
219373582|NCT01562028|DRUG|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
219373583|NCT01562028|DRUG|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
219373584|NCT02360098|OTHER|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
219373585|NCT00674011|DRUG|Bevacizumab|Given as part of standard of care or another research protocol
219373586|NCT03360929|DRUG|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
219373587|NCT01082276|DRUG|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
219373588|NCT00522860|PROCEDURE|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
219373589|NCT00522860|PROCEDURE|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
219373590|NCT04285918|PROCEDURE|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
219373591|NCT04080206|DRUG|188-0551 Spray|Applied topically twice daily for two weeks
219373592|NCT04080206|DRUG|RLD|Applied topically twice daily for two weeks
219373593|NCT03115450|DEVICE|Ultrasound|Type of imaging technology to look at organs and structures inside the body
219373594|NCT03115450|DEVICE|Pupilometer|A device that measures pupil size and how it changes.
219373595|NCT04938648|BEHAVIORAL|Pharmacist-led deprescribing intervention|1\) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
219373596|NCT03849729|DRUG|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
219373597|NCT03849729|OTHER|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
219373598|NCT00925847|DRUG|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
219373599|NCT06190483|DRUG|Diazepam 5 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
219373600|NCT06190483|DRUG|Ascorbic Acid 50 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
219373601|NCT05347823|DIAGNOSTIC_TEST|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
219373602|NCT05723055|DRUG|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
219373603|NCT05723055|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
219373604|NCT06508619|DEVICE|Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring|Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication
219373605|NCT06584110|OTHER|Buddy-Up Dyadic Physical Activity (BUDPA) program|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."
219373606|NCT06584110|OTHER|Usual care with waiting list|Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
219373607|NCT00808743|DRUG|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
219373608|NCT00808743|DRUG|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
219373609|NCT00808743|DRUG|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
219373610|NCT03135145|DEVICE|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
219373611|NCT03135145|OTHER|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
219373612|NCT03619213|DRUG|Dapagliflozin|10 mg tablets given once daily, per oral use.
219373613|NCT03619213|DRUG|Placebo|Placebo matching dapagliflozin 10 mg
219373614|NCT01002508|BIOLOGICAL|Influenza vaccine|One dose of influenza vaccine
219373615|NCT02296060|PROCEDURE|6 minutes walking test|
219373616|NCT00940004|BIOLOGICAL|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
219373617|NCT04000477|DEVICE|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
219373618|NCT04000477|DEVICE|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
219187852|NCT04018053|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
219187853|NCT04283149|DEVICE|EVO/EVO+ Visian ICL|The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
219373619|NCT02542176|OTHER|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
219373620|NCT02542176|OTHER|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
219373621|NCT00838357|DRUG|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
219373622|NCT01953952|PROCEDURE|therapeutic conventional surgery|Undergo transoral eHNS
219373623|NCT01953952|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219373624|NCT01953952|DRUG|cisplatin|Given IV
219373625|NCT01953952|PROCEDURE|quality-of-life assessment|Ancillary studies
219373626|NCT01953952|OTHER|laboratory biomarker analysis|Correlative studies
219373627|NCT04566484|DRUG|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
219373628|NCT04566484|DRUG|Normal Saline|Normal saline is the placebo
219373629|NCT00000148|PROCEDURE|Argon Laser Trabeculoplasty|
219187854|NCT02859038|PROCEDURE|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
219187855|NCT02859038|PROCEDURE|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
219187856|NCT05693675|DRUG|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
219187857|NCT05693675|DRUG|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
219187858|NCT05693675|DRUG|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
219187859|NCT06260254|RADIATION|Railway noise|Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.
219187860|NCT06260254|RADIATION|Low level railway vibration|36 single railway noise events at 0.5 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
219187861|NCT06260254|RADIATION|Intermediate level railway vibration|36 single railway noise events at 0.7 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
219187862|NCT06260254|RADIATION|High level railway vibration|36 single railway noise events at 0.9 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
219187863|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
219187864|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
219373630|NCT00000148|PROCEDURE|Trabeculectomy|
219373631|NCT03720314|OTHER|NA observational study|observational study
219187865|NCT03982459|BEHAVIORAL|Decision support tool|Internet-Based, interactive decision support tool
219187866|NCT04061148|DEVICE|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
219187867|NCT03780829|BEHAVIORAL|hypoxia|intermittent cycles of normoxia-hypoxia
219187868|NCT03780829|BEHAVIORAL|sham hypoxia|intermittent cycles of sham hypoxia
219187869|NCT03780829|DRUG|D-cycloserine|NMDA agonist treatment
219187870|NCT03780829|DRUG|sham-NMDA agonist|sham-NMDA agonist treatment
219187871|NCT03780829|BEHAVIORAL|exercise training|bimanual massed practice training
219187872|NCT06572150|PROCEDURE|Deep Brain Stimulation - Minimal Electrophysiology|Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.
219187873|NCT06572150|PROCEDURE|Deep Brain Stimulation - Standard|Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
219187874|NCT05979831|DRUG|DS-2325a|Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses
219373632|NCT02542267|DEVICE|Gore VIABAHN Endoprosthesis|
219373633|NCT02321592|DRUG|AFM13|
219187875|NCT05979831|OTHER|Placebo|Main Phase: IV infusion followed by SC doses
219373634|NCT04082104|DIAGNOSTIC_TEST|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
219373635|NCT00386841|DRUG|Escitalopram|Escitalopram 10 mg p.o. per day
219373636|NCT00386841|DRUG|Placebo|Placebo
219373637|NCT01636492|DRUG|bitopertin|Single oral dose
219373638|NCT01636492|DRUG|placebo|Single oral dose
219187876|NCT03738852|DEVICE|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
219187877|NCT03738852|DRUG|Insulin|standard insulin regimen
219187878|NCT01849146|DRUG|Adavosertib|Given PO
219187879|NCT01849146|RADIATION|Radiation Therapy|Undergo radiation therapy
219187880|NCT01849146|DRUG|Temozolomide|Given PO
219187881|NCT06821685|BIOLOGICAL|autologous decidual-like NK cells|intrauterine infusion
219187882|NCT06617715|BIOLOGICAL|Sinovac PCV13|One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
219373639|NCT00359892|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
219373640|NCT04488237|DRUG|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
219373641|NCT01627418|BEHAVIORAL|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
219373642|NCT01627418|BEHAVIORAL|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
219373643|NCT00550160|DRUG|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
219373644|NCT01206569|DRUG|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
219373645|NCT03437421|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|"* Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
219373646|NCT01323907|DRUG|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
219373647|NCT05736263|BEHAVIORAL|Moderate intensity exercise|moderate intensity aerobic exercise trial
219373648|NCT05736263|BEHAVIORAL|High intensity interval exercise|High intensity interval exercise trial
219373649|NCT05736263|BEHAVIORAL|Combined exercise|Combined aerobic and resistance exercise trial
219373650|NCT05736263|BEHAVIORAL|Resistance exercise|Resistance exercise trial
219373651|NCT01624584|BEHAVIORAL|Experimental treatment|six sessions of child anxiety treatment
219373652|NCT01624584|BEHAVIORAL|Traditional Treatment|six sessions of treatment consistent with current practice
219373653|NCT00054847|PROCEDURE|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
219373654|NCT00054847|PROCEDURE|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
219373655|NCT00245271|DRUG|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
219373656|NCT00245271|DRUG|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
219373657|NCT05213247|DEVICE|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
219373658|NCT00281814|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
219373659|NCT04271267|OTHER|No Intervention|
219373660|NCT00046722|DRUG|Smoked Marijuana|
219187883|NCT06617715|BIOLOGICAL|Prevnar®|One dose of Prevnar® (0.5 mL) is administered intramuscularly.
219187884|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
219187885|NCT06818994|DRUG|Psilocybin-assisted Psychotherapy|The intervention will be psilocybin-assisted psychotherapy. The first treatment period will include four preparation sessions with Managing Cancer and Living Meaningfully (CALM) therapy elements. The psilocybin dosing session will take place after these preparation sessions are completed. The dosing session will include an in-person visit lasting approximately 8 hours in which the participant will receive a capsule of psilocybin 25 mg under constant supervision of therapists. The following day, the first integration session will take place and two weeks later the second integration session along with CALM will be conducted. Participants who show a partial response will be offered a second dosing session, entering the second treatment period. The second treatment period includes a second dosing session using the same dose and safety measures as the first one. It will also be followed by an integration session the following day, and a second integration session with CALM two weeks later.
219373661|NCT00559091|DRUG|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
219373662|NCT02505256|OTHER|No intervention|
219373663|NCT00649454|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
219373664|NCT00649454|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
219373665|NCT04480151|OTHER|standard of care|retrospective study: standard of care
219373666|NCT02303925|DEVICE|NESTER COILS|
219373667|NCT01340183|DRUG|AZD5099|IV Dose
219187886|NCT04474834|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40 %).
219187887|NCT06822686|DEVICE|Harvest and injection of stem cells|Stem cells will be harvested from bone marrow aspirate and injected into the fistula tract The stem cells are the device intervention for this trial and we are looking to assess the procedure of harvesting and injecting the stem cells Patients will undergo study questionnaire: Harvey-Bradshaw Index, perianal Crohn's disease activity index, and Short IBD questionnaire will be administered before surgery and then at 6 weeks, 3 and 6 months after stem cell intervention.
219187888|NCT05056350|OTHER|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
219187889|NCT05056350|OTHER|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
219187890|NCT06778460|DRUG|Esketamine-lidocaine group|In the esketamine-lidocaine group, patients received esketamine (0.25 mg/kg) and lidocaine (1.5 mg/kg) at the induction of anesthesia, followed by the continuous infusion of esketamine (0.02 mg/kg∙h) and lidocaine (1.5 mg/kg∙h) until the end of surgery. Postoperatively, the patients received two pumps. One pump delivered a fixed-rate infusion of lidocaine at 1.0 mg.kg-1.h-1 and esketamine at 0.02 mg.kg-1.h-1 infusion for 72 hours. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
219187891|NCT06778460|OTHER|Placebo group|In the conventional analgesia group, patients received the same volume of normal saline instead of lidocaine and esketamine until the end of surgery. Postoperatively, the paitents received two pumps. One pump was the same volume of normal saline instead of lidocaine and esketamine. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
219187892|NCT02965014|BEHAVIORAL|Face-to-Face Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
219187893|NCT02965014|BEHAVIORAL|mHealth Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
219187894|NCT02965014|BEHAVIORAL|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing (HCT).
219187895|NCT05272735|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
219187896|NCT06530732|PROCEDURE|Deep Cervical lymphatlc-Venous Anastomosis Surgery|Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
219187897|NCT06530732|DRUG|Lecanemab|The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
219187898|NCT03240016|DRUG|Pembrolizumab|200mg IV D1
219187899|NCT03240016|DRUG|Abraxane|100mg/m\^2 D1 and D8
219373668|NCT01340183|DRUG|Placebo|IV Dose
219373669|NCT03044392|OTHER|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
219373670|NCT02899169|DRUG|Realgar-Indigo naturalis formula|
219373671|NCT02899169|DRUG|all-trans retinoic acid|
219373672|NCT02899169|DRUG|Arsenic trioxide|
219373673|NCT02899169|DRUG|Hydroxyurea|
219373674|NCT04738955|DRUG|Micafungin Sodium|micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
219373675|NCT04515355|BEHAVIORAL|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
219373676|NCT01856101|DRUG|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
219373677|NCT01350869|DEVICE|Xience|Patients with Xience
219373678|NCT03093155|DRUG|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
219373679|NCT03093155|DRUG|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
219373680|NCT02999087|DRUG|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
219373681|NCT02999087|DRUG|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
219373682|NCT02999087|DRUG|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
219373683|NCT02999087|RADIATION|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
219373684|NCT00000769|DRUG|Interleukin-4|
219373685|NCT00468234|DRUG|nicotine polacrilex|
219373686|NCT00468234|DRUG|nicotine transdermal system|
219373687|NCT00468234|DRUG|nicotine inhaler|
219373688|NCT05896007|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
219373689|NCT05896007|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
219373690|NCT05896007|DRUG|Methotrexate|3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
219373691|NCT05896007|DRUG|Temozolomide|150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
219373692|NCT06220695|BEHAVIORAL|Dietary intervention|The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
219373693|NCT06033729|DRUG|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
219373694|NCT06033729|DRUG|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
219373695|NCT06033729|DRUG|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
219373696|NCT06033729|DRUG|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
219373697|NCT01800188|PROCEDURE|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
219373698|NCT01800188|PROCEDURE|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
219373699|NCT01800188|PROCEDURE|Meal test|A 3 hour standardized liquid meal test without dialysis
219373700|NCT05932719|OTHER|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM"
219373701|NCT02906800|DRUG|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
219187900|NCT05335070|DRUG|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
219373702|NCT00619229|DRUG|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
219373703|NCT00619229|OTHER|Placebo|Placebo/d i.v. for 15 days
219373704|NCT05012748|OTHER|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
219373705|NCT04402047|OTHER|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
219373706|NCT04402047|DRUG|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
219187901|NCT03913442|DRUG|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
219187902|NCT03913442|DRUG|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
219187903|NCT05856448|DRUG|GLPG3667|Capsule
219187904|NCT05856448|DRUG|Placebo|Capsule
219373707|NCT06399783|DRUG|Simvastatin|Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
219373708|NCT06399783|DRUG|Mometasone Furoate|Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
219373709|NCT06399783|PROCEDURE|Fractional CO2 laser|Fractional CO2 laser will be used for assisted drug delivery for both topical simvastatin and mometasone Furoate.
219373710|NCT04845217|DRUG|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
219373711|NCT04845217|DRUG|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
219373712|NCT02548065|OTHER|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
219373713|NCT02548065|OTHER|Placebo|Bath with Thermal tap water
219373714|NCT01284881|DEVICE|MRA|daily wear overnight
219373715|NCT00061386|BEHAVIORAL|Nutrition and physical activity program|
219373716|NCT04819321|DEVICE|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
219373717|NCT03182764|OTHER|No intervention|No intervention
219373718|NCT01907620|OTHER|blood sample|
219373719|NCT01734343|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
219373720|NCT01734343|DEVICE|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
219373721|NCT02484027|DRUG|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
219373722|NCT06381583|DIAGNOSTIC_TEST|EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)|A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
219373723|NCT02086227|DRUG|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
219373724|NCT02086227|DRUG|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
219373725|NCT04626713|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
219373726|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
219187905|NCT00902603|DRUG|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
219373727|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
219373728|NCT02786901|DRUG|Vehicle Gel|Gel
219373729|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
219373730|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
219373731|NCT02476487|PROCEDURE|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2\. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
219373732|NCT03367871|DRUG|Pembrolizumab|IV
219373733|NCT03367871|DRUG|Paclitaxel|Administered intravenously (IV) on day 1
219373734|NCT03367871|DRUG|Cisplatin|Administered intravenously (IV) on day 1
219373735|NCT03367871|DRUG|Carboplatin|Administered intravenously (IV) on day 1
219373736|NCT03367871|DRUG|Bevacizumab|Administered intravenously (IV) on day 1
219373737|NCT01843010|DRUG|Parecoxib|Parecoxib 40mg will be intravenously infused.
219373738|NCT01843010|DRUG|Placebo|Normal saline 5ml will be intravenously infused.
219373739|NCT02983604|DRUG|GS-5829|Tablet(s) administered orally once daily
219373740|NCT02983604|DRUG|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
219373741|NCT02983604|DRUG|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
219373742|NCT04761796|OTHER|Sleeping condition self-questionnaire|Professional flight members will answer a self questionnaire related to their sleeping conditions
219373743|NCT03573713|OTHER|Care Groups|The Care Groups model has strong evidence of improvement of maternal and child health and maternal hygiene/nutrition behaviors.Through Care Groups, women will learn about proper water, sanitation, and hygiene behaviors; Infant and Young Child Feeding practices; management of childhood illnesses; home management, referral and care seeking for sick children; family planning; and use of preventive services available at health facilities (e.g., growth monitoring, deworming, vitamin A supplementation). All children under five years of age will also be screened for acute malnutrition by the Care Group Volunteers, and receive deworming medication and vitamin A supplementation twice a year through the Ministry of Health and Community Health Workers as part of national campaigns.
219373744|NCT03573713|BEHAVIORAL|IPT-G|"IPT-G is an effective, low-cost, short-duration community-based method for decreasing depression has been established that was first rigorously tested in Uganda. Several Private Voluntary Organizations in Africa have used this low-cost, short-duration, community-based group psychosocial approach and found it to be a culturally-sensitive, acceptable, and feasible approach to address depression.~IPT-G treatment spans 12 weeks of treatment, consisting of 3 phases (early, middle, and termination). Within this treatment, participants are also assessed for symptoms of depression every week."
219373745|NCT04531267|DIETARY_SUPPLEMENT|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
219373746|NCT01111604|BIOLOGICAL|Ramucirumab|8 mg/kg IV Q2W
219373747|NCT01111604|BIOLOGICAL|Icrucumab|15 mg/kg IV Q2W
219373748|NCT01111604|DRUG|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
219373749|NCT01687790|DEVICE|molecular breast imaging (Discovery)|
219373750|NCT03607721|DEVICE|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
219373751|NCT06548841|OTHER|Nanobiotechnology platforms|"The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal."
219373752|NCT01136395|DRUG|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
219373753|NCT01136395|PROCEDURE|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
219373754|NCT01136395|PROCEDURE|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
219373755|NCT00316264|BIOLOGICAL|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
219373756|NCT00316264|BIOLOGICAL|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
219373757|NCT00316264|BIOLOGICAL|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
219373758|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
219373759|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
219373760|NCT03744455|BIOLOGICAL|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
219373761|NCT04118803|DEVICE|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
219373762|NCT01287663|DRUG|Permethrin impregnated|
219373763|NCT01287663|DRUG|no Permethrin impregnated|
219373764|NCT00618150|BEHAVIORAL|Patient education|An educational program: Three lessons spaced over 2 weeks.
219373765|NCT00355264|DRUG|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
219373766|NCT00928330|DRUG|GDC-0941|Oral repeating dose
219373767|NCT00928330|DRUG|Trastuzumab|Intravenous repeating dose
219373768|NCT00928330|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
219373769|NCT02492945|DRUG|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
219373770|NCT02492945|DRUG|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
219373771|NCT01157117|BIOLOGICAL|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
219373772|NCT01157117|BIOLOGICAL|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
219373773|NCT01157117|DRUG|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
219373774|NCT00446303|DRUG|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
219373775|NCT02185391|PROCEDURE|Audience Response System|patients use during oral presentations an audience response system
219373776|NCT02185391|BEHAVIORAL|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
219373777|NCT02867696|OTHER|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
219373778|NCT02867696|BEHAVIORAL|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
219373779|NCT00002586|DRUG|13-cis retinoic acid|
219373780|NCT00002586|DIETARY_SUPPLEMENT|Tocopherol|
219373781|NCT04203914|DRUG|Empagliflozin Tablets|Add-on 25mg once daily
219373782|NCT02833025|DEVICE|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
219373783|NCT03217851|DIAGNOSTIC_TEST|Blood Collection|blood smear and/or rapid diagnostic
219373784|NCT03217851|DIAGNOSTIC_TEST|Dried Blood Spot|Dried Blood Spot on filter paper
219373785|NCT00093236|PROCEDURE|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
219373786|NCT00093236|PROCEDURE|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
219373787|NCT01976949|BEHAVIORAL|online social-networking intervention|
219373788|NCT06401356|DRUG|Pelabresib|Small molecule inhibitor of bromodomain and extraterminal (BET) protein
219373789|NCT00826514|DRUG|Tanezumab|Intravenous, 20 mg, single dose.
219373790|NCT00826514|DRUG|Placebo|Intravenous placebo, single dose
219373791|NCT06327230|PROCEDURE|Thoracic Epidural Analgesia|Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
219373792|NCT05179616|PROCEDURE|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
219373793|NCT03245879|BEHAVIORAL|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
219557763|NCT05377606|PROCEDURE|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
219187906|NCT04404595|BIOLOGICAL|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
219557764|NCT05377606|PROCEDURE|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
219557765|NCT00166452|DRUG|Lenalidamide|
219557766|NCT00120315|DRUG|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
219373794|NCT03245879|BEHAVIORAL|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
219373795|NCT03245879|BEHAVIORAL|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
219373796|NCT03251885|OTHER|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
219373797|NCT00135980|BEHAVIORAL|professional audit and feedback|
219373798|NCT00135980|BEHAVIORAL|integrated care programmes|
219373799|NCT05155098|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
219373800|NCT00643240|RADIATION|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
219373801|NCT00643240|RADIATION|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
219373802|NCT05957887|DRUG|Dapagliflozin|Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
219373803|NCT03859284|OTHER|flowable resin composite|gold standard
219373804|NCT03859284|OTHER|self adhering flowable|moist bonding self adhering flowable composite
219373805|NCT03859284|OTHER|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
219373806|NCT01916278|DEVICE|Emervel Lips Lidocaine|
219373807|NCT01916278|DEVICE|Juvéderma Volbella with Lidocaine|
219187907|NCT05615415|DRUG|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
219187908|NCT05615415|DRUG|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
219373808|NCT06156527|DRUG|Lazertinib|Lazertinib 240mg, QD, daily
219373809|NCT06156527|DRUG|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
219373810|NCT00064922|BEHAVIORAL|Behavior Therapy|
219373811|NCT04485455|DEVICE|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
219373812|NCT04485455|DEVICE|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
219373813|NCT03926143|DRUG|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
219373814|NCT01110187|DRUG|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
219373815|NCT01110187|DRUG|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
219373816|NCT03954626|BIOLOGICAL|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
219373817|NCT05100537|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
219373818|NCT05100537|OTHER|continuing a routine life|No intervention will be made in the control group.
219373819|NCT04424563|DEVICE|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
219373820|NCT04424563|DRUG|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
219373821|NCT04424563|DRUG|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
219373822|NCT03862027|DEVICE|Esophageal Balloon catheter|"Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
219373823|NCT00750984|PROCEDURE|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
219373824|NCT00750984|PROCEDURE|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
219373825|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
219373826|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
219373827|NCT02446587|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
219373828|NCT05569135|DEVICE|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
219373829|NCT01588223|OTHER|Lipid identification|The lipids are identified using Mass Spectrometry
219373830|NCT04579549|DEVICE|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
219373831|NCT03214835|DEVICE|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
219373832|NCT05627466|DRUG|Magrolimab|Administered intravenously
219373833|NCT05841472|DRUG|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
219373834|NCT01420133|OTHER|Regimen|regimen normal in salt and sugar
219373835|NCT01420133|OTHER|Standard regimen|with diet low in salt and sugar
219373836|NCT03932526|DRUG|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
219373837|NCT03932526|DRUG|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
219373838|NCT01818544|DRUG|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
219373839|NCT01818544|DRUG|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
219373840|NCT00728546|DRUG|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
219373841|NCT05670977|DIETARY_SUPPLEMENT|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
219373842|NCT05670977|DIETARY_SUPPLEMENT|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
219373843|NCT03139292|DEVICE|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
219373844|NCT03139292|DEVICE|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
219373845|NCT05576220|DEVICE|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
219373846|NCT02349126|DRUG|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
219373847|NCT05904444|PROCEDURE|microperimetric biofeedback training|Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
219373848|NCT02002143|BEHAVIORAL|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
219373849|NCT02002143|BEHAVIORAL|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
219373850|NCT02236169|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
219373851|NCT02236169|DRUG|Atrovent CFC inhalation aerosol|
219373852|NCT00013806|DRUG|131I-MIBG|
219373853|NCT05281263|BIOLOGICAL|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
219373854|NCT02680782|DRUG|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
219373855|NCT05628844|PROCEDURE|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
219373856|NCT04937023|DRUG|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
219373857|NCT02626728|PROCEDURE|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
219373858|NCT01822002|PROCEDURE|Canalith repositioning maneuver|
219373859|NCT02207907|DRUG|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
219373860|NCT02207907|DRUG|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
219373861|NCT06178068|DEVICE|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
219373862|NCT03024216|DRUG|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
219373863|NCT03024216|DRUG|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
219373864|NCT00873002|DRUG|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
219373865|NCT00873002|DRUG|sorafenib tosylate|400 mg PO BID
219754307|NCT06903000|DEVICE|specially designed stainless-steel instruments|Participants will receive instrument-assisted soft tissue mobilization applied using specially designed stainless-steel instruments. Techniques (Sweep, Fan, Brush) will be applied to cervical and upper-back musculature (splenius, suboccipital, upper-middle-lower trapezius) and related fascia between C1-T1 vertebrae, parallel to muscle fibers for approximately 6 minutes per session. Each technique will consist of 8-10 repetitions.
219187909|NCT05615415|DEVICE|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
219373866|NCT04568837|DRUG|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
219373867|NCT04934826|DIETARY_SUPPLEMENT|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
219373868|NCT04934826|DIETARY_SUPPLEMENT|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
219373869|NCT01617538|DRUG|atorvastatin|40mg per day,duration for 24 weeks
219373870|NCT02620020|DRUG|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
219373871|NCT02620020|DRUG|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
219373872|NCT05318521|DRUG|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
219557767|NCT00120315|PROCEDURE|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
219373873|NCT05318521|DRUG|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
219373874|NCT01973855|DRUG|Western Medicine|Physical cooling,Hydrocortisone
219373875|NCT01973855|DRUG|TCM and Western Medicine|Third Infectious diseases soup recipe
219373876|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
219373877|NCT03216993|OTHER|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
219373878|NCT00212329|PROCEDURE|T Cell Proliferation and Autoreactivity Assays|
219373879|NCT00212329|PROCEDURE|Cellular Immunoblot Assays|
219373880|NCT00212329|PROCEDURE|Tetramer Studies|
219373881|NCT00212329|PROCEDURE|Cytokine ELISPOT|
219373882|NCT03146286|DIETARY_SUPPLEMENT|Saturated fat|Palm stearin
219373883|NCT03146286|DIETARY_SUPPLEMENT|Placebo|Water
219373884|NCT03146286|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil, Omega 3 PUFA
219373885|NCT04506112|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation|Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
219373886|NCT01933087|BEHAVIORAL|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
219373887|NCT05495347|OTHER|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
219373888|NCT01287104|BIOLOGICAL|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
219373889|NCT01287104|BIOLOGICAL|Stem Cell Infusion|Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
219373890|NCT01755169|DRUG|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
219373891|NCT01755169|DRUG|Placebo|
219373892|NCT01293617|OTHER|Blackberries|300 g blackberries daily for 5 days
219373893|NCT01293617|OTHER|Gelatin|300 g gelatin per day for 5 days
219373894|NCT05671276|DRUG|aspirin and clopidogrel|DAPT (until 6 months) + ASA
219373895|NCT05671276|DRUG|Rivaroxaban|half-dose NOAC
219373896|NCT05431244|DRUG|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
219373897|NCT00643383|DRUG|Combination drug (Acetaminophen + Tramadol)|
219373898|NCT00643383|DRUG|Placebo|
219373899|NCT01849757|OTHER|prime crystalloid|used for priming the CPB circuit
219373900|NCT01849757|OTHER|Human Albumin|Used as a constituent for priming the CPB circuit
219373901|NCT01849757|OTHER|Voluven|Used as a constituent for priming the CPB circuit
219373902|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
219373903|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
219373904|NCT02598830|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
219373905|NCT02598830|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
219373906|NCT01276288|DRUG|BI 10773|multiple oral doses
219373907|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
219373908|NCT01276288|DRUG|torasemide|multiple oral doses
219373909|NCT01276288|DRUG|BI 10773|multiple oral doses
219373910|NCT01276288|DRUG|torasemide|multiple oral doses
219373911|NCT01276288|DRUG|BI 10773|multiple oral doses
219373912|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
219373913|NCT03429868|DEVICE|integrated PET/MRI|"The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
219373914|NCT03759158|DRUG|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
219373915|NCT03759158|DRUG|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
219373916|NCT03652922|DRUG|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
219373917|NCT06003062|DRUG|Narcissus Tazetta Bulb Extract and Novel Hemp Extract|Topical nightly application of phytonutraceutical
219373918|NCT00825604|PROCEDURE|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
219373919|NCT03168867|BEHAVIORAL|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
219373920|NCT04348851|BEHAVIORAL|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
219373921|NCT04348851|BEHAVIORAL|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
219373922|NCT02965378|DRUG|Docetaxel|Given IV
219373923|NCT02965378|DRUG|FGFR Inhibitor AZD4547|Given PO
219373924|NCT02965378|OTHER|Laboratory Biomarker Analysis|Correlative studies
219373925|NCT05837754|OTHER|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
219373926|NCT05837754|OTHER|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
219373927|NCT02536586|DRUG|LY3023414|LY3023414 administered orally.
219373928|NCT04552470|DRUG|Placebo|3 matching placebo tablets taken twice a day (BID)
219373929|NCT04552470|DRUG|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
219373930|NCT02867631|BEHAVIORAL|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
219373931|NCT03931018|OTHER|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
219373932|NCT05943730|DEVICE|Seismofit|The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
219373933|NCT00902629|PROCEDURE|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
219373934|NCT00058461|DRUG|ifosfamide|Given IV
219373935|NCT00058461|DRUG|etoposide|Given IV
219373936|NCT00058461|BIOLOGICAL|rituximab|Given IV
219373937|NCT00058461|DRUG|carboplatin|Given IV
219373938|NCT00058461|BIOLOGICAL|filgrastim|Given SC
219373939|NCT00058461|DRUG|methotrexate|Given IT
219373940|NCT00058461|DRUG|cytarabine|Given IT
219373941|NCT00058461|OTHER|laboratory biomarker analysis|Correlative studies
219373942|NCT00073190|BEHAVIORAL|Osteoporosis Education|
219373943|NCT03778489|OTHER|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
219373944|NCT00024687|DRUG|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
219373945|NCT06278623|DEVICE|Focal Muscle Vibratory Energy (EVM) Treatment|"The patients involved in the study will undergo muscle vibratory stimulation in association with conventional rehabilitation treatment three times a week, for three weeks for a total duration of 9 sessions in association with conventional treatment.~The vibration will be applied at a frequency of 100 Hz and an amplitude of 0.2 cm for 30 minutes (three sessions of 10 min each with 1 min break in between) three times a week for three weeks at the level of the quadriceps femoris and triceps surae bilaterally for balance improvement and stimulation of proprioception and in the trapezius and trunk extensor muscles bilaterally for pain relief."
219373946|NCT00629083|DEVICE|Bulkamid|Bulking injection with Bulkamid injection device
219373947|NCT00629083|DEVICE|Contigen|Transurethral bulking injection
219373948|NCT00223340|BEHAVIORAL|Patient Activation and Diabetes Registry|
219373949|NCT02909153|DRUG|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
219373950|NCT03026738|PROCEDURE|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
219373951|NCT03026738|PROCEDURE|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
219373952|NCT03026738|DEVICE|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
219373953|NCT00534534|BEHAVIORAL|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
219373954|NCT02515513|PROCEDURE|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
219373955|NCT04401059|DRUG|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
219373956|NCT04401059|DRUG|First or third generation EGFR-TKIs|refer to the drug label.
219373957|NCT00682656|DRUG|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
219373958|NCT00682656|DRUG|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
219373959|NCT01147809|DRUG|Eltrombopag olamine|thrombopoietin receptor agonist
219373960|NCT01147809|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
219373961|NCT05657262|OTHER|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
219373962|NCT05657262|BEHAVIORAL|experimental group|The experiment group will be applied with the Z technique.
219373963|NCT06294600|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
219373964|NCT06294600|DRUG|Tablets|Oral tablets of similar appearance to active study drug
219373965|NCT01307423|DRUG|Apremilast 20mg|Apremilast 20mg twice daily, orally
219373966|NCT01307423|DRUG|Apremilast 30mg|Apremilast 30mg twice daily, orally
219373967|NCT01307423|DRUG|Placebo|Placebo
219373968|NCT03112811|DEVICE|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
219373969|NCT03112811|DEVICE|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
219373970|NCT05934214|DRUG|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
219373971|NCT01482702|BEHAVIORAL|weight loss intervention|Behavioral weight loss intervention
219373972|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
219373973|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
219373974|NCT01956006|DRUG|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
219373975|NCT04318574|OTHER|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
219373976|NCT02227576|DRUG|Romiplostim|
219373977|NCT06027801|OTHER|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
219373978|NCT06027801|BIOLOGICAL|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
219373979|NCT06027801|BIOLOGICAL|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
219373980|NCT06027801|OTHER|non-fortified cookies|Study cookies containing no iron
219373981|NCT06337396|DIAGNOSTIC_TEST|WGS and transcriptome analysis|In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
219373982|NCT00550498|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
219373983|NCT04101110|OTHER|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
219373984|NCT03248921|PROCEDURE|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
219373985|NCT03295825|DIAGNOSTIC_TEST|Biomarker|Measument of heparin-binding protein in the serum of patients
219373986|NCT05779891|OTHER|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
219373987|NCT05779891|OTHER|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
219373988|NCT03989830|DRUG|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
219373989|NCT03989830|DRUG|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
219373990|NCT05192343|DEVICE|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
219373991|NCT05192343|OTHER|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
219373992|NCT00743795|DRUG|placebo|oral BID
219373993|NCT00743795|DRUG|GS-9190|40 mg oral BID
219373994|NCT00743795|DRUG|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
219373995|NCT00743795|DRUG|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
219373996|NCT04268030|OTHER|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
219373997|NCT00190775|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
219373998|NCT00190775|DRUG|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
219373999|NCT02568436|RADIATION|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
219374000|NCT00444015|DRUG|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
219374001|NCT03943329|PROCEDURE|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
219374002|NCT03943329|PROCEDURE|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
219374003|NCT00454233|DRUG|YM543|Oral
219374004|NCT00454233|DRUG|Metformin|Oral
219374005|NCT00454233|DRUG|Placebo|oral
219374006|NCT00519077|DRUG|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
219374007|NCT01967225|DRUG|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
219374008|NCT01967225|DRUG|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
219374009|NCT06006078|DEVICE|Endoscopic Patient Facemask|A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
219374010|NCT00012610|PROCEDURE|Telepsychiatry|
219374011|NCT05811065|DEVICE|OPTIVF dosage|Opt-IVF dosage
219374012|NCT05811065|DEVICE|traditional drug treament|Traditional drug treatment
219374013|NCT03547141|DRUG|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
219374014|NCT03547141|DRUG|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
219374015|NCT04261244|RADIATION|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
219374016|NCT04261244|RADIATION|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
219374017|NCT00257036|DRUG|levofloxacin|
219374018|NCT04610255|OTHER|Assigned Interventions|"* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
219374019|NCT04610255|OTHER|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
219374020|NCT00766805|DRUG|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
219374021|NCT00766805|OTHER|EVL alone|
219374022|NCT03896295|DRUG|M281|M281 injection administered as intravenous infusion
219374023|NCT00947648|OTHER|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
219374024|NCT00947648|OTHER|Cooked Foods|Diet containing only cooked foods.
219374025|NCT00700804|BEHAVIORAL|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
219374026|NCT00700804|BEHAVIORAL|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
219374027|NCT02567448|OTHER|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
219374028|NCT00312455|DRUG|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
219374029|NCT00312455|DRUG|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
219374030|NCT00312455|DRUG|Placebo|5 capsules/day
219374031|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
219374032|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
219374033|NCT06154629|DIETARY_SUPPLEMENT|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
219374034|NCT06154629|DIETARY_SUPPLEMENT|Control group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
219374035|NCT00372918|PROCEDURE|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
219374036|NCT05786950|DRUG|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)|inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
219374037|NCT06330909|RADIATION|Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT|"technique: IMRT/IGRT/SBRT~The HypoFocal-SBRT study combines ultra-hypofractionated RT / stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts."
219374038|NCT06330909|RADIATION|Radiotherapy (RT) Arm B - IMRT/IGRT|"technique: IMRT/IGRT~Moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide."
219374039|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
219374040|NCT05945264|BEHAVIORAL|Music Intervention (MI)|The intervention will involve listening, playing and/or singing melodies or songs, that are meaningful to the participant, with interpretation/reflection on their relevance/capacity to alter stress.
219374041|NCT05945264|OTHER|Sham Control (SC)|The intervention will be to support a woman to talk about anything she wants that is important to her.
219374042|NCT04696861|BEHAVIORAL|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
219374043|NCT04696861|BEHAVIORAL|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
219374044|NCT00243997|BEHAVIORAL|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
219374045|NCT06230354|DRUG|Tezepelumab|Tezepelumab subcutaneous injection
219374046|NCT06230354|DRUG|Placebo|Placebo subcutaneous injection
219374047|NCT03633500|OTHER|Sterile water|Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
219374048|NCT03633500|BIOLOGICAL|Breastmilk|Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
219374049|NCT01639326|DRUG|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
219374050|NCT01639326|DRUG|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
219374051|NCT01926626|DRUG|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
219374052|NCT01926626|DRUG|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
219374053|NCT05203250|RADIATION|Heavy-ion therapy (hadrontherapy)|Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.
219374054|NCT03809897|DRUG|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
219374055|NCT03809897|DRUG|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
219374056|NCT03146364|DEVICE|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
219374057|NCT04923594|DRUG|mazindol extended release|Dosed orally, once daily for up to 3 weeks
219374058|NCT04923594|DRUG|Placebo|Dosed orally, once daily for up to 4 weeks.
219374059|NCT06385704|PROCEDURE|DMR Procedure|Endoscopic procedure
219374060|NCT01393093|PROCEDURE|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
219374061|NCT04743050|DRUG|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
219374062|NCT04743050|DIAGNOSTIC_TEST|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
219374063|NCT06295445|PROCEDURE|care cardio-pulmonary ultrasound|Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome
219374064|NCT06295445|OTHER|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
219374065|NCT02254343|DEVICE|proximal robot-assisted therapy|
219374066|NCT02254343|DEVICE|distal robot-assisted therapy|
219374067|NCT02254343|BEHAVIORAL|individualized intensive therapy|
219374068|NCT00434200|PROCEDURE|long-term intensive exercise|
219374069|NCT01500837|DRUG|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
219374070|NCT01500837|DRUG|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
219374071|NCT00216567|DRUG|topamax|
219374072|NCT05335538|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
219374073|NCT00004486|DRUG|fluoxetine|
219374074|NCT02382133|DEVICE|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
219374075|NCT01348737|DRUG|AZD3839|Single Oral Dose
219374076|NCT01348737|DRUG|AZD3839 Placebo|Single Oral Dose
219374077|NCT04969055|OTHER|Not|Not
219374078|NCT02803333|OTHER|No Intervention|No intervention
219374079|NCT00655928|DRUG|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
219374080|NCT00655928|DRUG|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
219374081|NCT02125214|DEVICE|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
219374082|NCT04906707|DEVICE|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
219374083|NCT04906707|BEHAVIORAL|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
219374084|NCT00841451|DRUG|Lovaza (Fish Oils)|Double blinded placebo controlled
219374085|NCT05834738|DRUG|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
219374086|NCT05834738|DRUG|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
219374087|NCT05834738|DRUG|Placebo|Placebo
219374088|NCT00002310|DRUG|Crofelemer|
219374089|NCT05330026|COMBINATION_PRODUCT|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
219374090|NCT04409847|DIAGNOSTIC_TEST|ABPM|24 hour ambulatory blood pressure monitoring
219374091|NCT04409847|DIAGNOSTIC_TEST|ECG|Electrocardiogram
219374092|NCT04409847|DIAGNOSTIC_TEST|FMD|Flow mediated dilatation
219374093|NCT04409847|DIAGNOSTIC_TEST|PWV|Pulse wave velocity
219374094|NCT04409847|DIAGNOSTIC_TEST|Rarefaction|nailbed capillaroscopy
219374095|NCT05019937|BEHAVIORAL|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
219374096|NCT05019937|BEHAVIORAL|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
219374097|NCT05019937|BEHAVIORAL|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
219374098|NCT05019937|BEHAVIORAL|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
219374099|NCT05019937|BEHAVIORAL|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
219374100|NCT01512940|PROCEDURE|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
219374101|NCT01976806|DRUG|Aspirin|
219374102|NCT01976806|DRUG|Docosahexaenoic acid|
219374103|NCT01976806|DRUG|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
219374104|NCT06331091|OTHER|Home exercise|Home exercise are done at home without the supervision of a specialist.
219374105|NCT06331091|OTHER|Manual therapy|Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
219374106|NCT06331091|DEVICE|Neuromuscular electrical stimulation|"Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist."
219374107|NCT06331091|OTHER|Supervised exercise|Supervised exercise is done under the supervision of a physiotherapist.
219374108|NCT04188730|DRUG|Lofexidine (granules for reconstitution)|All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
219374109|NCT04188730|DRUG|LUCEMYRA (lofexidine) tablets|All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
219374110|NCT02484469|DEVICE|The Virtual Human Project|Virtual Human educational videos about leprosy
219374111|NCT03582358|OTHER|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
219374112|NCT02221492|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
219374113|NCT02221492|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
219374114|NCT02607215|DRUG|Vinorelbine|25 mg/m2, D1, D8
219374115|NCT02607215|DRUG|DDP|75 mg/m2, D1
219374116|NCT00998738|DRUG|Calcium Gluconate|Given IV
219374117|NCT00998738|DRUG|Magnesium Sulfate|Given IV
219374118|NCT00998738|OTHER|Placebo|Given IV
219374119|NCT00998738|OTHER|Quality-of-Life Assessment|Ancillary studies
219374120|NCT00998738|OTHER|Questionnaire Administration|Ancillary studies
219374121|NCT00998738|DRUG|Ixabepilone|Given IV
219374122|NCT04391140|OTHER|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
219374123|NCT03445286|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
219374124|NCT03445286|OTHER|Normal Saline|Normal Saline for the control group
219374125|NCT05124223|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
219374126|NCT04188366|BEHAVIORAL|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
219374127|NCT04188366|BEHAVIORAL|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
219374128|NCT05783700|DIAGNOSTIC_TEST|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
219374129|NCT04394442|DRUG|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
219374130|NCT00933036|DEVICE|Crosstrees Pod system for PVA|Minimally invasive spine surgery
219374131|NCT06823973|BEHAVIORAL|CBT-based transdiagnostic approach to sexual distress|"It is constituted by 8 modules:~1. Psychoeducation about sexual function~2. Difficulties in emotional regulation~3. Non-judgmental emotional awareness~4. Cognitive flexibility~5. Worry and rumination~6. Perfectionism~7. Communication~8. Summary"
219374132|NCT06823973|BEHAVIORAL|Waiting list condition|The participants in the waiting list condition will receive the intervention after the participants in the intervention condition.
219374133|NCT06932016|BEHAVIORAL|Grammar Treatment|Behavioral intervention that focuses on improving passive sentence structure knowledge.
219374134|NCT06918509|DEVICE|OdonAssistTM|Innovative medical device for operative vaginal delivery as an alternative to vacuum or forceps
219374135|NCT06935292|DRUG|Dexmedetomidine|Nebulized Dexmedetomidine (1μg/kg)
219374136|NCT06935292|DRUG|Melatonin|Oral Melatonin tablet (5mg)
219374137|NCT03946449|DRUG|ARO-AAT|solution for subcutaneous injection
219374138|NCT04963413|BIOLOGICAL|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
219374139|NCT06399406|COMBINATION_PRODUCT|Medi-TBS|The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
219374140|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
219374141|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
219374142|NCT05053646|PROCEDURE|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
219374143|NCT05053646|PROCEDURE|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
219374144|NCT05948176|OTHER|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
219374145|NCT06398301|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
219374146|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
219374147|NCT05340309|OTHER|Survey Administration|Ancillary studies
219374148|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
219374149|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
219374150|NCT05436379|DEVICE|Theta Burst Stimulation|TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
219374151|NCT05979493|DRUG|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
219374152|NCT05979493|DRUG|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
219374153|NCT01610921|OTHER|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
219374154|NCT06448988|OTHER|Park Bench position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
219374155|NCT05798923|DRUG|LAM-001|LAM-001 administered via dry powder inhalation
219374156|NCT06376994|DEVICE|Air cleaner|The intervention is two active air cleaners with high efficiency particulate air (HEPA) filters which remove PM, as well as activated carbon filters to remove NO2 (and other trace gases). These will be run for a year in a participant's house.
219374157|NCT06376994|DEVICE|Sham air cleaner|The sham intervention is two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status. These will be run for a year in a participant's house.
219374158|NCT06161077|DIAGNOSTIC_TEST|Voice Biomarker Screening Too|The investigators will develop a screening tool using voice that can predict disease severity in idiopathic subglottic stenosis
219374159|NCT05764330|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219374160|NCT05764330|OTHER|Dietary Intervention|Undergo CER intervention
219374161|NCT05764330|OTHER|Dietary Intervention|Undergo IF intervention
219374162|NCT05764330|BEHAVIORAL|Fasting|Undergo fasting
219374163|NCT05954910|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
219374164|NCT03317964|OTHER|Saliva sample|Extract sample of saliva only once
219374165|NCT02237235|DRUG|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
219374166|NCT02237235|DRUG|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
219374167|NCT05286879|BEHAVIORAL|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
219374168|NCT05286879|BEHAVIORAL|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
219374169|NCT05053659|DRUG|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
219374170|NCT05053659|DRUG|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
219374171|NCT00873275|BIOLOGICAL|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
219374172|NCT00873275|DRUG|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
219374173|NCT00873275|DRUG|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
219754308|NCT06903000|OTHER|Conventional Exercise Group (Control)|Participants in this control group will receive conventional physiotherapy treatment alone. The treatment includes heat therapy applied to the cervical region for 20 minutes, TENS application at a frequency of 100 Hz to painful areas, ROM exercises performed in all cervical directions (2 sets of 10 repetitions, 2-second holds at end-range), and isometric strengthening exercises in cervical flexion, extension, and lateral flexion directions (2 sets of 10 repetitions, 6-second holds per repetition). Sessions will take place 4 days per week for 3 weeks.
219374174|NCT00873275|DRUG|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
219374175|NCT00873275|DRUG|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
219374176|NCT00873275|DRUG|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
219374177|NCT00873275|GENETIC|RNA analysis|Analysis on discard tissues
219374178|NCT00873275|GENETIC|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
219374179|NCT00873275|GENETIC|polymerase chain reaction|Analysis on discard tissues
219374180|NCT00873275|GENETIC|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
219374181|NCT00873275|OTHER|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
219374182|NCT00873275|OTHER|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
219374183|NCT00873275|OTHER|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
219374184|NCT00873275|PROCEDURE|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
219374185|NCT06094010|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as an oral suspension per body weight (≥80 kilograms (kg): 80 milligrams (mg); ≥20 kg to \< 80 kg: 40 mg; \<20 kg: 2 mg/kg).
219374186|NCT06360822|BEHAVIORAL|ED-LCS|This is a lung cancer educational intervention for patients in the emergency department.
219374187|NCT05372172|OTHER|none, observational study|none, observational study
219374188|NCT05604807|OTHER|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
219374189|NCT05604807|OTHER|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
219374190|NCT03896581|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219374191|NCT03896581|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
219374192|NCT06834880|DEVICE|No intervention; Observational study|Sample bank with Health Questionnaire
219374193|NCT06833463|DRUG|LCP Tacro (tacrolimus)|Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.
219374194|NCT04375761|PROCEDURE|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
219374195|NCT04375761|PROCEDURE|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
219374196|NCT03797001|DRUG|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
219374197|NCT03797001|DRUG|Placebo|subcutaneous injection, daily for 24 weeks
219374198|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
219754309|NCT05019079|OTHER|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
219187910|NCT06002919|BEHAVIORAL|MindWalk Intervention|The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
219374199|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
219374200|NCT05630846|BIOLOGICAL|Investigational MMRV(H)NS vaccine|1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
219374201|NCT05630846|BIOLOGICAL|Investigational MM(H)RVNS vaccine|1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
219374202|NCT05630846|BIOLOGICAL|Investigational M(L)M(L)R(L)V(L)NS vaccine|1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
219374203|NCT05630846|BIOLOGICAL|Marketed MMRV_Lot 1 and Lot 2 vaccine|1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
219374204|NCT05690048|DRUG|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
219374205|NCT05690048|DRUG|Vancomycin Oral Capsule|Vancomycin orally (250 mg 4xd, day -3 to 0).
219374206|NCT05690048|DRUG|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
219374207|NCT05690048|DRUG|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (4xd, day -3 to 0).
219374208|NCT05690048|DRUG|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule on day 0 and day 21.
219374209|NCT06357221|DRUG|Cetaphil|Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
219374210|NCT05868616|DEVICE|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
219374211|NCT06954220|OTHER|Baduanjin exercises|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for post thyroidectomy patients. The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
219374212|NCT06951906|DIAGNOSTIC_TEST|fMRI|Baseline imaging will utilize advanced diffusion MRI metrics to determine which brain areas are structurally connected to the stimulation target and their structural integrity. Post-operative assessments will include behavioral measures of FOG response and imaging measures of neural response to stimulation. Pre- and post-operative data will be used to evaluate the association between structural integrity, connectivity and behavioral response.
219374213|NCT06258993|BEHAVIORAL|Core Exercise Promotion Program|Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
219374214|NCT06258993|BEHAVIORAL|Affect-based exercise prescription|"Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale."
219374215|NCT06258993|BEHAVIORAL|Effort-based exercise prescription|"Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale."
219374216|NCT05394402|DRUG|SHR0410 Injection|SHR0410 Injection
219374217|NCT05394402|DRUG|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
219374218|NCT06521489|DEVICE|Asymmetrical High Flow Nasal Cannula Oxygenation|Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
219374219|NCT06521489|DEVICE|Conventional High Flow Nasal Cannula Oxygenation|Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
219374220|NCT06054737|PROCEDURE|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
219374221|NCT05622747|OTHER|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
219374222|NCT04552145|PROCEDURE|surgery|standard decompression surgery
219374223|NCT04552145|BEHAVIORAL|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
219374224|NCT06222268|DRUG|Cannabidiol (CBD) only|Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.
219374225|NCT06222268|DRUG|Placebo only|Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
219374226|NCT06222268|DRUG|Delta-9-tetrahydrocannabinol (THC) only|Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.
219374227|NCT06222268|DRUG|THC:CBD 1:1|Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
219187911|NCT06540404|OTHER|Pulse traction|The subjects underwent impulse traction of the knee joint in the second degree according to the Kaltenborn concept.
219187912|NCT06540404|OTHER|Continuous traction|The subjects underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.
219187913|NCT06540404|OTHER|Sham therapy|The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
219374228|NCT06222268|DRUG|THC:CBD 1:10|Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
219374229|NCT04155749|DRUG|anitocabtagene-autoleucel|Chimeric Antigen Receptor T cells
219374230|NCT04913766|BEHAVIORAL|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
219374231|NCT04913766|BEHAVIORAL|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
219374232|NCT05554939|BIOLOGICAL|Allogenic CD19 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.
219374233|NCT05554939|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
219374234|NCT05554939|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
219374235|NCT05091346|DRUG|E7386|E7386 tablet.
219374236|NCT05091346|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
219374237|NCT05091346|DRUG|Lenvatinib|Lenvatinib capsule.
219374238|NCT03900195|OTHER|BottlePEP|Positive expiratory device with a bottle
219374239|NCT04285528|DRUG|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
219374240|NCT04285528|COMBINATION_PRODUCT|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
219374241|NCT01149200|DRUG|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
219374242|NCT01149200|DRUG|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
219374243|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 5mg QD
219374244|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD
219374245|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
219374246|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 25 mg QD
219374247|NCT00659295|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
219374248|NCT03417388|DRUG|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
219374249|NCT03417388|DRUG|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
219374250|NCT03417388|DRUG|Aspirin 81 enteric coated tablet daily|Will be recommended to IMT women without contraindications or bleeding risk.
219374251|NCT03417388|BEHAVIORAL|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
219374252|NCT03417388|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
219754310|NCT06924138|OTHER|Exercise|The patients included in the study will be randomly divided into two groups as the study and control groups. Randomization will be provided by a computer-aided program. The patients in the study and control groups will be evaluated at the beginning and after six weeks. Functional Respiratory Muscle Training will be given to the study group with the Powerbreathe Respironics® (UK) device. The initial training intensity will be set at 50% (threshold loading) of the MIP value measured in the patient's first evaluation. The patient will be re-evaluated and the new MIP value will be measured, increasing by 10% every 2 weeks, and the training intensity will be adjusted by calculating the measured MIP value. Patients will be asked to work four days a week until the exercise sets are completed.
219754311|NCT06924138|OTHER|Standart therapy|In the control group, the same balance exercises will be performed and will not be changed for six weeks.
219187914|NCT06534671|DRUG|diltiazem|IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
219374253|NCT02243878|RADIATION|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
219374254|NCT02243878|DRUG|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
219374255|NCT03667820|DRUG|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
219374256|NCT03667820|RADIATION|SABR|Stereotactic Ablative Radiation (SABR)
219374257|NCT03890679|DIAGNOSTIC_TEST|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
219374258|NCT05011396|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
219374259|NCT05011396|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
219374260|NCT02251743|DEVICE|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)"
219374261|NCT00215150|DRUG|Ziprasidone|Sertraline augmentation with ziprasidone
219374262|NCT00215150|DRUG|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
219374263|NCT00077454|DRUG|erlotinib hydrochloride|Given orally (PO)
219374264|NCT00077454|DRUG|temozolomide|Given PO
219374265|NCT00077454|OTHER|pharmacological study|Correlative studies
219374266|NCT00077454|OTHER|laboratory biomarker analysis|Correlative studies
219374267|NCT01810887|DRUG|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
219374268|NCT01810887|DRUG|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
219374269|NCT03052153|OTHER|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
219374270|NCT00716521|DRUG|placebo|single oral dose placebo
219374271|NCT00716521|DRUG|zolpidem|single oral dose, 5 mg zolpidem
219374272|NCT00716521|DRUG|zolpidem|single oral dose, 10 mg zolpidem
219374273|NCT04154488|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
219374274|NCT03581942|DRUG|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
219374275|NCT03581942|DRUG|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
219374276|NCT06144515|PROCEDURE|Blood test|"Blood is collected in order to perform in vitro research:~1. If a routine blood test is performed for clinical tests, the sponsor will receive the results of the Complete blood count (CBC) and an additional blood sample from the same puncture of 20ml to maximum 40ml will be collected for this study.~2. If no routine blood test is performed for clinical tests, a CBC will be performed for the study and an additional blood sample of 20ml to maximum 40ml will be collected.~Additional Bone marrow (BM) material will be obtained from the same puncture performed for routine clinical tests:"
219374277|NCT05464355|PROCEDURE|Intraoperative electroencephalography recording|Intraoperative electroencephalography measurements, a non-invasive routine monitoring device used during anaesthesia to measure the brain's electrical activity
219374278|NCT05464355|PROCEDURE|Neurofilament light chain measurement|Measurement of the level of neurofilament light chain in a blood sample
219374279|NCT05464355|PROCEDURE|Tau protein measurement|Measurement of the level of tau protein in a blood sample
219374280|NCT03021577|DEVICE|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
219374281|NCT03021577|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
219374282|NCT03021577|PROCEDURE|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
219374283|NCT02231775|DRUG|Dabrafenib|Given PO
219374284|NCT02231775|OTHER|Laboratory Biomarker Analysis|Correlative studies
219374285|NCT02231775|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219374286|NCT02231775|DRUG|Trametinib|Given PO
219374287|NCT04057105|DEVICE|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
219374288|NCT04057105|DEVICE|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
219374289|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
219374290|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
219754312|NCT06900439|OTHER|Dietary Intervention|To carry out a dietary intervention using a standardized test meal where the participant's postprandial glucose to the meal is measured with a continuous glucose monitor and compared to the participant's postprandial glucose from the same standardized test meal 4 months prior.
219754313|NCT05961709|DRUG|Cemiplimab|Given by IV (vein)
219754314|NCT06747468|DRUG|Avexitide|Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
219754315|NCT06747468|OTHER|Placebo|Matching placebo comparator
219754316|NCT06777121|OTHER|Shoulder exercises + Thoracic extension exercise|Shoulder exercises and thoracic extension exercises were performed 5 days a week for 3 weeks.
219754317|NCT06777121|OTHER|Shoulder exercises + Thoracic kinesio taping|In addition to shoulder exercises, thoracic kinesio taping was applied. Shoulder exercises were performed 5 days a week for 3 weeks. TKT was applied once a week and remained in place for 5 days.
219374291|NCT02407535|DEVICE|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
219754318|NCT06777121|OTHER|Shoulder exercises|Shoulder exercises were performed. They were performed 5 days a week for 3 weeks.
219374292|NCT04489654|BIOLOGICAL|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
219374293|NCT02935972|DRUG|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
219374294|NCT02935972|DRUG|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
219374295|NCT02935972|DRUG|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
219374296|NCT02768376|DRUG|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
219374297|NCT02768376|DRUG|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
219374298|NCT02947919|BEHAVIORAL|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
219374299|NCT04627740|DRUG|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
219374300|NCT06147024|OTHER|historical control|Received a conventional preoperative assessment
219374301|NCT06147024|OTHER|3D printed lesion model|Received 3D printed lesion models for preoperative planning
219374302|NCT04339868|DRUG|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
219374303|NCT04339868|DRUG|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
219374304|NCT02718820|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
219374305|NCT02718820|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
219374306|NCT02670876|BEHAVIORAL|Anti-bullying intervention|"The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem"
219754319|NCT06906926|RADIATION|Certain imaging assessments can be non-Standard of Care|Pre-Implant CT, Chest X-Ray at discharge and any related assessments during the following up visit, can be non-standard of care depending on site's / countries.
219187915|NCT02460458|DRUG|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
219374307|NCT05738915|DIAGNOSTIC_TEST|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
219374308|NCT01816503|DRUG|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
219374309|NCT05388851|OTHER|Educational Intervention|Complete educational training module
219374310|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
219374311|NCT00755820|BEHAVIORAL|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
219374312|NCT00755820|BEHAVIORAL|Exposure Therapy + Placebo|Exposure therapy with placebo medication
219374313|NCT00755820|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy
219374314|NCT00975091|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
219374315|NCT00975091|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
219374316|NCT03904927|OTHER|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
219374317|NCT03904927|DRUG|Systemic therapy|"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
219374318|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
219374319|NCT01121289|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219374320|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
219374321|NCT01121289|DRUG|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
219374322|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
219374323|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
219374324|NCT00260208|DRUG|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
219754320|NCT06828406|BEHAVIORAL|TeamBirth|TeamBirth
219754321|NCT07103304|OTHER|Search for activating somatic genetic mutations|"This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation.~These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care)."
219754322|NCT06914479|GENETIC|Ad-hCMV-Flt3L|Given via injection
219374325|NCT00260208|DRUG|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
219374326|NCT06144008|BEHAVIORAL|Answering questionnaire|A questionnaires for each group has been developped and will be distributed for voluntary and anonymous completion.
219374327|NCT02979314|DEVICE|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
219374328|NCT01929252|DRUG|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
219374329|NCT01929252|DRUG|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
219374330|NCT02091440|DEVICE|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
219374331|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
219374332|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
219374333|NCT02144649|OTHER|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
219374334|NCT02144649|OTHER|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
219374335|NCT06109545|PROCEDURE|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
219374336|NCT02154646|DRUG|LY2157299|Administered orally
219374337|NCT02154646|DRUG|Gemcitabine|Administered IV
219374338|NCT00768222|DEVICE|silk suture|skin closure
219374339|NCT00768222|DEVICE|VICRYL* Plus suture|skin closure
219374340|NCT02602509|DRUG|Celecoxib|
219374341|NCT02602509|DRUG|Rifampicin|
219374342|NCT02602509|DRUG|Pyrazinamide|
219374343|NCT04153630|BIOLOGICAL|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
219374344|NCT05152186|DRUG|Topical Solution|Topical administration
219374345|NCT05152186|DRUG|Topical Foam|Topical administration
219374346|NCT05152186|OTHER|Topical|Topical administration
219187916|NCT06408714|DRUG|Nalmefene Injection|"Subjects in this arm will be administered intravenous nalmefene with a dosing scheme of:~0.5 mg Nalmefene IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 1.0 mg nalmefene will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
219374347|NCT03576144|DRUG|BI 1265162|Multiple rising inhaled doses
219374348|NCT03576144|DRUG|Placebo|Multiple rising inhaled doses
219374349|NCT00779129|DRUG|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
219374350|NCT00779129|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
219374351|NCT02505048|DRUG|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
219374352|NCT00278629|BIOLOGICAL|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
219374353|NCT06390670|DIETARY_SUPPLEMENT|Colostrum Bovinum supplementation|In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.
219374354|NCT06390670|OTHER|Placebo treatment|In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
219374355|NCT04250584|DEVICE|iSlpr™|mandibular advancement device
219374356|NCT04250584|DEVICE|SomnoDent® Classic|mandibular advancement device
219374357|NCT01444716|BIOLOGICAL|Ofatumumab|Given IV
219374358|NCT03420976|DIETARY_SUPPLEMENT|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
219374359|NCT01716819|OTHER|Urine sample|dosages on one spot and 24h collection
219374360|NCT01716819|OTHER|Blood sample|dosages
219374361|NCT01716819|OTHER|Assessment of sleep apnea syndrome|
219374362|NCT01716819|OTHER|Electrocardiogram|
219187917|NCT06408714|DRUG|Naloxone Injection|"Subjects in this arm will be administered intravenous naloxone with a dosing scheme of:~0.4 mg Naloxone IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 0.4 mg of naloxone will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
219187918|NCT06207994|DEVICE|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
219187919|NCT06207994|DEVICE|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
219187920|NCT03446391|PROCEDURE|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
219187921|NCT03446391|PROCEDURE|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
219187922|NCT03446391|DEVICE|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
219187923|NCT05892861|BEHAVIORAL|cognitive stimulation|video education, board games, and 24-hour dietary recall record
219187924|NCT05892861|OTHER|as usual care|history taking, explain data, and discuss how to control healthy condition
219187925|NCT05464537|OTHER|Unipolar Polarity Switch Left|10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP
219187926|NCT05464537|OTHER|Unipolar Polarity Switch Right|10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins
219187927|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
219187928|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
219187929|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
219187930|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
219187931|NCT06096272|DEVICE|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
219187932|NCT06061471|DRUG|AK111|AK111 regimen 1-subcutaneous injection,until week 24.
219187933|NCT06061471|DRUG|AK111|AK111 regimen 2-subcutaneous injection,until week 24.
219187934|NCT05866627|DRUG|Famotidine|Specified dose on specified days
219187935|NCT05866627|DRUG|Afimetoran|Specified dose on specified days
219187936|NCT05778851|DEVICE|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
219187937|NCT06274593|DEVICE|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
219374363|NCT01716819|OTHER|Glucose tolerance test|
219374364|NCT01716819|OTHER|Echocardiography|
219374365|NCT01716819|OTHER|cardiac and abdominal magnetic resonance imaging|
219374366|NCT01716819|OTHER|Ambulatory blood pressure monitoring|
219754323|NCT06914479|GENETIC|Ad-hCMV-TK|Given via injection
219187938|NCT06185660|DRUG|sodium zirconium cyclosilicate (SZC)|sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
219187939|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
219187940|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
219374367|NCT01716819|OTHER|Echotracking|
219374368|NCT01716819|OTHER|Pulse wave velocity|
219374369|NCT01716819|OTHER|Composition of body mass by Dual x-ray absorptiometry|
219374370|NCT00507715|DRUG|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
219754324|NCT06914479|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219754325|NCT06914479|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219754326|NCT06914479|OTHER|Survey Administration|Ancillary studies
219754327|NCT06914479|PROCEDURE|Tumor Resection|Undergo standard of care tumor resection
219754328|NCT06914479|DRUG|Valacyclovir|Given PO
219754329|NCT01400412|DRUG|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
219754330|NCT01400412|DRUG|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
219374371|NCT00507715|OTHER|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
219374372|NCT00659672|DIETARY_SUPPLEMENT|Whey Protein|40 grams per day Whey Protein
219374373|NCT00659672|DIETARY_SUPPLEMENT|Soy Protein|40 grams per day soy protein
219374374|NCT00659672|DIETARY_SUPPLEMENT|Control (carbohydrate)|40 grams per day maltodextrin
219374375|NCT04996056|DRUG|TNX-1300|TNX 1300 200 mg Intravenous injection
219374376|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
219374377|NCT06456177|DEVICE|Assessment of nociception in obstetric patients during epidural analgesia|Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index
219374378|NCT00762151|OTHER|Negative Control (Regular Toothpaste)|Regular Toothpaste
219374379|NCT00762151|OTHER|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
219374380|NCT00762151|DRUG|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
219374381|NCT03714893|DEVICE|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
219374382|NCT01979107|BEHAVIORAL|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
219374383|NCT00826748|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
219374384|NCT02261623|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
219374385|NCT02261623|DEVICE|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
219374386|NCT02261623|DEVICE|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
219374387|NCT04214080|OTHER|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
219374388|NCT04214080|OTHER|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
219374389|NCT04214080|OTHER|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
219374390|NCT04807361|BEHAVIORAL|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
219374391|NCT00537719|DRUG|GSK716155|albiglutide subcutaneous injection
219374392|NCT00537719|DRUG|Placebo|placebo injection
219374393|NCT00044447|DRUG|Glimepiride|
219374394|NCT02063529|DRUG|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
219374395|NCT02063529|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
219374396|NCT05367531|DEVICE|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
219374397|NCT05367531|DEVICE|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
219754331|NCT01400412|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
219754332|NCT01400412|DRUG|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
219754333|NCT01400412|DRUG|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
219187941|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
219187942|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
219187943|NCT05700071|DIAGNOSTIC_TEST|MRI|MRI without contrast agent
219187944|NCT03022942|OTHER|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
219187945|NCT03022942|OTHER|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
219187946|NCT05330767|DEVICE|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
219187947|NCT05330767|DEVICE|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
219187948|NCT05330767|DEVICE|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
219187949|NCT06218355|OTHER|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
219187950|NCT06218355|OTHER|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
219187951|NCT04496895|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
219187952|NCT04496895|DIETARY_SUPPLEMENT|orange peel fermentation|consume 1 sachet per day for 2 months
219187953|NCT04347187|DRUG|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
219187954|NCT06730295|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 39-42Gy/3 fractions, administered once daily. FBCT and 4DCT will be acquired.
219187955|NCT05658224|BEHAVIORAL|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
219374398|NCT05367531|DEVICE|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
219374399|NCT04529265|DRUG|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia for 1 h and 1mg/kg MB with 30 min before the end of surgery
219374400|NCT04529265|DRUG|Placebo|Equal volume of normal saline after induction of anesthesia for 1 h and Equal volume of normal saline within 30 min before the end of surgery
219374401|NCT05802810|DRUG|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
219374402|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
219754334|NCT01400412|DRUG|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
219754335|NCT01400412|DRUG|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
219187956|NCT05407792|DRUG|Staphylococcus and Neisseria Tablets|0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
219187957|NCT05407792|OTHER|On-demand treatment|At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
219374403|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
219754336|NCT07149597|RADIATION|Mobile CBCT Three-Dimensional Scanning|Mobile CBCT Three-Dimensional Scanning
219754337|NCT07159334|DRUG|Lignocaine Ointment|Applied to the anal wound three time daily after hemorrhoidectomy.
219754338|NCT07159334|DRUG|Glyceryl Trinitrate Ointment 0.2%|Applied to the anal wound three time daily after hemorrhoidectomy.
219374404|NCT04181424|BEHAVIORAL|Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
219374405|NCT04181424|BEHAVIORAL|Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
219374406|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
219374407|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
219374408|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
219374409|NCT01702116|PROCEDURE|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
219374410|NCT01702116|PROCEDURE|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
219374411|NCT02747784|BEHAVIORAL|Cognitive training program RehaCom®|Cognitive training program RehaCom®
219374412|NCT06499636|OTHER|other|other
219374413|NCT03765645|DRUG|Piperacillin + Tazobactam|Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
219374414|NCT01649700|BIOLOGICAL|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
219374415|NCT02354833|DRUG|Phenylephrine|
219374416|NCT02354833|DRUG|Norepinephrine|
219374417|NCT06640907|BEHAVIORAL|e-Perinatal personalized mHealth intervention integrated into routine maternal care|The e-Perinatal intervention combines a personalized mobile health (mHealth) app with targeted training for healthcare professionals to support perinatal mental health within routine maternal care. Participants allocated to the intervention arm will use the app for a period of two months. The app offers psychoeducational content, video-guided physical activities, mindfulness exercises, mood-tracking tools, personalized recommendations through a rule-based algorithm, and social-community features. Healthcare professionals assigned to the intervention arm receive specialized training to integrate the app into their daily practice, enhancing their ability to promote and support mental health during the perinatal period.
219374418|NCT06640907|OTHER|Standard routine maternal care with general perinatal health information|Standard maternal care as routinely provided by the Andalusian public healthcare system (Spain). This includes scheduled visits with midwives, nurses, and pediatrician for maternal and infant health monitoring, as well as access to childbirth education programmes. Participants also receive monthly psychoeducational emails (two months) containing general information on perinatal mental health, pregnancy, and infant development. Healthcare professionals in this arm do not receive specialized training in perinatal mental health or in the use of digital interventions, and participants do not have access to the e-Perinatal app.
219374419|NCT05485480|DRUG|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
219374420|NCT05485480|DRUG|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
219374421|NCT05196269|DEVICE|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and postoperative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have access to the software installed, and they will have access to all the information about the type of treatment they will receive. All the questions and questionnaires will be filled out online, and they can visualise the expected outcome from excellent to poor.
219374422|NCT01762579|DIETARY_SUPPLEMENT|wheat flour|wheat flour is administered three times per day for 15 days
219374423|NCT01762579|DIETARY_SUPPLEMENT|Xylose|Xylose will be administered three times per day for 15 days
219374424|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
219374425|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
219374426|NCT05528146|DIETARY_SUPPLEMENT|Psyllium huks|psyllium in 250ml of water
219187958|NCT03288948|OTHER|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
219187959|NCT04562441|DRUG|Axitinib|Axitinib: 5 mg bd po Day 1 to Day 28
219187960|NCT04562441|DRUG|Avelumab|Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
219187961|NCT05070728|DRUG|Sham Injector|Intravitreal sham injection
219187962|NCT05070728|DRUG|FAI Insert|"Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle."
219187963|NCT03029429|DRUG|Theophylline|oral theophylline
219187964|NCT03029429|DRUG|Placebos|oral placebo
219187965|NCT05217615|BEHAVIORAL|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
219187966|NCT05217615|BEHAVIORAL|Coaching calls|The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
219187967|NCT05217615|BEHAVIORAL|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
219187968|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
219187969|NCT06038162|PROCEDURE|Parallel connection|The RRT machine is connected on a separate vascular access (dialysis catheter).
219187970|NCT06038162|PROCEDURE|Integrated connection|A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
219187971|NCT04197310|DRUG|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
219187972|NCT04197310|DRUG|Cabozantinib|40mg, orally, Daily for a 28 day cycle
219187973|NCT02589795|BIOLOGICAL|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
219187974|NCT02589795|BIOLOGICAL|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
219187975|NCT02589795|DEVICE|Trigrid Delivery System - Intramuscular|Electroporation
219187976|NCT02589795|DEVICE|Trigrid Delivery System - Intradermal|Electroporation
219187977|NCT06303518|OTHER|High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'High Normal ETCO2' (50 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
219187978|NCT06303518|OTHER|Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Normal ETCO2' (40 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
219187979|NCT06303518|OTHER|Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Low Normal ETCO2' (30 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
219187980|NCT04879615|DRUG|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
219187981|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
219187982|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
219187983|NCT03746964|PROCEDURE|Cardiac MRI|Preoperative cardiac MRI
219187984|NCT03746964|OTHER|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
219187985|NCT05698290|OTHER|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
219374427|NCT06140927|DRUG|Ketamine|Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
219374428|NCT06654726|DRUG|aldafermin|aldafermin
219374429|NCT06654726|DRUG|Placebo|placebo
219374430|NCT06161012|DEVICE|Senofilcon A contact lenses (TEST)|Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
219374431|NCT06161012|DEVICE|Delefilcon A contact lenses (CONTROL)|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
219374432|NCT02601950|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
219374433|NCT06136546|DRUG|Infliximab|Intravenous infusion of infliximab
219374434|NCT06136546|OTHER|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
219374435|NCT03481647|PROCEDURE|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
219187986|NCT04046861|DIETARY_SUPPLEMENT|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
219187987|NCT04046861|OTHER|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
219187988|NCT04942613|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
219187989|NCT04942613|OTHER|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
219187990|NCT04942613|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
219187991|NCT04942613|OTHER|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
219187992|NCT05668260|DEVICE|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
219187993|NCT02570373|DRUG|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
219187994|NCT05235113|DEVICE|Tele-Exergame Platform|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
219187995|NCT05235113|DEVICE|No Tele-Exergame Platform|Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
219187996|NCT05060315|COMBINATION_PRODUCT|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
219187997|NCT06364631|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
219187998|NCT06364631|DRUG|Ipilimumab|"The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle."
219187999|NCT06364631|DRUG|Pembrolizumab|Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
219188000|NCT06364631|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
219188001|NCT06364631|DRUG|Axitinib|Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
219188002|NCT06364631|DRUG|Lenvatinib|Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
219188003|NCT06525571|DRUG|Cysview|Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
219188004|NCT06525571|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
219188005|NCT06555484|DEVICE|Cross Over Assignment Supplemental Oxygen and Supplemental Air|"Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned)."
219188006|NCT05297773|BEHAVIORAL|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to 80% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
219374436|NCT06617039|DRUG|Remifentanil and ciprofol|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
219374437|NCT06617039|DRUG|esketamine 0.3mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
219374438|NCT06617039|DRUG|esketamine 0.5mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
219374439|NCT06617039|DRUG|Ciprofol|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
219374440|NCT06405425|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219374441|NCT06405425|DRUG|PD-1|Administration by intravenous infusion for a cycle of 3 weeks.
219374442|NCT04642287|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
219374443|NCT04642287|DRUG|Vaseline|Placebo
219374444|NCT04642287|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
219374445|NCT05817045|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
219374446|NCT05817045|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
219374447|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
219374448|NCT03829579|DRUG|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
219374449|NCT06417515|DRUG|Xiao-Yao-San|Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
219374450|NCT06417515|OTHER|Weight loss class(WLC) group|Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
219374451|NCT04962373|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
219374452|NCT03818269|PROCEDURE|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
219374453|NCT02148029|OTHER|Exercise|Upper and Lower extremity exercise
219374454|NCT02148029|OTHER|Standard Care|anticoagulation, compression, and ad-lib ambulation
219374455|NCT05424081|BEHAVIORAL|EMBER|Self-help tool to increase weight management engagement
219374456|NCT05424081|BEHAVIORAL|Control|List of weight management programs
219374457|NCT05010148|DRUG|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
219374458|NCT05010148|DRUG|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
219374459|NCT04676802|DRUG|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
219374460|NCT04676802|DRUG|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
219374461|NCT05505422|DEVICE|Routine ECMO|Routine ECMO during lung tansplant
219374462|NCT05505422|DEVICE|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field"
219374463|NCT01491087|BIOLOGICAL|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
219374464|NCT06159478|DRUG|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
219374465|NCT01725165|OTHER|Clinical Observation|Undergo clinical observation
219374466|NCT01725165|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219374467|NCT01725165|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219374468|NCT01725165|OTHER|Quality-of-Life Assessment|Ancillary studies
219374469|NCT01725165|PROCEDURE|Standard Follow-Up Care|Undergo standard maintenance therapy
219374470|NCT01725165|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219374471|NCT02896582|DRUG|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
219374472|NCT02896582|DRUG|Dexamethasone|40 mg D1 to D4 in GA-DHAP
219374473|NCT02896582|DRUG|Aracytine|2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
219374474|NCT02896582|DRUG|Cisplatinum|100 mg/m² D1 in GA-DHAP
219374475|NCT02896582|DRUG|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
219374476|NCT02896582|DRUG|Melphalan|140 mg/m² D-2 in GA-BEAM
219374477|NCT02896582|DRUG|Carmustine|300 mg/m² D-7 in GA-BEAM
219374478|NCT05113940|DRUG|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
219374479|NCT05113940|DRUG|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
219374480|NCT05113940|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
219374481|NCT05826353|DRUG|Ripasudil|K-321 ophthalmic solution
219374482|NCT05826353|DRUG|Placebo|Placebo ophthalmic solution
219374483|NCT05475002|OTHER|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
219374484|NCT05475002|OTHER|dementia education|dementia education manual and family support group
219374485|NCT04122196|DRUG|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
219374486|NCT04122196|DRUG|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
219374487|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Monococcum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Monococcum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
219374488|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Aestivum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Aestivum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
219374489|NCT04298762|OTHER|No peer comparison email|The comparison group received no email communication on their cancer stage documentation activity.
219374490|NCT04298762|OTHER|Peer comparison email|The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
219374491|NCT03389945|PROCEDURE|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
219374492|NCT03389945|PROCEDURE|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
219374493|NCT05881382|DRUG|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
219374494|NCT05881382|DRUG|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
219374495|NCT02688647|DRUG|Belumosudil|
219374496|NCT02688647|OTHER|BSC|Treatment/drug as determined by each subject's prescribing physician
219374497|NCT06500663|OTHER|haemodialysis|haemodialysis effect on thyroid function
219374498|NCT00382967|PROCEDURE|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
219374499|NCT03499431|DEVICE|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
219374500|NCT04384237|PROCEDURE|Er,Cr:YSGG laser-aided CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface
219557768|NCT06341504|BEHAVIORAL|Prevention pop-up messages|"Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages."
219374501|NCT04384237|PROCEDURE|Conventional CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
219374502|NCT04901572|DIAGNOSTIC_TEST|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
219374503|NCT05762926|OTHER|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
219374504|NCT03288298|DRUG|luteolin|flavonoid natural extract
219374505|NCT03288298|DRUG|nano-luteolin|nanoparticles of luteolin
219374506|NCT00378326|DRUG|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
219374507|NCT03881709|BEHAVIORAL|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
219374508|NCT04375306|PROCEDURE|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
219374509|NCT04375306|PROCEDURE|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
219374510|NCT01350089|DRUG|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
219374511|NCT01350089|DRUG|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
219374512|NCT01350089|DRUG|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
219374513|NCT01350089|DRUG|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
219374514|NCT05789992|DRUG|Propofol|Propofol (Random:3-5ug/ml)
219374515|NCT05789992|DRUG|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
219374516|NCT05789992|DRUG|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
219374517|NCT05789992|PROCEDURE|Intubation|Endotracheal intubation before surgery
219374518|NCT05789992|PROCEDURE|tetanic electrical stimulation|tetanic electrical stimulation before surgery
219374519|NCT02073487|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
219374520|NCT02073487|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
219374521|NCT02073487|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
219374522|NCT02073487|DRUG|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
219374523|NCT02073487|DRUG|Paclitaxel|chemotherapy - microtubule inhibitor
219374524|NCT02073487|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
219374525|NCT00000257|DRUG|0% N2O and 10% N2O|
219374526|NCT00000257|DRUG|0% N2O and 20% N2O|
219374527|NCT00000257|DRUG|0% N2O and 30% N2O|
219374528|NCT00000257|DRUG|0% N2O and 40% N2O|
219374529|NCT03049449|BIOLOGICAL|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
219374530|NCT03049449|DRUG|Cyclophosphamide|300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
219374531|NCT03049449|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
219374532|NCT00472693|DRUG|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
219374533|NCT04089956|OTHER|No interventation|A retrospective cohort Observational study with no intervention
219374534|NCT02281890|OTHER|Proven sepsis|Exposure is proven sepsis
219374535|NCT02075801|OTHER|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
219374536|NCT02075801|OTHER|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
219374537|NCT02069691|DEVICE|virtual reality-cycling training system|
219374538|NCT04106388|BEHAVIORAL|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
219374539|NCT00474240|DRUG|Atorvastatin 20 mg|
219374540|NCT00474240|DRUG|AEGR-733 5 mg|
219374541|NCT00474240|DRUG|AEGR-733 10 mg|
219374542|NCT00474240|DRUG|Placebo|
219374543|NCT00474240|DRUG|AEGR-733 5 mg + atorvastatin 20 mg|
219374544|NCT00474240|DRUG|AEGR-733 10 mg + atorvastatin 20 mg|
219374545|NCT02358811|DEVICE|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present."
219374546|NCT02358811|BEHAVIORAL|Cognitive assessment|"This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)"
219374547|NCT02493647|BEHAVIORAL|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
219374548|NCT02336477|DRUG|Mexiletine|"* Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~* Patients will receive gradual dose of the treatment as it would be done in clinical practice.~* Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~* The duration of each treatment period is 18 days minimum (maximum 22 days)."
219374549|NCT02336477|DRUG|placebo|
219374550|NCT05029050|DRUG|Dexmedetomidine|Continous intravenous infusion
219374551|NCT05029050|DRUG|Clonidine|Continous intravenous infusion
219374552|NCT05029050|DRUG|Natriumchlorid|Continous intravenous infusion NaCl
219374553|NCT00435422|PROCEDURE|Stroke volume optimization|Stroke volume optimization
219374554|NCT04653519|DEVICE|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
219374555|NCT05946343|DIAGNOSTIC_TEST|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
219374556|NCT01147497|DRUG|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
219374557|NCT01147497|DRUG|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
219374558|NCT00972699|BEHAVIORAL|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
219374559|NCT02818699|DIETARY_SUPPLEMENT|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
219374560|NCT02818699|DIETARY_SUPPLEMENT|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
219374561|NCT04134650|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
219374562|NCT04134650|DRUG|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
219374563|NCT03691714|DRUG|Durvalumab|Two hour infusion
219374564|NCT03691714|DRUG|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
219374565|NCT01994083|DRUG|Placebo|Administered orally
219374566|NCT01994083|DRUG|IX-01|Administered orally
219374567|NCT03495492|DEVICE|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
219374568|NCT03495492|DIETARY_SUPPLEMENT|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
219374569|NCT00753389|OTHER|None (anesthesia)|anesthesia
219374570|NCT04528485|OTHER|Sea swimming|8 sessions of swimming activities in the sea
219374571|NCT02991599|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
219374572|NCT02991599|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
219374573|NCT04698876|PROCEDURE|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
219374574|NCT04698876|PROCEDURE|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
219374575|NCT04698876|PROCEDURE|Blood pressure|Blood pressure measurement for 24 h
219374576|NCT00316823|GENETIC|gene expression analysis|
219374577|NCT00316823|GENETIC|polymerase chain reaction|
219374578|NCT00316823|GENETIC|reverse transcriptase-polymerase chain reaction|
219374579|NCT00316823|OTHER|diagnostic laboratory biomarker analysis|
219374580|NCT00316823|OTHER|immunohistochemistry staining method|
219374581|NCT00316823|PROCEDURE|needle biopsy|
219374582|NCT04864587|DIAGNOSTIC_TEST|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
219374583|NCT01262898|DRUG|GSK962040 (5 mg tablet)|5 mg tablet
219374584|NCT01262898|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
219374585|NCT01262898|DRUG|GSK962040 (125 mg tablet)|125 mg tablet
219374586|NCT01262898|DRUG|Placebo|matching placebo tablet
219374587|NCT00575861|DRUG|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
219374588|NCT04073550|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
219374589|NCT04073550|DRUG|Placebos|Anlotinib blank analog capsule.
219374590|NCT04073550|DRUG|Topotecan|A topoisomerase I inhibitor.
219374591|NCT05838326|DEVICE|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
219374592|NCT05838326|DEVICE|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
219374593|NCT02731742|BIOLOGICAL|MK-1966|MK-1966 administered as an intravenous (IV) infusion
219374594|NCT02731742|DRUG|SD-101|SD-101 administered as an intratumoral (IT) injection
219374595|NCT04035876|DRUG|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
219374596|NCT00055640|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
219374597|NCT00055640|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
219374598|NCT00055640|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
219374599|NCT00055640|DRUG|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
219374600|NCT00055640|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
219374601|NCT00055640|GENETIC|microarray analysis|genetic testing
219374602|NCT02363179|BEHAVIORAL|Live preferential music|Live preferential music will be performed for patients in the emergency department.
219374603|NCT03846245|OTHER|No intervention|No intervention
219374604|NCT04436302|DEVICE|Exergame device|motor-cognitive training
219374605|NCT00000402|DRUG|Calcium|
219374606|NCT03792048|PROCEDURE|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
219374607|NCT00921869|DRUG|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
219374608|NCT01412853|OTHER|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
219374609|NCT01576640|DRUG|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
219374610|NCT01576640|DRUG|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
219374611|NCT01576640|OTHER|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
219374612|NCT04857021|DIETARY_SUPPLEMENT|GABA|oral administration of GABA capsule once daily before sleep
219374613|NCT04857021|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo capsule once daily before sleep
219374614|NCT01617044|DIETARY_SUPPLEMENT|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
219374615|NCT01617044|DIETARY_SUPPLEMENT|Placebo|Placebo
219374616|NCT01316042|DRUG|sugar pill|2 pills per day for 12 months
219374617|NCT01316042|DRUG|Metformin, glucophage|2 212.5mg pills/day for 12 months
219374618|NCT04900402|OTHER|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
219374619|NCT04026568|DRUG|4-Aminopyridine|Single drug test for nerve continuity
219374620|NCT04026568|DRUG|Placebo oral tablet|Placebo arm
219374621|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
219374622|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
219374623|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
219374624|NCT00502840|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
219374625|NCT02197377|DEVICE|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
219374626|NCT02197377|DEVICE|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
219374627|NCT04278794|OTHER|Transitional Care Stroke Intervention (TCSI)|"Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
219374628|NCT01962220|BEHAVIORAL|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
219374629|NCT01974323|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
219754339|NCT07159724|DEVICE|back up, mollii-suit, compex, tens|"In order to be included in this study, individuals must have undergone at least one session of treatment with a biomedical device.~In the validity and reliability study of the Turkish version of the questionnaire, permission was first obtained from the questionnaire's author via e-mail. The Usefulness, Satisfaction and Ease of Use Questionnaire (USE) was translated from English into Turkish by two independent translators: one was a physiotherapist with a doctoral degree, and the other a faculty member at Hacettepe University School of Foreign Languages. Both translators were native Turkish speakers, fluent in English, and had no personal or professional interaction with each other. They evaluated the original questionnaire in terms of meaning and grammar to produce the Turkish version of the Usefulness, Satisfaction and Ease of Use Questionnaire (USE).~The independently translated Turkish versions of the questionnaire were then reviewed by an expert panel to reach consensus. This exp"
219374630|NCT01974323|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
219374631|NCT04076826|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
219374632|NCT04076826|DRUG|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
219374633|NCT04076826|DIAGNOSTIC_TEST|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
219374634|NCT05211167|DRUG|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
219374635|NCT05211167|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
219374636|NCT00331760|DRUG|cisplatin|
219374637|NCT00331760|RADIATION|intensity-modulated radiation therapy|
219374638|NCT01597947|DRUG|ACHN-975|Intravenous single dose
219374639|NCT01597947|DRUG|placebo|Intravenous single dose
219374640|NCT01380054|BEHAVIORAL|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
219374641|NCT04574726|OTHER|static balance|30-second right and left unipodal static balance test
219374642|NCT04574726|OTHER|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point"
219374643|NCT02786069|DRUG|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
219374644|NCT01969266|DRUG|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
219374645|NCT01969266|DRUG|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
219374646|NCT00347815|DRUG|Buprenorphine|
219374647|NCT02339948|RADIATION|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
219374648|NCT02514044|DRUG|Dexedrine|10 mg immediate release of Dexedrine
219374649|NCT02514044|DEVICE|Active tDCS|1.5 mA tDCS anodal tDCS
219374650|NCT02514044|BEHAVIORAL|Speech Therapy|60 min of speech therapy
219374651|NCT02514044|DRUG|Placebo|
219374652|NCT02514044|DEVICE|Sham tDCS|
219374653|NCT05631132|PROCEDURE|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
219374654|NCT01700829|DRUG|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
219374655|NCT01700829|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
219374656|NCT04177303|DRUG|Metformin|Participants will be randomized to metformin 2000 mg
219374657|NCT04177303|DRUG|Placebo|Participants will be randomized to placebo
219374658|NCT05357794|DRUG|Brentuximab vedotin|Given by Vein (IV)
219374659|NCT00431392|DRUG|Phenylephrine|
219374660|NCT00431392|DRUG|NG-Monomethyl-L-Arginine|
219374661|NCT00431392|DRUG|Propanolol|
219374662|NCT00431392|DRUG|Atropine|
219374663|NCT05871203|OTHER|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
219374664|NCT04996719|DRUG|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
219374665|NCT01629303|PROCEDURE|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
219374666|NCT00645086|DRUG|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
219374667|NCT00645086|DRUG|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
219374668|NCT04345419|DRUG|Remdesivir|Remdesivir as antiviral drug
219374669|NCT04345419|OTHER|Standard of care treatment|Standard of care treatment
219374670|NCT05146167|BEHAVIORAL|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
219374671|NCT05146167|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
219374672|NCT02331576|DRUG|rocaine|
219374673|NCT02331576|DRUG|Fentanyl|
219374674|NCT02739087|PROCEDURE|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
219374675|NCT02739087|DEVICE|Magnetic resonance imaging|
219374676|NCT05244772|OTHER|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
219374677|NCT05628922|DRUG|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
219374678|NCT05628922|OTHER|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles."
219374679|NCT00058864|DEVICE|Energy absorbing and distributing trochanteric pad|
219374680|NCT02561156|DRUG|TAK-653 Placebo|TAK-653 placebo-matching tablets.
219374681|NCT02561156|DRUG|TAK-653|TAK-653 tablets.
219374682|NCT05247411|OTHER|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
219374683|NCT00596544|BEHAVIORAL|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
219374684|NCT00596544|BEHAVIORAL|questionnaires|Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
219374685|NCT04007614|OTHER|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
219374686|NCT03898635|DRUG|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
219374687|NCT01330901|DRUG|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
219374688|NCT00358813|DRUG|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
219374689|NCT02351362|BEHAVIORAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
219374690|NCT04902235|DRUG|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
219374691|NCT04902235|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
219374692|NCT01071070|DRUG|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
219374693|NCT01130506|DRUG|Cytarabine|Given IV
219374694|NCT01130506|DRUG|Decitabine|Given IV
219374695|NCT01130506|OTHER|Laboratory Biomarker Analysis|Correlative studies
219374696|NCT01130506|OTHER|Pharmacological Study|Correlative studies
219374697|NCT01130506|DRUG|Vorinostat|Given PO
219374698|NCT05859087|BEHAVIORAL|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
219374699|NCT05859087|BEHAVIORAL|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
219374700|NCT03651843|OTHER|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
219374701|NCT00021294|DRUG|eflornithine|
219374702|NCT00021294|DRUG|triamcinolone|
219374703|NCT01591980|DRUG|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
219374704|NCT01591980|DRUG|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
219374705|NCT01591980|DRUG|placebo|Identical placebo capsules will be administered in the same way.
219374706|NCT05137938|DRUG|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
219374707|NCT00745108|DRUG|tibolone|oral 1.25 mg tablet, once daily, for 2 years
219374708|NCT00745108|DRUG|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
219374709|NCT00745108|DRUG|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
219374710|NCT05503953|DRUG|AGSAVI|Uptitation
219374711|NCT05503953|DRUG|AGLS|Uptitration
219374712|NCT02760628|BEHAVIORAL|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
219374713|NCT02760628|BEHAVIORAL|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
219374714|NCT03469076|OTHER|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
219374715|NCT04894799|OTHER|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
219374716|NCT04894799|OTHER|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
219374717|NCT03152292|OTHER|Real-world, non-interventional|N/A - non-interventional
219374718|NCT05329116|DRUG|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
219374719|NCT05329116|BIOLOGICAL|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
219374720|NCT04714112|DRUG|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
219374721|NCT01549990|DRUG|Sevoflurane|maintenance of general anesthesia with sevoflurane
219374722|NCT01549990|DRUG|desflurane|maintenance of general anesthesia with desflurane
219374723|NCT01948492|DIETARY_SUPPLEMENT|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
219374724|NCT00267735|BEHAVIORAL|Use of Computerized Decision Aid on Childbirth|
219374725|NCT03058484|BEHAVIORAL|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
219374726|NCT06124989|DIAGNOSTIC_TEST|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
219374727|NCT03415165|DRUG|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
219374728|NCT03415165|DRUG|Corticosteroids Topical|kenacort in orabase 4 times aday
219374729|NCT02594501|DEVICE|COBRA PzF|
219374730|NCT02594501|DEVICE|Drug Eluting Stent|
219374731|NCT00426348|DRUG|Valsartan|Valsartan (80-160mg/day)
219374732|NCT00426348|DRUG|Probucol|Probucol (750mg/day)
219374733|NCT00426348|DRUG|Placebo|Placebo
219374734|NCT03128463|DRUG|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
219374735|NCT02351102|DRUG|Valacyclovir|
219374736|NCT02351102|DRUG|Placebo|
219374737|NCT03205579|OTHER|Video group|Using video for educate cancer pain patients
219374738|NCT03205579|OTHER|conventional group|Face to face cancer pain education by trained nurse
219374739|NCT02000609|DRUG|CHF 1535 NEXThaler 800/48|
219374740|NCT02000609|DRUG|CHF 1535 NEXThaler 200/12|
219374741|NCT02000609|DRUG|CHF 1535 NEXThaler PLACEBO|
219374742|NCT02000609|DRUG|CHF 1535 pMDI 200/12|
219374743|NCT02000609|DRUG|CHF1535 pMDI 800/48|
219374744|NCT02862769|DRUG|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
219374745|NCT02862769|DRUG|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
219374746|NCT03723447|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
219374747|NCT03723447|DRUG|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
219374748|NCT03733652|DRUG|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
219374749|NCT00533962|DRUG|Anterior Juxtascleral Depot of Anecortave Acetate|
219374750|NCT00864240|DRUG|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
219374751|NCT00691665|DRUG|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
219374752|NCT00691665|DRUG|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
219374753|NCT05750940|DIAGNOSTIC_TEST|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
219374754|NCT01492010|DIETARY_SUPPLEMENT|whey protein|25 g whey protein
219374755|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
219374756|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
219374757|NCT01865292|DRUG|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
219374758|NCT01865292|DRUG|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
219374759|NCT03505268|BEHAVIORAL|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
219374760|NCT00006120|DRUG|docetaxel|
219374761|NCT00006120|DRUG|paclitaxel|
219374762|NCT05468970|OTHER|NO Intervention|NO Intervention
219374763|NCT05595525|DEVICE|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
219374764|NCT05595525|DEVICE|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
219374765|NCT03048630|BEHAVIORAL|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
219374766|NCT04917926|BEHAVIORAL|Financial and social incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
219374767|NCT04917926|BEHAVIORAL|Financial incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
219374768|NCT03456115|DEVICE|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
219374769|NCT00476099|DRUG|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
219374770|NCT00476099|DRUG|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
219374771|NCT00476099|DRUG|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
219374772|NCT00152633|DRUG|Losartan|
219374773|NCT00152633|DRUG|Metoprolol|
219374774|NCT00152633|DRUG|Losartan|Treatment with Losartan
219374775|NCT05555004|OTHER|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
219374776|NCT05555004|OTHER|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
219374777|NCT04586491|COMBINATION_PRODUCT|Oral care protocol|Oral care protocol
219374778|NCT05567523|DRUG|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
219374779|NCT05567523|DRUG|Normal saline|normal saline
219374780|NCT05567523|DRUG|Midazolam|midazolam
219374781|NCT04417257|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
219374782|NCT04417257|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
219374783|NCT03314285|OTHER|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
219374784|NCT04453111|BIOLOGICAL|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
219374785|NCT04453111|BIOLOGICAL|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
219374786|NCT04453111|DRUG|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
219374787|NCT05379751|PROCEDURE|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
219374788|NCT02209506|DRUG|MLN3126|MLN3126 tablets
219374789|NCT02209506|DRUG|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
219374790|NCT05963503|OTHER|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
219374791|NCT05886361|OTHER|No intervention involved|No intervention involved
219374792|NCT02100384|PROCEDURE|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
219374793|NCT00098787|BIOLOGICAL|bevacizumab|Given IV
219374794|NCT00098787|DRUG|fluorouracil|Given IV
219374795|NCT00098787|DRUG|irinotecan hydrochloride|Given IV
219374796|NCT00098787|DRUG|leucovorin calcium|Given IV
219188007|NCT05297773|BEHAVIORAL|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
219188008|NCT05297773|OTHER|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
219188009|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
219188010|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
219188011|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219374797|NCT00098787|DRUG|Oxaliplatin|Given IV
219374798|NCT01422330|DRUG|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
219374799|NCT00003688|BIOLOGICAL|dactinomycin|
219374800|NCT04421326|OTHER|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
219374801|NCT04427254|DRUG|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
219557769|NCT06341504|BEHAVIORAL|Mandatory time limit|Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
219188012|NCT05574114|RADIATION|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
219188013|NCT05574114|DRUG|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
219188014|NCT05574114|BIOLOGICAL|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
219188015|NCT04934527|DRUG|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
219374802|NCT03827161|DIETARY_SUPPLEMENT|Glucosamine|Given PO
219374803|NCT03827161|OTHER|Placebo|Given PO
219374804|NCT03501862|BEHAVIORAL|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
219374805|NCT03501862|BEHAVIORAL|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
219374806|NCT01834404|DRUG|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
219374807|NCT01834404|DRUG|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
219374808|NCT00116025|DRUG|Human acylated ghrelin|
219374809|NCT01520246|GENETIC|gene expression analysis|
219374810|NCT01520246|OTHER|laboratory biomarker analysis|
219374811|NCT02203149|DRUG|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
219374812|NCT02203149|DRUG|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
219374813|NCT02203149|DRUG|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
219374814|NCT02203149|DRUG|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
219374815|NCT02537678|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
219374816|NCT02537678|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
219374817|NCT01360996|DRUG|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
219374818|NCT02229734|RADIATION|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
219374819|NCT02229734|DRUG|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
219374820|NCT03496701|DEVICE|Test lens|contact lens
219374821|NCT03496701|DEVICE|control lens|contact lens
219374822|NCT02633176|DRUG|Cetuximab|400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
219374823|NCT02633176|DRUG|Cisplatin|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
219374824|NCT02633176|DRUG|Docetaxel|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
219374825|NCT02633176|DRUG|Capecitabine|1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
219374826|NCT02633176|RADIATION|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
219557770|NCT06341504|BEHAVIORAL|Responsible gambling information|Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
219188016|NCT05347745|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
219188017|NCT06530277|BEHAVIORAL|REMINDer (A digital environmental enrichment intervention)|"REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3."
219188018|NCT03670524|OTHER|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
219188019|NCT06252597|BEHAVIORAL|education and training|education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training
219188020|NCT06106607|BEHAVIORAL|Intervention group|"A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises."
219188021|NCT03344848|DEVICE|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
219374827|NCT01766648|DEVICE|Far Cortical locking screw fixation|Standard screw fixation
219374828|NCT01766648|DEVICE|Standard screw fixation|
219374829|NCT02604004|DRUG|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
219374830|NCT02604004|DRUG|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
219374831|NCT00646893|PROCEDURE|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
219374832|NCT04125537|BEHAVIORAL|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
219374833|NCT02747485|DEVICE|Cardiac MRI|
219374834|NCT02747485|BIOLOGICAL|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
219374835|NCT02747485|PROCEDURE|myocardial biopsy|
219374836|NCT02747485|GENETIC|blood samples|extract DNA to look for genomic mutations associated with the disease.
219374837|NCT00242918|DRUG|docetaxel|
219374838|NCT00242918|DRUG|ZD1839|
219374839|NCT01454076|DRUG|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
219374840|NCT01454076|DRUG|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
219374841|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
219188022|NCT05706857|BEHAVIORAL|Ultra Fast-track|Patients are extubated in the operating room
219188023|NCT05402436|OTHER|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
219188024|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
219374842|NCT01454076|DRUG|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
219374843|NCT01454076|DRUG|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
219374844|NCT01454076|DRUG|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
219374845|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
219374846|NCT05658757|OTHER|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
219374847|NCT05658757|OTHER|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
219374848|NCT05658757|OTHER|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
219374849|NCT05054855|BEHAVIORAL|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
219374850|NCT04964258|DRUG|TAK-105-a|TAK-105-a subcutaneous solution.
219374851|NCT04964258|DRUG|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
219374852|NCT01361256|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
219374853|NCT01361256|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
219374854|NCT01311778|DRUG|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
219374855|NCT01311778|DRUG|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
219188025|NCT04769310|DEVICE|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
219188026|NCT03928093|DRUG|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
219188027|NCT05184738|OTHER|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
219188028|NCT05184738|OTHER|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
219374856|NCT00895063|BEHAVIORAL|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
219374857|NCT02836561|OTHER|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
219374858|NCT02769598|DEVICE|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
219374859|NCT00817271|DRUG|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
219374860|NCT00817271|DRUG|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
219374861|NCT05747989|PROCEDURE|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
219374862|NCT05747989|PROCEDURE|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
219374863|NCT03182530|DEVICE|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
219374864|NCT03182530|DEVICE|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
219374865|NCT03182530|DEVICE|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
219374866|NCT00211406|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
219374867|NCT02190734|OTHER|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
219374868|NCT02190734|OTHER|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
219374869|NCT02190734|OTHER|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
219374870|NCT06488677|BEHAVIORAL|Lifestyle changes (diet and physical activity)|Nurse-led telephone personalized dietary and PA advice
219374871|NCT04077333|PROCEDURE|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
219374872|NCT03634982|DRUG|RMC-4630|RMC-4630 for oral administration
219374873|NCT01504503|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
219374874|NCT01504503|DRUG|Aricept|Aricept 10 mg Tablets
219374875|NCT02235818|DEVICE|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
219374876|NCT02235818|DEVICE|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
219374877|NCT06351202|OTHER|Abdominal massage|An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
219374878|NCT01478958|DIETARY_SUPPLEMENT|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
219374879|NCT01478958|DIETARY_SUPPLEMENT|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
219374880|NCT01478958|DIETARY_SUPPLEMENT|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
219374881|NCT04003129|OTHER|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
219374882|NCT01274221|DRUG|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
219374883|NCT01274221|OTHER|Placebo|1 capsule per day for one week of the double-blind crossover phase
219374884|NCT04288245|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
219374885|NCT04288245|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
219374886|NCT05465135|DRUG|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
219374887|NCT00003176|DRUG|carmustine|
219374888|NCT00003176|DRUG|temozolomide|
219374889|NCT05144425|PROCEDURE|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
219374890|NCT03401749|DRUG|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
219374891|NCT03401749|OTHER|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
219374892|NCT05213871|OTHER|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
219374893|NCT05213871|OTHER|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
219374894|NCT05213871|OTHER|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
219374895|NCT01193686|OTHER|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
219374896|NCT05003115|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
219374897|NCT04352920|OTHER|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
219188029|NCT06851715|OTHER|Clinic consultation focused on asthma self-management|The clinic healthcare professionals (HCPs) will be provided with the completed Adolescent Asthma Self-efficacy Questionnaire (AASEQ), which will help identify areas where participants need additional support to improve their asthma self-management skills. Targeted behavioural interventions, developed during the 'ItsMyAsthma' study, will be applied during the clinic consultation to address individual needs.
219188030|NCT06342102|PROCEDURE|PENG + LFCN block|The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.
219188031|NCT06342102|PROCEDURE|FIC block|FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
219374898|NCT01993472|DRUG|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
219374899|NCT01993472|DRUG|Capecitabine|
219374900|NCT03860506|DRUG|PSI-697|
219374901|NCT03860506|DRUG|Placebo|
219374902|NCT03075839|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
219188032|NCT05452564|DRUG|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
219374903|NCT04748029|OTHER|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
219374904|NCT02687269|DRUG|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
219374905|NCT02687269|DRUG|Placebo|Patients receive Placebo twice daily in the three days before surgery
219188033|NCT05452564|DRUG|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
219188034|NCT06851078|DRUG|Levetiracetam IV|1000 mg twice a day during 7 days maximum
219188035|NCT06851078|OTHER|Placebo control|NaCl 0.9% sodium chloride in the same route and method of administration as experimental treatment
219188036|NCT06851728|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
219188037|NCT02317887|BIOLOGICAL|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
219188038|NCT06758856|DIETARY_SUPPLEMENT|Trimethylglycine|Betaine anhydrous from sugar beets
219188039|NCT06758856|OTHER|Eggs|3 whole eggs
219188040|NCT06758856|DIETARY_SUPPLEMENT|Cellulose|Cellulose
219188041|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
219188042|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
219188043|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
219188044|NCT03172975|BIOLOGICAL|Placebo|Physiological sterile saline solution
219188045|NCT03172975|DRUG|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
219188046|NCT03172975|OTHER|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
219188047|NCT06828393|DRUG|S-1117|S-1117 via subcutaneous or intravenous administration.
219188048|NCT06828393|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
219188049|NCT05299671|BEHAVIORAL|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
219188050|NCT06451341|BEHAVIORAL|Acceptability of Intervention Measure (AIM)|"The Acceptability of Intervention Measure (AIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The AIM will measure the extent to which participants believe CAB+RPV LA implementation is acceptable."
219188051|NCT06451341|BEHAVIORAL|Intervention Appropriateness Measure (IAM)|"The Intervention Appropriateness Measure (IAM) questionnaire will be administered at Baseline to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The IAM will measure the extent to which participants believe CAB+RPV LA implementation is appropriate."
219188052|NCT06451341|BEHAVIORAL|Feasibility of Intervention Measure (FIM)|"The Feasibility of Intervention Measure (FIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The FIM will measure the extent to which participants believe CAB+RPV LA implementation is feasible."
219188053|NCT06451341|BEHAVIORAL|HIV Stigma Scale Questionnaire|"The HIV Stigma Scale Questionnaire used in this study is a shortened version of the validated 40-item HIV stigma scale. This 12-item questionnaire measures the same four stigma subscales measured in the original version, for a streamlined approach to collecting this data on personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image.~This will be administered at Baseline, Month 7 and Month 15."
219188054|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The status version will be administered at Baseline, Month 7 and Month 15."
219188055|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The change version will be administered at Month 15."
219188056|NCT06451341|BEHAVIORAL|Needs and Barriers Assessment|"The Needs and Barriers Assessment is a questionnaire designed to assess patient participant barriers and social determinants of health, emotional challenges related to antiretroviral therapy, and the impact of switching to CAB+RPV LA treatment.~This will be administered at Baseline, Month 7 and Month 15."
219374906|NCT01901887|DRUG|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
219374907|NCT01901887|DRUG|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
219374908|NCT01499290|DRUG|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
219374909|NCT01499290|DRUG|Metronidazole|500 mg of Metronidazole
219374910|NCT01499290|DRUG|Meropenem|1 gram of Meropenem
219374911|NCT03885921|DRUG|Ezetimibe|oral tablet
219374912|NCT03885921|DRUG|Atorvastatin|oral tablet
219374913|NCT03885921|DRUG|Simvastatin|oral tablet
219374914|NCT03561727|PROCEDURE|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
219188057|NCT06451341|BEHAVIORAL|Pre-visit Outreach|Patient participants will be contacted prior to each clinical injection visit for an appointment reminder and a needs assessment.
219188058|NCT06451341|BEHAVIORAL|Qualitative interview|Qualitative interviews will be conducted within thirty days after study completion at Month 15 to further evaluate the participant's experience with the implementation of CAB+RPV LA treatment.
219374915|NCT03561727|PROCEDURE|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
219374916|NCT00495027|BEHAVIORAL|Internet-delivered Stress Innoculation Training|
219374917|NCT04052139|DRUG|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
219374918|NCT04052139|DRUG|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
219374919|NCT04052139|DRUG|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
219374920|NCT03603743|BEHAVIORAL|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
219374921|NCT06162455|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
219188059|NCT06451341|BEHAVIORAL|Staff education|Staff participants will participate in Extension for Community Healthcare Outcomes (Project ECHO) educational sessions with topics such as fundamentals of HIV treatment and care, HIV outcomes, delivery of antiretroviral therapies (ART) including long-acting ART, cultural sensitivity, and social determinants of health in rural areas.
219374922|NCT06162455|DRUG|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
219374923|NCT03406962|DRUG|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
219374924|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
219374925|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
219374926|NCT03955367|RADIATION|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
219557771|NCT06341504|DEVICE|Electronic gambling machine (model IGT GL20)|"EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand."
219374927|NCT03955367|RADIATION|Pelvic irradiation|CTV covers pelvis.
219374928|NCT03955367|RADIATION|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
219374929|NCT03955367|DRUG|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
219374930|NCT03747952|PROCEDURE|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
219374931|NCT03747952|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
219374932|NCT02134600|DIETARY_SUPPLEMENT|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
219374933|NCT04960891|DRUG|Tebentafusp|Concentrate solution for intravenous infusion
219374934|NCT04884828|DEVICE|external gas during NIV|The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
219374935|NCT02646904|DRUG|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
219374936|NCT02646904|DRUG|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
219374937|NCT04782622|DRUG|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
219374938|NCT05681728|DRUG|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
219374939|NCT05681728|DRUG|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
219374940|NCT05681728|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
219374941|NCT05681728|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
219188060|NCT06848179|DIAGNOSTIC_TEST|Computer algorithms|Collection of computer algorithms called ausculto® that is designed to perform heart sound analysis to estimate heart rate and heart rate variability
219188061|NCT06848179|BEHAVIORAL|Exercise|Participants will be requested to exercise to raise their HR over the resting range while heart-related physiological signals are collected.
219188062|NCT06848725|BEHAVIORAL|Data quality development toolkit concerning the medical quality indicators (MQI)|"The toolkit uses a train-the-trainer strategy.~The research team will:~* develop training and support materials for external training providers and delegated staff (champions) from the long-term care facilities~* prepare external training providers within a one 3h session to train champions from the long-term care facilities~* organize an e-mail contact centre for MQI related questions for the participating facilities.~The external training providers will:~\- train the champions in one full day (8h) in-person training session and in 2 online sessions a 4h and 2h to support their co-workers to collect reliable MQI data.~Based on the received training, the champions will:~* provide internal trainings to the care and nursing team,~* perform data quality monitoring,~* provide feedback on data quality and act as a contact person for questions on MQI in their facility."
219188063|NCT06849063|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D MRE#DCE-MRI#IVIM-DWI#T1/T2 mapping.
219188064|NCT06851819|RADIATION|radiotherapy|Palliative radiotherapy for oligometastases can be combined with chemoradiotherapy and immunomaintenance therapy period. The investigator determines the number, timing and regimen of oligometastases according to the location, size, symptoms and patient tolerance of oligometastases
219188065|NCT06851819|DRUG|immunechemotherapy|Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )
219188066|NCT05762133|BEHAVIORAL|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of Perinatal Depression (PND) with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
219188067|NCT02715271|PROCEDURE|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
219188068|NCT06852183|OTHER|VR -FME|The VR-FME intervention specifically focuses on improving body representation and the body-self relationship by working on multisensory integration processes and embodied cognition techniques. This is thanks to the combination of immersive virtual reality experiences of body illusion combined with traditional psychological techniques. The experimental group will receive this intervention in addition to the usual treatment, which will continue as usual for the control group. The intervention consists of 8 sessions spread over 4 weeks, with 2 sessions per week.
219188069|NCT06318520|OTHER|Use of Calcium silicate based resin cement and resin modified glass ionomer cement|Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.
219188070|NCT06422845|DEVICE|Dissolve AV Peripheral Scoring Drug-coated Balloon|Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
219188071|NCT06368765|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
219374942|NCT02290210|DRUG|URC102 0.25mg|
219374943|NCT02290210|DRUG|URC102 0.5mg|
219374944|NCT02290210|DRUG|URC102 1.0mg|
219374945|NCT02290210|DRUG|URC102 2.0mg|
219374946|NCT02290210|DRUG|placebo|
219374947|NCT03229577|BEHAVIORAL|Sudarshan Kriya Yoga|Yoga-based breathing program.
219374948|NCT03229577|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness program.
219374949|NCT03229577|BEHAVIORAL|Emotional Intelligence|Emotional Intelligence program.
219374950|NCT06143410|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
219374951|NCT06143410|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
219374952|NCT06143410|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
219374953|NCT06143410|PROCEDURE|gastroscopy|esogastroduodenoscopy
219374954|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
219374955|NCT00327444|DRUG|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
219374956|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
219374957|NCT04941326|OTHER|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
219374958|NCT04941326|OTHER|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
219374959|NCT04941326|OTHER|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
219374960|NCT04941326|OTHER|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
219188072|NCT06368765|OTHER|Water|Participants will be administered water during one of the study visits
219188073|NCT04123418|BIOLOGICAL|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
219188074|NCT04123418|DRUG|WHG626|WHG626 will be administered orally in a dose escalation schedule
219188075|NCT01752491|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
219188076|NCT01752491|DRUG|Temozolomide|Oral chemotherapeutic
219188077|NCT01752491|RADIATION|Radiation therapy|External beam radiation therapy
219188078|NCT06333704|BIOLOGICAL|SPIKEVAX Bivalent|No study drug will be administered during this study as this is an observational study.
219188079|NCT06333704|BIOLOGICAL|SPIKEVAX X|No study drug will be administered during this study as this is an observational study.
219188080|NCT01815242|DRUG|nab-Paclitaxel|
219188081|NCT01815242|DRUG|Gemcitabine|
219188082|NCT01815242|DRUG|Carboplatin|
219374961|NCT04941326|OTHER|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
219374962|NCT02516930|BEHAVIORAL|crowdsourced video|video promoting condom use
219374963|NCT02516930|BEHAVIORAL|social marketing video|
219188083|NCT00906997|PROCEDURE|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
219188084|NCT00906997|PROCEDURE|Colonoscopy|Every 10 years, with sedation.
219188085|NCT04634799|DRUG|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
219188086|NCT04634799|OTHER|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
219188087|NCT06431256|DRUG|HLD200 methylphenidate hydrochloride capsules|Doses: 20mg capsules
219188088|NCT06431256|DRUG|Placebo HLD200 capsules|Doses: 20mg capsules
219188089|NCT05864638|DEVICE|Endovascular treatment|Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis
219188090|NCT05208112|DRUG|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
219188091|NCT05884476|OTHER|Treatment-as-usual|Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
219191726|NCT06834620|BEHAVIORAL|Rhythmic and Gymnastic Activities-Based School Physical Education Program|A structured, year-long school-based physical education program integrating rhythmic movements, gymnastics, and small equipment exercises designed to enhance motor and physical fitness. The program included 80 sessions (two per week) focusing on rhythmic activities such as twisting, partner balance, animal walks, tumbling, and rope exercises. The intervention aimed to improve strength, flexibility, agility, and cardiovascular endurance compared to traditional physical education classes.
219191727|NCT05015192|DRUG|NH102|tablets, orally
219191728|NCT05015192|DRUG|Placebo|tablets, orally
219374964|NCT06016543|PROCEDURE|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
219374965|NCT05861583|OTHER|fat tissue|fat tissue sample collected while cosmetical liposuction
219374966|NCT05861583|OTHER|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
219374967|NCT05861583|OTHER|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
219374968|NCT05861583|OTHER|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
219188092|NCT05884476|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|"REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition."
219188093|NCT04083378|PROCEDURE|Ablation Therapy|Undergo standard of care ablation
219188094|NCT04083378|PROCEDURE|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
219188095|NCT04083378|OTHER|Quality-of-Life Assessment|Ancillary studies
219188096|NCT04083378|OTHER|Questionnaire Administration|Ancillary studies
219188097|NCT05931003|PROCEDURE|Carotid stenting|In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
219188098|NCT05931003|PROCEDURE|Carotid endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery."
219188099|NCT05346042|OTHER|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
219188100|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
219188101|NCT06551038|BEHAVIORAL|Primary suicide prevention intervention|Psychoeducation workshop
219188102|NCT06551038|BEHAVIORAL|Art-based control intervention|Slam poetry workshop
219188103|NCT05803980|PROCEDURE|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
219188104|NCT03996850|PROCEDURE|Computed Tomography|Undergo SPECT/CT
219188105|NCT03996850|OTHER|Questionnaire Administration|Ancillary studies
219188106|NCT03996850|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219188107|NCT03996850|RADIATION|Technetium Tc-99m Sestamibi|Given IV
219188108|NCT06406140|DRUG|Niacin tablets 500 mg|tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
219188109|NCT02043691|DEVICE|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
219188110|NCT02043691|DEVICE|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
219188111|NCT02043691|DEVICE|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
219188112|NCT05174572|PROCEDURE|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
219188113|NCT06052046|DEVICE|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
219188114|NCT03851796|BEHAVIORAL|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
219188115|NCT03851796|BEHAVIORAL|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
219188116|NCT05784753|BEHAVIORAL|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
219374969|NCT02678806|RADIATION|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
219374970|NCT02678806|DRUG|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
219374971|NCT00049387|DRUG|tipifarnib|Given PO
219374972|NCT00049387|DRUG|temozolomide|Given PO
219374973|NCT00049387|RADIATION|radiation therapy|Undergo partial brain radiation therapy
219188117|NCT05784753|BEHAVIORAL|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
219188118|NCT01922050|DRUG|LEO 43204 Formulation 1|
219188119|NCT01922050|DRUG|LEO 43204 Formulation 2|
219188120|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose X|
219188121|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose Y|
219188122|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose XX|
219188123|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose YY|
219188124|NCT01922050|DRUG|Placebo Formulation 1|
219188125|NCT01922050|DRUG|Placebo Formulation 2|
219188126|NCT04248257|BEHAVIORAL|PeACE|3 session peer coaching intervention
219188127|NCT04248257|BEHAVIORAL|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
219188128|NCT04979039|OTHER|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
219188129|NCT05332899|BIOLOGICAL|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device, by natural exposure to infected participants, or by inhalation from an aerosol generator or nebulizer. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
219188130|NCT06559683|OTHER|Sensory Assessment|Patients scheduled for open-heart surgery will receive a deep/superficial parasternal intercostal plane block preoperatively, and sensory block status will be evaluated after 30 minutes.
219188131|NCT06295523|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
219188132|NCT06295523|OTHER|Control|Participants will NOT receive water spraying on their body throughout the climate exposure.
219188133|NCT05715086|PROCEDURE|Ureteroscopy|Upfront ureteroscopy
219188134|NCT06025617|OTHER|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
219188135|NCT06025617|OTHER|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
219188136|NCT06507111|DIETARY_SUPPLEMENT|Lab4P|"Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20 and Bifidobacterium animalis subsp. lactis CUL-34 at a dose of 50 billion bacteria per/ day combined with vitamin C (80 mg/day), Vitamin D (400 IU/day) and Zinc (10 mg/day) on a microcrystaline cellulose (MCC) base~Daily dose: 50 billion bacteria per day"
219188137|NCT06507111|OTHER|Placebo|MCC alone
219188138|NCT05971173|DRUG|Juven|Nutritional supplements
219188139|NCT05971173|DRUG|Centrum Silver 50+|Over the counter nutritional supplement
219188140|NCT05653193|DRUG|Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
219188141|NCT05653193|DRUG|Antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
219188142|NCT06551285|DIETARY_SUPPLEMENT|Ovapro (Lifepro)|Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.
219188143|NCT06398808|DRUG|Arm1|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
219188144|NCT06398808|DRUG|Arm 2|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
219188145|NCT04101344|OTHER|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
219191729|NCT06827184|DEVICE|Electrical Impedance Tomography|It utilizes electrical impedance tomography to analyze a series of physiological changes in the lungs following treatment
219374974|NCT03899701|PROCEDURE|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
219374975|NCT03609580|DRUG|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
219374976|NCT03609580|DRUG|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
219374977|NCT03155646|DRUG|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
219374978|NCT03155646|DRUG|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
219374979|NCT03155646|DRUG|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
219374980|NCT05023031|DRUG|NVP-2102|Tablet formulation for oral administration, single dose of NVP-2102 at Day 1
219374981|NCT05023031|DRUG|NVP-2102-R|Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
219374982|NCT03787589|BEHAVIORAL|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence."
219374983|NCT04439344|DRUG|Binimetinib|Given PO
219374984|NCT05284201|DEVICE|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
219374985|NCT03464669|OTHER|Prenatal education|Observational study : natural distribution of participants between groups
219374986|NCT03607773|BEHAVIORAL|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
219374987|NCT01587742|DRUG|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
219374988|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
219374989|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
219374990|NCT00552110|DRUG|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
219374991|NCT00552110|DRUG|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
219374992|NCT00552110|DRUG|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
219374993|NCT00834015|OTHER|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
219374994|NCT04901156|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
219374995|NCT04901156|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
219374996|NCT04901156|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
219374997|NCT03012581|DRUG|Nivolumab|Treatment
219374998|NCT04207476|DEVICE|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
219374999|NCT04207476|DEVICE|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
219375000|NCT05451719|DRUG|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
219375001|NCT05451719|DRUG|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
219375002|NCT00542711|DRUG|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
219375003|NCT01364987|DRUG|ASP015K|oral
219375004|NCT01364987|DRUG|Mycophenolate Mofetil|oral
219375005|NCT02581709|BEHAVIORAL|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
219375006|NCT04439890|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
219375007|NCT04439890|DRUG|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
219375008|NCT04439890|DRUG|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
219375009|NCT04439890|DRUG|Placebo|Placebo
219375010|NCT00373074|OTHER|Epidural Blood Patch|Use 15 cc of blood
219375011|NCT00373074|OTHER|Epidural Blood Patch|Inject 20 cc of blood into epidural space
219375012|NCT00373074|OTHER|Epidural Blood Patch|Inject 30 cc of autologous blood
219375013|NCT00518349|DEVICE|Passive bending function|Colonoscope with a passive bending function
219375014|NCT00518349|DEVICE|No passive bending function|Examination using standard colonoscope without passive bending function
219375015|NCT00005630|BIOLOGICAL|ras peptide cancer vaccine|
219375016|NCT00005630|BIOLOGICAL|sargramostim|
219375017|NCT00157547|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
219375018|NCT04325477|DEVICE|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
219375019|NCT00351364|DRUG|Montelukast Sodium|100 mg P.O. One time only
219375020|NCT05588388|DRUG|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
219375021|NCT03529747|OTHER|Online self-help|As detailed in experimental arm description.
219375022|NCT05506943|DRUG|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
219375023|NCT05506943|DRUG|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
219375024|NCT02132442|DIETARY_SUPPLEMENT|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
219375025|NCT02617355|DEVICE|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
219375026|NCT02617355|DEVICE|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
219375027|NCT02617355|DEVICE|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
219375028|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
219375029|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
219375030|NCT02823158|PROCEDURE|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS."
219375031|NCT02823158|PROCEDURE|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
219375032|NCT05812716|BEHAVIORAL|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
219375033|NCT02906514|DRUG|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
219375034|NCT02906514|DRUG|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
219375035|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
219375036|NCT06787651|PROCEDURE|RIMA-SVG|Saphenous vein grafts (SVGs) are connected to the right internal mammary artery (RIMA)
219375037|NCT06787651|PROCEDURE|Ao-SVG|The ascending aorta is clamped, and SVGs are anastomosed to the aorta.
219375038|NCT06033404|PROCEDURE|Normal Clinical practice|Normal Clinical practice
219375039|NCT06123988|BEHAVIORAL|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
219375040|NCT06123988|BEHAVIORAL|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
219375041|NCT06123988|BEHAVIORAL|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
219375042|NCT06834035|BIOLOGICAL|Immunoglobulin G|Purified IgG from human serum, delivered via IV
219375043|NCT05556616|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
219375044|NCT05556616|DRUG|Lenalidomide|Lenalidomide capsules orally.
219375045|NCT05556616|DRUG|Bortezomib|Bortezomib injection subcutaneously.
219375046|NCT05556616|DRUG|Carfilzomib|Carfilzomib intravenous infusion.
219375047|NCT05556616|DRUG|Daratumumab|Daratumumab injection subcutaneously.
219375048|NCT05556616|DRUG|Pomalidomide|Pomalidomide capsules orally.
219375049|NCT05507203|DRUG|ABX464|Administered once daily in the morning with food
219375050|NCT05507203|DRUG|Placebo|Administered once daily in the morning with food
219375051|NCT05726370|DRUG|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
219375052|NCT05726370|DRUG|CISPLATIN|Platinum agent, via IV infusion
219375053|NCT05726370|DRUG|Carboplatin|Platinum agent, via IV infusion
219375054|NCT05726370|DRUG|Docetaxel|Antineoplastic agent, via IV infusion.
219375055|NCT01848314|PROCEDURE|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
219375056|NCT04746521|DIAGNOSTIC_TEST|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
219375057|NCT04746521|BIOLOGICAL|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
219375058|NCT00075881|DRUG|bortezomib|Given IV
219375059|NCT00075881|OTHER|laboratory biomarker analysis|Optional correlative studies
219375060|NCT03019549|DRUG|Lanabecestat|Administered orally
219375061|NCT03019549|DRUG|Rosuvastatin|Administered orally
219375062|NCT06959550|DRUG|Ivonescimab|Given by IV
219375063|NCT00205192|PROCEDURE|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
219375064|NCT06369246|DEVICE|Stereotactic Body Radiation Therapy|Undergo Radiation Therapy
219375065|NCT04194060|COMBINATION_PRODUCT|Enhanced Recovery after Surgery group|"* Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics."
219375066|NCT04194060|COMBINATION_PRODUCT|Conventional|"Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics."
219375067|NCT05332860|PROCEDURE|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
219375068|NCT02850302|OTHER|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
219375069|NCT02850302|OTHER|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
219375070|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
219375071|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
219375072|NCT00626873|DRUG|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
219375073|NCT00626873|OTHER|medical chart review|
219375074|NCT06368726|DEVICE|tDCS or Transcranial Direct Current Stimulation|We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
219375075|NCT06368726|DRUG|Risperidone|Risperidone Risperidone according to child's weighs
219375076|NCT01083108|OTHER|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
219375077|NCT01083108|OTHER|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
219375078|NCT05741021|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
219375079|NCT05741021|DRUG|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
219375080|NCT05741021|DRUG|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
219375081|NCT05741021|DRUG|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
219375082|NCT03263091|DRUG|Roxadustat|Oral tablets
219375083|NCT03263091|DRUG|Placebo|Oral tablets
219375084|NCT06124703|DRUG|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
219375085|NCT06124703|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
219375086|NCT04294888|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
219375087|NCT00742781|DIETARY_SUPPLEMENT|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
219375088|NCT00728338|DIETARY_SUPPLEMENT|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
219375089|NCT00728338|DIETARY_SUPPLEMENT|Olive oil|7.5 g olive oil/day
219375090|NCT05723146|BEHAVIORAL|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
219375091|NCT03707561|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
219375092|NCT04064710|PROCEDURE|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
219375093|NCT04064710|DEVICE|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
219375094|NCT00368173|DRUG|rhIGF-I/rhIGFBP-3|
219375095|NCT02555800|DRUG|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
219375096|NCT02555800|DRUG|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
219375097|NCT02555800|OTHER|Placebo|Saline solution
219375098|NCT01836861|DRUG|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
219375099|NCT00000790|DRUG|Thalidomide|
219375100|NCT02318004|OTHER|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
219375101|NCT03802721|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
219375102|NCT03802721|DRUG|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
219375103|NCT03802721|DRUG|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
219375104|NCT03739619|DRUG|Bendamustine|Given IV
219375105|NCT03739619|DRUG|Gemcitabine|Given IV
219375106|NCT03739619|BIOLOGICAL|Nivolumab|Given IV
219375107|NCT04612075|DIAGNOSTIC_TEST|FDG-PET/MRI|Performed at baseline, interim and at 12-16 weeks post radiotherapy.
219375108|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
219375109|NCT04778839|DRUG|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
219375110|NCT04778839|DRUG|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
219375111|NCT02325674|DRUG|Metreleptin|
219375112|NCT06385886|BEHAVIORAL|Linkage Coordinator|The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
219375113|NCT06556108|BIOLOGICAL|ALPP CAR-T cells|T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
219375114|NCT06556108|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219375115|NCT06556108|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219375116|NCT04797286|DRUG|Sildenafil|Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
219375117|NCT04797286|OTHER|Placebo|Oral pill placebo.
219375118|NCT06295146|OTHER|Intervention A: 1-on-1 wheelchair skills training by a peer coach|"Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback."
219375119|NCT06295146|OTHER|Intervention B: Training via educational videos|Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
219375120|NCT06487780|BEHAVIORAL|Lifestyle-focused Occupational Therapy Intervention|The proposed intervention, led by trained occupational therapists, will focus on establishing sustainable self-care routines. It will consist of approximately 12 biweekly sessions, each lasting about an hour on average. Therapists will customize session timing and duration based on participant needs.
219375121|NCT06487780|OTHER|Education|Participants in the education group will receive standardized education materials on diabetic foot ulcers (DFUs), foot care, and offloading treatment to prevent foot ulcer recurrence.
219375122|NCT05787613|DRUG|HLX26|Anti-LAG-3 monoclonal Antibody Injection
219375123|NCT05787613|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
219188146|NCT03225677|PROCEDURE|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
219188147|NCT06481462|PROCEDURE|Intrathecal Morphine (ITM)|morphine 100 mcg + 12.5 mg bupivacaine + 20 mcg fentanyl
219188148|NCT06481462|PROCEDURE|Quadratus Lumborum II (QLB-II) Block|12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
219188149|NCT05907434|DIAGNOSTIC_TEST|Nephrocheck (AKI score)|Early biomarker of AKI
219188150|NCT06187584|DRUG|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
219188151|NCT06187584|DRUG|Acetaminophen|15mg/kg PO q6 hours
219188152|NCT06187584|DRUG|Ibuprofen|10mg/kg PO q6 hours
219188153|NCT04707625|DRUG|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
219188154|NCT00321048|DEVICE|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
219375124|NCT05787613|DRUG|Chemotherapy drug|non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
219375125|NCT05787613|DRUG|Placebo|placebo
219375126|NCT05166057|OTHER|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
219375127|NCT05166057|OTHER|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
219375128|NCT05166057|OTHER|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
219375129|NCT05265208|DRUG|Capecitabine|Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
219375130|NCT05265208|DEVICE|Selective Internal Radiotherapy (SIRT)|During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.
219375131|NCT05265208|PROCEDURE|Surgery|Surgery will be performed according to local practice.
219375132|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
219375133|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
219375134|NCT06331884|DRUG|Placebo|Application of placebo
219188155|NCT06308510|OTHER|collection additional peritoneal lavage fluid|collection additional peritoneal lavage fluid
219188156|NCT03825757|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219188157|NCT03825757|DRUG|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
219188158|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
219188159|NCT01817452|DRUG|Trastuzumab|
219188160|NCT01817452|DRUG|Pertuzumab|
219188161|NCT01817452|DRUG|Paclitaxel|
219188162|NCT06283537|OTHER|Effect of training method|The effect of the training method given to midwifery students on their episiotomy application skills, satisfaction with the teaching method and self-confidence.
219375135|NCT02750358|DRUG|Enzalutamide|
219375136|NCT02750358|BEHAVIORAL|assessment|
219375137|NCT03539432|DRUG|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
219375138|NCT03539432|DRUG|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
219375139|NCT03352401|OTHER|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
219375140|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
219375141|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
219375142|NCT03934645|OTHER|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
219375143|NCT03427437|DRUG|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
219375144|NCT03427437|DRUG|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
219375145|NCT03427437|DEVICE|Ultrasound|caudal block was performed by ultrasound method
219375146|NCT01977287|DEVICE|Functional Electrical Stimulation|
219375147|NCT01977287|DEVICE|Ankle Foot Orthosis|
219375148|NCT03543969|DRUG|Encorafenib|450 mg encorafenib daily by mouth
219375149|NCT03543969|DRUG|Binimetinib|45 mg binimetinib daily by mouth
219375150|NCT03543969|DRUG|Nivolumab|240 mg Nivolumab IV every 2 weeks
219375151|NCT06538155|DEVICE|Wearable device|Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked
219375152|NCT06538155|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
219375153|NCT06538155|OTHER|CT scan, TEE exam, or chest X ray|Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
219375154|NCT00318292|DRUG|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
219375155|NCT00318292|DRUG|Placebo|20 ml normal saline injection.
219375156|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
219375157|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
219375158|NCT01062477|BIOLOGICAL|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
219375159|NCT03975192|DEVICE|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
219375160|NCT03332888|DRUG|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
219375161|NCT02241486|DRUG|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
219375162|NCT00220363|DRUG|SPM 907|
219375163|NCT02770521|DRUG|Treprostinil|Administered SC.
219375164|NCT02770521|DRUG|Placebo|Administered SC.
219375165|NCT02770521|DRUG|LY900014|Administered SC.
219375166|NCT02770521|DRUG|Insulin Lispro|Administered SC.
219375167|NCT00824564|DRUG|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
219375168|NCT00824564|PROCEDURE|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
219375169|NCT04927273|OTHER|Survey|Surveyed neurological and orthopedic surgeons
219375170|NCT04404335|DIAGNOSTIC_TEST|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
219375171|NCT03892421|DRUG|Rituximab|Rituximab 375 mg/m²
219375172|NCT03892421|DRUG|Carboplatin|Carboplatin AUC5
219375173|NCT03892421|DRUG|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
219375174|NCT03892421|DRUG|Dexamethasone|Dexamethasone 40 mg
219375175|NCT03892421|DRUG|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
219375176|NCT00003060|BIOLOGICAL|filgrastim|
219375177|NCT00003060|DRUG|busulfan|
219375178|NCT00003060|DRUG|cyclophosphamide|
219375179|NCT00003060|DRUG|cyclosporine|
219375180|NCT00003060|DRUG|methotrexate|
219375181|NCT00003060|PROCEDURE|allogeneic bone marrow transplantation|
219375182|NCT02363829|DRUG|Nelfinavir|
219375183|NCT02363829|BIOLOGICAL|Cisplatin|
219375184|NCT03819075|DEVICE|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
219375185|NCT03819075|OTHER|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
219375186|NCT01046812|DRUG|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
219375187|NCT04453150|OTHER|Standard hypocaloric die|Standard hypocaloric diet
219375188|NCT04453150|OTHER|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
219375189|NCT04453150|OTHER|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
219375190|NCT04453150|OTHER|Alternate-day fasting|Alternate-day fasting
219375191|NCT04453150|OTHER|Ketogenic diet|Ketogenic diet
219375192|NCT04504318|DRUG|Apixaban 2.5 MG Oral Tablet|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
219375193|NCT04504318|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
219375194|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
219375195|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
219375196|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
219375197|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
219375198|NCT04726085|DRUG|Indomethacin 150mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
219375199|NCT04726085|DRUG|Ibuprofen 2400mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
219375200|NCT02935738|DRUG|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
219375201|NCT04072770|DIETARY_SUPPLEMENT|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
219375202|NCT04072770|DIETARY_SUPPLEMENT|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
219375203|NCT06960135|PROCEDURE|open partial nephrectomy|open partial nephrectomy
219557772|NCT06341504|DEVICE|Square terminal|This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
219557773|NCT01102452|DIETARY_SUPPLEMENT|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
219188163|NCT03755167|DRUG|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
219375204|NCT06960135|PROCEDURE|laparoscopic partial nephrectomy|laparoscopic partial nephrectomy
219375205|NCT06960447|DEVICE|Nd:YAG Laser|Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
219557774|NCT01102452|DIETARY_SUPPLEMENT|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
219188164|NCT06206434|DIAGNOSTIC_TEST|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
219375206|NCT06960447|DEVICE|Alexandrite Laser|Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
219557775|NCT03090490|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
219557776|NCT03090490|OTHER|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
219557777|NCT04395599|OTHER|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
219557778|NCT03399006|DEVICE|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
219557779|NCT03399006|DEVICE|Doppler Ultrasound|"measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
219191730|NCT06836674|OTHER|Jigsaw|In this learning method, students will be divided into main and expert groups. Then, an expert from each group will come and the student will be provided with expertise in the subject given to him/her by the instructor. After the student has specialized, he/she will return to his/her own group and will provide training to his/her friends on the subject he/she has specialized in under the supervision of the instructor of the course. During the student\&#39;s specialization process on the subject given, the necessary literature support and controls will be provided by the instructor of the course.
219191731|NCT06836674|OTHER|Metaverse|In this learning method, the topics determined on pediatric drug applications will be prepared weekly by the relevant instructor of the course and will be transferred to the metaverse and presented to the student in the form of weekly modules.
219191732|NCT06836674|OTHER|Classical Education|In this learning method, the subjects determined by the instructor will be explained to the students in a laboratory environment by the instructor using a presentation (power point) method.
219191733|NCT04975945|DRUG|Ceftriaxone Sodium|Intravenous vs local action
219191734|NCT06835816|DIETARY_SUPPLEMENT|Amino acid supplementation (Glavamin, Fresenius Kabi)|Mixture of amino acids (67 g / 500 ml) given intravenously
219191735|NCT06837558|DIAGNOSTIC_TEST|fibroblast growth factor 23|"Investigations: including the different following modalititis~A. Laboratory investigations include:~1. Complete blood picture, PT PC INR, RBS Kidney function tests, eGFR Urine analysis, 24 hours' protein in urine~2. Specific laboratory investigations for SLE and lupus nephritis: ANA,AntiDsDNA,C3,C4~3. Laboratory investigations of Bone mineral density predictors Ca, phosphorus, PTH, vitamin D (OH), Alkaline phosphatase, Fibroblast Growth Factor 23 (FGF 23)~B. Imaging studies:~1 - Abdominal ultrasound 2- chest x-ray 3- Echocardiography (in lupus nephritis with activity form) 4- DEXA bone scan~C. Invasive modality:~Renal biopsy of Patients with SLE with lupus nephritis"
219191736|NCT05435638|DIAGNOSTIC_TEST|Serum chemistry|"Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine."
219191737|NCT05435638|DIAGNOSTIC_TEST|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
219191738|NCT05435638|DIAGNOSTIC_TEST|Urinalysis|"General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
219191739|NCT05435638|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
219191740|NCT05435638|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
219191741|NCT05435638|DIAGNOSTIC_TEST|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
219191742|NCT05435638|DIAGNOSTIC_TEST|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126)."
219188165|NCT05579210|BEHAVIORAL|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
219188166|NCT05579210|BEHAVIORAL|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
219188167|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
219188168|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
219188169|NCT05408052|PROCEDURE|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
219188170|NCT05408052|PROCEDURE|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
219188171|NCT05265715|OTHER|Low AGE diet|"The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
219188172|NCT05265715|PROCEDURE|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
219188173|NCT04471246|DRUG|Cephalexin|1000 mg PO QID for 7 days
219188174|NCT04471246|DRUG|Cephalexin + placebo|500 mg PO QID plus oral placebo for 7 days
219188175|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
219188176|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
219188177|NCT06444919|DRUG|Capsaicin 179 Mg Cutaneous Patch|patch application for 30 minutes on the painful fingers.
219188178|NCT06444919|DRUG|Capsaicine low dose 0.04 %|patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).
219188179|NCT05182905|DRUG|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
219188180|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
219188181|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
219188182|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
219188183|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
219188184|NCT06558604|DRUG|Obinutuzumab|1000 mg/40mL
219188185|NCT06558604|DRUG|Glofitamab|10mg/mL
219188186|NCT06558604|DRUG|Venetoclax Oral Product|10mg, 50mg and 100mg tablets
219188187|NCT06558604|DRUG|Zanubrutinib Oral Capsule|80mg capsules
219188188|NCT03999593|PROCEDURE|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
219188189|NCT06840431|BEHAVIORAL|in-person condition|participants will receive program components in a classroom setting with a trained non-clinical facilitator.
219188190|NCT06840431|BEHAVIORAL|online condition|Participants will receive program components in an asynchronous online format.
219188191|NCT06840431|BEHAVIORAL|self-help condition|Participants will read a self-help book on how to manage their divorce and take a quiz to ensure that the book has been read.
219188192|NCT06839430|OTHER|hypertonic saline 5% sodium chloride|Hypertonic saline acts as an analgesic by alleviating nociceptive pain from inflamed tissues, which may include bone, connective tissue , synovium , or a combination of these Hypertonic saline results in safe and remarkable outcomes on knee pain, stiffness and function compared with intra-articular dextrose injection
219188193|NCT06839430|OTHER|hypertonic dextrose 20%|A recent study showed the sensorineural analgesic effect of 5% dextrose prolotherapy in the treatment of chronic low back pain ,Therefore, the mechanism of action for dextrose prolotherapy is hypothesized to work through reducing peripheral sensitization and targeting structural dysfunction
219188194|NCT06838858|PROCEDURE|Motor Imagery Training|The study group will receive motor imagery training in addition to control group's exercise program. This process will proceed as follows; In motor imagery training videos taken with a 9-year-old healthy child will be watched.• The content of the videos will include exercises such as ankle dorsiflexion, heel tapping while walking, climbing and descending stairs, walking on a ramp, standing on a ramp, walking on soft ground, and walking on a treadmill.• The patients will watch these videos and then the relaxation, imagination and return to environment phases of motor imagery will be applied respectively.
219188195|NCT06838858|PROCEDURE|Conventional Post-operative Exercises|"This group will receive conventional exercises in the post-op process. The exercises included in the conventional exercise program are;~* Balance board exercises~* Balance disc exercises~* Bosu exercises~* Balance pad exercises~* Wobble board exercises~* Walking on soft ground~* Balance exercises on soft ground~* Apraximations and tractions~* Target angle exercise for ankle~* General standing balance exercises (Eyes open and closed - single foot, double foot)~* Ankle bidirectional ROM~* Ankle bidirectional strengthening~* Exercises to increase foot intrinsic muscle strength and balance~* Functional exercises"
219188196|NCT04706988|OTHER|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
219188197|NCT06834204|OTHER|PC2: Primary Care Connect|Primary Care Connect is a health system intervention that includes patient education, electronic medical record optimization, protocolized communication from cancer care team to primary care.
219188198|NCT06083246|OTHER|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
219188199|NCT06083246|OTHER|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
219188200|NCT06831240|OTHER|Local wheelchair service provider questionnaires|The local wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
219188201|NCT06831240|OTHER|Global wheelchair service provider questionnaires|The global wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
219188202|NCT06831240|OTHER|End-users questionnaires|The end-users will complete a questionnaire that includes demographic and clnical data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
219188203|NCT06832150|OTHER|sample collection|"Participants may collected their own cheek swabs and will collect their own urine samples.~Clinical professionals at participating sites will collect blood samples."
219188204|NCT06832150|OTHER|Discussing study|Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants
219188205|NCT06832150|OTHER|Seeking consent|Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.
219188206|NCT02987946|DEVICE|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
219188207|NCT02987946|DRUG|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
219188208|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
219188209|NCT06263114|DIAGNOSTIC_TEST|TruGraf® Liver gene expression panel (GEP)|Test done on blood sample collected during for cause or routine liver biopsy
219188210|NCT06751355|DEVICE|SkinScan3D camera|The SkinScan3D (SS3D) is a portable, battery-powered imaging prototype which can successfully achieve all-focus, 3D images using low-cost, off-the-shelf components.
219188211|NCT06831643|DRUG|Standard Medical treatment|Standard Medical treatment
219188212|NCT06831643|BIOLOGICAL|Therapeutic Plasma Excahnge|Therapeutic Plasma Excahnge
219188213|NCT03376646|DEVICE|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
219188214|NCT03376646|DEVICE|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
219188215|NCT03376646|DEVICE|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
219188216|NCT06564545|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219188217|NCT06564545|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219188218|NCT06564545|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
219188219|NCT05764525|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
219188220|NCT05764525|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
219188221|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy: The interval between radiotherapy and immunotherapy should be within 3 weeks, with no specific order required. Different radiotherapy techniques will be selected based on the size and location of the metastatic lesions:~Stereotactic Body Radiation Therapy (SBRT), Spatially Fractionated Radiation Therapy (SFRT), Low-dose Radiotherapy (LDRT)."
219375207|NCT04721873|DRUG|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
219375208|NCT04721873|DRUG|Placebo|Matching placebo, titrated as active intervention
219375209|NCT06836830|PROCEDURE|PEEP 5 mbar|Positiv-End-Expiratory Pressure
219375210|NCT06836830|PROCEDURE|ZEEP 0 mbar|Zero-End-Expiratory Pressure
219375211|NCT01552057|DRUG|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
219375212|NCT01552057|DRUG|Placebo|Placebo taken orally once every day for 15 weeks
219375213|NCT03211182|BEHAVIORAL|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
219375214|NCT05303454|BEHAVIORAL|Cartoons|cartoons were found to be effective in reducing children's pain and fear levels.
219375215|NCT05303454|BEHAVIORAL|musical-moving toys|musical-moving toys were found to be effective in reducing children's pain and fear levels.
219375216|NCT06139770|BEHAVIORAL|Family based therapy- Metacognitive therapy|Family based therapy and Metacognitive therapy
219375217|NCT02411123|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
219375218|NCT00003029|DRUG|cisplatin|
219375219|NCT00003029|DRUG|fluorouracil|
219375220|NCT05127486|DRUG|Galcanezumab|Administered SC.
219188222|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Delayed Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy:~If there is intracranial disease progression but extracranial disease remains stable, the systemic treatment regimen of Adelumab + VEX metronomic chemotherapy will be continued, with the addition of intracranial radiotherapy.~If there is intracranial disease progression and extracranial disease progression, the systemic treatment regimen will be modified, with the addition of intracranial radiotherapy.~The radiotherapy positioning and techniques will be the same as those used in the experimental group."
219188223|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
219188224|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
219188225|NCT05591131|OTHER|genetic testing|Undergo genetic testing
219375221|NCT05127486|DRUG|Rimegepant|Administered orally.
219375222|NCT05127486|DRUG|Placebo|Administered orally.
219375223|NCT05127486|DRUG|Placebo|Administered SC.
219375224|NCT03175523|DEVICE|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
219375225|NCT03175523|DEVICE|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
219375226|NCT03020511|OTHER|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
219375227|NCT06962332|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
219375228|NCT03566212|DEVICE|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
219375229|NCT03566212|DEVICE|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
219375230|NCT01287754|DRUG|erlotinib [Tarceva]|150 mg daily orally
219375231|NCT06962111|BEHAVIORAL|Psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss who live alone. In addition, during this intervention, participants will have access to general and personalized virtual resources with materials for use during and after the intervention.
219375232|NCT03193866|DRUG|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
219188226|NCT05591131|OTHER|Survey Administration|Complete survey
219188227|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
219188228|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
219188229|NCT06839625|BEHAVIORAL|emotional freedom technıque|EFT application
219375233|NCT06526026|BEHAVIORAL|Virtual crisis stabilization support with a multi-disciplinary team|Daily 1:1 sessions with multidisciplinary team via a range of virtual modalities (videoconferencing, phone, text, email), group programming, self-management resources, remote home monitoring app, referrals and linkages to community programs.
219375234|NCT02637687|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
219375235|NCT04439266|DRUG|Crizotinib|Given PO
219188230|NCT00586391|GENETIC|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
219188231|NCT00586391|DRUG|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
219188232|NCT06378151|OTHER|TLT training|"Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed."
219188233|NCT04987502|OTHER|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
219188234|NCT04987502|BEHAVIORAL|Standard treatment|counselling, relaxation techniques, sound enrichment
219188235|NCT05425784|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
219188236|NCT05425784|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
219188237|NCT03542578|DEVICE|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
219188238|NCT06838637|DEVICE|"Spinal COrd NEuromodulation (SCONE) Device"|A non-invasive electrical device that provides transcutaneous spinal cord stimulation (TSCS) to the spinal cord by electrodes connected to a battery-powered source.
219188239|NCT06839885|OTHER|Interventional group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the last year and completed treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. The patients were planned to be treated in the hydrotherapy unit during lunch breaks, under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the study group will perform aquatic exercises in groups of 5 or 7 participants, three times a week for 6 weeks, under the supervision of a physiotherapist.Patients in the intervention group will receive a home exercise program and self-drainage."
219191743|NCT05435638|DIAGNOSTIC_TEST|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
219191744|NCT05435638|DRUG|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
219191745|NCT05435638|DIAGNOSTIC_TEST|Clinician global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
219191746|NCT05435638|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
219191747|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has."
219375236|NCT06642974|OTHER|Education module on learning disabilities|Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
219375237|NCT06642974|OTHER|pamphlet on learning disability|Education pamphlets will be provided to total of 67 samples
219375238|NCT04600570|OTHER|ultrasound|ultrasound measurement for optic nerve outer diameter
219375239|NCT06176521|PROCEDURE|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
219375240|NCT06642753|BIOLOGICAL|immediate implant with buccal plate augmentation using sticky bone|"* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch ."
219375241|NCT06642753|BIOLOGICAL|immediate implant with sticky bone as a filling material in the jumping gap|"Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap."
219375242|NCT06638099|BEHAVIORAL|CGM Toolkit Prescriber Training|A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
219375243|NCT04971226|DRUG|Imatinib|Comes in 100 mg and 400 mg tablets and taken orally
219375244|NCT04971226|DRUG|Nilotinib|Comes in 150 mg and 200 mg capsules and taken orally
219375245|NCT04971226|DRUG|Bosutinib|Comes in 100 mg and 400 mg tablets and taken orally
219375246|NCT04971226|DRUG|Dasatinib|Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally
219375247|NCT04971226|DRUG|Asciminib|Comes in 40 mg tablets and taken orally
219375248|NCT02516657|DRUG|Liraglutide|Liraglutide 0.6 mg
219375249|NCT06261385|BEHAVIORAL|typology-based intervention|"The typology-based intervention includes:~1. typology-based counselling,~2. personalized E-message based on the counselling content discussed~3. a booklet introducing the typology of quit identity.~All interventions and materials are delivered by smoking counselling."
219375250|NCT06261385|BEHAVIORAL|Routine Treatment|"The routine smoking cessation intervention includes:~1. Routine counselling generic advice on preventing smoking relapse~2. Brief e-messages that consist of general quit advice for 4 weeks.~Counsellors implement both routine practices."
219375251|NCT05548634|DRUG|TAVO412|Biologic
219375252|NCT03398161|OTHER|Quality-of-Life Assessment|Ancillary studies
219375253|NCT03398161|OTHER|Questionnaire Administration|Ancillary studies
219375254|NCT03398161|RADIATION|Radiation Therapy|Undergo ultra low dose radiation therapy
219375255|NCT04203147|BEHAVIORAL|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
219375256|NCT04203147|BEHAVIORAL|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
219375257|NCT00001337|DRUG|Etoposide|"Etoposide 50mg/m\^2/day were delivered as continuous intravenous (CIV) infusions over 96 hours starting on day 1 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375258|NCT00001337|BIOLOGICAL|Rituximab|"Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375259|NCT00001337|DRUG|Prednisone|"Prednisone 100mg by mouth (PO) twice a day (bid) on days 1 through 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375260|NCT00001337|DRUG|Cyclophosphamide|"Cyclophosphamide 750mg/m\^2 on day 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375261|NCT00001337|DRUG|Vincristine|"Vincristine 0.4mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375262|NCT00001337|DRUG|Doxorubicin|"Doxorubicin 10mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
219375263|NCT00001337|DIAGNOSTIC_TEST|MRI|Baseline and/or on completion of therapy.
219375264|NCT00001337|DIAGNOSTIC_TEST|CT|Baseline and/or on completion of therapy.
219375265|NCT00001337|PROCEDURE|Biopsy|Baseline and/or on completion of therapy.
219375266|NCT00001337|DIAGNOSTIC_TEST|PET scan|As clinically indicated.
219375267|NCT00001337|PROCEDURE|Laparotomy|As clinically indicated.
219375268|NCT00001337|OTHER|Ondansetron|Nausea and/or vomiting.
219375269|NCT00001337|OTHER|Prochlorperazine|Nausea and/or vomiting.
219375270|NCT00001337|OTHER|Omeprazole|Gastroesophageal reflux disease (GERD).
219375271|NCT00001337|OTHER|Docusate Sodium + Sennosides|Constipation.
219375272|NCT00001337|OTHER|Lactulose|Constipation
219375273|NCT04506892|BEHAVIORAL|Meditation|meditation
219375274|NCT04609904|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
219375275|NCT04609904|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
219375276|NCT04609904|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
219375277|NCT04609904|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
219375278|NCT04006808|BIOLOGICAL|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
219375279|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
219375280|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
219375281|NCT04516252|BEHAVIORAL|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
219375282|NCT04516252|BEHAVIORAL|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
219375283|NCT04516252|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
219375284|NCT04516252|BEHAVIORAL|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
219375285|NCT06099288|BEHAVIORAL|Home-Based Video and Motivational Interviewing Intervention|The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
219375286|NCT06099288|BEHAVIORAL|Read Educate and Develop Youth (READY) Comparison|The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
219375287|NCT06182293|OTHER|Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota|Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
219375288|NCT02623972|DRUG|Eribulin|administered IV for 4 cycles
219375289|NCT02623972|DRUG|Adriamycin|administered IV with cyclophosphamide for 4 cycles
219375290|NCT02623972|DRUG|Cyclophosphamide|administered IV with adriamycin for 4 cycles
219375291|NCT06617429|DRUG|GTX-102|antisense oligonucleotide
219375292|NCT06617429|PROCEDURE|Sham-LP|Small needle prick on the lower back at the location where the LP injection is normally made
219375293|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
219375294|NCT03878147|BEHAVIORAL|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
219375295|NCT04774354|DIAGNOSTIC_TEST|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
219375296|NCT01875497|DIETARY_SUPPLEMENT|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
219375297|NCT06771492|DRUG|Amoxicillin|Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
219375298|NCT06771492|OTHER|Placebo|Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
219375299|NCT05085561|DRUG|REC-994|REC-994 200 mg tablets
219375300|NCT05085561|DRUG|Placebo|Placebo Tablets
219375301|NCT05760898|BEHAVIORAL|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
219375302|NCT06460350|DEVICE|NEUROCUPLE™ Patch|nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.
219375303|NCT06460350|DEVICE|Placebo Patch|The placebo patch is identical to the active patch but with no active agents.
219375304|NCT03754049|DRUG|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
219375305|NCT03754049|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
219375306|NCT03584022|DEVICE|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
219375307|NCT03584022|PROCEDURE|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
219375308|NCT04889209|BIOLOGICAL|Ad26.COV2.S|Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.
219375309|NCT04889209|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
219375310|NCT04889209|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.
219375311|NCT04889209|BIOLOGICAL|mRNA-1273.211|Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
219375312|NCT04889209|BIOLOGICAL|mRNA-1273.222|Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
219375313|NCT04889209|BIOLOGICAL|SARS-CoV-2 rS/M1|SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume \[w/v\]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
219375314|NCT05862272|DRUG|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
219375315|NCT06517121|DEVICE|Personalized Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
219375316|NCT06517121|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
219375317|NCT06517121|DEVICE|Conventional Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
219375318|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
219375319|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
219375320|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
219375321|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
219375322|NCT05432999|DEVICE|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
219375323|NCT05039086|DRUG|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
219375324|NCT05039086|DRUG|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
219375325|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 5mg; (3) If not succeed, the second subject takes 7mg; (4) Until seven sequence reversal inflection points."
219375326|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
219375327|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
219375328|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
219375329|NCT06021080|PROCEDURE|CVVH|CVVH therapy
219375330|NCT06021080|PROCEDURE|CVVHD|CVVHD therapy
219375331|NCT04193371|OTHER|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
219375332|NCT04193371|OTHER|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
219375333|NCT04193371|OTHER|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
219375334|NCT05207826|DIAGNOSTIC_TEST|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
219375335|NCT05074264|PROCEDURE|Biopsy|Undergo biopsy
219375336|NCT05074264|PROCEDURE|Biospecimen Collection - Anal|Undergo collection of anal swabs
219375337|NCT05074264|PROCEDURE|Biospecimen Collection - Cervical|Undergo collection of cervical swabs
219375338|NCT05074264|PROCEDURE|Colposcopy|Undergo colposcopy
219375339|NCT05074264|PROCEDURE|High Resolution Anoscopy|Undergo high-resolution anoscopy
219375340|NCT05074264|PROCEDURE|Imaging Technique|Undergo cervical imaging
219375341|NCT05095142|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219375342|NCT06121726|OTHER|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
219375343|NCT06121726|DRUG|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
219375344|NCT00092508|DRUG|OPC-6535|
219375345|NCT00092508|DRUG|Asacol®|
219375346|NCT05891665|PROCEDURE|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
219375347|NCT05891665|PROCEDURE|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
219375348|NCT00660894|DRUG|folinate calcium|
219375349|NCT00660894|DRUG|tegafur-uracil|
219375350|NCT00660894|DRUG|tegafur-gimeracil-oteracil potassium|
219375351|NCT04481022|OTHER|proximal control exercises|"study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010)."
219375352|NCT03091504|DEVICE|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
219375353|NCT03091504|DRUG|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
219375354|NCT06033586|DRUG|Open-label rusfertide|subcutaneous rusfertide
219375355|NCT01256541|DRUG|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
219375356|NCT05397236|DRUG|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
219375357|NCT05397236|DRUG|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
219375358|NCT05397236|DRUG|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
219375359|NCT00442598|DRUG|Glufosfamide|
219375360|NCT05046756|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
219375361|NCT01073579|DRUG|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
219375362|NCT06546033|OTHER|application of different types of diet|application of different types of diet
219375363|NCT03160014|DRUG|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
219375364|NCT02113202|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
219375365|NCT02113202|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
219375366|NCT04337437|DRUG|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
219375367|NCT04337437|DRUG|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
219375368|NCT00906438|DIETARY_SUPPLEMENT|2006-RD-05|300 mg daily, once a day for 28 consecutive days
219375369|NCT00906438|DIETARY_SUPPLEMENT|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
219375370|NCT01808560|DEVICE|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
219375371|NCT01808560|DEVICE|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
219375372|NCT03330327|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
219375373|NCT03985176|DEVICE|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
219375374|NCT03985176|PROCEDURE|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
219375375|NCT03985176|PROCEDURE|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
219375376|NCT04801407|PROCEDURE|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
219375377|NCT04801407|PROCEDURE|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
219375378|NCT00211614|DRUG|Lansoprazole|
219375379|NCT06056947|DRUG|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
219375380|NCT06056947|DRUG|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
219375381|NCT06056947|DRUG|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
219375382|NCT00375544|DEVICE|Low level light therapy|
219375383|NCT05595538|BIOLOGICAL|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
219375384|NCT01486420|PROCEDURE|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
219375385|NCT01486420|PROCEDURE|Open surgery|Open A1-pulley release
219375386|NCT01203657|BEHAVIORAL|Tai Chi|Tai Chi classes, 60 minutes, 2x week
219375387|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
219375388|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
219375389|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
219375390|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
219375391|NCT00427856|DRUG|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
219375392|NCT00427856|DRUG|Rituximab|Rituximab
219375393|NCT05173584|DRUG|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
219375394|NCT05173584|DRUG|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
219375395|NCT03341884|DRUG|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
219375396|NCT06418620|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
219375397|NCT04284540|RADIATION|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
219375398|NCT04284540|RADIATION|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
219375399|NCT01743573|OTHER|yoga|
219375400|NCT02305563|DRUG|BMS-936564|
219375401|NCT02305563|DRUG|Cytarabine|
219375402|NCT03084133|BEHAVIORAL|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
219375403|NCT02704598|DRUG|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
219375404|NCT02704598|DRUG|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
219375405|NCT03624647|DEVICE|Power toothbrush|Experimental power toothbrush
219375406|NCT03624647|DEVICE|Manual toothbrush|Marketed manual toothbrush
219375407|NCT02700451|DRUG|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
219375408|NCT02700451|DRUG|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
219375409|NCT02700451|DRUG|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
219375410|NCT04373460|BIOLOGICAL|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
219375411|NCT04373460|BIOLOGICAL|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
219375412|NCT06300801|DIAGNOSTIC_TEST|Is the preoperative c-reactive protein/albumin ratio successful in predicting postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy?|In this study, predicting pancreatic fistula before surgery will reduce postoperative complications and mortality.
219375413|NCT00977392|BEHAVIORAL|compliance monitoring|
219375414|NCT00977392|OTHER|cervical Papanicolaou test|
219375415|NCT00977392|OTHER|educational intervention|
219375416|NCT00977392|OTHER|screening questionnaire administration|
219375417|NCT00977392|OTHER|survey administration|
219375418|NCT00977392|PROCEDURE|colposcopy|
219375419|NCT00938730|DRUG|YM150|oral
219375420|NCT00938730|DRUG|Warfarin|oral
219375421|NCT00454207|DRUG|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
219375422|NCT03103893|DRUG|Rapamycin|topical formulation
219375423|NCT06044896|PROCEDURE|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
219375424|NCT06044896|PROCEDURE|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
219375425|NCT01672957|DRUG|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
219375426|NCT01672957|DRUG|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
219375427|NCT05345470|OTHER|140 calories per 30 gram test meal|Food
219375428|NCT05383924|PROCEDURE|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
219375429|NCT05383924|PROCEDURE|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
219375430|NCT04466033|DEVICE|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
219375431|NCT05320575|DRUG|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
219375432|NCT04909905|DIETARY_SUPPLEMENT|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
219375433|NCT04909905|COMBINATION_PRODUCT|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
219375434|NCT02210663|DRUG|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
219375435|NCT01658267|OTHER|nutritional supplement|2 servings per day
219375436|NCT05220267|DRUG|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
219375437|NCT05726214|OTHER|Exercise|"The face-to-face multicomponent program entailed:~* Strength training of upper and lower limbs. Familiarization phase included 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets lasted 1-3 minutes.~* Balance exercises included proprioception, agility and weight transfer exercises. Difficulty progressively increased by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~* Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant was given according to their functional level type."
219375438|NCT05726214|OTHER|Recommendations for active lifestyle|After the baseline assessments, all participants received individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants were encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations were transmitted verbally and through written material.
219375439|NCT01557790|RADIATION|Proton Radiation Therapy|
219375440|NCT02115308|DRUG|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
219375441|NCT02345798|PROCEDURE|Standard Follow-Up Care|Undergo usual care
219375442|NCT02345798|OTHER|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
219375443|NCT02345798|OTHER|Educational Intervention|Undergo video-assisted intervention
219375444|NCT02345798|OTHER|Quality-of-Life Assessment|Undergo quality of life assessment
219375445|NCT02345798|OTHER|Questionnaire Administration|Undergo questionnaire administration
219375446|NCT00714779|DRUG|Fluoxetine|20-40 mg / day orally
219375447|NCT00714779|BEHAVIORAL|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
219375448|NCT01800942|DRUG|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
219375449|NCT00642642|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
219375450|NCT00642642|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
219375451|NCT01459978|OTHER|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
219375452|NCT04770519|GENETIC|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
219375453|NCT03670355|DRUG|Tenofovir (TFV) IVR|Contains 1.4 g TFV
219375454|NCT03670355|DRUG|Placebo IVR|Contains placebo
219375455|NCT02375867|DRUG|prednisolone|Oral administration of 1 mg/Kg/day
219375456|NCT02375867|DRUG|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
219375457|NCT03543813|DRUG|CX-2029|CX-2029 Monotherapy
219375458|NCT02423096|DRUG|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
219375459|NCT05427474|DRUG|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
219375460|NCT03452267|DRUG|Metformin|oral, 850 mg twice daily
219375461|NCT03452267|DRUG|Pioglitazone|oral, 45 mg daily
219375462|NCT03452267|DRUG|Placebo|oral, once daily
219375463|NCT05397314|DIETARY_SUPPLEMENT|Punalpin|
219375464|NCT05397314|OTHER|Placebo|
219375465|NCT06261879|DEVICE|Special sanitary pad|The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
219375466|NCT03668756|PROCEDURE|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
219375467|NCT04351412|OTHER|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
219375468|NCT04351412|OTHER|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
219375469|NCT04351412|OTHER|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
219375470|NCT02179840|PROCEDURE|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
219375471|NCT00712101|DRUG|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
219375472|NCT00712101|DRUG|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
219375473|NCT01778244|DRUG|metformin|1000mg/day for 24 weeks
219375474|NCT00370344|PROCEDURE|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
219375475|NCT00370344|PROCEDURE|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
219375476|NCT01413893|DRUG|linifanib|QD daily
219375477|NCT04523740|DRUG|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
219375478|NCT04523740|DRUG|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
219375479|NCT00269009|BEHAVIORAL|CHERL|
219375480|NCT06095830|DIAGNOSTIC_TEST|Complete blood count|Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
219375481|NCT02340650|DEVICE|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
219375482|NCT04976452|OTHER|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
219375483|NCT04233125|PROCEDURE|Core Decompression|Core Decompression
219375484|NCT04233125|PROCEDURE|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
219375485|NCT04574843|PROCEDURE|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
219375486|NCT05674448|BIOLOGICAL|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
219375487|NCT05674448|BIOLOGICAL|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
219375488|NCT02413203|DRUG|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
219188240|NCT06839885|OTHER|Control group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the past year and completed their treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. Patients were planned to be treated in the hydrotherapy unit during lunch breaks under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the control group will receive a home exercise program and self-drainage."
219188241|NCT06834854|DRUG|fentanyl|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), 100 ml of isotonic saline over 15 minutes. Fentanyl 1 mcg/kg (1 ampoule contains 100mcg over 10cc syringe). Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done~Maintenance: Anesthesia will be maintained with Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03mg/kg/30min. Another IV cannula will be placed with two infusion pumps of normal saline 50cc and fentanyl infusion 1-2 mcg/kg/hour (max 300 mcg total)."
219188242|NCT06834854|DRUG|Lidocaine (drug)|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with IV propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), lidocaine 2% (1.5 mg/kg (7.5cc bolus dose)), MgSO4 10% (50 mg/kg in 100 ml of isotonic saline over 15 minutes), Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done.~Maintenance: Anesthesia will be maintained using Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03 mg/kg/30min. Another IV cannula will be placed with 2 infusion pump one of them containing mixture of (lidocaine 2% 1.5 mg/kg/hour as infusion along with MgSO4 10% in 10-15 mg/kg/hour with 50cc normal saline over 50ml/hour), while the second contains propofol at 6-10 mg/kg/hour."
219188243|NCT03334630|DEVICE|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
219188244|NCT03334630|DEVICE|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
219188245|NCT06464146|DRUG|Morphine|oral morphine (0.5 mg / kg)
219188246|NCT06464146|DRUG|IN fentanyl|IN fentanyl (1.5 µg/kg)
219188247|NCT06464146|DRUG|IN ketamine|IN ketamine (1 mg/kg)
219188248|NCT06464146|DRUG|NaCl 0,9 %|Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
219188249|NCT06454708|DRUG|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
219188250|NCT06789653|DIAGNOSTIC_TEST|p16INK4a mRNA level assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined
219375489|NCT02413203|DRUG|Placebo|Blood and urine collections before and 3 hours after placebo administration.
219375490|NCT02337387|BIOLOGICAL|Blosozumab|Administered SC
219375491|NCT02337387|OTHER|Placebo|Administered SC
219375492|NCT03731663|BEHAVIORAL|Exposure to pictures of appetizing food (known as Foodporn)|\- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
219375493|NCT03731663|BEHAVIORAL|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
219375494|NCT03372525|DEVICE|HFOV|Infants were randomized to HFOV
219375495|NCT03372525|DEVICE|CMV|Infants were randomized to CMV
219188251|NCT06789653|DIAGNOSTIC_TEST|organ-specific protein signatures assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.
219188252|NCT06442787|DEVICE|conventional splints|only intermediate and final splint will be used during the surgery
219375496|NCT04947293|OTHER|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
219375497|NCT00790517|BEHAVIORAL|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
219375498|NCT00707356|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
219375499|NCT05021809|DRUG|Calcium hydroxide intracanal medication application|The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
219375500|NCT05052489|OTHER|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
219375501|NCT02160457|OTHER|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
219375502|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
219375503|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
219375504|NCT03394638|OTHER|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
219375505|NCT03394638|OTHER|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
219375506|NCT03394638|PROCEDURE|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
219375507|NCT02968355|OTHER|Observational study|Observational study
219375508|NCT00716716|DRUG|rFIXFc|As specified in the treatment arm
219375509|NCT02272790|DRUG|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
219375510|NCT02272790|DRUG|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
219375511|NCT02272790|DRUG|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
219375512|NCT02272790|DRUG|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
219375513|NCT02272790|DRUG|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
219375514|NCT03036878|OTHER|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
219375515|NCT01206907|DRUG|oxymorphone IR|oxymorphone IR liquid
219375516|NCT02193789|PROCEDURE|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
219375517|NCT02193789|DEVICE|Covered Self-expandable Metallic Stents|
219375518|NCT05975229|OTHER|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
219375519|NCT05975229|OTHER|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
219375520|NCT01882361|DRUG|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
219375521|NCT01882361|DRUG|placebo comparator|this placebo has no specific pharmacological activity
219188253|NCT06442787|DEVICE|cutting guides and positioning guides|patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
219375522|NCT00332202|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
219375523|NCT00332202|DRUG|placebo|oral, daily
219375524|NCT05079438|DRUG|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
219375525|NCT00036114|DRUG|aripiprazole|
219375526|NCT00836940|DRUG|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
219375527|NCT01068561|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
219188254|NCT06442787|DEVICE|cutting guides and fixation plates|patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
219188255|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
219188256|NCT05653336|DEVICE|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
219188257|NCT06299410|DRUG|ITI-1284 10 mg|ITI-1284 tablet
219188258|NCT06299410|DRUG|ITI-1284 20 mg|ITI-1284 tablet
219188259|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
219188260|NCT02302885|OTHER|Blood collection|Blood Collection
219188261|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Intravaginally|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
219188262|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Laporoscopic|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
219188263|NCT04815213|BIOLOGICAL|EV|Extracellular vesicles injection
219188264|NCT04246112|OTHER|Handwriting intervention|children will practice handwriting 5 days p/week, 15-20 minutes p/day for 12 weeks using the movalyzer software program.
219188265|NCT06355713|DEVICE|Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination|"An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over."
219188266|NCT06355713|BIOLOGICAL|blood sample|"Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)"
219188267|NCT06355713|BIOLOGICAL|urine collection|"Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)"
219188268|NCT06355713|BIOLOGICAL|Collection of a lock of hair|Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
219188269|NCT06355713|OTHER|questionnaire|"Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score"
219188270|NCT05178888|DRUG|MRTX849|KRAS G12C inhibitor
219188271|NCT05178888|DRUG|Palbociclib|CDK 4 and 6 inhibitor
219188272|NCT06344416|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
219188273|NCT06077136|OTHER|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
219188274|NCT06077136|OTHER|standard physical therapy|all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
219188275|NCT02413970|DEVICE|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
219188276|NCT04252573|DEVICE|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
219188277|NCT05116514|OTHER|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
219188278|NCT06112639|DEVICE|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
219188279|NCT06112639|DEVICE|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
219188280|NCT06112639|DEVICE|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
219188281|NCT03138161|DRUG|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
219188282|NCT03138161|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
219188283|NCT03138161|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
219188284|NCT04833010|OTHER|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
219188285|NCT04833010|OTHER|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
219188286|NCT04555590|BEHAVIORAL|H-HOPE Intervention|The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
219188287|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
219188288|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
219375528|NCT02901171|BEHAVIORAL|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
219375529|NCT02901171|BEHAVIORAL|ACT group treatment|
219375530|NCT02901171|BEHAVIORAL|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
219375531|NCT03034941|DRUG|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
219375532|NCT03034941|DRUG|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
219375533|NCT05006053|OTHER|Interviews/Focus groups|Qualitative study (no intervention delivered)
219375534|NCT04812561|DIETARY_SUPPLEMENT|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
219375535|NCT04812561|DIETARY_SUPPLEMENT|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
219375536|NCT00378118|OTHER|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
219375537|NCT00378118|OTHER|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
219375538|NCT01061489|OTHER|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
219375539|NCT01061489|OTHER|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
219375540|NCT06551623|DRUG|Midazolam|Midazolam Oral Solution 2 mg
219375541|NCT06551623|DRUG|Clarithromycin|Clarithromycin tablets 0.5 g
219375542|NCT06551623|DRUG|TNP-2198|TNP-2198 Capsules 400 mg
219375543|NCT01656642|DRUG|Atezolizumab|Atezolizumab will be administered q3w or q2w.
219375544|NCT01656642|DRUG|Cobimetinib|Oral repeating dose
219375545|NCT01656642|DRUG|Vemurafenib|Oral repeating dose, depending on arm/cohort
219375546|NCT03006653|BEHAVIORAL|Assessment only|Mobile ecological assessment only.
219375547|NCT00291304|PROCEDURE|MRI|pre-surgery
219375548|NCT02682329|OTHER|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
219375549|NCT02682329|OTHER|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
219375550|NCT01883037|OTHER|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
219375551|NCT04934293|PROCEDURE|Virtual reality|Before proton therapy, virtual reality sessions will be performed.
219375552|NCT02977715|BIOLOGICAL|JYNNEOS (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
219375553|NCT02977715|BIOLOGICAL|JYNNEOS (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
219375554|NCT06583343|DRUG|OnabotulinumtoxinA|Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
219375555|NCT06583343|OTHER|Conventional Physical Therapy|Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
219375556|NCT05143021|OTHER|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
219375557|NCT03871491|DRUG|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
219375558|NCT03871491|DRUG|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
219375559|NCT05238584|PROCEDURE|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
219375560|NCT00142948|DRUG|Naltrexone|naltrexone
219375561|NCT00142948|DRUG|Placebo|placebo
219375562|NCT01082484|DRUG|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
219375563|NCT01082484|DRUG|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
219375564|NCT01082484|DRUG|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
219375565|NCT03594994|BEHAVIORAL|Sleep extension|Extend time-in-bed by one hour
219375566|NCT05919797|DRUG|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
219375567|NCT05838417|BEHAVIORAL|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
219375568|NCT05292196|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
219375569|NCT05292196|DRUG|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
219375570|NCT05202808|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
219375571|NCT05202808|DEVICE|Control IOL|Control treatment group will receive a Control IOL
219375572|NCT06439862|OTHER|Children with PUV|Male children aged 6 to 17 years old treated for PUV in their first year of life between 2006 and 2018 in Lyon, and managed in the Femme-Mère-Enfant Hospital in Lyon
219375575|NCT05879159|BEHAVIORAL|Questionnaires|Survey
219375576|NCT04439331|DRUG|Defactinib Hydrochloride|Given PO
219375577|NCT05519215|DEVICE|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
219375578|NCT05618197|OTHER|Passive heating|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
219375579|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
219375580|NCT02882256|OTHER|Video discharge instructions|Discharge instructions provided in video form
219375581|NCT06302257|DRUG|Chlorprocaine|we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
219375582|NCT06302257|DRUG|Lidocaine|Study participants will receive lidocaine alone
219375583|NCT06302257|DRUG|Lidocaine-chlorprocaine combination|study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
219375584|NCT00283556|DRUG|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
219375585|NCT04612738|BEHAVIORAL|Hello (serious game)|Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with \>100 patients/caregivers from diverse backgrounds.
219375586|NCT04612738|BEHAVIORAL|The Conversation Project (CP) Starter Kit|"The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program."
219375587|NCT04612738|OTHER|Table Topics (general conversation game)|Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
219375588|NCT01009528|DEVICE|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
219375589|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
219375590|NCT04149314|OTHER|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
219375591|NCT02901314|OTHER|on-demand audio messages of heart failure education themes|
219375592|NCT02495948|DEVICE|Lotrafilcon B contact lenses|
219375593|NCT02495948|DEVICE|Samfilcon A contact lenses|
219375594|NCT02495948|DEVICE|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
219375595|NCT02495948|DEVICE|Saline solution|Used for rinsing contact lenses, as needed
219375596|NCT01701622|DRUG|febuxostat|"If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
219375597|NCT02920125|DRUG|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
219375598|NCT02920125|COMBINATION_PRODUCT|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
219375599|NCT02920125|OTHER|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
219375600|NCT01931046|DRUG|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
219375601|NCT01752283|PROCEDURE|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
219375602|NCT01752283|PROCEDURE|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
219375603|NCT04073667|BEHAVIORAL|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
219375604|NCT01936038|OTHER|CPAP|CPAP
219375605|NCT01936038|PROCEDURE|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
219375606|NCT04766853|DRUG|Dexamethasone|Dexamethasone 5mg/ml
219375607|NCT04766853|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
219375608|NCT02747004|DRUG|Abemaciclib|Administered orally
219375609|NCT02747004|DRUG|Tamoxifen|Administered orally
219375610|NCT02747004|DRUG|Prophylactic Loperamide|Administered orally
219375611|NCT05116384|DEVICE|catheter ablation|cryo energy via cryoballoon
219375612|NCT05116384|DEVICE|renal artery denervation|RF energy delivery to multiple sites within each major renal artery
219375613|NCT06218251|DRUG|BOTOX|Intramuscular Injections
219375614|NCT04899908|RADIATION|Stereotactic Radiation|Focused radiation beams to treat tumors
219375615|NCT04899908|DRUG|AGuIX gadolinium-based nanoparticles|Intravenous injection
219375616|NCT04899908|OTHER|Placebo|Intravenous infusion
219375617|NCT04930770|DRUG|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
219375618|NCT05087030|DRUG|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
219375619|NCT05087030|DRUG|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
219375620|NCT05327062|DEVICE|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
219375621|NCT02749305|OTHER|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
219375622|NCT06160466|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
219375623|NCT06160466|DEVICE|White light|White light endoscopy
219375624|NCT06486012|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device home-use with a marker substance
219375625|NCT06486012|OTHER|Standard oral hygiene|Standard oral hygiene performed at home
219375626|NCT04109729|DRUG|Nivolumab|Nivolumab 480mg IV every 4 weeks for up to 2 years
219375627|NCT04109729|DRUG|Radium-223|Radium-223 55 kilobecquerel (kBq)/kg IV q4 weeks for 6 cycles total
219375628|NCT02998385|DRUG|Cisplatin|intravenous, concomitant to irradiation
219375629|NCT02998385|RADIATION|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
219375630|NCT06090994|DRUG|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
219375631|NCT06090994|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
219375632|NCT01444300|DRUG|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
219375633|NCT01444300|DRUG|Placebo|placebo pill, bid for 12 weeks
219375634|NCT05607628|COMBINATION_PRODUCT|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
219375635|NCT05607628|COMBINATION_PRODUCT|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
219375636|NCT05662826|BEHAVIORAL|Avatar-based Social Physical Activity|Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
219375637|NCT02619851|BIOLOGICAL|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
219375638|NCT02619851|DEVICE|Conventional Therapy|Typical therapy conducted for burn injury patients
219375639|NCT00490542|DRUG|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
219375640|NCT00490542|DRUG|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
219375641|NCT03884465|DRUG|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
219375642|NCT01048346|BEHAVIORAL|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
219375643|NCT05254795|OTHER|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
219375644|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
219375645|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
219375646|NCT00898547|OTHER|immunoenzyme technique|
219375647|NCT00898547|OTHER|laboratory biomarker analysis|
219375648|NCT01517035|PROCEDURE|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
219375649|NCT02598414|PROCEDURE|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
219375650|NCT02598414|PROCEDURE|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
219375651|NCT02598414|DEVICE|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
219375652|NCT02113293|DRUG|CyclASol®|Cyclosporine A Solution
219375653|NCT02113293|DRUG|Placebo (vehicle)|Vehicle Solution
219375654|NCT06194877|DRUG|BGB-3245|Oral capsule
219375655|NCT06194877|DRUG|Panitumumab|Intravenous (IV) infusion via an infusion pump
219375656|NCT06649058|OTHER|Systemic Therapy|Participants will receive systemic therapy as a standard of care therapeutic option
219375657|NCT06649058|RADIATION|Stereotactic Radiosurgery|Participants will receive systemic therapy as a standard of care therapeutic option
219375658|NCT02390518|RADIATION|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
219375659|NCT06573853|PROCEDURE|Focal Pulsed Field Ablation (PFA)|Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
219375660|NCT06573853|PROCEDURE|Focal Radiofrequecy Ablation (RFA)|Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
219375661|NCT05178420|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
219375662|NCT03158766|OTHER|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
219375663|NCT03860922|DEVICE|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
219375664|NCT01813994|DRUG|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
219375665|NCT01813994|DRUG|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
219375666|NCT01501591|DRUG|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
219375667|NCT01501591|OTHER|Placebo|Matching placebo once on two different days, 72 hours apart.
219375668|NCT01501591|DRUG|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
219375669|NCT04992702|BEHAVIORAL|Animated Video|Animated video to improve learning and motivation
219375670|NCT01289496|DRUG|Peg-interferon alpha-2a, Ribavirin|"* 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
219375671|NCT06255873|DIETARY_SUPPLEMENT|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
219375672|NCT06255873|OTHER|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
219375673|NCT03843047|DRUG|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
219375674|NCT03843047|DRUG|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
219375675|NCT03843047|DRUG|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
219375676|NCT03843047|DRUG|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
219375677|NCT00004826|DRUG|clozapine|
219375678|NCT05338229|DEVICE|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
219375679|NCT03216629|BEHAVIORAL|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
219375680|NCT03658954|BEHAVIORAL|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
219375681|NCT03658954|BEHAVIORAL|Self-monitoring|Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
219375682|NCT03658954|BEHAVIORAL|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& smartphone diaries \& tailored coaching with a health coach
219375683|NCT04549532|BEHAVIORAL|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
219375684|NCT04549532|BEHAVIORAL|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
219375685|NCT06386406|DEVICE|TAP insole|"The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender."
219375686|NCT06267560|DRUG|TQJ230|TQJ230 80mg QM s.c.
219375687|NCT06267560|DRUG|Placebo|matching placebo
219375688|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
219375689|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
219375690|NCT06186375|OTHER|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
219375691|NCT02399033|DRUG|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
219375692|NCT00818259|DRUG|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
219375693|NCT00818259|DRUG|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
219375694|NCT00818259|DRUG|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
219375695|NCT00818259|DRUG|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
219375696|NCT00818259|DRUG|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
219375697|NCT00421330|PROCEDURE|Open Aneurysm Repair|
219375698|NCT00421330|PROCEDURE|Endovascular Aneurysm Repair|
219375699|NCT02129673|DRUG|VS101 Insert Dose A|Sustained release of latanoprost into the eye
219375700|NCT02129673|DRUG|VS101 Insert Dose B|Sustained release of latanoprost into the eye
219375701|NCT02129673|DRUG|VS101 Insert Dose C|Sustained release of latanoprost into the eye
219375702|NCT02129673|DRUG|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
219375703|NCT03223571|OTHER|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
219375704|NCT06190457|OTHER|intrathecal rituximab|All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
219375705|NCT05391438|OTHER|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
219375706|NCT05941104|OTHER|frailty|Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
219375707|NCT00120003|DRUG|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
219375708|NCT00120003|DRUG|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
219375709|NCT05754775|BEHAVIORAL|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
219375710|NCT03629548|PROCEDURE|early amniotomy|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
219375711|NCT03629548|DEVICE|foley catheter balloon placement|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
219375712|NCT02863198|DEVICE|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
219375713|NCT03679325|DIETARY_SUPPLEMENT|vitamine D|a dose once a week
219375714|NCT03679325|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
219375715|NCT06544239|BEHAVIORAL|Virtual reality basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
219375716|NCT06544239|BEHAVIORAL|Traditional basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
219375717|NCT06115109|OTHER|Non intervention, Observational study|Non intervention, Observational study
219375718|NCT05466643|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
219375719|NCT05466643|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
219375720|NCT01483677|OTHER|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
219375721|NCT01483677|OTHER|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
219375722|NCT01526421|OTHER|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
219375723|NCT06206096|DRUG|oxaliplatin+capecitabine+bevacizumab+PD-1 antibody|oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
219375724|NCT05943080|DRUG|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
219375725|NCT05943080|DRUG|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
219375726|NCT05943080|DRUG|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
219375727|NCT01832740|DEVICE|brain stimulation|oscillating direct current brain stimulation
219375728|NCT01832740|DEVICE|SHAM|no stimulation
219375729|NCT04762030|DRUG|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
219375730|NCT02380755|DRUG|Clomiphene Citrate|50 mg orally daily during 12 weeks
219375731|NCT02380755|DRUG|Placebo|1 pill orally daily during 12 weeks
219375732|NCT06545227|DEVICE|continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.|To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
219375733|NCT06545227|OTHER|Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)|To study maternal metabolome
219188289|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
219188290|NCT05249101|DRUG|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
219188291|NCT05249101|DRUG|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
219188292|NCT04019977|OTHER|Nurse Home Visiting Program|Brief nurse home visiting program
219188293|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
219188294|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
219188295|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
219188296|NCT00999856|DEVICE|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
219188297|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
219188298|NCT00999856|DEVICE|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
219188299|NCT00999856|DEVICE|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
219188300|NCT02234388|OTHER|Observation|There are no interventions associated with this registry as it is purely observational.
219188301|NCT05059639|OTHER|Almond|Consume 2 ounces of almond daily for 8 weeks
219188302|NCT05059639|OTHER|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
219188303|NCT04214184|BEHAVIORAL|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
219188304|NCT01711190|PROCEDURE|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
219188305|NCT06568081|OTHER|SloMo|SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
219188306|NCT01478542|DRUG|Conventional Vincristine|
219188307|NCT01478542|DRUG|Liposomal Vincristine|
219188308|NCT01478542|DRUG|Ricover-scheme rituximab|
219188309|NCT01478542|DRUG|optimised rituximab-schedule|
219188310|NCT04722887|BIOLOGICAL|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
219188311|NCT04722887|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
219188312|NCT04971109|DRUG|TPOXX|Study is based on Animal Regulatory Rule
219188313|NCT04971109|OTHER|TPOXX Placebo|Does not apply
219188314|NCT06568861|DRUG|ALG-097558|Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
219188315|NCT03910478|DEVICE|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
219188316|NCT03910478|OTHER|Standard Control Strategy|Standard of care with office-based testing.
219188317|NCT05043961|PROCEDURE|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
219188318|NCT03953417|DEVICE|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
219188319|NCT05293171|DRUG|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
219188320|NCT05293171|DRUG|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
219188321|NCT05293171|DRUG|BL-8040-matching placebo|Administered subcutaneous (SC) injection
219188322|NCT05293171|DRUG|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
219188323|NCT05133739|DEVICE|injection of RHA®4 in Midface|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
219188324|NCT05133739|DEVICE|injection of Comparator Product in Midface|"Comparator product is sterile, biodegradable, colorless gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
219188325|NCT05454839|OTHER|Survey|Interviewer-administered survey
219188326|NCT05454839|OTHER|Focus group|Focus group for selected participants
219188327|NCT04313712|DRUG|ibogaine with magnesium treatment|Participants will receive magnesium sulfate intravenously and ibogaine orally.
219188328|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART is a web-based intervention that adapted and modified components from the Transdiagnostic Sleep and Circadian intervention for youth and included four cross-cutting components (sleep complaint, education, behavior change and motivation, and goal-setting) that were integrated into each module. To begin the intervention, participants were provided a link to the SLEEPSMART intervention website for one of the above modules and an online sleep coach each week. At the end of each week, children and parents uploaded the weekly activities and goals via the REDCap link and set up a meeting with the sleep coach to review. The modules took 20 to 30 minutes to complete.
219188329|NCT06438159|OTHER|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations."
219188330|NCT06438159|OTHER|Conventional cardiac rehabilitation|The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
219188331|NCT04844866|GENETIC|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
219188332|NCT04844866|DRUG|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
219188333|NCT06577428|DRUG|RAY1225|administered SC
219188334|NCT02641639|DRUG|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
219188335|NCT02641639|DRUG|Placebo|Saline for infusion
219188336|NCT06415292|DRUG|Winlevi (clascoterone) 1% cream|Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.
219188337|NCT06835023|DRUG|Ringer lactate (RLS)|50 patients will receive only Ringer Lactat
219188338|NCT06835023|DRUG|Dextran+Ringer Lactat(D+RLS)|50 patients Dextran+RInger Lactat 1:3 ratio
219188339|NCT05332457|DRUG|Reduced dosage of beta-blocker|"Phase I:~1. CPET performed at trough BB concentration: participants will undergo CPET at least 30 hours after last beta-blocker usage.~2. CPET performed at peak BB concentration : participants will undergo CPET at 3 hours after last beta-blocker usage.~Phase II:~BB dosage will be reduced."
219188340|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
219188341|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
219188342|NCT01712490|DRUG|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
219188343|NCT01712490|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
219188344|NCT01712490|DRUG|bleomycin|Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
219188345|NCT01712490|DRUG|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
219188346|NCT01712490|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
219188347|NCT05871970|BIOLOGICAL|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
219188348|NCT06780683|DRUG|Upadacitinib|"Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered."
219188349|NCT04986423|DRUG|ZEN003694|72 mg PO QD
219188350|NCT04986423|DRUG|Enzalutamide|160 mg PO QD
219188351|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
219375734|NCT06545227|OTHER|Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)|To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.
219375735|NCT06545227|OTHER|Maternal and neonatal outcome data collection for all women in the study|Data for maternal and neonatal outcomes will be collected
219375736|NCT00457574|DRUG|GMX1777|
219375737|NCT06217679|OTHER|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
219375738|NCT06217679|OTHER|Mixed Exercise|exercise performed in randomized order
219375739|NCT05042726|DEVICE|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
219375740|NCT05042726|DEVICE|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
219375741|NCT00825370|DRUG|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
219375742|NCT00825370|DRUG|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
219375743|NCT01237951|DRUG|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
219375744|NCT01237951|DRUG|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
219375745|NCT01237951|DRUG|Gemcitabine|1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
219375746|NCT01237951|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
219375747|NCT01237951|DRUG|Melphalan|60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
219375748|NCT01237951|PROCEDURE|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
219375749|NCT01237951|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
219375750|NCT01053429|DRUG|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
219375751|NCT01943656|DEVICE|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
219375752|NCT01841892|BEHAVIORAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
219375753|NCT05337618|DIAGNOSTIC_TEST|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
219375754|NCT05337618|COMBINATION_PRODUCT|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
219375755|NCT03498820|DEVICE|Analgesia Nociception Index|: Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
219188352|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
219375756|NCT03498820|DRUG|Remifentanil|intravenous short-acting opioid routinely administered during general anesthesia
219375757|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
219375758|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
219375759|NCT04708587|DRUG|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
219375760|NCT04708587|DRUG|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
219375761|NCT06296563|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion for 2 times.
219375762|NCT06296563|DRUG|Adebrelimab|Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
219375763|NCT06296563|DRUG|Apatinib|Apatinib 250mg, po, qd,q3w,up to one year of use at most.
219375764|NCT06100783|DEVICE|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
219375765|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219375766|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219375767|NCT00752986|DRUG|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
219375768|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
219375769|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219375770|NCT06202248|DEVICE|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
219375771|NCT02226965|DRUG|PNT2258|
219375772|NCT03481270|BEHAVIORAL|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
219375773|NCT00792779|DRUG|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
219375774|NCT05394259|DRUG|Piflufolastat F18|Given by vein (IV)
219375775|NCT02662790|OTHER|Doppler|
219375776|NCT00924703|DRUG|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
219000896|NCT05984732|BEHAVIORAL|Reminiscence with digital storytelling|The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
219000897|NCT05984732|BEHAVIORAL|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
219000898|NCT02156596|DRUG|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
219000899|NCT02156596|DRUG|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
219000900|NCT02156596|DRUG|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
219000901|NCT02156596|DRUG|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
219000902|NCT01737515|OTHER|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
219000903|NCT03024450|DRUG|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
219000904|NCT00153075|DEVICE|Berodual Respimat|
219000905|NCT00153075|DEVICE|Berodual HFA-MDI|
219000906|NCT05436392|BEHAVIORAL|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
219000907|NCT05436392|BEHAVIORAL|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
219000908|NCT03194022|OTHER|Blood sample|measurement of electrolytes and blood count
219000909|NCT06287411|DIAGNOSTIC_TEST|FAPI PET/MR combined with gadoxetate disodium|Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.
219000910|NCT04047940|DRUG|LY900020|Administered orally
219000911|NCT04047940|DRUG|Metformin XR|Administered orally
219000912|NCT04047940|DRUG|Atorvastatin|Administered orally
219000913|NCT04047940|DRUG|Valsartan|Administered orally
219000914|NCT03867006|DIETARY_SUPPLEMENT|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
219000915|NCT03867006|DIETARY_SUPPLEMENT|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
219375777|NCT00666562|DIETARY_SUPPLEMENT|Defined Green Tea Catechin Extract|Given orally
219375778|NCT00666562|OTHER|Laboratory Biomarker Analysis|Correlative studies
219375779|NCT00666562|OTHER|Pharmacological Study|Correlative studies
219375780|NCT00666562|DRUG|Placebo|Given orally
219375781|NCT00666562|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219375782|NCT06290440|OTHER|Telepharmacy-led counselling|The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
219375783|NCT06290440|OTHER|Pharmacist-led counselling|Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
219375784|NCT05491759|DRUG|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
219375785|NCT05491759|DRUG|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
219375786|NCT05491759|DRUG|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
219375787|NCT02029742|BEHAVIORAL|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
219375788|NCT02029742|BEHAVIORAL|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
219375789|NCT06055166|DRUG|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
219375790|NCT01106040|DRUG|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
219375791|NCT05792202|PROCEDURE|microfracture procedure|double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
219375792|NCT05792202|PROCEDURE|only double raw repair|the double raw repair was used to repair the tendon tear
219375793|NCT04695873|DEVICE|Corn Foam Cushion|An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
219375794|NCT02238535|DRUG|Ventavis|
219375795|NCT02238535|DRUG|Warfarin|
219375796|NCT06381830|OTHER|Apheresis|Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.
219375797|NCT06381830|OTHER|Autologous Stem Cell Transplantation|Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.
219375798|NCT06381830|DRUG|CAR-T Cell Therapy|CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
219375799|NCT00003721|DRUG|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
219375800|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 1-12
219375801|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 13-24
219375802|NCT01587989|DRUG|placebo|methotrexate placebo orally weekly, Weeks 13-24
219375803|NCT01587989|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
219375804|NCT02570672|DRUG|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
219375805|NCT02570672|DRUG|Placebo|Subjects will randomized to placebo will receive placebo
219375806|NCT02053688|DEVICE|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
219375807|NCT02053688|DEVICE|Toric Soft Contact Lenses|astigmatism correction using toric optics
219188353|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
219188354|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
219188355|NCT04432506|BIOLOGICAL|Anakinra|Given SC
219188356|NCT04432506|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
219188357|NCT04432506|DRUG|Cyclophosphamide|Given IV
219188358|NCT04432506|DRUG|Fludarabine|Given IV
219188359|NCT06536387|BEHAVIORAL|Storytelling Through Music|Storytelling Through Music is a six-week intervention that combines storytelling, reflective writing, song-writing, and self-care skills to improve emotion regulation through affective and cognitive coping skills.
219188360|NCT05990465|DRUG|Pirtobrutinib|Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
219188361|NCT05990465|DRUG|LV20.19 CAR T cells|Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
219188362|NCT06537544|OTHER|Comprehensive Rehabilitation Program|Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education
219188363|NCT06537544|OTHER|Conventional Pelvic Floor Training|Kegels exercises in different body positions
219188364|NCT03987022|DRUG|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
219188365|NCT03987022|DRUG|Opioids|Use of narcotic for pain control postoperatively
219188366|NCT03987022|OTHER|Ice Packs|Placement of Ice packs on surgical sites postoperatively
219188367|NCT03987022|DRUG|Tylenol|Use of pain medication postoperatively
219188368|NCT03987022|DRUG|Motrin|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
219188369|NCT03987022|DRUG|Dilaudid Injectable Product|Use of narcotic for pain control postoperatively
219188370|NCT03987022|DRUG|Percocet 5Mg-325Mg Tablet|Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
219188371|NCT03822936|DRUG|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
219188372|NCT03822936|RADIATION|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
219188373|NCT03478956|DRUG|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
219188374|NCT03481075|OTHER|Biomechanical computer program|Fusion assisting software for image-guided intervention
219188375|NCT05617794|DEVICE|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
219188376|NCT05617794|DEVICE|Control Spectacle Lens|Control Spectacles
219188377|NCT04800211|OTHER|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
219188378|NCT04800211|OTHER|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
219188379|NCT02550522|DEVICE|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
219188380|NCT05849337|BEHAVIORAL|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
219188381|NCT05849337|BEHAVIORAL|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
219188382|NCT05849337|OTHER|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
219188383|NCT04290806|OTHER|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
219188384|NCT04698031|DRUG|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
219188385|NCT04698031|DRUG|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
219188386|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
219188387|NCT06270199|BIOLOGICAL|Control|Standard treatment
219188388|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
219188389|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
219191748|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now."
219191749|NCT05435638|DIAGNOSTIC_TEST|Lesion photography|High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
219375808|NCT02503605|DRUG|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
219375809|NCT02503605|DRUG|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
219375810|NCT04312087|PROCEDURE|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
219375811|NCT04312087|PROCEDURE|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
219375812|NCT04312087|PROCEDURE|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
219375813|NCT00275561|DRUG|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
219375814|NCT00275561|DRUG|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
219375815|NCT06158243|OTHER|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
219375816|NCT01530243|DRUG|Placebo|same as tolterodine and terazosin dose
219375817|NCT01530243|DRUG|Terazosine|2 mg BID
219375818|NCT01530243|DRUG|Tolterodine|2 mg daily
219375819|NCT01530243|DRUG|Tolterodine + Terazosin|2mg daily and 2mg BID
219375820|NCT06127329|PROCEDURE|BAI combine with DEB-BACE|"1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
219375821|NCT02300649|DRUG|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
219375822|NCT02300649|DRUG|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
219375823|NCT03637049|DRUG|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
219375824|NCT00407355|DRUG|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
219375825|NCT00407355|DRUG|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
219375826|NCT05166707|DEVICE|BIXINK OC Free|OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
219375827|NCT04915196|DIETARY_SUPPLEMENT|Liposomally-bound Iron|Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
219375828|NCT06960525|OTHER|Cervical joint mobilization|Passive cervical joint mobilization following Maitland's approach for 3 sets of 1 minute on the most painful segment with one minute rest between sets.
219375829|NCT06960525|OTHER|cervical strengthening exercises|concentric and eccentric training of the craniocervical, cervical flexors, extensors, muscles involved in cervical spine rotation and axioscapular muscles.
219375830|NCT03128957|DEVICE|IVOS cerebral oximeter|Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
219375831|NCT03128957|DEVICE|Licox cerebral oxygenation monitor|Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
219375832|NCT03128957|OTHER|Cerebral oxygenation|Measuring cerebral oxygenation with varying ventilation strategy
219375833|NCT04915287|DRUG|Avatrombopag maleate|"1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
219375834|NCT04915287|BIOLOGICAL|Platelet transfusion|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed
219191750|NCT05435638|DRUG|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
219375835|NCT04915287|DRUG|Medicine|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
219375836|NCT00684177|DRUG|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
219375837|NCT00684177|DRUG|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
219375838|NCT04590001|DEVICE|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
219375839|NCT03776656|DRUG|Allopurinol|Daily oral administration
219375840|NCT06382090|OTHER|Laughter yoga|This practice, which includes deep breathing exercises and laughter exercises, takes approximately 45 minutes. The sessions will be conducted by the principal investigator.
219375841|NCT03542994|OTHER|EDP1066|EDP1066 is an orally administered monoclonal microbial
219375842|NCT03542994|DRUG|Placebo oral capsule|placebo
219375843|NCT05852756|BEHAVIORAL|pecha kucha|pecha kucha training
219375844|NCT06507904|DRUG|Osivelotor|A medicine to treat sickle cell disease.
219375845|NCT06507904|OTHER|Famotidine|Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
219375846|NCT06873308|DEVICE|UCP-LF CAA assay|dry LF-CAA, or CAA
219375847|NCT06930209|DEVICE|CelluJuve®|CelluJuve® injected into upper brachium
219375848|NCT06907732|PROCEDURE|Fetoscopic robotic open spina bifida closure|"Three 9 mm laparoscopic trocars will be inserted into the uterus after the uterus is exteriorized through a maternal laparotomy. Partial amniotic carbon dioxide insufflation will be done with heated humidified gas. Using a surgical robot, multilayer closure of the lesion will be performed, similar to our current protocol in open fetal spina bifida closure (durapatch, myofascial flap, skin closure).~Pre- and postoperative management will be similar to our current open fetal surgery protocol. Delivery will be by cesarean section, either when spontaneous labor occurs or at 39 weeks, whichever presents first."
219375849|NCT06936800|DRUG|Pinaverium bromide|Preoperative, intraoperative, and postoperative oral administration of 100mg povidonium bromide in P-ESWL
219375850|NCT06936800|DRUG|Placebo for control group|Preoperative, intraoperative, and postoperative oral placebo 100mg for P-ESWL
219375851|NCT06935175|DRUG|SHR-1826|SHR-1826 will be administrated per dose level in which the patients are assigned.
219375852|NCT06935175|DRUG|SHR-1826 and immunotherapy combination therapy|SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.
219375853|NCT06936761|DRUG|Propofol|This is an observational study about routines of anesthesia induction and extubation
219375854|NCT06936761|DRUG|Sevoflurane|This is a retrospective evolution of anesthesia drugs used routinely in an anesthesia clinic.
219375855|NCT06935097|BEHAVIORAL|Mediterranean diet-based Intervention|"Through existing collaboration with the Harris Health system's innovative food pharmacy, participants will be provided fresh fruit, vegetables and other foods every other week during the study.~Participants will receive olive oil and walnuts during the 8 week intervention (consistent with the PREDIMED6 intervention) to supplement their (and their families') diet during the 8-week intervention (while personalized education about diet, food choices and preparation is still occurring)."
219375856|NCT06936072|PROCEDURE|Titanium Ring Inlay Eminence Augmentation|"* Preauricular approach with subperiosteal dissection~* Dual osteotomy (transverse mid-eminence + vertical parallel to skull base)~* Titanium ring inlay placement with anatomical contouring~* Intraoperative functional assessment"
219375857|NCT05372809|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
219375858|NCT05372809|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
219375859|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
219375860|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
219375861|NCT00787293|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
219375862|NCT06950476|PROCEDURE|Oocyte Retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
219375863|NCT03408132|DRUG|FE203799|FE203799 5 mg subcutaneous once weekly
219375864|NCT03704766|DIAGNOSTIC_TEST|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375865|NCT03704766|DIAGNOSTIC_TEST|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375866|NCT03704766|DIAGNOSTIC_TEST|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
219375867|NCT03704766|DIAGNOSTIC_TEST|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375868|NCT03704766|DIAGNOSTIC_TEST|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375869|NCT03704766|DIAGNOSTIC_TEST|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375870|NCT03704766|DIAGNOSTIC_TEST|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375871|NCT03704766|DIAGNOSTIC_TEST|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
219375872|NCT03704766|DIAGNOSTIC_TEST|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
219375873|NCT03704766|DIAGNOSTIC_TEST|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
219375874|NCT03704766|DIAGNOSTIC_TEST|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
219375875|NCT03704766|DIAGNOSTIC_TEST|Synovial PCR for Kingella kingae|In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
219375876|NCT03704766|DIAGNOSTIC_TEST|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
219375877|NCT03704766|DIAGNOSTIC_TEST|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
219375878|NCT03704766|DIAGNOSTIC_TEST|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
219375879|NCT03704766|DIAGNOSTIC_TEST|Serum D-dimer|A blood test performed at the hospital.
219375880|NCT03704766|DIAGNOSTIC_TEST|Serum Procalcitonin|A blood test performed at the hospital.
219375881|NCT03704766|DIAGNOSTIC_TEST|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
219375882|NCT03704766|DIAGNOSTIC_TEST|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
219375883|NCT04840836|BEHAVIORAL|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
219375884|NCT06799195|DRUG|Attenuated-dose Cyclophosphamide|Cyclophosphamide administered at an attenuated dose of 25 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
219375885|NCT06799195|DRUG|High-dose Cyclophosphamide|Cyclophosphamide administered at the standard high dose of 50 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
219375886|NCT06799195|DRUG|Sirolimus|Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.
219375887|NCT06799195|DRUG|Mycophenolate Mofetil (MMF)|MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.
219375888|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
219375889|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
219375890|NCT03697564|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
219375891|NCT03697564|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
219375892|NCT03697564|DRUG|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
219375893|NCT03055026|DRUG|Rivaroxaban|Tablets
219375894|NCT03055026|DRUG|Placebo|Tablets
219375895|NCT01377493|DIETARY_SUPPLEMENT|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
219375896|NCT06443086|PROCEDURE|Radical operation and perioperative therapy|Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
219375897|NCT02031679|DRUG|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
219375898|NCT02031679|DRUG|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
219375899|NCT00520026|DRUG|lithium|
219375900|NCT00520026|DRUG|placebo|
219375901|NCT05139524|OTHER|Evidence of past or recent RVF exposure|Detection of RVF exposure.
219375902|NCT02189265|OTHER|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
219375903|NCT04030195|GENETIC|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
219375904|NCT04030195|DRUG|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
219375905|NCT04030195|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
219188390|NCT06441773|PROCEDURE|Respiratory Rehabilitation|"An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support"
219375906|NCT01228773|BEHAVIORAL|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
219375907|NCT00784407|DEVICE|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
219375908|NCT01812525|DRUG|NaCl 3%|NaCl 3%: 4ml QID
219375909|NCT01812525|OTHER|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
219375910|NCT03025412|PROCEDURE|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
219375911|NCT03025412|BEHAVIORAL|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
219375912|NCT01980446|PROCEDURE|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
219375913|NCT03916068|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
219375914|NCT03916068|DRUG|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
219375915|NCT03916068|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
219375916|NCT04057170|OTHER|accelerated protocol and mulligan method|manual therapy technic
219375917|NCT05136391|DRUG|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
219375918|NCT02443402|DRUG|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
219375919|NCT02443402|DRUG|Placebo|One pill daily until discharge
219375920|NCT02443402|DRUG|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
219375921|NCT02443402|DRUG|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine"
219375922|NCT02443402|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
219375923|NCT02443402|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart"
219375924|NCT05272514|OTHER|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
219375925|NCT06261788|DEVICE|Temporary pacing|Transvenous temporary cardiac pacing - right internal jugular insertion
219375926|NCT00321516|DRUG|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
219375927|NCT06318208|DIAGNOSTIC_TEST|lung function testing|lung function testing including LCI, FEV1, FVC, DLCO
219375928|NCT05250856|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
219375929|NCT05250856|DRUG|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
219375930|NCT05629702|DRUG|Nabiximols|Oromucosal spray
219375931|NCT05629702|DRUG|Temozolomide|Oral capsule
219375932|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
219375933|NCT04545307|BIOLOGICAL|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
219375934|NCT06404489|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
219375935|NCT05292469|BEHAVIORAL|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
219375936|NCT06656819|DEVICE|Magstim Rapid2|"AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females"
219375937|NCT06657339|PROCEDURE|Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)|"The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach."
219375938|NCT03396549|DEVICE|new sham tDCS|1 ch TCT transcranial stimulator
219375939|NCT03396549|DEVICE|real tDCS|1 ch TCT transcranial stimulator
219375940|NCT02214979|DRUG|Telmisartan/Ramipril|fixed dose combination tablet
219375941|NCT02214979|DRUG|Telmisartan|
219375942|NCT02214979|DRUG|Ramipril capsule|
219375943|NCT02214979|DRUG|Ramipril tablet|
219375944|NCT06960395|DRUG|VIR-5525|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
219375945|NCT06960395|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
219375946|NCT00469508|DRUG|Modafinil|400mg pills taken orally daily for 12 wks.
219375947|NCT00469508|DRUG|Placebo|400mg pills taken orally daily for 12 wks
219375948|NCT03446677|OTHER|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
219188391|NCT06345066|DRUG|Tirzepatide|Administered SC.
219188392|NCT06345066|DRUG|LY3841136|Administered SC.
219188393|NCT06345066|DRUG|Placebo|Administered SC.
219375949|NCT05387356|OTHER|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 \<150 despite a PEEP \>10 cmH2O.
219375950|NCT00864760|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
219375951|NCT00864760|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
219375952|NCT00476086|DRUG|Gemcitabine|
219375953|NCT00476086|DRUG|Oxaliplatin|
219375954|NCT00476086|RADIATION|Radiation|
219375955|NCT05192603|DIETARY_SUPPLEMENT|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
219375956|NCT04727515|DRUG|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
219375957|NCT04727515|PROCEDURE|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
219557780|NCT03399006|DEVICE|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
219188394|NCT01050036|PROCEDURE|autologous hematopoietic cell transplantation|"1. Autologous peripheral blood stem cell (PBSCs) harvesting~   * After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~  * Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~  * Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~2. Conditioning regimen for autologous HCT~   * Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~  * Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~3. Autologous cell infusion and waiting for engraftment"
219188395|NCT06079398|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
219188396|NCT06079398|DRUG|Placebo for Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
219188397|NCT04874870|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
219188398|NCT04874870|COMBINATION_PRODUCT|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
219188399|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
219188400|NCT05162547|DEVICE|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
219188401|NCT06304428|OTHER|Deprescribing Care Model|The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
219188402|NCT06304428|OTHER|Bone Health Service Model|The Bone Health Service Model is designed to provide osteoporosis evaluation and management
219188403|NCT06304428|OTHER|Injury Prevention Service Model|The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
219188404|NCT05855746|DRUG|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
219375958|NCT02427061|BEHAVIORAL|Intervention Program (Manhood 2.0)|
219375959|NCT02427061|BEHAVIORAL|Control Program (Job Skills Training)|
219375960|NCT02811705|OTHER|Quality of life|Quality of life
219375961|NCT04178590|DRUG|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
219375962|NCT04178590|DRUG|SRP + placebo|Saline application during scaling and root planing
219375963|NCT06786767|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.
219375964|NCT05067088|OTHER|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
219375965|NCT05899348|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
219375966|NCT06161116|BIOLOGICAL|MK-6194|SC Injection
219375967|NCT06161116|BIOLOGICAL|Placebo|SC Injection
219375968|NCT00863616|DEVICE|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
219375969|NCT02601417|OTHER|Ignoring result of bile culture|the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
219375970|NCT01389245|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
219375971|NCT02065778|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
219375972|NCT03317587|BEHAVIORAL|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
219375973|NCT05388357|OTHER|Intervention Procedure: PCI|Percutaneous Coronary Intervention
219375974|NCT02975128|DEVICE|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
219375975|NCT03445481|DEVICE|Medacta femoral prosthesis|patients' treatment with a new implant prosthesis
219375976|NCT06850298|OTHER|Pasteurized milk contaminated with killed A(H5) virus|Milk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.
219375977|NCT06432959|BEHAVIORAL|Psychotherapy, Positive Affect Promoting Activities|"The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions."
219375978|NCT06432959|BEHAVIORAL|Psychotherapy|Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
219375979|NCT04666207|DIAGNOSTIC_TEST|PCR|RT-PCR for SARS-CoV-2
219375980|NCT02292849|BEHAVIORAL|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
219375981|NCT02292849|OTHER|Standard Mental Health Referral|Standard mental health referral to a community agency
219375982|NCT02623179|OTHER|culture versus Molecular diagnostics|Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
219375983|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
219375984|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
219375985|NCT05844917|DEVICE|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
219375986|NCT04274296|DEVICE|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
219375987|NCT02479347|DRUG|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
219375988|NCT02479347|DRUG|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
219375989|NCT01849926|DRUG|Ibuprofen|
219375990|NCT01849926|DRUG|Mecillinam|
219375991|NCT02883699|BEHAVIORAL|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
219375992|NCT02883699|BEHAVIORAL|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
219375993|NCT02883699|BEHAVIORAL|Standard resistance training|Machine based hypertrophy training 2 x per week
219375994|NCT02883699|BEHAVIORAL|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
219375995|NCT04957888|OTHER|none intervention|none intervention.
219375996|NCT04561505|PROCEDURE|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
219375997|NCT04561505|PROCEDURE|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
219375998|NCT05731960|DRUG|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
219375999|NCT05731960|DRUG|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
219376000|NCT04791384|DRUG|Abemaciclib|taken orally
219376001|NCT04791384|DRUG|Elacestrant|taken orally
219376002|NCT05383820|DRUG|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
219754340|NCT07160049|DEVICE|Cold Pressor Task - Upper Limb|"This study uses a three-session cold pressor paradigm to evaluate feasibility of a wearable focused ultrasound (FUS) device for peripheral nerve stimulation.~Session 1 (Baseline): After consent, participants immerse the dominant hand in 0-1 °C water (\~10 cm depth) in an insulated bucket. Time to first pain is recorded, with 5 min rests between immersions (12 total; max single immersion 6 min). Water temperature is digitally monitored, with ice added as needed.~Session 2 (Sham): The median/ulnar/radial nerve in the dominant forearm is located by ultrasound. The FUS device is applied with hydrogel but set to sham (no output). The cold pressor protocol is repeated.~Session 3 (Active FUS): After nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The cold pressor test is repeated to record pain tolerance as an exploratory physiological response during feasibility testing."
219000916|NCT05825846|DEVICE|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (\~2 min) involves the participant physically walking down a \~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
219376003|NCT00251602|DRUG|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
219376004|NCT00251602|DRUG|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
219376005|NCT00251602|DRUG|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
219376006|NCT02016014|DEVICE|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
219376007|NCT02016014|BEHAVIORAL|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
219376008|NCT00886938|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
219376009|NCT03492164|DRUG|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
219376010|NCT01689558|DRUG|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
219376011|NCT04407715|PROCEDURE|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
219376012|NCT00364793|DRUG|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
219376013|NCT05090241|DIAGNOSTIC_TEST|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
219376014|NCT00002025|DRUG|Ganciclovir|
219376015|NCT03423355|DRUG|Dapagliflozin (Forxiga®)|10mg p.o. daily
219376016|NCT03423355|DRUG|Hydrochlorothiazide 25 mg|25mg p.o. daily
219376017|NCT03423355|DRUG|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
219376018|NCT02397252|DEVICE|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
219376019|NCT02397252|DEVICE|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
219376020|NCT02397252|PROCEDURE|Physician-collected sampling|Routine colposcopy sample collected by a physician.
219376021|NCT05393154|DEVICE|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
219376022|NCT03037294|DIETARY_SUPPLEMENT|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
219376023|NCT00972608|OTHER|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
219376024|NCT05902585|BEHAVIORAL|Virtual reality|In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
219376025|NCT00310310|BEHAVIORAL|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
219376026|NCT00310310|BEHAVIORAL|Usual care|Usual sleep apnea and cpap care
219376027|NCT06076044|DEVICE|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
219000917|NCT02842918|PROCEDURE|Spinal Manual Therapy|
219376028|NCT06076044|DEVICE|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
219376029|NCT06076044|DEVICE|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
219376030|NCT06076044|DEVICE|sham|The subgroup treated by sham stimulation.
219376031|NCT04740957|OTHER|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
219376032|NCT05041738|PROCEDURE|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
219376033|NCT05041738|PROCEDURE|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
219376034|NCT03615092|PROCEDURE|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
219376035|NCT01065935|DRUG|ALN-RSV01|Administered by nebulization once daily for 5 days
219376036|NCT01065935|DRUG|Normal Saline|Administered by nebulization once daily for 5 days
219376037|NCT05527925|DEVICE|MRI|Brain testing of patients using MRI
219376038|NCT04732663|OTHER|No Intervention|Cross-sectional study, no intervention.
219376039|NCT04234438|DEVICE|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
219376040|NCT03456479|DIAGNOSTIC_TEST|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
219376041|NCT01179295|DRUG|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
219376042|NCT01179295|DRUG|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
219376043|NCT01179295|DRUG|BAY86-9766|BAY86-9766 100 mg once a day (od)
219376044|NCT01179295|DRUG|BAY86-9766|BAY86-9766 60 mg once a day (od)
219376045|NCT00363415|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
219376046|NCT00363415|DRUG|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
219376047|NCT00363415|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
219376048|NCT04802837|DRUG|Ridinilazole|Ridinilazole 200mg dosed BID for 10 days.
219376049|NCT04802837|DRUG|Vancomycin|Vancomycin 125mg dosed QID for 10 days.
219376050|NCT04945655|OTHER|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
219000918|NCT02842918|PROCEDURE|Spinal Range of Motion|
219376051|NCT04945655|OTHER|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
219557781|NCT02991352|DEVICE|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
219557782|NCT05202288|BIOLOGICAL|Ervebo|Administration of r-VSV-ZEBOV vaccine
219376052|NCT04945655|OTHER|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
219376053|NCT01722006|BEHAVIORAL|Pairing condition|
219376054|NCT01722006|BEHAVIORAL|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
219376055|NCT05449392|DRUG|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
219376056|NCT05449392|OTHER|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
219376057|NCT04475094|DRUG|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
219376058|NCT04475094|BEHAVIORAL|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
219376059|NCT04475094|BEHAVIORAL|Rose Dyspnea Scale|Consented subjects will complete a RDS.
219376060|NCT05022446|OTHER|Survey Administration|Complete survey
219376061|NCT01128985|DRUG|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
219376062|NCT01128985|DRUG|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
219376063|NCT01128985|DRUG|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
219376064|NCT01128985|DRUG|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
219376065|NCT06962878|PROCEDURE|Xenograft|The jumping gap and surrounding space will be augmented and packed with Xenograft
219376066|NCT06962878|PROCEDURE|Allograft|The jumping gap and surrounding space will be augmented and packed with Allograft
219376067|NCT06960954|DIAGNOSTIC_TEST|Prothrombin induced by vitamin K absence II (PIVKA-II)|Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
219376068|NCT03392233|RADIATION|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
219376069|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
219376070|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
219188405|NCT05855746|DRUG|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
219188406|NCT05832190|OTHER|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
219376071|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
219376072|NCT03457961|DRUG|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
219376073|NCT04442607|DEVICE|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
219376074|NCT06643455|BEHAVIORAL|Behavioral Dietary Intervention|Participate in the MIND program
219376075|NCT06643455|OTHER|Best Practice|Participate in SOC
219376076|NCT06643455|OTHER|Electronic Medical Record|Ancillary studies
219376077|NCT06643455|OTHER|Questionnaire Administration|Ancillary studies
219376078|NCT06577675|BEHAVIORAL|Group programme for DBT training|This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
219376079|NCT05027802|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
219376080|NCT06498895|RADIATION|lung ultrasound|"Lung ultrasound score will be done within one hour of admission,12 hours post admission then 24 hours in intensive care unit,follow up of patients will continue for 72 hours .~a complete lung ultrasound evaluation will be performed using low frequency curved probe (2MHz-5MHz) according to the lung ultrasound score . The external lung fields will be examined by longitudinal and transverse plane scans, dividing the surface of the thorax into 12 zones: 6 on the right (anterior: upper R1 and lower R2; lateral; upper R3 and lower R4; posterior: upper R5 and lower R6) and 6 on the left side (front: upper L1 and lower L2; lateral: upper L3 and lower L4; rear: upper L5 and lower L6). LUS assigns 0 points to A lines or \< 2 separate B lines plus regular sliding; 1 point with lines B ≥ 3 or spaced focal points plus regular sliding; 2 points with coalescing B lines, and 3 points to pulmonary consolidations for each zone with a score ranging from 0 (normal lungs) to 36 (worst case scenario)"
219376081|NCT04318366|OTHER|Observational Study|Not required
219376082|NCT03797560|OTHER|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
219376083|NCT03797560|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
219376084|NCT05898074|DEVICE|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
219376085|NCT05898074|DEVICE|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
219376086|NCT06059586|BEHAVIORAL|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
219376087|NCT06059586|DEVICE|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
219376088|NCT05932732|DEVICE|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
219376089|NCT05932732|DRUG|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
219376090|NCT05932732|DEVICE|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
219376091|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
219376092|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
219376093|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
219376094|NCT03452839|DRUG|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
219376095|NCT06093672|DRUG|Givinostat|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
219376096|NCT06093672|DRUG|Hydroxyurea|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
219376097|NCT05755386|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
219376098|NCT05755386|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
219376099|NCT05344833|DRUG|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
219376100|NCT05344833|DRUG|Lenalidomide|Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
219376101|NCT02884635|DRUG|ASP1707|Oral
219000919|NCT05439512|PROCEDURE|transantral orbital floor reconstruction by titanium mesh|reconstruction of orbital floor fracture by patient specific titanium mesh
219376102|NCT02884635|DRUG|Placebo|Oral
219376103|NCT02884635|DRUG|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
219376104|NCT03733041|DEVICE|rTMS|This group will receive rTMS treatment
219376105|NCT03733041|DEVICE|Sham|This group will receive sham treatment
219376106|NCT03733041|OTHER|No intervention|This group will receive no intervention
219376107|NCT05561751|DRUG|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
219376108|NCT05561751|DRUG|Propranolol|propranolol
219376109|NCT05561751|DRUG|G-CSF|G-CSF
219557783|NCT05202288|DRUG|Inmazeb|Administration of Inmazeb
219376110|NCT04677647|OTHER|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
219376111|NCT05910892|DRUG|Aromatherapy packet|5 deep breaths from packet prior to treatment
219376112|NCT05910892|DRUG|Placebo packet|5 deep breaths from packet prior to treatment
219376113|NCT05491200|DRUG|Prasugrel based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
219376114|NCT05491200|DRUG|Prasugrel based standard DAPT|Prasugrel based DAPT for 1 year
219376115|NCT05491200|DEVICE|OCT guided revascularization|OCT guided revascularization of the non-culprit lesions
219000920|NCT06799494|BIOLOGICAL|Gardasil-9|"The 9-valent HPV VLP vaccine is a sterile liquid suspension prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer. The 9-valent HPV vaccine, or Gardasil-9, is a sterile suspension for intramuscular administration. Each 0.5-mL dose of the vaccine also contains approximately 500 mcg of aluminum (provided as AAHS), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, \<7 mcg yeast protein, and water for injection. The product does not contain a preservative or antibiotics.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap. After thorough agitation, GARDASIL 9 is a white, cloudy liquid."
219188407|NCT05832190|DIETARY_SUPPLEMENT|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
219376116|NCT05491200|DEVICE|Angio guided revascularization|Angio guided revascularization of the non-culprit lesions
219376117|NCT05848622|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
219376118|NCT05848622|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
219376119|NCT06043817|DRUG|STX-721 (Escalated)|STX-721 dose will be escalated per cBLRM-design.
219376120|NCT06043817|DRUG|STX-721 (3 dose levels)|Participants will receive STX-721 at one of two dose levels.
219376121|NCT06043817|DRUG|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
219376122|NCT06035887|DIAGNOSTIC_TEST|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
219376123|NCT06035887|DIAGNOSTIC_TEST|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
219376124|NCT06035887|DIAGNOSTIC_TEST|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
219376125|NCT06035887|DIAGNOSTIC_TEST|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
219376126|NCT03279094|BIOLOGICAL|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
219376127|NCT05414071|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
219376128|NCT03896763|OTHER|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
219376129|NCT05085366|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
219376130|NCT05085366|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219376131|NCT06213883|OTHER|Biobehavioral Response to in-lab exposure to physical activity|ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
219376132|NCT05416060|BEHAVIORAL|Dulce Digital Text-Based Education|Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
219376133|NCT05416060|BEHAVIORAL|Project Dulce Telehealth|Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
219376134|NCT05416060|BEHAVIORAL|Project Dulce Live|Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
219376135|NCT05469984|DRUG|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
219376136|NCT05469984|DRUG|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
219376137|NCT06379347|DIAGNOSTIC_TEST|POCUS performed on clinical indication|POCUS performed on clinical indication
219376138|NCT05286047|DIETARY_SUPPLEMENT|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
219376139|NCT05286047|DIETARY_SUPPLEMENT|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
219376140|NCT06508892|BEHAVIORAL|risk of fall|Gather information that will assist in determining risk of fall. The researchers will ask the subjects to perform several motor tests and study-related questionnaires.
219376141|NCT02725788|DEVICE|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
219376142|NCT02725788|DEVICE|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
219376143|NCT05275101|BEHAVIORAL|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
219376144|NCT05275101|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
219376145|NCT05543681|DRUG|IGC-AD1-Active|A non-sterile solution for oral administration.
219376146|NCT05543681|DRUG|IGC-AD1-Placebo|A non-sterile solution for oral administration similar in color and texture to the Active.
219376147|NCT05590377|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion
219376148|NCT05590377|DRUG|Daratumumab|Daratumumab SC injection
219376149|NCT06334367|DRUG|CD25 treatment|CD25 prophylaxis
219376150|NCT06334367|DRUG|low-dose ATG|HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
219376151|NCT02292823|DEVICE|MGuard™ Prime Embolic Protection Stent System|
219376152|NCT00828464|DRUG|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
219376153|NCT04285060|DEVICE|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
219376154|NCT03007264|DEVICE|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
219376155|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
219376156|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
219376157|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
219376158|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
219376159|NCT00809133|DRUG|BIBW2992|MTD dose of part A
219376160|NCT00809133|DRUG|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
219376161|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
219376162|NCT00809133|DRUG|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
219376163|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
219376164|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
219376165|NCT03420534|DRUG|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
219376166|NCT03420534|DRUG|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
219376167|NCT03420534|DIETARY_SUPPLEMENT|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
219376168|NCT03420534|DIETARY_SUPPLEMENT|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
219376169|NCT01321047|DRUG|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)
219376170|NCT01321047|DRUG|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
219376171|NCT00833092|DIETARY_SUPPLEMENT|Sugar Pill|Sugar pill supplementation for 9 weeks
219376172|NCT00833092|DIETARY_SUPPLEMENT|magnesium|300 milligrams daily for 8 weeks
219376173|NCT04912167|DRUG|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
219376174|NCT04912167|DRUG|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
219376175|NCT04912167|DRUG|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
219376176|NCT06334679|OTHER|Cold Gel Packet Application|Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
219376177|NCT03510793|DRUG|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
219376178|NCT03510793|DRUG|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
219376179|NCT06165588|OTHER|Tour de France|Participating in the Tour de France as cyclist
219376180|NCT02357511|DEVICE|Study Monitor used|
219376181|NCT01103739|DRUG|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
219376182|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
219376183|NCT01103739|DRUG|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
219376184|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
219376185|NCT03714126|DEVICE|Cordio Medical|Recording to an app, no interference to the regular care
219376186|NCT00005104|DRUG|clomiphene citrate|
219376187|NCT00005104|DRUG|metformin|
219376188|NCT06438328|DIAGNOSTIC_TEST|Left/ Right affected arm|Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval
219376189|NCT06438328|OTHER|Grip strength|assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
219376190|NCT05662592|DEVICE|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
219376191|NCT05366829|DRUG|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
219376192|NCT00699192|DRUG|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
219376193|NCT00699192|DRUG|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
219376194|NCT00699192|DRUG|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
219376195|NCT00699192|DRUG|Placebo|1 capsule placebo to match valsartan orally once daily
219376196|NCT03409549|RADIATION|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
219760855|NCT01923766|DRUG|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
219376197|NCT02588378|PROCEDURE|multi-modal cSLO imaging|
219376198|NCT02490657|DRUG|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
219376199|NCT02490657|DRUG|normal saline (Saline 0.9%)|
219376200|NCT05900141|DRUG|Pelacarsen|Pelacarsen 80mg s.c. monthly
219376201|NCT03681717|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219376202|NCT03078062|DRUG|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
219376203|NCT03078062|DRUG|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
219376204|NCT05069779|DRUG|Diazepam|Oral administration of 10 mg of diazepam
219376205|NCT00422279|DEVICE|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
219376206|NCT01178021|DRUG|Chloroquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
219376207|NCT01178021|DRUG|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
219376208|NCT04017403|DRUG|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
219376209|NCT04017403|DRUG|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
219376210|NCT03431610|DRUG|SB414 2%|Twice daily
219376211|NCT03431610|DRUG|SB414 6%|Twice daily
219376212|NCT03431610|DRUG|Vehicle|Placebo comparator
219376213|NCT00605826|DEVICE|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
219376214|NCT00605826|DEVICE|Sham Injection|Sham injection at the start of the blinded phase.
219376215|NCT00099671|DRUG|Recombinant human interleukin-7|
219188408|NCT05832190|DIETARY_SUPPLEMENT|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
219376216|NCT05766592|BEHAVIORAL|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
219376217|NCT05766592|BEHAVIORAL|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
219376218|NCT04523662|DRUG|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
219376219|NCT03431012|OTHER|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
219376220|NCT03431012|OTHER|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
219376221|NCT04853940|OTHER|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
219376222|NCT04520477|DIAGNOSTIC_TEST|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
219376223|NCT04520477|DIAGNOSTIC_TEST|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
219376224|NCT04520477|DIETARY_SUPPLEMENT|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
219376225|NCT04520477|DIAGNOSTIC_TEST|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
219376226|NCT03018548|OTHER|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
219376227|NCT05595876|PROCEDURE|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
219376228|NCT05595876|PROCEDURE|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
219376229|NCT02815215|PROCEDURE|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
219376230|NCT02815215|PROCEDURE|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
219376231|NCT00562419|DRUG|CT-322|IV solution, weekly
219376232|NCT00562419|DRUG|irinotecan hydrochloride|IV solution, biweekly
219376233|NCT02589977|DRUG|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
219376234|NCT02024776|BEHAVIORAL|Prehabilitation|Tailored exercise training program
219376235|NCT01025635|DRUG|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
219376236|NCT01025635|DRUG|Vehicle foam|Applied topically twice daily for 12 weeks
219760856|NCT01436110|DRUG|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
219760857|NCT01436110|DRUG|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
219760858|NCT01436110|DRUG|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
219760859|NCT03912610|DIAGNOSTIC_TEST|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
219760860|NCT04321616|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
219760861|NCT04321616|DRUG|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
219760862|NCT04321616|OTHER|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
219760863|NCT00124930|DRUG|Olanzapine|
219760864|NCT00124930|DRUG|Haldol|
219760865|NCT00537472|DRUG|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
219760866|NCT00537472|DRUG|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
219376237|NCT06322082|DEVICE|The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)|"The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks"
219376238|NCT04621903|OTHER|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
219376239|NCT04239209|BEHAVIORAL|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
219000921|NCT06799494|DRUG|Lidocaine injection|Lidocaine 1% will be injected intradermally and subcutaneously into the margin of the lymph node to be sampled to numb the area. To confer local anesthesia, 1-2% will be injected into the tissue surrounding the area where the bone marrow will be removed.
219000922|NCT06799494|DRUG|Lorazepam|Lorazepam, an FDA-approved benzodiazepine, will be administered as an anxiolytic before the bone marrow aspirate procedure per the clinician who will perform the procedure. If needed, lorazepam will be administered sublingually per manufacturer dosing recommendations.
219376240|NCT04239209|BEHAVIORAL|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
219376241|NCT04239209|BEHAVIORAL|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
219376242|NCT04239209|BEHAVIORAL|Direct communication|Video of a direct response.
219376243|NCT01511731|DRUG|Famotidine|Famotidine Tablets 40 mg
219376244|NCT01511731|DRUG|Pepcid|40mg tablets
219376245|NCT05763602|DRUG|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
219376246|NCT03716479|OTHER|Low Fiber|20 g of acacia gum will be added to orange juice
219376247|NCT03716479|OTHER|High Fiber|40 g of acacia gum will be added to orange juice
219376248|NCT03716479|OTHER|Placebo/Control|No acacia gum will be added to orange juice.
219376249|NCT05887999|DRUG|LY3532226|Administered subcutaneously (SC).
219376250|NCT05887999|DRUG|Placebo|Administered SC.
219376251|NCT00929240|DRUG|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
219376252|NCT00929240|DRUG|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
219376253|NCT01270334|OTHER|PH meassurment|meassuring ph USING PROBE
219376254|NCT00002283|DRUG|Trimethoprim|
219376255|NCT00002283|DRUG|Sulfamethoxazole|
219376256|NCT00002283|DRUG|Dapsone|
219376257|NCT03500744|PROCEDURE|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
219376258|NCT03500744|PROCEDURE|Sham block|Skin infiltration only
219376259|NCT04210726|DRUG|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
219376260|NCT04210726|OTHER|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
219376261|NCT01892488|DRUG|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
219376262|NCT01892488|DRUG|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
219376263|NCT02617914|PROCEDURE|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
219376264|NCT02635230|DRUG|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
219557784|NCT05762887|OTHER|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
219376265|NCT04210479|PROCEDURE|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
219376266|NCT04210479|PROCEDURE|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
219557785|NCT05762887|OTHER|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
219376267|NCT00001189|PROCEDURE|radiotherapy|
219376268|NCT05292755|DRUG|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
219376269|NCT05292755|DRUG|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
219376270|NCT00005912|DRUG|Voriconazole|
219376271|NCT05078489|OTHER|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
219376272|NCT05078489|OTHER|Placebo|Participants will watch a natural landscape without any human.
219376273|NCT01026584|DRUG|Aripiprazole|6 week prospective study
219376274|NCT02155400|DEVICE|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
219376275|NCT02155400|DEVICE|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
219376276|NCT03171922|BEHAVIORAL|Internet Diet|ID group have online dietary coach every 2 weeks
219376277|NCT03171922|BEHAVIORAL|Clinic Diet|CD group have every 2 weeks visit at clinic
219376278|NCT02586480|DEVICE|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
219376279|NCT00175305|DRUG|Sandostatin LAR|
219376280|NCT06292897|OTHER|observational study|observational study
219376281|NCT05437887|DIETARY_SUPPLEMENT|Fucoidan|All patients consumed fucoidan.
219376282|NCT05490992|OTHER|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
219376283|NCT03804151|BEHAVIORAL|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
219376284|NCT05987215|COMBINATION_PRODUCT|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
219376285|NCT05987215|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
219376286|NCT01418755|BIOLOGICAL|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
219376287|NCT05199584|DRUG|ENV-101 (taladegib)|tablets dosed once-daily
219376288|NCT00432809|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
219760867|NCT03461939|OTHER|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
219760868|NCT01175343|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219760869|NCT01175343|OTHER|Laboratory Biomarker Analysis|Correlative studies
219376289|NCT00432809|PROCEDURE|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
219376290|NCT03142607|DRUG|Metronidazole gel|1% Metronidazole gel
219376291|NCT03142607|DRUG|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
219376292|NCT04810273|BEHAVIORAL|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
219376293|NCT04980131|DEVICE|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
219376294|NCT04980131|DEVICE|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
219376295|NCT05878509|OTHER|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
219376296|NCT05878509|OTHER|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
219376297|NCT04613011|DEVICE|Ultrasound|Checking vein width snd copression using US
219376298|NCT01073150|DRUG|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
219376299|NCT04433117|BIOLOGICAL|Shefabone|Silica-calcium phosphate composite.
219376300|NCT04433117|BIOLOGICAL|Bio-Oss|Xenograft Bone substitute. Bone from animals.
219376301|NCT05313438|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
219376302|NCT03360812|OTHER|Online training resource|Please see information included in the description of the intervention group.
219376303|NCT00535340|DRUG|SR58611A|
219376304|NCT03758586|OTHER|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
219376305|NCT03758586|OTHER|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
219376306|NCT04833036|DRUG|Irinotecan|180 mg/m2, ivgtt d1，q2w
219376307|NCT04833036|DRUG|cetuximab|500 mg/m2, ivgtt d1，q2w
219376308|NCT00558090|DRUG|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
219376309|NCT01051739|PROCEDURE|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
219376310|NCT00839631|DRUG|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
219376311|NCT04381000|OTHER|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
219376312|NCT00707577|BEHAVIORAL|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
219376313|NCT02293681|DRUG|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
219376314|NCT02293681|DRUG|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
219376315|NCT02293681|DRUG|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
219376316|NCT03853694|DRUG|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
219376317|NCT03853694|DRUG|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
219376318|NCT03853694|DRUG|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
219376319|NCT02499952|DRUG|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
219376320|NCT04938856|DRUG|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
219376321|NCT02934607|DRUG|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
219376322|NCT02934607|DRUG|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
219376323|NCT05089708|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
219760870|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
219000923|NCT03275051|OTHER|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
219000924|NCT00410046|DRUG|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
219000925|NCT05975021|DRUG|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.
219000926|NCT05975021|DRUG|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
219376324|NCT05089708|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
219376325|NCT01819792|OTHER|Multiplex respiratory viral PCR|
219376326|NCT04265391|DIETARY_SUPPLEMENT|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
219376327|NCT00227058|DRUG|Orotic acid and Glutathione-(Nutritional Supplements)|
219376328|NCT02038062|PROCEDURE|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
219376329|NCT03333577|DEVICE|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
219376330|NCT06137352|OTHER|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
219376331|NCT01768299|DRUG|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
219376332|NCT01768299|DRUG|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
219376333|NCT01443013|OTHER|Renal Transplant|urinary sample at month 3, 6 and 12
219376334|NCT00507247|DRUG|Daptomycin|6mg/kg/day IV for at least 10 days.
219376335|NCT02209766|DRUG|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
219376336|NCT02209766|DRUG|Placebo|"1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
219376337|NCT02832050|BEHAVIORAL|Play therapy|See previous description of play therapy intervention arm.
219376338|NCT02832050|BEHAVIORAL|Standard of care|See previous description of comparator arm.
219760871|NCT06169618|OTHER|normal group|this group will have normal subjects
219760872|NCT03940807|DRUG|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
219000927|NCT02486432|DRUG|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
219376339|NCT02421861|BEHAVIORAL|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
219376340|NCT02421861|OTHER|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
219376341|NCT03384043|BEHAVIORAL|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
219376342|NCT03384043|BEHAVIORAL|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
219376343|NCT02541630|BEHAVIORAL|Big Mind|mindfulness based intervention
219376344|NCT04381234|DEVICE|dialyzer|Asymmetric triacetate dialyzer
219376345|NCT04381234|COMBINATION_PRODUCT|hemodialysis with citrate-containing dialysate|acetate-free dialysate
219376346|NCT04381234|OTHER|predilution hemodiafiltration|predilution hemodiafiltration
219376347|NCT06007612|BEHAVIORAL|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
219376348|NCT05418712|DRUG|Placebo|Placebo matched to VX-150 for oral administration.
219376349|NCT05418712|DRUG|VX-150|Solution or Suspension for oral administration.
219376350|NCT01645163|BEHAVIORAL|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
219376351|NCT03376828|DEVICE|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
219376352|NCT03376828|DEVICE|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
219376353|NCT06001606|DRUG|Shingrix|Shingrix vaccination
219376354|NCT06001606|DRUG|Placebo|Placebo vaccination
219376355|NCT03978650|OTHER|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
219376356|NCT00805207|DRUG|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
219376357|NCT00805207|DRUG|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
219376358|NCT00805207|DRUG|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
219376359|NCT00805207|DEVICE|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
219376360|NCT00805207|DRUG|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
219376361|NCT00805207|OTHER|Control|No treatment with studies performed 31 to 72 days apart
219376362|NCT00064701|DRUG|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
219376363|NCT00064701|DRUG|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
219000928|NCT02035878|OTHER|Probiotics|probiotic intervention: 400mg of probiotic capsule
219000929|NCT02035878|DRUG|Placebo|placebo comparator
219376364|NCT00064701|DRUG|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
219376365|NCT00064701|DRUG|mycophenolate mofetil|Oral
219376366|NCT00002676|DRUG|carmustine|
219376367|NCT00002676|DRUG|cyclophosphamide|
219376368|NCT00002676|DRUG|cytarabine|
219760873|NCT03940807|DRUG|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
219376369|NCT00002676|DRUG|dexamethasone|
219376370|NCT00002676|DRUG|doxorubicin hydrochloride|
219376371|NCT00002676|DRUG|methotrexate|
219376372|NCT00002676|DRUG|vincristine sulfate|
219376373|NCT00002676|RADIATION|low-LET cobalt-60 gamma ray therapy|
219376374|NCT00002676|RADIATION|low-LET photon therapy|
219376375|NCT01405079|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
219376376|NCT01405079|DRUG|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
219376377|NCT02249052|DRUG|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
219376378|NCT02249052|DRUG|placebo|Placebo
219376379|NCT00588679|OTHER|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
219376380|NCT01432639|OTHER|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
219376381|NCT03135093|OTHER|No intervention|No Intervention
219376382|NCT04536194|DRUG|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
219376383|NCT04536194|DRUG|dopamine|to treat hypotension under general anesthesia with dopamine
219376384|NCT03540095|DRUG|Erector Spinae Plane Block|See arm description
219376385|NCT03540095|DRUG|Paravertebral Nerve Block|See arm description
219376386|NCT00482846|BIOLOGICAL|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
219376387|NCT00482846|DRUG|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
219376388|NCT00482846|OTHER|questionnaire administration|Day -5 to Day +28
219376389|NCT00482846|PROCEDURE|autologous peripheral blood stem cell transplantation|Day 0
219376390|NCT00482846|OTHER|quality-of-life assessment|Day -5 to Day +28
219376391|NCT00000899|DRUG|Nelfinavir mesylate|
219376392|NCT00000899|DRUG|Lamivudine|
219376393|NCT00000899|DRUG|Filgrastim|
219376394|NCT00000899|DRUG|Stavudine|
219376395|NCT00000899|DRUG|Cyclophosphamide|
219376396|NCT01491945|DEVICE|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
219376397|NCT05787704|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
219376398|NCT05460208|DIETARY_SUPPLEMENT|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
219376399|NCT05460208|DIETARY_SUPPLEMENT|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
219376400|NCT02603523|BEHAVIORAL|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
219376401|NCT02137668|DRUG|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
219376404|NCT04670653|DRUG|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
219376405|NCT04670653|DRUG|MOMETASONE FUROATE|Mometasone furoate nasal spray
219376406|NCT02575209|OTHER|GENDER|
219376407|NCT01524380|DRUG|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
219376408|NCT01524380|DRUG|Placebo|twice a day, 10 weeks
219376409|NCT05681715|DRUG|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
219376410|NCT01148173|DRUG|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
219376411|NCT03770403|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
219376412|NCT03633084|DRUG|RBM-007 Injectable Solution|(No additional description)
219376413|NCT00183742|DRUG|liposomal doxorubicin and docetaxel|
219376414|NCT04409704|DEVICE|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
219376415|NCT05678803|OTHER|xrays and CT|A dedicated sheet will be used to record patients' data including all demographic data, detailed analysis of the mechanism of injury, time of injury, time and details of surgery (if any), neurological status on admission and all radiological findings. All patients will undergo plain X-rays and CT imaging. Patients with suspected discoligamentous injuries and/or neurological deficits will also be assessed by MRI.
219376416|NCT03591900|DEVICE|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
219376417|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
219376418|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
219376419|NCT03696472|PROCEDURE|robotic assisted surgery|robotic assisted surgery was benefit to operation
219376420|NCT03696472|PROCEDURE|laparoscopic|conventional laparoscopic surgery
219376421|NCT03758560|OTHER|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
219376422|NCT02548702|BEHAVIORAL|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
219376423|NCT00582894|DRUG|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
219000930|NCT03421028|DEVICE|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
219376424|NCT03416231|DRUG|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
219376425|NCT03416231|DRUG|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
219376426|NCT03185546|OTHER|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
219376427|NCT03185546|OTHER|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
219000931|NCT03421028|OTHER|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
219000932|NCT01675271|OTHER|individual exercise|individual exercise and dietary prescription
219000933|NCT01675271|OTHER|general exercise|general exercise counselling
219376428|NCT03185546|OTHER|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
219376429|NCT03185546|OTHER|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
219376430|NCT03185546|OTHER|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
219376431|NCT03185546|OTHER|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
219376432|NCT02237690|DRUG|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
219376433|NCT00815958|PROCEDURE|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
219376434|NCT00815958|PROCEDURE|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
219376435|NCT00006187|DRUG|Investigational drug|
219376436|NCT03692416|DRUG|Ibuprofen|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
219376437|NCT03692416|DRUG|Prednisone|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
219376438|NCT03692416|DRUG|Methotrexate|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
219376439|NCT02840136|DRUG|Piperacillin-tazobactam combination product|
219376440|NCT02840136|DRUG|Meropenem|
219376441|NCT02840136|DRUG|Ceftazidime|
219376442|NCT00308724|BEHAVIORAL|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
219376443|NCT00308724|BEHAVIORAL|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
219376444|NCT05535179|DRUG|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
219376445|NCT01207466|DEVICE|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
219376446|NCT01207466|DEVICE|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
219376447|NCT02847884|BIOLOGICAL|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
219376448|NCT02707185|BEHAVIORAL|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
219376449|NCT02463461|DEVICE|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
219376450|NCT02463461|DEVICE|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
219376451|NCT02463461|DEVICE|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
219376452|NCT02463461|DEVICE|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
219376453|NCT02463461|DEVICE|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
219376454|NCT04573101|OTHER|Music listening / EEG recording|Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
219376455|NCT01422954|DRUG|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
219376456|NCT01422954|DRUG|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
219376457|NCT01422954|BIOLOGICAL|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
219376458|NCT01422954|BIOLOGICAL|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
219376459|NCT01422954|DRUG|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
219376460|NCT00588367|DEVICE|Mayo Interactive Breath Hold Monitor|Biofeedback device
219376461|NCT01554657|OTHER|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
219376462|NCT01554657|OTHER|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
219376463|NCT01938287|DEVICE|SENSIMED Triggerfish|
219000934|NCT01776333|BEHAVIORAL|video decision aid|
219000935|NCT01717807|OTHER|C11-Erlotinib PET/CT|
219376464|NCT04613986|DEVICE|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
219376465|NCT02964598|BEHAVIORAL|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
219376466|NCT02964598|BEHAVIORAL|Sleep coaching|A new personalized program, duration 4-6 weeks
219376467|NCT02964598|DEVICE|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
219376468|NCT02964598|OTHER|Control|Minimal information on sleep timing and advancing the sleep rhythm
219376469|NCT02964598|OTHER|Psychoeducation|An extensive information platform in the internet created for this purpose
219376470|NCT01166048|DRUG|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
219376471|NCT01166048|DRUG|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
219376472|NCT05159414|DEVICE|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
219376473|NCT01852084|DEVICE|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
219376474|NCT01852084|DEVICE|enVista control lens|Spherical Control lens
219376475|NCT00842933|DRUG|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
219376476|NCT00842933|DRUG|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
219376477|NCT01339442|DRUG|BKM120|
219376478|NCT01339442|DRUG|Fulvestrant|
219376479|NCT01339442|PROCEDURE|biopsy|Correlative studies
219376480|NCT04371796|DRUG|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
219376481|NCT01205009|DRUG|Ovitrelle|One dose of Ovitrelle 250 mcg
219376482|NCT01578902|RADIATION|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
219376483|NCT01364805|DRUG|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
219376484|NCT01364805|DRUG|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
219376485|NCT04178655|DRUG|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
219376486|NCT04178655|DRUG|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
219376487|NCT06154902|DRUG|Idecabtagene vicleucel|According to approved product label in France
219376488|NCT06154902|OTHER|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
219376489|NCT03544580|PROCEDURE|immediate implant with dentine chips|Using dentin chips
219376490|NCT03544580|PROCEDURE|conventional immediate implant|using xenograft
219376491|NCT01575613|DRUG|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
219376492|NCT01575613|BIOLOGICAL|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
219376493|NCT01575613|BIOLOGICAL|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
219376494|NCT01575613|BIOLOGICAL|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
219376495|NCT03322358|OTHER|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
219376496|NCT03322358|DEVICE|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
219376497|NCT03322358|OTHER|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
219376498|NCT04214652|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
219376499|NCT04214652|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
219376500|NCT03666351|DRUG|Amlodipine 5mg|Amlodipine 5 mg
219376501|NCT03666351|DRUG|Losartan|Losartan Potassium 50 mg
219376502|NCT03666351|DRUG|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
219376503|NCT03666351|DRUG|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
219376504|NCT03666351|DRUG|current treatment|treatment is done by maintaining the current treatment
219557786|NCT00867854|OTHER|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
219557787|NCT01669824|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
219557788|NCT00834158|PROCEDURE|TACE|1 time
219557789|NCT00834158|PROCEDURE|PVE|1 time
219557790|NCT01774630|DRUG|Nilotinib|300 mg/twice a day
219557791|NCT02343965|OTHER|Touch-massage|
219557792|NCT00096239|DRUG|CP-547,632|
219376505|NCT03189979|BEHAVIORAL|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
219376506|NCT01649336|DRUG|MEK162, MEK inhibitor; oral|multiple dose, escalating
219376507|NCT01649336|DRUG|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
219376508|NCT06129630|PROCEDURE|Conventional occupational therapy sessions.|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
219376509|NCT06129630|PROCEDURE|Conventional occupational therapy sessions + Nintendo Switch|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
219376510|NCT04376450|PROCEDURE|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
219376511|NCT04376450|PROCEDURE|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
219376512|NCT01219556|DRUG|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
219376513|NCT00738816|OTHER|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
219376514|NCT01992822|OTHER|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
219376515|NCT01237860|DEVICE|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
219376516|NCT00265655|DRUG|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
219376517|NCT02658461|DRUG|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
219376518|NCT05124626|PROCEDURE|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
219376519|NCT05124626|PROCEDURE|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
219376520|NCT05159193|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
219376521|NCT05159193|DRUG|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
219376522|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
219376523|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
219376524|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
219376525|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
219376526|NCT05159193|DRUG|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
219376527|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
219376528|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
219376529|NCT03622281|OTHER|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
219376530|NCT02344576|BEHAVIORAL|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
219376531|NCT03773952|DRUG|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
219376532|NCT03773952|DRUG|Placebo oral capsule|Oral capsules
219376533|NCT00468897|DRUG|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
219376534|NCT04760184|OTHER|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
219376535|NCT05059990|OTHER|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
219376536|NCT05059990|OTHER|Active Exercises Group|Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
219376537|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
219376538|NCT02319369|DRUG|AZA|AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
219376539|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
219376540|NCT02323022|DRUG|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
219376541|NCT02323022|DRUG|IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
219376542|NCT01503216|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
219376543|NCT01503216|DIETARY_SUPPLEMENT|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
219376544|NCT01503216|DIETARY_SUPPLEMENT|Placebo|Placebo
219376545|NCT00705237|PROCEDURE|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
219376546|NCT03817918|PROCEDURE|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
219376547|NCT04839861|BEHAVIORAL|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
219376548|NCT04839861|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
219376549|NCT03326934|DIETARY_SUPPLEMENT|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
219376550|NCT03326934|DIETARY_SUPPLEMENT|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
219376551|NCT04325503|DRUG|carbidopa|carbidopa and carbidopa-levodopa standard treatment
219376552|NCT00340470|BEHAVIORAL|Driver Education|
219376553|NCT04297943|DEVICE|Orthosis fabrication|see summary
219376554|NCT04297943|DEVICE|Thermal Sensor Monitoring of Orthosis Use|see summary
219376555|NCT04297943|DIAGNOSTIC_TEST|4D CT Scan|see summary
219376556|NCT05607134|OTHER|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
219376557|NCT05607134|DEVICE|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
219376558|NCT05607134|DEVICE|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
219376559|NCT01856114|DRUG|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
219376560|NCT01856114|OTHER|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
219376561|NCT01856114|BEHAVIORAL|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
219376562|NCT01992029|OTHER|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
219557793|NCT01688882|DRUG|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
219376563|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy at M0
219376564|NCT01992029|PROCEDURE|Lumbar puncture|Lumbar puncture at M0 and M12
219376565|NCT01992029|PROCEDURE|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
219376566|NCT01992029|OTHER|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
219376567|NCT01992029|PROCEDURE|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
219376568|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy for patient explored for myopathy
219376569|NCT01992029|PROCEDURE|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
219376570|NCT01992029|DEVICE|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
219376571|NCT01337401|DRUG|Cediranib|30mg once daily, oral until disease progression
219376572|NCT01337401|DRUG|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
219376573|NCT06152887|DEVICE|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
219376574|NCT06152887|DEVICE|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
219376575|NCT00981526|DRUG|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
219376576|NCT00981526|DRUG|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
219376577|NCT00981526|DRUG|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
219376578|NCT00981526|DRUG|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
219376579|NCT00887952|PROCEDURE|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
219376580|NCT00887952|PROCEDURE|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
219376581|NCT01564784|DRUG|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
219376582|NCT01564784|DRUG|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
219376583|NCT01564784|DRUG|HIDAC (high dose cytarabine)|cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
219376584|NCT01564784|DRUG|cytarabine and mitoxantrone|mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
219376585|NCT00324103|DRUG|Structured Treatment Interruptions|
219376586|NCT01869335|DEVICE|radiography|
219376587|NCT01869335|DEVICE|MRI (magnetic resonance imaging)|
219376588|NCT03512236|DRUG|BC Pram Ins|Injection of BC Pram Ins
219376589|NCT03512236|DRUG|Symlin® and Humulin®|Injection of pramlintide and human insulin
219376590|NCT03512236|DRUG|Humalog®|Injection of lispro
219376591|NCT03512236|DRUG|Placebo|Injection of 0.9% NaCl
219376592|NCT00831376|DRUG|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
219376593|NCT00831376|DRUG|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
219376594|NCT00831376|DRUG|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
219376595|NCT04074486|DEVICE|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
219376596|NCT04074486|DIAGNOSTIC_TEST|SCAT5|Sports Concussion Assessment Tool 5
219376597|NCT04074486|DIAGNOSTIC_TEST|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
219376598|NCT02347293|OTHER|High levels of indigestible carbohydrates|
219376599|NCT02347293|OTHER|Low levels of indigestible carbohydrates|
219376600|NCT00730093|DIETARY_SUPPLEMENT|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
219376601|NCT01929070|DRUG|HCP1007|
219376602|NCT01929070|DRUG|Omarco and Crestor|
219376603|NCT00679887|PROCEDURE|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
219376604|NCT04126837|OTHER|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
219376605|NCT05546489|BEHAVIORAL|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
219557794|NCT01688882|DRUG|Placebo|Placebo will be used to control for normal variability in disease severity.
219557795|NCT06616727|DRUG|SNC109|SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
219557796|NCT03858127|OTHER|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
219376606|NCT04825054|DEVICE|Mechanical ventilation with NAVA mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
219376607|NCT04825054|DEVICE|Mechanical ventilation with PCV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
219557797|NCT03858127|OTHER|Examination of genitalia|Examination of genitalia
219557798|NCT03858127|OTHER|Video messaging|Short video of infant recorded at home by the parents
219376608|NCT04825054|DEVICE|Mechanical ventilation with PSV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
219376609|NCT01254903|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
219376610|NCT03911414|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
219376611|NCT03911414|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
219376612|NCT03114033|OTHER|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg
219376613|NCT03114033|OTHER|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
219376614|NCT05239689|BIOLOGICAL|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
219376615|NCT00004987|DRUG|Dextrin 2-sulfate|
219376616|NCT04143633|OTHER|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
219376617|NCT04143633|OTHER|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
219376618|NCT02139150|RADIATION|[18F] FLT|
219376619|NCT02139150|DEVICE|PET/CT scans|
219376620|NCT03280251|DRUG|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
219376621|NCT03280251|DRUG|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
219376622|NCT03280251|OTHER|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
219376623|NCT03280251|OTHER|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
219376624|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
219376625|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
219376626|NCT05308212|BIOLOGICAL|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
219376627|NCT04894955|DEVICE|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
219376628|NCT06299943|OTHER|Biofeedback gait training by biomechanical target parameter|The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
219376629|NCT06213636|BIOLOGICAL|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
219376630|NCT00000191|DRUG|Carbamazepine|
219557799|NCT01676129|PROCEDURE|Nocipoint Therapy|
219557800|NCT01676129|PROCEDURE|Physical Therapy|
219557801|NCT05038891|DIAGNOSTIC_TEST|Digital Cervical Exam|Standard Digital Cervical Exam by an experienced OB provider
219557802|NCT05038891|DIAGNOSTIC_TEST|Transperineal Ultrasound|Self-administered transperineal ultrasound after instruction by a health care professional
219557803|NCT05038891|DIAGNOSTIC_TEST|Transvaginal Ultrasound|Self-administered transvaginal ultrasound after instruction by a health care professional
219557804|NCT02546050|DRUG|Metformin|
219557805|NCT01071031|BIOLOGICAL|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
219376631|NCT01908348|DIETARY_SUPPLEMENT|Erythritol|
219376632|NCT02370121|DRUG|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
219376633|NCT02370121|DRUG|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
219376634|NCT06089044|DRUG|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
219376635|NCT03971721|DEVICE|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
219376636|NCT03286673|DIETARY_SUPPLEMENT|calcium phosphate|
219376637|NCT03286673|DIETARY_SUPPLEMENT|Tricalcium Phosphate|
219376638|NCT03286673|DIETARY_SUPPLEMENT|Calcium carbonate|
219376639|NCT03286673|DIETARY_SUPPLEMENT|Placebo|
219376640|NCT01848275|DEVICE|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
219376641|NCT01848275|DEVICE|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
219376642|NCT04429022|DRUG|Gabapentin|600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
219376643|NCT04429022|DRUG|Acetaminophen|Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
219376644|NCT04429022|DRUG|Celecoxib|Celecoxib 200mg PO q 12h x 7d post op
219376645|NCT04429022|DRUG|Ketorolac|30mg IV once at end of hysterectomy procedure
219376646|NCT04429022|PROCEDURE|Paracervical block with ropivacaine|0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
219376647|NCT04429022|PROCEDURE|Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites|0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
219376648|NCT04429022|DRUG|Hydromorphone|1mg IV PRN q3h, post op, while inpatient
219376649|NCT04429022|DRUG|Oxycodone|To be discharged home with: 12 tabs of 5mg PRN q4h
219376650|NCT01984021|DEVICE|Acupuncture|
219376651|NCT01984021|DEVICE|Sham acupuncture|
219376652|NCT02590393|COMBINATION_PRODUCT|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
219376653|NCT01540643|DEVICE|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
219376654|NCT01769105|DEVICE|Lipiflow|Patients receive a single Lipiflow-treatment
219376655|NCT01769105|BEHAVIORAL|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
219376656|NCT01495143|PROCEDURE|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
219376657|NCT01374061|DEVICE|Classical intubation|Classical intubation
219376658|NCT01374061|DEVICE|GLIDESCOPE|GLIDESCOPE intubation
219376659|NCT00963807|DRUG|Cisplatin|Given IV
219376660|NCT00963807|PROCEDURE|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
219376661|NCT00963807|DRUG|Docetaxel|Given IV
219376662|NCT00963807|DRUG|FDG|Undergo FDG PET/CT
219376663|NCT00963807|DRUG|FLT|Undergo FLT PET/CT
219376664|NCT00963807|PROCEDURE|PET/CT|Undergo FDG PET/CT and FLT PET/CT
219376665|NCT00963807|PROCEDURE|Surgery|Undergo surgery
219376666|NCT04087226|DEVICE|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
219376667|NCT03121391|PROCEDURE|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
219376668|NCT01417754|DRUG|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
219376669|NCT05198713|DEVICE|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
219376670|NCT06606028|PROCEDURE|Blood Specimen Collection|Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
219376671|NCT06606028|PROCEDURE|Tumor Tissue Collection|Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
219376672|NCT06606028|OTHER|Medical Record Review|Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
219376673|NCT00844233|DEVICE|Irinotecan Bead|Irinotecan eluting bead
219376674|NCT06856187|DRUG|TAS-102+bevacizumab+local treatment|patients achieve disease control after second-line induction therapy with standard therapy(FOLFOX/FOLFIRI/XELOX/ mXELIRI＋bevacizumab/cetuximab), then achieve TAS-102+bevacizumab+local treatment
219376675|NCT06856187|DRUG|Standard chemotherapy|Standard therapy：FOLFOX/FOLFIRI/XELOX/ mXELIRI±bevacizumab/cetuximab
219376676|NCT06858488|PROCEDURE|Extremity Surgery|Patients 18 years of age or older with high energy closed extremity fractures. Provision of informed consent.
219376677|NCT06682299|DEVICE|Transmagnetic Stimulation|TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).
219376678|NCT06682299|DEVICE|Electroconvulsive Therapy|Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression
219376679|NCT06723171|DRUG|IRX4204|Active Treatment
219376680|NCT06723171|OTHER|Placebo|Placebo
219376681|NCT03709992|DRUG|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
219376682|NCT03709992|DRUG|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
219376683|NCT06773780|DRUG|local infiltration|The block procedure will be performed before the surgical procedure, following the induction of sedoanalgesia. Under sterile conditions, 30 mL of 0.25% bupivacaine will be administered to the targeted infiltration area. The local anesthetic will be specifically applied around the arterial and venous puncture sites.
219376684|NCT06773780|DRUG|PENG|With the patient in the supine position, a convex ultrasound (US) probe (4-8 MHz, Vivid Q) will be covered with a sterile sheath. An 80-mm block needle (Braun 360°) will be used. The probe will be placed transversely over the anterior inferior iliac spine. Subsequently, the probe will be rotated 45 degrees to visualize the pubic ramus. Once the femoral artery, iliopubic eminence, and psoas muscle are identified under ultrasound guidance, the needle will be advanced using an in-plane technique and positioned between the pubic ramus and the psoas tendon. After confirming the block site with 5 mL of saline, 30 mL of 0.25% bupivacaine will be injected as the local anesthetic.
219376685|NCT06773780|DRUG|FİB|The patient's legs will be positioned slightly externally rotated. A high-frequency ultrasound probe will be placed transversely along the inguinal ligament. Under ultrasound guidance, the femoral artery, iliopsoas muscle, and fascia iliaca will be identified. The needle will be advanced parallel to the ultrasound probe using the in-plane technique and positioned beneath the fascia iliaca. After confirming negative aspiration, 30 mL of 0.25% bupivacaine will be injected, and the spread of the solution beneath the fascia iliaca will be verified using ultrasound.
219376686|NCT06420765|DRUG|VX-150|Suspension for oral administration.
219376687|NCT06420765|DRUG|VX-548|Solution or suspension for oral administration.
219376688|NCT06420765|DRUG|VX-993|Suspension for oral administration.
219376689|NCT06420765|DRUG|Placebo|Suspension for oral administration.
219376690|NCT07108088|DEVICE|NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
219376691|NCT07108088|DEVICE|Carbon orthosis (control)|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
219376692|NCT05968209|DIETARY_SUPPLEMENT|Lab4P|Multi-strain Probiotic Product: Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20, Bifidobacterium animalis subsp lactis CUL-34 (total 50 billion bacteria), Vitamin D (400 IU), Vitamin C (80 mg) \& Zinc (10 mg)
219376693|NCT06918327|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets.
219376694|NCT06918327|OTHER|non-CGF|The other extraction socket is left empty for control purposes.
219376695|NCT06932575|DEVICE|Andullation Therapy Bed|andullation therapy applied for 30 minutes after oocyte retrieval
219376696|NCT03311971|DEVICE|Virtual reality glasses|Patients will be treated with virtual glasses
219376697|NCT03311971|DEVICE|No VR glasses|Patients will not use VR glasses
219376698|NCT06930937|OTHER|Lixiana® Film Coated Tablet|Lixiana® 60 mg filmtabletten (Film Coated Tablet) (Edoxaban)
219376699|NCT06930937|OTHER|Edoxaban Film Coated Tablet|Edoxaban 60 mg Film Coated Tablet
219376700|NCT06936826|OTHER|Delphi Consensus Process|Round 1: Evaluation of current Medical Screening Tools and Scoping Review Results Round 2: Rating previous Statements from Round 1 Round 3: Consensus Round 4: Testing Content and Construct Validity of the new Medical Screening Tool with Clinical Vignettes
219376701|NCT06935721|DRUG|Y-4 tablet|Subjects will be admitted to research center in the afternoon of Day-1 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 1), subjects will be administered with one tablet of Y-4 , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 4.
219376702|NCT06935721|DRUG|Pregabalin capsule|Subjects will be admitted to research center in the afternoon of Day 7 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 8), subjects will be administered with one pregabalin capsule , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 11.
219376703|NCT06935721|DRUG|Riluzole tablet|Subjects will be admitted to research center in the afternoon of Day 14 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 15), subjects will be administered with one riluzole tablet, then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 18 after safety evaluation.
219376704|NCT06936345|BEHAVIORAL|Cawthorne-Cooksey Exercises|A set of vestibular rehabilitation exercises aimed at improving balance and reducing dizziness through repeated head and body movements, delivered via home-based digital instructions.
219376705|NCT06936345|BEHAVIORAL|Brandt-Daroff Exercises|A traditional home-based vestibular exercise program for treating positional dizziness, involving repetitive lateral head movements performed daily.
219376706|NCT06936345|OTHER|Theta Binaural Beats|A digital auditory stimulation using two tones of slightly different frequencies to create a theta-frequency beat, intended to modulate anxiety and enhance vestibular rehabilitation effects.
219557806|NCT01071031|BIOLOGICAL|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
219557807|NCT01071031|BIOLOGICAL|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
219557808|NCT01879631|PROCEDURE|radial keratotomy|
219376707|NCT06936293|BEHAVIORAL|Mindfulness Meditation|"The experimental group received 30 minutes of mindfulness meditation according to Smith's (2005) protocol, which is a standardized theory-based intervention. Smith's (2005) protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email to be accessed by their cell phones and headsets. The audio-recorded intervention contents were validated by two psychologists and experts in meditation."
219376708|NCT06935942|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
219376709|NCT06935240|DEVICE|Treatment|Nöromusculer and Transcutaneus Electrical Neuron stimulations
219376710|NCT06936956|OTHER|Acupressure|Acupressure is a noninvasive type of acupuncture. It is applied using fingers, joints or a suitable acupressure tool.
219376711|NCT06936995|DRUG|Preemptive Multimodal Intravenous Analgesia|Combination of opioids, NSAIDs, and adjunctive medications to manage postoperative pain before and during surgery.
219376712|NCT06936995|PROCEDURE|Femoral Triangle Block|Local anesthetic injection around the femoral nerve to manage postoperative pain via regional anesthesia.
219376713|NCT06946160|DRUG|Abobotulinumtoxin A (Espad Pharmed Darou Co.)|Vial of Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection
219376714|NCT06946160|DRUG|Abobotulinumtoxin A (Ipsen Co.)|Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection
219376715|NCT06951893|OTHER|Hospital Anxiety and Depression Scale|It is a self-assessment questionnaire to identify the existence of anxious and depressive symptoms and to assess their severity.
219376716|NCT06951893|OTHER|Dutch Eating Behaviour Questionnary|"It allows the assessment of 3 distinct factors of eating behavior: cognitive restriction, emotional eating and externality. This tool was developed to better characterize the eating habits of obese subjects.~10min"
219376717|NCT06951893|OTHER|Impact of Weight on Quality Of Life|The EQVOD is a validated French scale created from the Impact of Weight on Quality of Life (IWQOL) questionnaire. This self-administered questionnaire is specific to the sociocultural factors of obesity and its dietary treatment in France. The questionnaire is composed of five dimensions: physical impact (11 items), psychosocial impact (11 items), impact on sexual life (4 items), dietary well-being (5 items), and experience of diet/dietetics (5 items). The total number of items is 36.
219376718|NCT06951893|OTHER|body schema|Tactile assessment of the body schema using a motorized caliper applied to different parts of the individual's body. The caliper is connected to a touch pad on which the person can report the difference felt between the two pressure points on their skin, using their thumb and index finger.
219376719|NCT06951893|OTHER|body mass index|patient weighing at each visit
219376720|NCT06951893|OTHER|waist size|waist size measure
219376721|NCT04355988|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
219376722|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
219376723|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
219376724|NCT02759822|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
219376725|NCT01024244|DRUG|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
219376726|NCT01024244|DRUG|LY2599506|Administered po for 12 weeks
219376727|NCT02981212|DRUG|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
219376728|NCT02981212|DRUG|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
219376729|NCT02981212|DRUG|Corticosteroid|combination with Mycophenolate Mofetil
219376730|NCT02981212|DRUG|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
219376731|NCT03120910|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
219376732|NCT00539344|DRUG|ANG1005|IV infusion once every 21 days
219376733|NCT01753492|DEVICE|Ologen|
219760874|NCT03940807|DRUG|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
219376734|NCT00608465|DRUG|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
219376735|NCT00608465|DRUG|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
219376736|NCT01912885|DEVICE|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
219376737|NCT01912885|DEVICE|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
219376738|NCT01912885|DEVICE|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
219376739|NCT01912885|DEVICE|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
219376740|NCT01912885|DEVICE|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
219376741|NCT02393092|BEHAVIORAL|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
219376742|NCT02393092|BEHAVIORAL|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
219376743|NCT02393092|BEHAVIORAL|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
219376744|NCT02477098|DRUG|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
219376745|NCT02477098|DRUG|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
219376746|NCT02395315|DEVICE|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
219376747|NCT02395315|DEVICE|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
219376748|NCT00928980|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
219376749|NCT00928980|DRUG|Optimal Medical Care|Therapeutic dose of antidepressant medication
219376750|NCT01987544|OTHER|Ergometer Training|
219376751|NCT01987544|OTHER|Motivation|
219376752|NCT05692349|DEVICE|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
219376753|NCT04215094|DIAGNOSTIC_TEST|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
219376754|NCT02511522|OTHER|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
219376755|NCT02511522|RADIATION|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
219376756|NCT00267254|DRUG|torcetrapib/atorvastatin|
219376757|NCT00267254|DRUG|simvastatin|
219376758|NCT06111326|DRUG|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
219376759|NCT06111326|DRUG|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
219376760|NCT01596205|BEHAVIORAL|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
219000936|NCT01372137|DRUG|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
219376761|NCT01596205|BEHAVIORAL|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
219376762|NCT05992779|OTHER|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
219376763|NCT05992779|OTHER|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
219376764|NCT00036218|DRUG|sumanirole|
219376765|NCT00036218|DRUG|ropinirole|
219376766|NCT06098885|OTHER|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
219376767|NCT02660580|DRUG|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
219376768|NCT02660580|DRUG|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
219376769|NCT05794165|DRUG|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
219376770|NCT05794165|DRUG|Placebo|Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
219376771|NCT05723185|OTHER|Outpatient visit|Patients will be seen and treated at the outpatient clinic like in the usual care
219376772|NCT05823558|DIAGNOSTIC_TEST|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
219376773|NCT04632199|DRUG|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
219376774|NCT04632199|DRUG|111In-IPN01087 High dose|Administered once via slow intravenous injection.
219376775|NCT05324072|OTHER|no intervention|observational study
219376776|NCT00377962|DRUG|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
219376777|NCT00377962|DRUG|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
219376778|NCT00377962|DRUG|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
219376779|NCT00377962|DRUG|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
219376780|NCT00186602|BEHAVIORAL|Peer counseling|
219376781|NCT05751408|PROCEDURE|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
219376782|NCT06118879|DEVICE|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
219376783|NCT05034679|BIOLOGICAL|Vcinated|Patients who were vacinated.
219376784|NCT04677842|DRUG|ART Therapy|
219376785|NCT05671900|DRUG|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
219376786|NCT02856737|OTHER|eye masks and earplugs|Materials similar to those offered on long commercial flights
219557809|NCT05997940|DRUG|PENG block|The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
219557810|NCT03710044|DRUG|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
219557811|NCT00267358|DRUG|RC-1291 HCl|
219188409|NCT06552728|OTHER|Energy Healing|EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
219188410|NCT05916417|DEVICE|TMS-fNIRS over the dl-PFC|Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.
219376787|NCT04511299|OTHER|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
219376788|NCT04511299|OTHER|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
219376789|NCT02202603|DRUG|Teriparatide|single oral tablet
219376790|NCT02202603|DRUG|Teriparatide|subcutaneous standard injection
219376791|NCT02202603|DRUG|placebo|Oral placebo
219376792|NCT02786641|DRUG|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
219376793|NCT02786641|DRUG|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
219376794|NCT02786641|DRUG|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
219376795|NCT02786641|RADIATION|IMRT|IMRT for all patients
219376796|NCT02786641|DRUG|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
219376797|NCT04972383|COMBINATION_PRODUCT|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
219376798|NCT04972383|COMBINATION_PRODUCT|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
219376799|NCT02997124|PROCEDURE|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
219376800|NCT02997124|PROCEDURE|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
219376801|NCT02042066|DEVICE|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
219376802|NCT03206658|DRUG|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
219376803|NCT03206658|DRUG|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
219376804|NCT00367809|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
219376805|NCT00367809|BEHAVIORAL|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
219376806|NCT00367809|BEHAVIORAL|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
219376807|NCT02691273|BEHAVIORAL|cellular application treating diabetes using breathing technique|
219376808|NCT05442385|OTHER|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
219376809|NCT03951987|DRUG|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
219376810|NCT03951987|DRUG|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
219376811|NCT00919659|DIETARY_SUPPLEMENT|parenteral nutrition|25kcal/kg bw with parenteral nutrition
219376812|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
219376813|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
219376814|NCT02357992|RADIATION|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
219376815|NCT05144165|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
219376816|NCT01284192|DRUG|ASP3026|Tablet
219376817|NCT01671904|DRUG|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
219376818|NCT01671904|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
219376819|NCT01671904|DRUG|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
219376820|NCT01671904|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
219376821|NCT02863263|DEVICE|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
219376822|NCT02863263|DEVICE|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
219376823|NCT03026803|DRUG|Oxaliplatin|Given IV
219376824|NCT03026803|DRUG|Capecitabine|Given PO
219376825|NCT02139189|DEVICE|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
219376826|NCT00998101|DRUG|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
219376827|NCT00998101|DRUG|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
219376828|NCT00998101|DRUG|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
219376829|NCT01586728|OTHER|Air - oxygen|"1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
219000937|NCT01372137|OTHER|Glucose 5%|Placebo
219000938|NCT01007084|DRUG|Propranolol|40 mg
219376830|NCT01586728|OTHER|Oxygen - Air|"1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
219376831|NCT04079777|DRUG|Clinical treatment|Liquid Resuscitation, Anti-infection
219376832|NCT06265545|DRUG|Ivosidenib,Venetoclax,gilteritinib,Selinexor|if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
219376833|NCT05394298|DRUG|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
219376834|NCT05394298|DRUG|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
219376835|NCT06434168|BEHAVIORAL|Yoga intervention|Patients in the yoga group will receive a 60-minute session, twice per week over 12 weeks for a total of 24 sessions. Each yoga session consists of a warm-up, yoga postures standing or seated depending on the capability of the patient, and relaxation.
219376836|NCT06434168|BEHAVIORAL|Control condition|Patients in the control group will receive care-as-usual from their healthcare providers and will be asked to avoid engaging in yoga during their 3 months in the study.
219376837|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
219376838|NCT06387615|OTHER|Active cTBS|Active stimulation
219000939|NCT01007084|DRUG|Propranolol ER|120 mg twice per day
219000940|NCT01007084|DRUG|Sugar pills|sugar pill
219376839|NCT06387615|OTHER|Sham|Control stimulation
219376840|NCT01381094|DRUG|AKB-6548|oral dose administered once daily for 42 days
219376841|NCT01381094|DRUG|Placebo|oral Placebo administered once daily for 42 days
219376842|NCT03530449|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
219376843|NCT03530449|DEVICE|Color Fundus Photography|Non-contact white light photography
219557812|NCT00267358|DRUG|Placebo|
219557813|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
219376844|NCT03530449|DEVICE|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
219376845|NCT00221676|BIOLOGICAL|Alfarix|
219376846|NCT06276569|DRUG|Sivelestat|(1)Experimental group: Received intravenous sivelestat sodium admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.
219376847|NCT06276569|OTHER|placebo|2)Control group: Receiving the same dose of placebo, 50 ml of saline, were administered intravenously at a rate of 0.2 mg/kg throughout the treatment period without any discernible impact on patient's regular treatment regimen.
219376848|NCT05075642|OTHER|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
219376849|NCT01490593|BEHAVIORAL|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
219376850|NCT02665689|DRUG|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
219376851|NCT00486902|DRUG|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
219376852|NCT00486902|DRUG|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
219376853|NCT04825548|OTHER|No intervention|Examination of patients with previous DVT
219376854|NCT03396289|OTHER|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
219376855|NCT03396289|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
219376856|NCT00277537|DRUG|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
219376857|NCT00277537|DRUG|placebo|BD for 12 weeks
219376858|NCT02521129|DEVICE|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
219376859|NCT00003417|DRUG|carmustine|
219376860|NCT00003417|RADIATION|radiation therapy|
219376861|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
219376862|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
219557814|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
219557815|NCT01706263|DRUG|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
219188411|NCT02202772|DRUG|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
219376863|NCT01035151|BEHAVIORAL|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
219376864|NCT01035151|BEHAVIORAL|Control|Written Cessation Materials
219376865|NCT06489288|OTHER|ERAS protocol|The ERAS process mainly includes removing the urethral catheter before the recovery of anesthesia, removing the abdominal drainage tube within 3 days after surgery, removing the nasogastric feeding tu
219376866|NCT05203939|DRUG|OCU400 Low Dose|subretinal injection of up to 1.66×10E10 vg/mL
219376867|NCT05203939|DRUG|OCU400 Med Dose|subretinal injection of up to 3.33×10E10 vg/mL
219376868|NCT05203939|DRUG|OCU400 High Dose|subretinal injection of up to 1.66×10E11 vg/mL
219376869|NCT05203939|DRUG|OCU400 Second Eye Dosing|subretinal injection of 1.0x10E11vg/mL in 250 μl
219376870|NCT05122806|GENETIC|RNAseq|"1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
219376871|NCT04964869|PROCEDURE|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
219376872|NCT05947149|OTHER|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43."
219376873|NCT03771625|RADIATION|radiotherapy|whole brain with/without spinal cord
219376874|NCT05283733|PROCEDURE|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
219557816|NCT00889252|DEVICE|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
219557817|NCT00889252|DEVICE|contact lens|Placebo contact lens
219557818|NCT06315387|DRUG|4-MUST, 1 tablet|4-methylumbelliferyl trimebutine sulfate, 128 mg
219557819|NCT06315387|DRUG|4-MUST, 2 tablets|4-methylumbelliferyl trimebutine sulfate, 256 mg
219557820|NCT06315387|DRUG|4-MUST, 3 tablets|4-methylumbelliferyl trimebutine sulfate, 384 mg
219376875|NCT04696549|BEHAVIORAL|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
219376876|NCT00541307|DEVICE|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
219376877|NCT03222661|DIAGNOSTIC_TEST|Refraction|Refractive error measurement
219376878|NCT04466124|RADIATION|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
219376879|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
219376880|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
219376881|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
219376882|NCT02543268|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
219376883|NCT02543268|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
219376884|NCT03750825|DEVICE|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
219376885|NCT06474663|DRUG|Cladribine|Given by IV
219376886|NCT06474663|DRUG|Cytarabine|Given by SC
219376887|NCT06474663|DRUG|Sorafenib|Given by PO
219376888|NCT06474663|DRUG|Decitabine|Given by IV
219376889|NCT06334835|DIAGNOSTIC_TEST|lncRNA signature analyses|Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.
219376890|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
219376891|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219188412|NCT02202772|DRUG|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
219188413|NCT02202772|DRUG|Cisplatin|Intravesical installation of Cisplatin for 2hours
219376892|NCT06960239|DEVICE|IRE System|Irreversible Electroporation (IRE) System for the Treatment of Upper Airway Obstruction due to Adenotonsillar Hypertrophy in Children
219376893|NCT02481765|DEVICE|High definition transcranial direct current stimulation|
219376894|NCT04728633|DRUG|Carmustine|Given via infusion
219376895|NCT04728633|DRUG|Ethiodized Oil|Given via infusion
219376896|NCT04728633|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
219376897|NCT04728633|OTHER|Medical Device Usage and Evaluation|Given gelatin sponge via injection
219376898|NCT03173469|OTHER|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
219376899|NCT04253132|DRUG|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
219376900|NCT04253132|DRUG|Placebos|oral placebo
219376901|NCT04704180|BEHAVIORAL|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
219376902|NCT06260787|PROCEDURE|In Vitro Fertilisation|Assisted reproductive technology in the form of in vitro fertilisation
219376903|NCT04705454|BIOLOGICAL|Loncastuximab Tesirine|
219376904|NCT02900092|DRUG|Ganaxolone|Participants received ganaxolone
219376905|NCT00743886|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
219376906|NCT00743886|DRUG|saline|injection of 6 cc of saline into injured area
219376907|NCT00418288|DRUG|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
219376908|NCT00418288|DRUG|placebo|intravenous infusion of 1.2pmol/kg/min
219376909|NCT03895203|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219376910|NCT03895203|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
219376911|NCT03895203|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
219376912|NCT01001585|DRUG|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
219557821|NCT02111122|DRUG|Sodium Oxybate|
219557822|NCT02111122|DRUG|Placebo|
219557823|NCT02095340|OTHER|Positive Interpretation Bias Training|
219376913|NCT06258278|PROCEDURE|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
219376914|NCT00996840|DRUG|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
219376915|NCT00996840|DRUG|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
219376916|NCT00996840|DRUG|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
219376917|NCT00996840|DRUG|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
219376918|NCT00996840|OTHER|Placebo|Placebo to match intervention
219376919|NCT02381158|DRUG|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
219376920|NCT02281812|PROCEDURE|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
219376921|NCT03237676|OTHER|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
219376922|NCT03237676|OTHER|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
219376923|NCT03455387|DIAGNOSTIC_TEST|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
219376924|NCT02914626|DRUG|Intravitreal ranibizumab|Intravitreal ranibizumab injection
219376925|NCT05526560|DEVICE|MITRIS RESILIA Mitral Valve, Model 11400M|Replacement of mitral valve with MITRIS RESLIA Mitral Valve
219376926|NCT02433509|OTHER|hUCB|"1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
219376927|NCT02146781|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
219376928|NCT02146781|OTHER|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
219376929|NCT01655407|DRUG|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
219376930|NCT01655407|DRUG|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
219376931|NCT03038724|DIAGNOSTIC_TEST|Rapid HIV test|
219376932|NCT04439669|DEVICE|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
219376933|NCT04439669|DEVICE|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
219376934|NCT04645797|DRUG|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
219376935|NCT06324149|DIAGNOSTIC_TEST|completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis|The sub-investigator performs a multidimentional geriatric evaluation
219376936|NCT03975998|PROCEDURE|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
219376937|NCT03424109|BEHAVIORAL|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
219557824|NCT02095340|OTHER|Neutral Interpretation Bias Training|
219376938|NCT06502990|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
219376939|NCT02848755|DEVICE|Cranial ultrasonography|
219376940|NCT03755622|DEVICE|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
219376941|NCT03755622|DEVICE|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
219376942|NCT03604731|DEVICE|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
219376943|NCT01485614|DRUG|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
219376944|NCT01485614|DRUG|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
219376945|NCT01485614|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
219376946|NCT01485614|DRUG|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
219376947|NCT01485614|DRUG|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
219376948|NCT01485614|BIOLOGICAL|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
219376949|NCT01290926|DRUG|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
219376950|NCT06054217|DRUG|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
219376951|NCT05206461|OTHER|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
219376952|NCT03180814|OTHER|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
219376953|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
219376954|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
219376955|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
219376956|NCT00733902|BIOLOGICAL|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
219376957|NCT02891421|BEHAVIORAL|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
219376958|NCT02891421|OTHER|Standard Care|Standard Care: Participants received standard care
219376959|NCT01477021|DRUG|cyclophosphamide|Given IV
219376960|NCT01477021|BIOLOGICAL|NY-ESO-1-specific T cells|Given IV
219376961|NCT01477021|OTHER|laboratory biomarker analysis|Correlative studies
219376962|NCT03840629|OTHER|No study intervention.|
219376963|NCT01162850|DIETARY_SUPPLEMENT|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
219376964|NCT01162850|DIETARY_SUPPLEMENT|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
219376965|NCT02406664|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
219376966|NCT03763786|DRUG|Cetrorelix Acetate|Used a standard
219376967|NCT00475163|BEHAVIORAL|Behavior modification|
219376968|NCT02510807|OTHER|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
219376969|NCT00006383|DRUG|liposomal vincristine sulfate|
219376970|NCT05026073|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
219188414|NCT06565572|DRUG|nL-FLVC-001|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
219376971|NCT05026073|PROCEDURE|Blood and endometrial tissue sampling|"* All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
219376972|NCT05026073|PROCEDURE|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
219376973|NCT00889356|DRUG|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
219376974|NCT00889356|DRUG|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
219376975|NCT01209858|DRUG|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
219376976|NCT01209858|DRUG|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
219376977|NCT02582515|DRUG|D-cycloserine|
219376978|NCT02582515|DRUG|Placebo|
219376979|NCT04548310|OTHER|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
219376980|NCT01029561|DEVICE|CPAP|Treatment with Continuous Positive Airway Pressure
219376981|NCT01029561|BEHAVIORAL|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
219376982|NCT01093495|DEVICE|CPAP|CPAP
219376983|NCT01093495|DEVICE|Nasal Cannula|Nasal Cannula
219376984|NCT06059885|DRUG|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
219376985|NCT03465956|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
219376986|NCT00775021|DEVICE|etafilcon A|Contact Lens
219376987|NCT00775021|DEVICE|nelfilcon A|Contact Lens
219376988|NCT00427414|DRUG|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
219376989|NCT03394222|DRUG|preoperative budesonide inhalation|
219376990|NCT03394222|DRUG|preoperative normal saline inhalation|
219376991|NCT02488278|DEVICE|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
219376992|NCT00117767|DRUG|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
219376993|NCT00117767|DRUG|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
219376994|NCT00997074|DRUG|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
219376995|NCT01969656|DRUG|2MD|
219376996|NCT01969656|DRUG|Calcitriol|
219557825|NCT04227041|DRUG|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
219557826|NCT03978416|BEHAVIORAL|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
219557827|NCT01514123|DRUG|VGX-100|VGX-100 will be administered by IV infusion once every week
219376997|NCT01969656|DRUG|Placebo|
219376998|NCT00870688|DRUG|sodium valproate|valproate sustained release minitablets, once daily.
219376999|NCT00188188|DRUG|quinipril|
219377000|NCT05988814|DRUG|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"
219377001|NCT03963583|BEHAVIORAL|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
219377002|NCT06483074|DRUG|Empagliflozin 10 MG|empagliflozin oral 10mg daily for 6 months
219377003|NCT05218811|DEVICE|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
219377004|NCT06278519|BIOLOGICAL|Blood, urinary and feces collection|Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.
219377005|NCT06278519|DEVICE|Cardiac MRI|Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
219377006|NCT06278519|OTHER|Quality of life and cognitive status questionnaire|Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up
219377007|NCT06642480|DRUG|Post Operative Analgesia|administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
219377008|NCT06642480|DRUG|Post Operative Analgesia|VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
219377009|NCT05426057|BEHAVIORAL|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
219557828|NCT01514123|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
219377010|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
219377011|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
219377012|NCT06379698|OTHER|personalized 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group
219377013|NCT06379698|OTHER|generic 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
219377014|NCT05000905|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
219377015|NCT05000905|BEHAVIORAL|Questionnaires|Computer based assessments measuring attention, memory, daily habits, and mental health
219377016|NCT03464045|DRUG|empagliflozin|empagliflozin
219377017|NCT03464045|DRUG|DPP-4 inhibitors|DPP-4 inhibitors
219377018|NCT04218370|PROCEDURE|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
219377019|NCT05347407|PROCEDURE|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
219377020|NCT06150599|DEVICE|Sacral neuromodulation|Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.
219377021|NCT00928915|DRUG|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
219377022|NCT05124808|OTHER|Intensive glycemic targets|Fasting blood glucose \<90 mg/dL, 1 hour post-prandial blood glucose \<120 mg/dL
219377023|NCT05124808|OTHER|Standard glycemic targets|Fasting blood glucose \<95 mg/dL, 1 hour post-prandial blood glucose \<140 mg/dL
219377024|NCT03826875|DRUG|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
219377025|NCT03826875|DRUG|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
219377026|NCT04889274|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
219377027|NCT04889274|BIOLOGICAL|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
219377028|NCT04889274|BIOLOGICAL|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
219377029|NCT05375201|OTHER|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
219377030|NCT06108050|DRUG|JZP898|Investigational drug monotherapy
219377031|NCT06108050|DRUG|Pembrolizumab|Anti-PD1 antibody
219557829|NCT04614584|DRUG|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
219557830|NCT04614584|DRUG|Methamphetamine|Methamphetamine 30 mg IV once
219557831|NCT04013074|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
219557832|NCT04013074|OTHER|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
219377032|NCT06121232|DEVICE|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
219377033|NCT06121232|OTHER|Control Group|Participants will not receive any intervention
219377034|NCT03872180|DRUG|Bendamustine|Given IV
219377035|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
219377036|NCT03872180|DRUG|Venetoclax|Given PO
219377037|NCT01506141|DRUG|Idursulfase-IT|Idursulfase-IT once monthly via IDDD.
219377038|NCT01506141|DRUG|Elaprase|Weekly IV infusions of commercially available Elaprase.
219377039|NCT06408363|BEHAVIORAL|Maneuver group|These maneuvers for Eustachian tube opening will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase.
219377040|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
219377041|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
219377042|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
219377043|NCT06273527|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
219377044|NCT06273527|OTHER|Sham Program|The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
219377045|NCT04726748|PROCEDURE|Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts|"Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
219377046|NCT04726748|PROCEDURE|Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts|"Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
219377047|NCT04986007|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
219377048|NCT06304233|DIAGNOSTIC_TEST|Echocardiography|ultrasound assessment of heart structure, volume and function
219377049|NCT06304233|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|MRI assessment of heart structure, volume, function and tissue characteristics
219377050|NCT06304233|DIAGNOSTIC_TEST|Electrocardiography|Assessment of cardiac rhythm and electrical activity
219377051|NCT06304233|OTHER|Blood sampling|To measure DISC1 mRNA expression and other potential biomarkers
219377052|NCT04497285|OTHER|blood sample collection and collection of tumor tissue block|blood sample collection and collection of tumor tissue block
219377053|NCT06334939|DEVICE|Bispectral Index Monitoring|"Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia."
219377054|NCT04845347|DEVICE|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
219377055|NCT04845347|DEVICE|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
219377056|NCT05698732|DEVICE|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
219377057|NCT04586504|DRUG|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
219377058|NCT05899322|BEHAVIORAL|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
219377059|NCT05899322|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
219377060|NCT06294587|PROCEDURE|FGG Before GBR|Free Gingival Graft before the guided bone regeneration,
219377061|NCT06294587|PROCEDURE|FGG after GBR|Free Gingival Graft after the guided bone regeneration,
219377062|NCT06197984|PROCEDURE|ERCP|ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.
219377063|NCT05917145|DRUG|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
219188415|NCT06565949|OTHER|Education group|aregivers in the experimental group will be given a detailed and planned training programme on pressure sores. The trainings will be held in a total of four sessions, with twenty minutes in each session, two weeks apart.
219377064|NCT04443348|RADIATION|Radiation Therapy Boost|Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.
219377065|NCT04443348|DRUG|Pembrolizumab|"Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor."
219377066|NCT04443348|DRUG|Paclitaxel|Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes.
219377067|NCT04443348|DRUG|Carboplatin|"Carboplatin is optional for TNBC patients and should be discussed with the study doctor.~Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes."
219377068|NCT04443348|DRUG|Cyclophosphamide|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
219377069|NCT04443348|DRUG|Doxorubicin|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
219377070|NCT04443348|DRUG|Capecitabine|"Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks)."
219377071|NCT05372159|OTHER|none, observational study|none, observational study
219377072|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
219377073|NCT04754529|OTHER|Survey Administration|Ancillary studies
219188416|NCT06565949|OTHER|control group|In the first stage of the study, the participants in the experimental and control groups were asked to complete the 'Introductory Information Form' and '' Pressure sore knowledge test' will be completed. In the second stage of the research, no intervention will be made to the caregivers in the control group, and in the last stage of the research, 'Pressure sore knowledge test' will be filled in as post-test data for all participants.
219377074|NCT04754529|OTHER|Yoga|Receive yoga intervention
219377075|NCT05116813|DRUG|Dipraglurant|Oral 50 mg and 100 mg tablet
219377076|NCT06500754|OTHER|Ultra-strict gluten-free diet|ultra-strict gluten-free diet (avoiding traces and contamination) under dietitian supervision
219377077|NCT03227263|DRUG|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
219377078|NCT03227263|DRUG|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
219377079|NCT00274391|DRUG|7% NaCl|
219377080|NCT00274391|DRUG|Amiloride HCl|
219377081|NCT06528600|DEVICE|Hymovis ONE|Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
219377082|NCT06528600|DEVICE|Monovisc|Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
219377083|NCT06340919|DEVICE|Sudden Sound Reduction Setting|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
219377084|NCT02744976|DRUG|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
219377085|NCT02744976|BEHAVIORAL|Lifestyle recommendations|Standard lifestyle recommendations
219377086|NCT06483646|OTHER|Gaseous sampling:|the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
219377087|NCT03821857|DRUG|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
219377088|NCT02599402|DRUG|Nivolumab|
219377089|NCT02599402|DRUG|Ipilimumab|
219377090|NCT05443022|RADIATION|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
219377091|NCT05443022|RADIATION|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
219377092|NCT05664620|DIAGNOSTIC_TEST|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
219377093|NCT01851967|OTHER|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
219377094|NCT03375385|DRUG|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
219377095|NCT03488199|DEVICE|Stent Acculink ™|Carotid Artery Revascularization using Stents
219377096|NCT03488199|DEVICE|CGuardTM™|Carotid Artery Revascularization using Stents
219377097|NCT04814264|BIOLOGICAL|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
219377098|NCT06286501|DEVICE|Lumoral Treatment|Home-use photodynamic antibacterial dual-light oral health care device with a marker substance
219377099|NCT06286501|OTHER|Standard, personalized oral health care|Home-based oral health care instructed by a professional, with emphasis on personal needs according to oral condition and previous oral health care habits.
219377100|NCT04274322|OTHER|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
219377101|NCT04866927|DIETARY_SUPPLEMENT|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
219377102|NCT04548076|OTHER|Block group|Control group
219377103|NCT04663750|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy
219377104|NCT04663750|DRUG|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
219377105|NCT04663750|DRUG|subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls|Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
219377106|NCT04663750|DRUG|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
219377107|NCT04975958|DRUG|AN2025|oral administration
219377108|NCT04975958|DRUG|AN0025|oral administration
219377109|NCT04975958|DRUG|Atezolizumab 1200 mg in 20 ML Injection|infusion
219760875|NCT03273907|DEVICE|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
219377110|NCT06457126|BEHAVIORAL|Attention Training Technique|"Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A)."
219377111|NCT02980614|DEVICE|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
219377112|NCT01773473|DRUG|Insulin Lispro Mix25|Administered SC
219377113|NCT01773473|DRUG|Insulin Lispro Mix50|Administered SC
219377114|NCT00116454|DRUG|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
219377115|NCT03190343|PROCEDURE|cholangio-pancreatoscopy|
219377116|NCT06323824|DRUG|Methadone|"Drug: Methadone~Possible formulations:~10 and 50 mg tablets"
219377117|NCT06323824|DRUG|Buprenorphine (BUP)|"Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)"
219377118|NCT02506738|DEVICE|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
219377119|NCT06131710|OTHER|Isolated Strengthening Exercises|Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
219377120|NCT06131710|OTHER|Combined Strengthening Exercises|Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
219377121|NCT00206973|PROCEDURE|mannitol test|
219377122|NCT01783834|DRUG|Gefitinib|compare progression free survivla rate and safety to both drugs
219377123|NCT01783834|DRUG|Pemetrexed|compare PFS rate, safety to both drugs
219377124|NCT04927312|DRUG|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
219377125|NCT04927312|DRUG|Metronidazole|Metronidazole 0.5 g solution for injection.
219377126|NCT04179903|OTHER|Physical activity|Physical Activity program is performed in a group in a gym and at home
219377127|NCT00893711|OTHER|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
219377128|NCT00893711|OTHER|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
219377129|NCT00893711|DIETARY_SUPPLEMENT|L.reuteri + Vit D|
219377130|NCT00893711|DIETARY_SUPPLEMENT|Vit D placebo|
219377131|NCT01706913|OTHER|Dermatology consult|
219377132|NCT04919564|DRUG|Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)|Furosemide 2 mg/hour infusion for 12 hours since induction
219377133|NCT04919564|DRUG|NaCl 0.9%|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
219377134|NCT01241786|DRUG|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
219760876|NCT03273907|PROCEDURE|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
219760877|NCT02491281|DRUG|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
219760878|NCT02491281|DRUG|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
219377135|NCT01241786|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
219377136|NCT03030287|DRUG|OMP-305B83|intravenous (in the vein) infusion
219377137|NCT03030287|DRUG|Paclitaxel|administered intravenously
219377138|NCT04796402|BIOLOGICAL|Bamlanivimab|700 mg/20mL IV over at least one hour OD
219377139|NCT04796402|OTHER|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
219377140|NCT06310369|RADIATION|radiation therapy|"Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents."
219377141|NCT02343692|PROCEDURE|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
219377142|NCT06353672|DEVICE|Robotic liver resection|Liver resection using Da Vinci robotic system
219377143|NCT03735940|OTHER|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
219377144|NCT00632580|DRUG|intraarticular injection with ropivacaine|
219377145|NCT00632580|DRUG|extraarticular injection with ropivacaine|
219377146|NCT02850796|BEHAVIORAL|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
219377147|NCT02850796|OTHER|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
219377148|NCT03754153|DEVICE|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
219377149|NCT03754153|OTHER|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
219377150|NCT04438421|DRUG|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
219377151|NCT04438421|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
219377152|NCT04438421|DRUG|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
219377153|NCT01152853|DRUG|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
219377154|NCT02371629|DRUG|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
219377155|NCT02371629|DRUG|Placebo|Placebo to NVA237
219377156|NCT02371629|DRUG|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
219377157|NCT01995890|DRUG|nepafenac|
219377158|NCT00312130|DRUG|Vildagliptin|
219377159|NCT04837612|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
219377160|NCT03662295|BEHAVIORAL|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
219377161|NCT03754985|DEVICE|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
219377162|NCT00599768|OTHER|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
219377163|NCT05416892|OTHER|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
219377164|NCT02764879|DIETARY_SUPPLEMENT|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
219377165|NCT02764879|PROCEDURE|scaling and root planing|
219377166|NCT02764879|OTHER|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
219377167|NCT04582240|OTHER|no intervention|no intervention
219377168|NCT01440101|DRUG|Natalizumab (BG00002)|
219377169|NCT01440101|DRUG|Placebo|
219377170|NCT03758937|PROCEDURE|volume-controlled ventilation|
219377171|NCT03758937|PROCEDURE|pressure-controlled ventilation|
219377172|NCT02688075|OTHER|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
219377173|NCT01919892|DRUG|Lithium|
219377174|NCT05071131|DIETARY_SUPPLEMENT|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
219377175|NCT05071131|DIETARY_SUPPLEMENT|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
219377176|NCT01425099|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
219377177|NCT01425099|DRUG|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
219377178|NCT01894672|DRUG|LGX818|
219377179|NCT00184457|BEHAVIORAL|Strength training intervention|
219377180|NCT02682836|BEHAVIORAL|Walk with Ease|
219377181|NCT05798520|DRUG|BIIB091|Administered as specified in the treatment arm.
219377182|NCT05798520|DRUG|DRF|Administered as specified in the treatment arm.
219377183|NCT05798520|DRUG|Placebo|Administered as specified in the treatment arm.
219377184|NCT03835091|OTHER|BRASS score|Brainstem response on neurologic examination
219377185|NCT00216034|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
219377186|NCT00216034|DRUG|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
219377187|NCT00854269|PROCEDURE|surgery|cervical biopsy or specimen of hysterectomy
219377188|NCT03832387|DEVICE|Non-invasive mechanical ventilation|
219377189|NCT03832387|DEVICE|Continuous positive airway pressure|
219377190|NCT03832387|DEVICE|Venturi mask|
219377191|NCT03832387|DEVICE|Reservoir mask|
219377192|NCT04604925|BEHAVIORAL|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
219377193|NCT05991024|BEHAVIORAL|the incisional hernia recurrent|Recurrence after repair was the main outcome
219377194|NCT00144170|DRUG|Tipranavir (with low dose ritonavir)|
219377195|NCT00144170|DRUG|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
219377196|NCT04753125|BEHAVIORAL|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
219377197|NCT04753125|BEHAVIORAL|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
219377198|NCT04753125|BEHAVIORAL|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
219377199|NCT02066064|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
219377200|NCT02066064|PROCEDURE|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
219000941|NCT02546804|PROCEDURE|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
219000942|NCT02546804|PROCEDURE|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
219000943|NCT02546804|PROCEDURE|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
219377201|NCT03653520|DRUG|Diazepam|5 or 10mg
219377202|NCT03653520|DRUG|Tramadol|50mg or 100mg
219377203|NCT03653520|DRUG|Ondansetron|1 or two tabs
219377204|NCT03653520|DRUG|MKO melt|1 or 2 MKO melts
219377205|NCT01879657|DRUG|68Ga-DOTATATE|68Ga-DOTATATE (3-5 mCi ±25%; 111-185 MBq) is administered as a single intravenous bolus injection in each participant. These injections were performed within 28 days after the Octreoscan.
219377206|NCT01879657|DIAGNOSTIC_TEST|PET/CT|68Ga-DOTATATE PET images will be acquired 60 ±30 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET images were performed within 28 days after the Octreoscan.
219377207|NCT01879657|DIAGNOSTIC_TEST|111In-pentetreotide OctreoScan|OctreoScan™ was performed after intravenous injection of 111In-pentetreotide, a radiopharmaceutical that binds to somatostatin receptors, if the patient had not undergone such imaging as a standard of care. Subsequent planar and/or SPECT imaging was used to detect somatostatin receptor-positive lesions.
219377208|NCT01879657|DIAGNOSTIC_TEST|MRI|MRI (Standard of Care)
219377209|NCT02680353|PROCEDURE|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
219377210|NCT04093830|DEVICE|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
219377211|NCT02522637|OTHER|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
219377212|NCT03107195|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
219377213|NCT04356456|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
219377214|NCT03563300|OTHER|Wheat flour|Wheat flour will be administered once daily for 7 days
219377215|NCT03563300|OTHER|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
219377216|NCT00986531|DRUG|AZD8529|2 capsules by mouth for 3 days
219377217|NCT00986531|DRUG|Placebo to match AZD8529|2 capsules by mouth for 3 days
219377218|NCT05195606|OTHER|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
219377219|NCT05195606|OTHER|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
219377220|NCT04684199|DIETARY_SUPPLEMENT|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
219377221|NCT04684199|DIETARY_SUPPLEMENT|Placebo|
219377222|NCT00988390|BEHAVIORAL|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
219377223|NCT03784196|OTHER|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
219377224|NCT01260558|DEVICE|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
219377225|NCT01260558|DEVICE|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
219377226|NCT03388814|DRUG|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
219377227|NCT03388814|DRUG|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
219377228|NCT02784093|DRUG|Gastrograﬁn|
219377229|NCT02784093|PROCEDURE|enemas|
219377230|NCT03770143|OTHER|Feeding with palm olein formula|
219377231|NCT00245232|BEHAVIORAL|Cognitive Therapy|
219377232|NCT00245232|BEHAVIORAL|Cognitive Processing Therapy|
219377233|NCT00245232|BEHAVIORAL|Written Exposure|
219377234|NCT03088514|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
219377235|NCT02054858|PROCEDURE|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
219377236|NCT04293016|BEHAVIORAL|Support as usual|This group receives current best practice which includes participation in ICU support groups and provision of community support resources
219377237|NCT04293016|BEHAVIORAL|Problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
219377238|NCT04293016|BEHAVIORAL|ICU diary|This group will be provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
219377239|NCT05104944|RADIATION|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
219377240|NCT05232734|DRUG|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
219377241|NCT05983848|RADIATION|99mMaracticaltide imaging|7.3.1 99mTc-maraciclatide imaging This will be undertaken at baseline and optionally at 8-12 weeks. Not more than 75 µg of 99mTc-maraciclatide will be administered intravenously with an activity as close as possible to 740 MBq. Static whole-body imaging will be undertaken after a maximum of 2 hours with further dedicated views of the hands and feet. Total image acquisition time will be approximately 30 minutes. Images will be scored by quantitative and semi-quantitative methods by a blinded observer.
219377242|NCT06078176|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
219377243|NCT03818698|OTHER|Eplets mismatching numbers|In this study, the HLA high-resolution typing data of kidney transplant recipients from 2014 to the end of 2017 were analyzed with HLA Matchmaker for eplets mismatching number. To analyze the incidence of dnDSA and AMR after kidney transplant recipients with different eplets mismatching number posttransplant, and to elucidate the important role of tissue configuration patterns based on HLA eplets matching in long-term graft survival.
219377244|NCT00519870|DRUG|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
219377245|NCT00519870|DRUG|losartan|II: losartan
219377246|NCT00519870|DRUG|Nifedipine, losartan|I: nifedipine II: losartan
219377247|NCT06657755|DIAGNOSTIC_TEST|Immunohistochemistry|This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
219377248|NCT06657495|DRUG|TD0015|TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
219377249|NCT06657495|DRUG|TD0015 Placebo|Placebo was packed in pack 5g
219377250|NCT00013078|PROCEDURE|Physical restoration intervention|
219377251|NCT06580327|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
219377252|NCT06580327|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
219377253|NCT06550661|BEHAVIORAL|Ba duan jin|a kind of exercise
219377254|NCT06657521|DIETARY_SUPPLEMENT|osteoimplant|Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
219377255|NCT06657521|DIETARY_SUPPLEMENT|Placebo Oral Tablet|2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
219377256|NCT05075161|DRUG|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
219188417|NCT05017012|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.
219188418|NCT05017012|BIOLOGICAL|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
219188419|NCT05017012|DRUG|Pemetrexed|Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
219188420|NCT05017012|DRUG|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
219188421|NCT05017012|DRUG|Paclitaxel|Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
219188422|NCT05017012|DRUG|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
219188423|NCT05017012|DRUG|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
219188424|NCT05017012|DRUG|Cisplatin|Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
219188425|NCT02701829|OTHER|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
219188426|NCT02701829|OTHER|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
219188427|NCT02701829|OTHER|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
219188428|NCT05742685|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
219377257|NCT05075161|DRUG|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
219760879|NCT01074073|DRUG|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
219760880|NCT00110214|DRUG|docetaxel|Given IV
219760881|NCT00110214|OTHER|placebo|Given IV
219760882|NCT00110214|DRUG|prednisone|Given orally
219760883|NCT00110214|BIOLOGICAL|bevacizumab|Given IV
219760884|NCT00110214|OTHER|laboratory biomarker analysis|Correlative studies
219377258|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
219377259|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
219377260|NCT01077765|DEVICE|Eutrophill|Polyacrylamide Hydrogel
219377261|NCT03534648|DRUG|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
219377262|NCT03534648|DRUG|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
219377263|NCT03534648|DRUG|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
219377264|NCT03534648|DRUG|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
219377265|NCT06988462|OTHER|Bottarga|Participants will consume prepackaged daily doses of Bottarga, each containing the required amount (20 grams/day) for 8 weeks.
219377266|NCT06988462|OTHER|Comparator|Participants will consume 28g of cream cheese/day for 8 weeks.
219377267|NCT06592638|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219377268|NCT06478368|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
219377269|NCT03228121|PROCEDURE|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
219377270|NCT03228121|PROCEDURE|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
219377271|NCT01360203|OTHER|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
219377272|NCT01726179|DEVICE|Resin infiltration|Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.
219377273|NCT01726179|DEVICE|Control|Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.
219377274|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
219377275|NCT01783665|OTHER|aerobic exercise|
219377276|NCT01783665|OTHER|home exercise program|
219377277|NCT02730546|DRUG|Carboplatin|Given IV
219377278|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
219377279|NCT02730546|DRUG|Fluorouracil|Given IV
219377280|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
219377281|NCT02730546|DRUG|Leucovorin Calcium|Given IV
219377282|NCT02730546|DRUG|Oxaliplatin|Given IV
219377283|NCT02730546|DRUG|Paclitaxel|Given IV
219377284|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
219377285|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219377286|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
219377287|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
219377288|NCT05821270|OTHER|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
219377289|NCT05798988|BEHAVIORAL|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
219377290|NCT00000479|DRUG|Aspirin|Participants will receive 100 mg of aspirin every other day.
219377291|NCT00000479|DRUG|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
219377292|NCT00000479|BEHAVIORAL|Placebo|Participants will receive placebo.
219377293|NCT04203173|BEHAVIORAL|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
219760885|NCT01088503|DRUG|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
219377294|NCT04203173|BEHAVIORAL|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
219377295|NCT04103918|DEVICE|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
219377296|NCT03435900|DRUG|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
219377297|NCT03435900|DRUG|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
219377298|NCT02282787|DRUG|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
219188429|NCT04142606|OTHER|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
219377299|NCT06238999|DEVICE|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
219377300|NCT03740334|DRUG|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
219377301|NCT03740334|DRUG|Dexamethasone|Corticosteroids are commonly used to treat ALL.
219377302|NCT03740334|DRUG|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
219377303|NCT05803564|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
219377304|NCT03507140|OTHER|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
219377305|NCT06614855|DRUG|C134|Initial Treatment . C134 Dose #1
219377306|NCT06614855|DRUG|C134|2nd Treatment. C134 Dose #2
219377307|NCT04984889|DRUG|TAK-662|Lyophilized, sterile concentrate of human protein C
219377308|NCT05211778|BEHAVIORAL|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
219377309|NCT06994507|DRUG|GM1|GM1 was administered intravenously one day before the administration of each cycle of chemotherapy. The experimental group was given 400 mg of GM1 injection. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
219377310|NCT06994507|DRUG|Placebo|Placebo was administered intravenously one day before the administration of each cycle of chemotherapy. The control group was given placebo. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
219377311|NCT05818670|DRUG|Tamsulosin|long term follow up
219377312|NCT05818670|DRUG|Tadalafil|long term follow up
219377313|NCT00562809|DRUG|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
219377314|NCT05791058|PROCEDURE|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
219377315|NCT05791058|PROCEDURE|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
219377316|NCT05791058|OTHER|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
219377317|NCT06863246|OTHER|Evaluation of cognitive task on static balance|Static balance with and without cognitive task (i.e., 1-back task)
219377318|NCT06863246|OTHER|Evaluation of visual feedback on static balance|Static balance with and without visual feedback (i.e., eyes closed and open).
219377319|NCT06676514|DIETARY_SUPPLEMENT|Probiotic Clostridium butyricum CBM588®|This group received probiotic Clostridium butyricum CBM588® treatment for IBS-D as three tablets daily for 8 weeks.
219377320|NCT06676514|OTHER|Standard of care IBS-D treatment|Patients in this group received standard of care IBS-D treatment of Trimebutine maleate maleate and followed a lactose-free, no-slag diet.
219377321|NCT05905783|DRUG|Placebo|Solution for injection
219377322|NCT05905783|DRUG|Izokibep|Solution for injection
219377323|NCT06251011|BEHAVIORAL|Exercise training|"1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation"
219000944|NCT05119205|DIAGNOSTIC_TEST|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
219377324|NCT04708041|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
219377325|NCT06607991|DRUG|Blinatumomab Treatment|Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
219377326|NCT06867627|BEHAVIORAL|Moderate-intensity combined aerobic and resistance exercise training|Training sessions begin with a 10-minute warm-up period that includes jogging and dynamic muscle stretching. This is followed by 20 minutes of running/jumping rope on the playground. Each intervention participant will wear a heart rate armband (Polar OH1, Finland) for real-time heart rate detection to maintain achievement of a predetermined target heart rate and training intensity. Then, after 10 minutes of rest adjustment and preparation, a 20-minute resistance training session will be performed, including all major muscle groups. Resistance training will start at 50% of 1RM and increases intensity by 10% after every three sessions, with two sets of repetitions and 60-90 seconds of rest between sets. By the third week, it will reach 70% of 1RM, and repeat 3 sets at 70% of 1RM starting at week 4. After the end of week 6, re-evaluate the RM every 3 weeks and repeat 3 sets at 70% of the new 1RM (i.e., starting from Week 7 and Week 10), maintaining a 60-90 second rest between each sets.
219377327|NCT03765593|PROCEDURE|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
219377328|NCT02760290|PROCEDURE|Extraperitoneal cesarean section|
219377329|NCT02760290|PROCEDURE|Intraperitoneal cesarean section|
219377330|NCT06127797|BEHAVIORAL|Questionnaire/Interview|Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
219377331|NCT06683482|OTHER|No intervention|No study drug will be administered as a part of this study.
219377332|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
219377333|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
219377334|NCT03431233|DIETARY_SUPPLEMENT|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
219377335|NCT05906914|DRUG|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
219377336|NCT06688942|BEHAVIORAL|Horizons App Intervention|Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.
219377337|NCT07013019|OTHER|Measures of overall (internal+external) knee rotational amplitudes|Measures of overall (internal+external) knee rotational amplitudes by Dyneelax
219377338|NCT07015697|DRUG|Trastuzumab Deruxtecan|"Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE.~Expansion Part: Trastuzumab Deruxtecan will be administered at RDE."
219377339|NCT05698589|BEHAVIORAL|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
219377340|NCT05698589|BEHAVIORAL|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
219377341|NCT04488458|DIAGNOSTIC_TEST|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
219377342|NCT02489214|DRUG|donafenib tosilate tablets|200mg bid
219377343|NCT02926807|OTHER|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
219377344|NCT02926807|OTHER|MDCT|a MDCT to calculate the Agatston score
219377345|NCT02926807|OTHER|biopsy and blood collection|biopsy and blood collection to assess biomarkers
219377346|NCT07107464|DEVICE|Short Neck Implant - Crestal Placement|A one-piece endosseous dental implant with a 1.8 mm short convergent neck, placed at the bone crest. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface treatment.
219377347|NCT07107464|DEVICE|Standard Neck Implant - 1 mm Subcrestal Placement|A one-piece endosseous dental implant with a standard-length neck (2.8 mm total; 0.8 mm cylindrical + 2 mm convergent), placed 1 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
219000945|NCT03098550|BIOLOGICAL|Nivolumab|Specified dose on specified days
219377348|NCT07107464|DEVICE|Long Neck Implant - 2 mm Subcrestal Placement|A one-piece endosseous dental implant with a long transmucosal neck (3.8 mm total; 0.8 mm cylindrical + 3 mm convergent), placed 2 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
219377349|NCT06628713|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
219377350|NCT06686108|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
219377351|NCT06686108|DRUG|Decitabine (DAC)|decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
219377352|NCT06686108|DRUG|Venetoclax|venetoclax, 400mg/d, days 1-7 of each 28-day cycle
219377353|NCT07021859|DRUG|Calcitonin-gene related peptide (CGRP)|The participants will receive a continuous intravenous infusion of 1.5 μg/min of CGRP over 60 minutes.
219377354|NCT07021859|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 60 mL of placebo (isotonic saline) over 60 minutes.
219377355|NCT02747524|OTHER|Vita Mamba peanut butter paste|
219377356|NCT06699563|BEHAVIORAL|Mobilization Motivation Card|On the morning of the surgery, the Mobilization Motivation Card and Pedometer will be introduced and the patient will be informed. On the morning of the first postoperative day, before the patient's first mobilization, pain assessment will be made with the Visual Analog Scale (VAS), and the Mobilization Motivation Card will be hung at the bedside during the day and will help increase the patient's participation in mobilization. Later, after a pedometer is attached to the patient's waist, the patient will be mobilized.
219377357|NCT06698822|DRUG|tofacitinib 2% cream|Given topical
219377358|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
219377359|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
219377360|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
219377361|NCT05516914|DRUG|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
219377362|NCT05516914|DRUG|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
219377363|NCT05516914|DRUG|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
219377364|NCT05516914|DRUG|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
219377365|NCT05516914|DRUG|Docetaxel injection|Initial dose；Q3W; intravenous infusion
219377366|NCT06438757|DRUG|JYB1904|Participants will receive JYB1904 every 8 weeks for 24 weeks.
219377367|NCT06438757|DRUG|Omalizumab|Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
219377368|NCT07029152|DIAGNOSTIC_TEST|Anal smear|"The intervention in this study involves the anal smear collection using the FLOQSwab® (COPAN, pouch type 502CS01). The swab is inserted 3-5 cm into the anal canal, reaching the transitional zone, the pressed against the canal wall and withdrawn in a spiral motion over approximately 20 seconds. After collection, the swab is immediately placed into a ThinPrep vial containing 20 ml of PreservCyt® and rinsed vigorously.~The procedure is performed by a physician or trained study team member and is designed to be quick, minimally invasive, and comfortable for participants. The FLOQSwab®'s patient-friendly design reduces irritation and false-positive results in comparison to earlier methods.~Samples collected in the ThinPrep PreservCyt® solution should be stored at room temperature and transferred to AML within a maximum of six weeks"
219377369|NCT07029152|BEHAVIORAL|Self-administered questionnaire|"It includes questions related to:~Socio-demographic characteristics Health-related issues Past HPV vaccination (indication? age at vaccination?) History of condylomata and/or other STIs Drug use, tobacco use, alcohol use Anal symptoms: discomfort, itch, pain, nodules, blood loss/discharge, constipation Sexual behavior Insertive/receptive intercourse, chemsex, number of sex partners (stable, occasional, anonymous), condom use."
219377370|NCT07029152|BEHAVIORAL|EQ-5D-5L questionnaire|"This questionnaire will be used after a negative HRA or during the communication of the results (per telephone) and during the treatment if indicated. This questionnaire assesses the impact of health conditions and treatments on person's quality of life. We will use an adapted version of the EQ-5D-5L. This modified version includes additional questions tailored to assess specific domains highlighted in the A-HRSI.~The additional items cover:~* Physical Symptoms: Question on anal symptoms such as pain, discharge, and burning sensations.~* Impact on Physical Functioning: Question on how these symptoms affect daily activities, including work, sitting, and social interactions.~* Impact on Psychological Functioning: Question on psychological and sexual well-being, including enjoyment and desire for sex, as well as challenges with intimacy."
219377371|NCT07029152|DIAGNOSTIC_TEST|High Resolution Anoscopy (HRA)|"HRA will be conducted using advanced tools, such as the Zeiss Extaro at UZ Brussel.~HRA will be conducted at participating centers with expertise in the technique, including UZ Brussel, UZ Gent, UZ Leuven, UZ Antwerpen, CHU St Pierre, AZ Sint-Jan Brugge, and Citadelle Liège. However, all biopsy specimens will be sent to AML Lab for analysis and stored in the biobank (BB190002).~In certain centers, HRA is performed using high-resolution scopes."
219377372|NCT07023016|DRUG|Sacubitril / Valsartan|Patients will receive sacubitril/valsartan at an initial dose of 24/26 mg Bid.
219377373|NCT07023016|DRUG|Ramipril (ACE-inhibitor)|Patients will receive ramipril at an initial dose of 2.5 mg Bid.
219377374|NCT06691958|OTHER|Tortilla corn chips 4-5 pieces, eat one piece at time|Snack
219377375|NCT06691958|OTHER|Tortilla corn chips 90 grams|Snack
219377376|NCT06691958|OTHER|Extruded corn chips 90 grams|Snack
219377377|NCT06691958|OTHER|Extruded corn chips 4-5 pieces, eat one piece at time|Snack
219377378|NCT06683612|DRUG|PIPE-791|Subjects will receive a single oral dose of PIPE-791.
219377379|NCT03079440|DRUG|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
219377380|NCT06697171|OTHER|Group 1 Not an ad disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #NotAnAd in the narrative body of the social media post
219377381|NCT06697171|OTHER|Group 2 Basic Disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #ad in the narrative body of the social media post
219760886|NCT01883921|OTHER|Immunoglobulin Therapy|
219000946|NCT03098550|BIOLOGICAL|Daratumumab|Specified dose on specified days
219760887|NCT02943694|DEVICE|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
219377382|NCT06697171|OTHER|Group 3 Basic + Paid Partnership Disclosure|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post;~#ad and #sponsored at the bottom of the narrative body of the social media post."
219377383|NCT06697171|OTHER|Control|No COI disclosure elements (i.e. no hashtags ). Only the @brandname is included within the narrative body of the social media post.
219377384|NCT06697171|OTHER|Group 4 Basic + Paid Partnership + Image label|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post; #ad and #sponsored at the bottom of the narrative body of the social media post; #ad (black text, white background) appears on the photo associated with the social media post"
219377385|NCT05818124|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
219377386|NCT05818124|DRUG|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
219377387|NCT05818124|DRUG|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
219377388|NCT05818124|DRUG|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
219377389|NCT05818124|BIOLOGICAL|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
219377390|NCT07030140|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT to the primary tumor and metastatic lymph node at a dose of either 5 Gy × 5-8 fractions or 4 Gy × 15 fractions, delivered prior to systemic therapy.
219377391|NCT07030140|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously every 3 weeks (on Day 1 of each 21-day cycle), for three to six cycles depending on surgical eligibility.
219377392|NCT07030140|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² administered intravenously on Days 1 and 8 of each 21-day cycle, for three to six cycles.
219377393|NCT07030140|DRUG|Cisplatin or Oxaliplatin|Cisplatin 25 mg/m² on Days 1 and 8 or oxaliplatin 100 mg/m² on Day 1 of each 21-day cycle, selected based on patient condition, for three to six cycles.
219377394|NCT06687837|BIOLOGICAL|autologous dopaminergic cell implantation|Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)
219377395|NCT06688435|BIOLOGICAL|SYS6020 injection|The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days according to the protocol design.
219377396|NCT06707142|DRUG|TBD11|TBD11 will be administered orally.
219377397|NCT06707142|DRUG|Placebo|Placebo will be administered orally.
219377398|NCT06710847|DRUG|GSK4418959|GSK4418959 will be administered.
219377399|NCT06710847|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor will be administered.
219377400|NCT07036796|DRUG|Melatonin|"Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway.~Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice."
219377401|NCT06718491|BEHAVIORAL|Managing Physical Reactions to Overwhelming Emotions (IMPROVE)|Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.
219377402|NCT06718491|BEHAVIORAL|Health Education Training (HET)|Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.
219377403|NCT07040930|DRUG|GenSci120|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
219377404|NCT07040930|DRUG|Placebo|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
219377405|NCT06723691|DRUG|Acetaminophen|Acetaminophen
219377406|NCT06723691|DRUG|Metformin|Metformin
219377407|NCT06723691|DRUG|Warfarin|Warfarin
219377408|NCT06723691|DRUG|Atorvastatin|Atorvastatin
219377409|NCT06723691|DRUG|Digoxin|Digoxin
219377410|NCT06723691|DRUG|HRS9531|HRS9531
219377411|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 5.0 g|Active Powder
219377412|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 3.5 g|Active Powder
219377413|NCT06884449|OTHER|Placebo|Placebo Powder
219377414|NCT06409208|BEHAVIORAL|mHealth intervention (video and reminder SMSs)|intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
219377415|NCT06668805|DRUG|Vosoritide Injection|Modified recombinant human C-type natriuretic peptide Vosoritide
219377416|NCT06668805|DRUG|Human Growth Hormone|Commercial product containing somatotropin.
219377417|NCT06887829|RADIATION|Low dose radiotherapy|Participants will receive low dose radiotherapy (0.5 Gy) 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device.
219377418|NCT06887829|OTHER|Sham comparator|Participants will receive identical treatment 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device, without radiation.
219377419|NCT06735248|BIOLOGICAL|mRNA-1195|IM injection
219377420|NCT06735248|BIOLOGICAL|Placebo|IM injection
219377421|NCT06744413|BEHAVIORAL|Multimodal prehabilitation program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of these three domains will be utilized to maximize their synergistic anabolic effect.~The duration of the program will be set at 4 weeks."
219377422|NCT06733974|OTHER|Multi-faceted Intervention|The participant, i.e. relative, will receive the multifaceted intervention which include: a first meeting with the healthcare team including written information about palliative care for dying patients, information on possibility to participate in care, pro-active communication, and dedicated interview and brochure after the patient's death with possibility of psychological follow up.
219377423|NCT06895681|PROCEDURE|Blood Sample|Obtained at the time of non-study related routine blood draw.
219377424|NCT06895681|PROCEDURE|Tissue Sample|Obtained at the time of non-study related routine biopsy or surgical procedure.
219377425|NCT06895681|PROCEDURE|Excess fluid Sample|Obtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.
219377426|NCT06895681|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the medical record
219377427|NCT06702995|DRUG|XNW5004|Oral continuous
219377428|NCT06702995|DRUG|enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
219377429|NCT06751030|BEHAVIORAL|The Mother Mentor program|The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
219377430|NCT06751030|DIAGNOSTIC_TEST|GeneXpert HPV test|A cervical cancer screening tool.
219377431|NCT06753136|DEVICE|percutaneous, laparoscopic or laparotomy lesion electrochemotherapy|All patients will receive Bleomycin intravenously with a dosage of 15.000 IU/m2. After a drug distribution time of 8 minutes, the lesions will be electroporated using the Cliniporator (IGEA S.P.A., Carpi, Italy), applying special handpieces depending on the route used: laparoscopic electrode, flexible and expandable for the laparoscopic procedure, linear or hexagonal electrode for laparotomy surgical access, variable geometry electrode for percutaneous access. The ECT procedure must be completed within 40 minutes.
219377432|NCT06764992|OTHER|Questionnaire|Participants will be asked to complete a questionnaire on demographics, risk beliefs and perception and prostate cancer screening behaviors, intentions and awareness of informed decision making.
219377433|NCT06764992|OTHER|Saliva Sample|Participants will be asked to provide a saliva sample for genetic risk testing to generate a SNP risk profile using a saliva sample collection kit with collection, storage and mailing instructions. We will assess the proportion of consented men who will provide a saliva sample.
219377434|NCT05006794|DRUG|zamzetoclax|Tablet(s) administered orally
219377435|NCT05006794|DRUG|Docetaxel|Administered intravenously
219377436|NCT05006794|DRUG|sacituzumab govitecan-hziy|Administered intravenously
219377437|NCT06589414|OTHER|Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)|"A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre."
219377438|NCT07064187|DRUG|Cationorm single-dose eye drop|Cationorm single-dose eye drop is a preservative-free, cationic oil-in-water nano-emulsion.
219377439|NCT07064187|DRUG|Artificial tear eye drop|Artificial tear eye drops are hyaluronic acid, polymers or cellulose derivatives eye drops
219000947|NCT02804932|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
219000948|NCT02804932|OTHER|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
219377440|NCT07061145|DRUG|Tirosin Kinase Inhibitors|Tyrosine kinase inhibitor (TKI) administered as part of standard clinical care for CML. No experimental treatment is applied. Exposure to the drug will be analyzed in association with erectile dysfunction outcomes.
219377441|NCT06781190|BEHAVIORAL|Green motherhood education|Pregnant women selected for the experimental group will receive 4 weeks of green motherhood training.
219377442|NCT07072624|DRUG|Phenytoin|The Phenytoin group will be given a loading dose of phenytoin 20 mg/kg intravenously (maximum, 2 gm) at 50 mg per minute and then started on a maintenance dose (5-6 mg/kg/d, rounded to the nearest 100 mg, intravenously administered every 8 hours). The intravenous will be switched to oral once the patient is fit to take it orally or via Ryles tube. The oral dose would be a single 300 mg ER (extended-release) tablet per day. Both IV and/or oral doses of phenytoin will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Phenytoin loading dose IV (20 mg/kg) followed by 100 mg IV TDS till patient accepts orally. Oral dose will be administered as a single 300 mg ER tablet per day. Both IV and oral phenytoin will be given for 1 week after traumatic brain injury and then stopped. Comparator= Matching Placebo
219377443|NCT07072624|DRUG|Levetiracetam|The Levetiracetam group will receive 25-30 mg/kg/d in two divided doses (rounded to 750 mg, administered intravenously every 12 hourly). The intravenous dose will be switched to oral form once the patient is fit to take it orally or via Ryles tube. The oral dose would be two tablets of 750 mg ER (extended-release) levetiracetam daily. Both IV and/or oral doses of levetiracetam will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Levetiracetam IV dosing will be 25-30 mg/Kg/d in 2 divided doses (rounded to 750 mg IV BD) followed by 2 tablets of 750 mg ER once patient fit to take orally or via Ryles tube. Comparator= Matching Placebo.
219377444|NCT07072624|DRUG|Placebo|The Placebo group will be administered normal saline intravenously of similar amount that of intervention group and matching placebo tablets orally (double dummy) once the patient is fit to take orally. Similar to the intervention group, both IV and oral placebo will be given till 1 week after traumatic brain injury.
219377445|NCT07070115|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
219377446|NCT06761404|DEVICE|taVNS|Experimental. The current will be increased gradually for both sham and real stimulation at the beginning of the 90-minute stimulation to lessen the itchy/numb skin sensation and to create the same skin sensation for subject blinding.
219377447|NCT06900569|DIETARY_SUPPLEMENT|Ashwagandha|600 mg/d Ashwagandha
219377448|NCT06900569|DIETARY_SUPPLEMENT|Placebo|600 mg/d placebo
219377449|NCT06842589|BIOLOGICAL|anti-CD19 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
219377450|NCT06758063|OTHER|exercises therapy|exercises to improve balance of the body
219377451|NCT07074379|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications primarily include quitting smoking and alcohol consumption, as well as engaging in physical exercise.
219377452|NCT07074379|DRUG|Pancreatic enzyme (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose , Metformin, Glimepirde Tablets, Insulin)|"This intervention involves the use of medications to control the pancreatic exocrine and endocrine dysfunction caused by chronic pancreatitis.~1. Pancreatic enzyme therapy: Patients will use pancreatic enzymes (pancreatin enteric-coated capsules or oryz-aspergillus enzyme and pancreatin tablets) to control the symptoms of exocrine pancreatic insufficiency.~2. Diabetes treatment: Patients with diabetes will also use antidiabetic medications (such as oral hypoglycemic drugs or insulin, depending on glycemic control needs)."
219377453|NCT07074379|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)|This intervention involves the application of endoscopic retrograde cholangiopancreatography (ERCP) and/or extracorporeal shockwave lithotripsy (ESWL), conducted in accordance with established clinical guidelines. The procedures are tailored to the individual patient's condition, which may include sphincterotomy, balloon dilation of pancreatic duct strictures, stone extraction, and stent placement as indicated. ESWL may be used prior to ERCP to fragment pancreatic duct stones, facilitating their removal.
219377454|NCT03781986|DRUG|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
219377455|NCT03781986|DRUG|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
219377456|NCT06809010|BIOLOGICAL|Whole blood donation|This intervention involves the collection of a whole blood bag.
219377457|NCT06809010|BIOLOGICAL|Apheresis donation|This procedure involves the collection of a plasma/platelets bag by apheresis
219377458|NCT06922825|DRUG|68Ga-FAPI-46|Participants will receive an IV injection of 68Ga-FAPI-46. Then, shortly after will undergo a PET/CT imaging using the 68Ga-FAPI-46. Additionally, MRI or contrast CT imaging will be conducted, either on the same day or within 14 days.
219377459|NCT06931015|OTHER|No interventions|No interventions
219377460|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
219377461|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
219377462|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
219377463|NCT03683186|DRUG|Ralinepag|Active
219377464|NCT07084298|DIETARY_SUPPLEMENT|Oral iron supplement|Encapsulated ferrous sulphate (150mg elemental iron)
219377465|NCT07084298|OTHER|Placebo|Encapsulated polysaccharide (maltodextrin)
219377466|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
219377467|NCT04620382|DRUG|Placebo pill|single oral dose
219377468|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
219377469|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
219377470|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
219377471|NCT03275909|BEHAVIORAL|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
219377472|NCT01075347|OTHER|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
219377473|NCT01075347|OTHER|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
219377474|NCT06905327|DRUG|QCZ484|doses of 50, 150, 300 or 600 mg via subcutaneous injection
219377475|NCT06905327|DRUG|Placebo|via subcutaneous injection
219377476|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
219377477|NCT04869137|DRUG|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
219377478|NCT04869137|DRUG|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
219377479|NCT07082530|PROCEDURE|Labor Induction at 39 Weeks|Labor induction at 39 weeks 0 days to 39 weeks 4 days
219377480|NCT07082530|PROCEDURE|Expectant management|Expectant management until spontaneous labor or induction at 41 weeks.
219377481|NCT06755996|DRUG|Dexmedetomidine injection|Dexmedetomidine injection 3μg/kg
219377482|NCT06755996|DRUG|Remimazolam|remimazolam 0.5mg / kg
219377483|NCT07088471|DRUG|Sacubtril/Valsartan|Angiotensin-receptor blocker and neprilysin inhibitor therapy
219377484|NCT07097376|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist Veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
219377485|NCT07097376|OTHER|Transitional Work|Provides individuals with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TW is time-limited. TW is staffed by vocational rehabilitation specialists (VRS).
219377486|NCT07095296|BEHAVIORAL|Health Education|"The intervention-a culturally tailored and redesigned health education-will be guided by established behavioral theories, namely the Theory of Planned Behavior (TPB) and Social Cognitive Theory (SCT) and implemented in a culturally sensitive manner. The TPB focuses on attitudes toward utilizing PNC services, the influence of subjective norms such as cultural norm, and their perceived behavioral control including transportation (34), while SCT emphasizes self-efficacy, social modeling, and reinforcement(35). Both TPB and SCT have been extensively validated in various health behavior studies, supporting their relevance and applicability in this context(36, 37).~Our intervention will consist of a structured training and mentorship program for midwives, focusing on health education delivery. The intervention package, including the training curriculum and implementation manual, will be developed in accordance with guidelines from the World Health Organization (WHO) and the Federal Ministry"
219377487|NCT04634539|DRUG|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
219377488|NCT04634539|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
219377489|NCT04634539|DRUG|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
219377490|NCT07099963|OTHER|one lung ventilation|Arterial blood gases during one lung ventilation
219377491|NCT07099677|DRUG|Beta Blocker|Participants in this group will receive standard antihypertensive treatment with a beta-adrenergic receptor blocker. The exact agent and dosage will be determined by the cardiology clinic according to clinical guidelines. Balance and fall risk assessments will be conducted at baseline (T0), week 2 (T1), and week 4 (T2).
219377492|NCT07099677|DRUG|ACE inhibitor|Participants in this group will receive standard antihypertensive treatment with an angiotensin-converting enzyme inhibitor. The dose and specific agent will be prescribed based on routine clinical criteria. Assessments will take place at T0, T1, and T2.
219377493|NCT07099677|DRUG|Calcium channel blocker|This group will receive a calcium channel blocker as part of their standard hypertension management. Dosage and agent will follow standard cardiology practice. Postural balance and fall risk will be measured at all study time points.
219377494|NCT07094711|BIOLOGICAL|Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine|"Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.~Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally."
219377495|NCT07094711|DRUG|preservative-free saline|Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.
219377496|NCT07100691|DRUG|Metoclopramide|Oral metoclopramide 10 mg, administered as three doses the day before surgery and one dose on the morning of surgery (total four doses over 24 hours). Used to enhance gastric emptying in patients taking GLP-1 receptor agonists.
219377497|NCT07089823|DRUG|YP05002|Tablet, QD
219377498|NCT07089823|OTHER|Placebo|Tablet, QD
219377499|NCT00648401|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
219377500|NCT00648401|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
219377501|NCT06249139|BEHAVIORAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
219377502|NCT06249139|BEHAVIORAL|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
219377503|NCT07107048|DEVICE|Pacemaker and defibrillator|Patients will be randomly assigned at enrollment (1:1) to undergo either LBBAP or CRT with biventricular stimulation. The devices implanted maybe defibrillators or pacemekers.
219377504|NCT07105540|DRUG|5% Dextrose|Ultrasound-guided hydrodissection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.
219377505|NCT07105540|DRUG|Betamethasone and local anesthetic|Ultrasound-guided perineural injection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.
219377506|NCT07107581|DEVICE|Prospective / Subjects Knee Arthroplasty|Knee Arthroplasty
219377507|NCT07107581|DEVICE|Retrospective to Prospective|Knee Arthroplasty
219377508|NCT07107581|DEVICE|Retrospective Only Subjects|Knee Arthroplasty
219377509|NCT07108218|PROCEDURE|lateral postion|The children will be positioned on their sides with their heads elevated by 30°, a thin pillow behind their backs, the upper legs bent, and the lower legs straightened.
219377510|NCT07108218|PROCEDURE|supine position|The children will be changed to a supine flat-lying position for extubation.
219377511|NCT06914856|BEHAVIORAL|Financial Capability Support with Peer Support Services|The participants in this arm will receive one-on-one financial coaching, which entails monthly or more frequent meetings with a financial coach. Participants will also receive access to safe and affordable financial services, which includes support with managing any existing bank accounts, or supporting a person to open a new overdraft-free account. Coaches can also help people to access other financial products such as free tax preparation (VITA), credit builder loans, online bank accounts, or other products recommended by our Justice Tech partner. The participants will also receive will receive the additional services of one-on-one peer support provided by a trained Recovery Support Specialist. Recovery Support Specialist, also referred to as Wellness coaches, will provide weekly meetings (30-60 minutes in duration) to the participants.
219377512|NCT06935383|DEVICE|Therapeutic sequence|the required dose of treatment is administered through the CoFI system
219377513|NCT06935383|DEVICE|Diagnostic sequence|Diagnostic sequence to detect MVO
219377514|NCT02581995|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
219377515|NCT01374282|DRUG|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
219377516|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
219377517|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
219377518|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
219377519|NCT03404362|PROCEDURE|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
219377520|NCT02058121|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
219377521|NCT02058121|BEHAVIORAL|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
219377522|NCT02593929|DRUG|ruxolitinib|
219377523|NCT03018015|DRUG|Ibuprofen 400 mg oral powder|
219377524|NCT03018015|DRUG|Ibuprofen 400 mg film-coated tablet|
219377525|NCT03018015|DRUG|Ibuprofen 400 mg soft capsule|
219377526|NCT03232112|DRUG|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
219377527|NCT03232112|DRUG|BD PosiFlush (saline)|Subcutaneous injection once-weekly
219377528|NCT03328039|DEVICE|Garmin wearable device|Physiological data capture only
219377529|NCT01232946|DRUG|liraglutide|1.8mg subcutaneous qd for 3 months
219377530|NCT01232946|DRUG|insulin detemir|5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
219377531|NCT01232946|DRUG|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
219377532|NCT02748369|DRUG|Somatostatin|Somatostatin infusion to create a low insulin state.
219377533|NCT02748369|DRUG|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
219377534|NCT04052828|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
219377535|NCT06187506|DRUG|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
219377536|NCT06187506|DRUG|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
219377537|NCT00345072|DEVICE|Web-based decision aid system|
219377538|NCT01817257|DRUG|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
219377539|NCT04349930|DRUG|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
219377540|NCT04349930|DRUG|Placebo vaginal suppository|Placebo vaginal suppository
219377541|NCT03095703|DRUG|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
219377542|NCT05476796|DRUG|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
219377543|NCT05476796|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
219377544|NCT05476796|DRUG|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
219377545|NCT05476796|DRUG|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
219377546|NCT06272643|DIAGNOSTIC_TEST|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
219377547|NCT04905797|DIAGNOSTIC_TEST|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
219377548|NCT04905797|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
219377549|NCT04905797|OTHER|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
219377550|NCT04905797|DIAGNOSTIC_TEST|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
219377551|NCT04905797|DIAGNOSTIC_TEST|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
219377552|NCT04905797|DIAGNOSTIC_TEST|Intra-Extra Dimensional Set Shift (CANTAB)|"1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
219377553|NCT04905797|DIAGNOSTIC_TEST|Spatial Working Memory Test (CANTAB)|"1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
219377554|NCT04905797|DIAGNOSTIC_TEST|Multitasking Test (CANTAB)|"1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
219377555|NCT04905797|DIAGNOSTIC_TEST|Cambridge Gambling Task Test|"1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
219377556|NCT06583083|DRUG|Sintilimab with P-GEMOX Regimen|Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
219377557|NCT06583083|DRUG|P-GEMOX Regimen|Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
219557833|NCT05435534|OTHER|ActiveFLS intervention|"* A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
219557834|NCT05435534|OTHER|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
219557835|NCT00044876|DRUG|CDB-2914|
219557836|NCT01160640|DRUG|Ceftriaxone|ceftrixone 250mg IM single dose
219557837|NCT01160640|DRUG|Doxycycline|Doxycycline 100 mg PO bid x 14 days
219377558|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
219377559|NCT04440267|DRUG|vincristine|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377560|NCT04440267|DRUG|daunorubicin|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377561|NCT04440267|DRUG|cyclophosphamide|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377562|NCT04440267|DRUG|L-Asparaginase|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377563|NCT04440267|DRUG|prednisone|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377564|NCT04440267|DRUG|mercaptopurine|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377565|NCT04440267|DRUG|methotrexate|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377566|NCT04440267|DRUG|dexamethasone|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377567|NCT04440267|DRUG|Tyrosine kinase inhibitor|acute lymphoblastic leukemia (ALL) -based chemotherapy
219377568|NCT01501487|DRUG|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
219377569|NCT01501487|DRUG|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
219377570|NCT01501487|DRUG|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
219377571|NCT01501487|DRUG|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
219377572|NCT01501487|DRUG|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
219377573|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
219377574|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
219377575|NCT01501487|DRUG|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
219377576|NCT00686556|DRUG|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
219377577|NCT00686556|DRUG|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
219377578|NCT00686556|DRUG|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
219377579|NCT00686556|DRUG|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
219377580|NCT00686556|RADIATION|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
219377581|NCT00686556|PROCEDURE|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
219377582|NCT00686556|BIOLOGICAL|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
219377583|NCT00686556|BIOLOGICAL|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
219377584|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
219377585|NCT02986672|OTHER|Medical Paraffin|2ml per day
219377586|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
219377587|NCT05354960|OTHER|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
219377588|NCT03744650|BEHAVIORAL|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
219377589|NCT01934504|PROCEDURE|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
219377590|NCT01295333|DRUG|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
219377591|NCT01295333|DRUG|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
219377592|NCT02455557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219377593|NCT02455557|DRUG|Montanide ISA 51 VG|Given SC
219377594|NCT02455557|BIOLOGICAL|Sargramostim|Given SC
219377595|NCT02455557|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
219377596|NCT02455557|DRUG|Temozolomide|Given PO or IV
219377597|NCT02210780|DRUG|Dupilumab|Administered via subcutaneous injection.
219377598|NCT02210780|DRUG|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
219377599|NCT06488950|BIOLOGICAL|GC203 TIL(gene-edited TIL) or autologous TILs|the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
219377600|NCT00049127|DRUG|Imatinib Mesylate|Given PO
219377601|NCT00049127|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219377602|NCT00049127|OTHER|Pharmacological Study|Optional correlative studies
219377603|NCT00336102|OTHER|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
219377604|NCT00336102|PROCEDURE|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
219377605|NCT00336102|PROCEDURE|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
219377606|NCT01122927|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
219377607|NCT04836286|BEHAVIORAL|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
219377608|NCT04290637|OTHER|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
219377609|NCT04290637|OTHER|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
219377610|NCT01656525|DRUG|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
219377611|NCT01656525|DRUG|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
219377612|NCT01656525|DRUG|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
219377613|NCT01656525|DRUG|Placebo|subcutaneous doses every 4 weeks for 24 weeks
219557838|NCT01160640|DRUG|Metronidazole|metronidazole 500 mg PO bid x 14 days
219557839|NCT01160640|DRUG|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
219557840|NCT01105182|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
219760888|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
219760889|NCT02626169|DRUG|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
219760890|NCT02626169|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
219760891|NCT02637986|DIETARY_SUPPLEMENT|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
219760892|NCT02637986|OTHER|Placebo - capsule with no active ingredient|2 capsules will be given per day
219377614|NCT06326944|PROCEDURE|Ultrasound- guided Fascia Transversalis plane block|Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia
219377615|NCT06326944|PROCEDURE|Ultrasound-guided Transversus abdominus plane block|the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.
219377616|NCT06326944|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
219377617|NCT06326944|DRUG|Pethidine|Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
219377618|NCT06326944|DRUG|Acetaminophen|patients will be given paracetamol (15 mg /kg/8 hrs ).
219377619|NCT01774448|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
219377620|NCT03592862|DRUG|HTL0018318|Oral capsule
219377621|NCT03592862|DRUG|Placebo|Oral capsule
219377622|NCT02612597|OTHER|Bedrest|
219377623|NCT02612597|OTHER|Exercise Training|
219377624|NCT02747082|PROCEDURE|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
219377625|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
219377626|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
219377627|NCT00278525|DRUG|standard of care|standard of care medication will be given
219377628|NCT00278525|PROCEDURE|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
219377629|NCT02735213|DEVICE|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
219377630|NCT02735213|DEVICE|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
219377631|NCT05616143|DEVICE|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
219377632|NCT03771872|DEVICE|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
219377633|NCT03771872|DEVICE|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
219377634|NCT02277171|DEVICE|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
219377635|NCT00201539|DRUG|single dose Morphine|
219377636|NCT00201539|DRUG|double dose Morphine|
219377637|NCT00201539|DRUG|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
219377638|NCT06172101|OTHER|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
219377639|NCT01676961|BIOLOGICAL|romiplostim|Given SC
219377640|NCT01239927|PROCEDURE|Primary sigmoid resection with end colostomy (Hartmann)|
219377641|NCT01239927|PROCEDURE|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
219377642|NCT05035498|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
219377643|NCT05035498|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
219377644|NCT03582111|OTHER|Study of medical records|Study of medical records
219377645|NCT02498210|OTHER|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
219377646|NCT04003714|DEVICE|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
219377647|NCT04003714|DEVICE|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
219377648|NCT01215084|DRUG|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
219377649|NCT01811914|OTHER|intraoperative TTE|
219377650|NCT02224950|DEVICE|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
219377651|NCT02224950|OTHER|Non-medicated Emollient plus Cotton Sleeve|
219377652|NCT02224950|OTHER|Placebo Sleeve|
219377653|NCT04012255|DRUG|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
219377654|NCT04012255|DRUG|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
219377655|NCT02543242|DEVICE|InToneTM (InControl Medical, LLC) - Medical Device|
219377656|NCT04237493|DRUG|Metformin and Glimepiride (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
219377657|NCT04237493|DRUG|Metformin and Vildagliptin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])"
219377658|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
219377659|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])"
219377660|NCT04237493|DRUG|Metformin and Glimepiride (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
219377661|NCT04237493|DRUG|Metformin and Vildagliptin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])"
219377662|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
219377663|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])"
219377664|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
219377665|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
219377666|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
219377667|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
219377668|NCT00195650|BIOLOGICAL|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
219377669|NCT05653895|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
219377670|NCT05653895|DRUG|Metformin|Metformin
219377671|NCT05653895|COMBINATION_PRODUCT|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
219377672|NCT02602067|COMBINATION_PRODUCT|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
219377673|NCT05564338|DRUG|Sitravatinib|Administered orally
219377674|NCT05564338|DRUG|Tislelizumab|Administered intravenously
219377675|NCT05564338|DRUG|sitravatinib-matching placebo|administered orally
219377676|NCT05564338|DRUG|tislelizumab-matching placebo|administered intravenously
219377677|NCT04824989|BEHAVIORAL|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
219377678|NCT04824989|BEHAVIORAL|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
219377679|NCT04824989|BEHAVIORAL|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
219377680|NCT00312520|DRUG|prednisolone|
219377681|NCT00312520|DRUG|methylprednisolone|
219377682|NCT02886429|DRUG|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
219377683|NCT02886429|DRUG|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
219557841|NCT04993417|OTHER|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
219377684|NCT02950506|DEVICE|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
219377685|NCT02950506|OTHER|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
219377686|NCT02696083|DEVICE|Provant Therapy System|
219377687|NCT00294125|DRUG|Flavocoxid|Daily flavocoxid for 12 weeks
219377688|NCT00294125|DRUG|Placebo|Daily placebo for 12 weeks
219377689|NCT05705726|DEVICE|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
219377690|NCT05705726|DRUG|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
219377691|NCT01420575|BEHAVIORAL|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
219377692|NCT01420575|BEHAVIORAL|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
219377693|NCT04685148|DRUG|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
219377694|NCT04685148|DRUG|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
219377695|NCT00201851|DRUG|Tamoxifen|20 mg po daily x 5 years
219377696|NCT00201851|PROCEDURE|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
219377697|NCT00677261|PROCEDURE|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
219377698|NCT00677261|PROCEDURE|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
219377699|NCT00677261|PROCEDURE|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
219377700|NCT02469246|DRUG|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
219377701|NCT02469246|DRUG|ABC/3TC|600/300 mg FDC tablets administered orally once daily
219377702|NCT02469246|DRUG|ABC/3TC Placebo|Tablets administered orally once daily
219377703|NCT02469246|DRUG|F/TAF Placebo|Tablets administered orally once daily
219377704|NCT02469246|DRUG|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
219377705|NCT03257046|DRUG|ITI-214|Oral
219377706|NCT03257046|OTHER|Placebo|Oral
219377707|NCT00046566|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
219377708|NCT00046566|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
219377709|NCT00046566|BEHAVIORAL|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
219377710|NCT05917743|OTHER|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
219377711|NCT05917743|OTHER|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
219377712|NCT03289689|DEVICE|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
219377713|NCT03094247|DRUG|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
219377714|NCT03094247|DIETARY_SUPPLEMENT|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
219377715|NCT03094247|DIETARY_SUPPLEMENT|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
219377716|NCT03094247|DIETARY_SUPPLEMENT|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
219377717|NCT03035812|DRUG|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
219377718|NCT00636818|DRUG|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
219377719|NCT02557503|DRUG|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
219377720|NCT02756455|OTHER|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
219377721|NCT00074958|BIOLOGICAL|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
219377722|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
219377723|NCT06175624|OTHER|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
219377724|NCT06175624|OTHER|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
219377725|NCT06175624|OTHER|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
219377726|NCT03227874|DIETARY_SUPPLEMENT|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
219377727|NCT03227874|DIETARY_SUPPLEMENT|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
219377728|NCT02835430|PROCEDURE|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
219377729|NCT02835430|PROCEDURE|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
219377730|NCT06080594|BEHAVIORAL|High-intensity exercise training|Eight sessions of high-intensity interval exercise using a single-leg cycle ergometer are conducted on separate days over a 2-week period.
219377731|NCT06278688|DIETARY_SUPPLEMENT|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
219377732|NCT02643095|DEVICE|scleral contact lens|Scleral contact lens
219377733|NCT05785884|BEHAVIORAL|Diet|A 6 week randomized diet
219377734|NCT02553135|BIOLOGICAL|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
219377735|NCT02790489|DIETARY_SUPPLEMENT|Valedia|
219188430|NCT04799184|DRUG|Levobupivacaine 0.25% with epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
219377736|NCT06644989|PROCEDURE|Spencer Technique|Spencer technique on the hip
219377737|NCT06644989|OTHER|Sham (No Treatment)|Spencer technique position but no pressure
219377738|NCT03779438|DRUG|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
219377739|NCT03779438|DRUG|placebo to 17-OHPC|patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
219377740|NCT02107755|BIOLOGICAL|ipilimumab|Given IV
219377741|NCT02107755|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
219377742|NCT02107755|OTHER|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
219377743|NCT06443658|OTHER|Hypertonic saline|Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique
219377744|NCT06443658|DRUG|Isotonic saline|Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
219377745|NCT06443658|OTHER|ELTGOL|Patients from control group will perform the ELTGOL technique twice-daily
219377746|NCT06319300|DEVICE|AI-assisted insulin dose adjustment model|We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
219377747|NCT06319300|OTHER|doctor's insulin dose adjustment|participants' insulin doses are adjusted by doctors
219377748|NCT06582342|PROCEDURE|Three dimensional imaging technology (3D-PANC MSP model)|The processing of the CT images obtained in each center for the creation of the 3D model will be performed centrally by the team of radiologists and computer scientists of the company Cella Medical Solutions. This team will be blinded to the reports of the CT scans.For each patient 4 NCCN check-lists will be filled in without knowing the result of the surgery or the AP study: 2 based on the conventional CT and two based on the 3D-MSP study.
219377749|NCT06582342|PROCEDURE|Computerized tomography group (conventional CT)|A multiphase CT (venous phase and pancreatographic phase) with 1mm thick slices and series of images in coronal, axial and sagittal reconstructions will be performed. This CT model will be performed at disease diagnosis and after completion of neoadjuvant chemotherapy treatment. Both CT scans will be independently reported by a radiologist from the hospital of origin. The preoperative CT scan will also be evaluated a posteriori by a radiologist from the sponsoring center with expertise in PAC. Both reports (the one from the radiologist of the center and the one from the radiologist of the sponsoring center) will be used to fill out the imaging study variables sheet based on the latest version of the NCCN 2022 guidelines. The radiologists will not know the outcome of the surgery or the anatomic pathology study at the time of the completion of the report.
219377750|NCT01658514|DRUG|Met DR|metformin delayed-release tablets
219377751|NCT01658514|DRUG|Met XR|metformin extended-release tablets
219377752|NCT01658514|DRUG|Placebo|
219377753|NCT00797420|DRUG|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
219377754|NCT00797420|DRUG|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
219377755|NCT05426356|DEVICE|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
219377756|NCT05426356|OTHER|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
219377757|NCT00158366|BEHAVIORAL|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
219377758|NCT00158366|BEHAVIORAL|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
219377759|NCT00158366|BEHAVIORAL|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
219377760|NCT00749203|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
219377761|NCT00749203|DRUG|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
219188431|NCT04799184|DRUG|Levobupivacaine 0.25% without epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
219377762|NCT04828824|DRUG|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
219377763|NCT01572155|PROCEDURE|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
219377764|NCT01572155|PROCEDURE|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
219377765|NCT00222079|DRUG|Esomeprazole (Nexium)|
219377766|NCT01677845|RADIATION|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
219377767|NCT00384579|DRUG|Botulinum toxin B|Botulinum Toxin B
219377768|NCT00384579|DRUG|Placebo|Placebo
219377769|NCT03821584|OTHER|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
219377770|NCT00830921|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
219377771|NCT02614209|DEVICE|In Vitro diagnostic tests|Prospective blood collection
219377772|NCT05240144|OTHER|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
219377773|NCT05240144|OTHER|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
219377774|NCT05240144|OTHER|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
219377775|NCT02295202|DEVICE|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
219377776|NCT02295202|DEVICE|Nasal strips|
219377777|NCT04514614|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
219377778|NCT00511303|DRUG|STI571|
219377779|NCT00302393|DRUG|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
219377780|NCT00302393|DRUG|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
219377781|NCT02823457|BEHAVIORAL|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
219377782|NCT02214849|BEHAVIORAL|LATCH Intervention|
219377783|NCT01993979|DRUG|Chemotherapy|
219377784|NCT01993979|OTHER|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
219377785|NCT02509208|DEVICE|SurgiClot haemostatic dressing|haemostatic dressing
219377786|NCT00426673|DRUG|Brivaracetam (ucb34714)|
219377787|NCT04493047|BEHAVIORAL|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
219377788|NCT00284830|DEVICE|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
219377789|NCT02913989|OTHER|Smoking habits characterization|
219377790|NCT00441688|DRUG|GI265235|
219377791|NCT04476264|PROCEDURE|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
219377792|NCT04994925|OTHER|Control ready meal|Supermarket brand lasagne ready meal
219377793|NCT04994925|OTHER|Test ready meal|The Slimming World lasagne ready meal
219377794|NCT01833871|OTHER|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
219377795|NCT01833871|OTHER|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
219377796|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
219377797|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
219377798|NCT00372892|DRUG|Rituximab|375mg/m2 per week for 4 consecutive weeks
219377799|NCT00372892|DRUG|Placebo|Saline IV placebo once per week for 4 consecutive weeks
219377800|NCT04295590|BEHAVIORAL|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
219377801|NCT04295590|BEHAVIORAL|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
219377802|NCT05422092|DRUG|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
219377803|NCT05422092|DRUG|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
219377804|NCT03170830|DIAGNOSTIC_TEST|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
219377805|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
219377806|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
219377807|NCT03339895|OTHER|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
219377808|NCT03339895|OTHER|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
219377809|NCT00211003|DRUG|doripenem|
219377810|NCT00667706|PROCEDURE|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
219377811|NCT00667706|PROCEDURE|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
219377812|NCT02853760|BEHAVIORAL|walking|
219377813|NCT02853760|DEVICE|Treadmill|
219377814|NCT00240435|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
219377815|NCT00240435|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
219377816|NCT04658602|PROCEDURE|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
219377817|NCT00277758|BIOLOGICAL|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
219377818|NCT00277758|DRUG|Ribavirin|Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
219377819|NCT00277758|BIOLOGICAL|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
219377820|NCT00277758|BIOLOGICAL|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
219377821|NCT00277758|DRUG|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
219377822|NCT05872048|DEVICE|periodontal distractor|custom made device from hyrex screw
219377823|NCT02043886|DRUG|Acarbose|Acarbose 50 mg by mouth given during Meal Test
219377824|NCT02043886|DRUG|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
219377825|NCT03333473|BEHAVIORAL|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
219377826|NCT03333473|BEHAVIORAL|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
219377827|NCT00849589|BEHAVIORAL|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
219377828|NCT00849589|BEHAVIORAL|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
219377829|NCT01642212|DRUG|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
219377830|NCT01642212|DRUG|Placebo|
219377831|NCT06028620|BEHAVIORAL|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
219377832|NCT02095301|OTHER|Herbal Beverage|
219377833|NCT01061281|DEVICE|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
219377834|NCT01061281|DEVICE|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
219377835|NCT03097887|PROCEDURE|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
219377836|NCT03097887|DEVICE|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
219377837|NCT03097887|DEVICE|V-Loc|Sewing device to perform the anti-reflux sutures.
219377838|NCT05962008|DIETARY_SUPPLEMENT|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
219377839|NCT05962008|DIETARY_SUPPLEMENT|BioPS® product|Take 4 capsules per day after breakfast with warm water.
219377840|NCT05962008|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules per day after breakfast with warm water.
219377841|NCT01106001|DRUG|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
219377842|NCT01106001|DRUG|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
219377843|NCT01574573|BEHAVIORAL|Self support, group sessions|Self support,group sessions
219377844|NCT00346827|DRUG|Apomorphine Nasal Powder|
219377845|NCT00743704|OTHER|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
219377846|NCT00187590|BEHAVIORAL|Case manager phone call after an ER visit|
219377847|NCT00156663|BEHAVIORAL|Caring for Women Veterans|
219377848|NCT02191748|PROCEDURE|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
219377849|NCT02191748|DRUG|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
219377850|NCT00049348|BIOLOGICAL|epoetin alfa|
219377851|NCT00049348|BIOLOGICAL|filgrastim|
219377852|NCT00049348|DRUG|cisplatin|
219377853|NCT00049348|DRUG|fluorouracil|
219377854|NCT00049348|DRUG|gemcitabine hydrochloride|
219377855|NCT00049348|PROCEDURE|adjuvant therapy|
219377856|NCT00049348|PROCEDURE|conventional surgery|
219377857|NCT00049348|PROCEDURE|neoadjuvant therapy|
219377858|NCT00049348|RADIATION|radiation therapy|
219377859|NCT00123929|DRUG|docetaxel|100 mg/m2 every 3 weeks times 4
219377860|NCT00123929|DRUG|doxorubicin|75 mg/m2 every 3 weeks times 4
219377861|NCT04681261|OTHER|this study is not an intervention study|this study is not an intervention study
219377862|NCT01117376|DRUG|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
219377863|NCT01117376|DRUG|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
219377864|NCT06427109|DIETARY_SUPPLEMENT|Dietary intake of omega-3 fatty acid|Participants were stratified into omega-3 consumption quartiles to assess colorectal adenoma incidence trends
219377865|NCT03205787|DIETARY_SUPPLEMENT|Trifolium pratense|Red Clover extract standardized to isoflavone content.
219377866|NCT00663130|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
219377867|NCT00663130|DRUG|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
219377868|NCT03744689|PROCEDURE|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
219377869|NCT03744689|PROCEDURE|Sham block|Sham block will be done with serum physiologic.
219377870|NCT03744689|DRUG|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
219377871|NCT03744689|DEVICE|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
219377872|NCT00260130|OTHER|food in fluid form|dietary intake of fluid forms of vegetables
219377873|NCT00260130|OTHER|food in solid form|dietary intake of solid forms of vegetables
219377874|NCT05619848|DRUG|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
219377875|NCT04449692|DRUG|Dasiglucagon|Abdominal s.c. administration
219377876|NCT04449692|OTHER|Carbohydrate (dextrose tablets)|Oral administration
219377877|NCT01243268|DRUG|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
219377878|NCT01931514|DRUG|Torrent's Montelukast Sodium chewable Tablets 5mg|
219377879|NCT01931514|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
219377880|NCT03315429|DIAGNOSTIC_TEST|stress echocardiography|stress testing of patients with functional mitral regurgitation
219377881|NCT01042262|OTHER|Oxygen|100% Oxygen at a flow of 2 L/min
219377882|NCT01042262|OTHER|Placebo|No oxygen flow
219377883|NCT03394950|DRUG|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
219188432|NCT03806790|DRUG|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
219377884|NCT03394950|DRUG|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
219377885|NCT01620125|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
219377886|NCT01501643|DEVICE|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
219377887|NCT01501643|DEVICE|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
219377888|NCT01999738|DRUG|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
219377889|NCT00279747|DRUG|meloxicam 0.25 mg/kg|
219377890|NCT00279747|DRUG|meloxicam 0.125 mg/kg|
219377891|NCT00279747|DRUG|naproxen 10 mg/kg|
219377892|NCT00957853|DRUG|Cetuximab|First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
219377893|NCT00957853|DRUG|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
219377894|NCT00957853|PROCEDURE|Surgical tumor resection|Surgical tumor resection on Day 10.
219377895|NCT04519944|DRUG|Edoxaban|This is an observational, prospective study; no treatment will be administered.
219377896|NCT00004980|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
219377897|NCT00004980|DEVICE|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
219377898|NCT05707130|OTHER|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
219377899|NCT05707130|OTHER|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
219377900|NCT00702143|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
219377901|NCT01245244|DRUG|Morphine|Morphine oral mixture
219377902|NCT01245244|OTHER|orange juice|orange juice
219377903|NCT02229773|DRUG|BIBB 1464 MS low dose|
219377904|NCT02229773|DRUG|Placebo|
219377905|NCT02229773|DRUG|Pravastatin|
219377906|NCT02229773|DRUG|BIBB 1464 MS medium dose|
219377907|NCT02229773|DRUG|BIBB 1464 MS high dose|
219377908|NCT02631304|PROCEDURE|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
219377909|NCT02896478|OTHER|No intervention. Only observational study|
219377910|NCT03381443|OTHER|different assessments|coded survey about NTS and assessment
219377911|NCT03671122|DIAGNOSTIC_TEST|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
219377912|NCT03671122|OTHER|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
219377913|NCT03671122|PROCEDURE|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
219377914|NCT04351659|OTHER|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
219377915|NCT02145130|BIOLOGICAL|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
219377916|NCT02145130|BIOLOGICAL|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
219377917|NCT02800174|DEVICE|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
219377918|NCT02800174|DRUG|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
219377919|NCT00655720|OTHER|infant formula|"1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics"
219377920|NCT04472689|DRUG|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
219377921|NCT04472689|DRUG|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
219377922|NCT03577990|BEHAVIORAL|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
219377923|NCT03577990|BEHAVIORAL|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
219377924|NCT04178148|OTHER|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
219377925|NCT00463437|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
219188433|NCT03806790|DRUG|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
219377926|NCT00463437|BIOLOGICAL|Prevenar|Intramuscular injection, 1 dose.
219377927|NCT00463437|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
219377928|NCT00463437|BIOLOGICAL|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
219377929|NCT00463437|BIOLOGICAL|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
219377930|NCT00463437|BIOLOGICAL|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
219377931|NCT00463437|BIOLOGICAL|Meningitec|Intramuscular injection, 1 dose.
219377932|NCT00463437|BIOLOGICAL|NeisVac-C|Intramuscular injection, 1 dose.
219377933|NCT00463437|BIOLOGICAL|Menitorix|Intramuscular injection, 1 dose.
219377934|NCT05052203|OTHER|Exposure of interest: study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes|The primary objective is to study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge
219377935|NCT03694158|DRUG|Dupilumab|anti-IL4 receptor antagonist
219377936|NCT03694158|OTHER|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
219377937|NCT03836144|DIETARY_SUPPLEMENT|Potassium citrate|
219377938|NCT00361530|DRUG|Statin|
219377939|NCT04388384|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
219377940|NCT04266938|BEHAVIORAL|Rapid start of antiretrovirals|Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days
219377941|NCT04266938|BEHAVIORAL|Retrospective analysis|Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.
219377942|NCT04266938|BEHAVIORAL|Non- RAPID start|Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
219377943|NCT06561087|DRUG|Nivolumab|Given by injections
219377944|NCT04990167|DRUG|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
219188434|NCT05123586|DRUG|LY3361237|Administered SC
219188435|NCT05123586|DRUG|Placebo|Administered SC
219377945|NCT05106387|DRUG|Noninterventional|No investigational treatment will be given in this noninterventional extension study
219377946|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
219377947|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
219377948|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
219377949|NCT05979259|OTHER|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
219377950|NCT05979259|OTHER|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
219377951|NCT06581393|DEVICE|Moda-flx Hemodialysis System|All participants will complete up to 4 dialysis treatments on the Moda-flx Hemodialysis System over a period of up to 2 weeks.
219377952|NCT05936580|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
219377953|NCT02758769|BIOLOGICAL|ORENCIA Subcutaneous Injection|
219377954|NCT04451863|DRUG|Low THC|Vaporized THC (5 mg)
219377955|NCT04451863|DRUG|High THC|Vaporized THC (15 mg)
219377956|NCT04451863|DRUG|Low Myrcene|Vaporized Myrcene (0.5 mg)
219377957|NCT04451863|DRUG|High Myrcene|Vaporized Myrcene (12.0 mg)
219377958|NCT04451863|DRUG|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
219377959|NCT04451863|DRUG|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
219377960|NCT04451863|DRUG|Placebo|Vaporized Placebo
219377961|NCT06344130|RADIATION|Radiation Therapy|Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.
219377962|NCT06303505|DRUG|TUB-040|A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
219377963|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
219377964|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
219377965|NCT04996797|DRUG|Tulisokibart|Administered by IV infusion
219377966|NCT04996797|DEVICE|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
219377967|NCT04996797|OTHER|Placebo|Placebo administered by IV infusion
219377968|NCT02793544|DRUG|Fludarabine|"* Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
219377969|NCT02793544|DRUG|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"* Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
219377970|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy on Day -1|"* 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
219377971|NCT02793544|PROCEDURE|Infusion of non-T-cell depleted bone marrow on Day 0|"* On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
219377972|NCT02793544|DRUG|Busulfan|"* Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)"
219377973|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
219760893|NCT03983447|BEHAVIORAL|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers"
219760894|NCT06452693|DRUG|TQA3038 injection/placebo|TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
219760895|NCT06452693|DRUG|Nucleotide drugs Control group|Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
219760896|NCT03461471|BEHAVIORAL|Exercise Intervention|Exercise intervention
219377974|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
219377975|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"* 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
219377976|NCT02793544|DRUG|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"* Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
219377977|NCT02793544|DRUG|Sirolimus|"* Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
219377978|NCT02793544|DRUG|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
219377979|NCT02793544|DRUG|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
219377980|NCT02793544|DRUG|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
219377981|NCT02793544|DRUG|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
219377982|NCT02793544|DRUG|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
219377983|NCT02793544|DRUG|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
219377984|NCT04174599|DRUG|F-627|Day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy
219377985|NCT04174599|DRUG|GRAN®|Since day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy, continuous treatment for ≤ 2 weeks or until ANC recovers to 5.0 × 10\^9/L from nadir (investigators may refer to ANC test results from the Department of Laboratory Medicine of each study sites to decide when to discontinue GRAN®)
219377986|NCT06428045|PROCEDURE|Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)|Participants will be administered MR-guided Laser Interstitial Thermal Therapy (LITT) as a single procedure, following stereotactic needle biopsy.
219377987|NCT06428045|DRUG|Abacavir|Participants will take one 600mg tablet of Abacavir orally once daily, as part of combination antiretroviral therapy (ART).
219377988|NCT06428045|DRUG|Lamivudine|Participants will take one 300mg tablet of Lamivudine orally once daily, as part of combination antiretroviral therapy (ART)
219377989|NCT06428045|DRUG|Ritonavir|"Participants will take one tablet of Ritonavir (RTV) orally twice daily, as part of combination antiretroviral therapy (ART), at one of the following dose levels:~* Dose Level 1: 100mg~* Dose Level 2 (starting dose): 300mg~* Dose Level 3: 400mg~* Dose Level 4: 600mg"
219377990|NCT06428045|DRUG|Temozolomide|Participants will take Temozolomide (TMZ) via capsule orally, during and after focal radiotherapy, as part of standard of care adjuvant therapy. During focal radiotherapy, Temozolomide will be administered at a dose of 75 mg/m2 once daily for six weeks (42 days) on a continuous dosing regimen, including weekends and holidays. After completion of focal radiotherapy, Temozolomide will be administered at 150 mg/m\^2 on days 1 through 5 of Cycle 1, and at 200 mg/m\^2 on days 1 through 5 of Cycles 2 through 6, for a total of six 28-day cycles of maintenance therapy.
219377991|NCT06428045|RADIATION|Focal Radiotherapy|Participants will be administered focal radiotherapy for six weeks (42 days), as part of adjuvant therapy, at a total dose of 50-60 grays (Gy) in 1.8-2.0 Gy fractions, depending on prognosis and as determined by the treating radiation oncologist.
219377992|NCT05259566|BEHAVIORAL|menthol ban in cigarettes only|menthol ban in cigarettes only, menthol available in e-cigarette
219377993|NCT05259566|BEHAVIORAL|total menthol ban|menthol ban in both cigarettes and e-cigarettes
219377994|NCT06348355|DRUG|[11C]savolitinib|Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration
219377995|NCT06348355|DRUG|Savolitinib|IMP; 300 mg tablet, oral single administration
219377996|NCT06567327|DRUG|Danuglipron|Danuglipron oral tablets
219377997|NCT06567327|DRUG|Atorvastatin|Atorvastatin oral tablets
219377998|NCT06567327|DRUG|Rosuvastatin|Rosuvastatin oral tablets
219377999|NCT05090345|OTHER|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
219378000|NCT06090552|BEHAVIORAL|Letter|Letter about ACP
219378001|NCT06090552|BEHAVIORAL|AD|PREPARE advanced directive (AD)
219378002|NCT06090552|BEHAVIORAL|PREPARE website|PREPARE website
219378003|NCT06090552|BEHAVIORAL|reminders|reminders to complete the advance directive
219378004|NCT06090552|BEHAVIORAL|healthcare navigator|healthcare navigators provide assistance to complete the advance directive
219378005|NCT06471205|DRUG|BL-B01D1|Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
219378006|NCT06471205|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
219378007|NCT04714086|DRUG|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
219378008|NCT05638568|DIAGNOSTIC_TEST|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
219378009|NCT04680650|DRUG|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
219378010|NCT04680650|DRUG|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
219378011|NCT00363961|BEHAVIORAL|Resistance exercise|resistance exercise vs sham comparison
219378012|NCT00217633|PROCEDURE|Conventional Surgery|
219378013|NCT04888611|BIOLOGICAL|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
219378014|NCT04888611|BIOLOGICAL|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
219378015|NCT03399383|OTHER|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
219378016|NCT03437187|PROCEDURE|Cholecystectomy|Laparoscopic technique
219378017|NCT01639820|PROCEDURE|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
219378018|NCT01639820|PROCEDURE|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
219378019|NCT06159114|DRUG|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
219378020|NCT06159114|DRUG|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
219378021|NCT06159114|DRUG|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
219378022|NCT06159114|DRUG|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
219378023|NCT04222023|DRUG|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
219378024|NCT05922553|BEHAVIORAL|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
219378025|NCT05922553|BEHAVIORAL|General short videos|Short videos that don't contain any food cues.
219378026|NCT05425459|DEVICE|Corvia Atrial Shunt System / IASD System II|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
219378027|NCT05425459|OTHER|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
219378028|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（low dose）
219378029|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（high dose）
219378030|NCT04863885|DRUG|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
219378031|NCT04863885|DRUG|Nivolumab|Participants will receive Nivoumab 1mg/kg
219378032|NCT04863885|DRUG|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
219378033|NCT06645509|DRUG|TTB gel (dose 1)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
219378034|NCT06645509|DRUG|TTB gel (dose 2)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
219378035|NCT06645509|DRUG|Placebo|A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
219378036|NCT05692830|DRUG|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
219378037|NCT06645756|OTHER|Test meal|Test meal consisting of fries, chicken nuggets and eggs
219378038|NCT06217783|DEVICE|Introcan Safety IV Catheter|Given by IV
219378039|NCT05332769|GENETIC|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
219378040|NCT00646659|BIOLOGICAL|cetuximab|
219378041|NCT00646659|DRUG|carboplatin|
219378042|NCT00646659|DRUG|cisplatin|
219378043|NCT00646659|DRUG|docetaxel|
219378044|NCT00646659|DRUG|fluorouracil|
219378045|NCT00646659|GENETIC|fluorescence in situ hybridization|
219378046|NCT00646659|GENETIC|molecular genetic technique|
219378047|NCT00646659|GENETIC|reverse transcriptase-polymerase chain reaction|
219378048|NCT00646659|OTHER|immunoenzyme technique|
219378049|NCT00646659|OTHER|immunohistochemistry staining method|
219378050|NCT00646659|OTHER|laboratory biomarker analysis|
219378051|NCT00646659|PROCEDURE|biopsy|
219378052|NCT00646659|RADIATION|3-dimensional conformal radiation therapy|
219378053|NCT00646659|RADIATION|intensity-modulated radiation therapy|
219378054|NCT01016626|DRUG|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
219378055|NCT01016626|DRUG|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
219378056|NCT00100048|DRUG|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
219378057|NCT00100048|DRUG|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
219378058|NCT00100048|DRUG|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
219378059|NCT00100048|DRUG|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
219378060|NCT00100048|DRUG|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
219378061|NCT00100048|DRUG|Placebo monotherapy|Placebo to MK0518 twice daily
219378062|NCT04034017|OTHER|no intervention|descriptive study, no intervention
219378063|NCT03878485|DEVICE|MRIdian Linac System from ViewRay|"* 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
219378064|NCT03878485|RADIATION|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
219378065|NCT01822561|DRUG|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
219378066|NCT01054066|BEHAVIORAL|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
219378067|NCT04992988|DRUG|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
219378068|NCT01624142|BIOLOGICAL|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
219378069|NCT00879450|OTHER|Booklet|booklet given to parents for home exercises
219378070|NCT01006343|OTHER|Higher Protein (HP)|
219378071|NCT01006343|OTHER|Lower Protein (LP)|
219378072|NCT00900003|GENETIC|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
219378073|NCT00900003|OTHER|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
219378074|NCT05807308|BEHAVIORAL|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
219378075|NCT04116099|OTHER|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
219378076|NCT04116099|DEVICE|Flexitouch Plus|Flexitouch Plus treatment.
219378077|NCT04230109|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)
219378078|NCT04230109|DRUG|Pembrolizumab|Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
219378079|NCT06107192|OTHER|Dietary intervention - apple catechin diet|The intervention will provide a catechin-containing apple juice, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
219378080|NCT06107192|OTHER|Dietary intervention - low catechin diet|The intervention will provide a nutritionally-matched beverage without catechins, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
219378081|NCT03991637|DEVICE|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
219378082|NCT05088148|OTHER|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
219378083|NCT06584591|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
219378084|NCT06584591|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
219378085|NCT05350150|DEVICE|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
219378086|NCT06665074|BIOLOGICAL|Endotoxin (E. coli O:113, Reference Endotoxin)|Dosage of endotoxin is 0.8 ng/Kg body Weight
219378087|NCT06665074|OTHER|Saline (Placebo)|Volume of saline to be the same as volume of endotoxin
219378088|NCT04870424|DRUG|Colchicine|Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.
219378089|NCT04870424|DRUG|Placebo|Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
219378090|NCT06974396|BIOLOGICAL|Prothrombin time|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
219378091|NCT06466733|PROCEDURE|Embolization of the middle meningeal artery|Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.
219378092|NCT06466733|PROCEDURE|Surgical Evacuation via burr hole or craniotomy|The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.
219378093|NCT06667843|BEHAVIORAL|Lifestyle Management|Behavioral intervention for lifestyle change
219378094|NCT06667843|DEVICE|Intervention|Full access to DTx function in the app, and digital follow up/communication with helthcare professionals at the Healthy Lives Center
219378095|NCT06667843|DEVICE|Control|Basic access to the app (daily logging functions). No digital follow up or communication with healthcare professionals at the Healthy Lives Center.
219378096|NCT06265558|PROCEDURE|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
219378097|NCT06265558|PROCEDURE|Dressing|Fatty dressing or hydrocellular dressing
219378098|NCT04828226|DRUG|Clonidine|Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
219378099|NCT04828226|DRUG|Placebo|Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
219378100|NCT05293249|COMBINATION_PRODUCT|dMAb AZD5396|Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
219378101|NCT05293249|COMBINATION_PRODUCT|dMAb AZD8076|Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
219378102|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
219378103|NCT05293249|DRUG|Hylenex|Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
219378104|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
219378105|NCT05723484|DEVICE|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
219378106|NCT00656890|BIOLOGICAL|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
219378107|NCT00656890|BIOLOGICAL|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
219378108|NCT03726775|DRUG|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
219378109|NCT06459674|DEVICE|PrO2 Fit (IMT Trainer)|The device is used four times a week over a period of 8 weeks.
219378110|NCT04447053|DRUG|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
219378111|NCT05366309|OTHER|Tailored education|Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
219378112|NCT05366309|OTHER|Standard care education|Participants randomised to this group will receive usual care in terms of their education.
219378113|NCT01281176|DRUG|Carboplatin|Given IV
219378114|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
219378115|NCT01281176|DRUG|Paclitaxel|Given IV
219188436|NCT06201884|DEVICE|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
219188437|NCT05797857|OTHER|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
219378116|NCT01281176|OTHER|Pharmacological Study|Correlative studies
219378117|NCT01281176|DRUG|Vorinostat|Given PO
219188438|NCT04929496|PROCEDURE|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
219188439|NCT06384222|DRUG|Abiraterone acetate|Given orally
219378118|NCT02527213|DRUG|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
219378119|NCT02527213|DRUG|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
219378120|NCT06975735|PROCEDURE|TAP Plane Block|The transversus abdominis plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
219378121|NCT06975735|PROCEDURE|TFP Block|The transversalis fascia plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
219378122|NCT03267524|BEHAVIORAL|Exercise Intervention|Receive Walking for Recovery from Surgery prehabilitation intervention
219378123|NCT03267524|OTHER|Quality-of-Life Assessment|Ancillary studies
219378124|NCT03267524|OTHER|Survey Administration|Ancillary studies
219378125|NCT06973837|OTHER|Real-life monitoring, experimental pain testing, brain imaging, blood and stool sampling.|See detailed study description and outcome measures.
219378126|NCT05167227|OTHER|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
219378127|NCT06376422|PROCEDURE|Spongioflex®|partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.
219378128|NCT06376422|OTHER|non-operated|no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
219378129|NCT04524585|DRUG|Neuromuscular blockade|Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
219378130|NCT00697996|DRUG|Rituximab for transplant rejection|
219378131|NCT03011645|DRUG|Ziprasidone|Given by mouth, single dose of 60 mg.
219378132|NCT03011645|DRUG|Lorcaserin|Given by mouth, single dose of 20 mg.
219378133|NCT03011645|DRUG|Placebo Oral Tablet|Given by mouth, single dose.
219378134|NCT02954380|DEVICE|Zio|long term continuous monitoring
219378135|NCT02740309|BEHAVIORAL|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
219378136|NCT02740309|BEHAVIORAL|Treatment as usual|Facilitated community referral for mental health treatment
219378137|NCT01696357|DEVICE|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
219378138|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219378139|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219378140|NCT04826900|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
219378141|NCT04826900|OTHER|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
219557842|NCT04993417|OTHER|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
219188440|NCT06384222|DRUG|Prednisone|Given orally
219188441|NCT06384222|DRUG|Hyperpolarized [1-13C] pyruvate (HP 13C)|Given IV
219188442|NCT06384222|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
219188443|NCT06384222|PROCEDURE|Non-investigational radical prostatectomy (RP)|Planned, standard of care surgical procedure occurring outside of this study.
219378142|NCT04826900|OTHER|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
219378143|NCT04826900|OTHER|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
219378144|NCT04320836|PROCEDURE|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
219378145|NCT03772912|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
219378146|NCT00202592|DRUG|Perindopril|
219378147|NCT04699630|DRUG|U3-1402|All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
219378148|NCT02348073|DRUG|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
219378149|NCT02348073|DRUG|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
219378150|NCT03947229|DRUG|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
219378151|NCT03947229|DRUG|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
219378152|NCT06581484|BEHAVIORAL|Digital patient empowerment intervention|The intervention has features such as a digital medical passport, updated health-related information, community support and patient/peer stories and advice
219378153|NCT03746470|PROCEDURE|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
219378154|NCT03746470|PROCEDURE|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
219000949|NCT00664872|OTHER|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
219378155|NCT06314243|DIETARY_SUPPLEMENT|"Pumpkin Seed Oil  Ronkin®, KMT PHARMA, Egypt. "|Ronkin soft gelatin capsules, each containing 1010 mg of pumpkin seed oil (Latin name: Curcurbita pepo), standardized to contain palmitic acid (8-15%), stearic acid (3-8%), oleic acid (15-35%), linoleic acid (40-65%), and other fatty acids (≤ 2.4%)
219378156|NCT01357811|DRUG|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
219378157|NCT01357811|DRUG|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
219378158|NCT05131607|PROCEDURE|Supine MRI|After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
219378159|NCT03372941|DRUG|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
219378160|NCT00741819|DRUG|Inhaled treprostinil|
219378161|NCT02804360|DEVICE|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
219378162|NCT01921998|PROCEDURE|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
219557843|NCT00996697|DRUG|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
219557844|NCT00996697|DRUG|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
219378163|NCT06273969|OTHER|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
219378164|NCT01126580|DRUG|Metformin|
219378165|NCT01126580|DRUG|LY2189265|
219378166|NCT01126580|DRUG|Placebo (oral)|
219378167|NCT01126580|DRUG|Placebo (subcutaneous)|
219378168|NCT00877344|PROCEDURE|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
219378169|NCT00877344|PROCEDURE|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
219378170|NCT02550899|PROCEDURE|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
219378171|NCT02550899|PROCEDURE|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
219378172|NCT02550899|PROCEDURE|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
219378173|NCT03461055|OTHER|Lavender|Lavender aromatherapy
219378174|NCT03461055|OTHER|Water|Water
219378175|NCT00686543|DRUG|Posaconazole|Posaconazole will be used for prophylaxis
219378176|NCT00926926|DRUG|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
219378177|NCT00926926|DRUG|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
219378178|NCT06247969|DEVICE|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
219378179|NCT00609622|DRUG|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
219378180|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
219378181|NCT00609622|DRUG|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
219378182|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
219378183|NCT02221609|OTHER|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
219378184|NCT02221609|OTHER|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
219378185|NCT02770157|DRUG|DA-3002|
219378186|NCT02770157|DRUG|Genotropin®|
219378187|NCT01696461|DRUG|Plerixafor|
219378188|NCT02631720|PROCEDURE|Blood Draw|
219378189|NCT02631720|PROCEDURE|Bronchoscopy|
219378190|NCT01708057|DRUG|AZD8683|AZD8683 administered via inhalation
219000950|NCT00664872|BEHAVIORAL|case management|
219378191|NCT01708057|DRUG|Placebo|Placebo administered via inhalation
219378192|NCT01708057|DRUG|Tiotropium|Tiotropium administered via inhalation
219378193|NCT05646810|DIAGNOSTIC_TEST|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
219378194|NCT05646810|DIAGNOSTIC_TEST|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
219378195|NCT03184948|DEVICE|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
219378196|NCT02288637|OTHER|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
219378197|NCT02288637|OTHER|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
219378198|NCT02288637|OTHER|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
219378199|NCT02504255|BIOLOGICAL|Biological samplings|Blood, urine and faecal sampling every 3 months
219378200|NCT02504255|OTHER|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
219378201|NCT04740411|BEHAVIORAL|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
219378202|NCT04095520|PROCEDURE|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
219378203|NCT04095520|PROCEDURE|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
219378204|NCT05718362|BEHAVIORAL|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
219378205|NCT05718362|BEHAVIORAL|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
219378206|NCT00682630|DRUG|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
219378207|NCT00682630|DRUG|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
219378208|NCT04635176|DRUG|Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)|real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
219378209|NCT04635176|DRUG|Sham iPACK block with 20ml normal saline|Sham iPACK block with 20 ml Normal saline
219378210|NCT04769557|DRUG|paracetamol|tablet paracetamol 500 mg
219378211|NCT04769557|DRUG|Placebo|placebo
219378212|NCT00843570|DRUG|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
219378213|NCT03941002|DIAGNOSTIC_TEST|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
219378214|NCT03880877|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
219378215|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
219378216|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
219378217|NCT03880877|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
219378218|NCT03880877|DRUG|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
219378219|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
219378220|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
219378221|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
219378222|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
219378223|NCT00947349|DRUG|BI 201335 NA low placebo|Placebo
219378224|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
219378225|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
219378226|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
219000951|NCT01927237|OTHER|HLR|
219000952|NCT01927237|OTHER|EHR|
219378227|NCT00947349|DRUG|BI 201335 NA low|BI 201335 NA
219378228|NCT00947349|DRUG|BI 201335 NA high placebo|placebo
219378229|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
219378230|NCT00947349|DRUG|Placebo|
219378231|NCT06201143|OTHER|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
219378232|NCT06201143|OTHER|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
219378233|NCT00794586|DRUG|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
219378234|NCT00794586|DRUG|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
219378235|NCT03354845|OTHER|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
219378236|NCT00538681|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
219378237|NCT00538681|DRUG|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
219378238|NCT00538681|DRUG|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
219378239|NCT00538681|DRUG|placebo|po, QD
219378240|NCT02970929|DRUG|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
219378241|NCT01798303|DRUG|LY2940094|Administered orally
219378242|NCT01798303|DRUG|Placebo|Administered orally
219378243|NCT00291343|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
219378244|NCT00291343|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
219378245|NCT00291343|BIOLOGICAL|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
219378246|NCT01209715|DRUG|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
219378247|NCT01209715|DRUG|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
219378248|NCT03895138|OTHER|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
219378249|NCT03895138|OTHER|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
219378250|NCT00302640|DRUG|Alinia (nitazoxanide)|
219378251|NCT03321799|DEVICE|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
219378252|NCT03321799|DEVICE|Sterile Antimicrobial Dressings|Control group, current hospital standard.
219378253|NCT02812004|DEVICE|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
219378254|NCT05422976|DEVICE|EVI-01|High molecular weight Hyaluronic Acid
219378255|NCT04407169|OTHER|no intervention|There will be no intervention. It is only an observationnal study
219378256|NCT03987945|DEVICE|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
219378257|NCT00977652|PROCEDURE|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
219378258|NCT00977652|PROCEDURE|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
219378259|NCT01511757|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
219378260|NCT01511757|DRUG|Fluconazole|fluconazole 200 mg
219378261|NCT02168582|BEHAVIORAL|physiotherapy as usual in primary care|
219378262|NCT03376633|BEHAVIORAL|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
219378263|NCT01245647|DRUG|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
219378264|NCT01245647|OTHER|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
219378265|NCT04416022|DIAGNOSTIC_TEST|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
219378266|NCT00342355|DRUG|Zidovudine|600 mg once daily
219378267|NCT00342355|DRUG|Stavudine|40 mg once daily
219378268|NCT00342355|DRUG|Didanosine|\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
219378269|NCT00342355|DRUG|Lamivudine|300 mg once daily
219378270|NCT00342355|DRUG|Efavirenz|600 mg once daily
219378271|NCT00342355|DRUG|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
219378272|NCT03929250|DRUG|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
219378273|NCT03929250|DRUG|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
219378274|NCT03072602|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
219378275|NCT03072602|OTHER|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
219378276|NCT05843214|OTHER|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
219378277|NCT00482716|BIOLOGICAL|epoetin alfa|
219378278|NCT00482716|BIOLOGICAL|epoetin beta|
219378279|NCT00482716|DIETARY_SUPPLEMENT|iron dextran complex|
219378280|NCT00482716|DIETARY_SUPPLEMENT|iron sucrose injection|
219378281|NCT06653621|DRUG|Bupivacaine liposome|Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
219378282|NCT06653621|PROCEDURE|Nerve block mode : adductor block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
219378283|NCT06653621|DRUG|Bupivacaine|Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
219378284|NCT06653621|PROCEDURE|Nerve block mode: femoral triangle block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
219378285|NCT03912584|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
219378286|NCT03912584|DEVICE|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
219378287|NCT01236391|DRUG|PCI-32765|560 mg daily
219378288|NCT05242887|DIAGNOSTIC_TEST|Delirium screening using 3D-CAM and UB-CAM|Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.
219378289|NCT04321343|DRUG|PXL065|PXL065 oral tablet
219378290|NCT04321343|DRUG|Placebo oral tablet|Placebo oral tablet
219378291|NCT04792294|DEVICE|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
219378292|NCT05003362|BEHAVIORAL|ACT|mindfulness intervention for patients with pain/migraine
219378293|NCT02691000|DEVICE|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
219000953|NCT03825315|BIOLOGICAL|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
219378294|NCT02691000|DEVICE|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
219378295|NCT06249529|DEVICE|Airway Bypass|Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
219378296|NCT05462093|DEVICE|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
219378297|NCT05462093|DEVICE|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
219378298|NCT05462093|DEVICE|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
219378299|NCT03399461|OTHER|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
219378300|NCT03399461|OTHER|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
219378301|NCT03399461|OTHER|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
219378302|NCT03399461|OTHER|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
219378303|NCT03399461|OTHER|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
219378304|NCT02643550|BIOLOGICAL|Monalizumab|
219378305|NCT02643550|BIOLOGICAL|Cetuximab|
219378306|NCT02643550|BIOLOGICAL|Anti-PD(L)1|
219378307|NCT04194944|DRUG|Selpercatinib|Administered orally
219378308|NCT04194944|DRUG|Carboplatin|Administered IV
219378309|NCT04194944|DRUG|Cisplatin|Administered IV
219378310|NCT04194944|DRUG|Pemetrexed|Administered IV
219378311|NCT04194944|DRUG|Pembrolizumab|Administered IV
219378312|NCT03614247|PROCEDURE|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
219378313|NCT03614247|PROCEDURE|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
219378314|NCT03614247|PROCEDURE|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
219378315|NCT03614247|PROCEDURE|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
219378316|NCT03614247|PROCEDURE|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
219378317|NCT06732466|DRUG|Chlorhexidine toothpaste|A toothpaste containing 0.3% chlorhexidine + 3% AmCl
219378318|NCT06732466|DEVICE|Toothbrush|Commercially available adult soft bristle toothbrush
219378319|NCT06732466|DRUG|Placebo toothpaste without chlorhexidine and AmCl|Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.
219378320|NCT06162624|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
219378321|NCT06162624|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|As control condition, reflective journaling will be used.
219378322|NCT07094776|OTHER|No intervention (observational study)|This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.
219378323|NCT07107724|OTHER|Noradrenalin|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
219378324|NCT07107724|OTHER|Fluid bolus|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
219378325|NCT07106567|BEHAVIORAL|Mediterranean diet education|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months). The intervention group will be trained on the Mediterranean Diet at the first meeting.
219378326|NCT07106567|OTHER|Control|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months).
219378327|NCT07106840|OTHER|No intervention (observational study)|This is an observational study with no intervention applied.
219378328|NCT07106749|BIOLOGICAL|CD180 CART|Subjects screened to meet the requirements for CD180 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to CD180 CART infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of CD180 CART must be performed 24 hours after completion of chemotherapy preconditioning. CD180 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
219378329|NCT07106918|BIOLOGICAL|SIBP-A16 injection|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
219378330|NCT07106918|BIOLOGICAL|Nirsevimab|Single administration via intramuscular.
219378331|NCT07106918|OTHER|SIBP-A16 buffer solution|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
219378332|NCT07106736|BIOLOGICAL|BCMA CAR-T|Patients will receive single-dose infusion of autologous BCMA-directed CAR-T cellsBCMA CAR-T single dose (3.0 x 10\^6 cells /kg).
219378333|NCT07106736|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion.
219378335|NCT07107178|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
219378336|NCT07106307|OTHER|Bioceramic Sealer|This intervention involves the use of Bioceramic Sealer during root canal obturation. The sealer will be combined with the cold lateral compaction or warm vertical compaction technique depending on the study arm.
219378337|NCT07106307|PROCEDURE|Warm Vertical Compaction|Warm vertical obturation is performed using a heat delivery device, which thermosoftens gutta-percha and allows vertical compaction into the root canal system. This technique will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
219378338|NCT07106307|OTHER|Epoxy Resin-Based Sealer|This intervention involves the use of an epoxy resin-based root canal sealer during root canal obturation. The material will be applied in combination with either cold lateral compaction or warm vertical compaction techniques, depending on the study group.
219378339|NCT07106307|PROCEDURE|Cold Lateral Compaction|Cold lateral compaction is a root canal obturation technique in which a master gutta-percha cone is placed to working length and compacted laterally using a finger spreader. This method will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
219378340|NCT06233331|DRUG|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
219378341|NCT06233331|DRUG|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
219378342|NCT06233331|DRUG|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
219378343|NCT06233331|PROCEDURE|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
219378344|NCT07107165|BEHAVIORAL|Dyadic Problem Solving Training|DPST consists of teaching the patient and family caregiver problem-solving skills that they can apply to help them manage the medical regimen after stem cell transplant.
219378345|NCT07107165|BEHAVIORAL|Supportive Care|Supportive Care consists of providing support to the patient and family caregiver as they manage the medical regimen after stem cell transplant
219378346|NCT07107880|OTHER|Communication Assessment through AI and Human|Participants will remotely engage in an AI-generated simulation that presents an voice-based conversation with a simulated parent of a pediatric patient. The scenario involves discussing a clinical scenario concerning their child. Following the simulation, the participant's communication skills will be assessed using an artificial intelligence (AI) system trained to evaluate the key aspects of communication using standardized rating scales. In addition, two human evaluators will assess the participant's communication skills using the same rating scales.
219378347|NCT07107373|DRUG|Mavacamten|According to the product label
219378348|NCT07106931|OTHER|This is an observational study with no intervention|This is an observational study with no intervention
219378349|NCT07108062|OTHER|Experimental|(lifestyle + dietary advice)
219378350|NCT07108062|OTHER|Placebo|No intervention
219378351|NCT07106112|PROCEDURE|Ultrasound-guided carbon suspension (Black Eye) injection|"Under ultrasound guidance, 0.5 mL of sterile carbon particle suspension (Black Eye) is injected into the capsule of the metastatic axillary lymph node(s).~Technique: Performed using a high-frequency linear ultrasound probe (e.g., 12 MHz) and a 22G needle.~Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of neoadjuvant systemic therapy (NST).~Rationale:~Carbon suspension provides long-term visual localization due to its black staining properties.~Inert and biocompatible, with minimal risk of allergic reactions. Patients proceed to standard NST based on tumor subtype (chemotherapy, targeted therapy, or endocrine therapy).~Post-NST imaging (ultrasound, CT, or PET-CT) to assess treatment response.~Surgical Intervention:~Targeted axillary dissection (TAD) with removal of marked nodes + sentinel lymph node biopsy (SLNB) using fluorescent dye.~Intraoperative frozen section analysis (hematoxylin \& eosin staining) of excised nodes."
219378352|NCT07106112|PROCEDURE|Ultrasound-guided metallic marker (TWIRL ULTRACOR) placement|"A 4-mm nitinol (nickel-titanium alloy) marker (TWIRL ULTRACOR) is deployed into the metastatic lymph node(s) under ultrasound guidance.~Technique: Uses a specialized introducer kit for precise placement. Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of NST.~Rationale:~Nitinol markers are radiopaque, MRI-compatible, and resistant to migration. Standard method for tumor localization in breast cancer.~Post-Marking Protocol:~Identical NST and imaging follow-up as Group 1.~Surgical Intervention:~TAD with marker localization (palpation/imaging-guided excision) + SLNB. Intraoperative frozen section analysis."
219378353|NCT07108179|DEVICE|Continuous Glucose Monitoring (CGM) System|Continuous Glucose Monitoring (CGM) System
219378354|NCT07106723|DRUG|ASCT+CD7-CART|Intravenous infusion of CD7-CART 3 days after ASCT
219378355|NCT07107438|OTHER|The interventional group will be trained on ECG interpretation through thinqi digital interactive platform|The conventional group will be trained on ECG interpretation through handout exercises
219557845|NCT03433404|PROCEDURE|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
219760897|NCT02266563|DRUG|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
219760898|NCT02266563|DRUG|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
219760899|NCT00888537|OTHER|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
219378356|NCT07106164|PROCEDURE|total body massage|Massage was done using the Field's Technique after starting phototherapy till discontinuation of phototherapy for 15 - 20 minutes, three times daily 1 hour after the morning, mid- day feeds and at night.
219378357|NCT07106164|DEVICE|photo therapy|neonates received phototherapy for the neonatal hyperbilirubinemia
219378358|NCT07106827|DRUG|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks
219378359|NCT07107308|DEVICE|Microfocused Ultrasound|Before treatment, clean the treatment area, mark the treatment zone, and evenly apply a layer of ultrasound coupling agent about the thickness of a coin on the treatment area. The patient's face was treated with S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0 and P4.5 treatment heads respectively. After the treatment, the face was cleaned and a medical mask was applied for 15 minutes. After the treatment, attention was paid to moisturizing and sun protection.
219378360|NCT07107308|DEVICE|Erbium-Doped Fiber Laser|Doctors and patients wear corresponding protective glasses. Apply cold gel to the treatment area on the patient's face and select certain treatment parameters based on the patient's skin lesion condition and skin type. After the treatment, clean your face. Decide whether to apply ice based on the severity of the skin lesion reaction. If ice application is necessary, the regular ice application time is 15 to 30 minutes, and apply a medical mask for 15 minutes. After the treatment, pay attention to moisturizing and sun protection.
219378361|NCT07105943|OTHER|Control|"The intervention will be implemented in the 8 weeks phase 2 cardiac rehabilitation program.~Both groups will receive a pre-exercise evaluation and 16 individualized training sessions (two per week) based on FITT-VP principles and according to the European Association of Preventive Cardiology (EAPC) guidelines. A complementary physical activity program integrated into their daily life will be prescribed. It will receive regular briefing sessions regarding the health-related benefits of exercise. After these sessions, it will be recommended to maintain physical activity aiming to reach at least 150 min/week of moderate intensity PA."
219378362|NCT07105943|OTHER|Experimental|As for the experimental group, in the 16 individualized training sessions (two per week), attention will be given to exercise intensity assessment and manipulation, with the goal of optimizing the affective experience of exercise, while also respecting minimum and maximum intensity thresholds as proposed by the EAPC (self-selected intensity within individually defined limits). The pre-exercise evaluation, the number of sessions, and methodological approach will be the same to the control group. In this group it will be presented some awareness of the potential of choosing fun and pleasant activities.
219378363|NCT07107620|DIAGNOSTIC_TEST|one task|Single task tests consist of measuring walking times with normal walking (easy), walking with a 50% reduction in the base of support measured between the medial malleoli (medium difficulty) and tandem walking (difficult) tasks while applying the 10 meter walk test and time up go tests.
219378364|NCT07107620|DIAGNOSTIC_TEST|dual task|Dual task consists of single task plus tests of carrying glasses of water or counting backwards from a given number.
219378365|NCT07108023|OTHER|No intervention (Observational Study)|This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only
219378366|NCT07107503|PROCEDURE|Radiofrequency ablation alone|RFA was performed by four US physicians with ≥ 10 years of experience in in-terventional US. Before ablation, the patients were placed in the supine position with the neck extended, and local anesthesia was administered with lidocaine (1%). RFAs were performed using the hydro-dissection, trans-isthmic and moving-shot techniques according to previously published guidelines. Ablation was terminated when the target tumor changed to a transient hyperechoic zone. Contrast-enhanced US (CEUS) was performed immediately after ablation to evaluate the ablation area. The presence of complications during or after thermal ablation and corresponding treatments was carefully evaluated. All patients were closely observed for 1-2 h after ablation in the hospital.
219378367|NCT07107503|PROCEDURE|surgical resection|SR was performed under general anesthesia by surgeons with\>15 years of expe-rience in thyroid surgery. The decision to perform total thyroidectomy or lobectomy was made by individual surgeons and patients, based on patient preferences in consu
219378368|NCT07105800|BEHAVIORAL|Music-based dance|The dance routines emphasized perceptual-motor training through mutual physical guidance, spatial coordination, and social interaction among participants. The intervention aimed to enhance executive function, balance, and lower limb mobility by incorporating dual-task elements that challenge memory, attention, and physical control in a dynamic, enjoyable setting.
219378369|NCT07105800|BEHAVIORAL|Control|The training content is delivered through standardized, non-musical instructional videos. Participants in the control group follow fixed video demonstrations to perform functional lower limb exercises. The movement components include independent lower limb strength training and balance training.
219378370|NCT07107451|DIETARY_SUPPLEMENT|OIT with low dose sesame protein|"After 8 months of continued low-dose sesame OIT, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to evaluate desensitization.~Patients who had a negative OFC after 3 months in the initial phase of the study-and thus confirmed desensitization-will skip the pre-break OFC and proceed directly to the next stage.~Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to assess sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed at this visit."
219557846|NCT03433404|PROCEDURE|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
219557847|NCT00642811|DRUG|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
219000954|NCT03825315|BIOLOGICAL|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
219378371|NCT07106047|BEHAVIORAL|Nurse-Led Climate-Responsive Asthma Management Program|A structured behavioral intervention delivered by trained nurses, focusing on climate-adapted asthma self-management for older adults. The program includes personalized coaching on symptom monitoring, environmental risk response, inhaler technique, and safe physical activity planning during climate stress events. Intervention is delivered weekly over 12 weeks through a combination of phone and in-person sessions, supported by tools such as symptom diaries, air quality alerts, and peak flow meters.
219378372|NCT07105553|DEVICE|Surgical Glove Compression|Participants wore two tight-fitting surgical gloves (one size smaller than standard) on the non-dominant hand. The gloves were applied 30 minutes prior to each paclitaxel infusion, remained in place during the infusion, and were removed 30 minutes afterward. The dominant hand remained ungloved and served as an internal control. This intervention was entirely non-pharmacologic and was integrated into routine chemotherapy sessions.
219378373|NCT07107100|OTHER|a silicon jig/key is used to place/bond fixed retainer on teeth|a silicon jig/key is used to place/bond fixed retainer on teeth
219378374|NCT07107022|DEVICE|Penumbra System ®|Neurovacular Mechanical Thrombectomy with the Penumbra System®
219378375|NCT07105774|BEHAVIORAL|stress inoculation training program|The intervention group received the SIT program for 12 weeks. From 1st-2nd weeks, participants were admitted to an online training group set up via DingTalk, attending an offline stress reduction workshop were grouped into groups of 5-6, with games and small activities to promote group bonding. Psychiatric-psychological nurse specialist introduced the participants to the concept of SIT, the curriculum, and asked them to describe their initial knowledge and understanding of SIT. In addition, through cognitive restructuring training, the participants were made to review their work experience, understand the work stress and psychological pain they faced, and correctly recognize the role of cognition and emotion in causing and maintaining stress. From 3rd-6th weeks, participants were portrayed and discussed through videos and images, exploring personal, organizational and environmental stressors for new psychiatric nurses. Psychiatrists led relaxation exercises (e.g. positive thinking, med
219378376|NCT07105774|BEHAVIORAL|routine training|"The control group received training in accordance with the New Entry Nurse Training Syllabus (Trial), which included routine theoretical knowledge training and clinical practice training."
219378377|NCT07106190|OTHER|Patients will be informed during the rehabilitation process|Patients will be informed during the rehabilitation process about secondary complications of stroke
219378378|NCT07105813|DEVICE|Navigational Positioning System for Puncture Surgery|Suitable for puncture surgery navigation and localization systems to assist in the procedure
219378379|NCT07106671|DRUG|Siltuximab|Siltuximab 11mg/kg
219378380|NCT07105618|DRUG|Dexmedetomidine|Dexmedetomidine as an adjunct to total intravenous anesthesia.
219378381|NCT07105618|DRUG|Fentanyl|Fentanyl as an adjunct to total intravenous anesthesia.
219378382|NCT07105618|DRUG|Magnesium|Magnesium sulphate as an adjunct to total intravenous anesthesia.
219378383|NCT07106541|BEHAVIORAL|Replicating Effective Programs (REP)|The study team will deploy this stakeholder informed REP package across the 68 sites in the MSQC-COHR collaborative. The REP program uses a blend of formats including didactics, flipped classroom design, and narrative storytelling, the REP will address key barriers to adherence previously identified by surgeons.
219378384|NCT07106541|BEHAVIORAL|REP with facilitation (REP-PLUS)|This intervention is a stepped-up REP plus virtual facilitation. The facilitator will: 1) Initiate implementation and benchmark goals: The facilitator will partner with the identified site champions but be masked to primary and secondary outcomes. Together, the facilitator and site champions will review processes to organizationally embed clinical practice guidelines into practice, assess potential barriers and facilitators to these processes, and set measurable goals for adherence to recommendations; 2) Track adherence and provide feedback: Facilitators will use abstracted MSQC-COHR and site-specific operative data to track adherence to clinical practice guidelines, identify barriers to adherence, provide solutions to identified barriers, re-engage stakeholder groups responsible for unsatisfactory measurements, and continuously promote awareness of the guidelines.
219378385|NCT07108140|BIOLOGICAL|Anti ALPP CAR-T cells treatment|anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
219378386|NCT03905434|GENETIC|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
219378387|NCT07108127|DRUG|Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX|Trastuzumab biosimilars and pertuzumab biosimilars combined with oxaliplatin and capecitabine
219378388|NCT06916767|DRUG|BAFF CAR-T|Single infusion
219378389|NCT06916767|DRUG|Obinutuzumab|IV administered
219378390|NCT06916767|DRUG|Cyclophosphamide|500mg/m2 on days -5 to -3
219378391|NCT06916767|DRUG|Fludarabine|30mg/m2 daily on days -5 to -3
219378392|NCT05639413|OTHER|Collection of blood samples|A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
219378393|NCT06935123|DIETARY_SUPPLEMENT|Sleep Supplements|Sleep supplements
219557848|NCT00642811|DRUG|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
219557849|NCT00642811|DRUG|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
219000955|NCT03825315|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
219378394|NCT06935123|OTHER|Placebo|Matching placebo
219378395|NCT06935916|PROCEDURE|pedicled or free tissue transfer|pedicled or free tissue transfer
219378396|NCT06935786|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Single appointment with a registered physiotherapist educating the patient for rehabilitating physical training and exercise to be performed independently and regularly by the patient at home, minimum of three times a week, during the study period.
219378397|NCT06936839|OTHER|Obversation|Observing the optimal flow rate to reduce left ventricular stress and enhance peripheral organ perfusion during ramp tests (conducted at QECMO levels of 100%, 75%, 50%, and 25%, provided that SVO₂ remains \>55% and NIRS rSO₂ remains \>50%)
219378398|NCT06935968|DEVICE|Levonorgestrel intrautrine system|Insertion of levonorgestrel intrautrine system and take a blood sample from the women to analyse it
219557850|NCT00268762|DRUG|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
219378399|NCT06936215|DRUG|tab baricitinib 4 mg daily|Group A participants will be given tab. Baricitinib 4 mg daily
219378400|NCT06936215|DRUG|tab methotrexate 25 mg weekly with folic acid 5 mg weekly|group A participants will be given tab. baricitinib 4 mg daily and group B participants will be given tab. methotrexate 25 mg weekly with folic acid 5 mg weekly
219378401|NCT06941727|DIAGNOSTIC_TEST|ultrasonographic imaging|masseter muscle elasticity
219378402|NCT06943716|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|A modified bilateral catheter antegrade cerebral perfusion technique used for acute Type A aortic dissection repair. This approach aims to reduce surgical trauma by avoiding additional right axillary access while maintaining stable cerebral perfusion.
219378403|NCT06943716|PROCEDURE|Conventional Brain Perfusion|Patients receiving the conventional perfusion strategy for aortic arch surgery, which may include standard bilateral ACP based on the surgeon's preference and the patient's condition.
219378404|NCT06936085|OTHER|Training|The Crime Scene Forensic Evidence Management training, which included theoretical knowledge and the presentation of sample cases, was completed for 144 volunteer participants. The content of the training includes topics such as forensic incidents, evidence, crime scene management, and evidence management, as well as the roles and responsibilities of paramedics in forensic cases such as injuries, violence, abuse, sexual assault, and suicide. Training was given to 4 groups of 35-37 students in each group in the classroom environment in two class hours (30+ 30 minutes + 1 break). Trainings were given by a single lecturer to avoid bias and ensure standardization.
219378405|NCT06935409|DRUG|HS-20093|Study participants in the experimental group shall continue to receive HS-20093 by intravenous infusion at a dose of 12.0 mg/kg, once every 3 weeks (Q3W) with a 21-day treatment cycle. Treatment shall continue until objective disease progression (excluding cases of treatment beyond PD or crossover treatment) or until other criteria for termination of study treatment specified in the protocol are met.
219378406|NCT06935409|DRUG|Gemcitabine combined with docetaxel|Study participants in the control arm will receive gemcitabine in combination with docetaxel. Gemcitabine (1000 mg/m2) will be administered intravenously over approximately 30 minutes on Days 1 and 8 of each 21-day treatment cycle, followed by docetaxel (75 mg/m2) on Day 8, intravenously over approximately 1 hour until objective disease progression or other criteria for treatment discontinuation are met.
219378407|NCT06936033|OTHER|Kinesiology taping|This study used Kinesio taping as an intervention to compare the biomechanical effects of stair descent in patients with acute ankle injuries before and after taping. Participants participated in two intervention conditions: the KT experimental group (Kinetoscopy taping) and the ST control group (no Kinesio taping), and each condition performed 20 separate stair descent tests.
219378408|NCT06935305|DEVICE|OSNA|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the OSNA method
219378409|NCT06935305|DEVICE|Ultrastaging|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the ultrastaging method
219378410|NCT06935981|OTHER|school-based mental health program|Week 1 Session 1-Beginning-Getting Acquainted Week 2 Session 2-Emotion, Thought and Behavior Wheel Week 3 Session 3- Optimism Week 4 Session 4- Forgiveness Week 5 Session 5- Saying No Week 6 Session 6- Effective Communication Week 7 Session 7- Problem Solving Week 8 Session 8- Saying Goodbye
219378411|NCT06935695|DEVICE|Bronchoscopy|Bronchoscopy is a procedure that uses a bronchoscope (a thin, tube-like instrument with a light and a lens for viewing) to examine the inside of the trachea, bronchi (air passages that lead to the lungs), and lungs. The bronchoscope is inserted through the nose or mouth.
219378412|NCT06936046|DRUG|Dual antibody A|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/VEGF dual antibody will be used as adjuvant therapy. PD-1/VEGF dual antibody 20mg/kg intravenous infusion once, with a cycle of 21 days.
219378413|NCT06936046|DRUG|Dual antibody B|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/CTLA-4 dual antibody will be used as adjuvant therapy. PD-1/CTLA-4 dual antibody 6mg/kg intravenous infusion once, with a cycle of 14 days.
219378414|NCT06936046|RADIATION|Modified Stupp|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. For partially resected lesions or short-term recurrence and progression lesions after surgery, high-dose PGTV 66Gy/30Gy will be given locally. PTV1 in high-risk areas around the tumor bed will be 60Gy/30F, and in low-risk areas will be 54Gy/30F. After completing synchronous radiotherapy and chemotherapy for 28 days, 6 cycles of adjuvant TMZ chemotherapy will be started.
219378415|NCT06936046|DRUG|Stupp protocol|Synchronized TMZ radiotherapy and chemotherapy will begin 2-6 weeks after surgery, and 6 cycles of adjuvant TMZ chemotherapy will begin 28 days after completing the synchronized radiotherapy and chemotherapy. Radiotherapy regimen: PTV1 60Gy/30F in high-risk areas around the tumor bed, 54Gy/30F in low-risk areas. TMZ synchronous chemotherapy regimen: 75mg/m2 po qd. TMZ adjuvant chemotherapy regimen: The first cycle is 150mg/m2 po qd on d1-5,28 days; Cycle 2-6: Cycle 1: 200mg/m2 po qd for d1-5,28 days.
219378416|NCT06935487|DIAGNOSTIC_TEST|transrectal ultrasound of prostate (TRUS) with AI software algorithm|Transrectal ultrasound of prostate (TRUS) with AI software algorithm for detection of lesions suspected for prostate cancer
219378417|NCT06935487|DIAGNOSTIC_TEST|MRI prostate|MRI for detection of lesions suspected for prostate cancer
219378418|NCT06935851|BEHAVIORAL|VOCAB +|"The purpose of the study is to investigate how word characteristics (e.g., phonotactic probability) and orthography effect vocabulary learning by children with low oral language levels. We will be using a 2 x 2 within-subjects factorial design where every participant serves as their own control. This 12-week study aims to improve the Efficiency of vocabulary learning for children with low oral language levels.~The four interventions that are all participants will be exposed to are the following: high pp words with orthography; high pp words without orthography; low pp words with orthography; low pp words without orthography."
219378419|NCT06935448|OTHER|enhanced recovery after surgery|ERAS group follows the enhanced recovery after surgery program which involves 20 elements
219378420|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg of caffeine in pill form
219378421|NCT06935214|DIETARY_SUPPLEMENT|Placebo|5 mg/kg dose of maltodextrin in pill form
219557851|NCT00938782|DEVICE|Sedline|
219188444|NCT06384222|PROCEDURE|Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)|Imaging procedure
219378422|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg dose of caffeine in pill form
219378423|NCT04547582|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
219378424|NCT06936488|DRUG|Ivonescimab,TAS-102|Ivonescimab,20mg/kg,i.v.,D1,Q3w TAS-102,35mg/m2,bid,D1-5,Q2W
219378425|NCT00452725|DRUG|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
219378426|NCT06946875|OTHER|Pain Threshold|The pain thresholds of the participants will be measured with an algometer device. With this device, the minimum pressure threshold that causes pain is recorded.
219378427|NCT06947356|DRUG|TAF group|Pregnant women will start TAF treatment (25 mg tablet taken orally once daily) from 28 weeks of gestation until delivery. After that, they will be randomly assigned to two subgroups among postpartum mothers without treatment indications: one subgroup will stop treatment, while the other subgroup will continue with an additional 12 weeks of TAF treatment. The mothers and their infants will be followed up at 28 weeks postpartum. Infants will receive the hepatitis B vaccine and HBIG within 12 hours after birth, as well as booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
219378428|NCT06947356|DRUG|TDF group|The mother will start receiving TDF treatment (300 mg tablet taken orally once daily) at 28 weeks of pregnancy until delivery. After that, mothers without treatment indications will be randomly assigned to two subgroups: one subgroup will stop treatment, while the other subgroup will receive an additional 12 weeks of TDF treatment. Infants will be vaccinated with the hepatitis B vaccine and HBIG within 12 hours after birth, as well as receive booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
219378429|NCT06948682|DEVICE|Occlusal Splint and Bite Correction Therapy|Participants receive individualized occlusal therapy involving occlusal splint use and bite correction (if needed). The treatment is applied continuously over a 6-month period. Monthly follow-up visits are conducted to monitor symptoms, adjust therapy, and evaluate radiographic changes in the TMJ.
219378430|NCT06948682|OTHER|Conventional TMJ Therapy|Participants undergo a 6-month conventional management program including pain medication (NSAIDs), physical therapy (jaw exercises, hot/cold therapy), and lifestyle guidance (diet modifications, stress reduction). Monthly clinical evaluations assess functional improvement and symptom reduction.
219378431|NCT06948682|OTHER|Routine TMJ Care (Medication Only)|Participants receive standard pharmacological management for TMJ disorders (e.g., NSAIDs or analgesics) with no occlusal or physical therapy interventions. Follow-up assessments occur monthly for 6 months to monitor symptom progression and response to minimal intervention.
219378432|NCT06952686|BIOLOGICAL|SRP-9005|Solution for single IV infusion
219378433|NCT06952686|DRUG|Corticosteroid|Oral tablet (prophylactic)
219378434|NCT00047567|DRUG|zonisamide|
219378435|NCT05457595|RADIATION|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
219378436|NCT02412280|OTHER|retrospecive observational|
219378437|NCT04907045|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
219378438|NCT04907045|BEHAVIORAL|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
219378439|NCT04907045|BEHAVIORAL|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
219378440|NCT03396575|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
219378441|NCT03396575|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
219378442|NCT03396575|DRUG|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
219378443|NCT03396575|DRUG|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
219378444|NCT03396575|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
219760900|NCT00888537|OTHER|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
219378445|NCT03396575|BIOLOGICAL|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
219378446|NCT06111209|DRUG|Testosterone cypionate|weekly by intramuscular injection
219378447|NCT06111209|DRUG|Placebo|weekly by intramuscular injection
219378448|NCT03176290|DIAGNOSTIC_TEST|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
219378449|NCT05060861|OTHER|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
219378450|NCT00643539|DRUG|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
219760901|NCT03018158|DEVICE|denture wear.|MR Imaging was collected with or without denture wear.
219378451|NCT00643539|DRUG|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
219378452|NCT03410147|DIAGNOSTIC_TEST|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
219378453|NCT00745030|DRUG|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
219378454|NCT00745030|DRUG|Placebo|Placebo 8 mg tablets
219378455|NCT03361670|OTHER|Observational Study|
219378456|NCT01526226|DEVICE|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
219378457|NCT01526226|DEVICE|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
219378458|NCT06512402|DRUG|Norepinephrine|patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
219378459|NCT06512402|DRUG|Epinephrine|patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
219378460|NCT04567251|OTHER|Noona® application|A digital symptom tracking application focused on Health-Related Quality of Life (HRQOL) and cognition in cancer survivors who received brain irradiation
219378461|NCT05675709|BEHAVIORAL|Training and Education|Undergo group trainings
219378462|NCT06843902|OTHER|Health Education|Health Education
219378463|NCT06843902|OTHER|Subspecialty clinic referral|This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
219378464|NCT04886414|OTHER|Phone-based monitoring|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
219378465|NCT04886414|OTHER|Oxygen saturation monitoring|Oxygen saturation will be monitored and recorded at regular intervals.
219378466|NCT04886414|OTHER|Alcohol-based hand sanitizer|Alcohol-based hand sanitizer will be distributed to subjects.
219378467|NCT04987281|PROCEDURE|Computed Tomography|Undergo CT
219378468|NCT04987281|DRUG|Indocyanine Green Solution|Given via injection
219378469|NCT04987281|DEVICE|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
219378470|NCT06394063|BIOLOGICAL|Telitacicept|Telitacicept 160 mg SC every other week
219378471|NCT06394063|DRUG|Placebo|Placebo to Telitacicept
219378472|NCT02912871|OTHER|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
219378473|NCT05955742|DEVICE|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
219378474|NCT05955742|DEVICE|ProGlider|The operator prepared the glide path using the ProGlider file.
219557852|NCT03972696|RADIATION|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
219557853|NCT02827682|DEVICE|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
219378475|NCT05955742|DEVICE|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
219378476|NCT01166269|BIOLOGICAL|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
219378477|NCT01166269|BIOLOGICAL|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
219378478|NCT01166269|OTHER|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
219378479|NCT05659121|DEVICE|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
219378480|NCT02094846|BEHAVIORAL|Voice messages|Voice messages reinforced with self-efficacy
219378481|NCT02864875|DRUG|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
219378482|NCT00229840|PROCEDURE|Functional MRI, Diffusion Tensor Imaging|
219378483|NCT02194881|DRUG|CF patients with a G551D mutation and treated with Ivacaftor|
219378484|NCT01213810|BIOLOGICAL|Zostavax|Biological/Vaccine
219378485|NCT02857465|DRUG|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
219378486|NCT02857465|DRUG|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
219378487|NCT02857465|DRUG|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
219378488|NCT02857465|DRUG|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
219378489|NCT02553603|DRUG|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
219378490|NCT02553603|DRUG|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
219557854|NCT02827682|DEVICE|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
219760902|NCT00002907|DRUG|bryostatin 1|
219378491|NCT04599790|DRUG|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
219378492|NCT01183962|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 3000 IU daily
219378493|NCT01183962|OTHER|No medication|No intervention
219378494|NCT05780840|OTHER|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
219378495|NCT05780840|OTHER|Placebo|Application of lotion to the skin (2 mg per square cm skin)
219378496|NCT01225263|DRUG|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
219378497|NCT01225263|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
219378498|NCT01225263|OTHER|Placebo|Two placebo pills, taken twice daily for 6 months
219378499|NCT02203370|DEVICE|NIRS - Near-infrared spectroscopy|
219378500|NCT06152120|OTHER|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
219378501|NCT05679882|OTHER|Masking Sounds|Masking sounds will be played from outdoor speakers.
219378502|NCT05679882|OTHER|No Masking Sounds|No masking sounds will be played from outdoor speakers.
219378503|NCT04146688|OTHER|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
219378504|NCT04831450|DRUG|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
219378505|NCT03088501|BEHAVIORAL|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
219378506|NCT03088501|BEHAVIORAL|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
219378507|NCT01568216|DRUG|AMG 747|Three dose levels once-daily oral administration
219378508|NCT01568216|DRUG|Placebo|Once-daily oral administration
219378509|NCT00473694|DRUG|sugammadex|Administered as an intravenous (IV) infusion
219378510|NCT00473694|DRUG|neostigmine|Administered as an IV infusion
219378511|NCT00473694|DRUG|vecuronium|Administered as an IV infusion
219378512|NCT00473694|DRUG|rocuronium|Administered as an IV infusion
219378513|NCT00473694|DRUG|glycopyrrolate|Administered as an IV infusion
219378514|NCT06236217|OTHER|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
219378515|NCT06236217|OTHER|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
219378516|NCT03062917|DIAGNOSTIC_TEST|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
219378517|NCT02197325|DEVICE|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
219378518|NCT03285529|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
219378519|NCT03285529|DEVICE|VICRYL|Vicryl #1
219378520|NCT02502929|BEHAVIORAL|Social Services|
219378521|NCT02502929|BEHAVIORAL|Lifestyle|
219378522|NCT02502929|BEHAVIORAL|Lifestyle Plus Medication Therapy Management|
219378523|NCT04368754|OTHER|Questionnaire|Patients evaluated with different questionnaire.
219188445|NCT06255951|DRUG|Itraconazole|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
219378524|NCT02870673|DRUG|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
219378525|NCT02870673|DRUG|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
219378526|NCT02870673|DEVICE|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
219378527|NCT02870673|DEVICE|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
219378528|NCT06246682|PROCEDURE|Transcanal Endoscopic removal of atticoantral cholesteatoma|removal of the cholesteatoma presented in the atticoantral region by otoendoscope
219378529|NCT03325309|OTHER|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
219378530|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219378531|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
219378532|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
219378533|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
219378534|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
219378535|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
219378536|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
219378537|NCT02372162|OTHER|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
219378538|NCT02372162|OTHER|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
219378539|NCT04689308|DRUG|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
219378540|NCT02132221|BEHAVIORAL|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
219378541|NCT05738863|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
219378542|NCT05738863|DEVICE|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
219378543|NCT03893292|PROCEDURE|Total knee replacement|Patients will undergo total knee replacement surgery.
219378544|NCT03893292|DEVICE|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
219378545|NCT05928143|PROCEDURE|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
219378546|NCT05928143|PROCEDURE|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
219378547|NCT06380140|PROCEDURE|Open Tension-free Inguinal Hernia Repair|A blood sample is taken the day after surgery
219378548|NCT04410302|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
219378549|NCT00015548|DRUG|Olanzapine|
219378550|NCT00015548|DRUG|Quetiapine|
219378551|NCT00015548|DRUG|Risperidone|
219378552|NCT00015548|DRUG|Citalopram|
219378553|NCT03001544|BIOLOGICAL|TS23|comparison of different doses
219378554|NCT00609921|DRUG|ARQ197|treatment
219378555|NCT04662593|BEHAVIORAL|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
219378556|NCT03874234|DRUG|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
219378557|NCT03874234|DRUG|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
219378558|NCT02303587|DRUG|methylprednisolone|
219378559|NCT02803034|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
219378560|NCT05580289|OTHER|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
219378561|NCT01104389|DEVICE|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
219378562|NCT00559338|DRUG|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
219378563|NCT00559338|DRUG|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
219378564|NCT01046318|DRUG|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
219378565|NCT02085577|DRUG|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
219378566|NCT02085577|DRUG|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
219378567|NCT02085577|DRUG|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
219378568|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
219378569|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
219378570|NCT02085577|DRUG|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
219378571|NCT02085577|DRUG|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
219378572|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
219378573|NCT02085577|DRUG|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
219378574|NCT05918510|DIAGNOSTIC_TEST|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
219378575|NCT00281450|BEHAVIORAL|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
219378576|NCT03648450|OTHER|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
219378577|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
219378578|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
219378579|NCT00332657|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
219378580|NCT05619926|DRUG|STSP-0601 for Injection|Intravenous Injection
219378581|NCT00783289|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
219378582|NCT00783289|BIOLOGICAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
219378583|NCT00783289|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
219378584|NCT00783289|BIOLOGICAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
219378585|NCT00652821|DRUG|Tramadol/ APAP|Tablets 37.5mg /325mg
219378586|NCT00652821|DRUG|Ultracet|Tablets, 37.5mg/325mg
219378587|NCT05598086|DRUG|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
219378588|NCT00506389|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
219760903|NCT05129956|DEVICE|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
219760904|NCT01531998|DRUG|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
219378589|NCT00506389|DRUG|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
219378590|NCT04634669|DRUG|AXS-05 (dextromethorphan-bupropion)|\- AXS-05 tablet, taken daily (up to 15 months)
219378591|NCT00749099|DRUG|pancrelipase|"The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
219378592|NCT00749099|DRUG|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
219378593|NCT02424370|PROCEDURE|TAVR|Percutaneous aortic valve replacement
219378594|NCT05224258|DEVICE|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
219378595|NCT05147246|BEHAVIORAL|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
219378596|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
219378597|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
219378598|NCT05452382|PROCEDURE|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
219378599|NCT05452382|PROCEDURE|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
219378600|NCT04406571|OTHER|Data record|Data record
219378601|NCT05159180|DEVICE|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
219378602|NCT01217749|DRUG|PCI-32765|420 mg PO daily
219378603|NCT01217749|DRUG|ofatumumab|per package insert as an IV infusion
219378604|NCT00437905|PROCEDURE|angioplasty|
219378605|NCT00810797|DRUG|exemestane|Given orally
219378606|NCT00810797|OTHER|laboratory biomarker analysis|One year after completion of study treatment
219378607|NCT00810797|PROCEDURE|quality-of-life assessment|One year after completion of study treatment
219760905|NCT01531998|DRUG|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
219378608|NCT00810797|OTHER|immunohistochemistry staining method|Correlative studies
219378609|NCT01154413|BEHAVIORAL|Intensive education of the doctor/nursing team on the protocol|
219378610|NCT02795234|OTHER|Blood samples|
219378611|NCT03125642|DRUG|Etoposide|"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
219378612|NCT03125642|DRUG|BCNU|BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
219378613|NCT03125642|DRUG|AraC|BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
219378614|NCT03125642|DRUG|Melphalan|BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
219378615|NCT03125642|PROCEDURE|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
219378616|NCT03125642|BIOLOGICAL|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
219378617|NCT03125642|DRUG|Cyclophosphamide|"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
219378618|NCT03125642|RADIATION|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
219378619|NCT04240743|DEVICE|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
219378620|NCT04240743|DEVICE|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
219378621|NCT01774916|GENETIC|blood samples|
219378622|NCT05904392|OTHER|Music|Music played prior to injection
219378623|NCT06245356|DRUG|Lonsurf|Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)
219378624|NCT06245356|DRUG|Oxaliplatin|Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)
219000956|NCT02393508|OTHER|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
219378625|NCT06245356|DRUG|Panitumumab|Panitumumab intravenous injection 6 mg/kg (D1=D15)
219378626|NCT06245356|DRUG|Bevacizumab|Bevacizumab intravenous injection 5 mg/kg (D1=D15)
219378627|NCT06245356|DRUG|Trastuzumab|Trastuzumab intravenous injection 4 mg/kg (D1=D15)
219378628|NCT06245356|DRUG|Nivolumab|Nivolumab intravenous injection 240 mg (D1=D15)
219378629|NCT00235157|DEVICE|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
219378630|NCT05819229|DRUG|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
219378631|NCT02351115|DRUG|A=Placebo|
219378632|NCT02351115|DRUG|B=Inhaled Alprazolam 0.5 mg|
219378633|NCT02351115|DRUG|C=Inhaled Alprazolam 1 m|
219378634|NCT02351115|DRUG|D= Inhaled Alprazolam 2 mg|
219378635|NCT02351115|DRUG|E=Placebo|
219378636|NCT05966818|DRUG|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
219378637|NCT05966818|DRUG|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
219378638|NCT03062501|DRUG|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
219378639|NCT04435340|DIAGNOSTIC_TEST|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
219378640|NCT02667184|DIETARY_SUPPLEMENT|Low FODMAP Oral Nutrition Supplement|
219378641|NCT00224562|DRUG|TNF-alpha antagonists|
219378642|NCT06226402|DRUG|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
219378643|NCT06226402|DRUG|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
219378644|NCT00389155|DRUG|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
219378645|NCT00389155|DRUG|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
219378646|NCT00389155|OTHER|Placebo|
219378647|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
219378648|NCT02890719|DRUG|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
219378649|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
219378650|NCT02890719|DRUG|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
219378651|NCT02890719|DRUG|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
219378652|NCT05957081|DRUG|PMC-309 monotherapy|PMC-309 will be administered intravenously.
219378653|NCT05957081|DRUG|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
219378654|NCT05957081|DRUG|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  \- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
219378655|NCT05280561|DIETARY_SUPPLEMENT|DHM|DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
219378656|NCT05280561|DIETARY_SUPPLEMENT|Placebo|Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
219378657|NCT04779502|OTHER|oregawash|mouthwash containing oregano essential oil
219378658|NCT04779502|OTHER|corsodyl|0.2% chlorhexidine mouthwash
219378659|NCT04779502|OTHER|placebo|distilled water
219378660|NCT00651040|DRUG|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
219378661|NCT00651040|DRUG|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
219378662|NCT03494647|DEVICE|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
219378663|NCT03494647|DEVICE|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
219378664|NCT05802329|DRUG|OCU200|Intravitreal Injection
219378665|NCT00215930|DRUG|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
219378666|NCT00215930|DRUG|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
219378667|NCT00215930|DRUG|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
219378668|NCT00215930|DRUG|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
219378669|NCT03563534|DRUG|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
219378670|NCT03563534|DRUG|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
219378671|NCT02060422|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
219378672|NCT02060422|BEHAVIORAL|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
219378673|NCT06393283|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
219378674|NCT02335684|OTHER|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
219378675|NCT02335684|OTHER|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
219378676|NCT00470496|DRUG|HPPH|Given IV
219378677|NCT00470496|DRUG|photodynamic therapy|Undergo laser light exposure
219378678|NCT00470496|PROCEDURE|conventional surgery|Undergo surgery
219188446|NCT06255951|DRUG|Rifampicin|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
219378679|NCT01727960|BEHAVIORAL|Education and posture correction|a lecture concerning the fine posture for health and exercises
219378680|NCT04947202|DEVICE|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
219378681|NCT06185920|OTHER|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
219378682|NCT06042374|OTHER|Progressive Core Stabilization Training|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
219378683|NCT06042374|OTHER|Standard Core Strengthening Exercises|The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
219378684|NCT02585557|OTHER|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
219378685|NCT01012908|DIETARY_SUPPLEMENT|Norzyme - Bergamo|2 - 8 tablets per day.
219378686|NCT01012908|DIETARY_SUPPLEMENT|Creon|2 - 8 tablets pet day
219378687|NCT04271163|DEVICE|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
219378688|NCT03273621|PROCEDURE|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
219378689|NCT05319964|BEHAVIORAL|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
219378690|NCT05319964|BEHAVIORAL|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
219378691|NCT05319964|BEHAVIORAL|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
219378692|NCT04716322|BEHAVIORAL|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
219378693|NCT05657769|DEVICE|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
219378694|NCT05657769|DEVICE|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
219378695|NCT01814657|DRUG|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
219378696|NCT01814657|DRUG|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
219378697|NCT01612234|DIETARY_SUPPLEMENT|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
219378698|NCT01021566|DEVICE|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
219378699|NCT01021566|DRUG|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
219378700|NCT03455946|BEHAVIORAL|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
219378701|NCT03253640|OTHER|Exposure|Healthcare associated infection (HAI)
219378702|NCT03217760|PROCEDURE|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
219378703|NCT03217760|OTHER|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
219378704|NCT03217760|OTHER|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
219378705|NCT03217760|OTHER|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
219378706|NCT03217760|OTHER|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.
219378707|NCT03217760|OTHER|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
219188447|NCT06373601|DEVICE|sirolimus-eluting balloon (Selution)|PCI treatment with DCB, in particular sirolimus coated balloon
219378708|NCT03217760|OTHER|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
219378709|NCT03217760|OTHER|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
219378710|NCT03217760|OTHER|student preferences.|"When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
219378711|NCT02683369|DIETARY_SUPPLEMENT|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root"
219378712|NCT01880450|BEHAVIORAL|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
219378713|NCT01880450|BEHAVIORAL|TEEN|Control condition the promote communication, decision-making skills etc.
219378714|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
219378715|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
219378716|NCT02224430|DEVICE|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
219378717|NCT00608140|PROCEDURE|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
219378718|NCT00608140|DRUG|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
219378719|NCT01129947|DRUG|DHEA|DHEA 25 mg tid
219378720|NCT03783910|DRUG|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
219378721|NCT03783910|DRUG|Placebo|Placebo matching GRT9906 tablets
219378722|NCT03812510|DRUG|A-101|hydrogen peroxide topical solution 45%
219378723|NCT02406157|DEVICE|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
219378724|NCT02406157|DEVICE|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
219378725|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
219378726|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
219378727|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
219378728|NCT03003819|DEVICE|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
219378729|NCT03003819|DEVICE|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
219378730|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
219378731|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
219378732|NCT03629509|BEHAVIORAL|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
219378733|NCT04130815|DRUG|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
219760906|NCT01531998|DRUG|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
219760907|NCT01531998|DRUG|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
219760908|NCT01531998|BEHAVIORAL|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
219760909|NCT03037970|DRUG|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
219378734|NCT05957874|OTHER|Combined package program|"Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles."
219378735|NCT01636557|DRUG|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
219378736|NCT01636557|DRUG|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
219378737|NCT01636557|DRUG|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
219378738|NCT01636557|DRUG|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
219378739|NCT01636557|DRUG|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
219378740|NCT01636557|DRUG|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
219378748|NCT01120626|DRUG|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
219378749|NCT01120626|DRUG|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
219378750|NCT06464211|BEHAVIORAL|Cognitive Behavioral Model-Based Family Counseling Program|A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
219378751|NCT01128387|DRUG|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
219378752|NCT00146042|DRUG|Docetaxel|
219378753|NCT00146042|DRUG|Trastuzumab|
219378754|NCT00146042|PROCEDURE|Erythromycin Breath Test (ERMBT)|
219378755|NCT03069911|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
219378756|NCT03069911|BIOLOGICAL|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
219378757|NCT02898012|DRUG|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
219378758|NCT02898012|DRUG|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
219188448|NCT06373601|DEVICE|paclitaxel-eluting balloon (SeQuent Please Neo)|PCI treatment with DCB, in particular paclitaxel coated balloon
219378759|NCT04957173|OTHER|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
219378760|NCT04446208|PROCEDURE|Endoscopy|Endoscopic treatment will consist in placement of a metal stent in a patient with early fistula (\< 15 days) and/or a large fistula orifice, and no abscess, or double pigtail plastic stents if the fistula is older than 15 days and the orifice is small.
219378761|NCT03534037|DRUG|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
219378762|NCT03534037|DRUG|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
219378763|NCT03534037|OTHER|Control|Dietary control only
219378764|NCT02635204|DRUG|DFD06 Cream|Twice daily topical application for 14 days.
219378765|NCT02635204|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
219378766|NCT03883893|DRUG|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
219378767|NCT03883893|OTHER|Normal saline|Normal saline will given if randomized to this group.
219378768|NCT01535235|DRUG|Lisinopril|Lisinopril 20mg QD x 24 weeks
219378769|NCT01535235|DRUG|Placebo|Placebo QD x24wks
219378770|NCT03853421|DRUG|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
219760910|NCT03037970|OTHER|Placebo|Collagen Wound Dressing wetted with buffer.
219760911|NCT02604459|DEVICE|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
219378771|NCT01021111|DEVICE|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
219378772|NCT01796132|DRUG|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
219378773|NCT00858832|DRUG|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
219378774|NCT03717740|DRUG|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
219378775|NCT03717740|DRUG|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
219378776|NCT03475225|DRUG|Cholecalciferol|Cholecalciferol delivery
219378777|NCT03475225|DRUG|Placebo Oral|manufactured to mimic Cholecalciferol
219378778|NCT04800380|OTHER|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
219378779|NCT00416533|DRUG|docetaxel|
219378780|NCT00416533|DRUG|doxorubicin hydrochloride|
219378781|NCT00416533|DRUG|prednisone|
219378782|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
219378783|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
219378784|NCT03944837|OTHER|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
219378785|NCT00389207|DRUG|nevirapine bid|nevirapine twice daily
219378786|NCT00389207|DRUG|nevirapine qd|nevirapine once daily
219378787|NCT00389207|DRUG|atazanavir|atazanavir once daily
219378788|NCT06349629|DEVICE|3D printed WE43 magnesium alloy|This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
219378789|NCT03140826|DRUG|meropenem|Antibiotics to treat infections.
219378790|NCT03973814|DEVICE|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
219378791|NCT04265664|BEHAVIORAL|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
219378792|NCT05461443|DIETARY_SUPPLEMENT|Probiotic|
219378793|NCT03676309|DRUG|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
219378794|NCT03676309|DRUG|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
219378795|NCT05316896|OTHER|Internal Perturbation|"* Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
219378796|NCT05316896|OTHER|Eksternal Perturbation|"* Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
219378797|NCT05258227|OTHER|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
219378798|NCT05258227|OTHER|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
219378799|NCT00515125|BEHAVIORAL|Dietary Advice|Dietary Advice sheet
219378800|NCT00515125|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
219378801|NCT01496664|PROCEDURE|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
219378802|NCT03325764|OTHER|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
219760912|NCT02604459|DEVICE|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
219378803|NCT01916577|DRUG|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
219378804|NCT00104130|DRUG|KOS-862|
219378805|NCT04516304|DIETARY_SUPPLEMENT|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
219378806|NCT04516304|DIETARY_SUPPLEMENT|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
219378807|NCT04737044|OTHER|Study 1: MRBS|MRBS as added sugar based on their habitual diet
219378808|NCT04737044|OTHER|Study 2: White sugar & education module|White sugar for daily usage (\<10% daily energy intake)
219378809|NCT04737044|OTHER|Study 2: MRBS & education module|MRBS for daily usage (\<10% daily energy intake)
219378810|NCT00420030|DRUG|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
219378811|NCT05157425|DIETARY_SUPPLEMENT|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
219378812|NCT05157425|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
219378813|NCT03456492|DIAGNOSTIC_TEST|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
219378814|NCT01588821|DRUG|Cabozantinib|60 mg daily by mouth
219378815|NCT02093611|DIETARY_SUPPLEMENT|Placebo|
219378816|NCT02093611|DIETARY_SUPPLEMENT|ATP|400 mg of ATP
219378817|NCT04722978|DRUG|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
219378818|NCT04722978|DRUG|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
219378819|NCT01159262|DRUG|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
219378820|NCT01159262|DRUG|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
219188449|NCT06354712|DRUG|N-Acetyl-Cysteine with Institutional standard care|A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
219188450|NCT06354712|DRUG|Institutional standard care|Benzydamine Mouthwash
219378821|NCT01159262|DRUG|Dexmedetomidine|
219378822|NCT05282940|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
219378823|NCT05282940|DRUG|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
219378824|NCT06228157|BEHAVIORAL|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
219378825|NCT06228157|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219378826|NCT05162157|DEVICE|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
219378827|NCT01664026|BEHAVIORAL|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
219378828|NCT01664026|BEHAVIORAL|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
219378829|NCT00251069|DRUG|Glucosamine sulphate|
219378830|NCT03820492|DIAGNOSTIC_TEST|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
219378831|NCT02970773|DRUG|Rivaroxaban Oral Tablet|oral application of Xarelto
219378832|NCT01497392|DRUG|dovitinib lactate|Given PO
219378833|NCT01497392|DRUG|gemcitabine hydrochloride|Given IV
219378834|NCT01497392|DRUG|capecitabine|Given PO
219378835|NCT01497392|OTHER|laboratory biomarker analysis|Correlative studies
219378836|NCT01497392|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219378837|NCT01497392|OTHER|pharmacological study|Correlative studies
219378838|NCT02522819|DEVICE|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
219378839|NCT02226354|DIETARY_SUPPLEMENT|Ahiflower oil|9.73 ml per day for 28 days
219378840|NCT02226354|DIETARY_SUPPLEMENT|Flaxseed oil|9.73ml per day for 28 days
219378841|NCT00635622|DRUG|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
219760913|NCT02604459|PROCEDURE|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
219760914|NCT02604459|PROCEDURE|General anesthesia|General anesthesia will be used in both groups
219760915|NCT02604459|DRUG|propofol|propofol per protocol
219760916|NCT02604459|DRUG|fentanyl|fentanyl per protocol
219760917|NCT02604459|DRUG|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
219760918|NCT00186628|PROCEDURE|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
219760919|NCT00186628|DRUG|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
219378842|NCT00635622|DRUG|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
219378843|NCT00222911|DEVICE|dorsiflexion night splint|
219378844|NCT00222911|DEVICE|medial arch support|
219378845|NCT00584974|DRUG|SEP-225289|0.5 mg SEP-225289
219378846|NCT00584974|DRUG|SEP-225289|2.0 mg SEP-225289
219378847|NCT00584974|DRUG|Venlafaxine|150 mg Venlafaxine
219378848|NCT00584974|DRUG|placebo|Placebo
219378849|NCT02085811|OTHER|radiography standard|
219378850|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
219378851|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
219378852|NCT05026775|BEHAVIORAL|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
219378853|NCT05026775|OTHER|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
219378854|NCT03668132|OTHER|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
219378855|NCT00371319|DRUG|tacrolimus|0.06-0.1 mg/kg/day
219378856|NCT00371319|DRUG|mycophenolate mofetil|2-3 gm/day
219378857|NCT05844384|DEVICE|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
219378858|NCT05844384|DEVICE|Regular dropper|Delivers full eye drop volume
219378859|NCT06203431|DRUG|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
219378860|NCT06203431|DRUG|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
219378861|NCT02421874|BEHAVIORAL|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
219378862|NCT02421874|BEHAVIORAL|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
219378863|NCT04067336|DRUG|Ziftomenib|Oral administration
219378864|NCT04067336|DRUG|Midazolam|Oral administration
219378865|NCT04067336|DRUG|Itraconazole|Oral administration
219378866|NCT05241587|OTHER|Gum Group:|"Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010)."
219378867|NCT05241587|OTHER|Mouth Spray Group:|"Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request."
219378868|NCT03394495|OTHER|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
219378869|NCT02366962|BIOLOGICAL|ASP7374|subcutaneous
219378870|NCT03202654|OTHER|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
219378871|NCT03202654|OTHER|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
219378872|NCT01220219|DRUG|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
219378873|NCT01220219|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
219378874|NCT01220219|DRUG|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
219378875|NCT01794780|DRUG|LABA based treatment: indacaterol|LABA based treatment: indacaterol
219378876|NCT01794780|DRUG|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
219378877|NCT01794780|DRUG|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
219378878|NCT01794780|DRUG|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
219378879|NCT01794780|DRUG|theophylline based treatment|theophylline based treatment
219378880|NCT01794780|DRUG|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
219378881|NCT05077514|BEHAVIORAL|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
219378882|NCT05077514|BEHAVIORAL|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
219378883|NCT04814537|DRUG|Bupivacaine Hydrochloride|Local Anesthetic Agent
219378884|NCT02803216|DRUG|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
219378885|NCT02803216|DRUG|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
219378886|NCT02803216|DRUG|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
219378887|NCT04740229|BEHAVIORAL|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
219378888|NCT03545243|DRUG|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
219378889|NCT03545243|OTHER|PPI withdrawal|PPI withdrawal for 8 weeks
219378890|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
219378891|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
219378892|NCT01118910|DRUG|Vusion|Vusion will be applied to areas of intertrigo
219378893|NCT05344547|DIAGNOSTIC_TEST|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
219378894|NCT05328947|OTHER|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
219378895|NCT00668005|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
219378896|NCT00668005|DRUG|Placebo|Matching placebo
219378897|NCT00599651|DEVICE|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
219378898|NCT00599651|OTHER|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
219378899|NCT04697225|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
219378900|NCT04697225|BEHAVIORAL|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
219378901|NCT03120143|OTHER|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
219378902|NCT03120143|OTHER|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
219378903|NCT05220150|DEVICE|FFC-MRI scan|Undergo one FFC-MRI scan.
219378904|NCT02286102|DEVICE|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
219378905|NCT02286102|DEVICE|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
219378906|NCT04541069|BEHAVIORAL|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
219378907|NCT05400460|PROCEDURE|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
219378908|NCT05400460|PROCEDURE|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
219378909|NCT05400460|PROCEDURE|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
219760920|NCT00186628|DRUG|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
219760921|NCT00186628|DRUG|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
219760922|NCT00186628|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
219378910|NCT05400460|OTHER|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
219378911|NCT05400460|OTHER|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
219378912|NCT04673383|DRUG|SPL026|Intravenous solution
219378913|NCT04673383|DRUG|Placebo|SPL026-matched placebo
219378914|NCT05215522|DEVICE|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
219378915|NCT01962142|OTHER|Assessment of activity capacities|
219378916|NCT00615537|PROCEDURE|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
219378917|NCT04763525|BEHAVIORAL|Pythagorean Self-Awareness Intervention(PSAI)|The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
219378918|NCT05387655|BIOLOGICAL|BCG|BCG vaccination
219378919|NCT05387655|BIOLOGICAL|Placebo vaccine|Placebo vaccination
219378920|NCT03411343|PROCEDURE|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
219378921|NCT03411343|PROCEDURE|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
219378922|NCT02626377|BEHAVIORAL|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
219378923|NCT02626377|OTHER|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
219378924|NCT01368068|DRUG|Tibolone|2.5mg/oral/daily
219378925|NCT01368068|DRUG|Escitalopram|10mg/oral/daily
219378926|NCT01368068|DRUG|Natvia|serving size: 0.09g per tablet
219378927|NCT01953315|BIOLOGICAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
219378928|NCT06192121|OTHER|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
219378929|NCT03025581|OTHER|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
219378930|NCT01261676|OTHER|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
219378931|NCT04180605|OTHER|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
219378932|NCT04180605|PROCEDURE|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
219378933|NCT05931770|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
219378934|NCT05931770|PROCEDURE|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
219378935|NCT03921112|DEVICE|lung ultrasound|bedside lung ultrasound will be done for patients
219378936|NCT03921112|OTHER|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
219760923|NCT00186628|DRUG|Filgrastim|Filgrastim provided as needed for neutrophil support
219378937|NCT06279923|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
219378938|NCT04339504|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
219378939|NCT04339504|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
219378940|NCT04339504|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
219378941|NCT06197607|OTHER|theraputty hand exercises|Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each
219378942|NCT06197607|OTHER|sensory stimulation|Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
219378943|NCT06456710|BEHAVIORAL|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
219378944|NCT06456710|BEHAVIORAL|Based on ACT Theory of Psychological Intervention|"On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT."
219378945|NCT01104831|DEVICE|Cryotherapy|cooled sleeve placed over fracture site.
219378946|NCT01104831|DEVICE|Room temperature cuff|sleeve with room temperature water placed over fracture site.
219378947|NCT03007277|OTHER|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
219378948|NCT04169477|DEVICE|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
219378949|NCT04910750|DEVICE|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
219378950|NCT04910750|DEVICE|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
219378951|NCT02450253|DRUG|Tadalafil|single dose, 20 mg capsule p.o.
219378952|NCT02450253|DRUG|Placebo|single dose, matching capsule p.o.
219378953|NCT02450253|BEHAVIORAL|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
219378954|NCT02450253|BEHAVIORAL|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
219000957|NCT02393508|OTHER|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
219378955|NCT02450253|OTHER|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
219378956|NCT02362373|DRUG|levonorgestrel IUS|placement of levonorgestrel intrauterine system
219378957|NCT01588080|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
219378958|NCT01588080|DEVICE|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
219378959|NCT03293680|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
219378960|NCT02201940|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
219378961|NCT02201940|DRUG|Placebo|Tablet administered orally once daily
219378962|NCT02126488|BEHAVIORAL|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
219378963|NCT02126488|BEHAVIORAL|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
219378964|NCT02126488|BEHAVIORAL|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
219378965|NCT06683521|OTHER|Supervised Low-Dose Oral Food Challenge (OFC)|All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.
219378966|NCT06683521|OTHER|At-Home Low-Dose Oral Food Challenge (OFC)|Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.
219378967|NCT06683521|OTHER|Supervised High-Dose Oral Food Challenge (OFC)|Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.
219378968|NCT00942682|DRUG|Sorafenib|Taken orally twice daily
219378969|NCT00942682|DRUG|RAD001|Taken orally once daily in the morning
219378970|NCT00013052|BEHAVIORAL|Peer led classes. Led by trained veterans with a chronic disease.|
219378971|NCT03287492|OTHER|Informational Intervention|Receive QPS
219378972|NCT03287492|OTHER|Informational Intervention|Receive GIS
219378973|NCT03287492|OTHER|Questionnaire Administration|Ancillary studies
219378974|NCT06448377|PROCEDURE|Videolaryngoscopy|Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
219378975|NCT06448377|PROCEDURE|FOB|Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
219378976|NCT06448377|PROCEDURE|FOB+Aintree|Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
219378977|NCT06448377|PROCEDURE|Classic intubation with laryngoscopy|Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
219378978|NCT06448377|PROCEDURE|Others|Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
219378979|NCT05928884|OTHER|There is no intervention. It is a phenotyping study only|See above, this is only a phenotyping study but NIH required us to register it as a trial.
219378980|NCT01883505|DRUG|Levodopa and carbidopa|Subcutaneous continuous administration
219378981|NCT01883505|DRUG|Placebo|Subcutaneous continuous administration
219378982|NCT02404987|OTHER|Nutritional Supplement|
219378983|NCT03709927|DRUG|ZTI-01|6g IV fosfomycin
219378984|NCT03709927|DRUG|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
219378985|NCT03709927|OTHER|Placebo IV|IV Placebo (0.9% Normal Saline)
219378986|NCT05112731|DIAGNOSTIC_TEST|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
219378987|NCT04030000|DRUG|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
219378988|NCT04030000|RADIATION|Pelvic radiation therapy|EBRT and vaginal brachytherapy
219378989|NCT03437603|DRUG|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
219378990|NCT04869241|DIAGNOSTIC_TEST|surface EMG|Carrying backpacks forward or backward
219378991|NCT04045067|PROCEDURE|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
219378992|NCT04045067|PROCEDURE|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
219378993|NCT03192904|DEVICE|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
219378994|NCT03192904|DEVICE|Stapling Device|Stapling Device, including linear stapler and curved stapler.
219378995|NCT03352245|BEHAVIORAL|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
219378996|NCT03782337|BEHAVIORAL|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
219378997|NCT03619629|OTHER|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
219378998|NCT03619629|OTHER|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
219378999|NCT03619629|OTHER|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
219379000|NCT03619629|OTHER|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
219379001|NCT00940277|BEHAVIORAL|Group Counseling|Group counseling
219379002|NCT03635931|PROCEDURE|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
219379003|NCT02771834|OTHER|Biomechanical analysis|
219379004|NCT02771834|OTHER|Kiphosis analysis|
219379005|NCT02771834|OTHER|Vitamin D level|
219379006|NCT01130922|DRUG|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
219379007|NCT01130922|DRUG|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
219379008|NCT05123560|OTHER|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
219379009|NCT06031415|DRUG|GS-0272|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
219379010|NCT06031415|DRUG|Placebo|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
219379011|NCT02690701|DRUG|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
219379012|NCT02690701|BIOLOGICAL|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
219379013|NCT05865184|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
219379014|NCT03091023|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|
219379015|NCT05841940|DRUG|[14C]HLX208|Carbon-14 labeled HLX208
219379016|NCT01309737|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
219379017|NCT01309737|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
219379018|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
219379019|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
219379020|NCT01442181|PROCEDURE|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
219379021|NCT01442181|OTHER|Medical therapy|Patients are treated with rhythm and rate control medications.
219379022|NCT00539019|OTHER|calories measured 5x following wound healing|measure REE at various time points postburn
219379023|NCT01907165|DRUG|Temozolomide|
219379024|NCT01907165|DRUG|Disulfiram|
219379025|NCT01907165|DIETARY_SUPPLEMENT|Copper gluconate|
219379026|NCT02150031|DRUG|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
219379027|NCT02150031|DRUG|1% Chlorhexidine|subgingival irrigation
219379028|NCT02150031|DRUG|1% Chlorhexidine|supragingival irrigation
219379029|NCT02150031|PROCEDURE|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
219379030|NCT02150031|DRUG|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
219379031|NCT02150031|PROCEDURE|Tooth extraction|dental extraction
219379032|NCT00882414|DRUG|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
219379033|NCT00882414|DRUG|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
219379034|NCT00709202|DRUG|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
219379035|NCT00709202|DRUG|Placebo Oral Tablet|
219379036|NCT02184637|DRUG|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
219379037|NCT02184637|DRUG|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
219379038|NCT02184637|DRUG|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
219379039|NCT01070420|OTHER|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
219379040|NCT01070420|OTHER|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
219379041|NCT00989599|OTHER|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
219379042|NCT00989599|OTHER|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
219379043|NCT04671797|BEHAVIORAL|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
219379044|NCT04671797|BEHAVIORAL|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
219379045|NCT04671797|BEHAVIORAL|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
219379046|NCT04495660|DEVICE|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
219379047|NCT04495660|BEHAVIORAL|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
219379048|NCT04495660|BEHAVIORAL|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
219379049|NCT04495660|BEHAVIORAL|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
219379050|NCT04495660|BEHAVIORAL|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
219379051|NCT04495660|BEHAVIORAL|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
219379052|NCT04495660|BEHAVIORAL|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
219379053|NCT06314126|DIETARY_SUPPLEMENT|D-Chiro-Inositol|Patients in the experimental group will receive 1200 mg of oral D-Chiro-Inositol per day.
219379054|NCT06314126|OTHER|Placebo|Patients in the control group will receive 1200 mg of placebo per day.
219379055|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
219379056|NCT06359340|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
219379057|NCT05646836|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
219379058|NCT05646836|DRUG|XmAb24306|XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
219379059|NCT05646836|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
219379060|NCT03550560|PROCEDURE|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
219379061|NCT02597062|DRUG|Carfilzomib|
219379062|NCT02597062|DRUG|Cyclophosphamide|
219379063|NCT02597062|DRUG|Dexamethasone|
219379064|NCT04025645|DIAGNOSTIC_TEST|MEASUREMENT OF COMMON BILE DUCT PRESSURES|THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
219379065|NCT02034045|OTHER|Community Paramedicine|
219379066|NCT02034045|OTHER|Usual Care|
219379067|NCT00212407|BIOLOGICAL|Umbilical Cord Blood Transplantation|
219379068|NCT00423826|DRUG|Busulfan|3 mg/kg intravenously over 3 hours
219379069|NCT00423826|DRUG|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
219379070|NCT00423826|DRUG|Fludarabine phosphate|25 mg/M2/day IV
219379071|NCT00423826|DRUG|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
219379072|NCT00423826|DRUG|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
219379073|NCT00423826|PROCEDURE|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
219379074|NCT00423826|PROCEDURE|umbilical cord blood transplantation|10 days post drug intervention
219379075|NCT00423826|RADIATION|total-body irradiation|10 days post drug intervention
219379076|NCT02948166|PROCEDURE|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
219379077|NCT02948166|PROCEDURE|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
219379078|NCT01106547|DRUG|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
219379079|NCT01106547|DRUG|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
219379080|NCT01917786|DEVICE|ECG|
219379081|NCT03240900|DEVICE|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
219379082|NCT03240900|PROCEDURE|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
219379083|NCT05718401|DEVICE|NMR|nuclear magnetic resonance in genomics
219379084|NCT04447547|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
219379085|NCT00859755|DRUG|ARRY-403, glucokinase activator; oral|single dose, escalating
219379086|NCT00859755|DRUG|Placebo; oral|matching placebo
219379087|NCT05369806|BEHAVIORAL|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
219379088|NCT04101175|PROCEDURE|Evaluation of the procedure of abortion|Observational study using questionnaires
219379089|NCT06451874|BEHAVIORAL|Functional Power Training (FPT)|Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.
219379090|NCT06451874|BEHAVIORAL|Music-Based Digital Therapy (MBDT)|Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.
219379091|NCT06451874|BEHAVIORAL|FPT + MBDT|For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
219379092|NCT05040529|PROCEDURE|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
219379093|NCT05040529|PROCEDURE|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
219379094|NCT00001303|DRUG|Reference Endotoxin|
219379095|NCT00001303|DRUG|Inhaled Nitric Oxide|
219379096|NCT01392183|DRUG|Pazopanib|800 mg by mouth daily in 4 week study cycle.
219379097|NCT01392183|DRUG|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
219379098|NCT01392183|BEHAVIORAL|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
219379099|NCT01392183|DRUG|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
219379100|NCT00011115|BEHAVIORAL|Weight loss motivations|
219379101|NCT03810989|DEVICE|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
219379102|NCT03810989|DEVICE|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
219379103|NCT03810989|DEVICE|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
219379104|NCT04604327|DRUG|Bemiparin sodium|Prophilactic vs full-dose for 10 days
219379105|NCT01305915|BEHAVIORAL|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
219379106|NCT03430310|OTHER|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
219379107|NCT03430310|OTHER|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
219379108|NCT02134886|DRUG|Erlotinib Hydrochloride|Given PO
219379109|NCT02134886|OTHER|Laboratory Biomarker Analysis|Correlative studies
219379110|NCT02134886|OTHER|Pharmacological Study|Correlative studies
219379111|NCT02134886|OTHER|Quality-of-Life Assessment|Ancillary studies
219379112|NCT00765765|DRUG|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
219379113|NCT00765765|DRUG|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
219379114|NCT06654648|OTHER|Combined exercise nutrition intervention group|Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
219379115|NCT06654648|OTHER|Conventional medial care group|"Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
219379116|NCT03476239|DRUG|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
219379117|NCT03476239|DRUG|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
219379118|NCT04905862|DIAGNOSTIC_TEST|Immune response|"1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
219379119|NCT04905862|OTHER|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
219379120|NCT01999673|BIOLOGICAL|bavituximab|
219379121|NCT01999673|DRUG|Docetaxel|
219379122|NCT01999673|OTHER|Placebo (for bavituximab)|
219379123|NCT04836039|OTHER|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
219379124|NCT02278913|DRUG|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
219379125|NCT02278913|DRUG|Human Insulin|NPH twice a day + Regular insulin before meals
219379126|NCT03977246|BEHAVIORAL|Open-placebo|Application of the open-placebo intervention
219379127|NCT03977246|BEHAVIORAL|Control|Application of the control session
219379128|NCT02871479|DRUG|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
219379129|NCT02871479|DRUG|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
219379130|NCT02871479|DRUG|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
219379131|NCT02157454|OTHER|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
219379132|NCT00365755|DRUG|carboplatin|
219379133|NCT00365755|DRUG|cisplatin|
219379134|NCT00365755|DRUG|cyclophosphamide|
219379135|NCT00365755|DRUG|etoposide|
219379136|NCT00365755|DRUG|melphalan|
219379137|NCT00365755|DRUG|vincristine sulfate|
219379138|NCT00365755|PROCEDURE|autologous bone marrow transplantation|
219379139|NCT00365755|PROCEDURE|conventional surgery|
219379140|NCT06316479|DEVICE|PTMC Dermal Filler|A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
219379141|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth as a strategy to increase mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
219379142|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
219379143|NCT02600299|BEHAVIORAL|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
219379144|NCT02600299|BEHAVIORAL|Usual Care|Usual Care
219379145|NCT05792826|OTHER|BSZY Cream|The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
219760924|NCT00186628|DRUG|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
219379146|NCT05792826|OTHER|emulsion matrix|The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
219379147|NCT01097044|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
219379148|NCT01097044|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
219379149|NCT01262430|PROCEDURE|OtisMed|OtisMed Custom-fit Shapematching Guides
219379150|NCT01262430|PROCEDURE|Computer Assisted Surgery (CAS)|Stryker Navigation System
219379151|NCT01331161|BIOLOGICAL|ZOSTAVAX|shingles vaccine, one dose
219379152|NCT01920906|PROCEDURE|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
219379153|NCT01865734|OTHER|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
219379154|NCT01865734|OTHER|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
219379155|NCT05728814|DRUG|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
219379156|NCT06657573|BEHAVIORAL|An AI-enabled chatbot tailored for influenza vaccine consultation|The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
219379157|NCT06656832|OTHER|Heart Failure network care|Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
219379158|NCT01682044|BIOLOGICAL|pegfilgrastim|Given SC
219379159|NCT01682044|BIOLOGICAL|rituximab|Given IV
219379160|NCT01682044|OTHER|flow cytometry|Correlative studies
219379161|NCT01682044|PROCEDURE|biopsy|Correlative studies
219379162|NCT01682044|OTHER|immunohistochemistry staining method|Correlative studies
219379163|NCT01682044|GENETIC|western blotting|Correlative studies
219379164|NCT00757315|DEVICE|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
219379165|NCT00757315|DRUG|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
219379166|NCT00083161|DRUG|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
219379167|NCT00083161|DRUG|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
219379168|NCT00083161|DRUG|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
219379169|NCT06979557|DEVICE|Odyssey IOL|Bilateral implantation with the Odyssey IOL
219379170|NCT06985758|DRUG|Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg|Intravenous administration of a first dose of Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg to study the pharmacokinetic parameters of the drug.
219379171|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
219379172|NCT03435978|BEHAVIORAL|MetS+|
219379173|NCT03435978|OTHER|MetS-|Data processing from Patient Medical Files
219379174|NCT06817980|BEHAVIORAL|Physical activity|"\- Physical activity: We will compare the impact of 3 different environments (with no object in the environment, vs. with some objects but no hidden objects vs. with objects at the fore- and background) during (total of 9 sessions of 30 minutes + 3\*5 minutes of testing), on the measure of self (see below).~Visit 10: We will repeat a walking session. Participants will wear mixed-reality goggles, which allow them to visualize the environment and superimpose a continuous stream of light. This session is intended to test the idea that this flow would enable SZ patients to suffer less from the discontinuous appearance of information when moving around.~Measure of 'self' : the participants will decide whether the line presented on a computer screen is static or moving. They will be immobile, walking on the spot in front of the computer, or passively mobilized with a whole-body movement platform. The latter condition will be used only in the first phase of the protocol"
219379175|NCT06817005|DEVICE|Intervention arm|Prior to general anesthesia induction, a finger is inserted into the probe which is connected to the PMD200® to provide the NOL index. This output, a single dimensionless number from 0 to 100, correlated proportionally to nociception.
219379176|NCT06657040|OTHER|MUSIC|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
219379177|NCT06656871|DIETARY_SUPPLEMENT|iron supplementation|The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
219379178|NCT06656871|DIETARY_SUPPLEMENT|Biostimulated lettuce supplementation|the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
219379179|NCT06657261|PROCEDURE|The patient group receiving deep and superficial serratus anterior plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
219379180|NCT06657261|PROCEDURE|The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
219379181|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
219379182|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
219379183|NCT06656546|DIAGNOSTIC_TEST|Tracheal Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.
219379184|NCT06656546|DIAGNOSTIC_TEST|Lung Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.
219379185|NCT06656546|DIAGNOSTIC_TEST|Diaphragm Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
219379186|NCT06656468|DEVICE|Pacemaker and defibrillator|Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
219379187|NCT06092437|OTHER|Urine sodium guided diuretic algorithm|Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
219379188|NCT06092437|OTHER|Usual care|Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
219379189|NCT06679790|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|All participants will receive 8 sessions of CBIT following a published treatment manual.
219379190|NCT06855836|BEHAVIORAL|MI-CHANCE (TS + FTIR + MI)|MI-CHANCE was built following key principles of MI (partnership, acceptance, compassion and evocation) to empower PWUD, help them identify potential benefits of DCS and strategies to integrate these into their daily lives. The manual follows three key stages: 1) introducing DCS, 2) generating change talk, and 3) verbalizing commitment, using open questions, affirmations, reflections and summaries. Pros and cons for regularly using CheckSD and changing drug use behaviors accordingly were identified in the literature and through discussions with PWUD and HRCSD staff. Peer support specialists are urged to mirror participants' own language (e.g., oxy or M30s=oxycontin; carga= heroin; malilla=withdrawal, fetty=fentanyl). Challenges were categorized into 8 key areas: legal, financial, scheduling, transportation, ability to change drug use behaviors, communication with SSP staff, managing mood and substance use.
219379191|NCT06855836|BEHAVIORAL|TS + FTIR + Flu and Hepatitis A Education|Naloxone and educational materials (i.e. pamphlets) on overdose prevention, videos (English or Spanish) on naloxone, flu and Hepatitis A education.
219379192|NCT06985914|PROCEDURE|CT scan|CT scan in the emergency department
219379193|NCT02205450|DRUG|Recombinant Somatropin|
219379194|NCT02837679|OTHER|Geriatric Follow up|
219379195|NCT06411444|DEVICE|Grape Design Nasal Stent|Grape Design Nasal Stent
219379196|NCT07107633|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
219379197|NCT06861608|BEHAVIORAL|Screening Questionnaire|"Individuals will complete an online screening survey through an online study advertisement to determine initial eligibility. The screening survey will ask participants to report their gender and age and complete the Eating Attitudes Test - 26-item (EAT-26). EAT-26 scores equal to or greater than 20 indicate risk for an eating disorder. EAT-26, participants will meet the referral criteria which includes a score of 20 or more or meeting frequency criteria on bingeing, purging, laxative/diuretic use, and/or exercise. If an interested individual is not eligible, they will be notified that they are not currently eligible for the study and provided with resources."
219379198|NCT06861608|BEHAVIORAL|Pre-Intervention Questionnaires (~10 minutes)|Eligible participants will complete pre-intervention questionnaires including demographics and symptom measures.
219379199|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) Active arm|The SSI will consist of four components: 1)psychoeducation, 2) real-life examples, 3) common questions and misconceptions, and 4) providing advice to other young adults. Psychoeducation will focus on the brain bases of habit formation and EDs, as per REACH+ treatment manual. Participants will then be asked to think of a real-life example of an eating habit in which they have been engaged, such as limiting their intake of dessert foods. Participants will then be provided with REACH+ developed psychoeducation regarding changing habits, including information on competing responses, stimulus control, and exposure. Participants will have the opportunity to write out how they could use one of these strategies to tackle the habit that they previously wrote about. They will be provided with a worksheet to help them move through each aspect of changing their habit based on what they learned.
219379200|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) control arm|The control condition will be matched to the SSI by including both reading and writing exercises. The control intervention will consist of supportive therapy focusing on sharing emotions and include an introduction to emotions, writing about emotions, testimonials from other adolescents about the power of sharing emotions, and an exercise asking adolescents how different situations might make them feel.
219379201|NCT06861608|BEHAVIORAL|End-of-Intervention Questionnaires (~5 minutes)|Participants will complete additional questionnaires at the end of the intervention, including acceptability ratings and program feedback. Participants will provide an email address at the end of the questionnaires for receipt of four-week follow-up questionnaires.
219379202|NCT06322810|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral ESP: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
219379203|NCT06322810|PROCEDURE|Pecto-intercostal fascial plane blok (PIFB)|Bilateral PIFB: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
219379204|NCT05929924|DIETARY_SUPPLEMENT|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
219379205|NCT06158100|DRUG|Venetoclax|Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
219379206|NCT06158100|DRUG|Azacitidine|Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
219379207|NCT06158100|BIOLOGICAL|Donor Lymphocyte Infusion|"Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~* DLI 1: 1x10\^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~* DLI 2: 5x10\^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~* DLI 3: 1x10\^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD."
219379208|NCT07015047|DIETARY_SUPPLEMENT|Magnesium L-Threonate|Participants in this arm will take 1 gram of magnesium L-threonate (Magtein), provided in capsule form, once daily in the evening for 4 weeks. This supplement is known for its ability to cross the blood-brain barrier and may enhance sleep architecture, autonomic recovery, and cognitive function.
219379209|NCT07015047|OTHER|Placebo|Identical-looking inert capsule taken nightly for 4 weeks. Used as a comparator to magnesium L-threonate to assess changes in sleep, recovery, and performance metrics.
219379210|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
219379211|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
219379212|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
219379213|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
219379214|NCT07016672|PROCEDURE|intra-articular injection of HA|3 injections at 7-day intervals
219379215|NCT07016672|PROCEDURE|intra-articular injection of PRP|3 injections at 15-day intervals
219379216|NCT07021066|DRUG|BL-M05D1|BL-M05D1 will be administered on D1 every 3 weeks.
219379217|NCT06235229|BIOLOGICAL|GC012F|GC012F is a BCMA/CD19 dual CAR product
219379218|NCT07032129|BIOLOGICAL|BCMA/GPRC5D CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/GPRC5D Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/GPRC5D CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/GPRC5D CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
219379219|NCT07037784|OTHER|Continuous monitoring of vital constants with OXYFLEX® biosensor.|The comparison of physiological data (heart rate, respiratory rate, temperature, pulse oxygen saturation, hemoglobin levels) collected by the OXYFLEX® biosensor with those obtained through standard monitoring over a maximum duration of 10 hours.
219379220|NCT06884072|DRUG|Pimicotinib capsule|Pimicotinib capsule
219379221|NCT07043803|OTHER|Reduction of anticholinergic medication|Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.
219379222|NCT06926296|OTHER|Self-Questionnaires for Healthcare Workers|Health workers will be invited to complete an online self-questionnaire.
219379223|NCT06732518|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
219379224|NCT06732518|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
219379225|NCT06732518|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
219379226|NCT06732518|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
219379227|NCT07049744|DEVICE|XII Medical HGNS System|XII Medical HGNS System
219379229|NCT07053852|DRUG|Ameluz|broad band light (BBL) with the use of Ameluz
219379230|NCT07053852|DEVICE|Sciton HEROic|Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage.
219379231|NCT06857396|PROCEDURE|PREPA-TRACH|Tracheal exposure without tracheostomy completion during trans-oral robotic oncologic surgery
219379232|NCT06578520|DRUG|Dapagliflozin|10 mg once per day, oral tablets
219379233|NCT06591468|DRUG|Prednisone|Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
219379234|NCT06591468|DRUG|UDCA (Ursodeoxycholic acid)|13-15 mg/kg/day
219379235|NCT06843473|OTHER|No treatment given|No treatment given
219379236|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
219379237|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.
219379238|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
219379239|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
219379240|NCT04468360|BEHAVIORAL|3-day differential fear conditioning, extinction, and extinction retention testing paradigm|Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
219379241|NCT04468360|DRUG|Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
219379242|NCT04468360|OTHER|Matching IV Placebo|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
219379243|NCT06842082|DEVICE|Intubation with standard laryngoscope|Anesthesia resident will intubate using a standard laryngoscope.
219379244|NCT06842082|DEVICE|Intubation with video laryngoscope|Anesthesia resident will intubate using a videolaryngoscope (Storz C-MAC, McGrath, Glidescope or other videolaryngoscope)
219379245|NCT07106255|OTHER|Task-oriented training|"Participants included in the experimental group will underwent an 8-week TOT intervention, administered twice weekly, with each session lasting 45 minutes.~Within this framework, the intervention will comprise sessions involving meaningful and repetitive activities tailored to both the patient and their specific context. The occupations will be selected by each participant through the Canadian Occupational Performance Measure (COMP) tool in the initial assessment. The activities were randomly ordered and focused on the reconstruction of complete tasks. To support task segmentation, a range of custom-designed materials will be employed, alongside therapeutic tools and materials such as therapeutic putty, TheraBand, and others commonly used in physical rehabilitation interventions. Throughout the intervention, participants will receive positive reinforcement that will fade over the time to prevent unnecessary dependency."
219379246|NCT07106255|OTHER|Standar medical care and leaflet fatigue management|Participants included in the control group will continue with their usual treatment and will receive a pamphlet containing information on fatigue management.
219379247|NCT07106710|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
219379248|NCT07106710|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
219379249|NCT07106710|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
219379250|NCT07107594|BEHAVIORAL|Multimodal prehabilitation|Multimodal prehabilitation program during NACT (4-6 months) that will combine: 1) Physical exercise: cardiovascular and strength exercises designed by specialized physiotherapists, structured in 1-hour sessions twice a week. The characteristics of the activity will be adapted to the treatment phase and the physical condition of each woman. 2) Psychological therapies: standardized mindfullness practice by a specialized psychologist. As an alternative, patients who refuse mindfullness could receive psychological sessions on stress and anxiety management. 3) Nutritional counseling: periodic sessions with a specialized nutritionist providing dietary recommendations and nutritional advice adapted to the disease and condition of the patients.
219379251|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)|Participants will use an EEG-based rehabilitation training device (L-B300). After wearing an EEG cap and lying supine, their lower limbs will be positioned on a pedal with the hip, knee, and ankle joints of the unaffected (stronger) leg maintained at 90°. The leg support will be adjusted to the mid-calf and secured with straps. Participants will be instructed to focus on a screen and perform MI training. If they fail to activate the device within 30 seconds under guidance, the EEG difficulty level will be reduced until successful activation within 30 seconds. The EEG difficulty level will be adjusted throughout the trial based on the participant's MI ability.
219379252|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)（Not connected）|Participants will lie supine, with their lower limbs fixed to the L-B300 device using the same method as Group A. The computer screen will be turned off, and the machine will be set to drive passive or active cycling movements of the lower limbs.
219379253|NCT07105436|DIAGNOSTIC_TEST|Persistent air leak quantification|"In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.~Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician."
219379254|NCT07105488|BIOLOGICAL|BFB759|BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis
219379255|NCT07105488|DRUG|Placebo|Placebo for BFB759
219379256|NCT07101367|DRUG|Normal saline|After induction of anesthesia give 10 ml of normal saline then followed by infusion of normal saline till extubation of patient in ICU
219379257|NCT07101367|DRUG|Dexmedetomidine|After induction of anesthesia give loading dose of precedex 1 mcg/kg diluted in 10 ml normal saline then attach syringe pump of precedex infusion of 0.5mcg/kg/hr till extubation in ICU
219379258|NCT07101367|DRUG|Methylprednisolone|After induction of anesthesia give solumedrol of a dose 10mg/kg diluted in 10ml of normal saline followed by a normal saline infusion till the extubation of the patient in the ICU
219379259|NCT07107789|OTHER|Diabetes education with video animation|Providing diabetes education to the experimental group through a video animation Following the routine diabetes education provided by the hospital, the experimental group will receive diabetes education using a video animation prepared and staged by the researcher and approved by experts.
219760925|NCT00186628|DRUG|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
219760926|NCT00186628|DRUG|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
219760927|NCT00186628|DRUG|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
219760928|NCT00186628|DRUG|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
219379260|NCT07106684|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
219379261|NCT07106684|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
219379262|NCT07106684|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
219379263|NCT06911983|DRUG|Metformin|Metformin • Initial dose: 500 mg twice daily • Titration: increased to 1,000 mg twice daily by Week 2 if tolerated • Maximal dose: 2,000 mg/day
219379264|NCT06911983|DIETARY_SUPPLEMENT|Berberine|"Berberine~* Dose: 500 mg three times daily (1,500 mg/day total)~* Formulation: standardized berberine HCl tablets~* Duration: 12 weeks"
219379265|NCT07106996|DRUG|red yeast rice，RYR|Participants will take 6 grams of red yeast rice daily for 6 months.
219379266|NCT06755437|DEVICE|Rehabilitation with a computerized device (in the morning)|Each group received face-to-face cognitive rehabilitation with the electronic device for 45 min. The exercises were selected by the therapist and divided into four sessions of 2 to 3 days each. Each session included 40 min of activity and 5 minute of break
219379267|NCT06755437|DEVICE|Self-treatment with a computerized device (in the afternoon)|In the afternoon, the experimental group performed 60 min. self-guided treatment with the electronic device.
219379268|NCT06755437|BEHAVIORAL|self-treatment with pencil-and-paper exercises (in the afternoon)|In the afternoon, the control group performed 60 min of cognitive self-treatment with conventional paper-and-pencil instruments. The therapist created a variety of exercises every day
219379269|NCT07106619|DEVICE|Isokinetic Exercises|Exercises will be performed at three different angular speeds (90 ̊/sec, 5 repetitions, 5 sets; 120 ̊/sec, 8 repetitions, 5 sets; 150 ̊/sec, 10 repetitions, 5 sets).
219379270|NCT07106619|OTHER|Conventional rehabilitation program|Ambulation and balance exercises
219379271|NCT07106372|BIOLOGICAL|Stapokibatrt|Stapokibatrt Subcutaneous injection
219379272|NCT07106346|PROCEDURE|The timing of endoscopic intervention for necrotizing pancreatitis is determined based on the degree of encapsulation|In the encapsulation-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis when the degree of encapsulation reaches ≥80%, as confirmed by cross-sectional imaging (preferably contrast-enhanced CT). Imaging is repeated every 7-10 days after enrollment to assess encapsulation. Once sufficient encapsulation is observed and the patient presents with symptoms such as infection, abdominal pain, GOO or biliary obstruction, endoscopic drainage is performed. Drainage is typically performed using a lumen-apposing metal stent (LAMS) placed under EUS guidance, often accompanied by placement of an external drain. Step-up therapy, including endoscopic necrosectomy or additional drainage procedures, may be used if symptoms do not improve. If the patient improves with conservative therapy before encapsulation is achieved, drainage may be deferred. Endoscopic/percutaneous interventions should, in principle, be discussed with the expert panel beforehand.
219379273|NCT07106346|PROCEDURE|EUS-guided drainage based on the interval from the onset of acute pancreatitis|In the timing-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis at 4 to 5 weeks after the onset of acute pancreatitis, regardless of the degree of encapsulation. Drainage is performed only in symptomatic patients who meet predefined clinical criteria, such as signs of infection, significant pain, GOO, or biliary obstruction. Imaging is performed before the procedure. The standard approach involves placing a LAMS under EUS guidance, optionally supplemented by external drains. If symptoms do not improve, step-up interventions such as endoscopic necrosectomy, percutaneous drainage may be considered. If inflammation and symptoms improve with conservative treatment (e.g., antibiotics), EUS-guided drainage may be omitted. Conversely, even before 4-5 weeks from onset, early drainage is allowed if conservative treatment is deemed insufficient by the attending physician. In principle, intervention decisions should be discussed with the expert panel.
219379274|NCT06923111|DRUG|Xromi|Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age as part of standard clinical practice
219379275|NCT06915298|BEHAVIORAL|Alcohol health warning label - cancer|A sticker with health information on alcohol causing cancer is applied to alcoholic beverage containers purchased by the participants.
219379276|NCT06915298|BEHAVIORAL|Responsibility message on alcohol label|A sticker with a message to drink responsibly will be applied to alcoholic beverage containers purchased by the participants.
219379277|NCT06915298|BEHAVIORAL|Front label|A sticker will be applied to the front of the alcoholic beverage containers purchased by the participants.
219379278|NCT06915298|BEHAVIORAL|Back label|A sticker will be applied to the back of the alcoholic beverage containers purchased by the participants.
219379279|NCT06915298|OTHER|Outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is tested at baseline.
219379280|NCT06915298|OTHER|No outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is not tested at baseline.
219379281|NCT06935669|DRUG|Ketamine|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
219379282|NCT06935669|DRUG|Bupivacaine|Control group to evaluate the additional effect of ketamine in the experimental arm.
219379283|NCT06935669|DRUG|Bupivacain|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
219379284|NCT06946862|OTHER|no treatment, medication or intervention|will make an observational assessment of the participants' treatment expectations. Participants will not be subjected to any treatment or intervention, only their current situation will be observed.
219379285|NCT03277196|DRUG|IVA|Granules for oral administration.
219379286|NCT06305182|DRUG|Metreleptin|"Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection."
219379287|NCT06305182|DRUG|Sodium chloride|The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
219379288|NCT02464150|DIETARY_SUPPLEMENT|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
219379289|NCT03665155|DRUG|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
219379290|NCT03665155|DEVICE|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
219379291|NCT03665155|OTHER|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
219379292|NCT05277012|DRUG|Etrumadenant|Etrumadenant capsule and tablet formulations
219379293|NCT01826214|DRUG|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
219379294|NCT00525291|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
219379295|NCT00525291|DEVICE|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
219379296|NCT06543992|DRUG|Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
219379297|NCT03067220|OTHER|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
219379298|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
219379299|NCT04792229|OTHER|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
219379300|NCT04484909|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
219379301|NCT04484909|RADIATION|Radiation Therapy|Undergo radiation therapy
219379302|NCT04622852|DEVICE|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
219379303|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
219379304|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
219379305|NCT04034615|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
219379306|NCT02350543|DRUG|Aspirin|
219379307|NCT01158183|DRUG|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
219379308|NCT01317849|DRUG|Folic Acid|0.8mg
219379309|NCT01317849|DRUG|Vitamin B6|10mg
219379310|NCT01317849|DRUG|Vitamin B12|500ug
219379311|NCT01317849|DRUG|placebo|0.8 mg
219379312|NCT01317849|DRUG|placebo|10mg
219379313|NCT01317849|DRUG|placebo|500ug
219379314|NCT06132568|DEVICE|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
219379315|NCT01403298|BEHAVIORAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
219379316|NCT01403298|OTHER|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
219379317|NCT02801175|PROCEDURE|Pulmonary vein isolation|
219379318|NCT06070363|OTHER|Manual Acupuncture|Acupuncture Needle Insertion
219379319|NCT00849550|DRUG|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
219379320|NCT04314687|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
219379321|NCT04314687|BIOLOGICAL|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
219379322|NCT04314687|OTHER|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
219379323|NCT03409302|BEHAVIORAL|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
219379324|NCT03409302|BEHAVIORAL|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
219379325|NCT03184870|DRUG|BMS-813160|Specified dose on specified days
219379326|NCT03184870|BIOLOGICAL|Nivolumab|Specified dose on specified days
219379327|NCT03184870|DRUG|Nab-paclitaxel|Specified dose on specified days
219379328|NCT03184870|DRUG|Gemcitabine|Specified dose on specified days
219379329|NCT03184870|DRUG|5-fluorouracil (5-FU)|Specified dose on specified days
219379330|NCT03184870|DRUG|Leucovorin|Specified dose on specified days
219379331|NCT03184870|DRUG|Irinotecan|Specified dose on specified days
219379332|NCT06176703|DEVICE|mobile application|using mobile application along with standard treatment of diabetes mellitus
219379333|NCT06049316|OTHER|Scapular stabilization exercises|"In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks."
219379334|NCT06049316|OTHER|Scapular functional exercises|"In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks."
219379335|NCT01979510|DRUG|MK-0663B|MK-0663B once daily for 8 days.
219379336|NCT01979510|DRUG|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
219379337|NCT01979510|DRUG|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
219379338|NCT04329936|BEHAVIORAL|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
219379339|NCT02821286|OTHER|Observational study|Blood sampling
219379340|NCT06793644|DRUG|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
219379341|NCT02108457|RADIATION|[18F]Fluorothymidine (FLT) PET/CT Imaging|
219379342|NCT03984526|DRUG|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
219379343|NCT03984526|DRUG|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
219379344|NCT03984526|DRUG|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
219379345|NCT02655198|DRUG|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
219379346|NCT02592564|BEHAVIORAL|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
219379347|NCT03050684|PROCEDURE|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
219379348|NCT03050684|PROCEDURE|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
219379349|NCT05600010|OTHER|Microplastics|Detection of microplastics as a yes/no value
219379350|NCT04782739|OTHER|None - Descriptive study|Descriptive study
219379351|NCT03545516|DRUG|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
219379352|NCT03545516|DRUG|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
219379353|NCT03545516|DRUG|Placebo|Injection of a placebo into the surgical wound
219379354|NCT04558008|BEHAVIORAL|Online MBSR|Described previously
219379355|NCT04086043|DEVICE|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
219379356|NCT01344122|OTHER|KPI training only|See comparison arm description.
219379357|NCT01344122|OTHER|KPI plus OLI|See experimental arm description.
219379358|NCT06394622|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
219379359|NCT01471327|BIOLOGICAL|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
219379360|NCT01471327|OTHER|Placebo|Saline IV, single dose at Day 1
219379361|NCT01056107|DRUG|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
219379362|NCT01056107|DRUG|Placebo|Placebo subcutaneous injection daily
219379363|NCT06382688|DIETARY_SUPPLEMENT|NAD+ (nicotinamide adenine dinucleotide) IV|NAD+ enables cells to generate cellular energy from the food that one eats
219379364|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) IV|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
219379365|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) oral|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
219379366|NCT06382688|OTHER|Placebo|These individuals received a saline IV
219379367|NCT05195359|BEHAVIORAL|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
219379368|NCT01839994|RADIATION|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
219379369|NCT01839994|RADIATION|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
219379370|NCT01839994|DRUG|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
219379371|NCT04219306|OTHER|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
219379372|NCT04275752|OTHER|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
219379373|NCT02017444|DRUG|AZD4017|
219379374|NCT02017444|OTHER|Placebo|Matched placebo (matched to AZD4017 arm)
219379375|NCT01614457|DRUG|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
219379376|NCT01614457|DRUG|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
219379377|NCT04183101|DRUG|Aliskiren|Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
219379378|NCT04183101|DRUG|Enalapril|Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
219379379|NCT06128512|OTHER|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
219379380|NCT06128512|OTHER|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
219379381|NCT04577768|DEVICE|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
219379382|NCT04577768|DEVICE|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
219379383|NCT04577768|DEVICE|HD-tDCS sham|sham stimulation of the right primary motor cortex
219379384|NCT05863429|BIOLOGICAL|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
219379385|NCT02950623|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
219379386|NCT02950623|OTHER|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
219379387|NCT05604105|OTHER|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
219379388|NCT02795910|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
219379389|NCT02795910|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
219379390|NCT00381316|DRUG|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
219379391|NCT00381316|DRUG|Thallous Chloride T1-201|Myoview SPECT Imaging
219379392|NCT01341873|OTHER|educational intervention|Undergo APN FCI
219379393|NCT01341873|OTHER|psychosocial support for caregiver|Undergo APN FCI
219379394|NCT01341873|PROCEDURE|quality-of-life assessment|Ancillary studies
219379395|NCT01341873|OTHER|questionnaire administration|Ancillary studies
219379396|NCT03397420|OTHER|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
219379397|NCT01854567|BIOLOGICAL|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
219379398|NCT01854567|BIOLOGICAL|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
219379399|NCT04296136|OTHER|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
219379400|NCT06069687|BIOLOGICAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
219379401|NCT04985708|OTHER|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
219379402|NCT01186653|DRUG|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
219379403|NCT01186653|DRUG|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
219379404|NCT05762705|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
219379405|NCT05762705|BEHAVIORAL|Treatment as Usual +|non-PrEP related mobile gaming application
219379406|NCT03707093|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
219379407|NCT03903055|DIAGNOSTIC_TEST|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
219379408|NCT01512524|OTHER|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
219379409|NCT05424692|DRUG|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
219379410|NCT06443073|OTHER|Patient-reported outcomes for speech disorders: positive|The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
219379411|NCT04570579|DEVICE|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
219379412|NCT05804162|DRUG|Cagrilintide|Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
219379413|NCT05804162|DRUG|Cagrilintide Placebo|Participants will receive cagrilintide placebo subcutaneously once weekly.
219379414|NCT05804162|DRUG|Moxifloxacin|Partcipants will receive a single dose of moxifloxacin orally.
219379415|NCT05804162|DRUG|Moxifloxacin Placebo|Partcipants will receive a single dose of moxifloxacin orally.
219379416|NCT05349955|OTHER|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
219379417|NCT05349955|OTHER|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
219379418|NCT01380899|PROCEDURE|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
219379419|NCT01568723|GENETIC|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
219379420|NCT01355406|DEVICE|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
219379421|NCT05352191|DRUG|Beclomethasone|inhaled 800ug
219379422|NCT04207398|PROCEDURE|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
219379423|NCT04207398|OTHER|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
219379424|NCT01938859|DRUG|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
219379425|NCT01938859|DRUG|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
219379426|NCT01938859|DRUG|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
219379427|NCT00648986|DRUG|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
219379428|NCT05268848|OTHER|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
219379429|NCT00673855|OTHER|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
219379430|NCT00673855|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
219379431|NCT06282692|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg|Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
219379432|NCT04775823|PROCEDURE|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
219379433|NCT04036084|DIAGNOSTIC_TEST|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
219379434|NCT04909567|BEHAVIORAL|Optimisation|Defined optimisation
219379435|NCT05178537|OTHER|AAS users|no intervention
219379436|NCT00087295|DRUG|Depsipeptide|Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
219379437|NCT04113629|DEVICE|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
219379438|NCT01821963|DRUG|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
219379439|NCT01821963|DRUG|Ribavirin|Starting dose: 1,000 mg by mouth daily.
219379440|NCT01821963|DRUG|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
219379441|NCT03195101|PROCEDURE|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
219379442|NCT02214173|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
219379443|NCT02214173|DIETARY_SUPPLEMENT|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
219379444|NCT05704530|OTHER|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
219379445|NCT03952130|DRUG|LY900014|Administered SC
219379446|NCT03952130|DRUG|Insulin Lispro|Administered SC
219379447|NCT03952130|DRUG|Insulin Glargine|Administered SC
219379448|NCT03952130|DRUG|Insulin Degludec|Administered SC
219379449|NCT01713348|DEVICE|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
219379450|NCT01713348|DEVICE|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
219379451|NCT03021837|OTHER|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
219379452|NCT01896232|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
219379453|NCT01896232|DRUG|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
219379454|NCT01896232|DRUG|Oral Placebo|Administered orally once a day.
219379455|NCT01896232|DRUG|Intravenous Placebo|Administered intravenously (IV) three times per week.
219379456|NCT05375292|OTHER|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises."
219379457|NCT00852644|PROCEDURE|computed tomography|Standard CT scans
219379458|NCT00852644|RADIATION|fludeoxyglucose F 18|standard doses with CT scans
219379459|NCT00852644|RADIATION|hypofractionated radiation therapy|4 doses over 2 weeks
219379460|NCT00852644|RADIATION|stereotactic radiosurgery|CyberKnife radiosurgery
219379461|NCT03088241|OTHER|switch|switch to second-line ART
219379462|NCT04243044|DEVICE|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
219379463|NCT04600999|DRUG|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
219379464|NCT03848520|PROCEDURE|TKA|TKA performed in the past
219379465|NCT04293848|OTHER|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
219379466|NCT04293848|OTHER|Only music (no vibrations)|listening to music, no vibrations
219379467|NCT04185467|OTHER|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
219379468|NCT01086683|BEHAVIORAL|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
219379469|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
219379470|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a lyophilized formulation
219379471|NCT00006418|PROCEDURE|DNA collection|
219379472|NCT05976737|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
219379473|NCT05976737|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
219379474|NCT06223425|BEHAVIORAL|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
219379475|NCT01972477|DRUG|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
219379476|NCT01972477|OTHER|Placebo|Placebo will be given every day for 8 weeks.
219379477|NCT02721004|DRUG|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
219379478|NCT04150432|DEVICE|Edmon|New device for exhaled propofol concentration measurements
219379479|NCT00686205|DEVICE|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
219379480|NCT00265941|DRUG|cetuximab|Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks
219379481|NCT00265941|DRUG|cisplatin|Cisplatin 100 mg/m\^2 IV on days 1 and 22
219379482|NCT00265941|RADIATION|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
219379483|NCT00265941|RADIATION|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
219379484|NCT03741439|DEVICE|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
219379485|NCT03741439|DEVICE|Sham|Sham treatment
219379486|NCT04154553|DIAGNOSTIC_TEST|Buccal swab|Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.
219379487|NCT04154553|DIAGNOSTIC_TEST|EDTA Blood sample (4.9mL)|Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.
219379488|NCT04154553|DIAGNOSTIC_TEST|Serum sample (7.5mL)|blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).
219379489|NCT04154553|OTHER|communication of test results|Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician
219379490|NCT04154553|OTHER|unstructured interview|One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes
219379491|NCT02373930|DRUG|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
219379492|NCT02373930|DRUG|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
219379493|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
219379494|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
219379495|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
219379496|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
219379497|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
219379498|NCT00898053|OTHER|laboratory biomarker analysis|Correlative studies
219379499|NCT01583647|DRUG|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
219379500|NCT01583647|DRUG|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
219379501|NCT00173953|PROCEDURE|immune response|
219379502|NCT03816995|DEVICE|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
219379503|NCT03816995|DEVICE|Alexis O Wound Protector|wound retraction
219379504|NCT03691558|OTHER|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
219379505|NCT03691558|OTHER|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
219379506|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at T0|
219379507|NCT03123523|DIAGNOSTIC_TEST|Exercise test|
219379508|NCT03123523|BIOLOGICAL|Biological assays|Creatinin, hematocrit and BNP assays
219379509|NCT03123523|DEVICE|MRI with contrast agent injection|With injection of gadolinium
219379510|NCT03123523|DEVICE|MRI without contrast agent injection|Without injection of gadolinium
219379511|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at M24|
219379512|NCT01864577|OTHER|Negative Pleural Suction at -20 cm H2O|
219379513|NCT01864577|OTHER|Water seal|
219379514|NCT06082778|BEHAVIORAL|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
219379515|NCT03109951|DRUG|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
219379516|NCT05258461|OTHER|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
219379517|NCT05258461|OTHER|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
219379518|NCT03747445|PROCEDURE|Roux-en-Y gastric bypass|laparoscopic surgical procedure
219379519|NCT06098014|DRUG|Thalidomide Capsules|To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
219379520|NCT06098014|DRUG|Placebo|compare with Thalidomide
219379521|NCT00704470|OTHER|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
219379522|NCT00704470|OTHER|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
219379523|NCT00960271|PROCEDURE|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
219379524|NCT00098631|DRUG|lapatinib ditosylate|Given orally
219379525|NCT00098631|OTHER|laboratory biomarker analysis|Correlative studies
219379526|NCT04345549|OTHER|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
219379527|NCT04436913|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
219379528|NCT04436913|OTHER|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
219379529|NCT04436913|OTHER|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
219379530|NCT04731064|PROCEDURE|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
219379531|NCT05887635|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
219379532|NCT02217735|BEHAVIORAL|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
219379533|NCT03780517|DRUG|BOS172738|Oral capsules
219379534|NCT05051085|BEHAVIORAL|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
219379535|NCT05613270|DIAGNOSTIC_TEST|18F-FES PET/CT scan|Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
219379536|NCT04548843|PROCEDURE|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
219379537|NCT04548843|PROCEDURE|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
219379538|NCT04548843|BIOLOGICAL|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
219379539|NCT00112476|DRUG|bryostatin 1|Given IV
219379540|NCT00112476|DRUG|temsirolimus|Given IV
219379541|NCT03118622|DEVICE|Pentax|Intubation using Pentax video laryngoscope in Pentax group
219379542|NCT02781974|OTHER|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
219379543|NCT01419509|GENETIC|DNA methylation analysis|
219379544|NCT01419509|GENETIC|microarray analysis|
219379545|NCT01419509|GENETIC|polymerase chain reaction|
219379546|NCT01419509|OTHER|laboratory biomarker analysis|
219000958|NCT05237531|BEHAVIORAL|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
219379547|NCT01283256|DRUG|zonisamide|zonisamide 100mg tablets
219379548|NCT01324830|DRUG|day 1 to day 5|low to high dose
219379549|NCT01324830|DRUG|day 1 to day 14|low to high dose
219379550|NCT03677674|OTHER|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
219379551|NCT03467620|DRUG|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
219379552|NCT03467620|DRUG|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
219379553|NCT04700267|DRUG|GLPG3970 film-coated tablet|GLPG3970 for oral administration
219379554|NCT04700267|DRUG|Placebo film-coated tablet|Placebo for oral administration
219379555|NCT03538028|BIOLOGICAL|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
219379556|NCT01938183|PROCEDURE|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
219379557|NCT01938183|DRUG|Metronidazole tablet|750 mg metronidazole tablets
219379558|NCT01938183|DRUG|placebo gel|semi-solid suspension containing carbopol
219379559|NCT01938183|DRUG|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
219379560|NCT00942409|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
219379561|NCT03537664|PROCEDURE|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
219379562|NCT03537664|PROCEDURE|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
219379563|NCT03529656|BEHAVIORAL|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
219379564|NCT03864276|DRUG|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
219379565|NCT03864276|DRUG|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
219379566|NCT01240070|OTHER|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
219379567|NCT03617926|DEVICE|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
219379568|NCT03617926|OTHER|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
219379569|NCT06491043|OTHER|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells
219379570|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
219379571|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
219379572|NCT01503021|DRUG|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
219379573|NCT01503021|OTHER|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
219379574|NCT01802944|DRUG|Intranasal Insulin|
219379575|NCT01802944|DRUG|Placebos|
219379576|NCT00817414|DRUG|LCI699-matching placebo|LCI699-matching placebo oral capsules
219379577|NCT00817414|DRUG|LCI699|LCI699 oral capsules
219379578|NCT06075056|OTHER|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
219379579|NCT01449838|DRUG|Colistimethate sodium|active
219379580|NCT01449838|DRUG|Saline|placebo
219379581|NCT02809248|DEVICE|ZES|stent implantation (zotarolimus eluting stent)
219379582|NCT02809248|DEVICE|BMS|stent implantation (bare metal stent)
219379583|NCT00097539|BIOLOGICAL|Somatrem|
219379584|NCT00097539|BIOLOGICAL|Somatropin|
219379585|NCT01552876|DEVICE|etafilcon A|A daily wear contact lens
219379586|NCT01552876|DEVICE|nelfilcon A|A daily wear contact lens
219379587|NCT01552876|DEVICE|Filcon II 3|a daily disposable
219379588|NCT06486831|OTHER|Squeeze the stress ball.|The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
219760929|NCT05822310|PROCEDURE|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
219379589|NCT01455350|PROCEDURE|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
219379590|NCT01455350|DRUG|lidocaine|10 weeks of daily topical 5% lidocaine application
219379591|NCT01331395|OTHER|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
219379592|NCT01232725|DIETARY_SUPPLEMENT|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
219379593|NCT01079715|DRUG|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
219379594|NCT04006769|DRUG|Entacapone|Entacapone tablet
219000959|NCT05237531|BEHAVIORAL|Standard of care|Education per provider preference (no standardization, current standard of care)
219379595|NCT04006769|DRUG|Imatinib Mesylate|Imatinib Mesylate tablet
219379596|NCT01971879|PROCEDURE|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
219379597|NCT01971879|PROCEDURE|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
219379598|NCT06487351|BEHAVIORAL|The adapted PHBI|The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
219379599|NCT06487351|BEHAVIORAL|The NIH Implicit Bias course|The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
219379600|NCT02015819|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
219379601|NCT02015819|DRUG|flucytosine|Given orally
219379602|NCT02015819|DRUG|leucovorin calcium|Given orally
219379603|NCT02015819|OTHER|pharmacological study|Correlative studies
219379604|NCT02015819|OTHER|laboratory biomarker analysis|Correlative studies
219379605|NCT05862363|DIETARY_SUPPLEMENT|Microbiota-directed balanced energy protein (MD-BEP)|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
219379606|NCT05862363|DIETARY_SUPPLEMENT|Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)|RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
219379607|NCT05862363|PROCEDURE|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
219379608|NCT05862363|BEHAVIORAL|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care.
219379609|NCT06118528|DEVICE|Blur Obfuscation|Blurring is applied to the RGB images.
219379610|NCT06118528|DEVICE|Cartoon Obfuscation|Cartoonization is applied to the RGB images.
219379611|NCT06118528|DEVICE|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
219379612|NCT06118528|DEVICE|No Obfuscation (raw)|No editing is performed on the RGB images.
219379613|NCT06328010|BIOLOGICAL|Advanced Treatment Modalities for wound and injuries|Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts
219379614|NCT06328010|BIOLOGICAL|Standard of care|Standard of care without use of grafts or scaffolded grafts
219379615|NCT06328010|OTHER|Retrospective wound treatment data collection|Completed wound care treatment regardless of modality.
219379616|NCT06645340|OTHER|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
219379617|NCT05071664|DRUG|Guselkumab|Guselkumab will be administered as a SC injection.
219379618|NCT05071664|DRUG|Golimumab|Golimumab will be administered as a SC injection.
219379619|NCT05071664|DRUG|Placebo|Placebo will be administered as a SC injection.
219379620|NCT06544837|DIAGNOSTIC_TEST|Window of Implantation|Determine the subject's window of implantation through testing and adjust the embryo implantation time
219379621|NCT02372968|OTHER|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
219379622|NCT06022783|OTHER|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
219379623|NCT05850234|BIOLOGICAL|GC012F (AZD0120)|GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
219379624|NCT05256537|OTHER|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
219379625|NCT02662478|PROCEDURE|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
219379626|NCT05722002|DRUG|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
219379627|NCT05722002|DRUG|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
219379628|NCT05722002|DRUG|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
219379629|NCT05268380|DIAGNOSTIC_TEST|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
219379630|NCT03822949|DEVICE|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
219379631|NCT03822949|DEVICE|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
219379632|NCT03822949|DEVICE|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
219379633|NCT03822949|DEVICE|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
219379634|NCT02421198|BEHAVIORAL|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
219379635|NCT05592340|BEHAVIORAL|Exposure to calorie information|Calories for all foods and beverages
219379636|NCT05592340|BEHAVIORAL|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
219379637|NCT00803556|DRUG|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
219379638|NCT00803556|DRUG|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
219379639|NCT00803556|DRUG|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
219379640|NCT05916352|DIETARY_SUPPLEMENT|Caffeine Supplement|Caffeine tablet
219379641|NCT02945657|DRUG|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
219379642|NCT03424226|DRUG|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
219379643|NCT01602731|DEVICE|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
219379644|NCT05040191|OTHER|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
219379645|NCT05040191|OTHER|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
219379646|NCT05040191|OTHER|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
219379647|NCT01779609|DRUG|Bosentan|
219379648|NCT01779609|DRUG|Placebo|
219379649|NCT01779609|BEHAVIORAL|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
219379650|NCT00606515|DRUG|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
219379651|NCT00606515|DRUG|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
219379652|NCT00283387|DRUG|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
219379653|NCT00283387|DRUG|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
219379654|NCT00982605|PROCEDURE|EBUS_TBNA|EBUS during bronchoscopy
219379655|NCT00827489|DRUG|HTC-867|
219379656|NCT00827489|OTHER|Placebo|
219379657|NCT04894383|DEVICE|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
219379658|NCT04894383|DEVICE|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
219379659|NCT01517438|BEHAVIORAL|agitation|agitation score after desflurane anesthesia
219379660|NCT00327392|DRUG|AQUAVAN® (fospropofol disodium) Injection|
219379661|NCT03614936|OTHER|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
219379662|NCT03614936|OTHER|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)"
219379663|NCT01069848|DEVICE|Vedera KXS|One treatment session with Vedera KXS
219379664|NCT01871792|DRUG|Pitavastatin|
219379665|NCT01871792|DRUG|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
219379666|NCT00143325|DRUG|varenicline (CP-526,555)|
219379667|NCT05983640|OTHER|Video|Just in time training video on hands only CPR
219379668|NCT05983640|OTHER|AHA course|AHA Heartsaver CPR course
219379669|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
219379670|NCT02595242|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
219188451|NCT06504628|DIAGNOSTIC_TEST|screening risk for falling and identifiy the risk level low-intermediate-high|"3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk"
219379671|NCT02595242|DRUG|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
219188452|NCT06504628|DIAGNOSTIC_TEST|3 mnth-follow-up|patient's phone call, and data collected from electronic medical record
219188453|NCT02328599|PROCEDURE|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
219188454|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
219379672|NCT02595242|DRUG|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
219379673|NCT01767233|PROCEDURE|ERCP and pancreatic stenting|
219379674|NCT02793284|RADIATION|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
219379675|NCT03584009|DRUG|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
219379676|NCT03584009|DRUG|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
219379677|NCT00446030|DRUG|Docetaxel|"75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
219379678|NCT00446030|DRUG|Doxorubicin|50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
219379679|NCT00446030|DRUG|Carboplatin|6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6
219379680|NCT00446030|DRUG|Cyclophosphamide|500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
219379681|NCT00446030|DRUG|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
219379682|NCT00446030|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
219379683|NCT02886715|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
219379684|NCT02886715|DRUG|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
219379685|NCT02886715|DRUG|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
219379686|NCT00222105|DRUG|Doxil|Doxil 40 mg/m2 IV day 1
219379687|NCT00222105|DRUG|Thalidomide|50-100 mg day 1-28
219379688|NCT00222105|DRUG|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
219379689|NCT02420457|PROCEDURE|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
219379690|NCT02420457|DRUG|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
219379691|NCT03473873|OTHER|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
219379692|NCT00503399|DRUG|Teriparatide|20 µg/day sc for 18 months
219379693|NCT00503399|DRUG|Risedronate|35 mg/week po for 18 months
219379694|NCT04724889|DIAGNOSTIC_TEST|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
219379695|NCT01172067|DEVICE|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
219379696|NCT01172067|DEVICE|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
219379697|NCT00204087|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
219379698|NCT00204087|BEHAVIORAL|Supportive Counselling (SC)|
219379699|NCT02473406|DRUG|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
219379700|NCT02473406|DRUG|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
219379701|NCT00597649|DRUG|Bicifadine|SR dosage form of 400 mg bid or tid for one year
219379702|NCT01152099|OTHER|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
219379703|NCT01152099|OTHER|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
219379704|NCT03864965|OTHER|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
219379705|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
219379706|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
219188455|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
219379707|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
219188456|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
219191751|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
219379708|NCT02469129|DRUG|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
219379709|NCT05638321|DEVICE|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
219379710|NCT00962715|BIOLOGICAL|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
219379711|NCT00962715|DRUG|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
219379712|NCT00962715|DRUG|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
219379713|NCT01343615|PROCEDURE|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
219379714|NCT01343615|PROCEDURE|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
219379715|NCT04626830|OTHER|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
219379716|NCT00326820|DRUG|ibandronate sodium|
219379717|NCT00326820|DRUG|zoledronic acid|
219379718|NCT00326820|DRUG|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
219379719|NCT00089557|DRUG|Capsaicin Dermal Patch|
219379720|NCT03104582|PROCEDURE|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
219379721|NCT03104582|PROCEDURE|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
219379722|NCT01744561|BEHAVIORAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
219379723|NCT03431220|DEVICE|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
219188457|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
219188458|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
219188459|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
219188460|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
219760930|NCT05822310|PROCEDURE|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
219188461|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
219188462|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
219188463|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
219379724|NCT01989663|DRUG|1% vaginally applied tenofovir gel|
219379725|NCT01989663|DRUG|Tenofovir film- 10mg|
219379726|NCT01989663|DRUG|Tenofovir Film-40 mg|
219379727|NCT01989663|OTHER|HEC Placebo Gel|
219379728|NCT01989663|OTHER|Placebo Vaginal Film|
219379729|NCT02413658|DRUG|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
219379730|NCT02413658|DRUG|Sugar solution|
219379731|NCT03932240|DRUG|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
219188464|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
219379732|NCT03932240|DRUG|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
219188465|NCT05590728|DRUG|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
219188466|NCT02852213|DRUG|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
219188467|NCT03734679|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
219188468|NCT06526754|DEVICE|3D-Printed Liver Model|Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.
219188469|NCT06526754|PROCEDURE|Digital Simulation-Based Surgical Planning|Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
219188470|NCT04339101|DRUG|Fludarabine|Given via infusion
219188471|NCT04339101|DRUG|Itacitinib Adipate|Given PO
219188472|NCT04339101|DRUG|Melphalan|Given IV
219188473|NCT04339101|OTHER|Quality-of-Life Assessment|Ancillary studies
219188474|NCT04339101|OTHER|Questionnaire Administration|Ancillary studies
219188475|NCT04339101|DRUG|Sirolimus|Given PO
219188476|NCT04339101|DRUG|Tacrolimus|Given IV or PO
219188477|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
219188478|NCT05772104|DRUG|Shugan Jieyu Capsules Placebo|"Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
219188479|NCT05336201|BEHAVIORAL|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
219188480|NCT02432261|DRUG|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
219188481|NCT02432261|DRUG|Testosterone only gel|Testosterone only gel
219188482|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after photorefractive keratectomy (PRK)
219188483|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after photorefractive keratectomy (PRK)
219188484|NCT02260557|DRUG|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
219188485|NCT02260557|DRUG|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
219188486|NCT05756088|DIAGNOSTIC_TEST|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
219188487|NCT06786507|DRUG|Ustekinumab 90 mg|Ustekinumab is a human monoclonal IgG1 antibody that blocks the p40 subunit of both IL-12 and IL-23 this antagonistic action inhibits the interaction of these cytokines with the IL-12Rβ1 receptor. The IL-12Rβ1 receptor is found on the surface of NK cells and T cells which reduces inflammation and alters the body's immune response
219188488|NCT06786507|DRUG|Infliximab|Infliximab is a biological therapy/immunotherapy medication designed to stimulate the body's immune system and treat certain diseases. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha (TNF-α). TNF-α is a signaling protein involved in acute phase reactions and systemic inflammation. Macrophages, CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons produce TNF-α. This TNF-α inhibition inhibits the inflammatory reaction's cascade, leading to improved disease condition inflammatory bowel disease
219188489|NCT06783738|OTHER|Exercise|The participants will come to our lab twice. In the first visit we will perform a fitness assessment, using a noninvasive, cardiopulmonary exercise testing used routinely to measure fitness in children.
219188490|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
219379733|NCT04154098|DEVICE|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
219188491|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
219188492|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
219188493|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
219188494|NCT06852287|DRUG|chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.|Toripalimab: 240mg ivd d1, q3w; Lenvatinib: 8-12mg po qd (body weight\<60kg, 8mg po qd; body weight ≥ 60kg, 12mg po qd) Chemotherapy by hepatic arterial infusion (GOLD HAIC): d1 oxaliplatin: 100-125mg+gemcitabine: 800-1000mg; q3w.
219188495|NCT06250608|DEVICE|Pulse oximeter, NIRSITX|It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
219379734|NCT04154098|PROCEDURE|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
219379735|NCT04154098|OTHER|No assistance|Participants are elevating their arm without being assisted
219379736|NCT04154098|OTHER|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
219379737|NCT05696938|DIETARY_SUPPLEMENT|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
219379738|NCT05696938|DIETARY_SUPPLEMENT|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
219379739|NCT05288465|DRUG|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
219379740|NCT03124043|OTHER|Livongo for Diabetes program|See description in arm/group description.
219379741|NCT00666744|OTHER|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
219379742|NCT02213718|DRUG|Desflurane|desflurane (7%-8% end-tidal concentration)
219379743|NCT02213718|DRUG|propofol|propofol (TCI:3.5-4.0μg/min)
219379744|NCT02213718|DRUG|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
219379745|NCT04657848|PROCEDURE|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
219379746|NCT03348514|DRUG|CPX-POM - 30 mg/m^2|CPX-POM
219379747|NCT03348514|DRUG|CPX-POM - 60 mg/m^2|CPX-POM
219379748|NCT03348514|DRUG|CPX-POM - 120 mg/m^2|CPX-POM
219379749|NCT03348514|DRUG|CPX-POM - 240 mg/m^2|CPX-POM
219379750|NCT03348514|DRUG|CPX-POM - 360 mg/m^2|CPX-POM
219379751|NCT03348514|DRUG|CPX-POM - 600 mg/m^2|CPX-POM
219379752|NCT03348514|DRUG|CPX-POM - 900 mg/m^2|CPX-POM
219379753|NCT03348514|DRUG|CPX-POM - 1200 mg/m^2|CPX-POM
219379754|NCT00318955|DRUG|Dexmedetomidine|
219379755|NCT00318955|DRUG|Propofol|
219379756|NCT02053974|DRUG|Spironolactone|Spironolactone
219379757|NCT02053974|OTHER|Placebo|Placebo
219379758|NCT03502746|DRUG|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
219379759|NCT03502746|DRUG|Ramucirumab|8mg/kg, IV over 60 minutes.
219188496|NCT04200911|DRUG|Rapamune|Sirolimus 1mg capsules
219188497|NCT06849232|PROCEDURE|Platelet-Rich Plasma (PRP) Injections|wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly
219379760|NCT03497299|DEVICE|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
219379761|NCT03497299|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
219379762|NCT02700529|DRUG|ubenimex|
219379763|NCT02700529|OTHER|placebo|
219379764|NCT00551707|DRUG|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
219379765|NCT00551707|DRUG|prednisolone|prednisolone (2.7 mg)
219379766|NCT00551707|DRUG|dipyridamole|dipyridamole 360 mg
219379767|NCT00551707|DRUG|placebo|placebo
219379768|NCT00551707|DRUG|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
219379769|NCT01883570|OTHER|training in visual search strategy|
219379770|NCT01883570|OTHER|access to a library of chest x-rays without search strategy|
219379771|NCT01073943|DRUG|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
219379772|NCT01073943|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
219379773|NCT01073943|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
219379774|NCT05412706|DRUG|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
219379775|NCT01296906|BEHAVIORAL|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
219379776|NCT01296906|BEHAVIORAL|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
219379777|NCT03823664|DIAGNOSTIC_TEST|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
219379778|NCT04987593|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
219379779|NCT03232307|DRUG|Dexamethasone|Given PO
219379780|NCT03232307|DRUG|Ibrutinib|Given PO
219379781|NCT03232307|DRUG|Lenalidomide|Given PO
219379782|NCT03232307|BIOLOGICAL|Rituximab|Given IV
219379783|NCT01571492|PROCEDURE|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
219379784|NCT01571492|PROCEDURE|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
219379785|NCT01644877|DRUG|DAS181 dry powder, formulation F02|
219379786|NCT01644877|DRUG|Lactose Placebo|
219379787|NCT05288088|DIAGNOSTIC_TEST|No intervention|This is an observational study
219379788|NCT06213571|OTHER|Exercise Counseling|Participate in exercise coaching sessions
219379789|NCT06213571|OTHER|Exercise Intervention|Participate in home-based exercise program
219379790|NCT06213571|OTHER|Health Promotion and Education|Receive resistance band and exercise booklets
219379791|NCT06213571|OTHER|Interview|Ancillary studies
219379792|NCT06213571|OTHER|Physical Performance Testing|Ancillary studies
219379793|NCT06213571|OTHER|Questionnaire Administration|Ancillary studies
219379794|NCT06213571|OTHER|Telemedicine|Participate in sessions remotely
219379795|NCT05445193|BEHAVIORAL|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
219379796|NCT03792503|DRUG|Apatinib|Apatinib 500 mg Po qd
219379797|NCT03792503|DRUG|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
219379798|NCT04462237|PROCEDURE|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
219379799|NCT05059132|BEHAVIORAL|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
219379800|NCT05059132|OTHER|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
219379801|NCT03527043|DRUG|Escitalopram|10mg by mouth daily for 6 weeks
219379802|NCT03527043|OTHER|Placebo|matched placebo control by mouth for 6 weeks
219379803|NCT05696340|OTHER|semi-structured interview|"Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation."
219379804|NCT06010810|DRUG|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
219379805|NCT06010810|DRUG|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
219379806|NCT03839602|RADIATION|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
219379807|NCT00125333|DRUG|NF-kappaB Decoy|
219379808|NCT03716791|DIETARY_SUPPLEMENT|methylsulfonylmethane|3g per day
219379809|NCT03716791|DIETARY_SUPPLEMENT|placebo|white rice flour
219379810|NCT02605577|PROCEDURE|new systemic nutrition management protocol|a new established systemic nutrition management protocol
219379811|NCT03830281|DRUG|Ultra-Rapid Lispro|Administered SC
219379812|NCT03830281|DRUG|Insulin Lispro|Administered SC
219379813|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
219379814|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
219379815|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
219379816|NCT02615301|DIETARY_SUPPLEMENT|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
219379817|NCT02226068|DRUG|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
219379818|NCT02226068|OTHER|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
219379819|NCT04194177|OTHER|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
219379820|NCT01985321|DRUG|ethanol/glycolic acid solution|ethanol/glycolic acid solution
219379821|NCT01985321|DRUG|Placebo/Ethanol|ethanol solution
219379822|NCT01462513|BIOLOGICAL|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
219379823|NCT01462513|BIOLOGICAL|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
219379824|NCT06423417|BEHAVIORAL|LifeHack|See arm description
219379825|NCT05102474|OTHER|Polysomnography (PSG)|PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
219379826|NCT05347615|PROCEDURE|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
219379827|NCT05347615|PROCEDURE|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
219379828|NCT03271710|DEVICE|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
219379829|NCT03379519|BEHAVIORAL|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
219379830|NCT03379519|BEHAVIORAL|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
219379831|NCT00814931|DRUG|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
219379832|NCT00814931|DRUG|Placebo|matching oral liquid suspension placebo twice a day for 8 days
219379833|NCT00931164|DRUG|Sodium Oxybate|dosage is by weight
219379834|NCT05523180|DIETARY_SUPPLEMENT|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
219379835|NCT05523180|OTHER|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
219379836|NCT04454411|DRUG|Brixadi|Extended release injectable Buprenorphine
219379837|NCT04454411|DRUG|Vivitrol|Extended release injectable Naltrexone
219379838|NCT05405829|OTHER|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
219379839|NCT01283737|DEVICE|DBX Putty|OCD of the knee will be treated with DBX Putty
219379840|NCT01283737|PROCEDURE|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
219379841|NCT05229965|DRUG|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
219379842|NCT05229965|DRUG|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
219379843|NCT05229965|DRUG|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
219379844|NCT03746730|DEVICE|ultrasound|gray scale and doppler ultrasound
219379845|NCT04976465|DRUG|Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
219379846|NCT04976465|DRUG|Without Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
219379847|NCT04661696|DRUG|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
219379848|NCT00189826|DRUG|tacrolimus|immunosuppression
219379849|NCT06853171|DRUG|KarXT|Specified dose on specified days
219379850|NCT06853171|DRUG|KarX-EC|Specified dose on specified days
219379851|NCT00040157|DRUG|ACH126-443 (Beta-L-Fd4C)|
219379852|NCT01299025|OTHER|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
219379853|NCT06197126|RADIATION|Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .|The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
219379854|NCT05634603|DIETARY_SUPPLEMENT|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
219379855|NCT05641688|DRUG|[18F]PI-2620|The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
219379856|NCT02215681|DEVICE|acupuncture|
219379857|NCT03991247|BEHAVIORAL|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
219188498|NCT04166526|DEVICE|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
219188499|NCT04166526|DEVICE|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
219188500|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
219188501|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
219188502|NCT06565624|PROCEDURE|Cotton Swab Nasal Stimulation|Nostril probing for the purpose of producing reflex tearing
219188503|NCT05546385|DEVICE|Partial Rebreathing Device|Partial Rebreathing Device
219188504|NCT05546385|DEVICE|Sham breathing device|Sham breathing device
219188505|NCT05050539|BEHAVIORAL|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
219188506|NCT05050539|BEHAVIORAL|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
219188507|NCT06614920|OTHER|Plant-Based Food Provision (with or without food prescription)|"Food Prescription: Participants will bring the food prescription obtained from the nutrition class to Village FREEdge, food pantry at the Freedom Lab, where it will function as a voucher. Each voucher will allow for participants to pick up enough plant-based food for 6 meals per person in their household (with household maximum of 5 people)(enough meals for 3 days- 2 meals per person per day). We expect that participants will pick up food twice per week from Village FREEdge to obtain enough meals to feed each participant's household for 6 days out of the week for up to 1 year.~Without food prescription: Participants will be given plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up) without the use of a food prescription."
219188508|NCT06614920|OTHER|Plant-Based Nutrition Education|"A once weekly classes for a 5-week nutrition course. The parents/guardians would bring their children and any additional household member(s) to the nutrition class, which will organize participants in different classrooms by age (children 4 years, 4-12 years old, 12-14 years old, 14+ years old). Each classrooms will engage in age-appropriate interactive nutrition-based activities. All children below 18 will engage in interactive activities for the full 1.5 hours. Adolescents aged 14 up will join the classroom with adults and listen to a 45 minute lecture and engage in a subsequent 45 minute interactive activity that incorporates content from the lecture. The interactive activities for the children range from creating a fruit and veggie Tik Tok song and performing it, drawing foods on a balanced plate, etc. The interactive activities for participants 14 year old and older range from discussions about fiber in diet, guided plant-based meal preparation, reading nutrition label etc."
219188509|NCT05338060|OTHER|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
219188510|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
219188511|NCT05636995|DIAGNOSTIC_TEST|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
219188512|NCT05204888|DEVICE|myAirvo3|For patients assigned to the HFNT intervention group, a myAirvo 3 device will be provided. The myAirvo 3 is for the treatment of spontaneously breathing patients, infant to adult, who would benefit from receiving high flow warmed and humidified respiratory gases. This includes patients who have had upper airways bypassed. The flow may be from 2 - 60 L/min depending on the patient interface. The myAirvo 3 is for patients in homes and long-term care facilities.
219188513|NCT05204888|DEVICE|Pulse oximeter|A pulse oximeter will be provided to measure heart rate and pulse oximetry; subjects will enter and transmit the data on the smartphone once daily before 11AM. Heart rate and pulse oximetry measures will be taken after wearing the device for approximately 2 minutes.
219188514|NCT06455527|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
219188515|NCT06455527|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
219188516|NCT00559156|DIETARY_SUPPLEMENT|arginine/omega-3 fatty acids/nucleotides oral supplement|
219188517|NCT00559156|DRUG|cisplatin|
219188518|NCT00559156|PROCEDURE|adjuvant therapy|
219188519|NCT00559156|RADIATION|radiation therapy|
219188520|NCT05558384|BEHAVIORAL|Aerobic Exercise|"A 15-week standardized aerobic exercise intervention.~* Frequency: 5 days/wk (2 supervised)~* Intensity: 50-59% heart rate reserve~* Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~* Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)"
219188521|NCT05777070|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
219188522|NCT05027074|DRUG|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
219188523|NCT05027074|DRUG|Placebo|Normal saline administered via IV infusion
219379858|NCT03991247|OTHER|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
219379859|NCT00779168|DRUG|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
219379860|NCT00779168|OTHER|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
219379861|NCT00779168|OTHER|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
219379862|NCT00779168|OTHER|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
219379863|NCT00779168|OTHER|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
219379864|NCT00779168|OTHER|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
219379865|NCT05246410|DEVICE|Spot stent system|Spot stent system designed and produced by Acotec
219379866|NCT05246410|DEVICE|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
219379867|NCT00375245|DRUG|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
219379868|NCT00375245|OTHER|Grapefruit Juice|Daily oral doses starting during the second week on study.
219379869|NCT03934684|DRUG|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
219379870|NCT03934684|DRUG|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
219379871|NCT06577818|PROCEDURE|CC+SI (Chest compression during sustained inflation)|CC+SI (Chest compression during sustained inflation)
219379872|NCT06577818|PROCEDURE|3:1 C:V (3:1 Compression:Ventilation ratio)|"3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC."
219379873|NCT05816954|DIAGNOSTIC_TEST|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
219379874|NCT04798339|DRUG|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
219379875|NCT04798339|DRUG|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
219379876|NCT06506136|DRUG|Fluoxetine|"Participants will receive fluoxetine tablets, 40 mg once daily, administered 30 minutes after breakfast for 12 weeks.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
219379877|NCT06506136|DRUG|Placebo|"Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
219379878|NCT02892305|PROCEDURE|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
219379879|NCT00458471|DEVICE|Insertion of a urinary catheter coated with benign E. coli|
219379880|NCT06146101|DRUG|IHL-42X Low Dose|Softgel capsule
219379881|NCT06146101|DRUG|IHL-42X High Dose|Softgel capsule
219379882|NCT06146101|DRUG|Placebo|Softgel capsule
219379883|NCT06146101|DRUG|IHL-42X (Optimal Dose)|Softgel capsule
219379884|NCT06146101|DRUG|Dronabinol|Softgel capsule
219379885|NCT06146101|DRUG|Acetazolamide|Softgel capsule
219379886|NCT06146101|DRUG|Placebo|Softgel capsule
219379887|NCT04091217|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
219379888|NCT04091217|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
219379889|NCT05885555|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
219379890|NCT01978002|BEHAVIORAL|Pain sensitivity testing|
219379891|NCT01978002|BEHAVIORAL|Urodynamic testing|
219379892|NCT03573024|DRUG|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
219379893|NCT03573024|DRUG|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
219379894|NCT05662332|DRUG|Insulin Efsitora Alfa|Administered SC
219379895|NCT05662332|DRUG|Insulin Glargine|Administered SC
219379896|NCT05558566|OTHER|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
219379897|NCT05558566|OTHER|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
219379898|NCT06503016|DRUG|Phosphocreatine|Administration of Phosphocreatine
219379899|NCT06503016|DRUG|Placebo|Saline solution of NaCl 0.9%
219379900|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
219379901|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
219379902|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
219379903|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
219379904|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
219379905|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
219379906|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
219379907|NCT01042379|DRUG|Ganetespib|Arm is closed.
219379908|NCT01042379|DRUG|ABT-888|Arm is closed.
219379909|NCT01042379|DRUG|Neratinib|Arm is closed.
219379910|NCT01042379|DRUG|PLX3397|Arm is closed.
219379911|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
219379912|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
219379913|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
219379914|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
219379915|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
219379916|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
219379917|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
219379918|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
219379919|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
219379920|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
219379921|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
219379922|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
219429092|NCT05112484|DIAGNOSTIC_TEST|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
219379923|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
219379924|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
219379925|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
219379926|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
219379927|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
219379928|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
219379929|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
219379930|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
219379931|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
219379932|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
219379933|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
219379934|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
219379935|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
219379936|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
219379937|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
219379938|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
219379939|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
219379940|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
219379941|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
219379942|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
219379943|NCT01042379|DRUG|GSK 5733584|Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection. Will receive a max of 12 weeks.
219379944|NCT01042379|DRUG|GSK 5733584 + Dostarlimab|"GSK 5733584 Route: Intravenous Infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection x 12 weeks max.~Dostarlimab Route: Intravenous Infusion Dosage Form: 500 mg fixed dose intravenous Q3W for infusion x 12 weeks max."
219379945|NCT05623670|PROCEDURE|minimally invasive cardiac surgery using a VJI cannula.|Observation of postinterventional internal jugular vein thrombus after minimally invasive cardiac surgery using VJI cannulation to achieve complete CPB.
219379946|NCT04350333|BEHAVIORAL|CBT-I|Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
219379947|NCT04350333|BEHAVIORAL|Assertive communication training|Intervention based on improving assertive communication and regulating emotions.
219379948|NCT02429999|DRUG|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
219379949|NCT02429999|DRUG|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
219379950|NCT06976112|BEHAVIORAL|Pork Diet|The diet will follow the Dietary Guidelines for Americans with 80% of the meat consumption per week being pork. Other animal protein (e.g., turkey, chicken, beef) will be minimized in the dietary plans (≤ 20%) so lean and processed pork are the primary protein source consumed. Within each day, \~80% of the daily pork intake will be fresh, unprocessed lean cuts (e.g., tenderloin, loin chops, sirloin roast, flank, and rump roast) and \~20% will be cured sources (e.g., Canadian bacon, pork sausage).
219379951|NCT06976112|BEHAVIORAL|Plant Diet|The diet will be a Lacto-Ovo Vegetarian Diet following the Dietary Guidelines for Americans with no more than 21 oz per week of animal protein (e.g., eggs, cheese).
219379952|NCT06806137|BIOLOGICAL|Investigational varicella vaccine|Investigational varicella vaccine administered subcutaneously.
219379953|NCT06806137|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
219379954|NCT06806137|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
219379955|NCT06806137|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
219379956|NCT06806137|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219379957|NCT06806137|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219379958|NCT06806137|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219379959|NCT06074887|BEHAVIORAL|transtheoretical model-based intervention|"Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, post-tests will be collected in the hospital."
219379960|NCT06561438|DRUG|Vortioxetine 20Mg Tab|20 mg oral vortioxetine tablet 2 hours before the procedure
219379961|NCT04543331|DRUG|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
219379962|NCT02471690|DRUG|Oritavancin|IV - Single dose 1200 mg Oritavancin
219379963|NCT02471690|DRUG|Dextrose|D5W 5% in Water
219379964|NCT05163704|DRUG|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
219379965|NCT00195130|BEHAVIORAL|There are no interventions in this study|
219379966|NCT03706586|PROCEDURE|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
219379967|NCT03706586|PROCEDURE|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
219379968|NCT05368675|DRUG|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
219379969|NCT06807164|DRUG|Capsaicin 8% Patch|One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.
219379970|NCT06807164|PROCEDURE|Serratus Plane Block|The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.
219379971|NCT06807164|PROCEDURE|Botulinum Toxin A|Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.
219379972|NCT04885257|DRUG|Methylphenidate|Methylphenidate oral pill. Dosing instructions given to
219379973|NCT04885257|DRUG|Placebo|Placebo arm
219429093|NCT05112484|DIAGNOSTIC_TEST|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
219429094|NCT05112484|DIAGNOSTIC_TEST|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
219429095|NCT05112484|OTHER|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
219379974|NCT01746433|OTHER|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
219379975|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
219379976|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
219379977|NCT04576442|BEHAVIORAL|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
219379978|NCT04576442|BEHAVIORAL|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
219379979|NCT04576442|BEHAVIORAL|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
219379980|NCT00256295|DRUG|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
219379981|NCT00256295|DRUG|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
219379982|NCT05982340|DIAGNOSTIC_TEST|Lithium clearance|Blood and urine samples
219379983|NCT01868360|DRUG|Subconjunctival aflibercept|subconjunctival aflibercept injection
219379984|NCT01868360|OTHER|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
219379985|NCT04760145|OTHER|Multicomponent Exercise with Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
219379986|NCT04760145|OTHER|Multicomponent Exercise without Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
219379987|NCT01667263|DRUG|All-trans retinoic acid|
219379988|NCT01667263|DRUG|Danazol|
219379989|NCT00803114|DRUG|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
219379990|NCT00803114|DRUG|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
219379991|NCT03704337|DIETARY_SUPPLEMENT|Commercially Available Food Bar|Active
219379992|NCT03704337|DIETARY_SUPPLEMENT|Placebo|Placebo
219379993|NCT01697345|DRUG|Testosterone|
219379994|NCT00140855|BIOLOGICAL|ipilimumab|
219379995|NCT01815957|DRUG|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
219379996|NCT04357171|PROCEDURE|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
219379997|NCT04357171|PROCEDURE|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
219379998|NCT03501927|DIAGNOSTIC_TEST|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion"
219379999|NCT04567563|DEVICE|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
219380000|NCT01085188|BEHAVIORAL|ACC|Weekly community based behavioral counseling and case management
219380001|NCT01085188|BEHAVIORAL|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
219380002|NCT01085188|BEHAVIORAL|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
219380003|NCT00000984|DRUG|CD4 Antigens|
219380004|NCT02876978|GENETIC|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
219380005|NCT02876978|DRUG|Fludarabine|30 mg/m\^2/day x 4 days
219380006|NCT02876978|DRUG|Cyclophosphamide|500 mg/m\^2/day x 2 days
219380007|NCT04532788|PROCEDURE|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
219380008|NCT04532788|PROCEDURE|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
219380009|NCT02071238|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
219380010|NCT02071238|BEHAVIORAL|Group Consultation|Informed consent discussion in group-format
219380011|NCT00342368|PROCEDURE|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
219380012|NCT00108329|BEHAVIORAL|Weight Loss|
219380013|NCT05262764|DRUG|JARDIANCE®|Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).
219380014|NCT04747405|OTHER|therapy group|therapy group of maximum 8 people repeated twice
219380015|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
219380016|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
219380017|NCT00820430|OTHER|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
219380018|NCT00670787|DRUG|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
219380019|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
219380020|NCT03793543|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
219380021|NCT03981601|DRUG|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
219380022|NCT03981601|PROCEDURE|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
219380023|NCT01916772|OTHER|no interventions|no interventions
219380024|NCT04419103|OTHER|no intervention|Natural exposure of iodine.
219380025|NCT01261403|BIOLOGICAL|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
219380026|NCT01261403|DRUG|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
219429096|NCT02253641|BEHAVIORAL|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
219429097|NCT02253641|BEHAVIORAL|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
219380027|NCT06593652|BEHAVIORAL|Teen Intervene - Adolescent Only|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills.
219380028|NCT06593652|BEHAVIORAL|Teen Intervene with Caregiver Session|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills. In this condition, the caregiver session will address caregiver expectations around youth substance use and strategies for promoting positive youth behavior change including reduced substance use.
219380029|NCT06593652|BEHAVIORAL|Family Check Up|Family Check-Up Online (FCU-O) is a self-paced, parent-driven, fully HIPAA compliant online version of the Family Check-Up (FCU), a brief intervention that integrates assessment, motivation-enhancement, and skill building to help parents effectively manage behavior and build positive relationships with their children aged 2-17 in order to reduce emotional and behavioral problems among youth.
219380030|NCT05243771|PROCEDURE|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
219380031|NCT05243771|PROCEDURE|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
219380032|NCT05243771|PROCEDURE|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
219380033|NCT05602428|DRUG|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
219380034|NCT05602428|DRUG|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
219380035|NCT05602428|DRUG|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
219380036|NCT01960010|DRUG|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
219380037|NCT01960010|DRUG|Vehicle|Vehicle dosed BID
219380038|NCT05437796|DEVICE|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
219380039|NCT05437796|DEVICE|No Hypnotic virtual reality|Group without Hypnotic virtual reality
219380040|NCT01835444|OTHER|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
219380041|NCT02519660|DRUG|Lidocaine/Tetracaine patch|
219380042|NCT02519660|DRUG|Lidocaine/Prilocaine cream|
219380043|NCT01446809|DRUG|Doxorubicin Hydrochloride|Given IV
219380044|NCT01446809|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219380045|NCT01446809|DRUG|Ifosfamide|Given IV
219380046|NCT01446809|OTHER|Laboratory Biomarker Analysis|Correlative studies
219380047|NCT01446809|DRUG|Pazopanib Hydrochloride|Given PO
219380048|NCT01446809|OTHER|Pharmacological Study|Correlative studies
219380049|NCT01446809|OTHER|Placebo|Given PO
219380050|NCT01446809|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219380051|NCT00785577|DRUG|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
219380052|NCT00785577|DRUG|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
219380053|NCT00785577|DRUG|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
219380054|NCT00785577|DRUG|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
219380055|NCT00785577|DRUG|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
219380056|NCT02342834|DIETARY_SUPPLEMENT|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
219380057|NCT00025038|DRUG|tipifarnib|Given orally
219380058|NCT00025038|DRUG|isotretinoin|Given orally
219380059|NCT00025038|DRUG|fludarabine phosphate|Given IV
219380060|NCT00025038|DRUG|cytarabine|Given IV
219380061|NCT00025038|RADIATION|radiation therapy|Undergo total body irradiation
219380062|NCT00025038|DRUG|cyclophosphamide|Given IV
219380063|NCT00025038|BIOLOGICAL|anti-thymocyte globulin|Given IV
219380064|NCT00025038|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
219380065|NCT00025038|PROCEDURE|double-unit umbilical cord blood transplantation|
219380066|NCT00025038|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
219380067|NCT00025038|OTHER|laboratory biomarker analysis|Correlative studies
219380068|NCT01212445|DRUG|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
219380069|NCT00991900|DEVICE|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
219380070|NCT01583036|DRUG|Digoxin Alone|Single administration of digoxin 0.25mg
219380071|NCT01583036|DRUG|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
219380072|NCT02532049|BIOLOGICAL|ChAd63 Pfs25-IMX313|
219380073|NCT02532049|BIOLOGICAL|MVA Pfs25-IMX313|
219380074|NCT06842199|DRUG|ICP-488 Tablets|Eligible patients will receive ICP-488 orally as per the protocol
219380075|NCT06842199|DRUG|ICP-488 Placebo|Eligible patients will receive ICP-488 Placebo orally as per the protocol
219380076|NCT06792539|DEVICE|Polymotion Hip Resurfacing (PHR) System|Surgical
219380077|NCT06812715|DRUG|Pirtobrutinib|Pirtobrutinib is a first-in-class, oral noncovalent Bruton tyrosine kinase (BTK) inhibitor (BTKi) that was approved in January 2023 in the United States for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL) and later that same year CLL. It is currently being investigated across several global randomised phase III trials for frontline and R/R chronic lymphocytic leukaemia (CLL).
219380078|NCT01167296|DEVICE|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
219380079|NCT06656403|DRUG|0.1% sodium hyaluronate|After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
219380080|NCT06656585|OTHER|Individual food selectivity protocol|"Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used."
219380081|NCT06656585|OTHER|Traditional food selectivity protocol|"Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur"
219380082|NCT06656767|OTHER|No intervention|This study utilises pre-collected samples only.
219380083|NCT06657404|DRUG|use Amiodarone, Bisoprolol and Digoxin|"Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally."
219380084|NCT01659151|DRUG|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
219380085|NCT01659151|PROCEDURE|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
219380086|NCT01659151|DRUG|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
219380087|NCT01659151|DRUG|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
219380088|NCT05114772|DIAGNOSTIC_TEST|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
219380089|NCT04535063|BIOLOGICAL|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
219380090|NCT06819696|PROCEDURE|ACL reconstruction with a dual-flow arthroscopy sheath|ACL reconstruction will be performed by the surgeon without a tourniquet but using a dual-flow arthroscopy sheath.
219380091|NCT06819696|PROCEDURE|ACL reconstruction with a thigh tourniquet|ACL reconstruction will be performed by the surgeon using a thight tourniquet
219380092|NCT03972488|DRUG|Lutathera|Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
219380093|NCT03972488|DRUG|30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
219188524|NCT06461455|DEVICE|Lehfilcon A multifocal for astigmatism contact lenses|Investigational multifocal contact lenses for astigmatism
219429098|NCT06186804|DRUG|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
219380094|NCT03972488|DRUG|2.5% Lys-Arg sterile amino acid solution|Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
219380095|NCT03972488|DRUG|High dose 60 mg octreotide long-acting repeatable|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
219380096|NCT00138762|DRUG|torcetrapib/atorvastatin|
219380097|NCT00138762|DRUG|atorvastatin|
219380098|NCT00138762|DRUG|placebo|
219380099|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
219380100|NCT01191593|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
219380101|NCT01191593|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
219380102|NCT05622500|PROCEDURE|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
219380103|NCT05622500|COMBINATION_PRODUCT|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
219380104|NCT06988761|BEHAVIORAL|Standard of care treatment for Fibromyalgia|Patients will receive standard of care as decided by treating physician which may include patient education, physical therapy, occupational therapy, cognitive behavioral therapy, biofeedback therapy, massage, acupuncture, graded activity therapy, sleep hygiene therapy, relaxation therapies, and meditative movement therapies.
219380105|NCT06988761|BEHAVIORAL|Longitudinal Behavioral Health Techniques|Patients will receive standard of care as decided by treating physician, along with the integration of longitudinal behavioral health techniques provided by Lin Health. Patients have 24/7 access to digital content and will be able to interact directly with care team members on average three times per week.
219380106|NCT03320629|COMBINATION_PRODUCT|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
219380107|NCT03320629|COMBINATION_PRODUCT|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
219380108|NCT04325594|BIOLOGICAL|Intracoronary administration of umbilical cord-derived MSCs|A suspension of 1×10⁷ umbilical cord-derived mesenchymal stromal cells in 20 ml of heparinized saline was administered by intracoronary infusion into the left coronary artery via a standard 6 Fr catheter over 10 minutes (2 ml/min). The infusion was performed without balloon occlusion or interruption of coronary blood flow.
219380109|NCT07004699|PROCEDURE|Laryngoscopy|Introduction of the laryngoscope to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
219380110|NCT07004699|PROCEDURE|High-flow oxygen therapy|Introduction of High-flow oxygen therapy to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
219429099|NCT06450353|BEHAVIORAL|Patient Ancestry Questionnaires|Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
219429100|NCT00188357|BEHAVIORAL|Education|
219429101|NCT02722772|DRUG|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
219429102|NCT02722772|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
219429103|NCT04265898|DEVICE|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
219429104|NCT02287870|DRUG|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
219380111|NCT06546839|DRUG|SPSIPB blcok|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
219380112|NCT06546839|DRUG|SAPB block|In the lateral decubitus position, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane concerning the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be injected for correction. Following confirmation of the correct position of the needle, 30 ml %0.25 bupivacaine will be administered for the block.
219380113|NCT06546839|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219380114|NCT06867055|BIOLOGICAL|Injectable platelet-rich fibrin (I-PRF)|I-PRF were produced with 11-mL plastic tubes (16\*10 mm) using a Nuve NF 200 centrifugation device with a rotor angulation with a radius of 101 mm at the clot (Nuve NF 200, Nuve Industrial Materials Manufacturing and Trade Company, Ankara, Türkiye). The I-PRF at the top of the tube was collected with a syringe and transferred to the metal bowl. It was held for 20-25 min for polymerization.
219380115|NCT06867055|DRUG|0.8% hyaluronic acide (HA)|0.8% polyvinylpyrrolidone sodium hyaluronate (HA) (Gengigel Prof, Ricerfarma SRL.) gel was impregnated on a sterile gelatin sponge and sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Türkiye) on the palate area and bleeding control was provided with SX bioplast plate.
219380116|NCT06867055|OTHER|control group|Sterile gelatin sponge was sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Turkey) in the palatal region where FGG was taken and bleeding was controlled with SX bioplast plate.
219380117|NCT05885009|GENETIC|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
219380118|NCT05885009|GENETIC|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
219380119|NCT07015840|BEHAVIORAL|Visual perceptual learning|Evaluation of the effect of visual training on cortical activity during sleep
219380120|NCT06685120|COMBINATION_PRODUCT|PRP + HA injection|Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.
219380121|NCT06685120|BIOLOGICAL|PRP injection|Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.
219380122|NCT06685120|DEVICE|HA injection|Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
219380123|NCT02971592|DEVICE|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
219380124|NCT02971592|OTHER|Mock Device|reception of device that does not apply the electromagnetic field
219380125|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
219380126|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
219380127|NCT06127472|OTHER|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
219188525|NCT06461455|DEVICE|Samfilcon A multifocal for astigmatism contact lenses|Commercially available multifocal contact lenses for astigmatism
219380128|NCT06127472|OTHER|PE program|An adapted PE program for older adults with a (probability) diagnosis of ASD. The PE program consists of eight, two-hour group meetings on a weekly basis.
219380129|NCT05405231|BEHAVIORAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
219380130|NCT05405231|BEHAVIORAL|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
219380131|NCT04008524|BIOLOGICAL|CAR-T cells|Chimeric Antigen Receptor-T cells
219380132|NCT07023536|BEHAVIORAL|TELEREHABILITATION-YES|This intervention consists of a structured 8-week cardiac rehabilitation program performed at the patient's home using a certified telemedicine platform. Sessions are delivered in synchronous mode with real-time supervision by a physiotherapist through secure video conferencing. Each session includes warm-up, endurance training, and cooldown exercises, with personalized intensity based on cardiopulmonary exercise testing. Patients are equipped with wearable medical devices for continuous monitoring of vital signs (ECG, heart rate, blood pressure, oxygen saturation) and motion sensors to assess exercise execution and adherence. All data are transmitted securely and stored automatically in the system's database. In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and quality-of-life questionnaires.
219380133|NCT07023536|BEHAVIORAL|TELEREHABILITATION-NO|This intervention involves a traditional 8-week cardiac rehabilitation program carried out at a hospital-based outpatient facility. Patients attend sessions in person under the direct supervision of a physiotherapist. Each session includes warm-up, endurance training using a stationary bike, and cooldown. Vital signs (e.g., heart rate, blood pressure, oxygen saturation) are monitored manually by the physiotherapist, and exercise tolerance is assessed using standardized clinical scales (e.g., Borg and RPE). In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and validated quality-of-life questionnaires. This group serves as the control for evaluating the effectiveness of the home-based telerehabilitation model.
219380134|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
219380135|NCT05898126|PROCEDURE|Usual care|Standard of care
219380136|NCT07030920|DRUG|Fostemsavir|Addition of fostemsavir to the patient's current antiretroviral regimen: once daily oral administration (Rukobia 600 mg extended-release tablets) for 24 months
219380137|NCT07031791|OTHER|PETRA questionnaire|The questionnaire is given to the patient to complete in the waiting room. The completed questionnaire is given to the doctor at the end of the consultation.
219380138|NCT07031908|PROCEDURE|Minimally invasive cytoreduction|Minimally invasive cytoreduction in patients with advanced ovarian cancer treated with 6 cycles of neoadjuvant chemotherpy
219380139|NCT06717321|PROCEDURE|(Arm 1): PEG|A 20-French pull type percutaneous endoscopic feeding tube placed into the stomach using endoscopic guidance
219380140|NCT06717321|PROCEDURE|(Arm 2): PEG-J|24-French pull type percutaneous endoscopic feeding tube placed into the stomach with a 12-French jejunal extension tube advanced through the PEG and positioned post-pyloric in the small bowel using endoscopic guidance
219380141|NCT06434077|BIOLOGICAL|GcMAF injections (100 ng)|The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.
219380142|NCT06434077|OTHER|placebo|the placebo solution will be injected subcutaneously 100 ng.
219380143|NCT06744816|DRUG|Qutenza Patch|Given topical
219380144|NCT06757348|DIAGNOSTIC_TEST|Fecal elastase|\*\*Stool Samples\*\* To investigate exocrine pancreatic insufficiency (EPI), a stool sample will be requested from all patients for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be stored refrigerated at 4-8 °C for no more than 48 hours. The concentrations of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), and fecal elastase will be extracted and analyzed according to the manufacturer's instructions.
219380145|NCT06757348|DIAGNOSTIC_TEST|Ecoendoscopy|\*\*Diagnosis of Pancreatic Steatosis\*\* The diagnosis of pancreatic steatosis will be performed using endoscopic ultrasound. A Pentax EG-3870UTK endoscope will be used in conjunction with Hitachi Avius ultrasound equipment. The procedure is performed under anesthesia using propofol.
219380146|NCT06757348|DIAGNOSTIC_TEST|Fibroscan|\*\*Fibroscan Procedure:\*\* This is a new technique based on the evaluation of liver elasticity or stiffness that allows for the measurement of liver hardness and quantification of liver fibrosis in a simple and completely painless manner using ultrasound. The results are obtained immediately and can be safely repeated periodically.
219380147|NCT06757348|DIAGNOSTIC_TEST|Serum cytokines|Peripheral blood will be drawn from all participants in the Gastroenterology Division of the Hospital de Clínicas. Samples will be collected in EDTA tubes, centrifuged, and the serum will be frozen at -80 °C until processing. Serum cytokine levels will be measured using a commercial kit (Bio-Plex Pro human cytokine, Bio-Rad Lab., Inc.), which includes a panel of 27 cytokines: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, MIP-1α, IL-12 (p70), MIP-1β, IL-13, PDGF-BB, IL-15, RANTES, IL-17, TNF-α, IP-10, VEGF, MCP-1 (MCAF).
219380148|NCT06765122|BEHAVIORAL|Program for Alleviating Relationship Trauma and Stress through New Behaviors (PARTS-NB)|"PARTS-NB (Program For Alleviating Relationship Trauma and Stress through New Behaviors) is a group-based program for people who use violence and aggression in intimate relationships. Phase I is 4-weeks of 120 minutes of weekly group-based sessions focused on clarifying the way parts work in the mind, increasing inner compassion and emotion regulation, and explaining the role of trauma and stress in substance use and the use of violence in relationships. Phase II lasts 8-weeks, maintaining the 120 minutes of weekly group-based sessions. This phase introduces the model and focuses on practicing unblending, helping individuals gain awareness and acceptance of internal and external experiences. The final phase, Phase III runs 8 weeks and consists of weekly 120-minute group sessions which addresses and releases trauma-based beliefs and experiences through a process called unburdening."
219429105|NCT02287870|DRUG|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
219380149|NCT07100145|OTHER|Coconut oil|The composition per 100 g of virgin coconut oil 50% in oral mucoadhesive gel will be coconut oil (50 ml), tween 20 (surfactant-2.5 g) or span 60 (surfactant-2.5 g), Carbopol 940 (gelling agent-1 g), triethanolamine (viscous organic compound-0.2 g) and vanillin (0.001 g)
219380150|NCT07100145|DRUG|Triamcinolone Acetonide|topical corticosteroid
219380151|NCT07105696|OTHER|Web-Based CORE|"The intervention planned for the study is a web-based digital CORE method. Students in the intervention group taking the Health Diagnosis course will be administered a web-based digital CORE to assess the cardiovascular, respiratory, musculoskeletal, and gastrointestinal systems.~Students in the experimental group will be administered the web-based digital CORE exam. Students in the control group will be asked the same multiple-choice questions in a digital environment. Two weeks later, students in the experimental and control groups will be administered another exam. Differences in achievement scores between the two groups will be evaluated."
219380152|NCT07108257|DEVICE|ExAblate Neuro 4000|ExAblate Neuro 4000 is an MR-guided focused ultrasound (MRgFUS) device used to perform noninvasive thermal ablation of targeted brain tissue. In this study, ExAblate Neuro 4000 will be used to ablate the anterior limb of the internal capsule (capsulotomy) in patients with treatment-resistant bipolar depression (TRBD). The procedure is conducted under real-time MRI guidance and thermometry to assess safety and initial effectiveness in improving clinical symptoms and quality of life.
219380153|NCT07107672|DRUG|[14C]X842|50 mg/100 µCi \[14C\] X842 suspension
219380154|NCT07106476|OTHER|Single-Leg Squat with Internal Focus Intervention|"Administration: Participants were instructed to focus on specific muscular or joint movements during single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included contract your glutes or keep your knee aligned. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
219380155|NCT07106476|OTHER|External Focus Intervention|"Administration: Participants were instructed to focus on the environmental effects of single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included push against the floor or drive your foot downward. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
219380156|NCT07106476|OTHER|No Focus Intervention|"Administration: Participants performed single-leg squats naturally without specific attentional instructions (3 sets of 8 repetitions on the affected side, 1-minute rest between sets).~Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
219380157|NCT07107360|OTHER|Pain Neuroscience Education|The study included two groups, consisting of participants who met the inclusion criteria and adhered to the procedures. Participants in the intervention group received a 20-minute Pain Neuroscience Education (PNE) session delivered face-to-face one hour prior to their scheduled surgery. The PNE focused on the biopsychosocial aspects of pain and included both theoretical and practical strategies for postoperative pain management.
219380158|NCT07107360|OTHER|Conventional preoperative education|Participants in the experimental group received pain neuroscience education, while participants in the control group received a booklet summarizing this education in addition to routine preoperative care.
219380159|NCT07105449|DRUG|Cannabis (30% THC Concentrate)|Participants will vape 30% THC concentration of liquid cannabis ad libitum.
219380160|NCT07105449|DRUG|Cannabis (60% THC Concentrate)|Participants will vape 60% THC concentration of liquid cannabis ad libitum.
219380161|NCT07105449|DRUG|Cannabis (90% THC Concentrate)|Participants will vape 90% THC concentration of liquid cannabis ad libitum.
219380162|NCT07105462|DEVICE|Arm 1 - Experimental Group Intervention Name: ADRRPs Vergence Training Intervention Description: Participants wore an Automatic Dual Rotational Risley Prism (ADRRPs) headset to perform vergence eye|"ADRRPs Vergence Training~Intervention Description:~Participants wore an ADRRPs headset that applied alternating base-in and base-out prism power to stimulate vergence eye movements. Prism levels were customized based on each participant's fusional vergence. Training was performed twice weekly for 15 minutes over four weeks while viewing a near video target.~Sham Visual Training with Plano Lenses~Intervention Description:~Participants wore an identical ADRRPs headset fitted with plano lenses that produced no prism effect. The procedure and schedule matched the experimental group but provided no vergence stimulation, serving as a sham control."
219380163|NCT07105462|DEVICE|1. Experimental Group Intervention Name: ADRRPs-Based Vergence Training; 2. Control Group Intervention Name: Sham Training with Plano Lenses.|"ADRRPs-Based Vergence Training This intervention used the Automatic Dual Rotational Risley Prisms (ADRRPs) system to deliver alternating base-in and base-out prism stimulation for vergence training. Prism levels were customized based on each participant's fusional vergence. Training was conducted twice per week for four weeks, 15 minutes per session, while participants viewed a near video target. This protocol provides automated and symmetric vergence demand, distinguishing it from conventional near-point or static prism exercises.~Sham Training with Plano Lenses Participants used the same ADRRPs headset as the experimental group but with plano lenses that produced no prism effect. The training schedule and visual tasks matched the experimental condition, but no vergence stimulus was applied. This design enabled participant masking while providing no active optical stimulation, serving as a sham comparator distinct from both active training and no-treatment controls."
219000960|NCT05237531|BEHAVIORAL|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
219380164|NCT07108192|OTHER|Hand Holding|Hand holding intervention will be performed by the researcher. Before cataract surgery, the researcher will sit in a chair next to the patient and warm his/her hands to a level that does not disturb the patient. 1-2 minutes before cataract surgery, the researcher will hold the patient's hand without gloves, with one hand, with moderate pressure, without rubbing or squeezing it uncomfortably. The hand holding intervention will continue until the cataract surgery is completed
219380165|NCT07108192|OTHER|Stress Ball|According to the randomization, the patient in the stress ball group will first be taught the use of stress balls face to face by the researcher. The researcher will place a round, medium-hard, high-quality stress ball of the same brand in the patient's active hand 1-2 minutes before the cataract surgery is started. The patient will be asked to squeeze and relax the stress ball by counting to 5 during cataract surgery. After squeezing the stress ball, he/she should count to 5 and then loosen it. The patient will be asked to continue this process until the cataract surgery is completed.
219380166|NCT07108192|OTHER|Control Group|Patients who did not receive any intervention other than standard treatment and care during cataract surgery were defined as the control group.
219380167|NCT07108101|BEHAVIORAL|tDCS stimulation (sham)|"Participants will receive sham tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Sham tDCS will target the motor cortex at 2mA for 15 sec at the beginning of the session, and then the stimulator will turn off. The participant will then sit for the remaining time of the session with the electrode cap on their heads but turned off and not delivering stimulation.~All participants will receive sham tDCS stimulation (n=120)."
219380168|NCT07108101|BEHAVIORAL|tDCS stimulation (real)|"In their second session, participants will receive real tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Real tDCS stimulation will target the motor cortex at 2mA for 20 minutes (full duration of task).~All participants will receive real tDCS stimulation (n=120)."
219380169|NCT07108101|BEHAVIORAL|Mindful state induction|"Experimenters trained in high-competence and high-warmth will train Group 1 participants on mindful state induction (n=60). Participants will undergo two stages for this training: 1) pain education to increase beliefs in endogenous brain regulatory capacities; and 2) the Stanford Hypnotic Induction Profile (HIP) test of hypnotizability and hypnotic induction of a relaxed state receptive to suggestion.~In Stage 1, participants will receive education that pain and affect are processes designed to protect the body from danger, which are transmitted rapidly and automatically to the brain. In Stage 2, participants are (a) seated in an upright, alert posture; and (b) receive suggestions that the ability to attend to and discriminate affective perceptions is achievable and that suppressing attention to the body and focusing on the task will allow them to perform optimally under pressure. Mindful state induction will only be explicitly instructed during session 1 for Group 1 participants."
219380170|NCT07108101|BEHAVIORAL|No minfulness induction|Participants in the No-mindfulness group will go through comparable stages but with different instructions. In the first stage, they will receive education about pain and affect as protective processes of the body. In the second stage, they will be seated in an upright, alert posture and receive suggestions to focus on the task and suppress attention to the body.
219380171|NCT07107490|DRUG|ALPS12|ALPS12 as an IV infusion
219380172|NCT07107490|DRUG|obinutuzumab|Obinutuzumab as an IV infusion
219380173|NCT07105852|DRUG|Sacituzumab tirumotecan (iv)+Putolizumab injection (iv)|"When administering sacituzumab tirumotecan and putolizumab on the same day, the drugs should be given sequentially. Putolizumab is administered first. For the first co-administration, a 4-hour interval is required. If no severe infusion reactions or allergic reactions occur, subsequent administrations may proceed with a minimum interval of 60 minutes before administering sacituzumab tirumotecan.~Putolizumab dosing:~Dosage: 200 mg, intravenous (IV) infusion Dosing cycle: Every 3 weeks (administered on Day 1 of each cycle) Dose interruptions due to adverse events (AEs): Refer to the prescribing information.~Sacituzumab tirumotecan dosing:~Dosage: 4 mg/kg, intravenous (IV) infusion Dosing cycle: Every 2 weeks (administered on Day 1 of each cycle, with a permissible dosing window of 14 ± 3 days between doses) Dose interruptions due to adverse events (AEs): Refer to the prescribing information."
219380174|NCT04362540|DIAGNOSTIC_TEST|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
219380175|NCT07106411|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Conventional EUS will be performed to evaluate lesion size, echogenicity, border, and layer of origin for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
219380176|NCT07106411|DIAGNOSTIC_TEST|Contrast-Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS)|CEH-EUS will be conducted using a contrast agent to assess vascularity and enhancement patterns of the lesion for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
219380177|NCT07106606|BEHAVIORAL|Mandala coloring activity|This technique is a creative art-based relaxation method that aims to reduce children's anxiety and fear levels. The application was carried out to make children feel psychologically safer and calmer before the examination. The selected mandala forms were created in accordance with the attention span, motor skill capacity and visual perception development of children between the ages of 9 and 12 by choosing simple but symbolic structures with moderate level of detail.
219188526|NCT06461455|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfection system
219188527|NCT05252416|DRUG|BLU-222|Oral administration
219188528|NCT05252416|DRUG|Carboplatin|IV Infusion
219188529|NCT05252416|DRUG|Ribociclib|Oral administration
219188530|NCT05252416|DRUG|Fulvestrant|Intra muscular administration
219380178|NCT07106697|BEHAVIORAL|First Aid Training Combined With Video-Assisted Guidance|Participants received a 45-minute structured first aid training session on unconscious victim management, followed by a 15-minute video-guidance instruction. During simulation, children received real-time video guidance from a dispatcher via smartphone.
219380179|NCT07106697|BEHAVIORAL|Video-Assisted Guidance Without Prior Training|Participants received a 15-minute instruction on video-assisted guidance use, without prior first aid training. During simulation, real-time video guidance was provided by a dispatcher via smartphone to assist with first aid tasks.
219380180|NCT07107750|DRUG|CA-4948|Provided by Curis.
219380181|NCT07107750|DRUG|Gemcitabine|Standard of care.
219380182|NCT07107750|DRUG|Cisplatin|Standard of care.
219380183|NCT07107750|BIOLOGICAL|Durvalumab|Standard of care.
219380184|NCT06930105|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|"Newly diagnosed Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (Ph-negative B-ALL) patients aged 18-60 years were enrolled.~Treatment Protocol~1. Low-intensity chemotherapy (VIP regimen)~   * V (Vincristine): 1.4 mg/m² (max 2 mg) on days 1 and 8.~  * I (Idarubicin): 8 mg/m²/day on days 1 and 8.~  * P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.~2. Sequential induction therapy:~   * Blinatumomab administered for 2 weeks following the VIP regimen.~3. Consolidation therapy for morphological complete remission (CR)~   * Patients achieving CR receive two cycles of consolidation chemotherapy:~  * Cycle 1: VDCP regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone).~  * Cycle 2: VP + HD-MTX regimen (Vincristine, Prednisone + High-Dose Methotrexate).~4. Allogeneic hematopoietic stem cell transplantation (allo-HSCT):~   * Patients with multiparameter flow cytometry-confirmed minimal res"
219380185|NCT06936852|PROCEDURE|Serratus posterior superior intercostal plane block|Under complete aseptic technique, a high frequency linear probe will be placed adjacent to upper medial part of scapula to visualize the second and third ribs. The needle will be introduced with in plane approach, from caudal to cranial and 30 ml of 0.25% bupivacaine will be injected in the fascial plane between serratus posterior superior and intercostal muscles at the level of second and third ribs.
219380186|NCT06936852|PROCEDURE|PECS II block|. Under complete aseptic technique, a high frequency linear probe will be placed in the infraclavicular region, angulated and directed laterally towards the axilla to visualize the third and fourth ribs with pectoralis major, minor and serratus anterior muscles from superficial to deep. The needle will be introduced with in plane approach from medial to lateral, 10 ml of 0.25% bupivacaine will be injected in the fascial plane between pectoralis major and pectoralis minor then the needle will be further introduced to the fascial plane between pectoralis minor and serratus anterior muscles with injection of 20 ml of 0.25% bupivacaine.
219188531|NCT05580406|BEHAVIORAL|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
219188532|NCT05899439|OTHER|blood draw|a peripheral blood draw
219380187|NCT06943898|OTHER|Core Egzercise|The core exercise group will perform core stabilization exercises for a total of 15 sessions, five days a week for three weeks. Exercises will include pelvic tilt, bridge, dead bug, bird dog, mini squats on a balance board, and wall planks. The number of repetitions will be increased from 10 to 20, and plank duration will be increased from 30 seconds to 45 seconds. A 5-minute warm-up and cool-down session will be included.
219380188|NCT06943898|OTHER|Core Exercises + Breathing Exercises|"This group will perform core stabilization exercises combined with the 360-degree breathing technique, for a total of 15 sessions over three weeks (five days a week).~360-degree breathing is a novel breathing method targeting deep and controlled inhalations into various regions of the body. Unlike traditional breathing exercises, 360-degree breathing ensures that all directions of the lungs are equally ventilated."
219380189|NCT02770807|DRUG|EryDex Low dose DSP|EDS-EP dose range of \~5-10 mg DSP/infusion
219380190|NCT02770807|DRUG|EryDex High dose DSP|EDS-EP dose range of \~14-22 mg DSP/infusion
219380191|NCT02770807|DRUG|Pooled Placebo|EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
219380192|NCT00341328|BIOLOGICAL|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
219380193|NCT06159335|RADIATION|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
219380194|NCT06524297|OTHER|Metaverse system (Patients)|The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.
219380195|NCT06524297|OTHER|Metaverse system (Resident Physician)|The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
219557855|NCT04044573|PROCEDURE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
219380196|NCT02639676|OTHER|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
219380197|NCT06051630|DRUG|Lidocaine intravenous|Perioperative lidocaine intravenous administration
219380198|NCT06051630|DRUG|Serum saline intravenous|Perioperative serum saline intravenous administration
219380199|NCT00664170|DRUG|ANX-514|75 mg/m\^2
219380200|NCT00664170|DRUG|docetaxel|75 mg/m\^2
219380201|NCT04865848|PROCEDURE|Dental local anesthesia|Dental local anesthesia
219380202|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
219380203|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
219380204|NCT05902728|DRUG|HLX208|450 mg
219380205|NCT05902728|DRUG|HLX208|900 mg
219380206|NCT05902728|DRUG|Itraconazole 200 mg|200 mg
219380207|NCT05902728|DRUG|Rifampicin|600mg
219380208|NCT01959360|PROCEDURE|Direct lateral|Total hip replacement; direct lateral approach
219380209|NCT01959360|PROCEDURE|minimal invasive|Total hip replacement; minimal invasive approach
219380210|NCT01959360|PROCEDURE|modified minimal invasive|Total hip replacement; modified minimal invasive approach
219380211|NCT01309126|BIOLOGICAL|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
219380212|NCT01309126|DRUG|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
219380213|NCT06091501|BEHAVIORAL|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
219380214|NCT01710761|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
219380215|NCT01710761|DIETARY_SUPPLEMENT|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
219380216|NCT06116383|DEVICE|NIRS|Renal perfusion will be evaluated with NIRS
219380217|NCT03607370|PROCEDURE|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
219380218|NCT04553887|DRUG|Almonertinib|single agent, 110mg p.o once daily until disease progressed
219380219|NCT06958679|DRUG|SYS6005|SYS6005 administered via IV infusion on , Day 1 of each 21-day cycle
219380220|NCT02993237|DRUG|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
219380221|NCT02993237|DRUG|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
219380222|NCT01538771|DRUG|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
219380223|NCT01538771|DRUG|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
219380224|NCT00459927|DEVICE|Floseal tonsillectomy|
219380225|NCT00459927|DEVICE|Coblation tonsillectomy|
219380226|NCT00934895|DRUG|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
219380227|NCT00934895|DRUG|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
219380228|NCT01695369|DEVICE|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
219380229|NCT01695369|DEVICE|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
219380230|NCT05617092|OTHER|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
219380231|NCT06247150|BIOLOGICAL|Additional blood sample|The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)
219380232|NCT06247150|BIOLOGICAL|cGVHD target tissue biopsy|For chronic GVH patients only, cGVHD target tissue biopsy
219380233|NCT03804541|DRUG|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
219380234|NCT00374556|DRUG|Placebo|3mg placebo capsule, once daily at bedtime
219380235|NCT00374556|DRUG|Eszopiclone|3mg capsule, once daily at bedtime
219380236|NCT04345185|OTHER|Infant egg consumption (i.e., age of introduction and frequency of intake)|
219380237|NCT06387056|DRUG|Rezvilutamide|240mg by mouth once a day for 24 weeks.
219380238|NCT06387056|DRUG|Goserelin Microspheres for Injection|3.6mg by intramuscular injection once 4 weeks for 24 weeks.
219380239|NCT06387056|DRUG|Docetaxel|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
219380240|NCT06387056|DRUG|Pamiparib|60mg by mouth twice a day for 20 weeks.
219380241|NCT06387056|DRUG|Cisplatin|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
219380242|NCT06387056|DRUG|Tislelizumab|200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
219380243|NCT01836315|OTHER|Observational Study|
219380244|NCT00942162|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
219380245|NCT06214728|PROCEDURE|Hyaluronic acid gel application|HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
219380246|NCT06214728|PROCEDURE|Placebo gel application|The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
219380247|NCT03941444|DRUG|ANAVEX2-73|Liquid oral solution
219380248|NCT03941444|DRUG|Placebo|Liquid oral solution
219380249|NCT05581043|DIETARY_SUPPLEMENT|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
219380250|NCT03739970|DIETARY_SUPPLEMENT|Investigational Product (Silk Peptide)|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
219380251|NCT03739970|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
219380252|NCT02293109|DRUG|carfilzomib|Given IV
219380253|NCT02293109|DRUG|cyclophosphamide|Given IV
219380254|NCT02293109|DRUG|vincristine sulfate|Given IV
219380255|NCT02293109|DRUG|doxorubicin hydrochloride|Given IV
219380256|NCT02293109|DRUG|dexamethasone|Given PO
219380257|NCT02293109|DRUG|methotrexate|Given IV
219380258|NCT02293109|DRUG|cytarabine|Given IV
219380259|NCT02293109|DRUG|leucovorin calcium|Given IV or PO
219380260|NCT02293109|DRUG|methylprednisolone|Given IV
219380261|NCT02293109|BIOLOGICAL|rituximab|
219380262|NCT02293109|OTHER|laboratory biomarker analysis|Correlative studies
219380263|NCT04057443|OTHER|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
219380264|NCT04057443|OTHER|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
219380265|NCT04057443|DRUG|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
219380266|NCT02833311|BEHAVIORAL|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
219380267|NCT02833311|BEHAVIORAL|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
219380268|NCT02833311|BEHAVIORAL|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
219380269|NCT03265691|OTHER|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
219380270|NCT03265691|OTHER|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
219380271|NCT04087499|DEVICE|Acupuncture|acupuncture treatment on selected acupoint
219380272|NCT02153840|DRUG|PSORI-CM01（YXBCM01） granule|
219380273|NCT02153840|DRUG|placebo|
219380274|NCT00509886|DRUG|Drysol|20% aluminum chloride hexahydrate
219380275|NCT00509886|DRUG|Drioff|1% aluminum acetate
219380276|NCT01670201|DEVICE|Mepilex Transfer Ag|Silver dressing
219380277|NCT04619407|DIAGNOSTIC_TEST|Nasopharyngeal swab|SARS-CoV-2 PCR
219380278|NCT04619407|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
219380279|NCT05170737|DRUG|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
219380280|NCT05170737|DRUG|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
219380281|NCT03560362|DRUG|Bupivacaine liposome|
219380282|NCT03560362|DRUG|Bupivacaine / Epinephrine|
219380283|NCT06476080|PROCEDURE|ultrasound guided erector spine block|Ultrasound guided thoracic erector spinae block
219380284|NCT06476080|PROCEDURE|Serratus anterior block|Ultrasound guided serratus anterior block
219380285|NCT01319955|BIOLOGICAL|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
219380286|NCT02486068|DEVICE|ABSORB scaffold|
219380287|NCT02486068|DEVICE|Xience|
219380288|NCT00388089|DRUG|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
219380289|NCT00388089|DRUG|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
219380290|NCT00388089|OTHER|flow cytometry|No description
219000961|NCT03487068|DEVICE|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
219380291|NCT00388089|OTHER|immunoenzyme technique|No description
219380292|NCT00388089|OTHER|immunohistochemistry staining method|No description
219380293|NCT00388089|OTHER|laboratory biomarker analysis|No description
219380294|NCT02211339|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
219380295|NCT02211339|OTHER|Usual care|Staff-led social activity
219380296|NCT04438655|DRUG|Oral antibiotic drugs|"Oral antibiotic drugs:~\- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
219380297|NCT04438655|DRUG|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
219380298|NCT06001580|DRUG|BR101|BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
219380299|NCT04101890|DRUG|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
219380300|NCT00825071|DRUG|Dexamethasone|8 mg, Intravenous
219380301|NCT00825071|DRUG|Ondansetron|4 mg, intravenously
219380302|NCT00825071|DRUG|normal saline|2 ml, intravenously
219380303|NCT00679107|DEVICE|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
219380304|NCT01358110|OTHER|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
219380305|NCT01358110|OTHER|Care as usual|Standard care as usual which may or may not include palliative care consultation
219380306|NCT00583401|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
219380307|NCT02189382|DEVICE|Potassium Oxalate|
219380308|NCT02189382|OTHER|Water|
219380309|NCT01175928|DEVICE|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
219380310|NCT01175928|DEVICE|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
219380311|NCT02514538|DRUG|Non- effervescent Paracetamol kern|1g
219380312|NCT02514538|DRUG|Effervescent paracetamol termalgin|1 g
219380313|NCT03868722|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
219380314|NCT03868722|DRUG|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
219380315|NCT02812680|OTHER|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
219380316|NCT03016234|DRUG|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
219380317|NCT03016234|DRUG|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
219557856|NCT06063590|BIOLOGICAL|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
219380318|NCT01351662|BEHAVIORAL|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
219380319|NCT03388970|DRUG|Vitamin K 1|Research group use Vitamin K1
219380320|NCT03388970|DRUG|normal saline|Placebo group use normal saline
219380321|NCT00267241|OTHER|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
219380322|NCT02638181|PROCEDURE|trabeculectomy|
219380323|NCT02308280|DRUG|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
219380324|NCT03103399|DRUG|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
219380325|NCT03103399|DRUG|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
219380326|NCT03103399|DRUG|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
219380327|NCT03103399|DRUG|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
219380328|NCT01623466|DRUG|levonorgestrel|transdermal contraceptive delivery system
219380329|NCT02799381|DRUG|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
219380330|NCT02799381|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
219380331|NCT02799381|DEVICE|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
219380332|NCT02799381|DEVICE|Percutaneous endoscopic gastrostomy tube|(PEG tube)
219380333|NCT02799381|DEVICE|Jejunal extension tube|(J-tube)
219380334|NCT04063943|DEVICE|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
219380335|NCT01701700|PROCEDURE|portable electronic magnifier|
219557857|NCT04046380|DIAGNOSTIC_TEST|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
219380336|NCT01701700|PROCEDURE|optical aids|
219380337|NCT04556604|BEHAVIORAL|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
219380338|NCT02562729|PROCEDURE|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
219380339|NCT04425850|COMBINATION_PRODUCT|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
219380340|NCT01701791|OTHER|Computerized Decision Support System|
219380341|NCT02413983|PROCEDURE|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
219380342|NCT02413983|PROCEDURE|hepatectomy midline incision|
219380343|NCT02413983|PROCEDURE|hepatectomy transverse incision|
219380344|NCT01668082|PROCEDURE|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
219380345|NCT05882890|OTHER|Craniosacral Therapy|Manual treatment, 5 grams, on the airway system, the throat, the neck, the meninges, the cranial nerve sleeves, the visceral cranium, and the soft tissue in the mouth.
219380346|NCT05882890|OTHER|Exercices Targeting Upper Posture and Respiration|Exercises targeting upper posture and breathing exercises. The exercises is given when the therapist has reached some anatomical milestones in the treatment protocol. For example, an exercise with diaphragmatic breathing is given after manual treatment of diaphragma.
219380347|NCT06488755|DRUG|SIM0718 injection|"Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks"
219557858|NCT05179122|PROCEDURE|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
219380348|NCT06488755|DRUG|SIM0718 injection of placebo|"Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks"
219380349|NCT03187561|BEHAVIORAL|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
219380350|NCT06225050|DEVICE|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
219380351|NCT06475807|DIETARY_SUPPLEMENT|High-fermented food|Step 1: patients will consume high-fermented food
219380352|NCT06475807|DIETARY_SUPPLEMENT|High fiber supplementation|Step 2: High fiber supplementation
219380353|NCT06373003|OTHER|Diagnostic accuracy|To assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/ recurrent adverse pregnancy outcomes
219380354|NCT02239172|BIOLOGICAL|PA83-FhCMB|
219380355|NCT03370757|OTHER|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
219380356|NCT03370757|OTHER|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
219380357|NCT00932087|PROCEDURE|Blood sample|Blood sample for lipidomic study
219380358|NCT01770184|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
219380359|NCT01617486|BEHAVIORAL|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
219380360|NCT05200988|DRUG|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
219380361|NCT01986335|BIOLOGICAL|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
219380362|NCT05726695|DIAGNOSTIC_TEST|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
219380363|NCT05726695|DIAGNOSTIC_TEST|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
219380364|NCT00775567|DIETARY_SUPPLEMENT|Fructose powder|30g in 250ml water twice a day
219380365|NCT05015101|OTHER|Cohort observation|Cohort observation
219380366|NCT05429814|OTHER|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
219380367|NCT06312306|DEVICE|transcranial direct current stimulation|Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
219380368|NCT06312306|OTHER|Pilates based core training|The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
219380369|NCT06312306|OTHER|conventional physiotherapy program|"Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs"
219380370|NCT03057444|DIETARY_SUPPLEMENT|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
219380371|NCT04549987|DEVICE|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
219380372|NCT04549987|DEVICE|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
219380373|NCT00002669|BIOLOGICAL|aldesleukin|
219380374|NCT00002669|BIOLOGICAL|recombinant interferon alfa|
219380375|NCT00002669|DRUG|cisplatin|
219380376|NCT00002669|DRUG|dacarbazine|
219380377|NCT04581187|OTHER|Quality of life assessment|Quality of life questionnaires
219380378|NCT02956889|DRUG|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
219380379|NCT02956889|RADIATION|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
219557859|NCT03578822|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
219380380|NCT02523586|OTHER|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
219380381|NCT02599389|DEVICE|Drug-coated balloons|
219380382|NCT02599389|DEVICE|Excimer Laser|
219380383|NCT04066621|DRUG|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
219380384|NCT03033108|DRUG|Emixustat|Once daily, tablet for oral administration
219380385|NCT02061995|DRUG|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
219380386|NCT00680732|DIETARY_SUPPLEMENT|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
219380387|NCT00680732|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
219380388|NCT00680732|DRUG|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
219380389|NCT00680732|DRUG|Sulphadoxyne-pyrimethamine (SP)|Tablets
219380390|NCT00085969|DRUG|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
219380391|NCT00085969|DRUG|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
219380392|NCT00085969|DRUG|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
219380393|NCT00085969|DRUG|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
219380394|NCT00085969|DRUG|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
219380395|NCT00085969|DRUG|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
219380396|NCT03090191|BIOLOGICAL|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
219380397|NCT03090191|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
219380398|NCT02221076|DEVICE|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
219380399|NCT06340594|PROCEDURE|Laproscopic cholecystectomy (LC)|Removal of gallbladder via laparoscopy
219380400|NCT06340594|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Removal of bile duct stones via endoscopy
219380401|NCT03450772|DRUG|Creon® 25000|Experimental drug
219380402|NCT03450772|DRUG|Creon® 10000|Active comparator
219380403|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
219380404|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
219380405|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
219380406|NCT04930250|OTHER|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
219380407|NCT04930250|OTHER|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
219380408|NCT02506777|DRUG|metformin|
219380409|NCT02506777|DRUG|Fluoruracil|
219380410|NCT02506777|DRUG|Doxorubicin|
219380411|NCT02506777|DRUG|Cyclophosphamide|
219380412|NCT02506777|DRUG|melatonin|
219380413|NCT05128617|DRUG|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
219380414|NCT05128617|DRUG|Paclitaxel|1 cycle of Paclitaxel
219380415|NCT04463394|DRUG|Vasopressin|Vasopressin administered intravenously
219380416|NCT03068962|OTHER|beetroot Juice|Beetroot Juice
219380417|NCT03068962|OTHER|Buxton water|natural mineral water
219380418|NCT03068962|OTHER|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
219380419|NCT05267028|OTHER|AD-TAR|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
219380420|NCT05267028|OTHER|AD-Cognitive Stimulation|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
219380421|NCT00193843|PROCEDURE|Post-operative chemoradiotherapy / accelerated radiotherapy|
219380422|NCT04503980|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
219380423|NCT01099345|PROCEDURE|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
219380424|NCT01099345|PROCEDURE|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
219380425|NCT05265351|DIAGNOSTIC_TEST|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
219380426|NCT05265351|DIAGNOSTIC_TEST|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
219380427|NCT03554512|OTHER|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
219557860|NCT03578822|DRUG|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
219380428|NCT04723537|DRUG|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
219380429|NCT04723537|DRUG|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
219380430|NCT04723537|DRUG|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
219380431|NCT04723537|DRUG|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
219380432|NCT00502060|DRUG|AZD2171|
219380433|NCT00502060|DRUG|ZD1839|
219380434|NCT04984135|PROCEDURE|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
219380435|NCT00746772|DRUG|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
219380436|NCT00746772|DRUG|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
219380437|NCT02195115|PROCEDURE|Laparoscopic Cholecystectomy|
219380438|NCT02195115|DRUG|amitriptyline|
219380439|NCT02195115|OTHER|low-fat and low cholesterol diet|
219380440|NCT05489068|BEHAVIORAL|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
219380441|NCT05489068|BEHAVIORAL|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
219380442|NCT01146470|DIETARY_SUPPLEMENT|RGC|dosage of Red Grape Cells once a day, during 3 months
219380443|NCT01146470|DIETARY_SUPPLEMENT|Placebo|dosage of Placebo once a day, during 3 months
219380444|NCT03751202|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
219380445|NCT03751202|DRUG|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
219380446|NCT02432807|DRUG|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
219380447|NCT02432807|DRUG|Placebo|Placebo
219380448|NCT01045954|DRUG|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
219380449|NCT02406755|OTHER|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
219380450|NCT02406755|OTHER|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
219380451|NCT02406755|OTHER|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
219380452|NCT05381961|DEVICE|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
219380453|NCT02353949|DRUG|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
219380454|NCT00432198|DRUG|Zolpidem (Myslee®)|Oral
219380455|NCT00432198|DRUG|placebo|Oral
219380456|NCT06056973|DRUG|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
219380457|NCT02997930|BEHAVIORAL|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
219380458|NCT02997930|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
219380459|NCT02997930|BEHAVIORAL|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
219380460|NCT02997930|BEHAVIORAL|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
219380461|NCT02997930|BEHAVIORAL|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
219380462|NCT02997930|BEHAVIORAL|General Depression Scale (GDS)|A measure of the of presence of depression.
219557861|NCT03578822|DRUG|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
219380463|NCT01441544|BEHAVIORAL|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
219380464|NCT03115385|DIETARY_SUPPLEMENT|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
219380465|NCT03115385|DIETARY_SUPPLEMENT|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
219380466|NCT06510478|BEHAVIORAL|Group Life Skill Intervention|This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
219380467|NCT06510478|BEHAVIORAL|Treatment as Usual for Control Group|Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
219380468|NCT03530540|DEVICE|low-intensity extracorporeal shockwave therapy|Active shockwaves
219380469|NCT03530540|DEVICE|Placebo LI-ESWT|Placebo shockwaves
219380470|NCT03530540|DEVICE|Penile pump|both groups will be treated with a penile pump
219380471|NCT02755636|BEHAVIORAL|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
219380472|NCT02755636|OTHER|Usual care|Primary care as usual
219380473|NCT03888495|BEHAVIORAL|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
219380474|NCT03888495|BEHAVIORAL|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
219380475|NCT03888495|BEHAVIORAL|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
219380476|NCT03393351|OTHER|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
219380477|NCT03393351|OTHER|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
219380478|NCT03042949|DEVICE|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
219380479|NCT03042949|DEVICE|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
219380480|NCT06378710|PROCEDURE|Optimized PEEP|Optimized PEEP
219380481|NCT02864303|OTHER|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
219380482|NCT00058799|BIOLOGICAL|Dose Level 1|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
219380483|NCT00058799|BIOLOGICAL|Dose Level 2|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
219380484|NCT00058799|BIOLOGICAL|Dose Level 3|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
219380485|NCT04419506|DRUG|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
219380486|NCT04419506|DRUG|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
219380487|NCT05839132|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
219380488|NCT00715715|DRUG|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
219380489|NCT02396862|DRUG|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
219380490|NCT05352217|DEVICE|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
219380491|NCT01268397|PROCEDURE|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
219380492|NCT01268397|PROCEDURE|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
219557862|NCT03578822|DRUG|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
219380493|NCT04933097|DEVICE|Microfet2®|"Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity"
219380494|NCT05374941|DEVICE|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
219380495|NCT05983302|DRUG|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
219380496|NCT05983302|DRUG|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
219380497|NCT05983302|DRUG|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
219380498|NCT05983302|OTHER|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
219380499|NCT01845025|DRUG|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
219380500|NCT01845025|DRUG|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
219380501|NCT01845025|DRUG|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
219380502|NCT01845025|DRUG|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
219380503|NCT01845025|DRUG|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
219380504|NCT02513940|DRUG|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
219380505|NCT02513940|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
219380506|NCT02513940|DRUG|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
219380507|NCT02513940|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
219380508|NCT06281873|PROCEDURE|closure by PRF membrane|Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
219380509|NCT03976401|DRUG|EFX|Administered by subcutaneous injection
219380510|NCT03976401|DRUG|Placebo|Administered by subcutaneous injection
219380511|NCT00089128|DRUG|gemcitabine hydrochloride|
219380512|NCT00089128|DRUG|irinotecan hydrochloride|
219380513|NCT00862381|DRUG|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
219380514|NCT00862381|DRUG|Placebo|NaCl 0.9%
219380515|NCT03367845|BEHAVIORAL|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
219380516|NCT03367845|BEHAVIORAL|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
219380517|NCT03367845|BEHAVIORAL|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
219380518|NCT03367845|BEHAVIORAL|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
219380519|NCT06170658|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, silicone hydrogel investigational lenses for one week
219380520|NCT06170658|DEVICE|Control Lenses (omafilcon A)|Daily disposable, hydrogel commercially available lenses for one week
219380521|NCT02783560|BEHAVIORAL|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
219380522|NCT02783560|BEHAVIORAL|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
219380523|NCT06408844|BEHAVIORAL|Physical activity behavior change program implemented with 5A model|"According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week."
219380524|NCT02912663|DRUG|Verapamil and Magnesium Sulfate|Single dose strategy will be used
219380525|NCT02912663|OTHER|Placebo|Single matching dosing strategy will be used
219380526|NCT04518384|PROCEDURE|colon or rectum resection|surgical procedure to resect the colon or rectum
219380527|NCT01973283|DRUG|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
219380528|NCT03023748|DRUG|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
219380529|NCT06196411|BEHAVIORAL|Task-oriented Training|Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.
219380530|NCT06196411|BEHAVIORAL|Bobath Training|Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
219380531|NCT03339141|PROCEDURE|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
219380532|NCT03550248|BEHAVIORAL|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
219380533|NCT01867489|OTHER|No intervention|
219380534|NCT00275080|DRUG|vorinostat|Given orally
219380535|NCT00275080|DRUG|decitabine|Given IV
219380536|NCT05015387|PROCEDURE|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
219380537|NCT05015387|COMBINATION_PRODUCT|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
219380538|NCT05015387|DIAGNOSTIC_TEST|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
219380539|NCT01478555|DRUG|ISV 101|Bromfenac in DuraSite
219380540|NCT04940923|DIAGNOSTIC_TEST|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
219380541|NCT02339714|OTHER|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
219380542|NCT02339714|DRUG|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
219380543|NCT03369847|DRUG|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
219380544|NCT06022770|DIETARY_SUPPLEMENT|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
219380545|NCT02966314|DRUG|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
219380546|NCT02966314|DRUG|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
219380547|NCT00054470|BIOLOGICAL|trastuzumab|
219380548|NCT00054470|DRUG|tipifarnib|
219380549|NCT01023529|RADIATION|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
219380550|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
219380551|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
219380552|NCT03941548|DRUG|CTP-543|Administered as 12 mg tablets.
219380553|NCT03941548|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
219380554|NCT02081963|DRUG|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
219380555|NCT02081963|DRUG|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
219380556|NCT01128712|DRUG|Pregabalin|150 mg /day
219380557|NCT01128712|DRUG|Pregabalin|450 mg/day
219380558|NCT01898663|BIOLOGICAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
219380559|NCT00358163|DRUG|PTK787/ZK 222584|Taken in tablet form daily
219380560|NCT00358163|DRUG|paclitaxel|Given as a 3-hour infusion once every 21 days
219380561|NCT01818349|OTHER|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
219380562|NCT01818349|OTHER|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
219380563|NCT01571271|PROCEDURE|Laser Lithotripsy|Laser Lithotripsy
219380564|NCT01571271|PROCEDURE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
219380565|NCT04259515|DRUG|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
219380566|NCT04259515|DRUG|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
219380567|NCT06118983|OTHER|I-TRANSFER-HF|"I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US."
219380568|NCT03710109|OTHER|EEG|non-invasive, non-interventional sensor
219380569|NCT00250393|DRUG|Istradefylline (KW-6002)|
219380570|NCT02038322|DEVICE|The Stork - Conception Aid|
219380571|NCT01357213|DRUG|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
219380572|NCT01357213|OTHER|Placebo|Normal saline 100 ml
219380573|NCT01591005|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
219380574|NCT01591005|PROCEDURE|endarterectomy|carotid endarterectomy
219380575|NCT01591005|PROCEDURE|carotid stenting|percutaneous transluminal angioplasty and stenting
219000962|NCT01020227|BEHAVIORAL|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
219000963|NCT00666627|DRUG|Ibandronate|once monthly
219380576|NCT01276886|DRUG|antibiotic|
219380577|NCT01276886|PROCEDURE|Colonic resection with or without stoma|
219380578|NCT01075087|DRUG|Placebo|Bilateral TAP block using sterile normal saline.
219380579|NCT01075087|DRUG|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
219380580|NCT01049776|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
219380581|NCT01305499|DRUG|Entinostat days 3, 10|Given orally on days 3, 10
219380582|NCT01305499|DRUG|5AC|
219380583|NCT01305499|DRUG|Entinostat days 10,17|Given orally on days 10, 17
219380584|NCT00994617|DRUG|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
219380585|NCT00994617|DRUG|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
219380586|NCT03766243|BEHAVIORAL|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
219380587|NCT03766243|BEHAVIORAL|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
219380588|NCT04460703|OTHER|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
219380589|NCT04460703|OTHER|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
219380590|NCT04460703|OTHER|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
219557863|NCT05820828|DIAGNOSTIC_TEST|Volume control|Volume control in venous reservoir during extracorporeal circulation.
219000964|NCT00666627|DRUG|Risedronate|Risedronate 35mg once weekly
219380591|NCT04460703|OTHER|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
219380592|NCT04460703|OTHER|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
219380593|NCT04460703|OTHER|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
219380594|NCT04460703|OTHER|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
219380595|NCT04460703|OTHER|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
219380596|NCT04460703|OTHER|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
219380597|NCT04460703|OTHER|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
219380598|NCT04460703|OTHER|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
219380599|NCT04460703|OTHER|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
219380600|NCT04681326|DEVICE|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
219380601|NCT03425903|DEVICE|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
219380602|NCT06041750|PROCEDURE|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
219380603|NCT00811252|DRUG|Placebo|capsules; daily; orally
219380604|NCT00811252|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
219380605|NCT00811252|DRUG|Duloxetine|encapsulated tablets; daily; orally
219380606|NCT05732129|DRUG|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
219380607|NCT05732129|DRUG|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
219380608|NCT03420638|DRUG|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
219380609|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
219380610|NCT05293418|OTHER|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
219380611|NCT00932997|BEHAVIORAL|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
219000965|NCT00666627|DRUG|Alendronate|Alendronate 70mg once weekly
219000966|NCT01942330|PROCEDURE|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
219000967|NCT03602183|DEVICE|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
219380612|NCT00932997|OTHER|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
219380613|NCT00932997|OTHER|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
219380614|NCT00932997|OTHER|questionnaire administration|Baseline and 9 months after enrollment and intervention
219380615|NCT00932997|PROCEDURE|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
219380616|NCT00932997|PROCEDURE|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
219380617|NCT03903757|OTHER|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
219380618|NCT03553173|OTHER|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
219380619|NCT03553173|BEHAVIORAL|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
219000968|NCT03602183|DEVICE|Miller laryngoscope|intubation will be performed using Miller laryngoscope
219380620|NCT03553173|DRUG|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
219380621|NCT03553173|DRUG|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
219380622|NCT05448079|OTHER|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
219380623|NCT00184587|DRUG|candesartan cilexetil|
219380624|NCT00184587|DRUG|placebo|
219380625|NCT02363205|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
219380626|NCT03728049|DIAGNOSTIC_TEST|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
219380627|NCT03728049|OTHER|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
219380628|NCT01486264|BIOLOGICAL|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
219380629|NCT00813748|DRUG|Xolair|
219380630|NCT02978014|DEVICE|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
219380631|NCT03678974|BEHAVIORAL|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
219380632|NCT04247048|OTHER|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
219380633|NCT05459597|DRUG|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
219380634|NCT01931865|DRUG|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
219380635|NCT00047411|OTHER|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
219380636|NCT00047411|DEVICE|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
219380637|NCT02774590|DRUG|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
219380638|NCT01495871|DIETARY_SUPPLEMENT|Amino Acids|15 grams amino acids two times per day for 6 weeks
219380639|NCT01495871|DIETARY_SUPPLEMENT|Placebo of inert compounds|Placebo two times per day for 6 weeks
219380640|NCT01495871|DIETARY_SUPPLEMENT|Valine|2.5 grams valine supplementation two times a day for 6 weeks
219380641|NCT01162525|PROCEDURE|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
219380642|NCT02748343|DEVICE|allograft bone|Use of the allograft bone to treat the bone defect in patients
219380643|NCT02748343|DEVICE|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
219380644|NCT06329388|DIETARY_SUPPLEMENT|TruHeight Growth Protein Shake|Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
219000969|NCT03602183|DEVICE|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
219380645|NCT02762058|DEVICE|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
219557864|NCT03108820|BEHAVIORAL|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
219380646|NCT02762058|PROCEDURE|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
219380647|NCT00013884|DRUG|T-20|
219380648|NCT05385562|DRUG|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
219380649|NCT05385562|DRUG|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
219380650|NCT00009672|DRUG|Nortriptyline|
219380651|NCT00009672|DRUG|Morphine|
219380652|NCT00035893|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
219380653|NCT03876587|DRUG|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
219380654|NCT02176486|DRUG|Ixazomib|Ixazomib capsules.
219380655|NCT02176486|DRUG|Placebo|Ixazomib placebo-matching capsules.
219380656|NCT03268798|DEVICE|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
219380657|NCT00872066|DEVICE|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
219380658|NCT00872066|DEVICE|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
219380659|NCT01175512|DRUG|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
219380660|NCT01175512|DRUG|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
219380661|NCT03613428|DRUG|Ruxolitinib|Dose escalation up to 80 mg administered orally
219380662|NCT03613428|DRUG|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
219380663|NCT03613428|DRUG|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
219188533|NCT04580680|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
219557865|NCT03108820|OTHER|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
219000970|NCT03602183|DEVICE|GlideScope|intubation will be performed using GlideScope video - laryngoscope
219000971|NCT00002876|DRUG|cisplatin|
219000972|NCT00002876|DRUG|etoposide|
219188534|NCT06328036|BIOLOGICAL|Atezolizumab|Given IV
219188535|NCT06328036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219188536|NCT06328036|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219380664|NCT05078814|OTHER|Observational research|Observational research
219380665|NCT00838487|OTHER|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
219380666|NCT00838487|OTHER|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
219380667|NCT02625038|DEVICE|EUDAMED CIV-14-03-011940|
219380668|NCT04698928|DEVICE|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
219380669|NCT04629729|DRUG|FT819|Experimental Interventional Therapy
219380670|NCT04629729|DRUG|Cyclophosphamide|Lympho-conditioning agent
219380671|NCT04629729|DRUG|Fludarabine|Lympho-conditioning agent
219380672|NCT04629729|DRUG|IL-2|Biologic response modifier
219380673|NCT04629729|DRUG|Bendamustine|Lympho-conditioning agent
219380674|NCT04273724|OTHER|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
219380675|NCT03591887|BIOLOGICAL|ABY-035|ABY-035 solution for injection
219380676|NCT03591887|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
219380677|NCT01787071|OTHER|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
219380678|NCT04036825|DIETARY_SUPPLEMENT|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
219380679|NCT04036825|DIETARY_SUPPLEMENT|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
219380680|NCT01400646|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
219380681|NCT01400646|DRUG|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
219380682|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
219380683|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
219380684|NCT01400646|DRUG|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
219380685|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
219380686|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
219380687|NCT03147027|PROCEDURE|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
219380688|NCT03147027|OTHER|medication|medication to prevent sustained VT and ICD therapies
219000973|NCT01216306|BEHAVIORAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
219380689|NCT05330520|PROCEDURE|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
219380690|NCT01088425|OTHER|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
219380691|NCT01126229|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo daily for 12 weeks
219380692|NCT01126229|DRUG|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
219380693|NCT01126229|DRUG|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
219380694|NCT03016611|DRUG|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
219380695|NCT03016611|DRUG|Chewing Prasugrel LD|60 mg Chewing Prasugrel
219380696|NCT03116880|PROCEDURE|Endovascular aortic repair|Endovascular aortic repair
219380697|NCT00001923|PROCEDURE|Transcranial magnetic stimulation|
219380698|NCT00710190|DEVICE|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
219380699|NCT05495607|DEVICE|CARPEDIEN|Continuous renal replacement therapy
219380700|NCT02704104|DEVICE|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
219380701|NCT04820270|OTHER|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
219380702|NCT06292481|OTHER|Brunnstorm movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
219380703|NCT06292481|OTHER|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
219380704|NCT00824421|DRUG|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
219380705|NCT00824421|DRUG|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
219380706|NCT00824421|DRUG|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
219380707|NCT03578406|DRUG|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
219380708|NCT01027689|DRUG|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
219380709|NCT01027689|DRUG|alprazolam test sublingual tablet|1 mg tablet, single dose
219380710|NCT03489213|OTHER|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
219380711|NCT03489213|BEHAVIORAL|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
219380712|NCT03489213|OTHER|Laboratory Biomarker Analysis|Correlative studies
219380713|NCT03489213|DIETARY_SUPPLEMENT|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
219380714|NCT03489213|OTHER|Questionnaire Administration|Ancillary studies
219380715|NCT04046302|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
219380716|NCT04046302|DRUG|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
219000974|NCT03767504|DIETARY_SUPPLEMENT|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
219000975|NCT03962920|DRUG|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
219380717|NCT04407377|DRUG|Tolperisone Hydrochloride|Study Drug
219380718|NCT04407377|DRUG|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
219380719|NCT04407377|OTHER|Placebo|Placebo Comparator
219380720|NCT03205969|DEVICE|Functional mobile game|Functional mobile game for chemotherapy side effect education
219380721|NCT04871815|DRUG|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
219380722|NCT01906840|DRUG|Turmeric|
219380723|NCT01906840|DRUG|placebo|
219380724|NCT02120417|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
219380725|NCT02120417|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
219380726|NCT02120417|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
219380727|NCT03114761|RADIATION|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
219380728|NCT02448550|DRUG|Bivalirudin|
219380729|NCT02448550|DRUG|Unfractionated heparin|
219380730|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
219380731|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin|2 capsules hesperidin
219380732|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: flaxseed|30 g flaxseed
219380733|NCT03734510|OTHER|control|no supplementation
219380734|NCT05695547|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
219380735|NCT02822365|PROCEDURE|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
219380736|NCT02822365|DEVICE|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
219380737|NCT02822365|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
219380738|NCT05493514|DEVICE|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
219380739|NCT03885297|DRUG|Saxenda|Obesity pharmacotherapy
219380740|NCT03885297|OTHER|Lifestyle modification|Tier 3 NHS weight management
219380741|NCT03885297|DIAGNOSTIC_TEST|Metabolomics|Small molecule intermediates and products of metabolism
219380742|NCT03885297|DIAGNOSTIC_TEST|miRNA|Small non-coding RNA molecules
219380743|NCT04227444|DIAGNOSTIC_TEST|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
219380744|NCT03844438|DRUG|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
219380745|NCT05990530|BIOLOGICAL|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
219380746|NCT03304808|DEVICE|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
219380747|NCT03304808|BEHAVIORAL|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
219380748|NCT00594399|BEHAVIORAL|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
219380749|NCT01018407|BEHAVIORAL|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
219380750|NCT01018407|BEHAVIORAL|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
219380751|NCT01965925|DRUG|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
219380752|NCT01965925|DRUG|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
219380753|NCT04265612|PROCEDURE|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
219380754|NCT04265612|PROCEDURE|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
219000976|NCT03962920|OTHER|Placebo|Local instillation of sterile water directly to the tumour tissue
219000977|NCT06352281|BIOLOGICAL|CAR-T cells|CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
219000978|NCT01479517|DRUG|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
219188537|NCT06328036|PROCEDURE|Surgical Procedure|Undergo surgical resection
219380755|NCT05863936|DRUG|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
219380756|NCT05863936|DRUG|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
219380757|NCT05863936|DRUG|Immunosuppressive Agents|"1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day."
219380758|NCT03578705|DEVICE|"Electrical Impedance Myography unit or EIM"|
219380759|NCT00016315|DRUG|carboplatin|
219380760|NCT00016315|DRUG|gemcitabine hydrochloride|
219380761|NCT00016315|DRUG|paclitaxel|
219380762|NCT00016315|RADIATION|radiation therapy|
219380763|NCT05712668|BEHAVIORAL|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
219380764|NCT05712668|BEHAVIORAL|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
219380765|NCT03162718|BEHAVIORAL|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
219380766|NCT05597748|DEVICE|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
219380767|NCT05597748|DEVICE|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
219380768|NCT01413386|DEVICE|biliary stent|palliative treatment for malignant patients
219380769|NCT05897541|DRUG|S-217622|Administered as a tablet.
219380770|NCT05897541|DRUG|Placebo|Administered as a tablet.
219380771|NCT00937222|DIETARY_SUPPLEMENT|Peanuts and peanut butter|Peanuts and peanut butter
219380772|NCT05607550|DRUG|furmonertinib 240 mg oral, daily|furmonertinib tablet
219380773|NCT05607550|DRUG|furmonertinib 160 mg oral, daily|furmonertinib tablet
219380774|NCT05607550|DRUG|platinum-based chemotherapy|(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
219380775|NCT04765137|DRUG|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
219380776|NCT03648164|OTHER|CHAT-CS Survey|Students will complete a computer-based survey
219380777|NCT00424398|DRUG|Bepreve|sterile ophthalmic solution
219380778|NCT00424398|DRUG|Placebo|sterile ophthalmic solution
219380779|NCT00424398|DRUG|Bepotastine Besilate|sterile ophthalmic solution
219380780|NCT01023789|DEVICE|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
219380781|NCT03097380|DRUG|AZD2115|AZD2115
219380782|NCT03097380|DRUG|SPIRIVA|Tiotropium
219380783|NCT03097380|RADIATION|[11C]AZ13754366|Radioligand
219380784|NCT02747914|DEVICE|Transcranial magnetic stimulation|TMS 1Hz under the motor zone of cortex.
219380785|NCT02747914|OTHER|Conventional exercise|Exercise will be administrated in a conventional way.
219380786|NCT02533089|OTHER|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
219380787|NCT01284803|BEHAVIORAL|an educational intervention|To elaborate an educational program for the management of depression in primary care
219380788|NCT04268719|DIAGNOSTIC_TEST|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
219380789|NCT00095563|DRUG|lapatinib ditosylate|Given orally
219380790|NCT00095563|OTHER|laboratory biomarker analysis|Correlative studies
219380791|NCT05974306|DEVICE|implantable loop recorder|Implantation of an implantable loop recorder
219380792|NCT04846114|PROCEDURE|Dental implant surgery|
219380793|NCT02335502|DEVICE|Implantation with the commercially available Axium neurostimulator|
219380794|NCT00898092|GENETIC|microarray analysis|
219380795|NCT00898092|GENETIC|molecular genetic technique|
219380796|NCT00898092|GENETIC|mutation analysis|
219380797|NCT00898092|GENETIC|polymerase chain reaction|
219380798|NCT00898092|GENETIC|reverse transcriptase-polymerase chain reaction|
219380799|NCT00898092|OTHER|diagnostic laboratory biomarker analysis|
219380800|NCT00166348|BEHAVIORAL|Cognitive Group Therapy|
219380801|NCT03589001|OTHER|Activity modification|Activity modification, exercises and gradual return to sport
219380802|NCT00908284|BEHAVIORAL|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
219380803|NCT00908284|BEHAVIORAL|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
219380804|NCT05303740|DRUG|Anlotinib|This is an observational study.
219380805|NCT00056199|DRUG|EYE001|
219380806|NCT02034123|DRUG|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
219380807|NCT05230147|PROCEDURE|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
219380808|NCT05230147|PROCEDURE|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
219380809|NCT00465257|DRUG|artesunate + amodiaquine|
219380810|NCT04193683|OTHER|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
219380811|NCT04193683|OTHER|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
219380812|NCT04275427|DEVICE|LA-400 laser acupuncture|low level laser
219380813|NCT00199004|DRUG|Cyclophosphamide|
219380814|NCT00199004|DRUG|Dexamethasone / Prednisolone|
219380815|NCT00199004|DRUG|Vincristine|
219380816|NCT00199004|DRUG|Daunorubicin|
219380817|NCT00199004|DRUG|Asparaginase|
219380818|NCT00199004|DRUG|Methotrexate|
219380819|NCT00199004|DRUG|Cytarabine|
219380820|NCT00199004|DRUG|Mercaptopurine|
219380821|NCT00199004|DRUG|G-CSF|
219380822|NCT00199004|DRUG|Vindesine|
219380823|NCT00199004|DRUG|VP16|
219380824|NCT00199004|DRUG|Adriamycin|
219380825|NCT00199004|DRUG|Thioguanine|
219380826|NCT00199004|DRUG|VM26|
219380827|NCT00199004|DRUG|Rituximab|
219380828|NCT00199004|PROCEDURE|CNS irradiation|
219380829|NCT00199004|PROCEDURE|Mediastinal irradiation (if residual TU)|
219380830|NCT00199004|PROCEDURE|Stem cell transplantation|
219380831|NCT01411787|BEHAVIORAL|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
219380832|NCT02903004|DRUG|Trabectedin|
219380833|NCT02903004|DRUG|Pegylated Liposomal Doxorubicin|
219380834|NCT02903004|DRUG|Topotecan|
219380835|NCT02903004|DRUG|Gemcitabine|
219380836|NCT02903004|DRUG|Weekly Paclitaxel|
219380837|NCT02903004|DRUG|Carboplatin|
219380838|NCT05668221|BEHAVIORAL|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
219380839|NCT01271686|DRUG|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
219380840|NCT04558502|DRUG|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
219380841|NCT04558502|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
219380842|NCT04558502|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219380843|NCT04558502|DRUG|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
219380844|NCT04558502|DRUG|esomeprazole|Proton pump inhibitor
219380845|NCT00717730|DIETARY_SUPPLEMENT|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
219380846|NCT00717730|DIETARY_SUPPLEMENT|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
219380847|NCT00717730|DIETARY_SUPPLEMENT|Placebo|Placebo with no active ingredients
219380848|NCT00717730|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
219380849|NCT05413330|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
219380850|NCT04623957|DEVICE|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
219380851|NCT01175369|BEHAVIORAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
219380852|NCT02240706|PROCEDURE|Best Supportive Care|At Discretion of the Investigator (Transfusions)
219380853|NCT02240706|DRUG|BI 836858|Monotherapy with BI 836858
219380854|NCT03301857|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
219380855|NCT00109811|BIOLOGICAL|PSA:154-163(155L) peptide vaccine|Given subcutaneously
219380856|NCT00109811|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
219380857|NCT00109811|OTHER|laboratory biomarker analysis|Correlative studies
219380858|NCT05328050|OTHER|Registry|observational, data collection
219380859|NCT06329050|DRUG|Losartan|Administration of Losartan tablets(50 mg)
219380860|NCT06329050|DRUG|Placebo|Administration of Placebo tablets
219380861|NCT00553995|DRUG|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
219380862|NCT00553995|DRUG|Placebo|
219380863|NCT03270748|DRUG|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
219380864|NCT00730340|PROCEDURE|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
219380865|NCT00730340|PROCEDURE|Tonsillectomy with open fossa|SOP for a tonsillectomy.
219380866|NCT04614818|OTHER|Non-intervention research|Non-intervention research
219380867|NCT02655484|DEVICE|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
219380868|NCT03140319|BIOLOGICAL|Fibroblast|Transplantation of 20 million cell by three injection
219380869|NCT03140319|BIOLOGICAL|Placebo|Injection of Placebo
219380870|NCT02210338|DEVICE|Karl Storz C-MAC|
219380871|NCT02210338|DEVICE|Bonfils Intubation Fibrescope|
219380872|NCT01090557|OTHER|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
219380873|NCT02998502|DEVICE|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
219380874|NCT02792868|OTHER|24 h urines analyses|patient collects urines during 24h
219380875|NCT01288768|PROCEDURE|Knee arthroscopy|Knee arthroscopy within 4 weeks.
219380876|NCT05072405|DRUG|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
219380877|NCT05072405|DRUG|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
219380878|NCT03639740|DRUG|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
219380879|NCT03419793|DEVICE|segmental vibration device|segmental vibration device
219380880|NCT03419793|OTHER|physical therapy exercises|
219380881|NCT04203901|BIOLOGICAL|CMN-001|Autologous Dendritic Cell Therapy
219380882|NCT04203901|BIOLOGICAL|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
219380883|NCT04203901|DRUG|Lenvatinib+Everolimus|TKI+mTOR inhibitors
219380884|NCT01002781|DRUG|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
219380885|NCT06037876|DRUG|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
219380886|NCT06037876|DRUG|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
219380887|NCT01089192|DRUG|Metformin|
219380888|NCT04538404|PROCEDURE|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
219380889|NCT06371339|DEVICE|"Additional acquisitions with the investigational gamma-camera  MoTI ."|"The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy within 4 hours of treatment before the patient returns home (Day 0).~For the study, scintigraphic acquisitions will be carried out respectively using both the standard gamma camera Syngula and the gamma camera MoTI."
219380890|NCT02531815|BIOLOGICAL|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
219380891|NCT02531815|DRUG|Placebo|Placebo for PF-06741086, single dose
219380892|NCT02497703|DEVICE|Knee robot|
219380893|NCT01402219|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
219380894|NCT01402219|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
219380895|NCT00477087|DRUG|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
219380896|NCT00477087|DRUG|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
219380897|NCT01397851|DEVICE|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
219188538|NCT06328036|BIOLOGICAL|Tiragolumab|Given IV
219380898|NCT01442298|PROCEDURE|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
219380899|NCT01442298|PROCEDURE|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
219380900|NCT00613626|DRUG|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
219380901|NCT00613626|DRUG|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
219380902|NCT00613626|DRUG|Placebo|Matched placebo oral daily
219380903|NCT00613626|DRUG|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
219380904|NCT04108507|PROCEDURE|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
219380905|NCT05432570|PROCEDURE|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
219380906|NCT05432570|PROCEDURE|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
219380907|NCT05301244|OTHER|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
219380908|NCT05301244|OTHER|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
219380909|NCT05301244|OTHER|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
219380910|NCT05301244|OTHER|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
219380911|NCT05301244|OTHER|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
219380912|NCT00708396|DRUG|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
219380913|NCT05194319|OTHER|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
219380914|NCT02149992|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
219380915|NCT02149992|DEVICE|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
219380916|NCT02149992|DEVICE|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
219380917|NCT03059290|DEVICE|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
219380918|NCT04879940|DEVICE|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
219380919|NCT04879940|RADIATION|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
219380920|NCT04557527|PROCEDURE|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
219380921|NCT04557527|DEVICE|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
219380922|NCT05776160|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
219380923|NCT05071937|DRUG|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
219380924|NCT05071937|DRUG|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
219380925|NCT06546319|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
219380926|NCT04039230|DRUG|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
219380927|NCT04039230|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
219380928|NCT06802159|BEHAVIORAL|Conventional therapy|"The methods of traditional neuropsychological rehabilitation used in the classes included:~* attention tasks: proofreading tests, Schulte's Table;~* spatial thinking tasks: copying, drawing, tasks using Nikitin cubes;~* text reading tasks: texts from the Luria album. Each session began with oculomotor exercises. The correction programs differed by the type of feedback given to the patient in the course of correction.~Feedback in this type of intervention is in the form of prompts from a specialist."
219380929|NCT06802159|BEHAVIORAL|Eye tracking based therapy|"Rehabilitation in this group was carried out using an alternative communication device - oculograph C-Eye Pro (Assistech). The use of the device is characterized by a number of features: the presence of the eye movement biofeedback function (the patient and the specialist can see where the patient's gaze is directed by the movement of the red dot on the screen), the device needs to be pre-calibrated before the beginning of the session. To implement rehabilitation activities such tasks were used as:~* Visual field training;~* Word composing;~* Vowel insertion;~* Reading;~* etc. The peculiarity of correction on the apparatus of alternative communication - oculograph - was the use of visual biological communication, visual biological communication, also in case of wrong answer a sound signal followed."
219380930|NCT06802159|BEHAVIORAL|Cognitive therapy|"Rehabilitation of patients in the second experimental group was carried out on the RehaCom modular therapeutic system. The modular system includes a dedicated keyboard that has: numbers 1-9, 4 ok buttons, 4 arrow buttons, 2 pause/tip buttons and 2 exit/cancel buttons. Most of the tasks are performed using the keyboard, some of the tasks involved touch screen control. Tasks with stimulus images in the left screen space were used for rehabilitation activities:~* Saccades;~* Attention and Concentration;~* Planar Imagination;~* General Presentation and Reading;~* Shopping;~* Daily routine. A feature of the correction on the modular therapy system was the involvement of a motor component, playing a sound cue or visual cue when an error occurred."
219380931|NCT02078349|DRUG|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
219380932|NCT02912273|OTHER|Baseline Participant Assessment|"* Section 1 contains demographic questions~* Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~* Section 3 has the participant list all medication~* Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~* Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~* Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
219380933|NCT02912273|OTHER|Baseline Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
219380934|NCT02912273|OTHER|Follow-up Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
219380935|NCT02912273|OTHER|Follow-up Healthcare Provider Assessment|"* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
219380936|NCT02912273|OTHER|End-of-study Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~* Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
219429106|NCT05060172|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
219380937|NCT02912273|OTHER|End-of-study Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
219380938|NCT06504667|DEVICE|Point Mini|The Point Mini finger prosthetic system consists of 1-4 ratcheting mechanical digits and mounting brackets
219380939|NCT06127602|BEHAVIORAL|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
219380940|NCT06127602|BEHAVIORAL|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
219380941|NCT06418308|DRUG|Dexmedetomidine|5 mcg of dexmedetomidine
219380942|NCT06418308|DRUG|Epinephrine|200 mcg of epinephrine
219380943|NCT06418308|DRUG|Standardized Spinal Mixture|Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
219188539|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
219188540|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
219380944|NCT02867007|DRUG|KHK2455|oral dosing
219380945|NCT02867007|DRUG|Mogamulizumab|i.v. administration
219380946|NCT00000584|DRUG|immunoglobulins|
219380947|NCT03980314|DRUG|Nivolumab|Specified dose on specified days
219380948|NCT01730248|DRUG|INC424|5 mg tablets administered orally twice daily
219380949|NCT01730248|DRUG|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
219380950|NCT05606172|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11|This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
219380951|NCT05606172|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
219380952|NCT01586845|DRUG|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
219380953|NCT01586845|DRUG|tacrolimus|tacrolimus as per labeled dose
219380954|NCT06485128|DIAGNOSTIC_TEST|Optical coherence tomography(-angiography) OCT(A)|OCTA is a non-invasive diagnostic tool capable of generating cross-sectional coupes of the retina and choroid. Novel algorithms allow to render a 3-dimensional model of the ocular microcirculation based merely on the motion contrast of the circulating blood.
219380955|NCT06485128|DIAGNOSTIC_TEST|Fundus pictures|Visucam (Zeiss), Topcon NW8 fundus camera, NFC 600 (Crystalvue)
219380956|NCT06485128|DIAGNOSTIC_TEST|DVA 3.0|IMEDOS GmbH
219380957|NCT06485128|DIAGNOSTIC_TEST|Hyperspectral retinal images|Ximea SNm4x4 hyperspectral snapshot camera
219380958|NCT06485128|DIAGNOSTIC_TEST|SphygmoCor|Sphygmocor Excell
219188541|NCT05924789|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
219188542|NCT05661448|BEHAVIORAL|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
219188543|NCT05661448|BEHAVIORAL|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
219380959|NCT06485128|DIAGNOSTIC_TEST|Sphygmomanometer|For the measurement of the blood pressure.
219380960|NCT06485128|DIAGNOSTIC_TEST|Blood sample|For both routine cardiovascular health biomarkers as well as genetic markers (DNA, mRNA, miRNA).
219188544|NCT03807414|DEVICE|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
219380961|NCT06485128|DIAGNOSTIC_TEST|Skin biopsy|Spatial proteomics and transcriptomics for endothelial function.
219380962|NCT06485128|DIAGNOSTIC_TEST|Neuropsychological examination|Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS
219380963|NCT03521947|DIAGNOSTIC_TEST|Complete blood picture|Iaboratory investigation
219380964|NCT01328457|DRUG|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
219380965|NCT05522426|DEVICE|SyntrFuge System|Microsized Adipose Tissue
219380966|NCT04109599|BEHAVIORAL|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
219380967|NCT04109599|BEHAVIORAL|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
219380968|NCT04109599|BEHAVIORAL|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
219380969|NCT03058744|DRUG|IDP-118 Lotion|Lotion
219380970|NCT03058744|DRUG|HP Monad Lotion|Lotion
219380971|NCT03058744|DRUG|Ultravate Cream|Cream
219380972|NCT03058744|DRUG|Tazorac Cream|Cream
219380973|NCT05564559|OTHER|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
219380974|NCT04807959|OTHER|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
219380975|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
219380976|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
219380977|NCT01731002|DRUG|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
219380978|NCT04820751|DRUG|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
219380979|NCT03590860|DRUG|LY3322207|Administered by SC injection
219380980|NCT03590860|DRUG|Placebo|Administered by SC injection
219380981|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
219380982|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
219380983|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
219380984|NCT04423848|OTHER|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
219380985|NCT04474730|DEVICE|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
219380986|NCT04474730|OTHER|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
219380987|NCT04223466|PROCEDURE|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
219380988|NCT04223466|PROCEDURE|VATS surgery procedure|VATS procedure for thymectomy
219380989|NCT06239194|DRUG|MDX2001|MDX2001 intravenous infusion
219380990|NCT04444570|DEVICE|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
219380991|NCT03040154|OTHER|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
219380992|NCT03040154|OTHER|Usual Care Video that is publicly available|
219380993|NCT05141682|DRUG|Oral Azacitidine|Given PO
219380994|NCT01390168|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
219380995|NCT01390168|BEHAVIORAL|Waitlist|active waitlist
219380996|NCT01140087|PROCEDURE|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
219380997|NCT00628355|DRUG|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
219380998|NCT00628355|PROCEDURE|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
219380999|NCT05519631|OTHER|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
219381000|NCT04032340|OTHER|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
219381001|NCT01571479|PROCEDURE|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
219381002|NCT00797121|PROCEDURE|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
219381003|NCT04975802|OTHER|Placebo|10 oz (296 ml) cherry flavored still beverage
219381004|NCT04975802|DIETARY_SUPPLEMENT|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
219381005|NCT04975802|DIETARY_SUPPLEMENT|Caffeine|10 oz (296 ml) cherry flavored still beverage
219381006|NCT00433888|DRUG|R744|100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
219381007|NCT00433888|DRUG|R744|150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
219381008|NCT01466244|BIOLOGICAL|cetuximab|
219381009|NCT01466244|DRUG|cisplatin|
219381010|NCT01466244|GENETIC|gene expression analysis|
219381011|NCT01466244|GENETIC|microarray analysis|
219381012|NCT01466244|OTHER|immunohistochemistry staining method|
219381013|NCT01466244|OTHER|laboratory biomarker analysis|
219381014|NCT03935516|OTHER|Cast|The use of plaster and/or fiberglass for casting of subject arm.
219381015|NCT00319514|DRUG|Docetaxel|
219381016|NCT03392766|DEVICE|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
219381017|NCT03392766|DEVICE|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
219381018|NCT03202693|DRUG|PA-824|
219381019|NCT05295628|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
219381020|NCT05295628|DEVICE|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
219381021|NCT03542682|DEVICE|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
219381022|NCT03542682|DEVICE|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
219381023|NCT04812860|DRUG|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
219381024|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
219381025|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
219381026|NCT04812860|DRUG|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
219381027|NCT04812860|DRUG|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
219381028|NCT06745947|BEHAVIORAL|EFT|Participants who meet the eligibility criteria will receive the EFT intervention, a cognitive training exercise designed to help them generate and visualize future events or goals. The intervention will be administered individually, in person, by a trained counselor
219381029|NCT03086850|BEHAVIORAL|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps"
219381030|NCT03086850|OTHER|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
219381031|NCT06558344|DRUG|BI 1569912|BI 1569912
219381032|NCT06558344|DRUG|Placebo matching BI 1569912|Placebo matching BI 1569912
219381033|NCT07106333|OTHER|Topical Ozone Therapy|"The intervention involves local application of ozone in two forms:~Ozonated Water - used for irrigation of the extraction socket.~Ozonated Gel - applied topically inside the socket to promote healing and reduce pain.~Both are used after socket debridement and bleeding provocation, followed by standard analgesic administration (Diclofenac potassium)."
219381034|NCT07106333|OTHER|Irrigation with saline|The intervention involves irrigation with saline
219381035|NCT07107477|PROCEDURE|Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes|"In Arm A, Amniocentesis will be performed once a week until delivery, with a maximum of seven procedures per patient. If the pregnancy continues beyond this period, follow-up will proceed without further amniocentesis.~* If IL-6 ≥ 2600:~* steroids and initial broad spectrum ABX will be administered,~* rotation of ABX according to cultures and PCR.~* If steroids already administered, a second course can be administered prior to 34+0 if at least 7 days have passed after the previous course."
219381036|NCT07107477|DRUG|Antenatal steroids administration|"1. Clinical and/or laboratory signs of chorioamnionitis will result in an intervention consisting of the course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course), initial broad spectrum antibiotics, or delivery, depending on the week of pregnancy and clinical status.~2. Uterine activity with progression of vaginal finding will result in course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course) and tocolysis"
219381037|NCT07107477|DRUG|Neuroprotection|In patients with imminent preterm birth prior 32+0 week of pregnancy, foetal neuroprotection will be administered consisting of MgSO4 in an intravenous loading dose of 4 g (administered slowly over 20-30 min), followed by a 1 g per hour maintenance dose. This regimen should continue until birth but should be stopped after 24 h if undelivered.
219381038|NCT07107477|DRUG|antibiotic prophylaxis|Antibiotics - Group B Streptococcus (GBS) prophylaxis + macrolides, always at admission.
219381039|NCT07107477|DRUG|Antibiotics administration|"1. GBS prophylaxis + macrolides: Penicillin G (benzylpenicillin) 5mil IU IV initially and then 2-3 IU (dose adjusted to body weight) IV every 4h twice, then every 6h + Clarithromycin 500mg po every 12h for 7-10 days or till delivery.~2. Initial broad spectrum ABX: Ampicillin/sulbactam 3g IV every 6 hours + Gentamicin 5 mg/kg IV (\<60 kg 240 mg, 61-80 kg 320 mg, \>80 kg 400 mg) every 24h for 5-7 days according to the clinical state.~Comments:~Alternative ABX in patients with allergy to PCN/AMP: Vancomycin 1g IV every 12 h or Clindamycin 600-900g IV every 8h taking antibiotic sensitivity into account.~Before administering the third dose of gentamicin, its serum level should be determined (at a level \>4 umol/l, the dose must be reduced)."
219381040|NCT06860750|DRUG|SHR-1314 Injection|SHR-1314 injection.
219381041|NCT06860750|DRUG|SHR-1314 Placebo Injection|SHR-1314 placebo injection.
219381042|NCT06994260|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|"MSOT is an advanced imaging technology that combines laser-induced ultrasound and light absorption to visualize biological tissues. By detecting ultrasound waves generated from tissue absorption of multispectral light, MSOT provides high-resolution, real-time images with functional and molecular information. One of its use is in biomedical research and clinical applications to study blood oxygenation and tissue composition, making it valuable for areas such as vascular research.~In this study, we aim to utilize MSOT to differentiate between venous, arteriovenous and lymphatic malformations."
219000979|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
219000980|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
219000981|NCT03751488|DRUG|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
219000982|NCT03751488|DRUG|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
219381043|NCT06994260|DIAGNOSTIC_TEST|Ultrasound Localization Microscopy|"ULM is a cutting-edge imaging technique that significantly enhances the resolution of traditional ultrasound by tracking the movement of microbubble contrast agents within blood vessels. This approach enables the visualization of microvascular structures and blood flow dynamics at a super-resolution scale, beyond the diffraction limit of conventional ultrasound.~In this study, we aim to utilize ULM to differentiate between venous, arteriovenous and lymphatic malformations."
219381044|NCT05591911|DIAGNOSTIC_TEST|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
219429107|NCT02682160|OTHER|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
219381045|NCT06303349|OTHER|Samples collection|"from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it."
219381046|NCT06871670|OTHER|Submaximal isometric contractions of knee extensors|Brief isometric contractions performed at 10, 20, 30, 40, 50 and 60% of maximal voluntary force in a random order.
219381047|NCT03463070|DRUG|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
219381048|NCT07015216|OTHER|VR-Assisted Dual Task Training|Virtual reality-based training will be conducted at ISÜFİZYOTEM in a custom-designed augmented VR environment. A 3D avatar and interactive scene (a 1 km crowded street) will be developed using Blender and Adobe Mixamo, with audio components from the Unity Asset Store. Participants will follow the avatar and perform exercises via a VR headset. After 1 minute of self-paced walking, a three-stage Stroop test will be introduced as a dual-task challenge. Sessions will be 20 minutes, supervised by a physiotherapist, with optional breaks. The intervention will be performed 3 times per week for 6 weeks.
219381049|NCT07015216|OTHER|Conventional Therapy Program|A pulmonary rehabilitation program will be administered to individuals with COPD once daily, three days per week for six weeks. The program will include diaphragmatic, chest, and bilateral segmental breathing exercises, breathing control training, relaxation positioning, peripheral muscle strengthening, and airway clearance techniques. Exercises will be explained and prescribed as a home-based program, to be performed twice daily with 10 repetitions. Patients will be given a daily log sheet to record adherence, which will be regularly monitored.
219381050|NCT01381081|BIOLOGICAL|platelet-rich plasma|a single intra-articular injection
219381051|NCT01381081|DRUG|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
219381052|NCT07018518|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency:~   day 0 and day 3, per 3 weeks for 8 cycles; PIN injection dosage: Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion: PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase: Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
219381053|NCT07022184|DEVICE|Personalized Lifestyle Intervention|"The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse.~The Patient Journey App integrates four digital health tools within a single smartphone application:~1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity.~2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals.~3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals.~4. Monitoring of depression symptoms over time to support measurement-based care.~General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes."
219381054|NCT02656472|DRUG|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
219381055|NCT02656472|DRUG|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
219381056|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction associated with acromioclavicular ligament reconstruction|The Gracilis or SemiT graft will be harvested from the ipsilateral knee. An oblique skin incision will be made starting from the ACJ and extended distally towards the tip of coracoid process. 2 drill holes will be prepared on the superior cortex of the clavicle at the footprint of the original 2 ligaments, using a 4.5-mm drill bit. The 2 holes will be around 1 cm apart and the lateral hole was around 2 to 2.5 cm proximal to the distal end of the clavicle. Another 4.5 mm drill bit hole was created in the acromion. The graft exiting laterally around the coracoid will be then passed through the conoid tunnel from inferior to superior and then passed through the acromial tunnel from superior to inferior. The graft exiting the acromion tunnel will be passed through the trapezoid tunnel from superior to inferior. The two free ends of the hamstring graft will be tied to one another with Ethibond No.2 sutures
219381057|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction with acromioclavicular temporary k wire fixation|Two 2.4-mm tunnels corresponding to the origins of the conoid and trapezoid ligaments will be created through the distal clavicle, approximately 1.5cm apart from each other. The distal tunnel will be 2.5cm away from the AC joint. After harvesting the Gracilis or Semitendinosus from the ipsilateral leg, the graft was prepared with no. 2 Ethibond sutures and passed beneath the coracoid. Both ends of the graft will be passed inside out through the tunnels after enlarging the tunnels by 4.5 drill bit making a figure of 8 sling. The AC joint will be provisionally reduced with two 1.5/1.8-mm smooth K-wires while keeping the graft ends under adequate manual tension. The ends of the graft will be sutured onto themselves and the surrounding soft tissues. The wound will be closed in layers.
219381058|NCT07031856|OTHER|3D printer partial crown|Comprasion of partial restorations made with 3D printer
219381059|NCT07031856|OTHER|Treatment as usual|Cad-cam printer partial crown
219381060|NCT03232073|DRUG|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
219429108|NCT05389384|DEVICE|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
219429109|NCT05389384|BEHAVIORAL|Fatigue protocol|Participants complete a fatiguing protocol
219429110|NCT05389384|DEVICE|No exoskeleton support|Exoskeleton is worn, but no support provided
219429111|NCT05389384|BEHAVIORAL|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
219000983|NCT04610268|DEVICE|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
219381061|NCT07108244|DIAGNOSTIC_TEST|[18F]FET PET-MRI|All participants will undergo both \[18F\]fluoroethyltyrosine positron emission tomography-magnetic resonance imaging (\[18F\]FET-PET-MRI) and inferior petrosal sinus sampling (IPSS) as part of the diagnostic work-up for ACTH-dependent hypercortisolism. The purpose is to compare the diagnostic accuracy of these two modalities in distinguishing Cushing's disease from ectopic ACTH secretion. The results from both diagnostic tests will be communicated to the treating medical team and the participant to guide further clinical management.
219381062|NCT07106281|DIETARY_SUPPLEMENT|Grape Seed Extract|600mg of Grape Seed Extract
219381063|NCT07106281|DIETARY_SUPPLEMENT|Placebo|Placebo
219381064|NCT07106645|DEVICE|Active iTBS|Patients in this condition will undergo 20 sessions of iTBS, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Intermittent theta burst stimulation will involve the delivery of triplets of pulses at 50 Hz, repeated at 5 Hz, at 100% of the individual motor threshold.
219381065|NCT07106645|DEVICE|Sham stimulation|Patients in this condition will undergo 20 sessions of sham stimulation, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Sham stimulation will be identical to active stimulation, with the only difference being the use of a sham coil, which produces the same sound as the real coil without generating a magnetic field
219381066|NCT07107854|OTHER|cosmetic: EFFACLAR ULTRA CONCENTRATED SERUM|Transparent solution (gel)
219381067|NCT07107087|OTHER|Multi-Modal Integrated Intervention Combining Exercise, Anti-inflammatory & Dietary Advice (MMIEAD)|In addition to their standard care, the intervention group will receive MMIEAD - an individualised exercise programme, oral omega-3 supplementation and dietary advice.
219381068|NCT07106151|BEHAVIORAL|Transmission of additional AKI-D recovery information|Measuring residual kidney function at the time of hospital discharge by timed urine collection (6-24 hours in duration), transmitting the results (urine volume, urea clearance, and creatinine clearance) to the accepting nephrologist and to the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.
219381069|NCT07106151|OTHER|No additional AKI-D recovery information|The same timed urine collection will be collected at the time of hospital discharge as in the intervention arm, but in the control arm the results will not be transmitted to the accepting nephrologist or to the patient and no information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule will be transmitted. Instead, the research team will call the accepting nephrologist to alert them that this is an AKI-D patient that is being followed by the research team for recovery for up to 60 days.
219381070|NCT07107399|OTHER|microfragmented adipose tissue|"Receive micro fragmented adipose tissue obtained from the buccal pad of fat after arthrocentessis.~* Direct access to the buccal fat pad, is found at distobuccal depth of the maxillary tuberosity.~* It may be dissected during the resection an upper mucosal incision posterior to the second molar~* After a single scissor stab through the periosteum the (BFP)extrude into the operative site.~* Closure of the flap by suitable suture.~* Collection of lipids then manually manipulated with two syringes connecting together and pushing the lipids against each other to receive the injectable amount of micro fragmented adipose tissue .~* Ready for TMJ injection."
219381071|NCT07107399|OTHER|platelet-rich plasma|I - double-puncture arthrocentesis technique was followed, and 300 mL of Ringer's lactate solution was used to irrigate the joint space through the marked points . After arthrocentesis PRP was prepared from 5 mL of autologous venous blood sample taken from the antecubital vein. The collected blood was then transferred to a test tube containing 0.5 mL of sodium citrate (anticoagulant) (0.5 mL) and was centrifuged at a rate of 2100 rpm for 15 min. The plasma from the first harvest was fractionated by centrifugation at 3500 rpm for 10 min to prepare PRP.
219381072|NCT07105839|DRUG|Intraoperative rescue analgesia|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV remifentanil infusion rate will be titrated upward within the safety margin.
219381073|NCT07105839|DRUG|Intraoperative rescue analgesia:|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV dexmedetomidine infusion rate will be titrated upward (up to maximum safe dose).
219188545|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
219188546|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
219381074|NCT07107035|OTHER|No Intervention: Observational Cohort|No intervention
219381075|NCT07105683|OTHER|hot pack therapy|Application of a commercial hot pack to the lumbar region for 20-30 minutes per session, twice daily, for 6 weeks.
219429112|NCT02884271|PROCEDURE|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
219429113|NCT00888069|DRUG|CTAP101 Capsules|Single dose oral administration
219429114|NCT00888069|DRUG|CTAP101 Injection|single IV injection
219429115|NCT00188968|PROCEDURE|Nasal Continuous Positive Airway Pressure|
219429116|NCT00188968|PROCEDURE|Synchronized Nasal Positive Pressure Ventilation|
219557866|NCT05289557|DRUG|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
219000984|NCT01288066|PROCEDURE|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
219381076|NCT07105683|GENETIC|Kinetic control training|is an evidence-based rehabilitation approach, focused on retraining movement patterns by addressing and improving motor control of the lumbar spine and pelvis, correcting faulty movement strategies, enhancing stability in functional tasks. The principles of KCT entail the identification of direction-specific motor control deficit, uncontrolled extension, followed by focused retraining of movement control through specific exercises designed to improve the coordination and activation of deep stabilizing muscle systems, including the transversus abdominis, multifidus, and pelvic floor muscles. This approach is especially relevant in postpartum women, where motor control deficits and poor load transfer capabilities are commonly observed . Based on the clinical presentation of patients with postnatal low back pain, demonstrated symptoms that were aggravated during lumbar extension movements or when maintaining prolonged upright postures. The
219381077|NCT07106957|OTHER|CICAPLAST BAUME B5+|Twice a day (morning and evening) on face
219381078|NCT07106957|OTHER|Standard cream|Twice a day (morning and evening) on face
219381079|NCT05428176|OTHER|Best Practice|Receive usual care
219381080|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
219381081|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
219381082|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
219381083|NCT06515587|DIAGNOSTIC_TEST|Lewis genotype detection reagent|By evaluating the results of the Lewis gene test combined with the CA19-9 test, different subtypes of pancreatic cancer patients were differentiated to evaluate the prognosis
219381084|NCT05987527|DIAGNOSTIC_TEST|Blood sample|Routine procedures
219381085|NCT00248729|DRUG|Etomidate (20mg) or Midazolam (7mg)|
219381086|NCT06459687|DRUG|Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
219381087|NCT06459687|DRUG|Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
219381088|NCT04259359|DRUG|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
219381089|NCT03116529|COMBINATION_PRODUCT|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
219188547|NCT04575688|DRUG|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
219188548|NCT04575688|DRUG|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
219188549|NCT02887521|OTHER|education|pulmonary rehabilitation participant manual
219381090|NCT06963229|PROCEDURE|Spinal Anesthesia (bupivacaine)|L3-L4 or L4-L5 3cc of 2% bupivacaine
219381091|NCT06963229|PROCEDURE|Peripheral Nerve Block|"Sciatic Nerve Block 20ml of Anesthetic Mixture, Paravertebral Nerve Block (L3-L4 and L4-L5) 20ml of Anesthetic Mixture~Mixture Details:~* 5ml Lidocaine 2%~* 5ml Lidocaine 1% with Adrenaline (1-200000)~* 10ml Bupivacaine 0.5%"
219381092|NCT05218213|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
219381093|NCT03226197|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone ester drink
219188550|NCT02887521|PROCEDURE|rehabilitation|pulmonary rehabilitation
219188551|NCT02887521|DEVICE|pedometer|receive a pedometer
219188552|NCT02887521|OTHER|education|receive a pamphlet with exercises plus the standard course of care
219188553|NCT02887521|PROCEDURE|surgery|patients undergo surgery
219188554|NCT06188780|DIAGNOSTIC_TEST|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
219188555|NCT05878431|OTHER|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
219188556|NCT04785131|OTHER|Prune|daily consumption of 50 grams prune.
219381094|NCT05200351|BEHAVIORAL|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
219381095|NCT00853632|DEVICE|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
219381096|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
219557867|NCT05289557|DRUG|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
219381097|NCT04164667|BEHAVIORAL|Mental and physical (MAP) training intervention|"In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise."
219381098|NCT06082401|DEVICE|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
219381099|NCT06082401|DEVICE|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
219381100|NCT04633343|OTHER|Small volume breath and fast breathing rate for 5 minutes|Small volume breath and fast breathing rate delivered via mechanical ventilator.
219381101|NCT04633343|OTHER|Large volume breath and slow breathing rate for 5 minutes|Large volume breath and slow breathing rate delivered via mechanical ventilator.
219381102|NCT06084806|DRUG|[18F]F-ARAG PET|Two imaging sessions
219188557|NCT04102176|OTHER|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
219381103|NCT06782906|BEHAVIORAL|≥10,000 daily steps (≥5 days/week) and stopping evening snacking|Participants in the intervention arm will be asked to perform ≥10,000 daily steps (≥5 days/week) and omit evening snacking after 8:00 p.m.
219381104|NCT04568330|OTHER|best support care|Best support care
219381105|NCT04568330|OTHER|moisture cream|BSC plus moisture cream
219381106|NCT04568330|OTHER|10% urea-based cream|BSC plus 10% urea-based cream.
219381107|NCT03609164|PROCEDURE|Suture-bridge augmentation of single-row repair|
219381108|NCT02172118|DRUG|BI 1774 CL|
219381109|NCT00001446|DRUG|thalidomide|
219381110|NCT03974919|OTHER|NO intervention required|NO intervention required
219381111|NCT05415280|BEHAVIORAL|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
219381112|NCT03552783|BEHAVIORAL|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
219381113|NCT03552783|BEHAVIORAL|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community"
219381114|NCT04007484|DEVICE|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
219381115|NCT03176849|DIETARY_SUPPLEMENT|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
219381116|NCT03176849|DIETARY_SUPPLEMENT|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
219381117|NCT02851654|DEVICE|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
219381118|NCT00022932|DRUG|Iodine-131 Anti-B1 Antibody|
219188558|NCT04102176|OTHER|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
219000985|NCT01288066|PROCEDURE|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
219188559|NCT06587412|OTHER|Radial shock waves treatment|Subjects in this group will receive radial shock waves
219188560|NCT06587412|OTHER|Focal Shock Waves treatment|Subjects in this group will receive focal shock waves
219188561|NCT06587412|OTHER|shock waves placebo treatment|Subjects in this group will receive a shock waves placebo treatment with very low energy settings
219381119|NCT03101072|OTHER|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
219381120|NCT03101072|OTHER|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
219381121|NCT03101072|OTHER|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
219381122|NCT02463942|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
219381123|NCT02463942|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
219381124|NCT02463942|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
219381125|NCT02455115|OTHER|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
219381126|NCT02455115|DRUG|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
219381127|NCT02455115|DRUG|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
219381128|NCT03783156|PROCEDURE|hot snare|polypectomy with hot snare
219381129|NCT03783156|PROCEDURE|cold snare|polypectomy with cold snare
219381130|NCT01672892|RADIATION|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
219381131|NCT01672892|RADIATION|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
219381132|NCT05374343|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
219188562|NCT04965935|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
219188563|NCT04965935|DRUG|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
219188564|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
219188565|NCT05757739|PROCEDURE|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
219188566|NCT06151106|DRUG|Chidamide combined with Duvillisib|Specified dose on specified days
219188567|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
219381133|NCT01861197|DRUG|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
219381134|NCT02976506|BEHAVIORAL|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
219381135|NCT02976506|BEHAVIORAL|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
219381136|NCT05714371|DRUG|Nivolumab|Patients receiving nivolumab
219381137|NCT05714371|DRUG|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
219381138|NCT05714371|DRUG|Pembrolizumab|Patients receiving pembrolizumab
219381139|NCT05714371|DRUG|Dabrafenib + trametinib|Dabrafenib + trametinib
219381140|NCT01936246|DIETARY_SUPPLEMENT|Increased protein|
219381141|NCT01491958|DRUG|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
219381142|NCT01491958|DRUG|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
219381143|NCT01491958|DRUG|methotrexate|Day +1, +3, and +6 and +11
219381144|NCT01954290|DRUG|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
219381145|NCT01954290|DRUG|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
219381146|NCT01954290|DRUG|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
219381147|NCT04181281|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
219381148|NCT04181281|DIAGNOSTIC_TEST|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
219381149|NCT06959199|PROCEDURE|Endovascular Treatment|EVT procedures may include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, or stenting, or other intra-arterial procedures as deemed appropriate by the treating physician.
219381150|NCT06959199|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
219381151|NCT02101437|PROCEDURE|miRNA within 24hr|miRNA within 24hr
219381152|NCT02101437|PROCEDURE|miRNA after 1 week|miRNA after 1 week
219381153|NCT02101437|PROCEDURE|miRNA after 1 month|miRNA after 1 month
219381154|NCT01106638|BEHAVIORAL|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
219381155|NCT01106638|BEHAVIORAL|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
219381156|NCT03401606|DRUG|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
219381157|NCT03401606|DRUG|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
219381158|NCT03312855|DRUG|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
219381159|NCT03312855|DRUG|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
219381160|NCT03312855|DRUG|Placebo|single dose, intravenous application of Placebo solution
219381161|NCT01385696|DEVICE|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
219381162|NCT01385696|DEVICE|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
219381163|NCT02652429|DRUG|Inhaled Nitric Oxide|
219188568|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
219381164|NCT02012816|OTHER|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
219381165|NCT04188158|COMBINATION_PRODUCT|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
219381166|NCT04264104|OTHER|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
219381167|NCT00656214|DRUG|Lycopene|08 mg/day in two divided dosage
219188569|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
219381168|NCT00656214|DRUG|Placebo|Two divided dosage
219381169|NCT05307471|OTHER|Thoracotomy/scopy|
219381170|NCT01826669|PROCEDURE|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
219381171|NCT05926206|DRUG|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
219381172|NCT05926206|DRUG|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
219381173|NCT02589587|PROCEDURE|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
219381174|NCT02589587|OTHER|no intervention|lean control group
219381175|NCT02813538|DRUG|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
219381176|NCT02813538|OTHER|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
219381177|NCT03160144|PROCEDURE|open lung approach|
219381178|NCT01519843|DEVICE|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
219381179|NCT01519843|DEVICE|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
219381180|NCT04676243|DRUG|Quizartinib|20 mg coated tablets, orally administered
219381181|NCT04676243|DRUG|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
219381182|NCT04676243|DRUG|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
219381183|NCT05978869|OTHER|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
219381184|NCT00597558|DRUG|Egg white protein|Egg white protein powder
219381185|NCT00798512|DEVICE|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
219381186|NCT02687308|PROCEDURE|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
219381187|NCT02687308|PROCEDURE|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
219381188|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
219381189|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
219381190|NCT01809236|BIOLOGICAL|Conbercept|intravitreal injection of 0.5 mg Conbercept
219381191|NCT00252850|GENETIC|CERE-120: AAV2-NTN|
219381192|NCT00918723|DRUG|Fludarabine Phosphate|Given IV
219381193|NCT00918723|DRUG|Cyclophosphamide|Given IV
219381194|NCT00918723|BIOLOGICAL|Rituximab|Given IV
219381195|NCT00918723|DRUG|Vorinostat|Given PO
219381196|NCT00051844|DRUG|Capravirine|
219557868|NCT02225457|OTHER|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
219557869|NCT02225457|DIETARY_SUPPLEMENT|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
219188570|NCT02397954|DRUG|Avacincaptad Pegol|Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.
219381197|NCT04072042|DRUG|Apatinib monotherapy|patients will receive Apatinib 250mg tablet by mouth, bid.
219381198|NCT03513380|BEHAVIORAL|Exergaming|free access to the exergame PedalTanks during 6 months
219381199|NCT00886821|BIOLOGICAL|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
219381200|NCT04177654|DRUG|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
219381201|NCT06097936|DIAGNOSTIC_TEST|HPV-ASSOCIATED OROPHARYNGEAL CANCER|The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
219381202|NCT05872425|DRUG|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
219381203|NCT05872425|DRUG|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
219381204|NCT00914628|GENETIC|HSV-Tk|Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
219381205|NCT00914628|OTHER|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
219557870|NCT02225457|DIETARY_SUPPLEMENT|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
219557871|NCT00178711|DEVICE|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
219557872|NCT00089973|DRUG|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
219557873|NCT02159820|DRUG|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
219381206|NCT03624660|RADIATION|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
219381207|NCT03624660|RADIATION|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
219381208|NCT03359291|DRUG|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
219381209|NCT03359291|DRUG|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
219381210|NCT05581576|DRUG|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
219381211|NCT04720729|BIOLOGICAL|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 \& L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (\> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
219381212|NCT03404960|DRUG|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
219381213|NCT03404960|DRUG|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
219381214|NCT02823522|OTHER|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
219381215|NCT05117970|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
219381216|NCT04585685|BEHAVIORAL|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
219381217|NCT04585685|BEHAVIORAL|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
219381218|NCT03311126|DRUG|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
219381219|NCT03311126|DRUG|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
219381220|NCT00885443|DRUG|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
219381221|NCT00885443|DRUG|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
219381222|NCT00014742|DRUG|collagenase|
219381223|NCT03335124|DRUG|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
219381224|NCT03335124|DRUG|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
219381225|NCT03335124|DRUG|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
219381226|NCT03335124|DRUG|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
219381227|NCT01717846|DRUG|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
219381228|NCT01717846|OTHER|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
219381229|NCT02641899|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
219381230|NCT02641899|DRUG|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
219381231|NCT02641899|DRUG|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
219381232|NCT02641899|DRUG|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
219381233|NCT02641899|DRUG|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
219381234|NCT02641899|DRUG|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
219381235|NCT02579603|DRUG|Nintedanib|Nintedanib 150mg bid
219381236|NCT02579603|DRUG|Pirfenidone|
219381237|NCT05281315|OTHER|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
219381238|NCT03540823|BIOLOGICAL|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
219381239|NCT03028493|BEHAVIORAL|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
219381240|NCT03028493|BEHAVIORAL|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
219381241|NCT00469079|DRUG|Nicotine gum and lozenge|Nicotine replacement
219381242|NCT00469079|OTHER|Taboka|smokeless tobacco product
219381243|NCT00469079|OTHER|Camel Snus|smokeless tobacco product
219381244|NCT05645094|DRUG|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
219381245|NCT03932955|BIOLOGICAL|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
219381246|NCT00203567|DRUG|carbamazepine ER|Active study drug, no comparator
219381247|NCT06453694|DRUG|Efgartigimod Alfa|"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
219381248|NCT06453694|DRUG|Placebo|"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
219381249|NCT00577187|DEVICE|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
219381250|NCT01006356|DRUG|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
219381251|NCT00003554|BIOLOGICAL|rituximab|
219381252|NCT00003554|DRUG|melphalan|
219381253|NCT00003554|DRUG|prednisone|
219381254|NCT01046149|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
219381255|NCT01046149|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
219381256|NCT02265328|DIETARY_SUPPLEMENT|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
219381257|NCT02265328|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
219381258|NCT02265328|OTHER|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
219381259|NCT00775164|DRUG|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
219381260|NCT00775164|DRUG|Metformin|Metformin XR; 1000 mg once daily
219381261|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
219381262|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
219381263|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
219381264|NCT04209738|OTHER|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
219429117|NCT04914871|BEHAVIORAL|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
219429118|NCT04914871|BEHAVIORAL|Educational session accident prevention and wound management|It will be provided to the control group
219429119|NCT04671069|DRUG|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
219381265|NCT05813821|BEHAVIORAL|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
219381266|NCT02655861|OTHER|Observation|
219381267|NCT03560440|OTHER|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
219381268|NCT05794529|OTHER|There are no interventions in the present study|There are no interventions in the present study
219381269|NCT05080829|DIAGNOSTIC_TEST|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
219381270|NCT01587963|DRUG|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
219381271|NCT01587963|OTHER|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
219381272|NCT00430040|DRUG|Carvedilol Controlled Release (CR)|"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"
219381273|NCT00430040|DRUG|lisinopril|lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
219381274|NCT04807491|OTHER|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
219381275|NCT04807491|OTHER|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
219381276|NCT00725738|GENETIC|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
219381277|NCT01756157|BIOLOGICAL|CINRYZE with rHuPH20|
219381278|NCT02140125|DRUG|ASP2408|subcutaneous administration
219381279|NCT02140125|DRUG|Placebo|subcutaneous administration
219381280|NCT00181298|DRUG|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
219381281|NCT00181298|DRUG|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
219381282|NCT02860793|OTHER|Bone marrow aspiration|
219381283|NCT02860793|OTHER|Blood sampling|
219381284|NCT04712175|DIAGNOSTIC_TEST|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
219381285|NCT04712175|DIAGNOSTIC_TEST|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
219381286|NCT05631925|DRUG|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
219381287|NCT05631925|DRUG|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
219381288|NCT03351673|DIAGNOSTIC_TEST|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
219381289|NCT03368859|DRUG|Leucovorin|Intravenous
219381290|NCT03368859|DRUG|Fluorouracil - bolus|Intravenous
219381291|NCT03368859|DRUG|Bevacizumab|Intravenous
219381292|NCT03368859|DRUG|Fluorouracil - infusion|Intravenous
219381293|NCT03368859|DRUG|ABT-165|Intravenous
219381294|NCT03368859|DRUG|Irinotecan|Intravenous
219381295|NCT02698410|DRUG|Lanreotide (Autogel formulation) and Temozolomide|
219381296|NCT03397186|PROCEDURE|Biopsy|Undergo biopsy
219381297|NCT03397186|OTHER|Laboratory Biomarker Analysis|Correlative studies
219381298|NCT03397186|DRUG|Trabectedin|Given as standard of care
219381299|NCT05285852|OTHER|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
219381300|NCT05285852|OTHER|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
219381301|NCT05325164|DRUG|Methadone|Methadone
219381302|NCT05325164|DRUG|Morphine|Morphine
219381303|NCT01733563|PROCEDURE|Soft drink consumption|
219381304|NCT04611477|OTHER|Rice Hulk|Placebo
219381305|NCT04611477|OTHER|Synbiotic365 Ver 5|Active Comparator
219381306|NCT04611477|OTHER|Synbiotic365 Ver 7|Active Comparator
219381307|NCT05133596|OTHER|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
219381308|NCT05133596|OTHER|Blood collection|12ml-blood sample
219381309|NCT05133596|OTHER|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
219381310|NCT05133596|OTHER|Brushing of olfactory slits|collection of olfactory slits cells.
219381311|NCT05133596|OTHER|Neurological examination and neuropsychological assessment|"* MOCA, BREF~* CVLT~* WAIS IV, MEM III~* Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~* Benton's Line Judgement, VOSP~* Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression \& anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
219381312|NCT05133596|OTHER|Nasal endoscopy|Nasal endoscopy
219381313|NCT05133596|OTHER|Assessment of olfactory and taste functions|"* scales: VAS and TSS~* Sniffin Stick test"
219381314|NCT03864354|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
219381315|NCT00003323|DRUG|finasteride|5 mg/d PO
219381316|NCT00003323|DRUG|flutamide|250 mg PO tid
219381317|NCT00003323|OTHER|quality-of-life assessment|Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
219381318|NCT02475460|PROCEDURE|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
219381319|NCT02475460|DEVICE|HeartMate 3™|HM 3 LIS
219381320|NCT00984789|DRUG|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
219381321|NCT00984789|DRUG|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
219381322|NCT01407120|BEHAVIORAL|New Beginnings Program|A preventive intervention for divorced families.
219381323|NCT04813744|PROCEDURE|Atraumatic restorative treatment|
219381324|NCT01584024|DEVICE|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
219381325|NCT01584024|DEVICE|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
219381326|NCT01217606|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
219381327|NCT01217606|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
219381328|NCT02677779|PROCEDURE|CO2 laser|Single session of CO2 laser debridement
219381329|NCT02677779|PROCEDURE|traditional surgery|Single session of traditional debridement
219381330|NCT00753636|DRUG|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
219381331|NCT01773824|BEHAVIORAL|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
219381332|NCT01773824|BEHAVIORAL|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
219381333|NCT03095105|DRUG|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
219381334|NCT01962454|DRUG|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
219381335|NCT01962454|DRUG|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
219381336|NCT01962454|DRUG|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
219381337|NCT00702624|DRUG|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
219381338|NCT00702624|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
219381339|NCT00702624|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
219381340|NCT00702624|BIOLOGICAL|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
219381341|NCT00702624|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
219381342|NCT00702624|DRUG|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
219381343|NCT00702624|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
219381344|NCT00702624|BIOLOGICAL|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
219381345|NCT01320228|DIETARY_SUPPLEMENT|Control|Alli treatment plus placebo (rice flour)
219381346|NCT01320228|DIETARY_SUPPLEMENT|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
219381347|NCT01320228|DIETARY_SUPPLEMENT|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
219381348|NCT01320228|DIETARY_SUPPLEMENT|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
219381349|NCT02384720|OTHER|Age: 20-40years|
219381350|NCT02384720|OTHER|Age: 41-64years|
219381351|NCT02384720|OTHER|Age: ≥65years|
219381352|NCT02314806|DRUG|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
219381353|NCT02314806|DRUG|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
219381354|NCT02314806|DRUG|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
219381355|NCT04008212|OTHER|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
219381356|NCT02650310|DEVICE|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
219381357|NCT03037216|OTHER|Exercise Intervention|10 Week aerobic exercise training
219381358|NCT03139370|DRUG|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
219381359|NCT03139370|DRUG|Cyclophosphamide|Administered intravenously
219381360|NCT03139370|DRUG|Fludarabine|Administered intravenously
219381361|NCT03139370|DEVICE|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
219381362|NCT06392490|OTHER|Technology Based Asthma Program|Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
219381363|NCT03154138|DEVICE|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
219381364|NCT03154138|DEVICE|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
219381365|NCT03926403|OTHER|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
219381366|NCT03926403|PROCEDURE|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
219381367|NCT03926403|PROCEDURE|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
219381368|NCT05321186|PROCEDURE|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
219381369|NCT02859701|DRUG|AK002|IV AK002
219381370|NCT02859701|OTHER|Placebo|
219381371|NCT00719810|DRUG|delafloxacin|300 mg intravenous every 12 hours
219381372|NCT00719810|DRUG|delafloxacin|450 mg intravenous every 12 hours
219381373|NCT00719810|DRUG|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
219381374|NCT01137630|DRUG|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
219381375|NCT01137630|DRUG|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
219381376|NCT01137630|DRUG|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
219381377|NCT01101074|OTHER|This is non-intervention observational study|This is non-intervention observational study
219381378|NCT01718314|DRUG|Sublingual Misoprostol|
219381379|NCT01718314|DRUG|Lidocaine pump spray|
219000986|NCT04813406|DRUG|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
219000987|NCT00412659|PROCEDURE|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
219381380|NCT01718314|DRUG|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
219381381|NCT01718314|DRUG|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
219381382|NCT03873207|DEVICE|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
219000988|NCT00412659|PROCEDURE|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
219188571|NCT05574959|DEVICE|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
219188572|NCT05574959|DEVICE|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
219188573|NCT05835804|DRUG|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
219381383|NCT03873207|DEVICE|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
219381384|NCT04893265|BEHAVIORAL|Text Messaging Only|Active Comparator
219381385|NCT04893265|BEHAVIORAL|INFORMED|Experimental
219381386|NCT02985346|BIOLOGICAL|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
219381387|NCT03787433|DEVICE|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
219381388|NCT02498223|OTHER|experiment protocol|"the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
219381389|NCT00072722|DRUG|CC-4047|
219381390|NCT06132490|DEVICE|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
219188574|NCT05278728|DRUG|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
219188575|NCT05278728|DRUG|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
219188576|NCT07039981|DEVICE|Omnipod M system|The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control
219188577|NCT07058792|OTHER|Medjool dates|Medjool dates are a dried fruit.
219188578|NCT07064213|BEHAVIORAL|Behavioral: Educational Video|Participants will watch a 2-minute educational video in Hebrew about perineal tears and episiotomy. The video includes information about types and grades of tears, risk factors, prevention strategies, episiotomy use, healing process, and when to seek help. The video is presented on a secure mobile device by the research team before the onset of active labor.
219188579|NCT03260465|DEVICE|seleXys PC|Total hip arthroplasty using the seleXys PC cup
219188580|NCT03260465|DEVICE|RM|Total hip arthroplasty using the RM cup
219188581|NCT06440694|DRUG|Colchicine 0.5 mg po|Colchicine 0.5 mg po once daily for 180 days.
219188582|NCT06440694|DRUG|Placebo 0.5 mg po|Placebo 0.5 mg po once daily for 180 days.
219188583|NCT04713969|DRUG|Pantoprazole 40mg|Pantoprazole 40mg twice daily
219188584|NCT03369821|DIAGNOSTIC_TEST|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
219381391|NCT06132490|DEVICE|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
219381392|NCT00573131|DRUG|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
219381393|NCT00573131|DRUG|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
219188585|NCT03369821|OTHER|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
219188586|NCT05752500|BEHAVIORAL|Cognitive Behavioral Intervention for Physical Activity|Interventionist will use cognitive and behavioral techniques to help the participant increase facilitators and decrease barriers to physical activity, particularly barriers such as lack of motivation, depression, and chronic pain. Meetings will occur every other week for 4 months.
219188587|NCT05752500|BEHAVIORAL|Social Support for Physical Activity|This component will leverage the social functionality of the Fitbit app, promoting social support and friendly competition via a moderated Facebook group.
219188588|NCT05752500|BEHAVIORAL|Physical Activity Coaching|The PA coach will meet with the participant to set goals for physical activity (steps) and encourage self-monitoring. Meetings will occur every other week for 4 months.
219381394|NCT00573131|DRUG|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
219381395|NCT00573131|RADIATION|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
219381396|NCT00573131|PROCEDURE|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
219381397|NCT03500107|DEVICE|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
219381398|NCT02900677|BEHAVIORAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
219381399|NCT01827501|DEVICE|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
219381400|NCT00400387|DRUG|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
219381401|NCT00400387|DIETARY_SUPPLEMENT|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
219381402|NCT05948878|DEVICE|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
219381403|NCT05948878|DEVICE|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
219381404|NCT05948878|DEVICE|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
219381405|NCT03393962|BIOLOGICAL|OC-EIEs|2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
219188589|NCT05752500|BEHAVIORAL|Brief Advice and Self-Monitoring|Participants will receive a single session with brief advice about increasing physical activity, and instructions on how to use their study-provided FitBit.
219381406|NCT02990884|DRUG|ketamine|
219381407|NCT02482220|BEHAVIORAL|Physical activity intervention|
219381408|NCT01251575|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
219381409|NCT01251575|DRUG|Cyclosporine|Given PO or IV
219381410|NCT01251575|DRUG|Fludarabine Phosphate|Given IV
219381411|NCT01251575|OTHER|Laboratory Biomarker Analysis|Correlative studies
219381412|NCT01251575|DRUG|Mycophenolate Mofetil|Given PO
219381413|NCT01251575|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
219381414|NCT01251575|DRUG|Sirolimus|Given PO
219188590|NCT01924819|DRUG|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
219381415|NCT01251575|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
219381416|NCT03340740|DRUG|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
219381417|NCT03340740|DRUG|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
219381418|NCT00687050|DIETARY_SUPPLEMENT|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
219381419|NCT00687050|DIETARY_SUPPLEMENT|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
219381420|NCT05013060|DIETARY_SUPPLEMENT|Probiotics and microcapsulated sodium butyrate|The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.
219381421|NCT05013060|DIETARY_SUPPLEMENT|Maltodextrin|The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
219381422|NCT00841724|DRUG|Fludarabine, Busulfan, Thymoglobuline|
219381423|NCT00893789|DRUG|Armodafinil|Armodafinil 50 mg/day
219381424|NCT00893789|DRUG|Armodafinil|Armodafinil 150 mg/day
219381425|NCT00893789|DRUG|Armodafinil|Armodafinil 250 mg/day
219381426|NCT00893789|OTHER|Placebo|Placebo
219381427|NCT01174914|OTHER|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
219381428|NCT01174914|DRUG|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
219381429|NCT01174914|DRUG|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
219381430|NCT04127136|BEHAVIORAL|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
219381431|NCT02316444|BIOLOGICAL|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
219381432|NCT04427085|OTHER|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
219381433|NCT00723658|BIOLOGICAL|rituximab|
219381434|NCT00723658|DRUG|bortezomib|
219381435|NCT00723658|DRUG|carmustine|
219381436|NCT00723658|DRUG|cisplatin|
219381437|NCT00723658|DRUG|cyclophosphamide|
219381438|NCT00723658|DRUG|cytarabine|
219381439|NCT00723658|DRUG|dexamethasone|
219381440|NCT00723658|DRUG|doxorubicin hydrochloride|
219381441|NCT00723658|DRUG|etoposide|
219381442|NCT00723658|DRUG|melphalan|
219381443|NCT00723658|DRUG|thalidomide|
219381444|NCT00723658|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
219381445|NCT00723658|PROCEDURE|peripheral blood stem cell transplantation|
219381446|NCT05065021|DRUG|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
219381447|NCT05065021|DRUG|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
219381448|NCT05065021|DRUG|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
219381449|NCT05065021|DRUG|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
219381450|NCT02024464|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
219381451|NCT02024464|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
219381452|NCT02024464|PROCEDURE|Cataract removal and intraocular lens (IOL) implantation|Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
219381453|NCT01479725|PROCEDURE|HBOT|HBOT
219381454|NCT02551172|DRUG|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
219381455|NCT02551172|DRUG|HGP0816|Rosuvastatin
219381456|NCT02551172|DRUG|Placebo of HCP1105|Soybean Oil
219381457|NCT02551172|DRUG|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
219381458|NCT01223248|RADIATION|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
219381459|NCT01223248|RADIATION|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& within 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
219381460|NCT04887298|DRUG|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
219381461|NCT05089630|BIOLOGICAL|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
219381462|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
219381463|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
219381464|NCT05089630|BIOLOGICAL|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
219381465|NCT05089630|COMBINATION_PRODUCT|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
219381466|NCT00691548|DRUG|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
219381467|NCT06145230|OTHER||
219381468|NCT05439031|RADIATION|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
219381469|NCT00499707|DRUG|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
219381470|NCT06085066|PROCEDURE|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional Ultrafiltration was used on Cardiopulmonary bypass for patients who underwent open heart surgery
219381471|NCT06085066|PROCEDURE|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified Ultrafiltration was used following the Conventional Ultrafiltration on Cardiopulmonary bypass for patients who underwent open heart surgery
219381472|NCT04382261|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
219381473|NCT04062955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary counseling
219000989|NCT00039832|DRUG|Abciximab (ReoPro) and Reteplase (Retavase)|
219000990|NCT02771002|DEVICE|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
219381474|NCT04062955|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
219381475|NCT04062955|OTHER|Questionnaire Administration|Ancillary studies
219381476|NCT03818815|COMBINATION_PRODUCT|OP0201|OP0201 20mg per day in two divided doses for 10 days
219381477|NCT03818815|COMBINATION_PRODUCT|Placebo|Placebo 0mg per day in two divided doses for 10 days
219381478|NCT03818815|DRUG|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
219381479|NCT02466256|PROCEDURE|Intraocular lens implantation|Intraocular lens implantation
219381480|NCT02466256|DEVICE|Autosert Injector|Motorised injection device for intraocular lens implantation
219381481|NCT02466256|DEVICE|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
219381482|NCT02466256|DEVICE|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
219381483|NCT00242879|DRUG|Physician determined comparator PI + ritonavir|
219381484|NCT00242879|DRUG|GW640385 + ritonavir|
219381485|NCT03514147|OTHER|Experimental|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
219381486|NCT03514147|OTHER|Control|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
219381487|NCT06807996|DIETARY_SUPPLEMENT|Zinc-enriched yeast capsule|Daily zinc supplementation: zinc-enriched yeast capsules (15 mg) for a total of 6 months.
219381488|NCT06807996|DIETARY_SUPPLEMENT|Edible yeast placebo capsule|Daily edible yeast placebo capsules (not zinc-enriched) (15 mg) for a total of 6 months.
219381489|NCT02458976|DEVICE|PDL|
219381490|NCT01335646|PROCEDURE|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
219381491|NCT01335646|OTHER|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
219381492|NCT05288842|BIOLOGICAL|Lumbar puncture|5 mL of CSF
219381493|NCT05288842|BIOLOGICAL|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
219381494|NCT02719054|BEHAVIORAL|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
219381495|NCT01613092|DRUG|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
219381496|NCT01613092|DRUG|Cefazolin|Preoperative antibiotic
219381497|NCT03950323|RADIATION|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
219381498|NCT01657123|OTHER|ergometry|ergometry measurements
219381499|NCT01657123|OTHER|ergometry|Ergometry measurements
219381500|NCT05632172|PROCEDURE|implant insertion|bone level dental implant insertion
219381501|NCT00847340|PROCEDURE|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
219381502|NCT06478836|OTHER|planter pressure|no intervention
219381503|NCT01998607|OTHER|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
219381504|NCT01563601|DRUG|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
219381505|NCT01563601|DRUG|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
219381506|NCT00378846|PROCEDURE|infrared thermography|
219381507|NCT01242111|DRUG|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
219381508|NCT04586712|DRUG|Active CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
219381509|NCT04586712|DRUG|Vehicle Control (Placebo)|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
219429120|NCT04671069|DRUG|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
219429121|NCT02539303|DRUG|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
219381510|NCT02132338|BEHAVIORAL|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
219381511|NCT00848991|DRUG|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
219381512|NCT00848991|DRUG|Propofol|evaulation of propofol for emergence from anesthesia
219381513|NCT04250805|DRUG|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
219381514|NCT04250805|DRUG|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
219381515|NCT06002022|DEVICE|REBECCA system (smartwatch + mobile app use)|Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
219381516|NCT01021007|DRUG|Iodine|Rinse 2 times per day for 6 weeks
219381517|NCT01021007|OTHER|water|Use 2 times per day for 6 weeks
219381518|NCT01477905|DEVICE|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
219381519|NCT01477905|DEVICE|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
219381520|NCT04287153|DEVICE|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
219381521|NCT05075564|DRUG|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219381522|NCT05075564|DRUG|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219381523|NCT00525252|DRUG|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
219381524|NCT00525252|DRUG|placebo|Placebo will be orally administered for 12 consecutive weeks
219381525|NCT05511961|BEHAVIORAL|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
219381526|NCT06154291|DRUG|XON7|The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
219381527|NCT05199870|DEVICE|RingLoc Bipolar Acetabular Cup|Patients that have been implanted with a RingLoc Bipolar acetabular cup.
219381528|NCT05199870|DEVICE|Endo II Femoral Head|Subjects that have been implanted with an Endo II Femoral Head
219381529|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
219381530|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
219381531|NCT06526312|BEHAVIORAL|Fidelity Monitoring (Lyssn and COACH)|"Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists.~The COACH fidelity rating system assesses clinical skills in five domains considered essential for the effective provision of the FCU and the EDP intervention sessions. The COACH rating form is used to assess the extent to which the provider is:~Conceptually accurate and adherent to the intervention model Observant and responsive to the family's needs Active in structuring the session Careful when teaching and providing feedback Helpful in building hope and motivation"
219381532|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
219381533|NCT06550076|DRUG|TAK-279|TAK-279 oral tablet
219381534|NCT04908995|DRUG|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
219381535|NCT04908995|OTHER|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
219381536|NCT02547727|BIOLOGICAL|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
219381537|NCT02386774|DEVICE|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
219381538|NCT02386774|DEVICE|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine"
219381539|NCT02386774|PROCEDURE|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
219381540|NCT04390685|DRUG|Tacrolimus ointment|Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
219381541|NCT05283993|OTHER|No intervention|No intervention
219381542|NCT02436109|DEVICE|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
219381543|NCT03698734|DRUG|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
219381544|NCT03698734|DRUG|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
219381545|NCT00087438|RADIATION|stereotactic body radiation therapy|
219381546|NCT00466505|BIOLOGICAL|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
219381547|NCT00466505|DRUG|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
219381548|NCT00466505|GENETIC|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
219381549|NCT00466505|OTHER|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
219381550|NCT00466505|OTHER|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
219381551|NCT00466505|OTHER|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
219381552|NCT03456011|OTHER|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
219381553|NCT01543750|DRUG|4-Aminopyridine|
219381554|NCT01543750|DRUG|Placebo|Placebo
219381555|NCT03848819|DEVICE|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
219381556|NCT04872725|BEHAVIORAL|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
219381557|NCT03250741|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
219381558|NCT03250741|OTHER|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
219381559|NCT04328480|DRUG|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
219557874|NCT02159820|DRUG|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
219381560|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
219381561|NCT01050621|DIETARY_SUPPLEMENT|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
219381562|NCT03425708|DRUG|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
219381563|NCT03425708|DRUG|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
219381564|NCT00904254|RADIATION|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
219381565|NCT03979729|OTHER|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
219381566|NCT03979729|OTHER|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
219381567|NCT03979729|OTHER|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
219381568|NCT03752905|DRUG|PTR-01|Recombinant human collagen 7 (rC7)
219381569|NCT03752905|DRUG|Normal saline|Saline control
219381570|NCT00002523|DRUG|fluorouracil|
219381571|NCT00002523|DRUG|leucovorin calcium|
219381572|NCT00002523|PROCEDURE|conventional surgery|
219381573|NCT00002523|RADIATION|radiation therapy|
219381574|NCT00716443|DRUG|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
219381575|NCT00716443|DRUG|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
219381576|NCT01590329|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
219381577|NCT00744289|OTHER|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
219381578|NCT03777514|DRUG|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
219381579|NCT03777514|DRUG|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
219381580|NCT03777514|OTHER|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
219381581|NCT03777514|OTHER|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
219381582|NCT04776343|OTHER|telemedecine follow-up|weekly home-based follow-up of visual acuity on electronic tablet
219381583|NCT00759577|DRUG|Solifenacin|5mg and 10 mg, oral once daily
219381584|NCT03971981|DIETARY_SUPPLEMENT|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
219381585|NCT03971981|DIETARY_SUPPLEMENT|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
219381586|NCT00719199|DRUG|IMO-2055|SC weekly injections
219381587|NCT00719199|DRUG|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
219381588|NCT00719199|DRUG|FOLFIRI|Given day 1 of each cycle
219381589|NCT02560454|BEHAVIORAL|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
219381590|NCT02560454|BEHAVIORAL|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
219381591|NCT02195843|OTHER|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
219381592|NCT02195843|OTHER|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
219381593|NCT02195843|DEVICE|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
219381594|NCT00927485|DRUG|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
219381595|NCT00927485|OTHER|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
219381596|NCT00927485|OTHER|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
219381597|NCT00927485|OTHER|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
219381598|NCT00927485|OTHER|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
219381599|NCT03607227|DRUG|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
219381600|NCT03607227|DRUG|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
219381601|NCT04619576|BEHAVIORAL|Occupational health workers|Questionnaire online
219381602|NCT04109040|DEVICE|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
219381603|NCT01948752|OTHER|Nutrition information on menus|
219381604|NCT05531240|PROCEDURE|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
219381605|NCT05531240|PROCEDURE|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
219381606|NCT04224623|BEHAVIORAL|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
219381607|NCT01874483|DRUG|Placebo|placebo
219381608|NCT01874483|DRUG|BI 187004|BI 187004, dose 2
219381609|NCT01874483|DRUG|BI 187004|BI 187004, dose 4
219381610|NCT01874483|DRUG|BI 187004|BI 187004, dose 5
219381611|NCT01874483|DRUG|BI 187004|BI 187004, dose 6
219381612|NCT01874483|DRUG|BI 187004|BI 187004, dose 7
219381613|NCT01874483|DRUG|BI 187004|BI 187004, dose 1
219381614|NCT01874483|DRUG|BI 187004|BI 187004, dose 3
219000991|NCT01563302|DRUG|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
219381615|NCT03364218|DRUG|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
219381616|NCT04304677|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES"
219381617|NCT02534337|DRUG|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
219381618|NCT02534337|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
219381619|NCT05223101|DRUG|Telminone 80 mg|Single administration of telmisartan 80 mg
219381620|NCT05223101|DRUG|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
219381621|NCT05152355|DRUG|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
219381622|NCT05152355|DRUG|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
219381623|NCT05259475|OTHER|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
219381624|NCT05259475|OTHER|Diet Intervention|Calorie-restricted meals (lunch and dinner)
219381625|NCT05259475|OTHER|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
219381626|NCT03906877|PROCEDURE|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
219381627|NCT03906877|BEHAVIORAL|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
219381628|NCT03906877|OTHER|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
219381629|NCT03906877|OTHER|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
219381630|NCT02112110|DRUG|BMS-791325|
219381631|NCT02112110|DRUG|[13C]-BMS-791325|
219381632|NCT01966510|OTHER|Cord Blood Transplantation|
219381633|NCT04107220|DRUG|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
219381634|NCT01872351|DRUG|Nutraceuticals|
219381635|NCT00761111|BEHAVIORAL|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
219381636|NCT06231043|DRUG|Diclofenac/Tramadol|"Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse."
219381637|NCT06028815|BEHAVIORAL|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
219381638|NCT03203629|DEVICE|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
219381639|NCT01595217|DEVICE|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
219381640|NCT00167622|PROCEDURE|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
219381641|NCT00167622|PROCEDURE|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
219381642|NCT00579904|DIETARY_SUPPLEMENT|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
219381643|NCT00579904|DIETARY_SUPPLEMENT|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
219381644|NCT00749086|DEVICE|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
219381645|NCT00749086|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
219381646|NCT06065722|DRUG|Akynzeo|OLANZAPINE
219381647|NCT03953118|DRUG|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
219381648|NCT03953118|DRUG|Placebo Oral|Oral placebo tablet
219381649|NCT00929630|PROCEDURE|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
219381650|NCT00929630|PROCEDURE|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
219381651|NCT00929630|PROCEDURE|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
219381652|NCT00929630|PROCEDURE|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
219381653|NCT04438135|OTHER|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
219381654|NCT01119040|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
219381655|NCT05653908|OTHER|StudentMood|StudentMood is an app that uses ecological momentary assessment method to asses mood and other mental health corelates. Participants will have to complete the application (the mood wheel, heart rate and other behavioral data as well as standardized scales) daily throughout the entire semester
219381656|NCT03124069|DEVICE|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
219381657|NCT02604264|DEVICE|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
219381658|NCT00623571|OTHER|Treatment of elderly patients in a GMW|
219381659|NCT00623571|OTHER|Treatment of elderly patients in GHHS|
219381660|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
219381661|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
219381662|NCT00246259|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
219381663|NCT00246259|DRUG|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
219381664|NCT05971797|BEHAVIORAL|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
219381665|NCT03133767|DRUG|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
219381666|NCT03133767|DRUG|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
219381667|NCT00976755|DRUG|everolimus|"Everolimus:~10mg daily"
219381668|NCT03664726|BEHAVIORAL|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
219381669|NCT03664726|BEHAVIORAL|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
219381670|NCT03664726|BEHAVIORAL|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
219381671|NCT03664726|BEHAVIORAL|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
219381672|NCT03032744|OTHER|Asthma Assessment & Management|Asthma Assessment \& Management based on NAEPP-EPR3 guidelines
219381673|NCT03032744|OTHER|Asthma Education|Asthma education on medications
219381674|NCT03032744|OTHER|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
219381675|NCT00298714|DRUG|Losartan|
219381676|NCT01726361|BEHAVIORAL|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
219381677|NCT01726361|BEHAVIORAL|Treatment as usual|Other kinds of out of home placement
219381678|NCT00206141|DRUG|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
219381679|NCT03295305|BEHAVIORAL|Action-Based Cognitive Remediation|
219381680|NCT03295305|BEHAVIORAL|Unstructured support group|
219381681|NCT03328819|OTHER|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
219381682|NCT03679403|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219381683|NCT02380131|DRUG|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
219381684|NCT02380131|DRUG|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
219381685|NCT00855439|DRUG|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
219381686|NCT00855439|DRUG|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
219381687|NCT03728244|DRUG|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
219381688|NCT03728244|DRUG|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
219381689|NCT02485392|DEVICE|Da Vinci Single Site Robot-Assisted Cholecystectomy|
219381690|NCT02485392|DEVICE|Single Incision Laparoscopic Cholecystectomy|
219381691|NCT05523934|DRUG|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
219381692|NCT00123084|BEHAVIORAL|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
219381693|NCT00123084|BEHAVIORAL|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
219381694|NCT01179529|DRUG|Omalizumab (Xolair®)|
219381695|NCT04078750|BEHAVIORAL|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
219381696|NCT05531357|DIAGNOSTIC_TEST|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
219381697|NCT03406026|OTHER|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
219381698|NCT03406026|OTHER|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
219381699|NCT01246492|DIETARY_SUPPLEMENT|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
219381700|NCT01014884|OTHER|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
219381701|NCT01014884|OTHER|Multidisciplinary team bimonthly visits either in person or via telephone.|
219381702|NCT01014884|OTHER|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
219381703|NCT02226666|DRUG|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
219381704|NCT02226666|DRUG|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
219381705|NCT05752448|BEHAVIORAL|POSTCare Survivorship transition process|Survivorship coaching intervention
219381706|NCT00133926|PROCEDURE|Treatment of periodontal disease|
219381707|NCT05994170|RADIATION|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
219381708|NCT05994170|RADIATION|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
219381709|NCT02186392|DEVICE|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
219381710|NCT04032366|DRUG|inhaled nitric oxide|using of inhaled nitric oxide
219381711|NCT04032366|DEVICE|PEEP|increasing PEEP or decreasing PEEP
219381712|NCT05904587|DEVICE|SureSmile® VPro™|the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure
219381713|NCT05904587|OTHER|ortho technology, sports advantage, thermal forming soft EVA 3mm|the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure
219381714|NCT05904587|OTHER|cotton roll|the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
219381715|NCT00257751|PROCEDURE|Aprotinine|
219381716|NCT04626622|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
219381717|NCT04626622|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
219381718|NCT01640847|DRUG|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
219381719|NCT05346302|DRUG|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
219381720|NCT05346302|DRUG|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
219381721|NCT05346302|OTHER|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
219381722|NCT01416129|DEVICE|Standard of care socket|Amputees' preferred socket.
219381723|NCT01416129|DEVICE|Prosthetic brimless socket|Study socket
219381724|NCT00853983|DRUG|[14C] AZD0530|Solution, Oral, once
219381725|NCT02033226|DEVICE|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
219381726|NCT02033226|DEVICE|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
219381727|NCT05480514|DEVICE|TEST LENS|etafilcon A with cosmetic pattern
219381728|NCT05480514|DEVICE|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
219381729|NCT03384056|DEVICE|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
219381730|NCT03384056|DEVICE|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
219381731|NCT05716919|DRUG|Ivaltinostat|Ivaltinostat capsule
219381732|NCT05716919|OTHER|Placebo|Placebo capsule
219381733|NCT05660161|PROCEDURE|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
219381734|NCT06555068|DRUG|HRS-6209 in Combination with Fulvestrant|HRS-6209 in Combination with Fulvestrant
219381735|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
219381736|NCT06555068|DRUG|HRS-6209 in Combination with Letrozole|HRS-6209 in Combination with Letrozole
219381737|NCT06555068|DRUG|HRS-6209 in Combination with HRS-8080|HRS-6209 in Combination with HRS-8080
219381738|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
219381739|NCT05534724|OTHER|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
219381740|NCT05534724|OTHER|Complete weight-bearing|Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
219381741|NCT04111588|OTHER|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
219381742|NCT03192579|DRUG|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
219381743|NCT03192579|DRUG|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
219381744|NCT00457639|DRUG|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
219381745|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
219381746|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
219381747|NCT03638830|OTHER|placebo+Maxipim|placebo
219381748|NCT04790591|PROCEDURE|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
219381749|NCT07010133|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
219381750|NCT06869187|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
219381751|NCT01901328|DRUG|CB-5945|
219381752|NCT01901328|DRUG|Placebo|
219381753|NCT07031076|DIETARY_SUPPLEMENT|Ready-to-eat lean pork in frozen, 5-oz packages|The dietary intervention lasts 16 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 4 portions of ready-to eat lean pork in frozen packages per week; each portion of ready-to-eat lean pork in this intervention will weigh 5 ounces.
219381754|NCT07031011|BIOLOGICAL|PD-1-M1-NK Cells|At dose escalation stage, four dose groups were initially determined: 5×106CAR NK cells/kg, 1×107CARNK cells/kg, 2×107CARNK cells/kg, and 5×107 CARNK cells/kg. Administration cycle: In Cycle 1 (C1), the drug was administered once on days 1, 4, 7, 10 and 13 respectively. A complete cycle was formed by five consecutive administrations. For subjects with stable, partial response or complete response in the tumor assessment at the first time in week 4, the treatment in Cycle 2 will continue subsequently. In Cycle 2, the drug was administered once every two weeks (Q2W: D14±7 days and D28±7 days).
219381755|NCT07031648|OTHER|Laughter Yoga Group|iving information about the yoga of meeting and laughter, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, P
219381756|NCT07031648|OTHER|Pilates Group|Providing information about meetings and Pilates, Obtaining written consent through an informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, Doing a total of 8 sessions of pregnant pilates exercises for 4 weeks, 2 times a week, Sessions should consist of a maximum of 10 people, A total of 45 minutes of pilates exercise for pregnant women, At the end of the fourth week, the final test will be administered
219381757|NCT07031648|OTHER|Education Group|Providing information about the research, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school (pregnancy, postpartum care, baby care, breastfeeding, etc.) At the end of the fourth week, the final test will be administered
219381758|NCT07030296|BEHAVIORAL|Sprint Training With Weighted Vest|Participants performed a sprint training program wearing a weighted vest equal to approximately 10% of their body weight. The program lasted 6 weeks and included 16 sessions of linear and change-of-direction sprint drills. The goal was to examine whether the added external load improved running speed over 30 and 60 yards.
219381759|NCT07030296|BEHAVIORAL|Sprint Training Without Weighted Vest|Participants completed the same sprint training program as the experimental group but without the use of a weighted vest. The intervention lasted 6 weeks and consisted of 16 sessions including sprint and agility exercises. This group served as the control condition to assess the effect of external resistance.
219381760|NCT07030816|DEVICE|Guardner Belt|The Guardner Belt is a commercially available elastic lumbar support belt designed to reduce low-back pain and improve posture. Participants wore the belt sized according to waist circumference for at least 8 hours per day during working hours for 4 weeks.
219381761|NCT07030829|DEVICE|Laser Lithotripsy|Laser Lithotripsy
219381762|NCT07030829|DEVICE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
219381763|NCT07030114|DIAGNOSTIC_TEST|complete blood tests|"Complete Blood Count (CBC): Using automated hematology analyzers to measure various blood cell parameters.~* C-Reactive Protein (CRP): Quantitative analysis using immunoturbidimetric assay.~* Erythrocyte Sedimentation Rate (ESR): Measured using the Westergren method.~* Coagulation profile:~* Prothrombin Time (PT): Using thromboplastin reagents and automated coagulation analyzers.~* Activated Partial Thromboplastin Time (aPTT): Using phospholipid-based reagents and automated analyzers.~* International Normalized Ratio (INR): Calculated from PT results.~* Bleeding Time: Ivy method or template bleeding time.~* Liver function tests: Including ALT, AST, ALP, bilirubin using spectrophotometric methods.~* Kidney function tests: Creatinine and BUN using enzymatic methods."
219381764|NCT07030114|DEVICE|mechanical ventilation (MV)|"Mechanical Ventilation Parameters~* \- Ventilation Mode: Ventilator settings will record modes such as volume-controlled ventilation or synchronized intermittent mandatory ventilation (SIMV), which deliver breaths based on patient needs.~* Tidal Volume: Measured in milliliters per kilogram of predicted body weight. Tidal volume settings aim to optimize oxygenation while minimizing lung injury risks by adhering to evidence-based limits (\<6 mL/kg).~* Positive End-Expiratory Pressure (PEEP): PEEP levels will be recorded in cmH₂O to prevent alveolar collapse and improve oxygenation. Adjustments will balance oxygenation benefits with potential risks like reduced venous return or lung overdistension.~* Fraction of Inspired Oxygen (FiO₂): FiO₂ values will be documented as decimals, starting at 1.0 (100% oxygen) and adjusted downward based on patient oxygenation needs."
219381765|NCT07031492|DEVICE|FLEX-AP system will be implemented to T1D patients|A FLEX-AP system will be implemented to T1D patients after they have been given a Minimed 780G hybrid closed-loop system
219381766|NCT07031167|BEHAVIORAL|Cognitive and functional stimulation using digital platforms|Participants in the intervention group receive personalized cognitive and functional stimulation over one year through digital platforms developed by the COMFORTage project. These include Eligence, a brain-training tool featuring interactive games targeting memory, attention, and language; Language Games, which assess and train linguistic and cognitive skills in realistic scenarios; and Healthentia, a platform that monitors daily health metrics and provides virtual coaching. Sessions are conducted both in person and remotely, and are adapted to each participant's abilities and level of digital literacy. The intervention aims to support cognitive health and daily functioning in individuals with MCI or mild AD.
219381767|NCT07030335|OTHER|Mobile-Atrial Fibrillation Training Program|Patient Information Form, Atrial Fibrillation Information Scale, Atrial Fibrillation Severity Scale and Atrial Fibrillation Impact on Quality of Life Questionnaire will be administered face-to-face by the researcher using Mobile Atrial Fibrillation Education Program (M-AFEP). The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants and the application will be added to the main screens by entering the relevant address from their phones. Participants will be asked to use M-AFEP for twelve weeks / at least ten minutes a week and the frequency and duration of use will be recorded on the mobile application. Participants in the intervention group will be followed up by phone once a week in the first, fourth and eighth weeks and a reminder message (sms) will be sent for the use of M-AFEP. At the end of the twelfth week, the scales will be filled in again through the application.
219381768|NCT07030335|OTHER|Routine Outpatient Clinic Care|"* Participants in the control group will be given M-AFEP application usage training by the researchers.~* The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants in the control group.~* Participants in the control group will enter the relevant address of the mobile application from their phones and the application will be added to their home screens.~* In the M-AFEP application of the participants in the control group, there will be a short general information section containing information specific to AF, different from the intervention group content.~Participants in the control group will continue only routine outpatient follow-up throughout the process and no intervention will be applied."
219381769|NCT07030192|BEHAVIORAL|Peer support service|"Peers approach identified patients who could potentially benefit from peer support services. Peers offer a range of supports tailored to individual patients' needs, which include referrals to clinical and social support services (e.g., social work, addictions specialist, Indigenous patient navigator, community-based addictions resources), resources (e.g., blankets, food, naloxone kit, sterile drug use supplies, information brochures), providing emotional support, and liaising between patients and healthcare providers to communicate information about patients' condition and ED trajectory.~Peer support workers share their personal experiences to guide patients through their ED visit and to facilitate awareness and understanding of available resources."
219381770|NCT07031583|PROCEDURE|Delayed Umbilical Cord Clamping (DCC)|The umbilical cord was clamped between 60 and 180 seconds after birth or after the cessation of cord pulsation, in accordance with WHO recommendations. This procedure allows for additional placental transfusion and potential enhancement of neonatal antioxidant capacity.
219381771|NCT07031583|PROCEDURE|Early Umbilical Cord Clamping (ECC)|The umbilical cord was clamped within the first 60 seconds after birth. This represents the standard or traditional approach used for comparison with delayed clamping in terms of oxidative stress outcomes.
219381772|NCT07031505|DEVICE|Active Photobiomodulation|Local photobiomodulation using a high-power superpulsed diode laser (GeminiEvo, Ultradent, USA) with dual infrared wavelengths (810 nm and 980 nm). Eight sessions will be conducted (twice a week for 4 weeks). Application will be at one point each on the masseter, temporal, trapezius, and temporomandibular joint regions. Each point will be irradiated for 13 seconds with 4 J of energy (10.52 J/cm²), in contact mode. The procedure includes safety measures such as protective eyewear and disinfection of the laser tip.
219381773|NCT07031505|DEVICE|Sham Photobiomodulation|The same application protocol as the experimental group will be followed, using the same laser device (GeminiEvo, Ultradent, USA), but with the laser emission deactivated. The guide light and sound will remain active to preserve participant blinding. Application points, duration, frequency, and session environment will be identical to the active group.
219381774|NCT07032064|PROCEDURE|Sequential ventricular pacing at five sites|"This intervention involves sequential temporary pacing at five distinct ventricular sites within the same patient during a single electrophysiological study. The pacing sites include:His bundle pacing (HBP),Deep septal pacing (DSP),Left ventricular septal pacing (LVSP),Non-selective left bundle branch pacing (NS-LBBP),Selective left bundle branch pacing (SLBBP).~Each pacing modality is tested under identical hemodynamic and electrophysiological conditions using a fixed output and AV delay. Electrical parameters and acute hemodynamic responses are recorded for each site. The study uses a within-subject crossover design, allowing direct intra-individual comparison of different pacing strategies in patients meeting standard CRT indications. No long-term device implantation is involved during this phase of the study."
219381775|NCT07031960|DEVICE|3D Eyeball Movement Simulator Group|"A physical, interactive 3D-printed educational model that replicates human eyeball movements and demonstrates the biomechanical action of extraocular muscles. The simulator allows hands-on manipulation to demonstrate all cardinal eye movements (adduction, abduction, elevation, depression, intorsion, and extorsion) through mechanical actuation of synthetic muscle analogues."
219000992|NCT03940404|DRUG|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
219381776|NCT07031960|OTHER|Conventional Teaching Methods Group|Standard medical education methods for teaching eye anatomy and movements, including: (1) didactic classroom lectures with 2D illustrations, (2) static anatomical models of the orbit and eyeball, and (3) textbook-based learning materials. This represents the current conventional approach to teaching this content in medical curricula
219381777|NCT07031778|DRUG|Simvastatin|Simvastatin gel with 1.2% simvastatin
219381778|NCT07031778|DRUG|Simvastatin 10 mg|sponge of collagen impregned in saline solution with 10 mg of simvastatin
219381779|NCT07031778|DRUG|Simvastatin Placebo|Collagen sponge impregned in simvastatin placebo gel without simvastatin
219381780|NCT07030621|DRUG|Semaglutide 0.5 mg|Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) analog, which has been found to have neuroprotective effects.
219381781|NCT07030621|DRUG|Normal Saline|Normal saline is the placebo drug.
219381782|NCT07031115|DRUG|Linperlisib|Linperlisib 40 mg, orally, once daily. Following 2 weeks of treatment, efficacy was assessed. If the reticulocyte count remained \<20×10⁹/L, the dose was escalated to 60 mg, once daily. After an additional 2 weeks of therapy, a second efficacy assessment was performed. Patients failing to achieve partial response (PR) underwent further dose escalation to 80 mg, once daily. Treatment was discontinued if PR was not attained after 8 weeks at the maximum dose. Responding patients maintained therapy at their effective dose level. The core study period comprised 12 weeks, with responders continuing treatment at the investigator's discretion.
219381783|NCT07030400|DRUG|Bruton's tyrosine kinase inhibitor|BTKi
219381784|NCT07030400|DRUG|B-Cell Lymphoma 2 Protein Inhibitor|BCL2i
219381785|NCT07030374|OTHER|conscious connected breathing exercises|conscious connected mouth breathing session where the diaphragm is activated
219381786|NCT07031440|BEHAVIORAL|digital LWWCOPD|LWWCOPD (Living well with COPD) contains six modules conventionally delivered by trained LWWCOPD Coaches. For the digital delivery the six modules are as closely adapted to the conventional LWWCOPD program as possible to make the two approaches comparable. Participants can access the digital LWWCOPD application by a weblink using a smartphone, tablet or desktop computer. Since the program duration of the conventional LWWCOPD is 6 weeks (one module per week), patients will be instructed to complete the digital LWWCOPD also within 6 weeks at their own pace, although completion within 12 weeks (3 months) is still possible. Modules can be repeated as chosen by the user. In contrast to the conventional delivery, the online delivery of LWWCOPD does not preview face-to-face contact between participants and healthcare providers, however if needed additional phone calls or meetings are still possible.
219381787|NCT07031154|DRUG|Adebrelimab|Adebrelimab 1200mg, iv, D1，Q3W
219381788|NCT07031154|DRUG|Apatinib|Apatinib 250mg，P.O，qd，Q3W
219188591|NCT01924819|RADIATION|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
219381789|NCT07030634|OTHER|conventional physical therapy|"consist of Strengthening exercise: will begin with isometric exercises performed against an immovable object in four directions of ankle movement (dorsiflexion, planter flexion, inversion, and eversion) and will be progressed to dynamic resistive exercises (isotonic exercises) using ankle weights.~and Bracing: The participants will receive instructions from the therapist about using and applying the soft brace. The soft brace will be based on the principles of the functional tape bandage"
219381790|NCT07030634|OTHER|Low load blood flow restriction|Patients in blood flow restriction training groups will receive low load resistance exercise (20-40 % 1RM) using tourniquet around thigh proximally to knee joint to occlude arterial blood flow by 50-80 %.
219381791|NCT07030634|OTHER|proprioception training|Patients will receive proprioception exercises in duration of 30 minutes per session, frequencies will be 3 times per week, and lengths for 4 weeks (Matthew et al., 2017). Progression of the proprioceptive training should be static to dynamic (such as lateral movements, backward movements, jumping, cutting, twisting, pivoting), slow speeds to faster speeds with balance and control, two legs to one leg, and with visual control to no visual control.
219381792|NCT07030387|BEHAVIORAL|Smoking cessation counselling group|3A-OR very brief intervention for smoking cessation
219381793|NCT07030387|BEHAVIORAL|Control group patients were those who had not received the 3A-OR intervention|Control Group (Patients of the other family physicians in the same family health centers)
219381794|NCT07031258|DRUG|Dose of docetaxel|According to the relative dose intensity of docetaxel (RDI; Defined as the ratio of the dose received to the full planned dose of 75mg/m2 per 6 cycles specified in the protocol) were divided into cohort 1 (patients receiving docetaxel dose intensity ≤80%) and cohort 2 (patients receiving docetaxel dose intensity ≤80%). A total of 50 patients who received docetaxel dose intensity \> 80% were planned to be enrolled, including 25 patients in the docetaxel dose intensity ≤80% group and 25 patients in the docetaxel dose intensity \> 80% group
219381795|NCT07031986|DEVICE|One-Lung ventilation with Double-Lumen Tube|To achieve the required one-lung ventilation during lung resection, patients will be managed with a double-lumen tube.
219381796|NCT07031986|DEVICE|One-Lung Ventilation with Bronchial Blocker|To achieve the required one-lung ventilation during lung resection, patients will be managed with a bronchial blocker.
219381797|NCT07030582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The intervention group received a comprehensive core muscle training protocol delivered through a digital rehabilitation platform from hospital admission to 6 months post-surgery. The protocol began with initial screening, including online assessments of cognitive misconceptions, kinesiophobia, and posture analysis. Pain-related cognitive restructuring was addressed through virtual reality sessions, educational videos, and mindfulness breathing guidance. Behavioral activation incorporated graded exposure therapy with EMG biofeedback, interactive knowledge quizzes, and peer modeling. Exercise skills were developed through personalized progressive training with real-time video guidance, and protocols were adjusted based on mid-term assessments. Behavioral reinforcement strategies included recovery support groups, compliance tracking, and integration of exercises into daily activities. A three-tier warning system (Red/Yellow/Green) was implemented to monitor safety and compliance, trigger
219381798|NCT07030582|BEHAVIORAL|Basic Postoperative Care|All participants were instructed to maintain their usual daily activities and abstain from additional treatments throughout the 6-month study period.
219381799|NCT07030582|BEHAVIORAL|Conventional Postoperative Care|The control group received conventional postoperative care, which included the establishment of a WeChat support group and provision of a rehabilitation manual focusing on core muscle training on the first postoperative day. Physical therapists provided individualized bedside instruction to ensure proper exercise techniques. Structured follow-up was conducted via telephone or social media (weekly during the first month, then monthly from months 2-6, with each session lasting at least 15 minutes) to provide psychological support and exercise guidance through relaxation techniques and individualized core muscle training progression.
219381800|NCT07032025|PROCEDURE|Innovative Device Group|Catheter-based thrombectomy is performed within 4 hours after baseline CTPA acquisition. Pre-procedural anticoagulation with either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) is administered prior to thrombectomy. Post-procedural oral anticoagulation is transitioned to rivaroxaban 20 mg once daily (QD).
219381801|NCT07032025|DRUG|Standard Pharmacological Therapy Group|Following thrombolytic agent administration, anticoagulation with rivaroxaban is initiated and maintained at 15 mg twice daily (BID) for the initial 3 weeks, then switched to 20 mg once daily (QD) thereafter.
219381802|NCT06710184|DRUG|Aspirin|Aspirin bolus of 300 mg followed by 75 mg daily until CAG
219381803|NCT06710184|DRUG|Fondaparinux Sodium|Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)
219381804|NCT00002884|DRUG|chemotherapy|
219381805|NCT00002884|DRUG|cisplatin|
219381806|NCT00002884|DRUG|fluorouracil|
219381807|NCT00002884|RADIATION|brachytherapy|
219381808|NCT00002884|RADIATION|radiation therapy|
219381809|NCT06843499|OTHER|The VeriSee AI-assisted diagnostic system|VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.
219381810|NCT06843499|OTHER|Data collection from the patient's clinical history|Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.
219381811|NCT06900634|BEHAVIORAL|Kisoboka Amaka|"KISOBOKA AMAKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component focuses on depositing earnings into mobile savings programs. Kisoboka Amaka content will be finalized in aims 1 and 2. However, we expect core intervention components to remain unchanged including: 4 counseling sessions (2 individual, 2 group), 2x weekly text message reminders of goals and mobile money set up. Potential additional components include: 1 family focused couples session, self monitoring of alcohol use (via mobile breathalyzer) and PEth (an objective biomarker measure of alcohol use) boosted alcohol counseling."
219381812|NCT06900634|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
219381813|NCT06899191|DIAGNOSTIC_TEST|Hemoglobin A1c|Prompt to order A1c
219381814|NCT06899191|BEHAVIORAL|Observation Unit|Electronic prompt nudging ED provider to consider admitting patient to the Observation Unit for care coordination and more aggressive glycemic control
219381815|NCT03900598|DRUG|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
219381816|NCT07075341|OTHER|None - Observational study|None - Observational study
219381817|NCT05225324|DRUG|Equfina 50 mg|Equfina 50 mg tablets.
219381818|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
219381819|NCT03856216|DRUG|Bendamustine|Given IV
219381820|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
219381821|NCT03856216|DRUG|Fludarabine|Given IV
219381822|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219381823|NCT03856216|DRUG|Melphalan|Given IV
219381824|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
219381825|NCT03856216|BIOLOGICAL|Rituximab|Given IV
219381826|NCT03856216|DRUG|Tacrolimus|Given IV and PO
219381827|NCT06904105|DRUG|HRS-7535 Tablets|HRS-7535 tablets.
219381828|NCT06904105|DRUG|HRS-7535 Placebo Tablets|HRS-7535 placebo tablets.
219381829|NCT07108036|DRUG|N-803 (IL-15 Superagonist)|N-803 administered subcutaneously.
219381830|NCT07107828|OTHER|Ambient air|Standard ambient air will be breathed during endurance training.
219381831|NCT07107828|OTHER|Oxygen|SSOT will be applied during endurance training
219381832|NCT07107828|OTHER|Altitude|Training will be performed at moderate altitude
219381833|NCT07108075|DRUG|Carvedilol|Carvedilol 12. 5mg
219381834|NCT07108075|DRUG|Metformin|Metformin 1000 mg
219381835|NCT07107334|DRUG|Glucagon-like peptide 1 receptor agonist|Subjects will receive a glucagon-like peptide 1 receptor agonist by self-injection for as long as clinically indicated by the treating physician or until the subject receives clearance for staging hysterectomy or for pregnancy pursuit. The choice of glucagon-like peptide 1 receptor agonist for each subject will be at the treating physician's discretion. Subjects will discontinue the glucagon-like peptide 1 receptor agonist 2 weeks before any elective surgical procedure.
219381836|NCT07105579|DRUG|BITE and DLI|"Blinatumomab dosage:~Cycle 1 (starting at day 60 post-transplant):Days 1-3: 9 μg/day，Days 4-14: 28 μg/day Cycles 2-4:Days 1-14: 28 μg/day Administration method: Continuous 24-hour intravenous infusion, one cycle every 3 months.~DLI eligibility criteria:No history of grade III-IV acute GVHD (aGVHD).No active aGVHD or chronic GVHD (cGVHD) at the time of infusion~DLI dosage:Administered at day 120 post-HSCT, CD3+ cell dose: 1 × 10⁷/kg"
219381837|NCT07106905|OTHER|Measurements|These measurements are used in other clinical applications. However, the effectiveness of these measurements in discriminating the presence of low back pain in mothers of children with disabilities over the past year has been identified.
219381838|NCT07107893|DEVICE|double lumen tube with video|Methods used to confirm tube placement in one-lung ventilation: auscultation, fiberoptic bronchoscopy, and video to evaluate double-lumen tube use
219381839|NCT07106983|OTHER|No intervention (observational study)|Observational survey only
219381840|NCT05936359|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
219381841|NCT05936359|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
219381842|NCT07106489|OTHER|beetroot juice - Placebo|Participants receive the beetroot and placebo in the form of waffles to ensure the study is blinded, as the 6 mmol of nitrates used require a high concentration of beetroot, which is masked by the waffle ingredients and food coloring.
219381843|NCT07106489|OTHER|40 meters sprint|The participant performs a race at maximum speed with two attempts, times are taken at 10, 30 and 40 meters, to evaluate acceleration and speed, the attempt with the shortest times is the one taken for the research.
219381844|NCT07106489|OTHER|Fitness test by bronco test|The participant runs a distance of 20, 40, and 60 meters, back and forth, 5 times at maximum speed. The variable to be measured is the total time taken to complete the test.
219381845|NCT07106489|OTHER|Maximal strength|Each participant performs squats and bench press to evaluate lower-body and upper-body maximal strength, thus identifying their maximum strength taken per kilogram lifted.
219381846|NCT07106489|OTHER|Borg scale|At the end of the tests, each participant is asked to evaluate their perception of fatigue by giving a number between 1 and 10, with 1 being the lowest level of fatigue and 10 being the highest.
219381847|NCT07107282|DEVICE|MyHip Verifier|Numerical information on the position of the implant is provided to the surgeon.
219381848|NCT07107074|DRUG|AD04|Each patient will receive 6 single s.c. injections of IMP at monthly intervals over a 5-month treatment period.
219381849|NCT07107074|DRUG|Placebo|Each patient will receive 6 single s.c. injections of Placebo at monthly intervals over a 5-month treatment period.
219381850|NCT07106944|OTHER|Community pregnant women: rectal and throat swab|Community pregnant women: rectal and throat swab
219381851|NCT07106099|BEHAVIORAL|Training given with the tell-what-you-learned method|Students in the intervention group will be given training on diagnosing the symptoms and risks of child abuse and neglect, given by the tell-what-you-learned method, and will be given a practice in which its effectiveness will be evaluated.
219381852|NCT07105566|DIAGNOSTIC_TEST|serum TPI|serum TPI level
219381853|NCT07107542|OTHER|Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) Assessment|Participants undergo standard fieldwork assessments using Mini-CEX and EPAs during their internship to evaluate fieldwork competence and readiness for independent practice. These are observational assessments without additional experimental interventions.
219381854|NCT07106359|BEHAVIORAL|booklet|a clinical letter with a booklet for at-risk families highlighting implications of family history, testing motivators, steps for genetic testing, and potential costs.
219381855|NCT07106359|BEHAVIORAL|control clinical letter|a clinical letter with basic information about LS and implications of counseling and testing of LS, and a few websites for more information and locating genetic counselors.
219381856|NCT07108153|DRUG|SION-719|All participants receive SION-719, as specified by their treatment sequence assignment
219381857|NCT07108153|DRUG|Placebo-to-match SION-719|All participants receive placebo to match SION-719, as specified by their treatment sequence assignment
219381858|NCT07106892|DRUG|HLX43 Dose 1;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
219381859|NCT07106892|DRUG|HLX43 Dose 2;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 2.5mg/kg
219381860|NCT07106892|DRUG|HLX43 Dose 3;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 3.0mg/kg
219381861|NCT07107126|DRUG|RPT1G|RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.
219381862|NCT07107958|PROCEDURE|Electroacupuncture|Electroacupuncture is applied using standardized stroke rehabilitation protocols. Needles are inserted at acupoints including LI15 (Jianyu), LI11 (Quchi), TE5 (Waiguan), LI4 (Hegu), GB30 (Huantiao), ST36 (Zusanli), and GB34 (Yanglingquan), and connected to an electroacupuncture device delivering alternating current stimulation at 10-20 Hz. Each session lasts 15-20 minutes, performed once daily, 5 days per week, for 4 weeks. The intervention follows Vietnam's national traditional medicine guidelines for post-stroke recovery.
219381863|NCT07106866|PROCEDURE|sacrospinous ligament fixation|A longitudinal incision was made at the midline of the posterior vaginal wall, extending approximately 2-3 cm from the perineal body to the vaginal apex to form a tunnel. The incised vaginal epithelium was dissected from the underlying muscularis layer. Dissection was continued to the level of the ischial spine. The rectum was medialized to access the perirectal space. Upon palpating the ischial spine, the sacrospinous ligament was identified medial to it. Long retractors were placed over the ischial spine to protect the pudendal neurovascular structures. The bladder was retracted superiorly, and the rectum medially, for optimal visualization. Two separate or a loop 1-0 polypropylene suture(s) were placed approximately 1.5 fingerbreadths medial to the ischial spine on the ligament using a needle holder. These sutures were passed through the posterior vaginal tunnel to the apex and tied to secure the vaginal apex to the ligament
219381864|NCT07106320|DEVICE|VDW Ultra Ultrasonic Irrigation Activation|Irrigation will be activated using an ultrasonic tip (IRRI S 21/25) connected to the VDW Ultra device (VDW GmbH, Munich, Germany), 2 mm short of working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
219381865|NCT07106320|DEVICE|EDDY Sonic Irrigation Activation|Irrigation solution will be activated using the EDDY sonic tip (VDW GmbH, Munich, Germany), positioned 2 mm short of the working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
219381866|NCT07106320|PROCEDURE|Conventional Needle Irrigation|Irrigation will be performed using a syringe and needle without activation. A total of 6 ml NaOCl, 2 ml EDTA and 5 mL of sterile saline will be used during final irrigation.
219381867|NCT07106021|BIOLOGICAL|RNDP-001|Stem cells
219381868|NCT07106021|DEVICE|Syringe Front-Loading Device|Delivers the stem cells
219381869|NCT07105787|OTHER|SDTT + VR triggered adaptations|The SDTT+ VR triggered adaptations program will trigger reactive gait adaptations by presenting obstacles in VR.
219381870|NCT07105787|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. To ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
219381871|NCT07107191|OTHER|Assessment|Data will be collected from all participants in assessmnet group.
219381872|NCT07105995|OTHER|Examination and questionnaire|Participants will be enrolled in the study and will complete the Temporomandibular Disorders/Diagnostic Criteria (TMD/DC) questionnaire. Subsequently, the investigator will conduct a clinical examination to assess each participant's eligibility based on the predefined inclusion criteria.
219381873|NCT07105995|OTHER|Intraoral scanning|The investigator will perform intraoral scanning of the participants' maxillary and mandibular dentitions, as well as record the bite registration.
219381874|NCT07105995|OTHER|Facebow registrations|The investigator will perform facebow registrations on the participants utilizing an optoelectronic tracking device.
219381875|NCT07105995|OTHER|Mandibular border movement registrations|The investigator will perform mandibular border movement registrations utilizing an optoelectronic mandibular movement tracking device.
219381876|NCT07105995|OTHER|Chewing registrations|The investigator will perform 5 chewing registrations with different test foods utilizing an optoelectronic mandibular movement tracking device.
219381877|NCT07107932|DRUG|Siltartoxatug Injection (Brand name: Sintetol®)|The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
219381878|NCT07107919|OTHER|18F PET/MR|"Tracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered.~• Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds.~1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function~2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema~3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects~4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis~5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis~6. T2 Mapping (Pre Contrast):Quantify myocardial edema~7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data"
219381879|NCT07106242|DEVICE|Adaptive DBS|Subjects will receive Dual or Single Threshold aDBS which are acceptable
219381880|NCT07106242|DEVICE|cDBS|cDBS
219381881|NCT07105475|DEVICE|Paired Associative Transcranial Magnetic Stimulation (TMS)|"Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that uses magnetic fields to stimulate nerve cells in the brain. By placing a coil on the scalp, TMS generates magnetic pulses that induce electrical currents in specific brain regions. This can alter brain activity and potentially influence behavior and symptoms of various neurological and psychiatric conditions.~PAS involves the use of transcranial magnetic stimulation (TMS) at a low and high frequency to stimulate the prefrontal cortex at different areas of the brain. The goal is to assess its effects on cortical arousal and ADHD symptoms. Participants will receive daily sessions of this stimulation for three weeks, with the stimulation designed to influence brain activity and potentially alleviate symptoms of ADHD."
219381882|NCT07105930|DEVICE|Debulging approach using the orbital atherectomy system|A uniform approach using only the orbital atherectomy system (Diamondback 360®), which sands away the calcium with a rotating crown
219381883|NCT07105930|PROCEDURE|Debulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy|A tailored approach, where the operator chooses from various available methods based on the patient's specific type of calcium
219381884|NCT07107269|OTHER|Low plant diversity beverage|Blended drink made from 3 organic vegetables (Power Greens mix)
219381885|NCT07107269|OTHER|Functional Food intervention|This is a 4oz shot made from 30 different organic vegetables and packaged in mylar pouches.
219381886|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with two sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 2 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
219381887|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with four sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
219381888|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with six sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 6 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
219381889|NCT04292717|BEHAVIORAL|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
219381890|NCT07105592|DRUG|Nimotuzumab+Adebrelimab+Chemotherapy|"Phase Ib Treatment Regimen:~Nimotuzumab: Three dose groups (200 mg, 400 mg, 600 mg), administered via intravenous infusion over at least 60 minutes, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via intravenous infusion, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Albumin-bound Paclitaxel: 100 mg/m², administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Carboplatin: AUC=2 (calculated using the Calvert formula), administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Phase II Treatment Regimen:~Nimotuzumab: Recommended Phase II dose (RP2D) as determined from Phase Ib, administered via intravenous infusion on Day 1, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via"
219381891|NCT06936605|DRUG|RGD Peptide|RGD peptide is an integrin binding site
219381892|NCT06936423|PROCEDURE|Open herniotomy|Open inguinal herniotomy through inguinal incision then dissection and separation/ligation of the hernial sac
219381893|NCT06936423|PROCEDURE|Needlescopic percutaneous Internal ring suturing|Laparoscopic extracorporeal percutaneous Internal ring suturing using epidural needle and prolene/ethibond suture
219381894|NCT06936150|OTHER|Electrocardiography|Electrocardiography (ECG) is a non-invasive test used to measure the electrical activity of the heart. It involves placing electrodes on all four extremities and the chest area of the person and measuring the derivation between these electrodes. This procedure is painless and does not contain any elements that will disrupt the integrity of the body.
219381895|NCT06935734|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.
219381896|NCT06955975|DIETARY_SUPPLEMENT|Pectin|10g of pectin with 10g of whey protein and 10g of cocoa powder added as flavour were randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
219381897|NCT06955975|OTHER|Whey protein|10g of whey protein with 10g of cocoa powder added as flavour served as the control/ placebo to compare the effects observed with pectin.
219381898|NCT04067661|BEHAVIORAL|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
219381899|NCT04067661|BEHAVIORAL|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
219381900|NCT03809624|DRUG|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
219381901|NCT03809624|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
219381902|NCT01163422|DEVICE|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
219381903|NCT04359966|DRUG|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
219381904|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
219381905|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
219381906|NCT04359966|DRUG|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
219381907|NCT03551028|DEVICE|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
219381908|NCT05089565|DIAGNOSTIC_TEST|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
219381909|NCT04377529|BEHAVIORAL|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
219381910|NCT04163783|DRUG|[14C]-BGB-3111|20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
219381911|NCT04163783|DRUG|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
219381912|NCT03927976|BEHAVIORAL|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
219000993|NCT01993147|BEHAVIORAL|Dual task paradigm pilot|
219381913|NCT01756976|DEVICE|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
219381914|NCT00335712|DRUG|ONO-5129|
219381915|NCT02267928|OTHER|Check Symptoms|"Symptoms are Checked"
219381916|NCT02267928|OTHER|Uncheck Symptoms|"Symptoms are Un-checked"
219381917|NCT02267928|OTHER|Experienced|Focus of instructions is on symptoms the participant has experienced
219381918|NCT02267928|OTHER|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
219188592|NCT01924819|PROCEDURE|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
219188593|NCT03951480|OTHER|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.
219381919|NCT00834548|PROCEDURE|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
219381920|NCT02693977|PROCEDURE|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
219381921|NCT01498991|DEVICE|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
219381922|NCT00621023|DRUG|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
219381923|NCT01759303|DRUG|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
219381924|NCT01712360|DRUG|NAFT500 (pediatric)|Applied to both feet and groin area
219381925|NCT01712360|DRUG|NAFT600 (pediatric)|Applied to both feet only
219381926|NCT01712360|DRUG|NAFT500 (adult)|Applied to both feet and groin area
219381927|NCT01712360|DRUG|NAFT600 (adult)|Applied to both feet
219381928|NCT01418872|OTHER|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
219381929|NCT06513468|OTHER|Group education session by DESMOND Program|is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
219381930|NCT02347358|DEVICE|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
219381931|NCT02347358|DRUG|IV r-tPA|intravenous recombinant human tissue plasminogen activator
219381932|NCT00275379|DRUG|ERB-041|
219381933|NCT05395169|OTHER|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
219381934|NCT04086303|OTHER|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
219188594|NCT03951480|DRUG|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
219188595|NCT04141371|DRUG|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
219381935|NCT00368368|DRUG|GK Activator (2)|100mg po
219381936|NCT02559505|BIOLOGICAL|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
219381937|NCT02559505|OTHER|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
219188596|NCT04141371|DRUG|physiological serum|daily saline infusion over 3 hours during the vasospasm period
219188597|NCT06214559|DEVICE|Sérum VERRUPRO|To be applied twice a day
219381938|NCT02559505|BIOLOGICAL|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
219381939|NCT01144546|PROCEDURE|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
219381940|NCT03623269|PROCEDURE|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
219381941|NCT02933515|OTHER|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
219381942|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 100mg
219381943|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 200mg
219381944|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 300mg
219381945|NCT01557010|DRUG|Control|Tablets, oral administration, Placebo
219381946|NCT03133897|DRUG|Dexamethasone|experimental group will receive 2 day treatment
219381947|NCT03133897|DRUG|Prednisone|control group will receive 4 day treatment
219381948|NCT05182333|OTHER|Examination|History taking, examination of upper limb
219381949|NCT06379295|OTHER|Questionnaire|Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
219381950|NCT04187820|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
219381951|NCT05577754|DRUG|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
219381952|NCT05577754|DRUG|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
219381953|NCT05577754|PROCEDURE|Optional lumbar puncture + blood sample|Between 6 and 24 months of treatment with Alpelisib
219381954|NCT03791970|DEVICE|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
219381955|NCT03791970|DEVICE|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
219381956|NCT02537860|OTHER|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
219381957|NCT02537860|OTHER|Placebo at T11 and L3|Two injections that contain saline are performed
219381958|NCT02537860|OTHER|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
219381959|NCT02537860|PROCEDURE|Herniorrhaphy|Unilateral inguinal hernia repair
219000994|NCT02601690|OTHER|Blood Sampling|
219381960|NCT02537860|DRUG|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
219381961|NCT02537860|DRUG|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
219381962|NCT01011257|DRUG|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
219381963|NCT01011257|DRUG|Clopidogrel|clopidogrel 75 mg bid
219381964|NCT03158584|DRUG|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
219381965|NCT05013840|BEHAVIORAL|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
219381966|NCT00189761|DRUG|Tacrolimus|
219381967|NCT05952414|BEHAVIORAL|self-efficacy-based interventions|The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
219381968|NCT01495988|DRUG|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
219381969|NCT01495988|DRUG|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
219381970|NCT01495988|DRUG|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
219381971|NCT04880174|DIAGNOSTIC_TEST|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
219381972|NCT01218022|DRUG|Losartan Potassium Tablets|
219381973|NCT00738738|DRUG|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
219381974|NCT04079023|PROCEDURE|Sleeve Gastrectomy|Subtotal vertical gastrectomy
219381975|NCT05812508|DEVICE|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
219381976|NCT03943381|DEVICE|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
219381977|NCT06566209|DEVICE|Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)|Receive 18F-FDG PET/CT
219381978|NCT01568944|DRUG|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
219381979|NCT01568944|PROCEDURE|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
219381980|NCT04298411|DEVICE|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
219381981|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia|FDA022-BB05, intravenously infusion, q3w
219381982|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib|FDA022-BB05, intravenously infusion, q3w
219381983|NCT00023348|DRUG|Isoniazid|
219381984|NCT00023348|DRUG|Rifabutin|
219381985|NCT06265896|OTHER|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
219381986|NCT06265896|OTHER|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
219381987|NCT06203808|OTHER|COMPLETION OF QUESTIONNAIRES|Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
219381988|NCT00284115|DEVICE|Gait trainer|Mechanical gait repetitive training
219381989|NCT00284115|DEVICE|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
219381990|NCT02262637|DRUG|Micardis®|
219381991|NCT02262637|DRUG|MicardisPlus®|
219381992|NCT06251388|DRUG|AK104|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
219381993|NCT04331899|DRUG|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
219381994|NCT04331899|OTHER|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
219381995|NCT01817010|BEHAVIORAL|Multi-Component Rehabilitation (CMC)|
219381996|NCT01817010|BEHAVIORAL|Control (CON)|
219381997|NCT02424669|OTHER|ALS Functional rating Scale-revised (ALS FRS-R)|
219381998|NCT02424669|OTHER|slow vital capacity|
219381999|NCT02424669|OTHER|Blood sample|
219382000|NCT02424669|OTHER|Cerebrospinal Fluid (CSF) sample|
219382001|NCT06346912|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
219382002|NCT00101361|DRUG|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
219382003|NCT00101361|DRUG|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
219382004|NCT02669563|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
219382005|NCT02669563|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
219382006|NCT02669563|DRUG|[13N]ammonia|IV injection of \[13N\]ammonia
219382007|NCT02669563|DRUG|[11C]HED|IV injection of \[11C\]HED
219382008|NCT02446639|OTHER|Blood collection|
219382009|NCT02424539|DRUG|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
219382010|NCT02424539|OTHER|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
219382011|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
219382012|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
219382013|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
219382014|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
219382015|NCT03083912|DIETARY_SUPPLEMENT|Fortimel Complete|The residents included receive 2 bottle por day.
219382016|NCT02536482|DIETARY_SUPPLEMENT|Amix|Treat the children with cow's milk allergy for 5 months.
219382017|NCT00450463|DRUG|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
219382018|NCT00450463|DRUG|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
219382019|NCT00450463|BIOLOGICAL|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
219382020|NCT00450463|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
219382021|NCT02545374|OTHER|Telemedicine|
219382022|NCT02545374|OTHER|Control|
219382023|NCT04169568|PROCEDURE|Manual cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
219382024|NCT04272307|BIOLOGICAL|Blood samples|"At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection."
219382025|NCT04272307|PROCEDURE|Stool samples|"One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode."
219382026|NCT04272307|PROCEDURE|Colorectal biopsies|During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
219382027|NCT05408858|BEHAVIORAL|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
219382028|NCT03618641|DRUG|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
219382029|NCT03618641|BIOLOGICAL|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
219382030|NCT00920543|DRUG|Placebo|Twice daily dosing
219382031|NCT00920543|DRUG|FP 100mcg|Twice daily dosing
219382032|NCT00920543|DRUG|FP 500mcg|Twice daily dosing
219382033|NCT00920543|DRUG|FP 250mcg|Twice daily dosing
219382034|NCT00920543|DRUG|FSC 100/50mcg|Twice daily dosing
219382035|NCT00920543|DRUG|FSC 250/50mcg|Twice daily dosing
219382036|NCT00920543|DRUG|FSC 500/50mcg|Twice daily dosing
219382037|NCT03980093|BEHAVIORAL|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
219382038|NCT03980093|BEHAVIORAL|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
219382039|NCT04074993|DRUG|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
219382040|NCT03014869|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
219382041|NCT00989326|OTHER|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
219382042|NCT00334750|OTHER|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
219382043|NCT01381523|DRUG|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
219382044|NCT01381523|DRUG|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
219382045|NCT05965570|DRUG|Brensocatib|Oral tablets.
219382046|NCT05965570|DRUG|Clarithromycin|Oral tablets.
219382047|NCT03928470|DRUG|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
219382048|NCT03168061|DRUG|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
219382049|NCT00602628|OTHER|questionnaire administration|
219382050|NCT00602628|PROCEDURE|adjuvant therapy|
219382051|NCT00602628|PROCEDURE|biopsy|
219382052|NCT00602628|PROCEDURE|computed tomography|
219382053|NCT00602628|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219382054|NCT00602628|PROCEDURE|magnetic resonance imaging|
219382055|NCT00602628|PROCEDURE|therapeutic conventional surgery|
219382056|NCT00602628|PROCEDURE|ultrasound imaging|
219382057|NCT00602628|RADIATION|radiation therapy|
219382058|NCT05186532|RADIATION|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
219382059|NCT05186532|OTHER|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
219382060|NCT04369339|OTHER|Colposcopy|
219382061|NCT04086940|DRUG|Esmolol|preventive
219382062|NCT02207387|DRUG|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
219382063|NCT02207387|BEHAVIORAL|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
219382064|NCT02207387|OTHER|Music|
219382065|NCT05325112|DIAGNOSTIC_TEST|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
219382066|NCT05951127|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer and regional lymph nodes dissection.
219382067|NCT04059809|DEVICE|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
219382068|NCT01519115|OTHER|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
219382069|NCT01519115|OTHER|usual care|one physical therapy visit in hospital following ACF surgery
219382070|NCT04372589|DRUG|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
219382071|NCT04777955|OTHER|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
219382072|NCT06485544|DRUG|Adebrelimab + Etoposide + Platinum-based Therapy|"Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
219382073|NCT06485544|DRUG|Etoposide + Platinum-based Therapy|"Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
219382074|NCT00354068|DRUG|imatinib mesylate|
219382075|NCT00354068|DRUG|temozolomide|
219382076|NCT00354068|OTHER|pharmacological study|
219382077|NCT01599351|RADIATION|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
219382078|NCT00875771|DRUG|Capecitabine+Irinotecan+Bevacizumab|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
219382079|NCT05823493|BEHAVIORAL|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
219382080|NCT05823493|DEVICE|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
219382081|NCT03102736|DRUG|Placebos|Placebo saline
219382082|NCT03102736|DRUG|Ketamine|0.5 mg/kg ketamine
219382083|NCT03102736|DRUG|Nitroprusside|0.5 mcg/kg nitroprusside
219382084|NCT02037919|OTHER|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
219382085|NCT02037919|OTHER|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
219382086|NCT00242177|DRUG|ACTOS (Pioglitazone)|
219382087|NCT04110249|PROCEDURE|Photoacoustic Imaging|Undergo PAI
219382088|NCT04110249|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
219382089|NCT00247481|DRUG|Gefitinib|
219382090|NCT00247481|DRUG|Docetaxel|
219382091|NCT06240598|PROCEDURE|Second Look Laparoscopy|Second Look Laparoscopy (SLL)
219382092|NCT00430807|DRUG|hydroxychloroquine/placebo|
219382093|NCT02079727|DRUG|chondroitin sulfate|
219382094|NCT02079727|DRUG|celecoxib|
219382095|NCT02079727|DRUG|placebo|
219382096|NCT05549388|OTHER|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
219382097|NCT01475955|DRUG|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
219382098|NCT01475955|DRUG|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
219382099|NCT01475955|DRUG|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
219382100|NCT01475955|DRUG|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
219382101|NCT01475955|DRUG|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
219382102|NCT01475955|DEVICE|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
219382103|NCT06487052|COMBINATION_PRODUCT|Standard Catheter-Directed Low Dose Thrombolysis|Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
219382104|NCT06487052|DRUG|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
219382105|NCT02872103|DRUG|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
219382106|NCT02872103|DRUG|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
219382107|NCT00294151|PROCEDURE|Vertebroplasty|
219382108|NCT01855230|DRUG|ASM-024|ASM-024 b.i.d for 14 days
219382109|NCT01855230|DRUG|Placebo|Placebo b.i.d. for 14 days
219382110|NCT01160731|DRUG|cisplatin|
219382111|NCT01160731|DRUG|etoposide phosphate|
219382112|NCT01160731|DRUG|panobinostat|
219382113|NCT01160731|OTHER|laboratory biomarker analysis|
219382114|NCT01160731|OTHER|pharmacological study|
219382115|NCT05611138|DIETARY_SUPPLEMENT|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
219382116|NCT03444337|DEVICE|Catheter Ablation|
219382117|NCT03795350|DRUG|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
219382118|NCT00861185|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
219382119|NCT00861185|DRUG|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
219382120|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Amygdala|Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
219382121|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex|Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
219382122|NCT01671410|DRUG|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
219382123|NCT01671410|DRUG|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
219382124|NCT00290472|DRUG|temsirolimus|
219382125|NCT04223089|DIAGNOSTIC_TEST|Near Infrared Spectroscopy|"The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues."
219382126|NCT06380998|DIETARY_SUPPLEMENT|whey protien|Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
219382127|NCT01718717|OTHER|Thoracic Epidural Analgesia (TEA)|
219382128|NCT01718717|OTHER|TEA followed by Intravenous morphine|
219382129|NCT03767738|DRUG|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
219382130|NCT01837082|DRUG|ferric carboxymaltose|
219382131|NCT01837082|DRUG|Placebo|
219382132|NCT06468202|DRUG|Aspirin 81 mg|Participants will be assigned to 81mg Aspirin
219382133|NCT06468202|DRUG|Aspirin 162 mg|Participants will be assigned to 162mg Aspirin
219382134|NCT05153408|DRUG|BLU-701|BLU-701 for oral administration
219382135|NCT05153408|DRUG|osimertinib|Osimertinib tablets for oral administration
219382136|NCT05153408|DRUG|carboplatin|IV infusion of carboplatin
219382137|NCT05153408|DRUG|pemetrexed|IV infusion of pemetrexed
219382138|NCT03648645|DEVICE|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
219382139|NCT03047005|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
219382140|NCT03047005|OTHER|Placebo|Placebo
219382141|NCT00450606|PROCEDURE|Balneotherapy and hydrotherapy|
219382142|NCT01599559|OTHER|observation|observation
219382143|NCT01599559|RADIATION|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
219382144|NCT02607527|DEVICE|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
219382145|NCT00987415|DRUG|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
219382146|NCT00987415|DRUG|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
219382147|NCT05050240|OTHER|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar\_CoolFlow\_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
219382148|NCT05050240|OTHER|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
219382149|NCT06280625|OTHER|Replacement of wheat flour by soyflour|The intervention consist in replacing a fraction of wheat flour by soyflour
219382150|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
219382151|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
219382152|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
219382153|NCT05922904|DRUG|Brentuximab vedotin|Given by IV (vein)
219382154|NCT05922904|DRUG|Doxorubicin Hydrochloride|Given by IV (vein)
219382155|NCT05922904|DRUG|Pembrolizumab|Given by IV (vein)
219382156|NCT05922904|DRUG|Dacarbazine|Given by IV (vein)
219382157|NCT01697215|OTHER|AirWave|
219382158|NCT05748379|PROCEDURE|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.
219382159|NCT05748379|PROCEDURE|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
219382160|NCT05320367|DRUG|Cannabis, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
219382161|NCT02406846|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
219382162|NCT02406846|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219382163|NCT03106233|PROCEDURE|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
219382164|NCT02555163|DEVICE|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
219382165|NCT02555163|DEVICE|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
219382166|NCT00340431|DRUG|MSP1(42)-FVO & MSP1(42)-3D7|
219382167|NCT00036335|DRUG|Duloxetine Hydrochloride|
219382168|NCT01929083|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
219382169|NCT01929083|DRUG|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
219382170|NCT01929083|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
219382171|NCT05225155|DRUG|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
219382172|NCT02233842|BEHAVIORAL|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
219382173|NCT04082221|OTHER|no intervention|no intervention
219382174|NCT01057277|DRUG|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
219382175|NCT04258618|BEHAVIORAL|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
219382176|NCT04258618|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
219382177|NCT02595034|DRUG|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
219382178|NCT02595034|DRUG|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
219382179|NCT02595034|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
219382180|NCT03981029|OTHER|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
219382181|NCT03981029|OTHER|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
219382182|NCT05102565|BEHAVIORAL|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
219382183|NCT02586805|DRUG|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
219382184|NCT02586805|DRUG|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
219382185|NCT02586805|DRUG|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
219382186|NCT02586805|DRUG|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
219382187|NCT04982133|DIETARY_SUPPLEMENT|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
219382188|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
219382189|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
219382190|NCT00000851|DRUG|Stavudine|
219382191|NCT00000851|DRUG|Didanosine|
219382192|NCT04295902|DEVICE|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
219382193|NCT04295902|DEVICE|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
219382194|NCT00367757|PROCEDURE|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
219382195|NCT00367757|PROCEDURE|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
219382196|NCT00367757|PROCEDURE|Combined approach for AF ablation|Combined trigger and substrate based approach
219382197|NCT01829048|DRUG|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
219382198|NCT01829048|DRUG|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
219382199|NCT01829048|DRUG|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
219382200|NCT01829048|DRUG|Placebo|Placebo Q12h
219382201|NCT03038022|DRUG|MGL-3196|Oral
219382202|NCT03038022|DRUG|Placebo|Oral
219382203|NCT00002103|DRUG|Trimetrexate glucuronate|
219382204|NCT00002103|DRUG|Leucovorin calcium|
219382205|NCT03270722|DEVICE|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
219382206|NCT03270722|PROCEDURE|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
219382207|NCT00504257|DRUG|Avastin|Day 1, every 21 day cycle
219382208|NCT00504257|DRUG|Docetaxel|Day 1, 8, every 21 day cycle
219382209|NCT02515240|BIOLOGICAL|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
219382210|NCT01033994|BIOLOGICAL|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
219382211|NCT03689218|DIETARY_SUPPLEMENT|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
219382212|NCT03689218|DIETARY_SUPPLEMENT|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
219382213|NCT05157633|OTHER|Controls|questionnaire food scale: HME data collection of food survey
219382214|NCT02453399|DEVICE|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
219382215|NCT04295187|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
219382216|NCT04295187|OTHER|Physical development and General Health|Physical development and General health examination
219382217|NCT04295187|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
219382218|NCT04219371|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219382219|NCT01945892|DRUG|Ozurdex|"\- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
219382220|NCT05326919|OTHER|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
219382221|NCT02504541|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
219382222|NCT00940706|DEVICE|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
219382223|NCT00940706|OTHER|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
219382224|NCT00940706|BEHAVIORAL|Monitoring physical activity|Activity monitoring with accelerometers
219382225|NCT03645291|DIAGNOSTIC_TEST|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
219382226|NCT04168086|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
219382227|NCT04168086|OTHER|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
219382228|NCT00497224|DRUG|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
219382229|NCT06103110|DEVICE|Photobiomodulation|Laser therapy using low level laser
219382230|NCT04249882|DRUG|Placebo|Matched to active medication
219382231|NCT04249882|DRUG|Naltrexone|50 mg once a day
219382232|NCT04249882|DRUG|Varenicline|1 mg twice a day
219382233|NCT00608088|BEHAVIORAL|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
219382234|NCT00608088|BEHAVIORAL|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
219382235|NCT04893668|OTHER|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
219382236|NCT04893668|OTHER|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
219382237|NCT02952716|BIOLOGICAL|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
219382238|NCT02952716|OTHER|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
219382239|NCT00634673|OTHER|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
219382240|NCT02440750|PROCEDURE|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
219382241|NCT02440750|DRUG|Dienogest|21 days administration of dienogest 2 mg/die
219382242|NCT02440750|DRUG|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
219188598|NCT06128655|OTHER|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
219382243|NCT05727774|OTHER|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
219382244|NCT05727774|OTHER|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
219382245|NCT00986960|DRUG|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
219382246|NCT00986960|DRUG|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
219382247|NCT02252367|DRUG|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
219382248|NCT02252367|OTHER|Placebo|Placebo tablet once daily for 12 weeks.
219382249|NCT00365781|DRUG|ISIS 113715|
219382250|NCT01608334|DRUG|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
219382251|NCT01608334|DRUG|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
219382252|NCT05239104|OTHER|No intervention|This is an observational study with no intervention
219382253|NCT02317510|PROCEDURE|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
219382254|NCT02317510|PROCEDURE|general anesthesia|General anesthesia for laparoscopic cholecystectomy
219382255|NCT04937699|DRUG|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
219382256|NCT04937699|DRUG|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
219382257|NCT02375022|DRUG|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
219382258|NCT00552266|DRUG|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
219382259|NCT00787007|DRUG|S-equol|capsule, oral, single dose
219382260|NCT00787007|DRUG|Placebo|capsule, oral, single dose
219382261|NCT01476930|PROCEDURE|cupping and serkangabin syrup|wet cupping serkangabin syrup
219382262|NCT01476930|DRUG|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
219382263|NCT01412437|DIETARY_SUPPLEMENT|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
219382264|NCT01412437|DRUG|sapropterin dihydrochloride|20 mg/kg for 4 months
219382265|NCT01412437|DRUG|sapropterin dihydrochloride|
219382266|NCT00500071|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
219382267|NCT05516329|DRUG|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
219382268|NCT00472303|DRUG|Tapentadol Extended Release|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
219382269|NCT00472303|DRUG|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
219382270|NCT00472303|DRUG|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
219382271|NCT01519726|DRUG|Midazolam|
219382272|NCT02365428|BEHAVIORAL|Physical activity text messages|
219382273|NCT05782088|PROCEDURE|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
219382274|NCT05782088|PROCEDURE|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
219382275|NCT02904226|DRUG|JTX-2011|Specified dose on specified days
219382276|NCT02904226|DRUG|Nivolumab|Specified dose on specified days
219382277|NCT02904226|DRUG|Ipilimumab|Specified dose on specified days
219382278|NCT02904226|DRUG|Pembrolizumab|Specified dose on specified days
219382279|NCT05170360|DIAGNOSTIC_TEST|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
219382280|NCT01906437|DEVICE|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
219382281|NCT05983393|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed
219000995|NCT05538221|DIAGNOSTIC_TEST|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
219000996|NCT00719134|DRUG|Maxalt|anti-migraine drug
219000997|NCT00719134|DRUG|placebo pill|placebo pills
219000998|NCT00719134|DRUG|placebo pills|placebo pills
219382282|NCT05983393|PROCEDURE|Control|Erector spinae plane block was not applied.
219382283|NCT03182738|BEHAVIORAL|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
219382284|NCT03182738|BEHAVIORAL|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
219382285|NCT03934762|BIOLOGICAL|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
219382286|NCT03934762|BIOLOGICAL|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
219382287|NCT03934762|BIOLOGICAL|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
219382288|NCT04329026|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
219382289|NCT04329026|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
219382290|NCT03835663|DIAGNOSTIC_TEST|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
219382291|NCT01043640|DRUG|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
219382292|NCT01043640|DRUG|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
219382293|NCT01043640|DRUG|Busulfan|Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
219382294|NCT01043640|PROCEDURE|Allogeneic stem cell transplantation|Administered \> 24 hours after last dose of busulfan.
219382295|NCT01043640|DRUG|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV\_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
219382296|NCT01043640|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
219382297|NCT00304473|DRUG|Quetiapine fumarate|
219382298|NCT00728416|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
219382299|NCT00728416|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
219382300|NCT00527202|DRUG|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
219382301|NCT04421651|BEHAVIORAL|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
219382302|NCT01912118|DRUG|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
219382303|NCT01912118|DRUG|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
219382304|NCT01251523|BEHAVIORAL|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
219382305|NCT01251523|BEHAVIORAL|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
219382306|NCT05669521|DRUG|TK-112690|TK112690 treatment Post 5-FU chemotherapy
219382307|NCT05669521|DRUG|Placebo|Placebo treatment Post 5-FU chemotherapy
219382308|NCT00296322|DRUG|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
219382309|NCT00527449|DRUG|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
219382310|NCT06021743|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
219382311|NCT06021743|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
219382312|NCT06021743|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
219382313|NCT06021743|DIAGNOSTIC_TEST|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
219382314|NCT04937257|OTHER|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
219382315|NCT04937257|OTHER|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
219382316|NCT02389881|DRUG|TAK-058|TAK-058 Solution
219382317|NCT02389881|DRUG|TAK-058 Placebo|TAK-058 placebo-matching solution
219382318|NCT02456220|DEVICE|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
219382319|NCT06075823|DEVICE|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
219382320|NCT06075823|OTHER|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
219382321|NCT02013219|DRUG|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
219382322|NCT02013219|DRUG|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
219382323|NCT02013219|DRUG|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
219382324|NCT03879291|OTHER|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
219382325|NCT03984409|DIETARY_SUPPLEMENT|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
219382326|NCT06379334|DIAGNOSTIC_TEST|Urine test|Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
219382327|NCT05363917|DRUG|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
219382328|NCT05363917|DRUG|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
219382329|NCT01696812|PROCEDURE|electrode position|
219382330|NCT05600127|DRUG|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
219382331|NCT02566512|OTHER|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
219382332|NCT02566512|OTHER|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
219382333|NCT01244737|DRUG|[18F] FLT|\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
219382334|NCT05830383|BEHAVIORAL|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
219382335|NCT03506503|PROCEDURE|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
219382336|NCT02304003|OTHER|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
219382337|NCT02304003|OTHER|Standard Care|Standard follow up in primary care.
219382338|NCT03547050|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
219382339|NCT03547050|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
219382340|NCT01667848|DEVICE|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
219382341|NCT01667848|DEVICE|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
219382342|NCT00030784|DRUG|ifosfamide|
219382343|NCT00030784|DRUG|pegylated liposomal doxorubicin hydrochloride|
219382344|NCT02204865|DEVICE|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
219382345|NCT00874380|OTHER|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
219382346|NCT01243931|DRUG|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
219382347|NCT04579861|OTHER|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
219382348|NCT01642355|BEHAVIORAL|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
219382349|NCT01642355|BEHAVIORAL|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
219382350|NCT02059824|DEVICE|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
219382351|NCT06116305|OTHER|No intervention|No intervention
219188599|NCT06439043|OTHER|EMDR Psychotherapy|EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
219382352|NCT03384992|OTHER|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
219382353|NCT03384992|OTHER|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
219382354|NCT03384992|OTHER|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
219382355|NCT03384992|OTHER|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
219382356|NCT03384992|OTHER|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
219382357|NCT03963973|DRUG|RDN-929 oral capsule|low, medium and high dose
219382358|NCT03963973|DRUG|Placebo oral capsule|matching placebo dose
219382359|NCT02712775|DRUG|Minocycline (yes/no)|
219382360|NCT02712775|DRUG|Placebo|Saline
219382361|NCT02180386|BEHAVIORAL|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
219382362|NCT02087566|DRUG|600 mg linezolid|
219382363|NCT04073615|DRUG|Rivoceranib|Film-coated tablets
219382364|NCT04073615|DRUG|Trifluridine/Tipiracil|Film-coated tablets
219382365|NCT03252782|DEVICE|Herbst Appliance|Acrylic Splint Herbst Appliance
219382366|NCT03252782|DEVICE|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
219382367|NCT04460430|DRUG|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
219382368|NCT03571464|DEVICE|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
219382369|NCT04352829|OTHER|VIDEO-TRAINING-SESSION ABOUT MDI USE|The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
219000999|NCT03933345|OTHER|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
219382370|NCT06487156|DRUG|Nivolumab + ipilimumab|As per product label
219382371|NCT00343902|DRUG|Crataegus Special Extract WS 1442|
219382372|NCT00356915|DRUG|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
219382373|NCT00356915|DRUG|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
219382374|NCT00356915|DRUG|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
219382375|NCT00674531|PROCEDURE|Artery resection|Artery resection
219382376|NCT01225354|DRUG|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
219382377|NCT01091129|DEVICE|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
219382378|NCT01627704|DRUG|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
219382379|NCT00509106|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
219382380|NCT00509106|DRUG|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
219382381|NCT00509106|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
219382382|NCT05152212|BIOLOGICAL|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
219382383|NCT03736044|DRUG|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
219382384|NCT06356740|BIOLOGICAL|Blood sample|"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
219382385|NCT06356740|DRUG|Treatment :Abacavir 600 mg/lamivudine 300 mg|Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
219382386|NCT06356740|OTHER|Lupus Impact Tracker questionnaire|Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
219382387|NCT04425655|DRUG|Fludarabine|30mg/m2 days 1 through 5
219382388|NCT04425655|DRUG|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
219382389|NCT01596491|PROCEDURE|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
219382390|NCT00488631|BIOLOGICAL|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
219382391|NCT00488631|BIOLOGICAL|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
219382392|NCT00488631|BIOLOGICAL|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
219382393|NCT00488631|BIOLOGICAL|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
219382394|NCT01873950|DRUG|Ranolazine|
219382395|NCT01873950|DRUG|Dofetilide|
219382396|NCT01873950|DRUG|Verapamil|
219382397|NCT01873950|DRUG|Quinidine sulfate|
219382398|NCT01873950|DRUG|Placebo|
219382399|NCT05219812|DRUG|BAY2395840|Tablet, intake orally.
219382400|NCT05219812|DRUG|Placebo for BAY2395840|Tablet, intake orally.
219382401|NCT02712502|DRUG|Levofloxacin|"* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
219382402|NCT02712502|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
219382403|NCT03457298|DEVICE|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
219382404|NCT03457298|DEVICE|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
219382405|NCT03398772|BEHAVIORAL|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
219382406|NCT03785080|OTHER|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
219382407|NCT03785080|OTHER|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
219382408|NCT00816803|PROCEDURE|Autologous bone marrow transplant|
219382409|NCT00816803|PROCEDURE|Physical therapy|
219382410|NCT01539629|DEVICE|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
219382411|NCT04808687|DRUG|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
219382412|NCT04767425|RADIATION|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
219382413|NCT03693872|DRUG|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
219382414|NCT03693872|DRUG|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
219382415|NCT03834948|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
219382416|NCT03834948|DRUG|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
219382417|NCT03834948|DRUG|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
219382418|NCT05762341|OTHER|PRESSURE INJURY PREVENTION TRAINING|PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
219382419|NCT04874272|OTHER|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
219382420|NCT01876589|DEVICE|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
219382421|NCT01876589|DEVICE|Xience Prime|Drug eluting metallic stent
219382422|NCT03797287|DEVICE|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
219382423|NCT03797287|PROCEDURE|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
219382424|NCT01663649|BEHAVIORAL|Deprexis|web-based treatment program for depression
219382425|NCT01663649|BEHAVIORAL|Wait-list|the wait-list group receives Deprexis after 6 month
219382426|NCT02201810|BEHAVIORAL|Rate reduction intervention|
219382427|NCT02201810|BEHAVIORAL|Recycling Group|
219382428|NCT02201810|BEHAVIORAL|Choice Group|
219382429|NCT02201810|BEHAVIORAL|Proactive QL|
219382430|NCT00226642|DRUG|Sertralin|
219382431|NCT00226642|BEHAVIORAL|Cognitive-behavioral therapy|
219382432|NCT00226642|DRUG|Placebo|
219382433|NCT00226642|BEHAVIORAL|Non-specific supporting group therapy|
219382434|NCT02844738|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
219382435|NCT04299529|DIAGNOSTIC_TEST|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
219382436|NCT04554368|PROCEDURE|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
219382437|NCT01187225|DRUG|Fibrinogen concentrate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
219382438|NCT01187225|DRUG|Cryoprecipitate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
219382439|NCT05942690|PROCEDURE|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
219382440|NCT00071773|PROCEDURE|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
219382441|NCT00071773|PROCEDURE|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
219382442|NCT03642561|DEVICE|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
219382443|NCT03642561|DEVICE|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
219382444|NCT05453799|DRUG|Vudalimab|Given IV
219382445|NCT01723306|GENETIC|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
219382446|NCT01567436|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
219382447|NCT04184648|OTHER|no interventions|no intervention
219382448|NCT01144754|DRUG|Rituximab|Calculated per patient
219382449|NCT06075303|BEHAVIORAL|Modified Cycles|
219382450|NCT00730236|DRUG|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
219382451|NCT02317731|OTHER|Straw|Bowel preparation ingestion with a straw
219382452|NCT02160418|BEHAVIORAL|Financial Incentives|
219382453|NCT02160418|BEHAVIORAL|Cognitive Incentives|
219382454|NCT02160418|BEHAVIORAL|Financial and Cognitive Incentives|
219382455|NCT05434546|DRUG|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
219382456|NCT02039947|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
219382457|NCT02039947|DRUG|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
219382458|NCT06024252|DRUG|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
219382459|NCT05251545|OTHER|Pulmonary vein isolation|Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
219382460|NCT00644267|BEHAVIORAL|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
219382461|NCT05939284|DRUG|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
219382462|NCT05939284|DRUG|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
219382463|NCT01772134|DRUG|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
219382464|NCT01772134|DRUG|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
219382465|NCT01772134|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
219382466|NCT01772134|DRUG|Placebo|Inhalation Powder, Placebo
219382467|NCT06404190|COMBINATION_PRODUCT|Diode laser and 3% hydrogen peroxide|"Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes."
219382468|NCT05749588|DRUG|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
219382469|NCT05749588|DRUG|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
219382470|NCT05749588|DRUG|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
219382471|NCT05749588|DRUG|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
219382472|NCT05749588|DRUG|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
219382473|NCT05749588|DRUG|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
219382474|NCT05749588|DRUG|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
219382475|NCT05749588|DRUG|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
219382476|NCT05749588|DRUG|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
219382477|NCT05749588|DRUG|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
219382478|NCT05749588|DRUG|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
219382479|NCT05749588|DRUG|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
219382480|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
219382481|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
219382482|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
219382483|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
219382484|NCT04702230|DIAGNOSTIC_TEST|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
219382485|NCT03486314|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
219382486|NCT03486314|DRUG|Rifampin|Rifampin capsules.
219382487|NCT03486314|DRUG|Docetaxel|Docetaxel intravenous infusion.
219382488|NCT03486314|DRUG|Carboplatin|Carboplatin intravenous infusion.
219382489|NCT03486314|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
219382490|NCT01047410|OTHER|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
219382491|NCT01047410|OTHER|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
219382492|NCT00138840|DRUG|STA-5326 mesylate|
219382493|NCT02680288|DRUG|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
219382494|NCT02680288|DRUG|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
219382495|NCT02680288|OTHER|Oral Placebo|Oral inert treatment
219382496|NCT03928873|DEVICE|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
219382497|NCT03928873|DEVICE|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
219382498|NCT03928873|DEVICE|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
219382499|NCT02354950|DRUG|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
219382500|NCT05076968|PROCEDURE|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
219382501|NCT04392986|OTHER|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
219382502|NCT00659438|DRUG|ZD6474 (Vandetanib)|300mg orally, once daily
219382503|NCT00659438|DRUG|Bicalutamide|150mg orally, once daily
219382504|NCT00659438|DRUG|Placebo|orally, once daily
219382505|NCT00763893|DRUG|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
219382506|NCT00763893|DRUG|Losartan|50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
219382507|NCT03133715|PROCEDURE|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
219382508|NCT03133715|PROCEDURE|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
219382509|NCT00410891|DRUG|gatifloxacin|
219382510|NCT00155402|DRUG|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
219382511|NCT01177215|PROCEDURE|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
219382512|NCT04650633|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
219382513|NCT05596266|BIOLOGICAL|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
219382514|NCT04003610|DRUG|Pemigatinib|13.5 mg once a day orally
219382515|NCT04003610|DRUG|Pembrolizumab|200 mg Q3W intravenously
219382516|NCT04003610|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
219382517|NCT04003610|DRUG|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
219382518|NCT03502122|OTHER|VR rehabilitation for motor function|rehabilitation for motor function
219382519|NCT00889096|DRUG|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
219382520|NCT00889096|DRUG|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
219382521|NCT01523821|DRUG|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
219382522|NCT02310373|OTHER|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
219382523|NCT00206167|DRUG|Budesonide/formoterol pMDI|
219382524|NCT00206167|DRUG|Formoterol Turbuhaler|
219382525|NCT01349309|BEHAVIORAL|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
219382526|NCT01798914|DRUG|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
219382527|NCT02814721|DEVICE|Sonic Window ultrasound device|
219382528|NCT00872222|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
219382529|NCT04410874|BIOLOGICAL|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
219382530|NCT04522869|BIOLOGICAL|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
219382531|NCT06003959|OTHER|Routine nursing care|Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
219382532|NCT06003959|OTHER|breastfeeding support system|The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
219382533|NCT05212051|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
219382534|NCT05212051|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
219382535|NCT06491134|DRUG|Liposomal Irinotecan Hydrochloride|liposomal irinotecan With Cisplatin and Concurrent Radiotherapy
219382536|NCT03588689|PROCEDURE|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
219001000|NCT03547180|BEHAVIORAL|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
219188600|NCT06439043|OTHER|Online EMDR Psychotherapy|Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
219382537|NCT03588689|DRUG|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
219382538|NCT03700957|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
219382539|NCT03700957|OTHER|placebo|placebo
219382540|NCT00629395|BEHAVIORAL|Captain's Log Computer Program|12 Computer Program
219382541|NCT03441126|OTHER|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
219382542|NCT03643692|DEVICE|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
219382543|NCT03831087|DIAGNOSTIC_TEST|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
219382544|NCT03831087|DIAGNOSTIC_TEST|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
219382545|NCT06061445|COMBINATION_PRODUCT|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
219382546|NCT06105138|DIETARY_SUPPLEMENT|200mg Cannabidiol oral solution|"200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
219382547|NCT06105138|DIETARY_SUPPLEMENT|30mg Cannabidiol oral solution|"30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
219382548|NCT06105138|DIETARY_SUPPLEMENT|Placebo|"Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%."
219382549|NCT02698189|DRUG|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
219382550|NCT04730895|DRUG|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
219382551|NCT04730895|DRUG|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
219382552|NCT04730895|COMBINATION_PRODUCT|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
219382553|NCT04730895|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
219382554|NCT04730895|BIOLOGICAL|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
219382555|NCT00109421|BEHAVIORAL|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
219382556|NCT05068856|DRUG|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
219382557|NCT00264407|DRUG|Hormone Replacement Therapy - HRT|
219382558|NCT03471026|DIAGNOSTIC_TEST|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
219382559|NCT06544109|DRUG|venetoclax|patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
219382560|NCT05502289|DEVICE|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
219382561|NCT05502289|DEVICE|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
219382562|NCT06002464|PROCEDURE|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
219382563|NCT06002464|PROCEDURE|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
219382564|NCT04756934|DRUG|HX008|HX008: 200mg, Q3W
219382565|NCT04756934|DRUG|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
219382566|NCT01122329|DIETARY_SUPPLEMENT|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
219382567|NCT01122329|DIETARY_SUPPLEMENT|Placebo|
219382568|NCT04658069|OTHER|no specific interventions|no specific interventions
219382569|NCT00968734|DIETARY_SUPPLEMENT|colecalciferol|50.000UI single oral dose
219382570|NCT01250821|DRUG|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
219382571|NCT06062719|DRUG|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
219382572|NCT06062719|DRUG|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
219382573|NCT03369795|DRUG|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
219382574|NCT03369795|OTHER|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
219382575|NCT01349348|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
219382576|NCT01349348|DRUG|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
219382577|NCT01349348|DRUG|placebo|tablet, 7.5/15mg , Qd, 7days.
219382578|NCT01851837|OTHER|Exercise time|Continuous training, Interval training
219382579|NCT02956655|OTHER|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
219382580|NCT02956655|DRUG|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
219382581|NCT02956655|OTHER|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
219382582|NCT02956655|BEHAVIORAL|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
219382583|NCT02956655|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
219382584|NCT04259502|PROCEDURE|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
219382585|NCT04259502|PROCEDURE|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
219557875|NCT05978791|PROCEDURE|collection of venous blood or arterial blood|"1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
219001001|NCT03547180|BEHAVIORAL|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
219188601|NCT03669523|DRUG|Denosumab-nivolumab combination|"* Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks"
219382586|NCT01605474|OTHER|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
219382587|NCT01605474|OTHER|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
219382588|NCT03467906|OTHER|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
219382589|NCT05647993|DRUG|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
219382590|NCT05647993|DRUG|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
219382591|NCT05647993|DRUG|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
219382592|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
219382593|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
219382594|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
219382595|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
219382596|NCT04654507|DRUG|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
219382597|NCT04654507|DRUG|Placebo|Placebo
219382598|NCT04837560|DEVICE|ElastiMed's SACS 2.0|A wearable medical device that improve circulation using smart materials
219382599|NCT01137214|DEVICE|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
219382600|NCT03845530|DIAGNOSTIC_TEST|Blood Test|Blood test taken and sent for laboratory analysis
219382601|NCT04728945|PROCEDURE|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
219382602|NCT04728945|PROCEDURE|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
219382603|NCT05110066|PROCEDURE|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
219382604|NCT05110066|PROCEDURE|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
219382605|NCT03119649|DRUG|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
219382606|NCT03119649|DRUG|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
219382607|NCT03119649|DRUG|Placebo|Matching oral tablet(s) containing placebo
219382608|NCT03119649|DRUG|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
219382609|NCT03119649|DRUG|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
219382610|NCT05639764|DEVICE|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
219382611|NCT05639764|DEVICE|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
219382612|NCT03529487|DRUG|Oxymetazoline|Oxymetazoline gel applied intra-analy
219382613|NCT05822856|OTHER|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
219382614|NCT02219230|DEVICE|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
219382615|NCT02219230|DEVICE|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
219382616|NCT02219230|DEVICE|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
219382617|NCT05485103|DRUG|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
219382618|NCT03862456|OTHER|Azithromycin|azithromycin (500 mg/24h/3 days)
219382619|NCT03862456|OTHER|Metronidazole|metronidazole (500 mg/8h/7 days)
219382620|NCT05002309|BEHAVIORAL|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
219382621|NCT05002309|DRUG|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
219382622|NCT06056284|BEHAVIORAL|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
219382623|NCT02031094|OTHER|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
219382624|NCT02333227|DIETARY_SUPPLEMENT|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
219382625|NCT01954823|DEVICE|e-diary|"The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created"
219001002|NCT03547180|BEHAVIORAL|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
219001003|NCT00822835|BIOLOGICAL|ILV-095|
219382626|NCT01211691|DRUG|KB004, Monoclonal Antibody|
219382627|NCT03436264|OTHER|MRI|fMRI
219557876|NCT03545880|OTHER|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
219001004|NCT00822835|BIOLOGICAL|Placebo|
219382628|NCT01151072|DRUG|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
219382629|NCT02730806|BEHAVIORAL|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
219382630|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
219382631|NCT00831051|DRUG|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
219382632|NCT00831051|DRUG|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
219382633|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
219382634|NCT00831051|DRUG|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
219382635|NCT00831051|DRUG|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
219382636|NCT05435521|BEHAVIORAL|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
219382637|NCT05435521|OTHER|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
219382638|NCT05435521|OTHER|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
219382639|NCT03343964|DIAGNOSTIC_TEST|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
219382640|NCT05888116|DEVICE|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
219382641|NCT05888116|DEVICE|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
219382642|NCT05004675|BIOLOGICAL|lerodalcibep|300 mg
219382643|NCT05004675|DRUG|Inclisiran|284 mg
219382644|NCT05771922|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
219382645|NCT01639183|DEVICE|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
219382646|NCT01639183|OTHER|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
219382647|NCT04863716|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
219382648|NCT04863716|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
219382649|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
219382650|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
219382651|NCT00816036|BEHAVIORAL|Smoking Cessation Guideline Implementation|"1\. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
219382652|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
219382653|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
219382654|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
219382655|NCT05124275|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
219382656|NCT04396587|DRUG|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
219382657|NCT04396587|DRUG|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
219382658|NCT04396587|DRUG|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
219382659|NCT04396587|DRUG|normal Saline|normal saline 10ml
219382660|NCT03433625|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
219382661|NCT01624194|DRUG|Oxytocin nasal spray|24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
219382662|NCT01624194|DRUG|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
219382663|NCT03234114|DRUG|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
219382664|NCT03234114|DRUG|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
219382665|NCT03234114|DRUG|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
219382666|NCT03212261|BEHAVIORAL|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
219382667|NCT00499551|DEVICE|Iontophoresis second generation Eyegate II device|
219382668|NCT02270567|DEVICE|NETest|Non-invasive blood test
219382669|NCT00388466|DEVICE|GALILEO|
219382670|NCT00274430|DRUG|dexamethasone 8 mg bid|
219382671|NCT00274430|DRUG|tadalafil 10mg bid|
219382672|NCT02981290|DRUG|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
219382673|NCT02981290|DRUG|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
219382674|NCT02981290|DRUG|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
219382675|NCT02981290|DRUG|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
219382676|NCT00000889|DRUG|Aldesleukin|
219382677|NCT05596981|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
219557877|NCT03545880|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
219557878|NCT06626542|OTHER|resistance and aerobic training exercises|resistance and aerobic training exercises
219557879|NCT05993390|DRUG|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
219557880|NCT05993390|DRUG|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
219557881|NCT06223724|DEVICE|STOP|Software to measure impedance telemetry data
219001005|NCT05213650|OTHER|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
219382678|NCT02765841|DRUG|Lomitapide|
219382679|NCT02739412|BIOLOGICAL|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
219382680|NCT02659449|DEVICE|made to measure compression gloves|Patients achieve tests with compression glove
219382681|NCT02659449|DEVICE|Compression bandaging|Patients achieve tests with compression bandaging
219382682|NCT02659449|OTHER|Free Hands|Patients achieve tests without device
219382683|NCT05893134|OTHER|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
219382684|NCT06380244|OTHER|anesthesia without opioids|Opioid free general anesthesia
219382685|NCT04686890|PROCEDURE|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
219382686|NCT04686890|PROCEDURE|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
219382687|NCT00002700|DRUG|asparaginase|
219382688|NCT00002700|DRUG|cyclophosphamide|
219382689|NCT00002700|DRUG|cytarabine|
219382690|NCT00002700|DRUG|daunorubicin hydrochloride|
219382691|NCT00002700|DRUG|dexamethasone|
219382692|NCT00002700|DRUG|doxorubicin hydrochloride|
219382693|NCT00002700|DRUG|leucovorin calcium|
219382694|NCT00002700|DRUG|mercaptopurine|
219382695|NCT00002700|DRUG|methotrexate|
219382696|NCT00002700|DRUG|mitoxantrone hydrochloride|
219382697|NCT00002700|DRUG|prednisolone|
219382698|NCT00002700|DRUG|prednisone|
219382699|NCT00002700|DRUG|therapeutic hydrocortisone|
219382700|NCT00002700|DRUG|vincristine sulfate|
219382701|NCT00002700|PROCEDURE|allogeneic bone marrow transplantation|
219382702|NCT00002700|PROCEDURE|autologous bone marrow transplantation|
219382703|NCT00002700|RADIATION|radiation therapy|
219382704|NCT03304457|DRUG|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
219382705|NCT03304457|DRUG|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
219382706|NCT05232825|DRUG|Ocrelizumab IV|IV Injection
219382707|NCT05232825|DRUG|Ocrelizumab SC|SC Injection
219382708|NCT05232825|DRUG|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
219382709|NCT05232825|DRUG|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
219382710|NCT05232825|DRUG|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
219382711|NCT05232825|DRUG|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
219382712|NCT03945279|DRUG|BIIB100|Administered as specified in the treatment arm.
219382713|NCT03945279|DRUG|Placebo|Administered as specified in the treatment arm.
219382714|NCT05195632|DRUG|Encorafenib|Hard capsule
219382715|NCT05195632|DRUG|Binimetinib|Film-coated tablet
219557882|NCT06223724|DEVICE|MAESTRO|Software to measure impedance telemetry data
219557883|NCT05691153|DRUG|ThisCART19A with Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
219382716|NCT05066984|OTHER|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
219382717|NCT01579695|DRUG|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
219382718|NCT00843986|DRUG|conivaptan|Premix bag
219382719|NCT00843986|DRUG|placebo|Premix bag
219382720|NCT06994819|DEVICE|niostem headset (Active)|The niostem headset is a non-invasive electronic stimulation device designed to reduce hair loss and improve hair growth. It delivers low-level electrical stimulation through brush electrodes that contact the scalp. Used once daily for 30 minutes for 6 months. Sessions are guided via a smartphone app.
219382721|NCT06994819|DEVICE|Sham niostem headset (Placebo)|he sham niostem headset is visually identical to the active device but does not deliver electrical stimulation. Used once daily for 30 minutes for 6 months. Allows for blinding and placebo-controlled comparison.
219382722|NCT00777543|OTHER|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
219382723|NCT00777543|DIETARY_SUPPLEMENT|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
219382724|NCT00777543|DIETARY_SUPPLEMENT|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
219382725|NCT05768789|DIETARY_SUPPLEMENT|Buoy Electrolyte|Each subject consumed Beverage 1 (Buoy Hydration Drops) at a dose containing 600 mg/L of Na+ over 4 hours while measuring urine output over 6 hours.
219382726|NCT05768789|OTHER|Water only|Each subjected ingested 1 L of Kirkland® bottled water at a rate of 6.25% of the total amount of water every 15 minutes for four hours
219382727|NCT05768789|DIETARY_SUPPLEMENT|Nuun Electrolyte|Each subject consumed 1 L of water with two dissolved Nuun® Sport Hydration tabs (Nuun, Seattle, WA), containing 600 mg of sodium, over 30 minutes (2 equal volumes every 15 minutes) while measuring urine output over 6 hours (
219382728|NCT06489678|DIAGNOSTIC_TEST|Robotic Assisted Bronchoscopy|Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.
219382729|NCT01084252|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219382730|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219382731|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
219382732|NCT04980703|DEVICE|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
219382733|NCT04980703|DEVICE|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
219382734|NCT04980703|OTHER|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
219382735|NCT06060938|OTHER|Risk stratified arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every 1-4 years according to the risk-group)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~* Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~* Receive a screening schedule recommendation."
219382736|NCT06060938|OTHER|Control arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every second year)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
219382737|NCT06288594|BEHAVIORAL|Application Plus Online Therapist Support Group|Participants in the therapist-supported group will receive weekly 20-30 minute online sessions for five weeks, with content based on a semi-structured manual. After 80% completion of the psychoeducation module, the coping module becomes available, and similarly, the exposure module follows. These sessions will be conducted in adherence to a structured manual, with the therapist introducing the module of the week, guiding through exercises, assigning homework, and reviewing the previous assignments. Sessions include module introductions, exercises, homework assignments, and application use review. Feedback and PCL-5 scores guide post-session recommendations. A random 40% of sessions will undergo fidelity checks by doctoral-level psychologists.
219557884|NCT05691153|DRUG|ThisCART19A with Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
219382738|NCT06288594|BEHAVIORAL|Application Only Group|"Participants allocated to this group will have access to the TraumaRelief mobile application over a five-week period, with the exception of the online module component. The application's deployment strategy ensures a structured progression through its features: participants will gain access to the subsequent modules only after completing 80% of the preceding module. Initially, they will engage with the psychoeducation module; upon completion of at least 80% of this module, the coping with symptoms module will become available. Similarly, successful engagement with 80% of the coping module will unlock the imaginary exposure module. This sequential module access is designed to reinforce the acquisition of knowledge and skills in a stepwise manner, paralleling the structure provided to the TraumaRelief Mobile Application with Therapist Support group, yet without the additional therapist interaction."
219382739|NCT04909463|DEVICE|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
219382740|NCT02047955|DEVICE|Shoulder Arthroplasty|"Data will be collected for commercially available Sponsor devices. These systems treat both the humeral and glenoid side of the shoulder joint. The following products will be included in the study in the geographies where they are commercially available.~* Aequalis Ascend Flex Convertible Shoulder System~* Pyrocarbon Humeral Head (used with Aequalis Ascend Flex)~* Simpliciti Shoulder Prosthesis~* Aequalis Reversed Fracture Prosthesis~* Aequalis PerFORM Glenoid~* Aequalis PerFORM+ Glenoid~* Aequalis PerFORM Reversed Glenoid~Devices previously included, but discontinued under clinical investigation plan (CIP) version 4.0:~* Aequalis Resurfacing Head~* Aequalis Ascend Anatomic Shoulder System~* Aequalis IM Humeral Nail - Short and Long~* ORTHOLOC™ SPS (Shoulder Plating System)~* Aequalis Reversed II Shoulder System~* Aequalis Adjustable Reversed Prosthesis~* Aequalis Flex Revive Shoulder System"
219382741|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
219382742|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
219382743|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
219382744|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
219382745|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
219382746|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
219382747|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
219382748|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
219382749|NCT04294368|OTHER|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
219382750|NCT06469970|DRUG|Glucose 30% Intravenous Solution|"Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients."
219382751|NCT05614219|OTHER|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
219382752|NCT04098601|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
219188602|NCT05450510|OTHER|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
219382753|NCT04163809|DEVICE|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
219382754|NCT06044285|OTHER|Low UP (meals provided)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
219382755|NCT06044285|OTHER|Low UP (self-guided)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
219382756|NCT06044285|OTHER|Active Control|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
219382757|NCT03020186|OTHER|Physical activity|
219382758|NCT03020186|OTHER|Physical activity+ MED diet|
219382759|NCT03020186|OTHER|Physical activity+green MED diet|\*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
219382760|NCT00452621|PROCEDURE|blood draw|
219382761|NCT05076422|DRUG|BI 3006337|BI 3006337
219382762|NCT05076422|DRUG|Placebo|Placebo
219382763|NCT03008551|DRUG|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
219382764|NCT03008551|DRUG|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
219382765|NCT00188448|DEVICE|MRI|
219382766|NCT00292773|PROCEDURE|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
219382767|NCT00775307|DRUG|PAZOPANIB|400 mg/day (24 weeks)
219382768|NCT00775307|DRUG|Placebo|Placebo 400 mg/day (24 weeks)
219382769|NCT01719575|DRUG|Motilitone|
219188603|NCT05450510|OTHER|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
219382770|NCT01719575|DRUG|Placebo|
219382771|NCT02125994|PROCEDURE|Interscalene nerve block|
219382772|NCT04237883|BEHAVIORAL|Standard communication email|This is the base communication that all physicians will receive.
219382773|NCT04237883|BEHAVIORAL|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
219382774|NCT04237883|BEHAVIORAL|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
219382775|NCT02045199|DEVICE|Tested product : V0111 cream|Application twice a day during 28 days
219382776|NCT02045199|DEVICE|Placebo|Application twice a day during 28 days
219382777|NCT03149835|OTHER|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
219382778|NCT00676039|DRUG|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
219188604|NCT06185985|DRUG|SPN-812|SPN-812 (200mg to 600mg once daily)
219382779|NCT00676039|DRUG|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
219382780|NCT00676039|DRUG|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
219382781|NCT00676039|DRUG|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
219382782|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
219382783|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
219382784|NCT03528681|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
219382785|NCT00955110|DRUG|Oxymorphone ER|15mg or 30mg
219382786|NCT00955110|DRUG|Oxycodone CR|30mg or 60mg
219382787|NCT00955110|DRUG|Placebo|The placebo was a sugar pill.
219382788|NCT00955110|DRUG|Hydromorphone|8 mg
219382789|NCT04072640|DRUG|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
219382790|NCT04072640|DRUG|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
219382791|NCT04072640|DRUG|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
219382792|NCT01195025|DRUG|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
219382793|NCT01195025|DRUG|colloid|Infusion of starch 10 ml/kg over 30 min
219382794|NCT01195025|DRUG|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
219382795|NCT01195025|DEVICE|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
219382796|NCT03390231|COMBINATION_PRODUCT|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
219382797|NCT06103552|BEHAVIORAL|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
219382798|NCT00920309|DRUG|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
219382799|NCT00920309|OTHER|Standard of Care-Placebo|
219382800|NCT06298097|DEVICE|Connectivity measures|Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
219382801|NCT01673880|DRUG|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
219382802|NCT00942201|DRUG|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
219382803|NCT00942201|DRUG|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
219382804|NCT05004467|OTHER|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
219382805|NCT04907604|DEVICE|A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace|It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
219382806|NCT04512885|OTHER|Survey|Survey via questionnaire
219382807|NCT02975869|OTHER|Standard Leukemia Care|
219382808|NCT02975869|OTHER|Palliative Care|
219382809|NCT02725255|DIETARY_SUPPLEMENT|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
219188605|NCT04228042|DRUG|Infigratinib|Given PO
219382810|NCT02725255|DRUG|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
219382811|NCT02725255|DIETARY_SUPPLEMENT|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
219382812|NCT06146114|DIAGNOSTIC_TEST|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
219382813|NCT02981472|DRUG|Apixaban|Specified dose on specified days
219382814|NCT02981472|DRUG|Vitamin K Antagonist (VKA)|Specified dose on specified days
219382815|NCT02981472|DRUG|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
219382816|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
219382817|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
219382818|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
219188606|NCT04228042|OTHER|Quality-of-Life Assessment|Ancillary studies
219382819|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
219382820|NCT00839163|DRUG|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
219382821|NCT00001515|DEVICE|virtual bronchoscopy|
219382822|NCT04191668|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
219382823|NCT04154540|OTHER|Motion analysis|Gait and posture recording
219382824|NCT03636828|DIAGNOSTIC_TEST|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
219382825|NCT05906446|OTHER|Multicomponent (Exercise + Protein Supplementation)|"* Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised"
219557885|NCT03911115|OTHER|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
219557886|NCT03235141|DRUG|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
219382826|NCT02123329|BEHAVIORAL|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
219382827|NCT02123329|OTHER|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
219382828|NCT01728259|DRUG|pomalidomide|Given PO
219382829|NCT01728259|DRUG|bortezomib|Given IV
219382830|NCT01728259|DRUG|dexamethasone|Given PO
219382831|NCT01728259|OTHER|Laboratory Biomarker Analysis|Correlative studies
219382832|NCT02907944|BEHAVIORAL|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services"
219382833|NCT03255278|BIOLOGICAL|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
219382834|NCT03255278|BIOLOGICAL|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
219382835|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
219382836|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
219382837|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
219382838|NCT04430348|DRUG|PTX-35|Monoclonal antibody PTX-35
219382839|NCT05414968|DEVICE|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
219382840|NCT06512701|OTHER||This study is an observational study without any intervention measures.
219382841|NCT04038775|BEHAVIORAL|Volunteering|Subjects recommended volunteer by their provider.
219382842|NCT03341403|DIETARY_SUPPLEMENT|Probiotical®/Bactecal®|"Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
219382843|NCT03341403|OTHER|Placebo|pills containing placebo
219382844|NCT06394219|PROCEDURE|traditional transperitoneal laparoscopic pyelolithotomy|Performing anterior Pyelotomy.
219382845|NCT06394219|PROCEDURE|modified transperitoneal laparoscopic pyelolithotomy|Performing posterior pyelotomy
219382846|NCT03478241|DEVICE|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
219382847|NCT03478241|DEVICE|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
219382848|NCT03478241|DEVICE|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
219382849|NCT03715465|DRUG|Melatonin 0.5 MG|Melatonin tablet
219382850|NCT03715465|OTHER|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
219382851|NCT01737814|DRUG|Saline|
219382852|NCT01737814|DRUG|MST-188|
219382853|NCT00904124|DIETARY_SUPPLEMENT|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
219382854|NCT01671670|OTHER|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
219382855|NCT01671670|OTHER|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
219382856|NCT01057264|DRUG|HAI Abraxane|Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
219382857|NCT01057264|DRUG|Gemcitabine|Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
219382858|NCT01057264|DRUG|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
219382859|NCT01057264|DRUG|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
219557887|NCT03235141|DRUG|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
219382860|NCT04902885|DRUG|Trilaciclib, carboplatin, etoposide，or Topotecan|Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
219382861|NCT04902885|DRUG|placebo, carboplatin, etoposide，or Topotecan|placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
219382862|NCT02652819|DRUG|FG-4592|
219382863|NCT02652819|DRUG|Placebo|
219382864|NCT00410371|DRUG|Lamotrigine|Lamotrigine
219382865|NCT00410371|DRUG|GI267119|25 mg ODT
219382866|NCT05733481|DEVICE|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
219382867|NCT02094469|DRUG|Cilostazol|Oral, Bid, 24 weeks
219382868|NCT04336150|OTHER|Hypopressive exercises|See information included in arm/group descriptions.
219382869|NCT04336150|OTHER|Hypopressive maneuver|See information included in arm/group descriptions.
219382870|NCT04336150|OTHER|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
219382871|NCT04336150|OTHER|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
219382872|NCT03356847|DEVICE|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
219382873|NCT00082823|BIOLOGICAL|ziv-aflibercept|
219382874|NCT04642144|OTHER|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
219382875|NCT04642144|OTHER|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
219382876|NCT00756002|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
219382877|NCT00756002|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
219382878|NCT03040050|OTHER|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
219382879|NCT03040050|OTHER|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
219382880|NCT00666185|DRUG|Micafungin|IV
219382881|NCT00666185|DRUG|Fluconazole|IV
219382882|NCT02454114|OTHER|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
219382883|NCT02454114|OTHER|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
219382884|NCT04112758|OTHER|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
219382885|NCT04194931|BIOLOGICAL|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
219382886|NCT03624998|OTHER|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
219382887|NCT02417415|OTHER|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
219382888|NCT02417415|OTHER|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
219382889|NCT06553781|DRUG|Temozolomide、Fruquintinib、Cadonilimab|"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."
219382890|NCT06962475|OTHER|Podiatric advice|A podiatrist with 11 years of clinical experience will take the negative foot impressions using a semi-weightbearing method with a foam box for both groups to ensure adequate blinding of participants. Then, the foam boxes of the experimental group will be scanned so that the FOs can be 3D printed. Both groups will receive identical clinical guideline-based information and support at the beginning of the trial. The instructions will be as follows: (1) undertake a familiarization protocol of 14 consecutive full days (2) wear the FOs (customized or sham) at all time when they are standing (targeted minimum of 5 hours per day), (3) avoid positions that cause the metatarsophalangeal joints to dorsiflex (e.g., squatting or tiptoeing), (4) mechanical stress load management according to the tissue stress model, (5) do not walk barefoot and (6) wear shoes with good cushioning in which the FOs will be properly placed.
219557888|NCT03685409|DRUG|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
219557889|NCT03685409|DRUG|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
219382891|NCT06962475|OTHER|Customized foot orthoses|The customized foot orthoses will be manufactured with a Nylon-11 shell with 6° medially wedged forefoot-rearfoot posts (2.6 mm if the participants' weight (PW) is inferior or equal to 45 kg; 3.2 mm if 45\<PW\<100 kg; 4.0 mm if PW\>100 kg), a full-length 3 mm Poron top cover and a metatarsal pad (15 shore A) located 5 mm proximal to the metatarsal heads.
219382892|NCT06962475|OTHER|Sham foot orthoses|The molded sham FOs will be manufactured from 3 mm ethylene vinyl acetate. They will have an identical top cover material, color and a similar shape than the customized FOs, however, they will provide negligible mechanical support, considering the very low stiffness of their medial arch. The only impact of these FOs on plantar pressure is under the heel. These devices have been used as a sham condition in previous trials and a study has validated them as being credible.
219382893|NCT06392919|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
219382894|NCT05809687|DRUG|DKP21102_C|Placebo
219382895|NCT05809687|DRUG|DKP21102_B|Treatment
219382896|NCT05809687|DRUG|DKP21102_A|Active Control
219382897|NCT05796661|OTHER|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
219382898|NCT02132390|DRUG|Goserelin|
219382899|NCT02132390|DRUG|Toremifene|
219382900|NCT05206110|DRUG|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
219382901|NCT05206110|DRUG|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
219382902|NCT01735110|PROCEDURE|transfemoral intervention (TFI)|
219382903|NCT01735110|PROCEDURE|Transradial intervention|
219382904|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
219382905|NCT06353711|BEHAVIORAL|CA-LINC Intervention|Participants received the CA-LINC intervention.
219382906|NCT06353711|BEHAVIORAL|Treatment as Usual|Participants received Treatment as Usual
219382907|NCT05379504|BEHAVIORAL|Standard Health Education|Participants randomized to the standard health education arm will receive the intervention at month 1 and then months 3, 6, 9, and 12 (coinciding with the quarterly interviews). The participant will use the tablet and telehealth platform to complete the interview and education session with research staff. The content of these sessions will be focused on helping the participant (and family member/caregiver as appropriate) understand their health data, assisting them with any technology issues and providing the participant with education on their condition(s) and any requested resources. Research staff will will also provide any additional health education if there are changes to conditions or new diagnoses after an outside provider visit.
219382908|NCT05379504|BEHAVIORAL|Self Management|"The self-management intervention will be delivered over the course of a year. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN and SW) for 12 visits per participant. The team (OT, RN and SW) will meet twice during the first 2 months to determine a lead interventionist based on the participant's SMART goals and areas of concern. The lead interventionist will have three additional sessions with the participant and will be the point-person for sensor system alerts and messages. Goal Attainment Scaling \[83\] will be administered during the quarterly interview to assess participant progress on SMART goals. This measure is administered collectively with the participant, provides further accountability, offers opportunities to the participant for reflection on progress, and is a concrete measure of success of the self-management intervention."
219382909|NCT05357690|PROCEDURE|Stellate ganglion block|Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
219382910|NCT05357690|DRUG|Bupivacaine|10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
219382911|NCT05357690|DRUG|Placebo|10 mL of saline injected in the plane of the right stellate ganglion
219188607|NCT04228042|OTHER|Questionnaire Administration|Ancillary studies
219188608|NCT04228042|PROCEDURE|Surgical Procedure|Undergo surgery
219382912|NCT03031210|DRUG|Amoxicillin|(90 mg/kg/day) twice daily
219382913|NCT01464697|DRUG|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
219382914|NCT01464697|DRUG|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
219382915|NCT04896853|BIOLOGICAL|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
219382916|NCT06533384|DRUG|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
219382917|NCT06533384|DRUG|9 cycles of Camrelizumab as adjuvant therapy.|9 cycles of Camrelizumab as adjuvant therapy.
219382918|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
219382919|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
219382920|NCT05751369|BEHAVIORAL|Education plus Support|Brief behavioral support for using TECW Tracker
219382921|NCT04164212|DRUG|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
219382922|NCT05036278|BIOLOGICAL|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
219382923|NCT04899271|DRUG|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
219382924|NCT04899271|OTHER|Placebo|Placebo was administered orally with the same scheme of administration of LDX to preserve blinding
219001006|NCT05213650|OTHER|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
219382925|NCT02416869|PROCEDURE|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
219382926|NCT02416869|PROCEDURE|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
219382927|NCT02416869|DRUG|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
219382928|NCT02416869|DRUG|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
219382929|NCT02416869|PROCEDURE|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
219382930|NCT02416869|PROCEDURE|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
219382931|NCT03511365|BIOLOGICAL|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
219382932|NCT00167479|DRUG|risperidone (Risperdal)|
219382933|NCT01315574|DRUG|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
219382934|NCT01315574|DRUG|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
219382935|NCT00644592|DRUG|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
219382936|NCT00644592|DRUG|Fenofibrate|160 mg/day orally for 4 weeks
219382937|NCT00900796|OTHER|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
219382938|NCT00332904|DRUG|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
219382939|NCT00332904|DRUG|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
219382940|NCT02207114|OTHER|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
219188609|NCT05494593|DRUG|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
219188610|NCT05494593|DRUG|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m\^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
219382941|NCT06030934|DRUG|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (\<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
219382942|NCT04117750|DIETARY_SUPPLEMENT|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
219382943|NCT04452643|BIOLOGICAL|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
219382944|NCT04452643|OTHER|Placebo|Placebo is a solution on sodium chloride at 0.9%
219382945|NCT00235521|DRUG|aerosolized iloprost|
219382946|NCT03160729|DRUG|Dexamethasone|pre-operative, single-shot injection
219382947|NCT01621932|PROCEDURE|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
219382948|NCT01621932|PROCEDURE|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
219382949|NCT02945982|DRUG|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
219382950|NCT02945982|DRUG|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
219382951|NCT04376619|OTHER|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
219382952|NCT04376619|OTHER|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
219382953|NCT03947541|OTHER|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
219382954|NCT03947541|OTHER|No Bracing|Participants will not wear a brace in the study.
219382955|NCT03094130|OTHER|News items with spin|Interpretation of news items with spin
219382956|NCT03094130|OTHER|News items without spin|Interpretation of news items without spin
219382957|NCT01859403|GENETIC|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
219382958|NCT01859403|GENETIC|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
219382959|NCT01120639|DRUG|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
219382960|NCT01120639|PROCEDURE|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
219382961|NCT03917121|DEVICE|Jet injector|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
219382962|NCT03917121|DEVICE|Needle attached dental syringe|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
219382963|NCT01926587|DRUG|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
219382964|NCT01926587|DRUG|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
219382965|NCT01839474|DEVICE|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
219382966|NCT02852226|OTHER|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
219382967|NCT02852226|BEHAVIORAL|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
219382968|NCT02852226|BEHAVIORAL|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
219382969|NCT03014648|DRUG|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
219382970|NCT00811226|DRUG|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
219382971|NCT00147927|BEHAVIORAL|Sequential emails and web support|
219382972|NCT05698186|DRUG|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
219382973|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
219382974|NCT05698186|DRUG|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
219382975|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
219382976|NCT04996693|DIAGNOSTIC_TEST|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
219382977|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
219382978|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
219382979|NCT04917874|BIOLOGICAL|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
219382980|NCT01606462|DRUG|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
219382981|NCT01183494|DRUG|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
219382982|NCT02750410|DRUG|Dulaglutide|Administered subcutaneously (SC)
219382983|NCT02750410|DRUG|Placebo|Administered SC
219382984|NCT01886664|DRUG|sevoflurane|
219382985|NCT01886664|DRUG|Desflurane|
219382986|NCT01860170|DRUG|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
219382987|NCT01860170|DRUG|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
219382988|NCT01860170|DRUG|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
219382989|NCT03823729|DEVICE|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
219382990|NCT01531725|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
219382991|NCT02844790|DRUG|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
219382992|NCT03467178|DRUG|Decitabine|Nucleic Acid Synthesis Inhibitor
219382993|NCT03467178|DRUG|Carboplatin|Chemotherapy medication
219382994|NCT03467178|DRUG|Pegylated Liposomal Doxorubicin|Chemotherapy medication
219382995|NCT03467178|DRUG|Gemcitabine|Chemotherapy medication
219382996|NCT03467178|DRUG|Paclitaxel|Chemotherapy medication
219382997|NCT03851601|OTHER|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
219188611|NCT05494593|DRUG|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
219382998|NCT05343195|OTHER|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
219382999|NCT05343195|OTHER|Control|Control intervention: conventional physiotherapy after hip replacement
219383000|NCT00481481|DRUG|tacrolimus|immunosuppression
219383001|NCT04386889|OTHER|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
219383002|NCT05212025|DRUG|Adavosertib|Taken Orally
219383003|NCT05212025|DRUG|Gemcitabine|Intravenous Infusion
219383004|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using a vial and syringe.
219383005|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using AI.
219383006|NCT04696744|BIOLOGICAL|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
219383007|NCT02167477|DEVICE|Macintosh laryngoscopy|Tracheal intubation
219383008|NCT02167477|DEVICE|Storz C-MAC, standard blade|Tracheal intubation
219383009|NCT02167477|DEVICE|Storz C-MAC, D-BLADE|Tracheal intubation
219383010|NCT02048514|DEVICE|The Nellix® EndoVascular Aneurysm Sealing System|
219383011|NCT06075940|DEVICE|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
219383012|NCT04599426|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 ."
219383013|NCT02888626|DEVICE|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
219383014|NCT00864734|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
219383015|NCT00864734|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
219383016|NCT02152969|DRUG|Telmisartan|
219383017|NCT02152969|DRUG|Amlodipine|
219383018|NCT02152969|DRUG|Chlorthalidone|
219383019|NCT03596164|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
219383020|NCT03596164|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
219383021|NCT03596164|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
219383022|NCT03596164|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
219383023|NCT04112914|BEHAVIORAL|Post-concussion education for families|An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
219383024|NCT01457248|DEVICE|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
219383025|NCT01457248|DEVICE|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
219383026|NCT04457921|OTHER|deep tissue massage|DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
219383027|NCT03669705|PROCEDURE|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
219383028|NCT03679221|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
219383029|NCT02931448|DEVICE|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
219383030|NCT03427073|DRUG|ALM201|Drug: ALM201 administered subcutaneously
219383031|NCT01358383|DRUG|naproxen|250mg, oral dose
219383032|NCT01358383|DRUG|esomeprazole|20mg, oral dose
219383033|NCT04048577|DRUG|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
219383034|NCT00508729|DRUG|Qingyi granules|
219188612|NCT05494593|DRUG|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
219383035|NCT05523492|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
219383036|NCT01660815|DRUG|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
219383037|NCT01748227|BEHAVIORAL|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
219383038|NCT01955616|DRUG|RM-131|
219383039|NCT01955616|DRUG|Placebo|
219383040|NCT02955329|DRUG|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
219383041|NCT02955329|DRUG|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
219383042|NCT02955329|DEVICE|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
219383043|NCT01564979|DRUG|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
219383044|NCT01564979|DRUG|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
219383045|NCT01486238|DRUG|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
219383046|NCT00332787|DRUG|Fluoxetine|
219383047|NCT00759603|DRUG|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
219383048|NCT00759603|DRUG|Rituximab|Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
219383049|NCT02835495|BEHAVIORAL|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
219383050|NCT02835495|BEHAVIORAL|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
219383051|NCT00669773|DRUG|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
219383052|NCT00669773|DRUG|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
219383053|NCT04551443|BIOLOGICAL|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
219383054|NCT04551443|BIOLOGICAL|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
219383055|NCT02318602|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219383056|NCT04300348|DEVICE|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
219383057|NCT04300348|OTHER|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
219383058|NCT00693706|BIOLOGICAL|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
219383059|NCT00693706|BIOLOGICAL|Fluarix|IM injection on Day 0
219383060|NCT04147949|DRUG|AV-101|Oral capsules taken twice daily for 14 days
219383061|NCT04147949|DRUG|Placebo|Oral capsules taken twice a day for 14 days
219383062|NCT00942006|DRUG|doxycycline|100 mg bid, 14 days
219383063|NCT00942006|DRUG|ceftriaxone|2g x 1 iv, 14 days
219383064|NCT05025943|OTHER|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
219383065|NCT05025943|OTHER|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
219383066|NCT04242537|DEVICE|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
219383067|NCT04242537|DEVICE|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
219383068|NCT06229509|DEVICE|Effective noninvasive ventilation|Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
219383069|NCT06229509|DEVICE|Sham noninvasive ventilation|Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
219383070|NCT05786170|DIAGNOSTIC_TEST|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
219383071|NCT03615027|BEHAVIORAL|Dementia-specific advance care planning|see detailed description
219383072|NCT04603248|DRUG|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
219383073|NCT02631161|OTHER|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
219383074|NCT02631161|OTHER|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
219383075|NCT05421754|DEVICE|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
219383076|NCT05038761|DEVICE|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
219383077|NCT05038761|PROCEDURE|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
219383078|NCT01318616|OTHER|Strength training of the hip adductors|Adductor strength training
219383079|NCT01994343|OTHER|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
219383080|NCT06448156|DIAGNOSTIC_TEST|"cardiac arrest and sudden death"|"Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated"
219383081|NCT04687124|DIETARY_SUPPLEMENT|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
219383082|NCT04687124|OTHER|standard care|No specified intervention
219383083|NCT03880812|OTHER|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
219383084|NCT03593694|BEHAVIORAL|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
219383085|NCT03593694|BEHAVIORAL|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
219383086|NCT03593694|BEHAVIORAL|TECH DMBAT Other|Technology delivered diabetes education
219383087|NCT02580058|BIOLOGICAL|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
219383088|NCT02580058|DRUG|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
219383089|NCT04758793|OTHER|blood samples|3 citrated tubes and 3 EDTA tubes
219383090|NCT04758793|OTHER|biopsy of abdominal paroie|a muscle biopsy will be performed on the incision area
219383091|NCT05125653|PROCEDURE|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
219383092|NCT05125653|PROCEDURE|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
219383093|NCT00117078|DRUG|Aranesp®|
219383094|NCT05382481|DIAGNOSTIC_TEST|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
219383095|NCT05382481|DIAGNOSTIC_TEST|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
219383096|NCT05382481|DIAGNOSTIC_TEST|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
219383097|NCT04837911|DEVICE|Spirobank Smart|Patients using the Spirobank Smart
219383098|NCT01152138|DEVICE|Open cells stent|Cobalt Chromium Stent with open cell design
219383099|NCT01152138|DEVICE|Closed Cells Stent|Cobalt Chromium stent with closed cell design
219383100|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
219383101|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
219383102|NCT01697332|DRUG|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
219383103|NCT00683943|DRUG|Lithium Carbonate|
219383104|NCT03436589|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
219383105|NCT03306147|BEHAVIORAL|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
219383106|NCT01733329|DRUG|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
219383107|NCT01733329|DRUG|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
219383108|NCT03950986|OTHER|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
219383109|NCT05218629|DRUG|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
219383110|NCT00288210|PROCEDURE|Primary angioplasty in acute myocardial infarction|
219383111|NCT05689060|OTHER|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
219383112|NCT05689060|OTHER|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
219383113|NCT00542828|BIOLOGICAL|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
219383114|NCT01843556|DRUG|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
219383115|NCT03759652|BEHAVIORAL|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
219383116|NCT06382753|OTHER|Gingival inflammation|Patients were scored for their status of gingival inflammation using Gingival Index and Bleeding on Probing Scores
219383117|NCT06266637|OTHER|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
219383118|NCT06266637|OTHER|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
219383119|NCT03228186|DRUG|Pevonedistat|25mg/m2 days 1, 3, 5
219383120|NCT03228186|DRUG|Docetaxel|75mg/m2 day 1
219383121|NCT05537181|DEVICE|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
219383122|NCT01548664|OTHER|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
219383123|NCT01548664|OTHER|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
219383124|NCT03784430|PROCEDURE|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
219383125|NCT03784430|PROCEDURE|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
219383126|NCT02016066|DRUG|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
219383127|NCT02016066|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
219383128|NCT03671083|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
219383129|NCT00181077|DRUG|2% buffered hypertonic saline administration|
219383130|NCT04246047|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
219383131|NCT04246047|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
219383132|NCT04246047|DRUG|Bortezomib|Proteasome Inhibitor
219383133|NCT04246047|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
219383134|NCT02481505|DRUG|Chloroprocaine HCl 1%|Intrathecal Route
219383135|NCT04768582|DIAGNOSTIC_TEST|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
219383136|NCT05888896|OTHER|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
219383137|NCT05888896|OTHER|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
219383138|NCT01559103|BIOLOGICAL|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
219383139|NCT01559103|BIOLOGICAL|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
219383140|NCT05139030|DRUG|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
219383141|NCT05139030|DRUG|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
219383142|NCT03655444|DRUG|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
219383143|NCT03655444|DRUG|Nivolumab|Nivolumab is commercially available
219383144|NCT03655444|PROCEDURE|Tumor biopsy|"* Phase II patients only~* If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
219383145|NCT03655444|PROCEDURE|Peripheral blood|"* Phase II patients only~* Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression."
219383146|NCT03655444|OTHER|EORTC QLQ-30|"* Phase II patients only~* Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
219383147|NCT04216173|OTHER|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
219383148|NCT05585749|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
219383149|NCT05547945|BEHAVIORAL|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
219383150|NCT05547945|BEHAVIORAL|Control group|The control group received as usual care.
219383151|NCT01917123|DRUG|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
219383152|NCT05740150|DEVICE|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
219383153|NCT05740150|DEVICE|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
219383154|NCT05937477|OTHER|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
219383155|NCT02502864|DRUG|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
219383156|NCT02502864|DRUG|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
219383157|NCT02502864|OTHER|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
219383158|NCT04096534|PROCEDURE|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
219383159|NCT04096534|PROCEDURE|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
219383160|NCT03772327|DEVICE|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
219383161|NCT03772327|BEHAVIORAL|Routine adherence counseling|Participants will be provided with routine adherence counseling
219383162|NCT04576312|DRUG|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
219383163|NCT04576312|DRUG|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
219383164|NCT04324853|DIAGNOSTIC_TEST|Microscopy ( Urine filtration), UCAA test, qPCR,|Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
219383165|NCT04324853|DIAGNOSTIC_TEST|Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,|Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
219383166|NCT01770340|BIOLOGICAL|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
219383167|NCT01770340|PROCEDURE|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
219383168|NCT05623566|DEVICE|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
219383169|NCT03632642|DRUG|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
219383170|NCT03632642|DRUG|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
219383171|NCT04233424|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
219383172|NCT04233424|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
219383173|NCT03517436|DEVICE|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
219383174|NCT05320939|DRUG|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
219383175|NCT04378426|DRUG|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
219383176|NCT04378426|DRUG|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
219383177|NCT04378426|DRUG|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
219383178|NCT04378426|DRUG|Oxygen|inhaled gas
219383179|NCT04378426|DRUG|Saline|Placebo infusion
219383180|NCT00157300|DRUG|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
219383181|NCT03580330|OTHER|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
219383182|NCT00001325|DRUG|18 FDG|
219383183|NCT04903860|DEVICE|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
219383184|NCT04903860|DEVICE|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
219383185|NCT02016807|DEVICE|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
219383186|NCT02375776|OTHER|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
219001007|NCT05213650|OTHER|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
219383187|NCT01113528|OTHER|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
219383188|NCT01113528|DRUG|Sugar pill|3 times daily
219001008|NCT05213650|OTHER|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
219383189|NCT05356793|DRUG|SCH-1|Novel anti-infective eyedrop
219383190|NCT05356793|DRUG|Placebo|SCH-1 vehicle minus active components eyedrop
219383191|NCT01044355|DEVICE|CPAP|6 weeks treatment with fixed CPAP
219383192|NCT01044355|DEVICE|APAP|6 weeks of treatment with auto-titrating positive airway pressure
219383193|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
219383194|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
219383195|NCT05095389|DEVICE|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
219383196|NCT05095389|OTHER|standard care|standard care
219383197|NCT05095389|OTHER|Placebo|placebo
219383198|NCT06468371|DRUG|Dopamine Agonist (Ropinirole)|Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
219383199|NCT06468371|OTHER|Excercise training|Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
219383200|NCT03206502|DEVICE|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
219383201|NCT04751500|PROCEDURE|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
219383202|NCT04751500|BEHAVIORAL|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
219383203|NCT04751500|DRUG|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
219383204|NCT04751500|DRUG|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
219383205|NCT04751500|PROCEDURE|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
219383206|NCT01254344|DRUG|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
219001009|NCT02603094|PROCEDURE|clear fluid ingestion|drinking of clear fluid in preoperative period
219001010|NCT03529916|OTHER|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
219001011|NCT00482612|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
219383207|NCT01254344|DRUG|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
219383208|NCT01254344|DRUG|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
219383209|NCT01254344|DRUG|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
219383210|NCT00789126|DRUG|VX-509|
219383211|NCT05947019|DEVICE|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
219383212|NCT05947019|DEVICE|Glasses|Optometry with glasses as a routine treatment
219383213|NCT04848805|PROCEDURE|liver transplantation|total hepatectomy material was examined by pathology laboratory
219383214|NCT03022461|OTHER|Long term follow-up|
219383215|NCT02341612|OTHER|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
219383216|NCT02341612|OTHER|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
219383217|NCT02341612|OTHER|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
219383218|NCT02341612|OTHER|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
219383219|NCT02341612|OTHER|passive recovery|The control group was exposed to treatment after the EIMD protocol.
219383220|NCT01982630|DRUG|MK-8521|
219383221|NCT01982630|DRUG|Liraglutide|
219383222|NCT01982630|DRUG|Placebo|
219383223|NCT05829057|BIOLOGICAL|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
219383224|NCT05829057|BIOLOGICAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
219383225|NCT01978561|BIOLOGICAL|Post dosing with NT100|
219383226|NCT01978561|OTHER|Post dosing with Placebo|
219383227|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
219383228|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
219383229|NCT00444184|DRUG|Travoprost/timolol fixed combination, travoprost|
219383230|NCT01059149|DEVICE|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
219383231|NCT02812511|PROCEDURE|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
219383232|NCT06085157|OTHER|electronic diary|a smartphone application for self-documentation of drinking pattern
219383233|NCT02070432|DRUG|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
219383234|NCT05221190|PROCEDURE|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
219383235|NCT05221190|PROCEDURE|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
219383236|NCT04439786|DRUG|placebo|the control group will be given the same volume of saline.
219383237|NCT04439786|DRUG|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
219383238|NCT04990076|PROCEDURE|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
219001012|NCT00482612|DRUG|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
219383239|NCT03165396|DRUG|Propofol|Propofol is the most common clinical anesthetics.
219383240|NCT03165396|DRUG|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
219383241|NCT02237027|BIOLOGICAL|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
219383242|NCT02237027|BIOLOGICAL|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
219383243|NCT00070447|BIOLOGICAL|rituximab|
219383244|NCT00070447|DRUG|cyclophosphamide|
219383245|NCT00070447|DRUG|doxorubicin hydrochloride|
219383246|NCT00070447|DRUG|prednisone|
219383247|NCT00070447|DRUG|vincristine sulfate|
219383248|NCT00070447|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219383249|NCT03451448|DIAGNOSTIC_TEST|PET/MRI|PET/MRI with USPIO contrast
219383250|NCT03451448|DIAGNOSTIC_TEST|MRI|MRI with USPIO contrast
219383251|NCT03310125|DRUG|Colchicine|Over-encapsulated 0.5mg tablet twice daily
219383252|NCT03310125|DRUG|Placebo|Matching placebo capsule twice daily
219383253|NCT05821543|DRUG|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
219383254|NCT05821543|DRUG|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
219383255|NCT06367322|DRUG|Statin|"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."
219383256|NCT03459040|DRUG|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
219383257|NCT04847986|BEHAVIORAL|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
219383258|NCT04847986|BEHAVIORAL|Control group|The control group will receive care as usual with psychoeducation materials provided.
219383259|NCT04636918|DRUG|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
219383260|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
219383261|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
219383262|NCT00986349|DEVICE|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
219383263|NCT01585649|DRUG|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
219383264|NCT02299934|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
219383265|NCT02299934|DIAGNOSTIC_TEST|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
219383266|NCT05367661|DRUG|CHK336|Tablet
219383267|NCT05367661|DRUG|Placebo|Tablet
219383268|NCT05015712|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
219383269|NCT00561353|DRUG|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
219383270|NCT00561353|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
219383271|NCT00561353|DRUG|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
219383272|NCT00561353|DRUG|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
219383273|NCT03142100|DEVICE|cochlear implants and hearing aids|speech perception tests and bimodal fitting
219383274|NCT04205552|DRUG|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
219383275|NCT04205552|DRUG|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
219383276|NCT02511210|BEHAVIORAL|regional anesthesia|preoperative anxiety
219383277|NCT02511210|BEHAVIORAL|general anesthesia|preoperative anxiety
219383278|NCT06372977|DIAGNOSTIC_TEST|kappa index|CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
219383279|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
219383280|NCT03732924|DIAGNOSTIC_TEST|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
219383281|NCT02601144|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
219383282|NCT05954039|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
219383283|NCT05954039|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
219383284|NCT03425383|DIAGNOSTIC_TEST|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
219383285|NCT03431948|DRUG|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
219383286|NCT03431948|DRUG|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
219383287|NCT03431948|DRUG|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
219383288|NCT03431948|RADIATION|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
219383289|NCT02974244|DRUG|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
219383290|NCT02974244|DRUG|basal insulin|basal insulin treatment in the customary clinical care in USA
219383291|NCT05295277|OTHER|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
219383292|NCT01273818|DRUG|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
219383293|NCT01273818|DRUG|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
219383294|NCT01273818|DRUG|Gentamicin|80 mg gentamicin application intraoperatively
219383295|NCT02634515|DRUG|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
219383296|NCT02634515|DRUG|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
219383297|NCT03815175|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
219001013|NCT06152978|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
219001014|NCT06152978|DRUG|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
219383298|NCT03815175|DRUG|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
219383299|NCT05833880|BEHAVIORAL|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
219383300|NCT06316427|DRUG|Autologous CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
219383301|NCT06316427|DRUG|Prior-HSCT donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
219383302|NCT06316427|DRUG|New donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
219383303|NCT06244927|PROCEDURE|Replantation surgery|Surgery
219383304|NCT05817201|DRUG|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
219383305|NCT05817201|DRUG|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
219383306|NCT05817201|RADIATION|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
219383307|NCT05498298|DEVICE|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
219383308|NCT04255134|DRUG|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
219383309|NCT04255134|DRUG|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
219383310|NCT02032628|BEHAVIORAL|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
219383311|NCT01663441|DRUG|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
219383312|NCT01663441|DRUG|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
219383313|NCT01663441|DRUG|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
219383314|NCT01663441|DRUG|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
219383315|NCT01636037|DRUG|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
219383316|NCT04813510|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
219383317|NCT04813510|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
219383318|NCT05324215|PROCEDURE|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
219383319|NCT05324215|DEVICE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
219383320|NCT05124938|DIAGNOSTIC_TEST|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
219383321|NCT03180762|DRUG|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
219383322|NCT03180762|DRUG|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
219383323|NCT03180762|DRUG|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
219383324|NCT03180762|DRUG|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
219383325|NCT03180762|DRUG|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
219001015|NCT01366521|BIOLOGICAL|Mepolizumab|Monoclonal antibody
219383326|NCT03180762|DRUG|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
219383327|NCT03180762|DRUG|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
219383328|NCT03180762|DRUG|Placebo|Matching placebo will be administered.
219383329|NCT00866437|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
219001016|NCT03804047|OTHER|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
219001017|NCT00684307|DRUG|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
219001018|NCT00684307|DRUG|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
219001019|NCT00684307|DRUG|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
219001020|NCT03898154|DRUG|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
219383330|NCT00866437|DRUG|Skin test panel|"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
219383331|NCT05207462|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
219001021|NCT03898154|DRUG|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
219383332|NCT05033210|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
219383333|NCT05033210|BEHAVIORAL|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
219383334|NCT05033210|BEHAVIORAL|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte \& Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
219383335|NCT05033210|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
219383336|NCT00820040|DEVICE|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
219383337|NCT02058381|DRUG|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
219383338|NCT02058381|DRUG|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
219383339|NCT06217991|PROCEDURE|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
219383340|NCT00749632|DRUG|oxybutynin|low dose oxybutynin administered daily
219383341|NCT00749632|DRUG|oxybutynin|middle dose oxybutynin administered daily
219383342|NCT00749632|DRUG|oxybutynin|high dose oxybutynin administered daily
219383343|NCT01666132|OTHER|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
219383344|NCT01666132|OTHER|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
219383345|NCT01666132|OTHER|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
219383346|NCT00772395|DRUG|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
219383347|NCT00772395|DRUG|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
219383348|NCT04898452|OTHER|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
219001022|NCT00759031|DRUG|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
219001023|NCT00759031|DRUG|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
219001024|NCT02067169|BIOLOGICAL|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
219383349|NCT00789204|OTHER|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
219383350|NCT00789204|OTHER|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
219383351|NCT03460418|OTHER|Phone contact|Assessment of the different outcomes by means of a phone contact
219383352|NCT01420185|GENETIC|RNA analysis|
219383353|NCT01420185|GENETIC|gene expression analysis|
219383354|NCT01420185|GENETIC|microarray analysis|
219383355|NCT01420185|GENETIC|reverse transcriptase-polymerase chain reaction|
219383356|NCT01420185|OTHER|laboratory biomarker analysis|
219383357|NCT04432428|DRUG|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
219383358|NCT02252978|DRUG|ciprofloxacin|Given PO
219383359|NCT02252978|OTHER|placebo|Given PO
219191752|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
219383360|NCT02252978|OTHER|quality-of-life assessment|Ancillary studies
219383361|NCT02252978|OTHER|laboratory biomarker analysis|Correlative studies
219383362|NCT04934735|PROCEDURE|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
219383363|NCT02493751|DRUG|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
219383364|NCT02493751|DRUG|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
219383365|NCT02183454|DEVICE|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
219383366|NCT03195140|DEVICE|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
219383367|NCT06017323|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
219383368|NCT06017323|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
219383369|NCT06017323|DRUG|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
219383370|NCT06017323|DRUG|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
219383371|NCT03968510|PROCEDURE|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
219383372|NCT01824602|DRUG|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
219383373|NCT01824602|DRUG|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
219383374|NCT01824602|DRUG|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
219383375|NCT01824602|DRUG|Placebo|Placebo sugar pills
219383376|NCT04396457|DRUG|Pembrolizumab|Human PD-1 Monoclonal antibody
219383377|NCT04396457|DRUG|Pemetrexed|Antineoplastic antimetabolite
219383378|NCT05313230|OTHER|CITRASATE SLED|Applying of CITRASATE SLED
219383379|NCT02077322|DEVICE|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
219383380|NCT02077322|DEVICE|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
219383381|NCT02713750|OTHER|reversible contraceptive methods|"1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom"
219383382|NCT04853797|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
219383383|NCT04853797|DRUG|Ivabradine|15 mg oral Ivabradine.
219383384|NCT04853797|DRUG|Placebo|Oral placebo (calcium supplements).
219383385|NCT00248950|BEHAVIORAL|Positive affect induction and /or self affirmation induction|
219383386|NCT03420677|DEVICE|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
219383387|NCT03420677|DEVICE|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
219383388|NCT04374994|DRUG|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
219383389|NCT04374994|DRUG|Placebo oral tablet|lactose and maize starch, Egypt
219383390|NCT02513446|DRUG|BI 1026706|Single dose of BI 1026706 on Day 1
219383391|NCT02513446|DRUG|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
219383392|NCT04299269|OTHER|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
219383393|NCT00204386|DRUG|Topiramate|
219383394|NCT06449625|DRUG|Semaglutide Pen Injector [Ozempic]|Semaglutide active drug
219383395|NCT06449625|DRUG|Placebo|semaglutide placebo
219383396|NCT01310530|RADIATION|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
219383397|NCT03987750|DRUG|Safinamide Methanesulfonate 150mg|150 mg (free base)
219383398|NCT03987750|DRUG|Safinamide Methanesulfonate 100mg|100 mg (free base)
219383399|NCT03987750|DRUG|Safinamide Methanesulfonate matching placebo|placebo
219383400|NCT03767010|OTHER|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
219383401|NCT03767010|OTHER|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
219383402|NCT02485717|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
219383403|NCT02485717|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
219383404|NCT02024256|OTHER|Cold pads soaked in Magnesium sulfate solution|
219383405|NCT02024256|OTHER|Cold pads soaked in water|
219383406|NCT05452070|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
219383407|NCT05903781|DIAGNOSTIC_TEST|Prostate MRI|MRI of the prostate
219383408|NCT02568904|OTHER|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
219383409|NCT02568904|OTHER|Glucose|oral Glucose tolerance test
219383410|NCT02568904|OTHER|Fructose|oral fructose tolerance test
219383411|NCT02568904|OTHER|vehicle|control (water)
219383412|NCT00448461|DRUG|heparin|comparison between heparin and bivalirudin
219383413|NCT00448461|DRUG|bivalirudin|comparison between heparin and bivalirudin
219383414|NCT03822468|DRUG|Ribociclib|Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib was supplied as 200 mg tablets as individual patient supply packaged bottles.
219383415|NCT03822468|DRUG|Anastrozole|Anastrozole 1 mg tablets for oral use QD continuously
219383416|NCT03822468|DRUG|Letrozole|Letrozole 2.5 mg tablets for oral use QD continuously
219383417|NCT03822468|DRUG|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
219383418|NCT02722044|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
219383419|NCT02722044|DEVICE|Autoinjector|Subcutaneous administration
219383420|NCT01158612|DRUG|Growth Hormone|infusion of Growth hormone in the patella tendon.
219383421|NCT00215254|DRUG|quetiapine|
219383422|NCT05024994|DRUG|E7820|100mg of E7820 QD
219383423|NCT04057378|DEVICE|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
219383424|NCT00927641|DRUG|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
219383425|NCT00927641|OTHER|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
219383426|NCT02117687|DRUG|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
219383427|NCT02117687|DRUG|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
219383428|NCT03419858|BEHAVIORAL|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
219383429|NCT03419858|BEHAVIORAL|Placebo Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
219383430|NCT03419858|BEHAVIORAL|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
219383431|NCT03419858|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
219383432|NCT03419858|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
219383433|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
219383434|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
219383435|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
219383436|NCT00002850|DRUG|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
219383437|NCT00002850|DRUG|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
219383438|NCT00002850|DRUG|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
219383439|NCT05846633|DEVICE|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
219383440|NCT04756544|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
219383441|NCT04756544|OTHER|placebo|placebo
219383442|NCT04820192|OTHER|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
219383443|NCT05772364|OTHER|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
219557890|NCT02378909|DEVICE|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
219557891|NCT04620057|DIETARY_SUPPLEMENT|butyrate|sodium butyrate (20 mg/kg body weight/day)
219557892|NCT04620057|OTHER|placebo|cornstarch
219383444|NCT05636280|OTHER|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
219383445|NCT05636280|OTHER|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
219383446|NCT00303550|DRUG|Intravenous iclaprim|
219383447|NCT00303550|DRUG|Intravenous linezolid|
219383448|NCT01312194|PROCEDURE|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
219383449|NCT01312194|PROCEDURE|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
219383450|NCT01360125|GENETIC|proteomic profiling|
219383451|NCT01360125|OTHER|flow cytometry|
219383452|NCT01360125|OTHER|laboratory biomarker analysis|
219557893|NCT05341154|DRUG|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
219557894|NCT02845154|OTHER|bolus purge|complete and uninterrupted purge
219557895|NCT02845154|OTHER|Intermittent purge|intermittent portal purge
219557896|NCT00521508|PROCEDURE|gene transcription and cytometry|samply of 30 ml of blood
219383453|NCT00787436|DRUG|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
219383454|NCT04817540|DRUG|Herzuma|8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
219383455|NCT05651971|BEHAVIORAL|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
219383456|NCT06657287|OTHER|Mixed meal test|The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
219383457|NCT01200433|DRUG|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
219383458|NCT01200433|DRUG|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
219383459|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
219383460|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
219383461|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
219383462|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
219383463|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
219383464|NCT04052737|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
219383465|NCT04052737|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
219383466|NCT06479603|DRUG|Nintedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
219383467|NCT06479603|DRUG|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
219383468|NCT06989788|BIOLOGICAL|AVX70371|AstriVax Therapeutics' HBV immunotherapeutic
219383469|NCT06989788|OTHER|Placebo|Placebo
219383470|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
219383471|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
219383472|NCT05988385|DEVICE|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
219383473|NCT05988385|DEVICE|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
219383474|NCT05988385|DEVICE|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
219383475|NCT06991855|DIETARY_SUPPLEMENT|Animal-Based Oil Group|Participants in animal-based oil group will follow a diet in which the primary fat source is animal-based oil. The diet will supplement for 12 weeks.
219383476|NCT06991855|DIETARY_SUPPLEMENT|Plant-Based Oil Group|Participants in plant-based oil group will follow a diet in which the primary fat source is plant-based oil. The diet will supplement for 12 weeks.
219383477|NCT04256928|PROCEDURE|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
219383478|NCT01725880|OTHER|Observation|
219383479|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
219557897|NCT04436133|BIOLOGICAL|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
219557898|NCT04436133|BIOLOGICAL|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
219557899|NCT04922827|DRUG|Infliximab|single intravenous administration of 5 milligrams/kilogram
219383480|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
219383481|NCT07008404|DEVICE|online cognitive behavioral therapy|unguided online cognitive behavioral therapy app
219383482|NCT05563493|OTHER|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
219383483|NCT05563493|OTHER|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
219383484|NCT03132077|PROCEDURE|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
219383485|NCT05940597|DEVICE|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
219383486|NCT05940597|DEVICE|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
219383487|NCT06620107|DEVICE|noninvasive high frequency oscillation ventilation|"cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2."
219383488|NCT06620107|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied."
219383489|NCT07022015|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
219383490|NCT07023042|OTHER|Abdominal Kinesio taping|Application of medical-grade Kinesio tape (NKH-50R) to the abdomen using a standardized circular technique, in addition to standard care for malignant bowel obstruction and ascites. Tape is applied by trained professionals after a skin sensitivity test and changed every three days or as needed. The procedure avoids open wounds and tumor sites. Participants and caregivers are educated on tape care and removal.
219383491|NCT07023042|OTHER|Standard Care Arm|Standard palliative care for malignant bowel obstruction and ascites, including symptom management, nutritional support, and medical treatment according to institutional protocols.
219383492|NCT07024693|DRUG|DT-168|Active
219383493|NCT00805415|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
219383494|NCT00805415|DRUG|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
219383495|NCT07030946|BEHAVIORAL|Multimedia Health Education|A 10-minute multimedia video is provided to the intervention group during their final preoperative clinic visit. All participants receive standard verbal and printed education from the ophthalmologist. The video includes visual and auditory content on cataract surgery, preoperative instructions, postoperative care, and common concerns. Baseline data (T0) are collected before the intervention, including demographics, visual acuity, physiological indicators, BAI, and self-care knowledge. Follow-ups occur at T1 (surgery day), T2 (1 week postop), and T3 (1 month postop), assessing anxiety, physiology, vision, and self-care.
219383496|NCT07030881|DRUG|pMDI Triple Inhaler and Spacer|Participants in this group will use a valved mouthpiece spacer in combination with standard triple inhaled therapy delivered by a pressurized metered-dose inhaler (ICS/LABA/LAMA). The spacer device helps reduce the need for hand-breath coordination, prolongs aerosol suspension time, and improves drug delivery to the lungs. Participants will be trained in proper spacer use, including device attachment, timing of actuation and inhalation, mouth seal technique, cleaning, and daily maintenance. This intervention aims to optimize inhalation technique, improve treatment adherence, and potentially reduce the incidence of moderate-to-severe exacerbations.
219383497|NCT07030881|DRUG|pMDI Triple Inhaler Only|Participants in the control group will receive a standard fixed-dose combination of inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA) administered via pressurized metered-dose inhaler (pMDI). No spacer will be used. All participants will receive standardized inhalation technique training at baseline, including hand-held device usage, actuation-inhalation timing, breath-hold, and mouth rinsing. This group represents the current standard-of-care for stable, high-risk COPD or asthma patients as per GOLD and GINA guidelines.
219383498|NCT07030556|OTHER|Healthy Sleep Intervention|This intervention has a duration of nine weeks and starts with a kick-off event where the students of the action group provide explanations to fellow students. Furthermore, the intervention is structured in five themes of approximately two weeks each: 1) importance of healthy sleep, 2) sleep and wake cycle, 3) screen time, 4) exercise and nutrition and 5) screen use and mental well-being. Three posters are provided for each theme, five to seven Instagram posts and a class discussion. In addition, healthy sleep is explained during the biology lesson. Furthermore, a competition between classes is organized to sleep as well as possible with the help of an app, classes are given a planner to visualize the workload of school tasks, exercise snacks will be introduced during the lessons and students are given a notebook to write things down in case of worrying. Finally, a closing moment is provided. Flyers with information about healthy sleep in young people are distributed to parents.
219383499|NCT07030556|OTHER|Co-creation process|co-creation process with students and teachers: to adapt the existing intervention to the needs of the school. For this, schools can recruit 6 to 8 students via purposeful sampling to form an action group. They will be asked to participate in two sessions during the lunch break in which 1) the needs of the students at school in relation to healthy sleep are mapped out and the goals of the already developed intervention are supplemented or not based on the needs 2) a choice is made from the already developed intervention components 3) necessary adjustments are made to intervention components.
219383500|NCT07030556|OTHER|Training for teachers|implementation of the implementation intervention for teachers. The implementation intervention consists of a one-off training for all teachers of the 1st and 2nd year of secondary school in which the importance of sleep and the intervention and its materials are explained. A manual per theme is then provided to the teachers who will implement components (see also appendix 'Manual Sleep Project'). Consultation moments will be planned in consultation to discuss the progress of the implementation.
219383501|NCT07031999|COMBINATION_PRODUCT|PLA spacer|This is a phase 1/2 prospective, interventional, non-randomized, single-arm clinical study designed to evaluate the safety of using temporary articular spacers printed in PLA (polylactic acid) impregnated with vancomycin in patients with periprosthetic infections of the hip, knee, or shoulder.
219383502|NCT07031206|DRUG|Paracervical block- Lidocaine without epinephrine|1-2 cc of Lidocaine at the tenaculum site on the cervix at 12 o-clock will be injected after pain scale #1 is completed. Pain scale #2 will be done then 3 cc of 1% lidocaine at 4 and 8 o'clock position of the cervix will be administered. The IUD insertion or EMB will be performed nd pain scale #3 will be done.
219383503|NCT07031206|DRUG|Benzocaine Gel applied to the cervix|After pain scale #1 is performed , topical benzocaine will be applied to the cervix with Procto swabs and this will be allowed to remain on cervix for 203 minutes. Then Betadine will be applied to the cervix and surrounding vaginal tissue followed by pain scale #2. IUD insertion or EMB will be done followed by pain scale #3.
219383504|NCT07031206|DRUG|Hydroxyzine Hydrochloride|Preprocedure, a GAD 7 scoring will be performed to determine level of anxiety. If \> 10 indicating Moderate anxiety, participants will be offered pretreatment with Anxiolytic (Hydroxyzine 25mg) approximately 15-20 mins before procedure. If this is done at the preceding visit, participants will be sent home with a prescription for hydroxyzine to be taken 10-15 mins before the procedure when participants are brought back for procedure visit.
219383505|NCT07032103|DRUG|Immunochemotherapy|Systemic chemotherapy with curative intent
219383506|NCT07030803|OTHER|Oxybutynin|oxybutynin
219383507|NCT07030803|DEVICE|medical device Urostim|medical device used to deliver posterior tibial nerve stimulation (PTNS)
219383508|NCT07032155|DEVICE|Resynk VR session|The study will use hardware and software to achieve this immersive virtual reality. The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used. Immersive virtual reality (VR) is when technology makes you feel like you're inside a different world. You wear a virtual reality headset that covers your eyes and ears, showing you a 3D world and playing matching sounds. The headset's head tracking, changing the view in the VR world as you look around. You can then interact with this virtual reality world depending on the application or game you use. The Resynk VR software launches automatically, guiding them through therapist-designed games that make rehabilitation engaging. The system uses advanced hand-tracking technology, eliminating the need for physical controllers. It detects joint movements in the hands and fingers, allowing users to perform key rehabilitation exercises such as supination, pronation, grasping, and pinching.
219383509|NCT07032155|OTHER|Using Resynk VR on stroke survivors|The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used by Occupational therapy participants to treat the stroke survivor participants
219383510|NCT07032142|DRUG|I-01/23|The I-01/23 will be administered over a 5-day period, with dosing adjusted according to the patient's body surface area (BSA).
219383511|NCT07030153|GENETIC|Oral swab DNA analyzed for myopia-related gene variants|Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.
219383512|NCT07031362|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|All patients who participated in the pulmonary rehabilitation and physiotherapy program underwent sessions lasting approximately two hours, conducted twice weekly over a period of eight weeks. The exercise program included breathing exercises, relaxation and stretching exercises, peripheral muscle strengthening exercises, and aerobic training.
219557900|NCT04922827|OTHER|Standard of Care|Standard of Care
219383513|NCT07030205|OTHER|Blood sample|A blood sample (fasting), for biobanking purposes to measure certain bone biological markers known to be indicators of bone remodeling (osteocalcin, sclerostin, periostin, irisin, procollagen type 1 N-terminal propeptide (P1NP), Dickkopf-related protein 1 (DKK1), and collagen type 1 C-terminal telopeptides (CTX)).
219383514|NCT07030205|OTHER|Bone density exam|A bone density exam will be performed in order to verify the non-osteoporotic status of the healthy volunteers group.
219383515|NCT07030205|OTHER|Tests and questionnaires of study|An assessment of cognitive functions will be realized using Montreal Cognitive Assessment (MoCA), Cantab® tests (MOT, MTS, RTI, DGS), the Trail Making Test (TMT), verbal fluency, the Stroop test, the Dubois 5-word test, and the oral picture naming test. Other questionnaires will be used, assessing: sleep quality (Pittsburgh Physical Activity Questionnaire (PSQI)), anxiety and depression (the anxiety/depression scale (HAD)), quality of life (Short Form-36 quality of life questionnaire (SF-36)), physical activity (International Physical Activity Questionnaire (IPAQ)), and pain with the Brief Pain Inventory questionnaire (BPI) and the numerical scale (EN).
219383516|NCT07030205|OTHER|Functional connectivity value of brain networks at rest|A Resting-State Functional Magnetic Resonance Imaging will be conducted in order to evaluate and compared functional connectivity value of brain networks at rest between three groups.
219383517|NCT06742125|DEVICE|Drug-coated balloon (DCB)|Drug-coated balloon treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
219383518|NCT06742125|DEVICE|Drug-eluting stent (DES)|Drug-eluting stent treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
219383519|NCT06781294|DEVICE|Extracorporeal Cytokine hemadsorption therapy|Extracorporeal blood purification with oXiris set connected to cardiopulmonary bypass during all CPB time. Ultrafiltration was permitted.
219383520|NCT06853418|DEVICE|Oocyte Cryopreservation|"The DaVitri System is intended to semi-automate vitrification preparation of human oocytes.~The Overture Semi-Automated Vitrification System (DaVitri) is a medical device that uses semi-automated oocyte vitrification.~The system comprises the DaVitri Station, and the DaVitri Dish. The DaVitri Station is a piece of capital equipment with touch screen control that manages the vitrification preparation. The DaVitri Dish is a cartridge-like device onto which oocytes and vitrification reagents are loaded. When the DaVitri Dish is loaded into the DaVitri Station, and the cryo process is initiated, a microfluidic pump controls the flow of reagents to and from the DaVitri Dish containing the oocytes."
219383521|NCT06903182|PROCEDURE|Preoperative TAP Block|Patients will receive preoperative TAP block
219383522|NCT06903182|PROCEDURE|Postoperative TAP block|Patients will receive postoperative TAP block
219383523|NCT05592847|OTHER|Nurse Navigator Program|Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
219383524|NCT07087574|DEVICE|adapted cutlery handle printed with 3D printer|"The patient's autonomy will be assessed by the same ergotherapist, and the quantity of food ingested will be measured by a dietician at 3 similar lunch times:~* before using the adapted cutlery handles (Day0);~* when the adapted cutlery handles are used for the first time (Day1);~* after 3 days' use of the adapted cutlery handles (Day3) On Day0 and Day3, the ergotherapist will carry out an ecological assessment of the meals. Ecological assessment is used in occupational therapy to observe and analyze the patient's interactions with his environment and their repercussions on his ability to perform a task. The aim here is to assess whether the patient exhibits compensation of the upper limb (such as shoulder elevation or trunk inclination) during the meal performed without technical aids (Day0) and that performed after the learning phase of using the adapted handle (Day3).~The patient's participation will end at the end of the Day3 assessments."
219383525|NCT06456554|DEVICE|Acellular Dermal Matrix (Cortiva Tissue Matrix)|non-crosslinked dermis
219383526|NCT00036790|DRUG|doxorubicin hydrochloride|
219383527|NCT00036790|DRUG|motexafin gadolinium|
219383528|NCT07106073|OTHER|Collection of demographic, anthropometric and clinical data.|"Data collected is:~* demographic data: age, sex;~* anthropometric data: weight, height, body mass index;~* clinical data:~  * Palliative Performance Scale;~ * Palliative Prognostic Index;~ * comorbidities;~ * therapy;~ * presence of medical devices;~ * presence of pressure injuries;~ * time on waiting list;~ * place of care;~ * primary diagnosis;~ * length of stay;~ * symptom burden at admission (Edmonton Symptom Assessment System);~ * onset of fever and its characteristics (duration, intensity, treatment, etiology);~ * need for sedation (duration, refractory symptom(s));~ * outcome."
219383529|NCT07108231|DEVICE|Inspiratory muscle trainning|"The IMT protocol will involve the use of the Power Breath® linear resistor device, classic light model (Anvisa Registration: 81001390001). The IMT group will perform the protocol with a load ranging from 30% to 50% of maximal inspiratory pressure (MIP). Two daily sessions of 30 repetitions each will be conducted, starting with a minimum load of 30%, with a 10-minute interval between sessions, and a proposed weekly load increase based on patient tolerance.~For training load progression, patient effort will be taken into account, aiming to maintain a perceived exertion level between light and moderate fatigue (BORG scale less than 4).~Patients will remain seated at a 90° angle, using a nasal clip, and will be encouraged to perform consecutive inspirations with their mouth on the device's mouthpiece. Vital signs-including blood pressure (BP), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), respiratory rate (RR), heart rate (HR)-and dyspnea sensat"
219383530|NCT07108231|DEVICE|Sham (No Treatment)|The control group (IMTsham) will perform two daily sessions of 30 repetitions each without any load, using the same resistor device.
219383531|NCT05881408|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219383532|NCT05881408|GENETIC|placebo|Single IV infusion of matching placebo
219383533|NCT07106502|PROCEDURE|testicular palpation training on a mannequin|Study of testicular palpation training on a mannequin on the ability to perform a testicular examination and diagnose testicular positioning abnormalities
219429122|NCT03512470|DEVICE|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
219383534|NCT07107867|BEHAVIORAL|breastfeding counseling|Pregnant women assigned to the intervention group then participated in a breastfeeding counseling training program held at the gynecology and obstetrics unit of an university training and research hospital. The training sessions lasted 60 to 90 minutes and included small groups of 5 to 6 participants, based on recommendations from the literature. The training was delivered through a slide presentation, and participants received a printed training booklet beforehand. Visual aids, including a baby model and breast model, were also used to enhance understanding. The training content was developed in line with infant feeding guidelines from UNICEF, the Turkish Ministry of Health, and relevant literature.
219383535|NCT07106086|OTHER|Scapulothoracic mobilization|"Scapulothoracic Mobilization and Buteyko Breathing Technique:~Subjects lay supine with arms crossed, hands on opposite scapulae. The interventionist stabilized elbows and applied pressure to shoulders, with one hand on the spine using a loose fist to mobilize vertebrae. Various spinal motions-rotation, flexion, lateral flexion, and translation-were assessed. In a lateral position, the subject bent both knees and placed the upper arm on a cushion. The interventionist stood close, placing fingers under the scapula's medial border."
219383536|NCT07106086|OTHER|Buteyko breathing|Buteyko Breathing: Subjects sat upright, relaxed respiratory muscles, and breathed gently through the nose. The sequence included calm nasal inhalation and exhalation using the diaphragm, followed by shallow inhalation and slow exhalation. A brief post-exhalation breath hold was added. The cycle was repeated for several minutes.
219383537|NCT07105735|BIOLOGICAL|allogeneic CAR-T|Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.
219383538|NCT07106177|OTHER|Scanning with verification jig|Comparing Relative Implant Positions of the 4 implants in each case obtained through desktop scanning of intraoral provisional verification jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
219383539|NCT07106177|OTHER|Direct intraoral scanning|Comparing Relative Implant Positions of the 4 implants in each case obtained through direct intraoral scanning without jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
219383540|NCT07106528|DRUG|Organoid Drug Sensitivity Testing-Guided Therapy|Personalized drug selection (chemotherapy/targeted therapy/immunotherapy) based on ex vivo organoid drug response testing
219383541|NCT07106528|DRUG|Topotecan|Intravenous topotecan 1.25 mg/m² daily on days 1-5 of each 21-day cycle
219383542|NCT07107711|PROCEDURE|One-Stop Hybrid Surgery|With the patient under moderate hypothermia (approx. 28°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using a standard 4-branched graft. After the open repair is complete, a separate, distinct covered stent graft is deployed antegradely into the descending aorta through the open distal end of the arch graft. Completion angiography confirms correct placement.
219383543|NCT07107711|PROCEDURE|Conventional Total Arch Replacement with Frozen Elephant Trunk|With the patient under deep hypothermic circulatory arrest (23°C-25°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using an integrated hybrid prosthesis (Frozen Elephant Trunk), which consists of a vascular graft sutured to a covered stent graft. This single device is deployed antegradely into the descending aorta, and the arch vessels are then reattached to the branches of the prosthetic graft.
219383544|NCT06152328|OTHER|Virtual reality applications based on mirror therapy|Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
219383545|NCT06152328|OTHER|Conventional treatment|Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
219383546|NCT06152328|OTHER|Mirror therapy|In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
219383547|NCT06152328|OTHER|Placebo virtual reality|For 8 weeks, watching the uninteractive virtual environment for 10 minutes
219383548|NCT00316875|DRUG|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
219383549|NCT00316875|DRUG|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
219383550|NCT06953687|BEHAVIORAL|Prolonged Exposure Therapy|PE is a cognitive-behavioral treatment for PTSD that is typically delivered in ten 90-minute sessions . For the current study using a variable length approach, participants may complete up to 24 sessions. Based on emotional processing theory PE addresses trauma-related avoidance of thoughts, behaviors, and situations, as well as unhelpful beliefs about oneself, others, and the world that were learned as a result of trauma.
219383551|NCT06953687|BEHAVIORAL|Cognitive Processing Therapy|CPT is a 12-session, cognitive behavioral PTSD treatment typically delivered in 60-minute sessions that can be personalized to include fewer or additional sessions. For the current study using a variable length approach, participants may complete up to 24 sessions. CPT is based in cognitive theory and posits that impeded recovery following trauma occurs due to unhelpful and unrealistic beliefs that may develop after trauma, leading to chronic anger, guilt, shame, and avoidance of trauma reminders. During CPT, patients learn about PTSD symptoms, impeded recovery and cognitive theory, and the connection between trauma-based thoughts and feelings.
219429123|NCT03512470|OTHER|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
219429124|NCT06391476|OTHER|Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age|"* Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years."
219383552|NCT06953687|BEHAVIORAL|Written Exposure Therapy|WET is a cognitive behavioral therapy for PTSD that typically consists of 5 weekly 50-minute sessions. For the current study using a variable length approach, participants may complete up to 7 sessions. WET is based on an extinction and emotional processing treatment model. First, patients learn about PTSD and the role of avoidance in maintaining PTSD symptoms. Next, patients are guided to write about their trauma for 30 minutes and afterwards, the therapist briefly checks in with the patient. This procedure is followed for the next 4 sessions, with guidance to first write about the trauma, and in later sessions to write about consequences of the trauma and the patient's current meaning of their lives. The goals of WET are to assist the patient in emotionally processing the event and reduce avoidance of trauma-related thoughts and memories, which facilities recovery.
219383553|NCT06953687|OTHER|Shared Decision Making (SHARE)|"The study will use the SHARE Approach to facilitate treatment planning and decision-making. SHARE stands for:~1. Seek the patient's participation~2. Help the patient explore and compare treatment options~3. Assess the patient's values and preferences~4. Reach a decision with the patient~5. Evaluate the patient's decision The Shared Decision Making Patient Preference Checklist will be used to determine the participant's preference for type of treatment, frequency of treatment sessions, and treatment delivery modality. Step 5 also includes following up with the patient and making changes if something it not working well for the patient."
219383554|NCT01689038|DRUG|F17464|Single dose
219383555|NCT02446964|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
219383556|NCT02446964|DRUG|Cyclophosphamide|Given IV
219383557|NCT02446964|DRUG|Fludarabine Phosphate|Given IV
219383558|NCT02446964|OTHER|Laboratory Biomarker Analysis|Correlative studies
219383559|NCT02446964|DRUG|Mycophenolate Mofetil|Given PO or IV
219383560|NCT02446964|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
219383561|NCT02446964|DRUG|Tacrolimus|Given IV and PO
219383562|NCT02446964|RADIATION|Total Marrow Irradiation|Undergo TMLI
219383563|NCT00005592|BIOLOGICAL|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
219383564|NCT00005592|BIOLOGICAL|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
219383565|NCT00005592|RADIATION|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
219383566|NCT06035497|DRUG|BMS-986369|Specified dose on specified days
219383567|NCT04277572|PROCEDURE|Aortic valve replacement|Aortic valve surgery
219383568|NCT06411795|DRUG|Bupivacaine|Given via epidural and injection
219383569|NCT06411795|DRUG|Hydromorphone|Given via epidural
219383570|NCT06411795|DRUG|Iopamidol|Given via epidural
219383571|NCT06411795|DRUG|Liposomal Bupivacaine|Given injection
219383572|NCT06411795|OTHER|Medical Chart Review|Ancillary studies
219383573|NCT06411795|OTHER|Questionnaire Administration|Ancillary studies
219383574|NCT06411795|DRUG|Thoracic Epidural Analgesia|Undergo thoracic epidural placement
219557901|NCT03506594|DEVICE|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
219557902|NCT01992094|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
219557903|NCT01992094|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
219383575|NCT06411795|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219383576|NCT06411795|PROCEDURE|X-Ray Imaging|Undergo x-ray
219383577|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
219383578|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
219383579|NCT01733706|DEVICE|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
219383580|NCT01733706|OTHER|Standard counseling|standard counseling
219383581|NCT04680884|DRUG|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
219383582|NCT04680884|DRUG|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
219383583|NCT04680884|DRUG|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
219383584|NCT04680884|OTHER|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
219383585|NCT01416181|DRUG|natalizumab|Administered as specified in the treatment arm
219383586|NCT01416181|DRUG|Placebo|Matched placebo in part 1
219383587|NCT05446675|PROCEDURE|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
219383588|NCT05446675|PROCEDURE|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
219383589|NCT04878783|DIAGNOSTIC_TEST|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
219383590|NCT06058234|DRUG|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
219383591|NCT01789879|DRUG|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
219383592|NCT01789879|DRUG|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
219383593|NCT01789879|DRUG|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
219383594|NCT02983058|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner
219383595|NCT02983058|DEVICE|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
219383596|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
219383597|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
219383598|NCT02357277|DRUG|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
219383599|NCT02357277|OTHER|Placebo Inhaler|inhaled placebo
219383600|NCT04311905|DEVICE|Diode laser|Diode laser activated irrigation
219383601|NCT04311905|OTHER|Placebo|mock Laser activated irrigation
219383602|NCT00003881|BIOLOGICAL|trastuzumab|
219383603|NCT00003881|DRUG|carboplatin|
219383604|NCT00003881|DRUG|paclitaxel|
219557904|NCT01992094|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
219001025|NCT00751829|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
219383605|NCT01411410|DRUG|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
219383606|NCT01411410|DRUG|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
219383607|NCT06040177|DRUG|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
219383608|NCT06040177|RADIATION|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry
219383609|NCT06040177|DRUG|Renvatinib|Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
219383610|NCT04630314|DEVICE|Percutaneus Coronary Intervention|Covered Stent
219383611|NCT06434740|RADIATION|Stereotactic Body Radiation Therapy，SBRT|The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
219383612|NCT06434740|DRUG|Puterizumab|Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
219557905|NCT01214239|DRUG|Placebo|once a day
219557906|NCT01214239|DRUG|Linagliptin|once a day
219557907|NCT05147740|DRUG|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
219557908|NCT01463891|DRUG|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
219383613|NCT04945993|DEVICE|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
219383614|NCT05574972|DEVICE|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
219383615|NCT05574972|DEVICE|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
219383616|NCT05347732|DIAGNOSTIC_TEST|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
219383617|NCT05442892|PROCEDURE|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
219383618|NCT00698516|DRUG|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
219383619|NCT05949125|OTHER|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
219383620|NCT05949125|OTHER|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
219383621|NCT05949125|DRUG|R-TM123|Intravenous infusion over 20 days
219383622|NCT05949125|DRUG|Allo-RevCAR01-T|Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.
219383623|NCT04260607|DRUG|Ketamine Hydrochloride|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
219383624|NCT04260607|DRUG|Normal saline|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
219383625|NCT03215914|DEVICE|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
219383626|NCT06488196|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
219383627|NCT06488196|OTHER|Treatment As Usual|TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
219383628|NCT04297644|OTHER|There is no intervention|There is no intervention
219383629|NCT02988648|RADIATION|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
219383630|NCT01733355|RADIATION|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
219383631|NCT00003248|BIOLOGICAL|rituximab|
219383632|NCT00003248|DRUG|fludarabine phosphate|
219383633|NCT02362607|BEHAVIORAL|Integrated Diabetes Management Protocol|
219191753|NCT06839638|PROCEDURE|100% Trichloroacetic Acid (TCA)|Patients in this group will receive 100% TCA application to xanthelasma lesions using the dipstick method. The surrounding skin will be protected with white soft paraffin to prevent chemical spillage. Post-treatment, Fusidic acid 2% will be applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
219383634|NCT02362607|BEHAVIORAL|Standard Diabetes Management Protocol|
219557909|NCT05820919|BEHAVIORAL|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
219557910|NCT05820919|OTHER|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
219383635|NCT02163330|DRUG|Acetazolamide|
219383636|NCT02163330|DRUG|sugar pill|
219383637|NCT06148610|DEVICE|NewSpringForMe digital solution|Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
219383638|NCT03085069|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
219383639|NCT03445676|BEHAVIORAL|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
219383640|NCT04596657|DIETARY_SUPPLEMENT|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
219383641|NCT03453060|DRUG|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
219383642|NCT03453060|DRUG|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
219383643|NCT03453060|DRUG|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
219383644|NCT03453060|DRUG|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
219383645|NCT03453060|OTHER|Placebo|Participants received a single intravenous dose of placebo.
219383646|NCT00292123|DRUG|Methadone|
219383647|NCT00292123|BEHAVIORAL|Contingency Management|
219383648|NCT01095484|DRUG|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
219383649|NCT04524975|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
219383650|NCT04524975|DRUG|Placebo|Placebo capsules
219383651|NCT00722059|PROCEDURE|Breast Tomosynthesis|3D breast imaging
219383652|NCT01142323|DRUG|fenofibrate|160 mg po daily
219383653|NCT01959204|DRUG|Oxycodone|Pain
219383654|NCT04374903|DRUG|HCQ & AZ vs HCQ+SIR|Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
219383655|NCT00089180|DRUG|liposomal T4N5 lotion|Given topically
219383656|NCT00089180|OTHER|placebo|Given topically
219383657|NCT00089180|OTHER|laboratory biomarker analysis|Correlative studies
219383658|NCT00446394|BEHAVIORAL|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
219383659|NCT00446394|BEHAVIORAL|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
219383660|NCT01506791|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
219383661|NCT05946252|OTHER|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~1. To imagine walking activity in different environments (seaside, beach, walking path).~2. The rest activity will be imagined by sitting on a bench.~3. Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~4. The rest activity will be imagined by sitting on a bench.~5. Imagination will end with homecoming and domestic activities."
219383662|NCT05946252|OTHER|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
219383663|NCT01269567|PROCEDURE|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
219383664|NCT01269567|PROCEDURE|No pelvic drainage|no aspiration drain at the end of intervention
219383665|NCT00622934|DRUG|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
219383666|NCT00622934|DRUG|placebo|placebo
219383667|NCT00501319|BEHAVIORAL|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
219383668|NCT00501319|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
219383669|NCT00190463|DRUG|Amphotericin B|
219383670|NCT02580734|DIETARY_SUPPLEMENT|melatonin|Cross-over randomized clinical trials
219383671|NCT01576081|DEVICE|HEPHAISTOS|HEPHAISTOS unloading orthotic
219383672|NCT00445783|GENETIC|gene expression analysis|
219383673|NCT00445783|GENETIC|mutation analysis|
219383674|NCT00445783|OTHER|immunohistochemistry staining method|
219383675|NCT00445783|OTHER|laboratory biomarker analysis|
219383676|NCT00445783|PROCEDURE|examination|
219383677|NCT00445783|PROCEDURE|mutation carrier screening|
219383678|NCT00445783|PROCEDURE|study of high risk factors|
219383679|NCT04648371|OTHER|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
219383680|NCT05027269|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
219383681|NCT05027269|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
219383682|NCT03940105|BEHAVIORAL|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
219383683|NCT06498908|DRUG|Nitrous oxide|Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
219383684|NCT06498908|DRUG|Oxygen|Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
219383685|NCT02158533|DRUG|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
219383686|NCT02158533|DRUG|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
219383687|NCT02158533|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
219383688|NCT02801357|DRUG|lofexidine administration in subjects seeking buprenorphine dose reduction|
219383689|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"
219383690|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"
219383691|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"
219383692|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
219383693|NCT04036760|BEHAVIORAL|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
219383694|NCT00548314|OTHER|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
219383695|NCT00548314|PROCEDURE|Split skin graft|
219383696|NCT00548314|DEVICE|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
219383697|NCT02526849|DRUG|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
219001026|NCT00751829|DRUG|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
219001027|NCT00948987|DRUG|Aspirin|325 mg enteric coated single dose p.o.
219001028|NCT00616200|OTHER|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
219383698|NCT02526849|BEHAVIORAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
219383699|NCT02642861|DRUG|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
219383700|NCT02642861|DRUG|Calcium Carbonate|Calcium carbonate for 2 weeks
219383701|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
219383702|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
219383703|NCT01691729|DEVICE|Ostomy accessory|Wearing each of the devices for 10 days each
219383704|NCT03499054|OTHER|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
219383705|NCT00180115|DRUG|Cytarabine Dosage|
219383706|NCT00236561|DRUG|topiramate, propranolol|
219383707|NCT06209697|DIETARY_SUPPLEMENT|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
219383708|NCT01744899|OTHER|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
219383709|NCT06330753|OTHER|Trauma-informed Care Plan-|Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
219383710|NCT02322307|OTHER|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
219383711|NCT02322307|OTHER|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
219383712|NCT01380756|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
219383713|NCT01380756|DRUG|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
219383714|NCT06094179|DRUG|Monoclonal antibody BAT6026|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
219383715|NCT06094179|DRUG|sodium chloride injection|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
219383716|NCT02494141|DRUG|Curcumin|Dietary Supplement
219383717|NCT02494141|OTHER|Placebo|
219383718|NCT06332443|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
219191754|NCT06839638|PROCEDURE|Cryotherapy (Liquid Nitrogen)|Patients in this group will receive cryotherapy using liquid nitrogen. A single freeze-thaw cycle will be performed until a narrow halo of white ice forms around the lesion. Post-treatment care will include Fusidic acid 2% applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
219383719|NCT06332443|PROCEDURE|Sedation epidural anesthesia|Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
219383720|NCT00917384|BIOLOGICAL|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
219383721|NCT00917384|DRUG|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
219383722|NCT00917384|OTHER|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
219383723|NCT02636309|BEHAVIORAL|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
219383724|NCT00658229|BEHAVIORAL|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
219383725|NCT01518530|DEVICE|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
219383726|NCT00262405|DRUG|zileuton|
219383727|NCT00262405|DRUG|azathioprine/prednisone|
219383728|NCT00149214|DRUG|pemetrexed|500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
219383729|NCT00149214|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
219383730|NCT00149214|DRUG|doxorubicin|60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
219383731|NCT00149214|DRUG|docetaxel|100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
219383732|NCT00467844|DRUG|GTx-024|1 mg GTx 024
219383733|NCT00467844|DRUG|GTx-024|3 mg GTx-024
219383734|NCT00467844|DRUG|Placebo|Matching Placebo
219557911|NCT05909969|OTHER|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
219557912|NCT05909969|OTHER|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
219383735|NCT05877677|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
219383736|NCT05877677|DIETARY_SUPPLEMENT|Polygonatum kingianum extract drink|consume 1 bottle per day
219383737|NCT00308815|DEVICE|Automatic CPR machine|
219383738|NCT00440323|DRUG|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
219383739|NCT00440323|DRUG|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
219383740|NCT00440323|DRUG|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
219383741|NCT01655511|DRUG|Tafamidis|240 mg, solution, single dose
219383742|NCT01655511|DRUG|Tafamidis|480 mg, solution, single dose
219383743|NCT01655511|DRUG|Tafamidis|TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
219383744|NCT06338644|DRUG|Palbociclib|3 weeks on, 1 week off
219383745|NCT03723096|DRUG|CC-4047|CC-4047 will be administered orally
219383746|NCT04320095|DEVICE|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
219383747|NCT03010189|DEVICE|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
219383748|NCT03010189|DEVICE|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
219383749|NCT03010189|DEVICE|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
219383750|NCT01928979|OTHER|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
219383751|NCT05952830|OTHER|ESWT group|subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
219383752|NCT05952830|OTHER|DN group|Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
219383753|NCT04590612|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
219383754|NCT04590612|DRUG|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
219383755|NCT05771571|OTHER|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
219383756|NCT05771571|OTHER|Control|Refined olive oil
219383757|NCT05164328|OTHER|No intervention|No intervention
219383758|NCT03623750|DRUG|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
219383759|NCT03623750|BIOLOGICAL|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
219383760|NCT03623750|DRUG|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
219191755|NCT04771897|DRUG|BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
219383761|NCT01674426|BEHAVIORAL|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
219383762|NCT04691258|BEHAVIORAL|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
219383763|NCT04691258|BEHAVIORAL|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
219383764|NCT06067113|PROCEDURE|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
219383765|NCT00257127|BIOLOGICAL|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
219383766|NCT00257127|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
219383767|NCT00257127|BIOLOGICAL|Hepatitis B vaccine|0.5 mL administered intramuscularly
219383768|NCT00257127|BIOLOGICAL|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
219383769|NCT01538615|BEHAVIORAL|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
219383770|NCT05932433|BEHAVIORAL|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
219383771|NCT05565924|OTHER|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
219383772|NCT05565924|OTHER|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
219383773|NCT05565924|OTHER|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
219383774|NCT05565924|OTHER|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
219383775|NCT05565924|OTHER|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
219383776|NCT04627545|OTHER|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
219383777|NCT04627545|OTHER|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
219383778|NCT02185469|PROCEDURE|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
219383779|NCT02185469|PROCEDURE|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
219383780|NCT02185469|DRUG|sulfur hexafluoride (SF6)|
219383781|NCT02185469|DEVICE|5/8-in 25-gauge needle|
219383782|NCT02185469|DEVICE|laser|intraoperative laser retinopexy
219383783|NCT00174941|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
219383784|NCT00174941|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
219383785|NCT00174941|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
219383786|NCT02621385|DRUG|tradipitant|test agent
219383787|NCT02621385|DRUG|Midazolam|substrate for drug-drug interaction assessment
219383788|NCT01594099|RADIATION|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
219383789|NCT01594099|DRUG|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
219383790|NCT01594099|DRUG|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
219383791|NCT04230538|DEVICE|DJO Walker|
219383792|NCT04230538|DEVICE|Traditional plaster cast|
219383793|NCT03126227|BIOLOGICAL|AR101|AR101 powder provided in capsules
219383794|NCT03126227|BIOLOGICAL|Placebo|Placebo powder provided in capsules
219383795|NCT01569204|DRUG|Etoposide|
219383796|NCT01569204|DRUG|Cyclophosphamide|
219383797|NCT01569204|DRUG|Doxorubicin|
219383798|NCT01569204|DRUG|Prednisone|
219383799|NCT01569204|DRUG|Procarbazine|
219383800|NCT01569204|DRUG|Dexamethasone|
219383801|NCT01569204|DRUG|Dacarbazine|
219383802|NCT01569204|DRUG|Brentuximab Vedotin|
219383803|NCT00427661|OTHER|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
219383804|NCT03127020|DRUG|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
219383805|NCT01982110|BEHAVIORAL|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
219383806|NCT01982110|BEHAVIORAL|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
219383807|NCT06497647|DRUG|Sulbutiamine|"sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C"
219383808|NCT06497647|DRUG|Imipramine|"imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C"
219557913|NCT01049581|PROCEDURE|aquatic therapy|two hours per week, one hour per time, total 12 weeks
219557914|NCT02578277|DRUG|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
219383809|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
219383810|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
219383811|NCT01025778|DRUG|Clofarabine for remission induction|
219383812|NCT01025778|DRUG|Etoposide for remission induction|
219383813|NCT01025778|DRUG|Cyclophosphamide for remission induction|
219383814|NCT01025778|DRUG|Clofarabine in conditioning before transplantation|
219383815|NCT01025778|DRUG|Thiotepa in conditioning before transplantation|
219383816|NCT01025778|DRUG|Melfalan in conditioning before transplantation|
219383817|NCT01025778|PROCEDURE|Haploidentical transplantation of T-cell depleted graft|
219383818|NCT01025778|PROCEDURE|Donor lymphocyte infusion|
219383819|NCT06961071|BIOLOGICAL|Parathyroid Allotransplant|Parathyroid Allotransplant
219383820|NCT06091423|DRUG|XELOX combined with Fruquintinib and Sintilimab|XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
219383821|NCT05485012|DRUG|Marijuana|Double-blind administration of marijuana
219383822|NCT05485012|DRUG|Opioid|Double-blind administration of an opioid agonist
219383823|NCT03567577|DRUG|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
219383824|NCT03567577|DRUG|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
219383825|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
219383826|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
219383827|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
219383830|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
219383831|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
219383832|NCT00428168|DRUG|Betahistine|Betahistine 24mg BID
219383833|NCT03186456|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 \*10\^6/kg. once a month, total 3 times.
219383834|NCT03186456|DRUG|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
219383835|NCT04281537|DRUG|Enzyme Replacement Therapy (ERT)|ERT infusion every other week
219383836|NCT03230097|DRUG|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
219383837|NCT03230097|DRUG|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
219383838|NCT05509257|DRUG|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
219383839|NCT05509257|DRUG|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
219383840|NCT03669133|DRUG|Vitamin E|Vitamin E 800 IU/daily
219383841|NCT03669133|DRUG|Placebo|Matching placebo daily
219383842|NCT01601392|PROCEDURE|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
219383843|NCT01601392|PROCEDURE|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
219383844|NCT01601392|PROCEDURE|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
219557915|NCT02578277|DRUG|BMS-955176|BMS-955176
219383845|NCT06042049|DRUG|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
219191756|NCT04771897|DRUG|BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
219383846|NCT04819828|PROCEDURE|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
219383847|NCT04819828|DRUG|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
219383848|NCT04819828|DRUG|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
219383849|NCT05912816|DRUG|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
219383850|NCT06428630|DRUG|dexamethasone oral rinse|"The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study."
219383851|NCT02549950|PROCEDURE|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
219383852|NCT02549950|PROCEDURE|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
219383853|NCT02730559|OTHER|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
219383854|NCT02939521|PROCEDURE|Surgery|
219383855|NCT04932889|OTHER|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
219383856|NCT04932889|OTHER|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
219383857|NCT04932889|OTHER|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
219383858|NCT01147783|OTHER|CT, MRI|
219383859|NCT02113657|DRUG|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
219383860|NCT04373083|DRUG|Cemiplimab|Administered in 3-week intervals
219383861|NCT04373083|RADIATION|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
219383862|NCT00800072|DEVICE|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
219383863|NCT04988230|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
219383864|NCT04988230|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
219383865|NCT03884634|DEVICE|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
219383866|NCT00749606|BEHAVIORAL|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
219557916|NCT02578277|DRUG|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
219557917|NCT03176433|DEVICE|Normothermic Machine Liver Perfusion|Liver Preservation Method
219557918|NCT01344031|DRUG|Akt Inhibitor MK2206|Given PO
219383867|NCT00749606|BEHAVIORAL|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
219383868|NCT04979884|DRUG|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
219383869|NCT03088579|DEVICE|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
219383870|NCT01403129|PROCEDURE|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
219383871|NCT01403129|PROCEDURE|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
219383872|NCT01879020|DRUG|TA-8995|Drug: TA-8995 1mg
219383873|NCT01879020|DRUG|TA-8995|Drug: TA-8995 2.5mg
219383874|NCT01879020|DRUG|TA-8995|Drug: TA-8995 5mg
219383875|NCT01879020|DRUG|TA-8995|Drug: TA-8995 10mg
219383876|NCT01879020|DRUG|TA-8995|Drug: TA-8995 25mg
219383877|NCT01879020|DRUG|Placebo|Placebo (TA-8995 1mg)
219383878|NCT01879020|DRUG|Placebo|Placebo (TA-8995 2.5mg)
219383879|NCT01879020|DRUG|Placebo|Placebo (TA-8995 5mg)
219383880|NCT01879020|DRUG|Placebo|Placebo (TA-8995 10mg)
219383881|NCT01879020|DRUG|Placebo|Placebo (TA-8995 25mg)
219383882|NCT00783640|DRUG|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
219383883|NCT01121406|DRUG|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
219383884|NCT01121406|DRUG|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
219383885|NCT01121406|DRUG|Topotecan|Patients receive topotecan in 3 or 4 week schedule
219383886|NCT01121406|DRUG|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
219383887|NCT01121406|DRUG|BI 6727|Patients receive BI 6727 infusion every 3 weeks
219383888|NCT05970887|BIOLOGICAL|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
219383889|NCT05970887|BIOLOGICAL|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
219383890|NCT01153490|BEHAVIORAL|Behavioral Intervention|Substance-related
219383891|NCT05614011|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
219383892|NCT05614011|DIAGNOSTIC_TEST|Real-time PCR Test|Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
219191757|NCT00313196|DRUG|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
219383893|NCT00661375|DRUG|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
219383894|NCT04735029|DEVICE|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
219383895|NCT04735029|OTHER|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
219383896|NCT00264277|DRUG|Vitamin K antagonist (Coumarin anticoagulants)|
219383897|NCT03216616|BEHAVIORAL|Cognitive Behavioural Therapy|
219383898|NCT04210570|DEVICE|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
219383899|NCT04210570|DRUG|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
219383900|NCT01774942|PROCEDURE|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
219383901|NCT02137044|BEHAVIORAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
219383902|NCT04057183|DIAGNOSTIC_TEST|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
219383903|NCT00302692|DRUG|Esmolol|
219383904|NCT00302692|DRUG|Metoprolol|
219383905|NCT02183389|DRUG|Warfarin|
219383906|NCT02183389|DRUG|BI 1356|
219383907|NCT04391764|DRUG|Naltrexone|Naltrexone at a dose of 50 mg per day
219383908|NCT04391764|DRUG|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
219383909|NCT01917331|DRUG|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
219383910|NCT01917331|DRUG|Beclometasone/Formoterol|Active comparator
219383911|NCT01078753|DRUG|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
219383912|NCT01078753|DRUG|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
219383913|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
219383914|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
219383915|NCT00462423|DRUG|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
219383916|NCT00462423|DRUG|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
219383917|NCT00349128|DRUG|fenofibrate and metformin combination (drug)|
219383918|NCT03543371|DIAGNOSTIC_TEST|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
219383919|NCT04543500|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
219383920|NCT01565525|BEHAVIORAL|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
219383921|NCT01565525|BEHAVIORAL|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
219383922|NCT03193268|OTHER|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
219383923|NCT03193268|OTHER|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
219383924|NCT03982225|DRUG|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
219383925|NCT03982225|DRUG|Placebo|Phosphate buffered saline placebo for injection
219383926|NCT01576471|BIOLOGICAL|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
219383927|NCT01576471|BIOLOGICAL|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
219001029|NCT01450436|OTHER|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
219383928|NCT06278636|DIAGNOSTIC_TEST|Laparoscopi ultrasound examination|Analysis of feasibility and fellow surgeons learning curve in minimally invasive gynecological procedures
219383929|NCT05343910|OTHER|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
219383930|NCT02913625|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
219383931|NCT02913625|OTHER|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
219383932|NCT05742620|DRUG|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
219383933|NCT04459962|DIAGNOSTIC_TEST|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
219383934|NCT00408278|DRUG|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
219383935|NCT00408278|DRUG|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
219383936|NCT00408278|DRUG|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
219383937|NCT00408278|DRUG|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
219383938|NCT04925115|OTHER|Brisk walking|"* Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)"
219383939|NCT00336362|DRUG|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
219383940|NCT00283010|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
219383941|NCT00283010|OTHER|Educational DVDs|
219383942|NCT02032953|DIETARY_SUPPLEMENT|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
219383943|NCT02032953|DRUG|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
219383944|NCT02500550|BIOLOGICAL|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
219383945|NCT02500550|PROCEDURE|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"
219383946|NCT02500550|PROCEDURE|TBI regime|"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
219383947|NCT02500550|PROCEDURE|Non-TBI regime|"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
219383948|NCT01668277|DRUG|7.2% NaCl|
219383949|NCT01668277|DRUG|0.9% NaCl|
219383950|NCT02333708|OTHER|Blood sample|
219383951|NCT06411184|DRUG|Regulator T Cells|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
219383952|NCT02852629|OTHER|observational study|
219383953|NCT00930410|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
219383954|NCT04143022|DEVICE|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
219383955|NCT01626040|DRUG|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
219383956|NCT02599012|DRUG|Ferinject®|intravenous Ferinject 1000mg injection
219383957|NCT05510986|DRUG|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
219383958|NCT05510986|DRUG|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
219383959|NCT04038333|OTHER|No intervention|This is an observational study without any interventions.
219383960|NCT02721862|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
219383961|NCT02721862|DRUG|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
219383962|NCT02721862|RADIATION|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
219383963|NCT00488527|DRUG|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
219383964|NCT02729961|DRUG|Brentuximab Vedotin|Given IV
219383965|NCT02729961|DRUG|Ceritinib|Given PO
219001030|NCT01713972|DRUG|dabrafenib|Given PO
219001031|NCT01713972|DRUG|pazopanib hydrochloride|Given PO
219191758|NCT02950259|DRUG|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
219383966|NCT02729961|OTHER|Laboratory Biomarker Analysis|Correlative studies
219383967|NCT02729961|OTHER|Pharmacological Study|Correlative studies
219383968|NCT05123157|OTHER|NO intervention|"N/:~NO intervention"
219383969|NCT00954785|DEVICE|Ankle brace|Sports Stirrup ankle brace (Aircast)
219383970|NCT00954785|DRUG|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
219383971|NCT00954785|DRUG|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
219383972|NCT02028949|DRUG|Zavedos®|
219383973|NCT02028949|OTHER|Blood samples|
219383974|NCT06392815|DIAGNOSTIC_TEST|Cu DOTATATE PET|The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
219383975|NCT03724708|DEVICE|IUD|IUD insertion
219383976|NCT04516681|DRUG|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
219383977|NCT04516681|DRUG|FOLFOX Protocol|Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
219383978|NCT04516681|DRUG|Adebrelimab|20mg/Kg intravenously every 3 weeks
219383979|NCT02388776|DEVICE|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
219383980|NCT02464631|DRUG|Sofosbuvir + Ribavirin 1|
219383981|NCT02464631|DRUG|Sofosbuvir + Ribavirin 2|
219383982|NCT02464631|DRUG|Sofosbuvir + Ribavirin 3|
219001032|NCT01713972|OTHER|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
219383983|NCT01946009|DRUG|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
219383984|NCT03210844|PROCEDURE|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
219383985|NCT03826914|DIETARY_SUPPLEMENT|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
219191759|NCT02950259|DRUG|Indomethacin|Indomethacin 25 mg three times a day for 21 days
219383986|NCT03826914|DIETARY_SUPPLEMENT|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
219383987|NCT05981950|DIAGNOSTIC_TEST|artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
219383988|NCT04252378|PROCEDURE|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
219383989|NCT04252378|PROCEDURE|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
219383990|NCT05174715|OTHER|BIA|nutritional status was evaluated using BIA
219383991|NCT04334148|DRUG|Hydroxychloroquine|oral self administered tablet
219383992|NCT04334148|DRUG|Placebo oral tablet|oral self administered tablet
219383993|NCT02379858|DRUG|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
219383994|NCT02379858|DRUG|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
219383995|NCT00796783|DRUG|Cushing's syndrome confirmation|
219383996|NCT02164565|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
219191760|NCT02950259|DRUG|Omeprazole|One tablet of omeprazole daily for 21 days
219383997|NCT02164565|DRUG|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
219383998|NCT00567931|DRUG|1-methyl-d-tryptophan|Given orally
219383999|NCT00567931|OTHER|pharmacological study|Correlative studies
219384000|NCT00567931|OTHER|laboratory biomarker analysis|Correlative studies
219384001|NCT03314168|OTHER|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
219384002|NCT03314168|OTHER|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
219384003|NCT05068804|PROCEDURE|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
219384004|NCT05068804|OTHER|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
219384005|NCT00947102|OTHER|Observation|
219384006|NCT02558023|DRUG|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
219384007|NCT02558023|DRUG|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
219384008|NCT05098288|BEHAVIORAL|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
219384009|NCT04950231|OTHER|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
219384010|NCT01773395|BIOLOGICAL|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
219384011|NCT01773395|BIOLOGICAL|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
219384012|NCT01773395|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
219384013|NCT01773395|DRUG|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
219384014|NCT01773395|DRUG|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
219384015|NCT01773395|DRUG|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
219384016|NCT01773395|DRUG|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
219384017|NCT06295926|DRUG|Serplulimab|Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
219384018|NCT04312997|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
219384019|NCT04312997|DRUG|Placebo|Sterile saline for inhalation
219384020|NCT04548947|PROCEDURE|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
219384021|NCT04283461|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
219384022|NCT05227846|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
219384023|NCT02580539|BIOLOGICAL|Group A|Peptide-stimulated T cells 2 x 10\^7/m\^2
219384024|NCT02580539|BIOLOGICAL|Group B|Peptide-stimulated T cells per dose-escalation protocol
219384025|NCT01472484|OTHER|586/8x87 white|2 x 50 g
219001033|NCT01382953|DEVICE|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
219384026|NCT01472484|OTHER|586/8x87 brown|2 x 50 g
219384027|NCT01472484|OTHER|BAT 881|2 x 50 g
219384028|NCT01472484|OTHER|586/8|2 x 50 g
219384029|NCT01136239|DRUG|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
219384030|NCT01136239|DRUG|Placebo|Placebo (600mg twice daily)
219001034|NCT06476262|BEHAVIORAL|This research has only one arm. The intervention focuses on occupational issue|During the post-stroke consultation, each participant is invited to complete questionnaires on occupational gaps, mood disorders, fatigue, cognition, and quality of life.
219384031|NCT01368796|BIOLOGICAL|Agriflu|0.5mL dose IM vaccination
219384032|NCT01368796|BIOLOGICAL|Fluad|0.5mL dose of vaccine given IM
219384033|NCT01368796|BIOLOGICAL|Intanza|0.5mL dose vaccine given IM
219384034|NCT01368796|BIOLOGICAL|Vaxigrip|0.5mL dose vaccine given IM
219384035|NCT02228499|OTHER|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
219384036|NCT05669742|DRUG|Empagliflozin|sodium-glucose transport protein two inhibitor
219384037|NCT05669742|DRUG|olanzapine|antipsychotics
219384038|NCT02495779|DRUG|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
219384039|NCT02495779|BEHAVIORAL|CBT-based counseling|Brief CBT-based counseling to promote adherence
219384040|NCT04342065|DRUG|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
219384041|NCT04342065|DRUG|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
219384042|NCT01558687|DRUG|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
219384043|NCT01558687|OTHER|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
219384044|NCT00748657|BIOLOGICAL|Bevacizumab|Given IV
219384045|NCT00748657|OTHER|Laboratory Biomarker Analysis|Correlative studies
219384046|NCT01805648|DRUG|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
219384047|NCT04313946|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
219384048|NCT06042686|DEVICE|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
219384049|NCT01213056|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
219384050|NCT02478684|OTHER|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
219384051|NCT02478684|OTHER|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
219384052|NCT05270603|OTHER|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
219384053|NCT01416311|DRUG|Eltrombopag|
219384054|NCT02739464|OTHER|Exercise + SOC PT/OT|
219191761|NCT02950259|DIETARY_SUPPLEMENT|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
219384055|NCT02739464|OTHER|SOC PT/OT|
219384056|NCT02279511|DRUG|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
219384057|NCT02279511|DRUG|PLACEBO|Infusion of 500 mL of saline solution. (IV)
219384058|NCT04549012|DRUG|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
219384059|NCT04549012|DRUG|Oxytocin|Oxytocin
219384060|NCT00002365|DRUG|LXR015-1|
219384061|NCT00397150|BEHAVIORAL|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
219384062|NCT05850377|DRUG|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
219384063|NCT05850377|PROCEDURE|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
219384064|NCT04375878|DRUG|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
219384065|NCT04375878|DRUG|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
219384066|NCT03659435|DRUG|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
219384067|NCT03659435|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
219384068|NCT00428363|DEVICE|Cataract surgery with implantation of an intraocular lens|
219384069|NCT04382508|OTHER|Questionnaire|A weekly questionnaire will be filled in
219384070|NCT04355286|DRUG|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
219384071|NCT04744558|OTHER|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
219384072|NCT04744558|OTHER|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
219384073|NCT02512796|DRUG|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
219384074|NCT03677570|DIAGNOSTIC_TEST|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
219384075|NCT03280212|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
219384076|NCT03550690|DEVICE|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
219384077|NCT03550690|DEVICE|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
219384078|NCT03759275|OTHER|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
219384079|NCT05290220|DRUG|HLX07|1500 mg
219384080|NCT05290220|DRUG|HLX10|300 mg
219384081|NCT05290220|DRUG|HLX04|15mg/kg
219384082|NCT05290220|DRUG|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
219384083|NCT00194350|PROCEDURE|Test for Factor V Leiden gene mutation|
219384084|NCT06189820|DIAGNOSTIC_TEST|FAPI PET/CT|"In the department of Nuclear Medicine:~* Installation in a relax chair after weight and height control~* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.~* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46"
219384085|NCT01629849|DRUG|Placebo to BI 1021958 qd|tablet
219384086|NCT01629849|DRUG|BI 1021958 bid|tablets
219384087|NCT01629849|DRUG|Placebo to BI 1021958 bid|tablets
219384088|NCT01629849|DRUG|BI 1021958 qd|tablet
219384089|NCT02673281|OTHER|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
219384090|NCT02673281|OTHER|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
219384091|NCT02441530|DIETARY_SUPPLEMENT|Vitamin D|
219384092|NCT02441530|DIETARY_SUPPLEMENT|Vitamin E|
219384093|NCT02441530|DRUG|Ibuprofen|
219384094|NCT03150940|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram used to demonstrate cardiac function
219384095|NCT03150940|DIAGNOSTIC_TEST|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
219384096|NCT01097902|DRUG|Ibuprofen|800 mg oral one time only
219384097|NCT01097902|DRUG|Placebo tablet|Placebo tablet oral one time only
219384098|NCT03482661|OTHER|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
219384099|NCT04930939|OTHER|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
219384100|NCT02146846|DRUG|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
219384101|NCT00195351|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
219384102|NCT00195351|DRUG|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
219384103|NCT04512079|DRUG|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
219384104|NCT04512079|DRUG|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
219384105|NCT02783781|PROCEDURE|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
219384106|NCT03319199|DIETARY_SUPPLEMENT|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
219384107|NCT03319199|OTHER|Placebo - water|for a duration of 16 weeks
219384108|NCT00540540|DEVICE|Diffuse Optical Spectroscopy|Breast properties scanning
219384109|NCT01203488|DRUG|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
219384110|NCT01203488|OTHER|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
219384111|NCT05641454|DIETARY_SUPPLEMENT|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
219384112|NCT05641454|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219384113|NCT00877838|DRUG|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
219384114|NCT00877838|DRUG|Placebo|Gelatin capsules resembling the ones containing the active substance
219384115|NCT02344940|DRUG|Toremifene|patients will take toremifene 60 mg qd.
219384116|NCT02344940|DRUG|Tamoxifen|patients will take tamoxifen 10 mg bid.
219384117|NCT03381040|DEVICE|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
219384118|NCT03381040|DEVICE|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
219384119|NCT02715648|DRUG|Phenazopyridine|
219384120|NCT05000801|BIOLOGICAL|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
219384121|NCT04350515|OTHER|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
219384122|NCT04350515|OTHER|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
219384123|NCT04350515|OTHER|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
219384124|NCT04350515|OTHER|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
219384125|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
219384126|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
219384127|NCT02916446|BIOLOGICAL|Viaskin Peanut 250 mcg|
219384128|NCT02916446|BIOLOGICAL|Placebo|
219384129|NCT01132014|BIOLOGICAL|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
219384130|NCT02940964|BEHAVIORAL|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
219384131|NCT02940964|BEHAVIORAL|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
219384132|NCT00863668|DRUG|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
219384133|NCT00863668|DRUG|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
219384134|NCT00863668|PROCEDURE|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
219384135|NCT00863668|PROCEDURE|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
219384136|NCT02112968|PROCEDURE|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
219384137|NCT02112968|PROCEDURE|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
219384138|NCT02112968|PROCEDURE|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
219384139|NCT03542552|DRUG|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
219384140|NCT03542552|DRUG|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
219384141|NCT05292677|DRUG|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
219384142|NCT05292677|DRUG|Placebo|2 mL of Normal Saline
219384143|NCT02367092|BEHAVIORAL|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
219384144|NCT01259466|DRUG|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
219384145|NCT02596776|PROCEDURE|Fat biopsy|up to 16 biopsy samples will be taken from each subject
219384146|NCT02596776|DRUG|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
219384147|NCT02596776|OTHER|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
219384148|NCT04282577|DIAGNOSTIC_TEST|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
219384149|NCT06559618|DRUG|Phage Therapy|A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
219384150|NCT06559618|OTHER|Placebo|Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
219384151|NCT02842814|OTHER|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
219384152|NCT02842814|DRUG|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
219384153|NCT02842814|DRUG|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
219384154|NCT03157557|BEHAVIORAL|Lifestyle treatment|Lifestyle treatment
219384155|NCT05707065|OTHER|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
219384156|NCT05707065|OTHER|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
219384157|NCT03141437|OTHER|Best Practice|Receive standard of care
219384158|NCT03141437|OTHER|Educational Intervention|Receive educational materials
219384159|NCT03141437|OTHER|Internet-Based Intervention|Use decision-making website
219384160|NCT03141437|OTHER|Questionnaire Administration|Ancillary studies
219384161|NCT01812161|OTHER|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
219384162|NCT01812161|OTHER|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
219384163|NCT05036785|OTHER|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
219384164|NCT05207761|DRUG|D565|Q.D. in both eye
219384165|NCT05207761|DRUG|D930|T.I.D in both eye
219384166|NCT04215679|OTHER|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
219384167|NCT04215679|OTHER|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
219384168|NCT04215679|OTHER|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
219384169|NCT06338891|OTHER|Main questionnaire|Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
219384170|NCT06338891|OTHER|Secondary questionnaire|Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
219384171|NCT05300087|DRUG|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
219384172|NCT05300087|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
219384173|NCT01390545|DRUG|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
219384174|NCT02810990|DRUG|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
219384175|NCT02246361|PROCEDURE|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
219384176|NCT02882607|BEHAVIORAL|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
219384177|NCT02725502|DRUG|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
219384178|NCT02725502|DRUG|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
219384179|NCT03992313|OTHER|Community-based HCV rapid test|HCV rapid tests will be done in the village
219384180|NCT03992313|OTHER|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
219384181|NCT03992313|OTHER|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
219384182|NCT03992313|OTHER|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
219384183|NCT06971458|PROCEDURE|Sclerotherapy|ultrasound (US)-guided sclerotherapy for the treatment of ovarian endometrioma
219384184|NCT06970145|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).
219384185|NCT06970938|OTHER|Cardiac rehabilitation program|The experimental group patients were included in the cardiac rehabilitation program. The cardiac rehabilitation program was implemented in the cardiopulmonary rehabilitation unit with bicycle ergometry devices by a team consisting of a physical medicine and rehabilitation physician, physiotherapist and nurse. The target heart rate that could be achieved during exercise was determined according to the patient's age and the medications he/she used. The exercise intensity was planned as low and moderate according to the target heart rate percentage. The program was organized as 30 sessions, 5 days a week, for 6 weeks. The sessions were implemented for half an hour while the patients were monitored from the bicycle ergometry device.
219384186|NCT05662514|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
219384187|NCT05662514|OTHER|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
219384188|NCT04201379|OTHER|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
219384189|NCT01561287|PROCEDURE|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
219384190|NCT01561287|PROCEDURE|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
219384191|NCT03050164|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
219384192|NCT03050164|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
219384193|NCT00867750|DEVICE|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
219384194|NCT00867750|DRUG|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
219384195|NCT03822910|DIAGNOSTIC_TEST|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
219384196|NCT03822910|DIAGNOSTIC_TEST|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
219384197|NCT03822910|DIAGNOSTIC_TEST|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
219384198|NCT02302495|DRUG|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
219384199|NCT00460928|DRUG|intravenous immune globulin (IVIG)|
219384200|NCT05057351|OTHER|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
219001035|NCT00208091|DRUG|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
219384201|NCT05057351|OTHER|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
219384202|NCT00604578|DRUG|Pioglitazone Hydrochloride|
219384203|NCT02826057|OTHER|Targeted temperature management (33 degree Celsius)|
219384204|NCT05422300|BEHAVIORAL|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine.
219557919|NCT01344031|DRUG|Anastrozole|Given PO
219557920|NCT01344031|DRUG|Fulvestrant|Given IM
219557921|NCT01344031|OTHER|Laboratory Biomarker Analysis|Correlative studies
219557922|NCT02042599|DRUG|Sedation with sevoflurane during 48-hr in ICU|
219384205|NCT05422300|BEHAVIORAL|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine."
219384206|NCT03742804|BIOLOGICAL|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
219384207|NCT00377650|DEVICE|Percutaneous thrombectomy|
219384208|NCT03248128|DRUG|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
219384209|NCT03248128|DRUG|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
219384210|NCT06107829|DRUG|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
219384211|NCT01914679|DEVICE|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
219384212|NCT00297414|OTHER|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
219384213|NCT04026789|OTHER|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
219384214|NCT04026789|OTHER|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
219384215|NCT02051101|OTHER|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
219384216|NCT01363050|DRUG|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
219384217|NCT03180463|DRUG|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,
219384218|NCT03180463|PROCEDURE|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
219384219|NCT06159855|OTHER|Intervention group: nurse-led education for bowel preparation of colonoscopy|"1. PRE-TEST~   a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. INTERVENTION~   1. Patients will be given face-to-face training in the clinic training room of the unit.~  2. After face-to-face training is given, an educational brochure will be given to the patient.~  3. If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~  4. After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~3. LAST TEST~   1. Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
219384220|NCT02848547|BEHAVIORAL|Text Messaging via Short Message Service|
219384221|NCT00049764|DRUG|Drotrecogin alfa (activated)|
219384222|NCT00049764|DRUG|Placebo|
219384223|NCT02001740|DRUG|Triamcinalone (steroid) and lidocaine|receive once
219384224|NCT02001740|OTHER|Lidocaine|receive once
219384225|NCT06418542|DEVICE|use of florescein|Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
219384226|NCT04630054|DEVICE|Face mask|Intervention individuals will be given cloth or surgical face masks.
219384227|NCT04630054|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
219384228|NCT04632979|PROCEDURE|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
219384229|NCT02866344|PROCEDURE|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
219384230|NCT02866344|PROCEDURE|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
219001036|NCT01075724|DEVICE|Patient Warming with Forced Air|Forced Air warming via BairHugger
219384231|NCT04002167|BEHAVIORAL|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
219384232|NCT04002167|BEHAVIORAL|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
219384233|NCT03200951|DRUG|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
219384234|NCT03200951|DRUG|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
219384235|NCT01253733|BEHAVIORAL|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
219384236|NCT02412865|BEHAVIORAL|Quit4Baby|
219384237|NCT02412865|BEHAVIORAL|Text4Baby|
219384238|NCT01729689|OTHER|counseling intervention|Undergo cognitive behavioral therapy
219384239|NCT01729689|OTHER|questionnaire administration|Ancillary studies
219384240|NCT01729689|PROCEDURE|quality-of-life assessment|Ancillary studies
219384241|NCT05347654|OTHER|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
219384242|NCT05347654|OTHER|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
219384243|NCT02297789|DEVICE|Investigative Full Face Mask with Headgear|
219384244|NCT04176861|DEVICE|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
219384245|NCT05599958|DIAGNOSTIC_TEST|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
219384246|NCT05599958|GENETIC|genetic testing|detection of CFTR mutation
219384247|NCT02049502|BIOLOGICAL|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
219384248|NCT02049502|PROCEDURE|sigmoidoscopy|
219384249|NCT01321489|DRUG|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
219384250|NCT01321489|DRUG|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
219384251|NCT06154070|DRUG|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
219384252|NCT03781557|DIETARY_SUPPLEMENT|Docosahexaenoic acid|High-concentrated DHA
219384253|NCT03781557|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|High-concentrated EPA
219384254|NCT03781557|DIETARY_SUPPLEMENT|Olive oil|Olive Oil softgels
219384255|NCT00004829|DRUG|tobramycin|
219384256|NCT01447693|PROCEDURE|application of ointment (olive-omega 3 ointment)|
219384257|NCT02421393|OTHER|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
219384258|NCT01904487|RADIATION|[11C]flumazenil|\[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
219384259|NCT01904487|DRUG|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
219384260|NCT00642330|DRUG|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
219384261|NCT00642330|DRUG|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
219001037|NCT01075724|DEVICE|Resistive Warming|Resistive Warming via HotDog device
219001038|NCT01599234|DRUG|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
219001039|NCT01599234|DRUG|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
219001040|NCT01443650|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
219001041|NCT04190394|OTHER|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
219001042|NCT02033694|DEVICE|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
219384262|NCT01974791|BEHAVIORAL|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
219384263|NCT00003729|DRUG|cytarabine|
219384264|NCT00003729|DRUG|fludarabine phosphate|
219384265|NCT00003729|DRUG|idarubicin|
219384266|NCT01058603|OTHER|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
219384267|NCT01058603|OTHER|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
219384268|NCT01561131|DIETARY_SUPPLEMENT|Whey protein|45g protein/d; Dosage 3x15g protein daily
219384269|NCT01561131|DIETARY_SUPPLEMENT|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
219384270|NCT01561131|DIETARY_SUPPLEMENT|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
219384271|NCT01561131|DIETARY_SUPPLEMENT|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
219384272|NCT00590161|DRUG|pentoxifylline (PTX)|400 mg PO tid
219384273|NCT00590161|DRUG|placebo|placebo tid
219384274|NCT03875235|DRUG|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
219384275|NCT03875235|DRUG|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
219384276|NCT03791632|OTHER|classical lecture style presentation|classical lecture style presentation
219384277|NCT03791632|OTHER|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
219384278|NCT03791632|OTHER|digital media intervention|digital media intervention
219384279|NCT02503891|DEVICE|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
219384280|NCT00246168|DRUG|tramadol hydrochloride + acetaminophen|
219384281|NCT04054310|DIAGNOSTIC_TEST|Liver Multi Scan|MRI to create cT1, T2\* and PDFF images of patients liver.
219384282|NCT03260647|OTHER|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
219384283|NCT03751384|DIETARY_SUPPLEMENT|Möllers Omega-3 Ekstra Sterk|
219001043|NCT02895906|DRUG|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
219001044|NCT01633333|OTHER|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
219384284|NCT03751384|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|
219384285|NCT04150458|DRUG|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
219384286|NCT05115084|OTHER|no intervention|no intervention
219384287|NCT04152759|DRUG|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
219384288|NCT06602336|DEVICE|Continuous Lactate Monitoring Device|Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
219384289|NCT06600906|DRUG|Hyperpolarized 13C-Pyruvate|Given intravenously (IV)
219384290|NCT06600906|PROCEDURE|Computed tomography (CT)|Undergo CT imaging
219384291|NCT06600906|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
219384292|NCT00735332|DRUG|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
219384293|NCT06444438|DIAGNOSTIC_TEST|subarachnoid hemorrhage|CT presented subarachnoid hemorrhage
219384294|NCT03528525|OTHER||observation
219384295|NCT03153852|DRUG|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
219384296|NCT03153852|DRUG|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
219384297|NCT03153852|DRUG|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
219384298|NCT06657014|OTHER|mind-mindedness|The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
219384299|NCT06656624|DRUG|Ribociclib combined with AI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
219384300|NCT06656624|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
219384301|NCT06656156|OTHER|Proprioceptive neuromuscular facilitation technique|"Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)"
219384302|NCT06656156|OTHER|Conventional treatment|"Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)"
219384303|NCT06657417|DEVICE|Video laryngoscopy|Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
219384304|NCT06657417|DEVICE|Video larnygoscopy|Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
219384305|NCT06656130|OTHER|Pranayama|Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
219557923|NCT03203642|DRUG|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
219384306|NCT06656130|OTHER|Jacobson's progressive muscle relaxation technique|Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
219384307|NCT00345891|BEHAVIORAL|Coping-focused counseling telephone calls|
219384308|NCT05171387|DRUG|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
219384309|NCT05171387|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
219384310|NCT02001012|DRUG|Artemether-lumefantrine combination|
219384311|NCT02001012|DRUG|Chloroquine|
219384312|NCT06818422|OTHER|Home exercise and recommendations for nonspecific neck pain|The intervention involves neck exercises and recommendations for nonspecific neck pain. Patients will perform the exercises at home three times a day for 2 weeks and record their progress in an exercise diary. They will be monitored by a physician for pain levels and receive additional support at the 15th day, 30th day and 3rd months.
219384313|NCT06819943|PROCEDURE|Automated Lateral Rotation Therapy|Platform-based automated lateral tilt system integrated into the Linet Multicare bed, which allows the entire bed platform to be tilted laterally up to 30 degrees along the axial axis, either manually or automatically. The system includes Continuous Low Pressure (CLP) mode, which automatically redistributes pressure to maintain low interface pressure, and Microclimate Management (MCM) to control moisture and heat at the skin interface. The intervention is designed to redistribute interface pressure as a preventive strategy against pressure injuries in critically ill patients.
219384314|NCT04905082|OTHER|Best Practice|Receive usual care
219384315|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
219384316|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics before sequencing results are available
219384317|NCT04905082|PROCEDURE|Genomic Profile|Receive genomics test results
219384318|NCT04905082|OTHER|Survey Administration|Ancillary studies
219384319|NCT06656611|OTHER|HPV self sampling|Selected women will perform a vaginal self-sampling using a swab
219384320|NCT06657625|OTHER|Sepsis Performance Improvement Program|Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
219001045|NCT01633333|OTHER|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
219384321|NCT06657209|PROCEDURE|Insulin resistance testing|Steady state Plasma Glucose test
219384322|NCT06657209|PROCEDURE|OGTT|Will collect 5 blood draws during the test to measure insulin secretion
219384323|NCT06657209|PROCEDURE|Fat biopsy|Needle biopsy to gather a sample of abdominal subcutaneous fat
219384324|NCT06657209|RADIATION|DXA scan|Whole body DXA scan
219384325|NCT06657209|PROCEDURE|MRI|Abdominal MRI
219384326|NCT06657209|PROCEDURE|1H-MRS|Spectroscopy of the abdominal region
219384327|NCT06657209|DRUG|Tirzepatide|16 weeks started at 2.5mg/week and increased to 5mg/week dose
219384328|NCT06657209|DRUG|Pioglitazone|16 weeks at a 45mg/day dose
219384329|NCT06655922|DIAGNOSTIC_TEST|FAPI Imaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
219384330|NCT06655961|OTHER|Garden Activities Program|When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
219384331|NCT06655961|OTHER|Clinical routine treatment and nursing care protocol|Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
219384332|NCT06656533|OTHER|Repeated Transcranial magnetic stimulation (rTMS)|Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
219384333|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
219384334|NCT03849326|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
219384335|NCT03849326|BIOLOGICAL|blood test|complete blood count and cytokine concentration
219384336|NCT03849326|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
219384337|NCT03849326|DEVICE|actigraphy|assessment of sleep quality
219384338|NCT03849326|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)"
219384339|NCT02625402|BEHAVIORAL|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
219384340|NCT02625402|BEHAVIORAL|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
219384341|NCT02173600|BEHAVIORAL|Group-level Intensive dietary Counselling|
219384342|NCT02173600|BEHAVIORAL|Individual-level Intensive Dietary Counselling|
219384343|NCT05446844|OTHER|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
219384344|NCT05446844|OTHER|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
219384345|NCT05750914|DEVICE|Broadband Light|Broadband Light treatment using standard protocol
219384346|NCT06388057|DIAGNOSTIC_TEST|Intraoperative Small Bowel Ultrasonography|An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
219384347|NCT06825390|DEVICE|Cryo-auriculotherapy|The cryo-IQ device (containing compressed nitrous oxide) with a narrow-tip nozzle will be used. After disinfection of the device and both ears, 7 inter-related points in the auricular cartography will be treated with a 1-2 second application of cold gas, applied to both ears. Treatment points will be: mesoderm master, spine, reticular formation, sensory master point, thalamus, adrenocorticotropic hormone, and corpus callosum.
219384348|NCT06825390|DEVICE|Sham auriculotherapy|For the sham procedure, an empty gas canister will be used in the cryo-IQ device. This will make the same noise and temporary skin imprint on the ear, but does not deliver any cooling effect. The same 7 ear points will be sham-treated in a protocol that is imperceptibly different from the verum auriculotherapy treatment.
219384349|NCT06825390|OTHER|Experimental auricular stimulation|Three points on each ear will be repeatedly stimulated with a plastic (von Frey) filament. This will be felt, but not be painful and should not result in lasting irritation.
219384350|NCT02053805|OTHER|PSA|PSA. Serum \& plasma will be stored for future investigations
219384351|NCT02053805|OTHER|IPSS questionnaire|the validated International Prostate Symptom Score
219384352|NCT02053805|OTHER|DRE (Digital Rectal Examination )|physical examination for the prostate gland
219384353|NCT02053805|OTHER|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
219384354|NCT02053805|PROCEDURE|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
219384355|NCT02053805|PROCEDURE|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
219384356|NCT04321863|OTHER|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
219384357|NCT04321863|OTHER|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
219384358|NCT04321863|OTHER|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
219384359|NCT04926155|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
219384360|NCT02514057|OTHER|Questionnaire|Form filling only
219384361|NCT01877655|BIOLOGICAL|ASP0113|Intramuscular injection
219384362|NCT01877655|DRUG|Placebo|Intramuscular injection
219384363|NCT01355432|OTHER|Observation|There is no intervention, this is an observational study.
219384364|NCT02332915|BEHAVIORAL|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
219384365|NCT02798081|BEHAVIORAL|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
219384366|NCT07026435|PROCEDURE|LSTR|Lesion Sterilization and Tissue Repair (LSTR) is a minimally invasive pulp therapy using ciprofloxacin and metronidazole mixed with iodoform-calcium hydroxide, without canal instrumentation. The access cavity is sealed and restored with SSC or compomer.
219384367|NCT07026435|PROCEDURE|Pulpectomy|Pulpectomy includes mechanical canal preparation, irrigation, and obturation using iodoform-calcium hydroxide paste, followed by final restoration with stainless steel crown or compomer.
219384368|NCT07032246|DEVICE|quantitative brain MRI (icobrain mr)|"Quantitative brain MRI refers to using a specialised software to compute volumes of brain structures and of MS lesions from brain MRI scans, and to measures differences between a previous brain MRI scan and the current brain MRI scan.~The quantitative brain MRI solution being investigated in the PROCLAIM study is icobrain mr, a software solution that uses artificial intelligence (AI) to help with tracking of MS disease progression by measuring brain structures and lesions on magnetic resonance imaging (MRI)."
219384369|NCT07032246|OTHER|Standard of Care (SOC)|Standard of Care practices at each participating site for management of multiple sclerosis.
219557924|NCT03203642|DRUG|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
219384370|NCT07030491|OTHER|Lactation Cookies|Participants will consume 2 cookies per day (approximately 40g daily) for 30 consecutive days. The lactation cookies contain ingredients commonly believed to enhance milk production, including moringa, fenugreek, and ginger.
219384371|NCT07030491|OTHER|Control Cookies|Participants in the control group will consume 2 cookies per day (approximately 40g total) for 30 consecutive days. These cookies are matched in taste, appearance, and caloric content but do not contain any known galactagogue ingredients.
219384372|NCT07030660|OTHER|Model-Informed Precision Dosing (MIPD)|Model-Informed Precision Dosing (MIPD) of tacrolimus in kidney transplantation
219384373|NCT07030504|DRUG|SAL0133|once daily single dose or seven days multiple dose of SAL0133 tables
219384374|NCT07030504|DRUG|SAL0133 placebo|once daily single dose or seven days multiple dose of SAL0133 placebo
219384375|NCT06749054|DRUG|Oral Lenacapavir|Tablets administered without regard to food
219384376|NCT06749054|DRUG|Subcutaneous Lenacapavir|Administered via subcutaneous injections
219384377|NCT06749054|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
219384378|NCT06900595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219384379|NCT06900595|DRUG|Cabozantinib|Given PO
219384380|NCT06900595|BIOLOGICAL|Cemiplimab|Given IV
219384381|NCT06900595|PROCEDURE|Computed Tomography|Undergo CT scan
219384382|NCT06900595|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219384383|NCT07106450|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
219001046|NCT04410224|DRUG|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
219384384|NCT07107971|DEVICE|Paclitaxel-eluting balloon|Participants in the intervention group will receive local treatment of non-obstructive, lipid-rich coronary plaques using a paclitaxel-coated drug-eluting balloon (DCB) in addition to guideline-directed medical therapy (GDMT). The DCB will be applied to plaques identified as high-risk based on near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) imaging, defined by a maxLCBI4mm ≥325. The balloon catheter diameter will be sized 1:1 according to the true lumen diameter as derived from IVUS. Balloon length will be sized to the LRP length as measured with IVUS including a 5 mm margin on each side. The balloon will be inflated at nominal pressure (6-8 ATM) during a period of at least 60 seconds, but preferably for 90 seconds if tolerated. A 5 mm margin is taken into account to differentiate between single or multiple LRPs within the same coronary artery.
219384385|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
219384386|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
219384387|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
219384388|NCT06938854|DEVICE|Peripheral Intravascular Lithotripsy (IVL)|For the Disrupt PAD Japan study, the Shockwave Medical Peripheral IVL System (SWM-831) is intended for lithotripsy enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the femoropopliteal arteries.
219384389|NCT05847881|BEHAVIORAL|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
219384390|NCT06953310|OTHER|Shamba Maisha|"The Shamba Maisha Intervention intervention has three key parts:~Farming Equipment and Training: The study will provide families with water pumps, seeds, and other farming tools to improve their ability to grow food. Caregivers and girls will also get training on how to use these tools.~School-based Farming: Girls will participate in practical farming activities at school, where they can learn and practice the farming skills. This also benefits the entire school because the crops grown can be used to provide food for students.~Caregiver and Adolescent Relationship Strengthening: Families will take part in special sessions where they will learn how to improve their communication, reduce stress, and talk about important topics like sexual health."
219384391|NCT00435552|PROCEDURE|Ease-It Spray|
219384392|NCT06046560|DRUG|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
219384393|NCT06046560|BEHAVIORAL|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
219384394|NCT04513158|BIOLOGICAL|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
219384395|NCT04420793|OTHER|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
219384396|NCT06834009|DRUG|SUZ|Powder for oral administration.
219384397|NCT06025136|OTHER|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
219384398|NCT02558946|BEHAVIORAL|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
219384399|NCT02558946|BEHAVIORAL|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
219384400|NCT05188235|DEVICE|Acoustical Resonance Device|"Infants will be studied for 15 min using an electronic tuning fork to transmit sound through the hip from a point on the skin while transmitted sounds FDA-approved stethoscope"
219384401|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
219384402|NCT05635838|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219384403|NCT05635838|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
219384404|NCT05634512|DRUG|Laronidase therapy and a stem cell transplant|To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
219384405|NCT06383520|DRUG|68Ga-aGPC3-scFv/Fab|"For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
219384406|NCT05955027|DRUG|ZX-7101A|a drug to treat influenza, oral
219384407|NCT05955027|DRUG|Placebo|placebo control, oral
219384408|NCT06963684|DEVICE|Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)|This is the first clinical study to evaluate repeat bilateral Direct Selective Laser Trabeculoplasty (DSLT) in treatment-naïve patients, using a paired-eye design. Unlike prior SLT studies, which focused on monocular treatment or repeat treatment following IOP rebound, this study randomizes one eye to receive a second DSLT treatment three months after the first, while the fellow eye receives only a single treatment. This allows for a direct intra-subject comparison of efficacy and durability. Existing studies, including GLAUrious and LiGHT, suggest the potential benefits of repeat laser, but no data currently exist for early, scheduled repeat treatment with DSLT. This trial uniquely investigates whether proactively repeating the procedure in a controlled eye extends IOP reduction and delays or reduces the need for topical medications.
219384409|NCT06964802|OTHER|Cold salt water foot bath|The application of 175 grams of salt to cold water at a constant 22 degrees
219384410|NCT06964802|OTHER|Cold water foot bath|Constant 22 degree cold water application
219384411|NCT06964828|DEVICE|Flat-knitted compression garment|Flat knitted compression garments
219384412|NCT04677114|DRUG|Buprenorphine and Outpatient Parenteral Antibiotic Therapy|Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
219384413|NCT04677114|DRUG|Buprenorphine and standard of care antibiotic treatment|All participants will receive treatment of OUD and the infection per usual clinical care.
219384414|NCT04933812|BEHAVIORAL|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
219384415|NCT04493619|DRUG|PLX2853|PLX2853 tablets
219384416|NCT04493619|DRUG|Carboplatin|Carboplatin IV injection, 5 mg•min/mL
219384417|NCT06157242|DRUG|Xeruborbactam Oral Prodrug|Experimental
219384418|NCT06157242|DRUG|Ceftibuten|Experimental
219384419|NCT05589493|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
219001047|NCT04893967|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
219001048|NCT04893967|DEVICE|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
219001049|NCT02899988|DRUG|Mirikizumab|Administered SC
219001050|NCT02899988|DRUG|Placebo|Administered SC
219384420|NCT02257606|OTHER|I-TRAVLE training|
219384421|NCT01674764|PROCEDURE|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
219384422|NCT01674764|PROCEDURE|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
219384423|NCT06076746|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
219384424|NCT06076746|BEHAVIORAL|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
219384425|NCT05888259|OTHER|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
219384426|NCT05879263|OTHER|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
219384427|NCT05879263|OTHER|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
219384428|NCT06956833|OTHER|Ìmmersive virtual reality simulation with self-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric Airway, Breathing, Circulation, Disability, Exposure (ABCDE) assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with self-guided debriefing (2 hours)"
219384429|NCT06956833|OTHER|Ìmmersive virtual reality simulation with facilitator-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric ABCDE assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with facilitator-guided debriefing (2 hours)"
219384430|NCT00227461|DRUG|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
219384431|NCT00227461|DRUG|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
219384432|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
219384433|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
219384434|NCT05394077|DIAGNOSTIC_TEST|Active Release Technique|Using Active Release Technique
219384435|NCT05394077|DIAGNOSTIC_TEST|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
219384436|NCT01419171|DEVICE|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
219384437|NCT01836601|BEHAVIORAL|Family-centered nighttime communication bundle|
219384438|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
219384439|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
219384440|NCT04884087|BEHAVIORAL|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
219384441|NCT04884087|BEHAVIORAL|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
219384442|NCT00216008|DRUG|docetaxel|
219191762|NCT06119646|OTHER|Warm Pads Applied to the Breast|Applying a warm pad to a breast during episiotomy repair
219384443|NCT00216008|DRUG|cisplatin|
219384444|NCT00216008|PROCEDURE|radiation|
219384445|NCT00216008|PROCEDURE|surgery|
219384446|NCT03719573|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
219384447|NCT02128490|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
219384448|NCT02128490|DRUG|Febuxostat XR|Febuxostat over-encapsulated capsules
219384449|NCT02128490|DRUG|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
219384450|NCT02128490|DRUG|Colchicine|Colchicine tablets
219384451|NCT02128490|DRUG|Naproxen|Naproxen tablets
219384452|NCT02128490|DRUG|Lansoprazole|Lansoprazole capsules
219384453|NCT02243176|DRUG|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
219384454|NCT02243176|DRUG|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
219384455|NCT02040246|DRUG|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
219384456|NCT02040246|DRUG|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
219384457|NCT03533790|DRUG|DEP-Ru|"* Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone"
219384458|NCT01620996|BEHAVIORAL|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
219384459|NCT01620996|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
219384460|NCT01620996|BEHAVIORAL|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
219384461|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
219384462|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
219384463|NCT01810809|PROCEDURE|articular lavage with saline injection|Patients will receive articular lavage with saline injection
219384464|NCT01810809|DRUG|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
219384465|NCT01810809|DRUG|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
219384466|NCT01810809|DRUG|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
219384467|NCT03063385|BEHAVIORAL|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
219384468|NCT03063385|BEHAVIORAL|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
219384469|NCT04442581|DRUG|Cabozantinib S-malate|Given PO
219384470|NCT04442581|BIOLOGICAL|Pembrolizumab|Given IV
219384471|NCT02627846|DEVICE|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
219384472|NCT02627846|DEVICE|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
219384473|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
219191763|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
219191764|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
219191765|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
219384474|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
219384475|NCT02627846|DRUG|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
219384476|NCT02627846|DRUG|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
219384477|NCT06511388|OTHER|Non-Interventional Study|Non-interventional study
219384478|NCT00181688|DRUG|Iressa (ZD1839)|
219384479|NCT00181688|DRUG|Arimidex (Anastrozole)|
219384480|NCT03345862|BEHAVIORAL|non-pharmacological multicomponent|Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
219384481|NCT02359123|OTHER|Cannabics capsules|Cannabis extract in an oil formulation
219384482|NCT00679562|DRUG|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
219384483|NCT00679562|OTHER|Distilled water|Application of patches containing distilled water for 24 hours
219384484|NCT02342171|OTHER|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
219384485|NCT04205591|PROCEDURE|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
219384486|NCT06350162|DRUG|Serplulimab|4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
219188613|NCT05790486|BEHAVIORAL|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
219188614|NCT05790486|BEHAVIORAL|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
219384487|NCT06350162|RADIATION|Chest Radiation|30Gy-45Gy/QD/3Gy
219384488|NCT02261480|OTHER|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
219384489|NCT02261480|OTHER|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
219384490|NCT03943667|DRUG|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
219384491|NCT03943667|DRUG|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
219384492|NCT02229994|OTHER|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
219384493|NCT01904461|DEVICE|Vacuum device|
219384494|NCT01904461|PROCEDURE|Conventional surgery|
219384495|NCT05077189|OTHER|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)"
219384496|NCT03068026|DEVICE|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
219384497|NCT03068026|OTHER|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
219384498|NCT06512857|OTHER|Hand puppet method|Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.
219384499|NCT06512857|OTHER|Kaleidoscope method|Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
219384500|NCT03142997|DIAGNOSTIC_TEST|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
219384501|NCT06468579|DRUG|GT20029|Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
219384502|NCT06468579|DRUG|GT20029 matching placebo|Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
219384503|NCT02199522|PROCEDURE|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
219191766|NCT05864196|RADIATION|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
219384504|NCT05640986|BEHAVIORAL|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
219384505|NCT05640986|BEHAVIORAL|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
219384506|NCT03704051|BEHAVIORAL|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
219384507|NCT03990662|OTHER|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
219384508|NCT06047691|BEHAVIORAL|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
219384509|NCT06047691|BEHAVIORAL|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
219384510|NCT02629393|DRUG|ORGN001 (formerly ALXN1101)|
219384511|NCT01226667|DRUG|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
219384512|NCT04412603|OTHER|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
219384513|NCT03947879|DRUG|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
219384514|NCT03947879|OTHER|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
219384515|NCT06449599|DEVICE|ultrasound|"Local anesthesia 400 mg(20ml) prilocaine 2% to surgical field and additionally ultrasound-guided RIB with 0,25% bupivacaine 20 ml will be applied to the patients who will be inserted cardiac implantable electronic devices An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol 1 g, IV will be administered with dosing intervals not shorter than 6 hours."
219001051|NCT06306040|DRUG|Nalbuphine Versus Magnesium Sulfate|"Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions."
219001052|NCT01717404|DRUG|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
219001053|NCT02835807|BEHAVIORAL|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
219001054|NCT02835807|BEHAVIORAL|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
219001055|NCT01819402|DRUG|Pioglitazone vs Glimepiride|
219384516|NCT06449599|PROCEDURE|parenteral local anesthesia|"Only local anesthesia 400 mg(20ml) prilocaine 2% prilocaine to surgical field will be applied to the patients who will be inserted cardiac implantable electronic devices.~An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol (1 g, IV) will be administered with dosing intervals not shorter than 6 hours."
219384517|NCT06431542|PROCEDURE|physician-applied Triamcinolone Acetonide Econazole Cream|The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
219384518|NCT06431542|PROCEDURE|patient-applied Triamcinolone Acetonide Econazole Cream|The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
219384519|NCT04746326|PROCEDURE|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
219384520|NCT04746326|PROCEDURE|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
219384521|NCT04746326|OTHER|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
219384522|NCT00159484|DRUG|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
219384523|NCT05624372|DIAGNOSTIC_TEST|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
219384524|NCT01943539|DEVICE|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
219384525|NCT00304590|DRUG|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
219384526|NCT06097741|DEVICE|MRI sequences|Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
219384527|NCT03549520|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
219384528|NCT06264726|OTHER|HealtheRx|CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support.
219384529|NCT03486236|DRUG|VX-440|VX-440 was administered in TC with TEZ and IVA.
219384530|NCT03486236|DRUG|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
219384531|NCT03486236|DRUG|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
219384532|NCT03486236|DRUG|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
219384533|NCT06408792|DEVICE|Deepithelized graft and protection technique|To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
219384534|NCT02014948|OTHER|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
219384535|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
219384536|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
219384537|NCT05093127|DEVICE|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
219384538|NCT00454597|PROCEDURE|omentectomy|surgery omentectomy
219384539|NCT02083276|DRUG|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
219384540|NCT03361501|DRUG|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
219384541|NCT03361501|DRUG|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
219384542|NCT00638872|DRUG|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
219384543|NCT00638872|OTHER|0.9% NaCl|same as PDRN
219384544|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
219384545|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
219384546|NCT02758795|DIETARY_SUPPLEMENT|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
219384547|NCT02758795|DIETARY_SUPPLEMENT|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
219384548|NCT00565500|DRUG|celecoxib|celecoxib capsules 200 mg bid for 1 week
219384549|NCT00565500|DRUG|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
219384550|NCT00565500|DRUG|placebo|placebo capsules tid for 1 week
219384551|NCT06145919|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
219384552|NCT06145919|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
219384553|NCT02991651|DRUG|IRX4204|RXR agonist
219384554|NCT02991651|DRUG|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
219384555|NCT02007239|DRUG|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
219384556|NCT00337636|PROCEDURE|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
219384557|NCT00337636|DRUG|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
219384558|NCT06478953|DIAGNOSTIC_TEST|FA Pneumonia Panel|A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
219384559|NCT04939896|OTHER|observation|Observed patients' compliance with rehabilitation at different time
219384560|NCT04526522|OTHER|No intervention|No intervention
219384561|NCT00598130|BIOLOGICAL|Fleece|Fibrin Patch
219384562|NCT00029796|DRUG|soy isoflavones|
219384563|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
219384564|NCT05006807|DEVICE|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
219384565|NCT05006807|DEVICE|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
219384566|NCT05006807|DEVICE|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
219384567|NCT05006807|DEVICE|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
219384568|NCT05006807|DEVICE|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
219384569|NCT05006807|OTHER|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
219384570|NCT05563532|BEHAVIORAL|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
219384571|NCT05418049|DRUG|Baclofen|30mg - Supplied as 10mg and 20mg tablets
219384572|NCT05418049|DRUG|Memantine|two 10 mg tablets
219384573|NCT05418049|DRUG|Roflumilast|250 mcg capsule
219384574|NCT05418049|DRUG|Placebo|Placebo pill
219384575|NCT06190314|DIAGNOSTIC_TEST|Measure serum vitamin b12 levels|Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind
219384576|NCT00345605|DRUG|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
219384577|NCT00345605|DRUG|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
219384578|NCT01335971|DRUG|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
219384579|NCT01335971|DIETARY_SUPPLEMENT|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
219384580|NCT01335971|OTHER|Placebo|Microcrystalline cellulose once daily by mouth
219384581|NCT00384956|DRUG|Azacitidine|
219384582|NCT03095092|DRUG|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
219384583|NCT01249170|BEHAVIORAL|First year program|Information on group that underwent new educational program
219384584|NCT01249170|OTHER|Control comparison|Information from group that did not undergo new first year program
219384585|NCT04075643|DRUG|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
219384586|NCT04075643|DRUG|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
219384587|NCT06234904|BIOLOGICAL|IBR733 Cell Injection|The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
219384588|NCT02591992|OTHER|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
219384589|NCT02591992|OTHER|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
219384590|NCT01095861|DEVICE|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
219384591|NCT01095861|DEVICE|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
219384592|NCT00969722|BIOLOGICAL|MAb-3F8|
219384593|NCT00969722|BIOLOGICAL|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
219384594|NCT00969722|BIOLOGICAL|13-cis-Retinoic Acid|
219384595|NCT03295422|PROCEDURE|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
219188615|NCT05790486|OTHER|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
219188616|NCT05790486|OTHER|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
219188617|NCT04979572|DRUG|TS-172|"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"
219188618|NCT04979572|DRUG|Placebo|"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"
219188619|NCT06246799|DRUG|Tirzepatide|Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
219188620|NCT06246799|DRUG|Pioglitazone|Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
219188621|NCT06246799|DRUG|Sitagliptin|Sitagliptin: will be administered as a 100mg dose once daily.
219188622|NCT06246799|DRUG|Metformin HCI XR|Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
219188623|NCT04642352|DRUG|superior laryngeal nerve block|A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
219188624|NCT05790304|DRUG|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
219384596|NCT03295422|PROCEDURE|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
219384597|NCT06562816|DRUG|Trypsin-Chymotrypsin|100000 IU
219384598|NCT06562816|DRUG|Naproxen Sodium 550mg|550mg
219384599|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
219384600|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
219188625|NCT06011577|DRUG|REL-1017|REL-1017 tablet
219188626|NCT06011577|DRUG|Placebo|Placebo tablet
219188627|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
219384601|NCT04456322|DRUG|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
219384602|NCT04456322|DRUG|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
219001056|NCT00338689|DIETARY_SUPPLEMENT|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
219188628|NCT03812549|DRUG|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
219188629|NCT03812549|RADIATION|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
219188630|NCT03812549|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
219188631|NCT05299723|BEHAVIORAL|BLT Intervention|BLT will be administered via a Luminette 3 light therapy visor. The Luminette 3 is a visor worn above the eyes containing light emitting diode (LEDs) emitting a blue-enriched white light reflecting to the retina at 1,000 lux via a holographic system in order to ensure correct penetration into the eye without impeding vision. This range of light and intensity is sufficient to synchronize the circadian clock.
219384603|NCT05187533|OTHER|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
219384604|NCT02749487|OTHER|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
219384605|NCT03389334|OTHER|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
219384606|NCT06272214|RADIATION|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
219384607|NCT06272214|OTHER|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
219384608|NCT04186208|DRUG|NOVOCART 3D|Autologous Chondrocyte Implantation
219384609|NCT04069767|PROCEDURE|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
219384610|NCT04069767|PROCEDURE|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
219001057|NCT01934530|PROCEDURE|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
219001058|NCT03836937|DRUG|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
219001059|NCT04425161|OTHER|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
219001060|NCT01948622|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
219001061|NCT01948622|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
219001062|NCT01295502|DRUG|Carboplatin|Given IV
219001063|NCT01295502|DRUG|Cisplatin|Given IV
219001064|NCT01295502|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219001065|NCT01295502|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
219001066|NCT01295502|DRUG|Paclitaxel|Given IV
219001067|NCT01618994|PROCEDURE|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
219001068|NCT05809401|BEHAVIORAL|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
219001069|NCT05809401|BEHAVIORAL|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
219001070|NCT00107471|BIOLOGICAL|filgrastim|Given PO
219001071|NCT00107471|DRUG|topotecan hydrochloride|Given IV
219001072|NCT00107471|RADIATION|radiation therapy|
219001073|NCT01652560|DRUG|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
219001074|NCT03140553|DRUG|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
219001075|NCT00033215|DRUG|S-3304|
219001076|NCT02889484|PROCEDURE|Lumbar disc hernia surgery|
219001077|NCT04497506|BEHAVIORAL|Wise Intervention (Self-affirmation and Incremental theory of personality)|The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
219001078|NCT04497506|BEHAVIORAL|Standard preventive intervention|It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
219384611|NCT04513418|DIETARY_SUPPLEMENT|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
219384612|NCT04363307|DEVICE|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
219384613|NCT04363307|DEVICE|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
219384614|NCT03351244|DRUG|BI 409306|28 week treatment period
219384615|NCT03351244|DRUG|Placebo|28 week treatment period
219384616|NCT06584279|DIAGNOSTIC_TEST|Biopsy of the prostate and pathological diagnosis|Whether the index-lesion-contralateral systematic biopsy was performed
219188632|NCT05299723|BEHAVIORAL|BLB Intervention|BLB will be administered via orange lenses that filter out short-wavelength blue light, while allowing the other visible spectrum light to pass. The BLB lenses result in a reduction in melanopic irradiance (i.e., the light that affects sleep) of about 85%. The BLB lenses only make the overall light environment about 30% dimmer. Therefore, the BLB lenses are effective in blocking out most of the blue light in the visible environment that impacts sleep, but do not result in drastic overall dimming/darkening of the light environment.
219188633|NCT05299723|BEHAVIORAL|Sleep Hygiene Education|The sleep hygiene education will consist of watching a sleep education video (background on the regulation of sleep, the impacts of insufficient sleep on mental and physical health, etc.) and a sleep hygiene video (providing overview of sleep hygiene approaches).
219188634|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
219188635|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
219188636|NCT03581773|DRUG|Folic Acid|5 mg pr day for 12 weeks
219188637|NCT03581773|DRUG|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
219188638|NCT05181020|BEHAVIORAL|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
219188639|NCT05582785|DIAGNOSTIC_TEST|Hyperfine MRI|Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
219188640|NCT03220035|OTHER|Laboratory Biomarker Analysis|Correlative studies
219188641|NCT03220035|DRUG|Vemurafenib|Given PO
219188642|NCT05490680|DRUG|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
219384617|NCT04998656|DEVICE|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
219384618|NCT04998656|OTHER|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
219188643|NCT05490680|DRUG|Placebo|Placebo Oral Film
219188644|NCT03639883|DRUG|AIV001|Intradermal injection
219188645|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
219188646|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
219188647|NCT03162783|DRUG|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
219188648|NCT03649880|DRUG|¹⁸F-Fluoromisonidazole|Given IV
219188649|NCT03649880|PROCEDURE|Computed Tomography|Undergo PET/CT
219188650|NCT03649880|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI or PET/CT
219188651|NCT03649880|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219188652|NCT03649880|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
219188653|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
219188654|NCT06227338|DRUG|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
219188655|NCT05739864|BIOLOGICAL|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
219188656|NCT05739864|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
219188657|NCT06093997|OTHER|Massage treatment|The patient sits upright and the neck naturally relaxes. The doctor uses techniques such as pressing and kneading to relax the soft tissues of the neck, and massages points such as FengMen, FengChi, JingJiaji, JianJing,Tianzong and so on. The focus is on using muscle relaxation techniques around the soft tissues of spasms and pain areas to relax the patient's neck and shoulders. All procedures were performed from mild to severe, once a week for 15 minutes each time, for a total of 4 weeks of treatment.
219188658|NCT06093997|OTHER|Cupping|Use a 4-5cm diameter suction cupping for cupping. The treatment area is coated with glycerol, and the cupping is aspirated and adsorbed on the skin. The cupping is slowly pushed along the patient's neck, along the urinary bladder channel of Foot-Taiyang and governor's meridians from top to bottom, repeating back and forth 9 times. Once a week, for a total of 4 weeks of treatment.
219384619|NCT00187083|DRUG|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
219384620|NCT00187083|DRUG|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
219384621|NCT00187083|DRUG|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
219384622|NCT00187083|DRUG|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
219384623|NCT00187083|DRUG|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
219384624|NCT00187083|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
219384625|NCT05146908|BIOLOGICAL|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
219384626|NCT05146908|OTHER|Echography|"In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition"
219384627|NCT05146908|OTHER|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
219384628|NCT04748263|OTHER|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
219384629|NCT00892437|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
219384630|NCT00892437|DRUG|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
219384631|NCT00892437|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
219384632|NCT00892437|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
219384633|NCT00892437|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
219384634|NCT00892437|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
219384635|NCT05187169|DRUG|VS-6766|Dual RAF/MEK inhibitor
219384636|NCT01961531|DEVICE|Accuboost APBI|28Gy delivered in 5 daily fractions
219384637|NCT05057728|BEHAVIORAL|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
219384638|NCT03185130|DRUG|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
219384639|NCT03185130|DRUG|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
219384640|NCT03185130|DRUG|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
219384641|NCT03185130|DRUG|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
219384642|NCT02950129|OTHER|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
219384643|NCT01925703|DRUG|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
219384644|NCT05936086|DRUG|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
219384645|NCT05936086|DRUG|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
219384646|NCT05936086|DRUG|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
219384647|NCT05936086|DRUG|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
219384648|NCT02000843|PROCEDURE|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
219384649|NCT03392129|OTHER|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
219384650|NCT03392129|OTHER|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
219384651|NCT03064282|OTHER|Placebo|observation of skin changes if any
219384652|NCT03064282|DRUG|papaverine|observation of symptoms
219384653|NCT02832089|DRUG|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
219384654|NCT01349738|DRUG|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
219384655|NCT04306042|DRUG|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
219384656|NCT03390829|OTHER|semi-directed interviews|semi-directed interviews
219384657|NCT04509089|DEVICE|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
219384658|NCT02284724|PROCEDURE|Dry Needling|
219384659|NCT02284724|PROCEDURE|Sham Needling|
219384660|NCT00058370|DRUG|cisplatin|
219384661|NCT00058370|DRUG|lomustine|
219384662|NCT00058370|DRUG|vincristine sulfate|
219384663|NCT00058370|PROCEDURE|adjuvant therapy|
219384664|NCT00058370|RADIATION|iodine I 131 monoclonal antibody 3F8|
219384665|NCT00058370|RADIATION|radiation therapy|
219384666|NCT03215277|DRUG|Bimekizumab|One bimekizumab dose will be administered.
219384667|NCT03215277|DRUG|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
219384668|NCT03215277|OTHER|Placebo|Placebo will be provided to maintain the blinding.
219384669|NCT00540215|OTHER|Glucagonlike peptide|450 nmol native form, synthetic
219384670|NCT05232955|DEVICE|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
219384671|NCT03794986|BEHAVIORAL|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
219384672|NCT03794986|BEHAVIORAL|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
219384673|NCT04518371|OTHER|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
219384674|NCT06067477|DIETARY_SUPPLEMENT|Vitamin D Supplement|Vitamin D Supplement
219384675|NCT01882725|DEVICE|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
219384676|NCT04562337|DRUG|SHR1316|Anti-PD-L1 antibody
219384677|NCT04562337|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
219384678|NCT04562337|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
219384679|NCT04562337|RADIATION|Radiation therapy|Thoracic radiation therapy ,TRT
219384680|NCT04562337|DRUG|Cisplatin|Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
219384681|NCT04236453|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
219384682|NCT04236453|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
219384683|NCT04236453|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
219384684|NCT04236453|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
219384685|NCT01854177|DRUG|Aprepitant|
219384686|NCT01854177|DRUG|Placebo|
219384687|NCT03155451|DIAGNOSTIC_TEST|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
219384688|NCT05352685|DRUG|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
219384689|NCT01238120|DRUG|Ibuprofen|200 mg BID and 8 hours apart
219384690|NCT01238120|BEHAVIORAL|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
219384691|NCT01238120|DRUG|Placebo|200mg BID and 8 hours apart
219384692|NCT01661257|DRUG|Infliximab|
219384693|NCT04558697|DRUG|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
219384694|NCT04558697|DRUG|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
219384695|NCT04558697|DRUG|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
219384696|NCT04558697|DRUG|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
219384697|NCT02277886|DRUG|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
219384698|NCT02277886|DRUG|esomeprazole|40mg/tablet, one tablet once before breakfast
219384699|NCT04896177|DEVICE|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
219384700|NCT04896177|DEVICE|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
219384701|NCT05742945|PROCEDURE|Immediate lymphatic reconstruction|Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
219384702|NCT00269763|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
219384703|NCT00699790|DRUG|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
219384704|NCT00699790|DRUG|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
219384705|NCT01776125|OTHER|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
219384706|NCT00019955|PROCEDURE|laparoscopic surgery|
219384707|NCT00019955|PROCEDURE|radiofrequency ablation|
219384708|NCT00019955|PROCEDURE|thermal ablation therapy|
219384709|NCT04071665|PROCEDURE|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
219384710|NCT03338946|DEVICE|CIED interrogation|CareLink Express interrogation
219384711|NCT04881877|DEVICE|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
219384712|NCT04881877|DEVICE|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
219384713|NCT04881877|DEVICE|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
219384714|NCT04273984|DRUG|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
219384715|NCT01870544|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
219384716|NCT01870544|DIETARY_SUPPLEMENT|Placebo|placebo will be administered daily for 44 days
219384717|NCT01415960|DRUG|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
219384718|NCT04733820|DRUG|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
219384719|NCT04520789|DIAGNOSTIC_TEST|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
219384720|NCT04520789|PROCEDURE|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
219384721|NCT04520789|PROCEDURE|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
219384722|NCT02167061|DRUG|DA-1229_01|complex single administration
219384723|NCT02167061|DRUG|E+M|co-administration of 2 drugs
219384724|NCT02167061|DRUG|DA-1229_01 fast|
219384725|NCT02167061|DRUG|DA-1229_01 fed|
219384726|NCT01901744|PROCEDURE|Cataract Surgery|
219384727|NCT04242030|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
219384728|NCT04242030|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
219384729|NCT00234949|DRUG|cefdinir|
219384730|NCT00234949|DRUG|cephalexin|
219384731|NCT03219125|DEVICE|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
219384732|NCT03219125|DEVICE|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
219384733|NCT01382069|DRUG|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
219384734|NCT01382069|DRUG|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
219384735|NCT00003565|DRUG|docetaxel|
219384736|NCT04278742|OTHER|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
219384737|NCT06023108|DEVICE|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
219384738|NCT06023108|DEVICE|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
219384739|NCT01449825|DRUG|Pazopanib use|Treatment with pazopanib
219384740|NCT01449825|DRUG|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
219384741|NCT05741203|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound
219384742|NCT01330290|DRUG|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
219384743|NCT02095561|OTHER|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
219384744|NCT02498652|DRUG|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
219384745|NCT02498652|DRUG|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
219384746|NCT00548912|DRUG|Spironolactone|
219384747|NCT02302911|BEHAVIORAL|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
219384748|NCT02302911|BEHAVIORAL|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
219384749|NCT02302911|OTHER|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
219384750|NCT03069638|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
219384751|NCT03069638|DRUG|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
219384752|NCT02988804|DEVICE|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
219384753|NCT02988804|DEVICE|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
219384754|NCT01561638|PROCEDURE|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
219384755|NCT01561638|PROCEDURE|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
219384756|NCT01561638|PROCEDURE|Sham|will receive puncture for 4 minutes
219384757|NCT02331264|OTHER|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
219384758|NCT04207710|DRUG|Gebauer's Pain Ease Top Aerosol Mist Spray|Topical refrigerant spray
219384759|NCT04207710|DRUG|Gebauer's Ethyl Chloride|Topical refrigerant spray
219384760|NCT03660501|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
219384761|NCT00465569|DRUG|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
219384762|NCT00465569|OTHER|Placebo|
219384763|NCT05959499|DRUG|BR6002A|One tablet administered alone
219384764|NCT05959499|DRUG|BR6002B|One tablet administered alone
219384765|NCT05959499|DRUG|BR6002|One capsule administered alone
219384766|NCT04718064|DRUG|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
219384767|NCT04718064|DRUG|placebo|placebo once daily, for three consecutive days,
219384768|NCT04706572|OTHER|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
219384769|NCT05387590|BEHAVIORAL|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
219384770|NCT04950738|OTHER|pess tack acupuncture|Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
219384771|NCT04950738|OTHER|pess tack placebo|pess tack stickers without a needle
219384772|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
219384773|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
219384774|NCT00163540|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
219384775|NCT01121016|DRUG|Montelukast|10mg, qn, 4 weeks
219384776|NCT01121016|OTHER|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
219384777|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
219384778|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
219384779|NCT02339298|OTHER|music application|music is applied during anaesthesia using headphones
219384780|NCT02339298|OTHER|only headphones|music is not applied, only headphones are placed
219384781|NCT02339298|DRUG|a caudal block|
219384782|NCT03564249|DEVICE|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
219384783|NCT03009695|DEVICE|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
219384784|NCT03009695|DEVICE|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
219384785|NCT03009695|DEVICE|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
219384786|NCT03501212|DRUG|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
219384787|NCT03501212|DRUG|Placebo|Placebo Cream 2.5gr applied to both wrist
219384788|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
219384789|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
219384790|NCT00004415|DEVICE|Medlink spinal cord electrode|
219384791|NCT06554496|DEVICE|CPAP Treatment|Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
219384792|NCT01038492|BEHAVIORAL|p16 Methylation and Lung Cancer Education|"* patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits."
219384793|NCT00922935|DEVICE|Cresco|Cresco components loading 10 days post surgery
219384794|NCT00922935|DEVICE|Cresco|Cresco loading at 6-8 weeks post surgery
219384795|NCT00922935|DEVICE|Straumann components|Straumann components loading 6-8 weeks post surgery
219384796|NCT01607723|OTHER|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
219384797|NCT01607723|OTHER|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
219384798|NCT01619618|GENETIC|mutation analysis|
219384799|NCT01619618|GENETIC|polymerase chain reaction|
219384800|NCT01619618|GENETIC|polymorphism analysis|
219384801|NCT01619618|OTHER|laboratory biomarker analysis|
219384802|NCT04952727|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
219384803|NCT04952727|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
219384804|NCT04493749|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
219384805|NCT00849212|DRUG|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
219384806|NCT05335525|DEVICE|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
219384807|NCT03584802|OTHER|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
219384808|NCT03584802|OTHER|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
219384809|NCT00158977|DEVICE|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
219384810|NCT04478422|OTHER|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
219384811|NCT04478422|OTHER|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
219384812|NCT01864135|DEVICE|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
219384813|NCT01864135|DEVICE|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
219384814|NCT00722176|DRUG|BL-1020|10 mg
219384815|NCT00722176|DRUG|BL-1020 10-30 mg|BL-1020 10-30 mg
219384816|NCT00722176|DRUG|risperidone|risperidone
219384817|NCT01486680|PROCEDURE|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
219384818|NCT01486680|PROCEDURE|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
219384819|NCT00095303|BEHAVIORAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
219384820|NCT00095303|BEHAVIORAL|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
219384821|NCT01108991|BEHAVIORAL|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
219384822|NCT01108991|OTHER|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
219384823|NCT03426969|DRUG|Cyclophosphamide|Given IV
219384824|NCT03426969|BIOLOGICAL|Filgrastim|Given SC
219384825|NCT03426969|DRUG|Fludarabine Phosphate|Given IV
219384826|NCT03426969|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219384827|NCT03426969|DRUG|Melphalan|Given IV
219384828|NCT03426969|DRUG|Mycophenolate Mofetil|Given PO
219384829|NCT03426969|DRUG|Tacrolimus|IV or PO
219384830|NCT03426969|RADIATION|Total-Body Irradiation|Undergo TBI
219384831|NCT01364467|DRUG|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
219384832|NCT01364467|DRUG|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
219384833|NCT01499576|PROCEDURE|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
219384834|NCT03953560|DIAGNOSTIC_TEST|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
219384835|NCT01634243|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
219384836|NCT03291327|DIETARY_SUPPLEMENT|Probiotics|Lozenges for Home use
219384837|NCT04956484|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg
219384838|NCT04956484|DRUG|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
219384839|NCT01048229|DRUG|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
219384840|NCT01048229|DRUG|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
219384841|NCT03993015|OTHER|Help to diagnosis software|Help to diagnosis software
219384842|NCT03842137|DEVICE|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
219384843|NCT03842137|DEVICE|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
219384844|NCT06637540|DEVICE|RescueDoppler|Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
219384845|NCT06637540|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
219384846|NCT01793987|DEVICE|Coblation polypectomy|
219384847|NCT04755374|OTHER|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
219384848|NCT04755374|OTHER|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
219001079|NCT03935529|BEHAVIORAL|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
219384849|NCT02755402|DEVICE|Xpert HCV Viral load|HCV viral load testing
219384850|NCT02755402|DEVICE|Transient elastography|Evaluation of liver fibrosis
219384851|NCT01805271|DRUG|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
219384852|NCT01805271|DRUG|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
219001080|NCT06163170|DRUG|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
219001081|NCT06163170|DRUG|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
219001082|NCT02079181|RADIATION|fluorine F 18 d-FMAU|Given IV
219384853|NCT05269576|OTHER|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
219384854|NCT05269576|OTHER|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
219384855|NCT00693186|BIOLOGICAL|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
219384856|NCT00693186|BIOLOGICAL|Engerix B® 10 µg / 0.5 mL|10 µg
219384857|NCT05574140|DIAGNOSTIC_TEST|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
219384858|NCT01543321|DRUG|Tetrabenazine|"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
219384859|NCT01543321|DRUG|Placebo|"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
219384860|NCT00997971|OTHER|Modilac Rose 1|Infant formula used for non-breastfed children
219384861|NCT04512261|DRUG|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
219384862|NCT04512261|DRUG|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
219384863|NCT04512261|DRUG|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
219384864|NCT01193764|DIETARY_SUPPLEMENT|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
219001083|NCT02079181|PROCEDURE|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
219001084|NCT02079181|PROCEDURE|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
219001085|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
219384865|NCT01193764|DIETARY_SUPPLEMENT|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
219384866|NCT05008887|DRUG|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
219384867|NCT05008887|DRUG|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
219384868|NCT05008887|DEVICE|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
219384869|NCT02111369|DRUG|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
219384870|NCT02111369|PROCEDURE|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
219384871|NCT05760495|OTHER|blood sampling|Blood sampling for evaluation of oxidative stress markers
219384872|NCT06395272|DEVICE|SURA|The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.
219384873|NCT01300143|OTHER|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
219384874|NCT01300143|OTHER|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
219384875|NCT05911997|DRUG|MTC 01|Slurry to be administered via colonoscopy
219384876|NCT05911997|DRUG|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
219384877|NCT05401071|OTHER|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
219384878|NCT05401071|COMBINATION_PRODUCT|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
219384879|NCT05401071|OTHER|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
219384880|NCT05401071|OTHER|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
219384881|NCT02256358|DRUG|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
219384882|NCT02256358|DRUG|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
219384883|NCT03959189|DRUG|ERX-963|Active medicine
219384884|NCT03959189|DRUG|Placebo|Comparator
219384885|NCT03267355|DEVICE|Endoscopic Ultrasound|Indication of EUS
219001086|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
219001087|NCT02062034|DRUG|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
219001088|NCT02062034|DRUG|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
219384886|NCT01302275|DRUG|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
219001089|NCT02062034|DRUG|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
219001090|NCT06045767|DRUG|Pembrolizumab 50 MG Injection [Keytruda]|Chemo-immunotherapy combination
219384887|NCT01815684|DRUG|ASP3652|Oral
219384888|NCT01815684|DRUG|Placebo|Oral
219384889|NCT01020331|DRUG|Memantine|
219384890|NCT03832231|DEVICE|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
219384891|NCT02037945|PROCEDURE|18F-FCH PET Scan|
219384892|NCT05634564|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
219384893|NCT05634564|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
219384894|NCT05634564|DRUG|Nab paclitaxel|Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
219384895|NCT05634564|RADIATION|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
219384896|NCT02426606|OTHER|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
219384897|NCT04477122|OTHER|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
219384898|NCT04606121|COMBINATION_PRODUCT|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
219384899|NCT04192604|OTHER|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
219384900|NCT01600781|DIETARY_SUPPLEMENT|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
219384901|NCT00971321|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
219384902|NCT00202540|DRUG|S18986|
219384903|NCT01968876|OTHER|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
219384904|NCT06447792|OTHER|Loading protocol|The prosthetic restoration and functional loading of the dental implant.
219384905|NCT05233995|PROCEDURE|Damage Control Surgery|Delayed anastomosis
219384906|NCT01850810|OTHER|Experimental Study Product|
219384907|NCT01850810|OTHER|Control Study Product|
219384908|NCT03446924|DIETARY_SUPPLEMENT|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
219384909|NCT03446924|DIETARY_SUPPLEMENT|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
219384910|NCT00004046|DRUG|exatecan mesylate|
219384911|NCT03322657|DRUG|Neostigmine|Neostigmine injection
219384912|NCT03322657|DRUG|Glycopyrrolate|Glycopyrrolate injection
219384913|NCT03322657|DRUG|Sugammadex|Sugammadex injection
219384914|NCT00519623|OTHER|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
219384915|NCT02662439|DEVICE|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
219384916|NCT03679494|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
219384917|NCT02527304|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
219384918|NCT02527304|OTHER|Quality-of-Life Assessment|Ancillary studies
219384919|NCT02527304|OTHER|Questionnaire Administration|Ancillary studies
219384920|NCT02527304|RADIATION|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
219384921|NCT01750021|DIETARY_SUPPLEMENT|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
219384922|NCT01750021|DIETARY_SUPPLEMENT|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
219384923|NCT02433249|BEHAVIORAL|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
219384924|NCT02433249|BEHAVIORAL|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
219384925|NCT02433249|BEHAVIORAL|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
219384926|NCT05042245|DRUG|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
219384927|NCT05042245|DRUG|Silymarin capsule|Silymarin capsules in the active comparator arm.
219384928|NCT05042245|DRUG|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
219384929|NCT05042245|DRUG|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
219384930|NCT04403867|PROCEDURE|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
219384931|NCT00208468|DEVICE|European Hip|A cementless femoral component for use in total hip replacement
219384932|NCT00208468|DEVICE|Zweymüller|A cementless femoral component for use in total hip replacement
219384933|NCT00208468|DEVICE|CLS Spotorno|A cementless femoral component for use in total hip replacement
219384934|NCT00291629|DRUG|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
219384935|NCT00291629|PROCEDURE|collection of mobilized peripheral blood stem cells|
219384936|NCT00291629|PROCEDURE|Intracoronary infusion of mobilized cells|
219384937|NCT06513702|PROCEDURE|Transesophageal lung ultrasound (TELUS) guided recruitment maneuver|"1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring"
219384938|NCT06513702|OTHER|Manual bag lung reinflation|"After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery"
219384939|NCT05394844|DEVICE|Dexcom G6|Dexcom G6 CGM device
219384940|NCT01898546|PROCEDURE|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
219384941|NCT01898546|PROCEDURE|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
219384942|NCT02296840|DRUG|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
219384943|NCT02296840|DRUG|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
219384944|NCT04641286|OTHER|Body motion categorisation|All patients will receive passive motion categorisation monitoring
219384945|NCT05555342|PROCEDURE|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
219384946|NCT05555342|RADIATION|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
219384947|NCT00843180|OTHER|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
219384948|NCT00104871|DRUG|Bortezomib|Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
219001091|NCT04021004|OTHER|Survey Questionnaire|Survey Questionnaire
219001092|NCT00869895|DRUG|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
219001093|NCT01549444|OTHER|presence of maternal risk factor for hypertension|
219384949|NCT00385021|DRUG|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
219384950|NCT06533553|DRUG|Dexpramipexole Dihydrochloride|Administration of dexpramipexole tablet
219384951|NCT06294028|OTHER|Adverse events collection|Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
219384952|NCT06294028|OTHER|Quality of life questionnaire EQ-5D-5L|"Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100"
219384953|NCT06294028|OTHER|Medical-economic evaluation|"Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS)."
219384954|NCT03808311|OTHER|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
219384955|NCT01336101|DEVICE|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
219384956|NCT04373603|DRUG|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
219384957|NCT04373603|OTHER|Saline|sodium chloride and water for use as control
219384958|NCT04373603|DRUG|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
219384959|NCT00761215|DRUG|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
219384960|NCT00761215|DRUG|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
219384961|NCT00761215|DRUG|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
219384962|NCT06970691|DIAGNOSTIC_TEST|panoramic radiograph|Panoramic radiographs for aggressive periodontitis previously diagnosed cases were interpreted by single examiner (NY). The included radiographs had to fulfill the following; 1) sufficient image quality; 2) All teeth with the surrounding alveolar bone had to be clear enough to facilitate alveolar bone tracing; 3) Only pre-operative radiographs were enrolled (before the surgical management of bony defects).
219384963|NCT06970067|BEHAVIORAL|Active Middle School Communities|This intervention will engage multi-sectoral and multi-generational community members and middle school students to co-produce (co-design, co-implementation, and co-evaluation) contextually-responsive intervention strategies to improve access to active transport and leisure, resulting in increased physical activity and decreased risk for chronic disease in middle school communities. This intervention will use community-based participatory methods, with resources provided for changes in the built environment around the school catchment area.
219384964|NCT06969937|DRUG|Ketamine|A single dose of ketamine 0.8 mg ketamine (i.v.) per kilogram bodyweight
219384965|NCT06969937|BEHAVIORAL|Real-time fMRI Neurofeedback Training|Participants will undergo a closed-loop rt-fMRI paradigm over 25 minutes. Participants will be instructed to use strategies to downregulate cue-induced cravings. The Intensity of cues will adjust based on the participants neural activity in response to cues. This dynamic feedback mechanism allows for personalized training aimed at improving the participant's ability to manage cravings.
219384966|NCT06969937|DRUG|Placebo|Single dose of placebo (0.9% NaCl infusion)
219384967|NCT06969937|BEHAVIORAL|Sham Neurofeedback Training/ Ketamine|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight. The use of sham-NFT allows for a rigorous assessment of the specific effects of combined rt-fMRI NFT and ketamine by controlling for non-specific factors such as expectancy effects or the therapeutic context.
219384968|NCT06970054|DEVICE|OPEP|-Patients are provided with a networked handheld respiratory training device. -Patients are provided with a wearable device for monitoring data. -Patients receive an OPEP training plan and instructions on using the respiratory training device. -Training on the OPEP device is conducted: -Inpatients: Twice daily training during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
219384969|NCT06970054|BEHAVIORAL|Aerobic Exercise|-Patients are provided with a wearable device for monitoring data. -Patients receive an aerobic exercise training plan and instructions on using the device. -Exercise training is conducted: -Inpatients: Daily aerobic exercise during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
219384970|NCT06971822|DIETARY_SUPPLEMENT|Protein Supplementation|We are assessing the supplementation of a controlled diet with beta-lactoglobulin protein compared to regular isonitrogenous whey protein. We will make these comparisons over both the 24 hour rested and 24 hour post-exercise states. Beta-lactoglobulin has a higher leucine content than traditional whey protein, with this leucine amino acid thought to have a critical role as an anabolic stimulus to initiate muscle protein synthesis.
219384971|NCT06350383|BEHAVIORAL|WINGS+PM+|WINGS+PM+ is a safety, harm reduction, and brief psychological intervention combined and adapted by community members from informal settlements in Kenya (IPV survivors, health clinic staff, and CHVs) from two evidence-based interventions: Wings of Hope (WINGS) and Problem Management Plus (PM+). This intervention was designed to be facilitated by non-specialists (e.g., CHVs). It involves seven 90-minute weekly sessions. The intervention is informed by social cognitive theory.
219384972|NCT06350383|BEHAVIORAL|PM+-only|PM+: is a brief psychological intervention also designed to be facilitated by non-specialists (e.g. CHVs) and focused on problem management and evidence-based behavioral strategies to enhance one's capacity to adaptively manage psychological distress. It has been shown to be effective at reducing psychological distress among women who have experienced gender-based violence in informal settlements in Nairobi, Kenya. PM+ involves five 90-minute, weekly individual sessions.
219384973|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
219384974|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
219384975|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
219384976|NCT03796403|OTHER|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
219384977|NCT02364817|BEHAVIORAL|cognitive and psychiatric assessment|"Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS"
219384978|NCT00420914|PROCEDURE|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
219384979|NCT02732158|OTHER|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
219384980|NCT03024775|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour will be administered three times per day for 15 days.
219384981|NCT03024775|DIETARY_SUPPLEMENT|Placebo|Placebo (xylose) will be administered three times per day for 15 days.
219557925|NCT05554887|OTHER|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
219384982|NCT03968146|PROCEDURE|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
219384983|NCT03968146|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
219384984|NCT03968146|DRUG|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
219384985|NCT03968146|DRUG|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
219384986|NCT03968146|DRUG|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
219384987|NCT03968146|DRUG|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
219384988|NCT03968146|DRUG|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
219384989|NCT03968146|DRUG|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
219384990|NCT03518515|OTHER|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
219384991|NCT03518515|OTHER|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
219384992|NCT03518515|OTHER|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
219384993|NCT04902287|BEHAVIORAL|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
219384994|NCT01477450|DEVICE|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
219384995|NCT01477450|DEVICE|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
219384996|NCT01955486|OTHER|flight simulation|
219384997|NCT01167127|DRUG|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
219384998|NCT04580147|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
219384999|NCT04580147|OTHER|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
219385000|NCT04876547|PROCEDURE|appendectomy|appendectomy performance
219385001|NCT04970667|DRUG|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
219385002|NCT01586091|DRUG|Levocetirizine Oral Tablet|
219385003|NCT01586091|DRUG|Fexofenadine 60 Mg Oral Tablet|
219385004|NCT01586091|DRUG|Placebo Oral Tablet|
219385005|NCT01935219|BEHAVIORAL|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
219385006|NCT01935219|BEHAVIORAL|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
219385007|NCT01935219|BEHAVIORAL|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
219385008|NCT03730896|PROCEDURE|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
219385009|NCT01687673|DRUG|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
219385010|NCT01687673|DRUG|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
219385011|NCT02234622|BEHAVIORAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
219385012|NCT02234622|BEHAVIORAL|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
219385013|NCT01574781|PROCEDURE|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
219385014|NCT01574781|PROCEDURE|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
219385015|NCT01199341|DRUG|AZD1981|100 mg per oral, twice daily for 14 days
219001094|NCT02555189|DRUG|Enzalutamide|Given PO
219001095|NCT02555189|DRUG|Ribociclib|Given PO
219001096|NCT02555189|OTHER|Laboratory Biomarker Analysis|Correlative studies
219385016|NCT01199341|DRUG|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
219385017|NCT01199341|DRUG|AZD1981|4 x 100 mg per oral, twice daily for 14 days
219385018|NCT02291159|DEVICE|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
219385019|NCT02291159|DEVICE|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
219001097|NCT02555189|OTHER|Pharmacological Study|Correlative studies
219001098|NCT02555189|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219385020|NCT05747404|DIAGNOSTIC_TEST|Echocardiography|\- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
219385021|NCT05012566|DEVICE|Juvederm|"* Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
219385022|NCT05012566|DRUG|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
219385023|NCT00618956|DRUG|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
219385024|NCT00618956|DRUG|Placebo|Placebo
219385025|NCT02388230|DEVICE|Ultrasound imaging|
219385026|NCT02212418|OTHER|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
219385027|NCT01658800|BIOLOGICAL|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
219385028|NCT04882007|DRUG|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
219385029|NCT04882007|DRUG|Placebo|Normal saline
219385030|NCT02006576|DRUG|600 mg ibuprofen three times daily for 48 weeks|
219385031|NCT02006576|OTHER|Placebo three times daily|
219385032|NCT00904787|DRUG|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
219385033|NCT04642235|OTHER|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
219001099|NCT02555189|PROCEDURE|Biopsy|Undergo tumor biopsy
219001100|NCT02555189|PROCEDURE|Echocardiography|Undergo ECHO
219001101|NCT02555189|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219001102|NCT02555189|PROCEDURE|Bone Scan|Undergo bone scan
219001103|NCT02555189|PROCEDURE|Computed Tomography|Undergo CT
219001104|NCT02555189|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219001105|NCT01401283|DEVICE|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
219001106|NCT03007576|BIOLOGICAL|RegStem|RegStem, 1.5 ml, one injection
219385034|NCT04642235|BEHAVIORAL|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
219385035|NCT04642235|OTHER|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
219385036|NCT05559814|DRUG|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
219385037|NCT05559814|DRUG|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
219385038|NCT02587494|PROCEDURE|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
219385039|NCT00986336|DRUG|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
219385040|NCT00986336|DRUG|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
219385041|NCT00986336|DRUG|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
219385042|NCT00986336|DRUG|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
219385043|NCT03478683|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
219385044|NCT03478683|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
219385045|NCT03478683|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
219385046|NCT03478683|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
219385047|NCT03478683|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
219385048|NCT03478683|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
219385049|NCT03478683|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
219385050|NCT03478683|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
219385051|NCT03478683|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
219385052|NCT03478683|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
219385053|NCT01999829|DRUG|citrate of caffeine|
219385054|NCT01999829|DRUG|placebo|
219385055|NCT03483532|DIETARY_SUPPLEMENT|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
219385056|NCT03483532|DIETARY_SUPPLEMENT|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
219385057|NCT00337051|DRUG|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
219385058|NCT00337051|DRUG|Propofol|General anesthesia with propofol TCI
219385059|NCT02593370|DRUG|Lidocaine-epinephrine added gadoterate meglumine|
219385060|NCT03690791|DRUG|MediCabilis CBD Oil|50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
219001107|NCT00812890|DEVICE|semi-quantitative pregnancy test|
219385061|NCT03690791|DRUG|Placebo Oil|Placebo will contain only hemp seed oil.
219385062|NCT06596304|OTHER|Low intensity-resistance training with lower limb blood flow restriction|In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
219385063|NCT06596304|OTHER|High Intensity Resistance Training|In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
219385064|NCT05175170|BEHAVIORAL|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
219385065|NCT04965519|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
219385066|NCT06656858|OTHER|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
219385067|NCT06656858|OTHER|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
219385068|NCT06656858|OTHER|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
219385069|NCT06656858|OTHER|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
219385070|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
219385071|NCT06657300|DRUG|PRP|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
219385072|NCT06657300|DRUG|Corticosteroid|A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
219188659|NCT06093997|OTHER|Bloodletting|the doctor takes JianZhongShu, one on the left and one on the right, with a total of 2 acupoints. After disinfecting with 75% alcohol cotton balls, the patient is quickly pricked 5 times with a blood collection needle, and cupping is performed at the needle hole. After 5 minutes, remove the jar, wipe the blood clean, and disinfect the needle hole. Once a week, for a total of 4 weeks of treatment.
219188660|NCT03504683|BEHAVIORAL|Early TRE|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
219385073|NCT06657469|OTHER|Attention Functions Training (AFT)|The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.
219385074|NCT06657469|OTHER|Executive Functions Training (EFT)|The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
219385075|NCT06656182|OTHER|Cervical and Thoracic SNAGs|cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
219385076|NCT06656182|OTHER|traditional physical therapy and scapular mobilizations|scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
219385077|NCT06657482|BEHAVIORAL|Delayed school start time|The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
219385078|NCT06657066|DRUG|Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii|Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
219385079|NCT06657066|DRUG|Control (Standard treatment)|The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
219385080|NCT06656897|BEHAVIORAL|FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)|FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
219385081|NCT06656234|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
219385082|NCT06656234|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
219385083|NCT06656806|DRUG|Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD|Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
219385084|NCT06656806|DRUG|Determine the presence and concentration of CBD in subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
219385085|NCT06656559|DRUG|Envafolimab and Surufatinib|Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
219385086|NCT06656429|DRUG|Transforaminal Epidural Steroid Injections|Transforaminal Epidural Steroid Injections
219385087|NCT00128687|BEHAVIORAL|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
219385088|NCT00323661|DEVICE|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
219385089|NCT00323661|DEVICE|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
219385090|NCT03820115|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
219385091|NCT03505242|DEVICE|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
219385092|NCT03505242|DEVICE|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
219385093|NCT06377995|OTHER|Placebo technique|The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
219385094|NCT06377995|OTHER|Diaphragm protocol|The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
219385095|NCT05059353|DEVICE|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
219385096|NCT01650805|DRUG|ponatinib|45 mg tablet, taken orally once daily
219385097|NCT01650805|DRUG|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
219385098|NCT06656091|DRUG|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
219385099|NCT06656091|DRUG|investigator's choice of chemotherapy,include docetaxel or irinotecan.|docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
219385100|NCT03999970|OTHER|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
219385101|NCT01986530|DIETARY_SUPPLEMENT|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
219385102|NCT01986530|OTHER|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
219385103|NCT00222846|BEHAVIORAL|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
219385104|NCT00222846|BEHAVIORAL|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
219385105|NCT05650827|BEHAVIORAL|Resistance training|10 weeks of resistance training 3 times pr. week.
219385106|NCT05650827|DIETARY_SUPPLEMENT|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
219385107|NCT05631028|DRUG|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
219385108|NCT05631028|DRUG|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
219385109|NCT03697239|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
219385110|NCT03697239|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
219385111|NCT03697239|DRUG|Cisplatin|25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
219385112|NCT03697239|DRUG|Gemcitabine|1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
219385113|NCT02452359|DEVICE|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
219385114|NCT01887210|BEHAVIORAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
219385115|NCT01887210|BEHAVIORAL|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
219385116|NCT04770103|BEHAVIORAL|Balance recovery|"Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
219385117|NCT04770103|BEHAVIORAL|Postural Sway|"Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
219385118|NCT02287246|DRUG|Extended-Release liposomal bupivacaine (Exparel)|20mL
219385119|NCT02287246|DRUG|Normal saline|20mL
219385120|NCT00500097|DEVICE|Digital retina image|
219385121|NCT00500097|DEVICE|direct ophthalmoscopy|
219385122|NCT00500097|PROCEDURE|comprehensive eye exam|
219385123|NCT00584350|OTHER|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
219385124|NCT00584350|OTHER|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
219385125|NCT00584350|OTHER|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
219385126|NCT00770861|DRUG|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
219385127|NCT00770861|DRUG|Placebo|Matching placebo tablets, oral administration
219385128|NCT00662155|DRUG|Zolpidem|sedative-hypnotic
219385129|NCT00662155|DRUG|Placebos|Placebo
219385130|NCT03358628|OTHER|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
219188661|NCT03504683|BEHAVIORAL|Mid-day TRE|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
219385131|NCT06483893|PROCEDURE|US-guided thyroid cartilage plane block (group TCPB)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
219557926|NCT05554887|OTHER|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
219188662|NCT03504683|BEHAVIORAL|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
219188663|NCT06047509|PROCEDURE|Focal Laser Ablation|Removal of cancerous tissue through the direct application of laser energy
219188664|NCT00248807|DRUG|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
219188665|NCT00248807|OTHER|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
219188666|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
219188667|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
219188668|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
219385132|NCT06483893|PROCEDURE|US-guided traditional superior laryngeal nerve block (group traditional SLNB)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
219385133|NCT01468519|DRUG|Insulin|Insulin via continuous subcutaneous insulin infusion
219385134|NCT01468519|DRUG|Insulin|insulin via multiple daily injections
219385135|NCT04596813|DEVICE|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
219385136|NCT03237403|OTHER|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
219385137|NCT05032508|DRUG|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
219385138|NCT05032508|DRUG|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
219385139|NCT06080750|GENETIC|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
219385140|NCT06080750|DIAGNOSTIC_TEST|ELISA and colorimeter|IL-6 and total LDH
219385141|NCT02291341|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
219385142|NCT02291341|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
219385143|NCT03942614|BEHAVIORAL|Nordic pole walking|
219385144|NCT02119130|DEVICE|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
219188669|NCT04063592|PROCEDURE|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
219188670|NCT06402669|OTHER|Packed Red Blood Cell Administration|Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
219188671|NCT03501576|BIOLOGICAL|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
219188672|NCT05715268|DEVICE|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
219188673|NCT05715268|OTHER|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
219188674|NCT05583006|DRUG|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
219385145|NCT03261869|OTHER|Cold application|
219385146|NCT00994188|PROCEDURE|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
219385147|NCT02985801|DRUG|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
219385148|NCT02985801|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
219385149|NCT03738124|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
219385150|NCT02464319|DRUG|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
219385151|NCT02464319|DRUG|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
219385152|NCT03858582|DRUG|pembrolizumab|pembrolizumab 200mg
219385153|NCT03858582|RADIATION|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
219385154|NCT01479972|BIOLOGICAL|VPM1002|Tuberculosis vaccine
219385155|NCT01479972|BIOLOGICAL|BCG|commercially available live vaccine BCG
219385156|NCT01160367|OTHER|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
219385157|NCT01160367|OTHER|standard of care|Patient-family dyads will receive standard of care in health decision-making
219385158|NCT05581719|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
219385159|NCT05581719|DRUG|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
219385160|NCT05581719|DRUG|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
219385161|NCT02035943|DIETARY_SUPPLEMENT|Insulin separated|separate continuos infusion of insulin
219385162|NCT02035943|DIETARY_SUPPLEMENT|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
219385163|NCT00630032|DRUG|cyclophosphamide|500 mg/m² every 3 weeks
219385164|NCT00630032|DRUG|Docetaxel|100 mg/m² every 3 weeks
219188675|NCT05702749|PROCEDURE|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
219188676|NCT05702749|RADIATION|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
219385165|NCT00630032|DRUG|epirubicin hydrochloride|100 mg/m² every 3 weeks
219385166|NCT00630032|DRUG|fluorouracil|500 mg/m² every 3 weeks
219385167|NCT00630032|DRUG|ixabepilone|40 mg/m² every 3 weeks
219385168|NCT00870493|DRUG|Aliskiren|Aliskiren 300 mg daily oral
219385169|NCT00870493|DRUG|Placebo|starch tablet, 300 mg/day
219385170|NCT03071432|DIAGNOSTIC_TEST|Paced breathing at 6, 10 and 15 breaths per minute|
219385171|NCT02769871|BEHAVIORAL|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
219385172|NCT02769871|BEHAVIORAL|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
219385173|NCT04210713|DRUG|Minocycline|200 mg/day
219385174|NCT04210713|DRUG|Sugar pill|Matched placebo
219385175|NCT05370469|OTHER|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
219385176|NCT05370469|DEVICE|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
219385177|NCT05370469|DEVICE|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
219385178|NCT05370469|OTHER|Surveys|Electronic and paper surveys will be administered throughout the study.
219385179|NCT02509338|DEVICE|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
219385180|NCT04282915|OTHER|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
219385181|NCT04282915|OTHER|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
219385182|NCT05735054|PROCEDURE|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
219188677|NCT05702749|OTHER|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
219385183|NCT06870994|DEVICE|Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy
219557927|NCT01090245|BEHAVIORAL|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
219557928|NCT01090245|BEHAVIORAL|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
219385184|NCT04413799|COMBINATION_PRODUCT|lidocaine, ketamine intravenous infusion|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
219385185|NCT04413799|DRUG|paravertebral block with ropivicaine|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
219385186|NCT04015141|DRUG|Perampanel Oral Suspension|Perampanel oral suspension.
219385187|NCT04015141|DRUG|Perampanel Tablet|Perampanel tablet.
219385188|NCT02475200|DEVICE|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
219385189|NCT04561180|DRUG|EG-009A|Administered as an Intramuscular injection
219385190|NCT04561180|DRUG|EG-009A Placebo|Administered as an Intramuscular injection
219385191|NCT04561180|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
219385192|NCT04561180|DRUG|Dexamethasone|The comparator, Administered as an Intravenous infusion
219385193|NCT07031479|DRUG|Itopride HCI 50 mg|Enteral Itopride 50 mg enterally tid ac
219385194|NCT07031479|DRUG|Metoclopramide 10 mg ampoule|"Intravenous Metoclopramide (10 mg IV q 6 hours)~CrCl 15-60 ml/min: Metoclopramide 5 mg IV q 6 hours CrCl \<15 ml/min: Metoclopramide 5 mg IV q 12 hours Hepatic impairment/ cirrhosis: Metoclopramide 5 mg IV q 6 hours"
219385195|NCT07031713|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
219385196|NCT07031661|OTHER|This was an observational study with no intervention.|This was an observational study with no intervention.
219385197|NCT07030361|BEHAVIORAL|suit group|elbise giydirme ve video izletme uygulaması
219385198|NCT07030361|BEHAVIORAL|training group|video izletme uygulaması
219007026|NCT05560984|COMBINATION_PRODUCT|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
219385199|NCT07030361|BEHAVIORAL|control group|rutin hemş bakımı uygulaması, herhangi bir müdahale yok
219385200|NCT07030478|DRUG|EP0089-101|EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)
219385201|NCT07030790|DRUG|KLA480 injection|Subcutaneous injection，Single dose
219385202|NCT07030790|DRUG|Placebo|Subcutaneous injection，Single dose
219385203|NCT07031128|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
219385204|NCT07031128|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219385205|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) in second intervention period (after washout period: at least 7 days)
219385206|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) in second intervention period (after washout period: at least 7 days)
219385207|NCT06718751|DRUG|Tranexamic Acid 650 MG|PO administration of TXA tablet
219385208|NCT06718751|DRUG|Placebo|PO administration of placebo tablet
219385209|NCT02258412|DRUG|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
219385210|NCT02258412|DRUG|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
219385211|NCT06741111|OTHER|No treatment given|No treatment given
219385212|NCT04015557|DRUG|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
219385213|NCT04015557|DRUG|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
219385214|NCT03497689|DRUG|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
219385215|NCT03191786|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
219385216|NCT03191786|DRUG|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
219385217|NCT03191786|DRUG|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
219385218|NCT05706129|DRUG|[68Ga]Ga-DPI-4452|\[68Ga\]Ga-DPI-4452, administered as IV injection.
219385219|NCT05706129|DRUG|[177Lu]Lu-DPI-4452|\[177Lu\]Lu-DPI-4452, administered as IV infusion.
219385220|NCT06017869|BIOLOGICAL|MNV-201|Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.
219385221|NCT00528229|RADIATION|Computer Tomography|
219385222|NCT04266574|DEVICE|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
219385223|NCT04266574|DEVICE|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
219385224|NCT02610023|OTHER|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
219385225|NCT02610023|OTHER|Laboratory Biomarker Analysis|Correlative studies
219385226|NCT02610023|DEVICE|Spectroscopy|Undergo resonance Raman spectroscopy
219385227|NCT02951598|DRUG|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
219385228|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
219385229|NCT05207397|OTHER|Lactate infusion|The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions were made by a pharmacy and tested to be sterile and pyrogen free. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[13C3\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[13C3\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
219385230|NCT06226090|DRUG|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
219385231|NCT06226090|DRUG|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
219385232|NCT06226090|DRUG|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
219385233|NCT06226090|DRUG|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
219385234|NCT06226090|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
219385235|NCT06226090|DRUG|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
219385236|NCT05964738|DRUG|Diuretics withdrawal|Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
219385237|NCT05964738|DRUG|Diuretics maintenance|Any diuretic could be used
219385238|NCT05125081|DRUG|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
219007027|NCT06152757|BIOLOGICAL|First dose|1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
219007028|NCT06152757|BIOLOGICAL|Second dose|3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
219385239|NCT05125081|DRUG|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
219385240|NCT05562193|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
219385241|NCT05562193|OTHER|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
219385242|NCT05519696|BEHAVIORAL|Intervention|Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
219385243|NCT05519696|BEHAVIORAL|Comparison|Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
219385244|NCT05111210|OTHER|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
219385245|NCT05111210|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
219385246|NCT05111210|OTHER|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
219385247|NCT06194201|DRUG|HRS9432|Dosing frequency: intravenously once week
219385248|NCT06194201|DRUG|Caspofungin Acetate for Injection|Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
219385249|NCT05067777|PROCEDURE|Massage Therapy|Receive SMT
219385250|NCT05067777|OTHER|Questionnaire Administration|Ancillary studies
219385251|NCT05067777|PROCEDURE|Sham Intervention|Receive light touch control procedure
219385252|NCT05715190|OTHER|Education|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment. Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
219385253|NCT06964789|DEVICE|Mechatronic Remote Physiotherapy System (MRPS)|The MRPS is an Online Rehabilitation Platform for neurology patients. The platform has been designed to provide supervised and monitored remote rehabilitation therapy, initially focusing on patients who have suffered a stroke. The system comprises of a patent pending mirror therapy strengthening device, which is a neural therapy device using mirror therapy and exercise apparatus for upper limb rehabilitation. The platform also permits the addition of modules beneficial to the patients' recovery. A sensory substitution balance apparatus and motion detecting sensors are also being designed to connect to the system to allow for lower limb rehabilitation.
219385254|NCT06964789|OTHER|Early Supported Discharge|ESD is a multidisciplinary service providing medically stable patients continued therapy and healthcare in the community.
219385255|NCT05443399|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
219385256|NCT05443399|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
219385257|NCT05443399|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
219385258|NCT06623981|BEHAVIORAL|Enhanced Brief Interpersonal Psychotherapy|Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
219385259|NCT06623981|BEHAVIORAL|Supplemented Usual Care|Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
219007029|NCT06152757|BIOLOGICAL|The third dose|1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
219385260|NCT06219863|BEHAVIORAL|Body weight supported harness|A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
219385261|NCT06511050|DIETARY_SUPPLEMENT|Lumbrokinase|Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
219385262|NCT04296630|OTHER|Social media message #1|Social media message promoting colorectal cancer screening
219188678|NCT06851650|OTHER|Rehabilition protocol after rotator cuff repair surgery|adding early scapular strengthening (lower trapezius and serratus anterior) exercise in Rehabilition program after rotator cuff repair surgery
219385263|NCT04296630|OTHER|Social media message #2|A different social media message promoting colorectal cancer screening
219188679|NCT05725655|OTHER|Thermotherapy|Hot baths directly after an exercise session
219385264|NCT04296630|OTHER|Social media message #3|A different social media message promoting colorectal cancer screening
219385265|NCT04296630|OTHER|Social Media Message #4|A different social media message promoting colorectal cancer screening.
219385266|NCT04296630|OTHER|Tailored Social Media Message|Tailored social media messages promoting colorectal cancer screening.
219385267|NCT05640908|DEVICE|iFuse Bedrock Granite Implant System|Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
219385268|NCT04644900|OTHER|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
219385269|NCT04644900|OTHER|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
219385270|NCT03913910|PROCEDURE|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
219188680|NCT06493955|OTHER|Adapted physical activity for 12 months|6 additional months of adapted physical activity after the 6 first months
219188681|NCT06493955|OTHER|Adapted physical activity for 6 months|standard 6-month prescription for adapted physical activity
219188682|NCT04263181|PROCEDURE|Peripheral blood draw|"* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
219188683|NCT04263181|PROCEDURE|Bone marrow aspirate|"* Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
219188684|NCT04263181|PROCEDURE|Buccal swab|"* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
219385271|NCT05824208|BEHAVIORAL|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
219385272|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
219385273|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
219385274|NCT03166800|DRUG|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
219385275|NCT00468715|DRUG|bicalutamide|
219385276|NCT00468715|OTHER|diagnostic laboratory biomarker analysis|
219385277|NCT00468715|OTHER|immunohistochemistry staining method|
219385278|NCT04704076|OTHER|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
219385279|NCT04704076|OTHER|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
219385280|NCT03707717|DRUG|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
219385281|NCT06425744|OTHER|self-myofascial release combined reformer Pilates|"The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
219385282|NCT06425744|OTHER|Reformer Pilates|"The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
219385283|NCT00711451|BEHAVIORAL|Manual removal|Manual removal of placenta during cesarean delivery
219385284|NCT00711451|PROCEDURE|Expressed removal|Surgeon will perform an expressed delivery of the placenta
219385285|NCT03550339|PROCEDURE|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
219385286|NCT03550339|BEHAVIORAL|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
219385287|NCT03550339|BEHAVIORAL|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
219385288|NCT02062177|DRUG|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
219385289|NCT02062177|DRUG|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
219385290|NCT04309721|DRUG|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
219385291|NCT04309721|DRUG|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
219385292|NCT03708692|BEHAVIORAL|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
219385293|NCT03518840|DEVICE|SIJ Belt|Support Belts
219385294|NCT01448551|BEHAVIORAL|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
219385295|NCT03110822|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
219385296|NCT03110822|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
219385297|NCT03110822|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
219385298|NCT00693212|DRUG|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
219385299|NCT00693212|DRUG|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
219385300|NCT00693212|DRUG|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
219385301|NCT03890276|OTHER|HMS EL&C training module|No additional information
219385302|NCT03890276|OTHER|Videos used to supplement live trainer|\[Cherrie to add\]
219385303|NCT05346562|DIETARY_SUPPLEMENT|Cannabidiol|Cannabidiol tablets
219385304|NCT05346562|DIETARY_SUPPLEMENT|Placebo|Cannabidiol-matched placebo tablets
219385305|NCT02742389|OTHER|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
219385306|NCT04354025|BIOLOGICAL|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
219385307|NCT04354025|DRUG|Fludarabine|-Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
219385308|NCT04354025|DRUG|Ara-C|-Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
219385309|NCT04354025|DRUG|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
219385310|NCT04354025|DRUG|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
219385311|NCT04354025|PROCEDURE|Leukapheresis|-Donor only
219385312|NCT01207544|BEHAVIORAL|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
219385313|NCT01207544|BEHAVIORAL|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
219385314|NCT05652660|DRUG|ARV-471|Experimental
219385315|NCT05652660|DRUG|Rosuvastatin|Probe substrate
219385316|NCT00875420|DRUG|RAD1901|10 mg Oral once a day for 28 days.
219385317|NCT00875420|DRUG|RAD1901|25 mg Oral once a day for 28 days
219385318|NCT00875420|DRUG|RAD1901|50 mg Oral once a day for 28 days.
219385319|NCT00875420|DRUG|RAD1901|100 mg Oral once a day for 28 days
219385320|NCT00875420|DRUG|Placebo|Placebo Oral once a day for 28 days
219385321|NCT03425565|DRUG|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
219385322|NCT01612793|DEVICE|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
219385323|NCT00001259|DRUG|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
219385324|NCT00001259|DRUG|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
219385325|NCT00001259|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
219385326|NCT00001259|DRUG|Placebo patch|Placebo by skin patch
219385327|NCT00001259|DRUG|Placebo injection|Placebo given intramuscularly monthly
219385328|NCT00001259|DRUG|Placebo suppository|Placebo vaginal suppository
219385329|NCT03633578|BEHAVIORAL|walk test|"The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed"
219385330|NCT04160403|OTHER|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
219385331|NCT03806569|BEHAVIORAL|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
219385332|NCT03806569|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
219385333|NCT03705494|OTHER|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
219385334|NCT02101606|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
219385335|NCT03551418|BEHAVIORAL|Watching a video|Watching a video of an adult with DS washing his hands
219385336|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
219385337|NCT04795804|DIETARY_SUPPLEMENT|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
219385338|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
219385339|NCT01712386|DIETARY_SUPPLEMENT|Beetroot|
219385340|NCT01712386|DIETARY_SUPPLEMENT|Beetroot placebo|
219385341|NCT02385695|PROCEDURE|Posterior Dynamic Stabilization|
219385342|NCT02385695|PROCEDURE|Internal Fixation and Fusion|
219385343|NCT05409885|OTHER|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
219385344|NCT05409885|OTHER|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
219385345|NCT03170336|DRUG|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
219385346|NCT03170336|DRUG|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
219385347|NCT06442709|DRUG|Tocilizumab Asprin|"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
219385348|NCT06442709|OTHER|Placebo|Placebo replaces tocilizumab and asprin in advanced NPC patients.
219385349|NCT04640597|DEVICE|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
219385350|NCT06513598|PROCEDURE|Major visceral surgery for gastrointestinal cancer|This is a longitudinal observational study of the patients undergoing major visceral surgery for gastrointestinal cancer. Biological samples will be collected to compare gastrointestinal and infection site metastases and develop biomarkers for postoperative infections.
219385351|NCT02060825|DEVICE|Regional saturation monitor|
219385352|NCT02522910|DRUG|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
219385353|NCT05284110|BEHAVIORAL|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
219385354|NCT02097199|OTHER|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
219385355|NCT04573777|DRUG|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
219385356|NCT03493503|DRUG|Salbutamol|Intravenous Salbutamol loading dose
219385357|NCT03493503|DRUG|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
219385358|NCT06407362|DIAGNOSTIC_TEST|Cerebral Oxygen Saturation|We have designed this study to evaluate the accuracy of PVI, PI and rSO2 in both ventilation modes in patients undergoing septorhinoplasty operation under general anaesthesia
219385359|NCT02935881|DEVICE|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
219385360|NCT02935881|PROCEDURE|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
219385361|NCT04223167|DIETARY_SUPPLEMENT|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
219385362|NCT04223167|DIETARY_SUPPLEMENT|Water|473 ml Water
219385363|NCT04745832|DRUG|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
219385364|NCT04745832|DRUG|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
219385365|NCT04745832|DRUG|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
219385366|NCT04745832|DRUG|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
219385367|NCT03343821|OTHER|Balance and daily life questionnaire|Patients complete questionnaire
219385368|NCT03716726|BEHAVIORAL|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
219385369|NCT03716726|BEHAVIORAL|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
219385370|NCT03716726|OTHER|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
219385371|NCT02752542|BEHAVIORAL|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
219385372|NCT02752542|DRUG|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
219385373|NCT00337532|DRUG|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
219385374|NCT00337532|DRUG|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
219385375|NCT04935736|DEVICE|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
219385376|NCT04935736|DEVICE|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
219385377|NCT00065910|BEHAVIORAL|Caregiver joint attention intervention|
219385378|NCT00252863|DRUG|Symbicort, used twice daily (b.i.d) and as needed (prn)|
219385379|NCT00252863|DRUG|Budesonide Turbuhaler 200 µg|
219385380|NCT00252863|DRUG|Fluticasone Discus 250 µg|
219385381|NCT00252863|DRUG|Formoterol Turbuhaler 4.5 µg|
219385382|NCT00252863|DRUG|Terbutaline Turbuhaler 0.5 mg|
219385383|NCT00252863|DRUG|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
219385384|NCT00252863|DRUG|Salmeterol Discus 50 µg|
219385385|NCT00252863|DRUG|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
219385386|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 250/50 µg|
219385387|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 500/50 µg|
219385388|NCT00252863|DRUG|Theophylline 200 mg|
219385389|NCT00252863|DRUG|Theophylline 300 mg|
219385390|NCT00252863|DRUG|Singulair 10 mg|
219385391|NCT03638011|DRUG|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
219385392|NCT03715257|DEVICE|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
219385393|NCT03715257|DEVICE|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
219385394|NCT05528276|PROCEDURE|Repair surgery|"1. a circumscribing skin incision was made 2 mm below the hypospadias meatus,~2. penile degloving,~3. the para-urethral plate incision was made,~4. A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~5. The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~6. The neomeatus was formed on a catheter 2 F larger than the urethral stent.~7. A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~8. A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~   * Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
219188685|NCT03626597|DIAGNOSTIC_TEST|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
219385395|NCT06319911|DEVICE|AETOS|The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
219385396|NCT01327430|DIETARY_SUPPLEMENT|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
219385397|NCT01981187|DRUG|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
219385398|NCT00929292|OTHER|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
219385399|NCT00929292|OTHER|Modilac 1|Infant formula used for non breastfed children
219385400|NCT03576872|OTHER|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
219385401|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
219385402|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
219385403|NCT03440112|DRUG|Clarithromycin (Not used as of 4/2020)|Clarithromycin (generic) capsule 250mg each
219385404|NCT03440112|DRUG|Placebo (Not used as of 4/2020)|Lactose in a gel capsule
219385405|NCT03440112|DRUG|Transdermal flumazenil (Added 4/2020)|Transdermal flumazenil 24mg/mL
219385406|NCT03440112|DRUG|Placebo (Added 4/2020)|Transdermal placebo
219385407|NCT03199911|DRUG|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
219385408|NCT03199911|DRUG|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
219385409|NCT01009463|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
219385410|NCT01009463|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
219385411|NCT02413255|DRUG|TAK-020|TAK-020 oral solution
219385412|NCT02413255|DRUG|TAK-020 Placebo|TAK-020 placebo-matching oral solution
219385413|NCT06282380|DEVICE|FibriCheck Mobile Application|PPG measurement with reference diagnosis
219385414|NCT02641704|BEHAVIORAL|Multidisciplinary program|Coordinated multidisciplinary program
219385415|NCT02333331|DRUG|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
219385416|NCT02333331|OTHER|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
219385417|NCT00003995|BIOLOGICAL|trastuzumab|
219385418|NCT00003995|DRUG|irinotecan hydrochloride|
219385419|NCT03644576|DRUG|ozanimod|ozanimod
219385420|NCT03644576|DRUG|Pseudoephedrine|Pseudoephedrine
219188686|NCT03626597|BEHAVIORAL|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling \& referral to care
219188687|NCT03626597|BEHAVIORAL|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
219385421|NCT03644576|DRUG|ozanimod placebo|ozanimod placebo
219385422|NCT03016715|DRUG|Sirolimus 2%|
219385423|NCT03016715|DRUG|Vehicle|
219385424|NCT05542615|DRUG|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
219385425|NCT01494038|DRUG|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
219385426|NCT01494038|DRUG|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
219385427|NCT05741697|DRUG|bi-level ventillation|non-invasive mechanical ventilation
219385428|NCT06554990|OTHER|physical therapy excersies|1- selected physical therapy exercises
219385429|NCT06554990|OTHER|sensory perceptual motor exercises|selected sensory perceptual motor exercises
219385430|NCT05671094|BEHAVIORAL|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
219385431|NCT05309668|DRUG|Selumetinib granule formulation|"Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment."
219385432|NCT05309668|DRUG|Selumetinib capsule formulation|Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
219385433|NCT06379256|RADIATION|Photon or proton radiotherapy|"* 39.6-72.6 Gy (or Cobalt Gray Equivalent, CGE) in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy (or CGE) in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-60 Gy (or CGE) in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
219385434|NCT03707340|DRUG|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
219385435|NCT05957640|COMBINATION_PRODUCT|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
219385436|NCT04392414|BIOLOGICAL|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
219385437|NCT04392414|BIOLOGICAL|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
219385438|NCT04038346|DRUG|Naproxen|Patients will be randomized to an NSAID (naproxen)
219385439|NCT04038346|DRUG|Acetaminophen|Patients will be randomized to acetaminophen
219385440|NCT03815292|DRUG|MMH-MAP|Oral administration
219385441|NCT03815292|DRUG|Placebo|Oral administration
219385442|NCT03437928|DEVICE|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
219385443|NCT01401140|DRUG|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
219385444|NCT01401140|DRUG|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
219385445|NCT04988373|DEVICE|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
219385446|NCT04988373|DEVICE|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
219385447|NCT02574221|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
219385448|NCT02574221|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
219385449|NCT06114654|BEHAVIORAL|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
219385450|NCT05854134|DIAGNOSTIC_TEST|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
219385451|NCT05854134|DIAGNOSTIC_TEST|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
219385452|NCT03963544|DRUG|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
219385453|NCT02401256|DRUG|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
219385454|NCT02401256|DRUG|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
219385455|NCT02401256|DRUG|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
219385456|NCT02401256|DRUG|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
219385457|NCT00430781|DRUG|pazopanib (GW786034)|
219007030|NCT06152757|BIOLOGICAL|The fourth dose|3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
219007031|NCT02069743|OTHER|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
219385458|NCT00430781|DRUG|lapatinib (GW572016)|
219385459|NCT01403077|DEVICE|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
219385460|NCT05000320|DIAGNOSTIC_TEST|Neuronal Injury Panel|A panel of neuronal and astroglial assays that may be a marker of brain injury.
219385461|NCT06369155|DRUG|Azenosertib|Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
219385462|NCT06510335|OTHER|Lavender essential oil-based product system|"Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks."
219385463|NCT03115645|OTHER|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
219385464|NCT01950936|OTHER|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
219385465|NCT01092442|PROCEDURE|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
219385466|NCT02066662|DRUG|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
219385467|NCT04243369|DEVICE|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
219385468|NCT02112266|OTHER|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
219385469|NCT02112266|OTHER|no mail support|follow-up without mail support
219385470|NCT05890391|OTHER|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
219385471|NCT05890391|OTHER|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
219385472|NCT01825434|DIETARY_SUPPLEMENT|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
219385473|NCT04329949|DRUG|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
219385474|NCT04329949|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
219385475|NCT02234401|DEVICE|Bi level pressure support|
219385476|NCT02234401|OTHER|Standard Care|
219385477|NCT02556086|DRUG|Daclatasvir|
219385478|NCT02556086|DRUG|Sofosbuvir|
219385479|NCT03841877|PROCEDURE|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
219385480|NCT03851744|OTHER|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
219385481|NCT03851744|OTHER|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
219385482|NCT05511389|OTHER|Anterolateral electrode position|As described previously
219385483|NCT05511389|OTHER|Anteroposterior electrode position|As described previously
219385484|NCT05511389|OTHER|Manual pressure|Manual pressure applied to the anterior electrode
219385485|NCT02266550|DRUG|[14C] BILL 284 BS|
219385486|NCT02688569|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
219385487|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose under fasted conditions
219385488|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
219385489|NCT03180736|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
219385490|NCT03180736|DRUG|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
219385491|NCT03180736|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
219385492|NCT01059812|DRUG|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
219385493|NCT01059812|DRUG|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
219385494|NCT03421548|DEVICE|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
219385495|NCT03433066|PROCEDURE|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
219385496|NCT03433066|PROCEDURE|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
219385497|NCT01521845|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
219385498|NCT01451515|DRUG|Prednisone|Given orally (PO).
219385499|NCT01451515|DRUG|Vincristine|Given intravenously (IV).
219385500|NCT01451515|DRUG|Daunorubicin|Given IV.
219385501|NCT01451515|DRUG|PEG-asparaginase|Given intramuscularly (IM) or IV.
219385502|NCT01451515|DRUG|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
219385503|NCT01451515|DRUG|Doxorubicin|Given IV.
219385504|NCT01451515|DRUG|Cyclophosphamide|Given IV.
219385505|NCT01451515|DRUG|Cytarabine|Given IV or IT.
219385506|NCT01451515|DRUG|Thioguanine|Given PO.
219385507|NCT01451515|DRUG|Clofarabine|Given IV.
219385508|NCT01451515|DRUG|Methotrexate|Given IV, IM or IT.
219385509|NCT01451515|DRUG|Mercaptopurine|Given PO.
219385510|NCT01451515|DRUG|Dexamethasone|Given PO or IV.
219385511|NCT01451515|DRUG|Hydrocortisone|Given IT.
219385512|NCT01451515|DRUG|Etoposide|Given IV.
219385513|NCT06112925|OTHER|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
219188688|NCT06844006|COMBINATION_PRODUCT|Nudging|Clinicians will be nudged with a prompt, based on remote monitoring data, current medication data, contraindications, in the electronic patient dossier whether further optimization to guideline directed medical therapy (GDMT) is possible.
219385514|NCT02682810|DEVICE|DNA PCR HIV diagnostic test|standard of care
219385515|NCT02682810|DEVICE|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
219385516|NCT04923373|OTHER|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
219385517|NCT04923373|PROCEDURE|standard physiotherapy|standard physiotherapy
219385518|NCT00131443|DRUG|Topiramate|
219385519|NCT01532453|DEVICE|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
219385520|NCT01532453|OTHER|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
219385521|NCT01507194|DRUG|Ondansetron|Single IV dose
219385522|NCT01507194|DRUG|Vestipitant|Single IV dose
219385523|NCT01458340|DRUG|TD-9855|Once daily
219385524|NCT01458340|DRUG|TD-9855|Once daily
219385525|NCT01458340|DRUG|Placebo|Once daily
219385526|NCT04524741|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
219385527|NCT05847972|PROCEDURE|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
219385528|NCT05847972|DEVICE|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
219385529|NCT04727216|DEVICE|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
219385530|NCT02237053|DRUG|Glucagon|
219385531|NCT02237053|DRUG|Octreotide|
219385532|NCT02237053|BEHAVIORAL|Placebo|
219385533|NCT02237053|DRUG|Insulin|
219385534|NCT03471754|DEVICE|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
219385535|NCT04144062|OTHER|CAD/CAM crowns|CAD/CAM crowns
219385536|NCT00716937|PROCEDURE|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
219385537|NCT00716937|PROCEDURE|laying open|laying open the site of excision of sinus or cyst without any flap
219385538|NCT05154747|DRUG|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
219385539|NCT05154747|DRUG|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
219385540|NCT05174806|DRUG|Topical Pravibismane|Topical Pravibismane
219385541|NCT05174806|OTHER|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
219385542|NCT04230577|DEVICE|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
219385543|NCT04230577|DEVICE|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
219385544|NCT04880811|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
219385545|NCT04880811|DRUG|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
219385546|NCT00480961|PROCEDURE|intramiocardiac autograft of autologous stem cells|
219385547|NCT04282928|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
219385548|NCT04282928|PROCEDURE|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
219385549|NCT05869643|DRUG|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
219385550|NCT05869643|DRUG|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
219385551|NCT05869643|DRUG|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
219385552|NCT05869643|DRUG|Placebo|Matching placebo capsule, taken orally once daily after breakfast
219385553|NCT03951571|DRUG|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
219385554|NCT03951571|DRUG|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
219385555|NCT05058872|DRUG|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
219385556|NCT05058872|DRUG|Placebo|Placebo comparator
219385557|NCT03056287|BEHAVIORAL|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
219385558|NCT03056287|OTHER|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
219385559|NCT01481571|DEVICE|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
219385560|NCT04788628|OTHER|Baseline|Hippocampal and scalp EEG monitoring during overnight sleep
219385561|NCT04788628|OTHER|Motor procedural memory task|Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning
219385562|NCT04788628|OTHER|Motor procedural memory task plus auditory stimulation|Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
219385563|NCT05772494|OTHER|Assessment of activity limitations, SDO and DOA|The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
219385564|NCT05772494|OTHER|Control group|All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
219385565|NCT06161415|DRUG|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
219760931|NCT05822310|PROCEDURE|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
219188689|NCT06852391|DRUG|Semaglutide Pen Injector|Semaglutide will be delivered by a subcutaneous injection using an injectable pen once weekly. Semaglutide is formulated with 5 approved doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). Treatment will commence with the lowest dose and will be increased every 4 weeks to the maximum tolerable dose where they will remain for the remainder of the treatment. Participants who are taking the drug will have monthly visits to assess any adverse events, dose titration and drug adherence.
219385566|NCT00671151|DRUG|Theophylline|Theophylline 100 mg bid for 3 months
219385567|NCT04291157|OTHER|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
219385568|NCT04291157|OTHER|Standard GP care|Usual GP care (opportunistic CVD prevention)
219385569|NCT01241539|DRUG|Dabigatran etexilate|150 mg capsule
219385570|NCT01241539|DRUG|Dabigatran etexilate|75 mg capsule
219385571|NCT01241539|DRUG|Dabigatran etexilate|110 mg capsule
219385572|NCT04621747|OTHER|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
219385573|NCT04847115|PROCEDURE|Operative|Intramedullary screw fixation
219385574|NCT04847115|OTHER|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
219385575|NCT00091793|DRUG|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
219385576|NCT00091793|DRUG|Placebo|Placebo given at day 1, month 6, month 12 and month 18
219385577|NCT00378729|DRUG|Metformin and FSHr|treatment for infertility
219385578|NCT00378729|PROCEDURE|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
219385579|NCT04120688|DEVICE|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
219385580|NCT00288340|DEVICE|functional magnetic resonance imaging|
219385581|NCT03002506|DRUG|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
219385582|NCT00154505|DEVICE|Lateral trunk support of wheelchair seating|
219385583|NCT02957708|OTHER|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
219385584|NCT02957708|OTHER|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
219385585|NCT03684083|PROCEDURE|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
219385586|NCT05111314|RADIATION|Gallium Ga 68 Gozetotide|Given IA
219385587|NCT05111314|PROCEDURE|Hepatic Artery Embolization|Undergo hepatic artery embolization
219385588|NCT05111314|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
219385589|NCT01220778|BEHAVIORAL|Exercise|
219385590|NCT05162235|DEVICE|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
219385591|NCT03636815|OTHER|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
219385592|NCT01052064|DEVICE|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
219385593|NCT05309083|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
219385594|NCT00610636|PROCEDURE|Hepatic resection|Hepatic resection
219385595|NCT05738980|BIOLOGICAL|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
219385596|NCT05190835|DEVICE|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
219385597|NCT02651610|BIOLOGICAL|Bavituximab|Biological: bavituximab
219385598|NCT02651610|DRUG|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
219385599|NCT05257122|DRUG|Fruquintinib|Fruquintinib 5mg qd, d1-21, q28d
219385600|NCT01050777|DRUG|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
219385601|NCT01050777|DRUG|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
219385602|NCT01050777|DRUG|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
219385603|NCT01050777|DRUG|Placebo|Placebo
219385604|NCT02424487|PROCEDURE|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
219385605|NCT02515695|DRUG|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
219385606|NCT02654925|PROCEDURE|Adipose Tissue Biopsy|
219385607|NCT02951923|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
219385608|NCT02951923|DIETARY_SUPPLEMENT|Soy|
219385609|NCT02355340|OTHER|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
219385610|NCT02355340|OTHER|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
219385611|NCT01165229|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
219385612|NCT01165229|BIOLOGICAL|Placebo|Intramuscular injection.
219385613|NCT01451333|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
219385614|NCT01451333|DRUG|Efavirenz|400mg qd; 2 x 200mg
219385615|NCT01720251|DRUG|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
219385616|NCT01720251|DRUG|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
219385617|NCT01720251|DRUG|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
219385618|NCT01277575|DEVICE|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
219385619|NCT01277575|DEVICE|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
219760932|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
219385620|NCT04510259|PROCEDURE|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
219385621|NCT01370070|DRUG|MK-2206|200mg weekly repeated q 28 days
219385622|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
219385623|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
219385624|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
219385625|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
219385626|NCT00520598|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
219385627|NCT00520598|BIOLOGICAL|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
219385628|NCT01530490|DRUG|Cabergoline and Hydroxyethyl Starch|0.5mg
219385629|NCT01530490|DRUG|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
219385630|NCT01243476|DRUG|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
219385631|NCT01243476|OTHER|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
219385632|NCT00881205|DRUG|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
219385633|NCT00881205|DRUG|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
219385634|NCT02569034|OTHER|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
219385635|NCT02569034|OTHER|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
219385636|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
219001108|NCT02968407|OTHER|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
219385637|NCT00982566|DRUG|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
219385638|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
219385639|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
219385640|NCT03502135|DRUG|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
219385641|NCT02966457|DRUG|Colistimethate Sodium|Selective oral intestinal decolonization
219001109|NCT02433483|DRUG|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
219385642|NCT04543448|OTHER|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
219385643|NCT04543448|OTHER|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
219385644|NCT03823638|DIETARY_SUPPLEMENT|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
219385645|NCT03702257|PROCEDURE|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
219001110|NCT02433483|DRUG|Intrathecal Triples|given IT.
219385646|NCT05011461|OTHER|Almond Oil|Almond Oil Pressed Cold
219385647|NCT05966701|DRUG|SSGJ-613|SSGJ-613 subcutaneous injection.
219385648|NCT05966701|DRUG|Placebo|Placebo subcutaneous injection.
219385649|NCT02278978|DRUG|BIBF1120|BIBF1120 200 mg two times per day orally
219385650|NCT03903328|OTHER|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
219385651|NCT06361459|BEHAVIORAL|Stop smoking|Sine fuma program is offered. nicotine is checked in urine
219385652|NCT00319163|DRUG|levonorgestrel/ethinyl estradiol|
219385653|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
219385654|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
219385655|NCT06270225|DRUG|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
219385656|NCT03380858|DEVICE|colectomy|colectomy resection
219385657|NCT03886077|DRUG|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
219385658|NCT05920213|DRUG|Polyethylene Glycols|280g/ 24 hours for 5 days
219385659|NCT05920213|DRUG|Lactulose oral solution|60-120 ml per day for 5 days
219385660|NCT05920213|DRUG|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
219385661|NCT00364260|DRUG|epoetin alfa|
219385662|NCT01397019|DRUG|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
219385663|NCT02594592|OTHER|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
219385664|NCT05637450|DIETARY_SUPPLEMENT|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
219385665|NCT05637450|DIETARY_SUPPLEMENT|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
219385666|NCT02234037|DRUG|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
219385667|NCT02234037|BEHAVIORAL|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise \> 10 minutes of muscle strengthening, \> 10 minutes of aerobic exercise (treadmill walking or cycling), \> 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
219385668|NCT03560076|OTHER|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
219385669|NCT01472276|BEHAVIORAL|Web-based program|Provided with the web-based program
219385670|NCT01647763|PROCEDURE|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
219760933|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
219385671|NCT01647763|PROCEDURE|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
219385672|NCT00903084|DRUG|Tenofovir Disoproxil Fumarate|300-mg tablet
219385673|NCT05855356|PROCEDURE|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
219385674|NCT05855356|PROCEDURE|Standard of Care|Behavioural and Medical management
219385675|NCT03888625|PROCEDURE|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
219385676|NCT03888625|PROCEDURE|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
219385677|NCT00780403|DRUG|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
219385678|NCT00780403|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
219001111|NCT02433483|BIOLOGICAL|HPC-A|Given IV.
219001112|NCT03012906|OTHER|the prevalence of ischemic events|
219385679|NCT04354454|OTHER|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
219385680|NCT04354454|OTHER|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only"
219385681|NCT06851013|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
219385682|NCT04327648|DEVICE|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
219385683|NCT04327648|DEVICE|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
219385684|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment.
219385685|NCT02094599|DRUG|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
219385686|NCT02094599|DRUG|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
219385687|NCT02094599|DRUG|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
219385688|NCT02585427|DIETARY_SUPPLEMENT|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
219385689|NCT04322708|OTHER|Placebo|Placebo
219385690|NCT04322708|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
219385691|NCT02320578|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
219385692|NCT02320578|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
219385693|NCT06849557|BEHAVIORAL|Exergaming|This intervention will last 12 weeks. Frail/ pre-frail participants will engage in supervised chair-bound exergaming.
219385694|NCT00795730|DRUG|NSA-789|
219385695|NCT00795730|OTHER|placebo|
219385696|NCT02509962|DIETARY_SUPPLEMENT|Slow sodium tablets|6 g sodium chloride per day over 14 days
219385697|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
219385698|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
219385699|NCT00845429|BIOLOGICAL|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
219385700|NCT04910217|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation
219385701|NCT04910217|PROCEDURE|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
219385702|NCT04910217|PROCEDURE|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
219385703|NCT03603132|DRUG|Hetrombopag Olamine|7.5mg in each cycle
219385704|NCT00746538|DEVICE|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
219385705|NCT01907685|DRUG|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219385706|NCT01907685|DRUG|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
219385707|NCT05784090|OTHER|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
219385708|NCT02090543|DRUG|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
219385709|NCT02090543|DRUG|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
219385710|NCT01715025|DRUG|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
219385711|NCT00228371|DEVICE|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
219385712|NCT01161225|BEHAVIORAL|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
219385713|NCT01161225|BEHAVIORAL|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
219385714|NCT06221644|DIAGNOSTIC_TEST|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
219385715|NCT00243737|DRUG|Artesunate-Mefloquine|
219385716|NCT03247400|DRUG|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
219385717|NCT03247400|DRUG|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
219001113|NCT02037698|DEVICE|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
219001114|NCT02835508|DRUG|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
219385718|NCT05776537|DEVICE|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
219385719|NCT00587223|DEVICE|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
219385720|NCT00587223|OTHER|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
219385721|NCT04632147|OTHER|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
219385722|NCT06187818|DRUG|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
219001115|NCT02835508|DRUG|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
219001116|NCT02835508|DRUG|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
219001117|NCT02933125|BEHAVIORAL|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
219001118|NCT02933125|BEHAVIORAL|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
219385723|NCT03370146|BEHAVIORAL|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
219385724|NCT03370146|BEHAVIORAL|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
219385725|NCT03370146|BEHAVIORAL|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
219385726|NCT00413751|DRUG|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
219760934|NCT01585727|PROCEDURE|TME|Total mesorectal excision
219385727|NCT02999503|BEHAVIORAL|Nutritional education|Nutritional education trough a personal online nutritional consultant
219385728|NCT05167201|DEVICE|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
219385729|NCT04666883|OTHER|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
219385730|NCT01233726|DIETARY_SUPPLEMENT|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
219001119|NCT05183373|OTHER|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
219001120|NCT01647815|PROCEDURE|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
219385731|NCT01233726|DIETARY_SUPPLEMENT|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
219385732|NCT01233726|DIETARY_SUPPLEMENT|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
219385733|NCT06432777|OTHER|Characteristics of patients and Campylobacter bacteraemia episodes|Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
219385734|NCT05307744|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
219385735|NCT05307744|OTHER|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
219385736|NCT03946267|DEVICE|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
219385737|NCT04773769|DIETARY_SUPPLEMENT|Tea Made of Graviola Leaves|"Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment."
219385738|NCT02818010|OTHER|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
219385739|NCT02739139|DIETARY_SUPPLEMENT|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
219385740|NCT01813487|DRUG|HBsAg vaccine with Entecavir|
219760935|NCT01585727|PROCEDURE|TME|Total mesorectal excision
219385741|NCT03240081|DRUG|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
219385742|NCT03240081|DRUG|100mcg estradiol cream|Use of study drug nightly
219385743|NCT05962307|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
219385744|NCT05063370|DRUG|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
219385745|NCT05063370|DRUG|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
219385746|NCT00944944|BEHAVIORAL|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
219385747|NCT00944944|BEHAVIORAL|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
219385748|NCT00883753|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
219385749|NCT00648310|DRUG|Tolterodine 4 mg|
219385750|NCT00648310|DRUG|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
219385751|NCT05426343|BIOLOGICAL|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
219760936|NCT01585727|PROCEDURE|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
219760937|NCT01076010|DRUG|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
219760938|NCT01076010|DRUG|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
219385752|NCT05426343|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
219385753|NCT00760175|BIOLOGICAL|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
219385754|NCT04720352|DEVICE|Active treatment|Active treatment delivers radiofrequency and cryogen
219385755|NCT04720352|DEVICE|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
219385756|NCT04696406|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
219385757|NCT01370954|OTHER|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
219385758|NCT01731015|DRUG|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
219385759|NCT00030758|BIOLOGICAL|filgrastim|
219385760|NCT00030758|BIOLOGICAL|pegfilgrastim|
219385761|NCT05981521|DIAGNOSTIC_TEST|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
219385762|NCT03867253|DRUG|ORY-2001 Low dose|0.6mg ORY-2001 capsule
219385763|NCT03867253|DRUG|ORY-2001 High dose|1.2mg ORY-2001 capsule
219385764|NCT03867253|DRUG|Placebo|Placebo capsule
219385765|NCT01771094|BEHAVIORAL|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
219385766|NCT05412329|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
219385767|NCT01480180|DRUG|turoctocog alfa pegol|Administered i.v.
219385768|NCT00677950|PROCEDURE|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
219385769|NCT03243903|DEVICE|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
219385770|NCT03243903|DEVICE|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
219385771|NCT02334709|RADIATION|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
219385772|NCT00393822|DRUG|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
219385773|NCT00393822|DRUG|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
219385774|NCT06011070|BEHAVIORAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
219385775|NCT01341912|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
219385776|NCT03541577|DEVICE|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
219001121|NCT04271891|DEVICE|WBPC|The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
219001122|NCT04271891|DEVICE|Without WBPC|Not treat with WBPC
219001123|NCT00709046|DRUG|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
219385777|NCT03541577|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
219385778|NCT02131701|BEHAVIORAL|Physical activity|
219385779|NCT04721314|DEVICE|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF \>50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
219385780|NCT04721314|DEVICE|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
219385781|NCT00424307|DEVICE|HiResolution Bionic Ear System|
219385782|NCT03721328|COMBINATION_PRODUCT|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
219385783|NCT02604966|DRUG|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
219385784|NCT02604966|DRUG|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
219760939|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
219385785|NCT05508152|DRUG|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
219385786|NCT05508152|DRUG|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
219001124|NCT00709046|DRUG|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
219001125|NCT01138553|DRUG|Mifepristone|200mg capsules daily for 5-28 days
219385787|NCT03008512|DRUG|Genexol-PM|
219385788|NCT03940885|PROCEDURE|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
219385789|NCT03940885|PROCEDURE|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
219385790|NCT03940885|PROCEDURE|Control group|this group will receive only standard general anesthesia
219385791|NCT04045912|OTHER|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
219385792|NCT04045912|OTHER|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
219385793|NCT05899725|DRUG|Corticosteroids|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
219385794|NCT05899725|DRUG|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
219385795|NCT03852225|DIAGNOSTIC_TEST|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
219385796|NCT05146622|BEHAVIORAL|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
219385797|NCT02984475|DRUG|Metformin|
219001126|NCT00031863|DRUG|rofecoxib|
219001127|NCT00031863|PROCEDURE|adjuvant therapy|
219001128|NCT03780907|DRUG|E2007|1 mg of E2007 was administered by mouth once daily.
219001129|NCT03780907|DRUG|E2007|2 mg of E2007 was administered by mouth once daily.
219385798|NCT00667277|DRUG|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
219385799|NCT00575679|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
219385800|NCT00921921|DRUG|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
219385801|NCT00921921|DRUG|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
219385802|NCT00364910|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
219385803|NCT00364910|BEHAVIORAL|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
219385804|NCT05121103|DRUG|EZM0414|Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
219385805|NCT04795180|DRUG|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
219385806|NCT06970730|PROCEDURE|virtual surgical planning and patient specific implants in craniomaxillofacial reconstruction|Image acquisition by computed tomography (CT slice thickness 1 mm or less) + laser scanning of patient models. Virtual surgical planning and design of patient specific implants. Patient specific implants manufacturing (milling technique) and 3D printing of surgical guides and fit models.
219385807|NCT03429075|DRUG|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
219385808|NCT03429075|DRUG|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
219385809|NCT03138564|BEHAVIORAL|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
219385810|NCT03138564|BEHAVIORAL|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
219385811|NCT02670304|DRUG|letrozole|letrozole from the day of oocyte retrieval for 5 days
219385812|NCT02670304|DRUG|Aspirin|aspirin from the day of oocyte retrieval for 5 days
219385813|NCT03486730|DRUG|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
219385814|NCT04068597|DRUG|CCS1477|Oral capsule
219385815|NCT04068597|DRUG|Pomalidomide|oral capsule
219385816|NCT04068597|DRUG|Dexamethasone|oral tablet
219385817|NCT04068597|DRUG|Azacitidine|Powder suspension for Injection
219385818|NCT04068597|DRUG|Venetoclax|Oral tablet
219385819|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
219385820|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
219385821|NCT02279316|DRUG|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
219385822|NCT02279316|OTHER|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
219385823|NCT02279316|OTHER|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
219385824|NCT01041092|DRUG|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
219385825|NCT06971068|PROCEDURE|Procedure: EVLA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring fiber
219385826|NCT06971068|PROCEDURE|Procedure: VALA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring Pro fiber
219385827|NCT00814710|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
219001130|NCT03780907|DRUG|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
219001131|NCT01760707|BEHAVIORAL|exercise training|
219385828|NCT00814710|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
219385829|NCT00814710|BIOLOGICAL|Hiberix|Intramuscular injection, 3 doses
219385830|NCT00814710|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 3 doses
219385831|NCT05406908|BIOLOGICAL|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
219385832|NCT02280811|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
219385833|NCT02280811|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
219385834|NCT02280811|BIOLOGICAL|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
219385835|NCT02280811|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219385836|NCT02437838|OTHER|No Intervention|No Intervention
219385837|NCT00032929|DRUG|Selegiline|
219385838|NCT02830165|OTHER|Laboratory Biomarker Analysis|Correlative studies
219385839|NCT02830165|OTHER|Quality-of-Life Assessment|Ancillary studies
219385840|NCT02830165|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219385841|NCT02677584|DRUG|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
219385842|NCT02677584|DRUG|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
219385843|NCT03746197|DEVICE|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
219385844|NCT05329792|DRUG|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
219385845|NCT03885284|DRUG|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
219385846|NCT03885284|RADIATION|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
219385847|NCT06358872|DRUG|Azithromycin for Oral Suspension|Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
219385848|NCT04045210|OTHER|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
219385849|NCT04333966|BEHAVIORAL|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
219385850|NCT04333966|BEHAVIORAL|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
219385851|NCT00484354|DRUG|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
219385852|NCT00484354|OTHER|Normal saline|IV Normal saline with volume given determined by patient weight
219385853|NCT00484354|OTHER|Bicarbonate|IV bicarbonate, dosed by weight
219385854|NCT00484354|OTHER|Placebo|Normal saline, with volume given based on patient weight
219385855|NCT00820638|DEVICE|myomo e100|use of the myomo e100 in home
219385856|NCT06674356|BEHAVIORAL|chin tuck against resistance exercise|"Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises.~For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions."
219385857|NCT02942498|DRUG|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
219001132|NCT01760707|BEHAVIORAL|usual care|
219385858|NCT02942498|DRUG|Placebo|Placebo
219385859|NCT01476787|DRUG|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219385860|NCT01476787|DRUG|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
219385861|NCT01476787|DRUG|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219385862|NCT01476787|DRUG|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219385863|NCT01476787|DRUG|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219385864|NCT01112709|BEHAVIORAL|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
219385865|NCT01112709|OTHER|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
219385866|NCT04626063|DRUG|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
219385867|NCT04626063|DRUG|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
219385868|NCT04626063|DRUG|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
219385869|NCT00315861|DRUG|pemetrexed|
219385870|NCT00315861|DRUG|topotecan|
219385871|NCT00368706|DRUG|solifenacin succinate|Oral
219385872|NCT00368706|DRUG|tolterodine|oral
219385873|NCT01201499|DRUG|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
219385874|NCT01201499|DRUG|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
219001133|NCT00680667|BIOLOGICAL|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
219001134|NCT04271605|BEHAVIORAL|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
219385875|NCT01936740|PROCEDURE|cataract surgery|
219385876|NCT01780233|DRUG|Fentanyl 400 µg sublingual spray|
219385877|NCT01780233|DRUG|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
219385878|NCT01780233|DRUG|Fentanyl citrate injection 100 µg intravenously|
219385879|NCT01780233|DRUG|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
219385880|NCT03530514|DRUG|REGN4461|REGN4461
219385881|NCT03530514|DRUG|Placebo|Placebo-matching REGN4461
219385882|NCT05312502|OTHER|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
219385883|NCT05384301|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
219007032|NCT01121887|BEHAVIORAL|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
219385884|NCT05676710|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
219385885|NCT05005884|DRUG|Oral intake of medication|Prescription of oral phenolics 250 mg two times daily
219385886|NCT05005884|DRUG|Placebo|Prescription of oral phenolics 250 mg two times daily
219385887|NCT02567695|DRUG|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
219385888|NCT01747902|PROCEDURE|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
219385889|NCT01747902|PROCEDURE|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
219385890|NCT00934609|BEHAVIORAL|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
219385891|NCT01916395|DRUG|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
219385892|NCT04990739|DRUG|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
219385893|NCT04377945|DRUG|Part 1, JM-010 component Group A|JM-010 component Group A
219385894|NCT04377945|DRUG|Part 1, JM-010 component Group B|JM-010 component Group B
219385895|NCT04377945|DRUG|Part 1, JM-010 component Group C|JM-010 component Group C
219385896|NCT04377945|DRUG|Part 1, Placebo Group|Placebo Group
219385897|NCT04377945|DRUG|Part 2, JM-010 combination Group A|JM-010 combination Group A
219385898|NCT04377945|DRUG|Part 2, JM-010 combination Group B|JM-010 combination Group B
219385899|NCT04377945|DRUG|Part 2, JM-010 component Group C|JM-010 component Group C
219385900|NCT04377945|DRUG|Part 2, Placebo Group|Placebo Group
219385901|NCT01645761|DRUG|Endonase|PPI- based triple therapy with endonase
219001135|NCT01923701|BEHAVIORAL|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
219385902|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
219385903|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
219385904|NCT05150132|DEVICE|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
219385905|NCT02544776|DRUG|Clomifene citrate ( clomid 50 mg )|
219385906|NCT02544776|DRUG|Amlodipine|
219385907|NCT01450137|DRUG|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
219385908|NCT01450137|DRUG|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
219385909|NCT04946318|DRUG|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
219385910|NCT04946318|DRUG|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
219385911|NCT04232449|DRUG|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
219385912|NCT04232449|DRUG|placebo tablets|5 daily- doses of placebo (2 tablets)
219385913|NCT04037085|DRUG|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
219385914|NCT04653662|DEVICE|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
219385915|NCT05158348|DRUG|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
219385916|NCT05158348|DRUG|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
219385917|NCT05158348|DRUG|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
219385918|NCT01346800|DRUG|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
219385919|NCT01346800|DRUG|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
219385920|NCT05187117|BEHAVIORAL|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
219385921|NCT05187117|BEHAVIORAL|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
219385922|NCT02449330|DRUG|Teneligliptin|
219385923|NCT05191628|BIOLOGICAL|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
219385924|NCT01129752|OTHER|No intervention|there is no intervention for this study
219385925|NCT03580447|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
219385926|NCT03580447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219385927|NCT03251547|DRUG|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
219385928|NCT05694598|GENETIC|VGR-R01|CYP4v2-coding gene delivered by AAV vector
219385929|NCT05077761|DEVICE|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~1. Wavelength- 980 nm~2. Intensity/Power density- 3W/cm2~3. Emission mode- Continuous Emission~4. Energy (Joules)- 490 J~5. Irradiation time- 70 Sec on each point~6. Peak power- 15 Watt~7. Irradiation points- 09"
219385930|NCT05077761|DEVICE|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
219001136|NCT04496544|OTHER|Retrospective data collection|No intervention; retrospective data collection
219385931|NCT01106755|DEVICE|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
219385932|NCT01106755|DEVICE|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
219385933|NCT03426046|PROCEDURE|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
219385934|NCT03426046|DRUG|Pulp Capping Agents|Biocompatible materials
219385935|NCT03903471|DEVICE|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
219385936|NCT03903471|DEVICE|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
219385937|NCT04387279|OTHER|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
219385938|NCT05907915|DEVICE|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
219385939|NCT05907915|BEHAVIORAL|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
219385940|NCT05502588|BEHAVIORAL|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
219385941|NCT05502588|BEHAVIORAL|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
219385942|NCT02852369|BEHAVIORAL|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
219385943|NCT05430867|DRUG|Memantine Oral Tablet|Memantine 20mg once-daily
219385944|NCT05430867|DRUG|GV-971 capsule|GV-971 450mg twice a day
219385945|NCT04124367|DRUG|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
219188690|NCT06852391|BEHAVIORAL|Behavioural Lifestyle Program (BLP)|The BLP will be delivered by the Growing Healthy Weight Management (GHWM) pediatric program at McMaster Children's Hospital. GHWM is a family-based program addressing health behaviours (nutritional pattern and eating behaviours, physical activity, sedentary time and sleep) and physical and mental health issues. In Year 1, the program typically includes 2 group sessions and monthly individualized sessions with the participant and their family. The interdisciplinary weight management team is comprised of a registered dietician, exercise physiologist, kinesiologist, social worker and/or psychologist, general pediatrician and pediatric endocrinologists.
219188691|NCT06852339|BEHAVIORAL|EAPOC-COPD|The EAPOC-COPD system consists of: 1) a smart phone / tablet app or Personal Computer-based questionnaire which collects information directly from patients upon prompting, up to 1 week before their clinical appointment; and 2) a point-of-care clinical decision support system that wirelessly receives and processes questionnaire data in order to produce a symptom severity/exacerbation risk assessment, medication change recommendation, and COPD action plan, all of which is made available to providers through a prompt, upon opening the patient chart in the existing EMR. Once approved, the personalized COPD action plan is automatically populated within the patient app/portal, enabling anywhere/anytime access for patients. Patients are also provided with educational resources within their app/portal, designed to improve health literacy, inhaler technique, and adherence to their action plan
219385946|NCT04124367|DEVICE|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
219385947|NCT04124367|DRUG|Placebo|100 ml once daily 0.9% saline
219385948|NCT04124367|DEVICE|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
219385949|NCT00230763|PROCEDURE|GSS questionnaire|D0, D30 and D84
219385950|NCT00230763|PROCEDURE|IOP|D0, D30 and D84
219385951|NCT00230763|DRUG|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
219001137|NCT03311815|DIAGNOSTIC_TEST|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
219001138|NCT04806854|DRUG|LUM-201|Administered orally once daily
219001139|NCT02485301|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
219188692|NCT06852339|OTHER|Usual Care|Usual care
219188693|NCT06851624|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
219188694|NCT06852703|OTHER|Infection during pregnancy|any bacterial or viral infection acquired during pregnancy
219385952|NCT00230763|PROCEDURE|Visual acuity|D0 and D84
219385953|NCT05591833|PROCEDURE|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
219385954|NCT05591833|PROCEDURE|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
219385955|NCT01450540|DEVICE|REMstar Auto A-Flex|Standard CPAP
219385956|NCT01450540|DEVICE|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
219385957|NCT00083538|DRUG|Dexamethasone|
219385958|NCT00083538|DRUG|Thalidomide|
219385959|NCT00083538|DRUG|Cisplatinum|
219385960|NCT00083538|DRUG|Adriamycin|
219385961|NCT00083538|DRUG|Cyclophosphamide|
219385962|NCT00083538|DRUG|Etoposide|
219385963|NCT01926886|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
219385964|NCT04562363|PROCEDURE|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
219385965|NCT02551848|DRUG|Botulinum toxin type A|
219385966|NCT01597869|DEVICE|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
219385967|NCT06428773|OTHER|Exercise|Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
219385968|NCT04429932|OTHER|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
219385969|NCT04429932|OTHER|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
219385970|NCT04429932|OTHER|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
219385971|NCT04429932|OTHER|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
219385972|NCT04429932|OTHER|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
219385973|NCT04429932|OTHER|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
219385974|NCT04429932|OTHER|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
219385975|NCT04429932|OTHER|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
219385976|NCT04802746|DRUG|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
219385977|NCT04802746|OTHER|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
219385978|NCT01381107|DRUG|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
219385979|NCT01381107|DRUG|Placebo|Sublingual administration once daily for 7 consecutive days.
219385980|NCT03533166|OTHER|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
219001140|NCT02485301|DRUG|Placebo|A single dose administrated intramuscular
219385981|NCT03533166|OTHER|Placebo|Placebo mouth rinse
219385982|NCT00543179|DRUG|Somatuline (Lanreotide Autogel®)|
219385983|NCT01662999|DRUG|Saxagliptin|
219385984|NCT01662999|DRUG|Dapagliflozin|
219385985|NCT05832762|PROCEDURE|Endovascular treatment (EVT) + Best medical treatment (BMT)|"Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.~Best medical treatment (BMT) : Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies."
219385986|NCT05832762|PROCEDURE|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
219188695|NCT05773859|BIOLOGICAL|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
219385987|NCT03490487|DRUG|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
219385988|NCT03490487|DRUG|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
219385989|NCT01665937|DRUG|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
219385990|NCT01322815|DRUG|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
219385991|NCT01322815|DRUG|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
219385992|NCT02932267|DRUG|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
219385993|NCT05609526|OTHER|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
219385994|NCT05609526|OTHER|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
219385995|NCT05609526|OTHER|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
219385996|NCT05863247|OTHER|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
219385997|NCT02628587|DRUG|Generic clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
219385998|NCT02628587|DRUG|Patent clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
219385999|NCT02554305|DEVICE|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
219386000|NCT02554305|DEVICE|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
219386001|NCT01530139|BEHAVIORAL|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
219386002|NCT01530139|BEHAVIORAL|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
219386003|NCT01530139|BEHAVIORAL|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
219386004|NCT01530139|BEHAVIORAL|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
219386005|NCT00583739|BEHAVIORAL|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
219386006|NCT02429505|DRUG|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
219386007|NCT06970912|DRUG|Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy|"Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: （1）ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years； （2）ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to:~* Arm B1: Dalpiciclib + ET for 2 years.~* Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years；（3）Persistently ctDNA-positive or ctDNA-negative → positive:~Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists."
219386008|NCT06970912|DRUG|Taxane-Based Neoadjuvant Chemotherapy|Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.
219386009|NCT00584662|DRUG|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
219386010|NCT02453841|DRUG|Oxymetazoline|
219386011|NCT06655077|OTHER|RA PRO Dashboard|The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
219386012|NCT04248166|DEVICE|Photoacoustic imaging|"1. Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~2. The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
219386013|NCT04082247|BEHAVIORAL|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
219386014|NCT04494165|OTHER|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
219386015|NCT04494165|OTHER|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
219386016|NCT04226352|DRUG|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
219557929|NCT05089890|DEVICE|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
219001141|NCT06291025|PROCEDURE|PEX-FREE|The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
219386017|NCT03851510|DEVICE|Vector ventilator|The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.
219386018|NCT03851510|DEVICE|Resmon Pro|The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
219386019|NCT03643887|DRUG|FMT Capsule DE|30 capsule one-time oral dose
219386020|NCT03643887|DRUG|Placebo oral capsule|30 capsule one-time oral dose
219386021|NCT01151137|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
219386022|NCT01151137|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
219386023|NCT03906682|BEHAVIORAL|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
219386024|NCT03906682|BEHAVIORAL|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
219386025|NCT06657742|OTHER|SCIM-SR|SCIM-SR was a self-reported scale that evaluated the independence of patients.
219386026|NCT06656273|BEHAVIORAL|FT LCP|FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
219386027|NCT02421250|DEVICE|Radical-7 Noninvasive Hgb Monitor|
219386028|NCT04804215|PROCEDURE|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
219386029|NCT04804215|PROCEDURE|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
219386030|NCT02062086|DIETARY_SUPPLEMENT|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
219386031|NCT02952742|DRUG|Black Cohosh|Vital Nutrients Black Cohosh Extract
219386032|NCT02952742|OTHER|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
219386033|NCT05334589|DEVICE|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
219386034|NCT03352856|OTHER|Barley starch|Highly purified barley starch
219386035|NCT03352856|OTHER|Maize starch|Maize starch
219386036|NCT06616415|DRUG|Belumosudil|Pharmaceutical form: Tablet Route of administration: Oral
219386037|NCT06458140|PROCEDURE|Cardioneuroablation|Radiofrequency ablation of ganglionated plexi of the heart
219386038|NCT03011125|DRUG|dexlansoprazole injection|
219386039|NCT03011125|OTHER|placebo|
219386040|NCT05436249|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
219386041|NCT05436249|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
219386042|NCT02874911|OTHER|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
219386043|NCT00538642|DRUG|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
219386044|NCT01857895|DRUG|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
219386045|NCT03439345|DRUG|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
219001142|NCT01021540|DRUG|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
219386046|NCT03439345|DRUG|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
219386047|NCT04974307|DEVICE|OrCam MyEye 2|The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
219386048|NCT04806568|OTHER|Cognitive Training|The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
219386049|NCT04806568|DEVICE|Monitoring of daily activity|Monitoring of daily activity via Fitbit Charge 4 smartwatch.
219386050|NCT06173752|BEHAVIORAL|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
219386051|NCT03417765|DRUG|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
219386052|NCT00717470|DRUG|Prograf®|oral
219386053|NCT00717470|DRUG|Advagraf®|oral
219386054|NCT00717470|DRUG|Mycophenolate Mofetil|oral
219386055|NCT00717470|DRUG|Simulect|oral
219386056|NCT00717470|DRUG|methylprednisolone / prednisone|oral
219386057|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
219386058|NCT02082561|BEHAVIORAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
219386059|NCT03590457|DEVICE|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
219386060|NCT02459171|OTHER|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
219386061|NCT02459171|OTHER|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
219386062|NCT02459171|OTHER|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
219386063|NCT02459171|OTHER|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
219386064|NCT05282212|DIAGNOSTIC_TEST|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
219386065|NCT02574299|OTHER|E-learning|Management of auditory processing disorders with serious game (E-learning)
219386066|NCT02574299|DEVICE|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
219386067|NCT01956643|OTHER|gum chewing|gum chewing
219386068|NCT01956643|OTHER|Control|Routine care during NPO
219386069|NCT05738512|PROCEDURE|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
219386070|NCT05738512|PROCEDURE|Submucous Resection|Submucous Resection
219001143|NCT01282268|DRUG|arbaclofen|orally disintegrating tablet
219001144|NCT01282268|DRUG|placebo|orally disintegrating tablet
219001145|NCT04006249|DIAGNOSTIC_TEST|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
219386071|NCT00639067|DEVICE|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
219386072|NCT04832438|DRUG|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
219386073|NCT04832438|DRUG|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
219386074|NCT04002453|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
219386075|NCT01893788|DRUG|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
219386076|NCT01893788|DRUG|Eplerenone|50 to 100 mg daily for 48 weeks
219386077|NCT04776369|DRUG|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
219386078|NCT04776369|DRUG|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
219386079|NCT04776369|DRUG|IV saline|Saline IV 50 ml
219386080|NCT04215549|OTHER|No intervention|cross sectional study，no intervention
219386081|NCT06481189|BIOLOGICAL|GNR-086|The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
219386082|NCT06481189|BIOLOGICAL|Ilaris®|The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
219386083|NCT03636594|OTHER|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
219386084|NCT05165394|DRUG|Placebo|Tablets for oral administration
219386085|NCT05165394|DRUG|NBI-1065846|Tablets for oral administration
219386086|NCT02967120|OTHER|no intervention|
219386087|NCT05336370|BEHAVIORAL|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
219386088|NCT05336370|DEVICE|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
219386089|NCT05336370|DEVICE|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
219386090|NCT03819283|DIAGNOSTIC_TEST|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
219386091|NCT01332435|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
219386092|NCT04510727|DEVICE|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
219386093|NCT04510727|PROCEDURE|Curettage & Desiccation (C&D) Procedure|Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
219386094|NCT00492622|DRUG|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
219386095|NCT00492622|DRUG|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
219386096|NCT05986344|DEVICE|Copper intrauterine contraceptive device|copper T-380 IUD
219386097|NCT05986344|DEVICE|LNG-IUS|Levonorgestrel Intrauterine System
219386098|NCT05829720|DIETARY_SUPPLEMENT|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
219386099|NCT05829720|DIETARY_SUPPLEMENT|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
219386100|NCT04745442|DRUG|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
219386101|NCT04745442|DRUG|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
219386102|NCT02376439|OTHER|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
219386103|NCT01828125|PROCEDURE|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
219386104|NCT01828125|DRUG|Glucagon|
219386105|NCT02047123|DIETARY_SUPPLEMENT|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
219386106|NCT02135640|DRUG|denosumab 60mg|solution
219386107|NCT02135640|DRUG|denosumab 120 mg|solution
219386108|NCT02135640|DRUG|placebo|solution
219386109|NCT05202977|DEVICE|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
219386110|NCT02517515|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219386111|NCT02517515|DRUG|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
219386112|NCT04291300|DRUG|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
219386113|NCT06287424|DIETARY_SUPPLEMENT|Aged Garlic Extract|Subjects will be instructed to continue using their regular home oral hygiene products until the Product Distribution Visit (Visit 2). They will also be instructed not to add or change any of their regular home oral hygiene products during that time.
219386114|NCT06287424|DIETARY_SUPPLEMENT|Placebo|Placebo
219386115|NCT02786537|DRUG|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
219386116|NCT02786537|DRUG|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
219386117|NCT02786537|DRUG|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
219001146|NCT03589950|DRUG|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
219001147|NCT03589950|DRUG|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
219386118|NCT02786537|DRUG|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
219386119|NCT02638012|DRUG|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
219386120|NCT02638012|OTHER|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
219386121|NCT00443560|OTHER|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
219386122|NCT05829577|OTHER|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
219386123|NCT05829577|OTHER|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
219386124|NCT05829577|OTHER|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
219386125|NCT04050748|PROCEDURE|Achilles tendon repair|Patients will be undergoing achilles tendon repair
219386126|NCT05453253|BIOLOGICAL|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
219386127|NCT05453253|BIOLOGICAL|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
219386128|NCT03271827|DEVICE|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
219386129|NCT04359953|DRUG|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
219386130|NCT04359953|DRUG|Azithromycin|Azithromycin 2 x per day during 14 days
219386131|NCT04359953|DRUG|Telmisartan|Telmisartan 2 x per day during 14 days
219386132|NCT06507020|BEHAVIORAL|Fall prevention knowledge education|"Frequency of Intervention: 4 sessions, 60 mins each, weeks 1, 3, 5, 8.~Intervention format：group intervention, 12-15 participants in one group.~Intervention content: Elderly fall risks, home safety improvements, community hazard identification, behavior modification.~Intervention tools: digital teaching PPTs.~Intervention deliverers: 2 members per community, one as leader for organizing health ed. activities (lectures, discussions, exercises, Q\&A), the other as assistant for support and participant safety during exercises."
219557930|NCT05089890|DEVICE|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
219001148|NCT02338661|DEVICE|SBG hip stem|
219001149|NCT01091493|DRUG|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
219001150|NCT01059825|DRUG|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
219001151|NCT01059825|DRUG|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
219001152|NCT01059825|DRUG|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
219386133|NCT06507020|BEHAVIORAL|Exercise education|"Frequency of intervention: 4 sessions Duration of intervention: 30 minutes/session, once in each of the 1st, 3rd, 5th and 8th weeks of the intervention period.~Intervention format: group intervention, 12 people in a group (in principle, no more than 15 people).~Intervention content: The content of health education included (1) basic knowledge of exercise safety, 4 methods of balance function exercise (2) review 4 methods of balance function exercise(3) methods of exercising muscle strength (4) 2 methods of endurance exercise.~Intervention tools: accompanying teaching materials Intervention deliverers: same as before."
219386134|NCT06507020|BEHAVIORAL|Home hazard reduction education|"Intervention Time:~One home fall risk assessment and modification instruction at week 6 of health education.~Frequency of Intervention:~Single session.~Intervention Format:~Project staff conduct in-home fall risk assessments by appointment.~Intervention Content:~1. Evaluate fall risks in elderly living areas.~2. Provide personal guidance, complete two written forms-one for records, one for the participants.~3. Supply night lights, anti-slip mats, warning signs, and carpet mats; more services encouraged where possible.~Intervention Tools:~Utilize Elderly Home Fall Risk and Retrofitting Guide for detailed assessments and suggestions. Include tools like night lights, mats, and signs.~Intervention Deliverers:~Skilled community social workers or community health center staff."
219386135|NCT05170945|OTHER|Early bowel preparation for colonoscopy|Early (\<24 hours) bowel cleansing prior to colonoscopy.
219001153|NCT01059825|DRUG|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
219386136|NCT00643045|DRUG|Safinamide|
219386137|NCT00643045|DRUG|Safinamide|
219386138|NCT00643045|DRUG|Placebo|
219386139|NCT01688648|DRUG|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
219386140|NCT01688648|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
219386141|NCT02102061|OTHER|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
219386142|NCT01147965|BIOLOGICAL|AD5 CEA Vaccine|AD5\[E1-, E2b-\]-CEA Vector Vaccine
219386143|NCT02968030|OTHER|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
219386144|NCT05491642|DRUG|BAY3283142|Oral administration
219386145|NCT05491642|DRUG|Placebo to BAY3283142|Oral administration
219386146|NCT00002042|DRUG|Epoetin alfa|
219386147|NCT02734732|DRUG|Trimethoprim/Sulfamethoxazole|
219386148|NCT02734732|DRUG|Ciprofloxacin|
219386149|NCT05099991|DEVICE|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
219386150|NCT05099991|DEVICE|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
219386151|NCT04889703|DRUG|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
219386152|NCT04889703|DRUG|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
219001154|NCT01059825|DRUG|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
219386153|NCT03540121|BEHAVIORAL|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
219386154|NCT00599586|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
219386155|NCT00215501|DRUG|Capecitabine|Orally twice a day for 14 days (dosage will vary)
219386156|NCT00215501|DRUG|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
219386157|NCT00215501|DRUG|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
219386158|NCT00215501|DRUG|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
219386159|NCT01516450|DRUG|GSK1550188 IV|Single IV dose of belimumab 200 mg
219386160|NCT01516450|DRUG|GSK1550188 SC|Single SC dose of belimumab 200mg
219001155|NCT01059825|DRUG|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
219001156|NCT01059825|DRUG|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
219001157|NCT05639374|BEHAVIORAL|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
219386161|NCT02227212|DRUG|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219386162|NCT00310245|PROCEDURE|STI (structured Treatment Interruption)|
219386163|NCT06119698|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
219386164|NCT04303390|DRUG|Cefuroxime|second generation cephalosporin
219386165|NCT04303390|DRUG|Cefazolin|First generation cephalosporin
219386166|NCT04303390|OTHER|24 hours|Duration of antibiotic therapy
219386167|NCT04303390|OTHER|48 hours|Duration of antibiotic therapy
219386168|NCT05405543|DRUG|MYK-224|Specified dose on specified days
219386169|NCT05405543|OTHER|Placebo|Specified dose on specified days
219386170|NCT06480929|OTHER|Contrast TTE procedure, the SonoVue ultrasound agent|The intervention involved using contrast-enhanced transthoracic echocardiography (TTE) to improve the detection of left ventricular thrombus in patients with anterior ST-elevation myocardial infarction (STEMI).
219386171|NCT01447056|BIOLOGICAL|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
219386172|NCT00431860|PROCEDURE|Coronary computed tomographic angiography|
219386173|NCT03938662|DIETARY_SUPPLEMENT|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
219386174|NCT03938662|DIETARY_SUPPLEMENT|Placebo|Placebo of same appearance, colour and taste,
219386175|NCT01382589|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
219386176|NCT01382589|DEVICE|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
219386177|NCT03855072|PROCEDURE|customized fixation plate|"* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
219386178|NCT03855072|PROCEDURE|maxillomandibular fixation|"* All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
219001158|NCT04830020|DRUG|HMW-HA|Aerolized administration b.i.d.
219001159|NCT04977908|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
219001160|NCT04977908|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Dexcom G6 CGM
219001161|NCT04416594|OTHER|Data collection|Only data collection
219001162|NCT02058667|RADIATION|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
219007033|NCT01121887|BEHAVIORAL|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
219007034|NCT00427466|DRUG|Pemetrexed|
219386179|NCT06127212|DRUG|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
219386180|NCT06127212|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
219386181|NCT04020432|BEHAVIORAL|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
219386182|NCT04942639|DEVICE|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
219386183|NCT04527757|PROCEDURE|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
219386184|NCT04527757|PROCEDURE|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
219386185|NCT01389128|OTHER|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
219386186|NCT01389128|OTHER|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
219386187|NCT05842798|DRUG|TNM002|TNM002, intramuscular injection
219386188|NCT05842798|DRUG|Placebo|Placebo, intramuscular injection
219386189|NCT03918993|DRUG|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
219386190|NCT05060042|OTHER|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
219386191|NCT05060042|OTHER|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
219386192|NCT05518786|OTHER|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
219386193|NCT04954846|DIETARY_SUPPLEMENT|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
219386194|NCT04954846|DIETARY_SUPPLEMENT|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
219386195|NCT05117801|DEVICE|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
219386196|NCT01596829|DIETARY_SUPPLEMENT|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
219386197|NCT01596829|DIETARY_SUPPLEMENT|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
219386198|NCT04277702|DRUG|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
219386199|NCT04277702|PROCEDURE|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
219386200|NCT04277702|DRUG|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
219386201|NCT06247540|PROCEDURE|Biopsy|Undergo tissue biopsy
219386202|NCT06247540|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219386203|NCT06247540|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219386204|NCT06247540|PROCEDURE|Computed Tomography|Undergo PET/CT, CT
219386205|NCT06247540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219386206|NCT06247540|BIOLOGICAL|Nivolumab|Receive IV
219386207|NCT06247540|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219001163|NCT02090569|DEVICE|Functional micro-Doppler Sonography (fmDS)|"1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure"
219001164|NCT00831168|BEHAVIORAL|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
219386208|NCT06247540|BIOLOGICAL|Rituximab|Receive IV
219386209|NCT06247540|DRUG|Venetoclax|Receive PO
219386210|NCT04929873|BEHAVIORAL|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
219386211|NCT04929873|BEHAVIORAL|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
219386212|NCT00061308|DRUG|Topotecan|
219386213|NCT00061308|DRUG|Gemcitabine|
219386214|NCT06962943|OTHER|Auto-regulated Blood Flow Restriction Training|This group was recruited to conduct auto-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used to automatically determine the individualized 50% arterial blood occlusion pressure for the BFRT group at the femoral artery, the cuff was connected to the smart tool device for the auto-regulated group to regulate the cuff pressure during muscle contraction and relaxation. The cuff was deflated in between exercises.
219386215|NCT06962943|OTHER|Non-regulated Blood Flow Restriction Training|This group was recruited to conduct a non-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device in the non-regulated blood flow restriction training group and the pressure was stabilized as the initial pressure determined by the device in the non-regulated group. The cuff was deflated in between exercises.
219386216|NCT06962943|OTHER|Control group|This group was recruited to conduct no blood flow restriction exercise 30 min, three times a week for 6 weeks. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device and the pressure was 0 (zero) in this group. The cuff was deflated in between exercises.
219386217|NCT00524095|DRUG|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
219386218|NCT00524095|DRUG|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
219386219|NCT06963099|OTHER|INTACS implantation|intra corneal segments implantation
219386220|NCT05463601|DRUG|Mecapegfilgrastim|Mecapegfilgrastim
219386221|NCT05463601|DRUG|dalpiciclib|dalpiciclib
219386222|NCT05463601|DRUG|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
219386223|NCT06506279|DEVICE|CorTec Brain Interchange (BIC) System|Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
219386224|NCT00015249|DRUG|Amantadine|
219386225|NCT06472570|RADIATION|Stereotactic radiotherapy boost|"A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy"
219386226|NCT02963467|PROCEDURE|cigarette|smoking 4 conventional cigarettes
219386227|NCT02963467|PROCEDURE|"dummy cigarette"|"smoking a dummy cigarette"
219386228|NCT03987217|DIETARY_SUPPLEMENT|Creatine Monohydrate|Given orally
219386229|NCT03987217|BEHAVIORAL|Exercise Intervention|Complete POWER resistance training program
219386230|NCT03987217|OTHER|Questionnaire Administration|Ancillary studies
219386231|NCT05953662|PROCEDURE|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
219386232|NCT05953662|PROCEDURE|conventional laparoscopic surgery|conventional laparoscopic surgery
219386233|NCT00980083|DRUG|Saline|
219386234|NCT00980083|DRUG|Exendin(9-39)amide|
219386235|NCT00981435|DRUG|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
219386236|NCT00981435|DRUG|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
219386237|NCT00981435|DRUG|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
219386238|NCT00402350|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
219386239|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
219386240|NCT00402350|DRUG|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
219386241|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
219386242|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
219386243|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
219386244|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
219386245|NCT02659345|BEHAVIORAL|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
219386246|NCT02659345|BEHAVIORAL|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
219386247|NCT00602407|DRUG|Cilostazol|
219386248|NCT06445322|DIAGNOSTIC_TEST|Prescreening Assessments|Various genetic and visual assessments.
219386249|NCT05113004|DRUG|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
219386250|NCT05113004|DRUG|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
219386251|NCT05113004|DRUG|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
219386252|NCT05113004|DRUG|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
219386253|NCT05113004|DRUG|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
219386254|NCT05113004|DRUG|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
219386255|NCT05306678|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
219386256|NCT05306678|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
219557931|NCT05089890|DEVICE|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
219557932|NCT00265681|BEHAVIORAL|Phone counseling and written materials|
219557933|NCT03095781|DRUG|XL888|Given PO
219386257|NCT00947154|DRUG|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
219386258|NCT01247233|RADIATION|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
219386259|NCT01247233|RADIATION|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
219386260|NCT02260011|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
219386261|NCT02260011|DRUG|Atrovent® CFC inhalation aerosol|
219386262|NCT02260011|DRUG|Placebo|
219386263|NCT00645242|DRUG|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
219386264|NCT04265534|DRUG|Telaglenastat|Oral Glutaminase Inhibitor
219386265|NCT04265534|DRUG|Carboplatin Chemotherapy|IV infusion
219386266|NCT04265534|DRUG|Pemetrexed Chemotherapy|IV infusion
219386267|NCT04265534|BIOLOGICAL|Pembrolizumab Immunotherapy|IV infusion
219386268|NCT04265534|DRUG|Placebo|Oral placebo
219386269|NCT04265534|DIETARY_SUPPLEMENT|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
219386270|NCT04265534|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
219386271|NCT04265534|DRUG|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
219386272|NCT02616653|PROCEDURE|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
219386273|NCT05089305|DRUG|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
219386274|NCT02943551|OTHER|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
219386275|NCT02943551|OTHER|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
219386276|NCT02943551|OTHER|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
219386277|NCT02943551|OTHER|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
219386278|NCT02943551|OTHER|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
219386279|NCT01570725|BEHAVIORAL|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
219386280|NCT01570725|BEHAVIORAL|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
219386281|NCT04097288|DRUG|Citalopram 40mg|Single dose
219001165|NCT06432920|DEVICE|ResWave|Prototype wearable in-phase chest wall vibration device
219001166|NCT01129479|DRUG|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
219386282|NCT04097288|DRUG|Reboxetine 8 mg|Single dose
219386283|NCT04097288|DRUG|Placebo oral tablet|Single dose
219386284|NCT04097288|DRUG|Placebo oral tablet|Single dose
219386285|NCT01726777|DIETARY_SUPPLEMENT|Control|Normal cheddar cheese
219386286|NCT01726777|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 supplemented cheddar cheese
219386287|NCT00884507|DRUG|Placebo|po daily for 24 weeks
219386288|NCT00884507|DRUG|RO5313534|1mg po daily for 24 weeks
219386289|NCT00884507|DRUG|RO5313534|5mg po daily for 24 weeks
219386290|NCT00884507|DRUG|RO5313534|15mg po daily for 24 weeks
219386291|NCT03607734|DRUG|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
219386292|NCT03778255|PROCEDURE|Sentinel Lymph Node Biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
219386293|NCT04764032|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
219386294|NCT03196050|DEVICE|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
219386295|NCT01332032|BEHAVIORAL|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
219386296|NCT01332032|BEHAVIORAL|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
219386297|NCT01332032|BEHAVIORAL|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
219386298|NCT00609271|BEHAVIORAL|low carbohydrate diet|\<40 grams carbohydrate/day
219386299|NCT00609271|BEHAVIORAL|low fat diet|\<30% fat, \<7% saturated fat
219386300|NCT03650439|DIAGNOSTIC_TEST|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
219386301|NCT06477159|DRUG|Pancrelipase Capsules|Treatment with Pancreatic Enzyme Replacement Therapy
219386302|NCT03601026|BEHAVIORAL|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
219386303|NCT01217775|DRUG|PH80|PH80 intranasal spray 800 nanograms
219386304|NCT01217775|DRUG|Placebo intranasal spray|Placebo intranasal spray
219386305|NCT00396396|DRUG|Acetylcysteine|
219386306|NCT00315302|DRUG|Atropine|Atropine 1% once each weekend day
219386307|NCT00315302|DEVICE|Plano Lens|Plano lens for the sound eye
219001167|NCT01129479|DRUG|Placebo pill|Placebo pill each morning with food for 12 weeks.
219386308|NCT04252417|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
219386309|NCT00217438|DRUG|melphalan|Given IV
219386310|NCT00217438|DRUG|amifostine trihydrate|Given IV
219386311|NCT00217438|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
219386312|NCT00217438|GENETIC|fluorescence in situ hybridization|Correlative study
219386313|NCT00217438|PROCEDURE|bone marrow ablation with stem cell support|Undergo transplant
219386314|NCT03939208|BEHAVIORAL|BRISC|
219386315|NCT03939208|BEHAVIORAL|SAU|
219386316|NCT00000249|DRUG|20% N2O|20% inhaled N2O
219386317|NCT00000249|DRUG|30% N2O|30% inhaled N2O
219386318|NCT00000249|DRUG|40% N2O|40% inhaled N2O
219386319|NCT02082691|DRUG|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
219386320|NCT05736315|OTHER|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
219386321|NCT04297007|OTHER|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219386322|NCT04297007|OTHER|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219386323|NCT00704106|DRUG|Entecavir|0.5 or 1 mg dose qd
219386324|NCT01400828|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
219386325|NCT01400828|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
219386326|NCT01400828|DRUG|Placebo|(encapsulated) Tablets QD/14 days
219386327|NCT02286960|DRUG|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
219386328|NCT02286960|DIETARY_SUPPLEMENT|Lactose Pills|4 day course 2 x 20mg per da
219386329|NCT00440401|DRUG|fibrinogen (human) + thrombin (human)|
219386330|NCT00440401|DRUG|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
219386331|NCT05064241|OTHER|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
219386332|NCT01288183|PROCEDURE|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
219386333|NCT01288183|PROCEDURE|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
219386334|NCT02420886|OTHER|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
219001168|NCT02664701|OTHER|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
219386335|NCT04616586|DRUG|Siltuximab|11 mg/kg IV administered over 1 hour
219001169|NCT02664701|OTHER|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
219001170|NCT02664701|OTHER|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
219001171|NCT02664701|OTHER|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
219386336|NCT04616586|OTHER|Normal Saline|IV administered over 1 hour
219386337|NCT00550238|DRUG|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
219386338|NCT03669393|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
219386339|NCT02418494|OTHER|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
219386340|NCT02418494|OTHER|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
219386341|NCT00200681|DRUG|Velcade|
219386342|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
219386343|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
219386344|NCT04350203|PROCEDURE|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
219386345|NCT04350203|PROCEDURE|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
219386346|NCT05413447|COMBINATION_PRODUCT|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
219386347|NCT02198144|OTHER|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
219386348|NCT06033443|OTHER|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
219386349|NCT00779038|DRUG|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
219386350|NCT05255614|DEVICE|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device \& software at Swedan
219386351|NCT05255614|DEVICE|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
219386352|NCT04300725|OTHER|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
219386353|NCT04341610|DRUG|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
219386354|NCT00537745|DRUG|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
219386355|NCT00537745|OTHER|Medication Management Therapy|Medication Management Therapy once a month.
219386356|NCT00219180|DRUG|aliskiren|
219386357|NCT04837391|DEVICE|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
219386358|NCT04837391|DIAGNOSTIC_TEST|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
219386359|NCT04837391|DIAGNOSTIC_TEST|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
219386360|NCT04837391|DIAGNOSTIC_TEST|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
219386361|NCT00816946|BEHAVIORAL|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI"
219386362|NCT02047552|DRUG|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
219386363|NCT02047552|DRUG|Oxandrolone|10 mg PO Q12 hours for seven days
219386364|NCT02047552|DRUG|IV iron placebo|100 mL normal saline
219386365|NCT02047552|DRUG|Oxandrolone placebo|similar color and size sugar pill
219386366|NCT03295097|OTHER|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
219386367|NCT04468750|DEVICE|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
219386368|NCT01905735|DRUG|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
219386369|NCT01905735|DRUG|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
219386370|NCT05266638|OTHER|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
219386371|NCT05370157|BEHAVIORAL|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
219386372|NCT03700892|OTHER|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
219386373|NCT03700892|OTHER|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
219386374|NCT03306771|DIAGNOSTIC_TEST|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
219386375|NCT00414622|DRUG|DMXB-A|
219386376|NCT04293250|PROCEDURE|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
219386377|NCT03652454|DEVICE|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
219001172|NCT03026101|OTHER|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
219001173|NCT00453297|DRUG|MF101|
219001174|NCT05985889|OTHER|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
219001175|NCT05985889|OTHER|Fizio|Patients do state-funded physical therapy.
219386378|NCT03652454|OTHER|conventional fixed appliance treatment|conventional fixed appliance treatment
219386379|NCT01304862|BEHAVIORAL|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
219386380|NCT01304862|BEHAVIORAL|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
219386381|NCT02556879|BIOLOGICAL|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
219386382|NCT02556879|BIOLOGICAL|Serum bank|Additional samples for serum bank at each visit if possible
219386383|NCT02556879|BIOLOGICAL|DNA bank|Additional sample for DNA bank at inclusion visit if possible
219386384|NCT02556879|PROCEDURE|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
219386385|NCT02556879|PROCEDURE|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
219557934|NCT03095781|BIOLOGICAL|Pembrolizumab|Given IV
219386386|NCT06227923|DEVICE|PRO-HOME intervention|Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
219386387|NCT03583424|DRUG|Carmustine|Given IV
219386388|NCT03583424|DRUG|Cytarabine|Given IV
219386389|NCT03583424|DRUG|Etoposide|Given IV
219386390|NCT03583424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
219386391|NCT03583424|DRUG|Melphalan|Given IV
219386392|NCT03583424|DRUG|Venetoclax|Given PO
219386393|NCT01144637|BIOLOGICAL|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
219386394|NCT01144637|OTHER|Placebo|0.5 ml TBS
219386395|NCT00455637|BIOLOGICAL|Botulinum toxin type A|
219386396|NCT00396578|DRUG|aerosolized vancomycin or gentamicin|
219386397|NCT00003789|DRUG|isolated limb perfusion|Undergo isolated limb perfusion
219386398|NCT00003789|DRUG|melphalan|Given via limb perfusion
219386399|NCT00003789|BIOLOGICAL|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
219386400|NCT00003789|OTHER|pharmacological study|Correlative studies
219386401|NCT00003789|OTHER|laboratory biomarker analysis|Correlative studies
219386402|NCT02197962|DEVICE|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
219386403|NCT02197962|DEVICE|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
219386404|NCT00184054|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
219386405|NCT00184054|DRUG|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
219386406|NCT01274377|BIOLOGICAL|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
219386407|NCT05804110|OTHER|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
219386408|NCT04241029|DIETARY_SUPPLEMENT|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
219386409|NCT02843711|GENETIC|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
219386410|NCT06965933|PROCEDURE|ESP block group|The patient will undergo an ESP blockade under the control of ultrasound during the implementation of anesthetic support. A local anesthetic will be injected into the fascial space of the muscles straightening the spine: ropivacaine 0.375%, 3 mg / kg, on both sides.
219386411|NCT06965933|DRUG|IV Lidocaine|During the implementation of anesthetic support, the patient will receive a constant intravenous infusion of lidocaine: a loading dose of 1.5 mg/kg/ h (1 hour), followed by an infusion of 1 mg/kg/h for 24 hours during the perioperative period.
219386412|NCT05802914|DEVICE|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
219386413|NCT04620603|RADIATION|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
219386414|NCT04620603|DRUG|Standard-of-Care Immunotherapy|Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
219386415|NCT02971358|PROCEDURE|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
219386416|NCT06970626|DRUG|Dexmedetomidine infusion|Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
219386417|NCT06970626|PROCEDURE|Paragastric neural block|Paragastric neural block (PGNB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophago-gastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
219386418|NCT06970626|PROCEDURE|Laparoscopic Transversus Abdominis Plane (LTAP) block|LTAP will be administered after insufflation before insertion of the right and left-handed ports. 30 mL of 0.25% bupivacaine will be injected into the posterolateral subcostal regions on both sides. The correct placement will be confirmed by observing the spread of fluid between the transversus abdominis and the internal oblique muscle layers laparoscopically
219386419|NCT06971562|DEVICE|Aquacel AG|Hydrocellulose wound dressing containing 1.2% cationic silver
219386420|NCT06971562|DEVICE|Aquacel|Hydrocellulose wound dressing
219386421|NCT06970444|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive therapy that modulates brain activity by delivering electrical impulses to the auricular branch of the vagus nerve at the outer ear (Badran et al., 2018). taVNS subsequently stimulates the nucleus of tractus solitarius via the afferent vagus nerve fibers. The nucleus solitarius sends outputs to the hypothalamus, which is critical for sensory processing, including auditory processing, and also activates various brain regions, including the locus coeruleus, resulting in the release of neurotransmitters such as norepinephrine and serotonin, which are involved in neural plasticity and cognitive function, which is important for CAP. Another theory for taVNS effects is the release of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, which may further help to balance abnormal neural activity in auditory circuits.
219386422|NCT06970444|OTHER|Sham device|the control group received sham stimulation with the stimulator closed and electrodes placed in their left ear
219386423|NCT06971991|DEVICE|qDSA Blood Flow Measurement|The research intervention is limited to several additional qDSA image acquisitions, which include administration of additional iodinated contrast medium.
219386424|NCT06969586|DRUG|Netarsudil 0.02% Ophthalmic Solution|Topical Netarsudil 0.02% 1x daily for 30 days postoperatively
219386425|NCT06969586|DRUG|artificial tear substitute|Topical artificial tear substitute 1x daily for 30 days postoperatively.
219386426|NCT06971718|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment of the vessel treated before and after treatment|OCT and pressure wire of the main vessel and side branch of the bifurcation are undertaken prior to and after treating the lesion and at 3-9 month follow up.
219386427|NCT06969690|OTHER|Survey questionnaire V1|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
219386428|NCT06969690|OTHER|Survey questionnaire V2|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
219386429|NCT06970002|DEVICE|Use of NIV during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
219386430|NCT06970002|DEVICE|Use of HFNC during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
219386431|NCT06382194|OTHER|Decision aid|The intervention is a newly developed decision aid designed to guide decisions about storage of firearms among older gun owners with early dementia and/or depression.
219386432|NCT06572267|DRUG|Mepolizumab low dose group|Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
219386433|NCT06572267|DRUG|Mepolizumab middle dose group|Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
219386434|NCT06572267|DRUG|Mepolizumab high dose group|Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
219386435|NCT06572267|DRUG|Saline|Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
219386436|NCT02605525|BIOLOGICAL|SM101|Human soluble recombinant Fcγ Receptor IIB
219386437|NCT02605525|OTHER|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
219386438|NCT03115190|DIAGNOSTIC_TEST|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
219386439|NCT00876642|DRUG|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
219386440|NCT05502497|OTHER|Observational|No application will be made to the control group.
219386441|NCT05502497|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
219386442|NCT04468477|DEVICE|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
219386443|NCT00676507|BIOLOGICAL|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
219386444|NCT00676507|OTHER|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
219386445|NCT03569267|DRUG|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
219386446|NCT03569267|DRUG|Placebo|Placebo
219386447|NCT00351715|DRUG|Sublingual Methadone|
219386448|NCT04400500|DIAGNOSTIC_TEST|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
219386449|NCT00828451|BIOLOGICAL|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
219386450|NCT03542188|BEHAVIORAL|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
219386451|NCT03542188|BEHAVIORAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
219386452|NCT03883061|OTHER|regular medical treatment|regular medical treatment
219386453|NCT01374698|DRUG|Aspirin|Aspirin 325 mg
219386454|NCT05116969|DRUG|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
219386455|NCT05091138|DRUG|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
219386456|NCT05091138|DRUG|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
219386457|NCT02456623|BEHAVIORAL|Intervention|Home-based session targeting the parent
219386458|NCT02456623|BEHAVIORAL|Attention Control|Attention condition with newsletters and support phone calls
219386459|NCT04422587|OTHER|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
219386460|NCT04801914|PROCEDURE|Percutaneous biliary drainage|Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
219386461|NCT06459752|OTHER|visceral manipulation and noble technique|"First, the patient will lie face-up on a massage or exam table. Physiotherapists feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Physiotherapist manual poking, pressing, and massage actions do three things:~1. Reveals visceral adhesions.~2. Find tender spots.~3. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that makeup fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Minor adhesions may resolve after one session. Tough, stubborn adhesions may require several sessions plus self-manipulation between sessions"
219386462|NCT06459752|OTHER|noble technique|The patient is positioned in supine with both knees bent and feet flat on a firm surface. The patient then places her crossed hands over her abdomen to support and pull the rectus abdominis muscles towards the midline. Finally, the patient is asked to slowly raise her head until a slight contraction is felt in the abdomen, holding for 20 seconds and repeating the exercise up to 20 times a day
219386463|NCT00513344|DIETARY_SUPPLEMENT|Dark Chocolate|1 portion
219386464|NCT00513344|DIETARY_SUPPLEMENT|Milk Chocolate|1 portion
219386465|NCT00513344|DIETARY_SUPPLEMENT|"Control (polyphenol-free) Chocolate"|one portion
219386466|NCT02313480|OTHER|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
219386467|NCT00001542|DRUG|fluconazole|
219386468|NCT06970301|DRUG|glovadalen|Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.
219386469|NCT06970301|OTHER|Placebo|Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.
219386470|NCT05593432|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219386471|NCT05593432|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
219386472|NCT03476850|PROCEDURE|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
219386473|NCT03476850|PROCEDURE|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
219386474|NCT00152256|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
219386475|NCT00152256|DRUG|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
219386476|NCT00152256|DRUG|Placebo|Placebo Tablet, oral Daily for 6 months
219386477|NCT03411070|DEVICE|Implanted Medical Device|Undergo SCOUT reflector placement
219386478|NCT03411070|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219386479|NCT02809066|OTHER|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~* 50 gr kashkaval cheese,~* 400 ml milk and~* 150 gr yogurt for each day."
219386480|NCT04004052|OTHER|Ultrasound guided injection|
219386481|NCT04004052|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
219386482|NCT04004052|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
219386483|NCT03030040|BEHAVIORAL|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
219386484|NCT01870466|DRUG|Cilostazol|cilostazol bid for 7 days
219386485|NCT01870466|DRUG|Simvastatin|simvastatin qd for 7 days
219386486|NCT01870466|DRUG|Rosuvastatin|rosuvastatin qd for 7 days
219386487|NCT02830802|OTHER|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
219386488|NCT02830802|OTHER|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
219386489|NCT00886990|DRUG|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
219386490|NCT00886990|DRUG|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
219001176|NCT05985889|OTHER|EXE1|Patients undergo intensive virtual reality therapy once a day.
219007035|NCT00022009|DRUG|gemcitabine hydrochloride|
219386491|NCT00263926|BIOLOGICAL|wasp venom|
219386492|NCT01814423|DRUG|Chloroquine-base 50 mg|
219386493|NCT01814423|DRUG|Chloroquine-base 70 mg|
219386494|NCT01591330|DRUG|LY2140023 Reference form|80-mg tablet administered orally
219386495|NCT01591330|DRUG|LY2140023 Test-Low|80-mg tablet administered orally
219386496|NCT01591330|DRUG|LY2140023 Test-Medium|80-mg tablet administered orally
219386497|NCT01591330|DRUG|LY2140023 Test-High|80-mg tablet administered orally
219386498|NCT02520479|DRUG|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
219386499|NCT02520479|RADIATION|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
219386500|NCT02520479|DRUG|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
219386501|NCT00175981|DRUG|sildenafil, fluvoxamine|
219386502|NCT03542214|COMBINATION_PRODUCT|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
219386503|NCT01525758|DRUG|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
219386504|NCT01525758|DRUG|microcrystalline cellulose|identical number of tablets to active drug groups
219386505|NCT04033289|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
219386506|NCT02912364|DRUG|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
219386507|NCT02912364|DRUG|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
219386508|NCT02964078|DRUG|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
219386509|NCT02964078|DRUG|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
219386510|NCT04980547|DEVICE|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
219386511|NCT04708912|OTHER|Observation|The study parameters will be obtained at the time of recuirement (Basal)
219386512|NCT00121823|BIOLOGICAL|FP9 ME-TRAP|
219386513|NCT00121823|BIOLOGICAL|MVA ME-TRAP|
219386514|NCT01939795|OTHER|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
219386515|NCT01275638|DRUG|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
219386516|NCT04554576|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
219386517|NCT04554576|BEHAVIORAL|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
219386518|NCT04554576|BEHAVIORAL|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
219386519|NCT04752787|OTHER|Online breastfeeding training|Online breastfeeding training will be provided to pregnant women expecting twin babies.
219386520|NCT04752787|OTHER|QR code supported online breastfeeding training|QR code supported online breastfeeding training will be given to pregnant women who are expecting twin babies.
219386521|NCT04746040|DRUG|Test|2 inhalations of Test and Reference product in each study period
219386522|NCT04746040|DRUG|Reference|2 inhalations of Test and Reference product in each study period
219386523|NCT05200767|OTHER|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
219386524|NCT01748383|PROCEDURE|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
219386525|NCT01748383|PROCEDURE|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
219386526|NCT01748383|PROCEDURE|stenting of IRA|The only stent implantation
219386527|NCT03701503|BEHAVIORAL|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
219386528|NCT00430534|BIOLOGICAL|EBV vaccine (268664)|
219001177|NCT05985889|OTHER|EXE2|Patients undergo intensive virtual reality therapy twice a day.
219386529|NCT01983865|OTHER|Exposure to birch pollen|
219386530|NCT01272531|DRUG|Mood stabilizer treatment|lithium or valproate
219386531|NCT02838030|DRUG|L-arginine|3 gr per day
219386532|NCT02838030|DRUG|Placebo (for L-arginine)|3 gr per day
219386533|NCT02838030|DRUG|acetylsalicylic acid|3 gr per day
219386534|NCT00404729|DRUG|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
219386535|NCT04403737|DEVICE|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
219386536|NCT00631462|DRUG|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
219386537|NCT03466554|DEVICE|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
219386538|NCT01930071|DEVICE|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
219386539|NCT02319772|DRUG|BCX4430|
219386540|NCT02319772|DRUG|Placebo|
219386541|NCT06457438|DIAGNOSTIC_TEST|Elecsys Anti-HEV IgG, IgM|Diagnostic test used to determine antibodies in blood and serum.
219386542|NCT06156098|OTHER|No Intervention|No Intervention
219386543|NCT00055198|DRUG|daptomycin|
219386544|NCT00094120|DRUG|MSI-1256F (Squalamine Lactate)|
219386545|NCT05134623|DIAGNOSTIC_TEST|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
219386546|NCT05707572|DRUG|methylprednisolone|a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
219386547|NCT05707572|PROCEDURE|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
219386548|NCT04800315|DRUG|CC-93538|Specified dosages on specified days
219386549|NCT04800315|OTHER|Placebo|Specified dosages on specified days
219386550|NCT05261217|DEVICE|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
219386551|NCT00753922|DEVICE|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
219386552|NCT05078034|DEVICE|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
219386553|NCT05078034|DEVICE|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
219386554|NCT00839111|DRUG|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
219386555|NCT00839111|DRUG|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
219386556|NCT02016287|OTHER|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
219386557|NCT05263843|DIAGNOSTIC_TEST|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
219386558|NCT01301326|DEVICE|subthreshold and threshold laser treatment|subthreshold laser treatment
219386559|NCT01301326|DEVICE|Threshold laser treatment|threshold laser treatment
219386560|NCT03973450|OTHER|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
219557935|NCT06105450|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
219557936|NCT00677872|DRUG|PRX-08066|
219557937|NCT01050556|OTHER|Placebo|daily, 24 weeks
219557938|NCT01050556|DIETARY_SUPPLEMENT|folic acid|400 ug/d for 12 or 24 weeks
219557939|NCT01050556|DIETARY_SUPPLEMENT|folic acid|800 µg/d for 12 or 24 weeks
219557940|NCT01050556|DIETARY_SUPPLEMENT|creatine|3 mg/d for 12 weeks
219386561|NCT04644718|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
219386562|NCT01323296|OTHER|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
219386563|NCT05056831|BEHAVIORAL|Behavioral Intervention|Attend face-to-face mind-body sessions
219386564|NCT05056831|OTHER|Best Practice|Receive usual care
219386565|NCT05056831|OTHER|Informational Intervention|Receive targeted text messages
219386566|NCT05056831|OTHER|Quality-of-Life Assessment|Ancillary studies
219386567|NCT05056831|OTHER|Questionnaire Administration|Ancillary studies
219386568|NCT03977077|DRUG|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
219386569|NCT04933630|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
219386570|NCT02858479|OTHER|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
219386571|NCT02858479|OTHER|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
219386572|NCT02858479|RADIATION|MRI scan|"2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
219386573|NCT04937270|DEVICE|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
219386574|NCT04937270|DEVICE|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
219386575|NCT04937270|DEVICE|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
219386576|NCT04937270|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
219386577|NCT02514070|DRUG|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
219386578|NCT02514070|DRUG|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
219386579|NCT06011486|COMBINATION_PRODUCT|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
219386580|NCT06498037|DRUG|Fentanyl|Administration of subcutaneously administered fentanyl loading boluses
219386581|NCT01430247|OTHER|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
219386582|NCT00191529|DRUG|somatropin|
219386583|NCT01944215|DIETARY_SUPPLEMENT|Meal|effect of meal
219386584|NCT01944215|OTHER|Exercise|effect of exercise
219386585|NCT01944215|RADIATION|Sestamibi|reduce radiation dose
219386586|NCT01944215|DRUG|Caffeine Tablet|effect of caffeine
219386587|NCT01944215|OTHER|External Heating|Heating Pad and warm blanket robe
219386588|NCT02495363|PROCEDURE|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
219386589|NCT02495363|DRUG|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
219386590|NCT02232789|DRUG|Mephedrone|Single oral dose mephedrone
219386591|NCT02232789|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
219386592|NCT02232789|DRUG|Placebo|Single oal dose placebo
219386593|NCT05813470|BIOLOGICAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
219386594|NCT05813470|BIOLOGICAL|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
219386595|NCT06463912|OTHER|Does not apply|A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
219386596|NCT04409678|BEHAVIORAL|activity|physical activity
219386597|NCT02049567|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
219386598|NCT02049567|PROCEDURE|Cataract Surgery|Performed using standard microsurgical techniques
219557941|NCT01050556|DIETARY_SUPPLEMENT|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
219386599|NCT02158078|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
219386600|NCT01919411|DRUG|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
219386601|NCT01919411|DRUG|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
219386602|NCT05998343|BEHAVIORAL|Intergenerational HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
219386603|NCT05998343|BEHAVIORAL|Same-Generation Peer Support HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
219386604|NCT02438930|BEHAVIORAL|Motivational interviewing intervention during HIV testing|
219386605|NCT02438930|BEHAVIORAL|Standard-of-care counseling during HIV testing|
219386606|NCT00003937|DRUG|cisplatin|
219386607|NCT00003937|DRUG|dexrazoxane hydrochloride|
219386608|NCT00003937|DRUG|doxorubicin hydrochloride|
219386609|NCT00003937|DRUG|etoposide|
219386610|NCT00003937|DRUG|ifosfamide|
219386611|NCT00003937|DRUG|methotrexate|
219386612|NCT00003937|PROCEDURE|conventional surgery|
219386613|NCT01656239|DRUG|fedovapagon 1 mg|
219386614|NCT01656239|DRUG|fedovapagon 2 mg|
219386615|NCT01656239|DRUG|fedovapagon 4 mg|
219386616|NCT01656239|DRUG|Placebo ( sugar pill)|
219386617|NCT02128568|BEHAVIORAL|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
219386618|NCT02007837|DRUG|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
219386619|NCT02007837|OTHER|Daily text reminder text messages|
219386620|NCT01031095|OTHER|coronary intervention|elective coronary intervention
219386621|NCT00123201|DRUG|Dronabinol MDI|
219386622|NCT05243329|DRUG|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
219386623|NCT04125745|DRUG|CXA-10|Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
219386624|NCT02426086|DRUG|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
219386625|NCT02426086|DRUG|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
219386626|NCT00524303|DRUG|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
219386627|NCT00524303|DRUG|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
219386628|NCT00524303|DRUG|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
219386629|NCT00524303|DRUG|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
219386630|NCT04760548|OTHER|Observational study|
219386631|NCT04361110|RADIATION|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
219386632|NCT04453644|OTHER|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
219386633|NCT00833859|DRUG|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
219386634|NCT00833859|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
219386635|NCT00705900|DRUG|LCD|2 applications / day for 12 weeks
219386636|NCT00705900|DRUG|calcipotriol|2 applications / day for 12 weeks
219386637|NCT02652000|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
219386638|NCT02510599|DRUG|solithromycin|
219386639|NCT00499915|BEHAVIORAL|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
219386640|NCT00499915|BEHAVIORAL|Asthma Education|Asthma education will be provided at NICU discharge.
219386641|NCT00887042|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
219386642|NCT01690832|DRUG|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
219386643|NCT01690832|DRUG|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
219386644|NCT02986451|DRUG|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
219386645|NCT02986451|DRUG|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
219386646|NCT02986451|DRUG|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
219386647|NCT00984451|BIOLOGICAL|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
219386648|NCT04854655|OTHER|Conventional resin composite|nanofilled resin composite
219386649|NCT04854655|OTHER|Activa Presto|calcium and phosphate hybrid material
219386650|NCT04854655|OTHER|Giomer|fluoride releasing hybrid material
219386651|NCT02914743|BEHAVIORAL|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
219188696|NCT02593773|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
219386652|NCT02914743|PROCEDURE|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
219386653|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise with Music|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
219386654|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
219386655|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
219386656|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
219386657|NCT06592833|DRUG|Placebo|Matching placebo.
219386658|NCT03803852|DEVICE|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL and PODEYE Toric IOL on the axis according to the steep meridian of the cornea"
219386659|NCT04865081|DEVICE|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
219386660|NCT03117933|DRUG|Olaparib|Tablet, 100mg and 150mg
219386661|NCT03117933|DRUG|Cediranib|Tablet 15mg and 20mg
219386662|NCT03117933|DRUG|Paclitaxel|Intravenous (IV)
219386663|NCT06656962|DRUG|Telitacicept 160mg|Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).
219386664|NCT06656962|DRUG|Prednisone (and methylprednisolone)|Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).
219386665|NCT06656962|DRUG|Cyclophosphamide|Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
219386666|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
219386667|NCT03373812|PROCEDURE|Blepharoptosis repair|levator advancement or mullerectomy
219386668|NCT06653751|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
219386669|NCT05240261|DRUG|Quetiapine|Quetiapine 25 mg / day
219386670|NCT05501925|DEVICE|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
219386671|NCT05501925|DEVICE|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
219386672|NCT03650504|PROCEDURE|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
219386673|NCT03650504|PROCEDURE|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
219557942|NCT01164657|DEVICE|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
219557943|NCT02367872|DRUG|TAK-272|TAK-272 tablet
219386674|NCT04176510|BEHAVIORAL|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
219386675|NCT04789824|BEHAVIORAL|eyelid hygiene|EH
219386676|NCT03949777|DEVICE|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
219386677|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
219386678|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
219386679|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
219386680|NCT06605664|DIAGNOSTIC_TEST|Hyperpolarized 13C pyruvate MRI|The subject enrolled in this trial will receive DNP-MRI scanning for two times through hyperpolarized \[1-13C\]pyruvate injection (\~250 mM, 0.43 mL/Kg) before and 2-5 weeks after radiotherapy.
219386681|NCT05426044|DRUG|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
219386682|NCT05426044|DEVICE|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
219386683|NCT00193505|DRUG|Ifosfamide|
219386684|NCT00193505|DRUG|Carboplatin|
219386685|NCT00193505|DRUG|Etoposide|
219386686|NCT00193505|DRUG|Rituximab|
219386687|NCT00193505|DRUG|90Y Zevalin|
219386688|NCT03670576|PROCEDURE|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
219386689|NCT03670576|OTHER|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
219386690|NCT03670576|OTHER|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
219386691|NCT03670576|OTHER|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
219386692|NCT00289705|PROCEDURE|Surgery|Laparoscopic Roux-en-Y gastric bypass
219386693|NCT00840463|DRUG|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
219386694|NCT00840463|OTHER|Placebo|Sugar pill
219386695|NCT03485612|DIAGNOSTIC_TEST|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
219386696|NCT04201912|DIAGNOSTIC_TEST|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
219386697|NCT02043574|BEHAVIORAL|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
219386698|NCT02043574|BEHAVIORAL|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
219386699|NCT02621333|BIOLOGICAL|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
219386700|NCT02621333|DRUG|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
219386701|NCT01259739|OTHER|Cocoa|dissolved in water twice-daily intervention
219386702|NCT03329872|OTHER|Data collection|data collection about symptoms without any specific clinical or biological intervention
219386703|NCT01739595|DRUG|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
219386704|NCT01739595|DRUG|Placebo|Oral capsule taken one time daily for 3 months
219557944|NCT04791007|DRUG|OB-002|vaginal or rectal administration
219386705|NCT00148239|BEHAVIORAL|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
219386706|NCT00148239|BEHAVIORAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
219386707|NCT00148239|BEHAVIORAL|Control|Participants given written educational materials at beginning of study; no treatment beyond this
219386708|NCT02515669|DRUG|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
219386709|NCT02515669|DRUG|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
219386710|NCT03880396|RADIATION|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
219386711|NCT04379583|DEVICE|HairDx Sample Collection Kit|Saliva collection using FDA OTC cleared sample collection device
219386712|NCT00006061|DRUG|phosphatidylcholine|
219386713|NCT02708511|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
219386714|NCT02708511|DRUG|Copper Cu 64-DOTA B-Fab|Given IV
219386715|NCT02708511|OTHER|Laboratory Biomarker Analysis|Correlative studies
219386716|NCT02708511|OTHER|Pharmacological Study|Correlative studies
219386717|NCT02708511|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo PET/CT
219386718|NCT02415725|DRUG|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
219386719|NCT04278573|DRUG|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
219557945|NCT04791007|DRUG|Placebo|vaginal or rectal administration
219001178|NCT05985889|OTHER|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
219386720|NCT04278573|DRUG|Placebo|0.3 ml injection of sterilized sesame oil with no active study ingredient
219386721|NCT00815789|BEHAVIORAL|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
219386722|NCT02215629|DRUG|VS-4718|
219386723|NCT03045146|OTHER|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
219386724|NCT03750838|BEHAVIORAL|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
219386725|NCT00863954|DEVICE|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
219386726|NCT01581411|DRUG|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
219386727|NCT04335825|PROCEDURE|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
219386728|NCT04335825|PROCEDURE|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
219386729|NCT06374810|BEHAVIORAL|Conscious Connected Breathwork|Participants were taught the Conscious Connected Breathwork Technique. 2 facilitators were monitoring and coaching the participants to ensure adherence to the technique
219386730|NCT06374810|OTHER|Placebo waitlist|Participants were told the study was full and that they were placed on a waiting list until the 1st cohort had completed the breathwork program
219386731|NCT02024581|DRUG|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
219386732|NCT02024581|DRUG|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
219386733|NCT01791439|OTHER|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
219386734|NCT01791439|OTHER|placebo|
219557946|NCT02625298|DEVICE|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
219557947|NCT02625298|DEVICE|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
219557948|NCT03169816|DRUG|Lorcaserin|Lorcaserin 10mg, twice daily
219557949|NCT03169816|DRUG|Placebo|Matched placebo for lorcaserin condition dosed twice daily
219557950|NCT05068284|DRUG|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
219557951|NCT05068284|DRUG|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
219557952|NCT05068284|DRUG|ABBV-154|Subcutaneous Injection
219557953|NCT05068284|DRUG|Placebo|Subcutaneous Injection
219386735|NCT01408238|BIOLOGICAL|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
219386736|NCT04779021|OTHER|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
219386737|NCT01962662|OTHER|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
219386738|NCT01962662|OTHER|U/E exercise|strengthening and stretching
219386739|NCT06170255|BEHAVIORAL|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
219386740|NCT00479362|DRUG|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
219386741|NCT00479362|DRUG|Aspirin|Aspirin is continued without interruption prior to device implantation
219386742|NCT00479362|DEVICE|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
219386743|NCT00479362|DEVICE|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
219386744|NCT06510426|DRUG|Rebif 44 MCG Per 0.5 ML Prefilled Syringe|Rebif 44mcg per 0.5ml administered subcutaneously
219386745|NCT06510426|DRUG|Saline|0.5mL of saline administered subcutaneously
219386746|NCT05387330|DIAGNOSTIC_TEST|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
219386747|NCT01676116|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
219386748|NCT01676116|DRUG|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
219386749|NCT01676116|DRUG|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
219386750|NCT02236624|BEHAVIORAL|Aerobic exercise|
219386751|NCT01287117|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
219386752|NCT01287117|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
219386753|NCT02778698|DIETARY_SUPPLEMENT|Omegaven|
219386754|NCT01893177|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
219386755|NCT00385333|PROCEDURE|Feasibility Study - Imaging System|
219386756|NCT05459805|DRUG|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
219386757|NCT05459805|DRUG|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
219386758|NCT02798523|DRUG|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
219386759|NCT02798523|DRUG|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
219386760|NCT06342167|RADIATION|Radiotherapy|Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
219386761|NCT06342167|DRUG|Programmed Cell Death Protein 1 Inhibitor|200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
219386762|NCT06342167|DIETARY_SUPPLEMENT|Immunonutrition support|600-1600 ml of TPF-T per day according to the nutrition status evaluation
219386763|NCT01170156|DEVICE|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
219007036|NCT02709785|DRUG|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
219007037|NCT02709785|DRUG|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
219386764|NCT01236885|OTHER|computer-assisted intervention|Undergo blood glucose management using Glucommander
219386765|NCT00609440|OTHER|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
219386766|NCT04119908|DEVICE|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
219386767|NCT04119908|BIOLOGICAL|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
219386768|NCT02628223|PROCEDURE|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
219386769|NCT02628223|DEVICE|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
219386770|NCT00787735|BEHAVIORAL|Counseling compliance|Rates of attendance to call counseling session over specific time points
219386771|NCT05047393|OTHER|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
219386772|NCT05113524|OTHER|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
219386773|NCT05113524|OTHER|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
219386774|NCT01769404|BIOLOGICAL|LY2605541|
219386775|NCT01769404|BIOLOGICAL|Insulin Glargine|
219386776|NCT01859429|OTHER|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
219386777|NCT01214512|OTHER|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
219386778|NCT02050932|DIETARY_SUPPLEMENT|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
219386779|NCT00538733|DRUG|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
219386780|NCT00538733|DRUG|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
219386781|NCT00538733|DRUG|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
219386782|NCT00538733|DRUG|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
219386783|NCT06304272|PROCEDURE|Irrigating Traumatic Wound with Drinking Water|Irrigating Traumatic Wound with Drinking Water and Normal Saline
219386784|NCT03921372|DIAGNOSTIC_TEST|Isometric exercise|Squatting for 5 minutes
219386785|NCT03299504|OTHER|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
219386786|NCT02680301|DRUG|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
219386787|NCT02680301|DRUG|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
219386788|NCT02862912|DRUG|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
219386789|NCT02862912|DRUG|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
219386790|NCT02862912|DRUG|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
219754341|NCT07160049|DEVICE|Algometry Pain Tests in the Upper Limb|"This session records pressure pain thresholds in the dominant hand with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the median, ulnar, and radial nerves at three points on the dominant hand (wrist, palm, finger) are located via ultrasound and marked. A pressure algometer is applied to each site, with pressure gradually increased until pain is first reported. Thresholds are recorded, with each location tested three times with short breaks.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
219386791|NCT02862912|DRUG|Saline|Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
219386792|NCT04427657|PROCEDURE|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
219386793|NCT04427657|PROCEDURE|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
219386794|NCT00095121|DRUG|Placebo (PLB)|Matching placebo
219386795|NCT00095121|DRUG|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
219557954|NCT02681588|PROCEDURE|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
219557955|NCT00965731|DRUG|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
219386796|NCT00095121|DRUG|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
219386797|NCT03050463|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
219386798|NCT03050463|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
219386799|NCT03050463|OTHER|Questionnaire Administration|Ancillary studies
219386800|NCT04741243|DEVICE|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
219386801|NCT00576498|OTHER|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
219386802|NCT00576498|OTHER|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
219386803|NCT05987670|DEVICE|AI-stethoscope|"Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines."
219386804|NCT05073770|DEVICE|Titan Condom|"The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
219386805|NCT03129438|DIAGNOSTIC_TEST|continuous EEG (cEEG)|differential use of continuous versus routine EEG
219386806|NCT03129438|DIAGNOSTIC_TEST|routine EEG (rEEG)|differential use of continuous versus routine EEG
219386807|NCT02473653|BIOLOGICAL|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
219386808|NCT02378753|BIOLOGICAL|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
219386809|NCT03572634|DRUG|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
219386810|NCT03572634|COMBINATION_PRODUCT|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
219386811|NCT00072969|DRUG|Daclizumab|
219386812|NCT05536648|OTHER|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
219386813|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
219386814|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
219386815|NCT06294925|DRUG|Etrasimod|As provided in real world practice
219386816|NCT02188446|BEHAVIORAL|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
219386817|NCT02677740|DEVICE|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
219386818|NCT02677740|DEVICE|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
219386819|NCT01613105|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
219386820|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
219386821|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
219386822|NCT06997003|DEVICE|Total treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
219386823|NCT06066736|OTHER|observational|No intervention, observational group
219386824|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
219386825|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
219386826|NCT06869434|PROCEDURE|Group VBL (Thoracolumbal vertebral body length) received 0.2 mg x VBL cm of %0.5 hyperbaric bupivacaine|intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight. A dosage was derived using Harten's dose chart formulated for Caucasian parturients
219386827|NCT06869434|PROCEDURE|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm
219386828|NCT06869434|PROCEDURE|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.
219386829|NCT05073692|DRUG|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
219386830|NCT05073692|DRUG|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
219557956|NCT00965731|DRUG|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
219007038|NCT02709785|DRUG|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
219007039|NCT03415841|DEVICE|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
219386831|NCT05073692|DRUG|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
219386832|NCT05073692|DRUG|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
219386833|NCT05073692|DRUG|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
219386834|NCT05073692|DRUG|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
219386835|NCT05073692|DRUG|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
219386836|NCT05073692|DRUG|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
219386837|NCT05073692|DRUG|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
219386838|NCT05073692|DRUG|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
219386839|NCT05073692|DRUG|Glipizide (SU)|Exposure to Glimepiride (SU)
219386840|NCT05073692|DRUG|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
219557957|NCT00965731|DRUG|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
219557958|NCT02671474|OTHER|4-dimensional volume-rendered computed tomography|
219386841|NCT05073692|DRUG|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
219386842|NCT05073692|DRUG|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
219386843|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
219386844|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 25 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
219386845|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
219386846|NCT02975349|DRUG|Placebo|Placebo were administered for 24 weeks in active treatment period.
219386847|NCT02975349|DRUG|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period received Tecfidera 120 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
219386848|NCT00165737|DRUG|Donepezil Hydrochloride|
219386849|NCT01613612|PROCEDURE|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
219386850|NCT01613612|PROCEDURE|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
219386851|NCT02542995|OTHER|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
219386852|NCT01497171|PROCEDURE|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
219386853|NCT01497171|PROCEDURE|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
219386854|NCT07026383|BEHAVIORAL|performance test|Injury risk was evaluated using the Lower Extremity Functional Test (LEFT), which involves eight agility drills performed consecutively on a diamond-shaped course without rest intervals. The test includes eight components-forward run, backward run, side shuffle, carioca, figure-eight run, 45-degree cuts, 90-degree cuts, and a counter vertical jump-along with the single-leg hop for distance, following a standardized testing protocol known to predict injury risk. Participants who took longer to complete the test were categorized into the high injury risk group, while those with shorter completion times were classified into the low injury risk group.
219386855|NCT07032012|OTHER|control - anxiety evaluation before Pre-anesthetic|If allocated to the group control, the anxiety questionnaire will be applied, and then the pre-anesthetic evaluation will be conducted.
219386856|NCT07032012|OTHER|group intervention - anxiety evaluation after Pre-anesthetic|If allocated to the group intervention, the first contact of the participant with the interviewer will be on the eve of surgery, in the ward. At that moment, the pre-anesthetic evaluation will be conducted. The next day, upon admission to the preoperative room, the anxiety questionnaire will be applied.
219386857|NCT07030569|DRUG|Trastuzumab deruxtecan (DS-8201a)|A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting
219386858|NCT07031882|DEVICE|Liberty Analyzer WBC System|Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
219557959|NCT03380195|OTHER|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
219386859|NCT07031609|BEHAVIORAL|Robot-assisted gait training using Lokomat|This intervention involves robotic-assisted gait training with the Lokomat device. Sessions will last 40 minutes, twice a week for 6 weeks. The intervention targets lower extremity motor function in children with spastic hemiparetic cerebral palsy. The robotic system provides adjustable support and real-time feedback to improve gait patterns and mobility.
219386860|NCT07031609|BEHAVIORAL|Hydrotherapy|Participants will engage in supervised aquatic therapy including structured exercises in a therapeutic pool. Each session lasts 40 minutes, twice a week, for 6 weeks. Exercises include water walking, floating resistance training, jumping, and balance activities designed for children with spastic hemiparetic cerebral palsy to improve strength, coordination, and functional mobility.
219386861|NCT07031609|BEHAVIORAL|Conventional Physiotherapy|This intervention includes 20 minutes of faradic electrical stimulation and 20 minutes of therapeutic exercises such as stretching, positioning, range of motion, and gait training. Administered twice a week for 6 weeks. The protocol aims to support neuromuscular activation and improve gait and mobility in children with spastic hemiparetic cerebral palsy.
219386862|NCT07032181|PROCEDURE|Virtual reality, guided imagery|"Before the procedure, children will be informed via the Child Consent Form, and parents through the Informed Consent Form. Verbal and written consents will be obtained, and data will be recorded in the Child Patient Introductory Information Form. Pre-procedural pain will be assessed using the Faces Pain Scale-Revised scale, and the child will mark their pain. Parents will use the VAS scale for pain assessment. The CFS scale will be explained to both the child and parent to assess the child's fear. A pulse oximeter will measure SPO2 and pulse one minute before the procedure.~The blood collection procedure will be performed by an experienced nurse, and heart rate and oxygen saturation will be recorded in the Application Record Form.~After the procedure, measurements will be taken immediately after the procedure and one minute later.~Children will mark their pain and fear levels on the FPS-R and CFS scales. Parents and observers will also assess the child's pain (VAS) and fear (CFS)."
219386863|NCT07031752|OTHER|Postprandial Vegan Meat|Postprandial responses to one single intake of vegan meat (VM) under fasting conditions.
219386864|NCT07031752|OTHER|Postprandial Meat|Postprandial responses to one single intake of genuine meat (GM) under fasting conditions,
219557960|NCT03380195|OTHER|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
219557961|NCT03380195|OTHER|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
219557962|NCT03380195|OTHER|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
219386865|NCT07031700|DRUG|Mosunetuzumab|"* Cycle 1: Day 1: 1 mg; Day 8: 2 mg; Day 15: 30 mg~* Cycles 2-8: 30 mg every 3 weeks~* Cycles 9-17: 30 mg every 3 weeks (if applicable） A treatment cycle is 21 days. Patients achieving complete remission (CR) by cycle 8 will stop treatment, while those with partial response (PR) or stable disease (SD) may continue up to 17 cycles or until disease progression or intolerable toxicity occurs."
219386866|NCT07031700|DRUG|Tislelizumab|\- Cycles 2-8: 200 mg IV every 3 weeks
219386867|NCT07031050|DEVICE|sacrocolpopexy or sacrocervicopexy|Robotic-assisted sacrocolpopexy or sacrocervicopexy with the Dexter robotic surgery system
219386868|NCT07031232|PROCEDURE|Bone-Level Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol Using Healing Abutments|"All participants will receive a single bone-level dental implant placed in a healed posterior site of the maxilla or mandible. The implants will be placed using a biological drilling protocol and inserted with a final torque of at least 30 Ncm. A 2 mm transmucosal one-piece abutment (mono-block) will be connected at the time of surgery, following a one abutment-one time philosophy.~Each patient will receive a healing abutment immediately after implant placement according to their allocated study group (standard, wide, or customized). The assigned healing abutment will not be removed throughout the healing period. All procedures will be carried out under local anesthesia in a standard clinical setting."
219386869|NCT07031466|OTHER|Retrospective analysis of assigned treatment|Retrospective analysis of assigned treatment will be performed
219386870|NCT07031466|OTHER|Quality of Life (SF-36)|The quality of life will be assessed using the SF-36 (Short-Form Health Subject Questionnaire).
219386871|NCT07031466|OTHER|Quality of Life (EQ-5D)|The quality of life will be assessed using the EQ-5D (European Quality of Life Questionnaire)
219386872|NCT07031466|OTHER|Hospital Anxiety and Depression (HADS)|Hospital Anxiety and Depression will be assessed using the HADS (Hospital Anxiety and Depression Scale)
219386873|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). Ingredients : Stachyose, fructooligosaccharides, isomaltooligosaccharides, maltodextrin, Lactiplantibacillus plantarum CECT7527, Lactiplantibacillus plantarum CECT7528, Lactiplantibacillus plantarum CECT7529, Lactobacillus acidophilus GOLDGUT-LA100, and Epigallocatechin gallate (EGCG).~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
219386874|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.~Ingredients :~S100 Components : As above. Weight Management Components : Isomaltooligosaccharides, fructooligosaccharides, maltodextrin, Lactobacillus fermentum K7-Lb1, Lactobacillus fermentum K8-Lb1, Lactobacillus fermentum K11-Lb3, Euglena gracilis, and phosphatidylserine.~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
219386875|NCT07031596|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of maltodextrin-based placebo (identical in taste, appearance, and packaging to probiotic products) twice daily (2 bottles per dose) for 12 weeks.
219386876|NCT07031947|OTHER|Core stabilization exercise with telerehabilitation|In addition to a brochure containing patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, the intervention group (G1) will receive a back school program in a total of 2 sessions of videoconference interviews, and the exercises will be explained to them, supported by visuals and videos. In addition, patients will be provided with the application that will be provided with your support, and will be provided with core stabilization exercises 3 times a week for 8 weeks.
219386877|NCT07031947|OTHER|Face-to-face core stabilization exercise|The control group (G2) will receive a brochure that includes patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, as well as a face-to-face back school program in our hospital for a total of 2 sessions. The exercise program will be carried out face to face, 3 sessions per week for 8 weeks, at the Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, under the supervision of a physician, with each exercise session being in groups of 8 people.
219386878|NCT07031323|BEHAVIORAL|OnTrackCF|OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.
219007040|NCT05000125|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
219007041|NCT01910610|BIOLOGICAL|FOLFIRI-cetuximab|
219386879|NCT07031622|OTHER|Yoga Exercises|The control and intervention groups received birth preparation training for 45 minutes one day a week for 5 weeks. The experimental group additionally received a total of 10 sessions of a yoga program for 45 minutes, 2 days a week. The content of each yoga session included 10 minutes of mindful breathing, 20 minutes of yoga asanas, and 15 minutes of meditation.
219386880|NCT00813228|DRUG|Sitagliptin (Januvia)|
219386881|NCT05911022|DRUG|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
219386882|NCT05911022|DIETARY_SUPPLEMENT|Probiotic Formula|oral sachets once daily for two weeks
219386883|NCT05911022|OTHER|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
219386884|NCT05575310|PROCEDURE|Total Knee Arthroplasty|Articular knee surface replacement
219386885|NCT00001332|PROCEDURE|CHPP with cisplatin|
219386886|NCT03667651|DRUG|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
219386887|NCT02240498|DRUG|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
219386888|NCT02240498|DRUG|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
219386889|NCT02240498|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
219386890|NCT02240498|DEVICE|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386891|NCT02240498|DEVICE|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386892|NCT02240498|DEVICE|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386893|NCT02240498|DEVICE|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386894|NCT02240498|DEVICE|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386895|NCT02240498|DEVICE|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
219386896|NCT02240498|DEVICE|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
219386897|NCT06340204|DRUG|Irinotecan Hydrochloride Liposome Injection|Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
219386898|NCT01284556|DRUG|Phenobarbital|tablet
219386899|NCT01284556|DRUG|Placebo tablet|tablet
219386900|NCT00204893|DRUG|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
219386901|NCT01754896|OTHER|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
219386902|NCT01754896|OTHER|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
219386903|NCT01754896|OTHER|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
219386904|NCT01754896|OTHER|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
219386905|NCT02420652|DRUG|Aspirin|Given PO
219386906|NCT02420652|OTHER|Laboratory Biomarker Analysis|Correlative studies
219386907|NCT02420652|DRUG|Metformin Hydrochloride|Given PO
219386908|NCT02420652|OTHER|Placebo|Given metformin hydrochloride placebo PO
219386909|NCT02420652|OTHER|Placebo|Given aspirin placebo PO
219386910|NCT02463591|DRUG|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
219386911|NCT03524872|DEVICE|Original CAD/CAM prosthetic abutment|Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
219386912|NCT03524872|DEVICE|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
219386913|NCT03524872|PROCEDURE|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
219386914|NCT03524872|DRUG|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
219386915|NCT03524872|DRUG|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
219386916|NCT03524872|DEVICE|Implant placement|Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
219386917|NCT04569539|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
219386918|NCT05734872|DEVICE|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
219386919|NCT05734872|OTHER|Routine mental health course training|Conduct mental health education for patients by making a speech.
219386920|NCT00772460|DEVICE|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
219386921|NCT04244045|OTHER|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
219386922|NCT03069768|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
219386923|NCT03069768|DRUG|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
219386924|NCT00909285|DEVICE|TMS stimulation|TMS stimulation and cognitive training
219386925|NCT00909285|DEVICE|Sham comparator|Sham comparator
219386926|NCT00909285|BEHAVIORAL|Cognitive training|TMS stimulation and cognitive training
219386927|NCT03922399|PROCEDURE|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
219386928|NCT00210561|DRUG|tramadol hydrochloride , acetaminophen|
219386929|NCT02021968|BIOLOGICAL|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
219386930|NCT02021968|BIOLOGICAL|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
219386931|NCT02021968|BIOLOGICAL|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
219386932|NCT03911674|OTHER|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
219386933|NCT00830830|DRUG|Hyalgan (sodium hyaluronate)|
219386934|NCT04763382|OTHER|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
219386935|NCT04763382|OTHER|Control gruop|Pre-test, post-test and urinalysis
219386936|NCT00803088|DEVICE|The Alair System|Treatment of airways with the Alair System
219386937|NCT04681664|OTHER|High fat diet|50 % fat
219386938|NCT01232972|PROCEDURE|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
219386939|NCT01266148|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
219386940|NCT01266148|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
219386941|NCT01266148|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
219386942|NCT01266148|DRUG|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
219386943|NCT01266148|DRUG|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
219386944|NCT05523726|BEHAVIORAL|pCBT-I|Telehealth coaching
219007042|NCT01910610|BIOLOGICAL|mFOLFOX6-bevacizumab|
219007043|NCT01910610|BIOLOGICAL|OPTIMOX-bevacizumab|
219007044|NCT01910610|BIOLOGICAL|irinotecan-based chemo + bevacizumab|
219386945|NCT05890222|BEHAVIORAL|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
219386946|NCT05890222|BEHAVIORAL|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
219386947|NCT03270787|DRUG|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
219386948|NCT03270787|DRUG|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
219386949|NCT02850250|DRUG|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
219386950|NCT01079923|DIETARY_SUPPLEMENT|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
219386951|NCT01079923|DIETARY_SUPPLEMENT|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
219386952|NCT02412007|OTHER|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing"
219386953|NCT05283707|BEHAVIORAL|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
219386954|NCT01525511|DRUG|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
219386955|NCT01525511|DRUG|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
219386956|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
219386957|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
219386958|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
219386959|NCT01525212|DRUG|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
219386960|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
219386961|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
219386962|NCT06351410|DEVICE|Eye Wearing Contact Lens|Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
219386963|NCT00534846|DRUG|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
219386964|NCT00534846|DRUG|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
219386965|NCT03000114|PROCEDURE|Percutaneous Needle Aponeurotomy|
219386966|NCT03000114|DRUG|XIAFLEX|
219386967|NCT01853228|DRUG|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
219386968|NCT01853228|DRUG|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
219386969|NCT01853228|DRUG|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
219001179|NCT05231395|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
219007045|NCT01910610|BIOLOGICAL|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
219007046|NCT01910610|BIOLOGICAL|XELOX + bevacizumab|
219386970|NCT01398254|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
219386971|NCT04354051|DRUG|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
219386972|NCT05107414|PROCEDURE|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
219386973|NCT03167619|DRUG|Olaparib Oral Product|olaparib 300mg twice daily
219386974|NCT03167619|DRUG|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
219386975|NCT06316323|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
219386976|NCT06316323|DRUG|Sodium fluoride|Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
219386977|NCT03587909|PROCEDURE|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
219386978|NCT03587909|PROCEDURE|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
219386979|NCT02831868|DEVICE|HAVAI|implantation of the HAVAI device to correct the IMA angle
219386980|NCT05115201|PROCEDURE|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
219386981|NCT05115201|PROCEDURE|Scaling and root planing only|Patients will be treated with scaling and root planing
219386982|NCT02927223|DRUG|Atropine|
219386983|NCT02927223|PROCEDURE|Exercise treadmill test|
219386984|NCT01348919|DRUG|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
219386985|NCT01348919|DRUG|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
219386986|NCT01348919|DRUG|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
219386987|NCT03054727|OTHER|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
219386988|NCT03054727|OTHER|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
219188697|NCT06853028|OTHER|ultrasound measurement|Muscle thickness measurements were performed with the ultrasound device immediately before root canal treatment, 1 week after, and 3 months after the treatment.
219188698|NCT04982419|DEVICE|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
219188699|NCT04982419|DEVICE|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
219386989|NCT03065803|PROCEDURE|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
219188700|NCT04245176|BEHAVIORAL|Standard Genetic Counseling|Standard genetic counseling: Standard of care discussion
219386990|NCT03065803|PROCEDURE|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
219386991|NCT02453412|DEVICE|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
219386992|NCT04842344|DEVICE|ECCO2R|extracorporeal carbon dioxide removal
219386993|NCT01918215|DEVICE|ICD|
219386994|NCT01918215|DEVICE|ILR|
219386995|NCT06274359|BEHAVIORAL|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
219386996|NCT02636790|PROCEDURE|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
219386997|NCT02089737|DRUG|Panitumumab|Panitumumab for intravenous infusion
219386998|NCT03498872|DEVICE|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
219386999|NCT03498872|OTHER|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
219387000|NCT00234117|DRUG|Rabeprazole|
219387001|NCT00281411|PROCEDURE|Computed Tomography Angiography|Computed Tomography Angiography
219387002|NCT00281411|PROCEDURE|Magnetic Resonance Angiography|Magnetic Resonance Angiography
219387003|NCT04463160|OTHER|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
219387004|NCT01196910|DEVICE|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
219387005|NCT05658029|DRUG|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
219387006|NCT02363647|OTHER|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
219387007|NCT02976831|DRUG|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
219387008|NCT02976831|DRUG|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
219387009|NCT00812110|DRUG|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
219387010|NCT00004934|DRUG|carboplatin|
219387011|NCT00004934|DRUG|epirubicin hydrochloride|
219001180|NCT05231395|OTHER|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
219001181|NCT03793777|DIETARY_SUPPLEMENT|Aronia|daily supplementation
219001182|NCT03793777|DIETARY_SUPPLEMENT|Placebo|daily supplementation
219188701|NCT04245176|BEHAVIORAL|Quantitative Genetic Counseling|Quantitative genetic counseling: Discussion is guided by tables and graphs.
219188702|NCT05446129|DRUG|Ezabenlimab|Ezabenlimab
219188703|NCT05446129|DRUG|BI 765063|BI 765063
219188704|NCT05446129|DRUG|Pembrolizumab|Pembrolizumab
219188705|NCT04413201|DRUG|Afatinib|Afatinib followed by osimertinib or ICT
219188706|NCT04413201|DRUG|Osimertinib|Osimertinib followed by ICT
219188707|NCT05049850|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
219188708|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
219188709|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
219387012|NCT00004934|DRUG|paclitaxel|
219387013|NCT00004934|PROCEDURE|conventional surgery|
219387014|NCT04248777|OTHER|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
219387015|NCT02750566|PROCEDURE|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
219387016|NCT02750566|OTHER|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
219387017|NCT04394169|BEHAVIORAL|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
219387018|NCT06153381|OTHER|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
219387019|NCT06153381|OTHER|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
219387020|NCT01855438|BEHAVIORAL|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
219387021|NCT04883073|DEVICE|Use of Endo App|Use of Endo App
219387022|NCT02896140|OTHER|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
219387023|NCT02082184|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
219387024|NCT02082184|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
219387025|NCT01887444|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
219387026|NCT01887444|OTHER|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
219387027|NCT05879939|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
219387028|NCT04762355|DRUG|Palovarotene|ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
219387029|NCT04762355|DRUG|Vehicle|Placebo-to-match palovarotene ophthalmic solution vials
219387030|NCT01488981|OTHER|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
219387031|NCT01488981|DEVICE|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
219387032|NCT03177252|DRUG|Lidocaine|-2% lidocaine will be given
219387033|NCT03177252|DRUG|Sodium chloride|-Normal saline will be given
219387034|NCT03177252|DRUG|Bupivacaine|-0.5% bupivacaine will be given
219387035|NCT00147771|DRUG|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
219387036|NCT01425866|BEHAVIORAL|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
219001183|NCT00320892|DRUG|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
219001184|NCT00321802|DRUG|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
219001185|NCT00321802|DRUG|Placebo|Placebo
219387037|NCT05488301|OTHER|chest physiotherapy|"chest physiotherapy session including:~* nasal ventilation~* decrease of respiratory rate without increasement of Tidal volume~* abdomino-diaphragmatic ventilation"
219387038|NCT01009112|BEHAVIORAL|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
219387039|NCT01009112|BEHAVIORAL|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
219387040|NCT01197573|DRUG|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
219387041|NCT01197573|OTHER|No TPA Treatment|Standard of Care
219387042|NCT02964104|DRUG|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
219387043|NCT02964104|DRUG|placebo|Administered once daily subcutaneously for 35 days
219387044|NCT02964104|DRUG|insulin degludec|Administered once daily subcutaneously for 35 days
219387045|NCT02964104|DRUG|placebo|Administered once weekly subcutaneously for 35 days
219387046|NCT05744986|DEVICE|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
219387047|NCT03456765|DIAGNOSTIC_TEST|Ultrasound|US will be made to assess kidneys
219387048|NCT05835258|DIETARY_SUPPLEMENT|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
219387049|NCT05835258|DIETARY_SUPPLEMENT|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
219387050|NCT00405041|DIETARY_SUPPLEMENT|Dietary supplement GVG 2|2.670 g/day for 14 days
219387051|NCT05590299|OTHER|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
219387052|NCT05590299|OTHER|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
219387053|NCT02447107|OTHER|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
219188710|NCT05929599|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
219387054|NCT02447107|OTHER|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
219387055|NCT05555030|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
219387056|NCT05555030|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
219387057|NCT02097836|DEVICE|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
219387058|NCT01466751|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
219387059|NCT05857956|OTHER|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
219387060|NCT02690896|BEHAVIORAL|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
219387061|NCT02690896|BEHAVIORAL|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
219387062|NCT03187379|DRUG|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
219001186|NCT04956497|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
219001187|NCT04350489|OTHER|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
219001188|NCT04804878|PROCEDURE|Collection of blood, tissue, and other biological samples.|Behavioral health assessments, including quality of life.
219001189|NCT04804878|OTHER|Medical Chart Review|Health data abstracted directly from patient's health records
219387063|NCT03187379|DRUG|Bupivacaine|60cc Bupivacaine
219387064|NCT03471221|BEHAVIORAL|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed."
219387065|NCT01742221|BIOLOGICAL|HemaMax|single subcutaneous 12 microgram dose of HemaMax
219387066|NCT01742221|DRUG|Placebo|single subcutaneous dose
219387067|NCT00770185|DRUG|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
219387068|NCT00770185|GENETIC|gene expression analysis|
219387069|NCT00770185|OTHER|immunohistochemistry staining method|
219387070|NCT00770185|OTHER|laboratory biomarker analysis|
219387071|NCT01566344|OTHER|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
219387072|NCT02494908|BEHAVIORAL|Playing a computer game simulating a car race|Playing a computer game simulating a car race
219188711|NCT05929599|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
219387073|NCT04555213|DRUG|NOX66|NOX66 Suppository
219387074|NCT01469923|DRUG|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
219387075|NCT01469923|DRUG|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
219387076|NCT04507308|BEHAVIORAL|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
219387077|NCT01099826|BEHAVIORAL|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
219387078|NCT01099826|BEHAVIORAL|Motivational Interview|motivational interview by trained MI counselors by phone
219387079|NCT04834986|DRUG|Tislelizumab combined with Lenvatinib|"Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year."
219387080|NCT01205243|DRUG|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219387081|NCT00006669|BIOLOGICAL|rituximab|
219387082|NCT00006669|BIOLOGICAL|sargramostim|
219387083|NCT00006669|DRUG|EPOCH regimen|
219387084|NCT00006669|DRUG|cyclophosphamide|
219188712|NCT02249442|DRUG|Tipranavir (TPV)|
219188713|NCT02249442|DRUG|Ritonavir (r)|
219188714|NCT04943588|DIAGNOSTIC_TEST|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
219188715|NCT04943588|DIAGNOSTIC_TEST|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
219188716|NCT04943588|DIAGNOSTIC_TEST|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
219387085|NCT00006669|DRUG|doxorubicin hydrochloride|
219387086|NCT00006669|DRUG|etoposide|
219387087|NCT00006669|DRUG|prednisone|
219387088|NCT00006669|DRUG|vincristine sulfate|
219387089|NCT00479440|DRUG|SAM-315|
219387090|NCT04424498|PROCEDURE|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
219387091|NCT00728507|DRUG|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
219387092|NCT00728507|DRUG|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
219387093|NCT02690467|DEVICE|Insupen G34x3,5mm|
219387094|NCT02690467|DEVICE|Insupen G32x4mm|
219387095|NCT01852864|DRUG|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
219387096|NCT00677963|DRUG|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
219387097|NCT02413398|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
219387098|NCT02413398|DRUG|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
219387099|NCT03435029|BEHAVIORAL|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
219387100|NCT03435029|OTHER|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
219387101|NCT01893723|PROCEDURE|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
219387102|NCT01893723|PROCEDURE|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
219387103|NCT04576351|OTHER|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
219387104|NCT03119376|OTHER|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
219387105|NCT01827540|DRUG|Cenicriviroc|
219387106|NCT01827540|DRUG|Dolutegravir|
219387107|NCT01827540|DRUG|Midazolam|
219387108|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 10mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
219387109|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 20mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
219387110|NCT02874794|DRUG|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
219387111|NCT02874794|DRUG|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
219387112|NCT02874794|DRUG|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
219387113|NCT02874794|DRUG|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
219387114|NCT02199977|OTHER|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
219387115|NCT02199977|OTHER|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
219387116|NCT02199977|OTHER|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
219387117|NCT04498858|OTHER|Patient interview|"Patient will be interviewed :~* tobacco consumption~* reported question asked by the dentist about his/her tobacco consumption~* presence and nature of reported advices given by the dentist~* presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~* presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~* contact with the general practioner~* Fagerstrom score (2 questions)~* demographic variables, age, sex, level of education~* satisfaction"
219387118|NCT01556945|BIOLOGICAL|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
219387119|NCT01556945|BIOLOGICAL|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
219387120|NCT01556945|OTHER|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
219387121|NCT01556945|OTHER|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
219387122|NCT00537940|DRUG|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
219387123|NCT00537940|DRUG|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
219387124|NCT01400334|RADIATION|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
219387125|NCT00001933|DRUG|Nefiracetam|
219387126|NCT01496261|DRUG|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
219387127|NCT01496261|DRUG|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
219387128|NCT01369719|DRUG|osveral|receive 20 mg/kg daily orally
219387129|NCT01369719|DRUG|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
219387130|NCT06554613|DRUG|Olanzapine|Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
219387131|NCT06554613|DRUG|Nivolumab|Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
219387132|NCT01432314|OTHER|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
219387133|NCT01432314|OTHER|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
219387134|NCT06638502|DRUG|HRX215 capsules|HRX215 capsules 250 mg orally twice daily
219387135|NCT06638502|DRUG|Placebo capsules|placebo capsules matching appearance of HRX215
219387136|NCT04804124|BEHAVIORAL|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
219387137|NCT02974075|PROCEDURE|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
219188717|NCT05381103|DIAGNOSTIC_TEST|PSMA-PET and SOC MRI|60 min continuous acquisition of PET data after 3-6 mCI injection of \[68Ga\]P16-093 followed by contrast-CT
219188718|NCT05381103|DIAGNOSTIC_TEST|SOC MRI|Standard of care MRI
219188719|NCT04292379|OTHER|Standard care|Standard procedures and assessments
219188720|NCT04292379|OTHER|Care Bundle|Suicide risk screening tool, mental health assessment tool, follow-up appointment
219387138|NCT06528171|PROCEDURE|Brain MRI|non injected brain MRI
219387139|NCT06528171|BIOLOGICAL|Specific blood samples|blood samples to find immunological and inflammatory markers
219557963|NCT06529874|OTHER|Pressure pain tolerance measurement using Digital Pressure Algometer|Pressure pain tolerance will be measured using pressure algometer for all participants in both groups. Pressure pain tolerance will be measured in a relaxed sitting position to evaluate on quadriceps muscle. Initially, a teddy bear will be used for demonstration.
219387140|NCT03874884|DRUG|Olaparib|"During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42."
219387141|NCT03874884|COMBINATION_PRODUCT|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
219387142|NCT05344092|BEHAVIORAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
219387143|NCT04364672|DRUG|18F-labeled DPA-714 PET scan|One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
219387144|NCT03352440|DEVICE|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
219387145|NCT03352440|DEVICE|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
219387146|NCT03352440|DEVICE|Control Group - Kinect|Group with typical development that will perform the task on Kinect
219387147|NCT03352440|DEVICE|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
219387148|NCT03531229|DRUG|Placebo|Placebo to Lu AF76432 oral solution
219387149|NCT03531229|DRUG|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
219387150|NCT02660554|OTHER|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
219387151|NCT01993355|OTHER|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
219387152|NCT01993355|OTHER|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
219387153|NCT01993355|BEHAVIORAL|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
219387154|NCT01691118|DRUG|Fimasartan|
219387155|NCT01691118|DRUG|Antihypertensive treatment|
219387156|NCT03210077|DEVICE|Monitoring|Monitoring
219387157|NCT02298244|PROCEDURE|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
219387158|NCT02298244|PROCEDURE|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
219387159|NCT04427592|DIAGNOSTIC_TEST|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
219387160|NCT04427592|PROCEDURE|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
219387161|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
219387162|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
219387163|NCT00693381|DRUG|Tacrolimus|oral
219387164|NCT00693381|DRUG|Mycophenolate Mofetil|oral
219387165|NCT00693381|DRUG|methylprednisolone and prednisone|IV and oral
219387166|NCT02590679|DEVICE|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
219387167|NCT04269512|PROCEDURE|lymph node dissection|At least 10 lymph nodes must be removed.
219387168|NCT01062399|DRUG|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
219387169|NCT01062399|DRUG|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
219387170|NCT01062399|RADIATION|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
219387171|NCT01062399|DRUG|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
219387172|NCT01062399|DRUG|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
219387173|NCT01062399|DRUG|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
219387174|NCT01062399|DRUG|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
219387175|NCT02803372|OTHER|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
219760940|NCT03259295|DEVICE|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
219387176|NCT02803372|OTHER|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
219387177|NCT00623012|DRUG|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
219387178|NCT00623012|DRUG|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
219387179|NCT04886830|PROCEDURE|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
219387180|NCT04886830|PROCEDURE|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
219387181|NCT04886830|PROCEDURE|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
219387182|NCT04018170|DRUG|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
219387183|NCT04018170|DRUG|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
219387184|NCT04308369|BIOLOGICAL|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
219387185|NCT05573165|OTHER|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
219387186|NCT05573165|OTHER|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
219387187|NCT00634543|DRUG|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
219387188|NCT00634543|DRUG|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
219387189|NCT00249379|DRUG|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
219387190|NCT01105403|DRUG|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
219387191|NCT02136394|OTHER|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
219387192|NCT02465034|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
219387193|NCT02465034|DEVICE|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
219387194|NCT02465034|DEVICE|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
219387195|NCT02465034|DEVICE|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
219387196|NCT02465034|DEVICE|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
219387197|NCT03372954|DRUG|BMAC|retrograde administration on non-selected BMAC via coronary sinus
219387198|NCT04841668|DRUG|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
219387199|NCT03717324|OTHER|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
219387200|NCT00581711|OTHER|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
219387201|NCT00581711|OTHER|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
219387202|NCT00581711|OTHER|1-part intervention|Provision of feedback on otitis media quality indicators
219387203|NCT00120796|DRUG|Lamivudine|
219387204|NCT00120796|BIOLOGICAL|Recombinant hepatitis B surface antigen|
219387205|NCT01264991|PROCEDURE|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
219760941|NCT06470516|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA.
219387206|NCT01264991|PROCEDURE|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
219387207|NCT05299892|DEVICE|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
219387208|NCT01878565|DRUG|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
219387209|NCT01878565|DRUG|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
219387210|NCT03099759|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D2/D3
219387211|NCT03431389|DEVICE|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
219387212|NCT03405103|BEHAVIORAL|Striving|
219387213|NCT03405103|BEHAVIORAL|Boning-Up|
219387214|NCT03405103|BEHAVIORAL|Personal Choice|
219387215|NCT01646710|BEHAVIORAL|Pretesting food based recommendations|
219387216|NCT00298532|PROCEDURE|Advanced Life Support|
219387217|NCT04429750|PROCEDURE|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
219387218|NCT04429750|PROCEDURE|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
219387219|NCT01736683|DRUG|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
219387220|NCT02941731|DRUG|HIP1403|Oseltamivir 6mg/mL
219387221|NCT02941731|DRUG|HGP0919|Oseltamivir phosphate 6mg/mL
219387222|NCT05021614|DEVICE|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
219387223|NCT02734121|BEHAVIORAL|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
219387224|NCT05611463|DRUG|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
219387225|NCT02250040|OTHER|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
219387226|NCT02250040|OTHER|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
219387227|NCT01588197|BEHAVIORAL|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
219387228|NCT01588197|BEHAVIORAL|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
219387229|NCT01588197|BEHAVIORAL|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
219387230|NCT05891743|DIAGNOSTIC_TEST|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
219387231|NCT06145425|OTHER|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
219387232|NCT04969393|DEVICE|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
219387233|NCT04969393|OTHER|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
219387234|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
219387235|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
219387236|NCT06430892|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
219387237|NCT01023282|DRUG|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
219387238|NCT01023282|DRUG|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
219387239|NCT04939155|BIOLOGICAL|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
219387240|NCT01627145|DRUG|Solifenacin|Solifenacin 5 mg qd,
219387241|NCT04945382|DEVICE|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
219387242|NCT04945382|DEVICE|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
219387243|NCT02622932|DRUG|Anlotinib and 14C-labeled Anlotinib|oral
219387244|NCT02688413|DEVICE|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
219387245|NCT02688413|OTHER|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
219387246|NCT05212129|DEVICE|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
219387247|NCT05212129|OTHER|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
219387248|NCT03968965|DEVICE|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
219387249|NCT03968965|OTHER|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
219387250|NCT02495337|OTHER|Tissue Collection|
219387251|NCT03898934|DRUG|Vitamin D|receive 6000iu daily for 8 weeks
219387252|NCT03898934|DRUG|Placebo Oral Tablet|placebo for the same period
219387253|NCT01939379|DRUG|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
219387254|NCT01939379|DRUG|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
219387255|NCT02065089|OTHER|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
219387256|NCT02060734|PROCEDURE|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
219387257|NCT02060734|OTHER|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
219387258|NCT03185676|OTHER|Bilberry|A bilberry based probiotic beverage
219387259|NCT03185676|OTHER|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
219387260|NCT05252689|OTHER|monolithic zirconia single posterior crowns with deep chamfer finish line|deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
219387261|NCT05252689|OTHER|monolithic zirconia single posterior crowns with vertical finish line|using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
219387262|NCT03741361|OTHER|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
219387263|NCT01844076|DRUG|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
219387264|NCT02734563|OTHER|Collagen turnover|Type IV and V collagen synthesis and breakdown
219387265|NCT03641300|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219387266|NCT03641300|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
219387267|NCT03982667|DIAGNOSTIC_TEST|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
219387268|NCT06346275|PROCEDURE|Acupuncture|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
219387269|NCT06023914|OTHER|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
219387270|NCT06023914|OTHER|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
219387271|NCT05483127|DEVICE|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
219387272|NCT05483127|DEVICE|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
219387273|NCT06104683|DRUG|Placebo|Administered orally
219387274|NCT06104683|DRUG|Pirtobrutinib|Administered orally
219387275|NCT06052462|DRUG|[14C]-LY3556050|Administered orally
219387276|NCT05299710|PROCEDURE|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
219387277|NCT04887311|DRUG|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
219387278|NCT05839561|DRUG|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
219387279|NCT05839561|DRUG|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
219387280|NCT02195830|OTHER|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
219387281|NCT01386671|DRUG|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
219387282|NCT01386671|DRUG|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
219387283|NCT05635565|OTHER|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
219387284|NCT05635565|OTHER|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
219387285|NCT06447012|DIAGNOSTIC_TEST|Colonoscopy|No intervention required from this study, however images will be obtained from patient presenting for colonoscopy
219387286|NCT03976089|BEHAVIORAL|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
219387287|NCT03976089|BEHAVIORAL|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
219387288|NCT04754373|DIETARY_SUPPLEMENT|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
219387289|NCT04754373|OTHER|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
219387290|NCT02337842|BIOLOGICAL|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
219387291|NCT02337842|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
219387292|NCT02886104|PROCEDURE|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
219387293|NCT02886104|DEVICE|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
219387294|NCT01937312|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
219387295|NCT01937312|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
219387296|NCT01937312|DRUG|Prostaglandin analogue|
219387297|NCT06370247|DIAGNOSTIC_TEST|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
219387298|NCT01940718|DRUG|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
219387299|NCT02910440|DRUG|DCL-101 vs Golytely|
219387300|NCT00006812|DRUG|capecitabine|
219387301|NCT02699775|OTHER|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
219387302|NCT00474253|DRUG|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
219387303|NCT00474253|DRUG|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
219387304|NCT00474253|DRUG|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
219387305|NCT06338449|BEHAVIORAL|Aerobic training (AT)|An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
219387306|NCT06338449|BEHAVIORAL|Resistance training (RT)|Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
219387307|NCT06338449|BEHAVIORAL|Combined aerobic and resistance training (AT + RT)|Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
219387308|NCT05182736|BEHAVIORAL|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
219387309|NCT00030576|DRUG|cisplatin|
219387310|NCT00030576|DRUG|erlotinib hydrochloride|
219387311|NCT04227691|DEVICE|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
219387312|NCT04227691|DEVICE|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
219387313|NCT02273115|DRUG|Oxytocin|
219387314|NCT02273115|DEVICE|Transcervical Foley catheter|
219387315|NCT04348903|BEHAVIORAL|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
219387316|NCT04348903|BEHAVIORAL|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
219387317|NCT05841849|DRUG|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
219387318|NCT05841849|DRUG|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
219387319|NCT05841849|DRUG|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
219387320|NCT02823912|DRUG|Capsaicin|
219387321|NCT02823912|DRUG|Magnesia calcinada|
219387322|NCT00986778|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
219387323|NCT00986778|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
219387324|NCT00986778|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
219387325|NCT05073289|BEHAVIORAL|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
219387326|NCT05073289|OTHER|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
219387327|NCT00543647|DRUG|Fenofibrate 160 mg tablet|
219387328|NCT00543647|DRUG|Placebo|
219387329|NCT00262704|BEHAVIORAL|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
219387330|NCT00262704|BEHAVIORAL|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
219387331|NCT06487949|DRUG|valsartan-amlodipine 80/5 mg FDC|fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
219387332|NCT06487949|DRUG|valsartan 80 mg and amlodipine 5 mg as free combination|Free combination of valsartan 80 mg and amlodipine 5 mg given separately
219387333|NCT00184990|DRUG|Aminoguanidine|
219387334|NCT00184990|DRUG|endotoxin|
219387335|NCT05585372|OTHER|CT guided opening mobilization of cervical intervertebral foreman|"1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
219007047|NCT03272074|OTHER|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
219007048|NCT00000507|DRUG|streptokinase|
219188721|NCT05452460|BEHAVIORAL|Mindfulness intervention|"The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes."
219387336|NCT05217862|DIAGNOSTIC_TEST|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
219387337|NCT00593112|DRUG|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
219387338|NCT00593112|OTHER|No intervention|No intervention
219387339|NCT04610307|PROCEDURE|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
219387340|NCT00950027|DRUG|povidone iodine|oropharyngeal decontamination every 4 hours
219387341|NCT00950027|DRUG|Placebo|oropharyngeal decontamination every 4 hours
219387342|NCT02328716|PROCEDURE|Cytoreduction|Cytoreduction
219387343|NCT02328716|DRUG|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
219387344|NCT03446547|DRUG|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
219387345|NCT01258439|DRUG|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
219387346|NCT01258439|DRUG|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
219387347|NCT03619122|PROCEDURE|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
219387348|NCT01501344|DIETARY_SUPPLEMENT|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
219387349|NCT02163408|OTHER|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
219387350|NCT02873546|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
219387351|NCT01426048|OTHER|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
219387352|NCT00482001|DRUG|donepezil|
219387353|NCT00482001|DRUG|Placebo (cornstarch)|
219387354|NCT00380159|DRUG|Elvucitabine|Elvucitabine 10 mg in combination with background ART
219387355|NCT00380159|DRUG|Lamivudine|
219387356|NCT00380159|DRUG|Emtricitabine|
219387357|NCT02119208|BEHAVIORAL|Intensity and timing of exercise|
219387358|NCT04098380|PROCEDURE|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
219387359|NCT04098380|PROCEDURE|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
219387360|NCT04300218|BEHAVIORAL|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
219387361|NCT04300218|OTHER|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
219387362|NCT00258154|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
219387363|NCT00258154|BIOLOGICAL|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
219387364|NCT00258154|BIOLOGICAL|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
219387365|NCT04870151|PROCEDURE|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
219387366|NCT04870151|PROCEDURE|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
219387367|NCT05700747|BEHAVIORAL|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
219387368|NCT01661322|DRUG|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
219387369|NCT01983891|OTHER|Cooking course|6-week nutrition education and cooking course
219387370|NCT05641649|DRUG|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
219387371|NCT02344810|DRUG|c-Met inhibitor AMG 337|Given PO
219387372|NCT02344810|OTHER|placebo|Given PO
219387373|NCT02344810|DRUG|oxaliplatin|Given IV
219387374|NCT02344810|DRUG|leucovorin calcium|Given IV
219387375|NCT02344810|DRUG|fluorouracil|Given IV
219387376|NCT02344810|OTHER|pharmacological study|Correlative studies
219387377|NCT02344810|OTHER|laboratory biomarker analysis|Correlative studies
219387378|NCT03731793|BIOLOGICAL|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
219387379|NCT03731793|OTHER|Placebo|Placebo
219387380|NCT01941225|DRUG|Inhaled iloprost 5.0 mcg|Single administration
219387381|NCT01941225|DRUG|Placebo|Single administration
219387382|NCT04276558|DRUG|Udonitrectag|Eye drop solution in single dose unit.
219387383|NCT04276558|OTHER|Vehicle|Eye drop solution with no active substance in single dose unit.
219387384|NCT05797129|DEVICE|CEDM|Women underwent CEDM screening
219387385|NCT04454814|OTHER|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
219387386|NCT04454814|OTHER|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
219387387|NCT05450068|OTHER|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
219387388|NCT05450068|OTHER|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
219387389|NCT05450068|OTHER|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
219387390|NCT00212914|BEHAVIORAL|Reminder letter|
219387391|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
219387392|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
219387393|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
219387394|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
219387395|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
219387396|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
219387397|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
219387398|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
219387399|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
219387400|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
219387401|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
219387402|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
219188722|NCT06012487|DRUG|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
219188723|NCT05227742|DRUG|Psilocybin|Participants will receive oral psilocybin once per week for 5 weeks.
219188724|NCT05227742|DRUG|Placebo|Participants will receive inert placebo once per week for 5 weeks.
219188725|NCT06375512|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
219387403|NCT01609283|BIOLOGICAL|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
219387404|NCT00862602|BEHAVIORAL|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
219387405|NCT00322114|DIETARY_SUPPLEMENT|lycopene|Given orally
219387406|NCT00322114|OTHER|placebo|Given orally
219387407|NCT01532661|OTHER|observational study|data collected by investigators
219387408|NCT02039154|BEHAVIORAL|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
219387409|NCT02039154|BEHAVIORAL|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
219387410|NCT02882477|DRUG|Deferiprone|
219387411|NCT02882477|DRUG|Acetylcysteine|
219387412|NCT02882477|DRUG|Sitagliptin and Metformin|
219387413|NCT04935944|RADIATION|CBCT radiation|CBCT scanning
219387414|NCT05572099|DIAGNOSTIC_TEST|ExoDx Prostate|Observational only.
219188726|NCT06375512|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) for injection
219188727|NCT06375512|BIOLOGICAL|Shingrix|Sterile suspension for injection
219188728|NCT04636151|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
219188729|NCT06258174|DRUG|Pirtobrutinib|Administered orally.
219188730|NCT03860233|DRUG|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
219188731|NCT03860233|DRUG|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
219387415|NCT01009294|DRUG|Ataluren|Oral powder
219387416|NCT01009294|DRUG|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
219387417|NCT03469310|DRUG|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
219387418|NCT03469310|DRUG|Tylenol #3 Oral Tablet|Narcotic medication first
219387419|NCT03469310|DRUG|Tramadol|non-narcotic medication first with narcotic as second choice
219387420|NCT04537442|DRUG|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
219387421|NCT01122355|DRUG|lipid modification|1\) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
219387422|NCT02716376|DEVICE|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
219387423|NCT00201799|DRUG|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
219387424|NCT04155879|DRUG|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
219387425|NCT04155879|PROCEDURE|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
219387426|NCT00198705|BEHAVIORAL|Improved management of severe neonatal infections|
219387427|NCT06297304|BEHAVIORAL|Sedentary and physical activity behaviors|The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
219387428|NCT01856673|BEHAVIORAL|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
219188732|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (I)|"1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g"
219188733|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (II)|Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
219188734|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (III)|"1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g"
219188735|NCT04790240|DRUG|Standard of care|remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
219188736|NCT06192485|OTHER|proactive balance training|20 participants will receive a proactive balance training program
219188737|NCT06192485|OTHER|Reactive balance training|20 participants will receive a Reactive balance training program
219188738|NCT04178798|DRUG|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
219188739|NCT05224154|BEHAVIORAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
219188740|NCT05224154|BEHAVIORAL|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
219188741|NCT05098899|GENETIC|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
219188742|NCT05098899|OTHER|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
219188743|NCT04829188|BEHAVIORAL|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
219188744|NCT04829188|BEHAVIORAL|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
219387429|NCT01856673|BEHAVIORAL|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
219387430|NCT01856673|OTHER|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
219387431|NCT00303810|DRUG|carboplatin|
219387432|NCT00303810|DRUG|cisplatin|
219387433|NCT00303810|DRUG|cyclophosphamide|
219387434|NCT00303810|DRUG|etoposide phosphate|
219387435|NCT00303810|DRUG|high-dose chemotherapy|
219387436|NCT00303810|DRUG|lomustine|
219387437|NCT00303810|DRUG|methotrexate|
219387438|NCT00303810|DRUG|thiotepa|
219387439|NCT00303810|DRUG|vincristine sulfate|
219387440|NCT00303810|RADIATION|radiation therapy|
219387441|NCT05279378|RADIATION|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
219387442|NCT04803812|OTHER|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
219387443|NCT01310738|DRUG|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
219387444|NCT01310738|DRUG|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
219387445|NCT01310738|DRUG|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
219387446|NCT01310738|DRUG|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
219387447|NCT01310738|DRUG|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
219387448|NCT04332419|DEVICE|PET/CT|Standard Imaging
219387449|NCT04332419|DEVICE|PET/MR|Additional Imaging
219387450|NCT04332419|RADIATION|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
219387451|NCT00073944|DRUG|forodesine hydrochloride|
219387452|NCT02472483|BEHAVIORAL|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
219387453|NCT02472483|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
219387454|NCT01845389|DEVICE|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
219387455|NCT01845389|DEVICE|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
219387456|NCT05372705|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
219387457|NCT04835272|PROCEDURE|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
219387458|NCT00172380|DRUG|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
219387459|NCT06198257|DEVICE|spider cage|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
219387460|NCT06198257|DEVICE|modified suits therapy|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
219387461|NCT02436239|DRUG|Vilazodone|Vilazodone tablets, once daily, oral administration
219387462|NCT03935646|DRUG|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
219387463|NCT03935646|DRUG|Placebo|Placebo
219387464|NCT04129723|OTHER|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
219387465|NCT03020693|PROCEDURE|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
219387466|NCT03020693|PROCEDURE|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
219387467|NCT02386423|DEVICE|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
219387468|NCT02906046|DEVICE|Weight in Lower Limbs|
219387469|NCT03693027|DIETARY_SUPPLEMENT|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
219387470|NCT03693027|DIETARY_SUPPLEMENT|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
219387471|NCT05539053|DRUG|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
219387472|NCT05539053|DRUG|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
219387473|NCT02247830|OTHER|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
219387474|NCT02247830|DRUG|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
219387475|NCT01429649|PROCEDURE|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
219387476|NCT03183635|PROCEDURE|Balance training|Improvement of balance ability in stroke patients
219387477|NCT04953455|OTHER|no intervention|no intervention
219387478|NCT04047992|DEVICE|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
219387479|NCT04937166|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
219387480|NCT04937166|DRUG|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
219387481|NCT04937166|DRUG|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
219387482|NCT03592238|OTHER|Aerobic Exercise Intervention|The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.
219387483|NCT03592238|OTHER|Trier Social Stress Test for Children|Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
219387484|NCT03592238|OTHER|Seated Rest|Children will be asked to sit quietly or read a book of their choosing.
219387485|NCT04341571|DIETARY_SUPPLEMENT|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
219387486|NCT04341571|DRUG|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
219387487|NCT02252861|OTHER|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
219387488|NCT01392690|BEHAVIORAL|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
219387489|NCT04925570|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
219387490|NCT04925570|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
219387491|NCT04705480|DRUG|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
219387492|NCT04705480|DRUG|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
219387493|NCT04705480|DRUG|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
219387494|NCT00658333|DRUG|Enteric-coated Mycophenolate Acid (EC-MPA)|
219387495|NCT00658333|DRUG|Mycophenolate Mofetil (MMF)|
219387496|NCT00658333|DRUG|Placebo MMF|
219387497|NCT00658333|DRUG|Placebo EC-MPA|
219387498|NCT04210492|RADIATION|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
219387499|NCT04977544|DEVICE|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
219387500|NCT04977544|DRUG|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
219387501|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, and consultation (FTFC) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
219387502|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, consultation, and incentivization (FTFCI) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and incentivization.
219387503|NCT06048159|DEVICE|HD-tACS|High definition tACS will be applied during speech therapy.
219387504|NCT06048159|DEVICE|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
219387505|NCT06971692|BEHAVIORAL|Metacognitive therapy (MCT)|MCT is delivered in weekly face-to-face sessions
219001190|NCT04430543|BEHAVIORAL|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
219387506|NCT06971692|BEHAVIORAL|Unified protocol (UP)|UP is delivered in weekly face-to-face sessions
219387507|NCT06971172|DEVICE|Low energy diode Laser|Diode Laser
219387508|NCT06971172|DRUG|Medication|pulse steriod therapy and immunosuppressive drugs
219387509|NCT06971315|DIETARY_SUPPLEMENT|Vitamin C|Three doses of 900 mg vitamin C taken orally (baseline, 12 hours and 24 hours)
219387510|NCT06971315|OTHER|Placebo|Three doses of 900 mg placebo taken orally (baseline, 12 hours and 24 hours)
219387511|NCT06970561|PROCEDURE|enlarged resection|patients underwent secondary enlarged resection within 1 month after the diagnosis of IDP combined with ADH,
219387512|NCT06970951|BIOLOGICAL|UTAA91 injection|Infusion of UTAA91 injection in subjects screened after signing informed consent.
219387513|NCT06970457|BEHAVIORAL|Resistance Exercise Training|12-week progressive and individualized resistance exercise training program
219387514|NCT06970457|BEHAVIORAL|Aerobic Exercise Training|12-week progressive and individualized aerobic exercise training program
219001191|NCT04430543|BEHAVIORAL|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
219001192|NCT00068471|DRUG|anidulafungin|
219001193|NCT03378362|PROCEDURE|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
219001194|NCT06379477|PROCEDURE|Refractive surgeries|after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
219001195|NCT06166160|OTHER|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
219188745|NCT04829188|BEHAVIORAL|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
219188746|NCT04829188|BEHAVIORAL|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
219387515|NCT06970392|BEHAVIORAL|Bedtime Pass|The Bedtime Pass is a small paper card that children will be allowed to exchange for a trip out of their bedroom after bedtime. Once the card has been exchanged, participants will be instructed to ignore any additional pleas from their child. Participants will also be provided with general information about good sleep hygiene.
219001196|NCT00743340|DRUG|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
219001197|NCT04648072|PROCEDURE|Adductor Canal Block|As previously described.
219001198|NCT04648072|PROCEDURE|Periarticular Injection|As previously described.
219001199|NCT01425281|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
219001200|NCT01425281|DEVICE|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
219387516|NCT06972186|DIAGNOSTIC_TEST|Fatigue Protocol + Joint Position Sense Testing|Groups will undergo an isokinetic fatigue protocol at 180°/s using a Biodex dynamometer. Passive and active joint position sense tests will be performed before and after fatigue.
219387517|NCT06971081|OTHER|LED light|(Dental Light Cure), LED light at wavelengths of 420-480nm and will be applied for 30 seconds at a distance of 1cm from the extraction site
219387518|NCT06970210|BEHAVIORAL|Group-Based Education|The group-based education will consist of group sessions led by research staff, covering topics such as physical activity, sedentary behavior, balance and fall prevention, and activities of daily living. Social interactions amongst group members will be facilitated through group activities and discussions regarding the topics being discussed.
219387519|NCT06970210|BEHAVIORAL|Individualized Coaching|Individualized coaching aims to increase the participants daily step count. Participants will be encouraged to achieve step count increases of 2%, 5%, or 10% per week or visit, depending on their readiness and willingness to progress. SMART goal-setting strategies will be employed to assist with the goal setting. Participants may also receive coaching related to reducing sedentary behavior and engaging in physical activities.
219387520|NCT06972199|BEHAVIORAL|Reflexology|Reflexology application
219387521|NCT06972199|BEHAVIORAL|Hot water foot bath|Hot water foot bath application
219760942|NCT06470516|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
219760943|NCT03939585|BIOLOGICAL|Cellular therapy product|"Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~* Infused using venous catheter on post-transplant Day 28 (+ 7 days).~* Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized)."
219387522|NCT06971302|OTHER|Mindfullnes Based Breastfeeding Education|Pregnant women in the intervention group will receive mindfulness-based breastfeeding training, conducted face-to-face and online by the researcher at designated days and times. The intervention group will undergo a total of 12 sessions of mindfulness-based breastfeeding training over a six-week period. The training will be made memorable and easy to understand through the support of visual presentations, videos, and models prepared by the researcher.
219387523|NCT06970964|DIETARY_SUPPLEMENT|Intervention Name: Fermented milk containing Lacticaseibacillus paracasei strain Shirota. Intervention Name: Non-fermented milk (placebo)|Participants will ingest 80 mL per day of fermented milk containing 40 billion colony-forming units (CFU) of Lacticaseibacillus paracasei strain Shirota (LcS), starting 30 days before a triathlon competition and continuing until 14 days post-race. The fermented milk is stored refrigerated and consumed once daily.
219387524|NCT06970964|DIETARY_SUPPLEMENT|Non-fermented milk (placebo)|Participants will ingest 80 mL per day of non-fermented milk identical in taste, appearance, and packaging to the probiotic drink, but without Lacticaseibacillus paracasei strain Shirota. Administration follows the same schedule as the probiotic group.
219387525|NCT01994187|PROCEDURE|Carotid endarterectomy|
219387526|NCT01994187|PROCEDURE|carotid angioplasty|
219387527|NCT03191175|OTHER|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
219387528|NCT00519532|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
219387529|NCT02039388|PROCEDURE|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
219387530|NCT02200107|BEHAVIORAL|self management education|
219387531|NCT01179763|OTHER|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
219387532|NCT02267785|OTHER|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
219387533|NCT02267785|OTHER|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
219387534|NCT02267785|OTHER|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
219387535|NCT06397261|DEVICE|LarynGuide|Artificial Intelligence assisted tracheal video intubation
219387536|NCT03114501|BEHAVIORAL|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
219387537|NCT03114501|BEHAVIORAL|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
219387538|NCT03114501|BEHAVIORAL|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
219387539|NCT06559436|DRUG|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
219387540|NCT06559436|OTHER|Standard medical management|Standard medical management
219387541|NCT05474092|DEVICE|Aeson Total Artificial Heart|Heart Replacement Therapy
219387542|NCT00443521|DRUG|Triamcinolone Acetonide 4 mg intravitreal injection|
219387543|NCT00443521|PROCEDURE|Panretinal photocoagulation|
219387544|NCT00820105|DRUG|ADX10059|oral administration
219387545|NCT00820105|DRUG|ADX10059|Oral administration
219387546|NCT00820105|DRUG|ADX10059|Oral administration
219387547|NCT00820105|DRUG|ADX10059 Matching Placebo|Oral administration
219387548|NCT00624338|DRUG|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
219387549|NCT00624338|DRUG|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
219387550|NCT00624338|OTHER|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
219387551|NCT01548638|DRUG|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
219387552|NCT06970600|DRUG|Artemether-lumefantrine (Coartem)|Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure. Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication. Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. To differentiate recrudescence from new infection by polymerase chain reaction (PCR) analysis.The Molecular markers associated with suboptimal response to ACTs will be investigated.
219387553|NCT06969755|DRUG|aripiprazole|aripiprazole arm (titrated dose)
219387554|NCT06969755|DRUG|risperidone|risperidone arm (titrated dose)
219387555|NCT06969755|DRUG|clozapine|clozapine (titrated dose)
219387556|NCT06159595|DEVICE|Intracranial electrodes|Surgically-implanted intracranial electrodes.
219387557|NCT00470821|DRUG|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
219387558|NCT00470821|DRUG|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
219387559|NCT05107180|DIAGNOSTIC_TEST|drug screen|urine sample
219387560|NCT05021926|DEVICE|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
219387561|NCT05021926|DEVICE|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
219387562|NCT06495151|DIAGNOSTIC_TEST|Mannose-binding lectin-associated serine protease-3 (MASP-3) Level|Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
219387563|NCT06495151|DIAGNOSTIC_TEST|Adipsin Level|Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
219387564|NCT06495151|DIAGNOSTIC_TEST|Properdin Level|Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
219387565|NCT06495151|DIAGNOSTIC_TEST|Complement Factor H (CFH) Level|Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
219387566|NCT06495151|DIAGNOSTIC_TEST|Cancer Antigen 125 (CA-125) Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
219387567|NCT02609399|DRUG|Oseltamivir|Oral
219387568|NCT02609399|DRUG|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
219387569|NCT05300529|OTHER|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
219387570|NCT05300529|OTHER|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
219387571|NCT02936895|DRUG|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
219387572|NCT02936895|DRUG|Placebo|Placebo for 2 days
219387573|NCT01615510|DRUG|Tapentadol immediate release|100 mg, single administration
219387574|NCT01615510|DRUG|placebo|placebo, single administration
219387575|NCT00337948|DRUG|Epoetin alfa|
219387576|NCT00542984|DRUG|teriparatide 20 micrograms/day subcutaneous|
219387577|NCT00542984|DRUG|salmon calcitonin 100 IU/day subcutaneous|
219387578|NCT01563510|PROCEDURE|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
219387579|NCT01563510|PROCEDURE|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
219387580|NCT00104507|DRUG|APD356|
219387581|NCT04292938|DIETARY_SUPPLEMENT|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
219387582|NCT00758615|BEHAVIORAL|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
219387583|NCT05227573|PROCEDURE|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
219387584|NCT00902837|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
219760944|NCT05669222|DIAGNOSTIC_TEST|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
219760945|NCT05669222|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
219188747|NCT04829188|BEHAVIORAL|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
219387585|NCT00902837|DRUG|oxycodone prolonged release tablet|
219387586|NCT00902837|DRUG|oxycodone naloxone tablet|
219387587|NCT06041347|DIAGNOSTIC_TEST|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
219387588|NCT02190591|DEVICE|Peanut Labor Ball|Peanut Labor Ball
219387589|NCT02908802|DIETARY_SUPPLEMENT|Probiotic|Probiotic
219387590|NCT02908802|DIETARY_SUPPLEMENT|Placebo|Probiotics capsules without the active ingredient
219387591|NCT03598777|BIOLOGICAL|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
219387592|NCT03598777|DRUG|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
219387593|NCT04820985|OTHER|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
219387594|NCT04820985|OTHER|Blood test|Blood sample to measure plasma dose of progesterone
219387595|NCT03299023|OTHER|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
219387596|NCT04358250|PROCEDURE|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
219387597|NCT04358250|PROCEDURE|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
219387598|NCT03488992|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
219387599|NCT03488992|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
219387600|NCT06454968|DRUG|Orelabrutinib, obinutuzumab, lenalidomide|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
219188748|NCT05934942|DRUG|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
219188749|NCT05934942|DRUG|BI 1358894|BI 1358894
219188750|NCT05815147|DIETARY_SUPPLEMENT|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
219387601|NCT02405312|BEHAVIORAL|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
219387602|NCT02894515|DRUG|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
219387603|NCT02894515|DRUG|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
219387604|NCT04931602|DIAGNOSTIC_TEST|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
219387605|NCT00105872|BEHAVIORAL|Cognitive-Behavioral Therapy|
219387606|NCT03085784|DRUG|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
219387607|NCT05275114|DEVICE|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
219387608|NCT05275114|DEVICE|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
219387609|NCT00072189|DRUG|7-hydroxystaurosporine|Given IV
219387610|NCT00072189|OTHER|laboratory biomarker analysis|Correlative studies
219387611|NCT00072189|OTHER|pharmacological study|Correlative studies
219387612|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
219387613|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
219387614|NCT00144300|DRUG|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
219387615|NCT00144300|DRUG|Requip|Standard marketed product dispensed according to manufacturer's guidelines
219188751|NCT06087588|DRUG|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
219387616|NCT01933672|DRUG|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
219387617|NCT01933672|DRUG|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
219387618|NCT01933672|DRUG|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
219387619|NCT04680923|PROCEDURE|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
219387620|NCT04680923|OTHER|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
219387621|NCT04680923|DRUG|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
219387622|NCT02633111|OTHER|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
219387623|NCT02633111|OTHER|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
219387624|NCT02633111|DEVICE|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
219387625|NCT06663371|BEHAVIORAL|Basic Physical Fitness|The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).
219387626|NCT06663371|BEHAVIORAL|Traditional Physical Training|In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
219387627|NCT05161962|COMBINATION_PRODUCT|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
219387628|NCT05161962|COMBINATION_PRODUCT|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
219387629|NCT05910463|OTHER|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
219387630|NCT04665102|OTHER|Image classification using deep learning algorithm|Image classification using deep learning algorithm
219387631|NCT03792009|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219387632|NCT03792009|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219387633|NCT03792009|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219387634|NCT03843580|DEVICE|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
219387635|NCT04884243|DRUG|CBT-006|ophthalmic solution
219387636|NCT03162289|OTHER|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
219760946|NCT03545048|OTHER|Internet based exercises|Exercises for knee OA (online- digital health)
219760947|NCT06043336|DRUG|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
219760948|NCT02957630|DRUG|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
219188752|NCT06087588|DRUG|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
219188753|NCT05715125|DRUG|Dose A VTX958|Dose A VTX958
219188754|NCT05715125|DRUG|Dose B VTX958|Dose B VTX958
219188755|NCT05715125|DRUG|Placebo|Placebo
219387637|NCT03162289|OTHER|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
219387638|NCT05870475|DRUG|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
219760949|NCT02957630|DRUG|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
219387639|NCT05870475|DRUG|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
219387640|NCT03505866|BEHAVIORAL|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
219387641|NCT04073212|OTHER|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
219387642|NCT04073212|OTHER|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
219387643|NCT04073212|OTHER|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
219387644|NCT04073212|OTHER|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
219387645|NCT03866551|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
219387646|NCT00778999|DRUG|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
219387647|NCT02063555|BIOLOGICAL|DAR-901|
219387648|NCT02063555|BIOLOGICAL|BCG|
219387649|NCT02063555|BIOLOGICAL|Sterile saline|
219387650|NCT06672328|PROCEDURE|Training with Action Observation Therapy|"AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
219387651|NCT06672328|PROCEDURE|Training without Action Observation Therapy|"Cerebral Palsy patients will receive balance and mobility training without action observation in various stances of sitting, standing and turning.~Activities are fun based and include reaching for objects, tower building and taking turns in different positions."
219387652|NCT02032524|DRUG|Avalglucosidase Alfa|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
219387653|NCT06859528|BEHAVIORAL|Community Walking Program|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to drive behavioral change (increased physical and social engagement in their communities) throughout the week.
219387654|NCT06856902|BEHAVIORAL|B-COMPASS implementation|The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
219387655|NCT06856902|BEHAVIORAL|B-COMPASS implementation|At the first data collection, patients will complete the BEAMER questionnaire and adherence-related measures will be collected. Based on patients' answers, the B-COMPASS will assign them into groups, list their support needs, and predict their relative adherence, forming their B-COMPASS description. Patients will then be randomised into either 1) an intervention arm, or 2) a control arm using stratified randomisation via the Adherence Intelligence Visualisation Platform (AIVP), ensuring balance in B-COMPASS descriptions, gender, and age. The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
219387656|NCT06586489|BEHAVIORAL|Virtual Reality Natural Landscape Exposure|Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.
219387657|NCT06586489|BEHAVIORAL|Tablet Screen Natural Landscape Exposure|Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
219387658|NCT06617481|DRUG|18F-rhPSMA-7.3 (Posluma)|PET Scan using Posluma for detection of early recurrence of prostate cancer.
219188756|NCT06751485|DRUG|JSKN003|Experimental drug
219387659|NCT05823168|DRUG|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
219387660|NCT01186432|DRUG|PDS 1.0|
219188757|NCT06751485|DRUG|Doxorubicin|Active Comparator
219188758|NCT06751485|DRUG|Paclitaxel|Active Comparator
219188759|NCT06751485|DRUG|Topotecan|Active Comparator
219387661|NCT07030738|BEHAVIORAL|Legume-Based High-Protein Diet + Resistance Training|Participants receive a hypocaloric, high-protein diet primarily based on legumes (e.g., lentils, beans, peas) designed to meet protein goals (\~2g/kg body weight). Diet is combined with a structured home-based resistance training program performed 3 times per week for 12 weeks. The exercise includes progressive resistance exercises focusing on major muscle groups using body weight and resistance bands.
219387662|NCT07030738|BEHAVIORAL|Meat-Based High-Protein Diet + Resistance Training|Participants follow a hypocaloric, high-protein diet emphasizing animal-based protein sources, mainly lean meats, to achieve \~2g/kg body weight protein intake. This dietary intervention is combined with a 12-week, home-based resistance training protocol, performed thrice weekly, targeting major muscle groups with progressive overload using body weight and resistance bands.
219387663|NCT07030738|BEHAVIORAL|Mixed Legume and Meat High-Protein Diet + Resistance Training|Participants adhere to a hypocaloric, high-protein diet combining both legumes and lean meats as protein sources to reach \~2g/kg body weight. The dietary plan is paired with a 12-week home-based resistance training program, performed 3 times per week, emphasizing progressive resistance exercises for all major muscle groups using body weight and resistance bands.
219387664|NCT07031037|OTHER|Scales|"Five questionnaires were administered at inclusion, socio-demographic and clinical data were collected during an interview (anxiety-depression, treatments).~The following questionnaires were used: The Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Eating Disorder Examination Self-Report Questionnaire (EDE-Q), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS), the Hospital anxiety and depression scale (HAD) and the Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIA-2)."
219387665|NCT07032220|DRUG|carbon suspension|Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.
219387666|NCT07031375|BEHAVIORAL|Social prescribing|This two-day family-centered forest therapy program incorporates the six core elements of Forest Therapy-plants, water, diet, psychology, climate, and exercise therapy-while integrating multi-sensory experiences and group interaction.
219387667|NCT06875089|GENETIC|pGS-NBS|Collection of a second DBS card if the parents accept the pGS-NBS for their newborn
219387668|NCT06875089|OTHER|Satisfaction questionnaire|questionnaire on information process of parents informed about pGS-NBS
219387669|NCT06875089|OTHER|interview with HSS researcher|interview with a member of the HSS team on reasons for declining /accepting pGS-NBS
219387670|NCT06875089|OTHER|satisfaction questionnaire|questionnaire on results delivery in parents having accepted the pGS-NBS
219387671|NCT06875089|OTHER|Qualitative and quantitative longitudinal exploration|validated anxiety and depression scales to assess the psychosocial impact and perceived utility for 90 families whose child screened negative among which 30 families will be interviewed. Interviews and validated anxiety and depression scales will be suggested to all families receiving positive screening results
219387672|NCT06875089|OTHER|Medical follow up|follow-up of true positives and false negatives based on medical records (vital status, care pathways) until 5 years after results delivery
219387673|NCT06723561|DRUG|4.5mg daily dose of naltrexone|Study subjects will take a daily 4.5mg dose of naltrexone.
219387674|NCT06725290|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI) questionnaire|The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
219387675|NCT06925581|DRUG|HRS-6768|HRS-6768
219387676|NCT06729216|DIAGNOSTIC_TEST|Antifungal susceptibility testing (AFST)|testing the fungal susceptibility to different drugs
219387677|NCT00476931|BIOLOGICAL|SB-509|60 mg dose
219387678|NCT00476931|OTHER|Placebo|Saline
219387679|NCT03567187|DEVICE|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
219387680|NCT06774963|DRUG|LNCB74|LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
219387681|NCT01225068|DRUG|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
219387682|NCT01225068|DRUG|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
219387683|NCT03121690|DRUG|Prednisone|prednisone 40 mg/day for 7 days
219387684|NCT03121690|DRUG|placebo|5ml saline / day for 7 days
219387685|NCT02032875|DRUG|Daclatasvir|
219387686|NCT02032875|DRUG|Sofosbuvir|
219387687|NCT02032875|DRUG|Ribavirin|
219387688|NCT06768229|OTHER|Consumption of a freeze-dried strains-mix.|One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.
219387689|NCT04358458|BIOLOGICAL|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
219387690|NCT04358458|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
219188760|NCT04263597|DRUG|2'-fucosyllactose|2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
219188761|NCT06479148|DEVICE|enVista® Aspire™|Eyes will receive enVista® Aspire™ lenses
219188762|NCT06479148|DEVICE|An IOL with a slightly extended depth of focus|Eyes will receive lenses with a slightly extended depth of focus
219387691|NCT06935201|BEHAVIORAL|Get Back|A rehabilitation program, targeting physical activity behavior, with a person-centered approach led by a physical therapist during 12 weeks (1 week before surgery until 12 weeks after surgery) in a digital format.
219387692|NCT06374498|DEVICE|OCT-NIRAF|Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
219387693|NCT06057129|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
219387694|NCT06057129|DEVICE|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for six weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
219387695|NCT06358417|BEHAVIORAL|Nutrition-enhanced CHW|CHW provides nutrition education and skills training in addition to the usual care (Basic CHW) hypertension management.
219387696|NCT06358417|BEHAVIORAL|Basic CHW|CHW provide usual care for hypertension management.
219387697|NCT06105957|BEHAVIORAL|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
219387698|NCT06105957|BEHAVIORAL|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
219387699|NCT06105957|BEHAVIORAL|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
219387700|NCT06105957|BEHAVIORAL|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
219387701|NCT06105957|BEHAVIORAL|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
219387702|NCT00178412|BEHAVIORAL|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
219387703|NCT00178412|BEHAVIORAL|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
219387704|NCT06479005|DEVICE|Oura Ring|The Oura ring will remotely monitor the patients vitals at home continuously
219188763|NCT06479148|DEVICE|MX60E|Eyes will receive MX60E lenses
219188764|NCT05871372|DEVICE|Brain Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
219387705|NCT01122810|PROCEDURE|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
219387706|NCT04385901|BEHAVIORAL|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
219387707|NCT05126615|DRUG|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
219387708|NCT05126615|BEHAVIORAL|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
219387709|NCT04837404|PROCEDURE|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
219387710|NCT04837404|PROCEDURE|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
219387711|NCT03863444|OTHER|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
219387712|NCT03863444|OTHER|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
219387713|NCT01326598|DEVICE|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
219387714|NCT00878046|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
219387715|NCT02602873|OTHER|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
219387716|NCT03412630|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
219387717|NCT02183467|DRUG|BI 1356, low dose|
219387718|NCT02183467|DRUG|BI 1356, high dose|
219387719|NCT02183467|DRUG|Placebo|
219387720|NCT02183467|DRUG|Moxifloxacin|
219387721|NCT02031146|PROCEDURE|Lumbar puncture|
219387722|NCT04957498|BEHAVIORAL|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
219387723|NCT04957498|BEHAVIORAL|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
219387724|NCT02726867|DRUG|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
219387725|NCT02726867|DRUG|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
219387726|NCT02726867|DRUG|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
219387727|NCT02726867|DRUG|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
219387728|NCT00336193|BEHAVIORAL|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
219387729|NCT03822403|DEVICE|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
219387730|NCT03822403|DEVICE|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
219387731|NCT03526432|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
219387732|NCT03526432|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
219387733|NCT03474003|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
219387734|NCT00001269|DRUG|IL-3|
219387735|NCT02175563|DEVICE|Audiovisual feedback from smartphone based app|
219387736|NCT04844671|DEVICE|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
219387737|NCT03445039|DEVICE|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
219387738|NCT03445039|PROCEDURE|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
219387739|NCT03445039|DEVICE|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
219387740|NCT03445039|PROCEDURE|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
219387741|NCT03626467|BIOLOGICAL|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
219387742|NCT00053612|DRUG|Vitamin A|
219387743|NCT00266110|BIOLOGICAL|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
219387744|NCT00266110|BIOLOGICAL|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
219387745|NCT00266110|BIOLOGICAL|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
219387746|NCT00266110|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
219387747|NCT02735317|DRUG|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
219387748|NCT02735317|DRUG|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
219387749|NCT04050501|DEVICE|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
219387750|NCT06247033|DEVICE|Tibial Nerve Stimulation with TENS device|Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.
219387751|NCT06247033|BEHAVIORAL|Pelvic muscle training exercise with bladder training|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
219387752|NCT03995771|OTHER|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
219387753|NCT02502422|DEVICE|Classic laryngeal mask airway|"1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * \# 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
219387754|NCT00345371|DRUG|Topiramate|
219387755|NCT00345371|DRUG|Placebo Oral Tablet|
219387756|NCT00678496|OTHER|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
219387757|NCT00678496|OTHER|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
219387758|NCT02226016|DEVICE|FG-5000A|a measuring device for the assessment of levator muscle strength
219188765|NCT05871372|DEVICE|sEEG Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
219188766|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
219387759|NCT00021866|BEHAVIORAL|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
219387760|NCT00021866|BEHAVIORAL|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
219387761|NCT05205239|DIAGNOSTIC_TEST|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
219387762|NCT02625519|DRUG|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
219387763|NCT02625519|DRUG|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
219387764|NCT06302634|OTHER|Exercise-based cardio-oncology rehabilitation|Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
219387765|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
219387766|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
219387767|NCT02114203|DRUG|placebo for PDE9i|oral dose, every 12 hours for 28 days
219387768|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
219387769|NCT00601289|DRUG|temozolomide|
219387770|NCT00601289|GENETIC|DNA methylation analysis|
219387771|NCT00601289|GENETIC|microarray analysis|
219387772|NCT00601289|GENETIC|protein expression analysis|
219387773|NCT00601289|GENETIC|proteomic profiling|
219387774|NCT00601289|OTHER|laboratory biomarker analysis|
219387775|NCT02368444|BEHAVIORAL|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
219387776|NCT04646317|DRUG|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
219387777|NCT04646317|DRUG|Normal Saline|0.9% as placebo
219387778|NCT01518699|DRUG|Ha44|Abametapir Lotion 0.74%
219387779|NCT01518699|DRUG|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
219387780|NCT01518699|DRUG|Moxifloxacin Placebo|Moxifloxacin Placebo
219387781|NCT01518699|DRUG|Moxifloxacin|Moxifloxacin 400mg
219188767|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
219387782|NCT00217477|DRUG|gemcitabine hydrochloride|Given IV
219387783|NCT00217477|DRUG|paricalcitol|Given IV
219387784|NCT05019183|OTHER|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
219387785|NCT05019183|OTHER|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
219387786|NCT05019183|DEVICE|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
219387787|NCT05019183|BIOLOGICAL|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
219387788|NCT03546478|BIOLOGICAL|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
219387789|NCT04724486|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
219387790|NCT04724486|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
219387791|NCT04724486|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
219387792|NCT04724486|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
219387793|NCT01707823|DRUG|acetylsalicylic acid|Given PO
219387794|NCT01707823|OTHER|laboratory biomarker analysis|Correlative studies
219387795|NCT00008164|PROCEDURE|umbilical cord blood transplantation|
219387796|NCT02767570|OTHER|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
219387797|NCT02767570|OTHER|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
219387798|NCT01009775|DRUG|YM155|intravenous infusion
219387799|NCT01009775|DRUG|Docetaxel|intravenous infusion
219387800|NCT06574269|DRUG|TLC590|Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
219188768|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
219387801|NCT06574269|DRUG|TLC590|TLC590 Dose 1
219387802|NCT06574269|DRUG|TLC590|TLC590 Dose 2
219387803|NCT06574269|DRUG|TLC590|The MTD of TLC590
219387804|NCT06574269|DRUG|TLC590|TLC590 Dose 3 (The SMC-suggested dose)
219387805|NCT06574269|DRUG|Ropivacaine|Ropivacaine
219387806|NCT06574269|DRUG|TLC590|TLC590
219387807|NCT05327478|PROCEDURE|NRP|Normothermic Regional Perfusion
219387808|NCT05327478|PROCEDURE|DHOPE|Dual Hypothermic Oxygenated Perfusion
219188769|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
219387809|NCT05327478|PROCEDURE|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
219387810|NCT00151411|DRUG|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
219387811|NCT00151411|DRUG|Placebo|Placebo
219387812|NCT00151411|BEHAVIORAL|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
219387813|NCT03533478|DIETARY_SUPPLEMENT|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
219387814|NCT03533478|DIETARY_SUPPLEMENT|Placebo|Placebo treatment
219387815|NCT01712438|BIOLOGICAL|Human cl rhFVIII|
219387816|NCT00764972|DRUG|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
219387817|NCT00440128|DRUG|Docetaxel|Docetaxel
219387818|NCT00440128|DRUG|Casopitant/Docetaxel|Casopitant/Docetaxel
219387819|NCT00253617|DRUG|porfimer sodium|
219387820|NCT00253617|PROCEDURE|adjuvant therapy|
219387821|NCT00253617|PROCEDURE|laser therapy|
219387822|NCT00253617|PROCEDURE|photodynamic therapy|
219387823|NCT00253617|PROCEDURE|phototherapy|
219387824|NCT05284006|DIAGNOSTIC_TEST|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
219387825|NCT06569537|DRUG|Lidocaine topical|4%
219387826|NCT06569537|DRUG|BLT|Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
219188770|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
219188771|NCT04447040|DRUG|Placebo|Placebo tablets administered as a single two-tablet dose.
219387827|NCT05108324|PROCEDURE|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
219387828|NCT05108324|PROCEDURE|conventional implant|patients will receive 4 conventional dental implant
219387829|NCT03126136|DEVICE|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
219387830|NCT06062368|BEHAVIORAL|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
219387831|NCT02819596|DRUG|Savolitinib|
219387832|NCT02819596|DRUG|MEDI4736|
219387833|NCT02819596|DRUG|Tremelimumab|
219387834|NCT04094506|DRUG|ASP1948|Intravenous
219387835|NCT05907928|OTHER|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
219387836|NCT05907928|OTHER|Single bond Universal|Radiolucent universal adhesive
219387837|NCT04426630|OTHER|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
219387838|NCT04219540|DRUG|XR-B (SUBLOCADETM)|XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.
219387839|NCT04219540|DRUG|XR-NTX|XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
219387840|NCT02983084|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
219387841|NCT02924792|DEVICE|Reinfusion - Sternal IO needle|
219387842|NCT02924792|DEVICE|Reinfusion - Intravenous needle|
219387843|NCT06364748|DEVICE|Cellular enabled blood pressure cuff|Smart cuff
219387844|NCT06364748|DEVICE|Standard of Care Cuff|Standard blood pressure cuff
219387845|NCT03808207|OTHER|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
219387846|NCT02911987|OTHER|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
219387847|NCT02911987|OTHER|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
219387848|NCT03846362|OTHER|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
219387849|NCT02242279|DRUG|BEA 2180 BR|
219387850|NCT02242279|DRUG|Tiotropium|
219387851|NCT02242279|DRUG|Placebo|
219387852|NCT00156728|DEVICE|Vitatron biventricular pacemaker|
219387853|NCT01819935|DRUG|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
219387854|NCT01819935|DRUG|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
219387855|NCT02571413|OTHER|score before teaching|score the check-point of correct INCS usage before teaching
219387856|NCT02571413|OTHER|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
219387857|NCT02571413|OTHER|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
219387858|NCT00488943|DEVICE|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
219387859|NCT03429647|DIAGNOSTIC_TEST|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
219387860|NCT00080210|DRUG|Puricase|
219387861|NCT04133753|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
219001201|NCT04165785|DEVICE|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
219001202|NCT04165785|DEVICE|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
219001203|NCT04165785|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
219387862|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
219188772|NCT04115241|DEVICE|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
219188773|NCT04115241|OTHER|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
219387863|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
219387864|NCT03442127|BEHAVIORAL|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
219387865|NCT06034223|OTHER|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
219387866|NCT06034223|OTHER|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
219387867|NCT03251690|DRUG|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
219387868|NCT03251690|DRUG|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
219387869|NCT05295329|DRUG|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
219387870|NCT05295329|DRUG|Placebo|use placebo
219387871|NCT05337449|OTHER|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
219387872|NCT05337449|OTHER|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
219387873|NCT01123889|BIOLOGICAL|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
219387874|NCT01123889|DRUG|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
219387875|NCT03730389|DEVICE|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
219387876|NCT02857712|DRUG|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
219387877|NCT03551886|BEHAVIORAL|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
219387878|NCT03551886|BEHAVIORAL|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
219387879|NCT02928419|DRUG|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
219387880|NCT02928419|OTHER|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
219387881|NCT02928419|DRUG|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
219387882|NCT00117962|BIOLOGICAL|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
219387883|NCT00117962|DRUG|carboplatin|AUC = 5 q 21 days for 4 cycles
219387884|NCT00117962|DRUG|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
219387885|NCT00117962|RADIATION|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
219387886|NCT05036538|DEVICE|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
219387887|NCT05036538|DEVICE|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
219387888|NCT05036538|DEVICE|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
219387889|NCT05036538|DEVICE|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
219387890|NCT01938222|PROCEDURE|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
219387891|NCT01805115|DRUG|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
219387892|NCT01805115|DRUG|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
219387893|NCT01805115|DRUG|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
219387894|NCT01805115|DRUG|Control|The control group was not given any cervical priming agents or placebo.
219387895|NCT04732377|PROCEDURE|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
219387896|NCT04732377|PROCEDURE|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
219387897|NCT03933501|DRUG|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
219387898|NCT03933501|DRUG|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
219387899|NCT00600002|BIOLOGICAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
219387900|NCT03194425|DIAGNOSTIC_TEST|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
219387901|NCT00189358|DRUG|ZD1839|
219387902|NCT00189358|DRUG|tamoxifen|
219387903|NCT02396147|DRUG|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
219387904|NCT02396147|DRUG|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
219387905|NCT02396147|DRUG|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
219387906|NCT04752280|RADIATION|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
219387907|NCT04752280|RADIATION|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
219387908|NCT01927458|DEVICE|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
219001204|NCT03817788|DRUG|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
219387909|NCT01960686|BIOLOGICAL|Low dose RSV F Antigen|
219387910|NCT01960686|BIOLOGICAL|High dose RSV F Antigen|
219188774|NCT06433401|BEHAVIORAL|Transitional care training with brochures, posters and slide training materials|Education at 1 and 2 months after the first interview
219387911|NCT01960686|BIOLOGICAL|Dose 1 of Aluminum Adjuvant|
219387912|NCT01960686|BIOLOGICAL|Dose 2 of Aluminum Adjuvant|
219387913|NCT01960686|BIOLOGICAL|Dose 3 of Aluminum Adjuvant|
219387914|NCT01960686|BIOLOGICAL|Dose 4 of Aluminum Adjuvant|
219387915|NCT01960686|BIOLOGICAL|Placebo|
219387916|NCT06140108|DRUG|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 6 months.
219387917|NCT06140108|DRUG|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 6 months.
219387918|NCT02598713|DRUG|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
219387919|NCT02525172|DRUG|Rituximab|
219387920|NCT02525172|DRUG|intravenous immune globulin|
219387921|NCT02525172|DRUG|Bortezomib|
219387922|NCT02525172|DRUG|Methotrexate|
219387923|NCT02329925|DEVICE|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
219387924|NCT06482060|DEVICE|Stabilization splint|Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
219387925|NCT03846947|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
219387926|NCT03202121|OTHER|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
219387927|NCT03202121|OTHER|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
219387928|NCT03202121|OTHER|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
219387929|NCT03851341|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
219387930|NCT03851341|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
219387931|NCT04964726|BEHAVIORAL|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
219387932|NCT05927909|DIAGNOSTIC_TEST|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
219387933|NCT04352660|DRUG|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
219387934|NCT04352660|DRUG|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
219387935|NCT02832271|DRUG|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
219387936|NCT02832271|DRUG|Placebo|Placebo
219387937|NCT03414125|OTHER|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
219387938|NCT03414125|OTHER|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
219387939|NCT02066090|DEVICE|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
219387940|NCT02066090|DEVICE|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
219387941|NCT00863733|DRUG|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
219387942|NCT03406195|DEVICE|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
219387943|NCT04889677|DRUG|Danicopan|
219387944|NCT04889677|DRUG|Placebo|
219387945|NCT03977532|OTHER|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
219387946|NCT01483404|PROCEDURE|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
219387947|NCT01362322|BIOLOGICAL|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
219387948|NCT01362322|BIOLOGICAL|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
219387949|NCT04913324|BEHAVIORAL|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
219387950|NCT06337851|OTHER|Simultaneous burr hole craniostomy|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
219387951|NCT06337851|OTHER|Consecutive burr hole craniostomy|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
219001205|NCT03817788|DRUG|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
219001206|NCT03520803|OTHER|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
219387952|NCT04802356|DRUG|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
219387953|NCT04802356|DRUG|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
219387954|NCT04802356|DRUG|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
219387955|NCT04802356|DRUG|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
219387956|NCT04802356|PROCEDURE|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
219387957|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
219387958|NCT05450055|PROCEDURE|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
219387959|NCT05221125|BEHAVIORAL|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
219387960|NCT03626753|DRUG|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
219387961|NCT03626753|DRUG|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
219387962|NCT03626753|DRUG|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
219387963|NCT03626753|DRUG|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
219001207|NCT06220201|DRUG|CC-97540|Specified dose on specified days
219001208|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
219387964|NCT03626753|DRUG|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
219387965|NCT03626753|DRUG|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
219387966|NCT02018510|BIOLOGICAL|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
219387967|NCT02018510|BIOLOGICAL|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
219387968|NCT02018510|BIOLOGICAL|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
219387969|NCT02018510|BIOLOGICAL|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
219387970|NCT02018510|BIOLOGICAL|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
219387971|NCT02018510|BIOLOGICAL|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
219387972|NCT05401097|DRUG|Azacitidine|Given IV or SC
219387973|NCT05401097|PROCEDURE|Biopsy|Undergo biopsy of the bone marrow
219387974|NCT05401097|DRUG|Enasidenib|Given PO
219387975|NCT05401097|DRUG|Ivosidenib|Given PO
219387976|NCT05401097|DRUG|Venetoclax|Given PO
219387977|NCT02698761|OTHER|Comprehensive Care Plan|"Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
219387978|NCT04317222|DEVICE|eCRRT|"eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment"
219387979|NCT02350829|OTHER|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
219387980|NCT03279237|DRUG|Irinotecan|May help shrink tumor before surgery.
219387981|NCT03279237|DRUG|Oxaliplatin|May help shrink tumor before surgery.
219387982|NCT03279237|DRUG|Leucovorin|May help shrink tumor before surgery.
219387983|NCT03279237|DRUG|5-Fluorouracil|May help shrink tumor before surgery.
219387984|NCT03279237|DRUG|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
219001209|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
219387985|NCT03279237|RADIATION|Radiation Therapy|May help shrink tumor.
219387986|NCT03279237|DRUG|Carboplatin|Carboplatin may stop cancer cells from growing.
219387987|NCT03671863|OTHER|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
219387988|NCT03671863|OTHER|Prenatal management|Prenatal management
219387989|NCT01435993|DRUG|GSK1223249|Intravenous infusion
219387990|NCT01435993|OTHER|Saline placebo|placebo intravenous infusion
219387991|NCT01616615|DRUG|Aspirin|150 mg/day oral use
219387992|NCT01616615|DRUG|placebo|1 capsule / day oral use
219387993|NCT06504550|OTHER|Schroth Exercises|The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
219387994|NCT06504550|OTHER|Klapp Exercises|The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
219387995|NCT04553809|PROCEDURE|ENB|ENB for biopsy sampling of peripheral lung lesion
219387996|NCT04553809|PROCEDURE|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
219387997|NCT00971646|OTHER|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
219387998|NCT00971646|OTHER|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
219387999|NCT00971646|OTHER|EuroQol-5D|This questionnaire grades the health condition of the subject.
219388000|NCT00971646|OTHER|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
219388001|NCT04391868|DRUG|Viagra Tablet|50 mg tablet on Day 1 of each period
219388002|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
219388003|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
219388004|NCT00320671|DRUG|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
219388005|NCT00320671|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
219388006|NCT06149884|PROCEDURE|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
219388007|NCT05496426|DRUG|KL130008/Placebo|Drug: KL130008 Drug: Placebo
219388008|NCT05675280|OTHER|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
219388009|NCT01454089|DRUG|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
219388010|NCT01454089|DRUG|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
219388011|NCT01454089|DRUG|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
219388012|NCT01454089|DRUG|Gemcitabine|Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
219388013|NCT01454089|DRUG|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
219001210|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
219388014|NCT01454089|DRUG|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
219388015|NCT06179212|DIAGNOSTIC_TEST|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
219388016|NCT05851846|BEHAVIORAL|Amygdala insula retraining|Mind body intrevention
219388017|NCT05921916|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
219388018|NCT05921916|DRUG|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
219388019|NCT01407562|DRUG|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
219388020|NCT01407562|DRUG|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
219388021|NCT01407562|DRUG|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
219388022|NCT01593982|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
219388023|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
219388024|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
219388025|NCT02580162|BEHAVIORAL|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
219001211|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
219760950|NCT02957630|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
219760951|NCT01361659|PROCEDURE|shockwave treatment|9 treatments in 3 months
219760952|NCT05047042|BEHAVIORAL|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The study intervention will consist of an individualized 8-week program of online exercise modules, supervised interactive group class and one-to-one consultations with an exercise or rehabilitation specialist and a pain and symptom physician, delivered via secure live Zoom sessions.
219760953|NCT02099396|DRUG|Docetaxel+lobaplatin|
219388026|NCT02305433|OTHER|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
219388027|NCT00367471|DRUG|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
219388028|NCT00367471|DRUG|carboplatin|An alkylating agent used in the treatment of some cancers
219388029|NCT00367471|DRUG|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
219388030|NCT00367471|DRUG|paclitaxel|A mitotic inhibitor used in cancer treatment
219388031|NCT05274438|DRUG|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
219388032|NCT02214589|OTHER|Oral glucose, facilitated tucking, NNS|
219388033|NCT02214589|OTHER|Oral glucose and NNS|
219388034|NCT02214589|OTHER|Facilitated tucking and NNS|
219388035|NCT05881850|OTHER|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
219388036|NCT00211523|DRUG|MBI 226 Acne Solutions|
219388037|NCT04632849|BEHAVIORAL|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
219388038|NCT05977543|OTHER|Functional crackers enriched with grape seed flour|The crackers was enriched with 10% grape seed flour
219388039|NCT05977543|OTHER|Functional crackers with 40% barley flour and enriched with β-glucans|The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
219388040|NCT05293938|DRUG|Obeticholic Acid 5 MG|once daily, oral administration
219388041|NCT05293938|DRUG|Obeticholic Acid 10 MG|once daily, oral administration
219388042|NCT05293938|DRUG|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
219001212|NCT05220202|BEHAVIORAL|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
219388043|NCT06270992|DIAGNOSTIC_TEST|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
219388044|NCT00793923|DRUG|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
219388045|NCT00793923|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
219388046|NCT01359540|DEVICE|OMNI Apex Modular™ Hip Device|
219388047|NCT01359540|DEVICE|OMNI Apex ARC™ Hip Device|
219388048|NCT01923064|DRUG|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
219388049|NCT01923064|DRUG|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
219388050|NCT03580057|BEHAVIORAL|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
219388051|NCT03580057|BEHAVIORAL|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
219760954|NCT02099396|DRUG|Gemcitabine+lobaplatin|
219760955|NCT00219089|DRUG|aliskiren|
219760956|NCT00198471|DRUG|Vitrase|
219760957|NCT00089622|DRUG|Intravenous Levodopa|
219760958|NCT00089622|DRUG|Lisuride Transdermal System|
219760959|NCT04741906|PROCEDURE|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
219760960|NCT04741906|PROCEDURE|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
219188775|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
219388052|NCT03910699|DEVICE|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
219388053|NCT03910699|DEVICE|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
219388054|NCT04649853|OTHER|Standardized nursing care|All patients will receive standardized evidence based nursing care
219388055|NCT01755481|OTHER|Probiotic|
219388056|NCT01755481|OTHER|Whey protein concentrate|
219388057|NCT05597046|OTHER|Interview|Interviews
219388058|NCT04154618|DEVICE|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
219388059|NCT04675346|OTHER|Questionnaire|Questionnaire
219388060|NCT06513715|DIETARY_SUPPLEMENT|Control|This intervention will be made with a placebo
219388061|NCT06513715|DIETARY_SUPPLEMENT|Jubanine|This intervention will be made with jubanine or prickly pear extract
219388062|NCT02429648|PROCEDURE|DCC first then PVI|DCC performed prior to PVI
219388063|NCT02429648|PROCEDURE|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
219388064|NCT03223727|DIAGNOSTIC_TEST|Blood tests|Blood tests for several bone markers (see summary)
219001213|NCT06147362|DRUG|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
219001214|NCT03487263|BIOLOGICAL|IC14|chimeric monoclonal antibody against human IC14
219001215|NCT03607162|DIAGNOSTIC_TEST|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
219001216|NCT02516345|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
219001217|NCT02516345|BEHAVIORAL|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
219388065|NCT04649281|DEVICE|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
219388066|NCT03334214|DRUG|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
219388067|NCT03334214|DRUG|Placebo|Saline 0.9%
219388068|NCT02033980|DEVICE|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
219388069|NCT00003820|DRUG|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
219388070|NCT03528252|OTHER|Written advice LDL Cholesterol|One A4 paper with written information on both sides
219388071|NCT03528252|OTHER|Written advice Triglycerides|One A4 paper with written information on both sides
219388072|NCT00312780|DRUG|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
219388073|NCT05603286|PROCEDURE|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
219388074|NCT04303585|PROCEDURE|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
219388075|NCT04303585|PROCEDURE|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
219388076|NCT00216021|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
219388077|NCT00216021|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
219388078|NCT05428371|DIAGNOSTIC_TEST|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
219388079|NCT02297217|DRUG|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
219388080|NCT02297217|RADIATION|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
219388081|NCT03551145|OTHER|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
219388082|NCT03551145|OTHER|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
219388083|NCT05339464|OTHER|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
219388084|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
219388085|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
219388086|NCT06613061|OTHER|Breathing exercise|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
219388087|NCT06095284|OTHER|Pre-Extraction Phase|This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
219388088|NCT06095284|OTHER|Extraction Phase|Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
219388089|NCT06095284|OTHER|Post-Extraction Phase|Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
219388090|NCT05227274|OTHER|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
219388091|NCT01980147|BEHAVIORAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
219388092|NCT04523792|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
219388093|NCT05951153|COMBINATION_PRODUCT|Tributyrin|Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
219388094|NCT02952547|DRUG|Co-administration of DWC20155 and DWC20156|
219388095|NCT02952547|DRUG|DWJ1366 Tab.|
219388096|NCT02554643|OTHER|Diet|Nutrition intervention, once a week during 12 weeks
219001218|NCT04047745|DRUG|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
219388097|NCT02554643|OTHER|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
219388098|NCT02554643|OTHER|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
219388099|NCT04049188|RADIATION|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
219388100|NCT04628871|BIOLOGICAL|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
219388101|NCT04628871|BIOLOGICAL|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
219001219|NCT04047745|DRUG|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
219388102|NCT04628871|BIOLOGICAL|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
219001220|NCT04370938|BEHAVIORAL|Coping strategies video|No additional description
219001221|NCT02709733|BEHAVIORAL|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
219388103|NCT03161418|DRUG|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
219388104|NCT03161418|DRUG|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
219388105|NCT04245124|OTHER|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
219388106|NCT04245124|OTHER|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
219388107|NCT01260181|DRUG|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
219388108|NCT03690414|DRUG|Experimental BHVI2|Experimental BHVI2 eye drops
219388109|NCT03690414|DRUG|Atropine sulfate 0.02% eye drops|Atropine eye drops
219388110|NCT03690414|COMBINATION_PRODUCT|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
219388111|NCT01330446|DRUG|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
219388112|NCT01330446|OTHER|Placebo|1 by mouth every morning for a 28 day cycle.
219388113|NCT01330446|BEHAVIORAL|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
219388114|NCT00384280|DRUG|Rifampin|
219388115|NCT05144698|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
219388116|NCT05144698|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Outpatient Carboplatin + Paclitaxel Regimen (CP Regimen)
219388117|NCT05144698|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|Drug Therapy After RAPA-201 Therapy
219388118|NCT05970055|PROCEDURE|elective surgery|All elective surgical procedures performed under the study period will be included.
219388119|NCT05255757|BEHAVIORAL|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
219388120|NCT05255757|BEHAVIORAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
219388121|NCT04520698|BEHAVIORAL|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
219388122|NCT01677689|DRUG|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
219388123|NCT01677689|DRUG|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
219388124|NCT06108284|DEVICE|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
219388125|NCT04652258|DRUG|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
219388126|NCT02437669|DRUG|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
219388127|NCT05780281|BIOLOGICAL|VIR-7831|VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
219388128|NCT05780281|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
219388129|NCT05780281|BIOLOGICAL|Remdesivir|Antiviral agent
219388130|NCT01025336|OTHER|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
219388131|NCT01025336|OTHER|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
219388132|NCT01573468|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
219388133|NCT01573468|DRUG|Placebo|Placebo orally once on Day 1 of each cycle
219388134|NCT01573468|DRUG|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
219388135|NCT02689700|OTHER|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
219388136|NCT05929534|DEVICE|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
219388137|NCT05929534|DEVICE|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
219388138|NCT02608164|DIETARY_SUPPLEMENT|3000IU(75μg) vitamin D3|
219388139|NCT00152412|DRUG|Levocetirizine oral solution|
219388140|NCT03359603|DEVICE|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
219388141|NCT01215630|BEHAVIORAL|Aerobic Interval Training|One interval training session
219388142|NCT01046188|OTHER|Knowledge Questionnaire|Administered before and after teaching intervention
219388143|NCT01046188|OTHER|Perceived Stress Scale|Administered before and after teaching intervention
219388144|NCT01046188|OTHER|Satisfaction questionnaire|Administered after the intervention and at study completion
219388145|NCT01046188|OTHER|Web-based IVF teaching|Web-based IVF teaching
219388146|NCT01046188|OTHER|Didactic lecture|Didactic lecture
219388147|NCT03484026|DIETARY_SUPPLEMENT|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
219388148|NCT02743637|DRUG|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
219388149|NCT04519554|DEVICE|Endometrial sampling|Endometrial sampling with 2 different forceps
219388150|NCT04442529|BEHAVIORAL|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
219388151|NCT01480986|DRUG|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
219388152|NCT05728801|DIAGNOSTIC_TEST|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
219388153|NCT03133481|PROCEDURE|Adductor Canal Nerve Block|Adductor Canal never technique
219001222|NCT06239454|DEVICE|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
219001223|NCT06239454|DEVICE|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
219388154|NCT03133481|DRUG|Femoral Nerve Block|Traditional technique
219388155|NCT03402763|BEHAVIORAL|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
219388156|NCT03402763|BEHAVIORAL|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
219388157|NCT01409889|BEHAVIORAL|Diabetes Prevention Program|
219388158|NCT01409889|BEHAVIORAL|Healthy Living Program|
219388159|NCT03461926|BEHAVIORAL|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
219388160|NCT01329757|DRUG|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
219388161|NCT01329757|DRUG|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
219388162|NCT05689827|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
219388163|NCT05689827|DRUG|Placebo|Placebo was used in the same way
219388164|NCT02413515|DRUG|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
219388165|NCT04336176|DEVICE|PulseFlow DF boot|Offloading boot
219388166|NCT04336176|DEVICE|Usual standard of care|Usual standard of care (offloading device)
219388167|NCT04336176|DEVICE|Sham|Sham shoe (closest to barefoot or baseline pressures)
219388168|NCT06375850|OTHER|Sesame oil|"A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air."
219388169|NCT06375850|OTHER|Saline solution|After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
219388170|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
219388171|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
219388172|NCT02102230|BEHAVIORAL|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
219388173|NCT02837172|OTHER|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
219388174|NCT04132726|OTHER|Massage therapy|Massage therapy performed by a physiotherapist
219388175|NCT04132726|OTHER|non-effective treatment|non-effective treatment
219388176|NCT00736229|DRUG|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
219388177|NCT04133324|DIAGNOSTIC_TEST|C-reactive protein|C-reactive protein at postoperative days four and two.
219388178|NCT00660140|DRUG|Gemcitabine|
219388179|NCT00660140|DRUG|Carboplatin|
219388180|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
219388181|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
219388182|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
219388183|NCT00080327|DRUG|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
219388184|NCT05690321|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
219388185|NCT05690321|DRUG|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
219388186|NCT00637728|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
219388187|NCT00637728|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
219388188|NCT03385668|DRUG|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
219388189|NCT03619915|DIAGNOSTIC_TEST|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
219388190|NCT03619915|OTHER|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
219388191|NCT00345111|PROCEDURE|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
219388192|NCT03940781|BEHAVIORAL|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
219388193|NCT02348567|OTHER|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
219388194|NCT02348567|OTHER|announced hospital surveys|
219388195|NCT00325572|DRUG|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
219388196|NCT00325572|OTHER|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
219388197|NCT05225532|OTHER|Radiofrequency ablation|Radiofrequency ablation of ganglionated plexi located in the left or right atrium
219388198|NCT03172650|DIAGNOSTIC_TEST|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
219001224|NCT06077318|OTHER|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
219388199|NCT00736281|OTHER|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
219388200|NCT03611140|DIETARY_SUPPLEMENT|DP|a package containing a mix of functional foods
219388201|NCT03611140|DIETARY_SUPPLEMENT|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
219388202|NCT04673903|OTHER|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
219388203|NCT04673903|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
219388204|NCT02830373|DEVICE|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
219388205|NCT02723630|DRUG|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"
219388206|NCT02685150|DEVICE|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
219388207|NCT02685150|DRUG|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
219388208|NCT02685150|OTHER|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
219388209|NCT04036565|BEHAVIORAL|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
219388210|NCT01161836|DRUG|Iniparib|"Solution for infusion~60-minute intravenous infusion"
219388211|NCT01184989|DRUG|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
219388212|NCT01231191|DRUG|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
219388213|NCT01231191|DRUG|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
219388214|NCT04970680|PROCEDURE|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
219388215|NCT02242396|DRUG|Telmisartan|
219388216|NCT02242396|DRUG|Telmisartan hydrochlorothiazide|
219388217|NCT01570491|OTHER|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
219388218|NCT01570491|OTHER|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
219388219|NCT01606722|DRUG|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
219388220|NCT05575518|DRUG|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
219388221|NCT01582724|PROCEDURE|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
219388222|NCT03047213|DRUG|Sapanisertib|Given PO
219388223|NCT05434910|OTHER|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
219388224|NCT03656640|DRUG|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
219388225|NCT03692273|PROCEDURE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
219388226|NCT03692273|PROCEDURE|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
219388227|NCT05561621|OTHER|Voice analysis|Voice analysis
219388228|NCT01479790|DEVICE|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
219388229|NCT01635569|BEHAVIORAL|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
219388230|NCT01635569|OTHER|Waitlist|Baseline and post-12 sessions
219388231|NCT01154725|BEHAVIORAL|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
219388232|NCT01154725|BEHAVIORAL|habitual patient education|habitual patient education
219388233|NCT01522495|DEVICE|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
219388234|NCT01522495|DEVICE|SPY Imaging|SPY Imaging to assess tissue perfusion
219388235|NCT01066416|PROCEDURE|Endoscopic Sinus Surgery|
219388236|NCT01066416|OTHER|medical therapy|Subjects will undergo surgery 6 months after randomization
219388237|NCT05760937|DRUG|BMS-986447|Specified dose on specified days
219388238|NCT05760937|DRUG|Placebo|Specified dose on specified days
219388239|NCT01015443|BIOLOGICAL|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
219388240|NCT01015443|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
219388241|NCT01015443|DRUG|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
219388242|NCT01015443|OTHER|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
219388243|NCT01015443|OTHER|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
219388244|NCT00690872|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
219388245|NCT00690872|DRUG|carboplatin|
219388246|NCT00690872|DRUG|gemcitabine hydrochloride|
219388247|NCT00690872|GENETIC|polymerase chain reaction|
219388248|NCT00690872|OTHER|fluorescence activated cell sorting|
219388249|NCT00690872|OTHER|immunoenzyme technique|
219388250|NCT04407507|DRUG|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
219388251|NCT04407507|DRUG|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
219388252|NCT02129764|DRUG|Prednisone|
219388253|NCT02129764|DRUG|Allopurinol|
219388254|NCT03633331|DRUG|Palbociclib|Given PO
219388255|NCT03633331|DRUG|Letrozole|Given PO
219388256|NCT03633331|DRUG|Fulvestrant|Given IM
219388257|NCT03633331|OTHER|Questionnaire Administration|Ancillary studies
219388258|NCT03633331|OTHER|Quality-of-Life Assessment|Ancillary studies
219388259|NCT06430320|OTHER|NA- no intervention|NA- no intervention
219388260|NCT05195879|DIAGNOSTIC_TEST|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
219760961|NCT02149459|RADIATION|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
219388261|NCT02756871|OTHER|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
219388262|NCT00110643|DEVICE|CoolTouch II laser|
219388263|NCT02039557|GENETIC|NiCord®/CordIn™ (omidubicel)|
219388264|NCT02404506|DRUG|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
219388265|NCT00463970|BEHAVIORAL|Brief Intervention|Physical examination, education and follow up by a physiotherapist
219388266|NCT00463970|BEHAVIORAL|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
219388267|NCT00463970|DIETARY_SUPPLEMENT|Seal oil|20 capsules per day for 3 months
219388268|NCT00463970|DIETARY_SUPPLEMENT|Soy oil|20 capsules per day for 3 months
219388269|NCT01707875|OTHER|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
219388270|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
219388271|NCT04788563|DRUG|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
219388272|NCT04788563|OTHER|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
219388273|NCT04788563|DRUG|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
219388274|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
219388275|NCT04788563|DRUG|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
219388276|NCT03178461|OTHER|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
219388277|NCT03518957|BEHAVIORAL|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
219388278|NCT00691574|DIETARY_SUPPLEMENT|Melatonin|up to 3 mg, daily, for up to 1 year
219388279|NCT00691574|DEVICE|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
219388280|NCT00446212|DRUG|Propofol|target controlled infusion of propofol
219388281|NCT00446212|DRUG|desflurane|Anaesthetic maintenance with desflurane
219388282|NCT00851110|PROCEDURE|stem cell reinfusion|hematopoietic stem cell reinfusion
219388283|NCT00851110|DRUG|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
219001225|NCT06077318|OTHER|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
219001226|NCT05009615|DIETARY_SUPPLEMENT|Green coffee extract|150 mg polyphenols from green coffee, twice daily
219001227|NCT05009615|DIETARY_SUPPLEMENT|Beta glucan|2.5 g BG twice daily
219001228|NCT05009615|DIETARY_SUPPLEMENT|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
219001229|NCT03392701|BIOLOGICAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
219388284|NCT06038448|PROCEDURE|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
219388285|NCT00294346|DRUG|AV608|
219388286|NCT05616234|PROCEDURE|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
219388287|NCT03154450|DEVICE|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
219388288|NCT03154450|DEVICE|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
219388289|NCT01073072|PROCEDURE|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
219388290|NCT01073072|PROCEDURE|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
219388291|NCT01411540|DIETARY_SUPPLEMENT|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
219388292|NCT04634162|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
219388293|NCT04634162|DRUG|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
219388294|NCT00477373|DRUG|depakine chrono|Depakine Chrono 500 mg
219388295|NCT04222725|DRUG|TRS01 eye drops|Dosed 4 times a day (QID)
219388296|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
219388297|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
219388298|NCT04222725|DRUG|Placebo eye drops|Dosed QID
219388299|NCT00985452|OTHER|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
219388300|NCT00985452|OTHER|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
219388301|NCT05785338|DIAGNOSTIC_TEST|Posterior angle of the hard palate|Fetal ultrasound
219388302|NCT01142648|DRUG|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
219388303|NCT01142648|DRUG|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
219388304|NCT03401177|DRUG|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
219388305|NCT03401177|DRUG|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
219388306|NCT03401177|OTHER|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
219388307|NCT04813679|DIAGNOSTIC_TEST|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
219388308|NCT02712684|PROCEDURE|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
219388309|NCT05684978|DRUG|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
219388310|NCT02892097|DEVICE|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
219388311|NCT02892097|DEVICE|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
219388312|NCT02892097|BEHAVIORAL|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
219001230|NCT01402492|DRUG|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
219001231|NCT01402492|DRUG|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
219001232|NCT04254705|PROCEDURE|Rectal Biopsy|Suction biopsy or forceps biopsy
219388313|NCT05798975|OTHER|Aerobic Exercise. 1 session of acute exercise|40 minutes on cycle ergometer, 60% of heart rate reserve
219388314|NCT05798975|OTHER|Resistance Exercise. 1 session of acute exercise|2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
219388315|NCT05798975|OTHER|no exercise|Rest
219388316|NCT06971003|BEHAVIORAL|Ho'ouna Pono|An efficacious culturally grounded substance use prevention intervention developed and tested with Hawaii Island students. Teachers deliver the 11 lesson program through 30-45 minute weekly sessions. The modular intervention can be customized to students by teachers.
219388317|NCT06971653|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
219388318|NCT06971653|PROCEDURE|piezoelectric surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
219388319|NCT04615871|DRUG|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
219388320|NCT03554590|BEHAVIORAL|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
219388321|NCT03554590|BEHAVIORAL|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
219388322|NCT06971523|DRUG|CTS3497|CTS3497: Orally via capsules
219388323|NCT06315114|BEHAVIORAL|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
219388324|NCT06315114|BEHAVIORAL|Care as usual (CAU)|"1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.~Parents are offered the possibility of bringing their spouse or offspring to one of the sessions."
219388325|NCT04960358|PROCEDURE|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
219760962|NCT02149459|DRUG|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
219760963|NCT02149459|BEHAVIORAL|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
219388326|NCT01816087|OTHER|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
219388327|NCT04515719|BIOLOGICAL|Belimumab|Belimumab 2mg/kg intravenously
219388328|NCT04515719|BIOLOGICAL|Placebo|Placebo intravenously
219388329|NCT04652934|OTHER|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
219388330|NCT04652934|OTHER|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
219388331|NCT05059197|DIETARY_SUPPLEMENT|AP collagen peptide|Health functional food
219388332|NCT05059197|DIETARY_SUPPLEMENT|Placebo|placebo
219388333|NCT01440725|BIOLOGICAL|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
219388334|NCT01440725|PROCEDURE|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
219388335|NCT02772783|OTHER|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
219388336|NCT02772783|OTHER|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
219388337|NCT02772783|DRUG|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
219388338|NCT02772783|DRUG|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
219388339|NCT04723030|DRUG|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
219388340|NCT03443024|BIOLOGICAL|Lebrikizumab|Sterile liquid solution administered subcutaneously.
219388341|NCT03443024|DRUG|Placebo|Solution administered subcutaneously.
219388342|NCT05088317|DIAGNOSTIC_TEST|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
219388343|NCT05574153|DIAGNOSTIC_TEST|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
219388344|NCT02986373|BIOLOGICAL|risankizumab|Risankizumab administered by subcutaneous injection.
219388345|NCT06090474|DRUG|NDC-002|Combination of NDC-002B and NDC-002C
219388346|NCT04573959|DEVICE|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
219388347|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
219388348|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
219388349|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
219388350|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
219388351|NCT04909021|OTHER|Placebo (single-dose)|Single dose administered intranasally on Day 1
219388352|NCT04909021|OTHER|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
219388353|NCT03504033|DRUG|Xenon|inhalation to maintain anesthesia
219388354|NCT03504033|DRUG|Desflurane|inhalation to maintain anesthesia
219388355|NCT03690518|OTHER|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
219388356|NCT02391610|OTHER|No intervention|
219388357|NCT02913807|PROCEDURE|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
219388358|NCT02913807|PROCEDURE|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
219388359|NCT06232434|DRUG|Prospidelong|Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
219388360|NCT06232434|PROCEDURE|chemotherapy|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1"
219388361|NCT06652828|OTHER|Conventional Treadmill Walking (CTT)|The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.
219388362|NCT06652828|OTHER|Perturbation-Based Balance Training (PBT)|Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
219388363|NCT05439928|DEVICE|DEXCOM G6 CGM|Continuous glucose monitoring
219388364|NCT01526356|DRUG|Placebo|Study cream is applied nightly to the affected areas on the face.
219388365|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
219388366|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
219388367|NCT05475873|DRUG|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
219388368|NCT05475873|DRUG|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
219388369|NCT05475873|DRUG|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
219388370|NCT03449888|PROCEDURE|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
219388371|NCT03449888|PROCEDURE|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
219388372|NCT03449888|PROCEDURE|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
219388373|NCT03449888|PROCEDURE|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease \> 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
219388374|NCT00995371|DEVICE|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
219388375|NCT00995371|DRUG|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
219388376|NCT04358393|DRUG|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
219388377|NCT04358393|DRUG|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
219388378|NCT03193905|PROCEDURE|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
219388379|NCT03193905|PROCEDURE|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
219388380|NCT05409105|DIETARY_SUPPLEMENT|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
219388381|NCT05409105|DIETARY_SUPPLEMENT|Water|2 cups/day bottled water, 2 weeks
219388382|NCT01849133|RADIATION|external fractionated radiotherapy|conventional external beam radiotherapy
219388383|NCT01849133|RADIATION|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
219388384|NCT00403104|DRUG|ONO-2506PO|1200 mg QD / 18 months
219388385|NCT00403104|DRUG|ONO-2506PO|0 mg QD / 18 months
219388386|NCT04725682|DRUG|Tacrolimus|a single dose of 1 mg capsule per period
219388387|NCT05718115|DIAGNOSTIC_TEST|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
219388388|NCT01075425|DRUG|bortezomib|Given IV
219388389|NCT01075425|DRUG|belinostat|Given IV
219388390|NCT01075425|OTHER|laboratory biomarker analysis|Correlative studies
219388391|NCT01075425|GENETIC|western blotting|Correlative studies
219388392|NCT01075425|OTHER|pharmacological study|Correlative studies
219388393|NCT01075425|OTHER|flow cytometry|Correlative studies
219388394|NCT04065763|OTHER|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
219388395|NCT01215539|DRUG|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
219388396|NCT01237470|PROCEDURE|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
219388397|NCT01237470|PROCEDURE|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
219388398|NCT00041899|DRUG|CDB-2914|
219388399|NCT00041899|DRUG|COB-2914|
219388400|NCT06075914|OTHER|Ketogenic Intervention|Participants will receive ready-to-eat Ketogenic Diet meals.
219388401|NCT06075914|OTHER|Mediterranean Intervention|Participants will receive ready-to-eat Mediterranean Diet meals.
219388402|NCT06075914|DIETARY_SUPPLEMENT|Placebo|Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.
219388403|NCT06075914|DIETARY_SUPPLEMENT|Ketone Ester|Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
219388404|NCT06656949|PROCEDURE|injecting indocyanine green (ICG) dye Intraoperative|injecting indocyanine green (ICG) dye Intraoperative for patients with endometrial cancer
219388405|NCT05128240|DIETARY_SUPPLEMENT|Placebo|1g corn oil capsules
219388406|NCT05128240|DIETARY_SUPPLEMENT|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
219388407|NCT04138667|OTHER|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
219388408|NCT03946566|PROCEDURE|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
219388409|NCT01703312|DRUG|QGE031|Drug administered by subcutaneous injection
219388410|NCT01703312|DRUG|omalizumab|Drug administered by subcutaneous injection
219388411|NCT01703312|DRUG|placebo|Drug administered by subcutaneous injection
219388412|NCT06657664|PROCEDURE|cryotherapy with sterile saline at 2.5ºC|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
219388413|NCT06657664|PROCEDURE|intaoral cryotherapy|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
219388414|NCT06657664|PROCEDURE|Both intracanal and intraoral cryotherapy|Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
219388415|NCT06657664|DEVICE|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
219388416|NCT06657664|PROCEDURE|Control (Standard treatment)|, all occlusal contacts were reduced by 1 mm
219388417|NCT03497169|DRUG|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
219388418|NCT01684826|RADIATION|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
219388419|NCT01684826|RADIATION|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
219001233|NCT00965042|DRUG|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
219388420|NCT00260221|BEHAVIORAL|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
219388421|NCT06819202|OTHER|Hyperbaric oxygen treatment|HBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.
219388422|NCT05824767|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
219388423|NCT01607892|DRUG|KPT-330|
219388424|NCT04726306|DIAGNOSTIC_TEST|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
219760964|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
219388425|NCT03467230|DEVICE|NoL Index|Use of the PMD-200 in an observational study
219388426|NCT04002687|DRUG|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
219388427|NCT03983941|DRUG|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
219388428|NCT04642664|DRUG|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
219388429|NCT03414359|DRUG|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
219388430|NCT03414359|DRUG|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
219388431|NCT02346448|PROCEDURE|endoscopic sphincterotomy|sphincterotomy during ERCP
219388432|NCT02346448|PROCEDURE|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
219388433|NCT02346448|PROCEDURE|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
219388434|NCT05505058|BEHAVIORAL|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
219388435|NCT02273973|DRUG|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
219388436|NCT02273973|OTHER|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
219760965|NCT02307630|BIOLOGICAL|124I-Humanized 3F8|
219760966|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
219760967|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
219388437|NCT02273973|DRUG|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
219388438|NCT03294304|DRUG|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
219388439|NCT03294304|DRUG|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
219388440|NCT03294304|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
219388441|NCT04966221|DIAGNOSTIC_TEST|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
219388442|NCT01442584|PROCEDURE|ovarian transplantation|ovarian transplantation
219388443|NCT02156700|PROCEDURE|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
219388444|NCT05674773|PROCEDURE|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
219388445|NCT03022422|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
219388446|NCT03022422|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
219388447|NCT03554239|GENETIC|genotyping|Blood sample
219388448|NCT02312986|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
219388449|NCT00533000|PROCEDURE|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
219388450|NCT01282814|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
219388451|NCT01282814|DRUG|Effexor® XR|150 mg Extended-Release Capsule
219388452|NCT02403206|DEVICE|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
219388453|NCT02403206|PROCEDURE|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
219388454|NCT00957372|DRUG|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
219388455|NCT00957372|DRUG|placebo (Part I)|once daily placebo comparator
219388456|NCT00957372|DRUG|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
219388457|NCT02788539|BEHAVIORAL|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
219388458|NCT01444391|DEVICE|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
219388459|NCT02991612|DRUG|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
219388460|NCT00653315|DRUG|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
219388461|NCT00653315|DRUG|Ultracet|Tablets, 37.5mg/325mg
219388462|NCT04259710|BEHAVIORAL|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
219388463|NCT04259710|BEHAVIORAL|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
219388464|NCT04259710|BEHAVIORAL|Pedometer only|the participant will be given a pedometer and instructed how to use it.
219388465|NCT03331211|DRUG|TKIs|Dasatinib combined with Chematherapy
219388466|NCT04467112|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
219388467|NCT01264003|DRUG|sefazolin|In prophylaxis
219388468|NCT03731715|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
219388469|NCT04939493|OTHER|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
219388470|NCT04939493|OTHER|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
219388471|NCT04939493|OTHER|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
219388472|NCT04831944|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
219388473|NCT03703531|PROCEDURE|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
219388474|NCT01786018|DRUG|Thiotepa|
219388475|NCT01786018|DRUG|Busulfan|
219388476|NCT01786018|DRUG|Fludarabin|
219388477|NCT01786018|PROCEDURE|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
219388478|NCT01786018|RADIATION|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
219388479|NCT01786018|DRUG|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
219388480|NCT01786018|DRUG|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
219388481|NCT01786018|DRUG|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
219388482|NCT01786018|DRUG|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
219388483|NCT01786018|PROCEDURE|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
219388484|NCT05349461|PROCEDURE|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
219388485|NCT05349461|PROCEDURE|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
219388486|NCT05578521|DRUG|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
219388487|NCT05578521|DRUG|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
219388488|NCT00720707|PROCEDURE|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
219388489|NCT00720707|PROCEDURE|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
219388490|NCT00114907|BEHAVIORAL|Consumption of black tea|
219388491|NCT03088423|RADIATION|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
219388492|NCT00108810|DRUG|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
219388493|NCT00108810|DRUG|Placebo transdermal patch|12 hours application for 28 days
219388494|NCT03939910|DEVICE|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
219388495|NCT05126095|RADIATION|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
219388496|NCT02444169|DEVICE|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
219388497|NCT02444169|DRUG|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
219388498|NCT02444169|DEVICE|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
219388499|NCT02444169|DEVICE|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
219388500|NCT00986193|PROCEDURE|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
219388501|NCT00986193|PROCEDURE|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
219388502|NCT02768129|DEVICE|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
219388503|NCT02768129|DEVICE|sham transcranial direct current stimulation|sham stimulation
219388504|NCT05761327|OTHER|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
219388505|NCT05761327|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
219388506|NCT05761327|DIETARY_SUPPLEMENT|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
219388507|NCT02209597|DRUG|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
219388508|NCT03988712|DIAGNOSTIC_TEST|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
219388509|NCT01364610|DEVICE|Bravo|Bravo pH Monitoring System sited manometrically.
219388510|NCT01364610|DEVICE|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
219388511|NCT02253875|DRUG|Tipranavir (TPV)|
219388512|NCT02253875|DRUG|Ritonavir|
219388513|NCT02253875|DRUG|Omeprazole|
219388514|NCT00003270|BIOLOGICAL|anti-thymocyte globulin|IV
219388515|NCT00003270|BIOLOGICAL|filgrastim|IV
219388516|NCT00003270|DRUG|busulfan|IV
219388517|NCT00003270|DRUG|cyclophosphamide|IV
219388518|NCT00003270|DRUG|cyclosporine|IV
219388519|NCT00003270|DRUG|methylprednisolone|IV
219388520|NCT00003270|PROCEDURE|bone marrow ablation with stem cell support|IV
219388521|NCT00003270|PROCEDURE|umbilical cord blood transplantation|IV
219388522|NCT00003270|RADIATION|radiation therapy|High energy X-rays
219388523|NCT01855789|DRUG|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
219388524|NCT01855789|DRUG|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
219388525|NCT01855789|DRUG|Placebo (PBO)|PBO matching to MTX will be administered orally.
219388526|NCT03067311|BEHAVIORAL|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
219388527|NCT03067311|BEHAVIORAL|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
219388528|NCT01843322|PROCEDURE|endoleak repair procedure (navigation technology )|
219388529|NCT06509698|OTHER|virtual reality|STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
219388530|NCT06509698|OTHER|Frenkel's exercise|Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
219388531|NCT00193362|DRUG|Paclitaxel|
219388532|NCT00193362|DRUG|Carboplatin|
219388533|NCT00193362|DRUG|Gemcitabine|
219388534|NCT00193362|DRUG|Vinorelbine|
219388535|NCT04468958|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
219388536|NCT04468958|OTHER|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
219388537|NCT04583865|OTHER|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
219388538|NCT04304222|DEVICE|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
219388539|NCT00144105|DRUG|TPV500mg/RTV200mgBID|
219388540|NCT00144105|DRUG|TPV500mg/RTV100mgBID|
219388541|NCT00144105|DRUG|LPV400mg/RTV100mgBID|
219388542|NCT04021784|DEVICE|SDS|The patient is implanted with SDS.
219388543|NCT04021784|DEVICE|NEMOST|The patient is implanted with NEMOST.
219388544|NCT02016157|DRUG|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
219388545|NCT03726671|OTHER|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219388546|NCT03726671|OTHER|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219388547|NCT03726671|OTHER|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219388548|NCT03983876|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
219388549|NCT03723564|DRUG|Lactated Ringers Solution for Injection|Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
219388550|NCT04307966|BEHAVIORAL|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
219388551|NCT04661319|PROCEDURE|video editing training|"1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
219388552|NCT02233725|DEVICE|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
219388553|NCT03590561|OTHER|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
219388554|NCT03348683|DRUG|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
219388555|NCT03348683|DRUG|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
219388556|NCT04507217|DRUG|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
219388557|NCT01483846|DRUG|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
219388558|NCT01483846|DRUG|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
219388559|NCT04735900|PROCEDURE|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
219388560|NCT03937986|DRUG|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
219388561|NCT03937986|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
219388562|NCT03937986|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
219388563|NCT02414295|DRUG|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
219388564|NCT01312155|OTHER|Intubation|Intubation, endotracheal
219388565|NCT02752308|DRUG|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
219388566|NCT02752308|PROCEDURE|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
219388567|NCT02752308|DRUG|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
219388568|NCT02752308|DRUG|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
219388569|NCT02752308|DRUG|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
219388570|NCT02752308|DRUG|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
219388571|NCT02752308|PROCEDURE|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
219388572|NCT05495399|PROCEDURE|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
219388573|NCT05495399|RADIATION|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
219388574|NCT00249886|DRUG|Citalopram|
219388575|NCT03328611|DEVICE|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
219388576|NCT02110108|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
219388577|NCT02887846|DEVICE|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
219388578|NCT01623687|DEVICE|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
219388579|NCT01623687|DEVICE|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
219388580|NCT01623687|DEVICE|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
219388581|NCT01623687|DEVICE|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
219388582|NCT05823506|COMBINATION_PRODUCT|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
219388583|NCT05823506|DRUG|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
219388584|NCT00122499|DRUG|tadalafil|
219388585|NCT04988126|OTHER|Interventions|Observational study, not applicable
219388586|NCT01463852|DRUG|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
219388587|NCT06283095|PROCEDURE|expansion palatoplasty|surgical procedure
219388588|NCT00612846|PROCEDURE|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
219388589|NCT00612846|PROCEDURE|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
219388590|NCT02231216|PROCEDURE|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
219388591|NCT02231216|PROCEDURE|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
219388592|NCT02231216|PROCEDURE|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
219388593|NCT00744055|DRUG|Prazosin|prazosin (16mg/day) 2 times a day
219388594|NCT00744055|DRUG|Placebo|Placebo
219388595|NCT02565823|OTHER|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
219388596|NCT00623155|DRUG|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
219388597|NCT00842517|BEHAVIORAL|Contingency Management|
219388598|NCT00147108|DEVICE|ExAblate 2000|
219388599|NCT00056212|BEHAVIORAL|Yoga|
219388600|NCT00056212|BEHAVIORAL|Exercise|
219188776|NCT06348680|OTHER|Video assisted episiotomy repair training|Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
219388601|NCT05506332|DRUG|Venetoclax|Venetoclax and 6-mercaptopurine
219388602|NCT05506332|DRUG|6-mercaptopurine|Venetoclax and 6-mercaptopurine
219388603|NCT06119178|DEVICE|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
219388604|NCT06119178|DEVICE|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
219388605|NCT06014814|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation
219388606|NCT03441191|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
219388607|NCT03351322|DRUG|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
219388608|NCT03351322|DRUG|Regaine|Regaine are applied for treatment of hair loss.
219388609|NCT03774745|DRUG|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
219388610|NCT03774745|DRUG|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
219388611|NCT03774745|DRUG|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
219388612|NCT04079556|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
219388613|NCT03499041|DRUG|LY3314814|Administered orally
219388614|NCT05011552|BEHAVIORAL|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
219388615|NCT05011552|BEHAVIORAL|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
219388616|NCT04298346|OTHER|no intervention|no intervention
219388617|NCT02238613|DEVICE|radioactive stent|radioactive stent carrying seed iodine 125
219388618|NCT02238613|DEVICE|plastic stent|common plastic stent without carrying seed iodine 125
219388619|NCT06152601|PROCEDURE|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
219388620|NCT05316363|OTHER|OMT|"Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt."
219388621|NCT02187640|BEHAVIORAL|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
219388622|NCT02187640|BEHAVIORAL|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
219388623|NCT05198986|OTHER|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
219001234|NCT03498027|DEVICE|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
219388624|NCT03426215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
219388625|NCT04448249|BEHAVIORAL|APN intervention|"APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
219388626|NCT03847337|OTHER|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
219388627|NCT03847337|OTHER|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
219388628|NCT02004405|OTHER|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
219388629|NCT02004405|OTHER|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
219388630|NCT03763487|DIAGNOSTIC_TEST|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
219388631|NCT03763487|PROCEDURE|spleen volumetry|Ultrasound examination of spleen to scaled the size.
219388632|NCT00920465|DRUG|mifegyne and cytotec|One day dosage versus two days dosage
219388633|NCT03388983|OTHER|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
219388634|NCT03955029|OTHER|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
219388635|NCT03955029|OTHER|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
219388636|NCT03743558|BEHAVIORAL|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
219388637|NCT04864977|DRUG|Basal Insulin|Participants administered basal insulin
219388638|NCT04221074|PROCEDURE|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
219388639|NCT03249896|BEHAVIORAL|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
219388640|NCT05354284|OTHER|online questionnaire|Questionnaire at three timepoints
219388641|NCT04328623|PROCEDURE|Hypnosis|"conversational hypnosis technique call the magic glove"
219388642|NCT04328623|PROCEDURE|Infiltration|Ultrasound-guided hand infiltration
219388643|NCT00849693|DRUG|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
219388644|NCT00849693|DRUG|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
219388645|NCT00849693|DRUG|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
219388646|NCT00849693|DRUG|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
219388647|NCT05435248|DRUG|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
219388648|NCT05370248|OTHER|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
219388649|NCT05370248|OTHER|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
219388650|NCT04550546|DRUG|Nystatin|600,000 U/mL of nystatin in a rinse suspension
219388651|NCT00731445|DRUG|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
219388652|NCT00338936|DRUG|Valsartan + Hydrochlorothiazide|
219388653|NCT00844298|DRUG|Nilotinib+mVPD|"1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT"
219388654|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
219388655|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
219388656|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
219388657|NCT05116982|DIETARY_SUPPLEMENT|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
219388658|NCT01771679|BIOLOGICAL|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
219388659|NCT02094079|OTHER|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
219388660|NCT05134974|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
219388661|NCT05134974|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
219188777|NCT05778162|DIAGNOSTIC_TEST|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments \[CLIA\] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
219188778|NCT05036590|OTHER|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
219388662|NCT02292134|DEVICE|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
219388663|NCT02917863|DRUG|L-Thyroxine (tablet, per os)|
219388664|NCT02917863|DRUG|L-Thyroxine (oral drops, solution)|
219388665|NCT01408537|BIOLOGICAL|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
219388666|NCT03287297|DIAGNOSTIC_TEST|OGTT & HBA1c|oral glucose tolerance test \& HBA1c: by measuring glycated hemoglobin
219388667|NCT01878006|DRUG|Morphine|
219388668|NCT01878006|DRUG|Placebo|
219388669|NCT02389413|DRUG|PQ912 oral|
219388670|NCT02389413|OTHER|Placebo|
219388671|NCT04792151|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
219388672|NCT01376739|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
219388673|NCT03663244|BEHAVIORAL|MBSR|Standardised stress reduction programme with established efficacy
219388674|NCT03663244|BEHAVIORAL|LSR|Existing stress reduction programme in a Danish municipality
219388675|NCT00100555|DRUG|zoledronic acid|
219388676|NCT02502630|DEVICE|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
219388677|NCT05074784|DEVICE|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
219388678|NCT05074784|DEVICE|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
219388679|NCT04611464|DRUG|Misoprostol|Misoprostol is a PGE1 analog
219388680|NCT02760602|DRUG|Solanezumab|Administered IV
219388681|NCT02760602|DRUG|Placebo|Administered IV
219388682|NCT02137551|OTHER|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
219388683|NCT06449105|BEHAVIORAL|1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
219388684|NCT06449105|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219388685|NCT06449105|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
219388686|NCT06449105|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219388687|NCT06449105|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
219388688|NCT06449105|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219388689|NCT06449105|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
219388690|NCT06449105|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
219388691|NCT03159754|PROCEDURE|Early Appendectomy|Removal of the appendix within 24 hours of admission
219388692|NCT03159754|PROCEDURE|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
219388693|NCT03159754|DRUG|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
219388694|NCT00708877|PROCEDURE|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
219388695|NCT05441046|DRUG|Genakumab|genakumab plus tislelizumab 200 mg
219388696|NCT05414123|DEVICE|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
219388697|NCT03323307|DEVICE|OCT imaging|imaging of retina using OCT device
219388698|NCT06128941|OTHER|Repeated sprint|"* Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets."
219388699|NCT04681287|DRUG|inetetamab and PD-1 inhibitor combined with chemotherapy.|"1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
219388700|NCT02185170|PROCEDURE|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
219388701|NCT02185170|DEVICE|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
219388702|NCT02185170|DEVICE|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
219388703|NCT06005506|DIETARY_SUPPLEMENT|Prebiotic fiber|Moradyn active prebiotic fiber product
219388704|NCT06005506|DIETARY_SUPPLEMENT|Dietary fiber|Fibregum non-active fiber product
219388705|NCT06005506|DIETARY_SUPPLEMENT|Probiotic|Defense Plus probiotic complex
219388706|NCT04908137|DRUG|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
219388707|NCT05385614|BEHAVIORAL|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
219388708|NCT00212238|BEHAVIORAL|internet behavioral weight loss program|
219388709|NCT00978575|DRUG|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
219388710|NCT00978575|DRUG|Ferrosulfate|200mg daily for 12 weeks
219388711|NCT00978575|DRUG|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
219388712|NCT05517759|OTHER|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
219388713|NCT02626052|BEHAVIORAL|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
219388714|NCT02626052|BEHAVIORAL|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
219388715|NCT02626052|BEHAVIORAL|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
219388716|NCT02626052|PROCEDURE|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
219388717|NCT02626052|PROCEDURE|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
219388718|NCT02626052|PROCEDURE|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
219388719|NCT01362400|DRUG|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
219388720|NCT01362400|DRUG|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
219388721|NCT00052429|DRUG|cisplatin|
219388722|NCT00052429|DRUG|fluorouracil|
219388723|NCT00052429|PROCEDURE|adjuvant therapy|
219388724|NCT00052429|RADIATION|radiation therapy|
219388725|NCT00683189|DRUG|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
219388726|NCT02897193|DEVICE|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
219388727|NCT02897193|DEVICE|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
219388728|NCT02897193|DEVICE|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
219388729|NCT02897193|DEVICE|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
219388730|NCT04770168|BEHAVIORAL|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
219388731|NCT05952219|DRUG|CKD-379|2 tablet administration under fed condition
219388732|NCT05952219|DRUG|D759+D745+D029+D150|4 tablet co-administration under fed condition
219388733|NCT00073333|BEHAVIORAL|Social Skills Training|Social skills training once per week
219388734|NCT00073333|BEHAVIORAL|Exposure Treatment|Exposure once per week
219388735|NCT00073333|BEHAVIORAL|Placebo|Placebo
219388736|NCT05041764|OTHER|NO INTERVENTION|No INTERVENTION
219388737|NCT01651923|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
219388738|NCT03163342|BIOLOGICAL|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
219388739|NCT02817438|BEHAVIORAL|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
219388740|NCT04229147|RADIATION|Radiotherapy|Patients who received a total dose of 30 Gy
219388741|NCT04021472|BEHAVIORAL|Text message|Two months of daily text messages to support meeting a health goal
219188779|NCT05036590|OTHER|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
219188780|NCT05739994|OTHER|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
219388742|NCT04562324|DRUG|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
219388743|NCT04562324|DEVICE|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
219388744|NCT05784792|OTHER|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
219388745|NCT01042301|OTHER|Blood samplings|
219388746|NCT01855555|DRUG|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
219388747|NCT04751279|OTHER|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
219388748|NCT06481358|DIAGNOSTIC_TEST|Artificial intelligence|AI extract intestinal region and reconstruct into 3D image.
219388749|NCT00676559|DRUG|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
219388750|NCT00676559|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
219388751|NCT01309425|DRUG|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
219388752|NCT01309425|DRUG|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
219388753|NCT01309425|DRUG|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
219388754|NCT01309425|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
219388755|NCT03264638|DRUG|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
219388756|NCT03264638|DRUG|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
219388757|NCT03264638|DRUG|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
219388758|NCT00750347|DRUG|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
219388759|NCT04641546|PROCEDURE|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
219388760|NCT04641546|PROCEDURE|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
219388761|NCT05024838|OTHER|Machine learning methods|This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
219388762|NCT02046564|DRUG|ASC-01|
219388763|NCT02046564|DRUG|Placebo|
219388764|NCT00149331|BEHAVIORAL|Structured education program|
219388765|NCT00893594|DRUG|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
219388766|NCT00893594|DRUG|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
219388767|NCT03933917|PROCEDURE|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
219388768|NCT02975323|DRUG|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
219188781|NCT05739994|OTHER|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
219388769|NCT05717179|DIAGNOSTIC_TEST|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
219388770|NCT04330508|OTHER|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
219388771|NCT06470308|OTHER|Medication Reviews and Deprescribing|General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria and STOPP/START criteria.
219388772|NCT03183245|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
219388773|NCT03183245|PROCEDURE|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
219388774|NCT03183245|OTHER|Hemodialysis|Procedure that filters a person's blood when their kidneys are no longer functioning properly
219388775|NCT01804205|DRUG|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
219388776|NCT01804205|DRUG|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
219388777|NCT00593086|PROCEDURE|Pain management|Pain mamagement for burn care procedures.
219388778|NCT00593086|OTHER|Standard of care/no virtual reality game|no intervention for standard of care
219388779|NCT00984659|DRUG|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
219388780|NCT00984659|DRUG|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
219388781|NCT00984659|DRUG|Placebo|Placebo DISKUS twice a day for 8 weeks
219388782|NCT00719173|DRUG|aprepitant|Given orally
219388783|NCT00719173|DRUG|cyclophosphamide|Given IV
219388784|NCT00719173|OTHER|placebo|Given orally
219388785|NCT06583395|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
219388786|NCT01395238|BEHAVIORAL|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
219388787|NCT05026658|DEVICE|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
219388788|NCT01777633|RADIATION|Palliative re-irradiation for progressive DIPG in children|
219388789|NCT03873597|BEHAVIORAL|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
219388790|NCT05422079|OTHER|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
219388791|NCT05422079|OTHER|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
219388792|NCT05422079|OTHER|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
219388793|NCT06274138|BEHAVIORAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
219388794|NCT01713634|OTHER|Preflight|4-d controlled diet sessions will occur twice before flight.
219388795|NCT01713634|OTHER|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
219388796|NCT05712421|DRUG|North Star|North Star
219388797|NCT05712421|DRUG|Levothyroxine|Levothyroxine
219388798|NCT00644579|DRUG|bLAC|bLAC high and low dose and placebo
219388799|NCT00644579|DRUG|Placebo|Placebo
219388800|NCT02261441|OTHER|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
219388801|NCT02951273|OTHER|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
219388802|NCT00121225|DRUG|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
219388803|NCT04220892|DRUG|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
219388804|NCT04220892|DRUG|Pemetrexed|900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
219388805|NCT04220892|DRUG|Abemaciclib|150 mg twice a day, by mouth.
219001235|NCT05740397|OTHER|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
219388806|NCT00850512|DRUG|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
219388807|NCT00850512|DRUG|Zevalin|12-week safety period for Zevalin
219388808|NCT03078361|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
219388809|NCT03078361|BEHAVIORAL|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
219388810|NCT03078361|BEHAVIORAL|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
219388811|NCT00366236|DRUG|Nitazoxanide|
219388812|NCT01708226|BEHAVIORAL|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
219388813|NCT01598181|DEVICE|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
219388814|NCT01598181|DEVICE|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
219388815|NCT02917590|OTHER|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
219388816|NCT02917590|OTHER|Single-task obstacle crossing training|Obstacle crossing training
219388817|NCT00635102|DRUG|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
219388818|NCT00635102|DRUG|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
219388819|NCT00635102|DRUG|Placebo D-Cycloserine PO and Glycine IV|
219388820|NCT00635102|DRUG|D-Cycloserine PO and placebo Glycine IV|
219388821|NCT04063683|DRUG|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
219388822|NCT03900676|DRUG|VB-1953 - 2%|Topical Gel
219388823|NCT03900676|DRUG|VB-1953 - 0% (Vehicle)|Topical Gel
219388824|NCT04964401|PROCEDURE|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
219388825|NCT01570010|OTHER|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
219001236|NCT03925974|DRUG|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
219001237|NCT03925974|DRUG|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
219001238|NCT03925974|DRUG|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
219388826|NCT03792711|DIETARY_SUPPLEMENT|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
219188782|NCT00621114|DEVICE|GamCath® central venous catheter|Choice of central venous catheter type
219388827|NCT06076330|BIOLOGICAL|20% Albumin|S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
219388828|NCT06076330|BIOLOGICAL|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
219388829|NCT06076330|DRUG|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
219388830|NCT05015361|DRUG|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
219388831|NCT05015361|DRUG|Propofol Injection.|Treatment group C: Propofol Injection.
219388832|NCT01938625|DRUG|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
219388833|NCT01938625|DRUG|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
219388834|NCT01938625|DRUG|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
219388835|NCT01938625|DRUG|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
219388836|NCT01938625|DRUG|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
219388837|NCT02797561|OTHER|5 year Follow-up|
219388838|NCT04861038|DEVICE|aerSleep II|Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
219388839|NCT00300027|DRUG|BMS-582664|
219388840|NCT02088034|BEHAVIORAL|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
219388841|NCT02088034|DRUG|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
219388842|NCT02088034|OTHER|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
219388843|NCT04364217|DEVICE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
219388844|NCT05290870|DEVICE|Posterior-chamber intraocular lens|Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
219388845|NCT02117089|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
219388846|NCT00546351|DRUG|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
219388847|NCT01689506|DRUG|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
219388848|NCT01689506|DRUG|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
219388849|NCT04269408|DRUG|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
219388850|NCT04269408|OTHER|Standard of care|Both arms receive the usual standard of care.
219388851|NCT03952650|DRUG|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
219388852|NCT03952650|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
219388853|NCT03952650|DRUG|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
219388854|NCT03952650|DRUG|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
219388855|NCT03952650|DRUG|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
219388856|NCT05797766|BEHAVIORAL|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
219388857|NCT05013528|OTHER|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
219388858|NCT05013528|OTHER|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
219388859|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
219388860|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
219388861|NCT04915521|OTHER|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
219388862|NCT03411603|OTHER|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
219388863|NCT02424149|DRUG|Phenazopyridine|
219001239|NCT04742010|DRUG|Zoledronic Acid|"* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes"
219001240|NCT04742010|DRUG|Placebo|as above
219001241|NCT01352858|DRUG|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
219001242|NCT01352858|DRUG|Arthroscopy & saline irrigation alone|
219001243|NCT00050934|DRUG|oxcarbazepine|
219388864|NCT04316481|DEVICE|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
219388865|NCT02283944|DEVICE|TMS|Pulsed non-invasive brain stimulation using electromagnets
219388866|NCT03063255|DRUG|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
219388867|NCT03063255|DRUG|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
219388868|NCT00592683|DRUG|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
219388869|NCT00592683|DIETARY_SUPPLEMENT|fish oil|1600mg (4 capsules) daily for 12 weeks
219388870|NCT00592683|DRUG|Placebo|Placebo
219388871|NCT05776472|DRUG|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
219388872|NCT00545818|DEVICE|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
219388873|NCT00545818|DEVICE|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
219388874|NCT03614390|BEHAVIORAL|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
219388875|NCT03045380|OTHER|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
219388876|NCT03045380|OTHER|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
219388877|NCT01333618|DEVICE|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
219388878|NCT01333618|DEVICE|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
219388879|NCT02330029|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
219388880|NCT02330029|DEVICE|Atractylodes|Atractylodes (\~10-15g)
219388881|NCT02330029|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
219388882|NCT02330029|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
219388883|NCT02330029|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
219388884|NCT02330029|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
219388885|NCT02330029|DRUG|Radix curcumae|Radix curcumae (\~10g)
219388886|NCT02330029|DRUG|Fingered citron|Fingered citron (\~10g)
219388887|NCT02330029|DRUG|Tuckahoe|Tuckahoe (15g)
219388888|NCT02330029|DRUG|Placebo|Placebo is blindly given to patients.
219388889|NCT03419702|DIETARY_SUPPLEMENT|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
219388890|NCT04180592|PROCEDURE|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
219388891|NCT03681860|BIOLOGICAL|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
219388892|NCT03681860|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
219388893|NCT03681860|BIOLOGICAL|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
219388894|NCT01538173|DRUG|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
219388895|NCT01538173|DRUG|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
219388896|NCT03043365|DRUG|control fish oil|4 capsules, 3 times a day after meals
219388897|NCT03043365|DRUG|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
219388898|NCT00168012|DRUG|Immunoglobulins Intravenous (Human)|
219388899|NCT03455543|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
219388900|NCT03455543|DEVICE|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
219388901|NCT05667519|PROCEDURE|Additional guidance of lead implantation by transesophageal echocardiography|Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
219388902|NCT02884115|DRUG|benzathine penicillin|
219388903|NCT01917825|DRUG|MDT-15|
219388904|NCT05858502|BIOLOGICAL|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
219388905|NCT05858502|OTHER|Saliva sample collection|Saliva sample collection between inclusion and 3 months
219388906|NCT05858502|OTHER|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
219388907|NCT05858502|OTHER|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
219388908|NCT01776099|DIETARY_SUPPLEMENT|Dietary supplement (4 arms, 2 active, 2 placebo)|
219388909|NCT02873221|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
219388910|NCT02873221|DRUG|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
219388911|NCT02873221|DRUG|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
219388912|NCT00636623|OTHER|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
219388913|NCT00636623|OTHER|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
219388914|NCT05418361|DRUG|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
219388915|NCT03811951|DRUG|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
219388916|NCT02491541|BIOLOGICAL|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
219388917|NCT02491541|BIOLOGICAL|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
219388918|NCT05357183|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
219388919|NCT04020874|BEHAVIORAL|HuTT-2x|tackling and blocking training twice/week
219388920|NCT04020874|BEHAVIORAL|HuTT-4x|tackling and blocking training four times/week
219388921|NCT06331949|OTHER|video assisted training|Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
219388922|NCT03838848|DRUG|KN046|3mg/kg, Q2W, intravenous injection (IV)
219388923|NCT03838848|DRUG|KN046|5mg/kg, Q2W, intravenous injection (IV)
219388924|NCT03838848|DRUG|KN046|5mg/kg, Q3W, intravenous injection (IV)
219388925|NCT03838848|DRUG|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
219388926|NCT03838848|DRUG|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
219388927|NCT03838848|DRUG|Ningetinib|Oral, QD
219388928|NCT04170140|OTHER|No intervention|Questionnaire
219388929|NCT06244966|DIAGNOSTIC_TEST|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
219388930|NCT01325493|DRUG|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
219388931|NCT01325493|DRUG|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
219388932|NCT02610283|DRUG|QPI-1002|IV injection
219388933|NCT02610283|DRUG|Placebo|isotonic saline
219388934|NCT01094899|RADIATION|Radiography|Radiography, microscanner, osteodensitometry
219388935|NCT01094899|OTHER|Urine and Blood sampling|mainly dosage of bones metabolism
219388936|NCT01094899|OTHER|Echography|body bones echography
219388937|NCT05602467|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
219388938|NCT05602467|OTHER|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
219388939|NCT03530163|DEVICE|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
219388940|NCT03530163|DEVICE|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
219388941|NCT02723435|DRUG|Midostaurin|Given PO
219388942|NCT01458769|DRUG|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
219388943|NCT01458769|DRUG|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
219388944|NCT01458769|DRUG|C-10297|C-10297 200 mg, oral, single dose
219388945|NCT01458769|DRUG|C-10299|C-10299 200 mg, oral, single dose
219388946|NCT01458769|DRUG|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
219388947|NCT01458769|DRUG|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
219388948|NCT01458769|DRUG|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
219388949|NCT01458769|DRUG|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
219388950|NCT01923610|BIOLOGICAL|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
219388951|NCT02270177|OTHER|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
219388952|NCT02255838|DEVICE|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
219388953|NCT02255838|DEVICE|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
219388954|NCT01367132|PROCEDURE|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
219388955|NCT04902248|DEVICE|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
219388956|NCT04902248|PROCEDURE|angiographic embolization|Transcatheter selective embolization to bleeding arteries
219388957|NCT03792958|DRUG|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
219388958|NCT04076566|DEVICE|alfapump system|active implantable device for treatment of malignant ascites
219388959|NCT01784510|PROCEDURE|distance of dissection of gastrocolic ligament from pylorus|
219388960|NCT05372315|DRUG|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
219388961|NCT00802477|PROCEDURE|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
219388962|NCT00802477|PROCEDURE|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
219388963|NCT00388739|DRUG|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
219388964|NCT00388739|DRUG|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
219388965|NCT04346225|DRUG|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
219388966|NCT04346225|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
219388967|NCT01283620|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
219001244|NCT03445104|OTHER|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
219388968|NCT01283620|OTHER|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
219388969|NCT05109390|DRUG|Danicopan|Oral tablet.
219388970|NCT05109390|DRUG|Cyclosporine|Oral capsule.
219388971|NCT05109390|DRUG|Tacrolimus|Oral capsule.
219388972|NCT05109390|DRUG|Calcium Carbonate|Chewable tablet.
219388973|NCT05109390|DRUG|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
219388974|NCT05109390|DRUG|Omeprazole|Oral, delayed-release capsule.
219388975|NCT01421849|PROCEDURE|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
219388976|NCT03570229|OTHER|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
219388977|NCT02797873|OTHER|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
219388978|NCT02797873|OTHER|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
219388979|NCT02797873|BEHAVIORAL|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
219388980|NCT02797873|OTHER|SCID-II|See Detailed Study Description.
219388981|NCT02797873|OTHER|SDQ|See Detailed Study Description.
219388982|NCT02797873|OTHER|ASRS|See Detailed Study Description.
219388983|NCT02797873|OTHER|AQ|See Detailed Study Description.
219388984|NCT02797873|OTHER|TAS-20|See Detailed Study Description.
219388985|NCT02797873|OTHER|Raven's SPM|See Detailed Study Description.
219388986|NCT02797873|OTHER|Reading ability|See Detailed Study Description.
219388987|NCT02797873|OTHER|Ishihara's tests for colour deficiency|See Detailed Study Description.
219388988|NCT02797873|OTHER|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
219388989|NCT02797873|OTHER|Brown-ADD|See Detailed Study Description.
219388990|NCT02797873|OTHER|MFQ|See Detailed Study Description.
219388991|NCT02797873|OTHER|STAI-T|See Detailed Study Description.
219388992|NCT02797873|OTHER|BIS|See Detailed Study Description.
219388993|NCT02797873|OTHER|DAWBA|See Detailed Study Description.
219388994|NCT02797873|OTHER|STAI-S|See Detailed Study Description.
219388995|NCT02797873|OTHER|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
219388996|NCT02797873|OTHER|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
219388997|NCT02797873|BEHAVIORAL|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
219388998|NCT02797873|OTHER|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
219388999|NCT02797873|OTHER|Structural T2 MRI scan|See Detailed Study Description.
219389000|NCT02797873|OTHER|DTI MRI scan|See Detailed Study Description and Outcome Measures.
219389001|NCT02797873|OTHER|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
219389002|NCT01515072|OTHER|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
219389003|NCT03887832|OTHER|SMBI digital app|Digital platform on the smartphone for the media package
219389004|NCT03887832|BEHAVIORAL|media package|The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
219389005|NCT03887832|OTHER|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
219389006|NCT03990948|OTHER|Blood sampling|Blood sample collection
219389007|NCT02333539|BEHAVIORAL|Adherence behaviors and recommendations for improvement.|
219389008|NCT02333539|BEHAVIORAL|Adherence behavior that needs improvement is targeted|
219389009|NCT01508676|DRUG|Pennsaid|
219389010|NCT01508676|DRUG|Placebo (2.3% DMSO solution)|
219389011|NCT06289725|DRUG|antiviral treatment|The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
219389012|NCT00650585|BEHAVIORAL|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
219389013|NCT00609128|DRUG|olopatadine|olopatadine one drop in one eye for one week
219389014|NCT05087186|BEHAVIORAL|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique"
219389015|NCT02532543|BIOLOGICAL|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
219389016|NCT02532543|BIOLOGICAL|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
219389017|NCT02532543|BIOLOGICAL|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
219389018|NCT02532543|BIOLOGICAL|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
219389019|NCT01103050|DRUG|QAV680 + Cetirizine Placebo|
219389020|NCT01103050|DRUG|QAV680 + Cetirizine|
219389021|NCT01103050|DRUG|Cetirizine + QAV680 Placebo|
219389022|NCT01103050|DRUG|QAV680 Placebo + Cetirizine Placebo|
219389023|NCT00994565|BEHAVIORAL|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
219389024|NCT04609384|DEVICE|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
219389025|NCT00231140|DRUG|Thalidomide (drug)|
219389026|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
219389027|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
219389028|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
219389029|NCT06408831|BEHAVIORAL|Classroom Teaching University Students Intervention Group|Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
219389030|NCT06002581|DEVICE|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
219389031|NCT06002581|DEVICE|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
219389032|NCT06002581|DEVICE|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
219389033|NCT03186469|BEHAVIORAL|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
219389034|NCT03186469|BEHAVIORAL|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
219389035|NCT00002208|DRUG|Indinavir sulfate|
219389036|NCT00002208|DRUG|Lamivudine|
219389037|NCT00002208|DRUG|Stavudine|
219389038|NCT00002208|DRUG|Zidovudine|
219389039|NCT00846612|DRUG|Doxil|1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
219389040|NCT00846612|DRUG|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
219389041|NCT00247325|DRUG|Iodixanol(Drug)|
219389042|NCT02614794|DRUG|tucatinib|300 mg orally twice daily
219389043|NCT02614794|DRUG|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
219389044|NCT02614794|DRUG|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
219389045|NCT02614794|DRUG|placebo|Oral dose twice daily
219389046|NCT00906789|BEHAVIORAL|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
219389047|NCT03701789|DRUG|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
219389048|NCT03425110|OTHER|Modified Ketogenic Diet|
219389049|NCT04928365|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
219389050|NCT02562196|DEVICE|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219389051|NCT02334267|DEVICE|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
219389052|NCT02334267|DEVICE|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
219389053|NCT01420640|BEHAVIORAL|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
219389054|NCT01420640|BEHAVIORAL|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
219389055|NCT01420640|BEHAVIORAL|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
219389056|NCT01420640|BEHAVIORAL|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
219389057|NCT01420640|BEHAVIORAL|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
219389058|NCT00244205|PROCEDURE|Identifying genes methylated in urine|
219389059|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
219389060|NCT00923091|DRUG|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
219389061|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
219389062|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
219389063|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
219389064|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
219001245|NCT03445104|OTHER|Placebo|During one of the two experimental sessions, participants will be given a placebo.
219389065|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
219389066|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
219389067|NCT02140320|DRUG|RV1729 single dose|Safety and tolerability of single dose
219389068|NCT02140320|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single dose
219389069|NCT02140320|DRUG|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
219389070|NCT02140320|DRUG|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
219389071|NCT02140320|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
219389072|NCT02140320|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
219389073|NCT02796144|DRUG|Lorcaserin|Max dose of 10 mg BID
219389074|NCT02796144|DRUG|Metformin|Max dose of 1,000 mg BID
219389075|NCT02796144|DRUG|Placebo|Matching placebos will be administered for each drug.
219389076|NCT02297893|BEHAVIORAL|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
219389077|NCT02297893|BEHAVIORAL|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
219389078|NCT05378789|PROCEDURE|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
219389079|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
219389080|NCT00178321|DEVICE|earplugs|
219389081|NCT05638386|PROCEDURE|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
219389082|NCT05221294|DRUG|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
219389083|NCT00887692|BEHAVIORAL|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
219389084|NCT03407391|OTHER|None - observational|No intervention - observational only
219389085|NCT04673409|DIAGNOSTIC_TEST|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
219389086|NCT02848846|DEVICE|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
219389087|NCT03598231|DEVICE|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
219389088|NCT04479501|OTHER|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
219389089|NCT05875935|PROCEDURE|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
219389090|NCT05144295|DRUG|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
219389091|NCT05144295|DRUG|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
219389092|NCT05144295|DRUG|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
219389093|NCT05144295|DRUG|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
219389094|NCT00239200|DRUG|Lapatinib|
219389095|NCT03630640|DRUG|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
219389096|NCT04626219|OTHER|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
219389097|NCT04626219|BEHAVIORAL|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
219389098|NCT04626219|BEHAVIORAL|regulated meals|standardized diet from noon until 9 a.m. the next day
219389099|NCT05443438|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
219389100|NCT05443438|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
219389101|NCT05443438|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
219389102|NCT03879668|DEVICE|eIPOS|Electronic version of IPOS
219389103|NCT06964360|BEHAVIORAL|REDOCVR Psychoeducational Program|A clinician-guided, group-based psychoeducational program combining pain neuroscience education, emotional regulation techniques, physical activation, and immersive virtual reality experiences. Delivered in eight weekly 90-minute sessions. Includes structured medication tapering support provided by primary care physicians.
219389104|NCT06964360|BEHAVIORAL|Standard Educational Materials|Participants receive written and audiovisual materials on chronic pain self-management. Materials are used independently without group sessions or virtual reality. No structured tapering support is provided beyond usual care.
219389105|NCT06963853|DIAGNOSTIC_TEST|Blood cultures will be obtained from three sources: 1. The central venous catheter (CVC), 2. The dialysis machine circuit, and 3. A peripheral vein|PTH levels during sepsis and compare them to baseline pre-infection levels, with serial follow-up of PTH values post-recovery.
219389106|NCT04402502|DEVICE|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
219389107|NCT06490965|OTHER|Repetitive Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
219389108|NCT06490965|OTHER|Neuronavigation|Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.
219389109|NCT06490965|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
219389110|NCT03711019|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219389111|NCT03711019|DEVICE|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219389112|NCT03711019|DEVICE|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219389113|NCT06097806|OTHER|low and high flow|low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
219389114|NCT04770272|DRUG|Atezolizumab 840 MG in 14 ML Injection|840 mg Day 1 for two weeks
219389115|NCT04770272|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg Day 1 every 3 weeks for 8 cycles
219389116|NCT04770272|DRUG|Carboplatin|Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
219389117|NCT04770272|DRUG|Paclitaxel|Paclitaxel 80 mg/m² IV weekly x 12 cycles
219389118|NCT04770272|DRUG|Epirubicin|90 mg/m2, day 1 for 4 cycles (12 weeks)
219389119|NCT04770272|DRUG|Cyclophosphamide|600 mg/m2, day 1 for 4 cycles (12 weeks)
219389120|NCT04770272|PROCEDURE|Biopsy Arm A|1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
219001246|NCT03053284|DRUG|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
219001247|NCT03053284|DRUG|Saline Solution|Saline Solution injection will be given once per study visit
219001248|NCT03167411|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
219389121|NCT04770272|PROCEDURE|Biopsy Arm B|1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
219389122|NCT04770272|PROCEDURE|Surgery|After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
219389123|NCT04060992|DRUG|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
219389124|NCT00467649|DRUG|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
219389125|NCT00467649|DRUG|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
219389126|NCT00467649|DRUG|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
219389127|NCT00807664|DEVICE|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
219389128|NCT00807664|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
219389129|NCT00759629|OTHER|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
219389130|NCT00759629|OTHER|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
219389131|NCT00160927|DEVICE|local heating|
219389132|NCT00160927|DEVICE|iontophoresis|
219389133|NCT00160927|DRUG|actylcholine|
219389134|NCT00160927|DRUG|sodium nitroprusside|
219389135|NCT02248376|DRUG|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
219389136|NCT05189899|DEVICE|Virtual reality|One hemodialysis session with virtual reality and one other without it
219389137|NCT00040534|DRUG|Farnesyl Protein Transferase Inhibitor|
219389138|NCT05895851|RADIATION|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
219188783|NCT00621114|DEVICE|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
219389139|NCT04655625|BIOLOGICAL|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
219389140|NCT04655625|BIOLOGICAL|Group A (Placebo)|Placebo twice at 2-week intervals
219389141|NCT04655625|BIOLOGICAL|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
219389142|NCT04655625|BIOLOGICAL|Group B (Placebo)|Placebo twice at 4-week intervals
219389143|NCT03233048|DEVICE|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
219389144|NCT01309516|BEHAVIORAL|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
219389145|NCT00084786|DRUG|docetaxel|
219389146|NCT00084786|DRUG|gefitinib|
219389147|NCT01883583|DEVICE|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
219001249|NCT03167411|DRUG|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
219188784|NCT06393062|DIAGNOSTIC_TEST|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
219389148|NCT01852344|DRUG|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
219389149|NCT01852344|DRUG|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
219389150|NCT01852344|BEHAVIORAL|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
219389151|NCT01852344|BEHAVIORAL|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
219389152|NCT01848444|OTHER|Breastmilk|to measure levels of contaminants in human breastmilk samples
219389153|NCT01556919|PROCEDURE|Standard of care endoscopy|standard of care endoscopy
219389154|NCT01665781|DRUG|Erythropoietin|
219389155|NCT06488807|OTHER|Olfactory Enrichment|Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.
219389156|NCT06488807|OTHER|Sham|The containers provided to the sham group will be odorless. The odor containers and labels will appear identical to those used in the olfactory enrichment group.
219389157|NCT06966180|BEHAVIORAL|Alcohol Intervention Program (AIP)|A brief behavioral intervention consisting of six bi-weekly group sessions based on motivational interviewing and cognitive-behavioral strategies. The aim was to reduce alcohol use and related problems and increase motivation to change.
219389158|NCT03308630|BEHAVIORAL|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
219389159|NCT06970431|OTHER|eoperative Education + Intraoperative Music Therapy Arm|The experimental group implemented standardized preoperative education one day before the operation (covering knowledge such as the surgical procedure), headphone fitting one hour before the operation (with a volume of 45-55 decibels), and music therapy throughout the operation and for 30 minutes after the operation (parturients can choose personalized music). Full-time nurses were responsible for the preoperative education, and trained operating room nurses implemented the music therapy. Meanwhile, data such as anxiety scores, pain scores, shivering index, postoperative complications, postoperative recovery status, and satisfaction surveys were collected at multiple time points through standardized tools.
219389160|NCT06970431|OTHER|Preoperative Education Alone Arm|"The control group received the same standardized preoperative education by full-time nurses one day before the operation, covering surgical procedures, precautions, anesthesia, and postoperative recovery.~Data were collected at multiple time points using standardized tools, including anxiety scores (before and 6, 12, 24 h after surgery via GAD-7), pain scores (before and 6, 12, 24 h after via VAS), shivering index (before surgery, before wearing headphones, when leaving OR), postoperative complications (wound infection, urinary retention, etc.), postoperative recovery indicators (time to get out of bed, anal exhaust, breastfeeding start, hospital stay), and satisfaction surveys (24 h after surgery).~Importantly, the control group had no music therapy intervention before, during, or after surgery."
219389161|NCT06971627|BEHAVIORAL|Nurse-led Telehealth Monitoring Program|Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.
219389162|NCT06971627|OTHER|No intervention|Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.
219389163|NCT06970795|DRUG|SYS6040 for injection|"Intravenous infusion; including dose escalation and backfilling (5 preset dose groups) and cohort expansion.~Treatment Period: All subjects receive trial treatment until disease progression, death, intolerance of toxicity, loss to follow-up, withdrawal of consent, or end of the trial (whichever occurs first)"
219389164|NCT06971510|DEVICE|Exoskeleton Training|Using EksoNR to train balance control and walking and turning abilities in patients with incomplete spinal cord injury.
219389165|NCT06971510|OTHER|Conventional Physical Therapy|Using conventional physical therapy methods to train the balance control and walking and turning abilities in patients with incomplete spinal cord injury.
219389166|NCT06971419|OTHER|intervention is the use of aTriage-Based Patient Redirection Using an Electronic Decision Support Toolin the emergency department (ED)|"Name: Logibec Réorientation software-assisted triage and redirection~Type: Decision support system for emergency triage~Implementation:~* Applied during patient triage in the emergency department~* Assists in identifying low-acuity (SETS 4) and semi-urgent (SETS 3) patients eligible for redirection~* Uses standardized inclusion/exclusion criteria to guide redirection decisions~Comparator: Standard nurse-led triage and redirection based only on the Swiss Emergency Triage Scale (SETS)~Key Distinction:~* The investigated group receives Logibec-assisted triage and redirection.~* The comparator group follows traditional nurse-led triage without electronic support, limiting redirection to SETS 4 patients only."
219389167|NCT04901507|DEVICE|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
219389168|NCT00729430|DRUG|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
219389169|NCT00729430|DRUG|Placebo|Placebo tablets taken orally once per day for 6 months
219389170|NCT02054832|DIETARY_SUPPLEMENT|Glycosade|
219389171|NCT05859958|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
219389172|NCT05347056|DIAGNOSTIC_TEST|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
219389173|NCT05347056|DIAGNOSTIC_TEST|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
219389174|NCT05347056|DIAGNOSTIC_TEST|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
219389175|NCT05347056|DIAGNOSTIC_TEST|Radiograph|spinal radiograph AP/Lateral
219389176|NCT05347056|BEHAVIORAL|SRS 22|SRS-22 Patient Questionnaire
219389177|NCT00863187|BIOLOGICAL|rituximab|b cell depletion
219389178|NCT06970574|DRUG|Levobupivacaine|to compare the clinical intraoperative effects of intrathecal administration of fentanyl in comparison with dexmedetomidine on shoulder tip pain in patients undergoing laparoscopic cholecystectomy.
219389179|NCT03395522|DEVICE|iTind|device implanted for 5-7 days
219389180|NCT06532617|DRUG|Cadonilimab+S-1or Capecitabine|Eligible patients will receive Cadonilimab (6mg/k, iv, D1,Q3W)combined with S-1 (40-60mg po BID Q3W D1-14）or Capecitabine (1250mg/m2, po BID Q3W D1-14）until disease progression or unacceptable toxicity. Patients who had used S-1 in the first line should choose capecitabine; patients who had used capecitabine in the first line should choose S-1; otherwise decided by investigator's choice.
219389181|NCT06511661|PROCEDURE|Complete lymphadenectomy|At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
219389182|NCT06511661|PROCEDURE|Incomplete lymphadenectomy|Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
219389183|NCT06969859|DEVICE|PEMF|The PEMF will be delivered using a BIXEPS device (Quantum Tx, Singapore) ; It is utilised by the patient placing the leg into the machine. This device is operated by participant individualized NFC cards, which will be centrally programmed to deliver either active PEMF (uniform 1mT, 50Hz) or sham PEMF (0mT, 0Hz) for 30 minutes. Because this biophysical intervention is non-invasive, and the electromagnetic fields emitted into the legs do not generate any sensation (e.g. heat, sound), participants will be blinded to the treatment. The protocol will be 180 minutes of PEMF therapy, performed in six 30-minute sessions 3 times a week and completed in 2 weeks.
219001250|NCT03962010|DRUG|GX-G6|long acting anti-diabetic drug
219001251|NCT03962010|DRUG|Control|Control
219001252|NCT05407935|BEHAVIORAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
219389184|NCT06969859|BEHAVIORAL|Alfredson eccentric training program|All participants will be subject to a standardised rehabilitation exercise region consisting of stretching and eccentric exercises following the Alfredson protocol. The 12-week program will be taught by a physiotherapist or athletic trainer and supplemented by video tutorials. The regime begins with three 30-second static stretches for the gastrocnemius (knee extension) and soleus (knee flexion) muscles with 1-minute rest between each stretch. The 2nd part is eccentric exercises to the calves following the Alfredson protocol. This will be three sets of eccentric exercises lasting 12 weeks, with 15 sets twice a day. If participants are unable to complete three sets of 15 repetitions, they can start with fewer repetitions and sets (at least 2 sets of 10 repetitions each) and gradually increase to the total number of sets. Participants will perform the static stretching exercises from Step 1 at the end of each session
219389185|NCT03529214|BEHAVIORAL|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
219389186|NCT06363721|DIETARY_SUPPLEMENT|PerioPull™|PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
219389187|NCT03246074|DRUG|Fostamatinib 100 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
219389188|NCT03246074|DRUG|Fostamatinib 150 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
219389189|NCT03246074|DRUG|Fostamatinib 200 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
219389190|NCT06969924|DEVICE|Cardiac resynchronization therapy|Cardiac resynchronization therapy pacemaker or defibrillator with a transvenous or epicardial systemic ventricle lead
219389191|NCT01350700|OTHER|Scars assessment & QOL|Scar assessment and quality of life questionnaires
219389192|NCT05108376|DEVICE|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
219389193|NCT01053910|DRUG|Ramipril|tablet of Ramipril once daily
219389194|NCT01039207|OTHER|Laboratory Biomarker Analysis|Correlative studies
219389195|NCT01039207|BIOLOGICAL|Rilotumumab|Given IV
219389196|NCT00499265|DRUG|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
219389197|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
219389198|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
219389199|NCT03088150|PROCEDURE|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
219389200|NCT03088150|PROCEDURE|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
219389201|NCT02782715|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
219389202|NCT02782715|PROCEDURE|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
219389203|NCT04458857|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
219389204|NCT04458857|DRUG|Placebo|Matching placebo
219389205|NCT00960817|DRUG|Statin, aspirin|
219389206|NCT00960817|DRUG|Dipyridamole|
219389207|NCT00232037|DRUG|Tegaserod|
219389208|NCT00203346|PROCEDURE|Greater Occipital Nerve Block|
219389209|NCT04169607|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
219389210|NCT03685656|OTHER|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
219389211|NCT03685656|OTHER|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
219389212|NCT03515187|DRUG|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
219389213|NCT03515187|DRUG|0.1% sodium bromide solution|one to two drops in eye, twice per day
219389214|NCT03515187|OTHER|Meibomian gland massage|Physiotherapy
219389215|NCT03515187|OTHER|Placebo|Vehicle
219389216|NCT05572476|DRUG|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
219389217|NCT05572476|DRUG|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
219389218|NCT04618705|BEHAVIORAL|Smoking Cessation|Participants will start a smoking cessation program.
219389219|NCT04868240|BEHAVIORAL|Concurrent training program|"The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet."
219389220|NCT02806401|DEVICE|landmark|
219389221|NCT02806401|DEVICE|US_Ax|
219389222|NCT00968344|DIETARY_SUPPLEMENT|Leucine|3-4g Leucine added to daily meals
219389223|NCT00968344|DIETARY_SUPPLEMENT|Alanine|Powered amino acid
219389224|NCT03368404|DEVICE|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
219389225|NCT03368404|DEVICE|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
219389226|NCT02983292|DEVICE|PyroTITAN™ HRA|Humeral Resurfacing
219389227|NCT00964795|DRUG|Intravitreal Aflibercept Injection 2mg|
219389228|NCT03949673|DRUG|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
219389229|NCT03949673|DRUG|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
219389230|NCT03949673|DRUG|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
219389231|NCT03949673|DRUG|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
219389232|NCT03949673|DRUG|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
219389233|NCT01144273|PROCEDURE|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
219389234|NCT01328873|OTHER|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
219389235|NCT04399278|DIAGNOSTIC_TEST|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
219389236|NCT01870492|DRUG|Activase|Patients treated with Activase
219389237|NCT01870492|DEVICE|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
219389238|NCT02471963|DRUG|Empagliflozin|
219389239|NCT02471963|DRUG|Placebo|
219389240|NCT00586690|DEVICE|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
219389241|NCT00586690|PROCEDURE|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
219389242|NCT06811805|DEVICE|RenalGuard Therapy|RenalGuard Therapy
219389243|NCT06811805|OTHER|Standard of Care (SOC)|Standard of care
219389244|NCT01073189|DRUG|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
219389245|NCT01073189|DRUG|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
219389246|NCT03670173|DRUG|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
219389247|NCT00857246|DRUG|Cetuximab|
219389248|NCT00857246|DRUG|Irinotecan|
219389249|NCT00857246|DRUG|Cisplatin|
219389250|NCT00857246|PROCEDURE|Surgery|
219389251|NCT00857246|DRUG|5-FU|
219389252|NCT00857246|RADIATION|Radiation|
219389253|NCT00098059|DRUG|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
219389254|NCT02167269|DEVICE|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
219389255|NCT06604325|DRUG|Tranexamic acid injection|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
219389256|NCT06604325|DRUG|Placebo|All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
219389257|NCT04612088|BEHAVIORAL|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
219389258|NCT00686751|DRUG|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
219389259|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
219389260|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
219389261|NCT02957773|BEHAVIORAL|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
219389262|NCT02957773|BEHAVIORAL|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
219389263|NCT02957773|BEHAVIORAL|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
219389264|NCT02957773|BEHAVIORAL|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
219389265|NCT02786862|OTHER|independent ventilation|comparison conventional and independent 1:1 ventilation
219389266|NCT05396118|DRUG|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
219389267|NCT05396118|DRUG|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
219389268|NCT05396118|PROCEDURE|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
219389269|NCT02711371|OTHER|fMRI|
219389270|NCT06143384|DEVICE|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
219389271|NCT01784471|DEVICE|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
219389272|NCT02803502|DEVICE|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
219389273|NCT02803502|DEVICE|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
219389274|NCT02803502|DEVICE|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
219389275|NCT05612997|OTHER|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
219389276|NCT00964418|DRUG|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
219389277|NCT00964418|DRUG|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
219389278|NCT06346795|OTHER|High-filling flowable dental composite|Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
219389279|NCT00133744|DIETARY_SUPPLEMENT|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
219389280|NCT00133744|DIETARY_SUPPLEMENT|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
219389281|NCT00133744|DIETARY_SUPPLEMENT|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
219389282|NCT02127762|BEHAVIORAL|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
219389283|NCT02104180|DEVICE|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
219389284|NCT02104180|DEVICE|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
219389285|NCT03879590|DRUG|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
219389286|NCT03879590|DRUG|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
219389287|NCT01524289|DRUG|Anacetrapib|One oral tablet, orally once daily for 52 weeks
219389288|NCT01524289|DRUG|Placebo|One oral tablet once daily for 52 weeks
219389289|NCT03400293|OTHER|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
219389290|NCT03400293|OTHER|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
219389291|NCT03400293|OTHER|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
219389292|NCT03400293|OTHER|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
219389293|NCT03400293|OTHER|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
219389294|NCT03400293|OTHER|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
219389295|NCT01642537|DEVICE|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
219389296|NCT00949338|PROCEDURE|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
219389297|NCT06292312|OTHER|Craniosacral therapy|Craniosacral therapy is defined as an alternative, massage-like treatment approach using gentle manual force to address somatic dysfunctions of the head and the rest of the body.
219389298|NCT06292312|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises. Spasticity inhibition Balance and coordination exercises Walking training Stabilization exercises Breathing exercises
219389299|NCT01595204|PROCEDURE|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
219389300|NCT03901378|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
219389301|NCT02704429|DRUG|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
219389302|NCT06207344|DRUG|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
219389303|NCT06207344|DRUG|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
219389304|NCT03048448|DRUG|Fevipiprant|Single 450mg dose
219389305|NCT02490540|DRUG|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
219389306|NCT02490540|DRUG|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
219389307|NCT02490540|DRUG|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
219389308|NCT00392873|BEHAVIORAL|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
219389309|NCT02163369|DRUG|Peppermint and Lavender Essential Oils|
219389310|NCT01125891|DRUG|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
219389311|NCT01125891|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
219389312|NCT03385356|DRUG|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
219389313|NCT01821677|DRUG|Danazol Capsules|
219389314|NCT01821677|DRUG|Placebo|
219389315|NCT01188018|BEHAVIORAL|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
219389316|NCT01188018|BEHAVIORAL|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
219389317|NCT01188018|BEHAVIORAL|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
219389318|NCT02627950|DRUG|Morphinhydrochloricum|5 mg morphine intravenously
219389319|NCT02627950|DRUG|Metoclopramide|10 mg MCP intravenously
219389320|NCT02627950|DRUG|Ticagrelor|180 mg ticagrelor orally
219389321|NCT02627950|DRUG|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
219389322|NCT02773992|BEHAVIORAL|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
219389323|NCT05084989|BIOLOGICAL|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
219389324|NCT05084989|BIOLOGICAL|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
219001253|NCT05407935|BEHAVIORAL|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
219001254|NCT05501730|DIAGNOSTIC_TEST|Quantra QPlus System|Coagulation monitoring system
219001255|NCT03524898|DRUG|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
219001256|NCT03524898|DRUG|gemcitabine|1000 mg/m2
219389325|NCT05084989|BIOLOGICAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
219389326|NCT05084989|BIOLOGICAL|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
219389327|NCT04102774|DEVICE|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
219389328|NCT06674382|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|"This is a single-arm study in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.~Pre-transplant Evaluation:~Evaluation includes status of primary Disease, donor specific antibodies (DSA), organ function (assessments for heart, liver, lungs, kidneys, and the nervous system), and Spleen size.~Transplantation Protocol:~Conditioning Regimen:~Dac/TT/Bu/Flu/ATG regimen:~Decitabine 100 mg/m², on day -12. Thiotepa (TT) 5 mg/kg/day, on days -11 and -10. Busulfan 0.8 mg/kg body weight, every 6 hours, on days -8 to -6. Fludarabine 30 mg/m², once daily, on days -6 to -2. Anti-thymocyte globulin (ATG) 2.5 mg/kg body weight, once daily, on days -5 to -2.~Transplant Donor: Haploidentical donor. GVHD (Graft-versus-Host Disease) Prophylaxis Regimen: Cyclosporine, mycophenolate mofetil, and short-course methotrexate for GVHD prevention.~Graft:~Target MNC (Mononuclear Cells): 6-8 × 10⁸/kg. Target CD34+ stem cells: 5 × 10⁶/kg"
219389329|NCT07013175|PROCEDURE|Choosing wisely protocol|Se arm description
219389330|NCT07030647|DRUG|Bupivacaine 0.25%|At the end of gynecologic laparoscopic surgery and prior to trocar removal, 40 mL of Bupivacaine 0.25% is instilled intraperitoneal under direct vision to evaluate its analgesic effect.
219389331|NCT07030647|DRUG|Bupivacaine 0.25%|Before trocar insertion in gynecologic laparoscopic surgery, 5 mL of Bupivacaine 0.25% is infiltrated subcutaneously at each trocar port site to assess its effect on postoperative pain.
219389332|NCT05606939|DEVICE|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
219389333|NCT05135052|DEVICE|Rhenium-SCT|Rhenium-SCT irradiation device
219389334|NCT00960557|DRUG|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
219389335|NCT06843317|BIOLOGICAL|Candidate vaccine, SCB-1019T|SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.
219389336|NCT06843317|BIOLOGICAL|AREXVY|positive comparator
219389337|NCT06843317|OTHER|placebo|Placebo Comparator
219389338|NCT00907738|DRUG|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
219389339|NCT06940401|DRUG|JS111 capsules (AP-L1898)|In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. After all subjects have completed at least 21 days observation following the first dose, the Safety Monitoring Committee (SMC) will review safety and pharmacokinetic data to make decisions. Phase II will continue enrollment at the RP2D dose level until approximately 30 subjects have been treated at that dose.
219389340|NCT03366311|PROCEDURE|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
219389341|NCT04912128|DRUG|Anlotinib|"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
219389342|NCT06944925|DRUG|BBT002|BBT002 will be administered.
219389343|NCT06944925|DRUG|Placebo|Placebo will be administered.
219389344|NCT06945627|OTHER|This research doesn't involve any kind of intervention on the study participants|This research doesn't involve any kind of intervention on the study participants
219389345|NCT05680220|DEVICE|Neurostimulation System (NSS): Active Setting|Exposure to the active device for 1 hour a day for 6 weeks
219389346|NCT05680220|DEVICE|Neurostimulation System (NSS): Sham Setting|Exposure to the sham device for 1 hour a day for 6 weeks
219389347|NCT00288470|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
219389348|NCT01089725|BIOLOGICAL|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
219389349|NCT01089725|BIOLOGICAL|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
219389350|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
219389351|NCT01089725|BIOLOGICAL|Placebo IV|1 ml placebo administered IV every 8 weeks
219389352|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
219389353|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
219389354|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
219389355|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
219389356|NCT01089725|BIOLOGICAL|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
219389357|NCT01089725|BIOLOGICAL|Placebo SC|1ml placebo administered SC every 8 weeks
219389358|NCT06499259|OTHER|Mandala coloring|Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
219389359|NCT02858193|DRUG|SCMC-lys powder 1.35 g|"Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments."
219389360|NCT02858193|DRUG|Fluifort® syrup|"Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments."
219389361|NCT04121910|DRUG|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
219389362|NCT04121910|DRUG|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
219389363|NCT05366608|DIAGNOSTIC_TEST|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL\_.6 were estimated for all participants by ELISA.
219389364|NCT04885049|DRUG|Racecadotril|Anti secretary
219389365|NCT04885049|DRUG|DiaResQ Children's Powder for Suspension|oral immunoglobulins
219389366|NCT00662870|BIOLOGICAL|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
219389367|NCT00662870|BIOLOGICAL|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
219389368|NCT05858411|PROCEDURE|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
219389369|NCT05858411|PROCEDURE|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
219389370|NCT05858411|PROCEDURE|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
219389371|NCT05751005|DIETARY_SUPPLEMENT|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
219389372|NCT00922545|OTHER|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
219389373|NCT03741881|OTHER|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
219389374|NCT00883194|DRUG|PRF-108|Ropivacaine
219389375|NCT00883194|DRUG|Placebo|PRF-108 Placebo
219389376|NCT00883194|DRUG|Ropivacaine|Solution
219389377|NCT00883194|DRUG|PRF-110|
219389378|NCT01582282|DIETARY_SUPPLEMENT|placebo|fiber-free placebo
219389379|NCT01582282|DIETARY_SUPPLEMENT|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
219389380|NCT01582282|DIETARY_SUPPLEMENT|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
219389381|NCT03920852|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
219389382|NCT01812304|OTHER|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
219389383|NCT01812304|OTHER|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
219389384|NCT02076672|DRUG|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
219389385|NCT05782218|DIETARY_SUPPLEMENT|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
219389386|NCT05782218|DIETARY_SUPPLEMENT|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
219389387|NCT05280015|DIETARY_SUPPLEMENT|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
219389388|NCT05280015|OTHER|placebo|placebo add-on venlafaxine
219389389|NCT01486316|DEVICE|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
219389390|NCT01486316|OTHER|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
219389391|NCT03968861|DRUG|Xenon|Inhaled xenon gas given via purposely designed ventilator
219389392|NCT00112151|DRUG|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
219389393|NCT00112151|BEHAVIORAL|Resistance Training|Weight training 45-60 minutes 3 times per week
219389394|NCT00112151|DRUG|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
219389395|NCT00112151|DRUG|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
219389396|NCT00830453|PROCEDURE|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
219389397|NCT01990599|OTHER|Nasopharyngeal Tube|
219389398|NCT02137434|OTHER|Dietary calcium|Dietary calcium from skimmed milk
219389399|NCT02137434|DIETARY_SUPPLEMENT|Supplementary calcium|Supplementary calcium from calcium carbonate
219389400|NCT06447181|DEVICE|3D visualization technology ; ICG fluorescence technology .|"Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety."
219389401|NCT02717767|OTHER|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
219389402|NCT03020810|DRUG|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
219389403|NCT02031380|DEVICE|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
219389404|NCT00296348|DRUG|tacrolimus|immunosuppression
219389405|NCT00296348|DRUG|mycophenolate mofetil|oral
219389406|NCT00296348|DRUG|daclizumab|oral
219389407|NCT00296348|DRUG|steroids|oral
219389408|NCT03177135|DEVICE|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
219389409|NCT05645666|BEHAVIORAL|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
219389410|NCT00664274|BEHAVIORAL|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
219389411|NCT00664274|GENETIC|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
219389412|NCT06554457|DRUG|Multimodal analgesia with oral strong opioids|Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
219389413|NCT04713917|DEVICE|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
219389414|NCT04713917|DEVICE|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
219389415|NCT04713917|DEVICE|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
219389416|NCT02175667|PROCEDURE|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
219389417|NCT00004154|DRUG|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
219389418|NCT00004154|OTHER|Placebo|Two placebo capsules for 25 days of 28 day cycle.
219389419|NCT01638689|DRUG|Escitalopram|20 mg p.o.
219389420|NCT04389606|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
219001257|NCT04983654|DIAGNOSTIC_TEST|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment"
219389421|NCT04389606|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
219389422|NCT02495077|BIOLOGICAL|Infliximab|A single dose, of 3mg/kg infusion
219389423|NCT02495077|DRUG|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
219389424|NCT02495077|DRUG|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
219389425|NCT02495077|DRUG|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
219389426|NCT02495077|BIOLOGICAL|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
219389427|NCT02495077|DRUG|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form"
219389428|NCT02495077|DRUG|Loratadine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
219389429|NCT02495077|BIOLOGICAL|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
219389430|NCT02495077|DRUG|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
219389431|NCT02495077|DRUG|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
219389432|NCT01176396|OTHER|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
219389433|NCT01176396|OTHER|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
219389434|NCT00872716|DRUG|Quetiapine XR|100 mg single-dose Quetiapine XR
219389435|NCT00872716|OTHER|Placebo|Placebo
219389436|NCT04297384|OTHER|Informational Intervention|Receive standard chemotherapy educational materials
219389437|NCT04297384|OTHER|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
219389438|NCT04297384|OTHER|Quality-of-Life Assessment|Ancillary studies
219389439|NCT04297384|OTHER|Survey Administration|Complete surveys
219389440|NCT02013934|DIETARY_SUPPLEMENT|Probiotic|
219389441|NCT02013934|DIETARY_SUPPLEMENT|Placebo|
219389442|NCT04898907|DRUG|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
219389443|NCT04898907|DRUG|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
219389444|NCT04898907|DRUG|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
219389445|NCT04898907|DRUG|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
219389446|NCT02742649|DRUG|Fixed Combination|Continuous elution from the ocular insert.
219389447|NCT02742649|DRUG|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
219389448|NCT02742649|DRUG|Timolol|Continuous elution from the ocular insert. This is an active control arm.
219389449|NCT02742649|DEVICE|Placebo Segment|One segment of placebo (no drug product)
219389450|NCT02742649|DRUG|Timolol 0.5%|0.5% timolol drops twice daily.
219389451|NCT01465737|OTHER|Histologic types|evaluate survival among different histologic types
219389452|NCT03959540|DRUG|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
219389453|NCT03959540|DRUG|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
219389454|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
219389455|NCT05127096|DIAGNOSTIC_TEST|FirstSight blood test|FirstSight blood test for colorectal cancer screening
219389456|NCT00001761|DRUG|Interleukin-10|
219389457|NCT02850198|DEVICE|scalp electroacupuncture|
219389458|NCT02850198|DEVICE|sham scalp electroacupuncture|
219389459|NCT00244218|DRUG|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
219389460|NCT01709799|BEHAVIORAL|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
219389461|NCT01709799|BEHAVIORAL|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
219389462|NCT01709799|BEHAVIORAL|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
219389463|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
219389464|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
219389465|NCT00435539|DRUG|Sham Comparator|Intravitreal sham injection
219389466|NCT00795626|BEHAVIORAL|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
219389467|NCT01248806|RADIATION|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
219389468|NCT02162875|DRUG|Praziquantel|Six different treatment strategies with praziquantel
219389469|NCT00970203|BIOLOGICAL|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
219389470|NCT00970203|BIOLOGICAL|DC1 vaccine|3-5 x 10e6 cells total
219389471|NCT00417612|DRUG|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
219389472|NCT00417612|OTHER|Placebo|Placebo sugar pill
219389473|NCT02268565|DRUG|Aspirin|81mg aspirin daily at bedtime over a 2 week period
219389474|NCT02268565|DRUG|Placebo|pill that looks like aspirin without the effects of aspirin
219389475|NCT01094340|DRUG|Thalidomide|fixed dose over 8 clinic visits
219389476|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
219389477|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
219389478|NCT03849469|BIOLOGICAL|XmAb®22841|Monoclonal bispecific antibody
219389479|NCT03849469|BIOLOGICAL|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
219389480|NCT03701165|DEVICE|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
219389481|NCT00224107|DRUG|Silodosin|8 mg daily for 12 weeks
219389482|NCT00224107|OTHER|Placebo|1 capsule daily for 12 weeks
219389483|NCT05431582|DRUG|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
219389484|NCT05431582|DRUG|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
219389485|NCT05431582|DRUG|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
219389486|NCT06382493|DRUG|Tegoprazan-containing sequential H. pylori eradication therapy|tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
219389487|NCT06382493|DRUG|Esomeprazole-containing sequential H. pylori eradication therapy|Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
219389488|NCT00685178|DRUG|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
219389489|NCT00685178|BEHAVIORAL|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
219001258|NCT04983654|DIAGNOSTIC_TEST|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks"
219389490|NCT00685178|DRUG|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
219389491|NCT04076124|DEVICE|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
219389492|NCT04076124|DEVICE|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
219389493|NCT04076124|DEVICE|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
219389494|NCT03247907|DEVICE|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
219389495|NCT03247907|DEVICE|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
219389496|NCT03247907|DEVICE|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
219389497|NCT03247907|DEVICE|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
219389498|NCT03247907|DEVICE|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
219389499|NCT03247907|DEVICE|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
219389500|NCT03247907|DEVICE|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
219389501|NCT03247907|DEVICE|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
219389502|NCT06512766|DRUG|Hydroxychloroquine|Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
219389503|NCT06512766|DRUG|Methotrexate|This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
219389504|NCT06512766|DRUG|Cyclosporine A|Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
219389505|NCT06512766|DRUG|Retinoids|This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
219389506|NCT06056739|DEVICE|Alio platform|Remote monitoring platform
219389507|NCT00077623|DRUG|epoetin alfa or beta|iv 3 times weekly, as prescribed
219389508|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
219389509|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
219389510|NCT00974077|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
219389511|NCT00974077|OTHER|Waiting List Control|Patients receive MBCT with a delay of 6 months.
219389512|NCT03378401|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
219389513|NCT03378401|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
219389514|NCT01240993|BEHAVIORAL|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
219389515|NCT01240993|BEHAVIORAL|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
219389516|NCT06020976|DIAGNOSTIC_TEST|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
219389517|NCT02412644|DRUG|apremilast|
219389518|NCT04220866|DRUG|Ulevostinag|IT injection
219389519|NCT04220866|BIOLOGICAL|Pembrolizumab|IV infusion
219389520|NCT05187338|DRUG|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
219389521|NCT04804956|PROCEDURE|Stool sample|One stool sample will be taken at baseline for microbiota characterization
219389522|NCT04804956|PROCEDURE|Rectal mucosa sample|Characterization of tissue microbiota before and after surgery.
219389523|NCT04804956|PROCEDURE|Mesorectal adipose tissue sample|Characterization of tissue microbiota and dysfunction
219389524|NCT04804956|PROCEDURE|Subcutaneous adipose tissue sample|Characterization of tissue microbiota and dysfunction
219001259|NCT06236178|DRUG|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
219001260|NCT06236178|DRUG|Autologous Blood|1 ml of autologous venous blood
219389525|NCT04804956|PROCEDURE|Visceral adipose tissue sample|Characterization of tissue microbiota and dysfunction
219389526|NCT04804956|BEHAVIORAL|Dietary assessment|Dietary assessment will be taken at baseline
219389527|NCT02138110|DEVICE|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
219389528|NCT03969433|DEVICE|TMSi Porti|Data collections
219389529|NCT03969433|DEVICE|Bloomlife sensor|Data collections
219389530|NCT06365333|PROCEDURE|Fluoroscopic-guided air-enema reduction (FGAR)|A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
219389531|NCT02947451|OTHER|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
219389532|NCT02947451|OTHER|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
219389533|NCT00882713|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
219389534|NCT06956521|DRUG|Magnesium sulfate|Following MT and IA injection of MgSO4, patients will also receive a continuous infusion of 16g MgSO4 diluted in 240 ml of 0.9% normal saline, infusing at a rate of 10 ml per hour for 24 hours.
219389535|NCT00270920|BEHAVIORAL|Lactation counseling|
219389536|NCT04647136|DIAGNOSTIC_TEST|Fertility Health Screening|Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.
219389537|NCT04647136|BEHAVIORAL|Fertility Awareness Tools|Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
219389538|NCT05523362|DEVICE|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
219389539|NCT05477771|PROCEDURE|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
219389540|NCT02971644|DEVICE|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
219389541|NCT01868087|DIETARY_SUPPLEMENT|Boost Plus®|
219389542|NCT01868087|DIETARY_SUPPLEMENT|Impact Advanced Recovery®|
219389543|NCT03515538|DRUG|RRx-001|RRx-001 for injection
219389544|NCT03515538|DRUG|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
219760968|NCT05993793|DEVICE|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
219001261|NCT06236178|DRUG|Local Anesthetic|1 ml of 2% prilocaine HCl
219188785|NCT06830837|OTHER|Mandala coloring|Eight pre-selected mandala drawings will be printed on separate A4 (21.0 cm × 29.7 cm) papers. After the patients are admitted to the hospital for the surgery process, the patients in the experimental group will be provided with at least 2 hours of mandala coloring per day until the day of their surgery. No intervention will be applied to the control group patients. Studies examining the effect of mandala coloring on reducing psychological symptoms have reported that using a circularly designed pattern in the mandala template, instead of a square design, has a greater effect on symptom management. Therefore, a circular-shaped mandala template will be used. Each participant will be provided with mandala coloring sheets and 12 colored pencils (red, orange, yellow, pink, light green, green, sky blue, blue, purple, brown, reddish-brown, and black) by the researcher.
219188786|NCT05622968|DEVICE|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
219389545|NCT03515538|RADIATION|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
219389546|NCT04952012|DRUG|LT4|LT4 is used to improve the thyroid function of pregnant women.
219389547|NCT01972425|OTHER|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
219389548|NCT00784069|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
219389549|NCT05418608|DRUG|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
219389550|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
219389551|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
219389552|NCT01954628|DRUG|AQX-1125|Synthetic SHIP1 activator
219389553|NCT01954628|DRUG|Placebo|Placebo control
219389554|NCT02740153|OTHER|No Intervention Given|
219389555|NCT00045838|DRUG|VCR-HIVDNA006-00-VP|
219389556|NCT00950352|DRUG|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
219389557|NCT00950352|DRUG|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
219389558|NCT04493710|DIAGNOSTIC_TEST|Sarcopenia estimation|Analysis of pre-existing CT imaging
219389559|NCT06145490|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 250 mg, oral intake
219389560|NCT06145490|DRUG|Placebo|Placebo capsule, oral intake
219389561|NCT00306436|PROCEDURE|comprehensive management|
219389562|NCT00577330|DIETARY_SUPPLEMENT|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
219389563|NCT02279329|OTHER|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
219389564|NCT00358189|DEVICE|Deep Brain Stimulation|
219389565|NCT00598962|DRUG|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
219389566|NCT00598962|DRUG|Rifabutin/rifampin|
219389567|NCT02352246|PROCEDURE|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
219389568|NCT02352246|PROCEDURE|Physical activity programs high intensity intermittent exercise (HIIE)|
219389569|NCT01489787|PROCEDURE|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
219389570|NCT01489787|PROCEDURE|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
219389571|NCT01489787|PROCEDURE|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
219389572|NCT00471380|DRUG|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
219389573|NCT00471380|DRUG|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
219389574|NCT03224962|DEVICE|fluorescence camera|drug - diagnostic test
219389575|NCT04001686|OTHER|incidence aplastic anemia|Ambispective chart review
219389576|NCT06326151|BEHAVIORAL|Interdisciplinary Psychoeducational Programme|This intervention is based on the principle of complementing and integrating both disciplines in order to meet the psychological needs of family carers and to train them in knowledge and strategies aimed at the correct performance of activities of daily living in order to promote the maximum autonomy and functionality of dependent people with cognitive impairment, and that this favours discharge, self-care, improvement of the affective state and quality of life of family carers.
219389577|NCT06326151|BEHAVIORAL|Health Education Programme|Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.
219389578|NCT01674543|OTHER|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
219389579|NCT01674543|OTHER|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
219389580|NCT01674543|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
219389581|NCT03711071|OTHER|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
219389582|NCT04992832|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
219389583|NCT04992832|OTHER|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
219389584|NCT03174743|PROCEDURE|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
219389585|NCT03174743|PROCEDURE|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
219389586|NCT03174743|PROCEDURE|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
219389587|NCT03174743|PROCEDURE|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
219389588|NCT05648838|DEVICE|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
219389589|NCT01566123|RADIATION|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
219389590|NCT01566123|RADIATION|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
219389591|NCT00192335|BIOLOGICAL|CAIV-T|
219389592|NCT00192335|BIOLOGICAL|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
219389593|NCT00192335|BIOLOGICAL|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
219389594|NCT02353078|DRUG|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
219389595|NCT02353078|PROCEDURE|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
219389596|NCT02353078|DEVICE|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
219389597|NCT01419249|OTHER|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
219389598|NCT01295905|DEVICE|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
219389599|NCT01295905|DEVICE|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
219389600|NCT05404854|OTHER|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
219389601|NCT05404854|OTHER|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
219389602|NCT05404854|OTHER|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
219389603|NCT05404854|OTHER|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
219389604|NCT03204227|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
219389605|NCT03204227|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
219389606|NCT06215339|BEHAVIORAL|diet therapy training|diet education
219389607|NCT03140254|DRUG|Chlorhexidine gluconate|
219389608|NCT03140254|DRUG|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
219389609|NCT03140254|DRUG|Placebo|
219389610|NCT06639347|DRUG|SHR-A2102|SHR-A2102
219001262|NCT04185545|BIOLOGICAL|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
219001263|NCT04185545|OTHER|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
219389611|NCT06639347|DRUG|Adebrelimab injection|Adebrelimab injection
219389612|NCT06639347|DRUG|SHR-8068 injection|SHR-8068 injection
219389613|NCT00640783|BEHAVIORAL|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
219389614|NCT00640783|BEHAVIORAL|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
219760969|NCT06127433|DRUG|Insulin Glargine|Insulin Glargine
219760970|NCT06127433|DRUG|Metformin|Metformin
219760971|NCT06127433|DRUG|Dapagliflozin|Dapagliflozin
219760972|NCT06127433|DRUG|Insulin aspart|Insulin aspart
219389615|NCT00722605|PROCEDURE|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
219389616|NCT05624255|OTHER|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
219389617|NCT06178510|DEVICE|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
219389618|NCT06298773|OTHER|Spatial analysis of paraffin samples from solid tumors|The intervention involves the collection of tumour samples included in paraffin present in the pathological anatomy archive or requested to external archives for samples older than 2003 and the subsequent multiparametric spatial analysis of the main populations of the microenvironment tumor.
219389619|NCT00676481|BEHAVIORAL|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
219389620|NCT05805371|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
219389621|NCT05805371|PROCEDURE|Biopsy|Undergo tumor biopsy
219389622|NCT05805371|PROCEDURE|Biospecimen Collection|Undergo blood, stool, and urine sample collection
219389623|NCT05805371|PROCEDURE|Bone Scan|Undergo bone scan
219389624|NCT05805371|PROCEDURE|Computed Tomography|Undergo CT scan
219389625|NCT05805371|RADIATION|External Beam Radiation Therapy|Undergo radiation
219389626|NCT05805371|PROCEDURE|Leukapheresis|Undergo leukapheresis
219389627|NCT05805371|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
219389628|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
219389629|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
219389630|NCT01496573|OTHER|laboratory biomarker analysis|Correlative studies
219389631|NCT03842709|DRUG|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
219389632|NCT03842709|OTHER|Placebo|Administration of placebo
219389633|NCT06092398|OTHER|PRP and PRFG in treatment of anal fistula|The tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place of fistula
219389634|NCT04729530|DEVICE|Dyson Pure Cool - Active Purifier|Free standing air purifier
219389635|NCT04729530|DEVICE|Dyson Pure Cool - Placebo purifier|Placebo air purifier
219389636|NCT00791128|DEVICE|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
219389637|NCT03300453|DRUG|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
219389638|NCT01414088|OTHER|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
219389639|NCT01414088|OTHER|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
219389640|NCT01414088|OTHER|glucose 5%|infusion, 23 ml/kg, during 50 minutes
219389641|NCT05926089|DIAGNOSTIC_TEST|Blood sampling|blood sampling to measure APR
219389642|NCT06151756|BEHAVIORAL|Video Supported Mobile Application|The video-supported mobile application was developed to be interactively utilized on smartphones. T
219389643|NCT06051253|DRUG|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
219389644|NCT06051253|DRUG|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
219389645|NCT05043610|BIOLOGICAL|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
219389646|NCT05043610|OTHER|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
219389647|NCT06372639|DEVICE|Trans-Cranial Magnetic Stimulation|Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
219389648|NCT01011205|DRUG|Advagraf|Capsule
219389649|NCT01011205|DRUG|Mycophenolate Mofetil|Solution for infusion
219389650|NCT01011205|DRUG|Basiliximab|IV infusion
219389651|NCT01011205|DRUG|Corticosteroids|IV bolus
219389652|NCT05085002|DRUG|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
219389653|NCT01047787|OTHER|Polysomnography|examination for sleep disorders
219389654|NCT01409317|DEVICE|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
219389655|NCT01409317|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
219389656|NCT02517879|OTHER|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
219389657|NCT02517879|OTHER|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
219389658|NCT01089855|DRUG|Carbamazepine|
219389659|NCT00308620|DRUG|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
219389660|NCT00308620|DRUG|Placebo|Placebo once daily for 8 weeks
219389661|NCT02220374|OTHER|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
219389662|NCT05545397|DRUG|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
219389663|NCT05545397|DEVICE|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
219389664|NCT05631951|PROCEDURE|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
219188787|NCT05622968|DRUG|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
219389665|NCT05631951|PROCEDURE|bone transport|Debridement done then external fixator was applied then bone transport started.
219389666|NCT00628810|BIOLOGICAL|bevacizumab|
219389667|NCT00628810|DRUG|fluorouracil|
219389668|NCT00628810|DRUG|irinotecan hydrochloride|
219389669|NCT00628810|DRUG|leucovorin calcium|
219389670|NCT02757547|DEVICE|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
219389671|NCT02757547|DEVICE|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
219389672|NCT04708990|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
219389673|NCT02075164|DIETARY_SUPPLEMENT|Fructose|High oral Fructose challenge (150g per day for 56 days)
219389674|NCT02075164|DIETARY_SUPPLEMENT|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
219389675|NCT00475449|PROCEDURE|percutaneous coronary intervention|
219389676|NCT00475449|PROCEDURE|coronary artery bypass grafting|
219389677|NCT05308147|DIETARY_SUPPLEMENT|First Reference product|Dextrose (containing 25 grams of carbohydrates)
219389678|NCT05308147|DIETARY_SUPPLEMENT|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
219389679|NCT05308147|DIETARY_SUPPLEMENT|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
219389680|NCT05308147|DIETARY_SUPPLEMENT|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
219389681|NCT05308147|DIETARY_SUPPLEMENT|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
219389682|NCT05308147|DIETARY_SUPPLEMENT|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
219389683|NCT03379350|PROCEDURE|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
219389684|NCT03317808|DIAGNOSTIC_TEST|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
219389685|NCT02426307|PROCEDURE|TAVR|TAVR: Transcatheter Aortic Valve Replacement
219389686|NCT02426307|PROCEDURE|SAVR|SAVR: surgical Aortic Valve Replacement
219389687|NCT05466435|OTHER|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
219389688|NCT05466435|OTHER|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
219389689|NCT04990570|OTHER|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
219389690|NCT03399890|DIAGNOSTIC_TEST|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
219389691|NCT02162979|DRUG|sildenafil|sildenafil 50mg BID for 2 weeks
219389692|NCT02162979|DRUG|Placebo|
219389693|NCT03386708|PROCEDURE|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
219389694|NCT03386708|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2 \* 10\^7 cells (2ml)
219389695|NCT00161317|BEHAVIORAL|Living with Hope Program|
219389696|NCT04100525|BEHAVIORAL|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
219389697|NCT03289715|DEVICE|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
219389698|NCT01644045|DEVICE|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
219389699|NCT02672956|PROCEDURE|Ten mm trocar|
219389700|NCT01738399|DIETARY_SUPPLEMENT|Coffee|
219389701|NCT01738399|DIETARY_SUPPLEMENT|Placebo|
219389702|NCT01357239|DRUG|AFQ056|
219389703|NCT01357239|DRUG|Placebo|
219389704|NCT04439734|DEVICE|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
219389705|NCT04901897|DEVICE|kalifilcon A|kalifilcon A daily disposable contact lens
219389706|NCT04901897|DEVICE|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
219389707|NCT04901897|DEVICE|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
219389708|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
219389709|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
219389710|NCT03702933|DIETARY_SUPPLEMENT|D-serine|dosage
219389711|NCT02333838|DRUG|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
219389712|NCT02333838|DRUG|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
219389713|NCT02333838|DRUG|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
219389714|NCT02333838|DRUG|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
219389715|NCT00577590|DRUG|Metformin|Metformin is taken alone
219389716|NCT00577590|DRUG|Rosiglitazone|Rosiglitizone is taken with Metformin
219389717|NCT00577590|DRUG|Lovaza|Lovaza is taken with Metformin
219389718|NCT05755789|DRUG|Loading bolus of cefoxitin|Cefoxitin \[2g\] before incision
219389719|NCT05755789|DRUG|Intermittent cefoxitin|Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
219389720|NCT05755789|DRUG|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
219389721|NCT05755789|DRUG|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
219389722|NCT05755789|DRUG|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
219389723|NCT04516902|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
219389724|NCT04516902|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
219389725|NCT04516902|OTHER|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
219389726|NCT04516902|OTHER|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
219389727|NCT06244186|DIETARY_SUPPLEMENT|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
219389728|NCT06244186|DIETARY_SUPPLEMENT|Placebo|Placebo is provided by TCI CO., Ltd.
219389729|NCT01984814|BIOLOGICAL|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
219389730|NCT04740749|DEVICE|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
219389731|NCT05659615|OTHER|Study will not have intervention|Study will not have intervention
219389732|NCT04850950|DRUG|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
219389733|NCT02280005|DEVICE|WAK Treatment|Hemodialysis with WAK device.
219389734|NCT00609609|PROCEDURE|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
219389735|NCT00609609|DRUG|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
219389736|NCT03170284|DRUG|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
219389737|NCT04575350|GENETIC|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
219389738|NCT00102037|DRUG|eptacog alfa (activated)|
219389739|NCT06046508|OTHER|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
219389740|NCT02446782|DRUG|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
219389741|NCT02446782|OTHER|saline|100 mL normal saline 15-30 minutes before the start of the procedure
219389742|NCT06073314|DIAGNOSTIC_TEST|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
219389743|NCT06073314|DIAGNOSTIC_TEST|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
219389744|NCT01050062|DRUG|Telmisartan 80mg|Combination tablet
219001264|NCT03911804|PROCEDURE|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
219001265|NCT02137174|OTHER|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
219389745|NCT01050062|DRUG|Telmisartan 40mg|Combination tablet
219389746|NCT01050062|DRUG|Hydrochlorothiazide 12.5mg|Combination tablet
219389747|NCT05886192|DRUG|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
219389748|NCT05886192|DRUG|Norepinephrine|norepinephrine
219389749|NCT04084392|OTHER|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
219389750|NCT04084392|OTHER|Usual Care|Referral to an outpatient provider for addiction treatment.
219389751|NCT01525394|DRUG|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
219389752|NCT01525394|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
219389753|NCT01525394|DRUG|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
219389754|NCT05355012|OTHER|5A organizational innovation|"This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
219389755|NCT04652024|DEVICE|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
219389756|NCT00955240|BIOLOGICAL|cetuximab|
219389757|NCT00955240|DRUG|cisplatin|
219389758|NCT00955240|DRUG|fluorouracil|
219389759|NCT00955240|OTHER|laboratory biomarker analysis|
219389760|NCT00955240|RADIATION|radiation therapy|
219389761|NCT03246269|DIAGNOSTIC_TEST|MoCA|
219389762|NCT03196713|BEHAVIORAL|Early Intensive Behavioral Intervention|
219389763|NCT06399081|OTHER|Observational|Observational
219389764|NCT00299377|DRUG|Abciximab i.v.|
219389765|NCT00299377|DRUG|Abciximab i.c.|
219389766|NCT03244371|OTHER|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
219389767|NCT03992235|OTHER|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
219389768|NCT03992235|OTHER|Educational material|Exercise brochure with photos and explanations
219389769|NCT00001081|DRUG|Nitazoxanide|
219389770|NCT05896176|DIAGNOSTIC_TEST|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
219389771|NCT02348047|DEVICE|Hamilton T1|
219389772|NCT00060892|GENETIC|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
219389773|NCT01585389|GENETIC|gene expression analysis|
219389774|NCT01585389|GENETIC|genetic linkage analysis|
219389775|NCT01585389|GENETIC|microarray analysis|
219389776|NCT01585389|OTHER|immunohistochemistry staining method|
219389777|NCT01585389|OTHER|laboratory biomarker analysis|
219389778|NCT00893607|DRUG|NRL001|10mg NRL001 was administered as a slow release suppository
219389779|NCT03280329|OTHER|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
219389780|NCT03280329|OTHER|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
219389781|NCT00670111|DEVICE|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
219389782|NCT03988751|BEHAVIORAL|Ambulation|Variation in ambulatory intensity.
219389783|NCT05123287|DRUG|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
219389784|NCT05861947|DRUG|AUR106|Once or twice daily
219389785|NCT01277146|DRUG|OMP-59R5|IV infusion
219389786|NCT00249561|BEHAVIORAL|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
219389787|NCT00249561|BEHAVIORAL|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
219389788|NCT05651087|DRUG|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
219389789|NCT02849769|DEVICE|Implant of an MR-conditional Tachy device system|
219389790|NCT02623361|DRUG|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
219389791|NCT02623361|DRUG|Sham Block|Sham Block by saline injection
219389792|NCT02220881|DEVICE|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
219389793|NCT02220881|OTHER|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
219389794|NCT00177346|DEVICE|CAS with cerebral protection|
219389795|NCT00177346|DEVICE|CAS without cerebral protection|
219389796|NCT00844883|DRUG|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
219389797|NCT00844883|PROCEDURE|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
219389798|NCT01673061|DRUG|Lidocaine|See associated Arm Description
219389799|NCT01673061|DRUG|Vapocoolant|See associated Arm Description
219389800|NCT03511339|DEVICE|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
219389801|NCT00000960|DRUG|Zidovudine|
219389802|NCT01479049|DRUG|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
219389803|NCT01479049|DRUG|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
219389804|NCT01938170|BIOLOGICAL|FluMist|Subjects receiving Flumist vaccine
219389805|NCT03894540|DRUG|IPN60090|Oral capsules given daily
219389806|NCT03894540|DRUG|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
219389807|NCT03894540|DRUG|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
219389808|NCT03894540|DRUG|IPN60090 single administration|Oral capsules given once
219389809|NCT01588301|BEHAVIORAL|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
219389810|NCT01588301|BEHAVIORAL|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
219389811|NCT01850381|DRUG|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
219389812|NCT01850381|DRUG|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
219188788|NCT06191900|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
219389813|NCT00990015|DRUG|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
219389814|NCT00990015|DRUG|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
219389815|NCT02718846|DRUG|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
219389816|NCT02718846|DRUG|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
219389817|NCT01625169|DRUG|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
219389818|NCT04165265|DEVICE|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
219389819|NCT03000452|DRUG|DARATUMUMAB|DARATUMUMAB
219389820|NCT03000452|DRUG|DURVALUMAB|DURVALUMAB
219389821|NCT02511080|DEVICE|Spot-On|use of active hot measures
219389822|NCT01467739|DEVICE|Ambu ® aScope®|
219389823|NCT01467739|DEVICE|a conventional reusable fiberscope|
219389824|NCT02561377|BEHAVIORAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
219389825|NCT02561377|BEHAVIORAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
219389826|NCT03083951|PROCEDURE|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
219389827|NCT03083951|PROCEDURE|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
219389828|NCT00129714|OTHER|cervical collar|
219389829|NCT00129714|OTHER|physiotherapy|
219389830|NCT01857986|DEVICE|AnapnoGuard 100 control unit|
219389831|NCT05056480|OTHER|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
219389832|NCT01803165|PROCEDURE|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
219389833|NCT00003530|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219001266|NCT00802139|DRUG|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
219188789|NCT05905705|DIAGNOSTIC_TEST|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
219389834|NCT05518591|BEHAVIORAL|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
219389835|NCT00702312|BEHAVIORAL|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
219389836|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
219389837|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
219389838|NCT00537823|DRUG|Cetuximab|
219389839|NCT00537823|DRUG|Bevacizumab|
219389840|NCT00537823|DRUG|Leucovorin|
219389841|NCT00537823|DRUG|Oxaliplatin|
219389842|NCT00537823|DRUG|Fluorouracil|
219389843|NCT03163030|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
219389844|NCT00542698|BEHAVIORAL|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
219389845|NCT06070129|PROCEDURE|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
219389846|NCT02281058|DRUG|Abatacept|self-injected subcutaneous biologic medication
219389847|NCT00401583|DRUG|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
219389848|NCT00401583|DRUG|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
219389849|NCT05041543|DRUG|NTX-101|Eye drops, topical administration
219389850|NCT05041543|DRUG|Placebo|Placebo as eye drops
219389851|NCT03065530|DRUG|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
219389852|NCT03065530|DRUG|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
219389853|NCT03065530|DRUG|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
219389854|NCT03065530|DRUG|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
219389855|NCT02629705|DIETARY_SUPPLEMENT|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
219389856|NCT02629705|DIETARY_SUPPLEMENT|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
219389857|NCT02718677|DRUG|Refacto AF|Observational - Non-Interventional Study
219389858|NCT00852930|PROCEDURE|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
219389859|NCT00852930|PROCEDURE|laser alone|The intervention is therapist administered laser
219389860|NCT00852930|PROCEDURE|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
219389861|NCT00479466|DRUG|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
219001267|NCT00802139|DRUG|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
219389862|NCT00479466|DRUG|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
219389863|NCT00479466|DRUG|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
219389864|NCT00479466|DRUG|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
219389865|NCT03827148|OTHER|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
219389866|NCT00124423|PROCEDURE|Megavoltage CT scan|
219389867|NCT03803215|DRUG|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
219389868|NCT05763940|DIETARY_SUPPLEMENT|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
219389869|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
219389870|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
219389871|NCT02625142|OTHER|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
219389872|NCT00066781|DRUG|gemcitabine hydrochloride|Given IV
219389873|NCT00066781|DRUG|irinotecan hydrochloride|Given IV
219389874|NCT01823653|DEVICE|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
219389875|NCT05901181|BEHAVIORAL|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
219389876|NCT05429684|DRUG|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
219389877|NCT05429684|DRUG|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
219389878|NCT05429684|DRUG|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
219389879|NCT05429684|DRUG|Pyrotinib|Pyroltinib (400mg po qd)
219389880|NCT05429684|DRUG|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
219389881|NCT05429684|DRUG|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
219389882|NCT05429684|DRUG|Everolimus|Everolimus (4mg, po, qd)
219389883|NCT05429684|DRUG|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
219389884|NCT05429684|DRUG|AI|Letrozole (2.5mg, qd).
219389885|NCT05429684|DRUG|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
219389886|NCT02984878|DEVICE|Revanesse Ultra|Nasolabial Fold correction
219389887|NCT06094712|DRUG|CORT125134|CORT125134 150-mg capsule
219389888|NCT02019381|DIETARY_SUPPLEMENT|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
219389889|NCT02019381|DIETARY_SUPPLEMENT|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
219389890|NCT02019381|DIETARY_SUPPLEMENT|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
219389891|NCT03718494|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
219389892|NCT03718494|DIAGNOSTIC_TEST|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
219389893|NCT03718494|DIAGNOSTIC_TEST|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
219389894|NCT03718494|OTHER|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
219389895|NCT00014573|BIOLOGICAL|aldesleukin|
219389896|NCT00014573|BIOLOGICAL|autologous tumor cell vaccine|
219389897|NCT00014573|BIOLOGICAL|filgrastim|
219389898|NCT00014573|BIOLOGICAL|sargramostim|
219389899|NCT00014573|BIOLOGICAL|therapeutic autologous lymphocytes|
219389900|NCT00014573|DRUG|carmustine|
219389901|NCT00014573|DRUG|cisplatin|
219389902|NCT00014573|DRUG|cyclophosphamide|
219389903|NCT00014573|DRUG|paclitaxel|
219389904|NCT00014573|PROCEDURE|autologous bone marrow transplantation|
219389905|NCT00014573|PROCEDURE|conventional surgery|
219389906|NCT00014573|PROCEDURE|peripheral blood stem cell transplantation|
219389907|NCT01252888|DEVICE|iStents|Implantation of two iStents through a small temporal clear corneal incision
219389908|NCT01943279|OTHER|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
219389909|NCT01943279|OTHER|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
219389910|NCT05898503|BEHAVIORAL|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
219389911|NCT05898503|BEHAVIORAL|Resistance training|Resistance training for 12 weeks
219389912|NCT05898503|BEHAVIORAL|Walking exercise|Walking exercise for 12 weeks
219389913|NCT05898503|BEHAVIORAL|Health promotion|Health promotion for 12 weeks
219389914|NCT04990544|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
219389915|NCT04990544|BIOLOGICAL|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
219389916|NCT04990544|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
219389917|NCT04990544|BIOLOGICAL|Placebo|Normal saline solution
219389918|NCT00992303|OTHER|biologic sample preservation procedure|
219389919|NCT00992303|OTHER|medical chart review|
219389920|NCT00992303|OTHER|questionnaire administration|
219389921|NCT06135597|OTHER|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
219389922|NCT03291197|DRUG|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
219389923|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
219389924|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
219389925|NCT05165329|COMBINATION_PRODUCT|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
219389926|NCT00916799|DEVICE|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
219389927|NCT05634590|DRUG|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
219389928|NCT05634590|DRUG|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
219389929|NCT05634590|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
219389930|NCT01401088|DEVICE|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
219389931|NCT05278260|DIETARY_SUPPLEMENT|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
219389932|NCT05278260|DIETARY_SUPPLEMENT|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
219389933|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 35%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
219389934|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 6%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
219389935|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
219389936|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
219389937|NCT06069531|DIETARY_SUPPLEMENT|Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract|Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
219389938|NCT05758038|PROCEDURE|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
219389939|NCT01851096|DRUG|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
219389940|NCT01633060|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
219389941|NCT01633060|DRUG|BKM120|BKM120 100 mg once daily
219389942|NCT01633060|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
219389943|NCT04332549|DRUG|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
219389944|NCT04068883|OTHER|Q collar|An externally-worn medical device that applies mild jugular compression
219389945|NCT04970706|PROCEDURE|ACL reconstruction|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
219389946|NCT03146312|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
219389947|NCT03146312|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
219389948|NCT04881539|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
219389949|NCT05133986|OTHER|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
219389950|NCT05133986|OTHER|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
219389951|NCT05133986|OTHER|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
219389952|NCT05593601|DRUG|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
219389953|NCT01293669|DRUG|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
219389954|NCT01293669|DRUG|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
219389955|NCT05643300|OTHER|Survey|Data collection from participants via questionnaire
219389956|NCT03471910|DRUG|Diosmin|Diosmin 600mg tablet, once daily
219389957|NCT03471910|DRUG|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
219389958|NCT00765583|DRUG|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
219389959|NCT03797443|DRUG|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
219389960|NCT03797443|DRUG|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
219389961|NCT03797443|DRUG|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
219389962|NCT03797443|DRUG|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
219389963|NCT01305369|DRUG|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
219389964|NCT00806117|RADIATION|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
219389965|NCT00806117|OTHER|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
219389966|NCT00806117|OTHER|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
219389967|NCT00900432|OTHER|immunoenzyme technique|
219389968|NCT00900432|OTHER|laboratory biomarker analysis|
219389969|NCT05914272|DRUG|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
219389970|NCT01396525|DEVICE|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
219389971|NCT02742740|BEHAVIORAL|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
219389972|NCT03114969|DEVICE|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
219389973|NCT03114969|DEVICE|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
219389974|NCT03114969|DEVICE|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
219389975|NCT03114969|DEVICE|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
219389976|NCT03114969|DEVICE|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
219389977|NCT03114969|DEVICE|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
219389978|NCT03114969|DEVICE|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
219389979|NCT00027131|BIOLOGICAL|Heat Shock Protein 70-peptide complexes (HSP70)|
219389980|NCT02583750|BEHAVIORAL|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
219389981|NCT02583750|BEHAVIORAL|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
219389982|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
219389983|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
219389984|NCT01158898|DRUG|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
219389985|NCT06130384|DRUG|Use of bromfenac 0.09% to reduce intravitreal injection pain|The eyedrop (bromfenac) will be given to the assigned eye.
219389986|NCT06130384|DRUG|Use of artificial tears to reduce intravitreal injection pain|The eyedrop (artificial tears) will be given to the assigned eye.
219188790|NCT05905705|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
219389987|NCT02924753|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
219389988|NCT02924753|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
219389989|NCT02924753|BIOLOGICAL|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
219389990|NCT02143271|DRUG|KHK7580|Oral administration
219389991|NCT05067660|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
219389992|NCT05067660|RADIATION|Current standard template-based salvage therapy|In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
219389993|NCT03647943|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
219188791|NCT06047808|BEHAVIORAL|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
219389994|NCT03647943|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
219389995|NCT02457897|DRUG|Liothyronine|Oral supplement given every 8 hours
219389996|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
219389997|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
219389998|NCT01176851|DRUG|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
219389999|NCT05362162|PROCEDURE|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
219390000|NCT02232438|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
219390001|NCT05259046|DIETARY_SUPPLEMENT|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
219390002|NCT05259046|DIETARY_SUPPLEMENT|Placebo tablet|One placebo tablet per day
219390003|NCT03134963|OTHER|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
219390004|NCT03134963|OTHER|Blood pressure monitoring|Continuous blood pressure recording
219390005|NCT03134963|OTHER|Heart rate monitoring|Continuous heart rate monitoring
219390006|NCT03134963|OTHER|End tidal CO2 monitoring|Continuous ETCO2 monitoring
219390007|NCT03134963|OTHER|Addenbrooke's cognitive examination|Performance of a memory test
219390008|NCT04962165|DEVICE|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
219390009|NCT05448534|DIAGNOSTIC_TEST|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
219390010|NCT01874782|DEVICE|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
219390011|NCT01743027|DRUG|AL-4943A ophthalmic solution|
219390012|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
219390013|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.1%|
219390014|NCT01743027|DRUG|AL-4943A ophthalmic solution vehicle|
219390015|NCT04098614|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
219390016|NCT04640636|DRUG|Ketamine hydrochloride injection|single IM injection of ketamine hydrochloride 0.5 mg/kg
219390017|NCT04640636|DRUG|Midazolam injection|single IM injection of midazolam 0.06 mg/kg
219390018|NCT06969846|DEVICE|CSN electrode was implanted around tissue including CSN branches|Using a novel surgical approach, a custom electrode was implanted around tissue including CSN branches in anesthetized adults. Following functional mapping, presumed baroafferent fibers were identified via response and stimulated. Outcome measures included change in systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) during and after stimulation using multi-level modeling. Secondarily, dose dependency was examined.
219390019|NCT06970041|DEVICE|Use of NIV during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
219390020|NCT06970041|DEVICE|Use of HFNC during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
219390021|NCT05066815|OTHER|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
219390022|NCT01275248|DRUG|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
219390023|NCT01275248|DRUG|Placebo|Oral tablet to match the experimental interventions
219390024|NCT06972108|DRUG|Caffeine citrate|Caffeine citrate loading at 10 mg/kg, followed by daily maintenance of 5 mg/kg PO
219390025|NCT06972108|OTHER|Saline (NaCl 0,9 %) (placebo)|Saline PO for loading and daily maintenance
219390026|NCT06610630|DIAGNOSTIC_TEST|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications
219390027|NCT06970015|OTHER|No intervention|No intervention, this is an observational study on patients with suspected acute mesenteric ischemia
219390028|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
219390029|NCT02973672|DRUG|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
219390030|NCT00499993|DRUG|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
219390031|NCT05361512|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
219390032|NCT05361512|DEVICE|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
219390033|NCT03305250|DEVICE|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
219390034|NCT00278824|DRUG|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
219390035|NCT00278824|DRUG|Placebo Patch|Placebo patch applied every 3 days for 15 days
219390036|NCT06277661|BEHAVIORAL|MOMI PODS|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
219390037|NCT06277661|BEHAVIORAL|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
219390038|NCT03812016|DEVICE|Feedback-enabled magnetic device|The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode and one sensor, a magnetic actuator, an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the feedback-enabled magnetic device.
219390039|NCT06324097|DIAGNOSTIC_TEST|endocytoscopy|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue.
219390040|NCT03708900|DRUG|LCI699|osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration
219390041|NCT00938548|DRUG|Pregabalin|Pregabalin 75 mg orally
219390042|NCT00938548|DRUG|Vitamin Complex (placebo)|Vitamin Complex orally
219390043|NCT04856761|DRUG|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
219390044|NCT04856761|DRUG|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
219390045|NCT05954754|OTHER|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
219390046|NCT00069121|DRUG|Capecitabine|1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
219390047|NCT00069121|DRUG|Oxaliplatin|130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
219390048|NCT00069121|DRUG|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
219390049|NCT00069121|DRUG|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
219390050|NCT01631162|OTHER|Breath sample in all patients|Breath sample will be collected by a special nylon bag
219390051|NCT00982722|DRUG|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
219390052|NCT00982722|DRUG|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
219390053|NCT02603575|DRUG|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
219390054|NCT02603575|DRUG|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
219390055|NCT02603575|DRUG|Sulfanilamides|1.92g q8h
219390056|NCT05149378|DRUG|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
219390057|NCT00565422|DRUG|Escitalopram|10 mg/day
219390058|NCT02035384|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
219390059|NCT01925521|DRUG|Part1 : OPS-2071|single oral dose under fasted condition
219390060|NCT01925521|DRUG|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
219390061|NCT01925521|DRUG|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
219390062|NCT01925521|DRUG|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
219390063|NCT01832961|DEVICE|Flutter valve exercises|30 minutes of flutter exercises
219390064|NCT01832961|DEVICE|Flutter Sham exercises|30 minutes of flutter-sham exercises
219390065|NCT01832961|DEVICE|Flutter and bronchodilator exercises|Flutter + bronchodilator exercises with an interval of 3 to 5 days
219390066|NCT06219252|DEVICE|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
219390067|NCT06219252|OTHER|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
219390068|NCT04617288|OTHER|Ultrasound Therapy, SNAGs|
219390069|NCT02817607|PROCEDURE|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
219390070|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 5mg
219390071|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 10mg
219390072|NCT05513976|DRUG|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
219390073|NCT05513976|DRUG|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
219390074|NCT06812156|OTHER|Cardiovascular Health Education|This intervention aims to promote healthy behavioral changes at both individual and community levels by supporting education with virtual reality technology.
219390075|NCT05435430|OTHER|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
219390076|NCT02696746|OTHER|Observation|No intervention
219390077|NCT00824694|OTHER|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
219390078|NCT00824694|OTHER|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
219390079|NCT00824694|OTHER|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
219390080|NCT05476692|OTHER|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
219390081|NCT01500174|DEVICE|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
219390082|NCT01500174|DEVICE|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
219390083|NCT00458250|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|
219390084|NCT00458250|DRUG|Busulfan|
219390085|NCT00458250|DRUG|Cyclophosphamide|
219390086|NCT00458250|DRUG|CAMPATH-1H|
219390087|NCT00458250|DRUG|Cyclosporin A|
219390088|NCT00458250|DRUG|Methotrexate|
219390089|NCT03661541|DRUG|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
219390090|NCT01815398|BEHAVIORAL|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
219390091|NCT01815398|BEHAVIORAL|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
219390092|NCT00231478|DRUG|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
219390093|NCT00231478|DRUG|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
219390094|NCT04095416|DEVICE|ACE compression wrap|Bilateral lower extremity ACE compression wraps
219390095|NCT00152373|DRUG|Levetiracetam|
219390096|NCT02330991|DRUG|Temozolomide|
219390097|NCT06656728|OTHER|Blood-based liquid biopsy|Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
219390098|NCT01958567|OTHER|Optical Coherence Tomography|
219390099|NCT01134510|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
219390100|NCT01134510|DRUG|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
219390101|NCT06596447|DEVICE|Deep Brain Stimulation|While most patients with obsessive compulsive disorder (OCD) eventually respond to treatment with medication and/or behavioral therapy, a small minority do not improve following all conventional treatments. Obsessive-compulsive disorder (OCD) can sometimes be difficult to treat with medication and psychotherapy. For these patients, in this study, we employ deep brain stimulation (DBS), an advanced surgical treatment that uses electrical impulses.
219390102|NCT05387161|OTHER|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
219390103|NCT03244098|BEHAVIORAL|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
219390104|NCT04971590|OTHER|Participant completed survey|Participants will be required to complete the participant survey.
219390105|NCT04971590|OTHER|Medical chart review|Data will be collected from medical charts of participants.
219390106|NCT01098968|BEHAVIORAL|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
219390107|NCT00745316|DRUG|Tonapofylline|Oral Tonapofylline - 2 capsules bid
219390108|NCT00745316|DRUG|Placebo|Oral placebo - 2 capsules bid
219390109|NCT04301453|OTHER|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
219390110|NCT04596371|OTHER|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
219390111|NCT02628730|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
219390112|NCT02628730|DEVICE|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
219390113|NCT00936949|PROCEDURE|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
219390114|NCT00936949|PROCEDURE|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
219390115|NCT02638246|BEHAVIORAL|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
219390116|NCT02638246|BEHAVIORAL|Internet-delivered, non-contingent incentives + Motivational Interviewing|
219390117|NCT01347164|BEHAVIORAL|RISE life coaching intervention|6 2-hour sessions
219390118|NCT01347164|BEHAVIORAL|HIV Counseling|Standard one-hour HIV counseling session
219390119|NCT00603044|DRUG|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
219390120|NCT00393458|DRUG|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219390121|NCT00393458|DRUG|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
219390122|NCT00393458|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219390123|NCT00393458|DRUG|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
219390124|NCT02509546|DRUG|8-Chloroadenosine|Given IV
219390125|NCT02509546|OTHER|Laboratory Biomarker Analysis|Correlative studies
219390126|NCT02509546|OTHER|Pharmacological Study|Correlative studies
219390127|NCT01535937|DRUG|Ketamine|0.5 mg/kg IV over 40 minutes
219390128|NCT01535937|DRUG|Midazolam|0.025 mg/kg IV over 40 minutes
219390129|NCT04289883|COMBINATION_PRODUCT|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
219390130|NCT04289883|COMBINATION_PRODUCT|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
219390131|NCT03169283|OTHER|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
219390132|NCT03169283|OTHER|Cereal without B glucan|Cereal without B glucan
219390133|NCT00003018|DRUG|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
219390134|NCT00003018|DRUG|fluorouracil|200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
219390135|NCT00003018|DRUG|leucovorin calcium|30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
219390136|NCT00003018|DRUG|mitomycin C|10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
219390137|NCT04415138|DEVICE|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
219390138|NCT00104104|DRUG|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
219390139|NCT01274897|BIOLOGICAL|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
219390140|NCT01274897|BIOLOGICAL|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
219390141|NCT03901183|OTHER|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
219390142|NCT06163781|DEVICE|Blood culture prediction tool|Machine learning based predicition tool
219390143|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
219390144|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
219390145|NCT02552407|DEVICE|Manual Aspiration Thrombectomy|Thrombus aspiration
219390146|NCT05278793|DRUG|Ferrous fumarate|Ferrous fumarate 200mg oral
219390147|NCT00804440|DRUG|Ibuprofen Tablets, 800 mg|
219390148|NCT00162877|DRUG|Rabeprazole vs. Esomeprazole|
219390149|NCT00035815|DRUG|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
219390150|NCT00035815|DRUG|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
219390151|NCT06272253|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
219390152|NCT04908072|DEVICE|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
219390153|NCT06696417|DRUG|Drug group：vunakizumab (IL-17A inhibitor)|The recommended dose of vunakizumab was 240 mg, administered subcutaneously at weeks 0, 2, and 4, then every 4 weeks, with a final injection at 48 weeks
219390154|NCT03551522|DRUG|Seladelpar|10 mg, 20 mg, or 50 mg
219390155|NCT03551522|DRUG|Placebos|Matching placebo Capsule
219390156|NCT06735560|RADIATION|89Zr-TLX250 PET/CT|Patients will receive 89Zr-TLX250 for detection of CAIX-expressing tumor by PET imaging.
219390157|NCT06725303|DEVICE|Excimer|Light energy
219390158|NCT06739668|DEVICE|Pascal device|The study devices consist of a tabletop Console with user interface and a head-worn applicator (Headset) that is connected via coaxial cable. The Headset is positioned on the head per instructions, and then the study subject powers on the device by pressing the power button and initiates a 15-minute treatment by pressing the start button. LED lights on the console count down during the treatment to indicate time remaining and, once the treatment is complete, the device automatically powers off.
219390159|NCT06739668|DEVICE|Sham Device|The sham device will look identical to the active device and will have the same indicator lights and sounds, but will not emit magnetic field therapy.
219390160|NCT06666673|DRUG|Tizanidine|Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.
219390161|NCT06666673|DRUG|Placebo|Administered as control
219390162|NCT06747624|DIETARY_SUPPLEMENT|Geranylgeraniol 300 mg|300 mg of trans-geranylgeraniol (GG)
219390163|NCT06747624|DIETARY_SUPPLEMENT|Placebo|300 mg medium chain triglycerides
219390164|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
219390165|NCT05222386|OTHER|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
219390166|NCT05222386|OTHER|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
219390167|NCT03590574|BIOLOGICAL|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
219390168|NCT02632825|DEVICE|Nasal High Flow|Nasal High Flow Therapy
219390169|NCT06477913|DEVICE|Rauha|A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
219390170|NCT04652635|PROCEDURE|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
219390171|NCT06166771|DEVICE|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
219390172|NCT01894516|DRUG|GLPG0634|GLPG0634 capsules.
219390173|NCT01894516|DRUG|Placebo|Placebo capsules.
219390174|NCT05791825|BEHAVIORAL|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
219390175|NCT02002078|DRUG|methylprednisolon|
219390176|NCT01792986|BEHAVIORAL|water-only 24-hour fasting once per week for 6 weeks|
219390177|NCT05099601|COMBINATION_PRODUCT|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
219390178|NCT05099601|PROCEDURE|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
219001268|NCT03618498|PROCEDURE|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
219390179|NCT03191396|DRUG|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
219390180|NCT03191396|DRUG|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
219390181|NCT01025245|DRUG|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
219390182|NCT02980835|DRUG|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
219390183|NCT02980835|DRUG|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
219390184|NCT02980835|DRUG|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
219001269|NCT02020330|DRUG|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
219390185|NCT02980835|DRUG|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
219390186|NCT05892185|DEVICE|GELA|GELA glaucoma implant
219390187|NCT05892185|DEVICE|XEN|XEN gel stent implant
219390188|NCT04833075|OTHER|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
219390189|NCT01675921|OTHER|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
219390190|NCT03714386|DEVICE|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
219390191|NCT03714386|DEVICE|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
219390192|NCT05506904|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
219390193|NCT02525224|DIETARY_SUPPLEMENT|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
219390194|NCT04296292|OTHER|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
219390195|NCT02189330|DRUG|Tafamidis|20 mg of current commercial formulation.
219390196|NCT02189330|DRUG|Tafamidis|12.2 mgA free acid tablet.
219390197|NCT02189330|DRUG|Tafamidis|20 mg new soft gelatin capsule.
219390198|NCT02189330|DRUG|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
219390199|NCT02189330|DRUG|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
219390200|NCT00067522|BEHAVIORAL|User-independent contraception program|
219390201|NCT00067522|BEHAVIORAL|Future Planning Perspectives program|
219390202|NCT00917410|BEHAVIORAL|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
219390203|NCT05574816|DEVICE|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
219390204|NCT01601015|OTHER|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
219390205|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
219390206|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
219390207|NCT01601015|OTHER|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
219390208|NCT00379483|DRUG|Deferasirox|
219390209|NCT00674934|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
219001270|NCT02020330|DRUG|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
219390210|NCT02770287|DEVICE|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
219390211|NCT03630068|PROCEDURE|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
219390212|NCT05477238|PROCEDURE|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
219390213|NCT02666911|PROCEDURE|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
219390214|NCT02666911|PROCEDURE|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
219390215|NCT05378659|BEHAVIORAL|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
219390216|NCT05378659|BEHAVIORAL|Stroop Test|Evaluates Processing Speed and Executive Control
219390217|NCT05378659|DIAGNOSTIC_TEST|4AT Delirium|Screening tool to test for delirium post surgery
219390218|NCT05378659|BEHAVIORAL|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
219390219|NCT05378659|BEHAVIORAL|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
219390220|NCT05378659|DIAGNOSTIC_TEST|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
219390221|NCT05378659|DIAGNOSTIC_TEST|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
219390222|NCT05378659|DIAGNOSTIC_TEST|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
219390223|NCT05416606|PROCEDURE|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
219390224|NCT05416606|PROCEDURE|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
219390225|NCT04805372|OTHER|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
219390226|NCT04805372|OTHER|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
219390227|NCT01204112|DRUG|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
219390228|NCT01292395|OTHER|Dietary Protein Intake|Protein intakes within the current recommendation
219390229|NCT05351086|DRUG|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
219390230|NCT05351086|DRUG|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
219390231|NCT05351086|OTHER|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
219390232|NCT05351086|OTHER|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
219001271|NCT06373991|BIOLOGICAL|ATHENA CAR-T|Phase 1 dose escalation (3+3): dose 1 and dose 2.
219390233|NCT00893503|PROCEDURE|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
219390234|NCT03635190|DEVICE|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
219390235|NCT00077987|DRUG|SU011248|
219390236|NCT06673225|OTHER|Analysis of results|Analysis of previous imaging and/or laboratory tests, vital signs, body composition, pulmonary function, peripheral muscle strength, calf circumference, nutritional risk, quality of life, frailty level, and anxiety and depression. Screening for respiratory diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, and other lung lesions, is based on spirometry and thoracic radiological images after the health professional's examination. After the multiprofessional procedures, patients will be evaluated by a physician to start specific treatment and/or perform complementary exams if necessary. Every year, they will be re-evaluated to record acute exacerbations of chronic respiratory diseases and assess disease progression through spirometry and thoracic radiological images.
219390237|NCT03692910|DRUG|SAGE-217|SAGE-217 capsule
219390238|NCT03692910|DRUG|Placebo|SAGE-217 matching placebo capsule
219390239|NCT06252610|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
219390240|NCT06252610|DRUG|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected."
219390241|NCT06252610|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
219390242|NCT04716439|PROCEDURE|Spine Surgery|spine decompression and fixation
219390243|NCT02632058|OTHER|Cognitive Behavioral Therapy|
219390244|NCT01322607|BEHAVIORAL|High-intensity Treadmill Exercise|High-intensity treadmill walking program
219390245|NCT01322607|BEHAVIORAL|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
219390246|NCT03207256|DRUG|TGR-1202|Oral Daily TGR-1202
219390247|NCT03207256|DRUG|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
219390248|NCT00400491|DRUG|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
219390249|NCT00400491|DRUG|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
219390250|NCT06386588|OTHER|Closed loop auditory stimulation during sleep|Short bursts of pink noise delivered at precise times during overnight sleep at home.
219390251|NCT05447130|PROCEDURE|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
219390252|NCT02318394|BIOLOGICAL|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
219390253|NCT03891069|DEVICE|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
219390254|NCT01841008|DRUG|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
219001272|NCT06373991|DRUG|Fludarabine|Intravenous injection of fludarabine.
219390255|NCT01841008|DRUG|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
219390256|NCT00417365|DEVICE|WaterWorks Douching Device|
219390257|NCT03601338|DRUG|Bemiparin|second generation low molecular weight Heparin
219001273|NCT06373991|DRUG|Cyclophosphamide|Intravenous injection of cyclophosphamide.
219390258|NCT03601338|OTHER|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
219390259|NCT01680224|BEHAVIORAL|Healthy Weight|
219390260|NCT01680224|BEHAVIORAL|Project Health|
219390261|NCT01680224|BEHAVIORAL|Placebo Control|Participants will view a video on overweight and obesity
219390262|NCT01483040|DEVICE|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
219390263|NCT01646008|OTHER|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
219390264|NCT01646008|OTHER|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
219390265|NCT04789746|BEHAVIORAL|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
219390266|NCT01981122|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
219390267|NCT01981122|DRUG|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
219390268|NCT02425267|OTHER|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
219390269|NCT03640091|PROCEDURE|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
219390270|NCT04547244|OTHER|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
219390271|NCT00017316|DRUG|semaxanib|
219390272|NCT00017316|DRUG|thalidomide|
219390273|NCT05183958|RADIATION|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
219390274|NCT05183958|DRUG|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
219390275|NCT05183958|DRUG|Chemotherapy|4 cycles for combined therapy.
219390276|NCT01444521|DRUG|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
219390277|NCT01879605|DRUG|Docusate natrium and sorbitol|
219390278|NCT01879605|DRUG|Bisacodyl|
219390279|NCT06535399|DRUG|BMS-986369|Specified dose on specified days
219390280|NCT05358691|DRUG|AN0025|To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
219390281|NCT04608097|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
219390282|NCT04608097|BEHAVIORAL|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
219390283|NCT06369324|OTHER|Pain education|It consisted of holding information sessions on each of the days that the subjects were scheduled for treatment. These sessions will be supported by supplementary material in the form of brochures, posters and videos which briefly explain interesting knowledge about spondyloarthropathies.
219390284|NCT06369324|OTHER|Exercise supervised by external focus|This therapeutic exercise involves proprioceptive training with external feedback to enhance exercise execution and promote optimal postural control, particularly for individuals with back pain. The method, based on research by Abdollahipour et al. and Chiviacowsky et al., focuses on automatic control, reducing the cognitive load during exercises and improving movement retention. The Motion Guidance Clinician Kit will be utilized, consisting of a panel and laser guide for precise cervical movement. Exercises progress in difficulty over 12 sessions, targeting cervical and lumbopelvic stabilization, flexion-extension, rotations, and lateral flexions. Sessions start with seated exercises and progress to standing, with increasing distance between laser targets to expand cervical range of motion. Thoracic and lumbar exercises involve 10 repetitions each. The entire program lasts around 20 minutes and follows Tidier recommendations for intervention.
219390285|NCT06369324|OTHER|Therapy by means of electrical stimulation (electro-massage)|This technique combines manual therapy (massage) with interferential current. Following a supervised therapeutic exercise program, this intervention targets the spine for 15 minutes. Using a Sonopuls 692® device, a bipolar current mode with specific frequencies is applied. The physiotherapist moistens sponges with warm water and administers the current through them while performing manual soft tissue therapy on the neck, shoulders, scapulae, thoracic, lumbar, and sacral areas. The intensity is adjusted to provide a strong but comfortable tingling sensation, without muscle twitching. The therapy sequence includes superficial stroking, deep gliding movements, trapezius kneading, muscle stretching, and deep rubbing on the thoracic and lumbar areas. The electro-massage protocol lasts 14 minutes.
219390286|NCT02293343|OTHER|blood profile|
219390287|NCT01419990|DRUG|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
219390288|NCT01419990|DRUG|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
219390289|NCT01419990|DRUG|Placebo|Placebo oral capsules, qd, 10 days
219390290|NCT03905772|OTHER|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
219390291|NCT03905772|OTHER|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
219390292|NCT03905772|OTHER|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
219390293|NCT03905772|OTHER|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
219390294|NCT02606773|DRUG|Ascorbic Acid|Ascorbic acid in different ways and doses
219390295|NCT04222621|OTHER|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
219390296|NCT01330381|DRUG|prucalopride|"prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily"
219390297|NCT01330381|DRUG|Placebo|Matching oral solution or oral tablets given once daily
219390298|NCT01330381|DRUG|PEG 4000|
219390299|NCT03245476|OTHER|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
219390300|NCT03245476|OTHER|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
219390301|NCT00552799|DRUG|Penicillin VK|Biconcave tablet 250mg oral, b.d.
219390302|NCT00552799|OTHER|placebo|biconcave tablet matching active comparator as much as possible in size and shape
219390303|NCT03060577|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
219390304|NCT03060577|DRUG|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
219390305|NCT00148629|DRUG|multivitamin, mebendazole|
219390306|NCT05483543|DRUG|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
219390307|NCT00005963|DRUG|carboplatin|
219390308|NCT00005963|DRUG|docetaxel|
219390309|NCT05483972|BEHAVIORAL|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
219390310|NCT00097422|DRUG|OPT-80|
219390311|NCT02884466|BEHAVIORAL|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
219390312|NCT01717612|DRUG|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
219390313|NCT01717612|DRUG|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
219390314|NCT04111367|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
219390315|NCT04111367|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
219390316|NCT01471873|PROCEDURE|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
219390317|NCT02435173|DRUG|CDZ173|CDZ173 10 and 70 mg capsules for oral administration.
219390318|NCT02435173|OTHER|Placebo|Placebo capsules for oral administration
219390319|NCT01477632|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
219390320|NCT01477632|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
219390321|NCT01477632|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
219390322|NCT00471471|BIOLOGICAL|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
219390323|NCT00471471|BIOLOGICAL|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
219390324|NCT00471471|BIOLOGICAL|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
219390325|NCT05706467|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
219390326|NCT05706467|DEVICE|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
219390327|NCT02162745|DRUG|Isotonic solution (NaCl 0.9%)|
219390328|NCT02162745|DRUG|Hypertonic solution (NaCl 3%)|
219390329|NCT04467541|BIOLOGICAL|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
219390330|NCT00068952|DRUG|Edotecarin|
219390331|NCT00068952|DRUG|Temozolomide|
219390332|NCT00068952|DRUG|Carmustine (BCNU)|
219390333|NCT00068952|DRUG|Lomustine (CCNU)|
219390334|NCT02847611|DEVICE|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
219390335|NCT02399878|DRUG|Inspiratory oxygen|
219390336|NCT03216265|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
219390337|NCT03216265|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
219390338|NCT03216265|OTHER|No treatment|No treatment.
219390339|NCT02392208|DRUG|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
219390340|NCT02392208|PROCEDURE|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
219390341|NCT03645252|PROCEDURE|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
219390342|NCT03645252|PROCEDURE|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
219390343|NCT00358592|DEVICE|Mobius™ retractor|
219390344|NCT00358592|DEVICE|traditional metal retraction instruments|
219390345|NCT02448823|OTHER|Mass media and Stylish Events|"1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
219390346|NCT02448823|OTHER|Mass Media|1\. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
219390347|NCT01277289|DRUG|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
219390348|NCT00546858|OTHER|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
219390349|NCT06024577|BEHAVIORAL|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
219390350|NCT06024577|BEHAVIORAL|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
219390351|NCT06024577|BEHAVIORAL|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
219390352|NCT00000451|DRUG|sertraline|16 week outpatient study
219390353|NCT00000451|DRUG|naltrexone|16 week outpatient study
219390354|NCT03679481|DRUG|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
219390355|NCT03679481|DRUG|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
219390356|NCT06111573|DIETARY_SUPPLEMENT|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
219390357|NCT06111573|DRUG|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
219390358|NCT05588492|DRUG|Rifamycin-containing regimen|Rifamycin-containing regimen
219390359|NCT05588492|DRUG|Rifamycin-free regimen|Rifamycin-free regimen
219390360|NCT00092547|BIOLOGICAL|V501|0.5 mL intramuscular injection of V501
219390361|NCT00092547|BIOLOGICAL|Comparator: Placebo|0.5 mL intramuscular injection of placebo
219390362|NCT02772497|DRUG|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
219390363|NCT05640232|DRUG|CDE100 association|Experimental drug.
219390364|NCT05640232|DRUG|Buscopan® Composto association|Active comparator.
219390365|NCT00199511|DRUG|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
219390366|NCT05366907|OTHER|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
219390367|NCT03375658|OTHER|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
219390368|NCT03139955|DEVICE|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
219390369|NCT06472895|DRUG|AK112 monotherapy|A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
219390370|NCT00653796|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
219390371|NCT00653796|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
219390372|NCT03544060|DRUG|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
219390373|NCT05615701|DIAGNOSTIC_TEST|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
219390374|NCT03804346|DIAGNOSTIC_TEST|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
219390375|NCT04988516|DEVICE|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
219390376|NCT04988516|OTHER|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
219390377|NCT01127425|PROCEDURE|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
219390378|NCT01127425|PROCEDURE|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
219390379|NCT00130299|BEHAVIORAL|low glycemic load diet|
219390380|NCT00130299|BEHAVIORAL|low fat diet|
219390381|NCT06017063|OTHER|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
219390382|NCT06044753|DEVICE|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
219390383|NCT01539837|DRUG|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
219390384|NCT01539837|DRUG|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
219390385|NCT01539837|DRUG|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
219390386|NCT05794997|DRUG|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
219390387|NCT05794997|DRUG|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
219390388|NCT00235729|DRUG|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
219390389|NCT00235729|DRUG|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
219390390|NCT05397613|BEHAVIORAL|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
219390391|NCT05734781|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
219390392|NCT03807973|DRUG|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
219390393|NCT03993353|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
219390394|NCT03993353|DRUG|Tadalafil|10 mg by mouth daily
219390395|NCT04925544|DRUG|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
219390396|NCT02484261|DRUG|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
219390397|NCT02484261|DRUG|Pravastatin|10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
219390398|NCT02988986|DRUG|TAK-228|MTORC1/2 inhibitor
219390399|NCT02988986|DRUG|Tamoxifen|Non-steroidal anti-estrogen
219390400|NCT03925844|OTHER|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
219390401|NCT01998646|DRUG|ASP4058|Oral tablet
219390402|NCT01998646|DRUG|Placebo|Oral tablet
219390403|NCT06017232|OTHER|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
219390404|NCT02844205|OTHER|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
219390405|NCT02355912|DEVICE|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
219390406|NCT02778048|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter
219390407|NCT02778048|OTHER|US (ultra sound)|Assessment of the sphincter
219390408|NCT02778048|OTHER|FLIP (functional lumen imaging probe)|Assessment of the sphincter
219390409|NCT02778048|OTHER|HRAM (high resolution anal manometry)|Assessment of the sphincter
219390410|NCT04893330|DIETARY_SUPPLEMENT|pepticate syneo|follow up of pepticate syneo for one month
219390411|NCT01978912|DRUG|KTP-001|KTP-001 is one time dose intradiscally.
219390412|NCT01819688|PROCEDURE|laparoscopic liver resection|
219390413|NCT00973830|OTHER|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
219390414|NCT00670917|OTHER|questionnaire administration|
219390415|NCT00670917|PROCEDURE|acupressure therapy|
219390416|NCT00670917|PROCEDURE|biopsy|
219390417|NCT00670917|PROCEDURE|bone marrow aspiration|
219390418|NCT00670917|PROCEDURE|pain therapy|
219390419|NCT00380484|DRUG|Budesonide|200µg daily
219390420|NCT00380484|DRUG|Montelukast|5 mg daily
219390421|NCT00401973|DRUG|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
219390422|NCT00401973|DRUG|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
219390423|NCT00401973|DRUG|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
219390424|NCT00401973|DRUG|zonisamide|Zonisamide, 100-400mg, oral, daily.
219390425|NCT00401973|BEHAVIORAL|Wellness education|weight management
219390426|NCT04789785|DIAGNOSTIC_TEST|ultrasound|observation with usg
219390427|NCT04075604|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219390428|NCT04075604|DRUG|Anastrozole|Specified Dose on Specified Days
219390429|NCT04075604|DRUG|Palbociclib|Specified Dose on Specified Days
219390430|NCT02893254|DRUG|IBI303|12 cycles. IBI303: 40 mg, iH
219390431|NCT02893254|DRUG|Adalimumab|12 cycles. Adalimumab: 40mg, iH
219390432|NCT03976856|DRUG|GB226|Geptanolimab, 210mg，q2w，ivgtt.
219390433|NCT03976856|DRUG|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
219390434|NCT00445055|DRUG|Droperidol|Intravenous injection
219390435|NCT01650779|BIOLOGICAL|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
219390436|NCT03406949|BIOLOGICAL|obrindatamab|B7-H3 x CD3 DART protein
219390437|NCT03406949|BIOLOGICAL|retifanlimab|anti-PD-1 antibody
219390438|NCT02280681|OTHER|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
219390439|NCT03828838|DRUG|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
219390440|NCT06474741|BEHAVIORAL|in-app notification|Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
219390441|NCT03666143|DRUG|Sitravatinib|Administered orally as a capsule
219390442|NCT03666143|DRUG|Tislelizumab|Administered intravenously
219390443|NCT00370786|DRUG|bevacizumab|
219390444|NCT03321786|OTHER|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
219390445|NCT01680406|DRUG|Artemether-lumefantrine combination|
219390446|NCT01680406|DRUG|Primaquine|
219390447|NCT01680406|DRUG|Chloroquine|
219390448|NCT03642795|OTHER|Questionnaire|Patients are asked to complete several questionnaires
219390449|NCT05363007|DRUG|nanoliposomal irinotecan|"Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)"
219390450|NCT05363007|RADIATION|spleen irradiation|"Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin"
219390451|NCT05836961|OTHER|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
219390452|NCT04767880|DIETARY_SUPPLEMENT|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
219390453|NCT04767880|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
219390454|NCT00251797|DRUG|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
219390455|NCT00251797|DRUG|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
219390456|NCT04696835|DIAGNOSTIC_TEST|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
219390457|NCT00941980|BIOLOGICAL|Osteocel Plus|biologic
219390458|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
219390459|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
219390460|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
219390461|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
219390462|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
219390463|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
219390464|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
219390465|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
219390466|NCT04595955|OTHER|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
219390467|NCT03689231|OTHER|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
219390468|NCT02127112|PROCEDURE|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
219390469|NCT02127112|PROCEDURE|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
219390470|NCT00283712|DRUG|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
219390471|NCT00283712|OTHER|Placebo Comparator|Placebo administered in place of infliximab for control group
219390472|NCT00129077|PROCEDURE|plastic wrap over eye & lubrication applied q6 hrs|
219390473|NCT03622411|DEVICE|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
219390474|NCT03622411|DEVICE|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
219390475|NCT03622411|BEHAVIORAL|aphasia therapy|language exercises provided by the speech therapist in hospital
219390476|NCT02727114|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
219390477|NCT00480194|DRUG|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
219390478|NCT02395679|BIOLOGICAL|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
219390479|NCT04329923|DRUG|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
219390480|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
219390481|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
219390482|NCT04329923|DRUG|Placebo oral tablet|Placebo
219390483|NCT01702012|DIETARY_SUPPLEMENT|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
219390484|NCT01702012|BEHAVIORAL|Group-Based Lifestyle Intervention|
219390485|NCT03370367|DRUG|13-cis retinoic acid|Taken daily.
219390486|NCT03370367|OTHER|Placebo|Placebo
219390487|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
219390488|NCT01272180|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
219390489|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
219390490|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
219390491|NCT02962635|DEVICE|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
219557964|NCT06529874|OTHER|Balance assessment using HUMAC balance system|"HUMAC balance system will be calibrated, then will conduct~1. center of pressure: will instructed child to stand on platform, and maintain own body stability, and focus on the red dot in the center of screen that will move in response to body sway. after a rest, second trial will be done.~2. Eye open/ closed firm surface tests: First for Eye open firm surface test; the child will be asked to look at a target on the wall that was set at his/ her eye level, and to stare at this target for 30 seconds while standing on firm surface. After 5 seconds rest. Eye closed firm surface test; child will be asked to close his/ her eyes for 30 seconds, and conducting the same procedures for balance testing.~The researcher will documented the values resented on the screen ."
219390492|NCT03466710|PROCEDURE|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
219390493|NCT03466710|OTHER|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (\>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or \>LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is \>/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
219390494|NCT03466710|DIAGNOSTIC_TEST|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
219390495|NCT05718076|PROCEDURE|cataract surgery|Phacoemulsification combined trifocal lens implantation
219390496|NCT00850772|DIETARY_SUPPLEMENT|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
219390497|NCT03288467|PROCEDURE|Root canal treatment with 5% NaOCl|
219390498|NCT03288467|PROCEDURE|Root canal treatment with 1% NaOCl|
219390499|NCT03614715|DRUG|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
219390500|NCT04668378|OTHER|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
219390501|NCT04668378|OTHER|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
219390502|NCT03412227|BEHAVIORAL|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
219390503|NCT03412227|BEHAVIORAL|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, \& Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, \& LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b).
219390504|NCT03412227|BEHAVIORAL|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall \& Hedtke, 2006; Kendall, Choudhury, Hudson, \& Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
219557965|NCT06529874|OTHER|Lower limb muscular strength using Lafayette hand held dynamometer|Lower limb muscular ' Isometric quadriceps strength' will be measured for all participants in both groups. each participating child will be instructed to sit to assess the strength of knee extension, which minimize positional changes, and enhance feasibility of this clinical test. then The researcher will apply resistance to child's quadriceps to gain maximal voluntary isometric contraction with pressing the activated Lafayette hand held dynamometer padded stirrup against quadriceps belly, then recorded and documented measured value.
219557966|NCT05645224|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
219390505|NCT03412227|OTHER|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
219390506|NCT03606746|BIOLOGICAL|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
219390507|NCT01183858|DRUG|Erlotinib [Tarceva]|Single daily oral dose
219390508|NCT02241018|DRUG|CD25 monoclonal antibody|
219390509|NCT02241018|DRUG|calcineurin inhibitors|
219390510|NCT02241018|BIOLOGICAL|MSCs|
219390511|NCT02094105|PROCEDURE|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
219390512|NCT00887445|DRUG|SLV341|5 - 1000mg once daily
219390513|NCT00887445|DRUG|placebo|
219390514|NCT03690622|DRUG|Dexmedetomidine|Instillation of eyedrops
219390515|NCT03690622|DRUG|Balanced salt solution|instillation of eyedrop
219390516|NCT04332692|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
219390517|NCT04332692|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
219390518|NCT04332692|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
219390519|NCT04332692|PROCEDURE|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
219390520|NCT04332692|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
219390521|NCT04637321|PROCEDURE|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
219390522|NCT04807569|OTHER|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
219390523|NCT04807569|DRUG|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
219390524|NCT03015272|BEHAVIORAL|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
219390525|NCT03015272|BEHAVIORAL|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
219390526|NCT04083911|DRUG|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
219390527|NCT03477630|BIOLOGICAL|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
219390528|NCT03477630|DRUG|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
219390529|NCT00105729|BEHAVIORAL|Intensive referral to 12-step self-help groups|
219390530|NCT02039271|OTHER|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
219390531|NCT01048125|DEVICE|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
219390532|NCT01048125|BEHAVIORAL|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
219390533|NCT01048125|DRUG|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
219390534|NCT01048125|OTHER|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
219390535|NCT01048125|DEVICE|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
219557967|NCT03388008|DRUG|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
219390536|NCT02747043|BIOLOGICAL|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
219390537|NCT02747043|BIOLOGICAL|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
219390538|NCT02140918|DRUG|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
219390539|NCT02140918|DRUG|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
219390540|NCT02140918|DRUG|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
219390541|NCT02140918|DRUG|Placebo|
219390542|NCT02288975|DEVICE|CytoSorb 300ml device (3804606CE01)|
219390543|NCT04146272|DEVICE|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
219390544|NCT04146272|DEVICE|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
219390545|NCT04146272|DEVICE|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
219390546|NCT04146272|DEVICE|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
219390547|NCT05195905|DEVICE|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
219390548|NCT04919486|BEHAVIORAL|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
219390549|NCT04919486|BEHAVIORAL|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
219390550|NCT03465800|BEHAVIORAL|self-monitoring|self-monitoring of physical activity
219390551|NCT03465800|BEHAVIORAL|daily incentives|daily incentive payments for physical activity
219390552|NCT03465800|BEHAVIORAL|delayed lump sum incentives|delayed lump sum payments for physical activity
219390553|NCT01676480|BEHAVIORAL|Endurance training|12 weeks of endurance training 3 times per week
219390554|NCT05595473|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
219001274|NCT03749070|DIETARY_SUPPLEMENT|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
219390555|NCT05595473|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
219390556|NCT05595473|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
219390557|NCT05595473|DRUG|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
219390558|NCT03121742|BEHAVIORAL|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
219390559|NCT03121742|BEHAVIORAL|Treatment as Usual|Standard care as part of inpatient hospitalization.
219390560|NCT04367701|DIAGNOSTIC_TEST|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
219390561|NCT03897712|DEVICE|Custom Samfilcon B Contact Lenses|Contact lens
219390562|NCT03897712|DEVICE|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
219390563|NCT03897712|DEVICE|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
219390564|NCT03897712|DEVICE|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
219390565|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
219390566|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
219390567|NCT01629667|OTHER|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
219390568|NCT06509061|OTHER|Physical Activity Self-Definition|6 week behavioural change program designed to increase PASD and PA
219390569|NCT06509061|OTHER|Control|6 week program designed to as an attention control, delivering content on general health behaviour.
219390570|NCT05654415|OTHER|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
219390571|NCT05654415|OTHER|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
219390572|NCT04976075|OTHER|no interventions|no interventions
219390573|NCT01505062|DRUG|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
219390574|NCT04459910|PROCEDURE|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
219390575|NCT01686204|OTHER|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
219390576|NCT01686204|OTHER|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
219390577|NCT01277224|BEHAVIORAL|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
219390578|NCT01512368|OTHER|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
219390579|NCT05537363|OTHER|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
219390580|NCT05537363|OTHER|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
219390581|NCT05537363|OTHER|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
219390582|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
219390583|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
219390584|NCT05006612|PROCEDURE|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
219390585|NCT00188994|DRUG|Insulin Cardioplegia|
219390586|NCT05814029|OTHER|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
219390587|NCT02648230|DEVICE|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
219390588|NCT02648230|DEVICE|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
219390589|NCT05509244|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
219390590|NCT05509244|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
219390591|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
219390592|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
219390593|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
219390594|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
219390595|NCT02717546|DEVICE|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
219390596|NCT05937711|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
219390597|NCT05937711|DRUG|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
219390598|NCT02120586|OTHER|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
219557968|NCT03388008|DRUG|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
219557969|NCT03388008|DRUG|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
219390599|NCT02120586|OTHER|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
219390600|NCT05207436|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
219390601|NCT05207436|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
219390602|NCT03756012|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
219390603|NCT01731691|BIOLOGICAL|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
219390604|NCT01731691|DRUG|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
219390605|NCT03865342|BEHAVIORAL|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
219390606|NCT02183545|DRUG|BI 1060469|single rising doses given as tablet
219390607|NCT02183545|DRUG|Placebo|given as tablet (matching placebo of BI 1060469)
219390608|NCT02460822|DEVICE|MyChemoCare iPad application|
219390609|NCT04967430|DRUG|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
219390610|NCT04967430|OTHER|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
219390611|NCT05004012|DEVICE|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
219390612|NCT04924725|PROCEDURE|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
219390613|NCT03597906|PROCEDURE|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
219001275|NCT05538702|DEVICE|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
219001276|NCT05538702|DEVICE|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
219001277|NCT05538702|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
219390614|NCT03597906|PROCEDURE|manifest refraction|using for ablation the exact manifest refraction
219390615|NCT03597906|PROCEDURE|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
219390616|NCT03597906|PROCEDURE|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
219390617|NCT04460027|OTHER|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
219390618|NCT00576914|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
219390619|NCT04507750|DRUG|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
219390620|NCT04291014|DEVICE|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
219390621|NCT03321812|PROCEDURE|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
219390622|NCT03321812|PROCEDURE|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
219390623|NCT06331585|RADIATION|low dose radiotherapy|LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
219390624|NCT04265989|DEVICE|Single BMS|Single bare metal stent covered the coronary artery aneurysm
219390625|NCT04265989|DEVICE|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
219390626|NCT04265989|DEVICE|Single or Double BMS|Treated with single or double layer bare metal stents
219390627|NCT04265989|DEVICE|BMS+DES|Treated with bare metal stent combined with drug eluting stent
219390628|NCT00949650|DRUG|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
219390629|NCT00949650|DRUG|BIBW 2992|BIBW 2992 once daily until progression
219390630|NCT00949650|DRUG|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
219390631|NCT04601272|BEHAVIORAL|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
219390632|NCT03576677|DRUG|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
219390633|NCT03576677|DRUG|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
219390634|NCT01210937|PROCEDURE|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
219390635|NCT00414440|DRUG|Placebo|placebo comparator
219390636|NCT00414440|DRUG|Everolimus|experimental
219390637|NCT02291380|DRUG|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
219390638|NCT02291380|DRUG|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
219390639|NCT00112138|DRUG|gabapentin|
219390640|NCT02875288|DRUG|liposomal bupivicaine|"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"
219390641|NCT02846077|OTHER|No intervention. Observation only|No intervention. Observation only
219390642|NCT02168946|DRUG|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
219390643|NCT02168946|DRUG|Best Available Therapy|Antibiotic(s) chosen by Investigator
219390644|NCT03332953|OTHER|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
219390645|NCT02067221|DEVICE|RIRS|"* RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
219390646|NCT02067221|DEVICE|MPCNL|"* MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
219390647|NCT01285921|OTHER|vestibular test before and after hippocampal surgery|"* Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
219390648|NCT00065975|PROCEDURE|massage therapy|
219001278|NCT05538702|DEVICE|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
219001279|NCT01428544|DRUG|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
219390649|NCT00065975|PROCEDURE|chiropractic|
219390650|NCT00065975|PROCEDURE|acupuncture|
219390651|NCT03429907|BEHAVIORAL|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
219390652|NCT03429907|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
219390653|NCT04982913|DRUG|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
219390654|NCT01116245|BIOLOGICAL|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
219390655|NCT01116245|DRUG|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
219390656|NCT06544408|DEVICE|Cool B70 AP Coil - Active (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
219390657|NCT06544408|DEVICE|Cool B70 AP Coil- Sham (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
219188792|NCT03652740|DRUG|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
219188793|NCT03808831|DEVICE|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
219390658|NCT06544408|DEVICE|Cool D-B80 AP Coil - Active (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
219390659|NCT06544408|DEVICE|Cool D-B80 AP Coil - Sham (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
219390660|NCT06544408|DEVICE|Cool B70 Treatment Coil - Active Only|The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
219390661|NCT05096169|DRUG|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
219390662|NCT05096169|DRUG|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
219390663|NCT02498821|DEVICE|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
219390664|NCT02498821|DEVICE|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
219390665|NCT02498821|PROCEDURE|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
219390666|NCT06970119|DRUG|INR102 injection|INR102 injection is a lutetium-177 (\[177Lu\])-labeled radiopharmaceutical agent targeting prostate-specific membrane antigen (PSMA). It is clinically indicated for the treatment of patients with PSMA-positive prostate cancer.
219390667|NCT06971549|OTHER|Accelerated iTBS|Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
219390668|NCT06971536|DIETARY_SUPPLEMENT|Standard Green Tea|A maximum single dose of 300 mg green tea (hard gel capsules)
219390669|NCT06971536|DIETARY_SUPPLEMENT|Phytosome Green Tea|A maximum single dose of 250 mg green tea (hard gel capsules)
219390670|NCT06971536|DIETARY_SUPPLEMENT|LipoMicel Green Tea|A maximum single dose of 300 mg green tea (soft gel capsules)
219390671|NCT06969599|DIAGNOSTIC_TEST|No intervention measures|No intervention measures
219390672|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version does not provide any normative feedback information."
219390673|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive norms information about local HIV testing rates."
219390674|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with injunctive norms information about local HIV stigma rates."
219390675|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive and injunctive norms information about both local HIV testing rates and local HIV stigma rates."
219390676|NCT03738956|DRUG|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
219390677|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
219390678|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
219188794|NCT03808831|DEVICE|Sham fall detection and prevention system|The sham system with record but no alert function
219390679|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
219390680|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
219390681|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
219390682|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
219188795|NCT05382702|OTHER|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
219188796|NCT01208662|DRUG|Lenalidomide|oral administration
219188797|NCT01208662|DRUG|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
219188798|NCT01208662|DRUG|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
219188799|NCT01208662|PROCEDURE|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
219188800|NCT05714020|OTHER|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
219188801|NCT05714020|OTHER|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
219188802|NCT01624129|DRUG|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
219188803|NCT04076618|DEVICE|Vest|Weighted Vest worn \> or = 8 hours per day
219188804|NCT04076618|BEHAVIORAL|Resistance Exercise Training|Structured exercise training 3 days a week
219390683|NCT04165395|DEVICE|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
219390684|NCT04165395|DEVICE|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
219390685|NCT05774470|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
219390686|NCT03446170|BEHAVIORAL|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
219390687|NCT06970587|PROCEDURE|percutaneous cystolithotripsy|to compare percutaneous cystolithotripsy with transurethral cystolithotripsy as minimally invasive surgical treatments for urinary bladder stones in pre-school age boys, and to assess the safety and the possible complications of both procedures
219390688|NCT06971679|BEHAVIORAL|Flipped Method|In the first week of the clinical practice, the E-learning module prepared by the researchers within the scope of the flipped education method was shared with the intervention group students and all students were shown in a conference room. After the training, PBL modules (different cases related to patient safety for each group) were shared with the students divided into groups of 3-5 students within the scope of PBL and they were given one week to prepare. In the other weeks of the clinical practice, face-to-face case discussions were held with the groups. These case discussions lasted an average of 40 minutes.
219390689|NCT06969560|DEVICE|Remote Physiologic Monitoring (RPM)|The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks.
219188805|NCT04076618|BEHAVIORAL|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
219188806|NCT04978480|OTHER|no intervention|There is no intervention. We are only collecting standard of care data.
219188807|NCT04903678|DRUG|Melphalan|Melphalan is performed for intrathecal chemotherapy
219188808|NCT05943665|DRUG|MDMA|medication and therapy combined
219188809|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
219188810|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
219188811|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
219001280|NCT00530309|DRUG|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
219001281|NCT00530309|DRUG|Placebo|Subjects will also receive placebo.
219001282|NCT03706105|BEHAVIORAL|Cardiac Rehabilitation|3 x week \~1 hour of exercise + education
219188812|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
219188813|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 1)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²"
219188814|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 2)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²"
219188815|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 3)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²"
219188816|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 4)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²"
219188817|NCT05796167|DRUG|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
219390690|NCT06969508|OTHER|core stabilitation exercises|The core stabilization exercise program aimed to strengthen deep spinal muscles: transversus abdominis (abdominal bracing), multifidus (segmental stability), and pelvic floor muscles (pelvic support). Participants received videotaped instructions for performing these exercises at home regularly for 6 months, with a gradual increase in difficulty.
219390691|NCT06339424|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
219390692|NCT06339424|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
219390693|NCT06339424|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
219390694|NCT04978753|DRUG|Anlotinib|"1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;"
219390695|NCT04219137|GENETIC|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
219390696|NCT05395416|DRUG|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
219390697|NCT05395416|DRUG|Placebo|administered orally once daily for 12 weeks
219390698|NCT04491279|PROCEDURE|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
219390699|NCT04491279|PROCEDURE|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
219390700|NCT04491279|PROCEDURE|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
219390701|NCT04491279|PROCEDURE|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
219390702|NCT06165419|RADIATION|SBRT to the spine|Stereotactic body radiation therapy (SBRT) administered to spine metastases
219390703|NCT02111811|OTHER|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
219390704|NCT02101008|DRUG|disulfiram and chelated zinc|
219390705|NCT02845869|DEVICE|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
219390706|NCT02845869|DEVICE|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
219390707|NCT03013595|BEHAVIORAL|TRAM feedback|
219390708|NCT01363843|DRUG|FOLFOX6|FOLFOX6
219390709|NCT01363843|RADIATION|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
219390710|NCT01363843|PROCEDURE|Surgery|
219390711|NCT02708212|PROCEDURE|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
219390712|NCT05738616|COMBINATION_PRODUCT|Lenvatinib combined with TACE and Camrelizumab|Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
219390713|NCT04238845|DRUG|AQSP Administration|Three days treatment of all children with AQSP for SMC
219390714|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
219390715|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
219390716|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Zinc|Daily supplementation with Zinc
219390717|NCT05734937|OTHER|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
219390718|NCT02467114|DEVICE|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
219390719|NCT02467114|DEVICE|Sham coil stimulation|Stimulation with a sham coil as a comparison
219390720|NCT02467114|OTHER|Control without stimulation|
219390721|NCT06971952|BEHAVIORAL|Conditional Cash Transfer Incentive for Household Contact Screening|Households with index people with TB (PWTB) will be consecutively recruited and offered a conditional cash transfer once all HHCs complete the facility-based tuberculosis (TB) screening procedures. The participants will be notified of the cash transfer during the consenting process for this phase. They will be informed that if all household contacts complete the recommended TB screening, the cash transfer will be given to the head of household during the home visit at 2 months.
219390722|NCT06971198|DRUG|HSK39004|0.75\~4mg
219390723|NCT06971198|DRUG|Placebo|0.75\~4mg
219390724|NCT06971601|DIAGNOSTIC_TEST|Provocative test|The clinical evaluation specific to Infrapatellar fat pad is based on a series of five standardized clinical tests, extensively described in the specialized literature: provoked palpation of the fat pad, provoked passive extension, Hoffa's test, gliding test, and provoked passive flexion. These tests are performed in a randomized order to limit sequence bias. A test is considered positive if it reproduces the patient's typical anterior knee pain with an intensity greater than 2/10 on the numerical pain scale. Although widely used, these tests have not yet undergone rigorous methodological validation, which this study specifically aims to address.
219390725|NCT06969976|PROCEDURE|curl exericse|we use the curl exercise for control group to investigate the immediate effect of it on muscle strength in normal adults
219390726|NCT06969976|PROCEDURE|dry cupping and curl exercise|use dynamometer to measure biceps muscle strength in normal adults during the application of dry cupping with curl exercise
219390727|NCT06971237|DRUG|Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization|"Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT.~\- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control"
219390728|NCT06971237|DRUG|Atezolizumab ± Bevacizumab|Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.
219390729|NCT06971328|OTHER|ACT-based psychoeducation|It is thought that ACT-based psychoeducation will be an effective psychiatric nursing practice in reducing the care burden of individuals caring for schizophrenia patients and increasing their post-traumatic development and psychological resilience. However, no study has been found in the literature evaluating the effects of these three parameters. In general, the number of ACT-based psychoeducation studies applied to schizophrenia caregivers is quite low. Three thesis studies were found in our country, and no study examining the effect of ACT-based psychoeducation on the post-traumatic development levels of schizophrenia caregivers was found in the domestic and foreign literature. Based on this gap in the literature, the planned study is aimed to be presented to the literature as an intervention that can be used in holistic psychiatric nursing care and to reveal its effects in the specified parameters.
219390730|NCT03897491|DRUG|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
219390731|NCT06971965|DRUG|Levothyroxin|During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.
219390732|NCT06971770|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219188818|NCT05218889|DRUG|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
219188819|NCT05218889|DRUG|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
219390733|NCT06964867|OTHER|Multimedia Health Education|Multimedia health education was designed as an intervention. This intervention was administered by a single vitreoretinal specialist with over a decade of clinical experience. This standardized protocol comprised a 30-minute didactic session utilizing power point presentations (PPT), systematically covering: 1) Etiopathogenesis: Molecular mechanisms of vitreous syneresis and collagen aggregation; 2) Symptomatology: Characteristic visual phenomena and differential diagnosis; 3) Therapeutic modalities: Evidence hierarchy from observation to vitrectomy (including Nd:YAG laser efficacy controversies); 4) Follow-up necessity: Red flag symptoms warranting urgent re-evaluation (sudden floaters with photopsia)
219390734|NCT06970132|DRUG|SY-5933|KRAS p.G12C inhibitor
219390735|NCT06970132|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
219390736|NCT06971575|DIAGNOSTIC_TEST|Magnetic resonance neurography|Patients will undergo a cervical MRI with specialized magnetic resonance neurography sequences to evaluate the extraforaminal cervical nerve roots.
219390737|NCT05341466|OTHER|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
219188820|NCT05752071|DEVICE|Gastric electrical stimulation|Mounting of a temporary gastric pacemaker
219188821|NCT03920358|DEVICE|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
219390738|NCT05341466|OTHER|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
219390741|NCT05161468|DRUG|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
219390742|NCT05161468|DRUG|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
219390743|NCT05161468|DRUG|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
219390744|NCT05542342|DRUG|Tislelizumab|200 mg IV once every 3 weeks
219188822|NCT02270814|DRUG|nab-paclitaxel|
219390745|NCT05542342|DRUG|Sitravatinib Malate|100 mg orally once daily
219390746|NCT06007170|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
219390747|NCT05514665|DEVICE|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
219390748|NCT03291379|DRUG|BTG-002814|BTG-002814 containing 100 mg vandetanib
219390749|NCT01165008|DRUG|Anakinra|
219390750|NCT05569577|DRUG|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
219390751|NCT05569577|DRUG|estrogen and dydrogesterone|estrogen and dydrogesterone
219390752|NCT01478347|BIOLOGICAL|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
219390753|NCT00196937|BIOLOGICAL|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
219390754|NCT05176028|OTHER|conventional physiotherapy|For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
219390755|NCT05176028|OTHER|fascial release|Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
219390756|NCT00097266|DRUG|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
219390757|NCT00097266|DRUG|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
219390758|NCT00097266|DRUG|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
219390759|NCT02450357|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
219001283|NCT01386827|BIOLOGICAL|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later
219188823|NCT02270814|DRUG|Cisplatin|
219188824|NCT02270814|DRUG|Carboplatin|
219188825|NCT02270814|BIOLOGICAL|Cetuximab|
219188826|NCT01928394|BIOLOGICAL|Nivolumab|
219188827|NCT01928394|BIOLOGICAL|Ipilimumab|
219188828|NCT01928394|DRUG|Cobimetinib|
219390760|NCT02450357|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219390761|NCT03489291|GENETIC|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
219390762|NCT03195790|BEHAVIORAL|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
219390763|NCT02556762|RADIATION|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
219390764|NCT02556762|RADIATION|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
219390765|NCT02556762|DRUG|PF|Chemotherapy: Cisplatin and 5fluorouracil
219390766|NCT05621512|OTHER|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
219390767|NCT00001737|DRUG|Cyclosporin A Implant|
219390768|NCT06513195|PROCEDURE|endoscopic ultrasound-guided portal pressure measurement|The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
219390769|NCT05717322|BEHAVIORAL|TENS|apply TENS after orthognathic surgery
219390770|NCT05717322|BEHAVIORAL|sham TENS|apply non active TENS after orthognathic surgery
219390771|NCT06969950|OTHER|App-Delivered Mindfulness Training (MT).|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based for two weeks
219390772|NCT06969950|OTHER|Online Virtual Training|A sub-group of 25 participants, either from the both intervention or control group, the will receive a virtual online training delivered via zoom calls. It is a group session program which includes 4 mindfulness-based sessions of about 60 minutes of brief didactic and experience-based for four weeks.
219390773|NCT00153166|DRUG|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
219390774|NCT00153166|DRUG|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
219390775|NCT00153166|DRUG|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
219390776|NCT00153166|DRUG|placebo/placebo|placebo orally three times daily
219390777|NCT01462292|DRUG|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
219390778|NCT01462292|DRUG|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
219390779|NCT01462292|DRUG|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
219390780|NCT01462292|DRUG|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
219390781|NCT01863862|RADIATION|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
219390782|NCT02333045|DRUG|Truvada qd|Truvada 1 tablet PO daily for 7 days
219390783|NCT02333045|DRUG|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
219390784|NCT00495846|DRUG|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
219390785|NCT00495846|OTHER|Locoregional treatments|
219390786|NCT00997685|DRUG|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
219390787|NCT04211324|DEVICE|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
219390788|NCT04211324|DEVICE|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
219390789|NCT05677945|DRUG|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
219390790|NCT05677945|DRUG|3Mix: Modified triple antibiotic mix in propylene glycol|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
219390791|NCT02827552|OTHER|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
219390792|NCT02973815|BEHAVIORAL|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
219390793|NCT03690258|DEVICE|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
219390794|NCT03993743|BIOLOGICAL|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
219390795|NCT04387474|DEVICE|Brain-computer interface|brain-computer interface rehabilitation training.
219390796|NCT04387474|OTHER|Traditional rehabilitation|traditional rehabilitation training.
219390797|NCT04710940|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
219390798|NCT04710940|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
219390799|NCT00953121|DRUG|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
219390800|NCT00847717|PROCEDURE|Selective neck dissection|Level IIb preserving neck dissection
219390801|NCT00847717|PROCEDURE|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
219390802|NCT00000681|DRUG|Bleomycin sulfate|
219390803|NCT00000681|DRUG|Vincristine sulfate|
219001284|NCT01386827|BIOLOGICAL|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later
219390804|NCT00000681|DRUG|Doxorubicin hydrochloride|
219390805|NCT00000681|DRUG|Zidovudine|
219390806|NCT00000681|DRUG|Sargramostim|
219390807|NCT03992300|DEVICE|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
219390808|NCT02226510|DRUG|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
219390809|NCT02226510|DRUG|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
219390810|NCT02342561|DEVICE|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
219390811|NCT01145105|PROCEDURE|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
219390812|NCT01145105|PROCEDURE|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
219390813|NCT04634968|BEHAVIORAL|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
219390814|NCT04634968|BEHAVIORAL|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
219390815|NCT04494711|BEHAVIORAL|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
219390816|NCT06326229|OTHER|ICF entities assessment|A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
219390817|NCT03997630|DEVICE|High flow Oxygenation|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
219390818|NCT03997630|DEVICE|Standard oxygen|Control group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
219390819|NCT04219267|BEHAVIORAL|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
219390820|NCT04219267|BEHAVIORAL|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
219390821|NCT02818634|PROCEDURE|Harvesting rib cartilage|
219390822|NCT00974779|DEVICE|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
219390823|NCT00974779|DEVICE|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
219390824|NCT01057303|GENETIC|RNA analysis|
219390825|NCT01057303|GENETIC|gene expression analysis|
219390826|NCT01057303|GENETIC|reverse transcriptase-polymerase chain reaction|
219001285|NCT01386827|BIOLOGICAL|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
219001286|NCT01386827|BIOLOGICAL|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
219001287|NCT05101005|DEVICE|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
219390827|NCT01057303|OTHER|laboratory biomarker analysis|
219390828|NCT01145391|OTHER|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
219390829|NCT04606511|DIAGNOSTIC_TEST|Circumference tape measurements|centimeter and volume criterias
219390830|NCT04606511|DIAGNOSTIC_TEST|Indocyanine green lymphangiography|Presence of dermal backflow
219390831|NCT04606511|DIAGNOSTIC_TEST|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
219390832|NCT04606511|DIAGNOSTIC_TEST|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
219390833|NCT04940598|OTHER|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
219390834|NCT04940598|OTHER|No-exercise control group|No-exercise control group
219390835|NCT02975154|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
219390836|NCT04914130|OTHER|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
219390837|NCT05258058|BEHAVIORAL|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
219390838|NCT04138706|DRUG|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
219390839|NCT04138706|DRUG|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
219390840|NCT04630340|DEVICE|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
219390841|NCT03715543|PROCEDURE|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
219390842|NCT03312010|DEVICE|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
219390843|NCT03312010|DEVICE|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
219390844|NCT05610969|OTHER|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
219390845|NCT05610969|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
219390846|NCT03037905|DEVICE|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
219390847|NCT03689738|OTHER|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
219390848|NCT03689738|OTHER|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
219390849|NCT06667128|OTHER|Rapid Uptitration of Guideline-Directed Medical Therapy|Rapid up-titration of GDMT guided by protocol-specific guideline.
219390850|NCT06667128|DIAGNOSTIC_TEST|Elecsys® NT-proBNP - Roche Diagnostics|An assay provided by Roche (Elecsys® NT-proBNP - Roche Diagnostics) will be used to assess NT-proBNP levels in the Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring, with the purpose of evaluating any differences in marker dosage between the indicated method and the monitoring by the hospital laboratory analysis.
219390851|NCT06667128|OTHER|Rapid Up-Titration GDMT Group with Hospital Monitoring|Rapid Up-Titration GDMT Group guided by protocol-specific guideline and hospital monitoring.
219390852|NCT06661759|BEHAVIORAL|Clinic-based and technology-supported sleep intervention|CATS sleep intervention: The in-person sleep education and consultation will consist of 3 face-to-face, one-on-one sessions held 3 months apart during the child's routine clinic visit.The digital component of the sleep intervention will extend in-person education by providing ongoing support. Participants will receive one digital session per week for four weeks after the baseline, 3-month, and 6-month clinic visits, totaling 12 sessions.
219390853|NCT05913401|BEHAVIORAL|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
219390854|NCT05913401|BEHAVIORAL|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
219390855|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.2% Ointment|Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks. GTN functions as a nitric oxide donor, reducing internal anal sphincter tone to improve blood flow and promote fissure healing. The study aims to assess its effectiveness in symptom relief, fissure healing, and associated side effects such as headaches and dizziness.
219001288|NCT05101005|DEVICE|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
219001289|NCT05685966|OTHER|no intervention|no intervention
219001290|NCT05351125|PROCEDURE|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
219001291|NCT03321123|DRUG|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
219001292|NCT02905552|OTHER|No intervention|
219390856|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.4% Ointment|Participants will apply 0.4% Glyceryl Trinitrate (GTN) ointment twice daily for four weeks. This increased concentration aims to determine dose-dependent efficacy and adverse effects in treating acute anal fissures. GTN acts by relaxing smooth muscle, decreasing sphincter tone, and enhancing mucosal blood flow to promote healing.
219390857|NCT06859554|DRUG|Nifedipine 0.2% Ointment|Participants will apply 0.2% Nifedipine ointment twice daily for four weeks. Nifedipine, a calcium channel blocker, reduces sphincter tone by inhibiting calcium influx into smooth muscle cells, leading to improved fissure healing. This arm will assess its effectiveness in symptom relief and healing rates, with a focus on side effects such as local irritation or hypotension.
219390858|NCT06859554|DRUG|Nifedipine 0.5% Ointment|Participants will apply 0.5% Nifedipine ointment twice daily for four weeks. This higher concentration is used to evaluate whether increased potency provides superior symptom resolution and healing rates compared to 0.2% Nifedipine. The study will also assess any potential adverse effects, including local irritation, dizziness, and hypotension.
219390859|NCT04579393|DRUG|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
219390860|NCT04579393|DRUG|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
219390861|NCT00101088|DRUG|imatinib mesylate|Given orally
219390862|NCT00101088|DRUG|temsirolimus|Given IV
219390863|NCT00101088|OTHER|laboratory biomarker analysis|Correlative studies
219390864|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
219390865|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
219390866|NCT03763279|DEVICE|Monofilament suture|Use of Polydioxanone monofilament suture
219390867|NCT06178640|DRUG|Simvastatin 40 mg film-coated tablet|Simvastatin 40 mg film-coated tablet
219390868|NCT06178640|DRUG|Zocor 40 mg film-coated tablet|Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
219390869|NCT05296057|DEVICE|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
219390870|NCT03303430|DIAGNOSTIC_TEST|MRI|Diffusion weighted imaging 24 hours after revascularisation
219390871|NCT03762980|OTHER|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
219390872|NCT03560895|DEVICE|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
219390873|NCT03560895|DEVICE|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
219390874|NCT04775043|DIAGNOSTIC_TEST|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
219390875|NCT04891601|PROCEDURE|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
219390876|NCT01064089|DRUG|HSP990|
219390877|NCT05054946|PROCEDURE|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
219390878|NCT01928030|BIOLOGICAL|recombinant human hyaluronidase|Given SC
219390879|NCT03557372|RADIATION|Mathematical Model-Adapted Radiation Fractionation Schedule|"* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
219390880|NCT05778318|DRUG|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
219390881|NCT05778318|OTHER|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
219390882|NCT01720771|DIETARY_SUPPLEMENT|probiotic tablet|Intake of one probiotic lozenge tablet per day
219390883|NCT01720771|DIETARY_SUPPLEMENT|sugar pill|one tablet daily
219390884|NCT03972371|DEVICE|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
219390885|NCT04397133|OTHER|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
219188829|NCT05719584|OTHER|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
219390886|NCT04397133|OTHER|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
219001293|NCT00090974|PROCEDURE|quality-of-life assessment|
219390887|NCT04713319|DRUG|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
219001294|NCT02495805|PROCEDURE|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
219390888|NCT04713319|OTHER|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
219390889|NCT03540017|DRUG|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
219390890|NCT03666767|OTHER|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
219390891|NCT01252329|PROCEDURE|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
219390892|NCT05418946|DRUG|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
219390893|NCT00735423|DEVICE|No intervention|IDE used for outcome measurement not intervention
219390894|NCT00196885|DRUG|N-acetylcysteine|
219390895|NCT03667131|DRUG|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
219390896|NCT03667131|DRUG|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
219390897|NCT03167697|DIETARY_SUPPLEMENT|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
219390898|NCT03167697|OTHER|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
219390899|NCT05045053|DRUG|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
219390900|NCT02042131|BEHAVIORAL|Treatment As Usual (TAU)|
219390901|NCT02042131|BEHAVIORAL|Standard Crisis Response Plan (S-CRP)|
219390902|NCT02042131|BEHAVIORAL|Enhanced Crisis Response Plan (E-CRP)|
219390903|NCT01787591|OTHER|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
219390904|NCT01787591|OTHER|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
219390905|NCT01787591|OTHER|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
219390906|NCT01787591|OTHER|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
219001295|NCT02495805|PROCEDURE|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
219001296|NCT01717261|RADIATION|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
219001297|NCT00171730|DRUG|Pasireotide|
219390907|NCT02513381|OTHER|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
219390908|NCT02513381|OTHER|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
219390909|NCT01565486|DEVICE|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
219390910|NCT01565486|DEVICE|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
219390911|NCT01581190|DIETARY_SUPPLEMENT|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
219390912|NCT00011895|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
219390913|NCT00011895|DRUG|Efavirenz|
219390914|NCT05739708|OTHER|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
219390915|NCT02725177|DRUG|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
219390916|NCT02725177|DRUG|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
219390917|NCT01513018|OTHER|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
219390918|NCT01513018|OTHER|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
219390919|NCT02108730|PROCEDURE|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
219390920|NCT04419415|DIETARY_SUPPLEMENT|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
219390921|NCT04419415|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
219390922|NCT04419415|OTHER|Skipping breakfast|Participants will be asked to skip breakfast.
219390923|NCT00793585|DRUG|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
219390924|NCT00793585|OTHER|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
219390925|NCT02438072|DRUG|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
219390926|NCT01936337|DRUG|DLX105 Hydrogel|topical administration on psoriatic plaque
219390927|NCT01936337|DRUG|Placebo|topical administration on psoriatic plaque
219390928|NCT03373786|DRUG|RG012|RG012 in 0.3% sodium chloride
219390929|NCT00316901|PROCEDURE|computed tomography|
219390930|NCT00316901|PROCEDURE|positron emission tomography|
219390931|NCT00316901|RADIATION|fludeoxyglucose F 18|
219390932|NCT06509516|OTHER|Modified Sleeper-Stretch|Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
219390933|NCT04711421|DEVICE|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
219390934|NCT00377299|DRUG|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
219390935|NCT00377299|DRUG|Placebo|Placebo matching active medication in all other physical aspects
219390936|NCT02519764|OTHER|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
219390937|NCT02519764|OTHER|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
219390938|NCT02789696|OTHER|Diagnosis of acromegaly|Biological analysis of IGF-1
219390939|NCT04805931|BEHAVIORAL|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
219390940|NCT00710645|DEVICE|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
219390941|NCT01470339|DRUG|duloxetine|duloxetine 60mg once a day for 5 weeks
219390942|NCT06774417|OTHER|Digital nudge|Digital help seeking advancement strategies over text and online.
219001298|NCT01655706|DRUG|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
219390943|NCT06911255|DRUG|Tremelimumab Plus Durvalumab (MEDI4736)|Study subjects will receive 1,500 mg of durvalumab intravenously every 4 weeks until PD is observed. However, treatment will be discontinued if unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria are met. Tremelimumab will be administered first, and durvalumab infusion will begin approximately 1 hour (up to 2 hours) after the completion of tremelimumab infusion. The standard infusion time for each drug is 1 hour, but if the infusion is temporarily interrupted, the total duration should not exceed 8 hours at room temperature.
219390944|NCT06911255|PROCEDURE|Transarterial chemoembolization (TACE)|TACE will be carried out 1 to 2 weeks (7 to 14 days) after the administration of tremelimumab + durvalumab, and thereafter, it will be performed as needed at the discretion of the investigator during the treatment period. If additional TACE is performed, there must be at least a 1-week interval between the additional TACE and the administration of durvalumab.
219390945|NCT06916468|DEVICE|VAD with Cotton Dampener|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants. For each anatomical site, one side (either right or left) will receive vibration with cotton, and the opposite side will receive vibration without cotton in a randomized order.
219390946|NCT06916468|DEVICE|Vibratory Anesthetic Device (VAD)|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants.
219390947|NCT06916364|DEVICE|Fiberoptic Assisted Endotracheal Rod Intubation|Fiberoptic-Assisted Endotracheal Rod for Endotracheal Intubation Through a Supraglottic Airway
219390948|NCT06943885|OTHER|5G Mobile Stroke Unit Management|5G MSU is a specialized stroke ambulance equipped with point of care lab, CT scanner, Telemedicine, allowing patients to receive intravenous thrombolysis.
219390949|NCT06943885|OTHER|Standard Management|A regular ambulance. The standard management by EMS includes Electrocardiographic（ECG）monitoring, blood glucose management, airway, respiration, and blood pressure control, complication management, intravenous access establishment and other emergency measures.
219390950|NCT06946537|OTHER|Exposures and measurements|Anthropometry, Body composition (BIA), Nutritional screening (GLIM, SNAQ, NIS, NRS-2002), Functional tests, Seisomocardiography, Muscle strength, Blood tests, Fecal swabs, Indirect calorimetry Orientation-Memory-Concentration (OMC), Sarcopenia, Frailty (Clinical Frailty Scale), Comobidity, Polypharmacy, Portrait photo.
219390951|NCT06952439|DEVICE|Images and cines captured through the capture card (ICC)|A screen capture/recording of the entire exam performed by the ARDMS as per the Image Acquisition Protocol for the FDA Study will be obtained, and the images/cines required for the study that correspond to IUS shall be obtained. The independent research coordinator for the study will review the screen recording and identify the frame/cine for each diagnostic view (ICC) that corresponds to IUS based on the time stamps.
219390952|NCT06954766|DEVICE|CKD-981(1)|20 minutes per day, 5 days a week for 6 weeks.
219390953|NCT06954766|DEVICE|CKD-981(2)|20 minutes per day, 5 days a week for 6 weeks.
219390954|NCT06954766|DEVICE|Sham device|20 minutes per day, 5 days a week for 6 weeks.
219390955|NCT06954766|DRUG|Reference Drug|QD for 6 weeks
219390956|NCT06954766|DRUG|Placebo Drug|QD for 6 weeks
219390957|NCT05842681|DRUG|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
219390958|NCT05842681|DRUG|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
219001299|NCT01655706|DRUG|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
219001300|NCT01753791|DRUG|80 mg PF-06473871|80 mg of PF-06473871 or placebo
219001301|NCT01753791|DRUG|160 mg PF-06473871|160 mg of PF-06473871 or placebo
219001302|NCT01753791|DRUG|320 mg PF-06473871|320 mg of PF-06473871 or placebo
219001303|NCT01753791|DRUG|480 mg PF-06473871|480 mg of PF-06473871 or placebo
219001304|NCT05311540|DRUG|Zinc Sulfate|
219188830|NCT05719584|OTHER|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
219390959|NCT04317482|BEHAVIORAL|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
219390960|NCT04317482|BEHAVIORAL|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
219390961|NCT03165981|BIOLOGICAL|PCV13|ACIP Recommended vaccine
219390962|NCT03165981|BIOLOGICAL|DTaP|ACIP Recommended vaccine
219390963|NCT03165981|BIOLOGICAL|IIV|ACIP Recommended vaccine
219390964|NCT04735835|OTHER|Dietary Intervention|To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
219390965|NCT06140966|DRUG|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
219390966|NCT06140966|DRUG|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
219390967|NCT06140966|DRUG|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
219390968|NCT06140966|DRUG|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
219390969|NCT06140966|DRUG|Cisplatin|Given by vein: days 1-4 of each Induction cycle
219390970|NCT06140966|DRUG|epirubicin|Given by vein: days 1-4 of each Induction cycle
219390971|NCT06140966|DRUG|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
219390972|NCT06140966|DRUG|Etoposide|Given by vein: days 1-4 of each Induction cycle
219390973|NCT06140966|DRUG|Melphalan|Given by vein: day -1 of Transplant
219390974|NCT06140966|PROCEDURE|ASCT|day 0 of Transplant
219390975|NCT06140966|DRUG|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
219390976|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
219390977|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
219390978|NCT05872438|DIAGNOSTIC_TEST|Vaginal, Oral and anal sampling|The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
219390979|NCT05176847|BEHAVIORAL|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
219390980|NCT05176847|BEHAVIORAL|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
219188831|NCT05782075|OTHER|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
219390981|NCT05176847|BEHAVIORAL|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
219390982|NCT05176847|BEHAVIORAL|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
219390983|NCT00608335|DRUG|Micafungin|IV
219390984|NCT06384989|OTHER|Child restraint system with load leg feature|The primary objective is to assess the usability of the load leg design for caregivers who must install the child safety seat into a vehicle. The specific aims are to quantify any errors committed by the participants while installing the car seat (especially related to the use of the load leg) and to assess participants' opinions on the car seat's load leg design.
219390985|NCT04570943|COMBINATION_PRODUCT|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
219390986|NCT04570943|RADIATION|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
219390987|NCT05043116|DIETARY_SUPPLEMENT|Cholecalciferol D3|2000 IU of Vitamin D provided as oral suspension for one year
219188832|NCT04533763|BEHAVIORAL|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
219390988|NCT05043116|OTHER|Oral placebo suspension|Oral suspension with no active substance tasting like the active supplement.
219390989|NCT05720910|OTHER|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
219390990|NCT02699515|DRUG|MSB0011359C|Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
219390991|NCT06523426|DIAGNOSTIC_TEST|Patient treated by spinal endoscopy|Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
219390992|NCT05520619|DRUG|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
219390993|NCT05520619|DRUG|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
219390994|NCT05520619|RADIATION|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
219390995|NCT05417971|OTHER|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
219390996|NCT06362408|DRUG|Dexmedetomidine|Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
219390997|NCT04537390|DIAGNOSTIC_TEST|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
219390998|NCT06396156|PROCEDURE|Anterior enclavation|Anterior enclavation of iris-claw lens
219390999|NCT06396156|PROCEDURE|Posterior enclavation|Posterior enclavation of iris-claw lens
219391000|NCT01815710|OTHER|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
219391001|NCT01815710|OTHER|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
219391002|NCT05238896|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
219391003|NCT05238896|DRUG|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
219391004|NCT00375934|DRUG|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
219391005|NCT00375934|DRUG|Placebo|Oral placebo capsule, every 6 hours
219391006|NCT01605305|DRUG|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
219391007|NCT00293072|DRUG|Rituximab|
219391008|NCT01677611|DRUG|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
219391009|NCT01677611|DRUG|Placebo|
219391010|NCT01300286|DRUG|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
219391011|NCT02901717|DRUG|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
219391012|NCT02901717|DRUG|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
219391013|NCT00631722|DRUG|Quatiapine Fumarate|600-750mg/day
219391014|NCT00631722|DRUG|Haloperidol|12-20mg/day
219391015|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
219391016|NCT00569920|DRUG|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
219391017|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
219391018|NCT04797975|BIOLOGICAL|KDS-1000|"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"
219391019|NCT04797975|OTHER|Placebo|0.9% Normal Saline
219391020|NCT06332144|BEHAVIORAL|Structural vs. Random sequences of stimuli|Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.
219391021|NCT06332144|BEHAVIORAL|Intact vs. Degraded speech|"Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded."
219391022|NCT06332144|BEHAVIORAL|Repeating 5-syllable nonwords or 2-syllable nonwords|Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.
219391023|NCT06332144|BEHAVIORAL|Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.|Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
219391024|NCT06328075|OTHER|non interventional study|non interventional study
219391025|NCT04713020|OTHER|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
219391026|NCT04713020|OTHER|No Intervention:general care|general care
219391027|NCT01257126|DRUG|diclofenac potassium|
219391028|NCT01257126|DRUG|nimesulide|
219391029|NCT06027320|BEHAVIORAL|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
219188833|NCT04533763|BEHAVIORAL|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
219188834|NCT02342613|BIOLOGICAL|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
219188835|NCT04433208|DIETARY_SUPPLEMENT|Complex oligosaccharide|Complex oligosaccharide concentrate
219391030|NCT06027320|BEHAVIORAL|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
219391031|NCT02889510|DRUG|liraglutide|7-week subcutaneous liraglutide once daily
219391032|NCT02889510|DRUG|placebo|7-week subcutaneous placebo once daily
219391033|NCT01959386|DRUG|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
219391034|NCT02706093|OTHER|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
219391035|NCT02706093|OTHER|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
219391036|NCT02706093|OTHER|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]
219391037|NCT02706093|OTHER|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
219391038|NCT03952546|DEVICE|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
219188836|NCT04433208|DIETARY_SUPPLEMENT|Probiotic|Probiotic
219391039|NCT03952546|DEVICE|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
219001305|NCT05349994|OTHER|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
219188837|NCT04433208|OTHER|PPI|Over-the-counter proton pump inhibitor (PPI)
219188838|NCT04433208|OTHER|H2 Blocker|Over-the-counter H2 blocker
219188839|NCT05492825|OTHER|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
219391040|NCT00218244|OTHER|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
219391041|NCT00218244|OTHER|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
219391042|NCT04315363|BEHAVIORAL|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
219391043|NCT04315363|BEHAVIORAL|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
219391044|NCT00292292|DEVICE|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
219391045|NCT00292292|DEVICE|Charite Artificial Disc|Insertion of the Charite
219391046|NCT02734992|BEHAVIORAL|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
219391047|NCT02734992|BEHAVIORAL|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
219391048|NCT03416582|BEHAVIORAL|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
219391049|NCT03416582|BEHAVIORAL|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
219391050|NCT05265013|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion
219391051|NCT05265013|BIOLOGICAL|pembrolizumab|200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion
219391052|NCT00124540|DRUG|misoprostol|
219391053|NCT00124540|DRUG|placebo|placebo resembling misoprosotl
219391054|NCT02584634|DRUG|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
219391055|NCT02584634|DRUG|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
219391056|NCT02584634|DRUG|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
219391057|NCT03345212|OTHER|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
219391058|NCT03976232|DEVICE|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
219391059|NCT03976232|OTHER|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
219391060|NCT03976232|OTHER|tDCS+ CST|This group will receive tDCS along with CST
219391061|NCT00241111|DRUG|zoledronic acid|
219391062|NCT00243893|DRUG|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
219391063|NCT00243893|DRUG|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
219391064|NCT06097585|DRUG|SGLT2 inhibitor|case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
219391065|NCT04904042|DEVICE|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
219391066|NCT01790061|PROCEDURE|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
219391067|NCT01790061|DRUG|Traditional treatments|Medications
219391068|NCT01709877|PROCEDURE|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
219391069|NCT03707977|DRUG|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
219391070|NCT03707977|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
219391071|NCT03707977|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
219391072|NCT03512223|DRUG|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
219391073|NCT05458232|DRUG|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
219391074|NCT04116034|DEVICE|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
219391075|NCT00641147|DRUG|Curcumin|Given PO
219391076|NCT00641147|OTHER|Laboratory Biomarker Analysis|Correlative studies
219391077|NCT00641147|OTHER|Placebo|Given PO
219391078|NCT05035186|DRUG|Amoxicillin|Anti-H. pylori regimens
219391079|NCT04260724|DEVICE|TMS|"* stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
219391080|NCT04260724|DEVICE|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
219391081|NCT03324256|OTHER|energy drink|16 oz cold commercially-available energy drink
219391082|NCT03324256|OTHER|caffeinated drink|16oz cold commercially-available caffeinated drink
219391083|NCT03324256|OTHER|Energy gum|2 pieces of commercially-available energy gum
219391084|NCT03324256|OTHER|placebo gum|2 pieces of commercially-available placebo gum
219391085|NCT03324256|OTHER|Control drink|16oz cold control drink
219391086|NCT03324256|OTHER|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
219391087|NCT06498063|OTHER|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
219391088|NCT06498063|OTHER|Placebo|Placebo (0.9% NaCl).
219391089|NCT06498063|OTHER|Glucagon and exendin 9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
219391090|NCT04879446|PROCEDURE|Concentrated growth factor(CGF)|Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
219391091|NCT04879446|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
219391092|NCT04879446|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied.
219391093|NCT04879446|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied.
219391094|NCT05923905|DRUG|FB1006|30mg/day
219391095|NCT05923905|DRUG|Placebo|30mg/day
219391096|NCT01439958|DRUG|Inhalation|Twice daily inhalation for a maximum of three years.
219391097|NCT01966731|DRUG|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
219391098|NCT06189443|OTHER|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
219391099|NCT02835729|DRUG|Idarubicin|Chemotherapy
219391100|NCT02835729|DRUG|Cytarabine|Chemotherapy
219391101|NCT02835729|DRUG|Indoximod Freebase|IDO pathway inhibitor
219391102|NCT02835729|DRUG|Indoximod HCL F1|IDO pathway inhibitor
219391103|NCT02835729|DRUG|Indoximod HCL F2|IDO pathway inhibitor
219391104|NCT05568745|DEVICE|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
219391105|NCT05568745|DRUG|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
219391106|NCT05568745|DRUG|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
219391107|NCT00353977|BIOLOGICAL|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
219391108|NCT00641940|BEHAVIORAL|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
219391109|NCT00641940|BEHAVIORAL|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
219391110|NCT03631329|DIAGNOSTIC_TEST|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
219391111|NCT03240640|PROCEDURE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
219391112|NCT03240640|PROCEDURE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
219391113|NCT01380093|DRUG|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
219391114|NCT01380093|DRUG|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
219391115|NCT01380093|DRUG|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
219391116|NCT04062812|OTHER|the same citrate dosification in both types|match concentrated and dilute citrate protocol
219391117|NCT02365857|DRUG|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine \& Bupivacaine.
219391118|NCT02365857|DRUG|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
219391119|NCT06511154|OTHER|Cognitive Rehabilitation|"Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises"
219391120|NCT06511154|OTHER|Core-based Upper Extremity Exercises|Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
219391121|NCT05668156|OTHER|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
219391122|NCT04824261|DRUG|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
219391123|NCT04824261|DRUG|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
219391124|NCT04230850|OTHER|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
219391125|NCT04230850|OTHER|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
219391126|NCT04230850|OTHER|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
219391127|NCT04734873|DRUG|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
219391128|NCT04734873|DRUG|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
219391129|NCT04734873|DRUG|Placebo + SOC|IV placebo plus standard of care
219391130|NCT00293280|DRUG|lomustine|
219391131|NCT01939262|OTHER|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
219391132|NCT01939262|OTHER|Control|Participants assigned to the control group will be instructed to follow their usual diets.
219391133|NCT03077048|DRUG|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
219391134|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
219557970|NCT03388008|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
219557971|NCT03388008|DRUG|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
219391135|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
219391136|NCT04024410|OTHER|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
219391137|NCT00230490|DRUG|pradefovir mesylate|
219391138|NCT00230490|DRUG|adefovir dipivoxyl|
219391139|NCT06443112|PROCEDURE|transvaginal cervical cerclage by Mc Donald technique|In the McDonald operation, a suture is is inserted around the exo-cervix as high as possible to approximate to the level of the internal os and thereby prevent second-trimester abortion.
219391140|NCT01742923|BEHAVIORAL|Complex tailored intervention|
219391141|NCT01742923|BEHAVIORAL|Usual care|
219391142|NCT00564928|DRUG|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
219391143|NCT00002187|DRUG|Fomivirsen sodium|
219391144|NCT02175550|DEVICE|NR CC|
219391145|NCT02865369|DRUG|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
219391146|NCT02533115|DRUG|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
219391147|NCT01172080|OTHER|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
219391148|NCT00043147|DRUG|beclomethasone dipropionate|
219391149|NCT00043147|DRUG|methylprednisolone|
219391150|NCT00043147|DRUG|prednisone|
219391151|NCT01683500|DEVICE|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
219391152|NCT00887081|DRUG|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
219391153|NCT03004560|PROCEDURE|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
219391154|NCT03004560|PROCEDURE|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
219391155|NCT05071339|DRUG|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
219391156|NCT01542372|DRUG|Medication augmentation|
219391157|NCT01542372|BEHAVIORAL|CBT|
219391158|NCT04372264|DRUG|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb\_UK) intravenous (IV) was given 70 patients,
219391159|NCT04372264|DRUG|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
219391160|NCT04372264|DRUG|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
219391161|NCT03574207|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
219391162|NCT05240937|BEHAVIORAL|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
219391163|NCT05982977|OTHER|Acupuncture|The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.
219391164|NCT05982977|BEHAVIORAL|Conventional rehabilitation|swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
219391165|NCT02673112|BEHAVIORAL|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
219391166|NCT02673112|BEHAVIORAL|Light stretching (LS)|Brief daily stretching routine.
219391167|NCT02521246|DRUG|Candesartan + Chlorthalidone|
219391168|NCT02521246|DRUG|Candesartan + Chlorthalidone|
219391169|NCT02521246|DRUG|Losartan+hydrochlorothiazide|
219557972|NCT03388008|DRUG|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
219557973|NCT00327691|DRUG|Atorvastatin|
219391170|NCT05361096|OTHER|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
219391171|NCT01853124|DRUG|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
219391172|NCT01853124|DRUG|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
219391173|NCT02267577|DEVICE|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
219391174|NCT02267577|DEVICE|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
219391175|NCT02441803|DRUG|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
219391176|NCT02441803|DRUG|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
219391177|NCT02441803|DRUG|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
219391178|NCT02441803|RADIATION|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
219391179|NCT02441803|DRUG|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
219391180|NCT02441803|BIOLOGICAL|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or \>3.0 X 108 marrow mononuclear cells/kg if bone marrow.
219391181|NCT02441803|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
219391182|NCT02441803|DRUG|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
219391183|NCT02441803|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
219391184|NCT02441803|DRUG|Decitabine|20 mg/m2 by vein on Days 1 - 5.
219391185|NCT02441803|DRUG|Cytarabine|1 g/m2 by vein on Days 6 - 10.
219391186|NCT02441803|DRUG|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
219391187|NCT04710589|RADIATION|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
219391188|NCT02398123|OTHER|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
219391189|NCT02398123|OTHER|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
219391190|NCT02398123|DRUG|Bupivacaine|
219391191|NCT02609711|DRUG|Candesartan cilexetil|
219391192|NCT00442312|DRUG|Combigan Ophthalmic Solutiom|
219391193|NCT00318708|DRUG|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
219391194|NCT00318708|DRUG|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
219391195|NCT00318708|DRUG|placebo clarithromycin|placebo clarithromycin twice daily
219391196|NCT00824538|DRUG|sunitinib malate|
219391197|NCT00824538|OTHER|flow cytometry|
219391198|NCT00824538|OTHER|immunohistochemistry staining method|
219391199|NCT00824538|OTHER|laboratory biomarker analysis|
219391200|NCT02439385|DRUG|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
219391201|NCT02439385|DIETARY_SUPPLEMENT|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
219391202|NCT03342443|DRUG|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
219391203|NCT03342443|DRUG|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
219391204|NCT03675399|OTHER|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
219391205|NCT03675399|OTHER|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
219391206|NCT03424551|DEVICE|vibrator|Local or whole body vibration was applied at six different frequencies
219391207|NCT06128837|DRUG|Irinotecan hydrochloride liposome Injection|Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
219391208|NCT06128837|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
219391209|NCT01979744|PROCEDURE|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
219391210|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
219391211|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
219391212|NCT01979744|PROCEDURE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
219391213|NCT01373554|DRUG|Placebo|30mig/bid or 60mg/bid P.O
219391214|NCT01373554|DRUG|Oltipraz|30mig/bid or 60mg/bid P.O
219391215|NCT02225886|DRUG|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
219391216|NCT02971696|DRUG|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
219391217|NCT02971696|DRUG|Best Supportive care|Liver Support, pain management
219391218|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
219391219|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
219391220|NCT01819961|DRUG|MCT/LCT and fish oil|
219391221|NCT01819961|DRUG|MCT/LCT|
219391222|NCT05721885|BEHAVIORAL|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
219391223|NCT05446597|PROCEDURE|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
219391224|NCT05446597|OTHER|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
219391225|NCT05446597|BEHAVIORAL|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
219391226|NCT04567836|OTHER|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
219391227|NCT02928393|DRUG|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
219391228|NCT02928393|DRUG|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
219391229|NCT02194296|DRUG|Ambroxol hydrochloride - lozenge|
219391230|NCT02194296|DRUG|Ambroxol hydrochloride - syrup|
219391231|NCT06067646|BEHAVIORAL|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
219391232|NCT03396471|DRUG|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
219391233|NCT03396471|RADIATION|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
219391234|NCT02252952|OTHER|Beverage Consumption|
219557974|NCT03915561|DRUG|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
219391235|NCT05760625|DIAGNOSTIC_TEST|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
219391236|NCT02563873|DEVICE|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
219391237|NCT06274333|DRUG|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
219391238|NCT06274333|DRUG|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
219391239|NCT06274333|DRUG|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
219391240|NCT04820478|DIETARY_SUPPLEMENT|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
219391241|NCT04820478|DIETARY_SUPPLEMENT|Placebo|see arm/group description
219557975|NCT03915561|DRUG|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
219391242|NCT02542449|DIETARY_SUPPLEMENT|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
219391243|NCT02542449|DIETARY_SUPPLEMENT|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
219391244|NCT05934760|OTHER|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot"
219391245|NCT05934760|OTHER|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~* 2 min warm-up jogging on the spot~* 2 sets of 12-15 repetitions of:~* Squats~* Hip flexion~* Hip extension~* Hip abduction~* Seated row~* Bench press~* Lateral raises~* 2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
219557976|NCT06081140|DIETARY_SUPPLEMENT|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
219391246|NCT01947673|OTHER|Mindfulness Meditation|
219391247|NCT01947673|OTHER|Health Education|
219391248|NCT00692705|DRUG|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
219391249|NCT00692705|DRUG|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
219391250|NCT01652677|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
219391251|NCT04706390|BIOLOGICAL|covid-19 vaccine|vaccination
219391252|NCT05309070|DIETARY_SUPPLEMENT|N-acetyl cysteine|Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
219391253|NCT05309070|OTHER|placebo|Control group will receive a placebo, in unmarked boxes, during two months
219391254|NCT00164905|DEVICE|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
219557977|NCT02710240|DRUG|Indocyanine Green (ICG)|
219557978|NCT02710240|RADIATION|Intraoperative near-infrared (NIR)|
219391255|NCT06498102|OTHER|Intermittent Fasting: Time Restricted Feeding During 6 Weeks|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
219391256|NCT02904967|BIOLOGICAL|Extra Blood Draw|
219391257|NCT00718861|DRUG|Placebo|
219391258|NCT00718861|DRUG|Zoledronic acid|
219391259|NCT01690234|PROCEDURE|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
219391260|NCT01690234|PROCEDURE|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
219391261|NCT03237845|DRUG|Rimegepant|75 mg tablet QD
219391262|NCT03237845|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
219391263|NCT05174689|DIAGNOSTIC_TEST|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
219391264|NCT05174689|DIAGNOSTIC_TEST|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
219391265|NCT05174689|DIAGNOSTIC_TEST|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
219391266|NCT06343207|DEVICE|Percussive massage gun therapy|Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.
219391267|NCT03037320|PROCEDURE|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
219391268|NCT06106165|OTHER|In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
219391269|NCT06106165|OTHER|Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
219391270|NCT06497725|DEVICE|Teleguidance-facilitated Airway Management|tele-guidence will be provided by an experienced airway expert
219391271|NCT04355117|DRUG|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
219557979|NCT00000243|DRUG|Buprenorphine|
219391272|NCT01256619|DRUG|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
219391273|NCT00092911|DRUG|DVS-233 SR|
219391274|NCT05876572|DRUG|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
219391275|NCT05876572|DEVICE|microneedle injection|Intradermal delivery of naloxone using microneedle
219391276|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
219391277|NCT04132752|OTHER|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
219557980|NCT05626387|DRUG|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
219391278|NCT01889810|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
219391279|NCT05782413|OTHER|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
219391280|NCT05782413|OTHER|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
219391281|NCT03865407|DRUG|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
219391282|NCT02117050|DRUG|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
219391283|NCT03877185|DIAGNOSTIC_TEST|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
219391284|NCT04241003|DEVICE|SmartDrive Mx2+|Rear-mounted power assist
219391285|NCT04459299|DEVICE|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
219391286|NCT03855306|DRUG|Glibesyn|1 tablet contains 5 mg Glibenclamide
219391287|NCT03855306|DRUG|Daonil|1 tablet contains 5 mg Glibenclamide
219391288|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
219391289|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
219391290|NCT03747016|DIETARY_SUPPLEMENT|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
219391291|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
219391292|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G1|The women in delivery room are given glucose injection 300ml.
219391293|NCT03747016|DIETARY_SUPPLEMENT|normal saline N1|The women in delivery room are given normal saline 300ml.
219391294|NCT01140516|DRUG|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
219391295|NCT01140516|OTHER|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
219391296|NCT00916955|OTHER|Observation|Observe development of syndrome over time
219391297|NCT01645280|DRUG|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
219391298|NCT01645280|DRUG|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
219391299|NCT01645280|DRUG|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
219391300|NCT01645280|DRUG|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
219391301|NCT01645280|DRUG|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
219391302|NCT02723162|DRUG|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
219391303|NCT02723162|DRUG|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
219391304|NCT02723162|DRUG|Placebo|Matched placebo
219391305|NCT04174885|PROCEDURE|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
219391306|NCT00973908|DRUG|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
219391307|NCT00973908|DRUG|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
219391308|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
219391309|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
219391310|NCT06024005|DRUG|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
219391311|NCT06024005|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
219391312|NCT00234104|DRUG|OPC-41061(Tolvaptan)|
219391313|NCT02157272|DRUG|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
219391314|NCT04215354|DEVICE|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
219391315|NCT04215354|DEVICE|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
219391316|NCT05186558|DRUG|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
219391317|NCT00493948|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
219391318|NCT01180140|DEVICE|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
219391319|NCT05890638|DRUG|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
219391320|NCT05890638|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
219391321|NCT03430882|DRUG|Carboplatin|Given IV
219391322|NCT03430882|DRUG|Paclitaxel|Given IV
219391323|NCT03430882|DRUG|Sapanisertib|Given PO
219391324|NCT01082913|DEVICE|SSE|Use of SSE or not use of SSE
219391325|NCT01883882|BEHAVIORAL|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
219391326|NCT02361749|DRUG|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
219391327|NCT02361749|PROCEDURE|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
219391328|NCT01819922|DRUG|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
219391329|NCT01819922|DRUG|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
219391330|NCT03120390|OTHER|Best Practice|Undergo usual care
219391331|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo AE
219391332|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo RE
219391333|NCT03120390|OTHER|Laboratory Biomarker Analysis|Correlative studies
219391334|NCT03120390|DEVICE|Monitoring Device|Receive Polar heart rate monitor
219391335|NCT03120390|OTHER|Quality-of-Life Assessment|Ancillary studies
219391336|NCT03120390|OTHER|Questionnaire Administration|Ancillary studies
219391337|NCT01411293|OTHER|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
219391338|NCT01411293|OTHER|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
219391339|NCT00546819|BIOLOGICAL|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
219391340|NCT00546819|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
219391341|NCT04547296|DRUG|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
219391342|NCT05646641|OTHER|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
219391343|NCT03048721|PROCEDURE|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
219391344|NCT03048721|PROCEDURE|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
219391345|NCT03088904|BIOLOGICAL|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
219391346|NCT03088904|BIOLOGICAL|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
219391347|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with a marked tip
219391348|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
219391349|NCT02703116|BEHAVIORAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
219391350|NCT02703116|BEHAVIORAL|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
219391351|NCT04825093|DIETARY_SUPPLEMENT|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
219391352|NCT05967234|BEHAVIORAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
219391353|NCT03476018|DRUG|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
219391354|NCT03476018|DRUG|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
219391355|NCT04686734|OTHER|No active intervention (observational only)|No active intervention (observational only)
219391356|NCT01386099|DRUG|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
219391357|NCT01386099|DRUG|Placebo|Placebo twice a day for 12 weeks.
219391358|NCT05933291|DRUG|steroid|Moderate- or high-dose steroids
219391359|NCT00055419|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
219391360|NCT04399967|BEHAVIORAL|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
219391361|NCT04399967|BEHAVIORAL|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
219391362|NCT04399967|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
219391363|NCT04399967|BEHAVIORAL|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
219391364|NCT04399967|BEHAVIORAL|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
219391365|NCT04399967|BEHAVIORAL|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
219391366|NCT04399967|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
219391367|NCT04399967|BEHAVIORAL|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
219557981|NCT05626387|DRUG|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
219391368|NCT00175006|OTHER|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
219391369|NCT04217902|OTHER|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
219391370|NCT04217902|OTHER|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
219391371|NCT04445467|DRUG|Favipiravir|Favipiravir
219391372|NCT01543451|DRUG|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
219391373|NCT01543451|DRUG|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
219557982|NCT00029211|DRUG|Echinacea|
219557983|NCT04684511|DRUG|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
219557984|NCT04684511|DRUG|Placebo|Matching Placebo
219557985|NCT02798328|DEVICE|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
219188840|NCT05492825|OTHER|Physical Therapy|The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
219188841|NCT05492825|OTHER|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
219188842|NCT02658253|BIOLOGICAL|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
219188843|NCT02658253|BIOLOGICAL|GLA-SE|2.56 µg of GLA content
219391374|NCT01729910|BEHAVIORAL|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
219391375|NCT01729910|BEHAVIORAL|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
219391376|NCT01380496|DRUG|doxycycline monohydrate|tablet, 100 mg, single, oral dose
219391377|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
219391378|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
219391379|NCT02052960|DRUG|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
219391380|NCT02052960|DRUG|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
219391381|NCT02052960|DRUG|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
219391382|NCT03166358|BEHAVIORAL|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
219391383|NCT02166593|DRUG|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
219188844|NCT02658253|BIOLOGICAL|Alhydrogel|0.85 mg og Aluminium content
219188845|NCT02658253|BIOLOGICAL|Placebo|0.9% Na cl
219188846|NCT06080113|RADIATION|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
219391384|NCT02166593|DRUG|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
219391385|NCT00303342|BEHAVIORAL|mind body treatment|regulation of attention, respiration and posture
219391386|NCT00303342|BEHAVIORAL|desensitization|mentation on insomnia behaviors and cognitive activity
219188847|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
219391387|NCT02126644|DRUG|70% glycolic acid|
219391388|NCT06284018|OTHER|Progressive Muscle Relaxation Exercises|"* Focus on the targeted muscle group.~* Take a slow, deep breath while squeezing on muscle group as hard as she can (not to the point of strain). Keep the muscle tensed for 5 seconds.~Hands and arms, forehead ,Eyes and Cheek, Mouth and Jaw , Neck and Shoulder ,Stomach , Leg and Toes"
219391389|NCT06284018|OTHER|Pilates Exercises|Pilates exercise program consisted of floor exercises on a rubber mat, including the following exercises: a- Pelvic Curl. b- Single-Leg Lift. c- Chest Lift. d- Supine Spine Twist. e- Basic Back Extension.
219391390|NCT04180813|DRUG|Linagliptin|drug
219391391|NCT04180813|DRUG|Acarbose|drug
219391392|NCT03849560|BIOLOGICAL|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
219391393|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
219391394|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
219391395|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
219391396|NCT04045613|DRUG|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
219391397|NCT04045613|DRUG|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
219391398|NCT04045613|DRUG|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
219391399|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
219391400|NCT04045613|DRUG|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
219391401|NCT04045613|DRUG|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
219391402|NCT04983901|DRUG|Imipenem/Cilastatin/Relebactam|Given IV
219391403|NCT04983901|DRUG|Cefepime|Given IV
219391404|NCT04983901|DRUG|Meropenem|Given IV
219391405|NCT04983901|DRUG|Piperacillin-Tazobactam|Given IV
219391406|NCT04983901|DRUG|Vancomycin|Given IV
219391407|NCT04983901|DRUG|Daptomycin|Given IV
219391408|NCT04983901|DRUG|Linezolid|Given IV or PO
219391409|NCT01243593|PROCEDURE|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
219391410|NCT01243593|PROCEDURE|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
219391411|NCT01189773|DRUG|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
219391412|NCT01057121|DRUG|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
219391413|NCT03845283|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
219391414|NCT03845283|BEHAVIORAL|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
219391415|NCT03845283|BEHAVIORAL|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
219391416|NCT03845283|BEHAVIORAL|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
219391417|NCT03845283|BEHAVIORAL|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
219391418|NCT05986656|PROCEDURE|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
219391419|NCT03576027|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
219391420|NCT02859415|DRUG|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
219391421|NCT03705923|PROCEDURE|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
219391422|NCT01174784|DEVICE|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
219391423|NCT02282332|DRUG|Ticagrelor|
219391424|NCT01300377|DRUG|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
219391425|NCT01300377|DRUG|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
219391426|NCT01678846|BEHAVIORAL|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good\_school\_toolkit.php).
219391427|NCT04096937|OTHER|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
219391428|NCT02046135|DRUG|Sodium Bicarbonate|
219391429|NCT02046135|DRUG|Sodium Chloride|
219391430|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
219391431|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
219391432|NCT04486521|DRUG|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
219391433|NCT00802165|DEVICE|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
219391434|NCT00802165|DEVICE|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
219391435|NCT00005628|BIOLOGICAL|vitespen|
219391436|NCT00364039|DRUG|AV650|
219391437|NCT00450866|BIOLOGICAL|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
219391438|NCT03558321|PROCEDURE|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
219391439|NCT03558321|PROCEDURE|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
219391440|NCT02183298|DRUG|BI 1356 BS - intravenous|
219391441|NCT02183298|DRUG|BI 1356 BS - Tablet|
219391442|NCT02183298|DRUG|Placebo|
219391443|NCT04877782|DEVICE|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
219391444|NCT02225067|DRUG|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
219391445|NCT04354753|OTHER|No Intervention|No intervention
219391446|NCT05297305|DEVICE|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
219391447|NCT05297305|DEVICE|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
219391448|NCT06970548|DRUG|Levobupivacaine|To evaluate efficacy of addition of dexamethasone to levopubivacaine in tranversusabdominis plane block (TAP) in postoperative pain management, postoperative analgesic consumption, and patient comfort after laparoscopic bariatric surgery.
219391449|NCT06969820|PROCEDURE|Low-dose Radiation Therapy (LDRT) using MRI-based imaging techniques|LDRT using MRI-based imaging techniques by developing an MRI imaging protocol, deep learning-based image enhancement and resolution increase.
219391450|NCT06970639|DRUG|Furmonertinib Mesilate Tablets|Usage and dosage: 80mg, 240mg, or 160mg QD orally Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
219391451|NCT06970639|DRUG|Carboplatin Injection|"Usage and dosage: Administer via IV infusion, with a dosage of AUC5, not exceeding 750 mg.~Medication schedule: every 3 weeks as a cycle, D1 administration per cycle, immediate administration of carboplatin upon completion of pemetrexed infusion, intravenous infusion, carboplatin can be used for up to 4 cycles."
219391452|NCT06970639|DRUG|Cisplatin for injection|Usage and dosage: Administer via IV infusion at a dose of 75 mg/m2. Medication schedule: Every 3 weeks as a cycle, with D1 administration per cycle. Cisplatin is administered approximately 30 minutes after the infusion of pemetrexed, via intravenous infusion. Adequate hydration therapy must be received before and after cisplatin treatment. Cisplatin can be used for up to 4 cycles.
219391453|NCT06970639|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: Intravenous (IV) infusion administration, dosage of 500 mg/m2 Medication schedule: Administer on the first day of each cycle (21 days per cycle, i.e. every 3 weeks) until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs.
219391454|NCT06970639|DRUG|Osimertinib Mesylate Tablets|Usage and dosage: 80mg, QD administration Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
219391455|NCT06969781|DEVICE|MWA|Enrolled participants undergo microwave ablation (MWA) after comprehensive assessment of lesion location, size, and individual condition. CT or other imaging modalities are used to monitor changes in the ablation zone. The puncture needle is appropriately distributed within the lesion based on its morphology, and ablation duration is determined by imaging-confirmed coverage of the lesion. All procedures are performed under general anesthesia. Ablation time, power, and cycles are recorded intraoperatively, with continuous ECG monitoring throughout. Immediate post-procedure chest CT or other imaging is performed to document intraoperative complications (e.g., pneumothorax, bleeding). Participants are routinely observed for 24 hours post-procedure, followed by CT re-examination and documentation of any complications.
219391456|NCT06969781|DRUG|TKI|"1. Study Drug: Furmonertinib (Shanghai Allist Pharmaceuticals Co.,Ltd.);~2. Administration: Oral, 80 mg once daily. In the MWA-TKI group, targeted therapy is initiated post-MWA if no significant complications occur, continuing for up to 24 months without severe toxicity. In the TKI-MWA-TKI group, a 3-month induction with Furmonertinib is followed by CT re-evaluation; if no contraindications are present, MWA is performed, and targeted therapy resumes post-procedure, continuing for up to 21 months without severe toxicity."
219391457|NCT06971406|DRUG|Combination therapy prospective cohort|high-dose firmonertinib (240 mg, daily), bevacizumab (15 mg/kg, every 3 weeks), and pemetrexed (50 mg, intrathecal chemotherapy C1d1d5, then every 3 weeks)
219391458|NCT06971913|DRUG|Interleukin-2 (IL-2)|Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.
219391459|NCT06971913|DRUG|Ganciclovir (GCV)|Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.
219391460|NCT06970197|OTHER|simülation group|İncludes high reality simulation applications.
219391461|NCT06970197|OTHER|out-of-class educational activities group|"It includes a tour of the sales facility, a sapling planting activity and an action for the environment activity to provide experiential learning."
219391462|NCT06969729|PROCEDURE|Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)|Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.
219391463|NCT06970899|DEVICE|PATH EX CycloPE® Device|Participants in this arm will receive two extracorporeal blood filtration treatments using the PATH EX CycloPE® device. The first treatment will be initiated following baseline assessments, and the second treatment will occur 24-36 hours after the start of the first treatment. Each treatment will last up to 4 hours. The device is designed to target and remove bacteria from the bloodstream. All participants will also receive standard-of-care treatment for sepsis, including IV antibiotics, as determined by the treating physician.
219391464|NCT06969885|BEHAVIORAL|Intervention application with virtual reality glasses|In the preoperative period, approximately 1 hour before the procedure, a video will be watched for 15 minutes with virtual reality glasses. Approximately 10 minutes before the procedure, the patients will be administered the Physiological Parameters Monitoring Form, Distress Thermometer and VAS, and the data collection process will be completed.
219391465|NCT06969885|BEHAVIORAL|Standard application|No intervention will be made to the patients outside of the hospital routine, and approximately 10 minutes before the procedure, the Physiological Parameters Monitoring Form, Distress Thermometer and VAS will be applied again and the data collection process will be completed.
219391466|NCT06971809|BEHAVIORAL|Pain resilience|A strengths-based approach to pain recovery
219391467|NCT06971809|BEHAVIORAL|Pain education|A health literacy approach
219391470|NCT05468957|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
219391471|NCT05468957|DRUG|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
219391472|NCT02820259|DRUG|Tacrolimus|
219391473|NCT01568411|DRUG|TD-1211|Period 1
219391474|NCT01568411|DRUG|TD-1211+ itraconazole|Period 2
219557986|NCT01104571|BIOLOGICAL|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery
219557987|NCT01104571|DRUG|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
219557988|NCT01104571|OTHER|laboratory biomarker analysis|
219557989|NCT01104571|PROCEDURE|adjuvant therapy|
219557990|NCT01104571|PROCEDURE|neoadjuvant therapy|
219557991|NCT01104571|PROCEDURE|therapeutic conventional surgery|therapeutic conventional surgery
219557992|NCT00510003|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
219557993|NCT01947309|DRUG|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
219557994|NCT03876028|BIOLOGICAL|Tisagenlecleucel|Infusion
219557995|NCT03876028|DRUG|Ibrutinib|Oral (tablets or capsules)
219391475|NCT01716169|DEVICE|Helicoll|Helicoll Collagen I Wound Dressing
219391476|NCT01716169|DEVICE|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
219391477|NCT03304951|DEVICE|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
219391478|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
219391479|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
219391480|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
219391481|NCT04463030|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
219391482|NCT00553787|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
219391483|NCT00553787|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
219391484|NCT00553787|DRUG|VI-0521|placebo
219391485|NCT03444025|DRUG|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
219391486|NCT02011503|PROCEDURE|Multi-layer compression therapy|Application of multi-layer compression therapy.
219391487|NCT02011503|OTHER|Application of dHACM|Application of dHACM to ulcer.
219391488|NCT00005037|DRUG|temozolomide|
219391489|NCT00005037|DRUG|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
219391490|NCT01088412|DRUG|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
219557996|NCT02832167|BIOLOGICAL|Nivolumab|Specified dose on specified days
219557997|NCT00806962|DRUG|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
219557998|NCT00806962|DEVICE|placebo|intranasal, puff of air, 2 doses, 21 days apart
219557999|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
219558000|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
219558001|NCT03801317|DIETARY_SUPPLEMENT|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
219558002|NCT03801317|DIETARY_SUPPLEMENT|Control|15 grams corn-soya blend
219188848|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
219188849|NCT06503497|BIOLOGICAL|chemotherapy sequential CAR-NK cell infusion|In each chemotherapy cycle, patients received 2 intravenous infusions of CAR-NK on days 2 and 3 after each chemotherapy was discontinued.
219188850|NCT00005095|OTHER|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
219391491|NCT02285010|DRUG|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
219391492|NCT02285010|DRUG|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
219391493|NCT02851446|OTHER|measure dyspnoea> Borg 7|
219391494|NCT02031900|DEVICE|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
219391495|NCT02700581|PROCEDURE|low PEEP conventional ventilation|
219391496|NCT02700581|PROCEDURE|moderate PEEP conventional ventilation|
219391497|NCT02700581|PROCEDURE|low PEEP protective ventilation|
219391498|NCT02700581|PROCEDURE|moderate PEEP protective ventilation|
219391499|NCT04204681|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
219391500|NCT02844608|OTHER|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
219391501|NCT02261740|BEHAVIORAL|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
219391502|NCT05597566|PROCEDURE|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
219391503|NCT02997189|DRUG|OTO-104|12 mg dexamethasone administered intratympanically
219391504|NCT04568174|DRUG|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
219391505|NCT04568174|DRUG|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
219391506|NCT00006168|DRUG|Methotrexate|
219391507|NCT01919372|DEVICE|Telemedic assistance with a technological system|
219391508|NCT01919372|OTHER|Standard care|
219391509|NCT00521963|BIOLOGICAL|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
219391510|NCT00939263|OTHER|assessment of disease activity using the EEsAI|disease activity index
219188851|NCT00005095|OTHER|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
219188852|NCT00005095|PROCEDURE|Surgery|Subjects will be assessed for high risk factors.
219188853|NCT05779969|OTHER|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
219188854|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
219391511|NCT05215210|OTHER|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
219391512|NCT05215210|OTHER|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
219391513|NCT02400112|DRUG|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
219391514|NCT02231203|DRUG|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
219391515|NCT02231203|DRUG|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
219391516|NCT01656616|DRUG|Cyanide antidote administration|
219558003|NCT03801317|DIETARY_SUPPLEMENT|multiple micronutrient|multiple micronutrient sprinkle powder
219558004|NCT01531504|DEVICE|ViKY UP|laparoscopic-assisted hysterectomy procedure
219391517|NCT00611793|DRUG|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
219391518|NCT00754767|DRUG|L-carnitine L-tartrate|Given orally
219391519|NCT00754767|OTHER|placebo|Given orally
219391520|NCT04149522|DEVICE|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
219391521|NCT06496503|BEHAVIORAL|Physical activity Protocol|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
219391522|NCT04635644|PROCEDURE|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
219391523|NCT04635644|PROCEDURE|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
219391524|NCT05938088|DRUG|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
219391525|NCT05938088|DRUG|Arm II (placebo group)|It is performed in the same way as Arm l.
219391526|NCT03809286|DEVICE|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
219391527|NCT03809286|BEHAVIORAL|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
219391528|NCT03809286|DEVICE|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
219391529|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Verisol®|Supplementation with Verisol® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
219391530|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 2.5G|Supplementation with Peptech® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
219391531|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 10.0G|Supplementation with Peptech® collagen will be administered at a dose of 10.0 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
219391532|NCT06971029|DIAGNOSTIC_TEST|Control group|The control group will not receive supplementation.
219391533|NCT06970379|OTHER|T-PRF|Patients received T-PRF placement at the fracture line.
219391534|NCT06970379|OTHER|T-PRF and Laser biomodulation|Subjects underwent the process of bio-stimulation of the fracture line using low-level laser therapy. Wavelength \[λ\]: 660 nm, Power: 100 mW, Spot size \[Ø\]: 0.06 cm2, and for 60 seconds
219391535|NCT06969911|PROCEDURE|Laminate veneer CAD/CAM|Minimally invasive therapeutic intervention with CAD/CAM veneers
219391536|NCT06969911|PROCEDURE|Laminate Veneer Convetional|Minimally invasive therapeutic intervention with CAD/CAM veneers
219391537|NCT06970808|DEVICE|Sampling from the resection margins|"After polypectomy, the base will be irrigated and assessed by the endoscopist, who may also use virtual or vital chromoendoscopy, if needed.~Any residual adenomatous tissue will be removed using the same technique. To confirm the completeness of each polypectomy, two biopsies will be taken from the resection margins for polyps ≤ 5 mm, and three biopsies for polyps 6-9 mm, using standard biopsy forces."
219391538|NCT06969716|OTHER|Detailed geriatric assessment|The demographic characteristics of the patients, comorbid diseases, history and number of falls in the last 6 months will be questioned, and the thyroid stimulating hormone, calciferol, cobalamin, glycosylated hemoglobin, folic acid and glomerular filtration rate levels routinely requested from each patient in the last 3 months will be recorded. During the outpatient clinic application, the patients will undergo neurocognitive assessment, mood assessment, daily living activities assessment, balance and walking assessment, nutritional assessment and frailty assessment. The patients' handgrip strength from their dominant hand will be assessed with a hand dynamometer. The walking speed of the patients will be measured as the number of seconds it takes to walk 4 meters and recorded in seconds. All patients will be questioned about the presence of body pain with the numerical pain scale score and all patients will be evaluated for the presence of fibromyalgia syndrome.
219391539|NCT04914286|DRUG|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
219391540|NCT04914286|DRUG|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
219391541|NCT06971211|DRUG|Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.|Induction therapy, fluzoparib (150mg BID orally), abiraterone acetate tablets (II) (300mg QD orally), and prednisone (5mg BID orally). IMRT was administered as follows: For patients with low metastatic burden tumors: Prostate ± pelvic lymph node radiation + metastatic lesion radiation.For patients with non-low metastatic burden tumors: Prostate±pelvic lymph node radiation.IMRT dosage:Prostate: 70 Gy in 28 fractions (2.5 Gy/fraction, 5 fractions per week).Pelvic lymph nodes: 50.4 Gy in 28 fractions (1.8 Gy/fraction, 5 fractions per week).Fluzoparib and abiraterone acetate (II) were administered concurrently with radiotherapy. Maintenance treatment,patients received the same doses of fluzoparib,abiraterone acetate (II), and prednisone. Each treatment cycle lasted 28 days.
219391542|NCT04022369|BEHAVIORAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
219391543|NCT01333189|OTHER|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
219391544|NCT01333189|OTHER|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
219391545|NCT02426866|DRUG|Efavirenz|
219391546|NCT03477916|BIOLOGICAL|FMT|fecal microbial transplantation (FMT)
219391547|NCT03477916|BIOLOGICAL|Placebo FMT|Placebo fecal microbial transplantation (FMT)
219391548|NCT03477916|DIETARY_SUPPLEMENT|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
219391549|NCT03477916|DIETARY_SUPPLEMENT|Cellulose|Cellulose
219391550|NCT06217406|DRUG|Intravenous acyclovir (ACYCLOVIR )|Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
219188855|NCT02520713|GENETIC|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
219188856|NCT03941405|DRUG|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
219391551|NCT06217406|DRUG|Saline bags|Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
219391552|NCT01240018|DIETARY_SUPPLEMENT|Probiotic|Parallel, randomized, controlled 2 arms study.
219391553|NCT03854487|BEHAVIORAL|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
219391554|NCT03854487|BEHAVIORAL|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
219391555|NCT03854487|BEHAVIORAL|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
219188857|NCT06448299|PROCEDURE|TAPB|Patients will receive ultrasound guided bilateral oblique subcostal TAPB using 25 mL bupivacaine 0.25% in each side
219188858|NCT06448299|BIOLOGICAL|ESPB|Patients will receive ultrasound guided bilateral ESPB at T8 level using 25 mL bupivacaine 0.25% in each side
219188859|NCT06394271|DEVICE|EVAR|Catheter based insertion of aortic endograft via iliac or femoral arteries
219391556|NCT03163238|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
219391557|NCT03163238|DRUG|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
219391558|NCT02343328|BIOLOGICAL|Fecal Microbiota Transplant|
219391559|NCT02343328|BIOLOGICAL|Placebo|
219391560|NCT00649961|DRUG|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
219391561|NCT00661765|DRUG|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
219391562|NCT00661765|DRUG|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
219391563|NCT03744234|PROCEDURE|PRP|Autologous platelet-rich plasma
219391564|NCT03744234|PROCEDURE|Steroid Injection|Steroid injection
219391565|NCT06405204|DRUG|Myoinositol|an enzymatic isoform of inositol and belongs to the vitamin B complex family
219391566|NCT06405204|DRUG|Co-Enzyme Q10|a lipid-soluble quinone, acting as an effective antioxidant,
219391567|NCT06405204|DRUG|Melatonin|an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
219391568|NCT06405204|DRUG|Folic acid|control
219391569|NCT00934063|DRUG|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219391570|NCT00934063|OTHER|No treatment given|Control group not receiving treatment
219391571|NCT02218203|DRUG|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
219391572|NCT02218203|DRUG|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
219391573|NCT02218203|DRUG|Placebo (Dextromethorphan)|0mg Dextromethorphan
219391574|NCT02218203|DRUG|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
219391575|NCT00989703|DRUG|placebo|oral solution, daily for 14 days
219391576|NCT00989703|DRUG|GLPG0259|oral solution
219391577|NCT00989703|DRUG|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
219391578|NCT04718090|PROCEDURE|PENG Block|Pericapsular nerve group block in shoulder surgery.
219391579|NCT02650011|OTHER|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
219391580|NCT00298571|DRUG|.5% bupivacaine with epinephrine|
219391581|NCT02904564|DRUG|MMP with 5-FU|MMP with 5-FU using tattoo device
219391582|NCT02904564|DRUG|MMP with Saline infusion|MMP with saline infusion using tattoo device
219391583|NCT05275413|BEHAVIORAL|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
219391584|NCT05275413|BEHAVIORAL|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
219391585|NCT05275413|OTHER|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
219391586|NCT00649298|PROCEDURE|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
219391587|NCT02489630|DRUG|Ketamine|0.1mg/kg ketamine IV
219391588|NCT02489630|DRUG|Normal Saline|1ml/kg normal saline placebo
219391589|NCT02489630|DRUG|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
219391590|NCT03077295|OTHER|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
219391591|NCT03077295|OTHER|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
219391592|NCT02054650|OTHER|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
219391593|NCT02054650|OTHER|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
219391594|NCT03550144|BEHAVIORAL|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
219391595|NCT03550144|BEHAVIORAL|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
219391596|NCT00033839|DRUG|Civamide (Zucapsaicin)|
219391597|NCT03429556|BIOLOGICAL|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
219391598|NCT03429556|DRUG|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
219391599|NCT01788085|DEVICE|Bravo pH monitoring procedure|Bravo pH monitoring procedure
219391600|NCT03461965|BEHAVIORAL|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
219391601|NCT03461965|BEHAVIORAL|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
219188860|NCT06335849|BIOLOGICAL|LYB004 25µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
219391602|NCT02153515|OTHER|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
219391603|NCT01399827|DRUG|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
219391604|NCT01399827|DRUG|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
219391605|NCT02409498|DRUG|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
219391606|NCT02409498|DRUG|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
219391607|NCT03248466|BIOLOGICAL|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
219391608|NCT01863758|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
219391609|NCT02603640|DEVICE|MRI scanning|
219391610|NCT04232501|DEVICE|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
219391611|NCT02232646|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
219391612|NCT02369510|DRUG|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
219391613|NCT02369510|DRUG|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
219391614|NCT02369510|DRUG|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
219391615|NCT05885685|DRUG|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
219391616|NCT05209243|RADIATION|SBRT|SBRT (all metastatic lesions)
219391617|NCT05209243|RADIATION|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
219391618|NCT01019590|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
219391619|NCT01019590|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|
219391620|NCT02050048|OTHER|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
219391621|NCT00360516|BEHAVIORAL|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
219391622|NCT06279585|OTHER|Physical therapy|Health education sessions and combined therapeutic exercise sessions, based on muscular strength training and cardiorespiratory endurance.
219391623|NCT04591665|OTHER|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
219391624|NCT06336824|DRUG|Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
219391625|NCT06336824|DRUG|IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
219391626|NCT06670677|OTHER|Lifestyle survey completion|For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
219391627|NCT06670677|OTHER|Unlimited on-demand blood pressure measurements with G2C|For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
219391628|NCT06670677|OTHER|Continual blood pressure measurements with G1|For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
219391629|NCT02417220|BEHAVIORAL|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
219391630|NCT02417220|OTHER|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
219391631|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
219391632|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
219391633|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
219391634|NCT03619148|DEVICE|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
219391635|NCT02088216|DRUG|N-acetylcysteine|600mg po twice a day for 12 months
219391636|NCT02088216|OTHER|On-demand treatment|receive as-needed therapy
219391637|NCT04661813|OTHER|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
219391638|NCT02001350|OTHER|Ultrasonography|
219391639|NCT00474227|BEHAVIORAL|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
219391640|NCT01804595|OTHER|Sunscreen|
219391641|NCT01804595|BEHAVIORAL|Text-Message Reminders|
219391642|NCT01804595|OTHER|Sunscreen and Text Message Reminders|
219391643|NCT01804595|BEHAVIORAL|Education|
219391644|NCT04285723|OTHER|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
219391645|NCT03118843|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
219391646|NCT00813475|DRUG|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
219391647|NCT00813475|DRUG|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
219391648|NCT04036617|DRUG|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
219391649|NCT04036617|DRUG|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
219391650|NCT04439578|DRUG|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
219391651|NCT00010023|DRUG|capecitabine|
219391652|NCT00010023|DRUG|cisplatin|
219391653|NCT04283877|DRUG|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
219391654|NCT04283877|DRUG|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
219391655|NCT00372164|PROCEDURE|American Society of Interventional Pain Physician Guidelines|
219391656|NCT04627350|OTHER|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
219391657|NCT06345040|BEHAVIORAL|Virtual-reality intervention|For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
219391658|NCT06345040|BEHAVIORAL|TAU - specialized treatment|The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
219391659|NCT06209957|DRUG|Local corticosteroid injection|Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
219391660|NCT06209957|DRUG|Platelet-rich Plasma Local injection|Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
219391661|NCT05552638|OTHER|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
219391662|NCT03078725|DRUG|Glyburide|oral hypoglycemic agent
219391663|NCT03078725|DRUG|Metformin|oral hypoglycemic agent
219391664|NCT04128657|DIAGNOSTIC_TEST|MA_LARS|Validation of the MA\_LARS and MA\_Wexner
219391665|NCT02204540|BEHAVIORAL|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
219391666|NCT03175380|BIOLOGICAL|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
219391667|NCT06672263|DRUG|TQB3911 tablets|TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
219391668|NCT06863558|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
219391669|NCT06594640|DRUG|Mitoxantrone Hydrochloride Liposome|assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2
219391670|NCT06594640|DRUG|Rituximab (R)|375mg/m2, D2
219391671|NCT06594640|DRUG|Cyclophosphamide (CTX)|750mg/m2, D2
219391672|NCT06594640|DRUG|Vincristin|1.2mg/m2, maximum 2mg， D2
219391673|NCT06594640|DRUG|Prednisolone|60mg/m2, D2-6
219391674|NCT04936425|DEVICE|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
219391675|NCT03063073|DRUG|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
219391676|NCT03063073|DRUG|Bupivacaine|
219391677|NCT02597595|OTHER|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
219391678|NCT01982201|DRUG|Lesinurad 400 mg|
219391679|NCT01982201|DRUG|Tums 500 mg and 750 mg|
219391680|NCT01982201|DRUG|MINTOX 10 mL|
219391681|NCT05178901|BIOLOGICAL|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
219391682|NCT05178901|OTHER|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
219391683|NCT02762864|OTHER|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
219391684|NCT02762864|DRUG|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
219391685|NCT02762864|DRUG|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
219391686|NCT06260150|DEVICE|Intermittent Pneumatic Compression Devices|During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
219391687|NCT00003803|DRUG|cisplatin|
219391688|NCT00003803|DRUG|gemcitabine hydrochloride|
219391689|NCT00003803|RADIATION|radiation therapy|
219391690|NCT02730702|DEVICE|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
219391691|NCT06117592|OTHER|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
219391692|NCT03826992|DRUG|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
219391693|NCT03826992|DRUG|Venetoclax|"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"
219188861|NCT06335849|BIOLOGICAL|LYB004 50µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
219391694|NCT04224987|DRUG|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
219391695|NCT04224987|OTHER|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
219391696|NCT02979067|PROCEDURE|Nasal oxygen flow|Nasal oxygen flow during apnoea
219391697|NCT04603378|OTHER|KB195|KB195 is a novel glycan
219391698|NCT04603378|OTHER|Polydextrose|Polydextrose is an oligosaccharide
219391699|NCT04603378|OTHER|Pullulan|Pullulan is an oligosaccharide
219391700|NCT04603378|OTHER|Maltodextrin|Maltodextrin is a digestible carbohydrate
219391701|NCT06626789|BIOLOGICAL|Amygdala neurofeedback|Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
219391702|NCT06626789|BEHAVIORAL|Sham neurofeedback|Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
219391703|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
219391704|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
219391705|NCT06710405|DRUG|Lidocaine (drug)|a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr.
219391706|NCT06710405|DRUG|Saline infusion (placebo)|Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
219391707|NCT01613235|OTHER|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
219391708|NCT02903511|DRUG|Metformin|Monitoring of safety and tolerability
219391709|NCT02903511|DRUG|Placebo|Monitoring of safety and tolerability
219391710|NCT06710444|PROCEDURE|ultrasound-guided erector spinae plane block|ESPB
219391711|NCT06710444|PROCEDURE|ultrasound-guided retrolaminar plane block|RLB
219391712|NCT06706258|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
219391713|NCT06706258|DRUG|Pepcid (Famotidine) 20 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
219391714|NCT00969618|DRUG|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
219391715|NCT03401489|DEVICE|PACESETTER|Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
219391716|NCT01105351|DIETARY_SUPPLEMENT|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
219391717|NCT01105351|DIETARY_SUPPLEMENT|folic acid|folic acid 400 µg
219391718|NCT06884293|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC): starting dose is 2.0 mg, after 4 weeks of administration, increase to 4.0 mg; After another 4 weeks, increase to 6mg; After another 4 weeks, increase to the maximum dose 9mg for 36 weeks
219391719|NCT06884293|DRUG|semaglutide|Once-weekly injections of gradually increased doses, subcutaneously (SC): starting dose is 0.25 mg, after 4 weeks of administration, increase to 0.5 mg; After another 4 weeks, increase to 1mg; After another 4 weeks, increase to 1.7mg; After another 4 weeks, increase to the maximum 2.5mg for 32 weeks
219391720|NCT06738446|DIETARY_SUPPLEMENT|Multicomponent dietary supplement group|Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks
219391721|NCT01039168|BEHAVIORAL|Workplace dialogue|
219391722|NCT01039168|OTHER|Care as usual|
219391723|NCT05980026|DRUG|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
219391724|NCT05980026|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
219391725|NCT00542347|DRUG|Esomeprazole first|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
219391726|NCT00542347|DRUG|Generic omeprazole first|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
219391727|NCT06748664|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
219391728|NCT06748664|DRUG|Placebo|Take 75mg qd of oral Rimegepan oral tablets with placebo
219391729|NCT06757504|DRUG|TTYP01 Tablets (12mg or 18mg)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
219391730|NCT06757504|DRUG|Placebo (Simulant TTYP01 Tablets)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
219391731|NCT06752811|DRUG|paclitaxel polymeric micelles for injection|Paclitaxel polymeric micelles for injection at a dose of 300 mg/m2 (based on body surface area), administered on Day 1, with intravenous infusion for ≥ 3 hours, every 3 weeks as a cycle.
219391732|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1 and D8 every 3 weeks.
219391733|NCT06752811|DRUG|Paclitaxel for Injection (albumin bound )|Patients in the control group will receive intravenous infusion of paclitaxel for Injection (albumin bound ) at a dose of 125 mg/m2 (based on body surface area), administered at D1, D8, and D15, every 4 weeks as a cycle.
219391734|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1, D8, and D15 every 4 weeks.
219391735|NCT06768164|PROCEDURE|Billroth 2 (B2)|B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy
219391736|NCT06768164|PROCEDURE|Roux-En-Y (REY)|REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy
219391737|NCT00362388|PROCEDURE|Intramyocardial injection of autologous bone marrow cells|
219391738|NCT06891729|DEVICE|Delivery Lumen Access Device|Delivery Lumen Access Device use prior to Vasectomy
219391739|NCT06891729|DEVICE|DLAD|Participants will be exposed to the DLAD during their planned vasectomy
219391740|NCT06901063|DEVICE|ultrasound|Using ultrasound probe to scan and record the bilateral interscalene brachial plexus
219391741|NCT05136885|DRUG|SLS-005|Administration: Infusion Dose: 0.75 g/kg weekly
219391742|NCT05136885|DRUG|Matching Placebo|Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
219391743|NCT04892797|OTHER|Covid-19+ observational|This is observational--there is no intervention
219391744|NCT02653092|DRUG|Insulin|
219391745|NCT02653092|DRUG|Intralipid|
219391746|NCT02653092|DRUG|Dextrose|
219391747|NCT02653092|DRUG|Heparin|
219391748|NCT02653092|DRUG|GnRH|
219391749|NCT02653092|PROCEDURE|Hyperinsulinemic Euglycemic Clamp|
219391750|NCT06743828|OTHER|Fermented meat alternative|Participants incorporate a novel fermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
219391751|NCT06743828|OTHER|Unfermented meat alternative|Participants incorporate an unfermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
219391752|NCT06888414|DIAGNOSTIC_TEST|transvaginal ultrasound|Fifty perimenopausal women presenting with AUB were recruited from the outpatient clinic. Baseline data, including demographic, obstetric, and medical history, BMI, and laboratory investigations (CBC, renal and liver function tests, coagulation profile), were collected. All patients underwent transvaginal 3D ultrasonography and hysteroscopy.
219391753|NCT06826404|DEVICE|Training provided with a wearable ostomy model and standardized patient|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible director in a session and for a maximum of 30 minutes with plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, stoma care will be performed on a wearable colostomy model by a volunteer student who is doing her doctorate in Surgical Diseases Nursing in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the director of the study based on literature, and nursing students will be given the opportunity to ask questions, and then the skill will be demonstrated twice on the wearable stoma model by following the steps in the learning guide."
219391754|NCT06826404|OTHER|Training low fidelity simulator|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible facilitator in one session and for a maximum of 30 minutes, using plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, skill training will be carried out on a lifeless mannequin in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the facilitator of the study based on literature."
219391755|NCT06892704|DRUG|Dupilumab - Standard Dose|24 weeks of dupilumab 300mg q2 weeks
219391756|NCT05363293|DRUG|AL001|a crystal engineered lithium-salicylate-proline lithium delivery product
219391757|NCT05363293|OTHER|Placebo|matching placebo formulation
219391758|NCT06528873|COMBINATION_PRODUCT|Concurrent optical and magnetic stimulation (COMS) treatment|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
219391759|NCT06321419|BEHAVIORAL|Advanced Trauma Life Support training|Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
219391760|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
219391761|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
219391762|NCT06908031|RADIATION|Short-Course Radiotherapy|Patients undergo SCRT at a dose of 5Gy × 5 fractions
219391763|NCT06908031|DRUG|PD-1 monoclonal antibody|Patients complete immune therapy with PD-1 monoclonal antibody for 4 cycles.
219391764|NCT06908031|DRUG|mFOLFOX6 regimen|Patients complete chemotherapy with mFOLFOX6 regimen for 4 cycles.
219391765|NCT06908031|DRUG|Cetuximab|Patients with RAS/BRAF wild-type receive targeting therapy with Cetuximab for 4 cycles.
219391766|NCT06908031|DRUG|Bevacizumab|Patients with RAS/BRAF mutations receive targeting therapy with Bevacizumab for 3 cycles. (Bevacizumab is not used in the last cycle of the bevacizumab group)
219391767|NCT06908031|PROCEDURE|Surgical resection|Surgery either local excition or total mesorectal excision is performed 8-10 weeks after the completion of short-course radiotherapy.
219391768|NCT02726750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219391769|NCT02726750|OTHER|Laboratory Biomarker Analysis|Correlative studies
219391770|NCT04109079|PROCEDURE|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
219391771|NCT04109079|RADIATION|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
219391772|NCT04109079|RADIATION|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
219391773|NCT01318902|DRUG|Ixazomib|Ixazomib capsules.
219391774|NCT01318902|DRUG|Dexamethasone|Dexamethasone tablets.
219391775|NCT06912607|BEHAVIORAL|Balance in Motion Exercise class|8 weeks of 2 meetings/wk exercise class, with a once weekly homework exercise, delivered entirely in ASL
219391776|NCT06828692|COMBINATION_PRODUCT|Group A (clinical guideline+machine learning)|Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
219391777|NCT06828692|COMBINATION_PRODUCT|Group B (clinical guideline+impedance cardiograph+machine learning)|Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
219391778|NCT06828692|OTHER|Group C (usual care)|Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.
219391779|NCT05303675|OTHER|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
219391780|NCT06735131|RADIATION|radiotherapy 5 Gy × 5 fractions, once a day|5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
219391781|NCT06735131|RADIATION|radiotherapy 8 Gy × 5 fractions, once a day|8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
219391782|NCT06735131|RADIATION|radiotherapy 8 Gy × 3 fractions, once every other day|8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
219391783|NCT06735131|RADIATION|radiotherapy 10 Gy× 3 fractions, once every other day|10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
219391784|NCT06735131|RADIATION|radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)
219391785|NCT06735131|DRUG|Toripalimab|Toripalimab (240 mg IV, d1, Q3W)
219391786|NCT06735131|DRUG|chemotherapy regimen selected by the investigator|Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
219391787|NCT06920537|OTHER|Postpartum Cardio-obstetric Rehabilitation Program|The intervention consists of an 8-week exercise and education program with a hybrid format (in person, virtual and pre-recorded sessions). The aerobic exercise intensity will progressively increase from 50 to 85% of Targeted Heart Rate Range (THRR), calculated for middle-aged women using the maximal heart rate (HR) estimated as 206 - (0.88 x age) . First and second weeks training will target an intensity of 50-65% THRR, third and fourth weeks will target 65 to 75% of THRR, fifth to seventh weeks will target 75 to 80%, and eighth week will target 85%. Participants will use Fitbit Charge-6 to monitor THRR during exercise sessions. Pelvic floor, body alignment/core stability, balance, and low back pain prevention exercises will be added to each in-person session and repeated during the online session. Participants from the intervention group will receive recommendations to progressively reach daily 10,000 steps throughout the intervention period.
219001306|NCT06460220|BEHAVIORAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P)|The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
219188862|NCT06335849|BIOLOGICAL|SHINGRIX|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
219188863|NCT02019004|DRUG|Onabotulinum Toxin A|
219391788|NCT06922357|DRUG|HRS-6719|HRS-6719
219188864|NCT02019004|DRUG|Incobotulinum Toxin A|
219188865|NCT03231085|DRUG|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
219391789|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
219391790|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
219391791|NCT06509932|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
219391792|NCT06509932|DEVICE|MoliCare Premium Bed Mats|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
219391793|NCT02747628|DRUG|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
219391794|NCT02747628|DRUG|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
219391795|NCT02747628|DRUG|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
219391796|NCT06949813|BEHAVIORAL|BE-OR: Brief Intervention to the Operating Room|See intervention group section for details
219391797|NCT06949813|OTHER|Interaction: Facetime with Clinical Provider|See Interaction group section for details
219391798|NCT01859351|DRUG|WX-037|
219391799|NCT01859351|DRUG|WX-554|
219391800|NCT00584064|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
219391801|NCT06503991|BEHAVIORAL|Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)|Clinic-based hypertension educational intervention delivered by a Community Health Worker.
219391802|NCT06503991|BEHAVIORAL|Control of Blood Pressure and Risk Attenuation (COBRA)|Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
219429125|NCT05666440|PROCEDURE|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
219429126|NCT05666440|PROCEDURE|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
219429127|NCT03051828|PROCEDURE|fencing|No intervention: practice fencing
219429128|NCT02098005|OTHER|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
219429129|NCT02098005|OTHER|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
219429130|NCT01245205|DRUG|Akt inhibitor MK2206|Given PO
219429131|NCT01245205|DRUG|lapatinib ditosylate|Given PO
219429132|NCT01245205|OTHER|pharmacological study|Correlative studies
219429133|NCT01245205|OTHER|laboratory biomarker analysis|Correlative studies
219429134|NCT03763799|PROCEDURE|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
219429135|NCT03763799|PROCEDURE|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
219429136|NCT04828369|PROCEDURE|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
219429137|NCT04828369|PROCEDURE|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
219429138|NCT03689387|OTHER|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
219391803|NCT04294264|DRUG|Oxaliplatin|Given IV
219391804|NCT04294264|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219391805|NCT06378658|DRUG|BAY2927088|Oral administration
219391806|NCT06378658|DRUG|Esomeprazole|Oral administration
219391807|NCT06378658|OTHER|Food|light low-fat meal or high fat, high calorie meal
219391808|NCT05480137|PROCEDURE|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
219391809|NCT03095534|BEHAVIORAL|3-Step Workout for Life|a 10-week moderate exercise program
219391810|NCT01025180|OTHER|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used"
219391811|NCT03270085|DRUG|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
219391812|NCT03270085|OTHER|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
219391813|NCT00397956|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
219391814|NCT06408090|OTHER|IDECIDE-HOSPICE|12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
219391815|NCT01724606|RADIATION|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
219391816|NCT01724606|DRUG|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
219391817|NCT06211283|DRUG|Sodium valproate|fasted
219391818|NCT06211283|DRUG|Sodium valproate|fed
219391819|NCT03957083|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
219391820|NCT01223911|DRUG|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
219391821|NCT01223911|DRUG|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
219391822|NCT02533960|OTHER|not applicable (observational study)|Observational study without study related intervention.
219391823|NCT02501356|DIETARY_SUPPLEMENT|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
219391824|NCT02501356|DIETARY_SUPPLEMENT|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
219391825|NCT02400346|DRUG|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
219391826|NCT02400346|DRUG|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
219391827|NCT03946306|DRUG|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
219391828|NCT03946306|DEVICE|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
219391829|NCT00683553|DRUG|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
219391830|NCT00683553|DRUG|Placebo|Single IV injection of saline
219391831|NCT02340104|DRUG|Baricitinib|4 milligrams (mg) administered orally
219391832|NCT02340104|DRUG|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
219391833|NCT01269125|DRUG|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
219391834|NCT01269125|PROCEDURE|IVF|Assisted Reproduction Technique.
219391835|NCT03337841|DRUG|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
219391836|NCT01067638|DRUG|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
219391837|NCT01915875|OTHER|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
219391838|NCT04579081|DEVICE|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
219391839|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
219391840|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
219391841|NCT04510922|DRUG|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
219391842|NCT01772225|OTHER|Data collection|Medical record abstraction form and patient survey questionnaire.
219391843|NCT00318838|DRUG|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
219391844|NCT00318838|DRUG|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
219391845|NCT03556722|DEVICE|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
219391846|NCT03556722|DEVICE|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
219391847|NCT01005472|DRUG|sunitinib malate|
219391848|NCT01005472|DRUG|temozolomide|
219391849|NCT01348178|PROCEDURE|Follow-up|Follow-up
219391850|NCT00688493|DRUG|Dapagliflozin|3 x 50 mg tablets, single oral dose
219391851|NCT00688493|DRUG|Dapagliflozin|2 x 10 mg capsules, single oral dose
219391852|NCT00688493|DRUG|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
219391853|NCT00688493|DRUG|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
219391854|NCT01283581|DRUG|Delafloxacin|300mg IV every 12 hours for 5-14 days
219391855|NCT01283581|DRUG|Linezolid|600mg IV every 12 hours for 5-14 days
219391856|NCT01283581|DRUG|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
219391857|NCT01682369|BIOLOGICAL|TIV (Aggripal)|
219391858|NCT01682369|BIOLOGICAL|ATIV (Fluad)|
219391859|NCT03474523|OTHER|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
219391860|NCT03474523|OTHER|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
219391861|NCT00959296|DEVICE|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
219391862|NCT00486226|DEVICE|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
219391863|NCT04457726|BIOLOGICAL|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
219391864|NCT06497426|OTHER|Study intervention|Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
219391865|NCT05682807|DRUG|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
219391866|NCT05682807|DRUG|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
219391867|NCT02983903|PROCEDURE|transbronchial biopsy|
219391868|NCT00366834|DRUG|Casopitant (GW679769) oral tablets|
219391869|NCT00366834|DRUG|Casopitant (GW679769) intravenous|
219391870|NCT00366834|DRUG|Dexamethasone intravenous|
219391871|NCT00366834|DRUG|Ondansetron oral tablets|
219391872|NCT00366834|DRUG|placebo|casopitant placebo
219391873|NCT01869894|PROCEDURE|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
219391874|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
219391875|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
219391876|NCT04704882|OTHER|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
219391877|NCT01259492|DRUG|Placebo|Placebo Comparator: Placebo
219391878|NCT01259492|DRUG|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
219391879|NCT01259492|DRUG|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
219391880|NCT01685294|BEHAVIORAL|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
219391881|NCT00989430|BEHAVIORAL|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
219391882|NCT00734422|BEHAVIORAL|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
219391883|NCT05393583|PROCEDURE|Outpatient hysterectomy|Discharge on the day of the hysterectomy
219391884|NCT05393583|PROCEDURE|Inpatient hysterectomy|1 night hospital stay after hysterectomy
219391885|NCT01062646|BEHAVIORAL|Multimodal music therapy|
219391886|NCT01062646|BEHAVIORAL|Community treatment as usual|
219391887|NCT04413240|DEVICE|Telerehabilitation|"* VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
219391888|NCT04413240|OTHER|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
219391889|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
219391890|NCT02773758|OTHER|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
219391891|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
219391892|NCT02286115|BEHAVIORAL|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
219391893|NCT05720611|BEHAVIORAL|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
219391894|NCT04473261|DRUG|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
219391895|NCT04473261|DRUG|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
219391896|NCT04473261|DRUG|Placebo|Empty capsule will be given as placebo
219391897|NCT04473261|DRUG|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
219391898|NCT05615597|PROCEDURE|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
219391899|NCT01107977|BEHAVIORAL|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
219391900|NCT02046031|DRUG|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
219391901|NCT04749108|DRUG|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
219391902|NCT04749108|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
219391903|NCT04749108|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
219391904|NCT04749108|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
219391905|NCT04510857|DEVICE|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
219391906|NCT04510857|BEHAVIORAL|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
219391907|NCT05241171|DEVICE|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
219391908|NCT06169748|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
219391909|NCT06169748|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
219391910|NCT06169748|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
219391911|NCT04744415|OTHER|Epidemiology of admissions|Cardiology Intensive Care Unit admission
219391912|NCT02571361|DRUG|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
219391913|NCT02571361|DRUG|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
219391914|NCT02571361|DRUG|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
219391915|NCT02571361|DRUG|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
219391916|NCT02571361|DRUG|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
219391917|NCT00663858|DRUG|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
219391918|NCT00663858|DRUG|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
219391919|NCT00663858|OTHER|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
219391920|NCT04685330|PROCEDURE|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
219391921|NCT04685330|DEVICE|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
219391922|NCT00619541|DRUG|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
219391923|NCT00619541|DRUG|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
219188866|NCT06005571|PROCEDURE|composite restoration repair by traditional acid etch treatment procedure and adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
219188867|NCT06005571|PROCEDURE|Composite restoration repair by acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
219391924|NCT00520689|DEVICE|Silicone Hydrogel Contact Lens|use of lens over 2 days
219391925|NCT06451237|DRUG|Isotretinoin capsules|A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
219391926|NCT03188211|OTHER|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
219391927|NCT03188211|OTHER|Control|Any educational program will be delivered to clinicians assigned to control arm
219391928|NCT05746780|PROCEDURE|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
219391929|NCT02778880|DRUG|Ketamine|
219391930|NCT02778880|DRUG|Fentanyl|
219391931|NCT01818375|PROCEDURE|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
219391932|NCT01818375|OTHER|Standard fluid therapy|
219391933|NCT01374581|DRUG|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose"
219391934|NCT01374581|DRUG|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days"
219391935|NCT01374581|DRUG|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
219391936|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
219391937|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
219391938|NCT01008930|PROCEDURE|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
219391939|NCT00680420|PROCEDURE|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
219391940|NCT06529289|OTHER|Training|"We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills."
219391941|NCT01949064|DEVICE|Grindcare|
219391942|NCT01949064|DEVICE|Michigan-type occlusal splint|
219391943|NCT03454048|DRUG|Piperaquine (low dose)|subcurative regimen (480 mg)
219391944|NCT03454048|DRUG|Piperaquine (high dose)|Curative regimen (960mg)
219391945|NCT03454048|DRUG|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
219391946|NCT03454048|DRUG|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
219391947|NCT03454048|OTHER|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
219391948|NCT03454048|OTHER|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
219391949|NCT05197868|PROCEDURE|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
219391950|NCT05197868|PROCEDURE|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
219391951|NCT05197868|PROCEDURE|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
219391952|NCT01008254|BEHAVIORAL|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
219391953|NCT01008254|BEHAVIORAL|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
219391954|NCT01008254|OTHER|No musical prompt|No intervention.
219391955|NCT01166659|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
219391956|NCT02024711|DEVICE|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
219391957|NCT02024711|DEVICE|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
219391958|NCT04536324|PROCEDURE|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
219391959|NCT03463265|DRUG|nab-sirolimus|nab-sirolimus, single agent
219391960|NCT03463265|DRUG|nab-sirolimus + temozolomide|temozolomide, combination
219391961|NCT03463265|DRUG|nab-sirolimus + bevacizumab|bevacizumab, combination
219391962|NCT03463265|DRUG|nab-sirolimus + lomustine|lomustine, combination
219391963|NCT03463265|DRUG|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
219391964|NCT03463265|DRUG|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
219391965|NCT00416351|DRUG|clofarabine|
219391966|NCT04936672|BEHAVIORAL|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
219391967|NCT04137172|PROCEDURE|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
219391968|NCT04137172|PROCEDURE|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
219391969|NCT04137172|PROCEDURE|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
219391970|NCT01371838|DRUG|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
219391971|NCT01371838|DRUG|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
219391972|NCT01334125|DRUG|Metformin|Metformin 1000 mg once daily by mouth for 9 months
219391973|NCT01334125|DRUG|Placebo|2 capsules once daily by mouth for 9 months
219391974|NCT01275261|BEHAVIORAL|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
219391975|NCT01509586|DRUG|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
219391976|NCT06957002|DRUG|Bosentan|Bosentan : 62.5 mg twice a day for 4 weeks and 125 mg twice a day during 9 weeks (treatment length 3 months)
219391977|NCT06957002|DRUG|Glucocorticoids|prespecified GC tapering schedule
219391978|NCT04901026|OTHER|An in-house manikin|Participants obtain an in-house manikin
219391979|NCT03525977|PROCEDURE|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
219391980|NCT04102891|OTHER|Microbiota modulation diet|The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
219391981|NCT02612090|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry
219391982|NCT02612090|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|Placebo
219391983|NCT01264133|DRUG|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
219391984|NCT02242071|BIOLOGICAL|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
219001307|NCT06460220|BEHAVIORAL|Treatment As Usual (TAU)|TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
219391985|NCT00641043|DRUG|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
219391986|NCT00641043|DRUG|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
219391987|NCT01613469|DRUG|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
219391988|NCT06192199|DIAGNOSTIC_TEST|2018 edition of the Guidelines for Diagnosis|According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
219391989|NCT04275310|BEHAVIORAL|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
219391990|NCT05506371|DRUG|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
219391991|NCT05506371|DRUG|SRP|Scaling and root planning (SRP) treatment of periodontitis
219391992|NCT05506371|DRUG|No interventions|Diagnostocs to confirm the healthy state of the gingiva
219391993|NCT03131297|PROCEDURE|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
219391994|NCT00051688|DRUG|tezacitabine|
219391995|NCT00051688|DRUG|oxaliplatin|
219391996|NCT01713985|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219391997|NCT01713985|DEVICE|Thermage|Radiofrequency treatment focusing radiofrequency energy
219391998|NCT00987051|PROCEDURE|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
219391999|NCT01977534|DEVICE|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
219392000|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
219392001|NCT00856752|DRUG|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
219392002|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
219392003|NCT05164952|DRUG|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
219392004|NCT03839433|DRUG|Ciclesonide|
219392005|NCT04471103|OTHER|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
219392006|NCT01759784|BIOLOGICAL|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
219392007|NCT03952923|BIOLOGICAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
219392008|NCT02687113|DEVICE|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
219392009|NCT03952364|OTHER|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
219392010|NCT03586804|OTHER|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
219392011|NCT06060080|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
219392012|NCT03227926|DRUG|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
219392013|NCT03227926|DIAGNOSTIC_TEST|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
219392014|NCT02584985|PROCEDURE|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
219392015|NCT02584985|PROCEDURE|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
219392016|NCT03661385|DRUG|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
219392017|NCT04373122|DEVICE|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
219392018|NCT06032403|BEHAVIORAL|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
219392019|NCT04635735|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
219392020|NCT03989687|DEVICE|Fuji Triage|glass ionomer sealant
219392021|NCT03989687|OTHER|isolation|rubber dam or cotton roll isolation
219392022|NCT03796741|OTHER|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
219392023|NCT03609229|PROCEDURE|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
219392024|NCT03609229|PROCEDURE|Abdominal Sacrocolpopexy|"* By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
219392025|NCT00098345|DRUG|ZD6474 (vandetanib)|oral once daily tablet
219392026|NCT00038194|DRUG|imatinib mesylate|
219392027|NCT00038194|DRUG|docetaxel|
219392028|NCT01823796|OTHER|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
219392029|NCT01823796|OTHER|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
219392030|NCT05167292|OTHER|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
219392031|NCT02078622|OTHER|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
219392032|NCT02349906|DRUG|Treosulfan|
219392033|NCT02349906|DRUG|Busilvex|
219392034|NCT04546256|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
219392035|NCT04546256|DRUG|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
219392036|NCT04297163|OTHER|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
219392037|NCT04297163|OTHER|In Hospital|Face-to-face follow up
219392038|NCT06555094|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
219392039|NCT06555094|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
219392040|NCT06555094|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
219001308|NCT03107936|BEHAVIORAL|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
219188868|NCT06005571|PROCEDURE|Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
219188869|NCT05679375|DRUG|Intrathecal ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine
219392041|NCT00402974|DRUG|menaquinone 7|
219392042|NCT05321797|OTHER|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
219392043|NCT05321797|OTHER|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
219392044|NCT06430749|DEVICE|Microtaze|Targeted Microwave Tissue Coagulation
219392045|NCT05255562|PROCEDURE|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
219392046|NCT05255562|DRUG|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
219392047|NCT01263535|DEVICE|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
219392048|NCT00006270|DRUG|cosyntropin|
219392049|NCT00006270|DRUG|metyrapone|
219392050|NCT01576861|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
219392051|NCT01936649|DRUG|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
219392052|NCT06326840|DRUG|Metformin|All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
219392053|NCT01748396|DRUG|Calcitriol|
219392054|NCT01748396|DRUG|Calcium Carbonate|
219392055|NCT03136705|DRUG|Nicotinamide|Nicotinamide tablet
219392056|NCT03136705|DRUG|Lanthanum Carbonate|Lanthanum Carbonate tablet
219392057|NCT03136705|DRUG|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
219392058|NCT03136705|DRUG|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
219001309|NCT02460614|PROCEDURE|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
219001310|NCT02460614|PROCEDURE|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
219001311|NCT02460614|OTHER|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
219188870|NCT05679375|DRUG|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal
219188871|NCT06837974|OTHER|AI guided TIPS|The TIPS procedure will be conducted under the guidance of AI model which was constructed based on the pre-operation enhanced CT images and intra-operation DSA images.
219188872|NCT06837974|OTHER|Artificially blinded TIPS|The TIPS procedure will be conducted based on the experience of operators.
219392059|NCT03859999|DIAGNOSTIC_TEST|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
219392060|NCT04103372|DIAGNOSTIC_TEST|MRI scan|MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
219392061|NCT04103372|OTHER|Radiologist training|Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
219392062|NCT06637826|BEHAVIORAL|Quaternary Ammonium Compound Disinfectants|"Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
219392063|NCT06637826|BEHAVIORAL|Alcohol-based Disinfectants|"Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
219392064|NCT02991300|DEVICE|BioPoly RS Partial Resurfacing Patella Implant|
219392065|NCT02267512|DRUG|ATG-F|Intravenous (IV)
219392066|NCT04470752|DRUG|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
219392067|NCT04470752|DRUG|InOrpha Solution|glycerol based suspension vehicle
219392068|NCT03510143|DEVICE|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
219392069|NCT03999567|OTHER|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
219392070|NCT03999567|OTHER|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
219392071|NCT01958606|OTHER|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
219392072|NCT01958606|OTHER|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
219392073|NCT04610242|DIAGNOSTIC_TEST|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
219392074|NCT01842893|DRUG|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
219392075|NCT00510588|OTHER|training|regular physical exercise training for 6 months
219392076|NCT00510588|OTHER|training + metformin|regular physical exercise training in combination with metformin for 6 months
219392077|NCT00510588|OTHER|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
219392078|NCT01943123|DIETARY_SUPPLEMENT|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
219392079|NCT01943123|DIETARY_SUPPLEMENT|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
219001312|NCT03465202|DRUG|Capecitabine|
219392080|NCT01651130|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
219392081|NCT05032443|OTHER|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
219392082|NCT00861042|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
219392083|NCT02604719|DRUG|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
219392084|NCT01215318|DEVICE|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
219392085|NCT01466114|DRUG|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
219392086|NCT01466114|OTHER|Placebo|4 capsules PO QD
219392087|NCT01466114|DRUG|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
219392088|NCT01466114|OTHER|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
219392089|NCT01900275|OTHER|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
219392090|NCT04655586|DRUG|rNAPc2|two dose levels of rNAPc2
219392091|NCT04655586|DRUG|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
219392092|NCT05575804|DRUG|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
219392093|NCT05575804|DRUG|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
219392094|NCT03045484|DRUG|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
219392095|NCT03045484|OTHER|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
219392096|NCT02345369|DEVICE|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
219392097|NCT02345369|DEVICE|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
219392098|NCT04578145|DIAGNOSTIC_TEST|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
219392099|NCT04818450|DRUG|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
219392100|NCT01810367|DRUG|ABX Combined With Cisplatin|
219392101|NCT01810367|DRUG|Gemcitabine Combined With Cisplatin|
219392102|NCT03291002|BIOLOGICAL|CV8102|CV8102 alone
219392103|NCT03291002|BIOLOGICAL|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
219392104|NCT05425771|PROCEDURE|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
219392105|NCT04996576|PROCEDURE|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
219392106|NCT04996576|PROCEDURE|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
219392107|NCT01772979|DRUG|Trabectedin|
219392108|NCT04637451|PROCEDURE|Root coverage treatment|Gingival unit graft Connective tissue graft
219558005|NCT04522804|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
219558006|NCT00282581|BIOLOGICAL|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
219558007|NCT00269334|DRUG|Using Citalopram(drug) or Paroxetine(drug)|
219392109|NCT00000110|PROCEDURE|magnetic resonance spectroscopy|
219392110|NCT00000110|DRUG|dietary fat|
219392111|NCT00201201|OTHER|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
219392112|NCT00201201|OTHER|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
219392113|NCT05573685|DEVICE|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
219392114|NCT05573685|DEVICE|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
219392115|NCT01342640|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
219392116|NCT04885738|OTHER|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
219392117|NCT05399693|PROCEDURE|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
219392118|NCT04918693|DEVICE|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
219392119|NCT03863938|DRUG|Tegoprazan 50mg|K-CAB
219392120|NCT01745055|DRUG|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
219392121|NCT01745055|DRUG|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
219392122|NCT01225783|OTHER|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
219392123|NCT04396912|PROCEDURE|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
219392124|NCT04689646|BEHAVIORAL|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
219392125|NCT04689646|BEHAVIORAL|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
219392126|NCT01589120|BEHAVIORAL|Video decision aid|Video decision aid of the goals of care
219392127|NCT04101422|BEHAVIORAL|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
219392128|NCT04101422|BEHAVIORAL|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
219392129|NCT04101422|BEHAVIORAL|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
219392130|NCT04101422|BEHAVIORAL|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
219392131|NCT02640612|DRUG|BI 695501|
219392132|NCT01720667|DRUG|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
219392133|NCT01720667|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
219558008|NCT02734524|BIOLOGICAL|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4
219558009|NCT02734524|DRUG|Taxol|135-175mg/m2,q28d\*4
219001313|NCT04168060|PROCEDURE|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
219392134|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, low dose
219392135|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, high dose
219392136|NCT04824872|DRUG|Placebo|placebo for dasiglucagon
219392137|NCT03472534|DRUG|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
219392138|NCT03714412|DEVICE|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
219392139|NCT05197101|PROCEDURE|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
219392140|NCT00020852|PROCEDURE|conventional surgery|
219392141|NCT00020852|PROCEDURE|cryosurgery|
219392142|NCT05930873|BEHAVIORAL|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
219558010|NCT02734524|DRUG|Carboplatin|AUC=5,q28d\*4
219558011|NCT03623893|PROCEDURE|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
219558012|NCT02523794|OTHER|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
219558013|NCT02523794|OTHER|Placebo|Purified Drinking Water
219392143|NCT05930873|BEHAVIORAL|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
219392144|NCT04174963|BEHAVIORAL|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
219392145|NCT03531268|OTHER|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
219392146|NCT01834326|BIOLOGICAL|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
219392147|NCT01834326|BIOLOGICAL|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
219392148|NCT03881163|DRUG|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
219392149|NCT00029315|DRUG|Recombinant Tissue Plasminogen Activator (rt-PA)|
219392150|NCT02891993|OTHER|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
219392151|NCT02891993|OTHER|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
219392152|NCT04109443|BEHAVIORAL|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
219392153|NCT04109443|BEHAVIORAL|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
219392154|NCT02004340|DEVICE|ear vagus nerve stimulator|
219392155|NCT02558699|PROCEDURE|physician's personal experience|physician's personal experience
219392156|NCT02558699|PROCEDURE|Virtual rotor mapping|Virtual rotor mapping
219392157|NCT03921892|BEHAVIORAL|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
219392158|NCT00005860|DRUG|floxuridine|
219392159|NCT00005860|DRUG|leucovorin calcium|
219392160|NCT00005860|DRUG|oxaliplatin|
219392161|NCT06293092|DEVICE|leg pedaling cycling device|Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
219392162|NCT06293092|DEVICE|sand bags|Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
219392163|NCT06293092|DEVICE|hemodialysis sessions|hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
219392164|NCT05721625|OTHER|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
219392165|NCT05721625|OTHER|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
219392166|NCT00562510|DRUG|Raltegravir|Raltegravir 400 mg BID added to stable HAART
219392167|NCT00562510|DRUG|Placebo|Placebo BID added to stable HAART
219558014|NCT06199960|OTHER|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
219392168|NCT05091801|BEHAVIORAL|Intervention|Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
219392169|NCT02393599|DRUG|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
219392170|NCT02393599|DRUG|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
219392171|NCT02393599|DRUG|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
219392172|NCT05497505|DEVICE|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
219392173|NCT05068596|OTHER|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
219392174|NCT05068596|OTHER|CONTROL|Designed physical therapy program
219392175|NCT03013751|DRUG|Udenafil|Active drug
219392176|NCT01319929|DRUG|LY2828360|Administered orally
219558015|NCT02293460|DRUG|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
219558016|NCT02991560|OTHER|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
219558017|NCT02991560|OTHER|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
219558018|NCT02991560|DEVICE|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
219558019|NCT02991560|DEVICE|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
219558020|NCT02361814|PROCEDURE|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
219558021|NCT03540849|DRUG|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
219558022|NCT00792441|DEVICE|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
219558023|NCT02992613|PROCEDURE|total knee arthroplasty with ultra-congruent (UC) insert|
219558024|NCT02992613|PROCEDURE|total knee arthroplasty with posterior-stabilized (PS) insert|
219558025|NCT05752435|PROCEDURE|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
219392177|NCT01319929|DRUG|Placebo|Administered orally
219392178|NCT00306566|BIOLOGICAL|CYT004-MelQbG10|
219558026|NCT06535035|DEVICE|laser therapy After implant surgery, laser therapy (LLLT) was applied|After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
219558027|NCT06535035|DEVICE|SHAM|After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
219558028|NCT05391659|DEVICE|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
219558029|NCT05391659|DIAGNOSTIC_TEST|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
219558030|NCT05391659|DIAGNOSTIC_TEST|gold standard|examination by ophthalmologist
219558031|NCT03842852|PROCEDURE|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
219558032|NCT03620617|DIETARY_SUPPLEMENT|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
219558033|NCT06433206|OTHER|no intervention|no intervention
219558034|NCT05054049|DEVICE|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
219558035|NCT05054049|OTHER|Usual care|Usual care provided to patient without use of point of care testing device
219558036|NCT04554706|BEHAVIORAL|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
219558037|NCT05290337|DRUG|zanubrutinib|BTK inhibitor
219558038|NCT02993705|DRUG|Trabectedin|Chemotherapy drug
219558039|NCT03023709|BIOLOGICAL|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
219558040|NCT03023709|BIOLOGICAL|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
219001314|NCT04168060|PROCEDURE|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
219001315|NCT04168060|PROCEDURE|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
219392179|NCT03197675|OTHER|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
219392180|NCT02004990|PROCEDURE|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
219392181|NCT01749735|DEVICE|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
219392182|NCT01749735|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
219392183|NCT01749735|DEVICE|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
219392184|NCT02337504|OTHER|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
219558041|NCT00095862|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|
219558042|NCT00095862|BIOLOGICAL|recombinant interferon alfa|
219392185|NCT04182191|DRUG|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
219392186|NCT04549038|OTHER|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
219392187|NCT01221233|OTHER|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
219392188|NCT01221233|OTHER|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
219392189|NCT04618497|DRUG|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
219392190|NCT04618497|DRUG|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
219392191|NCT00084422|DRUG|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
219392192|NCT05180305|DIAGNOSTIC_TEST|Mitomic Prostate Test|Mitomic Prostate Test
219392193|NCT00282958|DRUG|Botulinum Toxin type a (Botox)|
219392194|NCT01439529|OTHER|Device programming: nominal|CRT device is programmed to nominal values
219558043|NCT00095862|DRUG|cyclophosphamide|
219558044|NCT00699244|PROCEDURE|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
219392195|NCT01439529|OTHER|Programming optimization by QRS|CRT device is programmed by QRS optimization
219001316|NCT00257478|DRUG|YM155|
219188873|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
219188874|NCT06180759|DRUG|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
219392196|NCT02648048|DRUG|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
219392197|NCT02648048|DRUG|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
219392198|NCT03743584|PROCEDURE|Targeted temperature management|Target temperature management at 33°C
219392199|NCT03743584|PROCEDURE|Standard care, early treatment of fever|Standard of care with early treatment of fever
219392200|NCT03099369|BEHAVIORAL|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
219188875|NCT06180759|DRUG|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
219392201|NCT03099369|BEHAVIORAL|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
219392202|NCT03099369|OTHER|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
219392203|NCT00416637|BIOLOGICAL|Bevacizumab (Avastin)|
219558045|NCT00699244|PROCEDURE|Central placement of local anesthesia|Central placement of local anesthesia
219558046|NCT06679491|OTHER|Resistance periodized training program (N-PF)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the follicular phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated based on the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are performed at a higher training load during both early and late follicular phases. The increased intensity leverages higher estrogen levels, which may support greater muscle strength and recovery during this phase.~Luteal Phase (Days 15-28): Training sessions are conducted at a lower training load during both early and late luteal phases to accommodate the hormonal shifts associated with elevated progesterone."
219558047|NCT06679491|OTHER|Resistance peioridized training program (N-PL)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the luteal phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated according to the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are conducted at a lower training load during both early and late follicular phases to accommodate the hormonal environment of this phase.~Luteal Phase (Days 15-28): Training sessions are performed at a higher training load during both early and late luteal phases. The increased intensity leverages the hormonal environment associated with elevated progesterone, which may affect muscle endurance and neuromuscular adaptations during this phase."
219558048|NCT06679491|OTHER|Continuous resistance training program (C)|"This intervention consists of a 13-week structured resistance training program with a continuous training intensity maintained throughout the menstrual cycle. Participants perform two resistance training sessions per week, each lasting 90 minutes, with a consistent training load applied across all phases.~Intensity Modulation:~All Phases: Training sessions are conducted at a steady training load regardless of menstrual phase. This continuous approach is designed to provide a baseline for assessing neuromuscular adaptations without the influence of phase-specific intensity adjustments."
219558049|NCT03028064|OTHER|blood taking|in this cohort study, we will take blood to examine the platelet function
219392204|NCT04748276|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
219392205|NCT00611455|DRUG|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
219392206|NCT00611455|DRUG|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
219392207|NCT02676310|DRUG|Bimatoprost|
219392208|NCT04850040|DRUG|Apatinib Mesylate|250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
219558050|NCT04124250|OTHER|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
219558051|NCT04225260|BIOLOGICAL|botulinum toxin neuromodulator|A dose of QM1114-DP will be injected in the GL area and in the LCL area.
219558052|NCT04299776|DEVICE|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
219558053|NCT04299776|DEVICE|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
219558054|NCT01785394|DRUG|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
219558055|NCT06036550|DIAGNOSTIC_TEST|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
219558056|NCT00001108|DRUG|Ritonavir|
219558057|NCT00001108|DRUG|Nelfinavir mesylate|
219558058|NCT00001108|DRUG|Saquinavir|
219558059|NCT00001108|DRUG|Nevirapine|
219558060|NCT00001108|DRUG|Lamivudine|
219558061|NCT00001108|DRUG|Stavudine|
219392209|NCT04850040|DRUG|Camrelizumab|200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
219558062|NCT00001108|DRUG|Didanosine|
219558063|NCT03651908|PROCEDURE|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
219392210|NCT04850040|DRUG|Oxaliplatin|85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
219392211|NCT06435195|PROCEDURE|Surgical Removal|Resection of pituitary pathologies.
219558064|NCT01204125|DRUG|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
219392212|NCT06435195|PROCEDURE|Biopsy|Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
219392213|NCT01670630|PROCEDURE|Sheathed speculum examination|
219392214|NCT01670630|PROCEDURE|Standard speculum examination|
219558065|NCT01204125|DRUG|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
219558066|NCT00731224|DRUG|Rivastigmine transdermal patch|
219558067|NCT04702035|DEVICE|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
219392215|NCT00813839|OTHER|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
219392216|NCT00827619|DEVICE|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
219392217|NCT05187195|OTHER|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
219392218|NCT05187195|OTHER|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
219392219|NCT00491530|DRUG|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
219558068|NCT02781935|PROCEDURE|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
219558069|NCT01940302|DIETARY_SUPPLEMENT|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
219392220|NCT00491530|DRUG|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
219392221|NCT00491530|DRUG|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
219392222|NCT00491530|DRUG|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
219392223|NCT05094440|BEHAVIORAL|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
219392224|NCT02741531|OTHER|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
219392225|NCT02741531|OTHER|saline solution|Saline solution will be used to partially fill patients' bladders
219392226|NCT02061137|DRUG|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
219558070|NCT01074008|DRUG|ABT-450|50 mg capsules co-administered with ritonavir
219558071|NCT01074008|DRUG|ABT-072|50 mg tablet
219558072|NCT01074008|DRUG|ABT-333|400 mg tablet
219392227|NCT06399549|DIAGNOSTIC_TEST|Dead bug exercise|the participant in supine, lying on a mat with shoulders, hip joints and knees flexed to 90°. With the lumbopelvic region being maintained in the neutral position, the participant will be instructed to draw in the abdomen, lower two contra lateral limbs (opposite arm and leg) toward the floor, hold for the stipulated time, then return to starting position. The same movement will be repeated with the opposite limbs. In the DBG, both pairs of limbs will be moved an equal number of times withinthe stipulated time. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises.
219392228|NCT06399549|DIAGNOSTIC_TEST|The McGill Curl Up|"Lie down on your back. Extend one leg and bend the knee of the other leg. The Side Bridge. Lie on your side, with your forearm on the floor and elbow underneath your shoulder.~The Bird Dog. Assume a hands-and-knees position on the floor. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises. The exercise program includes a warm-up session of five exercises (awareness of the back, pelvic tilt, lumbar rotation, arm movements, whole-body movement in standing), well-known exercises targeting the muscles of the back extensors, abdominals, lateral buttocks, trunk rotators, posterior buttocks, leg muscles, oblique abdominals (e.g. the plank, diagonal arm and leg lift), as well as exercises for flexibility. The exercises will be taught to the patients at the end of the first session in both groups."
219392229|NCT02894073|DEVICE|skin transilluminator|VeinViewer
219392230|NCT02542345|PROCEDURE|magnetic resonance imaging|
219392231|NCT03644797|GENETIC|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
219392232|NCT01580475|OTHER|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
219558073|NCT01074008|DRUG|Ritonavir|100 mg capsules co-administered with ABT-450
219558074|NCT01074008|DRUG|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
219558075|NCT01074008|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
219558076|NCT01074008|OTHER|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
219558077|NCT04890964|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
219558078|NCT00136890|PROCEDURE|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
219558079|NCT00224484|BIOLOGICAL|GSK208141|3 intramuscular doses
219558080|NCT00224484|BIOLOGICAL|Havrix (investigational formulation)|3 intramuscular doses
219558081|NCT00224484|BIOLOGICAL|Placebo|3 intramuscular doses
219392233|NCT03247998|DRUG|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
219392234|NCT03247998|DRUG|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
219392235|NCT00933946|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
219392236|NCT04880057|OTHER|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT."
219392237|NCT04880057|OTHER|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
219392238|NCT00107107|DRUG|pramlintide acetate|Syringe vial and Pen-cartridge
219392239|NCT03320148|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
219392240|NCT03320148|OTHER|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
219392241|NCT02278146|DEVICE|ParaPatch|A device for the treatment of urinary incontinence
219392242|NCT03671369|OTHER|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
219558082|NCT05696509|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
219558083|NCT05696509|DRUG|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
219558084|NCT05696509|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
219558085|NCT01121107|DEVICE|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
219558086|NCT01121107|DEVICE|Patient Advisory Module|Handheld device that provides medication reminders
219558087|NCT06617507|OTHER|Group 1|The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
219558088|NCT02805309|BEHAVIORAL|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
219558089|NCT02805309|BEHAVIORAL|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
219558090|NCT02805309|BEHAVIORAL|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
219558091|NCT00320853|DRUG|Vitamin D|
219558092|NCT02166853|DRUG|sevoflurane|Sedation with inhaled sevoflurane
219558093|NCT02166853|DRUG|midazolam|Sedation with intravenous midazolam
219001317|NCT02266225|OTHER|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
219001318|NCT02600702|OTHER|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
219001319|NCT02600702|OTHER|Physical modalities|
219188876|NCT06180759|DRUG|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
219392243|NCT04408157|BEHAVIORAL|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
219558094|NCT00578968|DRUG|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
219558095|NCT00578968|DRUG|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
219558096|NCT02106533|OTHER|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
219558097|NCT03064243|DRUG|apatinib|apatinib 500mg po. qd.
219558098|NCT03027908|OTHER|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
219558099|NCT03027908|OTHER|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
219558100|NCT05080608|OTHER|Surgery|Treatment according to clinical practise
219558101|NCT04489303|BEHAVIORAL|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
219558102|NCT04489303|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
219558103|NCT00603564|PROCEDURE|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
219558104|NCT04253015|OTHER|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
219558105|NCT01004315|DRUG|KUC-7483|
219558106|NCT01004315|DRUG|Placebo|
219558107|NCT01004315|DRUG|Tolterodine|
219558108|NCT05386056|DRUG|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
219558109|NCT05386056|DRUG|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
219558110|NCT05386056|PROCEDURE|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
219558111|NCT02629588|BEHAVIORAL|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
219558112|NCT04683588|OTHER|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
219558113|NCT05372497|OTHER|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~* Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~* Right / Left Discrimination Training~* Localization Training Level 1- Level 2 Training~* Visual imagination Training~* Visual Imagery Training~* Mirror Therapy~* Isometric and functional exercises"
219558114|NCT05372497|OTHER|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~* Electrotherapy~* Scapular mobilization~* Passive stretches~* Stick Exercises~* Pendulum Exercises~* Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
219558115|NCT03263078|DRUG|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
219558116|NCT03263078|DRUG|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
219558117|NCT00108628|BEHAVIORAL|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
219558118|NCT00108628|BEHAVIORAL|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
219558119|NCT01828645|DIETARY_SUPPLEMENT|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
219392244|NCT04971811|OTHER|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
219392245|NCT04971811|OTHER|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
219392246|NCT00002993|DRUG|cisplatin|
219558120|NCT05799196|PROCEDURE|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
219558121|NCT04649697|DRUG|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
219558122|NCT04649697|DRUG|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
219558123|NCT04649697|DRUG|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
219558124|NCT04372134|DEVICE|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
219558125|NCT01350934|DRUG|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
219558126|NCT01350934|DRUG|Calcitriol|0.25 μg once daily orally
219392247|NCT00002993|DRUG|doxorubicin hydrochloride|
219392248|NCT00002993|DRUG|mitomycin C|
219392249|NCT04828876|BEHAVIORAL|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
219392250|NCT02060708|DEVICE|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
219392251|NCT02360943|OTHER|4 blood samples|PK and / or PD measurements during hospitalization
219392252|NCT00539786|DRUG|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
219392253|NCT02732912|DEVICE|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
219392254|NCT02732912|DEVICE|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
219392255|NCT02732912|DRUG|Zopiclone|This night sedation will be given to any patient requesting it, in either group
219392256|NCT04382651|DRUG|MAS825|MAS825 liquid solution for intravenous infusion
219392257|NCT04382651|OTHER|Placebo|Placebo liquid solution for intravenous infusion
219392258|NCT04382651|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
219392259|NCT00004048|BIOLOGICAL|filgrastim|
219392260|NCT00004048|DRUG|doxorubicin hydrochloride|
219392261|NCT00004048|PROCEDURE|autologous bone marrow transplantation|
219392262|NCT00004048|PROCEDURE|peripheral blood stem cell transplantation|
219392263|NCT00004048|RADIATION|indium In 111 monoclonal antibody MN-14|
219392264|NCT00004048|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
219392265|NCT00090649|DRUG|DVS-233 SR|
219392266|NCT00211822|PROCEDURE|fMRI|fMRI
219392267|NCT05669885|DRUG|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
219392268|NCT05669885|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
219392269|NCT04569305|PROCEDURE|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
219392270|NCT04569305|PROCEDURE|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
219392271|NCT03414918|DRUG|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
219392272|NCT02881307|DIETARY_SUPPLEMENT|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
219392273|NCT02881307|BEHAVIORAL|Dietary Counseling|Dietary Counseling
219392274|NCT02881307|BEHAVIORAL|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
219392275|NCT00126451|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
219392276|NCT00126451|DRUG|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
219392277|NCT06480071|DRUG|Oxymetazoline, 0.05% Nasal Spray|2 sprays each nostril before the excercise test.
219392278|NCT01666873|PROCEDURE|patients that undergo a total knee prosthesis|
219392279|NCT01507545|DRUG|MORAb-004|MORAb-004 8mg per kg IV once a week
219392280|NCT01507545|DRUG|Placebo|Placebo - normal saline IV once a week
219558127|NCT01350934|DIETARY_SUPPLEMENT|Calcium 500 mg|one 500 mg tablet once daily
219558128|NCT01196117|DEVICE|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
219558129|NCT01196117|DEVICE|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
219392281|NCT01507545|OTHER|Best supportive care|Best supportive care to improve quality of life
219392282|NCT01873742|OTHER|STIC feedback system|This condition includes the use of the STIC feedback system.
219392283|NCT02508714|DEVICE|Orsiro|stents will be implanted in case of significant coronary artery disease
219392284|NCT02508714|DEVICE|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
219392285|NCT00193674|DRUG|Dydrogesterone|20 mg/day, oral
219392286|NCT00193674|DRUG|Placebo|Placebo
219392287|NCT02035072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2
219392288|NCT02035072|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2
219392289|NCT02035072|RADIATION|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
219392290|NCT03545152|BEHAVIORAL|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
219392291|NCT03545152|BEHAVIORAL|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
219392292|NCT03545152|BEHAVIORAL|New life-style|Combination of exercise and cognitive interventions
219392293|NCT05839990|PROCEDURE|Surgery|Replacement of the ascending aorta in case of anerysm and dilatation
219188877|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
219392294|NCT03739983|DEVICE|Vaginal Renewal Program|Therapeutic vibrating wand.
219392295|NCT00790296|DRUG|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
219392296|NCT00790296|DRUG|Placebo|Saline
219392297|NCT05700344|DRUG|Avelumab|Single Group Assignment
219392298|NCT05541692|BEHAVIORAL|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
219392299|NCT04704765|OTHER|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
219188878|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
219188879|NCT03404115|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
219188880|NCT05585190|OTHER|Control|No intervention.
219392300|NCT01671488|BIOLOGICAL|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
219392301|NCT01671488|DRUG|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
219392302|NCT01671488|DRUG|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
219188881|NCT05585190|OTHER|Sit-Stand Desk at Work|Subjects will receive a sit-stand desk at their work location.
219188882|NCT06089967|OTHER|Medical chart review|Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
219392303|NCT01671488|RADIATION|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
219392304|NCT05055635|RADIATION|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
219392305|NCT00247910|DRUG|Hydrochlorothiazide|Not recorded in detailed description.
219392306|NCT01914445|DRUG|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
219392307|NCT02612077|OTHER|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
219392308|NCT02612077|DRUG|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
219392309|NCT01312350|DRUG|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
219392310|NCT01312350|DRUG|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
219392311|NCT02251730|BEHAVIORAL|Smoking cessation|Refer for smoking cessation
219392312|NCT01022853|DRUG|BI 6727|intravenous each 21 days
219392313|NCT01022853|DRUG|BIBF 1120|oral continuously
219392314|NCT05588362|OTHER|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
219392315|NCT04846153|OTHER|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
219392316|NCT04846153|DEVICE|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
219392317|NCT02807116|DRUG|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
219392318|NCT02807116|DRUG|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
219392319|NCT02807116|DRUG|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
219392320|NCT03391011|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
219392321|NCT01753518|DEVICE|Subcuticular suture|subcuticular Monocryl suture closure
219392322|NCT01753518|DEVICE|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
219392323|NCT01962259|BEHAVIORAL|Physical activity|
219188883|NCT05177822|DRUG|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
219392324|NCT01220310|BEHAVIORAL|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
219392325|NCT01720511|DIETARY_SUPPLEMENT|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
219392326|NCT01720511|DIETARY_SUPPLEMENT|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
219392327|NCT03629626|PROCEDURE|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
219392328|NCT03726216|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
219392329|NCT02060396|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
219392330|NCT03927534|BEHAVIORAL|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
219188884|NCT05177822|OTHER|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
219188885|NCT05397431|DRUG|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
219188886|NCT03386578|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
219188887|NCT03386578|BEHAVIORAL|Behavioral HIV risk reduction package|Included cohort-appropriate SMS messages.
219392331|NCT04045223|OTHER|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
219392332|NCT01971476|DRUG|volasertib|intravenous administration on day 1of a treatment course
219392333|NCT02498080|PROCEDURE|DEB PTA|paclitaxel drug eluting balloon PTA
219392334|NCT02498080|PROCEDURE|Standard PTA|Standard PTA
219392335|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
219392336|NCT02075255|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
219392337|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
219188888|NCT03386578|BEHAVIORAL|Enhanced adherence support|Included two-way SMS messaging and tailored counseling with drug level feedback.
219188889|NCT02260856|DEVICE|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
219392338|NCT00020930|BIOLOGICAL|cetuximab|
219392339|NCT05895825|DRUG|EOC237|EOC237 for orally
219188890|NCT02260856|PROCEDURE|Percutaneous Drill Epiphysiodesis|
219188891|NCT02260856|PROCEDURE|Percutaneous Screw Epiphysiodesis|
219188892|NCT00278785|BEHAVIORAL|Brief Motivational Interview|10-20 minute brief motivational interview
219392340|NCT00000539|DRUG|niacin|
219392341|NCT00000539|DRUG|pravastatin|
219392342|NCT00000539|DRUG|beta-carotene|
219392343|NCT00000539|DRUG|vitamin E|
219392344|NCT00000539|BEHAVIORAL|dietary supplements|
219392345|NCT00000539|DRUG|vitamin C|
219392346|NCT00000539|DRUG|warfarin|
219392347|NCT03994926|DEVICE|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
219392348|NCT03994926|DRUG|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
219392349|NCT04742517|DRUG|ASP1128|Intravenous
219392350|NCT04742517|DRUG|Placebo|Intravenous
219392351|NCT02236585|PROCEDURE|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
219392352|NCT02236585|PROCEDURE|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
219392353|NCT01948934|PROCEDURE|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
219392354|NCT06971380|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
219392355|NCT06969625|PROCEDURE|(SHAC) block|The shoulder anterior capsular block targets interfacial and pericapsular space. A 25-gauge 80-mm insulated stimulating needle will be used for injections and in-plane needling will be from lateral to medial side. After aspiration is negative, 10 ml of 0.5 % bupivacaine plus dexamethasone 4 mg as adjuvant will be injected in the interfacial plane. Once the injection into the fascial space is achieved, the operator can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle and the second injection after negative aspiration will be 10 ml 0.5 % bupivacaine plus dexamethasone 4 mg in pericapsular space.
219392356|NCT06969625|PROCEDURE|(SSNB-ANB) block|"Suprascapular Nerve Block (SNB): Using an in-plane ultrasound guidance from the medial side, 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg as adjuvant will be injected after contacting the lateral aspect of the supraspinous fossa and negative aspiration confirmed. The LA should spread beneath the supraspinatus, lifting up the muscle.~Axillary Nerve Block (ANB):~The ANB is performed from behind the patient with the patient seated. The axillary nerve will be identified within the quadrilateral space by placing high frequency linear probe (Sono site M turbo) parallel to the long axis of the humeral shaft. The nerve was identified next to the circumflex artery. The skin will be anesthetized with 1% lidocaine (3mL). 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg will be injected against the surface of the humerus, just posterior and lateral to the artery after confirming negative aspiration."
219392357|NCT06970171|DEVICE|MAD of the Scheu Dental type with lateral guidance wings (MAD-1)|The vertical dimension is raised to achieve an incisal edge distance (IED) of 5 mm using a George Gauge, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
219392358|NCT06970171|DEVICE|MAD of the Panthera X3 type with lateral guidance wings (MAD-2)|The vertical dimension is raised to achieve a minimum 2 mm interocclusal cusp distance and the lowest possible IED, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
219392359|NCT06972082|DEVICE|VEXUS|Goal-directed fluid and drug therapy according to VEXUS measurements to minimize AKI
219392360|NCT05279092|DRUG|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
219392361|NCT05279092|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
219392362|NCT06095674|DRUG|Anti-PD-1 antibody balstilimab|Both antibodies will be neoadjuvantly administered around the cervical tumor.
219392363|NCT01670851|DEVICE|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
219392364|NCT05848713|DRUG|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
219392365|NCT01030042|DRUG|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
219392366|NCT01030042|DRUG|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
219392367|NCT03912467|OTHER|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
219392368|NCT01101724|BEHAVIORAL|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
219392369|NCT05937685|BEHAVIORAL|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
219392370|NCT04170621|DEVICE|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
219392371|NCT00987766|DRUG|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
219392372|NCT00987766|DRUG|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
219392373|NCT00987766|DRUG|oxaliplatin|Given through a vein in the arm 1 time every other week.
219392374|NCT00987766|OTHER|laboratory biomarker analysis|Blood and tissue collection.
219392375|NCT03856450|DEVICE|DTS|Subjects undergo wrist imaging using DTS.
219392376|NCT03856450|DEVICE|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
219558130|NCT06120634|PROCEDURE|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
219558131|NCT06120634|PROCEDURE|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
219558132|NCT00317434|DRUG|lapatinib|
219392377|NCT03856450|DEVICE|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
219392378|NCT01426386|DRUG|FE 999049|
219392379|NCT01426386|DRUG|Gonal - F|
219392380|NCT02772380|DEVICE|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
219392381|NCT03831503|BIOLOGICAL|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
219392382|NCT03831503|DEVICE|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
219392383|NCT03831503|DEVICE|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
219392384|NCT05115318|DRUG|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
219392385|NCT04575129|OTHER|No intervention will be applied|No intervention will be applied
219392386|NCT01096667|DRUG|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
219392387|NCT01096667|DRUG|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
219392388|NCT01096667|DRUG|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
219392389|NCT01096667|DRUG|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
219392390|NCT01096667|DRUG|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
219392391|NCT01096667|DRUG|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
219392392|NCT01096667|DRUG|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
219392393|NCT01612910|DRUG|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
219001320|NCT05298631|OTHER|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
219001321|NCT05298631|OTHER|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
219001322|NCT02560532|DRUG|Clazosentan|Concentrated solution for intravenous injection
219001323|NCT00680706|DRUG|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
219392394|NCT01612910|OTHER|laboratory biomarker analysis|Correlative studies
219392395|NCT00918762|PROCEDURE|assessment of therapy complications|
219392396|NCT00918762|PROCEDURE|diagnostic endoscopic surgery|
219001324|NCT00680706|DRUG|Placebo|D5W (50 ml)
219001325|NCT00686933|DRUG|ABT-089|Subjects will take up to 80 mg daily for 24 months
219392397|NCT00918762|PROCEDURE|quality-of-life assessment|
219392398|NCT00918762|PROCEDURE|therapeutic conventional surgery|
219392399|NCT00918762|PROCEDURE|therapeutic endoscopic surgery|
219392400|NCT00918762|PROCEDURE|transoral robotic surgery|
219392401|NCT00918762|PROCEDURE|video-assisted surgery|
219392402|NCT02657239|BEHAVIORAL|MOVE UP|Weight management behavioral program
219392403|NCT06034730|DEVICE|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
219392404|NCT03330691|BIOLOGICAL|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
219392405|NCT01894282|PROCEDURE|Manual Therapy|Manual Therapy Arm
219392406|NCT01894282|PROCEDURE|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
219392407|NCT03427840|PROCEDURE|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
219392408|NCT01094483|DRUG|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
219392409|NCT01094483|DRUG|ASA|Asprin 81 mg enteric coated tablet
219392410|NCT01094483|DRUG|Placebo|
219392411|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
219392412|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
219392413|NCT04172025|DIAGNOSTIC_TEST|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
219392414|NCT02997514|BEHAVIORAL|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
219392415|NCT02997514|BEHAVIORAL|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
219392416|NCT00018863|DRUG|Methylphenidate|
219392417|NCT03224533|DIAGNOSTIC_TEST|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
219392418|NCT03156153|DRUG|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
219392419|NCT03156153|DRUG|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
219392420|NCT00165568|DRUG|Bevacizumab|
219392421|NCT02335450|BEHAVIORAL|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
219392422|NCT02335450|DEVICE|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
219392423|NCT01475292|DRUG|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
219392424|NCT01475292|DRUG|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
219392425|NCT01475292|DRUG|Placebo|Placebo administered via a nebuliser once daily for 14 days
219392426|NCT02937610|PROCEDURE|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
219392427|NCT04371510|OTHER|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
219392428|NCT00203645|BEHAVIORAL|Self-help treatment|"Workbook Becoming a Winner,"
219392429|NCT02613572|DRUG|alpha lipoic acid|
219392430|NCT02613572|DRUG|Placebo|
219392431|NCT02124720|BEHAVIORAL|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
219392432|NCT04542291|DRUG|Dapagliflozin|Dapagliflozin will be provided for this trial
219392433|NCT04542291|DEVICE|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
219392434|NCT00731029|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
219392435|NCT00731029|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
219392436|NCT01143597|OTHER|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
219392437|NCT05228912|DRUG|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
219392438|NCT00853905|DRUG|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
219392439|NCT00853905|DRUG|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
219392440|NCT01716260|DRUG|Chloroquine|
219392441|NCT01716260|DRUG|Primaquine|
219392442|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
219392443|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
219392444|NCT04338945|BEHAVIORAL|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
219392445|NCT01746992|DRUG|Cyclophosphamide 750mg/m2|day 1 in both arms
219392446|NCT01746992|DRUG|Vincristine 1.4mg/m2|day 1
219392447|NCT01746992|DRUG|Doxorubicin 50mg/m2|day 1
219392448|NCT01746992|DRUG|prednisone 60mg/m2|day1-day5
219392449|NCT01746992|DRUG|ifosfamide 2000mg/m2|day 22-day 24
219392450|NCT01746992|DRUG|pirarubicin 50mg/m2|day 1
219392451|NCT01746992|DRUG|pirarubicin 25mg/m2|day 22
219392452|NCT01746992|DRUG|Etoposide phosphate 100mg/m2|day 22-day 24
219392453|NCT01746992|DRUG|methotrexate 1500mg/m2|day 43
219392454|NCT01558817|BEHAVIORAL|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
219392455|NCT01558817|BEHAVIORAL|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
219392456|NCT01748695|DRUG|V158866|
219392457|NCT01748695|DRUG|Placebo|
219392458|NCT05294900|DRUG|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5"
219392459|NCT00970294|BEHAVIORAL|Health Promotion Program|10 week health promotion program 3-4 times per week
219558133|NCT05527158|BEHAVIORAL|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
219392460|NCT03709615|BEHAVIORAL|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
219392461|NCT06821126|BIOLOGICAL|LVT-001|Intranasal administration
219392462|NCT06821126|BIOLOGICAL|Cormirnaty|Intramuscular administration
219392463|NCT06600698|DRUG|INM176|The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.
219392464|NCT05717738|PROCEDURE|TACE|Procedure of TACE is standardized.
219392465|NCT05717738|DRUG|Lenvatinib|8mg; p.o.; q.d.
219392466|NCT05717738|DRUG|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
219392467|NCT05717738|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
219392468|NCT05717738|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
219392469|NCT05717738|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
219392470|NCT05717738|DRUG|Sorafenib|400mg; p.o. bid
219392471|NCT05717738|DRUG|Donafenib|200mg; p.o. bid
219392472|NCT05717738|DRUG|Regorafenib|160 mg; p.o.; q.d.
219392473|NCT00307229|BIOLOGICAL|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
219392474|NCT04783207|DIETARY_SUPPLEMENT|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
219392475|NCT04783207|DIETARY_SUPPLEMENT|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
219392476|NCT04146532|DRUG|Aspirin 500 MG|Single 500mg aspirin capsule.
219392477|NCT04146532|DRUG|Placebo|Single 500mg placebo capsule.
219392478|NCT00847561|BEHAVIORAL|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
219392479|NCT00847561|BEHAVIORAL|Information Monitoring|Packet providing information on strategies for coping with anxiety
219392480|NCT02757495|DRUG|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
219392481|NCT03235908|OTHER|Observation only|Observation only
219392482|NCT00002828|DRUG|fluorouracil|
219392483|NCT00002828|DRUG|raltitrexed|
219392484|NCT03899740|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
219392485|NCT03899740|OTHER|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219392486|NCT03899740|OTHER|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219392487|NCT03899740|OTHER|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219392488|NCT01363505|DEVICE|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
219392489|NCT00006072|DRUG|Rituxan|
219392490|NCT02107664|RADIATION|Palliative RT for bone cancer pain|
219392491|NCT05828940|DRUG|Losartan Potassium|oral tablet, over-encapsulated
219392492|NCT05828940|DRUG|Placebo|oral tablet, over-encapuslated
219392493|NCT03556696|DEVICE|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
219392494|NCT03556696|DEVICE|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
219392495|NCT03556696|DRUG|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
219392496|NCT03556696|DRUG|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
219392497|NCT03556696|DEVICE|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std\_practice arm for guidance of the remifentanil Ce target"
219392498|NCT03526640|DEVICE|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
219392499|NCT02471417|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
219392500|NCT02471417|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
219392501|NCT06482879|DEVICE|Oxygen delivery|Oxygen is delivered with high flow nasal canula or simple nasal canula to prevent hypoxia during procedures under deep sedation.
219392502|NCT02203682|DRUG|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
219392503|NCT02203682|DRUG|Placebo|Tablet placebo for 12 weeks
219392504|NCT02449564|DRUG|sirolimus|sirolimus 1mg daily
219392505|NCT04044638|OTHER|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
219392506|NCT00465738|DRUG|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
219392507|NCT01902160|DRUG|Brentuximab Vedotin|Given IV
219392508|NCT01902160|OTHER|Laboratory Biomarker Analysis|Correlative studies
219392509|NCT01902160|DRUG|Temsirolimus|Given IV
219392510|NCT02234011|DRUG|Ketamine|
219392511|NCT02234011|DRUG|Placebo|
219392512|NCT02729129|OTHER|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
219392513|NCT02729129|OTHER|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
219392514|NCT00575796|DRUG|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
219392515|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
219392516|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
219392517|NCT04859491|DIETARY_SUPPLEMENT|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
219392518|NCT03614624|DEVICE|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
219392519|NCT04936880|DEVICE|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
219392520|NCT04936880|DRUG|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
219392521|NCT01326962|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
219392522|NCT03403244|PROCEDURE|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
219392523|NCT03403244|PROCEDURE|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
219392524|NCT03619785|DRUG|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
219558134|NCT03547635|OTHER|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
219392525|NCT03619785|DRUG|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
219392526|NCT05164523|DIAGNOSTIC_TEST|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
219392527|NCT05164523|DIAGNOSTIC_TEST|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
219392528|NCT01056523|DRUG|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
219392529|NCT01056523|DRUG|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
219392530|NCT04760132|BIOLOGICAL|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
219392531|NCT04760132|BIOLOGICAL|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
219392532|NCT04760132|BIOLOGICAL|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
219392533|NCT02648815|PROCEDURE|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
219392534|NCT02648815|PROCEDURE|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
219392535|NCT03425656|DRUG|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
219392536|NCT04560101|DRUG|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
219392537|NCT03750162|DEVICE|VDW Ultra|supplementary disinfection technique
219392538|NCT03750162|DEVICE|AMD picasso|supplementary disinfection technique
219392539|NCT03750162|DEVICE|ProtaperNext X3 gutta-percha|supplementary disinfection technique
219392540|NCT00486980|DRUG|Peramivir 150mg|
219392541|NCT00486980|DRUG|Peramivir 300mg|
219392542|NCT04362267|OTHER|self-administered questionnaire|Every14 days, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
219392543|NCT04362267|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every14 days, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
219392544|NCT00315601|DRUG|Telithromycin|800 mg once a day for 5 days
219392545|NCT00315601|DRUG|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
219392546|NCT00315601|PROCEDURE|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
219392547|NCT00315601|DRUG|Telithromycin|Telithromycin 800 mg once a day
219392548|NCT05466110|DEVICE|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
219392549|NCT05466110|PROCEDURE|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
219392550|NCT05799144|BIOLOGICAL|DNA Vaccine|Given pBI-11 IM
219392551|NCT05799144|BIOLOGICAL|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
219392552|NCT05799144|BIOLOGICAL|Pembrolizumab|Given into vein
219392553|NCT05799144|PROCEDURE|Computed Tomography (CT)|Undergo a CT
219392554|NCT05799144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo an MRI
219392555|NCT05799144|PROCEDURE|Magnetic Resonance Imaging|Undergo blood sample collection
219392556|NCT05799144|PROCEDURE|Biopsy|Undergo tumor biopsy
219392557|NCT06512480|PROCEDURE|colonic resection|colonic resection with the Hugo RAS robotic platform.
219392558|NCT04952389|DEVICE|Acupuncture Therapy|Consists of two treatments per week for five weeks
219392559|NCT04952389|DRUG|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
219392560|NCT04952389|OTHER|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
219392561|NCT05331989|OTHER|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
219392562|NCT00934531|DRUG|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
219392563|NCT02500030|PROCEDURE|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
219392564|NCT02500030|PROCEDURE|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
219392565|NCT03442426|OTHER|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
219392566|NCT02664246|DEVICE|percutaneous coronary intervention|
219392567|NCT02855814|OTHER|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
219392568|NCT03536429|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219392569|NCT03536429|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219392570|NCT01477216|OTHER|ELSA 1-9|Measuring GI and II values for Finnish foods
219392571|NCT06143631|DRUG|Letrozole 2.5mg|Oral letrozole 2.5mg/day
219392572|NCT06143631|OTHER|Placebo|Placebo capsule
219392573|NCT01507246|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
219392574|NCT01507246|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
219392575|NCT03044665|DRUG|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
219392576|NCT03044665|DRUG|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
219392577|NCT00213018|DRUG|Carraguard (PC-515)|
219392578|NCT04411238|OTHER|interview|interview
219392579|NCT06673173|OTHER|Implant|A long cone paralleling approach with a specially made film holder will be used to assess each patient's vertical marginal bone loss to ensure standardized radiography analysis and avoid any magnification errors. The linear distance between the proximal crestal bone level and the implant shoulder will be measured at the mesial and distal aspects of the implant measured in millimeters (mm). Measurements will performed using image measurement software patient satisfaction comparison between 2 groups
219392580|NCT06869642|BEHAVIORAL|Doing Pasat-Test|PASAT-Test either with or without doing chest compressions
219392581|NCT06869642|PROCEDURE|Chest compressions|Performing chest compressions as desribed in the ERC Guidelines
219392582|NCT03199092|BEHAVIORAL|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
219392583|NCT03199092|BEHAVIORAL|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
219392584|NCT04358913|DEVICE|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
219392585|NCT02975648|BEHAVIORAL|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
219392586|NCT02975648|BEHAVIORAL|usual care|Hospital health professionals offered orientation on care after discharge
219001326|NCT01858298|OTHER|Conservative treatment: pulpectomy and composite resin crown|
219392587|NCT05588284|DEVICE|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
219392588|NCT05588284|OTHER|anticoagulation alone|a medicine for anticoagulation therapy
219392589|NCT06877988|DEVICE|AI|Retinal photography-based deep learning algorithm for detection of disease-related visual impairment cases
219392590|NCT04634123|OTHER|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
219392591|NCT04634123|OTHER|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
219392592|NCT01900548|DIETARY_SUPPLEMENT|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
219392593|NCT01900548|DIETARY_SUPPLEMENT|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
219392594|NCT01900548|DIETARY_SUPPLEMENT|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
219392595|NCT01900548|OTHER|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
219001327|NCT01858298|OTHER|Non-conservative treatment: Tooth extraction|
219392596|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
219392597|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
219392598|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
219392599|NCT06906471|DRUG|AS1986NS|Single dose, IV, 100 µg of AS1986NS
219392600|NCT05979844|DRUG|3,4-methylenedioxymethamphetamine (MDMA)|2 MDMA sessions; PTSD+ Veteran partner only
219392601|NCT05979844|BEHAVIORAL|Brief Cognitive Behavioral Conjoint Therapy (bCBCT)|8 bCBCT sessions; Both partners
219392602|NCT04762290|OTHER|Dance|The intervention is a series of expressive dance movements.
219392603|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
219392604|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
219392605|NCT05339308|OTHER|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
219392606|NCT05339308|OTHER|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
219392607|NCT05738252|DIAGNOSTIC_TEST|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
219392608|NCT05738252|DIAGNOSTIC_TEST|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
219392609|NCT04115033|DEVICE|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
219392610|NCT05287893|DRUG|Pyronaridine|Single dose
219558135|NCT03547635|DEVICE|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
219558136|NCT03547635|OTHER|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate"
219392611|NCT05287893|BIOLOGICAL|P. falciparum IBSM infection|Induced Blood Stage Malaria
219392612|NCT05243550|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
219392613|NCT05454176|DEVICE|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
219392614|NCT05454176|DEVICE|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
219392615|NCT06099717|DEVICE|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
219392616|NCT06099717|DEVICE|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
219558137|NCT00883935|DRUG|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
219558138|NCT00883935|DRUG|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
219558139|NCT00883935|DRUG|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
219558140|NCT00883935|DRUG|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
219558141|NCT00078741|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219558142|NCT06469619|BEHAVIORAL|Music listening|Listening to music of one's choice one hour daily.
219558143|NCT03297619|BEHAVIORAL|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
219558144|NCT03297619|BEHAVIORAL|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
219392617|NCT03277170|DRUG|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
219392618|NCT06027463|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
219392619|NCT06265532|DRUG|EGCG 300 mg|"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
219392620|NCT06265532|DRUG|Placebo for EGCG 300 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
219392621|NCT06265532|DRUG|EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
219392622|NCT06265532|DRUG|Placebo for EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
219392623|NCT04185610|OTHER|Qi Gong|Guided Qi Gong class
219392624|NCT05217069|DRUG|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
219392625|NCT05217069|DRUG|Folinic Acid|400mg/m2
219392626|NCT05217069|DRUG|Irinotecan|180 mg/m2
219392627|NCT05217069|DRUG|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
219392628|NCT05217069|DRUG|Avelumab|10mg/kg IV (day 1 q2w)
219558145|NCT03028896|PROCEDURE|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
219558146|NCT03798379|OTHER|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
219558147|NCT04083352|DIETARY_SUPPLEMENT|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
219558148|NCT04083352|DIETARY_SUPPLEMENT|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
219558149|NCT03492970|BIOLOGICAL|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
219558150|NCT05623046|BEHAVIORAL|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
219558151|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
219558152|NCT04129944|DRUG|UBX0101|Investigational drug intra-articular injection
219558153|NCT04129944|OTHER|Placebo|Placebo intra-articular injection
219558154|NCT05281172|BEHAVIORAL|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
219392629|NCT05667428|DRUG|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
219558155|NCT05281172|BEHAVIORAL|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
219558156|NCT00493792|DEVICE|X3 Polyethylene|Highly cross-linked polyethylene (HXLPE).
219558157|NCT00493792|DEVICE|N2Vac Polyethylene|Ultra-high-molecular-weight polyethylene (UHMWPE).
219558158|NCT00004416|DRUG|botulinum toxin type A|
219558159|NCT02302937|PROCEDURE|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
219558160|NCT02302937|PROCEDURE|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
219558161|NCT03889691|PROCEDURE|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
219558162|NCT06239428|BEHAVIORAL|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
219558163|NCT06239428|OTHER|Waitlist|A 12-week waitlist with access to online mindfulness material.
219558164|NCT04313426|OTHER|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
219558165|NCT00891072|DRUG|R-(-)-gossypol acetic acid|Given orally
219558166|NCT00891072|DRUG|paclitaxel|Given IV
219392630|NCT05667428|DRUG|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
219392631|NCT01783522|DRUG|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
219392632|NCT01783522|OTHER|quality-of-life assessment|Ancillary studies
219392633|NCT01783522|OTHER|placebo|Given PO
219392634|NCT02948231|DEVICE|Mistral implantation|Mistral Implant is implanted in the Mitral valve
219392635|NCT03729869|DRUG|Progesterone|200 mg of exogenous progesterone twice a day
219392636|NCT03729869|DRUG|Placebo|One dose of matched placebo twice a day.
219392637|NCT01429246|DIETARY_SUPPLEMENT|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
219392638|NCT01429246|DIETARY_SUPPLEMENT|Salt Substitute|Estimated 30 grams per day per household member
219392639|NCT05782920|DEVICE|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
219392640|NCT05782920|DEVICE|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
219392641|NCT05782920|DEVICE|topical HA gel|the standard treatment of vaginal atrophy and dryness
219392642|NCT03444363|DEVICE|Laser group|Laser application in addition to SRP
219392643|NCT03444363|DEVICE|Control group|Placebo laser application in addition to SRP
219392644|NCT04340869|OTHER|Theobromine|Natural extract from Cocoa
219392645|NCT04340869|OTHER|Remin Pro|Remin Pro
219392646|NCT05337267|DRUG|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
219558167|NCT00891072|DRUG|carboplatin|Given IV
219558168|NCT00891072|OTHER|pharmacological study|Correlative studies
219558169|NCT02102269|DEVICE|actimove sling|
219558170|NCT02102269|DEVICE|shoulderlift|
219558171|NCT03361124|DRUG|Oxytocin|Administration of additional 20 mU Oxytocin
219558172|NCT00685035|DEVICE|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
219558173|NCT00685035|DEVICE|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
219558174|NCT04241133|BEHAVIORAL|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
219558175|NCT04982445|DRUG|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
219558176|NCT04719611|DIETARY_SUPPLEMENT|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
219558177|NCT02340689|OTHER|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
219392647|NCT05337267|DRUG|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
219392648|NCT03215472|OTHER|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
219392649|NCT03215472|OTHER|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
219392650|NCT02605863|DRUG|Enzalutamide|160 mg by mouth daily for 12 months
219392651|NCT03856073|BEHAVIORAL|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
219392652|NCT02806427|OTHER|Enteral Formula|
219392653|NCT01378390|DRUG|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
219558178|NCT02864004|DRUG|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
219558179|NCT02864004|OTHER|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
219558180|NCT04892316|DIAGNOSTIC_TEST|Diagnostic test|The training dataset was used to train the model, which was validated and tested by the other two datasets.
219558181|NCT03307564|DEVICE|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
219392654|NCT01378390|DRUG|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
219392655|NCT01394029|DRUG|deferasirox|
219392656|NCT02645747|DRUG|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
219392657|NCT04290650|BEHAVIORAL|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
219392658|NCT04290650|BEHAVIORAL|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
219392659|NCT06029816|DRUG|Neratinib tablets|Neratinib tablets
219392660|NCT04089605|DRUG|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
219392661|NCT04089605|DRUG|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
219392662|NCT02222727|DRUG|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
219558182|NCT04306640|OTHER|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
219558183|NCT03857672|BEHAVIORAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
219558184|NCT05962450|BIOLOGICAL|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
219558185|NCT05962450|DRUG|PD-1|Intravenous infusion, according to the drug instructions.
219558186|NCT05962450|DRUG|Regorafenib|Oral administration, according to the drug instructions.
219558187|NCT05567835|DRUG|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
219392663|NCT01438710|DRUG|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
219392664|NCT01438710|DRUG|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
219392665|NCT05484986|OTHER|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
219392666|NCT02452970|DRUG|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
219392667|NCT02452970|DRUG|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
219392668|NCT03554499|PROCEDURE|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
219392669|NCT03554499|PROCEDURE|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
219392670|NCT01775488|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
219392671|NCT00893113|DRUG|Placebo|Alfuzosin-matched One tablet once daily
219392672|NCT00893113|DRUG|Alfuzosin|10 mg once daily
219392673|NCT02372292|DRUG|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
219558188|NCT05567835|DRUG|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
219001328|NCT05337228|DRUG|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
219392674|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
219392675|NCT06177834|DEVICE|Alisklamp|Alisklamp
219392676|NCT06177834|OTHER|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
219392677|NCT05087602|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219392678|NCT04561843|DIAGNOSTIC_TEST|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
219392679|NCT03518229|DEVICE|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
219392680|NCT03518229|DEVICE|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
219392681|NCT00004106|DRUG|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
219392682|NCT02009137|DEVICE|EVERA|EVERA apply for 12 weeks
219558189|NCT05567835|DRUG|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
219558190|NCT05567835|DRUG|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
219558191|NCT05567835|BIOLOGICAL|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
219558192|NCT02842684|DEVICE|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
219558193|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
219558194|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
219558195|NCT01529307|DRUG|TAS266|TAS266 IV infusions given weekly
219558196|NCT03844724|DEVICE|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
219558197|NCT03844724|DEVICE|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
219558198|NCT03566407|PROCEDURE|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
219558199|NCT00348816|DRUG|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
219558200|NCT00348816|DRUG|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
219558201|NCT00348816|PROCEDURE|Radical prostatectomy|Radical prostatectomy as part of standard care
219558202|NCT00348816|RADIATION|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
219558203|NCT05120817|BEHAVIORAL|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
219558204|NCT05120817|BEHAVIORAL|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
219392683|NCT02009137|DEVICE|ESTES|ESTES apply for 12 weeks
219392684|NCT00683241|BIOLOGICAL|DCVac-L|Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
219392685|NCT02654327|DEVICE|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
219392686|NCT01247818|DRUG|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
219392687|NCT01247818|DRUG|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
219392688|NCT01247818|DRUG|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
219558205|NCT05120817|BEHAVIORAL|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
219558206|NCT05393323|OTHER|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
219558207|NCT05393323|OTHER|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
219558208|NCT05212116|DRUG|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
219558209|NCT05212116|DRUG|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
219558210|NCT00584103|DEVICE|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
219558211|NCT00584103|DEVICE|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
219392689|NCT01247818|DRUG|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
219392690|NCT04192448|OTHER|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
219392691|NCT04192448|OTHER|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
219392692|NCT01842061|BEHAVIORAL|Active Living Program|
219392693|NCT01842061|BEHAVIORAL|Education|
219392694|NCT01383200|DRUG|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
219558212|NCT02050321|DRUG|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
219558213|NCT02050321|DRUG|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
219558214|NCT01354470|DRUG|Modafinil|600 mg Modafinil capsule
219558215|NCT01228552|DRUG|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
219558216|NCT01228552|OTHER|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
219558217|NCT04821388|DEVICE|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
219392695|NCT01383200|DRUG|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
219392696|NCT00128206|DRUG|Isoniazid|Isoniazid 900 mg twice weekly
219558218|NCT01937767|DRUG|Remimazolam|
219558219|NCT01937767|DRUG|Propofol|
219558220|NCT01937767|DRUG|Sevoflurane|
219558221|NCT01937767|DRUG|Remifentanil|
219558222|NCT01937767|DRUG|Fentanyl|
219558223|NCT01937767|DRUG|Rocuronium|
219558224|NCT06317584|OTHER|Experimental: Empowerment Application for CAM Health Education|Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
219558225|NCT06317584|OTHER|Written Paper for CAM Health Education|Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
219558226|NCT06223490|PROCEDURE|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
219558227|NCT03428542|BEHAVIORAL|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
219558228|NCT03428542|BEHAVIORAL|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
219558229|NCT02305407|PROCEDURE|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
219001329|NCT05337228|DRUG|RPN301|RPN301 will be injected continuously for 3 days.
219392697|NCT00128206|DRUG|Rifampin|Rifampin 600mg once per day
219392698|NCT00250471|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
219392699|NCT01959867|DEVICE|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
219392700|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
219392701|NCT01757639|BIOLOGICAL|Ipilimumab|Given IV
219392702|NCT01757639|OTHER|Laboratory Biomarker Analysis|Correlative studies
219392703|NCT02041715|DRUG|TKM-100802 for Injection|IV infusion
219392704|NCT02041715|DRUG|Placebo|IV infusion
219392705|NCT03958682|DEVICE|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
219392706|NCT05664048|BEHAVIORAL|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
219392707|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
219392708|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
219392709|NCT03387904|DRUG|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
219392710|NCT03387904|DRUG|Irinotecan|Irinotecan Day 1,8 ivgtt
219392711|NCT00896519|BIOLOGICAL|rituximab|
219392712|NCT00896519|BIOLOGICAL|sargramostim|
219392713|NCT00896519|DRUG|cyclophosphamide|
219392714|NCT00896519|DRUG|doxorubicin hydrochloride|
219392715|NCT00896519|DRUG|prednisone|
219392716|NCT00896519|DRUG|vincristine sulfate|
219392717|NCT00896519|GENETIC|gene expression analysis|
219392718|NCT00896519|GENETIC|gene rearrangement analysis|
219392719|NCT00896519|GENETIC|polymerase chain reaction|
219392720|NCT00896519|OTHER|R-CHOP regimen|
219392721|NCT00896519|OTHER|laboratory biomarker analysis|
219392722|NCT01591590|OTHER|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
219392723|NCT01591590|OTHER|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
219392724|NCT01591590|OTHER|Blood samples (plasma preparation and CTC)|
219392725|NCT05429515|PROCEDURE|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
219558230|NCT02305407|OTHER|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
219558231|NCT01292668|DRUG|methyl-5-aminolevulinate hydrochloride cream|Applied topically
219558232|NCT01292668|DRUG|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
219558233|NCT01292668|PROCEDURE|laser therapy|Undergo laser light photodynamic therapy
219392726|NCT05429515|PROCEDURE|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
219392727|NCT05429515|DRUG|Chemotherapy|chemotherapy protocol will be made by hematologists.
219558234|NCT00595673|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
219392728|NCT02688855|DEVICE|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
219392729|NCT02688855|DEVICE|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
219558235|NCT02005276|BEHAVIORAL|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
219392730|NCT04286308|OTHER|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
219392731|NCT01654575|DRUG|Methotrexate|Methotrexate 25mg/week for 16 weeks
219392732|NCT01654575|DRUG|Placebo|Placebo tablets once a week for 16 weeks
219558236|NCT02005276|BEHAVIORAL|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
219392733|NCT00449059|DRUG|acute infusion of nitroglycerine into the pulmonary artery|
219392734|NCT01040832|DRUG|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
219392735|NCT01040832|DRUG|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
219392736|NCT03549273|DIETARY_SUPPLEMENT|Glizigen® + Ocoxin-Viusid®|"* Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
219392737|NCT01565629|BEHAVIORAL|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
219188893|NCT05825183|PROCEDURE|Ultrasound-guided manual vaccum|"For managing with miscarriage or termination of pregnancy (TOP) in first trimester loss, ultrasound-guided manual vacuum aspiration (USG-MVA) is one of the treatment options.~The USG-MVA device works by aspirating the uterine content via the cannula into the syringe. Furthermore, product of conception derived from USG-MVA can be sent for karyotyping analysis.~POCs obtained from MVA procedure were rinsed in normal saline thoroughly in the kidney basin to minimize maternal blood. Chorionic villi were considered as a proxy of fetal genetics, appeared to be yellowish in color and tree-projection-like in appearance, floating on the surface of the waterline. Decidua are originated from the mother, appeared substantive in structure and sank in the basin. The two different types of tissues are separated from each other for different testing."
219558237|NCT02005276|BEHAVIORAL|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
219558238|NCT05103644|DRUG|Atorvastatin 80mg|patients received statin experimental group
219392738|NCT02940886|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
219558239|NCT05103644|OTHER|placebo|patients received placebo control group
219558240|NCT02699762|OTHER|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
219558241|NCT01963260|DRUG|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
219558242|NCT01963260|DRUG|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
219558243|NCT04994431|DRUG|Tamsulosin Hydrochloride|0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
219558244|NCT03672240|DRUG|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
219558245|NCT04654039|OTHER|Other: Non intervention|Non intervention
219392739|NCT02940886|DRUG|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
219392740|NCT05492383|DEVICE|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
219392741|NCT01969175|OTHER|Low-glycemic-load and milk-free diet|
219392742|NCT01306058|DRUG|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
219392743|NCT01306058|DRUG|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
219392744|NCT05413967|OTHER|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
219392745|NCT05413967|OTHER|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
219392746|NCT01947374|PROCEDURE|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
219392747|NCT01947374|PROCEDURE|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
219392748|NCT01666444|DRUG|pegylated liposomal doxorubicin (PLD)|
219392749|NCT01666444|DRUG|VTX-2337|TLR8 Agonist
219392750|NCT01666444|DRUG|Placebo|
219392751|NCT01390701|DEVICE|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
219392752|NCT01390701|DRUG|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
219392753|NCT02098317|DRUG|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
219392754|NCT02098317|DRUG|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
219392755|NCT02615106|DRUG|Endostar|7.5 mg/m2/day, day 1-14
219392756|NCT02615106|RADIATION|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
219392757|NCT03843658|OTHER|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
219392758|NCT00592358|DRUG|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
219392759|NCT01143350|OTHER|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
219392760|NCT01143350|OTHER|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
219392761|NCT00000615|BEHAVIORAL|diet, reducing|
219392762|NCT00084682|DRUG|romidepsin|Given IV
219392763|NCT04011436|OTHER|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
219392764|NCT00813553|DIETARY_SUPPLEMENT|placebo|daily
219392765|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
219392766|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
219392767|NCT03152136|DEVICE|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
219392768|NCT03623984|DRUG|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
219392769|NCT01587872|PROCEDURE|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
219392770|NCT02657252|DRUG|Glucose|Sclerotherapy of telangiectasis in one lower limb.
219392771|NCT02657252|DRUG|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
219392772|NCT05826197|OTHER|Radiomics|PET Radiomics
219392773|NCT04346069|OTHER|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
219392774|NCT03455478|DEVICE|spectacles|dispending spectacles for uncorrected refractive error
219392775|NCT05070273|DIAGNOSTIC_TEST|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
219558246|NCT03945058|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
219558247|NCT03945058|DEVICE|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
219392776|NCT05070273|DIAGNOSTIC_TEST|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
219392777|NCT01366222|DIETARY_SUPPLEMENT|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
219392778|NCT06105879|DEVICE|covered or open skin|transcutaneous mesarument of covered or open skin area
219392779|NCT00120445|PROCEDURE|air|0.3 ml of filtered air
219392780|NCT00120445|PROCEDURE|expansile gas|0.3 ml of perfluoropropane gas
219392781|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
219558248|NCT06678763|PROCEDURE|CRS-HIPEC|Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
219558249|NCT04554186|PROCEDURE|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
219392782|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
219188894|NCT06461546|DRUG|Imlifidase|"* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
219188895|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
219392783|NCT04843111|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
219392784|NCT03238248|DRUG|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
219392785|NCT03238248|DRUG|Pevonedistat Infusion|20 mg/m2
219392786|NCT03238248|PROCEDURE|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
219188896|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
219188897|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
219188898|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
219188899|NCT05705453|DEVICE|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
219188900|NCT06802965|PROCEDURE|catheter ablation, left atrial appendage closure|Compare the clinical prognosis of patients with AF underwent the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation and single LAAC.
219392787|NCT05462587|DRUG|AVTX-803 (L-Fucose)|L-fucose crystalline powder
219392788|NCT04730323|DRUG|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
219392789|NCT05874245|DRUG|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
219392790|NCT05874245|DRUG|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
219392791|NCT05874245|DRUG|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
219392792|NCT02751307|DRUG|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
219392793|NCT02751307|DRUG|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
219558250|NCT04554186|PROCEDURE|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
219558251|NCT04554186|PROCEDURE|Control|Place a fentanyl patch 50 microgram
219558252|NCT02463019|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
219392794|NCT02860468|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
219392795|NCT02860468|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
219558253|NCT05685550|DRUG|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
219558254|NCT00722436|DRUG|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
219392796|NCT04020237|BEHAVIORAL|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1\) Start air purifier~* 2\) Do not go out and make it to the minimum when absolutely necessary~* 3\) It is recommended to wear a mask when going out.~* 4\) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5\) Prepare an inhaler and use it when symptoms get worse."
219392797|NCT04827056|DRUG|Placebo|Placebo will be administered orally, as individual films in the SL space.
219392798|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
219392799|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
219558255|NCT00722436|DRUG|saline|Placebo
219392800|NCT04827056|PROCEDURE|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
219392801|NCT04827056|BEHAVIORAL|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
219558256|NCT03644043|DEVICE|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
219558257|NCT00681018|OTHER|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
219558258|NCT00681018|OTHER|Powder human milk fortifier|Powder human milk fortifier added to human milk
219558259|NCT01067521|DRUG|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
219392802|NCT04827056|BEHAVIORAL|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
219392803|NCT03796169|BEHAVIORAL|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
219392804|NCT03796169|BEHAVIORAL|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
219558260|NCT01067521|DRUG|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
219558261|NCT04011787|DIETARY_SUPPLEMENT|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
219392805|NCT03796169|BEHAVIORAL|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
219392806|NCT05319951|DRUG|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
219392807|NCT05319951|DIETARY_SUPPLEMENT|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
219392808|NCT05319951|DIETARY_SUPPLEMENT|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
219392809|NCT02698592|DEVICE|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
219392810|NCT02698592|DEVICE|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
219558262|NCT04011787|DIETARY_SUPPLEMENT|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
219392811|NCT02698592|DEVICE|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
219392812|NCT01369693|PROCEDURE|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
219392813|NCT01187797|OTHER|Emotional stimulation|Increase of the physical correlates of an emotion
219392814|NCT03341104|DRUG|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
219558263|NCT04011787|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
219558264|NCT04011787|DIAGNOSTIC_TEST|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
219558265|NCT04011787|RADIATION|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
219558266|NCT05659680|DEVICE|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
219558267|NCT02169752|DRUG|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
219392815|NCT02241512|DRUG|Ibuprofen|
219392816|NCT02241512|DRUG|placebo|
219392817|NCT04013737|DEVICE|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
219392818|NCT02952066|PROCEDURE|Bronchial biopsy|Bronchial tissue taken during biopsy
219558268|NCT00055809|BIOLOGICAL|PEG-interferon alfa-2b|Given SC
219558269|NCT00055809|BIOLOGICAL|bevacizumab|Given IV
219392819|NCT01970579|DEVICE|Paclitaxel coated balloon|"* Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
219558270|NCT00055809|OTHER|laboratory biomarker analysis|Optional correlative studies
219392820|NCT01970579|DEVICE|uncoated PTA catheter|"* Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
219392821|NCT02203253|DRUG|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
219558271|NCT03784274|BEHAVIORAL|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
219558272|NCT00024154|BIOLOGICAL|trastuzumab|Given IV
219558273|NCT00024154|DRUG|gefitinib|Given orally
219558274|NCT00024154|OTHER|laboratory biomarker analysis|Correlative studies
219558275|NCT04442854|OTHER|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
219392822|NCT02203253|DRUG|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
219392823|NCT02203253|DRUG|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
219392824|NCT01629342|BEHAVIORAL|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)"
219392825|NCT00455247|DRUG|Glutamine|
219392826|NCT00474630|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
219392827|NCT00474630|DRUG|Placebo|
219392828|NCT00474630|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
219558276|NCT03508154|OTHER|Control Meal 1|carbohydrate test meal
219558277|NCT03508154|OTHER|Control Meal 2|carbohydrate test meal
219558278|NCT03508154|OTHER|Experimental Nutritional Product|ready to drink nutritional formulation
219558279|NCT04986254|OTHER|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
219392829|NCT04685603|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
219392830|NCT00538603|DRUG|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
219392831|NCT00538603|DRUG|Paclitaxel & Carboplatin|Chemotherapy
219392832|NCT00077181|DRUG|cytarabine|Given IV
219392833|NCT00077181|DRUG|triapine|Given IV
219392834|NCT00077181|OTHER|laboratory biomarker analysis|Correlative studies
219558280|NCT04986254|OTHER|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
219558281|NCT04986254|OTHER|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
219558282|NCT04986254|DRUG|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
219558283|NCT05150405|DRUG|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
219558284|NCT05805527|DIAGNOSTIC_TEST|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
219392835|NCT05696366|DRUG|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
219392836|NCT05696366|DRUG|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
219392837|NCT03088605|DRUG|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
219558285|NCT01196949|OTHER|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
219558286|NCT01196949|OTHER|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
219558287|NCT02911636|RADIATION|Pelvic SABR with intra-prostatic SABR|described elsewhere
219558288|NCT04181398|DIAGNOSTIC_TEST|Anthropometry|"* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference."
219558289|NCT04181398|DIAGNOSTIC_TEST|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
219558290|NCT04181398|DIAGNOSTIC_TEST|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
219558291|NCT04181398|OTHER|Questionnaire|General questionnaire on cardiovascular risk factors
219558292|NCT04181398|DIAGNOSTIC_TEST|Blood sample|Blood sample for hs-CRP
219558293|NCT00766493|DEVICE|GORE® Embolic Filter|Embolic protection during carotid stenting
219558294|NCT05778760|OTHER|Retinol|Topical retinol (0.5%) applied to the face
219558295|NCT05778760|OTHER|Adapinoid|Topical Adapinoid (0.5%) applied to the face
219558296|NCT04009876|DRUG|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
219558297|NCT04009876|PROCEDURE|Surgical resection|Surgical resection of the tumour
219558298|NCT04009876|OTHER|Watch-and-wait|No surgery approach
219558299|NCT04009876|DRUG|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
219558300|NCT04009876|DRUG|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
219558301|NCT03993080|DEVICE|Virtual reality relaxation|1-3.5 minute 360° videos
219558302|NCT04450693|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
219558303|NCT04450693|OTHER|Standard care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
219558304|NCT00225329|PROCEDURE|Labour assessment and support|
219558305|NCT00452543|DRUG|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
219558306|NCT00452543|DRUG|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
219558307|NCT00452543|BEHAVIORAL|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
219558308|NCT00452543|DRUG|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
219558309|NCT03419962|DRUG|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
219558310|NCT05561257|DRUG|Vitamin C|Vitamin C
219392838|NCT03088605|DRUG|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
219392839|NCT00352781|DRUG|nicotine replacement therapy|nicotine transdermal patches as per product monograph
219392840|NCT00352781|BEHAVIORAL|behavioural intervention|Smoking cessation counselling and relapse prevention
219392841|NCT05132738|DRUG|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
219392842|NCT03835208|BEHAVIORAL|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
219392843|NCT02225223|DEVICE|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
219392844|NCT02225223|DEVICE|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
219392845|NCT01810159|OTHER|Integrated collaborative care|
219392846|NCT01810159|OTHER|Education and Resources|
219392847|NCT05272059|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
219392848|NCT05272059|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
219392849|NCT00355589|DRUG|Ramipril and hydrochlorothiazide|
219392850|NCT02538146|DIETARY_SUPPLEMENT|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
219392851|NCT00004033|DRUG|liposomal NDDP|
219392852|NCT00004033|PROCEDURE|therapeutic thoracoscopy|
219392853|NCT03267329|DRUG|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
219392854|NCT03267329|DRUG|Telmisartan|telmisartan 80mg
219392855|NCT02028689|DRUG|Lesinurad 400 mg|
219392856|NCT02028689|DRUG|Metformin 850 mg|
219392857|NCT02028689|DRUG|Furosemide 40 mg|
219392858|NCT02711670|DRUG|chlorthalidone|
219392859|NCT02711670|DRUG|Hydrochlorothiazide|
219392860|NCT03318107|DEVICE|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
219392861|NCT03827577|PROCEDURE|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
219392862|NCT03827577|RADIATION|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
219392863|NCT03827577|DRUG|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
219392864|NCT04715724|OTHER|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
219392865|NCT03399539|DRUG|Dexamethasone|Given PO
219392866|NCT03399539|DRUG|Ixazomib Citrate|Given PO
219392867|NCT03399539|OTHER|Laboratory Biomarker Analysis|Correlative studies
219392868|NCT03399539|DRUG|Venetoclax|Given PO
219392869|NCT00404781|DRUG|cilostazol in addition to aspirin and clopidogrel|
219392870|NCT03912571|DIAGNOSTIC_TEST|Structural 3T MRI|measures of global and hippocampal atrophy)
219392871|NCT03912571|DIAGNOSTIC_TEST|MRI Based Perfusion Imaging|brain blood flow
219392872|NCT03912571|DIAGNOSTIC_TEST|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
219392873|NCT04897503|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
219392874|NCT00000800|DRUG|Methadone hydrochloride|
219392875|NCT00000800|DRUG|Zidovudine|
219392876|NCT03645837|OTHER|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
219392877|NCT02381756|DEVICE|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
219392878|NCT04241237|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
219392879|NCT00958568|DRUG|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
219392880|NCT00958568|DRUG|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
219392881|NCT00434850|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
219392882|NCT00434850|DRUG|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
219392883|NCT00434850|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
219392884|NCT00434850|BIOLOGICAL|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
219392885|NCT00434850|DRUG|Sirolimus|Maintenance immunosuppressive therapy
219392886|NCT00434850|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
219392887|NCT00434850|BIOLOGICAL|Etanercept|Blocks TNF-alpha which is toxic to islet cells
219392888|NCT05426148|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
219392889|NCT00262106|DRUG|PRO 2000/5|Gel
219392890|NCT00262106|DRUG|Placebo|Placebo
219558311|NCT02519543|DRUG|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
219558312|NCT02519543|DRUG|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
219558313|NCT05917262|BEHAVIORAL|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
219558314|NCT05917262|BEHAVIORAL|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
219558315|NCT05917262|BEHAVIORAL|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
219558316|NCT02914457|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
219558317|NCT03043040|BEHAVIORAL|Telephone follow up|Already described in previous page
219558318|NCT03043040|BEHAVIORAL|Treatment as usual|Already described in previous page
219558319|NCT00600873|DRUG|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
219392891|NCT04978376|BEHAVIORAL|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
219392892|NCT04239560|DRUG|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
219392893|NCT04239560|DRUG|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
219392894|NCT02383394|OTHER|follow up antenatal care|ultrasound follow up of pregnancy
219392895|NCT03321617|DRUG|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
219392896|NCT00915967|DRUG|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
219558320|NCT00248092|DRUG|NRP104|
219558321|NCT04677686|BEHAVIORAL|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
219558322|NCT06172439|OTHER|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
219558323|NCT01769222|BIOLOGICAL|Ipilimumab|Given intratumorally
219558324|NCT01769222|RADIATION|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
219392897|NCT00915967|DRUG|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
219392898|NCT01501149|DRUG|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
219392899|NCT01501149|DRUG|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
219392900|NCT02605733|DEVICE|EEG|amplitude integrated electroencephalography
219392901|NCT02605733|DEVICE|NIRS|regional tissue oximetry
219392902|NCT00126542|BIOLOGICAL|bevacizumab|Given IV
219392903|NCT00126542|DRUG|erlotinib hydrochloride|Given orally
219392904|NCT00126542|OTHER|laboratory biomarker analysis|Correlative studies
219558325|NCT02451644|DEVICE|pedometer|patient will cary pedometer
219558326|NCT03024801|DRUG|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
219558327|NCT03024801|DRUG|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
219558328|NCT00105040|DRUG|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
219558329|NCT00105040|OTHER|Placebo (PB)|Oral tablets and oral solution
219558330|NCT00672217|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
219558331|NCT00672217|BEHAVIORAL|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
219558332|NCT01849458|DEVICE|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
219558333|NCT00058435|BIOLOGICAL|abagovomab|
219558334|NCT05594641|OTHER|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
219558335|NCT05594641|OTHER|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
219558336|NCT05965986|OTHER|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
219558337|NCT05965986|OTHER|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
219558338|NCT01781234|DRUG|Intranasal Insulin|
219558339|NCT01781234|DRUG|Placebo|
219558340|NCT06613334|BIOLOGICAL|Blood test: measurement of plasma antipsychotic concentration|Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
219558341|NCT06613334|OTHER|Voice interviews and questionnaires carried out via the CALLYOPE application|"Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant).~The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement.~In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application.~These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6)."
219558342|NCT05714241|OTHER|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm)."
219191767|NCT05255120|OTHER|Intiensified structured perioperative information|The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
219392905|NCT02243124|DRUG|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
219392906|NCT02243124|DRUG|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
219392907|NCT05795465|DRUG|GEn-1124|Intravenous infusion
219392908|NCT05795465|DRUG|Placebo|Intravenous infusion
219392909|NCT04418583|DIAGNOSTIC_TEST|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
219392910|NCT02945761|PROCEDURE|High concentration of sugar solution|
219392911|NCT02945761|PROCEDURE|conventional surgical dressing change|
219558343|NCT05714241|OTHER|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
219558344|NCT05714241|OTHER|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
219392912|NCT03952286|DRUG|ED-Dispensing home and school supervision|"1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms."
219392913|NCT03827876|DRUG|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
219392914|NCT00631319|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
219392915|NCT00631319|DRUG|Placebo|Placebo
219392916|NCT01037712|DRUG|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
219392917|NCT01037712|DRUG|Placebo|placebo
219558345|NCT03208517|OTHER|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
219558346|NCT02682108|DEVICE|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
219558347|NCT05915923|PROCEDURE|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
219558348|NCT05915923|PROCEDURE|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
219558349|NCT05915923|PROCEDURE|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
219558350|NCT04286295|DRUG|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
219558351|NCT04286295|DRUG|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
219558352|NCT04286295|DRUG|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
219558353|NCT03259113|DEVICE|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
219001330|NCT00350909|BEHAVIORAL|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
219001331|NCT03808532|OTHER|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
219001332|NCT03570645|DRUG|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
219001333|NCT03570645|DRUG|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
219001334|NCT03570645|DRUG|control group|block with only ropivacaine
219001335|NCT05367401|DRUG|Sabatolimab|Solution for intravenous infusion
219001336|NCT05367401|DRUG|Magrolimab|Solution for intravenous infusion
219001337|NCT05367401|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
219001338|NCT00603668|BIOLOGICAL|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
219001339|NCT03992001|BIOLOGICAL|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
219001340|NCT03992001|BIOLOGICAL|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
219392918|NCT04207073|DEVICE|Mobilization of median nerve|Neural mobilization
219392919|NCT05671120|PROCEDURE|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
219392920|NCT05171738|DEVICE|skeletally anchored distal jet|used from day one and activated every month
219392921|NCT04707144|DEVICE|MRI 1.5 tesla|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~* 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
219392922|NCT02739698|DRUG|Paclitaxel|
219392923|NCT02739698|PROCEDURE|Radical surgery-peritonectomy|
219392924|NCT02927171|OTHER|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
219392925|NCT01065480|BEHAVIORAL|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
219392926|NCT01065480|BEHAVIORAL|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
219392927|NCT06498271|DEVICE|Personalized and automated digital coaching using a mobile application|Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
219392928|NCT00147628|DRUG|sildenafil citrate|
219392929|NCT00147628|DRUG|placebo for sildenafil citrate|
219392930|NCT02677701|DRUG|azithromycin|500mg tablet over-encapsulated to match placebo
219392931|NCT02677701|DRUG|placebo (for azithromycin)|
219392932|NCT02677701|DRUG|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
219392933|NCT02808715|OTHER|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
219392934|NCT00816972|DRUG|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
219392935|NCT00816972|DRUG|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
219392936|NCT00816972|DRUG|Placebo for Desloratadine 2.5 mg|Placebo BID
219392937|NCT00816972|DRUG|Placebo for Oxybutynin 2.5 mg|Placebo BID
219392938|NCT06512090|DIETARY_SUPPLEMENT|LGI steam bread|"LGI Steam bread called Mangusteam bread"
219392939|NCT06512090|DIETARY_SUPPLEMENT|Diabetic diet|the calorie intake of Diabetic diet will by recommended by nutritionist
219392940|NCT01789073|DIETARY_SUPPLEMENT|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
219392941|NCT02265211|BEHAVIORAL|Self-Help App|
219392942|NCT02201823|DRUG|ABTL0812|ABTL0812. Five cohorts and one extension phase.
219392943|NCT02251223|DRUG|Tipranavir low dose|
219001341|NCT03699098|DIAGNOSTIC_TEST|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
219392944|NCT02251223|DRUG|Tipranavir medium dose|
219392945|NCT02251223|DRUG|Tipranavir high dose|
219392946|NCT02251223|DRUG|Ritonavir low dose|
219392947|NCT02251223|DRUG|Ritonavir high dose|
219392948|NCT03870022|DEVICE|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
219392949|NCT03870022|DEVICE|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
219392950|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 25 mg tablet
219392951|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 50 mg tablet
219392952|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 100 mg tablet
219392953|NCT03909685|BEHAVIORAL|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
219392954|NCT01472237|OTHER|Nutritional intervention|Modification of diet
219392955|NCT00552305|DRUG|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
219392956|NCT05646771|BEHAVIORAL|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
219392957|NCT04068389|PROCEDURE|Pulmonary Tissue Collection|Pulmonary Tissue Collection
219392958|NCT02049528|DRUG|CC-122|CC-122
219392959|NCT02049528|DRUG|CC-122|CC-122
219392960|NCT02049528|DRUG|CC-122|CC-122
219392961|NCT03336398|DRUG|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
219392962|NCT03336398|DRUG|Saline|Saline will be administered with the other MRS scan
219392963|NCT05864157|OTHER|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
219392964|NCT05864157|OTHER|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
219392965|NCT05864157|OTHER|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
219392966|NCT03503773|DRUG|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
219392967|NCT03503773|OTHER|Sham control|endovascular, renal angiography
219392968|NCT06369467|DRUG|linvoseltamab|Administered by intravenous (IV) infusion
219392969|NCT06369467|DRUG|dupilumab|Administered by subcutaneous (SC) injection
219558354|NCT05611723|OTHER|Exposure to disability|Disability status assessed by functional measures
219392970|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
219392971|NCT02624700|DRUG|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
219392972|NCT02624700|DRUG|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
219392973|NCT02624700|DRUG|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
219392974|NCT02624700|DRUG|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
219392975|NCT00004177|BIOLOGICAL|filgrastim|as prescribed by physician
219392976|NCT00004177|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks from treatment
219392977|NCT00004177|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
219392978|NCT00004177|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
219392979|NCT02675517|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
219392980|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
219392981|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
219392982|NCT01801397|DRUG|osteoanabolic therapy|
219392983|NCT03869073|DRUG|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
219392984|NCT03869073|DRUG|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
219558355|NCT01590199|DRUG|RAD001|
219558356|NCT01590199|DRUG|SOM230|
219558357|NCT03439085|BIOLOGICAL|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
219001342|NCT01814514|DRUG|Timolol-trusopt|
219001343|NCT01814514|DRUG|placebo|
219001344|NCT00401453|BEHAVIORAL|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
219392985|NCT00425438|DRUG|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
219392986|NCT00425438|DRUG|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
219392987|NCT00425438|DRUG|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
219392988|NCT00425438|DRUG|Cyclophosphamide|0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
219392989|NCT03988816|DRUG|Roflumilast|500Mcg Tab, once daily
219392990|NCT03988816|DRUG|Placebo oral tablet|once daily
219392991|NCT06065956|DRUG|Intravenous morphine|"Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation."
219392992|NCT05762822|DIETARY_SUPPLEMENT|3-OHB (KE4)|60 ml (30 g) of 3-OHB
219392993|NCT05762822|DIETARY_SUPPLEMENT|water|60 ml water (added bitter taste)
219392994|NCT06969742|OTHER|Psycho-education and Psychological intervention_After cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions. The after cancer treatment group undergoes 7 core sessions and 3 elective sessions, a total of 10 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
219392995|NCT06969742|OTHER|Psycho-education and Psychological intervention_In cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions.~The intervention is divided into two sessions; core sessions and elective sessions. The in cancer treatment group undergoes 4 core sessions and 1 elective session, which is selected out of the given three topics, a total of 5 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
219558358|NCT03439085|BIOLOGICAL|Durvalumab|Given IV
219558359|NCT00111137|DRUG|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
219558360|NCT00111137|DRUG|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
219558361|NCT04192032|OTHER|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
219558362|NCT04192032|OTHER|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
219558363|NCT04192032|OTHER|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
219558364|NCT04192032|OTHER|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
219558365|NCT04192032|OTHER|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
219558366|NCT01863433|BIOLOGICAL|Trivalent Influenza Vaccine|
219558367|NCT02381197|DEVICE|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
219392996|NCT04471220|DEVICE|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
219392997|NCT04010422|DIAGNOSTIC_TEST|no intervention|no intervention
219392998|NCT02764840|OTHER|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
219558368|NCT05046951|BEHAVIORAL|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
219558369|NCT05046951|BEHAVIORAL|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
219558370|NCT01070745|DRUG|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
219558371|NCT01070745|DRUG|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
219558372|NCT05493566|BIOLOGICAL|Aldesleukin|Given SC
219558373|NCT05493566|BIOLOGICAL|Pembrolizumab|Given IV
219558374|NCT02357927|BEHAVIORAL|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
219558375|NCT02357927|BEHAVIORAL|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
219558376|NCT02929927|PROCEDURE|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
219558377|NCT02929927|DEVICE|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
219392999|NCT02764840|OTHER|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
219393000|NCT05191082|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
219393001|NCT05191082|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
219558378|NCT02929927|DRUG|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
219558379|NCT02929927|DRUG|2.5%NaClO|use 2.5% NaClO as irrigants
219558380|NCT02929927|PROCEDURE|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
219558381|NCT02929927|PROCEDURE|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
219558382|NCT04989569|DIETARY_SUPPLEMENT|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
219001345|NCT04333797|OTHER|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
219558383|NCT02476331|BEHAVIORAL|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
219558384|NCT01206439|DRUG|nebivolol|nebivolol 5 or 10 mg oral, daily
219393002|NCT05191082|DEVICE|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
219393003|NCT00959244|OTHER|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
219393004|NCT00959244|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
219558385|NCT00131092|BEHAVIORAL|The Stanford Active Choices program|
219558386|NCT00131092|BEHAVIORAL|The TLC system|
219558387|NCT03975439|DIAGNOSTIC_TEST|Hemoglobin A1C|Finger stick hemoglobin A1C
219558388|NCT03975439|DIAGNOSTIC_TEST|Urinalysis|Urinalysis by dip stick looking for urine protein level
219191768|NCT06003985|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
219558389|NCT03975439|DIAGNOSTIC_TEST|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
219558390|NCT03799224|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
219558391|NCT03799224|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
219558392|NCT03799224|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
219393005|NCT00959244|OTHER|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
219558393|NCT03976934|DRUG|Tamsulosin|administration of tamsulosin tablets
219558394|NCT03976934|DRUG|Placebo oral tablet|sugar pills
219558395|NCT00388063|DRUG|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
219558396|NCT00355524|DRUG|TMC114|TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
219558397|NCT00355524|DRUG|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
219558398|NCT00781079|BEHAVIORAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
219558399|NCT01524016|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
219191769|NCT06806319|DEVICE|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm.single intervention the follow-up until 6 months
219558400|NCT05318755|DRUG|GAHT for transgender men|Testosterone undecanoate
219558401|NCT05318755|DRUG|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
219558402|NCT03519438|OTHER|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
219558403|NCT04188808|OTHER|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
219558404|NCT06428955|DEVICE|CT LUCIA 621P|The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
219558405|NCT01218035|DRUG|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
219558406|NCT00006942|DRUG|bryostatin 1|Given IV
219558407|NCT00006942|DRUG|cisplatin|Given IV
219558408|NCT00006942|OTHER|laboratory biomarker analysis|Correlative studies
219558409|NCT04153786|OTHER|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
219558410|NCT01828437|DRUG|Pyridoxine plus prednisolone|
219558411|NCT01828437|DRUG|Prednisolone|
219558412|NCT00345033|DRUG|Aripiprazole|15-mg dose once a day for 8 weeks
219558413|NCT00345033|DRUG|Placebo|1 tablet placebo dose once a day for 8 weeks
219393006|NCT00959244|OTHER|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
219393007|NCT05110586|OTHER|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
219393008|NCT01729832|PROCEDURE|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
219393009|NCT01729832|PROCEDURE|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
219393010|NCT05321953|OTHER|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
219393011|NCT05321953|OTHER|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
219393012|NCT06136338|BEHAVIORAL|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
219393013|NCT04446143|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
219393014|NCT05870501|DRUG|Ketamine|0.5mg/kg IV infusion
219393015|NCT05870501|DRUG|Midazolam|0.045mg/kg IV infusion
219393016|NCT03285880|BEHAVIORAL|Napping|Children nap during the nap opportunity
219393017|NCT06672380|OTHER|Remote Physical Exercise Program for Breast Cancer Survivors|Structured and remotely guided physical exercise program The participants in the intervention group took part in a remote physical exercise program for 12 weeks. The telepresence sessions, conducted three times a week via Google Meet®, lasted 60 minutes and consisted of three phases: warm-up (10 minutes), multi-joint functional exercises (40 minutes) and stretching (10 minutes). The exercises were progressively intensified over the weeks, using the Borg scale to monitor effort. The intensity was adjusted in three cycles: in the first 4 weeks (60 seconds of exercise/90 seconds of rest), in weeks 5 to 8 (75 seconds of exercise/60 seconds of rest) and in weeks 9 to 12 (90 seconds of exercise/30 seconds of rest).
219393018|NCT06672380|OTHER|Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance|Participants in the Ebook group received an illustrated manual containing detailed guidelines for practicing simple physical exercises at home, using only their body weight. The manual suggested a frequency of 3 to 5 times a week, with 30 to 60 minutes of activities such as stretching, squats and exercises for the upper and lower limbs. The participants were encouraged to follow these guidelines and, 30 days after receiving the ebook, an additional stimulus was sent by text message, reinforcing the importance of following the protocol.
219393019|NCT06672380|OTHER|Initial Incentive for Eating Habits in Women Surviving Breast Cancer|The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
219393020|NCT01111981|DRUG|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
219393021|NCT03651999|OTHER|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
219188901|NCT05205460|DEVICE|Home-based telerehabilitation|A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.
219393022|NCT02008929|BIOLOGICAL|MG4101|Ex vivo expanded allogeneic NK cell
219393023|NCT03112837|OTHER|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
219393024|NCT05773157|BEHAVIORAL|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
219393025|NCT02619253|DRUG|Pembrolizumab|
219393026|NCT02619253|DRUG|Vorinostat|
219393027|NCT06970834|DIETARY_SUPPLEMENT|bitter melon peptides|Momordica charantia extract
219393028|NCT06970717|DEVICE|M5Stick Programmable watch|This smart watch is fashioned using a M5StickC, an IOT platform which is programmable and allows us to measure specific exercises.
219001346|NCT02080949|RADIATION|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
219001347|NCT02091492|DRUG|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
219393029|NCT06971471|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
219393030|NCT06969417|DRUG|Pregabalin|o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
219393031|NCT06969417|DRUG|Lacosamide|o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
219393032|NCT05470790|OTHER|patient reported outcome measures|Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
219393033|NCT00514449|DRUG|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
219393034|NCT00514449|DRUG|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
219393035|NCT05562570|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
219393036|NCT05562570|OTHER|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
219393037|NCT04557904|OTHER|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
219558414|NCT00499824|BEHAVIORAL|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
219558415|NCT02566096|DRUG|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
219558416|NCT00004216|BIOLOGICAL|salmonella VNP20009|
219558417|NCT00004216|DRUG|cefixime|
219558418|NCT00004216|DRUG|ceftriaxone sodium|
219558419|NCT00004216|DRUG|ciprofloxacin|
219558420|NCT00004216|DRUG|trimethoprim-sulfamethoxazole|
219558421|NCT01226524|DRUG|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
219001348|NCT02091492|DRUG|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
219001349|NCT00130936|DRUG|Epirubicin|
219001350|NCT00130936|DRUG|Carboplatin|
219001351|NCT00130936|DRUG|Capecitabine|
219188902|NCT05205460|BEHAVIORAL|Education and self-exercise|The participants will receive a exercise prescription suggestion. Then, they will maintain their usual lifestyles without exercise reminders.
219188903|NCT03996291|DRUG|Tolebrutinib|Pharmaceutical form: Film coated tablet Route of administration: Oral
219188904|NCT05994976|PROCEDURE|Blood samples collection|biomarkers and optional genetic analysis
219558422|NCT03310619|BIOLOGICAL|JCAR017|Gene modified autologous T cells
219558423|NCT03310619|DRUG|Durvalumab|Anti-PD-L1
219558424|NCT03310619|DRUG|CC-122|Pleiotropic Pathway Modifier
219558425|NCT03310619|DRUG|Ibrutinib|Ibrutinib
219393038|NCT04557904|OTHER|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
219393039|NCT06971900|DRUG|PORT-77|Active oral dose form
219393040|NCT06971900|DRUG|Placebo|Matching inactive oral dose form
219393041|NCT02172612|OTHER|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
219393042|NCT05117710|DRUG|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
219393043|NCT05117710|DRUG|Placebo|Matched placebo capsules
219558426|NCT03310619|DRUG|CC-220|CC-220
219558427|NCT03310619|DRUG|Relatlimab|Relatlimab
219558428|NCT03310619|DRUG|Nivolumab|Nivolumab
219558429|NCT03310619|DRUG|CC-99282|CC-99282
219558430|NCT02642523|DRUG|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
219558431|NCT02642523|DRUG|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
219558432|NCT02642523|OTHER|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
219558433|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
219558434|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
219558435|NCT03885336|OTHER|No Interventions|There are no interventions in this study. Participants are observed.
219558436|NCT01115933|DEVICE|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
219558437|NCT02427399|OTHER|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
219558438|NCT02427399|OTHER|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
219558439|NCT02427399|OTHER|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
219558440|NCT02427399|OTHER|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
219393044|NCT05761951|DRUG|DKN-01|Given by IV (vein)
219558441|NCT01830309|DRUG|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
219393045|NCT05761951|DRUG|Pembrolizumab|Given by IV (vein)
219393046|NCT05227651|DRUG|AK104|IV infusion,Specified dose on specified days
219393047|NCT04116502|DRUG|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
219558442|NCT06480825|OTHER|Performance of ultrasonographic scan|Ultra-high frequency ultrasonographic scan of gingival tissues
219558443|NCT03493035|DIAGNOSTIC_TEST|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
219558444|NCT03493035|DIAGNOSTIC_TEST|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
219558445|NCT00249990|DRUG|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
219393048|NCT04116502|DRUG|Hydroxycarbamide|Via standard hospital mechanisms
219393049|NCT04116502|DRUG|Interferon-Alpha|Any formulation, via standard hospital mechanisms
219393050|NCT04353947|DIAGNOSTIC_TEST|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
219393051|NCT04353947|DIAGNOSTIC_TEST|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
219393052|NCT04353947|DIAGNOSTIC_TEST|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
219393053|NCT04353947|DIAGNOSTIC_TEST|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
219393054|NCT04353947|DIAGNOSTIC_TEST|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
219393055|NCT04353947|DIAGNOSTIC_TEST|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
219393056|NCT04353947|DIAGNOSTIC_TEST|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
219393057|NCT04353947|DIAGNOSTIC_TEST|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
219393058|NCT04353947|DIAGNOSTIC_TEST|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
219393059|NCT04353947|DIAGNOSTIC_TEST|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
219393060|NCT03464097|DRUG|Ozanimod|Specified dose on specified days
219188905|NCT05994976|PROCEDURE|Oral samples collection|biomarkers analysis
219393061|NCT03464097|OTHER|Placebo|Specified dose on specified days
219393062|NCT05564624|OTHER|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
219393063|NCT04916197|DRUG|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
219393064|NCT04916197|DRUG|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
219393065|NCT03925428|DRUG|Entinostat|Given PO
219393066|NCT03925428|DRUG|Molibresib|Given PO
219393067|NCT01430221|BEHAVIORAL|Mindfulness-based Personalized Health Planning|
219393068|NCT01430221|OTHER|Structured & Guided Education|
219393069|NCT05464277|OTHER|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
219393070|NCT05840705|PROCEDURE|Small curved incision with apex lateral|Small curved incision with apex lateral
219393071|NCT06430255|OTHER|Global Postural Re-education|Program for treatment
219393072|NCT06430255|OTHER|Laser-guided Supervised Exercise|Program for treatment
219393073|NCT00145340|DRUG|pioglitazone|30 Mg/day
219393074|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
219393075|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
219393076|NCT05878444|DIETARY_SUPPLEMENT|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
219393077|NCT02894983|OTHER|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
219393078|NCT02894983|OTHER|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
219393079|NCT01914133|DRUG|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
219393080|NCT01914133|DRUG|Placebo|Placebo given prior to meal the standardized meal
219393081|NCT02694029|DEVICE|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
219393082|NCT02694029|DEVICE|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
219393083|NCT01898312|DRUG|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
219393084|NCT01334112|DRUG|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
219393085|NCT02879500|OTHER|Diet beverages|
219393086|NCT01516801|OTHER|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
219393087|NCT05677789|DIAGNOSTIC_TEST|Medical observation|Likely suitable for home treatment
219393088|NCT05677789|DIAGNOSTIC_TEST|Supportive treatment (BSC)|Consider hospital supervised treatment
219393089|NCT05677789|DIAGNOSTIC_TEST|Intensive care management|Manage in hospital as severe pneumonia
219393090|NCT02609893|OTHER|modified directly observed therapy (mDOT)|
219393091|NCT02609893|OTHER|unobserved dosing|
219393092|NCT02609893|OTHER|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
219393093|NCT04194593|OTHER|PCR (Polymerase Chain Reaction)|"Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm."
219393094|NCT04726267|DEVICE|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
219393095|NCT05873140|BEHAVIORAL|application LINE|Online lifestyle modification education for weight loss
219393096|NCT01417286|RADIATION|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
219393097|NCT05955859|PROCEDURE|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
219393098|NCT00301067|DIETARY_SUPPLEMENT|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
219393099|NCT00301067|DRUG|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
219393100|NCT03662152|DEVICE|Foam roller|Foam roller massage after DOMS
219393101|NCT03662152|DEVICE|Vibration foam roller|Foam roller massage with vibration after DOMS
219393102|NCT02533648|DRUG|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
219393103|NCT02533648|DRUG|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
219393104|NCT00149825|DRUG|Escitalopram|5 to 20 mg for 12 weeks
219393105|NCT00149825|BEHAVIORAL|CBTI|Cognitive Behavioral Treatment for Insomnia
219393106|NCT00149825|BEHAVIORAL|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
219393107|NCT06387719|DIAGNOSTIC_TEST|Magnetic resonance imaging|"* Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles."
219393108|NCT01359982|DRUG|RRx-001|Dose level 1 (10 mg/m2)
219393109|NCT01359982|DRUG|RRx-001|Dose Level 2 (16.7 mg/m2)
219393110|NCT01359982|DRUG|RRx-001|Dose Level 3 (24.6 mg/m2)
219393111|NCT01359982|DRUG|RRx-001|Dose Level 4 (33 mg/m2)
219393112|NCT01359982|DRUG|RRx-001|Dose Level 5 (55.0 mg/m2)
219393113|NCT01359982|DRUG|RRx-001|Dose Level 6 (83 mg/m2)
219393114|NCT06971159|DEVICE|Systemic vibratory therapy|Systemic vibratory therapy is an intervention in which mechanical vibration, generated by the vibrating platform, is transmitted to the whole-body of the individual generating whole-body vibration exercise.
219393115|NCT06971159|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative treatment is defined by the WHO as a diagnostic and therapeutic method that uses manual contact for these purposes. It concerns the relationship between body, mind and spirit in health and illness, emphasizing the structural and functional integrity of the body and the body's intrinsic tendency to direct itself towards healing.
219393116|NCT06971159|OTHER|Sham|In the sham group, the interventions are simulated, as described in the sham group protocol.
219393117|NCT01062451|DRUG|Perindopril|8 mg taken orally from days 0 through 7.
219393118|NCT01062451|DRUG|Placebo|Placebo treatment daily.
219393119|NCT01062451|DRUG|Candesartan|16 mg taken orally from days 0 through 7.
219393120|NCT02186327|BEHAVIORAL|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
219393121|NCT06244368|DRUG|GVM±R regimen|"Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
219393122|NCT06518863|BEHAVIORAL|Education|Educational handouts on how to adhere to the corresponding diet.
219393123|NCT02165852|PROCEDURE|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
219393124|NCT02165852|PROCEDURE|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
219393125|NCT06483633|BEHAVIORAL|MICT + CPT, HIIT + CPT, SIT + CPT|Single acute intervention, each exercise mode had a washout period of at least 7 days.
219393126|NCT03411733|OTHER|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
219558446|NCT04536506|OTHER|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
219393127|NCT06249542|OTHER|Care Delivery Improvement Intervention|"KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use"
219393128|NCT04984226|DRUG|Sodium bicarbonate|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
219393129|NCT04984226|DRUG|placebo|The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
219393130|NCT00346515|DEVICE|FiberNet Emboli Protection System|
219393131|NCT01634347|DRUG|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
219558447|NCT04536506|OTHER|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
219558448|NCT04988737|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
219558449|NCT02105909|OTHER|GWAS|
219558450|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
219558451|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
219558452|NCT06176885|DRUG|Camrelizumab|Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
219558453|NCT04134637|DEVICE|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
219558454|NCT04134637|DRUG|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
219558455|NCT02176278|OTHER|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
219558456|NCT02176278|OTHER|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
219558457|NCT02176278|OTHER|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
219558458|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
219558459|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
219558460|NCT06678607|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
219558461|NCT06678607|BIOLOGICAL|Placebo|One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine
219188906|NCT05994976|PROCEDURE|Hair samples collection|biomarkers analysis
219393132|NCT01634347|DRUG|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
219393133|NCT02195648|OTHER|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
219393134|NCT00607750|DRUG|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
219393135|NCT00607750|DRUG|Placebo|Placebo eyedrops, BID, 48 weeks
219393136|NCT00310505|DRUG|Amphotericin B deoxycholate given as daily administration|
219393137|NCT05646550|DRUG|CC-1 Infusion|Short term (3h) infusion of CC-1
219393138|NCT04697147|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
219393139|NCT04036266|PROCEDURE|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
219393140|NCT05086237|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
219393141|NCT03622645|DEVICE|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
219393142|NCT03520049|DRUG|Oseltamivir|
219393143|NCT03520049|DRUG|Placebo|
219393144|NCT04706598|DRUG|Camrelizumab|Solution for Infusion (Intravesical)
219393145|NCT02680067|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
219393146|NCT02680067|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
219393147|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
219393148|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
219393149|NCT03929042|DEVICE|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
219393150|NCT02785757|OTHER|Thrombin Generation Assay|
219393151|NCT03466762|OTHER|Non applicable|Non applicable
219393152|NCT05263882|DRUG|Gemcitabine combined with eribulin|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
219393153|NCT01172171|DRUG|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
219393154|NCT01172171|DRUG|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
219558462|NCT00846898|DIETARY_SUPPLEMENT|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
219393155|NCT03777930|DRUG|Chemotherapy drugs|According to the NCCN Guidelines
219393156|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
219393157|NCT03777930|OTHER|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
219558463|NCT00333853|DEVICE|OneTouch(r) UltraSmart(r)|
219558464|NCT03275857|DRUG|Cisplatin|Weekly IV
219558465|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
219393158|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
219393159|NCT01661647|DEVICE|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
219393160|NCT00705510|DRUG|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
219393161|NCT05777525|COMBINATION_PRODUCT|"application of cream La Chinata"|application of cream enriched with essential oil
219393162|NCT01208181|DRUG|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
219393163|NCT01208181|DRUG|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
219393164|NCT01208181|DRUG|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
219393165|NCT01208181|DRUG|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
219393166|NCT00527852|DEVICE|Flocked swab|
219393167|NCT04598438|BEHAVIORAL|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
219393168|NCT04598438|BEHAVIORAL|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
219393169|NCT00451087|PROCEDURE|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
219393170|NCT00451087|PROCEDURE|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
219393171|NCT02354001|DRUG|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
219558466|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
219393172|NCT02354001|DRUG|Placebo|1 capsule daily for 12 week trial - lactose
219558467|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
219558468|NCT03998592|OTHER|Placebo|Placebo without active component
219558469|NCT03911180|DEVICE|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
219558470|NCT03934996|OTHER|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
219558471|NCT02870439|OTHER|Blood drawn|
219558472|NCT00959439|DRUG|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
219558473|NCT00959439|DRUG|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
219558474|NCT05499416|DRUG|Bimekizumab|Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
219558475|NCT01616316|PROCEDURE|subfascial flap|subfacial dissection to thyroid
219558476|NCT01616316|PROCEDURE|subplatysmal flap|subplatysmal approach to thyroid
219558477|NCT02050035|OTHER|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
219393173|NCT01430195|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
219393174|NCT01430195|PROCEDURE|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
219393175|NCT00411515|DRUG|Mycophenolate Mofetil 2x 1g|
219393176|NCT05207267|DEVICE|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
219393177|NCT00256555|DRUG|Nutropin AQ|
219393178|NCT00810160|DIETARY_SUPPLEMENT|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
219393179|NCT00810160|DIETARY_SUPPLEMENT|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
219393180|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
219558478|NCT01845064|DRUG|DM199|
219558479|NCT01845064|DRUG|Placebo|
219558480|NCT00707187|DRUG|Cialis|35 pills of study medication (20 mg)
219558481|NCT04499378|DIAGNOSTIC_TEST|Lung CT|Computed tomography of the thorax
219558482|NCT02686762|DRUG|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
219558483|NCT02686762|DRUG|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
219558484|NCT02686762|DRUG|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
219558485|NCT01557062|OTHER|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
219558486|NCT01557062|OTHER|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
219188907|NCT05994976|PROCEDURE|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
219393181|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
219188908|NCT05994976|PROCEDURE|Skin surface material samples|biomarkers analysis
219393182|NCT00855712|DEVICE|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
219393183|NCT00855712|DEVICE|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
219558487|NCT01557062|OTHER|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
219558488|NCT04011449|DEVICE|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
219558489|NCT01583634|DEVICE|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
219558490|NCT01583634|DEVICE|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
219558491|NCT06110286|OTHER|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
219558492|NCT05188924|DRUG|DKF-306|Active ingredients
219558493|NCT05188924|DRUG|Placebo|Placebo
219558494|NCT00756717|DRUG|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
219393184|NCT06232122|DIAGNOSTIC_TEST|68Ga-FAPI-46|Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
219393185|NCT06232122|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 5-10mCi 18F-FDG
219558495|NCT00603512|DRUG|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
219558496|NCT00603512|DRUG|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
219558497|NCT00603512|DRUG|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
219558498|NCT00603512|DRUG|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
219558499|NCT00603512|DRUG|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
219558500|NCT03266055|DIETARY_SUPPLEMENT|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
219558501|NCT03266055|DIETARY_SUPPLEMENT|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
219558502|NCT05815849|DIETARY_SUPPLEMENT|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
219558503|NCT04979858|DEVICE|Focal Mask|The treatment group will receive and use the focal mask.
219558504|NCT04066413|OTHER|Standard infant formula|Standard infant formula
219558505|NCT04066413|OTHER|Infant formula supplemented with HMO|Infant formula supplemented with HMO
219558506|NCT04547933|DIAGNOSTIC_TEST|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
219558507|NCT02262559|DRUG|BIBR 277 tablet|
219558508|NCT02262559|DRUG|BIBR 277 capsule|
219558509|NCT05794087|OTHER|Clean Air|Subjects will be exposed to clean air for 3 hours.
219558510|NCT05794087|OTHER|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
219558511|NCT02150356|OTHER|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
219558512|NCT02150356|OTHER|Control|Diet based on refined cereal products for a period of 8 weeks.
219188909|NCT05994976|PROCEDURE|Drainage fluid samples collection|biomarkers analysis
219188910|NCT05994976|PROCEDURE|Stool samples collection|biomarkers analysis
219558513|NCT03077009|DRUG|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
219558514|NCT02654015|DEVICE|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
219558515|NCT02654015|OTHER|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
219558516|NCT03860337|DIETARY_SUPPLEMENT|Alginate Sausage|Alginate sausage
219558517|NCT03860337|OTHER|Control Sausage|Control Sausage
219558518|NCT02846233|DRUG|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
219558519|NCT02846233|DRUG|basal insulin|The participant will continue with the basal insulin.
219558520|NCT02846233|DRUG|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
219558521|NCT02846233|DRUG|Metformin|The participant will continue with metformin.
219558522|NCT02171897|PROCEDURE|Osteosynthesis|
219188911|NCT05636215|BIOLOGICAL|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
219558523|NCT02171897|PROCEDURE|Total hip replacement|
219558524|NCT01896505|DRUG|KCP-330|
219558525|NCT03082651|OTHER|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
219558526|NCT03082651|OTHER|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
219188912|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
219188913|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
219188914|NCT04534582|DRUG|HLX14|healthy volunteers receive HLX14 (60mg) once
219393186|NCT05082870|BEHAVIORAL|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
219393187|NCT01115712|DRUG|Placebo|Placebo (to match pioglitazone 30 mg) once daily
219393188|NCT01115712|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
219393189|NCT01115712|DRUG|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
219393190|NCT00942708|DRUG|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
219393191|NCT03836521|DEVICE|Transcatheter aortic valve replacement|
219393192|NCT02243566|DRUG|MicardisPlus®|
219393193|NCT02355379|DRUG|LV5FU2 or capectitabine|
219393194|NCT02355379|DRUG|FOLFOX4 or XELOX|
219393195|NCT02355379|OTHER|Observation|
219393196|NCT02355379|DRUG|LV5FU2 or capecitabine|
219558527|NCT03082651|OTHER|Constant training|Runners will be assigned identical training sessions over a 7-day period.
219558528|NCT03082651|OTHER|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
219188915|NCT04534582|DRUG|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
219188916|NCT04534582|DRUG|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
219188917|NCT04534582|DRUG|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
219188918|NCT06318429|BEHAVIORAL|stretching exercise group|stretching exercise group
219188919|NCT06566378|DEVICE|Buzzy|In children pre-procedure, buzzy was placed under the armpit. The children were made before starting the application. It continued until the end of vaccination procedure.
219188920|NCT06566378|DEVICE|Buzzy (Placed in standard)|In children pre-procedure, buzzy was placed on the arm. The children were made before starting the application. It continued until the end of vaccination procedure.
219188921|NCT04807764|COMBINATION_PRODUCT|Standing transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219188922|NCT04807764|COMBINATION_PRODUCT|Lying transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219393197|NCT02427581|BIOLOGICAL|Personalized synthetic long peptide vaccine (Poly ICLC)|
219393198|NCT02427581|DRUG|Poly ICLC|
219393199|NCT00954577|BEHAVIORAL|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
219393200|NCT01975025|PROCEDURE|Short daily dialysis for 2 weeks|
219393201|NCT01134484|DRUG|Velcade|"* INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
219393202|NCT01134484|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
219393203|NCT01134484|DRUG|Dexamethasone|"* INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
219393204|NCT01134484|PROCEDURE|Peripheral Blood Stem Cell (PBSC) collection|"* Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
219393205|NCT01134484|PROCEDURE|First Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
219393206|NCT01134484|PROCEDURE|Second Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
219393207|NCT00156078|DRUG|pregabalin|
219393208|NCT00943878|BIOLOGICAL|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
219393209|NCT00943878|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
219393210|NCT00943878|DRUG|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
219393211|NCT02596880|DRUG|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
219393212|NCT02596880|DRUG|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
219393213|NCT02596880|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
219393214|NCT02443844|PROCEDURE|Transurethral Resection|Endoscopic treatment of bladder cancer
219558529|NCT00047047|DRUG|gemcitabine hydrochloride|Given IV
219558530|NCT00047047|DRUG|tanespimycin|Given IV
219558531|NCT00047047|DRUG|cisplatin|Given IV
219558532|NCT00047047|OTHER|laboratory biomarker analysis|Correlative studies
219558533|NCT05426954|OTHER|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
219558534|NCT02418754|DRUG|REGN2176-3|
219558535|NCT02418754|DRUG|Intravitreal Aflibercept Injection (IAI)|
219558536|NCT03671343|BEHAVIORAL|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
219558537|NCT04197154|BEHAVIORAL|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
219188923|NCT04807764|OTHER|Standing sham transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219393215|NCT02443844|DRUG|Tamsulosin|Medical treatment for benign prostate hyperplasia
219393216|NCT00974662|DRUG|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
219393217|NCT01457339|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
219393218|NCT01457339|DRUG|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
219558538|NCT04197154|BEHAVIORAL|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
219558539|NCT04197154|BEHAVIORAL|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
219558540|NCT04197154|BEHAVIORAL|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
219558541|NCT04197154|BEHAVIORAL|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
219188924|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
219393219|NCT03389672|PROCEDURE|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
219393220|NCT03389672|PROCEDURE|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
219393221|NCT03389672|PROCEDURE|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
219393222|NCT01784549|DRUG|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
219393223|NCT02660658|DRUG|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
219393224|NCT06092502|OTHER|Graded Motor Imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
219393225|NCT06092502|OTHER|Traditional Physiotherapy Program|This protocol included stretching and strengthening exercises
219393226|NCT04155385|OTHER|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
219393227|NCT04155385|OTHER|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
219393228|NCT02730247|DRUG|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
219393229|NCT02730247|DRUG|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
219393230|NCT00002423|DRUG|Indinavir sulfate|
219393231|NCT00002423|DRUG|Abacavir sulfate|
219393232|NCT00002423|DRUG|Amprenavir|
219393233|NCT00002423|DRUG|Nelfinavir mesylate|
219393234|NCT00002423|DRUG|Lamivudine|
219393235|NCT00765479|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
219393236|NCT00765479|OTHER|placebo|Given orally
219558542|NCT04974580|DRUG|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
219001352|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
219001353|NCT05952011|DRUG|Topical Nitroglycerine|Application of topical Nitroglycerin solution to the LIMA pedicle graft during dissection of the vessel in both study arms.
219001354|NCT03792698|OTHER|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
219001355|NCT03910374|PROCEDURE|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
219001356|NCT01154790|DRUG|CG100649|6 subjects: study drug 2 subjects: placebo
219001357|NCT01154790|DRUG|Placebo|6 subjects: study drug 2 subjects: placebo
219001358|NCT01154790|DRUG|Naproxen|6 subjects: study drug 2 subjects: placebo
219001359|NCT05142943|OTHER|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
219001360|NCT05142943|OTHER|Physical exercise|"* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
219001361|NCT05142943|OTHER|Sham Visual illusion|only the placebo visual illusion
219001362|NCT05914298|DIAGNOSTIC_TEST|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
219001363|NCT05914298|DIAGNOSTIC_TEST|PUL|measurement of ulnar length with anthropometer and patient's height
219001364|NCT05914298|DIAGNOSTIC_TEST|Range of motion|measurement of range of motion of elbow, forearm and wrist
219393237|NCT01157858|DRUG|Everolimus|2.5 mg every day orally
219393238|NCT01157858|DRUG|Octreotide LAR|40 mg every 28 days IM
219393239|NCT03495505|DEVICE|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
219393240|NCT03890224|DEVICE|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
219393241|NCT03694522|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
219393242|NCT03694522|DRUG|Placebo|Administered by intravenous infusion over approximately 30 minutes
219393243|NCT03694522|DRUG|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
219393244|NCT03940144|DEVICE|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
219393245|NCT02320331|BEHAVIORAL|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
219393246|NCT02976467|DRUG|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
219393247|NCT02976467|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
219393248|NCT05427630|DRUG|THC ~2.5%|Cannabis flower containing THC \~2.5%
219393249|NCT05427630|DRUG|THC ~5%|Cannabis flower containing THC \~5%
219393250|NCT05427630|DRUG|THC ~10%|Cannabis flower containing THC \~5%
219393251|NCT05427630|DRUG|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
219393252|NCT05999305|OTHER|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
219393253|NCT05999305|OTHER|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
219393254|NCT05374356|DRUG|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
219393255|NCT01235533|DIETARY_SUPPLEMENT|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
219393256|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
219393257|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
219393258|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
219393259|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
219393260|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
219393261|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
219393262|NCT01112215|DRUG|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
219188925|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
219188926|NCT03541720|DRUG|18F-DA|18F-DA is an investigational PET radiotracer
219393263|NCT01112215|DRUG|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
219393264|NCT03260738|DEVICE|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
219393265|NCT03260738|OTHER|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
219393266|NCT03085732|DRUG|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
219393267|NCT00306891|DRUG|Cediranib|45 mg oral dose
219393268|NCT00306891|DRUG|Cediranib 30 - 90 mg|oral tablet dose escalation
219393269|NCT00673673|DRUG|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
219393270|NCT00673673|DRUG|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
219393271|NCT02435628|OTHER|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
219393272|NCT00907725|OTHER|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
219558543|NCT04974580|BEHAVIORAL|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
219558544|NCT04974580|BEHAVIORAL|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
219558545|NCT01814358|DIETARY_SUPPLEMENT|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
219558546|NCT01814358|DIETARY_SUPPLEMENT|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
219558547|NCT05445570|DIAGNOSTIC_TEST|Non-Interventional|This is an observational, non interventional study
219558548|NCT00462839|PROCEDURE|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
219558549|NCT04606017|DRUG|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
219558550|NCT05853783|OTHER|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
219558551|NCT03944161|DIETARY_SUPPLEMENT|Oral nutrition supplement|Hypercaloric and high protein supplement
219558552|NCT03944161|OTHER|Nutritional advice|Advice given by the clinician
219558553|NCT06678061|DEVICE|radiofrequency|block of neurolytic retrocrural celiac plexus block
219558554|NCT05676008|BEHAVIORAL|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
219558555|NCT03129776|DRUG|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
219558556|NCT03129776|DRUG|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
219558557|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (rabbit)|
219558558|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (horse)|
219558559|NCT00260689|DRUG|Cyclosporine|
219558560|NCT00260689|DRUG|Alemtuzumab|
219558561|NCT01557686|BEHAVIORAL|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
219558562|NCT01858922|DRUG|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
219558563|NCT01858922|DRUG|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
219558564|NCT01493596|DRUG|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
219558565|NCT01493596|DRUG|Placebo|An equal volume of water mixed with juice will be administered.
219558566|NCT03980210|PROCEDURE|Hyperbaric oxygen therapy|"1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
219558567|NCT00935623|BIOLOGICAL|Malaria Challenge|Malaria challenge
219558568|NCT01166815|DIETARY_SUPPLEMENT|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
219191770|NCT06806319|DEVICE|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.single intervention then follow-up until 6 months
219558569|NCT01166815|OTHER|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
219393273|NCT00907725|OTHER|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
219558570|NCT04784637|DEVICE|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
219558571|NCT04784637|DEVICE|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
219558572|NCT04784637|DEVICE|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
219558573|NCT04784637|DEVICE|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
219558574|NCT00535028|DRUG|AER 001|AER 001 25 mgs s.c. once daily for 28 days
219558575|NCT00535028|DRUG|placebo|sterile saline
219558576|NCT03919695|BEHAVIORAL|Kisoboka: Behavioral and Structural Intervention|"The intervention has two components; a structural component and a behavioral component. The intervention draws from behavioral economics and motivational interviewing.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals."
219558577|NCT03919695|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
219558578|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
219558579|NCT03259789|DRUG|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
219558580|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
219558581|NCT04972331|PROCEDURE|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
219191771|NCT03213873|BEHAVIORAL|HiBalance|Intervention of highly challenging balance training for 10 weeks.
219558582|NCT04972331|PROCEDURE|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.
219558583|NCT04972331|OTHER|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
219558584|NCT01143831|DIETARY_SUPPLEMENT|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
219558585|NCT03901157|DIETARY_SUPPLEMENT|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
219558586|NCT03901157|DIETARY_SUPPLEMENT|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
219558587|NCT01279382|BEHAVIORAL|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
219393274|NCT06656741|BEHAVIORAL|Resting State|Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
219393275|NCT06656741|BEHAVIORAL|Mindful Breathing|Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.
219558588|NCT01279382|BEHAVIORAL|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
219558589|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
219558590|NCT05550792|DEVICE|optimizer smart|The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
219001365|NCT01699204|DIETARY_SUPPLEMENT|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
219191772|NCT03213873|BEHAVIORAL|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
219558591|NCT02898701|BEHAVIORAL|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
219188927|NCT05737303|DRUG|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
219188928|NCT05861427|DRUG|Atogepant|Oral Tablet
219188929|NCT05861427|DRUG|Placebo for Atogepant|Oral Tablet
219393276|NCT06656741|BEHAVIORAL|Guided Breathing|Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).
219393277|NCT06656741|BEHAVIORAL|Breath Counting|Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
219393278|NCT04538950|DIAGNOSTIC_TEST|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
219393279|NCT04538950|DRUG|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
219393280|NCT02620540|DEVICE|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
219393281|NCT03490786|DRUG|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
219393282|NCT01668069|DRUG|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
219393283|NCT02765893|OTHER|No Foley|Patients will have Foley catheter removed 6 hours post-op.
219393284|NCT03610412|OTHER|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
219393285|NCT03610412|OTHER|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
219393286|NCT03551899|OTHER|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
219393287|NCT00467883|DRUG|Liposomal Amphotericin B|high dosage
219393288|NCT02792777|OTHER|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
219558592|NCT05776381|OTHER|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
219558593|NCT00005858|BIOLOGICAL|LMB-9 immunotoxin|
219393289|NCT02792777|OTHER|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
219393290|NCT00025649|BIOLOGICAL|filgrastim|
219393291|NCT00025649|DRUG|busulfan|
219393292|NCT00025649|DRUG|carboplatin|
219393293|NCT00025649|DRUG|cyclophosphamide|
219393294|NCT00025649|DRUG|doxorubicin hydrochloride|
219393295|NCT00025649|DRUG|etoposide|
219393296|NCT00025649|DRUG|melphalan|
219558594|NCT02104869|BIOLOGICAL|Trivalent influenza vaccine (inactivated and fragmented).|
219558595|NCT02063217|DRUG|Sodium Oxybate|Sodium oxybate h.s.
219558596|NCT02063217|BEHAVIORAL|Sleep deprivation|36hr sleep deprivation
219393297|NCT00025649|DRUG|vincristine sulfate|
219558597|NCT00233155|DRUG|Capsaicin Dermal Patch|
219558598|NCT06435832|DRUG|Absorbable Gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
219558599|NCT06435832|DRUG|Chlorhexidine|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
219393298|NCT00025649|PROCEDURE|autologous bone marrow transplantation|
219393299|NCT00025649|PROCEDURE|conventional surgery|
219393300|NCT00025649|PROCEDURE|peripheral blood stem cell transplantation|
219393301|NCT04205422|PROCEDURE|BIPAP|Biphasic Intermittent Positive Airway Pressure
219558600|NCT06435832|DRUG|Tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
219558601|NCT01004445|DRUG|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
219558602|NCT01004445|DRUG|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
219558603|NCT01004445|DRUG|Placebo|Two aerosol treatments per day (one treatment every 12hr)
219393302|NCT04205422|PROCEDURE|APRV|Airway Pressure Release Ventilation
219393303|NCT02035423|DIETARY_SUPPLEMENT|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
219558604|NCT02416934|DRUG|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
219558605|NCT02416934|DRUG|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
219558606|NCT06096350|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
219558607|NCT06096350|DIAGNOSTIC_TEST|hematochemical analysis|Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
219558608|NCT06096350|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
219558609|NCT06096350|DIAGNOSTIC_TEST|nutritional assessment, MNA,|nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
219558610|NCT06096350|DIAGNOSTIC_TEST|stool sampling|stool will be collected at T0 and at T1
219558611|NCT06096350|DIAGNOSTIC_TEST|urine sampling|the first morning urine will be collected at T0 and at T1
219393304|NCT02035423|DIETARY_SUPPLEMENT|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
219558612|NCT06096350|DEVICE|indirect calorimetry analysis|indirect calorimetry analysis with K5 (COSMED, Italy) during six minute walk test or timed up and go test.
219558613|NCT01020526|DRUG|pregabalin|Oral capsule 75-450 mg/day
219558614|NCT03367780|DEVICE|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
219558615|NCT04304209|DRUG|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
219558616|NCT04304209|DRUG|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
219558617|NCT04304209|DRUG|Sintilimab|200mg, d1 q3w, intravenous infusion
219558618|NCT04304209|RADIATION|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
219558619|NCT04304209|PROCEDURE|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
219393305|NCT02035423|DIETARY_SUPPLEMENT|Non-Fortified Milk|Daily consumption of non-fortified milk
219393306|NCT05960955|DRUG|Cadonilimab|IV infusion,Specified dose on specified days
219558620|NCT04304209|OTHER|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
219558621|NCT00078923|DIETARY_SUPPLEMENT|soy isoflavones|
219558622|NCT00078923|PROCEDURE|neoadjuvant therapy|Prostatectomy or Brachytherapy
219393307|NCT05960955|DRUG|AK117|IV infusion,Specified dose on specified days
219393308|NCT05960955|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
219393309|NCT05960955|DRUG|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
219393310|NCT05960955|DRUG|Docetaxel|IV infusion,Specified dose on specified days
219393311|NCT05960955|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
219393312|NCT04786288|OTHER|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
219393313|NCT04786288|OTHER|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
219558623|NCT00078923|OTHER|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
219558624|NCT05040139|PROCEDURE|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
219558625|NCT05040139|PROCEDURE|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
219558626|NCT03269955|DRUG|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
219558627|NCT01821157|PROCEDURE|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
219558628|NCT01821157|PROCEDURE|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
219558629|NCT05290233|BEHAVIORAL|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
219558630|NCT06384482|DRUG|SNC115 injection|SNC115 Injection is DLL3 CART.
219558631|NCT05761392|OTHER|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
219558632|NCT00386646|DRUG|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
219558633|NCT03581162|DIAGNOSTIC_TEST|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
219393314|NCT03636412|OTHER|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
219393315|NCT00000530|DRUG|nifedipine|
219393316|NCT00000530|BEHAVIORAL|biofeedback (psychology)|
219393317|NCT00000530|PROCEDURE|electromyography|
219393318|NCT01874704|BEHAVIORAL|Comparison of biomarkers of stress|
219393319|NCT02005523|DRUG|RNS60|
219393320|NCT02005523|DRUG|Saline|
219393321|NCT05417529|OTHER|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
219393322|NCT05417529|DRUG|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
219393323|NCT01821248|DRUG|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
219393324|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
219393325|NCT05333562|OTHER|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
219558634|NCT05995873|DEVICE|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
219393326|NCT05440955|DEVICE|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
219393327|NCT05046210|BEHAVIORAL|LHA intervention|The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
219393328|NCT05046210|BEHAVIORAL|Oral exercise intervention|Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
219393329|NCT04799782|DRUG|Mirtazapine|15 mg dose before bed-time
219393330|NCT04799782|DRUG|Placebo|One placebo pill before bed-time
219393331|NCT01466725|DRUG|CC-930|
219393332|NCT01466725|DRUG|Placebo|Placebo
219393333|NCT04272125|BIOLOGICAL|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
219393334|NCT04666961|DRUG|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
219393335|NCT04666961|DRUG|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
219393336|NCT04118361|DIAGNOSTIC_TEST|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
219393337|NCT04118361|DIAGNOSTIC_TEST|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
219393338|NCT04798417|DIETARY_SUPPLEMENT|Probiotic supplement|Use of a probiotic sachet
219393339|NCT04798417|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic sachets
219393340|NCT04798417|DIETARY_SUPPLEMENT|Maltodextrin|Placebo comparator
219393341|NCT02584621|BEHAVIORAL|Check Yourself App with Feedback|
219393342|NCT03271255|DRUG|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
219393343|NCT03271255|DRUG|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
219393344|NCT02109003|DEVICE|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
219393345|NCT02109003|DEVICE|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
219393346|NCT03687177|OTHER|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
219558635|NCT01237080|DEVICE|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
219558636|NCT01237080|DEVICE|Fastrach|The Fastrach is an intubation laryngeal mask.
219393347|NCT03687177|OTHER|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
219393348|NCT04258553|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
219393349|NCT04258553|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
219393350|NCT04258553|DIAGNOSTIC_TEST|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
219393351|NCT01123447|PROCEDURE|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
219393352|NCT01123447|PROCEDURE|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
219393353|NCT01058577|DEVICE|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
219393354|NCT01058577|PROCEDURE|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
219393355|NCT06511609|PROCEDURE|double-flap technique（DFT）; double-tract reconstruction(DTR),|DFT (experiment group). Patients receive double flap technique after laparoscopic proximal gastrectomy. DTR (control group). Patients receive double-tract reconstruction after laparoscopic proximal gastrectomy.
219393356|NCT02606877|DRUG|nintedanib|
219393357|NCT02606877|DRUG|pirfenidone|
219393358|NCT03727711|OTHER|TPTNS|We will be comparing hospital treatment to TPTNS at home
219393359|NCT00756977|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
219393360|NCT00756977|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
219393361|NCT02989727|DRUG|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
219393362|NCT02989727|DRUG|Placebos|Placebo tablets
219558637|NCT02141048|BEHAVIORAL|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
219393363|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
219393364|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
219393365|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
219393366|NCT04534894|DIAGNOSTIC_TEST|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
219393367|NCT01319760|DEVICE|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
219393368|NCT01319760|OTHER|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
219393369|NCT01236222|BEHAVIORAL|Cycling to school|Regular cycling to school
219393370|NCT02616822|DIETARY_SUPPLEMENT|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
219558638|NCT00002592|BIOLOGICAL|c-myb antisense oligonucleotide G4460|
219558639|NCT00002592|BIOLOGICAL|filgrastim|
219393371|NCT02616822|OTHER|Placebo|Used for placebo substance single dose
219393372|NCT02029430|DRUG|50 mg/m2 aldoxorubicin|
219393373|NCT02029430|DRUG|100 mg/m2 aldoxorubicin|
219393374|NCT02029430|DRUG|150 mg/m2 aldoxorubicin|
219393375|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
219393376|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
219393377|NCT01081210|OTHER|Ultrasound examination|Screening with bedside ultrasound examination
219393378|NCT05045755|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
219393379|NCT03633643|DRUG|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
219558640|NCT00002592|DRUG|busulfan|
219558641|NCT00002592|DRUG|cyclophosphamide|
219393380|NCT03633643|DRUG|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
219393381|NCT05242588|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
219558642|NCT00002592|PROCEDURE|autologous bone marrow transplantation|
219393382|NCT05242588|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
219558643|NCT00002592|PROCEDURE|in vitro-treated bone marrow transplantation|
219558644|NCT04680780|OTHER|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
219558645|NCT04680780|OTHER|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
219558646|NCT04680780|OTHER|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
219558647|NCT05467540|DEVICE|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
219558648|NCT03544840|OTHER|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
219558649|NCT02169336|DRUG|Intranasal Dexmedetomidine|
219558650|NCT02169336|OTHER|Intranasal Placebo|
219558651|NCT03555136|DRUG|Vortioxetine|Treatment with vortioxetine as per local SmPC
219558652|NCT00943813|BEHAVIORAL|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
219558653|NCT02132650|BEHAVIORAL|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
219558654|NCT02132650|BEHAVIORAL|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
219558655|NCT01148225|DRUG|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
219558656|NCT04117893|DRUG|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
219558657|NCT04117893|DRUG|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
219558658|NCT02910687|OTHER|This is an observational study|
219558659|NCT06857045|DEVICE|NOVA intracranial sirolimus-eluting stent system|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon.
219393383|NCT01411397|OTHER|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
219393384|NCT01411397|OTHER|mesh repair|mesh repair of strangulated hernia without resection
219001366|NCT01699204|OTHER|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
219001367|NCT01699204|OTHER|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
219001368|NCT04552847|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
219393385|NCT06667440|OTHER|Cryotherapy|Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
219393386|NCT06667804|OTHER|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). - The researcher is certified as an International Leader of Laughter Yoga. As a nursing intervention, patients with T2DM were made to do laughter yoga by the researcher. The laughter yoga program was conducted online (Google meet online) due to the ongoing COVID-19 pandemic at the time of the study. - The sessions were organized as follows: Monday-Thursday 10:00-10:45, Tuesday-Friday 10:00-10:45, Wednesday-Saturday 10:00-10:45. Participants participated in two sessions that were suitable for them within a week. A participant in a group was not allowed to change days in the following weeks.
219393387|NCT05078567|DEVICE|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
219393388|NCT01571882|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
219393389|NCT01571882|OTHER|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
219393390|NCT01571882|OTHER|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
219393391|NCT03663985|OTHER|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
219393392|NCT02571179|DRUG|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
219393393|NCT01361529|DRUG|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
219393394|NCT02255591|DRUG|Lidocaine-adrenaline added gadolinium.|
219393395|NCT03465735|COMBINATION_PRODUCT|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
219393396|NCT03465735|DRUG|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
219393397|NCT02377934|RADIATION|Cardiac Magnetic Resonance Imaging (MRI)|
219393398|NCT01884285|DRUG|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
219393399|NCT01884285|DRUG|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
219393400|NCT01884285|DRUG|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
219393401|NCT01884285|DRUG|Part D1: AZD2014 combination with AZD8186|Dose \& schedule finding of AZD8186 in combination with AZD2014
219393402|NCT01884285|DRUG|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
219393403|NCT01884285|DRUG|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
219393404|NCT02267499|OTHER|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
219393405|NCT02442999|OTHER|Screening for obstructive sleep apnea|
219393406|NCT02442999|DEVICE|CPAP - continuous positive airway pressure|
219393407|NCT03212547|BEHAVIORAL|Verbal Intervention|"Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
219393408|NCT00116311|BEHAVIORAL|allergen inhalation|
219393409|NCT00116311|BEHAVIORAL|withdrawal of medication|
219393410|NCT00116311|PROCEDURE|sputum induction|
219393411|NCT04986293|DEVICE|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
219393412|NCT03766997|DRUG|Compound Betamethasone Injection|local injection
219393413|NCT03766997|DRUG|Hydrocortisone Butyrate 0.1% Cream|topical use
219558660|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients|"Completion by patients of a 28-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
219558661|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients' life partner|"Completion by the patients' life partner of a 30-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
219558662|NCT04624594|OTHER|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
219558663|NCT04624594|OTHER|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
219558664|NCT03434691|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
219558665|NCT03434691|DRUG|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
219558666|NCT02212457|BIOLOGICAL|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB\_0\_2 Group.
219558667|NCT02212457|OTHER|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group, Month 2 in ABCWY\_0\_6 Group and ABCWY\_0\_11 Group and Month 6 in ABCWY\_0\_1 Group.
219558668|NCT02212457|BIOLOGICAL|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY\_0\_1 Group, Month 1 and 12 in Group ABCWY\_0\_6 Group and ABCWY\_0\_2\_6 Group , Month 0 and 6 in ABCWY\_0\_11 Group and Month 6 and 12 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
219558669|NCT02212457|BIOLOGICAL|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY\_0\_1 Group, Month 0 and 6 in ABCWY\_0\_6 Group, Month 1 and 12 in ABCWY\_0\_11 Group, Month 0, 2 and 6 in ABCWY\_0\_2\_6 Group, Month 0 and 2 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
219558670|NCT03671187|OTHER|Exercise|8 week exercise program
219558671|NCT02455947|OTHER|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
219558672|NCT05211505|DEVICE|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
219558673|NCT00016653|DRUG|Creatine Monohydrate|
219558674|NCT00016653|DRUG|Glutamine|
219558675|NCT05886803|OTHER|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
219558676|NCT03734458|OTHER|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
219558677|NCT03734458|OTHER|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
219558678|NCT03734458|OTHER|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
219558679|NCT06265753|OTHER|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
219558680|NCT06265753|OTHER|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
219558681|NCT01601353|DEVICE|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
219558682|NCT00310674|BIOLOGICAL|Meningococcal C Conjugate Vaccine|
219558683|NCT04734704|PROCEDURE|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
219558684|NCT04734704|PROCEDURE|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
219558685|NCT04543084|BEHAVIORAL|Logbook|Participants will record practice in a logbook.
219558686|NCT03473002|OTHER|Placebo|0.9% Sodium Chloride
219558687|NCT03473002|BIOLOGICAL|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
219558688|NCT03675763|OTHER|Manual treatment|Craniosacral therapy protocol.
219558689|NCT05937126|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
219001369|NCT04552847|DEVICE|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
219001370|NCT04552847|DEVICE|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
219558690|NCT05937126|DIAGNOSTIC_TEST|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
219558691|NCT05702905|DRUG|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
219001371|NCT00691418|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
219001372|NCT00691418|DIETARY_SUPPLEMENT|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
219188930|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
219393414|NCT04902950|DRUG|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
219393415|NCT04902950|DRUG|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
219393416|NCT05508568|DIAGNOSTIC_TEST|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
219393417|NCT03311178|DRUG|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
219393418|NCT03492450|OTHER|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
219393419|NCT06332053|DRUG|SY-5007|SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
219393420|NCT06332053|DRUG|Itraconazole|Itraconazole 200 mg, Capsules, Day 8-Day 18
219393421|NCT06332053|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
219393422|NCT06332053|DRUG|Rifampin|Rifampin 600 mg, Capsules, Day 8-Day 21
219393423|NCT00005655|BIOLOGICAL|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
219393424|NCT00005655|BIOLOGICAL|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
219393425|NCT02123017|DRUG|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
219393426|NCT02123017|DRUG|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
219393427|NCT02123017|DRUG|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
219393428|NCT01592851|DRUG|Stannous Fluoride|dentifrice containing stannous fluoride
219001373|NCT04061213|DIAGNOSTIC_TEST|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
219188931|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
219393429|NCT01592851|DRUG|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
219393430|NCT01058369|DRUG|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
219558692|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
219188932|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
219558693|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
219558694|NCT05702905|BEHAVIORAL|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
219558695|NCT05702905|BEHAVIORAL|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
219393431|NCT00483288|OTHER|educational intervention|
219393432|NCT00483288|OTHER|questionnaire administration|
219393433|NCT00483288|OTHER|study of socioeconomic and demographic variables|
219393434|NCT00483288|OTHER|survey administration|
219393435|NCT05682664|OTHER|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
219393436|NCT05682664|OTHER|Usual care|Routine outpatient clinical visits every 3 months.
219558696|NCT00168558|BIOLOGICAL|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
219558697|NCT01906190|BIOLOGICAL|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
219558698|NCT03668457|BEHAVIORAL|Intervention to Patients|"Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app."
219558699|NCT03668457|BEHAVIORAL|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
219558700|NCT03668457|OTHER|Control|Other: Usual care Usual care for depressive disorder received in mental health units
219558701|NCT02174185|BEHAVIORAL|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
219558702|NCT04580615|DEVICE|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
219558703|NCT02208336|OTHER|medical chart review|Ancillary studies
219188933|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
219393437|NCT00815984|PROCEDURE|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
219393438|NCT00502905|DRUG|Busulfan|130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
219393439|NCT00502905|DRUG|Fludarabine|40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
219393440|NCT02158143|DIETARY_SUPPLEMENT|vitamin D3|
219393441|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
219393442|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
219393443|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
219393444|NCT05163561|BIOLOGICAL|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
219393445|NCT00935857|DEVICE|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
219393446|NCT00935857|DEVICE|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
219393447|NCT03517046|DRUG|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
219393448|NCT00845923|DRUG|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
219393449|NCT01340235|DRUG|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
219393450|NCT02917187|DRUG|BIIB074|Administered as specified in the treatment arm
219393451|NCT02917187|DRUG|Placebo|Matched placebo
219393452|NCT04284644|DRUG|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
219393453|NCT04284644|DRUG|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
219393454|NCT04284644|DRUG|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
219393455|NCT06435715|OTHER|10 Repetitions of Deep Breathing Exercise|Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
219393456|NCT06435715|OTHER|3 Repetitions of Deep Breathing Exercise|Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
219393457|NCT03413644|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
219393458|NCT00082082|DRUG|Thymalfasin (thymosin alpha-1)|
219393459|NCT00082082|PROCEDURE|Trans arterial chemoembolization (TACE)|
219393460|NCT04210973|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
219393461|NCT04210973|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
219393462|NCT03887572|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
219393463|NCT00389415|DRUG|Vildagliptin|
219393464|NCT03964012|BIOLOGICAL|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
219393465|NCT03964012|BIOLOGICAL|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
219393466|NCT01903239|PROCEDURE|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
219393467|NCT06338865|OTHER|Carbon dioxide|Gas used for insufflation pressure
219393468|NCT06338865|DRUG|Bupivacaine|Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
219393469|NCT06338865|DRUG|Oxycodone|All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
219393470|NCT04356105|DRUG|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
219393471|NCT04356105|DRUG|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
219393472|NCT04356105|PROCEDURE|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
219393473|NCT01591018|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
219393474|NCT01591018|PROCEDURE|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
219393475|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
219393476|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
219393477|NCT02777840|DEVICE|face mask oxygen|oxygen given by face mask as per routine practice
219393478|NCT02777840|DEVICE|High flow oxygen|High flow oxygen given via optiflo machine / device
219558704|NCT04022941|DRUG|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
219393479|NCT04050904|DEVICE|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
219558705|NCT04022941|OTHER|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
219558706|NCT04065607|PROCEDURE|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
219558707|NCT06301269|OTHER||
219558708|NCT04156737|DEVICE|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
219558709|NCT04156737|DEVICE|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
219558710|NCT00033527|DRUG|INS316|
219558711|NCT00033527|OTHER|sputum cytology|
219558712|NCT05704491|DIAGNOSTIC_TEST|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
219558713|NCT00949091|DRUG|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
219558714|NCT02490800|DRUG|Lisavanbulin Phase 1 dose escalation portion|Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
219558715|NCT02490800|DRUG|Lisavanbulin Phase 2a expansion portion|Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
219558716|NCT01513941|DRUG|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
219558717|NCT01513941|DRUG|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
219393480|NCT01924715|BEHAVIORAL|ISTDP|An emotion focused brief psychotherapy format.
219393481|NCT02016742|DRUG|RDC5|
219393482|NCT02405039|DRUG|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
219393483|NCT02405039|DRUG|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
219393484|NCT03268746|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
219393485|NCT01733069|DEVICE|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
219393486|NCT02432677|DRUG|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
219393487|NCT02432677|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
219558718|NCT01513941|DRUG|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
219558719|NCT05421039|BEHAVIORAL|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
219393488|NCT02432677|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
219393489|NCT02432677|DRUG|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
219393490|NCT03988777|DEVICE|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
219393491|NCT00404443|DEVICE|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
219393492|NCT00002516|BIOLOGICAL|dactinomycin|
219393493|NCT00002516|DRUG|cyclophosphamide|
219393494|NCT00002516|DRUG|doxorubicin hydrochloride|
219393495|NCT00002516|DRUG|etoposide|
219393496|NCT00002516|DRUG|ifosfamide|
219393497|NCT00002516|DRUG|mesna|
219558720|NCT04083326|DEVICE|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
219558721|NCT01614262|OTHER|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
219558722|NCT00948792|PROCEDURE|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
219558723|NCT00948792|PROCEDURE|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
219558724|NCT00654641|PROCEDURE|Negative pressure wound closure|Applying negative pressure to primary wound closure
219558725|NCT00654641|PROCEDURE|Standard wound closure|Standard wound closure
219558726|NCT04755673|OTHER|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
219393498|NCT00002516|DRUG|vincristine sulfate|
219393499|NCT00002516|PROCEDURE|conventional surgery|
219393500|NCT00002516|RADIATION|low-LET cobalt-60 gamma ray therapy|
219393501|NCT00002516|RADIATION|low-LET photon therapy|
219393502|NCT02910778|DRUG|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
219393503|NCT02910778|DRUG|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
219558727|NCT03724682|DEVICE|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
219558728|NCT01337596|DRUG|LY2951742|Administered subcutaneously
219188934|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
219393504|NCT02910778|DRUG|Ticagrelor|
219393505|NCT02296346|DRUG|SoluMedrol|Infusion of drug subcutaneously, once a month.
219393506|NCT02296346|DEVICE|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
219393507|NCT04331301|PROCEDURE|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
219393508|NCT04331301|PROCEDURE|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
219393509|NCT00891657|DEVICE|SprayShield™|Anti-adhesion barrier
219393510|NCT00326261|PROCEDURE|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
219393511|NCT00326261|PROCEDURE|Ultrasound|
219393512|NCT01412242|OTHER|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
219393513|NCT02410369|DRUG|S-588410|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
219393514|NCT02410369|DRUG|Placebo|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
219393515|NCT02420964|OTHER|video instruction|Patient Directed Video Instruction
219393516|NCT02420964|OTHER|Nurse instruction|Nurse directed instruction
219558729|NCT01337596|DRUG|Placebo|Administered subcutaneously
219393517|NCT03408080|DRUG|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
219393518|NCT03520023|OTHER|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
219393519|NCT03805295|OTHER|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
219393520|NCT05200949|PROCEDURE|Kidney transplant|Transplant surgery of Kidney
219393521|NCT00638066|DRUG|botulinum toxin|500 units of botulinum toxin for the second arm
219558730|NCT01652586|DRUG|dexmedetomidine-remifentanil|
219558731|NCT01652586|DRUG|midazolam-remifentanil|
219558732|NCT03693950|BIOLOGICAL|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
219558733|NCT03693950|BIOLOGICAL|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
219558734|NCT05405049|DRUG|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
219558735|NCT05405049|DRUG|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
219558736|NCT01978691|DIETARY_SUPPLEMENT|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
219558737|NCT01978691|DIETARY_SUPPLEMENT|Polydextrose|Studied as a prebiotic
219558738|NCT01978691|OTHER|Placebo|Control
219393522|NCT00638066|DRUG|botulinum toxin A|250 units of botulinum toxin A once
219393523|NCT03189225|OTHER|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
219393524|NCT04530825|OTHER|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
219393525|NCT04530825|OTHER|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
219393526|NCT04080115|BEHAVIORAL|Attention Training Technique|ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
219393527|NCT04080115|BEHAVIORAL|Sham intervention control condition|The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
219393528|NCT03855254|BEHAVIORAL|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
219393529|NCT05170139|DIETARY_SUPPLEMENT|Caffeine|Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
219393530|NCT05170139|DIETARY_SUPPLEMENT|Placebo drink|Participants will ingest the exact same drink without caffeine
219393531|NCT00850499|DRUG|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
219558739|NCT03900234|OTHER|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
219558740|NCT02726841|PROCEDURE|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
219558741|NCT02726841|PROCEDURE|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
219558742|NCT02642809|DRUG|Pembrolizumab|
219558743|NCT02642809|RADIATION|Brachytherapy|
219558744|NCT02642809|PROCEDURE|Endoscopic biopsy|
219558745|NCT02642809|PROCEDURE|Computed tomography-guided biopsy|
219558746|NCT02642809|PROCEDURE|Peripheral blood collection|
219558747|NCT03973151|DRUG|HL-085|HL-085 is one MEK inhibitor.
219558748|NCT04926701|DRUG|ETD001 single dose|Single ascending doses of inhaled ETD001
219558749|NCT04926701|DRUG|Placebo single dose|Single doses of inhaled placebo
219558750|NCT04926701|DRUG|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
219558751|NCT04926701|DRUG|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
219558752|NCT04926701|DRUG|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
219558753|NCT04926701|DRUG|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
219558754|NCT05740553|DEVICE|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
219558755|NCT05259956|BEHAVIORAL|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
219558756|NCT05259956|BEHAVIORAL|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
219558757|NCT01652963|OTHER|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
219393532|NCT00850499|DRUG|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
219558758|NCT00468338|DEVICE|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
219558759|NCT03590834|BEHAVIORAL|Center-based Intervention|"1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks"
219393533|NCT00850499|DRUG|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
219393534|NCT01970150|DEVICE|rTMS real|
219558760|NCT03590834|BEHAVIORAL|Home-based Intervention|"1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
219558761|NCT03590834|BEHAVIORAL|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
219558762|NCT05189691|BEHAVIORAL|walking exercise|Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
219558763|NCT05419817|DRUG|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
219558764|NCT05419817|DRUG|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
219558765|NCT03610919|DRUG|Nasal Sprays|Intranasal administration of 24 international units per dose.
219558766|NCT01465568|DRUG|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
219393535|NCT05391763|PROCEDURE|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
219393536|NCT05810779|OTHER|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
219393537|NCT05810779|OTHER|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
219393538|NCT03749642|DRUG|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
219558767|NCT01465568|DRUG|bisphosphonates|continue present bisphosphonate treatment
219558768|NCT04681508|DIAGNOSTIC_TEST|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
219558769|NCT01393951|BIOLOGICAL|ASP7374|subcutaneous and intramuscular
219558770|NCT02511860|DIETARY_SUPPLEMENT|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
219558771|NCT02511860|DIETARY_SUPPLEMENT|Placebo|Methylcellulose (inert) tablet taken as placebo
219558772|NCT05672173|PROCEDURE|Biopsy|Undergo tumor biopsy
219558773|NCT05672173|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219393539|NCT03749642|DRUG|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
219558774|NCT05672173|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
219558775|NCT05672173|PROCEDURE|Computed Tomography|Undergo PET/CT
219558776|NCT05672173|DRUG|Cyclophosphamide|Given IV
219558777|NCT05672173|DRUG|Fludarabine|Given IV
219188935|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
219188936|NCT05931497|DEVICE|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
219393540|NCT03749642|DRUG|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
219393541|NCT03749642|DRUG|Gabapentin|"The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)"
219393542|NCT03749642|DRUG|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
219393543|NCT01675037|OTHER|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
219393544|NCT01977144|OTHER|Comprehensive Chromosomal Screening|
219393545|NCT02012972|BEHAVIORAL|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
219393546|NCT01579201|DRUG|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
219393547|NCT01984112|DEVICE|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
219393548|NCT01984112|DEVICE|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
219393549|NCT00856427|RADIATION|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
219393550|NCT00856427|PROCEDURE|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
219393551|NCT04765462|BIOLOGICAL|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
219393552|NCT04498910|DRUG|LY3451838|Administered IV
219393553|NCT04498910|DRUG|Placebo|Administered IV
219393554|NCT02958163|PROCEDURE|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
219393555|NCT02958163|DRUG|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
219393556|NCT02958163|RADIATION|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
219393557|NCT06077422|DRUG|bupivacaine liposome injectable suspension|Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
219393558|NCT06077422|DRUG|Bupivacaine Hydrochloride|Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
219393559|NCT01849848|DRUG|SyB L-0501|The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
219393560|NCT00659685|DRUG|Ondansetron|ODT, single-dose, fasting
219393561|NCT00659685|DRUG|Zofran ODT|
219393562|NCT03501355|DEVICE|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
219188937|NCT05370079|BIOLOGICAL|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
219393563|NCT03501355|DEVICE|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
219393564|NCT04002323|DRUG|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
219393565|NCT04002323|DRUG|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
219558778|NCT05672173|DRUG|Ibrutinib|Given PO
219558779|NCT05672173|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219558780|NCT05672173|BIOLOGICAL|Nivolumab|Given IV
219558781|NCT05672173|PROCEDURE|Pheresis|Undergo apheresis
219558782|NCT05672173|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219558783|NCT00003751|DRUG|penicillamine|
219558784|NCT00003751|RADIATION|radiation therapy|
219558785|NCT04323722|PROCEDURE|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
219558786|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
219188938|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
219558787|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
219558788|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
219558789|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
219188939|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
219558790|NCT02320162|BEHAVIORAL|Experiential learning oral health education|
219558791|NCT04238546|DEVICE|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
219558792|NCT04238546|DEVICE|uncoated balloon catheter|angioplasty with uncoated balloon catheter
219558793|NCT02371096|DRUG|MabThera (rituximab)|
219393566|NCT03232723|DIAGNOSTIC_TEST|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
219558794|NCT02371096|DRUG|RGB-03|
219558795|NCT02651064|OTHER|HIP|
219558796|NCT00004490|DRUG|sodium dichloroacetate|
219558797|NCT00559637|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
219558798|NCT05780450|DEVICE|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
219558799|NCT00950716|BEHAVIORAL|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
219558800|NCT00950716|BEHAVIORAL|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
219558801|NCT01124435|DRUG|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
219558802|NCT05632796|PROCEDURE|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
219558803|NCT04687241|DRUG|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
219558804|NCT04687241|DRUG|Placebo Almonertinib|Placebo Almonertinib
219188940|NCT05655312|DRUG|[203Pb]VMT01|\[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
219188941|NCT05655312|DRUG|[212Pb]VMT01|Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
219188942|NCT05655312|DRUG|Nivolumab|For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
219188943|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
219188944|NCT05340062|DEVICE|bedside sonography|TCD and ONSD sonography twice a day per 2 days
219393567|NCT00483951|DEVICE|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
219558805|NCT01093196|DRUG|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
219393568|NCT00483951|DEVICE|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
219558806|NCT01093196|DRUG|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
219558807|NCT01093196|DRUG|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
219558808|NCT00968019|DEVICE|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
219558809|NCT01109576|BEHAVIORAL|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
219558810|NCT01958060|DRUG|BI 1034020|intravenous part
219558811|NCT01958060|DRUG|Placebo to BI 1034020|intravenous part
219558812|NCT05058768|DIAGNOSTIC_TEST|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
219558813|NCT04251858|PROCEDURE|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
219558814|NCT04251858|OTHER|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
219558815|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
219558816|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
219558817|NCT04021758|BEHAVIORAL|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
219558818|NCT04916275|OTHER|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
219558819|NCT05671952|OTHER|Application of integrated intervention system programs|Application of integrated intervention system programs
219558820|NCT04028856|DRUG|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
219558821|NCT00692315|DRUG|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
219558822|NCT00435305|DRUG|Meropenem|
219558823|NCT00435305|DRUG|Vancomycin|
219558824|NCT00435305|DRUG|Linezolid|
219558825|NCT00435305|DRUG|Piperacillin/Tazobactam|
219393569|NCT06498375|DIAGNOSTIC_TEST|Bioelectrical impedance|Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
219393570|NCT05212532|DRUG|EOM613|peptide nucleic acid (PNA)
219393571|NCT00909090|DIETARY_SUPPLEMENT|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
219393572|NCT00909090|DIETARY_SUPPLEMENT|Visually identical placebo|Visually identical placebo, taken once daily for one year
219558826|NCT00435305|DRUG|Cefepim|
219558827|NCT00435305|DRUG|Ceftazidim|
219558828|NCT01550367|DRUG|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
219558829|NCT01550367|DRUG|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
219558830|NCT01597453|BEHAVIORAL|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
219558831|NCT00105495|DRUG|Ferriprox (deferiprone)|
219558832|NCT00105495|DRUG|Desferal (deferoxamine)|
219558833|NCT03230734|DRUG|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
219558834|NCT03230734|DRUG|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
219558835|NCT05381896|OTHER|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
219558836|NCT05381896|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
219558837|NCT05119660|DEVICE|Intermittent Theta Burst Stimulation|iTBS
219188945|NCT04385264|DRUG|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
219393573|NCT05978895|OTHER|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
219558838|NCT00198224|PROCEDURE|phlebotomy|
219393574|NCT02786459|DEVICE|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
219558839|NCT00139906|DRUG|Bifeprunox|
219558840|NCT05610449|DIAGNOSTIC_TEST|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
219558841|NCT04284553|OTHER|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
219393575|NCT02786459|DEVICE|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
219393576|NCT02786459|DEVICE|SPECT-CT|Used as a comparative to ProxiScan.
219393577|NCT05777811|PROCEDURE|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
219558842|NCT04284553|OTHER|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
219558843|NCT04284553|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
219558844|NCT04284553|OTHER|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
219558845|NCT04284553|OTHER|Simplified|The alert language itself will be simplified.
219558846|NCT04284553|OTHER|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
219558847|NCT04284553|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
219558848|NCT04284553|OTHER|Different Risks|Risks of the high-risk medications will be framed differently.
219558849|NCT04284553|OTHER|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
219558850|NCT04284553|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
219558851|NCT03703453|DEVICE|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
219188946|NCT04385264|DRUG|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
219188947|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219188948|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
219558852|NCT05911087|BIOLOGICAL|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
219558853|NCT05911087|BIOLOGICAL|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
219558854|NCT05911087|BIOLOGICAL|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
219558855|NCT05911087|BIOLOGICAL|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
219558856|NCT04148105|DRUG|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
219393578|NCT05777811|PROCEDURE|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
219393579|NCT00644319|DRUG|ibuprofen|
219558857|NCT04148105|OTHER|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
219558858|NCT06157853|PROCEDURE|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
219393580|NCT00644319|DRUG|morphine sulfate|
219393581|NCT00644319|PROCEDURE|management of therapy complications|
219393582|NCT00644319|PROCEDURE|pleurodesis|
219393583|NCT02057237|DRUG|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
219393584|NCT05000606|OTHER|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
219393585|NCT01742351|BEHAVIORAL|Guided internet-based cognitive behavior therapy|
219393586|NCT02944747|BEHAVIORAL|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
219393587|NCT02944747|BEHAVIORAL|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
219393588|NCT02944747|BEHAVIORAL|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
219393589|NCT01897415|BIOLOGICAL|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
219393590|NCT00259259|BEHAVIORAL|SALATRIM|
219393591|NCT00674336|PROCEDURE|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
219393592|NCT03824977|DIAGNOSTIC_TEST|Six minutes stepper test (6MST)|"The 6MST is done using a stepper (Stepper essential, Decathlon(TM), France), with a walking height of 20 cm, placed in front of a wall or parallel bars, so patients can hold on if necessary.~Patients are instructed to make the maximum number of steps possible in 6 minutes, and are given a time check at one minute intervals."
219558859|NCT06157853|OTHER|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
219558860|NCT06157853|OTHER|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
219558861|NCT06157853|OTHER|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
219393593|NCT03824977|DIAGNOSTIC_TEST|Sit to stand test (STST)|The STST is done using a chair measuring 47 cm in height. The patient are instructed to sit in the chair and then to do the maximum number of lifts possible from the chair, in 1 minute, with arms folded and without leaning against the chair.
219393594|NCT06469658|OTHER|The standard practice dietary supplements intervention|Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
219393595|NCT06469658|OTHER|The AI-guided practice dietary supplements group|Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
219393596|NCT00602862|DRUG|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
219393597|NCT00602862|DRUG|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
219393598|NCT00602862|DRUG|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
219393599|NCT02926573|DRUG|Gabapentin|
219393600|NCT02926573|DRUG|Placebo|
219393601|NCT00984464|BIOLOGICAL|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
219393602|NCT00984464|DRUG|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
219393603|NCT00984464|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
219393604|NCT01241513|DRUG|NAC|NAC provided to determine if beneficial at altitude
219393605|NCT01241513|DRUG|Placebo|Placebo
219393606|NCT00858702|DRUG|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
219393607|NCT00858702|DRUG|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
219558862|NCT04826289|RADIATION|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
219558863|NCT00354562|DRUG|ABT-751|200mg ABT-751 daily for 14 days every 21 days
219558864|NCT00354562|DRUG|Placebo|Placebo daily for 14 days every 21 days
219558865|NCT00354562|DRUG|Docetaxel|Standard Docetaxel every 21 days
219558866|NCT04139460|DEVICE|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
219188949|NCT05963880|DEVICE|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
219393608|NCT02602236|DEVICE|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
219393609|NCT02522962|BEHAVIORAL|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
219393610|NCT02522962|BEHAVIORAL|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
219393611|NCT02728934|BIOLOGICAL|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
219393612|NCT02728934|BIOLOGICAL|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
219393613|NCT02728934|BIOLOGICAL|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
219393614|NCT02875210|PROCEDURE|Laximeter measurement|
219558867|NCT04139460|DEVICE|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
219558868|NCT05140668|DEVICE|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
219558869|NCT00660868|DRUG|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
219558870|NCT02959008|DEVICE|measure TOI and BP|Both groups measure TOI and BP.
219558871|NCT02844010|OTHER|weighing|
219558872|NCT00223938|DRUG|Oral Iron|Oral Iron
219558873|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 1
219558874|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 2
219558875|NCT01873339|DRUG|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
219393615|NCT02417623|BEHAVIORAL|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
219393616|NCT01738035|DRUG|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
219393617|NCT01738035|OTHER|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
219558876|NCT01873339|DRUG|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
219393618|NCT01089777|DEVICE|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
219393619|NCT01933984|DRUG|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
219558877|NCT01110317|DRUG|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
219393620|NCT04385030|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
219393621|NCT04995744|PROCEDURE|Pectoralis Major Pedicle Bone Graft|It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
219393622|NCT03667677|DRUG|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
219393623|NCT03667677|DRUG|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
219393624|NCT03667677|DRUG|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
219393625|NCT03667677|DRUG|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
219558878|NCT00973934|DEVICE|Magstim Theta|
219558879|NCT00973934|DEVICE|Thymatron System IV|
219558880|NCT00757679|DRUG|Milnacipran|capsules
219558881|NCT00757679|DRUG|Placebo|capsules
219558882|NCT00772616|DRUG|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
219558883|NCT00772616|DRUG|Sufentanil|dosage according to usual criteria
219558884|NCT00006102|DRUG|becatecarin|
219558885|NCT00673764|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
219558886|NCT00673764|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
219558887|NCT03239496|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
219558888|NCT03239496|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
219558889|NCT02688296|DEVICE|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
219191773|NCT06232655|DRUG|Cladribine|A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
219393626|NCT03538873|BEHAVIORAL|Physical activity|
219393627|NCT00062738|DRUG|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
219558890|NCT05507996|DRUG|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
219558891|NCT00275275|DRUG|Requip PR|Requip 24-Hour once a day for one month
219558892|NCT00275275|DRUG|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
219558893|NCT06276699|PROCEDURE|1.Isometric exercise 2.combined conservative treatment|Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
219558894|NCT06531642|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
219558895|NCT06531642|DRUG|Protonix (pantoprazole) 40 mg q 24 hrs for 2 days|Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
219558896|NCT00319787|DRUG|Iressa|
219558897|NCT04760587|BEHAVIORAL|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
219558898|NCT02415387|BIOLOGICAL|typhoid vaccine|Given IM
219558899|NCT02415387|OTHER|Placebo|Given IM
219558900|NCT04619199|DIAGNOSTIC_TEST|Blood sample|Blood sample performed at the inclusion and during the follow-up.
219558901|NCT05251506|DEVICE|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
219558902|NCT02339415|DRUG|Edoxaban 30mg daily|
219558903|NCT02339415|DRUG|Matching placebo|
219558904|NCT05246787|BEHAVIORAL|breastfeeding|nonphamacological methods
219558905|NCT05246787|COMBINATION_PRODUCT|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
219558906|NCT05246787|DEVICE|shotblocker|it is a small plastic tool
219558907|NCT03701711|DRUG|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
219558908|NCT01263886|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
219558909|NCT01263886|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
219558910|NCT00063830|DRUG|Alicaforsen|
219191774|NCT06232655|DRUG|Venetoclax|A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
219393628|NCT00062738|DRUG|Nortriptyline|nortriptyline 25 - 75 mg q hs
219393629|NCT00062738|OTHER|placebo|matching placebo
219393630|NCT00163722|OTHER|Culture and histology|
219393631|NCT00163722|OTHER|Aspergillus galactomannan and PCR|
219393632|NCT02221427|OTHER|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
219393633|NCT02221427|OTHER|Static labour progression curve (F)|
219393634|NCT03340441|DEVICE|Prizma|sensor unit with mobile application installed on smartphone
219393635|NCT05196932|DEVICE|Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies|"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."
219393636|NCT02235285|PROCEDURE|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
219393637|NCT02796950|DRUG|Acipimox|P.o. administration of 250 mg acipimox
219393638|NCT06313905|DIETARY_SUPPLEMENT|EVADRY|"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."
219393639|NCT06313905|OTHER|Placebo|"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."
219393640|NCT05331365|OTHER|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8"
219393641|NCT03084159|BEHAVIORAL|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
219393642|NCT04565561|DEVICE|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3."
219393643|NCT02544984|DRUG|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
219393644|NCT02544984|DRUG|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
219393645|NCT00956644|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
219393646|NCT00956644|DRUG|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
219393647|NCT02477865|DRUG|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
219393648|NCT02477865|DRUG|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
219558911|NCT01085448|OTHER|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
219393649|NCT02477865|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
219393650|NCT00006386|DRUG|carmustine|
219558912|NCT03577886|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
219558913|NCT03577886|DRUG|Placebo|Phosphate Buffer Diluent oral solution
219558914|NCT05751876|DRUG|Dienogest|Dienogest 2mg was prescribed once per day orally
219558915|NCT05982184|OTHER|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
219393651|NCT00006386|RADIATION|radiation therapy|
219393652|NCT00006386|RADIATION|stereotactic radiosurgery|
219393653|NCT00999128|DRUG|GDC-0941|Oral repeating dose
219393654|NCT00999128|DRUG|rabeprazole|Oral repeating dose
219393655|NCT02307305|DRUG|Duloxetine|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)"
219558916|NCT00277043|DRUG|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
219558917|NCT00277043|DRUG|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
219558918|NCT04674150|DEVICE|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
219558919|NCT04674150|DEVICE|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
219558920|NCT00501332|BIOLOGICAL|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
219393656|NCT02307305|DRUG|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
219393657|NCT02178618|DEVICE|Deployment of Partially covered biliary self expandable metal stent|
219393658|NCT02178618|DEVICE|Deployment of uncovered biliary self expandable metal stent|
219393659|NCT03482310|DEVICE|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
219393660|NCT02206711|DRUG|BMS-955176|Single dose of drug on Day 1
219393661|NCT02592304|DEVICE|Dual energy computed tomography|one extra scanning with a dual energy ct.
219393662|NCT00349791|DRUG|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
219393663|NCT00349791|DRUG|Placebo patch|placebo patch replaced twice a week for two years
219558921|NCT00468871|DRUG|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
219558922|NCT00468871|DRUG|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
219558923|NCT04747795|DRUG|Vitamin C|IV
219558924|NCT04747795|DRUG|Normal saline|IV
219558925|NCT00003404|RADIATION|Adjuvant Radiotherapy|Adjuvant radiation therapy
219558926|NCT03310086|DEVICE|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
219558927|NCT03310086|PROCEDURE|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
219558928|NCT06378567|DIETARY_SUPPLEMENT|Dietary supplement liquid shot beverage products|Participants will use their product as instructed for 3 of the 4 study weeks
219558929|NCT06137404|OTHER|Splint|Comparison of splints for trigger finger
219558930|NCT05110911|BIOLOGICAL|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
219558931|NCT05110911|BIOLOGICAL|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
219558932|NCT05695651|DIAGNOSTIC_TEST|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
219558933|NCT06045390|OTHER|App|"App features (App will be used during the office visit):~* Pictorial representation of drops (color-coded) and schedule.~* Quiz to assess understanding of the regimen.~* Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~* Graphical print-out of the regimen."
219558934|NCT00676650|DRUG|Prednisone|5 mg BID, oral
219558935|NCT00676650|DRUG|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
219558936|NCT00676650|DRUG|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
219558937|NCT00676650|DRUG|Prednisone|5 mg BID, oral
219558938|NCT00774241|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
219393664|NCT03614429|DRUG|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
219393665|NCT01214434|DEVICE|Promiseb Topical Cream|topical non steroidal cream, twice daily
219393666|NCT01214434|OTHER|Bland emollient|Eucerin cream twice daily
219393667|NCT01641016|DRUG|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
219393668|NCT03100435|DEVICE|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
219558939|NCT00774241|DRUG|docetaxel|75mg/m2 every 3 weeks for 18 weeks
219558940|NCT02059811|OTHER|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
219393669|NCT03100435|OTHER|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
219393670|NCT03792750|DRUG|BMS-986205|Specified Dose on Specified Day
219393671|NCT03792750|BIOLOGICAL|Nivolumab|Specified Dose on Specified Day
219558941|NCT02059811|OTHER|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
219558942|NCT02301741|BEHAVIORAL|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
219558943|NCT04979923|DRUG|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
219558944|NCT00676741|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219558945|NCT00676741|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219558946|NCT00676741|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219558947|NCT05992987|DIAGNOSTIC_TEST|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
219558948|NCT05992987|DIAGNOSTIC_TEST|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
219558949|NCT00560924|DRUG|estradiol, 25 mcg|
219558950|NCT00292591|DRUG|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
219558951|NCT00292591|DRUG|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
219558952|NCT00442650|DRUG|Efalizumab|
219558953|NCT02297841|DEVICE|Experimental: Novel lubricant Miami Fragrance|
219191775|NCT06232655|DRUG|Azacitidine|Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
219191776|NCT05804942|BEHAVIORAL|High glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\>70), 20% fat and 20% protein.
219393672|NCT00138151|BIOLOGICAL|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
219393673|NCT00138151|DRUG|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
219393674|NCT00138151|DRUG|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
219393675|NCT05216991|OTHER|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
219393676|NCT05216991|OTHER|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
219393677|NCT00607828|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
219393678|NCT06392100|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
219558954|NCT02297841|DEVICE|Experimental: Novel lubricant Miami no Fragrance|
219558955|NCT02297841|DEVICE|KY Liquid lubricant|
219558956|NCT02297841|DEVICE|Astroglide Gel lubricant|
219558957|NCT02332005|DRUG|diepalrestat choline|aldose reductase inhibitor
219558958|NCT02332005|DRUG|Placebo|Placebo
219558959|NCT03465150|OTHER|acne|Patient with acne
219393679|NCT02596490|BEHAVIORAL|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
219393680|NCT02596490|BEHAVIORAL|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
219001374|NCT03174834|OTHER|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
219558960|NCT01681862|BEHAVIORAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
219558961|NCT05376137|DEVICE|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
219558962|NCT03756337|DEVICE|Neuro 1 & Neuro 2|participant common fitting map used for tests
219558963|NCT03756337|DEVICE|Neuro 2 & Neuro 1|participant common fitting map used for tests
219558964|NCT01099306|OTHER|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
219558965|NCT02656251|DRUG|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
219558966|NCT02656251|DRUG|placebo|Use of placebo every 12 hours for 04 days
219558967|NCT02656251|DRUG|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
219558968|NCT04310254|PROCEDURE|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
219558969|NCT04310254|PROCEDURE|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
219558970|NCT04310254|PROCEDURE|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
219558971|NCT00506116|BEHAVIORAL|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
219558972|NCT00506116|BEHAVIORAL|PME practice and record keeping (in diaries)|
219558973|NCT00506116|BEHAVIORAL|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
219558974|NCT00506116|PROCEDURE|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
219558975|NCT03525249|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume a capsule for eight weeks
219558976|NCT00005887|DRUG|efaproxiral|
219558977|NCT00005887|RADIATION|radiation therapy|
219558978|NCT03721887|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
219191777|NCT05804942|BEHAVIORAL|Medium glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
219191778|NCT05804942|BEHAVIORAL|Low glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\<55), 20% fat and 20% protein.
219191779|NCT06650579|DRUG|Abiraterone Acetate|Given abiraterone acetate
219191780|NCT06650579|DRUG|Bicalutamide|Given PO
219191781|NCT06650579|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219191782|NCT06650579|PROCEDURE|Computed Tomography Angiography|Undergo CCTA
219191783|NCT06650579|DRUG|Leuprolide|Given IM or SC
219558979|NCT02463630|PROCEDURE|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
219558980|NCT05604651|OTHER|no intervention|no intervention
219393681|NCT02596490|BEHAVIORAL|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
219558981|NCT06176560|DRUG|Mesalazine|Oral Formulation
219558982|NCT04515420|DRUG|noradrenaline|noradrenaline infusion
219393682|NCT06260176|BEHAVIORAL|exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
219393683|NCT06260176|BEHAVIORAL|exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
219393684|NCT06260176|BEHAVIORAL|exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
219558983|NCT00683592|DRUG|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
219558984|NCT00683592|DRUG|placebo|placebo
219558985|NCT05732181|DRUG|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
219558986|NCT05732181|DRUG|Placebo|patch without drugs
219558987|NCT03504124|OTHER|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
219558988|NCT04834895|OTHER|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
219393685|NCT06260176|BEHAVIORAL|exposure to sweetened beverage tax messaging|Message reminding consumers to make healthier choices
219393686|NCT02018250|DRUG|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
219558989|NCT04834895|OTHER|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
219001375|NCT04587232|DIAGNOSTIC_TEST|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
219001376|NCT04587232|DIAGNOSTIC_TEST|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
219191784|NCT06650579|DRUG|Prednisone|Given prednisone
219393687|NCT02018250|DRUG|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
219558990|NCT02814708|BIOLOGICAL|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 binding Ab titer .
219558991|NCT00344214|BEHAVIORAL|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
219558992|NCT00344214|BEHAVIORAL|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
219191785|NCT06650579|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219191786|NCT06650579|DRUG|Relugolix|Given PO
219393688|NCT00187161|DRUG|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
219558993|NCT01616121|OTHER|Usual treatment of patients with developing acute heart failure|
219558994|NCT01616121|DEVICE|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
219558995|NCT03523247|BEHAVIORAL|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
219393689|NCT02440724|DEVICE|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
219393690|NCT02440724|DEVICE|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
219393691|NCT04199754|DRUG|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
219393692|NCT04199754|RADIATION|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
219393693|NCT04199754|RADIATION|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
219393694|NCT04199754|DRUG|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
219393695|NCT05734547|BEHAVIORAL|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
219558996|NCT01949753|BEHAVIORAL|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
219558997|NCT01949753|BEHAVIORAL|Exposure therapy|Exposure with response prevention without pharmacological facilitation
219558998|NCT05112419|DRUG|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
219558999|NCT01514994|DEVICE|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
219001377|NCT04587232|DIAGNOSTIC_TEST|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
219559000|NCT04688580|DRUG|XW10172|Various formulations
219559001|NCT00128141|BEHAVIORAL|Tactile stimulus|four times a day
219559002|NCT05511441|PROCEDURE|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
219559003|NCT04983524|DIETARY_SUPPLEMENT|propolis|resinous product of honeybees
219559004|NCT04983524|DRUG|Calcium Hydroxide|Gold standard control intracanal medicament
219559005|NCT00235417|PROCEDURE|Bone marrow transplantation|
219559006|NCT05908617|OTHER|Video Discharge|Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
219559007|NCT02497079|DEVICE|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
219393696|NCT05734547|BEHAVIORAL|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
219393697|NCT04102839|OTHER|Interview|Qualitative Interview
219001378|NCT04587232|DIAGNOSTIC_TEST|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
219001379|NCT04334070|DRUG|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
219191787|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
219191788|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
219191789|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
219393698|NCT01963052|DRUG|AGS15E|intravenous (IV) infusion
219393699|NCT06972160|OTHER|Arm1: intervention 1 (SMS+call)|The intervention will consist in two text messages (one and two weeks after received the screening test, respectively), an automated non-human call or a call made by the administrative assistant (three weeks after received the screening test), and a phone call made by a physician (four weeks after received the screening test)
219393700|NCT06972160|OTHER|Control group|The control group will not be subjected to any interventions to increase the adherence to screening.
219393701|NCT06970678|DRUG|Dexmedetomidine infusion|Patients will receive intravenous loading dose of dexmedetomidine at 0.5 μg/kg ideal body weight (concentration 2 μg/ml) over 15 minutes prior to anesthesia induction, followed by 10 ml of 0.9% sodium chloride over 60 seconds during anesthetic induction. Post-intubation, Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
219393702|NCT06970678|PROCEDURE|paragastric autonomic neural block|Paragastric autonomic neural block (PGANB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophagogastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
219393703|NCT00276289|DRUG|Spironolactone|
219393704|NCT05144022|BEHAVIORAL|Bungee jump|Bungee jump from a cran
219393705|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|
219393706|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|
219393707|NCT04674163|BIOLOGICAL|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
219393708|NCT02902809|BIOLOGICAL|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
219393709|NCT00167908|DRUG|Ethyol (drug)|
219393710|NCT05176678|DIETARY_SUPPLEMENT|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
219393711|NCT05176678|DIETARY_SUPPLEMENT|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
219393712|NCT05176678|DIETARY_SUPPLEMENT|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
219393713|NCT05176678|DIETARY_SUPPLEMENT|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
219559008|NCT02497079|DEVICE|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
219393714|NCT00009867|DRUG|arsenic trioxide|Given IV
219393715|NCT01771302|DEVICE|Bio-Oss|It is a bone substitute of bovine origin
219393716|NCT01771302|DEVICE|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
219393717|NCT00532259|DRUG|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
219393718|NCT04481100|DRUG|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
219393719|NCT00793104|PROCEDURE|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
219393720|NCT00169468|DRUG|Rituximab -CHOP plus Velcade|
219393721|NCT00744367|DRUG|metformin|\>1500 mg/day or maximum tolerated dose (MTD)
219393722|NCT00744367|DRUG|pioglitazone|\>= 30 mg/day
219393723|NCT00744367|DRUG|placebo|sc once weekly
219393724|NCT00744367|DRUG|taspoglutide|10 mg sc once weekly;
219393725|NCT00744367|DRUG|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
219559009|NCT02497079|DEVICE|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
219559010|NCT02262741|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
219559011|NCT02262741|BIOLOGICAL|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
219559012|NCT04542915|OTHER|No intervention|No intervention.
219559013|NCT04815109|OTHER|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
219559014|NCT00236145|DRUG|ACTIQ (Oral transmucosal fentanyl citrate)|
219393726|NCT03453086|PROCEDURE|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
219393727|NCT05701852|OTHER|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
219393728|NCT04535570|OTHER|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
219559015|NCT05179161|DEVICE|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
219559016|NCT01189682|PROCEDURE|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
219559017|NCT03947398|DEVICE|BLIMP balloon|Using BLIMP balloon to cross lesion
219559018|NCT03947398|DEVICE|Low profile balloon|using low profile balloon to cross lesion
219559019|NCT01765270|DRUG|Saxagliptin|one 5-mg saxagliptin tablet daily
219559020|NCT01765270|DRUG|Placebo|5mg placebo tablet daily
219559021|NCT01927991|BEHAVIORAL|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
219559022|NCT05274191|DRUG|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
219559023|NCT05274191|OTHER|standard regimen|standard regimen
219559024|NCT04390230|PROCEDURE|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
219559025|NCT01459757|OTHER|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
219559026|NCT05167045|BEHAVIORAL|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
219559027|NCT03656263|DIAGNOSTIC_TEST|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
219559028|NCT02252445|DRUG|Propofol|Propofol will be administered.
219559029|NCT02252445|DRUG|Sevoflurane|Sevoflurane will be administered.
219559030|NCT03431337|DRUG|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
219559031|NCT03431337|DIETARY_SUPPLEMENT|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
219559032|NCT04459676|DRUG|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
219559033|NCT04459676|DRUG|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
219191790|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
219191791|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
219559034|NCT00329160|DRUG|Rosuvastatin|2.5-20 mg
219393729|NCT03421223|OTHER|No intervention|No intervention
219393730|NCT03320733|DIAGNOSTIC_TEST|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
219559035|NCT00329160|DRUG|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
219559036|NCT00485004|DEVICE|Cutting balloon|Cutting balloon
219559037|NCT00485004|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
219559038|NCT06551129|DRUG|Mavacamten|As prescribed by treating physician
219559039|NCT00458289|DRUG|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
219559040|NCT04501094|DRUG|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
219393731|NCT01910506|DRUG|RDEA3170 10 mg|
219393732|NCT03057873|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
219559041|NCT00026923|PROCEDURE|Laparoscopic surgery|
219559042|NCT00164372|BEHAVIORAL|Peer Education Intervention|
219559043|NCT02682550|PROCEDURE|blood drawing|blood drawing
219559044|NCT04313010|OTHER|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
219559045|NCT04313010|OTHER|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
219559046|NCT04601350|DRUG|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
219559047|NCT04601350|DRUG|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
219393733|NCT03057873|DIETARY_SUPPLEMENT|Placebo|Dry powder to be mixed with 10 ounces of cold water
219393734|NCT02349230|OTHER|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
219393735|NCT01920139|PROCEDURE|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
219559048|NCT00963430|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
219559049|NCT04815434|OTHER|Interview|Interviews will be conducted.
219559050|NCT02871050|OTHER|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
219559051|NCT05284084|OTHER|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
219559052|NCT05284084|OTHER|Data collection for comparison|Data collection for comparison
219559053|NCT04491916|DRUG|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
219559054|NCT06382506|DIETARY_SUPPLEMENT|Consumption of Cornbread with Hazelnut Bread|Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
219559055|NCT01230645|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
219191792|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
219393736|NCT01920139|PROCEDURE|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
219559056|NCT01230645|DRUG|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
219559057|NCT02565017|BEHAVIORAL|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
219559058|NCT00361478|BEHAVIORAL|Exercise and education|Weekly exercise and education program for 8 weeks
219559059|NCT00361478|BEHAVIORAL|Education|Written educational material
219559060|NCT05850884|DIAGNOSTIC_TEST|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
219559061|NCT00869687|DEVICE|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
219559062|NCT04025294|DEVICE|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
219559063|NCT04025294|BEHAVIORAL|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
219559064|NCT05771935|PROCEDURE|ultrasound guided radial versus ulnar artery cannulation|"Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study."
219559065|NCT02315261|PROCEDURE|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
219559066|NCT06503887|OTHER|Stool sample collection|Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
219559067|NCT02407067|DEVICE|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
219559068|NCT02407067|DEVICE|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
219559069|NCT04204226|BEHAVIORAL|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
219559070|NCT04204226|BEHAVIORAL|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
219559071|NCT04204226|BEHAVIORAL|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
219559072|NCT04204226|BEHAVIORAL|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
219559073|NCT04725591|DEVICE|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
219559074|NCT04725591|DEVICE|MEDISAFE WITH External Insulin Pump|Insulin delivery
219559075|NCT04725591|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
219559076|NCT04725591|OTHER|Declaration of meals|Patient inputs related to meals
219559077|NCT04725591|OTHER|No declaration of meals|No patient inputs related to meals
219559078|NCT04725591|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
219559079|NCT01525576|BEHAVIORAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
219559080|NCT05684224|BEHAVIORAL|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
219559081|NCT02083172|DEVICE|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
219191793|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
219393737|NCT01920139|OTHER|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
219393738|NCT05069363|DEVICE|Whole-Body Photobiomodulation Therapy|"* All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
219393739|NCT02795598|PROCEDURE|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
219393740|NCT02795598|PROCEDURE|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
219393741|NCT04982549|DRUG|Durvalumab|Durvalumab (intravenous infusion)
219393742|NCT04982549|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
219393743|NCT04982549|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
219393744|NCT04982549|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
219393745|NCT04982549|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
219393746|NCT00379730|DRUG|Prednisolone|
219393747|NCT00939172|DRUG|TTP607|3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
219393748|NCT06135818|DIAGNOSTIC_TEST|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
219393749|NCT05308095|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
219393750|NCT06510465|DRUG|utidelone|utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
219393751|NCT06510465|DRUG|Cisplatin|cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
219393752|NCT06510465|DRUG|Trastuzumab|Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
219393753|NCT06510465|DRUG|Pertuzumab|Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
219393754|NCT00317070|DRUG|dimethyl sulfoxide|intravesical installation 50 ml
219393755|NCT00317070|DRUG|IC Cocktail|"* Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml"
219393756|NCT05196698|OTHER|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation \> 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
219393757|NCT05196698|OTHER|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
219393758|NCT02928237|DEVICE|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
219393759|NCT05609422|OTHER|Physical therapy program|"* Stretching exercises~* Strength Training Kneeling exercises~* Standing exercises~* Gait Training"
219393760|NCT05609422|OTHER|scooter board activities|"1. Scooter board bear walk.~2. Scooter board crab walk.~3. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~4. Cross sitting on scooter board, pulls along the rope using his/her hands~5. Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~6. Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~7. Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8. Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~9. Supine flexion on scooter board, Clip clothespins to a rope hanging above."
219393761|NCT03072511|BEHAVIORAL|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
219393762|NCT03072511|DRUG|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
219559082|NCT02672969|DEVICE|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
219559083|NCT03638596|BEHAVIORAL|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
219559084|NCT03638596|BEHAVIORAL|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
219559085|NCT00063258|DRUG|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
219559086|NCT00063258|DRUG|Paclitaxel|Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
219559087|NCT00063258|DRUG|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
219559088|NCT04187924|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
219559089|NCT04187924|DEVICE|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
219559090|NCT00603395|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
219559091|NCT04619550|OTHER|High tibial osteotomy|Realignment surgery
219559092|NCT03761498|OTHER|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
219559093|NCT03468712|PROCEDURE|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
219559094|NCT00623636|DRUG|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
219559095|NCT00623636|DRUG|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
219559096|NCT01530308|DRUG|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
219393763|NCT01302769|DEVICE|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
219559097|NCT01530308|DRUG|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
219559098|NCT06176755|OTHER|Treadmill training with weighted ankle cuffs|"Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently."
219559099|NCT06176755|OTHER|Treadmill training|Treadmill training only
219559100|NCT04692584|BEHAVIORAL|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
219559101|NCT03653026|DRUG|Placebo|Tablet for oral administration
219559102|NCT03653026|DRUG|Upadacitinib|Tablet for oral administration
219001380|NCT00795106|DRUG|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
219191794|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
219191795|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
219393764|NCT03494725|DIETARY_SUPPLEMENT|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
219393765|NCT03494725|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
219393766|NCT05938881|PROCEDURE|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
219393767|NCT05938881|PROCEDURE|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
219559103|NCT06123026|DRUG|Cabergoline|1mg oral cabergoline given to participants once
219559104|NCT06123026|DRUG|Placebo|1 encapsulated placebo tablet given to participants after procedure
219393768|NCT03267095|BEHAVIORAL|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
219393769|NCT06152263|OTHER|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
219559105|NCT01158326|DRUG|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
219559106|NCT01158326|OTHER|Placebo|10 ml of oral placebo every 6 hours for 48 hours
219559107|NCT00628979|BEHAVIORAL|CBT|cognitive- behavioral treatment for panic disorder.
219559108|NCT06480500|DRUG|Ketamine hydrochloride|55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
219559109|NCT06480500|BEHAVIORAL|i-CBT (Internet-based Cognitive Behavioural Therapy)|Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
219559110|NCT06480500|DRUG|Midazolam Hydrochloride|55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
219559111|NCT03747653|DRUG|ADVATE|Patients will be administered a single dose of ADVATE.
219559112|NCT03747653|DRUG|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
219559113|NCT05945992|BEHAVIORAL|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
219559114|NCT05945992|BEHAVIORAL|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
219559115|NCT05945992|BEHAVIORAL|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
219001381|NCT00795106|DRUG|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
219001382|NCT04991415|OTHER|Manual Therapy|
219001383|NCT05200091|OTHER|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
219001384|NCT05363644|BIOLOGICAL|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
219001385|NCT05985577|OTHER|Without any intervention|There were no special interventions for the two groups.
219001386|NCT05416398|OTHER|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
219001387|NCT06260085|OTHER|Relatives vioce record|In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
219393770|NCT00337298|DRUG|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
219393771|NCT00337298|DRUG|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
219393772|NCT04983940|DRUG|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
219393773|NCT05346952|DRUG|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
219393774|NCT04097717|BEHAVIORAL|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
219393775|NCT04097717|OTHER|Usual Care|Usual medical care will vary among participants.
219001388|NCT06013670|PROCEDURE|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
219001389|NCT06013670|PROCEDURE|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
219393776|NCT06971185|DRUG|Luspatercept|As per product label
219393777|NCT06971185|DRUG|Erythropoiesis-stimulating agent (ESA)|As per product label
219393778|NCT05852171|DRUG|Baricitinib|Baricitinib administered orally
219393779|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
219393780|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
219393781|NCT04083144|DRUG|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
219393782|NCT05326893|OTHER|Femoral nerve neurodynamic mobilization|The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
219393783|NCT05326893|OTHER|Femoral nerve placebo neurodynamic mobilization|The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
219393784|NCT04663867|DEVICE|AngioSafe Peripheral CTO Crossing System|The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
219393785|NCT06443879|OTHER|Axillary brachial plexus nerve block: loss and return of sensation|Evaluating loss and return of sensation after axillary brachial plexus nerve block
219393786|NCT04803786|DRUG|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
219393787|NCT00950417|DRUG|Nimotuzumab|
219393788|NCT05450861|OTHER|SF DNA extraction composition|the composition of small fragments of DNA from fish
219393789|NCT05450861|OTHER|Placebo|the scalp conditioning solution without SF DNA extraction composition
219393790|NCT02949661|PROCEDURE|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
219393791|NCT02949661|PROCEDURE|Local wound infiltration|Patients will receive local wound infiltration
219001390|NCT00119054|BEHAVIORAL|In Home Health Messaging Device|
219001391|NCT00382278|PROCEDURE|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
219001392|NCT05551039|OTHER|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
219393792|NCT05310383|COMBINATION_PRODUCT|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
219393793|NCT04977999|OTHER|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
219393794|NCT03378206|DEVICE|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
219393795|NCT03378206|DEVICE|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
219393796|NCT06335940|OTHER|Videoregulation|"To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation."
219393797|NCT05121597|DEVICE|HugeMed Videolaryngoscope|Macintosh laryngoscope
219393798|NCT02391727|BIOLOGICAL|SYN004|subjects who have received effective treatment for their cancers are eligible
219393799|NCT00434460|BEHAVIORAL|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
219393800|NCT05914220|DEVICE|AI Insights Application|Predictive AI Model Risk score
219559116|NCT05945992|BEHAVIORAL|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
219393801|NCT02760407|DRUG|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
219393802|NCT02760407|DRUG|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
219393803|NCT02760407|DRUG|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
219393804|NCT02760407|DRUG|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
219393805|NCT05760456|DRUG|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
219393806|NCT05760456|DRUG|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
219393807|NCT01533155|DRUG|Nektar 118|Oral 25 mg tablet
219393808|NCT01533155|DRUG|Quinidine|Oral 200 mg tablet
219393809|NCT01533155|DRUG|Quinidine placebo|Oral Tablet
219393810|NCT01533155|DRUG|Morphine|10 mg/ml, intravenously
219393811|NCT03768401|OTHER|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
219393812|NCT03768401|BEHAVIORAL|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
219393813|NCT01288378|DRUG|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
219001393|NCT06045897|DEVICE|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
219001394|NCT06045897|DEVICE|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
219001395|NCT06045897|BEHAVIORAL|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
219001396|NCT06045897|BIOLOGICAL|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
219001397|NCT06045897|BEHAVIORAL|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
219001398|NCT06045897|DEVICE|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
219001399|NCT00467571|DRUG|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
219393814|NCT03744169|DIAGNOSTIC_TEST|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
219393815|NCT03744169|DIAGNOSTIC_TEST|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
219393816|NCT03744169|DIAGNOSTIC_TEST|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
219393817|NCT01645930|DRUG|Ixazomib|Ixazomib capsules
219393818|NCT01645930|DRUG|Lenalidomide|Lenalidomide capsules
219393819|NCT01645930|DRUG|Dexamethasone|Dexamethasone tablets
219393820|NCT01809366|PROCEDURE|seminal plasma insemination|
219393821|NCT03319550|DIETARY_SUPPLEMENT|Casein|see experimental description
219393822|NCT03319550|DIETARY_SUPPLEMENT|Whey|see experimental description
219393823|NCT03319550|DIETARY_SUPPLEMENT|Leucine-enriched whey|see experimental description
219393824|NCT05413694|OTHER|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
219393825|NCT01748760|BEHAVIORAL|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
219393826|NCT01748760|OTHER|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
219393827|NCT02085655|DRUG|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219393828|NCT02085655|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219393829|NCT02085655|DRUG|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
219393830|NCT02085655|DRUG|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219393831|NCT02085655|DRUG|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219559117|NCT05945992|BEHAVIORAL|Control component 1_social behaviors in groups|Control component for emotion regulation
219559118|NCT05945992|BEHAVIORAL|Control component 2_communication skills|Control component for self-acceptance
219559119|NCT05945992|BEHAVIORAL|Control component 3_stress management|Control component for mindfulness
219559120|NCT05945992|BEHAVIORAL|Control component 4_constructive conflict resolution|Control component for resource activation
219393832|NCT02085655|DRUG|Thalidomide|100-200mg, PO, after chemotherapy
219559121|NCT02457819|DRUG|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
219393833|NCT06035718|DRUG|Probiotic Blend Capsule|By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).
219393834|NCT06035718|DEVICE|tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.
219393835|NCT06035718|DEVICE|Sham tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
219393836|NCT03245814|BEHAVIORAL|Service Dog|A service dog trained to perform tasks that are specific to PTSD
219393837|NCT01665638|DRUG|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
219393838|NCT01665638|DRUG|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
219393839|NCT01665638|DRUG|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
219393840|NCT01665638|DRUG|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
219559122|NCT06217796|COMBINATION_PRODUCT|MydCombi|A single metered spray administered with the MydCombi dispenser
219559123|NCT01155102|DRUG|Anastrozole|1 mg tablet
219559124|NCT06353308|BEHAVIORAL|Sexual Violence Prevention|The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.
219001400|NCT06117657|DRUG|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
219393841|NCT01769521|DEVICE|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
219559125|NCT06353308|BEHAVIORAL|Sexual health intervention|This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
219559126|NCT04025138|OTHER|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)"
219001401|NCT06117657|DRUG|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
219393842|NCT04302181|DRUG|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
219393843|NCT02846675|BIOLOGICAL|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
219393844|NCT02846675|BIOLOGICAL|Placebo|a Placebo treatment without SVF cells
219393845|NCT02122289|DEVICE|Application of Smartphone|Weekly questionnaire on smartphone
219559127|NCT04025138|DEVICE|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
219001402|NCT06117657|DRUG|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
219001403|NCT02737293|OTHER|Control Diet|4-week intake of Control Diet 5 day rotating menu
219001404|NCT02737293|OTHER|Med Diet|4-week intake of Med Diet 5 day rotating menu
219393846|NCT02122289|OTHER|No application Smartphone|No weekly questionnaire on smartphone
219393847|NCT01708564|BIOLOGICAL|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
219393848|NCT04320303|BIOLOGICAL|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
219393849|NCT00946270|DRUG|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
219393850|NCT00946270|DRUG|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
219393851|NCT00946270|DRUG|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
219393852|NCT02522377|DRUG|Ketamine|inter venous injections
219393853|NCT02522377|DRUG|Midazolam|inter venous injections
219393854|NCT05465681|DRUG|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
219393855|NCT05449353|BEHAVIORAL|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
219393856|NCT00581607|DRUG|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
219393857|NCT00581607|DRUG|Placebo|Placebo twice a day
219393858|NCT00581607|DRUG|Bosentan|drug given for 16 weeks
219393859|NCT00581607|DRUG|Placebo|placebo
219393860|NCT04771715|DRUG|Regorafenib|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219393861|NCT04771715|DRUG|Nivolumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219393862|NCT04771715|DRUG|Pembrolizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219559128|NCT04025138|OTHER|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
219559129|NCT04025138|OTHER|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
219559130|NCT04025138|BIOLOGICAL|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
219559131|NCT04025138|BIOLOGICAL|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
219559132|NCT03330236|DEVICE|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
219559133|NCT01625507|BEHAVIORAL|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
219559134|NCT05291052|DRUG|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
219559135|NCT05291052|DRUG|Lenvatinib|Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
219559136|NCT05291052|DRUG|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
219559137|NCT05291052|DRUG|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
219559138|NCT03788915|BEHAVIORAL|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
219393863|NCT04771715|DRUG|Camrelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219393864|NCT04771715|DRUG|Sintilimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219559139|NCT03788915|BEHAVIORAL|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
219559140|NCT03355352|DRUG|Sufentanil|Sufentail sublingual 15ug nanopills
219559141|NCT01901848|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
219559142|NCT01901848|DRUG|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
219393865|NCT04771715|DRUG|Toripalimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219559143|NCT01901848|DRUG|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
219559144|NCT01901848|BEHAVIORAL|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
219559145|NCT01901848|BEHAVIORAL|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
219559146|NCT04664816|DRUG|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
219559147|NCT04664816|DRUG|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
219559148|NCT00763555|DRUG|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
219559149|NCT00763555|DRUG|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
219559150|NCT04936919|DEVICE|BroadBand Light|Treatment arm will receive Broadband light treatment
219559151|NCT06133218|OTHER|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
219559152|NCT05824858|DRUG|LY3537982|Administered orally.
219559153|NCT01563458|DRUG|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
219559154|NCT01563458|DRUG|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
219559155|NCT01563458|DRUG|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
219559156|NCT01865929|DEVICE|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
219559157|NCT01865929|PROCEDURE|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
219559158|NCT01729026|OTHER|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
219393866|NCT04771715|DRUG|Tislelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
219393867|NCT01158950|DRUG|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
219559159|NCT03710590|OTHER|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
219559160|NCT03710590|OTHER|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
219393868|NCT01158950|OTHER|Placebo|Placebo (200mg) administered at study visit
219393869|NCT01513915|OTHER|Group cognitive behavioral intervention|A Group cognitive behavioral intervention \_based on parent training component of FRIENDS program\_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
219393870|NCT02367612|DIETARY_SUPPLEMENT|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
219393871|NCT02367612|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219559161|NCT03710590|OTHER|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
219559162|NCT03710590|OTHER|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
219559163|NCT03710590|OTHER|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
219559164|NCT03710590|OTHER|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
219559165|NCT05676983|OTHER|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
219559166|NCT05676983|OTHER|Pediatric neurodevelopmental therapy|Bobath therapy
219001405|NCT02737293|OTHER|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
219393872|NCT02814214|DEVICE|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
219393873|NCT02263365|DRUG|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
219393874|NCT01757457|DRUG|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
219393875|NCT01757457|DRUG|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
219393876|NCT03891277|DRUG|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
219393877|NCT06511414|DEVICE|duramesh|Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure
219393878|NCT06511414|DEVICE|Control|standard closure of fascia
219393879|NCT04345939|DIAGNOSTIC_TEST|Detection method|Different methods for pathogen diagnosis
219001406|NCT02108470|OTHER|Dental consultation using OHIP|The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
219393880|NCT06512324|DEVICE|Ampa One TMS System|Transcranial Magnetic Stimulation
219393881|NCT06513364|DRUG|WH002|"Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
219393882|NCT06513364|DRUG|paclitaxel injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
219393883|NCT04368130|BEHAVIORAL|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
219393884|NCT03078517|DEVICE|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
219393885|NCT03078517|DEVICE|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
219393886|NCT06972043|OTHER|Intervention Group|The functions performed by the robot include guiding patients through unit-specific locations for environmental orientation and equipment usage instructions, playing educational videos related to care, reminding patients of important examination precautions, providing health education on specimen collection, and delivering responses through an expert-developed medical Q\&A system.
219393887|NCT03115255|DRUG|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
219393888|NCT03672617|OTHER|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
219393889|NCT01224899|PROCEDURE|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
219393890|NCT01804361|DRUG|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
219393891|NCT01804361|DRUG|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
219393892|NCT04760795|OTHER|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
219393893|NCT04760795|OTHER|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
219393894|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
219393895|NCT04760795|OTHER|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
219393896|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
219393897|NCT04760795|OTHER|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
219393898|NCT04760795|OTHER|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
219393899|NCT04522752|OTHER|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
219393900|NCT00945191|DRUG|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
219393901|NCT00945191|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
219393902|NCT00945191|DRUG|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
219393903|NCT01180725|DIETARY_SUPPLEMENT|Dried Plum|
219001407|NCT01835587|DRUG|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
219001408|NCT04360915|DRUG|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
219001409|NCT04360915|DIETARY_SUPPLEMENT|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
219001410|NCT00451308|PROCEDURE|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
219001411|NCT00451308|PROCEDURE|Induction of labor with foley balloon with 30cc|30cc of saline in foley
219001412|NCT05979701|OTHER|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
219393904|NCT01180725|DIETARY_SUPPLEMENT|Metamucil|
219393905|NCT03078985|PROCEDURE|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
219393906|NCT03078985|DEVICE|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
219393907|NCT00206518|DRUG|Taxotere/Docetaxel|Taxotere
219393908|NCT00206518|DRUG|Adriamycin/Cytoxan|Adriamycin/Cytoxan
219393909|NCT00206518|DRUG|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
219393910|NCT01052285|PROCEDURE|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
219393911|NCT01052285|PROCEDURE|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
219393912|NCT01052285|PROCEDURE|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
219393913|NCT02083250|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
219393914|NCT02083250|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
219393915|NCT02083250|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219393916|NCT02083250|DRUG|Busulfan|Given IV
219393917|NCT02083250|DRUG|Clofarabine|Given IV
219393918|NCT02083250|DRUG|Fludarabine Phosphate|Given IV
219393919|NCT02083250|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
219393920|NCT02083250|OTHER|Pharmacological Study|Correlative studies
219393921|NCT02083250|DRUG|Vorinostat|Given PO
219393922|NCT02093975|DEVICE|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
219393923|NCT03048097|DRUG|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
219559167|NCT05676983|OTHER|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
219393924|NCT03048097|DRUG|Rubidium|used in PET scans
219393925|NCT03048097|DIAGNOSTIC_TEST|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
219393926|NCT03940170|DEVICE|vistacam proof|Light fluorescence device
219393927|NCT03940170|OTHER|ICDASII|visual examination
219393928|NCT03940170|PROCEDURE|fissurotomy|histological validation
219393929|NCT06389370|OTHER|HU-DBI questionnaire|a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
219393930|NCT06657534|PROCEDURE|Push-pull technique|push-pull technique as described by McBride et al, J Infus Nurs 2018
219393931|NCT06657534|PROCEDURE|SOC (Standard of care)|Standard of care method to obtain blood with waste blood
219393932|NCT01258829|OTHER|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
219393933|NCT01258829|OTHER|ECHO optimisation|Standard ECHO optimisation method
219393934|NCT01004146|PROCEDURE|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
219393935|NCT00148590|DRUG|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
219393936|NCT00148590|DRUG|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
219393937|NCT06670924|PROCEDURE|Running suture for vesico-urethral anastomosis in open radical prostatectomy|The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.
219393938|NCT06670924|PROCEDURE|interrupted suture for vesico-urethral anastomosis in open radical prostatectomy|The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
219393939|NCT04472104|BEHAVIORAL|MBCT-S|Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
219393940|NCT04472104|BEHAVIORAL|SexEd|Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
219393941|NCT01001494|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
219393942|NCT01001494|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
219393943|NCT01001494|DRUG|Placebo|Placebo twice-daily by inhalation for 24 weeks
219393944|NCT02179398|BIOLOGICAL|Allocation to the Lab-score group|
219393945|NCT02179398|BIOLOGICAL|Allocation to the control group|
219393946|NCT00591383|DRUG|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
219559168|NCT03844828|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
219393947|NCT00591383|DRUG|erlotinib|erlotinib taken at 150 mg every morning with food.
219001413|NCT03210597|OTHER|Exercise|The subjects performed training in aquatic environment
219001414|NCT02300532|OTHER|No intervention|
219393948|NCT01914718|DRUG|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
219393949|NCT02905773|OTHER|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
219393950|NCT02905773|OTHER|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
219393951|NCT01011686|BIOLOGICAL|ANT-SM|autologous adipose-derived stem cell
219393952|NCT05969210|OTHER|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
219393953|NCT05969210|OTHER|Control Group|12 participants will be in control group they will do only there running training.
219393954|NCT00233571|BIOLOGICAL|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
219393955|NCT06010667|DRUG|Envafolimab|With or without Envafolimab
219393956|NCT00163137|DRUG|lasofoxifene|lasofoxifene 0.25mg
219393957|NCT00163137|DRUG|raloxifene|raloxifene 60 mg/day
219393958|NCT00163137|DRUG|Placebo|0 mg/day
219393959|NCT03896425|DEVICE|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
219393960|NCT03004846|DRUG|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
219393961|NCT03004846|DRUG|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
219393962|NCT03790735|DIAGNOSTIC_TEST|FISH|Targeted chromosomal aberrations detection
219393963|NCT00408681|DRUG|lithium carbonate|Given orally
219393964|NCT00408681|OTHER|laboratory biomarker analysis|Correlative studies
219393965|NCT01050660|OTHER|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
219559169|NCT00852917|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
219559170|NCT00852917|DRUG|Placebo|One Placebo tablet daily.
219001415|NCT02837198|DRUG|FYU-981|
219001416|NCT02837198|DRUG|Topiroxostat|
219001417|NCT06139432|DEVICE|Active tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
219393966|NCT01050660|OTHER|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
219393967|NCT01367743|DRUG|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
219393968|NCT01367743|DRUG|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
219393969|NCT00652587|PROCEDURE|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
219393970|NCT00652587|PROCEDURE|hepatectomy|hepatectomy alone
219393971|NCT04986527|PROCEDURE|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
219393972|NCT05558345|BEHAVIORAL|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
219393973|NCT02519231|DRUG|Naproxen|Naproxen 440mg 1x pid
219393974|NCT02519231|DRUG|Placebo|Placebo tablet 440mg 1x pid
219393975|NCT03714841|OTHER|CRP|Knowledge of CRP value
219393976|NCT00233779|DEVICE|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
219393977|NCT00447421|DRUG|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
219393978|NCT00447421|DRUG|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
219393979|NCT00447421|RADIATION|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
219559171|NCT01997684|PROCEDURE|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
219559172|NCT01997684|PROCEDURE|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
219393980|NCT03566966|BIOLOGICAL|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
219393981|NCT03566966|BIOLOGICAL|Non-organ-specific Ab negative|direct-acting antiviral agents
219393982|NCT02764619|DRUG|Spironolactone|
219393983|NCT02764619|DRUG|Placebo|
219393984|NCT00296439|BEHAVIORAL|Behavior|
219393985|NCT01383122|DEVICE|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
219393986|NCT01383122|DEVICE|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
219393987|NCT02167555|DIETARY_SUPPLEMENT|Active Comparator|Wild Blueberry Beverage
219393988|NCT02167555|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Beverage
219393989|NCT04698408|OTHER|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
219393990|NCT04698408|OTHER|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
219393991|NCT02408250|PROCEDURE|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
219393992|NCT02106208|OTHER|Cheese diet|
219393993|NCT02106208|OTHER|Butter diet|
219393994|NCT02106208|OTHER|CHO diet|
219393995|NCT02106208|OTHER|MUFA diet|
219393996|NCT02106208|OTHER|PUFA diet|
219393997|NCT02246270|DRUG|Intravesical Heparin|Heparin bladder instillation
219393998|NCT02246270|OTHER|Placebo|Intravesical saline
219393999|NCT03851861|OTHER|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
219394000|NCT06388369|RADIATION|[177Lu]Lu-PSMA-617|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
219394001|NCT06388369|DRUG|Ipilimumab|4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
219394002|NCT04756895|OTHER|Vancomycin dose adjustment using the Bayesian method|This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
219394003|NCT04756895|OTHER|Vancomycin dose adjustment using the trough level method|This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
219394004|NCT02124798|DEVICE|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
219394005|NCT01421368|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
219394006|NCT01421368|DRUG|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
219394007|NCT01421368|DRUG|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
219001418|NCT06139432|DEVICE|Sham tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
219001419|NCT00357968|DRUG|Prasugrel|Administered orally
219001420|NCT00357968|DRUG|Clopidogrel|Administered orally
219001421|NCT00357968|DRUG|Placebo for Prasugrel|Administered orally
219001422|NCT00357968|DRUG|Placebo for Clopidogrel|Administered orally
219394008|NCT03958201|COMBINATION_PRODUCT|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
219394009|NCT00827203|DRUG|Elesclomol Sodium|Chemotherapy agent
219394010|NCT01435512|BEHAVIORAL|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
219394011|NCT06487884|OTHER|escape games|A suitable day and time will be determined in the curriculum of the students in the intervention group and escape games consisting of various games involving intravenous drug administration will be played. Games will be played within the determined game guidelines. Each group will play the games at the stations respectively and get a clue at the end of each game. After completing the last game, the time it takes to find the password and complete the game will be recorded. After all groups complete the game, the group that completes the games in the shortest time will win the game and receive the prize in the chest.
219394012|NCT02862795|PROCEDURE|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
219394013|NCT05968950|DEVICE|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
219394014|NCT04018287|OTHER|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
219394015|NCT00184847|DRUG|acetylcholine|
219394016|NCT00184847|PROCEDURE|twenty minutes of forearm ischemia|
219394017|NCT00184847|PROCEDURE|three 5-minute periods of forearm ischemia|
219394018|NCT00184847|DRUG|adenosine|
219394019|NCT00184847|DRUG|caffeine|
219394020|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
219001423|NCT05669495|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
219001424|NCT02882009|DRUG|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
219001425|NCT02882009|DRUG|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
219001426|NCT03181581|BIOLOGICAL|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
219001427|NCT03181581|BIOLOGICAL|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
219001428|NCT04540211|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
219001429|NCT04540211|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
219001430|NCT04540211|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
219001431|NCT04540211|DRUG|Cisplatin|Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
219001432|NCT04540211|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219001433|NCT04540211|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219001434|NCT00600483|DRUG|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
219001435|NCT04208698|DRUG|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
219001436|NCT04208698|DRUG|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
219001437|NCT04208698|DRUG|Placebo for CIN-102|Placebo
219394021|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
219394022|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
219394023|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
219394024|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
219394025|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
219559173|NCT01718730|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
219559174|NCT01718730|DEVICE|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
219559175|NCT04596306|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
219559176|NCT00625326|DRUG|COL-121|75 µg/g COL-121 Ointment
219559177|NCT00625326|DRUG|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
219559178|NCT00625326|DRUG|Placebo|Placebo
219191796|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
219559179|NCT00625326|DRUG|COL-121|150 µg/g COL-121 Ointment
219559180|NCT00625326|DRUG|COL-121|300 µg/g COL-121 Ointment
219559181|NCT03766139|BIOLOGICAL|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
219394026|NCT03364998|DRUG|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
219394027|NCT03364998|DRUG|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
219559182|NCT03766139|BIOLOGICAL|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
219394028|NCT01652833|OTHER|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
219559183|NCT02488824|PROCEDURE|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
219394029|NCT01707147|DRUG|Trajenta tablet|Linagliptin
219559184|NCT06441903|OTHER|Ultrasound|Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
219559185|NCT00493064|DRUG|Nicotinic acid|topical eye drops
219559186|NCT00493064|DRUG|Prednisolone acetate|topical eye drops
219559187|NCT01008384|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units taken orally once a week for 8 weeks
219559188|NCT05811221|DRUG|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
219559189|NCT05811221|DRUG|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
219559190|NCT05966311|DEVICE|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
219559191|NCT04626544|DEVICE|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable \[15\] and valid \[20\]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
219559192|NCT03123978|DRUG|Enzalutamide|Given PO
219559193|NCT03123978|DRUG|Niclosamide|Given PO
219559194|NCT00111956|DRUG|Etanercept|
219559195|NCT00111956|DRUG|Placebo|
219559196|NCT00356824|DRUG|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
219559197|NCT00356824|DRUG|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
219394030|NCT04905329|DRUG|Empegfilgrastim|Extimia®
219394031|NCT02355093|PROCEDURE|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
219394032|NCT02355093|PROCEDURE|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
219394033|NCT02355093|DRUG|ropivacaine|
219394034|NCT04330625|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
219394035|NCT05171530|DRUG|Lenvatinib plus taxane drugs|"* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
219559198|NCT05375019|BEHAVIORAL|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
219559199|NCT05375019|BEHAVIORAL|active control group|free interaction group consisting of topics determined by the families.
219559200|NCT00007761|BEHAVIORAL|Bipolar Disorder Program|
219559201|NCT00007761|BEHAVIORAL|Usual (psychiatric) Care|
219394036|NCT05596825|DEVICE|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
219394037|NCT05873530|OTHER|Grape|Reconstituted whole grape powder
219394038|NCT02011022|DRUG|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
219394039|NCT02011022|DRUG|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
219394040|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
219394041|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
219559202|NCT05270928|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
219559203|NCT03968731|OTHER|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
219559204|NCT06175429|DIAGNOSTIC_TEST|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
219559205|NCT06175429|DIAGNOSTIC_TEST|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
219559206|NCT06175429|DIAGNOSTIC_TEST|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
219559207|NCT06175429|DIAGNOSTIC_TEST|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
219559208|NCT00003467|DRUG|carmustine|
219559209|NCT00003467|DRUG|polifeprosan 20 with carmustine implant|
219559210|NCT00003467|PROCEDURE|surgical procedure|
219559211|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|250 mg
219559212|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|500 mg
219559213|NCT01397981|BEHAVIORAL|Gait retraining|Changing the kinematics of walking
219559214|NCT05176379|DRUG|Fluconazole 150 mg|A single acute 150 mg dose
219559215|NCT03258879|PROCEDURE|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
219559216|NCT03258879|PROCEDURE|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
219559217|NCT01219452|BIOLOGICAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
219394042|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
219394043|NCT02053246|DRUG|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
219394044|NCT03403972|DRUG|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
219394045|NCT05127772|DRUG|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
219394046|NCT05127772|DRUG|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
219394047|NCT03985137|OTHER|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
219394048|NCT02795156|DRUG|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
219394049|NCT02795156|DRUG|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
219394050|NCT02795156|DRUG|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
219394051|NCT05888337|DEVICE|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
219559218|NCT02644161|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
219559219|NCT02644161|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
219559220|NCT02644161|DRUG|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
219559221|NCT02644161|OTHER|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
219754342|NCT07160049|DEVICE|Algometry Pain Tests in the Lower Limb|"This session records pressure pain thresholds in the dominant foot with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the tibial, saphenous, and peroneal nerves at three standardized points on the dominant foot are located via ultrasound and marked. A pressure algometer is applied to each site, and pressure is gradually increased until pain is first reported. Thresholds are recorded, with repeated trials and short breaks between tests.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is then repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
219188950|NCT04490616|OTHER|rTMS treatment|"A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation."
219394052|NCT05888337|DEVICE|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
219394053|NCT05910593|DIAGNOSTIC_TEST|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
219394054|NCT00404040|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
219394055|NCT00404040|DRUG|Lactulose|
219394056|NCT03994640|COMBINATION_PRODUCT|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
219394057|NCT03994640|COMBINATION_PRODUCT|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
219394058|NCT05446246|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
219394059|NCT04663620|BEHAVIORAL|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
219394060|NCT04663620|BEHAVIORAL|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
219394061|NCT04430530|BIOLOGICAL|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
219394062|NCT04132544|OTHER|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
219394063|NCT04132544|OTHER|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
219394064|NCT04132544|OTHER|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
219394065|NCT04132544|OTHER|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
219394066|NCT00815308|DRUG|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
219394067|NCT00815308|DRUG|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
219394068|NCT00815308|DRUG|Cisplatin|Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
219394069|NCT00815308|RADIATION|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
219394070|NCT04214795|OTHER|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
219394071|NCT04541823|DRUG|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
219394072|NCT04541823|DRUG|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
219394073|NCT05205707|DIAGNOSTIC_TEST|ACE serum levels|Circulating ACE2 level will be measured
219394074|NCT02940665|OTHER|ERAS|Patients in the ERAS group received the ERAS protocol
219394075|NCT00456937|DRUG|Escitalopram|
219394076|NCT04370262|DRUG|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
219394077|NCT04370262|DRUG|SOC + Placebo|Standard of Care treatment plus IV placebo
219394078|NCT00046826|DRUG|docetaxel|
219394079|NCT00046826|DRUG|estramustine phosphate sodium|
219394080|NCT00046826|DRUG|thalidomide|
219394081|NCT05783258|PROCEDURE|Periodontal surgery with CAF+tSCTG|Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
219394082|NCT05783258|PROCEDURE|Periodontal surgery with CAF+L-PRF|Coronally advanced flap and L-PRF membranes
219394083|NCT02307968|OTHER|insulin injection site|insulin injected site between inner thigh and out thigh
219394084|NCT01520792|DRUG|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
219559222|NCT02644161|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
219559223|NCT05583110|DRUG|Tucatinib|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
219559224|NCT05583110|DRUG|Trastuzumab|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
219559225|NCT05583110|DRUG|Vinorelbine|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
219559226|NCT01685359|DRUG|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
219559227|NCT01201759|DRUG|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
219559228|NCT01201759|DRUG|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
219559229|NCT01838187|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
219559230|NCT01838187|DRUG|Vorinostat|180 mg/m2 orally once daily on days 0 to +13
219559231|NCT05881642|PROCEDURE|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
219559232|NCT05881642|PROCEDURE|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
219559233|NCT00491907|DRUG|folic acid 5mg/day|
219559234|NCT00989209|DRUG|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
219559235|NCT00989209|PROCEDURE|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
219559236|NCT00734942|OTHER|support service|"* professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life"
219559237|NCT04330911|PROCEDURE|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
219559238|NCT02512055|DRUG|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
219559239|NCT02297750|PROCEDURE|double-wire technique in patients undergoing ERCP with biliary cannulation|
219394085|NCT03320512|BEHAVIORAL|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
219394086|NCT03320512|BEHAVIORAL|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
219394087|NCT03320512|BEHAVIORAL|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
219394088|NCT01460836|DRUG|Tobramycin solution for inhalation|
219394089|NCT01460836|DRUG|Aztreonam lysine for inhalation|
219394090|NCT04248010|DEVICE|neuroConn DC-Stimulator MR|standard tDCS, active \& sham
219394091|NCT04248010|DEVICE|Soterix MxN HD-tES|HD-tDCS, active \& sham
219559240|NCT02297750|PROCEDURE|single-wire technique in patients undergoing ERCP with biliary cannulation|
219559241|NCT01095523|PROCEDURE|Laparotomy+ HIPEC +/- CRS|
219559242|NCT05341804|BEHAVIORAL|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
219559243|NCT05341804|BEHAVIORAL|balance training|Includes static balance, dynamic balance and strength training
219559244|NCT06065124|PROCEDURE|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
219559245|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
219559246|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
219559247|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
219559248|NCT06258798|RADIATION|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
219559249|NCT03329924|OTHER|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
219559250|NCT05676281|BEHAVIORAL|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals"
219394092|NCT02128581|DRUG|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
219559251|NCT05676281|BEHAVIORAL|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
219394093|NCT02128581|OTHER|Saline|
219394094|NCT00487812|PROCEDURE|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
219394095|NCT03844971|PROCEDURE|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
219394096|NCT06449261|OTHER|Spinal Manual therapy used in Physiotherapy Practice|C5-C6 and thoracic spine mobilization with postural correction
219394097|NCT04076761|DRUG|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
219394098|NCT06096194|DIETARY_SUPPLEMENT|vitamin D-enhanced egg|"In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D"
219394099|NCT06096194|OTHER|Control|Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
219559252|NCT05676281|BEHAVIORAL|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
219559253|NCT05676281|BEHAVIORAL|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
219559254|NCT05475431|DRUG|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
219559255|NCT05475431|DRUG|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
219559256|NCT05475431|DRUG|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
219559257|NCT05475431|DRUG|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
219559258|NCT05475431|DRUG|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
219559259|NCT03346850|DEVICE|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
219559260|NCT03346850|DEVICE|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
219559261|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
219559262|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
219559263|NCT02785627|OTHER|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
219559264|NCT00979212|DRUG|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
219559265|NCT00979212|DRUG|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
219559266|NCT00979212|DRUG|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
219559267|NCT00979212|PROCEDURE|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
219394100|NCT02569489|DRUG|HBI-8000|
219394101|NCT02569489|DRUG|Trastuzumab|
219394102|NCT02569489|DRUG|Paclitaxel|
219394103|NCT00638846|DEVICE|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
219394104|NCT00638846|DEVICE|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
219559268|NCT03294616|DEVICE|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
219559269|NCT04045808|OTHER|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
219559270|NCT03483311|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
219559271|NCT03971578|OTHER|No Intervention Provided|No Intervention Provided
219559272|NCT05208229|DIAGNOSTIC_TEST|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
219559273|NCT06496373|BIOLOGICAL|Fixed neoantigen tumor vaccine|Single/Fixed neoantigen mRNA vaccine includes pancreatic cancer driver mutations such as KRAS G12D, G12V, G12R, G12C, etc. Each vaccine has one neoantigen encoded by mRNA. Total of 4 cycles, 3 weeks each cycle.
219559274|NCT06496373|BIOLOGICAL|personalized neoantigen tumor vaccine|personalized neoantigen tumor vaccine include 5-20 neoantigens selected based on WES/RNA-seq of patients' tumor sample during surgery. Total of 9 cycles after finishing the first 4 cycles of fixed neoantigen tumor vaccine.
219559275|NCT06496373|DRUG|PD-1 inhibitor|Toripalimab
219559276|NCT04269993|DRUG|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis was administered to participants (placebo and medium THC/medium CBD).
219559277|NCT04886063|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
219559278|NCT05483907|DRUG|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
219394105|NCT04055935|PROCEDURE|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
219394106|NCT04055935|DEVICE|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
219394107|NCT02428140|DEVICE|Medtronic Reveal LINQ|
219394108|NCT02428140|DEVICE|Sorin Spiderflash-t|
219394109|NCT04653415|DRUG|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
219394110|NCT04653415|DRUG|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
219394111|NCT04653415|DRUG|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
219394112|NCT04653415|DRUG|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
219394113|NCT01070615|DRUG|Prucalopride|
219394114|NCT05519943|BEHAVIORAL|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
219394115|NCT05519943|BEHAVIORAL|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
219394116|NCT00823329|DEVICE|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
219394117|NCT04135625|BEHAVIORAL|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
219394118|NCT04135625|BEHAVIORAL|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
219394119|NCT00385086|DRUG|TNF blocker|Treatment with TNF-alpha blocker
219754343|NCT07161128|PROCEDURE|arthroscopic microfracture and biological scaffold implementation for osteochondral defects of talus|"All enrolled patients will undergo a standardized single-stage arthroscopic procedure under spinal or general anesthesia with the patient supine and the ankle placed in appropriated position. Standard anteromedial and anterolateral portals are established. The talar osteochondral defect is inspected, measured, and any unstable cartilage is sharply débrided to create stable vertical walls, exposing healthy subchondral bone. Using a 1.0- to 1.2-mm awl, multiple perforations are made perpendicular to the lesion base, 3-4 mm apart and \~2-4 mm deep, until uniform marrow fat-bleeding is observed-mobilizing mesenchymal stem cells .A sterile, resorbable, type-I/III collagen bilayer scaffold is trimmed to the exact defect footprint using a template fashioned intra-operatively."
219188951|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
219394120|NCT00385086|DRUG|Placebo|Treatment with placebo
219394121|NCT06126445|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
219394122|NCT06126445|DEVICE|Manual toothbrush|Device on plaque removal efficacy
219394123|NCT02758145|OTHER|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
219394124|NCT04589494|DRUG|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
219394125|NCT01910662|OTHER|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
219394126|NCT01910662|OTHER|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
219394127|NCT01910662|OTHER|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
219394128|NCT01910662|OTHER|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
219394129|NCT05502848|BEHAVIORAL|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
219394130|NCT05767957|OTHER|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
219394131|NCT05767957|OTHER|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
219394132|NCT02262130|DRUG|Omalizumab|
219559279|NCT05483907|DRUG|Placebo|Placebo 24 weeks + Follow-up 4 weeks
219394133|NCT00390923|DRUG|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
219394134|NCT00390923|DRUG|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
219559280|NCT05903170|DEVICE|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
219559281|NCT05903170|DEVICE|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
219559282|NCT03834922|OTHER|Prospective data collection|No intervention. It's a prospective data collection.
219559283|NCT05870163|DEVICE|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
219559284|NCT05870163|PROCEDURE|Nissen fundoplication|Standard of care Nissen fundoplication surgery
219559285|NCT02404857|DEVICE|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
219559286|NCT00108979|DRUG|Escitalopram|
219559287|NCT04523246|BIOLOGICAL|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
219559288|NCT04523246|DRUG|Normal Saline|Sterile normal saline, inactive control.
219559289|NCT04429867|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
219559290|NCT04429867|DRUG|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
219559291|NCT06227351|PROCEDURE|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
219559292|NCT06227351|PROCEDURE|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
219394135|NCT04397055|DIETARY_SUPPLEMENT|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
219394136|NCT04397055|DIETARY_SUPPLEMENT|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
219394137|NCT04963218|DIAGNOSTIC_TEST|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
219394138|NCT00298662|DRUG|Interferon beta-1b and Tacrolimus|
219394139|NCT00004429|DRUG|growth hormone|
219559293|NCT03287687|DRUG|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
219559294|NCT03287687|DRUG|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
219559295|NCT03880149|DIETARY_SUPPLEMENT|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
219754344|NCT07159815|OTHER|Digital follow-up|See the arm/group description.
219394140|NCT01171521|DEVICE|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
219394141|NCT03604328|DRUG|PA5108|single ocular implant, administered on day 1
219394142|NCT03996538|DRUG|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
219394143|NCT03996538|BIOLOGICAL|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
219394144|NCT04441931|DRUG|LY3832479|Administered IV.
219394145|NCT04441931|DRUG|Placebo|Administered IV.
219394146|NCT06070038|BEHAVIORAL|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
219394147|NCT03070132|DRUG|BIIB074|Administered as specified in the treatment arm
219394148|NCT03070132|DRUG|Placebo|Matched placebo
219394149|NCT03211078|PROCEDURE|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
219394150|NCT03384511|DRUG|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
219394151|NCT04252807|BEHAVIORAL|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
219394152|NCT04252807|OTHER|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
219394153|NCT00734929|DRUG|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
219394154|NCT00734929|DRUG|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
219394155|NCT04128592|DEVICE|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
219394156|NCT02499965|DRUG|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
219394157|NCT02499965|DRUG|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
219394158|NCT01687231|OTHER|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
219394159|NCT03004014|OTHER|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
219394160|NCT03067558|DIAGNOSTIC_TEST|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
219394161|NCT03067558|DIAGNOSTIC_TEST|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
219394162|NCT01422304|DRUG|Sugammadex|Sugammadex 4 mg/kg intravenously
219394163|NCT01422304|DRUG|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
219394164|NCT01422304|DRUG|Placebo to neostigmine|Normal saline (NaCl 0.9%)
219394165|NCT01422304|DRUG|Placebo to sugammadex|Normal saline (NaCl 0.9%)
219559296|NCT03880149|OTHER|Placebo|Medium-chain triglyceride (MCT) and vitamin E
219394166|NCT06511505|OTHER|TEMPUS AI-enabled ECG-based Screening Tool|The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.
219394167|NCT00259805|DRUG|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
219394168|NCT03074305|DEVICE|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy"
219394169|NCT06110234|BEHAVIORAL|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
219394170|NCT06110234|BEHAVIORAL|Associative Memory|Recalling word/picture pairs
219394171|NCT00865462|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
219394172|NCT00865462|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
219394173|NCT00048906|DRUG|DRX005B|
219394174|NCT02190435|DEVICE|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
219394175|NCT02190435|DEVICE|Conventional technique|Conventional Technique
219559297|NCT05902468|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 500 mg orally twice daily for 12 weeks
219559298|NCT02614833|BIOLOGICAL|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
219559299|NCT02614833|DRUG|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
219559300|NCT02614833|DRUG|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
219559301|NCT04384341|RADIATION|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
219559302|NCT04384341|BIOLOGICAL|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
219188952|NCT05903547|DEVICE|Dermabond Prineo|For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
219188953|NCT05903547|OTHER|Suture|For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
219188954|NCT04450953|DRUG|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
219559303|NCT06585306|BEHAVIORAL|jaw lift, increasing oxygen flow, mask ventilation, intubation|When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
219559304|NCT00115869|BEHAVIORAL|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
219394176|NCT05552586|DIETARY_SUPPLEMENT|Melatonin|patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
219394177|NCT05552586|OTHER|placebo|patients will receive capsules of the same size and color
219001438|NCT03092609|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
219394178|NCT00202410|BIOLOGICAL|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
219394179|NCT00202410|OTHER|placebo|subcutaneous administration of physiologic solution
219394180|NCT03136211|BEHAVIORAL|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
219394181|NCT06672393|DRUG|HS-10374 6mg tablets|Specified dose of HS-10374 tablets administered orally QD on specified days
219559305|NCT04309162|OTHER|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
219559306|NCT04975451|DRUG|Anlotinib|Anlotinib plus DCb
219559307|NCT03147924|OTHER|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
219559308|NCT02568280|DRUG|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
219559309|NCT02568280|DRUG|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
219754345|NCT07159815|OTHER|On-site follow-up|See the arm/group description.
219001439|NCT03092609|BEHAVIORAL|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
219188955|NCT04450953|OTHER|Period without eplerenone (cross over design)|6-month period without eplerenone
219188956|NCT03866668|DRUG|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
219188957|NCT02724969|BEHAVIORAL|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
219188958|NCT03662386|PROCEDURE|OCT-A|Optical coherence tomography angiography (OCT-A)
219188959|NCT03662386|PROCEDURE|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
219394182|NCT06672393|DRUG|HS-10374-matched placebo tablets|Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
219394183|NCT06672276|DRUG|TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.
219394184|NCT06673186|OTHER|overdenture|Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
219394185|NCT06672952|DIETARY_SUPPLEMENT|400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
219559310|NCT04276012|OTHER|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
219754346|NCT07159815|BEHAVIORAL|Resistance exercise|See the arm/group description.
219754347|NCT07160777|DEVICE|cross-linked hyaluronic acid|Semical Dermal Filler Fine Semical Dermal Filler Plus Semical Dermal Filler Ultra
219394186|NCT06672952|DIETARY_SUPPLEMENT|Placebo|The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
219394187|NCT06672952|DIETARY_SUPPLEMENT|200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
219394188|NCT06672848|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
219394189|NCT06672848|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|BPI is a chronic pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
219394190|NCT06672848|DIAGNOSTIC_TEST|The S-LANSS Pain Score|The Leeds assessment of neuropathic symptoms and signs (LANSS) Pain Scale is based on analysis of sensory description and bedside examination of sensory dysfunction, and provides immediate information in clinical settings. It was developed in two populations of chronic pain patients.
219559311|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
219559312|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
219559313|NCT01085578|DRUG|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
219559314|NCT03985046|DRUG|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
219559315|NCT05509088|DEVICE|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
219559316|NCT00630578|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
219559317|NCT03658434|RADIATION|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
219559318|NCT01015963|OTHER|laboratory biomarker analysis|Perform DNA sample analysis
219559319|NCT04013763|OTHER|wheat containing skin care products|stop or continue using wheat containing skin care products
219559320|NCT02448563|BEHAVIORAL|Nutrition and physical activity education|Eight weekly in-person groups
219559321|NCT04967950|DRUG|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
219559322|NCT04967950|DRUG|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
219559323|NCT04967950|DRUG|Methotrexate|methotrexate
219559324|NCT00147914|DRUG|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
219559325|NCT00147914|DRUG|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
219559326|NCT01887795|DRUG|Erlotinib|
219394191|NCT06671223|DRUG|Infiltration|The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
219394192|NCT06671223|OTHER|Conservative treatment|The control group is used to compare the effectiveness of infiltrations with a non-invasive approach in the treatment of plantar fasciopathy. This group will not receive any infiltration and will focus on conservative interventions.
219394193|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain|CBOT device with beta-caryophyllene
219394194|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactoy stimuli with no BCP
219394195|NCT02269319|DRUG|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
219559327|NCT01887795|DRUG|WBRT|
219559328|NCT03748095|DRUG|pipéracilline/tazobactam|There is not intervention description
219559329|NCT02913755|BEHAVIORAL|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
219559330|NCT05863221|DRUG|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
219559331|NCT01947738|DRUG|VBY-891|Cathepsin S inhibitor
219559332|NCT01947738|DRUG|Placebo|
219559333|NCT02745600|DEVICE|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
219559334|NCT04937998|PROCEDURE|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
219559335|NCT04937998|PROCEDURE|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
219559336|NCT02174276|DRUG|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
219559337|NCT02174276|BIOLOGICAL|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
219559338|NCT00001239|DRUG|FLAC with GM-CSF|
219754348|NCT07160777|DEVICE|Mesolifter|Stabilized hyaluronic acid with NONASEM Technology. Application with Multi-Aesthetic Point Technique (MAPs)
219394196|NCT02269319|DRUG|Linezolid|Oral linezolid 600mg given twice a day for 10 days
219394197|NCT00792766|DRUG|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
219001440|NCT03308734|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
219001441|NCT01990404|DRUG|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
219394198|NCT05421377|DIAGNOSTIC_TEST|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
219394199|NCT05821504|BEHAVIORAL|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
219394200|NCT01589094|DRUG|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
219394201|NCT01481246|BEHAVIORAL|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
219394202|NCT01481246|BEHAVIORAL|Psychosocial and Psychoeducational Group training|Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
219394203|NCT06698536|DEVICE|Aktiia G2C|Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
219394204|NCT03427775|COMBINATION_PRODUCT|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
219394205|NCT06742294|BEHAVIORAL|Movement education|(1) providing preschool teachers professional development training in pedagogical knowledge and methods in the physical domain, (2) creating a set of teaching materials (in printed and digital formats) and methods that could be incorporated into the overall and preschool-based curricula, (3) creating a parental toolkit with contents mirroring the school materials, to enhance parents' knowledge and promote family-school collaboration, and (4) developing a smartphone-based artificial intelligence rating system to help preschool teachers conveniently and accurately assess children's motor skills, and provide appropriate instructional feedback.
219394206|NCT06755671|DRUG|Danning Tablet|Danning Tablet is the only exposure in this observational study.
219394207|NCT03575468|BEHAVIORAL|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
219394208|NCT03575468|BEHAVIORAL|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
219394209|NCT02211495|DEVICE|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
219394210|NCT02211495|OTHER|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
219394211|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
219394212|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
219001442|NCT01990404|DRUG|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
219559339|NCT04149301|DIAGNOSTIC_TEST|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
219394213|NCT06045572|DEVICE|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
219394214|NCT06933485|OTHER|Exercise|These sessions of the postural exercise aim to increase student's knowledge and awarenes their benefits for trunk stabilization, posture correction and diaphragmatic breathing will be explained by the expert physiotherapist. In the exercise planning; the exercise session start with warm-up exercises; A transition to the flow of exercise is ensured with warm-ups that include arm, leg and trunk movements for approximately 10 minutes, and then all extremities are worked for approximately 40 minutes in the main exercise session to ensure trunk alignment. The last 10 minutes of the exercise session is completed with approximately 10 minutes of cool-down exercises to which light stretching is added, making the exercise session a total of 60 minutes.
219394215|NCT00432133|BEHAVIORAL|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
219394216|NCT00432133|BEHAVIORAL|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
219394217|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
219394218|NCT02646436|OTHER|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
219394219|NCT03237208|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
219394220|NCT03237208|DEVICE|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
219394221|NCT05910801|PROCEDURE|Biopsy|Undergo biopsy
219394222|NCT05910801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219394223|NCT05910801|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219394224|NCT05910801|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219394225|NCT05910801|PROCEDURE|Computed Tomography|Undergo CT scan
219559340|NCT04149301|DIAGNOSTIC_TEST|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
219559341|NCT02132624|BIOLOGICAL|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
219559342|NCT01580046|DRUG|iodixanol|"1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
219001443|NCT05048940|BIOLOGICAL|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
219559343|NCT01580046|DRUG|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
219559344|NCT06125002|DRUG|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
219559345|NCT06125002|DRUG|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
219001444|NCT05048940|BIOLOGICAL|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
219754349|NCT07158684|OTHER|Semi-structured interview|A qualitative semi-structured interview of the patient's anxiety before and one month after surgery.
219754350|NCT07158918|DRUG|ABL103|IV infusion
219001445|NCT01480050|DRUG|temozolomide|standard of care drug
219001446|NCT01480050|OTHER|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
219001447|NCT01480050|OTHER|pharmacological study|
219001448|NCT01480050|DRUG|Mibefradil|
219394226|NCT05910801|DRUG|Lenalidomide|Given PO
219394227|NCT05910801|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219394228|NCT05910801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219394229|NCT05910801|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219394230|NCT05910801|BIOLOGICAL|Tafasitamab|Given IV
219394231|NCT05910801|DRUG|Venetoclax|Given PO
219394232|NCT03998735|DRUG|Herbal Snuff (Smokeless Tobacco)|4 levels of \[D4\]nornicotine in herbal snuff
219394233|NCT05270694|BEHAVIORAL|Public Health Intervention Package|"The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
219394234|NCT05613010|BEHAVIORAL|mHealth Messaging Intervention Group|Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.
219754351|NCT07158918|DRUG|KEYTRUDA® (pembrolizumab)|IV infusion
219754352|NCT07158918|DRUG|Taxane|IV infusion
219559346|NCT05245955|DEVICE|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
219559347|NCT06167850|PROCEDURE|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
219559348|NCT04194606|PROCEDURE|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
219559349|NCT06417437|DRUG|SSRI|Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
219559350|NCT06417437|DEVICE|rTMS|Patients will be treated targeting either the traditional brain region or new region.
219559351|NCT06417437|BEHAVIORAL|Neuro-Feedback|Patients under 18 years old will first be considered this treatment before other methods.
219559352|NCT06417437|BEHAVIORAL|Game Regulation|Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
219394235|NCT05989477|OTHER|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
219559353|NCT01889797|BIOLOGICAL|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
219394236|NCT01991977|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
219394237|NCT01991977|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
219394238|NCT01991977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219394239|NCT01991977|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
219559354|NCT01889797|BIOLOGICAL|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
219559355|NCT00731991|OTHER|ART|ART to the levator scapulae.
219559356|NCT00731991|OTHER|PNF|PNF to the levator scapulae.
219559357|NCT00731991|OTHER|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
219559358|NCT00569660|DRUG|Azacitidine|75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
219559359|NCT00050076|DRUG|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
219559360|NCT00050076|DRUG|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
219559361|NCT00050076|DRUG|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
219559362|NCT00050076|DRUG|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
219001449|NCT05074212|OTHER|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
219394240|NCT01991977|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET
219394241|NCT01991977|OTHER|Quality-of-Life Assessment|Ancillary studies
219394242|NCT01991977|DRUG|Temozolomide|Receive temozolomide
219394243|NCT06272175|OTHER|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
219394244|NCT06272175|OTHER|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
219394245|NCT06583096|BEHAVIORAL|Surveys|Participants (in both arms) will complete surveys once per week and participants in the intervention arm will also complete additional 1-minute surveys daily. Study participation will be completed at the conclusion of the final follow-up survey administered 6-weeks after study enrollment.
219394246|NCT06583096|BEHAVIORAL|Supportive Text messages|Text messages will be sent Mondays-Sunday if participants are randomized to receive them in a given week, with a daily 50:50 send/no-send randomization. A bank of 25 text messages will be used for the study, providing tips/strategies across a range of topics, including managing time and academic stressors, recommendations for self-care and mood management, and messages geared towards fostering social connections and support. Some messages will contain links to videos, websites, or articles for more information on a topic.
219394247|NCT06583096|BEHAVIORAL|Personalized Feedback (PF) Report|For individuals that are randomized to receive a Personalized Feedback Report, the study team will send participants a text on a Monday with the feedback from the prior survey (baseline survey in the first week, weekly survey in the next five weeks). There will be graphs for depression, anxiety, stress, and flourishing.
219394248|NCT02311712|DEVICE|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
219394249|NCT05155631|BEHAVIORAL|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
219394250|NCT00260559|PROCEDURE|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
219394251|NCT05934799|DRUG|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
219394252|NCT05934799|DRUG|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
219559363|NCT04039360|COMBINATION_PRODUCT|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
219394253|NCT01053624|PROCEDURE|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
219559364|NCT04952168|DRUG|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
219559365|NCT04776304|BEHAVIORAL|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
219559366|NCT00571480|OTHER|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
219559367|NCT00571480|OTHER|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
219559368|NCT00571480|OTHER|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
219559369|NCT03782662|DRUG|Itraconazole|Itraconazole capsules
219559370|NCT03782662|DRUG|Verapamil|Verapamil tablets
219559371|NCT03782662|DRUG|Rifampicin|Rifampicin capsules
219559372|NCT03782662|DRUG|Midazolam|Midazolam oromucosal solution
219559373|NCT03782662|DRUG|Placebo for RV521|Placebo for RV521 capsules
219559374|NCT03782662|DRUG|RV521|RV521 capsules
219559375|NCT04792580|DRUG|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
219559376|NCT04792580|DRUG|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
219559377|NCT01974362|DEVICE|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
219559378|NCT01974362|DEVICE|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
219559379|NCT01974362|DEVICE|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
219559380|NCT01974362|DEVICE|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
219559381|NCT04966962|DIAGNOSTIC_TEST|serum and urine metabolomics|serum and urine samples will be collected for metabolomics analysis
219559382|NCT01937689|DRUG|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
219559383|NCT03240120|DRUG|Dabigatran etexilate|Pradaxa 150 mg hard capsules
219559384|NCT03240120|DRUG|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
219559385|NCT06449391|DEVICE|RAI|Immediate implantation
219559386|NCT02261220|BIOLOGICAL|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
219559387|NCT02261220|BIOLOGICAL|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
219559388|NCT01134991|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
219394254|NCT00746577|OTHER|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
219394255|NCT04755400|OTHER|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
219394256|NCT04755400|DIETARY_SUPPLEMENT|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
219559389|NCT05595720|DEVICE|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
219559390|NCT01362192|DEVICE|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius"
219559391|NCT00376740|DRUG|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
219559392|NCT02296957|PROCEDURE|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
219559393|NCT04781244|DEVICE|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
219559394|NCT04781244|DEVICE|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
219559395|NCT03552367|OTHER|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
219559396|NCT03552367|OTHER|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
219559397|NCT03710616|PROCEDURE|Surgeries|Surgical operations plus systematic lymphadenectomies
219559398|NCT02629016|OTHER|Mindfulness|
219559399|NCT02629016|OTHER|Wellness|
219559400|NCT01819064|DRUG|Atropine|intravenous atropine affect on heart rate
219559401|NCT00434837|PROCEDURE|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
219559402|NCT00515216|DRUG|5-fluorouracil|
219559403|NCT00515216|DRUG|Oxaliplatin|
219559404|NCT00515216|DRUG|Leucovorin|
219559405|NCT02937363|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
219394257|NCT04755400|DIETARY_SUPPLEMENT|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
219394258|NCT05724667|OTHER|Flippin' Pain Seminar Series|A chronic pain education campaign
219394259|NCT00945750|DRUG|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
219559406|NCT02937363|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
219559407|NCT00357539|DRUG|Azithromycin (T1225)|
219559408|NCT00464386|DEVICE|Continuous Glucose Monitoring|measure glucose levels on burn patients
219559409|NCT02557217|DRUG|NP202|Active
219559410|NCT02557217|OTHER|Placebo|Placebo
219559411|NCT04448041|OTHER|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
219559412|NCT00172016|DRUG|Zoledronic acid|
219559413|NCT03281096|DRUG|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
219559414|NCT03281096|DRUG|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
219559415|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered IM followed by Electroporation
219559416|NCT02464670|BIOLOGICAL|INO-4202|INO-4202 delivered IM followed by Electroporation
219559417|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered ID followed by Electroporation
219559418|NCT02464670|BIOLOGICAL|INO-4212|INO-4212 delivered IM followed by Electroporation
219394260|NCT00945750|DRUG|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
219394261|NCT00983450|OTHER|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
219394262|NCT00983450|OTHER|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
219394263|NCT05553548|PROCEDURE|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
219394264|NCT05553548|PROCEDURE|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
219394265|NCT02531035|DRUG|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
219394266|NCT02531035|DRUG|Placebo|Placebo, once daily, before the first meal of the day
219559419|NCT02464670|BIOLOGICAL|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
219559420|NCT02464670|BIOLOGICAL|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
219559421|NCT04079452|DRUG|Doravirine|Doravirine 100 mg tablet
219559422|NCT04079452|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
219559423|NCT04066257|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
219559424|NCT04066257|DRUG|Metronidazole|Metronidazole 250 mg tablet
219559425|NCT04066257|DRUG|Tetracycline|Tetracycline hydrochloride 250 mg capsule
219559426|NCT04066257|DRUG|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
219559427|NCT04659668|DEVICE|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
219559428|NCT03981809|DIAGNOSTIC_TEST|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
219559429|NCT00059709|PROCEDURE|Mediated Negotiation Training|
219559430|NCT00741754|OTHER|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
219559431|NCT05098951|DEVICE|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
219559432|NCT02786927|DRUG|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
219394267|NCT02892461|PROCEDURE|Umbilical cord milking|As same as that in arm descriptions.
219394268|NCT02898207|DRUG|Olaparib|Given PO
219394269|NCT02898207|DRUG|Onalespib|Given IV
219559433|NCT02786927|DRUG|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
219559434|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
219394270|NCT00071201|DRUG|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
219394271|NCT05768620|OTHER|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
219394272|NCT05768620|OTHER|TAU|This is the usual care used to train visuospatial processes
219394273|NCT01009801|DRUG|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
219559435|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
219559436|NCT03559127|PROCEDURE|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
219559437|NCT03559127|PROCEDURE|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
219001450|NCT04267198|BEHAVIORAL|Intention Treatment for Anomia|Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
219001451|NCT02324062|OTHER|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
219559438|NCT03559127|PROCEDURE|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
219001452|NCT02324062|OTHER|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
219559439|NCT02695927|DEVICE|Computer rehabilitation glasses|
219559440|NCT01801917|DRUG|Placebo|Matching placebo tablet for oral administration
219001453|NCT04344925|DEVICE|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
219001454|NCT04344925|DEVICE|Standard Mask|Patient will be put on BIPAP using the standard mask
219001455|NCT04943185|DEVICE|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
219001456|NCT03501069|DRUG|TAK-418|TAK-418 capsules.
219001457|NCT03501069|DRUG|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
219001458|NCT05412511|BEHAVIORAL|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
219001459|NCT05412511|BEHAVIORAL|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
219001460|NCT02059486|BEHAVIORAL|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
219394274|NCT01009801|DRUG|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
219394275|NCT01009801|OTHER|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
219394276|NCT02069223|PROCEDURE|Gastrectomy|
219394277|NCT02069223|PROCEDURE|BPD-DS|
219394278|NCT02193269|DRUG|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
219394279|NCT02193269|DRUG|Minocycline|you will receive 200 mg as a single daily dose for 4 days
219394280|NCT04885491|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
219394281|NCT04885491|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
219394282|NCT00912158|OTHER|standard therapy (ST)|standard medical therapy
219394283|NCT00912158|DEVICE|CPAP|Non-invasive mechanical ventilation (CPAP)
219394284|NCT00912158|DEVICE|BIPAP|Non-invasive mechanical ventilation (BIPAP)
219394285|NCT02252874|BEHAVIORAL|Slow-paced action video game|20 hours slow-paced action video games
219394286|NCT02252874|BEHAVIORAL|Fast-paced action video game|20 hours fast-paced action video games
219394287|NCT02252874|BEHAVIORAL|Control|20 hours leisure activities
219394288|NCT04424433|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
219394289|NCT00900380|OTHER|flow cytometry|
219394290|NCT00900380|OTHER|immunological diagnostic method|
219394291|NCT00900380|OTHER|laboratory biomarker analysis|
219559441|NCT01801917|DRUG|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
219559442|NCT02486614|PROCEDURE|CRRT|citrate based continuous renal replacement therapy
219559443|NCT03180255|COMBINATION_PRODUCT|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
219559444|NCT03180255|OTHER|Placebo|Ocular iontophoretic delivery of a placebo
219559445|NCT04307849|BEHAVIORAL|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
219559446|NCT04307849|OTHER|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
219559447|NCT02878408|GENETIC|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
219559448|NCT04043702|DRUG|The intervention being studied|Intervention Other Names have not been specified
219394292|NCT03254017|PROCEDURE|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
219394293|NCT03254017|OTHER|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
219394294|NCT04962542|OTHER|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
219394295|NCT03490669|BIOLOGICAL|MSC-1|humanized monoclonal antibody for intravenous administration
219394296|NCT04817085|DEVICE|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
219394297|NCT04817085|DEVICE|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
219394298|NCT03032068|OTHER|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
219394299|NCT04747548|BEHAVIORAL|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
219394300|NCT04747548|BEHAVIORAL|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
219394301|NCT04656964|DRUG|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
219394302|NCT04656964|DRUG|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
219559449|NCT05700136|BEHAVIORAL|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
219559450|NCT04761445|OTHER|Straumann Standard Plus implant and JDental care (JD) Octa implant|Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
219559451|NCT04791488|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
219559452|NCT04791488|PROCEDURE|Diving simulation|Hyperbaric chamber diving simulation protocol
219559453|NCT04113616|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
219559454|NCT04113616|DRUG|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
219559455|NCT04113616|DRUG|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
219559456|NCT05967936|DRUG|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
219394303|NCT03080220|DEVICE|Astym|therapeutic massage instrument
219559457|NCT00857558|DRUG|saxagliptin|orally administration at 1 mg once a day for 12 weeks
219559458|NCT00857558|DRUG|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
219559459|NCT00857558|DRUG|saxagliptin|orally administration at 5 mg once a day for 12 weeks
219559460|NCT00857558|DRUG|placebo|orally administration once a day for 12 weeks
219559461|NCT02185963|DRUG|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
219559462|NCT03602027|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
219559463|NCT03602027|DRUG|Gefitinib|Gefitinib 250mg orally daily for three weeks
219559464|NCT05467982|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
219188960|NCT05711082|OTHER|Précurseur de la dopamine|"In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house."
219188961|NCT05711082|OTHER|antagoniste D2|In the second condition, volunteers will receive Sulpiride 800 mg
219188962|NCT05711082|OTHER|PLACEBO|In the third condition, volunteers will receive placebo
219394304|NCT03080220|DEVICE|Stick|massage instrument
219394305|NCT03080220|DEVICE|Massage|massage instruments
219394306|NCT00841503|OTHER|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
219394307|NCT00146393|BEHAVIORAL|People with Arthritis Can Exercise program|
219394308|NCT01597622|DRUG|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
219394309|NCT04484779|DEVICE|IIM System|IIM System
219394310|NCT04484779|DRUG|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
219394311|NCT05238948|DRUG|Midazolam|Substrate of CYP3A4
219394312|NCT05238948|DRUG|CKD-506|Perpetrator of CYP3A4
219394313|NCT04126967|DIAGNOSTIC_TEST|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
219394314|NCT01358500|DRUG|Fentanyl|Intravenous infusion using STANPUMP
219394315|NCT04065022|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
219394316|NCT00673998|DEVICE|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
219394317|NCT01655264|BEHAVIORAL|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
219394318|NCT01655264|BEHAVIORAL|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
219394319|NCT05121727|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
219394320|NCT05121727|PROCEDURE|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
219394321|NCT06255470|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
219188963|NCT03828344|BIOLOGICAL|hUC-MSC suspension|Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
219188964|NCT03828344|BIOLOGICAL|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
219188965|NCT04670679|DRUG|ERAS-601|Administered orally
219188966|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
219394322|NCT03225781|DEVICE|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
219394323|NCT01458444|DEVICE|Non invasive ventilation (VNI)|BIPAP® vision
219394324|NCT01458444|DEVICE|Non invasive ventilation|OPTIFLOW system
219394325|NCT06257498|PROCEDURE|MRI scan|MRI scan on open scanner and some questionnaires
219394326|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
219394327|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
219394328|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
219188967|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
219559465|NCT05467982|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
219559466|NCT02997722|DRUG|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
219559467|NCT02997722|DRUG|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
219559468|NCT00791986|DEVICE|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
219559469|NCT04381481|BEHAVIORAL|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
219559470|NCT04381481|BEHAVIORAL|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
219559471|NCT04381481|BEHAVIORAL|Experimental snack: Text warning|The snack contains a text warning (task 2)
219559472|NCT04381481|BEHAVIORAL|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
219559473|NCT04381481|BEHAVIORAL|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
219559474|NCT06677632|OTHER|Palmitoylation Enzyme Expression Profiling Study|The expression of 23 zDHHC enzymes will be studied in human post-mortem hippocampi of AD patients and controls that have already been collected from UK brain biobanks. zDHHC enzymes will be analyzed at both mRNA and protein levels by Real Time PCR and Western blotting techniques, respectively
219559475|NCT01065389|BEHAVIORAL|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
219559476|NCT01065389|BEHAVIORAL|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
219559477|NCT05135624|DRUG|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
219559478|NCT05135624|OTHER|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
219559479|NCT05135624|DRUG|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
219559480|NCT01575041|DIETARY_SUPPLEMENT|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
219559481|NCT01575041|DRUG|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
219559482|NCT01575041|DRUG|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
219559483|NCT00244829|DRUG|imatinib mesylate|
219559484|NCT00244829|PROCEDURE|adjuvant therapy|
219559485|NCT04203433|DRUG|DLX105-DMP|1mg applied to target lesion
219559486|NCT02203578|DRUG|romidepsin|Given IV
219559487|NCT02203578|OTHER|laboratory biomarker analysis|Correlative studies
219559488|NCT05252247|OTHER|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
219559489|NCT05252247|OTHER|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
219001461|NCT05195125|PROCEDURE|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
219001462|NCT01234298|DRUG|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
219001463|NCT01234298|DRUG|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
219001464|NCT01234298|DRUG|Placebo|Placebo capsule taken once-daily for up to 26 weeks
219188968|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
219188969|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
219559490|NCT06599138|DEVICE|Ultrasound-guided maxillary nerve block|Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
219559491|NCT00899535|GENETIC|DNA analysis|
219559492|NCT00899535|GENETIC|RNA analysis|
219559493|NCT00899535|GENETIC|microarray analysis|
219559494|NCT00899535|GENETIC|mutation analysis|
219559495|NCT00899535|GENETIC|polymorphism analysis|
219559496|NCT04235660|RADIATION|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
219559497|NCT04235660|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
219559498|NCT00591760|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
219559499|NCT00398073|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
219559500|NCT00398073|DEVICE|The Dermal PowderMed® devices|
219559501|NCT00398073|OTHER|intramuscularly (IM injection)|
219559502|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
219559503|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
219559504|NCT03957694|DRUG|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
219559505|NCT01049464|DRUG|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
219559506|NCT01049464|DRUG|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
219559507|NCT01820962|PROCEDURE|heparin|when not in use CVCs are locked with heparin
219559508|NCT01820962|PROCEDURE|concentrated citrate|when not in use the CVC is locked with concentrated citrate
219559509|NCT04777305|OTHER|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
219559510|NCT01625403|DRUG|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
219394329|NCT03546725|DEVICE|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
219394330|NCT05380297|DEVICE|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
219394331|NCT04904653|DEVICE|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm"
219559511|NCT01625403|DRUG|standard of care|standard of care for heart failure
219559512|NCT00575601|DRUG|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
219559513|NCT03795012|DRUG|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
219559514|NCT00363857|DRUG|Ropinirole|
219559515|NCT01584882|BEHAVIORAL|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
219559516|NCT03359720|OTHER|no intervention survey|survey
219559517|NCT01825694|BEHAVIORAL|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
219188970|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
219394332|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
219394333|NCT04043507|OTHER|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
219394334|NCT01101568|DRUG|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
219394335|NCT01101568|DRUG|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
219394336|NCT01101568|DRUG|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
219394337|NCT05835752|DRUG|RAY1225|Administered SC
219394338|NCT05835752|DRUG|Placebo|Administered SC
219394339|NCT05835752|DRUG|RAY1225|Administered SC
219394340|NCT05835752|DRUG|Placebo|Administered SC
219394341|NCT05835752|DRUG|RAY1225|Administered SC
219394342|NCT05835752|DRUG|Placebo|Administered SC
219394343|NCT00004895|DRUG|octreotide acetate|
219394344|NCT01213433|DRUG|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
219559518|NCT03064620|BIOLOGICAL|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
219559519|NCT03113396|DRUG|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
219559520|NCT03113396|DRUG|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
219394345|NCT01976819|DEVICE|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
219394346|NCT03789682|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
219394347|NCT06513767|DEVICE|Zirconia Dental Ceramics|This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
219394348|NCT06352216|DIAGNOSTIC_TEST|Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)|Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
219394349|NCT05995522|DIETARY_SUPPLEMENT|Vitamin K2|100 µg per day for 90 days
219394350|NCT05995522|OTHER|Cornstarch|500 mg per day for 90 days
219394351|NCT04366271|BIOLOGICAL|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
219394352|NCT04366271|DRUG|Standard of care|Best treatment option for COVID-19 according to investigator criteria
219394353|NCT03569423|PROCEDURE|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
219394354|NCT03569423|PROCEDURE|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
219394355|NCT03348657|OTHER|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
219394356|NCT04854265|OTHER|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
219559521|NCT00991692|OTHER|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
219188971|NCT03402945|DEVICE|Prevena|Negative-Pressure Wound Management System
219188972|NCT03402945|DRUG|Cefazolin|antibiotic
219394357|NCT04930640|DIETARY_SUPPLEMENT|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
219394358|NCT04930640|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
219394359|NCT03566537|PROCEDURE|Thyroidectomy|Thyroidectomy
219394360|NCT02505555|DEVICE|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
219394361|NCT01289392|DEVICE|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
219394362|NCT01289392|DEVICE|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
219394363|NCT01289392|BEHAVIORAL|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
219394364|NCT02016417|DRUG|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
219559522|NCT02897934|DRUG|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
219559523|NCT01102127|DEVICE|Elastography|Performance of US, elastography and FNA.
219559524|NCT04506619|OTHER|No Intervention|This is a non-interventional study.
219559525|NCT03380325|DRUG|Iloprost infusion|Iloprost is a stable prostacyclin analogue
219559526|NCT04602741|BEHAVIORAL|A4i Intervention|6 months of the provision of A4i on the individual's own device.
219559527|NCT01833169|DRUG|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
219559528|NCT03718039|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
219559529|NCT03718039|DEVICE|Luer Lock applicator|Applicator for instillation.
219559530|NCT03718039|DEVICE|Vial access device|Device for withdrawal of drug product.
219188973|NCT03402945|DRUG|Vancomycin|antibiotic
219188974|NCT03402945|OTHER|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
219394365|NCT02016417|DRUG|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
219394366|NCT02787512|DEVICE|Stent|Endoscopic biliary stent insertion
219394367|NCT00000581|PROCEDURE|leukocyte transfusions|
219394368|NCT01579539|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
219394369|NCT01579539|DRUG|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
219394370|NCT05002192|DRUG|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
219559531|NCT03718039|DRUG|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
219559532|NCT02004717|DRUG|DS-8895a|
219559533|NCT02664350|GENETIC|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
219559534|NCT02664350|BEHAVIORAL|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
219559535|NCT02664350|BEHAVIORAL|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
219559536|NCT02664350|GENETIC|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
219559537|NCT00002116|DRUG|Cidofovir|
219559538|NCT01959802|PROCEDURE|Vitrectomy|
219559539|NCT01407484|DRUG|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
219559540|NCT01407484|DRUG|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
219001465|NCT06049680|DRUG|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
219001466|NCT02530489|DRUG|Atezolizumab|Given IV
219001467|NCT02530489|DRUG|Nab-paclitaxel|Given IV
219394371|NCT05002192|DRUG|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort
219559541|NCT02893163|BEHAVIORAL|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
219559542|NCT02893163|OTHER|Usual Care|Usual Care by Family Doctor
219754353|NCT07160582|BEHAVIORAL|Novel CogXergaming Training|In each session, participants will play 6 games in the same order (Fruit catch, Math, Tracking, Candy match, Letter Number Sequencing - LNS, Stroop), each of which contains 10-20 trials and will last for around 10 minutes (total = 60 minutes. The CXT program employs a progressive method to ensure the intensity of CXT remains challenging without overload. If a participant demonstrates ≥80% accuracy in 3 continuous trials for one game, then the exercises for this game will be progressed to the next level (levels: 1-9 in Table 3). Each session of CXT will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
219001468|NCT02591589|OTHER|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.
219001469|NCT02591589|OTHER|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
219559543|NCT05694130|DRUG|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
219559544|NCT05694130|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
219559545|NCT03371524|OTHER|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
219559546|NCT00879684|BIOLOGICAL|CVX-060|Weekly, intravenous dose
219559547|NCT00105157|DRUG|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
219559548|NCT00105157|DRUG|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
219559549|NCT00105157|DRUG|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
219559550|NCT00105157|DRUG|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
219559551|NCT00851006|DRUG|Creatine Monohydrate|Creapure brand of creatine monohydrate
219559552|NCT02945527|DRUG|Acetazolamide|As described above
219559553|NCT02945527|DRUG|Dexamethasone|As described above
219559554|NCT02304978|BIOLOGICAL|Group CRC|blood samples
219559555|NCT02304978|BIOLOGICAL|Group control|Blood samples
219001470|NCT02846779|OTHER|Low intensity|Low intensity telepharmacy outreach
219001471|NCT02846779|OTHER|Moderate intensity|Moderate intensity telepharmacy outreach
219001472|NCT02846779|OTHER|High intensity|High intensity telepharmacy outreach
219001473|NCT00803725|DRUG|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
219001474|NCT00803725|DRUG|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
219001475|NCT02959307|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
219188975|NCT04782713|OTHER|Completing surveys|Completing surveys at baseline, 3, 6, 9, and 12 months
219394372|NCT05002192|DRUG|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
219394373|NCT03251014|OTHER|YSS|Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
219559556|NCT02520453|DRUG|Durvalumab|
219559557|NCT02520453|DRUG|Placebo|
219559558|NCT04779034|OTHER|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
219559559|NCT00527917|DEVICE|placebo|bladder instillation
219559560|NCT00527917|DEVICE|Uracyst|20 ml sterile solution for weekly intravesical instillation
219559561|NCT02569541|DRUG|sodium fusidate|
219559562|NCT03460990|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
219559563|NCT03460990|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
219559564|NCT03460990|DRUG|IVA|Participants received IVA orally once daily in the evening.
219559565|NCT03460990|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
219559566|NCT03460990|DRUG|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
219394374|NCT03251014|OTHER|Salmon|Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
219394375|NCT02847936|PROCEDURE|vicryl plus suture|episiotomy with triclosan-coated sutures
219394376|NCT02847936|PROCEDURE|vicryl suture|episiotomy with non antibacterial coated suture
219559567|NCT03864185|BIOLOGICAL|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
219188976|NCT06808555|BEHAVIORAL|Pai.ACT Group|"The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated AI algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. Following interactions with the AI chatbot, Pai.ACT provides a stratified mental health support, categorizing into three risk levels:~* Low-risk: Users access self-help ACT digital modules tailored to their specific psychological inflexibility processes.~* Moderate-risk: In addition to the self-help modules, users receive 4-6 sessions of video-conferencing-based ACT interventions (45-60 minutes per session) conducted by our trained counseling team.~* High-risk: Users are directed to specialized mental health services provided by collaborating units."
219394377|NCT00038545|DRUG|Filgrastim SD/01|
219394378|NCT00038545|DRUG|Paclitaxel|
219394379|NCT00038545|DRUG|Topotecan|
219394380|NCT02996539|OTHER|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
219394381|NCT05406297|PROCEDURE|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
219394382|NCT01386580|DRUG|2B3-101|IV every 21 days
219559568|NCT03864185|OTHER|Placebo|Administer placebo IV infusion once weekly for 4 doses.
219559569|NCT02770144|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
219394383|NCT01386580|DRUG|Trastuzumab|IV every 21 days
219394384|NCT01386580|DRUG|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
219394385|NCT01386580|DRUG|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
219394386|NCT02560688|DRUG|DS-1040b|20 mg single 12-hour intravenous infusion
219394387|NCT02560688|DRUG|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
219394388|NCT00206999|DRUG|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
219394389|NCT04497662|DRUG|KPL-404|humanized IgG4 monoclonal antibody
219394390|NCT04497662|OTHER|Matching Placebo|Placebo
219394391|NCT05795218|DEVICE|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
219394392|NCT05864014|DRUG|Hetrombopag|Hetrombopag
219394393|NCT05864014|DRUG|Hetrombopag plus Placebo|Hetrombopag plus Placebo
219394394|NCT05864014|DRUG|Placebo|Placebo
219559570|NCT02770144|BEHAVIORAL|Access to Referral to Social Services|
219559571|NCT05387070|DRUG|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
219394395|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
219394396|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
219394397|NCT06359236|OTHER|BI'KILO Intervention|"The study consists of three stages: preparation phase, implementation phase and follow-up phase. During the preparation phase, participants' weight and body fat ratio will be calculated using a body analysis scale, and their height, waist and hip circumference will be measured.~The implementation phase will last six weeks and consists of six modules, each lasting one week. The skills and practices aimed to be acquired in each module will be required to be applied in the following practice modules.~At the end of the implementation phase, participants' weight, waist and hip circumferences will be measured again.~The final phase, called the follow-up phase, will last four weeks. During this phase, participants will continue to keep a self-monitoring record of their eating and physical exercise, complete a hunger scale, and application card notifications will continue to be displayed."
219394398|NCT02517112|OTHER|Parabolic flight|
219559572|NCT05387070|DRUG|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
219559573|NCT03624855|OTHER|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
219559574|NCT05934357|OTHER|Fiber|The intervention treatment will contain fiber.
219559575|NCT05934357|OTHER|Control|The control treatment will contain corn meal.
219559576|NCT00945334|DRUG|Neomycin|500 mg po bid for 14 days
219559577|NCT00945334|DRUG|Placebo|placebo for 14 days tid
219559578|NCT00945334|DRUG|Rifaximin|550 mg po tid
219559579|NCT00332124|DRUG|Choline|900 mg every day until birth of infant
219559580|NCT00332124|DIETARY_SUPPLEMENT|Placebo|Corn oil every day in place of choline
219559581|NCT01713088|OTHER|Multisystemic therapy|
219559582|NCT01713088|OTHER|YOT (usual services)|
219394399|NCT02517112|OTHER|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
219559583|NCT03471988|DRUG|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
219394400|NCT02517112|DEVICE|3D-BCG sensor|
219559584|NCT03471988|DRUG|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
219559585|NCT05920161|BEHAVIORAL|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
219559586|NCT05920161|BEHAVIORAL|Control|This is matched to the SECPT but with warm instead of cold water
219559587|NCT06467578|DEVICE|Breezing Portable Indirect Calorimeter|Indirect calorimeter with face mask and smartphone compatible application
219559588|NCT03745417|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
219559589|NCT01636934|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
219559590|NCT01636934|OTHER|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
219559591|NCT01636934|BEHAVIORAL|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
219559592|NCT01435824|DRUG|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
219559593|NCT01435824|DRUG|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
219559594|NCT01011335|BIOLOGICAL|Monovalent rAT|10, 25, 50 or 100 μg
219559595|NCT01011335|BIOLOGICAL|Monovalent rLukS-PV|10, 25, 50 or 100 μg
219559596|NCT01011335|BIOLOGICAL|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
219559597|NCT01011335|BIOLOGICAL|Placebo with adjuvant|Placebo with adjuvant
219559598|NCT01011335|BIOLOGICAL|Placebo|Placebo saline
219559599|NCT04667936|OTHER|Treatment group|None, solely treatment documentation
219559600|NCT02040519|BEHAVIORAL|Filling out voiding diaries.|
219559601|NCT00117806|BEHAVIORAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
219559602|NCT00117806|BEHAVIORAL|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
219754354|NCT07160582|BEHAVIORAL|Exercise and Education Training Program|EEP consists of a conventional exercise program and fall-prevention education. The conventional exercise program comprises 50 minutes of supervised exercises for stretching and strengthening. A fall-prevention education program will also be provided to Group B, for about 10 minutes after each session of the exercise program. Each session of EEP will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
219559603|NCT04231409|DEVICE|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
219559604|NCT01765751|PROCEDURE|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
219559605|NCT01665651|DRUG|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
219559606|NCT01665651|DRUG|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
219394401|NCT02074215|OTHER|Aerobic exercises|Aerobic exercises + dual task
219394402|NCT02074215|OTHER|Stretch exercise|Stretch exercise
219394403|NCT03952208|OTHER|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
219394404|NCT04347811|BEHAVIORAL|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
219394405|NCT00312351|DRUG|Pegaptanib sodium|
219394406|NCT03042611|DRUG|Rivoceranib|Oral tablet
219394407|NCT03042611|DRUG|Placebo|Oral tablet
219394408|NCT01741272|PROCEDURE|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
219394409|NCT01741272|PROCEDURE|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
219559607|NCT01665651|DRUG|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
219559608|NCT01665651|DRUG|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
219188977|NCT06808555|OTHER|Control Group|Both the Pai.ACT intervention group and the control group will receive standard family support through Hong Kong's family and children rehabilitation services, which are administered by government-funded units under the Social Welfare Department. Parents will participate in structured psychoeducation sessions focusing on positive parenting and will have access to peer support groups. Their children will receive individualized training plans tailored for neurodevelopmental conditions, in addition to referrals for speech and occupational therapy.
219188978|NCT05458141|BEHAVIORAL|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
219394410|NCT01809990|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
219394411|NCT01099410|PROCEDURE|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
219394412|NCT01099410|PROCEDURE|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
219394413|NCT01099410|PROCEDURE|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
219394414|NCT03218852|DRUG|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
219394415|NCT03218852|DRUG|prednisone alone|Prednisone is administered to participants in this group.
219394416|NCT04076722|BEHAVIORAL|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
219394417|NCT03527056|BIOLOGICAL|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
219394418|NCT05099757|BIOLOGICAL|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
219394419|NCT00216359|DRUG|Fuzeon (Enfuvirtide)|
219394420|NCT00216359|PROCEDURE|Laboratory diagnostic (CD4-cells)|
219394421|NCT00216359|PROCEDURE|Laboratory diagnostics (HIV-1 viral load)|
219394422|NCT00216359|DRUG|antiretroviral co-medication beside Fuzeon|
219394423|NCT02897973|OTHER|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
219394424|NCT05014698|GENETIC|WGS|Whole Genome sequencing
219394425|NCT04151563|BIOLOGICAL|nivolumab|Specified dose on Specified days
219394426|NCT04151563|BIOLOGICAL|ipilimumab|Specified dose on Specified days
219394427|NCT04151563|DRUG|cabozantinib|Specified dose on Specified days
219394428|NCT04151563|BIOLOGICAL|docetaxel|Specified dose on Specified days
219394429|NCT04151563|BIOLOGICAL|ramucirumab|Specified dose on Specified days
219394430|NCT04151563|DRUG|lucitanib|Specified dose on Specified days
219394431|NCT02418403|BEHAVIORAL|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
219394432|NCT02418403|BEHAVIORAL|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
219394433|NCT00392002|DRUG|Esomeprazole|
219394434|NCT01795469|DEVICE|Zoex compression garment|5-strap compression of abdomen, thighs and legs
219394435|NCT02470013|DIETARY_SUPPLEMENT|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
219394436|NCT04919993|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|Group presentation
219394437|NCT01096771|DRUG|ClinOleic 20%|96 hour continuous infusion.
219394438|NCT01096771|DRUG|Intralipid 20%|96 hour continuous infusion.
219394439|NCT02590016|DRUG|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
219394440|NCT01858883|DRUG|itacitinib|
219394441|NCT01858883|DRUG|Gemcitabine|
219394442|NCT01858883|DRUG|nab-paclitaxel|
219394443|NCT01858883|DRUG|filgrastim|
219394444|NCT03391518|PROCEDURE|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
219394445|NCT00000289|DRUG|Ondansetron|
219394446|NCT03567291|DRUG|TEV-50717|6, 9, and 12 mg oral tablets
219394447|NCT03567291|DRUG|Placebo|Placebo comparator
219394448|NCT05649124|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
219394449|NCT03799315|DRUG|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
219188979|NCT06372860|BEHAVIORAL|Diabetes Prevention Program|"The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences."
219191797|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
219394450|NCT03799315|BEHAVIORAL|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
219394451|NCT01103349|DRUG|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
219394452|NCT01103349|DRUG|Placebo|Patients receive placebo capsules and/or encapsulated tablets
219394453|NCT01103349|DRUG|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
219394454|NCT00000348|DRUG|Dihydrexidine|
219394455|NCT00158652|PROCEDURE|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
219394456|NCT00158652|PROCEDURE|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
219394457|NCT00158652|PROCEDURE|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
219394458|NCT00158652|DRUG|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
219394459|NCT05058131|DIETARY_SUPPLEMENT|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
219394460|NCT05058131|DIETARY_SUPPLEMENT|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
219394461|NCT00090285|BIOLOGICAL|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
219394462|NCT00090285|BIOLOGICAL|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
219394463|NCT00907478|BIOLOGICAL|romiplostim|Romiplostim administered by subcutaneous injection
219394464|NCT03053089|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
219394465|NCT00002410|DRUG|Indinavir sulfate|
219394466|NCT00002410|DRUG|Lamivudine|
219394467|NCT00002410|DRUG|Zidovudine|
219394468|NCT01362712|RADIATION|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
219394469|NCT03285217|DIETARY_SUPPLEMENT|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
219394470|NCT03285217|DIETARY_SUPPLEMENT|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
219394471|NCT06517849|BEHAVIORAL|Monetary Incentive for Take-Up of Cognitive Behavioral Therapy|Both treatment arms will be offered a monetary incentive (in form of a retail gift card) for undergoing a certain number of CBT sessions.
219394472|NCT05874986|OTHER|Resistance training|12-week resistance training intervention
219394473|NCT06424366|BEHAVIORAL|Ballet for All Kids|The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.
219394474|NCT05427851|PROCEDURE|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
219394475|NCT05427851|DEVICE|Diode laser - fonalaser|diode laser beam application
219394476|NCT02639182|DRUG|AGS-16C3F|Intravenous (IV) infusion
219394477|NCT02639182|DRUG|Axitinib|Oral
219559609|NCT03256994|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
219559610|NCT03256994|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
219394478|NCT06038474|DRUG|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
219559611|NCT04837079|OTHER|Clinical observational study|Clinical observational study
219559612|NCT01355354|DRUG|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
219559613|NCT01355354|DRUG|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
219559614|NCT06280417|DEVICE|Unreamed intramedullary tibial nail|Fixation of type IIIa tibial fractures by unreamed IMN
219559615|NCT03303417|DIAGNOSTIC_TEST|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
219559616|NCT03303417|OTHER|Kiwifruit|Kiwifruit
219559617|NCT03303417|OTHER|calorie-matched sugar drink|calorie-matched sugar drink
219559618|NCT01578317|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
219559619|NCT01578317|BIOLOGICAL|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
219559620|NCT04587258|BEHAVIORAL|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
219559621|NCT05752565|DEVICE|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
219559622|NCT02205502|DRUG|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
219559623|NCT02205502|DRUG|Normal saline|
219559624|NCT00498316|PROCEDURE|Cord Blood Infusion|Cord blood transplantation performed on day 0.
219559625|NCT00498316|DRUG|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
219559626|NCT00498316|DRUG|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
219559627|NCT00498316|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
219559628|NCT00498316|OTHER|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
219559629|NCT00498316|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
219191798|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
219191799|NCT06454175|BIOLOGICAL|Placebo|immunization schedule：Month 0，Month 2，Month 6
219191800|NCT06454175|BIOLOGICAL|15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)|immunization schedule：Month 0，Month 2，Month 6
219394479|NCT04454996|DRUG|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
219394480|NCT04454996|DRUG|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
219394481|NCT04454996|DRUG|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
219394482|NCT04454996|DRUG|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
219559630|NCT00498316|DRUG|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
219559631|NCT00498316|RADIATION|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
219559632|NCT00498316|DRUG|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
219559633|NCT00498316|DRUG|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
219559634|NCT00498316|DRUG|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
219559635|NCT00498316|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is \> 2.5 x 109/L.
219559636|NCT03690089|DRUG|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
219559637|NCT03690089|OTHER|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
219191801|NCT05223088|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
219559638|NCT01545739|DEVICE|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
219559639|NCT01848210|DRUG|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
219559640|NCT01848210|DRUG|Placebo|Coumarin + troxerutin placebo-matching tablets
219559641|NCT01710605|BIOLOGICAL|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
219559642|NCT03474328|DEVICE|AlcoChange|Smartphone app and breathalyser
219559643|NCT04970498|DIAGNOSTIC_TEST|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
219559644|NCT04970498|DIAGNOSTIC_TEST|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
219191802|NCT05223088|DRUG|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
219559645|NCT05338853|OTHER|Gongs mobilization|to deal adhesive capsulitis
219559646|NCT05338853|OTHER|scapular mobilization|scapular mobilization
219559647|NCT02992457|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily.
219559648|NCT02992457|DRUG|Ribavirin|Ribavirin 1000-1200 mg daily
219559649|NCT02992457|DRUG|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
219559650|NCT02992457|DRUG|Simeprevir|Olysio once daily.
219559651|NCT02992457|DRUG|Daclatasvir|Dakla once daily for three months.
219559652|NCT02992457|DRUG|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
219559653|NCT02992457|DRUG|Sofosbuvir and Ledipasvir|Once daily for three months
219559654|NCT02992457|DRUG|Salvage therapy|three months in repeated treatment failure
219559655|NCT02976051|RADIATION|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
219559656|NCT01089530|BEHAVIORAL|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
219559657|NCT01053091|BEHAVIORAL|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
219559658|NCT06678230|DRUG|Anlotinib|Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
219559659|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
219559660|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
219191803|NCT05223088|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
219559661|NCT02093871|DEVICE|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
219559662|NCT01247844|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
219559663|NCT05810857|DIAGNOSTIC_TEST|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
219559664|NCT05810857|DIAGNOSTIC_TEST|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
219191804|NCT05223088|DRUG|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
219559665|NCT01128868|DEVICE|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
219559666|NCT01128868|DEVICE|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
219559667|NCT01374724|BEHAVIORAL|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
219394483|NCT06539897|BEHAVIORAL|Sexual education|These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
219394484|NCT06120478|OTHER|observe|observational study
219394485|NCT04286191|COMBINATION_PRODUCT|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
219394486|NCT04286191|COMBINATION_PRODUCT|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
219394487|NCT00775359|DRUG|Fenofibrate 160 mg tablets|
219394488|NCT04756635|OTHER|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
219559668|NCT01374724|BEHAVIORAL|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
219394489|NCT03640143|OTHER|venous blood lead|data about ve,nous blood lead
219559669|NCT01374724|BEHAVIORAL|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
219394490|NCT03585374|COMBINATION_PRODUCT|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
219559670|NCT01374724|BEHAVIORAL|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
219559671|NCT02041858|OTHER|Altered Alarm Settings|An altered set of alarm parameter settings
219559672|NCT01561924|DRUG|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
219559673|NCT01787110|DRUG|Oxygen|see arm description
219559674|NCT05268419|DRUG|Ethanol|Inhalation of 35%-ethanol spray
219559675|NCT05268419|DRUG|Water Distilled|Inhalation of water distilled spray
219559676|NCT01142141|OTHER|manual therapy, kinesiotherapy|
219559677|NCT02333188|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219754355|NCT07158957|OTHER|knowledge|"-knowledge on pain in general and specifically pelvic girdle pain Pregnant women who in addition to usual care get our model WOMENinMOTION on a digital platform with self-directed content areas modules and linked tasks to promote physical activity and function by reducing concerns, pain, and building confidence for physical activity and realistic expectations.~When women consider the digital platform insufficient, they are referred to physiotherapy at clinic for physiotherapeutically individually coached content of WIM"
219754356|NCT07158957|BEHAVIORAL|motivation for behavioral change|motivation to be physically active
219559678|NCT02333188|DRUG|Leucovorin Calcium|Given IV
219559679|NCT02333188|DRUG|Irinotecan Hydrochloride|Given IV
219559680|NCT02333188|DRUG|Fluorouracil|Given IV
219559681|NCT02333188|OTHER|Laboratory Biomarker Analysis|Correlative studies
219559682|NCT03895619|OTHER|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
219559683|NCT04540718|OTHER|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
219559684|NCT04540718|OTHER|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
219559685|NCT00879541|BIOLOGICAL|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
219559686|NCT00879541|BIOLOGICAL|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
219559687|NCT00879541|BIOLOGICAL|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
219559688|NCT05995379|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
219559689|NCT00784979|DRUG|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
219559690|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
219559691|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
219394491|NCT03585374|DRUG|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
219394492|NCT03585374|DRUG|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
219559692|NCT04954690|BEHAVIORAL|Usual Care|Usual Care
219559693|NCT00004441|DRUG|tauroursodeoxycholic acid|
219559694|NCT00004441|DRUG|ursodiol|
219559695|NCT05484141|OTHER|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
219559696|NCT05484141|OTHER|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
219559697|NCT01198249|DRUG|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
219559698|NCT05373641|OTHER|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
219559699|NCT05373641|OTHER|Pain documentation audit|Monthly pain documentation audit
219559700|NCT02073136|OTHER|Diet with phosphate containing additives|
219559701|NCT02073136|OTHER|Diet without phosphate containing additives|
219559702|NCT03215459|DEVICE|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
219559703|NCT04747132|OTHER|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
219559704|NCT05547906|DRUG|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
219559705|NCT03747185|OTHER|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
219559706|NCT03747185|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
219559707|NCT04773509|PROCEDURE|Paravertebral block|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides.
219559708|NCT05436132|BEHAVIORAL|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
219559709|NCT05436132|BEHAVIORAL|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
219559710|NCT02430207|PROCEDURE|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
219559711|NCT02430207|PROCEDURE|temporary pacing subclavian vein|
219559712|NCT04292015|DIAGNOSTIC_TEST|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
219559713|NCT06009588|DEVICE|self-expandable valves|patients undergoing TAVR use self-expandable valves
219559714|NCT06009588|DEVICE|balloon-expandable valves|patients undergoing TAVR use balloon-expandable valves
219559715|NCT03731728|BEHAVIORAL|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
219754357|NCT07160595|OTHER|Early management of postoperative pain at 3 months detected using sms|During this period, patients with persistent post-operative pain, identified through SMS screening, will receive early treatment starting at 3 months.
219191805|NCT05456581|BEHAVIORAL|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
219394493|NCT03585374|DRUG|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
219559716|NCT03731728|BEHAVIORAL|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
219559717|NCT02885428|DEVICE|echography|
219559718|NCT03698487|OTHER|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
219394494|NCT02976493|OTHER|No Intervention|No Intervention
219394495|NCT03666260|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
219394496|NCT03666260|PROCEDURE|femoral block|femoral block with echography
219394497|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
219559719|NCT03727698|DEVICE|MR Linac|MR guided radiotherapy treatment
219394498|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
219394499|NCT02445378|PROCEDURE|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
219394500|NCT02445378|OTHER|Placebo|Undergo placebo intervention using rose water
219394501|NCT02445378|OTHER|Questionnaire Administration|Ancillary studies
219394502|NCT05907967|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
219394503|NCT06068725|BEHAVIORAL|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
219394504|NCT01372878|DEVICE|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
219394505|NCT01372878|PROCEDURE|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
219394506|NCT05911958|DRUG|SHR-A1811 for injection|SHR-A1811 for injection
219559720|NCT05919745|DRUG|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
219559721|NCT05919745|DRUG|Placebo|Preoperative delivery of placebo per os.
219559722|NCT05919745|DRUG|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
219559723|NCT06210945|DRUG|10 mg/kg CM-101|10 mg/kg CM-101
219559724|NCT06210945|DRUG|Placebo|Placebo
219559725|NCT05352477|OTHER|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
219559726|NCT05352477|OTHER|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
219559727|NCT04783545|DRUG|VLX-1005|VLX-1005 infusion
219191806|NCT05456581|BEHAVIORAL|Control Training|The task will be performed in the control group without the visible scotoma.
219559728|NCT04783545|DRUG|Placebo|Placebo infusion
219559729|NCT03523845|OTHER|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
219559730|NCT00894933|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
219559731|NCT05433259|DEVICE|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
219559732|NCT00876356|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
219559733|NCT00876356|DIETARY_SUPPLEMENT|Olive oil|Olive oil 4.5g/day x 12 weeks
219394507|NCT05588895|OTHER|Notification|"For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician."
219394508|NCT00002445|DRUG|IM862|
219559734|NCT02620059|BEHAVIORAL|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
219394509|NCT03670082|DRUG|Lu AF35700|20 mg Lu AF35700 single oral dose
219559735|NCT03886649|DRUG|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
219559736|NCT03886649|DRUG|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
219559737|NCT01359579|DRUG|varespladib methyl|Single oral 500 mg dose
219559738|NCT02812771|DRUG|Efinaconazole|Solution
219559739|NCT04767087|DRUG|Honey|0.5 gm/Kg/day honey
219559740|NCT04767087|DRUG|Nigella sativa seed|40 mg/Kg/day
219559741|NCT04767087|OTHER|Placebo|empty capsule with sugar water
219559742|NCT05240092|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
219559743|NCT00781092|OTHER|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
219559744|NCT00781092|OTHER|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
219559745|NCT05443919|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
219559746|NCT01477099|DEVICE|Toothbrushing with a manual brush|Toothbrushing with a manual brush
219559747|NCT01503333|BEHAVIORAL|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
219559748|NCT01247792|BEHAVIORAL|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
219559749|NCT00468208|DRUG|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
219559750|NCT03806335|OTHER|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
219191807|NCT06329518|DRUG|Rezafungin|After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
219394510|NCT03670082|DRUG|Lu AF35700 iv|100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
219559751|NCT03806335|OTHER|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
219559752|NCT03806335|OTHER|General anesthesia|All patients will receive general anesthesia prior to infiltration
219559753|NCT04759079|DEVICE|Acupuncture Needles|Acupuncture Needles placement at the PC6 in association to anti-emetic medication
219559754|NCT04759079|DRUG|Antiemetic Drug|Administration of Anti-emetic medication without acupuncture
219559755|NCT04372784|DEVICE|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
219754358|NCT07159932|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information
219754359|NCT07159802|PROCEDURE|Papillary reconstruction|"This study will be conducted to compare the effectiveness of three papillary reconstruction techniques: modified Beagle's technique, injection of albumin PRF, and injection of Hyaluronic Acid filler.~Primary outcome: volumetric assessment of papilla regeneration. Secondary outcome: improvement of pink esthetic score."
219754360|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
219754361|NCT06233448|DEVICE|Indirect cardiometry|Measurements of thorathic fluid content
219754362|NCT06275516|DEVICE|multi-sensory stimulation immersive VR+ treadmill training|Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group
219754363|NCT06275516|DEVICE|treadmill training|Only treadmill training in treadmill training group
219754364|NCT04119037|PROCEDURE|Cordotomy|Undergo cordotomy
219394511|NCT02385123|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
219394512|NCT01070303|BIOLOGICAL|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
219394513|NCT01549847|DRUG|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
219394514|NCT01549847|DRUG|Placebo|Placebo PO BID
219394515|NCT02584569|DRUG|TAK-915|TAK-915 oral suspension
219394516|NCT06012604|BIOLOGICAL|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
219394517|NCT01355991|DRUG|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
219394518|NCT01355991|DRUG|Salmeterol|50mcg inhalation twice daily for two weeks
219394519|NCT01782183|DEVICE|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
219394520|NCT02345434|OTHER|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
219394521|NCT03121352|DRUG|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
219394522|NCT03121352|DRUG|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
219394523|NCT03121352|DRUG|Pembrolizumab|200 mg IV every 21 days
219394524|NCT03789773|DEVICE|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
219394525|NCT04718987|RADIATION|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
219394526|NCT05221450|PROCEDURE|primary endodontic treatment|
219394527|NCT03791983|OTHER|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
219394528|NCT03791983|OTHER|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
219394529|NCT02367170|PROCEDURE|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
219394530|NCT02367170|DRUG|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
219394531|NCT02367170|PROCEDURE|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
219394532|NCT02367170|DEVICE|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
219754365|NCT04119037|DRUG|Morphine|Given via injection
219754366|NCT04119037|OTHER|Questionnaire Administration|Ancillary studies
219754367|NCT04119037|PROCEDURE|Sham Intervention|Undergo fake cordotomy
219754368|NCT05763563|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
219754369|NCT05763563|BEHAVIORAL|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
219191808|NCT05862129|PROCEDURE|surgical operation|Radical operation for the perianal abscess
219191809|NCT03042754|DIAGNOSTIC_TEST|XpertMTB/RIF|
219394533|NCT02367170|DEVICE|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
219394534|NCT02367170|PROCEDURE|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
219188980|NCT06372860|BEHAVIORAL|Breastfeeding|"Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants."
219188981|NCT06372860|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
219188982|NCT03720613|DRUG|Naldemedine|0.2 mg tablet once a day at any time with or without food
219188983|NCT03720613|DRUG|Lubiprostone|0.024 mg twice a day \[adjust dose based on liver function\]
219188984|NCT03720613|DRUG|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
219188985|NCT03756649|PROCEDURE|Blood Draw|50 ml will be collected
219188986|NCT03756649|PROCEDURE|Urine Collection|50 ml will be collected
219188987|NCT03756649|PROCEDURE|Stool Collection|Three 25 ml tubes will be collected
219188988|NCT03095313|OTHER|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
219191810|NCT03535545|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
219191811|NCT03535545|DIAGNOSTIC_TEST|PET Imaging|All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
219191812|NCT02361216|DRUG|Ingenol Mebutate|
219191813|NCT02361216|OTHER|Vehicle|Vehicle gel
219394535|NCT02367170|OTHER|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
219394536|NCT00032019|BIOLOGICAL|filgrastim|Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
219394537|NCT00032019|BIOLOGICAL|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
219394538|NCT00032019|DRUG|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
219394539|NCT00032019|DRUG|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
219394540|NCT00032019|DRUG|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
219394541|NCT00032019|DRUG|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
219394542|NCT00032019|DRUG|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
219394543|NCT01673724|DRUG|pramipexole|pramipexole
219394544|NCT01673724|DRUG|Bromocriptine|bromocriptine
219394545|NCT04504032|DRUG|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
219394546|NCT04504032|DRUG|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
219394547|NCT06121557|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
219394548|NCT06121557|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
219394549|NCT06121557|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
219394550|NCT06121557|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
219394551|NCT06121557|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
219559756|NCT04372784|PROCEDURE|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
219559757|NCT03068884|DEVICE|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
219559758|NCT03068884|DIETARY_SUPPLEMENT|L-Tyrosine|Administration of 2 grams tyrosine
219559759|NCT03068884|DEVICE|Transcranial direct current stimulation (sham)|Sham tDCS
219188989|NCT06103136|DEVICE|Laparoscopic surgery using the Maestro Platform|"Patients scheduled for laparoscopic surgery will be operated on as per standard of care, using standard port, surgical table and instrument placements (following local applicable guidelines), and off-the-shelf surgical equipment. Standard of care surgical technique following local applicable guidelines will be used.~The Maestro Platform may be used to position and hold the scope as well as the retractor in the locations determined by the surgeon during the procedure, with the ability to revert at any time to standard of care (manual minimally invasive surgery) without the usage of the Maestro Platform, or to convert to open surgery."
219559760|NCT03068884|DIETARY_SUPPLEMENT|Cellulose (placebo)|Administration of 2 grams cellulose
219559761|NCT02451306|DRUG|Quetiapine|See information in arm description.
219559762|NCT02451306|DRUG|Placebo|See information in arm description.
219559763|NCT03838341|DEVICE|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
219559764|NCT03838341|DRUG|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
219559765|NCT00930241|DRUG|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
219188990|NCT06823336|OTHER|Intervention|Participants will be encouraged to engage in independent exercise twice a week for 30 minutes. They will be randomly assigned to a peer-mentor, with whom they will engage in on-on-one exercise once a week for 30 minutes. Between sessions, they will engage in virtual communication with each other for about 30 minutes each week. Each participant-mentor duo will continue this protocol for 6-weeks.
219188991|NCT06823336|OTHER|Control|Participants will be encouraged to engage in exercise three times a week for thirty minutes, over a span of 6-weeks.
219188992|NCT03862170|DRUG|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
219188993|NCT03862170|DRUG|Cefazolin|
219559766|NCT00930241|DRUG|Prograf®|Prograf® (two daily doses of Tacrolimus)
219188994|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
219188995|NCT06379971|DRUG|Placebo|Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
219559767|NCT05425342|DEVICE|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
219559768|NCT03482206|DEVICE|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
219559769|NCT01967901|BEHAVIORAL|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
219001476|NCT02959307|DEVICE|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
219191814|NCT02939612|BEHAVIORAL|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
219191815|NCT02897427|OTHER|Biomarker Analysis|Complete HPV testing
219191816|NCT02897427|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral gargle samples
219559770|NCT01235715|DRUG|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
219559771|NCT02994394|DRUG|OPC-41061|
219559772|NCT03619876|DRUG|Abatacept|125 MG/ML subcutaneous injections
219559773|NCT03619876|DRUG|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
219559774|NCT02203617|BEHAVIORAL|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
219559775|NCT02203617|BEHAVIORAL|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
219559776|NCT04599621|DIAGNOSTIC_TEST|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
219559777|NCT04244799|BEHAVIORAL|Behavioral nudges|"Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
219188996|NCT06379971|DRUG|Choline|Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
219188997|NCT04009447|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
219188998|NCT02921893|DRUG|Dexamethasone|Given PO
219188999|NCT02921893|DRUG|Ixazomib Citrate|Given PO
219189000|NCT02921893|DRUG|Lenalidomide|Given PO
219189001|NCT02921893|OTHER|Questionnaire Administration|Ancillary studies
219189002|NCT05944783|DRUG|Dasatinib 100 MG|single dose of 100 mg Dasatinib tablets
219189003|NCT06724380|OTHER|unknown health risk situation|a unknown health risk situation detected at anestesiology consult
219189004|NCT06822868|DRUG|CAR T cells|chimeric antigen receptor T cells
219189005|NCT05442359|DRUG|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
219189006|NCT05442359|DEVICE|stent|Applied as a palatal stent for palatal wound
219394552|NCT06121557|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
219394553|NCT06121557|DRUG|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
219394554|NCT05503134|BIOLOGICAL|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
219559778|NCT04244799|BEHAVIORAL|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
219754370|NCT05763563|BEHAVIORAL|Optional Aerobic Exercise Procedure|"Participants will be encouraged to complete 3 tele-supervised aerobic training sessions per week, each lasting 30 minutes. Participants will be encouraged to achieve moderate exercise intensity based on heart rate visualized on PM5 monitors. Participants will report their heart rates every 3-5 minutes during an exercise session and be encouraged to adjust pedaling cadence or flywheel resistance accordingly to achieve moderate intensity.~Exercise trainers will access logged heart rate ranges (64-76% of age-predicted maximum heart rate) to provide individualized and appropriate guidance during sessions.~Participants who are untrained or otherwise uncomfortable maintaining moderate aerobic intensity for 30 minutes will be encouraged to gradually increase the duration and intensity of their sessions until they are meeting these guidelines."
219754371|NCT05763563|RADIATION|Optional In-Person Exercise Sessions|Participants who prefer to complete RT and/or aerobic exercise sessions in-person will be allowed to do so. These sessions will be conducted in the Moffitt Promotes Resilience in Oncology Via Exercise (MPROVE) Laboratory using the same equipment participants would use for Zoom sessions, with guidance and supervision from certified exercise trainers.
219189007|NCT05147116|OTHER|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
219189008|NCT06821438|PROCEDURE|Laparoscopy|Endoscopy
219189009|NCT05473676|DEVICE|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
219394555|NCT01839188|BIOLOGICAL|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
219754372|NCT06117930|OTHER|Non-Interventional Study|Non-interventional study
219754373|NCT06035042|PROCEDURE|Scheduled surgery|All subjects will be exposed to surgery
219189010|NCT03127631|BEHAVIORAL|Nutrition|Standardized advice on healthy diet practices.
219189011|NCT03127631|BEHAVIORAL|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
219189012|NCT03127631|BEHAVIORAL|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
219189013|NCT03127631|DRUG|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
219189014|NCT03127631|DRUG|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
219191817|NCT02897427|PROCEDURE|Ultrasonography|Undergo transcervical ultrasonography
219191818|NCT05342493|DRUG|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
219394556|NCT01839188|BIOLOGICAL|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
219394557|NCT01839188|BIOLOGICAL|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
219394558|NCT01839188|BIOLOGICAL|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
219394559|NCT01839188|BIOLOGICAL|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
219394560|NCT05570916|DEVICE|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
219394561|NCT05570916|DEVICE|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
219394562|NCT04420455|DRUG|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
219394563|NCT01615003|DRUG|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
219394564|NCT01615003|DRUG|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
219394565|NCT02734550|OTHER|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
219394566|NCT02734550|OTHER|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
219394567|NCT03418246|DEVICE|GIC|tooth colored filling
219394568|NCT03418246|DEVICE|Biodentine|White filling -Biodentine
219394569|NCT00006246|DRUG|busulfan|
219394570|NCT04693247|DEVICE|EQ103|Refraction device
219559779|NCT06616961|DRUG|Semaglutide Pen|"In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability."
219559780|NCT03331159|DEVICE|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
219559781|NCT03331159|DEVICE|Homologous Bone|Cage was filled with homologous bone
219559782|NCT04868565|DRUG|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
219559783|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
219559784|NCT05589337|BEHAVIORAL|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
219394571|NCT05652192|RADIATION|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
219394572|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
219394573|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
219559785|NCT05589337|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
219559786|NCT06829784|DRUG|TQC2731 injection|TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
219559787|NCT06829784|DRUG|Placebo|Placebo without drug substance.
219559788|NCT05375669|DEVICE|ISIS IOM System|"The constant-current TES stimulators will be used in this study with a high-precision oscilloscope. The calibration will assess 5-pulse trains with a 4 ms ISI and 100 mA output across a 1000 Ω resistor at 250, 500, and 1000 µs D. Measurements will include actual I and D of each pulse, and actual ISI.~Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement."
219559789|NCT06467825|DRUG|Potassium Supplement|Participants will be given a potassium supplement that will help prevent low blood potassium levels.
219559790|NCT06467825|DRUG|Furosemide 20 MG|Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
219754374|NCT02286609|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
219754375|NCT01131897|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
219754376|NCT06786572|OTHER|Mindfulness training|Brief mindfulness training focused on management of unwanted internal sensations
219754377|NCT06786572|BEHAVIORAL|Interoceptive exposure|Cognitive behavioral therapy focused in interoceptive exposure to unwanted internal sensations
219394574|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
219394575|NCT02439762|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
219559791|NCT06467825|DEVICE|Compression Garment|From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
219189015|NCT06823596|DRUG|Efavirenz 600mg|"Efavirenz induces pyroptosis of HIV expressing cells via the CARD8 inflammasome. In contrast to most ART drugs, and in addition to its anti-retroviral effect, EFV also induces intracellular Gag-Pol dimerization and premature HIV protease activation, causing cleavage of the inflammasome protein CARD8. CARD8 activation results in the production of effector molecules that rapidly kill virus-infected cells by pyroptosis. This effect of EFV has been called TACK or T cell activator of cell killing. We aim to harness this effect to reduce residual nonsuppresible viremia (NSV) in people on stable antiretroviral therapy (ART). Participants in this study will receive EFV in addition to their stable ART regimen for two months, during and after which we will monitor plasma HIV RNA and markers of viral persistence and immune activation."
219394576|NCT02439762|BEHAVIORAL|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
219394577|NCT01842464|PROCEDURE|Anterior Sacro-Spinous|Anterior Sacro-Spinous
219394578|NCT01220752|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
219394579|NCT05197972|OTHER|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
219394580|NCT01198444|DRUG|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
219394581|NCT03341468|DEVICE|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
219394582|NCT01450930|DRUG|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
219394583|NCT01450930|DRUG|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
219394584|NCT00729118|DRUG|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
219394585|NCT00729118|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
219394586|NCT03340077|OTHER|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
219394587|NCT03340077|OTHER|Standard of Care|Pharmacist review of ART medications
219394588|NCT05279469|OTHER|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
219394589|NCT00114114|DRUG|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
219394590|NCT00114114|DRUG|Goserelin acetate|3.6 gms sc every 4 weeks
219394591|NCT03340493|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
219559792|NCT06528756|PROCEDURE|shockwave therapy|ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.
219189016|NCT04696757|DRUG|Capecitabine|Capecitabine without surgery
219189017|NCT03843190|BEHAVIORAL|Take of Pounds Sensibly (TOPS)|Dietician-facilitated classes
219394592|NCT03081325|PROCEDURE|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
219559793|NCT06528756|PROCEDURE|Barbotage|"US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way."
219559794|NCT04841915|DIETARY_SUPPLEMENT|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
219559795|NCT04841915|BEHAVIORAL|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
219559796|NCT04841915|BEHAVIORAL|Weight loss|4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
219189018|NCT03843190|OTHER|Waitlist Control|At end of study, offered peer-led classes to attend.
219754378|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
219394593|NCT00957346|DRUG|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
219394594|NCT00957346|DRUG|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
219394595|NCT00087204|DRUG|becatecarin|Given IV
219394596|NCT00087204|OTHER|laboratory biomarker analysis|Correlative studies
219394597|NCT02125929|PROCEDURE|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
219394598|NCT02125929|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
219394599|NCT02125929|PROCEDURE|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
219394600|NCT01205490|OTHER|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
219394601|NCT05286398|PROCEDURE|Palatoplasty|Surgical closure of palatal defect
219394602|NCT05286398|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch
219394603|NCT01660841|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
219394604|NCT06344520|BEHAVIORAL|pektoralis minor shortnes|One factor that is effective in acceleration during swimming is the force of the arm pulling the water. While the pectoralis minor muscle pulls the crocoid process forward, it pulls its posterolateral corner down, which helps the latismus dorsi to make an extension movement and the lower trapezius to depress the scapula. When the pectoralis minor muscle is short, it prevents maximum reach in the arm because its full function cannot be revealed. It is thought that depression of the scapula will directly affect acceleration in swimming, as it increases the backward thrust of the arm.
219394605|NCT06344520|BEHAVIORAL|Group in which the Pectoralis Minor stretching exercise was performed in a sham manner|In most cases, exercise practices also affect the person psychologically. In order to ignore the psychological effects of the exercises, they were made to perform exercises that were similar to pectoralis minor stretching exercises but did not activate the muscle
219394606|NCT06344520|BEHAVIORAL|The group in which Pectoralis Minor stretching exercise was not applied|The Control Group was not given any exercise and they continued to do their own training.
219394607|NCT05452161|OTHER|Control group|All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).
219394608|NCT05452161|OTHER|Intervention group A|The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.
219394609|NCT05452161|OTHER|Intervention group B|"In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management."
219394610|NCT05367804|DIETARY_SUPPLEMENT|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
219394611|NCT02221739|DRUG|Ipilimumab|
219394612|NCT02221739|RADIATION|Radiotherapy (IMRT or 3-D CRT)|
219394613|NCT01883245|DEVICE|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
219559797|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
219559798|NCT02370199|DEVICE|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
219559799|NCT02370199|DRUG|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
219559800|NCT05269316|DRUG|IMP9064|IMP9064 Monotherapy administered for 21 days
219559801|NCT06800755|DEVICE|Dexeryl (RL3020-DP0364)|Product application on body (head excluded)
219559802|NCT05615376|DEVICE|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
219559803|NCT05615376|DEVICE|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
219394614|NCT01883245|DEVICE|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
219394615|NCT05743023|BEHAVIORAL|Ayurvedic lifestyle protocol|"Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique."
219394616|NCT02487745|BEHAVIORAL|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
219394617|NCT02487745|BEHAVIORAL|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
219394618|NCT00114205|DRUG|docetaxel|
219559804|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
219559805|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
219559806|NCT03977194|DRUG|Carboplatin|AUC 6 every 4 weeks
219559807|NCT03977194|DRUG|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
219559808|NCT03977194|DRUG|Atezolizumab|1200 mg every 3 weeks
219559809|NCT04467333|OTHER|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
219559810|NCT01104181|DEVICE|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
219559811|NCT00674908|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
219559812|NCT00674908|BIOLOGICAL|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
219559813|NCT03385135|DRUG|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
219559814|NCT03328390|OTHER|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
219559815|NCT03328390|OTHER|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
219559816|NCT01790308|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
219559817|NCT01790308|DRUG|Liraglutide|CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
219559818|NCT04077125|DRUG|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
219559819|NCT01388257|PROCEDURE|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
219559820|NCT01388257|PROCEDURE|Simple seton drain removal|Patients are simply followed after seton drain removal.
219559821|NCT00897923|PROCEDURE|radionuclide imaging|
219559822|NCT00897923|RADIATION|indium In 111-labeled autologous peripheral blood mononuclear cells|
219559823|NCT00897923|RADIATION|indium In 111-labeled autologous polymorphonuclear leukocytes|
219559824|NCT03599921|BEHAVIORAL|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
219559825|NCT03599921|BEHAVIORAL|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
219559826|NCT03599921|BEHAVIORAL|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
219754379|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
219189019|NCT06823830|DRUG|Jinfeng Pill|Jinfeng pills were compared with Diane-35 group and Jinfeng pills combined with Diane-35 group were compared with Diane-35 alone.
219189020|NCT06547541|BEHAVIORAL|Exercise|A body weight based resistance training.
219189021|NCT06822634|OTHER|Observational single centre feasibility study|Patients scheduled to undergo standard of care neo. adjuvant radiotherapy prior to surgery.
219189022|NCT06701136|DRUG|Sudapyridine|In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.
219189023|NCT06701136|DRUG|Itraconazole|In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.
219189024|NCT06701136|DRUG|Rifampin|In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
219189025|NCT05248191|BIOLOGICAL|Capsule fecal microbiota material (cap-FMT)|Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.
219394619|NCT00114205|PROCEDURE|therapeutic thoracoscopy|
219394620|NCT03988114|DRUG|Abemaciclib|Administered orally
219394621|NCT03988114|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
219394622|NCT04370249|OTHER|pulmonary ultrasound|pulmonary ultrasound on admission
219394623|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
219394624|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
219394625|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
219394626|NCT03452150|DRUG|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
219394627|NCT02461732|BEHAVIORAL|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
219394628|NCT02461732|BEHAVIORAL|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
219394629|NCT05436808|RADIATION|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
219394630|NCT01419366|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
219394631|NCT03873350|OTHER|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
219394632|NCT03873350|OTHER|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
219394633|NCT02844582|DRUG|Cabazitaxel|Given IV
219394634|NCT02844582|DRUG|Prednisone|Given PO
219394635|NCT00142103|DRUG|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
219394636|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
219394637|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
219394638|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
219394639|NCT00142103|DRUG|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
219394640|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
219394641|NCT05190575|DRUG|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
219394642|NCT00002089|DRUG|Azithromycin|
219394643|NCT04376346|BEHAVIORAL|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
219189026|NCT05248191|BIOLOGICAL|Colonoscopic fecal microbiota material (colo-FMT)|Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
219394644|NCT00443404|PROCEDURE|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
219189027|NCT04197336|DEVICE|Bariatric Embolization of Arteries with imaging visible Embolics|bariatric embolization will be performed using tiny (100-200 μm), radiopaque (visible on X-ray) beads (referred to as BTG-001933) in order to suppress the body's signals for feeling hungry, which we predict will lead to weight loss.
219189028|NCT06731413|DRUG|Reduced Dose of Chemotherapy and Immunotherapy|Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
219189029|NCT06817135|OTHER|scapular stabilization exercises|Cools exercise using the Thera-Band, including sidelying external rotation, side-lying forward flexion, prone horizontal abduction with external rotation, and prone extension exercises to promote lower trapezius and middle trapezius activity with minimal activation of the upper trapezius part.
219394645|NCT02974946|DEVICE|RenalGuard|
219394646|NCT02575313|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
219394647|NCT04039828|DRUG|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
219394648|NCT02157831|BIOLOGICAL|CP-870,893|
219394649|NCT02179307|BEHAVIORAL|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
219394650|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
219394651|NCT02634164|DIETARY_SUPPLEMENT|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
219394652|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
219394653|NCT02448901|DRUG|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
219394654|NCT05775692|DRUG|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
219394655|NCT02909296|PROCEDURE|Endoscopic drainage|
219394656|NCT03120403|PROCEDURE|intrathecal morphine|
219394657|NCT03561285|DIAGNOSTIC_TEST|antiphospholipid Abs|Laboratory test
219394658|NCT01985685|DRUG|Thiamine|200 mg IV thiamine
219394659|NCT01830452|PROCEDURE|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
219394660|NCT00615940|DRUG|WX-671|capsules taken per os once daily until progression or toxicity
219394661|NCT00615940|DRUG|placebo|capsule taken per os once daily until progression or toxicity
219394662|NCT00956475|BEHAVIORAL|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
219394663|NCT00956475|OTHER|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
219394664|NCT00956475|PROCEDURE|assessment of therapy complications|questionnaire via telephone
219394665|NCT00956475|PROCEDURE|fatigue assessment and management|questionnaire via telephone
219394666|NCT00956475|PROCEDURE|psychosocial assessment and care|questionnaire via telephone
219394667|NCT00956475|PROCEDURE|quality-of-life assessment|questionnaire via telephone
219394668|NCT03479879|DRUG|Estradiol|Estradiol
219394669|NCT03479879|DRUG|Placebo Oral Tablet|Placebo
219394670|NCT03479879|DRUG|Misoprostol|Misoprostol
219394671|NCT00931957|DRUG|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
219394672|NCT01364571|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
219394673|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219394674|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
219394675|NCT01364571|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
219394676|NCT01364571|PROCEDURE|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219394677|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
219189030|NCT06817135|OTHER|Muscle Energy Technique|Muscle Energy Technique for the 1.sternocleidomastoid 2. levator scapulae 3. upper trapezius 4. pectoralis major Through mild isometric contractions, it uses the intrinsic energy of a muscle to lengthen it and induce relaxation through autogenic inhibition.
219394678|NCT01364571|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
219394679|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219394680|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
219394681|NCT01364571|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
219394682|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219394683|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
219559827|NCT03599921|BEHAVIORAL|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
219559828|NCT00396630|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
219559829|NCT00396630|BIOLOGICAL|Placebo|Two-dose oral administration.
219559830|NCT00093730|DRUG|BMS-59926|
219394684|NCT06453447|DRUG|Prednisone|40 mg PO once daily for 14 days starting day of surgery
219001477|NCT04076176|DIETARY_SUPPLEMENT|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
219189031|NCT06817135|OTHER|Advice about the right the breastfeeding ergonomic.|The patients sit with their backs supported with pillows. Don't lean over the infant. Keep the arms supported and feet on the ground.
219394685|NCT06453447|DRUG|Placebo|Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
219394686|NCT05979090|BEHAVIORAL|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
219394687|NCT05248958|OTHER|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
219394688|NCT00675285|DRUG|montelukast sodium|one tablet 5 mg once/day for 4 weeks
219394689|NCT00675285|DRUG|placebo|one tablet 5 mg once/day for 4 weeks
219394690|NCT04343573|RADIATION|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
219394691|NCT04343573|RADIATION|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy \[RBE\] in 10 fractions)
219394692|NCT04343573|OTHER|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
219559831|NCT05869916|BEHAVIORAL|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
219559832|NCT04202705|DRUG|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
219559833|NCT06428162|OTHER|questionner|three sections questioner including: demographics, reported cases, unreported cases
219559834|NCT02327325|BEHAVIORAL|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
219559835|NCT02327325|BEHAVIORAL|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
219754380|NCT02107885|DRUG|DS-1971|6 subjects in each group will receive DS-1971.
219754381|NCT02107885|DRUG|placebo|2 subjects in each group will receive placebo.
219754382|NCT06101173|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
219754383|NCT06101173|BIOLOGICAL|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
219754384|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
219754385|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
219754386|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
219754387|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
219189032|NCT06512922|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
219559836|NCT01507233|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
219559837|NCT01507233|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
219559838|NCT01507207|PROCEDURE|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
219559839|NCT03105193|DRUG|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
219559840|NCT03105193|DRUG|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
219559841|NCT03105193|DRUG|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
219559842|NCT03105193|DRUG|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
219559843|NCT01617551|DRUG|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
219559844|NCT04776005|OTHER|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
219559845|NCT04212728|BIOLOGICAL|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
219559846|NCT04212728|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
219559847|NCT00357955|BEHAVIORAL|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
219559848|NCT00357955|BEHAVIORAL|Interactive Education|interactive lectures with hands-on learning
219559849|NCT00357955|BEHAVIORAL|Role modeling|learning from peers with similar disease and problems
219559850|NCT00357955|PROCEDURE|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
219559851|NCT01961258|OTHER|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
219559852|NCT02638519|OTHER|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
219189033|NCT06512922|DEVICE|placebo cognitive training|They received cognitive training tasks of fixed difficulty.
219189034|NCT06510998|BEHAVIORAL|isometric wall exercise|Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
219559853|NCT02638519|OTHER|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
219559854|NCT02638519|DRUG|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
219559855|NCT02638519|DEVICE|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
219754388|NCT01227785|DEVICE|INCEPTA ICD or CRT-D|
219754389|NCT05046626|OTHER|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
219754390|NCT00569933|BEHAVIORAL|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
219754391|NCT02147821|PROCEDURE|No Pleural Chest Tube|
219754392|NCT06633536|DRUG|Ravulizumab|open-label arm with ravulizumab administrated within the scope of routine clinical practice
219754393|NCT05456828|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
219394693|NCT04343573|OTHER|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
219394694|NCT05585385|DEVICE|Backward Walking Training|The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
219394695|NCT05585385|DEVICE|Balance Training|"Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training."
219394696|NCT05585385|OTHER|Conventional treatment|Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
219394697|NCT06180551|DIAGNOSTIC_TEST|DKK-3|DKK-3-Urine measurement
219394698|NCT01765712|PROCEDURE|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
219394699|NCT01765712|BIOLOGICAL|Platelet Rich Plasma|
219394700|NCT04086134|OTHER|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
219394701|NCT02406872|DRUG|Remimazolam Tosilate|IV pumping for anesthesia
219394702|NCT02406872|DRUG|Propofol|IV bolus for anesthesia
219394703|NCT05313919|DIAGNOSTIC_TEST|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines"
219394704|NCT04705298|DIETARY_SUPPLEMENT|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
219394705|NCT04705298|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
219394706|NCT05134298|DRUG|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
219394707|NCT03032887|BEHAVIORAL|voice prompts|voice prompts on disinfectant dispenser
219394708|NCT03032887|BEHAVIORAL|agitation|Education, reminders and optimising materials
219394709|NCT01004107|DEVICE|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
219394710|NCT01341509|PROCEDURE|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
219394711|NCT01341509|PROCEDURE|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
219394712|NCT01341509|PROCEDURE|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
219394713|NCT00002466|DRUG|cyclophosphamide|
219394714|NCT00002466|DRUG|doxorubicin hydrochloride|
219394715|NCT00002466|DRUG|etoposide|
219394716|NCT00002466|DRUG|ifosfamide|
219394717|NCT00002466|DRUG|vincristine sulfate|
219394718|NCT00002466|PROCEDURE|conventional surgery|
219394719|NCT00002466|RADIATION|radiation therapy|
219394720|NCT00221845|DRUG|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
219394721|NCT00221845|DRUG|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
219394722|NCT00221845|DRUG|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
219394723|NCT05441150|DRUG|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
219559856|NCT03300908|BEHAVIORAL|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
219559857|NCT03300908|BEHAVIORAL|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
219559858|NCT04398979|PROCEDURE|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
219559859|NCT04417647|DEVICE|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
219559860|NCT04417647|PROCEDURE|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
219394724|NCT05441150|DRUG|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
219394725|NCT01182129|DRUG|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
219394726|NCT01182129|DRUG|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
219394727|NCT00394914|DRUG|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
219394728|NCT00394914|DRUG|Placebo to Pleconaril|Placebo nasal suspension
219394729|NCT02379910|DRUG|AM1030-CREAM or placebo|
219559861|NCT01074645|DRUG|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
219559862|NCT03992547|OTHER|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
219559863|NCT04964674|BEHAVIORAL|Behavioral Measurement|Take measurements of behavioral performance
219394730|NCT00077233|DRUG|cetuximab|IV
219394731|NCT00077233|DRUG|5-FU|IV
219559864|NCT01280344|DRUG|Saline Solution for Injection|Intravenous (IV)
219559865|NCT01280344|DRUG|Ipamorelin|Intravenous (IV)
219559866|NCT06283836|DRUG|Dexmedetomidine|monitored anesthesia care (sedation)
219559867|NCT06283836|DRUG|Remifentanil|monitored anesthesia care (sedation)
219559868|NCT02389842|DRUG|Palbociclib + Taselisib / Pictilisib|
219559869|NCT00894842|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
219394732|NCT00077233|DRUG|irinotecan|IV
219559870|NCT00894842|DRUG|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
219559871|NCT03629106|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
219394733|NCT00077233|DRUG|leucovorin|IV
219394734|NCT00077233|DRUG|oxaliplatin|IV
219394735|NCT05916638|OTHER|blood sample|blood sample collection
219394736|NCT04706182|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
219394737|NCT04706182|PROCEDURE|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
219394738|NCT01499238|DEVICE|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
219394739|NCT01499238|DEVICE|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
219559872|NCT06490406|BEHAVIORAL|Multimodal intervention (communication and education simulations) for EG1|"In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices."
219394740|NCT04135781|DRUG|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
219394741|NCT04135781|DRUG|Tegafur|S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
219394742|NCT04135781|DRUG|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
219394743|NCT04135781|DRUG|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
219394744|NCT04337138|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
219394745|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
219394746|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
219394747|NCT02092415|DEVICE|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
219394748|NCT03095183|DEVICE|Grape flavored Puritan Junior tongue depressor|
219559873|NCT02996019|DRUG|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
219559874|NCT02996019|DEVICE|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
219559875|NCT02996019|DEVICE|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
219559876|NCT02347319|DRUG|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
219559877|NCT02347319|DRUG|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
219559878|NCT02347319|DRUG|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
219559879|NCT04492852|PROCEDURE|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
219559880|NCT04492852|PROCEDURE|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
219559881|NCT03239977|BEHAVIORAL|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
219559882|NCT03239977|BEHAVIORAL|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
219559883|NCT05505305|BEHAVIORAL|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
219559884|NCT05258851|DRUG|Ceftazidime-avibactam|Experimental
219394749|NCT03095183|DEVICE|Traditional unflavored Puritan Regular Tongue Depressor|
219394750|NCT06039254|DRUG|HRS-1780|Single dose in each arm
219394751|NCT02909166|DRUG|aliskiren|
219394752|NCT00879268|DEVICE|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
219394753|NCT00392444|DRUG|sunitinib malate|Given orally
219394754|NCT00387660|DRUG|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
219394755|NCT00387660|DRUG|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
219394756|NCT01786616|DRUG|Formoterol|
219394757|NCT05323552|PROCEDURE|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~* The anesthesia is general, the anesthetic products administered are identical,~* ventilation is ensured by the use of a laryngeal mask airway, without curare administered~* the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~* the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
219394758|NCT03689725|OTHER|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
219559885|NCT05258851|DRUG|Colistin|Control
219559886|NCT02861027|PROCEDURE|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
219394759|NCT05260931|DIAGNOSTIC_TEST|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
219394760|NCT04855721|DRUG|AUR101|Oral ROR-gamma inverse agonist
219559887|NCT02861027|PROCEDURE|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
219559888|NCT06495580|PROCEDURE|Optic Nerve Stimulation|Anterograde Stimulation of the Optic Neve.
219394761|NCT04855721|DRUG|Placebo|Placebo
219559889|NCT02176668|DRUG|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
219559890|NCT02176668|DRUG|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
219559891|NCT02176668|DRUG|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
219559892|NCT02176668|DRUG|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
219559893|NCT01454440|DRUG|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
219559894|NCT04443569|DRUG|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
219559895|NCT04443569|OTHER|Placebo patch|A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
219559896|NCT00996437|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
219559897|NCT00996437|DRUG|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
219559898|NCT00392457|DRUG|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
219559899|NCT00392457|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
219559900|NCT05041114|DEVICE|Motor Neuroprosthesis|Type of implantable brain computer interface
219559901|NCT01722955|OTHER|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
219394762|NCT04444700|DRUG|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
219559902|NCT01722955|OTHER|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
219559903|NCT04122781|DEVICE|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
219559904|NCT05178914|PROCEDURE|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
219559905|NCT01876238|OTHER|T-PAT|
219559906|NCT01876238|OTHER|Surveys|Pre-test and posttest surveys and questionnaires
219559907|NCT03715686|PROCEDURE|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
219559908|NCT02576717|DRUG|RPC1063|
219559909|NCT06416852|DRUG|18F-Alfatide Injection|A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
219559910|NCT06416852|DRUG|18F-FDG Injection|A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
219559911|NCT03655275|BIOLOGICAL|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
219559912|NCT03655275|BIOLOGICAL|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
219559913|NCT01755975|DRUG|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
219559914|NCT01755975|DRUG|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
219559915|NCT03081039|DRUG|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
219559916|NCT03081039|DRUG|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
219559917|NCT03081039|DRUG|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
219559918|NCT04413032|DEVICE|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
219559919|NCT05647707|DIETARY_SUPPLEMENT|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
219559920|NCT00006371|DRUG|aminoglutethimide|
219559921|NCT00006371|DRUG|ketoconazole|
219559922|NCT00006371|DRUG|therapeutic hydrocortisone|
219559923|NCT00399893|DRUG|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
219394763|NCT04914637|PROCEDURE|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
219394764|NCT04914637|PROCEDURE|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
219394765|NCT04914637|PROCEDURE|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
219394766|NCT00312377|DRUG|Docetaxel|infusion
219394767|NCT00312377|DRUG|Vandetanib|oral
219394768|NCT00872898|DRUG|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
219394769|NCT00872898|DRUG|Placebo|Placebo capsules, once daily, oral administration.
219394770|NCT00389077|DRUG|Perifosine|Perifosine 50 mg tablets
219394771|NCT03151525|DRUG|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
219394772|NCT03151525|DRUG|Infliximab|IFX treatment for maintenance of remission
219394773|NCT05064345|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
219394774|NCT05064345|DRUG|Placebo|Palcebo
219394775|NCT03709433|BEHAVIORAL|ACT groups and mobile app|See arm description.
219394776|NCT04095910|BEHAVIORAL|Planet Nutrition program|"1. \- Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. \- Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. \- Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
219394777|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
219394778|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
219394779|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
219394780|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
219394781|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
219394782|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
219394783|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
219394784|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
219394785|NCT01343719|DRUG|BI 661051|low dose tablet
219394786|NCT01343719|DRUG|Placebo|solution for administration
219394787|NCT01343719|DRUG|BI 661051|medium dose tablet
219394788|NCT02868502|DEVICE|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
219394789|NCT02868502|DEVICE|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
219394790|NCT02868502|DEVICE|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
219394791|NCT02868502|DEVICE|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
219394792|NCT01583192|PROCEDURE|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
219394793|NCT05661565|OTHER|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
219394794|NCT00447213|DRUG|Insulin glargine|Patient specific, injected, daily, 24 weeks
219394795|NCT00447213|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
219394796|NCT00447213|DRUG|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
219394797|NCT04792138|DIAGNOSTIC_TEST|VERDICT MRI|Advanced Diffusion Model
219394798|NCT04792138|DIAGNOSTIC_TEST|Luminal Index Imaging|Advanced T2 mapping
219394799|NCT03578354|DRUG|4-aminopyridine|an oral drug to be swallowed
219394800|NCT03578354|DRUG|Atenolol|an oral drug to be swallowed
219394801|NCT03578354|OTHER|Placebo|a masked placebo to be swallowed
219394802|NCT05665985|DRUG|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
219559924|NCT00399893|DRUG|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
219559925|NCT01205893|DEVICE|Neovasc Reducer|Implantation of the Reducer
219559926|NCT01205893|DEVICE|Control|Control - No device implanted
219559927|NCT03164109|DRUG|GC4419 IV|50mg infused IV over 15 minutes
219394803|NCT03760380|DEVICE|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
219394804|NCT03760380|DEVICE|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
219394805|NCT03760380|DEVICE|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
219394806|NCT03760380|DEVICE|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
219394807|NCT00044044|DRUG|Lurasidone 20 mg|Lurasidone 20mg/day tablets
219394808|NCT00044044|DRUG|Lurasidone 40mg|Lurasidone 40mg/day tablets
219394809|NCT00044044|DRUG|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
219394810|NCT00044044|DRUG|Haloperidol 10mg|Haloperidol 10mg/day tablets
219394811|NCT00044044|DRUG|Placebo|Matching Placebo to Lurasdione and Haloperidol
219394812|NCT01269034|DRUG|Exenatide|1.25 mcg before the boost sub-cutaneously.
219394813|NCT01269034|DRUG|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
219394814|NCT01269034|DRUG|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
219394815|NCT06656247|OTHER|Online consenting|The design and establishment of an innovative digital tool (a software application) to implement the dynamic consent and allowing interaction among healthcare professionals and patients
219394816|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
219394817|NCT06664515|PROCEDURE|Ciro Costagliola|invert flap tecnique
219394818|NCT00787332|DRUG|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
219394819|NCT04286867|OTHER|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
219394820|NCT04286867|BEHAVIORAL|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
219394821|NCT03863496|PROCEDURE|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
219394822|NCT06187415|BEHAVIORAL|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
219394823|NCT05798962|PROCEDURE|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
219394824|NCT02707757|DRUG|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
219394825|NCT02707757|DRUG|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
219394826|NCT04874740|OTHER|No intervention|No intervention
219394827|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
219394828|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
219394829|NCT02171715|DRUG|BIBW 2992 MA2|powder for oral solution
219394830|NCT01379586|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
219394831|NCT01379586|DRUG|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
219394832|NCT01667744|DRUG|Citalopram|10 mg/day
219394833|NCT00652093|DRUG|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
219394834|NCT00652093|DRUG|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
219394835|NCT00652093|DRUG|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
219559928|NCT03164109|DRUG|Placebo|Infused IV over 15 minutes
219559929|NCT03164109|DRUG|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
219394836|NCT00652093|DRUG|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
219394837|NCT00652093|DRUG|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
219559930|NCT01368302|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
219559931|NCT03105817|DEVICE|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
219559932|NCT02754284|BIOLOGICAL|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
219394838|NCT00652093|DRUG|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
219394839|NCT04591288|OTHER|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
219559933|NCT02754284|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
219559934|NCT00278174|BIOLOGICAL|recombinant interferon alpha-1b|
219394840|NCT04591288|OTHER|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
219394841|NCT05342831|OTHER|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
219394842|NCT06048016|DIAGNOSTIC_TEST|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
219394843|NCT05673135|DRUG|Anti-Hypertensive|For control of the blood pressure
219394844|NCT05673135|RADIATION|Ultrasound|For assessment of gestational age and fetal weight
219559935|NCT04874896|DIETARY_SUPPLEMENT|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
219559936|NCT04874896|DIETARY_SUPPLEMENT|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
219559937|NCT01955512|DRUG|Clopidogrel|Clopidogrel 75mg daily for 7 days
219559938|NCT01955512|DRUG|Placebo|Matched placebo
219559939|NCT01044394|DRUG|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
219559940|NCT05560555|DRUG|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
219559941|NCT03920306|DRUG|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
219559942|NCT00000555|DRUG|estrogen replacement therapy|
219559943|NCT00000555|DRUG|estrogens, conjugated|
219559944|NCT00000555|DRUG|progesterone|
219559945|NCT00000555|DRUG|hormone replacement therapy|
219559946|NCT00000555|DRUG|supplementation, food|
219001478|NCT04076176|DIETARY_SUPPLEMENT|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
219001479|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
219001480|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
219001481|NCT06971731|DRUG|Placebo Tablet: BID|Placebo Tablet: BID
219001482|NCT06969963|DRUG|Lepsiramp, 0.5 Mg/mL Oral Suspension|Test product
219001483|NCT06969963|DRUG|Fycompa, 0.5 Mg/mL Oral Suspension|Reference product
219559947|NCT00000555|DRUG|ascorbic acid|
219559948|NCT00000555|DRUG|vitamin e|
219559949|NCT02428582|DEVICE|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
219559950|NCT02428582|DEVICE|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
219559951|NCT02718287|BEHAVIORAL|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
219559952|NCT02718287|BEHAVIORAL|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
219559953|NCT02644798|OTHER|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
219559954|NCT02265406|DRUG|Anti-Infective Agents|
219559955|NCT02265406|DRUG|Placebo|
219394845|NCT05673135|RADIATION|Doppler ultrasound|Umbilical artery Doppler assessment
219394846|NCT05673135|DIAGNOSTIC_TEST|complete blood count|For assessment of platelet count
219559956|NCT01032460|DEVICE|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
219559957|NCT01032460|DEVICE|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
219559958|NCT01032460|DEVICE|intubate with the Airtraq device|intubate with the Airtraq device
219559959|NCT01917435|DEVICE|video-stylet|
219559960|NCT01917435|DEVICE|fiberoptic bronchoscope|
219559961|NCT03130348|DRUG|Bortezomib|Given SC
219559962|NCT03130348|DRUG|Dexamethasone|Given PO
219559963|NCT03130348|DRUG|Ibrutinib|Given PO
219559964|NCT03130348|OTHER|Laboratory Biomarker Analysis|Correlative studies
219559965|NCT04788446|BEHAVIORAL|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
219559966|NCT04788446|BEHAVIORAL|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
219559967|NCT04347525|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
219559968|NCT01729988|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
219559969|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
219559970|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
219394847|NCT05673135|DIAGNOSTIC_TEST|Body mass index|for assessment of maternal weight during pregnancy
219394848|NCT01410591|DEVICE|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
219394849|NCT01410591|DEVICE|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
219394850|NCT05101291|DRUG|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
219394851|NCT02725385|OTHER|Laboratory Biomarker Analysis|Correlative studies
219559971|NCT00906373|DRUG|Sorafenib|400 milligrams (mg) twice per day orally
219394852|NCT02725385|OTHER|Physiologic Testing|Undergo Trier Social Stress Test
219394853|NCT02725385|OTHER|Questionnaire Administration|Complete questionnaire
219394854|NCT04151004|OTHER|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
219559972|NCT00192673|DRUG|PEG-asparaginase|
219559973|NCT04965857|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
219559974|NCT06212050|DEVICE|Transcatheter Aortic Valve Implantation|TAVI in patients with severe BAV stenosis using ACURATE neo2
219559975|NCT01937819|DEVICE|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
219559976|NCT01597479|DRUG|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
219559977|NCT01573533|BIOLOGICAL|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
219559978|NCT01713179|DRUG|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
219559979|NCT05532488|DIETARY_SUPPLEMENT|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
219559980|NCT05532488|OTHER|Placebo|Placebo
219559981|NCT01045707|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
219559982|NCT01045707|DRUG|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
219559983|NCT00860678|OTHER|Physical activity|
219559984|NCT00860678|OTHER|no Intervention|
219559985|NCT05037773|BEHAVIORAL|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
219394855|NCT04151004|OTHER|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
219189035|NCT06510998|BEHAVIORAL|passive stretching|A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
219189036|NCT00178932|PROCEDURE|genetic analysis|genetic assay of blood sample drawn with patient's consent
219559986|NCT02291692|PROCEDURE|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
219559987|NCT03802617|DRUG|MR13A9|Intravenous administration
219559988|NCT03802617|DRUG|Placebo|Intravenous administration
219559989|NCT04923516|OTHER|Dosage of Delta-aminolevulinic acid and Porphobilinogen|Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
219559990|NCT03764735|DRUG|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
219559991|NCT03764735|DRUG|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
219559992|NCT03764735|DRUG|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
219559993|NCT00591435|OTHER|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
219559994|NCT02790541|DEVICE|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
219559995|NCT06083402|DIETARY_SUPPLEMENT|HyaCera™|1 Ritual HyaCera capsule once daily
219559996|NCT06083402|DIETARY_SUPPLEMENT|Placebo|1 placebo capsule once daily
219559997|NCT00833508|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
219559998|NCT03191708|DIAGNOSTIC_TEST|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
219189037|NCT00178932|PROCEDURE|genetic assay|genetic assay of blood sample drawn with patient's consent
219189038|NCT02084381|DEVICE|MCO-Ci 400|hemodialysis
219189039|NCT02084381|DEVICE|Revaclear 400|hemodialysis
219189040|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
219559999|NCT02227459|DRUG|ND-L02-s0201 Injection|
219560000|NCT00500006|DRUG|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
219189041|NCT04585815|DRUG|Encorafenib|capsules
219189042|NCT04585815|DRUG|Binimetinib|tablets
219189043|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
219189044|NCT04585815|DRUG|Axitinib|tablets
219560001|NCT00500006|DRUG|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
219560002|NCT00848042|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
219560003|NCT04317599|OTHER|Non Interventional study|Non Interventional study
219560004|NCT06161142|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
219560005|NCT06161142|DIAGNOSTIC_TEST|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
219560006|NCT06161142|DIAGNOSTIC_TEST|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
219560007|NCT06161142|DIAGNOSTIC_TEST|SF-36|Quality of life questionnaire
219560008|NCT06161142|DIAGNOSTIC_TEST|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
219560009|NCT06161142|DIAGNOSTIC_TEST|Physical examination|A full rheumatological examination will be performed.
219560010|NCT06161142|DIAGNOSTIC_TEST|Recording of vital signs|(including body temperature, blood pressure, heart rate)
219560011|NCT06161142|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
219560012|NCT06161142|DIAGNOSTIC_TEST|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
219189045|NCT04585815|DRUG|SEA-TGT|solution in vials
219189046|NCT03753347|BIOLOGICAL|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
219189047|NCT06302504|BEHAVIORAL|Nature-based mindfulness program|only one arm is included in this study
219394856|NCT04151004|OTHER|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
219394857|NCT04151004|OTHER|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
219394858|NCT04151004|OTHER|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
219394859|NCT00330629|BEHAVIORAL|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
219560013|NCT03123887|OTHER|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
219560014|NCT05630625|BEHAVIORAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
219560015|NCT06614699|OTHER|abdominal fat and muscle area|Abdominal fat and muscle area were calculated based on abdominal CT.
219189048|NCT05287594|BEHAVIORAL|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
219189049|NCT03926052|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
219189050|NCT03926052|DRUG|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
219189051|NCT06462820|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
219560016|NCT04670406|BEHAVIORAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
219560017|NCT03956602|OTHER|Pretzels|To examine postprandial responses of pretzel consumption
219560018|NCT03956602|OTHER|Brazil nuts|To examine postprandial responses of Brazil nut consumption
219560019|NCT03956602|OTHER|Potato chips|To examine postprandial responses of potato chip consumption
219560020|NCT03956602|OTHER|Mixed nuts|To examine postprandial responses of mixed nut consumption
219560021|NCT03956602|OTHER|White bread|To examine postprandial responses of white bread consumption
219560022|NCT03956602|OTHER|Dried mango|To examine postprandial responses of dried mango consumption
219560023|NCT03956602|OTHER|Mango fruit|To examine postprandial responses of fresh mango consumption
219560024|NCT04627571|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
219560025|NCT05690074|DEVICE|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
219560026|NCT04478526|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
219560027|NCT04478526|BEHAVIORAL|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
219189052|NCT06462820|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
219560028|NCT00611650|DRUG|defined green tea catechin extract|Given orally
219560029|NCT00611650|OTHER|placebo|Given orally
219560030|NCT01650155|DRUG|BI 1005273 s.c.|injection
219189053|NCT03164278|BEHAVIORAL|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
219394860|NCT00330629|BEHAVIORAL|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
219560031|NCT01650155|DRUG|BI 105273 i.v. Placebo|infusion
219189054|NCT05368974|DRUG|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
219189055|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
219394861|NCT03516799|OTHER|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
219560032|NCT01650155|DRUG|BI 1005273 s.c. Placebo|injection
219560033|NCT01650155|DRUG|BI 1005273 i.v.|infusion
219394862|NCT01883310|DEVICE|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
219394863|NCT01883310|DEVICE|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
219394864|NCT04838912|BEHAVIORAL|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
219394865|NCT02263339|BEHAVIORAL|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
219394866|NCT02263339|BEHAVIORAL|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
219560034|NCT04188964|DRUG|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
219560035|NCT06461442|PROCEDURE|Cryotherapy|Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.
219560036|NCT06461442|DRUG|5Fluorouracil|Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
219560037|NCT06217432|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
219560038|NCT00011609|DEVICE|Robotic Arm|
219560039|NCT03474393|OTHER|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
219189056|NCT06035445|BEHAVIORAL|In-person adolescent-friendly service (iPAS) intervention|Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
219189057|NCT06035445|BEHAVIORAL|mHealth (InTSHA) intervention|The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
219394867|NCT02263339|BEHAVIORAL|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
219394868|NCT04251312|OTHER|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
219394869|NCT04599816|DRUG|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
219560040|NCT03506087|BEHAVIORAL|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
219394870|NCT04599816|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
219394871|NCT04599816|DRUG|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
219560041|NCT03506087|BEHAVIORAL|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
219560042|NCT02011451|DRUG|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
219560043|NCT02011451|DRUG|Placebo Comparator:|
219189058|NCT06035445|BEHAVIORAL|Standard of Care|Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
219189059|NCT06024746|DRUG|Finerenone|Oral finerenone.
219394872|NCT05066893|OTHER|telehealth visits|intensive visits with doctor
219394873|NCT02351037|DRUG|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
219394874|NCT02351037|DRUG|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
219394875|NCT02351037|DRUG|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
219394876|NCT05376202|DRUG|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
219394877|NCT03176966|DRUG|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
219394878|NCT03176966|DRUG|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
219560044|NCT04409054|OTHER|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
219560045|NCT01316432|DRUG|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
219560046|NCT01316432|OTHER|Placebo|Placebo will be administered as a 24-hour SQ infusion
219560047|NCT03136562|DIAGNOSTIC_TEST|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
219394879|NCT03176966|OTHER|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
219394880|NCT03002493|DRUG|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
219394881|NCT03002493|DRUG|Eribulin mesylate|
219394882|NCT03002493|DRUG|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
219560048|NCT03681938|PROCEDURE|Autograft|Autograft
219560049|NCT05128136|DEVICE|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
219189060|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
219189061|NCT06480383|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
219189062|NCT06480383|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
219394883|NCT04792996|OTHER|No intervention|No intervention. case - control design.
219394884|NCT02955186|DRUG|Saracatinib|Saracatinib 125 mg once per day for 8 days
219394885|NCT02955186|DRUG|Placebos|Placebo once per day for 8 days
219394886|NCT04036136|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
219394887|NCT04036136|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
219560050|NCT03454737|PROCEDURE|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
219560051|NCT03454737|PROCEDURE|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
219560052|NCT06377007|DEVICE|IOLMaster 700 (Carl Zeiss Meditec AG)|Subjects will undergo measurements with the IOLMaster 700 device.
219560053|NCT06377007|DEVICE|Argos (Alcon Laboratories, Inc.)|Subjects will undergo measurements with the Argos device.
219560054|NCT01994915|OTHER|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
219754394|NCT05243030|BEHAVIORAL|Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
219189063|NCT06480383|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
219189064|NCT04182815|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
219189065|NCT05118074|DIAGNOSTIC_TEST|Creatinine, eGFR|Compare diagnostic tests to reference methods
219189066|NCT00866684|DRUG|Sirolimus|Treatment arm Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day
219189067|NCT00866684|DRUG|Azathioprine|control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
219189068|NCT00866684|DRUG|Mycophenolate|Control arm Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
219189069|NCT00866684|DRUG|Ciclosporin|Control arm Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
219189070|NCT00866684|DRUG|Tacrolimus|Control arm Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
219189071|NCT03808961|DIETARY_SUPPLEMENT|Niacin|100mg tablets twice daily
219189072|NCT03808961|DIETARY_SUPPLEMENT|Niacinamide|100mg tablets twice daily
219394888|NCT05632250|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
219394889|NCT05476549|DIETARY_SUPPLEMENT|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
219189073|NCT03808961|OTHER|Placebo|Placebo tablet twice daily
219189074|NCT05121441|DRUG|ARD-101|Twice daily, oral administration
219394890|NCT05476549|DIETARY_SUPPLEMENT|Placebo|Placebo supplement containing carrier material only
219394891|NCT04570449|DRUG|Fluoxetine|20 mg capsule
219394892|NCT04570449|DRUG|Placebo|fluoxetine placebo capsule
219394893|NCT01267435|PROCEDURE|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
219394894|NCT03245788|OTHER|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
219394895|NCT02457052|DEVICE|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
219394896|NCT01803802|BEHAVIORAL|Expressive writing|Five sessions of 30 minutes of expressive writing
219189075|NCT05121441|DRUG|Placebo|Twice daily, oral administration
219189076|NCT04531917|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
219189077|NCT04531917|OTHER|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
219189078|NCT04531917|OTHER|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
219560055|NCT03720704|DEVICE|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
219560056|NCT02538211|BIOLOGICAL|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
219560057|NCT05696327|OTHER|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
219001484|NCT02458820|PROCEDURE|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
219001485|NCT06969638|BEHAVIORAL|Black Ads|Food ads that feature Black individuals
219560058|NCT05696327|OTHER|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
219001486|NCT06969638|BEHAVIORAL|White Ads|Food ads that feature White individuals.
219001487|NCT06969638|BEHAVIORAL|Many Likes|"Food ads that have many likes"
219001488|NCT06969638|BEHAVIORAL|Few Likes|"Food ads that have few likes"
219001489|NCT01311479|PROCEDURE|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
219394897|NCT06396481|BIOLOGICAL|Vγ9Vδ2 T cell|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
219394898|NCT01696877|DRUG|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
219560059|NCT03632694|BEHAVIORAL|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
219394899|NCT01696877|DRUG|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
219394900|NCT01696877|DRUG|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
219394901|NCT03562780|DRUG|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
219560060|NCT03632694|BEHAVIORAL|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
219560061|NCT02340962|DRUG|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
219001490|NCT04051866|PROCEDURE|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
219001491|NCT04051866|OTHER|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
219394902|NCT03562780|DRUG|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
219394903|NCT02961764|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
219394904|NCT02961764|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
219394905|NCT01301612|DRUG|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
219394906|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
219394907|NCT01301612|RADIATION|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
219001492|NCT00231205|PROCEDURE|Revascularization|
219001493|NCT03159624|OTHER|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
219001494|NCT03159624|OTHER|Doyle silastic sheet|Doyle silastic sheet
219001495|NCT04532944|DIAGNOSTIC_TEST|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
219001496|NCT03589872|DIAGNOSTIC_TEST|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
219394908|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
219394909|NCT01301612|RADIATION|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
219394910|NCT00469014|DRUG|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
219394911|NCT00469014|DRUG|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7."
219394912|NCT00469014|DRUG|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
219394913|NCT00469014|OTHER|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
219394914|NCT00469014|DRUG|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
219394915|NCT00469014|DRUG|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
219394916|NCT01347684|BEHAVIORAL|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
219394917|NCT01347684|DRUG|Standard care using current drugs|Standard Drug therapy
219394918|NCT00472927|DRUG|Premarin/MPA 0.45 mg/1.5 mg|
219394919|NCT00396227|DRUG|vildagliptin|vildagliptin as add-on to metformin
219394920|NCT00396227|DRUG|thiazolidinedione (TZD)|TZD add-on to metformin
219394921|NCT03153397|OTHER|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
219394922|NCT03153397|OTHER|Osmolite|non-prebiotic fiber containing formula (Osmolite)
219394923|NCT03515980|DRUG|BMS-986231|Intravenous (IV) administration
219394924|NCT06085391|OTHER|REThink Game|REThink Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of seven levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change, positive bias, distinction between useful and useless thoughts, problem solving and compassion.
219394925|NCT06085391|OTHER|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
219394926|NCT06085391|OTHER|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress."
219394927|NCT03977389|PROCEDURE|Total wrist denervation|Study of the files
219394928|NCT05457530|DRUG|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
219394929|NCT05457530|COMBINATION_PRODUCT|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
219394930|NCT05457530|DRUG|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
219560062|NCT02340962|DRUG|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
219560063|NCT02340962|DRUG|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
219560064|NCT03243591|OTHER|Livionex gel|Brushing area of mucositis with gel
219560065|NCT03243591|OTHER|Aquafresh gel|Aquafresh gel
219394931|NCT00866294|DRUG|paroxetine IR 10mg tablet|1 or 2 tablets once a day
219394932|NCT00866294|DRUG|paroxetine IR 20mg tablet|1 tablet once a day
219394933|NCT00866294|DRUG|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
219394934|NCT00866294|DRUG|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
219394935|NCT00866294|DRUG|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
219394936|NCT00866294|DRUG|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
219394937|NCT04806581|DRUG|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
219394938|NCT02890771|PROCEDURE|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
219394939|NCT02890771|PROCEDURE|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
219394940|NCT02890771|PROCEDURE|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
219394941|NCT02963077|DRUG|A4250|
219394942|NCT02963077|DRUG|CRC (A3384)|
219394943|NCT02963077|DRUG|Questran|
219394944|NCT02963077|DRUG|Placebo|
219560066|NCT03390244|DEVICE|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
219560067|NCT00000317|DRUG|Risperidone|Risperidone (4mg/day)
219560068|NCT00000317|DRUG|Placebo|Placebo
219394945|NCT05299827|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
219394946|NCT03991377|BEHAVIORAL|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation."
219394947|NCT03991377|DRUG|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
219394948|NCT01245894|DRUG|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
219394949|NCT01245894|DRUG|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
219394950|NCT05044169|DRUG|Broncho-Vaxom|administration for 6 months after remmission
219394951|NCT00193310|DRUG|Paclitaxel|
219560069|NCT00000317|BEHAVIORAL|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
219560070|NCT02789839|PROCEDURE|Blood test|Blood test of 30mL
219394952|NCT00193310|DRUG|Carboplatin|
219394953|NCT00649519|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
219394954|NCT00649519|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
219394955|NCT02333955|DRUG|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
219394956|NCT01177150|DRUG|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
219189079|NCT04817774|BIOLOGICAL|TX200-TR101|TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A\*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
219394957|NCT01177150|DRUG|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
219560071|NCT02789839|PROCEDURE|Medullar test|Medullar test for 2-5mL and a smear
219560072|NCT01186016|BEHAVIORAL|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
219560073|NCT01186016|BEHAVIORAL|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
219560074|NCT02660541|DEVICE|Betafoam|Comparison between 2 medical devices
219560075|NCT02660541|DEVICE|Allevyn Silver Dressing|Comparison between 2 medical devices
219189080|NCT05623150|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
219394958|NCT04988607|DRUG|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
219394959|NCT04988607|DRUG|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
219394960|NCT04988607|DRUG|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
219394961|NCT03025191|BEHAVIORAL|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
219394962|NCT03025191|BEHAVIORAL|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
219560076|NCT02118987|DRUG|Omalizumab|
219560077|NCT01500005|DRUG|Baby D3 drops|2000-4000 iu per day
219560078|NCT00818298|DRUG|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
219560079|NCT04525898|DRUG|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
219001497|NCT02956421|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
219394963|NCT03025191|BEHAVIORAL|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
219394964|NCT03025191|BEHAVIORAL|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
219394965|NCT01250067|PROCEDURE|Motor-related cortical potential (Procedure)|
219560080|NCT03043898|OTHER|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
219560081|NCT03043898|OTHER|Lung sound recording|Lung sounds are recorded using a sensor array.
219560082|NCT01529554|DRUG|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
219560083|NCT01529554|DRUG|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
219560084|NCT00214682|DRUG|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
219560085|NCT00214682|BEHAVIORAL|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
219560086|NCT00214682|BEHAVIORAL|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
219560087|NCT00214682|DRUG|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
219560088|NCT00214682|BEHAVIORAL|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
219560089|NCT00214682|BEHAVIORAL|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
219560090|NCT00065949|DRUG|magnesium sulfate|
219560091|NCT01715649|BEHAVIORAL|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
219189081|NCT06585566|PROCEDURE|Cortical-shell graft|Retromolar cortical shell graft technique for SABG
219394966|NCT03863392|DRUG|Misoprostol|induction of labor
219394967|NCT01558089|DRUG|etanercept|according to SmPC and clinical practice
219394968|NCT01558089|DRUG|methotrexate|according to SmPC and clinical practice
219394969|NCT00916721|DRUG|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
219394970|NCT00916721|DRUG|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
219560092|NCT00841620|PROCEDURE|Haemorrhoidectomy a.m. Milligan|Surgery
219560093|NCT00841620|PROCEDURE|Stapled anopexy|Surgery
219560094|NCT03323450|BEHAVIORAL|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
219560095|NCT05892731|OTHER|with depression|age-related hearing loss with depression
219560096|NCT05892731|OTHER|without depression|age-related hearing loss without depression
219394971|NCT04099901|DRUG|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
219394972|NCT04099901|DRUG|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
219394973|NCT04331730|DRUG|AKST4290|Oral AKST4290
219394974|NCT04331730|DRUG|Placebo|Oral placebo
219394975|NCT04331730|DRUG|Aflibercept|Aflibercept intravitreal injection
219394976|NCT04442620|OTHER|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
219394977|NCT04442620|OTHER|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
219394978|NCT04442620|OTHER|Control diet (CD)|Control Diet
219394979|NCT01628991|BEHAVIORAL|behavioural program|interventional behavioural program
219560097|NCT03890757|OTHER|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
219560098|NCT01098539|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
219560099|NCT01098539|DRUG|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
219560100|NCT04136067|DRUG|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
219560101|NCT04136067|DRUG|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
219560102|NCT03058640|OTHER|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
219560103|NCT03605992|OTHER|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
219560104|NCT03605992|OTHER|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
219560105|NCT02104258|OTHER|Physiotherapy ASPETAR|Standardized physiotherapy protocol
219560106|NCT02104258|OTHER|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
219560107|NCT00721955|DRUG|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
219560108|NCT00721955|DRUG|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
219560109|NCT00721955|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
219560110|NCT04348955|BEHAVIORAL|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
219560111|NCT00490321|DEVICE|VentrAssistTM Left Ventricular Assist Device|
219394980|NCT01628991|DEVICE|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
219394981|NCT00855530|DRUG|amibegron (SR58611A)|oral administration of 300 mg twice daily
219394982|NCT01903434|DRUG|Evacetrapib|Administered orally
219560112|NCT02297087|GENETIC|Standard of care based on target(s) identified via GWS.|
219560113|NCT04959032|DRUG|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
219560114|NCT04959032|DRUG|Placebo|Matching capsules administered orally, once daily.
219001498|NCT02956421|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
219394983|NCT01202110|DRUG|Propranolol|
219394984|NCT04946110|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
219394985|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
219394986|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
219394987|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
219560115|NCT04698551|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
219560116|NCT04703751|DEVICE|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
219560117|NCT05036005|DRUG|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
219394988|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
219394989|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
219394990|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
219394991|NCT05552599|PROCEDURE|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
219394992|NCT00530699|DRUG|AZD1152|intravenous
219394993|NCT04390815|DRUG|Insulin|Adding insulin to conventional wound treatment
219394994|NCT03201328|OTHER|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
219394995|NCT03201328|OTHER|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
219394996|NCT03201328|OTHER|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
219394997|NCT04372693|OTHER|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
219394998|NCT05786261|DEVICE|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
219394999|NCT05786261|DEVICE|EEG task rTMS, fMRI|EEG task rTMS, fMRI
219560118|NCT05036005|DRUG|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
219560119|NCT05036005|DRUG|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
219560120|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
219560121|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
219560122|NCT04791345|DRUG|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
219560123|NCT04791345|DRUG|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
219560124|NCT04791345|DRUG|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
219560125|NCT06240065|OTHER|Green bean puree|Green bean puree as a proxy for fiber-foods
219395000|NCT06511011|DRUG|Modified Suan ZaoRen Tang-TianWang BuXin Dan|Chinese medicine granules for 6 weeks
219395001|NCT06511011|DRUG|Placebo|Placebo granules for 6 weeks
219395002|NCT00075751|DRUG|gemcitabine hydrochloride|Given IV
219395003|NCT00075751|DRUG|carboplatin|Given IV
219395004|NCT00075751|DRUG|bortezomib|Given IV
219395005|NCT03640897|DEVICE|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
219395006|NCT03640897|OTHER|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
219395007|NCT03640897|OTHER|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
219395008|NCT04743882|OTHER||
219395009|NCT03595215|DEVICE|TENS|Transcutaneous electrical nerve stimulation
219395010|NCT05924360|OTHER|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
219395011|NCT05924360|OTHER|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
219395012|NCT05924360|OTHER|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
219395013|NCT05924360|DEVICE|TENS|TENS application will be administered for 20 minutes at 100Hz
219395014|NCT05694078|OTHER|Hand Therapy Splinting Protocol|Relative motion splinting protocol
219395015|NCT01753752|DRUG|Chitosan- N- Acetylcysteine eye drops|
219395016|NCT01753752|DRUG|Placebo|
219395017|NCT05882162|PROCEDURE|Coronectomy|Removal of crown part of the mandibular third molar
219395018|NCT05882162|PROCEDURE|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
219395019|NCT00764842|DEVICE|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
219395020|NCT05819632|OTHER|curcumin gel 2%|curcumin gel 2%
219395021|NCT05055661|OTHER|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
219395022|NCT02101411|DIAGNOSTIC_TEST|PRU(Platelet reactivity unit)|measure by VeryfyNow.
219395023|NCT05477966|OTHER|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
219395024|NCT01662973|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
219395025|NCT01662973|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
219395026|NCT02595060|DRUG|inhaled molgramostim (rhGM-CSF)|
219560126|NCT02368262|OTHER|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
219560127|NCT02368262|PROCEDURE|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
219395027|NCT02595060|DRUG|inhaled placebo|formulated as the active substance without molgramostim
219395028|NCT01784562|DRUG|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
219395029|NCT01519427|DRUG|Akt inhibitor MK2206|Given PO
219395030|NCT01519427|DRUG|selumetinib|Given PO
219395031|NCT01519427|OTHER|laboratory biomarker analysis|Correlative studies
219395032|NCT02540174|PROCEDURE|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
219395033|NCT02540174|PROCEDURE|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
219560128|NCT00083772|DRUG|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
219560129|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
219560130|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
219560131|NCT04800926|DEVICE|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
219560132|NCT06394492|DRUG|SHR-A1921|SHR-A1921 dose 1
219560133|NCT06394492|DRUG|Doxorubicin|Doxorubicin dose 2
219560134|NCT06394492|DRUG|Paclitaxel|Paclitaxel dose 3
219395034|NCT02404831|OTHER|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
219560135|NCT06394492|DRUG|Topotecan|Topotecan dose 4
219560136|NCT05973331|OTHER|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
219560137|NCT00277030|DRUG|Surfactant|
219560138|NCT00277030|DEVICE|Nasal CPAP|
219560139|NCT00722839|BIOLOGICAL|PADRE-CMV fusion peptide vaccine|Given subcutaneously
219560140|NCT00722839|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given subcutaneously
219560141|NCT00722839|DRUG|agatolimod sodium|Given subcutaneously
219560142|NCT01643239|OTHER|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
219560143|NCT01643239|OTHER|Hospital-based mCIT|the mCIT group with individualized intervention
219560144|NCT01643239|OTHER|Hospital-based TR|OT or PT or therapist-based training
219560145|NCT02884986|DRUG|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
219395035|NCT02404831|OTHER|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
219395036|NCT03632512|DIETARY_SUPPLEMENT|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
219395037|NCT03632512|DIETARY_SUPPLEMENT|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
219395038|NCT00184912|DRUG|caffeine|
219395039|NCT00184912|DRUG|Technetium-TC99m-labeled Annexin A5|
219395040|NCT00184912|PROCEDURE|ten minutes forearm ischemia|
219395041|NCT00184912|PROCEDURE|ischemic forearm exercise|
219395042|NCT04556331|BEHAVIORAL|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
219395043|NCT03894904|DRUG|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
219395044|NCT03894904|DRUG|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
219560146|NCT02884986|DRUG|Placebo|120mg of placebo
219560147|NCT03417739|DRUG|BVD-523|ERK1 and ERK2 inhibitor
219560148|NCT03397667|OTHER|ABC ANSWERS|Primary Care plus ABC ANSWERS
219560149|NCT03397667|OTHER|Control|Primary Care as usual
219560150|NCT03926416|BIOLOGICAL|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
219560151|NCT03926416|BIOLOGICAL|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
219189082|NCT06820996|OTHER|Cryotherapy|The root canals were irrigated with 2 °C NaOCl solution in cryotherapy group.
219560152|NCT05469958|OTHER|Hypothermia prevention bundle|pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
219560153|NCT05469958|OTHER|Conventional care|the patient will be attended with textile blankets on patient demand
219560154|NCT05301816|DEVICE|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
219560155|NCT02134639|PROCEDURE|68Ga-DOTATOC PET-CT Imaging|
219560156|NCT04902963|DEVICE|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
219560157|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
219560158|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
219560159|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
219560160|NCT02079363|OTHER|No interventions, this is an observational study|
219560161|NCT06622486|DRUG|EGL-001|IV administration
219560162|NCT01055886|DRUG|nicotine patch|Nicotine patch, 7-21 mg.
219560163|NCT01055886|DRUG|placebo patch|placebo patch used from weeks 4-6
219560164|NCT04325516|BEHAVIORAL|Daily activities|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
219560165|NCT00428155|DEVICE|closure device placement|
219560166|NCT03430635|PROCEDURE|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
219560167|NCT04070079|DRUG|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
219560168|NCT03467737|OTHER|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
219001499|NCT02344277|DEVICE|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
219001500|NCT01325584|DRUG|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
219001501|NCT00887978|DRUG|UT-15C SR|treprostinil diolamine sustained release tablets
219001502|NCT00887978|DRUG|Placebo|
219001503|NCT05416593|BEHAVIORAL|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
219001504|NCT05416593|BEHAVIORAL|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
219001506|NCT05813015|DRUG|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
219001507|NCT05813015|DRUG|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
219001508|NCT05024591|DEVICE|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
219395045|NCT03894904|DRUG|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
219001509|NCT01104350|OTHER|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
219395046|NCT05032833|DRUG|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
219395047|NCT05032833|OTHER|Placebo|A single dose of placebo will be administered intranasally
219395048|NCT06338059|OTHER|Vitamin B12 Level|Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
219395049|NCT04272905|OTHER|Non-interventional study|The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
219560169|NCT03467737|OTHER|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
219560170|NCT03467737|OTHER|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
219560171|NCT03467737|OTHER|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
219001510|NCT06064604|OTHER|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
219001511|NCT06064604|DEVICE|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
219189083|NCT06820996|OTHER|Control (Standard treatment)|The root canals were irrigated with 25 °C NaOCl solution in normal group.
219395050|NCT00005029|DRUG|topotecan hydrochloride|
219560172|NCT03467737|OTHER|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
219001512|NCT06064604|DEVICE|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
219560173|NCT03467737|OTHER|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
219560174|NCT02399891|OTHER|Quality Assurance Implementation|
219560175|NCT02399891|OTHER|Standard of Care|
219560176|NCT05625269|OTHER|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
219560177|NCT03447444|OTHER|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
219560178|NCT00506012|DRUG|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
219560179|NCT00881231|DRUG|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
219560180|NCT00881231|DRUG|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
219560181|NCT03937791|BIOLOGICAL|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
219560182|NCT01259830|DRUG|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
219560183|NCT01259830|DRUG|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
219560184|NCT01589601|BEHAVIORAL|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
219001513|NCT05545930|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
219001514|NCT05545930|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
219395051|NCT05515549|OTHER|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
219395052|NCT01781026|DRUG|Vemurafenib|Single arm trial
219560185|NCT01589601|BEHAVIORAL|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
219560186|NCT00201396|RADIATION|CCRT|Radiation with weekly Cisplatin
219001517|NCT02947503|DRUG|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
219001518|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
219001519|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
219001520|NCT04102020|DRUG|Venetoclax|Tablet: Oral
219001521|NCT04102020|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
219395053|NCT06673420|OTHER|No Interventions|This is an observational study
219395054|NCT02502877|DRUG|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
219560187|NCT00201396|DRUG|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
219560188|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
219560189|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
219560190|NCT04265287|OTHER|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
219560191|NCT03254732|DRUG|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
219560192|NCT03254732|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
219560193|NCT02910596|DRUG|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
219001522|NCT04102020|DRUG|Azacitidine|Oral Tablet
219001523|NCT06117709|BEHAVIORAL|I-STAMP|A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
219001524|NCT03898362|OTHER|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
219560194|NCT02910596|DEVICE|early bladder training|early bladder training start on 3rd - 5thpostoperative day
219560195|NCT02910596|OTHER|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
219560196|NCT02910596|OTHER|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
219560197|NCT05753813|DRUG|Phexxi|intravaginal gel twice weekly for 4 weeks.
219560198|NCT01514513|DRUG|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
219560199|NCT01514513|DRUG|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
219560200|NCT00265785|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
219560201|NCT02243137|DRUG|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
219560202|NCT02243137|DRUG|prasugrel|Administration: one loading dose (60mg)
219560203|NCT02243137|DRUG|lysine acetylsalicylate|Administration: one dose (450mg iv)
219560204|NCT01287715|DRUG|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
219560205|NCT01287715|DRUG|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
219560206|NCT05858775|DEVICE|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
219560207|NCT05948033|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
219001525|NCT03898362|DEVICE|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
219001526|NCT03853616|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
219001527|NCT04216875|PROCEDURE|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
219001528|NCT04216329|DRUG|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
219001529|NCT04216329|DRUG|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
219001530|NCT04216329|RADIATION|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
219001531|NCT04216329|OTHER|Selective serotonin receptor (5-HT3) antagonists|Anti-emetic for breakthrough nausea.
219001532|NCT04216329|OTHER|Olanzapine|2.5mg to 5mg once a day if weight loss is rapid.
219560208|NCT00206245|DRUG|AZD0865|
219001533|NCT04216329|DIETARY_SUPPLEMENT|Salt tablets|To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
219560209|NCT00404053|DRUG|Clopidogrel|
219001534|NCT04216329|OTHER|Anti-diarrheal|Treat diarrhea with an anti-diarrheal per institutional guidelines
219001535|NCT06805565|DRUG|ONO-1110|ONO-1110 tablets once a day
219001536|NCT06805565|DRUG|Placebo|Placebo tablets once daily
219001537|NCT06457178|BEHAVIORAL|Acceptance and Commitment Therapy-Based Intervention for Oncology Patients|An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.
219001538|NCT06457178|BEHAVIORAL|Psychoeducation for Oncology Patients|A program was prepared to support oncology patients in physical and psychological symptom management.
219001539|NCT01333826|BEHAVIORAL|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
219560210|NCT03401918|DIAGNOSTIC_TEST|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
219560211|NCT03401918|DRUG|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
219560212|NCT00089427|DRUG|IL13-PE38QQR|
219560213|NCT00089427|PROCEDURE|Surgery for placement|
219560214|NCT00089427|PROCEDURE|Radiation therapy|
219560215|NCT00089427|DRUG|Temozolomide with radiation therapy|
219560216|NCT03267927|DEVICE|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
219560217|NCT03267927|DEVICE|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
219560218|NCT03267927|DEVICE|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
219560219|NCT05222360|OTHER|Education|3 educational sessions about body image and nutrition
219560220|NCT04329676|PROCEDURE|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
219560221|NCT00964873|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
219560222|NCT00052520|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
219395055|NCT02502877|DRUG|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
219560223|NCT00052520|BIOLOGICAL|aldesleukin|Given SC
219001540|NCT06648473|DIAGNOSTIC_TEST|MRI Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
219001541|NCT03857321|DRUG|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
219001542|NCT03857321|OTHER|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
219001543|NCT03857321|DEVICE|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
219560224|NCT00052520|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
219189084|NCT06585332|OTHER|Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))|"The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists."
219395056|NCT02502877|DRUG|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
219395057|NCT02502877|DEVICE|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
219395058|NCT06080347|OTHER|Anti-inflammatory Diet|Dietary intervention
219395059|NCT06080347|OTHER|Healthy Diet|Dietary intervention
219560225|NCT00052520|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
219560226|NCT00052520|OTHER|laboratory biomarker analysis|Correlative studies
219560227|NCT00052520|GENETIC|gene expression analysis|Correlative studies
219560228|NCT00052520|OTHER|immunologic technique|Correlative studies
219560229|NCT00052520|OTHER|flow cytometry|Correlative studies
219001544|NCT05318963|BIOLOGICAL|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
219001545|NCT06193499|PROCEDURE|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
219001546|NCT06193499|OTHER|Placebo|Intra-articular Saline injection (0,6-1ml)
219001547|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
219001548|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
219001549|NCT07132502|OTHER|ctDNA MRD|"Definition and Essence: ctDNA MRD involves detecting DNA fragments released by tumor cells into the bloodstream through highly sensitive techniques to determine the status of minimal residual disease in cancer patients.~Detection Methods: Technologies such as digital PCR and next-generation sequencing (NGS) are employed to achieve precise detection of low-frequency ctDNA mutations.~Clinical Significance: It is utilized for evaluating the prognosis of cancer patients and providing crucial evidence for the formulation of personalized treatment plans."
219001550|NCT07131215|OTHER|Home-based multimodal exercise|Mobile Applications
219001551|NCT07131215|OTHER|Supervised multimodal exercise program|In laboratory
219001552|NCT07131215|OTHER|Education|Menopause education
219395060|NCT06672614|OTHER|Post-Exercise Hot Water Immersion|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
219395061|NCT06672614|OTHER|Control Group|Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
219395062|NCT06673329|DRUG|Brodalumab|Brodalumab 210 mg subcutaneous injection
219395063|NCT06673329|RADIATION|CT scan|CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
219560230|NCT00052520|GENETIC|polymerase chain reaction|Correlative studies
219560231|NCT00052520|GENETIC|cytogenetic analysis|Correlative studies
219560232|NCT00052520|OTHER|staining method|Correlative studies
219560233|NCT01294449|DEVICE|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
219560234|NCT01294449|DEVICE|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
219560235|NCT06028646|DEVICE|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
219560236|NCT03211455|DRUG|Lidocaine|intravenous lidocaine versus placebo
219560237|NCT03211455|DRUG|isotonic saline|intravenous isotonic saline
219560238|NCT03095755|OTHER|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
219560239|NCT03095755|OTHER|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
219560240|NCT00800618|DRUG|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
219560241|NCT00800618|DRUG|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
219560242|NCT00800618|DRUG|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
219560243|NCT00800618|DRUG|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
219001553|NCT07131618|OTHER|cryocompression|"Cryocompression induces vasoconstriction in the applied area, thereby reducing blood flow. As a result, the delivery of the chemotherapeutic agent to peripheral nerves is limited, and it is aimed to protect nerve tissue from toxic effects. At the same time, low temperature slows down nerve conduction and cellular metabolism, helping to prevent damage to nerve cells.~30 minutes after the start of the paclitaxel infusion, cryocompression will be applied using ice gel gloves for the hands and socks for the feet, lasting 30 minutes. After paclitaxel ends, carboplatin will be infused intravenously in 250 cc isotonic solution over 1 hour. Cryocompression will again be applied 30 minutes after the start of the carboplatin infusion using the same method, for 30 minutes. This intervention will be performed weekly during each cycle of the 6-week carboplatin/paclitaxel protocol, for a total of 60 minutes per session."
219001554|NCT07002515|OTHER|Health education|Randomized controlled studies that explain behavior change as a process through health education aimed at promoting healthy behaviors in individuals with digital game addiction.
219001555|NCT07002021|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on dengue prevention and campus environmental governance, while the control group will continue with their standard school health education without any additional intervention. An health education including the knowledge of dengue fever, harm of mosquitoes, and measures of mosquito control, will be developed and reviewed by an expert group. The campus environmental governance includes organizing campus environmental cleaning once a week, focusing on removing mosquito breeding places such as water containers.
219395064|NCT02214758|OTHER|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
219395065|NCT06697327|DRUG|(Daunorubicin, Cytarabine, Venetoclax)|"* Drugs：Daunorubicin~  * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs：Venetoclax~  * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto"
219395066|NCT06697327|DRUG|(Daunorubicin, Cytarabine)|"* Drugs：Daunorubicin~  * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U"
219395067|NCT04950985|OTHER|Observational Study|Observational study
219395068|NCT02463123|DEVICE|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
219395069|NCT02924675|DRUG|Pregabalin|150mg daily in three doses during three weeks
219395070|NCT02924675|DRUG|Placebo|Three doses daily with lactose
219395071|NCT05534334|DRUG|Solu-Cortef|A vial sol. used for intra-mascular injection
219395072|NCT06270797|PROCEDURE|intubation for general anesthesia|routine intubation for general anesthesia
219395073|NCT05782556|DEVICE|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
219395074|NCT03339427|OTHER|vitamin D|different doses of vitamin D supplementation
219395075|NCT03339427|OTHER|control|control group
219395076|NCT06512428|DRUG|simmitinib plus irinotecan liposome|simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
219395077|NCT06512428|DRUG|irinotecan liposome|irinotecan liposome 70 mg/m\^2 every 2 weeks
219395078|NCT06512428|DRUG|irinotecan|irinotecan 180mg/m\^2 every 2 weeks
219395079|NCT04811677|OTHER|radiology|image analysis
219395080|NCT04220047|PROCEDURE|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
219395081|NCT03733678|BEHAVIORAL|Price discounts for SARCs|SARCs are offered free to the client
219395082|NCT03733678|BEHAVIORAL|Price discounts for LARCs|LARCs are offered at lower prices to the client
219395083|NCT03733678|BEHAVIORAL|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
219395084|NCT01118143|BEHAVIORAL|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
219395085|NCT06294847|DRUG|Ursolvan|single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
219395086|NCT06294847|DRUG|Placebo|Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
219395087|NCT01378754|DRUG|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
219395088|NCT01378754|DRUG|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
219395089|NCT01378754|DRUG|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
219395090|NCT05104151|DIETARY_SUPPLEMENT|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
219189085|NCT06827808|OTHER|Team based learning|The intervention planned within the scope of the research is a team-based learning method. Students in the intervention group taking the nursing fundamentals course will be formed into small groups in the nursing skills laboratory. The groups will remain the same throughout the six modules. First, students will be asked to solve the iRAT multiple-choice question set prepared on the relevant module skill. Then, students will be provided with the skill repetition in the determined groups. Then, they will be asked to discuss until they reach a consensus as a group and solve the tRAT, which includes the same multiple-choice question set as the iRAT.
219189086|NCT03679650|DRUG|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
219395091|NCT05104151|BEHAVIORAL|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
219395092|NCT05089864|OTHER|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
219395093|NCT05089864|OTHER|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
219395094|NCT02112448|DRUG|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
219395095|NCT02112448|DRUG|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
219395096|NCT02112448|DRUG|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
219395097|NCT02112448|DRUG|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
219395098|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
219395099|NCT05471297|OTHER|There is no intervention|There is no any intervention
219395100|NCT03624101|DRUG|Symdeko|CFTR modulator
219395101|NCT03624101|DRUG|Ivacaftor and Symdeko|CFTR modulator
219395102|NCT06519435|DEVICE|Mayo Dopplex ABIlity|Device used to measure lower extremity venous hemodynamic pressure
219560244|NCT00800618|DRUG|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
219560245|NCT00311649|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|
219395103|NCT06519435|DEVICE|Intermittent Pneumatic Compression (IPC)|Device used to measure lower extremity venous hemodynamic pressure
219395104|NCT06256380|BEHAVIORAL|Enhanced Cognitive-behavior therapy for adolescents with an eating disorder|Psychotherapy
219560246|NCT06048887|DRUG|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
219560247|NCT06048887|DRUG|Placebo Oral Solution|Placebo
219560248|NCT05233787|PROCEDURE|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
219560249|NCT05233787|PROCEDURE|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
219560250|NCT00024349|DRUG|fluorouracil|
219560251|NCT00024349|DRUG|mitomycin C|
219560252|NCT00024349|RADIATION|radiation therapy|
219560253|NCT01720849|DRUG|Fampyra|The will be given as per normal patient treatment plan
219189087|NCT03679650|BIOLOGICAL|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
219189088|NCT04004065|DRUG|Vesleteplirsen|Vesleteplirsen injection, for IV use
219395105|NCT06256380|BEHAVIORAL|Family-based therapy for adolescents with an eating disorder|Psychotherapy
219395106|NCT05378399|DRUG|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
219395107|NCT05378399|DEVICE|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
219395108|NCT05378399|DEVICE|Beiwe|Digital phenotyping app
219395109|NCT02934529|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
219395110|NCT02934529|DRUG|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
219395111|NCT02934529|DRUG|5-FU|5-FU 400 mg/m² bolus day 1, q d15
219395112|NCT02934529|DRUG|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
219395113|NCT02934529|DRUG|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
219395114|NCT02934529|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
219395115|NCT02934529|DRUG|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
219395116|NCT02934529|DRUG|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
219395117|NCT02934529|DRUG|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
219395118|NCT02934529|DRUG|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
219395119|NCT06738797|DIAGNOSTIC_TEST|SPHERTEST test|The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.
219395120|NCT03656835|PROCEDURE|Molecular Nanotechnology|Undergo ILN biochip testing
219395121|NCT04484220|DEVICE|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.
219395122|NCT04868773|DRUG|Cabozantinib|Oral cabozantinib
219395123|NCT04868773|DRUG|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
219395124|NCT04841304|DEVICE|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
219560254|NCT03222037|DEVICE|senofilcon A|Acuvue Oasys 1-Day
219001556|NCT07002437|OTHER|Augmented Acute Intermittent Hypoxia (aAIH)|"aAIH (augmented acute intermittent hypoxia) consists of 3, 5-minute episodes of low oxygen (9-13% O2), interspersed with 3-min room air intervals.~Each study participant will complete one session of augmented AIH (aAIH), which consists of 3, 5-minute exposures. Each exposure involves a 5-minute hypoxic episode (9-131% inspired O2), with a 3-min interval of room air breathing (21% O2). Gas mixtures will be delivered via Douglas bags (pre-filled with desired gas mixture) that are coupled to a non-rebreathing valve and facemask. A manual-control valve allows seamless gas mixture switching. Participant safety will be continuously monitored in real-time using non-invasive sensors and LabChart software. For instance, inspired and expired concentrations of O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, tidal volume, heart rate, and blood pressure) will be continuously monitored."
219189089|NCT06241976|OTHER|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
219189090|NCT06241976|OTHER|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
219189091|NCT04514471|OTHER|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
219395125|NCT04841304|DEVICE|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
219395126|NCT03559985|DRUG|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
219395127|NCT03559985|OTHER|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
219395128|NCT01818622|DEVICE|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
219395129|NCT01818622|DEVICE|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
219395130|NCT00814073|DRUG|Masitinib|Masitinib 6 mg/kg/day
219395131|NCT00814073|DRUG|Placebo|Matching placebo
219395132|NCT00814073|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
219395133|NCT01772342|OTHER|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
219395134|NCT01772342|OTHER|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
219395135|NCT03260335|BEHAVIORAL|Anxiety management strategy|Anxiety management strategy as per standard care plan
219395136|NCT01029288|OTHER|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
219395137|NCT01029288|OTHER|Statin Choice Decision Aid|Statin Choice Cards
219395138|NCT01029288|OTHER|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
219395139|NCT01029288|OTHER|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
219395140|NCT05094154|DRUG|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
219395141|NCT05094154|DRUG|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
219395142|NCT03919890|DRUG|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
219395143|NCT03919890|DRUG|ONO-7684 Placebo|Placebo comparator
219560255|NCT03222037|DEVICE|Control|Trial Frame with best spherocylindrical refraction (SCR)
219189092|NCT04514471|OTHER|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
219189093|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
219189094|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
219395144|NCT05732155|DRUG|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
219395145|NCT04160156|DEVICE|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
219395146|NCT04066556|OTHER|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
219560256|NCT04445233|DEVICE|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
219560257|NCT05966207|BEHAVIORAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
219560258|NCT01318161|DRUG|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
219560259|NCT01318161|DRUG|Morphine|Morphine via PCA pump
219560260|NCT06266754|BIOLOGICAL|Oral polio vaccine|Standard oral polio vaccine
219560261|NCT06266754|OTHER|Placebo|Saline 0.9%
219560262|NCT00559741|BIOLOGICAL|cetuximab|
219560263|NCT00559741|DRUG|fluorouracil|
219560264|NCT00559741|DRUG|irinotecan hydrochloride|
219560265|NCT00559741|DRUG|leucovorin calcium|
219560266|NCT00559741|OTHER|pharmacological study|
219189095|NCT03420482|DRUG|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
219189096|NCT03420482|DRUG|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
219560267|NCT03743259|DRUG|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
219560268|NCT03743259|DRUG|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
219560269|NCT03743259|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
219560270|NCT01195155|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
219560271|NCT05397795|DRUG|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
219189097|NCT05951387|DRUG|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
219560272|NCT05397795|DRUG|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
219560273|NCT00496262|BIOLOGICAL|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
219560274|NCT05787392|BEHAVIORAL|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
219560275|NCT06073886|DEVICE|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
219560276|NCT06073886|DEVICE|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
219560277|NCT06073886|BEHAVIORAL|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
219189098|NCT05951387|DRUG|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
219189099|NCT03876964|DEVICE|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
219560278|NCT03022539|RADIATION|Repeat CT scan|
219560279|NCT01618513|DRUG|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
219560280|NCT06338423|DEVICE|vacuum mattress|vacuum mattresses used to better positioning of the patient
219560281|NCT06338423|OTHER|Standard Mattress|Standard Mattress
219560282|NCT05907655|DRUG|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
219560283|NCT05907655|DIAGNOSTIC_TEST|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
219560284|NCT05907655|DIAGNOSTIC_TEST|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
219560285|NCT05907655|DEVICE|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
219560286|NCT04317638|OTHER|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
219560287|NCT02020109|RADIATION|splenic irradiation|
219560288|NCT03509285|DRUG|Alprazolam Placebo|100 mg lactose tablets
219560289|NCT03509285|DRUG|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
219560290|NCT03509285|DRUG|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
219560291|NCT03509285|DRUG|Cenobamate|100 mg tablet
219560292|NCT04389645|DIAGNOSTIC_TEST|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
219560293|NCT03547817|DEVICE|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
219001557|NCT07002437|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|"AIHH consists of 1-min episodes of low oxygen (9% O2) and elevated carbon dioxide (5% CO2), interspersed with 1.5 min room air.~Each participant will complete one session of AIHH exposure, which consists of 15, 1-minute hypercapnic hypoxic episodes (4-5% inspired CO2, 9-131% inspired O2), with 1.5-minute intervals of room air breathing (21% O2). Gas mixtures will be delivered in the same manner described for AIH intervention. Participant safety will be continuously monitored in real-time using LabChart software. For instance, inspired and expired concentrations of CO2 and O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, heart rate, and blood pressure) will be monitored."
219560294|NCT04502849|PROCEDURE|Bypass surgery|Creating a bypass with graft or vein.
219560295|NCT04502849|PROCEDURE|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
219001558|NCT07002437|OTHER|Sham AIH|"A single session of sham AIH with episodes of normal room air (21% O2).~Sham experiments will use methods identical to AIH/AIHH protocols except that normoxic gas (21% inspired O2) will be delivered. Since the timing and intervals vary with each protocol, the sham will use a distinct protocol involving 5, 3-min episodes with 2 min intervals between each episode. The valve on the non-rebreathing mask will be turned to deliver these episodes, but 21% O2 will be delivered throughout."
219395147|NCT01823627|PROCEDURE|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
219560296|NCT04502849|PROCEDURE|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
219560297|NCT04502849|DRUG|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
219560298|NCT04502849|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
219560299|NCT04502849|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
219560300|NCT04502849|DIAGNOSTIC_TEST|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
219560301|NCT02226991|DRUG|Tipranavir|
219560302|NCT02226991|DRUG|Ritonavir|
219560303|NCT02226991|DRUG|Efavirenz|
219395148|NCT04922892|PROCEDURE|Parathyroidectomy|Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
219560304|NCT03422224|DIAGNOSTIC_TEST|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
219560305|NCT05721157|OTHER|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
219001559|NCT07001709|DRUG|Oxycodone oral capsule 15 mg|Single dose of 15 mg oxycodone direct release (both arm 1 and arm 2)
219001560|NCT07001709|DRUG|Abiraterone Acetate Tablets 500 mg|Abiraterone group: 1000 mg abiraterone acetate (at steady state)
219001561|NCT07132671|RADIATION|Brachytherapy and MR-Guided SBRT|HDR Brachytherapy followed by MR-guided SBRT
219189100|NCT03321045|DRUG|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
219189101|NCT03321045|DIAGNOSTIC_TEST|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
219395149|NCT04383977|DRUG|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
219395150|NCT04383977|DRUG|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
219560306|NCT01684280|GENETIC|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
219560307|NCT01224457|DRUG|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
219560308|NCT03993639|DRUG|Pegfilgrastim|Single dose of SC administration
219560309|NCT04118946|BIOLOGICAL|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
219560310|NCT06396507|DRUG|Permethrin Solution|permethrin 5 % solution
219560311|NCT06396507|DRUG|Sulfur|Sulfur 10%+ vaseline 90 % ointment
219560312|NCT01714141|BEHAVIORAL|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
219560313|NCT01714141|BEHAVIORAL|Asthma education active control|
219560314|NCT00420095|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
219560315|NCT00420095|DRUG|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
219560316|NCT00393705|DRUG|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
219560317|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
219560318|NCT00393705|DRUG|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
219560319|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
219001562|NCT07131111|RADIATION|CT aortography|"Performed before and after stenting using a multidetector CT scanner (device model and parameters to be specified).~Analysis will include:~* Evaluation of aortic arch geometry (normal / gothic / crenel).~* Measurement of residual stenosis at the site of coarctation.~* Aortic diameter measurements at predefined anatomical levels:~Ascending aorta (AA), Proximal descending thoracic aorta (PDA), At the level of the diaphragm (DA), Abdominal aorta (AbAo).~\- Aortic tortuosity. All CT data will be interpreted by two independent observers blinded to clinical outcomes"
219189102|NCT04295512|BEHAVIORAL|Unstuck and on Target|Unstuck and on Target is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. Unstuck and on Target is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Unstuck and on Target will be adapted for use in mental health service settings. Mental health therapists will be trained in Unstuck and on Target and deliver to youth and caregivers.
219189103|NCT06422689|DRUG|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
219395151|NCT02426983|DEVICE|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
219395152|NCT02426983|DRUG|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
219395153|NCT06555692|BIOLOGICAL|Transplant acellular dermal matrix(ADM)|The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
219395154|NCT06126705|DRUG|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
219395155|NCT06126705|DRUG|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
219395156|NCT05017285|PROCEDURE|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
219560320|NCT02391233|BEHAVIORAL|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
219560321|NCT02391233|BEHAVIORAL|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
219395157|NCT05017285|PROCEDURE|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
219395158|NCT01311206|OTHER|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
219395159|NCT01311206|OTHER|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
219395160|NCT02133235|PROCEDURE|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
219560322|NCT05518331|DRUG|avatrombopag|Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
219395161|NCT02133235|PROCEDURE|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
219560323|NCT03393780|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
219560324|NCT04516187|DIAGNOSTIC_TEST|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
219560325|NCT00327587|DRUG|Valsartan + amlodipine|
219560326|NCT00327587|DRUG|Valsartan + HCTZ|
219560327|NCT00327587|DRUG|Amlodipine + HCTZ|
219395162|NCT05184296|PROCEDURE|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
219395163|NCT03766334|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
219560328|NCT00327587|DRUG|Valsartan + amlodipine + HCTZ|
219560329|NCT01240850|DRUG|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
219560330|NCT01240850|DRUG|Prednisone|
219560331|NCT03185741|BEHAVIORAL|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
219560332|NCT03185741|BEHAVIORAL|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
219560333|NCT05543395|BEHAVIORAL|Domestic Violence Questionnaire|Domestic Violence Questionnaire
219560334|NCT05348928|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
219560335|NCT05348928|OTHER|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
219395164|NCT01002859|DRUG|Sandimmum|Intravenous injection of cyclosporine
219395165|NCT01002859|DRUG|Placebo|Intravenous Injection of NaCl solution
219395166|NCT02030561|DRUG|Trastuzumab + NK cells|
219395167|NCT00384540|PROCEDURE|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
219395168|NCT01240811|DRUG|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
219395169|NCT01240811|DRUG|Levonorgestrel IUD|
219395170|NCT01240811|DRUG|Copper T380A IUD|
219395171|NCT02617732|DRUG|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
219395172|NCT02617732|DRUG|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
219560336|NCT01898845|DRUG|LEE011|
219560337|NCT01016054|BIOLOGICAL|AGS-8M4|IV infusion
219560338|NCT01016054|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
219560339|NCT01016054|DRUG|gemcitabine|IV infusion
219560340|NCT01016054|DRUG|carboplatin|IV infusion
219560341|NCT03365791|BIOLOGICAL|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
219560342|NCT03365791|BIOLOGICAL|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
219560343|NCT01475487|PROCEDURE|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
219560344|NCT00219986|DRUG|Potent HAART during acute or early HIV-1 infection|
219560345|NCT02386761|DRUG|Single Ascending Dose (SAD)|
219560346|NCT02386761|DRUG|Multiple Ascending Dose (MAD)|
219560347|NCT06233539|OTHER|Observational research without intervention|Observational research without intervention
219560348|NCT03761706|BEHAVIORAL|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
219560349|NCT03761706|OTHER|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
219560350|NCT03785691|DRUG|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
219395173|NCT04907006|DRUG|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
219395174|NCT03990766|DRUG|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
219395175|NCT03990766|DRUG|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
219395176|NCT05521685|PROCEDURE|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
219395177|NCT00006360|DRUG|radioprotection|
219395178|NCT00006360|RADIATION|radiation therapy|
219395179|NCT02272621|PROCEDURE|Minimally invasive aortic valve replacement|
219395180|NCT02272621|PROCEDURE|Full sternotomy aortic valve replacement|
219395181|NCT02575794|DRUG|Terameprocol|Given PO
219395182|NCT02575794|OTHER|Pharmacological Study|Correlative studies
219395183|NCT02232672|DEVICE|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
219395184|NCT00403117|DRUG|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
219395185|NCT00403117|DRUG|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
219395186|NCT00403117|DRUG|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
219395187|NCT00403117|DRUG|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
219395188|NCT00403117|DRUG|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
219395189|NCT00403117|DRUG|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
219395190|NCT00403117|DRUG|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
219395191|NCT00403117|DRUG|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
219395192|NCT00403117|DRUG|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
219395193|NCT00403117|DRUG|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
219395194|NCT06290830|BEHAVIORAL|Abdominal massage group|abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
219189104|NCT06668441|DRUG|Minimally invasive surgery plus low-dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.001mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
219395195|NCT06290830|BEHAVIORAL|Kegel Exercises group|Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
219395196|NCT06290830|BEHAVIORAL|Both abdominal massage and kegel exercises to gether|with both exercises are performed to accelerate the peristalsis movement by mechanical movements
219395197|NCT01543490|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
219395198|NCT01543490|OTHER|Vehicle|Vehicle twice daily for 2 weeks
219395199|NCT05445622|OTHER|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
219395200|NCT00119301|DRUG|leucovorin calcium|
219395201|NCT00119301|DRUG|methotrexate|
219395202|NCT00119301|DRUG|trimetrexate glucuronate|
219395203|NCT03026504|DRUG|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
219395204|NCT04435262|OTHER|Remote Monitoring|Remote Monitoring Follow-up
219395205|NCT04655950|OTHER|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
219395206|NCT05005559|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
219395207|NCT05005559|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
219560351|NCT03785691|DRUG|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
219560352|NCT03785691|DRUG|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
219560353|NCT01732679|OTHER|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
219560354|NCT00378027|DRUG|Fondaparinux|Administer Fondaparinux Risk Stratify
219560355|NCT01920750|BIOLOGICAL|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
219395208|NCT06348420|PROCEDURE|anti-reflux mucosal valvuloplasty (ARMV)|During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
219395209|NCT00092586|DRUG|MK0653, ezetimibe|
219560356|NCT01920750|BIOLOGICAL|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
219560357|NCT01920750|OTHER|Mock Antigen|Physiological saline
219560358|NCT03774199|DEVICE|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
219560359|NCT01129323|DRUG|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
219560360|NCT05868824|OTHER|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
219560361|NCT02971787|DIETARY_SUPPLEMENT|Probiotics|Day 1-21: 2 capsules per day
219560362|NCT02971787|DIETARY_SUPPLEMENT|Salt|Day 8-21: 10 tablets à 600 mg per day
219560363|NCT06024382|OTHER|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
219560364|NCT06024382|OTHER|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
219560365|NCT01977456|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
219189105|NCT06668441|DRUG|Minimally invasive surgery plus medium dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.003mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
219395210|NCT00092586|DRUG|Comparator: statins|
219395211|NCT02075502|BEHAVIORAL|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
219395212|NCT02075502|PROCEDURE|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
219395213|NCT02075502|PROCEDURE|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
219560366|NCT01142661|DRUG|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
219560367|NCT00409461|DRUG|ATG-Sirolimus-Tacrolimus|
219560368|NCT06030128|BEHAVIORAL|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
219560369|NCT04220736|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
219560370|NCT02350036|OTHER|ultrasound monitoring|Uterine artery Doppler assessment
219560371|NCT04651920|GENETIC|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
219560372|NCT00434590|DRUG|Enteric coated mycophenolate sodium (Myfortic®)|
219560373|NCT00779441|DRUG|Zolpidem 10mg tablets|
219560374|NCT02727725|OTHER|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
219395214|NCT05684159|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
219395215|NCT04723524|COMBINATION_PRODUCT|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
219395216|NCT04723524|OTHER|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
219395217|NCT06203548|BEHAVIORAL|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
219395218|NCT06036433|DEVICE|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
219395219|NCT06036433|DEVICE|Infrared & Red LED photobiomodulation device|Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
219395220|NCT05216211|DRUG|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
219395221|NCT04868461|DIETARY_SUPPLEMENT|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
219395222|NCT04868461|DIETARY_SUPPLEMENT|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
219395223|NCT04868461|DIETARY_SUPPLEMENT|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
219001563|NCT07131111|RADIATION|CMR|"CMR examinations will be performed using a commercially available 1.5 Tesla whole-body scanner (Ingenia, Philips Healthcare, release 4.1.3.0). In pediatric or uncooperative patients, free-breathing sequences were used when breath-holding was not feasible.~Brachial blood pressure was measured in the right arm in the supine position immediately before image acquisition using automated oscillometric devices.~Cine steady-state free precession (SSFP) sequences were obtained in multiple views including the short axis of the ascending aorta (AAO) and descending aorta (DAO), as well as the aortic root to evaluate aortic valve morphology (bicuspid vs tricuspid).~Left ventricular (LV) and left atrial (LA) functional parameters were assessed by standard volumetric analysis. The following CMR-derived parameters were collected:~Left ventricular ejection fraction (LVEF) Left ventricular strain Left ventricular mass index (LVMI) Left atrial volume Left atrial strain LV and LA strain were analyzed usi"
219001564|NCT03686657|DRUG|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
219560375|NCT00248937|BEHAVIORAL|Positive affect and self-affect induction|
219001565|NCT03686657|DRUG|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
219395224|NCT04868461|DIETARY_SUPPLEMENT|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
219395225|NCT02380352|DRUG|Amoxicillin|
219395226|NCT02380352|DRUG|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
219395227|NCT01452776|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
219560376|NCT04834336|DEVICE|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
219560377|NCT04834336|OTHER|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
219560378|NCT00176943|DRUG|Aldara Cream 5%|
219560379|NCT03902301|DIETARY_SUPPLEMENT|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
219001566|NCT03686657|DRUG|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
219001567|NCT04600921|DRUG|Ertugliflozin 5 mg|The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.
219001568|NCT04600921|DRUG|Placebo 5mg|The subject will receive Placebo 5mg orally daily for 52 weeks.
219395228|NCT01452776|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
219395229|NCT01840176|PROCEDURE|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
219395230|NCT04168645|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
219395231|NCT02343536|DRUG|Oral Azacitidine|
219001569|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
219001570|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
219001571|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
219001572|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
219001573|NCT06607484|DRUG|SR-878|Intravenous infusion
219395232|NCT02343536|DRUG|Rituximab|
219395233|NCT02343536|DRUG|cyclophosphamide|
219395234|NCT02343536|DRUG|Vincristine|
219395235|NCT02343536|DRUG|Prednisone|
219395236|NCT01797276|DRUG|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
219395237|NCT06369675|DRUG|MOB015B|Topical formulation
219395238|NCT06369675|DRUG|0.2% SLS|Positive control
219395239|NCT06369675|DRUG|0.9% Saline|Negative control
219395240|NCT06369675|DRUG|MOB015B vehicle|Topical formulation
219395241|NCT02155296|BEHAVIORAL|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
219395242|NCT05128435|DIAGNOSTIC_TEST|Blood sample|Blood sample taken 3 to 5 months after the infection
219395243|NCT06512415|DRUG|10 mcg Norepinephrine|The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe
219395244|NCT06512415|DRUG|15 mcg Norepinephrine|The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
219395245|NCT03459131|DEVICE|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
219395246|NCT03459131|DEVICE|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
219395247|NCT02004054|OTHER|measure of pupil diameter|The measure will use infra-red cameras
219395248|NCT02049255|DRUG|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
219001574|NCT06607484|DRUG|Placebo|Intravenous infusion
219001575|NCT06596031|BEHAVIORAL|Health coaching|The core belief in coaching is that people are resourceful and that the participant knows what is best for themselves. If the participants are assigned to the health coaching group, they will have access to a health coach with a physiotherapist background. Instead of offering physiotherapy advice, however, the health coaching will work with the participant to come up with ideas that work the best for them to manage their health and wellness to prepare for surgery, including addressing some difficulties the participant are facing when using the online resource.
219001576|NCT06596031|BEHAVIORAL|Digital toolkit|This intervention provides, via a website, self-management support of preoperative rehabilitation for hip or knee replacement based on NICE guidelines Joint replacement (primary): hip and knee. This includes guidance for patients to undertake a strengthening programme that will aid recovery, lifestyle behaviours including weight management, diet and smoking cessation, and maximising functional independence and quality of life before surgery.
219395249|NCT02049255|DRUG|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
219395250|NCT04703660|PROCEDURE|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
219395251|NCT02219555|DRUG|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
219395252|NCT02219555|PROCEDURE|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
219395253|NCT04623190|BEHAVIORAL|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
219395254|NCT04623190|BEHAVIORAL|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
219395255|NCT03132805|BEHAVIORAL|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
219395256|NCT03132805|BEHAVIORAL|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
219395257|NCT04646980|DIETARY_SUPPLEMENT|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
219395258|NCT04646980|OTHER|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
219395259|NCT03517748|DEVICE|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
219395260|NCT03517748|DEVICE|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
219395261|NCT04708392|DEVICE|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
219395262|NCT00665496|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
219395263|NCT00665496|DRUG|Placebo|Matching Placebo
219395264|NCT04254289|BEHAVIORAL|Usual Care|Usual care
219395265|NCT04254289|BEHAVIORAL|Home-based exercise program|Home-based program determined by exercise physiologist
219560380|NCT03902301|DIETARY_SUPPLEMENT|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
219560381|NCT01668823|DRUG|HPPH|Given IV
219560382|NCT01668823|DRUG|photodynamic therapy|Undergo photodynamic therapy with HPPH
219560383|NCT01668823|PROCEDURE|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
219560384|NCT04296201|DEVICE|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
219560385|NCT01474915|DRUG|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
219560386|NCT01474915|DRUG|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
219560387|NCT01474915|DRUG|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
219560388|NCT01474915|DRUG|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
219560389|NCT03499366|DIAGNOSTIC_TEST|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
219560390|NCT01031992|DRUG|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
219560391|NCT01031992|DRUG|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
219395266|NCT01608789|DEVICE|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
219395267|NCT06843889|DRUG|Toripalimab (240mg day1, Q3W*3cycle)|Phase 1: Toripalimab (240mg day1, Q3W\*2cycle) + investigator's choice of clinical conventional chemotherapy; Phase 2: Toripalimab (240mg day1, Q3W\*1cycle) + radiotherapy (intensity modulated radiotherapy, 40Gy/20F, 2Gy/F); Surgery was performed 4-6 weeks after completion, and subsequent treatment options were considered after surgery according to MDT discussion.
219395268|NCT04676464|DIAGNOSTIC_TEST|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
219395269|NCT03896399|PROCEDURE|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
219395270|NCT03950245|OTHER|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
219395271|NCT03950245|OTHER|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
219395272|NCT03950245|OTHER|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
219395273|NCT03950245|OTHER|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
219395274|NCT01520415|DRUG|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
219395275|NCT01520415|DRUG|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
219395276|NCT05055115|PROCEDURE|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
219395277|NCT03918642|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
219395278|NCT03918642|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
219560392|NCT05898113|OTHER|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
219560393|NCT05898113|OTHER|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
219560394|NCT02514395|OTHER|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2\[32\] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
219560395|NCT05131516|DIAGNOSTIC_TEST|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
219560396|NCT01487434|BEHAVIORAL|Check & Connect|Structured mentoring and case management
219560397|NCT03380416|OTHER|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
219560398|NCT03380416|OTHER|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
219560399|NCT01873781|DRUG|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
219560400|NCT02431624|DRUG|BTDS|
219560401|NCT03429049|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 injection
219560402|NCT03429049|DRUG|Placebo|Receiving Placebo injection
219560403|NCT05739734|DRUG|CRIS100|local application of CRIS100
219395279|NCT04349995|DEVICE|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
219395280|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
219395281|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
219395282|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
219395283|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
219395284|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
219395285|NCT03478124|BEHAVIORAL|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
219560404|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
219560405|NCT01919541|DEVICE|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
219560406|NCT01919541|DEVICE|hyperinsulinemic euglycemic hyperaminoacid clamp|
219001577|NCT06871410|DRUG|Autologous Anti-CD83 CAR T-cells|Given IV
219395286|NCT03825042|DIETARY_SUPPLEMENT|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
219395287|NCT03825042|DIETARY_SUPPLEMENT|Placebo|Inactive compound in oral tablets
219395288|NCT02385032|DRUG|Ursodiol|
219560407|NCT01919541|DIETARY_SUPPLEMENT|whey protein supplementation|
219560408|NCT01919541|OTHER|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
219560409|NCT03034434|DEVICE|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
219560410|NCT05139758|DIAGNOSTIC_TEST|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
219560411|NCT00996424|DRUG|Acetylcysteine|Inhalation with N-Acetylcysteine
219560412|NCT00996424|DRUG|normal saline|Inhalation with normal saline solution
219560413|NCT02685696|DEVICE|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
219560414|NCT02685696|DEVICE|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
219560415|NCT03092596|BEHAVIORAL|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
219560416|NCT03092596|BEHAVIORAL|Patient health navigator-administered screening tool|patient health navigator-administered screener
219560417|NCT03092596|BEHAVIORAL|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
219560418|NCT02321124|OTHER|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
219001578|NCT06871410|PROCEDURE|Biospecimen Collection|Undergo bone marrow aspiration blood sample collection
219395289|NCT02385032|DRUG|URSO Forte|
219395290|NCT00805883|PROCEDURE|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
219560419|NCT02321124|BEHAVIORAL|life style advice|We will apply life style advice for four weeks.
219560420|NCT03609242|BEHAVIORAL|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
219560421|NCT02491996|BEHAVIORAL|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
219560422|NCT00164255|DRUG|sulfadoxine/pyrimethamine|
219560423|NCT00164255|DRUG|sulfadoxine/pyrimethamine plus artesunate|
219001579|NCT06871410|PROCEDURE|Chest Radiography|Undergo chest x-ray
219001580|NCT06871410|PROCEDURE|Computed Tomography|Undergo CT
219001581|NCT06871410|DRUG|Cyclophosphamide|Given IV
219001582|NCT06871410|PROCEDURE|Echocardiography|Undergo ECHO
219001583|NCT06871410|DRUG|Fludarabine Phosphate|Given IV
219001584|NCT06871410|DRUG|Hydroxyurea|Given hydroxyurea
219001585|NCT06871410|PROCEDURE|Leukapheresis|Undergo leukapheresis
219001586|NCT06871410|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219001587|NCT06871410|PROCEDURE|Positron Emission Tomography|Undergo PET
219001588|NCT06871410|OTHER|Questionnaire Administration|Ancillary studies
219001589|NCT05193968|OTHER|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
219395291|NCT05801523|PROCEDURE|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
219395292|NCT05801523|PROCEDURE|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
219560424|NCT01723150|DRUG|Ciprofloxacin|
219560425|NCT01723150|DRUG|Ceftriaxone|
219560426|NCT01723150|DRUG|Trimethoprim/sulfamethoxazole|
219560427|NCT01723150|DRUG|Ertapenem|
219560428|NCT05945667|DRUG|Monural|1 sachet, only 1st day of trial
219560429|NCT05945667|DIETARY_SUPPLEMENT|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
219560430|NCT06021106|OTHER|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.
219395293|NCT05453370|DEVICE|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
219395294|NCT05453370|OTHER|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
219560431|NCT06021106|OTHER|routine treatment and care|routine treatment and care
219560432|NCT00661921|BIOLOGICAL|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
219560433|NCT00661921|BIOLOGICAL|Placebo|AMG 108 volume matching placebo
219560434|NCT05528302|OTHER|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
219560435|NCT00079521|PROCEDURE|Therapeutic Touch|
219560436|NCT04030013|OTHER|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
219395295|NCT05382676|DEVICE|Eyeswift Pro|assessment of visual function parameters
219395296|NCT01943630|DRUG|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
219395297|NCT01943630|DRUG|Vehicle|Administration of Vehicle once a day (overnight)
219395298|NCT01654562|DRUG|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
219395299|NCT01959555|OTHER|No treatment given|Patients will not be treated with any specific product. Data collection only.
219560437|NCT04654234|DEVICE|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
219395300|NCT03080922|BIOLOGICAL|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
219395301|NCT03710785|BEHAVIORAL|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
219560438|NCT04882137|BEHAVIORAL|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
219560439|NCT02902887|DEVICE|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
219560440|NCT04814459|OTHER|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
219560441|NCT04449536|DRUG|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
219560442|NCT01891812|DRUG|Nitrous oxide 50%|
219560443|NCT04865484|PROCEDURE|Surgical resection|Surgical resection of fibrostenotic area (\>4cm)
219560444|NCT04865484|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy of fibrostenotic area (≤4cm)
219560445|NCT04865484|PROCEDURE|Strictureplasty|Strictureplasty of fibrostenotic area (≤4cm)
219001590|NCT05193968|DRUG|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
219395302|NCT06169865|OTHER|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
219395303|NCT03723265|DEVICE|Cardiac Resynchronization Therapy|
219395304|NCT05644210|DRUG|Telitacicept|160mg once a week for 24 weeks
219395305|NCT05644210|DRUG|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
219395306|NCT05644210|DRUG|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
219395307|NCT05644210|DRUG|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
219395308|NCT05644210|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
219560446|NCT04380675|OTHER|Music|Music listening during ESWL
219560447|NCT04689100|DRUG|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
219560448|NCT04689100|DRUG|JMT101|IV infusion Q2W (28-day cycles)
219560449|NCT00144833|DRUG|fosamprenavir/ritonavir (700mg/100mg BID)|
219560450|NCT00144833|DRUG|fosamprenavir/ritonavir (1400mg/100mg BID)|
219560451|NCT00144833|DRUG|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
219560452|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
219560453|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Hamstring Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
219560454|NCT06394115|DEVICE|Ostomy pouch|Ostomy pouch coated with novel technology
219560455|NCT01841060|PROCEDURE|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
219560456|NCT03879486|OTHER|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
219001591|NCT05193968|DRUG|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
219001592|NCT05193968|DRUG|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
219001593|NCT05193968|DRUG|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
219001594|NCT06684743|BIOLOGICAL|RSV prefusion F protein-based vaccine|For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
219395309|NCT05644210|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
219395310|NCT04483362|BEHAVIORAL|Complex physical activity intervention|"Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items"
219395311|NCT05573594|OTHER|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
219395312|NCT05573594|OTHER|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
219560457|NCT04458168|BEHAVIORAL|Use of Purposeful app|"Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment."
219395313|NCT01225393|DRUG|MLTA3698A|Subcutaneous repeating dose
219395314|NCT01225393|DRUG|adalimumab|Subcutaneous repeating dose
219395315|NCT01225393|DRUG|leflunomide|Stable dose if not on methotrexate
219395316|NCT01225393|DRUG|methotrexate|Stable dose if not on leflunomide
219395317|NCT01225393|DRUG|placebo|Subcutaneous repeating dose
219395318|NCT04270851|DIAGNOSTIC_TEST|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
219395319|NCT04270851|DIAGNOSTIC_TEST|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
219395320|NCT03591705|DRUG|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
219395321|NCT03591705|DRUG|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
219395322|NCT02992470|DIETARY_SUPPLEMENT|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
219395323|NCT02992470|DIETARY_SUPPLEMENT|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
219395324|NCT04488692|OTHER|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
219395325|NCT04488692|OTHER|Sham intervention|friendly visit and education
219560458|NCT01467596|DEVICE|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
219560459|NCT06058364|DIETARY_SUPPLEMENT|Intervention 1 - Triglyceride|Triglyceride (1 softgel each morning with a glass of water)
219560460|NCT06058364|DIETARY_SUPPLEMENT|Intervention 2 - Placebo|Placebo (1 softgel each morning with a glass of water)
219560461|NCT00915434|DRUG|JNJ-31001074|
219560462|NCT00812318|DRUG|GSK1265744 10 mg oral solution|GSK1265744
219560463|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
219560464|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
219560465|NCT01833754|DRUG|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
219395326|NCT02316470|BIOLOGICAL|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
219395327|NCT02316470|BIOLOGICAL|Placebo|phosphate buffered saline (PBS) solution
219395328|NCT02467452|DRUG|BDP/FF/GB|
219395329|NCT02467452|DRUG|FlF/VI + Tiotropium|
219395330|NCT04451434|DRUG|Danicopan|Oral tablet
219395331|NCT04788303|OTHER|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
219395332|NCT04788303|OTHER|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
219395333|NCT03475407|DRUG|Ozurdex intravitreal injection|"1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
219395334|NCT03475888|DEVICE|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
219395335|NCT00404404|BIOLOGICAL|bevacizumab|
219395336|NCT00404404|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219395337|NCT03070457|OTHER|Early discharge|Patients randomised to early discharge or not
219395338|NCT03070457|OTHER|Conventional protocol|Discharge as usually done 48-72 hours after surgery
219395339|NCT04450355|DRUG|Nefopam 80mg/day|continuous nefopam infusion
219395340|NCT04450355|DRUG|Normal saline|continuous normal saline infusion
219395341|NCT01856491|DEVICE|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
219395342|NCT01210950|BIOLOGICAL|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
219395343|NCT02823262|OTHER|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
219395344|NCT02823262|OTHER|Usual Care|
219395345|NCT04695730|OTHER|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
219395346|NCT04695730|OTHER|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
219560466|NCT02934633|BEHAVIORAL|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
219560467|NCT02934633|BEHAVIORAL|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
219560468|NCT00462891|OTHER|IT System|
219560469|NCT04897113|PROCEDURE|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
219560470|NCT04897113|PROCEDURE|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
219560471|NCT00736918|BEHAVIORAL|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
219560472|NCT00736918|OTHER|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
219560473|NCT01731249|BIOLOGICAL|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
219560474|NCT01731249|BIOLOGICAL|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
219560475|NCT00440622|DRUG|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
219560476|NCT00440622|DRUG|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
219560477|NCT00440622|DRUG|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
219560478|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560479|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560480|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560481|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560482|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560483|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
219560484|NCT05597839|DRUG|DF9001|Immunotherapy agent targeting NK cells.
219560485|NCT05597839|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
219560486|NCT05597839|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
219754395|NCT05243030|BEHAVIORAL|Motivational Interactive Text Messaging (MTM)|"Participants will receive automated motivational text messages to promote PrEP initiation and adherence. These contents will be customized based on their readiness to change in regards to PrEP. The message content is individualized based on participant response to baseline survey. Those participants who indicate that they are ready to set the goal to take PrEP will receive text messages reminding them to take PrEP. Those who indicate that they are less than ready to take their PrEP can choose from a range of alternatives, such as taking on-demand PrEP or just think about taking PrEP. For those who are not ready to take PrEP, the content will be individualized based on the participant's choice, i.e., a daily message encouraging them to work toward their chosen goal. Participants who are currently not on PrEP will receive daily text messages regarding PrEP effectiveness, HIV risk and where to access PrEP."
219754396|NCT05243030|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3 and 6. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
219754397|NCT04630808|DRUG|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1%
219754398|NCT04630808|DRUG|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005%
219754399|NCT05722327|DRUG|MRTX849|Given by PO (mouth)
219754400|NCT05722327|DRUG|Irinotecan|Given by IV (vein)
219754401|NCT05722327|DRUG|Cetuximab|Given by IV (vein)
219754402|NCT05165472|OTHER|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
219754403|NCT05558644|OTHER|single arm for all patients|"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
219754404|NCT06225115|DRUG|KYN-5356|KYN-5356, oral tablet
219754405|NCT06225115|DRUG|placebo|placebo, oral tablet
219754406|NCT01301677|DRUG|Hydrocortisone|Hydrocortisone liquid formulation
219395347|NCT06513325|OTHER|Canadian Occupational Performance Measure|It is a semi-structured scale that helps to identify problematic areas of performance experienced by individuals and to measure their perceived occupational performance and satisfaction. This scale assesses the level of performance of self-care, productivity and leisureoccupations and satisfaction with these performances as perceived by the individual.
219395348|NCT05318625|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
219395349|NCT04056130|DRUG|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
219395350|NCT04056130|DRUG|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
219395351|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
219395352|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
219395353|NCT05031325|DEVICE|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
219395354|NCT00184639|DRUG|insulin detemir|
219395355|NCT00079612|DRUG|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
219560487|NCT02459418|DRUG|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
219560488|NCT02459418|DRUG|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
219560489|NCT04600739|PROCEDURE|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
219560490|NCT02332213|PROCEDURE|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
219560491|NCT02332213|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
219560492|NCT02332213|PROCEDURE|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
219560493|NCT02332213|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
219560494|NCT02332213|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
219560495|NCT02332213|PROCEDURE|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
219560496|NCT01137734|DEVICE|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
219560497|NCT01137734|DEVICE|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
219560498|NCT04665817|DIAGNOSTIC_TEST|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
219560499|NCT04665817|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
219395356|NCT00079612|DRUG|Placebo|2x 400mg tabs daily
219560500|NCT04665817|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
219395357|NCT02299908|DRUG|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
219395358|NCT02299908|DRUG|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
219395359|NCT00667758|DRUG|Cetrorelix|3-5 mg s.c. on days 1-5
219395360|NCT00667758|DRUG|Placebo|3-5 ml NaCl s.c. on days 1-5
219395361|NCT02601885|DRUG|ABT-555|Intravenous Infusion
219395362|NCT02601885|OTHER|Placebo|Intravenous Infusion
219395363|NCT03466346|DRUG|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
219395364|NCT03466346|BEHAVIORAL|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
219395365|NCT01207739|DRUG|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
219560501|NCT00781521|DRUG|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
219560502|NCT02678871|DEVICE|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
219560503|NCT02678871|DEVICE|WATCHMAN|LAA closure with the WATCHMAN device
219560504|NCT01872715|DRUG|Oracea|
219560505|NCT04085471|DIAGNOSTIC_TEST|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
219560506|NCT01404871|DRUG|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
219560507|NCT01404871|DRUG|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
219560508|NCT01404871|DRUG|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
219560509|NCT02340624|BEHAVIORAL|Referral to SmokeFreeMoms, Quitline or Brief intervention|"1. SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~2. The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~3. Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
219560510|NCT00564343|OTHER|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
219560511|NCT02034448|PROCEDURE|Continuous Renal Replacement Therapy|
219560512|NCT00963651|DEVICE|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
219560513|NCT01226251|DEVICE|In vitro chair side test|Colour evaluation of a strip
219560514|NCT04674397|RADIATION|Radioisotope GFR test|
219560515|NCT05258630|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
219560516|NCT05258630|BEHAVIORAL|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
219560517|NCT01926275|DEVICE|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
219560518|NCT01926275|DEVICE|NPPV|noninvasive positive pressure ventilation
219560519|NCT01926275|DEVICE|IMT|inspiratory muscle training
219560520|NCT03666481|BEHAVIORAL|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
219560521|NCT02893995|DRUG|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
219560522|NCT02893995|DRUG|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
219560523|NCT04405908|BIOLOGICAL|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
219560524|NCT04405908|BIOLOGICAL|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
219395366|NCT01207739|DRUG|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
219395367|NCT01207739|DRUG|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
219395368|NCT03716063|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
219754407|NCT01301677|DRUG|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
219395369|NCT03041376|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
219395370|NCT06534944|DRUG|Nicotinamide riboside|NR 1g daily for 4 weeks
219395371|NCT04082767|DRUG|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
219395372|NCT04082767|DRUG|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
219395373|NCT04393181|PROCEDURE|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
219395374|NCT04393181|PROCEDURE|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
219395375|NCT03092258|OTHER|Questionnaire|Questionnaire to be completed by staff
219395376|NCT05085392|BEHAVIORAL|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
219560525|NCT04405908|BIOLOGICAL|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
219560526|NCT04405908|BIOLOGICAL|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
219560527|NCT00363155|DRUG|KRN7000|
219560528|NCT04167618|DRUG|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
219560529|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
219560530|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
219001595|NCT04080492|OTHER|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
219560531|NCT01780480|DRUG|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
219560532|NCT01780480|DRUG|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
219395377|NCT01315119|PROCEDURE|SPY Intra-Operative Angiography|Calculated per patient
219395378|NCT00500149|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
219395379|NCT00500149|DRUG|Placebo|Placebo
219395380|NCT06516796|OTHER|No intervention|Patients were retrospectively screened.
219560533|NCT01780480|PROCEDURE|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
219560534|NCT00470860|BEHAVIORAL|Participation in LOFTS online tutorial|
219560535|NCT02518217|BEHAVIORAL|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
219560536|NCT02518217|BEHAVIORAL|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
219560537|NCT02518217|BEHAVIORAL|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
219560538|NCT02951936|DEVICE|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
219395381|NCT00058578|DRUG|Cyclophosphamide|
219395382|NCT00058578|DRUG|Mesna|
219395383|NCT00058578|DRUG|G-CSF|
219395384|NCT00058578|PROCEDURE|Leukopheresis|
219395385|NCT00058578|PROCEDURE|Total Body Irradiation|
219395386|NCT06444737|DRUG|Intravenous ondansetron|Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
219189106|NCT06668441|DRUG|Minimally invasive surgery plus high dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.009mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
219395387|NCT06444737|DRUG|Intravenous normal saline|Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
219395388|NCT01609959|DRUG|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
219395389|NCT01609959|DRUG|Valsartan|Valsartan 160 mg per day
219395390|NCT00353847|DEVICE|Acupuncture|
219395391|NCT04747574|DRUG|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
219395392|NCT03557398|DEVICE|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
219395393|NCT06482645|PROCEDURE|Perilesional/regional systematic biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
219395394|NCT06482645|PROCEDURE|Combination of systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
219395395|NCT04138524|OTHER|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
219395396|NCT01158534|DRUG|celecoxib|Given orally
219395397|NCT01158534|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously
219395398|NCT01158534|OTHER|polymerase chain reaction|Correlative studies
219395399|NCT01158534|OTHER|laboratory biomarker analysis|Correlative studies
219395400|NCT01158534|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
219395401|NCT01158534|OTHER|immunologic technique|Correlative studies
219395402|NCT01158534|OTHER|immunohistochemistry staining method|Correlative studies
219395403|NCT01158534|OTHER|flow cytometry|Correlative studies
219395404|NCT03357822|DRUG|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
219395405|NCT03357822|DRUG|Entecavir|0.5mg entecavir is orally taken every day
219395406|NCT03357822|DRUG|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
219395407|NCT04618692|OTHER|Surgical Loupes|Biliary reconstruction will be performed using surgical loupe
219395408|NCT04618692|OTHER|Microscope|Biliary reconstruction will be performed using microscope
219395409|NCT02588846|DEVICE|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
219395410|NCT02929992|OTHER|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
219395411|NCT02929992|OTHER|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
219395412|NCT02929992|OTHER|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
219395413|NCT02929992|OTHER|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
219395414|NCT01988012|BIOLOGICAL|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
219395415|NCT00521339|DRUG|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
219395416|NCT04503486|DIAGNOSTIC_TEST|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
219395417|NCT04503486|DIAGNOSTIC_TEST|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
219395418|NCT02372825|PROCEDURE|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
219395419|NCT00788658|BEHAVIORAL|Diet modifications|Diet consultation
219395420|NCT00788658|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
219395421|NCT04842721|DRUG|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
219395422|NCT04842721|OTHER|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
219395423|NCT00426049|DRUG|Everolimus|
219560539|NCT02951936|DEVICE|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
219560540|NCT01658202|DRUG|V0116 transdermal patch (Test treatment )|
219560541|NCT01658202|DRUG|Nicotine transdermal patch (Reference Treatment )|
219001596|NCT02048605|BEHAVIORAL|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
219560542|NCT05744700|DIETARY_SUPPLEMENT|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
219560543|NCT05744700|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
219560544|NCT02553655|PROCEDURE|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
219395424|NCT02467907|DRUG|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
219395425|NCT02467907|DRUG|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
219395426|NCT02467907|DRUG|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
219560545|NCT02553655|PROCEDURE|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
219560546|NCT02553655|PROCEDURE|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
219560547|NCT06065865|BEHAVIORAL|Guidance document|"The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task."
219560548|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
219754408|NCT01301677|DRUG|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
219001597|NCT02048605|BEHAVIORAL|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
219001598|NCT06626334|DEVICE|Bright Blue Light|Bright blue light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#132, Medium Blue) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
219754409|NCT05505461|DRUG|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
219189107|NCT04707326|DRUG|Dolutegravir / Lamivudine Pill|HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
219189108|NCT03690115|DRUG|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
219395427|NCT00648843|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
219395428|NCT00648843|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
219395429|NCT00089843|DRUG|Testosterone|Testosterone patch 150mcg daily
219395430|NCT00089843|DRUG|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
219754410|NCT04073056|DRUG|Bupivacaine|Bupivacaine Hcl 0.25% Inj
219754411|NCT03949023|PROCEDURE|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
219754412|NCT03371719|DRUG|Apalutamide|Given PO
219754413|NCT03371719|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219395431|NCT00089843|DRUG|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
219395432|NCT00089843|DRUG|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
219560549|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
219395433|NCT02664285|OTHER|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
219395434|NCT02664285|OTHER|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
219395435|NCT04712578|DIETARY_SUPPLEMENT|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
219395436|NCT04712578|DIETARY_SUPPLEMENT|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
219395437|NCT04712578|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
219395438|NCT02697461|OTHER|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
219395439|NCT02697461|OTHER|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
219560550|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
219560551|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
219560552|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
219189109|NCT05540262|DRUG|Edaravone|Edaravone injection 30mg three times a day
219560553|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
219189110|NCT05809830|DRUG|LB-100 plus Doxorrubicin|In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin
219189111|NCT05809830|DRUG|Doxorubicin|The control arm in Phase II will be Doxorrubicin alone
219395440|NCT03234868|DEVICE|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
219395441|NCT03234868|DEVICE|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
219395442|NCT01723501|DRUG|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
219395443|NCT01723501|DRUG|sterile water|Sterile water wipes (placebo)
219395444|NCT01351519|DRUG|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
219395445|NCT02768909|DEVICE|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
219560554|NCT05788276|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin active tablets
219560555|NCT05788276|DRUG|Placebo|Matched placebo tablets
219560556|NCT06227429|DRUG|Nitisinone|According to prescription
219395446|NCT02768909|OTHER|Survey & Physical Exam|2\. Perform a oriented survey for risk factors and a complete physical exam.
219395447|NCT02768909|OTHER|Chest X-ray|Perform anteroposterior chest X-ray
219395448|NCT02768909|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
219395449|NCT02768909|DEVICE|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
219395450|NCT02768909|DEVICE|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
219395451|NCT02768909|DEVICE|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
219395452|NCT02768909|DEVICE|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
219395453|NCT06390618|OTHER|Aerobic Exercise (AE) Group|"A total of 24 sessions of aerobic exercise will be performed in 8 weeks, 3 days a week.~For aerobic exercise, a moderate intensity (50-60%) aerobic exercise program will be applied using the karvonen method. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
219395454|NCT06390618|OTHER|Combined Exercise (CE) Group|"In the combined exercise group, biopsychosocial exercise will be performed in addition to aerobic exercise.~In the combined exercise group, in addition to aerobic exercise (3, 8 weeks, 24 sessions of aerobic exercise per week), 16 sessions of biopsychosocial-based group exercise treatment will be performed 2 days a week for a total of 8 weeks.~BETY approach will be used in group exercise treatment."
219560557|NCT06536439|DEVICE|Pre-operative explanation of the procedure (DIPLANN + CT)|Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
219560558|NCT06536439|DEVICE|Pre-operative surgical planning (DIPLANN + CT)|Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.
219560559|NCT06536439|PROCEDURE|RAPN (DIPLANN + CT)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.
219560560|NCT06536439|DEVICE|Pre-operative explanation of the procedure (CT only)|Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
219560561|NCT06536439|DEVICE|Pre-operative surgical planning (CT only)|Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.
219560562|NCT06536439|PROCEDURE|RAPN (CT only)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
219560563|NCT05914506|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
219395455|NCT05170191|BEHAVIORAL|Sleep Deprivation|The participants will stay awake for 24 hours.
219395456|NCT03920605|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
219560564|NCT05108883|DEVICE|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
219560565|NCT05478187|DEVICE|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
219560566|NCT05478187|OTHER|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
219560567|NCT06384196|BEHAVIORAL|Identity-Based Transdiagnostic Therapy (IBTT)|In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
219395457|NCT03920605|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
219395458|NCT03920605|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
219395459|NCT00865501|DRUG|spironolactone|25mg per oral once daily
219395460|NCT00865501|DRUG|placebo|placebo
219395461|NCT03333369|DRUG|200 mg levodopa/50 mg benserazide|
219395462|NCT03333369|DRUG|Dextrose|
219395463|NCT02240628|DEVICE|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
219395464|NCT02240628|DRUG|Saline|Patients in arm 2 will receive Saline with the Propofol.
219560568|NCT06384196|BEHAVIORAL|Unified Protocol|In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
219560569|NCT05053568|DEVICE|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
219754414|NCT03371719|OTHER|Placebo Administration|Given PO
219560570|NCT02046863|DEVICE|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
219560571|NCT00835796|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
219395465|NCT02240628|DRUG|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
219395466|NCT03450889|PROCEDURE|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
219395467|NCT05431465|OTHER|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
219395468|NCT05431465|OTHER|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
219395469|NCT01383044|PROCEDURE|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
219395470|NCT01383044|DRUG|carvedilol|carvedilol 6.25mg-12.5 mg per day
219395471|NCT01020292|DRUG|Nelfinavir|
219395472|NCT01140542|DRUG|Roflumilast|500µg, once daily
219395473|NCT04476771|BEHAVIORAL|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
219395474|NCT02107391|BIOLOGICAL|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
219395475|NCT02107391|DRUG|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
219395476|NCT02107391|DRUG|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
219395477|NCT02458651|OTHER|No intervention|No intervention administered in this study
219395478|NCT04003506|DRUG|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
219395479|NCT04003506|DRUG|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
219395480|NCT03626415|DRUG|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
219395481|NCT02022423|BEHAVIORAL|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
219395482|NCT02022423|BEHAVIORAL|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
219395483|NCT05159232|PROCEDURE|hospital stay|hospital stay in in inguinal hernia repair
219395484|NCT06212895|OTHER|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
219395485|NCT06035380|OTHER|placebo group|aromatherapy
219395486|NCT06035380|OTHER|mint oil group|aromatherapy
219395487|NCT06035380|OTHER|rose oil group|aromatherapy
219395488|NCT02897635|BEHAVIORAL|Individualized Integrative Medicine Intervention|
219560572|NCT00835796|DRUG|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
219395489|NCT02333240|OTHER|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
219395490|NCT05173272|DRUG|Neoadjuvant Therapy|Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
219395491|NCT05173272|RADIATION|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
219395492|NCT05173272|RADIATION|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
219395493|NCT01825044|DRUG|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
219395494|NCT01825044|DRUG|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
219395495|NCT02467595|DRUG|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
219395496|NCT02467595|DRUG|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
219395497|NCT02467595|DRUG|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
219395498|NCT02467595|DRUG|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
219395499|NCT02467595|DRUG|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
219395500|NCT00859898|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
219395501|NCT00859898|DRUG|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
219395502|NCT00859898|DRUG|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
219395503|NCT00859898|DRUG|dapagliflozin matching Placebo|Tablets
219395504|NCT00859898|DRUG|metformin HCl Modified Release matching Placebo|Tablets
219395505|NCT02253667|DEVICE|HFONC|
219560573|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
219560574|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
219560575|NCT01026857|DRUG|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
219560576|NCT01402128|DIETARY_SUPPLEMENT|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
219560577|NCT01402128|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219560578|NCT00651183|DRUG|Pramipexole immediate release|
219395506|NCT02253667|DEVICE|Conventional oxygen therapy|
219395507|NCT01302041|DRUG|Enzalutamide|Oral
219395508|NCT03697395|DIAGNOSTIC_TEST|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
219395509|NCT03697395|DRUG|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
219395510|NCT00565695|DEVICE|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
219395511|NCT01150994|BEHAVIORAL|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
219395512|NCT01872741|PROCEDURE|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
219395513|NCT01872741|PROCEDURE|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
219395514|NCT00771030|BIOLOGICAL|Brodalumab|Solution for subcutaneous or intravenous administration
219395515|NCT00771030|OTHER|Placebo|Solution for subcutaneous or intravenous administration
219395516|NCT01094964|BIOLOGICAL|BCG solution|
219560579|NCT02807441|DRUG|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
219560580|NCT01752530|OTHER|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
219560581|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
219560582|NCT02882269|DRUG|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
219560583|NCT02882269|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
219754415|NCT03772535|DIAGNOSTIC_TEST|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
219395517|NCT01094964|BIOLOGICAL|recombinant interferon alfa|
219395518|NCT01094964|DRUG|epirubicin hydrochloride|
219395519|NCT01094964|DRUG|mitomycin C|
219395520|NCT01094964|OTHER|laboratory biomarker analysis|
219395521|NCT01094964|PROCEDURE|hyperthermia treatment|
219395522|NCT01094964|PROCEDURE|quality-of-life assessment|
219395523|NCT02416908|DRUG|Selinexor|
219754416|NCT01300026|DRUG|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
219395524|NCT02416908|DRUG|Cladribine|
219395525|NCT02416908|DRUG|G-CSF|
219395526|NCT02416908|DRUG|Cytarabine|
219395527|NCT02416908|PROCEDURE|Bone marrow biopsy|
219395528|NCT04841135|OTHER|Multiomics quantification|One time blood, stool and urine samples will be taken.
219395529|NCT04841135|OTHER|Polysomnography|Facultative polysomnography
219395530|NCT02887105|OTHER|Standard neuropsychological assessment|
219395531|NCT02887105|OTHER|Brain MRI|
219395532|NCT04530812|OTHER|Best Practice|Maintain usual diet
219395533|NCT04530812|DIETARY_SUPPLEMENT|Kefir|Consume commercial kefir beverage
219395534|NCT04530812|OTHER|Quality-of-Life Assessment|Ancillary studies
219395535|NCT04530812|OTHER|Questionnaire Administration|Ancillary studies
219395536|NCT06532461|DEVICE|Mio Advanced infusions set|Insulin infusionsset fitting Medtronic 780 G insulin pump
219395537|NCT06532461|DRUG|Novorapid|Randomized to either Novorapid or Humalog
219395538|NCT06532461|DEVICE|Extended wear insulin infusion (EWIS)|Insulin infusionsset fitting Medtronic 780 G insulin pump
219395539|NCT06532461|DRUG|Humalog|Randomized to either Novorapid or Humalog
219395540|NCT00163553|DRUG|Pethidine|
219395541|NCT00163553|DRUG|Placebo|
219395542|NCT04877015|DEVICE|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
219560584|NCT03203772|OTHER|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
219560585|NCT04635332|BEHAVIORAL|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
219754417|NCT03232788|PROCEDURE|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
219754418|NCT03232788|DEVICE|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
219754419|NCT03232788|DEVICE|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
219754420|NCT04490278|OTHER|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
219395543|NCT04877015|DEVICE|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
219560586|NCT04635332|BEHAVIORAL|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
219560587|NCT03843515|DRUG|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
219560588|NCT01363011|DRUG|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
219560589|NCT01363011|DRUG|COBI|COBI 150 mg tablet administered with food orally once daily
219560590|NCT01363011|DRUG|ATV|ATV 300 mg tablet administered orally once daily
219560591|NCT01363011|DRUG|DRV|DRV 800 mg tablet administered orally once daily
219560592|NCT01363011|DRUG|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
219395544|NCT06138847|DIAGNOSTIC_TEST|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
219395545|NCT03333785|BEHAVIORAL|eOncoNote|"* Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
219395546|NCT01421290|PROCEDURE|Surgery|Knee surgery
219560593|NCT00585260|DRUG|mannitol|indirect mannitol challenge
219560594|NCT00680069|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
219560595|NCT05022368|DEVICE|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
219560596|NCT00148720|DRUG|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
219395547|NCT01421290|OTHER|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
219560597|NCT03153787|OTHER|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
219560598|NCT03558620|PROCEDURE|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
219560599|NCT03002792|PROCEDURE|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
219560600|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
219560601|NCT05999279|BEHAVIORAL|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
219560602|NCT00715091|DRUG|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
219560603|NCT00715091|DRUG|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
219560604|NCT01961882|DRUG|OCV-501|
219560605|NCT01961882|DRUG|Placebo|
219754421|NCT04490278|OTHER|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
219754422|NCT02180789|DRUG|Tamsulosin OCAS|oral
219754423|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
219395548|NCT00940342|DRUG|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
219395549|NCT00940342|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly for four weeks
219395550|NCT03330743|BEHAVIORAL|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
219395551|NCT03330743|BEHAVIORAL|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
219395552|NCT02341170|RADIATION|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
219395553|NCT04982432|DRUG|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
219560606|NCT01191476|DRUG|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
219754424|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
219754425|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
219560607|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
219395554|NCT05277155|DIETARY_SUPPLEMENT|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~* Zingiber officinale var. rubrum (Rhizome extract) 80 mg~* Foeniculi vulgare Fructus (Fennel) 25 mg~* Menthae arvensis Folium (Mint) 5 mg~* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~* Honey 7500 mg"
219395555|NCT05277155|OTHER|Placebo|Placebo composition: Substance without active ingredient
219395556|NCT05717920|DRUG|ADX-629 (Open-label)|ADX-629 (250 mg) administered twice daily for 90 days
219395557|NCT05182203|DRUG|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
219395558|NCT01832311|DRUG|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
219395559|NCT01327339|DRUG|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219395560|NCT03949582|OTHER|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
219395561|NCT06367270|DRUG|Pressured Intraperitoneal Aerosol Chemotherapy|PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
219395562|NCT04550507|BEHAVIORAL|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
219395563|NCT04550507|BEHAVIORAL|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
219395564|NCT05185232|OTHER|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
219395565|NCT00466752|DRUG|sorafenib tosylate|Given PO
219395566|NCT00466752|GENETIC|microarray analysis|Correlative studies
219395567|NCT00466752|OTHER|immunohistochemistry staining method|Correlative studies
219395568|NCT00466752|GENETIC|gene expression analysis|Correlative studies
219395569|NCT00466752|PROCEDURE|needle biopsy|Correlative studies
219395570|NCT00466752|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
219560608|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
219560609|NCT05331391|BEHAVIORAL|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
219189112|NCT04540107|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219189113|NCT04540107|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219395571|NCT00466752|OTHER|laboratory biomarker analysis|Correlative studies
219395572|NCT00466752|GENETIC|western blotting|Correlative studies
219395573|NCT00466752|GENETIC|RNA analysis|Correlative studies
219395574|NCT00239460|DRUG|Tiotropium|
219395575|NCT05084547|OTHER|No intervention|No intervention
219395576|NCT02810002|DEVICE|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
219395577|NCT02810002|DEVICE|Control infantry boot|Training: infantry basic training in the control boots
219395578|NCT02017249|DRUG|arginine in powder form|
219395579|NCT02017249|DRUG|Silica and cellulose placebo powder|
219560610|NCT00003396|BIOLOGICAL|anti-thymocyte globulin|
219560611|NCT00003396|BIOLOGICAL|graft-versus-tumor induction therapy|
219560612|NCT00003396|DRUG|cyclophosphamide|
219560613|NCT00003396|DRUG|melphalan|
219395580|NCT03046238|DRUG|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
219395581|NCT03046238|DRUG|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
219395582|NCT06480045|PROCEDURE|Performed PECS II block with AI integrated USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.
219395583|NCT06480045|PROCEDURE|Performed PECS II block with conventional USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
219395584|NCT00700752|DEVICE|senofilcon A|silicone hydrogel contact lens
219395585|NCT00700752|DEVICE|balafilcon A|silicone hydrogel contact lens
219395586|NCT05554900|PROCEDURE|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
219395587|NCT00541359|DRUG|bortezomib|Given IV
219560614|NCT00003396|PROCEDURE|peripheral blood stem cell transplantation|
219560615|NCT00003396|RADIATION|radiation therapy|
219395588|NCT00541359|DRUG|topotecan hydrochloride|Given IV
219395589|NCT00541359|OTHER|immunohistochemistry staining method|Correlative studies
219395590|NCT00541359|OTHER|pharmacological study|Correlative studies
219395591|NCT02481518|DRUG|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
219395592|NCT02481518|OTHER|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
219395593|NCT00590083|BIOLOGICAL|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
219395594|NCT00691197|DEVICE|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
219560616|NCT04063319|OTHER|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
219560617|NCT02154724|DEVICE|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
219560618|NCT02154724|DEVICE|DBS|The aDBS s applied for two hous in DBS modality.
219560619|NCT01593072|DRUG|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
219560620|NCT01593072|OTHER|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
219560621|NCT00900016|GENETIC|protein expression analysis|
219560622|NCT00900016|GENETIC|western blotting|
219560623|NCT00900016|OTHER|immunohistochemistry staining method|
219560624|NCT00900016|OTHER|immunologic technique|
219560625|NCT00900016|OTHER|laboratory biomarker analysis|
219560626|NCT05516888|PROCEDURE|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
219560627|NCT05516888|PROCEDURE|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
219560628|NCT05410028|OTHER|No intervention in clinical treatment|No intervention in clinical treatment
219754426|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
219754427|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
219754428|NCT01923883|PROCEDURE|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
219754429|NCT01923883|DEVICE|Echoendoscope Olympus GF-UCT240|
219754430|NCT01116284|PROCEDURE|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
219560629|NCT03991442|DRUG|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
219395595|NCT00691197|DEVICE|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
219395596|NCT03127202|DEVICE|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
219395597|NCT01097330|PROCEDURE|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
219395598|NCT01097330|DRUG|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
219395599|NCT04980183|DEVICE|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
219395600|NCT04980183|DEVICE|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
219395601|NCT01104818|BEHAVIORAL|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
219395602|NCT03830801|DEVICE|IVLCM tethered capsule|Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
219395603|NCT05887856|OTHER|comprehensive educational program for reduction of Pre-Operative Anxiety|"BSEP 1 makes use of modern media and aims to educate patients and their carers through educational videos comprising of various aspect of surgical treatment.~1. Introduction to surgery by consultant surgeon, Patient to receive video of their own surgeon.~2. Introduction to Anesthesia.~3. What are different type of breast surgeries in cancer patients (General Video)~4. Specific video pertaining to the type of surgery patient is undergoing (Mastectomy, Breast Conserving Surgery, Breast Re Construction surgery)~5. Explanation of Methicillin-resistant Staphylococcus aureus Decolonization protocol~6. What to expect on Surgery Day~7. Virtual tour of Holding bay and Operation Room~8. Post-Operative care including wound care, drain management and common post-operative complications."
219395604|NCT00083824|DRUG|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
219395605|NCT00083824|DRUG|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
219395606|NCT00083824|DRUG|Placebo|2 pills/day QID for 3 years
219189114|NCT04540107|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219189115|NCT06063395|PROCEDURE|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
219189116|NCT05795816|DRUG|Testofen|Twice daily dose of 1 capsule (300mg per capsule Testofen)
219189117|NCT05795816|DRUG|Microcrystalline cellulose|Twice daily dose of 1 capsule
219189118|NCT05064891|PROCEDURE|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
219189119|NCT03714360|DRUG|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
219189120|NCT03714360|DRUG|Sodium Chloride 0,9%|Sodium Chloride 0,9%
219189121|NCT05584540|BEHAVIORAL|UNTIRE App|Digital therapeutic application
219395607|NCT05606822|OTHER|Observational|Collection of data from electronic health record
219395608|NCT01811030|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
219395609|NCT03047460|OTHER|multimodal evoked potentials|
219754431|NCT05314660|DRUG|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
219754432|NCT05314660|PROCEDURE|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
219754433|NCT05314660|PROCEDURE|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
219754434|NCT01441960|DRUG|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
219754435|NCT01441960|DRUG|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
219189122|NCT04107181|DEVICE|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
219189123|NCT04107181|BEHAVIORAL|Interviews only|Healthy volunteer interviews
219189124|NCT06068244|OTHER|3D printed crowns|3D printed crowns
219395610|NCT03591029|OTHER|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
219395611|NCT06375330|DEVICE|PoliArt|PoliArt injections
219560630|NCT05598879|OTHER|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
219560631|NCT06335459|OTHER|epidemiology|Analysis of 2000 AP WB radiographs of Foot in Upper Egypt For Random People and determind cases of Hallux valgus and calculate the prevalence
219395612|NCT00510692|DRUG|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
219395613|NCT00510692|PROCEDURE|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
219395614|NCT00510692|PROCEDURE|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
219395615|NCT00510692|DRUG|Placebo|2 x 500mg placebo capsules twice daily for 6 months
219560632|NCT06446388|DRUG|QLS31905|Administered as an intravenous infusion.
219395616|NCT03358862|DEVICE|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
219395617|NCT05822999|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
219395618|NCT05822999|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
219395619|NCT01478750|DIETARY_SUPPLEMENT|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
219395620|NCT01478750|PROCEDURE|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
219560633|NCT06446388|DRUG|Oxaliplatin|130 mg/m2, intravenous infusion, D1, up to 8 cycles.
219560634|NCT06446388|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D14
219754436|NCT02266303|OTHER|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
219754437|NCT04578626|DEVICE|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
219754438|NCT04841408|OTHER|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
219001599|NCT06626334|DEVICE|Bright Full-Spectrum (White) Light|Bright full-spectrum (white) light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#211 0.9 ND) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
219189125|NCT06068244|OTHER|Zirconia crowns|Nu smile zirconia crowns
219189126|NCT05672108|PROCEDURE|Computed Tomography|Undergo CT
219189127|NCT05672108|DRUG|Ethiodized Oil|Given IA
219395621|NCT01845077|DRUG|2x500 mg Metformin (Glumetza)|2 tablets
219395622|NCT01845077|DRUG|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
219395623|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
219395624|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
219395625|NCT01845077|DRUG|3x500 mg Metformin (Glumetza)|3 tablets
219395626|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
219395627|NCT01845077|DRUG|2 x 500 mg Metformin (Glumetza)|2 tablets
219395628|NCT01845077|DRUG|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
219395629|NCT01845077|DRUG|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
219395630|NCT04253301|DEVICE|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
219395631|NCT02528695|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT
219560635|NCT06446388|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
219560636|NCT06446388|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
219560637|NCT06446388|DRUG|QL1706|5 mg/kg, intravenous infusion,D1
219560638|NCT06446388|DRUG|Chemotherapy drug|Standard chemotherapy recommended by guidelines.
219560639|NCT03498599|BEHAVIORAL|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
219560640|NCT03498599|BEHAVIORAL|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
219560641|NCT02857556|BIOLOGICAL|Blood sample|
219395632|NCT02528695|DEVICE|euglycemic clamp|euglycemic clamp
219560642|NCT02857556|OTHER|Retinal photography:|
219560643|NCT02857556|OTHER|dialyse|
219560644|NCT00407745|DRUG|placebo|Placebo
219560645|NCT00407745|DRUG|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
219560646|NCT05840471|DRUG|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
219560647|NCT05840471|OTHER|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
219560648|NCT04334928|DRUG|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
219560649|NCT04334928|DRUG|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
219560650|NCT04334928|DRUG|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
219560651|NCT04334928|DRUG|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
219560652|NCT00108082|DRUG|carvedilol MR|Study drug
219560653|NCT00108082|DRUG|atenolol|Comparator
219189128|NCT05672108|DRUG|Mitomycin|Given IA
219560654|NCT00108082|DRUG|lisinopril|Comparator
219560655|NCT02581072|DRUG|SB204 4%|Applied topically once
219560656|NCT02581072|DRUG|SB204 8% or 12%|Applied once topically
219560657|NCT02581072|DRUG|Vehicle|Applied topically once
219560658|NCT00295139|BEHAVIORAL|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
219560659|NCT00295139|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
219560660|NCT00295139|BEHAVIORAL|Critical Time Intervention (CTI)|Case management component
219560661|NCT00000486|PROCEDURE|coronary artery bypass|
219560662|NCT04008693|DIETARY_SUPPLEMENT|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
219560663|NCT04008693|OTHER|Placebo|800 mg of maltodextrin (four capsules)
219560664|NCT05192031|BEHAVIORAL|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
219560665|NCT00451152|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
219560666|NCT00451152|OTHER|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
219560667|NCT00955552|DRUG|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
219560668|NCT00955552|DRUG|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
219560669|NCT00784030|OTHER|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
219560670|NCT02607423|DRUG|Cisplatin|Given IV
219560671|NCT02607423|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
219560672|NCT02607423|DRUG|Docetaxel|Given IV
219395633|NCT02528695|DEVICE|hypoglycemic clamp|hypoglycemic clamp
219395634|NCT02928640|DEVICE|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
219395635|NCT00768378|DEVICE|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
219395636|NCT01554215|BEHAVIORAL|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
219395637|NCT01554215|BEHAVIORAL|Mom Power Attentional Control Group|at home control, weekly mailings
219560673|NCT02607423|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
219395638|NCT05946330|BEHAVIORAL|NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).|The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
219395639|NCT00248677|BEHAVIORAL|Behavioral Family-Based Intervention|Behavioral family intervention
219395640|NCT00248677|BEHAVIORAL|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
219395641|NCT04631718|RADIATION|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
219560674|NCT02607423|DRUG|Gemcitabine Hydrochloride|Given IV
219560675|NCT02607423|DRUG|Pemetrexed Disodium|Given IV
219560676|NCT02607423|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
219560677|NCT03462836|DRUG|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
219395642|NCT01296386|BIOLOGICAL|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
219395643|NCT01797432|DRUG|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
219395644|NCT01797432|DEVICE|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
219395645|NCT06037655|DRUG|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
219395646|NCT00395785|DEVICE|Carotid Stent Implantation|
219395647|NCT00395785|DEVICE|Embolic Protection|
219395648|NCT05478915|PROCEDURE|discectomy of the TMJ disc|removal of the TMJ disc
219395649|NCT05478915|PROCEDURE|TMJ discopexy|fixation of the TMJ disc
219395650|NCT03322137|DRUG|SNA-120|Pegcantratinib ointment
219395651|NCT03322137|DRUG|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
219395652|NCT01539265|DRUG|silodosin|
219395653|NCT01539265|DRUG|silodosin|
219395654|NCT01539265|DRUG|placebo|
219560678|NCT03462836|DRUG|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
219560679|NCT02940730|DRUG|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
219560680|NCT02940730|DRUG|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
219560681|NCT02655055|PROCEDURE|high frequency voluntary apheresis blood donation|
219560682|NCT00078481|DRUG|Idebenone|
219395655|NCT01666522|DRUG|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
219395656|NCT01666522|OTHER|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
219395657|NCT04701255|PROCEDURE|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
219395658|NCT04701255|DEVICE|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
219395659|NCT01498510|BEHAVIORAL|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
219395660|NCT05249595|DEVICE|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
219560683|NCT00060294|BIOLOGICAL|rituximab|
219560684|NCT00060294|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219560685|NCT02470117|DRUG|Alginate-based reflux suppressant|
219560686|NCT02470117|DRUG|magnesium-aluminium antacid gel|
219560687|NCT00347113|DRUG|Albendazole and praziquantel|
219560688|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
219560689|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
219560690|NCT01611207|DEVICE|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
219189129|NCT05672108|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
219189130|NCT05672108|DEVICE|Tris-acryl Gelatin Microspheres|Given IA
219189131|NCT05523856|PROCEDURE|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
219189132|NCT05523856|PROCEDURE|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
219189133|NCT05523856|RADIATION|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
219189134|NCT05523856|RADIATION|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
219189135|NCT04587453|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
219189136|NCT04587453|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
219189137|NCT04587453|OTHER|Topical corticosteroids (TCS)|TCS administered as needed.
219189138|NCT05688241|DRUG|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
219189139|NCT04381429|DRUG|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
219189140|NCT04381429|DRUG|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
219395661|NCT05249595|DEVICE|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
219560691|NCT01611207|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
219560692|NCT04203160|DRUG|CPI 613|Given intravenously
219560693|NCT04203160|DRUG|Gemcitabine|Given intravenously
219560694|NCT04203160|DRUG|Cisplatin|Given intravenously
219189141|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~\- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
219189142|NCT06313853|BEHAVIORAL|COACH-Cog|Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
219560695|NCT05132725|BEHAVIORAL|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
219560696|NCT03765086|PROCEDURE|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
219560697|NCT03765086|PROCEDURE|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
219560698|NCT03036839|DRUG|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
219560699|NCT03766217|COMBINATION_PRODUCT|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
219189143|NCT05591326|PROCEDURE|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
219189144|NCT04929483|DRUG|BIO89-100|Subcutaneous injection
219189145|NCT04929483|DRUG|Placebo|Subcutaneous injection
219189146|NCT03857945|OTHER|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
219560700|NCT03766217|COMBINATION_PRODUCT|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
219560701|NCT01386502|BIOLOGICAL|p53: 264-272 peptide|
219560702|NCT01386502|DRUG|CT-011|
219560703|NCT04682509|DRUG|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
219560704|NCT01701037|DRUG|dabrafenib|150 mg given PO
219560705|NCT01701037|DRUG|trametinib|2 mg given PO
219560706|NCT01701037|OTHER|laboratory biomarker analysis|Correlative studies
219560707|NCT00412737|DRUG|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
219560708|NCT00412737|DRUG|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
219560709|NCT00308360|DRUG|Risperidone, divalproex|
219754439|NCT04400435|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
219754440|NCT06484582|OTHER|workers|This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.
219754441|NCT03842735|OTHER|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
219754442|NCT03842735|BEHAVIORAL|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
219754443|NCT03680807|DIAGNOSTIC_TEST|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
219754444|NCT02481414|BIOLOGICAL|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
219754445|NCT02481414|BIOLOGICAL|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
219754446|NCT00216333|DRUG|combined fixed dose combination|
219754447|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
219754448|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
219754449|NCT02194790|BEHAVIORAL|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
219560710|NCT05054894|OTHER|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
219560711|NCT02556892|DRUG|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
219560712|NCT00935831|DRUG|GSK1278863A|50mg, 150mg
219560713|NCT00935831|DRUG|Placebo|matching placebo
219560714|NCT02792348|OTHER|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
219560715|NCT06375369|PROCEDURE|Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)|The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
219560716|NCT06004869|BEHAVIORAL|Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)|an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
219560717|NCT06004869|BEHAVIORAL|Self-help cognitive behavioural therapy for insomnia|An mobile app that delivers CBT-I content.
219560718|NCT02740920|DRUG|Pembrolizumab|
219560719|NCT02740920|PROCEDURE|CT Scan|
219189147|NCT06344741|BEHAVIORAL|Accepted in latent phase|Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.
219189148|NCT06344741|BEHAVIORAL|Accepted in active phase|Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
219189149|NCT05880199|DEVICE|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
219189150|NCT05169723|BEHAVIORAL|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
219189151|NCT03125070|OTHER|Best Practice and Internet site with links to existing resources|Receive usual care
219189152|NCT03125070|OTHER|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
219189153|NCT03125070|OTHER|Survey Administration|Ancillary studies
219189154|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
219189155|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
219189156|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
219560720|NCT01064531|DEVICE|MIS Femoral Neck Stem implant|
219560721|NCT02771041|PROCEDURE|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
219560722|NCT00513617|DRUG|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
219560723|NCT00513617|DRUG|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
219560724|NCT02854696|PROCEDURE|Islet graft|Patients will be transplanted with pancreatic islet cells
219560725|NCT02854696|DRUG|best medical care|Patients will continue their insulin treatment
219395662|NCT05249595|DEVICE|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
219560726|NCT01575717|DRUG|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
219395663|NCT06070610|DRUG|BI 1015550|BI 1015550
219560727|NCT01575717|DRUG|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
219560728|NCT02507245|DRUG|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
219560729|NCT02168140|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219560730|NCT02168140|DRUG|bendamustine hydrochloride|Given IV
219560731|NCT02935296|BEHAVIORAL|Integrated Intervention|systems navigation, psychosocial counseling
219560732|NCT00064584|DRUG|CT53518|
219560733|NCT05813379|COMBINATION_PRODUCT|exosime injection|Treatment- exosome injection
219560734|NCT03727737|DEVICE|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
219560735|NCT04301622|DEVICE|Primary Knee implants|Primary knee arthroplasty
219560736|NCT04840784|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
219560737|NCT06245759|OTHER|This was a retrospective study and no patient intervention was performed|This was a retrospective study and no patient intervention was performed
219560738|NCT06279806|OTHER|Mobile health application use|"Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed."
219560739|NCT06279806|OTHER|Information of the breast cancer survivor period booklet|Women in the control group will be given information of the breast cancer survivor period booklet.
219560740|NCT02165306|BEHAVIORAL|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
219560741|NCT02165306|BEHAVIORAL|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
219560742|NCT05086198|BEHAVIORAL|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
219395664|NCT06070610|DRUG|Nintedanib|Soft capsules
219395665|NCT06070610|DRUG|Pirfenidone|Film-coated tablets
219395666|NCT02139410|PROCEDURE|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
219560743|NCT05086198|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
219560744|NCT00809965|DRUG|Rivaroxaban 2.5 mg|One tablet twice daily
219189157|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
219560745|NCT00809965|DRUG|Rivaroxaban 5 mg|One tablet twice daily
219560746|NCT00809965|DRUG|Placebo|One placebo tablet twice daily
219560747|NCT00809965|DRUG|Standard of care|
219560748|NCT01726114|DEVICE|Non-invasive Optical Glucose Monitor™|Test device
219560749|NCT01726114|DEVICE|YSI blood glucose analyzer|Reference device
219560750|NCT05794724|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
219560751|NCT05653635|RADIATION|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
219395667|NCT04640246|BIOLOGICAL|TBX-3400|Autologous transfusion
219395668|NCT01916369|BIOLOGICAL|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
219395669|NCT02585804|DRUG|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
219395670|NCT02086773|BIOLOGICAL|Red blood cell transfusion|
219560752|NCT03471208|DEVICE|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
219560753|NCT03471208|PROCEDURE|Freehand Implant Surgery|Dental implant surgery via conventional freehand
219560754|NCT05712642|DRUG|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
219560755|NCT02459041|OTHER|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
219560756|NCT05384886|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
219560757|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
219560758|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
219395671|NCT02796989|DIETARY_SUPPLEMENT|Wheat bran|20 g each day
219395672|NCT02796989|DIETARY_SUPPLEMENT|Placebo|20 g each day
219395673|NCT03078491|OTHER|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
219560759|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
219560760|NCT01372124|DRUG|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
219754450|NCT02398812|OTHER|Medication assessment and treatment plan based on it|"Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
219754451|NCT01424800|DEVICE|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
219754452|NCT00078221|DEVICE|Rheopheresis blood filtration|
219754453|NCT03461718|DRUG|Ketamine|Experimental arm for sedation.
219754454|NCT03461718|DRUG|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
219754455|NCT03461718|DRUG|Fentanyl|Part of standard sedation regimen
219754456|NCT00069641|BIOLOGICAL|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
219395674|NCT03927729|DRUG|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
219395675|NCT01137435|BIOLOGICAL|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
219395676|NCT05315310|DEVICE|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
219395677|NCT05182515|DRUG|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
219395678|NCT04630015|OTHER|Survey Administration|Participants will complete study specific survey
219395679|NCT05058378|DEVICE|perfusion index measurement|Clip will be attached to the patient's toe for perfusion index measurement
219395680|NCT03534271|DEVICE|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
219395681|NCT02334969|DRUG|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
219395682|NCT02334969|DRUG|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
219395683|NCT03945331|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
219395684|NCT03945331|DEVICE|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
219395685|NCT04176822|OTHER|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
219395686|NCT04176822|OTHER|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
219395687|NCT05431686|BEHAVIORAL|SMA visits|SMA visit once every 3 months over a 12 month period
219395688|NCT02896725|DEVICE|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
219395689|NCT02896725|DEVICE|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
219395690|NCT05616390|DRUG|Sintilimab|200mg IV d1,Q3W
219395691|NCT05616390|DRUG|Bevacizumab|7.5mg/kg IV d1,Q3W
219395692|NCT05616390|COMBINATION_PRODUCT|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
219395693|NCT01363895|PROCEDURE|Percutaneous closure of LAA|Percutaneous closure of LAA
219395694|NCT01363895|PROCEDURE|Catheter ablation of AF|Catheter ablation of AF
219395695|NCT00764894|DEVICE|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
219395696|NCT04668846|OTHER|non-invasive sample collection of skin tissue|Both lesional and non-lesional skin will be sampled with up to 24 adhesive patches.
219395697|NCT01048515|DRUG|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
219395698|NCT04663035|DRUG|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
219395699|NCT04663035|PROCEDURE|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
219395700|NCT03531957|DRUG|ASN002|Daily dose of ASN002 for 12 weeks
219395701|NCT03531957|DRUG|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
219395702|NCT04512729|DIAGNOSTIC_TEST|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
219395703|NCT03668548|DIETARY_SUPPLEMENT|Leucine|192 mg/kg body mass/day
219395704|NCT03668548|DIETARY_SUPPLEMENT|Placebo|A taste and calorie-matched placebo
219395705|NCT02095730|DRUG|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
219395706|NCT02095730|DRUG|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
219395707|NCT02095730|DEVICE|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
219395708|NCT02095730|DEVICE|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
219395709|NCT03809546|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
219395710|NCT03809546|DRUG|dextrose|We are administering dextrose to health volunteers for our placebo group
219395711|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
219395712|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
219395713|NCT02746679|OTHER|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
219395714|NCT00487279|DEVICE|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
219395715|NCT00487279|OTHER|Control|No Intervention
219395716|NCT04859803|PROCEDURE|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
219395717|NCT04859803|DRUG|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
219395718|NCT03830138|GENETIC|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
219395719|NCT06085365|DRUG|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
219395720|NCT06085365|DRUG|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
219395721|NCT02467764|OTHER|Retrospective study|
219395722|NCT05574543|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
219395723|NCT05574543|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
219395724|NCT00125203|DRUG|Botulinum toxin type B (Myobloc)|
219395725|NCT00125203|PROCEDURE|Injection of salivary glands|
219395726|NCT02436798|DRUG|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
219395727|NCT01986205|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
219395728|NCT01986205|COMBINATION_PRODUCT|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
219395729|NCT04845776|DIETARY_SUPPLEMENT|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
219395730|NCT04125823|BEHAVIORAL|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
219395731|NCT04125823|BEHAVIORAL|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
219395732|NCT00997412|DRUG|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
219395733|NCT00997412|DRUG|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
219560761|NCT02582918|BEHAVIORAL|Outreach with patient education and patient navigation services|"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
219560762|NCT02315066|DRUG|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
219560763|NCT02315066|DRUG|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
219560764|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
219560765|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
219560766|NCT04413734|DRUG|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
219560767|NCT04413734|DRUG|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
219560768|NCT06067451|BEHAVIORAL|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
219560769|NCT05009368|DRUG|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
219189158|NCT04200274|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
219189159|NCT06059391|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT with donor peripheral blood stem cells
219189160|NCT06059391|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219189161|NCT06059391|DRUG|Granulocyte Colony-Stimulating Factor|Undergo stem cell mobilization with G-CSF
219395734|NCT00232570|DRUG|quetiapine|
219395735|NCT00501852|DRUG|NVA237|single-dose dry-powder inhaler (SDDPI)
219395736|NCT00501852|DRUG|Placebo|single-dose dry-powder inhaler (SDDPI)
219395737|NCT00501852|DRUG|Tiotropium|Handihaler inhaler
219395738|NCT00006452|DRUG|motexafin gadolinium|
219395739|NCT00006452|RADIATION|radiation therapy|
219395740|NCT05153005|OTHER|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
219395741|NCT02275572|PROCEDURE|Pharmacist Intervention|
219560770|NCT05009368|DRUG|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
219560771|NCT05009368|DRUG|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
219560772|NCT04549922|DRUG|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
219560773|NCT04549922|DRUG|Normal Saline|1.2 mL subcutaneous
219560774|NCT06206603|DIAGNOSTIC_TEST|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
219560775|NCT06206603|DIAGNOSTIC_TEST|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
219560776|NCT00112294|DRUG|Paclitaxel (Taxane)|IV, 225 mg/m\^2
219560777|NCT00112294|DRUG|Docetaxel (Taxane)|IV, 75 mg/m\^2
219560778|NCT00112294|DRUG|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
219560779|NCT00112294|DRUG|Cetuximab|Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
219560780|NCT05883787|OTHER|Exploration of a database|extraction of data
219560781|NCT04202094|DIAGNOSTIC_TEST|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
219560782|NCT04202094|DIAGNOSTIC_TEST|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
219754457|NCT00069641|BIOLOGICAL|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
219754458|NCT00069641|BIOLOGICAL|Placebo|Patients will receive weekly infusions of placebo.
219754459|NCT03186768|BEHAVIORAL|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
219395742|NCT05965206|BEHAVIORAL|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
219560783|NCT04202094|DIAGNOSTIC_TEST|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
219560784|NCT04202094|DIAGNOSTIC_TEST|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
219560785|NCT06050200|PROCEDURE|PVE|The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.
219560786|NCT06050200|PROCEDURE|LVD|"The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary."
219560787|NCT06050200|PROCEDURE|ALPPS|"The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane)."
219560788|NCT04550104|RADIATION|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
219560789|NCT04550104|DRUG|Olaparib Oral Tablet [Lynparza]|Oral tablet
219560790|NCT04550104|DRUG|AZD1390|Oral tablet
219560791|NCT04550104|DRUG|Ceralasertib|Oral Tablet
219560792|NCT04550104|DRUG|AZD5305|Oral Tablet
219001600|NCT06626334|DEVICE|Usual Ambient Light|"Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days."
219001601|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
219001602|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
219001603|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
219001604|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
219001605|NCT06630455|DIETARY_SUPPLEMENT|Meu-cinn|Meu-cinn 250 mg/day for 8 weeks
219189162|NCT06059391|DRUG|Hematopoietic Cell Transplantation Conditioning Regimen|Receive pre transplant conditioning
219395743|NCT01631357|BIOLOGICAL|CIK cell|CIK cell injection
219395744|NCT01631357|DRUG|Gemcitabine Injection|Gemcitabine injection
219395745|NCT01631357|DRUG|Cisplatin injection|Cisplatin injection
219395746|NCT02602431|DEVICE|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
219395747|NCT02602431|DEVICE|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
219560793|NCT04550104|DRUG|Durvalumab|1500mg iv infusion
219560794|NCT05252234|OTHER|Observation of hemodynamic status and post operative pain|No intervention
219560795|NCT01142908|BEHAVIORAL|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
219560796|NCT03803254|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219560797|NCT03803254|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
219001606|NCT06630455|DIETARY_SUPPLEMENT|Placebo|Placebo 250 mg/day for 8 weeks
219001607|NCT07034768|DRUG|EDG-7500|Single dose of EDG-7500
219001608|NCT07131579|DRUG|Normal Saline|equal volume of normal saline
219001609|NCT07131579|DRUG|Dexmedetomidine|0.5 mcg/kg of dexmedetomidine
219001610|NCT07132866|BEHAVIORAL|ADAPT|The ADAPT intervention consists of three group sessions (of 75-90 min), with 6-8 8th grade students in each group, administered over three consecutive weeks, plus one interactive parent component (of 45 min) administered during the three weeks (separate from the student sessions).
219189163|NCT06059391|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219189164|NCT06059391|PROCEDURE|Pheresis|Undergo apheresis
219189165|NCT06059391|DRUG|Placebo Administration|Given IM
219001611|NCT07132437|DRUG|ZKY001 EYE DROPS|"On the 1st postoperative day (Day1), ZKY001 eye drops were dropped into the experimental eyes (the operative eyes were taken as the experimental eyes). ZKY001 eye drops were given at 8:00 am ±1h from Day1 to Day5. 4 times a day, 1 drop each time, recommended interval of 4 to 6 hours.~Day6 was administered at 8:00 am ±1h, and ZKY001 eye drops were dropped into the test eye (the surgical eye was taken as the test eye). Day6 was given only once, 1 drop each time."
219001612|NCT07131345|DRUG|iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy|"Novel Bispecific Checkpoint Inhibition:~QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Chemotherapy for first-line treatment (pemetrexed plus cisplatin or carboplatin )~Chemotherapy for second-line treatment (pemetrexed, gemcitabine or vinorelbine)"
219001613|NCT07132307|DEVICE|Mandibular advancement device (MAD)|The intervention in this study involves fitting and using a mandibular advancement device (MAD), specifically the ProSomnus Sleep Device, to treat moderate to severe obstructive sleep apnea (OSA) in patients who are intolerant to CPAP and have failed hypoglossal nerve stimulation (HGNS) therapy.
219001614|NCT05846945|OTHER|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
219001615|NCT05846945|OTHER|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
219001616|NCT05846945|OTHER|Chest physiotherapy|Conventional chest physiotherapy
219001617|NCT06711484|OTHER|Speak up traning program|The intervention includes the training program to be applied to the experimental group. The aims and objectives of the training program, the training content and modules were prepared by the researcher in line with the needs analysis. The training program consists of four modules: Communication, Speaking UP, Patient Safety and Medical Error. Before the training program starts, the training booklet will be distributed to the experimental group participants. In the training, teaching techniques such as plain narration, question and answer, brainstorming, case study, case discussion, station technique, six thinking hats technique, video-based error scenario activity etc. will be used. The video activity to be used in the speak up session of the training program was created by recording the correct and incorrect scenarios of three patient safety errors by experienced actors.
219001618|NCT06704594|DRUG|sertraline 50 mg daily|The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
219001619|NCT06704594|DRUG|Placebo Oral Tablet|The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.
219001620|NCT07040787|DRUG|HRS-5965 Capsules|Oral HRS-5965 capsules.
219001621|NCT07040787|DRUG|Clopidogrel|Oral clopidogrel.
219001622|NCT07040787|DRUG|Clarithromycin|Oral clarithromycin.
219001623|NCT06706414|DRUG|Denosumab (Prolia)|Subcutaneous injection with 60 mg Denosumab once
219001624|NCT06706414|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole oral tablet 2.5 mg once daily
219189166|NCT06059391|DRUG|Stem Cell Mobilization Therapy|Undergo stem cell mobilization with G-CSF
219189167|NCT04534218|DRUG|Regorafenib|"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
219001625|NCT07035665|DRUG|HRS-5965 Capsules|Oral doses of HRS-5965 capsules at fasted and fed conditions.
219189168|NCT04534218|DRUG|Cyclophosphamide|50 mg per os, daily, for 6 months
219189169|NCT04534218|DRUG|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
219189170|NCT04534218|DRUG|Aspirin|75 mg orally and daily until progression
219189171|NCT05479552|DIAGNOSTIC_TEST|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
219395748|NCT02602431|DEVICE|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
219395749|NCT02602431|DEVICE|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
219395750|NCT02679066|DEVICE|Sugar-tong splint|Plaster immobilization including the elbow
219395751|NCT02679066|DEVICE|Short forearm cast|Fiberglass immobilization with elbow free
219395752|NCT00059761|DRUG|cisplatin|
219395753|NCT00059761|DRUG|irinotecan hydrochloride|
219395754|NCT00059761|RADIATION|radiation therapy|
219395755|NCT05101421|DIETARY_SUPPLEMENT|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
219395756|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
219395757|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
219395758|NCT03176212|DIETARY_SUPPLEMENT|Milk fat globule membrane|
219395759|NCT01221298|DRUG|ABT-450|tablets
219395760|NCT01221298|DRUG|ABT-072|tablets
219395761|NCT01221298|DRUG|Ribavirin|tablets
219395762|NCT01221298|DRUG|Ritonavir|capsules
219189172|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
219189173|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
219189174|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
219395763|NCT01511146|DRUG|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
219395764|NCT01511146|DRUG|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
219395765|NCT00149929|DRUG|Mycophenolate sodium (enteric coated)|
219395766|NCT01927562|DEVICE|Fractyl Duodenal Remodeling System|
219560798|NCT03803254|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219560799|NCT03803254|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
219001626|NCT06723821|OTHER|Neuromodulation group|During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
219001627|NCT06723821|OTHER|Neuromodulation sham group|During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
219001628|NCT06733285|DRUG|Sensodyne Rapid Relief|Toothpaste containing 0.454 % weight/weight (w/w) SnF2 (1100 parts per million \[ppm\] fluoride).
219189175|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
219395767|NCT06316089|BEHAVIORAL|PrEPared for Release|A multilevel, behavioral and navigation intervention administered over two sessions to promote PrEP initiation, adherence and linkage to PrEP care in the community for incarcerated men with a history of injection drug use.
219395768|NCT02891746|OTHER|non invasive sampling|
219395769|NCT05452746|DEVICE|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
219395770|NCT05452746|OTHER|Treatment as usual|Inpatient psychiatric care for depression
219395771|NCT00642616|DRUG|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
219395772|NCT00642616|DRUG|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
219395773|NCT05484063|OTHER|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
219395774|NCT05743543|OTHER|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
219560800|NCT04899492|BEHAVIORAL|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
219560801|NCT04899492|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
219560802|NCT04899492|BEHAVIORAL|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
219560803|NCT04899492|DRUG|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
219001629|NCT06733285|DRUG|Colgate Cavity Protection|A regular fluoride toothpaste containing 1000 ppm fluoride.
219001630|NCT06792136|DRUG|ONO-1110|ONO-1110 tablets once a day
219001631|NCT06792136|DRUG|Placebo|Placebo tablets once daily
219001632|NCT07061912|DEVICE|NSTI® HIV Self-Test|Each participant will be provided with the INSTI® HIV Self-Test(s) and asked to conduct self testing, unobserved. The participant will record their interpretation of the results. Subjects will perform the test without intervention or observation from the operator. The operator will then enter the room and also interpret the subject's self-test results then perform the comparator test. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing
219001633|NCT07070518|DRUG|GV20-0251|Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks
219189176|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
219395775|NCT00399802|DRUG|ZA|Single ZA 4 mg IV infusion at the start of treatment
219001634|NCT05601453|PROCEDURE|Elective redo transcatheter aortic valve implantation (redo-TAVI)|Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
219001635|NCT06816459|OTHER|Cigarette smell test|Undergo cigarette smell test of 16 cigarettes in vials, then rate the overall smell on a 5 pt scale (not at all, a little noticeable, noticeable, clearly/very noticeable , do not know what this is).
219189177|NCT02295306|DEVICE|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
219189178|NCT00621712|DEVICE|GamCath® central venous catheter|choice of catheter type
219189179|NCT00621712|DEVICE|GamCath Dolphin® Protect central venous catheter|choice of catheter type
219395776|NCT00399802|DRUG|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
219395777|NCT00399802|DRUG|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
219395778|NCT00399802|DRUG|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
219560804|NCT01086930|DEVICE|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
219560805|NCT01086930|OTHER|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
219560806|NCT05291351|OTHER|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
219560807|NCT05291351|OTHER|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
219560808|NCT05291351|OTHER|Porridge made with oat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
219560809|NCT00035555|DRUG|Belatacept|Solution, intravenous
219560810|NCT00035555|DRUG|Cyclosporine|Oral, capsule
219001636|NCT06816459|OTHER|Cigarette Taste Test|Participants will be present 3 vials , each containing a cigarette and sample in order specified on label, then complete a coolness measure on a 0-100 visual analog scale.
219395779|NCT00350064|BEHAVIORAL|Exercise Training|16 weeks of aerobic exercise training at two different intensities
219395780|NCT00492921|DRUG|Cyclophosphamide|
219395781|NCT03183921|OTHER|No intervention|No Interventions
219395782|NCT00542815|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
219395783|NCT00542815|DRUG|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
219395784|NCT04674137|DRUG|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
219395785|NCT04674137|DRUG|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
219395786|NCT00703807|DRUG|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
219395787|NCT00703807|DRUG|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
219395788|NCT02714946|DEVICE|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
219395789|NCT02714946|DEVICE|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
219395790|NCT00782080|DRUG|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
219395791|NCT00782080|DRUG|Placebo|Placebo
219001637|NCT06816459|OTHER|Study questionnaires|Sensory questionnaires will be administered using a web based application
219001638|NCT06807489|DEVICE|Digi-physical treatment tool|A digital treatment tool named Evira will be used to provide the treatment.
219395792|NCT06468410|OTHER|long duration Hatha Yoga|60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.
219395793|NCT06468410|OTHER|short duration Hatha Yoga|30 min of Hatha yoga for 4 weeks .
219001639|NCT06803823|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
219001640|NCT06803823|DRUG|Placebo|Two ONO-2020 placebo tablets will be orally administered once daily
219189180|NCT03571581|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
219395794|NCT06468410|OTHER|Control group|participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
219395795|NCT03251976|BEHAVIORAL|video|informational video
219395796|NCT03251976|BEHAVIORAL|usual care|usual physician counseling on end of life care
219395797|NCT06512311|DIAGNOSTIC_TEST|CBMed Drug Screening Plattform|The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.
219395798|NCT00081289|RADIATION|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
219395799|NCT00081289|DRUG|Capecitabine 1650 mg/m^2/day|825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.
219395800|NCT00081289|DRUG|Capecitabine 1200 mg/m^2/day|600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
219560811|NCT00035555|DRUG|Mycophenolate mofetil (MMF)|Oral, capsule
219560812|NCT00035555|DRUG|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
219560813|NCT03176524|DRUG|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
219560814|NCT03176524|DRUG|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
219560815|NCT03176524|DRUG|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
219560816|NCT04601337|PROCEDURE|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
219395801|NCT00081289|DRUG|Irinotecan|50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
219395802|NCT00081289|DRUG|Oxaliplatin|50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
219189181|NCT06510634|OTHER|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
219395803|NCT00081289|PROCEDURE|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
219395804|NCT00081289|DRUG|Folinic Acid|400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
219395805|NCT00081289|DRUG|Fluorouracil|"5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
219395806|NCT00081289|DRUG|Oxaliplatin|85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
219395807|NCT04552236|DEVICE|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
219395808|NCT03845998|PROCEDURE|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
219560817|NCT04027257|BEHAVIORAL|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
219560818|NCT03510338|DRUG|Sublingual sildenafil|100 mg biphasic sildenafil tablet
219560819|NCT03510338|DRUG|Oral sildenafil|50 mg oral sildenafil (Viagra)
219189182|NCT01387711|DRUG|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
219189183|NCT05861336|DRUG|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
219395809|NCT03845998|PROCEDURE|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
219395810|NCT03403101|DRUG|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
219395811|NCT03403101|DRUG|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
219395812|NCT03403101|DRUG|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
219395813|NCT02749370|DRUG|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
219395814|NCT03242759|DRUG|nintedanib|Drug
219395815|NCT03242759|DRUG|pirfenidone|Drug
219395816|NCT04064684|DRUG|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
219395817|NCT04064684|DRUG|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
219395818|NCT04064684|DEVICE|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
219395819|NCT04014504|DIAGNOSTIC_TEST|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
219395820|NCT01347918|DEVICE|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
219395821|NCT01347918|DIETARY_SUPPLEMENT|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
219395822|NCT00256828|DRUG|didanosine + lamivudine + efavirenz|
219395823|NCT04676139|DRUG|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
219395824|NCT04676139|DRUG|Placebo|placebo for 12 months
219395825|NCT01946048|BIOLOGICAL|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
219560820|NCT02255487|DEVICE|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
219560821|NCT02255487|OTHER|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
219560822|NCT02972515|BEHAVIORAL|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
219560823|NCT02972515|DEVICE|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
219560824|NCT02254109|DRUG|BEA 2180 BR - rising dose|
219560825|NCT02254109|DRUG|Placebo|
219560826|NCT04568577|OTHER|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
219560827|NCT04568577|OTHER|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
219560828|NCT01351363|DEVICE|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
219560829|NCT01351363|DEVICE|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
219560830|NCT01450800|DRUG|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
219560831|NCT01450800|DRUG|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
219560832|NCT03850613|BEHAVIORAL|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
219560833|NCT04302337|PROCEDURE|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
219189184|NCT05861336|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
219560834|NCT04302337|PROCEDURE|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
219560835|NCT03224520|BEHAVIORAL|Recommender CTHC|Enhanced Messaging
219560836|NCT03224520|BEHAVIORAL|Standard CTHC|Standard Messaging
219560837|NCT03224520|OTHER|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
219560838|NCT03224520|OTHER|Standard Online Recruitment|Search Engine and Social Media Advertisements
219560839|NCT02698930|DRUG|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
219560840|NCT02698930|DRUG|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
219560841|NCT04874363|OTHER|no intervention|no intervention
219560842|NCT01086969|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
219560843|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
219754460|NCT05125003|BEHAVIORAL|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
219754461|NCT05125003|BEHAVIORAL|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
219754462|NCT00017043|DRUG|ixabepilone|
219754463|NCT03186638|DRUG|Ibuprofen|Given PO
219754464|NCT03186638|OTHER|Placebo|Given PO
219754465|NCT03186638|OTHER|Questionnaire Administration|Ancillary studies
219754466|NCT05086861|DEVICE|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
219754467|NCT04363346|DRUG|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
219754468|NCT03237806|DRUG|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
219754469|NCT03237806|DRUG|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
219754470|NCT05251649|DEVICE|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
219001641|NCT07131436|OTHER|Horse therapy|Participating children received horseback riding and riding training twice a week for 30 minutes over an eight-week period. The training included developing body and object use skills, relationship building skills, language skills, social and self-care skills, and sensory skills. These included mounting and dismounting a horse; sitting correctly; holding and using the reins; bustling movements on the horse, forward and backward, sideways, and reaching with the hands; naming printed pictures; reading numbers; throwing objects at targets with the right and left hands; developing a dialogue with the trainer; standing up with and without stepping on the stirrups; sitting down and standing; reaching forward and backward and lying down on the horse; petting the horse with one's hands; trying to touch the horse's front legs with the right and left hands; and holding the horse's mane. At the end of the training, the parents of the participating children completed the Autism Behavior Checklist.
219001642|NCT07132996|DIAGNOSTIC_TEST|POCUS-based Splenic Volume Measurement|Splenic volume was measured at baseline and at 72 hours using the Butterfly iQ+ handheld ultrasound (Butterfly Network, Inc.) in abdominal preset mode. Certified POCUS operators obtained spleen length, width, and depth in standard orthogonal planes. Volumes were calculated using the prolate ellipsoid formula (length × width × depth × 0.523), a validated method in ultrasound volumetric studies. ΔSpleen was defined as the 72-hour value minus the baseline value.
219001643|NCT06922708|DIAGNOSTIC_TEST|Integrated PRS-Enhanced Breast Cancer Risk Assessment (CanRisk model)|Standard genetic counseling followed by a blood draw (0.5 mL) for DNA extraction. The sample is processed using a high-throughput SNP genotyping platform, and the PRS, based on 313 SNPs, is calculated and integrated into the CanRisk model for refined breast cancer risk stratification.
219001644|NCT07131722|DRUG|Trineumin|"Trineumin(Code name: PRG-N-01) is administered orally once daily. The study includes six dose levels.~Dose escalation decisions are based on observed DLTs."
219001645|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the lower dose selected from Phase 1 results.
219189185|NCT05861336|DRUG|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
219189186|NCT05861336|RADIATION|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
219189187|NCT05902117|DIAGNOSTIC_TEST|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
219189188|NCT04288635|BIOLOGICAL|Whole blood samples|Whole blood samples at admission, from day one to three after admission
219189189|NCT02800356|PROCEDURE|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
219189190|NCT03897361|GENETIC|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
219395826|NCT03412422|DIAGNOSTIC_TEST|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
219395827|NCT03028025|DEVICE|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
219395828|NCT03028025|DEVICE|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
219395829|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
219395830|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
219395831|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
219395832|NCT02644525|DRUG|Placebo|A single dose of placebo pill is given
219395833|NCT03255525|OTHER|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
219395834|NCT03255525|OTHER|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
219395835|NCT03255525|OTHER|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
219395836|NCT04631471|DRUG|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
219395837|NCT04631471|PROCEDURE|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
219395838|NCT04631471|DRUG|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
219395839|NCT03686254|COMBINATION_PRODUCT|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
219395840|NCT03686254|DRUG|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
219395841|NCT02660697|PROCEDURE|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
219395842|NCT03040583|OTHER|No intervention|Patients data will be collected during their disease follow-up
219395843|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
219395844|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
219395845|NCT00336492|BIOLOGICAL|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
219395846|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
219395847|NCT04295304|DEVICE|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
219395848|NCT00227877|BEHAVIORAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
219395849|NCT00227877|BEHAVIORAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
219395850|NCT03285009|OTHER|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
219395851|NCT00001056|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219395852|NCT04778761|BEHAVIORAL|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
219395853|NCT02517047|DEVICE|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
219395854|NCT05208983|BIOLOGICAL|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
219001646|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the higher dose selected from Phase 1 results.
219001647|NCT07131566|PROCEDURE|Sentinel Node detection and Biopsy|Fine Needle aspiration from sentinel Lymph Nodes
219395855|NCT03720080|DEVICE|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
219001648|NCT07132086|DRUG|Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting|Daridorexant 50 mg is administered once daily at bedtime, either as monotherapy or as add-on therapy in patients with chronic insomnia. The intervention is evaluated in a naturalistic, real-world setting over a 3-month observational period. Both subjective (questionnaires, sleep diary) and objective (actigraphy) sleep parameters are collected at baseline, 1 month, and 3 months. Actigraphy is used to assess total sleep time, sleep efficiency, wake after sleep onset, and circadian rhythm parameters. Sleep misperception is calculated as the discrepancy between subjective and objective sleep metrics. The study also explores potential predictors of treatment response such as age, sex, BMI, insomnia duration, and comorbid sleep disorders.
219189191|NCT04564703|DRUG|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
219189192|NCT01309672|DRUG|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
219189193|NCT01309672|DRUG|Prednisone|5 mg, oral, 5 mg twice daily
219189194|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
219189195|NCT04962061|OTHER|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
219189196|NCT04962061|OTHER|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
219395856|NCT01452425|DEVICE|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
219395857|NCT01452425|DEVICE|INVOS assessment|Near Infraread spectroscopy, non invasive
219395858|NCT01452425|DEVICE|EMG assessment|Electromyography, non invasive
219395859|NCT06671509|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
219395860|NCT06671691|RADIATION|SBRT level I|20Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
219395861|NCT06671691|RADIATION|SBRT level II|23Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
219395862|NCT06671691|RADIATION|SBRT level III|26Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
219395863|NCT06671691|RADIATION|SBRT level IV|28Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
219395864|NCT06671691|RADIATION|SBRT level V|30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
219395865|NCT06671444|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
219395866|NCT06302322|PROCEDURE|Thin Tissues|Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
219395867|NCT06302322|PROCEDURE|Thick Tissues|Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
219395868|NCT06302322|PROCEDURE|Surgically augmented thin tissues|Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
219395869|NCT00004697|DRUG|choline chloride|
219395870|NCT06672302|DIAGNOSTIC_TEST|ExoPred|Performing in vitro diagnostics with devices developed by EXoPERT
219395871|NCT06671769|DIETARY_SUPPLEMENT|Heart Health Supplement|This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
219395872|NCT04294784|DRUG|Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
219395873|NCT04294784|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
219395874|NCT04445077|OTHER|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
219395875|NCT04445077|OTHER|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
219395876|NCT03531372|DEVICE|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
219395877|NCT03531372|DEVICE|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
219395878|NCT02325999|PROCEDURE|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
219395879|NCT03932136|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
219001649|NCT06927297|BIOLOGICAL|Engineered mitochondria vaccine|Participants were assigned to receive subcutaneous injections of the low dose, medium dose, or high-dose of the engineered mitochondrial vaccine. The regimen consisted of 3 doses of primary immunization, 1 dose of boost immunization and subsequent personalized treatment.
219395880|NCT03932136|COMBINATION_PRODUCT|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
219395881|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
219395882|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
219395883|NCT05712031|PROCEDURE|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
219395884|NCT00677144|DRUG|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
219395885|NCT00677144|DRUG|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
219395886|NCT00318201|DRUG|Erythromycin|
219395887|NCT00318201|DRUG|Diltiazem|
219395888|NCT04670146|DIAGNOSTIC_TEST|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
219395889|NCT01861340|DRUG|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
219395890|NCT06296264|DEVICE|Standard ultrasound|Placement of IV line using standard ultrasound.
219395891|NCT06296264|DEVICE|Ultra-portable ultrasound|Placement of IV line using ultra-portable ultrasound.
219395892|NCT06003816|BEHAVIORAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is during group sessions by a health promoter to those residing in a ring around a cholera patient reinforced through weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended water, sanitation, and hygiene behaviors.
219395893|NCT06003816|BEHAVIORAL|Standard message|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
219395894|NCT04267237|DRUG|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
219395895|NCT04267237|DRUG|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
219395896|NCT05061225|BEHAVIORAL|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
219395897|NCT02522481|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
219395898|NCT02524080|PROCEDURE|Triage to optimal healthcare level|Triage to optimal healthcare level
219395899|NCT03291782|DRUG|D-0120|oral, single dose
219395900|NCT03340805|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
219395901|NCT03340805|DRUG|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
219395902|NCT06123429|BEHAVIORAL|Mindfulness Based Stress reduction|"The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection.~Mindfulness-Based Stress Reduction (MBSR) is a structured program designed to help individuals manage stress, increase self-awareness, and promote overall well-being. Developed by Dr. Jon Kabat-Zinn in the late 1970s, MBSR combines elements of mindfulness meditation and cognitive-behavioral techniques. MBSR is a comprehensive program that equips individuals with practical skills to better manage stress and enhance their mental and emotional well-being. Its emphasis on mindfulness, self-awareness, and the integration of these practices into daily life makes it a valuable resource for those seeking to reduce stress and improve their overall quality of life."
219395903|NCT00404768|DRUG|GSK221149A|6mg/h and 12 mg/h
219395904|NCT00404768|DRUG|Placebo|Matched Placebo to Drug
219395905|NCT01829789|BEHAVIORAL|Group Community Reinforcement Training for Parents|
219395906|NCT01829789|BEHAVIORAL|Individual Community Reinforcement Training for Parents|
219395907|NCT03123939|BIOLOGICAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
219395908|NCT04446234|DRUG|Risperidone|Use medicine according to patients condition
219395909|NCT04446234|DRUG|Aripiprazole|Use medicine according to patients condition
219395910|NCT04446234|DRUG|Ziprasidone|Use medicine according to patients condition
219395911|NCT04446234|DRUG|Amisulpride|Use medicine according to patients condition
219395912|NCT04446234|DRUG|Quetiapine|Use medicine according to patients condition
219395913|NCT01962636|DRUG|Fludarabine|25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
219395914|NCT01962636|DRUG|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
219395915|NCT01962636|RADIATION|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
219395916|NCT01962636|DRUG|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
219395917|NCT01962636|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
219395918|NCT01962636|BIOLOGICAL|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
219395919|NCT05836740|DRUG|Minocycline hydrochloride capsule|50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
219395920|NCT05836740|DRUG|Placebo capsules of Minocycline hydrochloride capsules|50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
219395921|NCT02717689|OTHER|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
219395922|NCT06864962|PROCEDURE|Renal sympathetic denervation|Under the guidance of the 3-dimensional navigation system, HFS was performed from the accessible branches to the proximal (the ostium of renal artery) segments of the bilateral renal arteries, and the target ablation sites were identified by HFS-induced SBP elevation \>5mmHg, and radiofrequency ablations were performed with a power setting of 8 to 12 Watts and a duration of 90 seconds. The endpoint of RSD was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
219395923|NCT06864962|PROCEDURE|Renal sympathetic denervation plus aorticorenal ganglion ablation|Following RSD, HFS was performed in the the junction area of abdominal aorta and renal arteries to recognize ARG. Radiofrequency ablations were performed with a power setting of 12 to 20 Watts and a duration of 90 seconds. The endpoint of ablation was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
219395924|NCT06257004|GENETIC|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
219395925|NCT06257004|GENETIC|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
219395926|NCT06055894|DIETARY_SUPPLEMENT|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
219395927|NCT06055894|DIETARY_SUPPLEMENT|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
219395928|NCT06055894|DIETARY_SUPPLEMENT|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
219395929|NCT06055894|OTHER|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
219395930|NCT06501872|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
219395931|NCT03101891|PROCEDURE|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
219395932|NCT03101891|DEVICE|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
219395933|NCT03101891|DRUG|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
219560844|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
219395934|NCT02026908|DEVICE|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
219395935|NCT06512363|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
219395936|NCT06512363|DRUG|Ramelteon placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
219395937|NCT02166840|PROCEDURE|Plastic stent (7-10Fr)|
219395938|NCT02166840|PROCEDURE|Self Expanding Metal Stent|
219395939|NCT04005209|DRUG|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
219395940|NCT04005209|OTHER|Pain management|Pain management
219395941|NCT04742257|DEVICE|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
219395942|NCT03083158|DRUG|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
219395943|NCT01074411|DRUG|Bortezomib|Given IP
219395944|NCT01074411|DRUG|Carboplatin|Given IP
219395945|NCT01074411|OTHER|Laboratory Biomarker Analysis|Correlative studies
219395946|NCT01074411|OTHER|Pharmacological Study|Correlative studies
219395947|NCT05776186|DRUG|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
219395948|NCT05279794|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
219560845|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
219560846|NCT04432207|DRUG|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
219560847|NCT04432207|DRUG|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
219560848|NCT00139932|DRUG|formoterol fumarate|
219560849|NCT04478240|BEHAVIORAL|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
219189197|NCT04962061|OTHER|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
219189198|NCT03338309|OTHER|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
219395949|NCT05279794|OTHER|Myofascial Induction Group|Myofascial Induction technique on the lumbar fascia
219395950|NCT05279794|OTHER|Placebo Group|No pain positioning of participants
219395951|NCT02963727|BIOLOGICAL|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
219395952|NCT00878540|DRUG|mirtazapine|30 mg mirtazapine once daily for 7 days
219395953|NCT03005847|DIETARY_SUPPLEMENT|fermented papaya preparation|dietary supplementation with fermented papaya preparation
219395954|NCT01937130|DRUG|IDN-6556|
219560850|NCT02005939|DIETARY_SUPPLEMENT|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
219560851|NCT01773239|BEHAVIORAL|TARA computer-based exercises|
219560852|NCT05780996|DEVICE|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
219560853|NCT05780996|DEVICE|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
219189199|NCT02336087|DRUG|Gemcitabine Hydrochloride|Given IV
219189200|NCT02336087|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219189201|NCT02336087|DRUG|Metformin Hydrochloride|Given PO
219189202|NCT02336087|DIETARY_SUPPLEMENT|Therapeutic Dietary Intervention|Given PO
219395955|NCT01937130|OTHER|Placebo|
219395956|NCT02618850|PROCEDURE|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
219395957|NCT02618850|DRUG|first-line chemotherapy|as prescribed by oncologist
219395958|NCT03158649|OTHER|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
219189203|NCT02336087|OTHER|Laboratory Biomarker Analysis|Correlative studies
219189204|NCT02336087|OTHER|Quality-of-Life Assessment|Ancillary studies
219395959|NCT06196476|BEHAVIORAL|Interactive digital-based educational program|"The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
219395960|NCT05807022|PROCEDURE|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
219395961|NCT00409422|BEHAVIORAL|weight management program|
219395962|NCT04018963|PROCEDURE|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
219395963|NCT04018963|PROCEDURE|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
219395964|NCT04861961|PROCEDURE|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
219560854|NCT06679712|PROCEDURE|Transbronchial PDT lung tumor ablation|Transbronchial photodynamic therapy ablation for peripheral lung cancer
219560855|NCT05685017|DIAGNOSTIC_TEST|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
219560856|NCT04039490|DEVICE|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
219560857|NCT05134116|OTHER|Treatment as usual + cerebral oximetry monitoring the first 72 hours of life|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
219560858|NCT02609516|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
219189205|NCT05318898|OTHER|Vegetal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
219395965|NCT02563288|DRUG|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
219395966|NCT02563288|DRUG|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
219395967|NCT02060201|DRUG|Saxagliptin|
219395968|NCT02060201|DRUG|Dapagliflozin|
219395969|NCT02060201|DRUG|Saxagliptin/Dapagliflozin FDC|
219395970|NCT02674997|BIOLOGICAL|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
219395971|NCT01550718|BEHAVIORAL|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
219395972|NCT01550718|BEHAVIORAL|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
219395973|NCT05072769|DIETARY_SUPPLEMENT|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
219395974|NCT04437017|DRUG|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
219395975|NCT04437017|DRUG|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
219395976|NCT00824499|OTHER|Complex regional intervention|"Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit"
219395977|NCT02060617|BEHAVIORAL|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
219395978|NCT02060617|PROCEDURE|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
219560859|NCT05970614|OTHER|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
219560860|NCT00558623|DIETARY_SUPPLEMENT|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
219560861|NCT05478928|OTHER|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
219560862|NCT05478928|DEVICE|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
219395979|NCT02060617|PROCEDURE|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
219395980|NCT02060617|PROCEDURE|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
219560863|NCT05478928|OTHER|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
219560864|NCT05478928|DEVICE|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
219560865|NCT05478928|DEVICE|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
219560866|NCT05478928|OTHER|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
219189206|NCT05318898|OTHER|Animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
219395981|NCT01124058|DRUG|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
219395982|NCT01124058|DRUG|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
219395983|NCT00466128|DRUG|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
219395984|NCT05676320|DEVICE|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
219395985|NCT05676320|DEVICE|V-Steady|Bone Cement alone
219395986|NCT02857907|OTHER|Blood sample|A blood sample is performed one year after kidney transplantation.
219560867|NCT06318377|DIETARY_SUPPLEMENT|Peanut group|These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
219754471|NCT05251649|DEVICE|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
219395987|NCT05158309|OTHER|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
219395988|NCT05158309|OTHER|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
219395989|NCT02115815|BIOLOGICAL|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
219560868|NCT05840276|DEVICE|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
219560869|NCT05840276|OTHER|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
219560870|NCT00432627|DRUG|Deferasirox|one dose of 20 mg/kg/day
219560871|NCT06678776|PROCEDURE|surgery|Explore the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty.
219560872|NCT04674982|DEVICE|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
219560873|NCT02247076|BEHAVIORAL|Grazing|
219560874|NCT02247076|BEHAVIORAL|Time-restricted feeding (early eating)|
219560875|NCT01337882|OTHER|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
219560876|NCT00176930|BIOLOGICAL|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
219560877|NCT00176930|DRUG|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
219560878|NCT00176930|RADIATION|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
219560879|NCT00176930|DRUG|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
219560880|NCT00176930|DRUG|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
219560881|NCT00176930|BIOLOGICAL|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
219560882|NCT02724826|BEHAVIORAL|Qigong therapy|Medical qigong
219560883|NCT02724826|BEHAVIORAL|Exercise therapy|Regular exercise
219560884|NCT02221817|PROCEDURE|Trochanter bursa injections|
219560885|NCT02221817|DEVICE|Ultrasound|
219560886|NCT01940263|DIETARY_SUPPLEMENT|Anthocyanin|
219560887|NCT01940263|DIETARY_SUPPLEMENT|Placebo|
219560888|NCT03847363|PROCEDURE|epidural anesthesia|epidural anesthesia
219560889|NCT03847363|PROCEDURE|nerve block|paravertebral or serratus anterior plane block
219560890|NCT06616441|DRUG|Bupivacaine|Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
219560891|NCT00585312|DRUG|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
219560892|NCT00585312|DRUG|Placebo|Masked, placebo comparator
219560893|NCT05796596|BEHAVIORAL|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
219560894|NCT05796596|BEHAVIORAL|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
219560895|NCT03858023|OTHER|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
219395990|NCT02115815|BIOLOGICAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
219395991|NCT02115815|BIOLOGICAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
219395992|NCT02115815|BIOLOGICAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
219560896|NCT06166758|BEHAVIORAL|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
219754472|NCT05251649|DEVICE|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
219560897|NCT03716323|DEVICE|immediate premolar implant with xenograft and allograft|"* A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
219395993|NCT02115815|BIOLOGICAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
219560898|NCT02463838|OTHER|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
219395994|NCT02115815|BIOLOGICAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
219395995|NCT02115815|BIOLOGICAL|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
219395996|NCT00112099|PROCEDURE|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
219560899|NCT04231123|PROCEDURE|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
219560900|NCT04231123|PROCEDURE|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
219560901|NCT00190450|BIOLOGICAL|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
219560902|NCT04096339|OTHER|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
219560903|NCT04096339|OTHER|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
219560904|NCT05409352|BEHAVIORAL|Self-administered acupressure|Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).
219001650|NCT07132294|BEHAVIORAL|Exercise Intervention|"Supramaximal Interval Running (SIR) This protocol was individualized based on each player's Maximal Aerobic Speed (MAS). Training intensities were prescribed at 100% to 110% of each player's MAS. Each session consisted of eight sets. During the first three weeks, each set involved a 2-minute maximal effort run followed by 2 minutes of passive recovery. In the final three weeks, the duration of each set was extended to a 3-minute maximal run with 3 minutes of passive rest, increasing intensity and volume. SIR sessions were designed to enhance anaerobic capacity and lactate tolerance.~Small-Sided Games (SSG) SSG sessions were implemented to develop agility, acceleration, tactical decision-making, and match-relevant conditioning. Training took place on regulation-size grass pitches, adjusted to maintain a consistent length-to-width ratio across all formats. Over the six-week intervention, game formats progressed from 4v4 to 7v7, with gradual increases in duration and pitch dimensions."
219001651|NCT07131826|OTHER|Observational study, non-interventional|Observational study, non-interventional
219001652|NCT06492330|DRUG|CS0159|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
219001653|NCT06492330|DRUG|CS0159 placebo|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
219001654|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
219001655|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
219001656|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219001657|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
219395997|NCT00112099|PROCEDURE|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
219395998|NCT00678509|BIOLOGICAL|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219395999|NCT01228071|DRUG|testosterone gel 2%|40 mg testosterone gel 2%
219396000|NCT05994794|DIETARY_SUPPLEMENT|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
219396001|NCT05994794|OTHER|Placebo|Microcrystalline Cellulose
219560905|NCT05409352|BEHAVIORAL|Aerobic exercise|Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
219560906|NCT04857151|BEHAVIORAL|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
219560907|NCT02230111|BEHAVIORAL|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
219560908|NCT02230111|BEHAVIORAL|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
219560909|NCT06808646|DRUG|pitavastatin|Single oral administration
219396002|NCT03487380|PROCEDURE|Fecal sample collection|Fecal sample collection
219396003|NCT02969343|BEHAVIORAL|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
219396004|NCT03314519|DIAGNOSTIC_TEST|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
219396005|NCT03314519|DIAGNOSTIC_TEST|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
219396006|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
219396007|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
219560910|NCT06808646|DRUG|pitavastatin single dose combined with ceftobiprole|Single oral pitavastatin co-administered with IV ceftobiprole
219560911|NCT04174573|OTHER|GTO|"1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
219560912|NCT04174573|OTHER|GT-tDCS|"1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
219560913|NCT03045822|DRUG|Bioimpedance analysis|
219560914|NCT03380130|DRUG|Nivolumab|An anti-programmed death 1 monoclonal antibody
219560915|NCT03380130|DEVICE|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
219560916|NCT01362673|DRUG|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
219560917|NCT01362673|DRUG|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
219560918|NCT01362673|DRUG|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
219560919|NCT01362673|DRUG|Placebo|Oral single dose as matching placebo
219560920|NCT01362673|DRUG|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
219396008|NCT04388657|DIAGNOSTIC_TEST|Echo-Doppler|Utrasound Doppler of the lower limbs
219396009|NCT04003155|DRUG|fezolinetant|Oral Tablet
219396010|NCT04003155|DRUG|placebo|Oral Tablet
219396011|NCT04664660|OTHER|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
219396012|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
219396013|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
219560921|NCT01362673|DRUG|Placebo|Oral multiple doses as matching placebo for 12 days
219396014|NCT05347914|BEHAVIORAL|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
219396015|NCT04897412|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
219396016|NCT04897412|OTHER|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
219396017|NCT05927246|DIAGNOSTIC_TEST|ECG|12 lead ecg for each participant
219396018|NCT01912872|DRUG|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
219396019|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
219396020|NCT01912872|DRUG|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
219396021|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
219396022|NCT01912872|DRUG|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
219396023|NCT00635531|OTHER|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
219396024|NCT00635531|DRUG|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
219560922|NCT02241694|OTHER|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
219560923|NCT06677827|DRUG|Bupivacaine|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
219560924|NCT06677827|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
219560925|NCT03011060|PROCEDURE|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
219560926|NCT03011060|DRUG|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
219560927|NCT01311427|BEHAVIORAL|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
219754473|NCT01385579|OTHER|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
219396025|NCT00834002|BIOLOGICAL|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
219396026|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 14 days
219396027|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 56 days
219560928|NCT01311427|BEHAVIORAL|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
219560929|NCT00134329|PROCEDURE|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
219560930|NCT02636829|OTHER|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
219560931|NCT02636829|OTHER|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
219560932|NCT05429489|PROCEDURE|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
219560933|NCT05429489|PROCEDURE|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
219560934|NCT05429489|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
219560935|NCT05886257|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
219560936|NCT05886257|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
219560937|NCT01334957|DRUG|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
219560938|NCT03255044|DRUG|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
219560939|NCT03255044|DRUG|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
219560940|NCT03255044|OTHER|guideline directed therapy|standard heart failure therapy
219560941|NCT04080596|DRUG|Dorzagliatin|GKA for T2DM currently under clinical development
219754474|NCT00006163|BEHAVIORAL|Personalized Self-management|
219754475|NCT00006163|BEHAVIORAL|Community Resources|
219754476|NCT03135860|DRUG|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
219560942|NCT01544439|PROCEDURE|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
219396028|NCT02967848|OTHER|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
219560943|NCT01544439|PROCEDURE|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
219560944|NCT00398684|DRUG|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
219560945|NCT00398684|DRUG|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
219560946|NCT00398684|DRUG|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
219560947|NCT02665884|OTHER|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
219560948|NCT00782561|DRUG|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
219560949|NCT05638607|BEHAVIORAL|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
219560950|NCT04291508|DRUG|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
219560951|NCT04291508|DRUG|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
219560952|NCT04291508|DRUG|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
219560953|NCT04291508|DRUG|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
219560954|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, low dose|infusion
219560955|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, high dose|infusion
219560956|NCT05445076|OTHER|placebo|infusion
219560957|NCT01429831|DRUG|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
219560958|NCT05144464|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
219560959|NCT00929058|DRUG|Bevacizumab|Intra-arterial infusion during 6 minutes
219560960|NCT02223286|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score
219560961|NCT00432055|DRUG|Botulinum toxin type A (Botox)|
219560962|NCT00432055|DRUG|placebo (saline)|
219560963|NCT03566238|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
219560964|NCT03566238|DRUG|Placebo|Placebo identical in appearance to active drug (A4250).
219560965|NCT02151175|DEVICE|LIFUP|
219560966|NCT06057506|DEVICE|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
219560967|NCT06057506|DEVICE|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
219560968|NCT06189911|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
219560969|NCT05601778|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
219560970|NCT05601778|DRUG|placebo|the placebo comparator of study
219560971|NCT01767727|PROCEDURE|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
219754481|NCT01370876|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
219754482|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
219754483|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
219754484|NCT00678704|DRUG|Placebo|Placebo tablet prior to intercourse on demand
219396029|NCT02967848|OTHER|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
219396030|NCT02967848|OTHER|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
219396031|NCT00161824|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
219396032|NCT06532019|OTHER|Targeted intervention based on risk factors|Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
219396033|NCT00260741|DRUG|Smoked Cannabis|
219560972|NCT02710591|DRUG|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"
219560973|NCT02300168|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
219560974|NCT00597428|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
219560975|NCT00597428|DRUG|Placebo|0 mcg capsules twice daily (BID)
219560976|NCT06492551|OTHER|Trak exercise prescription protocol|Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
219560977|NCT06492551|OTHER|Conventional rehabilitation plan in the gym|Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
219560978|NCT03744286|DEVICE|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
219560979|NCT05404451|DIAGNOSTIC_TEST|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
219560980|NCT05404451|DIAGNOSTIC_TEST|Mckenzie Exercises|Using Mckenzie Exercises
219189207|NCT05623228|COMBINATION_PRODUCT|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
219396034|NCT03428191|DRUG|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
219560981|NCT01570231|DEVICE|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
219560982|NCT01556867|OTHER|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
219560983|NCT01556867|OTHER|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
219754485|NCT04390282|BEHAVIORAL|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
219754486|NCT03218865|DEVICE|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
219754487|NCT03218865|DEVICE|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
219754488|NCT04975620|DEVICE|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
219754489|NCT03868501|BEHAVIORAL|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
219754490|NCT06512532|OTHER|fireworks eye injury|patients presented with eye injury during festivals due to fireworks
219189208|NCT03283722|DEVICE|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
219189209|NCT06245083|DRUG|Pyrroloquinoline quinone (PQQ)|Oral supplement taken daily
219189210|NCT06245083|DRUG|Placebo with soybean oil|Oral supplement taken daily
219396035|NCT04030481|OTHER|inhalation anesthesia|sevoflurane was used to maintain anesthesia
219396036|NCT04030481|OTHER|Total intravenous anesthesia|propofol was used to maintain anesthesia
219396037|NCT03252639|PROCEDURE|EVT for RAS & PBV acquisition protocol for target kidneys|
219396038|NCT03198169|DEVICE|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
219396039|NCT03198169|DEVICE|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
219396040|NCT00950690|DRUG|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
219396041|NCT03089177|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
219396042|NCT02629081|OTHER|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
219396043|NCT01713036|DRUG|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
219396044|NCT05868642|PROCEDURE|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
219396045|NCT02394444|OTHER|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
219396046|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
219396047|NCT03851393|OTHER|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
219396048|NCT03851393|PROCEDURE|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
219560984|NCT06013111|BIOLOGICAL|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
219560985|NCT03304431|DRUG|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
219560986|NCT06029582|DEVICE|VR headset|Virtual Reality Headset
219560987|NCT06369506|DIAGNOSTIC_TEST|GTmeasurement|GT was measured from the point corresponding to the base of the gingival sulcus and 1 mm and 2 mm apical to this point. If the GT was ≤1 mm, it was considered a thin phenotype, and if it was \>1 mm, it was considered a thick phenotype.
219560988|NCT02452879|DEVICE|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
219560989|NCT02452879|DEVICE|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
219560990|NCT02452879|DRUG|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
219560991|NCT04203667|DEVICE|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
219754491|NCT02369536|DIETARY_SUPPLEMENT|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
219754492|NCT02369536|DIETARY_SUPPLEMENT|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
219754493|NCT00002237|DRUG|Peldesine|
219396049|NCT03851393|DIAGNOSTIC_TEST|Peptest™|The Peptest™ lateral flow device
219396050|NCT06077058|OTHER|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
219560992|NCT04659096|DRUG|ION537|ION537 will be administered by IV injection.
219754494|NCT04573972|BEHAVIORAL|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
219560993|NCT03601845|OTHER|Stimuli|Visual stimulation while using additional sequencing
219560994|NCT03601845|OTHER|No stimuli|Additional sequencing only
219560995|NCT03062787|DEVICE|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
219560996|NCT03062787|DEVICE|Monovisc® (Sodium hyaluronate)|Intra-articular injection
219560997|NCT00132457|PROCEDURE|Self-collected vaginal swab for chlamydia testing|
219560998|NCT02507063|PROCEDURE|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
219560999|NCT00398593|BEHAVIORAL|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
219561000|NCT05717790|DRUG|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
219561001|NCT05717790|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
219561002|NCT05717790|DRUG|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
219561003|NCT05717790|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
219561004|NCT01696305|DEVICE|Hyalobarrier|
219561005|NCT01696305|DEVICE|Guardix-SG|
219561006|NCT01183884|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
219561007|NCT05549687|OTHER|Questionnaire Administration|Ancillary studies
219561008|NCT05549687|PROCEDURE|Supportive Care|Participate in Pack Health, an electronic support program
219754495|NCT04573972|BEHAVIORAL|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
219754496|NCT03005392|OTHER|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
219754497|NCT05322278|OTHER|Data collection|No interventions
219754498|NCT00046072|DRUG|E5564|
219561009|NCT05549687|PROCEDURE|Supportive Care|Access to telephone triage line for support care services
219001658|NCT07090616|DEVICE|Arm 1-Kronos brace|Subjects randomized to the treatment group will be measured and fitted with the KRONOS knee brace at their initial clinic visit after study enrollment
219561010|NCT00127166|DRUG|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
219561011|NCT00127166|DRUG|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
219561012|NCT00127166|DRUG|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
219561013|NCT00127166|DRUG|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
219561014|NCT00127166|DRUG|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
219561015|NCT02922582|DRUG|DepoTXA|
219561016|NCT02922582|DRUG|Tranexamic Acid|
219561017|NCT02369549|DRUG|Micro-particle Curcumin|as described in Arm
219561018|NCT02369549|DRUG|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
219561019|NCT01513395|BEHAVIORAL|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
219561020|NCT04439760|PROCEDURE|Superior Cervical Ganglion Block|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
219561021|NCT00708682|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
219561022|NCT03863041|OTHER|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
219561023|NCT04763473|DIETARY_SUPPLEMENT|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
219001659|NCT07090616|DEVICE|Arm 2-Breg T-Scope brace|Subjects randomized to Breg T-Scope Postoperative Brace will be placed in this standard postoperative hinged knee brace in the operating room that will be locked in full extension.
219561024|NCT04763473|DIETARY_SUPPLEMENT|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
219561025|NCT05554965|DRUG|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
219561026|NCT05554965|DRUG|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
219561027|NCT05430464|DEVICE|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
219189211|NCT06514040|DRUG|Precedex|Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to anaesthesia and surgical procedure.
219189212|NCT06514040|DRUG|Sumatriptan 25 mg|Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain (as substance -p), nausea, and other symptoms of migraine
219561028|NCT05430464|DEVICE|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
219561029|NCT03519490|DEVICE|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
219001660|NCT07093411|BIOLOGICAL|LUCAR-E9D or LUCAR-E9K cells product|Prior to infusion of the LUCAR-E9D or LUCAR-E9K cells product subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
219189213|NCT06405321|DRUG|Conversion or neoadjuvant therapy.|Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
219189214|NCT05837117|BEHAVIORAL|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
219189215|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
219561030|NCT00587249|BIOLOGICAL|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
219561031|NCT00587249|BIOLOGICAL|Alhydrogel|Aluminum hydroxide gel.
219561032|NCT00840190|DRUG|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
219561033|NCT04572204|OTHER|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
219561034|NCT04590339|PROCEDURE|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
219001661|NCT07096622|DEVICE|perceptual learning visual treatment,HVT|After receiving guidance from a trainer, treatment was conducted using the visual perception training therapy software (HVT, version number: V1.0.10000) on a network platform for 30 minutes per day, totaling 3 months.
219001662|NCT03685578|DEVICE|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
219561035|NCT04006873|DRUG|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
219561036|NCT04006873|DRUG|Placebo oral tablet|As per description in arms
219561037|NCT04728620|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
219561038|NCT05548920|OTHER|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
219561039|NCT05548920|OTHER|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
219754499|NCT01627041|DRUG|Cytarabine|Given IV
219754500|NCT01627041|DRUG|Daunorubicin Hydrochloride|Given IV
219754501|NCT01627041|DRUG|Decitabine|Given IV
219754502|NCT01627041|OTHER|Laboratory Biomarker Analysis|Correlative studies
219001663|NCT03685578|DEVICE|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
219754503|NCT01627041|OTHER|Pharmacological Study|Correlative studies
219754504|NCT01517984|DRUG|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
219754505|NCT01517984|DRUG|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
219754506|NCT05188989|DRUG|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
219754507|NCT05188989|DRUG|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
219189216|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
219561040|NCT00450567|PROCEDURE|computed tomography|
219561041|NCT00450567|PROCEDURE|positron emission tomography|
219561042|NCT00450567|RADIATION|fludeoxyglucose F 18|
219396051|NCT06077058|BEHAVIORAL|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
219561043|NCT04631380|OTHER|PRAYER|THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
219561044|NCT06004180|DRUG|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
219561045|NCT00026416|BIOLOGICAL|recombinant interferon alfa|
219561046|NCT00026416|DRUG|thalidomide|
219561047|NCT00026416|PROCEDURE|adjuvant therapy|
219561048|NCT05756465|DEVICE|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
219561049|NCT03689894|DRUG|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
219561050|NCT03689894|DRUG|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
219561051|NCT00957216|DRUG|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
219561052|NCT00957216|DRUG|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
219561053|NCT05303948|DEVICE|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
219561054|NCT05531682|OTHER|Placebo|Subjects will receive several injections of Placebo
219561055|NCT05531682|DRUG|HB0017|Subjects will receive HB0017 in different dosing regimens
219189217|NCT05866861|DRUG|CUG252|CUG252 will be administered by subcutaneous injection.
219189218|NCT05866861|DRUG|Placebo|Placebo will be administered by subcutaneous injection.
219189219|NCT04895592|DRUG|Dexamethasone|Given PO or IV
219561056|NCT01030887|BEHAVIORAL|Exercise programme|Moderate intensity exercise
219561057|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
219561058|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
219561059|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
219561060|NCT06811870|DEVICE|hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
219561061|NCT04913519|DRUG|TDM-105795|TDM-105795 topical solution
219561062|NCT04913519|DRUG|Placebo|Placebo for TDM-105795 topical solution
219561063|NCT06326528|DRUG|SGLT2 inhibitor|Dapagliflozin 10 mg or Empagliflozin 25mg
219561064|NCT03170102|OTHER|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
219561065|NCT06663475|BEHAVIORAL|TTM-based health education videos about smoking cessation for expectant fathers|Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
219561066|NCT06663475|BEHAVIORAL|usual care treatment|general health education videos about hazards of smoking for expectant fathers in obstetric clinic
219754508|NCT05188989|DRUG|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
219754509|NCT05188989|DRUG|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
219754510|NCT05067335|DRUG|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
219754511|NCT05067335|DRUG|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
219754512|NCT01842659|GENETIC|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
219754513|NCT00926614|DRUG|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
219189220|NCT04895592|PROCEDURE|Resection|Undergo surgical resection
219189221|NCT04895592|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219001664|NCT03685578|DEVICE|CEREGLIDE 71 Intermediate Catheter|CEREGLIDE 71 Intermediate Catheter
219001665|NCT07131553|OTHER|Wheelchair school|Wheelchair skills training with pysiotherapist and peer mentor
219001666|NCT07131553|OTHER|Comparison group, conventional rehabilitation|Conventional rehabilitation at the same unit of similiar length and intensity
219001667|NCT07132593|PROCEDURE|ventricular reconstruction|The Sandwich Procedure was developed at our institution to improve the strength and stability of heart wall reconstruction after tumor removal. It involves suturing two layers of treated biological tissue-both inside and outside the heart wall-to restore normal shape and function, while minimizing the risk of complications like aneurysm or bleeding.
219001668|NCT07132177|DRUG|Naltrexone (oral tablets)|All participants will receive 31 pills of 50 mg Naltrexone to take as needed over the month of January 2026.
219001669|NCT07131748|OTHER|Physical Exercise Session in heated Swimming Pool - HEx|Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
219001670|NCT07131748|OTHER|Physical Exercise Session in Land- LEx|Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
219001671|NCT07131748|OTHER|Control Session Without Exercise- CON|Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.
219001672|NCT07101094|DRUG|xanomeline and trospium chloride (X/T) therapy|According to the product label
219396052|NCT06077058|OTHER|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
219396053|NCT06077058|OTHER|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
219396054|NCT01518582|DEVICE|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
219396055|NCT05874219|DRUG|Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU|The intervention Sprayed 1 to 3 times /day
219396056|NCT05874219|DRUG|Mupirocin 2% ointment|10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
219396057|NCT00758914|DIETARY_SUPPLEMENT|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
219396058|NCT03626051|DEVICE|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
219396059|NCT03626051|DEVICE|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
219396060|NCT00628511|DEVICE|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
219396061|NCT02940054|OTHER|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
219396062|NCT03955107|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
219396063|NCT01109706|OTHER|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
219396064|NCT00480753|DRUG|Nitroglycerin|
219396065|NCT06034704|OTHER|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
219754514|NCT00926614|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
219396066|NCT06034704|OTHER|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
219396067|NCT04405804|DRUG|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg"
219396068|NCT00373971|BEHAVIORAL|Involving the patients in their own nutritional care|
219396069|NCT02653378|BEHAVIORAL|DIET|25% Energy Depletion by Diet only for 3 Days
219396070|NCT02653378|BEHAVIORAL|EX|25% Energy Depletion by Exercise only for 3 Days
219396071|NCT03090620|DRUG|Physostigmine|Administration of physostigmine bolus followed by an infusion
219396072|NCT03090620|DRUG|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
219396073|NCT00109317|DRUG|Raptiva (efalizumab)|
219396074|NCT00003750|BIOLOGICAL|hu14.18-IL2 fusion protein|
219396075|NCT04081883|OTHER|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
219396076|NCT02662777|DEVICE|Eso-SPONGE® vacuum treatment|
219396077|NCT05634031|RADIATION|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
219561067|NCT04994405|PROCEDURE|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
219561068|NCT00274495|DRUG|Rosiglitazone and Pegasys/Ribavirin|
219561069|NCT05775120|DIAGNOSTIC_TEST|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
219561070|NCT00374166|DRUG|SSR149415|Oral administration (capsules of 50 and 100 mg)
219561071|NCT00374166|DRUG|Placebo|Oral administration (capsules)
219561072|NCT00374166|DRUG|Paroxetine|Oral administration (capsules)
219561073|NCT06161701|OTHER|no intervention|no intervention
219561074|NCT03150901|DIAGNOSTIC_TEST|no drug|laboratory tests
219561075|NCT04319458|BEHAVIORAL|Fotonovela|Secret Feelings/Sentimientos Secretos
219561076|NCT04319458|BEHAVIORAL|Control|NIH Brochure: Depression: What You Need to Know
219396078|NCT05634031|RADIATION|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
219396079|NCT05634031|PROCEDURE|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
219561077|NCT02440555|OTHER|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
219561078|NCT02102919|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
219561079|NCT02102919|DEVICE|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
219561080|NCT02102919|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
219561081|NCT02102919|DEVICE|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
219561082|NCT02704195|PROCEDURE|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
219561083|NCT02704195|PROCEDURE|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
219561084|NCT00401154|OTHER|Stationary Cycling|Use of a stationary bicycle for exercise
219561085|NCT04084990|DEVICE|S9 VPAP Adapt|Auto-titrated positive airway pressure
219561086|NCT02270034|DRUG|Crizotinib|Crizotinib is added to Stupp method
219561087|NCT00681473|RADIATION|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
219561088|NCT05092464|DEVICE|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
219561089|NCT05768087|RADIATION|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
219396080|NCT05634031|PROCEDURE|Treadmill exercise stress study|A treadmill exercise stress study
219561090|NCT03252457|DRUG|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
219396081|NCT03313505|BIOLOGICAL|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
219561091|NCT03252457|DRUG|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
219561092|NCT01354301|DRUG|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
219561093|NCT01354301|DRUG|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
219561094|NCT01354301|DRUG|Basiliximabe|days 0 and 4, according to the package insert instructions.
219561095|NCT01354301|DRUG|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
219561096|NCT01354301|DRUG|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
219561097|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
219561098|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
219561099|NCT02806791|DRUG|FILGRASTIM|
219561100|NCT06336993|DRUG|herbal compound|patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
219561101|NCT06336993|DRUG|Celecoxib|Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
219561102|NCT01978964|BIOLOGICAL|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
219561103|NCT06873698|BEHAVIORAL|Neuro-behavioral Therapy|Neuro-behavioral therapy (NBT) is an evidence-based, multi-modality, time-limited, whole-person therapy, delivered in one hour, weekly, individual appointments. NBT has been used to treat epilepsy, nonepileptic (functional) seizures, and motor functional neurological disorder (mFND).
219561104|NCT06873698|OTHER|Standard Medical Care (SMC)|Standard Medical Care (SMC) involves the routine care received by the participant. SMC may include any of the following evaluation and followup appointments with neurology, physiatry, psychiatry, psychology, mental health, rehabilitation (e.g., Physical Therapy, Occupational Therapy, Speech and Language Therapy), primary care, among other specialists.
219561105|NCT04511208|DEVICE|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
219561106|NCT04511208|DEVICE|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
219561107|NCT00113061|PROCEDURE|Exercise|
219561108|NCT04485208|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
219561109|NCT04883450|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
219561110|NCT00912522|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
219561111|NCT04826250|PROCEDURE|Timing of medication|Either morning or nighttime medication
219561112|NCT03241836|DIAGNOSTIC_TEST|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
219561113|NCT04634630|GENETIC|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
219561114|NCT04547036|DEVICE|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
219561115|NCT04726215|DRUG|[18F]F AraG|PET imaging agent specific to activated T cells
219561116|NCT01169038|DRUG|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
219561117|NCT01634854|DRUG|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
219396082|NCT03313505|OTHER|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
219396083|NCT03864237|BEHAVIORAL|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
219396084|NCT03864237|BEHAVIORAL|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
219396085|NCT03952078|DRUG|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
219396086|NCT02546856|OTHER|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
219396087|NCT02546856|OTHER|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
219396088|NCT03735095|DRUG|Porfimer Sodium|Given IV
219396089|NCT03735095|PROCEDURE|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
219396090|NCT05346393|PROCEDURE|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
219561118|NCT01634854|DRUG|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
219396091|NCT05346393|DRUG|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
219396092|NCT05925114|DRUG|S-309309|Administered as oral capsules
219396093|NCT05925114|DRUG|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
219396094|NCT05307289|OTHER|Biposy|Biopsy at inclusion visit and at disease progression if applicable
219396095|NCT01097616|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219396096|NCT01097616|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219396097|NCT01097616|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219396098|NCT02324530|DEVICE|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
219396099|NCT00003386|BIOLOGICAL|BCG vaccine|
219396100|NCT00003386|BIOLOGICAL|autologous tumor cell vaccine|
219396101|NCT00003386|DRUG|carboplatin|
219396102|NCT00003386|DRUG|cisplatin|
219396103|NCT00003386|DRUG|cyclophosphamide|
219396104|NCT00003386|DRUG|paclitaxel|
219396105|NCT00003386|OTHER|dinitrophenyl|
219396106|NCT00003386|PROCEDURE|surgical procedure|
219396107|NCT01996319|DRUG|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
219396108|NCT01996319|DRUG|Placebo|Placebo once a day via Breezhaler® device
219561119|NCT01488448|DRUG|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
219561120|NCT01488448|DRUG|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
219396109|NCT03108755|DRUG|ASP7713|oral
219396110|NCT03108755|DRUG|Placebo|oral
219396111|NCT03627455|OTHER|Percutaneous coronary intervention|Percutaneous coronary intervention
219396112|NCT04446936|PROCEDURE|Flap covering for pressure ulcer|Flap covering for pressure ulcer
219396113|NCT00915811|DRUG|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
219396114|NCT00915811|DRUG|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
219396115|NCT00915811|DRUG|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
219396116|NCT00915811|PROCEDURE|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
219396117|NCT04430972|PROCEDURE|Aortic valve replacement|Open surgical replacement of aortic valve
219396118|NCT01820689|OTHER|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
219396119|NCT05834959|OTHER|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
219396120|NCT05348850|DEVICE|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
219396121|NCT04787809|BEHAVIORAL|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
219396122|NCT06804031|BEHAVIORAL|Nutrition and exercise education|Nutrition and exercise training was created as a result of literature review, and expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were taken for the training content and finalized. The training program consists of six sessions. It is planned to have one session per week and each session will last 30-45 minutes on average. The times when the students are available will be determined by discussing with the school administration in advance. Computers and barcovisions in schools will be utilized for the training of students. Trainings will be conducted through verbal expression, power point presentations, brainstorming, exercises, games, written and visual materials, video screenings and question-answer methods. Adolescents will be given bookmarks, magnets and brochures prepared to prevent obesity.
219396123|NCT05920096|OTHER|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
219396124|NCT05920096|BEHAVIORAL|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
219396125|NCT03229746|DRUG|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
219396126|NCT03229746|DRUG|vincristine|1mg intravenous weekly for 4 weeks
219396127|NCT03229746|DRUG|azathioprine|dose 100mg daily for at least 3 weeks
219396128|NCT03253406|BEHAVIORAL|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
219396129|NCT03253406|BEHAVIORAL|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
219396130|NCT00677027|OTHER|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
219396131|NCT00677027|OTHER|placebo|Placebo
219396132|NCT03781193|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
219396133|NCT03781193|OTHER|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
219396134|NCT03781193|OTHER|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
219396135|NCT03781193|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
219396136|NCT03781193|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
219396137|NCT03781193|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
219561121|NCT05683808|DRUG|Apixaban|Open label
219396138|NCT03781193|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
219396139|NCT03781193|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
219396140|NCT03781193|OTHER|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
219396141|NCT01052168|OTHER|skills training|participants will train using different performance goals (based on different metrics)
219396142|NCT00179920|DRUG|Carboplatin|
219396143|NCT00179920|DRUG|VP-16|
219396144|NCT00179920|PROCEDURE|Local Surgery|
219396145|NCT00179920|PROCEDURE|Cryotherapy|
219561122|NCT02329431|BEHAVIORAL|activation curriculum|psychosocial activation curriculum
219561123|NCT02329431|BEHAVIORAL|support group|parent directed support group
219561124|NCT02821949|BIOLOGICAL|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
219396146|NCT00179920|PROCEDURE|Laser hyperthermia|
219396147|NCT02205970|DEVICE|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
219396148|NCT02205970|DEVICE|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
219396149|NCT01780558|OTHER|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
219396150|NCT01780558|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
219396151|NCT03660371|PROCEDURE|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
219396152|NCT03660371|PROCEDURE|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
219396153|NCT00591227|DRUG|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
219396154|NCT00591227|DRUG|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
219396155|NCT00130208|DRUG|Sulodexide|100 mg sulodexide gelcaps
219396156|NCT00130208|DRUG|Placebo|0 mg gelcap
219396157|NCT03017586|DEVICE|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
219561125|NCT02148354|BEHAVIORAL|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
219561126|NCT01362296|DRUG|GSK1120212|Oral once daily
219561127|NCT01362296|DRUG|docetaxel|IV once every 3 weeks
219561128|NCT05194709|BIOLOGICAL|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
219561129|NCT01939106|DEVICE|One Piece Drainable Pouch|
219561130|NCT05347394|DRUG|VX-708|Solution or suspension for oral administration.
219561131|NCT05347394|DRUG|Placebo|Placebo matched to VX-708 for oral administration.
219561132|NCT05531617|PROCEDURE|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
219561133|NCT03201263|PROCEDURE|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
219561134|NCT03201263|PROCEDURE|Standard of care|Standard of care
219561135|NCT00826345|OTHER|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~\- Active"
219561136|NCT00826345|OTHER|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
219561137|NCT00115024|DRUG|Micronized 17B-estradiol|
219396158|NCT04015297|DIAGNOSTIC_TEST|raman analysis|negative or pozitive
219396159|NCT06330948|DIETARY_SUPPLEMENT|SugarCut® Unripe Guava Fruit Extract|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
219396160|NCT06330948|DIETARY_SUPPLEMENT|Placebo group|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
219396161|NCT06570902|DEVICE|WCD|An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
219561138|NCT00942812|OTHER|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
219561139|NCT00942812|OTHER|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
219561140|NCT05486299|PROCEDURE|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
219561141|NCT04906941|DEVICE|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~\* Sense 2 \* 2: 9min33s"
219561142|NCT02625974|DRUG|Nifurtimox (Lampit, BAYA2502)|"For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment"
219396162|NCT00302237|DEVICE|RX ACCULINK, RX ACCUNET Embolic Protection System|1\) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
219396163|NCT01586663|DEVICE|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
219396164|NCT01586663|DRUG|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
219396165|NCT03132246|DIAGNOSTIC_TEST|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
219561143|NCT02625974|DRUG|Placebo|Matching placebo
219561144|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg|200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.
219561145|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg weekly|200 mg of doxycycline taken by mouth weekly regardless of sexual activity
219561146|NCT01731028|DRUG|Somatropin|Somatropin powder and solvent for solution for injection
219561147|NCT05822375|BEHAVIORAL|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
219561148|NCT05462717|DRUG|RMC-6291|Oral tablet once or twice a day
219561149|NCT00548431|DRUG|6-mercaptopurine|Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
219561150|NCT06905574|OTHER|surgeon guided serratus block|Surgeon guided Serratus Block will be applied before closing dermoglandular flaps
219561151|NCT06905002|BEHAVIORAL|Educational program|Unique educational program that educates health care professionals on the unique advantages of the Clinical Trials Navigator program. This program is reserved for those centres entering the study. An interactive component of the study is central.
219561152|NCT06904651|DEVICE|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline ultrasound guided by dedicated vascular access team
219561153|NCT06055673|GENETIC|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
219561154|NCT06905821|BEHAVIORAL|Transformational Learning-Based Antenatal Education Program|The Transformational Learning-Based Antenatal Education Program helps pregnant women reduce birth-related anxiety and fear by utilizing transformational learning theory. Unlike traditional antenatal education, it emphasizes psychological preparedness, focusing on emotional well-being and coping strategies. The program includes interactive learning, group discussions, and self-reflection to engage participants actively. This approach aims to boost women's confidence and reduce stress as they approach labor and delivery.
219561155|NCT06904417|OTHER|The Feldenkrais-based intervention|The Feldenkrais-based intervention consisted of guided awareness exercises aimed at improving movement patterns, proprioception, and postural control. Sessions were conducted twice weekly for 12 weeks, with each session lasting approximately 45 minutes
219561156|NCT06904417|OTHER|conventional balance training program|a conventional balance training program consisting of static and dynamic balance exercises, gait training, and strength-building activities, matched for session frequency and duration
219561157|NCT06904729|BIOLOGICAL|Low-dose CAR-T cells group|This group of patients received low dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 5×100,000 cells/Kg.
219561158|NCT06904729|BIOLOGICAL|High-dose CAR-T cells group|This group of patients received high dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 1×1000,000 cells/Kg.
219561159|NCT06905730|DIAGNOSTIC_TEST|sensory integration deficits in balance|By assessing sensory integration deficits in balance recovery, the study will help establish meaningful thresholds for rehabilitation outcomes, guiding clinicians in tailoring therapy for improved post-stroke balance and functional independence
219561160|NCT06905613|DEVICE|Technical feasibility study of a novel wearable capnograph (MARIE) in an emergency care environment|MARIE will be connected to the patient by attaching the nasal adapter set and connecting the CO2 sensor. ETCO2 and RR values will be logged before and during the transport by writing down the values in the Case Report Form (CRF). On arrival at the hospital ETCO2 and RR will be measured by a reference instrument and logged in to the CRF. There will be trained study personnel responsible for operating the investigational device and populating the CRF, capturing all information which is required according to the study protocol.
219561161|NCT00291473|DRUG|CHP-HER2, CHP-NY-ESO-1|
219561162|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
219561163|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
219001673|NCT06913660|BEHAVIORAL|MyGoals|"A smartphone game for ALHIV aged 15-21 yrs~MyGoals includes 3 components:~1. A role-playing narrative in which all players make decisions for male and female characters navigating scenarios from adolescence and early adulthood.~2. A series of mini-games to reinforce knowledge, skills and related self-efficacy, explored in the narrative.~3. A metanarrative component, My Story, where players will create an avatar and set personal goals."
219561164|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
219561165|NCT02866591|OTHER|mammography according to an auto-compression procedure|
219561166|NCT02866591|OTHER|mammography according to a standard procedure|
219561167|NCT02866591|OTHER|questionary|
219561168|NCT06904118|DRUG|Nano-reinforced Novel Hydrogen peroxide gel|Group A (Novel Nano-enriched Hydrogen peroxide bleaching gel with Silky Corn hair fiber derived- titania nanoparticles)
219561169|NCT06904118|DRUG|Conventional Hydrogen peroxide gel without nanoparicles|Drug: Hydrogen peroxide without nanoparicles Group B ( Conventional Hydrogen peroxide gel without nanoparticles)
219561170|NCT06904248|DRUG|Meloxicam Injection|Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
219561171|NCT06904248|DRUG|Sodium Chloride Injection|Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses
219561172|NCT03359941|PROCEDURE|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
219561173|NCT06903949|PROCEDURE|Lumbar Dorsal Root Ganglia Pulsed Radiofrequency|It is an interventional pain management technique used to treat chronic radicular pain, often associated with conditions like lumbar disc herniation or degenerative disc disease. It involves the application of pulsed radiofrequency energy to the dorsal root ganglia (DRG), which are clusters of nerve cell bodies located just outside the spinal cord. DRG is involved in transmitting sensory signals from the periphery (e.g., the limbs) to the central nervous system.
219561174|NCT04149535|DEVICE|Sentinel® Cerebral Protection System|cerebral embolic protection system
219561175|NCT03849846|OTHER|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
219561176|NCT02175368|DEVICE|Adhese One F Upgrade|
219561177|NCT02518607|DRUG|MGB-BP-3|Treatment of CDI
219561178|NCT02518607|OTHER|Placebo|Placebo
219561179|NCT02875028|DRUG|Vorapaxar|10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
219561180|NCT02875028|DRUG|Placebo|
219561181|NCT02875028|OTHER|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
219561182|NCT05540171|OTHER|Oral health education and instructions/training for self-oral care|Education intervention
219561183|NCT06130969|OTHER|Cervical Retraction Exercise|Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.
219561184|NCT06130969|OTHER|Diaphragmatic Breathing|The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.
219561185|NCT06130969|OTHER|Baseline Treatment|"Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting."
219561186|NCT06212869|DEVICE|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
219561187|NCT06212869|DEVICE|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
219561188|NCT06212869|DEVICE|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
219561189|NCT06524817|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
219561190|NCT05422235|OTHER|Routine Medical Treatment|Subjects will continue their routine medical treatment.
219561191|NCT05422235|OTHER|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
219561192|NCT05422235|OTHER|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
219561193|NCT05385471|BIOLOGICAL|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
219396166|NCT04016493|PROCEDURE|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
219396167|NCT00575822|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
219396168|NCT00575822|DEVICE|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
219396169|NCT02829346|DRUG|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
219396170|NCT02829346|DRUG|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
219396171|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
219396172|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
219396173|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
219396174|NCT00589472|DRUG|Bicalutamide|Given PO
219396175|NCT00589472|DRUG|Goserelin Acetate|Given SC
219396176|NCT00589472|OTHER|Laboratory Biomarker Analysis|Correlative studies
219396177|NCT00589472|DRUG|Leuprolide Acetate|Given IM
219396178|NCT00589472|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical prostatectomy
219561194|NCT04436926|BEHAVIORAL|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
219561195|NCT04436926|BEHAVIORAL|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
219561196|NCT02847208|OTHER|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
219561197|NCT06331767|BEHAVIORAL|mSYNC|mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
219396179|NCT00589472|DRUG|Vorinostat|Given PO
219396180|NCT06297460|BEHAVIORAL|Systems Training for Emotional Predictability & Problem Solving (STEPPS)|STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
219396181|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
219396182|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
219561198|NCT06349096|DEVICE|Alma Harmony|The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
219561199|NCT04318769|BEHAVIORAL|AFFIRM|AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
219561200|NCT02129062|DRUG|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
219561201|NCT02129062|OTHER|Laboratory Biomarker Analysis|Correlative studies
219561202|NCT02773940|DEVICE|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
219561203|NCT04505735|DRUG|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
219561204|NCT03738787|PROCEDURE|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
219561205|NCT03738787|PROCEDURE|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
219561206|NCT06181253|OTHER|Preoperative education|The intervention will be an instructional video describing proper walking technique particularly up flights of stairs for patients to do at home. This will be shown at preoperative surgical clinic and will be available for access at home from patient's cell phones. The video is currently in production at BMC. Additionally, text reminders will be sent daily to remind patients to walk at home.
219561207|NCT06181253|BEHAVIORAL|Moderate aerobic exercise|Participants will be encouraged to compete 140-150 minutes of moderate aerobic exercise per week- achieved by two walking sessions per day 10-11 minutes in length (realistic/achievable goal)
219561208|NCT06181253|OTHER|Text messages|Text reminders will be sent daily to remind patients to walk at home.
219561209|NCT06181253|BEHAVIORAL|Pedometer|Participants will be encouraged to walk 10,000 steps daily which will be tracked with a pedometer
219561210|NCT05450991|PROCEDURE|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
219561211|NCT00516087|BIOLOGICAL|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"
219561212|NCT01643434|DRUG|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
219561213|NCT01643434|DRUG|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
219561214|NCT06616077|DRUG|Micronized Progesterone 600 mg|Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
219561215|NCT06616077|DRUG|mifepristone 200 mg|Post ovulatory single oral administration (LH+2, LH peak=LH+0)
219561216|NCT06616077|DRUG|Oral Placebo Tablet|Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
219754515|NCT01071460|DEVICE|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
219561217|NCT06616077|DRUG|Placebo Vaginal|Cocoa butter
219561218|NCT00890942|DRUG|naloxone|naloxone 0.4mg.(1 ml) intramuscular
219561219|NCT00890942|DRUG|normal saline|normal saline 1 ml IM
219561220|NCT00349401|DRUG|ketorolac|
219561221|NCT00349401|DRUG|morphine|
219396183|NCT00553059|DRUG|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
219396184|NCT00553059|DRUG|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
219396185|NCT00553059|DRUG|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
219396186|NCT00553059|OTHER|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
219396187|NCT02149654|DEVICE|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
219396188|NCT03761953|DRUG|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
219396189|NCT03462004|BIOLOGICAL|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
219396190|NCT03462004|BIOLOGICAL|Placebo|Administered intranasally
219396191|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
219396192|NCT03277573|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
219396193|NCT03277573|DRUG|Placebo|Inactive ingredient
219396194|NCT06517030|PROCEDURE|Tooth Extraction|After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.
219396195|NCT06517030|PROCEDURE|Immediate Implant Placement|After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.
219396196|NCT06517030|PROCEDURE|Socket reconstruction with DBBB+HA|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (DBBM+HA).
219396197|NCT06517030|PROCEDURE|Socket reconstruction with DBBB|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral (DBBM).
219396198|NCT06517030|PROCEDURE|CTG placement|Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.
219396199|NCT01863264|OTHER|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
219396200|NCT06553924|DRUG|Macitentan and Tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
219396201|NCT06553924|DRUG|PrOpsynvi® macitentan and tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
219396202|NCT00117338|DRUG|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
219396203|NCT00117338|DRUG|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
219754516|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by family health instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension."
219754517|NCT00261833|BIOLOGICAL|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
219396204|NCT05057988|BEHAVIORAL|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
219396205|NCT03283215|DIAGNOSTIC_TEST|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
219396206|NCT05141526|OTHER|Non-restrictive satiating intervention|Diet group containing satiating foods
219396207|NCT05141526|OTHER|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
219396208|NCT05141526|OTHER|Control group|This group will receive minimal healthy guidelines
219396209|NCT05314348|DEVICE|High-density surface EMG|High-density surface EMG for fasciculation detection
219396210|NCT05314348|DEVICE|Ultrasound|Ultrasound for fasciculation detection
219396211|NCT02061007|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
219396212|NCT02061007|DRUG|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
219396213|NCT02061007|PROCEDURE|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
219396214|NCT02383719|DEVICE|Oro-nasal Mask|
219396215|NCT01541605|DRUG|methylphenidate|tablets for oral use
219396216|NCT01541605|DRUG|Placebo|tablets for oral use
219396217|NCT04310137|BEHAVIORAL|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
219396218|NCT02876224|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
219561222|NCT02722616|DEVICE|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
219561223|NCT02722616|DEVICE|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
219561224|NCT02722616|DRUG|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
219561225|NCT02086344|PROCEDURE|PBS|TLH plus PBS
219561226|NCT02086344|PROCEDURE|TLH _adnexal preservation|TLH without PBS
219561227|NCT04167696|BIOLOGICAL|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
219561228|NCT04167696|DRUG|ENDOXAN|administered as preconditioning chemotherapy
219561229|NCT04167696|DRUG|Fludara|administered as preconditioning chemotherapy
219561230|NCT01923311|DRUG|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
219561231|NCT01923311|DRUG|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
219561232|NCT02031237|RADIATION|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
219561233|NCT02031237|RADIATION|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
219561234|NCT02031237|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
219561235|NCT02031237|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
219561236|NCT00825864|DRUG|diclofenac drops|one drop 4 times a day for 3 months
219561237|NCT00825864|DRUG|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
219561238|NCT04963608|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
219561239|NCT04451980|PROCEDURE|Subcutaneous adipose tissue biopsy|Percutaneous adipose tissue biopsy
219561240|NCT04451980|RADIATION|CT scan|CT scan of chest and abdomen without contrast
219561241|NCT04451980|DIAGNOSTIC_TEST|Oral glucose tolerance test|Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
219561242|NCT04451980|DIAGNOSTIC_TEST|Blood collection|Fasting blood collection for plasma cytokines and T cell phenotypes.
219561243|NCT00653159|DEVICE|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
219561244|NCT00653159|DEVICE|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
219561245|NCT05680779|OTHER|ultrasound-guided percutaneous neuromodulation|It´s an intervention of physiotherapy
219561246|NCT05680779|OTHER|dry needling|It´s an intervention of physiotherapy
219396219|NCT02876224|DRUG|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
219561247|NCT00109837|BIOLOGICAL|filgrastim|As needed per physician discretion
219561248|NCT00109837|DRUG|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
219561249|NCT00109837|DRUG|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
219561250|NCT00109837|DRUG|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
219561251|NCT00109837|DRUG|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
219561252|NCT00109837|DRUG|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
219561253|NCT00109837|DRUG|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
219561254|NCT00109837|DRUG|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
219396220|NCT02876224|DRUG|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
219396221|NCT01461031|DRUG|nefopam|nefopam infusion for postoperative 24 hours
219396222|NCT01461031|DRUG|normal saline (control)|normal saline infusion for postoperative 24 hours
219396223|NCT01618981|PROCEDURE|pace make active/inactive cross over|
219396224|NCT02242149|DRUG|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
219396225|NCT02242149|DRUG|Placebo|Sugar pill manufactured to mimic Diacerein
219561255|NCT00109837|DRUG|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
219561256|NCT00109837|DRUG|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
219561257|NCT00109837|DRUG|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
219561258|NCT00109837|DRUG|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
219561259|NCT00109837|DRUG|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
219561260|NCT00109837|DRUG|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
219561261|NCT00109837|RADIATION|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
219561262|NCT00109837|DRUG|allopurinol|300 mg/d PO Days 1-7
219561263|NCT00109837|DRUG|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
219561264|NCT00836147|DRUG|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
219561265|NCT00836147|DRUG|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
219561266|NCT05455164|DIETARY_SUPPLEMENT|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
219561267|NCT00381849|DRUG|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
219561268|NCT00381849|DRUG|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
219561269|NCT00160745|DRUG|Rosuvastatin|
219561270|NCT04219358|DRUG|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
219561271|NCT04219358|DRUG|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
219396226|NCT02518178|DEVICE|NFC Necklace|
219396227|NCT02518178|DEVICE|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
219561272|NCT04219358|DRUG|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
219561273|NCT04219358|DRUG|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
219561274|NCT04219358|DRUG|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
219561275|NCT04219358|DRUG|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
219561276|NCT01118819|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
219561277|NCT00019734|BIOLOGICAL|aldesleukin|
219561278|NCT00019734|BIOLOGICAL|fowlpox virus vaccine vector|
219396228|NCT02518178|DEVICE|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
219396229|NCT01084499|DRUG|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
219561279|NCT00019734|BIOLOGICAL|vaccinia-tyrosinase vaccine|
219561280|NCT01134341|DRUG|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
219754518|NCT00261833|OTHER|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
219754519|NCT00622726|DRUG|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
219754520|NCT00622726|PROCEDURE|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
219754521|NCT03330158|DEVICE|ASTS|Implantation of a motorized spinal distraction rod
219754522|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
219754523|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
219754524|NCT00402987|DRUG|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
219396230|NCT01084499|DRUG|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
219001674|NCT06913660|BEHAVIORAL|Standard of care|A minimum standard of care package will be identified prior to identification and recruitment of CCCs to ensure a comparable and adequate level of care is being offered to all control participants, since implementation of the range of support and care strategies recommended by the Kenya Ministry of Health differs by clinic.
219396231|NCT01084499|DRUG|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
219396232|NCT01084499|DRUG|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
219396233|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
219396234|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
219396235|NCT06207175|BIOLOGICAL|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
219396236|NCT06207175|BIOLOGICAL|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
219396237|NCT05312905|OTHER|Mirror Therapy|Mirror Therapy applied alone
219396238|NCT05312905|OTHER|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
219396239|NCT05670119|OTHER|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
219396240|NCT00330824|DRUG|antibiotic/steroid combination|1gtt, 4x/d, 15 days
219396241|NCT00330824|DRUG|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
219396242|NCT06513637|DIAGNOSTIC_TEST|12-Lead ECG and home sleep study (HST) diagnostics|"* 12-lead ECG hookup will be performed following standard placement procedures.~* The Home Sleep Study diagnostic device placement will be performed by study personnel following the manufacturer's instructions."
219396243|NCT01690949|DRUG|PUR118|inhaled PUR118, BID
219396244|NCT03469245|OTHER|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
219396245|NCT02238405|OTHER|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
219396246|NCT03968367|PROCEDURE|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
219396247|NCT05000580|PROCEDURE|Surgical|Conservative vs surgical management
219396248|NCT00816218|DRUG|Pioglitazone|pioglitazone, 45 mg daily
219396249|NCT00359814|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
219396250|NCT00359814|DRUG|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
219396251|NCT05920850|OTHER|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
219396252|NCT05920850|OTHER|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
219396253|NCT05920850|OTHER|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
219396254|NCT05920850|OTHER|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
219396255|NCT01703819|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
219396256|NCT01703819|OTHER|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
219396257|NCT02145156|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
219396258|NCT02145156|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
219396259|NCT02145156|BEHAVIORAL|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
219396260|NCT06317272|OTHER|DIBH using ABC technique|Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique
219561281|NCT01134341|DRUG|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
219561282|NCT01134341|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
219561283|NCT01134341|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
219561284|NCT02048696|OTHER|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
219561285|NCT05965817|DRUG|SGM-101 op top of ICG|SGM-101 op top of ICG
219561286|NCT04060134|OTHER|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
219561287|NCT04060134|OTHER|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
219561288|NCT04060134|OTHER|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
219561289|NCT04060134|OTHER|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
219561290|NCT04060134|OTHER|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
219561291|NCT00387517|DRUG|Aliskiren/HCTZ|
219561292|NCT02603549|OTHER|Pituitary panel will be drawn pre-op and post-op for all patients.|
219561293|NCT00114595|DRUG|eicosapentaenoic acid|
219561294|NCT03473067|BEHAVIORAL|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
219561295|NCT03473067|OTHER|Capacity Building|Schools will participate in teacher training and parent training.
219561296|NCT02550587|BEHAVIORAL|satisfaction|anesthesia satisfaction rates
219561297|NCT00664287|DRUG|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
219561298|NCT00664287|DRUG|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
219561299|NCT00081172|RADIATION|lutetium Lu 177 monoclonal antibody J591|
219561300|NCT04228978|BEHAVIORAL|Weight loss|Walking exercise combined with weight loss
219396261|NCT06317272|OTHER|DIBH using VC technique|Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
219396262|NCT00198341|PROCEDURE|Radiological Arm|Clinical Visit + X-Ray Chest
219396263|NCT00198341|PROCEDURE|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
219396264|NCT02481037|OTHER|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
219561301|NCT04228978|BEHAVIORAL|Exercise|Walking exercise
219561302|NCT06471478|COMBINATION_PRODUCT|intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion|patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.
219561303|NCT00695383|BEHAVIORAL|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
219561304|NCT00695383|BEHAVIORAL|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
219561305|NCT02076776|BEHAVIORAL|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
219561306|NCT02076776|BEHAVIORAL|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
219561307|NCT02076776|BEHAVIORAL|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
219561308|NCT06380257|OTHER|Observational study methods|Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
219561309|NCT04830982|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
219561310|NCT04830982|OTHER|Placebo|Placebo added to one liter of cardioplegia
219561311|NCT05050981|DRUG|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
219561312|NCT05050981|DRUG|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
219561313|NCT02426541|DRUG|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
219561314|NCT02426541|DRUG|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
219561315|NCT00745134|DRUG|Capecitabine|Given PO
219561316|NCT00745134|DIETARY_SUPPLEMENT|Curcumin|Given PO
219561317|NCT00745134|OTHER|Laboratory Biomarker Analysis|Correlative studies
219561318|NCT00745134|OTHER|Pharmacological Study|Optional correlative studies
219561319|NCT00745134|OTHER|Placebo|Given PO
219561320|NCT00745134|OTHER|Quality-of-Life Assessment|Ancillary studies
219561321|NCT00745134|RADIATION|Radiation Therapy|Undergo radiation therapy
219561322|NCT00040690|BIOLOGICAL|filgrastim|
219561323|NCT00040690|DRUG|cyclophosphamide|
219561324|NCT00040690|DRUG|cytarabine|
219561325|NCT00040690|DRUG|doxorubicin hydrochloride|
219396265|NCT02481037|OTHER|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
219396266|NCT02481037|OTHER|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
219561326|NCT00040690|DRUG|etoposide|
219561327|NCT00040690|DRUG|ifosfamide|
219561328|NCT00040690|DRUG|leucovorin calcium|
219561329|NCT00040690|DRUG|methotrexate|
219561330|NCT00040690|DRUG|vincristine sulfate|
219561331|NCT00040690|RADIATION|radiation therapy|
219561332|NCT05103449|OTHER|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
219561333|NCT00631007|DRUG|INT131 besylate|Once-daily, oral
219561334|NCT00631007|DRUG|Pioglitazone HCl|Once-daily, oral
219396267|NCT00299533|DRUG|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
219561335|NCT00631007|DRUG|Placebo|Once-daily, oral
219561336|NCT03010852|BEHAVIORAL|Focused incentive spirometer education and monitoring|
219561337|NCT00683787|DRUG|docetaxel|Given IV once every 3 weeks
219561338|NCT00683787|DRUG|vandetanib|Oral vandetanib once daily
219561339|NCT04615533|OTHER|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
219396268|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens with comfort additive|
219396269|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens|
219396270|NCT00532883|DRUG|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
219396271|NCT00532883|DRUG|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
219396272|NCT00532883|OTHER|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
219561340|NCT02674633|DEVICE|AKL-T01|Videogame-like digital therapy
219561341|NCT02674633|DEVICE|AKL-T09|Videogame-like digital therapy
219561342|NCT00235118|DEVICE|Cordis AAA Bilateral Device|
219561343|NCT00460109|BIOLOGICAL|denileukin diftitox|
219561344|NCT00460109|BIOLOGICAL|rituximab|
219561345|NCT05287399|DRUG|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
219561346|NCT05287399|DRUG|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
219561347|NCT05287399|DRUG|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
219561348|NCT05287399|DRUG|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
219001675|NCT04090619|OTHER|Questionnaire Administration|Complete questionnaires
219561349|NCT05287399|DRUG|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
219561350|NCT04638270|BIOLOGICAL|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
219396273|NCT03807999|DRUG|Nab-paclitaxel|
219396274|NCT03807999|DRUG|Gemcitabine|
219396275|NCT00658970|DRUG|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
219396276|NCT03593304|DRUG|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
219396277|NCT03593304|DRUG|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
219396278|NCT03593304|DRUG|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
219396279|NCT03593304|DRUG|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
219561351|NCT04027881|BEHAVIORAL|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
219561352|NCT03998319|DRUG|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
219561353|NCT03998319|OTHER|Sterile water for injection (WFI)|Placebo comparative arm.
219561354|NCT02397213|DRUG|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
219561355|NCT02397213|DRUG|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
219561356|NCT05979610|OTHER|Reiki therapy|"Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization."
219561357|NCT04422236|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
219561358|NCT06428695|BEHAVIORAL|one-hour dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
219561359|NCT03260842|DIAGNOSTIC_TEST|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
219396280|NCT02028104|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
219396281|NCT05556382|RADIATION|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
219396282|NCT02320799|BEHAVIORAL|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
219396283|NCT02320799|BEHAVIORAL|treatment as usual|Clinic psychosocial treatment as usual
219396284|NCT00000309|DRUG|Risperidone|
219396285|NCT03924024|DEVICE|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
219396286|NCT05832164|OTHER|Multifactorial intervention|"* Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities"
219396287|NCT02968043|OTHER|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
219396288|NCT02968043|OTHER|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
219396289|NCT01667575|DRUG|Esomeprazole|antisecretary drug of the quadruple therapy
219396290|NCT01667575|DRUG|Amoxicillin|antibiotic of the quadruple therapy
219561360|NCT05652270|BEHAVIORAL|Goal Attainment|Development of an attainable goal
219561361|NCT05652270|BEHAVIORAL|Goal Development|"A Systematic process to help patients create SMaRT  goals"
219561362|NCT05652270|BEHAVIORAL|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
219561363|NCT05996198|DEVICE|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
219396291|NCT01667575|DRUG|Clarithromycin|antibiotic of the quadruple therapy
219396292|NCT01667575|DRUG|Bismuth Potassium Citrate|one of a component of a quadruple therapy
219396293|NCT01667575|OTHER|long duration (14 day)|
219396294|NCT04090931|PROCEDURE|Orthodontic treatment|leveling and aligning stage in orthodontics
219396295|NCT04534062|OTHER|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
219396296|NCT03719560|DRUG|Methotrexate|Systemic methotrexate
219396297|NCT03719560|DRUG|Cytarabine|Systemic cytarabine
219396298|NCT01596842|DRUG|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
219396299|NCT01596842|OTHER|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
219396300|NCT01596842|OTHER|cholecalciferol|if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
219396301|NCT06429683|OTHER|Sexually transmitted diseases training for young adolescents aged 17-21|Education
219396302|NCT01967420|BEHAVIORAL|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
219396303|NCT01967420|BEHAVIORAL|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
219754525|NCT00402987|DRUG|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
219754526|NCT05738226|DEVICE|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
219396304|NCT06215898|OTHER|LSVT-BIG Group via Telerehabilitation|An aerobic supervised exercise protocol was implemented four times a week for four weeks in LSVT-BIG Group via a Tele-rehabilitation model.
219396305|NCT03075462|DRUG|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
219396306|NCT03075462|DRUG|Apatinib|Apatinib at 250mg once daily, tablet oral
219396307|NCT05232097|BEHAVIORAL|Behavioral therapy|Diaphragmatic breathing exercises
219396308|NCT05232097|BEHAVIORAL|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
219396309|NCT05508360|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
219396310|NCT04494503|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
219396311|NCT04494503|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
219396312|NCT04494503|DRUG|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
219561364|NCT05996198|DEVICE|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
219561365|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
219561366|NCT05672134|DIAGNOSTIC_TEST|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
219561367|NCT05672134|DRUG|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
219396313|NCT03691012|DIAGNOSTIC_TEST|Circulating tumour DNA testing|Circulating tumour DNA testing
219396314|NCT00813956|DRUG|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
219396315|NCT01172288|DRUG|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
219396316|NCT01172288|DRUG|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
219396317|NCT04048967|BEHAVIORAL|Professional development|professional development of preschool staff
219396318|NCT03819946|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
219396319|NCT03819946|OTHER|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
219561368|NCT05672134|DIAGNOSTIC_TEST|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
219561369|NCT05672134|DIAGNOSTIC_TEST|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
219561370|NCT05672134|DIAGNOSTIC_TEST|EndoPAT|Use of EndoPAT to measure endothelial function.
219561371|NCT05672134|DIAGNOSTIC_TEST|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
219561372|NCT05672134|DIAGNOSTIC_TEST|Electrocardiogram|12-lead Electrocardiogram
219396320|NCT03472482|DIAGNOSTIC_TEST|non-invasive retinal imaging|
219396321|NCT03100331|OTHER|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
219396322|NCT02409420|BEHAVIORAL|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
219396323|NCT04788199|OTHER|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
219396324|NCT06395142|OTHER|pedal walking|Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
219396325|NCT06395142|OTHER|visual-deprivation walking|visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
219396326|NCT02134314|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
219396327|NCT02134314|DRUG|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
219561373|NCT05877326|DRUG|General anesthesia with propofol or sevoflurane|General anesthesia
219561374|NCT05877326|BEHAVIORAL|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
219561375|NCT03962868|PROCEDURE|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)
219561376|NCT03962868|PROCEDURE|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
219561377|NCT01279915|DRUG|ASP0456|oral
219561378|NCT01279915|DRUG|Placebo|oral
219561379|NCT02833428|DEVICE|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
219561380|NCT04673708|DIAGNOSTIC_TEST|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
219396328|NCT05237882|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
219396329|NCT00428727|DRUG|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
219396330|NCT00428727|DRUG|placebo patch|daily application during 90 days
219396331|NCT00012727|PROCEDURE|Matching Symptom Severity to Service Intensity|
219396332|NCT00343304|DEVICE|Robot|
219396333|NCT00343304|DEVICE|Ergometer|
219396334|NCT06553378|OTHER|Geriatric Oncology Supportive Clinic|Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
219561381|NCT02014441|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
219561382|NCT00951093|PROCEDURE|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
219561383|NCT01383850|OTHER|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
219561384|NCT01383850|OTHER|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
219561385|NCT00225563|DEVICE|Electronic Health Record|e-prescribing methods
219561386|NCT06253338|RADIATION|genomic alterations|Alteration of the genome under radiotherapy
219561387|NCT02295813|BIOLOGICAL|FBF001|
219561388|NCT02295813|DRUG|Placebo|
219561389|NCT04595032|DEVICE|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
219561390|NCT04703842|BIOLOGICAL|SRD-001|AAV1/SERCA2a
219561391|NCT04703842|DRUG|Placebo|SRD-001 matching placebo
219561392|NCT02283671|BIOLOGICAL|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
219561393|NCT04412057|DRUG|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
219561394|NCT04412057|DRUG|Placebo|Administered once subcutaneously
219561395|NCT02558465|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
219561396|NCT00490503|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
219754527|NCT05528770|DEVICE|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
219754528|NCT05528770|DEVICE|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
219754529|NCT04281667|DRUG|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
219561397|NCT00490503|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
219561398|NCT06260826|DEVICE|Auto CPAP via nasal mask (JPAP machine)|Auto Continuous Positive Airway Pressure via nasal mask using the JPAP system (Metran, Saitama, Japan) which can provide CPAP with a range of 2-10 cmH2O, the initial CPAP 2 cmH2O, then reach 7.5 cmH2O after a ramping time. CPAP values may vary with each breath until the obstruction is resolved
219754530|NCT04281667|DRUG|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
219754531|NCT04281667|DRUG|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
219754532|NCT03931551|DRUG|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
219754533|NCT05941286|DEVICE|CGM system with both glucose predictive alerts and threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
219754534|NCT05941286|DEVICE|CGM system with only glucose threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on
219754535|NCT05941286|DEVICE|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
219396335|NCT05322863|DEVICE|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
219396336|NCT06211504|DEVICE|ProStop, sinus tarsi implant (STI)|Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
219396337|NCT06211504|PROCEDURE|Conventional surgery|MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
219396338|NCT06176040|DRUG|TAVO101|TAVO101 IV Infusion.
219396339|NCT05536453|DEVICE|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
219561399|NCT06260826|DEVICE|Constant CPAP via facial mask (O2-Max Trio system)|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask that was adjusted to maintain a CPAP at 7.5 cm H2O and FiO2 30% continuously for the following 1 hour
219561400|NCT02156154|DRUG|Intravenous Acetaminophen|
219561401|NCT04253353|DRUG|tafamidis|61 mg capsule
219561402|NCT04253353|DRUG|rosuvastatin|10 mg tablet
219396340|NCT05741710|DRUG|Methylone|Methylone capsules, given orally, once a week for 4 weeks
219396341|NCT05741710|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
219396342|NCT00871858|DRUG|anastrozole|Given orally
219561403|NCT04512326|PROCEDURE|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
219561404|NCT05773534|DIAGNOSTIC_TEST|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
219561405|NCT01185379|DIETARY_SUPPLEMENT|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
219561406|NCT01185379|DIETARY_SUPPLEMENT|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
219396343|NCT00871858|DRUG|fulvestrant|Given intramuscularly
219561407|NCT01185379|DIETARY_SUPPLEMENT|Placebo|4 x 500 mg capsules to be taken daily for 6 months
219561408|NCT01270490|DRUG|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
219561409|NCT06173596|DRUG|ALXN2080|Participants will receive ALXN2080 orally.
219561410|NCT06173596|DRUG|Itraconazole|Participants will receive Itraconazole orally.
219561411|NCT06173596|DRUG|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
219561412|NCT06173596|DRUG|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
219396344|NCT03758677|DRUG|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
219396345|NCT01851473|DRUG|cocaine|25 mg IV on days 1, 5, and 10
219396346|NCT01851473|DRUG|quinine|80 mg orally on days 7-10
219561413|NCT01473147|DRUG|Exenatide|Exenatide 5 microgram bid sc.
219561414|NCT01473147|DRUG|Normal saline|Normal saline 2 u bid sc.
219561415|NCT05244018|DRUG|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
219561416|NCT05244018|DRUG|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
219561417|NCT02762617|DRUG|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
219561418|NCT02762617|DRUG|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
219561419|NCT00379223|PROCEDURE|vitrectomy with radial optic neurotomy|
219561420|NCT00652756|DEVICE|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
219561421|NCT00652756|OTHER|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
219561422|NCT02419924|DEVICE|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
219561423|NCT05947526|PROCEDURE|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
219561424|NCT05724368|DIAGNOSTIC_TEST|Fecal Calprotectin ELISA kit|"* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
219561425|NCT01312181|BEHAVIORAL|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
219561426|NCT01312181|BEHAVIORAL|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
219561427|NCT01312181|BEHAVIORAL|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
219561428|NCT05992428|DRUG|DA-8010 5mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
219561429|NCT05992428|DRUG|Paroxetine 20mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg
219189222|NCT01279408|OTHER|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
219396347|NCT01851473|DRUG|acetazolamide|15 mg orally on days 2-5
219396348|NCT04965714|BIOLOGICAL|Nivolumab|Given IV
219396349|NCT04965714|BIOLOGICAL|Pegargiminase|Given IM
219561430|NCT05992428|DRUG|Mirabegron 50mg|\[Part 2\] DA-8010 5mg + Mirabegron 50mg
219561431|NCT00668720|DEVICE|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
219561432|NCT00668720|DEVICE|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
219561433|NCT04631887|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
219561434|NCT00149526|BEHAVIORAL|Shared Decision-Making|
219561435|NCT02299219|BEHAVIORAL|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
219754536|NCT00398814|DRUG|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
219754537|NCT00398814|DRUG|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
219396350|NCT04965714|PROCEDURE|Resection|Undergo surgical resection
219396351|NCT01737164|BEHAVIORAL|Aerobic Exercise|
219396352|NCT01534832|DEVICE|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
219754538|NCT02151240|DRUG|Foscarnet Sodium|
219396353|NCT05308485|OTHER|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
219189223|NCT04981522|BEHAVIORAL|Indigenously adapted problem management plus (IA-PM+)|The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
219396354|NCT03662334|DRUG|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
219396355|NCT03662334|DEVICE|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
219396356|NCT04135261|DRUG|HBM4003|Intravenous (IV) administration
219396357|NCT00000711|DRUG|Zidovudine|
219396358|NCT00000711|DRUG|Sargramostim|
219561436|NCT02299219|BEHAVIORAL|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
219561437|NCT03015064|OTHER|Myocardial Infarction|Observational study of myocardial Infarction patients
219561438|NCT05379790|DRUG|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
219561439|NCT05379790|DRUG|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
219189224|NCT05770687|DRUG|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
219396359|NCT00898261|GENETIC|microarray analysis|
219396360|NCT00898261|GENETIC|reverse transcriptase-polymerase chain reaction|
219561440|NCT03027011|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
219189225|NCT04141891|BEHAVIORAL|Driving Decision Aid|Healthwise DDA
219189226|NCT04141891|BEHAVIORAL|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
219189227|NCT06454461|DRUG|Upadacitinib 15 MG|Upadacinib 15mg once daily for the 8 weeks after NECS
219189228|NCT04361136|DRUG|Delgocitinib cream|Cream for topical application
219189229|NCT04361136|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219396361|NCT00898261|OTHER|flow cytometry|
219396362|NCT02305251|OTHER|Survey|Standard Gamble Survey
219396363|NCT03244891|OTHER|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis"
219396364|NCT03244891|OTHER|Ventilation mode|"Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
219396365|NCT03465852|BEHAVIORAL|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
219396366|NCT06192446|DRUG|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
219396367|NCT00298610|DRUG|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
219396368|NCT00298610|DRUG|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
219396369|NCT05387395|OTHER|NO intervention|no intervention
219396370|NCT04981340|BEHAVIORAL|Diaphragmatic breathing|Same as previously described
219396371|NCT04981340|BEHAVIORAL|Standard urotherapy|Same as previously described
219396372|NCT03236350|DEVICE|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
219396373|NCT03236350|DEVICE|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
219561441|NCT03027011|PROCEDURE|Control|Control group without remote ischemic preconditioning
219561442|NCT03907800|DRUG|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
219561443|NCT03907800|DRUG|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
219561444|NCT03907800|DRUG|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
219561445|NCT04447937|OTHER|No Interventions|There are no interventions associated with the study.
219561446|NCT02208115|DIETARY_SUPPLEMENT|Meal composition - Low versus high GI.|
219561447|NCT03519282|DEVICE|comfilcon A multifocal toric lens|contact lens
219561448|NCT03519282|DEVICE|omafilcon A Multifocal Toric Lens|contact lens
219561449|NCT01337765|DRUG|BEZ235 + MEK162|
219561450|NCT04057248|DEVICE|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
219561451|NCT04057248|BEHAVIORAL|CDE|Certified Diabetes Educator Sessions
219754539|NCT02151240|DRUG|Acyclovir|
219754540|NCT06451588|DRUG|FMT|Active FMT
219754541|NCT06451588|DRUG|Placebo|The placebo treatment will be prepared based on the patients' fecal samples (autologous).
219189230|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
219396374|NCT06109116|OTHER|Self myofascial release+ Conventional PT|The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
219396375|NCT06109116|OTHER|Conventional PT|"Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins"
219396376|NCT03077945|BEHAVIORAL|heart rate variability biofeedback and cognitive reappraisal|
219396377|NCT03077945|BEHAVIORAL|control tasks|
219396378|NCT04830995|DIETARY_SUPPLEMENT|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
219396379|NCT04742465|OTHER|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
219396380|NCT00717418|DRUG|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
219396381|NCT05868993|DRUG|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
219561452|NCT02836301|BEHAVIORAL|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
219754542|NCT05542953|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
219754543|NCT00056823|DRUG|rhuFab V2 (ranibizumab)|
219754544|NCT06793397|DRUG|CYB003|CYB003 is a deuterated psilocin analog.
219396382|NCT03483688|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
219396383|NCT02519751|DIETARY_SUPPLEMENT|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
219396384|NCT02519751|DIETARY_SUPPLEMENT|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
219396385|NCT00174161|BEHAVIORAL|self-care, health behavior|
219396386|NCT02796690|OTHER|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
219396387|NCT05607290|BEHAVIORAL|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
219396388|NCT06248320|PROCEDURE|Sigh ventilation|Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
219396389|NCT05848245|DEVICE|low suction|This group receives low-volume intraoral suction during procedures. Low suction typically refers to standard saliva ejectors, which provide minimal suction power and are commonly used in routine dental treatments.
219396390|NCT05848245|DEVICE|intraoral suction|This group receives conventional intraoral suction, likely using high-volume evacuators (HVE), which are more effective than low suction. This arm serves as the comparison or standard-of-care group against which other interventions are evaluated.
219396391|NCT05848245|DEVICE|high & low suction|Participants in this group receive both high-volume and low-volume intraoral suction simultaneously. The combined use aims to optimize fluid and aerosol control, with high suction capturing larger volumes and low suction assisting in continuous evacuation.
219396392|NCT05848245|DEVICE|extra-oral suction & low suction|This group receives a combination of extra-oral suction (a device placed outside the mouth to capture aerosols at the source) and low-volume intraoral suction. This setup is designed to reduce airborne particles during procedures by controlling both intraoral and environmental aerosols.
219754545|NCT06793397|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitator.
219754546|NCT03130569|BEHAVIORAL|Web-based Module Group|
219754547|NCT05466305|DEVICE|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
219754548|NCT01841996|DRUG|ME1111 solution|Once a day for 28 days
219754549|NCT01841996|DRUG|Vehicle Solution|Once a day for 28 days
219754550|NCT01500317|DRUG|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
219754551|NCT01500317|DRUG|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
219396393|NCT05848245|DEVICE|Extra-Oral Suction and Intraoral Suction|This group is treated using both extra-oral suction and intraoral suction, likely high-volume. The dual approach targets aerosol containment both at the oral cavity level and in the surrounding air, representing a comprehensive strategy for infection control during aerosol-generating procedures.
219561453|NCT02836301|BEHAVIORAL|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
219189231|NCT04289805|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
219189232|NCT04289805|OTHER|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
219396394|NCT03309670|OTHER|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
219396395|NCT02853331|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219396396|NCT02853331|DRUG|Axitinib|Oral tablet
219396397|NCT02853331|DRUG|Sunitinib|Oral capsule
219396398|NCT05808088|OTHER|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
219396399|NCT05176210|DRUG|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
219396400|NCT05176210|DRUG|Placebo|Placebo will be provided as a 120 mg tablet.
219396401|NCT01828827|DRUG|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
219396402|NCT04807946|PROCEDURE|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~* luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~* post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
219396403|NCT05571150|BEHAVIORAL|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
219396404|NCT05571150|BEHAVIORAL|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
219396405|NCT01079793|DRUG|ixabepilone|
219396406|NCT01079793|PROCEDURE|adjuvant therapy|
219396407|NCT01079793|RADIATION|intensity-modulated radiation therapy|
219396408|NCT05398874|COMBINATION_PRODUCT|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
219396409|NCT05398874|COMBINATION_PRODUCT|placebo in addition to the standard treatment|placebo in addition to the standard treatment
219396410|NCT00319618|DRUG|Gefitinib|
219396411|NCT00319618|DRUG|Docetaxel|
219396412|NCT00778323|PROCEDURE|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
219396413|NCT03511638|DEVICE|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
219396414|NCT03511638|DEVICE|Alcon VISCOAT®|Ophthalmic viscosurgical device
219396415|NCT02967523|DEVICE|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
219396416|NCT02609477|DRUG|Istradefylline|Istradefylline 40, 80, 160 mg
219396417|NCT02609477|DRUG|Phentermine 45 mg|Phentermine 45 or 90 mg
219396418|NCT02609477|OTHER|Placebo|Placebo
219396419|NCT06172543|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
219396420|NCT06172543|DIETARY_SUPPLEMENT|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
219754552|NCT01500317|DRUG|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
219396421|NCT03995407|DIETARY_SUPPLEMENT|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
219396422|NCT03995407|OTHER|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
219396423|NCT02383329|DIETARY_SUPPLEMENT|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
219396424|NCT00004346|DRUG|chenodeoxycholic acid|
219189233|NCT06216743|DIAGNOSTIC_TEST|MRI and CT|Patients will undergo an additional MRI, cineMRI and CineCT cscan.
219396425|NCT00004346|DRUG|lovastatin|
219189234|NCT06036420|DEVICE|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
219396426|NCT01812720|DRUG|carfilzomib|Given IV
219396427|NCT01812720|DRUG|dexamethasone|Given PO
219396428|NCT01812720|OTHER|laboratory biomarker analysis|Correlative studies
219561454|NCT02836301|BEHAVIORAL|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
219561455|NCT00750048|DRUG|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
219561456|NCT00485030|DEVICE|Cypher|sirolimus-eluting stent
219754553|NCT00335829|BIOLOGICAL|bevacizumab|
219754554|NCT00335829|DRUG|chemotherapy|
219189235|NCT06036420|BEHAVIORAL|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
219396429|NCT06143579|DRUG|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
219396430|NCT03854162|DEVICE|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
219396431|NCT03425799|DRUG|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
219396432|NCT03425799|DRUG|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
219561457|NCT00485030|DEVICE|Xience-V|everolimus-eluting stent
219561458|NCT01357434|BEHAVIORAL|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
219189236|NCT05781009|DRUG|Pregnenolone|300mg
219189237|NCT05781009|DRUG|Placebo|placebo
219189238|NCT04567030|DEVICE|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
219189239|NCT03423667|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
219561459|NCT05518916|OTHER|Nonfarmacology method|Yakson Method and Swaddling
219561460|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
219561461|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
219561462|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
219561463|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
219189240|NCT03423667|DRUG|Lactose powder|Placebo comparator.
219189241|NCT04966585|DRUG|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
219754555|NCT00335829|DRUG|embolization therapy|
219754556|NCT00335829|PROCEDURE|hepatic artery infusion|
219754557|NCT03942081|DEVICE|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
219754558|NCT03245918|DRUG|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
219396433|NCT05553379|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement at each visit
219396434|NCT03241056|BEHAVIORAL|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
219396435|NCT03241056|OTHER|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
219396436|NCT01858428|DEVICE|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
219561464|NCT00285519|DRUG|Doxazosin (drug)|
219189242|NCT04966585|DRUG|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
219396437|NCT01858428|DEVICE|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
219561465|NCT03449199|DRUG|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
219561466|NCT03449199|DRUG|Placebo|Matching placebo to be taken orally, once daily
219561467|NCT01091103|DRUG|Enzalutamide|
219561468|NCT03728023|DRUG|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
219396438|NCT04183257|DRUG|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
219561469|NCT03728023|DRUG|Placebo|Single dose in SAD and once daily for 14 days
219561470|NCT03172052|DRUG|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
219396439|NCT02563184|BIOLOGICAL|Fluzone|
219396440|NCT03290300|DEVICE|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
219561471|NCT03172052|DRUG|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
219561472|NCT03172052|DEVICE|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
219561473|NCT03172052|DEVICE|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
219561474|NCT04355299|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
219561475|NCT04355299|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
219561476|NCT04355299|BEHAVIORAL|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
219561477|NCT04355299|BEHAVIORAL|usual care|received usual care
219561478|NCT00026871|PROCEDURE|Radiotherapy|
219754559|NCT03245918|DRUG|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
219754560|NCT00364169|PROCEDURE|Degree of constipation|
219754561|NCT05643404|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
219754562|NCT05643404|DIAGNOSTIC_TEST|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
219754563|NCT05992272|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
219189243|NCT04179539|DIAGNOSTIC_TEST|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
219189244|NCT04179539|DIAGNOSTIC_TEST|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
219396441|NCT06858800|PROCEDURE|LTRI technique|"Hematoma distraction Artroplasty (HDA): A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid.~Ligament reconstruction with tendon interposition (LRTI): A complete removal of the trapezium bone with a radial-volar incision was made with posterior resection of the articular surface of the first metacarpal bone, and ligament transfer with a loop from hemi-tendonectomy of the flexor carpi radialis (FCR) was used to cushion the joint while occupying the space of the resected bone following modified Weilby Garcia-Elias technique"
219396442|NCT06858800|PROCEDURE|HDA technique|A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid
219396443|NCT05189015|DRUG|Olmesartan|\- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
219396444|NCT04416516|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
219396445|NCT00260000|DRUG|5,6,7,8-tetrahydrobiopterin|
219396446|NCT03618225|DRUG|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
219396447|NCT03618225|DRUG|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
219396448|NCT05328843|DRUG|PB119|"Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration."
219396449|NCT06133010|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
219396450|NCT06133010|BIOLOGICAL|Placebo|Sterile liquid for injection
219561479|NCT00003098|OTHER|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
219561480|NCT00003098|OTHER|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
219561481|NCT03497832|OTHER|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
219561482|NCT01270620|DRUG|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
219561483|NCT01270620|DRUG|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
219396451|NCT00444210|DEVICE|DL6049 (injectable poly-L-lactic acid)|
219396452|NCT00004184|BIOLOGICAL|monoclonal antibody 4B5 anti-idiotype vaccine|
219396453|NCT00004184|BIOLOGICAL|sargramostim|
219396454|NCT00004184|DRUG|alum adjuvant|
219396455|NCT03852212|OTHER|Manipulation|Thrust technique application
219396456|NCT02606786|OTHER|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
219396457|NCT02777463|OTHER|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
219189245|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
219189246|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
219561484|NCT05442203|DEVICE|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
219561485|NCT05442203|DEVICE|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
219561486|NCT04797442|DRUG|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
219561487|NCT04797442|DRUG|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
219189247|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
219189248|NCT05349240|DEVICE|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
219189249|NCT05943288|DEVICE|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
219396458|NCT05888714|DEVICE|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
219561488|NCT01915342|DEVICE|Focal muscular vibration|
219561489|NCT00890331|BEHAVIORAL|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
219561490|NCT00890331|BEHAVIORAL|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
219396459|NCT05888714|DEVICE|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
219396460|NCT05888714|OTHER|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
219396461|NCT05599217|OTHER|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
219396462|NCT05599217|OTHER|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
219396463|NCT05599217|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
219396464|NCT05599217|OTHER|Metabonomic test|Collect urine and stool samples from patients.
219561491|NCT00793117|PROCEDURE|packing|packing in middle meatus for duration of 5 day
219561492|NCT05802199|DIAGNOSTIC_TEST|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
219561493|NCT01727349|OTHER|HbA1c measurement|
219561494|NCT01727349|OTHER|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
219561495|NCT05310708|DIAGNOSTIC_TEST|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
219396465|NCT05599217|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
219396466|NCT04740866|RADIATION|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
219396467|NCT02182037|DRUG|Single rising doses of BIBT 1011 BS|
219561496|NCT05993598|OTHER|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
219561497|NCT01537731|PROCEDURE|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
219561498|NCT03138824|PROCEDURE|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
219561499|NCT03138824|PROCEDURE|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
219561500|NCT02404519|DIETARY_SUPPLEMENT|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
219561501|NCT02404519|DIETARY_SUPPLEMENT|Placebo|1 tablet without MK-7 taken orally every day during 1 year
219561502|NCT02780167|DRUG|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
219189250|NCT06418880|DEVICE|AID system with Remote Real-Time CGM|"The Omnipod 5 AID System is comprised of two components:~* Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology)~* Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses."
219561503|NCT02780167|DRUG|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
219561504|NCT02780167|DRUG|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
219561505|NCT02780167|DRUG|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
219561506|NCT02780167|DRUG|Placebo|Placebo QD for 12 weeks
219561507|NCT02336516|DRUG|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
219189251|NCT06418880|COMBINATION_PRODUCT|Standard of Care Insulin Therapy + CGM|"This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days).~Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns."
219189252|NCT05197790|DEVICE|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
219561508|NCT02336516|DRUG|Placebo (glucose solution 10%)|
219189253|NCT06162715|DRUG|Tirzepatide|Tirzepatide will be initiated 12 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 6 weeks following an adaptive maximum dose titration protocol. Patients will then complete a final 4 weeks of the study drug.
219561509|NCT02032355|PROCEDURE|spinal anesthesia|
219189254|NCT06162715|OTHER|Standard of Care post-gastric bypass|Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.
219189255|NCT03134755|DRUG|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
219189256|NCT06281080|PROCEDURE|En-Bloc Resection of Bladder Tumours|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
219396468|NCT02182037|DRUG|BIBT 1011 BS placebo|
219396469|NCT01520922|BIOLOGICAL|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
219396470|NCT01520922|DRUG|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
219396471|NCT06508996|DIAGNOSTIC_TEST|Xpert HCV|Detection of HCV RNA by Xpert HCV test
219396472|NCT05662358|DRUG|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
219396473|NCT05662358|DRUG|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
219396474|NCT05662358|DRUG|Placebo|oral placebo weekly
219396475|NCT03605134|DIAGNOSTIC_TEST|level of cardiac troponin|blood test
219561510|NCT05754424|DRUG|AT278|Concentrated rapid acting insulin aspart
219561511|NCT05754424|DRUG|NovoRapid|Rapid-acting insulin aspart
219561512|NCT05754424|DRUG|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
219561513|NCT01685593|DEVICE|abdominal binder|
219561514|NCT01685593|OTHER|no binder|
219754564|NCT05992272|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
219396476|NCT03605134|DIAGNOSTIC_TEST|diastolic function assessment|transthoracic echocardiography
219754565|NCT05992272|BEHAVIORAL|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
219754566|NCT05992272|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
219754567|NCT05992272|BEHAVIORAL|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
219754568|NCT05992272|BEHAVIORAL|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
219561515|NCT01699529|DEVICE|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
219561516|NCT02848066|PROCEDURE|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
219189257|NCT05397067|BEHAVIORAL|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
219561517|NCT03180801|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
219561518|NCT03180801|BIOLOGICAL|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
219561519|NCT03180801|OTHER|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
219561520|NCT04403217|OTHER|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
219561521|NCT02715219|OTHER|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
219561522|NCT04735068|DRUG|Binimetinib Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
219561523|NCT04735068|DRUG|Hydroxychloroquine Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
219561524|NCT02772094|BIOLOGICAL|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
219189258|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
219189259|NCT06262412|BEHAVIORAL|Internet-delivered cognitive-behaviour therapy (ICBT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD and strategies to resolve possible ambivalence towards psychological treatment. The main goal of the treatment is to help the young person to stop avoiding anxiety-provoking situations (e.g., going to school or participating in social situations) by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals (e.g., excessive mirror-checking, camouflaging), known as response prevention. Every module also contains homework tasks that are meant to be completed between modules and mainly consist of exposure and response prevention (ERP) tasks based on the young person's individual goals."
219189260|NCT06262412|BEHAVIORAL|Internet-delivered relaxation treatment (IRT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD, how anxiety and stress are major contributors to BDD symptoms, and that targeting and reducing stress will have a beneficial impact on those symptoms. The main goal of the treatment is to teach the young person to relax in order to cope with anxiety and appearance concerns. The intervention mainly consists of a relaxation treatment and includes different relaxation skills such as deep breathing, progressive muscle relaxation, and imagery (cognitive relaxation). Every module also contains homework tasks that are meant to be completed between modules and mainly consist of relaxation tasks."
219189261|NCT04737330|DRUG|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
219189262|NCT04737330|DRUG|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
219189263|NCT04625725|DRUG|AZD7442|"* Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
219189264|NCT04625725|DRUG|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
219189265|NCT05296928|PROCEDURE|laparoscopic incision|laparoscopic umbilical trocar entry pathways
219189266|NCT06367608|DEVICE|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
219561525|NCT05418816|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
219396477|NCT03713723|DEVICE|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
219396478|NCT00757523|DRUG|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
219561526|NCT05736380|DEVICE|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
219561527|NCT05736380|DEVICE|Sham cerebellar rTMS|Sham cerebellar rTMS
219561528|NCT05179447|RADIATION|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
219561529|NCT05179447|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
219561530|NCT05179447|OTHER|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
219189267|NCT06754241|BEHAVIORAL|conventional nursing care|(1) Preoperative education: An appropriate walking aid was provided for the patient and instructions were given to guide correct use, while isometric muscle exercises were taught. (2) Postoperative care: Six hours after anesthesia recovery, the head of the patient's bed could be elevated as needed, and the patient was instructed to perform ankle pumps (dorsiflexion and plantarflexion of the ankle).(3) Postoperative exercise: One to two days after surgery, following the removal of the drainage tube, the patient was encouraged to continue with ankle pumps and isometric quadriceps contractions, as well as to begin straight-leg raises. (4) Postoperative Day 3: In strict accordance with medical advice and under the guidance of a physiotherapist, patients engaged in continuous passive motion therapy for the affected knee, along with manual knee joint massage. (5) Postoperative Days 5-7: the patient would try to stand with the assistance of a walker, gradually progressing to walking exercises
219396479|NCT00757523|DRUG|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
219396480|NCT04379518|OTHER|Best Practice|Receive standard of care
219396481|NCT04379518|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
219396482|NCT04379518|DRUG|Rintatolimod|Given IV
219396483|NCT00615706|OTHER|No intervention|no intervention
219561531|NCT05179447|COMBINATION_PRODUCT|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
219561532|NCT06698133|OTHER|Participants in the intervention arm will be invited to join a private social media group|Education content
219561533|NCT06426927|OTHER|Colorectal Cancer Educational Videos in Spanish|Enrolled participants will watch three educational videos on Colorectal Cancer (CRC) in Spanish. Knowledge on CRC symptoms, risk factors, facts, screening and treatment will be assessed before and immediately after the educational video and at 30 +/- 7 days. In addition, the association between increase in CRC knowledge and willingness to participate in Cancer Clinical Trials (CCT) will be explored.
219561534|NCT00633698|DRUG|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
219561535|NCT00633698|DRUG|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
219561536|NCT01601691|DEVICE|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
219396484|NCT01301911|DRUG|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
219396485|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
219561537|NCT06614751|DRUG|DAT-2645 tablet|The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
219561538|NCT06614751|DRUG|DAT-2645 tablet|The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
219396486|NCT01815437|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
219396487|NCT01815437|DIETARY_SUPPLEMENT|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
219396488|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Extract|Same quantity of mushroom extract in a capsule
219396489|NCT01346137|DRUG|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
219561539|NCT02618382|DRUG|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
219561540|NCT01904006|PROCEDURE|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
219561541|NCT01904006|PROCEDURE|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
219561542|NCT00982631|DRUG|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
219396490|NCT01088815|DRUG|Gemcitabine, nab-Paclitaxel, GDC-0449|"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
219396491|NCT04509856|BEHAVIORAL|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
219396492|NCT01618656|DRUG|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
219396493|NCT01618656|DRUG|Placebo|Sugar pill
219396494|NCT02434887|DEVICE|KL029 Intimate Lubricant Gel|
219396495|NCT01032785|DEVICE|no interventions|no interventions
219396496|NCT02172222|DRUG|BI 10773|
219396497|NCT02172222|DRUG|Linagliptin|
219561543|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
219561544|NCT00309985|DRUG|docetaxel|Given IV
219561545|NCT00547625|DRUG|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
219561546|NCT00547625|DRUG|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
219561547|NCT03110380|DRUG|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
219561548|NCT03110380|DRUG|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
219396498|NCT02658162|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
219396499|NCT02658162|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
219396500|NCT01899144|DRUG|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
219396501|NCT01899144|DRUG|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
219396502|NCT01899144|DRUG|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
219396503|NCT03312673|OTHER|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
219396504|NCT00477529|DRUG|ABI-008|nab-docetaxel
219396505|NCT04756089|DEVICE|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
219396506|NCT04756089|OTHER|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
219561549|NCT03110380|DRUG|DTG|50 mg tablet(s) administered orally once daily
219561550|NCT03110380|DRUG|DTG Placebo|Tablet(s) administered orally once daily
219561551|NCT03110380|DRUG|F/TAF Placebo|Tablet(s) administered orally once daily
219561552|NCT03110380|DRUG|B/F/TAF Placebo|Tablet(s) administered orally once daily
219561553|NCT00826137|DIETARY_SUPPLEMENT|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
219561554|NCT00826137|DIETARY_SUPPLEMENT|Placebo|Placebo is base powder of product with no oligosaccharides.
219754569|NCT05992272|DIAGNOSTIC_TEST|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
219754570|NCT05992272|DIAGNOSTIC_TEST|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
219754571|NCT05992272|DIAGNOSTIC_TEST|questionnaires for chronic stress|"* Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic"
219754572|NCT05992272|DIAGNOSTIC_TEST|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
219754573|NCT05992272|DIAGNOSTIC_TEST|saliva samples|Assessing acute stress effects in AUD.
219754574|NCT05992272|DIAGNOSTIC_TEST|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
219754575|NCT05992272|DIAGNOSTIC_TEST|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
219754576|NCT06641011|DEVICE|Immediate restoration (resin- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
219754577|NCT06641011|DEVICE|Immediate restoration (GI- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
219754578|NCT06641011|DEVICE|Immediate restoration (Resin based) after rinsing silver fluoride application|Rinsing silver fluoride off followed by resin-based fissure sealant
219754579|NCT06641011|DEVICE|Immediate restoration (GIC) after rinsing silver fluoride application|Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
219396507|NCT04681846|PROCEDURE|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
219561555|NCT03457090|OTHER|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~* To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~* To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~* To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~* To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
219561556|NCT04919759|BEHAVIORAL|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
219561557|NCT04919759|BEHAVIORAL|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
219561558|NCT01339377|DEVICE|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
219561559|NCT02082249|DRUG|ABT-SLV187|Dose levels will be individually optimized
219561560|NCT05139628|DIAGNOSTIC_TEST|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
219561561|NCT04091802|PROCEDURE|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
219561562|NCT01456741|PROCEDURE|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
219396508|NCT01483092|DIETARY_SUPPLEMENT|inulin|20g/day for 4 weeks
219396509|NCT01483092|DIETARY_SUPPLEMENT|maltodextrin|20g/day for 4 weeks
219396510|NCT03634046|PROCEDURE|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
219396511|NCT03634046|PROCEDURE|Radiofrequency ablation|The same as the descriptions in active comparator group.
219561563|NCT01456741|PROCEDURE|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
219561564|NCT03636386|DEVICE|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
219561565|NCT03636386|DEVICE|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
219561566|NCT01817595|OTHER|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
219561567|NCT01817595|OTHER|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
219561568|NCT02227615|DIETARY_SUPPLEMENT|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
219561569|NCT02227615|DIETARY_SUPPLEMENT|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
219561570|NCT05936047|BIOLOGICAL|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
219561571|NCT00409942|DRUG|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
219396512|NCT03424330|DEVICE|ReX-C intervention|Patients receive medication by the ReX-C device
219396513|NCT03424330|OTHER|Standard of Care|Patients receive medication as usual
219396514|NCT00395122|DEVICE|Retinal nerve fiber layer and macular thickness measurements|
219396515|NCT02213757|DRUG|Premarin vaginal estrogen cream|
219396516|NCT02213757|DRUG|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
219396517|NCT05197244|BEHAVIORAL|Culinary Medicine Intervention|A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
219189268|NCT06754241|BEHAVIORAL|Intervention Care|(1) Intervention Day 1: (i) All patients in the observation group were provided with an introduction to the study and invited to join the WeChat group for the observation group. (2) Intervention Day 2: Exercise guidance for patients with KOA was shared via the WeChat group.(3) Intervention Day 3: Guidance for emotional regulation was sent to the patients with KOA via the WeChat group.(4) Intervention Week 1: A micro-lesson on KOA-related knowledge was delivered via the WeChat group to deepen patients' understanding. (5) Intervention Week 2: (i) Text instructions and related questions on common conservative treatments for KOA, including topical and oral painkillers, were shared, with correct answers provided the next day.(ii) A micro-lesson on exercise guidance for patients with KOA was uploaded to the WeChat group to reinforce patients' understanding.
219396518|NCT05805969|OTHER|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
219396519|NCT05805969|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
219396520|NCT03865069|OTHER|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
219396521|NCT03865069|OTHER|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
219396522|NCT04187001|OTHER|Content Validity|Use Delphi technique for achieve consensus
219396523|NCT04187001|OTHER|Cultural adaptation|Adapt the content to the target population
219396524|NCT04076072|DEVICE|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
219396525|NCT04076072|DEVICE|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
219396526|NCT00745264|DRUG|Diractin|100 mg Ketoprofen to 2 joints
219396527|NCT00745264|DRUG|Diractin|400 mg ketoprofen to 4 joints
219396528|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
219396529|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
219396530|NCT03049540|DRUG|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
219396531|NCT03049540|DRUG|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
219396532|NCT00205972|DEVICE|Humerus Nail or LC Plate|
219396533|NCT04910412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
219189270|NCT04884308|BIOLOGICAL|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
219189271|NCT06206148|DEVICE|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
219396534|NCT02601781|PROCEDURE|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
219396535|NCT02601781|DEVICE|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
219396536|NCT05028023|BIOLOGICAL|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
219396537|NCT01566838|DRUG|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
219396538|NCT01566838|DRUG|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
219396539|NCT04770155|DIETARY_SUPPLEMENT|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
219561572|NCT00409942|DRUG|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
219396540|NCT04770155|DIETARY_SUPPLEMENT|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
219396541|NCT04770155|DRUG|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
219396542|NCT04770155|DRUG|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
219561573|NCT03173560|DRUG|lenvatinib|lenvatinib capsules.
219561574|NCT03173560|DRUG|everolimus|everolimus tablets.
219561575|NCT02763631|OTHER|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
219561576|NCT02763631|OTHER|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
219561577|NCT02763631|OTHER|Sham Comparator: Stand Care Arm|No change will be made to participants care
219561578|NCT02864524|OTHER|Manipulative and Massage Therapy|
219561579|NCT02864524|OTHER|Exercise Program|
219561580|NCT05926635|DEVICE|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
219561581|NCT05642533|OTHER|No treatment given|No treatment given
219561582|NCT01222364|PROCEDURE|Standard Cord Clamping|Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
219561583|NCT01222364|PROCEDURE|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
219561584|NCT02119052|DRUG|octeotride|
219561585|NCT02119052|DRUG|placebo|
219561586|NCT04254809|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
219396543|NCT05087823|DIETARY_SUPPLEMENT|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
219396544|NCT05087823|DIETARY_SUPPLEMENT|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
219561587|NCT04254809|BEHAVIORAL|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
219561588|NCT00003615|BIOLOGICAL|denileukin diftitox|
219561589|NCT05606328|BEHAVIORAL|Emergency Department Delirium Screening and Detection Program (ED-DDP)|Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
219561590|NCT01132261|OTHER|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
219561591|NCT02494505|DRUG|Mycophenolate Mofetil|2g/day per os
219561592|NCT02494505|DRUG|placebo|
219561593|NCT04836182|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
219561594|NCT04836182|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
219561595|NCT00743860|DRUG|darapladib|experimental drug
219561596|NCT01546727|BEHAVIORAL|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
219754580|NCT06641011|DEVICE|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin based fissure sealant restoration one week after silver fluoride (AgF) application
219396545|NCT05087823|DIETARY_SUPPLEMENT|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
219396546|NCT04044547|DRUG|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
219561597|NCT01546727|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
219561598|NCT04480372|DRUG|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
219561599|NCT04480372|DRUG|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
219561600|NCT05188417|DRUG|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
219561601|NCT05188417|DRUG|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
219561602|NCT00570206|BEHAVIORAL|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
219561603|NCT03023137|BEHAVIORAL|Walking & dietary modification|"1. Daily walking at a moderate pace (4 km/h) \> 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding \>12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
219561604|NCT00769951|OTHER|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
219561605|NCT00769951|OTHER|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
219561606|NCT00769951|PROCEDURE|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
219561607|NCT00769951|PROCEDURE|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
219561608|NCT00769951|PROCEDURE|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
219561609|NCT04911205|OTHER|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
219189272|NCT06206148|OTHER|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
219189273|NCT06206148|OTHER|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
219189274|NCT04560920|OTHER|Availability of contextual PGHD at the visit|Contextual PGD will be available in a display at the visit.
219561610|NCT02608476|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
219561611|NCT02608476|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
219561612|NCT02795676|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
219561613|NCT02795676|BIOLOGICAL|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
219561614|NCT05427994|OTHER|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
219561615|NCT03468296|DRUG|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
219561616|NCT01080586|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
219189275|NCT05287633|DRUG|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
219561617|NCT02359539|PROCEDURE|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
219561618|NCT01745887|DRUG|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
219561619|NCT02365909|DRUG|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
219561620|NCT02365909|DRUG|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
219561621|NCT04337229|OTHER|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
219561622|NCT04560426|DEVICE|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
219396547|NCT04044547|DRUG|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
219561623|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
219561624|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
219561625|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
219561626|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
219561627|NCT01992874|DRUG|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
219561628|NCT02276625|BIOLOGICAL|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
219561629|NCT02721368|DEVICE|Neuramis® Volume Lidocaine|hyaluronic acid filler
219561630|NCT02721368|DEVICE|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
219561631|NCT02973581|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
219561632|NCT02973581|DRUG|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
219561633|NCT02973581|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
219561634|NCT02973581|DRUG|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
219561635|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
219561636|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
219561637|NCT04281524|DRUG|CSL312|CSL312 administered as an IV infusion
219561638|NCT04281524|DRUG|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
219561639|NCT02091310|DRUG|Placebo|
219561640|NCT02091310|DRUG|GFT505|
219561641|NCT02091310|DRUG|Moxifloxacin 400 mg|
219561642|NCT00214812|DRUG|HEC placebo gel|
219561643|NCT04238208|DRUG|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
219189276|NCT05287633|DRUG|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
219189277|NCT03173235|DIAGNOSTIC_TEST|Plasma level of vitamin D|messurement of plasma level of vitamin D
219561644|NCT04238208|DRUG|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
219561645|NCT00948337|BEHAVIORAL|Brochure of Secondary Cancer Screening|One kind of printed educational material
219561646|NCT01309854|DRUG|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
219561647|NCT01309854|DRUG|pioglitazone|oral tablets, 30mg single dose per period
219561648|NCT05922709|DRUG|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
219561649|NCT05922709|DRUG|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
219561650|NCT01041209|BEHAVIORAL|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
219561651|NCT01041209|BEHAVIORAL|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
219561652|NCT06519747|DEVICE|Cardiac monitoring device|Portable, up to 14 days of monitoring
219396548|NCT03344328|DRUG|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
219396549|NCT04281927|DEVICE|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
219396550|NCT05359627|DRUG|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
219396551|NCT02722577|PROCEDURE|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
219396552|NCT00864227|BIOLOGICAL|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1"
219396553|NCT00864227|BIOLOGICAL|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days."
219396554|NCT05191329|DIAGNOSTIC_TEST|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
219396555|NCT03418662|DEVICE|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
219561653|NCT01610024|DIETARY_SUPPLEMENT|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
219561654|NCT01647997|OTHER|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
219561655|NCT05025631|DRUG|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
219561656|NCT06293391|PROCEDURE|cardiac indices in supine and trendelenburg position|Cardiac indices in supine and trendelenburg position in patients undergoing open or laparoscopic major cancer surgery
219561657|NCT01909739|DRUG|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
219189278|NCT01005823|DRUG|LEO 29102 cream|Twice daily application for 7 days
219396556|NCT04590729|BEHAVIORAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
219561658|NCT01909739|DRUG|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
219561659|NCT03087435|DEVICE|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
219561660|NCT06398834|DRUG|Esketamine|In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
219561661|NCT06398834|DRUG|Butorphanol|In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
219561662|NCT02114112|OTHER|NCPAP cycling|
219561663|NCT02114112|OTHER|NCPAP continuous|
219561664|NCT06679218|OTHER|Activity Coaching Programme|The intervention will consist of individualized physical activity coaching sessions, which will take place twice a week for 8 weeks. These sessions will focus on encouraging progressive and personalized physical activity according to each participant's ability. The sessions will also include relaxation techniques, targeted ventilation and strategies to improve activity management.
219189279|NCT01005823|DRUG|LEO 29102 placebo cream|LEO 29102 placebo cream
219189280|NCT03298451|DRUG|Durvalumab|Durvalumab IV (intravenous infusion).
219189281|NCT03298451|DRUG|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
219189282|NCT03298451|DRUG|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
219561665|NCT06679218|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
219561666|NCT00002936|DRUG|altretamine|
219561667|NCT00002936|DRUG|etoposide|
219396557|NCT04590729|BEHAVIORAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
219396558|NCT03461289|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
219561668|NCT03722108|COMBINATION_PRODUCT|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
219561669|NCT03722108|DRUG|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
219396559|NCT03321929|COMBINATION_PRODUCT|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
219396560|NCT03453463|OTHER|exercise|3x week predominately resistance exercise for 18 months
219396561|NCT02805699|DRUG|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
219396562|NCT02805699|DRUG|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
219396563|NCT04083742|DEVICE|ANTERION|3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
219396564|NCT03911570|DRUG|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
219396565|NCT00897559|GENETIC|gene expression analysis|
219396566|NCT00897559|GENETIC|mutation analysis|
219396567|NCT00897559|GENETIC|polymorphism analysis|
219561670|NCT03354208|OTHER|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
219561671|NCT05484609|OTHER|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
219561672|NCT05484609|OTHER|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
219189283|NCT03298451|DRUG|Sorafenib|Sorafenib, as per standard of care
219396568|NCT00897559|GENETIC|protein analysis|
219396569|NCT00897559|OTHER|flow cytometry|
219396570|NCT00897559|OTHER|laboratory biomarker analysis|
219396571|NCT03540368|DRUG|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
219396572|NCT03540368|OTHER|Placebo|Administering placebo or sodium chloride 0,9% intravenously
219396573|NCT02575482|DRUG|SUVN-D4010|
219396574|NCT02575482|DRUG|Placebo|
219396575|NCT04526977|DIAGNOSTIC_TEST|Immune response study|"* ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization"
219396576|NCT00797927|DRUG|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
219396577|NCT00797927|OTHER|no intervention|keep the original conventional antipsychotic agent for 28 days
219561673|NCT05557656|DRUG|Regorafenib 40 MG|participants who received the treatment of Regorafenib
219561674|NCT03607045|DEVICE|headless screw|headless screw group
219561675|NCT06679647|BEHAVIORAL|Access to a trained ChatGPT|Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
219561676|NCT05607433|DEVICE|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
219561677|NCT05363982|DEVICE|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
219561678|NCT05363982|DEVICE|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
219396578|NCT04373980|DEVICE|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
219396579|NCT03538392|DEVICE|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
219561679|NCT01609582|DRUG|TAK-875|TAK-875 tablets
219561680|NCT01609582|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
219561681|NCT03934060|OTHER|Exercise|specific strength training
219189284|NCT03298451|DRUG|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
219189285|NCT03298451|DRUG|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
219189286|NCT05801068|DRUG|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
219189287|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
219396580|NCT03787004|DRUG|CNTX-6970|Oral dose CNTX-6970
219396581|NCT03787004|OTHER|Placebo|Oral dose placebo
219396582|NCT04649710|BIOLOGICAL|BMS-986036|Specified dose on specified days
219396583|NCT04649710|OTHER|Placebo|Specified dose on specified days
219561682|NCT05683860|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
219561683|NCT00206180|DRUG|esomeprazole magnesium (oral medication)|
219561684|NCT03067740|DRUG|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
219561685|NCT03067740|DRUG|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
219561686|NCT00051831|DRUG|Emtricitabine|Will be administered as one 200-mg capsule orally daily
219396584|NCT04876664|DEVICE|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
219396585|NCT03138850|DEVICE|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
219396586|NCT03138850|DEVICE|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
219396587|NCT03138850|DEVICE|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
219396588|NCT05113823|PROCEDURE|Simulation Training|Simulation Training using High and Low Fidelity Simulator
219561687|NCT00051831|DRUG|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
219561688|NCT00051831|DRUG|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
219396589|NCT00547937|DEVICE|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
219396590|NCT03311685|DEVICE|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
219396591|NCT01742962|PROCEDURE|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
219561689|NCT00051831|DRUG|Saquinavir|Will be administered as five hard gel capsules orally twice daily
219189288|NCT05920863|PROCEDURE|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
219396592|NCT02222129|DRUG|Bupivacaine|
219396593|NCT02222129|DRUG|liposomal bupivacaine|
219396594|NCT02886026|DEVICE|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
219396595|NCT02886026|DEVICE|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
219396596|NCT01797029|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
219396597|NCT01797029|BIOLOGICAL|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
219561690|NCT00051831|DRUG|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
219561691|NCT04161573|BEHAVIORAL|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
219561692|NCT02958930|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
219561693|NCT00819767|DRUG|Aliskiren|Aliskiren was supplied in 150 mg tablets.
219561694|NCT00819767|DRUG|Valsartan|Valsartan was supplied in 160 mg capsules.
219561695|NCT00819767|DRUG|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
219561696|NCT00819767|DRUG|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
219561697|NCT02690935|DRUG|2LALERG|Homeopathic drug
219561698|NCT02690935|DRUG|Placebo|Placebo
219561699|NCT01835535|DEVICE|TIVUS|
219561700|NCT02702986|PROCEDURE|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
219561701|NCT02702986|DEVICE|Laser|
219561702|NCT05918341|DRUG|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
219561703|NCT02250924|DIETARY_SUPPLEMENT|Caffeine|caffeinated gum
219561704|NCT02250924|OTHER|Gum|Chewing gum
219561705|NCT02250924|BEHAVIORAL|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
219561706|NCT06422481|OTHER|Fluid administration|Patients will receive fluid administration (500 mL of saline over 30 minutes). The indication of fluid administration will be left to the discretion of the attending physician.
219561707|NCT06422481|OTHER|Norepinephrine administration or increase in norepinephrine dosage|Patients will receive norepinephrine or norepinephrine dosage will be increased if necessary to achieve the appropriate mean arterial pressure level. The indication of norepinephrine administration or increase in norepinephrine dosage will be left to the discretion of the attending physician.
219561708|NCT00838981|DRUG|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
219561709|NCT00838981|DRUG|Sugar Pill|placebo, sugar pill will mirror active drug
219561710|NCT00838981|BEHAVIORAL|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
219396598|NCT03021525|PROCEDURE|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
219561711|NCT00838981|DRUG|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
219561712|NCT00838981|BEHAVIORAL|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
219561713|NCT00838981|BEHAVIORAL|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
219561714|NCT02464241|OTHER|only examination|
219561715|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
219561716|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
219561717|NCT02994290|DRUG|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
219561718|NCT02994290|BEHAVIORAL|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
219561719|NCT04928664|DRUG|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
219561720|NCT04928664|DRUG|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
219561721|NCT04985838|BEHAVIORAL|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
219561722|NCT02285933|OTHER|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
219561723|NCT02285933|OTHER|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
219561724|NCT03127306|DIAGNOSTIC_TEST|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
219561725|NCT04283370|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
219396599|NCT03021525|PROCEDURE|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
219396600|NCT01671436|BEHAVIORAL|Central Meditation and Imagery Therapy|
219396601|NCT00472342|BEHAVIORAL|exercise prescription|
219561726|NCT04283370|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
219561727|NCT03227133|OTHER|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
219561728|NCT03227133|OTHER|Psychiatric interview|
219561729|NCT03227133|OTHER|Cardiovascular risk assessment|
219561730|NCT04253236|DRUG|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
219561731|NCT04253236|DRUG|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
219561732|NCT03723837|BIOLOGICAL|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
219561733|NCT06678477|DEVICE|3D device|Use 3D machine to generate the 3D image
219561734|NCT03667859|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
219561735|NCT05735158|BIOLOGICAL|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
219561736|NCT05735158|OTHER|Placebo|Visually matched excipient gel
219561737|NCT05849688|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
219561738|NCT05849688|OTHER|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
219561739|NCT00754871|DRUG|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
219561740|NCT00754871|DRUG|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
219561741|NCT00754871|DRUG|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
219561742|NCT00754871|DRUG|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
219561743|NCT03776578|PROCEDURE|swallow fuction and swallow training|nasogastric tube dependence rate
219561744|NCT00808509|BIOLOGICAL|adalimumab|40 mg every other week via subcutaneous injection
219561745|NCT00808509|DRUG|methotrexate|At least 10 mg/week administered orally or subcutaneously
219561746|NCT02425384|BEHAVIORAL|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
219561747|NCT02425384|BEHAVIORAL|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
219396602|NCT01003587|BEHAVIORAL|District health information package|"The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages"
219754581|NCT06641011|DEVICE|GI- based fissure sealant restoration one week after silver fluoride (AgF) application|GI- based fissure sealant restoration one week after silver fluoride (AgF) application
219396603|NCT01627756|OTHER|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
219396604|NCT01627756|OTHER|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
219396605|NCT01359826|DRUG|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
219396606|NCT02167204|PROCEDURE|Computed Tomography|Undergo 18F-FLT PET/CT
219396607|NCT02167204|RADIATION|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
219396608|NCT02167204|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET/CT
219396609|NCT00991172|DRUG|REGN475|Single Subcutaneous injection dose level 1
219396610|NCT00991172|DRUG|REGN475|Single subcutaneous injection dose level 2
219396611|NCT00991172|DRUG|Placebo Injection|Placebo Subcutaneous injection
219396612|NCT04073823|DEVICE|Flexitouch Plus|Flexitouch Plus full arm and core treatment
219396613|NCT04073823|DEVICE|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
219396614|NCT00016861|DRUG|irinotecan hydrochloride|
219396615|NCT03837756|DRUG|Saline|Placebo
219189289|NCT05920863|DRUG|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
219396616|NCT03837756|DRUG|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
219396617|NCT03837756|DRUG|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
219396618|NCT05325138|OTHER|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
219396619|NCT02255786|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
219396620|NCT04739124|OTHER|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
219396621|NCT04739124|OTHER|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
219396622|NCT02617121|DRUG|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
219396623|NCT02617121|DRUG|Ramosetron|ramosetron 0.3 mg iv at end of surgery
219396624|NCT02617121|DRUG|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
219396625|NCT04180436|DRUG|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
219396626|NCT05329688|PROCEDURE|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
219396627|NCT02286011|BIOLOGICAL|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
219396628|NCT02286011|OTHER|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
219396629|NCT04848363|PROCEDURE|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
219396630|NCT00624130|DRUG|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
219396631|NCT00624130|DRUG|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
219396632|NCT00633139|BIOLOGICAL|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
219396633|NCT04108767|BEHAVIORAL|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
219396634|NCT06671067|DEVICE|Remote dielectric sensing system|The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
219396635|NCT06671886|BEHAVIORAL|E-trigger|The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned.
219396636|NCT06672913|BEHAVIORAL|skin to skin contact care|Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured
219396637|NCT06672432|OTHER|CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program)|The intervention is divided into daily tasks spread across eight weeks, with each day involving a variety of interactive elements such as videos, text-based content, guided reflections, and mental health check-ins. If the user misses a daily challenge, she can complete that challenge in the later days. Each week has a distinct focus that progressively builds the user's skills and understanding in managing emotional health. Tasks are designed to be short yet impactful, aiming to enhance engagement and adherence.
219396638|NCT06672432|OTHER|Matched Attention Control (a mobile app-based 8-week online relaxation training program)|This program is designed to mirror the structure and engagement level of the intervention group, providing participants with a similar amount of interaction and daily activities. Each day, participants in the control group will complete 1-2 daily tasks focused on relaxation techniques, such as breathing exercises, mindfulness meditation, and guided imagery. Each task is brief, approximately 3 minutes in duration, making it easy for participants to incorporate into their daily routine.
219561748|NCT02425384|OTHER|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
219561749|NCT04248517|OTHER|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
219561750|NCT04944472|BEHAVIORAL|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
219561751|NCT03466827|DRUG|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
219561752|NCT01679431|DIAGNOSTIC_TEST|Doppler-echocardiography|
219561753|NCT01679431|RADIATION|Computed tomography|
219561754|NCT01679431|OTHER|Magnetic resonance imaging|
219561755|NCT01679431|BIOLOGICAL|Fasting blood sample|
219561756|NCT00587431|DRUG|GnRh (Leuprolide)|Leuprolide LUPRON
219561757|NCT00587431|DRUG|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
219561758|NCT00587431|DRUG|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
219396639|NCT05115461|DEVICE|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
219396640|NCT05115461|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
219396641|NCT00259025|DRUG|lipid emulsion with a high content of n-3 fatty acids|
219396642|NCT06671808|OTHER|Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)|This meta-analysis examines the impact of HIV infection on the prevalence and outcomes of multi-drug resistant tuberculosis (MDR-TB) among affected populations. The analysis synthesizes data from multiple studies conducted across various countries, focusing on the correlation between HIV co-infection and MDR-TB rates, treatment outcomes, and demographic factors. The findings aim to enhance understanding of the complex interactions between HIV and MDR-TB, ultimately informing clinical practices and public health strategies.
219396643|NCT06673355|OTHER|dental implant prosthesis|patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
219561759|NCT04570176|PROCEDURE|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
219001676|NCT06829264|BEHAVIORAL|Individualized Placement and Support Model|The Individualized Placement and Support (IPS) model is an evidence-based approach to supported employment designed to help individuals with disabilities achieve and maintain competitive integrated employment (CIE). IPS emphasizes person-centered planning, rapid engagement, and focusing on individual strengths and preferences. Key features include prioritizing CIE, eligibility based on the desire to work, integration of employment services with mental health support, rapid job searches, tailored job development, and time-unlimited, individualized support. IPS also provides benefits counseling to help participants manage employment while maintaining government benefits. For this study, IPS is adapted to meet the needs of autistic individuals by enhancing provider training and family involvement to improve outcomes.
219189290|NCT05409872|DIETARY_SUPPLEMENT|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
219189291|NCT05409872|OTHER|Placebo|The subject takes the placebo twice a day for three months.
219396644|NCT06673108|DEVICE|SoLa Pelvic Therapy|SoLa Pelvic Therapy laser emits near-infrared (810-980 nm wavelength) energy to the vaginal tissues. The device treats at 5-8 W for 3-6 minutes and delivers a fluence of 3,000 and 5,000 J/cm2 through a sterile vaginal probe. Specific treatment time is calculated based on vaginal length. Based on a code input, the device can cycle between emitting laser energy or sham which is visible light without focused laser energy.
219396645|NCT06672783|PROCEDURE|echocardiogrphy|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening) o"
219561760|NCT02169791|DRUG|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
219561761|NCT04546269|PROCEDURE|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
219561762|NCT03019562|DRUG|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
219561763|NCT03019562|DRUG|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
219561764|NCT02124473|OTHER|Homeopathy|
219561765|NCT02124473|OTHER|Placebo|
219561766|NCT03890562|OTHER|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
219561767|NCT03454282|OTHER|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
219561768|NCT02855840|OTHER|completion of the quality of life questionnaire|
219561769|NCT05556226|DRUG|ABBV-154 Dose Formulation A|Subcutaneous Injection
219561770|NCT05556226|DRUG|ABBV-154 Dose Formulation B|Subcutaneous Injection
219561771|NCT00080431|DRUG|Daclizumab|
219561772|NCT05094596|DRUG|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
219561773|NCT05094596|DRUG|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
219561774|NCT05094596|DRUG|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
219561775|NCT00032916|DRUG|NS2359|
219561776|NCT05884255|DRUG|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
219396646|NCT06672744|OTHER|Exercise|Lumbar muscles (especially quadratus lumborum) and thoracolumbar fascia stretching exercises and strengthening exercises for the lumbar and abdominal muscles were described by the physiotherapist. Participants were asked to perform the exercises three times a day, five days a week
219396647|NCT06672744|OTHER|Myofascial release technique|Myofascial release technique was applied by the same researcher (YY) twice a week for four weeks.
219561777|NCT05884255|DRUG|long-acting Octreotide.|High-dose long-acting Octreotide.
219561778|NCT01042873|DRUG|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
219561779|NCT05312476|DRUG|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group)."
219561780|NCT02825576|DRUG|Sugammadex|Sugammadex 2mg/kg given for reversal agent
219561781|NCT02825576|DRUG|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
219561782|NCT04906876|DRUG|Gemcitabine|Gemcitabine as a 90-minute IV infusion
219561783|NCT04906876|DRUG|Docetaxel|Docetaxel as a 60-minute IV infusion
219561784|NCT04906876|DRUG|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
219561785|NCT01139294|DRUG|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
219561786|NCT02762994|DRUG|BCD-085|
219561787|NCT02762994|OTHER|Placebo|
219561788|NCT05860387|DIAGNOSTIC_TEST|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
219561789|NCT04234464|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
219561790|NCT04234464|COMBINATION_PRODUCT|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
219561791|NCT05021484|DRUG|Felzartamab|Intravenous infusion in regular intervals over 6 months
219561792|NCT05021484|DRUG|Placebo|Intravenous infusion in regular intervals over 6 months
219561793|NCT00828022|BIOLOGICAL|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
219561794|NCT01448148|OTHER|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
219561795|NCT01448148|OTHER|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
219561796|NCT06440863|PROCEDURE|Total Knee Arthroplasty|Patients undergoing total knee arthroplasty
219561797|NCT06440863|PROCEDURE|Total Hip arthroplasty|Patients undergoing total hip arthroplasty
219561798|NCT01885351|BEHAVIORAL|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
219561799|NCT01885351|BEHAVIORAL|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
219561800|NCT03700827|OTHER|Resistance Training|High-intensity Resistance Training Group
219561801|NCT03700827|OTHER|Aerobic Training|Aerobic Interval Training Group
219561802|NCT03721627|DRUG|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
219396648|NCT06672744|OTHER|Kinesiotaping|Kinesiotaping was performed by the same researcher (XX) for two sessions per week for four weeks with fascia correction technique
219396649|NCT06619990|BIOLOGICAL|XmAb942|Antibody
219396650|NCT06619990|DRUG|Placebo|Placebo
219396651|NCT02133014|PROCEDURE|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
219396652|NCT02133014|DRUG|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
219396653|NCT00328263|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
219561803|NCT01701973|DRUG|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
219754582|NCT06563518|DRUG|Meridol|toothpaste
219561804|NCT01701973|DRUG|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
219561805|NCT01701973|DRUG|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
219561806|NCT01701973|DRUG|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
219561807|NCT01701973|DRUG|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
219561808|NCT01446224|DRUG|Pazopanib|Patients treated with pazopanib
219561809|NCT01446224|DRUG|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
219561810|NCT04329715|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
219561811|NCT04329715|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
219561812|NCT04554147|BEHAVIORAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
219561813|NCT01104090|DEVICE|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
219561814|NCT01104090|DEVICE|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
219561815|NCT05193773|OTHER|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
219396654|NCT00328263|DIETARY_SUPPLEMENT|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
219396655|NCT06340555|OTHER|GUIA ATENCION MULTIDISCIPLINAR SANT BOI|Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
219561816|NCT04666597|PROCEDURE|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
219561817|NCT00419224|BIOLOGICAL|inactivated split-virus influenza vaccine|
219561818|NCT02515487|OTHER|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
219561819|NCT00337987|DRUG|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
219396656|NCT06340555|OTHER|USUAL CARE|Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
219561820|NCT00337987|DRUG|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
219561821|NCT03481517|DRUG|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
219561822|NCT05595122|DEVICE|EUS-CDS|EUS-CDS with FCSEMS through LAMS
219561823|NCT06312423|DRUG|Oligonucleotides, Phosphorothioate|Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
219561824|NCT00332943|PROCEDURE|MR colonography with fecal tagging|
219561825|NCT01526135|DRUG|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
219754583|NCT06563518|DRUG|Colgate Cavity Protection|toothpaste
219396657|NCT02309710|DEVICE|ShangRing|ShangRing administered to males seeking medical male circumcision
219396658|NCT01690962|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
219396659|NCT01690962|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
219561826|NCT01526135|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
219561827|NCT00055718|DIETARY_SUPPLEMENT|silymarin|
219396660|NCT01123304|DRUG|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
219396661|NCT00221091|PROCEDURE|ventriculo-peritoneal shunt|
219396662|NCT02081469|OTHER|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
219396663|NCT01810991|DEVICE|Nd:YAG Laser|Nd:YAG 1440nm Laser
219396664|NCT03649776|OTHER|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
219396665|NCT03876340|OTHER|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
219396666|NCT03876340|OTHER|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
219396667|NCT01201369|DEVICE|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
219396668|NCT01201369|DEVICE|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
219396669|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
219396670|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
219396671|NCT00765869|OTHER|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
219561828|NCT02390310|DEVICE|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
219396672|NCT05129839|DEVICE|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
219396673|NCT05687760|BIOLOGICAL|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
219396674|NCT05687760|DRUG|Calcium hydroxide|calcium hydroxide
219396675|NCT03527901|DIAGNOSTIC_TEST|GCF collection with aMMP-8 chair side test|
219561829|NCT02390310|DRUG|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
219561830|NCT02390310|DRUG|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
219561831|NCT00373425|DRUG|Erlotinib|150 mg tablet
219561832|NCT00373425|DRUG|Placebo|Placebo tablet
219561833|NCT06428513|BEHAVIORAL|HCTP|10 weekly 1-on-1 30-minute tele-sessions via Zoom, delivered by a certified health coach. At baseline assessment including full medical history, medications, lifestyle practices, self-reported health status, psychosocial status, and other relevant information will be taken. At the first session, participants identify their health vision and 3-month health goals. At subsequent meetings, participants review their progress towards reaching the prior week's goals and identify goals for the next week. An individualized action plan will be formulated to help each participant achieve their goals. The action plan will focus on important lifestyle practices (physical activity/exercise training, correct nutrition, weight management, tobacco cessation, and stress management. Patients can request further health care advice felt necessary for their progress, and will be referred to health care professionals in the rehabilitation hospital that provide care for lung transplantation candidates.
219561834|NCT01914016|OTHER|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
219561835|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
219561836|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
219561837|NCT05848401|DEVICE|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
219561838|NCT00004344|DRUG|leuprolide|
219396676|NCT03527901|OTHER|Saliva collection|
219429139|NCT04261452|DIAGNOSTIC_TEST|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
219396677|NCT06318923|OTHER|Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|"The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style."
219396678|NCT06318923|OTHER|MS questionnaire|This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
219396679|NCT06318923|OTHER|MONTREAL COGNITIVE ASSESSMENT (MoCA) test|The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
219561839|NCT00004344|DRUG|testosterone|
219561840|NCT04629274|PROCEDURE|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
219561841|NCT00551616|DRUG|CDB-2914|Single dose
219561842|NCT00551616|DRUG|Levonorgestrel|Single dose
219561843|NCT02270216|PROCEDURE|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
219561844|NCT02270216|PROCEDURE|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
219561845|NCT04282655|OTHER|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
219561846|NCT04282655|OTHER|Control|Standard warming procedure of breast milk in syringe prior to feeding.
219561847|NCT02968719|DRUG|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
219561848|NCT02968719|DRUG|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
219561849|NCT02968719|DRUG|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
219561850|NCT02968719|DRUG|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
219561851|NCT02968719|DRUG|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
219754584|NCT03685942|DEVICE|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
219754585|NCT03685942|DEVICE|placebo light therapy|placebo portable light visor device
219754586|NCT06198400|DIAGNOSTIC_TEST|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
219754587|NCT04846179|DIETARY_SUPPLEMENT|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
219396680|NCT04773041|PROCEDURE|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
219396681|NCT05314595|PROCEDURE|bilateral uterine artery ligation|"* Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
219561852|NCT04417751|BEHAVIORAL|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
219561853|NCT02630290|DRUG|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
219561854|NCT02630290|DRUG|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
219561855|NCT06595004|DRUG|HCP1004|Test Drug
219561856|NCT06595004|DRUG|RLD2401|Reference drug
219561857|NCT06656598|DRUG|Carboplatin|Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
219561858|NCT06656598|DRUG|Paclitaxel|Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
219561859|NCT06656598|DRUG|Cemiplimab|Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
219561860|NCT06656598|RADIATION|Curative hypofractionated radiotherapy|Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
219561861|NCT06656598|DRUG|Cemiplimab (maintenance)|Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
219561862|NCT00404625|BEHAVIORAL|Risk factors for infections due to ESBL+ Enterobacteriaceae|
219396682|NCT01643915|BEHAVIORAL|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
219396683|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
219396684|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
219561863|NCT00404625|BEHAVIORAL|Risk factors for inadequate initial antimicrobial therapy|
219561864|NCT00404625|BEHAVIORAL|Overall and 30-day mortality in bad first antibiotic therapy|
219561865|NCT04031560|BEHAVIORAL|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
219561866|NCT04326933|DRUG|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
219561867|NCT02376257|DRUG|250 mg DCS|Drug
219561868|NCT02376257|DRUG|100 mg Modafinil|Drug
219561869|NCT02376257|DRUG|Placebo|Drug
219561870|NCT04011098|DRUG|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
219561871|NCT04011098|DRUG|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
219561872|NCT04621045|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
219561873|NCT04621045|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
219561874|NCT04056663|BEHAVIORAL|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
219561875|NCT02248116|DRUG|Talsaclidine|
219754588|NCT04609982|DEVICE|ear plugs|giving half of the patients ear plugs
219754589|NCT05458739|DEVICE|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
219754590|NCT05819359|DRUG|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
219754591|NCT05819359|DRUG|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
219754592|NCT05819359|DRUG|Placebo|Placebo, once daily, oral administration.
219561876|NCT03437330|DRUG|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
219561877|NCT03437330|DRUG|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)"
219561878|NCT04608682|DRUG|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
219561879|NCT04608682|DRUG|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
219561880|NCT02771028|BEHAVIORAL|Emotional Freedom Techniques|
219561881|NCT00311220|DRUG|tuberculin for skin test|
219561882|NCT03693833|DRUG|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
219561883|NCT03693833|DRUG|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
219561884|NCT05425368|DRUG|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
219396685|NCT03246035|BEHAVIORAL|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
219396686|NCT03246035|OTHER|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
219396687|NCT04536415|DRUG|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
219396688|NCT04536415|DRUG|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
219396689|NCT01522651|DRUG|Ranolazine|Tablets administered orally twice daily.
219561885|NCT05425368|DRUG|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
219396690|NCT01522651|DRUG|Dronedarone|Capsule administered orally twice daily
219396691|NCT01522651|DRUG|Ranolazine placebo|Tablets administered orally twice daily.
219396692|NCT01522651|DRUG|Dronedarone placebo|Capsules administered orally twice daily
219396693|NCT02650778|PROCEDURE|Breast ultrasound|automated whole breast ultrasound
219396694|NCT06513221|DRUG|Chemotherapy, Bevacizumab, Adebrelimab|Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose
219396695|NCT01746602|DRUG|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
219396696|NCT01746602|DRUG|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
219561886|NCT04736394|DRUG|APL-1202|APL-1202 single-agent oral treatment
219561887|NCT04736394|DRUG|Epirubicin Hydrochloride|Epirubicin hydrochloride
219561888|NCT01304979|PROCEDURE|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
219754593|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
219754594|NCT05815602|DRUG|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
219754595|NCT05815602|DRUG|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
219754596|NCT03849209|DEVICE|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
219754597|NCT03849209|DEVICE|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
219754598|NCT01502735|BIOLOGICAL|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
219754599|NCT01502735|BIOLOGICAL|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
219754600|NCT03624725|PROCEDURE|modified BII+Braun|modified BII+Braun digestive tract reconstruction
219754601|NCT03775993|DRUG|Human growth hormone|Administration of growth hormone
219396697|NCT01746602|DEVICE|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
219396698|NCT01746602|DEVICE|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
219396699|NCT01746602|DEVICE|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
219396700|NCT03699345|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
219396701|NCT00340327|DRUG|IMA-638|
219561889|NCT01304979|PROCEDURE|Control|Indirect therapies that mimic direct therapy intervention
219561890|NCT03559725|OTHER|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
219561891|NCT03559725|OTHER|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
219561892|NCT03559725|DRUG|Nicotine gum (C)|4 mg nicotine gum
219561893|NCT04196348|PROCEDURE|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
219561894|NCT04196348|PROCEDURE|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
219561895|NCT00005087|BIOLOGICAL|filgrastim|
219561896|NCT00005087|DRUG|cisplatin|
219561897|NCT00005087|DRUG|paclitaxel|
219396702|NCT04644107|DRUG|Marizomib|Marizomib will be administered via IV
219561898|NCT00005087|PROCEDURE|conventional surgery|
219561899|NCT00005087|RADIATION|radiation therapy|
219561900|NCT05434351|OTHER|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
219561901|NCT06235268|OTHER|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
219396703|NCT06940635|DEVICE|closed-loop BCI-FES device|Closed-loop neurorehabilitation system that combines EEG-based brain-computer interface technology with functional electrical stimulation (FES) to facilitate neural and motor recovery.
219561902|NCT00250133|PROCEDURE|Blood draws|
219561903|NCT04830241|DRUG|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
219561904|NCT00569777|DEVICE|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
219561905|NCT00569777|DEVICE|Placebo Lens|contact lens without drug
219561906|NCT00384124|DRUG|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
219561907|NCT00480649|DRUG|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
219561908|NCT00709306|DEVICE|UV-Detect Photos|UV-Detect Photos
219396704|NCT00302601|PROCEDURE|Scintigraphic interpretation|Not relevant
219396705|NCT02658656|DEVICE|ReWalk 6.0|Exoskeletal Assisted Walking Device
219396706|NCT00284388|PROCEDURE|Simultaneous controlled power measurement|
219396707|NCT00284388|PROCEDURE|Surface EMG measurement|
219396708|NCT00247390|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
219396709|NCT00247390|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
219396710|NCT05565677|DEVICE|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
219561909|NCT00709306|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
219561910|NCT00709306|BEHAVIORAL|Education|Education
219396711|NCT05730439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219396712|NCT05730439|DRUG|Nicotine Oral Pouch|Receive ZYN brand NP
219396713|NCT05730439|DRUG|Nicotine Oral Pouch|Receive Rogue brand NP
219396714|NCT05730439|OTHER|Questionnaire Administration|Ancillary studies
219396715|NCT05730439|DRUG|Smokeless Tobacco|Receive usual SLT
219396716|NCT05180487|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
219396717|NCT06278987|DRUG|PENG block and cryoablation|will receive an ultrasound guided PENG block with 20 mL of 0.5% bupivacaine followed by cryoablation of the PENG nerves.
219396718|NCT06278987|DRUG|fascia iliaca compartment block|will receive an ultrasound guided fascia iliaca compartment catheter with initial bolus of 20 mL of 0.5% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour
219396719|NCT02811458|BEHAVIORAL|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
219561911|NCT05116059|DRUG|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
219561912|NCT00866645|DRUG|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
219561913|NCT00866645|DRUG|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
219561914|NCT03012893|DEVICE|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
219561915|NCT03012893|DEVICE|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
219396720|NCT05922423|BEHAVIORAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
219396721|NCT05922423|BEHAVIORAL|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
219396722|NCT04755543|DRUG|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
219396723|NCT04755543|DRUG|Cisplatin|50mg/m2 IV on Day 1, Q2W
219396724|NCT04755543|DRUG|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
219396725|NCT04755543|BIOLOGICAL|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
219396726|NCT02620332|DRUG|MultiPepT1De injection|A mix of peptides
219396727|NCT02620332|OTHER|Placebo|Water for injection
219396728|NCT01513798|BEHAVIORAL|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
219396729|NCT01513798|BEHAVIORAL|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
219396730|NCT02100657|DRUG|Plitidepsin|
219396731|NCT02100657|DRUG|Bortezomib|
219396732|NCT02100657|DRUG|Dexamethasone|
219396733|NCT01850563|DEVICE|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
219396734|NCT05402501|BEHAVIORAL|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
219396735|NCT04636008|DRUG|Sintilimab|Sintilimab+Hypofractionated radiotherapy
219396736|NCT04636008|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
219396737|NCT00104494|DRUG|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
219561916|NCT03012893|PROCEDURE|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
219561917|NCT00096005|DRUG|tanespimycin|Given IV
219561918|NCT00096005|DRUG|bortezomib|Given IV
219561919|NCT00096005|OTHER|laboratory biomarker analysis|Correlative studies
219396738|NCT00075244|DRUG|Replagal|
219396739|NCT05179031|DIETARY_SUPPLEMENT|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
219396740|NCT05179031|DIETARY_SUPPLEMENT|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
219396741|NCT05179031|DIETARY_SUPPLEMENT|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
219396742|NCT05179031|DIETARY_SUPPLEMENT|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
219396743|NCT05179031|DIETARY_SUPPLEMENT|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
219396744|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
219396745|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
219396746|NCT05179031|DIETARY_SUPPLEMENT|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
219396747|NCT05179031|DIETARY_SUPPLEMENT|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
219396748|NCT02829177|DRUG|Allopurinol|
219396749|NCT02829177|DRUG|Placebo|
219396750|NCT05392127|DRUG|SHR0302 Tablets|SHR0302 Tablets once daily
219396751|NCT05392127|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
219396752|NCT05392127|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
219396753|NCT05392127|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
219396754|NCT05392127|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
219396755|NCT05392127|DRUG|Repaglinide Tablets|Repaglinide Tablets single dose
219396756|NCT05326399|BEHAVIORAL|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
219396757|NCT00479804|DEVICE|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
219396758|NCT00479804|DEVICE|spirometry|spirometry for testing the ventilatory function
219561920|NCT00052286|DRUG|modafinil|
219396759|NCT00479804|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
219396760|NCT04297670|OTHER|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
219396761|NCT00246038|DEVICE|Boston Scientific ENOVUS AAA Endograft|
219561921|NCT05263635|OTHER|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
219396762|NCT02370849|DRUG|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
219396763|NCT02370849|DRUG|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
219396764|NCT02370849|DRUG|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
219561922|NCT05263635|OTHER|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
219561923|NCT02653235|BIOLOGICAL|Salmonella typhi vaccination|
219561924|NCT02653235|BIOLOGICAL|Placebo|
219561925|NCT05562648|OTHER|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
219561926|NCT05562648|OTHER|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
219561927|NCT03427801|DRUG|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
219561928|NCT03121937|BEHAVIORAL|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
219561929|NCT05766124|DRUG|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
219561930|NCT00198354|DRUG|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
219561931|NCT00198354|DRUG|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
219561932|NCT02847416|DEVICE|BreatheMAX breathing device|
219561933|NCT00537017|DRUG|Preladenant|5 mg BID capsules
219561934|NCT00537017|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
219561935|NCT00537017|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
219396765|NCT00108849|DRUG|estradiol, 10 mcg|
219396766|NCT04592380|DRUG|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
219396767|NCT04592380|DRUG|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
219396768|NCT04592380|DRUG|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
219396769|NCT04592380|DRUG|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
219561936|NCT04334850|PROCEDURE|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
219561937|NCT04334850|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
219754602|NCT03775993|OTHER|Placebo|Administration of placebo
219754603|NCT01820000|PROCEDURE|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
219754604|NCT05619237|DEVICE|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
219754605|NCT04497714|DIAGNOSTIC_TEST|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
219754606|NCT02219152|DRUG|tranexamic acid|
219754607|NCT02219152|DRUG|saline|
219754608|NCT01297855|DRUG|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
219396770|NCT01841424|BEHAVIORAL|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
219396771|NCT05789264|DEVICE|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
219396772|NCT05789264|DIAGNOSTIC_TEST|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
219396773|NCT04628403|OTHER|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
219396774|NCT04628403|DEVICE|lasertherapy|lasertherapy
219396775|NCT04628403|DEVICE|shock waves|shock waves
219396776|NCT00162396|DRUG|Albuterol|
219396777|NCT01445743|BIOLOGICAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
219561938|NCT01280227|BEHAVIORAL|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
219561939|NCT02701608|DRUG|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
219561940|NCT02701608|DRUG|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
219561941|NCT02701608|PROCEDURE|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
219561942|NCT00802373|DRUG|Solifenacin succinate|oral
219561943|NCT00802373|DRUG|Tolterodine|Oral
219561944|NCT02813382|DRUG|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
219561945|NCT02813382|DRUG|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
219561946|NCT02813382|DRUG|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
219561947|NCT05228249|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
219396778|NCT05855928|DIAGNOSTIC_TEST|Mime Therapy|electrical stimulation with the MIME therapy and protocol
219396779|NCT05855928|DIAGNOSTIC_TEST|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
219396780|NCT04054778|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
219561948|NCT05228249|DRUG|Carmustine|Given IV
219561949|NCT05228249|DRUG|Cytarabine|Given IV
219561950|NCT05228249|DRUG|Etoposide|Given IV
219561951|NCT05228249|BIOLOGICAL|Loncastuximab Tesirine|Given IV
219561952|NCT05228249|DRUG|Melphalan|Given IV
219561953|NCT03114345|OTHER|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
219561954|NCT03114345|OTHER|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
219561955|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
219561956|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
219561957|NCT06262503|DEVICE|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
219561958|NCT06262503|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
219754609|NCT01297855|DRUG|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
219754610|NCT02906111|DRUG|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
219754611|NCT02906111|PROCEDURE|vaginal surgery|Control Group
219396781|NCT04054778|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
219396782|NCT03323229|DIAGNOSTIC_TEST|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
219561959|NCT06262503|DEVICE|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
219396783|NCT02685384|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
219561960|NCT06262503|OTHER|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
219561961|NCT02528409|DRUG|Vortioxetine|Medication currently approved for major depression.
219561962|NCT02528409|DRUG|Placebo|
219561963|NCT01834027|BEHAVIORAL|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
219561964|NCT01834027|BEHAVIORAL|No music|In this group no music will be played in PACU
219561965|NCT04909645|DIAGNOSTIC_TEST|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
219561966|NCT04893941|DRUG|CM310|IL-4Rα monoclonal antibody
219561967|NCT04893941|DRUG|Placebo|Placebo
219561968|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement A|Oral administration of Supplement A
219561969|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement B|Oral administration of Supplement B
219561970|NCT00691041|BEHAVIORAL|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
219561971|NCT05753982|OTHER|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
219561972|NCT05065541|DRUG|CC-97489|Specified dose on specified days
219561973|NCT05065541|DRUG|[18F]T-401|Specified dose on specified days
219561974|NCT05065541|DRUG|[11C]MK-3168|Specified dose on specified days
219561975|NCT03168906|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
219561976|NCT03168906|DRUG|Placebo|Saline bag
219561977|NCT00972231|OTHER|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
219561978|NCT01321697|PROCEDURE|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
219561979|NCT02476188|PROCEDURE|Sample of Blood|
219561980|NCT02277951|DEVICE|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
219561981|NCT02277951|DEVICE|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
219561982|NCT02277951|DEVICE|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
219561983|NCT02277951|DEVICE|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
219561984|NCT02569307|DRUG|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
219561985|NCT02569307|DRUG|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
219561986|NCT02569307|DRUG|Placebo|Placebo added to TAU
219561987|NCT02569307|DRUG|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
219561988|NCT05337202|DEVICE|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
219561989|NCT04969354|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
219561990|NCT04489017|DIETARY_SUPPLEMENT|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
219561991|NCT04489017|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
219754612|NCT01874392|DRUG|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
219754613|NCT01874392|DEVICE|Artificial Pancreas (AP) device (APS©)|"Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
219561992|NCT04202458|DRUG|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
219396784|NCT01228266|BIOLOGICAL|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
219396785|NCT02322892|DRUG|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
219396786|NCT02322892|DRUG|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
219396787|NCT01104259|DRUG|veliparib|Given PO
219396788|NCT01104259|DRUG|cisplatin|Given IV
219396789|NCT01104259|DRUG|vinorelbine tartrate|Given IV
219396790|NCT01104259|OTHER|laboratory biomarker analysis|Correlative studies
219396791|NCT01104259|OTHER|pharmacological study|Correlative studies
219396792|NCT03802838|DEVICE|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
219396793|NCT03802838|DRUG|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
219001677|NCT06829264|BEHAVIORAL|Supportive Employment Intervention|This intervention consists of a weekly series of sessions designed for adult consumers, incorporating supportive elements inspired by the ACCESS (Acquiring Career, Coping, Executive, and Social Skills) program developed at the UC Davis MIND Institute. The sessions will provide time to discuss consumer experiences, give general guidance and some training in employment-related skills, including resume building, job interviewing, and strategies for giving and receiving feedback in the workplace.
219001678|NCT06828042|BIOLOGICAL|anti-CD19 CAR T cell therapy|anti-CD19 CAR-γδ T cell therapy
219001679|NCT06831526|DRUG|Azeliragon|Provided by Cantex Pharmaceuticals
219001680|NCT06831526|DRUG|Temozolomide|Standard of care.
219396794|NCT03478878|DRUG|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
219396795|NCT00943293|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
219396796|NCT00943293|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
219561993|NCT04906837|DIAGNOSTIC_TEST|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
219561994|NCT04734782|DIAGNOSTIC_TEST|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
219001681|NCT06831526|RADIATION|Radiation therapy|Standard of care.
219396797|NCT00943293|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
219396798|NCT01345877|PROCEDURE|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
219396799|NCT02125331|PROCEDURE|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
219396800|NCT02159391|BEHAVIORAL|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
219001682|NCT06831526|PROCEDURE|Surgery or LITT|Standard of care surgical resection or laser interstitial thermal therapy (LITT).
219396801|NCT05528003|PROCEDURE|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
219396802|NCT06848153|OTHER|Plantar Vibration|The patients in the study group will receive plantar vibration intervention with a frequency of 100 Hz on the affected plantar region for 30 minutes each day over 3 consecutive days.
219396803|NCT06848153|OTHER|Placebo Plantar Vibration|The patients in the placebo group will receive placebo plantar vibration intervention with a frequency of 100 Hz on the affected plantar region, without touching the skin, for 30 minutes each day over 3 consecutive days.
219396804|NCT05627934|DIAGNOSTIC_TEST|qICG|Evaluation of bowel fluorescence by pixel software, qICG
219396805|NCT05336266|DRUG|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
219396806|NCT03867669|OTHER|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
219396807|NCT03867669|OTHER|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
219396808|NCT04710524|DRUG|Placebo|Placebo BID for 13 weeks
219396809|NCT04710524|DRUG|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
219396810|NCT04710524|DRUG|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
219396811|NCT00710034|OTHER|Oral tobacco|Snus
219001683|NCT07121582|OTHER|Motor Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their primary motor hotspot region. Motor brain stimulation will involve 3 bursts of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
219396812|NCT00710034|DRUG|Nicotine Gum|4 mg Nicotine gum
219396813|NCT00482872|GENETIC|gene expression analysis|
219396814|NCT00482872|GENETIC|mutation analysis|
219396815|NCT00482872|GENETIC|polymerase chain reaction|
219396816|NCT00482872|GENETIC|polymorphism analysis|
219396817|NCT00482872|OTHER|flow cytometry|
219396818|NCT00482872|OTHER|laboratory biomarker analysis|
219396819|NCT01829802|DRUG|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
219396820|NCT01829802|DRUG|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
219396821|NCT01829802|DRUG|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
219396822|NCT06123208|OTHER|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
219396823|NCT06123208|OTHER|Pinto bean flour|Meal comprised of pinto bean flour
219396824|NCT06123208|OTHER|Control|Control meal
219396825|NCT03825289|DRUG|Hydroxychloroquine|Given PO
219396826|NCT03825289|DRUG|Trametinib|Given PO
219396827|NCT00218855|DRUG|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
219396828|NCT00218855|DRUG|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
219396829|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
219001684|NCT07121582|OTHER|Visual Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their ipsilesional occipital cortex region. Visual brain stimulation will involve 3 burst of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
219001685|NCT07131514|DRUG|HRS-4642+AG +Adebrelimab|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.
219001686|NCT07132814|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol combustible cigarette
219396830|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
219396831|NCT03799926|DRUG|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
219396832|NCT03799926|DRUG|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
219396833|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
219396834|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
219001687|NCT07132814|OTHER|Product B|8 mg nicotine oral product
219001688|NCT07132814|OTHER|Product C|12 mg nicotine oral product
219001689|NCT07132814|OTHER|Product D|6 mg nicotine oral product
219001690|NCT07132814|OTHER|Product E|8 mg nicotine oral product
219001691|NCT07132814|OTHER|Product F|8 mg nicotine oral product
219001692|NCT07132814|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine polacrilex gum
219001693|NCT07132333|BIOLOGICAL|Biologic Agent|Intervention with biologic agents
219001694|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
219001695|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
219001696|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
219396835|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
219396836|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
219396837|NCT04631458|OTHER|standard of care.|Observational trial.
219396838|NCT00186238|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
219396839|NCT02601001|DRUG|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
219396840|NCT02601001|DRUG|Placebo|Matching placebo tablets
219396841|NCT05722899|OTHER|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
219396842|NCT06440161|OTHER|Primary exposures were venous congestion defined by central venous pressure (CVP) and mean arterial pressure (MAP).|"After the induction of anaesthesia, a central venous or pulmonary artery catheter was positioned. Based on prior studies, thresholds for central venous pressure were set at 10, 12, 16, and 20 mm Hg. Venous congestion was quantified by time exceeding each CVP threshold and the area under the curve (AUC) surpassing each CVP threshold in mmHg × min. Assessments were limited to pre- and post-CPB periods, as the venous drainage cannulate generated negative CVP during CPB.~An arterial catheter was installed upon room admission. Continuous arterial blood pressure monitoring commenced after exposure to atmospheric pressure and calibration to zero. The MAP was determined using the formula: 2/3 × diastolic blood pressure + 1/3 × systolic blood pressure. Data were logged by automated software every minute. Established thresholds for MAP were 55, 65, and 75 mm Hg. Hypotension was quantified as (1) time under each MAP threshold in minutes and (2) the AUC below each MAP threshold in mmHg × min."
219396843|NCT04586894|DIAGNOSTIC_TEST|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
219396844|NCT04586894|DEVICE|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
219396845|NCT04586894|OTHER|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
219561995|NCT00243152|DRUG|Lamotrigine|: 25mg and 50mg tablets
219396846|NCT01543464|DRUG|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
219396847|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 3 months and 3 visits (at 0 month, 3rd and 6th month respectively).
219396848|NCT05566197|DIETARY_SUPPLEMENT|Diet Nusantara|Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily
219396849|NCT05566197|BEHAVIORAL|Nutrition Counseling|Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
219396850|NCT02485366|DRUG|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
219396851|NCT02485366|PROCEDURE|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
219396852|NCT05443958|OTHER||
219396853|NCT00598533|DEVICE|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
219396854|NCT00598533|DEVICE|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
219396855|NCT00905879|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
219396856|NCT02778867|OTHER|1 Food Elimination Diet Therapy|
219396857|NCT02778867|OTHER|6 Food Elimination Diet Therapy|
219396858|NCT02778867|OTHER|6 Food Elimination Diet (after 1FED failure)|
219396859|NCT02778867|DRUG|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
219396860|NCT04492956|DRUG|Ecopipam|Oral tablet
219396861|NCT04492956|DRUG|Placebo|Oral tablet
219396862|NCT05429723|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
219396863|NCT05429723|DRUG|HS-10383 Placebo|Placebo for HS-10383
219396864|NCT01278680|BEHAVIORAL|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
219396865|NCT03245671|DRUG|Kenalog Injectable Product|80 mg of Kenalog will be used.
219396866|NCT03245671|DRUG|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
219396867|NCT03245671|PROCEDURE|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
219561996|NCT00243152|DRUG|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
219561997|NCT05746052|PROCEDURE|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
219561998|NCT00476307|BIOLOGICAL|Fluarix™/Influsplit SSW® 2007/2008|
219561999|NCT05306197|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
219562000|NCT05306197|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
219562001|NCT05306197|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
219562002|NCT00668096|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
219562003|NCT00668096|DRUG|Placebo|Matching Placebo
219562004|NCT00949195|OTHER|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
219562005|NCT00949195|OTHER|Pulmonary pressure response during exercise|Semi-supine echocardiography test
219562006|NCT00857818|DRUG|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
219396868|NCT04141345|DIAGNOSTIC_TEST|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
219396869|NCT00426985|DRUG|Ketoprofen Topical Patch 20%|
219396870|NCT02884791|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
219396871|NCT06041529|DRUG|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
219396872|NCT06041529|DRUG|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
219562007|NCT00857818|DRUG|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
219562008|NCT03079388|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
219396873|NCT04280601|DIETARY_SUPPLEMENT|vitamin D|Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
219396874|NCT03357276|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
219562009|NCT03079388|DIETARY_SUPPLEMENT|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
219562010|NCT03079388|DRUG|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
219562011|NCT03079388|DRUG|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
219562012|NCT03079388|OTHER|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
219396875|NCT05425238|OTHER|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
219396876|NCT05425238|OTHER|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
219396877|NCT03233490|OTHER|web course|Web course Help Brain Heart was conducted Before CPR training.
219396878|NCT03233490|OTHER|CPR training|No web course was conducted
219396879|NCT03888300|OTHER|Physiotherapy|Chest Physiotherapy, physical exercises
219396880|NCT01005394|DEVICE|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
219396881|NCT02288767|DEVICE|Conventional arterial blood pressure monitoring|
219396882|NCT02288767|DEVICE|Stroke volume variation monitoring with arterial blood pressure monitoring|
219562013|NCT03079388|DRUG|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
219562014|NCT03079388|DRUG|Albendazole|Single dose albendazole 400mg given in the second trimester.
219562015|NCT03079388|COMBINATION_PRODUCT|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
219562016|NCT02219308|PROCEDURE|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
219562017|NCT02219308|PROCEDURE|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
219562018|NCT02413424|DIETARY_SUPPLEMENT|Sucralose|60 ml of 2mM sucralose
219562019|NCT02413424|OTHER|Water|60 ml of water
219562020|NCT02413424|DIETARY_SUPPLEMENT|glucose load|
219562021|NCT04217538|OTHER|clinical exam|clinical oral examination
219562022|NCT02103582|OTHER|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
219396883|NCT03393052|PROCEDURE|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
219396884|NCT00046319|DRUG|BSF 208075|
219396885|NCT06480305|DIETARY_SUPPLEMENT|Post dinner snack|one walnut, 2 cashews, 2 almonds, and 2 pistachios.
219396886|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-1|Prepackaged dose of 25 peanuts.
219396887|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-2|Prepackaged dose of 25 raisins
219396888|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-3|Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
219562023|NCT01706718|DIETARY_SUPPLEMENT|Bread|
219562024|NCT04934007|DEVICE|rTMS Treatment|1 Hz rTMS
219562025|NCT03233451|BEHAVIORAL|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
219562026|NCT05307276|OTHER|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
219562027|NCT05307276|OTHER|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
219562028|NCT04899076|DEVICE|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
219562029|NCT05427045|OTHER|home - exercise program|Home exercise program
219562030|NCT06876272|BEHAVIORAL|Healthy eating promoting programme|It is a comprehensive, multi-component intervention tailored specifically for higher education students. Unlike many traditional health programs, this intervention uniquely combines the use of social media campaigns, behavioral nudges in student cafeterias, and interactive boost workshops.
219562031|NCT06878222|DRUG|Neoadjuvant Chemotherapy|paclitaxel, 135-175mg/m2, q3w, 3 cycles
219562032|NCT06878222|DRUG|Neoadjuvant Chemotherapy|cisplatin, 75-80mg/m2, q3w, 3 cycles
219562033|NCT06878222|DRUG|Immunotherapy|Iparomlimab and Tuvonralimab, 5mg/kg, q3w, 3cycles
219562034|NCT06878222|PROCEDURE|Radical surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo radical hysterectomy plus lymphadenectomy
219562035|NCT06878222|PROCEDURE|Fertility-preserving surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Fertility-preserving surgery. For stage IB1/IB2 patients, conization or simple trachelectomy plus lymphadenectomy will be performed. For stage IIA1/IIA2 patients, radical trachelectomy plus lymphadenectomy will be performed.
219562036|NCT00003350|DRUG|paclitaxel|Given IV
219562037|NCT00003350|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
219396889|NCT02695485|PROCEDURE|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
219562038|NCT00003350|OTHER|laboratory biomarker analysis|Correlative studies
219562039|NCT00003350|PROCEDURE|quality-of-life assessment|Ancillary studies
219562040|NCT00031707|DIETARY_SUPPLEMENT|eicosapentaenoic acid|
219562041|NCT00031707|DRUG|megestrol acetate|
219562042|NCT00031707|OTHER|placebo|
219562043|NCT00588783|DEVICE|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
219562044|NCT00588783|DEVICE|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
219562045|NCT06715475|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take five capsules per day in the morning.
219562046|NCT06715475|DIETARY_SUPPLEMENT|Food not containing plasmalogen|Take five capsules per day in the morning.
219562047|NCT06732830|DEVICE|DayDrop Advanced ophthalmic drop|The patient will administer 1 or 2 drops of DayDrop Advanced in each eye 3 times a day for 3 months.
219562048|NCT03478007|DEVICE|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
219562049|NCT03478007|DEVICE|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
219562050|NCT00890279|DRUG|Cilnidipine|Cilnidipine up to 20 mg
219562051|NCT00890279|DRUG|Imidapril|Imidapril up to 10 mg per day
219562052|NCT02405793|DRUG|Meloxicam Test Capsules|
219562053|NCT02405793|DRUG|Meloxicam Test Capsules|
219562054|NCT02405793|DRUG|Meloxicam Tablets|
219562055|NCT02582307|DRUG|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
219562056|NCT02582307|DRUG|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
219562057|NCT06740500|DIETARY_SUPPLEMENT|Probiotic|probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
219562058|NCT06740500|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219562059|NCT01376882|DIETARY_SUPPLEMENT|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
219562060|NCT01376882|DIETARY_SUPPLEMENT|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
219562061|NCT01376882|DIETARY_SUPPLEMENT|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
219562062|NCT01376882|DIETARY_SUPPLEMENT|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
219396890|NCT03504774|DRUG|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
219396891|NCT02344628|DRUG|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
219396892|NCT05738096|OTHER|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
219562063|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
219396893|NCT05738096|OTHER|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
219562064|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
219562065|NCT00157066|DRUG|Ergocalciferol|
219562066|NCT06897072|BEHAVIORAL|Yoga|In the experimental group, yoga exercises were performed for 50 minutes with physical yoga movements (Vrksasana (tree pose), janusirsasana (head-knee pose), modifiedmarichyasana (great sage pose), baddhakonasana (connected angle pose), malasana (garland pose), sukhasana (meditation pose), ardhapadmasana (lotus sitting pose), gomukhasana (cow face pose), supta matyendrasana (spinal rotation pose on the back), bharmanasana (table pose), chakravasana (cat/cow pose), dandayamanabharmasana (balancing yoga pose), vajrasana (diamond pose), viraphadrasana 1-2 (warrior 1-2 pose). The class will include 15 minutes of meditation (deep relaxation with a focus on breath and self-awareness), breathing exercises in between and 10 minutes of relaxation.
219562067|NCT06204770|OTHER|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
219562068|NCT06746233|DEVICE|Drug (paclitaxel) coated balloon (DCB)|In the experimental arm, a drug-coated balloon (DCB) with a concentration of 3 μg of Paclitaxel per 1 mm² will be used in patients with STEMI following successful lesion preparation (defined as residual stenosis ≤30%, TIMI flow grade 2-3, and absence of flow-limiting dissection). If the result after DCB treatment is unsatisfactory, a bailout drug-eluting stent (DES) will be implanted.
219562069|NCT06746233|DEVICE|Second-generation Drug Eluting Stent (DES)|If the patient is randomized to the DES treatment arm, a second-generation drug-eluting stent (DES) will be implanted using standard techniques.
219562070|NCT04469725|DRUG|KN046|KN046 5 milligram per kilogram, every 2 weeks
219562071|NCT06898736|DEVICE|3d miniplate|3d miniplate was used for mandibular fracture fixation
219562072|NCT00833625|PROCEDURE|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
219562073|NCT00833625|OTHER|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
219396894|NCT05074849|BEHAVIORAL|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
219396895|NCT06381674|OTHER|Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback|During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
219396896|NCT06381674|OTHER|Vestibular therapy for mTBI|During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
219396897|NCT06483555|DRUG|Gemcitabine|1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
219396898|NCT06483555|DRUG|Nab paclitaxel|125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
219396899|NCT06483555|DRUG|Erlotinib|50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
219396900|NCT06483555|DRUG|NALIRIFOX|Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
219562074|NCT06245382|DIETARY_SUPPLEMENT|Goode Health Beverage|This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.
219562075|NCT06245382|DIETARY_SUPPLEMENT|Vanilla Base Beverage Blend|This is a commercially available beverage powder.
219396901|NCT06483555|DRUG|Folfirinox|Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
219396902|NCT06001372|DRUG|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
219396903|NCT04144881|DIAGNOSTIC_TEST|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
219396904|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
219396905|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
219396906|NCT06567106|OTHER|Ultrasound application|Apply ultrasound to the participant within a safe range.
219396907|NCT06567106|OTHER|No ultrasound application|No ultrasound application to the participant.
219396908|NCT03955848|BIOLOGICAL|Alloreactive NK cell infusion|Alloreactive NK cell infusion
219396909|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
219562076|NCT05758779|BEHAVIORAL|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
219562077|NCT02966496|BIOLOGICAL|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
219562078|NCT02966496|BIOLOGICAL|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
219562079|NCT05254158|DRUG|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
219562080|NCT04431635|DRUG|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
219562081|NCT04431635|DRUG|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
219562082|NCT04431635|DRUG|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
219562083|NCT00847743|DIETARY_SUPPLEMENT|Tart Cherry Juice|8 fl.oz. twice per day
219396910|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
219396911|NCT03336138|OTHER|AMA (Assistance for ambulatory patients)|telephone follow-up modality
219396912|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
219396913|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
219396914|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
219562084|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
219562085|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
219562086|NCT01150006|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
219562087|NCT02839798|DEVICE|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
219562088|NCT02447887|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
219562089|NCT02447887|DRUG|Pegylated IFN-alpha 2b|Weekly injection
219562090|NCT02561234|DRUG|Co-ArgI-PEG|Administered IV
219562091|NCT01297816|DRUG|placebo|100mg,BD, fo three month
219562092|NCT01297816|DRUG|Minocycline|100mg
219562093|NCT04992793|COMBINATION_PRODUCT|Congenital heart surgery|Paediatric congenital heart surgery
219562094|NCT06196593|DEVICE|AcrySof™ IQ Vivity™ Toric intraocular lens|Uneventful phacoemulsification and implantation of IOL
219562095|NCT03323411|BEHAVIORAL|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
219562096|NCT00752674|OTHER|Neuromuscular balance|
219562097|NCT00571194|DRUG|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
219396915|NCT00722345|BEHAVIORAL|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
219396916|NCT00722345|BEHAVIORAL|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
219396917|NCT01479088|DRUG|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
219396918|NCT02065947|PROCEDURE|paravertebral block|catheter with 3-level-injection
219396919|NCT02065947|DRUG|fentanyl, propofol, atracurium|endotracheal intubation
219562098|NCT05695755|DIAGNOSTIC_TEST|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
219562099|NCT01174355|DRUG|ND0801|Confidential
219562100|NCT01323452|DRUG|Entecavir|once daily
219562101|NCT06260579|BEHAVIORAL|Exercise/physical activity|personalized exercise training and physical activity program
219562102|NCT02013752|DEVICE|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
219562103|NCT02786719|DRUG|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
219562104|NCT02786719|DRUG|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
219562105|NCT02786719|DRUG|Cisplatin|Cycle 3+5 (given daily x 4 days)
219562106|NCT02786719|DRUG|Etoposide|Cycle 3+5 (given daily for 3 days)
219562107|NCT02786719|DRUG|Vincristine|Cycle 4+6 (given daily for 3 days)
219562108|NCT02786719|DRUG|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
219562109|NCT02786719|DRUG|Doxorubicin|Cycle 4+6 (given daily for 3 days)
219562110|NCT02786719|DRUG|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
219562111|NCT03477955|PROCEDURE|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
219562112|NCT06617767|OTHER|Reiki|The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
219562113|NCT00820508|DRUG|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
219562114|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 100 mg
219562115|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 50 mg
219562116|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
219562117|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg
219001697|NCT06931938|OTHER|Awake Prone Positioning|The clinical intervention in the Intervention Group is Awake Prone Positioning, a standard therapy in intensive care units worldwide in ARDS care. The intervention should not be started later than 24 hours after randomization. An earlier start, as soon as possible, after randomization is strongly recommended. In patients in the intervention group standard Awake Prone Positioning for at least 10 hours/day for a length of 72 hours should be applied. The reach the targeted 10 hours / day (per 24 hours), it is strongly recommended to use blocks of a longer time period (e.g. multiple 3-5 hours blocks) within the 24h period to reach the anticipated APP goal. It is recommended that the APP therapy within the targeted intervention for 10 hours/day (per 24 h period) is not interrupted for more than 2 hours till reaching the goal of 10 hours / day (per 24 h). It is further strongly recommended that one APP session should last at least 3 hours. (...) For more information please see the protol.
219001698|NCT06940271|PROCEDURE|Allografting|Undergo placement of MLG-Complete allograft
219001699|NCT06940271|OTHER|Survey Administration|Ancillary studies
219562118|NCT00401245|DRUG|Placebo|Tapering placebo
219562119|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
219562120|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
219562121|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
219562122|NCT04867811|OTHER|conventional therapy|conventional therapy
219562123|NCT04867811|OTHER|cupping therapy|cupping therapy
219562124|NCT04867811|DEVICE|TENS|transcutaneous electrical nerve stimulation
219562125|NCT04867811|OTHER|TENS and cupping therapy|TENS and cupping therapy
219562126|NCT00705315|DRUG|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
219562127|NCT00705315|DRUG|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
219396920|NCT02065947|DRUG|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
219562128|NCT00705315|DRUG|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
219562129|NCT01989676|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
219562130|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
219562131|NCT01989676|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
219396921|NCT02065947|DEVICE|catheter with 3-level-injection|
219396922|NCT02065947|DRUG|sevoflurane and 50% oxygen in air|
219001700|NCT03151837|DIETARY_SUPPLEMENT|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
219001701|NCT03151837|DIETARY_SUPPLEMENT|Placebo control|Starch
219001702|NCT02239978|BEHAVIORAL|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
219001703|NCT00018837|BEHAVIORAL|Community Re-Entry Program: What is Schizophrenia|
219001704|NCT03158376|DRUG|Gabapentin|
219001705|NCT03158376|DRUG|Placebo|
219001706|NCT00602953|OTHER|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
219001707|NCT01822431|RADIATION|metaiodobenzylguanidine scintigraphy|
219396923|NCT00916604|DRUG|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
219396924|NCT00916604|DRUG|Placebo|Placebo oral suspension, 8 days treatment
219396925|NCT04845698|DEVICE|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
219396926|NCT03634215|DIAGNOSTIC_TEST|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
219396927|NCT01320579|DRUG|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
219396928|NCT01320579|DRUG|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
219396929|NCT01320579|DRUG|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
219396930|NCT01320579|DRUG|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
219396931|NCT02393651|DEVICE|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
219396932|NCT06023238|PROCEDURE|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
219396933|NCT03527446|BEHAVIORAL|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
219396934|NCT04797013|DRUG|rt-PA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
219396935|NCT04797013|DRUG|rhTNK-tPA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
219396936|NCT03984760|DRUG|Ferric Citrate|Take the capsules with meals or immediately after meals.
219396937|NCT03984760|DRUG|Sevelamer Carbonate|Take the tablets with meals.
219396938|NCT03975972|OTHER|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
219396939|NCT04385797|OTHER|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
219396940|NCT00308542|DRUG|dexamethasone|
219396941|NCT06396039|DRUG|BMS-986374|Specified dose on specified days.
219396942|NCT04727112|DRUG|Usual care versus primary care|RCT study
219001708|NCT03731611|PROCEDURE|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
219001709|NCT02498314|OTHER|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
219001710|NCT02498314|OTHER|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
219001711|NCT02498314|OTHER|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
219001712|NCT02407821|DRUG|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
219396943|NCT04410783|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
219396944|NCT04410783|OTHER|Standard post intubation sedation practices|Usual care sedation provide in the ED
219562132|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
219562133|NCT03941834|DRUG|Rimegepant|BHV3000 (rimegepant) 75mg tablet
219562134|NCT03941834|DRUG|Placebo|Placebo
219562135|NCT03911596|DEVICE|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
219562136|NCT00130234|DRUG|Xolair® (Omalizumab)|
219562137|NCT02656316|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
219562138|NCT02656316|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
219562139|NCT00472953|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
219562140|NCT00472953|DRUG|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
219562141|NCT01114997|DRUG|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
219562142|NCT01114997|DRUG|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
219001713|NCT02407821|DRUG|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
219001714|NCT03883620|BIOLOGICAL|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
219001715|NCT03883620|BIOLOGICAL|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
219396945|NCT02870452|BEHAVIORAL|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
219396946|NCT02870452|BEHAVIORAL|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
219396947|NCT01198418|BEHAVIORAL|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
219562143|NCT01114997|DRUG|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
219562144|NCT05315245|OTHER|AGI|no intervention, only observation
219562145|NCT00441233|DEVICE|Silicone hydrogel contact lens|
219562146|NCT05247333|OTHER|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
219562147|NCT03034161|DEVICE|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
219396948|NCT02707094|DEVICE|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
219396949|NCT02707094|OTHER|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
219396950|NCT00295399|DEVICE|The Jerusalem Telerehabilitation System|
219396951|NCT00780468|BEHAVIORAL|Existing diet plan|
219396952|NCT00780468|BEHAVIORAL|New diet plan|
219396953|NCT01148056|RADIATION|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
219396954|NCT03493308|OTHER|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
219396955|NCT03493308|OTHER|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
219396956|NCT01902797|OTHER|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
219396957|NCT06334029|DIAGNOSTIC_TEST|Functional and structural Connectome|Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
219562148|NCT01560819|DRUG|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
219562149|NCT00864799|DRUG|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
219562150|NCT06307041|DEVICE|Dental floss+Gengigel|0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses
219562151|NCT06307041|DEVICE|Dental Floss|Dental Flosses
219562152|NCT05538637|DIAGNOSTIC_TEST|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
219562153|NCT03417609|DEVICE|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
219396958|NCT03293095|PROCEDURE|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
219562154|NCT03417609|PROCEDURE|Blood sampling|Blood sampling
219562155|NCT03417609|DIAGNOSTIC_TEST|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
219562156|NCT03417609|DIAGNOSTIC_TEST|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
219562157|NCT03417609|DIAGNOSTIC_TEST|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
219562158|NCT03417609|DEVICE|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
219001716|NCT03883620|BIOLOGICAL|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
219001717|NCT03883620|BIOLOGICAL|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
219001718|NCT03883620|BIOLOGICAL|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
219001719|NCT03883620|BIOLOGICAL|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
219001720|NCT03883620|BIOLOGICAL|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
219001721|NCT00876772|DRUG|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
219001722|NCT01945177|DEVICE|narrow band imaging|narrow band imaging
219396959|NCT00915005|RADIATION|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
219562159|NCT03417609|DIAGNOSTIC_TEST|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
219562160|NCT02625506|DRUG|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
219562161|NCT02625506|DRUG|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
219562162|NCT05141630|PROCEDURE|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
219562163|NCT02344745|OTHER|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
219562164|NCT02344745|OTHER|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
219562165|NCT03071913|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
219562166|NCT03071913|OTHER|Laboratory Biomarker Analysis|Correlative studies
219562167|NCT02067702|PROCEDURE|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
219562168|NCT02788513|DRUG|BI 425809 dose 1|
219001723|NCT01945177|DEVICE|white light endoscopy|white light endoscopy
219001724|NCT02597075|OTHER|standard therapy + physical activity program|
219562169|NCT02788513|DRUG|BI 425809 dose 2|
219562170|NCT02788513|DRUG|BI 425809 dose 3|
219562171|NCT02788513|DRUG|BI 425809 dose 4|
219001725|NCT02597075|OTHER|standard therapy|
219001726|NCT03605459|DEVICE|Comfort Plug™|
219001727|NCT00996216|DRUG|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
219001728|NCT00996216|DRUG|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
219001729|NCT03553134|DIAGNOSTIC_TEST|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
219396960|NCT00915005|RADIATION|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
219396961|NCT00915005|DRUG|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
219396962|NCT00915005|DRUG|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
219396963|NCT03069339|DRUG|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
219562172|NCT02788513|DRUG|Placebo|
219562173|NCT04958252|DRUG|BI 1569912|BI 1569912
219562174|NCT04958252|DRUG|Placebo|Placebo
219562175|NCT02607137|BEHAVIORAL|Health Education|Information on healthy living style in relation to physical activity
219562176|NCT03250455|DIAGNOSTIC_TEST|CTA CTP|CT Angiography myocardial CT Perfusion
219562177|NCT03250455|DIAGNOSTIC_TEST|CTA|CT Angiography
219562178|NCT02555319|DEVICE|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
219562179|NCT01834898|DRUG|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
219562180|NCT00898820|GENETIC|gene expression analysis|
219396964|NCT03069339|PROCEDURE|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
219396965|NCT04761497|OTHER|Actice music therapy|active music therapy sessions for three months
219396966|NCT04761497|OTHER|Watching nature videos|nature videos sessions for three months
219396967|NCT04761497|OTHER|Passive music therapy|passive music therapy for three months
219396968|NCT03070418|PROCEDURE|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
219396969|NCT04366986|OTHER|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
219396970|NCT04366986|OTHER|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
219396971|NCT03066817|DRUG|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
219396972|NCT03066817|DRUG|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
219396973|NCT02238028|BEHAVIORAL|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
219396974|NCT00719576|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
219396975|NCT00719576|PROCEDURE|Microfracture|Microfracture performed by arthroscopic surgery
219396976|NCT05217979|DEVICE|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
219396977|NCT05217979|DEVICE|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
219396978|NCT06148233|RADIATION|[18F]CSF-23|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
219396979|NCT04875819|DRUG|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
219396980|NCT04875819|DRUG|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
219562181|NCT00898820|GENETIC|polymorphism analysis|
219562182|NCT00898820|GENETIC|protein expression analysis|
219562183|NCT03380221|OTHER|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
219001730|NCT03553134|DIAGNOSTIC_TEST|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
219562184|NCT03380221|OTHER|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
219001731|NCT04398498|DIAGNOSTIC_TEST|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
219001732|NCT03758274|BEHAVIORAL|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
219396981|NCT02196142|DRUG|Cortisol 20mg|Drug: Cortisol 20mg
219562185|NCT05747924|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
219562186|NCT05747924|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion
219562187|NCT06099301|BEHAVIORAL|Brief advice of a list of mobile apps|The mobile apps in the list should: (1) focus primarily on anxiety/depression/stress, (2) be available for free download; (3) be available in English or Chinese; and (4) have a user star rating in the app store.
219562188|NCT05654493|DEVICE|MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device|The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers
219562189|NCT02367625|DEVICE|CryoPop|The new CryoPop device will be compared to standard cryotherapy
219562190|NCT02367625|DEVICE|MedGyn MGC 200|Standard cryotherapy
219562191|NCT02118168|OTHER|No intervention|No intervention is foreseen in this Observational Study
219396982|NCT02196142|DRUG|Placebo Mannitol|Drug: Placebo Mannitol
219396983|NCT05264571|DIAGNOSTIC_TEST|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
219396984|NCT05264571|OTHER|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
219396985|NCT05264571|OTHER|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
219562192|NCT03129230|PROCEDURE|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
219562193|NCT03917355|BEHAVIORAL|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
219562194|NCT01279655|DEVICE|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
219562195|NCT01279655|BEHAVIORAL|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
219562196|NCT04024319|PROCEDURE|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
219562197|NCT03657238|DRUG|RD01|single S.C. dose of RD01 for subjects in test group
219562198|NCT03657238|DRUG|Placebo|single S.C. dose of placebo for subjects in placebo group
219562199|NCT04138784|OTHER|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
219562200|NCT04138784|OTHER|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
219562201|NCT01675284|BIOLOGICAL|AT-301|Inactivated H5N1 Influenza Virion Vaccine
219562202|NCT02919111|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
219562203|NCT05632692|OTHER|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
219562204|NCT04116151|COMBINATION_PRODUCT|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
219562205|NCT04116151|COMBINATION_PRODUCT|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
219562206|NCT01260337|BEHAVIORAL|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
219562207|NCT01260337|OTHER|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
219562208|NCT00426530|DRUG|everolimus (RAD001)|
219562209|NCT00458419|DRUG|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
219562210|NCT00458419|DRUG|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
219562211|NCT00114231|DRUG|capecitabine|
219562212|NCT00114231|DRUG|oxaliplatin|Given IV
219562213|NCT00114231|PROCEDURE|neoadjuvant therapy|Undergo surgery
219562214|NCT00114231|RADIATION|radiation therapy|Undergo radiotherapy
219562215|NCT03608306|OTHER|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
219562216|NCT03608306|OTHER|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
219562217|NCT05499234|DRUG|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
219562218|NCT05499234|DRUG|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
219562219|NCT02754024|PROCEDURE|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
219562220|NCT02754024|PROCEDURE|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
219562221|NCT02754024|DEVICE|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
219562222|NCT01329224|OTHER|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
219562223|NCT06326034|DRUG|Dapagliflozin|Dapagliflozin 5 mg orally given once daily for four months.
219562224|NCT06614608|DRUG|5% ASKC200|5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
219562225|NCT06614608|DRUG|1% ASKC200|1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
219562226|NCT01933919|DRUG|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
219562227|NCT01933919|DRUG|Placebo|Placebo tablet matching to fluvoxamine maleate
219562228|NCT03998709|DRUG|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
219396986|NCT05264571|OTHER|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
219396987|NCT01626183|GENETIC|RNA analysis|
219396988|NCT01626183|GENETIC|proteomic profiling|
219396989|NCT01626183|OTHER|laboratory biomarker analysis|
219396990|NCT01023399|DRUG|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
219396991|NCT03777579|DRUG|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
219396992|NCT03777579|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
219396993|NCT03777579|DRUG|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
219396994|NCT00305006|PROCEDURE|Constraint-Induced Movement Therapy (CIMT)|90 hours
219396995|NCT00305006|PROCEDURE|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
219396996|NCT02834052|DRUG|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
219396997|NCT02834052|DRUG|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
219396998|NCT02484196|BEHAVIORAL|Questionnaires|Questionnaires
219396999|NCT00631488|DRUG|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
219397000|NCT00631488|DRUG|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
219397001|NCT00631488|DRUG|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
219397002|NCT00631488|DRUG|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
219397003|NCT00631488|DRUG|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
219397004|NCT00631488|DRUG|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
219397005|NCT02580487|PROCEDURE|appendicectomy|Appendix was removed either laparoscopically or open surgery
219397006|NCT06472700|OTHER|No intervention|No intervention
219397007|NCT00103194|DRUG|lapatinib ditosylate|Given PO
219397008|NCT00103194|OTHER|laboratory biomarker analysis|Correlative studies
219397009|NCT03648476|BEHAVIORAL|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
219397010|NCT03793816|DEVICE|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
219397011|NCT03071224|DRUG|[18F] MNI-946|Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
219397012|NCT03071224|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
219397013|NCT02855411|DRUG|PF-04958242|Administered as specified in the treatment arm
219397014|NCT02855411|DRUG|placebo|placebo, twice daily (BID) for 12 weeks, capsule
219397015|NCT05348187|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
219397016|NCT05909579|BEHAVIORAL|PelvicSense (R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
219397017|NCT06018831|OTHER|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
219562229|NCT03998709|OTHER|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
219562230|NCT03998709|DRUG|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
219562231|NCT03998709|OTHER|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
219001733|NCT03758274|OTHER|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
219397018|NCT03293199|PROCEDURE|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
219397019|NCT03293199|PROCEDURE|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
219397020|NCT01391312|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
219562232|NCT04065061|DIETARY_SUPPLEMENT|Erinacine A-enriched Hericium Erinaceus Mycelia|
219562233|NCT04065061|DIETARY_SUPPLEMENT|Placebo|Placebo supplement was given to the participants.
219562234|NCT03965728|DRUG|BAY1830839|Tablet, oral.
219562235|NCT03965728|DRUG|Placebo|Tablet, oral.
219562236|NCT03965728|DRUG|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
219562237|NCT03965728|DRUG|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
219562238|NCT02096822|BEHAVIORAL|Facilitated tucking + non-nutritive sucking|
219001734|NCT00822991|DEVICE|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
219001735|NCT00822991|DEVICE|B-mode US|screening by conventional B-mode US every 3-5 months
219001736|NCT00793403|OTHER|As per routinary clinical care|As per routine clinical care
219001737|NCT05058248|PROCEDURE|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
219397021|NCT01391312|DRUG|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
219397022|NCT02972723|DRUG|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
219397023|NCT02950662|OTHER|Overdenture|Active comparator will be metal housing and peek housing
219562239|NCT02096822|OTHER|non-nutritive sucking|
219562240|NCT04159181|OTHER|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
219562241|NCT04159181|OTHER|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
219562242|NCT04159181|OTHER|Placebo (water)|oral administration of Water (200mL).
219562243|NCT02000323|OTHER|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
219562244|NCT02000323|OTHER|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
219562245|NCT03070691|DRUG|LDE225B|Cream, 2x daily
219562246|NCT03070691|DRUG|Vehicle|cream, 2x daily
219562247|NCT00928226|RADIATION|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
219001738|NCT04081168|DEVICE|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
219001739|NCT04081168|DEVICE|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
219562248|NCT00928226|PROCEDURE|Surgical resection|Standard of care
219562249|NCT03942783|OTHER|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
219562250|NCT03942783|OTHER|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
219562251|NCT01714050|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
219562252|NCT01714050|DEVICE|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
219562253|NCT03297086|PROCEDURE|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
219397024|NCT02298270|BEHAVIORAL|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
219397025|NCT00225368|DEVICE|Insecticide treated bednets|
219562254|NCT06267209|OTHER|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
219562255|NCT01331577|BEHAVIORAL|Cognitive Behavioural Training|Two day seminar
219562256|NCT01331577|BEHAVIORAL|Integrative Kinesiology Intervention|Two day seminar
219562257|NCT04679142|DRUG|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
219562258|NCT05758909|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
219562259|NCT01961752|DRUG|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
219562260|NCT01961752|DRUG|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
219562261|NCT01961752|DRUG|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
219562262|NCT04546152|DEVICE|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
219562263|NCT02371993|DIETARY_SUPPLEMENT|Choline|
219562264|NCT02371993|OTHER|Placebo|
219562265|NCT02270424|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
219562266|NCT02270424|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
219562267|NCT02270424|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
219562268|NCT02270424|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
219562269|NCT02270424|DRUG|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
219562270|NCT02270424|DRUG|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
219562271|NCT02270424|DRUG|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
219562272|NCT00251914|DRUG|Esomeprazole|
219397026|NCT01671085|DRUG|LY3015014|Administered SQ
219397027|NCT01671085|DRUG|Placebo|Administered SQ
219397028|NCT03505697|OTHER|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
219397029|NCT03505697|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
219562273|NCT04573296|DEVICE|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
219397030|NCT05240950|DRUG|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
219397031|NCT00637273|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
219397032|NCT00637273|DRUG|sitagliptin|oral tablet, 100mg, once a day
219397033|NCT00637273|DRUG|pioglitazone|oral tablet, 45mg, once a day
219397034|NCT00637273|DRUG|placebo tablet|oral tablet, once a day
219397035|NCT00637273|DRUG|placebo once weekly|subcutaneous injection, once a week
219397036|NCT02733692|BEHAVIORAL|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
219397037|NCT03471845|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
219397038|NCT00012337|DRUG|gefitinib|
219397039|NCT01762293|DRUG|Famitinib|Famitinib 25 mg p.o. qd
219397040|NCT01762293|OTHER|placebo|p.o. qd
219397041|NCT00986258|DRUG|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
219562274|NCT04573296|BEHAVIORAL|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
219562275|NCT01695096|OTHER|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
219562276|NCT01695096|OTHER|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
219562277|NCT00697216|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
219562278|NCT00697216|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
219562279|NCT04591652|DRUG|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
219562280|NCT02970552|DRUG|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
219562281|NCT02970552|DRUG|Placebo|Indistinguishable placebo vaginal suppository
219562282|NCT02510261|DRUG|Patisiran|Patisiran was administered IV.
219562283|NCT01563237|DEVICE|MIDI Arrow|Implantation of MIDI Arrow
219562284|NCT01835704|OTHER|Radio-frequency dennervation of facet joint|
219397042|NCT04585945|DIAGNOSTIC_TEST|Positive for SARS-CoV-2 infection|Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
219397043|NCT04465370|DEVICE|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
219397044|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
219397045|NCT05361018|OTHER|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
219397046|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
219397047|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
219397048|NCT02616029|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
219397049|NCT06316661|DIAGNOSTIC_TEST|stress perfusion cardiac magnetic resonance|stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
219397050|NCT06316661|DIAGNOSTIC_TEST|cardiopulmonary exercise test|bike exercise with ECG and non invasive respiratory gas exchange monitoring
219397051|NCT03453749|DIETARY_SUPPLEMENT|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
219397052|NCT06099054|DEVICE|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
219397053|NCT06099054|DEVICE|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
219562285|NCT01835704|OTHER|Diagnostic nerve-blocks performed under direct x-ray vision|
219562286|NCT02246868|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
219397054|NCT02599467|OTHER|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
219562287|NCT02033135|PROCEDURE|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
219562288|NCT02033135|OTHER|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
219562289|NCT02033135|DEVICE|Zilver PTX|
219562290|NCT01124695|DRUG|tamoxifen|PO
219562291|NCT00891423|DRUG|Meropenem short infusion|
219397055|NCT01278628|OTHER|exercise training|exercise class once a year
219001740|NCT05601258|OTHER|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
219397056|NCT02832804|DEVICE|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
219397057|NCT01611077|DRUG|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
219397058|NCT01611077|DRUG|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
219397059|NCT01611077|DRUG|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
219397060|NCT00013039|BEHAVIORAL|Computer reminders|
219397061|NCT01648608|DRUG|Exemestane|Exemestane for neoadjuvant chemotherapy
219397062|NCT01497314|OTHER|Low Lactose Infant Formula|Low Lactose Infant Formula
219562292|NCT00891423|DRUG|Meropenem extended infusion|
219562293|NCT04600024|DIAGNOSTIC_TEST|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
219562294|NCT02495181|DRUG|Intravitreal Aflibercept|
219562295|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
219562296|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
219562297|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
219562298|NCT01269450|DRUG|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
219562299|NCT01269450|DRUG|placebo|placebo 200mg vaginal tablets
219562300|NCT01922219|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
219562301|NCT05389709|DRUG|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
219562302|NCT01607177|BEHAVIORAL|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
219562303|NCT02948790|DEVICE|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
219562304|NCT02948790|DEVICE|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
219562305|NCT01795079|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
219562306|NCT00978913|BIOLOGICAL|DC vaccine|DC vaccination, one vaccine biweekly
219397063|NCT05827146|DRUG|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
219397064|NCT05827146|DRUG|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
219562307|NCT02287324|PROCEDURE|Manipulation|
219562308|NCT02287324|PROCEDURE|Manual Contact|
219562309|NCT02443324|DRUG|Ramucirumab|Administered IV
219397065|NCT06203145|DRUG|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
219397066|NCT05275218|PROCEDURE|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
219397067|NCT02369978|DRUG|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
219397068|NCT02369978|DRUG|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
219562310|NCT02443324|DRUG|Pembrolizumab|Administered IV
219562311|NCT06256835|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219562312|NCT06256835|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219562313|NCT03543709|DIAGNOSTIC_TEST|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
219397069|NCT02369978|DRUG|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
219397070|NCT05360732|DRUG|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
219397071|NCT02005653|DRUG|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
219397072|NCT02005653|DRUG|Albendazole|Experimental
219397073|NCT02005653|DRUG|Doxycycline|Experimental
219397074|NCT03887637|DRUG|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
219397075|NCT01423240|DRUG|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
219562314|NCT03543709|OTHER|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
219562315|NCT04953078|BIOLOGICAL|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
219562316|NCT05915793|OTHER|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
219562317|NCT05915793|OTHER|Diaphragm strengthening|Diaphragm strengthening
219562318|NCT05093465|BEHAVIORAL|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
219562319|NCT05093465|OTHER|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
219562320|NCT06260020|BEHAVIORAL|Comprehensive module for management of sleep disorders[Behavioral and pharmacological therapy]|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
219562321|NCT05567939|OTHER|Natural course of disease|Sample and questionnaire collection
219562322|NCT05535439|PROCEDURE|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
219562323|NCT02860819|DRUG|Veliparib|Veliparib 250mg BID, continuously
219562324|NCT02860819|DRUG|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
219562325|NCT02860819|DRUG|Carboplatin|Carboplatin AUC = 4, day 1
219562326|NCT05685524|DIAGNOSTIC_TEST|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
219562327|NCT01052324|DRUG|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
219562328|NCT02524184|DRUG|sildenafil|sildenafil 100 mg per day for 7 days.
219562329|NCT02524184|DRUG|placebo|an identical placebo per day for 7 days
219562330|NCT01059721|PROCEDURE|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
219562331|NCT05171764|DEVICE|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
219562332|NCT04310306|DEVICE|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
219562333|NCT04610060|BEHAVIORAL|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day"
219397076|NCT01423240|DRUG|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
219397077|NCT01423240|DRUG|Placebo|Placebo once daily orally in the evening
219397078|NCT02758886|BEHAVIORAL|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
219397079|NCT02758886|BEHAVIORAL|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
219562334|NCT04610060|BEHAVIORAL|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
219562335|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane|Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
219397080|NCT02758886|BEHAVIORAL|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
219397081|NCT00227279|BIOLOGICAL|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
219397082|NCT00002206|DRUG|Adefovir dipivoxil|
219397083|NCT02633072|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
219397084|NCT02754778|BEHAVIORAL|conditional workout|6 month of regular conditional workout 1-3 times a weak
219397085|NCT06521008|DRUG|anti muscarinic drugs|a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
219397086|NCT06521008|OTHER|Instructions including bladder training|The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
219397087|NCT06521008|OTHER|pelvic floor muscle training (PFMT)|The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
219397088|NCT06521008|OTHER|abdominal exercise|Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
219397089|NCT06521008|OTHER|Diaphragmatic Training|The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
219397090|NCT03232424|DEVICE|NovoTTF-200A|"* Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
219397091|NCT03232424|DRUG|Temozolomide|"Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
219397092|NCT03232424|RADIATION|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
219397093|NCT06554938|DEVICE|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
219397094|NCT06554938|DEVICE|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
219397095|NCT01009996|PROCEDURE|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
219397096|NCT02191917|PROCEDURE|Respiratory muscle strength measurements by different techniques.|
219397097|NCT05828238|DRUG|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
219397098|NCT05828238|DRUG|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
219397099|NCT04964921|OTHER|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
219397100|NCT05257239|OTHER|no intervention|National University Health System,
219397101|NCT00653835|DRUG|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
219397102|NCT00653835|DRUG|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
219397103|NCT02307019|OTHER|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
219397104|NCT02307019|OTHER|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
219397105|NCT00193440|DRUG|Rituximab|
219397106|NCT00193440|DRUG|CHOP|
219562336|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)|Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
219397107|NCT00193440|DRUG|CVP|
219397108|NCT00193440|DRUG|Ibritumomab Tiuxetan|
219562337|NCT06331741|PROCEDURE|Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity|Arthroplasty with consequent collagen membrane implantation
219397109|NCT04230486|DEVICE|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
219562338|NCT01311401|OTHER|NONE intervention|NONE intervention
219397110|NCT01598584|DRUG|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
219397111|NCT01598584|DRUG|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
219397112|NCT00188500|BEHAVIORAL|atkins diet|
219397113|NCT00188500|BEHAVIORAL|ability to follow low carbohydrate diet|
219397114|NCT01840020|PROCEDURE|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
219397115|NCT01840020|PROCEDURE|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
219397116|NCT02027688|OTHER|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
219397117|NCT02027688|OTHER|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
219397118|NCT05447377|BIOLOGICAL|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 5 mg of sorbitol per dose."
219397119|NCT05447377|BIOLOGICAL|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 8 mg of sorbitol (E420) per dose."
219397120|NCT04645459|OTHER|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
219397121|NCT04645459|OTHER|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
219397122|NCT00205504|DRUG|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
219397123|NCT04175197|DEVICE|Drug Coated Balloon|Legflow Drug Coated Balloon
219397124|NCT01335568|PROCEDURE|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
219397125|NCT03537768|DRUG|Ulipristal Acetate|UPA Tablet
219397126|NCT03537768|DRUG|Levonorgestrel|LNG Tablet
219397127|NCT03537768|DRUG|Levonorgestrel|LNG Tablet (x2)
219562339|NCT00684567|RADIATION|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
219001741|NCT04405986|PROCEDURE|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
219397128|NCT03709888|DRUG|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
219397129|NCT02801097|DRUG|RRx-001|
219397130|NCT02801097|DRUG|Irinotecan|
219562340|NCT00684567|DRUG|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
219562341|NCT01083017|DRUG|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
219562342|NCT01083017|BEHAVIORAL|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
219562343|NCT01083017|DRUG|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
219562344|NCT05386095|PROCEDURE|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
219562345|NCT05386095|PROCEDURE|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
219562346|NCT02451150|DRUG|Azilsartan|Azilsartan tablets
219562347|NCT04100824|PROCEDURE|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
219562348|NCT04100824|DRUG|Nimodipine|Nimodipine 60mg every 4h
219001742|NCT04405986|PROCEDURE|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
219001743|NCT00038207|DRUG|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
219397131|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
219397132|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan|Pre-treatment scan
219397133|NCT02234583|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
219397134|NCT03463694|OTHER|Na Cl solution|\~2.6% NaCl solution prepared from sea salt
219397135|NCT04723108|OTHER|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
219397136|NCT00086710|DRUG|Fuzeon|
219397137|NCT05498961|OTHER|Gallstone characteristics|stone size, number, the thickness
219397138|NCT00386893|PROCEDURE|simultaneous EEG/fMRI|fMRI/EEG recordings
219397139|NCT00386893|DEVICE|fMRI|
219397140|NCT00541086|DRUG|anastrozole|1 mg per day, orally
219397141|NCT00541086|DRUG|exemestane|25 mg per day, orally
219397142|NCT00541086|DRUG|letrozole|2.5 mg per day, orally
219397143|NCT00541086|DRUG|tamoxifen citrate|20 mg per day, orally
219397144|NCT03032185|DEVICE|Transcutaneous Elevtrical Nerve Stimulation|
219397145|NCT00791440|BEHAVIORAL|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
219397146|NCT00791440|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
219397147|NCT01742468|DIETARY_SUPPLEMENT|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
219397148|NCT01742468|DIETARY_SUPPLEMENT|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
219397149|NCT01221467|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
219397150|NCT03002389|DRUG|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
219397151|NCT03002389|DRUG|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
219562349|NCT03601624|DRUG|Pomalidomide|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
219397152|NCT02805907|DRUG|Calcifediol|
219397153|NCT02805907|DRUG|Placebo|
219397154|NCT01595256|BEHAVIORAL|muscular strength|12-week moderate intensity walking program
219562350|NCT00908921|DRUG|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
219562351|NCT05419349|PROCEDURE|esophagogastric junction cancer surgery|esophagogastric junction cancer surgery
219397155|NCT06201572|OTHER|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
219397156|NCT03481764|GENETIC|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
219397157|NCT01264965|DRUG|long acting oxycodone|10mg twice daily
219397158|NCT01264965|DRUG|extra strength acetaminophen|1,000 mg twice daily
219397159|NCT00722592|DRUG|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
219397160|NCT00722592|DRUG|pegylated liposomal doxorubicin (PLD)|50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
219397161|NCT00722592|OTHER|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
219562352|NCT00746902|DEVICE|nCPAP|Active nCPAP
219562353|NCT05604079|DEVICE|Electrolarynx|The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
219562354|NCT00506506|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
219562355|NCT00506506|DRUG|Placebo|
219562356|NCT04778618|DRUG|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
219562357|NCT04859387|OTHER|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
219001744|NCT03912766|DIAGNOSTIC_TEST|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
219562358|NCT04859387|OTHER|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
219397162|NCT04561817|DRUG|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
219397163|NCT04561817|DRUG|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
219397164|NCT05922267|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
219397165|NCT05922267|OTHER|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
219397166|NCT03550716|PROCEDURE|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
219397167|NCT03550716|PROCEDURE|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
219397168|NCT06109623|OTHER|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
219397169|NCT06109623|OTHER|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
219397170|NCT03274336|BEHAVIORAL|questionnaire|questionnaire post preanesthetic interview
219562359|NCT01082887|OTHER|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
219562360|NCT03670732|OTHER|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
219562361|NCT03670732|OTHER|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
219562362|NCT03282006|DRUG|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
219562363|NCT05209828|DEVICE|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
219562364|NCT00588328|DEVICE|PET/CT scan|PET/CT scans
219562365|NCT01705431|BEHAVIORAL|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
219562366|NCT03404401|DRUG|BLI4700|Oral bowel preparation
219191819|NCT04170907|OTHER|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
219562367|NCT03404401|DRUG|Polyethylene glycol bowel preparation|Oral bowel preparation
219562368|NCT03056768|BEHAVIORAL|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
219562369|NCT03056768|BEHAVIORAL|Active control|Health promotion activities provided by local health bureau.
219562370|NCT00204022|DRUG|Mycophenolate mofetil|Mycophenolate mofetil
219562371|NCT00204022|DRUG|Azathioprine|Azathioprine
219562372|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil|Ready to Use Therapeutic Food
219562373|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
219562374|NCT01593969|DIETARY_SUPPLEMENT|Standard RUTF|Standard formulation RUTF given according to National Guidelines
219397171|NCT03274336|BEHAVIORAL|face-to-face interview|Group A = face-to-face interview
219397172|NCT03274336|BEHAVIORAL|brochure|after reading a brochure a face to face interview will take place
219397173|NCT03274336|BEHAVIORAL|movie|after seeing a film about the procedure a face-to-face interview will take place
219397174|NCT00542685|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
219397175|NCT00542685|DRUG|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
219397176|NCT00542685|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
219397177|NCT00542685|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
219397178|NCT01797107|DRUG|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
219397179|NCT04197297|DIAGNOSTIC_TEST|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
219397180|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
219562375|NCT00988208|DRUG|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
219562376|NCT00988208|DRUG|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
219562377|NCT00988208|DRUG|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
219397181|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
219397182|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
219397183|NCT01205191|BEHAVIORAL|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
219397184|NCT01205191|BEHAVIORAL|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
219397185|NCT01205191|BEHAVIORAL|CBT|CBT for anxiety disorders
219397186|NCT00601588|DRUG|Sertraline|
219397187|NCT00086840|DRUG|temsirolimus|Given IV
219397188|NCT00086840|OTHER|laboratory biomarker analysis|Correlative studies
219397189|NCT02508168|DRUG|Alogliptin|Alogliptin 12.5 mg tablets
219397190|NCT02508168|DRUG|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
219397191|NCT02508168|DRUG|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
219397192|NCT02332356|DRUG|azathioprine or adalimumab and infliximab|
219397193|NCT02411227|BEHAVIORAL|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
219397194|NCT04866420|BEHAVIORAL|The MenFAS Study|A cross over repeated exposure randomized design observational study
219397195|NCT02202031|BEHAVIORAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
219397196|NCT02202031|BEHAVIORAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
219397197|NCT02087319|OTHER|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
219397198|NCT05645484|DRUG|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
219397199|NCT05645484|DRUG|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
219397200|NCT05876650|OTHER|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
219562378|NCT00988208|DRUG|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
219562379|NCT00271739|DEVICE|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
219562380|NCT00271739|OTHER|usual care|usual diabetes care, as provided by primary care providers
219562381|NCT03008837|DEVICE|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
219562382|NCT03008837|OTHER|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
219397201|NCT05876650|OTHER|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
219562383|NCT00037687|DRUG|rPAF-AH|
219397202|NCT00000404|BEHAVIORAL|Patient education in self-care of knee OA|
219397203|NCT02487628|DEVICE|HQ® Matrix Soft Tissue Mesh|
219397204|NCT02487628|DEVICE|ULTRAPRO® Partially Absorbable Lightweight Mesh|
219562384|NCT05498493|BEHAVIORAL|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
219562385|NCT05498493|BEHAVIORAL|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
219562386|NCT05524311|DRUG|Baricitinib|Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
219562387|NCT05524311|BIOLOGICAL|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
219562388|NCT05524311|BIOLOGICAL|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
219562389|NCT05524311|BIOLOGICAL|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
219562390|NCT05524311|BEHAVIORAL|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
219562391|NCT05524311|BEHAVIORAL|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
219562392|NCT05524311|BIOLOGICAL|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
219562393|NCT02480426|DEVICE|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
219562394|NCT02480426|DRUG|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
219562395|NCT05073250|DRUG|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
219562396|NCT05073250|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
219562397|NCT06061406|DEVICE|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
219562398|NCT03907514|BEHAVIORAL|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
219562399|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
219562400|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
219397205|NCT05916677|OTHER|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
219562401|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
219562402|NCT04211519|DIAGNOSTIC_TEST|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
219562403|NCT02445287|RADIATION|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
219562404|NCT03235479|DRUG|Rimegepant|75 mg tablet QD
219397206|NCT05916677|OTHER|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
219397207|NCT02039180|DRUG|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
219397208|NCT02039180|DRUG|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
219397209|NCT02039180|DRUG|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
219397210|NCT01640587|DRUG|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
219397211|NCT01640587|DRUG|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
219397212|NCT03808623|DEVICE|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
219397213|NCT06058494|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
219397214|NCT00076219|PROCEDURE|renal replacement therapy|renal replacement therapy
219397215|NCT00149851|DRUG|Tegaserod|
219397216|NCT06027242|DIETARY_SUPPLEMENT|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
219397217|NCT06027242|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
219397218|NCT03233776|DRUG|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
219397219|NCT05527171|BEHAVIORAL|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
219562405|NCT03235479|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
219562406|NCT06251895|OTHER|DKA protocol|IV fluids and IV insulin as per guidelines. reference 1-2
219562407|NCT03643367|DRUG|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
219562408|NCT03643367|DRUG|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
219562409|NCT06167252|OTHER|Exploration of a database|extraction of data
219562410|NCT03868046|DRUG|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
219562411|NCT03868046|DIAGNOSTIC_TEST|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
219562412|NCT06462144|DRUG|IMPT-514 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
219562413|NCT03332251|DEVICE|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
219562414|NCT00367016|DRUG|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
219191820|NCT06167200|OTHER|No intervention, study is observational|No intervention, study is observational
219397220|NCT05527171|BEHAVIORAL|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
219397221|NCT04514367|DRUG|ANX005|Intravenous Infusion
219397222|NCT06443281|DIAGNOSTIC_TEST|Neurophysiology|Pain-related evoked potentials and nerve conduction studies
219397223|NCT06443281|DIAGNOSTIC_TEST|Cardiovascular test|Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability
219562415|NCT00367016|DRUG|Placebo|Placebo, given by subcutaneous injection.
219562416|NCT06616805|DEVICE|treadmill|Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
219562417|NCT06059417|OTHER|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
219562418|NCT05853809|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
219397224|NCT06443281|DIAGNOSTIC_TEST|Experimental pain paradigms|Temporal summation of pain, conditioned pain modulation
219397225|NCT06443281|DIAGNOSTIC_TEST|Quantitative sensory testing|Thermal and mechanical sensory testing
219397226|NCT06443281|DIAGNOSTIC_TEST|Clinical pain phenotype|Pain drawings, plus and minus signs of pain
219397227|NCT02392546|DRUG|elobixibat|
219397228|NCT02392546|DRUG|placebo|
219397229|NCT04925414|DRUG|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
219397230|NCT04925414|DRUG|placebo air aerosol|High concentration mask delivering 15L/min of air
219397231|NCT03736083|DEVICE|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
219397232|NCT02631187|DEVICE|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
219397233|NCT06404008|BEHAVIORAL|REST|After randomization, individuals will attend an in-person training session in the REST protocol. This is a 15 minute controlled breath protocol that includes 3 yoga breathing techniques: 3-part dirgha breath, alternate nostril breathing, and 2:1 breathing. Each technique will be completed for 5 minutes, for a total of 15 minutes. After the training session, participants will practice the REST protocol for 15 minutes twice a day with guidance from research staff over zoom (Days 1-7) with daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and exacerbation education. On Day 8, participants will attend the Trial Session where they will complete the REST protocol (15 minutes) while vitals, lung function, and ECG measurements are taken. Surveys will be administered before and after the REST protocol to document patient reported stress and dyspnea.
219397234|NCT06404008|OTHER|Education|After randomization, individuals will attend an in-person education session led by a research coordinator. For the following 7 days, the research staff will call patients daily and provide daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and COPD exacerbation education. On Day 8, participants will attend the Trial Session where they will do spontaneous breathing (15 minutes) while vitals, lung function, and EKG measurements are taken. Surveys will be administered before and after the spontaneous breathing period to document patient reported stress and dyspnea. After the study, participants will be asked to complete a close out survey and interview over zoom.
219562419|NCT04927325|OTHER|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
219562420|NCT04504006|PROCEDURE|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
219562421|NCT00258505|PROCEDURE|Procedure: intracranial monitoring up to 9 days after injury|
219397235|NCT05533554|BEHAVIORAL|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
219397236|NCT01388010|OTHER|1-Fermented Probiotic Dairy Product (test)|
219397237|NCT01388010|OTHER|2-Milk-based non-fermented dairy product(control)|
219397238|NCT05994651|BEHAVIORAL|Tidal Model improvement model|"1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
219397239|NCT00988962|BEHAVIORAL|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
219397240|NCT01188798|DRUG|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
219397241|NCT01188798|DRUG|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
219397242|NCT00999752|DRUG|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
219397243|NCT00999752|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
219562422|NCT02419833|PROCEDURE|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
219562423|NCT02419833|PROCEDURE|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
219397244|NCT06208709|DEVICE|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
219397245|NCT06208709|DEVICE|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
219397246|NCT02795767|DRUG|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
219397247|NCT01571674|PROCEDURE|Manipulation + Exercise Group|"First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
219397248|NCT01571674|PROCEDURE|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
219397249|NCT04263922|DRUG|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
219397250|NCT04263922|DRUG|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
219397251|NCT01450371|DEVICE|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
219397252|NCT01450371|DEVICE|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
219397253|NCT02947139|DRUG|Co-administration of DWC20155/DWC20156|
219397254|NCT02947139|DRUG|DWC20161|
219397255|NCT04722133|DRUG|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
219397256|NCT00199186|DRUG|imatinib|
219562424|NCT02419833|DEVICE|Coronary artery stenting|Implantation of coronary stents
219191821|NCT04617678|OTHER|Prehabilitation Program|We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
219397257|NCT00199186|DRUG|vincristine|
219562425|NCT03490409|DEVICE|Thigh compression stocking|Thigh compression stocking
219562426|NCT04836351|OTHER|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
219562427|NCT03270592|OTHER|Service dog|Use of a individualized certified service dog
219562428|NCT03419104|DIAGNOSTIC_TEST|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
219562429|NCT06674694|DRUG|Brexpiprazole long-acting injection|A single injection was administered.
219562430|NCT04474093|OTHER|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
219562431|NCT04197128|DEVICE|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
219191822|NCT05942924|PROCEDURE|Repeated tactile stimulation|See arm
219191823|NCT05942924|PROCEDURE|Selective tactile stimulation|See arm
219397258|NCT00199186|DRUG|cyclophosphamide|
219397259|NCT00199186|DRUG|cytosine arabinoside|
219397260|NCT00199186|DRUG|dexamethasone|
219397261|NCT00199186|DRUG|idarubicin|
219397262|NCT00199186|DRUG|methotrexate (intrathecal)|
219397263|NCT00199186|DRUG|AraC (intrathecal)|
219397264|NCT00199186|DRUG|dexamethasone (intrathecal)|
219397265|NCT01949493|DEVICE|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
219397266|NCT01949493|OTHER|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
219397267|NCT02553915|OTHER|Placebo|Soybean oil placebo
219397268|NCT02553915|DRUG|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
219397269|NCT02553915|DRUG|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
219562432|NCT04197128|DEVICE|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
219562433|NCT01254461|DRUG|AZD1981|100 mg per oral, twice daily for 8 days
219562434|NCT01254461|DRUG|AZD1981|4x100 mg per oral, twice daily for 8 days
219562435|NCT01254461|DRUG|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
219562436|NCT06033807|DIAGNOSTIC_TEST|QuantiFERON-TB Gold (QFT) test|Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
219562437|NCT03465072|OTHER|Exercise training|8 weeks, 3 times per week, 30-40 minutes
219562438|NCT01148524|BIOLOGICAL|No Vaccine|
219562439|NCT01148524|BIOLOGICAL|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
219562440|NCT01352364|OTHER|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
219562441|NCT01737541|DRUG|Fluoxetine|
219562442|NCT01737541|DRUG|Placebo|
219562443|NCT01734694|DRUG|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
219562444|NCT01734694|DRUG|Ceftaroline|"Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;"
219562445|NCT01734694|DRUG|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h"
219562446|NCT01734694|DRUG|Linezolid|600 mg IV/PO q12h
219562447|NCT05539534|BEHAVIORAL|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
219191824|NCT05878080|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
219191825|NCT06772922|OTHER|Exercise|effect of exercise after three months (comparison of the patient with himself)
219397270|NCT02553915|DRUG|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
219397271|NCT03061968|BEHAVIORAL|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
219397272|NCT01564654|DEVICE|iTotal KRS|Total Knee Replacement System
219397273|NCT02805088|OTHER|Electroencephalographic recordings|
219397274|NCT02805088|OTHER|neuropsychological evaluation|
219562448|NCT06192641|DRUG|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
219397275|NCT02805088|OTHER|clinical evaluation of symptoms|
219397276|NCT06269211|DRUG|Toripalimab|240mg IV, Q3W
219397277|NCT05908383|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
219562449|NCT03355196|DRUG|LRX712|Ascending single dose on Day 1
219562450|NCT03355196|DRUG|Placebo|Ascending single dose on Day 1
219562451|NCT04819854|DRUG|EP395|capsule for oral treatment
219562452|NCT04819854|DRUG|Placebo|capsule for oral treatment
219562453|NCT01355302|DRUG|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
219562454|NCT01355302|DRUG|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
219562455|NCT01355302|DRUG|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
219397278|NCT05908383|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
219397279|NCT02896426|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
219397280|NCT02896426|BEHAVIORAL|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
219397281|NCT04209868|DRUG|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
219562456|NCT05298592|BIOLOGICAL|BMS-986406|Specified dose on specified days
219562457|NCT05298592|BIOLOGICAL|Nivolumab|Specified dose on specified days
219562458|NCT05298592|DRUG|Carboplatin|Specified dose on specified days
219562459|NCT05298592|DRUG|Pemetrexed|Specified dose on specified days
219562460|NCT05298592|DRUG|Paclitaxel|Specified dose on specified days
219562461|NCT05187741|DEVICE|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
219562462|NCT01953887|DRUG|EC905|Oral
219562463|NCT01953887|DRUG|solifenacin|oral
219562464|NCT01953887|DRUG|tamsulosin|oral
219397282|NCT04209868|DRUG|0.9% Sodium Chloride 20mL Injection|As per arm description
219397283|NCT02270398|BEHAVIORAL|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
219397284|NCT02270398|BEHAVIORAL|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
219397285|NCT02270398|BEHAVIORAL|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
219562465|NCT00693225|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
219562466|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
219562467|NCT01315028|OTHER|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
219562468|NCT01315028|OTHER|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
219562469|NCT04546048|BEHAVIORAL|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
219562470|NCT01063959|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
219562471|NCT01063959|PROCEDURE|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
219562472|NCT04126486|OTHER|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
219562473|NCT00538655|DRUG|modafinil|400mg vs. 200mg (PO) daily
219562474|NCT03330314|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
219562475|NCT03353298|DRUG|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
219397286|NCT02083445|OTHER|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
219397287|NCT02083445|OTHER|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
219397288|NCT02083445|DEVICE|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
219397289|NCT02083445|OTHER|Intermittent hypobaric hypoxia|
219397290|NCT03868553|OTHER|No intervention|observational study
219397291|NCT03477188|BEHAVIORAL|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
219397292|NCT03477188|BEHAVIORAL|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
219397293|NCT04156646|DRUG|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
219397294|NCT04156646|DRUG|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
219397295|NCT05700240|DEVICE|orthokeratology|rigid contact lenses
219397296|NCT05700240|DEVICE|single-vision spectacle correction|simple wear of spectacle
219397297|NCT03682588|OTHER|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
219397298|NCT06013787|BEHAVIORAL|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
219397299|NCT00493389|DRUG|Adrenocorticotrophic hormone|
219397300|NCT02711748|DEVICE|electrostimulation|Electrostimulation using manual defibrillator
219397301|NCT02711748|DEVICE|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
219397302|NCT01175239|GENETIC|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
219397303|NCT04665544|PROCEDURE|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
219397304|NCT00751881|DRUG|Placebo|"Film-coated tablet~Oral administration"
219397305|NCT00751881|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219397306|NCT04372355|DRUG|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
219397307|NCT03152864|BEHAVIORAL|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
219397308|NCT02812030|OTHER|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
219397309|NCT01950884|DRUG|Ezetimibe|Ezetimibe tablets
219001745|NCT06089135|DEVICE|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
219397310|NCT01950884|BEHAVIORAL|Lifestyle|lifestyle
219562476|NCT03353298|DRUG|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
219001746|NCT06089135|DEVICE|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
219001747|NCT03339960|OTHER|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
219001748|NCT02597894|PROCEDURE|Biopsy of Prostate|Undergo biopsy
219001749|NCT02597894|OTHER|Laboratory Biomarker Analysis|Correlative studies
219397311|NCT00370656|DRUG|Pregabalin|capsule, 150mg bd, 300mg bd
219397312|NCT00370656|DRUG|Duloxetine|Capsule, 60mg on, 60mg bd
219397313|NCT00370656|DRUG|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
219397314|NCT03798561|DRUG|ASN008 TG|ASN008 TG
219397315|NCT03798561|DRUG|Placebo TG|Placebo TG
219397316|NCT00890968|DRUG|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
219397317|NCT00890968|DRUG|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
219397318|NCT00707018|DEVICE|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
219397319|NCT00707018|DEVICE|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
219397320|NCT01065129|DRUG|G-CSF|
219397321|NCT01065129|DRUG|Plerixafor|
219562477|NCT06094998|DIAGNOSTIC_TEST|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
219562478|NCT04281732|DEVICE|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
219562479|NCT04435002|OTHER|Acupressure|Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
219562480|NCT01355848|BEHAVIORAL|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
219562481|NCT02531594|BEHAVIORAL|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
219562482|NCT02531594|BEHAVIORAL|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
219397322|NCT01065129|DRUG|Azacitidine|
219397323|NCT05679726|BEHAVIORAL|massage|reflexology foot massage
219397324|NCT03870581|BEHAVIORAL|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
219397325|NCT03870581|BEHAVIORAL|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
219397326|NCT03509753|DIETARY_SUPPLEMENT|High Fiber|See intervention description.
219397327|NCT03509753|DIETARY_SUPPLEMENT|Low Fiber|See intervention description.
219397328|NCT02868125|RADIATION|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
219397329|NCT01765764|DRUG|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
219397330|NCT01765764|DRUG|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
219397331|NCT01455727|OTHER|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
219397332|NCT01455727|OTHER|Usual care|Control patients received usual care directed by their physician.
219562483|NCT02607020|OTHER|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1\. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
219397333|NCT00391638|DRUG|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
219397334|NCT00391638|BIOLOGICAL|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
219397335|NCT04522427|DEVICE|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
219397336|NCT04522427|DEVICE|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
219397337|NCT00196495|DEVICE|Polypropylene Mesh|
219397338|NCT00627640|DRUG|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
219397339|NCT00627640|DRUG|Matching Placebo|Matching Placebo
219397340|NCT05811572|DEVICE|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
219397341|NCT02662686|OTHER|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
219397342|NCT02662686|OTHER|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
219397343|NCT01553539|DRUG|therapeutic angiotensin-(1-7)|Given SC
219397344|NCT01553539|OTHER|laboratory biomarker analysis|Correlative study
219397345|NCT05547555|DIAGNOSTIC_TEST|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
219397346|NCT03005535|OTHER|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
219397347|NCT03005535|OTHER|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
219562484|NCT02607020|OTHER|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
219397348|NCT04660903|PROCEDURE|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
219397349|NCT01752517|DRUG|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
219397350|NCT00530712|DEVICE|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
219397351|NCT00800033|BEHAVIORAL|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
219562485|NCT00583518|DRUG|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
219562486|NCT01077817|DRUG|Alendronate|
219562487|NCT01077817|DRUG|Etidronate|
219562488|NCT01077817|DRUG|Ibandronate|
219562489|NCT01077817|DRUG|Risedronate|
219562490|NCT01077817|DRUG|Raloxifene|
219562491|NCT03027921|OTHER|elastography|
219562492|NCT03128736|DRUG|Esomeprazole group|Esomeprazole 40mg qd
219562493|NCT03128736|DRUG|Dexlansoprazole group|Dexlansoprazole 60mg qd
219562494|NCT05930405|PROCEDURE|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
219562495|NCT05930405|PROCEDURE|continuous epidural infusion|continuous epidural infusion
219562496|NCT04909112|OTHER|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
219562497|NCT04909112|OTHER|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
219562498|NCT04909112|OTHER|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
219562499|NCT03282539|DEVICE|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
219562500|NCT03282539|DEVICE|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
219562501|NCT04303624|OTHER|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
219562502|NCT03750695|BEHAVIORAL|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
219562503|NCT03750695|BEHAVIORAL|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
219562504|NCT03750695|BEHAVIORAL|Rest|40 minutes of quiet rest in semi-recumbent position
219562505|NCT00365690|BEHAVIORAL|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
219562506|NCT00365690|BEHAVIORAL|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
219562507|NCT00365690|BEHAVIORAL|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
219397352|NCT00800033|DIETARY_SUPPLEMENT|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
219397353|NCT02948192|OTHER|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
219397354|NCT03832868|BEHAVIORAL|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
219397355|NCT03832868|BEHAVIORAL|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
219562508|NCT06678009|DEVICE|the isokinetic training group with blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
219001750|NCT00842712|DRUG|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
219397356|NCT04830748|OTHER|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
219397357|NCT04830748|OTHER|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
219397358|NCT02241850|OTHER|High intensity training|9 weeks of supervised high intensity training
219397359|NCT00002195|DRUG|Amprenavir|
219397360|NCT00002195|DRUG|Lamivudine|
219397361|NCT00002195|DRUG|Zidovudine|
219397362|NCT03415464|OTHER|Exercise|neuromuscular training
219397363|NCT04918940|BIOLOGICAL|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
219397364|NCT05845164|DEVICE|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
219397365|NCT05845164|DEVICE|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
219397366|NCT04936139|BEHAVIORAL|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
219397367|NCT03114241|BEHAVIORAL|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
219397368|NCT01835990|DEVICE|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
219397369|NCT01835990|DEVICE|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
219397370|NCT05074095|OTHER|retrospective analysis|
219562509|NCT06678009|DEVICE|the isokinetic training group without blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
219562510|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1\) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
219562511|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
219562512|NCT06146660|DRUG|Mavacamten|According to approved product label
219562513|NCT04411173|DIETARY_SUPPLEMENT|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
219562514|NCT02883439|DRUG|MP29-02|local nasal application
219562515|NCT02883439|DRUG|Fluticasone propionate|local nasal application
219562516|NCT03843125|DRUG|Baricitinib|Administered orally.
219001751|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
219397371|NCT04133779|PROCEDURE|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
219397372|NCT04133779|PROCEDURE|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
219397373|NCT04133779|PROCEDURE|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
219397374|NCT06440590|PROCEDURE|suprapectineal quadrilateral buttress plating|15 cases will undergo anatomical supra-pectineal quadrilateral plate
219397375|NCT06440590|PROCEDURE|Infra-pectineal plating|15 cases will undergo conventional manually contoured infra-pectineal plate
219397376|NCT01072279|OTHER|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
219397377|NCT01072279|OTHER|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
219562517|NCT03843125|DRUG|Placebo|Administered orally.
219562518|NCT01586208|DRUG|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
219562519|NCT03494933|PROCEDURE|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
219562520|NCT03494933|PROCEDURE|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
219562521|NCT01285505|DRUG|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
219562522|NCT01285505|DRUG|alprazolam test sublingual tablet|0.5 mg tablet, single dose
219562523|NCT04534140|DIETARY_SUPPLEMENT|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
219562524|NCT04534140|OTHER|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
219562525|NCT01680601|PROCEDURE|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
219562526|NCT01680601|PROCEDURE|Placebo|
219001752|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
219001753|NCT00842712|DRUG|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
219001754|NCT00842712|DRUG|Cisplatin|Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
219001755|NCT00842712|DRUG|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
219001756|NCT00842712|DRUG|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
219001757|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
219001758|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
219562527|NCT04929730|OTHER|Nephrology care bundle|Nephrology care bundle
219562528|NCT01195220|BEHAVIORAL|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
219562529|NCT01195220|BEHAVIORAL|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
219397378|NCT02804802|OTHER|questionnaire|dietary habits and physical activity questionnaire
219397379|NCT05496803|OTHER|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
219397380|NCT05496803|OTHER|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
219397381|NCT00002221|DRUG|Peripheral blood stem cells|
219397382|NCT03851679|DIAGNOSTIC_TEST|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
219397383|NCT03851679|DEVICE|Pulmonary echography|"Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
219562530|NCT01195220|BEHAVIORAL|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
219562531|NCT02525263|BIOLOGICAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
219562532|NCT03460899|OTHER|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
219562533|NCT03460899|OTHER|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
219562534|NCT05009056|DEVICE|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
219562535|NCT04480307|DRUG|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
219562536|NCT04480307|DRUG|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
219562537|NCT04480307|DRUG|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
219562538|NCT04480307|DRUG|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
219562539|NCT06551948|DIETARY_SUPPLEMENT|psyllium|15 g psyllium
219562540|NCT06551948|DIETARY_SUPPLEMENT|methylcellulose|15 gm methylcellulose
219001759|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
219397384|NCT03851679|OTHER|urine collection|6 hour and 24 hour urine collection after Cesarean Section
219397385|NCT04077203|BEHAVIORAL|Biofeedback / No biofeedback|Biofeedback / No biofeedback
219397386|NCT05347589|OTHER|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
219562541|NCT06551948|DIETARY_SUPPLEMENT|maltodextrin|15 g maltodextrin
219562542|NCT06551948|DIETARY_SUPPLEMENT|inulin|15g inulin
219562543|NCT03171324|DRUG|Iron Supplement|2 mg/kg/day elemental iron
219562544|NCT04631133|DEVICE|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
219562545|NCT04592653|BIOLOGICAL|Nemvaleukin alfa|IV infusion over 30 minutes
219562546|NCT04592653|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes
219562547|NCT03549897|DRUG|Placebo|Placebo Product
219562548|NCT03549897|DRUG|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
219562549|NCT03549897|DRUG|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
219562550|NCT03549897|DRUG|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
219562551|NCT00344045|DRUG|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
219562552|NCT00344045|DRUG|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
219562553|NCT04012216|DEVICE|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
219562554|NCT04012216|DEVICE|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
219397387|NCT05347589|OTHER|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
219397388|NCT00092144|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
219397389|NCT00092144|DRUG|Comparator: placebo / Duration of Treatment: 4 weeks|
219397390|NCT06480474|DEVICE|Deprexis|The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.
219397391|NCT06480474|DEVICE|Deprexis with online forum|Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.
219562555|NCT05862844|BEHAVIORAL|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
219562556|NCT01843257|OTHER|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
219562557|NCT01843257|OTHER|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
219562558|NCT06074757|DRUG|Fulvestrant injection|phosphate ester of fulvestrant for test arm
219562559|NCT00020839|DRUG|temozolomide|
219562560|NCT00020839|RADIATION|radiation therapy|
219562561|NCT04859140|OTHER|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
219562562|NCT04859140|BEHAVIORAL|Range of motion measures|Sit-and-reach and toe touch tests
219562563|NCT04859140|BEHAVIORAL|Mental calculation task|Iterated substractions (for 2 minutes)
219562564|NCT04859140|DEVICE|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
219562565|NCT04859140|DEVICE|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
219562566|NCT04245358|DEVICE|Ainara|1g of gel per administration
219562567|NCT05856058|DRUG|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
219562568|NCT01203917|DRUG|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
219562569|NCT00361686|DRUG|tramadol|
219562570|NCT00361686|DRUG|remifentanyl|
219562571|NCT00361686|DEVICE|patient contolled analgesia|
219562572|NCT00239824|BEHAVIORAL|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
219562573|NCT00239824|BEHAVIORAL|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
219397392|NCT03020524|BIOLOGICAL|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
219562574|NCT06401941|PROCEDURE|Hyperbaric Oxygen Therapy|HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
219397393|NCT04766424|BEHAVIORAL|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
219397394|NCT04766424|BEHAVIORAL|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
219397395|NCT02273323|OTHER|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
219562575|NCT05157035|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
219562576|NCT03028155|DRUG|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
219562577|NCT03028155|DRUG|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
219562578|NCT05741502|DRUG|Clozapine|We will assess inflammatory/immune marker labs
219001760|NCT00842712|DRUG|Chemotherapy|Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
219397396|NCT02273323|OTHER|Placebo|Placebo: tea flavour, colouring and sugar
219397397|NCT04788719|OTHER|Gait analysis|Gait analysis
219562579|NCT05741502|DRUG|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
219562580|NCT01863355|DRUG|B0 group: bolus 0.6mcg/kg without background infusion|
219562581|NCT01863355|DRUG|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
219562582|NCT01863355|DRUG|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
219397398|NCT01209208|DRUG|Budesonide|9 mg per day
219397399|NCT01209208|DRUG|Mesalamine|3 g per day
219397400|NCT01209208|OTHER|Placebo|0 g per day
219397401|NCT03836118|PROCEDURE|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
219397402|NCT00651118|DRUG|Placebo|placebo
219397403|NCT00651118|DRUG|azelastine Hcl|azelastine Hcl 548 mcg
219397404|NCT00651118|DRUG|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
219397405|NCT00651118|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
219397406|NCT03117049|DRUG|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
219397407|NCT03117049|DRUG|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
219397408|NCT03117049|DRUG|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
219397409|NCT03117049|DRUG|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
219397410|NCT03117049|DRUG|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
219397411|NCT00042185|BEHAVIORAL|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
219397412|NCT00042185|BEHAVIORAL|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
219397413|NCT00042185|BEHAVIORAL|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
219397414|NCT03215888|PROCEDURE|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
219397415|NCT00839098|OTHER|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
219397416|NCT00839098|OTHER|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
219397417|NCT03078673|OTHER|training intervention, motor skill training|cross country specific motor skill strength training
219397418|NCT03078673|OTHER|training intervention, maximal strength training|general maximal strength training
219397419|NCT03078673|OTHER|control group|regular training
219397420|NCT00121810|DRUG|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
219397421|NCT00121810|DRUG|Corticosteroids|As prescribed
219397422|NCT00121810|DRUG|Calcineurin inhibitors|As prescribed
219397423|NCT00121810|DRUG|Sirolimus|As prescribed
219397424|NCT01340287|DIETARY_SUPPLEMENT|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
219397425|NCT01340287|DIETARY_SUPPLEMENT|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
219397426|NCT00003369|DRUG|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
219397427|NCT00003369|DRUG|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
219397428|NCT04490668|BIOLOGICAL|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
219397429|NCT00365976|DRUG|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
219001761|NCT03902067|BIOLOGICAL|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
219001762|NCT03902067|BIOLOGICAL|Control Group|Routine treatment without catheter infusion
219001763|NCT02298803|DEVICE|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
219001764|NCT01539057|DRUG|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
219397430|NCT00365976|DRUG|Placebo|Placebo nightly over duration of double blind study phase
219397431|NCT04993027|DRUG|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
219397432|NCT05840289|OTHER|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
219397433|NCT06313281|PROCEDURE|Preoperative Antiseptic preparation prior to transnasal skull base surgery|The patient received one of three antiseptic preparation before transnasal skull base surgery
219397434|NCT02222987|DRUG|Terbogrel|
219562583|NCT02995564|BEHAVIORAL|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
219562584|NCT03585309|PROCEDURE|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
219562585|NCT04415047|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
219191826|NCT06496945|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
219562586|NCT04437277|DIAGNOSTIC_TEST|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
219397435|NCT02222987|DRUG|Clopidogrel|
219397436|NCT01485679|OTHER|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
219562587|NCT01712451|DRUG|salmeterol xinafoate, fluticasone propionate|LIPO-102
219562588|NCT01712451|DRUG|Placebo|Placebo
219562589|NCT01712451|DRUG|salmeterol xinafoate|Salmeterol
219397437|NCT05328778|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
219397438|NCT02260193|DRUG|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219562590|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
219001765|NCT01539057|DRUG|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
219397439|NCT02260193|DRUG|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219397440|NCT02260193|DRUG|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
219397441|NCT03749993|OTHER|Screening|Use of bpMRI for opportunistic prostate cancer screening.
219397442|NCT06047431|DRUG|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
219397443|NCT02942550|DRUG|Methylnaltrexone bromide (Relistor®).|
219562591|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
219562592|NCT00605176|DRUG|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
219562593|NCT05513469|DRUG|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
219562594|NCT04396444|COMBINATION_PRODUCT|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
219562595|NCT05624762|DEVICE|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
219001766|NCT00875212|DRUG|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
219397444|NCT02942550|DRUG|Sodium Chloride 9mg/mL|
219397445|NCT03141801|DEVICE|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
219562596|NCT05624762|DEVICE|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
219562597|NCT02227550|DRUG|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
219397446|NCT03141801|OTHER|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
219001767|NCT00875212|DRUG|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
219001768|NCT00875212|DRUG|fluoride|use of a dentifrice containing fluoride (1500ppm) only
219001769|NCT00875212|DRUG|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
219397447|NCT03141801|OTHER|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
219397448|NCT00984802|DRUG|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
219397449|NCT00984802|DRUG|Placebo control|Vehicle solution for IV administration single dose.
219397450|NCT02416687|DEVICE|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
219397451|NCT00403702|DRUG|Oxane HD [oil-RMN3-mixture]|
219397452|NCT00403702|DRUG|Densiron [(F6H8)|
219397453|NCT00886132|DRUG|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
219397454|NCT05606354|OTHER|Intervention group|Experimental
219397455|NCT02290639|BEHAVIORAL|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
219397456|NCT02290639|BEHAVIORAL|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
219397457|NCT00935220|DRUG|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
219397458|NCT06270940|PROCEDURE|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
219397459|NCT03637868|DRUG|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
219397460|NCT00619931|DRUG|APD791|APD791 or matching placebo in escalating doses
219397461|NCT00985881|DEVICE|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
219397462|NCT00985881|DEVICE|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
219397463|NCT00876174|PROCEDURE|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
219562598|NCT02227550|DRUG|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
219397464|NCT00876174|PROCEDURE|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
219397465|NCT02389946|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
219397466|NCT02389946|DEVICE|Xience DES|
219562599|NCT04232527|DIAGNOSTIC_TEST|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
219001770|NCT02031666|DRUG|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
219397467|NCT00161304|DRUG|Testosterone Enanthate|Testosterone Enanthate
219397468|NCT00161304|OTHER|Placebo|placebo
219397469|NCT02474017|DRUG|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
219397470|NCT02474017|DEVICE|CRC749 inhaler|
219397471|NCT00798967|DRUG|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
219397472|NCT00798967|DRUG|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
219397473|NCT03515603|PROCEDURE|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
219397474|NCT03515603|PROCEDURE|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
219397475|NCT01377467|DRUG|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
219397476|NCT04348721|OTHER|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
219397477|NCT00800761|DRUG|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
219397478|NCT00800761|DRUG|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
219397479|NCT02838550|BEHAVIORAL|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
219397480|NCT02838550|BEHAVIORAL|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
219397481|NCT06102161|PROCEDURE|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
219397482|NCT03138915|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
219397483|NCT03138915|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
219397484|NCT05546788|PROCEDURE|scaling and root planing|subgingival Depridement
219397485|NCT05546788|DRUG|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
219397486|NCT05546788|DRUG|chlorhexidine|Received chlorhexidine gel
219397487|NCT05546788|DRUG|placebo|Received placebo gel
219397488|NCT05340400|OTHER|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
219397489|NCT01415440|DRUG|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
219397490|NCT01415440|DRUG|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
219397491|NCT01233219|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
219397492|NCT00620204|DRUG|atorvastatin|atorvastatin 40mg qd for 1 year
219397493|NCT01354691|DRUG|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
219397494|NCT02958137|PROCEDURE|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
219397495|NCT05707845|DRUG|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
219397496|NCT05707845|BEHAVIORAL|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
219397497|NCT05707845|OTHER|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
219397498|NCT04346394|DRUG|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
219397499|NCT05629416|BEHAVIORAL|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
219001771|NCT02031666|DRUG|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
219397500|NCT06671028|DRUG|Ropivacaine and Lidocaine|Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
219397501|NCT06671028|DRUG|Ropivacaine 0,5%|Popliteal sciatic block using ropivacaine 0.5% 20 mL
219397502|NCT06671145|DIAGNOSTIC_TEST|catheter ablation|Catheter ablation after differentiating Atrioventricular Nodal Reentry Tachycardia from Orthodromic Atrioventricular Reentry Tachycardia during electrophysiological study.
219397503|NCT06671288|OTHER|Balloon-blowing exercises with abdominal & lumbar core muscle activation position.|"Patients in this group will recieve Balloon-blowing exercises with abdominal and lumbar core muscles activation position Total 4 weeks protocol will be followed in which 3 sessions per week will be supervised by physical therapist.~FREQUENCY: 3 times a week, INTENSITY : Moderate, TIME: 4 sets of balloon-blowing with 1 min rest (30 mins) TYPE: Balloon-blowing with abdominal \& lumbar core muscle activation position, DURATION : 4 weeks"
219397504|NCT06671288|OTHER|Diaphragmatic breathing exercise|Participants in this group will only be receiving diaphragmatic breathing exercise for 4 weeks. FREQUENCY: 3 times a week , INTENSITY: Moderate, TIME: 4 sets of diaphragmatic breathing with 1 min rest, TYPE: Diaphragmatic breathing, DURATION: 4 weeks
219397505|NCT06672640|BEHAVIORAL|Remote Exercise Program|Participants in this group will engage in an eight-week exercise program conducted via video conferencing software. The sessions, which focus on balance, lower limb strength, and gait function, will be held twice weekly for 50 minutes each. Licensed physical therapists will supervise the sessions, and participants will exercise at home, with assistance from caregivers if necessary. The program aims to evaluate the effectiveness of remote exercise interventions in improving physical function and reducing the risk of falls in pre-frail older adults.
219397506|NCT06672640|BEHAVIORAL|In-Person Exercise Program|Participants in this group will take part in an eight-week in-person exercise program at a senior welfare center. The sessions will be held twice weekly for 50 minutes and will be led by a licensed physical therapist. The exercise program, which includes balance, lower limb strength, and gait training, is identical to that of the remote exercise group, with the primary difference being the mode of delivery (in-person at the welfare center). This group aims to assess the effectiveness of direct supervision in a controlled environment.
219562600|NCT04232527|DIAGNOSTIC_TEST|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
219562601|NCT04232527|DIAGNOSTIC_TEST|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
219562602|NCT04232527|DIAGNOSTIC_TEST|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
219562603|NCT04232527|DIAGNOSTIC_TEST|S_CODS (change of direction speed) Test|S\_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
219562604|NCT05857917|DEVICE|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
219562605|NCT03417206|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
219562606|NCT03417206|DEVICE|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
219562607|NCT01744964|DRUG|Apomorphine|1.5 mg Apomorphine
219562608|NCT04167384|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
219562609|NCT04167384|OTHER|Product B|Nicorette® Mint 4 mg nicotine lozenge
219562610|NCT04167384|OTHER|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
219562611|NCT04167384|OTHER|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
219562612|NCT04167384|OTHER|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
219562613|NCT04167384|OTHER|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
219562614|NCT04167384|OTHER|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
219562615|NCT04167384|OTHER|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
219562616|NCT03225352|DRUG|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
219562617|NCT03225352|DRUG|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
219562618|NCT03225352|DRUG|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
219562619|NCT03225352|DRUG|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
219562620|NCT02845011|DEVICE|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
219562621|NCT02845011|OTHER|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
219001772|NCT01384760|BEHAVIORAL|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
219562622|NCT06616649|DEVICE|Spinal cord stimulator implant|Participants will receive intervention in the operating room setting
219562623|NCT05757037|DEVICE|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
219562624|NCT01618487|PROCEDURE|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
219397507|NCT06672640|OTHER|Physical Activity Education|Participants in this group will receive educational materials about physical activity, including a booklet and one educational session. They will not participate in any structured exercise program but will be encouraged to maintain their usual activities. The control group serves as a baseline to compare the outcomes of exercise interventions against no structured exercise, focusing on evaluating usual care versus targeted exercise programs.
219397508|NCT06673030|BEHAVIORAL|Using Kaleidoscope glasses during pulpotomy procedures|Kaleidoscope is an instrument that shows an infinite number of fascinating geometric shapes in the form of a flower, repeating and reflecting images of coloured goggle fragments in the front section in a prism mirroring the inner surface.
219397509|NCT06673030|BEHAVIORAL|The Play-Doh Doctor Drill 'n Fill toy set|Consists of a plastic human head with slots into which Play-doh molded teeth can be inserted. A battery operated toy drill is used to drill into and clean the black, cavitated tooth model and filled with white Play-Doh compound to simulate cavity preparation and restoration using tooth colored cement.
219397510|NCT06673030|OTHER|Group 1 (Tell-Show-Do)|"In which Tell-Show-Do technique was done in three stages:~* Tell: The dental procedures were explained to the children using language and expressions appropriate for their age.~* Show: This began with showing the child the instruments and the topical anesthetic gel, high-speed handpiece and explaining the purpose of using the handpiece. and how the water removed using the suction device.~* Do: Performing the dental procedure immediately."
219397511|NCT06672796|OTHER|Resisted Toe Spread Out Exercise|new resistance exercise phase in addition to the standard protocol
219397512|NCT06672796|OTHER|Toe Spread Out Exercise|Standart protocol of toe spread out exercise
219397513|NCT06672796|OTHER|Stretching exercise|Toe stretching
219397514|NCT02160977|PROCEDURE|total knee arthroplasty|
219397515|NCT02977091|OTHER|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
219397516|NCT00827268|BEHAVIORAL|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
219397517|NCT00049413|BIOLOGICAL|rituximab|
219397518|NCT00049413|DRUG|cyclophosphamide|
219397519|NCT00049413|DRUG|pentostatin|
219397520|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
219397521|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
219397522|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
219397523|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
219397524|NCT03461692|DRUG|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
219397525|NCT03250520|DRUG|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
219397526|NCT01483573|OTHER|neural mobilization|stretch the nerve
219397527|NCT01483573|OTHER|straight leg raise|stretch the hamstring
219397528|NCT05392322|OTHER|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
219001773|NCT01384760|BEHAVIORAL|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
219001774|NCT00000752|DRUG|Pseudoephedrine hydrochloride|
219001775|NCT00000752|DRUG|Guaifenesin|
219001776|NCT00000752|DRUG|Cefuroxime axetil|
219001777|NCT00000752|DRUG|Beclomethasone dipropionate|
219397529|NCT05392322|DEVICE|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
219397530|NCT00410280|BIOLOGICAL|IMA-638 is a biologic|
219397531|NCT03344159|DRUG|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
219397532|NCT03344159|DRUG|Placebo|Placebo daily for a total of duration of 12 weeks
219397533|NCT03344159|RADIATION|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
219397534|NCT03344159|DIAGNOSTIC_TEST|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
219397535|NCT05060991|DRUG|Reduction in antimetabolite immunosuppression|Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
219397536|NCT04207853|OTHER|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
219562625|NCT01618487|PROCEDURE|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
219397537|NCT04207853|OTHER|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
219397538|NCT04207853|OTHER|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
219397539|NCT04207853|OTHER|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
219397540|NCT03408574|DRUG|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
219397541|NCT04359823|DRUG|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
219397542|NCT04359823|DRUG|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
219397543|NCT01073345|PROCEDURE|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
219397544|NCT01073345|PROCEDURE|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
219397545|NCT01073345|PROCEDURE|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
219397546|NCT01437670|DRUG|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
219397547|NCT00928616|DIETARY_SUPPLEMENT|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
219397548|NCT00928616|DIETARY_SUPPLEMENT|margarine (placebo)|non-sterol ester supplemented margarine
219397549|NCT02471248|DEVICE|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
219397550|NCT02471248|DEVICE|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
219397551|NCT05493865|BEHAVIORAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
219562626|NCT01618487|PROCEDURE|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
219562627|NCT01874977|BEHAVIORAL|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
219562628|NCT01874977|BEHAVIORAL|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
219562629|NCT01874977|BEHAVIORAL|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
219397552|NCT00021697|DRUG|AVP-923|
219562630|NCT01747577|DRUG|Solifenacin Succinate|Oral
219397553|NCT03700008|DIAGNOSTIC_TEST|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
219397554|NCT03700008|DIAGNOSTIC_TEST|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
219397555|NCT04463329|PROCEDURE|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
219397556|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
219397557|NCT04893746|DIETARY_SUPPLEMENT|Maltodextrin|0x1010 CFU/day
219397558|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
219397559|NCT01253512|DRUG|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
219397560|NCT01253512|DRUG|Placebo|Intravenous
219397561|NCT00219336|BEHAVIORAL|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
219562631|NCT01747577|DRUG|Placebo|Oral
219562632|NCT00985231|DEVICE|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
219562633|NCT00985231|DEVICE|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
219562634|NCT03869294|DRUG|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
219562635|NCT04491695|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
219562636|NCT04491695|DRUG|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
219562637|NCT05622994|DRUG|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
219562638|NCT05704673|DRUG|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
219562639|NCT05014880|BEHAVIORAL|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
219562640|NCT05014880|BEHAVIORAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
219562641|NCT06149091|DRUG|Tranexamic Acid；|Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
219562642|NCT06149091|DRUG|Adrenalin|In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
219562643|NCT06149091|DRUG|Hemagglutinase|Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
219397562|NCT00219336|BEHAVIORAL|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
219562644|NCT05321875|DRUG|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
219397563|NCT04220489|DRUG|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
219397564|NCT04220489|DRUG|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
219397565|NCT02338076|DRUG|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
219397566|NCT00269074|DRUG|IDEA-070|
219397567|NCT00408421|DRUG|Duloxetine|
219397568|NCT00408421|DRUG|placebo|
219397569|NCT00457054|DRUG|Lithium|starting dose 600 mg increase as tolerated
219397570|NCT01979796|DEVICE|Ecig 24 mg nicotine|Cigalike
219562645|NCT02861833|OTHER|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
219397571|NCT01979796|DEVICE|Ecig 0 mg nicotine|Cigalike
219562646|NCT02221440|DEVICE|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
219397572|NCT01979796|DEVICE|Nicotine free inhalator|Plastic CIG a Like
219397573|NCT02772965|DRUG|Methotrexate|"1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
219397574|NCT02772965|OTHER|Sugar pill (placebo)|"1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
219397575|NCT05365620|DEVICE|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
219397576|NCT05365620|PROCEDURE|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
219397577|NCT05608317|DEVICE|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer"
219397578|NCT03919916|PROCEDURE|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
219397579|NCT03919916|OTHER|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
219397580|NCT01477151|DRUG|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
219397581|NCT00664092|OTHER|Residential|living in a democratic, resident-run setting
219397582|NCT00664092|OTHER|Residential|Professionally-run substance abuse recovery setting
219397583|NCT04339569|DIAGNOSTIC_TEST|Biomechanical analysis|3D analysis of landing manoeuvres.
219001778|NCT00102726|DRUG|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
219397584|NCT04339569|OTHER|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
219397585|NCT02254668|OTHER|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
219397586|NCT02254668|OTHER|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
219562647|NCT02221440|DEVICE|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
219562648|NCT02010996|PROCEDURE|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
219562649|NCT02010996|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
219001779|NCT00102726|OTHER|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
219397587|NCT04031170|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
219562650|NCT03285919|DEVICE|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
219562651|NCT00732524|DRUG|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
219562652|NCT00732524|DRUG|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
219562653|NCT01642563|PROCEDURE|Platelet transfusion|One dose of pathogen reduced platelets
219562654|NCT01642563|PROCEDURE|Platelet transfusion|One dose of standard platelets
219562655|NCT06353412|PROCEDURE|Lumbar puncture|Medical treatment Lumbar puncture Theco peritoneal shunt
219562656|NCT04316195|DIAGNOSTIC_TEST|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
219562657|NCT03184012|DEVICE|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
219562658|NCT03184012|DEVICE|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
219562659|NCT06127745|DEVICE|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
219562660|NCT02466334|DRUG|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
219562661|NCT02466334|DRUG|Placebo|40 ml of normal saline over 20 mins
219562662|NCT02775539|DRUG|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
219562663|NCT02775539|DRUG|Placebo|
219562664|NCT00456482|DRUG|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
219562665|NCT00456482|DRUG|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
219001780|NCT00963547|DRUG|MK-2206|\[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
219001781|NCT00963547|BIOLOGICAL|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
219001782|NCT00963547|DRUG|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
219001783|NCT05367648|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
219001784|NCT05367648|OTHER|Placebo|Placebo comparator
219397588|NCT04031170|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
219562666|NCT04079582|OTHER|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
219562667|NCT04079582|OTHER|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
219562668|NCT04035382|PROCEDURE|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
219562669|NCT04347330|DRUG|Intensive BP Control|Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
219562670|NCT04347330|DRUG|Standard BP Control|Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
219562671|NCT05103657|DRUG|BI 1358894|BI 1358894
219562672|NCT05103657|DRUG|Placebo|Placebo
219562673|NCT04366596|DEVICE|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
219562674|NCT04366596|DEVICE|Angioplasty with plain old balloon|Angioplasty with plain old balloon
219397589|NCT04247932|BEHAVIORAL|Active labor market intervention|Behavior change intervention
219562675|NCT05681416|DIAGNOSTIC_TEST|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
219562676|NCT05091216|OTHER|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
219562677|NCT05091216|OTHER|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
219562678|NCT06429514|DIETARY_SUPPLEMENT|Ganoderma lucidum spore powder|One bag at a time, 2 times a day, 2g / bag
219562679|NCT06429514|OTHER|placebo|One bag at a time, 2 times a day, 2g / bag
219562680|NCT01216410|DRUG|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
219397590|NCT03913286|DEVICE|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
219397591|NCT04153812|DEVICE|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
219562681|NCT01216410|DRUG|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
219562682|NCT01216410|DRUG|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
219562683|NCT05530941|BEHAVIORAL|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
219562684|NCT05600023|DRUG|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
219562685|NCT05600023|DRUG|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
219562686|NCT01836614|DRUG|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
219562687|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
219562688|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
219562689|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
219001785|NCT05077397|DEVICE|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
219397592|NCT01997567|DRUG|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
219562690|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
219562691|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
219562692|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
219562693|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
219562694|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
219562695|NCT01418950|OTHER|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
219562696|NCT01614184|DRUG|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
219562697|NCT03635983|BIOLOGICAL|NKTR-214|Specified dose on specified days
219562698|NCT03635983|BIOLOGICAL|Nivolumab|Specified dose on specified days
219562699|NCT04763278|DEVICE|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
219562700|NCT03799848|DRUG|Vadadustat|Oral tablet
219562701|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot A|
219562702|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot B|
219562703|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot C|
219562704|NCT00489099|BIOLOGICAL|V232 Current Process Hepatitis B Vaccine|
219397593|NCT01997567|DRUG|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
219397594|NCT01115946|DRUG|ASP1585|oral
219397595|NCT01115946|DRUG|enalapril|oral
219397596|NCT02022683|DEVICE|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
219397597|NCT01139723|DRUG|MINT1526A|Intravenous escalating dose
219397598|NCT01139723|DRUG|bevacizumab|Intravenous repeating dose
219397599|NCT02815631|DEVICE|Cardiogoniometry (CGM)|
219397600|NCT02815631|DEVICE|Fractional Flow Reserve (FFR)|
219397601|NCT01437631|PROCEDURE|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
219562705|NCT05647616|OTHER|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
219562706|NCT06678750|DEVICE|TKA using computer navigation|TKA using Exactech GPS Newton Knee protocol
219562707|NCT06678750|PROCEDURE|TKA|TKA using manual instrumentation
219562708|NCT04126343|DRUG|Padsevonil|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
219562709|NCT04126343|DRUG|Moxifloxacin|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period"
219562710|NCT04126343|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
219562711|NCT01358084|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
219562712|NCT01358084|DRUG|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
219562713|NCT01358084|OTHER|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
219001786|NCT05077397|DEVICE|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
219001787|NCT00673569|DRUG|erlotinib hydrochloride|
219397602|NCT00733512|DEVICE|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
219397603|NCT01614769|DRUG|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
219397604|NCT01614769|DRUG|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
219397605|NCT01614769|DRUG|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
219397606|NCT01614769|PROCEDURE|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
219397607|NCT04655495|DIETARY_SUPPLEMENT|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet
219397608|NCT03123354|DEVICE|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
219397609|NCT03960138|DEVICE|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
219562714|NCT02389699|RADIATION|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
219562715|NCT02389699|RADIATION|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
219562716|NCT00736398|PROCEDURE|Spinal fusion|Spinal fusion
219562717|NCT02890225|PROCEDURE|3 days after|in 3 days after RIRS.
219562718|NCT02890225|PROCEDURE|10days after|in10 days after RIRS.
219562719|NCT02890225|PROCEDURE|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
219562720|NCT00801294|DRUG|BIBF 1120 and BIBW 2992|
219562721|NCT06525857|OTHER|LTOT|Patients with newly prescribed LTOT will be monitored for physiological changes
219562722|NCT03617120|DEVICE|Ergonomic Brace vs hard brace|"Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation"
219562723|NCT03712124|DRUG|CNSA-001|CNSA-001 Powder for Suspension
219562724|NCT03712124|DRUG|Placebo|Placebo Suspension
219562725|NCT01332721|DRUG|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
219562726|NCT02084927|BIOLOGICAL|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
219562727|NCT02412722|DRUG|Sapanisertib|Sapanisertib capsules
219562728|NCT02412722|DRUG|Paclitaxel|Paclitaxel injection
219562729|NCT03791294|DRUG|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
219397610|NCT03960138|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
219397611|NCT06173492|PROCEDURE|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
219397612|NCT06173492|DEVICE|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
219562730|NCT02941523|DRUG|NOX66|NOX66 administration
219562731|NCT02941523|DRUG|Carboplatin|Carboplatin administration
219562732|NCT04449341|DEVICE|Oculus Go headset with Ocean Rift application|Information already included in arm description
219562733|NCT02118025|PROCEDURE|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
219562734|NCT02118025|PROCEDURE|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
219562735|NCT03837171|BIOLOGICAL|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
219562736|NCT03837171|BIOLOGICAL|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
219562737|NCT04305730|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
219562738|NCT04305730|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
219562739|NCT04499482|OTHER|Food|Soy-fiber containing food
219562740|NCT01057173|PROCEDURE|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
219001788|NCT00673569|GENETIC|gene expression analysis|
219001789|NCT00673569|GENETIC|protein expression analysis|
219001790|NCT00673569|OTHER|immunoenzyme technique|
219562741|NCT01057173|PROCEDURE|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
219562742|NCT02773433|OTHER|Proportional Assist Ventilation|
219001791|NCT00673569|OTHER|immunologic technique|
219001792|NCT00673569|OTHER|laboratory biomarker analysis|
219001793|NCT00673569|PROCEDURE|needle biopsy|
219001794|NCT05006911|DRUG|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
219397613|NCT03903029|DRUG|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
219397614|NCT02169635|PROCEDURE|macular buckle|macular buckle with a three-armed silicone capsule
219397615|NCT00348972|DRUG|Lantus® (insulin glargine)|
219562743|NCT04618939|BIOLOGICAL|BR-TD-1001|0.5 mL, IM
219562744|NCT04618939|BIOLOGICAL|Td-pur inj|0.5 mL, IM
219562745|NCT00006009|BIOLOGICAL|visilizumab|
219562746|NCT03754530|DRUG|Icotinib|orally three times per day
219562747|NCT03754530|RADIATION|WBRT or SRS|\>3 with WBRT;\<=3 with SRS
219562748|NCT00873834|DRUG|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
219562749|NCT00873834|DRUG|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
219562750|NCT01899326|DRUG|Desipramine Hydrochloride|Given PO
219562751|NCT01899326|BIOLOGICAL|Filgrastim|Given PO
219562752|NCT01899326|OTHER|Laboratory Biomarker Analysis|Correlative studies
219562753|NCT02387567|DRUG|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
219562754|NCT02387567|DRUG|Sham Lidocaine|Sham injection, without lidocaine.
219562755|NCT02387567|OTHER|Standard treatment|Standard treatment only, without lidocaine or sham injection.
219562756|NCT02409940|BIOLOGICAL|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
219397616|NCT00711399|DEVICE|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
219562757|NCT01944384|DRUG|aldactone|aldactone 25 mg for 6 months
219562758|NCT00578838|OTHER|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
219562759|NCT00578838|OTHER|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
219562760|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
219562761|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
219562762|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
219562763|NCT00151255|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
219562764|NCT00151255|DRUG|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
219562765|NCT00151255|DRUG|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
219562766|NCT00151255|DRUG|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
219397617|NCT06438913|DRUG|Tezepelumab|Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.
219562767|NCT00151255|DRUG|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
219397618|NCT03572543|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
219397619|NCT03883022|DRUG|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
219562768|NCT04199416|DEVICE|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
219562769|NCT04199416|DEVICE|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
219562770|NCT02079233|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
219562771|NCT00876720|DEVICE|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
219001795|NCT03932227|DEVICE|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
219001796|NCT03932227|DEVICE|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
219397620|NCT03883022|DRUG|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
219562772|NCT00876720|DEVICE|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
219562773|NCT01263561|PROCEDURE|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
219562774|NCT01263561|PROCEDURE|trabeculectomy|trabeculectomy filtering surgery
219562775|NCT02129517|OTHER|IMPACT intervention|Tailored, web-based educational short video clips
219562776|NCT02129517|OTHER|Online education materials|Online NCI-based educational materials
219562777|NCT02129517|OTHER|survey administration|Ancillary studies
219562778|NCT03033524|DRUG|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
219562779|NCT01932190|PROCEDURE|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
219562780|NCT01932190|PROCEDURE|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
219001797|NCT01206608|DRUG|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
219001798|NCT01206608|DRUG|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
219001799|NCT00695487|DRUG|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
219397621|NCT03952897|OTHER|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
219397622|NCT03435991|OTHER|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
219397623|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
219397624|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
219397625|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
219562781|NCT02510950|BIOLOGICAL|Personalized peptide vaccine|
219562782|NCT02510950|DRUG|Poly-ICLC|
219562783|NCT02510950|DRUG|Temozolomide|
219562784|NCT01482117|DRUG|Clopidogrel|single oral administration of 300mg of clopidogrel
219001800|NCT01872988|DRUG|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
219397626|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
219397627|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
219397628|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
219397629|NCT05396066|DIAGNOSTIC_TEST|Muscle evaluation|Repeated maximal voluntary contraction
219562785|NCT01482117|DRUG|Cilostazol|single oral administration of 100mg cilostazol
219562786|NCT01482117|DRUG|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
219562787|NCT05852873|DRUG|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
219562788|NCT05852873|DRUG|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
219562789|NCT05736796|OTHER|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
219562790|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
219397630|NCT00211770|BEHAVIORAL|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
219397631|NCT00428506|DRUG|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
219397632|NCT00428506|DRUG|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
219562791|NCT02687958|DRUG|Everolimus|Maintenance therapy
219001801|NCT01872988|DRUG|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
219397633|NCT02669927|OTHER|Observational|
219562792|NCT03256864|DRUG|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
219562793|NCT05842720|PROCEDURE|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA\>=3
219562794|NCT03942211|DRUG|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
219397634|NCT04202562|PROCEDURE|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
219397635|NCT04202562|PROCEDURE|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
219397636|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
219397637|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
219562795|NCT03942211|DRUG|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
219562796|NCT04552028|OTHER|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
219562797|NCT06615947|DEVICE|Robotic gait training|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
219001802|NCT01654341|BEHAVIORAL|Exercise, dietary and educational program|
219001803|NCT03776383|OTHER|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
219001804|NCT00557960|DRUG|Mixed salts of a single-entity amphetamine|
219397638|NCT01635751|DRUG|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
219397639|NCT03601416|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
219397640|NCT03601416|DRUG|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
219397641|NCT04442958|OTHER|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
219397642|NCT03799003|DRUG|ASP1951|Intravenously (IV)
219001805|NCT00557960|DRUG|Atomoxetine hydrochloride|
219397643|NCT03799003|DRUG|pembrolizumab|Intravenously (IV)
219397644|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
219397645|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
219397646|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
219397647|NCT06031467|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
219562798|NCT06615947|OTHER|tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
219562799|NCT02587806|BIOLOGICAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
219562800|NCT02587806|OTHER|Liberation therapy|
219562801|NCT02913820|OTHER|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
219562802|NCT00200655|DRUG|Pravastatin|
219562803|NCT00200655|DRUG|Placebo|
219562804|NCT00170703|DEVICE|Cortical Electrical Stimulation|
219562805|NCT01396421|DRUG|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
219562806|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
219562807|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
219562808|NCT01396421|DRUG|Placebo|Placebo, once daily, for six weeks
219562809|NCT04881513|DIAGNOSTIC_TEST|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
219562810|NCT04881513|DIAGNOSTIC_TEST|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
219562811|NCT04881513|OTHER|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
219001806|NCT00928603|PROCEDURE|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
219001807|NCT00660023|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
219397648|NCT06031467|DEVICE|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
219397649|NCT04417088|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
219397650|NCT04417088|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
219397651|NCT02421120|DRUG|Ceftolozane/Tazobactam|1 hour intravenous infusion
219397652|NCT02996695|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
219397653|NCT02996695|DRUG|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
219397654|NCT02996695|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
219397655|NCT02996695|OTHER|Placebo|Placebo
219397656|NCT01523119|DRUG|Ondansetron|Orally Disintegrating Tablets 8 mg
219562812|NCT04881513|DIAGNOSTIC_TEST|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
219562813|NCT04881513|DIAGNOSTIC_TEST|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
219562814|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
219397657|NCT04099056|DEVICE|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
219189292|NCT05233150|BEHAVIORAL|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
219397658|NCT03962049|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
219397659|NCT04737122|DRUG|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
219397660|NCT04737122|DRUG|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
219397661|NCT00455546|DRUG|A-002|
219562815|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
219189293|NCT05928052|DEVICE|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
219189294|NCT04813055|PROCEDURE|Therapeutic EUS|"1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage"
219189295|NCT04813055|PROCEDURE|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
219189296|NCT04813055|PROCEDURE|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
219189297|NCT04813055|PROCEDURE|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
219189298|NCT02808208|BIOLOGICAL|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
219189299|NCT02808208|DRUG|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
219189300|NCT02808208|BIOLOGICAL|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
219189301|NCT05195281|PROCEDURE|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
219189302|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
219189303|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
219189304|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
219189305|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
219189306|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
219189307|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
219189308|NCT05928585|DRUG|HIB210|Experimental monoclonal antibody
219189309|NCT05928585|DRUG|Placebo|Placebo
219189310|NCT04231331|DRUG|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
219562816|NCT06403813|OTHER|Control Tooklit|The toolkit will have the same screening questions, with information, but without any decision support functions.
219189311|NCT04231331|DRUG|Placebo|Placebo qd for 12 months
219189312|NCT05295732|DRUG|TMB-001|Topical TMB-001 0.05% QD/BID
219189313|NCT05295732|DRUG|Matching Vehicle|Topical Vehicle
219189314|NCT03746106|DRUG|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
219189315|NCT03746106|DRUG|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
219189316|NCT03746106|DIETARY_SUPPLEMENT|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
219189317|NCT03026517|DRUG|Dabrafenib|
219189318|NCT03026517|DRUG|Trametinib|
219189319|NCT03026517|DRUG|Phenformin|
219189320|NCT05665881|DRUG|Ephedrine|vasopressor
219189321|NCT05665881|DRUG|Phenylephrine|vasopressor
219189322|NCT05665881|DRUG|Norepinephrine|vasopressor
219189323|NCT05236647|DRUG|Morphine|Intravenous morphine infusion compared to subcutaneous morphine infusion
219189324|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
219189325|NCT05084430|DRUG|M032|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
219189326|NCT05084430|DRUG|Pembrolizumab|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
219189327|NCT03028402|PROCEDURE|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
219189328|NCT06440395|BEHAVIORAL|Behavioural: Small Steps for Big Changes Diabetes Prevention Program|The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
219189329|NCT06597617|BEHAVIORAL|Adapted physical activity with aerobic training [GEA]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions."
219189330|NCT06597617|BEHAVIORAL|Adapted physical activity with strength training [GRM]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity."
219189331|NCT06800079|OTHER|EBT|Elastic Band Resistance Training
219189332|NCT04258033|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
219189333|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
219189334|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
219397662|NCT02345161|DRUG|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
219397663|NCT02345161|DRUG|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
219397664|NCT02345161|DRUG|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
219001808|NCT04097002|BIOLOGICAL|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
219397665|NCT02345161|DRUG|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
219397666|NCT02345161|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
219397667|NCT00230581|DRUG|DDP225|
219397668|NCT05269134|DRUG|Bacteriophage|Phage Therapy
219397669|NCT05269134|DRUG|Placebo|Placebo
219397670|NCT04151381|DRUG|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
219397671|NCT04012268|DEVICE|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219397672|NCT04012268|DRUG|Aspirin|patients will accept medication guided by neurologists
219562817|NCT04718129|BEHAVIORAL|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
219562818|NCT03591731|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
219562819|NCT03591731|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
219562820|NCT00684801|OTHER|questionnaire administration|Patients complete questionnaires.
219562821|NCT00684801|PROCEDURE|quality-of-life assessment|Patients undergo quality-of-life assessments.
219397673|NCT00003264|DRUG|cisplatin|
219397674|NCT00003264|DRUG|gemcitabine hydrochloride|
219397675|NCT04364074|DIETARY_SUPPLEMENT|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
219397676|NCT04364074|DIETARY_SUPPLEMENT|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
219562822|NCT00942721|BEHAVIORAL|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
219562823|NCT04087863|OTHER|Not applicable(observational study)|Not applicable(observational study)
219397677|NCT00763685|DRUG|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
219001809|NCT04883502|BIOLOGICAL|Blood sample collection|A blood sample will be collected at enrollment.
219397678|NCT01573208|DEVICE|Custom guides|Symbios custom guides for TKA
219397679|NCT05603624|PROCEDURE|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
219397680|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
219397681|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
219397682|NCT00322595|DRUG|Quetiapine fumarate|
219397683|NCT00322595|DRUG|Paroxetine|
219397684|NCT05367687|DRUG|Camrelizumab、Rivoceranib|Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
219397685|NCT05367687|DRUG|Camrelizumab|Camrelizumab: 200 mg, intravenous infusion.
219397686|NCT03554005|DRUG|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
219397687|NCT03554005|DRUG|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
219562824|NCT05548335|PROCEDURE|Ocular Ultrasound|1\. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
219562825|NCT05762653|DIAGNOSTIC_TEST|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
219562826|NCT02196467|BIOLOGICAL|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
219397688|NCT02606045|DRUG|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
219397689|NCT02606045|DRUG|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
219397690|NCT05690412|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
219397691|NCT00856271|DRUG|olmesartan medoxomil|oral tablets, once daily for 8 weeks
219397692|NCT00856271|DRUG|losartan potassium|capsules, once daily for 8 weeks
219562827|NCT02196467|PROCEDURE|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
219562828|NCT02030535|DRUG|olodaterol|free combination with tiotropium
219562829|NCT02030535|DRUG|tiotropium|free combination with olodaterol
219562830|NCT02030535|DRUG|Placebo|
219562831|NCT02030535|DRUG|tiotropium|fixed dose combination with olodaterol
219562832|NCT02030535|DRUG|olodaterol|fixed dose combination with tiotropium
219562833|NCT01878864|DRUG|Bupivacaine lozenge|
219562834|NCT01878864|DRUG|Lidocaine-adrenalin injection|
219562835|NCT01166464|BEHAVIORAL|text messaging for smoking cessation|A 7-week program of daily text messages
219562836|NCT01166464|BEHAVIORAL|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
219562837|NCT01588548|DRUG|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
219562838|NCT00998595|OTHER|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
219562839|NCT05729854|OTHER|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
219562840|NCT03764657|PROCEDURE|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
219562841|NCT03764657|PROCEDURE|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
219562842|NCT01275716|BEHAVIORAL|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
219562843|NCT02886676|DRUG|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
219562844|NCT01835548|DRUG|NT0102|NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
219562845|NCT01835548|DRUG|Placebo|Matching ODT placebo was given once daily.
219562846|NCT00844870|BEHAVIORAL|stabilization training|training of arm function with the trunk stabilized
219562847|NCT00844870|BEHAVIORAL|auditory training group|response to an auditory signal
219397693|NCT00907881|DRUG|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
219397694|NCT04344405|DRUG|Vitamin D|vitamin D supplementation
219397695|NCT04344405|DRUG|Steroid Drug|control
219562848|NCT02248012|DRUG|Everolimus , temozolomide|
219562849|NCT03257254|DRUG|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
219562850|NCT05389241|OTHER|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
219562851|NCT05389241|OTHER|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
219397696|NCT06642337|OTHER|Educational program +Oral Iron therapy|The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
219397697|NCT03440372|DRUG|Ozanimod|Specified dose on specified days
219397698|NCT03440372|OTHER|Placebo|Specified dose on specified days
219397699|NCT06527378|DIAGNOSTIC_TEST|AI in implant planning|Assessment of Current Technology for Supporting Implant Planning
219397700|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
219397701|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
219397702|NCT03965988|DRUG|DHA|Docosahexaenoic acid
219397703|NCT03965988|DRUG|Placebo|Placebo
219397704|NCT00050349|DRUG|EPO906 epothilone B|
219397705|NCT00483249|DEVICE|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
219397706|NCT03552705|DRUG|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
219397707|NCT03552705|DRUG|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
219397708|NCT05772650|BEHAVIORAL|e-Health Program|Lifestyle modification for health and disease management using digital solutions
219397709|NCT01266707|BIOLOGICAL|antiangiogenic paptide vaccine|for drugs include administration time frame
219397710|NCT05653778|DEVICE|Scrambler therapy|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
219397711|NCT05653778|DEVICE|TENS treatment|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
219397712|NCT01038284|BEHAVIORAL|Patient education|Pharmaceutical care of patients with PAH
219562852|NCT03977441|DRUG|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
219562853|NCT05772286|BIOLOGICAL|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
219562854|NCT01673841|PROCEDURE|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
219562855|NCT05093686|BEHAVIORAL|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
219397713|NCT01038284|OTHER|Data collection|Clinical and biological data, treatment, medication errors and ADEs
219562856|NCT05093686|BEHAVIORAL|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
219397714|NCT04332341|DRUG|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
219397715|NCT02597842|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
219397716|NCT01313104|PROCEDURE|colposcopy|Undergo colposcopy
219397717|NCT01313104|OTHER|cervical Papanicolaou test|Undergo cervical Pap smear
219397718|NCT01313104|PROCEDURE|screening method|Undergo anal Pap smear
219397719|NCT01313104|PROCEDURE|screening method|Undergo high resolution anoscopy
219397720|NCT02717871|DEVICE|PACK-CXL|"Local anesthesia~\- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~\- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
219397721|NCT02717871|DRUG|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
219397722|NCT02717871|DRUG|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
219397723|NCT02717871|DRUG|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
219397724|NCT02717871|DRUG|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
219397725|NCT01530399|DRUG|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
219397726|NCT01530399|DRUG|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
219397727|NCT01530399|DRUG|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
219397728|NCT01530399|DRUG|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
219397729|NCT01530399|DRUG|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
219397730|NCT01530399|DRUG|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
219397731|NCT01515982|BEHAVIORAL|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
219397732|NCT01515982|BEHAVIORAL|Control Group|All participants were asked not to commence any new exercise regimen.
219397733|NCT03215264|DRUG|hydroxychloroquine|600-1200mg daily
219397734|NCT03215264|DRUG|entinostat|3-5mg weekly
219397735|NCT03215264|DRUG|regorafenib|160mg daily
219397736|NCT01977209|DRUG|Gossypol|
219397737|NCT01977209|DRUG|Placebo|
219397738|NCT03803540|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
219397739|NCT02819648|DRUG|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
219397740|NCT02819648|OTHER|Control|Milk Tablet
219397741|NCT02629601|BEHAVIORAL|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
219397742|NCT02629601|BEHAVIORAL|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
219397743|NCT02629601|BEHAVIORAL|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
219397744|NCT02629601|BEHAVIORAL|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
219397745|NCT02629601|BEHAVIORAL|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
219397746|NCT02680223|DEVICE|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
219397747|NCT02680223|DEVICE|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
219397748|NCT01740440|DEVICE|BMR Face|BMR Face used in accordance with manufacturer IFU
219397749|NCT05178953|DRUG|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
219397750|NCT05178953|DRUG|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
219397751|NCT03914287|OTHER|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
219397752|NCT00008294|DRUG|FOLFOX regimen|
219397753|NCT00008294|DRUG|dexamethasone|
219397754|NCT00008294|DRUG|floxuridine|
219397755|NCT00008294|DRUG|fluorouracil|
219397756|NCT00008294|DRUG|leucovorin calcium|
219397757|NCT00008294|DRUG|oxaliplatin|
219397758|NCT05635552|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
219397759|NCT05635552|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
219397760|NCT05635552|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
219397761|NCT05635552|DIAGNOSTIC_TEST|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
219397762|NCT05635552|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
219397763|NCT03378011|OTHER|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
219397764|NCT01680419|BEHAVIORAL|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
219397765|NCT01680419|BEHAVIORAL|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
219397766|NCT04362579|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
219397767|NCT00908297|DIETARY_SUPPLEMENT|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~* 300 mg for two weeks~* 600 mg for two weeks~* 1200 mg for two weeks~* 1800 mg for final two weeks"
219397768|NCT04635696|DRUG|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
219397769|NCT04635696|OTHER|Tissue culture grade water|Pressurized water mist
219397770|NCT02223221|PROCEDURE|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
219397771|NCT02223221|GENETIC|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
219397772|NCT02223221|OTHER|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
219397773|NCT04729088|DRUG|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
219397774|NCT04998045|BEHAVIORAL|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
219397775|NCT04220632|DRUG|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
219397776|NCT04220632|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
219397777|NCT04220632|DRUG|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
219397778|NCT00614666|DRUG|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~* 50 mg BID (n=4) vs placebo capsule BID (n=1)~* 50 mg BID (n=4) vs 250 mg BID (n=4) vs Placebo capsule BID (n=2)~* 250 mg BID (n=4) vs 500 mg BID (n=4) vs Placebo capsule BID (n=2)~* 500 mg BID (n=4) vs Placebo capsule BID (n=1)~At least 4 subjects complete lower dose before randomization includes next higher dose.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
219397779|NCT00614666|DRUG|Placebo|Placebo comparator
219397780|NCT05912959|OTHER|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
219397781|NCT05083780|DRUG|Chlorphenesin Carbamate, Hydroxychloroquine|In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
219397782|NCT00000455|DRUG|naltrexone|
219397783|NCT02998892|BEHAVIORAL|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
219397784|NCT02998892|BEHAVIORAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
219397785|NCT03408873|DRUG|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
219397786|NCT03408873|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
219397787|NCT02990481|BIOLOGICAL|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
219397788|NCT02990481|BIOLOGICAL|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
219397789|NCT02990481|BIOLOGICAL|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
219397790|NCT01806870|DIETARY_SUPPLEMENT|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
219397791|NCT01600131|BEHAVIORAL|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
219397792|NCT01600131|OTHER|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
219397793|NCT01792622|OTHER|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
219397794|NCT01792622|OTHER|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
219397795|NCT00495560|DRUG|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
219397796|NCT03799718|BIOLOGICAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
219397797|NCT06250530|PROCEDURE|High tibial osteotomy using TOMOFIX|TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
219397798|NCT06250530|PROCEDURE|High tibial osteotomy using BodyCAD|BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
219397799|NCT00748826|BIOLOGICAL|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
219397800|NCT00819624|OTHER|Interactive Voice Response System (IVRS)|Telephone based system
219397801|NCT00819624|OTHER|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
219397802|NCT02214186|OTHER|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
219001810|NCT04883502|BIOLOGICAL|Other biological sample collection|"The following biological samples will be collected during the first surgery:~* 1 blood sample~* 3 fragments of induced membrane~* 1 fragment of periosteum"
219397803|NCT02754934|OTHER|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
219397804|NCT02353351|DEVICE|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
219397805|NCT02446054|DIETARY_SUPPLEMENT|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
219397806|NCT03407924|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
219397807|NCT03407924|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
219397808|NCT00904241|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219397809|NCT00904241|OTHER|Laboratory Biomarker Analysis|Correlative studies
219397810|NCT05357313|DEVICE|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
219397811|NCT05357313|DEVICE|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
219397812|NCT01651052|PROCEDURE|Heart Valve Surgery|Implant of an aortic valve, Model 11000
219397813|NCT02560701|OTHER|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
219397814|NCT02997020|OTHER|EDSPD|The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
219397815|NCT05748925|DRUG|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
219397816|NCT05748925|DRUG|placebo|Control group: will be maintained on their medication
219397817|NCT04855877|DRUG|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
219562857|NCT02966158|OTHER|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
219562858|NCT01886534|OTHER|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
219562859|NCT01886534|BEHAVIORAL|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
219562860|NCT01886534|OTHER|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
219562861|NCT01886534|OTHER|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
219562862|NCT01886534|OTHER|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
219562863|NCT04333134|DRUG|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
219397818|NCT04855877|DRUG|Placebo|Oral administration of lactose tablet (placebo)
219397819|NCT05942274|DIAGNOSTIC_TEST|We propose to validate these smartwatch ECG functions to support FDA submissions|1\) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
219397820|NCT05632133|DRUG|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
219397821|NCT05632133|DRUG|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
219397822|NCT00153634|DRUG|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
219397823|NCT00153634|DRUG|PO azithromycin|250 mg once daily
219397824|NCT00153634|DRUG|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
219397825|NCT00153634|DRUG|PO ciprofloxacin|500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
219397826|NCT00153634|DRUG|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
219397827|NCT00153634|DRUG|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
219397828|NCT00153634|DRUG|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
219001811|NCT04883502|DIAGNOSTIC_TEST|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
219001812|NCT04883502|DIAGNOSTIC_TEST|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
219001813|NCT06040060|DRUG|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
219001814|NCT06040060|OTHER|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
219001815|NCT02430311|DRUG|Olaparib|Tablet-150mg, Oral
219001816|NCT02430311|DRUG|Paclitaxel|Injection
219001817|NCT02430311|DRUG|Olaparib|Tablet-100mg, Oral
219001818|NCT04180488|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219001819|NCT04180488|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219001820|NCT04180488|DRUG|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
219001821|NCT00286169|DRUG|Amrubicin Hydrochloride|
219001822|NCT03506815|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
219001823|NCT01502449|BEHAVIORAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
219001824|NCT01502449|OTHER|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
219001825|NCT04497805|BIOLOGICAL|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
219001826|NCT00471068|DRUG|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
219001827|NCT00471068|DRUG|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
219001828|NCT00471068|DRUG|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
219001829|NCT06037395|BIOLOGICAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
219001830|NCT06037395|BIOLOGICAL|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
219001831|NCT05062798|PROCEDURE|Standart bottle|"1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
219001832|NCT05062798|PROCEDURE|Squeezable bottle|"1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
219001833|NCT02656784|BEHAVIORAL|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
219001834|NCT02656784|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
219001835|NCT02681562|DRUG|olaparib|
219001836|NCT01003730|OTHER|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
219001837|NCT04160091|DRUG|FX006|Single intra-articular injection
219001838|NCT04160091|DRUG|Normal Saline|Single intra-articular injection
219001839|NCT04458974|DEVICE|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
219001840|NCT04458974|PROCEDURE|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
219562864|NCT00568711|DRUG|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
219001841|NCT05486676|BEHAVIORAL|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
219001842|NCT02998593|DRUG|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
219001843|NCT02998593|DRUG|Placebo|Oral use of placebo capsules by patients for 3 months.
219001844|NCT00281255|DRUG|Allopurinol|
219001845|NCT00281255|DRUG|Dobutamine|
219001846|NCT04113304|BEHAVIORAL|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
219562865|NCT00568711|DRUG|rifampin|a 5-day course of daily 600-mg doses of rifampin
219562866|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~\--------------------------------------------------------------------------------"
219001847|NCT04250870|DIAGNOSTIC_TEST|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
219001848|NCT06227845|OTHER|Fecal microbiota transplant|0.1-0.3 ml liquid containing 3.5 mg/ml of maternal fecal content, (0.35mg/kg)
219001849|NCT06278467|DIAGNOSTIC_TEST|visual pain scale (VASpain/fatigue), Beck depression index (BDI),|VAS (0-10)
219001850|NCT06278467|DIAGNOSTIC_TEST|Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire|PCS (Pain catastrophizing scale); sleep quality with a single Likert type question in the Pittsburgh questionnaire (0-3)
219562867|NCT02076516|DEVICE|Drug-eluting stent: CORACTO®|
219562868|NCT01900457|OTHER|electromyography|
219001851|NCT06278467|DIAGNOSTIC_TEST|Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36),|functional disability level with Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36)
219001852|NCT06278467|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT)|cognitive status was measured by Montreal Cognitive Assessment Scale (MOCA) and Standard Mini mental test (SMMT)
219001853|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
219001854|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
219001855|NCT01842698|DEVICE|ultrasoundguided paravertebral catheter|
219001856|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
219001857|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
219001858|NCT01393704|DRUG|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
219001859|NCT03458273|PROCEDURE|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
219001860|NCT03458273|PROCEDURE|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
219001861|NCT03458273|PROCEDURE|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
219001862|NCT05830591|OTHER|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
219001863|NCT03675698|OTHER|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
219001864|NCT04684498|DRUG|Oseltamivir phosphate capsules|Treatment group vs. Control group
219001865|NCT06194565|DRUG|99mTc-ABH2|Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
219001866|NCT05647434|PROCEDURE|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
219001867|NCT04755127|PROCEDURE|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
219001868|NCT04755127|DRUG|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
219001869|NCT05822713|DRUG|Amisulpride|5mg/2ml
219001870|NCT05822713|DRUG|Amisulpride Placebo|2ml
219001871|NCT02877615|DRUG|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
219001872|NCT02877615|DRUG|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
219001873|NCT02877615|DRUG|Placebo|Two sachets of placebo twice a day
219001874|NCT01023230|DRUG|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
219001875|NCT01023230|DRUG|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
219001876|NCT06408532|DRUG|IDegLira|The participants in this group will be switched to IDegLira once daily injection therapy.
219001877|NCT06408532|DRUG|Premixed insulin|The participants in this group will be have optimized premixed insulin regimen.
219001878|NCT01804296|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
219562869|NCT01900457|OTHER|electroencephalography|
219562870|NCT01900457|OTHER|approaches from psychophysics|
219562871|NCT06905496|DRUG|High-Dose|Caffeine
219562872|NCT06905496|DRUG|Low Dose|Caffeine citrate is a combination of caffeine and citric acid, commonly used as a central nervous system stimulant. It is primarily used to treat apnea of prematurity in neonates.
219189335|NCT05935228|OTHER|Implementation of the A-DIVA Scale|Phase 2 aims to evaluate the impact of the implementation of the A-DIVA Scale (classification score for difficult intravenous access) on practitioners' approaches to the peripheral venous catheter placement. It consists of a systematic collection of peripheral venous catheter placement practices for quantitative data and a questionnaire of professionals' opinions on the use of the A-DIVA scale for qualitative data. The main objective of this phase is to recognize the potential appearance of changes in practices through the implementation of a tool for evaluating vascular access difficulties
219397829|NCT00153634|DRUG|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
219001879|NCT02091544|OTHER|Lifestyle intervention|
219001880|NCT04378218|BEHAVIORAL|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
219001881|NCT03866005|DIETARY_SUPPLEMENT|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
219001882|NCT03866005|OTHER|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
219001883|NCT03374878|OTHER|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
219001884|NCT03374878|OTHER|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
219001885|NCT04159025|DEVICE|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
219001886|NCT00381095|DRUG|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
219001887|NCT00381095|DRUG|Placebo|Placebo
219001888|NCT02612324|BEHAVIORAL|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
219001889|NCT02612324|BEHAVIORAL|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
219001890|NCT05397821|PROCEDURE|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
219001891|NCT05532592|OTHER|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
219001892|NCT04054388|BEHAVIORAL|LINE re-education|
219001893|NCT01405599|DRUG|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
219001894|NCT03653650|COMBINATION_PRODUCT|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
219001895|NCT03653650|COMBINATION_PRODUCT|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
219001896|NCT03653650|COMBINATION_PRODUCT|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
219001897|NCT06030791|DIAGNOSTIC_TEST|MRI|MRI of operated knee
219001898|NCT03620240|BEHAVIORAL|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
219001899|NCT01102400|DRUG|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
219001900|NCT01310621|DRUG|Bovine surfactant|"* Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)"
219001901|NCT00670683|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219001902|NCT03608449|OTHER|questionnaires|questionnaire about mental health status during psychotherapy
219001903|NCT05666492|OTHER|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
219001904|NCT05666492|OTHER|Saline|Saline will be placed on the olfactory epithelium topically.
219001905|NCT04070950|OTHER|Questionnaires|Two self-questionnaires
219001906|NCT04459091|DIETARY_SUPPLEMENT|Amino Essential Acid|8 gr die in two administration
219001907|NCT04459091|DIETARY_SUPPLEMENT|placebo|8 gr die in two administration
219001908|NCT01104493|BIOLOGICAL|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
219001909|NCT01104493|OTHER|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
219397830|NCT03074448|DEVICE|Aquanet|Aquanet bowel cleansing devices
219397831|NCT03074448|DRUG|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
219397832|NCT02898025|DEVICE|Active Interferential Current|Involves the application of medium frequency alternating currents
219397833|NCT02898025|DEVICE|Active Laser|Involves the application of low level laser over the knee
219397834|NCT02898025|DEVICE|Placebo Interferential Current|It is a sham interferential therapy
219397835|NCT02898025|DEVICE|Placebo Laser|It is a sham laser therapy
219397836|NCT01372111|DRUG|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
219397837|NCT01372111|RADIATION|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
219397838|NCT04397393|DRUG|Midazolam|Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
219397839|NCT04770610|DRUG|OT-101 Ophthalmic Solution|Atropine 0.01%
219397840|NCT04770610|DRUG|Vehicle|Investigational Product minus active ingredient
219397841|NCT04313335|DRUG|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
219397842|NCT04795713|DRUG|MT-6402|Experimental Treatment
219397843|NCT00057616|DRUG|CC-5013|
219397844|NCT02835638|DEVICE|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
219397845|NCT05490953|DRUG|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
219397846|NCT05490953|DRUG|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
219397847|NCT05924100|DRUG|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
219397848|NCT05456100|BEHAVIORAL|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
219397849|NCT05456100|BEHAVIORAL|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
219397850|NCT05456100|BEHAVIORAL|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
219397851|NCT00511082|DRUG|OPB-31121|100-mg tablet Dose: OPB-31121 50, 100, 200, 400, 600, 800, and 1000 mg Dosage regimen: ingestion with water after breakfast Treatment period: 4 weeks Mode of Administration: oral administration of OPB-31121 once daily
219562873|NCT06905028|OTHER|Fasting and Plant-Based Diet|The participants will undergo an initial 7-day fasting regime according to Buchinger (max. 350 kcal per day as liquids), followed by a dietary intervention that encompasses a plant-based diet (PBD) and time restricted eating (TRE) for 11 weeks.
219562874|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
219562875|NCT06905015|DEVICE|High stroke volume variation group|Anesthesiologists will perform methods to achieve and maintain SVV at 13-20% during liver parenchymal transection (fluid restrictive phase). Central venous pressure monitoring will be concealed with drapes, and the room anesthesiologist will use SVV for guiding fluid management only during parenchymal transection phase. If SVV exceeds 20%, a balanced salt crystalloid will be administered in the minimal amount necessary to reduce the SVV to below 20%.
219562876|NCT06904859|BIOLOGICAL|TCR-T Cells Injection|The TCR sequences of AML patients were analyzed by next generation sequencing to find the specific TCR clone against leukemia，then TCR gene-modified T cells were infused back into the patients
219397852|NCT03249350|BEHAVIORAL|Standard Contingency Management (CM)|"CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
219397853|NCT03249350|BEHAVIORAL|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
219562877|NCT02562287|DRUG|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
219562878|NCT02562287|DRUG|Risperidone|Risperidone, in a flexible dosage
219562879|NCT02562287|DRUG|Olanzapine|Olanzapine, flexible dosage
219562880|NCT02562287|DRUG|Quetiapine|Quetiapine, flexible dosage
219562881|NCT00375791|DRUG|perifosine|100 - 150 mg daily
219562882|NCT00375791|DRUG|dexamethasone|20 mg twice weekly
219397854|NCT06004115|DRUG|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
219397855|NCT06004115|OTHER|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
219397856|NCT01776268|OTHER|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
219397857|NCT04057963|OTHER|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
219397858|NCT04057963|OTHER|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
219397859|NCT00233636|DRUG|Iressa (Gefitinib)|
219397860|NCT00233636|PROCEDURE|Radiotherapy|
219397861|NCT01016483|DRUG|Pimasertib|
219397862|NCT01016483|DRUG|Gemcitabine|
219397863|NCT01016483|DRUG|Placebo|
219189336|NCT05935228|OTHER|Implementation of the algorithm composed of the A-DIVA Scale and the new decision-making tree (the A-DIVA Tool) in the centers|"The main objective of this phase is to evaluate the impact of the algorithm on the quality of peripheral venous catheter placement.~• Systematic collection of judgment criteria and socio-demographic and clinical characteristics of patients. Description of the care strategy implemented. Systematic collection of the A-DIVA Scale with identification of the patient's risk group, systematic rating of pain and evaluation of overall comfort."
219189337|NCT06601101|DRUG|Insulin|Insulin eye drops in the postoperative prescription for corneal crosslinking
219189338|NCT06601101|DRUG|Placebo eye drops of 0.5% Methylcellulose|Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
219189339|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
219189340|NCT04032847|BIOLOGICAL|ATL001|ATL001 infusion
219189341|NCT04032847|DRUG|Pembrolizumab|Checkpoint inhibitor
219189342|NCT06503406|DEVICE|SupraSDRM®|SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.
219189343|NCT06503406|DEVICE|NovoSorb® BTM|NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
219189344|NCT06620770|OTHER|questionnaires|Morisky and SF12 Questionnaires delivery at inclusion, 6, 12 and 18 months
219189345|NCT05892744|DRUG|Sertraline|50-200mg/day
219189346|NCT02831959|DEVICE|NovoTTF-200M device|
219189347|NCT02831959|OTHER|Best Standard of Care|
219189348|NCT06667037|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
219397864|NCT01379443|OTHER|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
219189349|NCT06667037|DRUG|0.01% Atropine|0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
219189350|NCT05873556|BEHAVIORAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
219189351|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
219189352|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
219189353|NCT04570956|DRUG|Tamoxifen|Oral Tamoxifen 10 mg/day
219189354|NCT04570956|DRUG|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
219189355|NCT04570956|DRUG|Placebo|placebo pill or placebo gel
219189356|NCT04570956|OTHER|Questionnaire Administration|Ancillary studies
219189357|NCT05622201|DRUG|Rituximab|Infusion
219189358|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
219189359|NCT06647732|DRUG|Zanubrutinib|160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
219189360|NCT06647732|DRUG|Rituximab|375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
219189361|NCT05646277|OTHER|e-Consultation|first orthodontic consultation in remote
219189362|NCT05646277|OTHER|Consultation|first orthodontic consultation in face-to-face
219189363|NCT06254443|OTHER|Enema Bowel preparation|Enema Group (Experimental Group): Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
219189364|NCT06254443|OTHER|PEG Bowel preparation|Oral PEG Group (Control Group): Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
219189365|NCT06475729|DRUG|Citrate-Free Mirikizumab|Administered SC
219189366|NCT03381586|DRUG|ALT-803|Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
219189367|NCT04146324|DRUG|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
219189368|NCT05651542|BEHAVIORAL|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
219189369|NCT05651542|OTHER|Control|The control group will receive standard care.
219397865|NCT02192710|PROCEDURE|electronic tab|classic use of an electronic tab with age specific games
219397866|NCT02192710|DRUG|Midazolam oral intake|
219397867|NCT01294254|DRUG|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
219397868|NCT01294254|PROCEDURE|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
219397869|NCT02295098|OTHER|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
219397870|NCT02295098|OTHER|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
219397871|NCT03288584|DRUG|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
219397872|NCT03288584|DRUG|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
219397873|NCT03288584|DRUG|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
219397874|NCT00614003|BEHAVIORAL|Decision support skills building Intervention|Decision support skills
219397875|NCT00287833|OTHER|placebo|Given orally
219397876|NCT00287833|DRUG|Bowman-Birk inhibitor concentrate|Given orally
219397877|NCT02864745|DEVICE|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
219397878|NCT02864745|OTHER|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
219397879|NCT05780853|DIAGNOSTIC_TEST|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
219397880|NCT05780853|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
219397881|NCT05780853|OTHER|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
219397882|NCT04558645|OTHER|Online Survey|Online surveys will be applied to all participants
219397883|NCT06361745|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
219397884|NCT03658330|DRUG|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
219397885|NCT03464058|DRUG|BOS172767 tablets|Oral tablets
219397886|NCT03464058|DRUG|BOS172767 liquid capsules|Oral capsules
219397887|NCT03464058|DRUG|BOS172767 micronized capsules|Oral capsules
219397888|NCT03464058|DRUG|BOS172767 immediate release capsules|Oral capsules
219397889|NCT03464058|DRUG|BOS172767 matching placebo capsules|Oral capsules
219397890|NCT03464058|DRUG|BOS172767 matching placebo tablets|Oral tablets
219397891|NCT03464058|DRUG|Rabeprazole|Oral tablets
219397892|NCT04937894|DRUG|Tigecycline|Efficacy and safety of Tigecycline
219397893|NCT05764798|DRUG|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
219397894|NCT05764798|DRUG|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
219397895|NCT00840645|DRUG|YM178|Oral
219397896|NCT04163146|DIAGNOSTIC_TEST|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
219397897|NCT02998008|BEHAVIORAL|high intensity interval training|
219397898|NCT06077630|OTHER|No intervention|There is no intervention, observational study
219397899|NCT05037903|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
219397900|NCT06275971|DEVICE|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
219397901|NCT06275971|DEVICE|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
219397902|NCT01024465|DEVICE|ReShape Duo Balloon|ReShape Duo Balloon
219397903|NCT03384290|DRUG|PRS-060|Drug
219397904|NCT03384290|DRUG|Placebo|PRS-060 Matching Placebo
219397905|NCT05762185|DEVICE|nursing consultation|nursing consultation
219397906|NCT05297539|OTHER|Point light display|Visualization of point-light human actions
219397907|NCT04770142|DEVICE|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
219397908|NCT03078608|BEHAVIORAL|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
219397909|NCT03078608|BEHAVIORAL|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
219397910|NCT00723840|OTHER|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
219397911|NCT03811600|DIAGNOSTIC_TEST|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
219397912|NCT06095973|DRUG|GB-6002|Depending on the cohort, volume will be varied to administer.
219397913|NCT06095973|DRUG|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
219397914|NCT06095973|DRUG|Naropin injection|Single dose of Naropin s.c. injection.
219397915|NCT03422991|OTHER|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
219397916|NCT06649903|BEHAVIORAL|Chiropractic|high speed low amplitude neck manipulation
219397917|NCT06649903|BEHAVIORAL|Osteopathy|the stomach and liver technique was applied
219397918|NCT06079476|DRUG|Romosozumab|Single-use prefilled syringe for SC injection.
219397919|NCT04485169|PROCEDURE|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
219397920|NCT03989063|BEHAVIORAL|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
219397921|NCT03383367|BEHAVIORAL|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
219397922|NCT03322683|PROCEDURE|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
219397923|NCT03322683|PROCEDURE|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
219397924|NCT04847830|DEVICE|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
219397925|NCT04847830|PROCEDURE|root surface dbridement|root surface debridement under local anaesthesia
219397926|NCT00785746|OTHER|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
219397927|NCT01964365|DRUG|Cresto 20mg|tablet, rosuvastatin 20mg
219397928|NCT01964365|DRUG|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
219397929|NCT01964365|DRUG|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
219397930|NCT04110834|DRUG|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
219397931|NCT04110834|DRUG|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
219397932|NCT04110834|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
219397933|NCT00882869|DRUG|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
219397934|NCT00882869|DRUG|Sorafenib|Sorafenib will be administered at 400 mg BID every day
219397935|NCT02396407|BEHAVIORAL|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
219397936|NCT00940927|DRUG|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
219397937|NCT03687034|DRUG|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
219397938|NCT03687034|DEVICE|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
219397939|NCT02769260|OTHER|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
219397940|NCT03762252|OTHER|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
219397941|NCT03762252|OTHER|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
219397942|NCT01747330|DRUG|Pancreatin|Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
219397943|NCT00026468|DRUG|exisulind|
219397944|NCT03919110|DIAGNOSTIC_TEST|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
219397945|NCT02672839|DRUG|LGD-6972 Solution|15 mg of LGD-6972
219189370|NCT05894252|OTHER|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
219562883|NCT01302509|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
219562884|NCT00735930|DRUG|Alvocidib Hydrochloride|Given IV
219562885|NCT00735930|DRUG|Lenalidomide|Given PO
219189371|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
219189372|NCT06649981|DIETARY_SUPPLEMENT|FMT capsule|"A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population."
219189373|NCT06649981|DIETARY_SUPPLEMENT|Placebo Capsule(s)|"A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results."
219562886|NCT00735930|OTHER|Pharmacological Study|Correlative studies
219562887|NCT00735930|OTHER|Laboratory Biomarker Analysis|Correlative studies
219001910|NCT03029377|OTHER|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
219562888|NCT06051409|DRUG|Olverembatinib|Orally, once every other day (QOD).
219189374|NCT04003454|OTHER|HCV Screening|The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
219397946|NCT02672839|DRUG|LGD-6972 Capsules|15 mg LGD-6972
219397947|NCT04554030|BEHAVIORAL|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
219397948|NCT00480454|BIOLOGICAL|MVA 85A|intradermal vaccine
219562889|NCT06051409|DRUG|Imatinib|Orally, once daily (QD).
219562890|NCT03209349|PROCEDURE|Water Exchange Sigmoidoscopy|See arm description.
219562891|NCT03209349|PROCEDURE|Air Insufflation Sigmoidoscopy|See arm description.
219562892|NCT06165263|BEHAVIORAL|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students\&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
219562893|NCT01471925|DRUG|Nexium®|"The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
219562894|NCT01471925|DRUG|Esomeprazol (40mg) + Sodium Bicarbonate (721mg)|"The medication, Esomeprazol (40 mg) + Sdium Bicarbonate (721 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
219562895|NCT05805813|COMBINATION_PRODUCT|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
219562896|NCT02677662|OTHER|Diesel Exhaust|Dilute diesel exhaust
219562897|NCT02677662|OTHER|Filtered air|Filtered air
219562898|NCT02856087|DRUG|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
219562899|NCT02856087|DRUG|Naloxone|naloxone infusion
219562900|NCT02856087|DRUG|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
219562901|NCT02856087|DRUG|Normal Saline|normal saline infusion
219562902|NCT03180528|DRUG|Remetinostat|Applied topically under bandage occlusion
219562903|NCT02999451|DEVICE|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips."
219562904|NCT02999451|DEVICE|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips."
219562905|NCT05746130|BEHAVIORAL|Plastic-free diet program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
219562906|NCT05746130|BEHAVIORAL|Plastic-free diet education program|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
219562907|NCT05746130|BEHAVIORAL|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
219001911|NCT01342796|BIOLOGICAL|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
219189375|NCT06363786|OTHER|Test patches|Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
219189376|NCT06772402|GENETIC|GCB-001|GCB-001 is a self-complementary AAV9 carrying a full length human SMN transgenetic product.
219189377|NCT04630470|BEHAVIORAL|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
219189378|NCT04630470|BEHAVIORAL|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
219189379|NCT06066099|DRUG|AP31969|Oral tablets
219397949|NCT04239274|DEVICE|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
219562908|NCT04455971|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
219397950|NCT04239274|DEVICE|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
219397951|NCT04239274|DEVICE|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
219397952|NCT02289755|DRUG|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
219397953|NCT01441167|BIOLOGICAL|PfSPZ|
219397954|NCT02086565|BEHAVIORAL|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
219397955|NCT02086565|BEHAVIORAL|Portal training|training in use of patient portal
219397956|NCT05616065|OTHER|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
219397957|NCT05616065|OTHER|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
219397958|NCT00751101|DRUG|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
219397959|NCT06030895|DRUG|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
219397960|NCT01019408|DRUG|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
219397961|NCT02850614|BEHAVIORAL|gaming application to encourage physical activity|
219397962|NCT02850614|DEVICE|FitBit|
219562909|NCT06467201|DRUG|KSHN001126 150mg|6 subjects will receive single oral dose of 150mg
219562910|NCT06467201|DRUG|KSHN001126 300mg|6 subjects will receive single oral dose of 300mg
219562911|NCT06467201|DRUG|KSHN001126 600mg|6 subjects will receive single oral dose of 600mg
219562912|NCT02092883|DRUG|ACTH|PK PET scan before and after ACTH treatment
219562913|NCT03441139|OTHER|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
219562914|NCT03441139|DRUG|Medical Analgesics|Best analgesic therapy at investigator's discretion
219562915|NCT04703855|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
219562916|NCT01556152|DRUG|GRC 17536 (Medium Dose)|1 BD for 28 days
219562917|NCT01556152|DRUG|GRC 17536 (Low Dose)|1 BD for 28 Days
219562918|NCT01556152|DRUG|Placebo|Matching Placebo for 28 Days
219562919|NCT04808349|OTHER|no intervention|no intervention
219562920|NCT04869371|DRUG|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
219397963|NCT03327922|DEVICE|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
219397964|NCT03332004|DRUG|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
219397965|NCT00758303|DRUG|Low Dose TRIA-662|One Capsule 3 times a day
219397966|NCT00758303|DRUG|High Dose TRIA-662|3 Capsules 3 times daily
219562921|NCT04869371|DRUG|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
219562922|NCT04869371|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
219562923|NCT00403949|DRUG|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
219562924|NCT00403949|DRUG|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
219562925|NCT03040752|DRUG|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
219562926|NCT03040752|DRUG|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
219562927|NCT03201978|DRUG|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
219562928|NCT03201978|DRUG|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
219562929|NCT03973788|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
219562930|NCT04266652|PROCEDURE|tooth block|tooth root blocks were used to increase the bone width
219562931|NCT04266652|PROCEDURE|autogenous bone block|autogenous bone block were used to increase the bone width
219001912|NCT01342796|BIOLOGICAL|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
219189380|NCT06066099|DRUG|Placebo|Oral tablets
219397967|NCT00758303|DRUG|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
219397968|NCT03882840|BIOLOGICAL|ITNK cell therapy|Infusion of ITNK/CAR-ITNK cells
219397969|NCT02116972|DRUG|FX006 32 mg|Single 5 mL IA injection
219397970|NCT02116972|DRUG|Placebo|Single 5 mL IA injection
219562932|NCT03358095|DEVICE|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
219562933|NCT00978887|OTHER|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
219562934|NCT00978887|OTHER|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
219562935|NCT00088387|DRUG|Divalproex|
219562936|NCT00088387|DRUG|Lithium|
219562937|NCT03721302|OTHER|Main study clinical sepsis|No intervention-Observational study
219562938|NCT03721302|OTHER|Microbiology sub study|Analysis of Bacterial isolates
219562939|NCT04261569|DEVICE|Ev-NIRT|Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
219562940|NCT00959322|DEVICE|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
219562941|NCT02394639|OTHER|video-EEG monitoring|
219562942|NCT02837133|BEHAVIORAL|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
219397971|NCT02116972|DRUG|FX006 16 mg|Single 5 mL IA injection
219397972|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
219397973|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
219397974|NCT00784784|BIOLOGICAL|Fluviral|One dose
219397975|NCT00784784|DRUG|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
219397976|NCT06258629|DIAGNOSTIC_TEST|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
219397977|NCT05713305|PROCEDURE|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
219397978|NCT05713305|PROCEDURE|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
219562943|NCT01241682|BIOLOGICAL|DC + CTX|3x 50x10e6 DC + cyclophosphamide
219562944|NCT06457620|BEHAVIORAL|Conventional Physiotherapy|Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
219562945|NCT06457620|OTHER|Traditional Physical Preatment|Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
219397979|NCT02067312|OTHER|Thai massage|
219562946|NCT05965791|DIAGNOSTIC_TEST|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
219562947|NCT00368316|BIOLOGICAL|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
219562948|NCT00991510|DRUG|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
219562949|NCT00991510|DRUG|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
219562950|NCT05472155|DEVICE|Bulb syringe|Suctioning with a bulb syringe
219562951|NCT05472155|DEVICE|Suction catheter|Suctioned with a suction catheter
219562952|NCT05831735|BEHAVIORAL|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
219397980|NCT06074822|OTHER|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
219397981|NCT05183581|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
219397982|NCT03663608|PROCEDURE|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
219397983|NCT04171128|BEHAVIORAL|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
219397984|NCT04593498|DIAGNOSTIC_TEST|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
219397985|NCT04593498|DIAGNOSTIC_TEST|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
219397986|NCT04593498|DIAGNOSTIC_TEST|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
219397987|NCT04593498|DIAGNOSTIC_TEST|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
219397988|NCT01901471|DRUG|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
219397989|NCT01901471|DRUG|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
219562953|NCT05831735|BEHAVIORAL|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
219562954|NCT04489186|DEVICE|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
219562955|NCT05007184|BEHAVIORAL|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
219562956|NCT05007184|BEHAVIORAL|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
219562957|NCT05533099|OTHER|Observational study|Observational study of a device implanted in a previous clinical study
219562958|NCT02356211|OTHER|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
219562959|NCT01976728|DRUG|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
219562960|NCT01976728|DRUG|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
219562961|NCT01976728|DRUG|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
219397990|NCT02956174|DEVICE|Co-Cr single crown|
219397991|NCT02956174|OTHER|Periodontal parameters|
219562962|NCT01976728|DRUG|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
219562963|NCT00777933|DRUG|tacrolimus|
219562964|NCT00777933|DRUG|cyclosporine|
219562965|NCT05975177|DEVICE|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
219562966|NCT05975177|PROCEDURE|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
219562967|NCT05393128|PROCEDURE|Control group (Supine Position)|"In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
219189381|NCT06155305|PROCEDURE|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
219189382|NCT04738890|BEHAVIORAL|Mindfulness-based cognitive therapy|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing
219397992|NCT00292474|DEVICE|percutaneous coronary intervention|
219397993|NCT01905397|DEVICE|Conventional wound therapy|Sterile bandages and wound coverings
219397994|NCT01905397|DEVICE|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
219397995|NCT04024683|PROCEDURE|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
219397996|NCT04766203|BEHAVIORAL|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
219397997|NCT00875784|DRUG|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
219397998|NCT00875784|DRUG|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
219397999|NCT00875784|DRUG|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
219398000|NCT00875784|DRUG|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
219398001|NCT02676349|DRUG|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
219398002|NCT02676349|RADIATION|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
219398003|NCT02676349|PROCEDURE|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
219398004|NCT02676349|DRUG|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
219398005|NCT02883582|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
219398006|NCT02883582|DEVICE|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
219398007|NCT01461954|DRUG|FST-100|FST-100
219398008|NCT01461954|DRUG|FST-100 Vehicle|FST-100 Vehicle
219398009|NCT02718794|PROCEDURE|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
219398010|NCT02718794|PROCEDURE|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
219398011|NCT05774457|BEHAVIORAL|Voice training|Traditional vs. virtual reality
219398012|NCT05379426|OTHER|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
219398013|NCT00844428|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
219398014|NCT06333470|OTHER|Primary angle closure diseases|Primary angle-closure suspect (PACS), which is characterized by appositional angle closure, is the earliest stage of primary angle closure diseases and can finally progress to primary angle-closure glaucoma (PACG).
219398015|NCT04263662|OTHER|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
219398016|NCT06300970|DRUG|Amodiaquine-artesunate (ASAQ)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
219398017|NCT06300970|DRUG|Artemether+Lumefantrine (AL)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
219189383|NCT04738890|OTHER|Treatment as usual|Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
219189384|NCT04408638|DRUG|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
219189385|NCT04408638|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
219398018|NCT03766750|DRUG|LIMA association|1 coated tablet, oral, once a day.
219398019|NCT03766750|DRUG|Tradjenta|1 coated tablet, oral, once a day.
219398020|NCT03766750|DRUG|Forxiga|1 coated tablet, oral, once a day.
219398021|NCT00789477|PROCEDURE|Laser Photocoagulation|laser every 16 weeks as needed
219398022|NCT00789477|DRUG|Intravitreal Aflibercept Injection|
219398023|NCT03908788|DEVICE|Intplex test|Blood sample at each tumor assessment
219398024|NCT06321744|OTHER|adapted physical activity program (APA Program)|"Content of the APA program:~* Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings.~* Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats.~* Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work~* Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task."
219189386|NCT04408638|DRUG|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
219398025|NCT04232891|DIAGNOSTIC_TEST|liquid biopsy|detection of tumor DNA alteration in cf-DNA
219398026|NCT06286852|BEHAVIORAL|Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)|Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
219398027|NCT06286852|BEHAVIORAL|Administration of ChEDE- Child Version of the EatingDisorder Examination|Administration of ChEDE- Child Version of the EatingDisorder Examination
219562968|NCT05393128|PROCEDURE|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
219562969|NCT05393128|PROCEDURE|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
219562970|NCT06617533|OTHER|PCF model|PCF practices practices receive (1) a per-beneficiary-per-month prospective payment that depends on the average health of their attributed Medicare beneficiaries; (2) a Flat Visit Fee for primary care visits, subject to a geographic adjustment factor, and (3) a Performance-based Adjustment (PBA). The PBAs depend on practices' performance on several quality measures in addition to their performance in reducing beneficiaries' use of inpatient care or total cost of care, relative to national and regional benchmarks. Practices must meet a limited set of care delivery requirements and can use the PCF Model's flexible use of payments to invest in strategies that best suit their practices' unique patient population and resources. In return, practices take on limited financial risk in exchange for performance-based payments that reward participants that meet certain performance and quality benchmarks for selected outcomes.
219562971|NCT04344132|PROCEDURE|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
219562972|NCT03527680|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
219562973|NCT03527680|DRUG|Placebo - Cap|daily one capsule of placebo
219562974|NCT00643734|DRUG|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
219562975|NCT00643734|OTHER|placebo|placebo
219562976|NCT00643734|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
219562977|NCT00643734|OTHER|placebo|placebo
219562978|NCT05108116|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
219562979|NCT04703517|DIAGNOSTIC_TEST|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
219562980|NCT03765996|OTHER|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
219562981|NCT03765996|OTHER|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
219189387|NCT04408638|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
219189388|NCT04408638|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
219189389|NCT04408638|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
219398028|NCT00854932|OTHER|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
219398029|NCT00865254|BEHAVIORAL|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
219398030|NCT00865254|BEHAVIORAL|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
219398031|NCT00865254|BEHAVIORAL|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
219562982|NCT02512614|OTHER|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
219562983|NCT02430415|DEVICE|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
219562984|NCT02430415|DEVICE|traditional lightwand intubation|traditional lightwand intubation
219562985|NCT00922259|BIOLOGICAL|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
219562986|NCT01185028|DRUG|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
219562987|NCT03063424|DIAGNOSTIC_TEST|Eucapnic voluntary hyperventilation|
219562988|NCT03063424|DIAGNOSTIC_TEST|Exercise challenge on a cycle ergometer|
219562989|NCT01569347|OTHER|Interviews|Interviews
219562990|NCT01569347|OTHER|Blood sample|Blood sample
219562991|NCT01569347|OTHER|Hair sample|Hair sample
219562992|NCT03389256|DRUG|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
219562993|NCT03389256|DRUG|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
219562994|NCT01904422|PROCEDURE|conventional periodontal treatment|
219189390|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
219398032|NCT06415578|OTHER|ergonomics training|In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.
219398033|NCT06415578|OTHER|Exercises|The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
219398034|NCT05664685|DRUG|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
219562995|NCT05303935|DRUG|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
219562996|NCT05303935|DRUG|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
219562997|NCT06678646|PROCEDURE|Elbow ultrasound-guided surgery|Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
219562998|NCT01938235|DRUG|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
219562999|NCT01938235|DRUG|Placebo|Intravenous bolus and 24-hour infusion of placebo
219563000|NCT03347357|DRUG|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
219563001|NCT04910828|OTHER|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
219563002|NCT04445064|BIOLOGICAL|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
219563003|NCT04445064|BIOLOGICAL|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
219563004|NCT00966381|OTHER|Exercise and weight loss intervention|randomized control trial, stratified by parity
219563005|NCT03176355|PROCEDURE|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
219563006|NCT00191464|DRUG|premeal insulin lispro mixtures|
219563007|NCT00191464|DRUG|insulin glargine|
219563008|NCT00191464|DRUG|metformin|
219563009|NCT04421092|PROCEDURE|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
219563010|NCT04421092|PROCEDURE|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
219563011|NCT04421092|PROCEDURE|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
219563012|NCT03782480|DRUG|Intrarosa|Prasterone intravaginal inserts
219398035|NCT05664685|DRUG|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
219398036|NCT01541592|OTHER|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
219398037|NCT01455571|DRUG|HM781-36B|Q1DX14/2W for 3W HM781-36B
219189391|NCT05540704|BEHAVIORAL|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
219398038|NCT00230386|DEVICE|MRI|
219398039|NCT03974646|BEHAVIORAL|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
219398040|NCT00594152|DRUG|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
219563013|NCT03782480|DRUG|Placebos|Placebo intravaginal inserts
219563014|NCT04130178|DRUG|Nerve block|block of the digital nerves in rheumatoid arthritis patient
219563015|NCT04130178|DRUG|Saline injection|subcutaneous saline injection
219563016|NCT04115709|DEVICE|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
219563017|NCT04115709|DEVICE|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
219563018|NCT01119807|DEVICE|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
219563019|NCT01119807|DEVICE|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
219563020|NCT01119807|DEVICE|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
219563021|NCT00097786|DRUG|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
219563022|NCT00097786|DRUG|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
219563023|NCT00097786|DRUG|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
219398041|NCT02099799|BEHAVIORAL|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
219189392|NCT05540704|OTHER|Usual Care|Usual care for problems in Type 1 diabetes management
219189393|NCT05861323|BEHAVIORAL|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
219189394|NCT06997068|DRUG|Celecoxib|Given PO
219189395|NCT06997068|DRUG|Erlotinib Hydrochloride|Given PO
219189396|NCT06997068|PROCEDURE|Imaging Procedure|Undergo SOC imaging scans
219189397|NCT06997068|OTHER|Interview|Ancillary studies
219398042|NCT03621969|OTHER|Physical exam and medical history|This will be completed by a medical doctor on the research team
219398043|NCT03621969|DIAGNOSTIC_TEST|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
219398044|NCT03621969|DEVICE|Patient Instruction and use of Device (RePlay)|"1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
219398045|NCT04942418|OTHER|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
219398046|NCT04942418|OTHER|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
219398047|NCT00863928|DRUG|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
219563024|NCT00097786|DRUG|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
219189398|NCT06997068|DRUG|Methotrexate|Given PO
219189399|NCT06997068|OTHER|Questionnaire Administration|Ancillary studies
219398048|NCT05534555|DIAGNOSTIC_TEST|FebriDx|Testing of finger-prick blood sample using FebriDx
219189400|NCT03011372|DRUG|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
219189401|NCT06674473|DEVICE|With robot assistance|Use a portable isokinetic device
219189402|NCT06674473|BEHAVIORAL|traditional bodyweight rehabilitation|Use traditional bodyweight rehabilitation
219189403|NCT06999564|BEHAVIORAL|EFT|"EFT involves the following steps:~1. Identification of the problem that is causing the person distress (e.g., fear of childbirth) and scoring or measuring the severity of this problem.~2. Tapping with the fingertips on certain points of the face and body, known as correction (i.e., regulation of the energy system), as well as the expression of an emphatic phrase (related to the person\&amp;#39;s problem and self-acceptance)."
219189404|NCT06875934|DRUG|SHR-1139 Injection|SHR-1139 injection.
219189405|NCT06875934|DRUG|SHR-1139 Injection Placebo|SHR-1139 injection placebo.
219189406|NCT07045337|OTHER|Hybrid Bracing|Hybrid Bracing includes daytime Underarm Brace(UAB) and nighttime Lateral Bending Brace(LBB)
219189407|NCT07045337|OTHER|Conventional fulltime Underarm Bracing|Conventional group includes fulltime Underarm Brace (UAB) only.
219398049|NCT03750110|OTHER|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
219398050|NCT03750110|OTHER|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
219398051|NCT05016128|DRUG|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
219398052|NCT05016128|DRUG|saline|saline is used for control
219398053|NCT04460287|DIETARY_SUPPLEMENT|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
219398054|NCT04460287|DIETARY_SUPPLEMENT|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
219398055|NCT04460287|DIETARY_SUPPLEMENT|Fish Oil|Children will have this intervention every day for 30 days
219398056|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
219398057|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
219398058|NCT02354391|DRUG|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
219398059|NCT02354391|DRUG|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
219398060|NCT02354391|PROCEDURE|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
219398061|NCT06821256|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator throught a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the over the cerebellum area (2 cm under the inion, using a 7 × 5 cm sponge electrode), with the cathode being applied either to the right deltoid muscle (arm 1: cerebellar stimulation) or over the spinal lumbar enlargement (2 cm under T11; arm 2: cerebellar-spinal stimulation) using a sponge electrode of the same size as the anode. Durng real stilumation a costant current of 2mA is applied for 20 minutes.
219398062|NCT06821256|DEVICE|Sham stimulation|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation
219398063|NCT05985070|DIETARY_SUPPLEMENT|Oral Sucrosomial iron|30 mg capsule
219398064|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric maltol|30 mg capsule
219398065|NCT05753761|BEHAVIORAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
219563025|NCT04632524|DRUG|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
219563026|NCT05403619|DIAGNOSTIC_TEST|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
219001913|NCT01529255|DRUG|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
219398066|NCT03392519|OTHER|Chronic stroke|MRI data acquisition and behavioral test
219398067|NCT06663358|DRUG|Pegunigalsidase-alfa|Administered via intravenous (IV) infusion under conditions of routine clinical care
219398068|NCT01373645|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
219398069|NCT00539721|DRUG|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
219398070|NCT00539721|DRUG|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
219398071|NCT00539721|DRUG|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
219398072|NCT00539721|DRUG|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
219398073|NCT00539721|DRUG|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
219398074|NCT00539721|DRUG|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
219563027|NCT01284855|DRUG|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
219563028|NCT02668822|DRUG|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
219563029|NCT02668822|DRUG|Placebo vaginal ring|Placebo vaginal ring
219563030|NCT02668822|DRUG|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
219563031|NCT01358539|BEHAVIORAL|Pain education|Patients receiving pain education
219398075|NCT03078101|DRUG|Empagliflozin 10 MG [Jardiance]|administered orally once daily
219398076|NCT03078101|DRUG|Placebo Oral Tablet|administered orally once daily
219398077|NCT05114863|OTHER|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
219398078|NCT05114863|OTHER|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
219398079|NCT05114863|OTHER|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
219398080|NCT05114863|OTHER|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
219398081|NCT05114863|OTHER|Product A2|Usual Brand (UB) filtered, menthol cigarette
219398082|NCT05114863|OTHER|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
219398083|NCT05114863|OTHER|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
219398084|NCT05114863|OTHER|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
219398085|NCT05114863|OTHER|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
219398086|NCT05114863|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
219398087|NCT04804852|OTHER|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
219398088|NCT02648035|BIOLOGICAL|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
219398089|NCT04031378|RADIATION|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
219398090|NCT04031378|DRUG|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
219398091|NCT02046915|DRUG|Imnovid (pomalidomide)|
219398092|NCT02046915|DRUG|Dexamethasone|
219398093|NCT02046915|DRUG|Endoxan (Cyclophosphamide)|
219398094|NCT06611631|PROCEDURE|Hyaluronic acid pulpotomy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
219398095|NCT06611631|PROCEDURE|mineral trioxide aggregate pulpotomy|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
219398096|NCT00772967|DRUG|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
219398097|NCT00772967|DRUG|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
219398098|NCT00772967|DRUG|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
219398099|NCT02612714|DRUG|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
219001914|NCT01529255|DRUG|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
219398100|NCT01070355|DRUG|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
219398101|NCT01070355|DRUG|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
219398102|NCT02247206|BEHAVIORAL|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
219398103|NCT01595646|DRUG|Saline|Saline, administered intranasally twice per day for a 16 week duration
219563032|NCT05707455|OTHER|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
219563033|NCT05633914|DRUG|Tucidinostat|20mg, po., biw, q3w
219563034|NCT05633914|DRUG|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
219001915|NCT02496273|BIOLOGICAL|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
219398104|NCT01595646|DRUG|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
219563035|NCT00970255|PROCEDURE|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
219563036|NCT00970255|PROCEDURE|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
219398105|NCT01595646|DRUG|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
219398106|NCT01237548|OTHER|Smoking Narghile for 30 min|No Other intervention will be used
219398107|NCT00693355|OTHER|Sodium butyrate|sodium butyrate
219398108|NCT00693355|OTHER|NaCl|NaCl
219398109|NCT05600712|DEVICE|REDAPT Sleeved Stem|The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
219398110|NCT00693719|DRUG|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
219398111|NCT00693719|DRUG|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
219398112|NCT04671680|DEVICE|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
219398113|NCT02865044|OTHER|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
219398114|NCT02865044|OTHER|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
219398115|NCT01418768|OTHER|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
219398116|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
219398117|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
219398118|NCT02446366|OTHER|Laboratory Biomarker Analysis|Correlative studies
219398119|NCT02446366|OTHER|Quality-of-Life Assessment|Ancillary studies
219398120|NCT02446366|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
219398121|NCT05770414|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
219398122|NCT00379938|BIOLOGICAL|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
219398123|NCT00379938|DRUG|Placebo|Saline control
219398124|NCT00379938|BIOLOGICAL|MF-59|Adjuvant
219398125|NCT04946344|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
219398126|NCT04946344|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
219398127|NCT04172831|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
219398128|NCT04172831|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
219398129|NCT01041573|BIOLOGICAL|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
219398130|NCT01041573|BIOLOGICAL|Havrix®720|0.5 ml im. at day 0 and month 7
219398131|NCT01041573|BIOLOGICAL|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
219398132|NCT02365532|DRUG|GS-6615|GS-6615 tablets administered orally
219398133|NCT02365532|DRUG|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
219398134|NCT02365532|DRUG|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
219398135|NCT02365532|DRUG|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
219398136|NCT02832492|BEHAVIORAL|pupil near response|
219398137|NCT03148171|OTHER|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
219398138|NCT02234115|DRUG|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
219398139|NCT01732263|DRUG|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
219398140|NCT00164424|DRUG|Acyclovir|
219398141|NCT01276847|DRUG|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16
219398142|NCT01276847|DRUG|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
219398143|NCT02064218|DRUG|Anti-hypertensive drugs|
219398144|NCT00695994|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
219398145|NCT00695994|DRUG|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
219398146|NCT01203462|OTHER|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
219398147|NCT01203462|OTHER|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
219398148|NCT02564822|PROCEDURE|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
219398149|NCT02813330|OTHER|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
219398150|NCT02813330|OTHER|saline injection|Saline injection in two points of low back pain
219398151|NCT01738139|DRUG|Imatinib Mesylate|Given PO
219398152|NCT01738139|BIOLOGICAL|Ipilimumab|Given IV
219563037|NCT01477814|BEHAVIORAL|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
219563038|NCT01477814|BEHAVIORAL|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
219563039|NCT01477814|BEHAVIORAL|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
219563040|NCT01522950|DRUG|Nebivolol|5 mg daily or 10 mg daily
219563041|NCT01522950|DRUG|atenolol|25 mg daily or 50 mg daily
219563042|NCT01522950|DRUG|placebo|one tablet daily
219563043|NCT03109119|DRUG|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
219563044|NCT03109119|DRUG|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
219563045|NCT03214302|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
219563046|NCT03965637|DRUG|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
219563047|NCT01378741|DRUG|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
219563048|NCT01378741|DRUG|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
219563049|NCT05616078|OTHER|laser treatment|a maximum of 4 sessions, with an interval of 3 to 4 weeks
219563050|NCT05616078|OTHER|cryotherapy|a maximum of 4 sessions, with an interval of 3 to 4 weeks
219563051|NCT05184699|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
219563052|NCT05184699|DIETARY_SUPPLEMENT|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
219001916|NCT04677374|OTHER|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
219398153|NCT04471740|PROCEDURE|CSF shunt diversion|Clinical response to a CSF shunt insertion
219398154|NCT02228512|DRUG|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
219398155|NCT02228512|DRUG|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
219398156|NCT02228512|DRUG|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
219563053|NCT03001999|BEHAVIORAL|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
219563054|NCT03264820|DEVICE|Laser Doppler|\- Laser measurements at the level of each finger at 47 °C and at ambient temperature
219563055|NCT03264820|DEVICE|Laser speckle|\- Laser measurements at the forearm
219563056|NCT03264820|BEHAVIORAL|pain evaluation|Visual scale assesment pain
219563057|NCT03264820|OTHER|Blood pressure and heart rate|Measurement of blood pressure and heart rate
219563058|NCT03235609|DRUG|Fentanyl|fentanyl used with propofol for sedation
219563059|NCT03235609|DRUG|Ketamine|ketamine used with propofol for sedation
219398157|NCT02228512|DRUG|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
219398158|NCT02228512|DRUG|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
219398159|NCT02228512|DRUG|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
219398160|NCT02228512|DRUG|Cyclophosphamide|Part B: 750 mg/m2 Day 5
219398161|NCT00502710|DRUG|Placebo|Placebo po daily.
219398162|NCT00502710|DRUG|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
219398163|NCT04500288|DEVICE|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
219398164|NCT05757999|DRUG|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
219398165|NCT05757999|DRUG|Saline|The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
219398166|NCT04100070|BEHAVIORAL|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
219398167|NCT00388752|PROCEDURE|Acupuncture|
219398168|NCT06022679|OTHER|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
219563060|NCT01188265|DRUG|Valproate|
219563061|NCT01188265|DRUG|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
219563062|NCT01188265|DRUG|Placebo|VPA plus placebo
219563063|NCT01188265|DRUG|Dextromethorphan 30 mg|VPA \& Dextromethorphan 30 mg per day
219563064|NCT06436352|PROCEDURE|Capsulotomy and fixation|"Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
219563065|NCT06436352|PROCEDURE|Fixation only|"we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
219563066|NCT02292511|BEHAVIORAL|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
219563067|NCT06200428|OTHER|sleep support pillow|A sleep support pillow will be used in this study.
219563068|NCT02039752|OTHER|Treatment|
219563069|NCT02384291|DEVICE|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
219563070|NCT02384291|DEVICE|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
219563071|NCT03684031|BEHAVIORAL|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
219563072|NCT03684031|BEHAVIORAL|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
219563073|NCT00298740|DEVICE|Aventis U-400 Insulin|
219563074|NCT04270006|BIOLOGICAL|adipose derived stem cells exosomes|they are small extracellular vesicles
219563075|NCT01465282|DRUG|CT327 0.05%|0.05% CT327 (w/w) ointment
219398169|NCT02152423|DRUG|LOVENOX|LMWH
219398170|NCT02152423|DRUG|ENOXAMED|LMWH
219398171|NCT04850911|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
219398172|NCT04850911|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
219398173|NCT02973646|DRUG|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
219398174|NCT02973646|DRUG|Peginterferon Alfa-2B|
219398175|NCT00398528|DRUG|Glatiramer acetate, (Copaxone®)|
219398176|NCT00398528|DRUG|IFN-β-1a, (Avonex®)|
219563076|NCT01465282|DRUG|CT327 0.1%|0.1% CT327 (w/w) ointment
219563077|NCT01465282|DRUG|CT327 0.5%|0.5% CT327 (w/w) ointment
219563078|NCT01465282|DRUG|Placebo|Placebo
219001917|NCT04677374|BEHAVIORAL|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
219001918|NCT04677374|BEHAVIORAL|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
219398177|NCT00740506|BEHAVIORAL|Frequency of Intercourse|
219398178|NCT02384369|DRUG|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
219563079|NCT05261789|OTHER|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
219398179|NCT05938439|DEVICE|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~* Placement through the endoscope of a soft guidewire through the upper GI tract;~* Insertion of the MAGUS system on the guidewire;~* Advancement of the MAGUS system until proximal magnet reach the top of the septum;~* Release and placement of the proximal magnet at the bottom of the septum, pouch side;~* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~* Release of the distal magnet and activate the retractable wire;~* Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
219398180|NCT05164276|OTHER|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
219398181|NCT04632329|DEVICE|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
219398182|NCT00863629|DRUG|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
219398183|NCT00233220|BEHAVIORAL|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
219398184|NCT00233220|BEHAVIORAL|Usual Care|Patients will receive usual care.
219398185|NCT01105338|BEHAVIORAL|Green tea drink|Green tea drink
219398186|NCT01105338|DIETARY_SUPPLEMENT|green tea capsules|green tea capsules
219398187|NCT01105338|OTHER|Green tea placebo capsules|Green tea placebo capsules
219398188|NCT01105338|DIETARY_SUPPLEMENT|Lycopene capsules|Lycopene capsules
219398189|NCT01105338|OTHER|Lycopene placebo capsules|Lycopene placebo capsules
219398190|NCT01105338|OTHER|Tomato rich diet|Tomato rich diet
219398191|NCT02119104|DRUG|Prevenar (13v)|Prevenar (13v)
219398192|NCT02088944|DRUG|Infliximab|
219398193|NCT05730608|OTHER|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
219563080|NCT05261789|OTHER|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
219563081|NCT05261789|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
219563082|NCT00607295|DRUG|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
219563083|NCT02419235|OTHER|20% ethanol|Unmedicated 20% ethanol.
219563084|NCT02419235|OTHER|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
219563085|NCT06424717|DRUG|Avelumab|Participants will be administered Avelumab intravenously (IV).
219563086|NCT06424717|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
219563087|NCT04199884|BEHAVIORAL|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
219398194|NCT05126225|BEHAVIORAL|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
219398195|NCT00929578|DRUG|Fluphenazine|Intralesional injection of Fluphenazine
219398196|NCT00929578|DRUG|Placebo|Intralesional injection of placebo
219398197|NCT05275829|OTHER|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
219563088|NCT04199884|BEHAVIORAL|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
219563089|NCT04377906|BEHAVIORAL|Modification Lifesyle|high protein-fiber and exercise
219563090|NCT04778306|PROCEDURE|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
219563091|NCT03136406|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219563092|NCT03136406|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219563093|NCT03136406|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219563094|NCT03136406|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219563095|NCT03136406|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219563096|NCT03136406|DRUG|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219563097|NCT03136406|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
219563098|NCT03136406|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
219563099|NCT03136406|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219563100|NCT03136406|BIOLOGICAL|aNK for Infusion|NK-92 cells
219563101|NCT03136406|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219563102|NCT03136406|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
219563103|NCT03244475|DEVICE|TES|"The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes."
219563104|NCT02177006|BEHAVIORAL|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
219563105|NCT03576287|DRUG|Apremilast Oral Product|Apremilast
219563106|NCT03323060|DEVICE|Transanal endoscopic surgical procedure|Resection of tumors or lesions
219563107|NCT00001662|DRUG|CX516 (Ampalex)|
219563108|NCT00333476|DRUG|MSI-1256F (Squalamine Lactate)|
219398198|NCT02239094|DRUG|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
219398199|NCT04570891|PROCEDURE|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
219398200|NCT04570891|PROCEDURE|Control|No regional block is provided at the end of surgery.
219563109|NCT06051604|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
219563110|NCT04341272|DEVICE|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
219563111|NCT04651322|DEVICE|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy"
219563112|NCT04651322|BEHAVIORAL|Conventional therapy|The control group received the usual conventional therapy \*Only Conventional occupational therapy
219563113|NCT01129739|OTHER|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
219563114|NCT01129739|OTHER|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
219563115|NCT01178164|GENETIC|Blood sampling for biological and genetic analysis|"* Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
219563116|NCT00846859|DRUG|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
219563117|NCT00846859|DRUG|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
219563118|NCT06286059|DRUG|Phentolamine|In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
219563119|NCT05357859|DIETARY_SUPPLEMENT|solubilized vitamin D3|solubilized vitamin D3
219563120|NCT05357859|DIETARY_SUPPLEMENT|medium chain triglyceride|MCT with same amount
219001919|NCT04677374|BEHAVIORAL|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
219001920|NCT02248155|DRUG|Pramipexole|
219398201|NCT01568580|DRUG|GreenGene|Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
219398202|NCT02008240|PROCEDURE|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
219398203|NCT02008240|PROCEDURE|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
219563121|NCT03767699|BEHAVIORAL|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never \< 1,500 kcal).
219563122|NCT01358799|DEVICE|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
219398204|NCT01144689|BEHAVIORAL|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
219398205|NCT01144689|BEHAVIORAL|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
219563123|NCT00641199|OTHER|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
219563124|NCT03115606|DEVICE|C-Mac D Blade|Videolaryngoscope
219563125|NCT03115606|DEVICE|Fastrach LMA|Laryngeal mask airway
219563126|NCT03803111|BEHAVIORAL|Initial exercise training|Initial exercise training program
219563127|NCT03803111|DRUG|Initial FCM|Initial intravenous iron supplementation (FCM)
219563128|NCT03803111|DRUG|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
219563129|NCT03803111|BEHAVIORAL|Subsequent exercise training|Subsequent exercise training program after 2 months
219563130|NCT05062915|DIAGNOSTIC_TEST|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
219563131|NCT01657084|DEVICE|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
219563132|NCT01657084|DEVICE|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
219563133|NCT04894084|DEVICE|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
219563134|NCT04452279|DEVICE|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
219563135|NCT04913207|PROCEDURE|method of device size selection|device size selection based on 3D-CTA
219398206|NCT03184701|OTHER|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
219563136|NCT02000531|DRUG|Erlotinib|150 mg oral dose of erlotinib given once daily
219563137|NCT02000531|DRUG|Chemotherapy|Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
219398207|NCT05690594|OTHER|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~* General questionnaire (to collect socio-demographic data)~* ICIQ score to evaluate urinary continence~* FLQI score to evaluate fecal continence~* FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~* SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
219563138|NCT03663790|OTHER|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
219563139|NCT03663790|OTHER|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
219563140|NCT02591563|OTHER|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
219563141|NCT04065568|DEVICE|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
219001921|NCT04740788|DEVICE|Monofocal IOL|Patients are already implanted with a monofocal lens
219563142|NCT03631368|DRUG|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
219563143|NCT02956616|DRUG|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
219001922|NCT05104892|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
219398208|NCT01863563|DEVICE|QuickClot|1 application of treatment to each tonsil/adenoid removal area
219398209|NCT00734409|DEVICE|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
219398210|NCT02573805|DEVICE|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
219398211|NCT03174860|DRUG|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
219398212|NCT03174860|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
219398213|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
219398214|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
219398215|NCT04195074|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
219398216|NCT04195074|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
219563144|NCT02956616|OTHER|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
219563145|NCT02956616|PROCEDURE|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
219563146|NCT01768819|BEHAVIORAL|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
219563147|NCT01345318|BIOLOGICAL|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
219563148|NCT01345318|BIOLOGICAL|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
219398217|NCT04195074|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
219398218|NCT03625219|DRUG|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
219398219|NCT03625219|DRUG|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
219398220|NCT00962923|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
219563149|NCT01022684|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
219563150|NCT01247779|PROCEDURE|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
219563151|NCT01247779|PROCEDURE|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
219563152|NCT00317642|DRUG|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
219563153|NCT00317642|DRUG|placebo|placebo (sodium Chloride) 1-hour IV infusion
219563154|NCT00317642|DRUG|cytarabine|cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
219563155|NCT00450983|BIOLOGICAL|muromonab-CD3|
219563156|NCT00450983|BIOLOGICAL|natural killer cell therapy|
219563157|NCT00450983|DRUG|fludarabine phosphate|
219563158|NCT00450983|DRUG|methotrexate|
219001923|NCT05104892|DRUG|placebo|Pharmaceutical form: Tablet Route of administration: Oral
219398221|NCT05348005|DEVICE|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
219398222|NCT03785197|OTHER|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
219398223|NCT05420519|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219398224|NCT02986958|OTHER|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
219398225|NCT02986958|OTHER|Usual care|routine primary care
219398226|NCT02111824|DEVICE|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
219563159|NCT00450983|DRUG|thiotepa|
219563160|NCT00450983|GENETIC|gene expression analysis|
219563161|NCT00450983|OTHER|flow cytometry|
219563162|NCT00450983|OTHER|immunologic technique|
219563163|NCT00450983|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219563164|NCT00450983|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219563165|NCT00450983|RADIATION|total-body irradiation|
219563166|NCT00031928|DRUG|mafosfamide|
219563167|NCT00213057|DRUG|Carraguard (PC-515)|
219563168|NCT01800435|DRUG|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
219563169|NCT01800435|DRUG|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
219563170|NCT00098228|DRUG|QAB149|
219189408|NCT07056101|DEVICE|A conventional dental syringe|The conventional dental syringe (C-K JECT) is a manual, metal aspirating syringe commonly used for local anesthesia administration in dental procedures. In this study, the device is used to perform buccal and intrapapillary infiltration using 4% articaine with 1:100,000 epinephrine. Injections are delivered manually at a standardized rate by the principal investigator. This arm serves as the active comparator to evaluate differences in pain perception between traditional syringe injections and those delivered via a computer-controlled device.
219398227|NCT02111824|DRUG|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
219398228|NCT02257814|BEHAVIORAL|Incredible Years Teacher Training|
219398229|NCT02257814|BEHAVIORAL|Preschool PATHS|
219398230|NCT02257814|BEHAVIORAL|Tools of the Mind|
219398231|NCT01950481|DRUG|LDK378|Oral LDK378 750 mg once
219398232|NCT02820610|DRUG|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
219398233|NCT02820610|DRUG|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
219398234|NCT02820610|DRUG|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
219398235|NCT02399475|DRUG|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
219398236|NCT02399475|DRUG|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
219398237|NCT02399475|DRUG|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
219398238|NCT02237807|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
219398239|NCT02237807|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
219398240|NCT02154854|DRUG|Tacrolimus targeted half-dose|
219398241|NCT02154854|DRUG|Tacrolimus targeted plain dose|
219398242|NCT00744146|BIOLOGICAL|Protexia|Single 50 mg IM dose
219398243|NCT00744146|BIOLOGICAL|Protexia|Single 100 mg dose
219398244|NCT00744146|BIOLOGICAL|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
219398245|NCT00744146|BIOLOGICAL|Protexia|Single 500 mg dose, IM
219398246|NCT00744146|BIOLOGICAL|Protexia|Single 750 mg dose, IM
219398247|NCT03393013|DRUG|KZR-616|Subcutaneous Injection of KZR-616
219398248|NCT00013403|PROCEDURE|Blindness|
219398249|NCT01009385|PROCEDURE|cervical epidural steroid injection|"* After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
219398250|NCT01009385|PROCEDURE|epidural pressure measurement|"* The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system."
219398251|NCT02133378|DEVICE|Hemopatch|Baxter Hemopatch
219398252|NCT02133378|BEHAVIORAL|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
219398253|NCT02532868|DRUG|MK-0457|
219398254|NCT01963117|RADIATION|Combined hyperthermia and radiation therapy|
219398255|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
219398256|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
219398257|NCT02082067|PROCEDURE|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
219398258|NCT02082067|PROCEDURE|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
219398259|NCT02082067|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
219398260|NCT02082067|PROCEDURE|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
219398261|NCT02082067|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
219398262|NCT02082067|DRUG|Ropivacaine 0,75%|
219398263|NCT02082067|DRUG|Levobupivacaine 0,5%|
219398264|NCT02082067|DRUG|Levobupivacaine 0,125%|
219398265|NCT02082067|DRUG|Ketorolac 30mg|
219398266|NCT02082067|DRUG|Morphine|
219398267|NCT02082067|DEVICE|stimulong sono, Pajunk, Germany|
219563171|NCT00556491|DRUG|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
219563172|NCT00556491|DRUG|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
219563173|NCT02921503|OTHER|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
219563174|NCT04305379|PROCEDURE|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
219563175|NCT04305379|PROCEDURE|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
219563176|NCT03269799|DRUG|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
219563177|NCT03269799|OTHER|placebo|non surgical periodontal treatment+placebo for 2 months
219563178|NCT02639728|OTHER|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
219563179|NCT02639728|OTHER|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
219563180|NCT02639728|OTHER|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
219563181|NCT01602471|DRUG|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
219563182|NCT06366945|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 1, 3, and 6
219563183|NCT06366945|DRUG|Tislelizumab|Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
219563184|NCT06366945|DRUG|Polymeric Micellar Paclitaxel|Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
219563185|NCT06366945|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
219563186|NCT06366945|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
219563187|NCT03648619|DIAGNOSTIC_TEST|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
219563188|NCT00519974|OTHER|counseling intervention|
219563189|NCT00519974|OTHER|study of socioeconomic and demographic variables|
219563190|NCT00519974|PROCEDURE|management of therapy complications|
219563191|NCT00519974|PROCEDURE|psychosocial assessment and care|
219563192|NCT01239472|DRUG|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
219563193|NCT03138902|DIETARY_SUPPLEMENT|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
219189409|NCT07056101|DEVICE|GENI High-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that automates the injection process using pressure feedback to regulate flow. In this arm, the device is set to high-speed mode to deliver the anesthetic solution at the fastest available flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The procedure is carried out by the principal investigator using a standardized technique. Pain perception is assessed following injection to evaluate the impact of delivery speed on patient experience.
219398268|NCT05232591|DIAGNOSTIC_TEST|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
219398269|NCT04126369|OTHER|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
219398270|NCT04126369|OTHER|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
219398271|NCT01938820|DRUG|entecavir|anti-viral therapy
219398272|NCT01938820|DRUG|Thymosin-α|antiviral and antifibrosis therapy
219563194|NCT01579760|DRUG|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
219563195|NCT01579760|DRUG|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
219563196|NCT04781114|DRUG|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
219563197|NCT04781114|DRUG|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
219563198|NCT02334241|DEVICE|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
219563199|NCT02334241|DEVICE|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
219563200|NCT02201979|PROCEDURE|Vertical breast lift with implants|
219563201|NCT01163084|DRUG|Goserelin Acetate|Given SC
219563202|NCT01163084|OTHER|Laboratory Biomarker Analysis|Correlative studies
219563203|NCT01163084|DRUG|Leuprolide Acetate|Given IM
219563204|NCT01163084|DRUG|Vismodegib|Given PO
219398273|NCT01636869|DRUG|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
219398274|NCT05186181|BEHAVIORAL|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
219398275|NCT01000064|DRUG|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
219398276|NCT01000064|PROCEDURE|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
219563205|NCT05752188|OTHER|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
219563206|NCT01145924|PROCEDURE|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
219563207|NCT01470196|DRUG|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
219563208|NCT01470196|DRUG|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
219563209|NCT01470196|DRUG|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
219563210|NCT04815252|BEHAVIORAL|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
219563211|NCT00002787|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
219563212|NCT00002787|BIOLOGICAL|sargramostim|Given SC
219398277|NCT01000064|DRUG|Placebo|Placebo capsules taken every morning for 6 weeks.
219563213|NCT00002787|BIOLOGICAL|aldesleukin|Given SC
219398278|NCT02309736|DEVICE|ReSure Sealant|
219398279|NCT00000849|DRUG|Aldesleukin|
219398280|NCT01518192|DRUG|doxycycline|100 mg bid; 15 days
219563214|NCT00002787|OTHER|laboratory biomarker analysis|Correlative studies
219563215|NCT03018093|BIOLOGICAL|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
219563216|NCT05840094|DRUG|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
219563217|NCT05840094|DEVICE|MR STIR|The overall scanning time of MR is about 13min.
219563218|NCT05840094|PROCEDURE|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
219563219|NCT03974165|OTHER|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
219563220|NCT03974165|OTHER|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
219563221|NCT03974165|OTHER|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
219563222|NCT03974165|OTHER|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
219563223|NCT04683757|OTHER|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
219563224|NCT02839486|OTHER|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
219001924|NCT03916328|DRUG|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
219398281|NCT01518192|DRUG|cefuroxime axetil|500 mg bid; 15 days
219398282|NCT00759512|OTHER|Therapeutic Touch|
219398283|NCT03911544|DEVICE|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
219398284|NCT02681887|DRUG|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
219398285|NCT02681887|DRUG|Placebo|placebo tablet identical to circadian
219398286|NCT02131467|DRUG|Perampanel|oral drug
219398287|NCT03670862|OTHER|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
219563225|NCT02839486|OTHER|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
219563226|NCT06296524|OTHER|Footcore exercises and conventional therapy|30 minutes exercises protocol will be provided
219563227|NCT06296524|OTHER|conventional therapy|conventional therapy will be provided.
219563228|NCT03119493|BEHAVIORAL|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
219563229|NCT03024931|OTHER|observational study|No intervention
219563230|NCT01120769|DRUG|Acetaminophen|single dose
219398288|NCT03090737|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219398289|NCT03141307|BEHAVIORAL|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
219398290|NCT03141307|BEHAVIORAL|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
219398291|NCT03141307|BEHAVIORAL|Control|Standard of care, paper-based brochure
219563231|NCT01120769|DRUG|Placebo|single dose
219563232|NCT02323165|OTHER|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
219563233|NCT03022669|BEHAVIORAL|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
219563234|NCT03022669|BEHAVIORAL|Mobile Application|
219563235|NCT03022669|OTHER|Website|American Heart Association patient education website
219563236|NCT05491239|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
219563237|NCT05491239|PROCEDURE|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
219563238|NCT05491239|PROCEDURE|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
219563239|NCT01049412|DRUG|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
219001925|NCT03916328|DRUG|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
219398292|NCT06671080|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
219001926|NCT03916328|OTHER|DMPA|Two thirds of the women will be on DMPA for contraception.
219001927|NCT03764189|PROCEDURE|microosteoperforation|small holes made using large round bur
219001928|NCT00080977|BIOLOGICAL|aldesleukin|
219398293|NCT03458000|DEVICE|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
219398294|NCT03458000|OTHER|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
219398295|NCT06672211|OTHER|video-supported training|Patients with stomas were provided with video-supported training in addition to standard stoma care training.
219398296|NCT02858388|DEVICE|Sinuclean Nebules 45|Nebulization of solution
219398297|NCT02858388|OTHER|Saline solution|Nebulization of solution
219398298|NCT06123416|BEHAVIORAL|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
219398299|NCT04654325|DIAGNOSTIC_TEST|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
219398300|NCT03604614|DRUG|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
219398301|NCT03604614|DRUG|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
219398302|NCT04430582|OTHER|Cognitive Assessment (not diagnostic)|Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
219398303|NCT04430582|DIAGNOSTIC_TEST|ECG|ECG will take place during screening visit.
219398304|NCT00031577|DRUG|paclitaxel|
219398305|NCT00031577|RADIATION|radiation therapy|
219398306|NCT06287125|DEVICE|Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147|"Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI"
219398307|NCT00204633|DRUG|Darbepoetin alfa|
219398308|NCT04019496|DRUG|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
219398309|NCT06757140|DRUG|Alprazolam|Participants will receive varying non-therapeutic experimental doses of oral alprazolam, alone and in combination with oral oxycodone
219001929|NCT06460857|OTHER|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.
219001930|NCT06460857|OTHER|Chest Wall Expansion Exercises|Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
219398310|NCT06757140|DRUG|Oxycodone|Participants will receive varying non-therapeutic experimental doses of oral oxycodone, alone and in combination with oral alprazolam
219398311|NCT06757140|DRUG|Placebo|Participants will receive inactive oral doses
219398312|NCT05091489|OTHER|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
219398313|NCT02444637|DRUG|Rivastigmine|
219398314|NCT02407574|DEVICE|External Pacing Box|Atrial pacing using an external pacing box
219398315|NCT06796946|DRUG|Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)|Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients
219398316|NCT06249503|DRUG|platelet rich plasma|The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.
219398317|NCT05695911|BEHAVIORAL|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
219398318|NCT05695911|OTHER|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
219398319|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
219398320|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
219398321|NCT03630614|DRUG|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
219398322|NCT03900559|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
219398323|NCT04955145|DRUG|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
219398324|NCT04496791|DEVICE|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
219398325|NCT04582734|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
219398326|NCT05029115|DRUG|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
219398327|NCT01869829|DRUG|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
219398328|NCT02547077|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
219398329|NCT02547077|PROCEDURE|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
219398330|NCT06224699|DRUG|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
219398331|NCT05047640|BIOLOGICAL|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
219398332|NCT05047640|BIOLOGICAL|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
219398333|NCT02391844|DRUG|Oxycodone|Oxycodone with Acetaminophen Extended Release
219563240|NCT01049412|DRUG|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
219563241|NCT03703024|DIETARY_SUPPLEMENT|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
219563242|NCT03703024|DIETARY_SUPPLEMENT|Placebo|Delivered in a capsule
219563243|NCT01944787|OTHER|Routine|IV Hydration at 125 cc hour
219398334|NCT05443672|DEVICE|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
219398335|NCT01570400|BEHAVIORAL|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
219398336|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
219398337|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
219398338|NCT02590445|DEVICE|deep brain stimulation system|
219398339|NCT00873769|DRUG|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
219398340|NCT03785886|BEHAVIORAL|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
219563244|NCT01944787|OTHER|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
219563245|NCT06685159|PROCEDURE|Laparoscopic Surgery|Laparoscopic surgery (with controlled pneumoperitoneum) in the Trendelenburg position
219563246|NCT00111462|DRUG|Darbepoetin alfa|
219563247|NCT04232657|DRUG|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
219563248|NCT04232657|DRUG|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
219001931|NCT06040112|DEVICE|Atelocollagen|Tendoregen (Atelocollagen) injection
219001932|NCT03446183|BEHAVIORAL|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
219563249|NCT04232657|DRUG|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
219563250|NCT00850681|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
219563251|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
219563252|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
219398341|NCT03785886|BEHAVIORAL|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
219563253|NCT03756883|DRUG|Placebo Inhalation Powder|No active content
219563254|NCT02044250|DRUG|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
219563255|NCT02044250|DRUG|Aspirin|Aspirin 100\~200mg 1\~2tab P.O. daily
219563256|NCT06617078|PROCEDURE|long-term oxygen therapy (LTOT)|Usual care with LTOT for 2 weeks
219563257|NCT06617078|PROCEDURE|High Flow Nasal Therapy (HFNT)|High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L/min, 34°C, identical O2 flow rate as LTOT) for 2 weeks
219398342|NCT03785886|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
219398343|NCT02309164|PROCEDURE|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
219398344|NCT02309164|BEHAVIORAL|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
219398345|NCT03009539|BEHAVIORAL|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
219398346|NCT03151148|BIOLOGICAL|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
219398347|NCT03151148|DRUG|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
219398348|NCT01986218|DRUG|BMS-986115|
219398349|NCT05239897|DEVICE|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
219398350|NCT03338751|DIAGNOSTIC_TEST|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
219398351|NCT03338751|DIAGNOSTIC_TEST|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
219398352|NCT00494871|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
219398353|NCT00494871|DRUG|Warfarin|Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
219398354|NCT00494871|DRUG|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
219398355|NCT00494871|DRUG|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
219563258|NCT06240364|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
219563259|NCT06240364|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 84 days.
219563260|NCT02358551|DEVICE|Placement of electrode lead through axillary vein puncture|
219563261|NCT02358551|DEVICE|Placement of electrode lead through subclavian vein puncture|
219563262|NCT06420609|OTHER|Go-TAD|The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
219563263|NCT05045469|DRUG|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
219563264|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
219563265|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
219563266|NCT03777904|DIAGNOSTIC_TEST|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
219563267|NCT03777904|DIAGNOSTIC_TEST|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
219563268|NCT03841890|DEVICE|the Clarus Video System as a video stylet|video-guided intubation
219398356|NCT01908621|DRUG|G-CSF (filgrastim)|
219398357|NCT01908621|DRUG|Cytosine arabinoside + G-CSF (filgrastim)|
219398358|NCT00688168|BEHAVIORAL|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
219398359|NCT00688168|BEHAVIORAL|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
219398360|NCT00688168|BEHAVIORAL|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
219398361|NCT04543955|DRUG|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
219398362|NCT04543955|DRUG|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
219398363|NCT02084836|OTHER|Functional Magnetic Resonance Imaging|
219398364|NCT05345886|BEHAVIORAL|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
219398365|NCT05502471|DIAGNOSTIC_TEST|Zonulin|Serum zonulin level
219398366|NCT05502471|DIAGNOSTIC_TEST|Occludin|Serum occludin level
219398367|NCT05436899|OTHER|LapSim training|Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.
219398368|NCT05436899|OTHER|LapSim exam|Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
219398369|NCT05824845|PROCEDURE|Hip/Knee Replacement|Hip/Knee Replacement
219398374|NCT03120338|DIAGNOSTIC_TEST|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
219398375|NCT03319992|DEVICE|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
219398376|NCT04157660|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
219398377|NCT04157660|PROCEDURE|Sham room air|Room air will be applied via mask
219398378|NCT02292381|OTHER|Isometric exercise|
219398379|NCT01847638|DRUG|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
219398380|NCT01847638|DRUG|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
219398381|NCT02951546|DIETARY_SUPPLEMENT|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
219563269|NCT03841890|DEVICE|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
219563270|NCT03841890|DEVICE|direct laryngoscope|Macintosh laryngoscope size 3
219563271|NCT03052114|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
219563272|NCT04119024|PROCEDURE|Biopsy|Undergo biopsy
219563273|NCT04119024|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219563274|NCT04119024|PROCEDURE|Computed Tomography|Undergo CT scan
219563275|NCT04119024|DRUG|Cyclophosphamide|Given IV
219398382|NCT02951546|DIETARY_SUPPLEMENT|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
219398383|NCT02951546|OTHER|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
219398384|NCT02528669|DEVICE|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
219563276|NCT04119024|DRUG|Fludarabine Phosphate|Given IV
219563277|NCT04119024|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
219563278|NCT04119024|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
219563279|NCT04119024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219563280|NCT04119024|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219563281|NCT06450873|DRUG|Coriolus Versicolor Extract|Dietary Supplement Given PO
219563282|NCT06450873|OTHER|Questionnaire Administration|Ancillary studies
219563283|NCT05894148|DRUG|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
219563284|NCT05894148|DRUG|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
219563285|NCT01040273|DRUG|Bupivacaine|
219563286|NCT01040273|DRUG|Placebo|
219563287|NCT04628481|DRUG|Ladarixin|Oral ladarixin twice a day for 13 cycles
219563288|NCT04628481|DRUG|Placebo|Oral placebo twice a day for 13 cycles
219563289|NCT00502658|BEHAVIORAL|Dietary supplement containing vitamins, minerals, and herbs|
219563290|NCT00502658|BEHAVIORAL|Shakes with nutrients and herbs|
219563291|NCT00502658|BEHAVIORAL|Control dietary supplement|
219563292|NCT00502658|BEHAVIORAL|Isocaloric, isonitrogenous control shakes without herbs|
219563293|NCT00502658|BEHAVIORAL|Personal energy tracking tool|
219563294|NCT03562949|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
219563295|NCT03562949|DRUG|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
219563296|NCT03562949|DRUG|Placebo|Placebo Product
219563297|NCT04245293|DEVICE|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
219563298|NCT04245293|DEVICE|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
219563299|NCT03816449|OTHER|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
219563300|NCT06532968|DEVICE|Sham|Sham
219563301|NCT06532968|DEVICE|ORION spinal lamina cover|an artificial lamina coverage of the ORION spinal system
219563302|NCT01889472|DEVICE|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
219563303|NCT01660477|DRUG|Isavuconazole|oral
219563304|NCT01660477|DRUG|Lopinavir/ritonavir|oral
219563305|NCT02136238|DEVICE|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
219563306|NCT02136238|DEVICE|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
219398385|NCT01945931|OTHER|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
219398386|NCT05071781|DRUG|Corticotropin-release hormone|intravenous CRH (100 µg)
219398387|NCT05071781|DRUG|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
219398388|NCT00950612|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
219398389|NCT00950612|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
219398390|NCT05892783|OTHER|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
219398391|NCT00900133|OTHER|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
219398392|NCT00900133|OTHER|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
219398393|NCT03935477|DEVICE|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
219398394|NCT02025972|PROCEDURE|Allogeneic umbilical cord blood therapy|
219563307|NCT04010734|PROCEDURE|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
219563308|NCT05878041|DIAGNOSTIC_TEST|Molecular and genetic screening|Molecular and genetic screening
219398395|NCT01823822|DIETARY_SUPPLEMENT|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
219398396|NCT01823822|DIETARY_SUPPLEMENT|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
219398397|NCT03762525|RADIATION|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
219398398|NCT03275883|PROCEDURE|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
219398399|NCT03564665|DIETARY_SUPPLEMENT|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
219398400|NCT03564665|OTHER|Placebo|Placebo BID for 8 weeks.
219398401|NCT02433210|DEVICE|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
219398402|NCT02433210|DEVICE|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
219398403|NCT02433210|DEVICE|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
219398404|NCT06259955|OTHER|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
219398405|NCT05055739|DEVICE|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
219563309|NCT02078011|DEVICE|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
219563310|NCT01899196|BIOLOGICAL|blood sampling,|
219563311|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
219563312|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
219398406|NCT00747890|PROCEDURE|Modified tonsillectomy|"* Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
219189410|NCT07056101|DEVICE|GENI Moderate-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system designed to regulate flow and pressure during injection using real-time feedback. In this arm, the device is set to moderate-speed mode, delivering anesthetic at an intermediate flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The injection is administered by the principal investigator using a standardized technique. This group is used to assess the impact of moderate-speed delivery on pain perception and physiological response in pediatric patients.
219398407|NCT00747890|OTHER|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
219563313|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
219563314|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
219563315|NCT00640458|DRUG|Sildenafil 100 mg|
219563316|NCT00640458|DRUG|Placebo|
219563317|NCT03928535|DEVICE|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
219563318|NCT03928535|DEVICE|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
219563319|NCT05402787|OTHER|Virtual visit|A virtual visit will be made to mothers whose babies are hospitalized in the neonatal intensive care unit
219563320|NCT05181800|OTHER|Degarelix Cohort|Non-interventional
219563321|NCT01546519|DRUG|Vismodegib|oral repeating dose of 150 mg once daily
219563322|NCT00792584|DRUG|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
219563323|NCT00792584|DRUG|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
219398408|NCT04171544|DEVICE|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
219398409|NCT03206944|DRUG|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
219398410|NCT03206944|DRUG|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
219563324|NCT02184741|DRUG|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
219563325|NCT02184741|DRUG|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
219563326|NCT02246088|PROCEDURE|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
219563327|NCT02246088|PROCEDURE|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
219563328|NCT00615849|PROCEDURE|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
219563329|NCT00263887|DRUG|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
219563330|NCT00263887|DRUG|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
219563331|NCT05236842|DRUG|Sulthiame|oral
219563332|NCT04513860|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
219563333|NCT01992016|DRUG|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
219398411|NCT02731040|DRUG|Bisphosphonate|
219398412|NCT00399269|DRUG|Recombinant Human Erythropoietin alpha|
219398413|NCT03574896|OTHER|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
219398414|NCT02298517|PROCEDURE|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
219398415|NCT02298517|PROCEDURE|inspiratory load equipment|Threshold and Power breathe
219563334|NCT02409186|DRUG|Nimotuzumab|400mg/w，d1, week 1-7
219563335|NCT02409186|RADIATION|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
219563336|NCT02409186|DRUG|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
219563337|NCT02409186|DRUG|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
219563338|NCT02409186|OTHER|placebo|400mg/w，d1, week 1-7
219563339|NCT01303068|DEVICE|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
219563340|NCT03920683|OTHER|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
219563341|NCT05290779|PROCEDURE|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
219189411|NCT07056101|DEVICE|GENI Low-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that maintains precise control over injection pressure and flow. In this arm, the device is set to low-speed mode, delivering the anesthetic solution at the slowest available rate to minimize tissue pressure and potential discomfort. Buccal and intrapapillary infiltration is administered using 4% articaine with 1:100,000 epinephrine. The injection is performed by the principal investigator using a standardized technique. This group evaluates whether low-speed delivery reduces pain perception and improves patient comfort compared to faster injection speeds and conventional methods.
219189412|NCT07062367|DRUG|Propofol|Patients' anesthesia will be maintained by manually adjusted propofol infusion at a rate of 100-250 mic/kg/min for bispectral index (BIS) maintained between 40-60.
219189413|NCT07062367|DRUG|Sevoflurane plus lidocaine infusion|Sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60 plus intravenous lidocaine infusion given as 2mg /kg IV bolus before induction then intraoperative infusion by a rate of 2 mg/kg/h until the end of surgery.
219189414|NCT07062367|DRUG|Sevoflurane|Patients will receive sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60.
219189415|NCT07064382|DEVICE|VR-based multi-dimensional intervention|VR-based multi-dimensional intervention, including LLMs, AI-agents
219398416|NCT02099916|DRUG|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
219398417|NCT02099916|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
219398418|NCT03046472|OTHER|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
219398419|NCT03823937|OTHER|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
219398420|NCT06022913|BEHAVIORAL|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
219398421|NCT01818791|BEHAVIORAL|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
219398422|NCT01818791|BEHAVIORAL|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
219398423|NCT04524936|DIAGNOSTIC_TEST|blood sample|
219398424|NCT04813237|OTHER|n a|the participants are not subjected to any type of intervention
219398425|NCT01958671|DRUG|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
219398426|NCT01958671|DRUG|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
219001933|NCT03342690|DRUG|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
219001934|NCT05803057|DEVICE|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
219001935|NCT05803057|DEVICE|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
219001936|NCT05898555|DEVICE|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
219001937|NCT02309879|DRUG|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
219001938|NCT02309879|DRUG|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
219001939|NCT02309879|DRUG|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
219001940|NCT02309879|DRUG|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
219001941|NCT04219631|DEVICE|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
219001942|NCT05922150|RADIATION|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
219398427|NCT01958671|DRUG|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
219398428|NCT01958671|DRUG|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
219398429|NCT01958671|DRUG|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
219398430|NCT01958671|DRUG|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
219398431|NCT00587418|DIETARY_SUPPLEMENT|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
219398432|NCT00587418|DIETARY_SUPPLEMENT|Placebo|Placebo powder 9.2g bid for 7 days
219398433|NCT02388529|DRUG|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
219398434|NCT02388529|DRUG|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
219398435|NCT02388529|DRUG|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
219398436|NCT02388529|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
219398437|NCT06034834|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
219398438|NCT00559052|DRUG|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
219398439|NCT04760314|DRUG|Lebrikizumab|Administered SC
219398440|NCT04760314|DRUG|Placebo|Administered SC
219398441|NCT04760314|DRUG|Topical Corticosteroid|Self-applied
219398442|NCT04279561|PROCEDURE|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
219398443|NCT04279561|DRUG|Gallium Ga 68 Gozetotide|Given IV
219398444|NCT04279561|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
219398445|NCT01290484|DRUG|Sildenafil|Sildenafil oral tablet three times daily
219398446|NCT02461914|DRUG|PEX168|200µg,injected subcutaneously,once a week.
219398447|NCT02461914|DRUG|Warfarin|5mg,oral,two times.
219398448|NCT01279538|DRUG|bleselumab|Intravenous (IV) infusion
219398449|NCT01279538|DRUG|Placebo|Intravenous (IV) infusion
219398450|NCT01803399|DRUG|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
219398451|NCT01803399|DRUG|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
219398452|NCT01803399|DRUG|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
219398453|NCT01803399|DRUG|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
219398454|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
219563342|NCT04886557|PROCEDURE|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
219563343|NCT05376618|OTHER|no intervention|no intervention
219563344|NCT04611984|PROCEDURE|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
219563345|NCT04611984|PROCEDURE|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
219563346|NCT05440019|DEVICE|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
219563347|NCT00707434|DEVICE|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
219563348|NCT04676880|DEVICE|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
219563349|NCT04344457|DRUG|Hydroxychloroquine|200 mg PO BID 7 days
219563350|NCT04344457|DRUG|Indomethacin|50 mg PO TID 14 Days
219563351|NCT04344457|DRUG|Zithromax Oral Product|500 mg PO QD 3 Days
219563352|NCT06407076|OTHER|Interviews|Following the design of the questionnaire, using open-ended questions based on the availability, accessibility, acceptability and quality (AAAQ) framework, qualitative semi-structured personal interviews were used to collect the data. In this way it was possible to collect information in a more detailed way. The subjects included in the study had to answer the questions posed by the main researcher, responding with open or closed answers, through a questionnaire created for this purpose.
219563353|NCT03540758|DRUG|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
219563354|NCT03540758|DRUG|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
219563355|NCT03540758|DRUG|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
219563356|NCT01165749|BEHAVIORAL|stop exercising|
219563357|NCT02572791|DRUG|Chlorhexidine|
219563358|NCT02572791|DRUG|Mupirocin|
219563359|NCT02572791|BEHAVIORAL|Household cleaning|
219563360|NCT02643927|BEHAVIORAL|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
219001943|NCT05922150|DRUG|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
219001944|NCT03131050|DRUG|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
219001945|NCT03131050|DRUG|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
219001946|NCT03131050|DRUG|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
219398455|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
219398456|NCT02207530|DRUG|MEDI4736|MEDI4736 monotherapy
219398457|NCT02636764|OTHER|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
219398458|NCT02636764|DEVICE|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
219398459|NCT02636764|DEVICE|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
219398460|NCT02636764|DEVICE|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
219398461|NCT02636764|DEVICE|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
219398462|NCT02045277|DRUG|IDP-118 Lotion|Lotion
219398463|NCT02045277|DRUG|IDP-118 Monad HP Lotion|Active Comparator
219398464|NCT02045277|DRUG|IDP-118 Monad Taz Lotion|Active Comparator
219398465|NCT02045277|DRUG|IDP-118 Vehicle Lotion|Vehicle
219398466|NCT03468283|OTHER|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
219398467|NCT05424900|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
219398468|NCT03642015|BEHAVIORAL|Music listening|listening the music 15 min
219398469|NCT04971044|BEHAVIORAL|COACH|Multi-Level Behavioral Intervention
219563361|NCT02643927|BEHAVIORAL|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
219563362|NCT01386125|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
219563363|NCT01386125|DRUG|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
219563364|NCT00153257|DEVICE|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
219563365|NCT01866644|DRUG|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
219398470|NCT04971044|BEHAVIORAL|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
219398471|NCT05152160|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
219563366|NCT01866644|DRUG|Saline|Bath saline transplanted liver
219398472|NCT06478758|DRUG|Ibuprofen 400 mg|The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
219398473|NCT06478758|DRUG|Acetaminophen 100 MG/ML|The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
219398474|NCT00935142|DRUG|[18F]VM4-037|Bolus IV injection of \[18F\]VM4-037
219563367|NCT02670785|DRUG|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
219563368|NCT02670785|DRUG|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
219563369|NCT00448227|DRUG|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
219563370|NCT05960422|PROCEDURE|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
219001947|NCT06124612|DIAGNOSTIC_TEST|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
219398475|NCT05973994|DEVICE|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
219398476|NCT00819533|DEVICE|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
219398477|NCT03466489|DEVICE|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
219398478|NCT04388735|BEHAVIORAL|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
219398479|NCT01873664|BEHAVIORAL|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
219398480|NCT00909987|DRUG|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
219398481|NCT00909987|DRUG|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
219398482|NCT00909987|DRUG|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
219398483|NCT00909987|RADIATION|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
219398484|NCT00909987|DRUG|Capecitabine during all Radiotherapy period|825 mg/m2 bid
219398485|NCT00909987|PROCEDURE|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
219563371|NCT05960422|PROCEDURE|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
219563372|NCT00280930|DRUG|Letrozole|
219563373|NCT01353716|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
219563374|NCT00564096|DEVICE|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
219563375|NCT00564096|DEVICE|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
219563376|NCT00391534|DRUG|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
219563377|NCT00391534|DRUG|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
219563378|NCT00658034|PROCEDURE|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
219563379|NCT00658034|PROCEDURE|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
219563380|NCT04832334|OTHER|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
219563381|NCT04832334|OTHER|Berg Balance Scale, Functional Reach Test|Balance level was determined.
219189416|NCT07062809|OTHER|Sub Occipital Myofascial release and (SNAGS).|The patient will instruct to be seated then will turned his head toward direction that will cause his dizziness. when subject will turn his head, The manual therapist will perform a constant PA glide (using his thumbs one over the other) to upper cervical C1 or C2 vertebra (Oriented toward patient's eyeballs). If flexion or extension movement will provoke the dizziness, an anterior glide will apply to the C2 spinous process. If rotation will provoke dizziness, then an anterior glide will be applied to the C1 transverse process.
219189417|NCT07062809|OTHER|Sub Occipital Myofascial release.|When using the technique, the patient will be in Upward-facing position with their head fully aided on the therapist's hands. The therapist will put three middle fingers simply inferior to the nuchal line, raise the tips of the fingers in the direction of the ceiling, and then simply pull them upward.
219189418|NCT07062627|GENETIC|Anbal-cel|"On Day 1 (D1), Anbal-cel will be administered only to subjects who meet the final inclusion/exclusion criteria for Anbal-cel administration before the infusion.~As premedication before Anbal-cel administration, acetaminophen or paracetamol, and diphenhydramine or H1 antihistamine will be given.~Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing, at the dose presented in the following table:~Dose: 2x10\^6 (CAR-T cells/kg)\* Maximum 2 x 10\^8 cells"
219189419|NCT07062250|DEVICE|Feasibility and safety of home-based blood count measurement and transfusions|Feasibility and safety of home-based blood count measurement and transfusions in patients with acute myeloid leukemia
219189420|NCT07063719|OTHER|Ophthalmological visit|"Uncorrected visual acuity (UCVA), best-corrected visual acuity (BSCVA), corneal topography, corneal pachymetry, ocular surface pictures (to evaluate disease status of the eye with and without fluorecein), Schirmer's test, Corneal esthesiometry, Tear film break-up time test, Intraocular pressure.~Below is a summary of steps to perform ocular surface pictures of the cornea.~1. Ensure slit lamp cleaning and appropriate magnification and light settings.~2. Ensure comfortable positioning of both the operator and the patient.~3. Examine external orbital structures and adnexa for inflammation, irritation, or lesions.~4. Examine lids and lashes for abnormalities.~5. Examine both bulbar and palpebral conjunctiva for signs of irritation and injection.~6. Examine the cornea for clarity and the presence of any defect.~7. Examine the anterior chamber depth and evaluate abnormalities that might affect its transparency (blood, purulent material, cells and flare).~8. Examine the surface of the iris an"
219189421|NCT07063719|OTHER|Questionnaires|Ocular Surface Disease Index (OSDI) questionnaire, Visual Analog Pain Scale (VAS) questionnaire
219189422|NCT07063719|OTHER|Blood sample collection|Blood samples from RED patients or control group are collected in BD Vacutainer K2 EDTA.
219189423|NCT07063719|OTHER|Impression cytology|Put one drop of oxybuprocaine hydrochloride 0.4% in patients' eyes and wait 10 seconds. Gently apply both side of one sterile nitrocellulose membrane onto the unexposed bulbar conjunctiva, superotemporally, inferotemporally, superonasally, and inferonasally, for approximately 20 seconds, please, keep the eyes separated.
219398486|NCT05884788|OTHER|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~* An attachment questionnaire: Relationship Scales Questionnaire~* A questionnaire on symptoms: Distress thermometer"
219398487|NCT06045546|PROCEDURE|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
219398488|NCT06045546|PROCEDURE|10-10-5-5 technique|the standard technique of 10-10-5-5 for laparoscopic cholecystectomy
219398489|NCT05721950|DRUG|Brigatinib|Brigatinib Tablets
219398490|NCT05520996|BEHAVIORAL|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
219398491|NCT06286098|DRUG|Alpha lipoic acid|THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
219398492|NCT06286098|OTHER|Placebo|Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
219398493|NCT01848821|DEVICE|OASIS Ultra|Porcine derived intestinal submucosa
219398494|NCT01848821|DEVICE|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
219398495|NCT01495546|OTHER|Early loading|Patients stepping down immediately after THA
219398496|NCT01495546|OTHER|Late loading|Patients stepping down after three weeks of HTA
219398497|NCT00019513|DRUG|fluorouracil|
219398498|NCT00019513|DRUG|gemcitabine hydrochloride|
219398499|NCT00019513|DRUG|leucovorin calcium|
219398500|NCT06031480|DRUG|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
219398501|NCT04438603|DRUG|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
219563382|NCT04832334|OTHER|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
219563383|NCT01020617|DIETARY_SUPPLEMENT|Ls-33|10\~10 CFU/day
219563384|NCT05453708|OTHER|Survey|One 15-20-minute survey
219563385|NCT03953664|OTHER|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
219563386|NCT00725764|DRUG|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
219563387|NCT00003808|DRUG|theophylline|
219563388|NCT03853499|OTHER|No intervention (observational study)|No intervention (observational study)
219398502|NCT04438603|DRUG|Intervention for patients at high risk of disease progression|"BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
219398503|NCT04205370|DEVICE|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
219398504|NCT04205370|DEVICE|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
219398505|NCT04162964|BEHAVIORAL|Virtual Chair Yoga|8-week virtual chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead on the software Zoom by a certified instructor in English and French.
219563389|NCT05580887|DRUG|mFOLFIRINOX|every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
219563390|NCT05580887|DRUG|Doxorubicin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
219563391|NCT05580887|DRUG|Cyclophosphamid|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
219398506|NCT06036446|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
219398507|NCT06036446|DRUG|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
219398508|NCT04809727|PROCEDURE|Cervical biopsy|4 quadrant biopsy
219563392|NCT05580887|DRUG|Paclitaxel|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
219563393|NCT05580887|DRUG|Carboplatin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
219563394|NCT00828828|BIOLOGICAL|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
219563395|NCT04939558|DEVICE|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
219398509|NCT02538237|DRUG|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
219563396|NCT03114358|OTHER|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
219563397|NCT01264835|DEVICE|Slotted Anoscope|SA411
219001948|NCT03219294|DRUG|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
219001949|NCT03219294|DRUG|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
219001950|NCT02187484|DRUG|BIBR 277|
219001951|NCT02599272|OTHER|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
219001952|NCT02599272|OTHER|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
219001953|NCT02599272|OTHER|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
219563398|NCT02909517|OTHER|cSLO imaging|
219563399|NCT05522634|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
219563400|NCT04073134|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219563401|NCT04073134|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219001954|NCT04519151|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
219001955|NCT04519151|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
219001956|NCT01373801|DEVICE|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
219001957|NCT01373801|DEVICE|Control|Standard packing gauze roll bandage.
219398510|NCT02538237|DRUG|Ibuprofen 2% mouthwash|
219563402|NCT02449616|DRUG|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
219563403|NCT01691586|DEVICE|Remote patient monitoring|Remote monitoring of ICD and heart failure data
219563404|NCT01691586|OTHER|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
219563405|NCT01659034|DRUG|Thienopyridine for 3 months|
219563406|NCT04139863|DIAGNOSTIC_TEST|aMMP-8 chairside test|No test
219563407|NCT00218335|BEHAVIORAL|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
219563408|NCT00218335|BEHAVIORAL|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
219001958|NCT01160250|DRUG|vismodegib (GDC-0449)|Oral repeating dose
219001959|NCT03224572|DRUG|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
219001960|NCT03224572|OTHER|normal saline|500ml normal saline, once per week, and total 4-week treatment
219189424|NCT07063719|OTHER|Tear fluid|One sterile minisponge per eye will be placed over the lids margin at the junction of the lateral and middle thirds of the lower eyelids and kept in place for 2 minutes. During application of sponges the patient needs to look up to facilitate the procedure. To avoid excessive tear reflex, as well as a mild discomfort, it is recommended that patients close their eyes during the collection. Remove sponge using sterile tweezers and put it into empty 0.5mL tube (pierced at the bottom with a sterile needle) placed into another empty 1.5 mL tube and keep it on ice until processing.
219189425|NCT07062796|DEVICE|Water Faucet|Access H2OTM faucet is a smart, hand free faucet that is designed for ease water access for physical limitations
219189426|NCT07064447|PROCEDURE|Cholangiopancreatoscopy|Direct cholangiopancreatoscopy by single operator
219189427|NCT07062120|OTHER|Nicotinamide(NAM)(10%)|The active niacinamide form of vitamin B3, NAM is routinely employed as a pigmentation-reducing agent in melasma treatment protocols
219189428|NCT07062120|OTHER|Supramolecular salicylic acid(SSA) (30%)|Salicylic acid, a superficial chemical peel, has been widely used in treating melasma. Breakthroughs in supramolecular design have addressed its irritancy profile through engineered SA complexes with improved water dispersibility
219189429|NCT07062120|OTHER|Supramolecular salicylic acid simulator|the same course of treatment in the same dosage form that does not contain salicylic acid
219189430|NCT07062120|OTHER|Nicotinamide simulator|the same course of treatment in the same dosage form that does not contain nicotinamide
219189431|NCT07064070|BEHAVIORAL|TRUST|The four online modules included: General Communication, Talking about Relationships and Sexual Health, Parental Monitoring, and Check-up and Check-in (content focused on the importance of alone time). Modules were in English, Chinese, or Spanish
219189432|NCT06772701|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
219189433|NCT06772701|OTHER|EPDS book|PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
219189434|NCT07063264|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
219398511|NCT06255977|DRUG|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
219398512|NCT04958564|DEVICE|DCP|"1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load."
219398513|NCT02310958|PROCEDURE|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
219398514|NCT02771808|OTHER|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
219398515|NCT00003753|DRUG|dexamethasone|
219398516|NCT00003753|DRUG|floxuridine|
219398517|NCT00003753|DRUG|irinotecan hydrochloride|
219398518|NCT00003753|PROCEDURE|adjuvant therapy|
219398519|NCT00003753|PROCEDURE|conventional surgery|
219398520|NCT04316689|BIOLOGICAL|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
219398521|NCT04316689|BIOLOGICAL|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
219398522|NCT02148458|OTHER|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
219398523|NCT02148458|OTHER|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
219398524|NCT05870007|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
219398525|NCT05870007|DRUG|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
219398526|NCT03808272|DEVICE|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
219398527|NCT05897138|DRUG|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
219398528|NCT02184416|OTHER|observational|The study is non interventional. All drugs will be prescribed
219398529|NCT00478660|DRUG|adalimumab (Humira)|
219563409|NCT00680524|OTHER|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
219563410|NCT04659486|BEHAVIORAL|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
219563411|NCT02673086|OTHER|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
219398530|NCT06035432|OTHER|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
219398531|NCT06035432|OTHER|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
219563412|NCT02673086|OTHER|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
219563413|NCT05696041|OTHER|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
219563414|NCT00108550|DRUG|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
219563415|NCT00108550|DRUG|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
219563416|NCT05126212|OTHER|User experience|User experience is assessed by validated scale
219563417|NCT01764750|DRUG|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
219001961|NCT05741567|PROCEDURE|correction of anterior prolapse|percentage of failed prolapse correction
219001962|NCT04912050|DEVICE|Tablo Hemodialysis System|Renal Replacement Therapy between 12\< to ≤ 24 hours.
219001963|NCT00168688|DIETARY_SUPPLEMENT|multi micronutrient supplement|
219001964|NCT00168688|DIETARY_SUPPLEMENT|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
219001965|NCT00168688|DIETARY_SUPPLEMENT|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
219398532|NCT06035432|OTHER|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
219563418|NCT01764750|DRUG|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
219563419|NCT04072003|DEVICE|intravascular ultrasound (IVUS)|use IVUS in the procedure
219563420|NCT04072003|OTHER|coronary angiography|Coronary angiography is required for all PCI procedure.
219563421|NCT03022890|BEHAVIORAL|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
219001966|NCT02329249|BEHAVIORAL|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
219001967|NCT02329249|OTHER|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
219001968|NCT05964244|DEVICE|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
219001969|NCT05964244|DEVICE|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
219398533|NCT06035432|OTHER|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
219398534|NCT04594408|DRUG|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
219563422|NCT03022890|BEHAVIORAL|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
219563423|NCT05885386|DRUG|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
219398535|NCT04594408|DRUG|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
219563424|NCT01867190|BIOLOGICAL|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
219563425|NCT00512538|DEVICE|Bi-layered cell therapy (Apligraf)|
219563426|NCT04379284|OTHER|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
219563427|NCT03039036|PROCEDURE|Amniotomy|Artificially rupturing membranes
219398536|NCT04594408|DRUG|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
219563428|NCT03039036|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
219563429|NCT03039036|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
219398537|NCT06342297|DEVICE|Dermatoscopy|Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
219398538|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
219398539|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
219398540|NCT05451121|DRUG|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
219398541|NCT05451121|DRUG|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
219398542|NCT05451121|DRUG|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
219563430|NCT04660032|BEHAVIORAL|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
219563431|NCT02729207|DRUG|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
219563432|NCT02111109|DEVICE|Side Stream Dark Field Microscopy|
219563433|NCT06403137|BEHAVIORAL|Resistance exercise|4 single-leg exercise sessions
219189435|NCT07063264|DEVICE|sham high-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219398543|NCT03938376|DIAGNOSTIC_TEST|Micro-Ultrasound guided biopsy|High-resolution imaging device
219398544|NCT04328064|DRUG|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
219398545|NCT04328064|DRUG|Placebo oral tablet|40 mg placebo for 12 months
219398546|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
219398547|NCT01505491|DRUG|BI695501|BI 695501 single s.c injection
219398548|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
219563434|NCT06403137|BEHAVIORAL|Standardized diet|Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.
219563435|NCT06403137|DIETARY_SUPPLEMENT|Plant protein supplement|Dissolved in water with breakfast and prior to sleep.
219563436|NCT06403137|DIETARY_SUPPLEMENT|Maltodextrin supplement|Dissolved in water with breakfast and prior to sleep.
219563437|NCT06403137|DIETARY_SUPPLEMENT|Milk protein supplement|Dissolved in water with breakfast and prior to sleep.
219563438|NCT00090753|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
219563439|NCT00090753|DRUG|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
219563440|NCT00090753|DRUG|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
219398549|NCT05415956|BEHAVIORAL|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
219398550|NCT05601999|BIOLOGICAL|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
219398551|NCT05601999|BIOLOGICAL|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
219398552|NCT02759146|OTHER|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
219398553|NCT02759146|OTHER|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
219398554|NCT05858294|BEHAVIORAL|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
219563441|NCT00090753|DRUG|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
219563442|NCT03895151|DIETARY_SUPPLEMENT|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
219563443|NCT03895151|OTHER|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
219563444|NCT01358253|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
219563445|NCT01358253|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
219563446|NCT01358253|DRUG|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
219563447|NCT01358253|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
219189436|NCT07064395|OTHER|bright light|Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.
219189437|NCT07064434|PROCEDURE|Sacral canal block combined with general anesthesia|"Sacral canal block: The patient lies on their side, with the back perpendicular to the edge of the operating table. The knee joints of the lower limbs are flexed, the thighs are close to the abdomen, and the waist is arched backward as much as possible, resembling a shrimp shape. The space between the sacrum and coccyx of the patient (sacral hiatus) is fully exposed. By using a low-frequency probe (such as 2-5 MHZ), the strong echo of the sacrum, the low echo of the sacral canal, and the echo of the surrounding soft tissues can be clearly seen. At the located sacral hiatus, hold the puncture needle and slowly insert it perpendicularly to the skin. When the puncture needle passes through the sacrococcygeal ligament, there will be a distinct breakthrough sensation, which indicates that the puncture needle has entered the sacral canal. The general depth of needle insertion is about 2 to 3cm. However, the specific depth varies depending on factors such as the patient's body type."
219189438|NCT07064434|PROCEDURE|Simple general anesthesia|General anesthesia: Midazolam (0.2mg/kg), sufentanil (0.2-0.4μg/kg), etomidate (0.15-0.3 mg/kg), and rocuronium (0.6 mg/kg) were induced. After the patient's muscles were completely relaxed, a laryngeal mask was placed. Connect the anesthesia machine and set the ventilator parameters: Vol.Mode, tidal volume 6-8ml/kg, frequency 10-14 times /min, inhalation-exhalation ratio 1:2, and maintain EtCO2 at 35-45mmHg during the operation. Propofol (4-12mg/kg/h) and remifentanil (0.05-2ug/kg/min) were maintained. According to the operation course, rocuronium (0.15mg/kg) and sevoflurane inhalation (1% - 7%) could be administered at a single time. Anesthesiologists adjust the drug infusion rate based on the patient's hemodynamic indicators SBP, MAP, HR and clinical experience. When HR was less than 45 times /min during the operation, atropine was intravenously injected (0.25-0.5mg per time). When MAP is less than 55mmHg and lasts for more than 3 minutes, ephedrine (6-12mg each time) is given.
219189439|NCT07063017|OTHER|Post- Isometric Relaxation|Post Isometric Relaxation Technique to Piriformis; Lay the patient in the supine position and have the practitioner stand on the same side as the affected piriformis muscle. Bend the knee of the affected side and place the foot of that side on the lateral aspect of the opposite knee. Have the practitioner push knee medially until meeting the restrictive barrier. Have the patient push against the practitioner's resistance for 3 to 5 seconds, allow for a period of isometric relaxation, then engage a new barrier; repeat three times. Return the patient to a neutral position and reassess using supine or prone piriformis testing.
219189440|NCT07063017|OTHER|Active Release Technique|Patient position is side lying on the sound side. Therapist stands behind the patient. The upper leg must be in flexion on knee and slight extension Now apply pressure with both thumbs on piriformis and ask patient to flex and extend his hip and also external and internal rotation on hip in flexion. The gluteal muscle is taken from a shortened position to a fully lengthened position while the physiotherapist's contact hand holds tension longitudinally along the soft tissue fibers.
219563448|NCT01358253|DRUG|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
219563449|NCT01358253|DRUG|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
219563450|NCT01358253|DRUG|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
219563451|NCT01358253|DRUG|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
219189441|NCT04574882|OTHER|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
219563452|NCT01358253|DRUG|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
219563453|NCT01358253|DRUG|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
219563454|NCT01845753|OTHER|Observation|Observation
219563455|NCT01160445|DRUG|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
219563456|NCT01160445|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
219563457|NCT04145245|DRUG|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
219563458|NCT02767947|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
219563459|NCT02767947|DRUG|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
219563460|NCT03363698|OTHER|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
219563461|NCT04221594|PROCEDURE|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
219563462|NCT04221594|PROCEDURE|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
219563463|NCT04221594|PROCEDURE|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
219563464|NCT02684396|DRUG|TAK-648|TAK-648 Solution
219563465|NCT02684396|DRUG|TAK-648 Placebo|TAK-648 placebo-matching solution
219563466|NCT00065117|DRUG|ZD6126|
219563467|NCT00065117|DRUG|Placebo|
219563468|NCT00065117|DRUG|5-fluorouracil|
219563469|NCT00065117|DRUG|leucovorin|
219563470|NCT00065117|DRUG|oxaliplatin|
219563471|NCT04912986|BEHAVIORAL|Early Lung Rehabilitation Training|It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.
219563472|NCT04912986|BEHAVIORAL|Routine treatment|Provide rehabilitation training as usual, without standard program
219563473|NCT01903564|DEVICE|magnetocardiography|recording of magnetic heart activity
219563474|NCT01903564|DEVICE|postnatal ECG|postnatal ECG
219189442|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
219563475|NCT01903564|DEVICE|fetal echocardiography|fetal echocardiography
219563476|NCT03904550|DRUG|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
219563477|NCT03904550|DRUG|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
219189443|NCT06249815|COMBINATION_PRODUCT|Misoprostol 200mcg Tab|ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
219189444|NCT06249815|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
219563478|NCT05152615|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
219563479|NCT02257437|DIETARY_SUPPLEMENT|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
219563480|NCT02257437|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
219563481|NCT02257437|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
219563482|NCT02257437|DIETARY_SUPPLEMENT|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
219563483|NCT03079427|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
219563484|NCT03079427|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
219563485|NCT00925873|DRUG|Active comparator (no fludarabine)|"1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
219563486|NCT00925873|DRUG|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
219001970|NCT05398211|BEHAVIORAL|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
219563487|NCT02324231|OTHER|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
219563488|NCT02324231|OTHER|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
219563489|NCT04946786|DIAGNOSTIC_TEST|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"1. Complete history taking.~2. Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3\. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5\. Body composition analysis: to detect water, muscle and fat percentage in the body.~6\. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
219398555|NCT06286787|OTHER|Intervention|The training programme will consist of a 3-hour lecture. The contents of the lecture will include knowledge of mountaineering in Hong Kong, country codes and care for the environment, environmental awareness when undertaking outdoor activities, hiking skills, knowledge and choice of hiking equipment and clothing, trip planning, mountain safety, map reading, the use of a compass, mountain safety, basic first aid, methods of calling for help in an emergency and sources of weather data. After completing the lecture, participants will be required to join a 6-day hiking training programme on weekends within a 3-month period (each training will be at least 5 kilometres and the duration will be at least 4 hours).
219398556|NCT06286787|OTHER|Placebo|Control participants will be asked to join six day-time leisure activities on weekends within a 3-month period. Leisure activities will be organised by the Asbury Methodist Social Service and will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and eating a healthy diet, and day visits to a museum and theme park. Children in the placebo control group will receive free access to leisure activities, including visits to museums and theme parks as an incentive for his/her participation.
219398557|NCT01073956|PROCEDURE|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
219398558|NCT01073956|PROCEDURE|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
219398559|NCT01073956|PROCEDURE|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
219398560|NCT00002452|DRUG|L-756423|
219398561|NCT00002452|DRUG|Indinavir sulfate|
219563490|NCT02816424|BEHAVIORAL|Teens Exploring and Managing Prevention Options (TEMPO)|
219563491|NCT05934539|DRUG|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
219189445|NCT06618014|DRUG|Toripalimab|Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.
219189446|NCT06618014|DRUG|Docetaxel|Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.
219189447|NCT06618014|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.
219563492|NCT03394716|RADIATION|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
219563493|NCT02351635|OTHER|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
219398562|NCT03862079|OTHER|Best Practice|Given standard of care
219398563|NCT03862079|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
219398564|NCT03862079|DRUG|Nystatin|Given PO
219398565|NCT03862079|DRUG|Piperacillin-Tazobactam|Given PO
219398566|NCT01695057|DRUG|vorinostat|Given PO
219398567|NCT01695057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219563494|NCT01921335|DRUG|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
219563495|NCT01921335|DRUG|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
219563496|NCT01921335|DRUG|Trastuzumab|6 mg/kg IV every 3 weeks
219398568|NCT01695057|OTHER|laboratory biomarker analysis|Correlative studies
219398569|NCT05808348|OTHER|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
219398570|NCT05631327|DRUG|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
219398571|NCT03329040|OTHER|No Intervention.|No intervention.
219398572|NCT00139854|DRUG|Alprazolam orally disintegrating tablets|
219563497|NCT01401335|BEHAVIORAL|Questionnaires|questionnaires at entry, month 4, 8 and 12
219563498|NCT04983602|OTHER|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
219563499|NCT04983602|OTHER|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
219563500|NCT04366284|OTHER|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
219563501|NCT04366284|OTHER|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
219563502|NCT04366284|OTHER|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
219398573|NCT01512641|OTHER|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
219398574|NCT01512641|OTHER|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
219398575|NCT03389061|DRUG|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
219398576|NCT03389061|DRUG|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
219398577|NCT04279912|DEVICE|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
219398578|NCT02003560|RADIATION|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
219398579|NCT03121872|PROCEDURE|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
219398580|NCT03121872|PROCEDURE|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
219398581|NCT05895279|OTHER|Media Intervention|Watch MiCaP Research Digest video
219398582|NCT05895279|OTHER|Media Intervention|Watch alternate video
219398583|NCT05895279|OTHER|Survey Administration|Complete survey
219398584|NCT04772365|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
219398585|NCT04772365|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels;
219398586|NCT02961647|PROCEDURE|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
219398587|NCT00013598|DRUG|Pioglitazone|
219563503|NCT04738838|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
219563504|NCT04738838|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
219398588|NCT02519244|DEVICE|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
219398589|NCT02065440|DRUG|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
219563505|NCT02626208|DEVICE|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
219563506|NCT02292550|DRUG|Ribociclib|CDK 4/6 inhibitor
219563507|NCT02292550|DRUG|Ceritinib|ALK inhibitor
219563508|NCT01839838|RADIATION|Proton Therapy|
219563509|NCT05609695|DRUG|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
219563510|NCT01466036|DRUG|Cabozantinib|60 mg QD orally in cycles of 28 days
219563511|NCT04747184|OTHER|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
219563512|NCT03293771|OTHER|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
219563513|NCT03293771|DIAGNOSTIC_TEST|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
219563514|NCT03267654|DRUG|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
219563515|NCT03267654|DRUG|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
219001971|NCT05398211|BEHAVIORAL|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
219001972|NCT06023823|OTHER|Toe spread out|toe-spread-out exercise.
219398590|NCT02065440|DRUG|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
219398591|NCT03253198|DRUG|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
219398592|NCT03253198|DRUG|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
219398593|NCT02739334|BEHAVIORAL|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
219563516|NCT03267654|DRUG|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
219563517|NCT05560451|BEHAVIORAL|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
219563518|NCT00348153|DRUG|Adalimumab|
219563519|NCT00981227|DRUG|Eslicarbazepine acetate|Scored tablets
219563520|NCT00981227|DRUG|Placebo|oral route
219563521|NCT06106334|DRUG|S309309|Administered as oral capsules
219563522|NCT06106334|DRUG|Itraconazole|Administered as oral capsules
219563523|NCT02462434|BEHAVIORAL|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
219563524|NCT05607563|DRUG|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
219563525|NCT01283646|DRUG|Apevitin BC|3.5 to 5 ml 3 times a daily
219563526|NCT01283646|DRUG|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
219398594|NCT02739334|BEHAVIORAL|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
219398595|NCT02713581|BIOLOGICAL|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
219398596|NCT00406315|DRUG|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
219563527|NCT04385095|DRUG|SNG001|SNG001 via inhalation
219563528|NCT04385095|DRUG|Placebo|Placebo via inhalation
219563529|NCT01325506|OTHER|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
219563530|NCT00436917|DRUG|zoledronic acid|zoledronic acid
219563531|NCT00436917|PROCEDURE|Letrozole as adjuvant therapy|standard care
219563532|NCT00196820|DRUG|Capecitabine|
219563533|NCT04855591|DRUG|SHR-1703|SHR-1703 will be administered subcutaneously
219563534|NCT04855591|DRUG|Placebo|Placebo of SHR-1703 will be administered subcutaneously
219563535|NCT00535080|DRUG|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
219563536|NCT05308368|DEVICE|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
219563537|NCT05308368|DEVICE|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
219563538|NCT05308368|DEVICE|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
219563539|NCT05308368|DEVICE|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
219563540|NCT03601494|OTHER|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
219001973|NCT06023823|OTHER|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
219001974|NCT02711540|PROCEDURE|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
219001975|NCT04362787|DEVICE|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
219001976|NCT01868750|DIETARY_SUPPLEMENT|Calcitriol|1.0ug twice daily for 7 days before surgery
219001977|NCT01868750|DIETARY_SUPPLEMENT|Control Pill|placebo pill taken twice daily for 7 days before surgery
219398597|NCT01312428|DEVICE|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
219398598|NCT01312428|DEVICE|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
219398599|NCT04191278|DRUG|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
219398600|NCT04191278|DEVICE|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
219563541|NCT03601494|DRUG|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
219563542|NCT06677931|PROCEDURE|Placebo Comparator:1565 non-ablative fractional laser combined with normal Saline|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply normal Saline.
219563543|NCT06677931|PROCEDURE|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell-derived exosomes.|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply exosomes.
219563544|NCT02438540|DRUG|metformin|metformin tablet 500 mg
219563545|NCT02438540|OTHER|acupuncture|Electro body acupuncture and auricular acupuncture
219563546|NCT02913131|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
219563547|NCT02913131|DEVICE|MRI|MRI scan following the pyruvate (13c) injection
219563548|NCT04374422|BEHAVIORAL|fsfi survey|sexual behavior Questionaire
219398601|NCT04191278|BEHAVIORAL|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
219398602|NCT03143582|OTHER|Running|A 13-week running program where youth run for 30 minutes twice weekly.
219398603|NCT02512263|PROCEDURE|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
219398604|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
219398605|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
219398606|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
219398607|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
219398608|NCT03474133|DRUG|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
219563549|NCT01503463|PROCEDURE|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
219563550|NCT02851719|OTHER|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
219563551|NCT02851719|OTHER|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
219563552|NCT03066895|DEVICE|BabyGentleStick|Experimental device.
219563553|NCT03066895|DEVICE|Standard Lancing Device|HMC standard of care.
219563554|NCT03028623|PROCEDURE|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
219563555|NCT03028623|PROCEDURE|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
219563556|NCT01287455|DRUG|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
219563557|NCT01287455|OTHER|placebo|drops, 70 placebo drops, once weekly for 6 weeks
219563558|NCT06678802|OTHER|Blood sampling|blood sampling from peripheral vein
219563559|NCT04181164|OTHER|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
219563560|NCT04181164|OTHER|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
219563561|NCT04181164|BIOLOGICAL|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
219563562|NCT05108506|BEHAVIORAL|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
219563563|NCT05108506|BEHAVIORAL|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
219563564|NCT05730452|BEHAVIORAL|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
219563565|NCT02715232|DRUG|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
219563566|NCT02715232|DRUG|Lynestrenol|2-3 tablets/day, if menstruation still occurs
219563567|NCT02715232|DRUG|Cyproterone Acetate|25mg daily
219563568|NCT02715232|DRUG|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
219563569|NCT02715232|DRUG|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
219563570|NCT00761176|DEVICE|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
219398609|NCT06397872|DRUG|100 mg Resmetirom Tablet|Once daily oral dose for 6 days
219398610|NCT01807507|DEVICE|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
219398611|NCT03939130|DIETARY_SUPPLEMENT|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
219398612|NCT03939130|DIETARY_SUPPLEMENT|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
219398613|NCT03939130|OTHER|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
219398614|NCT06329362|PROCEDURE|Minimally invasive implantation|Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
219563571|NCT03398590|BEHAVIORAL|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
219563572|NCT00109850|BIOLOGICAL|cetuximab|400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
219563573|NCT00109850|DRUG|cisplatin|30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
219563574|NCT00109850|DRUG|irinotecan hydrochloride|65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
219398615|NCT06329362|PROCEDURE|Open flap procedure for ridge expansion.|Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
219398616|NCT04860713|DRUG|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
219398617|NCT04860713|DRUG|Nurtec (Rimegepant)|Drug: 75 mg of ODT
219398618|NCT02226094|DEVICE|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
219563575|NCT00109850|RADIATION|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
219563576|NCT03549455|BEHAVIORAL|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
219563577|NCT00476593|DRUG|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
219563578|NCT00476593|DRUG|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
219563579|NCT03430011|BIOLOGICAL|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
219563580|NCT03430011|BIOLOGICAL|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
219563581|NCT01228227|DRUG|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
219563582|NCT01228227|DRUG|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
219563583|NCT03330860|OTHER|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
219563584|NCT03330860|OTHER|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
219563585|NCT01235442|DRUG|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
219563586|NCT01235442|DRUG|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
219563587|NCT00084799|BIOLOGICAL|monoclonal antibody hu3S193|
219563588|NCT03604432|DEVICE|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
219563589|NCT01672047|DRUG|Vitamin D2|25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
219563590|NCT05352282|PROCEDURE|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
219398619|NCT02226094|DEVICE|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
219563591|NCT05352282|PROCEDURE|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
219398620|NCT02226094|DEVICE|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
219398621|NCT02226094|DEVICE|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
219398622|NCT03813563|DRUG|RL|lactated Ringer's
219563592|NCT04323462|DRUG|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
219563593|NCT04323462|DRUG|Diabetic DM|Previously receiving OADs and/or basal insulin
219563594|NCT04258280|BEHAVIORAL|Education and counseling|Education includes a workbook, counseling includes peer support.
219563595|NCT04258280|BEHAVIORAL|Education|Education includes a workbook.
219563596|NCT00288925|DRUG|Z-360|
219563597|NCT02266940|DRUG|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
219563598|NCT02266940|DRUG|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
219563599|NCT04314843|DRUG|Cyclophosphamide|Administered according to package insert
219563600|NCT04314843|DRUG|Fludarabine|Administered according to package insert
219563601|NCT04314843|BIOLOGICAL|Lenzilumab|Administered as an IV infusion
219563602|NCT04314843|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
219563603|NCT06388031|DRUG|Immune checkpoint inhibitor|"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."
219189448|NCT05172843|PROCEDURE|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
219398623|NCT03813563|DRUG|PLA|PlasmaLyte
219398624|NCT05015400|OTHER|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
219563604|NCT04409587|DRUG|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
219563605|NCT03110016|DEVICE|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
219563606|NCT02335957|RADIATION|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
219563607|NCT00471991|DRUG|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
219563608|NCT00471991|DRUG|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
219563609|NCT00261417|DRUG|Tesaglitazar|
219189449|NCT05172843|BEHAVIORAL|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
219398625|NCT02786355|OTHER|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
219398626|NCT00023985|BIOLOGICAL|autologous tumor cell vaccine|
219398627|NCT00023985|BIOLOGICAL|therapeutic autologous dendritic cells|
219398628|NCT00023985|PROCEDURE|conventional surgery|
219398629|NCT02183025|DRUG|Meloxicam 7.5 mg|
219398630|NCT02183025|DRUG|Meloxicam 15 mg|
219398631|NCT02183025|DRUG|Mefenamic acid 500 mg|
219398632|NCT02183025|DRUG|Placebo matching 7.5 mg meloxicam|
219398633|NCT02183025|DRUG|Placebo matching 15 mg meloxicam|
219398634|NCT02183025|DRUG|Placebo matching 500 mg mefenamic acid|
219398635|NCT03140800|DEVICE|intrauterine device|a method of contraception inserted in the uterus
219398636|NCT01321996|PROCEDURE|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
219398637|NCT02273154|DRUG|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
219398638|NCT02273154|DRUG|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
219398639|NCT01449019|DRUG|exendin(9-39)amide|intravenous infusion of exendin(9-39)
219398640|NCT01449019|DRUG|saline|intravenous infusion of saline
219398641|NCT01449019|OTHER|duodenal meal|duodenal perfusion of a meal
219398642|NCT01449019|OTHER|duodenal saline|duodenal perfusion of saline
219398643|NCT04730986|BEHAVIORAL|ED GOAL Nursing|A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
219398644|NCT00200278|BEHAVIORAL|PROJECT STRIDE|
219398645|NCT00848692|DRUG|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
219398646|NCT00848692|DRUG|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
219398647|NCT02405052|OTHER|No intervention|Validation of the Panic Screening Score
219398648|NCT03238144|OTHER|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
219398649|NCT06373081|BIOLOGICAL|Anti-CD19-CD3E-CAR-T cells|The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
219398650|NCT01142219|DRUG|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
219398651|NCT01142219|DRUG|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
219398652|NCT03235570|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
219398653|NCT01615224|DRUG|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
219398654|NCT05870644|OTHER|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
219398655|NCT05870644|OTHER|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
219398656|NCT03868007|DEVICE|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219398657|NCT03868007|DEVICE|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219398658|NCT06250127|DEVICE|Modified 3D printed facemask|modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
219563610|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
219398659|NCT06250127|DEVICE|Conventional facemask appliance|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
219398660|NCT00339183|DRUG|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
219398661|NCT00339183|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
219398662|NCT00004880|BIOLOGICAL|dendritic cell vaccine therapy|
219398663|NCT00004880|PROCEDURE|conventional surgery|
219398664|NCT03454139|PROCEDURE|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
219398665|NCT05789446|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
219398666|NCT05394545|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
219398667|NCT04392011|DRUG|Midazolam HCl|Oral syrup, 2 mg/mL
219398668|NCT04392011|DRUG|Dextromethorphan HBr|Oral liquid capsules, 15 mg
219398669|NCT04392011|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
219398670|NCT00611130|DRUG|vigabatrin|Tablets twice a day for 9 weeks
219398671|NCT00611130|DRUG|placebo|tablets twice daily for 9 weeks
219563611|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
219563612|NCT04005963|DIAGNOSTIC_TEST|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
219189450|NCT03428646|DRUG|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
219398672|NCT01765647|OTHER|AGY|AGY is a natural health product produced in egg yolks
219398673|NCT04490954|DEVICE|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
219398674|NCT04490954|DEVICE|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
219398675|NCT03964415|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
219398676|NCT03964415|BIOLOGICAL|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
219398677|NCT03964415|BIOLOGICAL|Placebo|Participants will receive matching placebo.
219398678|NCT05463679|DRUG|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
219398679|NCT05463679|DRUG|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
219398680|NCT00596518|DRUG|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
219398681|NCT03747172|DIETARY_SUPPLEMENT|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
219398682|NCT03195634|DRUG|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day
219398683|NCT06322823|PROCEDURE|direct thawing|Vitrified blastocysts will be thawed directly into 1ml G-TL medium
219398684|NCT06322823|PROCEDURE|Vitrification|Vitrified blastocysts will be thawed using commercially available one-step media.
219398685|NCT03883048|OTHER|Observation of bronchiectasis with pulmonary hypertension|
219398686|NCT01704248|DEVICE|Eye Drop Guide technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
219398687|NCT01704248|BEHAVIORAL|Routine self-instillation technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
219398688|NCT00506051|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
219398689|NCT00506051|DRUG|pemetrexed|intravenous infusion
219398690|NCT00506051|DRUG|ZD6474 (vandetanib) 300mg|
219398691|NCT01252797|RADIATION|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
219398692|NCT01252797|RADIATION|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
219398693|NCT01734993|DRUG|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
219398694|NCT02096393|DEVICE|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
219398695|NCT02096393|DEVICE|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
219398696|NCT01257646|OTHER|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
219398697|NCT00733356|DRUG|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
219189451|NCT06230861|DIETARY_SUPPLEMENT|Quercetin|Quercetin tablets 500mg 1 x per day
219189452|NCT06230861|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
219398698|NCT01848964|DEVICE|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
219398699|NCT03411213|DEVICE|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
219398700|NCT00004284|DRUG|potassium citrate|
219398701|NCT00004284|DRUG|potassium phosphate|
219398702|NCT02836990|DEVICE|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
219398703|NCT02836990|DEVICE|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
219398704|NCT03917719|DRUG|Edasalonexent|100 mg/kg/day
219398705|NCT05967988|DEVICE|Immersive atmospheric projection|Projection of computer-generated videos or videos of real moving landscapes on the walls of the examination room
219398706|NCT05967988|DEVICE|Minimal atmospheric projection|Projection of a colors on the walls on the walls of the examination room
219398707|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
219398708|NCT05814770|DRUG|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
219398709|NCT05814770|DRUG|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
219398710|NCT02277132|DRUG|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
219398711|NCT02277132|DRUG|Placebo|Placebo tablets three times daily orally from randomization until delivery
219398712|NCT04617340|OTHER|Multifaceted clinical pharmacy intervention|"1. Assessing patient and caregiver preferences~2. Medication reconciliation on admission~3. Performing a comprehensive medication review before discharge~4. Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
219563613|NCT04825002|DIAGNOSTIC_TEST|Urinary multimarker sensor|We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
219563614|NCT03605823|DEVICE|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
219563615|NCT05375890|OTHER|no intervention|Narcolepsy patients in Russia gathered according to criteria.
219563616|NCT03993327|BIOLOGICAL|Iodine I 124 Monoclonal Antibody M5A|Given IV
219563617|NCT03993327|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219563618|NCT00280969|DRUG|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
219563619|NCT00280969|DRUG|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
219563620|NCT02323802|BEHAVIORAL|educational group intervention|
219563621|NCT02323802|BEHAVIORAL|prescriptive diet|
219563622|NCT04224194|COMBINATION_PRODUCT|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
219563623|NCT05220891|OTHER|Paracentesis|Paracentesis from ascitic patient
219189453|NCT06778031|DRUG|SHR-A1811|SHR-A1811.
219563624|NCT05680792|DRUG|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
219563625|NCT05680792|DRUG|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
219563626|NCT00037531|DRUG|Sirolimus (RAPAMUNE)|
219563627|NCT00521482|DRUG|Temozolomide|
219189454|NCT06778031|DRUG|SHR-1316|SHR-1316.
219189455|NCT06778031|DRUG|SHR-8068|SHR-8068.
219189456|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
219563628|NCT00521482|DRUG|Temozolomide plus Thalidomide|
219563629|NCT03134430|OTHER|Normal saline|Injection of Normal saline around peripheral nerve
219563630|NCT03134430|OTHER|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
219563631|NCT00003348|DRUG|O6-benzylguanine|
219563632|NCT00003348|DRUG|carmustine|
219398713|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to a PSS slightly greater than what was the mean calculated for normal subjects, with the goal of shifting the PSS in a direction associated with better clinical vestibular parameters and vestibular precision measurements (e.g. standard rotational testing VOR time constant, lower DHI, higher FGA score) . Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS desired or mean normal PSS), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
219398714|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
219563633|NCT02434263|DEVICE|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
219563634|NCT02589886|OTHER|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
219563635|NCT05390125|OTHER|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
219563636|NCT06275178|PROCEDURE|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
219563637|NCT04889391|DRUG|[14C]-Danicopan|Liquid-filled capsules.
219563638|NCT02285348|PROCEDURE|Lumbar puncture|Lumbar puncture is done according to general practice
219563639|NCT02697539|OTHER|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
219563640|NCT02697539|OTHER|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
219563641|NCT02241135|BIOLOGICAL|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
219563642|NCT05162729|BEHAVIORAL|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
219563643|NCT05162729|BEHAVIORAL|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
219563644|NCT05578469|PROCEDURE|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
219563645|NCT03530241|DIAGNOSTIC_TEST|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
219563646|NCT03530241|DIAGNOSTIC_TEST|Non-presence of bile duct stones|MRCP without bile duct stones
219563647|NCT01396694|OTHER|Questionnaire|Questionnaire
219563648|NCT04015531|RADIATION|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
219563649|NCT04015531|RADIATION|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
219563650|NCT03261024|DEVICE|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
219563651|NCT03261024|DEVICE|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
219398715|NCT04196933|BEHAVIORAL|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
219563652|NCT04459130|BEHAVIORAL|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
219563653|NCT04083443|OTHER|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
219563654|NCT06492408|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
219563655|NCT00099957|DRUG|vildagliptin|
219563656|NCT06409858|OTHER|Pilates|Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
219563657|NCT02725164|DRUG|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
219563658|NCT02725164|DRUG|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
219563659|NCT02725164|DRUG|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
219563660|NCT02725164|DRUG|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
219563661|NCT00655317|OTHER|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
219563662|NCT00655317|OTHER|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
219563663|NCT02378441|DRUG|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
219563664|NCT02378441|DRUG|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
219563665|NCT03840382|BEHAVIORAL|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
219563666|NCT06768099|OTHER|Linear Cognitive Aid|"Key features of this tool include:~* Minimal input: Teams input the patient's age and clinical scenario (e.g. arrest, childbirth, or trauma).~* Linear logic: Based on initial simple input, the tool provides straightforward guidance without requiring multiple Y/N input or advanced decision-making.~* Guidance based on individual characteristics: The tool tailors AHA guidance for the specific emergency scenario to the individual patient's size (estimated by age), emphasizing key interventions for the individual scenario and giving appropriate size-based guidance regarding choice of equipment, medication dosage, and resuscitation technique (e.g., chest compression depth).~* Time-based and on-demand guidance: Based on the time elapsed from the start of the resuscitation, the app will provide audio guidance regarding the next key steps."
219563667|NCT01195116|DRUG|Dexmedetomidine|1 mcg/kg/hour
219189457|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219189458|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
219189459|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219189460|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
219189461|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
219398716|NCT05772715|OTHER|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
219398717|NCT05772715|OTHER|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
219398718|NCT03433287|DIAGNOSTIC_TEST|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
219398719|NCT05033444|DRUG|PRV-002|"SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated."
219563668|NCT01195116|DRUG|Normal Saline|1mcg/kg/hr
219563669|NCT02040961|DEVICE|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
219563670|NCT01077505|BIOLOGICAL|albiglutide|albiglutide 50mg weekly subcutaneous injection
219563671|NCT01077505|DRUG|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
219563672|NCT00406016|DRUG|ATI355|
219563673|NCT03765190|COMBINATION_PRODUCT|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
219563674|NCT00067132|PROCEDURE|Juven (nutritional), HMB (nutritional)|
219563675|NCT06899438|DRUG|Botulinum Toxin A Injection|
219563676|NCT06899438|DRUG|Prilocaine HCl % 2 injectable solution|
219563677|NCT06903962|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular approximate 2 hour educational sessions and didactics learning mind body techniques. The sessions will be twice per week for the first 4 weeks and then subsequently once per week for a total of 13 weeks.
219563678|NCT01322334|BEHAVIORAL|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
219563679|NCT06904131|DRUG|Cell therapy with bispecific antibodies|"The dose-escalation phase is designed with three predefined dose levels, following a 3+3 design and progressing from low to high doses. The 3+3 dose-escalation scheme is as follows: if no dose-limiting toxicity (DLT) occurs in the three subjects at a given dose level during the observation period, the dose will be escalated to the next higher level. If one subject out of the initial three experiences DLT at a dose level, an additional three subjects will be enrolled at that dose level for further DLT observation. The dose level at which no more than one subject out of the final six subjects experiences DLT will be defined as the maximum tolerated dose (MTD)."
219563680|NCT06905678|OTHER|Questionnaires|The participants will fin in questionnaires about the financial and emotional burden they experience.
219563681|NCT06905678|OTHER|Semi-structured interviews|After the participants have filled in the questionnaires they will get the chance to participate in an interview to talk about their perceptions and experiences.
219563682|NCT06904911|DRUG|intra-arterial tenecteplase administration|Patients will receive a single dose of tenecteplase, administered intra-arterially after successful large vessel recanalization. The treatment will be administered via intra-arterial catheter in the distal M1 segment of the middle cerebral artery (distal to lenticulostriates).
219563683|NCT06903689|DRUG|Pentoxifylline 400 MG Oral Tablet|Oral tablet, 400 mg, administered twice daily with food for 6 months. To be taken in addition to conventional medications for chronic kidney disease.
219563684|NCT06903689|OTHER|Conventional Medications for Chronic Kidney Disease|This arm receives conventional medical management for chronic kidney disease (CKD). This includes medications and treatments as deemed necessary and appropriate by the participant's treating physician, according to established clinical guidelines for CKD. These may include, but are not limited to, medications for blood pressure control, management of diabetes, anemia treatment, mineral and bone disorder management, and fluid and electrolyte balance management. The specific medications and treatments are individualized and not dictated by the study protocol, but follow standard clinical practice for CKD.
219563685|NCT06904703|DRUG|General anesthesia|Patients will receive general anesthesia.
219563686|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block.
219563687|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block with pericapsular nerve block.
219398720|NCT05033444|DRUG|Placebo|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
219398721|NCT03735693|DIAGNOSTIC_TEST|Ulstrasound|measurement of right femoral cross-section
219398722|NCT05545813|DIETARY_SUPPLEMENT|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
219398723|NCT05545813|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
219398724|NCT06284928|OTHER|Gut Microbiota Analysis|This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
219398725|NCT01455428|DRUG|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
219398726|NCT01455428|DRUG|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
219398727|NCT04906005|DRUG|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
219398728|NCT04906005|DRUG|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
219398729|NCT02806765|DIETARY_SUPPLEMENT|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months
219398730|NCT02806765|OTHER|Control|Placebo in Softgel form
219398731|NCT02948595|OTHER|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
219398732|NCT02948595|OTHER|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
219398733|NCT00828386|PROCEDURE|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
219398734|NCT03303339|DRUG|Onvansertib|Onvansertib orally
219398735|NCT03303339|DRUG|Cytarabine|subcutaneously
219398736|NCT03303339|DRUG|Decitabine|intravenously
219398737|NCT05394272|OTHER|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
219398738|NCT06324487|OTHER|Progressive Exercises|Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
219398739|NCT06324487|OTHER|Blood Flow Restriction Therapy|Strengthening exercises performed by using cuff surrounding proximal part of the arm.
219398740|NCT03718104|OTHER|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
219398741|NCT03718104|OTHER|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
219398742|NCT03718104|GENETIC|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
219563688|NCT06904690|OTHER|Educational training|"The educational training is divided into the following five modules:~Module 1: Raising Awareness of eHealth and Health Literacy (Introduction to the aims and context of JACARDI and diabetes);~Module 2: Acquiring New Knowledge (Health Literacy and Self-Management of Diabetes);~Module 3: Acquiring New Knowledge (Technological and Non-Technological Strategies to Support the Self-Management of Diabetes);~Module 4: Practicing New Skills (Usability with Practice Sessions);~Module 5: Self-Evaluation and Sustainability of Improvement (Final Questionnaire).~The training will be conducted over 10 weeks (one session every other week), with each session lasting an average of 90 minutes."
219563689|NCT06256549|DRUG|GZR18|Titrated to low dose or middle or high dose
219563690|NCT06256549|DRUG|Semaglutide|Titrated to 1.0 mg once a week
219563691|NCT06021470|BEHAVIORAL|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
219398743|NCT03718104|OTHER|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
219398744|NCT02857023|BEHAVIORAL|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
219398745|NCT05692193|BEHAVIORAL|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
219398746|NCT00036205|DRUG|sumanirole|
219398747|NCT00469235|DRUG|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
219398748|NCT00477451|DRUG|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
219398749|NCT00477451|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
219398750|NCT00477451|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
219398751|NCT00477451|DRUG|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
219398752|NCT04440241|PROCEDURE|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
219563692|NCT02506205|BEHAVIORAL|Lee Silverman Voice Treatment (SVLT) LOUD|
219563693|NCT02910024|DEVICE|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
219563694|NCT02910024|DEVICE|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
219398753|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
219398754|NCT06298370|DRUG|Intrathecal bupivacaine and morphine|Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
219398755|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine and morphine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
219398756|NCT05427071|DEVICE|Magnetic seed localization|Magnetic seed guided localization
219398757|NCT00277472|DRUG|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
219398758|NCT00277472|DRUG|HCTZ|25 mg taken once daily orally
219398759|NCT01165801|PROCEDURE|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
219398760|NCT00884182|BIOLOGICAL|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
219398761|NCT01921270|DRUG|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
219398762|NCT00216606|DRUG|topiramate|
219563695|NCT03939949|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
219563696|NCT03939949|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
219398763|NCT01883128|DEVICE|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
219398764|NCT01883128|PROCEDURE|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
219398765|NCT01883128|PROCEDURE|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
219398766|NCT05535673|DRUG|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
219563697|NCT03939949|BEHAVIORAL|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
219563698|NCT04628936|DRUG|KZR-616|Subcutaneous 30 mg for 1 week, then 45 mg weekly
219563699|NCT06271902|OTHER|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
219563700|NCT06271902|OTHER|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
219563701|NCT00110695|DRUG|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
219563702|NCT05054322|DRUG|Fluticasone Propionate|Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
219563703|NCT04529876|DRUG|Tofacitinib|Tofacitinib claim is used as the reference group.
219563704|NCT04529876|DRUG|Abatacept|Abatacept claim is used as the exposure group.
219563705|NCT01877694|DRUG|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
219398767|NCT04429425|PROCEDURE|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
219398768|NCT00138125|DRUG|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
219398769|NCT00138125|BIOLOGICAL|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
219398770|NCT00002056|DRUG|Pentamidine isethionate|
219398771|NCT05979129|OTHER|zero PEEP|zero end-expiratory pressure during face mask ventilation
219563706|NCT01877694|DRUG|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
219563707|NCT05829850|DEVICE|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
219563708|NCT04372719|DRUG|H3N2|
219563709|NCT03458143|DRUG|Ketamine 150 ng/ml|conscious sedation in TCI-mode
219563710|NCT03458143|DRUG|Remifentanil|conscious sedation in TCI-mode
219563711|NCT03458143|PROCEDURE|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
219398772|NCT05979129|OTHER|low PEEP|4 cmH2O PEEP during mask ventilation
219398773|NCT05979129|OTHER|high PEEP|8 cmH2O PEEP during mask ventilation
219563712|NCT03458143|DRUG|Ketamine 200 ng/ml|conscious sedation in TCI-mode
219563713|NCT01806610|DRUG|BPS804|Single dose BPS804 administration.
219563714|NCT01806610|DRUG|Placebo|Single dose placebo administration.
219563715|NCT00000302|DRUG|Buprenorphine|
219563716|NCT04755621|OTHER|Core stability training|Core stability exercises
219563717|NCT04755621|OTHER|Rocabado Exercises|Exercises for Temporomandibular Disorders
219563718|NCT05756738|DIAGNOSTIC_TEST|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
219563719|NCT02121041|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg
219563720|NCT02121041|DRUG|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
219563721|NCT02121041|DRUG|Losartan|Losartan 50 mg or 100 mg
219563722|NCT02857387|BIOLOGICAL|blood sample withdrawn|
219563723|NCT03477383|DIAGNOSTIC_TEST|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
219563724|NCT03868111|DRUG|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
219563725|NCT03868111|DRUG|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
219563726|NCT05565261|DEVICE|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
219563727|NCT05672745|DEVICE|WB-LIFE|WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
219563728|NCT00813345|OTHER|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
219563729|NCT00813345|OTHER|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
219563730|NCT05571033|BEHAVIORAL|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
219563731|NCT00865449|DRUG|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
219563732|NCT00865449|DRUG|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
219563733|NCT02939261|BEHAVIORAL|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
219563734|NCT02939261|BEHAVIORAL|Control|monthly emails with general health information
219563735|NCT00237419|DRUG|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
219563736|NCT04500132|DRUG|EC-18|EC-18 QD
219398774|NCT01654497|DRUG|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
219398775|NCT00455858|DRUG|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
219398776|NCT05468450|DRUG|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
219398777|NCT05468450|DEVICE|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
219398778|NCT05930925|DRUG|[phenyl-14C]ARV-471|Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
219398779|NCT05930925|DRUG|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
219563737|NCT04500132|DRUG|Placebo EC-18|Placebo EC-18 QD
219563738|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
219563739|NCT06291090|BEHAVIORAL|OUD treatment intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
219398780|NCT00123526|BEHAVIORAL|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
219398781|NCT00123526|BEHAVIORAL|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
219563740|NCT05933473|PROCEDURE|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
219563741|NCT00088049|DRUG|Olanzapine|
219563742|NCT00088049|DRUG|Aripiprazole|
219563743|NCT02617641|BEHAVIORAL|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
219563744|NCT02617641|BEHAVIORAL|Publicly available websites|"* Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
219563745|NCT06676293|DRUG|Anti-PD1|Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month
219563746|NCT06676293|DRUG|asparaginase|The patients will receive asparaginase 10000IU/vail IM QD for three or five days.
219563747|NCT04904055|OTHER|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
219563748|NCT02238132|DRUG|ATROVENT® inhalets|
219563749|NCT02824185|DEVICE|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
219563750|NCT03245307|DRUG|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
219563751|NCT03245307|DRUG|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
219563752|NCT03245307|DRUG|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
219398782|NCT01242020|DRUG|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
219398783|NCT01695980|PROCEDURE|ETT with non modified retractor|adenotonsillectomy
219398784|NCT01695980|OTHER|LMA with modified retractor|LMA with modified retractor
219398785|NCT02402192|DRUG|Corifollitropin alfa|
219398786|NCT03418402|DEVICE|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
219398787|NCT03418402|DEVICE|Standard insufflator|Standard insufflator
219398788|NCT04521959|PROCEDURE|Blood flow restricted and normal aerobic exercise and resistance exercise|Interventions of the same duration and intensity will be applied to two groups.
219563753|NCT02464488|OTHER|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
219563754|NCT02192294|DRUG|Oral Bosutinib|a single dose of 500 mg oral bosutinib
219563755|NCT02192294|DRUG|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
219563756|NCT03561922|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
219563757|NCT04047953|DRUG|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
219563758|NCT01118026|DRUG|ABVD|doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
219563759|NCT01118026|DRUG|BEACOPP|bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
219563760|NCT01118026|RADIATION|radiation therapy|
219563761|NCT02809820|DRUG|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
219563762|NCT02809820|DRUG|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
219563763|NCT04467099|OTHER|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
219563764|NCT04467099|RADIATION|X-ray|Standard x-ray of the foot.
219563765|NCT04467099|OTHER|Questionnaire|All participants will complete a questionnaire.
219563766|NCT01956487|DRUG|Propafenone|Comparison of drug from 2 manufacturing sites
219398789|NCT06661265|PROCEDURE|adjuvant tomotherapy +- chemotherapy after the reconstructive surgery with flaps|adjuvant treatment in locally-advanced head and neck cancers submitted to upfront surgery with flap reconstruction, evaluation of toxicity and flap status performed at San Raffaele Hospital between December 2017-December 2022.
219398790|NCT00890630|PROCEDURE|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
219398791|NCT00890630|DRUG|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
219398792|NCT04819425|DEVICE|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
219398793|NCT04819425|DEVICE|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
219563767|NCT01338714|OTHER|Compound Herbal Formula (RHD-1)|100 ml/per day
219563768|NCT01338714|OTHER|dilute RHD-1|100 ml/per day
219563769|NCT06616116|DEVICE|Biosignal feedback|"1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs."
219563770|NCT06616116|DEVICE|Sham Comparator|Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
219563771|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
219563772|NCT02985619|DRUG|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
219563773|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
219563774|NCT06393660|DEVICE|CliniMACS® CD34 TCR Alpha/Beta|CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.
219563775|NCT02380313|DRUG|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
219563776|NCT02380313|DRUG|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
219563777|NCT02380313|DRUG|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
219563778|NCT02380313|DRUG|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
219563779|NCT06615856|OTHER|Questionnaire|"Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire"
219563780|NCT02978352|OTHER|learning|
219563781|NCT02171767|DRUG|BIBW 2992 MA2 - single rising dose|
219398794|NCT02021422|DRUG|anakinra|Dosage Route Administration 100 mg SC Every Other Day
219398795|NCT02021422|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
219563782|NCT00003330|BIOLOGICAL|recombinant interleukin-12|
219398796|NCT02021422|DRUG|Irinotecan|Irinotecan 180 mg/m2 90 minutes
219398797|NCT02021422|DRUG|fluorouracil|fluorouracil 2400 mg/m2 48 hours
219398798|NCT02185599|DEVICE|DySIS|Colposcopy performed with the DySIS digital colposcope
219563783|NCT00773942|BEHAVIORAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
219563784|NCT00773942|BEHAVIORAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
219563785|NCT00627471|DRUG|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
219563786|NCT00627471|DRUG|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
219563787|NCT03297372|DEVICE|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
219398799|NCT05615714|OTHER|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
219398800|NCT05615714|OTHER|Sham stimulation|Stimulation will be turned off.
219398801|NCT02946229|DEVICE|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
219398802|NCT01161524|DRUG|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
219398803|NCT01161524|DRUG|Placebo|Matching Placebo taken once daily.
219398804|NCT00339079|DRUG|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
219398805|NCT00339079|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
219398806|NCT00339079|OTHER|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
219398807|NCT00339079|DRUG|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
219398808|NCT02227407|DEVICE|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
219398809|NCT02688010|BEHAVIORAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
219398810|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
219398811|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
219398812|NCT02764866|OTHER|Sleep testing|Home sleep testing
219398813|NCT05846386|BEHAVIORAL|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
219398814|NCT05846386|BEHAVIORAL|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
219398815|NCT03224637|PROCEDURE|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
219398816|NCT03224637|DRUG|Paracetamol (conventional)|
219398817|NCT03224637|DRUG|Ketorolac Tromethamine (conventional)|
219398818|NCT00231062|DEVICE|Sinuplasty|
219398819|NCT02277210|OTHER|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
219398820|NCT02696512|DRUG|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
219398821|NCT02696512|DEVICE|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
219398822|NCT02696512|DIETARY_SUPPLEMENT|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
219398823|NCT02696512|OTHER|Standard of Care|Standard of Care treatment
219398824|NCT02688114|PROCEDURE|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
219398825|NCT02688114|PROCEDURE|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
219398826|NCT02688114|PROCEDURE|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
219398827|NCT02688114|PROCEDURE|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
219398828|NCT02688114|PROCEDURE|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
219398829|NCT03952312|BEHAVIORAL|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
219398830|NCT03952312|BEHAVIORAL|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
219398831|NCT01052012|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
219398832|NCT01052012|DRUG|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
219563788|NCT04265690|BEHAVIORAL|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
219563789|NCT04265690|BEHAVIORAL|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
219563790|NCT02063308|DIETARY_SUPPLEMENT|Oxaloacetate (OAA)|
219563791|NCT00528684|BIOLOGICAL|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
219563792|NCT02130167|DRUG|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
219563793|NCT03239236|PROCEDURE|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
219563794|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
219398833|NCT01052012|DRUG|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
219398834|NCT02873715|BEHAVIORAL|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
219398835|NCT02873715|BEHAVIORAL|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
219398836|NCT05386433|DRUG|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
219563795|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
219563796|NCT03239236|PROCEDURE|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
219563797|NCT03239236|PROCEDURE|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
219563798|NCT03239236|DRUG|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
219563799|NCT03239236|DIAGNOSTIC_TEST|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
219563800|NCT03239236|DIAGNOSTIC_TEST|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
219563801|NCT03239236|DIAGNOSTIC_TEST|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
219563802|NCT02916693|DRUG|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
219563803|NCT03433365|OTHER|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
219563804|NCT06616948|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
219563805|NCT06616948|BEHAVIORAL|coaching calls|individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
219563806|NCT06616948|BEHAVIORAL|No coaching calls|Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
219563807|NCT06616012|DEVICE|Neosense umbilical catheter|The Neosense umbilical catheter is used instead of a standard umbilical catheter
219398837|NCT05386433|DRUG|standard-of-care|standard-of-care of COVID-19
219398838|NCT00878228|DRUG|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
219398839|NCT00878228|DRUG|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
219398840|NCT00883428|OTHER|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
219398841|NCT03596125|DRUG|N-acetylcysteine|N-acetylcysteine supplementation
219398842|NCT03596125|DRUG|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
219398843|NCT02151539|OTHER|medical chart review|Ancillary studies
219398844|NCT02151539|OTHER|quality-of-life assessment|Ancillary studies
219398845|NCT04822922|GENETIC|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
219398846|NCT02147938|DRUG|Tacrolimus|oral
219398847|NCT00668525|DRUG|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
219398848|NCT00668525|DRUG|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
219398849|NCT00668525|DRUG|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
219398850|NCT03468023|PROCEDURE|Short arm cast|Application of a below-elbow cast
219398851|NCT03468023|PROCEDURE|Long arm cast|Application of an above-elbow cast
219398852|NCT00818038|DRUG|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
219398853|NCT00492401|DRUG|decitabine|Given IV
219398854|NCT00492401|OTHER|laboratory biomarker analysis|Correlative studies
219398855|NCT00492401|OTHER|pharmacological study|Correlative studies
219398856|NCT00492401|OTHER|high performance liquid chromatography|Correlative studies
219754614|NCT05069519|BEHAVIORAL|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
219398857|NCT00492401|GENETIC|microarray analysis|Correlative studies
219398858|NCT00492401|GENETIC|RNA analysis|Correlative studies
219001978|NCT00549302|DRUG|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
219398859|NCT00492401|OTHER|mass spectrometry|Correlative studies
219398860|NCT00492401|GENETIC|DNA methylation analysis|Correlative studies
219398861|NCT00492401|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
219398862|NCT00282490|DEVICE|Nerve stimulator|
219398863|NCT02229149|DRUG|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
219398864|NCT02229149|DRUG|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
219398865|NCT02229149|DRUG|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
219398866|NCT00050713|DRUG|Sirolimus|
219398867|NCT02698423|DEVICE|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
219398868|NCT02698423|OTHER|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
219398869|NCT06133777|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
219398870|NCT02466269|PROCEDURE|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
219398871|NCT03693365|PROCEDURE|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
219398872|NCT03211130|BEHAVIORAL|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
219398873|NCT03211130|BEHAVIORAL|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
219398874|NCT03279510|DEVICE|hearing aids|Subjects are fit with hearing aids.
219398875|NCT01187212|DRUG|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
219398876|NCT01187212|DRUG|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
219563808|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions|"The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive."
219398877|NCT01893593|OTHER|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
219398878|NCT01893593|OTHER|Control|Guideline summary and data feedback from a baseline medical record review
219398879|NCT04761380|DIAGNOSTIC_TEST|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
219398880|NCT04115397|DRUG|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
219398881|NCT04115397|DRUG|Placebo|Placebo
219398882|NCT00991627|DRUG|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
219398883|NCT00991627|DRUG|Morphine|200 µg of a 100 µg/ml solution, intrathecally
219398884|NCT00991627|DRUG|Lactated Ringer's solution|25 ml/min intravenously
219398885|NCT00991627|DRUG|Ephedrine, continuous infusion|37.5 mg/h intravenously
219398886|NCT00991627|DRUG|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
219398887|NCT00991627|DRUG|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
219398888|NCT06858124|OTHER|Mulligan+TE|"Mulligan Mobilizations plus Home Therapeutic Exercise~The protocol will last 25 minutes (Mulligan protocol: 5 minutes and Home Therapeutic Exercise protocol: 20 minutes) and will include the application of the following mulligan techniques and home exercises:~* Mulligan sustained natural apophyseal glide SNAG mobilizations with overpressure with the patients in seated position.~* 4 home-based therapeutic exercises: isometric exercises for cervical regions, head retractions, thoracic spine rotation mobility exercise and diagonal cervical mobility exercise pattern."
219398889|NCT06858124|OTHER|Maitland+TE|"The participants of this group will perform the same 4 home-based therapeutic exercises as the first group. In addition, they will receive a 5-minute maitland mobilization protocol.~Maitland mobilizations will include posterioranterior glides with oscillations with the patients in prone position."
219398890|NCT06858124|OTHER|Control|Participants in this group will only perform the same 4 home-based therapeutic exercises as the first group.
219398891|NCT03271008|DEVICE|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
219563809|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience|"The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios."
219563810|NCT02264535|DRUG|0.1mg/ml Ginkgolides Meglumine Injection|
219398892|NCT03271008|DEVICE|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
219398893|NCT03271008|DEVICE|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
219563811|NCT02264535|DRUG|1mg/ml Ginkgolides Meglumine Injection|
219398894|NCT01651260|OTHER|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
219398895|NCT04863287|BIOLOGICAL|2217LS|Fully Human Monoclonal Antibody
219398896|NCT04863287|OTHER|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
219398897|NCT00935233|GENETIC|DNA analysis|
219398898|NCT00935233|GENETIC|polymorphism analysis|
219398899|NCT00935233|GENETIC|protein analysis|
219398900|NCT00935233|OTHER|laboratory biomarker analysis|
219398901|NCT00935233|OTHER|questionnaire administration|
219398902|NCT00935233|OTHER|survey administration|
219398903|NCT01952015|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
219398904|NCT01597193|DRUG|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
219398905|NCT01597193|DRUG|anastrozole|1 mg/day
219398906|NCT01597193|DRUG|exemestane|The exemestane dose is 25mg daily.
219398907|NCT01597193|DRUG|fulvestrant|500 mg every 28 days
219398908|NCT01597193|DRUG|enzalutamide|160 mg (4 capsules) taken orally daily.
219398909|NCT01597193|DRUG|exemestane|The exemestane dose is 50 mg daily.
219398910|NCT00296283|BEHAVIORAL|integrative behavior couples therapy|
219563812|NCT02264535|DRUG|5mg/ml Ginkgolides Meglumine Injection|
219563813|NCT02667821|OTHER|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
219563814|NCT01996384|PROCEDURE|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
219398911|NCT01819220|DRUG|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
219398912|NCT01819220|DRUG|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
219398913|NCT03391440|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
219398914|NCT02508701|BEHAVIORAL|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
219398915|NCT00607360|BEHAVIORAL|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
219398916|NCT03475394|OTHER|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
219398917|NCT03475394|OTHER|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
219398918|NCT03475394|OTHER|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
219398919|NCT06403774|DRUG|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
219563815|NCT01996384|PROCEDURE|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
219398920|NCT06403774|DRUG|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
219398921|NCT04579068|BEHAVIORAL|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
219398922|NCT06359249|BEHAVIORAL|change of habits|change of habits
219398923|NCT06359249|OTHER|change of habits + auto abdominal massage|change of habits + auto abdominal massage
219398924|NCT01259297|DRUG|Aliskiren|Aliskiren 150/300 mg once daily
219398925|NCT01259297|DRUG|Amlodipine|Amlodipine 5 mg
219563816|NCT01996384|DRUG|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
219398926|NCT01259297|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
219398927|NCT01259297|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
219398928|NCT01259297|DRUG|Placebo for Amlodipine|Placebo for Amlodipine
219398929|NCT01259297|DRUG|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
219398930|NCT03290638|PROCEDURE|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
219398931|NCT00126464|DRUG|fulvestrant|
219398932|NCT00126464|DRUG|tamoxifen citrate|
219398933|NCT00126464|PROCEDURE|conventional surgery|
219398934|NCT00126464|PROCEDURE|neoadjuvant therapy|
219398935|NCT00592501|RADIATION|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
219398936|NCT00592501|DRUG|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
219398937|NCT00592501|DRUG|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
219398938|NCT01746667|BEHAVIORAL|Exposure in vivo|
219398939|NCT01746667|BEHAVIORAL|Virtual Reality Exposure Therapy|
219398940|NCT02014532|DRUG|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
219398941|NCT02014532|DRUG|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
219398942|NCT04927988|OTHER|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
219398943|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
219398944|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
219398945|NCT00690937|DRUG|Colesevelam Cholestagel|Drug comparator
219398946|NCT00690937|DRUG|Placebo|Placebo
219398947|NCT00690937|DRUG|Placebo|Placebo
219398948|NCT00279500|DEVICE|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
219398949|NCT01051388|DRUG|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
219398950|NCT01051388|DRUG|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
219398951|NCT01051388|DRUG|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
219398952|NCT02892851|DEVICE|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)"
219398953|NCT01563588|BEHAVIORAL|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
219398954|NCT06139380|DRUG|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
219398955|NCT06139380|DRUG|Sterile water|Intranasal sterile water was administered via syringe.
219398956|NCT01527604|OTHER|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
219398957|NCT01527604|OTHER|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
219398958|NCT05777434|PROCEDURE|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
219398959|NCT05777434|PROCEDURE|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
219398960|NCT01429012|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
219398961|NCT01429012|OTHER|Culture medium without MSC.|2 ml of culture medium.
219563817|NCT03384706|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
219563818|NCT03384706|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
219563819|NCT06364878|DIAGNOSTIC_TEST|In vivo confocal microscopy|The patients cornea will be examined non-invasively by IVCM
219563820|NCT06364878|DIAGNOSTIC_TEST|Tear film sampling|Patients tear film will be collected and stored at -80 degrees for analysis
219563821|NCT04236583|OTHER|Telehealth|Post-discharge virtual visit
219563822|NCT05517161|BEHAVIORAL|INSIGHT|See Keegan et al., 2020
219754615|NCT05069519|BEHAVIORAL|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
219001979|NCT00549302|DRUG|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
219398962|NCT01243606|BEHAVIORAL|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
219398963|NCT01243606|BEHAVIORAL|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
219398964|NCT04674852|DEVICE|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
219398965|NCT03902405|BEHAVIORAL|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
219398966|NCT03902405|BEHAVIORAL|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
219398967|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
219398968|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
219398969|NCT03698240|BEHAVIORAL|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
219398970|NCT03880227|DEVICE|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
219398971|NCT03880227|DEVICE|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
219398972|NCT03281226|DRUG|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
219398973|NCT03281226|DRUG|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
219398974|NCT05537324|OTHER|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
219398975|NCT05537324|OTHER|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
219398976|NCT04805021|OTHER|no intervention|no intervention
219398977|NCT00780000|DRUG|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
219398978|NCT03298854|DEVICE|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
219398979|NCT02832726|DIETARY_SUPPLEMENT|Vitamin B12|
219398980|NCT00006346|PROCEDURE|psychosocial assessment and care|
219398981|NCT00006346|PROCEDURE|quality-of-life assessment|
219398982|NCT03058458|DRUG|PIN201104|IV or SC administration
219398983|NCT03058458|DRUG|Placebo|IV or SC administration
219398984|NCT01185535|PROCEDURE|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
219563823|NCT06044194|DRUG|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
219754616|NCT01073969|OTHER|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
219398985|NCT01217658|BEHAVIORAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
219563824|NCT01283815|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
219563825|NCT01283815|PROCEDURE|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
219563826|NCT01969474|DRUG|Cannabis|Cannabis capsules given once daily for a month
219563827|NCT01969474|DRUG|Placebo|Placebo
219563828|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
219563829|NCT01014962|DRUG|Placebo|Placebo oral once daily for 5 days
219563830|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
219398986|NCT01217658|BEHAVIORAL|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
219398987|NCT06113354|DEVICE|Transcatheter mitral valve repair (MRace Implant and Delivery System)|"The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr"
219398988|NCT01775046|DEVICE|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
219398989|NCT03574467|BEHAVIORAL|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
219398990|NCT01959308|OTHER||
219398991|NCT01050179|OTHER|carbon dioxide|sinusoidal carbon dioxide delivery
219398992|NCT01147731|BIOLOGICAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
219398993|NCT05427682|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
219398994|NCT02313935|OTHER|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
219398995|NCT02313935|OTHER|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
219398996|NCT02313935|OTHER|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
219398997|NCT02313935|OTHER|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
219398998|NCT02639117|DRUG|Vismodegib|Vismodegib 150 mgs po qd for 3 months
219398999|NCT03693287|DRUG|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
219399000|NCT03693287|DRUG|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
219563831|NCT01014962|DRUG|Placebo|Placebo oral every 12 hours for 5 days
219563832|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
219563833|NCT01014962|DRUG|Placebo|Placebo oral every 8 hours for 5 days
219563834|NCT00002262|DRUG|Tumor Necrosis Factor|
219563835|NCT04968860|OTHER|This study is observational|"* Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life"
219399001|NCT03204838|GENETIC|IDH mutation test performed at diagnosis|Observation of the test result
219399002|NCT01070784|DRUG|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
219399003|NCT01070784|DRUG|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
219399004|NCT05769803|DIAGNOSTIC_TEST|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
219399005|NCT00797459|DEVICE|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
219399006|NCT05493956|RADIATION|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
219563836|NCT03367325|DEVICE|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
219563837|NCT02668848|DIETARY_SUPPLEMENT|water|If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
219563838|NCT00206830|DEVICE|Triage Profiler S.O.B. Panel|
219563839|NCT03418857|DRUG|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
219399007|NCT02682888|BEHAVIORAL|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
219399008|NCT02682888|DRUG|Oxytocin|intranasal administration of oxytocin
219399009|NCT02682888|DRUG|Placebo|intranasal administration of placebo
219563840|NCT03418857|DRUG|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
219563841|NCT00362830|DRUG|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
219754617|NCT01073969|OTHER|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
219399010|NCT03511261|DRUG|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
219399011|NCT03511261|DRUG|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
219399012|NCT03511261|DRUG|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
219399013|NCT03511261|DRUG|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
219399014|NCT02371733|OTHER|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
219399015|NCT02371733|OTHER|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
219399016|NCT03502759|BEHAVIORAL|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
219563842|NCT01842126|BIOLOGICAL|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
219563843|NCT01842126|BIOLOGICAL|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
219563844|NCT01842126|DRUG|Placebo IV|Ascending Doses intravenous (IV) of Placebo
219563845|NCT01842126|DRUG|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
219563846|NCT01655524|DRUG|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
219563847|NCT01638858|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
219399017|NCT06191354|GENETIC|SKG0201 Injection|SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
219399018|NCT01888354|DRUG|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
219399019|NCT04316572|BEHAVIORAL|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
219399020|NCT06276972|OTHER|no intervention|there's no intervention. it's a cross sectional study correlation study
219399021|NCT02515591|OTHER|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
219399022|NCT00620620|DRUG|Inhaled placebo|Inhaled Staccato Placebo
219399023|NCT00620620|DRUG|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
219399024|NCT00620620|DRUG|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
219399025|NCT00620620|DRUG|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
219399026|NCT00620620|DRUG|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
219399027|NCT01031758|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
219399028|NCT02582749|DRUG|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
219399029|NCT02582749|DRUG|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
219399030|NCT02582749|RADIATION|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
219399031|NCT06499753|OTHER|high molecular weight HA-based artificial tears|use of high molecular weight HA-based artificial tears three times per day
219399032|NCT02815397|DRUG|Metformin|given in addition to standard of care treatment
219399033|NCT02518620|BIOLOGICAL|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
219399034|NCT05652374|DEVICE|Ialuril 50ml Prefill|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
219399035|NCT05652374|DRUG|Nitrofurantoin|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
219399036|NCT00176566|DRUG|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
219399037|NCT01452074|OTHER|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
219399038|NCT01452074|OTHER|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
219399039|NCT00085540|DRUG|depsipeptide|Given IV
219399040|NCT03015350|DRUG|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
219399041|NCT03015350|DRUG|Desflurane|Measurement of blood desflurane level during one lung ventilation
219399042|NCT02619240|PROCEDURE|bronchoscopy|performance of bronchoscopy with BAL
219399043|NCT01605396|DRUG|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
219399044|NCT01605396|DRUG|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
219399045|NCT01605396|DRUG|Exemestane|Exemestane 25 mg tablet administered PO QD.
219399046|NCT02089386|DRUG|Tamoxifen|
219399047|NCT02089386|PROCEDURE|Endoscopy|
219399048|NCT03819803|BIOLOGICAL|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
219399049|NCT01360164|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
219399050|NCT02285764|OTHER|Nutritional Supplement|Modified carbohydrate
219399051|NCT02285764|OTHER|Standard of Care|As determined by the study site
219399052|NCT01175070|DRUG|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
219399053|NCT05174052|DRUG|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
219399054|NCT05174052|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
219399055|NCT02025738|DEVICE|MAGNET APPLICATION|
219399056|NCT02025738|DEVICE|REPROGRAMING|
219399057|NCT02025738|DEVICE|NO ACTION|
219399058|NCT02058199|DRUG|rivaroxaban|Single dose pharmacodynamic study
219399059|NCT00978445|OTHER|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
219563848|NCT02642796|DEVICE|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
219399060|NCT03736837|DRUG|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
219399061|NCT03124615|DRUG|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
219399062|NCT00903461|BIOLOGICAL|EGFR Antisense DNA|"* Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
219563849|NCT03585907|DIETARY_SUPPLEMENT|MAD|A high fat, low carbohydrate diet
219563850|NCT03585907|DIETARY_SUPPLEMENT|MIND|A combination of the Mediterranean and DASH diets
219563851|NCT00742599|DRUG|NPO-11|20 ml NPO-11
219563852|NCT00742599|DRUG|Placebo|20 ml NPO-11(Placebo)
219399063|NCT02380430|OTHER|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
219399064|NCT02124850|DRUG|Motolimod|
219399065|NCT02124850|DRUG|Cetuximab|
219399066|NCT02124850|DRUG|Nivolumab|
219399067|NCT06671639|DEVICE|da Vinci Xi Robotic Surgery System|"The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system."
219399068|NCT03067766|PROCEDURE|Art Therapy|Participate in a comic art creation workshop
219399069|NCT03067766|OTHER|Interview|Undergo qualitative interviews
219399070|NCT03067766|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219399071|NCT03067766|OTHER|Questionnaire Administration|Ancillary studies
219563853|NCT02594371|DRUG|Oraxol|
219563854|NCT02594371|DRUG|IV paclitaxel|
219563855|NCT03574311|DRUG|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
219563856|NCT03574311|OTHER|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
219563857|NCT00845234|BEHAVIORAL|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
219399072|NCT04341844|DRUG|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
219399073|NCT04341844|DRUG|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
219399074|NCT06920485|PROCEDURE|Third molar surgery|Effects of different gargles/mouth rinses/antiseptic agents applied after impacted surgical tooth extraction on postoperative wound healing and total bacterial load
219399075|NCT06920485|DIAGNOSTIC_TEST|Pain Medicine|After the extraction, patients will be given two separate forms with VAS scales for pain to mark every day for 7 days. The patient will be asked to mark the level of pain they feel on the scale. The amount of analgesic use on the home assessment form will also be recorded as part of the pain assessment. On the 7th day, healing in the wound area will also be assessed.
219399076|NCT06920485|DIAGNOSTIC_TEST|Wound healing|The degree of healing of the wound area will be checked using Landry scoring.
219399077|NCT06920485|OTHER|Total bacterial load|Total bacterial load will be evaluated by microbiological analysis of sutures obtained from all groups.
219563858|NCT04914624|BEHAVIORAL|ACBT training|Performed 5 days before surgery and one month after surgery, twice a day.
219563859|NCT04914624|DEVICE|acpella®PEP|Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
219563860|NCT04914624|DEVICE|EDP-type II external diaphragm pacemaker|Use external diaphragm pacemaker to stimulate patients' diaphragms.
219563861|NCT03452124|DEVICE|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
219563862|NCT03452124|OTHER|Conventional cigarette|Conventional cigarette smoking continuation
219563863|NCT06308835|OTHER|questionnaires|BREF(Batterie d'efficience Frontale), SDMT (Symbol Digit Modalities Test), TMT (Trail making test), Empans verbaux et BNT (Boston naming Test)
219563864|NCT05335213|DIAGNOSTIC_TEST|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
219563865|NCT03452072|DRUG|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
219563866|NCT03452072|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
219563867|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
219563868|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
219399078|NCT04652492|DRUG|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
219399079|NCT03331172|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
219399080|NCT06693427|PROCEDURE|Peripheral Nerve Block|Femoral and Sciatic Nerve Blocks
219399081|NCT01795040|DIETARY_SUPPLEMENT|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
219399082|NCT01663740|DRUG|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
219563869|NCT00692224|DRUG|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
219563870|NCT00692224|DRUG|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
219399083|NCT01958034|DIETARY_SUPPLEMENT|Bilberry extract|
219399084|NCT04446585|DEVICE|Automated External Defibrillator (AED)|Deployment of AEDs
219399085|NCT04446585|OTHER|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
219399086|NCT04446585|OTHER|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
219399087|NCT04207112|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
219399088|NCT04207112|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
219399089|NCT04207112|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
219399090|NCT04207112|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
219399091|NCT04207112|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
219563871|NCT00512837|BEHAVIORAL|Mobile phone technology|
219563872|NCT05135819|BEHAVIORAL|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
219563873|NCT06676449|DRUG|Immunotherapy|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
219563874|NCT06676449|DRUG|chemotherapy: Paclitaxel/Cisplatin|Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.
219563875|NCT06676449|RADIATION|TDLN-sparing RT|TDLN-sparing radiotherapy 50.4Gy/28Fx.
219399092|NCT04207112|DRUG|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
219399093|NCT05254522|OTHER|not aplicable since it is a Registry|not aplicable since it is a registry
219399094|NCT05688267|OTHER|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
219399095|NCT05688267|OTHER|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
219399096|NCT01271478|DRUG|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
219399097|NCT01271478|DRUG|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
219399098|NCT01271478|DRUG|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
219399099|NCT01271478|DRUG|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
219399100|NCT06925438|PROCEDURE|Computer-guided zygomatic implant system|Preoperative digital planning (DICOM data) to fabricate guides with metal sleeves for drill alignment
219399101|NCT06925438|PROCEDURE|free-hand zygomatic implant placement|Standard placement using sequential drills (2.8-3.6mm) under saline irrigation
219399102|NCT03953638|DIAGNOSTIC_TEST|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
219399103|NCT06722352|BEHAVIORAL|Palliative Care Training|Teaching about caring for individuals with
219563876|NCT04473716|DRUG|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
219563877|NCT04473716|DRUG|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
219563878|NCT04473716|DRUG|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
219399104|NCT03607682|PROCEDURE|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
219001980|NCT03495076|OTHER|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
219399105|NCT03607682|DEVICE|NovoTTF-200A Device|Undergo TTF therapy
219399106|NCT03607682|OTHER|Quality-of-Life Assessment|Ancillary studies
219399107|NCT01770353|DRUG|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
219399108|NCT01770353|DRUG|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
219399109|NCT02202681|DEVICE|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
219399110|NCT00376688|OTHER|Laboratory Biomarker Analysis|Correlative studies
219399111|NCT00376688|DRUG|Temsirolimus|Given IV
219399112|NCT02556645|OTHER|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
219399113|NCT02556645|OTHER|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
219399114|NCT06736483|DRUG|Dexmedetomidine|Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
219399115|NCT06736483|DRUG|Placebo administration|Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
219001981|NCT03495076|OTHER|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
219001982|NCT02326376|DRUG|anakinra (Kineret)|
219001983|NCT01442233|PROCEDURE|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
219001984|NCT01442233|PROCEDURE|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
219399116|NCT06736483|OTHER|Face Legs Activity Cry Consolability scale|The pain will be assessed on admission and every 15 minutes until discharge from the PACU
219399117|NCT06736483|OTHER|Post-Hospitalization Behavior Questionnaire|The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7
219399118|NCT06736483|OTHER|Postoperative pain measure|The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months
219399119|NCT06736483|OTHER|Post-operative quality of life questionnaire|The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months
219399120|NCT03466320|BIOLOGICAL|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
219399121|NCT01255397|PROCEDURE|Male Infertility Protocol|"1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6\) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
219399122|NCT06896604|DEVICE|Ocular Ultrasonography for measuring Optic Nerve Sheath Diameter|In the study, the investigators measured the optic nerve sheath diameter to observe its effects on intracranial pressure and used ocular ultrasonography for this measurement.
219399123|NCT06896032|OTHER|physical therapy intervention|retro-walking and forward-walking underwater treadmill training
219399124|NCT06738836|DRUG|[14C]-EDG-7500|Oral liquid suspension
219399125|NCT02875522|OTHER|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
219399126|NCT05574504|DRUG|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
219399127|NCT06768268|PROCEDURE|Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer|The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes
219399128|NCT06768268|DRUG|Mannitol (20%)|Adding Mannitol into Voluven and used as solvent of ICG
219399129|NCT06801314|OTHER|aerobic exercise using cycle ergometer in addition to usual care|"aerobic exercise group):Patients in this group will be received usual care and cycle ergometer aerobic exercise Mood of exercise: continuous aerobic exercise~* Modality of exercise: cycle ergometer~* Intensity of exercise: low to moderate intensity and HR (calculated as recommended by the American College of Sports Medicine (ACSM) and tolerated up to 20-30 bpm above the resting HR), BP, SpO2 and rate of perceived exertion through the Borg Scale (10-13) will be monitor during cycling~* Duration: 15-20 min including 5 min warm up and 5 min cool down and working phase from 5-10 min~* Frequency: daily until discharge aerobic exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guide and stop exercise when there is any adverse events will occur."
219563879|NCT04473716|PROCEDURE|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
219563880|NCT04473716|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
219563881|NCT06285240|DRUG|MK-1167|1 mg and 5 mg oral capsules
219563882|NCT06285240|DRUG|Donepezil|10 mg oral tablets
219563883|NCT06285240|DRUG|Placebo|MK-1167 matching placebo administered oral capsules
219563884|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
219563885|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
219563886|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
219563887|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
219563888|NCT02228109|DEVICE|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
219563889|NCT02228109|DEVICE|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
219563890|NCT02228109|DEVICE|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
219563891|NCT03536182|RADIATION|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
219563892|NCT03536182|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
219399130|NCT06801314|OTHER|resisted exercise using weights and dumbbells in addition to usual care|"resisted exercise group): Patients in this group will be received usual care and resisted exercise~* Mode: resisted exercise~* Modality: dumbbells or sand bags tied around main groups of muscles for upper and lower limbs Intensity of exercise: the load that the patient can lift for 10-12 repetition at RPE of 10-13 and 1-2 sets resisted exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guided and stop exercise when there is any adverse events will occur."
219399131|NCT06801314|OTHER|usual care using mobilization and breathing exercise|mobilization and breathing exercise
219399132|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
219399133|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
219563893|NCT04744428|BEHAVIORAL|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
219563894|NCT04744428|BEHAVIORAL|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
219563895|NCT04751045|PROCEDURE|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
219563896|NCT02001051|PROCEDURE|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
219399134|NCT06930430|PROCEDURE|Non-Surgical Periodontal Therapy (NSPT)|Scaling and root planing was performed using hand instruments under local anesthesia, if necessary. Oral hygiene instructions were provided using the modified Bass technique. GCF samples were collected from the same sites at baseline, 1 month, and 3 months to measure levels of IL-1β and S1P using ELISA.
219399135|NCT06929858|OTHER|cognitive-behavioral strategies training|"A structured training program focused on cognitive-behavioral strategies tailored to the challenges of caring for children with ASD. Examples include:~Techniques to manage stress (e.g., relaxation exercises). Cognitive reframing to address negative thoughts. Coping skills to enhance resilience in a demanding work environment."
219399136|NCT06929650|PROCEDURE|Radiofrequency ablation|"Radiofrequency energy is delivered to the thyroid nodule via the medical device. This device is a system consisting of 3 main components:~1. VIVA combo RF system (generator and pump)~2. single foot switch~3. electrode (5mm, 7mm, 10mm, or adjustable)."
219399137|NCT06930508|BEHAVIORAL|Patient participant screening|Patient participants will be provided with the standardized PrEP screening and initiation protocol.
219399138|NCT06930508|BEHAVIORAL|Physician participant training|Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.
219399139|NCT06930287|OTHER|250 mg Nimbus shoe|lightweight shoe
219399140|NCT03725046|OTHER|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
219399141|NCT01292772|PROCEDURE|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
219399142|NCT01292772|RADIATION|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
219399143|NCT04083040|PROCEDURE|transcatheter aortic valve implantation|"1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
219399144|NCT01059604|DRUG|Sumatriptan|Sumatriptan
219399145|NCT01059604|DRUG|Naratriptan|Naratriptan
219399146|NCT01059604|DRUG|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
219399147|NCT06100432|DRUG|DLBS5055 200mg|1x1 caplet
219399148|NCT06100432|DRUG|Placebo DLBS5055|1x1 caplet
219399149|NCT06100432|DRUG|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
219399150|NCT06100432|DRUG|Placebo Multivitamin|1x2 caplets
219399151|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated. It is degraded and discharged naturally through the cervix and vagina."
219399152|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
219399153|NCT03079739|DIAGNOSTIC_TEST|fractional flow reserve|assessment with FFR in at least one coronary lesion
219399154|NCT04975269|DRUG|Acetazolamide|Target dose: 500 mg / day
219399155|NCT04975269|DRUG|Placebo|Placebo
219399156|NCT06541730|DRUG|DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
219399157|NCT06541730|DRUG|Placebo of DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
219399158|NCT05551299|DRUG|Photosensitizer|A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
219399159|NCT05551299|PROCEDURE|Radiofrequency ablation (RFA)|RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.
219399160|NCT04061980|DRUG|Binimetinib|Given PO
219399161|NCT04061980|DRUG|Encorafenib|Given PO
219399162|NCT04061980|BIOLOGICAL|Nivolumab|Given IV
219399163|NCT03484299|PROCEDURE|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
219399164|NCT03484299|DRUG|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
219399165|NCT03484299|DRUG|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
219399166|NCT04267562|DEVICE|Minitouch System|The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
219399167|NCT06830980|DEVICE|intermittent theta burst stimulation (iTBS)|iTBS is an excitatory TMS paradigm that delivers 1800 pulses to the left dlPFC. Participants will receive 2 iTBS sessions separated by 50 minutes.
219399168|NCT06830980|DEVICE|continuous theta burst stimulation (cTBS)|cTBS is an inhibitory TMS paradigm that delivers 1800 pulses to the frontal pole. Participants will receive 2 iTBS sessions separated by 50 minutes.
219399169|NCT06830980|DEVICE|Sham TMS|Sham TMS delivered with the MagVenture B65 A/P coil
219399170|NCT06831968|DIAGNOSTIC_TEST|Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
219399171|NCT06313164|DIETARY_SUPPLEMENT|enhanced glutathione|L-glutathione (in combination with tannin, low molecular weight chitosan and polyethylene glycol)
219399172|NCT06313164|OTHER|placebo comparator|placebo group
219399173|NCT05396456|PROCEDURE|Muscle Fiber Fragment (MFF) Injections|The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
219399174|NCT06226285|DEVICE|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
219399175|NCT05938738|DEVICE|PEP-buddy|PEP-buddy
219399176|NCT03920410|OTHER|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
219399177|NCT03920410|OTHER|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
219001985|NCT06043089|DIETARY_SUPPLEMENT|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
219563897|NCT02001051|OTHER|Observation|Observation for 6 months prior to surgery
219563898|NCT05785806|BEHAVIORAL|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
219399178|NCT05885997|BEHAVIORAL|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices"
219399179|NCT05885997|OTHER|Usual care|Usual care
219399180|NCT05529706|OTHER|Brain Health Program|The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
219399181|NCT06794437|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Mobile Device Proficiency Questionnaire
219563899|NCT05785806|BEHAVIORAL|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
219563900|NCT05785806|BEHAVIORAL|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
219563901|NCT05785806|BEHAVIORAL|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
219563902|NCT05785806|BEHAVIORAL|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
219563903|NCT06080659|DIAGNOSTIC_TEST|fMRI|functional MRI
219563904|NCT06080659|DIAGNOSTIC_TEST|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
219563905|NCT03862573|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219563906|NCT03776734|OTHER|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
219563907|NCT05398835|BEHAVIORAL|Online interventions promoting HIV self-testing|1\) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
219563908|NCT00022841|DRUG|Pamidronate|
219563909|NCT00277407|PROCEDURE|NAET with acupressure and/or chiropractic procedures|
219399182|NCT05547438|DRUG|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
219563910|NCT03904901|DIETARY_SUPPLEMENT|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
219563911|NCT03904901|DIETARY_SUPPLEMENT|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
219563912|NCT03041207|BEHAVIORAL|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
219563913|NCT01140737|DRUG|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
219563914|NCT00003707|DRUG|gemcitabine hydrochloride|
219563915|NCT00003707|DRUG|tipifarnib|
219563916|NCT05631535|OTHER|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
219399183|NCT05547438|DRUG|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
219399184|NCT05158452|PROCEDURE|Discussion|Attend a focus group
219399185|NCT04550793|DRUG|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
219399186|NCT06552442|DRUG|Methylprednisolone|High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
219399187|NCT01012193|DRUG|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
219399188|NCT05294822|PROCEDURE|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
219399189|NCT02160379|OTHER|standard test meal|
219399190|NCT01446952|DRUG|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
219399191|NCT00625521|DRUG|ASF 1096 0.5 % cream applied twice daily|
219399192|NCT00625521|DRUG|Cream vehicle for ASF 1096 cream applied twice daily|
219399193|NCT02078713|BEHAVIORAL|Contraceptive Decision Support Tool|"The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit"
219399194|NCT00094341|DRUG|Etanercept|
219399195|NCT02096861|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
219399196|NCT02096861|BIOLOGICAL|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
219399197|NCT05050409|BEHAVIORAL|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
219399198|NCT05050409|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
219399199|NCT05050409|OTHER|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
219399200|NCT03383718|PROCEDURE|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
219001986|NCT03453944|DEVICE|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
219001987|NCT03453944|DEVICE|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
219399201|NCT03383718|OTHER|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
219399202|NCT03544554|BEHAVIORAL|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
219399203|NCT00696657|DRUG|semaglutide|0.1 mg, once weekly, s.c. injection
219399204|NCT00696657|DRUG|semaglutide|0.2 mg, once weekly, s.c. injection
219399205|NCT00696657|DRUG|semaglutide|0.4 mg, once weekly, s.c. injection
219399206|NCT00696657|DRUG|semaglutide|0.8 mg, once weekly, s.c. injection
219399207|NCT00696657|DRUG|semaglutide|0.8 mg with titration, once weekly, s.c. injection
219399208|NCT00696657|DRUG|semaglutide|1.6 mg with titration, once weekly, s.c. injection
219399209|NCT00696657|DRUG|placebo|0.1 mg, once weekly, s.c. injection
219399210|NCT00696657|DRUG|placebo|0.2 mg, once weekly, s.c. injection
219399211|NCT00696657|DRUG|placebo|0.4 mg, once weekly, s.c. injection
219399212|NCT00696657|DRUG|placebo|0.8 mg with titration, once weekly, s.c. injection
219399213|NCT00696657|DRUG|placebo|1.6 mg, once weekly, s.c. injection
219399214|NCT00696657|DRUG|liraglutide|1.2 mg with titration, once daily, s.c. injection
219399215|NCT00696657|DRUG|liraglutide|1.8 mg with titration, once daily, s.c. injection
219399216|NCT04914832|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
219399217|NCT00649376|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fasting
219399218|NCT00649376|DRUG|Allegra® Tablets 180 mg|180mg, single dose fasting
219399219|NCT04470492|COMBINATION_PRODUCT|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
219399220|NCT04470492|DRUG|Medical Management|Patients will be treated with conventional medication for 3 months.
219563917|NCT05631535|OTHER|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
219563918|NCT04088747|DIAGNOSTIC_TEST|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
219563919|NCT00030641|BIOLOGICAL|oblimersen sodium|
219563920|NCT00030641|DRUG|docetaxel|
219563921|NCT00779402|OTHER|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
219563922|NCT00779402|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
219563923|NCT04143282|DRUG|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
219563924|NCT04143282|DRUG|Chemotherapy|standard chemotherapy
219399221|NCT01368731|PROCEDURE|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
219399222|NCT01790438|DRUG|LY2605541|
219399223|NCT01790438|DRUG|Human Insulin NPH|
219399224|NCT01790438|DRUG|Oral Antihyperglycemic Medications (OAM)|
219399225|NCT00962065|DRUG|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
219399226|NCT00962065|DRUG|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
219399227|NCT00962065|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days
219399228|NCT05137522|DRUG|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
219399229|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
219399230|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
219399231|NCT03119038|DRUG|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
219563925|NCT01625117|BEHAVIORAL|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
219563926|NCT01841541|BEHAVIORAL|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
219563927|NCT03356106|DEVICE|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
219563928|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
219563929|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
219399232|NCT03119038|DRUG|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
219563930|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
219563931|NCT01712815|OTHER|laboratory biomarker analysis|Correlative studies
219399233|NCT03119038|DRUG|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
219399234|NCT03119038|DRUG|Ketorolac|Intraoperative periarticular injection of 30 mg
219399235|NCT03119038|DRUG|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
219399236|NCT02782455|DRUG|Flavonoids|Daflon is administered
219399237|NCT02782455|DRUG|CDobi|Calcium dobesylate is administered
219399238|NCT03027817|PROCEDURE|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
219399239|NCT02090114|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
219399240|NCT02090114|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
219399241|NCT02090114|DRUG|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
219399242|NCT02090114|DRUG|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
219399243|NCT04634058|DRUG|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
219399244|NCT04527224|DRUG|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
219399245|NCT02306772|DRUG|TP05 Coating A|One radio-labelled tablet given to subjects
219399246|NCT02306772|DRUG|TP05 Coating B|One radio-labelled tablet given to subjects
219399247|NCT00926055|DRUG|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
219399248|NCT00926055|DRUG|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
219399249|NCT04220528|DRUG|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
219563932|NCT01712815|OTHER|pharmacological study|Correlative studies
219399250|NCT01806077|DRUG|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
219563933|NCT01712815|OTHER|questionnaire administration|Ancillary studies
219563934|NCT01712815|RADIATION|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
219399251|NCT03018782|OTHER|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
219399252|NCT02269111|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
219399253|NCT02269111|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
219399254|NCT02269111|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219399255|NCT02269111|PROCEDURE|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
219399256|NCT01560546|DRUG|Testosterone|50 mg/dose/day for 24 weeks
219399257|NCT01560546|DRUG|Placebo|placebo on the skin for 24 weeks
219399258|NCT00002572|BIOLOGICAL|aldesleukin|
219399259|NCT00002572|BIOLOGICAL|muromonab-CD3|
219399260|NCT00002572|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219399261|NCT00002572|PROCEDURE|conventional surgery|
219399262|NCT03252704|OTHER|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
219399263|NCT03252704|OTHER|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
219399264|NCT02654704|BIOLOGICAL|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
219399265|NCT01488825|BEHAVIORAL|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
219563935|NCT01712815|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
219563936|NCT03068949|BIOLOGICAL|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
219563937|NCT03068949|BIOLOGICAL|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
219563938|NCT03068949|BIOLOGICAL|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
219563939|NCT03068949|BIOLOGICAL|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
219563940|NCT01519947|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
219563941|NCT00618033|PROCEDURE|Hemodialysis|varying concentration of glucose in dialysate
219563942|NCT01736787|DIETARY_SUPPLEMENT|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
219563943|NCT01736787|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
219754618|NCT00540631|BIOLOGICAL|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
219399266|NCT02454218|DEVICE|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
219399267|NCT01180413|DRUG|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
219399268|NCT01180413|DRUG|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
219399269|NCT01180413|DRUG|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
219399270|NCT01180413|DRUG|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
219399271|NCT03161639|OTHER|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
219399272|NCT01290172|DRUG|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
219399273|NCT01290172|DRUG|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
219399274|NCT03750032|PROCEDURE|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
219399275|NCT03750032|PROCEDURE|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
219399276|NCT03750032|PROCEDURE|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
219399277|NCT00157092|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
219399278|NCT04688346|DRUG|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
219399279|NCT01589068|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
219399280|NCT01589068|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
219399281|NCT04645472|DEVICE|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
219563944|NCT03633552|DRUG|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
219563945|NCT02427087|BEHAVIORAL|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
219563946|NCT02427087|BEHAVIORAL|Healthy Diet|Diet group (21) Recommendation for healthy diet.
219563947|NCT01281787|DRUG|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
219399282|NCT06291181|DIAGNOSTIC_TEST|antibiotic sensitivity test|"Disc diffusion method using modified Kirby-Bauer technique on Muller Hinton agar (MHA) will be carried out for antimicrobial susceptibility of S. aureus isolates. The following antibiotics will be tested: cefoxitin (30 µg ), Tetracyclin 30 µg (TE), Chloramphenicol 30 µg (C), Gentamycin 10µg (CN), Erythromycin 15µg(E),Clindamycin 2 µg (DA), Ciprofloxacin 5 µg (CIP), Trimethoprim/sulphamethoxazole 1.25/23.75 µg (SXT), Rifampin 5µg (RA), Linezolide 30µg (LZD); cefoxitin disc (FOX 30 g)~zone diameters interpretation will be done according to Clinical and Laboratory Standard Institute (CLSI 2018),"
219399283|NCT04739657|DEVICE|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
219399284|NCT04739657|DEVICE|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
219399285|NCT05465603|DEVICE|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
219399286|NCT04439838|DRUG|BI 1595043|BI 1595043
219399287|NCT04439838|DRUG|Placebo|Placebo
219399288|NCT03898336|OTHER|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
219399289|NCT03898336|OTHER|placebo|daily intake of capsules
219399290|NCT00244699|BEHAVIORAL|MI Alone or Plus Mindfulness-Based Skills Training|
219399291|NCT03174717|BEHAVIORAL|Music performance|residents of LTC will learn and perform songs with musicians from the community
219399292|NCT04494633|OTHER|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
219399293|NCT05764018|DIETARY_SUPPLEMENT|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
219563948|NCT01281787|DRUG|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
219563949|NCT02741154|DRUG|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
219563950|NCT02741154|DRUG|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
219563951|NCT02741154|DRUG|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
219399294|NCT05764018|OTHER|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
219563952|NCT02741154|DRUG|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
219563953|NCT05871333|DRUG|Losartan 50mg Tab|Losartan 50 mg oral tablets
219563954|NCT01226537|DRUG|Taurine|500 mg taurine capsules twice per day for 6 months
219563955|NCT03795584|PROCEDURE|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
219563956|NCT01028911|DRUG|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
219563957|NCT01028911|DRUG|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
219563958|NCT02559076|BEHAVIORAL|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
219563959|NCT03704974|BEHAVIORAL|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
219399295|NCT05764018|OTHER|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
219399296|NCT05764018|OTHER|Normoxia|Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
219563960|NCT03811132|OTHER|Observation|There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
219399297|NCT03196271|DIETARY_SUPPLEMENT|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
219399298|NCT06491628|BEHAVIORAL|Avoiding the risk factors|Exercise, Salt and lipid reduction in diet, smoking cessation
219399299|NCT00976768|DRUG|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
219399300|NCT05687201|DIAGNOSTIC_TEST|Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)|Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
219399301|NCT04964024|DIAGNOSTIC_TEST|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
219399302|NCT00914199|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
219399303|NCT03800706|DRUG|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
219399304|NCT02948777|DRUG|Evolocumab|
219399305|NCT02311478|DEVICE|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
219399306|NCT03242928|DRUG|AFQ056|50 mg and 100 mg tablets taken orally
219399307|NCT03242928|DRUG|Placebo|Matching placebo tablets taken orally BID
219399308|NCT04531319|DIAGNOSTIC_TEST|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
219563961|NCT06227702|OTHER|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
219563962|NCT02274948|DRUG|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
219563963|NCT02274948|DRUG|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
219563964|NCT04624152|BEHAVIORAL|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
219399309|NCT01099839|DRUG|ASP1941|oral
219399310|NCT01099839|DRUG|Miglitol|oral
219399311|NCT02379234|OTHER|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
219399312|NCT05248087|DEVICE|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
219399313|NCT05248087|DEVICE|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
219399314|NCT02205567|DIETARY_SUPPLEMENT|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
219399315|NCT00034970|BEHAVIORAL|Mindfulness-based at therapy|
219563965|NCT01704937|DRUG|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
219754619|NCT03014466|BEHAVIORAL|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
219754620|NCT03014466|BEHAVIORAL|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
219754621|NCT01394159|PROCEDURE|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
219754622|NCT01394159|PROCEDURE|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
219754623|NCT02951507|OTHER|O T unilateral attachment|O T unilateral attachment system
219754624|NCT02951507|OTHER|New design of extracoronal attachment system|O T unilateral attachment
219754625|NCT01798602|DRUG|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
219754626|NCT01798602|DRUG|Placebo|Identical placebo for rosuvastatin
219754627|NCT03121521|DRUG|Melatonin 10 mg|melatonin 10mg daily p.o.
219754628|NCT03121521|DRUG|Placebo|Placebo 10mg daily p.o.
219563966|NCT05021913|DEVICE|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
219563967|NCT05021913|DEVICE|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
219563968|NCT01765517|DIETARY_SUPPLEMENT|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
219563969|NCT01765517|DIETARY_SUPPLEMENT|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
219563970|NCT04158817|DRUG|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
219563971|NCT04158817|DRUG|Non-labeled PSMA|Patient will be injected with microdose (\<100 ug) of THP-PSMA
219563972|NCT05956964|BEHAVIORAL|Sleep Restriction|5 hours of sleep for 3 days
219563973|NCT05956964|BEHAVIORAL|Sleep Adequate|9 hours of sleep for 3 days
219563974|NCT03191110|OTHER|No intervention: observational study|
219563975|NCT00530348|BIOLOGICAL|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
219563976|NCT00530348|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
219563977|NCT04192929|DEVICE|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
219399316|NCT05092581|DRUG|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
219399317|NCT02797366|RADIATION|Proton radiotherapy|
219399318|NCT05034783|DRUG|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
219399319|NCT05034783|DRUG|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
219399320|NCT01686984|OTHER|Altered breath|
219399321|NCT06097195|DEVICE|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
219399322|NCT02021123|DRUG|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
219399323|NCT00956241|PROCEDURE|j-pouch coloanal anastomosis|
219563978|NCT04192929|OTHER|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
219563979|NCT04192929|OTHER|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
219563980|NCT05484791|OTHER|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
219563981|NCT04915222|OTHER|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
219754629|NCT02466828|DRUG|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
219754630|NCT05149820|OTHER|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
219754631|NCT05149820|DRUG|Magnesium|Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
219399324|NCT00956241|PROCEDURE|side-to-end coloanal anastomosis|
219399325|NCT00041236|DRUG|exatecan mesylate|
219399326|NCT00390780|DRUG|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
219399327|NCT00390780|DRUG|Clotrimazole|10mg troches administered Five Times a Day for 14 days
219399328|NCT01710228|DRUG|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
219399329|NCT03360981|DRUG|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
219399330|NCT00824486|BEHAVIORAL|Injury prevention education (TIPP)|using TIPP materials
219399331|NCT00824486|BEHAVIORAL|Injury prevention education (safe home)|using safe home model
219399332|NCT00028366|DRUG|Fosamprenavir|
219399333|NCT00028366|DRUG|Lopinavir/Ritonavir|
219399334|NCT00028366|DRUG|Ritonavir|
219399335|NCT00028366|DRUG|Tenofovir disoproxil fumarate|
219399336|NCT03452553|DEVICE|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
219399337|NCT04387058|DEVICE|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
219399338|NCT04050007|OTHER|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
219399339|NCT04050007|OTHER|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
219399340|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
219399341|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
219399342|NCT02829086|OTHER|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
219399343|NCT02829086|OTHER|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
219399344|NCT02829086|OTHER|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
219001988|NCT05608889|BEHAVIORAL|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
219399345|NCT03904446|DRUG|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
219399346|NCT03904446|DRUG|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
219399347|NCT03271931|BEHAVIORAL|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
219399348|NCT03271931|BEHAVIORAL|Passive choice|EHR passive alert to cardiologists about prescribing a statin
219399349|NCT05857202|DRUG|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
219399350|NCT05857202|DRUG|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
219399351|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
219563982|NCT04915222|OTHER|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
219399352|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
219399353|NCT04367116|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
219399354|NCT06360874|DRUG|ND-003 40mg|Participants receive 40mg ND-003 tablets once.
219563983|NCT04085744|DRUG|Lidocaine 10% Spray|lidocaine will be apply on the cuff
219563984|NCT04085744|DRUG|Mometasone nasal spray|mometasone spray will be applied on the cuff
219754632|NCT00888147|DIETARY_SUPPLEMENT|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
219001989|NCT03585504|DRUG|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
219001990|NCT03632525|DRUG|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
219399355|NCT06360874|DRUG|ND-003 placebo 40mg|Participants receive placebo tablet matching to receive 40mg of ND-003.
219399356|NCT06360874|DRUG|ND-003 80mg|Participants receive 80mg ND-003 tablets once.
219399357|NCT06360874|DRUG|ND-003 placebo 80mg|Participants receive placebo tablet matching to receive 80mg of ND-003.
219399358|NCT06360874|DRUG|ND-003 160mg|Participants receive 160mg ND-003 tablets once.
219399359|NCT06360874|DRUG|ND-003 placebo 160mg|Participants receive placebo tablet matching to receive 160mg of ND-003.
219399360|NCT06360874|DRUG|ND-003 240mg|Participants receive 240mg ND-003 tablets once.
219399361|NCT06360874|DRUG|ND-003 placebo 240mg|Participants receive placebo tablet matching to receive 240mg of ND-003.
219399362|NCT06360874|DRUG|ND-003 300mg|Participants receive 300mg ND-003 tablets once.
219399363|NCT06360874|DRUG|ND-003 placebo 300mg|Participants receive placebo tablet matching to receive 300mg of ND-003.
219399364|NCT06360874|DRUG|MAD_ND003_Dose 1|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
219399365|NCT06360874|DRUG|MAD_placebo_Dose 1|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 1
219399366|NCT06360874|DRUG|MAD_ND003_Dose 2|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
219399367|NCT06360874|DRUG|MAD_placebo_Dose 2|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 2
219399368|NCT06360874|DRUG|MAD_ND003_Dose 3|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
219399369|NCT06360874|DRUG|MAD_ placebo_Dose 3|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 3
219399370|NCT06360874|DRUG|Food effect_Cohort 1|Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
219399371|NCT06360874|DRUG|Food effect_Cohort 2|Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
219399372|NCT02519075|OTHER|No intervention|Observational study
219399373|NCT01218932|DRUG|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
219399374|NCT01218932|DRUG|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
219399375|NCT04065230|DRUG|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
219399376|NCT04776356|DEVICE|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
219399377|NCT02795351|DRUG|Sildenafil|Single oral administration of active or placebo one week apart
219563985|NCT04260035|DRUG|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
219563986|NCT04260035|DRUG|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
219563987|NCT05489796|DRUG|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
219399378|NCT02795351|DRUG|Placebo|
219399379|NCT00423410|DRUG|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
219399380|NCT05822895|DEVICE|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
219399381|NCT03616080|BEHAVIORAL|soccer play program|once a week for an hour of a soccer program for 8 weeks
219399382|NCT01286844|DRUG|GSK2190915A 5mg|Oral powder for dispersion in water
219399383|NCT01286844|DRUG|GSK2190915A 10mg|Oral powder for dispersion in water
219399384|NCT01286844|DRUG|GSK2190915A 25mg|Oral powder for dispersion in water
219399385|NCT01286844|DRUG|GSK2190915A 50mg|Oral powder for dispersion in water
219399386|NCT01286844|DRUG|GSK2190915A 100mg|Oral powder for dispersion in water
219399387|NCT02261870|DEVICE|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
219399388|NCT04143542|PROCEDURE|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
219399389|NCT06094296|DRUG|BMS-986315|Specified dose on specified days
219399390|NCT06094296|DRUG|Nivolumab|Specified dose on specified days
219399391|NCT06094296|DRUG|Pemetrexed|Specified dose on specified days
219399392|NCT06094296|DRUG|Cisplatin|Specified dose on specified days
219399393|NCT06094296|DRUG|Carboplatin|Specified dose on specified days
219399394|NCT06094296|DRUG|Paclitaxel|Specified dose on specified days
219399395|NCT04794699|DRUG|IDE397|IDE397 dosed orally
219399396|NCT04794699|DRUG|Docetaxel|Intravenous infusion
219399397|NCT04794699|DRUG|Paclitaxel|Intravenous infusion
219399398|NCT04794699|DRUG|Sacituzumab govitecan|Intravenous infusion
219399399|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
219399400|NCT05280704|PROCEDURE|Volar digital block with lidocaine|Volar digital block with lidocaine
219399401|NCT05280704|PROCEDURE|Volar digital block with saline|Volar digital block with saline
219399402|NCT05280704|PROCEDURE|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
219399403|NCT05280704|PROCEDURE|Dorsal digital block with saline|Dorsal digital block with saline
219399404|NCT03439865|DRUG|Ivacaftor|150 mg tablet PO BID x 14 days
219399405|NCT03439865|DRUG|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
219399406|NCT03332667|RADIATION|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
219399407|NCT03332667|DRUG|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
219399408|NCT03332667|DRUG|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
219399409|NCT03332667|DRUG|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
219563988|NCT05489796|DRUG|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
219399410|NCT03332667|DRUG|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
219399411|NCT03508752|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery dose is based on the largest tumor size
219399412|NCT05893537|DRUG|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
219399413|NCT05893537|DRUG|Placebo Comparator|123 participants will receive a single daily dose of placebo
219399414|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
219563989|NCT05489796|DRUG|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
219563990|NCT05971524|DIETARY_SUPPLEMENT|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
219754633|NCT01471184|DEVICE|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
219754634|NCT01471184|DEVICE|Placebo|Placebo Eye Drops/Nasal Spray
219754635|NCT01416025|DRUG|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
219754636|NCT02767076|PROCEDURE|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
219754637|NCT02767076|DEVICE|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
219399415|NCT04964063|OTHER|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
219399416|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
219399417|NCT01035606|BEHAVIORAL|training in goal-directed attention regulation|training in goal-directed attention regulation
219399418|NCT01035606|BEHAVIORAL|brain health education|brain health education workshops
219399419|NCT01035606|BEHAVIORAL|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
219399420|NCT02120651|PROCEDURE|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
219399421|NCT02120651|PROCEDURE|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
219399422|NCT06116461|DRUG|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
219399423|NCT03370081|DEVICE|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
219399424|NCT03802422|DRUG|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
219399425|NCT03802422|DRUG|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
219399426|NCT00779727|PROCEDURE|Placement of drainages|
219399427|NCT06041672|BEHAVIORAL|Warm Water Hand Baths|"1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
219399428|NCT04964830|DEVICE|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
219399429|NCT02629523|DRUG|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
219399430|NCT00695084|BEHAVIORAL|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
219563991|NCT05971524|DIETARY_SUPPLEMENT|Placebo|A placebo capsule once daily for 4 weeks
219563992|NCT01307943|OTHER|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
219754638|NCT04076267|OTHER|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
219754639|NCT03185468|GENETIC|4SCAR-PSMA|PSMA-specific 4th Generation CART
219754640|NCT03185468|GENETIC|4SCAR-FRa|FRa-specific 4th Generation CART
219399431|NCT01518608|DRUG|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
219399432|NCT06410781|OTHER|Radial Extracorporeal Shockwave|Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
219399433|NCT06410781|OTHER|traditional therapy|the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
219399434|NCT03237832|DRUG|ARN-6039|Ascending doses per Cohort
219399435|NCT03237832|OTHER|Placebo|Placebo to match ARN-6039
219399436|NCT01829035|OTHER|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
219399437|NCT00166010|DRUG|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
219399438|NCT04906239|PROCEDURE|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
219399439|NCT00679159|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
219399440|NCT00679159|BIOLOGICAL|Prevenar|Streptococcus pneumoniae vaccine
219399441|NCT06518109|OTHER|Zarit Caregiver Burden Scale|The Zarit Caregiver Burden Scale (ZCBS) is a widely used instrument for assessing the burden experienced by caregivers of individuals requiring long-term care. It consists of 22 items and the total score ranges from 0 to 88 (low/no burden to severe burden)
219399442|NCT02013024|OTHER|cryopreservation technique|
219399443|NCT01204840|DRUG|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
219399444|NCT01204840|DRUG|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
219399445|NCT03695523|BEHAVIORAL|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
219399446|NCT02021500|DRUG|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
219399447|NCT02432001|PROCEDURE|Image-Guided Biopsies|
219399448|NCT01397071|OTHER|Avocado|Fresh Avocado
219399449|NCT06012760|DRUG|Iron sucrose, Human Erythropoietin Injection, Vitamin C|The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
219399450|NCT06012760|DRUG|Standard Medical Care|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
219399451|NCT03397797|DRUG|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
219399452|NCT04419064|DIAGNOSTIC_TEST|Point of care ultrasound|Tracheal and lung ultrasonography
219399453|NCT03350750|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
219399454|NCT02433288|OTHER|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
219399455|NCT02433288|OTHER|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
219399456|NCT04314167|DRUG|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
219399457|NCT01572532|OTHER|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
219399458|NCT01849250|DRUG|Docosahexaenoic Acid|Given PO
219399459|NCT01849250|OTHER|Placebo|Given PO
219399460|NCT06504173|PROCEDURE|diced cartilage|In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
219399461|NCT05288634|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
219399462|NCT00367640|DRUG|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219399463|NCT00367640|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219399464|NCT00367640|DRUG|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219399465|NCT00367640|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219399466|NCT02772354|PROCEDURE|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
219399467|NCT02772354|DRUG|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
219399468|NCT02772354|DRUG|Verapamil|Verapamil 20-240 mg
219399469|NCT02772354|DEVICE|NAVI-STAR® RMT ThermoCool|
219399470|NCT00851734|DRUG|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
219399471|NCT02469831|DRUG|Rocuronium|
219399472|NCT03174821|DEVICE|Insulin pump|Blood glucose management device
219399473|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
219399474|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
219399475|NCT01943734|BEHAVIORAL|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
219399476|NCT05581589|PROCEDURE|Lymphadenectomy|Undergo pelvic lymph node dissection
219399477|NCT05581589|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
219399478|NCT05581589|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219399479|NCT02731391|PROCEDURE|Pelvic floor reconstruction（with or without mesh）|
219399480|NCT02409784|DIETARY_SUPPLEMENT|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
219399481|NCT02409784|DIETARY_SUPPLEMENT|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
219399482|NCT02541838|OTHER|Muscle power|
219399483|NCT02541838|OTHER|balance perturbation|
219399484|NCT02541838|OTHER|aerobic exercise|
219399485|NCT00828087|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
219399486|NCT00828087|DEVICE|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
219399487|NCT02688842|DEVICE|Rapamycin target-eluting coronary stent systems (38mm)|
219399488|NCT02812433|DRUG|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
219399489|NCT02812433|DRUG|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
219399490|NCT03982771|DRUG|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
219399491|NCT03982771|DRUG|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
219399492|NCT03982771|DRUG|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
219399493|NCT02000986|BEHAVIORAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
219399494|NCT03252496|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
219399495|NCT03252496|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
219001991|NCT04841031|BEHAVIORAL|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
219399496|NCT03252496|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
219399497|NCT03252496|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
219399498|NCT03252496|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
219399499|NCT03252496|DRUG|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
219399500|NCT03252496|DRUG|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
219399501|NCT03252496|DRUG|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
219399502|NCT03252496|DRUG|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
219399503|NCT03252496|DRUG|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
219399504|NCT03252496|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
219399505|NCT03252496|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
219399506|NCT00077805|DRUG|Enoxaparin sodium|
219399507|NCT04453839|DRUG|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
219399508|NCT01524445|OTHER|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
219399509|NCT01063751|DEVICE|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
219399510|NCT04018014|OTHER|CT angiography|CT angiography in detection of pulmonary embolism
219399511|NCT03534258|DEVICE|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
219563993|NCT01307943|OTHER|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
219563994|NCT06039774|DRUG|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
219563995|NCT06039774|DRUG|Placebo|Placebo
219563996|NCT02359864|RADIATION|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
219563997|NCT02359864|RADIATION|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
219399512|NCT05508776|DRUG|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
219399513|NCT05508776|DRUG|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
219399514|NCT05508776|DRUG|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
219399515|NCT01262261|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
219399516|NCT03542240|DIETARY_SUPPLEMENT|Curcumin|500 milligram daily supplement
219399517|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
219399518|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
219399519|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
219399520|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
219563998|NCT01788709|OTHER|preparation cleaning solution|
219754641|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
219399521|NCT05921006|DRUG|RJ4287|Oral，tablets，Once daily for 14 days
219399522|NCT05921006|DRUG|Placebo|Oral，tablets，Once daily daily for 14 days
219399523|NCT04412954|BEHAVIORAL|Smartphone + Text Messaging with Health Coach|The program includes (1) use of a free commercially available smartphone application program for 12 months, (2) a wearable Fitbit Charge device that will be provided by the study to monitor active minutes, and (3) one 45-minute behavioral counseling session focused on healthy eating and exercise and (4) personalized text messaging for 6 months by a health coach. The health coach will not send feedback during months 6-12. The intervention will be fully self-directed in these months, as there will be no contact between the 6 months visit and 12-month visit.
219399524|NCT04775212|DRUG|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
219399525|NCT04775212|DRUG|Sevoflurane|Sevoflurane
219563999|NCT05040737|DEVICE|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
219399526|NCT05208424|DIAGNOSTIC_TEST|Coronary angiography|Invasive coronary angiography
219399527|NCT04554849|OTHER|Gender dysphoria psychosocial health|Retrospective analysis of medical records
219399528|NCT04075201|BIOLOGICAL|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.
219564000|NCT01360437|DRUG|Prasugrel|Prasugrel 10mg/day
219564001|NCT01360437|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
219564002|NCT02625337|DRUG|Pembrolizumab|
219564003|NCT02625337|DRUG|Dabrafenib|
219564004|NCT02625337|DRUG|Trametinib|
219564005|NCT02625337|PROCEDURE|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
219564006|NCT02625337|PROCEDURE|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
219754642|NCT04713085|DEVICE|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
219399529|NCT04075201|BIOLOGICAL|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
219399530|NCT04075201|BIOLOGICAL|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2
219399531|NCT04075201|BIOLOGICAL|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
219399532|NCT05888428|DEVICE|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
219399533|NCT05888428|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
219564007|NCT01928615|DRUG|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
219564008|NCT01928615|DRUG|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
219564009|NCT01928615|DRUG|Chemotherapy|Standard chemotherapy for early breast cancer.
219564010|NCT01100905|OTHER|Iron-containing food product|
219564011|NCT06291454|DIAGNOSTIC_TEST|Routine periodontal examination|In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
219564012|NCT00002727|RADIATION|radiation therapy|
219564013|NCT02627274|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
219754643|NCT04713085|DEVICE|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
219754644|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
219754645|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
219399534|NCT01525849|DEVICE|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
219399535|NCT01525849|PROCEDURE|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
219564014|NCT02627274|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
219564015|NCT02627274|DRUG|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
219564016|NCT04692857|PROCEDURE|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
219564017|NCT00178724|OTHER|No Treatment Given|Intervention is not given.
219564018|NCT02190786|DRUG|KUX-1151|
219564019|NCT03837158|PROCEDURE|early loading|two TiZr implants on SLA surface
219564020|NCT03837158|PROCEDURE|immediate loading|four TiZr implants on SLA surface
219564021|NCT01723917|DIETARY_SUPPLEMENT|PhytoSERM tablet|
219564022|NCT01723917|DIETARY_SUPPLEMENT|placebo|
219564023|NCT01745081|DRUG|20% mannitol bolus administration|
219564024|NCT01745081|DRUG|Hypertonic saline 3% bolus administration|
219564025|NCT06453837|OTHER|Mentha Suaveolens extract incorporated into a food supplement|Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
219754646|NCT06459791|PROCEDURE|Biopsy|The recommandation done based on informative tumorogram is up to study investigator
219754647|NCT05141383|OTHER|Urine sampling|A blood sample and a urine sample after prostate massage will be carried out at baseline
219754648|NCT06409065|BEHAVIORAL|Meditation Program|Meditation and discussion sessions will be audio recorded
219399536|NCT05631015|OTHER|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
219399537|NCT00793819|DRUG|silodosin|α1-adrenergic antagonist
219399538|NCT00078962|BIOLOGICAL|GTI-2040|Given IV
219399539|NCT00078962|DRUG|gemcitabine hydrochloride|Given IV
219399540|NCT00078962|OTHER|laboratory biomarker analysis|Correlative studies
219399541|NCT00078962|OTHER|pharmacological study|Correlative studies
219399542|NCT00446446|DRUG|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
219399543|NCT05944991|OTHER|Olive oil message|Message of olive oil 2 times daily
219399544|NCT02142894|DEVICE|CST001|
219399545|NCT01488318|DRUG|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
219399546|NCT01488318|DRUG|Dasatinib|Dasatinib 150 mg po
219399547|NCT03421002|DRUG|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
219399548|NCT04520022|DRUG|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
219564026|NCT06453837|OTHER|Placebo product|Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
219564027|NCT02275754|BEHAVIORAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
219564028|NCT02275754|BEHAVIORAL|PN Only|Participants will be navigated by PN on request
219001992|NCT04841031|OTHER|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
219001993|NCT01414114|DRUG|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
219001994|NCT05576714|OTHER|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
219001995|NCT03787953|DRUG|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
219399549|NCT04912570|PROCEDURE|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
219399550|NCT04912570|PROCEDURE|Standard PCI|Standard PCI according to the most recent guidelines
219399551|NCT00639301|BEHAVIORAL|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
219399552|NCT00003342|BIOLOGICAL|filgrastim|
219399553|NCT00003342|DRUG|carboplatin|
219399554|NCT00003342|DRUG|doxorubicin hydrochloride|
219399555|NCT00003342|DRUG|gemcitabine hydrochloride|
219399556|NCT00003342|DRUG|paclitaxel|
219399557|NCT06387238|DIAGNOSTIC_TEST|PSMA PET/CT|pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
219399558|NCT05276713|DRUG|Tucidinostat|Tucidinostat in combination with endocrine drugs
219399559|NCT00539630|DRUG|Docetaxel|
219399560|NCT04776291|RADIATION|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
219399561|NCT05309226|OTHER|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
219399562|NCT03202069|OTHER|Even protein|Intake of even protein 5 day rotating menu
219399563|NCT03202069|OTHER|Skewed protein|Intake of skewed protein 5 day rotating menu
219399564|NCT00818142|BEHAVIORAL|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
219564029|NCT04785911|DRUG|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
219564030|NCT00002633|DRUG|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219564031|NCT00002633|DRUG|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219754649|NCT01916057|DEVICE|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
219399565|NCT05697939|DIAGNOSTIC_TEST|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
219399566|NCT06150209|DEVICE|Vendaje|Dehydrated Human Amniotic Membrane
219399567|NCT01719081|PROCEDURE|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
219399568|NCT00604448|OTHER|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
219399569|NCT00604448|OTHER|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
219399570|NCT05384743|DRUG|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
219399571|NCT01299597|DRUG|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
219399572|NCT01299597|DRUG|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
219399573|NCT01299597|DRUG|SB649868|20mg daily given for 14 days.
219399574|NCT00151762|DRUG|Colesevelam hydrochloride|
219399575|NCT00397228|DRUG|ALTROPANE®|ALTROPANE® SPECT imaging
219399576|NCT03524365|PROCEDURE|RYGB|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
219399577|NCT03524365|PROCEDURE|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
219754650|NCT06044740|DRUG|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
219754651|NCT06044740|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
219754652|NCT04512235|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
219754653|NCT04512235|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
219754654|NCT04512235|DRUG|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
219754655|NCT02303262|DRUG|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
219399578|NCT03524365|OTHER|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
219399579|NCT01588574|BIOLOGICAL|MT10109|Botulinum toxin type A
219399580|NCT01588574|BIOLOGICAL|BOTOX(Registered trade mark)|Botulinum toxin type A
219399581|NCT04004507|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
219399582|NCT04004507|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
219399583|NCT00257192|DRUG|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
219399584|NCT00257192|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
219399585|NCT02062151|OTHER|Acupuncture|Acupuncture
219001996|NCT04298892|OTHER|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
219399586|NCT01058174|DRUG|micafungin|intravenous infusion
219399587|NCT01058174|DRUG|fluconazole|intravenous infusion
219399588|NCT01058174|DRUG|liposomal amphotericin B|intravenous infusion
219754656|NCT02303262|DRUG|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
219754657|NCT04758507|BIOLOGICAL|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
219754658|NCT04758507|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
219754659|NCT05664373|PROCEDURE|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
219754660|NCT00538850|DRUG|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
219754661|NCT00538850|DRUG|Placebo|Matching placebo to fentanyl sublingual spray.
219754662|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
219754663|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
219001997|NCT00105482|DRUG|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
219399589|NCT01058174|DRUG|caspofungin|intravenous infusion
219399590|NCT00060086|DIETARY_SUPPLEMENT|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
219399591|NCT00004081|DRUG|docetaxel|
219399592|NCT01120327|DRUG|Placebo|Placebo
219399593|NCT01120327|DRUG|Amlodipine|Amlodipine
219399594|NCT00570739|DRUG|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
219399595|NCT00570739|DRUG|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
219399596|NCT00570739|DRUG|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
219399597|NCT00570739|DRUG|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
219399598|NCT04256746|OTHER|Boiled Rice|
219399599|NCT04256746|OTHER|Boiled Rice+0.37 gr mulberry fruit powdered extract|
219399600|NCT04256746|OTHER|Boiled Rice+0.75 gr mulberry fruit powdered extract|
219399601|NCT04256746|OTHER|Boiled Rice+1.12 gr mulberry fruit powdered extract|
219399602|NCT04256746|OTHER|Boiled Rice+1.50 gr mulberry fruit powdered extract|
219399603|NCT04256746|OTHER|Rice Porridge|
219399604|NCT04256746|OTHER|Rice porridge+1.50 gr mulberry fruit powdered extract|
219399605|NCT03774017|PROCEDURE|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
219399606|NCT03774017|PROCEDURE|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
219399607|NCT03268174|OTHER|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
219564032|NCT00002633|DRUG|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219754664|NCT04138056|BIOLOGICAL|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
219754665|NCT04138056|BIOLOGICAL|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
219754666|NCT04138056|DRUG|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
219754667|NCT05229744|DEVICE|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~\- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
219754668|NCT01215851|DRUG|PA-824|200 mg tablet, once daily for 14 days
219399608|NCT03268174|OTHER|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
219399609|NCT00832715|PROCEDURE|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
219399610|NCT04738045|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
219399611|NCT04738045|DRUG|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
219399612|NCT04440917|DRUG|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
219399613|NCT04440917|DRUG|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
219399614|NCT03145129|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
219399615|NCT02481960|PROCEDURE|CM-BC2 Irinotecan drug-eluting bead|
219399616|NCT00941772|OTHER|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
219399617|NCT00478972|DRUG|Rimonabant|Tablet, oral administration
219399618|NCT00478972|DRUG|placebo (for Rimonabant)|Tablet, oral administration
219399619|NCT00478972|OTHER|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
219399620|NCT02020343|BEHAVIORAL|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
219399621|NCT03809065|DRUG|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
219399622|NCT03809065|DRUG|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
219399623|NCT03591952|PROCEDURE|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
219399624|NCT03591952|PROCEDURE|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
219399625|NCT01206595|DRUG|SKY0402|Single dose of SKY0402 administered as a nerve block
219399626|NCT01206595|DRUG|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
219399627|NCT01595750|DRUG|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
219399628|NCT01595750|DRUG|Placebo|Placebo 500 mcg , 12 weeks of treatment
219399629|NCT01623778|DRUG|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
219399630|NCT04687202|OTHER|follow up and record|None additional intervention was applied to the subjects.
219399631|NCT00325442|DRUG|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
219399632|NCT00325442|DRUG|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
219399633|NCT01729598|DRUG|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
219399634|NCT01729598|DRUG|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
219399635|NCT02535949|DRUG|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
219399636|NCT02535949|OTHER|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
219399637|NCT05329181|BEHAVIORAL|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
219399638|NCT00724035|DRUG|Midazolam|"Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus"
219399639|NCT00724035|DRUG|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
219399640|NCT00724035|DRUG|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
219399641|NCT00724035|PROCEDURE|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
219399642|NCT00724035|PROCEDURE|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
219564033|NCT00002633|DRUG|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219754669|NCT01215851|DRUG|Pyrazinamide|Dosed by Weight
219564034|NCT00002633|DRUG|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219564035|NCT00002633|DRUG|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
219399643|NCT00724035|PROCEDURE|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
219399644|NCT03700476|DRUG|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
219399645|NCT03700476|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
219399646|NCT03700476|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219399647|NCT03700476|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
219189462|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
219399648|NCT04381819|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 E gene
219399649|NCT05438485|OTHER|Registry|Observational (Registry)
219399650|NCT02427594|DRUG|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
219399651|NCT02427594|OTHER|Controlled diet|Diet without sodium bicarbonate supplementation
219399652|NCT04579055|OTHER|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
219399653|NCT04579055|OTHER|1-min STS test: standardized|Standardized chair seat height of 46 cm
219399654|NCT00808691|OTHER|Critical care|Standard care for each group of patients
219399655|NCT03388125|DRUG|Injection Sclerotherapy|5% ethanolamine oleate group
219399656|NCT03388125|DRUG|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
219564036|NCT00002633|PROCEDURE|orchiectomy|Optional orchiectomy
219564037|NCT00002633|RADIATION|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
219564038|NCT01913054|DRUG|Fentanyl Injection|
219564039|NCT01913054|DRUG|Etomidate Fat Emulsion Injection|
219564040|NCT01913054|DRUG|Propofol Injection|
219564041|NCT02811341|DRUG|Scopolamine Hydrobromide|
219399657|NCT05785117|DEVICE|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
219399658|NCT05785117|OTHER|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
219399659|NCT04539301|DIAGNOSTIC_TEST|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
219399660|NCT00198159|DRUG|ZD1839 Iressa|
219399661|NCT03554538|BEHAVIORAL|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
219399662|NCT03554538|BEHAVIORAL|Exercise program|Exercise on an evidence based program for shoulder pain
219399663|NCT01844700|DRUG|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
219564042|NCT02811341|DRUG|normal saline|
219564043|NCT01638273|DRUG|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
219564044|NCT01638273|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
219754670|NCT01215851|DRUG|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
219754671|NCT01215851|DRUG|Rifafour|Rifafour e-275
219754672|NCT01215851|DRUG|Moxifloxacin|moxifloxacin 400 mg
219754673|NCT05672914|BEHAVIORAL|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
219754674|NCT05340413|DRUG|Olaparib|300mg twice daily
219754675|NCT01606150|DRUG|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
219754676|NCT01606150|DRUG|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
219754677|NCT05544318|OTHER|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
219564045|NCT01107327|PROCEDURE|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
219564046|NCT02907073|DRUG|BF4|Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
219399664|NCT01844700|DRUG|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
219399665|NCT06255561|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
219399666|NCT02375698|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
219399667|NCT02375698|BIOLOGICAL|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
219564047|NCT00732160|DRUG|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
219564048|NCT00732160|DRUG|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
219564049|NCT00732160|OTHER|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
219564050|NCT00732160|OTHER|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
219564051|NCT00676494|DEVICE|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
219564052|NCT04850027|PROCEDURE|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
219564053|NCT00000680|DRUG|Zidovudine|
219564054|NCT00000680|DRUG|Aldesleukin|
219564055|NCT03826394|BEHAVIORAL|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
219564056|NCT03826394|BEHAVIORAL|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
219564057|NCT03604549|DRUG|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
219564058|NCT03604549|DRUG|Saline|Up to 10cc of saline will be infused via intrauterine catheter
219399668|NCT02680847|DRUG|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
219564059|NCT00535353|DRUG|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
219564060|NCT00535353|DRUG|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
219564061|NCT04666753|DIETARY_SUPPLEMENT|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
219564062|NCT00776568|PROCEDURE|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
219564063|NCT00776568|DRUG|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
219564064|NCT01540344|PROCEDURE|CRS|complete macroscopic cytoreduction (CC-0/1)
219754678|NCT00862940|DRUG|Memantine|10 mg tablets twice daily
219754679|NCT00862940|DRUG|Placebo|Tablets twice daily
219754680|NCT05799118|GENETIC|GWAS|The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
219754681|NCT02321501|DRUG|Ceritinib|Given PO
219754682|NCT02321501|DRUG|Everolimus|Given PO
219754683|NCT02321501|OTHER|Laboratory Biomarker Analysis|Correlative studies
219399669|NCT06219928|PROCEDURE|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
219399670|NCT06219928|PROCEDURE|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
219754684|NCT02321501|OTHER|Pharmacological Study|Correlative studies
219754685|NCT01846312|OTHER|No treatment given|The participants will not receive any treatment.
219399671|NCT06219928|PROCEDURE|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
219564065|NCT01540344|DRUG|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
219754686|NCT05438147|OTHER|CT-100 DiNaMo|Active Treatment (Study App)
219754687|NCT05438147|OTHER|Care-as-Usual|Care-As-Usual control
219564066|NCT01256060|DRUG|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
219001998|NCT00105482|DRUG|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
219001999|NCT00105482|BEHAVIORAL|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
219189463|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
219189464|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
219399672|NCT03786692|DRUG|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
219399673|NCT03786692|DRUG|Arm B|Carboplatin + Pemetrexed + Bevacizumab
219399674|NCT06598007|DRUG|CT3001|CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
219399675|NCT06609616|DEVICE|Motion Sensor|The motion sensor is the 10-axis Bluetooth Gyro Inclinometer by Wit Motion and is marketed for rehabilitation exercises, workplace injury prevention, patient care, and healthy shortrange wireless motion measurements.
219399676|NCT06609616|DEVICE|Incentive Spirometer|a device that measures the volume of the air inhaled into the lungs during inspiration.
219399677|NCT02273310|BEHAVIORAL|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
219399678|NCT01288040|BEHAVIORAL|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
219399679|NCT00489983|DRUG|pemetrexed|
219399680|NCT00489983|DRUG|gemcitabine|
219399681|NCT02621268|DRUG|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
219399682|NCT00555945|PROCEDURE|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
219399683|NCT00555945|PROCEDURE|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
219399684|NCT05837260|OTHER|Sample collection only|Sample collection only
219399685|NCT00363025|PROCEDURE|Two post-remission strategies|
219399686|NCT00363025|DRUG|Idarubicin versus daunorubicin|
219564067|NCT05577494|OTHER|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
219002000|NCT05479071|DIAGNOSTIC_TEST|Blood test|Screening of antibodies against LDL
219399687|NCT03213639|DRUG|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
219399688|NCT03213639|DRUG|Placebo Oral Tablet|once daily oral tablets
219399689|NCT00775372|DRUG|Clarithromycin 250mg/5mL|
219399690|NCT00294593|DRUG|folinic acid|
219399691|NCT03307447|DRUG|Secukinumab|Secukinumab 300 mg subcutaneous injection
219399692|NCT04111822|DRUG|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
219399693|NCT04111822|DRUG|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
219399694|NCT03836638|DRUG|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
219399695|NCT03836638|DRUG|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
219399696|NCT05198167|OTHER|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
219399697|NCT05198167|OTHER|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
219399698|NCT02090582|OTHER|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
219399699|NCT02090582|OTHER|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
219399700|NCT00881829|DEVICE|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
219399701|NCT01221545|DRUG|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
219399702|NCT01221545|DRUG|Placebo|Placebo
219399703|NCT03029962|BEHAVIORAL|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
219399704|NCT04211545|DRUG|Rabeprazole|Rabeprazole
219399705|NCT04211545|DRUG|CC-92480|CC-92480
219399706|NCT04089124|PROCEDURE|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
219754688|NCT02023437|DEVICE|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
219002001|NCT04661085|DIAGNOSTIC_TEST|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
219002002|NCT04067895|PROCEDURE|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
219399707|NCT03177577|DEVICE|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
219399708|NCT03177577|DEVICE|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
219399709|NCT03210285|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing
219399710|NCT02430792|BEHAVIORAL|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
219399711|NCT01011062|PROCEDURE|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
219399712|NCT01011062|DRUG|Losartan|Acute administration of losartan 200mg total prior to clamp
219399713|NCT01011062|DRUG|Saline|Infusion of Saline as a volume control intervention
219399714|NCT03336840|DRUG|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
219399715|NCT03336840|DRUG|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
219399716|NCT03336840|DRUG|1. Metformin tablets; 2. ProMetS probiotics powder|"1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
219399717|NCT04346823|DRUG|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay."
219399718|NCT00950781|PROCEDURE|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
219399719|NCT03467022|DRUG|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
219399720|NCT01965548|PROCEDURE|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned"
219754689|NCT02023437|DEVICE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
219002003|NCT05620563|DRUG|LY3857210|Administered orally
219002004|NCT05620563|DRUG|Placebo|Administered orally
219002005|NCT04376372|DIAGNOSTIC_TEST|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
219002006|NCT00869206|DRUG|zoledronic acid|Given IV
219002007|NCT03578289|BEHAVIORAL|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
219399721|NCT02242539|BEHAVIORAL|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
219754690|NCT03588702|DEVICE|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
219754691|NCT01466088|DRUG|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
219189465|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
219189466|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
219189467|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
219399722|NCT02242539|BEHAVIORAL|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
219189468|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
219399723|NCT00803244|DRUG|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
219399724|NCT00803244|DRUG|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
219399725|NCT05102201|DEVICE|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
219399726|NCT00200148|PROCEDURE|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
219399727|NCT00200148|PROCEDURE|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
219399728|NCT05522114|PROCEDURE|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
219399729|NCT00299884|DRUG|Lipitor 20 mg|A/A for 6 weeks
219399730|NCT00299884|DRUG|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
219399731|NCT02138578|RADIATION|SBRT|
219399732|NCT02138578|RADIATION|RFA|
219399733|NCT03514472|DIETARY_SUPPLEMENT|Dried Moringa oleifera leaves|
219399734|NCT02159092|BEHAVIORAL|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
219399735|NCT01955174|DRUG|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
219399736|NCT01955174|OTHER|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
219399737|NCT02021812|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
219399738|NCT04246229|DIAGNOSTIC_TEST|Transcutaneous bilirubinometry|use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels
219399739|NCT04246229|DIAGNOSTIC_TEST|Serum bilirubin|use of blood draws to measure serum bilirubin level
219399740|NCT00564629|DRUG|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
219399741|NCT00564629|DRUG|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
219399742|NCT00564629|BIOLOGICAL|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
219399743|NCT03241173|DRUG|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
219399744|NCT03241173|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
219399745|NCT03241173|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
219399746|NCT02828319|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
219399747|NCT00538382|DRUG|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
219399748|NCT03634072|PROCEDURE|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
219399749|NCT01193725|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
219399750|NCT01193725|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
219399751|NCT01193725|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
219564068|NCT01467362|DRUG|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
219002008|NCT04519710|BIOLOGICAL|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
219002009|NCT03582202|PROCEDURE|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
219002010|NCT03582202|PROCEDURE|Standard care|Nutritional handling by nurse
219002011|NCT02175888|DIETARY_SUPPLEMENT|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
219002012|NCT02175888|DIETARY_SUPPLEMENT|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
219002013|NCT02050360|DRUG|Sildenafil 40 mg|
219002014|NCT02050360|DRUG|Sildenafil 80 mg|
219002015|NCT02050360|DRUG|Placebo|
219002016|NCT01781403|DRUG|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
219002017|NCT06049745|DRUG|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
219002018|NCT00546845|DEVICE|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
219002019|NCT00546845|DEVICE|Use of self-expanding Expert stent|Nitinol stent
219002020|NCT00085631|DRUG|cisplatin|Given IV
219002021|NCT00085631|PROCEDURE|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
219002022|NCT00085631|RADIATION|brachytherapy|Patients undergo brachytherapy for 2-3 days
219002023|NCT00085631|RADIATION|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
219002024|NCT01662258|DEVICE|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
219002025|NCT03535103|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
219002026|NCT03535103|DRUG|LM001|A single Subcutaneous injection, 225IU
219002027|NCT05417945|DEVICE|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
219399752|NCT06106425|DIAGNOSTIC_TEST|EEG|diagnostic tool
219399753|NCT03950102|RADIATION|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
219399754|NCT06667284|PROCEDURE|Roux en y procedure|subtotal gastrectomy en bloc with Roux-en-Y reconstruction, using TA 90 and GIA staplers. The length of the biliopancreatic limb was 50 cm, while the alimentary limb was 80 cm
219399755|NCT06667284|PROCEDURE|Omega brown procedure|Gastrojejunal anastomosis with jejunojejunal anastomosis
219399756|NCT03177876|PROCEDURE|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
219399757|NCT03177876|PROCEDURE|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
219399758|NCT02134704|OTHER|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
219399759|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
219564069|NCT01467362|DRUG|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
219564070|NCT01467362|DRUG|desonide 0.1% cream|cream, once a day (in the evening) during flares
219564071|NCT01467362|OTHER|Foaming gel|for the washing and cleaning
219564072|NCT01115062|DRUG|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
219399760|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
219399761|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
219399762|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
219399763|NCT02112604|DEVICE|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
219399764|NCT02112604|DEVICE|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
219191827|NCT06496945|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
219191828|NCT05996848|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide subcutaneously.
219399765|NCT02112604|OTHER|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
219399766|NCT02112604|OTHER|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
219399767|NCT02112604|OTHER|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
219399768|NCT02112604|DRUG|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
219399769|NCT03792269|DRUG|Irinotecan|intraperitoneal
219399770|NCT03792269|DRUG|Oxaliplatin|intravenous
219399771|NCT03792269|DRUG|Capecitabine|
219399772|NCT02917486|OTHER|blood sample|
219399773|NCT04051567|DRUG|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
219399774|NCT03959618|OTHER|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
219399775|NCT02077049|DEVICE|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
219399776|NCT02077049|OTHER|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
219399777|NCT00590681|DRUG|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
219564073|NCT01115062|DRUG|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
219564074|NCT01115062|DRUG|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
219002028|NCT02823288|OTHER|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
219399778|NCT02260414|DRUG|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
219564075|NCT06678282|DRUG|JY231 Injection|The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
219564076|NCT00579631|BEHAVIORAL|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
219564077|NCT01347320|OTHER|Preoperative MRI|Preoperative staging
219564078|NCT06024967|DRUG|PEG-somatropin|PEG-somatropin
219564079|NCT02126657|DRUG|70% glycolic acid|
219564080|NCT00786630|BEHAVIORAL|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
219564081|NCT00786630|BEHAVIORAL|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
219564082|NCT01889550|BEHAVIORAL|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
219564083|NCT01889550|BEHAVIORAL|Access to the website www.ouh.dk|Access to the usual information from the hospital website
219399779|NCT02260414|OTHER|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
219564084|NCT00671567|DRUG|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
219564085|NCT00671567|DRUG|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
219564086|NCT00671567|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
219564087|NCT00959569|DRUG|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
219564088|NCT00959569|DRUG|Placebo|normosaline (same ml of the study drug)
219564089|NCT04712916|BEHAVIORAL|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
219564090|NCT02414763|BEHAVIORAL|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
219399780|NCT05604612|PROCEDURE|Corticision|Incisions in the cortical plate of maxillary bone
219399781|NCT06096233|OTHER|Bouts of Exercise|The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
219564091|NCT00128817|RADIATION|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
219564092|NCT00128817|PROCEDURE|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
219564093|NCT04694703|DRUG|Covid-19 group|Routine COVID-19 treatment
219564094|NCT04226586|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
219564095|NCT04226586|DIETARY_SUPPLEMENT|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
219564096|NCT00386815|DRUG|pemetrexed|
219564097|NCT00386815|DRUG|cisplatin|
219564098|NCT04594720|OTHER|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
219564099|NCT04594720|OTHER|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
219564100|NCT02676960|OTHER|MRI without sedation|
219564101|NCT04611594|BEHAVIORAL|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
219564102|NCT00277160|DRUG|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
219564103|NCT03244982|DRUG|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
219564104|NCT03244982|DRUG|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
219754692|NCT01466088|DRUG|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
219754693|NCT05226494|DRUG|fb-PMT|Daily dosing based on patient weight
219002029|NCT00411645|DRUG|maribavir|100 mg twice daily for up to 12 weeks
219002030|NCT00411645|OTHER|placebo|twice daily for up to 12 weeks
219399782|NCT04791397|PROCEDURE|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
219399783|NCT04791397|PROCEDURE|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
219399784|NCT05022992|OTHER|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
219399785|NCT01276015|DRUG|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
219399786|NCT02991820|DEVICE|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
219399787|NCT02991820|DEVICE|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
219399788|NCT02991820|DEVICE|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
219399789|NCT02991820|DEVICE|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
219399790|NCT01750476|DRUG|Mirena|
219399791|NCT01750476|DRUG|Oral contraception|
219399792|NCT01750476|DRUG|Depo-Provera|
219399793|NCT03335631|BEHAVIORAL|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
219002031|NCT01649687|BIOLOGICAL|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
219002032|NCT00389363|DRUG|ALK HDM tablet|
219002033|NCT02326753|DEVICE|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
219002034|NCT02326753|DEVICE|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
219002035|NCT02326753|DEVICE|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
219002036|NCT06153511|PROCEDURE|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
219191829|NCT05996848|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide subcutaneously.
219191830|NCT05996848|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
219191831|NCT05996848|DRUG|Placebo Cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
219191832|NCT05511597|BEHAVIORAL|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
219191833|NCT05511597|BEHAVIORAL|Complex task practice|Overground gait flexibility training with added cognitive tasks
219399794|NCT00053846|DRUG|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
219399795|NCT00053846|DRUG|Placebo|Placebo
219399796|NCT01219244|BEHAVIORAL|caloric restriction|6 months of caloric restriction (15 %)
219399797|NCT01219244|BEHAVIORAL|omega-3 supplementation|6 months of omega-3 supplementation
219399798|NCT01219244|BEHAVIORAL|resveratrol supplementation|6 months of resveratrol supplementation
219399799|NCT01219244|BEHAVIORAL|Placebo|6 months of placebo intake
219399800|NCT01219244|BEHAVIORAL|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
219399801|NCT01219244|BEHAVIORAL|2nd step: intervention + control|most effective dietary intervention plus control
219399802|NCT06511856|DEVICE|ARROW|Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
219399803|NCT02033551|DRUG|Veliparib|
219399804|NCT02033551|DRUG|Carboplatin|
219399805|NCT02033551|DRUG|Paclitaxel|
219399806|NCT02033551|DRUG|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
219399807|NCT02692053|BIOLOGICAL|blood sampling|additional blood sampling (volume: 18 mL)
219399808|NCT00064662|PROCEDURE|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
219754694|NCT00224549|DRUG|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
219399809|NCT00064662|PROCEDURE|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
219564105|NCT06503003|DEVICE|Leonardo® Diode laser|The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
219564106|NCT04366180|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months
219564107|NCT04366180|DIETARY_SUPPLEMENT|Control|The control group will received one placebo capsule per day during 2 months
219564108|NCT01397266|PROCEDURE|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
219191834|NCT05511597|BEHAVIORAL|Static balance exercise|Mindfulness and breathing combined with static balance exercises
219399810|NCT02987673|PROCEDURE|MGB/OAGB|
219564109|NCT01397266|PROCEDURE|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
219564110|NCT02735694|DRUG|Cycloserine|Capsule containing 250 mg of Cycloserine
219564111|NCT02735694|DRUG|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
219564112|NCT01123291|PROCEDURE|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
219564113|NCT01123291|PROCEDURE|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
219564114|NCT04418531|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
219399811|NCT02987673|PROCEDURE|LSG|
219399812|NCT04384640|OTHER|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
219399813|NCT03242096|COMBINATION_PRODUCT|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
219399814|NCT03242096|COMBINATION_PRODUCT|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
219564115|NCT03002480|OTHER|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
219399815|NCT02512016|OTHER|Study Procedures|"* Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
219564116|NCT04190927|BIOLOGICAL|Compounded topical estradiol and compounded topical progesterone in a carrier cream|Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
219564117|NCT02527330|OTHER|MR T2* imaging|Cardiac magnetic resonance imaging with T2\* imaging
219564118|NCT05377125|BEHAVIORAL|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
219564119|NCT05377125|BEHAVIORAL|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
219564120|NCT01808248|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219564121|NCT01808248|DRUG|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
219564122|NCT01808248|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219564123|NCT02758548|PROCEDURE|Blood sample|Fingerprick and venous
219564124|NCT02758548|DEVICE|POCT device|Investigational device
219399816|NCT04292119|DRUG|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
219564125|NCT05939804|DEVICE|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
219564126|NCT06677944|RADIATION|Preoperative PBI|Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
219564127|NCT00560326|DRUG|Tacrolimus Ointment 0.03%|Once or twice daily topical application
219564128|NCT03690167|OTHER|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
219564129|NCT03690167|OTHER|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
219399817|NCT04292119|DRUG|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
219399818|NCT04292119|DRUG|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
219399819|NCT04292119|DRUG|TNO155|TNO155 will be taken orally once daily for 14 days.
219399820|NCT03008590|DRUG|Naltrexone|One 4.5 mg capsule each evening
219399821|NCT03008590|DRUG|Placebo|One capsule each evening
219399822|NCT05181917|BEHAVIORAL|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
219399823|NCT04615390|BEHAVIORAL|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
219564130|NCT03690167|OTHER|Control|Nothing applied after extraction
219564131|NCT00002244|DRUG|WF10|
219564132|NCT04810169|DEVICE|Smart inhaler|"* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
219564133|NCT03038763|OTHER|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
219564134|NCT03038763|DIAGNOSTIC_TEST|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
219399824|NCT04615390|BEHAVIORAL|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
219399825|NCT04615390|BEHAVIORAL|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
219399826|NCT04615390|BEHAVIORAL|Personalized ambulatory training|Low-intensity walking exercises at home
219399827|NCT04895059|DRUG|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
219399828|NCT04895059|DRUG|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
219399829|NCT04895059|DRUG|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
219399830|NCT03469193|PROCEDURE|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
219564135|NCT00110734|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
219564136|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
219564137|NCT04087317|DRUG|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
219564138|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
219564139|NCT04087317|DRUG|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
219564140|NCT04087317|DRUG|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
219191835|NCT03252938|DRUG|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
219191836|NCT03252938|DRUG|Avelumab|Avelumab i.v.
219191837|NCT06345989|PROCEDURE|Alginate impression|Alginate impressions are a traditional method for creating dental moulds which are used in orthodontic records. Plastic trays are sized to fit the upper and lower jaws, and the alginate is mixed into a putty before being placed in the trays. The putty is then used to take detailed impressions of the patient's teeth. To capture an accurate bite registration, the patient bites down on a piece of warmed wax.
219399831|NCT03469193|PROCEDURE|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
219399832|NCT01696409|DIETARY_SUPPLEMENT|400 IU vitamin D3|Take 400 IU once/day for 2 months
219399833|NCT01696409|DIETARY_SUPPLEMENT|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
219399834|NCT00023907|DRUG|paclitaxel|
219399835|NCT00002191|DRUG|Albendazole|
219399836|NCT04222127|OTHER|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
219399837|NCT04222127|OTHER|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
219399838|NCT03292627|DEVICE|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
219399839|NCT04736524|OTHER|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
219399840|NCT06070623|DEVICE|US|We use elastography and color Doppler from US machine and compare results with CT
219399841|NCT00192517|DRUG|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
219564141|NCT00165516|DRUG|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
219399842|NCT00192517|OTHER|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
219399843|NCT04743414|DRUG|CTP-543|Itraconazole in solution dosage form
219399844|NCT04499508|DEVICE|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
219399845|NCT03567499|DRUG|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
219399846|NCT03567499|DRUG|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
219399847|NCT02665442|DEVICE|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
219399848|NCT01713400|DRUG|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
219399849|NCT01713400|DRUG|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
219399850|NCT01713400|DRUG|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
219399851|NCT01713400|DRUG|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
219399852|NCT04254237|PROCEDURE|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
219399853|NCT04254237|PROCEDURE|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
219399854|NCT03172546|GENETIC|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
219399855|NCT01651182|DRUG|No tranexamic acid|Control
219399856|NCT01651182|DRUG|Tranexamic Acid|
219399857|NCT02796404|DEVICE|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
219399858|NCT02796404|OTHER|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
219399859|NCT02458612|OTHER|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
219564142|NCT00165516|DRUG|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
219564143|NCT05703841|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
219564144|NCT04754555|OTHER|Arm Activity Measure (ArmA) in french|The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
219564145|NCT05854706|DEVICE|Theta Burst Stimulation|Theta Burst Stimulation
219564146|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
219399860|NCT02458612|OTHER|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
219399861|NCT01531218|DRUG|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
219399862|NCT01531218|DRUG|Placebo|
219399863|NCT06020859|DEVICE|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
219399864|NCT06020859|DEVICE|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
219399865|NCT06020859|DEVICE|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
219399866|NCT03611400|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
219399867|NCT03611400|DIETARY_SUPPLEMENT|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
219399868|NCT03102775|OTHER|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
219564147|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
219564148|NCT03025776|BEHAVIORAL|Reaching|sitting reaching under various task conditions (size, speed, location)
219564149|NCT03025776|BEHAVIORAL|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
219564150|NCT00153205|BEHAVIORAL|computerized physician order entry|
219564151|NCT01416116|DRUG|QUTENZA|topical
219564152|NCT01416116|DRUG|Lidocaine|topical
219399869|NCT03102775|OTHER|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
219399870|NCT03653715|DEVICE|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
219399871|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
219564153|NCT01416116|DRUG|Tramadol|oral
219564154|NCT05507320|BEHAVIORAL|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
219564155|NCT00197080|DRUG|Ropinirole Extended Release (XR)|
219564156|NCT04936594|DEVICE|iTBS|1800 pulses of iTBS
219564157|NCT04936594|DEVICE|TMS|MagVenture MagPro x100 device. This will be used as the comparator.
219564158|NCT05193422|DIAGNOSTIC_TEST|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
219564159|NCT05193422|DIAGNOSTIC_TEST|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
219564160|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
219564161|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
219564162|NCT05193422|DIAGNOSTIC_TEST|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
219399872|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
219399873|NCT03653715|DEVICE|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
219399874|NCT00021853|BEHAVIORAL|constraint-induced movement therapy|
219399875|NCT06339229|OTHER|proteinuria|dipstick proteinuria values negative, trace, 1+, and ≥2+
219399876|NCT02527876|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training
219399877|NCT02527876|BEHAVIORAL|Moderate Intensity|Moderate Intensity Training
219399878|NCT02527876|BEHAVIORAL|Delayed Control|Delayed Control
219399879|NCT02527876|DEVICE|FitBit Flex|Use to measure increase in Physical Activity
219399880|NCT00897520|BIOLOGICAL|recombinant interferon alfa|
219399881|NCT00897520|GENETIC|proteomic profiling|
219399882|NCT00897520|OTHER|immunoenzyme technique|
219399883|NCT00897520|OTHER|laboratory biomarker analysis|
219399884|NCT02776280|OTHER|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
219399885|NCT00509873|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
219399886|NCT00509873|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
219399887|NCT01417780|DRUG|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
219399888|NCT01417780|DRUG|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
219399889|NCT00828867|DRUG|100 mg GSK investigational drug|
219399890|NCT00828867|DRUG|200 mg GSK investigational drug|
219399891|NCT00828867|DRUG|400 mg GSK investigational drug|
219399892|NCT00828867|DRUG|800 mg GSK investigational drug|
219399893|NCT00828867|DRUG|2000 mg GSK investigational drug|
219399894|NCT00828867|DRUG|1500 mg GSK investigational drug|
219399895|NCT00828867|DRUG|800mg fed GSK investigational drug|
219399896|NCT00828867|DRUG|3000mg GSK investigational drug|
219399897|NCT00828867|DRUG|4000mg GSK investigational drug|
219399898|NCT02145767|DRUG|Progesterone|
219564163|NCT05193422|DIAGNOSTIC_TEST|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
219564164|NCT05193422|DIAGNOSTIC_TEST|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
219191838|NCT06345989|PROCEDURE|Intraoral scan|Intraoral scanners capture multiple images of the mouth, which are combined to create a three-dimensional model of the patient's upper and lower teeth. The scanning wand is passed methodically over the surface of the teeth to gather all the necessary information, which is displayed in real-time on a computer screen.
219191839|NCT00957047|DRUG|eslicarbazepine acetate|oral tablets
219399899|NCT02145767|DRUG|Placebo|
219399900|NCT05975567|OTHER|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
219399901|NCT00053820|BIOLOGICAL|aldesleukin|
219399902|NCT00053820|BIOLOGICAL|recombinant interferon alfa|
219399903|NCT00053820|DRUG|fluorouracil|
219399904|NCT01345786|DRUG|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
219399905|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
219399906|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
219399907|NCT03953586|DIAGNOSTIC_TEST|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
219399908|NCT02096939|PROCEDURE|Adrenal extirpation|
219399909|NCT02096939|DRUG|Antihypertensive medication|
219399910|NCT00141635|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|
219399911|NCT01891747|DRUG|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
219399912|NCT01891747|DRUG|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
219399913|NCT01891747|DIETARY_SUPPLEMENT|Vitamin C|250 mg vitamin C once a day (oral) - Phase I \& Phase II
219399914|NCT01145027|OTHER|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
219399915|NCT03575091|OTHER|Non-individualized|Comparing two experimental interventions with standard care
219399916|NCT03575091|OTHER|Individualized|Comparing two experimental interventions with standard care
219564165|NCT05193422|DIAGNOSTIC_TEST|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
219564166|NCT05193422|DIAGNOSTIC_TEST|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
219564167|NCT05193422|DIAGNOSTIC_TEST|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
219564168|NCT05193422|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
219564169|NCT05193422|DIAGNOSTIC_TEST|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
219399917|NCT03179098|OTHER|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
219399918|NCT03179098|OTHER|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
219399919|NCT03179098|OTHER|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
219399920|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
219399921|NCT01929044|DRUG|654-II (anisodamine)|10mg injection
219399922|NCT01929044|DRUG|Buscopan® (hyoscine butylbromide)|20mg injection
219399923|NCT03555539|DRUG|Danicopan|Oral tablet.
219399924|NCT01974674|PROCEDURE|Allogeneic transplantation of intrahepatic islet|
219564170|NCT00418067|DEVICE|Endeavor|Zotarolimus-eluting stent
219564171|NCT00418067|DEVICE|Cypher|Sirolimus-eluting stent
219564172|NCT00418067|DEVICE|Taxus Liberte|Paclitaxel-eluting stent
219564173|NCT06427044|DRUG|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
219564174|NCT02166801|BEHAVIORAL|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
219191840|NCT00957047|DRUG|placebo|once daily placebo comparator
219191841|NCT00957047|DRUG|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
219399925|NCT00063648|BIOLOGICAL|EBV-specific autologous CTL|
219564175|NCT02166801|BEHAVIORAL|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
219564176|NCT01304186|BEHAVIORAL|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
219564177|NCT00091286|BIOLOGICAL|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
219564178|NCT01350596|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
219399926|NCT04037358|DRUG|Radium-223|Radium-223 plus SABR will be within two weeks.
219399927|NCT04037358|RADIATION|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
219399928|NCT04436510|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
219564179|NCT01350596|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
219002037|NCT05728307|DEVICE|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
219002038|NCT00002942|PROCEDURE|autologous bone marrow transplantation|
219399929|NCT04436510|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
219399930|NCT02807454|DRUG|Daratumumab|
219399931|NCT02807454|DRUG|Durvalumab|
219399932|NCT02807454|DRUG|Pomalidomide|
219399933|NCT02807454|DRUG|Dexamethasone|
219564180|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
219564181|NCT06276296|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
219564182|NCT06276296|PROCEDURE|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
219002039|NCT00002942|PROCEDURE|peripheral blood stem cell transplantation|
219399934|NCT03739944|PROCEDURE|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
219399935|NCT03739944|PROCEDURE|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
219399936|NCT03739944|PROCEDURE|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
219564183|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
219564184|NCT01118234|DRUG|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
219564185|NCT01710124|OTHER|Financial incentives|
219564186|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
219564187|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
219564188|NCT03692091|PROCEDURE|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
219564189|NCT02993419|DRUG|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
219399937|NCT03739944|PROCEDURE|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
219564190|NCT02993419|OTHER|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
219564191|NCT03696043|OTHER|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
219399938|NCT02769572|OTHER|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
219399939|NCT02769572|DRUG|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
219399940|NCT02769572|DRUG|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
219399941|NCT02769572|OTHER|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
219399942|NCT02205385|PROCEDURE|Targeted Muscle Reinnervation|
219399943|NCT02205385|PROCEDURE|Traction Neurectomy|
219399944|NCT05913557|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
219399945|NCT05077917|DRUG|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
219399946|NCT05077917|OTHER|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
219399947|NCT04885244|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
219399948|NCT03721081|DRUG|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
219399949|NCT03721081|OTHER|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
219399950|NCT00231985|BEHAVIORAL|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
219399951|NCT00231985|BEHAVIORAL|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
219399952|NCT01149278|DRUG|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
219399953|NCT01149278|OTHER|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
219399954|NCT00002141|DRUG|Abacavir sulfate|
219399955|NCT00907140|PROCEDURE|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
219399956|NCT06929377|OTHER|IPPON warm-up programme|The IPPON intervention is an injury prevention programme designed specifically to reduce injuries in judo athletes. The trainer-supervised IPPON intervention mainly focuses on preventing musculoskeletal injuries of the shoulder, knee and ankle. The IPPON intervention consists of 36 exercises divided into (1) flexibility and agility, (2) balance and coordination and (3) strength and stability. Each category consisted of 12 exercises with 3 levels of difficulty. Athletes performed 4 exercises per category and thus 12 exercises at the start of the training at least two times per week.
219399957|NCT06930313|BEHAVIORAL|Brief Compassion-Based Intervention (BCI)|"The intervention program is based on Compassion-Focused Therapy (CFT) and incorporates evidence-based compassion exercises.Drawing on insights from the literature, the program includes:Session 1: Introduction to caregiving challenges and emotional systems. Includes a soothing breathing exercise and group discussion on caregiving stress.~Session 2: Cultivating self-compassion. Includes reflecting on emotions, guided meditation, and a compassionate body scan practice.~Session 3: Transforming self-criticism into self-compassion. Caregivers explore self-critical thoughts, practice reframing, and engage in compassionate dialogue.~Session 4: Building resilience and connections. Focuses on gratitude, setting boundaries, and loving-kindness meditation, ending with daily intention setting."
219399958|NCT06930313|BEHAVIORAL|Telephone-Based Support and Education (TSE)|The session will address their questions and concerns, provide psychological support for managing difficult emotions (e.g., anxiety, fear, sadness, and guilt), and emphasize the importance of self-care, encouraging them to take time for themselves and seek support when needed.
219399959|NCT06834815|DRUG|Probiotic with Prebiotic|"After assigning the patients , all patients will submit an unstimulated salivary sample of 1ml will in sealed test tubes then stored in a deep freezer until microbiological evaluation, then they'll receive an oral prophylaxis session.~* The patients will receive probiotics for 14 days given to them in a sealed box.~* All patients will be followed up after 14 days and another salivary sample will be collected and sent for microbiological assessment."
219399960|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
219564192|NCT03696043|OTHER|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
219564193|NCT01406249|DRUG|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
219564194|NCT01406249|DRUG|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
219564195|NCT00347906|PROCEDURE|laser treatment|
219564196|NCT03046082|DRUG|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
219399961|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
219564197|NCT01017094|DRUG|silversulfadiazine|apply once a day
219399962|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
219564198|NCT00220727|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
219564199|NCT04037982|PROCEDURE|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
219399963|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
219399964|NCT05519761|DEVICE|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
219399965|NCT05419154|PROCEDURE|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
219191842|NCT05475379|BIOLOGICAL|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
219399966|NCT01395485|DRUG|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
219399967|NCT03334578|DRUG|Gastrografin|Gastrografin group
219399968|NCT06488326|DRUG|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
219399969|NCT06488326|DRUG|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
219399970|NCT06488326|DRUG|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
219399971|NCT06488326|DRUG|Placebo capsule|Take one capsule of the sample one time.
219399972|NCT03660904|BIOLOGICAL|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
219399973|NCT03660904|BIOLOGICAL|commercially made vitrification & thawing kit|commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
219399974|NCT03781882|PROCEDURE|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
219399975|NCT03781882|PROCEDURE|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
219399976|NCT00773760|OTHER|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
219399977|NCT02941107|DRUG|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
219399978|NCT02941107|DRUG|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
219399979|NCT02401750|DRUG|Oxycodone Naltrexone (a)|
219399980|NCT02401750|DRUG|Oxycodone Naltrexone (b)|
219399981|NCT02401750|DRUG|Placebo|Matches both experimental drugs
219399982|NCT01989546|DRUG|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
219399983|NCT01924546|OTHER|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
219399984|NCT00624572|DRUG|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
219399985|NCT02392039|DRUG|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
219399986|NCT02392039|DRUG|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
219564200|NCT04037982|PROCEDURE|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
219564201|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
219564202|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
219191843|NCT05486481|DRUG|Venetoclax|Given orally (PO)
219191844|NCT05486481|DRUG|Dexamethasone|Given PO
219191845|NCT05486481|DRUG|Daratumumab|Given Subcutaneously (SC)
219191846|NCT05486481|DEVICE|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
219191847|NCT02824731|RADIATION|Radiation with protons|
219564203|NCT00000425|DRUG|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
219564204|NCT00000425|DRUG|Acetaminophen|
219564205|NCT03097939|DRUG|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
219564206|NCT03097939|DRUG|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
219191848|NCT02824731|RADIATION|Radiation with photons|
219399987|NCT02392039|OTHER|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
219399988|NCT02392039|BEHAVIORAL|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
219399989|NCT03239756|BIOLOGICAL|TK006|Subcutaneous injection
219399990|NCT00541892|OTHER|Medium with no human serum albumine added|See above
219399991|NCT00541892|OTHER|Conventional medium|See above
219399992|NCT00429039|DRUG|L-leucyl-L-leucine methyl ester (LLME)|
219399993|NCT03664622|DRUG|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
219399994|NCT03664622|DRUG|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
219399995|NCT05308225|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
219399996|NCT03648281|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219399997|NCT01913249|PROCEDURE|LIFT|Ligation of intersphincteric fistula tract
219564207|NCT02020967|OTHER|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
219564208|NCT06151067|DIAGNOSTIC_TEST|High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing|High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
219564209|NCT00049296|DRUG|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
219564210|NCT00049296|DRUG|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
219564211|NCT02868996|DRUG|Recombinant human tissue kallikrein|Intravenous DM199
219564212|NCT03507686|DRUG|BIIB111|Administered as specified in the treatment arm.
219564213|NCT00075686|BIOLOGICAL|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
219564214|NCT00075686|DRUG|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
219564215|NCT05332886|BEHAVIORAL|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
219564216|NCT05332886|BEHAVIORAL|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
219564217|NCT02508116|GENETIC|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
219564218|NCT02630316|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
219564219|NCT02630316|DRUG|Placebo|Placebo administered four times daily
219564220|NCT03935841|DIETARY_SUPPLEMENT|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
219564221|NCT04944316|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet
219564222|NCT04944316|BEHAVIORAL|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
219564223|NCT00983528|BIOLOGICAL|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
219564224|NCT00983528|DRUG|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
219564225|NCT01942447|BIOLOGICAL|FMT|
219564226|NCT01942447|DRUG|Vancomycin|
219564227|NCT00004188|BIOLOGICAL|filgrastim|Given IV
219191849|NCT03367754|OTHER|Placebo|Single dose of Placebo given via intravenous (IV) infusion.
219399998|NCT03877120|DRUG|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
219399999|NCT03877120|DRUG|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
219400000|NCT04534439|DRUG|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
219400001|NCT04534439|DRUG|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
219400002|NCT01419275|DRUG|Xenon contrast agent|
219400003|NCT01419275|DEVICE|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
219400004|NCT00059215|DRUG|Prasugrel (CS-747)|Administered orally
219400005|NCT00059215|DRUG|Clopidogrel|Administered orally
219400006|NCT02645656|DRUG|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
219400007|NCT01044238|DRUG|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
219400008|NCT01044238|DRUG|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
219400009|NCT04789642|OTHER|blood pressure measurement whatsapp educational program|educational
219002040|NCT05548725|OTHER|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
219002041|NCT04528849|DRUG|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
219564228|NCT00004188|DRUG|carboplatin|Given IV
219564229|NCT00004188|DRUG|cisplatin|Given IV
219564230|NCT00004188|DRUG|cyclophosphamide|Given IV
219564231|NCT00004188|DRUG|doxorubicin hydrochloride|Given IV
219564232|NCT00004188|DRUG|etoposide|Given IV
219564233|NCT00004188|DRUG|isotretinoin|Given IV
219564234|NCT00004188|DRUG|melphalan|Given IV
219564235|NCT00004188|DRUG|topotecan hydrochloride|Given IV
219564236|NCT00004188|DRUG|vincristine sulfate|Given IV
219564237|NCT00004188|PROCEDURE|autologous bone marrow transplantation|
219564238|NCT00004188|PROCEDURE|bone marrow ablation with stem cell support|
219564239|NCT00004188|PROCEDURE|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
219564240|NCT00004188|PROCEDURE|peripheral blood stem cell transplantation|
219564241|NCT00004188|RADIATION|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
219564242|NCT05541640|DRUG|normal saline group|normal saline infusion at the start of surgery
219564243|NCT05541640|DRUG|lidocaine group|lidocaine infusion at the start of surgery
219564244|NCT00575380|DRUG|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
219564245|NCT00575380|DRUG|Vigamox Eye Drops|One drop three times a day for seven days
219564246|NCT00973089|OTHER|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
219564247|NCT03722862|DIETARY_SUPPLEMENT|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
219564248|NCT03722862|DIETARY_SUPPLEMENT|Placebo|Participants will receive the placebo/dextrose.
219564249|NCT03722862|DIETARY_SUPPLEMENT|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
219564250|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
219564251|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
219564252|NCT03110796|DEVICE|Dressing without LU3103209|Dressing without LU3103209
219564253|NCT02546024|DRUG|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
219564254|NCT03424655|PROCEDURE|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
219564255|NCT03424655|PROCEDURE|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
219564256|NCT03424655|PROCEDURE|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
219564257|NCT03424655|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
219564258|NCT04006938|BEHAVIORAL|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
219564259|NCT04006938|BEHAVIORAL|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
219564260|NCT00559364|DRUG|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
219564261|NCT00559364|DRUG|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
219564262|NCT00559364|DRUG|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
219002042|NCT05314855|DEVICE|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
219002043|NCT02302781|OTHER|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
219002044|NCT03273192|DRUG|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
219002045|NCT01901237|BEHAVIORAL|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
219564263|NCT00559364|DRUG|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
219564264|NCT01632384|BEHAVIORAL|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
219564265|NCT04458558|DRUG|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
219564266|NCT00384306|DRUG|prednisolone|
219564267|NCT02578745|DEVICE|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
219564268|NCT02578745|OTHER|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
219002046|NCT03358901|DRUG|YC-6|
219002047|NCT03358901|DRUG|Vehicle|
219400010|NCT04985799|DEVICE|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
219400011|NCT04985799|DEVICE|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
219400012|NCT01274442|OTHER|anamnesis|To update the anamnesis.
219400013|NCT01274442|PROCEDURE|oral examination|A brief clinical oral examination will be performed.
219400014|NCT01274442|PROCEDURE|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
219400015|NCT02523664|DRUG|Hydrocortisone|effects of hydrocortisone on memory while fMRI
219400016|NCT02523664|DRUG|Placebo|
219400017|NCT06072001|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219400018|NCT06072001|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
219400019|NCT02736292|BEHAVIORAL|Mindfulness Practices for Healthcare Professionals|
219191850|NCT03367754|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
219191851|NCT02852655|DRUG|MK-3475|
219400020|NCT05545527|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
219400021|NCT05545527|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
219400022|NCT05545527|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
219400023|NCT00414310|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days.
219400024|NCT00414310|DRUG|Valproic Acid|50 mg/kg orally daily for 7 days
219400025|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
219400026|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
219400027|NCT06258525|RADIATION|Standard of care oxaliplatin-based chemotherapy|mFOLFOX6 or CAPOX
219400028|NCT06258525|DIETARY_SUPPLEMENT|S-adenosylmethionine (SAMe) supplement|(400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
219400029|NCT06258525|PROCEDURE|Surgery|At 1-Month
219400030|NCT04542798|DEVICE|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
219191852|NCT02123082|DEVICE|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
219191853|NCT02123082|DEVICE|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
219400031|NCT01568190|BIOLOGICAL|AVANZ MITE|Immunotherapy Dermatophagoides mix
219400032|NCT01254604|DRUG|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
219400033|NCT01254604|DRUG|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
219400034|NCT03862534|PROCEDURE|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
219400035|NCT03862534|PROCEDURE|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
219400036|NCT03074162|DRUG|Diclofenac Sodium|twice daily
219400037|NCT03074162|DRUG|Diclofenac & Capsaicin|twice daily
219400038|NCT03074162|DRUG|Diclofenac Sodium Topical Gel|twice daily
219400039|NCT02692820|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
219400040|NCT02692820|OTHER|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
219400041|NCT04864535|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
219400042|NCT03402867|PROCEDURE|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
219400043|NCT03532971|OTHER|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
219400044|NCT03532971|DIAGNOSTIC_TEST|BK polyomavirus PCR|quantitative PCR testing
219400045|NCT03532971|OTHER|quality of life questionnaires|Standard questionnaires validated for HCT recipients
219400046|NCT05299203|DRUG|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
219400047|NCT01993329|DRUG|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
219400048|NCT01993329|DRUG|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
219400049|NCT01993329|DRUG|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
219400050|NCT01993329|DRUG|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
219400051|NCT03908138|DRUG|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
219400052|NCT03908138|DRUG|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
219400053|NCT04339946|DIAGNOSTIC_TEST|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
219189469|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
219400054|NCT04339946|DIAGNOSTIC_TEST|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
219400055|NCT06512818|DIETARY_SUPPLEMENT|Psiguavin|A purified guava extract will be used, enriched in psiguavin
219400056|NCT06512818|DRUG|Placebo|Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
219400057|NCT04211610|DIAGNOSTIC_TEST|Blood and urine sampling|"* Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
219400058|NCT03041116|DRUG|Fosmetpantotenate|Daily dosing
219400059|NCT03041116|DRUG|Placebo|Daily dosing
219400060|NCT01560728|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
219564269|NCT06591182|OTHER|Survey using a questionnaire.|Observational study, participants are not assigned an intervention as part of the study (Survey using a questionnaire).
219564270|NCT05683782|DRUG|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
219564271|NCT05683782|DRUG|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
219564272|NCT00136760|DRUG|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
219564273|NCT00136760|DRUG|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
219564274|NCT00136760|DRUG|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
219564275|NCT00136760|DRUG|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
219564276|NCT00330460|DRUG|Alendronate|ALN; 70 mg; oral; once weekly
219564277|NCT00330460|DRUG|Denosumab|60 mg; SC; every 6 months
219564278|NCT02979691|RADIATION|SIB-IMRT|
219564279|NCT02979691|DRUG|S-1|
219564280|NCT06360029|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
219564281|NCT06360029|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
219564282|NCT06360029|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
219400061|NCT01555112|DRUG|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
219400062|NCT00683956|DEVICE|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
219400063|NCT00683956|DRUG|Propofol|
219400064|NCT06552585|OTHER|12-weeks weight prevention program|Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
219564283|NCT04039048|DEVICE|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
219564284|NCT04039048|DEVICE|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
219564285|NCT04039048|OTHER|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
219400065|NCT06552585|OTHER|12-weeks elastic band prevention program|Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
219400066|NCT06552585|OTHER|sham intervention|The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
219400067|NCT03333057|DRUG|NOV03|Perfluorohexyloctane
219400068|NCT03333057|DRUG|Placebo|Saline solution (0.9% sodium chloride solution)
219400069|NCT05679687|DRUG|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
219400070|NCT01324583|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
219400071|NCT01324583|DRUG|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
219400072|NCT05126368|OTHER|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
219191854|NCT05100043|BIOLOGICAL|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
219400073|NCT03955887|BIOLOGICAL|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
219400074|NCT03955887|BIOLOGICAL|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
219400075|NCT03743662|RADIATION|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
219400076|NCT03743662|DRUG|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
219564286|NCT02663882|BEHAVIORAL|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
219564287|NCT02663882|BEHAVIORAL|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
219564288|NCT01571726|DRUG|Fluciclatide|7mCi
219564289|NCT04068987|DIAGNOSTIC_TEST|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
219564290|NCT00533806|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
219564291|NCT00533806|BEHAVIORAL|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
219564292|NCT04602793|DIAGNOSTIC_TEST|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
219400077|NCT03743662|DRUG|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
219400078|NCT03743662|PROCEDURE|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
219400079|NCT04302610|DEVICE|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
219400080|NCT04302610|DEVICE|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
219400081|NCT05741944|OTHER|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
219400082|NCT05741944|OTHER|standard care|All patients in control condition receive usual care.
219400083|NCT04598581|RADIATION|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
219400084|NCT04598581|OTHER|Sham irradiation|Sham irradiation
219400085|NCT04221906|DRUG|BOS-475|topical cream
219400086|NCT04221906|DRUG|Active ingredient-free vehicle cream|topical cream
219400087|NCT04221906|DRUG|Daivonex cream (calcipotriol 0.005%)|topical cream
219400088|NCT04221906|DRUG|Betnesol-V cream (betamethasone 0.1%)|topical cream
219400089|NCT01781429|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
219400090|NCT03740607|DEVICE|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
219400091|NCT03740607|PROCEDURE|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
219400092|NCT03533140|DEVICE|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
219400093|NCT03533140|DEVICE|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
219400094|NCT04397406|DRUG|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
219400095|NCT04397406|DRUG|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
219400096|NCT04397406|DRUG|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
219400097|NCT01368289|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
219564293|NCT00602537|DRUG|Venlafaxine|75 to 375 mg
219400098|NCT02678741|DRUG|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
219400099|NCT00903032|BEHAVIORAL|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
219564294|NCT00602537|DRUG|Lithium Carbonate|300 to 2400 mg
219400100|NCT00903032|BEHAVIORAL|Usual care|Usual care following ACS hospital discharge.
219400101|NCT02481336|OTHER|Questionnaires|EORTC CIPN20 and EQ-5D-3L
219400102|NCT02481336|PROCEDURE|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
219400103|NCT02481336|GENETIC|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
219400104|NCT01766297|RADIATION|Proton Radiotherapy|
219400105|NCT04523064|DRUG|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
219400106|NCT04906993|DRUG|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
219400107|NCT04906993|DRUG|platinum-based chemotherapy|Physician's choice chemotherapy
219400108|NCT04510194|DRUG|Metformin|Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
219564295|NCT03070015|BEHAVIORAL|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
219400109|NCT04510194|DRUG|Placebo|placebo; appearance and size are exact matching to the three study drugs.
219400110|NCT04510194|DRUG|Fluvoxamine|An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
219400111|NCT04510194|DRUG|Ivermectin|An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
219400112|NCT05588674|DIETARY_SUPPLEMENT|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
219400113|NCT05588674|OTHER|Placebo Capsule|8.5 week supplementation period. One capsule daily.
219400114|NCT05968352|DEVICE|Sacral Anterior Root Stimulation (SARS)|Comparison of High frequency versus low frequency stimulation
219400115|NCT06648161|OTHER|Labor Mirror|The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
219400116|NCT04903548|PROCEDURE|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
219400117|NCT05730829|OTHER|pain informed movement|group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.
219400118|NCT05730829|OTHER|standard neuromuscular exercise|group classes twice weekly for 8 weeks of neuromuscular exercise.
219400119|NCT05730829|OTHER|Pain Neuroscience Education (PNE)|The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
219400120|NCT05730829|OTHER|Standard osteoarthritis (OA) education|The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
219400121|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
219400122|NCT02880319|DRUG|Stereotactic Body Radiation Therapy (SBRT)|
219400123|NCT02880319|DEVICE|Stereotactic Linear Accelerator|
219400124|NCT05919108|PROCEDURE|Endocrine Therapy|Undergo endocrine therapy
219564296|NCT03070015|BEHAVIORAL|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
219564297|NCT00249015|BEHAVIORAL|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
219564298|NCT00388037|DRUG|sunitinib malate|Given PO
219564299|NCT00388037|OTHER|laboratory biomarker analysis|Correlative studies
219564300|NCT00329628|DRUG|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
219564301|NCT00329628|DRUG|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
219564302|NCT02537509|DRUG|Cholecalciferol|
219400125|NCT05919108|PROCEDURE|Biopsy of breast|Undergo breast biopsy
219400126|NCT05919108|DRUG|Neratinib|Taken by mouth
219400127|NCT05919108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219400128|NCT05919108|PROCEDURE|Mammogram|Undergo Mammogram
219400129|NCT05919108|PROCEDURE|Magnetic Resonance Imaging|Undergo breast Magnetic Resonance Imaging
219400130|NCT05919108|PROCEDURE|Breast Surgery|Undergo Breast Surgery
219400131|NCT05919108|PROCEDURE|Ultrasound|Undergo Ultrasound
219400132|NCT06828796|DRUG|Tacrolimus|Begins Day -1 and continues to Day +90 or Day +180 after transplant
219400133|NCT06828796|DRUG|Cyclophosphamide|Given Days +3 and +4 after transplant
219400134|NCT06828796|DRUG|Mycofenolate mofetil|Given Day 0 to Day +35 after transplant
219400135|NCT06301373|DRUG|Methotrexate Combined With Tofacitinib|Methotrexate Combined With Tofacitinib
219400136|NCT06301373|DRUG|Methotrexate|Methotrexate
219400137|NCT05886244|DRUG|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
219400138|NCT04750070|DRUG|Blood and Dopamine|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
219400139|NCT04750070|DRUG|Blood and adrenaline|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
219400140|NCT02678156|DEVICE|Lyoplant Onlay|
219400141|NCT03500133|RADIATION|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
219564303|NCT02537509|DRUG|Placebo of cholecalciferol|
219564304|NCT04451928|DIAGNOSTIC_TEST|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
219564305|NCT01310361|DRUG|Amoxicillin|
219400142|NCT03500133|DRUG|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
219400143|NCT03500133|DRUG|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
219400144|NCT03500133|RADIATION|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
219400145|NCT03500133|DRUG|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
219400146|NCT03500133|DRUG|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
219564306|NCT01310361|DRUG|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
219400147|NCT03500133|DRUG|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
219400148|NCT03500133|DRUG|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
219400149|NCT03500133|DRUG|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
219564307|NCT05181267|DIETARY_SUPPLEMENT|Intermittent fasting|Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
219564308|NCT04272489|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
219564309|NCT05070390|DRUG|Enlicitide Chloride|10 mg capsule administered orally
219564310|NCT03124290|OTHER|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
219564311|NCT06393764|OTHER|Collection of biological samples|Collecte of blood and urine samples
219400150|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
219400151|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
219400152|NCT06723028|BEHAVIORAL|Regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-T+ or mROC-Tc) will: 1. Read a brief essay about either the social justice benefits of eating healthy foods (POSITIVE, mROCT+) or critical of social justice aspects of unhealthy foods (CRITICAL, mROC-Tc). 2. Participants complete six free-response questions to ensure that they understood the essays.~3\. Participants are instructed to use the information from the essay. They are shown a cue matching the essay they read either: Think Positive or Think Critically.~4\. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat). 5. Finally, the participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
219400153|NCT01990521|PROCEDURE|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
219564312|NCT05247073|PROCEDURE|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
219400154|NCT01990521|DEVICE|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
219400155|NCT05951972|OTHER|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
219400156|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
219400157|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
219400158|NCT00135434|DRUG|Atazanavir/Ritonavir/Lopinavir/ritonavir|
219400159|NCT05014776|DRUG|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
219400160|NCT05014776|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
219400161|NCT05014776|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
219400162|NCT05014776|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
219400163|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
219400164|NCT06226883|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
219400165|NCT06226883|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
219400166|NCT05673603|DRUG|Brensocatib|Oral tablet
219400167|NCT05586581|DRUG|SV2A PET|SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
219400168|NCT05586581|DRUG|TSPO PET|TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
219400169|NCT05817773|DEVICE|breastfeeding cradle|Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
219400170|NCT05716607|DRUG|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
219400171|NCT05716607|DRUG|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
219400172|NCT04650321|DRUG|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
219400173|NCT05076851|OTHER|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
219400174|NCT05076851|DRUG|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
219400175|NCT04449068|OTHER|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
219400176|NCT00931892|DIETARY_SUPPLEMENT|Gluten|3g
219400177|NCT00931892|DIETARY_SUPPLEMENT|Gluten|10g
219400178|NCT04933006|DIAGNOSTIC_TEST|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
219400179|NCT01876732|DRUG|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
219400180|NCT03704597|OTHER|cryotherapy|Cooling of oral mucosa
219400181|NCT04462848|BIOLOGICAL|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
219400182|NCT00964548|DRUG|Dantrolene|1.25 mg/kg IV once over 60 min
219400183|NCT00964548|DRUG|Dantrolene|2.5 mg/kg IV once over 60 min
219400184|NCT02531373|BIOLOGICAL|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
219400185|NCT02531373|BIOLOGICAL|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
219400186|NCT02531373|BIOLOGICAL|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
219400187|NCT02531373|BIOLOGICAL|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
219400188|NCT02531373|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
219400189|NCT06381518|OTHER|Switch to SC CT-P13.|all patients in the study will switch from IFX to SC CT-P13
219564313|NCT05247073|PROCEDURE|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
219564314|NCT00703976|DRUG|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
219564315|NCT00703976|DRUG|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
219564316|NCT00703976|DRUG|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
219564317|NCT00703976|RADIATION|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
219564318|NCT05778240|BEHAVIORAL|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?"
219564319|NCT05778240|BEHAVIORAL|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
219400190|NCT05804305|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue
219400191|NCT05804305|DRUG|Placebo|Placebo contained substance that has no therapeutic value.
219400192|NCT00536731|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
219400193|NCT00536731|DRUG|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
219400194|NCT00536731|DRUG|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
219564320|NCT05778240|BEHAVIORAL|Control|Participants were given the vaccination appointment card.
219564321|NCT02119962|BEHAVIORAL|Working memory training|
219564322|NCT02119962|BEHAVIORAL|Placebo training|
219564323|NCT00932594|PROCEDURE|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
219564324|NCT00932594|OTHER|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
219564325|NCT04067154|DIAGNOSTIC_TEST|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
219564326|NCT05543694|DRUG|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
219564327|NCT00647894|DRUG|Alprazolam Extended-Release Tablets 1 mg|
219564328|NCT00647894|DRUG|Xanax XR Tablets 1 mg|
219564329|NCT02191566|DRUG|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
219564330|NCT02191566|DRUG|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
219564331|NCT00760526|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
219564332|NCT00760526|DEVICE|Home blood glucose monitor|Home monitoring 3 or more times a day
219564333|NCT01472926|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
219564334|NCT01472926|DRUG|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
219564335|NCT01199120|DIETARY_SUPPLEMENT|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
219564336|NCT05587257|DEVICE|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
219400195|NCT06382974|PROCEDURE|Cyst enucleation and bone grafting|cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
219400196|NCT03899194|DIETARY_SUPPLEMENT|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
219400197|NCT03899194|DRUG|escitalopram|escitalopram 10-20 mg/d
219400198|NCT00152815|DRUG|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
219400199|NCT00152815|BEHAVIORAL|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
219400200|NCT01675531|DRUG|Targin|Single arm for Targin
219564337|NCT05587257|DEVICE|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
219564338|NCT05587257|DRUG|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
219564339|NCT05587257|DRUG|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
219564340|NCT06384794|DEVICE|Sperm capacitation through the ZyMōt®Sperm Separation Device®|This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.
219564341|NCT06384794|PROCEDURE|Swim-up|The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
219400201|NCT05602441|BEHAVIORAL|VALID - diabetes supportive clubs|"The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities."
219400202|NCT04415216|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
219400203|NCT00623467|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
219400204|NCT02874690|DRUG|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
219400205|NCT02874690|DRUG|Placebo|Placebo pill identical in appearance to methylphenidate
219400206|NCT02597673|OTHER|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
219400207|NCT02597673|DEVICE|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
219400208|NCT02597673|DEVICE|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
219400209|NCT05483816|COMBINATION_PRODUCT|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
219400210|NCT04109625|DIAGNOSTIC_TEST|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
219400211|NCT02676076|DRUG|CHF 5993 100/6/12.5 µg|
219564342|NCT00898768|PROCEDURE|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
219564343|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with devices|Devices
219564344|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with no devices|No Devices
219564345|NCT03098693|BEHAVIORAL|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
219564346|NCT03098693|BEHAVIORAL|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
219564347|NCT03098693|BEHAVIORAL|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
219564348|NCT00027417|DRUG|Liothyronine sodium/triiodothyronine|
219400212|NCT02676076|DRUG|CHF 1535 100/6 µg|
219400213|NCT06351748|DRUG|Semaglutide|Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
219400214|NCT01134887|OTHER|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
219400215|NCT01134887|BEHAVIORAL|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
219400216|NCT01134887|OTHER|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
219400217|NCT01134887|BEHAVIORAL|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
219400218|NCT01134887|OTHER|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
219400219|NCT06438276|BEHAVIORAL|Psychiatric outreach nurse service|Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
219400220|NCT01430429|DRUG|NI-0801|
219400221|NCT04143971|OTHER|intermittent fasting diet|intermittent fasting diet
219400222|NCT04143971|OTHER|low calorie diet|continuous low calorie diet
219400223|NCT02795988|BIOLOGICAL|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
219400224|NCT02795988|DRUG|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
219400225|NCT03819244|DEVICE|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
219400226|NCT03819244|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
219400227|NCT05501444|OTHER|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
219400228|NCT05678790|OTHER|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
219400229|NCT05678790|OTHER|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
219400230|NCT05678790|OTHER|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
219400231|NCT05678790|OTHER|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~* Standing on one leg in front of the mirror,~* Tandem walking,~* Rhythmic Dynamic Stabilization,~* Swiss ball sitting (eyes open and closed),~* Counting the alphabet or numbers while marching"
219400232|NCT03808714|BEHAVIORAL|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
219400233|NCT03808714|BEHAVIORAL|Control Group|Alabama Quitline
219400234|NCT02834403|DRUG|L-NMMA|Nitric oxide synthase inhibitor
219400235|NCT02834403|DRUG|Docetaxel|Mitotic inhibitor, cytotoxic
219400236|NCT02834403|DRUG|Amlodipine|Long-acting calcium channel blocker
219400237|NCT02834403|DRUG|Pegfilgrastim|Colony-stimulating factor
219400238|NCT02834403|DRUG|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
219400239|NCT02438436|DIETARY_SUPPLEMENT|simo decoction|
219400240|NCT02438436|OTHER|gum chewing|
219400241|NCT02341014|DRUG|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
219400242|NCT02341014|DRUG|Romidepsin|
219400243|NCT02341014|DRUG|Lenalidomide|
219400244|NCT01157871|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
219400245|NCT01157871|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
219400246|NCT00004297|DRUG|diazepam|
219400247|NCT00004297|DRUG|lorazepam|
219400248|NCT03241797|PROCEDURE|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
219400249|NCT04667195|OTHER|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results"
219400250|NCT03384849|DIAGNOSTIC_TEST|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
219400251|NCT04705597|DRUG|BGE-175|Drug
219400252|NCT04705597|OTHER|Placebo|Placebo
219400253|NCT05222347|DIETARY_SUPPLEMENT|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
219400254|NCT03691623|DRUG|EDP-938 Dose 1|Oral suspension for 5 days
219400255|NCT03691623|DRUG|EDP-938 Dose 2|Oral suspension for 5 days
219400256|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
219400257|NCT03691623|DRUG|EDP-938 Dose 3|Oral suspension for 5 days
219400258|NCT03691623|DRUG|EDP-938 Dose 4|Oral suspension for 5 days
219400259|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
219400260|NCT02136823|DRUG|sugar pill|
219400261|NCT02136823|DRUG|Riluzole|
219400262|NCT02136823|DRUG|Isradipine|
219400263|NCT02136823|DRUG|Memantine|
219400264|NCT02136823|PROCEDURE|Therapeutic muscle stretching|
219400265|NCT03797950|BEHAVIORAL|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
219400266|NCT03797950|BEHAVIORAL|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
219400267|NCT02816710|DRUG|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
219400268|NCT05413499|OTHER|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
219400269|NCT02284399|OTHER|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
219400270|NCT00005999|DRUG|arsenic trioxide|
219400271|NCT05054933|OTHER|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
219400272|NCT00273858|OTHER|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
219400273|NCT01511289|DRUG|Imatinib|400mg/Tab, QD
219400274|NCT01511289|DRUG|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
219400275|NCT01564290|DIETARY_SUPPLEMENT|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
219400276|NCT01564290|DRUG|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
219400277|NCT04302883|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
219400278|NCT04302883|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
219400279|NCT02232516|DRUG|romidepsin|Given IV
219400280|NCT02232516|DRUG|lenalidomide|Given PO
219400281|NCT02232516|OTHER|laboratory biomarker analysis|Correlative studies
219400282|NCT03664986|DRUG|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
219400283|NCT01070550|DRUG|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
219400284|NCT03218293|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
219400285|NCT05469932|DEVICE|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
219400286|NCT04997837|DRUG|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
219400287|NCT04997837|DRUG|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
219400288|NCT04997837|DRUG|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
219400289|NCT04997837|DRUG|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
219400290|NCT04997837|DRUG|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
219400291|NCT04997837|RADIATION|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
219564349|NCT00027417|PROCEDURE|Cardiopulmonary bypass and cardiac surgery|
219564350|NCT04952467|DRUG|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
219564351|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
219564352|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
219564353|NCT00869440|DRUG|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
219564354|NCT00869440|DRUG|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
219564355|NCT05996692|OTHER|Evaluation of adherence to walking prescriptions|Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
219002048|NCT06071091|DEVICE|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
219400292|NCT04997837|DRUG|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
219400293|NCT05228652|OTHER|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
219400294|NCT02567344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
219400295|NCT02567344|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
219400296|NCT03389126|DRUG|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
219400297|NCT03532945|DEVICE|Bioactive Glass-Ceramic Spacer|
219400298|NCT03532945|DEVICE|Titanium cage|
219400299|NCT01585961|DEVICE|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
219400300|NCT01670513|DRUG|IDP-118 Low Strength|8 weeks
219400301|NCT01670513|DRUG|IDP-118 High Strength|8 weeks
219400302|NCT01258348|DRUG|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
219400303|NCT01258348|DRUG|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
219400304|NCT03685799|DIAGNOSTIC_TEST|Pathological revision|Pathological revision
219400305|NCT02704728|OTHER|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
219564356|NCT02095886|DRUG|BMS-955176|BMS-955176
219564357|NCT02586363|DRUG|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
219564358|NCT02586363|DRUG|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
219564359|NCT02586363|DRUG|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
219564360|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
219564361|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
219564362|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
219564363|NCT00267163|DRUG|donepezil|
219564364|NCT00267163|DRUG|Placebo|
219564365|NCT05186779|DRUG|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
219564366|NCT00426179|DRUG|Imatinib|
219564367|NCT00151216|BIOLOGICAL|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
219564368|NCT02588196|DRUG|Dexamethasone acetate|
219400306|NCT02704728|OTHER|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
219400307|NCT02902016|DRUG|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
219400308|NCT00003982|DRUG|sabarubicin|
219400309|NCT03751995|BEHAVIORAL|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
219400310|NCT01090089|DRUG|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
219400311|NCT01090089|DRUG|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
219400312|NCT03928834|BEHAVIORAL|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
219400313|NCT01809262|DRUG|single dose of 5 mcg|solution for inhalation
219400314|NCT01809262|DRUG|single dose of placebo|solution for inhalation
219400315|NCT01809262|DRUG|single dose of 40 mcg|solution for inhalation
219400316|NCT01809262|DRUG|single dose of 20 mcg|solution for inhalation
219400317|NCT01809262|DRUG|single dose of 2 mcg|solution for inhalation
219400318|NCT01809262|DRUG|single dose of 10 mcg|solution for inhalation
219400319|NCT00906022|DEVICE|Astron Pulsar Stent|Stenting with Astron Pulsar
219400320|NCT00906022|DEVICE|PTA alone|Balloon angioplasty alone
219400321|NCT02791789|OTHER|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
219400322|NCT02610556|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
219400323|NCT02610556|DRUG|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
219400324|NCT02610556|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
219400325|NCT02610556|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
219400326|NCT06101394|DRUG|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
219564369|NCT03143517|DIAGNOSTIC_TEST|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
219564370|NCT05470829|DRUG|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
219564371|NCT05470829|OTHER|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
219564372|NCT06139055|DRUG|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
219564373|NCT06139055|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
219400327|NCT00331786|DRUG|nitric oxide-releasing acetylsalicylic acid derivative|
219400328|NCT00331786|OTHER|laboratory biomarker analysis|
219400329|NCT00331786|PROCEDURE|biopsy|
219400330|NCT02942095|DRUG|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
219400331|NCT02942095|DRUG|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
219400332|NCT02404155|DRUG|Clozapine|
219400333|NCT02064439|DRUG|BAY 59-7939|10 mg tablet once daily for 12 months
219400334|NCT02064439|DRUG|BAY 59-7939|20 mg tablet once daily for 12 months
219400335|NCT02064439|DRUG|ASA|100 mg tablet once daily for 12 months
219400336|NCT01815892|DRUG|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
219400337|NCT01815892|DRUG|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
219400338|NCT06018584|OTHER|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
219400339|NCT02615535|DEVICE|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
219564374|NCT06139055|DRUG|Placebo|Participants will receive matching-placebo oral tablets.
219564375|NCT06139055|DRUG|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
219564376|NCT05896969|DRUG|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
219564377|NCT05896969|DRUG|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
219564378|NCT00613730|DRUG|Gemcitabine|Intravenous administration
219564379|NCT00613730|DRUG|panitumumab|Intravenous administration
219564380|NCT00479388|DRUG|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
219564381|NCT00479388|DRUG|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
219400340|NCT02615535|DEVICE|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
219400341|NCT00985855|DRUG|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
219564382|NCT00479388|DRUG|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
219564383|NCT06595147|BEHAVIORAL|Structured Exercise Training|Participants will complete 12-weeks of supervised, structured moderate-to-high intensity aerobic and resistance training three times per week.
219564384|NCT06595147|BEHAVIORAL|Group-based Yoga and Stretching|Participants will complete 12-weeks of supervised group-based yoga and stretching once per week.
219564385|NCT03737916|OTHER|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
219564386|NCT03737916|OTHER|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
219564387|NCT05467826|DRUG|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
219564388|NCT05467826|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
219564389|NCT05367765|DRUG|Flumatinib|Flumatinib 600mg orally daily
219564390|NCT05367765|DRUG|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
219564391|NCT00133679|DRUG|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
219564392|NCT00133679|DRUG|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
219564393|NCT03548662|BIOLOGICAL|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
219564394|NCT03548662|DRUG|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
219564395|NCT03548662|OTHER|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
219564396|NCT06534931|PROCEDURE|High velocity low amplitude thoracic spine manipulation|Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.
219400342|NCT00985855|DRUG|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
219400343|NCT05428748|OTHER|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
219400344|NCT05428748|OTHER|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
219400345|NCT05428748|OTHER|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
219564397|NCT06534931|PROCEDURE|Sham|A previously validated physiologically inert manual procedure to the thoracic spine
219564398|NCT01955044|DIETARY_SUPPLEMENT|LCPUFA supplement|
219564399|NCT01955044|DIETARY_SUPPLEMENT|placebo|
219564400|NCT01876368|DRUG|LCZ696|
219400346|NCT05428748|OTHER|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
219400347|NCT01834144|OTHER|Exercise Training|
219400348|NCT01120093|DRUG|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
219400349|NCT01120093|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
219400350|NCT01120093|DRUG|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
219564401|NCT01876368|DRUG|Olmesartan|
219564402|NCT01876368|DRUG|Placebo of LCZ696|
219564403|NCT01876368|DRUG|Placebo of Olmesartan|
219564404|NCT01451320|DRUG|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
219564405|NCT01451320|DRUG|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
219564406|NCT01451320|DRUG|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
219564407|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
219564408|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
219564409|NCT01755117|OTHER|Sciatic, femoral, obturator nerve blocks|
219400351|NCT01120093|DRUG|Placebo|Placebo via inhalation in the morning and evening for 7 days
219400352|NCT01120093|DRUG|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
219400353|NCT01880268|DEVICE|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
219400354|NCT01880268|BEHAVIORAL|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
219400355|NCT00003636|DRUG|carboplatin|
219400356|NCT00003636|DRUG|cisplatin|
219400357|NCT00003636|PROCEDURE|conventional surgery|
219400358|NCT00003636|PROCEDURE|neoadjuvant therapy|
219400359|NCT04436627|DEVICE|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
219400360|NCT04436627|DEVICE|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
219400361|NCT04436627|DEVICE|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
219400362|NCT04116814|DIAGNOSTIC_TEST|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
219400363|NCT02631135|DRUG|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
219400364|NCT02631135|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation
219400365|NCT02631135|DRUG|Dexmedetomidine|0.5 microgram/kg infusion, no changes
219400366|NCT02631135|DRUG|Rocuronium|0.5 mg/kg iv for intubation, no changes
219400367|NCT03677687|BEHAVIORAL|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
219400368|NCT03306134|DIAGNOSTIC_TEST|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
219400369|NCT02529761|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
219400370|NCT02529761|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
219400371|NCT02235116|OTHER|Survey|
219400372|NCT03649321|DRUG|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
219564410|NCT01755117|OTHER|Sciatic nerve block, posterior lumbar plexus block|
219400373|NCT03649321|DRUG|Nab-paclitaxel|25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
219400374|NCT03649321|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
219400375|NCT03649321|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
219400376|NCT04175704|DRUG|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
219400377|NCT01026701|DRUG|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
219400378|NCT04778267|DRUG|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
219400379|NCT04778267|DRUG|Dexamethasone phosphate|used as additive to bupivacaine
219400380|NCT04310150|DRUG|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
219400381|NCT04310150|DEVICE|Floseal|hemostatic agent that combine bovine-derived gelatin
219400382|NCT02709434|BEHAVIORAL|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
219400383|NCT02709434|OTHER|Standard care|Usual IBD management
219400384|NCT00415714|DEVICE|Portable Biofeedback|
219400385|NCT01702363|DRUG|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
219400386|NCT04629989|OTHER|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
219400387|NCT04629989|OTHER|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
219400388|NCT04629989|OTHER|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
219400389|NCT01881594|PROCEDURE|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
219564411|NCT02962089|DIETARY_SUPPLEMENT|Branched chain amino acids (BCAA)|
219564412|NCT02962089|DIETARY_SUPPLEMENT|Placebo|
219400390|NCT05365893|COMBINATION_PRODUCT|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
219400391|NCT05365893|OTHER|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
219400392|NCT04911101|DEVICE|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
219400393|NCT04911101|DEVICE|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
219400394|NCT00260572|BEHAVIORAL|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
219400395|NCT00260572|BEHAVIORAL|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
219400396|NCT00260572|BEHAVIORAL|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
219400397|NCT00260572|BEHAVIORAL|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
219400398|NCT02243527|OTHER|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
219400399|NCT02243527|OTHER|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
219400400|NCT02936505|DRUG|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
219400401|NCT02936505|DRUG|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
219400402|NCT02936505|DRUG|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
219400403|NCT02936505|DRUG|Corticosteroids|"Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months."
219400404|NCT02936505|DRUG|Tacrolimus|"* Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
219400405|NCT00870948|DRUG|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
219400406|NCT02237495|DRUG|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
219564413|NCT00679250|DRUG|levocetirizine|5 mg once nightly before visit
219754695|NCT06352346|BEHAVIORAL|Compensatory brain game supporting Goal Management Training intervention|o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
219754696|NCT04546789|DRUG|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
219754697|NCT04637529|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
219400407|NCT02237495|DRUG|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
219400408|NCT01540188|BEHAVIORAL|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
219400409|NCT05224622|DIAGNOSTIC_TEST|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
219400410|NCT02191202|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
219400411|NCT02262039|DEVICE|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
219400412|NCT02262039|DEVICE|Conventional pressure|15 mmHg target pressure
219400413|NCT04174638|OTHER|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
219400414|NCT02184143|BEHAVIORAL|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
219400415|NCT02184143|OTHER|Education|Patient education
219400416|NCT04506827|PROCEDURE|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
219400417|NCT04506827|DEVICE|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
219400418|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
219400419|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
219564414|NCT00679250|DRUG|placebo to levocetirizine|1 tablet once nightly before visit
219564415|NCT01644149|DEVICE|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
219564416|NCT01644149|DEVICE|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
219400420|NCT02364193|DEVICE|MRI|"Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis."
219400421|NCT02364193|DRUG|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
219564417|NCT01644149|BIOLOGICAL|2011-2012 Fluzone trivalent inactivated influenza vaccine|
219400422|NCT02364193|DEVICE|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
219400423|NCT02364193|DEVICE|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
219400424|NCT03491722|OTHER|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
219400425|NCT00602316|DRUG|gadolinium-chelate|
219400426|NCT00602316|PROCEDURE|conventional surgery|
219400427|NCT00602316|PROCEDURE|magnetic resonance imaging|
219400428|NCT00602316|PROCEDURE|magnetic resonance spectroscopic imaging|
219400429|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
219400430|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
219400431|NCT00321984|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
219400432|NCT03560193|DRUG|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
219400433|NCT03560193|DRUG|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
219400434|NCT02627131|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
219400435|NCT01593683|BEHAVIORAL|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
219400436|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
219400437|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
219400438|NCT04501653|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
219400439|NCT04501653|DRUG|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
219400440|NCT03656887|DEVICE|Continuous interstitial glucose sensor|Installing and removing the sensor
219400441|NCT03656887|OTHER|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
219400442|NCT00599430|DIETARY_SUPPLEMENT|Placebo|Inert excipient
219400443|NCT00599430|DIETARY_SUPPLEMENT|Lactobacillus acidophilus NCFM|1e10 CFU/day
219400444|NCT00599430|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
219400445|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
219400446|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
219400447|NCT05203302|OTHER|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
219400448|NCT05203302|OTHER|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
219564418|NCT06427187|DEVICE|an array of devices are used in thrombectomy. These include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems|each patient with distal vessel occlusion subjected to mechanical thrombectomy using aspiration technique or stent retriever
219564419|NCT03513536|OTHER|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219564420|NCT03513536|OTHER|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219400449|NCT05203302|OTHER|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
219400450|NCT05203302|OTHER|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
219400451|NCT00739297|DRUG|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
219400452|NCT00739297|DRUG|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
219400453|NCT01757704|PROCEDURE|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
219400454|NCT01757704|PROCEDURE|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
219564421|NCT03513536|OTHER|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219564422|NCT03513536|OTHER|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
219564423|NCT05555927|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
219564424|NCT06109701|PROCEDURE|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
219564425|NCT06109701|PROCEDURE|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
219564426|NCT00265772|DRUG|MODULEN IBD (R) (specific Enteral Nutrition)|
219564427|NCT00265772|DRUG|prednisolon|
219564428|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
219564429|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
219564430|NCT03024268|DEVICE|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
219564431|NCT05766787|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
219564432|NCT05766787|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
219564433|NCT05766787|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
219564434|NCT04759534|BIOLOGICAL|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
219564435|NCT01378962|DRUG|erlotinib|150 mg orally once a day for 12 months
219564436|NCT04612530|DEVICE|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
219564437|NCT04612530|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
219564438|NCT04612530|DRUG|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
219564439|NCT02885441|DRUG|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
219564440|NCT06682637|DRUG|Melflufen|Pepaxti 20 mg powder for concentrate for solution for infusion
219564441|NCT06682637|DRUG|Dexamethasone|SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
219564442|NCT02176057|DRUG|Azithromycin|
219564443|NCT05793632|DRUG|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
219564444|NCT00924963|DEVICE|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
219564445|NCT00924963|DEVICE|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
219564446|NCT00924963|DRUG|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
219564447|NCT01547507|DEVICE|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
219564448|NCT01435928|DRUG|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
219564449|NCT01435928|DRUG|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
219564450|NCT03922139|DRUG|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
219564451|NCT01932905|DEVICE|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
219400455|NCT05579093|COMBINATION_PRODUCT|Cognitive test + Pupillary measure|"Patients will be put into a quiet room with a computer and a webcam for a five minute assessment with the NeuroTrack™ testing. Study personnel will stay in the room, and be available for answering questions about using the online testing tool.~After Neurotrack, pupillary responses will be recorded with the pupillometer with the PLR -3000TM. In brief, an eye cup attached to a pupillometer will be placed over one eye to allow measurement of the pupillary response to light. Once the eye cup is properly positioned, the reading takes approximately 5 seconds, after which time the eye cup will be removed. The reading will then be taken in the contralateral eye."
219400456|NCT01623817|DRUG|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
219400457|NCT01337011|OTHER|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
219400458|NCT02549911|OTHER|HIPEC,Chemotherapy AND surgery|"1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
219400459|NCT00375882|PROCEDURE|hypothermia|
219400460|NCT00375882|PROCEDURE|cochlear implantation with mild hypothermia|
219400461|NCT03885739|OTHER|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
219564452|NCT06221124|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
219564453|NCT00292227|DRUG|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
219564454|NCT00292227|OTHER|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
219564455|NCT00292227|DRUG|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
219564456|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
219400462|NCT06536985|BEHAVIORAL|treatment group|Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to
219564457|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
219564458|NCT05148533|DRUG|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
219564459|NCT04158427|PROCEDURE|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
219564460|NCT04158427|PROCEDURE|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
219564461|NCT00163709|PROCEDURE|BNP test|
219754698|NCT04637529|DRUG|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
219754699|NCT05552859|DRUG|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
219754700|NCT05552859|DRUG|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
219564462|NCT05440695|DEVICE|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
219564463|NCT04038606|OTHER|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
219564464|NCT04795869|DRUG|Brentuximab Vedotin|Given IV
219564465|NCT04795869|BIOLOGICAL|Pembrolizumab|Given IV
219564466|NCT04615494|PROCEDURE|Position|Pneumoperitoneum with Steep Trendelenburg position
219564467|NCT02682134|DRUG|xylocaine|First group were given xylocaine
219564468|NCT02682134|DRUG|Dexamethasone|Second group were given Dexamethasone
219564469|NCT02682134|DRUG|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
219564470|NCT02093923|DRUG|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
219564471|NCT02093923|DRUG|Placebo|Participants will receive matching placebo subcutaneously.
219400463|NCT06536985|BEHAVIORAL|Contral group|Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
219400464|NCT06224894|OTHER|Music Therapy|Music Therapy
219564472|NCT02452528|DRUG|ARC-520|
219564473|NCT02452528|DRUG|Placebo|
219564474|NCT02452528|DRUG|Entecavir|0.5 or 1.0 mg/day orally
219754701|NCT04722822|BEHAVIORAL|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Practices are randomized to receive training on how to recommend HPV vaccine, including both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
219400465|NCT06224894|OTHER|antiemetic treatment|antiemetic treatment
219400466|NCT02401555|DEVICE|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
219400467|NCT00860340|DRUG|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
219400468|NCT01933191|BEHAVIORAL|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
219400469|NCT01933191|BEHAVIORAL|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
219400470|NCT00420394|PROCEDURE|Chemotherapy|
219400471|NCT00420394|PROCEDURE|surgery|
219400472|NCT00420394|PROCEDURE|radiotherapy|
219400473|NCT05545267|PROCEDURE|Angioplasties|Transluminal angioplastie
219564475|NCT02452528|DRUG|Tenofovir|300 mg/day orally
219564476|NCT02452528|DRUG|diphenhydramine|50 mg orally as pretreatment antihistamine
219564477|NCT04038645|OTHER|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
219564478|NCT04038645|OTHER|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
219564479|NCT01571817|BIOLOGICAL|Isolated Human Pancreatic Islets|
219564480|NCT01543867|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
219564481|NCT04938986|DIAGNOSTIC_TEST|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
219564482|NCT02282202|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
219564483|NCT04509999|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
219564484|NCT04509999|DRUG|Placebo|Placebo as formulated by mouth daily
219564485|NCT00006399|DRUG|Donepezil|
219564486|NCT00006399|DRUG|Estrogen|
219002049|NCT06071091|OTHER|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)"
219002050|NCT05321732|DRUG|DWP16001|DWP16001 A mg
219400474|NCT01882998|BEHAVIORAL|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
219400475|NCT06484530|DRUG|N acetyl cysteine|1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
219400476|NCT02946879|BIOLOGICAL|AAV OPTIRPE65|comparison of different doses of AAV RPE65
219564487|NCT00006399|DRUG|Progesterone|
219564488|NCT00442546|DRUG|pregabalin|150 milligram (mg)/ day (double blind)
219564489|NCT00442546|DRUG|pregabalin|300 mg/day (double blind)
219564490|NCT00442546|DRUG|Placebo|Placebo
219564491|NCT00248170|DRUG|Letrozole|2.5 mg tablets
219564492|NCT00248170|DRUG|Anastrozole|1 mg tablets
219564493|NCT02346682|DRUG|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
219002051|NCT05321732|DRUG|DWP202010|DWP202010 B mg
219002052|NCT01788332|DRUG|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
219002053|NCT01788332|OTHER|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
219002054|NCT02157467|DRUG|BMS-955176|
219002055|NCT02157467|DRUG|Ortho Cyclen|
219002056|NCT03290898|BEHAVIORAL|High Intensity Interval Training|Training (HIIT)
219002057|NCT02197845|BEHAVIORAL|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
219002058|NCT02197845|BEHAVIORAL|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
219400477|NCT05164861|DIETARY_SUPPLEMENT|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
219400478|NCT06114953|DRUG|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
219564494|NCT01557582|DEVICE|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
219564495|NCT04351347|DRUG|Ivermectin|ivermectin
219564496|NCT06020482|OTHER|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
219564497|NCT06427369|OTHER|Radioconjugate|1241-hJAA-F11 IV administration
219564498|NCT06427369|PROCEDURE|Positron Emission Tomography|PET/CT Imaging
219564499|NCT06427369|PROCEDURE|Computed Tomography|PET/CT Imaging
219564500|NCT06427369|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT Imaging
219564501|NCT06427369|PROCEDURE|Biospecimen Collection|Blood sample collection imaging
219564502|NCT05507528|DEVICE|reborn treatment|Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
219564503|NCT02843659|DRUG|BMS-931699|Specified dose on specified days
219564504|NCT02843659|DRUG|BMS-986142|Specified dose on specified days
219564505|NCT02843659|DRUG|Placebo|Specified dose on specified days
219564506|NCT02521181|DRUG|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
219400479|NCT06114953|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
219400480|NCT02242890|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
219400481|NCT00088582|DRUG|Pasireotide (SOM230), Octreotide (Sandostatin)|
219400482|NCT00694512|DIETARY_SUPPLEMENT|Low fat diet|20% fat diet
219400483|NCT00694512|DIETARY_SUPPLEMENT|High fat diet|40% fat diet
219400484|NCT00694512|DIETARY_SUPPLEMENT|MCT diet|Medium chain triglyceride diet
219400485|NCT04891250|DRUG|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
219400486|NCT04891250|OTHER|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
219400487|NCT02749721|DRUG|vortioxetine|Open-label vortioxetine
219400488|NCT03575520|DRUG|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
219400489|NCT03575520|DRUG|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
219564507|NCT02521181|DRUG|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
219564508|NCT02521181|DRUG|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
219564509|NCT02413294|DEVICE|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
219564510|NCT06357156|RADIATION|CBCT|The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
219564511|NCT01304381|OTHER|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
219564512|NCT01304381|OTHER|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
219564513|NCT06722755|DEVICE|CPAP device|Eligible participants with OSA will be started on automatically-adjusting CPAP.
219400490|NCT00002887|DRUG|cisplatin|
219400491|NCT00002887|DRUG|etoposide|
219400492|NCT00002887|DRUG|hydroxyurea|
219400493|NCT00002887|DRUG|vinblastine sulfate|
219400494|NCT00002887|DRUG|vindesine|
219564514|NCT06722755|BEHAVIORAL|CPAP technical support|Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.
219564515|NCT06722755|BEHAVIORAL|Phone follow-up for adherence feedback and self-management skills|The research coordinator will call participants approximately monthly to provide any needed support.
219564516|NCT06722755|BEHAVIORAL|myAir|Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.
219564517|NCT06722755|BEHAVIORAL|Tailored messages|Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.
219400495|NCT00002887|DRUG|vinorelbine tartrate|
219400496|NCT00002887|PROCEDURE|drug resistance inhibition treatment|
219400497|NCT00806780|PROCEDURE|on table cholangiography|x-ray imaging of common bile duct
219400498|NCT04311476|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
219400499|NCT04311476|DRUG|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
219400500|NCT05986539|OTHER|Observational|This study is only observational in nature and will not include an intervention.
219400501|NCT04713358|DRUG|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
219400502|NCT04713358|DRUG|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
219400503|NCT02137772|DRUG|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
219400504|NCT02137772|DRUG|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
219400505|NCT05416931|DRUG|ACD440 Gel 14mg/g|Topical application to painful area
219400506|NCT05416931|DRUG|Placebo Gel|Topical application to painful area
219400507|NCT03611309|OTHER|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
219400508|NCT03611309|OTHER|Surgeon team alone management|The surgeon and surgical team will manage
219400509|NCT03854955|OTHER|iScribes|Device-based scribing service.
219400510|NCT04107012|DEVICE|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
219400511|NCT03356314|OTHER|MRI between 30-35 GA|MRI between 30-35 GA
219400512|NCT03356314|OTHER|Pediatric surgeon meeting|Pediatric surgeon meeting
219564518|NCT06722755|BEHAVIORAL|Written Materials|A binder of written educational materials will be provided to participants.
219564519|NCT06722755|BEHAVIORAL|Motivational Enhancement Therapy (MET)|A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
219564520|NCT01631682|DRUG|Propranolol|40mg single pill
219564521|NCT01631682|BEHAVIORAL|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
219564522|NCT01631682|DRUG|Mifepristone|1800mg, 9 tablets
219564523|NCT01631682|DRUG|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
219564524|NCT02408445|DRUG|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
219564525|NCT05522218|DEVICE|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
219564526|NCT01253317|DRUG|rhIGF-1|1\) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
219564527|NCT04854213|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
219564528|NCT01962649|BIOLOGICAL|ICG|
219564529|NCT01962649|DEVICE|Optical molecular imaging|
219564530|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
219564531|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
219564532|NCT00503113|DRUG|Alendronate|70mg per oral (po) weekly
219564533|NCT01083862|BEHAVIORAL|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
219564534|NCT01083862|BEHAVIORAL|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
219564535|NCT02495532|OTHER|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
219564536|NCT02495532|OTHER|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
219564537|NCT01039454|DRUG|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
219564538|NCT01039454|DRUG|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
219564539|NCT04836520|DRUG|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
219564540|NCT06893562|BEHAVIORAL|Safe Hands and Safe Bladder intervention|Evaluating changes in urinary tract infections and bladder distension nine-year after implementing preventive measures
219564541|NCT06895382|PROCEDURE|Caudal Epidural Block|A caudal epidural block was performed after the induction of general anesthesia. Using a 35-mm 22G or 30-mm 25G block needle, the sacral hiatus was identified, and the needle was inserted through the sacrococcygeal ligament into the epidural space under aseptic conditions. After confirming negative aspiration for cerebrospinal fluid or blood, 1 mL/kg of 0.25% bupivacaine was administered.
219564542|NCT06895382|PROCEDURE|Transversus Abdominis Plane (TAP) Block|A transversus abdominis plane (TAP) block was performed after the induction of general anesthesia. Using a 22G, 50-mm insulated block needle, the injection was administered under ultrasound guidance using a linear probe and in-plane technique. The needle was advanced into the fascial plane between the internal oblique and transversus abdominis muscles. After confirming placement with a 0.5-1 mL test dose of 0.9% NaCl and negative aspiration for blood, 0.3 mL/kg of 0.25% bupivacaine was administered.
219564543|NCT06895382|DRUG|Bupivacaine 0.25%|"0.25% bupivacaine was administered in both intervention arms as part of the regional anesthesia procedure In the Caudal Block group, 1 mL/kg of 0.25% bupivacaine was administered into the caudal epidural space.~In the TAP Block group, 0.3 mL/kg of 0.25% bupivacaine was administered into the transversus abdominis plane under ultrasound guidance"
219564544|NCT06897085|DEVICE|viscoelastic gel containing polynucleotides and hyaluronic acid|"Defects randomized to test treatment will receive a viscoelastic gel containing polynucleotides and hyaluronic acid (PN-HA gel) immediately at the completion of intra-surgical instrumentation. PN-HA gel will be also applied on the surgical wound at the completion of the suturing phase."
219564545|NCT06897085|OTHER|No intervention|"Defects randomized to control group will be accessed with the SFA and no PN-HA gel will be applied."
219002059|NCT03073044|DIAGNOSTIC_TEST|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
219564546|NCT06897969|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|Monthly intralesional injection
219564547|NCT06897969|DRUG|Verapamil Injection|2.5 mg of intralesional Verapamil injection monthly
219002060|NCT06221293|DIAGNOSTIC_TEST|immunoenzyme analysis|immunoenzyme analysis with EVOLIS system
219400513|NCT03356314|OTHER|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
219400514|NCT03356314|OTHER|+/- prophylactic surgery|+/- prophylactic surgery
219400515|NCT01100021|DRUG|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
219564548|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations containing MLYAAT-1002® of the active comparator to randomly assigned split-face (the treatment side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
219564549|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations without MLYAAT-1002® of the placebo comparator to randomly assigned split-face (the control side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
219564550|NCT06900335|DRUG|GH treatment (Somatropin)|Treatment with Somatropin (recombinant GH), with doses starting from 0.2 mg/day and adjusted as necessary.
219564551|NCT06900335|BEHAVIORAL|Eating|Allowing patients to break fasting.
219564552|NCT03888612|DRUG|ARV-110|"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"
219564553|NCT06293326|DRUG|bi-layer calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
219564554|NCT06293326|DRUG|Immediate release calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
219564555|NCT02981316|BIOLOGICAL|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
219564556|NCT06331234|OTHER|Vena cava inferior diameter|he VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
219564557|NCT05195177|DRUG|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
219564558|NCT05195177|DRUG|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
219564559|NCT00137657|DRUG|Cotrimoxazole (trimethoprim sulfamethoxazole)|
219564560|NCT02137382|DRUG|Creon®|active comparator
219564561|NCT02137382|DRUG|Creon N|experimental drug
219564562|NCT01566279|DRUG|Everolimus|All patients will receive everolimus 10mg q.d.
219564563|NCT04729608|DRUG|Batiraxcept|Batiraxcept is an experimental drug
219564564|NCT04729608|DRUG|Paclitaxel|Paclitaxel is the standard of care, background therapy
219564565|NCT04729608|OTHER|Placebo|Matching placebo
219564566|NCT00831233|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
219002061|NCT01943890|DEVICE|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
219564567|NCT00831233|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
219564568|NCT00831233|DRUG|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
219002062|NCT01943890|PROCEDURE|Physiotherapy|
219002063|NCT00495339|DRUG|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
219400516|NCT01100021|DRUG|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
219400517|NCT04706546|OTHER|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
219400518|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219400519|NCT00003139|DRUG|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
219400520|NCT00003139|OTHER|Placebo|
219400521|NCT05504330|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
219400522|NCT03488810|OTHER|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
219400523|NCT03488810|DRUG|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
219400524|NCT03488810|DRUG|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
219564569|NCT01960868|OTHER|standard physiotherapy|
219564570|NCT01960868|OTHER|experimental physical therapy|
219564571|NCT03068845|DEVICE|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
219564572|NCT03068845|DEVICE|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
219002064|NCT03143894|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
219400525|NCT03488810|DRUG|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
219400526|NCT00024297|DRUG|warfarin|
219400527|NCT00616239|DRUG|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
219400528|NCT00616239|DRUG|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
219400529|NCT04967755|DRUG|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
219400530|NCT03094936|PROCEDURE|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
219400531|NCT03094936|DEVICE|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
219564573|NCT06068777|DRUG|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
219564574|NCT06068777|DRUG|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
219564575|NCT05276505|OTHER|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
219564576|NCT03397953|DRUG|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
219002065|NCT03143894|OTHER|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
219002066|NCT04626297|DRUG|Lebrikizumab|Given SC
219002067|NCT04626297|DRUG|Placebo|Given SC
219564577|NCT05562453|DEVICE|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
219564578|NCT05562453|DEVICE|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
219564579|NCT06677853|DRUG|Timolol Maleate Gel+Placebo|Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
219564580|NCT06677853|DRUG|Timolol Maleate Gel|Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
219564581|NCT06677853|DRUG|Placebo|Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
219564582|NCT00256529|PROCEDURE|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
219564583|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
219564584|NCT00648245|DRUG|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
219564585|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
219564586|NCT00648245|DRUG|Placebo|Placebo given once daily for 21 days by nebulizer
219564587|NCT00648245|DRUG|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
219002068|NCT00808366|DRUG|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
219002069|NCT00808366|DRUG|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
219400532|NCT03826953|OTHER|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
219400533|NCT01373905|PROCEDURE|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
219400534|NCT01373905|PROCEDURE|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
219400535|NCT04016363|OTHER|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
219400536|NCT04016363|OTHER|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
219400537|NCT02307526|DRUG|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
219400538|NCT02307526|DEVICE|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
219400539|NCT04390698|PROCEDURE|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
219400540|NCT04390698|DRUG|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
219400541|NCT04390698|PROCEDURE|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
219400542|NCT04390698|PROCEDURE|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
219400543|NCT02144220|OTHER|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
219400544|NCT05295160|BEHAVIORAL|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
219400545|NCT03648996|OTHER|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
219400546|NCT03648996|DRUG|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
219400547|NCT03648996|DRUG|Placebo|6 months of placebo treatment
219400548|NCT03648996|OTHER|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
219564588|NCT04628845|DEVICE|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
219564589|NCT04628845|DEVICE|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
219564590|NCT06613269|DRUG|68Ga-NY104 PET/CT|"68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104."
219564591|NCT06613269|DRUG|18F-FDG PET/CT|18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
219564592|NCT06613269|RADIATION|Radiation Therapy|Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
219400549|NCT01930734|DRUG|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
219564593|NCT06613269|DRUG|Systemic therapy|Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
219400550|NCT01930734|DRUG|Normal Saline|Normal Saline solution 0.9% Placebo Arm
219400551|NCT00300872|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
219400552|NCT00300872|DEVICE|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
219754702|NCT04722822|BEHAVIORAL|(Control) Recommending HPV vaccine for patients 11-12 years of age|Control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
219754703|NCT06364410|DRUG|Azenosertib|Given PO
219754704|NCT06364410|PROCEDURE|Biopsy Procedure|Undergo biopsy
219400553|NCT04052958|DEVICE|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
219400554|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject
219400555|NCT00317941|DRUG|Rebif|44ug administered with Rebiject II
219400556|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject light
219564594|NCT01328912|OTHER|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
219564595|NCT01328912|OTHER|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
219564596|NCT02801435|DRUG|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
219564597|NCT02801435|DRUG|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
219400557|NCT03961919|DRUG|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
219400558|NCT03961919|DRUG|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
219400559|NCT03961919|DRUG|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
219564598|NCT02801435|DRUG|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
219564599|NCT02801435|DRUG|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
219564600|NCT02801435|DRUG|Placebo|Topical administration for twice daily
219564601|NCT02541084|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
219564602|NCT05149924|DRUG|QL1012|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
219564603|NCT05149924|DRUG|Gonal-f ®|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
219564604|NCT01533649|BEHAVIORAL|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
219564605|NCT01533649|BEHAVIORAL|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
219564606|NCT04487899|DEVICE|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
219564607|NCT06334861|BIOLOGICAL|Herpes Zoster adjuvanted recombinant vaccine|patients will receive two doses of vaccine with an interval between the first and second dose of 2 months
219564608|NCT00698087|BIOLOGICAL|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
219564609|NCT00698087|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 or 3 doses
219564610|NCT04206722|DEVICE|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
219564611|NCT04206722|DEVICE|Ultrasound|Ultrasound 0.7W/cm2
219002070|NCT04829708|OTHER|MRI Surveillance|Receive MRI surveillance
219564612|NCT00622115|DRUG|Enoxaparin|
219564613|NCT04868864|DIAGNOSTIC_TEST|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
219564614|NCT04868864|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
219564615|NCT00640263|DRUG|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
219754705|NCT06364410|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219754706|NCT06364410|PROCEDURE|Computed Tomography|Undergo CT
219754707|NCT06364410|PROCEDURE|Echocardiography Test|Undergo ECHO
219754708|NCT06364410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219754709|NCT06364410|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219754710|NCT06364410|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219002071|NCT04829708|RADIATION|Prophylactic Cranial Irradiation|Receive PCI
219002072|NCT04813445|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
219400560|NCT03961919|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
219400561|NCT06295510|OTHER|No interventions.|It's only observational study.
219400562|NCT01095952|DEVICE|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
219400563|NCT03207828|BEHAVIORAL|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
219754711|NCT02266667|DEVICE|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
219400564|NCT03207828|OTHER|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
219400565|NCT03543891|OTHER||
219400566|NCT00004865|BIOLOGICAL|cetuximab|
219400567|NCT00004865|DRUG|cisplatin|
219400568|NCT00004865|DRUG|fluorouracil|
219400569|NCT00004865|DRUG|paclitaxel|
219400570|NCT01810146|OTHER|Digestive functions investigations|
219400571|NCT00898144|OTHER|Papanicolaou test|
219400572|NCT00898144|OTHER|laboratory biomarker analysis|
219400573|NCT01856946|DIETARY_SUPPLEMENT|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
219400574|NCT03074175|RADIATION|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
219400575|NCT00418262|DRUG|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
219564616|NCT00640263|DRUG|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
219564617|NCT05301686|PROCEDURE|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
219564618|NCT01087021|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
219564619|NCT03221452|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
219564620|NCT03064087|DEVICE|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
219002073|NCT05076903|DRUG|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
219400576|NCT01300780|DRUG|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
219400577|NCT01300780|OTHER|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
219564621|NCT03064087|DEVICE|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).
219564622|NCT03064087|DEVICE|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
219564623|NCT03064087|DEVICE|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
219400578|NCT02471131|DEVICE|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
219400579|NCT04134104|PROCEDURE|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
219400580|NCT03731416|PROCEDURE|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
219400581|NCT03855917|DRUG|Sofosbuvir 400mg [Sovaldi]|Four weeks.
219400582|NCT03855917|DRUG|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
219400583|NCT03568006|OTHER|Specific passive mobilization|Specific passive mobilizations for the shoulder
219400584|NCT03568006|OTHER|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
219400585|NCT00504166|DRUG|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
219400586|NCT00504166|OTHER|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
219400587|NCT03704792|DEVICE|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
219400588|NCT05090410|DRUG|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
219400589|NCT05090410|DRUG|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
219754712|NCT02266667|DEVICE|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
219400590|NCT04452812|BIOLOGICAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
219400591|NCT06314906|DEVICE|Electroacupuncture|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
219400592|NCT06314906|DRUG|Antiemetic Therapy|Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
219400593|NCT06314906|DEVICE|Sham electroacupuncture|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
219002074|NCT05076903|DRUG|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
219400594|NCT06314906|DRUG|Antiemetic Therapy|They will also receive the same antiemetic medications as the experimental group.
219400595|NCT05296421|PROCEDURE|Biopsy|Undergo biopsy
219400596|NCT05296421|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219400597|NCT05296421|OTHER|Uniformly-labeled [13C]glucose|Given IV
219400598|NCT02650284|DEVICE|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
219400599|NCT02650284|DEVICE|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
219400600|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
219400601|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
219400602|NCT03711552|OTHER|ObsQoR-11|Quality of recovery questionnaire
219400603|NCT03711552|OTHER|QoR-15|Quality of recovery questionnaire
219400604|NCT02270632|DRUG|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
219400605|NCT02270632|DRUG|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
219400606|NCT02270632|DRUG|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
219400607|NCT04523285|DRUG|TQB3728|TQB3728 tablets is a small molecule oral drug.
219400608|NCT06115577|DIAGNOSTIC_TEST|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
219400609|NCT00207376|DEVICE|Solysafe Septal Occluder|
219400610|NCT04877548|OTHER|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
219400611|NCT04877548|OTHER|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
219400612|NCT04877548|OTHER|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
219400613|NCT03753568|DEVICE|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
219400614|NCT05639920|COMBINATION_PRODUCT|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
219400615|NCT04174131|DEVICE|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
219400616|NCT04174131|DEVICE|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
219400617|NCT06549686|BIOLOGICAL|CLS2901C (human [allogeneic] chondrocyte sheets)|CLS2901C (human \[allogeneic\] chondrocyte sheets)
219400618|NCT00246883|PROCEDURE|Exercise|
219400619|NCT04149327|DRUG|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
219400620|NCT04149327|PROCEDURE|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
219400621|NCT05725798|DRUG|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
219400622|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
219400623|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
219400624|NCT00554294|BEHAVIORAL|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
219564624|NCT03064087|DIAGNOSTIC_TEST|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
219564625|NCT06317948|OTHER|treatment plan comparison|In order to assess inter-Institute variability of DVH prediction of the various models, for the different situations and the different OARs, DVH and dose statistics (min, mean, median, max and SD of the dose received by each OAR) predicted on the patients owning to the different centers by the different models will be compared
219564626|NCT03451604|OTHER|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
219564627|NCT06084169|DEVICE|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
219564628|NCT04823507|DEVICE|BIOFLEX DUO+|"* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
219564629|NCT02211014|DRUG|acalabrutinib|
219564630|NCT00519922|OTHER|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
219400625|NCT01080989|OTHER|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
219400626|NCT03907722|OTHER|Long pentraxin 3|Primary PCI
219400627|NCT01877330|PROCEDURE|Interscalene block for shoulder arthroscopy|
219564631|NCT00519922|OTHER|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
219564632|NCT06071195|DIAGNOSTIC_TEST|Prostate Cancer Patients|see arm/group description
219564633|NCT02577224|OTHER|Patient-initiated treatment|Please see Intervention Arm
219564634|NCT01741467|BEHAVIORAL|RT-CGM|Dexcom Seven+
219564635|NCT04987255|OTHER|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
219564636|NCT04987255|OTHER|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
219564637|NCT04987255|OTHER|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
219564638|NCT05547334|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
219564639|NCT02265341|OTHER|Laboratory Biomarker Analysis|Correlative studies
219564640|NCT02265341|DRUG|Ponatinib Hydrochloride|Given PO
219564641|NCT02265341|OTHER|Quality-of-Life Assessment|Ancillary studies
219564642|NCT02484313|OTHER|dietary treatments|commercially available food products
219564643|NCT04822376|DRUG|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
219564644|NCT04822376|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
219400628|NCT03268304|OTHER|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
219564645|NCT05664282|DEVICE|Damon self-ligating brackets|
219400629|NCT04408092|DRUG|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
219564646|NCT05664282|DEVICE|Victory self-ligating brackets|
219564647|NCT01706861|DEVICE|Celotres|Celotres following surgical removal of earlobe keloid.
219400630|NCT02788916|OTHER|No Intervention|
219400631|NCT02526615|DRUG|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
219400632|NCT02526615|DRUG|Metformin|Patients received either placebo, metformin or rosiglitazone
219564648|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
219564649|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
219564650|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
219564651|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
219400633|NCT02526615|DRUG|Placebo|Patients received either placebo, metformin or rosiglitazone
219400634|NCT01517789|DEVICE|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
219400635|NCT01193790|PROCEDURE|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
219400636|NCT01165203|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
219564652|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
219564653|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
219564654|NCT03301818|DEVICE|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
219564655|NCT02744755|BIOLOGICAL|Adalimumab - GP2017|Adalimumab - GP2017
219564656|NCT02744755|BIOLOGICAL|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
219564657|NCT01978899|BEHAVIORAL|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
219564658|NCT01978899|BEHAVIORAL|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
219564659|NCT02975037|DRUG|Sildenafil|sildenafil 25 mg PO
219564660|NCT02975037|DRUG|Clarithromycin|clarithromycin 250 mg PO
219564661|NCT02975037|DRUG|Itraconazole|itraconazole 100 mg PO
219564662|NCT02396173|OTHER|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
219564663|NCT04154826|DRUG|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
219564664|NCT01705860|BIOLOGICAL|Santyl|
219564665|NCT01854086|OTHER|Questionnaires about compliance and persistence with bisphosphonates treatment|
219564666|NCT05002686|DRUG|Sintilimab|200 mg Q3W on Day 1 by IV infusion
219564667|NCT05002686|DRUG|Albumin-Paclitaxel|200 mg/m\^2 Q3W on Day 1 by IV infusion
219564668|NCT05002686|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
219564669|NCT05002686|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
219564670|NCT05002686|RADIATION|Radiation|Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
219400637|NCT01165203|BIOLOGICAL|Placebo|intramuscular injection
219564671|NCT05002686|PROCEDURE|Radical gastric cancer surgery|Radical gastric cancer surgery with D2 lymph node dissection
219564672|NCT02823314|DEVICE|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
219564673|NCT02823314|DEVICE|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
219400638|NCT05182502|DEVICE|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
219564674|NCT05424614|OTHER|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
219400639|NCT04637659|PROCEDURE|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
219400640|NCT02572661|RADIATION|radiation in Squamous Head and Neck Cancer|
219564675|NCT03687879|OTHER|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
219564676|NCT05025579|OTHER|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
219564677|NCT00021489|DRUG|Abacavir sulfate|
219564678|NCT00021489|DRUG|Mycophenolate mofetil|
219564679|NCT02303886|DRUG|Methylene blue|In NaCL0.9% 100 ml
219564680|NCT02303886|DRUG|Methylene blue|in NaCl 0.9% 100 ml
219564681|NCT00752284|PROCEDURE|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
219564682|NCT00752284|PROCEDURE|Total Excision|Total excision of lower third molar
219564683|NCT02255188|PROCEDURE|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
219564684|NCT03173170|DRUG|TAK-954|TAK-954 Infusion
219564685|NCT03173170|DRUG|Itraconazole|Itraconazole Capsule
219564686|NCT01066117|OTHER|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
219564687|NCT00548379|DRUG|vitamin D|vitamin D 100,000 units once in 3 months
219564688|NCT00548379|DRUG|placebo|olive oil 1ml
219564689|NCT04880720|OTHER|Blood sampling|Blood sampling - 10mL
219564690|NCT02372591|DRUG|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219564691|NCT02372591|DRUG|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219564692|NCT02372591|DRUG|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219564693|NCT02358967|DIETARY_SUPPLEMENT|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
219564694|NCT02358967|DIETARY_SUPPLEMENT|Placebo|2 x 150 mg capsules
219564695|NCT03675334|PROCEDURE|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
219564696|NCT03675334|PROCEDURE|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
219564697|NCT03675334|OTHER|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
219564698|NCT01280617|DRUG|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
219400641|NCT03070977|OTHER|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
219400642|NCT01652378|DRUG|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
219400643|NCT00698126|DRUG|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
219400644|NCT00698126|DRUG|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
219400645|NCT04072237|BIOLOGICAL|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
219400646|NCT05971290|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
219400647|NCT05971290|DEVICE|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
219400648|NCT04420481|DRUG|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
219400649|NCT04420481|DRUG|Placebo|Placebo
219400650|NCT03431675|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
219400651|NCT00004778|DRUG|betamethasone|
219400652|NCT00004778|DRUG|dexamethasone|
219400653|NCT00004778|DRUG|thyrotropin-releasing hormone|
219400654|NCT01328288|DRUG|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
219400655|NCT00918528|PROCEDURE|Internal urethrotomy|
219400656|NCT00918528|DRUG|Mitomycin C - local injection|
219400657|NCT01780389|DRUG|Open-label flexibly dosed milnacipran|
219400658|NCT04985773|DEVICE|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
219400659|NCT05641376|DRUG|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
219564699|NCT01280617|DRUG|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
219564700|NCT05266079|DRUG|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
219564701|NCT05266079|DRUG|Control Group|Er-Xian decoction
219400660|NCT05641376|DRUG|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
219400661|NCT02778776|DRUG|Metformin|Metfomin in tablet presentation of 500 mg
219400662|NCT02778776|DIETARY_SUPPLEMENT|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
219400663|NCT02778776|OTHER|Placebo of agave inulin|Calcinated magnesia powder
219400664|NCT02778776|OTHER|Metformin placebo|Calcinated magnesia tablet
219564702|NCT04247984|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
219564703|NCT04247984|DRUG|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
219400665|NCT03715569|DIAGNOSTIC_TEST|Vestibular function|Vhit, Caloric test
219400666|NCT03715569|DIAGNOSTIC_TEST|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
219400667|NCT03715569|DIAGNOSTIC_TEST|Biomarker|Biomarker examination
219400668|NCT03715569|DIAGNOSTIC_TEST|MOCA, eGOS|Cognitive tests
219400669|NCT03715569|DIAGNOSTIC_TEST|Audiometry|Hearing test
219564704|NCT04247984|DRUG|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
219400670|NCT05663086|BIOLOGICAL|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
219400671|NCT05663086|BIOLOGICAL|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
219400672|NCT05663086|BIOLOGICAL|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
219400673|NCT05663086|BIOLOGICAL|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
219400674|NCT05725369|BEHAVIORAL|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
219400675|NCT03921281|OTHER|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total."
219400676|NCT03921281|OTHER|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
219400677|NCT02058355|BEHAVIORAL|Consequences List Feedback|
219400678|NCT02058355|BEHAVIORAL|Personalized Normative Feedback|
219400679|NCT00228488|DRUG|Gefitinib|
219400680|NCT01519570|OTHER|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
219400681|NCT04330235|OTHER|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
219400682|NCT00778752|DRUG|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
219400683|NCT04013581|DRUG|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
219400684|NCT04013581|DRUG|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
219400685|NCT00175175|BEHAVIORAL|"Allied health professional-run osteoporosis service (case-management)"|
219400686|NCT00692900|DRUG|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
219400687|NCT00692900|DRUG|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
219400688|NCT03014661|OTHER|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
219400689|NCT03464708|DIETARY_SUPPLEMENT|HMB|Powder form
219400690|NCT03464708|OTHER|Lactose (placebo)|Powder form
219400691|NCT01796353|OTHER|sexual rehabilitation|exercise plus psycho-education
219400692|NCT01796353|OTHER|Usual care|usual care
219400693|NCT03785717|PROCEDURE|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
219400694|NCT03785717|PROCEDURE|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
219400695|NCT04722393|OTHER|Exercise|Exercise training
219400696|NCT02207192|OTHER|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
219400697|NCT03388177|BEHAVIORAL|Yoga-based therapy|
219400698|NCT03388177|OTHER|Treatment as usual|
219400699|NCT03664817|BEHAVIORAL|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
219400700|NCT03664817|BEHAVIORAL|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
219400701|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
219400702|NCT00911664|DRUG|No supplementation|Control
219564705|NCT04247984|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
219400703|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
219400704|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
219400705|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
219400706|NCT03156556|BEHAVIORAL|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
219564706|NCT04247984|DRUG|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
219564707|NCT04247984|DRUG|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
219564708|NCT03744078|DEVICE|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
219564709|NCT05640336|PROCEDURE|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
219400707|NCT06671522|OTHER|Survey|It is a qualitatative research. Only a survey.
219400708|NCT02960932|DEVICE|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
219564710|NCT05640336|PROCEDURE|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
219564711|NCT05872334|DEVICE|Monofix|a new absorbable barbed suture device
219564712|NCT02079675|DRUG|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
219564713|NCT02079675|DRUG|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
219564714|NCT02079675|DRUG|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
219564715|NCT06125756|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
219564716|NCT06125756|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
219564717|NCT06125756|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
219400709|NCT05021536|OTHER|Placebo|Matching Placebo Comparator
219400710|NCT05021536|DRUG|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
219400711|NCT05185752|PROCEDURE|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
219400712|NCT05185752|PROCEDURE|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
219400713|NCT05185752|PROCEDURE|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
219400714|NCT03026543|PROCEDURE|Pulmonary Recruitment Maneuver|
219400715|NCT03026543|PROCEDURE|Laparoscopic cholecystectomy|
219002075|NCT05862233|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1 and Week 3.If the treatment is effective, MIL62 will continue be administered at W25 and W27
219400716|NCT03026543|DEVICE|Ventilator|
219400717|NCT06011005|OTHER|Ethyl Chloride spray (group A)|Cold test spray
219400718|NCT06011005|OTHER|Benzocaine gel 20% (group B)|Topical analgesia
219400719|NCT02566525|DEVICE|CytoSorb|Cytosorb device use during cardiopulmonary bypass
219400720|NCT00337467|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
219400721|NCT04035135|DRUG|ANX005|investigational drug
219400722|NCT04035135|DRUG|Intravenous immunoglobulin|investigational drug
219400723|NCT01881035|PROCEDURE|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
219400724|NCT06671860|OTHER|Exercise|"Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic."
219400725|NCT06671158|BEHAVIORAL|Psychotherapy|Individual psychotherapy for weekly 12-sessions
219400726|NCT06671431|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy with or without radiotherapy
219400727|NCT06672367|PROCEDURE|Balance training group|"It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously."
219400728|NCT06672367|PROCEDURE|Balance training combined with gaze stability exercises|"It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises"
219400729|NCT01723280|DRUG|Oxygen|During and 2 hrs after surgery
219400730|NCT04581681|BEHAVIORAL|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
219400731|NCT04581681|OTHER|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
219400732|NCT00308295|DRUG|Fish oil capsules|
219400733|NCT00308295|DRUG|matched placebo capsules|
219400734|NCT01418222|DRUG|5-FU|Intravenous repeating dose
219400735|NCT01418222|DRUG|FOLFOX regimen|Intravenous repeating dose
219400736|NCT01418222|DRUG|Placebo|Intravenous repeating dose
219400737|NCT01418222|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
219400738|NCT01418222|DRUG|leucovorin|Intravenous repeating dose
219400739|NCT01418222|DRUG|onartuzumab [MetMAb]|Intravenous repeating dose
219400740|NCT00360022|OTHER|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
219400741|NCT04083222|DRUG|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
219400742|NCT04083222|DRUG|ISIS 757456|ISIS 757456 administered as SC injection.
219400743|NCT05894993|DEVICE|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
219400744|NCT02944799|DRUG|Placebo|Discontinuation of alendronate treatment
219400745|NCT02944799|DRUG|Alendronate|
219400746|NCT02944799|DRUG|Calcium|Daily dietary supplement of 800mg calcium
219400747|NCT02944799|DRUG|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
219400748|NCT04151017|OTHER|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
219400749|NCT04151017|OTHER|Suture|Graft fixation using 10.0 mononylon
219400750|NCT06673251|OTHER|motor and sensory assessments, surveys|It does not include any intervention. Only evaluation will be made.
219400751|NCT06809361|BEHAVIORAL|Obesity prevention program|The Obesity Prevention Program was developed based on a literature review. Expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were obtained for the educational content, and the final version was formulated. The training program is planned in eight sessions. The program will be scheduled at times convenient for students after prior discussion with the school administration. Two sessions per week will be conducted, with each session expected to last approximately 30-40 minutes. Students will utilize school computers and projectors during the training. The program will include verbal presentations, PowerPoint slides, brainstorming, exercises, games, written and visual materials, video screenings, and Q\&A sessions. Adolescents will try on weighted T-shirts of different weights, fruit plates will be distributed during sessions, and bookmarks, magnets, and brochures will be provided at the end of the sessions.
219400752|NCT06809361|BEHAVIORAL|Social media messages|In addition to the program, a total of 36 short messages will be sent three times a week to the Education + Social Media Supported group.
219400753|NCT04075227|DRUG|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
219400754|NCT04075227|DRUG|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
219400755|NCT05710874|OTHER|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
219400756|NCT05710874|OTHER|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
219400757|NCT05710874|OTHER|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
219400758|NCT05710874|OTHER|Conventional|Twice daily use of conventional toothpaste.
219400759|NCT02832440|OTHER|Exercise programmes|
219400760|NCT02559232|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
219400761|NCT02457351|DRUG|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
219400762|NCT02457351|DRUG|Itraconazole (Sporanox)|Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
219400763|NCT03580577|DEVICE|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
219400764|NCT02816762|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
219400765|NCT02816762|DRUG|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
219400766|NCT02816762|OTHER|Diet|Conventional anti-diabetic diet recommendations
219400767|NCT02411812|DEVICE|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
219400768|NCT02411812|DEVICE|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
219400769|NCT02411812|DEVICE|Twin-Block appliance|Group treated with Twin-Block appliance
219400770|NCT04227977|DEVICE|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
219400771|NCT01782599|OTHER|Dual nicotine patch and electronic cigarette|
219400772|NCT05106972|DRUG|UC-MSC infusion|UC-MSC infusion by introvenus
219400773|NCT01168804|DRUG|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
219564718|NCT04423159|BIOLOGICAL|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
219002076|NCT05862233|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125\~175 ng/mL was reached.Optimized cyclosporine dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks.
219002077|NCT02442869|BEHAVIORAL|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
219002078|NCT02442869|BEHAVIORAL|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
219400774|NCT03103750|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
219400775|NCT03103750|DRUG|PHNO|Used as a tracer for in vivo imaging.
219400776|NCT03103750|DIETARY_SUPPLEMENT|calcitriol|three 0.5 mcg capsules
219400777|NCT03103750|DRUG|Placebo oral capsule|three 0.5 mcg capsules
219400778|NCT03103750|PROCEDURE|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
219400779|NCT03103750|DRUG|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
219400780|NCT05657977|OTHER|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
219002079|NCT02442869|BEHAVIORAL|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
219400781|NCT00807547|BIOLOGICAL|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
219400782|NCT00517686|OTHER|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
219400783|NCT03158545|DIETARY_SUPPLEMENT|Olive oil Placebo|olive oil
219400784|NCT03158545|DIETARY_SUPPLEMENT|EPA-rich|EPA-rich omega-3 oil
219400785|NCT03158545|DIETARY_SUPPLEMENT|DHA-rich|DHA-rich omega-3 oil
219400786|NCT06692413|OTHER|Questionnaire|Users who consent to the study will receive a questionnaire every 3 months
219400787|NCT01128972|DRUG|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
219400788|NCT01128972|DRUG|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
219400789|NCT01128972|DRUG|Sterile water|Sterile water rinse
219400790|NCT04624932|BEHAVIORAL|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
219400791|NCT04624932|BEHAVIORAL|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
219400792|NCT04661618|DEVICE|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
219400793|NCT06246825|DIAGNOSTIC_TEST|Polysomnography|Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
219400794|NCT06711835|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between.
219400795|NCT02429427|DRUG|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
219400796|NCT02429427|OTHER|Placebo|Two capsules once daily with food
219400797|NCT03397485|DIETARY_SUPPLEMENT|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
219400798|NCT03397485|DIETARY_SUPPLEMENT|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
219400799|NCT03697967|PROCEDURE|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
219400800|NCT00906256|DRUG|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
219400801|NCT00906256|DRUG|Placebo|Placebo
219564719|NCT00468793|PROCEDURE|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
219564720|NCT03074864|DRUG|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
219564721|NCT04186559|DRUG|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
219564722|NCT04186559|DRUG|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
219400802|NCT06854315|BEHAVIORAL|ChatGPT-Based Digital Counseling|Participants in this group received standard clinician-led chemotherapy education plus access to ChatGPT-based digital counseling. They could submit up to 10 personalized questions regarding their treatment, side effects, and supportive care. Oncology specialists reviewed ChatGPT-generated responses for accuracy. This intervention aimed to assess whether AI-assisted counseling could reduce anxiety and depression levels in newly diagnosed cancer patients.
219400803|NCT06854315|BEHAVIORAL|Standard Clinician-Led Education|Participants in this group received only standard clinician-led chemotherapy education, delivered by oncology physicians and nurses. The education covered key aspects of chemotherapy, including potential side effects, treatment schedules, and supportive care recommendations. Unlike the ChatGPT group, these participants did not receive AI-assisted counseling or additional interactive educational tools.
219400804|NCT06930196|OTHER|Counterstrain|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
219400805|NCT06930196|OTHER|Muscle Energy|Subjects were first analyzed with the Ultralign SA201/Spineliner, then treated with an osteopathic technique, and then reassessed with the SA201 for tissue texture changes.
219400806|NCT06930196|OTHER|High Velocity Low Amplitude|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
219400807|NCT06930196|DEVICE|The Ultralign SA201 used for measuring tissue texture changes|The Ultralign SA201 was used for diagnostic purposes to measure the tissue texture changes of the paraspinal cervical muscles pre and post treatment
219400808|NCT06930196|DEVICE|IsoTouch|The IsoTouch is a palpation monitoring system that uses capacitance pressure sensors in the pads of gloves to measure the palpation pressures used for both diagnosis and treatment using OMT. No sensation is felt by either the subject or operator other than a feeling of a glove being used during treatment. No electrical impulses are sent or should be experienced by either party as the sensors are merely pads that sense pressure.
219564723|NCT06090682|DEVICE|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
219564724|NCT04147962|DEVICE|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
219564725|NCT01162278|RADIATION|SBRT|Single fraction SBRT
219564726|NCT04044560|BIOLOGICAL|blinatumomab|Continuous intravenous infusion
219564727|NCT04082806|DRUG|GHB|50 mg/kg GHB at one experimental night
219564728|NCT04082806|DRUG|Trazodone|1.5 mg/kg trazodone at one experimental night
219564729|NCT04082806|DRUG|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
219564730|NCT03856606|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219564731|NCT03856606|BEHAVIORAL|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219564732|NCT04090879|OTHER|Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)|1\) Altering the nicotine content of the tobacco research cigarette
219564733|NCT04090879|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
219400809|NCT05579704|BEHAVIORAL|Web-based wellness platform|A web-based wellness platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
219400810|NCT05579704|BEHAVIORAL|Healthcare professional-facilitated online support group|Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
219400811|NCT05983146|DRUG|HRS-7053 Injection|HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks
219564734|NCT06327737|DIAGNOSTIC_TEST|Capnography|This is non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography.
219564735|NCT00232479|DRUG|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
219754713|NCT06425029|OTHER|Experimental Intervention (Music A)|Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.
219754714|NCT06425029|OTHER|Active Comparator Intervention (Music B)|Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.
219400812|NCT05647811|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
219564736|NCT06392542|BEHAVIORAL|Whole Selves|Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
219564737|NCT04763096|DRUG|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
219564738|NCT00020358|BIOLOGICAL|aldesleukin|
219400813|NCT01893840|DEVICE|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
219400814|NCT01752569|DRUG|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
219400815|NCT02995343|PROCEDURE|Hypogastric and/or uterine artery ligation|
219400816|NCT04094350|OTHER|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
219400817|NCT04094350|OTHER|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
219400818|NCT04094350|OTHER|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
219400819|NCT04094350|OTHER|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
219400820|NCT03335852|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
219564739|NCT00020358|BIOLOGICAL|gp100 antigen|
219564740|NCT00020358|BIOLOGICAL|incomplete Freund's adjuvant|
219564741|NCT00020358|BIOLOGICAL|tyrosinase peptide|
219564742|NCT00160888|DRUG|sodium nitroprusside, bradykinin, acetylcholine|
219564743|NCT04623528|DIAGNOSTIC_TEST|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
219564744|NCT04205162|DEVICE|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
219564745|NCT04205162|DEVICE|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
219564746|NCT03649945|DRUG|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
219564747|NCT03649945|DRUG|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
219002080|NCT02442869|BEHAVIORAL|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
219400821|NCT06082557|DRUG|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
219564748|NCT03649945|DRUG|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
219564749|NCT03124134|DEVICE|Gelesis200|Encapsulated hydrogel
219564750|NCT03124134|OTHER|Water, only (placebo)|300 mL of water
219564751|NCT02666924|DIETARY_SUPPLEMENT|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
219564752|NCT02666924|OTHER|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
219564753|NCT03460158|DRUG|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
219400822|NCT03111134|PROCEDURE|modified component separation technique|a new abdomen closure technique based on component separation technique
219400823|NCT05523063|OTHER|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
219400824|NCT00668655|DRUG|Metronidazole Gel|Topical, Once daily for 2 weeks
219400825|NCT03671824|OTHER|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
219400826|NCT01073527|DRUG|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
219400827|NCT01073527|DRUG|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
219400828|NCT03398369|DIAGNOSTIC_TEST|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
219564754|NCT03460158|DRUG|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
219564755|NCT03460158|DRUG|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
219564756|NCT01011556|DRUG|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
219564757|NCT01011556|DRUG|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
219564758|NCT03952988|DIETARY_SUPPLEMENT|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
219564759|NCT03952988|DIETARY_SUPPLEMENT|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
219002081|NCT05048784|DRUG|Sotorasib|Oral tablet
219400829|NCT00747617|DRUG|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
219400830|NCT02867345|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
219400831|NCT02867345|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
219400832|NCT02867345|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
219400833|NCT00988741|DRUG|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
219400834|NCT00988741|DRUG|Placebo|The placebo is provided in a capsule form.
219564760|NCT04888533|OTHER|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
219564761|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 24 or 48 weeks
219564762|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 48 weeks
219564763|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
219564764|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 48 weeks
219564765|NCT00869661|DRUG|RO5024048|1000mg bid for 24 weeks
219564766|NCT00869661|DRUG|RO5024048|500mg bid for 12 weeks
219002082|NCT03521934|DRUG|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
219002083|NCT03521934|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219002084|NCT00226707|DRUG|Pimecrolimus Cream 1%|
219002085|NCT03434275|DRUG|N1539|Once Daily
219002086|NCT03434275|DRUG|Placebo|Once Daily
219400835|NCT01746732|DRUG|Ortho-Cyclen|Oral administration
219400836|NCT01746732|DRUG|Evacetrapib|Oral administration
219400837|NCT02279524|DRUG|Aramchol|"Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
219400838|NCT00518219|DRUG|TW|TW,120mg/d
219400839|NCT03509207|DRUG|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
219400840|NCT01204619|BEHAVIORAL|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
219400841|NCT02222038|OTHER|skin biopsy|
219400842|NCT02817555|DRUG|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
219400843|NCT02817555|DRUG|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
219400844|NCT06177054|BEHAVIORAL|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
219564767|NCT00869661|DRUG|RO5024048|1000mg bid for 8 weeks
219564768|NCT00869661|DRUG|RO5024048|1000mg bid for 12 weeks
219564769|NCT04013698|OTHER|PEEP level 5 cmH2O|PEEP level set for 45 minutes
219564770|NCT04013698|OTHER|PEEP level 15 cmH2O|PEEP level set for 45 minutes
219564771|NCT03989011|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
219564772|NCT03989011|DIAGNOSTIC_TEST|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
219564773|NCT01845116|DRUG|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
219564774|NCT03776617|PROCEDURE|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
219564775|NCT00529217|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
219564776|NCT00004424|DRUG|fentanyl|
219564777|NCT00004424|DRUG|Midazolam|
219564778|NCT00004424|DRUG|propofol|
219564779|NCT03112148|DRUG|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
219564780|NCT01999894|DRUG|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
219564781|NCT01098110|DRUG|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
219564782|NCT01098110|DRUG|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
219564783|NCT01098110|DRUG|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
219564784|NCT05509959|BEHAVIORAL|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
219564785|NCT05509959|BEHAVIORAL|Control|Single group session and access to website
219564786|NCT02147587|DRUG|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
219400845|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
219400846|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
219400847|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
219400848|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing OneTouch® Verio|
219400849|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing GlucoMen® areo|
219400850|NCT05390450|DEVICE|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
219400851|NCT05390450|DEVICE|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
219400852|NCT01838174|DRUG|ACTHAR Gel (ACTH)|15 days of daily injections
219400853|NCT01838174|DRUG|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
219400854|NCT00137436|DRUG|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
219400855|NCT00137436|DRUG|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
219400856|NCT00137436|DRUG|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
219400857|NCT05745116|DEVICE|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
219400858|NCT00443378|BEHAVIORAL|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
219400859|NCT05412719|BEHAVIORAL|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
219400860|NCT02975440|DRUG|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
219400861|NCT02975440|DRUG|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
219400862|NCT02975440|DRUG|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
219564787|NCT02147587|DRUG|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
219400863|NCT02600026|DEVICE|DriveCam|Video event monitoring device
219400864|NCT02600026|BEHAVIORAL|Feedback|Video feedback intervention
219564788|NCT02759549|BEHAVIORAL|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
219564789|NCT02759549|OTHER|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
219564790|NCT02759549|BEHAVIORAL|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
219564791|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
219564792|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
219400865|NCT05263128|OTHER|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
219400866|NCT00738543|OTHER|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
219400867|NCT03609658|BEHAVIORAL|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
219400868|NCT03609658|BEHAVIORAL|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
219400869|NCT02726932|OTHER|No intervention, merely observational|
219400870|NCT06384924|DEVICE|Raman Spectroscopy handheld probe (EmVision, FL, USA)|The probe is approximately the size of a pen or pencil. The handheld probe is connected to the laser source using a cable. The probe is placed in light contact with the skin. The features of the laser light after it bounces off the skin is collected. This measurement can allow us to see tissue characteristics. This is a single session that will take approximately 15 minutes.
219400871|NCT06384924|DEVICE|Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)|This light source will create the laser light that will pass through the cable and through the handheld probe onto the skin.
219400872|NCT04765800|BEHAVIORAL|weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy|according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
219400873|NCT00912015|DRUG|Tramadol OAD|
219400874|NCT00912015|DRUG|Tramadol OAD|
219400875|NCT00912015|DRUG|Tramadol OAD|
219564793|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
219564794|NCT06617000|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
219400876|NCT00912015|DRUG|Tramadol OAD 100mg|
219564795|NCT00350987|BEHAVIORAL|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
219564796|NCT00660088|OTHER|Ketasyn|10g for 7 days, 20g for 7 or 14 days
219564797|NCT03691688|DRUG|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
219564798|NCT03691688|DRUG|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
219400877|NCT05647057|COMBINATION_PRODUCT|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
219400878|NCT05647057|COMBINATION_PRODUCT|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
219564799|NCT00055484|DRUG|zonisamide|
219564800|NCT04468906|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
219564801|NCT04468906|PROCEDURE|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
219564802|NCT03086876|BEHAVIORAL|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
219564803|NCT04891692|DEVICE|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
219564804|NCT05669807|DRUG|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
219564805|NCT05669807|DRUG|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
219564806|NCT05669807|DRUG|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
219564807|NCT04817215|DRUG|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
219754715|NCT06425029|OTHER|Active Comparator Intervention (Music C)|Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
219400879|NCT05647057|COMBINATION_PRODUCT|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
219400880|NCT01109901|PROCEDURE|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
219400881|NCT01109901|PROCEDURE|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
219400882|NCT04114994|DIAGNOSTIC_TEST|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
219400883|NCT03978494|DRUG|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
219400884|NCT03978494|DRUG|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
219400885|NCT01356602|DRUG|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
219400886|NCT01356602|DRUG|Canakinumab lyophilized powder|Canakinumab lyophilized powder
219400887|NCT01356602|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide
219400888|NCT01356602|DRUG|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
219400889|NCT05232942|OTHER|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
219400890|NCT02146807|DEVICE|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
219400891|NCT05904405|OTHER|quationaire|"Data will be collected through a semi-structured interview administered questionnaire which includes:~1. Socio-demographic characteristics of women~2. Family planning practice: This will include number of living children, current use of FP method and its type, and suggested causes of discontinuation of FP, previous contraceptive use, and reason for the visit 3-Facility factors such as gender of providers, qualification of providers, type of the health facility.~4-Quality of contraceptive counseling (QCC) scale: it is a 22-item scale which measures the quality of care received by women during family planning visits. It includes : 1) information exchange, 2) interpersonal relations, and 3) disrespect and abuse in contraceptive counseling. The information exchange subscale consists of ten items, the interpersonal relationship subscale consists of seven items, and the disrespect and abuse subscale consists of five items."
219400892|NCT00887718|BIOLOGICAL|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
219400893|NCT04990245|DIAGNOSTIC_TEST|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
219400894|NCT05142657|OTHER|diet survey|Dietary survey applied to all participants
219400895|NCT01115569|DRUG|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
219400896|NCT01707069|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
219400897|NCT04346134|PROCEDURE|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
219400898|NCT04346134|PROCEDURE|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
219400899|NCT03451864|PROCEDURE|Vaginal delivery|classic vaginal delivery
219400900|NCT03451864|PROCEDURE|Cesarean Section|routine lower segment cesarean scetion
219400901|NCT03811223|DRUG|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
219400902|NCT03811223|DRUG|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
219400903|NCT03587675|DIAGNOSTIC_TEST|EVH test|
219400904|NCT03640806|OTHER|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
219400905|NCT00004285|DEVICE|Standard dose, low flux hemodialysis|
219400906|NCT00004285|DEVICE|Standard dose, high flux hemodialysis|
219400907|NCT00004285|DEVICE|High dose, low flux hemodialysis|
219400908|NCT00004285|DEVICE|High dose, high flux hemodialysis|
219400909|NCT00527215|DRUG|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
219400910|NCT02258009|DRUG|Ranibizumab|0.5 mg intravitreal injections
219400911|NCT02258009|DRUG|Aflibercept|2 mg intravitreal injections
219400912|NCT04141787|DRUG|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
219400913|NCT04141787|DRUG|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
219400914|NCT02850887|OTHER|general endotracheal anesthesia|sedation with the use of endotracheal intubation
219400915|NCT02850887|OTHER|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
219400916|NCT02656992|DEVICE|Inspiratory muscle training group|
219400917|NCT01743586|OTHER|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
219400918|NCT02361762|BEHAVIORAL|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
219400919|NCT03940924|OTHER|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
219400920|NCT01931462|DEVICE|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
219400921|NCT02053389|BEHAVIORAL|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
219400922|NCT02053389|BEHAVIORAL|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
219400923|NCT01383395|DRUG|simvastatin/cilostazol|
219400924|NCT01452958|BIOLOGICAL|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
219400925|NCT01452958|BIOLOGICAL|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
219400926|NCT02819310|DRUG|BLI400 Laxative|oral laxative
219400927|NCT03415919|OTHER|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
219400928|NCT01557608|PROCEDURE|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
219400929|NCT01557608|PROCEDURE|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
219400930|NCT04811521|BEHAVIORAL|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
219400931|NCT04811521|BEHAVIORAL|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
219400932|NCT04811521|BEHAVIORAL|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
219400933|NCT03483324|BIOLOGICAL|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
219400934|NCT03483324|BIOLOGICAL|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
219400935|NCT03238586|BEHAVIORAL|WELL Program|
219400936|NCT00511407|DEVICE|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
219564808|NCT06363526|OTHER|Digital respiratory intervention program|"A 4 times a week for a period of 5 weeks will be done, for a duration of 55-60 minutes (20 sessions), with an intensity adapted to the characteristics of each participant. Moreover, an intervention program will be used based on respiratory muscle training exercises, upper limb strength work, yoga, diaphragmatic awareness exercises, always trying to do them through the use of games, and even try to include exercises that use motor imagery.~The intervention program is carried out and stimulated through videos and therapeutic teaching to the caregivers in the first evaluation session, as well as as well as with a weekly follow-up using WhatsApp or Zoom as forms of communication, or a telephone call to ensure correct follow-up of the intervention program. Moreover, YouTube videos, own videos prepared by the physiotherapy will be used to help optimally resolve doubts that arise when carrying out the program by video call."
219564809|NCT04380038|DRUG|Dupilumab Injectable Product|Nasal inoculation, single dose 300 TCID50 in 1ml.
219400937|NCT02046265|BEHAVIORAL|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
219564810|NCT03292263|DRUG|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
219564811|NCT03292263|DRUG|Nivolumab|iv infusion 100 mg on day -3, +17
219564812|NCT03292263|PROCEDURE|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
219564813|NCT04364763|DRUG|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
219400938|NCT02046265|BEHAVIORAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
219400939|NCT02046265|BEHAVIORAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
219400940|NCT02046265|BEHAVIORAL|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
219400941|NCT06530602|OTHER|3 D SPA (shoulder complex pain alignment) Moblization|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
219400942|NCT06530602|OTHER|Shoulder Moblization (KaltenBorn)|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
219400943|NCT01152008|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
219400944|NCT01241851|BEHAVIORAL|Aerobic exercise|
219754716|NCT05438667|BIOLOGICAL|TCR-T therapy|"1.Preprocessing strategy：~1. Cyclophosphamide: 300-450mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3-5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 5 days (10 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed."
219400945|NCT01241851|BEHAVIORAL|Resistance exercise|
219400946|NCT01793051|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
219400947|NCT01793051|OTHER|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
219400948|NCT01793051|BEHAVIORAL|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
219400949|NCT02266901|PROCEDURE|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
219400950|NCT02826733|DEVICE|Electroencephalogram (EEG)|
219400951|NCT02826733|DEVICE|Near Infra Red Spectroscopy (NIRS)|
219564814|NCT04364763|DRUG|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
219564815|NCT02051660|BEHAVIORAL|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
219564816|NCT02051660|BEHAVIORAL|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
219564817|NCT00153439|BEHAVIORAL|Motivational enhancements, parent training|
219564818|NCT04937738|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
219564819|NCT04937738|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
219564820|NCT04937738|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
219564821|NCT04937738|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
219564822|NCT04937738|DRUG|Capecitabine|1000 mg/m² two times per day (BID), d1-14
219400952|NCT02826733|DEVICE|magnetic resonance imaging (MRI)|
219400953|NCT04345991|DRUG|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
219400954|NCT02427256|DEVICE|Topcon Specular Microscope SP-1P|
219400955|NCT02427256|DEVICE|Konan Specular Microscope CELLCHEK XL|
219564823|NCT04937738|DRUG|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
219564824|NCT00361387|DRUG|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
219564825|NCT04496037|DRUG|Rituximab|See NCT03994783
219754717|NCT05537584|DRUG|Sertraline|Subjects will receive 8 weeks of sertraline while monitored by the study physician
219400956|NCT06239909|OTHER|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
219400957|NCT06239909|OTHER|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
219400958|NCT01790893|DRUG|aflibercept|
219400959|NCT01300468|DRUG|PHA-848125AC|
219400960|NCT01333267|DRUG|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
219400961|NCT01333267|DRUG|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
219400962|NCT01333267|DRUG|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
219400963|NCT05623904|PROCEDURE|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
219400964|NCT05623904|DRUG|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
219564826|NCT04924751|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
219564827|NCT00709137|DRUG|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
219564828|NCT00709137|DRUG|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
219564829|NCT01223209|DRUG|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
219754718|NCT05537584|DRUG|Bupropion|Subjects will receive 8 weeks of bupropion while monitored by the study physician
219400965|NCT00029848|DRUG|Rimonabant (SR141716)|
219400966|NCT04243135|DEVICE|ESWT|Extracorporeal shock wave therapy
219400967|NCT03169829|DIETARY_SUPPLEMENT|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only"
219400968|NCT03169829|DIETARY_SUPPLEMENT|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables"
219400969|NCT03169829|DIETARY_SUPPLEMENT|Standard|"•¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables"
219400970|NCT03478319|DRUG|ACE-2494 or placebo|Recombination fusion protein
219400971|NCT02668107|OTHER|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
219400972|NCT00344617|DRUG|Bevacizumab (tradename: Avastin)|
219400973|NCT01449552|DRUG|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
219400974|NCT01449552|PROCEDURE|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
219400975|NCT01449552|OTHER|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
219564830|NCT05476133|OTHER|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
219564831|NCT01239498|PROCEDURE|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
219564832|NCT01239498|PROCEDURE|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
219564833|NCT01424098|BEHAVIORAL|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
219564834|NCT02396927|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
219564835|NCT02396927|DEVICE|2D HD laparoscopy|Placebo
219564836|NCT05567627|BIOLOGICAL|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
219754719|NCT01863550|DRUG|Bortezomib|Given SC or IV
219754720|NCT01863550|DRUG|Carfilzomib|Given IV
219754721|NCT01863550|DRUG|Dexamethasone|Given PO
219400976|NCT01449552|OTHER|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
219400977|NCT03044015|BEHAVIORAL|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
219400978|NCT03044015|BEHAVIORAL|as usual|
219400979|NCT04489485|BEHAVIORAL|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
219400980|NCT05055232|DRUG|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
219400981|NCT05862792|DRUG|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
219564837|NCT04491734|DIETARY_SUPPLEMENT|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
219564838|NCT04371263|OTHER|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
219564839|NCT01710670|DRUG|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
219564840|NCT01710670|OTHER|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
219564841|NCT01710670|OTHER|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
219564842|NCT01710670|OTHER|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
219564843|NCT04973800|DRUG|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
219564844|NCT04973800|DRUG|Placebo|Sucrose placebo ON PO for 28-30 days
219564845|NCT03733587|DRUG|GX-I7|GX-I7 25mg/ml/vial
219564846|NCT03733587|DRUG|Cyclophosphamide|Cyclophosphamide 500mg/vial
219564847|NCT06251960|PROCEDURE|socket preservation with completely demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
219400982|NCT00743600|OTHER|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
219400983|NCT00743600|OTHER|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
219400984|NCT04940871|DRUG|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
219564848|NCT06251960|PROCEDURE|socket preservation with partially demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
219400985|NCT04940871|DRUG|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
219400986|NCT02304783|DRUG|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
219400987|NCT02304783|DRUG|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
219400988|NCT02304783|DRUG|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
219400989|NCT04067765|BEHAVIORAL|Cue Exposure|Participants will undergo a validated in-scanner alcohol cue and neutral cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor) and neutral beverages (water).
219002087|NCT04997811|DRUG|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
219400990|NCT03395171|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
219400991|NCT06579170|BEHAVIORAL|Cyanobacteria exposure during water contact|Cyanobacteria levels in beach water among participants who report water contact in the beach survey
219564849|NCT02833636|PROCEDURE|ACEF score|
219564850|NCT00669435|DRUG|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
219564851|NCT00669435|DRUG|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
219754722|NCT01863550|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219754723|NCT01863550|DRUG|Lenalidomide|Given PO
219754724|NCT01863550|OTHER|Quality-of-Life Assessment|Ancillary studies
219754725|NCT02616991|PROCEDURE|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
219754726|NCT06285916|DRUG|NORA520 Dose 1|Oral NORA520 tablets Dose 1 for 3 days
219400992|NCT04439630|DIETARY_SUPPLEMENT|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
219400993|NCT04439630|DIETARY_SUPPLEMENT|Test product without the active components|Test product without the active components
219400994|NCT00159744|DRUG|Asenapine|Asenapine, 3 weeks
219400995|NCT00159744|DRUG|Olanzapine|Olanzapine, 3 weeks
219002088|NCT04997811|DRUG|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
219400996|NCT00159744|DRUG|Placebo|placebo, 3 weeks
219400997|NCT02776696|DEVICE|Advanced Hybrid Closed Loop System|
219400998|NCT02776696|DEVICE|Hybrid Closed Loop System|
219400999|NCT03175393|DEVICE|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
219401000|NCT02752867|DRUG|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
219401001|NCT02752867|OTHER|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
219401002|NCT04040062|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
219401003|NCT02844101|DEVICE|GT3X Actigraph accelerometer.|
219401004|NCT01798784|BEHAVIORAL|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
219401005|NCT01798784|BEHAVIORAL|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
219401006|NCT01798784|BEHAVIORAL|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
219401007|NCT03282201|OTHER|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
219401008|NCT01244334|DRUG|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
219401009|NCT01244334|DRUG|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
219401010|NCT00779090|PROCEDURE|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
219401011|NCT04769583|DRUG|metronidazole based quadriple therapy|patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
219401012|NCT04769583|DRUG|placebo based quadriple therapy|patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
219401013|NCT03613090|DRUG|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
219401014|NCT03613090|DRUG|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
219401015|NCT02725892|OTHER|NIS observational stud|NIS observational study : Epidemiologic registry
219002089|NCT02455232|PROCEDURE|upper limb muscle block|
219002090|NCT02455232|DRUG|4cc of lidocaïne®|
219401016|NCT00592150|DRUG|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
219401017|NCT00592150|DRUG|Placebo|Placebo infusion for 3 hours
219401018|NCT05814393|DRUG|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
219401019|NCT05814393|DRUG|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
219401020|NCT05814393|DRUG|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
219401021|NCT05272917|OTHER|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
219401022|NCT05272917|BEHAVIORAL|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
219401023|NCT05070429|OTHER|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
219754727|NCT06285916|DRUG|NORA520 Dose 2|Oral NORA520 tablets Dose 2 for 3 days
219754728|NCT06285916|DRUG|Placebo|Oral Placebo tablets for 3 days
219564852|NCT04423445|OTHER|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
219401024|NCT05070429|OTHER|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
219401025|NCT00830661|PROCEDURE|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
219401026|NCT00830661|PROCEDURE|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
219401027|NCT00854529|DRUG|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
219401028|NCT04541849|OTHER|Critical Care|Critical care in the intensive care units
219401029|NCT01270672|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
219564853|NCT02045524|OTHER|Deep muscle injection|
219564854|NCT02045524|OTHER|Sub-Q Injection|
219564855|NCT00952224|OTHER|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
219564856|NCT04854408|OTHER|healthcare workers with the coronavac vaccine|Health workers who are vaccinated will fill in the 20-question survey electronically.
219564857|NCT04223284|OTHER|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
219564858|NCT04223284|OTHER|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
219564859|NCT02990078|DRUG|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
219401030|NCT01270672|DRUG|carvedilol|50 mg per os, single dose
219564860|NCT02990078|DEVICE|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
219754733|NCT02010502|DIETARY_SUPPLEMENT|Beetroot juice|
219754734|NCT02010502|DIETARY_SUPPLEMENT|Beetroot powder|
219754735|NCT02010502|DIETARY_SUPPLEMENT|Placebo|
219754736|NCT01435590|PROCEDURE|Curette v/s endocervical brush|
219401031|NCT01270672|DRUG|placebo|capsules identical to MDMA or carvedilol
219401032|NCT00200525|DRUG|apomorphine HCl injection|
219401033|NCT00708604|PROCEDURE|Islet Transplantation|Islet Transplantation
219401034|NCT00708604|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
219401035|NCT01399801|PROCEDURE|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
219401036|NCT01399801|PROCEDURE|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
219401037|NCT00742443|DRUG|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
219401038|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
219401039|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
219401040|NCT01031524|BIOLOGICAL|PfCS102|Antigen of the sporozoite protein
219401041|NCT01031524|BIOLOGICAL|Montanide ISA 720|adjuvant alone
219401042|NCT00004735|BIOLOGICAL|Tetanus toxoid|
219401043|NCT00004735|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
219401044|NCT01742624|DRUG|Advagraf|oral
219401045|NCT01742624|DRUG|Prograf|oral
219401046|NCT01742624|DRUG|Corticosteroid|oral
219401047|NCT01742624|DRUG|Mycophenolate mofetil|oral
219401048|NCT03381924|OTHER|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
219401049|NCT03381924|OTHER|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
219401050|NCT05257720|DIAGNOSTIC_TEST|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
219401051|NCT03025048|BEHAVIORAL|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
219401052|NCT01935908|DRUG|levetiracetam|
219754737|NCT05311046|DIAGNOSTIC_TEST|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
219401053|NCT02908958|BIOLOGICAL|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
219401054|NCT02908958|BIOLOGICAL|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
219401055|NCT03276936|DRUG|FMX103 1.5%|FMX103 1.5% minocycline foam
219401056|NCT03144141|OTHER|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
219401057|NCT04953949|DEVICE|NU-MAX®|Topical Hemostat
219401058|NCT05255055|OTHER|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
219401059|NCT05372068|OTHER|Concrete household floor|Household soil floors will be replaced with concrete floors
219401060|NCT02697955|DRUG|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
219401061|NCT02697955|OTHER|Placebo|9 mg sodium chloride pr. ml (0,9 %)
219401062|NCT05640713|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
219401063|NCT05640713|DRUG|Fludarabine Pill|Fludarabine is used for lymphodepletion.
219401064|NCT05640713|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219401065|NCT05640713|DRUG|VP-16 Protocol|VP-16 is used for lymphodepletion.
219401066|NCT03125746|DRUG|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
219401067|NCT03125746|DRUG|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
219401068|NCT01825590|OTHER|Dialysate and serum sodium concentration aligned|
219401069|NCT00461955|PROCEDURE|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
219401070|NCT01893944|OTHER|virtual reality|customized applications using virtual and augmented reality to be developed.
219401071|NCT00835887|DIETARY_SUPPLEMENT|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
219401072|NCT04949880|DEVICE|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
219401073|NCT00003546|DRUG|gemcitabine hydrochloride|given IV
219401074|NCT00003546|RADIATION|radiation therapy|1.8 Gy to tumor bed
219401075|NCT05078333|OTHER|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
219401076|NCT05078333|DEVICE|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
219401077|NCT03279783|DEVICE|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
219401078|NCT04987541|DEVICE|intermittent theta burst stimulation|stimulatory protocol
219401079|NCT02822339|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
219401080|NCT05741723|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
219401081|NCT00943319|DRUG|Busulfan|Daily intravenous dosing to target AVC
219401082|NCT00943319|DRUG|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
219401083|NCT00943319|DRUG|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
219401084|NCT00943319|PROCEDURE|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
219401085|NCT00055822|BIOLOGICAL|oblimersen sodium|
219401086|NCT00055822|DRUG|fluorouracil|
219401087|NCT00055822|DRUG|leucovorin calcium|
219564861|NCT02990078|OTHER|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
219401088|NCT00055822|DRUG|oxaliplatin|
219564862|NCT01740791|DRUG|Velpatasvir|Tablets administered orally
219564863|NCT01740791|DRUG|Placebo|Tablets administered orally
219564864|NCT05070962|OTHER|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
219564865|NCT00877994|BEHAVIORAL|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
219401089|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
219401090|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
219401091|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
219401092|NCT00151060|DRUG|Estramustine|
219401093|NCT00151060|DRUG|Etoposide|
219401094|NCT00151060|DRUG|Paclitaxel|
219564866|NCT00877994|BEHAVIORAL|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
219401095|NCT03097328|DRUG|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
219401096|NCT06103695|DRUG|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
219401097|NCT04804722|DEVICE|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
219401098|NCT02734589|OTHER|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
219564867|NCT02123524|DRUG|Rivaroxaban|
219564868|NCT02123524|DRUG|Placebo|
219564869|NCT02505724|BEHAVIORAL|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
219754738|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
219754739|NCT05115630|DRUG|Cyclophosphamide|Given by IV
219754740|NCT05115630|DRUG|Mesna|Given by IV
219754741|NCT05115630|DRUG|Filgrastim|Given by IV
219754742|NCT05115630|DRUG|Melphalan|Given by IV
219754743|NCT05115630|DRUG|Fludarabine phosphate|Given by IV
219754744|NCT05115630|DRUG|Tacrolimus|Given by IV
219754745|NCT05115630|DRUG|Mycophenolate mofetil|Given by IV
219401099|NCT02734589|OTHER|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
219401100|NCT02734589|OTHER|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
219401101|NCT01798134|DEVICE|TANDEM™|
219401102|NCT02653976|DRUG|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
219401103|NCT02932722|OTHER|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
219401104|NCT02932722|DRUG|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
219401105|NCT02932722|DRUG|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
219401106|NCT02023164|DRUG|JDP-205 Injection|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
219401107|NCT02023164|DRUG|Diphenhydramine|Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
219401108|NCT03272854|OTHER|No intervention performed, the study is observational|
219401109|NCT00883558|DRUG|Insulin Lispro|
219401110|NCT00883558|DRUG|regular human insulin|
219401111|NCT00883558|DRUG|recombinant human hyaluronidase PH20|
219401112|NCT00883558|DRUG|Insulin glargine|
219401113|NCT04772183|DEVICE|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
219401114|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
219401115|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
219754746|NCT05115630|DRUG|Total Body Irradiation One Dose|Given by IV
219754747|NCT02554565|PROCEDURE|Tumor biopsy|Tumor biopsy before treatment
219754748|NCT02554565|PROCEDURE|Blood sampling|Blood sample before, during and after treatment
219564870|NCT02505724|BEHAVIORAL|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
219564871|NCT03245216|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
219564872|NCT03245216|BEHAVIORAL|rest|Seated rest before motor learning
219401116|NCT02436577|DRUG|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
219401117|NCT03284619|DEVICE|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
219401118|NCT03219749|BEHAVIORAL|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
219401119|NCT01598857|DRUG|Blisibimod|
219401120|NCT01598857|DRUG|Placebo|
219401121|NCT00169494|BIOLOGICAL|HPV-16/18 L1/AS04|
219401122|NCT02038296|PROCEDURE|transarterial chemoembolization|
219401123|NCT06552520|DRUG|TQH2722 injection|Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
219564873|NCT03245216|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
219564874|NCT05363579|OTHER|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
219564875|NCT05363579|OTHER|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
219564876|NCT05363579|OTHER|Physio and Tuina therapy|Physiotherapy mixed with Tuina
219564877|NCT00144079|PROCEDURE|external beam radiotherapy|
219564878|NCT04598633|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
219564879|NCT04598633|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
219401124|NCT06552520|DRUG|Placebo of TQH2722 injection|Placebo without drug substance
219401125|NCT06553339|DRUG|Oral HS-10516|Oral HIF-2α inhibitor
219401126|NCT03703375|DRUG|Azacitidine|Azacitidine
219401127|NCT03703375|DRUG|Romidepsin|Romidepsin
219401128|NCT03703375|DRUG|Gemcitabine|Gemcitabine
219401129|NCT05915754|OTHER|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
219401130|NCT05915754|OTHER|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
219401131|NCT00137852|DRUG|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
219401132|NCT00137852|DRUG|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
219401133|NCT00137852|DRUG|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
219401134|NCT00137852|PROCEDURE|Radiation Therapy|5 days a week for 5-6 weeks
219401135|NCT00137852|PROCEDURE|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
219401136|NCT01675011|DEVICE|Embozene® Microspheres|
219401137|NCT01675011|DEVICE|Embosphere®|
219401138|NCT03851276|RADIATION|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
219401139|NCT01815333|DRUG|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
219401140|NCT01815333|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
219401141|NCT05160077|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
219401142|NCT04006899|DEVICE|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
219401143|NCT01336179|PROCEDURE|Salvadora persica|twice daily use, two minutes interval
219401144|NCT01336179|PROCEDURE|Toothbrush|Twice daily use two minutes interval
219401145|NCT01003561|PROCEDURE|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
219401146|NCT01821170|DRUG|Methylphenidate|Patient will take treatment during two months
219401147|NCT01821170|DEVICE|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
219401148|NCT01821170|BEHAVIORAL|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
219401149|NCT01821170|OTHER|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
219401150|NCT00003243|BIOLOGICAL|aldesleukin|
219401151|NCT00003243|BIOLOGICAL|filgrastim|
219564880|NCT03187587|DEVICE|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
219564881|NCT03187587|DRUG|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
219564882|NCT04983342|DEVICE|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
219564883|NCT06300606|DEVICE|NOL monitoring|Prospective observational study to assess pain during regional anesthesia for upper limb orthopedic surgery using NOL monitoring and the Algoplus pain scale
219564884|NCT04756778|PROCEDURE|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
219564885|NCT04362332|DRUG|Chloroquine Sulfate|cluster randomized
219564886|NCT04362332|DRUG|Hydroxychloroquine|cluster randomized
219564887|NCT04362332|OTHER|Standard supportive care|cluster randomized
219564888|NCT01432028|DRUG|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
219564889|NCT01432028|DRUG|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
219564890|NCT05303961|DRUG|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
219564891|NCT05303961|DRUG|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
219564892|NCT05303961|DRUG|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
219564893|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
219564894|NCT05303961|DRUG|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
219564895|NCT05303961|DRUG|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
219564896|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
219564897|NCT06216171|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy
219564898|NCT06216171|RADIATION|image guided radiotherapy without online adaptation|image guided radiotherapy without online adaptation
219401152|NCT00003243|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219401153|NCT00003243|DRUG|cyclophosphamide|
219401154|NCT00003243|DRUG|etoposide|
219564899|NCT00931463|DRUG|raltegravir|400 mg raltegravir tablet taken every 12 hours
219564900|NCT00931463|DRUG|2N(t)RTI|2N(t)RTIs as prescribed
219564901|NCT00931463|DRUG|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
219564902|NCT02802215|DRUG|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
219564903|NCT02802215|DRUG|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
219564904|NCT03285464|OTHER|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
219564905|NCT03327350|DEVICE|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
219564906|NCT03327350|DRUG|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
219564907|NCT03822273|PROCEDURE|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
219754749|NCT02876172|DRUG|MDMA|Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg midomafetamine HCl (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg midomafetamine HCl (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
219754750|NCT02876172|BEHAVIORAL|CBCT|A three-phase, 15-session, manualized treatment from the CBCT manual
219401155|NCT00003243|DRUG|pegylated liposomal doxorubicin hydrochloride|
219401156|NCT04477824|DIAGNOSTIC_TEST|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
219401157|NCT04860284|DRUG|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
219401158|NCT03725995|DRUG|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
219401159|NCT03725995|DRUG|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
219401160|NCT03725995|DRUG|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
219401161|NCT04041076|PROCEDURE|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
219564908|NCT03822273|PROCEDURE|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
219564909|NCT03822273|PROCEDURE|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
219564910|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
219564911|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
219401162|NCT06546124|OTHER|Deep Fascia Dry needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
219401163|NCT06546124|OTHER|Intramuscular Trigger Point Dry Needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
219401164|NCT01151995|OTHER|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
219401165|NCT01151995|OTHER|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
219401166|NCT04066816|OTHER|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
219401167|NCT01133210|DRUG|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
219401168|NCT01133210|OTHER|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
219401169|NCT06128005|BEHAVIORAL|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
219401170|NCT00625365|DRUG|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
219401171|NCT04022811|DRUG|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
219401172|NCT06024772|PROCEDURE|ultiparametric Magnetic Resonance Imaging|Undergo mp-MRI
219401173|NCT06024772|DRUG|Perflutren lipid microsphere|Given IV
219564912|NCT01410760|OTHER|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
219564913|NCT02625376|DIETARY_SUPPLEMENT|Resvega|Dietary supplementation with Resvega BD
219564914|NCT02625376|DIETARY_SUPPLEMENT|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
219564915|NCT02625376|DIETARY_SUPPLEMENT|placebo|Dietary supplementation with a placebo BD
219754751|NCT02876172|BEHAVIORAL|Therapy|Manualized MDMA-assisted therapy
219754752|NCT04221529|DRUG|Atezolizumab|1200 mg i.v. on day 1 of each cycle
219401174|NCT06024772|PROCEDURE|Transrectal Ultrasound|Undergo transrectal mp-US
219401175|NCT06024772|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsies
219401176|NCT06186882|BEHAVIORAL|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
219401177|NCT02673593|DRUG|DS102|
219401178|NCT02673593|DRUG|Placebo|
219754753|NCT05643495|DRUG|VX-864|Tablets for oral administration.
219401179|NCT06424873|RADIATION|PET/CT with FDG or FES|The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).
219401180|NCT05149794|OTHER|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
219401181|NCT02215421|BEHAVIORAL|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
219401182|NCT01622920|OTHER|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
219401183|NCT02969317|DRUG|Tiotropium|Fixed dose combination
219401184|NCT02969317|DRUG|Olodaterol|Fixed dose combination
219401185|NCT04417777|GENETIC|Blood Test|Blood analysis
219401186|NCT04820452|BIOLOGICAL|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
219401187|NCT04820452|BIOLOGICAL|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
219401188|NCT04820452|DRUG|Aflibercept|Intraocular injection
219401189|NCT05889702|BEHAVIORAL|KATR Linkage Strategy|"The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs."
219401190|NCT00682825|BEHAVIORAL|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
219401191|NCT00682825|BEHAVIORAL|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
219401192|NCT03652415|DEVICE|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
219401193|NCT01279135|RADIATION|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
219401194|NCT01279135|RADIATION|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
219401195|NCT00491114|DRUG|Gemcitabine|
219401196|NCT05552378|DEVICE|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
219401197|NCT03845036|BEHAVIORAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
219401198|NCT03845036|BEHAVIORAL|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
219401199|NCT04421196|OTHER|Exclusion of opioid analgesics|The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
219401200|NCT01966562|BEHAVIORAL|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
219401201|NCT01966562|BEHAVIORAL|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
219401202|NCT06224348|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
219401203|NCT06224348|DRUG|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
219401204|NCT06224348|DRUG|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
219401205|NCT06224348|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
219401206|NCT01234402|BIOLOGICAL|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
219401207|NCT01234402|BIOLOGICAL|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
219401208|NCT01234402|DRUG|Capecitabine|"1000 mg/m\^2 orally~Twice a day for 14 days"
219401209|NCT06473623|DEVICE|vagus nerve stimulation|Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS)
219401210|NCT04283890|DRUG|Ipilimumab and nivolumab|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
219754754|NCT00791635|OTHER|Quality-of-Life Assessment|Ancillary studies
219754755|NCT00791635|OTHER|Questionnaire Administration|Complete questionnaires
219189470|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
219401211|NCT04283890|DRUG|Melphalan chemosaturation via percutaneous hepatic perfusion|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
219401212|NCT05401877|PROCEDURE|therapies for breast cancer|the type of tumor removal surgery, combined therapy
219401213|NCT04212494|PROCEDURE|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
219401214|NCT04212494|PROCEDURE|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
219401215|NCT04655105|DEVICE|root canal rotary files|post operative pain evaluation using different rotary file system
219401216|NCT00385268|DRUG|acamprosate|1998 mg/dau fpr 8 weeks
219401217|NCT00385268|DRUG|placebo|placebo pills
219401218|NCT04770337|DEVICE|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
219401219|NCT04770337|DEVICE|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
219401220|NCT04156750|DRUG|LY3556050|Administered orally.
219401221|NCT04156750|DRUG|Placebo|Administered orally.
219401222|NCT04156750|DRUG|Iohexol|Administered IV.
219401223|NCT04156750|DRUG|Metformin|Administered orally.
219401224|NCT01975779|DRUG|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
219401225|NCT01975779|DRUG|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
219401226|NCT01975779|DRUG|Cohort B1: Lu AE58054|Two single oral doses 60 mg with \>=7 days washout.
219401227|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
219401228|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
219401229|NCT02173496|OTHER|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
219401230|NCT02710266|DRUG|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
219401231|NCT02710266|DRUG|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
219401232|NCT02710266|DRUG|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
219401233|NCT04713566|OTHER|oral rinces|natural and commercial oral rinses were compared for efficacy
219401234|NCT02389816|DRUG|Placebo|Placebo tablets
219401235|NCT02389816|DRUG|Vortioxetine|Vortioxetine tablets
219754756|NCT02257528|OTHER|Laboratory Biomarker Analysis|Correlative studies
219401236|NCT02417233|BEHAVIORAL|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
219401237|NCT02417233|BEHAVIORAL|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
219401238|NCT06367868|PROCEDURE|After 5 ml CSF Drainage|Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
219401239|NCT04929262|BEHAVIORAL|Supporting Anxious Youth: Strategies for Caregivers|The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
219401240|NCT00757939|OTHER|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
219401241|NCT00757939|OTHER|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
219401242|NCT01387295|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
219401243|NCT04746612|DRUG|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
219401244|NCT01847664|DRUG|Rifamycin SV-MMX® 400 mg b.i.d.|
219401245|NCT01847664|DRUG|Rifamycin SV-MMX® 600 mg t.i.d.|
219401246|NCT01847664|DRUG|Rifamycin SV-MMX® Placebo|
219401247|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
219754757|NCT02257528|BIOLOGICAL|Nivolumab|Given IV
219754758|NCT04765397|PROCEDURE|Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound|During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
219401248|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
219564916|NCT03170869|DEVICE|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
219564917|NCT00116480|DRUG|Misoprostol|600 mcg of sublingual misoprostol
219564918|NCT06165692|BIOLOGICAL|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
219564919|NCT02064140|DRUG|Rocuronium|
219564920|NCT03884725|DRUG|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
219564921|NCT03884725|OTHER|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
219564922|NCT05337644|DRUG|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
219564923|NCT04608201|DRUG|Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|"Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)"
219564924|NCT04608201|DRUG|Placebo of NICOTINE Transdermal patch|Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
219401249|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
219564925|NCT05371639|DRUG|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
219564926|NCT05371639|DRUG|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
219564927|NCT05678517|DRUG|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
219564928|NCT02421016|DEVICE|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
219564929|NCT02421016|DEVICE|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
219401250|NCT04336046|DRUG|Bupivacaine|bupivacaine
219564930|NCT04346940|OTHER|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
219564931|NCT04346940|OTHER|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
219564932|NCT04743817|DEVICE|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
219564933|NCT01601938|DIETARY_SUPPLEMENT|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
219564934|NCT01601938|DIETARY_SUPPLEMENT|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
219401251|NCT03392155|BEHAVIORAL|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
219401252|NCT02985450|BIOLOGICAL|Engerix-B|Hepatitis B Vaccine
219401253|NCT00816907|DRUG|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
219401254|NCT00816907|DRUG|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
219564935|NCT05623852|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
219564936|NCT06465875|OTHER|Reading a book|Individuals in the intervention group will be read a storybook for three nights.
219401255|NCT00431847|PROCEDURE|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
219401256|NCT00431847|PROCEDURE|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
219564937|NCT02354807|DRUG|Mirabegron|One-time dose of 100mg of Mirabegron
219564938|NCT02354807|OTHER|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
219401257|NCT02524860|DEVICE|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
219401258|NCT01469013|DRUG|Placebo|
219401259|NCT01469013|DRUG|Baricitinib|
219401260|NCT01469013|DRUG|Baricitinib|
219401261|NCT01469013|DRUG|Baricitinib|
219401262|NCT01469013|DRUG|Methotrexate|Administered orally as background therapy
219401263|NCT04081935|DEVICE|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
219401264|NCT01350349|BEHAVIORAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
219401265|NCT01350349|BEHAVIORAL|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
219401266|NCT04686006|DRUG|Potassium Iodide|
219401267|NCT00002663|BIOLOGICAL|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
219401268|NCT02040194|DRUG|AM-101|AM-101 gel for intratympanic injection
219401269|NCT02040194|DRUG|Placebo|Placebo gel for intratympanic injection
219564939|NCT06030115|OTHER|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
219564940|NCT01321437|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219564941|NCT01321437|OTHER|laboratory biomarker analysis|Correlative studies
219564942|NCT01321437|DRUG|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
219564943|NCT01321437|OTHER|pharmacological study|Correlative studies
219401270|NCT01351766|DRUG|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
219401271|NCT00002250|DRUG|CD4-IgG|
219401272|NCT03085706|BIOLOGICAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
219401273|NCT02000570|PROCEDURE|Sitting position (neurosurgery)|
219401274|NCT03106493|OTHER|None (observational)|None (observational)
219401275|NCT03721185|COMBINATION_PRODUCT|Dr.K. Treatment|Overweight and obesity treatment response
219401276|NCT00148733|DRUG|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
219401277|NCT01603641|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
219401278|NCT05889494|OTHER|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
219564944|NCT05442437|BIOLOGICAL|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
219754759|NCT03756961|DRUG|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
219754760|NCT03756961|BEHAVIORAL|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
219754761|NCT03756961|DRUG|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
219401279|NCT05889494|OTHER|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
219401280|NCT04131309|DRUG|Daratumumab|As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
219401281|NCT04131309|DRUG|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
219401282|NCT04131309|DRUG|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
219401283|NCT02255851|DEVICE|SENTINEL (Cerebral Protection System)|
219401284|NCT00000461|DRUG|pravastatin|
219401285|NCT00000461|DRUG|niacin|
219401286|NCT00000461|DRUG|cholestyramine|
219401287|NCT00000461|DRUG|gemfibrozil|
219401288|NCT00000461|DRUG|fatty acids, omega-3|
219401289|NCT06534346|DRUG|15 mg DA-302168S tablet|"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
219401290|NCT03161678|DRUG|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
219401291|NCT03161678|DRUG|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
219401292|NCT02110134|DEVICE|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
219401293|NCT02110134|OTHER|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
219401294|NCT03968445|DRUG|[18F]DPA-714-PET/MRI|\[18F\]DPA-714-PET/MRI
219401295|NCT05782101|DIAGNOSTIC_TEST|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
219564945|NCT01966809|DRUG|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
219564946|NCT04234061|COMBINATION_PRODUCT|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
219564947|NCT03668951|DRUG|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
219564948|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
219564949|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
219401296|NCT01154972|PROCEDURE|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
219401297|NCT04141644|DRUG|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
219401298|NCT04141644|DRUG|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
219401299|NCT01895010|DEVICE|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
219564950|NCT06222229|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
219564951|NCT06222229|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended"
219564952|NCT00206596|DRUG|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
219564953|NCT00206596|DRUG|Placebo|Once daily via subcutaneous injection for up 22 weeks
219564954|NCT03420768|DRUG|BMS-986263|Administered by intravenous (IV) infusion
219564955|NCT03420768|OTHER|Placebo|Administered by intravenous (IV) infusion
219564956|NCT05044494|PROCEDURE|non-prompt surgery|
219564957|NCT01405274|OTHER|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
219564958|NCT00083694|DRUG|Thalidomide|
219564959|NCT00531362|DRUG|Plain aspirin|Plain aspirin 75 mg or 150 mg
219564960|NCT02969876|DRUG|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
219564961|NCT02675374|DRUG|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
219564962|NCT02675374|DRUG|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
219564963|NCT00637091|DRUG|Cetuximab, irinotecan|cetuximab, irinotecan
219564964|NCT01575262|BEHAVIORAL|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
219401300|NCT01895010|DRUG|tropisetron|only tropisetron 6mg before TACE
219401301|NCT05632497|BIOLOGICAL|Stool and blood samples|Stool and blood samples
219401302|NCT04859127|OTHER|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
219401303|NCT03415074|BEHAVIORAL|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
219401304|NCT00814840|DEVICE|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
219401305|NCT00814840|DEVICE|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
219401306|NCT03962998|DRUG|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
219401307|NCT03962998|DRUG|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
219401308|NCT03919253|COMBINATION_PRODUCT|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
219401309|NCT01270646|DEVICE|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
219401310|NCT06401655|BEHAVIORAL|Financial Coaching for People living with Acquired Brain Injury (FC-ABI)|This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
219401311|NCT04933279|DIETARY_SUPPLEMENT|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
219401312|NCT04933279|DIETARY_SUPPLEMENT|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
219401313|NCT02005601|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
219401314|NCT02005601|DRUG|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
219401315|NCT06589713|DRUG|Enpatoran|Participants will receive a single oral dose of enpataron tablets once daily.
219401316|NCT04040712|OTHER|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
219401317|NCT04040712|OTHER|Sham FMT|Sham fecal microbiota transplantation
219401318|NCT02890329|DRUG|Decitabine|Given IV
219401319|NCT02890329|BIOLOGICAL|Ipilimumab|Given IV
219401320|NCT02890199|DRUG|Bupivacaine liposomal|
219401321|NCT02890199|DRUG|Lidocaine|
219401322|NCT03014219|DRUG|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
219401323|NCT01052987|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
219401324|NCT01052987|DRUG|Allopurinol|Allopurinol tablets 300 mg, QD
219401325|NCT01052987|DRUG|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
219401326|NCT01052987|DRUG|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
219401327|NCT01052987|DRUG|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
219401328|NCT02583789|DRUG|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
219401329|NCT02583789|DRUG|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
219401330|NCT02041351|DRUG|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
219401331|NCT00146705|PROCEDURE|blood samples are taken once|
219401332|NCT05801926|DEVICE|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
219002091|NCT00825591|DIETARY_SUPPLEMENT|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
219002092|NCT00825591|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration before bed. 6 week duration.
219401333|NCT03404414|DRUG|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
219401334|NCT01146067|DRUG|Rivastigmine|Rivastigmine capsules 1.5 mg
219401335|NCT03471091|DEVICE|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
219401336|NCT05336968|DRUG|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
219401337|NCT03339648|BEHAVIORAL|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
219401338|NCT01669369|DRUG|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
219401339|NCT01669369|DRUG|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
219401340|NCT02053220|BIOLOGICAL|Colo-Ad1|Oncolytic virus
219564965|NCT01575262|BEHAVIORAL|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
219564966|NCT06026631|PROCEDURE|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
219564967|NCT02090231|DEVICE|rTMS, Magstim Rapid2|5 Hz rTMS
219002093|NCT02315001|DRUG|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
219002094|NCT02315001|OTHER|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
219401341|NCT00326105|DRUG|Quetiapine fumarate|
219401342|NCT02607969|OTHER|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
219401343|NCT04841382|OTHER|Supporting information.|CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.
219401344|NCT00170248|DEVICE|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
219401345|NCT04611295|PROCEDURE|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
219564968|NCT05964673|DEVICE|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
219564969|NCT02887924|DEVICE|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
219564970|NCT00760786|DRUG|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
219564971|NCT00760786|DRUG|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
219564972|NCT00760786|DRUG|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
219564973|NCT00760786|DRUG|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
219564974|NCT01705002|DRUG|Promitil|2 mg/kg dose IV
219564975|NCT01705002|DRUG|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
219564976|NCT01705002|DRUG|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
219564977|NCT01236417|BEHAVIORAL|Exercising block|Exercising for 8 weeks using an elastic band
219002095|NCT02918175|BEHAVIORAL|mHealth|Personalized step count feedback and medication teaching tool.
219002096|NCT01890356|DEVICE|Transcranial electrical stimulation|
219002097|NCT03020160|DRUG|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
219189471|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
219002098|NCT04435860|OTHER|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
219189472|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
219189473|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
219189474|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
219189475|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
219189476|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
219189477|NCT02759172|BEHAVIORAL|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
219401346|NCT04848116|DRUG|Nivolumab|Nivolumab is an investigational drug in this study.
219401347|NCT04848116|DRUG|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
219401348|NCT04962321|BEHAVIORAL|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
219401349|NCT00002118|DRUG|Zalcitabine|
219401350|NCT05930249|BEHAVIORAL|Personalized multidomain intervention|"1. Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~2. Shared decision-making on risk factor of stroke between doctors and patients~3. Social support by grouping patients online to ensure close interaction with other patients in the same arm"
219401351|NCT02564159|OTHER|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"* Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
219401352|NCT01912040|DRUG|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
219401353|NCT00984230|OTHER|BSF|feeding amount according to individual baby need
219401354|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
219401355|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
219401356|NCT03940573|DEVICE|Eclipse Insert|Rectal Control System.
219401357|NCT06220344|BIOLOGICAL|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
219401358|NCT06220344|DRUG|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
219401359|NCT01347567|OTHER|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
219564978|NCT01083238|DRUG|AZD5069|120mg single oral dose
219002099|NCT04435860|OTHER|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
219002100|NCT04435860|OTHER|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
219002101|NCT04435860|OTHER|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
219002102|NCT04435860|OTHER|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
219002103|NCT04435860|OTHER|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
219002104|NCT04435860|OTHER|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
219002105|NCT04435860|OTHER|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
219002106|NCT04435860|OTHER|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
219401360|NCT01253460|DRUG|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
219401361|NCT01253460|DRUG|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
219401362|NCT01253460|DRUG|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
219401363|NCT02113748|OTHER|Downhill walking training|Walk on a treadmill with a negative inclination.
219401364|NCT02113748|OTHER|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
219401365|NCT06274346|OTHER|Multiangular Isometric exercise|already were described in arm descriptions
219401366|NCT01212328|OTHER|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
219401367|NCT01212328|OTHER|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
219401368|NCT00754429|DRUG|losartan|losartan 50mg qd for 30 weeks.
219401369|NCT00754429|DRUG|amlodipine|amlodipine 5 mg q.d for 30 weeks.
219401370|NCT02856789|OTHER|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
219401371|NCT02856789|OTHER|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
219401372|NCT02856789|OTHER|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
219401373|NCT02856789|OTHER|Specialized hemostasis tests|Coagulation factors
219401374|NCT02165540|OTHER|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
219401375|NCT00894530|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
219401376|NCT00894530|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
219401377|NCT03005782|DRUG|REGN3767|
219401378|NCT03005782|DRUG|cemiplimab|
219401379|NCT05138120|BEHAVIORAL|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
219401380|NCT06309810|RADIATION|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
219401381|NCT02644083|DRUG|Dimethyl fumarate|
219401382|NCT00443430|DRUG|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
219401383|NCT00443430|DRUG|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
219401384|NCT04954469|BIOLOGICAL|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
219401385|NCT04067531|DRUG|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
219564979|NCT02091349|OTHER|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
219564980|NCT02091349|OTHER|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
219564981|NCT03743090|DIAGNOSTIC_TEST|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
219564982|NCT04674709|DRUG|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
219401386|NCT03065673|PROCEDURE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
219401387|NCT03065673|PROCEDURE|Placebo gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
219401388|NCT04621123|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
219401389|NCT04621123|OTHER|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
219564983|NCT04674709|DRUG|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
219564984|NCT04674709|DRUG|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
219564985|NCT04674709|DRUG|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
219564986|NCT02839993|DEVICE|tDCS|
219564987|NCT02839993|BEHAVIORAL|training|
219564988|NCT02539368|DRUG|CT-P13|biosimilar infliximab
219564989|NCT02539368|DRUG|Remicade|infliximab
219564990|NCT03558139|DRUG|Magrolimab|Administered intravenously
219564991|NCT03558139|DRUG|Avelumab|Administered intravenously
219564992|NCT02752802|DEVICE|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
219564993|NCT02963584|OTHER|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
219564994|NCT03573817|DRUG|Revefenacin|Revefenacin is administered via a nebulizer.
219564995|NCT03573817|DRUG|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
219401390|NCT05941884|DIAGNOSTIC_TEST|Immunohistochemistry staining,|"Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions."
219564996|NCT03573817|DRUG|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
219564997|NCT04305990|DEVICE|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
219564998|NCT04305990|DEVICE|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
219564999|NCT05899920|DIAGNOSTIC_TEST|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
219565000|NCT01953094|PROCEDURE|Screening Anal Pap Smear - No High Resolution Anoscopy|
219565001|NCT01953094|PROCEDURE|Screening Anal Pap Smear - With High Resolution Anoscopy|
219565002|NCT02502331|BIOLOGICAL|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
219565003|NCT02502331|BIOLOGICAL|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
219565004|NCT00400582|DRUG|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
219565005|NCT02244931|DEVICE|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
219565006|NCT02244931|DEVICE|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
219565007|NCT02244931|DEVICE|Standard manual Wheelchair|Standard manual Wheelchair
219565008|NCT01275157|DRUG|LY2452473|Administered orally as a liquid suspension
219565009|NCT02013531|DRUG|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
219565010|NCT04476186|DRUG|Acyclovir|oral syrp
219565011|NCT04476186|DRUG|KOH 10 %|solution for local application
219565012|NCT04307472|BEHAVIORAL|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
219565013|NCT04307472|BEHAVIORAL|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
219565014|NCT05454358|DRUG|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
219565015|NCT05827640|OTHER|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
219565016|NCT00932217|DRUG|filgrastim|subcutaneous filgrastim administration
219565017|NCT00932217|DRUG|lenograstim|subcutaneous lenograstim administration
219565018|NCT01567241|OTHER|clinical hypnosis or relaxation music|25 minute tape recording
219565019|NCT00005075|PROCEDURE|high-intensity focused ultrasound ablation|
219565020|NCT00351286|DRUG|L-citrulline tablets, 1000 mg|
219565021|NCT00351286|DRUG|Placebo tablets matching L-citrulline tablets|
219565022|NCT00351286|DRUG|Background simvastatin at a stable dose of 40 mg qHS|
219565023|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
219565024|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
219565025|NCT00193973|DRUG|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
219565026|NCT00193973|RADIATION|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
219401391|NCT05941884|DIAGNOSTIC_TEST|microscopic examination of urine|"Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
219401392|NCT02229864|DEVICE|Coronary artery stenting: Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm"
219401393|NCT00002442|DRUG|Indinavir sulfate|
219401394|NCT00002442|DRUG|Nelfinavir mesylate|
219565027|NCT05118477|DEVICE|Ambulatory monitoring system|Patients will use AMS.
219565028|NCT05118477|DEVICE|Active alerting system|Clinical staff alerted if AMS detects deterioration
219565029|NCT03705871|DEVICE|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
219565030|NCT03705871|DEVICE|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
219565031|NCT04462744|OTHER|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
219565032|NCT02604576|DRUG|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
219565033|NCT02604576|DRUG|Bromopride 10 mg|Bromopride 10 mg
219565034|NCT02400476|DRUG|Neratinib|
219565035|NCT02400476|DRUG|Loperamide|
219565036|NCT02400476|DRUG|Colestipol|2 g twice daily with or without food for one 28 day cycle
219565037|NCT02400476|DRUG|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
219565038|NCT00003862|DRUG|cisplatin|
219565039|NCT00003862|DRUG|fluorouracil|
219565040|NCT00003862|DRUG|leucovorin calcium|
219189478|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
219565041|NCT00003862|DRUG|paclitaxel|
219401395|NCT00002442|DRUG|Lamivudine|
219401396|NCT00002442|DRUG|Stavudine|
219401397|NCT01227915|DRUG|Tobracort|tobramycin 0.3% + dexamethasone 1%
219401398|NCT01227915|DRUG|Tobradex|tobramycin 0.3% + dexamethasone 1%
219565042|NCT00003862|PROCEDURE|conventional surgery|
219401399|NCT05527704|DRUG|Salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
219401400|NCT05527704|DRUG|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
219401401|NCT01581112|BIOLOGICAL|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
219401402|NCT06512038|RADIATION|DEXA Scan|If the participant consents to take part in the trial, they will have an additional DEXA scan.
219401403|NCT00000637|DRUG|Zidovudine|
219401404|NCT00000637|DRUG|Didanosine|
219401405|NCT00564707|BEHAVIORAL|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
219401406|NCT00564707|PROCEDURE|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
219401407|NCT03435653|OTHER|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
219401408|NCT03435653|OTHER|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
219565043|NCT00003862|PROCEDURE|neoadjuvant therapy|
219565044|NCT00003862|RADIATION|radiation therapy|
219565045|NCT03396874|DRUG|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
219565046|NCT02803931|DEVICE|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
219565047|NCT02803931|DEVICE|12-lead ECG|
219565048|NCT06406322|OTHER|PFMT|Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
219565049|NCT06406322|OTHER|Aerobic Exercise|Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
219565050|NCT06678165|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
219565051|NCT04906330|DIAGNOSTIC_TEST|Oncoliq: test for early breast cancer detection.|Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
219565052|NCT05361486|OTHER|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
219401409|NCT00876980|DEVICE|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
219401410|NCT06024330|DIAGNOSTIC_TEST|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
219401411|NCT06024330|DIAGNOSTIC_TEST|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
219002107|NCT04435860|OTHER|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
219002108|NCT04435860|OTHER|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
219002109|NCT04435860|OTHER|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
219002110|NCT04435860|OTHER|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
219002111|NCT04435860|OTHER|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
219002112|NCT04435860|OTHER|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
219002113|NCT04435860|OTHER|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
219002114|NCT04435860|OTHER|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
219002115|NCT04435860|OTHER|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
219002116|NCT04435860|OTHER|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
219002117|NCT03048968|PROCEDURE|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
219002118|NCT03048968|PROCEDURE|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
219002119|NCT03048968|DEVICE|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
219002120|NCT03048968|DEVICE|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
219002121|NCT01513473|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
219002122|NCT01513473|DRUG|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
219002123|NCT01513473|DRUG|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
219189479|NCT05322239|DEVICE|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
219189480|NCT05322239|DEVICE|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
219401412|NCT06024330|DIAGNOSTIC_TEST|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
219401413|NCT05868967|DRUG|[14C]DWP14012|Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.
219401414|NCT03528044|PROCEDURE|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
219401415|NCT06171880|DRUG|JLP-1901|administration of JLP-1901
219401416|NCT06171880|DRUG|JC-001(active comparator)|administration of JC-001(tenofovir)
219401417|NCT02645448|OTHER|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
219401418|NCT05022004|DRUG|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
219401419|NCT05022004|DRUG|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
219401420|NCT02084134|DRUG|hydrocortisone|100mg at the time of surgery
219401421|NCT02084134|DRUG|dexamethasone|0.5mg every 6 hours for a total of four doses
219401422|NCT02456116|DEVICE|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
219401423|NCT02456116|DEVICE|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
219401424|NCT02456116|OTHER|PCA/NSAID|standard boli of morphine by pressing a button of PCA
219401425|NCT04185324|BEHAVIORAL|Standard zippering vest|Standard zippering vest used to teach zippering
219401426|NCT04185324|BEHAVIORAL|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
219401427|NCT02385461|DRUG|Low Molecular Weight Heparins (LMWHs)|
219401428|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
219401429|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
219401430|NCT05474040|DRUG|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
219401431|NCT04578717|PROCEDURE|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
219401432|NCT04578717|PROCEDURE|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
219401433|NCT04578717|BIOLOGICAL|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
219401434|NCT04559906|OTHER|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
219565053|NCT05361486|OTHER|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
219565054|NCT05361486|OTHER|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
219565055|NCT05361486|DIAGNOSTIC_TEST|G6PD testing|G6PD test after Malaria Vivax diagnosis
219565056|NCT05361486|DRUG|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
219565057|NCT05361486|DRUG|Primaquine|0.5mg/kg/7 days
219565058|NCT05361486|OTHER|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
219565059|NCT03463018|DIETARY_SUPPLEMENT|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
219565060|NCT03463018|DIETARY_SUPPLEMENT|Placebo|Placebo tablet containing matching excipients to the active intervention
219565061|NCT03788135|BEHAVIORAL|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
219565062|NCT01010035|OTHER|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
219565063|NCT00444821|DEVICE|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
219565064|NCT01739413|PROCEDURE|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
219565065|NCT02917252|OTHER|3-hydroxybuturate|Drink of ketone bodies
219565066|NCT02917252|OTHER|Placebo|Drink of saline
219754762|NCT03756961|DRUG|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
219401435|NCT04559906|OTHER|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
219401436|NCT05251935|OTHER|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
219401437|NCT05251935|COMBINATION_PRODUCT|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
219401438|NCT01629485|BEHAVIORAL|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
219401439|NCT01629485|BEHAVIORAL|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
219401440|NCT01629485|BEHAVIORAL|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
219401441|NCT00374907|DRUG|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
219401442|NCT00374907|DRUG|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
219401443|NCT00374907|DRUG|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
219401444|NCT00374907|DRUG|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
219401445|NCT03558932|DIAGNOSTIC_TEST|pleural biopsy|diagnostic sampling
219401446|NCT00002677|DRUG|chemotherapy|
219401447|NCT00002677|DRUG|tributyrin|
219401448|NCT06361277|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
219401449|NCT04736511|OTHER|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
219401450|NCT04736511|OTHER|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
219401451|NCT04736511|OTHER|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
219401452|NCT04736511|OTHER|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
219401453|NCT03262493|DEVICE|Interventional Group|Use of the feeding tube attachment device (FTAD).
219401454|NCT06069557|OTHER|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
219401455|NCT01512394|PROCEDURE|standard bowel prep|standard bowel prep
219401456|NCT01512394|PROCEDURE|no bowel prep|no bowel prep
219401457|NCT06554626|DRUG|Dexamethasone|Glucocorticoids
219401458|NCT06554626|DRUG|Blinatumomab|Bi-specific anti CD19/CD3 antibody
219754763|NCT03756961|DEVICE|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
219754764|NCT03756961|DRUG|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
219754765|NCT03756961|DRUG|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
219754766|NCT03756961|DRUG|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
219401459|NCT06554626|DRUG|Venetoclax|BCL-2 inhibotor
219754767|NCT03756961|DRUG|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
219189481|NCT03142802|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~   \- Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~   \- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~   * Patient goes off study"
219401460|NCT06554626|DRUG|Inotuzumab ozogamicin|a humanized monoclonal antibody-drug conjugate targeting CD22
219401461|NCT06554626|DRUG|Methotrexate|antifolate antineoplastic drug
219401462|NCT06554626|DRUG|Pegaspargase|antitumor drug
219401463|NCT06554626|DRUG|Cytarabine|Pyrimidine, antimetabolites
219401464|NCT03395340|DRUG|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
219401465|NCT03395340|DRUG|vehicle cream|Matching vehicle cream applied as a thin film
219189482|NCT02773810|OTHER|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
219189483|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
219189484|NCT00696111|DRUG|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
219189485|NCT06065215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
219189486|NCT06065215|DIAGNOSTIC_TEST|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
219189487|NCT06065215|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
219401466|NCT04691596|BEHAVIORAL|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
219401467|NCT04691596|BEHAVIORAL|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
219401468|NCT04691596|BEHAVIORAL|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
219401469|NCT04691596|BEHAVIORAL|App use instructions|Received a basic training with the StepUp app
219401470|NCT01293396|DRUG|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
219401471|NCT01293396|DRUG|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
219401472|NCT01293396|DRUG|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
219401473|NCT05399758|DEVICE|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
219401474|NCT04790006|DRUG|TG103|Administered SC
219401475|NCT04790006|DRUG|Placebo|Administered SC
219401476|NCT01266798|BEHAVIORAL|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation"
219401477|NCT00354549|DRUG|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
219401478|NCT00354549|DRUG|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219401479|NCT03230175|BIOLOGICAL|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
219002124|NCT02414984|BIOLOGICAL|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
219565067|NCT06533371|DIAGNOSTIC_TEST|Relationship between lung ultrasound and computed tomographic scan|"Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems."
219754768|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
219754769|NCT06813261|OTHER|GLYLO|"commercially available combination of glycation-lowering compounds that are GRAS (generally recognized as safe) by the FDA.~GLYLO Ingredients Benfotiamine (fat-soluble Vitamin B1 derivative)-100mg Vitamin B6 (Pyridoxine Hydrochloride)-50mg Nicotinamide-200mg Alpha Lipoic Acid-150mg Piperine-10mg~For the first week, one GLYLO capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of GLYLO daily, one capsule after the first meal and a second capsule after the last meal."
219754770|NCT06813261|OTHER|Placebo|"Visually matched capsule with microcrystalline cellulose as an inert ingredient.~For the first week, one placebo capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of the placebo daily, one capsule after the first meal and a second capsule after the last meal."
219754771|NCT06272383|DRUG|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
219754772|NCT06589999|DIAGNOSTIC_TEST|MP2RAGE sequence|Addition of MRI sequence MP2RAGE
219754773|NCT05994248|DEVICE|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
219189488|NCT06428786|OTHER|Female Sexual Function Index|As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
219189489|NCT06289166|DRUG|STSP-0601 for Injection|A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
219401480|NCT03230175|PROCEDURE|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
219565068|NCT00724620|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
219754774|NCT05994248|DEVICE|Marlex|Use of non-absorbable mesh in umbilical hernia repair
219754775|NCT02831634|PROCEDURE|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
219754776|NCT06667427|PROCEDURE|Nerve transfer techniques|Participants will undergo facial nerve reconstruction using nerve transfer techniques
219754777|NCT06656442|DRUG|Trimetazidine|an anti-ischemic medication.
219754778|NCT06204484|OTHER|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
219754779|NCT06204484|OTHER|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
219754780|NCT06204484|OTHER|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
219754781|NCT04885530|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
219754782|NCT04885530|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
219754783|NCT04885530|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
219189490|NCT02433379|DEVICE|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
219189491|NCT05624125|OTHER|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
219189492|NCT05624125|OTHER|Placebo|Two 70 ml placebo drinks daily for 4 months.
219401481|NCT03230175|DRUG|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
219401482|NCT03230175|DEVICE|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
219401483|NCT00854763|DRUG|olmesartan|olmesartan
219401484|NCT00607646|DRUG|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
219401485|NCT00607646|DRUG|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
219401486|NCT02553720|OTHER|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
219401487|NCT02553720|OTHER|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
219401488|NCT04187222|OTHER|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
219401489|NCT04187222|BIOLOGICAL|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
219401490|NCT03037957|DEVICE|ARIES Group A Strep Assay|
219401491|NCT02588274|DEVICE|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
219401492|NCT02588274|DEVICE|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
219401493|NCT01095250|DRUG|AIN457|
219401494|NCT01095250|DRUG|AIN457|
219401495|NCT01095250|DRUG|AIN457|
219401496|NCT01095250|DRUG|Placebo|
219401497|NCT00003771|BIOLOGICAL|therapeutic estradiol|
219401498|NCT00003771|DRUG|norethindrone acetate|
219401499|NCT02013193|DEVICE|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
219565069|NCT00724620|DRUG|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
219565070|NCT03337217|PROCEDURE|Position during colonoscopy|Position during colonoscopy
219565071|NCT00108576|DRUG|Divalproex|anticonvulsant; mood stabilizer
219565072|NCT00108576|OTHER|placebo|Look-a-like placebo
219565073|NCT03118219|OTHER|Positive adjustment coping intervention|see arm description
219565074|NCT03118219|OTHER|Brainteaser|see arm description
219002125|NCT03900078|OTHER|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
219401500|NCT02013193|DEVICE|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
219401501|NCT01323673|DRUG|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
219401502|NCT01323673|DRUG|Vehicle / Placebo|2 times a day, 14 total days of study treatment
219401503|NCT04598165|BEHAVIORAL|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
219401504|NCT00763204|DRUG|AN2728 Cream, 2%|
219401505|NCT00763204|DRUG|AN2728 Cream, 1%|
219401506|NCT00763204|DRUG|AN2728 Cream, 0.3%|
219401507|NCT00763204|DRUG|AN2728 Cream Vehicle|
219401508|NCT00763204|DRUG|Betnesol®-V Creme, 0.1%|
219565075|NCT00612677|DRUG|Oxaliplatin|Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
219565076|NCT00612677|DRUG|Pemetrexed|Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
219565077|NCT03417830|DRUG|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
219565078|NCT03417830|DRUG|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
219565079|NCT03417830|DRUG|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
219565080|NCT01415050|DEVICE|Whole body vibration|15 times WBV
219565081|NCT03359837|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219565082|NCT03359837|DRUG|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219565083|NCT03359837|DRUG|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219565084|NCT03359837|DRUG|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
219565085|NCT03359837|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
219565086|NCT03359837|DRUG|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
219565087|NCT05197829|DEVICE|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
219565088|NCT05197829|OTHER|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
219401509|NCT01142986|BEHAVIORAL|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
219401510|NCT01142986|BEHAVIORAL|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
219401511|NCT02379923|DEVICE|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
219401512|NCT05148208|DEVICE|Creatine supplementation to dialysate|Creatine supplementation to dialysate
219401513|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
219401514|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
219401515|NCT02151409|DRUG|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
219401516|NCT00100373|DRUG|RSV challenge material|
219401517|NCT04005092|DEVICE|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
219401518|NCT00005022|DRUG|cisplatin|
219401519|NCT00005022|DRUG|etoposide|
219401520|NCT00005022|RADIATION|radiation therapy|
219401521|NCT00156546|DRUG|antibiotic to reduce the recurrence of infection|
219401522|NCT03679208|DEVICE|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
219002126|NCT03900078|OTHER|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
219401523|NCT03679208|DEVICE|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
219401524|NCT04458038|OTHER|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
219401525|NCT00426751|DRUG|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
219401526|NCT00426751|DRUG|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
219401527|NCT00400933|BEHAVIORAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
219401528|NCT03682796|DRUG|TRPH-222|administered by IV, 21-day Cycle
219401529|NCT01200511|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219401530|NCT04708964|DRUG|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
219401531|NCT04708964|DRUG|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
219401532|NCT01554202|BEHAVIORAL|assessment of memory|
219401533|NCT01554202|BIOLOGICAL|circulating tPA dosage|
219565089|NCT04615845|BIOLOGICAL|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
219565090|NCT05022563|DRUG|Parenteral anticoagulant|Parenteral anticoagulant only
219565091|NCT05022563|DRUG|Warfarin|Warfarin-based
219565092|NCT05022563|DRUG|Apixaban|Apixaban
219565093|NCT05022563|DRUG|Rivaroxaban|Rivaroxaban
219565094|NCT05022563|DRUG|Dabigatran|Dabigatran
219002127|NCT06314542|OTHER|relaxing eligibility criteria|Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data
219401534|NCT01554202|GENETIC|ApoE4|
219401535|NCT01554202|OTHER|Brain imaging examination MRI and PET examinations|
219401536|NCT00540722|DRUG|R-(-)-gossypol acetic acid|Given PO
219401537|NCT00540722|OTHER|laboratory biomarker analysis|Correlative studies
219401538|NCT01593748|DRUG|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
219401539|NCT01593748|DRUG|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
219565095|NCT05022563|DRUG|Edoxaban|Edoxaban
219565096|NCT01684878|DRUG|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
219565097|NCT01684878|DRUG|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
219565098|NCT01684878|DRUG|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
219565099|NCT01684878|DRUG|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
219565100|NCT01684878|DRUG|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
219189493|NCT05656261|GENETIC|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
219189494|NCT06259305|OTHER|Creation of a memory track combined with the baby's heartbeat|This is as described above
219189495|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
219565101|NCT05618145|OTHER|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
219401540|NCT03366740|OTHER|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
219401541|NCT03366740|OTHER|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
219565102|NCT04060511|DRUG|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
219565103|NCT05434130|BEHAVIORAL|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
219565104|NCT02692482|DEVICE|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
219565105|NCT02692482|PROCEDURE|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
219189496|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
219401542|NCT03366740|OTHER|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
219401543|NCT02284334|OTHER|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
219401544|NCT00002263|DRUG|Zidovudine|
219565106|NCT03376620|DRUG|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
219565107|NCT03376620|DRUG|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
219189497|NCT03996772|DRUG|Apixaban Oral Tablet|Factor Xa Inhibitor
219401545|NCT00002263|DRUG|Sargramostim|
219401546|NCT06472258|DRUG|IV Artesunate|IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
219565108|NCT04995120|DRUG|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
219401547|NCT06472258|DRUG|IV Quinine Hydrochloride|IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
219401548|NCT05925816|BEHAVIORAL|Video|Video uses BA techniques for approximately 5 minutes
219401549|NCT05925816|BEHAVIORAL|Active game|Game provides positive feedback in response to decisions made by participants
219401550|NCT05925816|BEHAVIORAL|Neutral game|Game without feedback
219565109|NCT03639974|OTHER|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
219565110|NCT03639974|OTHER|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
219565111|NCT03639974|OTHER|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
219565112|NCT02927834|DRUG|6 day Prednisone|6 day prednisone burst
219565113|NCT02927834|DRUG|Augmentin|Antibiotic augmentin for 3 weeks
219565114|NCT02927834|DRUG|21 day Prednisone|21 day prednisone burst
219565115|NCT04818996|BEHAVIORAL|Mediterranean Diet|"While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated."
219565116|NCT02390648|DRUG|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
219565117|NCT02390648|DRUG|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
219565118|NCT01161394|DRUG|Pioglitazone 15mg|
219565119|NCT01161394|DRUG|pioglitazone 30mg|
219565120|NCT01161394|DRUG|placebo|
219565121|NCT00747292|PROCEDURE|epidural|Patients in this limb receive epidural analgesia
219565122|NCT00747292|PROCEDURE|PCA|Patients in this limb receive a PCA for their pain control
219565123|NCT00747292|PROCEDURE|Spinal|Patients in limb will receive spinal analgesia
219565124|NCT02483338|BEHAVIORAL|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
219565125|NCT05839145|OTHER|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
219565126|NCT05839145|OTHER|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
219565127|NCT05839145|OTHER|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
219565128|NCT05839145|OTHER|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
219565129|NCT05839145|DEVICE|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
219565130|NCT05839145|OTHER|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
219565131|NCT05839145|OTHER|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
219189498|NCT03996772|DRUG|Dabigatran|Direct Thrombin Inhibitor
219189499|NCT03996772|DRUG|Edoxaban Tablets|Factor Xa Inhibitor
219565132|NCT06070974|DIAGNOSTIC_TEST|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
219565133|NCT05057026|OTHER|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~* the use of contact-based education,~* skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~* tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
219565134|NCT06608355|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.
219002128|NCT00284050|DRUG|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
219189500|NCT03996772|DRUG|Rivaroxaban|Factor Xa Inhibitor
219189501|NCT05433454|OTHER|Outreach From Navigators|Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
219565135|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Formulation 1 (FM1) powder for oral suspension.
219565136|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Formulation 2 (FM2) powder for oral suspension.
219189502|NCT06543628|DRUG|Tadalafil 5mg|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
219401551|NCT05847270|PROCEDURE|Anterior and posterior treatment strategy|Before surgery, a large weight traction of 1/6 body weight was used to determine the reversibility of atlantoaxial dislocation. After determining that it is difficult to restore the dislocation, a technique of anterior oral release and posterior fixation fusion was used for reduction, with sequential release of the longus colli and longus capitis, the anterior longitudinal ligament, the blitateral lateral mass joints, the contracted soft-tissue mass between the odotiod and the anterior C1 tubercle, and the peri-odontoid ligaments (i.e., the alar ligaments and the apical ligament), followed by posterior internal fixation and bone grafting was used between C1 and C2 lamina.
219401552|NCT05847270|PROCEDURE|Simple posterior approach treatment strategy|Preceding the surgical procedure, an assessment was conducted utilizing 1/6 weight traction to ascertain the reducibility of atlantoaxial dislocation. Upon confirmation of IAAD, the chosen approach involved the utilization of a specially designed spreader, tailored to the patient's atlanto-axial joint morphology. Upon entering the joint space, the spreaders were skillfully maneuvered to gently open the joint through rotational and prying actions. Subsequently, two cages, pre-filled with autogenous bone grafts, and designed with the appropriate angle and height, were meticulously placed between the Atlanto-axial joints via a posterior approach. This procedure facilitated direct distraction and reduction of the dislocated joint. In the final step of the surgical process, stabilization was achieved by securing the atlas and axis with screws and rods. This surgical approach was selected to address the unique challenges posed by IAAD, with the aim of achieving optimal patient outcomes.
219401553|NCT02419183|OTHER|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
219401554|NCT02419183|OTHER|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
219401555|NCT06094777|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
219401556|NCT02488759|DRUG|Nivolumab|
219401557|NCT02488759|DRUG|Ipilimumab|
219565137|NCT02912767|BEHAVIORAL|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
219565138|NCT04736758|DRUG|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
219565139|NCT04736758|DRUG|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
219565140|NCT05002114|DRUG|Cannabidiol|Topical CBD cream - special formulation
219565141|NCT05002114|OTHER|Placebo|Not the drug
219565142|NCT06309914|DIETARY_SUPPLEMENT|Placebo|Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
219565143|NCT06309914|DIETARY_SUPPLEMENT|Enovita Grape Seed Extract|Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
219189503|NCT06543628|DEVICE|LIPUS (Low Intensity Pulsed Ultrasound)|Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
219189504|NCT06633835|BIOLOGICAL|protein subunit: Novavax COVID-19 vaccine|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
219401558|NCT02488759|DRUG|Relatlimab|
219401559|NCT02488759|DRUG|Daratumumab|
219401560|NCT06671990|DRUG|Vericiguat|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
219401561|NCT06671990|DRUG|Placebo|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
219565144|NCT06309914|DIETARY_SUPPLEMENT|Mirtoselect Bilberry Extract|Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
219565145|NCT06309914|DIETARY_SUPPLEMENT|Virtiva Plus Ginko Biloba Extract|Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
219565146|NCT01867606|BIOLOGICAL|serum-derived bovine immunoglobulin protein isolate|Given PO
219565147|NCT01867606|OTHER|placebo|Given PO
219565148|NCT01867606|OTHER|laboratory biomarker analysis|Correlative studies
219401562|NCT06673121|DRUG|Traditional Chinese Medicine|Received treatment with traditional Chinese medicine
219401563|NCT06672757|DEVICE|CV_AID|"Upon arrival at the scene, the paramedic utilizes a mobile app with an integrated camera to aid in conducting the National Institutes of Health Stroke Scale (NIHSS) assessment. The app assists in scoring the patient\&#39;s responses according to NIHSS criteria to determine the severity of stroke symptoms.~If the app assessment indicates a high likelihood of stroke, transport can be initiated without a conference with the neurovascular centre. The app shares the recorded NIHSS assessment and video of the patient with the neurovascular centre for review.~While en route, the paramedic confer with the neurovascular centre to discuss the patient\&#39;s condition and determine appropriate course of action. If the neurovascular centre decides not to treat the patient, transport can be diverted to the nearest hospital.~The paramedic documents all assessment findings, interventions, and communications related to the stroke patient in the patient care record. U"
219002129|NCT00284050|DRUG|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
219002130|NCT00284050|DRUG|Sham injection|Non-treatment control for sham intravitreal injection.
219189505|NCT06633835|BIOLOGICAL|Pfizer mRNA COVID-19 vaccine|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
219189506|NCT05727618|DRUG|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
219401564|NCT00972998|DRUG|Phenyephrine|Phenyephrine coated suppositories
219401565|NCT05196997|OTHER|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
219401566|NCT05050630|DRUG|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
219401567|NCT06671964|OTHER|Anthropometric measurements|Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection
219401568|NCT06671964|OTHER|Questionnaire|"The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection"
219189507|NCT05727618|DRUG|normal saline|Intravenous infusion of normal saline at the same dose and speed
219189508|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
219401569|NCT06671964|OTHER|Educational sessions|The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
219401570|NCT06862596|DRUG|Mexiletine hydrochloride|Mexiletine hydrochloride 300 mg is administered orally divided into three times a day after meals for 12 weeks.
219401571|NCT06862596|OTHER|Placebo|Placebo is administered orally divided into three times a day after meals for 12 weeks.
219565149|NCT01867606|OTHER|quality-of-life assessment|Ancillary studies
219565150|NCT01867606|OTHER|questionnaire administration|Ancillary studies
219565151|NCT05147974|BEHAVIORAL|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
219565152|NCT00002869|BIOLOGICAL|recombinant interferon alfa|
219565153|NCT00002869|DRUG|cytarabine|
219565154|NCT00002869|DRUG|hydroxyurea|
219565155|NCT00352196|DRUG|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
219401572|NCT06672354|PROCEDURE|Otago Exercise Program|"1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice"
219401573|NCT06672354|PROCEDURE|Non-Immersive Virtual Reality Training|In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
219401574|NCT02887144|DEVICE|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
219189509|NCT06230848|PROCEDURE|Multisensory Early Oral Administration of Human Milk (M-MILK)|M-MILK is implemented as droplets, at day 3 of life, after every hands-on care, and during the beginning of a full gavage feeding. The infant may be supportively positioned in bed, held skin-to-skin by caregiver, or held/cradled by nurse or caregiver. The nurse draws up 1 mL of milk into the 1-mL syringe from a prepared bottle or enteral feeding syringe. The nurse then proceeds to implement M-MILK while observing the infant's responses closely. The nurse talks to the infant with a soft calm voice while providing gentle touch throughout the intervention. The nurse begins M-MILK by first placing 1-2 drops of milk onto the infant's upper lip, allowing the infant to feel and smell the milk. The nurse gently strokes the infant's lips with a pacifier/swab or infant's fingers. M-MILK will be provided based on infants' responses and cues. M-MILK is concluded if the infant is no longer engaged or has finished the 1 mL of milk.
219401575|NCT02887144|DEVICE|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
219401576|NCT02945449|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
219401577|NCT02468089|DRUG|Carbepenem|
219565156|NCT00352196|OTHER|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
219401578|NCT02468089|DRUG|Albumin|
219401579|NCT02468089|DRUG|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
219565157|NCT05663372|DRUG|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
219565158|NCT05663372|DRUG|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
219565159|NCT05500768|PROCEDURE|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
219565160|NCT05500768|PROCEDURE|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
219565161|NCT03296735|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
219565162|NCT03296735|PROCEDURE|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
219565163|NCT02157363|PROCEDURE|Repositioning|
219565164|NCT02157363|PROCEDURE|Single positioning|
219565165|NCT02482558|OTHER|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
219565166|NCT03528096|DEVICE|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
219565167|NCT03528096|OTHER|Sound|Sound of the moving bed was recorded and played back during the baseline night.
219565168|NCT02751892|BEHAVIORAL|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
219401580|NCT06929689|PROCEDURE|three dental implants|fixed detachable prosthesis
219565169|NCT05747560|DIETARY_SUPPLEMENT|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
219565170|NCT05747560|DIETARY_SUPPLEMENT|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
219565171|NCT05747560|DIETARY_SUPPLEMENT|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
219565172|NCT02571933|OTHER|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
219565173|NCT02571933|OTHER|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
219565174|NCT02571933|OTHER|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
219754784|NCT04885530|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219754785|NCT04885530|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
219189510|NCT03541512|BEHAVIORAL|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
219189511|NCT03541512|BEHAVIORAL|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
219189512|NCT06852547|DIETARY_SUPPLEMENT|protein|protein
219189513|NCT04839224|DRUG|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
219189514|NCT04839224|DRUG|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
219189515|NCT03839498|DRUG|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
219401581|NCT06930742|DEVICE|Cognitive-Motor Dual-Task Training|"Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach:~Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks).~Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks.~Task difficulty is progressively adjusted based on participant performance."
219401582|NCT06930742|OTHER|Mindfulness Training|Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.
219401583|NCT06930742|DEVICE|Single-task Training|Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.
219401584|NCT06930742|OTHER|Quiet Rest|Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.
219401585|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
219401586|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
219401587|NCT05725148|DEVICE|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
219401588|NCT04497246|OTHER|Questionnaire|Data collection by means of various questionnaires
219401589|NCT03434132|PROCEDURE|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
219401590|NCT02004652|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
219401591|NCT02004652|DRUG|Placebo|Vitamin, 50mg, tablet.
219401592|NCT00436670|BIOLOGICAL|AMG 317 75 mg|75 mg SC weekly injection
219401593|NCT00436670|BIOLOGICAL|AMG 317 150 mg|150 mg SC once weekly injection
219401594|NCT00436670|BIOLOGICAL|AMG 317 300 mg|300 mg weekly SC injection
219401595|NCT00436670|BIOLOGICAL|Placebo|Placebo SC once weekly injection
219401596|NCT04384263|BEHAVIORAL|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
219401597|NCT01556399|OTHER|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
219401598|NCT05901597|DEVICE|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
219002131|NCT03662490|DEVICE|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
219401599|NCT05482646|BEHAVIORAL|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
219401600|NCT05482646|BEHAVIORAL|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
219401601|NCT05482646|BEHAVIORAL|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
219401602|NCT05329155|DRUG|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
219401603|NCT06327321|DRUG|Deucravacitinib|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
219401604|NCT06327321|OTHER|Volunteer without treatment|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
219401605|NCT06212232|PROCEDURE|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
219401606|NCT05117086|BEHAVIORAL|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
219401607|NCT04958096|DEVICE|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
219401608|NCT04958096|DEVICE|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
219401609|NCT04958096|DEVICE|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
219401610|NCT06417762|BEHAVIORAL|Science Communication Curriculum Cohort 1|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
219401611|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 2|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
219401612|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 3|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
219401613|NCT05664971|BIOLOGICAL|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
219401614|NCT05664971|BIOLOGICAL|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
219401615|NCT05664971|DRUG|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
219401616|NCT05664971|DRUG|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
219401617|NCT05664971|DRUG|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
219401618|NCT05664971|DRUG|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
219401619|NCT05664971|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
219401620|NCT05664971|DRUG|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
219401621|NCT05895513|DRUG|Pimavanserin 34 mg|5HT-2a receptor antagonist
219401622|NCT05895513|DRUG|Placebo|Inactive Comparator
219401623|NCT04838275|BEHAVIORAL|12-week mHealth home exercise prescription|3x/week home walking protocol, 2x/week resistance exercise program
219401624|NCT04307134|DRUG|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
219401625|NCT06362057|OTHER|Subperiosteal implant framework|"A 3D image of an edentulous maxilla bone will be derived from a computed tomography scan of an adult patient and saved as stl data. The solid geometry of the maxilla, including the cortical and spongious bone, was rebuilt from the stl data into the Digital Imaging and Communications in Medicine (DICOM) format with 3D-Doctor (Able Software Corp., MA, USA).~With the Boolean method, force loading will be achieved between prosthetic parts, subperiosteal implant screws and bone tissues"
219401626|NCT04400318|DRUG|Dupilumab|solution for injection subcutaneous
219401627|NCT04400318|DRUG|Placebo|Solution for injection subcutaneous
219565175|NCT06875791|COMBINATION_PRODUCT|Green Tea Extract with Morphine|TV5M01 is a novel oral rinse combining 5% green tea extract with 0.1% morphine in a gel formulation specifically designed for the treatment of radiation-induced oral mucositis. This unique combination leverages the antioxidant and anti-inflammatory properties of green tea polyphenols (particularly EGCG) with the analgesic effects of morphine delivered directly to the oral mucosa. Unlike other interventions, this formulation is administered as a 10 mL rinse three times daily with subsequent ingestion, targeting both local tissue healing and pain relief through a dual-action mechanism.
219565176|NCT06875791|COMBINATION_PRODUCT|Active Comparator: Triple Mixture Oral Rinse for Radiation-Induced Mucositis|This arm will receive a Triple Mixture oral rinse (combination of 0.19% w/w Lidocaine, 0.29% w/w Nystatin, and 5.50% w/v Hydroxides). Participants will use 10 mL of the preparation three times daily at 8-hour intervals (±2 hours) from the diagnosis of grade 1 or higher mucositis until mucositis resolves. The medication should be administered at consistent times daily without fasting requirements. Doses vomited while in clinic may be replaced; however, participants should not take replacement doses for self-administered doses vomited at home. Missed doses should be skipped rather than doubled at the next scheduled time
219565177|NCT03846063|OTHER|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
219565178|NCT05963841|DEVICE|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
219565179|NCT03179748|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
219565180|NCT03814122|BEHAVIORAL|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
219565181|NCT03814122|OTHER|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
219002132|NCT01602146|OTHER|ultramarathon running|"* blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon"
219002133|NCT02968251|BEHAVIORAL|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
219002134|NCT02150798|OTHER|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
219002135|NCT02150798|OTHER|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
219002136|NCT04771442|DRUG|Stromal vascular fraction|Single dose
219002137|NCT00727181|DEVICE|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
219002138|NCT00899262|OTHER|immunohistochemistry staining method|
219002139|NCT00899262|OTHER|laboratory biomarker analysis|
219002140|NCT00899262|OTHER|sputum cytology|
219002141|NCT00899262|PROCEDURE|Fourier transform infrared spectroscopy|
219002142|NCT00899262|PROCEDURE|diagnostic bronchoscopy|
219401628|NCT06315556|DRUG|Aflibercept (Eylea)|Eylea 40 mg/mL solution for injection in pre-filled syringe.
219401629|NCT01096446|DRUG|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
219401630|NCT05517525|DRUG|Brensocatib|Oral tablet.
219401631|NCT03355599|OTHER|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
219401632|NCT00136773|DRUG|amlodipine/benazepril|
219401633|NCT00913718|DRUG|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
219401634|NCT00913718|DRUG|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
219401635|NCT00092040|DRUG|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
219401636|NCT00092040|DRUG|Comparator: risedronate / Duration of Intervention: 12 mo|
219401637|NCT00000728|DRUG|Zidovudine|
219401638|NCT00000728|DRUG|Aldesleukin|
219401639|NCT06286436|OTHER|Dual-task training|The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
219401640|NCT06496321|PROCEDURE|Conventional Saphenous vein harvest|The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.
219401641|NCT06496321|PROCEDURE|No touch Saphenous vein harvest|"During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg."
219401642|NCT06106321|PROCEDURE|Transalveolar crest maxillary sinus floor lift|Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
219401643|NCT06106321|PROCEDURE|transalveolar crest parietal maxillary sinus floor secondary lift|Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
219401644|NCT04875039|DRUG|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
219401645|NCT04875039|DRUG|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
219401646|NCT05275738|DIETARY_SUPPLEMENT|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
219401647|NCT05275738|OTHER|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
219565182|NCT04086160|DEVICE|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
219565183|NCT04614857|OTHER|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
219565184|NCT00198536|DRUG|Ecabet 2.83%|
219565185|NCT00198536|DRUG|Ecabet 3.70%|
219565186|NCT00198536|DRUG|Vehicle|
219565187|NCT03695211|PROCEDURE|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
219565188|NCT03695211|PROCEDURE|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
219565189|NCT01066130|BEHAVIORAL|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
219565190|NCT01066130|BEHAVIORAL|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
219565191|NCT01680367|PROCEDURE|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
219189516|NCT06560281|OTHER|Motion Minder Therapy (MoMT)|Motion Minder Therapy (MoMT) total duration is 1 hour a day, 5 days a week for 4 weeks. The treatment is a carefully planned sequence of exercises intended to help children with spastic hemiplegic cerebral palsy develop their fine motor abilities. Activities includes Sticker Sorting, Beads on Parade, Pegboard Activities, Sensory Bins, Sculpture Building, Finger Painting \& Drawing with Different Tools, Musical Instrument Play. Smartwatches that have tactile sensations and auditory indications are used strategically during certain tasks to enhance proprioception and give real-time feedback, making the rehabilitation process vibrant and interesting.
219401648|NCT03416686|DEVICE|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode\_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
219565192|NCT01680367|PROCEDURE|wound care management|Receive native collagen wound dressing
219565193|NCT01680367|OTHER|questionnaire administration|Ancillary studies
219401649|NCT00827996|DRUG|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
219401650|NCT01093924|BEHAVIORAL|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
219401651|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day,|
219401652|NCT00200694|DRUG|ramipril 10 mg + valsartan 160 mg/day,|
219401653|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
219401654|NCT01996306|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
219401655|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
219401656|NCT01996306|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
219565194|NCT02401841|DRUG|Two different types of drug for resolution of neuro-muscular blockade|
219754786|NCT04885530|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
219754787|NCT01573117|DEVICE|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
219754788|NCT01573117|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
219401657|NCT01996306|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
219565195|NCT01629537|PROCEDURE|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
219401658|NCT01996306|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
219401659|NCT01996306|BIOLOGICAL|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
219401660|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
219401661|NCT01996306|DRUG|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
219401662|NCT00165646|DRUG|E3810|E3810 5mg: once daily orally for 4 weeks
219401663|NCT00165646|DRUG|E3810|E3810 10mg: once daily orally for 4 weeks
219401664|NCT00165646|DRUG|Placebo|Placebo: once daily orally for 4 weeks
219401665|NCT04743245|DEVICE|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
219401666|NCT04743245|DEVICE|PCI|Standard Care of PCI
219002143|NCT06138301|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
219002144|NCT06138301|BEHAVIORAL|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
219401667|NCT04657016|DRUG|Tirzepatide|Administered SC
219401668|NCT04657016|OTHER|Placebo|Administered SC
219401669|NCT04771052|OTHER|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
219401670|NCT01182623|OTHER|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
219401671|NCT03810690|BIOLOGICAL|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
219401672|NCT01755195|DRUG|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
219401673|NCT02139995|BEHAVIORAL|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
219401674|NCT01132677|DEVICE|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
219401675|NCT01132677|DRUG|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
219401676|NCT04452162|DIAGNOSTIC_TEST|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
219401677|NCT00419913|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA 25 mg tid
219401678|NCT05710887|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
219401679|NCT05710887|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
219401680|NCT04980833|DRUG|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
219401681|NCT05429736|BEHAVIORAL|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
219401682|NCT05429736|DEVICE|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
219401683|NCT04686318|DIAGNOSTIC_TEST|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
219401684|NCT00479024|DRUG|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
219401685|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer relaxing acupressure
219401686|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer sham acupressure
219401687|NCT06442891|OTHER|Internet-Based Intervention|Receive access to acupressure mobile app
219565196|NCT01629537|PROCEDURE|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
219565197|NCT01114581|DRUG|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
219565198|NCT01114581|DRUG|Placebo|Placebo given as 2 tablets
219565199|NCT00862537|DEVICE|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
219754789|NCT06981975|DEVICE|single plastic stent|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of a single plastic stent. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
219002145|NCT06076161|DIETARY_SUPPLEMENT|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
219002146|NCT01811160|DRUG|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
219002147|NCT01811160|DRUG|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
219565200|NCT05355519|OTHER|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
219565201|NCT05355519|OTHER|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
219565202|NCT05094570|DRUG|Dupilumab Prefilled Syringe|Dupilumab 300 mg
219002148|NCT04473924|DRUG|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
219002149|NCT04473924|DRUG|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
219401688|NCT06442891|OTHER|Interview|Ancillary studies
219401689|NCT06442891|OTHER|Medical Device Usage and Evaluation|Receive an AcuWand
219401690|NCT06442891|OTHER|Questionnaire Administration|Ancillary studies
219754790|NCT06981975|DEVICE|Multiple plastic stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of multiple plastic stents. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
219401691|NCT00772512|DRUG|PF-04802540|5 mg capsule, single dose
219401692|NCT00772512|DRUG|PF-04802540|15 mg capsule, single dose
219401693|NCT00772512|DRUG|Placebo|Placebo capsule, single dose
219401694|NCT03550326|PROCEDURE|airway management|patients will be intubated or will be placed an airway device
219401695|NCT01447173|DRUG|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
219401696|NCT01740622|OTHER|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
219401697|NCT00568789|DRUG|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
219401698|NCT03445013|DRUG|SB414 6%|Twice daily
219401699|NCT03445013|DRUG|Vehicle|Vehicle Comparator
219401700|NCT05791318|DRUG|VYD222|Monoclonal antibody
219401701|NCT05791318|OTHER|Placebo|Matching Placebo
219401702|NCT05027646|DRUG|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
219401703|NCT05027646|DRUG|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
219401704|NCT02887534|DRUG|SPARC1401-low dose|SPARC1401- low dose
219401705|NCT02887534|DRUG|SPARC1401-mid dose|SPARC1401- mid dose
219401706|NCT02887534|DRUG|SPARC1401-high dose|SPARC1401-high dose
219401707|NCT02887534|DRUG|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
219401708|NCT02887534|DRUG|Placebo1401|Placebo
219401709|NCT01150877|DRUG|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
219401710|NCT05482269|OTHER|no intervention|no intervention
219401711|NCT02423824|BIOLOGICAL|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
219401712|NCT01003028|DRUG|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
219401713|NCT01003028|DRUG|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
219401714|NCT03312777|DRUG|Omnitram|Omnitram tablets overencapsulated
219401715|NCT03312777|DRUG|Tramadol|Tramadol tablet overencapsulated
219401716|NCT03312777|DRUG|Placebo|Microcrystalline powder overencapsulated
219401717|NCT00595699|DRUG|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
219401718|NCT00595699|DRUG|placebo|Placebo
219401719|NCT04792853|BEHAVIORAL|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
219401720|NCT03470922|BIOLOGICAL|Relatlimab|Specified dose on specified day
219401721|NCT03470922|BIOLOGICAL|Nivolumab|Specified dose on specified days
219401722|NCT02340819|DRUG|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
219401723|NCT04423926|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
219401724|NCT04423926|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
219401725|NCT04423926|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
219401726|NCT04423926|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
219401727|NCT04423926|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
219401728|NCT00704743|DEVICE|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
219401729|NCT00704743|DEVICE|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
219401730|NCT00704743|DEVICE|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
219401731|NCT03830008|BEHAVIORAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
219401732|NCT04449783|OTHER|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
219401733|NCT04449783|OTHER|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
219401734|NCT02647762|DRUG|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
219401735|NCT02647762|DRUG|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
219401736|NCT02647762|DRUG|Placebo|Placebo tablets, 1mg BID for 12 weeks
219401737|NCT02647762|DRUG|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
219401738|NCT03217617|BIOLOGICAL|Direct intravenous injection of ivlv-X1 lentiviral vector|ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.
219401739|NCT03750201|DEVICE|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
219401740|NCT03750201|DEVICE|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
219401741|NCT04803708|BIOLOGICAL|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
219401742|NCT06579040|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device)|Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
219401743|NCT03070730|DRUG|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
219401744|NCT03070730|DRUG|Atenolol|Atenolol: 50 mg Q.D.
219401745|NCT03070730|DRUG|Placebos|Placebo: t.i.d
219401746|NCT03237260|DRUG|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
219401747|NCT04511078|DRUG|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
219401748|NCT04743037|BEHAVIORAL|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
219401749|NCT04467164|OTHER|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
219401750|NCT04467164|OTHER|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
219401751|NCT03209544|BEHAVIORAL|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
219401752|NCT02369835|DRUG|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
219401753|NCT02369835|OTHER|Placebo|Applied topically
219401754|NCT00690716|DRUG|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
219401755|NCT00690716|DRUG|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
219401756|NCT04420871|DRUG|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
219401757|NCT04420871|DRUG|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
219401758|NCT03940651|DRUG|Spinal Anesthesia|Patients will be randomized to type of anesthesia
219401759|NCT03940651|DRUG|General Anesthetics|Patients will be randomized to type of anesthesia
219401760|NCT03865017|BIOLOGICAL|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
219189517|NCT06198816|OTHER|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
219401761|NCT03865017|OTHER|Saline|Saline+cell suspension solution infusion
219401762|NCT05149937|OTHER|interprofessional, person-centered care concept|interprofessional, person-centered care concept
219401763|NCT03924674|OTHER|Education, clinical decision support tools|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
219401764|NCT05488561|DIAGNOSTIC_TEST|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
219401765|NCT04008433|DRUG|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
219401766|NCT04177056|RADIATION|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
219401767|NCT05863689|DIAGNOSTIC_TEST|Spectralis SD-OCT|Optical Coherence Tomography
219401768|NCT03879148|OTHER|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
219401769|NCT00490373|DRUG|pemetrexed|
219401770|NCT01152333|DRUG|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
219401771|NCT01152333|DRUG|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
219401772|NCT00174746|DRUG|AVE2635A|
219565203|NCT05271227|OTHER|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
219401773|NCT06332625|DIAGNOSTIC_TEST|Brain quantitative magnetic resonance imaging|Identification and predictability of early structural and metabolic markers from 3T and 7T quantitative magnetic resonance imaging (qMRI)
219401774|NCT03819179|OTHER|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
219401775|NCT03819179|OTHER|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
219401776|NCT03819179|OTHER|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
219565204|NCT03485001|OTHER|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
219565205|NCT03485001|PROCEDURE|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
219565206|NCT05397301|PROCEDURE|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
219565207|NCT04204096|BIOLOGICAL|Vi-DT (Multi-dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C"
219565208|NCT04204096|BIOLOGICAL|Vi-DT (Single dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C"
219189518|NCT06309433|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
219189519|NCT04579900|PROCEDURE|Endoscopy and duodenal biopsy and sampling|All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
219401777|NCT03819179|OTHER|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
219401778|NCT03819179|OTHER|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
219401779|NCT02983981|DRUG|Topicort Topical Spray|open label Topicort spray
219401780|NCT01224353|DRUG|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
219401781|NCT01224353|OTHER|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
219401782|NCT03115489|DRUG|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
219401783|NCT03115489|DRUG|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
219401784|NCT03177837|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
219401785|NCT03177837|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
219565209|NCT04204096|BIOLOGICAL|Control Vaccine|"* For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
219401786|NCT02690480|DRUG|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
219401787|NCT02690480|DRUG|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
219565210|NCT02375945|DEVICE|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
219565211|NCT02375945|DEVICE|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
219565212|NCT00703131|DEVICE|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
219401788|NCT02690480|DRUG|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
219401789|NCT02927808|BEHAVIORAL|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
219401790|NCT05170893|DIETARY_SUPPLEMENT|Coenzyme Q10|Oral capsules
219401791|NCT05170893|OTHER|Placebo|Oral capsules
219401792|NCT00377065|DRUG|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
219565213|NCT04593394|DIAGNOSTIC_TEST|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
219565214|NCT04593394|DIAGNOSTIC_TEST|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
219565215|NCT04802551|OTHER|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
219565216|NCT05659524|OTHER|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
219565217|NCT04618419|DIAGNOSTIC_TEST|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
219565218|NCT01097551|DRUG|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
219565219|NCT01097551|DRUG|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
219565220|NCT01097551|DRUG|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
219565221|NCT01097551|DEVICE|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
219565222|NCT05958056|OTHER|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
219401793|NCT06112990|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
219401794|NCT06112990|OTHER|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
219401795|NCT06112990|BEHAVIORAL|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
219401796|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
219401797|NCT01703286|DRUG|Linagliptin|given once daily for 28 days
219401798|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
219189520|NCT04169243|BEHAVIORAL|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
219189521|NCT04169243|OTHER|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
219401799|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
219401800|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
219401801|NCT01703286|DRUG|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
219401802|NCT01744847|DEVICE|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
219401803|NCT06121947|PROCEDURE|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
219401804|NCT06121947|PROCEDURE|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
219401805|NCT01984346|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
219401806|NCT01984346|DEVICE|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
219401807|NCT02973529|DEVICE|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
219401808|NCT02973529|DEVICE|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
219401809|NCT06245018|BIOLOGICAL|iNK Injection|Subjects will receive about 4 cycles of iNK
219401810|NCT04150874|DIAGNOSTIC_TEST|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
219401811|NCT06086639|OTHER|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
219401812|NCT06428643|OTHER|Chlamydia, gonorrhea, syphilis, and HIV screening|Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
219401813|NCT06528938|DEVICE|Theta Burst Stimulation|Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
219401814|NCT00427388|DRUG|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
219401815|NCT00427388|OTHER|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
219401816|NCT06960252|DEVICE|OPTRELL™ Mapping Catheter|PVI plus substrate modification of LA chamber coexisting with low unipolar voltage (\< 3.0 mv) or bipolar voltage (\< 0.5 mv) in SR and stable (STD \< 30), fast AF CL detected by CLM module and OPTRELL™ Mapping Catheter.
219401817|NCT03301766|DRUG|lidocaine 5% patch|transdermal patch
219401818|NCT03301766|DRUG|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
219401819|NCT03301766|DRUG|Non-medicated patch|non-medicated patch
219401820|NCT03165513|BEHAVIORAL|mhGAP-IG|psychosocial interventions
219401821|NCT05197595|BEHAVIORAL|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
219401822|NCT05197595|BEHAVIORAL|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
219401823|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|
219401824|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
219401825|NCT04738513|PROCEDURE|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
219401826|NCT04738513|PROCEDURE|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
219565223|NCT05327439|OTHER|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
219401827|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
219401828|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
219401829|NCT03997539|DRUG|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
219401830|NCT03997539|DRUG|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
219401831|NCT03997539|DRUG|vinorelbine|vinorelbine
219401832|NCT05699746|DRUG|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
219565224|NCT05327439|OTHER|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
219565225|NCT06627894|BEHAVIORAL|Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression|Good Days Ahead (MindStreet, Inc.)
219565226|NCT06627894|BEHAVIORAL|Active Control|Depression education, symptom monitoring, and standard depression care
219565227|NCT04403945|DEVICE|Sidestream dark field(SDF) imagining|SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
219565228|NCT04034654|OTHER|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
219565229|NCT03066934|OTHER|noninvasive ventilation respiratory support|
219565230|NCT05694117|BEHAVIORAL|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
219754791|NCT06981975|DEVICE|Fully covered self-expanding metal stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of fully covered self-expanding metal stents (fcSEMS) . Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
219754792|NCT00253422|DRUG|Anastrozole|This may be Anastrazole OR a placebo
219401833|NCT05699746|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
219401834|NCT02455791|PROCEDURE|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
219401835|NCT00290576|DIETARY_SUPPLEMENT|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
219401836|NCT01523808|DRUG|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
219401837|NCT03834129|DRUG|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
219401838|NCT03834129|DRUG|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
219754793|NCT00253422|DRUG|Exemestane|
219754794|NCT00253422|DRUG|Fulvestrant|
219754795|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
219754796|NCT02900404|OTHER|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
219754797|NCT02900404|OTHER|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
219754798|NCT06446518|DEVICE|Virtual reality exposure|Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
219189522|NCT03208049|BEHAVIORAL|Behavioral Therapy (BT)|Behavioral Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Behavioral therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
219189523|NCT03208049|BEHAVIORAL|Cognitive Therapy (CT)|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
219189524|NCT04627246|BIOLOGICAL|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab for a maximal duration of 2 years: intravenous, starting after the last chemotherapy cycle. Administered as flat dose of 240mg every 2 weeks during 14 weeks, then as flat dose of 480 mg every 4 weeks until the last vaccination. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity."
219189525|NCT03937362|DIAGNOSTIC_TEST|First clinical response evaluation (CRE-1)|Consisting of: endoscopy with bite-on-bite biopsies
219189526|NCT03937362|DIAGNOSTIC_TEST|Second clinical response evaluation (CRE-2)|Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
219189527|NCT02398656|DRUG|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
219189528|NCT02398656|DRUG|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
219189529|NCT04765696|OTHER|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
219189530|NCT01293214|PROCEDURE|Limb transplantation|
219189531|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
219189532|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
219189533|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
219189534|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
219189535|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
219189536|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
219189537|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
219189538|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
219189539|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
219189540|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
219401839|NCT06721338|DEVICE|Mechanical thrombectomy via blood flow reversal using BOBBY balloon guide catheter|After 2 min. of mechanical thrombectomy (MT), the side port of a BOBBY balloon guide catheter will be flushed again with heparin and the balloon deflated. A follow up angiogram will be performed to determine whether to proceed with another MT pass using the same procedure or to stop if successful recanalization has been achieved. At the end of the procedure, multiple angiograms will be performed and used to record the final TICI score. Angiograms of neck vessels will be used to rule out complications. Groin angiograms will evaluate the puncture site before closure. The catheters will then be removed, allowing hemostasis to be achieved in the groin. An angioseal closure device will be used on the arterial site if not contraindicated and a venous Vascade for the venous side.
219401840|NCT04753203|DRUG|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
219401841|NCT01037504|DRUG|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
219401842|NCT01037504|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
219401843|NCT02076555|BEHAVIORAL|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
219401844|NCT06452537|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
219401845|NCT06452537|DRUG|Prednisone|Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
219401846|NCT06077968|BIOLOGICAL|Prior standard of care receipt of Pfizer's ABRYSVO vaccine|Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
219401847|NCT04644419|OTHER|none (observational study)|This is an observational study and does not include intervention delivery.
219401848|NCT02440178|DRUG|Micafungin|
219401849|NCT00863785|DRUG|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
219401850|NCT05058664|BEHAVIORAL|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
219401851|NCT05058664|BEHAVIORAL|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
219401852|NCT03182205|OTHER|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
219401853|NCT03182205|OTHER|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
219401854|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
219401855|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
219401856|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
219401857|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
219401858|NCT03330899|BIOLOGICAL|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
219401859|NCT03330899|BIOLOGICAL|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
219401860|NCT06038097|PROCEDURE|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
219401861|NCT01004783|GENETIC|DNA methylation analysis|
219401862|NCT01004783|GENETIC|gene expression analysis|
219565231|NCT05694117|BEHAVIORAL|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
219401863|NCT01004783|GENETIC|loss of heterozygosity analysis|
219565232|NCT05694117|BEHAVIORAL|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
219754799|NCT02918942|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
219189541|NCT05811494|DEVICE|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
219401864|NCT01004783|GENETIC|microarray analysis|
219401865|NCT01004783|GENETIC|mutation analysis|
219401866|NCT01004783|GENETIC|polymerase chain reaction|
219401867|NCT01004783|GENETIC|reverse transcriptase-polymerase chain reaction|
219401868|NCT01004783|OTHER|laboratory biomarker analysis|
219401869|NCT03696069|OTHER|Non-Interventional|Non-Interventional
219401870|NCT00184249|PROCEDURE|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
219401871|NCT06295055|PROCEDURE|Ridge augmentation with semi-rigid shell barrier system|The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
219401872|NCT00748059|PROCEDURE|Standing or upright tilt|stand upright or tilt table test
219401873|NCT00748059|PROCEDURE|Microneurography|Recording from sympathetic nerve
219401874|NCT00748059|PROCEDURE|QSweat|quantitative sweat testing
219401875|NCT00748059|DEVICE|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
219754800|NCT04504071|DRUG|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
219754801|NCT06985147|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
219754802|NCT06037811|DRUG|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
219754803|NCT06037811|DRUG|Prednisone|Prednisone as per standard of care.
219754804|NCT06601335|DRUG|AK117 in combination with AK112|Following a predefined dose and date.
219754805|NCT06601335|DRUG|Placebo in combination with Pembrolizumab|Following a predefined dose and date.
219754806|NCT06590116|OTHER|Physical therapy|Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist
219754807|NCT06590116|OTHER|Physical therapist provider|Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
219565233|NCT05694117|BEHAVIORAL|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
219565234|NCT01981317|BEHAVIORAL|Stepped Care Cognitive Behavioral Therapy|
219565235|NCT01981317|BEHAVIORAL|Cognitive Behavioral Therapy|
219565236|NCT04715906|BEHAVIORAL|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
219754808|NCT06987487|BEHAVIORAL|Job Rotation Program|Nurses assigned to the intervention group will participate in a structured job rotation program across multiple cardiovascular units (e.g., intensive care, medical, surgical, rehabilitation) every two months for a period of 12 months. Each rotation cycle involves temporary reassignment to a different unit, followed by a return to the original unit. Each nurse will undergo orientation and receive support from a dedicated tutor in the host unit.
219401876|NCT00748059|DRUG|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
219401877|NCT00748059|DRUG|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
219401878|NCT00748059|PROCEDURE|BodPod|Determination of body composition
219401879|NCT00748059|PROCEDURE|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)"
219565237|NCT03236363|BEHAVIORAL|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
219565238|NCT03236363|BEHAVIORAL|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
219565239|NCT03683329|OTHER|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
219189542|NCT05811494|DEVICE|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
219189543|NCT05811494|DEVICE|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
219565240|NCT03683329|OTHER|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
219565241|NCT03200535|OTHER|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
219565242|NCT03200535|OTHER|Bulk outreach|A bulk letter or email will be sent
219401880|NCT00748059|PROCEDURE|Sleep study|Recording of sleep pattern overnight
219565243|NCT03200535|OTHER|Dietician call|Patients will receive a personalized call by a registered dietitian
219754809|NCT06987487|BEHAVIORAL|No Job Rotation (Standard Care)|Nurses in the control group will continue their usual duties in their respective units without participating in the job rotation program. They will be exposed to the same data collection tools as the intervention group, but without any planned rotation or inter-unit movement.
219754810|NCT06668896|DRUG|Progesterone|Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
219565244|NCT06695117|BIOLOGICAL|IIV-HD|Inactivated, split-virion
219401881|NCT00748059|PROCEDURE|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
219401882|NCT00748059|PROCEDURE|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
219401883|NCT00748059|PROCEDURE|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
219401884|NCT00748059|PROCEDURE|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
219401885|NCT02752529|DRUG|Tacrolimus（FK506）|
219401886|NCT00397969|OTHER|counseling intervention|
219401887|NCT00397969|PROCEDURE|screening colonoscopy|
219002150|NCT01283360|OTHER|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
219189544|NCT05811494|DEVICE|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
219401888|NCT06413173|COMBINATION_PRODUCT|Active tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
219401889|NCT06413173|COMBINATION_PRODUCT|Sham tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
219401890|NCT00972244|DRUG|Dapagliflozin|once daily, 12 weeks
219401891|NCT00972244|DRUG|Placebo|once daily, 12 weeks
219401892|NCT02871180|DIETARY_SUPPLEMENT|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
219401893|NCT02871180|OTHER|No late night snack|Patient consumed no nutrients at late night.
219401894|NCT00331825|DRUG|Risperidone and Olanzapine|
219401895|NCT00366730|DRUG|Nitazoxanide|
219401896|NCT00038688|BEHAVIORAL|Peer HIV Education Program|
219401897|NCT05582811|DRUG|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
219401898|NCT05582811|DRUG|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
219401899|NCT05582811|DRUG|Placebo|Placebo
219565245|NCT06695117|BIOLOGICAL|rC19 (dose 1)|Protein subunit
219565246|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 1)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
219565247|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 2)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
219565248|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 3)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
219565249|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 4)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
219565250|NCT06695117|OTHER|Placebo (0.9% NaCl)|Normal saline
219565251|NCT06631274|BEHAVIORAL|counseling|The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
219565252|NCT05966987|COMBINATION_PRODUCT|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
219565253|NCT05515107|DEVICE|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
219565254|NCT01314768|BEHAVIORAL|Brief intervention|Structured behavioural Brief intervention given by trained GPs
219565255|NCT01314768|OTHER|Business as usual|GPs to treat patient as they have until now based on best established practice
219565256|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
219565257|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
219565258|NCT03666325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
219565259|NCT03666325|DRUG|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
219565260|NCT06155773|PROCEDURE|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
219565261|NCT06155773|PROCEDURE|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
219565262|NCT06155773|PROCEDURE|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
219565263|NCT06155773|PROCEDURE|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
219565264|NCT02769741|OTHER|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
219401900|NCT01597557|DRUG|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
219401901|NCT01597557|OTHER|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
219401902|NCT05201859|DRUG|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
219565265|NCT02769741|OTHER|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
219565266|NCT04306172|OTHER|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
219565267|NCT04306172|OTHER|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
219565268|NCT04306172|OTHER|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
219754811|NCT06991140|OTHER|Thorocal Mobilization Exercises|Thoracic mobilisation exercises were performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. Thoracic mobilisation programme consisted of active self-mobilisation techniques, mobilisation exercises with foam rollers, stretching exercises including thoracic rotation and extension movements and dynamic postural exercises. Especially 'thread the needle' exercise in sitting or quadruped position, 'thoracic extension press-up' in prone position and 'extension on foam rollers' were preferred to increase the mobility of thoracic vertebral segments. The exercises were gradually made more difficult according to the tolerance of the individuals. Each exercise was performed as 10-15 repetitions and 2-3 sets. Exercise safety was ensured by informing the patients about the correct posture and movement patterns before all applications.
219754812|NCT06991140|OTHER|Core Stabilization Exercises|Core stabilization exercises were structured to target activation of deep muscle groups supporting cervical and thoracic spine stability. The exercise programme was performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. The programme included exercises to improve head and neck control (chin tuck, head lift in supine position), exercises to improve scapular stability (scapular retraction, wall slide, serratus anterior activation) and exercises to improve trunk control in neutral spine position (arm and leg extension in four-point position, plank variations). The exercises were gradually made more difficult according to the tolerance of the individuals and each session lasted approximately 40-45 minutes. By ensuring that the exercises were performed in the correct form and in a controlled manner, overloading of the musculoskeletal system was prevented.
219754813|NCT05782855|OTHER|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
219189545|NCT03493425|DRUG|Carboplatin|Given IV
219189546|NCT03493425|DRUG|Cisplatin|Given IV
219189547|NCT03493425|DRUG|Docetaxel|Given IV
219189548|NCT03493425|RADIATION|Image Guided Radiation Therapy|Undergo image guided IMRT
219401903|NCT05201859|DRUG|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
219401904|NCT03086200|BEHAVIORAL|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
219401905|NCT05897346|OTHER|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
219401906|NCT05897346|OTHER|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
219401907|NCT03480282|OTHER|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
219401908|NCT02912000|BEHAVIORAL|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
219401909|NCT01947049|OTHER|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
219565269|NCT01965626|DRUG|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
219565270|NCT01965626|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
219565271|NCT01662362|DEVICE|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
219189549|NCT03493425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
219189550|NCT03493425|OTHER|Laboratory Biomarker Analysis|Correlative studies
219189551|NCT03493425|OTHER|Questionnaire Administration|Ancillary studies
219189552|NCT03493425|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219401910|NCT00285298|DRUG|Pentoxifylline|
219565272|NCT00170144|DRUG|Branchamin 4%|
219565273|NCT01451996|DRUG|Claritin|Subject will be given 10mg Claritin tablet.
219565274|NCT00932724|DRUG|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
219401911|NCT00285298|DRUG|Placebo|
219401912|NCT02077075|BEHAVIORAL|Web-based weight loss program|A 4-week web-based wellness program.
219401913|NCT02077075|BEHAVIORAL|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
219401914|NCT03897270|PROCEDURE|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
219401915|NCT01163162|DRUG|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
219401916|NCT04719065|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
219401917|NCT02446730|DEVICE|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
219401918|NCT02446730|DRUG|Prasugel|
219401919|NCT02446730|DRUG|Clopidogrel|
219401920|NCT02424955|DRUG|perflutren lipid microspheres|
219401921|NCT02424955|DIAGNOSTIC_TEST|3D ultrasound|
219401922|NCT00878917|DRUG|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
219401923|NCT03871517|DRUG|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
219401924|NCT03871517|DRUG|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
219565275|NCT00932724|DRUG|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
219565276|NCT02197208|PROCEDURE|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
219565277|NCT02197208|PROCEDURE|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
219565278|NCT02197208|DEVICE|ultrasound|
219565279|NCT01181531|DRUG|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
219754814|NCT05782855|OTHER|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
219401925|NCT04752813|DRUG|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
219565280|NCT01181531|DRUG|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
219565281|NCT06010745|DIETARY_SUPPLEMENT|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
219401926|NCT04752813|OTHER|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg subcutaneously prior to the beginning of each week of BPM31510 therapy.
219401927|NCT04752813|DRUG|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for up to 12 cycles post BPM31510 treatment.
219401928|NCT04752813|RADIATION|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
219401929|NCT01492647|DRUG|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
219401930|NCT01492647|DRUG|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
219401931|NCT01492647|DRUG|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
219401932|NCT05945290|PROCEDURE|Biospecimen Collection|Undergo blood and leftover tissue sample collection
219401933|NCT05945290|OTHER|Electronic Health Record Review|Medical records are reviewed
219401934|NCT03667664|DIAGNOSTIC_TEST|Multidimensional assessments|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 following the exercise program including:~1. Clinical assessment by a geriatrician~2. Nutritional assessment~3. Physical capacity assessment~Following initial assessment (T0), older adults are included in the multicomponent exercise program if they present mobility disability risk factors including :~* At least pre-frailty regarding Fried frailty criteria AND/OR~* At least probable sarcopenia regarding EWGSOP2 algorithm AND/OR~* The presence of at least an intermediate fall risk AND/OR~* The presence of a fear of falling Following the exercise program (T3), all participants are re-assessed in the same way as T0. Investigators then set goals in physical activity with participants to maintain benefits and foster self-engagement in an healthy lifestyle. Additionnally, participants are orientated to exercise facilities and received an individualized booklet of exercises for home-based training."
219189553|NCT04299464|DRUG|Placebo|Participants will receive oral placebo for approximately 12 weeks.
219189554|NCT04299464|DRUG|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
219401935|NCT03667664|OTHER|Multicomponent group-based and supervised exercise program|The intervention consists in a progressive multicomponent exercise training protocol. There are 2 sessions per week of 1 hour each for a total of 12 weeks. Sessions involve functional, resistance and balance exercises. Intensity is based on rating perceived effort (Borg's scale CR1-10) and volume towards 1 to 3 sets of 6 to 15 repetitions. Progressiveness in intensity and volume was based on effort tolerance, contraction regimen, velocity and load. Training schedule is described elsewhere (Delaire et al, 2023 ; doi.org/10.3390/nu15194100). Participants are allocated to an homogenous group based on functional status and cardiorespiratory comorbidities. Trained kinesiologists supervised the exercise program. Participants used free weights and elastic bands.
219401936|NCT03667664|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3+6 months:~Investigators interviewed participants for 30 minutes. During the interview, data collection include:record of undesirable events in the interval T3 / T3+6 (falls, unscheduled hospitalization, illness, institutionalization), medication changes, ADL, IADL, FES-I, and RAPA. Goal-settings at T3 are adjusted if not reach. Finally, investigators stimulate intrinsic motivation for PA.~Follow-up at T3 + 12 months:~Investigators re-assessed physical capacity, physical activity level, quality of life, fall risk and frailty for the last visit. Data collection include:~* SPPB~* Handgrip test and maximal isometric strength of the quadriceps~* Questionnaires : SarQoL©, FES-I, RAPA~* Gait quality analysis using inertial sensors~* Undesirable events in the interval T3+6 / T3+12 (falls, unscheduled hospitalization, illness, institutionalization)~* Medication changes~* Body mass index~* ADL and IADL At last, goals in physical activity are adjusted if they are still not reach"
219565282|NCT06010745|DIETARY_SUPPLEMENT|Placebo|Inert ingredients only
219189555|NCT05821816|DEVICE|tDCS|Use of Transcranial direct current stimulation for 20 minutes per day, 5 days a week, at 2mA
219189556|NCT05821816|OTHER|Conventional rehabilitative treatment|Physiotherapy treatment consisting in two treatments per day of 40 minutes each
219189557|NCT03950570|DRUG|Abraxane|In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.
219189558|NCT03950570|DRUG|ORIN1001|ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
219189559|NCT04903223|DRUG|Rosuvastatin 10mg|Rosuvastatin will be administered to all participants on Study Day #2
219189560|NCT05384756|DRUG|Alemtuzumab|Given IV
219189561|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219189562|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
219565283|NCT03788356|DEVICE|Inspiratory muscle training|Inspiratory muscle training with a device
219189563|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
219189564|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
219189565|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
219189566|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
219189567|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
219189568|NCT04254627|DRUG|Etanercept|Etanercept 50 mg weekly injection
219189569|NCT04254627|DRUG|Mifepristone|Mifepristone 300 mg pill
219189570|NCT04728334|DRUG|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
219189571|NCT04234113|DRUG|Nanrilkefusp alfa|A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
219189572|NCT04234113|DRUG|Pembrolizumab|A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
219189573|NCT05328154|OTHER|Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0 and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Follow-up diary to be completed at months 1 and 12 of the study"
219189574|NCT05328154|DRUG|Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0; Visit 2: Day 0+9 months and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Magnesium intake for 1 period of 3 months~* Phone call~* Follow-up diary to be completed at months 1, 10, 11 and 12 of the study"
219189575|NCT06349772|DRUG|Zynrelef|Zynrelef will be injected at the 12mm port site
219189576|NCT06349772|DRUG|Exparel|Exparel will be injected at the 12mm port site
219189577|NCT06298461|DRUG|KleanLyte|Laxative for colonoscopy bowel preparation
219189578|NCT06298461|DRUG|Bi-PegLyte|Laxative for colonoscopy bowel preparation
219401937|NCT05430568|PROCEDURE|robot-assisted surgery|"1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement"
219401938|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
219401939|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
219754815|NCT01983345|PROCEDURE|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
219401940|NCT03932201|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
219401941|NCT06781099|DEVICE|Low-volume continuous veno-venous haemodialysis with MEX-CD1 use|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. Intervention includes 3 low-volume continuous veno-venous hemodialysis for a duration of 4 hours each. For non-hospitalized patients, the treatment is performed on an outpatient basis.
219401944|NCT02948140|PROCEDURE|MRI|
219401945|NCT02948140|PROCEDURE|Abdominal scanner|
219401946|NCT06667999|DRUG|Albumin|Albumin should be used for the following indications: 1. During circulatory failure in addition to crystalloids (resuscitation). 2. For substitution in case of: suspected or overt albumin loss OR P-albumin levels below or equal to 25 g/L. Decisions around timing, volume, and concentration of albumin, and its use for other indications, are at the clinician's discretion. P-albumin should be measured according to local practice.
219401947|NCT06667999|OTHER|No albumin use|Albumin should not be used. In case of the following special circumstances, albumin may be considered: 1. Large ascites drainage (i.e., equal to or more than 1 L tapped) 2. Spontaneous bacterial peritonitis 3. Hepatorenal syndrome.
219401948|NCT02758717|DRUG|Brentuximab Vedotin|Given IV
219401949|NCT02758717|BIOLOGICAL|Nivolumab|Given IV
219401950|NCT02992522|DRUG|Lenalidomide|Given PO
219401951|NCT02992522|BIOLOGICAL|Obinutuzumab|Given IV
219401952|NCT02992522|DRUG|Venetoclax|Given PO
219401953|NCT04459273|PROCEDURE|Computed Tomography|Undergo PET/CT
219401954|NCT04459273|DRUG|Gallium Ga 68 FAPi-46|Given IV
219401955|NCT04459273|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219401956|NCT04459273|RADIATION|18F-FDG|Given IV
219565284|NCT03788356|OTHER|Diaphragmatic breathing|Diaphragmatic breathing exercise
219565285|NCT00987831|OTHER|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
219565286|NCT00987831|OTHER|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
219565287|NCT00987831|DRUG|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
219565288|NCT04593147|OTHER|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
219754816|NCT05593380|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
219401957|NCT02774759|DEVICE|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
219401958|NCT02774759|BEHAVIORAL|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
219401959|NCT02774759|BEHAVIORAL|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
219401960|NCT02774759|BEHAVIORAL|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
219401961|NCT02774759|BEHAVIORAL|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
219401962|NCT02774759|BEHAVIORAL|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
219401963|NCT02774759|BEHAVIORAL|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
219401964|NCT06388122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219565289|NCT04593147|OTHER|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
219565290|NCT02246686|DRUG|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
219565291|NCT02246686|DRUG|Placebo|Application over 12 weeks 20 drops three time daily
219565292|NCT04243096|BEHAVIORAL|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
219565293|NCT05982249|DEVICE|Hypnosis|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.
219565294|NCT05982249|DEVICE|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
219401965|NCT05224206|DEVICE|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
219401966|NCT05224206|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
219401967|NCT06409013|OTHER|Non-Interventional Study|Non-interventional study
219565295|NCT04552912|BEHAVIORAL|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
219565296|NCT05338476|DRUG|Midazolam|Administered orally.
219565297|NCT05338476|DRUG|Selpercatinib|Administered orally.
219565298|NCT00810602|PROCEDURE|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
219565299|NCT00810602|DRUG|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
219565300|NCT00810602|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
219565301|NCT00810602|DRUG|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
219565302|NCT02792218|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
219565303|NCT02792218|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
219401968|NCT04457089|DRUG|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
219565304|NCT02792218|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
219565305|NCT02792218|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
219565306|NCT01745952|DEVICE|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
219565307|NCT01745952|DEVICE|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
219565308|NCT01745952|DEVICE|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
219565309|NCT00824369|DRUG|No drug will be administered|No drug will be administered.
219565310|NCT03167502|OTHER|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
219565311|NCT03167502|OTHER|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
219754817|NCT05593380|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
219565312|NCT04752488|OTHER|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
219565313|NCT04752488|OTHER|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
219565314|NCT05520606|PROCEDURE|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
219565315|NCT00392782|BIOLOGICAL|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
219754818|NCT06616155|PROCEDURE|Biopsy|Undergo tissue biopsy
219754819|NCT06616155|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219754820|NCT06616155|PROCEDURE|Bone Scan|Undergo bone scan
219754821|NCT06616155|PROCEDURE|Computed Tomography|Undergo CT
219754822|NCT06616155|DRUG|Enzalutamide|Given PO
219754823|NCT06616155|DRUG|Ruxolitinib|Given PO
219401969|NCT06182774|DRUG|Daratumumab|Dose determined at enrollment
219401970|NCT06182774|DRUG|Lenalidomide|Dose determined at enrollment
219401971|NCT06182774|DRUG|Dexamethasone|Dose determined at enrollment
219565316|NCT00392782|DRUG|fludarabine phosphate|Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
219401972|NCT05423899|BEHAVIORAL|Grace Robot|The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
219401973|NCT05423899|BEHAVIORAL|Treatment as Usual|The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
219401974|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401975|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401976|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401977|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219565317|NCT00392782|DRUG|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
219565318|NCT00392782|PROCEDURE|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
219565319|NCT00392782|RADIATION|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
219401978|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401979|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
219401980|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
219565320|NCT00101413|DRUG|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
219565321|NCT06188052|DRUG|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
219565322|NCT01463150|DRUG|Clopidogrel|Clopidogrel 150mg per day for 15 days
219565323|NCT01463150|DRUG|Prasugrel|Prasugrel 5mg per day for 15 days
219401981|NCT05262400|DRUG|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
219401982|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401983|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219565324|NCT03201354|PROCEDURE|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
219401984|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
219401985|NCT05770505|BEHAVIORAL|Exercise training using an e-health tool|Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
219565325|NCT03201354|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
219754824|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
219754825|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
219754826|NCT00955578|PROCEDURE|Punch Biopsy|5-6 punch biopsies of affected areas
219754827|NCT04866719|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
219565326|NCT03201354|PROCEDURE|Cataract extraction|Cataract surgery and IOL implantation
219565327|NCT02736630|OTHER|body temperature|intermittant tympanic temperature measurement during surgery
219565328|NCT00858013|DRUG|Nateglinide|Nateglinide 90\~120mg three times a day
219565329|NCT00858013|DRUG|Glimepiride|Glimepiride 1\~2mg once a day
219565330|NCT04762459|DRUG|Almonertinib|Almonertinib 110mg PO once daily
219565331|NCT04762459|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
219565332|NCT04762459|DRUG|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
219565333|NCT00700245|BEHAVIORAL|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
219189579|NCT06840327|OTHER|Blood and tissue samples|Blood samples will be taken from catheters placed for the purpose of surgery (arterial and venous catheters), or during routine venipunctures. (D-1 pre-op). Tissue samples will be taken from surgical waste generated by the surgery. They will therefore not require any additional incisions or surgical procedures.
219754828|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
219754829|NCT06990880|DRUG|GSK5458514|GSK5458514 will be administered.
219754830|NCT06592872|BEHAVIORAL|Bullying prevention|The intervention utilizes a serious (educational) videogame and teacher-led, interactive class sessions. Students exposed to the intervention will learn to respond to in-person and online bullying from the perspectives of perpetrator, victim, and bystander. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
219754831|NCT06861413|DRUG|VX-828|Tablets for Oral Administration.
219189580|NCT06840327|OTHER|walking test|The study includes a walking test between D5 and D7.
219189581|NCT04261686|DEVICE|Covera Vascular Covered Stent|This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
219189582|NCT06760715|BEHAVIORAL|an interactive m-health self-management|Description: The experimental group will undergo a lifestyle intervention based on the Transtheoretical Model (TTM), utilizing the MOSAC cloud platform. This intervention focuses on self-management to facilitate behavior changes aimed at weight loss and improving Obstructive Sleep Apnea (OSA) of T2DM patients. Key components include self-monitoring, tracking, real-time feedback, and customized weight loss plans, all enhanced by gamification features. The intervention emphasizes a healthy approach to weight loss, promoting a balanced diet, moderate calorie reduction, and increased physical activity, such as step counts. Each stage of the intervention outlines specific objectives, processes, and measures for achieving behavioral change and supporting healthy weight loss.
219189583|NCT06760715|BEHAVIORAL|In the control group|Description: In the control group, standard medical care will continue to be provided along with written educational pamphlets on weight loss and sleep hygiene. The interactive m-health cloud platform will not be offered. However, the results of the three questionnaires administered to each participant will be individually explained, and any questions will be addressed immediately. After the activity concludes, participants may choose to receive the same intervention as the experimental group, if they wish.
219189584|NCT02838316|DRUG|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
219189585|NCT03676192|DRUG|CT-P16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
219189586|NCT03676192|DRUG|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
219189587|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
219189588|NCT06835101|OTHER|Music intervention|"The music group will receive music beginning 20 minutes before spinal anesthesia until the end of surgery."
219189589|NCT06835101|DRUG|Midazolam (sedative)|"The midazolam group will receive increments of midazolam beginning 20 minutes before spinal anesthesia."
219189590|NCT06837168|DEVICE|Stainless steel fixed retainer|The Stainless steel fixed orthodontic retainer is fabricated from a 0.0215-inch, five-stranded stainless steel wire
219401986|NCT06283771|OTHER|Heated socks to be developed with wearable technology|The study group will wear heated socks to be developed with wearable technology
219401987|NCT05761444|DRUG|Atozet 10/40 mg or 10/80 mg|Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
219401988|NCT05761444|DRUG|Lipitor 40 mg or 80 mg|Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
219401989|NCT02055521|PROCEDURE|Blood sample, biopsy|
219401990|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
219401991|NCT02652858|PROCEDURE|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
219401992|NCT06798714|DRUG|NSAID|standard CABG without performing pericardial fenestration intraoperatively
219401993|NCT06798714|DRUG|Colchicine 0.5 MG|Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
219401994|NCT04609592|DRUG|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
219401995|NCT04609592|DRUG|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
219754832|NCT06861413|DRUG|VX-828|Suspension for Oral Administration.
219754833|NCT06207422|OTHER|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
219401996|NCT04609592|PROCEDURE|Computed Tomography (CT)|Medical Imaging
219401997|NCT04609592|PROCEDURE|Magnetic Resonance Imaging (MRI)|Medical Imaging
219401998|NCT04609592|PROCEDURE|PET/CT|Medical Imaging
219401999|NCT05169307|DRUG|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
219402000|NCT05009316|OTHER|Questionnaires|Online-based questionnaires
219402001|NCT02046343|BEHAVIORAL|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
219402002|NCT02046343|BEHAVIORAL|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
219402003|NCT02046343|OTHER|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
219754834|NCT06207422|OTHER|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
219754835|NCT07004062|OTHER|Structured Risk Assessment-Based Targeted Nursing Intervention|"Comprehensive Risk Assessment: Evaluation of lifestyle factors (diet, exercise, sleep), psychosocial stressors, medical history, and endocrine-specific biomarkers~Personalized Care Plan: Tailored interventions addressing identified risk factors~Psychological Component: Cognitive-behavioral techniques and stress management~Lifestyle Modification: Guided nutrition (low-glycemic, high-fiber diet) and physical activity plans~Reproductive Health Support: Menstrual cycle monitoring and fertility-related counseling"
219754836|NCT07003022|DRUG|cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.|Cadonilimab: 10mg/kg Q3W; Bevacizumab: 7.5mg/kg Q3W; Regorafenib: 80mg QD; Fruquintinib: 3mg QD.
219754837|NCT07003347|DEVICE|oral spray of MgCl2|Magnesium Salt Oral Spray Device
219754838|NCT07003347|DEVICE|Saline|oral saline aerosol
219754839|NCT07004491|OTHER|Conventional therapy|Ultrasound, Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application
219754840|NCT07004491|OTHER|Conventional therapy+ Mulligan mobilization|Conventional therapy+ Mulligan mobilization
219754841|NCT07004491|OTHER|Conventional therapy+ Graston|Conventional therapy+ Graston application
219754842|NCT07002801|COMBINATION_PRODUCT|remimazolam-remifentanil|For elderly patients scheduled for elective painless gastro-intestinal endoscopy, remimazolam 0.2mg/kg and remifentanil 0.2ug/kg are used for anesthesia induction. During the operation, the doses are adjusted according to the depth of sedation of the patients.
219402004|NCT02046343|OTHER|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
219402005|NCT00204425|DIETARY_SUPPLEMENT|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
219402006|NCT01954303|OTHER|Progress of CHD|
219754843|NCT07002801|COMBINATION_PRODUCT|remimazolam-esketamine|For elderly patients scheduled for painless gastroenterological endoscopy, remimazolam 0.2mg/kg and esketamine 0.15mg/kg are used for anesthesia induction. During the operation, the dosage is adjusted according to the patient's level of sedation.
219754844|NCT07004413|DRUG|FOLFIRI+cetuximab|Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.
219402007|NCT02413125|DEVICE|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
219402008|NCT02413125|DRUG|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
219402009|NCT02356406|RADIATION|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
219754845|NCT07004413|DIAGNOSTIC_TEST|Guardant360 ctDNA assay|Determination of circulating tumor DNA (ctDNA) in the peripheral blood, part 1: retrospective threshold determination to predict radiological disease progression in Arm 2; part 2: prospective validation of the in part 1 identified ctDNA threshold to guide the scheduled treatment breaks and treatment in Arm 2
219754846|NCT07004621|OTHER|measurment of intubation time in seconds|determine whether modern technologies such as videolaryngoscopy shorten intubation time.
219754847|NCT07003802|BEHAVIORAL|Resistance exercise|An acute bout of a 3 minute resistance exercise will be performed using a lumbar extension exercise machine
219754848|NCT07003815|DRUG|Envafolimab + Gemcitabine + Cisplatin + Simvastatin|"Envafolimab (generic name):~Dose: 300 mg, intravenous (IV) infusion. Schedule: Day 1 of each 21-day cycle (induction phase); every 28 days (maintenance phase).~Role: PD-L1 inhibitor immunotherapy.~Gemcitabine (generic name):~Dose: 1,000 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Cisplatin (generic name):~Dose: 25 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Simvastatin (generic name):~Dose: 40 mg, oral tablet. Schedule: Daily (continuously through induction and maintenance phases). Investigational Role: Potential immunomodulator and chemosensitizer in biliary tract cancer.~Treatment Phases:~Induction Phase (Cycles 1-8, 21-day cycles): All four drugs administered. Maintenance Phase (Post-Cycle 8): Envafolimab + Simvastatin only (28-day cycles)."
219754849|NCT07002788|DRUG|Bupivacaine|Used for regional anesthesia during VATS procedure (e.g., paravertebral or serratus anterior plane block)
219754850|NCT07002788|DRUG|Morphine|Used for postoperative pain control via PCA device.
219754851|NCT07002788|DRUG|Paracetamol|Used as part of postoperative multimodal analgesia
219754852|NCT07002788|DRUG|Diklofenak Sodyum|Administered for postoperative pain management
219754853|NCT07003178|DRUG|STR-P004|An in vivo CART drug administered intravenously
219754854|NCT06616610|BEHAVIORAL|Intervention with the Mobility Platform|The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
219754855|NCT06616610|BEHAVIORAL|Intervention with Traditional Therapy|The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
219402010|NCT05139368|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219402011|NCT02531789|OTHER|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
219402012|NCT03951857|OTHER|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
219402013|NCT01744509|DEVICE|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
219402014|NCT01293032|PROCEDURE|Neoadjuvant Therapy|Undergo neoadjuvant therapy
219402015|NCT01293032|PROCEDURE|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
219402016|NCT01293032|OTHER|Laboratory Biomarker Analysis|Correlative studies
219402017|NCT01293032|GENETIC|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
219402018|NCT01293032|DRUG|Systemic Chemotherapy|Undergo chemotherapy
219402019|NCT01293032|DRUG|Tamoxifen Citrate|Undergo hormonal therapy
219402020|NCT01293032|DRUG|Aromatase Inhibition Therapy|Undergo hormonal therapy
219754856|NCT04840186|PROCEDURE|Liver-resection or ablation|Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.
219754857|NCT04840186|DRUG|2nd line chemotherapy|2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
219754858|NCT06866145|PROCEDURE|functional endoscopic sinus surgery|sinus surgery
219402021|NCT01665326|OTHER|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
219402022|NCT05987293|DEVICE|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
219754859|NCT06866145|DRUG|Dexmedetomidine|precedex
219754860|NCT07003269|DRUG|Hetrombopag|In allogeneic hematopoietic stem cell transplantation, hetrombopag is initiated at 3 µg/kg subcutaneously on day +6 post-transplant. The dose is increased by 2 µg/kg weekly up to a maximum of 10 µg/kg. Treatment is discontinued when platelet counts rise to 100×10⁹/L. If platelet counts remain ≤20×10⁹/L on day +20, hetrombopag is combined with eltrombopag 25 mg orally once daily. Fresh apheresis platelet suspensions (1 therapeutic dose, containing \>2.5×10¹¹ platelets) are administered when platelet counts are ≤20×10⁹/L or when counts are between 21-50×10⁹/L with active bleeding. If engraftment has not occurred by day +28 post-transplant, re-transplantation is required, and hetrombopag is considered ineffective.
219754861|NCT02229630|RADIATION|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
219754862|NCT07004075|DRUG|Luvometinib|Luvometinib oral tablet
219754863|NCT07004075|BIOLOGICAL|Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide|Investigator's choice of chemotherapy administered IV or orally
219402023|NCT01666080|DRUG|Busulfan|0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
219402024|NCT01666080|DRUG|Fludarabine|40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
219402025|NCT01666080|RADIATION|Total body irradiation|200 cGy on Day -1
219402026|NCT01666080|BIOLOGICAL|Stem cell transplant|stem cell infusion on day 0
219402027|NCT01666080|DRUG|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
219402028|NCT01594476|DRUG|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
219402029|NCT01841658|DIETARY_SUPPLEMENT|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
219402030|NCT05399706|DIAGNOSTIC_TEST|CTA Aorta|Computed Tomography Angiography - Aorta Whole
219402031|NCT04664920|DEVICE|exergame|motor-cognitive training device
219402032|NCT02520804|DRUG|sterofundin|sterofundin for shock patients in the first 72 hours
219402033|NCT02520804|DRUG|normal saline|Normal saline for shock patients in the first 72 hours
219402034|NCT00745485|DRUG|zoledronic acid|
219402035|NCT00543751|DRUG|MK0767|
219402036|NCT03636776|OTHER|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
219754864|NCT07003360|PROCEDURE|application of beautiful blukfill II shofu composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, beautiful bluk fill II composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
219754865|NCT07003360|PROCEDURE|application of Ivoclar vivadent bulkfill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Ivoclar vivadent bulkfill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
219402037|NCT03434964|DIAGNOSTIC_TEST|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
219402038|NCT02641236|DRUG|Vancomycin-polymyxin B|
219402039|NCT05517447|OTHER|Observational cohort study|Observational cohort study
219402040|NCT05517447|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219402041|NCT02691247|BIOLOGICAL|CLBS03 Low Dose|
219402042|NCT02691247|BIOLOGICAL|CLBS03 High Dose|
219754866|NCT07003360|PROCEDURE|application of Predicta bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Predicta bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed
219402043|NCT02691247|BIOLOGICAL|Placebo|
219402044|NCT05742464|BEHAVIORAL|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
219402045|NCT02177669|OTHER|quick Contrast Sensitivity Function test|
219402046|NCT03553238|DRUG|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
219402047|NCT03553238|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
219402048|NCT03553238|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
219402049|NCT03553238|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
219402050|NCT03553238|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
219402051|NCT03553238|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
219402052|NCT03553238|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
219402053|NCT03553238|DRUG|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
219402054|NCT03553238|DRUG|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
219402055|NCT03553238|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
219402056|NCT03553238|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
219402057|NCT03553238|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
219402058|NCT03553238|PROCEDURE|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
219402059|NCT03553238|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
219402060|NCT03553238|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
219402061|NCT03553238|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
219402062|NCT03553238|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
219565334|NCT00700245|BEHAVIORAL|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
219565335|NCT00700245|BEHAVIORAL|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
219565336|NCT01598545|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
219565337|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
219565338|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
219565339|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
219565340|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
219565341|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
219565342|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
219565343|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
219402063|NCT03553238|DIAGNOSTIC_TEST|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
219402064|NCT03553238|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
219402065|NCT03553238|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
219402066|NCT03488940|DEVICE|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
219402067|NCT03488940|DEVICE|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
219565344|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
219565345|NCT06749925|BIOLOGICAL|Dendritic Cell Vaccine|This intervention distinguishes itself from others by utilizing allogeneic dendritic cells derived from healthy donors fused with autologous tumor cells from patients, which is a novel approach compared to the commonly used autologous DC-based vaccines (DCVax).
219565346|NCT06749925|COMBINATION_PRODUCT|Pembrolizumab|Recent findings have shown that the anti-PD1 monoclonal antibody, a checkpoint inhibitor, can sustainably enhance the anti-tumor immune response. In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
219565347|NCT06749925|OTHER|Placebo|In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
219565348|NCT01947686|DEVICE|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
219565349|NCT00475917|DRUG|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
219565350|NCT00475917|DRUG|Gemcitabine|once-weekly 30-minute IV infusion
219189591|NCT06837168|DEVICE|3D printed CAD/CAM Chrome cobalt fixed lingual retainers|CAD/CAM Chrome cobalt retainers; will be digitally designed by the dental technician using EXOCAD software. Then, they will be printed by DMP Flex100 metal 3D printer and then will be polished. Also, a projection like extensions will be added at the ends of the retainers to avoid slippage in addition to gingivally directed V notch shaped bend in the retainer to increase the retention in the anterior region
219189592|NCT06834269|DEVICE|Transcranial magnetic stimulation (tSMS)|Transcranial static magnetic stimulation (tSMS) will be delivered simultaneously to both hemispheres, at the motor cortex (M1), via magnets housed in a helmet.
219402068|NCT03488940|DEVICE|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
219402069|NCT03519308|DRUG|Nivolumab|Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
219402070|NCT03519308|DRUG|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
219402071|NCT03519308|DRUG|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
219402072|NCT03519308|DRUG|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
219402073|NCT02480075|OTHER|Observational|Observational Study only
219402074|NCT00739778|OTHER|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
219402075|NCT00739778|OTHER|food vehicle blank|water blank
219402076|NCT00739778|OTHER|food - sweetener, positive control|4.7% sucrose in water
219402077|NCT00739778|OTHER|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
219402078|NCT03688646|DIETARY_SUPPLEMENT|Intensive Nutrition Intervention|
219402079|NCT05754827|DIAGNOSTIC_TEST|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
219565351|NCT05924867|OTHER|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
219189593|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
219189594|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
219189595|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
219402080|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
219402081|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
219189596|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
219189597|NCT04194268|RADIATION|Carbon Ion|12 x 4 Gy (RBE)
219189598|NCT02912078|OTHER|Pocket-warming|Pocket-warming of epidural medication
219189599|NCT02912078|OTHER|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
219402082|NCT06242340|OTHER|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
219402083|NCT06242340|OTHER|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
219402084|NCT06242340|OTHER|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
219402085|NCT06242340|OTHER|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
219402086|NCT00632034|OTHER|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
219402087|NCT03105154|OTHER|Prevena Dressing|Prevena dressing is applied on one groin
219402088|NCT03105154|OTHER|Conventional Dressing|Conventional dressing is applied on the contralateral groin
219402089|NCT04734756|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
219754867|NCT07003360|PROCEDURE|application of Stela self-cure bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Stela self-cure bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
219402090|NCT05699616|PROCEDURE|Repair of perforated peptic ulcer|Repair of perforated peptic ulcer either open or laparoscopic.
219402091|NCT03067662|OTHER|Aerobic exercise|
219402092|NCT01461863|DIETARY_SUPPLEMENT|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
219402093|NCT01461863|DIETARY_SUPPLEMENT|multivitamin|Standard multivitamin
219402094|NCT02436486|DRUG|Placebo|Capsules, orally, single dose
219402095|NCT02436486|DRUG|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
219402096|NCT02436486|DRUG|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
219402097|NCT02436486|DRUG|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
219402098|NCT00049959|DRUG|verteporfin PDT|
219402099|NCT02974062|OTHER|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
219402100|NCT05544825|DIETARY_SUPPLEMENT|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
219402101|NCT05544825|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
219402102|NCT05883267|DEVICE|Virtual reality glasses|"PICO model neo 2 VR glasses"
219402103|NCT05883267|DEVICE|Vocal-guided affective imagery|Audio via telephone
219402104|NCT05468086|DEVICE|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
219402105|NCT01728272|DRUG|blood concentration of metoprolol|measure blood concentration of metoprolol
219402106|NCT05415202|DRUG|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
219402107|NCT04591314|BEHAVIORAL|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
219402108|NCT04098952|OTHER|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
219402109|NCT04098952|OTHER|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
219402110|NCT01937208|RADIATION|intensity modulated radiation therapy in both arms|
219402111|NCT01937208|DRUG|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
219402112|NCT02494349|DRUG|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
219402113|NCT02494349|DRUG|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
219402114|NCT00279903|DRUG|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
219402115|NCT00279903|DRUG|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
219402116|NCT03280732|DEVICE|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
219402117|NCT04869956|OTHER|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
219402118|NCT04869956|OTHER|Dietary pattern: Standard diet|standard nutritional recommendations
219402119|NCT02244359|BEHAVIORAL|Training|
219402120|NCT02244359|BEHAVIORAL|Usual care|
219402121|NCT01108809|DRUG|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
219402122|NCT01892254|DRUG|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
219189600|NCT06252402|BIOLOGICAL|CMV/HIV-CAR T Cells|Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
219189601|NCT06038552|DRUG|imatinib (IM)|Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
219189602|NCT06038552|PROCEDURE|hepatic resection (HR)|HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
219402123|NCT01892254|DRUG|Placebo|Placebo (to metformin)
219402124|NCT04815629|RADIATION|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
219402125|NCT05518344|DEVICE|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
219402126|NCT00393289|BEHAVIORAL|Calcium controlled diet|
219402127|NCT01283191|BEHAVIORAL|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
219402128|NCT01283191|BEHAVIORAL|Education Control|Education class
219402129|NCT03059303|DRUG|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
219402130|NCT03059303|DRUG|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
219402131|NCT03059303|DRUG|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
219402132|NCT03059303|DRUG|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
219402133|NCT03059303|DRUG|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
219402134|NCT03059303|DRUG|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
219402135|NCT03059303|DRUG|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
219402136|NCT01968044|DRUG|Gemigliptin|
219402137|NCT01968044|DRUG|Placebo to Linagliptin|
219402138|NCT05926986|OTHER|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
219402139|NCT05926986|OTHER|control|No additional treatment will be practiced to the control group.
219402140|NCT00034112|PROCEDURE|osteopathic manipulative treatment|
219402141|NCT01641315|BIOLOGICAL|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
219402142|NCT01129791|BEHAVIORAL|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
219402143|NCT01129791|BEHAVIORAL|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
219402144|NCT01129791|BEHAVIORAL|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
219402145|NCT00830427|DRUG|PF-00610355|100 mcg, QD, dry powder inhaler
219402146|NCT00830427|DRUG|PF - 00610355|600 mcg, QD, dry powder inhaler
219402147|NCT00830427|OTHER|Placebo|QD, dry powder inhaler
219402148|NCT00830427|DRUG|PF - 00610355|300 mcg, QD, dry powder inhaler
219402149|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
219402150|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
219402151|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
219402152|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
219402153|NCT01123239|BEHAVIORAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
219565352|NCT05924867|OTHER|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
219565353|NCT02214706|DRUG|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
219565354|NCT02214706|OTHER|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
219565355|NCT02214706|DEVICE|Pulsed Dye Laser|
219565356|NCT01008137|BIOLOGICAL|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
219565357|NCT01008137|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
219565358|NCT00383058|DRUG|the extract of green tea|
219565359|NCT06760273|OTHER|No Intervention: Observational Cohort|Observational study, no additional intervention
219565360|NCT00332267|PROCEDURE|Endotoxin infusion, Normobaric hypoxia|
219565361|NCT02608840|OTHER|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
219565362|NCT02608840|OTHER|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
219565363|NCT06767943|DIAGNOSTIC_TEST|12-lead electrocardiography|All patients were admitted to the intermediate care unit for the 1st 24-h PO for follow-up for the possibility of developing acute myocardial infarction (AMI), which was diagnosed according to the 2017 ESC Guidelines; by 12- lead electrocardiography
219565364|NCT06646887|OTHER|Electroporation|Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
219565365|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|nOPV1 containing \>10\^7.0 CCID50 per dose
219565366|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 2 (nOPV2)|nOPV2 containing ≥10\^5.0 CCID50 per dose
219565367|NCT06895486|BIOLOGICAL|Placebo (Sterile Water)|Sterile, nonpyrogenic preparation of water which contains no bacteriostat, antimicrobial agent, or added buffer
219565368|NCT06555289|DEVICE|Clareon PanOptix IOL|Spherical and toric T3
219189603|NCT06038552|PROCEDURE|radiofrequency ablation (RFA)|RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
219189604|NCT06038552|PROCEDURE|transarterial chemoembolization (TACE)|TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
219189605|NCT05902598|DRUG|VSA001 injection|also referred to as ARO-APOC3
219402154|NCT01123239|BEHAVIORAL|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
219565369|NCT06898528|BEHAVIORAL|The group-based mat exercise training on experimental group.|The training program is divided into two phases: the first phase focuses on fundamental movements, whereas the second phase introduces more advanced exercises. With progress, additional exercise equipment is incorporated, along with increased sets, duration, movement variations, and training intensity. Training sessions (10-week duration) can be conducted in a simple, progressive manner or a game-competitive format.The control group maintained their usual daily activities.
219565370|NCT06898528|BEHAVIORAL|The control group|The control group maintained their usual daily activities.
219565371|NCT05941611|DEVICE|Powered toothbrush|Oral-B powered toothbrush
219565372|NCT06442410|DEVICE|DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system|Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
219402155|NCT01037374|OTHER|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
219402156|NCT00708994|DRUG|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
219402157|NCT00708994|DRUG|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
219402158|NCT01984593|OTHER|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
219402159|NCT05951764|DIAGNOSTIC_TEST|Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)|For all patients PWV in (cm/s) will be collected from D-30 to D-1 before the procedure and at D3 postoperatively.
219402160|NCT00585299|OTHER|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
219402161|NCT00585299|OTHER|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
219402162|NCT03677089|BEHAVIORAL|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
219402163|NCT02269059|DRUG|MK-7680|MK-7680 10 mg and 100 mg capsules
219402164|NCT01221675|DRUG|Antibody TF2|preciblage with an antibody
219402165|NCT01221675|RADIATION|IMP-288-Lutetium|Internal Radiation
219402166|NCT01221675|RADIATION|IMP-288-Indium|Imaging
219402167|NCT05869851|OTHER|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
219402168|NCT00004747|DRUG|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
219402169|NCT04857398|DRUG|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
219565373|NCT06442410|OTHER|Conventional Medical Management (CMM)|The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
219189606|NCT05902598|DRUG|Placebo|Matching VSA001 injection
219402170|NCT05242276|DEVICE|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
219402171|NCT06058780|PROCEDURE|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
219402172|NCT06058780|PROCEDURE|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
219565374|NCT02500615|OTHER|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
219565375|NCT04163588|DRUG|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
219565376|NCT04163588|DRUG|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
219565377|NCT06903767|DEVICE|Automated Impaction (HAMMR)|For cases that are randomized to the automated impaction HAMMR group, the surgeon will utilize an automated impactor device for impaction of the implant during total hip arthroplasty.
219189607|NCT05907174|BEHAVIORAL|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
219189608|NCT06803225|DIAGNOSTIC_TEST|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
219402173|NCT04162886|OTHER|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
219402174|NCT01563627|OTHER|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
219402175|NCT01563627|DEVICE|Magnetic Resonance Imaging|
219402176|NCT06385964|DRUG|SHR-4597|SHR-4597 by dry powder inhalation
219402177|NCT06385964|DRUG|Placebo|Placebo by dry powder inhalation
219402178|NCT01800227|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
219402179|NCT04376268|DRUG|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219402180|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219402181|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219402182|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219402183|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219565378|NCT06903767|DEVICE|Manual Malleting|For cases that are randomized to the manual malleting group, the surgeon will utilize a mallet for impaction of the implant during total hip arthroplasty.
219565379|NCT06904092|DEVICE|Transcranial ultrasound stimulation|The TUS was administered using Transcranial Ultrasound Stimulator UNS-III (model UNS-III), which has passed the safety test for medical electrical equipment (GB9706.1-2007). Transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
219754868|NCT07003438|DRUG|Fecal microbiota transplantation (FMT)|FMT was slowly administered to the patient's small intestine with fecal suspension under anesthesia and patients received a second transplant through oral administration freeze-dried capsules containing the fecal matter.
219754869|NCT07003776|OTHER|Biological: Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against Pan- cytokeratin by immunohistochemical procedures.
219754870|NCT07005011|OTHER|oral irrigator|oral irrigator
219754871|NCT07002983|OTHER|motor control retraining exercises|"The motor control retraining package was targeted at correcting movement impairments of the scapula by re-educating muscle recruitment. There were two components to the package:~1. Motor control exercises to correct alignment and coordination, which involve a) learning optimal scapular orientation at rest and then controlling optimal orientation during active arm movements; b) muscle specific exercises for trapezius and serratus anterior~2. Manual therapy techniques commonly used in clinical practice to manage symptoms, as trigger point therapy and pectoralis minor supine manual stretch will be performed as necessary."
219002151|NCT01283360|DRUG|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
219565380|NCT06905379|OTHER|Moringa Oleifera|Moring Oleifera Varnish application Using a disposable bond brush, the varnish will be painted on the diagnosed surfaces, then the patient will be instructed to avoid brushing or flossing and to avoid hard and sticky food or any products that may contain alcohol (oral rinses, beverages, etc.) for the next 4 hours after application.
219754872|NCT07002983|OTHER|traditional physical therapy for shoulder dysfunction|shoulder joint mobilization, posterior capsule stretching and shoulder range of motion exercise (ROM) (Codman's pendulum exercises)
219754873|NCT07003711|OTHER|aerobic exercise and relaxation trainig|Aerobic exercise and progressive muscle relaxation training will be given to the exercise group.
219754874|NCT07003711|OTHER|aerobic exercise|Aerobic exercise will be applied to the control group.
219754875|NCT06673901|DEVICE|Measurments|Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
219754876|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level A|Oral, 21 days in each cycle
219754877|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level B|Oral, 21 days in each cycle
219402184|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219565381|NCT06905379|OTHER|Varnish|"MI Varnish application~The varnish will be applied on the clean surfaces according to manufacturer instructions as follows:~1. The foil cover of the MI Varnish unit dosage bottle will be peeled-off and MI Varnish will be stirred with the disposable brush before application.~2. The surfaces will be covered with a thin uniform layer using a disposable bond brush to avoid clumping.~3. The area will be allowed to become wet to ensure the setting of the varnish."
219565382|NCT06904950|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|Eight-sessions that include 1 session of psychoeducation and treatment orientation and 7 sessions of NDR. NDR consists of three stages: (1) nightmare image deconstruction, (2) meaning making and reprocessing of cognition and emotions related to images, (3) rescripting new dream images and rehearsal of new images.
219565383|NCT06904209|DEVICE|AI|"Each photo will be uploaded and analyzed by AI to predict the adequacy of their bowel preparation with immediate results of pass or not pass, indicating if their bowel preparation is adequate or inadequate. If the result is pass, patients will stop consuming the remaining PEG solution. If the result is not pass, patients will be advised to gently rub their lower abdomen in a clockwise direction or walk around and continue consuming the remaining PEG until the AI evaluation gives a pass result or until the full dose of 3 L PEG have been consumed. If the patient's rectal effluent deems IBP after consumption of the full dose of 3 L of PEG, an additional 1 L or more of PEG will be administered as a remedial dose at the discretion of the physician-in-charge."
219565384|NCT06905808|DEVICE|eSense 7Fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted into the body to measure pressure for urodynamics.
219565385|NCT02315547|DRUG|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
219754878|NCT06089070|DEVICE|FreeStyle Libre Continuous Glucose Monitor System|Continuous Glucose Monitor System for people with Type 2 Diabetes
219754879|NCT06679881|DRUG|Deucrictibant|Deucrictibant extended-release tablet for once daily oral use
219754880|NCT06629064|BEHAVIORAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
219754881|NCT06629064|OTHER|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
219754882|NCT06875141|BIOLOGICAL|DM199|DM199 is a synthetic form of rhKLK1
219754883|NCT06716021|DRUG|Placebo|The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.
219754884|NCT06716021|DRUG|Etripamil|The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
219402185|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219402186|NCT04376268|PROCEDURE|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
219754885|NCT07039058|BEHAVIORAL|Brief Dialectical Behavior Therapy-Skills Training|"The intervention is administered in a single session, lasting approximately 60 minutes and conducted in person. It is important to note that there are no ongoing sessions.~In the intervention, participants are provided with 5 basic skills of Dialectical Behavior Therapy: 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing body chemistry. These strategies are grouped under 3 categories: 1) Mindfulness, 2) Emotion regulation (mindfulness of current emotions, opposite-to-emotion action), 3) Tolerating distress (distraction, changing body chemistry). These skills are not designed to treat or solve the crisis. The main aim is to provide effective coping mechanisms that can be implemented quickly before the crisis escelates, to help overcome the intense emotional pain and keep the person alive."
219754886|NCT07039058|BEHAVIORAL|Relaxation|The control group will be subjected to a relaxation exercise, with the objective of managing participant expectations, researcher attention/interest, and time spent, as well as providing a coping strategy for stress.
219754887|NCT04187404|BIOLOGICAL|EO2401|Multiple dose of EO2401
219754888|NCT04187404|BIOLOGICAL|Nivolumab|Multiple dose of nivolumab
219754889|NCT07039084|DEVICE|Speech-generating device|The device is an iPad loaded with a grid-based and speech-generating communication application - a suitable application for the participant is determined at the beginning of the trial. This device is used in all 12 therapy sessions and implemented by a qualified speech pathologist in a natural, play-based setting.
219754890|NCT07039084|OTHER|Control|Participants will continue their current model of care. This means that if participants are receiving speech therapy locally, they may continue to do so given that no speech-generating device is introduced or used during this time. Participants will check in with the researching clinician at least once a week via telehealth or phone call - the aim is to stay in contact with families and reduce loss to follow-up. The clinician will also monitor treatment integrity and document any differences that may be present during this phase.
219754891|NCT06884670|DRUG|Interleukin-2|Tislelizumab 200mg ivd D1+Interleukin 2 100IU HD, d1-d14+ CapeOX (Capecitabine: 825mg/m2 bid po, d1-d14；Oxaliplatin 200 mg/m² ivd, d1)
219754892|NCT06884670|RADIATION|Radiotherapy|Radiotherapy 1.8Gy per time\*28
219754893|NCT06884670|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
219754894|NCT06884670|DRUG|Oxaliplatin|Oxaliplatin 200 mg/m² ivd, d1
219754895|NCT06884670|DRUG|Capecitabine|Capecitabine: 825mg/m2 bid po, d1-d14
219754896|NCT07040644|DRUG|Sacituzumab Govitecan (SG)|Sacituzumab govitecan will be administered at 10 mg/kg via intravenous infusion on Days 1 and 8 of each 21-day cycle. The treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
219754897|NCT07040644|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion on Day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
219754898|NCT07040644|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 125 mg/m² via intravenous infusion on Days 1 and 8 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
219754899|NCT06725095|OTHER|Placebo gel|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
219189609|NCT05471661|BIOLOGICAL|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
219189610|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
219402187|NCT04363086|BEHAVIORAL|iFightDepression online self-help tool|Computerized cognitive behavior therapy
219402188|NCT04363086|BEHAVIORAL|Treatment as Usual|TAU
219402189|NCT04363086|BEHAVIORAL|phone call|phone call
219402190|NCT01043523|DRUG|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
219402191|NCT05005208|OTHER|rehabilitation program with the support of the technological platform SI-ROBOTICS|"A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises."
219402192|NCT02558881|PROCEDURE|Virtual colonoscopy|
219402193|NCT02558881|PROCEDURE|Colon capsule|
219402194|NCT05901714|DRUG|Afimetoran|Specified dose on specified days
219402195|NCT05901714|DRUG|Phenytoin|Specified dose on specified days
219402196|NCT05901714|DRUG|Midazolam|Specified dose on specified days
219402197|NCT01724736|DRUG|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
219402198|NCT01724736|DRUG|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
219402199|NCT00307593|DRUG|Infliximab|Infliximab
219402200|NCT00307593|DRUG|Rituximab|Rituximab
219402201|NCT03633071|OTHER|Web-knee brace|Web -Knee Brace
219402202|NCT04034979|BEHAVIORAL|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
219402203|NCT02984826|OTHER|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
219754900|NCT06725095|OTHER|Enamel Matrix Proteins Derivative|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
219565386|NCT04947150|BEHAVIORAL|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
219754901|NCT06732999|BEHAVIORAL|Gaze-Contingent Music Reward Therapy (GC-MRT|Gaze-Contingent Music Reward Therapy (GC-MRT) is a treatment method for adults with social anxiety disorder found to be effective in reducing social anxiety in various RCTs. This method includes a computerized cognitive training to redirect threat-related attention patterns.
219402204|NCT02984826|OTHER|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
219402205|NCT04229446|BEHAVIORAL|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
219402206|NCT03549624|OTHER|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
219402207|NCT03527615|OTHER|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
219754902|NCT06926595|DRUG|Cyclophosphamide (primary intervention for GVHD prophylaxis)|This study evaluates the use of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) following allogeneic stem cell transplantation. The intervention involves administering PTCy on days +3 and +4 post-transplant, in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention. The goal is to assess the safety and efficacy of this regimen in patients undergoing reduced-intensity or non-myeloablative conditioning using peripheral blood stem cells from matched sibling, matched unrelated, and haploidentical donors
219565387|NCT04947150|BEHAVIORAL|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
219565388|NCT04947150|BEHAVIORAL|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
219402208|NCT05305638|OTHER|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
219402209|NCT02272322|DEVICE|cystocele repair with biomesh soft prolaps and endofast reliant|
219402210|NCT03186404|DRUG|Atorvastatin|Atorvastatin 40mg OD
219754903|NCT06689475|OTHER|Psychoacoustic approach|The psychoacoustic approach group will listen to normal heart sounds (S1, S2), abnormal heart sounds (S3, S4) and murmur sounds from the audio file uploaded to their mobile phones in the laboratory environment through headphones for 500 repetitions each.
219565389|NCT04947150|BEHAVIORAL|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
219754904|NCT06689475|OTHER|Simulation|The simulation group will practice auscultation of heart sounds in a one-to-one and repetitive manner, working with a high reality simulator. Trainers will act as facilitators during the cardiac auscultation practice of the students in the intervention groups.
219754905|NCT06888726|DEVICE|High-intensity transcranial alternating current stimulation (Hi-tACS)|The equipment used is the transcranial microcurrent stimulator (Nexalin ADI), operated by trained therapists following standardized instructions. Three Nexalin conductive electrodes are placed on the patient's head. A 4.45×9.53 cm electrode is placed on the forehead, corresponding to the Fpz region of the 10/20 international standard electrode placement system. Two 3.18×3.81 cm electrodes are placed on the bilateral dorsolateral prefrontal cortex, corresponding to the F3 and F4 regions of the international standard electrode placement system. The stimulation frequency is 77.5 Hz, and the current intensity is 15 mA.
219754906|NCT06888726|DEVICE|Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)|A sham device looks exactly the same as Nexalin ADI is used.
219754907|NCT06739291|DRUG|SIGX1094R|Single drug treatment by SIGX1094R, orally administered once daily.
219754908|NCT06740812|DRUG|Fosaprepitant for Injection|Fosaprepitant 150mg IV administered over 15 minutes
219754909|NCT06740812|DRUG|Metoclopramide Injection|Metoclopramide 10mg IV administered over 15 minutes
219754910|NCT06659705|DRUG|68Ga-FAPI-46 for PET / CT scan and 177Lu-EB-FAPI for therapy|Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.
219754911|NCT07056712|DIETARY_SUPPLEMENT|Fenugreek seed|Fenugreek seed: 1500 mg per day for 12 weeks
219754912|NCT07056712|OTHER|Placebo|Placebo: Calcined magnesia 1500 mg per day for 12 weeks
219754913|NCT06664788|DEVICE|ETHIZIA|ETHIZIA patch will be applied to bleeding site intraoperatively.
219754914|NCT06664788|DEVICE|SURGICEL Original|SURGICEL Original will be applied to bleeding site intraoperatively.
219754915|NCT06748989|DIETARY_SUPPLEMENT|Cortexium food supplement|Cortexium (a specially formulated dietary supplement with pyrroloquinoline quinone, γ-aminobutyric acid and B vitamins).
219402211|NCT03186404|DRUG|Placebo oral tablet|Placebo
219402212|NCT03356158|BIOLOGICAL|CPGJ602|Injection, q.w., 20 mg: 100 ml
219402213|NCT03356158|BIOLOGICAL|Cetuximab|Injection, q.w., 20 mg: 100 ml
219402214|NCT00921856|OTHER|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
219402215|NCT05784909|DEVICE|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
219402216|NCT04838691|BEHAVIORAL|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
219402217|NCT01675804|OTHER|Computerized cognitive rehabilitation|\- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
219402218|NCT01675804|DRUG|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
219402219|NCT01675804|OTHER|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
219189611|NCT01826071|OTHER|Static Stretch|Standing Gastrocnemius Stretch Standing Soleus Stretch Seated Gastrocnemius Stretch Seated Soleus Stretch Hamstring Stretch Quadriceps Stretch (Standing) Quadriceps Stretch (Side Lying)
219189612|NCT01826071|OTHER|Active Elongation|Mini Squat- Double Leg Mini Squat- Single Leg Prone Hip Extension with Knee Flexed 3 Position Straight Leg Raises Quadriceps Myofascial Release Heel Raises (Eccentric Strengthening) Single Leg and Double Leg Gastrocnemius Myofascial Release Calcaneal Glides
219189613|NCT06540651|OTHER|use of Luminettes ® with active light emission|Spectrum of 400 \< X \< 750 nm assumed active
219189614|NCT06540651|OTHER|use of Luminettes ® with a light emission presumed to have no therapeutic effect|Modification of spectrum parameters for wavelengths covered, with light emission in a spectrum of 560 \< X \< 650 nm assumed to have no therapeutic effect
219189615|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
219189616|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
219189617|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
219189618|NCT06517654|DEVICE|EMG-Biofeedback|The Neurotrac® Simplex device will be used for EMG-Biofeedback treatment. As in the muscle strength assessment procedure, the EMG reference electrode will be placed on the patient\&#39;s forearm, and 2 adhesive electrodes in the EMG channel will be placed on the patient\&#39;s perineal muscles. The patient will be asked to contract and relax the pelvic floor muscles at certain intervals in accordance with the visual and auditory stimuli made on the device screen or computer screen. The pelvic floor muscle contraction and rest period will last 5 seconds each. The program will continue for 2 days a week, 25 minutes per session and 8 weeks and will be performed in a clinical environment. During the treatment, the treatment will be visualized for the patient with different imagery. At the end of the games played, the patients'; scores (%), the lowest and highest EMG values will be recorded in mV. The treatment will be applied to the patients in two sessions per week.
219189619|NCT06517654|OTHER|Rebound Therapy|The program will be performed in a clinical environment for 8 weeks, 2 days a week, each session will be 30 minutes. The correct breathing pattern will be taught to the patient before starting the exercises. O2 saturation and maximum heart rate will be checked during the rest periods during the exercises. The maximum heart rate will be calculated with the formula (HRmax = 208 - 0.7 × age), and the exercise will be paused when it exceeds 80%. The patient will be asked to contract the pelvic floor muscles during the exercise. Necessary warnings regarding the preservation of posture will be made throughout the exercises. The exercise intensity will be increased progressively in order to ensure the patient's adaptation to the exercises.
219189620|NCT06517654|OTHER|Home Exercise Program|Home Exercise Program In addition to EMG-Biofeedback Therapy in Group 1, in addition to Rebound Therapy in Group 2, and in Group 3, only a home exercise program will be applied to patients 5 days a week. The exercise program consists of diaphragmatic breathing, piriformis stretching exercise, adductor stretching exercise, gluteal stretching exercise, cat-camel exercise, happy baby position, deep squat exercise, trunk rotator stretching exercises. Each exercise will be repeated 5 times on the right and left, and 20 seconds will be waited for each repetition.
219189621|NCT05906784|OTHER|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
219189622|NCT05906784|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
219189623|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
219189624|NCT06459843|OTHER|pursed lip breathing techniques|Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
219189625|NCT06459843|OTHER|coordinated breathing technique|Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
219565390|NCT06904976|BEHAVIORAL|Nature-focused mindfulness|The intervention consisted of a daily 30-minute self-guided practice structured in three parts: (1) participants first walked mindfully for 10 minutes in a natural environment of their choosing (e.g., local park, forest, garden), (2) upon reaching a suitable location, they engaged in a 10-minute guided mindfulness practice, and (3) concluded with a 10-minute mindful walk back.
219565391|NCT06904976|BEHAVIORAL|Noticing-nature|Participants allocated to the noticing-nature active control group will be instructed to walk in nature for 30 minutes per day and pay attention to how the natural objects/scenes they encounter in their daily surroundings make them feel over the 14-day period.
219002152|NCT03890172|OTHER|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
219189626|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
219189627|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
219402220|NCT00705224|BIOLOGICAL|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
219402221|NCT00705224|DRUG|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
219402222|NCT03960710|OTHER|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
219402223|NCT03960710|OTHER|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~\- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
219402224|NCT03960710|OTHER|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~\- Use of computer data to drive the artificial intelligence network."
219565392|NCT06905431|DIAGNOSTIC_TEST|Plyometric Training|"Frequency: Three sessions per week on non-consecutive days to allow for adequate recovery.~Intensity: High-intensity exercises performed at 80-90% of maximum effort. Exercises include box jumps, depth jumps, lateral bounds, and tuck jumps targeting explosive power and agility.~Time: Each session lasts approximately 45-60 minutes, including: Warm-up (10 minutes), Core Plyometric Exercises (30-40 minutes), Cool-down (5-10 minutes) Type: Explosive lower-body movements utilizing the stretch-shortening cycle (SSC) to improve neuromuscular coordination, sprint speed, and power."
219565393|NCT06905431|COMBINATION_PRODUCT|(High-Intensity Interval Training (HIIT)|Frequency: Three sessions per week (e.g., Tuesday, Thursday, Saturday) with a rest day between sessions. Intensity: Alternating between 85-95% of maximum heart rate during high-intensity intervals and 50-60% of maximum heart rate during recovery periods. Work-to-rest ratio of 1:2 (e.g., 30 seconds of high-intensity sprints followed by 60 seconds of low-intensity walking). Time: Each session lasts approximately 45-50 minutes, including: Warm-up (10 minutes), HIIT Intervals (25-30 minutes with 8-12 work-rest cycles), Cool-down (5-10 minutes) Type: Cardiovascular exercises such as sprinting, cycling, or shuttle runs designed to enhance anaerobic capacity, agility, and sprint speed.
219565394|NCT06905756|DIAGNOSTIC_TEST|Accelerated rehabilitation|15 subjects in group A will be receiving Accelerated Rehabilitation protocol alongwith baseline treatment. Accelerated rehabilitation consisting of three phases, following 12 week exercise regime. Pain reduction, mobility, strengthening, and functional recovery are part of the accelerated rehabilitation protocol for Achilles tendinopathy. Ice, TENS, range-of-motion exercises, isometric calf contractions, and a progressive transition to full weight-bearing based are the mainstays of Phase 1 (Weeks 1-4). Phase 2 (Weeks 5-8) focuses on balance training, resistance band exercises, and seated and standing calf raises as well as light functional workouts like cycling or walking. Phase 3 (Weeks 9-12) progresses to sport-specific and endurance exercises like swimming or running after including plyometric drills, eccentric heel drops, and advanced strengthening. Each exercise will be performed under supervision of skilled physiotherapist for 2 times daily, 2 sets of 5 repetitions.
219565395|NCT06905756|COMBINATION_PRODUCT|Eccentric strengthening exercises|Group B will be receiving eccentric strengthening exercises alongwith baseline treatment. Techniques of Curwin, Stanish et al will be used for eccentric training. For every exercise, participants do three sets of 15 repetitions, with a 30-second break in between. Weight is added gradually to enhance resistance (5-10 lbs or more, depending on tolerance). The eccentric strengthening regimen for Achilles tendinopathy advances every week. Participants use both feet without dorsiflexion to perform eccentric contractions in Week 1. By Week 3, the focus of the workouts is on the injured foot in maximum dorsiflexion. In Week 4, 10% body weight resistance is introduced, and in Week 5, an extra 5-10 pounds. From Week 6 to Week 8, resistance rises every two weeks. From Weeks 9 to 12, functional motions like hopping, single-leg heel drops, and sport-specific drills are incorporated, all of which are customized to meet individual goals.
219565396|NCT06903806|OTHER|Treadmill Exercise|Participants perform moderate to strenuous exercise for up to 20 minutes on a treadmill after swallowing a microbiome sampling capsule.
219565397|NCT06903806|DEVICE|Cooling Gloves|Cooling gloves to prevent rise in core body temperature during exercise
219565398|NCT06903806|DEVICE|Microbiome Capsule|Capsule used for collecting intestinal tract contents
219565399|NCT06905743|DIAGNOSTIC_TEST|Isometric Contraction-Based Pain Modulation Protocol for Achilles Tendinopathy|The standard recommendation for tendinopathy rehab became 30 to 45 second heavy isometric contractions repeated for 3 to 5 repetitions
219565400|NCT06905743|COMBINATION_PRODUCT|Eccentric Strengthening (Alfredson's Protocol for Achilles Tendinopathy )|The eccentric loading protocol, popularized by the research of Alfredson, consisted of 3 sets of 15 for both bent knee and straight knee heel raises with each heel lowering lasting 3-seconds
219002153|NCT03890172|OTHER|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
219002154|NCT02164760|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
219402225|NCT03960710|OTHER|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by an intern at the Lyon hospitals"
219402226|NCT03960710|OTHER|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by the neural network"
219402227|NCT05060510|DIAGNOSTIC_TEST|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
219402228|NCT06671847|DEVICE|THERABand resistance exercise bands|The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises
219402229|NCT06672562|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|NECT-Y consists of 14 90-minute sessions over the course of 14 weeks. The intervention combines psychoeducation, cognitive therapy, narrative therapy, goal-setting and peer support. Each group meeting includes educational materials, reflections, and active exercises that participants are guided through to personalize the content to their experiences. Participants will be provided with a workbook which allows them to follow the activities easier.
219402230|NCT06672562|OTHER|Usual care|Standard usual care. No study-specific care, but participants will be provided with information on community resources and support, and will also be encouraged to speak to their clinician if they are interested in learning about other services.
219402231|NCT06672965|DIETARY_SUPPLEMENT|anti-stress supplement|The anti-stress supplement was developed to provide relief from anxiety and depression levels.Subjects were given 60 capsules of calming supplement (30-day supply) and instructed to take two capsules each day orally with water.
219402232|NCT06672965|DIETARY_SUPPLEMENT|Placebo|Subjects were given 60 capsules of placebo (30-day supply) and instructed to take two capsules each day orally with water.
219402233|NCT00038259|DRUG|Aldesleukin|
219402234|NCT06671470|DRUG|YZJ-1139 tablets|Oral dose 20 mg
219402235|NCT06671470|DRUG|Ticagrelor Tablets|Oral dose 90 mg twice daily
219565401|NCT06611150|DRUG|Nab-paclitaxel|All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
219402236|NCT00000650|DRUG|Ditiocarb sodium|
219402237|NCT06671275|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
219402238|NCT06672770|OTHER|Functional Inspiratory Muscle Training|"The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises"
219402239|NCT06672770|OTHER|Basic Inspiratory Muscle Training|The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
219402240|NCT06672653|DRUG|"The monoterpenoid zinc tetra-ascorbo-camphorate (C14)"|The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
219402241|NCT06672653|DRUG|Distilled water group|Instead of C14, distilled water will be administered in this group.
219002155|NCT03508921|DRUG|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
219002156|NCT03508921|DRUG|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
219402242|NCT01066078|OTHER|Echocardiography and SonR recording|
219402243|NCT00787696|BEHAVIORAL|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
219565402|NCT03182751|DRUG|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
219565403|NCT03182751|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
219565404|NCT00550888|PROCEDURE|suture techniques|
219754916|NCT06748989|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement is completely identical weight and outlook capsule to Cortexium, with 50% microcrystalline cellulose and 50% starch.
219754917|NCT06747611|DRUG|Vancomycin, Neomycin and MTT capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
219754918|NCT06747611|DRUG|Placebo capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
219754919|NCT06738017|DRUG|BMN 349|250mg oral tablet
219754920|NCT06738017|DRUG|Placebo|250mg oral tablet
219402244|NCT06672887|OTHER|MiLES|The MiLES intervention is an open access website, accessible via an URL, but not traceable through any online search engine during the study period. Tailored for specific preferences and needs of different employees with cancer, the MiLES intervention consists of interactive videos, conversation checklists, tips and information regarding RTW guidance of employees with cancer, and an overview of involved stakeholders and relevant legislation. The MiLES intervention intends to optimize the RTW support the employer provides to the employee with cancer by enhancing the willingness and ability to implement the employer actions. The MiLES intervention focuses for example on fostering effective communication between the employer and employee, while disregarding assumptions based on previous experiences.
219402245|NCT04833985|PROCEDURE|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
219402246|NCT00027040|DRUG|Selegiline hydrochloride|
219565405|NCT06508840|OTHER|Verbal Health Literacy training session|"Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff."
219565406|NCT03146273|DIETARY_SUPPLEMENT|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
219565407|NCT03354455|DEVICE|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
219565408|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
219565409|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
219565410|NCT02374203|DIETARY_SUPPLEMENT|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
219565411|NCT03762837|OTHER|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
219565412|NCT01303237|DRUG|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
219565413|NCT01619579|DEVICE|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
219565414|NCT02124902|DRUG|Docetaxel|
219754921|NCT07058298|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment,the infusion doses will be (CAR-T cell count) 3 × 10\^5/kg.~Note: for subjects weighing ≤70 kg: number of infused CAR-T cells = 3 (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CART cells (fixed doses of GC012F Injection) = 3 (±20%) × 10\^5 × 70 kg."
219754922|NCT07060898|DIETARY_SUPPLEMENT|Active Product|Novel Nutritional Product targeting Cognition
219754923|NCT07060898|DIETARY_SUPPLEMENT|Placebo Product|Identical placebo product
219402247|NCT01833273|DRUG|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
219565415|NCT02124902|DRUG|Carboplatin|
219565416|NCT02124902|PROCEDURE|FDG-PET/MR|"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"
219565417|NCT06318832|OTHER|ICBT|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consists of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
219565418|NCT03907241|DRUG|Octanorm 16.5%|Human normal immunoglobulin
219565419|NCT04769115|DEVICE|Alert for temperature delta|If alert for potential complications refer to appropriate specialist
219565420|NCT03164837|DRUG|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
219565421|NCT02872051|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
219754924|NCT07060820|PROCEDURE|Radial Artery Puncture at 0-20 mm|Radial artery puncture performed 0-20 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
219754925|NCT07060820|PROCEDURE|Radial Artery Puncture at >21 mm|Radial artery puncture performed at a distance greater than 21 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
219754926|NCT05605093|DRUG|Shionogi Protease Inhibitor (S-217622)|S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
219754927|NCT05605093|DRUG|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
219754928|NCT02220985|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
219754929|NCT02220985|DRUG|Cyclophosphamide|Given IV
219754930|NCT02220985|DRUG|Fludarabine Phosphate|Given IV
219754931|NCT02220985|OTHER|Laboratory Biomarker Analysis|Correlative studies
219754932|NCT02220985|DRUG|Methotrexate|Given IV
219402248|NCT03344601|BEHAVIORAL|physical activity|The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
219402249|NCT04680286|DRUG|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
219402250|NCT04680286|OTHER|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
219402251|NCT05057585|BEHAVIORAL|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
219402252|NCT05998993|RADIATION|Stereotactic Body Radiation Therapy SBRT|This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
219565422|NCT02872051|OTHER|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
219565423|NCT02717078|OTHER|Diet Therapy|The intervention for both study groups will be a change in diet.
219565424|NCT02012452|BEHAVIORAL|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
219565425|NCT02012452|BEHAVIORAL|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
219565426|NCT03636087|PROCEDURE|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
219565427|NCT03636087|PROCEDURE|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
219754933|NCT02220985|DRUG|Mycophenolate Mofetil|Given IV and PO
219754934|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
219754935|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
219754936|NCT02220985|DRUG|Tacrolimus|Given IV or PO
219754937|NCT02220985|DRUG|Thiotepa|Given IV
219402253|NCT02004756|OTHER|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
219402254|NCT01635556|BEHAVIORAL|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
219402255|NCT04039685|OTHER|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
219402256|NCT04039685|OTHER|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
219565428|NCT03636087|PROCEDURE|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
219565429|NCT03636087|PROCEDURE|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
219565430|NCT03636087|PROCEDURE|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
219565431|NCT03636087|OTHER|Changing gloves before obturation|The treating dentist will change gloves before obturation
219565432|NCT03636087|OTHER|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
219754938|NCT02220985|RADIATION|Total-Body Irradiation|Undergo TBI
219754939|NCT06857487|DRUG|Qingre Huatan Formula|Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.
219754940|NCT06857487|DRUG|Qingre Huatan Formula placebo|Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.
219754941|NCT06857487|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
219754942|NCT06866236|DRUG|QRX-3|capsule
219402257|NCT04039685|OTHER|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
219189628|NCT06554912|PROCEDURE|Lymphatic Decompression|"Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures"
219402258|NCT00968253|DRUG|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
219402259|NCT00968253|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
219402260|NCT00968253|DRUG|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
219402261|NCT00968253|DRUG|Doxorubicin|50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
219402262|NCT00968253|DRUG|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
219189629|NCT05096338|OTHER|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
219402263|NCT00968253|DRUG|Mesna|600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
219402264|NCT00968253|DRUG|Methotrexate|200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
219402265|NCT00968253|DRUG|Ara-C (Cytarabine)|3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
219402266|NCT00968253|DRUG|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
219402267|NCT00968253|DRUG|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
219402268|NCT05256277|DRUG|CT101a|cytokine-induced memory-like NK cells
219402269|NCT03596177|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
219402270|NCT03596177|DRUG|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
219402271|NCT03659747|DIETARY_SUPPLEMENT|Probiotic|\- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
219402272|NCT03659747|DIETARY_SUPPLEMENT|Lactrase|\- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
219402273|NCT03659747|OTHER|Placebo|\- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
219402274|NCT02177851|DIETARY_SUPPLEMENT|Single oral iron dose of 120 mg per day for 3 consecutive days|
219402275|NCT02177851|DIETARY_SUPPLEMENT|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
219402276|NCT03569111|DEVICE|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
219402277|NCT01267097|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
219402278|NCT01267097|BEHAVIORAL|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
219402279|NCT03680794|OTHER|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
219402280|NCT01223976|OTHER|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
219565433|NCT03636087|OTHER|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
219565434|NCT03636087|RADIATION|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
219402281|NCT06047301|BEHAVIORAL|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
219402282|NCT06047301|BEHAVIORAL|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
219402283|NCT05599126|DRUG|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
219402284|NCT05599126|DRUG|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
219402285|NCT01736202|BIOLOGICAL|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
219402286|NCT00248313|DRUG|Rapamune®|
219565435|NCT03636087|RADIATION|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
219754943|NCT02796716|DEVICE|Testing on new technology called Accelerate ID/AST system|
219565436|NCT02688387|DRUG|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
219565437|NCT02688387|DRUG|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
219754944|NCT07131644|DRUG|Sirolimus|Comparison of different sirolimus discontinuation strategies.
219002157|NCT03508921|PROCEDURE|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
219002158|NCT01101932|DRUG|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
219002159|NCT01101932|DRUG|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
219002160|NCT01101932|DRUG|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
219002161|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
219402287|NCT02731508|DEVICE|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
219402288|NCT05052775|OTHER|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
219402289|NCT05052775|OTHER|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
219565438|NCT04529395|OTHER|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
219565439|NCT04529395|OTHER|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
219754945|NCT04533646|DRUG|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
219754946|NCT04533646|DEVICE|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
219754947|NCT05627674|BEHAVIORAL|Usual Care|Usual care incorporates guideline awareness and brief advice.
219754948|NCT05627674|BEHAVIORAL|RiskProfile-Clin|RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
219754949|NCT05627674|BEHAVIORAL|RiskProfile-Gen|RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
219754950|NCT07085117|DRUG|Teprotumumab|Participants received teprotumumab as an intravenous (IV) infusion.
219402290|NCT05052775|OTHER|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
219402291|NCT05509205|OTHER|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
219402292|NCT03398018|DRUG|repository corticotropin injection|80 units twice per week as a subcutaneous injection
219402293|NCT05633576|DRUG|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
219402294|NCT05633576|DRUG|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
219402295|NCT01916122|DRUG|Fluorestradiol (FES)|
219402296|NCT01916122|PROCEDURE|PET/CT Imaging|
219402297|NCT03912922|OTHER|Activity regime|Activity regime of 4 days followed by a test day.
219402298|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
219402299|NCT01301742|DRUG|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
219402300|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
219402301|NCT01321294|PROCEDURE|laparoscopic anti-reflux surgery|
219402302|NCT02614872|DRUG|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
219402303|NCT03141086|DRUG|LML134|LML134
219402304|NCT03141086|DRUG|Placebo|placebo
219402305|NCT00013624|DRUG|IV Levodopa|
219402306|NCT04666324|DRUG|Simethicone Solution|Oral daily treatment for four weeks
219402307|NCT04666324|DIETARY_SUPPLEMENT|Multilac Baby|Oral daily treatment for four weeks
219402308|NCT05196243|OTHER|Patients diagnosed as gastrointestinal mucosal lesions|Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer
219402309|NCT06673693|DRUG|Tislelizumab|SBRT
219402310|NCT01415622|DEVICE|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
219402311|NCT01415622|PROCEDURE|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
219402312|NCT01745627|DEVICE|755nm Alex laser|
219402313|NCT00390364|DRUG|everolimus|
219002162|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
219402314|NCT00390364|PROCEDURE|antiangiogenesis therapy|
219565440|NCT03813225|OTHER|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
219402315|NCT00390364|PROCEDURE|biopsy|
219402316|NCT00390364|PROCEDURE|diagnostic procedure|
219402317|NCT00390364|PROCEDURE|gene expression analysis|
219565441|NCT03388502|OTHER|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
219565442|NCT03388502|OTHER|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
219565443|NCT03730779|DRUG|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
219565444|NCT02938442|BIOLOGICAL|P10s-PADRE with MONTANIDE™ ISA 51 VG|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
219565445|NCT02938442|DRUG|Doxorubicin|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
219754951|NCT07083154|DRUG|Mazdutide|Mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
219754952|NCT07083154|DRUG|Placebo|Placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
219402318|NCT00390364|PROCEDURE|immunohistochemistry staining method|
219402319|NCT00390364|PROCEDURE|laboratory biomarker analysis|
219402320|NCT00390364|PROCEDURE|mutation analysis|
219402321|NCT00390364|PROCEDURE|protein tyrosine kinase inhibitor therapy|
219402322|NCT00390364|PROCEDURE|reverse transcriptase-polymerase chain reaction|
219402323|NCT01072864|OTHER|Walnuts|Consumption of 5 g of walnuts.
219402324|NCT01072864|OTHER|Walnuts|Consumption of 20 g of walnuts.
219402325|NCT01072864|OTHER|Walnuts|Consumption of 30 g of walnuts.
219402326|NCT01072864|OTHER|Walnuts|Consumption of 40 g of walnuts.
219402327|NCT04180410|DEVICE|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
219402328|NCT02630277|DRUG|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
219402329|NCT03201653|PROCEDURE|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
219402330|NCT05582577|COMBINATION_PRODUCT|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
219402331|NCT05582577|DRUG|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
219402332|NCT01052597|DRUG|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
219402333|NCT03228251|OTHER|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
219402334|NCT02994589|OTHER|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
219402335|NCT02994589|DEVICE|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
219402336|NCT02994589|OTHER|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
219402337|NCT06672029|OTHER|combining pattern-specific manual therapy, Schroth Best Practice exercise, and Gensingen brace application|"* The pattern-specific manual therapy: It was developed by our author. This therapy was done immediately before each SBP (Schroth Best Practice) exercise session, targeting both the spine and extra-spinal regions.~* The Schroth Best Practice exercises: It contains following 6 components: The physio-logic® program for sagittal profile correction, education on activities of daily living (ADLs), the 3D made easy program, the new Power Schroth program, the rehabilitation of walk, and neuromobilization.~* The Gensingen brace application: it was made according to the patients' Lehnert Schroth Classifications. the investigators recommended the patients to wear the brace for 21-23 hours per day during the first year. As the bone maturation reached Risser 4 to 4.5, the daily brace wearing time was gradually reduced."
219402338|NCT05585411|PROCEDURE|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
219402339|NCT05585411|PROCEDURE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
219402340|NCT06688084|OTHER|Molecular epidemiology of the collection|Next-generation genomic sequencing (MICRO\&BIO platform, MiSeq, Illumina) and bioinformatics analyses. After validating data quality, genomes will be re-assembled using Spades software (version 3.15.4) and CLC® (Qiagen), then compared with the National Center for Biotechnology Information GenBank database. They will also be analysed on the online Type-Strain Genomes Server platform to accurately identify the bacteria. Genome annotation will be done using the DDBJ Fast Annotation and Submission Tool. Single nucleotide polymorphisms (SNP) analysis based on the alignment of whole genomes and core-genomes will be carried out using version 7 of MAFFT (multiple alignment using fast Fourier transform) software, then quantified using snp-dists (version 0.6.3). This approach will enable the molecular epidemiology of the collection of strains in France and other European countries to be clarified, and the main circulating clades to be assessed, particularly depending on the origin of samples.
219402341|NCT06688084|OTHER|Study of the resistome of the S. pettenkoferi population|The resistome will be assessed by identifying known and described resistance genes in staphylococci using bioinformatics analyses of sequenced complete bacterial genomes. A search for plasmids will also be made using various specific software packages (ResFinder, CARD, PointFinder, Plasmidfinder, in-house pipeline).
219565446|NCT02938442|DRUG|Cyclophosphamide|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
219565447|NCT02938442|DRUG|Paclitaxel|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
219565448|NCT02928536|OTHER|no intervention|This is an observational study. No intervention is considered
219565449|NCT04403399|DRUG|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
219002163|NCT06197672|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
219002164|NCT05184244|OTHER|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
219754953|NCT07086703|OTHER|Induced hypothermia at 33°C|"Cooling and maintenance phase :~The aim is to achieve the target temperature of 33±0.5°C within 60 minutes after randomization. The target temperature of 33±0.5°C and device setting of 33°C will be maintained until 28 hours after randomization.~\- Rewarming: Normothermia will be restored by gradual rewarming at a rate of 0.2°C/h.~\- After rewarming: After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
219189630|NCT06066983|BEHAVIORAL|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
219189631|NCT06066983|OTHER|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
219402342|NCT06688084|OTHER|Study of the virulome of the S. pettenkoferi population|The virulome of the strains will be studied based on the genomic sequencing data obtained and with reference to the literature on Staphylococci. Various specific software packages (Pathogenfinder, Virulencefinder, in-house pipeline) will be used for this purpose.
219402343|NCT06688084|OTHER|Study of the resistance profiles of all S. pettenkoferi isolates|Antibiotic resistance will be assessed using a Sensititer® plate (Thermo ScientificTM, Illkirch) to evaluate the minimum inhibitory concentration of isolates against a series of antibiotics commonly used for S. pettenkoferi infections, including new molecules currently on the market or in development, such as Ceftaroline, Ceftobiprole, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Minimum inhibitory concentration values will be interpreted in accordance with the recommendations of the Antibiogram Committee of the Société Française de Microbiologie (https://www.sfm-microbiologie.org/2021/04/23/casfm-avril-2021-v1-0/).
219402344|NCT06688084|OTHER|Selection of strains for in-depth phenotypic study|"Different strains of S. pettenkoferi isolated from foot osteitis in diabetic patients and non-diabetic osteitis will be selected according to the clades identified and phenotypically characterised by further analysis:~* Observation of culture characteristics (culture requirements, growth time, colony size and haemolytic capacity), (n=20)~* Determination of growth curves by measuring absorbance at 600 nm using the Infinite M Mano automatic absorbance reader (TECAN, Lyon), (n=20)~* Study of the ability to form biofilm in the presence (antibiofilmogram) (n=85) or absence (BioFilm Ring® test, Biofilm Control, St Beauzire) (n=85) of various antibiotics commonly used for the treatment of S. pettenkoferi infection during osteitis."
219402345|NCT06688084|OTHER|Selection of strains (n=3) for the virulence study|"Three strains of S. pettenkoferi isolated from foot osteitis in diabetic patients will be selected on the basis of the clades identified and the study of the virulome in order to be analysed on :~* In vitro cell culture models of macrophages (RAW 264.7) and osteoblasts (MC3T3-E1) to assess the invasion potential of these isolates by measuring internalisation rates (TECAN, Lyon) and LDH release (CyQUANT LDH Cytotoxicity kit), a sign of cellular toxicity of the isolate.~* An in vivo wound model on diabetic zebrafish (Dario rerio) with evaluation of their survival at 48h in the presence of the isolates by immersion.~These models were developed at the MICRO\&BIO Platform and the INSERM 1047 VBIC unit."
219402346|NCT01764646|RADIATION|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
219402347|NCT01764646|RADIATION|Volumetric modulated arc therapy|Highly conformational dose distribution
219402348|NCT01764646|RADIATION|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
219402349|NCT04947566|DRUG|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
219402350|NCT03860844|DRUG|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
219402351|NCT03860844|DRUG|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
219402352|NCT03860844|DRUG|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402353|NCT03860844|DRUG|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402354|NCT03860844|DRUG|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402355|NCT03860844|DRUG|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219402356|NCT03860844|DRUG|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402357|NCT03860844|DRUG|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402358|NCT03860844|DRUG|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402359|NCT03860844|DRUG|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402360|NCT03860844|DRUG|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402361|NCT03860844|DRUG|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219402362|NCT03860844|DRUG|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219402363|NCT03860844|DRUG|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219002165|NCT04446520|PROCEDURE|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
219565450|NCT04403399|DRUG|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
219565451|NCT03093935|DEVICE|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
219565452|NCT00172068|DRUG|Zoledronic acid + Calcium/Vitamin D|
219565453|NCT01938352|BIOLOGICAL|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
219565454|NCT01938352|BIOLOGICAL|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
219565455|NCT01606228|DRUG|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
219565456|NCT00613860|DEVICE|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
219565457|NCT02915237|DIETARY_SUPPLEMENT|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
219565458|NCT02915237|DIETARY_SUPPLEMENT|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
219565459|NCT02765672|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
219565460|NCT02765672|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
219565461|NCT02765672|BEHAVIORAL|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
219565462|NCT02765672|BEHAVIORAL|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
219565463|NCT02765672|BEHAVIORAL|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
219565464|NCT02765672|BEHAVIORAL|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
219565465|NCT02765672|PROCEDURE|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
219565466|NCT02765672|PROCEDURE|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
219565467|NCT02765672|PROCEDURE|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
219565468|NCT02765672|PROCEDURE|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
219565469|NCT02765672|PROCEDURE|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
219565470|NCT02294448|DRUG|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
219565471|NCT02946606|DRUG|GX-H9|Human growth hormone
219565472|NCT02946606|DRUG|Genotropin|Human growth hormone
219565473|NCT01974076|DEVICE|Active tDCS + CBT|
219565474|NCT01974076|DEVICE|Sham tDCS + CBT|
219565475|NCT01675076|DRUG|Dabigatran|NOAC
219565476|NCT01675076|DRUG|Rivaroxaban|NOAC
219565477|NCT01675076|DRUG|Apixaban|NOAC
219565478|NCT02096367|OTHER|Gait analysis|
219565479|NCT02096367|OTHER|Kinematic gait analysis in lower limb|
219565480|NCT02096367|OTHER|Analysis of static posture|
219565481|NCT02096367|OTHER|Gait on treadmill|Treadmill during 2 minutes
219565482|NCT02096367|DEVICE|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
219565483|NCT04100096|DRUG|Brexpiprazole|Tablet
219565484|NCT04100096|OTHER|Placebo|Tablet
219565485|NCT02612181|DRUG|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
219565486|NCT05507034|DIAGNOSTIC_TEST|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
219565487|NCT04787952|OTHER|cold expossure|subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
219565488|NCT03232255|OTHER|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
219565489|NCT00517543|DRUG|GW856553|
219565490|NCT05382156|DRUG|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
219565491|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) orally
219565492|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
219565493|NCT04815395|DRUG|Placebo|Administration of placebo orally
219402364|NCT03860844|DRUG|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219402365|NCT03860844|DRUG|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
219402366|NCT03860844|DRUG|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
219402367|NCT03860844|DRUG|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
219402368|NCT03809572|BEHAVIORAL|Mindfulness Based Cognitive Therapy|See Arm description
219402369|NCT05582837|DRUG|nortriptyline + topiramate|nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
219402370|NCT06693596|DIAGNOSTIC_TEST|Group 2: Conservative management (follow-up)|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the adnexal mass is seen and if the decision is to manage the adnexal mass conservatively, the patient will be re-scanned at 6 weeks (maximal range 6-8 weeks), 3 months (+/- 2 weeks) and 12 months (maximal range 10-14 months)"
219402371|NCT06693596|PROCEDURE|Group 1: Surgical management|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the patient requires surgery, no further ultrasound scans will be required."
219402372|NCT06693453|OTHER|Electroacupuncture and Dry cupping|This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
219402373|NCT06693453|OTHER|Electroacupuncture and Sham Dry cupping|This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
219402374|NCT00968578|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
219402375|NCT00968578|DRUG|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
219402376|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
219402377|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
219402378|NCT06693206|OTHER|Evaluation of aerobic capacity|A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
219402379|NCT07035106|DEVICE|Wearable Health Monitoring|Participants receive a Garmin Vivosmart 5, Garmin Index S2 Smart Scale, and Garmin Index BPM blood pressure monitor for daily health tracking. Devices sync to the Fitrockr mobile application.
219402380|NCT07035106|BEHAVIORAL|Digital Health Summary and Lifestyle Counseling|Participants receive bi-weekly health summaries via email generated from wearable data and may opt in to monthly video-based lifestyle consultations with trained study staff.
219402381|NCT06713213|OTHER|Flow-regulated nasal oxygen delivery system (FRNDS)|"FRNDS is a novel cannula device that can both measure tidal volume (VT) in real time while simultaneously delivering air to the test subject.~After collecting data without any flow through the FRNDS cannula for 2 minutes, varying amounts of medical air ( 21% Fio2) starting with 2 Liters for two minutes , 4 liters for 2 minutes, 6 liters for two minutes and 8 liters for two minutes would be delivered while monitoring and recording data previously described with the FRNDS device."
219402382|NCT06926062|OTHER|Best Practice|Provide vaccinations per usual care
219402383|NCT06926062|OTHER|Educational Intervention|Review messages on safety and side effects
219402384|NCT06926062|OTHER|Educational Intervention|Review messages on vaccine effectiveness
219402385|NCT06926062|OTHER|Educational Intervention|Review messages on sexual activity
219402386|NCT06926062|OTHER|Educational Intervention|Review messages on HPV vaccine for boys
219402387|NCT06926062|OTHER|Educational Intervention|Review message on age to start vaccine
219402388|NCT06926062|OTHER|Educational Intervention|Review messages on school entry requirements
219754954|NCT07086703|OTHER|Control normothermia|"Participants whose initial temperature is below 33°C may be actively rewarmed to 36.5°-37.7°C, at which point active rewarming will be stopped and passive rewarming performed according to the latest guidelines. Participants whose initial temperature is above 33°C will not be actively rewarmed to normothermia. The goal will be to maintain temperature no higher than 37.8°C.~After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
219754955|NCT04163757|DIETARY_SUPPLEMENT|crocin|2 tablets crocin per day
219754956|NCT04163757|DIETARY_SUPPLEMENT|placebo|2 tablets placebo per day
219754957|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
219402389|NCT06926062|OTHER|Interview|Ancillary studies
219402390|NCT06926062|OTHER|Questionnaire Administration|Complete a survey
219402391|NCT06926062|OTHER|Questionnaire Administration|Ancillary studies
219402392|NCT06926062|BEHAVIORAL|Training and Education|Receive interpersonal communication training
219754958|NCT07091123|DEVICE|Pain pump|Spinal catheter place under local anesthesia.
219754959|NCT07091123|DRUG|Bupivacain 0.625%/Fentanyl 2mcg/ml|A solution containing fentanyl 2 mcg/mL and bupivacaine 0.625 mg/mL at an infusion rate of 0.5 ml/hr.
219402393|NCT06926062|BEHAVIORAL|Training and Education|Receive the vaccination workflow training
219402394|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the interpersonal communication strategy
219402395|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the vaccination workflow training strategy
219402396|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using both the interpersonal communication strategy and the vaccination workflow training strategy
219402397|NCT06703190|BIOLOGICAL|Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated|Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2
219402398|NCT06703190|BIOLOGICAL|Not vaccinated with 2024-2025 formulated COVID-19 vaccine|The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.
219565494|NCT03664050|DRUG|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
219565495|NCT03664050|PROCEDURE|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
219565496|NCT02749760|OTHER|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
219565497|NCT02749760|OTHER|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
219565498|NCT04825041|DIAGNOSTIC_TEST|Patency test|Successive flow test, bubble flow test and peristalsis test
219565499|NCT06064734|DEVICE|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
219565500|NCT06615882|DEVICE|stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)|"I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography."
219565501|NCT01647711|DRUG|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
219565502|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M2
219565503|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M3
219565504|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
219402399|NCT04379804|PROCEDURE|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
219402400|NCT04379804|PROCEDURE|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
219402401|NCT06715982|DRUG|JAK Inhibitor|JAK inhibitors for 28 days
219565505|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
219565506|NCT05403957|OTHER|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
219565507|NCT05403957|OTHER|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
219565508|NCT05403957|OTHER|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
219565509|NCT01123096|PROCEDURE|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
219565510|NCT01123096|OTHER|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
219565511|NCT03898102|DRUG|Regorafenib|regorafenib plus zinc gluconate
219565512|NCT03898102|DIETARY_SUPPLEMENT|Zinc gluconate supplement|Zinc gluconate supplement
219565513|NCT05019482|BEHAVIORAL|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~1. Design-based innovative workshops during the first week;~2. 8-weeks program of Physical Activity constructed by users~3. Information session focusing on the promotion of active behaviors~4. Feedback provided to the users with an individualized report"
219002166|NCT05000476|OTHER|eye mask and earplugs|Materials similar to those offered on long commercial flights
219565514|NCT01344616|BEHAVIORAL|lifestyle support|computer-based lifestyle improvement support and clinician support
219402402|NCT04805567|DEVICE|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
219402403|NCT04527172|DIAGNOSTIC_TEST|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
219402404|NCT01678807|BIOLOGICAL|MK-8237 6 DU|
219402405|NCT01678807|BIOLOGICAL|MK-8237 12 DU|
219402406|NCT01678807|BIOLOGICAL|Placebo|
219402407|NCT03306069|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
219402408|NCT03306069|OTHER|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min"
219402409|NCT03306069|OTHER|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min"
219402410|NCT03306069|OTHER|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min"
219402411|NCT03806595|DRUG|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
219402412|NCT03806595|DRUG|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
219402413|NCT02645305|BIOLOGICAL|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
219402414|NCT01173627|DRUG|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
219402415|NCT01173627|DRUG|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
219402416|NCT06786286|DRUG|[14C]-ITI-1284|\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
219402417|NCT00931788|DRUG|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
219402418|NCT00931788|OTHER|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
219402419|NCT00358618|DRUG|Propofol|See Detailed Description.
219402420|NCT06930144|DRUG|active folate|Daily oral intake of active folate 800ug combined with basic diabetic treatment
219002167|NCT05000476|OTHER|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
219002168|NCT01328925|DRUG|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
219402421|NCT06930144|DRUG|Placebo|take oral placebo daily combined with basic diabetic treatment
219402422|NCT06930924|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet. Parents will also attend a 60-minute online peer support and information workshop
219402423|NCT06929455|OTHER|Flavor additives|Various flavors will be added to API samples. The particular APIs and flavor additives to be studied will be determined in part by on-going in work using in vitro taste models (cell systems expressing taste receptor proteins), so there is no full prespecified list.
219402424|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine|• Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 hrs.
219402425|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant|Patients in group II with ongoing intravenous norepinephrine only
219402426|NCT06929728|DEVICE|blood pressure measurments devices|measure arterial blood pressure by arm cuff devises
219402427|NCT06926023|DEVICE|1550nm non-ablative fractional laser|Treatment with the 1550nm non-ablative fractional laser for female pattern hair loss to the frontal and crown of scalp.
219402428|NCT06926023|DEVICE|1927 thulium fractional laser|Treatment with the 1927 thulium fractional laser for female pattern hair loss to the frontal and crown of scalp.
219565515|NCT01014416|DRUG|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
219565516|NCT04694612|DRUG|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
219565517|NCT04694612|DRUG|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
219565518|NCT04694612|DRUG|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
219565519|NCT02760264|DRUG|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
219565520|NCT02760264|DRUG|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
219565521|NCT02760264|DRUG|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
219565522|NCT02760264|DRUG|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
219565523|NCT02480218|OTHER|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
219565524|NCT05918822|DRUG|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
219565525|NCT05918822|DRUG|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
219565526|NCT05918822|DRUG|Rabeprazole|Rabeprazole tablet.
219565527|NCT01739725|DEVICE|Stent insertion|The patient will receive the helical stent
219565528|NCT04617392|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
219565529|NCT04617392|OTHER|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
219402429|NCT03531645|DRUG|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
219402430|NCT03531645|DRUG|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
219402431|NCT00155285|PROCEDURE|computed tomography|
219402432|NCT06904794|BEHAVIORAL|GAMBL-OUT program|The GAMBL-OUT program consists of two sessions: the first one involves a digital escape room to be delivered in the classroom and a series of physical props to be used during the experience. In small groups (4-5 students), participants need to work together to solve different puzzles and riddles, all of them related to the story of young adults who are dealing with problem gambling. By the end of the game, which will have a limited time (50 minutes), each group will have gained access to a different password. The second session will start from here: each group will share their password so the final puzzle can be solved, and the game will conclude with in a group discussion about what was learned (40 minutes).
219402433|NCT07091448|DEVICE|Amnion chorion membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane Biotivity™ A/C Plus.
219402434|NCT07091448|DEVICE|Collagen membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane CopiOs..
219402435|NCT03245632|OTHER|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
219402436|NCT06679231|BEHAVIORAL|Stress Ball|After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable. In addition, the student's support to the patient will make the examination more comfortable and contribute to the participant's psychological well-being.
219402437|NCT01704872|DRUG|ch14.18/CHO|
219565530|NCT00013494|PROCEDURE|Stroke Rehabilitation|
219565531|NCT03360175|OTHER|No intervention - observational study|No intervention - observational study
219565532|NCT01796964|DRUG|ESBA1008 solution|For intravitreal (IVT) injection
219565533|NCT01796964|DRUG|Aflibercept|For intravitreal (IVT) injection
219189632|NCT03307863|DRUG|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
219189633|NCT03307863|DRUG|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
219402438|NCT00370149|DEVICE|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
219565534|NCT04025684|OTHER|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
219565535|NCT04025684|OTHER|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
219565536|NCT04025684|OTHER|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
219565537|NCT04025684|OTHER|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
219565538|NCT06130787|BIOLOGICAL|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
219565539|NCT04458961|PROCEDURE|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
219565540|NCT04458961|PROCEDURE|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
219565541|NCT00003293|DRUG|leflunomide|
219565542|NCT00003293|DRUG|procarbazine hydrochloride|
219565543|NCT04577885|DRUG|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
219402439|NCT00370149|DEVICE|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
219402440|NCT04389801|DRUG|Desferal 500 MG Injection|iron chelating agent
219402441|NCT06233032|DRUG|Ephedrine|Patient Will receive 6mg IV
219402442|NCT06233032|DRUG|Dexmedetomidine|Patient Will receive 30mcg IV
219565544|NCT05815082|PROCEDURE|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
219565545|NCT05815082|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
219565546|NCT02070757|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
219565547|NCT02070757|DRUG|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
219565548|NCT05896215|DRUG|KNP2002|Dairy topical administration for 12 weeks
219565549|NCT05896215|DRUG|Placebo of KNP2002|Dairy topical administration for 12 weeks
219565550|NCT04531787|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
219565551|NCT01546922|DRUG|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
219565552|NCT05281926|DRUG|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
219565553|NCT04171557|BEHAVIORAL|Bicycling|Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
219565554|NCT03918941|DEVICE|Carey|mobile application
219565555|NCT03918941|OTHER|conventional information|leaflet, internet link and oral information
219565556|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
219565557|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
219565558|NCT03122587|DEVICE|Active sham transcranial alternating current stimulation|Active sham (placebo)
219565559|NCT02940678|OTHER|No intervention|
219402443|NCT00719732|DEVICE|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
219402444|NCT03103269|BEHAVIORAL|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
219402445|NCT03103269|OTHER|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
219402446|NCT06910137|DRUG|retifanlimab|Administered intravenous as defined in the protocol.
219565560|NCT01613378|OTHER|No intervention|No intervention administered in this study
219565561|NCT03170388|DRUG|IDP-126 Gel|Gel
219565562|NCT03170388|DRUG|IDP-126 Component A|Component A
219565563|NCT03170388|DRUG|IDP-126 Component B|Component B
219565564|NCT03170388|DRUG|IDP-126 Component C|Component C
219565565|NCT03170388|DRUG|IDP-126 Vehicle Gel|Vehicle Gel
219565566|NCT03113526|PROCEDURE|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
219565567|NCT02285634|DRUG|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
219565568|NCT02285634|DRUG|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
219565569|NCT02285634|DRUG|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
219565570|NCT02285634|DRUG|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
219402450|NCT02719483|DEVICE|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
219402451|NCT02719483|PROCEDURE|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
219402452|NCT04977505|DEVICE|pushlock|The surgery procedure was performed with pushlock for fixation
219402453|NCT04977505|DEVICE|gryphon|The surgery procedure was performed with Gryphon for fixation
219402454|NCT00195559|DRUG|Levonorgestrel/Ethinyl Estradiol|
219402455|NCT03344497|OTHER|VC Group|VC (Conventional Consultation/Video) Group
219402456|NCT05636618|DRUG|[203Pb]VMT-α-NET|\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
219402457|NCT05636618|DRUG|[212Pb]VMT-α-NET|\[212Pb\]VMT-α-NET is administered by intravenous infusion for treatment of SSTR2 expressing neuroendocrine tumors.
219402458|NCT06915467|PROCEDURE|Umbilical vein catheterization through Wharton's jelly procedure|All patients included will receive the Umbilical vein catheterization through Wharton's jelly procedure as first-line treatment: placement of the umbilical line through Wharton's jelly, with simultaneous and systematic preparation of umbilical venous catheter (UVC)
219402459|NCT05295615|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
219402460|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
219402461|NCT06920901|DRUG|APG777|APG777 subcutaneous injection
219402462|NCT06920901|DRUG|Placebo|Matching placebo subcutaneous injection
219402463|NCT06922110|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.
219402464|NCT02158221|DRUG|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
219402465|NCT06931860|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
219402466|NCT06931860|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
219402467|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
219189634|NCT03307863|DRUG|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
219189635|NCT05393388|DRUG|[18F]AV-1451|\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
219402468|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
219402469|NCT00413569|PROCEDURE|cervical spine surgery|
219402470|NCT07146997|DIETARY_SUPPLEMENT|Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB|"Group I - Placebo Group (Control) Intervention: Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB.~Purpose: This group serves as the control to establish a baseline anesthetic success rate without active premedication.~Expected Outcome: Lower IANB success rate due to lack of anti-inflammatory intervention."
219402471|NCT07146997|DRUG|Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB|"Group II - Ibuprofen Group Intervention: Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB.~Purpose: Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and inflammation, which can enhance anesthetic efficacy.~Expected Outcome: Improved IANB success rate compared to placebo, but possibly lower than combination therapy."
219754960|NCT07091123|DEVICE|Spinal Cord Stimulator (SCS)|"Two spinal cord stimulation leads will then be advanced under fluoroscopy to the target area, typically around T7-T9 in the posterior epidural space.~Currently, there are six manufacturers of spinal cord stimulation devices with implanted programmable generators or receivers."
219754961|NCT04106505|BEHAVIORAL|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
219754962|NCT04106505|BEHAVIORAL|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
219754963|NCT06743308|OTHER|Best Practice|Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits
219754964|NCT06743308|OTHER|Questionnaire Administration|Ancillary studies
219754965|NCT06764121|OTHER|Haskap Berry Powder|The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.
219189636|NCT05125783|OTHER|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
219754966|NCT06764121|OTHER|Placebo Powder|The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.
219754967|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
219754968|NCT05743075|DRUG|Placebo|Placebo solution
219754969|NCT06829550|DIAGNOSTIC_TEST|indirect- 3D digital scanning|examination for dental caries, erosive tooth wear and dental fluorosis using direct assessment (visual) and indirect assessment (digital scanning)
219754970|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
219754971|NCT05405595|DRUG|ADG126|ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
219754972|NCT05405595|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
219754973|NCT05405595|DRUG|Standard of Care (Trifluridine/Tipiracil-Bevacizumab)|The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.
219754974|NCT05405595|DRUG|Standard of care (Fruquintinib)|The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.
219754975|NCT07116486|DIAGNOSTIC_TEST|Radiopharmaceutical 18F-FSPG|Given by injection
219189637|NCT06318182|OTHER|Education|Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
219402472|NCT07146997|DRUG|Group III - Serratiopeptidase Group|"Group III - Serratiopeptidase Group Intervention: Patients will receive serratiopeptidase (10 mg or standard dose) orally, 1 hour before the IANB.~Purpose: Serratiopeptidase is a proteolytic enzyme with anti-inflammatory, mucolytic, and fibrinolytic properties. It helps reduce tissue inflammation by breaking down inflammatory mediators and possibly inhibiting prostaglandin production.~Expected Outcome: Improved IANB success rate compared to placebo; effectiveness may vary compared to ibuprofen alone"
219402473|NCT07146997|COMBINATION_PRODUCT|Group IV - Combination Group (Ibuprofen and Serratiopeptidase)|"Group IV - Combination Group (Ibuprofen and Serratiopeptidase) Intervention: Patients will receive a combination of ibuprofen and serratiopeptidase orally, 1 hour before IANB. The doses will be the same as those used in Groups II and III, respectively.~Purpose: This group is designed to test the synergistic effect of combining an NSAID (ibuprofen) and a proteolytic enzyme (serratiopeptidase) to maximize inflammation control and increase the success of IANB in inflamed pulp tissue.~Expected Outcome: Highest success rate of IANB due to dual action on prostaglandin inhibition and tissue inflammation reduction"
219402474|NCT07147062|PROCEDURE|Rectus Sheath Block|A total volume of 0.5 mL/kg of 0.25% bupivacaine-distributed equally between both sides-will be injected bilaterally under direct ultrasound guidance.
219402475|NCT07147062|PROCEDURE|Caudal Epidural Block|"A 22G caudal epidural needle will be inserted at approximately a 45° angle toward the sacral hiatus, and the characteristic click sensation will be felt upon passing the sacrococcygeal ligament. The needle will then be advanced carefully in the cephalad direction, parallel to the longitudinal axis of the spinal canal. After confirming correct placement by negative aspiration, 1 mL/kg of 0.25% bupivacaine will be administered."
219402476|NCT01461577|DRUG|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
219402477|NCT07150520|DEVICE|Virtual Reality-Based Optokinetic Stimulation (OKS)|A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
219402478|NCT07161908|DEVICE|Pulse oximeter|"To ensure proper treatment, the infant will be continuously monitored with a pulse oximeter. Based on oxygen saturation levels, the treatment may be adjusted according to pre-established protocols. It is required that the saturation stays above a certain value for more than 95 % of the 12-hour measurement period. If the defined saturation values are reached, the parents will reduce the oxygen flow by one degree for 20 minutes in the hospital/home setting (20 minute test) and if the saturation values remain at 93 % or more during this period, overnight 12 hour monitoring will also be performed to confirm stable saturation values of 93 % or more for 95 % or more of the monitoring time.~Thanks to modern specialized pulse oximeters, it is possible to ensure accurate, long-term, remotely managed monitoring of the infant and to interactively optimize oxygen therapy based on current oxygen saturation levels."
219402479|NCT07162233|PROCEDURE|derotation osteotomy utilizing Kirschner wires for the correction of congenital proximal radioulnar synostosis|"The level of distal radial and proximal ulnar osteotomies is determined under C- arm. A k-wire is inserted in the outer border of the metaphysis of the radius distal to the level of the osteotomy, engaging and transfixing the radioulnar joint, small skin incision is made over the dorsal aspect of the forearm at the level of distal radial osteotomy, dissection of subcutaneous tissue with good exposure of the extensor tendons, transverse osteotomy is done using 2.5 mm drill bit and small sharp osteotme, allowing derotation movement of the distal part of the radius using the k-wire.~Another small skin incision is made over the level of proximal ulnar osteotomy, dissection of subcutaneous tissue, another ulnar transverse osteotomy is done distal to the level of the proximal radioulnar synostosis. Derotaion of the forearm is adjusted in the functional position of the forearm in around (10˚:20˚supination), wound closure using absorbable Vicryl sutures. Above elbow cast is used f"
219402480|NCT07162090|DRUG|Roxadustat|Patients were administered roxadustat orally to observe its impacts on renal anemia and sarcopenia.
219402481|NCT07162090|DRUG|Recombinant human erythropoietin (EPO)|Recombinant human erythropoietin was administered to patients as a control group to investigate its impacts on renal anemia and sarcopenia.
219402482|NCT07162545|OTHER|stroboskopic visual training|Players in the study group will wear stroboscopic glasses for 10 minutes a day, two days a week, for eight weeks during their routine training. Evaluations will be repeated at the end of the eight weeks.
219402483|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
219402484|NCT05110742|DRUG|Cyclophosphamide|Given by IV
219402485|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
219402486|NCT03272334|DRUG|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
219402487|NCT03404336|BEHAVIORAL|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
219402488|NCT03404336|OTHER|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
219402489|NCT04883437|DRUG|Acalabrutinib|Given PO
219402490|NCT04883437|BIOLOGICAL|Obinutuzumab|Given IV
219189638|NCT04567537|DEVICE|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
219402491|NCT04883437|OTHER|Quality-of-Life Assessment|Ancillary studies
219402492|NCT04883437|OTHER|Questionnaire Administration|Ancillary studies
219402493|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
219402494|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
219402495|NCT06246916|DRUG|fianlimab|Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
219402496|NCT06246916|DRUG|cemiplimab|IV administration Q3W in combination with fianlimab
219402497|NCT06246916|DRUG|relatlimab+nivolumab|IV administration every 4 weeks (Q4W)
219402498|NCT06303986|OTHER|NeoMonki|Collection of Data for assessing the reliability of Neomonki and Realtime monitoring
219402499|NCT03022032|DEVICE|Fitbit Zip|Fitbit Zip
219402500|NCT03022032|OTHER|HOPE App|HOPE App
219402501|NCT03022032|OTHER|Standard of Care|Standard of Care
219402502|NCT03022032|DEVICE|Fitbit Charge 2|Fitbit Charge 2
219402503|NCT03022032|OTHER|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
219402504|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
219402505|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
219402506|NCT06018350|BEHAVIORAL|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
219002169|NCT03649698|BEHAVIORAL|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
219189639|NCT04036253|BIOLOGICAL|Erythropoietin alfa|Prefilled syringes of erythropoietin
219189640|NCT02810197|BEHAVIORAL|Psychopathological assessment|
219189641|NCT02810197|BEHAVIORAL|Neuropsychological assessment|
219189642|NCT02810197|DEVICE|Functional magnetic resonance imaging (fMRI)|
219402507|NCT03894553|DEVICE|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
219402508|NCT01372696|OTHER|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
219402509|NCT06135753|OTHER|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
219402510|NCT06135753|BEHAVIORAL|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
219402511|NCT06135753|OTHER|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
219402512|NCT03625986|OTHER|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
219402513|NCT03625986|OTHER|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
219402514|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
219402515|NCT05875038|OTHER|Tele-alarm|Tele-alarm
219402516|NCT05102864|DEVICE|Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex|iTBS will be administered to the left DLPFC for 10 consecutive days
219402517|NCT06787781|DRUG|Alpha Lipoic Acid|ALA was administrated in capsules at a xed oral daily dose of 600 mg for the entire duration of the study in addition to the atypical antipsychotic therapy.
219402518|NCT01803451|DRUG|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
219402519|NCT01803451|DRUG|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
219402520|NCT02198729|PROCEDURE|Endoscopic Submucosal Dissection|
219402521|NCT02198729|PROCEDURE|Endoscopic Mucosal Resection|
219402522|NCT06426121|DIAGNOSTIC_TEST|test Aerobic/F Culture Vials|an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
219402523|NCT06426121|DIAGNOSTIC_TEST|control Aerobic/F Culture Vials|according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
219002170|NCT03649698|DIETARY_SUPPLEMENT|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
219402524|NCT05406700|DRUG|Niraparib|Oral, daily, dosage per protocol,4 Weeks
219402525|NCT05406700|DRUG|Resection/Treatment with Niraparib|"The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent."
219402526|NCT05495906|BIOLOGICAL|Nonavalent HPV vaccine|Routine dosing form and dosage
219402527|NCT06785025|BEHAVIORAL|Group-Based Dance Fitness Intervention|This group-based intervention will be conducted with women only. Women enrolled in the study and assigned to the intervention condition will complete 2 30-minute classes per week for 6 weeks. All classes will be held on a university campus and take place during the lunch hour (12:30-1pm). All classes will be led by a certified group fitness leader who is a member of the research team.
219402528|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
219402529|NCT06248593|DRUG|Continuous infusion of Norepinephrine|The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
219402530|NCT06248593|DRUG|Continuous infusion of Phenylephrine|The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
219402531|NCT05512130|DRUG|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
219402532|NCT05512130|DRUG|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
219402533|NCT05871268|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
219402534|NCT05871268|OTHER|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
219402535|NCT05784948|OTHER|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
219402536|NCT05784948|OTHER|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
219402537|NCT03958617|DEVICE|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
219402538|NCT01847833|OTHER|MRI scan|
219402539|NCT00620321|DRUG|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
219402540|NCT00620321|DRUG|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
219402541|NCT00620321|DRUG|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
219402542|NCT06280261|OTHER|parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire|Scales and questionnaires
219402543|NCT02299765|DRUG|Gefitinib|patients in arm A will be given gefitinib as target therapy
219402544|NCT02299765|DRUG|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
219402545|NCT02299765|DRUG|carboplatin|patients in arm A will be given carboplatin chemotherapy
219402546|NCT00547599|DRUG|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
219402547|NCT05892133|BEHAVIORAL|Maximal strength training|3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
219402548|NCT02156960|DRUG|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
219402549|NCT02156960|DRUG|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
219402550|NCT02156960|DRUG|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
219402551|NCT03148431|DRUG|LY3002815|Administered IV
219402552|NCT03148431|DRUG|Placebo|Administered IV
219402553|NCT04191967|DEVICE|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
219402554|NCT01431144|PROCEDURE|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
219402555|NCT01431144|PROCEDURE|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
219402556|NCT01734187|DIETARY_SUPPLEMENT|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
219402557|NCT01734187|DIETARY_SUPPLEMENT|Placebo|Placebo (30g/day)
219402558|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
219402559|NCT01109004|DRUG|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
219402560|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
219565571|NCT04567758|OTHER|Telerehabilitation|"The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
219565572|NCT04567758|OTHER|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
219565573|NCT01754818|DRUG|Bendavia 10mg|
219565574|NCT01754818|DRUG|Bendavia 50mg|
219565575|NCT01754818|DRUG|Bendavia 100mg|
219565576|NCT01754818|DRUG|Placebo|
219565577|NCT05281978|BEHAVIORAL|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
219402561|NCT03444818|DRUG|[14C]-E6007|Oral administration
219402562|NCT04169594|DIAGNOSTIC_TEST|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
219402563|NCT05836532|PROCEDURE|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
219402564|NCT06845514|OTHER|Condition LL-RE|"LL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• LL-RE: The low load intensity protocol consists of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
219402565|NCT06845514|OTHER|Control|Control condition: During the control condition, participants will sit quietly in a room maintained at a temperature of 22-24°C to prevent any influence on blood pressure values, for 60 minutes. During this period, they will perform a standardized non-fatiguing cognitive task: watching Earth, a documentary following the migration paths of four animal families.
219402566|NCT06845514|OTHER|Condition HL-RE|"HL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• HL-RE: The high load intensity protocol consists of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
219402567|NCT06260644|PROCEDURE|VertiseTM flowable composite (Kerr,USA)|self adhesive flowable resin composite restoration.
219402568|NCT04251208|OTHER|Observational Study|No intervention will be administered.
219402569|NCT03805932|DRUG|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
219402570|NCT03805932|BIOLOGICAL|Rituximab|Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
219565578|NCT05281978|BEHAVIORAL|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
219565579|NCT06177847|DEVICE|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
219565580|NCT00792623|BIOLOGICAL|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
219565581|NCT06196944|BEHAVIORAL|Augmentative Alternative Communication|Traditional Method
219754976|NCT06921148|DEVICE|Sylk Wound Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
219002171|NCT03649698|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
219402571|NCT03805932|BIOLOGICAL|Ruxience|Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
219402572|NCT03805932|DRUG|Dexamethasone|12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
219402573|NCT03805932|DRUG|Acetaminophen|650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
219402574|NCT03805932|DRUG|Diphenhydramine|25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
219002172|NCT03649698|DRUG|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
219402575|NCT03805932|DRUG|Famotidine|20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
219402576|NCT03805932|DRUG|Aspirin|81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
219402577|NCT04721236|OTHER|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
219565582|NCT06196944|OTHER|Augmentative Alternative Communication Device|Augmentative Alternative Communication Device 3 session for 40 minutes
219565583|NCT03618329|OTHER|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
219565584|NCT04344626|DEVICE|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
219565585|NCT03033719|PROCEDURE|Laparotomy|Open surgery
219002173|NCT03649698|DRUG|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
219565586|NCT03033719|PROCEDURE|Laparoscopy|Minimally invasive surgery
219189643|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris)|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
219189644|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
219402578|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
219402579|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of NHFOV|neonates assigned to NHFOV will be started with the following boundaries: a) Paw of 6 cmH2O (the range 6-10 cmH2O); b) frequency of 10 Hz (the range 8-12 Hz). c) Inspiratory time 50% (1:1). d) amplitude 15 cmH2O(the range 15-25 cmH2O) NHFOV will only be provided with piston/ membrane oscillators able to provide an active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A).
219402580|NCT05742087|OTHER|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
219402581|NCT05742087|OTHER|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
219402582|NCT02410902|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
219402583|NCT02410902|DRUG|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
219402584|NCT00953043|DRUG|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
219402585|NCT00953043|DRUG|Placebo|Placebo medication given for three days
219402586|NCT00953043|OTHER|Bowel preparation|Polyethylene glycol-based bowel preparation
219402587|NCT00219843|DRUG|PV-10 (rose bengal disodium, 10%)|
219402588|NCT03059810|DEVICE|etafilcon A|Investigational Contact Lens
219402589|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
219402590|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
219402591|NCT00909766|DRUG|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
219402592|NCT00909766|DRUG|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
219402593|NCT00909766|DRUG|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
219402594|NCT00909766|DRUG|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
219402595|NCT00909766|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
219402596|NCT03412474|DRUG|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
219402597|NCT03412474|DRUG|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
219402598|NCT03412474|DRUG|paracetamol|paracetamol
219402599|NCT06342804|DRUG|4-MUST, 2 tablets, fasted|2 tablets (256 mg), fasted
219402600|NCT06342804|DRUG|4-MUST, 2 tablets, after meals|2 tablets (256 mg), after meals
219402601|NCT03134950|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
219402602|NCT04002154|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
219402603|NCT05890417|OTHER|questionnaire|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy
219402604|NCT01810198|PROCEDURE|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
219402605|NCT01810198|PROCEDURE|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
219402606|NCT06049771|OTHER|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
219402607|NCT03021798|OTHER|No Drug and no aspecific intervention|No intervention
219402608|NCT01734941|DRUG|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
219402609|NCT01734941|DRUG|Placebo|
219402610|NCT02159326|DRUG|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
219402611|NCT02159326|DRUG|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
219402612|NCT00002288|DRUG|Zidovudine|
219565587|NCT03988452|DRUG|Darunavir|Antiretroviral therapy
219565588|NCT03988452|DRUG|Ritonavir|Antiretroviral therapy
219565589|NCT03988452|DRUG|Dolutegravir|Antiretroviral therapy
219565590|NCT03988452|DRUG|Zidovudine|Antiretroviral therapy
219565591|NCT03988452|DRUG|Tenofovir|Antiretroviral therapy
219565592|NCT03988452|DRUG|Lamivudine|Antiretroviral therapy
219565593|NCT06132152|PROCEDURE|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
219402613|NCT02194101|PROCEDURE|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
219402614|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours
219402615|NCT05041959|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
219402616|NCT03706534|DEVICE|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
219402617|NCT03706534|DEVICE|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
219402618|NCT03706534|DEVICE|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
219402619|NCT03706534|PROCEDURE|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
219402620|NCT04105205|DRUG|Apramycin injection|30-min infusion
219565594|NCT06132152|PROCEDURE|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
219565595|NCT03179449|DIAGNOSTIC_TEST|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
219565596|NCT03179449|PROCEDURE|Surgery|Undergo surgical resection
219565597|NCT03179449|DRUG|Ferumoxytol|Given IV
219565598|NCT03179449|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
219565599|NCT05234320|DRUG|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
219565600|NCT05234320|DRUG|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
219565601|NCT05234320|DRUG|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
219565602|NCT01343069|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
219565603|NCT02385201|DEVICE|Senza|Spinal Cord Stimulation
219002174|NCT04555291|DRUG|Ropivacaine injection|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
219002175|NCT04555291|OTHER|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
219002176|NCT04208789|DIAGNOSTIC_TEST|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
219402621|NCT04105205|DRUG|Placebo injection|30-min infusion
219402622|NCT06055881|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219402623|NCT06055881|OTHER|Surveys|"Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and Was it Worth It questionnaire."
219402624|NCT06055881|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .
219565604|NCT00894114|BIOLOGICAL|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
219565605|NCT00894114|BIOLOGICAL|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
219565606|NCT03669575|DIETARY_SUPPLEMENT|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
219565607|NCT03669575|DIETARY_SUPPLEMENT|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
219565608|NCT06503107|DRUG|Nanobody-based biepitope BCMA-targeting CAR-T cells|Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
219565609|NCT00377078|DRUG|recombinant human lactoferrin|
219565610|NCT03610828|OTHER|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
219754977|NCT06921148|DEVICE|Dermabond/Prineo Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
219402625|NCT06055881|PROCEDURE|Computed Tomography|Undergo CT, MRI and/or PET/CT
219402626|NCT06055881|PROCEDURE|Magnetic Resonance Imaging|Undergo CT, MRI and/or PET/CT
219402627|NCT06055881|PROCEDURE|Positron Emission Tomography|Undergo CT, MRI and/or PET/CT
219402628|NCT02709993|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
219402629|NCT00003207|DRUG|pegylated liposomal doxorubicin hydrochloride|
219402630|NCT00003207|DRUG|PSC 833|
219402631|NCT06200987|DEVICE|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
219402632|NCT01043185|DRUG|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
219402633|NCT01043185|DRUG|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
219402634|NCT01043185|DRUG|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
219754978|NCT07118215|DRUG|KarXT|Specified dose on specified days
219754979|NCT07118215|DRUG|Midazolam|Specified dose on specified days
219754980|NCT07118215|DRUG|Fexofenadine|Specified dose on specified days
219402635|NCT01043185|DRUG|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
219002177|NCT04208789|OTHER|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
219402636|NCT01043185|DRUG|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
219402637|NCT05214781|PROCEDURE|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
219402638|NCT01158833|OTHER|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
219402639|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
219402640|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
219402641|NCT03165591|BIOLOGICAL|V3-P|one tablet of V3-P given once daily for 2 months
219402642|NCT03971084|OTHER|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
219402643|NCT03971084|OTHER|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
219402644|NCT02242227|DRUG|Salmeterol xinafoate|
219402645|NCT02242227|DRUG|Serevent® Diskus®|
219402646|NCT02242227|DRUG|Placebo (HandiHaler®)|
219402647|NCT02242227|DRUG|Placebo (Diskus®)|
219402648|NCT04077307|DRUG|Karonudib|First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
219402649|NCT01697527|BIOLOGICAL|aldesleukin|Given SC
219402650|NCT01697527|DRUG|fludarabine phosphate|Given IV
219402651|NCT01697527|DRUG|cyclophosphamide|Given IV
219402652|NCT01697527|OTHER|laboratory biomarker analysis|Correlative studies
219402653|NCT01697527|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
219402654|NCT01697527|BIOLOGICAL|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
219402655|NCT01697527|RADIATION|fludeoxyglucose F 18|Undergo PET scan using \[18F\] FDG tracer
219402656|NCT01697527|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F18 PET
219402657|NCT01104558|DRUG|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
219402658|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
219402659|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
219402660|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
219402661|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
219402662|NCT02211976|DRUG|Bisacodyl|
219402663|NCT02211976|DRUG|Simeticone|
219402664|NCT03766724|DRUG|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
219402665|NCT03766724|DRUG|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
219402666|NCT03766724|DRUG|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
219754981|NCT07118215|DRUG|Digoxin|Specified dose on specified days
219402667|NCT03766724|DRUG|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
219754982|NCT04547075|OTHER|Turkish validity and reliability|"1. Contact with developers and formation of steering committee~2. Translation from English to Turkish~3. Back translation from Turkish to English~4. Comparison of translation~5. Review of translated versions.~6. Reaching consensus and development of pilot version~7. Testing in clinical setting~8. Revision of pilot version~9. Testing of final version"
219754983|NCT07139301|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within four days after symptom onset.
219402668|NCT05131880|OTHER|Gait Re-education Program Using the Fisior® Mat Sequential Training System in Subjects with Parkinson's Disease|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR®- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
219402669|NCT06490315|BEHAVIORAL|OkeyMind intervention|The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.
219402670|NCT06490315|BEHAVIORAL|Wait-list control|Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
219402671|NCT03395197|DRUG|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
219402672|NCT03395197|DRUG|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
219402673|NCT05901831|DRUG|Finerenone|Dose A, Dose B, oral
219402674|NCT05901831|OTHER|Placebo|Oral
219754984|NCT07139301|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 5-14 days after symptom onset.
219402675|NCT02545296|OTHER|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
219402676|NCT03067896|DRUG|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
219402677|NCT03067896|DRUG|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
219402678|NCT03067896|DRUG|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
219402679|NCT02460588|DRUG|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
219754985|NCT07140237|DRUG|Oxytocin lower does (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)
219754986|NCT07140237|DRUG|Oxytocin higher does (48IU)|Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)
219754987|NCT07140237|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
219402680|NCT02460588|DRUG|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
219402681|NCT02460588|DRUG|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
219402682|NCT05293132|DRUG|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
219402683|NCT05293132|DRUG|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
219754988|NCT07140237|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.
219402684|NCT05293132|DRUG|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
219402685|NCT01287234|OTHER|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
219402686|NCT00820703|DRUG|Nexagon®|
219402687|NCT00820703|DRUG|Nexagon® vehicle|
219402688|NCT04116632|DRUG|BMS-963272|Single dose with varying frequency among groups
219402689|NCT04116632|DRUG|Placebo|Specified dose on specified days
219402690|NCT06551077|PROCEDURE|POSTERIOR RECTUS SHEATH HIATAL AUGMENTATION (PORSHA)|Use of a novel permanent autologous vascularized biologic fascial flap to reconstruct the diaphragmatic hiatus following standard hiatal hernia repair in selected patients. This technique is called a posterior rectus sheath flap hiatal augmentation or PoRSHA.
219402691|NCT00392171|DRUG|Temozolomide|Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
219402692|NCT01605071|DRUG|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
219402693|NCT03499808|BIOLOGICAL|Isatuximab|Given IV
219402694|NCT03499808|OTHER|Laboratory Biomarker Analysis|Correlative studies
219565611|NCT00880087|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
219565612|NCT00880087|PROCEDURE|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
219565613|NCT02184559|DRUG|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
219565614|NCT02184559|DEVICE|The infiltration continues catheter|
219565615|NCT03159286|BEHAVIORAL|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
219754989|NCT06821542|DRUG|INCA034176|IV infusion
219754990|NCT06821542|DRUG|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
219402695|NCT03987412|BEHAVIORAL|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
219402696|NCT03779425|OTHER|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
219402697|NCT05946135|DRUG|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
219402698|NCT05946135|DRUG|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
219402699|NCT02856581|DRUG|Varenicline|Given PO
219754991|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
219754992|NCT05438940|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
219754993|NCT05438940|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
219754994|NCT05438940|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
219402700|NCT02856581|DRUG|Placebo|Given PO
219402701|NCT02856581|OTHER|Tobacco Cessation Counseling|Complete counseling session
219402702|NCT01880255|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
219754995|NCT07139626|OTHER|This is an observational Study.|This is an observational study with no study-assigned interventions.Only observational measurements (blood collection for biomarker analysis) will be performed without modifying existing treatments.
219402703|NCT02147704|DIETARY_SUPPLEMENT|High-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
219402704|NCT02147704|DIETARY_SUPPLEMENT|low-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet"
219402705|NCT02218658|DRUG|WE941 OD tablets|
219402706|NCT02218658|DRUG|Brotizolam|
219402707|NCT00028002|PROCEDURE|Conventional Surgery|Undergo surgical resection
219754996|NCT06929533|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.
219754997|NCT07141134|DEVICE|TAPAM|Device: Turn-Assist Alternating Pressure Air Mattress (TAPAM) Automated lateral turning with pressure redistribution.
219754998|NCT07141134|DEVICE|HSFM|Device: High-Specification Foam Mattress (HSFM) Standard ICU care support surface.
219754999|NCT07141134|OTHER|Manual Turning (with pillows, per protocol)|Nurse-performed scheduled manual turning (target every 2 hours, with pillows).
219402708|NCT00028002|DRUG|Imatinib Mesylate|Given orally
219402709|NCT03422406|OTHER|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
219402710|NCT05787353|OTHER|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
219402711|NCT03209180|DRUG|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
219402712|NCT03209180|DRUG|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
219402713|NCT03334162|BEHAVIORAL|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
219402714|NCT01972880|DRUG|ASP1941|Oral
219402715|NCT02477085|OTHER|all women with an induced labor|all women who have an induced labor
219402716|NCT00782015|DIETARY_SUPPLEMENT|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
219402717|NCT00782015|DIETARY_SUPPLEMENT|Placebo Comparator:|NCEP Step 2 diet
219402718|NCT03013322|DRUG|Physostigmine|
219402719|NCT03013322|DRUG|Isotonic Saline|
219402720|NCT01041690|DRUG|Bevacizumab|
219402721|NCT02073435|BEHAVIORAL|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
219402722|NCT03572439|DIAGNOSTIC_TEST|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
219402723|NCT03593967|BEHAVIORAL|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share"
219402724|NCT03742401|PROCEDURE|Surgery|Traditional open excisional surgery
219402725|NCT03742401|DEVICE|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
219402726|NCT01141634|OTHER|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
219402727|NCT04200677|OTHER|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
219402728|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
219402729|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
219402730|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
219402731|NCT04200677|OTHER|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
219402732|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
219402733|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
219402734|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
219402735|NCT04200677|OTHER|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
219402736|NCT04616443|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
219402737|NCT04616443|BIOLOGICAL|HX008 injection|Recombinant humanized anti-PD-1 monoclonal antibody of injection
219402738|NCT03046628|DEVICE|TcPO2|
219402739|NCT03046628|DEVICE|Green laser (at 532nm) and a fast camera|
219402740|NCT01710111|DEVICE|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
219402741|NCT06128798|DIETARY_SUPPLEMENT|Oral Impact|A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .
219402742|NCT06128798|DIETARY_SUPPLEMENT|Nutren Optimum|A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
219402743|NCT00510224|DRUG|Sandostatin|Sandostatin 30mg intramuscular every 28 days
219402744|NCT01585935|DRUG|SMOFLIPID|target dose: 3g/kg/d
219402745|NCT01585935|DRUG|INTRALIPID|target dose: 3g/kg/d
219402746|NCT01666418|DRUG|Pazopanib/Paclitaxel|
219402747|NCT05372341|OTHER|descriptive|posotcovid patients will be elective surgery postoperative outcomes
219402748|NCT03078036|GENETIC|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
219565616|NCT03159286|BEHAVIORAL|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
219565617|NCT03159286|BEHAVIORAL|Control|Participants view social networking site profiles with no alcohol content.
219402749|NCT03078036|GENETIC|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
219402750|NCT03078036|OTHER|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~\- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
219402751|NCT03425942|BEHAVIORAL|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
219402752|NCT03425942|BEHAVIORAL|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
219402753|NCT01881620|DEVICE|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
219402754|NCT03281772|OTHER|Clinical Decision Software - provider portal|As noted in Arms
219402755|NCT03281772|OTHER|Clinical Decision Software - patient portal|As noted in Arms
219402756|NCT04936724|OTHER|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
219402757|NCT04798261|DEVICE|Indigo Aspiration System|Indigo Aspiration System
219402758|NCT01808118|BIOLOGICAL|adalimumab|40 mg every other week
219402759|NCT01808118|BIOLOGICAL|Placebo|every other week
219402760|NCT03539172|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
219402761|NCT01768598|OTHER|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
219402762|NCT01768598|OTHER|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
219402763|NCT01768598|OTHER|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
219402764|NCT01768598|OTHER|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
219402765|NCT06471634|BEHAVIORAL|CBTi|A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
219402766|NCT06471634|OTHER|Control - usual care|Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
219402767|NCT06471634|BEHAVIORAL|Sedentary behaviour reduction|Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
219402768|NCT04841499|DRUG|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
219402769|NCT00921505|DRUG|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
219402770|NCT00921505|DRUG|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
219402771|NCT00921505|DRUG|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
219402772|NCT00921505|DRUG|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
219402773|NCT06021652|DEVICE|MindCotine Virtual reality|Virtual reality platform
219565618|NCT05260723|BEHAVIORAL|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
219565619|NCT06363630|DRUG|Itraconazole|Specified dose on specified days.
219402774|NCT01761955|OTHER|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
219402775|NCT03074513|DRUG|Atezolizumab|Given IV
219402776|NCT03074513|BIOLOGICAL|Bevacizumab|Given IV
219402777|NCT03074513|OTHER|Laboratory Biomarker Analysis|Correlative studies
219402778|NCT03074513|OTHER|Pharmacological Study|Correlative studies
219402779|NCT00589888|DRUG|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
219402780|NCT00589888|DRUG|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
219402781|NCT00589888|DRUG|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
219402782|NCT00589888|DIETARY_SUPPLEMENT|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
219402783|NCT00589888|DIETARY_SUPPLEMENT|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
219189645|NCT03249090|OTHER|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
219402784|NCT01102153|DEVICE|Coolgard|invasive cooling via femoral ICY-catheter
219402785|NCT01102153|DEVICE|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
219402786|NCT02752425|DEVICE|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
219402787|NCT06253286|DEVICE|clear aligner treatment for orthodontics patients|patient are instructed to wear aligners
219402788|NCT02306707|PROCEDURE|Endoscopic Mucosal Resection|
219402789|NCT04631120|OTHER|Integrated Dementia Practice Unit Design|"* Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
219402790|NCT04631120|OTHER|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
219402791|NCT05883592|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
219402792|NCT00615290|DRUG|tipranavir|
219402793|NCT02778516|DIETARY_SUPPLEMENT|Sodium Restriction|
219402794|NCT02220348|DRUG|linaclotide|
219565620|NCT06363630|DRUG|Rifampin|Specified dose on specified days
219565621|NCT06363630|DRUG|Golcadomide|Specified dose on specified days
219402795|NCT02739022|BEHAVIORAL|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
219402796|NCT02524652|DRUG|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
219402797|NCT05781815|PROCEDURE|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
219402798|NCT02979886|DRUG|GnRH-a|the hormone reaction to the down regulation of the patients
219402799|NCT02979886|DRUG|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
219402800|NCT04762108|OTHER|Standard of care|Patients will be given standard of care as per their clinical needs
219402801|NCT03515434|PROCEDURE|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
219402802|NCT03515434|PROCEDURE|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
219402803|NCT03515434|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
219402804|NCT01252134|DEVICE|Biotrue multipurpose solution|Contact lens care solution
219402805|NCT01252134|DEVICE|Sauflon Synergi multipurpose solution|Contact lens care solution
219402806|NCT01252134|DEVICE|OTE Elements multipurpose solution|Contact lens care solution
219402807|NCT01252134|DEVICE|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
219402808|NCT03073655|OTHER|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
219565622|NCT00002702|BIOLOGICAL|aldesleukin|
219565623|NCT00002702|PROCEDURE|adjuvant therapy|
219565624|NCT00002702|PROCEDURE|conventional surgery|
219565625|NCT00002702|PROCEDURE|neoadjuvant therapy|
219565626|NCT00002702|RADIATION|radiation therapy|
219402809|NCT03073655|OTHER|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
219402810|NCT03073655|OTHER|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
219402811|NCT04058119|BEHAVIORAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
219402812|NCT03650452|DRUG|TAK-935|TAK-935 tablets or mini-tablets.
219402813|NCT03650452|DRUG|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
219402814|NCT03257930|DRUG|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
219402815|NCT02273050|DRUG|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
219402816|NCT02273050|DRUG|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
219755000|NCT07141134|OTHER|Positioning Pillows|Supplemental pillows used to support and maintain patient position.
219402817|NCT02273050|DRUG|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
219402818|NCT02273050|DRUG|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
219402819|NCT06374342|DEVICE|Bone defect|Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
219402820|NCT06374342|DEVICE|Spine fusion|Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
219402821|NCT06374342|DEVICE|Cage filling|Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
219402822|NCT06413485|BEHAVIORAL|Level of recreational water contact activities|We will examine a graded classification of this exposure based on individuals' minimum level of water contact: 1) no water contact; 2) minimal contact; 3) body immersion; 4) swallowed water. Minimal contact is defined as water contact that does not result in body immersion (e.g., wading below one's waist, boating, fishing). Body immersion is defined as entering the water above one's waist (e.g., swimming, surfing, snorkelling), and swallowing water as ingestion of any amount of water.
219402823|NCT06296017|OTHER|Experimental: Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
219755001|NCT04697823|OTHER|use of hyaluronan-enriched transfer medium|In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
219755002|NCT05760404|PROCEDURE|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
219755003|NCT05760404|OTHER|in vitro study|on tissues from colorectal resections
219189646|NCT03249090|OTHER|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
219402824|NCT06296017|OTHER|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
219402825|NCT06296017|OTHER|Extracorporeal Shock Wave Therapy+ Trigger Finger Splint|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
219402826|NCT04085445|DEVICE|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
219402827|NCT06511713|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
219402828|NCT05008913|DRUG|[14C]Adavosertib|Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
219402829|NCT04486443|BEHAVIORAL|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
219402830|NCT06831838|BEHAVIORAL|Cognitive Behavioral Therapy based Pain Management Program|Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.
219755004|NCT07119281|PROCEDURE|Group A: Cordless paste with astringent (EXP): Expasyl (Acteon PVT LTD)|Chemical gingival retraction method
219189647|NCT05949281|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
219189648|NCT05949281|DRUG|Placebo|Placebo tablet once-daily
219189649|NCT06338709|DEVICE|BariClip® Device Treatment|Device Administration (Implantation)
219402831|NCT02574780|OTHER|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
219755005|NCT07119281|PROCEDURE|Group B: Cordless paste without astringent (MF): Magic FoamCord (Coltene Whaledent AG)|Chemical gingival retraction method
219755006|NCT07119281|PROCEDURE|Group C: Laser troughing (LT): Diode laser (iLase; Biolase Inc.)|Gingival retraction will be performed by using only laser. Cord will not be used.
219755007|NCT07119281|PROCEDURE|Group D: Retraction cord with astringent (RCA; Control group): Knitted cord impregnated with aluminum chloride (Ultrapak + Viscostat Clear; Ultradent Inc.)|Mechanical and chemical gingival retraction method will be used.
219189650|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
219189651|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
219402832|NCT02574780|OTHER|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
219402833|NCT02042404|DEVICE|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
219402834|NCT01230671|OTHER|Yoga|A 12 week yoga session will be offered to women with breast cancer.
219402835|NCT05826275|DRUG|TGN-S11|Small Molecule
219402836|NCT05826275|DRUG|Pembrolizumab|PD-1 checkpoint blockade
219402837|NCT04257162|OTHER|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
219565627|NCT06022367|DIAGNOSTIC_TEST|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
219565628|NCT06022367|DIAGNOSTIC_TEST|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
219565629|NCT04569513|BIOLOGICAL|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
219565630|NCT04813016|DRUG|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
219565631|NCT04813016|DRUG|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
219565632|NCT04813016|DRUG|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
219565633|NCT04813016|DRUG|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
219565634|NCT01610609|BEHAVIORAL|Population Health Management Intervention|"This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
219565635|NCT00757549|BIOLOGICAL|cetuximab|
219565636|NCT00757549|DRUG|cisplatin|
219565637|NCT00757549|GENETIC|TdT-mediated dUTP nick end labeling assay|
219565638|NCT00757549|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
219565639|NCT00757549|OTHER|immunohistochemistry staining method|
219565640|NCT00757549|OTHER|laboratory biomarker analysis|
219402838|NCT02794051|BEHAVIORAL|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
219565641|NCT00757549|RADIATION|fludeoxyglucose F 18|
219565642|NCT00757549|RADIATION|radiation therapy|
219565643|NCT00035321|DRUG|Olanzapine|
219565644|NCT00035321|DRUG|Fluoxetine|
219565645|NCT04397289|DRUG|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
219565646|NCT02084368|PROCEDURE|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
219565647|NCT02084368|PROCEDURE|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
219565648|NCT02084368|DRUG|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
219402839|NCT00390000|DRUG|vatalanib|Given orally
219402840|NCT00390000|DRUG|pemetrexed disodium|Given IV
219402841|NCT00390000|OTHER|pharmacological study|Correlative study
219402842|NCT00390000|PROCEDURE|ultrasound imaging|Correlative study
219402843|NCT00718419|DRUG|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
219402844|NCT00771407|DEVICE|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
219402845|NCT00771407|OTHER|Standard ostomy creation|Ostomy will be created as routinely performed
219402846|NCT03545724|DEVICE|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
219402847|NCT00000567|PROCEDURE|high-frequency ventilation|
219402848|NCT00878163|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219565649|NCT02084368|DRUG|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
219189652|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening|"The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice."
219402849|NCT00878163|DRUG|Erlotinib Hydrochloride|Given PO
219402850|NCT00878163|DRUG|Gemcitabine Hydrochloride|Given IV
219402851|NCT00878163|DRUG|Vismodegib|Given PO
219402852|NCT01902082|DRUG|Mesenchymal stem cells|
219402853|NCT01902082|DRUG|Placebo|
219402854|NCT03417011|DEVICE|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
219402855|NCT04628728|OTHER|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
219402856|NCT04378023|DRUG|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
219402857|NCT04378023|PROCEDURE|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
219565650|NCT04863157|BEHAVIORAL|Survivor-SHIP|Parent/guardian education about healthy sleep practices to improve their child's sleep health.
219565651|NCT02037282|DRUG|Anti-influenza IVIG|
219565652|NCT04239482|DIETARY_SUPPLEMENT|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
219565653|NCT04239482|DIETARY_SUPPLEMENT|Placebo|Longer-term supplementation (8 weeks)
219565654|NCT01470417|DRUG|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
219565655|NCT01470417|DRUG|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
219189653|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening + FDG PET/CT|The limited cancer screening (as described above) in combination with a FDG PET/CT.
219402858|NCT06187402|DRUG|LM-24C5|Administered intravenously
219402859|NCT06847022|PROCEDURE|US-guided transversalis fascia plane block|US-guided bilateral transversalis fascia plane block, using Sonotap 110 mm and 0.25% bupivacaine 20 ml on each side, will be done after wound closure.
219402860|NCT01072097|DRUG|Atorvastatin|Atorvastatin 20mg/day for 6 months
219402861|NCT01072097|DRUG|Placebo|Placebo for 6 months
219402862|NCT04893564|BIOLOGICAL|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
219402863|NCT04893564|BIOLOGICAL|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
219402864|NCT04263285|DEVICE|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
219402865|NCT06846697|OTHER|Home-based Exercise|The subjects in this group will be given the exercises included in the Physical Activity guideline of the Ministry of Health as a home programme.
219402866|NCT06846697|OTHER|Hatha Yoga Group|The sessions will begin with the classic sun salutation series (Suryanamaskar) consisting of 12 basic poses of yoga. The sun salutation series will be used as a warm-up for 10 minutes. After warming up, postures aimed at stretching the front group muscles of the body and strengthening the back group muscles will be preferred. In the cooling phase, the session will be ended by relaxing with Savasana pose for 10 minutes.
219402867|NCT06846697|OTHER|Reformer Pilates Group|Exercise sessions will start with the foot series and the starting position on the back will be preferred. This series, which is progressed by maintaining the body composition, is considered as a warm-up exercise of the body. Then, the body is continued with exercise series targeting the thoracic region and core region.
219402868|NCT05438875|DRUG|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
219402869|NCT05438875|DRUG|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
219565656|NCT02310516|DEVICE|preoperative adequate explanations about awake surgery|
219565657|NCT02310516|OTHER|no preoperative explanation|
219565658|NCT05453786|DRUG|SID1903|Single oral administration of SID1903 after an overnight fast
219565659|NCT05453786|DRUG|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
219565660|NCT02721706|OTHER|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
219565661|NCT00975962|DRUG|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
219565662|NCT00975962|PROCEDURE|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
219402870|NCT06138431|BEHAVIORAL|CBT|Virtual CBT groups
219402871|NCT06422234|OTHER|Exergame|Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.
219402872|NCT06422234|OTHER|Game-free Exercise|All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
219402873|NCT05902741|BEHAVIORAL|RiSE|RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.
219402874|NCT05902741|BEHAVIORAL|HEP|The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
219402875|NCT01480154|DRUG|Akt Inhibitor MK2206|Given PO
219402876|NCT01480154|DRUG|Hydroxychloroquine|Given PO
219402877|NCT01764178|DRUG|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
219402878|NCT01764178|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
219402879|NCT01660971|DRUG|Dasatinib|Given PO
219402880|NCT01660971|DRUG|Erlotinib Hydrochloride|Given PO
219402881|NCT01660971|DRUG|Gemcitabine Hydrochloride|Given IV
219402882|NCT05482126|DIAGNOSTIC_TEST|Intraoperative Behavioral Testing|During DBS surgery, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
219402883|NCT05482126|DIAGNOSTIC_TEST|Behavioral Testing|In the lab, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
219402884|NCT03838250|BIOLOGICAL|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
219565663|NCT04415684|DEVICE|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
219565664|NCT04415684|DEVICE|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
219565665|NCT02973321|DRUG|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
219565666|NCT02973321|DRUG|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
219565667|NCT02973321|DRUG|Liraglutide|Self-administered by SC injection using a pre-filled pen.
219565668|NCT02973321|DRUG|Metformin|Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
219565669|NCT01189526|DRUG|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
219565670|NCT01189526|PROCEDURE|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
219565671|NCT04685694|DRUG|Misoprostol|sl 800 mcg misoprostol
219565672|NCT03785769|PROCEDURE|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
219565673|NCT03785769|PROCEDURE|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
219565674|NCT02066337|PROCEDURE|scaling and root planing|
219565675|NCT02066337|DRUG|placebo gel|
219565676|NCT02066337|DRUG|Ozonated olive oil gel|
219565677|NCT00149149|OTHER|Zinc Carnosine coadministered with Indomethacin|
219565678|NCT00149149|OTHER|Placebo coadministered with Indomethacin|
219565679|NCT02827890|DRUG|Januvia Tab. 100mg|Januvia Tab. 100mg\*1T/day for 5days, QD, PO
219565680|NCT02827890|DRUG|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
219565681|NCT02407171|DRUG|MK-3475|200 mg every 2 weeks by IV infusion
219402885|NCT04869579|DRUG|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
219565682|NCT02407171|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
219565683|NCT05460221|DIETARY_SUPPLEMENT|Optimized oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
219565684|NCT05460221|DIETARY_SUPPLEMENT|Functional oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
219565685|NCT05460221|DIETARY_SUPPLEMENT|Control group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
219402886|NCT04869579|OTHER|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
219402887|NCT00726323|DRUG|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
219565686|NCT02714296|DRUG|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
219565687|NCT02714296|DIETARY_SUPPLEMENT|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
219402888|NCT02793908|DRUG|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
219565688|NCT00146796|DEVICE|Rapid diagnostic test for malaria|
219565689|NCT02833207|DRUG|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
219565690|NCT02833207|DRUG|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
219565691|NCT05722028|PROCEDURE|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
219402889|NCT02793908|DRUG|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
219402890|NCT00369434|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|
219402891|NCT04793672|OTHER|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
219402892|NCT00003068|DRUG|amifostine trihydrate|
219402893|NCT00003068|DRUG|cyclophosphamide|
219402894|NCT00003068|DRUG|mitoxantrone hydrochloride|
219402895|NCT00003068|DRUG|thiotepa|
219402896|NCT00003068|PROCEDURE|peripheral blood stem cell transplantation|
219402897|NCT01837147|BEHAVIORAL|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
219402898|NCT01837147|BEHAVIORAL|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
219402899|NCT03764215|DRUG|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
219402900|NCT05314166|OTHER|meditation practice|Description: meditation practice
219402901|NCT01532700|DRUG|Ofatumumab with GSK2110183|"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
219402902|NCT02549690|DRUG|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
219402903|NCT02549690|DRUG|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
219402904|NCT00676273|DEVICE|TVT-Obturator (TVT-O)|sub urethral sling
219402905|NCT00676273|DEVICE|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
219402906|NCT01984541|BIOLOGICAL|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
219402907|NCT05878808|DIAGNOSTIC_TEST|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
219402908|NCT02742870|OTHER|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
219402909|NCT01002534|DRUG|Vardenafil|Nasal instillation of Vardenafil
219402910|NCT01002534|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
219402911|NCT06241599|DRUG|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
219402912|NCT06241599|DRUG|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
219402913|NCT00257387|DRUG|Cyclosporine|
219189654|NCT05482932|DIAGNOSTIC_TEST|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
219402914|NCT03957109|PROCEDURE|general anesthesia|
219565692|NCT03318887|DRUG|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
219565693|NCT01501968|DRUG|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
219565694|NCT01501968|DRUG|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
219565695|NCT00003317|DRUG|carboplatin|
219565696|NCT00003317|DRUG|paclitaxel|
219189655|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
219402915|NCT05662137|BEHAVIORAL|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
219565697|NCT00003317|RADIATION|radiation therapy|
219565698|NCT00003317|PROCEDURE|surgery|
219402916|NCT06144528|OTHER|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
219402917|NCT03566524|DIETARY_SUPPLEMENT|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
219402918|NCT03566524|DIETARY_SUPPLEMENT|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
219402919|NCT06231199|OTHER|gastrocnemius release|The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non\_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
219402920|NCT06231199|OTHER|conventional treatment|the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
219402921|NCT05394584|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
219565699|NCT05380219|OTHER|dual task strength training|strength training and dual task
219565700|NCT01790113|DEVICE|Univers™|Control
219565701|NCT01790113|DEVICE|Eclipse™ Total Shoulder Replacement|Investigational
219565702|NCT04157478|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
219007049|NCT04417920|PROCEDURE|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
219402922|NCT03615547|DRUG|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
219565703|NCT04157478|RADIATION|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
219565704|NCT04157478|DRUG|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
219565705|NCT00552149|DRUG|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
219565706|NCT01935648|DRUG|Ropivacaine|
219565707|NCT03278509|DRUG|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
219565708|NCT03278509|DRUG|Bisoprolol|Please see the section above.
219565709|NCT03444441|PROCEDURE|Foot or ankle surgery|Surgery for foot or ankle
219565710|NCT02270749|DRUG|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
219189656|NCT05422274|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
219402923|NCT03615547|OTHER|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
219402924|NCT03685019|RADIATION|Valgus Stress|Valgus stress radiograph
219402925|NCT03685019|RADIATION|Varus stress|Varus stress radiograph
219402926|NCT03685019|RADIATION|0 degree flexion radiograph|0 degree flexion radiograph
219402927|NCT03685019|RADIATION|20 degree flexion radiograph|20 degree flexion radiograph
219402928|NCT03685019|RADIATION|45 degree flexion radiograph|45 degree flexion radiograph
219402929|NCT04289129|DIAGNOSTIC_TEST|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
219565711|NCT02270749|DRUG|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
219565712|NCT00697970|BIOLOGICAL|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
219402930|NCT04126603|DRUG|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
219402931|NCT04126603|DRUG|Placebos|Placebo injection
219402932|NCT00788515|DRUG|Volinanserin (M100907)|2 mg tablets QD
219402933|NCT00788515|DRUG|Lormetazepam|1 mg tablets (overencapsulated) QD
219402934|NCT06014554|OTHER|Low-risk subgroup|Self-managed exercise programme.
219402935|NCT06014554|OTHER|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
219402936|NCT06014554|OTHER|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
219402937|NCT06014554|OTHER|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
219402938|NCT05374408|BEHAVIORAL|Aim 2: BounceBack Now (BBN) for Trauma Informed Care Deployment|"Brief explanation of BounceBack Now (BBN) will be provided. Participants will be directed to areas of the application that are congruent with treatment focus identified during their standard of care appointment.~Participants will complete a baseline survey by either going online or being contacted by a member of the investigational team. The investigative assistant will contact all participants in 2-3 days to help the participant navigate the BBN and complete the baseline survey, if needed.~The participant will continue to meet with their behavioral health provider (BHP) as determined by the standard of care interactions. BHP will highlight features contained in BBN for participant to use in between appointments.~Follow-up phone calls will be scheduled for 2 weeks and 6 weeks after initial visit. During these phone- calls the participant will be contacted by a member of the investigational team to complete follow-up surveys."
219565713|NCT00697970|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
219565714|NCT00194792|DRUG|exemestane|Given PO
219565715|NCT00194792|DRUG|triptorelin pamoate|Given IM
219565716|NCT00194792|DRUG|capecitabine|Given PO
219565717|NCT00194792|DRUG|methotrexate|Given IV
219565718|NCT00194792|DRUG|vinorelbine tartrate|Given IV
219565719|NCT00194792|DRUG|paclitaxel|Given IV
219565720|NCT00194792|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
219565721|NCT00194792|RADIATION|radiation therapy|Undergo radiation therapy
219565722|NCT00194792|OTHER|laboratory biomarker analysis|Correlative studies
219565723|NCT02129309|PROCEDURE|Forearm plethysmography|Dose response study
219565724|NCT02129309|PROCEDURE|Haemodynamic studies|Dose response study
219565725|NCT02582788|OTHER|Bathing Additive|
219565726|NCT01714739|DRUG|Lirilumab|Specified dose on specified days.
219565727|NCT01714739|DRUG|Nivolumab|Specified dose on specified days.
219565728|NCT01714739|DRUG|Ipilimumab|Specified dose on specified days.
219565729|NCT01853241|PROCEDURE|Single Balloon|All patients in this group will undergo single balloon enteroscopy
219565730|NCT01853241|PROCEDURE|Spirus|All patients in this group will undergo Spirus Enteroscopy
219565731|NCT01570816|DEVICE|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
219565732|NCT00139724|DRUG|tolterodine extended release capsule|
219565733|NCT04783116|DIETARY_SUPPLEMENT|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
219565734|NCT04783116|DIETARY_SUPPLEMENT|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
219565735|NCT00092950|BEHAVIORAL|Physical activity|
219565736|NCT03585959|DEVICE|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
219565737|NCT01885416|OTHER|consumption of test meal based on dairy products|
219565738|NCT01885416|OTHER|consumption of high fat test meal without dairy products|
219565739|NCT01885416|OTHER|consumption of high fat test meal with dairy products|
219565740|NCT00006387|BIOLOGICAL|QS21|
219565741|NCT00006387|BIOLOGICAL|ras peptide cancer vaccine|
219402939|NCT05374408|BEHAVIORAL|Aim 1 Participant Focus Groups|"At the beginning of the focus group the patients will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the participants.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
219402940|NCT05374408|BEHAVIORAL|Aim 1 BHP Focus Groups|"At the beginning of the focus group the BHPs will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the BHPs.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
219402941|NCT05374408|BEHAVIORAL|Aim 2: BHP, Provider, Staff and Admin Focus Groups|Semi-structured interviews will be conducted with BHPs, Clinical Staff, Providers and Administration They will ask questions to BHPs, Clinical Staff, Providers and Administration about feasibility, acceptability, and usability of BBN and overall clinical protocol.
219760973|NCT03388892|DEVICE|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
219002178|NCT04208789|DIAGNOSTIC_TEST|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
219402942|NCT05374408|BEHAVIORAL|Aim 2 : Participant Focus Group|Semi-structured interviews will be conducted with Participants to assess the feasibility, acceptability, and usability of BBN.
219402943|NCT06534905|OTHER|E-cigarette|Each participant assigned to the e-cigarette group will given a rechargeable NJOY Ace e-cigarette that is either tobacco or mint-flavored (based on their preference). Participants will also be given disposable pods prefilled with nicotine. When the pod is empty, the participant will throw it away and replace it with a new pod provided by the study staff. Participants will be asked to use as little or as much of the e-cigarette during their study participation, including choosing not to use the product. Participants will also be given information on the relative harms of nicotine and tobacco products as recommended by the American Society of Addiction Medicine.
219402944|NCT06534905|BEHAVIORAL|Control/Standard Advice|Brief advice to quit according recommendations from the American Society of Addiction Medicine
219002179|NCT00913042|OTHER|sample blood|"* Early culture~* Bacterial DNA tests in blood"
219402945|NCT00109187|DRUG|Xolair (omalizumab)|
219402946|NCT06960083|OTHER|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
219402947|NCT00004879|BIOLOGICAL|panitumumab|
219402948|NCT04150497|BIOLOGICAL|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
219402949|NCT04150497|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
219402950|NCT03385473|GENETIC|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
219402951|NCT03385473|DIAGNOSTIC_TEST|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
219402952|NCT00280189|PROCEDURE|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
219402953|NCT00280189|BEHAVIORAL|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
219402954|NCT00280189|BEHAVIORAL|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
219402955|NCT04889872|DEVICE|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
219402956|NCT04763109|OTHER|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
219402957|NCT03585621|RADIATION|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
219002180|NCT03287661|BEHAVIORAL|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
219402958|NCT03802604|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10\^6 PFU/mL. On week 3 (i.e. 21 days \[± 2\] days), a second talimogene laherparepvec injection will be administered at a dose of 10\^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 \[± 2\] days). The maximum volume for each injection will be 4.0 mL.
219402959|NCT03802604|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 \[± 2\] days), for a total of 4 treatment courses.
219402960|NCT04694846|DRUG|Nicotine Replacement|Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
219402961|NCT04694846|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
219402962|NCT04694846|DRUG|Varenicline|Given PO
219402963|NCT04694846|OTHER|Tobacco Cessation Counseling|Receive counseling
219402964|NCT04694846|OTHER|Questionnaire Administration|Ancillary studies
219402965|NCT04694846|OTHER|Quality of Life Assessment|Ancillary studies
219402966|NCT04694846|OTHER|Best Practice|Receive standard treatment
219402967|NCT05786742|RADIATION|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
219402968|NCT06303648|DRUG|Methylone|Oral dose of methylone
219402969|NCT06303648|DRUG|Placebo|Placebo to match methylone
219402970|NCT04502407|RADIATION|Cisplatin-based Radiation Therapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
219402971|NCT04502407|DRUG|Cisplatin Chemotherapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
219402972|NCT06164028|OTHER|cognitive interview|Participants will take part in a semi-structured qualitative interview (\~1 hour).
219402973|NCT01552356|OTHER|Laboratory Biomarker Analysis|Correlative studies
219402974|NCT01552356|DRUG|Pazopanib Hydrochloride|Given PO
219402975|NCT01552356|OTHER|Pharmacological Study|Correlative studies
219402976|NCT01334021|PROCEDURE|Biopsy|Undergo tumor biopsy
219402977|NCT01334021|PROCEDURE|Conventional Surgery|Undergo surgery
219760974|NCT03388892|DEVICE|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
219002181|NCT03454776|DEVICE|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
219402978|NCT01334021|OTHER|Genetic Testing|Undergo genetic testing
219402979|NCT06272968|DIAGNOSTIC_TEST|Neuropsychological Testing|Neuropsychological Testing via Cambridge CANTAB Connect
219402980|NCT05478018|BEHAVIORAL|High Intensity Interval Training (HIIT)|Supervised high-intensity interval training for 12 weeks three times per week
219402981|NCT04807504|DRUG|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
219402982|NCT04686305|DRUG|T-DXd|T-DXd: administered as an IV infusion
219402983|NCT04686305|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
219402984|NCT04686305|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
219402985|NCT04686305|DRUG|Carboplatin|Carboplatin: administered as an IV infusion
219402986|NCT04686305|DRUG|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
219402987|NCT04686305|DRUG|Volrustomig|Volrustomig: administered as an IV infusion
219402988|NCT04686305|DRUG|Rilvegostomig|Rilvegostomig: administered as an IV infusion
219402989|NCT05524272|OTHER|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
219402990|NCT02540252|OTHER|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
219402991|NCT05151770|OTHER|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
219760975|NCT03767439|DRUG|Vismodegib|150 mg PO daily
219760976|NCT03767439|DRUG|Nivolumab|480 mg IV every 4 weeks
219760977|NCT03767439|DRUG|Ipilimumab|1 mg/kg IV every 6 weeks
219402992|NCT01869010|OTHER|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
219402993|NCT05548127|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
219402994|NCT05548127|DRUG|Abemaciclib|Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
219402995|NCT02778750|PROCEDURE|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
219402996|NCT06312956|DEVICE|Continuous Positive Airway Pressure Ventilotherapy|Breathing support device during sleeping
219402997|NCT01255748|RADIATION|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
219402998|NCT06535139|BEHAVIORAL|Brief training|Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.
219402999|NCT06535139|BEHAVIORAL|Parent-targeted motivational aids|Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.
219403000|NCT06535139|BEHAVIORAL|Healthcare access|Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
219403001|NCT04329039|DRUG|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
219403002|NCT05387720|PROCEDURE|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
219565742|NCT00865514|DRUG|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
219565743|NCT00865514|GENETIC|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
219565744|NCT00865514|OTHER|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
219002182|NCT03454776|DEVICE|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
219007050|NCT05328882|OTHER|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
219403003|NCT05387720|PROCEDURE|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
219565745|NCT00865514|OTHER|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
219565746|NCT03920280|DEVICE|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
219565747|NCT03920280|DEVICE|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
219565748|NCT03920280|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
219565749|NCT00258778|DRUG|Human Glucocerebrosidase (prGCD)|
219565750|NCT01463982|DRUG|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
219565751|NCT00650273|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fasting
219403004|NCT05387720|PROCEDURE|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
219403005|NCT01106534|DRUG|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
219403006|NCT01106534|DRUG|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
219403007|NCT01106534|DEVICE|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
219403008|NCT06302569|DRUG|Pembrolizumab + Enfortumab Vedotin|"* Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab are eligible for up to 1 year of additional pembrolizumab (second course) upon experiencing disease progression.~* Enfortumab Vedotin will be given for a maximum of 3 cycles on day 1 and day 3 each 3 weeks. EV treatment could be re-started in case of Progressive Disease RECIST v1.1 during pembrolizumab monotherapy treatment."
219403009|NCT06239467|DRUG|OKI-219|Oral twice daily
219403010|NCT06239467|DRUG|Fulvestrant|Intramuscular injection
219565752|NCT00650273|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fasting
219565753|NCT02577068|DRUG|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
219565754|NCT02577068|DRUG|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
219565755|NCT00916695|DEVICE|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
219565756|NCT02423317|DEVICE|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
219565757|NCT02423317|DEVICE|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
219565758|NCT03532750|DEVICE|Particle|"1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
219565759|NCT03532750|DEVICE|Coil|Ruby or Interlock detachable coils
219755008|NCT07119762|OTHER|Pilates sections|This intervention combines Pilates with dual-task training over 20 weeks, featuring twice-weekly 60-minute sessions at moderate to vigorous intensity. It is uniquely grounded in methods from the Polestar and PhysicalMind schools and adapted for older adults (≥65 years), utilizing chairs, elastic bands, and minimal equipment. Unlike typical exercise programs, this protocol integrates cognitive tasks within Pilates exercises to simultaneously challenge physical and executive functions. Exercise intensity is individualized using heart rate monitors and the Borg scale. Assessments include trunk strength (Biodex System 4), balance (Biodex SD), and cognitive function (MoCA, Stroop, WAIS-III, TMT), making it one of the few trials to rigorously evaluate physical, cognitive, and dual-task performance outcomes in older adults. This approach is low-cost, scalable, and focused on fall prevention and autonomy maintenance.
219403011|NCT06239467|DRUG|Trastuzumab|Intravenous (IV)
219403012|NCT06239467|DRUG|Tucatinib|Oral twice daily
219403013|NCT06239467|DRUG|Atirmociclib|Oral twice daily
219403014|NCT06239467|DRUG|Ribociclib|Oral once daily continuous for 21-days followed by 7 days off
219403015|NCT03683433|DRUG|Azacitidine|Given SC or IV
219403016|NCT03683433|DRUG|Enasidenib Mesylate|Given PO
219403017|NCT04431154|BEHAVIORAL|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
219403018|NCT06533293|DEVICE|Neck Brace Device|"The neck brace device will be manufactured in the Mechanical Department at Columbia University. The device measures head motion and EMG by electronic sensors, passively supports the head in certain configurations by springs, and actively assists head movement by motors.~Motor learning principles will be combined with robotics to apply gentle forces on the head-neck during training."
219403019|NCT00756587|DEVICE|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
219403020|NCT00756587|DEVICE|Bottle Feeding|receiving all feeding by bottle
219403021|NCT01956409|DRUG|18F-FCH|
219403022|NCT01956409|DRUG|Magnevist|
219403023|NCT03606252|OTHER|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
219403024|NCT03606252|OTHER|urine sampling|2 urine sample (1 at J0 and 1 at J7)
219403025|NCT04336241|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
219403026|NCT04336241|BIOLOGICAL|nivolumab|Programmed death receptor (PD-1) blocking antibody
219403027|NCT04488822|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
219403028|NCT06822530|OTHER|Best Practice|Receive usual care CRC screening program navigation
219755009|NCT06940141|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
219755010|NCT06940141|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
219755011|NCT07143396|BEHAVIORAL|Mind-body mobile application and guided movement|Self-directed: The study team recommends daily use of the mobile app for 6 weeks, with a minimum of 4 times per week, and engagement with the somatic education program at least 3 times per week for 6 weeks. Frequency of app usage and somatic education engagement will be monitored via weekly surveys.
219403029|NCT06822530|OTHER|Educational Intervention|Receive QR code and link to video addressing fears of colonoscopy
219403030|NCT06822530|OTHER|Electronic Health Record Review|Ancillary studies
219403031|NCT06822530|OTHER|Interview|Ancillary studies
219403032|NCT06822530|OTHER|Supportive Care|Receive rideshare transportation home after colonoscopy
219403033|NCT06822530|OTHER|Survey Administration|Ancillary studies
219403034|NCT03406104|GENETIC|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
219403035|NCT03406104|OTHER|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
219403036|NCT04734990|DRUG|Azacitidine|Given IV or SC
219403037|NCT04734990|DRUG|Seclidemstat|Given PO
219403038|NCT05358964|BEHAVIORAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
219403039|NCT05090150|OTHER|Home delivery of ART|Home ART refill and monitoring, adherence support
219403040|NCT05090150|OTHER|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
219403041|NCT05090150|OTHER|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
219403042|NCT05090150|OTHER|Best clinic practices|Continue with best clinic practices
219403043|NCT04397068|PROCEDURE|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
219403044|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
219403045|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
219403046|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
219403047|NCT02944071|DEVICE|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
219403048|NCT01684397|BIOLOGICAL|Bevacizumab|Given IV
219403049|NCT01684397|OTHER|Laboratory Biomarker Analysis|Correlative studies
219755012|NCT06942689|DRUG|Perform adductor canal block with liposomal bupivacaine.|"Patient Positioning: Supine with the surgical limb slightly flexed and externally rotated.~Operator Setup: The operator stands on the surgical side, with the ultrasound machine positioned contralaterally. The anterior thigh is sterilized and draped.~Ultrasound Technique: A high-frequency (5-12 MHz) linear ultrasound probe (Sonosite M-Turbo), protected by a 3M Tegaderm dressing, is placed perpendicular to the skin at the midpoint between the femoral trochanter and the superior patellar margin. The probe is maneuvered to visualize the adductor canal structures.~Needle Insertion: After local anesthesia at the insertion site, a 22G 80 mm needle is advanced using an in-plane technique until the tip reaches the triangular hypoechoic area lateral to the femoral artery. Following negative aspiration for blood, 1.33% liposomal bupivacaine is injected around the target site."
219755013|NCT07146243|BEHAVIORAL|Swedish Shoulder Control Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The physiotherapy component includes exercises for scapular control, rotator cuff strength, and shoulder mobility. The throwing block is excluded in this trial, as it is designed for the off-season and the programme is implemented during the competitive season. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
219403050|NCT01684397|DRUG|Pazopanib Hydrochloride|Given PO
219403051|NCT01684397|OTHER|Pharmacological Study|Correlative studies
219403052|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
219403053|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
219403054|NCT05836220|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
219403055|NCT05836220|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
219403056|NCT05836220|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
219403065|NCT05635084|DRUG|YN001|Dose ranges from 2-90mg
219403066|NCT05635084|DRUG|Placebo for YN001|5% dextrose injection to mimic the YN001
219403067|NCT05640999|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
219755014|NCT07146243|BEHAVIORAL|Norwegian OSTRC Shoulder Injury Prevention Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The programme focuses on exercises for scapular control, rotator cuff strength, and functional shoulder stability. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
219002183|NCT03867292|OTHER|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
219403068|NCT05640999|RADIATION|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
219403069|NCT05640999|OTHER|Observation|Observation
219403070|NCT03036592|BEHAVIORAL|Early OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
219403071|NCT03036592|BEHAVIORAL|Late OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
219403072|NCT06562543|DRUG|Fruquintinib|Oral capsules
219403073|NCT05407714|DEVICE|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
219403074|NCT05915351|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
219403075|NCT02499146|DRUG|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
219403076|NCT02499146|DRUG|Letrozole|2.5 mg , orally once daily (continuously)
219403077|NCT06313190|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
219403078|NCT06313190|DRUG|Sintilimab|Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
219403079|NCT05776758|DRUG|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
219403080|NCT05776758|PROCEDURE|Radical cystectomy alone|RC alone
219403081|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
219403082|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
219403083|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
219403084|NCT06400472|DRUG|LY4170156|Intravenous
219007051|NCT01095016|DRUG|Meptin swinghaler|"* Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days"
219007052|NCT01095016|DRUG|Berotec|"* Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days"
219403085|NCT06400472|DRUG|Bevacizumab|IV
219403086|NCT06400472|DRUG|carboplatin|IV
219403087|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
219403088|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
219403089|NCT04948736|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
219403090|NCT04948736|OTHER|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
219403091|NCT02781467|BIOLOGICAL|PNK-007|
219403092|NCT02781467|DRUG|Cyclophosphamide|
219403093|NCT02781467|DRUG|Fludarabine|
219403094|NCT02781467|DRUG|Human recombinant Interleukin-2 (rhIL-2)|
219403095|NCT05692154|DRUG|Fexofenadine|Fexofenadine oral tablet
219403096|NCT05692154|DRUG|Placebo|Fexofenadine matching placebo oral tablet
219403097|NCT05711407|GENETIC|Gene Polymorphisms of MMP-8|Saliva Samples
219403098|NCT01787500|BIOLOGICAL|Cetuximab|Given IV
219403099|NCT01787500|DRUG|Irinotecan Hydrochloride|Given IV
219403100|NCT01787500|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403101|NCT01787500|OTHER|Pharmacological Study|Correlative studies
219403102|NCT01787500|DRUG|Vemurafenib|Given PO
219403103|NCT03970447|DRUG|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
219403104|NCT03970447|DRUG|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
219403105|NCT03970447|DRUG|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
219403106|NCT03970447|RADIATION|Radiation|60 Gy
219403107|NCT03970447|DRUG|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
219755015|NCT07138586|RADIATION|low level laser therapy group|patients received low level laser therapy using diode laser 980 nm with a low power
219403108|NCT03970447|DRUG|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
219403109|NCT03970447|DRUG|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
219755016|NCT07138586|DRUG|Lidocaine gel group|patients was instructed to use Lidocaine gel (Oracure gel) 4 times daily.
219755017|NCT07138586|DRUG|Chlorhexidine mouthwash group (positive control group).|patients was instructed to use Chlorhexidine mouthwash (Orovex) 4 times daily (control group).
219755018|NCT07146308|OTHER|Lifestyle Management|Participants will undergo dietary and exercise interventions. The dietary intervention includes breakfast, lunch, and dinner, while the exercise intervention consists of both aerobic and resistance training.
219755019|NCT06051357|DRUG|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
219755020|NCT02586194|DRUG|ASP015K|Oral
219755021|NCT06952010|BIOLOGICAL|XB628|Intravenous infusion(s)
219755022|NCT06947291|DRUG|Glumetinib Tablets|glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.
219755023|NCT06947291|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.
219403110|NCT03970447|DRUG|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
219403111|NCT03970447|BIOLOGICAL|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
219403112|NCT03970447|DRUG|AZD1390|Standard Regimen Newly Diagnosed: Given once daily on days of radiation and once daily for 14 consecutive days after completion of radiation.
219403113|NCT00733382|DRUG|dexamethazone|injection form, 8 miligram, injected once
219403114|NCT06808321|DRUG|Benidipine Hydrochloride|The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris
219403115|NCT06038617|BIOLOGICAL|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
219403116|NCT06038617|BIOLOGICAL|Routine Childhood Vaccinations|ACIP Recommended Vaccines
219403117|NCT06339996|DIETARY_SUPPLEMENT|Male supplement|Participants will be administered supplements for a three-month treatment period
219403118|NCT06048003|OTHER|No specific intervention|No specific intervention
219403119|NCT01847144|DRUG|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
219403120|NCT01847144|DRUG|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
219403121|NCT01879618|DRUG|Fragmin|variable dosing regimen
219403122|NCT03075397|OTHER|blood sample|A sample of HIV-1 infected patients's blood is collected
219403123|NCT03075397|OTHER|sperm sample|A sample of HIV-1 infected patients's sperm is collected
219403124|NCT06842680|BEHAVIORAL|Control|Products do not carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
219403125|NCT06842680|BEHAVIORAL|Ultraprocessed warning label|Products carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
219403126|NCT06841627|OTHER|Osteopathic Manipulative Therapy|Evaluation looking for Somatic Dysfunction (SD) involving the head, neck, upper thoracic spine, rib cage and sacroiliac joint. OMT techniques will include a mix of the following: Osteopathic Cranial Manipulative Medicine, Muscle Energy Technique, Facilitated Positional Release, Indirect Myofascial Release, and Counterstrain.
219403127|NCT00138099|DRUG|Fragmin (dalteparin sodium)|
219403128|NCT02496728|BEHAVIORAL|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
219403129|NCT02496728|BEHAVIORAL|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
219755024|NCT07148336|OTHER|Symptom-based scoring system|The patients will be asked to complete the self-evaluation of symptoms and signs of neuropathy using a Neuropathy Tracker that questions symptoms quality, severity and distribution and guide the user through a systematic evaluation of pin-prick from a needle and vibration from the mobile on successive levels from the toes to the knee on both legs. Finally, the extension force or both great toes will be self-assessed by the participant. The self-examination is based on the structure of the Utah Early Neuropathy Score.
219755025|NCT06952790|BEHAVIORAL|EveryDose Mobile Application|Participants will use this application every day for up to 10 minutes, for up to 12 weeks. The purpose of the application is to improve medication adherence. Participants will receive an alert to the mobile device while at home to ensure medication was taken, and to serve as a medication log.
219755026|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
219755027|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
219755028|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
219755029|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
219755030|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
219755031|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
219755032|NCT06948292|DRUG|QRX-3|phase 2B CKD study
219755033|NCT06954740|DRUG|Amimestrocel|Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.
219403130|NCT02496728|BEHAVIORAL|Social Support|Participants may interact with each other through a private Facebook group.
219403131|NCT02496728|BEHAVIORAL|Educational Materials|Educational materials regarding healthy behaviors.
219403132|NCT03647371|PROCEDURE|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
219565760|NCT03996616|DEVICE|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
219565761|NCT03996616|DEVICE|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
219565762|NCT03996616|DEVICE|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
219565763|NCT02824887|OTHER|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
219565764|NCT02824887|OTHER|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
219565765|NCT03237299|OTHER|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
219565766|NCT03237299|OTHER|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
219565767|NCT04220775|DRUG|Bintrafusp Alfa|Given IV
219565768|NCT04220775|OTHER|Quality-of-Life Assessment|Ancillary studies
219565769|NCT04220775|OTHER|Questionnaire Administration|Ancillary studies
219565770|NCT04220775|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219565771|NCT03307811|OTHER|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
219565772|NCT05183711|BEHAVIORAL|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
219565773|NCT00004988|DRUG|VNP20009|
219565774|NCT00089076|BIOLOGICAL|ipilimumab|Given IV
219565775|NCT00089076|OTHER|laboratory biomarker analysis|Correlative studies
219565776|NCT04053673|DRUG|RBN-2397|an oral PARP7 Inhibitor
219565777|NCT04381676|OTHER|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
219565778|NCT05529368|BEHAVIORAL|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
219565779|NCT02314494|BEHAVIORAL|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
219565780|NCT02495376|BEHAVIORAL|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
219565781|NCT02828280|DEVICE|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
219565782|NCT02828280|DEVICE|Traditional mask|A traditional air inflated facemark used to ventilate patients
219403133|NCT03647371|PROCEDURE|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
219403134|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
219403135|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
219403136|NCT03628469|BEHAVIORAL|Proactive Health Support|Active listening, coaching and counselling
219403137|NCT01519245|DRUG|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
219403138|NCT01519245|DRUG|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
219565783|NCT01716676|OTHER|Telemedicine CPAP monitoring (webpage and televisit)|
219565784|NCT01716676|OTHER|Standard CPAP monitoring|
219565785|NCT05328700|OTHER|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
219565786|NCT05328700|OTHER|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
219403139|NCT01494961|BEHAVIORAL|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
219403140|NCT03616769|DRUG|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
219403141|NCT01818557|BEHAVIORAL|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
219403142|NCT00933335|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
219403143|NCT04196036|PROCEDURE|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
219565787|NCT05589259|PROCEDURE|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
219755034|NCT07159399|BEHAVIORAL|Pharmacist-led patient education|Trained pharnacists will provide information on: (1) the indication and the reason of DOAC prescription, (2) the name and the appearance of the DOAC agent, (3) the dose, frequency, time of administration, (4) the mechanism of action, (5) management of missed doses, (6) potential side effects and self-monitoring, and (7) perioperative management. An education leaflet about DOACs will also be provided to improve patients' understanding about the use of DOACs.
219755035|NCT07159399|OTHER|Usual Care|Patients in the usual care group will receive only usual care, without pharmacists providing additional DOAC education materials.
219755036|NCT07161531|DIAGNOSTIC_TEST|Surface Electromyography|The primary lower limb muscles to be monitored include the gluteus medius, rectus femoris, vastus lateralis (quadriceps ), biceps femoris (hamstrings), tibialis anterior, and gastrocnemius medialis (calves). This setup fully utilizes a 16-channel sEMG system by monitoring each muscle group bilaterally to capture comprehensive data on muscle activity and fatigue.
219002184|NCT03867292|OTHER|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
219002185|NCT02547649|BIOLOGICAL|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
219002186|NCT02547649|BIOLOGICAL|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
219002187|NCT02547649|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
219007053|NCT00010374|DEVICE|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
219403144|NCT02729454|OTHER|Mental practice and physical therapy|
219403145|NCT02729454|OTHER|physical therapy|
219403146|NCT02350894|BEHAVIORAL|Graded and behavevial theraphy|Graded and behavevial theraphy
219403147|NCT03829189|DIETARY_SUPPLEMENT|inulin|prebiotic supplement
219403148|NCT03829189|DIETARY_SUPPLEMENT|maltodextrin|placebo supplement
219403149|NCT00995735|PROCEDURE|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
219403150|NCT00995735|PROCEDURE|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
219403151|NCT02911363|DEVICE|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
219403152|NCT02911363|OTHER|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
219403153|NCT00022711|DRUG|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
219403154|NCT02275026|PROCEDURE|Functional magnetic resonance imaging|Diffusion tensor imaging
219403155|NCT01585129|DRUG|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
219403156|NCT01585129|DRUG|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
219403157|NCT00841295|DRUG|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
219403158|NCT00841295|DRUG|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
219403159|NCT01270893|DRUG|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
219403160|NCT02549677|DRUG|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
219403161|NCT02549677|DRUG|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
219403162|NCT02549677|DRUG|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
219403163|NCT01010841|DIETARY_SUPPLEMENT|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
219403164|NCT01010841|OTHER|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
219403165|NCT00493116|DRUG|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
219403166|NCT00493116|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
219403167|NCT05379023|BEHAVIORAL|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
219403168|NCT05379023|BEHAVIORAL|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
219403169|NCT02422043|OTHER|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
219565788|NCT05589259|PROCEDURE|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
219565789|NCT02289937|DRUG|Ropivacaine|
219565790|NCT02289937|DRUG|Placebo|
219565791|NCT02289937|DEVICE|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
219565792|NCT01009515|DRUG|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
219565793|NCT00466843|DRUG|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
219565794|NCT00466843|DRUG|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
219565795|NCT02024594|DRUG|Nitrous Oxide-Oxygen conscious sedation|
219565796|NCT02024594|BEHAVIORAL|cognitive-behavioral therapy|
219755037|NCT07161609|DEVICE|Particle counter|The collection of air samples will begin with the surgical incision and will continue for 10 minute
219760978|NCT04678258|PROCEDURE|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
219007054|NCT05611203|PROCEDURE|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
219403170|NCT01926379|BEHAVIORAL|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."
219403171|NCT01926379|DRUG|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
219403172|NCT04495361|OTHER|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
219403173|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
219403174|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
219403175|NCT02807909|DRUG|BMS-986177|
219403176|NCT02807909|DRUG|Itraconazole|
219403177|NCT02807909|DRUG|Diltiazem ER|
219403178|NCT04014153|PROCEDURE|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
219403179|NCT00933205|DRUG|Tipranavir|
219565797|NCT00983476|BEHAVIORAL|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
219565798|NCT00983476|BEHAVIORAL|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
219565799|NCT00779220|DRUG|placebo|Intravenous repeating dose
219565800|NCT00779220|DRUG|methotrexate|Oral repeating dose
219565801|NCT00779220|DRUG|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
219565802|NCT00779220|DRUG|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
219565803|NCT00779220|DRUG|ocrelizumab 500mg|Intravenous repeating dose (500mg)
219565804|NCT05062148|OTHER|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
219760979|NCT04678258|PROCEDURE|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
219403180|NCT05579561|OTHER|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
219403181|NCT00001262|DRUG|Copper Histidine|
219403182|NCT00783705|OTHER|placebo|Given orally
219403183|NCT00783705|DRUG|inositol|Given orally
219403184|NCT06245577|DEVICE|interdisciplinary mesh sacro colpopexy with resection rectopexy|surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
219403185|NCT03854591|OTHER|No intervention|No intervention
219403186|NCT01818167|DRUG|10% Benzoyl Peroxide Topical Body Wash|
219403187|NCT01818167|DRUG|Provodine Topical Cream|
219565805|NCT05062148|OTHER|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
219760980|NCT04815564|DEVICE|Invisalign|Invisalign clear aligner system
219189657|NCT06418100|PROCEDURE|The recto intercostal fascial plane block|After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
219403188|NCT04516486|OTHER|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
219403189|NCT04532463|DRUG|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
219403190|NCT04227249|PROCEDURE|no lymph node dissection|do not undergo lymph node dissection
219403191|NCT00758927|DRUG|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
219403192|NCT00758927|DRUG|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
219403193|NCT00194636|PROCEDURE|nerve block|
219403194|NCT01954121|DRUG|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)"
219403195|NCT01954121|DRUG|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)"
219403196|NCT03844633|DRUG|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
219403197|NCT03844633|DRUG|Placebos|Placebos -- Shot administered within 48 hours of childbirth
219565806|NCT01175473|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
219565807|NCT01175473|DEVICE|Pen auto-injector|
219189658|NCT05896033|BEHAVIORAL|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
219189659|NCT05896033|BEHAVIORAL|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
219403198|NCT02797106|OTHER|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
219403199|NCT02345642|DEVICE|ActiveCare+SFT Supine|
219403200|NCT02345642|DEVICE|VenaFlow Elite Supine|
219403201|NCT02345642|DEVICE|ActiveCare+SFT Standing|
219403202|NCT02345642|DEVICE|VenaFlow Elite Standing|
219565808|NCT01175473|DRUG|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
219565809|NCT01175473|DEVICE|Pre-filled pen injector|
219565810|NCT01175473|DRUG|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
219565811|NCT05099510|BIOLOGICAL|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
219565812|NCT05099510|BIOLOGICAL|Placebo|Placebo control for NatrunixTM subcutaneous injection.
219565813|NCT01290237|DRUG|vancomycin hydrocloride|see description of study arms
219565814|NCT03230123|DIETARY_SUPPLEMENT|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
219565815|NCT00931996|DRUG|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
219565816|NCT01655251|BEHAVIORAL|Intervention|
219565817|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
219565818|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
219565819|NCT00003531|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219565820|NCT00094367|DRUG|Abacavir/Lamivudine|
219565821|NCT00588731|DRUG|Cannabidiol|Active Cannabidiol daily over 6 weeks
219565822|NCT00588731|DRUG|Placebo|Placebo
219565823|NCT02601768|DEVICE|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
219565824|NCT00251316|DRUG|Lithium Carbonate|30 mCi of 131I
219565825|NCT00251316|DRUG|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
219565826|NCT05549050|OTHER|interdialytic weight gain|interdialytic weight gain during hemodialysis
219565827|NCT00346164|DRUG|doxorubicin hydrochloride|Given IV
219565828|NCT00346164|OTHER|clinical observation|Patients undergo observation
219565829|NCT00346164|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
219189660|NCT05896033|BEHAVIORAL|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
219403203|NCT05964725|DEVICE|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
219403204|NCT05964725|DEVICE|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
219403205|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
219403206|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
219403207|NCT02811484|DRUG|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
219755038|NCT07161245|OTHER|Multimodal prehabilitation|"The multimodal prehabilitation program will consist of:~1. twice-weekly supervised exercise training at the hospital gym for approximately 8 weeks (induction phase), followed by 16 weeks of telematic, supervised, home-based exercise (maintenance phase);~2. nutritional consultation, including diet optimization and supplementation if needed;~3. individual or group-based psychological support."
219755039|NCT07161245|OTHER|standard of care|Participants in the control group will follow the standard of care provided by the hospital and will receive general recommendations on physical activity, nutrition, and stress/anxiety management.
219755040|NCT07158827|DRUG|Tavapadon|Oral: Tablet
219760981|NCT06642415|PROCEDURE|Surgery under loupes|surgery performed under loupes
219760982|NCT06642415|PROCEDURE|surgery performed under microscope|surgery performed under microscope
219189661|NCT05896033|BEHAVIORAL|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
219189662|NCT04685135|DRUG|MRTX849|21 day cycles
219189663|NCT04685135|DRUG|Docetaxel|21 day cycles
219189664|NCT05832307|OTHER|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
219189665|NCT05832307|OTHER|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
219403208|NCT02811484|BEHAVIORAL|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
219403209|NCT01830153|DRUG|RAD001|
219403210|NCT05915819|OTHER|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
219403211|NCT05915819|OTHER|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
219403212|NCT05431413|DRUG|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
219403213|NCT05431413|DRUG|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
219403214|NCT05431413|DRUG|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
219403215|NCT01618955|DEVICE|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
219403216|NCT02372903|DRUG|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
219403217|NCT00661752|DEVICE|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
219403218|NCT00661752|DEVICE|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
219565830|NCT00346164|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
219565831|NCT00346164|DRUG|ifosfamide|Given IV
219565832|NCT02266849|DRUG|Loperamide|12 mg Loperamide each day for three days
219565833|NCT02266849|DRUG|Placebo|6 tablets daily for three days
219565834|NCT00692952|DRUG|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
219403219|NCT03901287|OTHER|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
219403220|NCT03403491|OTHER|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
219403221|NCT03403491|OTHER|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
219403222|NCT00424580|DRUG|Montelukast (10mg) and Desloratadine (5mg)|
219403223|NCT03516292|DIAGNOSTIC_TEST|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
219403224|NCT01492114|DIETARY_SUPPLEMENT|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
219403225|NCT01492114|DIETARY_SUPPLEMENT|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
219403226|NCT05380414|BIOLOGICAL|Tumor samples (archival FFPE) and blood samples|Molecular screening
219403227|NCT03544671|DIETARY_SUPPLEMENT|Vitamin D|
219403228|NCT02504892|DRUG|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
219565835|NCT00692952|DRUG|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
219565836|NCT04464109|PROCEDURE|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
219565837|NCT03370107|DEVICE|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
219565838|NCT02025088|PROCEDURE|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
219403229|NCT03130101|OTHER|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
219403230|NCT02329795|RADIATION|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
219565839|NCT02025088|PROCEDURE|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
219565840|NCT02283593|BEHAVIORAL|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
219565841|NCT06616493|OTHER|kinesio taping|measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
219403231|NCT02329795|DRUG|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
219403232|NCT03553017|DEVICE|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
219403233|NCT03921229|BEHAVIORAL|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
219403234|NCT01676376|DEVICE|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
219403235|NCT01676376|OTHER|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
219403236|NCT05329467|OTHER|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
219565842|NCT05085769|PROCEDURE|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
219565843|NCT05118360|DRUG|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
219565844|NCT05118360|DRUG|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
219403237|NCT00576693|DEVICE|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
219403238|NCT00576693|OTHER|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
219403239|NCT00812071|BIOLOGICAL|RiVax|vaccine
219403240|NCT01413178|DRUG|Busulfan|Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
219403241|NCT01413178|DRUG|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
219403242|NCT01413178|OTHER|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
219403243|NCT01413178|DRUG|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
219403244|NCT01413178|DRUG|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
219403245|NCT01413178|PROCEDURE|Stem cell transplant|Stem cell infusion on Day 0.
219403246|NCT00073593|DRUG|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).
219403247|NCT00073593|DRUG|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
219403248|NCT00073593|DRUG|Protamine|Per institutional practice. Batches from hospital stock.
219403249|NCT00657761|DRUG|Enfuvirtide|90 mg/12h sc for 7 days
219403250|NCT00657761|DRUG|Placebo|0.9% saline solution/12h sc for 7 days
219565845|NCT05118360|DRUG|Placebo|Matching placebo orally once daily for 52 weeks.
219565846|NCT05487755|DRUG|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
219565847|NCT05487755|DRUG|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
219565848|NCT00006143|DRUG|Somatropin|
219565849|NCT05183087|DIAGNOSTIC_TEST|3T Connectome MRI|MRI scan of structural connectivity
219565850|NCT05183087|DIAGNOSTIC_TEST|7 Tesla MRI|MRI scan of functional connectivity
219565851|NCT05183087|DIAGNOSTIC_TEST|TSPO PET|PET scan of neuroinflammation
219565852|NCT05183087|DIAGNOSTIC_TEST|Tau PET|PET scan of tau deposition
219403251|NCT04053179|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
219565853|NCT05183087|DIAGNOSTIC_TEST|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
219565854|NCT05183087|DIAGNOSTIC_TEST|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
219565855|NCT05049811|BEHAVIORAL|mini program|To design, construct, and test the mini program in patients managing cancer pain
219565856|NCT05049811|BEHAVIORAL|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
219565857|NCT02883517|GENETIC|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
219565858|NCT00004294|GENETIC|human glucocerebrosidase gene into autologous peripheral blood stem cells|
219403252|NCT02596347|PROCEDURE|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
219565859|NCT00003894|DRUG|thalidomide|
219565860|NCT02896543|OTHER|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
219565861|NCT02345291|DRUG|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
219565862|NCT02345291|DRUG|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
219565863|NCT00200317|BEHAVIORAL|Internet and print-based interventions|
219755041|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Cricket protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
219403253|NCT02596347|PROCEDURE|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
219403254|NCT04045249|DIETARY_SUPPLEMENT|Home based food|Home based food is compare able to RUTF
219403255|NCT04291417|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
219565864|NCT05563688|OTHER|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
219002188|NCT02988531|OTHER|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
219403256|NCT06228183|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219403257|NCT06228183|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219403258|NCT06228183|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219403259|NCT00416767|DRUG|fluorouracil|
219403260|NCT00416767|DRUG|irinotecan hydrochloride|
219403261|NCT00416767|DRUG|leucovorin calcium|
219403262|NCT00003667|DRUG|cyclophosphamide|
219403263|NCT00003667|DRUG|dexrazoxane hydrochloride|
219403264|NCT00003667|DRUG|disaccharide tripeptide glycerol dipalmitoyl|
219403265|NCT00003667|DRUG|doxorubicin hydrochloride|
219403266|NCT00003667|DRUG|vincristine sulfate|
219403267|NCT00003667|PROCEDURE|surgical procedure|
219403268|NCT00003667|RADIATION|radiation therapy|
219403269|NCT02805868|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219403270|NCT02805868|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403271|NCT02805868|BIOLOGICAL|Siltuximab|Given IV
219403272|NCT04438746|BEHAVIORAL|Emotion discussion|General discussion of emotions; no therapy or training is offered
219403273|NCT04438746|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger
219403274|NCT03782740|DRUG|Melatonin 10 mg|Melatonin capsule
219403275|NCT03782740|DRUG|Placebo|Sugar pill manufactured to mimic Melatonin capsule
219403276|NCT03782740|DRUG|Melatonin 20 mg|Melatonin capsule
219403277|NCT00059436|BEHAVIORAL|Mental effort in muscle strengthening|
219403278|NCT00398619|DRUG|INCB13739|
219403279|NCT01570985|DRUG|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
219403280|NCT01570985|DRUG|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
219403281|NCT05657288|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
219565865|NCT05563688|OTHER|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
219565866|NCT05563688|BEHAVIORAL|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;~* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
219565867|NCT06503549|OTHER|Assessments|Only the current assessments will be made
219565868|NCT05612087|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
219565869|NCT05365152|DIETARY_SUPPLEMENT|Meal Replacement|Meal Replacement
219755042|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Whey protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
219565870|NCT01198873|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
219565871|NCT01198873|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
219565872|NCT03139240|DRUG|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
219565873|NCT03139240|OTHER|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
219565874|NCT02810249|OTHER|No intervention used|
219565875|NCT05340192|DRUG|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
219403282|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension|topical suspension
219403283|NCT00804193|DRUG|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
219403284|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
219403285|NCT00206115|DRUG|Seroquel Sustained Release (SR)|
219403286|NCT00206115|DRUG|Seroquel Immediate Release (IR)|
219403287|NCT00206115|DRUG|Placebo|
219403288|NCT02352051|DRUG|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
219403289|NCT02352051|DRUG|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
219403290|NCT00543829|DRUG|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
219403291|NCT00543829|DRUG|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
219403292|NCT00262262|DRUG|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
219403293|NCT01831557|OTHER|Blood samples will be taken for gene sequencing|
219403294|NCT00757562|DRUG|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
219565876|NCT04751630|OTHER|Therapeutic Exercise|Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
219403295|NCT00757562|DRUG|Placebo|placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
219565877|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment (VRGAIT)|Subject watching Virtual reality video of acupuncture needle stimulation
219565878|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment control|Subject watching VR video of swab touching
219565879|NCT01253395|BEHAVIORAL|Strength training|Daily supervised strength training.
219565880|NCT01253395|BEHAVIORAL|Aerobic exercise|Daily supervised aerobic exercise.
219760983|NCT05943262|DEVICE|mesoscale nonlinear optical microscope|The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
219403296|NCT04072146|DRUG|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
219403297|NCT04072146|DRUG|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
219403298|NCT01987986|BIOLOGICAL|Collagenase Clostridium Histolyticum|injectible intervention
219403299|NCT01987986|BIOLOGICAL|Placebo|
219403300|NCT01617434|DRUG|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
219403301|NCT01617434|DRUG|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
219403302|NCT03283163|BEHAVIORAL|Exercise Testing and Training|The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
219403303|NCT00659919|DRUG|Placebo|
219403304|NCT00659919|DRUG|Trazodone|
219403305|NCT05646303|DRUG|Psilocybin|Psilocybin and psychotherapy
219403306|NCT05646303|DRUG|Placebo|Placebo and psychotherapy
219403307|NCT00237796|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
219403308|NCT00237796|BEHAVIORAL|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
219403309|NCT03881917|DIAGNOSTIC_TEST|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
219403310|NCT05774912|OTHER|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
219403311|NCT04372329|BEHAVIORAL|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
219403312|NCT06672835|BEHAVIORAL|eBASIS|eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.
219403313|NCT06672835|BEHAVIORAL|eAttention Control|eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
219002189|NCT03030924|DEVICE|Solace|Noninvasive physiologic monitor
219403314|NCT05438680|DIETARY_SUPPLEMENT|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
219403315|NCT05438680|DIETARY_SUPPLEMENT|Placebo|distilled water with no bovine colostrum
219403316|NCT04561388|PROCEDURE|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
219403317|NCT04561388|OTHER|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
219403318|NCT04561388|OTHER|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
219403319|NCT00231920|BIOLOGICAL|Fluzone|
219403320|NCT01686022|OTHER|Immunoblot|serum specific IgE binds to grass extract by immunoblot
219403321|NCT01568905|OTHER|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
219403322|NCT01568905|OTHER|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
219403323|NCT01568905|OTHER|High level nicotine cigarette|smoke the study cigarette exclusively for one week
219403324|NCT06671743|PROCEDURE|Root canal treatment|"History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale."
219403325|NCT06671418|PROCEDURE|Primary percutaneous stenting (PPS)|PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.
219403326|NCT06671418|PROCEDURE|Endoscopic biliary drainage|EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
219403327|NCT04238663|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
219403328|NCT04238663|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
219403329|NCT04238663|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
219565881|NCT06655974|OTHER|Health-related social needs decision support system|"The clinical decision support intervention will present emergency department clinicians at an Indianapolis, IN ED with a likelihood score for an adult patient screening positive for the following health-related social needs (HRSNs): housing instability, food insecurity, transportation barriers, financial strain, and history of legal involvement. For each HRSN, the likelihood of screening positive is reported as high, medium, or low. These categorizations are the product of logistic regression models. The clinical decision support intervention will be delivered through an existing FHIR (Fast Healthcare Interoperability Resources) standards-based clinical decision support platform."
219403330|NCT00387387|DRUG|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
219403331|NCT00387387|DRUG|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
219403332|NCT00387387|DRUG|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
219403333|NCT03796156|DRUG|Aspirin|75mg low dose non enteric coated or dispersible
219565882|NCT04051216|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention
219565883|NCT04051216|OTHER|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
219403334|NCT02756715|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
219403335|NCT02756715|DRUG|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
219002190|NCT06185374|BEHAVIORAL|Text Message Instructions/Motivation|For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
219002191|NCT01750242|DEVICE|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
219002192|NCT04445389|DRUG|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
219002193|NCT04445389|DRUG|Saline|Saline
219189666|NCT05507905|BEHAVIORAL|Music|Music associated with dance forms in dance classes.
219189667|NCT05507905|BEHAVIORAL|Dance Classes|Four Different dance forms taught for 6 weeks each
219755043|NCT07161466|BEHAVIORAL|lung recruitment maneuvre; PEEP|"After the patient enters the operating room, routine monitoring of ECG, non-invasive blood pressure, and SpO₂ is performed. Local anesthesia is used for radial artery puncture and catheterization to monitor invasive blood pressure.~After 3 minutes of pre-oxygenation, tracheal intubation is performed with the following ventilation parameters: VT 6-8 ml/kg, FiO₂ 60%, RR 15 breaths/min, I/E 1:2, and PEEP 4 cmH₂O. Ten minutes after the establishment of pneumoperitoneum during surgery, baseline levels of respiratory mechanical parameters and hemodynamic variables are recorded. Subsequently, alveolar recruitment is performed at a pressure of 30 cmH₂O for 30 seconds. Immediately after recruitment, the PEEP level is adjusted according to the group. The changes in respiratory mechanics parameters and hemodynamic variables after recruitment are recorded. After the outcome indicators recover to the new baseline level, the PEEP is readjusted to 4 cmH₂O."
219403336|NCT01273688|BEHAVIORAL|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
219403337|NCT01273688|DEVICE|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
219565884|NCT04051216|OTHER|Interview|Participants will be interviewed about their experience using the device(s)
219565885|NCT04051216|OTHER|Survey Administration|Participants will receive surveys
219565886|NCT04051216|OTHER|Laboratory Biomarker Analysis|Correlative studies
219755044|NCT07158736|PROCEDURE|Genicular nerve block with bupivacaine and corticosteroids|genicular nerve block with ideal body-weight dosing of bupivacaine 0.5% with 4 mg dexamethasone
219755045|NCT07158736|OTHER|Standard of Care|This involves standard of care pain relief for patients who do not receive the genicular nerve block for knee pain, such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids.
219755046|NCT07160140|OTHER|Participants will receive an 8-week pedal technique training protocol in addition to their regular cycling training.|Pedal Technique Training Protocol This training is designed as a technical training to observe pedaling data, analyze right and left leg power ratios, and determine how they change when pedaling at various intensities and cadences
219755047|NCT07160296|BEHAVIORAL|20-Week Lifestyle Program|"Nutrition counseling: Weekly group sessions with an oncology dietitian, including individualized calorie and protein goals.~Exercise: Home-based resistance and mobility exercises twice per week using online videos, and daily walking with self-tracking.~Wellness education: Weekly group sessions focused on stress management, sleep, fatigue, and mindset, facilitated by a health and wellness coach. Five of the 20 sessions will include a Speech, Voice, Swallowing, and Airway Care in Head \& Neck Cancer training series led by a speech pathologist."
219755048|NCT07158567|DEVICE|intermittent theta burst stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulatory treatment. TMS has been FDA cleared since 2008 for treatment resistant depression. It is now FDA cleared for a few other indications including migraine. Magnetic pulses are delivered through a coil placed on the scalp and when the magnetic field reaches brain cells, it changes to an electric current that can increase or decrease excitability depending on the treatment parameters. Intermittent theta burst stimulation (iTBS) is a type of patterned, excitatory TMS. iTBS only takes 3 minutes to deliver and is theorized to induce a window of neuroplasticity that lasts at least 1 hour. The Magventure with Magoption x100 Stimulator and associated coil the investigators are using can be set to deliver active (real) or sham (fake or inactive) TMS. The sham device is designed to look, sound and feel like real TMS.
219755049|NCT07158567|BEHAVIORAL|LoveYourBrain Yoga Program|This yoga program is evidence-based, standardized and manualized. It is developed by the LoveYourBrain Foundation (www.loveyourbrain.com). Each yoga session includes 10 min of breathing exercises, 45 min of gentle yoga or stretching exercises, 15 min of guided meditation, and 20 min of facilitated discussion with psychoeducation, detailed in a manual to ensure standardization of program content across time and instructors.
219755050|NCT07158840|DRUG|AK112|AK112 Monotherapy
219755051|NCT07158671|OTHER|Intervention Group|"Participants in the intervention group will:~Use the survivorship programme through mHealth every day for 3 months; Be called by the healthcare provider every 2 weeks for consultation"
219755052|NCT07159685|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation with RF, guided by navigation system
219755053|NCT07158762|OTHER|White bread|Two slices of white bread consumption along with 150 ml of pure orange juice and 10 g of butter
219403338|NCT06000722|OTHER|eDelphi method|This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
219755054|NCT07158762|OTHER|Wholemeal bread|Two slices of wholemeal bread consumption along with 150 ml of pure orange juice and 10 g of butter
219755055|NCT07161596|BEHAVIORAL|oral health educational program|oral health educational program to the hemophilic children guided by the oral and dental care instructions provided by the AAPD and World federation of hemophilia oral care instructions
219403339|NCT04388280|DIAGNOSTIC_TEST|Echocardiography|Functional assessment of coronary artery disease
219565887|NCT01419899|BEHAVIORAL|Brief motivational intervention|A 20-30 minute motivational based discussion
219565888|NCT00823199|DRUG|Allopurinal|300mg once daily by mouth for four weeks
219755056|NCT07159841|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth, weight-based dosing
219755057|NCT07159841|DRUG|Placebo|Placebo, tablets, once daily by mouth, weight-based dosing
219403340|NCT04388280|DIAGNOSTIC_TEST|CT angiography|Anatomical assessment of coronary artery disease
219403341|NCT04356755|DRUG|AdMSC|At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
219565889|NCT02360306|PROCEDURE|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
219565890|NCT01758237|DEVICE|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
219565891|NCT01758237|PROCEDURE|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
219755058|NCT07160920|OTHER|Collect clinical data of pregnant women|Collect clinical data of pregnant women
219755059|NCT07160088|OTHER|Observational|This is an observational study without study-related intervention. All the treatments will be depended on the attending doctors and according to the related guidelines.
219755060|NCT07159451|DRUG|Elacestrant|Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.
219755061|NCT07159451|DRUG|Leuprorelin|Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29
219007055|NCT05304156|OTHER|Biobanking blood and bone marrow specimens|"Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care)."
219007056|NCT06339723|BEHAVIORAL|Pecha Kucha|Pecha Kucha Method training was given
219403342|NCT04356755|DRUG|Placebo|At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
219403343|NCT02510729|DEVICE|Neurostimulation|
219007057|NCT02601131|BIOLOGICAL|Platelet transfusion|
219007058|NCT03305198|BIOLOGICAL|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
219403344|NCT02510729|DEVICE|Sham stimulation|
219403345|NCT06130696|OTHER|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
219403346|NCT06130696|OTHER|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
219403347|NCT04070378|DRUG|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
219403348|NCT01370278|OTHER|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
219403349|NCT01370278|OTHER|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
219403350|NCT00501033|DEVICE|Mechanical induction of labor|
219403351|NCT00501033|DEVICE|Double Balloon|
219403352|NCT00501033|DEVICE|Foley Catheter|
219403353|NCT00942045|BIOLOGICAL|Biologic - Osteocel Plus|Osteocel Plus
219403354|NCT05618457|DRUG|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
219403355|NCT06512441|DRUG|Vitamin B6 Tablets|The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
219565892|NCT02248506|OTHER|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
219565893|NCT01529931|DEVICE|Hair2Go|Hair2Go treatment once a month for 6 months
219565894|NCT05583682|OTHER|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
219565895|NCT00265044|BEHAVIORAL|Provider Education|
219565896|NCT00265044|BEHAVIORAL|Hypertension Alert|
219565897|NCT00265044|BEHAVIORAL|Patient Education|
219565898|NCT01584895|BEHAVIORAL|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
219565899|NCT02725424|DRUG|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
219565900|NCT02725424|DRUG|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
219565901|NCT02725424|DRUG|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
219565902|NCT02725424|DRUG|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
219565903|NCT03020784|DRUG|Placebo|Placebo
219565904|NCT03020784|DRUG|PF-06818883|Treatment
219565905|NCT00305916|PROCEDURE|Multislice spiral computed tomography coronary angiography|
219565906|NCT00305916|PROCEDURE|conventional coronary angiography|
219565907|NCT01576302|BEHAVIORAL|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
219565908|NCT01576302|BEHAVIORAL|Muscle relaxation|Progressive passive muscle relaxation
219565909|NCT03345264|BEHAVIORAL|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
219565910|NCT01998243|DEVICE|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
219760984|NCT04201535|DIAGNOSTIC_TEST|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
219403356|NCT06512441|DRUG|Placebo|The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
219403357|NCT03259334|DRUG|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
219403358|NCT03259334|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
219403359|NCT04775797|DRUG|AB-836|Capsules or Tablets
219403360|NCT04775797|DRUG|Placebo|Capsules of Tablets
219403361|NCT04775797|DRUG|AB-836|Tablets
219403362|NCT04775797|DRUG|Placebo|Tablets
219403363|NCT04775797|DRUG|Nucleos(t)ide Analogue|Tablets
219403364|NCT03839147|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
219403365|NCT00110656|OTHER|Observations|This is a non-interventional study- only observational.
219403366|NCT02551367|DRUG|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
219403367|NCT02551367|DRUG|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
219403368|NCT02551367|DRUG|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
219403369|NCT04027465|DIETARY_SUPPLEMENT|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
219403370|NCT07021573|DEVICE|KINEVO 900 S with BLUE 400|The investigational device consists of a CE marked (MDR) surgical microscope KINEVO 900 S by Carl Zeiss Meditec AG, including the BLUE 400 fluorescence option. This microscope is equipped with an additional component (CALLAO), provided by the Carl Zeiss Meditec AG, that allows for extended, multispectral, image acquisition in the operating room. CALLAO consists of an optical setup with additional cameras, that can be mounted on the main system KINEVO 900 S, and a second light source for specific illumination during image acquisition with the CALLAO cameras.
219403371|NCT01419704|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
219403372|NCT00246467|BIOLOGICAL|Alhydrogel|
219403373|NCT00246467|BIOLOGICAL|rF1 and rV protein antigens|
219403374|NCT03542045|DEVICE|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
219403375|NCT06043050|DRUG|Platelets|Observational data: all platelet transfusions recorded in routine care medical file data.
219403376|NCT04389749|DEVICE|CPM|CPM-continuous passive motion device.
219565911|NCT01998243|OTHER|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
219565912|NCT05516459|BIOLOGICAL|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
219565913|NCT04187209|DEVICE|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
219565914|NCT01908894|DRUG|BIOD-123|
219565915|NCT01908894|DRUG|BIOD-125|
219565916|NCT01908894|DRUG|Humalog|
219403377|NCT04821973|DEVICE|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
219403378|NCT04821973|DEVICE|usual monitoring|usual nurse respiratory monitoring
219403379|NCT00121030|DRUG|darbepoetin alfa|
219403380|NCT00121030|DRUG|recombinant human erythropoietin (rHuEPO)|
219403381|NCT00701727|DRUG|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
219403382|NCT00701727|DRUG|Placebo|1 tablet, once a day, for 7 weeks
219403383|NCT05291598|DRUG|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
219403384|NCT05291598|DRUG|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
219403385|NCT02855684|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219403386|NCT02855684|DRUG|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219565917|NCT02146976|DRUG|propofol|introvenious infusion of propofol
219565918|NCT02146976|DRUG|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
219565919|NCT00455026|DRUG|remifentanil|target effect site concentration during induction
219565920|NCT03585426|DRUG|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
219565921|NCT02800031|DEVICE|Transvaginal ultrasonography|
219403387|NCT02855684|DRUG|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
219403388|NCT02757066|DRUG|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
219403389|NCT02757066|DRUG|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
219403390|NCT02757066|DRUG|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
219403391|NCT00726817|DRUG|Butyrate|
219403392|NCT05113953|DRUG|Centanafadine|Sustained-release oral tablets
219403393|NCT05113953|DRUG|Placebo|Oral tablets
219007059|NCT03992820|DEVICE|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
219403394|NCT00523341|BIOLOGICAL|Denosumab|Administered by subcutaneous injection once every 6 months.
219403395|NCT04864392|DRUG|LNA043 Dosing Regimen A|Injection to the knee
219403396|NCT04864392|DRUG|LNA043 Dosing Regimen B|Injection to the knee
219403397|NCT04864392|DRUG|LNA043 Dosing Regimen C|Injection to the knee
219403398|NCT04864392|DRUG|LNA043 Dosing Regimen D|Injection to the knee
219403399|NCT04864392|DRUG|Placebo|Injection to the knee
219403400|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
219403401|NCT05137041|DEVICE|ITP FIRTECH|Infrared Therapy Patch
219403402|NCT03588767|DRUG|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
219403403|NCT03588767|OTHER|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
219403404|NCT04921722|DRUG|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
219403405|NCT04921722|DRUG|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
219403406|NCT02626819|BEHAVIORAL|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
219403407|NCT02626819|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
219403408|NCT01526018|BEHAVIORAL|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
219403409|NCT00313807|DRUG|Amino Acid|7% amino acid infusion
219403410|NCT00313807|DRUG|Placebo|0.9% Saline Infusion
219403411|NCT02773069|BEHAVIORAL|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
219403412|NCT00649649|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
219189668|NCT05540353|DEVICE|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
219403413|NCT00649649|DRUG|Accupril® Tablets 40 mg|40mg, single dose fed
219403414|NCT05655637|OTHER|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
219403415|NCT01094002|OTHER|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
219403416|NCT02491437|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
219403417|NCT02491437|DRUG|intravaginal progesterone gel 90 mg|
219403418|NCT00551720|BEHAVIORAL|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
219403419|NCT00551720|BEHAVIORAL|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
219403420|NCT01839292|DEVICE|uncovered D-type stent insertion|
219403421|NCT01839292|DEVICE|double-layered ComVi stent insertion|
219403422|NCT00502307|DRUG|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
219403423|NCT00502307|DRUG|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
219403424|NCT05297422|PROCEDURE|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
219403425|NCT05297422|DRUG|Ropivacaine|Ropivacaine
219403426|NCT05297422|DRUG|Ketamine|Ketamine
219403427|NCT05039580|DRUG|PD-1 monoclonal antibody|PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
219403428|NCT02297334|DEVICE|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
219403429|NCT03114306|PROCEDURE|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
219403430|NCT03114306|PROCEDURE|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
219403431|NCT04037670|PROCEDURE|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
219403432|NCT04907539|DRUG|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
219403433|NCT04907539|BIOLOGICAL|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
219403434|NCT04907539|BIOLOGICAL|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
219403435|NCT02141646|BEHAVIORAL|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
219403436|NCT02141646|BEHAVIORAL|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
219403437|NCT01914887|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
219403438|NCT01673503|DEVICE|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
219403439|NCT00051558|DRUG|Teriparatide|20 micrograms/day, injection, 36 months
219403440|NCT00051558|DRUG|Alendronate Sodium|10 mg/day, oral, 36 months
219403441|NCT00051558|DRUG|Placebo|Oral placebo, daily, 36 months
219403442|NCT00051558|DRUG|Placebo|Injection placebo, daily, 36 months
219403443|NCT06009224|OTHER|ERAS perioperative management|"* Epidural analgesia~* Fluid balance~* Other items are the same as conventional"
219403444|NCT05797454|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
219403445|NCT05797454|PROCEDURE|Wire-guided localization|Positioning guide wire in the center of the lesion
219403446|NCT02375958|DRUG|PCA062|
219403447|NCT05343806|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
219403448|NCT05343806|DRUG|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
219403449|NCT01604057|DRUG|ZT-034 Low Dose Nasal Spray|Nasal Spray
219403450|NCT01604057|DRUG|ZT-034 Mid Dose Nasal Spray|Nasal Spray
219403451|NCT01604057|DRUG|ZT-034 High Dose Nasal Spray|Nasal Spray
219403452|NCT01604057|DRUG|Teriparatide|20 mcg subcutaneous daily
219403453|NCT01604057|DRUG|Placebo|Nasal Spray
219403454|NCT05078606|DEVICE|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
219403455|NCT05078606|DEVICE|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
219403456|NCT05078606|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
219403457|NCT00295698|DRUG|Diethylcarbamazine|
219403458|NCT05978362|PROCEDURE|Latarjet technique|Realization of a stop according to Latarjet
219565922|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
219007060|NCT03992820|COMBINATION_PRODUCT|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
219403459|NCT04647227|DRUG|coagulation factor VIIa [recombinant]-jncw|a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
219403460|NCT02397993|PROCEDURE|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
219403461|NCT02397993|PROCEDURE|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
219403462|NCT02397993|PROCEDURE|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
219403463|NCT05858138|OTHER|Jing-Si Herbal Tea|patient will receive twice in a day for 24 weeks
219403464|NCT05858138|OTHER|Placebo Jing-Si Herbal Tea|Placebo Jing-Si Herbal Tea
219403465|NCT06629142|BEHAVIORAL|Default Order|A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
219403466|NCT06629142|BEHAVIORAL|Accountable Justification|An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.
219403467|NCT06629142|BEHAVIORAL|Standardized Usual Care|Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
219403468|NCT06188832|DIETARY_SUPPLEMENT|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
219403469|NCT06188832|OTHER|placebo|the subjects recieved placebo
219403470|NCT01801046|DRUG|mitoxantrone hydrochloride|Given IV
219403471|NCT01801046|DRUG|cytarabine|Given IV
219403472|NCT01801046|PROCEDURE|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
219403473|NCT01801046|OTHER|laboratory biomarker analysis|Correlative studies
219403474|NCT03902366|DIAGNOSTIC_TEST|Neuropsychological assessment|Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
219403475|NCT03902366|BEHAVIORAL|Neuroimaging|Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
219403476|NCT06527274|DEVICE|Experimental: Myopic defocus soft lens design (MDSL)|An optical device designed to provide a myopic defocus to control myopia progression
219403477|NCT06527274|DEVICE|Active Comparator: Single vision soft lens design (SVSL|An optical device designed to correct refractive error like myopia
219403478|NCT03393845|DRUG|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
219403479|NCT03393845|DRUG|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
219403480|NCT01701583|DRUG|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
219403481|NCT01441440|DRUG|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
219403482|NCT01441440|DRUG|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
219403483|NCT01441440|DRUG|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
219403484|NCT02929095|DRUG|dexmedetomidine|
219403485|NCT02929095|DRUG|midazolam|
219565923|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
219565924|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
219565925|NCT02403739|OTHER|No Intervention|No Intervention
219565926|NCT01048463|DRUG|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
219403486|NCT02929095|DRUG|remifentanil|\- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
219403487|NCT05636579|BIOLOGICAL|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
219403488|NCT05636579|DRUG|Ripasudil|Daily use of Ripasudil drops
219403489|NCT01294735|DRUG|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
219403490|NCT01294735|DRUG|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
219403491|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
219403492|NCT05645029|OTHER|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
219403493|NCT05645029|OTHER|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
219403494|NCT05645029|OTHER|glass ionomer|glass ionomer will be used without any additives
219403495|NCT02854137|DRUG|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
219403496|NCT02854137|DRUG|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
219403497|NCT02750813|DEVICE|Delefilcon A contact lenses|
219403498|NCT02750813|DEVICE|Senofilcon A contact lenses|
219403499|NCT00074100|DRUG|amonafide dihydrochloride|
219403500|NCT03299517|DRUG|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
219403501|NCT03299517|DRUG|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
219403502|NCT04430049|PROCEDURE|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
219403503|NCT06166914|DRUG|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
219403504|NCT06166914|DRUG|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
219403505|NCT03445052|BEHAVIORAL|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
219403506|NCT00751530|DRUG|raltegravir|New combination ART incorporating raltegravir with other ARVs.
219403507|NCT03927937|PROCEDURE|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
219007061|NCT00837304|DEVICE|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
219403508|NCT04060173|DRUG|ABP-671|ABP-671 is an investigational drug
219007062|NCT00837304|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
219403509|NCT04060173|OTHER|Placebo|Matching placebo
219403510|NCT06312267|DEVICE|Bioelectric dressing|Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
219403511|NCT05813171|DIETARY_SUPPLEMENT|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
219403512|NCT05813171|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
219403513|NCT05205434|OTHER|Synchronous telerehabilitation programme|Exercise program and educational program
219403514|NCT05205434|OTHER|Asynchronous telerehabilitation programme|Exercise program educational program
219403515|NCT05105438|DIETARY_SUPPLEMENT|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
219403516|NCT05105438|DIETARY_SUPPLEMENT|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
219403517|NCT05120622|DRUG|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
219403518|NCT02684019|DRUG|Dexmedetomidine|added to propofol sedation
219403519|NCT02684019|DRUG|Magnesium Sulphate|added to propofol sedation
219755062|NCT07160803|OTHER|Intervention Program for Social Network Use Based on Activity Theory|The intervention program is structured around a three - phase framework for migrant elderly's social network use: ① triggering motivation and building basic capabilities; ② reinforcing motivation and enhancing advanced capabilities; ③ sustaining motivation and maintaining usage habits. The process involves assessing baseline status (via scales like ASNSUS, eHEALS), implementing phased interventions (teaching WeChat skills, facilitating social connections), and evaluating effectiveness (process and outcome evaluations). The 12 - week program is executed by a team including researchers, community workers, and elderly volunteers.
219755063|NCT07160803|OTHER|Routine community activities only|After receiving regular community services and management, and understanding the overall situation and needs of the intervention targets, researchers and community managers will conduct a weekly health lecture, an offline social activity involving local elderly people (such as fitness, cultural and entertainment activities, etc.), or a lecture on policies and welfare related to migrant elderly people, etc., and regularly distribute relevant paper materials.
219007063|NCT01961323|DRUG|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
219403520|NCT01325831|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
219403521|NCT01325831|DEVICE|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
219403522|NCT02665234|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
219403523|NCT02665234|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
219403524|NCT02227017|DRUG|TPV capsule|
219403525|NCT02227017|DRUG|TPV solution|
219403526|NCT02227017|DRUG|RTV capsule|
219403527|NCT02227017|DRUG|RTV solution|
219403528|NCT02227017|OTHER|standard meal|
219403529|NCT03017248|DRUG|Ketamine|ketamine
219403530|NCT03017248|DRUG|Placebos|0.9% normal saline
219403531|NCT03017248|DRUG|Morphine|Morphine
219403532|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
219403533|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
219403534|NCT02849990|DRUG|Abiraterone Acetate|Given PO
219403535|NCT02849990|DRUG|Apalutamide|Given PO
219403536|NCT02849990|DRUG|Degarelix|Given SC
219403537|NCT02849990|DRUG|Indomethacin|Given PO
219403538|NCT02849990|OTHER|Laboratory Biomarker Analysis|Correlative study
219403539|NCT02849990|DRUG|Prednisone|Given PO
219565927|NCT01048463|DRUG|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
219403540|NCT03157154|OTHER|Non interventional study|A query form to all concerned patients by each investigating centre will be send
219403541|NCT03135587|PROCEDURE|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
219403542|NCT02584933|DRUG|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
219403543|NCT01184404|DRUG|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
219403544|NCT00133237|DEVICE|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
219403545|NCT00133237|DEVICE|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
219403546|NCT00556218|BEHAVIORAL|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
219403547|NCT00556218|BEHAVIORAL|No Meditation|No meditation; usual care.
219403548|NCT05201274|BEHAVIORAL|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
219403549|NCT05201274|BEHAVIORAL|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
219403550|NCT00750555|DRUG|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
219565928|NCT01048463|DRUG|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
219565929|NCT01048463|DRUG|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
219565930|NCT01048463|DRUG|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
219565931|NCT04569786|BIOLOGICAL|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
219565932|NCT04569786|OTHER|Placebo|Placebo administered via IM injection.
219755064|NCT07160283|DRUG|Bile duct cancer cohort|"Trilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
219755065|NCT07160283|DRUG|Pancreatic cancer cohort|"rilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
219755066|NCT07159152|DIETARY_SUPPLEMENT|Coffee|Participants will consume 3 cups of Arabica coffee (Guatemalan origin), providing a total of 400 mg of caffeine. Each cup is prepared with 6% coffee grounds per 100 mL of water, brewed at 90°C for 6 minutes using an electric drip coffee maker, yielding 100.8 mg caffeine per 100 mL. Immediately following coffee consumption, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before coffee), 1 hour after coffee intake, and hourly during the 3-hour sitting period.
219755067|NCT07159152|DIETARY_SUPPLEMENT|Hibiscus drink|Participants will consume 3 servings of hibiscus leaves tea per day, each serving containing 1.25 g of dried hibiscus leaves, totaling 3.75 g per session. The tea will be prepared by steeping the leaves in 240 mL of boiling water (100°C) for 10 minutes. Immediately after consuming the hibiscus tea, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before tea), 1 hour after tea intake, and hourly during the 3-hour sitting.
219403551|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
219403552|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
219403553|NCT01795898|DRUG|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
219403554|NCT01968720|DRUG|CAT-2003|
219755068|NCT07159217|DRUG|Disitamab Vedotin|2.0 mg/kg administered intravenously every three weeks
219755069|NCT07159217|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
219755070|NCT07159217|DRUG|Pembrolizumab|200 mg intravenously every three weeks
219755071|NCT07159217|DRUG|Toripalimab|240 mg intravenously every three weeks
219403555|NCT01968720|DRUG|Placebo|
219403556|NCT04376333|BEHAVIORAL|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
219403557|NCT04376333|BEHAVIORAL|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
219403558|NCT04376333|OTHER|Standard Conservative Care|Standard conservative dental care for orofacial pain
219403559|NCT05359445|BIOLOGICAL|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
219403560|NCT05359445|BIOLOGICAL|Pembrolizumab (Phase Ia)|Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab
219403561|NCT05359445|BIOLOGICAL|IMA 401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
219403562|NCT03539458|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
219403563|NCT02214836|DEVICE|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
219403564|NCT06567470|DRUG|CIT-013 low dose|Subcutaneous injection
219403565|NCT06567470|DRUG|CIT-013 high dose|Subcutaneous injection
219403566|NCT06567470|DRUG|Placebo|Subcutaneous injection
219403567|NCT06567470|DRUG|CIT-013 medium dose|CIT-013 medium dose
219403568|NCT05763199|DIETARY_SUPPLEMENT|AHCC|AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.
219565933|NCT01301924|DRUG|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
219565934|NCT01640184|PROCEDURE|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
219565935|NCT01640184|DRUG|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
219403569|NCT05763199|DRUG|Chemotherapy|Chemotherapy will be administered per standard of care.
219403570|NCT05763199|OTHER|Placebo|Dextrin
219403571|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219403572|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
219403573|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219403574|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
219403575|NCT06236698|DIAGNOSTIC_TEST|24-hour urinary aldosterone measurement|Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
219403576|NCT01770418|RADIATION|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
219403577|NCT05009472|DEVICE|expander with deferential opening and petit face mask|bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
219403578|NCT05490628|OTHER|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
219403579|NCT05490628|OTHER|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
219403580|NCT03406338|PROCEDURE|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
219403581|NCT03406338|DRUG|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
219403582|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (active laser device)|The RianCorp LTU-904 laser therapy unit (active laser device) will be used for photobiomodulation therapy (PBMT).
219403583|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)|The RianCorp LTU-904 laser therapy (sham/inactive laser device) unit will be used for sham therapy.
219403584|NCT04632095|PROCEDURE|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
219403585|NCT04632095|PROCEDURE|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
219403586|NCT03221322|BEHAVIORAL|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
219403587|NCT05960188|BEHAVIORAL|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
219403588|NCT04527562|DRUG|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
219403589|NCT04527562|DRUG|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
219403590|NCT05566678|OTHER|Cigarette|Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
219403591|NCT05566678|OTHER|THS|Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
219403592|NCT05566678|OTHER|Smoking Abstinence|Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
219403593|NCT00520195|BEHAVIORAL|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
219403594|NCT04358094|OTHER|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
219403595|NCT04358094|OTHER|Standard script|Standard script during peripherical veinous catheter set up
219403596|NCT05504148|DRUG|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
219403597|NCT05504148|DRUG|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
219403598|NCT02528500|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
219403599|NCT02076256|BEHAVIORAL|The helping relationships intervention program|
219403600|NCT00039273|BIOLOGICAL|panitumumab|
219403601|NCT02196194|DRUG|Tiotropium|
219403602|NCT03521154|DRUG|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
219403603|NCT03521154|DRUG|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
219403604|NCT02305290|PROCEDURE|Endoscopic Mucosal Resection|
219189669|NCT05540353|DEVICE|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
219403605|NCT02143362|DRUG|Anesthesia induction,propofol, remifentanil ,cisatracurium|"1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
219755072|NCT07159217|DRUG|Camrelizumab|200 mg intravenously every three weeks
219755073|NCT07160426|BIOLOGICAL|Fresh Frozen Plasma (blood product)|Fresh Frozen Plasma
219755074|NCT07160426|DRUG|MVI and lactated ringers|placebo
219403606|NCT02143362|DRUG|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg)."
219403607|NCT02143362|PROCEDURE|Awaken test|"1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test."
219403608|NCT02857855|PROCEDURE|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
219565936|NCT01640184|PROCEDURE|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
219565937|NCT06357923|DIAGNOSTIC_TEST|dosage|Presence of mutation on the gene panel and Frequency of allele variation
219403609|NCT02857855|PROCEDURE|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
219403610|NCT02594475|PROCEDURE|Endoscopic retrograde cholangiopancreatography|"1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
219403611|NCT02172521|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
219403612|NCT05100316|OTHER|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
219565938|NCT06126861|DRUG|[14C]LP-168|single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
219403613|NCT05401240|BEHAVIORAL|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
219403614|NCT04491942|DRUG|Cisplatin|Given IV
219403615|NCT04491942|DRUG|Elimusertib|Given PO
219403616|NCT04491942|DRUG|Gemcitabine Hydrochloride|Given IV
219403617|NCT04523727|DRUG|ferric citrate|oral tablets
219403618|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
219403619|NCT05954676|OTHER|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
219403620|NCT06077071|RADIATION|ViewRay MRIdian Stereotactic Radiosurgery|Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).
219403621|NCT04451590|OTHER|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
219403622|NCT04451590|OTHER|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
219403623|NCT04461639|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
219565939|NCT00539708|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
219565940|NCT02252523|DRUG|Dexmedetomidine|
219565941|NCT00810888|DRUG|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
219565942|NCT00810888|DRUG|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
219565943|NCT01521078|BEHAVIORAL|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
219565944|NCT01305876|BEHAVIORAL|yoga intervention|yoga session 2 x week over 3-1/2 months
219403624|NCT06638151|DRUG|aspirin + clopidogrel|Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
219403625|NCT06638151|DRUG|Aspirin|Aspirin 81 mg once daily alone
219403626|NCT06642402|DIAGNOSTIC_TEST|Kidney biopsy|Patient refered to kidney biopsy independent of the presented study
219403627|NCT06642402|DIAGNOSTIC_TEST|Urinary extracellular vesicle testing|Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
219403628|NCT06642402|DIAGNOSTIC_TEST|Autoimmunity in plasma|Expected autoimmunity in plasma isolated from blood samples
219403629|NCT01661361|PROCEDURE|blood levels|
219403630|NCT04318743|DRUG|Glepaglutide|GLP-2
219403631|NCT06643130|DRUG|JW0104+C2402|For 8 weeks(PO (Per Oral), QD)
219403632|NCT06643130|DRUG|JW0104+C2403|For 8 weeks(PO, QD)
219403633|NCT06643130|DRUG|C2402|For 8 weeks(PO, QD)
219403634|NCT06644534|DRUG|TTI-0102|(cysteamine-pantetheine disulfide)
219403635|NCT06644534|DRUG|Placebo|Pearlitol® 100 SD (mannitol)
219403636|NCT06013605|BEHAVIORAL|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
219403637|NCT06013605|BEHAVIORAL|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
219403638|NCT06358859|OTHER|Food is Medicine|Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
219403639|NCT00972478|DRUG|Cyclophosphamide|Given IV
219403640|NCT00972478|DRUG|Doxorubicin Hydrochloride|Given IV
219403641|NCT00972478|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403642|NCT00972478|DRUG|Prednisone|Given IV
219403643|NCT00972478|BIOLOGICAL|Rituximab|Given IV
219403644|NCT00972478|DRUG|Vincristine Sulfate|Given IV
219403645|NCT00972478|DRUG|Vorinostat|Given PO
219403646|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
219403647|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
219403648|NCT06701071|DRUG|Clomiphene Citrate|Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.
219403649|NCT05641519|BEHAVIORAL|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
219403650|NCT05641519|BEHAVIORAL|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
219403651|NCT00525720|DRUG|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
219565945|NCT01435031|DEVICE|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
219565946|NCT00913796|DRUG|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
219403652|NCT00525720|BEHAVIORAL|Questionnaire|Questionnaires taking 30 total minutes.
219403653|NCT02561000|DRUG|PZ-128|
219403654|NCT02561000|DRUG|Placebo|
219403655|NCT05391061|DRUG|Abrocitinib|Tablets
219403656|NCT04510597|PROCEDURE|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
219403657|NCT04510597|DRUG|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
219403658|NCT06008626|DEVICE|Cryosa Procedure|Cryotherapy
219403659|NCT01522976|DRUG|Azacitidine|Given SC or IV
219403660|NCT01522976|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403661|NCT01522976|DRUG|Lenalidomide|Given PO
219403662|NCT01522976|DRUG|Vorinostat|Given PO
219403663|NCT06138639|GENETIC|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
219403664|NCT04889144|OTHER|Communication Intervention|Participate in PLAN intervention
219403665|NCT04889144|OTHER|Best Practice|Receive usual care
219403666|NCT04889144|OTHER|Questionnaire Administration|Ancillary studies
219403667|NCT00815412|BEHAVIORAL|Counseling in use of health care|
219403668|NCT00815412|BEHAVIORAL|Counseling in diet, exercise|
219403669|NCT00815412|OTHER|Control|
219403670|NCT03368742|GENETIC|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
219403671|NCT06336005|DRUG|NNC6022-0001|Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
219403672|NCT06336005|DRUG|Placebo (NNC6022-0001)|Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
219403673|NCT05756764|DRUG|Semaglutide|Medication for weight loss
219403674|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
219403675|NCT05756764|DRUG|Phentermine|Medication for weight loss
219403676|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
219403677|NCT05756764|DRUG|Topiramate|Medication for weight loss
219403678|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
219403679|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
219403680|NCT05756764|DRUG|Liraglutide|Medication for weight loss
219403681|NCT05107674|DRUG|NX-1607|Oral NX-1607
219403682|NCT05107674|DRUG|Paclitaxel|Paclitaxel IV
219403683|NCT05313633|OTHER|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes
219403684|NCT05313633|OTHER|Plyometric training|The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.
219403685|NCT05313633|OTHER|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
219403686|NCT04886622|DRUG|DT2216|DT2216 will be administered by intravenous infusion
219403687|NCT04075266|DRUG|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
219403688|NCT06582056|PROCEDURE|Investigational Procedure|It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
219403689|NCT06111235|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
219403690|NCT06111235|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
219403691|NCT05132569|DRUG|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
219403692|NCT05132569|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
219403693|NCT04102098|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
219403694|NCT04102098|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219403695|NCT06158958|DRUG|ABBV-303|Intravenous (IV) Infusion
219403696|NCT06158958|DRUG|Budigalimab|IV Infusion
219403697|NCT04042961|OTHER|Reactive balance training|A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance \~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).
219403698|NCT04042961|OTHER|Aerobic and strength training (AST)|"AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum."
219403699|NCT00138710|DRUG|Letrozole (Femara)|
219403700|NCT04969016|PROCEDURE|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
219565947|NCT00913796|DRUG|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
219565948|NCT04825717|OTHER|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
219565949|NCT03752554|PROCEDURE|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
219565950|NCT02588547|DRUG|Granisetron|IV granisetron 1 mg before spinal anethesia
219565951|NCT02588547|DRUG|Granisetron|IV granisetron 0.7 mg before spinal anethesia
219403701|NCT04969016|PROCEDURE|stapler|surgical wound closure with stapler
219403702|NCT04070313|DRUG|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
219403703|NCT04627415|BEHAVIORAL|Promoting Engagement with ADHD Pre-Kindergarteners|Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
219429140|NCT04261452|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
219403704|NCT05610748|PROCEDURE|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
219403705|NCT05610748|PROCEDURE|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
219403706|NCT05680870|DRUG|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
219403707|NCT04742907|DRUG|TU-100|Treatment with investigational product
219403708|NCT04742907|DRUG|Placebo|Treatment with placebo product
219403709|NCT04372953|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
219403710|NCT00511589|OTHER|chagas disease diagnostic|
219403711|NCT04258111|BIOLOGICAL|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
219403712|NCT04258111|BIOLOGICAL|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
219403713|NCT06226233|OTHER|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
219403714|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
219403715|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
219565952|NCT02588547|DRUG|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
219565953|NCT02396082|BEHAVIORAL|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
219565954|NCT02396082|OTHER|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
219565955|NCT04978844|BEHAVIORAL|IWOTCH|Arm 1
219565956|NCT04978844|BEHAVIORAL|Dyadic therapy|Arm 2
219565957|NCT04661826|DRUG|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
219565958|NCT04359563|BEHAVIORAL|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
219565959|NCT01494441|PROCEDURE|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
219007064|NCT02664454|OTHER|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
219189670|NCT00179855|PROCEDURE|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
219189671|NCT06527664|DEVICE|custom-made acetabular implant|custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
219189672|NCT03411096|PROCEDURE|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
219189673|NCT03411096|PROCEDURE|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
219189674|NCT05826496|OTHER|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
219189675|NCT03978078|OTHER|Biological collection|\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
219189676|NCT03760588|DRUG|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
219189677|NCT06184997|OTHER|INTAKE OF ISOTONIC DRINK|Intake of natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
219189678|NCT06184997|OTHER|PLACEBO|Intake of natural mineral water
219403716|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
219403717|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
219403718|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
219403719|NCT02273440|DRUG|BIIL 284 BS|
219189679|NCT04387305|DRUG|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
219403720|NCT02273440|DRUG|Theophylline|
219403721|NCT02273440|DRUG|Placebo|
219565960|NCT01494441|DEVICE|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
219565961|NCT01494441|DEVICE|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
219565962|NCT01878721|RADIATION|PET/CT|positron emission tomography/computed tomography
219565963|NCT03275584|DRUG|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
219565964|NCT01211951|DRUG|KCT-0809|
219565965|NCT01211951|DRUG|KCT-0809|
219565966|NCT01211951|DRUG|KCT-0809|
219565967|NCT01211951|DRUG|Placebo|
219565968|NCT05117047|PROCEDURE|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
219189680|NCT04103567|OTHER|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
219189681|NCT06418191|PROCEDURE|Acupressure|Acupressure is a technique that involves applying pressure to specific points on the body. It is based on the same principles as acupuncture but uses pressure from fingers, palms, elbows, or specialized devices instead of needles.
219189682|NCT05997953|OTHER|Edinburgh Postnatal Depression Scale|Edinburgh Postnatal Depression Scale used as screening tool for postpartum depression
219189683|NCT04834297|OTHER|Prapela SVS mattress|The intervention will be using the Prapela SVS crib mattress to complement non-pharmacological management of NOWS for the purposes of prevention of pharmacological treatment of NOWS
219403722|NCT04209296|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
219403723|NCT01168713|DRUG|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
219403724|NCT01168713|DRUG|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
219403725|NCT05218850|DRUG|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
219565969|NCT01995331|DRUG|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L."
219565970|NCT02543151|PROCEDURE|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
219565971|NCT00777855|DRUG|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
219565972|NCT00777855|DRUG|warfarin|warfarin 7.5mg po x 1
219755075|NCT07158658|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219565973|NCT05460962|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
219403726|NCT02280291|DRUG|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
219565974|NCT05460962|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
219565975|NCT01878513|DRUG|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
219565976|NCT01264198|BEHAVIORAL|Resistance Training|Supervised Resistance Training
219403727|NCT02280291|DRUG|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
219403728|NCT02280291|DRUG|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
219403729|NCT02280291|DRUG|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
219403730|NCT05665465|DRUG|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
219403731|NCT05665465|DRUG|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
219403732|NCT02537301|OTHER|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
219403733|NCT05364905|DRUG|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
219403734|NCT06357715|OTHER|"slumpposition"|"neurodynamic sliding mobilisation in the slump position"
219403735|NCT06357715|OTHER|"no slump position"|placebo
219403736|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
219403737|NCT06455462|DRUG|Tezepelumab|tezepelumab treatment initiated between 1st January 2023 and 31st March 2024
219403738|NCT06150573|DRUG|Test Dentifrice|Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
219565977|NCT02260258|DRUG|Rocuronium|Neuromuscular Blockade
219565978|NCT02260258|DRUG|Normal Saline|Normal Saline
219565979|NCT04004845|DRUG|Cytotec|Misoprostol 25mcg vaginal
219565980|NCT04004845|DRUG|oxytocin|Oxytocin 10 IU/ml Solution for infusion
219565981|NCT04004845|DEVICE|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
219565982|NCT03655119|BEHAVIORAL|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
219565983|NCT03655119|BEHAVIORAL|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
219565984|NCT03655119|BEHAVIORAL|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
219565985|NCT06043622|OTHER|Optical coherence tomography angiography|Optical coherence tomography angiography
219565986|NCT06043622|OTHER|ophthalmological exam|ophthalmological exam
219403739|NCT06150573|DRUG|Reference Dentifrice (Aquafresh Cavity Protection)|Dentifrice containing 1150 ppm fluoride as sodium fluoride.
219403740|NCT05264298|OTHER|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
219565987|NCT05925725|DRUG|• harpagozid • boswellin = LOXACON|Exercise therapy
219565988|NCT05312086|OTHER|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
219403741|NCT05264298|OTHER|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
219565989|NCT02563769|DRUG|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
219565990|NCT02563769|DRUG|Intravenous cocaine|20/40mg Cocaine will be administered by IV
219565991|NCT02563769|DRUG|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
219565992|NCT00556101|PROCEDURE|Whole body magnetic resonance angiography|
219565993|NCT03357354|BEHAVIORAL|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
219565994|NCT04178031|DEVICE|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
219007065|NCT01327898|BEHAVIORAL|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
219403742|NCT04771806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219403743|NCT04771806|OTHER|Neurocognitive Assessment|Undergo neurocognitive testing
219403744|NCT04771806|OTHER|Quality-of-Life Assessment|Ancillary studies
219403745|NCT04771806|OTHER|Questionnaire Administration|Ancillary studies
219403746|NCT04331353|BEHAVIORAL|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
219403747|NCT04331353|BEHAVIORAL|Comparator 2 (insecticidal bait)|Cockroach bait
219403748|NCT05876377|BIOLOGICAL|Pfizer-BioNTech COVID-19 mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
219403749|NCT00069095|DRUG|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
219403750|NCT00069095|DRUG|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
219403751|NCT00069095|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
219565995|NCT04470531|DRUG|oral co-trimoxazole|oral co-trimoxazole + standard therapy
219565996|NCT01411488|DEVICE|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
219565997|NCT00690482|DRUG|AZD1981|Oral tablet, twice daily
219565998|NCT00690482|DRUG|Placebo|Placebo Oral tablet, twice daily
219007066|NCT01327898|BEHAVIORAL|individual resilience counseling|one individual resilience counseling session
219007067|NCT03791476|DRUG|rhC1INH|C1 esterase inhibitor
219007068|NCT03791476|OTHER|Saline Solution|saline solution
219007069|NCT04326907|PROCEDURE|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
219189684|NCT02740634|DRUG|F-18 AV 1451|Tau binding agent
219189685|NCT02740634|DRUG|C-11 PiB|Amyloid binding agent
219403752|NCT00069095|DRUG|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
219403753|NCT00069095|DRUG|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
219403754|NCT00069095|DRUG|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
219403755|NCT00069095|DRUG|Fluorouracil 400 mg/m^2|
219403756|NCT00069095|DRUG|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
219403757|NCT00069095|DRUG|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
219403758|NCT04145297|DRUG|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
219403759|NCT04145297|DRUG|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
219403760|NCT06238817|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219565999|NCT02777684|OTHER|Qualitative study|
219566000|NCT04851275|BEHAVIORAL|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
219566001|NCT04851275|BEHAVIORAL|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
219566002|NCT04565496|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
219566003|NCT04590768|OTHER|Fermotein based meals|various meal products: bread, soup and an occasional burgers
219566004|NCT04590768|OTHER|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
219403761|NCT06238817|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
219403762|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
219403763|NCT03508622|BEHAVIORAL|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
219403764|NCT03508622|BEHAVIORAL|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
219566005|NCT05924334|OTHER|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
219566006|NCT05924334|OTHER|placebo|placebo
219566007|NCT00484991|DRUG|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
219566008|NCT01610063|OTHER|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
219566009|NCT06609434|PROCEDURE|Radiofrequency ablation|This study is the first to apply radiofrequency ablation to multiple recurrent intrahepatic lesions of colorectal cancer liver metastases.
219403765|NCT04404660|BIOLOGICAL|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
219189686|NCT06145646|DEVICE|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
219403766|NCT03727555|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene
219403767|NCT06503900|BIOLOGICAL|mRNA COVID-19 vaccine|ACIP-CDC recommended vaccine
219403768|NCT06503900|BIOLOGICAL|IIV4 (quadrivalent inactivated influenza vaccine)|ACIP recommended vaccine
219403769|NCT06154369|BEHAVIORAL|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
219403770|NCT05175261|DIAGNOSTIC_TEST|Prolocor pFCG test|Perform pFCG test on patients admitted with myocardial infarction to assess prognosis
219403771|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
219403772|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
219566010|NCT04405739|DRUG|EIDD-2801|Oral capsule of EIDD-2801
219566011|NCT04405739|DRUG|Placebo|Oral placebo capsule
219566012|NCT04252716|DEVICE|OVD|Intraocular administration
219566013|NCT01436643|DRUG|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
219566014|NCT01436643|DRUG|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
219760985|NCT03767881|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
219403773|NCT00210158|PROCEDURE|Air|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of air and oxygen.
219403774|NCT00210158|PROCEDURE|Protox|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of oxygen and nitrous oxide.
219403775|NCT06533865|DRUG|Romosozumab|Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
219403776|NCT06533865|DRUG|Placebo|Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
219403777|NCT06533865|DRUG|Zoledronic acid|One intravenous infusion
219403778|NCT03214562|DRUG|Cytarabine|Given IV
219403779|NCT03214562|BIOLOGICAL|Filgrastim|Given SC
219403780|NCT03214562|DRUG|Fludarabine|Given IV
219403781|NCT03214562|DRUG|Idarubicin|Given IV
219403782|NCT03214562|BIOLOGICAL|Pegfilgrastim|Given SC
219403783|NCT03214562|DRUG|Venetoclax|Given PO
219403784|NCT05029570|DEVICE|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
219403785|NCT06128551|DRUG|Assigned interventions|Drug: RMC-6291 and RMC-6236 Oral tablets
219403786|NCT04716933|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
219403787|NCT04716933|DRUG|Carboplatin|IV infusion Q3W
219403788|NCT04716933|DRUG|Cisplatin|IV infusion Q3W
219403789|NCT04716933|DRUG|Pemetrexed|IV infusion Q3W
219403790|NCT04716933|DRUG|Lenvatinib|Oral capsule once daily
219566015|NCT01436643|DRUG|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
219403791|NCT04716933|DRUG|Placebo matching lenvatinib|Oral capsule once daily
219403792|NCT05832931|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
219403793|NCT05832931|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
219403794|NCT05832931|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
219403795|NCT03036228|DRUG|Karonudib|Dose escalation of administration with Karonudib.
219566016|NCT01436643|DRUG|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
219566017|NCT03171064|BEHAVIORAL|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
219566018|NCT06175715|PROCEDURE|carotid endarterectomy|carotid endarterectomy under local or general anethesia
219566019|NCT01246713|DRUG|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
219566020|NCT01246713|DRUG|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
219566021|NCT02568007|DRUG|Cyproheptadine|
219566022|NCT03459352|OTHER|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
219566023|NCT02056652|DEVICE|Bioteque cup pessary|
219566024|NCT06873035|DRUG|infigratinib 0.128 mg/kg/day|Oral infigratinib 0.128 mg/kg/day
219566025|NCT06873035|DRUG|infigratinib 0.25 mg/kg/day|Oral infigratinib 0.25 mg/kg/day
219566026|NCT00039910|DRUG|(PN-152,243)/ PN-196,444|
219566027|NCT04975724|DRUG|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
219403796|NCT04233749|DRUG|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
219403797|NCT05774392|OTHER|Observational|Observational
219403798|NCT01750567|DRUG|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
219403799|NCT02823665|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
219403800|NCT02823665|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
219566028|NCT04975724|DRUG|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
219566029|NCT04975724|OTHER|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
219566030|NCT03234608|BEHAVIORAL|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
219566031|NCT02105701|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
219566032|NCT02105701|DRUG|Ribavirin|200 mg capsule
219007070|NCT01808287|DEVICE|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
219007071|NCT02186912|DEVICE|Nobel Active, Nobel Procera IBO|
219007072|NCT03472469|DRUG|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
219007073|NCT03472469|DRUG|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
219007074|NCT03472469|DRUG|Ketorolac|Ketorolac 30mg IV once
219403801|NCT06402994|OTHER|Electrophysiological experiment|Neural envelope tracking to conversational speech at different intensities
219403802|NCT06402994|BEHAVIORAL|Speech audiometry|Speech perception assessment at different intensities
219403803|NCT05172271|DEVICE|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
219403804|NCT05172271|DEVICE|Thymatron(R) System IV|The Thymatron(R) System IV (Somatics LLC, Venice, FL, USA) is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
219403805|NCT05172271|DEVICE|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
219403806|NCT05172271|OTHER|ECT device without stimulation|Anesthesia alone
219566033|NCT05741931|DEVICE|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
219566034|NCT02170831|DRUG|BIBR 1048 MS low|
219403807|NCT06235684|OTHER|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
219403808|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
219403809|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
219403810|NCT06823271|OTHER|Resting and exercise right heart catheterization|At rest and after different modes of exercise, exercise right heart catheterization will be performed.
219403811|NCT06823271|OTHER|Right ventricular mapping|At the beginning and at the end of the exercise modes right ventricular mapping will be performed.
219403812|NCT05781321|RADIATION|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
219403813|NCT05781321|PROCEDURE|Computed Tomography|Undergo CT simulation
219403814|NCT05781321|DRUG|Fluorodopa F 18|Given IV
219403815|NCT05781321|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219566035|NCT02170831|DRUG|BIBR 1048 MS medium 1|
219566036|NCT02170831|DRUG|BIBR 1048 MS medium 2|
219566037|NCT02170831|DRUG|BIBR 1048 MS high|
219566038|NCT02170831|DRUG|BIBR 1048 MS placebo|
219566039|NCT04984187|OTHER|high intensity laser plus exercise|high intensity laser plus exercise
219566040|NCT04984187|DEVICE|high intensity laser only|high intensity laser only
219566041|NCT04984187|OTHER|exercise|exercise only
219566042|NCT01348204|OTHER|quercetin|health food supplement
219566043|NCT00411333|DRUG|triamcinolone acetonide (Kenalog)|
219566044|NCT05705791|DEVICE|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
219566045|NCT05783856|COMBINATION_PRODUCT|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
219002194|NCT05122676|BEHAVIORAL|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
219002195|NCT06637501|DRUG|Sonrotoclax|Administered orally
219002196|NCT06637501|DRUG|Zanubrutinib|Administered orally
219002197|NCT00134251|DRUG|SLV308|
219007075|NCT03472469|DRUG|Celebrex|Celebrex 200mg PO every 12 hours
219007076|NCT03472469|DRUG|Naproxen|Naproxen 500mg PO every 12 hours
219007077|NCT03472469|DRUG|Tramadol|Tramadol 100mg PO every 6 hours
219007078|NCT03472469|DRUG|Pregabalin|Pregabalin 100mg PO every 8 hours
219403816|NCT05781321|PROCEDURE|Positron Emission Tomography|Undergo PET
219403817|NCT05781321|OTHER|Quality-of-Life Assessment|Ancillary studies
219403818|NCT05781321|OTHER|Questionnaire Administration|Complete questionnaires
219403819|NCT05781321|RADIATION|Radiation Therapy|Undergo standard course RT
219403820|NCT05781321|DRUG|Temozolomide|Given PO
219403821|NCT05781321|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219403822|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation off
219403823|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation on
219403824|NCT02003742|DRUG|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
219566046|NCT05783856|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
219566047|NCT01029509|DRUG|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
219566048|NCT05697757|OTHER|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
219566049|NCT05697757|OTHER|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
219566050|NCT05734209|BEHAVIORAL|Virtual food|Virtual food eaten using immersive virtual reality equipment
219566051|NCT05734209|BEHAVIORAL|Real food|Real food eaten using regular utensils
219403825|NCT02003742|DRUG|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
219403826|NCT06448260|OTHER|Questionnary|Data from theses patients will be collected in our personnal data base with ask of consent according to the law Then each patient alive will have questionnary to answer by phone or during a visit.
219566052|NCT01921231|DRUG|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
219566053|NCT01921231|DRUG|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
219403827|NCT03909763|DRUG|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
219403828|NCT01244542|OTHER|unpleasant stimuli|
219403829|NCT04717843|OTHER|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
219403830|NCT04717843|OTHER|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
219403831|NCT04717843|OTHER|Holter ECG|48 hours ECG recording
219403832|NCT04717843|OTHER|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
219566054|NCT01177163|DRUG|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
219566055|NCT01177163|DRUG|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
219566056|NCT01177163|DRUG|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
219566057|NCT03255863|OTHER|Questionnaire|Patient Self reported questionnaire filled in.
219403833|NCT04717843|BIOLOGICAL|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
219403834|NCT04717843|OTHER|Standard MRI|Acquisitions of MR imagining
219403835|NCT02660424|DRUG|VX-150|
219403836|NCT02660424|DRUG|Placebo|
219403837|NCT05701969|DIETARY_SUPPLEMENT|Melatonin|Melatonin
219403838|NCT05701969|OTHER|Placebo|Placebo control
219403839|NCT00138931|PROCEDURE|Blood draw (genetic testing)|Blood draw (genetic testing)
219403840|NCT00041223|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|
219403841|NCT03521167|DRUG|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
219403842|NCT03521167|DRUG|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
219403843|NCT03521167|DRUG|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
219403844|NCT03521167|DRUG|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness
219403845|NCT03521167|DRUG|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
219403846|NCT03521167|DRUG|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
219403847|NCT03521167|DRUG|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
219403848|NCT06963554|BEHAVIORAL|Project Support|The Project Support intervention involves up to four 60-minute individual counseling sessions focused on teaching caregivers how to listen to and comfort their child. Participants will receive didactic instruction and feedback on their use of the skills in role-plays with a treatment provider and with their child. In the role-plays the provider first demonstrates how to use the skill in a brief example of typical situations in which the skill could be used. In these examples the caregiver takes on the role of their child and the provider takes on the role of the caregiver. Subsequently the caregiver and provider switch roles so the caregiver has an opportunity to practice executing the skill. The provider helps the caregiver process their experience of each role-play and provides real-time, targeted feedback to help the caregiver develop their ability to use the skills.
219566058|NCT03569488|DIAGNOSTIC_TEST|FT-LARS questionnaire|FT-LARS questionnaire
219566059|NCT00739973|DRUG|Placebo|
219566060|NCT00739973|DRUG|Aliskiren 150 mg tablet|
219566061|NCT00739973|DRUG|Aliskiren 300 mg tablet|
219566062|NCT00739973|DRUG|Amlodipine 5 mg capsule|
219566063|NCT00739973|DRUG|Amlodipine 10 mg capsule|
219566064|NCT00739973|DRUG|Aliskiren/amlodipine 150/5 mg tablet|
219566065|NCT00739973|DRUG|Aliskiren/amlodipine 150/10 mg tablet|
219566066|NCT00739973|DRUG|Aliskiren/amlodipine 300/5 mg tablet|
219566067|NCT00739973|DRUG|Aliskiren/amlodipine 300/10 mg tablet|
219566068|NCT03476031|DIAGNOSTIC_TEST|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
219566069|NCT01010789|DRUG|Armodafinil|flexible dose 150-250mg/day
219566070|NCT01010789|DRUG|Armodafinil|150-250mg/day; flexible dose
219566071|NCT01010789|DRUG|Matching placebo|Placebo comparator
219566072|NCT03078478|DRUG|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
219566073|NCT03078478|DRUG|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
219566074|NCT06397222|DRUG|Sin-Bev-SIRT|Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
219403849|NCT06963554|BEHAVIORAL|Case Management Services|"Case management services, or treatment as usual, may involve referrals for financial resources or donated goods, as well as assistance with court, law enforcement, or information about orders of protection. The nature of these services depends on the needs identified by the family and case manager. There is currently no standard treatment offered to families on the waitlist. This condition will receive individually tailored services, as needed."
219403850|NCT00145548|DEVICE|Intra Bronchial Valve|
219403851|NCT03196505|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
219403852|NCT03196505|DRUG|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
219403853|NCT01911624|DRUG|direct thrombin inhibition|
219403854|NCT01911624|DRUG|enoxaparin|
219403855|NCT02032537|DRUG|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
219403856|NCT02032537|DRUG|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
219002198|NCT01380275|DRUG|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
219403857|NCT01005719|DRUG|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
219403858|NCT01005719|DRUG|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
219403859|NCT05593497|DRUG|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
219403860|NCT05593497|DRUG|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
219403861|NCT01465698|BEHAVIORAL|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
219566075|NCT03253094|DRUG|Fluconazole|Oral Antifungal comparator
219566076|NCT03253094|DRUG|SCY-078|Investigational Antifungal
219007079|NCT03472469|DRUG|Gabapentin|Gabapentin 300mg PO every 8 hours
219007080|NCT03472469|DRUG|Lidocaine|Lidocaine patch every 12 hours
219403862|NCT01465698|BEHAVIORAL|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
219403863|NCT01465698|BEHAVIORAL|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
219403864|NCT01465698|OTHER|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
219403865|NCT03879317|DEVICE|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
219403866|NCT03179592|DRUG|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
219403867|NCT02080689|OTHER|Decipher|
219403868|NCT06018922|BEHAVIORAL|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
219760986|NCT02789982|DRUG|β-adrenergic blocker propranolol|
219760987|NCT02789982|BEHAVIORAL|Treatment as usual|
219566077|NCT00559026|BIOLOGICAL|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
219566078|NCT00559026|OTHER|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
219566079|NCT02339090|DRUG|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
219566080|NCT02339090|DRUG|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
219566081|NCT01168687|DRUG|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
219566082|NCT01168687|DRUG|Placebo|
219566083|NCT02123732|DIETARY_SUPPLEMENT|DbXell|
219566084|NCT02123732|DIETARY_SUPPLEMENT|Placebo|
219566085|NCT02593344|DEVICE|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
219403869|NCT01570712|OTHER|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
219403870|NCT01570712|OTHER|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices"
219403871|NCT05747690|DEVICE|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
219403872|NCT06623461|DRUG|Standard of Care Immune Checkpoint Blockade|Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
219403873|NCT06623461|DRUG|LND101|Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
219403874|NCT04735978|BIOLOGICAL|RP3|Genetically modified HSV-1
219403875|NCT04735978|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
219403876|NCT06435442|DRUG|Epaminurad, Naproxen|Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen
219403877|NCT06435442|DRUG|Epaminurad|Epaminurad
219403878|NCT06435442|DRUG|Epaminurad placebo|Epaminurad placebo
219403879|NCT06449677|DEVICE|iLet Bionic Pancreas System (BP)|The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.
219403880|NCT06449677|DEVICE|Usual Care (UC)|Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
219566086|NCT00433277|DRUG|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
219566087|NCT03220126|BIOLOGICAL|LY3074828|Administered IV
219566088|NCT03220126|BIOLOGICAL|LY900021|Administered SC
219566089|NCT02285205|DRUG|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
219566090|NCT02571803|BEHAVIORAL|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
219566091|NCT02571803|OTHER|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
219566092|NCT05057793|DEVICE|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
219403881|NCT03768570|DRUG|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
219566093|NCT00864617|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
219566094|NCT00864617|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
219403882|NCT06052072|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
219403883|NCT00969111|RADIATION|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
219403884|NCT00969111|RADIATION|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
219403885|NCT00969111|RADIATION|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
219403886|NCT00969111|RADIATION|Proton to 66.6 CGE|Post-Op Non High Risk
219403887|NCT00963521|BIOLOGICAL|therapeutic autologous dendritic cells|
219403888|NCT02047513|DRUG|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
219403889|NCT02047513|DRUG|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
219403890|NCT05544422|OTHER|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
219403891|NCT05955586|DRUG|SPR720|SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
219403892|NCT05437341|BIOLOGICAL|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
219403893|NCT05279612|RADIATION|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
219403894|NCT01940016|BEHAVIORAL|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
219403895|NCT01940016|BEHAVIORAL|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
219403896|NCT00496522|PROCEDURE|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
219403897|NCT04430738|DRUG|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
219403898|NCT04430738|DRUG|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
219403899|NCT04430738|DRUG|oxaliplatin|85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
219403900|NCT04430738|DRUG|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
219403901|NCT04430738|DRUG|fluorouracil|400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
219403902|NCT04430738|DRUG|capecitabine|1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
219403903|NCT04430738|DRUG|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
219403904|NCT02834312|DRUG|Estetrol|All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
219403905|NCT02834312|DRUG|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
219403906|NCT05590793|DRUG|Triptorelin pamoate (embonate) salt|Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
219403907|NCT05653739|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
219403908|NCT02978118|DEVICE|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
219403909|NCT04653545|DIAGNOSTIC_TEST|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
219566095|NCT06889935|OTHER|Exercise diary|The respiratory exercise diary was prepared by reviewing the literature in order to record the time, number and frequency of respiratory exercises performed by patients with the use of a spirometer. On the first page of the diary consisting of two pages; the patient's name and surname, date of surgery, date of birth, how and how often to use the spirometer, and a pictorial information note to remind the position to be taken were included, while on the second page; the chart in which the patients would write the number of exercises they performed with the spirometer during the first three postoperative days opposite the relevant hour was included.
219566096|NCT03512002|DEVICE|HIRREM|Technology
219007081|NCT03472469|DRUG|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
219403910|NCT06526169|OTHER|Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection|Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.
219403914|NCT06565416|BEHAVIORAL|Implementation Strategies|Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
219403915|NCT06519929|PROCEDURE|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.
219403916|NCT06519929|DRUG|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
219403917|NCT06969001|DRUG|SCAI-005 0.04% or placebo|axitinib 0.014mg or placebo
219403918|NCT06969001|DRUG|SCAI-005 0.08% or placebo|axitinib 0.028mg or placebo
219403919|NCT06969001|DRUG|SCAI-005 0.08% or placebo 2drops|axitinib 0.056mg or placebo
219566097|NCT03512002|OTHER|Continued Current Care|Continue their current clinical care.
219566098|NCT05338372|BEHAVIORAL|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
219566099|NCT05338372|BEHAVIORAL|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
219566100|NCT00986024|BEHAVIORAL|aerobic exercise|carried out 3 times per week for 12 weeks
219566101|NCT00986024|BEHAVIORAL|strength training|carried out 3 times per week for 12 weeks
219002199|NCT01380275|DRUG|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
219403920|NCT04380987|BIOLOGICAL|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
219403921|NCT00633438|OTHER|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
219403922|NCT00633438|DRUG|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
219403923|NCT04460378|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
219403924|NCT05526794|PROCEDURE|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
219403925|NCT00946946|DRUG|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
219403926|NCT00946946|DRUG|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
219403927|NCT00946946|DRUG|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
219403928|NCT00946946|DRUG|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
219403929|NCT03825276|DIETARY_SUPPLEMENT|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
219403930|NCT06576011|BEHAVIORAL|Gamified Social Norms Marketing Campaign|This intervention is a gamified social norms marketing campaign (SNMC) primarily disseminated via advertisements on Instagram. These advertisements will invite students to participate in a game about student life at their university, during which misperceived alcohol norms will be corrected. The gamified SNMC spans the first full six weeks of students' first fall semester in college and includes three rounds of play. Round one occurs during the first two weeks, round two during the third and fourth weeks, and round three during the fifth and sixth weeks. In the game, participants are asked to identify whether normative facts related to a variety of topics are true or false. Correct feedback is then provided, intended to reinforce accurate norms related to alcohol use, which are embedded alongside other facts about college life.
219403931|NCT06576011|BEHAVIORAL|Social Norms Marketing Campaign|This intervention is a social norms marketing campaign that is primarily delivered via advertisements on Instagram. These advertisements will contain normative facts related to student life at their university, during which misperceived alcohol norms will be corrected.
219403932|NCT06442761|DRUG|Motixafortide|Given Subcutaneously (under the skin).
219403933|NCT05478343|BIOLOGICAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
219403934|NCT05187013|BEHAVIORAL|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
219403935|NCT03838367|DRUG|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219403936|NCT03838367|DRUG|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219755076|NCT07159906|DRUG|Homoharringtonine|A cephalotaxine alkaloid and protein synthesis inhibitor that downregulates Myeloid Cell Leukemia 1 (MCL-1), administered intravenously in 21-day cycles. Dose escalation in Phase Ib will determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D).
219002200|NCT03597776|DRUG|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
219002201|NCT03597776|DRUG|Saline|Bolus of saline will be given over 5 minutes before skin incision
219002202|NCT03143413|OTHER|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
219002203|NCT05999032|BEHAVIORAL|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
219007082|NCT03472469|DRUG|Regional anesthesia|Regional anesthesia
219007083|NCT00192829|PROCEDURE|Blood sample withdrawal|
219007084|NCT02875860|DEVICE|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
219403937|NCT03838367|DRUG|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219403938|NCT03838367|DRUG|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
219403939|NCT03838367|DRUG|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
219566102|NCT00145613|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
219566103|NCT00145613|DEVICE|Miltenyi Biotec CliniMACS|stem cell selection device
219566104|NCT00145613|DRUG|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
219566105|NCT01363466|PROCEDURE|hysterectomy|
219566106|NCT02280226|DEVICE|magnetic resonance imaging (MRI)|
219566107|NCT04979845|OTHER|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
219566108|NCT04979845|OTHER|Video exercise|Patients will receive video instructions for home based exercises
219403940|NCT03277729|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
219403941|NCT03277729|DRUG|Cyclophosphamide|Given IV
219755077|NCT07159906|DRUG|BCL-2 inhibitor|An oral selective BCL2 inhibitor administered once daily D1-7. Combined with homoharringtonine, rituximab, and prednisone in 21-day cycles.
219755078|NCT07159906|DRUG|CD20 Antibody|An anti-CD20 monoclonal antibody administered intravenously, used in combination with chemotherapy or targeted regimens for B-cell malignancies.
219755079|NCT07159906|DRUG|Glucocorticoid (GC)|glucocorticoid , given as part of the combination regimen to enhance anti-lymphoma effect.
219755080|NCT07158580|DEVICE|Gait Tracker|Opti Gait is a wearable gait tracker
219755081|NCT07161492|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Individualized dual-target rTMS delivered using MRI-guided neuronavigation (Dolphin Robotics). Stimulation parameters:~* Targets: Left IPL and right dPFC connectivity hotspots~* Protocol: 100 pulse-pairs/session at 0.2Hz~* Intensities: Conditioning stimulus 90% RMT, test stimulus 120% RMT~* Duration: 8.3 min/session, 5 sessions/week × 4 weeks"
219403942|NCT03277729|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403943|NCT03277729|PROCEDURE|Leukapheresis|Undergo leukapheresis
219403944|NCT03277729|DRUG|Fludarabine Phosphate|Given IV
219403945|NCT05703802|DIAGNOSTIC_TEST|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
219403946|NCT03015610|DRUG|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
219403947|NCT03015610|DRUG|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
219403948|NCT05174039|DRUG|Miglustat 100 milligrams (mg) Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
219403949|NCT04687774|DEVICE|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
219403950|NCT06973434|DEVICE|intubation|intubation
219403951|NCT06969261|BEHAVIORAL|Penny COPILOT|The Penny COPILOT chatbot is an interactive short messaging system (SMS) program that provides educational and supportive content for postpartum individuals. The chatbot has been adapted to include information relevant to opioid use disorder recovery in order to decrease the risk of returning to use among people who use drugs. Messages are sent at specified intervals relevant to the postpartum course and the chatbot allows for two way messaging with an interactive lens.
219403952|NCT06665425|DRUG|Epaminurad 9 mg|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
219403953|NCT06665425|DRUG|C2406|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
219403954|NCT05471843|DRUG|BGB-11417|Administered orally
219403955|NCT02941783|DRUG|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
219403956|NCT05638711|DEVICE|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
219403957|NCT06227754|PROCEDURE|Angiography-guided PCI group|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
219403958|NCT06227754|PROCEDURE|Optical coherence tomography-guided PCI group|"\[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)"
219403959|NCT04408521|OTHER|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
219403960|NCT04408521|OTHER|CONTROL|EEG recording during passive TV viewing
219403961|NCT02059421|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"\- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education"
219403962|NCT02059421|OTHER|Johrei therapy|"* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
219429141|NCT04261452|DIAGNOSTIC_TEST|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
219403963|NCT06494059|OTHER|Intermittent theta burst stimulation (iTBS)|iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
219403964|NCT06494059|OTHER|Functional electrical stimulation (FES)|FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
219403965|NCT06494059|OTHER|Transcutaneous spinal cord stimulation (TSCS)|TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
219403966|NCT06494059|OTHER|Sham Intermittent theta burst stimulation (iTBS)|Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
219002204|NCT05999032|BEHAVIORAL|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
219007085|NCT02875860|DEVICE|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
219007086|NCT02875860|OTHER|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
219403967|NCT00938327|BIOLOGICAL|Rotarix™|Two doses of oral vaccine.
219403968|NCT02902705|OTHER|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
219403969|NCT05903833|DRUG|Pembrolizumab|400 mg Q6W
219403970|NCT05903833|DRUG|Lenvatinib|20 mg QD
219403971|NCT01220648|DRUG|Nilotinib, interferon-alfa|
219403972|NCT02552355|DRUG|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
219403973|NCT02552355|DRUG|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
219403974|NCT02552355|DIETARY_SUPPLEMENT|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
219403975|NCT02552355|DIETARY_SUPPLEMENT|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
219403976|NCT06659627|BEHAVIORAL|Aerobic exercise therapy|Participants will follow an aerobic exercise therapy program for 16 weeks.
219403977|NCT06659627|BEHAVIORAL|Cognitive behavioural therapy|Participants will follow an cognitive behavioural therapy program for 12-16 weeks.
219403978|NCT06659627|OTHER|Usual care|Participants do not follow a program, but continue with care as usual
219403979|NCT04293874|BEHAVIORAL|Personalized Meal Plan|Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
219429142|NCT04261452|DIAGNOSTIC_TEST|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
219429143|NCT04261452|DIAGNOSTIC_TEST|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
219429144|NCT04261452|DIAGNOSTIC_TEST|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
219429145|NCT02272283|DEVICE|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
219189687|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
219189688|NCT05529901|DEVICE|GORE® CARDIOFORM Septal Occluder|Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study
219189689|NCT06006013|BIOLOGICAL|Pembrolizumab|Given IV
219189690|NCT06006013|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219189691|NCT06006013|DRUG|Cabozantinib S-malate|Given PO
219189692|NCT06006013|PROCEDURE|Computed Tomography|Undergo CT
219189693|NCT06006013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219189694|NCT04134208|PROCEDURE|Computed Tomography|Undergo PET-CT scan
219189695|NCT04134208|DRUG|Fluciclovine F18|Given IV
219189696|NCT04134208|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
219189697|NCT03476343|DEVICE|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
219189698|NCT04160832|GENETIC|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
219566109|NCT03518216|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
219566110|NCT06880796|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy provided in a group format.
219189699|NCT06642090|BEHAVIORAL|Educational intervention for patients undergoing hemodialysis in Morocco|This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
219189700|NCT06099743|BEHAVIORAL|Psychosocial intervention|Intervention manual and six one-on-one coaching sessions.
219189701|NCT06099743|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.
219189702|NCT04726371|BEHAVIORAL|Generic Best Practices|GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy.
219189703|NCT04726371|BEHAVIORAL|Tailored Best Practices|TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization.
219189704|NCT02901977|DRUG|Ramipril|Antihypertensive therapy
219566111|NCT06880796|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usually provided.
219189705|NCT02901977|DRUG|Doxazosin|Antihypertensive therapy
219189706|NCT06495593|DRUG|Ocrelizumab|Standard ocrelizumab dosing
219189707|NCT03088878|DRUG|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
219189708|NCT03088878|DRUG|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
219566112|NCT01449045|DRUG|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
219403980|NCT04293874|BEHAVIORAL|Dietary Omega-3LC intervention|Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
219403981|NCT00004640|DRUG|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
219403982|NCT02492750|BIOLOGICAL|Anakinra|Given SC
219403983|NCT02492750|DRUG|Dexamethasone|Given PO
219403984|NCT02492750|OTHER|Laboratory Biomarker Analysis|Correlative studies
219403985|NCT02492750|DRUG|Lenalidomide|Given PO
219403986|NCT02492750|OTHER|Placebo|Given SC
219189709|NCT03088878|DRUG|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
219189710|NCT03088878|DRUG|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
219189711|NCT03088878|DRUG|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
219189712|NCT03088878|DRUG|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
219189713|NCT06450561|OTHER|cardiovascular event|In this single group observational trial the exposure of interest is a cardiovascular event.
219189714|NCT03831256|DIAGNOSTIC_TEST|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
219189715|NCT03831256|DIAGNOSTIC_TEST|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
219189716|NCT03831256|DIAGNOSTIC_TEST|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
219403987|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
219403988|NCT06236074|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
219403989|NCT05110898|DRUG|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
219403990|NCT05110898|DRUG|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
219189717|NCT03831256|DIAGNOSTIC_TEST|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
219189718|NCT05061745|DEVICE|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
219189719|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
219189720|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
219403991|NCT02200458|DEVICE|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
219403992|NCT03699982|OTHER|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
219403993|NCT00878072|DRUG|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
219403994|NCT01280123|DRUG|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
219403995|NCT01280123|DRUG|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
219403996|NCT00982306|BEHAVIORAL|Brief intervention|20 minute one to one counseling session
219403997|NCT05791799|DRUG|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
219403998|NCT05528042|OTHER|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
219403999|NCT05379361|BEHAVIORAL|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
219404000|NCT05379361|BEHAVIORAL|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
219404001|NCT04509492|DIAGNOSTIC_TEST|Endoscopic ultrasound ( EUS )|"\- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
219404002|NCT00122746|RADIATION|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
219404003|NCT00122746|RADIATION|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
219404004|NCT02588248|DRUG|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
219404005|NCT02588248|OTHER|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
219404006|NCT03742960|BEHAVIORAL|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
219404007|NCT04120792|BEHAVIORAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
219404008|NCT04120792|BEHAVIORAL|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
219404009|NCT04120792|BEHAVIORAL|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
219404010|NCT04120792|BEHAVIORAL|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
219404011|NCT02015598|DRUG|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
219404012|NCT02015598|DEVICE|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
219404013|NCT02493309|OTHER|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
219404014|NCT02493309|OTHER|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
219404015|NCT00571363|PROCEDURE|standard surgery|excision with 4 mm margins
219566113|NCT01449045|DRUG|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
219566114|NCT03672305|BIOLOGICAL|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
219566115|NCT00096122|DRUG|cytarabine|Given IV
219566116|NCT00096122|DRUG|idarubicin|Given IV
219566117|NCT00096122|DRUG|tipifarnib|Given orally
219566118|NCT05187325|OTHER|no intervention|there is no intervention
219404016|NCT00571363|PROCEDURE|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
219404017|NCT06175507|DRUG|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
219404018|NCT06175507|DRUG|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
219566119|NCT00749411|DRUG|Placebo|matching placebo
219566120|NCT00749411|DRUG|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
219566121|NCT06840093|BEHAVIORAL|Limited Restrictions|Patients will receive a handout with the following instructions: After discharge from the hospital, resume your normal activities as soon as you feel comfortable. There is no weight limit on lifting. There are no specific activities you should avoid (other than pelvic rest as described below). We recommend pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming) for 2 weeks.
219404019|NCT01596075|DRUG|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
219404020|NCT04473443|OTHER|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
219404021|NCT03643432|BEHAVIORAL|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
219404022|NCT03643432|BEHAVIORAL|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
219404023|NCT04415489|DEVICE|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
219404024|NCT04000672|PROCEDURE|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
219404025|NCT04000672|PROCEDURE|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
219404026|NCT06555367|DEVICE|scleral lenses|Wear scleral lenses
219404027|NCT02930655|DRUG|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
219404028|NCT02930655|DRUG|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
219404029|NCT00668434|DRUG|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
219404030|NCT00668434|DRUG|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
219404031|NCT04484519|OTHER|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
219404032|NCT06671951|OTHER|Focal Vibration|Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.
219404033|NCT06671951|OTHER|Sham focal vibration|Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
219404034|NCT02711761|DEVICE|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
219566122|NCT06840093|BEHAVIORAL|Standard Restrictions|Patient will receive a handout with the following instructions: After discharge from the hospital, avoid doing any strenuous activity (any activity that requires so much exertion that you cannot have a conversation comfortably while doing it). Do not lift anything over 15 pounds for 6 weeks after surgery. For 6 weeks, we recommend complete pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming).
219566123|NCT06874842|BIOLOGICAL|Low dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01C.
219566124|NCT06874842|BIOLOGICAL|Low dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01B.
219007087|NCT02550548|DRUG|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
219404035|NCT01193348|DRUG|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
219566125|NCT06874842|BIOLOGICAL|High dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01C.
219566126|NCT06874842|BIOLOGICAL|High dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01B.
219404036|NCT04475185|DEVICE|MakAir|MakAir artificial ventilator
219404037|NCT03063775|DEVICE|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
219404038|NCT03063775|OTHER|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
219404039|NCT03063775|OTHER|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
219404040|NCT03063775|DEVICE|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
219404041|NCT03008746|OTHER|water used for oral wash|
219404042|NCT03008746|OTHER|sputum|
219404043|NCT03008746|OTHER|oral wash|
219404044|NCT03414840|DRUG|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
219404045|NCT03638947|DEVICE|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
219404046|NCT02756390|BEHAVIORAL|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
219404047|NCT02756390|BEHAVIORAL|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
219404048|NCT02756390|BEHAVIORAL|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
219404049|NCT02929563|DRUG|Pantoprazole|
219404050|NCT02929563|DRUG|Placebo (for pantoprazole)|
219404051|NCT05264090|OTHER|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
219404052|NCT05264090|OTHER|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
219007088|NCT02550548|DRUG|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
219007089|NCT02550548|DRUG|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
219566127|NCT06874842|BIOLOGICAL|Placebo|0.5 mL per dose, without antigen and adjuvant.
219566128|NCT06874842|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
219566129|NCT06778265|BIOLOGICAL|UX-DA001|"UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery.~Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001."
219566130|NCT05049668|DRUG|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
219007090|NCT00162656|DRUG|half cyclophosphamide|
219007091|NCT00162656|DRUG|without COPADM3|
219007092|NCT00162656|DRUG|mini CYVE, without 3 maintenance courses|
219404053|NCT05264090|OTHER|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
219566131|NCT03183141|BIOLOGICAL|SER-109|SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
219755082|NCT07161492|BEHAVIORAL|Computerized Cognitive Remediation Therapy|Structured computer-based training targeting cognitive flexibility, consisting of 4-6 exercises per session. Each exercise includes 8-24 progressively challenging tasks. Administered for 45-60 minutes per session, 5 sessions/week over 4 weeks. Delivered via specialized software on desktop computers.
219755083|NCT07161492|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Inactive stimulation using identical equipment with:~* Coil tilted at 90° to scalp~* Magnetic shielding insert~* Matched acoustic artifact All other parameters identical to active rTMS arm."
219755084|NCT07161492|DRUG|Selective Serotonin Reuptake Inhibitors or Serotonin-Norepinephrine Reuptake Inhibitors|"Background antidepressant therapy maintained at stable doses throughout the study. Minimum dose requirements:~* SSRIs: Paroxetine ≥20mg/day, Sertraline ≥50mg/day~* SNRIs: Venlafaxine ≥75mg/day, Duloxetine ≥60mg/day Dosage adjustments prohibited during trial participation."
219755085|NCT07160751|OTHER|Self-questionnaire|FACT-Cog, HADS, FA12, EPICES, socio-professional and socio-demographic questionnaire
219404054|NCT06556056|OTHER|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical"
219404055|NCT06556056|OTHER|Minoxidil hair serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
219404056|NCT06556056|OTHER|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
219404057|NCT06556056|OTHER|Liposomal Form of SesZenBio|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
219429146|NCT00118911|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
219755086|NCT07160751|OTHER|Cognitive tests|Hopkins Verbal Learning Test (HVLT). Trail Making Test (TMT). Verbal fluency test. Digit memory WAIS-IV.
219755087|NCT07160751|OTHER|Assessment of the impact of social vulnerability on patient complaints|EPICES at month 12
219429147|NCT00118911|OTHER|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
219429148|NCT04699071|DRUG|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
219429149|NCT05656287|OTHER|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
219007093|NCT00162656|DRUG|LMB B|
219429150|NCT05656287|OTHER|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
219429151|NCT05656287|OTHER|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
219429152|NCT05479305|DEVICE|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
219429153|NCT05128604|DEVICE|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
219429154|NCT04220671|BIOLOGICAL|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
219429155|NCT04220671|OTHER|Saline|0.9% NaCl
219429156|NCT04904588|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
219429157|NCT04904588|DRUG|Busulfan|Given IV pre-transplant as part of conditioning regimen
219429158|NCT04904588|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
219429159|NCT04904588|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
219429160|NCT04904588|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
219429161|NCT04904588|DRUG|Melphalan|Given IV pre-transplant as part of conditioning regimen
219429162|NCT04904588|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
219429163|NCT04904588|PROCEDURE|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
219429164|NCT04904588|DRUG|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
219429165|NCT04904588|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
219404058|NCT06556056|OTHER|Minoxidil Hair Serum (5%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
219404059|NCT06556056|OTHER|SesZen-Bio Serum + SesZen-Bio 350 mg extract|"Mode of Usage of serum: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical Mode of Usage of Capsule: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Frequency: One time daily after meal Rout of administration: Oral"
219404060|NCT05319535|OTHER|Implementation Strategy: Foundational REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Caregivers FIRST for context and provides tools for ongoing Caregivers FIRST evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate Caregivers FIRST into routine practice.
219404061|NCT05319535|OTHER|Implementation Strategy: Enhanced REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators posit that higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
219404062|NCT06998550|OTHER|Patient Satisfaction Questionnaire|An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.
219404063|NCT06998550|OTHER|Institutional Survey on PR Program Structure and Team Composition|A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission
219404064|NCT00042081|DRUG|CGT003 (E2F Duplex Decoy)|
219404065|NCT04695847|DRUG|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
219404066|NCT04695847|DRUG|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
219404067|NCT03321240|PROCEDURE|visual and quantitative SEEG signal analysis|signal SEEG analysis
219404068|NCT03321240|PROCEDURE|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
219404069|NCT03421847|DIAGNOSTIC_TEST|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
219404070|NCT03328130|BIOLOGICAL|AAV2/5-hPDE6B|Subretinal administration in one eye
219404071|NCT01201538|DRUG|Nilotinib|
219404072|NCT05152446|OTHER|Infusion management scheme|"* To set up a pediatric intravenous infusion team;~* To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~* To observe the continued daily infusion practice in 6 months."
219404073|NCT06863649|OTHER|Gamified NON-IMMERSIVE VIRTUAL REALITY EXERCISES|The game phase lasts for 2 minutes. These targets are challenging for the participant.
219404074|NCT06863649|OTHER|video-based exercises|The participant will exercise by replicating the exercises demonstrated in a 2-minute video, recorded with the same movement patterns that they will find in the gamified intervention.
219566132|NCT03111667|BEHAVIORAL|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
219566133|NCT03111667|OTHER|Treatment as Usual|Referral to community resources
219566134|NCT03111667|BEHAVIORAL|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
219404075|NCT07003100|OTHER|Non-Interventional Study|Non-interventional study
219404076|NCT03760432|PROCEDURE|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
219404077|NCT06671249|PROCEDURE|Laparoscopic breast-conserving surgery|Use laparoscopic surgery to treat breast cancer patients who want and have the opportunity to preserve their breast
219404078|NCT06671249|PROCEDURE|Traditional open breast-conserving surgery|Treat breast cancer patients who want and have the opportunity to preserve their breast with traditional open breast-conserving surgery.
219404079|NCT06671652|BEHAVIORAL|Duyugoda igalenisodi (Starting again the right way)|Participants in the intervention arm will receive training and resources to build community resources and programming
219404080|NCT06672692|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA RSV viral RNA, and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
219404081|NCT07007195|DEVICE|Ad Libitum Use followed by Instructed Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will then be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™. When urges above 0 are reported, the app will instruct participants to use the Inspire device. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Instructed Use condition. Participants will then be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™.
219404082|NCT07007195|DEVICE|Instructed Use followed by Ad Libitum Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Ad Libitum condition. Participants will then control how often they use Inspire and will be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™.
219404083|NCT07007195|DEVICE|Smart-T Smoking Cessation App with the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks. Participants will also use the Inspire device.
219404084|NCT07007195|DEVICE|Smart-T Smoking Cessation App Without the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks.
219404085|NCT07007195|DRUG|Nicotine replacement therapy (NRT)|NRT patches will be provided to assist with cravings and withdrawal symptoms following the quit attempts.
219760988|NCT00766519|OTHER|volume optimization|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  \+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%"
219760989|NCT00766519|OTHER|standard volume administration|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
219760990|NCT02603757|DIETARY_SUPPLEMENT|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
219760991|NCT05747248|DEVICE|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
219404086|NCT07007195|DEVICE|Inspire Device|The Inspire Device is a novel olfactory stimulation delivery system. It is a self-contained system with seven sealed chambers, with six gel matrix's that contain a distinct odor and one odorless gel matrix. Participants will press a button on the device to release an odor for participants to smell.
219404087|NCT06622005|DRUG|Cxcr1/2 Inhibitor SX-682|Given PO
219404088|NCT06622005|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
219760992|NCT02668289|OTHER|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
219760993|NCT02668289|OTHER|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
219760994|NCT02668289|OTHER|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
219760995|NCT02668289|OTHER|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
219007094|NCT00162656|DRUG|LMB C|
219007095|NCT05487638|OTHER|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
219007096|NCT01835067|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
219007097|NCT01835067|DRUG|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
219007098|NCT01835067|DRUG|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
219007099|NCT03698747|DEVICE|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
219007100|NCT02402543|DRUG|Gabapentin|
219760996|NCT02668289|OTHER|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
219760997|NCT02668289|OTHER|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
219404089|NCT06622005|DRUG|Carfilzomib|Given IV
219755088|NCT07160465|OTHER|emma application|"1. Emma will allow the patient to spontaneously contact the VigilanS tele-clinician team via a simple and quick access (when the patient presses an ergonomic button with the VigilanS logo). He can also contact the National Service for Suicide Prevention (3114) or the French national emergency medical assistance service 24/7 (Samu).~2. Experts of the field have defined response thresholds for targeted questions on suicide risk and emotional tension. If the patient's answers to these questions reach these thresholds, emma will automatically send a message to the nearest VigilanS center. In this case, a message will appear indicating to the patient that the nearest center will contact him as soon as possible, encourage him to review his strategies and resources available on the app's Home and direct him to the breathing space.~3. Emma offers a Safety Plan module that will allow the patient to help him/her to put into practice what he/she will develop with the VigilanS team on a daily bas"
219755089|NCT07159633|BEHAVIORAL|Online Couple Intervention|The OurRelationship program is approximately 8-10 hours of online content and will delivered over the course of 5-8 weeks. For the current study, we have tailored the general OurRelationship content for couples in recovery from substance misuse. For example, all users receive informational material on the nature of addition and recovery. All of the videos in the adapted program depict couples struggling with recovery-related issues. Additionally, the assessments and feedback content has been tailored. In addition to the online content, couples receive up to 100 minutes of scheduled coach Zoom calls (up to five 20-minute calls).
219755090|NCT07160335|DRUG|HLX17|Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle
219755091|NCT07160335|DRUG|US-sourced Keytruda®|Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle
219755092|NCT07158853|DEVICE|Transcranial Direct Current Stimulation (tDCS)|We will deliver 2-mA tDCS current intensity during a 30 minute stimulation period (including a 30-second ramp-up and 30-second ramp-down period) to the dorsolateral prefrontal cortex. Electrodes will be fixed on marked locations based on the 10-20 EEG system. Anodal stimulating electrode will be over the left DLPFC (F3) and cathodal electrode over the right DLPFC (F4).
219755093|NCT07158853|DEVICE|Sham Stimulation|electrodes will have the same montage as active tDCS (F3/F4), but current will be ramped down after the initial 30 seconds ramp-up period. Thus, participants will feel the initial sensation associated with tDCS but will receive no active current for the rest of the stimulation period.
219189721|NCT04128761|BEHAVIORAL|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to listen and consider the scenario.
219189722|NCT04128761|BEHAVIORAL|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to listen and consider the scenario.
219404090|NCT06622005|DRUG|Dexamethasone|Given PO
219404091|NCT06622005|PROCEDURE|Biospecimen Collection|Undergo Blood sample collection
219404092|NCT06622005|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspiration
219404093|NCT06622005|PROCEDURE|Echocardiography|Undergo ECHO
219404094|NCT06622005|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219404095|NCT06622005|PROCEDURE|Computed Tomography|Undergo PET/CT
219404096|NCT06622005|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219404097|NCT07008677|OTHER|online questionaire|The online questionnaire includes demographic data: age, gender, instrument, professional background, and oral health behavior
219404098|NCT07007819|BEHAVIORAL|Modified Sleep and Circadian Intervention|The modified sleep and circadian intervention has 5 individual sessions that will be delivered via Zoom to parents over 12 weeks and consists of 4 cross-cutting modules (functional analysis, goal setting, motivational interviewing, sleep education), 5 core sessions, and 7 optional modules that are delivered based on personalized treatment goals. The intervention format is as follows: (1) 60-minute session with consultation on setting goals and developing an action plan to improve sleep timing, quantity, and regularity; (2) 5-minute weekly follow-ups and a 3-night sleep diary; and (3) four 30-45-minute booster sessions every 3 weeks. Child attendance is optional.
219404099|NCT07007819|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is an active comparison treatment balanced for time and attention. Participants will be asked to maintain their typical sleep schedules. EUC sessions will review the interrelationships between stress, diet, health, exercise, and behavior, with a sleep education portion \< 10 minutes and no encouragement to change behavior. EUC sessions will be used to establish rapport and promote study retention. EUC participants will not complete weekly sleep diaries. At the end of Week 12, EUC participants will receive a 1-hour optional Zoom session with the PI on sleep education.
219404100|NCT05605327|DEVICE|EUS-guided gastroenterostomy|EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.
219404101|NCT05605327|OTHER|Laparoscopic gastroenterostomy|Laparoscopic gastroenterostomy
219404102|NCT07007676|DEVICE|real-time CGM|real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
219404103|NCT06866613|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over consecutive 7 days
219404104|NCT06866613|DRUG|Placebo Patch|One placebo patch is applied to the injured area over consecutive 7 days
219404105|NCT06353945|DEVICE|vaginal moisturizer|vaginal moisturizer
219404106|NCT06682793|BIOLOGICAL|A2B395|Allogeneic logic-gated Tmod CAR T cells
219404107|NCT06682793|DIAGNOSTIC_TEST|xT CDx with HLA-LOH assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
219755094|NCT07160907|BEHAVIORAL|Ageing Simulation Experience Program|Ageing Simulation Experience Program is a structured training that includes a multimedia lecture, a hands-on aging simulation using the PengZu Suit, and a peer discussion. It aims to enhance care workers' aging knowledge, empathy, attitudes, and communication skills through experiential learning.
219755095|NCT07159750|DRUG|CGRP antibody or gepant|Patients will start anti-CGRP or its receptor antibody or gepants
219755096|NCT07160504|DRUG|Vaginal estradiol tablets|Vaginal estrogen tablets 10 µg at least 3 times a week (on indication, prescribed at the outpatient clinic).
219404108|NCT07018336|OTHER|Mirror Therapy|Mirror Therapy will be applied to the affected upper extremity of hemiplegic patients by placing a mirror in the midsagittal plane, reflecting movements of the non-paretic limb to create the illusion that both limbs are moving symmetrically. Each session will include task-specific, functional hand and arm movements (e.g., grasping, wrist flexion/extension) performed for 30 minutes. Patients will be instructed to focus on the mirror image while actively engaging in the exercises.
219404109|NCT07018336|OTHER|Virtual Reality (VR) Therapy|Virtual Reality (VR) therapy will consist of a single 30-minute immersive session designed to engage the upper extremity of hemiplegic patients. Participants will wear a VR headset and interact with a virtual environment using motion-tracking controllers. Activities are task-oriented and aim to stimulate functional movement through simulated real-life scenarios (e.g., reaching, grabbing, stacking). This intervention offers multisensory feedback and high user engagement.
219404110|NCT07018869|OTHER|Intervention website access|Receive access to CTAC intervention website with educational content and interactive modules
219404111|NCT07018869|OTHER|Control website access|Receive access to CTAC control website with general health education
219404112|NCT07018869|OTHER|Interview|Ancillary studies
219404113|NCT07018869|OTHER|Questionnaire Administration|Ancillary studies
219404114|NCT02415296|OTHER|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
219404115|NCT02415296|OTHER|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
219404116|NCT02415296|OTHER|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
219404117|NCT03988829|BEHAVIORAL|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
219404118|NCT03988829|BEHAVIORAL|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
219404119|NCT03988829|BEHAVIORAL|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
219404120|NCT06873802|OTHER|Non-Interventional Study|Non-interventional study
219404121|NCT06692218|DEVICE|Leadless pacemaker|Patients who will implant leadless pacemakers or already implanted leadless pacemakers since 1 Jan 2015 will be recruited. After the implantation, patients will be invited back for a noncontrast, ECG-gated CT heart. It will be timed at the end diastole and a 3D reconstruction will be performed.
219404122|NCT06693505|COMBINATION_PRODUCT|caffeinated chewing gum|two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA)
219404123|NCT06693505|COMBINATION_PRODUCT|placebo|two pieces of similar looking and tasting placebo gum that did not contain caffeine (xylitol, lime mint, green; Lotte, Saitama, Japan) (PLA trial)
219404124|NCT06693271|DIETARY_SUPPLEMENT|intervention of protein, blueberries|intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day.
219404125|NCT06693271|BEHAVIORAL|Exercise training|Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
219404126|NCT06502977|DRUG|Tarlatamab|IV infusion
219007101|NCT02402543|DRUG|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
219007102|NCT02402543|DRUG|Acetaminophen|
219007103|NCT02402543|DRUG|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
219007104|NCT02402543|DRUG|Placebo|
219007105|NCT03144388|PROCEDURE|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
219007106|NCT03144388|PROCEDURE|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
219007107|NCT05715073|DIETARY_SUPPLEMENT|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
219007108|NCT05715073|DIETARY_SUPPLEMENT|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
219007109|NCT05715073|OTHER|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
219007110|NCT03484481|DIETARY_SUPPLEMENT|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
219007111|NCT03484481|DIETARY_SUPPLEMENT|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
219007112|NCT01668550|DRUG|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
219189723|NCT02657005|DRUG|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
219189724|NCT05432583|BIOLOGICAL|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
219189725|NCT05432583|OTHER|Placebo|Placebo
219189726|NCT06803810|BEHAVIORAL|P2P Intervention|This group will complete the same study visits as the standard care group with an additional week 3 visit and 6 CPSS-led therapy intervention sessions. These CPSS led sessions will be completed by the end of the 12week study period. At each study visit you will complete questionnaires.
219189727|NCT06794853|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).
219189728|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
219189729|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
219189730|NCT06799429|BEHAVIORAL|Supervised in-person group|Individually prescribed and directed/supervised by a fitness trainer in-person, multi-mode exercise 2 x a week for 30-60 minutes The fitness trainer is with the participant while they exercise.
219189731|NCT06799429|BEHAVIORAL|Monitored distance group|Individually prescribed ulti-mode exercise 2 x a week for 30-60 minutes. Written plan/feedback and support by phone/text or email is provided by a fitness trainer who is not present with the participant when they exercise.
219189732|NCT01346540|DRUG|BIBF 1120|VEGF inhibitor
219189733|NCT01346540|DRUG|Placebo|BIBF 1120 placebo
219404140|NCT06693180|OTHER|HBOT|Hyperbaric Oxygen Therapy
219404141|NCT02718833|DRUG|Elotuzumab|
219189734|NCT05297201|DRUG|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
219189735|NCT05297201|DRUG|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
219404142|NCT02718833|DRUG|Pomalidomide|
219404143|NCT02718833|DRUG|Bortezomib|
219404144|NCT02718833|DRUG|Dexamethasone|
219404145|NCT07075276|PROCEDURE|Liquid Phase Concentrated Growth Factor|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with injection of liquid phase concentrated growth factor
219404146|NCT07075276|PROCEDURE|Conventional arthrocentesis|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with conventional arthrocentesis
219404147|NCT07076407|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
219404148|NCT07076407|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
219189736|NCT05297201|DRUG|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
219189737|NCT05193929|DEVICE|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
219404149|NCT06813651|DRUG|TBO-309: 60 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
219404150|NCT06813651|DRUG|TBO-309: 120 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
219404151|NCT06813651|DRUG|TBO-309: 30 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
219404152|NCT06894563|BEHAVIORAL|12-week exercise regimen|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week, and strength/balance exercise performed 2 days a week.
219404153|NCT06894563|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
219404154|NCT06816147|OTHER|Investigators will evaluate the acceptance and adherence to a healthy lifestyle recommender solution (HLRS), a digital app, among participants|The intervention will include collecting blood, stool, urinary samples as well as measuring anthropometrics and collecting data (socio-demographics, general health, well-being, PA, and eating patterns, among others) via questionnaires completed in part from a mobile application.
219404155|NCT06081621|BIOLOGICAL|REGEND001|REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
219404156|NCT06081621|BIOLOGICAL|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
219404157|NCT06930027|OTHER|Resistance Training (High-Intensity)|Leg press exercise performed at 70-80% of 1RM, structured as 4 sets × 10 repetitions, with controlled tempo and standardized rest intervals (2 minutes).
219404158|NCT06930027|OTHER|Resistance Training (Low-Intensity)|Leg press exercise performed at 20-30% of 1RM, structured as 4 sets (30/15/15/15 repetitions), with controlled tempo and shorter rest intervals (1 minute).
219404159|NCT06930027|OTHER|Normobaric Hypoxia|Environmental intervention simulating an altitude of approximately 3500 meters (\~13.5% FiO₂) using a normobaric hypoxic chamber.
219404160|NCT06930027|OTHER|Normoxia|Training under normal atmospheric oxygen conditions (\~20.9% FiO₂).
219404161|NCT06929494|OTHER|Identification of risk factors for candidemia|Identification of risk factors for candidemia
219404162|NCT06929325|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
219404163|NCT06929325|DRUG|Fulvestrant Injection|IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
219404164|NCT06929325|DRUG|Placebo for Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
219566135|NCT03111667|BEHAVIORAL|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
219566136|NCT04052698|DRUG|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
219566137|NCT02853864|DRUG|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
219566138|NCT02853864|DRUG|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
219566139|NCT02853864|DRUG|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
219566140|NCT02853864|DRUG|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
219566141|NCT02853864|DRUG|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
219566142|NCT05306951|DIAGNOSTIC_TEST|Computed tomography|Head computed tomography
219566143|NCT03319095|DEVICE|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
219566144|NCT01872845|DRUG|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
219566145|NCT01872845|DRUG|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
219566146|NCT01637831|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
219566147|NCT04846647|BEHAVIORAL|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
219755097|NCT07159490|DEVICE|Standard-of-care prosthetic foot|Widely prescribed prosthetic foot of stiffness category appropriate to the participant's body weight and activity level.
219566148|NCT05065437|OTHER|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
219755098|NCT07159490|DEVICE|Standard-of-care prosthetic foot with heel-stiffening wedge|Widely prescribed prosthetic foot with a wedge inserted between the heel and foot keels intended to stiffen the behavior of the heel.
219755099|NCT07159490|DEVICE|Standard-of-care prosthetic foot of one category greater stiffness|Widely prescribed prosthetic foot of one stiffness category greater than usually prescribed based on the participant's body weight and activity level.
219755100|NCT07159490|DEVICE|Dual keel prosthetic foot|A prosthetic foot with two forefoot keels intended for load carriage applications.
219189738|NCT05193929|DEVICE|Standard of Care offloading device|CAM boot
219404165|NCT06930573|DRUG|AK112|After enrollment, patients receive AK112 at 20 mg/kg, administered via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W). After four cycles, surgery is performed four weeks after the last dose. AK112 at 20 mg/kg is administered again four to eight weeks after surgery, via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W), until disease progression, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or other reasons specified in the protocol for discontinuation of treatment. The maximum postoperative treatment duration with AK112 is 12 months.
219404166|NCT06929091|OTHER|Prenatal Intervention|Antenatal Breast Milk Expression (ABME). Collection of colostrum before delivery.
219566149|NCT01523236|DRUG|Mometasone furoate|50 mcg/actuation Nasal Spray
219566150|NCT01523236|DRUG|Nasonex®|50 mcg/actuation Nasal Spray
219566151|NCT01523236|DRUG|Placebo|Nasal Spray
219755101|NCT07159490|DEVICE|Powered ankle-foot|A powered prosthetic ankle-foot.
219755102|NCT07159555|OTHER|Blood sampling for neurofilament analysis|An additional blood sample (maximum 1 mL) is collected during routine clinically indicated blood draws in late preterm infants (34-37 weeks of gestation). Samples are obtained at birth, day 2, and weekly until 37 weeks of gestation if blood draws are already planned. No separate venipuncture is performed. Samples are processed and stored for subsequent neurofilament concentration analysis.
219755103|NCT07159620|DRUG|VEN (Venetoclax)|Orally
219755104|NCT07159620|DRUG|Azacitidine (AZA)|Subcutaneous injection
219755105|NCT07159620|DRUG|Chidamide|Orally
219755106|NCT07159620|DRUG|vindesine|intravenous infusion
219404167|NCT06929091|OTHER|Postnatal Intervention|Follow a personalized Mediterranean-style meal plan for 6 months.
219404168|NCT06929819|RADIATION|Intraoperative Radiation Therapy in Malignant Cerebral Tumor|This technique can fully expose the tumor bed during the operation, and pull the brain tissue around the tumor under the microscope to de-radiation, so as to exceed the total dose level of standard conformal conventional external radiation therapy (EBRT), maximize the radiobiological effect of a single high-dose irradiation, and deliver precise radiation to the tumor bed, while minimizing the radiation dose of peripheral nerve tissue. This technique is also a good choice for patients with orthotopic recurrent tumors who can no longer tolerate one more EBRT. Intraoperative radiotherapy technology can reduce the chance of postoperative tumor recurrence and improve the survival and prognosis of patients by providing a higher effective total dose to the tumor bed, while promoting dose escalation without significantly increasing the occurrence of complications in normal tissues, and improving the local control rate.
219404169|NCT06930339|DEVICE|Portable Neuromodulation Stimulator (PoNS)|No intervention
219404170|NCT06929234|OTHER|Peer-Supported Health Education|Peer-supported health education will be provided to paticipants in 1 session for an average of 60 minutes in a suitable classroom. In this session, health education will be provided by the researchers and the peer will support the health education. The peer will share her experiences about each part of the training content with the target group in line with the guidance of the researchers, answer questions and make a motivational speech for screening.
219404171|NCT06929234|OTHER|Basic Health Education|What is cervical cancer, what is the importance of cervical cancer, what are the risk factors for cervical cancer, what are the symptoms of cervical cancer, how to screen for cervical cancer, where to get cervical cancer screenings. Participants will be given health education with a power point presentation in a suitable classroom for an average of 45-50 minutes in 1 session.
219404172|NCT06930599|PROCEDURE|Pulmonary vein isolation plus transition zone modification|For those who are randomized to PVI+TZM arm, additional TZM should be performed after finishing PVI ablation. PVI could be performed using open-irrigated contact-force catheter.
219404173|NCT06930599|PROCEDURE|Pulmonary vein isolation alone|In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl. PVI should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter.
219755107|NCT07159620|DRUG|Dexamethasone|intravenous infusion or orally
219755108|NCT07161583|DEVICE|Advanta VXT Vascular Graft|The Advanta VXT graft is a two (2)-layer graft employing a single layer ePTFE graft, which is then wrapped with an additional layer of ePTFE for increased support. Some Advanta VXT configurations include Helix, which is a monofilament bead wrapped circumferentially around a portion or the entire length of the graft (such a graft is also called a Ringed Graft). The helix rings are bonded to the exterior surface of the graft. Advanta VXT Tapers are formed by changing the graft diameter, expanding from a small Inner Diameter (ID) to a larger ID (with the result that one end is larger).
219189739|NCT06222710|PROCEDURE|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
219189740|NCT06222710|PROCEDURE|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
219189741|NCT04506866|DEVICE|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
219404174|NCT06930365|OTHER|Anti-itching and repairing treatment. Emollient.|Anti-itching and repairing treatment. Emollient.
219404175|NCT06930365|OTHER|Emollient cream|Emollient cream
219404176|NCT05887167|BIOLOGICAL|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
219404177|NCT06930456|DRUG|hydrocortisone|A deidentified syringe (10 mL) containing 100 mg hydrocortisone will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
219429166|NCT04904588|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
219429167|NCT04904588|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
219429168|NCT04904588|OTHER|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
219429169|NCT06270602|OTHER|Data collection (retrospective)|Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
219755109|NCT07161583|DEVICE|Flixene Vascular Graft|The Flixene vascular graft is a three (3)-layered graft comprised of ePTFE. The Flixene graft was designed with an additional layer of ePTFE. As a result of its design, ring support is not necessary
219755110|NCT07160348|OTHER|Questionnaire and Physical Exam|Translation and validation of the existing HPES-Symptom and HPES-Impact Questionnaires in the Greek population
219189742|NCT05061069|DIAGNOSTIC_TEST|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
219189743|NCT05821686|DRUG|Human Interleukin-2 (IL-2) (Proleukin)|All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
219189744|NCT05837286|DEVICE|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
219189745|NCT05837286|OTHER|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
219189746|NCT06306625|DEVICE|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.
219189747|NCT06306625|DEVICE|No remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
219189748|NCT03362476|BEHAVIORAL|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
219189749|NCT03362476|BEHAVIORAL|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
219189750|NCT03362476|BEHAVIORAL|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
219189751|NCT06640166|DRUG|encorafenib + cetuximab + FOLFIRI|"encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours)."
219189752|NCT06644716|DIAGNOSTIC_TEST|[18F]F-FAPI PET-CT|Each patient will receive a FAPI PET-CT.
219189753|NCT05613218|DRUG|Oxygen|"Patients will have nasal cannula or oxygen mask placed as the usual standard of care.~Patients will be screened and randomized in the emergency department to either liberal or restrictive oxygenation after providing informed written consent and oxygen is titrated to the prespecified target range using an automated feedback device (O2MATIC). Consented patients will be randomly allocated to study groups via the web-based system within REDCap. The allocation will be concealed. Time at randomization will be considered as study time zero (T0). All patients will receive usual standard of care except for their O2 management. The intervention will last for 24 h. After 24 h, patients will be switched over to usual care for oxygen therapy. If the treating physician thinks, that the patient need another oxygenation target and it is thought to be harmful to continue with the allocated target, the intervention-phase can be stopped prematurely."
219189754|NCT03893682|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
219189755|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
219404178|NCT06930456|DRUG|ondansetron|A deidentified syringe (10 mL) containing 8 mg ondansetron will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
219404179|NCT06930456|DRUG|Placebo|A deidentified syringe (10 mL) containing sterile distilled water for intravenous injection will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
219429170|NCT06270602|OTHER|Data collection (prospective)|Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
219429171|NCT01958879|DRUG|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
219429172|NCT01958879|DRUG|ringer without corticosteroid|200 mL Ringer solution
219429173|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
219429174|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
219429175|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
219429176|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
219429177|NCT05816252|DRUG|SKB264|intravenous (IV) infusion (Q2W or Q3W)
219429178|NCT05816252|DRUG|Pembrolizumab|intravenous (IV) infusion (400mg, Q6W)
219189756|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
219404180|NCT06930248|BIOLOGICAL|Platelet rich plasma injection|Our first step is the local anesthesia using a solution of decongestion nasal drops with 5% Emla and 10% Xylocaine spray in cotton, which is placed in the nose for 30 minutes. The 2nd step of the administration is the PRP injection in the olfactory area of the noseVia1 ml syringe with 30 G needle, PRP is injected in the olfactory area(located at superior turbinate and superior portion of lateral an medial portion of nasal cavity) approximately every 1 cm2 with the help of a nasal endoscope. The procedure is repeated 3 times with a 4 week interval with follow up patients for 6 months. A 4th time is injected after 3 months.
219404181|NCT07077746|DRUG|HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells|Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells). Dose: 200 million cells (+/- 20%) suspended in 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: HB-adMSCs syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
219404182|NCT07077746|DRUG|0.9% sodium chloride|0.9% sodium chloride Dose: N/A - 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: Placebo syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
219404183|NCT07087002|BIOLOGICAL|GPC2-CAR T cells|Autologous T cells transduced with retroviral vector encoding a second-generation GPC2-targeted chimeric antigen receptor (GPC2-CAR), administered intracerebroventricularly. Up to 8 doses are given every 28 days, following an intrapatient dose escalation schema.
219404184|NCT07087002|DRUG|Fludarabine|Administered as part of a lymphodepleting chemotherapy regimen prior to GPC2-CAR T cell infusion. Dose: 30 mg/m²/day for 3 days.
219404185|NCT07087002|DRUG|Cyclophosphamide|Administered with fludarabine for lymphodepletion. Dose: 500 mg/m²/day for 3 days.
219404186|NCT05581004|DRUG|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
219404187|NCT05581004|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
219404188|NCT05581004|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedules specified in the respective arms.
219404189|NCT06783569|DRUG|JR8603|IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
219404190|NCT01941368|DIETARY_SUPPLEMENT|Placebo|
219404191|NCT01941368|DIETARY_SUPPLEMENT|HMB-FA|
219404192|NCT01941368|PROCEDURE|High Intensity Interval Training|
219404193|NCT05891249|BIOLOGICAL|Luspatercept|Specified dose on specified days
219404194|NCT06417177|DRUG|Placebo|Participants will receive a placebo in pill form.
219404195|NCT06417177|DRUG|Propranolol|Participants will receive oral propranolol (1 mg/kg).
219404196|NCT06417177|DRUG|Gemtesa|Participants will receive oral gemtesa (75 mg).
219404197|NCT03398408|BEHAVIORAL|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
219404198|NCT05590637|DRUG|Pimavanserin|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
219404199|NCT05590637|DRUG|Quetiapine|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
219404200|NCT06241222|DRUG|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
219404201|NCT07092228|DEVICE|virtual reality and plyometric workout|to evaluate exercise capacity in teenage females with abdominal obesity using virtual reality and plyometric workouts
219404202|NCT07100847|PROCEDURE|Periprostatic neurolysis with dehydrated alcohol (ethanol)|Pre-operative ultrasound guided periprostatic neurolysis by injection of dehydrated alcohol
219404203|NCT06063967|DRUG|Risankizumab SC|subcutaneous (SC) injection
219404204|NCT06063967|DRUG|Placebo for risankizumab|subcutaneous (SC) injection
219404205|NCT07109856|DIAGNOSTIC_TEST|POP-Score Assessment|A non-invasive score calculated within the first 6 hours after birth using peripheral muscle oxygenation (pTOI, measured via near-infrared spectroscopy), heart rate, arterial oxygen saturation (SpO2), systolic blood pressure (SABP), and subcutaneous fat layer thickness. The score is evaluated for its ability to predict C-reactive protein (CRP) levels ≥ 20 mg/L within 48 hours.
219404206|NCT07109856|DEVICE|Near-Infrared Spectroscopy (NIRS)|NIRS measurements are performed within 6 hours after birth using the NIRO 200NX device at four anatomical sites (forearm, forehead, infraumbilical region, and left flank). Measurements assess peripheral muscle, cerebral, intestinal, and flank oxygenation to identify possible differences in tissue perfusion associated with early inflammation or infection.
219404207|NCT05602597|DRUG|Itraconazole 200 mg|Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
219429179|NCT05816252|DRUG|Carboplatin|intravenous (IV) infusion (AUC5, Q3W)
219429180|NCT05816252|DRUG|Osimertinib|80mg, QD
219429181|NCT05038592|DRUG|Decitabine|Given IV
219429182|NCT05038592|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219429183|NCT06533644|PROCEDURE|Partial Oncolysis|Partial tumor oncolysis will be completed by cryolysis.
219429184|NCT06533644|DRUG|SV-102|Intratumoral infusion of SV-102
219429185|NCT05507580|DRUG|Upadacitinib|Oral tablet
219429186|NCT02515708|DEVICE|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
219429187|NCT02891980|BIOLOGICAL|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
219429188|NCT02891980|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
219189757|NCT05214222|DRUG|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
219189758|NCT05214222|DRUG|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks."
219189759|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
219189760|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
219189761|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
219189762|NCT03899636|DRUG|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
219189763|NCT03899636|DEVICE|NanoKnife System|IRE using NanoKnife System
219189764|NCT05191264|OTHER|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
219189765|NCT05191264|OTHER|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
219189766|NCT05191264|OTHER|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
219189767|NCT06315842|OTHER|Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.|During the intervention periods, participating physicians will integrate into their usual clinical practice a tool for adjusting diagnostic and therapeutic intensity designed by Fontecha-Gómez and colleagues. The tool for adjusting the level of diagnostic and therapeutic intensity classifies patients' profiles into 5 groups based on the recommended level of adjustment.
219189768|NCT06315842|OTHER|Usual clinical practice|The participating physicians will carry out the standard clinical practice currently performed in the study centers. This means that during this period, the diagnostic and therapeutic adjustment tool or any similar tool will not be introduced into routine clinical practice.
219189769|NCT06318949|PROCEDURE|blood sampling|If the patient does not object to participating in the study, a blood sample is taken at each visit (an additional tube may be added to a routine blood sample taken for standard care), or a residual blood sample is reused after routine tests have been performed, and data is collected from the medical record.
219189770|NCT06606197|OTHER|Having sex with other men|Having sex with other men
219189771|NCT06528665|DRUG|ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults|"ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned."
219189772|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
219189773|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
219404208|NCT05602597|DRUG|Fluconazole 400 mg|Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
219404209|NCT05602597|DRUG|Rifampin 600 mg|Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
219404210|NCT05602597|DRUG|Rabeprazole 40 mg|Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
219429189|NCT00278096|BEHAVIORAL|occupational therapy|
219429190|NCT03239639|BEHAVIORAL|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
219429191|NCT03239639|OTHER|Wait list control|No intervention
219566152|NCT03169621|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
219404211|NCT06232772|DIAGNOSTIC_TEST|α- Synuclein Ultrafine Fluorescence Detection Method|This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
219404212|NCT07110090|BIOLOGICAL|Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002)|dosage form: Injection dosage: 10 mL/bag, 1×10⁷ cells/mL frequency: Each subject will be administered a single infusion of XJ-MK-001 at their respective enrolled dose level.
219566153|NCT00519103|OTHER|exercise|
219566154|NCT05194449|OTHER|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
219566155|NCT05194449|OTHER|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
219566156|NCT04292366|PROCEDURE|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
219566157|NCT04731584|BIOLOGICAL|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
219566158|NCT05497141|DEVICE|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
219566159|NCT00711841|DRUG|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
219404213|NCT07112222|DRUG|LM-350 for injection|Q3W,Intravenous Drip
219404214|NCT06923137|DRUG|BNT162b2|BNT162b2
219404215|NCT06920056|DRUG|Paracetamol|oral, postprandial
219404216|NCT06920056|DRUG|Metformin Hydrochloride|Oral , Fasting
219566160|NCT00711841|DRUG|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
219566161|NCT00711841|DRUG|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
219566162|NCT01507090|DEVICE|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
219566163|NCT01084018|BEHAVIORAL|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
219404217|NCT06920056|DRUG|Warfarin|Oral , Fasting
219404218|NCT06920056|DRUG|BGM0504|Administered SC
219404219|NCT07122661|BIOLOGICAL|ABRYSVO|This is a non-interventional retrospective study; therefore, ABRYSVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.
219760998|NCT02668289|OTHER|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
219189774|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
219189775|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
219189776|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine RDE 100 μg|CVGBM will be administered as an IM injection.
219189777|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
219404220|NCT06946550|DEVICE|1470nm non-ablative fractional laser|Patients with scarring alopecia will be treated with the non-ablative Sciton HALO laser (1470nm).
219404221|NCT07152860|OTHER|5 Hz electroacupuncture combined tipronone capsules|Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia. Frequency: 5 Hz Patients will also be administered SviShu (tipronone capsules) (Wei Cai Pharmaceutical Co., Ltd., National Drug Approval Number H20093656, dosage: 50 mg) orally, one capsule at a time, three times daily, after meals.
219404222|NCT07152860|DRUG|Simple tipronone capsules group(The basic treatment group)|Patients in the Simple tipronone capsules group(basic treatment group) will receive only conventional basic drug therapy. They will be given Svi-Shu (tipronone capsules) (Eisai Pharmaceutical Co., Ltd., national drug approval number H20093656, specification: 50 mg) orally, one capsule at a time, three times a day, after meals.
219404223|NCT05860881|DRUG|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
219002205|NCT05999032|BEHAVIORAL|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
219404224|NCT05860881|OTHER|Placebo|Cream containing only the base, or vehicle.
219404225|NCT07150156|BEHAVIORAL|brief intervention|Provision of personal feedback on drinking risk level and guidance that encourages the patient to develop a realistic plan to reduce his or her alcohol consumption to a less risky level
219404226|NCT07156708|OTHER|Aquatic aerobic exercise program|The aquatic exercise sessions include the following exercises: butt kick, frontal kick, cross-country skiing, and stationary running. These exercises are commonly used in water aerobics classes and provide controlled osteoarticular impact, being safe for older women (Alberton et al., 2019). Training intensity is prescribed using Borg's 6-20 rating of perceived exertion (RPE) scale. The adopted strategy is based on interval training, which alternates between high-intensity effort and low-intensity active recovery phases. Each block consists of 4 minutes of effort (RPE 13 - 15), with one minute for each exercise (butt kick, frontal kick, cross-country skiing, and stationary running) followed by 1 minute of active recovery (RPE 11), performed with stationary running. To facilitate monitoring, an RPE scale (measuring 0.90 × 1.20 m) is fixed to the outside of the pool, in front of the participants.
219404227|NCT07156708|OTHER|Cognitive tasks|This group performs the same aerobic training protocol used by the conventional aquatic program group. Additionally, cognitive tasks are performed during the active recovery phases. Cognitive training encompasses different domains of cognition in all sessions, including semantic fluency, processing speed, cognitive flexibility, inhibitory control, memory, attention, and reasoning. The exercises vary in each class, with progression in complexity in each mesocycle.
219404228|NCT07152470|BEHAVIORAL|Diet and Exercise Tracking|To determine if diet and/or exercise had any impact on weight loss while taking motus.
219404229|NCT07152613|DRUG|Saline (0.9%, sterile, for infusion)|Saline for control
219404230|NCT07152613|DRUG|Low Dose Corticosteroids|Methylprednisolone 0.5mg/kg ivgtt qd
219404231|NCT07152613|DRUG|Moderate dose corticosteroids|Methylprednisolone 1.0mg/kg ivgtt qd
219404232|NCT07162194|PROCEDURE|Digital Rectal Examination|Undergo DRE
219404233|NCT07162194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/TRUS
219404234|NCT07162194|PROCEDURE|Pathologic Examination|Undergo prostate tissue mapping and evaluation using a special mold
219404235|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy based on PIRADS
219760999|NCT02668289|PROCEDURE|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
219761000|NCT02668289|OTHER|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
219404236|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using GL AI predictions
219761001|NCT02249403|DRUG|Talsaclidine 6 mg|
219007113|NCT01541774|DEVICE|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
219404237|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using DL AI predictions
219404238|NCT07162194|PROCEDURE|Transrectal Ultrasound|Undergo MRI/TRUS
219404239|NCT07163884|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
219429192|NCT03245502|BIOLOGICAL|Blood transfusion|The transfusion of erythrocyte suspension
219429193|NCT01917890|DIETARY_SUPPLEMENT|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
219429194|NCT01917890|DIETARY_SUPPLEMENT|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
219429195|NCT00555568|BEHAVIORAL|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
219429196|NCT00555568|BEHAVIORAL|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
219429197|NCT00145912|BEHAVIORAL|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
219429198|NCT00145912|BEHAVIORAL|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
219429199|NCT06169995|DRUG|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
219429200|NCT00638417|BEHAVIORAL|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
219429201|NCT00638417|BEHAVIORAL|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
219429202|NCT04831567|RADIATION|MIBG-I131|Radiopharmaceutical
219755111|NCT07159984|BEHAVIORAL|Education on Changes During Pregnancy|In the first session of the researcher-prepared training presentation, women will be informed about the structure and functions of their internal and external reproductive organs, as well as changes in physical, hormonal, social, and lifestyle activities. After the first session, there will be a 15-minute break before the second session, which will include evidence-based training on the effects of pregnancy-related changes on stress, couple harmony, and quality of life. Methods for coping with stress and pregnancy-related complaints, process management that positively impacts couple harmony, and healthy lifestyle behaviors that enhance quality of life will be discussed.
219002206|NCT05999032|BEHAVIORAL|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
219404240|NCT07163884|OTHER|Facsial therapy|In addition to electrotherapy, the patients in the study group will receive a total of five sessions (one day per week for five weeks) of fascial therapy. The protocol will be developed by us. Fascial mobilization will be performed by a trained physiotherapist on the pectoral fascia, deltoid fascia, axillary fascia, and supscapularis fascia, once a week, for 180 seconds each repetition. These sessions will be performed at the pain threshold, and care will be taken to ensure that the pain does not exceed a VAS score of 2.
219002207|NCT02552771|PROCEDURE|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
219002208|NCT02552771|PROCEDURE|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
219404241|NCT07162272|DRUG|Melatonin Patches|Group 1 (n=26): Participants in the intervention group will receive two melatonin patches on their forearm (each containing 1mg of melatonin, AVEELA, USA) attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before melatonin patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
219404242|NCT07162272|OTHER|Placebo Group|Group 2 (n=26): Participants in the intervention group will receive two placebo patches on their forearm attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before placebo patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
219404243|NCT07162649|DRUG|Dexmedetomidine|30μl
219404244|NCT07162649|DRUG|Placebo|30μl
219404245|NCT07162298|OTHER|Dragon Boat Training|"The total training duration is 12 weeks, divided into cycles of 4 weeks each, with distinct training contents and goals for every cycle. Training sessions are held 3 times a week, and all participants train together on the same day. Each training session lasts approximately 60 minutes.~In the first 4 weeks, participants spend half an hour training on land and the subsequent half an hour training on dragon boats.~Then, from week 4 to week 8, they train for 20 minutes on land and 40 minutes on dragon boats.~Finally, from week 8 to week 12, they only conduct 10-15 minutes of land training (as warm-up) followed by nearly an hour of on-boat training.~This progressive training plan is designed to ensure that each participant can tolerate the training intensity as much as possible, preventing injuries caused by training."
219429203|NCT02565446|PROCEDURE|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
219002209|NCT01864811|BEHAVIORAL|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
219002210|NCT01864811|BEHAVIORAL|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
219002211|NCT04843293|BEHAVIORAL|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
219002212|NCT00187369|PROCEDURE|Method of Delivery|CS or VB
219002213|NCT00075959|DRUG|NXY-059|
219002214|NCT01506128|OTHER|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
219002215|NCT02197000|DIETARY_SUPPLEMENT|DIM-Avail 100mg|DIM 100 mg\*1 daily for 2 years
219002216|NCT01484197|DRUG|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
219002217|NCT01484197|DRUG|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
219429204|NCT06489782|OTHER|Model 1|Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
219755112|NCT07160699|DRUG|Botulinum Neurotoxin Type A|The effectiveness of the combination of BoNT with treatment goal specific non-pharmacological interventions will be evaluated.
219761002|NCT02249403|DRUG|Talsaclidine 12 mg|
219404246|NCT07162298|OTHER|Home-based Unsupervised Training|"The total training duration is 12 weeks. After a 15-minute warm-up (including walking, exercises, etc.), participants will perform the following 10 movements in sequence: squats, rowing simulation with rubber bands, lateral raises, sit-ups, shoulder presses, alternating bilateral lunges, dumbbell curls (for biceps), sit-ups, and planks.~Each movement lasts 60 seconds, with a 10-second rest allowed midway through the same movement (i.e., 15 seconds of exercise followed by a 10-second rest, then another 15 seconds to complete the movement). A 20-second rest is permitted before moving on to the next movement.~Once participants can complete 30 seconds of the same movement without needing rest or adjustment, the training intensity will be increased-progressing from one round of training (10 minutes) to two rounds (20 minutes) or even three rounds (30 minutes)."
219404247|NCT07163260|OTHER|No treatment given|No treatment given
219404248|NCT07163078|DIETARY_SUPPLEMENT|Common form supplementation|The intervention product would represent part of a typical supplement given to people including those with CF
219566164|NCT03973099|DIETARY_SUPPLEMENT|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
219566165|NCT02900482|OTHER|Sampling saliva|
219566166|NCT06152705|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
219566167|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
219566168|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
219566169|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
219566170|NCT06902168|OTHER|Intensive swimming program|The participants will be enrolled in an intensive swimming program for 8 weeks (45 minutes) in the swimming pool. The swimming program will be to improve safety and functional independence in the water. The hydrotherapy will be performed at a swimming pool temperature suitable for the weather temperature.
219566171|NCT05264831|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
219566172|NCT05264831|PROCEDURE|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
219566173|NCT06904560|OTHER|phacoemulsification|one group with BSS at room temperature and the other group with cold BSS
219566174|NCT06904573|DRUG|Probiotics Compound (Biolosion)|15g, PO, qd
219566175|NCT06904573|DRUG|Nab-paclitaxel|230mg/m2, IV, days 1, 8, q3w
219566176|NCT06904573|DRUG|Cisplatin|70mg/m2, IV, days 1-3, q3w
219566177|NCT06904573|DRUG|Gemcitabine|1.2g/m2, IV, days 1, 8, q3w
219566178|NCT06904573|DRUG|Disitamab vedotin|2.5mg/kg, IV, q2w
219566179|NCT06904573|DRUG|Enfortumab Vedotin|1.25mg/kg, IV, days 1, 8, q3w
219002218|NCT01484197|DRUG|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
219566180|NCT06904573|DRUG|Pembrolizumab|200mg, IV, q3w
219566181|NCT06904573|DRUG|Toripalimab|240mg, IV, q3w
219566182|NCT06905769|COMBINATION_PRODUCT|Aquatic Therapy|Group A was treated with Aquatic Therapy for 30-45 minutes for 3 sessions per week for 8 weeks . Patient should Seated .Therapist will standing or seated beside the patient Therapist Perform gentle stretching on wrist, hand, and finger joints. Exercises to improve range of motion and reduce stiffness. Then perform aquatic therapy for 10 minutes. Therapist instruct patients hands in bath tube. Water temperature 88°F - 94°F (31°C - 34°C).Water depth is Waist-deep or deeper depending on patient comfort
219566183|NCT06905769|DIAGNOSTIC_TEST|Neuro-Dynamic Technique|Group B (Neuro-Dynamic Technique) Group B was treated with Neuro-Dynamic Technique for 15 minutes 3 sessions per week for 8 weeks. Patient should Seated or supine with the affected hand relaxed. Therapist will standing or seated beside the patient. Techniques Time duration is 3 minutes for each technique. wrist distraction 3 sets for 3 minute rhythmic and gentle stretching of the transverse carpel ligament Release of palmar fascia gliding of finger flexor tendons release of upper forearm muscle and fascia.
219761003|NCT02249403|DRUG|Talsaclidine 24 mg|
219002219|NCT01484197|DRUG|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
219002220|NCT01484197|DRUG|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
219002221|NCT00811798|BIOLOGICAL|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219761004|NCT02249403|DRUG|Talsaclidine 36 mg|
219002222|NCT00586001|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
219002223|NCT02254252|DRUG|Nicorandil|nicorandil (10mg tablets, two times a day)
219002224|NCT02254252|DRUG|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
219002225|NCT06293495|DEVICE|Gamma 3 Nail (Stryker)|Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
219002226|NCT06293495|DEVICE|Chimaera Nail (Orthofix)|Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
219404249|NCT07163078|DIETARY_SUPPLEMENT|Uncommon nutrient supplementation|The intervention product would represent part of a possible new supplement given to people including those with CF
219404250|NCT07162480|DRUG|P-Sam|Given by IV
219404251|NCT07163663|OTHER|Hight intensity functional trainning|"Warm-up phase: Low-intensity walking 30-50% MHR combined with dynamic mobility exercises~High Intensity Functional Training (HIFT)~The raised HIFT intervention proposal is divided into three exercises:~1. Strength exercise of the lower limbs such as Sit to Stand / Stand to sit and elevation of the upper limbs up in a standing position or lateral gait with knee flexion of one limb among many others.~2. Upper limb strength exercises: In a standing position with a medicine ball and in front of the wall, throw the ball against it and catch it o Walk while taking the medicine ball from right to left with smooth rotation of the trunk among many others.~3. Coordination and balance exercises: Go up and down stairs or steps in four steps with arms stretched out in front of you and exercises such as standing, knee flexion and raising the contralateral hand with weights.~Cooling phase: Stretching of upper and lower limb muscle groups and head and neck muscles."
219404252|NCT07162246|RADIATION|Radiation Therapy|Adaptive radiation therapy with GK boost
219404253|NCT07164014|OTHER|Mediterranean diet|Mediterranean Diet Total Calories: \~1,980 kcal Protein: \~110 g Carbohydrates: \~132 g Fat: \~117 g Diet Type: Mediterranean: Moderate-calorie, high in unsaturated fats, includes fermented dairy Omega-3 Sources: Present: Fish, Olive Oil, Nuts Oil/Fat Types: Olive oil, tahini, nuts (mostly monounsaturated \& polyunsaturated)
219404254|NCT07164014|OTHER|Hospital diet|Hospital diet Total Calories: \~3,100 kcal Protein: \~160 g Carbohydrates: \~280 g Fat: \~150 g Diet Type: High Protein, High Calorie: High in saturated fats, refined carbs, and animal proteins Omega-3 Sources: Minimal: Mostly absent Oil/Fat Types: Animal fats (saturated), dairy fat, minimal unsaturated fat
219404255|NCT07162415|PROCEDURE|Open resection|A transverse or longitudinal incision is done depending on surgeon's preference. The ganglion and its pedicle are traced up to its origin. The pedicle is resected tangentially, usually, from the SL ligament for dorsal ganglions and depending on the site for volar ganglion. Wrist capsule is not closed.
219755113|NCT07160699|OTHER|Non-pharmacological therapies|Depending on the treatment goal different non-pharmacological therapies as a standard of care will be provided
219755114|NCT07159100|DEVICE|Active tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 20-30 minutes, either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current.~The intervention is unique as the target population is cancer survivors with persistent fatigue \>6 months post-treatment. Also, the tDCS is combined with neurophysiological assessments, including EMG, TMS, EEG, and MRI, to provide neurophysiological evidence of acute effects."
219761005|NCT02249403|DRUG|Placebo|
219761006|NCT02552576|BIOLOGICAL|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
219404256|NCT07162415|PROCEDURE|Arthroscopic resection|Portals are selected by surgeon's preference. The pedicle of the ganglion is located and resected with a shaver. It is not necessary to remove all the ganglion walls. The portal incisions do not need to be sutured.
219429205|NCT06489782|OTHER|Model 2|Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
219429206|NCT04702984|DEVICE|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
219429207|NCT04702984|DEVICE|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
219429208|NCT03167541|DRUG|Test|RB naproxen sodium tablets (2x220mg)
219429209|NCT03167541|DRUG|Reference|Aleve naproxen sodium tablets (2x220mg)
219429210|NCT02590419|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
219429211|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
219429212|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
219429213|NCT01989871|BEHAVIORAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
219429214|NCT00092482|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
219429215|NCT05333640|DEVICE|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
219429216|NCT05333640|DEVICE|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
219429217|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
219429218|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
219429219|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
219404257|NCT07162415|OTHER|Conservative treatment|Participant will be informed about the natural course of wrist ganglions. The conservative treatment may include needle aspiration of the ganglion, but it is not performed routinely. Participants are informed that wrist loading in extension may exacerbate the pain, and that the pain is not a sign of further injury to wrist joint. They can avoid heavy use it if they have too much pain, but they are advised to use hand as tolerated. Participants may use NSAIDs and acetaminophen for pain management as needed; however, the protocol does not specify a required course or dosage. A simple self-implemented exercise therapy instructions are given to every participant.
219404258|NCT05521074|DEVICE|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
219404259|NCT05521074|DEVICE|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
219404260|NCT06395441|DIETARY_SUPPLEMENT|American Ginseng|Given PO
219404261|NCT06395441|DRUG|Placebo Administration|Given PO
219404262|NCT06395441|OTHER|Questionnaire Administration|Ancillary studies
219404263|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
219404264|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
219404265|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
219404266|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
219404267|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
219404268|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
219404269|NCT06318897|DRUG|Carboplatin|Given by IV
219404270|NCT06318897|DRUG|Paclitaxel|Given by IV
219404271|NCT06318897|DRUG|Pembrolizumab|Given by IV
219404272|NCT06318897|DRUG|Doxorubicin|Given by IV
219404273|NCT06318897|DRUG|Cyclophosphamide|Given by IV
219002227|NCT04245787|DRUG|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
219404274|NCT03721068|BIOLOGICAL|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
219404275|NCT03721068|DRUG|Cyclophosphamide|500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
219404276|NCT03721068|DRUG|Fludarabine|30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
219404277|NCT06548386|DEVICE|Pleural gas analysis|"Patients enrolled in this study will undergo both VI and pleural gas analysis to assess for air leak following surgical chest tube placement.~For pleural gas analysis, an outlet gas analyzer will be kept on the outlet port of the chest drain for the entire duration of time that a chest tube is in place. We plan to collect both continuous data, looking for intermittent spikes and gas changes, along with episodic data collected during specific air leak assessments. The gas analyzer may better be able to measure an air leak during these specific procedures conducted twice per day, but it will also be used at the outlet port of the chest drain the rest of the time to continuously check for an air leak throughout the hospital stay."
219404278|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
219404279|NCT02816697|OTHER|CEASE|"* Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
219404280|NCT02816697|OTHER|Usual Care Tobacco Treatment Services|
219404281|NCT05096481|BIOLOGICAL|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
219404282|NCT05096481|DRUG|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
219404283|NCT05096481|BIOLOGICAL|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
219566184|NCT06904144|BEHAVIORAL|Health Coaching|12 virtual health coaching sessions will be provided over a 16 week period by a certified health coach.
219002228|NCT00622245|DRUG|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
219002229|NCT00622245|DRUG|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
219002230|NCT00622245|DRUG|Placebo|per oral doses, twice daily as capsules during 13 weeks
219002231|NCT03056885|OTHER|Conventional One-Lung Ventilation|Vt 10 ml/kg
219002232|NCT03056885|OTHER|Protective One-lung ventilation|Vt 5 ml/kg
219002233|NCT02348606|DRUG|JZP-110|
219002234|NCT02348606|DRUG|Placebo oral tablet|
219002235|NCT03849898|PROCEDURE|Surgery|Surgical fracture treatment
219002236|NCT03849898|OTHER|Non-Surgical fracture treatment|Non-Surgical fracture treatment
219404284|NCT06644755|DRUG|DS-2243a|"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
219404285|NCT05082597|DEVICE|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
219404286|NCT06506253|OTHER|Swedish Massage Therapy|Touch therapy
219404287|NCT06506253|OTHER|Light Touch Therapy|Touch therapy
219566185|NCT06905301|DRUG|Ribociclib|CDK4/6 inhibitor
219404288|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
219404289|NCT05306873|DRUG|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
219404290|NCT05306873|DRUG|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
219404291|NCT05306873|DRUG|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
219404292|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
219404293|NCT04590144|DEVICE|INVICTA lead|The implant or the attempt to implant an INVICTA lead
219404294|NCT06771739|OTHER|Electronic Health Record Review|Ancillary studies
219404295|NCT06771739|OTHER|Interview|Ancillary studies
219404296|NCT06771739|OTHER|Support|Receive $1000 preloaded cash card
219404297|NCT06771739|OTHER|Support|Receive $100 preloaded cash card
219404298|NCT06771739|OTHER|Survey Administration|Ancillary studies
219404299|NCT01608074|PROCEDURE|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
219404300|NCT01608074|OTHER|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
219404301|NCT06126380|DRUG|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
219404302|NCT06126380|DRUG|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
219404303|NCT06259708|DEVICE|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
219404304|NCT06789107|DRUG|Blinatumomab 9ug|Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
219404305|NCT01379495|BEHAVIORAL|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
219404306|NCT02420158|DEVICE|Trans-cutaneous vagal nerve electrical stimulation|
219404307|NCT04370093|DRUG|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
219404308|NCT04370093|BEHAVIORAL|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
219404309|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
219404310|NCT03514758|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
219404311|NCT02876770|DIETARY_SUPPLEMENT|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
219404312|NCT02876770|DIETARY_SUPPLEMENT|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
219404313|NCT02245568|DRUG|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
219404314|NCT06629675|DEVICE|Music walking application BeatClearWalker (BCW)|The music walking application (BCW) is a smartphone application that can monitor the walking pace and allow individuals to listen to music and give immediate feedback so they can correct their walking pace to match their target walking speed, as prescribed by the healthcare professional. The application provides real-time audio feedback in the form of music; the music sound quality will reduce whenever the walking speed drops below or exceeds the participant\&#39;s target walking speed. Simply, the application will work to supervise service users while exercising walking. The investigators are trying to assess the feasibility of this application with service users during their Pulmonary Rehabilitation programme (at the hospital/ home) to find out how participants interact with listening to music while exercise walking and how well they're able to keep to their target speed.
219404315|NCT01938963|BEHAVIORAL|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
219404316|NCT02987764|OTHER|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
219404317|NCT02150187|DIETARY_SUPPLEMENT|HCap Formula|Pill should be taken every other day during the treatment phase.
219404318|NCT02150187|DIETARY_SUPPLEMENT|Placebo|Similar pills without active ingredients
219404319|NCT03463941|BEHAVIORAL|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
219404320|NCT00294502|DRUG|Gentamycin/citrate, Minocycline/EDTA|
219404321|NCT03951688|OTHER|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
219404322|NCT05281783|DEVICE|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
219404323|NCT04573452|DIAGNOSTIC_TEST|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
219404324|NCT04573452|DIAGNOSTIC_TEST|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
219404325|NCT01051986|PROCEDURE|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
219404326|NCT01051986|PROCEDURE|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
219404327|NCT02728258|DRUG|Copanlisib|Given IV
219404328|NCT02728258|OTHER|Laboratory Biomarker Analysis|Correlative studies
219404329|NCT02145923|PROCEDURE|Peripheral blood stem cell mobilisation and collection|
219404330|NCT02145923|DRUG|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
219404331|NCT02145923|DRUG|Bone marrow derived allogeneic MMSCs infusion|
219404332|NCT02145923|PROCEDURE|Autologous peripheral blood stem cells infusion|
219404333|NCT05728086|OTHER|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
219404334|NCT03614169|PROCEDURE|Implantation of a HIS-pacing lead|This intervention is attempted first
219404335|NCT03614169|PROCEDURE|Implantation of a LV-pacing lead|This intervention is attempted first
219404336|NCT01725152|DRUG|Ganaxolone|oral suspension, given in 3 divided doses
219404337|NCT01725152|DRUG|Placebo|oral suspension, given in 3 divided doses
219404338|NCT01591226|DIETARY_SUPPLEMENT|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
219404339|NCT01591226|DIETARY_SUPPLEMENT|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
219404340|NCT01591226|DIETARY_SUPPLEMENT|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
219404341|NCT01591226|DIETARY_SUPPLEMENT|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
219404342|NCT02044159|DRUG|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
219404343|NCT02044159|OTHER|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
219404344|NCT01095575|DRUG|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
219404345|NCT01111539|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
219404346|NCT01111539|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
219002237|NCT01195558|OTHER|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
219002238|NCT02173327|DEVICE|Continuously helm CPAP|6 hours
219002239|NCT02173327|DEVICE|Intermittent Mask CPAP|10min every 2 hour for 18 hours
219002240|NCT02490332|DEVICE|Ventilation tube treatment|Tympanostomy
219404347|NCT01111539|DRUG|Blinded capsule|Blinded capsule administered orally, once daily.
219404348|NCT05078463|DEVICE|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
219404349|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
219404350|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
219404351|NCT05078463|DRUG|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
219404352|NCT05078463|DEVICE|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
219404353|NCT04695106|DRUG|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
219404354|NCT04695106|DRUG|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
219404355|NCT04695106|DRUG|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
219404356|NCT04695106|DRUG|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
219404357|NCT03628417|PROCEDURE|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
219404358|NCT03628417|PROCEDURE|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
219404359|NCT03263936|DRUG|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over \_\_ hour on days 1 through 5
219404360|NCT03263936|DRUG|Vorinostat|Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
219404361|NCT03263936|DRUG|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
219404362|NCT03263936|DRUG|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
219404363|NCT03263936|DRUG|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
219404364|NCT06163794|OTHER|Nutritional postprandial test|Metabolic responses to several test meals
219404365|NCT06540859|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.
219404366|NCT06540859|DEVICE|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver sham stimulation. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention.
219404367|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
219404368|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
219404369|NCT01816646|DRUG|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
219404370|NCT01816646|DRUG|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
219404371|NCT05327023|PROCEDURE|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
219404372|NCT05327023|DRUG|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
219404373|NCT05327023|DRUG|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
219404374|NCT05327023|DRUG|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
219404375|NCT05327023|DRUG|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
219404376|NCT05327023|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
219404377|NCT05635734|DRUG|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
219404378|NCT05635734|DRUG|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
219404379|NCT05635734|DRUG|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
219404380|NCT01619384|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
219404381|NCT01405846|DRUG|Gefitinib|250mg od for 6 months
219404382|NCT00372190|DEVICE|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
219404383|NCT00372190|PROCEDURE|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
219404384|NCT03095924|OTHER|News items with spin|Interpretation of news items with spin
219404385|NCT03095924|OTHER|News items without spin|Interpretation of news items without spin
219404386|NCT02288728|PROCEDURE|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
219429220|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
219429221|NCT04144179|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
219429222|NCT02060968|DEVICE|Promus PREMIER|
219429223|NCT06967961|OTHER|For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:|A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
219429224|NCT06226779|BEHAVIORAL|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
219429225|NCT06226779|BEHAVIORAL|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
219429226|NCT06226779|BEHAVIORAL|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
219429227|NCT06973902|DEVICE|Cardiac Contractility Modulation (CCM) implant|"Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device OPTIMIZER Smart Mini by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.~The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.~The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium."
219404387|NCT02288728|PROCEDURE|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
219404388|NCT02122861|BIOLOGICAL|ID-LV305|pembrolizumab
219404389|NCT00389896|DRUG|MK0733 / Duration of Treatment: 18 Weeks|
219404390|NCT00389896|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
219404391|NCT02599766|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
219404392|NCT02599766|OTHER|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
219404393|NCT00549237|DIETARY_SUPPLEMENT|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
219404394|NCT00549237|OTHER|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
219404395|NCT01620385|DEVICE|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
219404396|NCT03411746|OTHER|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
219404397|NCT01883440|DRUG|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
219404398|NCT01883440|DRUG|Saline+glucose|Placebo arm
219404399|NCT03514303|DIAGNOSTIC_TEST|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
219404400|NCT03526003|DIAGNOSTIC_TEST|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
219404401|NCT00587821|OTHER|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
219404402|NCT02422953|DIETARY_SUPPLEMENT|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
219404403|NCT02422953|DIETARY_SUPPLEMENT|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
219404404|NCT02422953|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
219404405|NCT02422953|BEHAVIORAL|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
219404406|NCT04808154|DRUG|SNP-630|Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
219404407|NCT01477697|DIETARY_SUPPLEMENT|Omega-3|50 mg/kg per day of omega-3 fatty acids
219404408|NCT01477697|DIETARY_SUPPLEMENT|Placebo|50 mg/kg per day of placebo equivalent
219566186|NCT06905301|DRUG|Letrozole|Aromatase inhibitor
219404409|NCT04386564|DIAGNOSTIC_TEST|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
219404410|NCT03657680|OTHER|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
219404411|NCT05894278|OTHER|Prescription data collection|Prescription data collection
219404412|NCT04547738|DRUG|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
219404413|NCT01836575|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
219404414|NCT01836575|DRUG|Carboplatin|Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
219404415|NCT01613287|DEVICE|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
219404416|NCT01785433|DRUG|Tiotropium HFA BAI 4.5 mcg|
219404417|NCT01785433|DRUG|Tiotropium HFA BAI 9.0 mcg|
219404418|NCT01785433|DRUG|SPIRIVA® HandiHaler® 18 mcg/day|
219404419|NCT01785433|DRUG|Spiriva® Respimat® 5 mcg/day|
219404420|NCT01649739|DRUG|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
219404421|NCT02939144|DIETARY_SUPPLEMENT|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
219404422|NCT02216253|DRUG|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
219404423|NCT02216253|OTHER|Placebo|Placebo tablet twice a day 7 days before and after surgery
219566187|NCT06905301|DRUG|Anastrozole|Aromatase inhibitor
219566188|NCT06904768|DEVICE|Shoulder Sling|Use of a shoulder sling (Reh4mat AM-SOB) on the affected upper limb during mobility and balance testing.
219566189|NCT06904768|OTHER|No Sling|Functional mobility tests performed without the use of any assistive shoulder device.
219566190|NCT06904014|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion
219566191|NCT06904014|DRUG|Sintilimab|200mg, ivgtt, D1, Q3W
219566192|NCT06904014|DRUG|Lenvatinib|8 mg，qd，D1-D21,Q3W
219566193|NCT06904014|PROCEDURE|surgery|surgery
219566194|NCT06905236|BEHAVIORAL|walking intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
219404424|NCT01487668|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
219404425|NCT03899129|PROCEDURE|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
219404426|NCT03899129|PROCEDURE|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
219404427|NCT02231658|DRUG|Liraglutide|
219404428|NCT02231658|DRUG|Lixisenatide|
219404429|NCT01856595|DRUG|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
219404430|NCT01856595|DRUG|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
219404431|NCT01057199|GENETIC|RNA analysis|
219404432|NCT01057199|GENETIC|gene expression analysis|
219404433|NCT01057199|GENETIC|mutation analysis|
219404434|NCT01057199|GENETIC|protein expression analysis|
219404435|NCT01057199|OTHER|fluorescence activated cell sorting|
219404436|NCT01057199|OTHER|laboratory biomarker analysis|
219404437|NCT01986569|DRUG|[18F]fluoroestradiol (FES)|\[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
219566195|NCT06905665|DEVICE|Virtual reality group|For the VR group, the purpose of the study was explained before the procedure, and both verbal and written informed consent were obtained. Additionally, patients were provided with detailed information about how to use the headset, what to expect, and the content of the video before viewing. Data collection forms and the State-Trait Anxiety Inventory (STAI I-II) were completed using a face-to-face interview technique before the procedure.During the urodynamic procedure, an Efnan G04EA VR Shinecon 3D headset was used. The patient was positioned appropriately on the examination table, and the VR headset was fitted onto their head with a smartphone placed inside. A thin pillow was placed under the patient's head, and efforts were made to ensure their privacy and comfort. Throughout the urodynamic procedure (approximately 30 minutes),
219566196|NCT06905106|BIOLOGICAL|Collection of tube bottoms from blood samples taken in the clinic|Collection of tube bottoms from blood samples taken in the clinic
219566197|NCT06905145|OTHER|Biomarkers evaluation|Evaluate the prognostic role of the markers TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, ERCC1 examined on biopsy samples.
219566198|NCT03757091|DEVICE|Laryngoscopy|Undergo video laryngoscopy
219566199|NCT03757091|PROCEDURE|Tracheal Intubation|Undergo flexible scope intubation
219404438|NCT01835496|DRUG|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
219404439|NCT04426825|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
219404440|NCT04426825|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219404441|NCT05081648|PROCEDURE|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
219404442|NCT05081648|PROCEDURE|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
219002241|NCT01980394|PROCEDURE|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
219002242|NCT02170597|DRUG|BIBR 1048 MS HPMC capsule|
219002243|NCT02170597|DRUG|BIBR 1048 MS gelatine capsule|
219404443|NCT03000309|DRUG|Apremilast|
219404444|NCT02280928|OTHER|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
219404445|NCT02280928|OTHER|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
219404446|NCT02280928|OTHER|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
219404447|NCT05485272|OTHER|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
219404448|NCT05485272|OTHER|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
219404449|NCT05485272|OTHER|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
219566200|NCT06903871|DRUG|TORIPALIMAB INJECTION(JS001 )|Participants will receive toripalimab 240 mg IV once every 3 weeks. Treatment continued until disease progression, death, unacceptable toxicity, investigator decision, withdrawal, or completion of 1 years of treatment, whichever occurred first.
219566201|NCT06904989|DEVICE|Silicone orthosis|"in addition to standard treatment, shoe and insole treatment, a new type of treatment for CIPN is being evaluated, a silicone orthosis.The silicone orthosis consists of a half-sock designed for indoor use.~The participants feet are examined, and the foot shape is scanned barefoot using a three-dimensional foot scanner from Volumental. This is performed to use a basis for manufacturing individual silicone orthoses. Activity measurement with an activity sensor, attached to the thigh with tape, is planned for two weeks after receiving the assistive device.~Participants who receive a silicone orthosis are asked to keep a diary of how much they have used it. The follow-up takes place at the Oncology Department 3-6 weeks after the participant has received the assistive device."
219404450|NCT06398743|DEVICE|MRD|ctDNA MRD test
219566202|NCT06904989|DEVICE|Standard Treatment|"The standard treatment is that patients are provided with customized insoles and shoes. Foot status is recorded during the orthopedic technical assessment at OTA, identifying signs of neuropathy, impaired blood circulation, foot deformities, and skin pathologies. A modified version of the validated D-Foot instrument is used to assess the risk of foot ulcers, especially in diabetic patients. The evaluation also includes lower extremity function, gait abnormalities, and existing footwear and insoles.~Differences in foot anthropometry are compared between scanned foot measurements of the study group and those of a control group representing a female Swedish normal population.~ActivePal is a reliable method for measuring and classifying activity levels. Activity measurement is conducted over two weeks."
219404451|NCT03708965|DRUG|JR-141|IV infusion (lyophilized powder)
219566203|NCT06904742|DRUG|Tea tree oil|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily . Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s. In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
219566204|NCT06904742|DRUG|Thyme oil hydrosol|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily (Santi et al., 2019). Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s (Santi et al., 2019). In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
219566205|NCT06904742|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily. Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s . In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
219566206|NCT06904742|DRUG|Placebo|Placebo mouthwash had been used in 13 patients for 3 months
219404452|NCT06361641|DIAGNOSTIC_TEST|Monocytes signatures in myeloproliferative neoplasms at diagnosis|The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
219404453|NCT00260585|PROCEDURE|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
219404454|NCT00260585|PROCEDURE|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
219404455|NCT00260585|PROCEDURE|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
219566207|NCT05828303|DRUG|TPX-0005|Oral TPX-0005 capsules
219566208|NCT05828303|DRUG|Metformin Hydrochloride|oral solution
219566209|NCT05828303|DRUG|Digoxin|oral tablet
219566210|NCT05828303|DRUG|Rosuvastatin Calcium|oral tablet
219007114|NCT06420843|DIETARY_SUPPLEMENT|FOODMAP|Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
219007115|NCT00560079|DRUG|Allopurinol|Allopurinol 600mg/day bid for 28 days
219007116|NCT00560079|DRUG|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
219404456|NCT00260585|PROCEDURE|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
219404457|NCT03484533|BEHAVIORAL|HIV self-test kit|Women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
219007117|NCT00560079|DRUG|Placebo|Placebo
219007118|NCT00005610|BIOLOGICAL|sargramostim|
219007119|NCT00190996|DRUG|Duloxetine Hydrochloride|
219404458|NCT03484533|BEHAVIORAL|Standard of Care (invitation letters for fast-track HIV testing in the clinic)|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
219404459|NCT03249792|DRUG|MK-2118 (IT)|IT injection
219404460|NCT03249792|DRUG|MK-2118 (SC)|SC injection
219404461|NCT03249792|BIOLOGICAL|Pembrolizumab|IV infusion
219404462|NCT04702711|OTHER|No intervention|No intervention
219404463|NCT01071044|DRUG|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
219404464|NCT01071044|DRUG|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
219404465|NCT03415477|DRUG|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
219404466|NCT03181165|BEHAVIORAL|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
219404467|NCT00124267|DRUG|Intrarectal quinine|
219404468|NCT04093739|DEVICE|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
219404469|NCT04653909|OTHER|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
219404470|NCT02840487|BIOLOGICAL|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
219404471|NCT02053272|DRUG|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
219404472|NCT02053272|DRUG|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
219404473|NCT03127215|DRUG|Olaparib|Olaparib 150 mg tablet
219404474|NCT03127215|DRUG|Physician's choice|treatment according to current guidelines
219404475|NCT03127215|DRUG|Trabectedin|Trabectedin 1.1mg/m² infusional solution
219404476|NCT03632681|DRUG|Intranasal Insulin|Intranasal insulin
219404477|NCT03632681|DRUG|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
219404478|NCT04017988|DIETARY_SUPPLEMENT|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
219404479|NCT04017988|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
219404480|NCT02275689|PROCEDURE|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
219404481|NCT02275689|PROCEDURE|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
219404482|NCT04332640|DEVICE|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
219404483|NCT05356624|OTHER|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
219404484|NCT05356624|OTHER|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
219404485|NCT00793702|BIOLOGICAL|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
219404486|NCT02307344|DIETARY_SUPPLEMENT|Nigella Sativa|
219404487|NCT02307344|DIETARY_SUPPLEMENT|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
219404488|NCT03219593|DRUG|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
219404489|NCT04368806|DRUG|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
219404490|NCT04368806|OTHER|Placebo Control|Normal Saline with autologous Serum
219404491|NCT03105440|OTHER|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
219404492|NCT03105440|OTHER|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
219404493|NCT03105440|OTHER|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
219404494|NCT03105440|OTHER|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
219404495|NCT03105440|OTHER|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
219404496|NCT03105440|OTHER|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
219404497|NCT00137774|DRUG|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
219404498|NCT00137774|DRUG|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
219404499|NCT04443127|DEVICE|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
219404500|NCT04443127|BEHAVIORAL|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
219404501|NCT00127556|PROCEDURE|Label applied to blood bag|
219404502|NCT00210340|DRUG|intrathecal rituximab|
219404503|NCT05115279|PROCEDURE|breast conservative surgery for post chemotherapy tumour size|"* Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique"
219007120|NCT00190996|DRUG|placebo|
219404504|NCT02096146|PROCEDURE|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
219404505|NCT02096146|PROCEDURE|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
219404506|NCT05565300|OTHER|Cycling exercise|30 minutes of cycling (90 rpm).
219404507|NCT05565300|OTHER|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
219404508|NCT03085641|DEVICE|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
219404509|NCT00069576|BEHAVIORAL|nutritional counseling|
219404510|NCT00069576|BEHAVIORAL|self blood glucose monitoring|
219404511|NCT01226420|DRUG|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
219404512|NCT02833610|DRUG|Denosumab Q4W|
219404513|NCT01107522|DRUG|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
219404514|NCT01107522|DRUG|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
219404515|NCT01107522|DRUG|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
219404516|NCT06439875|DIETARY_SUPPLEMENT|effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation|Patients with a certified diagnosis of COPD and chronic respiratory failure will be randomized in a 1:1 ratio into the interventional arm or the placebo controller arm. All patients will undergo multidisciplinary intensive pulmonary rehabilitation for 28 days. The patients in the interventional group will receive a twice-daily oral supplementation with either a combination of 1.66 g l-arginine plus 500 mg liposomal vitamin C
219404517|NCT06439875|OTHER|placebo|Patients in this arm will undergo multidisciplinary intensive pulmonary rehabilitation without any dietary supplementation.
219404518|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
219404519|NCT02388516|DIETARY_SUPPLEMENT|Vitamin D3|
219404520|NCT02388516|DIETARY_SUPPLEMENT|Placebo|
219404521|NCT06391294|PROCEDURE|Focal cortical cooling|Focal cortical cooling will be applied
219404522|NCT05127616|BEHAVIORAL|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
219404523|NCT05127616|BEHAVIORAL|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
219404527|NCT06968390|DEVICE|Transcranial Magnetic Stimulation|Non-invasive form of brain stimulation.
219404528|NCT05278962|DRUG|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
219404529|NCT05278962|OTHER|No SGLT2i|No SGLT2i
219755115|NCT07159100|DRUG|Sham tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 30 seconds to mimic the sensation of active tDCS (20 minutes long), either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current."
219404530|NCT05139498|PROCEDURE|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
219404531|NCT05139498|PROCEDURE|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
219404532|NCT01665417|DRUG|Experimental|Icotinib: 125mg, oral administration, three times per day.
219404533|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
219404534|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
219404535|NCT04906655|DRUG|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
219404536|NCT01631279|DRUG|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
219404537|NCT04697472|DEVICE|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
219404538|NCT00075348|GENETIC|mutation analysis|
219404539|NCT04272216|DEVICE|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
219404540|NCT03308084|DRUG|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
219404541|NCT03308084|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
219404542|NCT05100199|DRUG|OnabotulinumtoxinA X|Injection
219404543|NCT05100199|DRUG|Placebo|Injection
219404544|NCT06233435|BEHAVIORAL|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
219404545|NCT05061550|DRUG|Durvalumab|Participants will receive Durvalumab via intravenous route.
219404546|NCT05061550|DRUG|Oleclumab|Participants will receive Oleclumab via intravenous route.
219404547|NCT05061550|DRUG|Monalizumab|Participants will receive Monalizumab via intravenous route.
219404548|NCT05061550|DRUG|Dato-DXd|Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
219404549|NCT05061550|DRUG|AZD0171|Participants will receive AZD0171 via intravenous route.
219755116|NCT07160309|DEVICE|Densah Bur|Implant site preparation will be performed using the Densah bur system to achieve osseodensification in narrow alveolar ridges prior to implant placement.
219189778|NCT05769231|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
219189779|NCT04465344|DEVICE|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
219189780|NCT04465344|DEVICE|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
219189781|NCT05587972|OTHER|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
219189782|NCT04275869|OTHER|Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
219189783|NCT05974501|DRUG|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
219189784|NCT05974501|DRUG|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
219189785|NCT05974501|DRUG|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
219189786|NCT05974501|DRUG|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
219404550|NCT05061550|DRUG|Carboplatin|Carboplatin as chemotherapy
219404551|NCT05061550|DRUG|Cisplatin|Cisplatin as chemotherapy
219404552|NCT05061550|DRUG|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin as chemotherapy
219404553|NCT05061550|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin as chemotherapy
219404554|NCT05061550|DRUG|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as chemotherapy
219404555|NCT05061550|DRUG|Volrustomig|Participants will receive Volrustomig via intravenous route.
219404556|NCT05061550|DRUG|Rilvegostomig|Participants will receive Rilvegostomig via intravenous route.
219404557|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
219404558|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
219755117|NCT07160309|DEVICE|Magnetic Mallet|Implant site preparation will be performed using the Magnetic Mallet device to achieve osseodensification in narrow alveolar ridges prior to implant placement.
219755118|NCT07158723|OTHER|Higher protein dietary pattern|Follow energy-restricted (10% calorie reduction), higher protein dietary pattern (1.6 g protein/kg body weight)
219189787|NCT05974501|DRUG|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
219189788|NCT05974501|DRUG|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
219189789|NCT05974501|DRUG|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
219189790|NCT05245006|DRUG|89Zr-DFO-YS5|3 mCi will be administered intravenously
219189791|NCT05245006|BIOLOGICAL|YS5 antibody|20 or 50 mg administered intravenously
219189792|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
219404559|NCT04258059|DEVICE|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
219404560|NCT04258059|DEVICE|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
219404561|NCT00347711|DRUG|Intravitreal injection|
219404562|NCT00830037|DRUG|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
219404563|NCT00830037|DRUG|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
219189793|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
219404564|NCT03229915|BEHAVIORAL|cognitive processing therapy|Group therapy for PTSD patients
219404565|NCT05854615|BIOLOGICAL|Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
219404566|NCT05909514|BEHAVIORAL|PelvicSense(R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
219404567|NCT06357975|PROCEDURE|Biopsy Procedure|Undergo biopsy
219404568|NCT06357975|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219404569|NCT06357975|DRUG|Crizotinib|Given PO
219404570|NCT06357975|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219404571|NCT04434053|DEVICE|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
219566211|NCT06903858|DRUG|Toripalimab combined with celecoxib|Toripalimab is administered via intravenous infusion at 3 mg/kg over 30 minutes (initial infusion time is 60 minutes), once every two weeks, for a total of 12 doses before surgery. Celecoxib is taken orally at 200 mg per dose, twice daily, for a duration of 6 months.
219566212|NCT06903858|PROCEDURE|Curative resection of colorectal cancer|Patients who do not achieve cCR based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to undergo curative resection of colorectal cancer.
219566213|NCT06903858|OTHER|Watch-and-wait strategy|Patients achieving clinical complete response (cCR) based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to adopt a watch-and-wait strategy.
219566214|NCT06905795|DIAGNOSTIC_TEST|Fibroscan test|Perform Fibroscan testing on the study subjects every six months.
219566215|NCT06905795|BEHAVIORAL|Nutrition guidance|Each family will be matched with a nutritionist, who will provide daily online dietary guidance for parents and students during the first 21 days, followed by weekly sessions thereafter.
219566216|NCT06905795|BEHAVIORAL|Increase physical activity|Increase physical activity time in and out of school by professional sports trainer.
219566217|NCT06905795|OTHER|Health education|Knowledge of healthy lifestyle will be delivered in various forms such as health lectures, brochures, posters, etc.
219566218|NCT06904040|BIOLOGICAL|CM313 injection|600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment
219566219|NCT06904040|BIOLOGICAL|glucocorticoids|Administer medium- or long-acting glucocorticoids 1-3 hours before injection
219566220|NCT01117844|RADIATION|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
219566221|NCT06905522|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
219404572|NCT04434053|DEVICE|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
219566222|NCT06905522|DRUG|Sitafloxacin (S)|200mg once daily
219566223|NCT06905522|DRUG|Linezolid (L)|600mg once daily
219566224|NCT06905522|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
219566225|NCT06905522|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
219566226|NCT06905522|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
219566227|NCT06905522|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
219566228|NCT06905522|DRUG|Moxifloxacin (M)|400mg once daily
219566229|NCT06905522|DRUG|Pretomanid (Pa)|200mg once daily
219566230|NCT06905639|BEHAVIORAL|Aerobic and Strength Exercise|A supervised physical exercise intervention was carried out, specifically designed to improve post-breast cancer lymphedema. The program will include a combination of strength exercises and aerobic exercises, with the aim of improving mobility, reducing inflammation, and increasing muscle strength in the arm affected by lymphedema
219566231|NCT00924586|DRUG|ONO-1101|Placebo for one minute IV
219404573|NCT06973551|BEHAVIORAL|Brain Health Nostalgic VR Program|"The Brain Health Nostalgic VR Program is a culturally tailored virtual reality intervention integrating nostalgic content from Taiwanese culture (e.g., vintage photographs, familiar objects, historical TV clips, traditional settings) with interactive cognitive training tasks. The program targets seven cognitive domains: attention, imagination and creativity, observation, memory, reasoning, reading comprehension, and thinking. Each weekly session spans 60-90 minutes, with 10-30 minutes of actual VR use based on participant tolerance, each participant will use VR for no more than 30 minutes per session before taking a break. The intervention is delivered once per week over a 12-week period in long-term care settings, with researcher support provided throughout."
219404574|NCT01433458|DRUG|RLX030A|RLX030 is administered as a continuous 24 hour infusion
219404575|NCT04425772|DRUG|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
219404576|NCT04425772|DRUG|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
219404577|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
219566232|NCT00924586|DRUG|ONO-1101|0.125 mg/kg for one minute IV
219566233|NCT03769831|DRUG|SHR2285|Ascending dose oral adminstration
219566234|NCT03769831|DRUG|Placebo|Ascending dose oral adminstration
219566235|NCT02435316|OTHER|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
219404578|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
219566236|NCT02435316|OTHER|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
219566237|NCT02406638|OTHER|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
219566238|NCT04222114|DRUG|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
219566239|NCT04222114|DRUG|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
219404579|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS C|High casein-protein, high-caloric control product.
219566240|NCT02247050|BEHAVIORAL|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
219189794|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
219404580|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
219404581|NCT03519945|DRUG|Mirikizumab|Administered SC.
219404582|NCT00752609|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
219404583|NCT06286319|DEVICE|Angel Cooler|Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
219404584|NCT04246528|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
219404585|NCT05228002|OTHER|sFlt-1/PlGF ratio - Active Comparator: Standard|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation"
219404586|NCT05228002|OTHER|sFlt-1/PlGF ratio - Experimental: Biomarkers|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation."
219566241|NCT02449473|BIOLOGICAL|Tralokinumab|Subcutaneous Injection
219566242|NCT02449473|OTHER|Placebo|Subcutaneous Injection
219566243|NCT04712734|DRUG|Iloperidone|oral tablet, long-acting injection
219404587|NCT03115333|DIAGNOSTIC_TEST|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
219404588|NCT05216393|OTHER|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
219404589|NCT03969706|DRUG|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
219404590|NCT05079841|DEVICE|Electric breast pump|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
219404591|NCT05079841|DRUG|Exogenous oxytocin intravenous infusion without nipple stimulation.|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
219189795|NCT05485766|DRUG|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
219189796|NCT05485766|DRUG|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
219189797|NCT05485766|DRUG|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
219189798|NCT05485766|DRUG|Olaparib|300 mg BID (twice daily) orally
219189799|NCT05485766|PROCEDURE|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
219404592|NCT04857112|DRUG|Low Dose MT-1303|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
219404593|NCT04857112|DRUG|High Dose MT-1303|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
219404594|NCT04857112|DRUG|Placebo|Matching placebo, QD (Day 1-85)
219404595|NCT04857112|DRUG|MT-1303|0.4 mg MT-1303 QD for 36 weeks for those participants who continue on to the OLE period from the double-blind portion of the clinical study
219404596|NCT00992901|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
219404597|NCT00992901|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
219404598|NCT00992901|DRUG|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
219404599|NCT04908449|DRUG|Rectus sheath block with bupivacaine|Rectus sheath block with local anesthetic versus sham block with saline
219404600|NCT05301283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
219404601|NCT05301283|DIAGNOSTIC_TEST|MRI|Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
219189800|NCT06821412|DEVICE|ASTERISK System|This intervention uses an experimental socket fabricated by a certified prosthetist. The electronics within the experimental socket are set up with the ASTERISK system, which sends information collected from the EMG sensors to the prosthetic hand wirelessly rather than the current available method of wired control.
219189801|NCT06821412|DEVICE|Wired Configuration|This intervention uses the same experimental socket that is used for the ASTERISK intervention. The prosthesis is set-up with wired EMG control, which is the current available method for EMG-controlled prostheses.
219189802|NCT04001543|DIETARY_SUPPLEMENT|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
219189803|NCT04001543|DIETARY_SUPPLEMENT|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
219189804|NCT04260243|OTHER|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
219189805|NCT04260243|OTHER|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
219189806|NCT06823622|BEHAVIORAL|Stepstones transition program|"The STEPSTONES transition program is an 8-component intervention designed to support adolescents with chronic conditions transitioning to adult care. It includes: a transition coordinator (TC), education about the condition, phone support, guidance on transitioning to adult care, parental guidance, peer meetings, a personalized transition plan, and the actual transfer to adult care. The intervention is implemented in five steps, starting with outpatient visits and culminating in the transfer to adult care. Delivered via the Mitt vårdmöte digital platform, the program includes the HEADDDSS adolescent health interview and is conducted by trained specialized nurses."
219189807|NCT05627635|BIOLOGICAL|Balstilimab|Given IV
219189808|NCT05627635|BIOLOGICAL|Bevacizumab|Given IV
219189809|NCT05627635|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
219189810|NCT05627635|BIOLOGICAL|Botensilimab|Given IV
219189811|NCT05627635|PROCEDURE|Computed Tomography|Undergo a CT scan
219189812|NCT05627635|DRUG|Fluorouracil|Given IV
219189813|NCT05627635|DRUG|Leucovorin Calcium|Given IV
219189814|NCT05627635|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219189815|NCT05627635|DRUG|Oxaliplatin|Given IV
219189816|NCT05627635|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219189817|NCT05627635|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219404602|NCT03334617|DRUG|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
219755119|NCT07158723|OTHER|Calorie restriction|Follow energy-restricted (10% calorie reduction) dietary pattern for 16 weeks. No restrictions on macronutrient content.
219755120|NCT07159126|DRUG|DS3610a|Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.
219755121|NCT07160530|BEHAVIORAL|EAT Family Style|Rural family childcare home providers receive 7 online modules on responsive feeding practices over 16 weeks, plus 7 individual coaching sessions via Zoom with Extension agents. Providers record mealtime videos for personalized feedback, engage in goal-setting and action planning, and receive printed materials and conversation cards.
219755122|NCT07160530|BEHAVIORAL|Better Kid Care|Rural family childcare home providers receive 10 online modules about general childcare topics unrelated to nutrition, including child development, block play, oral health, supervising children, and managing a family childcare home through the Better Kid Care platform.
219189818|NCT04911296|OTHER|Mock-RP|Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
219189819|NCT06446817|DEVICE|LuxHighAdd IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
219189820|NCT06446817|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
219189821|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
219189822|NCT06502535|DIETARY_SUPPLEMENT|Inulin|15 g inulin once daily for 4 weeks.
219189823|NCT06502535|DIETARY_SUPPLEMENT|Potassium nitrate and inulin|1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
219189824|NCT03833921|DRUG|Abiraterone Acetate|1000 mg orally daily until disease progression
219189825|NCT03833921|DRUG|Prednisone|5 mg oral low dose prednisone, twice daily
219404603|NCT03334617|DRUG|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
219404604|NCT03334617|DRUG|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
219404605|NCT03334617|DRUG|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
219404606|NCT03334617|DRUG|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
219404607|NCT03334617|DRUG|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
219404608|NCT03334617|DRUG|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
219404609|NCT03334617|DRUG|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
219404610|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
219404611|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
219404612|NCT03334617|DRUG|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
219404613|NCT03334617|DRUG|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
219404614|NCT05114590|DRUG|Insulin glargine/Lixisenatide|Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
219404615|NCT05673018|DEVICE|Multi-Cancer Early Detection Test (Galleri®)|Blood collection and multi-cancer early detection testing with return of results.
219404616|NCT05438563|PROCEDURE|MRI-Guided Transurethral Ultrasound Ablation|Undergo MRI-Guided TULSA
219404617|NCT05438563|OTHER|Questionnaire Administration|Ancillary studies
219404618|NCT05438563|PROCEDURE|Digital Rectal Examination|Undergo DRE
219404619|NCT05438563|PROCEDURE|Cystoscopy|Undergo cystoscopy
219404620|NCT05438563|PROCEDURE|Biopsy|Undergo biopsy
219404621|NCT05438563|PROCEDURE|Bone Scan|Undergo bone scan
219404622|NCT05438563|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
219404623|NCT05438563|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
219404624|NCT03504800|DEVICE|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
219404625|NCT06514352|OTHER|Skin contact immediately after birth|In the immediate skin-to-skin contact group after birth, if the newborn does not need any intervention, he will be placed on the mother's chest immediately (without cord clamping) and skin-to-skin contact will begin. An average of 60 minutes of skin contact will be made until the first breastfeeding occurs. All routine practices for the newborn in the delivery room (except weight measurement) will be performed on the mother's chest. (n=48)
219566244|NCT05774652|BEHAVIORAL|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
219404626|NCT06514352|OTHER|Very Early Skin contact|In the very early skin-to-skin contact group, skin-to-skin contact will begin within the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, and skin-to-skin contact will be carried out for an average of 60 minutes until the first breastfeeding occurs.(n=48)
219404627|NCT06514352|OTHER|Early Skin contact|For newborns who need intervention after birth and whose skin-to-skin contact cannot be started in the delivery room, skin-to-skin contact will begin within the first 24 hours after birth, after the newborn becomes stable.(n=48)
219404628|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1（0.5mL）
219404629|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2（0.5mL）
219404630|NCT06474377|BIOLOGICAL|Pneumovax®|One dose of Pneumovax® (0.5 mL) contains 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F saccharides.
219404631|NCT06474377|BIOLOGICAL|Placebo|0.5 mL of 0.9%NaCl solution (normal saline)
219404632|NCT05854641|BIOLOGICAL|Stempeucel®|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
219404633|NCT03161067|DEVICE|BiCNS|Surgical implantation
219404634|NCT06804850|DRUG|Tislelizumab|200mg IV Q3W
219404635|NCT06804850|DRUG|Afatinib|30mg PO QD
219404636|NCT06804850|RADIATION|Low dose radiotherapy|4Gy / 2f. Intensity-modulated radiotherapy was used for radiotherapy.
219404637|NCT06550180|DRUG|Spinal anaesthesia group (S)|Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
219404638|NCT06550180|DRUG|Subcostal TAP block and spinal anesthesia group (STAP)|patient receive Subcostal TAP block before spinal anesthesia. Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anesthesia
219404639|NCT05374447|PROCEDURE|Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy|Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
219404640|NCT05186714|BEHAVIORAL|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
219429228|NCT05893420|DEVICE|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
219429229|NCT05893420|OTHER|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
219566245|NCT06002217|DRUG|Levobupivacaine|Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml
219566246|NCT06002217|OTHER|Placebo Tap block|Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
219566247|NCT04819373|DRUG|BDB001|BDB001 is an immunotherapy agent.
219566248|NCT05138926|OTHER|Cervical Manipulation|high speed, low amplitude cervical manipulation
219566249|NCT05138926|OTHER|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
219429230|NCT06220838|DRUG|SC-101|All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
219429231|NCT04609280|RADIATION|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
219429232|NCT05539807|BEHAVIORAL|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
219755123|NCT07158892|BEHAVIORAL|Diagnostic Advance Care Planning Discussion|The intervention consists of a structured, values-based conversation modeled after Advance Care Planning (ACP) principles, adapted for diagnostic decision-making. Participants will receive a hypothetical clinical vignette involving a musculoskeletal diagnostic test (e.g., MRI, X-ray, CT, or ultrasound), followed by a simulated discussion facilitated by a trained researcher. The conversation is guided by branching scripted prompts designed to elicit the participant's values, goals, expectations, and understanding of the potential benefits and harms of testing. Responses are transcribed using verbal-to-text technology. Unlike standard decision aids or educational materials, this intervention emphasizes patient reflection and shared decision-making by prompting participants to consider what matters most to them before making a decision about the test. The discussion does not involve actual test ordering or clinical decisions but is intended to simulate a real-world ACP discussion process.
219429233|NCT06206226|BEHAVIORAL|OHDC-DC|90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
219429234|NCT03496662|DRUG|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
219429235|NCT03496662|DRUG|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
219429236|NCT03496662|DRUG|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
219429237|NCT03496662|DRUG|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
219429238|NCT03496662|PROCEDURE|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
219429239|NCT03496662|PROCEDURE|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
219429240|NCT06620835|BIOLOGICAL|Blood samples for Hematology|Complete blood count will include erythrocytes, neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, leukocytes, hemoglobin, hematocrit.
219429241|NCT06620835|BIOLOGICAL|Blood samples for Chemistry|Clinical chemistry will include serum electrolytes (sodium, potassium, calcium, corrected calcium for hypoalbuminemia), creatinine, CrCl with local formula, and fasting blood glucose.
219429242|NCT06620835|BIOLOGICAL|Blood sample for liver function tests|Laboratory tests to assess liver function will include Aminotransferase Alanine (ALAT), Aminotransferase Aspartate (ASAT), Phosphatase Alkaline (ALP), Gamma-glutamyl Transferase (GGT), total and conjugated bilirubin.
219429243|NCT06620835|BIOLOGICAL|Pregnancy test|Pregnancy test will be performed in women of childbearing potential, including women who have had a tubal ligation. Childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy or not being postmenopausal (≥12 months of amenorrhea). Urine pregnancy tests will be based on the measurement of β-Human Chorionic Gonadotropin (HCG). If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed at screening.
219429244|NCT06620835|PROCEDURE|Tumour assessment|Tumor assessment according to the RECIST v1.1 include the following radiological evaluation: thoracic CT scan, brain MRI or CT scan (MRI is preferred), abdominopelvic scan, PET-CT scan mandatory and at the Investigator's discretion, if needed bone scintigraphy and chest X-ray.
219429245|NCT06620835|PROCEDURE|Local Ablative Therapy (LAT)|Local Ablative Treatment (LAT) (stereotactic body radiotherapy, surgery, thermal ablation)
219429246|NCT06015932|BEHAVIORAL|Cognitive Behavior Therapy|Participate in CBCSM group sessions
219429247|NCT06015932|OTHER|Questionnaire Administration|Complete questionnaires
219429248|NCT06310824|DRUG|MAB-22|60mg dose of a single subcutaneous injection
219429249|NCT06310824|DRUG|EU-Prolia®|60mg dose of a single subcutaneous injection
219429250|NCT06310824|DRUG|US-Prolia®|60mg dose of a single subcutaneous injection
219429251|NCT04643795|DRUG|MGL-3196|Once daily oral dose for 6 days
219429252|NCT05700201|BEHAVIORAL|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
219429253|NCT05700201|OTHER|standard care|Standard care (psychotherapy)
219429254|NCT04592237|DRUG|Cabazitaxel|Given IV
219429255|NCT04592237|DRUG|Carboplatin|Given IV
219429256|NCT04592237|BIOLOGICAL|Cetrelimab|Given IV
219429257|NCT04592237|DRUG|Niraparib|Given PO
219429258|NCT06731764|DRUG|Levothyroxine|"Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily."
219429259|NCT06731764|DRUG|Levothyroxine/Liothyronine once daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
219566250|NCT04014582|BEHAVIORAL|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
219566251|NCT04014582|BEHAVIORAL|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
219189826|NCT06636513|DIETARY_SUPPLEMENT|SMT04 (M3XTRA)|This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
219189827|NCT04718896|DRUG|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
219189828|NCT04270942|DRUG|teplizumab 1 mg/mL|"Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody).~Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily"
219189829|NCT06776887|DEVICE|The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks|"The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks ."
219189830|NCT06372782|DEVICE|Restylane Skinboosters Vital Lidocaine|Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
219189831|NCT06372782|DEVICE|Restylane Vital|Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
219189832|NCT06144762|BIOLOGICAL|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
219189833|NCT02408276|OTHER|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
219189834|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
219189835|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
219189836|NCT05336682|PROCEDURE|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
219404641|NCT06194136|DEVICE|PBM light therapy|The PBM machine consists of a dual light emitting diode (LED) cluster array with 105 light diodes within the 660 nanometer (nm) red light wavelength and the 850 nm near-infrared light wavelength. These wavelengths are both within the ranges noted in previous literature for neuropathic pain (1) and are within the World Association for Photobiomodulation (Laser) Therapy (WALT) guidelines for PBM therapy (2). Dosage will be determined according to the following equation: Laser output Power (Watts) x Time (seconds) divided by Beam Area (cm2)= J/cm2 (1). The PBM unit generates energy equal to 115 mW/cm2 with a surface area of 54.6 cm x 17 cm. Thus, for a target power output of 3.45 J, the participant will have a continuous irradiation duration of 30 seconds for each application (1). The participant will be asked to utilize the PBM device on breast tissue post-mastectomy for 30 seconds 3 times per week with at least 24 hours between each session. The duration of treatment will be 6 weeks.
219404642|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
219566252|NCT05247931|DIAGNOSTIC_TEST|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
219189837|NCT05166668|DRUG|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
219189838|NCT05958082|BEHAVIORAL|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
219189839|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
219189840|NCT06818591|DIAGNOSTIC_TEST|DEXA(Dual-Energy X-ray Absorptiometry)|Followed for up to 20 years
219189841|NCT06823427|DRUG|9MW2821|a nectin-4 ADC with MMAE payload
219189842|NCT06823427|DRUG|Toripalimab (JS001 )|anit-PD-1 antibody
219189843|NCT06357169|DEVICE|Venus Glow|two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
219189844|NCT06823869|OTHER|musical book|The child will indicate that he wants to play with the musical book. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
219189845|NCT06823869|OTHER|musical piano|The child will indicate that he wants to play with the musical piano. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
219189846|NCT06823869|OTHER|sham|The child will not play with toys during treatment. Before the treatment, the researcher demonstrates the process on himself with a nebul mask. Treatment begins after the child is ready. The process will take 10 minutes.
219189847|NCT03171545|BEHAVIORAL|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
219189848|NCT03171545|BEHAVIORAL|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
219189849|NCT06821529|BIOLOGICAL|ICA07 therapy|4 million iPSC-DAPs will be administrated into the putamen on each side of the brain
219189850|NCT06081309|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
219189851|NCT06015633|OTHER|No intervention|Observational only
219404643|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy with MediNiK|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
219404644|NCT06287489|OTHER|Mediterranean diet|Mediterranean diet for three month
219404645|NCT06287489|OTHER|Regular diet|regular diet
219404646|NCT05896384|DRUG|BI 456906|BI 456906
219404647|NCT05896384|DRUG|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
219404648|NCT06381466|DRUG|AZD0233|Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
219404649|NCT06381466|DRUG|AZD0233 Placebo|Randomized participants will receive matching placebo orally as a SAD or MAD.
219404650|NCT04833933|OTHER|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
219404651|NCT02439281|DRUG|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
219404652|NCT02439281|DRUG|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
219404653|NCT04591912|BEHAVIORAL|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
219404654|NCT03016442|DEVICE|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
219404655|NCT03016442|DRUG|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
219404656|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
219404657|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
219429260|NCT06731764|DRUG|Levothyroxine/Liothyronine twice daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
219429261|NCT05873205|BIOLOGICAL|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
219429262|NCT02378883|DEVICE|Apollo™ Onyx™ Delivery Micro Catheter|
219429263|NCT05756621|DRUG|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution."
219429264|NCT05756621|DRUG|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
219429265|NCT02140619|BEHAVIORAL|multiple health education interventions|
219429266|NCT02220361|DRUG|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
219404658|NCT04986449|BEHAVIORAL|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
219404659|NCT05937269|COMBINATION_PRODUCT|Near-infrared fluorescence lymphatic imaging|All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
219404660|NCT05937269|DEVICE|advanced pneumatic compression therapy|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
219404661|NCT05856773|RADIATION|Proton Therapy|Pencil Beam Scanning (PBS)
219404662|NCT06689085|COMBINATION_PRODUCT|Testosterone enanthate|XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
219404663|NCT00759473|DRUG|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
219404664|NCT00759473|DRUG|Placebo|
219566253|NCT04750668|OTHER|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
219566254|NCT01831986|DIETARY_SUPPLEMENT|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
219755124|NCT07158892|BEHAVIORAL|Informational Statement Only|Participants will be presented with a brief, standardized informational statement describing what the test involves, what it may show, and general risks or limitations. No individualized values-based discussion or simulated conversation will occur.
219404665|NCT01225406|DRUG|Tenofovir|
219404666|NCT02154750|DEVICE|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
219566255|NCT01831986|OTHER|Placebo|Caps
219189852|NCT06821360|DIAGNOSTIC_TEST|C-peptide test|Participants collect a single home finger-prick sample and post to the clinical laboratory for C-peptide analysis (a measure of endogenous insulin production).
219189853|NCT06108687|OTHER|water spray application|cold water kept in the refrigerator at +4 degrees
219189854|NCT05468151|OTHER|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
219189855|NCT05468151|OTHER|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
219566256|NCT00689845|BIOLOGICAL|bleomycin sulfate|Given IV
219566257|NCT00689845|BIOLOGICAL|filgrastim|Given subcutaneously
219566258|NCT00689845|BIOLOGICAL|rituximab|given IV
219566259|NCT00689845|DRUG|cyclophosphamide|Given IV
219566260|NCT00689845|DRUG|cytarabine|Given subcutaneously
219566261|NCT00689845|DRUG|doxorubicin hydrochloride|Given IV
219566262|NCT00689845|DRUG|etoposide phosphate|Given IV
219404667|NCT02154750|DEVICE|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
219404668|NCT03347617|DRUG|Ferumoxytol|Given IV
219566263|NCT00689845|DRUG|ifosfamide|Given IV
219566264|NCT00689845|DRUG|methotrexate|Given IV
219566265|NCT00689845|DRUG|prednisolone|Given orally
219566266|NCT00689845|DRUG|prednisone|Given orally
219566267|NCT00689845|DRUG|vincristine sulfate|Given IV
219404669|NCT03347617|OTHER|Laboratory Biomarker Analysis|Correlative studies
219404670|NCT03347617|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
219404671|NCT03347617|BIOLOGICAL|Pembrolizumab|Given IV
219404672|NCT05473520|DRUG|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
219404673|NCT05473520|DRUG|Placebo|Placebo + standard anti-tuberculous treatment
219404674|NCT05994846|DEVICE|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
219404675|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
219566268|NCT00689845|DRUG|vindesine|Given IV
219566269|NCT02107079|DRUG|Melatonin|swallowing 1 piece, collecting saliva afterwards
219566270|NCT04034355|DRUG|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
219566271|NCT04034355|OTHER|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
219566272|NCT01751919|DRUG|Imatinib mesylate tablet 400 mg, 1 Tablet|
219566273|NCT01751919|DRUG|Glivec film-coated tablet 100 mg, 4 Tablets|
219404676|NCT00498875|BEHAVIORAL|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
219404677|NCT00498875|BEHAVIORAL|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
219404678|NCT04026438|DRUG|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
219404679|NCT04740268|DEVICE|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
219404680|NCT05298033|DRUG|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
219404681|NCT05298033|DRUG|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
219404682|NCT05298033|DEVICE|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
219404683|NCT05298033|DEVICE|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
219404684|NCT05298033|DRUG|Vehicle|Twice daily vehicle ointment
219404685|NCT05384158|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy
219404686|NCT05384158|BEHAVIORAL|valuation with instruction|repeat laboratory sessions of computerized learning game
219404687|NCT05384158|BEHAVIORAL|valuation without instruction|repeat laboratory sessions of computerized learning game
219404688|NCT00931671|OTHER|Exercise training|aerobic exercise training
219404689|NCT06978231|PROCEDURE|EUS+ERCP|EUS were performed during the same session with ERCP under continuous sedation/anesthesia
219566274|NCT05276687|DRUG|Betadine|Wound irrigation
219566275|NCT05276687|DRUG|Vancomycin|instillation in the wound
219404690|NCT06978231|PROCEDURE|ERCP|Only ERCP was performed in the control group
219404691|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every other day.|6mg/kg of oral iron as ferrous sulfate administered every other day instead of 6 mg/kg of oral iron daily supplementation.
219404692|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every day.|6 mg/kg of oral iron as daily ferrous sulfate instead of 6mg/kg of oral iron supplementation administered every other day.
219755125|NCT07158983|OTHER|Registry review|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including registry review of parents to evaluate the effect of the program.
219404693|NCT00045682|DRUG|Paclitaxel Poliglumex|Given IV
219404694|NCT01379534|DRUG|TKI258|
219404695|NCT05730712|PROCEDURE|Biopsy|Undergo biopsy
219404696|NCT05730712|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219404697|NCT05730712|PROCEDURE|Computed Tomography|Undergo CT
219404698|NCT05730712|PROCEDURE|Echocardiography|Undergo ECHO
219404699|NCT05730712|DRUG|Enzalutamide|Given PO
219404700|NCT05730712|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
219404701|NCT05730712|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219404702|NCT05730712|OTHER|Questionnaire Administration|Ancillary studies
219404703|NCT06983405|OTHER|Physical Therapy Program for MDD|PT program for hospitalized adults with MDD: twice-weekly, 45-min sessions integrating: 1) Active joint mobility (gentle movements for ROM). 2) Progressive strength (bodyweight/bands, low-mod intensity, major muscles). 3) Balance (stability exercises, adapted difficulty). 4) Progressive muscle relaxation (end of session). Includes health education: exercise \& mental health link (biological/psychological mechanisms), benefits of each exercise type (mood, function, QoL), post-discharge activity strategies, self-assessment, community resources in Zaragoza. Delivered by trained PTs, adaptable to individual needs.
219404704|NCT04994821|DEVICE|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
219404705|NCT04994821|BEHAVIORAL|Cognitive Reappraisal|Emotion regulation therapy
219404706|NCT04086563|OTHER|Action observation|look at a clip of a hand doing neurodynamic exercises.
219404707|NCT04086563|OTHER|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
219404708|NCT04086563|OTHER|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
219404709|NCT04086563|OTHER|Strength|Execute a short strength training for the dominant hand
219404710|NCT01925001|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
219404711|NCT01925001|DRUG|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
219429267|NCT02220361|DRUG|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
219429268|NCT02220361|DRUG|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
219429269|NCT03064347|DIETARY_SUPPLEMENT|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429270|NCT03064347|DIETARY_SUPPLEMENT|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219189856|NCT05468151|OTHER|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
219189857|NCT06822725|OTHER|Control Group|normals without allergy, those with perennial allergic rhinitis
219189858|NCT06822725|PROCEDURE|Chronic rhinosinusitis (CRS) with and without Nasal Polyposis|Those with and without nasal polyps, and those with acute exacerbations
219404712|NCT06019780|OTHER|blood flow restriction trainin|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
219189859|NCT00476606|DRUG|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
219189860|NCT00476606|DRUG|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
219189861|NCT00476606|DRUG|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
219404713|NCT06019780|OTHER|exercise|"Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
219404714|NCT02026622|BEHAVIORAL|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
219404715|NCT02026622|DEVICE|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
219404716|NCT02026622|DEVICE|transcranial doppler and TPI|transcranial doppler TPI
219404717|NCT02026622|BEHAVIORAL|explicitative interview|
219566276|NCT05898763|DRUG|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
219189862|NCT04386057|DRUG|Hydroxychloroquine Sulfate|HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
219189863|NCT04386057|DRUG|LY3214996|LY3214996-daily oral dosage per protocol per 28 day cycle
219189864|NCT04586855|DIAGNOSTIC_TEST|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
219189865|NCT04586855|DIAGNOSTIC_TEST|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
219189866|NCT06295913|DIETARY_SUPPLEMENT|Group 1, hydroxytyrosol-rich extract capsule|Following a two-week washout period, the subjects will receive a bottle containing capsules (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule.
219404718|NCT05309369|BEHAVIORAL|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
219404719|NCT05309369|BEHAVIORAL|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
219404720|NCT04611685|DRUG|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
219566277|NCT04244006|DRUG|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
219566278|NCT04244006|OTHER|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
219404721|NCT04611685|DRUG|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
219404722|NCT02564848|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
219404723|NCT06605144|DRUG|1- Vasopressor - Mean arterial pressure 56-60|Vasopressor(s) will be titrated according to 56-60 range.
219404724|NCT06605144|DRUG|2- Vasopressor - Mean arterial pressure 61-65|Vasopressor(s) will be titrated according to 61-65 range.
219404725|NCT06605144|DRUG|3- Vasopressor - Mean arterial pressure 66-70|Vasopressor(s) will be titrated according to 66-70 range.
219404726|NCT06605144|DRUG|4- Vasopressor - Mean arterial pressure 71-75|Vasopressor(s) will be titrated according to 71-75 range.
219404727|NCT06605144|OTHER|1- Platelet less than 10 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109/L at the time of the planned procedure.
219404728|NCT06605144|OTHER|2- Platelet less than 20 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109/L at the time of the planned procedure.
219404729|NCT06605144|OTHER|3- Platelet less than 30 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109/L at the time of the planned procedure.
219566279|NCT02190279|DRUG|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
219566280|NCT02190279|DRUG|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
219566281|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
219566282|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
219189867|NCT06295913|DIETARY_SUPPLEMENT|Group 2, capsule of placebo|Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
219189868|NCT06521021|BEHAVIORAL|AVOID|"Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
219189869|NCT06521021|BEHAVIORAL|RESIST|"Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
219566283|NCT02209116|OTHER|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
219566284|NCT04490473|OTHER|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
219566285|NCT00546910|DRUG|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
219566286|NCT00546910|DRUG|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
219566287|NCT01115855|DRUG|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
219566288|NCT01115855|DRUG|Placebo|Placebo once daily or every once daily
219566289|NCT03658863|PROCEDURE|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
219566290|NCT03658863|PROCEDURE|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
219566291|NCT03658863|PROCEDURE|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
219566292|NCT03658863|DEVICE|Ultrasound endoscope|Endoscope with built-in ultrasound function
219189870|NCT05679908|DRUG|TNX-1900|Patients will spray TNX-1900 once into each nostril.
219566293|NCT00116493|DIETARY_SUPPLEMENT|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
219189871|NCT05679908|DRUG|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
219189872|NCT06821932|PROCEDURE|Photofunctionalized dental implant surgery|Dental implants subjected to photofunctionalization were placed in the experimental area of the mouth.
219566294|NCT00116493|DRUG|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
219566295|NCT00116493|DIETARY_SUPPLEMENT|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
219566296|NCT00116493|DRUG|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
219566297|NCT04893122|OTHER|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
219566298|NCT01467479|DRUG|Telaprevir|Tablet
219566299|NCT01467479|DRUG|Ribavirin|Tablet
219566300|NCT01467479|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
219566301|NCT01467479|DRUG|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
219566302|NCT03815240|OTHER|No dressing|no dressing at sacrum
219566303|NCT03815240|OTHER|Mepilex® Border Sacrum|adhesive sacrum dressing
219566304|NCT03815240|OTHER|ALLEVYN Life Sacrum|adhesive sacrum dressing
219566305|NCT03815240|OTHER|Optifoam® Gentle Sacrum|adhesive sacrum dressing
219189873|NCT06821932|PROCEDURE|Dental implant surgery|Dental implants not subjected to photofunctionalization were placed in the bone on the contralateral side of the mouth
219189874|NCT05169762|OTHER|standard treatment|starndard treatment for transgender women
219189875|NCT06566170|DRUG|Donanemab|Administered IV
219566306|NCT03512912|DEVICE|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
219566307|NCT06504498|DEVICE|0.5 mm-thick Duran® clear aligner|0.5 mm-thick clear aligner was used for orthodontic treatment.
219566308|NCT06504498|DEVICE|0.75 mm-thick Duran® clear aligner|0.75 mm-thick clear aligner was used for orthodontic treatment.
219566309|NCT03446365|BEHAVIORAL|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
219566310|NCT03446365|BEHAVIORAL|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
219566311|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
219404730|NCT06605144|OTHER|4- Platelet less than 40 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109/L at the time of the planned procedure.
219404731|NCT06605144|OTHER|5- Platelet less than 50 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109/L at the time of the planned procedure.
219404732|NCT04759248|DRUG|Atezolizumab + Trastuzumab + Vinorelbine|"* Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
219404733|NCT06853483|BEHAVIORAL|Family-School based smoking cessation intervention package|The Family-School based smoking cessation intervention programme will be developed using the multiple strategies provided by the BCW framework, with face-to-face + online as the primary mode of implementation. Specifically, educational training based on the school curriculum will be conducted to create a supportive environment for smokers to quit, guide smokers to discover motivation to quit, encourage smokers to cope with key barriers to quitting, as well as incorporate relapse prevention strategies, using formats such as online videos and supplemental materials, with interventions designed to help students and parents of smokers to understand the health hazards of smoking, to enhance cessation action and supportive skills, and inspire healthy action.
219404734|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
219404735|NCT02228278|BEHAVIORAL|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
219404736|NCT02228278|OTHER|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
219404737|NCT05366855|BIOLOGICAL|Imsidolimab|Solution for infusion; Solution for injection
219566312|NCT03009487|DRUG|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
219566313|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
219566314|NCT03550534|DRUG|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
219566315|NCT03550534|DRUG|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
219755126|NCT07158983|OTHER|Interviews|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including interviews with nurses to evaluate the effect of the program.
219189876|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
219404738|NCT05366855|OTHER|Placebo|Solution for injection
219404739|NCT03202316|DRUG|Atezolizumab|Given IV
219404740|NCT03202316|DRUG|Cobimetinib|Given PO
219404741|NCT03202316|DRUG|Eribulin|Given IV
219404742|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566316|NCT02327793|DRUG|Nitroglycerin|
219189877|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 80 Gy
219566317|NCT02327793|DRUG|Labetalol|
219566318|NCT03297567|BEHAVIORAL|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
219566319|NCT04514055|PROCEDURE|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
219755127|NCT07160790|DRUG|JP-1366 + placebo|taking JP-1366 + placebo
219755128|NCT07160790|DRUG|Placebo + Placebo|taking placebo + placebo
219755129|NCT07160218|DEVICE|tDCS|A 30-minute tDCS session with the cathode placed over the left dorsolateral prefrontal cortex (DLPFC), delivered in 10 sessions over 2 weeks. This protocol targets cognitive improvement in MS patients
219755130|NCT07160218|DEVICE|Cognitive Rehabilitation|computer-based cognitive rehabilitation exercises. Conducted in 10 sessions over 2 weeks to enhance attention, memory, and neuroplasticity in MS patients.
219404743|NCT03202316|OTHER|Pharmacological Study|Correlative studies
219404744|NCT06609668|BIOLOGICAL|Additional blood samples|"* 1 dry tube (5 mL)~* 1 EDTA tube (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)"
219404745|NCT06858813|DRUG|Lenvatinib|Oral Capsule
219404746|NCT06858813|DRUG|ABBV-324|Intravenous (IV) Infusion
219404747|NCT00515372|OTHER|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
219404748|NCT00515372|OTHER|Usual Care|Lists of professional resources and referral recommendations will be provided.
219404749|NCT02738827|PROCEDURE|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
219189878|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 130 Gy
219566320|NCT06417164|BEHAVIORAL|Functional Movement Training Group|The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
219566321|NCT00401284|DRUG|EVT 201|
219566322|NCT01915940|DRUG|Bimatoprost|Bimatoprost ocular insert
219566323|NCT01915940|DRUG|Timolol 0.5%|Timolol 0.5% solution
219566324|NCT01915940|DRUG|Placebo Eye Drops|Placebo topical eye drops
219404757|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
219566325|NCT01915940|DEVICE|Placebo Ocular Insert|Ocular insert without any active drug
219566326|NCT06400108|OTHER|Dementia Moves|"Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities."
219189879|NCT06137677|OTHER|Sweet Snack|A sweet food will be served for the snack
219189880|NCT06137677|OTHER|Savory Snack|A savory food will be served for the snack
219404758|NCT06992804|OTHER|sham NirsCure with Lecanemab|Sham near-infrared light therapy (where only the equipment appearance is consistent with the true near infrared light device, one session per day, 30 minutes per session, 6 sessions per week) in combined with lecanemab (10mg/kg).
219404759|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
219404760|NCT00552539|OTHER|'educational video'|'educational video'
219404761|NCT06600659|OTHER|Non-Interventional Study|Non-interventional study
219404762|NCT06991153|DEVICE|Lung Boost Device Training|Patients in the experimental group will train with the Lung Boost Respiratory Trainer (MD800) for 8 weeks, three times weekly, totaling 24 sessions. The procedure will be explained, and equipment sanitized before use. Training begins in strength mode at level 1, where patients inhale deeply through a mouthpiece, with feedback provided via on-screen balls. If level 5 is easily reached, resistance increases using a cone, restarting at level 1. Sessions include 15 repetitions of 2-3 second inhalations and exhalations, performed in three sets with 15-second rests to prevent fatigue. In endurance mode, patients inhale or exhale as long as possible, progressing gradually from level 1. Each session lasts 15 minutes, divided into three sets of five breaths with 15-second rests. This structured program enhances respiratory muscle strength and endurance.
219404763|NCT06991153|OTHER|Traditional physical therapy program|Patients in both groups will receive a traditional physical therapy program for the chest in form of diaphragmatic breathing exercise and pursed-lip breathing exercise for 8 weeks.
219404764|NCT06991153|DRUG|Medical Treatment|Patients in both groups will receive medical treatment for 8 weeks.
219404765|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
219404766|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
219566327|NCT05686148|OTHER|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
219566328|NCT02619448|DRUG|Carboplatin|chemotherapy
219566329|NCT02619448|DRUG|Paclitaxel|chemotherapy
219566330|NCT02619448|RADIATION|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
219566331|NCT02960438|DRUG|E6011|subcutaneous administration
219566332|NCT02960438|DRUG|Placebo|subcutaneous administration
219566333|NCT04933786|BEHAVIORAL|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
219566334|NCT03380520|DRUG|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
219566335|NCT03380520|DRUG|Placebo|IV nacl 0.9%
219566336|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
219404767|NCT00923910|DRUG|WT1 Peptide-Pulsed Dendritic Cells|
219566337|NCT01578668|DRUG|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
219566338|NCT01578668|DRUG|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
219404768|NCT00923910|DRUG|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
219404769|NCT00923910|DRUG|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
219566339|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
219404770|NCT00923910|DRUG|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
219404771|NCT00923910|DRUG|WT1 Peptides|dendritic cell vaccine
219404772|NCT00923910|DRUG|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
219404773|NCT00923910|DRUG|Diphenhydramine|Pre-medication
219566340|NCT06614660|OTHER|Metabolism genomics and imaging genomics|Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
219566341|NCT03326986|DRUG|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
219566342|NCT03326986|DRUG|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
219566343|NCT01546324|PROCEDURE|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
219566344|NCT05618535|DEVICE|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
219566345|NCT06446310|DRUG|QLG2198|Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
219566346|NCT06446310|DRUG|Placebo|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
219566347|NCT01316419|DRUG|Telmisartan|Telmisartan 40mg or 80mg
219566348|NCT01316419|DRUG|amlodipine|amlodipine 5mg or 10mg
219404774|NCT00923910|DRUG|Acetaminophen|Pre-medication
219404775|NCT05372575|BIOLOGICAL|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
219404776|NCT03746574|BEHAVIORAL|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
219404777|NCT05797350|DEVICE|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
219404778|NCT00009594|PROCEDURE|Naturopathic Medicine|
219404779|NCT00009594|PROCEDURE|Traditional Chinese Medicine|
219404780|NCT01096550|BEHAVIORAL|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
219566349|NCT04645979|OTHER|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
219566350|NCT02999984|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
219566351|NCT02999984|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
219566352|NCT02999984|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
219566353|NCT05402306|OTHER|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
219007121|NCT02089633|BIOLOGICAL|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
219404781|NCT01096550|BEHAVIORAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
219404782|NCT00275405|DRUG|Garlic Oil Macerate|
219404783|NCT00170157|DRUG|Bicalutamide|Given orally
219404784|NCT00170157|DRUG|Flutamide|Given orally
219404785|NCT00170157|DRUG|Goserelin Acetate|Given SC
219404786|NCT00170157|DRUG|Ipilimumab|Given IV
219404787|NCT00170157|DRUG|Leuprolide Acetate|Given IM
219404788|NCT00170157|OTHER|Pharmacological Study|Correlative study
219566354|NCT01304420|DEVICE|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
219566355|NCT04877171|OTHER|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
219566356|NCT04877171|OTHER|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
219566357|NCT03363477|DRUG|Enoxaparin|
219566358|NCT03363477|DRUG|Clexane|
219566359|NCT02611011|DEVICE|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
219404789|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
219404790|NCT02226614|DEVICE|University of Edinburgh head cooling device|head cooling
219404791|NCT05592470|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
219566360|NCT00513552|DRUG|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
219566361|NCT01556282|DEVICE|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
219566362|NCT00455962|DRUG|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
219566363|NCT00455962|DRUG|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
219566364|NCT00002829|BIOLOGICAL|Recombinant Interferon Alfa|Daily
219566365|NCT00002829|DRUG|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
219566366|NCT00002829|DRUG|Etoposide|Administered intravenously on Day -8
219566367|NCT00002829|DRUG|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
219566368|NCT00002829|PROCEDURE|Bone Marrow Transplantation|Infusion on Day 0.
219566369|NCT00002829|RADIATION|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
219002244|NCT01984177|DRUG|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
219404792|NCT02495649|OTHER|[18F]-DOPA|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
219404793|NCT02495649|DEVICE|PET-CT|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
219404794|NCT00001693|DRUG|Celecoxib (SC-58635)|
219566370|NCT00347529|BIOLOGICAL|pPML7789 with and without pPJV2012 administered by PMED|
219566371|NCT00388895|DRUG|chemotherapy|
219566372|NCT00388895|DRUG|Glivec|
219566373|NCT03609281|RADIATION|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
219566374|NCT01882179|DRUG|Mineralocorticoid receptor antagonist potassium-canrenoate|
219566375|NCT01882179|DRUG|placebo|
219566376|NCT05118516|DRUG|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
219404795|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
219002245|NCT02706691|DRUG|BGJ398|Given by mouth (oral)
219566377|NCT04039919|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
219566378|NCT04039919|DRUG|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
219566379|NCT00754013|DRUG|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
219566380|NCT00754013|DRUG|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
219566381|NCT02310789|DRUG|Ivacaftor|150mg administered orally twice daily.
219566382|NCT02310789|DRUG|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
219566383|NCT02310789|DRUG|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
219566384|NCT02310789|DEVICE|Macroduct sweat stimulator|
219566385|NCT05406024|DEVICE|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
219566386|NCT00164034|DEVICE|Real time computer prompted trauma algorithms|
219566387|NCT01347658|DIETARY_SUPPLEMENT|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
219566388|NCT02704234|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
219566389|NCT02704234|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
219755131|NCT07160218|DEVICE|Sham tDCS|Sham stimulation applied over the left DLPFC for 30 minutes, mimicking the sensation of tDCS without delivering active current, over 10 sessions, used as control to blind participants to the intervention
219755132|NCT07160868|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure - device to be used at night in the treatment of sleep apnoea
219755133|NCT07160179|DRUG|ABBV-6628|Intravitreal injection
219189881|NCT06641375|DEVICE|Anti reflux endoscopic theraphy|"o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
219189882|NCT06641375|OTHER|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
219404796|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
219189883|NCT05592275|DRUG|LY3540378|Administered SC
219189884|NCT05592275|DRUG|Placebo|Administered SC
219404797|NCT01901133|DRUG|MDV3100|Oral
219404798|NCT00518453|BIOLOGICAL|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
219404799|NCT02703805|OTHER|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
219404800|NCT02703805|OTHER|Standard YMCA membership|A 12 week standard YMCA membership.
219404801|NCT01544595|DRUG|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
219404802|NCT01544595|DRUG|Placebo|Placebo
219404803|NCT04525222|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via text notifications
219404804|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Actify app)|Use Actify app
219404805|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
219404806|NCT04525222|OTHER|Survey Administration|Ancillary studies
219404807|NCT05262595|DRUG|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
219404808|NCT05262595|DRUG|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
219404809|NCT05262595|DRUG|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
219404810|NCT05262595|DRUG|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
219404811|NCT02384499|BIOLOGICAL|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
219404812|NCT02384499|DRUG|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
219404813|NCT02114632|DIETARY_SUPPLEMENT|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
219404814|NCT02508727|OTHER|MRI|
219404815|NCT02508727|OTHER|3D cardiac ultrasound|
219755134|NCT07160179|DRUG|SYFOVRE|Intravitreal injection
219002246|NCT03647982|DRUG|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
219404816|NCT01401829|BEHAVIORAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
219002247|NCT03647982|DRUG|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
219404817|NCT01401829|BEHAVIORAL|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
219404818|NCT01401829|BEHAVIORAL|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
219404819|NCT03699839|BIOLOGICAL|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
219755135|NCT07159880|DRUG|Letrozole (aromatase inhibitor)|"Participants will be randomized into two groups:~Extended therapy group: 5 mg/day of letrozole for 10 days (cycle days 2-12). Standard therapy group: 5 mg/day of letrozole for 5 days (cycle days 2-6)."
219755136|NCT07158814|DRUG|Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody|ACIP Recommended Preventive Monoclonal Antibody
219404820|NCT03699839|BIOLOGICAL|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
219404821|NCT03699839|BIOLOGICAL|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
219404822|NCT02985125|DRUG|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
219404823|NCT02985125|DRUG|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
219404824|NCT00355004|OTHER|counseling intervention|
219404825|NCT00355004|PROCEDURE|fecal occult blood test|
219404826|NCT00355004|PROCEDURE|screening colonoscopy|
219404827|NCT04461847|PROCEDURE|subcutaneous mastectomy|Operating subcutaneous mastectomy
219404828|NCT04461847|PROCEDURE|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
219404829|NCT06993597|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
219404830|NCT06993597|DRUG|Beta Blocker|Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
219404831|NCT06993597|DEVICE|Brillouin Microscopy|Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
219404832|NCT02615717|BEHAVIORAL|Attention Bias Modification|comparison of treatment versus control
219404833|NCT04333433|DEVICE|PRESERFLO® MicroShunt|Device surgically implanted
219566390|NCT05649735|DEVICE|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
219566391|NCT05649735|DEVICE|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
219566392|NCT05649735|OTHER|Placebo|Sterile saline solution
219566393|NCT05703035|PROCEDURE|standby while firing staple|VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
219189885|NCT05500885|DEVICE|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
219404834|NCT04333433|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
219404835|NCT02434315|DEVICE|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
219404836|NCT02434315|DEVICE|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
219404837|NCT02434315|DEVICE|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
219404838|NCT00320385|DRUG|Lapatinib|oral lapatinib once daily
219404839|NCT00320385|BIOLOGICAL|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
219404840|NCT01598727|DEVICE|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
219404841|NCT06514469|DRUG|Sufentanil intravenous administration followed consultation of remote physician|Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
219404842|NCT06514469|DRUG|Sufentanil intravenous administration based on paramedic competency|Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
219404843|NCT02429596|DRUG|Experimental|Switch from brand to generic
219404844|NCT00376402|BIOLOGICAL|H5N1 Pandemic Influenza Vaccine|
219404845|NCT00713401|DRUG|Tecadenoson|Tecadenoson administered intravenously (i.v.)
219404846|NCT00713401|DRUG|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
219404847|NCT04240067|DIAGNOSTIC_TEST|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
219404848|NCT04470310|DRUG|Glimepiride|
219404849|NCT04470310|DRUG|Alogliptin 25Mg Tab|
219404850|NCT04470310|DRUG|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
219404851|NCT01704781|DRUG|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
219404852|NCT01704781|DRUG|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
219189886|NCT05500885|OTHER|Standard rehabilitation and sham PEMF therapy for CAI|Balance training and muscle strengthening
219189887|NCT06821828|COMBINATION_PRODUCT|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. The advantages of the improved device are as follows: bi-directional airflow, positive pressure and the function of voice prompts and automatic counting.
219002248|NCT05746949|PROCEDURE|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
219404853|NCT01704781|DRUG|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
219404854|NCT01704781|DRUG|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
219404855|NCT02702908|OTHER||Historical Reference group.
219404856|NCT03288779|DEVICE|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
219404857|NCT01222338|BIOLOGICAL|V-5 immunitor|once per day dosing for 2 months
219404858|NCT02526927|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
219404859|NCT02526927|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
219404860|NCT02526927|OTHER|Blood samples|
219404861|NCT01355068|DRUG|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
219404862|NCT01355068|DRUG|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
219404863|NCT02110810|DRUG|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
219404864|NCT02110810|DRUG|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
219404865|NCT05590195|DRUG|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
219404866|NCT05590195|OTHER|Placebo|Placebo capsules manufactured to look like Preforpro capsules
219404867|NCT00524745|BIOLOGICAL|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
219404868|NCT02883465|PROCEDURE|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
219404869|NCT03702582|DRUG|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
219404870|NCT03702582|DRUG|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
219404871|NCT02689336|BIOLOGICAL|Erlotinib|
219404872|NCT02689336|DRUG|Temozolomide|
219404873|NCT02028364|DRUG|Everolimus|10mg orally daily
219404874|NCT02028364|DRUG|Exemestane|25mg orally daily
219404875|NCT00872170|DRUG|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
219404876|NCT01571037|DRUG|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
219404877|NCT01571037|DRUG|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
219404878|NCT03767205|DEVICE|Ankle Assist Robot|"1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
219566394|NCT02049021|DEVICE|MECTA SPECTRUM 5000Q ECT|
219404879|NCT02659111|OTHER|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
219404880|NCT02659111|OTHER|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
219404881|NCT06671093|GENETIC|Tune-401|Epigenetic gene silencing therapy
219566395|NCT02049021|PROCEDURE|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
219566396|NCT00983918|DRUG|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
219566397|NCT00983918|DRUG|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
219755137|NCT07161024|DEVICE|Augmented reality|Augmented reality markers of different designs are tested to evaluate how they affect trainee performance.
219404882|NCT04323709|OTHER|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
219404883|NCT04323709|OTHER|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
219566398|NCT00983918|DRUG|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
219566399|NCT00983918|DRUG|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
219566400|NCT03736187|DRUG|Cephalexin|Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
219566401|NCT02477852|DRUG|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
219566402|NCT02477852|DRUG|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
219566403|NCT02477852|DRUG|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
219566404|NCT02477852|DRUG|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
219566405|NCT00282750|DEVICE|Bar coded sponge and scanner|
219566406|NCT03082235|DRUG|E6742|gelatin capsules
219566407|NCT03082235|DRUG|Placebo|gelatin capsules
219566408|NCT02265172|PROCEDURE|Physiotherapy screening|Physiotherapy screening.
219566409|NCT02265172|PROCEDURE|Standard practice|Orthopaedic surgeon assessment
219566410|NCT02804555|OTHER|Oxygen|Oxygen administration
219566411|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules|As previously published
219566412|NCT01205841|PROCEDURE|Buffalo Rule|As previously published
219566413|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
219566414|NCT01205841|PROCEDURE|Thompson Test|As previously published
219566415|NCT01205841|PROCEDURE|Palpation of the fibula|Palpation of the fibula over its entire length.
219566416|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
219566417|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
219566418|NCT01205841|PROCEDURE|Malleolar Zone Algorithm|As previously published
219566419|NCT01205841|PROCEDURE|Low Risk Exam|As previously published
219566420|NCT01205841|PROCEDURE|Bernese Ankle Rules|As previously published
219566421|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
219566422|NCT02604472|OTHER|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
219755138|NCT05287373|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
219755139|NCT05287373|OTHER|conventional medical management|Conventional medical management
219755140|NCT07161206|BEHAVIORAL|Digital Mindfulness Nudge Intervention|Participants will be guided through 28 Days of Mindfulness Exercises via a Telegram Channel (In a digital and nudge-based format)
219755141|NCT07160114|DEVICE|Electrical Stimulation Glove with Task-Oriented Training|Participants perform structured task-oriented training while wearing an electrical stimulation glove. The glove is embedded with electrodes that deliver low-intensity electrical impulses to the wrist and finger muscles during functional tasks. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard tasks, object manipulation, writing, and daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
219566423|NCT02604472|OTHER|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
219566424|NCT01197417|DRUG|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
219566425|NCT01197417|DRUG|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
219566426|NCT02575508|DRUG|Fluorouracil|Given IV
219566427|NCT02575508|DRUG|Irinotecan Hydrochloride|Given IV
219566428|NCT02575508|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566429|NCT02575508|DRUG|Oxaliplatin|Given IV
219566430|NCT02575508|DRUG|pan FGFR Kinase Inhibitor BGJ398|Given IV
219566431|NCT02575508|OTHER|Pharmacological Study|Correlative studies
219566432|NCT01572519|DRUG|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
219566433|NCT01572519|DRUG|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
219404884|NCT03400696|BEHAVIORAL|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
219404885|NCT03400696|BEHAVIORAL|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
219404886|NCT03400696|BEHAVIORAL|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
219404887|NCT04290962|BEHAVIORAL|Lifestyle Therapy|Complete web-based lifestyle intervention
219404888|NCT04290962|OTHER|Quality-of-Life Assessment|Ancillary studies
219404889|NCT04290962|OTHER|Questionnaire Administration|Ancillary studies
219404890|NCT01225640|DRUG|PNU-100480|600 mg twice daily (BID) for 14 days
219566434|NCT01572519|DRUG|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
219566435|NCT01572519|DRUG|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
219566436|NCT01572519|DRUG|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
219566437|NCT02560974|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
219566438|NCT02560974|DRUG|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
219566439|NCT00832221|DRUG|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
219566440|NCT00832221|DRUG|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
219566441|NCT00832221|DRUG|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
219566442|NCT01106521|RADIATION|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
219566443|NCT02771106|OTHER|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
219755142|NCT07160114|BEHAVIORAL|Task-Oriented Training Only|Participants receive task-oriented training without the electrical stimulation glove. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard placement, grasp-and-release, writing or drawing, and simulated daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
219755143|NCT07160738|DRUG|PF-07220060|Tablet given orally
219755144|NCT07160738|DRUG|Itraconazole|Capsule given orally
219755145|NCT07160738|DRUG|Probenecid|Tablet given orally
219755146|NCT07158606|DRUG|efanesoctacog alpha|Efanesoctacog alpha will be administered at a dose of 50 IU/kg two times weekly during the ITI Treatment Period. The site investigator will determine the dose of efanesoctacog alpha once the subjects reaches the Follow Up Period.
219755147|NCT07158606|DRUG|Emicizumab|Emicizumab will be prescribed as standard of care bleed prevention.
219755148|NCT07161505|DEVICE|TBS-EEG|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
219755149|NCT07161505|DEVICE|TBS-EEG / Spatial Control|Theta-burst stimulation (TBS) over the postcentral gyrus, synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
219755150|NCT07161505|DEVICE|TBS / Temporal Control|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) at a suprathreshold pulse intensity (up to 120% rMT).
219755151|NCT07161505|DEVICE|TBS-EEG / Dose Control|"Theta-burst stimulation (TBS) similar to the TBS-EEG condition but at a subthreshold pulse intensity (up to 80% rMT)."
219755152|NCT07158866|BEHAVIORAL|Ballroom Dance|"The intervention will involve twice-weekly dance sessions, lasting 45 minutes each, for 6 months. Each session will include:~1. Rhythmic warm-up with music.~2. Combination of aerobic, resistance, and coordination exercises.~3. Technical development and learning of dance routines.~4. Cool down with free-body movements to slow music."
219404891|NCT01225640|DRUG|PNU-100480|1200 mg once daily (QD) for 14 days
219404892|NCT01225640|DRUG|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
219404893|NCT04247022|OTHER|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
219404894|NCT01721408|DRUG|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
219404895|NCT01721408|DRUG|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
219404896|NCT04951648|DRUG|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
219404897|NCT04951648|DRUG|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
219404898|NCT06866262|PROCEDURE|Biopsy|Undergo biopsy
219404899|NCT06866262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219404900|NCT06866262|PROCEDURE|Computed Tomography|Undergo CT
219566444|NCT05558449|DEVICE|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
219404901|NCT06866262|DIETARY_SUPPLEMENT|Inulin|Given PO
219404902|NCT06866262|BIOLOGICAL|Ipilimumab|Given IV
219404903|NCT06866262|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219404904|NCT06866262|BIOLOGICAL|Nivolumab|Given IV
219404905|NCT06866262|OTHER|Questionnaire Administration|Ancillary studies
219404906|NCT07003763|DEVICE|Electroacupuncture treatment|"Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms.~* Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6).~* Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3).~All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes."
219404907|NCT07003763|OTHER|Superficial acupuncture at Non-Acupoints|"Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the electroacupuncture group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered.~All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, adhesive pads will be gently affixed to the designated locations. A blunt-tipped, retractable needle will then be used to lightly tap the pad, without penetrating the skin, until the patient perceives a tactile sensation, at which point the stimulation will be stopped. The needle will be retained for 30 minutes."
219404908|NCT07003763|OTHER|Standard care|"All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes:~* Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated.~* Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies.~* Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects."
219404909|NCT06244537|RADIATION|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
219404910|NCT04080154|DRUG|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
219404911|NCT03421990|PROCEDURE|General anesthesia|general anesthesia and regional anesthesia techniques are used
219404912|NCT04122001|DEVICE|Active, in-person HD-tDCS or active remote tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes. In the active, in-person HD-tDCS the current is delivered in a ring configuration. In the active remote tDCS current is delivered in one electrode patch.
219404913|NCT04122001|DEVICE|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
219404914|NCT04122001|OTHER|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
219755153|NCT07158866|BEHAVIORAL|Multicomponent Exercise|"The Multicomponent Exercise intervention will target several physical fitness components simultaneously, including strength, balance, and aerobic fitness. The program will consist of twice-weekly sessions, each lasting 45 minutes, for 6 months. Each session will include:~1. Warm-up with light stretching and joint mobility exercises.~2. Balance exercises~3. Strength training exercises~4. Aerobic exercises~5. Cool down with flexibility and relaxation exercises."
219755154|NCT07159139|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
219189888|NCT06821828|COMBINATION_PRODUCT|Conventional olfactory training device|This device involves four brown glass jars (total volume 5 mL) with one of the four odors in each (1mL each, soaked in cotton pads to prevent spilling). The following odors were used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. All jars were labeled with the odor name.
219189889|NCT06815328|OTHER|Shock Wave Therapy (SWT)|"Focused SWT sessions targeting spastic muscle groups. Parameters include standardized frequency, energy level, and session duration (30 minutes per session, once weekly for 8 weeks). This therapy aims to reduce muscle spasticity, improve joint mobility, and enhance quality of life.~Standard care consisting of physical therapy sessions (e.g., stretching, mobility exercises) and/or prescribed medications for spasticity management. The therapy follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
219189890|NCT06815328|OTHER|Active Comparator - Conventional Therapy|"Standard care consisting of physical therapy sessions (stretching, mobility exercises) and/or prescribed medications for spasticity management.~Follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
219404915|NCT06693128|DRUG|Camrelizumab|Camrelizumab 200mg
219404916|NCT06693128|DRUG|Apatinib|Apatinib 250mg
219404917|NCT06693128|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
219404918|NCT06695325|DIAGNOSTIC_TEST|HbA1c test|Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
219404919|NCT06688136|DRUG|ropivacaine|Ropivacaine 200 mg diluted to 50 mL
219404920|NCT06631833|BEHAVIORAL|Intervention measures based on the YPAP model.|The intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. The intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. At the end of the intervention period, relevant questionnaires were used for measurement.
219404921|NCT06701851|BEHAVIORAL|Voluntary and involuntary conditions|"An task fMRI/EEG acquisition during the prodromal phase preceding the episode of abnormal movements.~A task fMRI/EEG acquisition the episode of abnormal movements A task fMRI/EEG acquisition when the subject voluntary mimics the sequence of events (prdrosomal phase + episode of dyskinesia)"
219755155|NCT07160569|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST)|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST), resistome, viruloma, and phenotypic resistance of CRE
219755156|NCT07161050|BEHAVIORAL|Nicotine Content|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
219755157|NCT07161050|BEHAVIORAL|Illegal cigarette price|At each level of nicotine content, we will manipulate the price of illegal cigarettes (1xMP, 1.5x MP, 2x MP). MP is market price.
219404922|NCT06292494|DEVICE|Exablate 4000 Transcranial MRgfUS System|Focused ultrasound interrupt structure of epilepsy network to improve seizure.
219404923|NCT03654248|BEHAVIORAL|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
219404924|NCT03654248|DEVICE|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
219404925|NCT06692101|OTHER|oral care|We prepared the necessary tools and suction devices, then helped patients sit upright before starting oral care. Using a flashlight and toothbrush, we assessed the mouth and removed any food debris, aspirating saliva if needed. We cleaned the teeth using a toothbrush, dental floss, and an interdental brush with a small amount of fluoridated toothpaste. The Bass method was used for brushing. Finally, we cleaned the front two-thirds of the tongue with a damp toothbrush.
219404926|NCT06692101|DEVICE|Neuromuscular Electrical Stimulation (NMES)|We used the VitalStim® device to deliver neuromuscular electrical stimulation (NMES). Before placing the electrodes, participants were asked to shave any facial hair and clean their neck skin with alcohol wipes. We positioned four electrode pads horizontally, above and below the hyoid bone. The device provided stimulation at a pulse rate of 80 Hz with a biphasic pulse duration of 300 microseconds. Each session lasted 30 minutes, with the intensity gradually increased in 0.5 mA intervals, based on the patient's comfort level, and adjusted to their maximum tolerance.
219404927|NCT06693544|DIETARY_SUPPLEMENT|Peanut protein|Commercially available plant-based protein powders
219404928|NCT06693388|OTHER|Exercise|2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting
219404929|NCT06693388|OTHER|Whole-Body Vibration|WBV prior to serial casting
219404930|NCT06693388|OTHER|Serial Casting|Serial Casting as provided by standard of care
219404931|NCT04349254|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
219404932|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
219404933|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
219404934|NCT07030283|DRUG|Paclitaxel|Paclitaxel is a chemotherapy medication that is FDA-approved to treat a number of cancer types. In this study, paclitaxel will be administered via the intraperitoneal port. Intraperitoneal paclitaxel is not FDA approved for pancreatic cancer.
219755158|NCT07161050|BEHAVIORAL|E-cigarette price|At each level of nicotine content and illegal cigarette price, we will manipulate the price of e-cigarettes (1xMP, 1.5x MP, 2x MP). MP is the market price.
219755159|NCT07160647|DRUG|Ipalolimab and Tovorilimab|1.Active Ingredients: Ipalolimab and Tovorilimab (a dual-functional combination antibody consisting of Ipalolimab, a recombinant humanized monoclonal antibody targeting programmed death receptor-1 \[PD-1\], and Tovorilimab, a recombinant humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein-4 \[CTLA-4\]). 2.Specification: 50 mg (2 mL) per vial. 3.Dosage and Administration: Administer via intravenous infusion at a recommended dose of 5 mg/kg every 3 weeks.
219404935|NCT07030283|DRUG|NALIRIFOX|NALIRIFOX is a systemic chemotherapy treatment for metastatic pancreatic cancer that was approved by the FDA in February 2024. It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.
219404936|NCT06713083|OTHER|Exercise|Specifically designed and structured exercise program (based on resistance/strength, designed to be executed in bed or minimal mobility). It is an adaptation from the exercise program described by Brun CR et al (Brun CR, Shoemaker JK, Bocking A, Hammond JA, Poole M, Mottola MF. Bed-rest exercise, activity restriction, and high-risk pregnancies: a feasibility study. Applied Physiology, Nutrition, and Metabolism. 2011;36(4):577-582).
219404937|NCT06713694|OTHER|cognitive-behavioral therapy|The treatment will consist of eight weekly sessions, each lasting one hour. The first session will focus on the rationale of cognitive behavioral therapy, i.e. the influence of (irrational or dysfunctional) cognitions and attitudes on (restrictive) feelings and behaviors. Additionally, goal setting will be initiated. Since patients may have a wide diversity of psychiatric problems (i.e. PTSD, anxiety disorders and depression), the treatment manual will encompass five optional modules for the therapist that focus on each of these disorders (i.e. exposure based for anxiety and PTSD, behavioral activation for depression). The subsequent sessions (2-6) will target teaching the patient to identify and challenge dysfunctional cognitions and attitudes related to IBD. Each session will address specific illness-related cognitions. If possible, dysfunctional cognitions and attitudes will be replaced by helpful cognitions and attitudes.
219404938|NCT06713694|OTHER|Wait first, then cognitive-behavioral therapy|participants assigned to the waiting-list control condition will wait 3.5 months before they are treated with CBT. This period corresponds to the duration of the CBT intervention and follow-up assessment of the experimental group. After this 3.5 month waiting period the participants in the waiting-list control condition will be asked to complete a follow-up after waiting/baseline before CBT assessment before starting treatment.
219404939|NCT07031297|DIAGNOSTIC_TEST|Meal Study|"Participants will consume a mixed meal drink (Ensure) equivalent to 40% of basil metabolic rate as calculated via Harris Benedict equation.~Following consumption of the drink they will undergo a series of blood draws over the following 4 hours:~* Plasma glucose will be measured according to a mixed meal test protocol every 10 minutes for the first hour and then every 15, then 30 minutes for the last 3 hours.~* 1 ml plasma aliquots for exosome analysis and insulin concentrations will be drawn every 30 minutes following consumption of ensure for 4 hours.~* Blood gasses will be drawn every 30 minutes for the 4 hours following the meal.~Participants will undergo a second abdominal adipose tissue biopsy 3 hours following mixed meal drink."
219404940|NCT02991053|DRUG|ketamine|
219404941|NCT06704724|DRUG|PF-07985045|KRAS inhibitor
219404942|NCT06704724|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
219404943|NCT06704724|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
219404944|NCT06704724|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
219002249|NCT04382339|DRUG|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
219404945|NCT06704724|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
219404946|NCT06704724|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
219404947|NCT06704724|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
219404948|NCT06704724|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
219404949|NCT06704724|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor
219404950|NCT06704724|COMBINATION_PRODUCT|Sasanlimab|immune checkpoint inhibitor (PD-1 inhibitor)
219404951|NCT06704724|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
219404952|NCT06704724|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
219404953|NCT06704724|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
219404954|NCT06704724|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
219002250|NCT00904644|DRUG|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
219002251|NCT03196102|BEHAVIORAL|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
219404955|NCT06704724|COMBINATION_PRODUCT|PF-07284892|SHP2 Inhibitor
219404956|NCT06686030|DRUG|AK112 low dose|10mg/kg, Q3W, ivgtt
219404957|NCT06686030|DRUG|Chemotherapy|ivgtt
219404958|NCT06686030|DRUG|Olaparib|bid, oral
219404959|NCT06686030|DRUG|AK112 high dose|20mg/kg, Q3W, ivgtt
219404960|NCT07036458|DRUG|14C Epaminurad Oral Solution|Subjects will receive a single administration of 14C Epaminurad Oral Solution
219404961|NCT03227848|DEVICE|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
219404962|NCT02684240|DRUG|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
219404963|NCT02684240|OTHER|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
219404964|NCT07043335|DEVICE|Extracorporeal Shock Wave Therapy|For patients in Group 2, Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.
219404965|NCT07043335|PROCEDURE|Mesotherapy|Intradermal mesotherapy involving lidocaine, pentoxifylline, meloxicam, and thiocolchicoside will be applied to painful elbow points using a 4 mm, 30G needle in a point-by-point technique at a 90° angle (0.1 cc per point). A nappage technique at a 45° angle will then be applied around the common extensor tendon. A total of five sessions will be administered, one every 7 days.
219007122|NCT03297996|DIAGNOSTIC_TEST|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
219404966|NCT01064648|DRUG|Cediranib Maleate|Given orally
219404967|NCT01064648|DRUG|Cisplatin|Given IV
219566445|NCT05558449|DRUG|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
219404968|NCT01064648|OTHER|Laboratory Biomarker Analysis|Correlative studies
219404969|NCT01064648|DRUG|Pemetrexed Disodium|Given IV
219404970|NCT01064648|OTHER|Placebo Administration|Given orally
219404971|NCT06722846|BEHAVIORAL|Randomized Case Vignette Study|Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.
219404972|NCT06731933|DRUG|BVEC|The study drug will be administered by home nurse at Subjects home for the participants residing in US. No drug will be applied when at study site. The subjects enrolled in Bari, Italy will not be administered BVEC.
219566446|NCT05558449|DEVICE|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
219404973|NCT06733519|DRUG|Nalmefene|Th-104 Nalmefene Mucoadhesive Buccal strip
219404974|NCT06733519|DRUG|Placebo|Matching placebo to TH-104
219404975|NCT06741189|OTHER|Home monitoring|"The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child.~An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home.~The response will be standardized on the basis of a protocol shared by the 4 investigating centers."
219404976|NCT06741189|OTHER|usual medical monitoring|"During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures."
219566447|NCT00374075|DRUG|Valproic Acid|
219566448|NCT06403072|DIAGNOSTIC_TEST|The Gynecologic Imaging-Reporting and Data System (GI-RADS)|The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound
219566449|NCT06052020|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
219566450|NCT06052020|DRUG|Atorvastatin|Atorvastatin 20-40mg
219566451|NCT00699530|OTHER|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
219007123|NCT01481233|DRUG|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
219007124|NCT04071496|OTHER|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
219007125|NCT01390311|DRUG|Azacitidine|
219007126|NCT01390311|DRUG|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
219007127|NCT01390311|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|
219007128|NCT05505019|OTHER|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
219007129|NCT05505019|OTHER|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
219566452|NCT02380079|DRUG|SCD-101|Administered as gelatin capsules
219566453|NCT03100890|OTHER|Preoperative training (hospital)|Preoperative hospital training
219566454|NCT03100890|OTHER|Preoperative training (home)|Preoperative in-home training
219007130|NCT00740142|DRUG|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
219007131|NCT00740142|DRUG|placebo and lactulose|placebo 3 times a day for 7 days
219566455|NCT05619159|DEVICE|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
219566456|NCT01757899|DRUG|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
219566457|NCT01757899|DRUG|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
219755160|NCT07160959|BEHAVIORAL|Exercise|Patients will undergo a home-based low-intensity interval multi component exercise program including aerobic and strengthening exercise
219755161|NCT07160959|OTHER|Control (Standard treatment)|Patients will be treated with standard therapy based on their CKD stage
219755162|NCT07159035|PROCEDURE|Flexible ureteroscopy with FANS|The FANS with negative-pressure suction, enhancing intrarenal pressure control and fragment evacuation during flexible ureteroscopy.
219755163|NCT07159035|PROCEDURE|Mini-percutaneous nephrolithotomy (mini-PCNL)|Mini-PCNL is performed under general anesthesia with less than 20 Fr access tract, using rigid nephroscopy and stone fragmentation under direct visualization. Postoperative drainage is provided via nephrostomy or ureteral stent as per protocol.
219189891|NCT04356209|OTHER|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
219189892|NCT04356209|DRUG|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
219189893|NCT02857933|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
219404977|NCT06739226|BIOLOGICAL|Antigen-specific CAR T, CTL and DCvac to treat melanoma.|Antigen-specific CAR T, CTL and DCvac to treat melanoma.
219404978|NCT02798497|OTHER|Serum and Blood samples|
219404979|NCT07054710|DEVICE|LED Light Treatment|The device will guide participants through a treatment that cycles through Red (4 minutes), Red + Infrared (4 minutes), and Blue (4 minutes) LED therapy in combination with vibration therapy, for a 12-minute treatment. Participants will be asked to use the device Monday through Saturday, on a clean face, as part of their evening routine.
219404980|NCT07054710|DEVICE|Vibration Only|On each Sunday of the 12-week program, participants will be asked to complete a 15-minute vibration-only treatment session as part of their evening routine.
219404983|NCT07058077|DRUG|Enlicitide Decanoate|Enlicitide decanoate taken by mouth
219404984|NCT07058077|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth
219404985|NCT06754943|DRUG|Treatment A_Period 1|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
219404986|NCT06754943|DRUG|Treatment B_Period 2|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
219404987|NCT06754943|DRUG|Treatment A_Period 3|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
219404988|NCT06754943|DRUG|Treatment B_Period 4|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
219404989|NCT06754943|DRUG|Treatment B_Period 1|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
219404990|NCT06754943|DRUG|Treatment A_Period 2|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
219404991|NCT06754943|DRUG|Treatment B_Period 3|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
219404992|NCT06754943|DRUG|Treatment A_Period 4|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
219404993|NCT04322448|DEVICE|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
219404994|NCT06898047|DRUG|Rimegepant for acute migraine treatment|Rimegepant for acute migraine treatment
219404995|NCT06815354|DEVICE|TRAQinform Theranostics|This prospective, multi-center, non-interventional clinical study will evaluate actionable outputs from TRAQinform Theranostics, a software only medical device that identifies, quantifies, tracks, and compares lesions between different imaging modalities and multiple imaging timepoints.
219404996|NCT06758401|DRUG|Sigvotatug Vedotin|MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
219404997|NCT06758401|DRUG|Pembrolizumab|Anti-PD-(L)1
219404998|NCT06780423|PROCEDURE|Minimal invasive fine needle muscle biopsies|Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.
219755164|NCT07161284|OTHER|Exposition to trained peer-support registrars for a year|Exposition to trained peer-support registrars for a year
219755165|NCT07159594|OTHER|Energy restriction|Diet with LED and energy restricted diet with gradually inclusion of meals
219404999|NCT04212793|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
219405000|NCT04212793|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
219405001|NCT06842693|BEHAVIORAL|Control|"Products carry neutral control label when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
219405002|NCT06842693|BEHAVIORAL|Chilean non-nutritive sweetener label|"Products carry rectangular label that states contains non-nutritive sweeteners, not recommended for children when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
219405003|NCT06842693|BEHAVIORAL|Colombian non-nutritive sweetener label|"Products carry octagonal label that states contains non-nutritive sweeteners  when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
219405004|NCT06850870|OTHER|Door-through-door companion rideshare|Door-through-Door Companion Drivers, unlike traditional rideshare services, are certified in CPR and first aid, and undergo onboard training to support older adults, individuals with mobility impairments, and those with AD/ADRD. They are trained to observe behaviors of AD/ADRD patients, monitor and detect risk of falls, elopement, and other events that may require extra assistance or emergency care during transport. Drivers accompany riders continuously until they can hand off riders to clinicians or other caregivers, or return them to their home. Technology features in the rideshare platform enable continuity of care, for consistent rider-driver matching and matching of riders to drivers based on support needs.
219405005|NCT06850870|OTHER|Curb-to-curb rideshare services|Curb to curb rideshare services provided by a transportation network company (TNC) with drivers who don't have specialized training in supporting healthcare riders and who don't undergo fingerprint background checks or drug and alcohol testing.
219566458|NCT03328728|DEVICE|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
219566459|NCT03328728|DEVICE|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
219566460|NCT02994628|OTHER|Water|Water only without carbohydrate
219566461|NCT02994628|OTHER|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
219566462|NCT02994628|OTHER|Cavendish banana|Ingest Cavendish banana (common banana)
219566463|NCT02994628|OTHER|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
219566464|NCT02656082|DRUG|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
219566465|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
219566466|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
219566467|NCT03856684|BEHAVIORAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
219566468|NCT03856684|BEHAVIORAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
219405006|NCT06158841|DRUG|Etentamig|Intravenous (IV) Infusion
219405007|NCT06158841|DRUG|Carfilzomib|IV Infusion
219189894|NCT06822283|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
219189895|NCT06755697|OTHER|Intra-articular US-guided hypertonic dextrose injection, IA group|"IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance.~Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks."
219405008|NCT06158841|DRUG|Pomalidomide|Oral Capsule
219405009|NCT06158841|DRUG|Elotuzumab|IV Infusion
219405010|NCT06158841|DRUG|Selinexor|Oral Tablet
219405011|NCT06158841|DRUG|Bortezomib|Subcutaneous or IV Injection
219405012|NCT06158841|DRUG|Dexamethasone|Oral Tablet or IV Infusion
219405013|NCT07073976|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Non-invasive ultrasound imaging of the heart to evaluate right ventricular and right atrial function using parameters such as TAPSE, tricuspid S', RV-FAC, right atrial area, and pulmonary valve acceleration time. TTE will be performed once within 2 hours prior to extubation decision as part of routine care.
219405014|NCT07075926|DIAGNOSTIC_TEST|Echocardiographic Assessment|"All participants will receive a standardized transthoracic echocardiographic (TTE) examination within 2 hours after meeting weaning criteria. The following cardiac function parameters will be recorded:~LVOT Velocity Time Integral (VTI)~Mitral Annular Plane Systolic Excursion (MAPSE)~E/e' ratio~E/A ratio~Mitral Deceleration Time (MDT)~Myocardial Performance Index (Tei index)~The echocardiographic data will be used to investigate the association between left ventricular function and weaning success."
219405015|NCT06927375|DRUG|Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8. Flupentixol/Melitracen is given orally at a dose of 0.5 mg/10 mg twice daily for 8 consecutive weeks starting from Week 0.
219405016|NCT06927375|DRUG|Tocilizumab(400mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.
219405017|NCT03471676|OTHER|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
219405018|NCT07124013|DRUG|Olomorasib|Administered orally
219405019|NCT06746259|DIAGNOSTIC_TEST|Rapid point of care test to detect host immune response in ARI|FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
219405020|NCT07091591|BEHAVIORAL|Changing (version: pandemic)|The application explains that, faced with a complex situation such as a pandemic, decision-makers have to navigate through uncertainty, often without knowing exactly how the situation will evolve. Scientific research guides their choices, but early studies can sometimes prove inaccurate and require adjustments. For example, during the COVID-19 pandemic, some initial studies showed that certain drugs could help, but more rigorous research showed that they were not effective. Over time, accumulated knowledge enables us to better understand the situation and make informed decisions. Lessons learned from past crises help to better prepare for future complex situations.
219405021|NCT07091591|BEHAVIORAL|Changing (version: nutrition)|The intervention discusses the evolving nature of scientific research on diet and health. It explains how initial studies can suggest one thing, only for later studies to offer new insights or clarify previous findings. For example, while early research linked high fat intake with heart disease, more recent studies have shown that some fats, like those in nuts, avocados, and oily fish, are actually beneficial. It emphasizes that science often advances gradually, and rigorous, long-term studies help understanding. It also points out that health recommendations are influenced by multiple factors, and over time, accumulated knowledge enables us to better understand the situation and make informed decisions.
219566469|NCT03325972|DRUG|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
219566470|NCT03325972|OTHER|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
219405022|NCT04633239|DRUG|Abemaciclib|Given PO
219405023|NCT04633239|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219405024|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219405025|NCT04633239|DRUG|Olaparib|Given PO
219405026|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
219405027|NCT05128162|BEHAVIORAL|Psychotherapy|1\. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
219405028|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
219405029|NCT04902443|DRUG|Pomalidomide|Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
219002252|NCT03196102|BEHAVIORAL|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
219002253|NCT03196102|BEHAVIORAL|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
219405030|NCT04902443|DRUG|Nivolumab|Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
219405031|NCT06910943|DRUG|Choline Chloride for Injection|Intravenous use
219405032|NCT06910943|DRUG|Placebo|Water for injection
219405033|NCT07091734|DRUG|Tirzepatide|"Participants will receive study drug (Tirzepatide) according to the dose titration plan described in the FDA-approved Prescribing Information (starting with 2.5 mg/wk and increasing the dose every 4 weeks by increments of 2.5 mg.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
219405034|NCT07091734|DRUG|Usual care medications|"Participant's will continue on participant's regular diabetic and hypertriglyceridemia medications that were used during the run-in period for 24 weeks. This will be either Phase 1 or Phase 2 based on randomization.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
219405035|NCT06911905|DIETARY_SUPPLEMENT|Nutritional supplements|The nutritional supplements, including Vitamin B1, Vitamin B2, folic acid, Mecobalamin, Vitamin D3, Choline, and Coenzyme Q10, will be administered for a period of three months.
219405036|NCT06911905|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
219566471|NCT02373995|BIOLOGICAL|LAB4|Additional treatment with the specific LAB4 probiotic preparation
219566472|NCT02826941|OTHER|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
219566473|NCT02826941|OTHER|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
219566474|NCT06355479|DRUG|OsrHSA|Recombinant Human Serum Albumin from Oryza Sativa
219566475|NCT06355479|DRUG|Plasbumin®-20|Albumin (Human) 20%, USP
219566476|NCT03432988|BEHAVIORAL|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
219566477|NCT05709769|OTHER|There are no interventions.|There are no interventions.
219002254|NCT02798575|DEVICE|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
219002255|NCT04380116|DEVICE|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
219002256|NCT04826432|DRUG|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
219405037|NCT07098403|DRUG|SHR-1905 Injection|SHR-1905 injection.
219405038|NCT07098403|DRUG|SHR-1905 Placebo Injection|SHR-1905 placebo Injection.
219566478|NCT00794417|DRUG|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
219566479|NCT00794417|DRUG|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
219566480|NCT00794417|DRUG|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
219566481|NCT05187858|DRUG|LNP3794|LNP3794 capsules administered orally once daily
219566482|NCT02139618|DRUG|Methyl Aminolevulinate (MAL)|
219566483|NCT02139618|DRUG|Placebo|
219755166|NCT07161076|DEVICE|3d Printed space maintainer|using Next dent permanent crown resin, a digitally designed space maintainer will be 3d printed to maintain space after extraction
219755167|NCT07161076|DEVICE|stainless steel band and loop|lab fabricated metal band and loop
219755168|NCT07161401|OTHER|Observational assessment|Evaluation of sleep quality using the Children's Sleep Habits Questionnaire (CSHQ) and cephalometric analysis of mandibular position (SNB), vertical dimensions (SNGoGn, FMA), and upper airway measurements. No active intervention was performed.
219755169|NCT07158905|BIOLOGICAL|AV-1980R 20 µg|MultiTEP-based investigational tau vaccine formulated with the adjuvant. The vaccine is designed to elicit anti-tau antibodies in participants with preclinical Alzheimer's disease.
219755170|NCT07158905|BIOLOGICAL|AV-1980R 60 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 60 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
219755171|NCT07158905|BIOLOGICAL|AV-1980R 180 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 180 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
219405039|NCT06929169|DRUG|iSGLT2|"Participants randomized to the experimental arm will receive a once-daily dose of a sodium-glucose cotransporter 2 inhibitor (SGLT2i), administered orally, in addition to their standard hemodialysis care. The specific agent (e.g., dapagliflozin or empagliflozin) and dose will be selected based on safety data and clinical guidelines applicable to patients with end-stage renal disease (ESRD) on dialysis. The intervention will be maintained for 12 months. Dosing will be monitored by the research team to ensure tolerability and adherence. All patients in the experimental group will undergo comprehensive cardiovascular assessment, including serial cardiac MRI, echocardiography, and measurement of fibrosis-related biomarkers.~This intervention differs from standard care by introducing a pharmacologic agent not routinely administered in the dialysis population, targeting cardiac remodeling, fibrosis, and intradialytic complications."
219405040|NCT06929104|OTHER|No intervention|No intervention
219405041|NCT04359446|PROCEDURE|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
219405042|NCT04359446|PROCEDURE|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
219405043|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
219405044|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
219405045|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
219405046|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
219405047|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
219405048|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
219405049|NCT07101705|DRUG|OriV508 Injection|OriV508 injection is one kind of non-replicative self-inactivating lentivirus vector which carries an effective BCMA/CD19 dual-target CAR. OriV508 can be administered intravenously and produce BCMA/CD19 CAR-T in vivo.
219405050|NCT03321552|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
219405051|NCT03321552|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
219405052|NCT06916728|DEVICE|Marketed Product - MP01|Marketed Product - MP01 was implanted via a mini-arthrotomy or arthrotomy approach, using the designated surgical tools and surgical technique.
219405053|NCT06916728|PROCEDURE|Surgical Standard of Care|"As no single, current therapy could be used as a single comparator for the treatment of the knee lesions treated in the pivotal study which included focal cartilage lesions on the one hand and moderate knee osteoarthritis on the other, current general practice (e.g., SSOC: Deb and MFx) was used.~Deb (SSOC) is a common orthopedic surgical procedure that removes damaged cartilage and tissue from the knee. MFx (SSOC) is another common orthopedic surgical procedure that treats knee cartilage defects by creating small holes in the bone beneath the damaged cartilage."
219405054|NCT06930001|OTHER|Etamine Application Group /Intervention|Before the intervention, students in the intervention group will complete the Informed Consent Form, Personal Information Form, Perceived Stress Scale, and Attitudes Towards Learning Scale (pre-test). In the first week, a 45-minute etamine training (history, tools, basic techniques) will be given individually by the scholarship holder (Şeyma Demir). Techniques such as threading, knotting, and cross-stitching will be taught, and students will apply a simple pattern, correcting mistakes. Room conditions (21℃) and student comfort will be ensured, with restricted access. One week later, students will practice weekly for 3 weeks (45 minutes each) using the Etamine starter set. In week five, the project manager will provide 2 hours of theory and 4 hours of practical episiotomy training. Students will then be assessed with the Episiotomy Repair Skill Form (post-test). Final evaluations will include the Perceived Stress Scale and Attitudes Towards Learning Scale (post-test).
219405055|NCT06929520|BEHAVIORAL|ENDS Prevention Intervention (TBD)|The ENDS Prevention Intervention will consist of (1) a modular classroom curriculum with ENDS-focused lessons and lessons covering alcohol, tobacco, and other drug use; (2) social media content that is related to the classroom curriculum and video content, and (3) a print media campaign across school campuses on Hawaii Island.
219405056|NCT06933381|DEVICE|Vapocoolant spray|Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.
219405057|NCT06933381|OTHER|Placebo|Nature's Tears will be applied to the arm as a placebo spray
219405058|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
219405059|NCT06439719|PROCEDURE|Blood sample collection|Collection of blood sample
219566484|NCT05139277|DIAGNOSTIC_TEST|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
219755172|NCT07158905|OTHER|Placebo|10 mM phosphate buffer formulated with the adjuvant; intramuscular injections at Weeks 0, 4, 12, and 36; no active antigen.
219755173|NCT07160894|OTHER|Saliva and Serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
219755174|NCT07160894|OTHER|Saliva and Serum sampling|ELISA method will be used to measure IL-10 and IL-6 values in collected saliva and serum samples. For ELISA analysis, a commercial kit (Sunred Bio, Shanghai, China) pre-coated with human selected antibodies will be used.
219405060|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via auto-injector (AI)
219002257|NCT04826432|OTHER|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
219405061|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
219405062|NCT05094362|BEHAVIORAL|Spinal Reflex Operant Down Conditioning|This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
219405063|NCT07142707|DRUG|MBX 4291|MBX 4291 will be administered subcutaneously (SC)
219405064|NCT07142707|DRUG|Placebo|Placebo: Placebo will be administered subcutaneously (SC)
219405065|NCT01922427|DRUG|RNS60|
219405066|NCT07149584|PROCEDURE|ESPB|10 mL of 0.375% bupivacaine is injected on each side between the deep fascia of the erector spinae muscle and the transverse process. Additionally, tramadol is administered via intravenous patient-controlled analgesia.
219405067|NCT07149584|PROCEDURE|TPVB|10 mL of 0.375% bupivacaine is injected on each side between the superior costotransverse ligament and the pleura.
219405068|NCT07149584|PROCEDURE|IV|Tramadol is administered via intravenous patient-controlled analgesia.
219405069|NCT07154121|DRUG|5-fluorouracil group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; After suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in 12.5 mg/mL 5-fluorouracil for 3 minutes, after which the gelatin sponge was removed and the area thoroughly rinsed with saline.
219405070|NCT07154121|OTHER|saline group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; Similarly, after suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in saline solution for 3 minutes, after which the gelatin sponge was removed and the ostium was thoroughly rinsed with saline solution.
219405071|NCT07151118|OTHER|Blood Sampling for ctDNA Analysis|Approximately 20 mL of peripheral blood will be collected from patients with advanced biliary tract cancer. Samples will be obtained prior to systemic therapy initiation (in about two-thirds of patients) or prior to subsequent therapy (in about one-third of patients). Additional blood draws may be performed at progression in patients with FGFR2 fusion, IDH1 mutation, or HER2 amplification. Collected samples will be centrally analyzed for genomic alterations using ctDNA profiling.
219429271|NCT03064347|DIETARY_SUPPLEMENT|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429272|NCT03064347|DIETARY_SUPPLEMENT|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429273|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429274|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429275|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429276|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
219429277|NCT03037307|OTHER|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
219429278|NCT03037307|OTHER|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
219429279|NCT03037307|OTHER|Negative Control|No adhesive
219429280|NCT03118453|BEHAVIORAL|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
219429281|NCT03118453|BEHAVIORAL|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
219429282|NCT04786730|DRUG|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
219429283|NCT04523818|DRUG|Capecitabine|Given PO
219429284|NCT04523818|DRUG|Fluorouracil|Given IV
219429285|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
219429286|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
219755175|NCT07159854|DEVICE|RICORDO-DTx system|Participants with will undergo a cognitive enhancement program using the Astir RICORDO-DTx system (http://www.ricordo-dtx.com), which allows for the personalization of rehabilitative content based on the needs of the target population and can be delivered remotely.
219755176|NCT07159854|DEVICE|HOMING system|Participants will also undergo motor rehabilitation sessions focused on improving balance, gait, and muscular endurance using the HOMING system (https://www.tecnobody.com/homing).
219755177|NCT07159854|DEVICE|Home-based training program|Subjects will view videos on Tablet. The treatment will be provided via a digital medicine platform on a mobile device (tablet).
219405072|NCT07151716|DRUG|Dexmedetomidine|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.2 μg/kg/h dexmedetomidine and increased/decreased by 0.1 μg/kg/h dexmedetomidine every 15 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches 0.7 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.10 μg/kg/h dexmedetomidine and increased/decreased by 0.05 μg/kg/h dexmedetomidine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.2 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
219405073|NCT07151716|DRUG|Dexmedetomidine-esketamine combination|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, increased/decreased by 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine every 15 min, until the RASS reaches -2 to -1, maximal infusion rate reaches 0.35 μg/kg/h dexmedetomidine and 0.175 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine, and increased/decreased by 0.025 μg/kg/h dexmedetomidine and 0.0125 mg/kg/h esketamine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
219405074|NCT07160621|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Receive mobile CBT
219405075|NCT07160621|BEHAVIORAL|Education|Receive educational materials
219405076|NCT07160621|OTHER|Questionnaires|Ancillary studies
219405077|NCT07158632|BEHAVIORAL|handwashing education|Arm A: This arm receive handwashing education using social and behavioral change communication
219405078|NCT07158632|BEHAVIORAL|water chlorination|Arm B: This arm receives water chlorination intervention
219405079|NCT07158632|BEHAVIORAL|combined intervention|Arm C: This arm receives combined handwashing and water chlorination intervention
219566485|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
219566486|NCT04491578|BEHAVIORAL|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
219566487|NCT06092190|DEVICE|EMG|Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
219566488|NCT02052791|DRUG|nusinersen|Administered by intrathecal (IT) injection
219566489|NCT00005026|DRUG|carboplatin|
219566490|NCT00005026|DRUG|paclitaxel|
219566491|NCT00005026|DRUG|topotecan hydrochloride|
219566492|NCT04286919|BEHAVIORAL|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
219755178|NCT07161661|PROCEDURE|Usual VA Care|The usual treatment provided by PM\&R clinicians for CLBP
219755179|NCT07161661|PROCEDURE|Osteopathic manipulative treatment|Between your first visit (baseline) and 12 weeks, participants will receive up to 4 usual care visits plus OMT.
219755180|NCT07159230|DIAGNOSTIC_TEST|point-of-care multiplex PCR test|community health care center in intervention group were provided with point-of-care multiplex PCR test (POCT) plus routine test. POCT testing was recommended for all enrolled patients presenting with acute respiratory infections who meet the predefined inclusion criteria. The therapeutic interventions were determined by health-care workers on the basis of POCT result, clinical assessment and guideline.
219755181|NCT07159997|DIAGNOSTIC_TEST|Accuracy of rail sign by ultrasound st diagnosis placent previa|Accuracy of rail sign by ultrasound at derection of PAS
219755182|NCT07161414|DRUG|IV Rilvegostomig|Rilvegostomig administered IV.
219755183|NCT07161414|DRUG|Recombinant Human Hyaluronidase (rHu)|rHu administered subcutaneously.
219755184|NCT07161414|DRUG|SC Rilvegostomig|Rilvegostomig administered subcutaneously.
219755185|NCT07161414|DRUG|SC rilvegostomig + rHu|SC rilvegostomig + rHu administered subcutaneously.
219755186|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
219755187|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
219405080|NCT07162558|BEHAVIORAL|Child-Centered Empowerment Intervention|"Participants in this group receive the child-centered empowerment program, a structured behavioral intervention designed to enhance coping skills, promote self-efficacy, and improve lifestyle in children with leukemia. The program is based on four dimensions of empowerment:~Perceived Threat: Increasing awareness of illness, its complications, and the treatment process through group discussions.~Self-Efficacy: Practicing problem-solving and self-management techniques to strengthen self-belief, self-control, and confidence in handling illness-related challenges.~Educational Participation: Children receive educational cards at the end of each session and are encouraged to share the learned content with family members to reinforce responsibility and engagement.~Evaluation: Continuous follow-up and assessment of learning after each session to ensure understanding and active participation."
219405081|NCT07162402|OTHER|Super Skills for Life (SSL) Program|Its Cognitive Behaviour Therapy (CBT) Based 8 sessions Super Skills for Life (SSL) Program for childhood Anxiety Management.
219405082|NCT07162402|OTHER|No Active Intervention|Routine Activities in Class
219405083|NCT07162051|DRUG|Fuzaparib|"Folfoxapril:~Take 2 times a day (once in the morning and once in the evening, 150mg in the morning and 100mg in the evening; vice versa is also acceptable). Each 3-week period constitutes one cycle. For the first to fourth cycles, a total of 4 cycles are required."
219405084|NCT07162051|OTHER|standard chemotherapy|standard chemotherapy
219405085|NCT07163234|DEVICE|Cardiac surgery|cardiac surgery
219405086|NCT07162831|BEHAVIORAL|Mio-Training|The Mio-Training aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and coordinative skills to strenghten cognitive development in children and adolescents with ADHD.
219405087|NCT07163130|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation (tVNS) is an emerging therapeutic modality in cardiovascular diseases. tVNS has been shown to exert antiadrenergic and anti-inflammatory effects in humans. Recently, tVNS has been tested in experimental and human POTS, leading to improved autonomic function, reduction of anti-autonomic autoantibodies and inflammatory cytokines.~Parasym device; Parasym Health, London, United Kingdom Frequency: 20Hz, pulse width: 200μs, amplitude will be individually titrated to 1 mA below the level that caused mild discomfort."
219405088|NCT07162155|BEHAVIORAL|School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse|Psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription drug misuse among upper elementary school students.
219405089|NCT07163572|DRUG|Intravenous brivaracetam|Patients received intravenous brivaracetam as a loading dose of 2 mg/kg (maximum 100 mg) diluted in 100 ml of normal saline infused over 10 minutes.
219405090|NCT07163572|DRUG|Intravenous levetiracetam|Patients received intravenous levetiracetam as a loading dose of 40 mg/kg (maximum 3000 mg) diluted in 100 ml of normal saline infused over 10 minutes.
219405091|NCT07162779|DRUG|Radioactive drugs are administered through intravenous injection.|\[68Ga\]DOTA-IR-780-C-4 is administered through a superficial vein on the back of the hand. A PET/CT scan was performed approximately 1 h,2 h and 3 h after injection
219405094|NCT07163975|PROCEDURE|complete pulpotomy|the exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 5 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 5 minutes. After hemostasis, MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using a carrier. This will be followed by application of a layer of light-cure RMGIC and light-curing for 20 sec. The tooth then will be restored using composite resin following etch and rinse technique.
219405095|NCT07163975|PROCEDURE|Root canal treatment|"RCT will be performed in single visit. Root canal orifices will be explored using a DG 16 probe. A size 10 or 15 K-file will be passively inserted into the coronal two- thirds of the canal to verify a smooth glide path.~Coronal enlargement will be done using Gates-Glidden drills. Working length will be determined with the help of electronic apex locator and will be confirmed radiographically. Canals will be prepared using the crown down technique with NiTi rotary instruments. The master apical file (MAF) size for each canal will be selected to be three sizes larger than the initial apical binding file at the WL. 5ml of 5.25% sodium hypochlorite using a 30-gauge side-vented needle will be used for optimal irrigation after each instrument.~After completion of canal instrumentation, the canals will be irrigated with 5.0 ml of 17% ethylene-diamine-tetra acetic acid for 1 minute followed by a final irrigation with 5.0 ml of 5.25% sodium hypochlorite. Canals will be dried with"
219405096|NCT07162883|DRUG|QL2107|IV infusion.
219405097|NCT07162883|DRUG|Keytruda®|IV infusion.
219405098|NCT07164118|BEHAVIORAL|Pranayama Breathing Exercise|Pranayama breathing technique consisting of 6 cycles, demonstrated by the researcher before the operation, supported by the brochure, and lasting 8-10 minutes every 2 hours from the 4th post-operative hour.
219405099|NCT07164118|BEHAVIORAL|Deep Breathing Exercise|Deep breathing exercise, demonstrated one-on-one before surgery and supported by a guide, applied 6 times every 2 hours from the 4th post-operative hour onwards.
219755188|NCT07159243|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
219755189|NCT07159074|DRUG|Tc 99m tilmanocept|150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.
219755190|NCT07159373|DRUG|MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole|"Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
219755191|NCT07159373|DRUG|IDA - Ivermectin + DEC + albendazole|"Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
219405100|NCT07161791|DRUG|Camrelizumab Combined With Pirfenidone and Chemotherapy|"Treatment Regimen:~Camrelizumab: 200 mg intravenous (IV) every 3 weeks (q3w). Pirfenidone: 200 mg three times daily (tid), escalated to 600 mg tid based on tolerability.~Chemotherapy: Investigator's choice of standard regimens (e.g., paclitaxel 175 mg/m² IV q3w or capecitabine 1000 mg/m² orally bid on days 1-14 of a 21-day cycle)."
219755192|NCT05691647|BEHAVIORAL|Chronotherapy|Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, outpatients will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Patients already admitted to inpatient treatment will be temporary transferred to the ward selected to oversee the sleep deprivation. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
219755193|NCT05691647|BEHAVIORAL|Treatment as usual|Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient or the inpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
219755194|NCT06414668|BEHAVIORAL|Cycling Intervention Group|A eight-weeks school-based cycling program. The school-based cycling intervention consists of 2 Bikeability sessions of 60 min at Physical Education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training. In addition, participants will receive encouragement strategies, one for each week of the intervention, for cycling to and from school during eight weeks.
219405101|NCT07161726|COMBINATION_PRODUCT|(-)-Epicatechin-rich cocoa supplementation combined with exercise training|12 weeks of daily cocoa (2 capsules/d containing 450 mg cocoa flavanols/d, including 80 mg of (-)-epicatechin) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
219405102|NCT07161726|COMBINATION_PRODUCT|Placebo combined with exercise training|12 weeks of placebo (alike-looking cellulose-based capsules) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
219405103|NCT07162285|DEVICE|Delivery Room Bubble CPAP|delivery room bubble CPAP initiated within 10 minutes of birth for preterm neonates \<34 weeks, using water-seal oscillation system via nasal prongs.
219405104|NCT07162285|OTHER|Delivery Room Supplemental Oxygen|Standard oxygen therapy initiated within 10 minutes of birth via mask/tubing, without positive pressure support.
219405105|NCT07164066|DEVICE|Digital Occlusal Analysis Device|Computerized occlusal analysis performed using T-Scan and ModJaw devices to record occlusal contacts, timing, and force distribution during prosthesis fitting and function.
219405106|NCT07161674|BEHAVIORAL|Digital health literacy program|A 6-week digital health literacy program delivered through weekly face-to-face training sessions and WhatsApp activities. Additional support may be provided if needed.
219405107|NCT07163403|BIOLOGICAL|Autologous Tolerogenic Dendritic cells|Autologous peripheral blood differentiated and matured adult dendritic cells loaded with Frameshift-derived neopeptides (FSDN) (DC-DELAY). Eligible participants will receive six intradermal immunizations of DC-DELAY at week 0, 2, 4, 6, 8 and 10.
219405108|NCT07163325|DRUG|EP102|EP102 will be administered orally
219566493|NCT02317679|DRUG|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
219566494|NCT02317679|DEVICE|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
219566495|NCT01580657|BEHAVIORAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
219566496|NCT01580657|BEHAVIORAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
219002258|NCT01599767|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
219405109|NCT07161973|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
219405110|NCT07161973|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-free beetroot juice
219566497|NCT01580657|BEHAVIORAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
219755195|NCT04095234|PROCEDURE|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
219566498|NCT01580657|BEHAVIORAL|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
219755196|NCT04095234|PROCEDURE|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
219755197|NCT05986929|OTHER|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
219755198|NCT05986929|OTHER|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
219755199|NCT04861584|DRUG|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
219755200|NCT05639881|BEHAVIORAL|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
219755201|NCT05823896|DRUG|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
219755202|NCT05823896|DRUG|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
219755203|NCT02203643|DRUG|Carfilzomib|
219755204|NCT02203643|DRUG|Cyclophosphamide|
219405111|NCT07162636|OTHER|NMES+|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions, using resistance exercises combined with the use of NMES
219405112|NCT07162636|OTHER|NMES -|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions using only resistance exercises.
219755205|NCT02203643|DRUG|Lenalidomide|
219405113|NCT07162142|PROCEDURE|elastic nailing with pollar K.wire|retrograde elastic nailing of metaphyseal diaphyseal fracture of distal radius in pediatrics
219405114|NCT07163312|PROCEDURE|Endovenous Ablation for Varicose Veins|Participants will receive standard endovenous treatment for lower limb varicose veins as part of their routine clinical care. The procedure may include radiofrequency ablation (RFA), endovenous laser ablation (EVLA), or other accepted thermal ablation techniques, with or without adjunctive phlebectomy or foam sclerotherapy if clinically indicated. The intervention is performed under tumescent local anesthesia by vascular surgeons according to established guidelines. No experimental techniques or investigational devices are used.
219405115|NCT07163013|OTHER|Digital cognitive behavioral therapy(DCBT)|Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.
219566499|NCT01580657|BEHAVIORAL|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
219566500|NCT01580657|BEHAVIORAL|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
219566501|NCT05557448|DRUG|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
219755206|NCT02203643|DRUG|Dexamethasone|
219755207|NCT02979574|PROCEDURE|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
219755208|NCT02979574|PROCEDURE|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
219755209|NCT02979574|DEVICE|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
219405116|NCT07163013|OTHER|Regular mental health curriculum|The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.
219566502|NCT05557448|DRUG|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
219566503|NCT01477502|OTHER|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
219755210|NCT05341310|BEHAVIORAL|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
219755211|NCT05341310|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
219755212|NCT04696146|DRUG|Berinert|Intrarenal dose of 500 U of Berinert
219755213|NCT04696146|DRUG|Placebo|Normal Saline placebo
219755214|NCT06270407|DRUG|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
219755215|NCT06270407|DRUG|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
219405117|NCT07162961|DRUG|Nintedanib|Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.
219405118|NCT07162961|DRUG|Progesterone|For control group
219405119|NCT07162532|DIAGNOSTIC_TEST|1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR|Complete blood picture (CBC) with blood film, lymphocytic count 2 Routine liver and kidney function and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests 6 Erythrocyte sedimentation rate (ESR). 7 C reactive protein (CRP). 8 Cytogenetic profiles: del(17p) 9 molecular study :IGHV mutation status.
219405120|NCT07162662|DIETARY_SUPPLEMENT|Oral Sialic acid|This study employs a before-after self-control trial design, recruiting 42 volunteers to take oral sialic acid and collecting fecal samples before and after the intervention.
219405121|NCT07162519|DRUG|romiplostim N01|Eligible subjects who pass the screening will undergo a baseline visit and will receive romiplostim N01 administration once weekly for a maximum of 4 weeks. Dosing will be discontinued when the platelet count rises to ≥100×10⁹/L. When a subject resumes anti-tumor therapy, those with a baseline platelet count of \<50×10⁹/L will receive prophylactic administration of romiplostim N01 (administered 2 hours prior to anti-tumor therapy) before the anti-tumor drugs are given.
219405122|NCT07163351|OTHER|CAD/CAM allogenic bone block|CAD/CAM allogenic bone block augmentation with immediate non-functional implant loading
219405123|NCT07161687|DRUG|Marstacimab|For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.
219405124|NCT07162623|OTHER|Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
219405125|NCT07162623|OTHER|Placebo Effervescent Tablets 4.1 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
219405126|NCT07163676|BEHAVIORAL|Baduanjin exercise|group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks.
219566504|NCT01477502|OTHER|standard treatment without homeopathy|participants receive standard UTI prophylaxis
219566505|NCT04372849|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
219405127|NCT07162116|DRUG|XY0206|12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
219566506|NCT04372849|OTHER|Placebo|Single dose of placebo solution as nasal spray
219405128|NCT07162116|DRUG|Moxifloxacin (400 mg)|400mg，On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach
219405129|NCT07162116|OTHER|XY0206 Placebo|12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
219405130|NCT07162259|DRUG|First-line T-DXd followed by SG upon disease progression|Patients will be assigned to Cohort 1 (HER2 IHC 2+) based on different HER2 immunohistochemical expression levels, where they will first receive T-DXd treatment, followed by SG treatment upon disease progression.
219405131|NCT07162259|DRUG|First-line SG followed by T-DXd upon progression|Patients will be assigned to Cohort 2 (HER2 IHC ≤1+) based on different HER2 immunohistochemical expression levels, where they will first receive SG treatment, followed by T-DXd treatment upon disease progression.
219405132|NCT07163377|OTHER|Experimental Group|Participants in the intervention group will undergo art therapy sessions
219566507|NCT00856505|DRUG|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
219566508|NCT05952089|DRUG|Danicamtiv|Specified dose on specified days
219566509|NCT05952089|DRUG|Midazolam|Specified dose on specified days
219566510|NCT04681625|BEHAVIORAL|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
219755216|NCT05849597|DRUG|Dexmedetomidine|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.
219405133|NCT07162818|DRUG|Nepafenac 0.1% eyedrops|The study eye drops were nepavenac 0.1% eye drops (NEVANAC 0.1%®, Alcon Laboratories, Inc., Fort Worth, Texas). Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
219755217|NCT05849597|DRUG|Propofol|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.
219405134|NCT07162818|DRUG|Control (placebo) group|Cenfresh® eye drops (Cendo pharmaceutical, Indonesia) for the control group. Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
219405135|NCT07163702|DRUG|High-dose Xinglou Chengqi granules|Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
219405136|NCT07163702|DRUG|Low-dose Xinglou Chengqi granules and placebo|Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
219405137|NCT07161986|BEHAVIORAL|Mindfullness based Sobriety (MBS)|MBS is combination of Mindfullness , Relapse prevention, motivational interviewing , acceptance and commitment therapy. It helps in dealing underlying depression and anxiety issues among Polysubstance use. it Cover most of underlying problem faced by person with addiction.
219405138|NCT07162727|DEVICE|titanium foil in ridge augmentation|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed titanium foil depending on the size and extent of defect was placed. Foil was stabilized with the help of stainless steel screws of diameter 1.5 cm and length varied depending on the depth of the defect. The flaps were approximated and sutured without tension. Periodontal dressing was given.
219405139|NCT07162727|DEVICE|collagen membrane|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed collagen membrane depending on the size and extent of defect was placed. The flaps were approximated and sutured without tension. Periodontal dressing was given.
219405140|NCT07162571|BIOLOGICAL|CD19/22 CAR-T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 150 x 10⁶ CD19/CD22 CAR-T cells
219405141|NCT07163598|OTHER|No Intervention: Observational Cohort|This study is a observational cohort study, and we have no intervention.
219405142|NCT07163780|BEHAVIORAL|HEP Intervention|"This intervention is administered to the HEP Intervention arm.~The HEP approach, which includes intervention, is a child-centered, family-based early intervention approach based on the principles of enriched environment and plasticity, emphasizing the importance of homeostasis. It is based on theories that argue that development occurs as a result of the dynamic interaction between the environment, time, task, and individual (Ecological Theory, Dynamic Systems Theory, Perception-Action Theory, Neuronal Group Selection Theory, and the Person-Environment-Occupation Model). Hypotheses for intervention are generated based on a comprehensive assessment of these four fundamental factors (environment, time, task, and individual), and 10 core principles derived from environmental enrichment studies are applied with the guidance of ecological models."
219405143|NCT07163780|BEHAVIORAL|Traditional Therapy|Participants in this arm will receive conventional pediatric therapy, consisting of 12 weekly sessions of 45 minutes each. Sessions will focus on standard motor and sensory development exercises, delivered by a physical therapist experienced in pediatric rehabilitation.
219405144|NCT07163533|OTHER|wearble vibrotactile feedback sensor and kendel exercises|Wearable vibrotactile feedback sensor will be applied to the neck for assessment and management and secondly kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
219405145|NCT07163533|OTHER|kendel exercises|kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
219405146|NCT07163585|DRUG|Brivaracetam|Brivaracetam was initiated at a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.
219405147|NCT07163585|DRUG|Levetiracetam|Levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.
219405148|NCT07162441|DRUG|treatment A|UIC202502 1 Tab/day for 7 days
219405149|NCT07162441|DRUG|treatment B|UIC202505 1 Tab/day for 7 days
219405150|NCT07162441|DRUG|treatment C|UIC202502+UIC202505 2 Tab/day for 7 days
219405151|NCT07163195|DEVICE|Smart Bandage with Telemonitoring|A smart wound bandage with integrated sensors (pH, temperature, moisture) connected to a mobile telemonitoring platform. Wound data are transmitted securely to a mobile application monitored by wound care nurses. The device is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education).
219405152|NCT07163195|DEVICE|Conventional Bandage|A conventional wound bandage without digital monitoring features. It is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education). This represents usual care according to international guidelines.
219405153|NCT07162974|DRUG|anhydrous citric acid - 1197.0 mg, potassium bicarbonate - 967.5 mg, sodium citrate anhydrous - 835.5 mg|The dosage was selected individually for each patient, the target pH was considered to be 7.2
219405154|NCT07162220|OTHER|The clinic's routine education program|As part of the clinic's routine education program, information about kidney function, CKD, nutrition, exercise, medications, and stress management is provided verbally by a nephrology clinic nurse in approximately 20 minutes.
219405155|NCT07162220|DEVICE|Mobile game app|The mobile game software developed for patients with chronic renal failure contains information for children on daily life activities such as nutrition, exercise, personal hygiene, etc.
219405156|NCT07163065|PROCEDURE|Inferior Alveolar Nerve Block Anesthesia|Standard inferior alveolar nerve block anesthesia performed with lidocaine and epinephrine for mandibular dental treatment. Success rate and postoperative pain outcomes will be recorded
219405157|NCT07163091|OTHER|ankel stirrup|Ankel stirrups are a patient preferred ankel brace that allow active ankle dorsal and plantar flexion during weightbearing while maintaining lateral stability.
219002259|NCT02637739|DEVICE|hysteroscope|Women of PUL with β-hCG \> 1000 IU/L or abnormal β-hCG trend (increase \< 66% or decrease \< 15%) were offered HSC.
219405158|NCT07163091|OTHER|Foot-ankel brace (walker)|Walkers immobilise and stabilise the ankle during weightbearing.
219405159|NCT07163611|DRUG|Obinutuzumab administration|All participants will receive obinutuzumab 1000 mg on day 1 and 15, with two additional infusions after 6 months if the anti-PLA2R antibody IFT assay is still positive with proteinuria \> 2 gram/24 hours and stable kidney function.
219405160|NCT05625360|OTHER|eHealth Mindful Movement and Breathing|The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
219405161|NCT05625360|OTHER|Life Impacts Reflection|"This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session."
219405162|NCT05625360|OTHER|PROMIS Questionnaires|Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
219405163|NCT05137262|OTHER|Abiraterone acetate|Given by IV
219405164|NCT05137262|DRUG|Durvalumab|Given by IV
219405165|NCT05137262|DRUG|Methotrexate|Given by IV
219405166|NCT05137262|DRUG|Vinblastine|Given by IV
219405167|NCT05137262|DRUG|Doxorubicin Hydrochloride|Given by IV
219405168|NCT05137262|DRUG|Cisplatin|Given by IV
219405169|NCT04038255|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
219566511|NCT01529658|PROCEDURE|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
219566512|NCT02516384|BIOLOGICAL|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
219566513|NCT02948920|DRUG|Ephedrine|9 mg of ephedrine (3 ml)
219566514|NCT02948920|DRUG|NSS|3 ml of normal saline
219566515|NCT01364324|DRUG|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
219566516|NCT01223235|BIOLOGICAL|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
219405170|NCT04038255|BEHAVIORAL|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.
219405171|NCT04038255|BEHAVIORAL|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
219405172|NCT04038255|BEHAVIORAL|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
219405173|NCT04038255|BEHAVIORAL|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
219405174|NCT04038255|BEHAVIORAL|Brief advice on quitting smoking|Standard advice on how to quit smoking.
219405175|NCT04038255|BEHAVIORAL|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
219405176|NCT03124173|OTHER|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
219405177|NCT03124173|OTHER|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
219405178|NCT03124173|OTHER|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
219405179|NCT03124173|OTHER|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
219405180|NCT06386315|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219405181|NCT06386315|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
219405182|NCT06386315|RADIATION|Involved-site Radiation Therapy (3 Fractions)|Undergo ISRT in 3 fractions
219405183|NCT06386315|RADIATION|Involved-site Radiation Therapy (12 Fractions)|Undergo ISRT in 12 fractions
219405184|NCT06386315|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219405185|NCT06386315|OTHER|Questionnaire Administration|Ancillary studies
219405186|NCT05521568|DIAGNOSTIC_TEST|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
219405187|NCT05521568|DIAGNOSTIC_TEST|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
219405188|NCT05521568|DIAGNOSTIC_TEST|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
219405189|NCT05470491|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.
219405190|NCT05470491|DRUG|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
219405191|NCT05470491|PROCEDURE|allo HCT|bone marrow transplant
219405192|NCT05470491|DRUG|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
219405193|NCT05470491|DRUG|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
219755218|NCT04376593|DRUG|18F-αvβ6-BP|Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
219405194|NCT01286272|DRUG|Bendamustine Hydrochloride|Given IV
219405195|NCT01286272|DRUG|Bortezomib|Given IV or SC
219405196|NCT01286272|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET
219405197|NCT01286272|OTHER|Laboratory Biomarker Analysis|Correlative studies
219405198|NCT01286272|BIOLOGICAL|Ofatumumab|Given IV
219405199|NCT01286272|PROCEDURE|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
219405200|NCT06799845|DRUG|ATX101|ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
219405201|NCT06799845|DRUG|bupivacaine hydrochloride|bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
219405202|NCT06799845|DRUG|saline placebo|normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
219405203|NCT02165800|PROCEDURE|L-PANP-TME|
219405204|NCT02165800|PROCEDURE|O-PANP-TME|
219405205|NCT02486887|DEVICE|telemonitoring of weight, pulse and blood pressure|
219405206|NCT04310215|BIOLOGICAL|CARTISTEM®|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
219405207|NCT04310215|PROCEDURE|Microfracture|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1\. Procedure: Microfracture"
219405208|NCT00074412|DRUG|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
219405209|NCT00074412|DRUG|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
219405210|NCT02891798|DRUG|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
219405211|NCT02891798|DRUG|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
219405212|NCT02917551|OTHER|7 days of adequate antibiotic treatment|
219405213|NCT02917551|OTHER|14 days of adequate antibiotic treatment|
219405214|NCT00924352|DRUG|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
219755219|NCT06224023|DIAGNOSTIC_TEST|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
219755220|NCT02172794|DRUG|Tiotropium|
219755221|NCT02172794|DRUG|Placebo to tiotropium|
219755222|NCT02172794|DRUG|Salmeterol|
219755223|NCT02172794|DRUG|Placebo to salmeterol|
219755224|NCT00285779|DRUG|Etanercept|etanercept 50 mg twice weekly for 12 weeks
219755225|NCT00285779|DRUG|Placebo|
219755226|NCT03561311|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
219755227|NCT03561311|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
219755228|NCT02485015|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
219755229|NCT02485015|DRUG|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
219755230|NCT04164277|BEHAVIORAL|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
219755231|NCT04164277|BEHAVIORAL|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
219755232|NCT04164277|BEHAVIORAL|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
219755233|NCT05157061|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
219755234|NCT05157061|DIETARY_SUPPLEMENT|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
219755235|NCT06715748|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
219405215|NCT00924352|DRUG|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
219405216|NCT05390424|DIAGNOSTIC_TEST|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
219429287|NCT06236464|OTHER|Multiparameter analysis of each sample|Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
219755236|NCT06715748|DIETARY_SUPPLEMENT|Placebo|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
219755237|NCT00529633|DRUG|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
219429288|NCT04788849|DIAGNOSTIC_TEST|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
219429289|NCT03703362|OTHER|Resistance training|30 supervised training-sessions over 12 weeks
219429290|NCT00691093|DRUG|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
219429291|NCT00051129|DRUG|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
219429292|NCT00051129|OTHER|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
219429293|NCT03024840|DRUG|Sevoflurane|Sevoflurane: 1%\~2%
219429294|NCT03024840|DRUG|Propofol|Propofol: 9-15 mg/kg/h
219429295|NCT02892825|OTHER|Music|headphones with music
219405217|NCT05656716|BEHAVIORAL|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
219405218|NCT05656716|BEHAVIORAL|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
219405219|NCT06166095|OTHER|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
219405220|NCT06166095|OTHER|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
219405221|NCT06166095|OTHER|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
219405222|NCT05487716|BEHAVIORAL|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
219405223|NCT03617367|BIOLOGICAL|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
219405224|NCT01904734|DRUG|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
219405225|NCT00418834|DRUG|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
219405226|NCT00418834|DRUG|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
219405227|NCT00418834|DRUG|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
219405228|NCT03813745|OTHER|early denudation|COCs will be denudated in 30 min after oocyte retrieval
219405229|NCT03813745|OTHER|late denudation|COCs will be denudated 2 hr after oocyte retrieval
219405230|NCT01953328|DRUG|Atorvastatin|Administered orally once a day
219405231|NCT01953328|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219566517|NCT04364737|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
219566518|NCT04364737|OTHER|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
219566519|NCT02777515|BEHAVIORAL|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram"
219566520|NCT01220609|DRUG|Ixabepilone|Given IV
219566521|NCT01220609|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566522|NCT00474435|DRUG|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~* emtricitabine 200 mg~* tenofovir DF 300 mg~* efavirenz 600 mg"
219566523|NCT05983666|DIAGNOSTIC_TEST|Ultrasound Oesophageal Intubation|Ultrasound Oesophageal intubation detection
219566524|NCT02106650|DRUG|Folotyn and Leucovorin|
219566525|NCT02106650|DRUG|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
219566526|NCT02106650|DRUG|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
219566527|NCT02986035|OTHER|ECA cream|
219566528|NCT03456024|OTHER|Questinnaire|
219566529|NCT00070616|DRUG|Palifermin 6 x 60 μg/kg/day|
219566530|NCT00070616|DRUG|Palifermin 2 x 180 μg/kg/day|
219566531|NCT00070616|RADIATION|radiotherapy|
219566532|NCT00070616|DRUG|Chemotherapy|
219566533|NCT01825135|DEVICE|Neuromuscular electrical stimulation|
219566534|NCT01825135|DEVICE|sham stimulation|sham stimulation will be applied to the quadriceps
219755238|NCT00529633|OTHER|Sugar pill|Placebo by mouth at night for a total of 24 weeks
219755239|NCT00307957|DEVICE|Pillar Palatal Implants|
219755240|NCT04681144|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
219755241|NCT04796584|OTHER|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
219755242|NCT04572334|OTHER|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
219405232|NCT01953328|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
219405233|NCT02775760|BEHAVIORAL|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
219405234|NCT02775760|BEHAVIORAL|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
219189896|NCT06755697|OTHER|Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.|Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.
219405235|NCT01760941|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219405236|NCT01760941|OTHER|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
219405237|NCT01760941|OTHER|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
219405238|NCT05279014|OTHER|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
219405239|NCT03300752|BEHAVIORAL|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
219405240|NCT03300752|BEHAVIORAL|Control Intervention|PCP will provide discussion of healthy lifestyles.
219405241|NCT05023655|DRUG|Tazemetostat|800mg po twice daily
219405242|NCT04502810|RADIATION|High-level laser therapy|Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
219405243|NCT05164406|PROCEDURE|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
219405244|NCT01488942|OTHER|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
219405245|NCT01371487|DRUG|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
219405246|NCT04704895|DIETARY_SUPPLEMENT|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
219405247|NCT04704895|DIETARY_SUPPLEMENT|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
219405248|NCT01350960|DRUG|SPC5001|3 weekly SC injections
219405249|NCT01350960|DRUG|Saline 0.9%|3 weekly SC injections
219405250|NCT01350960|DRUG|SPC5001|3 weekly SC injections
219405251|NCT01350960|DRUG|SPC5001|3 weekly SC injections
219002260|NCT02602496|OTHER|Fruits and Vegetables|5 servings of fruits or vegetables
219002261|NCT02602496|OTHER|Whole Grain|3 servings of whole grain
219405252|NCT01350960|DRUG|SPC5001|3 weekly SC injections
219405253|NCT01350960|DRUG|SPC5001|3 weekly SC injections
219405254|NCT04671485|OTHER|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
219405255|NCT04671485|OTHER|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
219405256|NCT04671485|OTHER|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
219405257|NCT06545747|RADIATION|DCE-MRI based split-course hypo-RT|Tumor delineation will be based on DCE-MRI and CT. MRI help define the tumor boundary. Different radiation doses will be delivered based on the Ktrans value of the tumor area on DCE-MRI.
219405258|NCT06545747|RADIATION|CT based split-course hypo-RT|Tumor delineation will be based on CT. The total dose for both the first and boost courses of hypo-RT to the tumor area will be constant.
219405259|NCT06545747|DRUG|Concurrent chemotherapy|Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.
219405260|NCT06545747|DRUG|Consolidative immunotherapy|Consolidative PD-1/PD-L1 inhibitors
219429296|NCT02892825|OTHER|No Music|headphones without music
219429297|NCT03790384|DRUG|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
219429298|NCT02294006|DRUG|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
219429299|NCT00378755|DRUG|velcade|
219429300|NCT01588353|DRUG|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
219429301|NCT02131246|DRUG|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
219405261|NCT05955209|DRUG|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
219405262|NCT06500494|DRUG|Vinorelbine Tartrate Oral|The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.
219405263|NCT04710862|BEHAVIORAL|Breathing training without a device|Breathing training without a mouth device
219405264|NCT04710862|BEHAVIORAL|Breathing training with a device|Breathing training with a mouth device
219405265|NCT06410612|DRUG|regional anesthesia and PAI|this is the block portion of the study
219405266|NCT06410612|DRUG|PAI|this is the no block portion of the study
219405267|NCT06414499|DRUG|rhTNK-tPA|rhTNK-tPA 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds. Additionally, placebo oral aspirin and clopidogrel are given. Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy.
219405268|NCT06414499|DRUG|Control group (Aspirin combined with clopidogrel)|Dual antiplatelets with aspirin 100mg and clopidogrel 300mg, plus placebo intravenous rhTNK-tPA. Placebo oral aspirin and clopidogrel are administered within 6 ± 2 hours following intravenous placebo.
219405269|NCT05732532|DRUG|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
219405270|NCT05732532|DRUG|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
219566535|NCT05723718|OTHER|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
219566536|NCT05265819|DEVICE|X-BOX kinetic360|1\) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
219566537|NCT05265819|DIETARY_SUPPLEMENT|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
219566538|NCT05265819|DRUG|thyroid hormone replacement therapy|thyroid hormone replacement therapy
219405271|NCT05732532|DRUG|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
219405272|NCT05732532|DRUG|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
219405273|NCT05732532|PROCEDURE|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
219405274|NCT05574400|DRUG|Dextrose Water|Dextrose 5% in water
219405275|NCT05574400|DRUG|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
219405276|NCT05574400|DRUG|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
219405277|NCT01119274|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
219405278|NCT01119274|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
219405279|NCT04649203|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
219002262|NCT02602496|OTHER|Control|3 servings of refined grain
219405280|NCT04649203|DRUG|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
219405281|NCT05726019|DRUG|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
219405282|NCT03773341|OTHER|research questionnaire|Patient personal data History taking clinical knee examination
219405283|NCT06464367|DRUG|Psilocybin|synthetic psilocybin 10 mg (oral)
219405284|NCT06464367|DRUG|Placebo|synthetic THC 2.5 mg (oral)
219405285|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Once Daily|
219405286|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Twice Daily|
219405287|NCT02293018|DRUG|1.5% (w/w) MTC896 Gel Once Daily|
219405288|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
219405289|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
219755243|NCT06032611|DIAGNOSTIC_TEST|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days."
219002263|NCT06076616|BEHAVIORAL|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
219405290|NCT02586753|OTHER|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
219405291|NCT02586753|OTHER|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
219405292|NCT01724983|DRUG|ketamine|
219405293|NCT01724983|DRUG|fentanyl|
219405294|NCT01626911|PROCEDURE|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
219405295|NCT01626911|OTHER|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
219405296|NCT02094872|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
219405297|NCT02094872|DRUG|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
219405298|NCT02094872|PROCEDURE|therapeutic procedure|
219405299|NCT02094872|OTHER|laboratory biomarker analysis|Correlative studies
219405300|NCT02094872|OTHER|quality-of-life assessment|Ancillary studies
219405301|NCT01258972|DEVICE|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
219405302|NCT01258972|DEVICE|POBA|Balloon angioplasty
219405303|NCT03938441|OTHER|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
219405304|NCT02729558|RADIATION|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
219405305|NCT05247619|DRUG|Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin|Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
219566539|NCT00602134|DRUG|6-Mercaptopurine|
219566540|NCT00289003|DRUG|Soluble beta-1,3/1,6-glucan|
219566541|NCT02621801|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
219566542|NCT03432234|OTHER|Biomarkers|This is an observational study, there is no intervention
219405306|NCT04674618|DEVICE|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
219405307|NCT02364947|DRUG|Nalmefene hydrochloride|As-needed; tablets, orally
219405308|NCT02364947|DRUG|Placebo|As-needed; tablets, orally
219405309|NCT02527551|OTHER|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
219405310|NCT04940442|BEHAVIORAL|Outreach|Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
219566543|NCT04147988|OTHER|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
219566544|NCT02199015|DEVICE|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
219566545|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
219566546|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
219755244|NCT01270529|OTHER|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
219755245|NCT00736983|DRUG|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
219755246|NCT00736983|DRUG|ciprofloxacin|12 weeks; daily 2 x 500mg
219755247|NCT05615402|OTHER|Bone-specific strength training|Muscular strength and rate of force development (RFD) will be assessed in the key exercises of the intervention protocol
219566547|NCT02225665|GENETIC|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
219405311|NCT00358995|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
219405312|NCT00358995|BEHAVIORAL|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
219755248|NCT05615402|DIETARY_SUPPLEMENT|Nutrition optimalisation|Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records
219755249|NCT02951637|DRUG|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
219755250|NCT02951637|DRUG|Gefitinib|Gefitinib (250mg daily)
219755251|NCT04240340|OTHER|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
219755252|NCT01576783|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
219755253|NCT01576783|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
219405313|NCT00423085|DRUG|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
219405314|NCT00423085|DRUG|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
219405315|NCT03904641|RADIATION|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
219405316|NCT03904641|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
219405317|NCT02260466|OTHER|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
219566548|NCT02225665|GENETIC|SB-728mR-T|\- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
219566549|NCT02225665|DRUG|Cyclophosphamide|\- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
219566550|NCT06525922|BEHAVIORAL|Center M|Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
219755254|NCT05916300|OTHER|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
219755255|NCT03521700|DRUG|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
219755256|NCT04096417|DRUG|Pemigatinib|Given PO
219755257|NCT04096417|OTHER|Quality-of-Life Assessment|Ancillary studies
219755258|NCT02228538|DEVICE|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
219755259|NCT01897493|DRUG|Evacetrapib|Administered orally
219755260|NCT01897493|DRUG|Digoxin|Administered orally
219755261|NCT04161534|DEVICE|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
219755262|NCT04161534|DEVICE|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
219755263|NCT04015258|DIETARY_SUPPLEMENT|Blueberries|fresh spanish blueberries
219755264|NCT04015258|DIETARY_SUPPLEMENT|Blueberry powder|freeze-dried blueberry powder
219566551|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
219755265|NCT04015258|DIETARY_SUPPLEMENT|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
219755266|NCT02298725|OTHER|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
219405318|NCT04561713|PROCEDURE|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
219405319|NCT02365493|DRUG|Beta-Lactam|
219405320|NCT06048406|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
219405321|NCT02163993|DRUG|Galcanezumab|Administered SQ
219405322|NCT02163993|DRUG|Placebo|Administered SQ
219405323|NCT00853489|DEVICE|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
219405324|NCT00853489|PROCEDURE|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
219405325|NCT05525975|OTHER|Educational materials|Educational materials will be developed by our interdisciplinary research team. Will consist of a brochure and a video. Both materials highlight important information about opioid medications, explain proper disposal of excess of opioid medications and provide drug-free pain management tools for postoperative pain.
219405326|NCT06200740|DEVICE|Sonara|web application facilitating asynchronous observation of methadone dosing
219405327|NCT00539253|DRUG|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
219405328|NCT05936034|OTHER|Patients suffering from chemotherapy-induced ototoxicity|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
219405329|NCT05936034|OTHER|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
219405330|NCT06203912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219405331|NCT06203912|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219405332|NCT06203912|DRUG|Cyclophosphamide|Given IV
219405333|NCT06203912|DRUG|Dexamethasone|Given PO
219405334|NCT06203912|PROCEDURE|Echocardiography|Undergo echocardiography
219405335|NCT06203912|BIOLOGICAL|Isatuximab|Given IV
219405336|NCT06203912|OTHER|Questionnaire Administration|Ancillary study
219405337|NCT06203912|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
219429302|NCT02131246|DRUG|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
219755267|NCT02298725|OTHER|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
219755268|NCT01067430|DRUG|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
219007132|NCT05013567|DRUG|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
219429303|NCT00493467|DRUG|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
219429304|NCT00493467|DRUG|Rituximab|250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
219429305|NCT05653804|PROCEDURE|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
219429306|NCT06444165|DRUG|Lebrikizumab Pen|Injected into a practice pad.
219429307|NCT05489081|BEHAVIORAL|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
219429308|NCT06270316|DRUG|AMT-191|"A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease."
219429309|NCT01213498|DRUG|Atorvastatin|Zarator, 80 mg pr. day for 5 days
219429310|NCT01213498|DRUG|Unikalk|1 tablet Unikalk pr day for 5. days
219405338|NCT05505643|DEVICE|Endocare SlimLine Cryoprobe|"The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures."
219405339|NCT05505643|PROCEDURE|Lumpectomy|Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
219405340|NCT02991950|DRUG|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
219405341|NCT01691872|DRUG|Retigabine|Retigabine
219405342|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
219405343|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
219405344|NCT05271019|DEVICE|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
219405345|NCT02928549|BEHAVIORAL|semi-structured interviews|
219405346|NCT02273752|DRUG|Everolimus|Given PO
219405347|NCT00266721|DRUG|Pancrelipase (Creon) 2 tablets with each meal|
219405348|NCT05798689|COMBINATION_PRODUCT|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
219405349|NCT05798689|COMBINATION_PRODUCT|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
219405350|NCT03065712|DRUG|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
219405351|NCT03065712|PROCEDURE|Computed Tomography|Undergo PET/CT
219405352|NCT03065712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219405353|NCT03065712|OTHER|Laboratory Biomarker Analysis|Correlative studies
219755269|NCT01067430|DRUG|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
219405354|NCT01503060|BEHAVIORAL|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
219405355|NCT01503060|BEHAVIORAL|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
219405356|NCT01503060|DRUG|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
219755270|NCT05489328|OTHER|Candidate-1|Biological
219755271|NCT05489328|OTHER|Candidate-2|Biological
219755272|NCT05489328|OTHER|Candidate-3|Biological
219755273|NCT05489328|OTHER|Candidate-4|Biological
219755274|NCT05489328|OTHER|Candidate-5|Biological
219405357|NCT01503060|DRUG|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
219405358|NCT01503060|DRUG|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
219405359|NCT01503060|DRUG|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
219405360|NCT01274741|BEHAVIORAL|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
219566552|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
219566553|NCT00607152|DRUG|Rasburicase|0.20mg/kg per day IV
219566554|NCT00607152|DRUG|Allopurinol|100mg tablets
219566555|NCT03642353|DRUG|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
219566556|NCT03642353|DRUG|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
219566557|NCT00365937|BIOLOGICAL|Immunological peptides and immunological adjuvants|
219566558|NCT00365937|BIOLOGICAL|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
219566559|NCT00365937|BIOLOGICAL|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
219755275|NCT05489328|OTHER|Candidate-6|Biological
219755276|NCT05489328|OTHER|Candidate Control|Biological
219755277|NCT05489328|BIOLOGICAL|13vPnC|13-valent pneumococcal conjugate vaccine
219755278|NCT05489328|BIOLOGICAL|PCV15|15-valent pneumococcal conjugate vaccine
219755279|NCT01083602|DRUG|panobinostat|PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
219755280|NCT01083602|DRUG|bortezomib|
219405361|NCT01274741|BEHAVIORAL|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
219405362|NCT02808312|DRUG|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
219566560|NCT00365937|BIOLOGICAL|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
219566561|NCT00572039|BEHAVIORAL|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
219566562|NCT00572039|BEHAVIORAL|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
219755281|NCT01083602|DRUG|dexamethasone|
219002264|NCT03326765|OTHER|Questionnaires|"* Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary"
219002265|NCT03326765|PROCEDURE|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
219002266|NCT03326765|PROCEDURE|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
219002267|NCT03326765|PROCEDURE|Actigraphy|type of sleep study based on bracelet around the wrist
219002268|NCT05965154|DRUG|Carrilizumab, bevacizumab,capecitabine|"1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
219002269|NCT04982809|DRUG|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
219002270|NCT06304220|DRUG|Cerazet|Comparation of the utilization of two distinct progestogens for pituitary suppression
219405363|NCT03009656|OTHER|No study specific interventions|
219405364|NCT02713230|DRUG|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
219405365|NCT02713230|DRUG|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
219405366|NCT02713230|DRUG|Placebo|20 mL normal saline as single-injection
219405367|NCT04972071|OTHER|Knowledge translation (KT) of the CSRS based practice recommendations|The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
219566563|NCT04257383|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
219566564|NCT03984123|DEVICE|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
219566565|NCT04127214|OTHER|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
219566566|NCT03852524|DRUG|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
219755282|NCT04326452|DEVICE|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
219755283|NCT05745155|DEVICE|Senti Wear device system with Senti-AI subsystem|"This device is a smart garment, with a similar form to a T-Shirt, jacket or tabard, embedded with ten sensor modules (nine acoustic sensors, one kinetic sensor - all able to detect signals from the chest wall and underlying structures, including the lungs) encased in silicone; the device is charged via a charging port in the garment. The device has two modes of operation: recording mode and charging mode. The device is internally (battery) powered during recording mode and mains-powered during charging mode. The device is accompanied by cloud-based software to listen to both contemporaneous and historically recorded breath sounds, for each Senti patient. To use the device, the user puts the garment on (overhead, like a T-Shirt, before joining the back piece to the front like a tabard).~Additionally, Senti-AI adds an anomaly burden score and an alert flag for review against each acoustic record for each patient."
219405368|NCT02474940|BEHAVIORAL|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
219405369|NCT02474940|BEHAVIORAL|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
219405370|NCT02474940|BEHAVIORAL|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
219405371|NCT04257110|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
219405372|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
219405373|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
219405374|NCT01132573|DRUG|entinostat|Given PO
219405375|NCT01132573|DRUG|clofarabine|Given IV
219405376|NCT01132573|OTHER|pharmacological study|Correlative studies
219405377|NCT01132573|OTHER|laboratory biomarker analysis|Correlative studies
219405378|NCT00909142|DRUG|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
219405379|NCT01134692|DRUG|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
219405380|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
219405381|NCT04520763|OTHER|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
219405382|NCT04520763|OTHER|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
219405383|NCT02259036|OTHER|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
219002271|NCT05025241|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
219007133|NCT05013567|OTHER|Placebo|Placebo gel topically four times a day
219405384|NCT06334822|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
219755284|NCT02543775|PROCEDURE|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
219405385|NCT06334822|OTHER|Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
219405386|NCT06334822|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
219405387|NCT06334822|DEVICE|Heartfelt Device in pharmacy|Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.
219405388|NCT06334822|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
219405389|NCT01188915|PROCEDURE|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
219405390|NCT03747835|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
219405391|NCT03747835|BEHAVIORAL|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
219405392|NCT00824187|DRUG|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
219405393|NCT00824187|DRUG|Placebo|Inert tablet
219405394|NCT06235463|OTHER|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
219405395|NCT06235463|OTHER|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
219405396|NCT03297099|PROCEDURE|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
219755285|NCT05420948|DRUG|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
219755286|NCT05420948|DRUG|Carboplatin|A chemotherapy drug used to treat cancer.
219405397|NCT03297099|PROCEDURE|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
219405398|NCT02745223|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
219405399|NCT02745223|DRUG|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
219405400|NCT02568033|DRUG|Pemetrexed|
219405401|NCT02568033|DRUG|Carboplatin|
219405402|NCT02568033|DRUG|Cisplatin|
219405403|NCT02568033|DRUG|Docetaxel|
219405404|NCT02568033|DRUG|Paclitaxel|
219566567|NCT03852524|OTHER|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
219755287|NCT05420948|DRUG|Paclitaxel|A chemotherapy drug used to treat cancer.
219405405|NCT02568033|RADIATION|stereotactic radiosurgery|
219002272|NCT01053221|DRUG|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
219002273|NCT01053221|DRUG|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
219405406|NCT05020652|DRUG|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
219405407|NCT05020652|DRUG|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
219405408|NCT01623531|DRUG|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
219566568|NCT06311019|DEVICE|Continuous glucose monitoring and use of connected insulinpen for bolus insulin|Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
219566569|NCT02622659|DRUG|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
219566570|NCT02622659|DRUG|Xiaoer Jiebiao Oral Liquid|"1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
219002274|NCT05510804|COMBINATION_PRODUCT|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
219002275|NCT06279091|BEHAVIORAL|Diaphragmatic Breathing|apply breathing exercises to evaluate the effectiveness on anxiety reduction
219405409|NCT02947516|PROCEDURE|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
219405410|NCT02947516|PROCEDURE|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
219566571|NCT02872350|DEVICE|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
219566572|NCT03478865|DRUG|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
219566573|NCT05309720|PROCEDURE|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
219566574|NCT03500367|DRUG|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
219566575|NCT02418455|DRUG|UX003|solution for intravenous infusion
219566576|NCT02539784|DEVICE|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
219566577|NCT05927779|DRUG|TFX06 tablet|TFX06 tablet taken orally
219566578|NCT00270933|DEVICE|Registry|
219566579|NCT06037278|DEVICE|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
219566580|NCT03966391|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
219566581|NCT04000191|PROCEDURE|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
219566582|NCT04000191|OTHER|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
219566583|NCT02057536|OTHER|Arm A Directed exercise program|
219566584|NCT02057536|OTHER|Observation|
219002276|NCT06279091|BEHAVIORAL|Bubble Blower Breathing|apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction
219002277|NCT06279091|BEHAVIORAL|Tell Show Do|apply basic behavioral management technique as control group
219002278|NCT06158594|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
219405411|NCT00861367|DRUG|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
219405412|NCT01672606|DRUG|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
219405413|NCT01429792|DRUG|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
219405414|NCT01429792|DRUG|ribavirin [Copegus]|standard treatment, orally daily
219405415|NCT03620266|DIETARY_SUPPLEMENT|Bilberry|The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
219566585|NCT01514825|DRUG|YM150|oral
219566586|NCT01514825|DRUG|Placebo|oral
219566587|NCT05871086|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
219566588|NCT05871086|OTHER|Placebo|Placebo Capsules
219007134|NCT03128112|OTHER|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
219189897|NCT06818682|DRUG|ADT for 9 months and ARTA for 6 months|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 9 months and ARTA for 6 months
219566589|NCT05871086|DRUG|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~* Leflunomide - Weight based, 10-20 mg once daily~* Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~* Etanercept - 0.8 mg/kg/dose once weekly~* Adalimumab - Weight based, 10-40 mg every other week"
219566590|NCT01934738|DRUG|PF-06273340|Tablets, 100 mg TID, 14 days
219566591|NCT01934738|DRUG|Placebo|Tablets, TID, 14 days
219566592|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
219566593|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
219566594|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
219566595|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
219566596|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
219566597|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
219566598|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
219566599|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
219566600|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
219566601|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
219566602|NCT01834209|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
219566603|NCT01834209|DRUG|Prednisone or prednisolone|5 mg tablet taken orally once daily
219566604|NCT03059485|BIOLOGICAL|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
219405416|NCT03620266|DIETARY_SUPPLEMENT|Placebo|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
219405417|NCT03620266|DIETARY_SUPPLEMENT|Bioprocessed oat bran|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
219405418|NCT03620266|DIETARY_SUPPLEMENT|Combination bilberry/oats|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
219405419|NCT03432910|OTHER|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
219405420|NCT04179968|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
219405421|NCT04179968|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
219405422|NCT06126874|OTHER|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
219405423|NCT06126874|OTHER|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
219405424|NCT06126874|OTHER|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
219755288|NCT06520397|DRUG|Ustekinumab and Upadacitinib|Participants in this group will maintain the original Ustekinumab regimen, receiving 90 mg administered subcutaneously every 8 weeks. In addition, they will receive Upadacitinib administered orally at a dosage of 45 mg daily for 12 weeks. After the 12-week period, the dosage of Upadacitinib will be adjusted based on patient condition and clinical judgment, continuing until the evaluation at week 16. Clinical efficacy of the dual-target therapy will be evaluated at week 16.
219755289|NCT06520397|DRUG|Ustekinumab|Participants will receive an additional induction dose of Ustekinumab administered intravenously at 6 mg/kg at baseline. This will be followed by subcutaneous maintenance therapy of 90 mg every 4 weeks. Clinical efficacy will be evaluated at week 16.
219755290|NCT00054522|DIETARY_SUPPLEMENT|calcitriol|
219755291|NCT00054522|DRUG|dexamethasone|
219755292|NCT05395936|OTHER|Myocardial Probe Temperature Screen|The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.
219755293|NCT05395936|OTHER|Data Collection|Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
219755294|NCT03697850|DRUG|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
219755295|NCT06549153|OTHER|Education Content|Participants will be offered group based education sessions expected to last 90 minutes
219755296|NCT06549153|OTHER|Focus Group|Participants will attend via Zoom
219007135|NCT03909256|OTHER|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
219405425|NCT06126874|OTHER|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
219405426|NCT04218916|DRUG|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
219405427|NCT04218916|DRUG|Placebo|2 placebo capsules once, three times a day
219405428|NCT04119726|BEHAVIORAL|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
219405429|NCT04119726|BEHAVIORAL|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
219405430|NCT04119726|BEHAVIORAL|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
219405431|NCT04790474|DRUG|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
219405432|NCT01583998|BEHAVIORAL|e-MBC|antidepressant treatment
219405433|NCT04184622|DRUG|Tirzepatide|Administered SC
219405434|NCT04184622|DRUG|Placebo|Administered SC
219566605|NCT03059485|OTHER|Observation|Traditional care provided by the hospital.
219566606|NCT05844631|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
219566607|NCT05435586|OTHER|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
219566608|NCT04554095|OTHER|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
219566609|NCT00010413|DRUG|cyclophosphamide|
219566610|NCT00010413|DRUG|filgrastim|
219566611|NCT05965102|DRUG|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
219755297|NCT02724202|DRUG|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
219755298|NCT02724202|DRUG|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
219007136|NCT00639054|PROCEDURE|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
219007137|NCT00639054|PROCEDURE|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
219405435|NCT06115421|DRUG|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
219405436|NCT02719418|DRUG|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
219566612|NCT03093272|DRUG|Leuprolide Acetate|a GnRH agonist
219566613|NCT03093272|DRUG|Prednisone|Prednisone is a corticosteroid
219566614|NCT03093272|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
219566615|NCT03093272|DRUG|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
219566616|NCT01368926|DRUG|RO4917523|single oral doses
219566617|NCT01368926|DRUG|RO4917523|multiple oral doses
219566618|NCT01368926|DRUG|placebo|oral doses
219566619|NCT00951951|PROCEDURE|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
219566620|NCT00951951|PROCEDURE|Posterior Approach|
219566621|NCT02054013|PROCEDURE|Prostatic artery embolization|
219566622|NCT02054013|PROCEDURE|monopolar transurethral prostatectomy|
219566623|NCT00272506|DRUG|inhaled corticosteroid|
219566624|NCT00272506|DRUG|long-acting beta2-agonist|
219566625|NCT06586151|BEHAVIORAL|Transcendent Health|Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
219755299|NCT02182518|DRUG|Epinastine|
219755300|NCT02182518|DRUG|Pseudoephedrine|
219755301|NCT02182518|DRUG|Placebo|Placebo during run-in period
219566626|NCT06586151|BEHAVIORAL|Text Messaging with Information|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
219566627|NCT05064748|DRUG|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
219566628|NCT03527251|DRUG|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
219566629|NCT03527251|DRUG|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
219566630|NCT00614822|DRUG|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
219566631|NCT00755768|BEHAVIORAL|additional review by dietician|
219566632|NCT00604903|DEVICE|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
219755302|NCT01887405|DRUG|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
219755303|NCT04232852|DIETARY_SUPPLEMENT|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
219755304|NCT04232852|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
219755305|NCT01674790|BEHAVIORAL|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
219755306|NCT01674790|BEHAVIORAL|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
219566633|NCT02464826|DRUG|Nailprotex|Nailprotex apply to the abnormal nail twice daily
219755307|NCT01674790|BEHAVIORAL|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
219755308|NCT01674790|BEHAVIORAL|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
219755309|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219566634|NCT03601546|OTHER|Clinical examination|Blood test and patient interview as for standard patient care
219566635|NCT00097045|DRUG|omega interferon|
219566636|NCT00097045|DRUG|Ribavirin|
219566637|NCT01557920|DRUG|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
219566638|NCT01557920|DRUG|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
219755310|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219755311|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219755312|NCT03698279|BIOLOGICAL|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
219755313|NCT03698279|BIOLOGICAL|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
219755314|NCT04128709|DEVICE|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
219189898|NCT06818682|DRUG|ADT for 2 years|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 2 years
219189899|NCT05713877|DRUG|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
219566639|NCT01072799|BIOLOGICAL|Placebo|Two doses (Day 1 and Day 22); 0.5mL
219566640|NCT01072799|BIOLOGICAL|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 \& Day 22); 0.5mL
219566641|NCT03634059|DRUG|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
219566642|NCT01996423|DIETARY_SUPPLEMENT|Vitamin D3|
219566643|NCT01996423|DIETARY_SUPPLEMENT|Placebo|
219566644|NCT04393623|BEHAVIORAL|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
219566645|NCT04393623|BEHAVIORAL|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
219566646|NCT01997723|DEVICE|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
219566647|NCT01997723|OTHER|Polysomnography|One attended diagnostic sleep study.
219566648|NCT01997723|DEVICE|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
219566649|NCT01997723|DEVICE|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
219566650|NCT01857206|BIOLOGICAL|Mammalian cell based flu vaccine|
219566651|NCT01857206|BIOLOGICAL|Egg based flu vaccine|
219566652|NCT05518032|PROCEDURE|Biopsy|Undergo biopsy
219566653|NCT05518032|BIOLOGICAL|Pembrolizumab|Given IV
219566654|NCT05518032|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given intratumorally
219566655|NCT02656654|OTHER|Whole-body compression|
219566656|NCT01082224|DRUG|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
219566657|NCT01082224|DRUG|motexafin gadolinium|motexafin gadolinium
219755315|NCT06632626|OTHER|Task oriented training exercises|Task oriented training is a type of exercises in form of tasks using papers, pens, scissors, clips, coins, screws and clay
219405437|NCT06300619|BEHAVIORAL|Pilates+4|12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
219755316|NCT06632626|OTHER|Traditional physical therapy|Traditional physical therapy inform of mobilization, strengthening exercises of hand and streching exercises.
219405438|NCT06300619|BEHAVIORAL|Pilates|12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
219405439|NCT05420467|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
219405440|NCT05420467|DRUG|Carboplatin|AUC 6, d1, q3w,6 cycles
219405441|NCT05420467|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
219405442|NCT05420467|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
219405443|NCT05420467|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
219405444|NCT05420467|DRUG|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
219405445|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
219405446|NCT05420467|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
219405447|NCT05420467|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
219566658|NCT01082224|OTHER|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
219566659|NCT03776929|BEHAVIORAL|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
219566660|NCT00273416|DRUG|PF-00592379|
219566661|NCT00273416|DRUG|Sildenafil 100mg|
219566662|NCT00090116|DRUG|Neramexane|
219566663|NCT04329299|DIAGNOSTIC_TEST|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
219566664|NCT04114942|BEHAVIORAL|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
219566665|NCT04114942|BEHAVIORAL|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
219566666|NCT04114942|BEHAVIORAL|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
219566667|NCT04029454|BIOLOGICAL|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B"
219405448|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
219405449|NCT05420467|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
219405450|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
219405451|NCT04319289|OTHER|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
219405452|NCT04319289|DRUG|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
219566668|NCT01118845|DRUG|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
219566669|NCT01118845|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
219566670|NCT04540692|DRUG|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
219566671|NCT04540692|DRUG|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
219755317|NCT05481736|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
219755318|NCT03767868|OTHER|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
219755319|NCT00491478|DRUG|sertraline|
219755320|NCT04275804|DEVICE|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
219755321|NCT04275804|OTHER|Conventional Dressing|Alternate Day Dressing
219566672|NCT01857973|DEVICE|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
219566673|NCT02588820|DRUG|Antiretroviral Therapy (Experimental)|"1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day"
219566674|NCT04139031|DEVICE|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
219566675|NCT02277431|DIETARY_SUPPLEMENT|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
219566676|NCT02277431|DIETARY_SUPPLEMENT|placebo|
219566677|NCT05806931|DRUG|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
219566678|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
219566679|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
219566680|NCT01634412|DRUG|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
219566681|NCT01634412|DRUG|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
219566682|NCT00908882|BEHAVIORAL|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
219566683|NCT00574067|DRUG|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
219566684|NCT00574067|DRUG|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
219566685|NCT00574067|DRUG|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
219566686|NCT00574067|DRUG|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
219405453|NCT04319289|OTHER|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks"
219405454|NCT05590234|DRUG|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
219566687|NCT04458467|DEVICE|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
219189900|NCT05713877|DRUG|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
219405455|NCT05590234|DRUG|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
219405456|NCT05590234|DRUG|normal saline|20 ml of normal saline 0.9%.
219755322|NCT02180828|DRUG|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
219405457|NCT00769704|BIOLOGICAL|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
219405458|NCT00769704|BIOLOGICAL|GM-CSF|125 µg/m² subcutaneous injection
219405459|NCT03852888|BIOLOGICAL|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
219405460|NCT00011193|BEHAVIORAL|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
219405461|NCT04051593|OTHER|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
219405462|NCT01351077|OTHER|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
219405463|NCT05553756|DIETARY_SUPPLEMENT|Maltodextrin|200 ml maltodextrin given 2 hours before cesarean section
219405464|NCT05163990|OTHER|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
219405465|NCT03548597|DEVICE|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
219007138|NCT03470818|OTHER|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
219405466|NCT02664636|PROCEDURE|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
219405467|NCT02664636|PROCEDURE|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
219405468|NCT02664636|PROCEDURE|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
219405469|NCT01531491|PROCEDURE|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
219405470|NCT01531491|PROCEDURE|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
219405471|NCT02743403|DEVICE|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
219405472|NCT02743403|DEVICE|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
219405473|NCT02743403|DEVICE|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
219405474|NCT04200170|DEVICE|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
219405475|NCT04801537|OTHER|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
219405476|NCT04801537|OTHER|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
219405477|NCT03022305|BEHAVIORAL|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
219405478|NCT03022305|BEHAVIORAL|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
219566688|NCT04458467|DEVICE|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
219566689|NCT02215772|DRUG|BI 44370 BS|
219566690|NCT02291367|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
219566691|NCT02291367|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
219566692|NCT05787067|BEHAVIORAL|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
219566693|NCT03754504|DIETARY_SUPPLEMENT|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
219566694|NCT03754504|DIETARY_SUPPLEMENT|Placebo|3 capsules/day of a placebo comparator
219566695|NCT01662934|DEVICE|I RUNE|
219566696|NCT01662934|DEVICE|sham|
219566697|NCT06157463|RADIATION|Ga-68 FAPI|FAPI PET scans will be performed in addition to other staging/restaging work-up
219405479|NCT03344731|BEHAVIORAL|Cognitive evaluation|Cognitive task
219405480|NCT03344731|DEVICE|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
219405481|NCT05853562|OTHER|structured vestibular rehabilitation program|The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
219405482|NCT01171547|DRUG|Daptomycin|once daily over 5 days
219405483|NCT01617681|DRUG|VAL489|Valsartan 3mg/kg oral solution
219405484|NCT01617681|DRUG|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
219405485|NCT03311607|DRUG|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
219405486|NCT03653611|OTHER|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
219566698|NCT04766216|OTHER|Patient self-management|Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools
219566699|NCT04766216|OTHER|Usual care provided by anticoagulation providers|Normal care provided by anticoagulation providers
219405487|NCT03653611|OTHER|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
219405488|NCT03653611|OTHER|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
219566700|NCT01731886|PROCEDURE|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
219566701|NCT01731886|DRUG|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
219566702|NCT01731886|DRUG|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
219566703|NCT01731886|PROCEDURE|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.
219566704|NCT01731886|DRUG|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
219566705|NCT01731886|DRUG|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
219566706|NCT01731886|DRUG|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
219566707|NCT01731886|DRUG|Mesna|Mesna will be provided with the cyclophosphamide.
219566708|NCT05368558|DRUG|Cariprazine|Oral Capsule
219405489|NCT03653611|OTHER|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
219405490|NCT03653611|OTHER|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
219405491|NCT03200457|DEVICE|1,5 Tesla abdominal MRI|Measurement of the fat and iron
219405492|NCT03200457|DEVICE|3 Tesla abdominal MRI|Measurement of the fat and iron
219405493|NCT00035425|DRUG|linezolid|600mg every 12 hours
219405494|NCT00035425|DRUG|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
219405495|NCT02241395|BIOLOGICAL|Intrathecal autologous bone marrow mononuclear cell transplantation|
219405496|NCT03696758|PROCEDURE|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
219405497|NCT03696758|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
219566709|NCT05368558|DRUG|Placebo|Oral Capsule
219566710|NCT00117117|DRUG|Aranesp|
219566711|NCT05260034|OTHER|FAST Program|This program aims to teach how to effectively reduce impact forces during a sideways fall by 1) changing the trunk/knee angles during descent to decrease body acceleration, 2) using a rolling movement to allow for an optimal distribution of impact forces applied to any site along the contact path; and 3) tucking the chin to protect the head.
219566712|NCT05260034|OTHER|Otago Exercise Program|The Otago Exercise Program (OEP) was chosen, rather than no control intervention, to increase the level of evidence required to demonstrate efficacy, and because, similar to the safe fall training used here, it was designed to be performed individually or in small groups.
219566713|NCT00334763|BIOLOGICAL|bevacizumab|
219566714|NCT00334763|DRUG|carboplatin|
219566715|NCT00334763|DRUG|chemoprotection|
219566716|NCT00334763|DRUG|paclitaxel|
219566717|NCT00334763|RADIATION|radiation therapy|
219566718|NCT00271024|DRUG|Naltrexone (drug)|50 mg q.d. for 13 weeks
219566719|NCT00271024|DRUG|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
219566720|NCT04225286|OTHER|Human breast milk|Intranasal human breast milk
219566721|NCT00129116|BIOLOGICAL|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
219566722|NCT00129116|BIOLOGICAL|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
219566723|NCT00129116|BIOLOGICAL|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
219002279|NCT01612936|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
219405498|NCT03696758|PROCEDURE|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
219405499|NCT03696758|DRUG|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
219405500|NCT03696758|DRUG|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
219405501|NCT02083510|DRUG|Colchicine|
219405502|NCT06387888|OTHER|Listening to mother's voice|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter (Official Gazette, 2018). Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
219405503|NCT00395252|DRUG|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
219405504|NCT06523452|OTHER|Laser Speckle Imaging|At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
219405505|NCT02882399|OTHER|Shortystrap|
219405506|NCT02002442|OTHER|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
219405507|NCT02145299|DEVICE|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
219405508|NCT02145299|DEVICE|CROSSER CTO Device|
219566724|NCT00129116|BIOLOGICAL|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
219566725|NCT00129116|BIOLOGICAL|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
219755323|NCT02180828|DRUG|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
219755324|NCT04972253|DRUG|Infigratinib|Oral, dosage per protocol
219405509|NCT00458406|DEVICE|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
219405510|NCT00458406|DEVICE|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
219405511|NCT03191656|DEVICE|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
219405512|NCT00147732|RADIATION|Accelerated radiotherapy|68 Gy over 5.5 weeks
219405513|NCT00147732|RADIATION|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
219405514|NCT01380106|DRUG|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
219405515|NCT01380106|DRUG|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
219405516|NCT01763905|BIOLOGICAL|Evolocumab|Subcutaneous injection
219405517|NCT01763905|DRUG|Placebo to Evolocumab|Subcutaneous injection
219405518|NCT01763905|DRUG|Ezetimibe|Tablet for oral administration
219566726|NCT03739216|DEVICE|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
219566727|NCT03969316|PROCEDURE|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
219566728|NCT03493321|OTHER|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
219755325|NCT01617473|PROCEDURE|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
219755326|NCT00871026|PROCEDURE|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
219755327|NCT00871026|PROCEDURE|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
219755328|NCT05662657|DIAGNOSTIC_TEST|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
219755329|NCT01276704|DRUG|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
219755330|NCT01276704|DRUG|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
219755331|NCT00654108|DRUG|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
219405519|NCT01763905|DRUG|Placebo to Ezetimibe|Tablet for oral administration
219007139|NCT03470818|OTHER|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
219405520|NCT00314756|DRUG|imiquimod|
219405521|NCT04346628|DRUG|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
219405522|NCT04346628|DRUG|Placebo|Placebo to match favipiravir administered orally through day 10.
219405523|NCT04346628|OTHER|Standard of care treatment|Standard of care treatment for COVID-19 infection
219405524|NCT00227383|DEVICE|Electroacupuncture (device)|
219405525|NCT00260637|PROCEDURE|Acupuncture|
219405526|NCT02364206|DRUG|LY2228820|
219405527|NCT02364206|DRUG|Temozolomide|
219405528|NCT02364206|RADIATION|radiotherapy|
219405529|NCT00646971|DEVICE|CPAP device|for 4 weeks
219405530|NCT00646971|DEVICE|Placebo device|for 4 weeks
219405531|NCT03163199|DEVICE|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
219405532|NCT03926559|DRUG|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
219405533|NCT06122428|DRUG|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
219405534|NCT06122428|DRUG|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
219405535|NCT04514237|DRUG|BOS172767 enantiomer E1 or E2|Oral tablets
219405536|NCT04514237|DRUG|Placebo|Oral tablets
219405537|NCT00083070|DRUG|temozolomide|
219755332|NCT00654108|BIOLOGICAL|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
219405538|NCT06502470|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
219405539|NCT03051334|OTHER|diagnosed as bicuspid aortic valve|
219007140|NCT00344747|BEHAVIORAL|dietary, behavioral, physical activity|
219007141|NCT03259854|DEVICE|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
219405540|NCT02640846|DRUG|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
219405541|NCT02640846|DRUG|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
219405542|NCT02640846|DRUG|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
219405543|NCT06519006|PROCEDURE|Pelvic floor exercise|Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.
219405544|NCT01236612|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
219405545|NCT01236612|BIOLOGICAL|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
219405546|NCT01236612|BIOLOGICAL|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
219405547|NCT01236612|BIOLOGICAL|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
219405548|NCT01236612|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
219405549|NCT01000194|DIETARY_SUPPLEMENT|High fat meal|A high fat milkshake containing 55g of fat
219405550|NCT02810262|OTHER|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
219405551|NCT02814968|DRUG|Enzalutamide|
219405552|NCT02814968|DEVICE|18-FDG PET/CT|
219405553|NCT02814968|DEVICE|Whole body MRI|
219405554|NCT02814968|DEVICE|Bone scan|
219405555|NCT04336592|BEHAVIORAL|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
219405556|NCT04664595|DRUG|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
219405557|NCT00016874|DRUG|cisplatin|
219405558|NCT00016874|DRUG|paclitaxel|
219405559|NCT00016874|DRUG|triapine|
219405560|NCT00002789|DRUG|busulfan|
219405561|NCT00002789|DRUG|cyclophosphamide|
219405562|NCT00002789|DRUG|cyclosporine|
219755333|NCT00654108|OTHER|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
219405563|NCT00002789|DRUG|methotrexate|
219405564|NCT00002789|PROCEDURE|allogeneic bone marrow transplantation|
219405565|NCT00002789|PROCEDURE|peripheral blood stem cell transplantation|
219405566|NCT03161938|DRUG|Dexamethasone|intravenous
219566729|NCT06535555|DEVICE|Investigational Safety and Feasibility|"Technical feasibility will be assessed based on a five-point rating scale assessing the ease-of-use, ureteral visibility, and time required to identify the ureter using ActivSight™. All images and video of the ureter will be recorded, but surgeon feedback will be used to assess technical success based on a five point scale, rather than these (subsequently de-identified) recordings.~Safety will be confirmed through clinical assessments and evaluation of adverse events intraoperatively and through a 28-day follow-up period using the criteria listed below. All adverse events will be adjudicated by the site's Principal Investigator (PI) to judge the relatedness of the adverse event to either the administration of riboflavin or the use of the prototype ActivSight™ device (or whether the adverse event was unrelated to either)"
219566730|NCT04152369|PROCEDURE|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
219566731|NCT01677208|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
219566732|NCT01677208|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
219566733|NCT01677208|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
219566734|NCT05279638|DIAGNOSTIC_TEST|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
219566735|NCT04904484|DEVICE|iZephyr hood|Assessment of an aerosol containment device
219755334|NCT02411409|BEHAVIORAL|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
219405567|NCT03531177|BEHAVIORAL|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
219405568|NCT03531177|BEHAVIORAL|Control|Participants receive usual care from their healthcare team.
219405569|NCT06324994|DRUG|Linperlisib in combination with Obinutuzumab and Venetoclax|Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
219405570|NCT03615755|OTHER|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
219405571|NCT06279897|OTHER|Skin Surface Rewarming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~90°F and held here for the duration of the LBNP test.
219405572|NCT06279897|OTHER|Skin Surface Warming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~93°F and held here for the duration of the LBNP test.
219405573|NCT06279897|OTHER|Skin Surface Heating|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~95°F and held here for the duration of the LBNP test.
219405574|NCT06279897|OTHER|Skin Surface Cooling|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will remain lowered to \~82°F for the duration of the LBNP test.
219566736|NCT06025552|DRUG|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
219566737|NCT06025552|DRUG|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
219566738|NCT04741152|PROCEDURE|Pancreatic resection|Different pancreatic resections
219566739|NCT06014879|BEHAVIORAL|Type 1 Doing Well (T1DW) Program|"Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites."
219566740|NCT06014879|OTHER|Diabetes-Related Information and Resources Program|Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
219566741|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
219566742|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
219566743|NCT01040793|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
219566744|NCT01040793|DRUG|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
219566745|NCT01040793|DRUG|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
219755335|NCT02276040|DRUG|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
219755336|NCT02196350|BEHAVIORAL|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
219755337|NCT02196350|BEHAVIORAL|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
219007142|NCT03259854|DEVICE|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
219405575|NCT04898374|DRUG|Gemcitabin/cisplatin|chemotherapy combination
219405576|NCT02712372|DRUG|AZD4831|AZD4831 1-50 mg/g oral suspension
219007143|NCT03449082|BIOLOGICAL|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
219566746|NCT04689893|DRUG|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
219566747|NCT04689893|DRUG|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
219566748|NCT00807209|DRUG|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
219405577|NCT02712372|DRUG|AZD4831 placebo|AZD4831 placebo oral suspension
219405578|NCT06552598|DRUG|KD01(the recombinant oncolytic adenovirus)|"Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged."
219566749|NCT00807209|DRUG|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
219566750|NCT00807209|DRUG|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
219566751|NCT00807209|DRUG|Fentanyl via PCA|Fentanyl via PCA
219566752|NCT00807209|DRUG|Bupivacaine via epidural|Bupivacaine via epidural
219566753|NCT04285827|BIOLOGICAL|CSL889|Administered as an IV infusion
219566754|NCT01922960|OTHER|micro-imaging|micro-imaging
219566755|NCT01456429|PROCEDURE|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
219566756|NCT02740907|PROCEDURE|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
219566757|NCT04643392|PROCEDURE|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
219566758|NCT00843830|RADIATION|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
219566759|NCT00843830|BIOLOGICAL|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
219566760|NCT01826916|DRUG|DX-88 (ecallantide)|solution for injection 10 mg/mL
219566761|NCT02309424|DIETARY_SUPPLEMENT|Vinegar|0,50mmol vinegar (6% acetic acid)
219566762|NCT02309424|OTHER|Placebo|50 ml water
219566763|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment A|Single oral dose
219566764|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment B|Single oral dose
219566765|NCT05363995|BEHAVIORAL|i-Sleep & BioClock Intervention|"The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily."
219566766|NCT03946917|DRUG|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
219566767|NCT03946917|DRUG|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
219566768|NCT01913795|OTHER|integrated pest management|integrated pest management and environmental strategy
219566769|NCT01913795|OTHER|air purifier|air purifiers
219566770|NCT01913795|OTHER|Sham air purifier|sham air purifiers
219566771|NCT04071054|DIAGNOSTIC_TEST|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
219566772|NCT01780376|PROCEDURE|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
219566773|NCT04750382|DRUG|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
219566774|NCT06615934|OTHER|Aerobic and resistance exercise|"From the first day of transplantation in the ICU until 10 days after transfer to the ward or discharge from the hospital, if needed, the patients of the group will undergo respiratory physiotherapy once a day. The process of this program includes patient assessment, clinical decision-making, and implementation of therapeutic interventions.~The interventions of the therapeutic exercise group are divided into three phases:~1. From the time the patient enters the ICU until the time of extubation;~2. From the time of extubation to the time of transfer to the ward;~3. Duration of the patient's stay in the ward."
219566775|NCT06615934|OTHER|Respiratory physiotherapy|The participants of this group will receive respiratory physiotherapy daily after transplant until discharge.
219566776|NCT04533906|DEVICE|Coldamaris lozenges|sucking carageenan containing lozenge
219755338|NCT02196350|BEHAVIORAL|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
219755339|NCT06327438|OTHER|Complex decongestive therapy|"1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care."
219566777|NCT05424731|COMBINATION_PRODUCT|DBV712 250 mcg|Daily epicutaneous delivery.
219566778|NCT03695809|BIOLOGICAL|G9a protein|To assess G9a protein expression on vulvar cancer
219566779|NCT06461377|DRUG|Glucagon-like peptide-1 receptor agonist：Semaglutide|The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
219755340|NCT06327438|DEVICE|Cryotherapy|It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.
219755341|NCT06327438|OTHER|Kinesio taping|It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
219755342|NCT05160389|DRUG|PBI-200|Single dose of PBI-200
219755343|NCT01015521|DRUG|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
219566780|NCT04721496|BEHAVIORAL|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
219755344|NCT02995590|DRUG|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
219755345|NCT02239926|DRUG|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
219566781|NCT00672776|DRUG|paroxetine|
219566782|NCT00672776|DRUG|placebo|
219566783|NCT00946491|DRUG|Haloperidol 10 mg Tablets (Cord Laboratories)|
219755346|NCT02239926|DRUG|Placebo|
219755347|NCT05213806|OTHER|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
219405579|NCT01057719|OTHER|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
219755348|NCT05213806|OTHER|Continued feeds around transfusion|Continued enteral feeds
219755349|NCT01332214|DRUG|AZD2820|Subcutaneous Injection in abdomen or Thigh
219755350|NCT01332214|DRUG|Placebo|Subcutaneous Injection in abdomen or Thigh
219755351|NCT01434004|BEHAVIORAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
219755352|NCT03187509|DRUG|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
219755353|NCT03187509|OTHER|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
219189901|NCT06746662|BEHAVIORAL|Hypnobreastfeeding training and consultancy|"Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-up"
219189902|NCT06438965|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
219405580|NCT00492947|BIOLOGICAL|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
219405581|NCT04551573|DRUG|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
219755354|NCT00224393|DRUG|Enbrel|
219755355|NCT02121093|PROCEDURE|vibration|
219755356|NCT03719807|OTHER|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
219755357|NCT03719807|OTHER|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
219755358|NCT00097630|PROCEDURE|SAT: Spontaneous Awakening Trial|
219755359|NCT00097630|PROCEDURE|SBT: Spontaneous Breathing Trial|
219189903|NCT06821776|PROCEDURE|Gastric feeding|Subjects will be fed through a feeding tube that empties into the stomach.
219189904|NCT06821776|PROCEDURE|Transpyloric feeding|Subjects will be fed through a feeding tube that passes through the stomach and empties directly into the small intestine.
219189905|NCT06295562|DRUG|Atomoxetine 80mg combined with oxybutynin 5mg|Atomoxetine 80mg combined with oxybutynin 5mg
219189906|NCT06295562|DRUG|Venlafaxine 37.5mg|Venlafaxine 37.5mg
219189907|NCT06295562|DRUG|Atomoxetine 80mg combined with trazodone 100mg|Atomoxetine 80mg combined with trazodone 100mg
219189908|NCT06295562|DRUG|Placebo|Placebo tablet
219405582|NCT04551573|DRUG|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
219755360|NCT06372795|OTHER|pure effortful swallowing|"The investigator instructed the patient to swallow forcefully while squeezing the tongue upward and backward in the direction of the soft palate based on the sounds of an electronic timer."
219755361|NCT06372795|OTHER|progressive resistance swallowing training|Patients in the test group, resistance swallowing exercise was performed by providing external resistance through Iowa Oral Performance Instrument (IOPI), and all other protocols were performed the same as those in the control group.
219755362|NCT03801525|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion"
219755363|NCT03801525|DRUG|Umbralisib|"* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form"
219405583|NCT02225444|OTHER|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
219405584|NCT02890082|DRUG|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
219755364|NCT03801525|DRUG|Venetoclax|"* B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form"
219755365|NCT04573855|BIOLOGICAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
219755366|NCT00022178|DRUG|cisplatin|
219755367|NCT00022178|DRUG|cyclophosphamide|
219755368|NCT00022178|DRUG|doxorubicin hydrochloride|
219755369|NCT00022178|DRUG|epirubicin hydrochloride|
219755370|NCT00022178|DRUG|fluorouracil|
219755371|NCT00022178|DRUG|vincristine sulfate|
219755372|NCT05586373|DRUG|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
219755373|NCT05586373|DRUG|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
219755374|NCT02542618|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
219755375|NCT02542618|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219405585|NCT02890082|DRUG|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
219405586|NCT02890082|DRUG|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
219405587|NCT05547763|PROCEDURE|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
219405588|NCT04628013|DEVICE|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
219405589|NCT02482363|RADIATION|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
219405590|NCT02482363|RADIATION|Sham Control|20 minutes of sham control exposure
219405591|NCT05187806|BEHAVIORAL|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
219405592|NCT00174616|DRUG|Oxaliplatin, capecitabine, radiotherapy|"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
219405593|NCT06517615|BEHAVIORAL|Home Visit Supported Nursing Training Program|Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
219405594|NCT01139385|PROCEDURE|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
219566784|NCT00946491|DRUG|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
219566785|NCT06076369|PROCEDURE|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
219566786|NCT05857462|PROCEDURE|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
219405595|NCT01139385|PROCEDURE|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
219566787|NCT02893280|DRUG|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
219566788|NCT00939627|BIOLOGICAL|cetuximab|Given IV
219566789|NCT00939627|OTHER|placebo|Given orally
219566790|NCT00939627|DRUG|sorafenib tosylate|Given orally
219566791|NCT00939627|OTHER|laboratory biomarker analysis|Correlative studies
219566792|NCT00939627|PROCEDURE|quality-of-life assessment|Ancillary studies
219755376|NCT02673944|DEVICE|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
219755377|NCT01889992|RADIATION|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
219755378|NCT01889992|PROCEDURE|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
219755379|NCT01889992|OTHER|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
219405596|NCT03913624|OTHER|Neuromuscular electrical stimulation|
219405597|NCT05943977|DRUG|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
219405598|NCT05943977|DRUG|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
219405599|NCT05943977|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
219405600|NCT00377143|DRUG|Warfarin Dosing|
219405601|NCT01028651|DRUG|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
219405602|NCT03747224|DRUG|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
219405603|NCT03747224|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
219405604|NCT00376597|OTHER|quality of life assessment|Ancillary studies
219405605|NCT00376597|OTHER|educational intervention|Receive lymphedema educational materials
219405606|NCT00376597|PROCEDURE|Physical therapy|Complete physical therapy-focused intervention
219405607|NCT02194400|BIOLOGICAL|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
219566793|NCT02918682|OTHER|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
219755380|NCT01889992|DRUG|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
219755381|NCT01889992|PROCEDURE|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
219755382|NCT01889992|GENETIC|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
219755383|NCT01889992|OTHER|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
219755384|NCT05077969|DRUG|Famotidine|80 mg tablet, QID for 14 days
219755385|NCT05077969|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
219405608|NCT02146079|DRUG|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
219405609|NCT02146079|DRUG|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
219405610|NCT00633581|DIETARY_SUPPLEMENT|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
219405611|NCT00633581|DIETARY_SUPPLEMENT|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
219405612|NCT06271070|OTHER|Non-intervention|Non
219007144|NCT03449082|BIOLOGICAL|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
219405613|NCT06305104|BIOLOGICAL|2.5μg/ml EEC|0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
219405614|NCT06305104|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
219405615|NCT06305104|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
219007145|NCT03449082|DRUG|Fibrin glue|Fibrin glue 0.5cc
219007146|NCT03449082|DRUG|Normal saline|Normal saline 0.5cc
219405616|NCT01554956|BIOLOGICAL|Human Plasminogen|Eye Drops
219405617|NCT06551857|OTHER|Chemotherapy, chemoradiation, radiation therapy|Cancer treatment
219405618|NCT05257408|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
219405619|NCT05257408|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
219405620|NCT05257408|DRUG|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
219405621|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
219405622|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
219405623|NCT04548089|BEHAVIORAL|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
219405624|NCT00629694|PROCEDURE|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
219405625|NCT00629694|PROCEDURE|A-M|adenoidectomy and myringotomy alone
219405626|NCT01735747|RADIATION|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
219405627|NCT01735747|DRUG|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
219405628|NCT01735747|DRUG|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
219405629|NCT01735747|DRUG|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
219405630|NCT06141213|DIAGNOSTIC_TEST|Ultrasound screening|Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
219405631|NCT04153006|DEVICE|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
219405632|NCT03165136|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
219405633|NCT03165136|DRUG|Placebo|placebo of hydroxychloroquine
219405634|NCT03034304|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
219405635|NCT03034304|DRUG|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
219405636|NCT03034304|DRUG|PD1 antibody|200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
219405637|NCT03034304|DRUG|Adriamycin|60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
219405638|NCT03034304|DRUG|Gemcitabine|1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
219405639|NCT03034304|DRUG|Cisplatin|70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
219405640|NCT03034304|DRUG|Carboplatin|5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
219405641|NCT05951738|PROCEDURE|Blood and saliva collection|Blood and saliva samples from pregnant women; saliva samples from babies.
219007147|NCT02812147|DRUG|L-DOPS|Added as described in the Arm/Group Descriptions.
219007148|NCT02812147|DRUG|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
219405642|NCT05951738|BEHAVIORAL|Psychometric scales|A battery of psychometric scales and questionnaires.
219405643|NCT05951738|OTHER|Smartphone app|A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
219405644|NCT03446534|DRUG|Amoxicillin|Imacillin mixture
219755386|NCT05077969|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
219755387|NCT00352300|PROCEDURE|Adjuvant Therapy|
219405645|NCT03446534|DRUG|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
219755388|NCT00352300|DRUG|Carboplatin|Given IV
219755389|NCT00352300|DRUG|Paclitaxel|Given IV
219755390|NCT00352300|BIOLOGICAL|Pegfilgrastim|Given IV
219755391|NCT04388826|DRUG|Veru-111|Respiratory Distress Syndrome, Adult
219755392|NCT00098800|DRUG|fenretinide|
219755393|NCT05832892|DRUG|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
219755394|NCT05832892|DRUG|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
219405646|NCT00913978|DEVICE|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
219405647|NCT00913978|DEVICE|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
219405648|NCT06475989|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219405649|NCT06475989|DRUG|Cabozantinib|Given PO
219405650|NCT06475989|PROCEDURE|Computed Tomography|Undergo CT scan
219405651|NCT06475989|DRUG|Dabrafenib|Given PO
219405652|NCT06475989|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219405653|NCT06475989|OTHER|Questionnaire Administration|Ancillary study
219566794|NCT02918682|OTHER|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
219566795|NCT02918682|OTHER|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
219566796|NCT02918682|OTHER|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
219755395|NCT05832892|DRUG|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
219755396|NCT05832892|DRUG|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
219755397|NCT05393700|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
219755398|NCT00025415|DRUG|imatinib mesylate|Given orally
219755399|NCT00025415|OTHER|pharmacological study|Correlative studies
219755400|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
219755401|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
219405654|NCT06475989|DRUG|Trametinib|Given PO
219405655|NCT02869854|BEHAVIORAL|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
219405656|NCT02869854|BEHAVIORAL|PAP|Physical Activity on Prescription, after 3 months a new prescription
219405657|NCT03610256|PROCEDURE|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI \< 50
219405658|NCT03610256|PROCEDURE|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
219405659|NCT06368830|DIAGNOSTIC_TEST|3-ounce water swallow test|Bedside water swallow dysphagia screen where vocal quality of the participant is assessed before and after swallowing 3 ounces of water
219755402|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
219755403|NCT02862574|DRUG|Andecaliximab|Administered via subcutaneous injection once weekly
219755404|NCT02862574|DRUG|Placebo|Administered via subcutaneous injection once weekly
219755405|NCT02862574|DRUG|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
219755406|NCT02862574|DRUG|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
219755407|NCT03985202|OTHER|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
219189909|NCT05951660|BEHAVIORAL|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
219189910|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
219189911|NCT06331338|BEHAVIORAL|Decision Cycle for Person-Centered Glycemic Management|It is defined as a purposefully designed holistic care intervention that improve self-management .
219189912|NCT06331338|OTHER|Traditional diabetes self-management education|Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
219405660|NCT06368830|DIAGNOSTIC_TEST|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Scored assessment of the lymph nodes, lips, tongue, tissue inside of cheek, floor and roof of mouth, gums between teeth and/or under artificial teeth, saliva, condition of natural/artificial teeth, chewing position of teeth, and oral cleanliness
219405661|NCT06368830|DIAGNOSTIC_TEST|Tongue pressure|"Maximum isometric lingual pressure at the front and back of tongue will be measured by placing an air-filled pressure bulb on the surface of the oral tongue and having participants press the bulb as hard as possible against the hard palate"
219405662|NCT06368830|DIAGNOSTIC_TEST|Test of Masticating and Swallowing Solids (TOMASS)|Measurement of bites, masticatory cycles, swallows, and time taken to consume a cracker
219405663|NCT06368830|DIAGNOSTIC_TEST|Respiratory function tests|Participants will take a maximum inhalation and forcefully exhale into a spirometer to measure maximum expiratory pressure (MEP), fully exhale their air and take a maximal inhalation into the spirometer to measure maximum inspiratory pressure (MIP), and produce a single strong cough into to spirometer to measure peak expiratory flow (PEF) and forced expiratory volume (FEV1)
219405664|NCT06246058|BEHAVIORAL|Partner support|The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
219566797|NCT06617676|DEVICE|Transcutaneous tibial nerve stimulation|Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.
219566798|NCT02152462|OTHER|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
219566799|NCT03668431|DRUG|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
219189913|NCT05663359|PROCEDURE|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
219405665|NCT06246058|BEHAVIORAL|Formal recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority."
219566800|NCT03668431|DRUG|Trametinib|Trametinib will be taken once a day for 28 consecutive days
219566801|NCT03668431|DRUG|PDR001|PDR001 will be administered IV every 28 days
219566802|NCT02487082|DRUG|Melatonin and Donepezil|10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
219566803|NCT02487082|OTHER|Placebo|For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
219755408|NCT03759496|BIOLOGICAL|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
219755409|NCT02150161|DRUG|Lidocaine/ ketamine|
219755410|NCT02150161|DRUG|Fentanyl|
219755411|NCT04487444|DRUG|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
219755412|NCT05557396|OTHER|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
219755413|NCT02018211|OTHER|control|passive recovery following exercise test
219755414|NCT02018211|DEVICE|graduated compression socks|graduated compression socks worn after test exercise
219755415|NCT02018211|DEVICE|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
219405666|NCT06246058|BEHAVIORAL|Without Partner support|The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
219405667|NCT06246058|BEHAVIORAL|Casual recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case."
219405668|NCT05411198|DEVICE|XEN45 (Glaucoma Gel Stent)|Ab externo implant
219405669|NCT04472260|PROCEDURE|Verticalization and Prone position|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
219405670|NCT06501534|DRUG|Febuxostat|Tablets, Once a day (QD), Per oral
219405671|NCT06501534|DRUG|IBI128|Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
219405672|NCT04261543|OTHER|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
219566804|NCT02369120|OTHER|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
219566805|NCT02369120|OTHER|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
219566806|NCT04733248|OTHER|Kinesiotaping group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
219566807|NCT04733248|OTHER|stretching group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
219566808|NCT03160586|DIAGNOSTIC_TEST|Stuttering severity instrument-3|To measure of degree of stuttering in child
219566809|NCT03160586|DIAGNOSTIC_TEST|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
219566810|NCT03588650|DRUG|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
219566811|NCT06000761|PROCEDURE|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
219566812|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
219566813|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
219755416|NCT05821855|DEVICE|XEN45 Glaucoma Treatment System|Ab interno implantation
219755417|NCT05821855|PROCEDURE|Trabeculectomy|Surgical Intervention
219755418|NCT01937065|OTHER|No treatment|
219755419|NCT00642044|PROCEDURE|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
219755420|NCT03276182|DEVICE|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
219405673|NCT04261543|OTHER|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
219405674|NCT01327651|DRUG|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
219405675|NCT01327651|DRUG|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
219405676|NCT01327651|DRUG|Event-driven dosing|TDF/FTC as needed with a post exposure dose
219189914|NCT05663359|PROCEDURE|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
219405677|NCT05378425|DRUG|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
219405678|NCT05378425|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
219405679|NCT05643482|DEVICE|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
219405680|NCT05643482|OTHER|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
219566814|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
219755421|NCT01020357|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
219405681|NCT06079268|OTHER|the initial gastric ultrasound|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
219566815|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
219566816|NCT02341521|DRUG|OC000459|Taken orally for 8 days
219566817|NCT00489164|DEVICE|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
219566818|NCT02613078|BEHAVIORAL|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
219566819|NCT02613078|DIETARY_SUPPLEMENT|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
219566820|NCT02613078|BEHAVIORAL|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
219566821|NCT01698593|DRUG|Bupivacaine 0.5%|
219566822|NCT01698593|DRUG|Bupivacaine 0.5% + Epinephrine (1:200,000)|
219566823|NCT01413282|RADIATION|Cardiac CT|Calcium scan and CT coronary angiography
219566824|NCT05596292|DEVICE|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
219566825|NCT05596292|OTHER|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
219566826|NCT04958382|DRUG|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
219566827|NCT04958382|DRUG|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
219566828|NCT02624167|DRUG|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
219755422|NCT01020357|DRUG|placebo|normal saline
219755423|NCT03271866|DRUG|metformin|metformin 1500mg per day
219755424|NCT04313465|OTHER|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
219007149|NCT02296268|BEHAVIORAL|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
219755425|NCT05159674|DEVICE|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
219755426|NCT02068144|DIETARY_SUPPLEMENT|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
219755427|NCT02068144|OTHER|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
219007150|NCT01669915|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
219405682|NCT06079268|OTHER|the gastric ultrasound last 3 minutes|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
219405683|NCT05669001|BIOLOGICAL|TCD601|Investigational Product
219405684|NCT05669001|BIOLOGICAL|belatacept|Study Product
219405685|NCT05669001|DRUG|ATG|Comparator
219755428|NCT02001168|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
219755429|NCT02001168|DRUG|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
219405686|NCT05669001|DRUG|TAC|Comparator
219405687|NCT05669001|DRUG|MPA|Immunosuppression Therapy
219405688|NCT05669001|DRUG|Corticosteroids|Immunosuppression Therapy
219566829|NCT02624167|DRUG|Placebo|Patients will be given oral dose of matching Placebo
219566830|NCT00608595|DRUG|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
219566831|NCT00608595|GENETIC|gene expression analysis|not noted
219566832|NCT00608595|GENETIC|protein expression analysis|Not noted
219566833|NCT00608595|OTHER|immunohistochemistry staining method|not noted
219405689|NCT03147144|OTHER|Ultrasonographic imaging|Ultrasound pelvic scan
219405690|NCT04111276|DEVICE|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
219405691|NCT04111276|OTHER|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
219405692|NCT04111276|DIAGNOSTIC_TEST|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
219405693|NCT04111276|DIAGNOSTIC_TEST|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
219566834|NCT00608595|OTHER|laboratory biomarker analysis|not noted
219566835|NCT00608595|OTHER|mass spectrometry|
219755430|NCT02001168|DRUG|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
219566836|NCT00608595|PROCEDURE|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
219566837|NCT00608595|PROCEDURE|neoadjuvant therapy|not noted
219566838|NCT00608595|PROCEDURE|therapeutic conventional surgery|not noted
219566839|NCT05909917|OTHER|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
219566840|NCT04351841|OTHER|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
219755431|NCT02001168|DRUG|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
219755432|NCT03386773|BEHAVIORAL|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
219755433|NCT03386773|BEHAVIORAL|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
219755434|NCT03274778|DRUG|Ruxolitinib 20 MG|tablets
219755435|NCT03639610|DRUG|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
219755436|NCT03639610|DRUG|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
219755437|NCT04328389|BEHAVIORAL|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
219566841|NCT04351841|OTHER|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
219566842|NCT05048641|OTHER|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
219755438|NCT04328389|PROCEDURE|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
219755439|NCT03136055|DRUG|Pembrolizumab|Given Intravenously (IV)
219755440|NCT03136055|DRUG|Irinotecan|Given IV
219007151|NCT01669915|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219405694|NCT02648412|DRUG|ketamine|bolus 1 mg/kg
219405695|NCT02648412|PROCEDURE|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
219405696|NCT04097756|DRUG|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
219566843|NCT04431414|OTHER|Sample collection|"* blood, nasal swab, nasal wash, and saliva~* optional stool swab"
219566844|NCT02868541|OTHER|Naso pharyngeal swab|Naso pharyngeal swab
219566845|NCT02492841|DRUG|Mineral trioxide aggregate|Mineral trioxide aggregate
219566846|NCT02492841|DRUG|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
219566847|NCT02492841|DRUG|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
219566848|NCT03746002|DRUG|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
219755441|NCT03136055|DRUG|Paclitaxel|Given IV
219755442|NCT01115504|DRUG|Thiamine|300 mg daily for 30 days
219755443|NCT04115462|DRUG|Morphine|A 20 mg tablet of morphine
219755444|NCT04115462|DRUG|Placebo oral tablet|Matching tablet of placebo
219755445|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
219755446|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
219755447|NCT04115462|DRUG|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
219755448|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
219405697|NCT04597034|PROCEDURE|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
219405698|NCT04597034|PROCEDURE|AN69-Standard|Standard treatment.
219405699|NCT06072872|DEVICE|Use of portable CPAP|Patients use portable CPAP during exercise
219405700|NCT04236206|BEHAVIORAL|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered."
219405701|NCT04592432|OTHER|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
219405702|NCT04592432|OTHER|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
219405703|NCT00584220|DEVICE|senofilcon A toric|contact lens
219405704|NCT00584220|DEVICE|alphafilcon A toric|contact lens
219405705|NCT04972032|DEVICE|Estrogen Intrauterine Stent System|A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.
219405706|NCT04972032|DEVICE|Foley balloon combined with self-cross-link sodium hyaluronate gel|Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days
219405707|NCT00042354|DRUG|clofarabine (IV formulation)|
219405708|NCT03359005|DRUG|Vincristine|vincristine 1.5mg/m2 iv D1,D8
219405709|NCT03359005|DRUG|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
219405710|NCT05186883|BIOLOGICAL|Allogenic parathyroid cells|Allogenic parathyroid cells
219405711|NCT05186883|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
219405712|NCT00782665|PROCEDURE|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
219405713|NCT06819657|DEVICE|Remote Ischemic Conditioning Treatment Instrument|Remote ischemic conditioning (RIC) was administered twice daily to the unilateral lower limb using a blood pressure cuff inflated to 200 mmHg for 7 consecutive days post-clipping
219405714|NCT06819657|OTHER|Guideline-based therapy|Guideline-based therapy
219405715|NCT06989086|BEHAVIORAL|Fearless in Neuro-Oncology|FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.
219405716|NCT04729452|OTHER|blood test|blood test to test immune response to SARS-CoV-2
219405717|NCT02316093|OTHER|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
219405718|NCT04367337|OTHER|No intervention|Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
219405719|NCT04590937|DRUG|BI 730357|Film-coated tablet
219405720|NCT04590937|DRUG|CRESTOR®|Film-coated tablet
219405721|NCT04590937|DRUG|Lenoxin®|Tablet
219405722|NCT04590937|DRUG|MetfoLiquid GeriaSan®|Oral solution
219405723|NCT04590937|DRUG|Lasix®|Oral solution
219405724|NCT03272477|DRUG|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
219405725|NCT03272477|DRUG|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
219405726|NCT03272477|DRUG|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
219405727|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
219405728|NCT03272477|DRUG|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
219566849|NCT03746002|DRUG|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
219755449|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
219405729|NCT03272477|DRUG|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
219755450|NCT03618537|DRUG|Ixazomib|Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
219755451|NCT03618537|DRUG|Dexamethasone|Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
219405730|NCT03272477|DRUG|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
219405731|NCT03272477|DRUG|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
219405732|NCT03272477|DRUG|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
219405733|NCT03272477|DRUG|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
219405734|NCT03272477|DRUG|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
219405735|NCT03272477|DRUG|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
219405736|NCT03272477|DRUG|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
219405737|NCT03272477|DRUG|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
219405738|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
219189915|NCT06823700|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|To percutaneously repair the mitral valve via the femoral vein and atrial septum, offering a treatment for symptomatic functional mitral regurgitation through edge-to-edge valve clipping.
219405739|NCT03272477|DRUG|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
219405740|NCT03272477|DRUG|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
219405741|NCT03272477|DRUG|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
219405742|NCT03272477|DIAGNOSTIC_TEST|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
219189916|NCT04666688|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
219189917|NCT04666688|DRUG|Tislelizumab|anti-PD-1 monoclonal antibody
219405743|NCT03272477|PROCEDURE|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
219405744|NCT05283083|DRUG|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
219405745|NCT01635933|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
219405746|NCT01635933|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
219405747|NCT04742153|DRUG|MRG002|Administrated intravenously
219189918|NCT04666688|DRUG|Gemcitabine/nab-paclitaxel|chemotherapy
219405748|NCT02818153|OTHER|Self questionnaire for allergic rhinitis control|
219405749|NCT00573326|DRUG|Imatinib|200 mg p.o. once a day for 6 months
219405750|NCT06427681|DRUG|BH006 for injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
219405751|NCT06427681|DRUG|Fosaprepitant for injection+Palonosetron hydrochloride injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
219405752|NCT04340830|PROCEDURE|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
219405753|NCT03873129|BEHAVIORAL|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
219405754|NCT00409630|DRUG|fluticasone|
219405755|NCT00282165|DRUG|naratriptan|four weeks double blind experimental treatment using oral naratriptan
219405756|NCT00282165|DRUG|placebo|four weeks double blind placebo treatment
219405757|NCT00716404|DEVICE|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
219429311|NCT04942119|OTHER|Multifactorial intervention|"1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
219429312|NCT05514145|DEVICE|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
219429313|NCT05514145|DEVICE|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
219429314|NCT02600741|OTHER|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
219429315|NCT02600741|OTHER|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
219429316|NCT02600741|DRUG|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
219429317|NCT02600741|DRUG|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219007152|NCT01669915|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
219007153|NCT01669915|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219405758|NCT04122768|BEHAVIORAL|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
219405759|NCT04122768|BEHAVIORAL|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
219405760|NCT03208192|PROCEDURE|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
219405761|NCT04922125|COMBINATION_PRODUCT|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
219405762|NCT04922125|COMBINATION_PRODUCT|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
219405763|NCT06442917|BEHAVIORAL|Breathing Exercise|"32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction."
219405764|NCT06442917|BEHAVIORAL|Affirmation Method|"32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction."
219405765|NCT06442917|BEHAVIORAL|Breathing Exercise and Affirmation Method|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
219405766|NCT00069082|DRUG|Civamide (Zucapsaicin)|Nasal Solution 0.01%
219405767|NCT00069082|DRUG|Sodium Chloride|Nasal Solution 10%
219405768|NCT04743635|DEVICE|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
219566850|NCT04925713|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
219566851|NCT03708159|DEVICE|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
219566852|NCT03708159|OTHER|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
219755452|NCT02410772|DRUG|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
219007154|NCT00946959|PROCEDURE|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
219755453|NCT02410772|DRUG|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
219755454|NCT02410772|DRUG|control|standard six-month treatment
219405769|NCT02055027|OTHER|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
219405770|NCT06377644|DIAGNOSTIC_TEST|Kinesio taping|Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.
219405771|NCT06377644|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
219405772|NCT00113802|DRUG|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
219405773|NCT05029076|DRUG|Liraglutide injection|Human glucagon-like peptides-1 analogue
219405774|NCT05029076|DRUG|Victoza|Human glucagon-like peptides-1 analogue
219405775|NCT03382899|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Pembrolizumab
219405776|NCT03382899|DRUG|Pembrolizumab|Pembrolizumab Alone
219007155|NCT05025189|OTHER|Table Grape Powder|Freeze Dried Whole Table Grape Powder
219007156|NCT05025189|OTHER|Beige Diet|Low Fiber, low polyphenol Diet
219189919|NCT05263297|OTHER|control group|no intervention will be made.
219189920|NCT05005819|DRUG|[18F] APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
219405777|NCT03387124|OTHER|Breastfed infants|Breastmilk
219405778|NCT00540449|DRUG|TMC278|25 mg tablet once daily for 96 weeks
219405779|NCT00540449|DRUG|Efavirenz|600mg once daily for 96 weeks
219429318|NCT02600741|DRUG|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219007157|NCT03251820|DRUG|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
219007158|NCT03892109|OTHER|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
219429319|NCT02600741|DRUG|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219007159|NCT03892109|DEVICE|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
219007160|NCT03892109|OTHER|Gingitrac|packed into the sulcus
219007161|NCT00914524|DRUG|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
219007162|NCT02232633|DRUG|BBI503|
219007163|NCT05634460|DRUG|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
219429320|NCT02600741|DRUG|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429321|NCT02600741|DRUG|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429322|NCT02600741|DRUG|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429323|NCT02600741|DRUG|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429324|NCT02600741|DRUG|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429325|NCT02600741|DRUG|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429326|NCT02600741|DRUG|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429327|NCT02600741|DRUG|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429328|NCT02600741|DRUG|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429329|NCT02600741|DRUG|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429330|NCT02600741|DRUG|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429331|NCT02600741|DRUG|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429332|NCT02600741|DRUG|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219405780|NCT04350658|PROCEDURE|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
219405781|NCT03590262|DRUG|Metformin|take the metformin 500mg twice or three times a day
219405782|NCT05873101|DIAGNOSTIC_TEST|Mobilization With Movement (MWM)|Mobilization With Movement
219405783|NCT05873101|DIAGNOSTIC_TEST|Kelternborn Treatment Technique|Kelternborn Treatment Technique
219405784|NCT03801304|DRUG|Atezolizumab|Atezolizumab in IV infusions
219405785|NCT03801304|DRUG|Vinorelbine|Vinorelbine capsules
219405786|NCT03160404|DRUG|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
219405787|NCT03160404|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
219405788|NCT02329873|BEHAVIORAL|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
219566853|NCT03544814|DRUG|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
219566854|NCT03544814|DRUG|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
219566855|NCT02489591|DEVICE|Oral appliance|Patients will bring their prescribed oral appliance.
219566856|NCT02489591|DEVICE|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
219566857|NCT02826291|DEVICE|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
219566858|NCT03923231|DRUG|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
219566859|NCT03923231|DRUG|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
219566860|NCT01841216|DEVICE|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
219566861|NCT05122221|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
219566862|NCT05122221|DRUG|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
219566863|NCT05122221|BIOLOGICAL|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
219566864|NCT02156921|OTHER|App-based training|
219566865|NCT04331964|PROCEDURE|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
219566866|NCT03966859|DRUG|Atorvastatin 20mg|oral dose, once daily for 7 days
219189921|NCT06821646|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|18F-N-((2-(2-(fluoro-18f)ethoxy)phenyl)methyl)-N-(4-phenoxy-3-pyridinyl) acetamide
219189922|NCT06821646|DIAGNOSTIC_TEST|transcranial magnetic stimulation and electroencephalography(TMS-EEG)|single pulse and paired pulse
219405789|NCT06198621|DEVICE|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
219566867|NCT03966859|OTHER|Lactose placebo|oral dose, once daily for 7 days
219566868|NCT02187107|DRUG|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
219566869|NCT02187107|DRUG|rtv|100 mg tablet of Norvir®
219405790|NCT00252902|BEHAVIORAL|Behavior change counseling|
219405791|NCT00601523|DRUG|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
219405792|NCT00601523|DRUG|Pramipexole|ER 0.375-4,5 mg
219405793|NCT04527016|PROCEDURE|Microbiota and eosinophils based therapy|"1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
219405794|NCT04527016|DRUG|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
219405795|NCT04352634|OTHER|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
219405796|NCT03136549|OTHER|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
219405797|NCT03136549|OTHER|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
219405798|NCT05108909|DEVICE|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
219405799|NCT05360277|DRUG|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
219405800|NCT05360277|OTHER|Best supportive care|Best supportive care
219405801|NCT06261138|DRUG|Transarterial chemoembolization|A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
219405802|NCT06261138|OTHER|Systemic treatment|"sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China)."
219405803|NCT03362346|DEVICE|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
219405804|NCT02458079|DRUG|Pentoxiphylline|
219405805|NCT02458079|DRUG|Stool microbiota transplantation|
219405806|NCT03436446|OTHER|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
219405807|NCT04129684|OTHER|Probiotics|subgingival delivery and lozenges
219405808|NCT05313932|OTHER|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
219405809|NCT02514460|DEVICE|plaque excision system|
219405810|NCT02514460|DEVICE|Stent|
219405811|NCT00524316|DRUG|doxorubicin hydrochloride|Transarterial chemoembolization
219405812|NCT00524316|DRUG|sunitinib malate|Given Orally
219405813|NCT00524316|OTHER|laboratory biomarker analysis|Correlative Study
219405814|NCT00524316|PROCEDURE|hepatic artery embolization|Surgical procedure
219405815|NCT00524316|PROCEDURE|quality-of-life assessment|Correlative Study
219405816|NCT02426658|OTHER|Laboratory Biomarker Analysis|Correlative studies
219405817|NCT02426658|DRUG|Pemetrexed Disodium|Given IV
219405818|NCT02426658|OTHER|Quality-of-Life Assessment|QOL studies
219405819|NCT02619019|DRUG|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
219405820|NCT02619019|DRUG|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
219405821|NCT02619019|DRUG|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
219405822|NCT03691402|BEHAVIORAL|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
219429333|NCT02600741|DRUG|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429334|NCT02600741|DRUG|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429335|NCT02600741|DRUG|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429336|NCT02600741|DRUG|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
219429337|NCT02645591|PROCEDURE|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
219007164|NCT00434655|PROCEDURE|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
219405823|NCT03691402|BEHAVIORAL|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
219405824|NCT03017924|DEVICE|Q collar|q-collar concussion prevention device
219405825|NCT01402284|DRUG|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
219405826|NCT01402284|DRUG|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
219405827|NCT01402284|DRUG|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
219405828|NCT01402284|DRUG|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
219405829|NCT01402284|DRUG|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
219405830|NCT01199263|OTHER|Laboratory Biomarker Analysis|Correlative studies
219405831|NCT01199263|DRUG|Paclitaxel|Given IV
219566870|NCT03851588|OTHER|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
219566871|NCT03851588|DRUG|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
219566872|NCT02355756|DRUG|Maxadilan|
219566873|NCT02355756|DRUG|Placebo|
219566874|NCT02237547|BIOLOGICAL|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
219566875|NCT02330744|BEHAVIORAL|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
219566876|NCT02330744|BEHAVIORAL|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
219566877|NCT02220595|PROCEDURE|Carotid endarterectomy vs. carotid stenting|
219405832|NCT01199263|BIOLOGICAL|Pelareorep|Given IV
219566878|NCT02479477|OTHER|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
219566879|NCT04127292|BEHAVIORAL|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
219405833|NCT05129813|BEHAVIORAL|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
219566880|NCT01898234|DEVICE|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
219189923|NCT05826652|OTHER|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
219189924|NCT05826652|OTHER|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
219189925|NCT05826652|PROCEDURE|Without Block|The patients in this group will not receive block
219566881|NCT01898234|DEVICE|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
219566882|NCT01898234|DEVICE|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
219566883|NCT01898234|DEVICE|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
219566884|NCT00611325|DRUG|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
219007165|NCT04828447|DIETARY_SUPPLEMENT|Olive Oil|Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
219007166|NCT05678309|OTHER|Blood samples|"At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA"
219405834|NCT02928406|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
219405835|NCT03987620|DRUG|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
219007167|NCT05678309|OTHER|skin swab sample|At inclusion a skin swab sample will be collected
219007168|NCT05678309|OTHER|skin biopsy sample|At inclusion a skin biopsy sample will be collected
219007169|NCT05678309|OTHER|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
219405836|NCT03987620|DRUG|Placebo|Matching Placebo
219405837|NCT05029544|OTHER|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
219405838|NCT05029544|OTHER|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
219755455|NCT05871931|OTHER|Tidal Model-based psychiatric nursing approach|"The intervention group will receive an eight-session Tidal Model-based psychiatric nursing approach. The sessions will take place once a week over an 8-week period. All sessions will be conducted face-to-face.~The content of the interview plan, consisting of a total of 8 interviews, is as follows:~The first interview was 'Meeting and Pretesting', the second interview was 'Creating a Personal Safety Plan, Making a Holistic Assessment', the third interview was 'Recognizing Emotions, Emotion Management and Communication Skills', the fourth interview was 'Coping Skills', and the fifth interview was 'Self Perception', The sixth interview consisted of 'Strengthening Socialisation', the seventh interview consisted of 'Planning for the Future' and the eighth interview consisted of 'Defining the achievements that will accompany him/her in the next voyages of exploration, ending the relationship between the captain and the lifeguard and making a process evaluation'."
219755456|NCT01645176|DRUG|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
219755457|NCT05948553|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
219755458|NCT05948553|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
219405839|NCT05029544|OTHER|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
219405840|NCT03859986|DRUG|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
219405841|NCT03859986|DRUG|ALX-101 Gel 5%|ALX-101 Gel 5%
219405842|NCT03003416|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
219755459|NCT03308357|DIAGNOSTIC_TEST|Drug assays to measure infliximab|See protocol
219405843|NCT02305901|DRUG|repaglinide|single dose on day 1 of visits 2 and 3
219405844|NCT02305901|DRUG|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
219405845|NCT02305901|DRUG|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
219405846|NCT04523844|DRUG|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
219405847|NCT03653702|DRUG|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
219429338|NCT02645591|BIOLOGICAL|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
219429339|NCT02645591|BEHAVIORAL|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
219007170|NCT04464629|DRUG|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
219007171|NCT04464629|DRUG|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
219007172|NCT04388202|DRUG|Sertraline|FDA approved antidepressant
219429340|NCT03345732|DIAGNOSTIC_TEST|ICG and SPY system for wound complications|
219429341|NCT00810810|BIOLOGICAL|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
219429342|NCT00810810|BIOLOGICAL|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
219429343|NCT00810810|BIOLOGICAL|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
219429344|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every week
219429345|NCT01101243|RADIATION|Broadband UVB|UVB dose: 4 SED every second week
219429346|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every second week
219429347|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every month
219429348|NCT01101243|OTHER|Control group|No intervention
219429349|NCT03444571|PROCEDURE|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
219429350|NCT03661892|DRUG|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
219429351|NCT01429610|DRUG|Rituximab+mVPDL|"1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   \- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT"
219429352|NCT01080144|OTHER|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
219429353|NCT01501669|DRUG|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
219429354|NCT04104295|DIAGNOSTIC_TEST|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
219755460|NCT05472493|BIOLOGICAL|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
219405848|NCT02149836|DRUG|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
219755461|NCT00830050|DRUG|Naproxen|500 mg BID 7 days
219755462|NCT00830050|DRUG|Placebo|BID 7 days
219405849|NCT00914836|DRUG|Betamethasone Sodium Phosphate|1cc:2cc
219405850|NCT00914836|DRUG|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
219405851|NCT00914836|DRUG|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
219405852|NCT00108927|BEHAVIORAL|TRANSLATE|
219755463|NCT03981276|OTHER|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
219405853|NCT01433627|OTHER|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
219429355|NCT00553657|DRUG|DETROL LA (drug)|
219429356|NCT04054739|DEVICE|Robot-assisted gait training|intervention with robot-assisted gait training
219429357|NCT04054739|DEVICE|Treadmill gait training|intervention with treadmill gait training
219755464|NCT03981276|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
219755465|NCT02234362|DRUG|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
219002280|NCT01612936|PROCEDURE|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
219002281|NCT00280631|DRUG|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
219002282|NCT03981211|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
219002283|NCT03981211|DRUG|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
219002284|NCT02365792|PROCEDURE|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
219002285|NCT05130320|OTHER|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
219007173|NCT04388202|DRUG|Escitalopram|FDA approved antidepressant
219007174|NCT03293589|PROCEDURE|open revascularization|surgical revascularization (i.e. Bypass surgery)
219007175|NCT03293589|PROCEDURE|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
219007176|NCT00372112|DRUG|GW642444|GW642444H
219007177|NCT00372112|OTHER|Placebo|Placebo administered twice daily
219429358|NCT06978309|OTHER|No Interventions|Observational study.
219429359|NCT01664156|DRUG|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
219429360|NCT01664156|DRUG|Placebo|
219429361|NCT04055987|BEHAVIORAL|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
219429362|NCT02258867|DRUG|Placebo|Solution for subcutaneous injection
219429363|NCT02258867|DRUG|Gevokizumab|Solution for subcutaneous injection
219429364|NCT00206778|DRUG|Lamotrigine|
219429365|NCT00206778|DRUG|Sodium Valproate|
219429366|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Plasma
219755466|NCT03913351|BEHAVIORAL|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
219755467|NCT05338138|DEVICE|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
219755468|NCT03126487|PROCEDURE|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
219405854|NCT01433627|OTHER|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
219755469|NCT00560417|DRUG|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
219755470|NCT00560417|DRUG|Insulin Glargine|Administered subcutaneously once a day at bedtime
219755471|NCT03807089|DEVICE|Conventional Pediatric Colonoscope|
219755472|NCT03807089|DEVICE|Short-Turn Radius Colonoscope|
219755473|NCT02164864|DRUG|Dabigatran Etexilate 110mg|Active treatment
219405855|NCT01433627|OTHER|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
219405856|NCT01433627|OTHER|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
219755474|NCT02164864|DRUG|Warfarin 3mg|Active comparator
219755475|NCT02164864|DRUG|Aspirin|Active comparator
219755476|NCT02164864|DRUG|Dabigatran Etexilate 150mg|Active treatment
219755477|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
219755478|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
219755479|NCT02164864|DRUG|Warfarin 5mg|Active comparator
219755480|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
219755481|NCT02164864|DRUG|Warfarin 1mg|Active comparator
219429367|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Serum
219429368|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Urine
219429369|NCT01700985|DRUG|122-0551|Applied twice daily for two weeks
219429370|NCT01700985|DRUG|Vehicle|Applied twice daily for two weeks
219429371|NCT01409993|DRUG|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
219429372|NCT01409993|DRUG|Placebo|Matching placebo three times a day for three months
219429373|NCT01409993|DIAGNOSTIC_TEST|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
219429374|NCT01409993|DIAGNOSTIC_TEST|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
219429375|NCT05474911|DEVICE|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
219429376|NCT05474911|OTHER|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
219429377|NCT06290271|OTHER|Intracranial artery flow pattern|the cerebral blood flow patterns observed after the occluded artery has been recanalized.
219429378|NCT00249977|DRUG|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
219755482|NCT03257891|DRUG|Cabazitaxel|Cabazitaxel will be administered every 21 days
219755483|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
219755484|NCT02569853|DRUG|DFN-11|
219755485|NCT02569853|OTHER|Placebo|
219755486|NCT01135472|DRUG|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
219755487|NCT03243461|DRUG|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
219755488|NCT04142489|OTHER|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
219405857|NCT01433627|OTHER|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
219405858|NCT01433627|OTHER|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
219405859|NCT06555926|OTHER|Acupressure|The pregnant women will receive acupressure on the (Pc-6/Lung-7 )acupoints one minute for each point with 3 repetitions on both side( about 30minutes /session),2 times per week in addition to advices for 12 weeks.
219405860|NCT06555926|OTHER|advices for relieving carpal tunnel syndrome|"The pregnant women will receive advices for 12 weeks as follows:~* Avoid heavy lifting.~* Avoid repetitive tasks.~* Sit on chairs with armrests and elevate affected hand on the armrest~* Avoid sleeping on the side of the affected hand.~* Keep the wrist in a neutral (straight) position.~* Avoid positions of full flexion and extension.~* Reduce general swelling by:~  * eating less salty food .~ * elevating legs when sitting .~ * wearing compression garments.~* Apply cold water over the wrist."
219405861|NCT04018469|OTHER|No Interventions|No Interventions
219405862|NCT02738437|DEVICE|Kryptonite-bone cement|
219405863|NCT05909215|DRUG|Normal saline|Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
219405864|NCT05909215|DRUG|Dexmedetomidine 0.5 microgram/kg|Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
219405865|NCT05909215|DRUG|Dexmedetomidine 0.75 microgram/kg|Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
219405866|NCT00849264|DRUG|chemotherapy with endostar|15mg/d×14d
219405867|NCT00849264|DRUG|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
219405868|NCT00849264|DRUG|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
219405869|NCT06064708|BEHAVIORAL|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes)."
219405870|NCT03047863|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
219566885|NCT00611325|DRUG|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
219566886|NCT00566280|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
219566887|NCT05259904|DRUG|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
219566888|NCT05259904|DRUG|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
219566889|NCT05184179|DRUG|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
219566890|NCT05210049|DIAGNOSTIC_TEST|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
219566891|NCT04229290|DRUG|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
219566892|NCT03710317|DRUG|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
219566893|NCT03710317|DRUG|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
219566894|NCT03710317|DRUG|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
219566895|NCT05227677|OTHER|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
219566896|NCT05227677|OTHER|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
219566897|NCT04709224|DRUG|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
219566898|NCT02078921|DRUG|Sodium Nitrate|
219566899|NCT02078921|DRUG|Placebo|
219566900|NCT06412302|OTHER|Whey Protein+Resistance Training|WP group received 25g protein on one scoop of Whey Protein Isolate (Iso100 Dymatize) with 8 weeks of resistance training 3 days a week.
219566901|NCT06412302|OTHER|High protein yogurt+Resistance Training|PY group received 24.6g protein on two High Protein yogurts (Lonco Leche) with 8 weeks of resistance training 3 days a week.
219566902|NCT03401554|PROCEDURE|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
219405871|NCT03047863|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
219405872|NCT04217577|DIETARY_SUPPLEMENT|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
219405873|NCT06350344|DEVICE|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
219405874|NCT02592629|DRUG|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
219405875|NCT02592629|DRUG|ethyl chloride|topical spray
219405876|NCT02592629|DRUG|Kenalog|used with lidocaine in shoulder injection
219405877|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
219405878|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
219405879|NCT01204658|BIOLOGICAL|Synflorix|Intramuscular injection
219405880|NCT01204658|BIOLOGICAL|Prevenar 13|Intramuscular injection
219405881|NCT01204658|BIOLOGICAL|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
219405882|NCT05980832|OTHER|Peer practitioner training - Peer Education Supported Psychosocial Skills Education|"Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse."
219405883|NCT05980832|OTHER|Peer Education Supported Psychosocial Skills Education|"It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed."
219405884|NCT00916500|DRUG|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
219405885|NCT01918098|DRUG|Oxycodone/naloxone prolonged release tablets|
219405886|NCT00214851|DRUG|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
219405887|NCT04136353|DRUG|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
219566903|NCT03401554|PROCEDURE|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
219007178|NCT04176978|DRUG|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
219405888|NCT04136353|DRUG|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
219007179|NCT04176978|OTHER|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
219007180|NCT04649060|DRUG|Melflufen|Powder for solution for i.v. infusion
219007181|NCT04649060|DRUG|Dexamethasone|Oral tablets
219007182|NCT04649060|DRUG|Daratumumab|Solution for s.c. injection
219405889|NCT04136353|DRUG|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
219405890|NCT04136353|RADIATION|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
219405891|NCT01977053|OTHER|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
219566904|NCT04701424|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
219566905|NCT04701424|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
219566906|NCT05105919|DRUG|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
219566907|NCT01722682|BIOLOGICAL|Human pancreatic islet transplantation|
219566908|NCT00382629|DRUG|BHT-3009 0.5 mg|
219566909|NCT00382629|DRUG|BHT-3009 1.5 mg|
219566910|NCT00382629|DRUG|Placebo|
219566911|NCT05295654|OTHER|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
219405892|NCT01762657|DRUG|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
219755489|NCT04607343|DEVICE|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
219755490|NCT04358406|DRUG|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
219755491|NCT04358406|OTHER|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
219405893|NCT01762657|DRUG|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
219405894|NCT04983329|OTHER|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
219405895|NCT04937816|DRUG|Placebo|Placebo
219405896|NCT04937816|DRUG|Empagliflozin|Empagliflozin once daily
219405897|NCT06920368|PROCEDURE|septoplasty with nasal packs|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then nasal packs in inserted at the end of operation for prevention of post operative complication
219405898|NCT06920368|PROCEDURE|septoplasty with intra-nasal silicon splint|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then intra-nasal silicon splint is inserted at the end of operation for prevention of post operative complication
219405899|NCT06920368|PROCEDURE|septoplasty with trans--septal quilting sutures|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then trans-septal quilting sutures is done at the end of operation for prevention of post operative complication
219405900|NCT06918977|DEVICE|InPen Smart insulin pen|InPen is a reusable pen injector which allows the user to dial the desired dose of insulin to be administered. The dose calculator a component of the InPen app calculates an insulin dose or carbohydrate intake based on user entered data. Prior to use, the patient -specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters are to be programmed into the software.
219405901|NCT06918977|OTHER|traditional/standard insulin pen|personal prescribed insulin pen
219405902|NCT06677892|OTHER|No Intervention|This is non-interventional study.
219405903|NCT06618235|BIOLOGICAL|THEO-260|Oncolytic Virus
219405904|NCT07007559|DRUG|Evorpacept (ALX148)|IV infusion
219405905|NCT07007559|DRUG|Trastuzumab|IV infusion
219405906|NCT07007559|DRUG|Paclitaxel|IV infusion
219405907|NCT07007559|DRUG|Capecitabine|Oral administration
219405908|NCT07007559|DRUG|Eribulin|IV infusion
219405909|NCT07007559|DRUG|Gemcitabine|IV infusion
219405910|NCT07007559|DRUG|Vinorelbine|IV infusion
219566912|NCT00738361|DRUG|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
219566913|NCT00429624|PROCEDURE|Chiropractic manipulation|
219566914|NCT00429624|DRUG|acetaminophen|
219566915|NCT02596633|BEHAVIORAL|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
219566916|NCT05098457|DEVICE|GP0112|Injectable gel
219566917|NCT05098457|DEVICE|Restylane Lyft Lidocaine|Injectable gel
219405911|NCT03566108|PROCEDURE|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
219405912|NCT03566108|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
219405913|NCT06683014|DRUG|MDMA|Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
219566918|NCT02598895|DRUG|Carboplatin|Given IV
219566919|NCT02598895|DRUG|Docetaxel|Given IV
219566920|NCT02598895|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566921|NCT04144426|BEHAVIORAL|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
219566922|NCT04144426|BEHAVIORAL|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
219566923|NCT00104247|DRUG|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
219566924|NCT04221126|DEVICE|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
219405914|NCT07015151|DIAGNOSTIC_TEST|Low-dose Chest CT Screening|Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
219566925|NCT04221126|DRUG|ALA cream|ALA compounded in a cream
219566926|NCT04221126|DRUG|ALA gel|ALA compounded in a gel
219566927|NCT04558333|OTHER|blood and exhaled breath specimens|identification of possible biomarkers
219566928|NCT01978652|BIOLOGICAL|Peginterferon Beta-1a|As specified in the treatment arm
219566929|NCT05040126|DRUG|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
219566930|NCT05040126|DRUG|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
219566931|NCT05040126|DRUG|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
219566932|NCT03496987|DEVICE|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
219566933|NCT01509482|OTHER|blood samples|blood samples to test for primary and secondary outcome measures
219566934|NCT01509482|OTHER|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
219566935|NCT01886937|DRUG|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
219566936|NCT01886937|DRUG|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
219566937|NCT00925756|DRUG|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
219566938|NCT01051180|PROCEDURE|HALO|Ligation of haemorrhoidal arteries
219566939|NCT03944109|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
219566940|NCT03944109|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
219566941|NCT04108832|DRUG|TCM OA2|Usage: 3g twice daily
219566942|NCT04108832|DRUG|PLACEBO|Usage: 3g twice daily
219566943|NCT06128187|OTHER|Control Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
219566944|NCT06128187|OTHER|Study Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
219566945|NCT02060045|OTHER|Bundle implementation|
219566946|NCT02767934|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566947|NCT02767934|BIOLOGICAL|Pembrolizumab|Given IV
219566948|NCT02631252|DRUG|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
219566949|NCT02631252|DRUG|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
219566950|NCT02631252|DRUG|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
219189926|NCT05182255|DEVICE|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
219405915|NCT07015151|DIAGNOSTIC_TEST|Spirometry|Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
219405916|NCT07015151|DIAGNOSTIC_TEST|Cardiovascular Risk Assessment|Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
219405917|NCT07015151|BEHAVIORAL|Smoking Cessation Support|Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
219566951|NCT00190489|DRUG|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
219566952|NCT00190489|DRUG|Docetaxel 60mg/m2 every 21 days for 6 cycles|
219566953|NCT00190489|DRUG|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
219566954|NCT01443689|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
219566955|NCT01443689|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
219566956|NCT01443689|DRUG|Conventional therapy|Participants will be given conventional therapy only.
219566957|NCT01917968|DEVICE|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
219566958|NCT01917968|PROCEDURE|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
219566959|NCT05255302|DRUG|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
219566960|NCT05255302|DRUG|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
219566961|NCT05255302|DRUG|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
219566962|NCT05255302|DRUG|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
219566963|NCT03400215|DIAGNOSTIC_TEST|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
219566964|NCT03400215|DIAGNOSTIC_TEST|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
219405918|NCT07015151|OTHER|Optional Biospecimen Collection (Bio-ILYAD)|Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
219405919|NCT05412212|OTHER|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
219405920|NCT06686797|DRUG|PF-08049820|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
219405921|NCT06686797|DRUG|Placebo|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
219007183|NCT01427686|DRUG|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
219405922|NCT06622434|BIOLOGICAL|immunization|One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
219405923|NCT04626245|BEHAVIORAL|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
219405924|NCT01380405|BEHAVIORAL|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
219429379|NCT00609011|DRUG|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
219429380|NCT05067452|OTHER|Food support|Diabetes-tailored food support. Project Open Hand (POH) will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
219429381|NCT05067452|OTHER|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
219429382|NCT00163904|BEHAVIORAL|High mono-unsaturated fat/low carbohydrate diet|
219429383|NCT00163904|BEHAVIORAL|High carbohydrate/low fat diet|
219429384|NCT03380338|BEHAVIORAL|Combined aerobic and strength exercise|
219429385|NCT03859960|DIAGNOSTIC_TEST|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
219429386|NCT03859960|DIAGNOSTIC_TEST|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
219429387|NCT00019227|DRUG|pentetic acid calcium|
219429388|NCT00019227|RADIATION|yttrium Y 90 daclizumab|
219429389|NCT00067470|DRUG|Placebo|
219429390|NCT00067470|DRUG|N-acetylgalactosamine 4-sulfatase|
219429391|NCT03538132|OTHER|dental regenerative techniques|dental regenerative techniques
219429392|NCT01539785|PROCEDURE|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
219429393|NCT01539785|PROCEDURE|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
219429394|NCT04869176|DIAGNOSTIC_TEST|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
219429395|NCT04869176|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
219429396|NCT04869176|DRUG|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
219405925|NCT06875479|DIAGNOSTIC_TEST|Five Seasons [5S] Sleep Tracking Mat|The Five Seasons \[5S\] Sleep Tracking Mat consists of a main control box, monitoring mat, temperature/humidity sensor, power adapter, and light sensor. It utilizes Ballistocardiogram (BCG) technology to detect heartbeat, respiration, body movements, and snoring. The collected data is analyzed by a proprietary pre-trained AI model, enabling automatic detection of respiratory events, calculation of the Apnea-Hypopnea Index (AHI), and sleep stage interpretation. Compared to other sleep monitoring devices, it is non-contact and requires no wearable components, making it particularly suitable for long-term, daily home use.
219405926|NCT06693349|DRUG|the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to give superior effects than other procedure used in this study
219405927|NCT06693349|DRUG|the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to be replaced by other procedure be used in this study
219405928|NCT06713642|DEVICE|SPOTFIRE ST System|Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes
219566965|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
219566966|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
219566967|NCT05486845|OTHER|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
219566968|NCT03371329|BIOLOGICAL|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
219566969|NCT01222949|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
219566970|NCT05668026|DRUG|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
219566971|NCT02214563|DIETARY_SUPPLEMENT|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
219566972|NCT02214563|DIETARY_SUPPLEMENT|Olive oil|
219566973|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
219566974|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
219566975|NCT02528058|PROCEDURE|Vitrectomy with internal limiting membrane peeling|
219566976|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
219566977|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
219566978|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
219566979|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
219566980|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
219566981|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
219566982|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
219566983|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
219566984|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
219007184|NCT01427686|DRUG|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
219007185|NCT03759847|OTHER|Fluid intake app|Use of fluid app to monitor intake of fluids
219405929|NCT04832841|DIAGNOSTIC_TEST|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
219566985|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
219405930|NCT00540176|DRUG|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
219405931|NCT01911182|OTHER|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
219405932|NCT06881459|OTHER|Placebo|Saline
219405933|NCT06881459|DRUG|Oxytocin|Oxytocin
219405934|NCT07039045|DRUG|LY4065967|Oral dose
219405935|NCT07039045|RADIATION|[14C]-LY4065967 Oral|Oral dose
219405936|NCT07039045|RADIATION|[14C]-LY4065967 IV|IV dose
219405937|NCT06445504|DEVICE|Robotic-Assisted Surgery (RAS) Hernia Repair Surgery|Patients indicated for Robotic-Assisted Surgery (RAS) for ventral and inguinal hernia repair will have the RAS surgery using the Medtronic Hugo RAS system
219405938|NCT00977574|BIOLOGICAL|Bevacizumab|Given IV
219405939|NCT00977574|DRUG|Carboplatin|Given IV
219405940|NCT00977574|DRUG|Ixabepilone|Given IV
219566986|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
219405941|NCT00977574|OTHER|Laboratory Biomarker Analysis|Correlative studies
219566987|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
219405942|NCT00977574|DRUG|Paclitaxel|Given IV
219405943|NCT00977574|DRUG|Temsirolimus|Given IV
219405944|NCT05673811|DRUG|Nab-paclitaxel|Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
219405945|NCT05673811|DRUG|Gemcitabine|Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
219405946|NCT05673811|GENETIC|VCN-01|VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
219405947|NCT06773949|DEVICE|Theta burst stimulation|Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
219405948|NCT06512207|DRUG|Leuprorelin acetate + Sintilimab|Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.
219405949|NCT06512207|DRUG|Sintilimab|PD-1 inhibitor
219405950|NCT05281523|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) was administered using a pre-filled syringe.
219405951|NCT05281523|DRUG|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
219405952|NCT07042516|DRUG|Asimadoline|Asimadoline TP0052 2.5 mg two (2) tablets bid (two on awakening and two before bed), total of four (4) tablets daily (10 mg) for 8 weeks.
219405953|NCT05513391|BIOLOGICAL|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
219405954|NCT05513391|BIOLOGICAL|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
219405955|NCT07051915|DRUG|Avatrombopag|Daily tablets
219566988|NCT04920058|DEVICE|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
219566989|NCT04920058|OTHER|<Active Comparator?>|\<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
219405956|NCT07051915|DRUG|Rituximab (Arm B)|I.V.
219566990|NCT02556853|DEVICE|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
219566991|NCT02556853|OTHER|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
219405957|NCT07051954|OTHER|Core Stabilization|12-week supervised core stabilization training, 3 sessions per week, 45 minutes per session.
219405958|NCT07051954|OTHER|Functional Inspiratory Muscle Training (IMT)|IMT using a portable inspiratory muscle training device at 60% MIP, progressively increased over 12 weeks.
219405959|NCT06751056|DEVICE|Cervical Traction Device|"Participants will use their home neck traction devices daily for 12 weeks, while continuing their prescriptions for gabapentin or pregabalin.~At study initiation and every 2 weeks thereafter for a total of 12 weeks, they will receive an electronic survey assessing their itch score. Based on survey results, they will receive a call from the study team to adjust their dosage of gabapentin or pregabalin by up to 33%."
219405960|NCT06896513|OTHER|Isthmus|The neck skin thickness from the thyroid isthmus to the skin will be measured in millimeters using a linear ultrasound probe (3-13 Hz) in the supine position with neck hyperextension. Measurements will be taken in a transverse view at the level of the 2nd-3rd tracheal rings, and the average of three measurements will be recorded.
219405961|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide
219405962|NCT06895408|OTHER|Intravenous Infusion|Glucagon-Like Peptide 1
219405963|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
219405964|NCT06895408|OTHER|Intravenous Infusion|Saline
219405965|NCT04182659|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
219405966|NCT04182659|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
219405967|NCT02924506|DEVICE|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
219405968|NCT02924506|DEVICE|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
219405969|NCT00005051|DRUG|carboplatin|
219405970|NCT00005051|DRUG|cisplatin|
219405971|NCT00005051|DRUG|paclitaxel|
219405972|NCT00005051|DRUG|topotecan hydrochloride|
219405973|NCT06899204|DRUG|Abrocitinib|Study Drug for Observational Data Collection.
219405974|NCT05100056|OTHER|No Intervention|This is a non-interventional study.
219002286|NCT05238090|OTHER|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
219566992|NCT00973310|OTHER|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
219405975|NCT06771674|DRUG|Pembrolizumab|Given as monotherapy.
219405976|NCT06771674|DRUG|Nivolumab|Given in combination with chemotherapy.
219405977|NCT06771674|DRUG|Nivolumab|Given without chemotherapy.
219405978|NCT06771674|DRUG|Pembrolizumab|Given in combination with chemotherapy.
219405979|NCT06771674|DRUG|Pembrolizumab|Given without chemotherapy.
219405980|NCT06772896|OTHER|Reordered PHQ-8|Participants will be administered the PHQ-8 somatic items separately from the psychological items, outside the context of a depression questionnaire.
219405981|NCT03949049|DRUG|Citicoline|Citacoline as neuroprotector
219405982|NCT03949049|OTHER|Placebo|placebo group
219429397|NCT00050622|DRUG|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
219429398|NCT00050622|BEHAVIORAL|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
219429399|NCT00050622|DRUG|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
219429400|NCT00050622|DRUG|Placebo|
219429401|NCT00050622|DRUG|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
219429402|NCT00050622|BEHAVIORAL|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
219405983|NCT01653366|BEHAVIORAL|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
219405984|NCT03645460|GENETIC|Direct intravenous injection of ivlv-ADA lentiviral vector|Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
219755492|NCT05482061|OTHER|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
219755493|NCT05447403|OTHER|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
219755494|NCT04475666|OTHER|Replenish protein group|For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
219405985|NCT07067775|DRUG|Vicagrel Capsules|Vicagrel Capsules qd per period, for two periods
219405986|NCT07067775|DRUG|Clopidogrel Tablets|Clopidogrel Tablets qd per period, for two periods
219405987|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
219405988|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
219405989|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
219405990|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
219755495|NCT04475666|OTHER|Standard protein group|For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
219755496|NCT00633685|DRUG|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
219002287|NCT05238090|OTHER|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
219002288|NCT03446469|OTHER|Fascial Manipulation|Myofascial release of densified centers of coordination
219755497|NCT00633685|DRUG|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
219002289|NCT00754260|BEHAVIORAL|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
219405991|NCT06331377|OTHER|Non-Interventional Study|Non-interventional study
219405992|NCT04339738|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219405993|NCT04339738|DRUG|Cabozantinib S-malate|Given PO
219405994|NCT04339738|PROCEDURE|Computed Tomography|Undergo CT, spiral CT
219405995|NCT04339738|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
219405996|NCT04339738|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219405997|NCT04339738|BIOLOGICAL|Nivolumab|Given IV
219405998|NCT04339738|DRUG|Paclitaxel|Given IV
219405999|NCT04339738|OTHER|Quality-of-Life Assessment|Ancillary studies
219406000|NCT04339738|OTHER|Questionnaire Administration|Ancillary studies
219406001|NCT06926764|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same v
219406002|NCT06926764|PROCEDURE|Sham Block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
219406003|NCT06926764|DRUG|Levobupivacaine 0.25%|Drug used for intertransverse process block (intervention group)
219406004|NCT06926764|DRUG|Sodium Chloride (NaCl) 0.9 %|As placebo for sham block group
219406005|NCT06926764|DEVICE|Ultrasound guided injection with local anaestethic|Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany)
219189927|NCT06454344|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-I is a structured program with a robust empirical evidence supporting its efficacy for improving sleep quality and quantity. The cognitive component of CBT-I teaching individuals how to recognize and change the beliefs they hold about sleep that negatively impact sleep, such as negative thoughts and emotions. The behavioral component includes several strategies to help improve sleep, including: improved sleep hygiene, improving the sleep environment, relaxation training, stimulus control therapy (consistent wake/sleep times, using the bed only for sleep, etc), and sleep restriction. Sleep restriction consists of reducing the time spend in bed initially to increase sleep drive in subsequent nights. Once sleep has improved, the time in bed is gradually increased again.
219189928|NCT04449198|DRUG|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
219189929|NCT04449198|OTHER|Placebo|placebo for 12 weeks
219189930|NCT06357962|OTHER|Semi-permanent acupuncture|These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.
219189931|NCT06357962|OTHER|Sham of semi-permanent acupuncture|A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
219189932|NCT04788823|DRUG|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
219406006|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education with Mindful Eating Intervention|Mindful Eating Intervention applied to Obesity treatment for Adolescent alongside with Nutrition and Physical Activity Education from Nutritionist and Psychologist
219406007|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education|Nutrition and physical activity education from Nutritionist applied as Obesity treatment for Adolescent
219406008|NCT07083830|DEVICE|ECP-DL treated mononuclear cell infusion|Participants in this study will undergo the infusion of donor white blood cells treated with ECP one week before their living donor kidney transplant, combined with standard of care antirejection medications. You will also then have ECP treatments using your own blood on two consecutive days once per month for 6 months. This combination is intended to cause your immune system to create a state called tolerance to the donor kidney. The ECP procedure has not been approved to prevent rejection after kidney transplant and the use of ECP to prevent rejection of transplanted organs is experimental, and is not a part of standard treatment which is based on the long term use of anti-rejection drugs such as tacrolimus (Prograf), everolimus, and prednisone.
219406009|NCT06930131|BEHAVIORAL|Semantic rehabilitation|Semantic rehabilitation, consisting of validated lexico-phonological training exercises
219406010|NCT06929715|OTHER|Intervention for Teaching the First Link in the Chain of Survival to 7- and 8-Year-Old Children|Unlike traditional CPR training programs designed primarily for older children or adults, this intervention is uniquely tailored for 7- and 8-year-old schoolchildren. It employs a narrative-based, age-appropriate educational approach that incorporates storytelling, interactive activities, and practical simulation exercises aligned with the cognitive and motor development of young learners. Delivered by school nurses in a classroom setting, the program not only focuses on teaching the first link in the chain of survival but also ensures that its content and methods are rigorously validated by experts. Moreover, the intervention includes a follow-up evaluation at three months to assess the retention of knowledge and skills, distinguishing it from other clinical studies that lack such long-term assessment.
219406011|NCT06929715|OTHER|Placebo Intervention - First Aid (Excluding Basic CPR)|In the control arm, participants receive a structured first aid educational program that intentionally excludes any training on the first link in the chain of survival. This intervention focuses on general first aid skills-such as wound care, management of minor injuries, and other non-cardiac emergency procedures-ensuring that no content related to recognizing a cardiac emergency or activating the emergency response system is provided. Delivered in a classroom setting by qualified personnel, the program is designed to mirror the overall structure, duration, and engagement level of the CPR intervention without overlapping its core content. Expert validation has been obtained to confirm that the curriculum remains neutral and strictly adheres to general first aid, thereby serving as a robust comparator to isolate the specific effects of CPR training in young schoolchildren.
219406012|NCT04902703|DRUG|Sargramostim|Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
219406013|NCT04902703|DRUG|Saline - placebo comparator|Saline will be administered subcutaneously, 5 days/week, for 24 weeks
219566993|NCT01795235|DRUG|Saline|Saline s.c.
219189933|NCT06822218|DEVICE|high tone power therapy|patients will be assigned into 2 groups with pre and post treatment protocol application. all patients will be thoroughly evaluated before and after treatment protocol application.
219189934|NCT06822218|DEVICE|TENS|These patients will receive TENS with applied frequencies range from 2 to 120 Hz. for 3 times per week for 30 minutes every session during 3 months of intervention in addition to medications.
219189935|NCT05826288|OTHER|BioIntelliSense BioButton Rechargable|This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
219189936|NCT05826288|OTHER|Memora Health two-way patient engagement platform provided by RC|The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
219189937|NCT04083170|DRUG|Fludarabine|Given IV
219189938|NCT04083170|DRUG|Cyclophosphamide|Given IV
219189939|NCT04083170|DRUG|Thiotepa|Given IV
219189940|NCT04083170|RADIATION|Total-Body Irradiation|Undergo TBI
219189941|NCT04083170|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
219189942|NCT04083170|BIOLOGICAL|Dilanubicel|Given IV
219189943|NCT06488248|PROCEDURE|Endoscopic third ventriculostomy (ETV)|The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.
219406014|NCT06910124|BIOLOGICAL|Linvoseltamab|"Participants will receive Linvoseltamab intravenously (IV) according to the following schedule and regimen, for up to 24 cycles, each cycle lasting 28 days:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 25mg~* Cycle 1 Days 15, 22: 100mg~* Cycles 2 and 3, Days 1, 8, 15, 22: 100mg~* Cycles 3 and 6, Days 1 and 15: 100mg~* Cycles 7 through 24: 100mg"
219406015|NCT06910124|DRUG|Lenalidomide|Participants will take 10mg of Lenalidomide maintenance therapy standard of care by mouth daily from days 1 through 21 of each 28 day cycle of Linvoseltamab therapy. Lenalidomide therapy will begin on Cycle 2 Day 1 of Linvoseltamab therapy.
219406016|NCT07099560|PROCEDURE|Ultrasound-guided sacral erector spinae plane block (sESPB)|After induction of general anesthesia, bilateral sESPB is performed under ultrasound guidance. Needle advanced to the sacral interfascial plane near the median sacral crest; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine 0.5 mg/kg if FLACC ≥4.
219406017|NCT07099560|PROCEDURE|Ultrasound-guided caudal epidural block|After induction of general anesthesia, caudal epidural injection via sacral hiatus under ultrasound guidance; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine if FLACC ≥4.
219406018|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of personalized activity (1st cycle based on BSA and eGFR; cycles 2-6 based on renal dosimetry), maximum 22.2 GBq, every 6 weeks
219406019|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of 7.4 GBq every 6 weeks
219406020|NCT07162064|DRUG|Heparin - Therapeutic dosage|Intra-arterial sheath injection of heparin 2500 units before operation
219406021|NCT07162064|DRUG|Saline (0.9% NaCl)|Intra-arterial sheath injection of 2mL saline (0.9% sodium chloride)
219406022|NCT07162311|DEVICE|tDCS|Home-Based Transcranial Direct Current Stimulation
219406023|NCT07163910|DRUG|homoharringtonine|Intravenous infusion of 1mg homoharringtonine plus 250ml of 5% glucose injection, administered once daily for two consecutive days.
219406024|NCT07163910|PROCEDURE|Radical prostatectomy|All patients will undergo radical prostatectomy within 3 weeks (±7 days) after the completion of treatment.
219406025|NCT07164079|DIETARY_SUPPLEMENT|blackberry root|Patients in the intervention group will receive a Rubus Sanctus root extract, which they will consume with breakfast for 8 weeks. The tea will be packaged as 5 grams of Rubus Sanctus root and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the intervention group will receive the Rubus Sanctus root tea along with the necessary equipment (a 200 ml beaker and thermometer). Measurements of TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibodies, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be taken at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital before and after the study.
219429403|NCT04145713|DIETARY_SUPPLEMENT|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
219566994|NCT01795235|DRUG|Glucagon|Glucagon s.c.
219566995|NCT01795235|DRUG|Placebo|Sugar Pill
219755498|NCT05504122|PROCEDURE|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
219755499|NCT06528691|DRUG|Entrectinib|Given orally (PO) or enterally
219755500|NCT06528691|DRUG|Cyclophosphamide|Given intravenous (IV)
219755501|NCT06528691|DRUG|Etoposide|Given IV
219755502|NCT06528691|DRUG|Carboplatin|Given IV
219755503|NCT06528691|BIOLOGICAL|G-CSF|Given subcutaneous (SQ) or IV
219755504|NCT06528691|BIOLOGICAL|Pegfilgrastim|Given SQ as part of recommended Bridging Therapy instead of G-CSF.
219755505|NCT06528691|PROCEDURE|Surgery|A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
219755506|NCT00906763|DIETARY_SUPPLEMENT|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
219755507|NCT04398576|BEHAVIORAL|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
219755508|NCT04398576|BEHAVIORAL|Community actions|There will be embedded community-based actions within a local strategy.
219755509|NCT02102009|DIETARY_SUPPLEMENT|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
219755510|NCT02102009|OTHER|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
219566996|NCT01795235|DRUG|Atenolol|Beta-1 receptor antagonist
219566997|NCT00834236|OTHER|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
219566998|NCT00834236|OTHER|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
219566999|NCT03133728|DIAGNOSTIC_TEST|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
219406026|NCT07164079|DIETARY_SUPPLEMENT|black tea|Patients with Graves' disease assigned to the control group will be asked to consume black tea (Camellia sinensis) with their breakfast for 8 weeks. Black tea is a product consumed almost daily in Turkish society. Black tea will be prepared in 5-g doses and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the control group will be provided with black tea bags along with the necessary equipment (a 200 ml beaker and thermometer). TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibody, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be obtained before and after the study at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital.
219406027|NCT07164027|PROCEDURE|Biopsy of Prostate|Undergo biopsy
219406028|NCT07164027|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219406029|NCT07164027|PROCEDURE|Computed Tomography|Undergo PET/CT
219567000|NCT02921516|BEHAVIORAL|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
219007186|NCT03759847|OTHER|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
219406030|NCT07164027|RADIATION|Flotufolastat F-18 Gallium|Given IV
219406031|NCT07164027|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219406032|NCT07164092|DRUG|Atropine 0.05% Eye drops|The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
219406033|NCT07164092|DRUG|Placebo ophthalmic solution|The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
219406034|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
219406035|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins wit application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
219567001|NCT02921516|BEHAVIORAL|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
219567002|NCT02921516|BEHAVIORAL|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
219567003|NCT04807062|PROCEDURE|surgery|tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
219567004|NCT00000953|DRUG|Sorivudine|
219567005|NCT00000953|DRUG|Acyclovir|
219755511|NCT03190122|PROCEDURE|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
219755512|NCT01862003|DRUG|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
219755513|NCT01862003|DRUG|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
219755514|NCT01862003|DRUG|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
219755515|NCT01862003|DRUG|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
219755516|NCT01862003|DRUG|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
219406036|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
219406037|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins with application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
219406038|NCT07162740|PROCEDURE|Right atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to right atrial ablation. The patients receive a right atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
219406039|NCT07162740|PROCEDURE|Bi-atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to bi-atrial ablation. The patients receive a bi-atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
219406040|NCT07161778|DRUG|Triamcinolone acetonide IM injection|"An initial loading dosage will be given and then every 4 weeks the patient will be given triamcinolone. Triamcinolone acetonide IM injection should be administered as per individual sites local procedures.~The number of Triamcinolone injections, the volume and the site of administration will be documented in the CRF. The initial dose can be split according to local administration procedures.~Cycle 1~Day 1 Week 1 (loading dose given once only)~o 360 mg IM injection~Subsequent cycles (given 4 weekly thereafter until progression +/-3 days)~Day 1~o 120 mg IM injection"
219406041|NCT07163338|OTHER|Collectio nof blood|Collection of an additional volume of blood in the initial blood test.
219567006|NCT03391115|BEHAVIORAL|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
219567007|NCT03391115|BEHAVIORAL|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
219567008|NCT03680261|RADIATION|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
219567009|NCT03680261|DRUG|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
219567010|NCT04232540|DEVICE|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
219567011|NCT01174667|PROCEDURE|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
219567012|NCT01174667|OTHER|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
219567013|NCT03105973|BEHAVIORAL|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
219567014|NCT02148445|OTHER|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
219406042|NCT07163624|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
219406043|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
219567015|NCT02148445|OTHER|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
219567016|NCT02148445|DRUG|Nicotine replacement therapy|
219567017|NCT03799822|DRUG|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
219567018|NCT03799822|DIETARY_SUPPLEMENT|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
219567019|NCT03799822|DRUG|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
219567020|NCT03652831|OTHER|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
219567021|NCT03652831|OTHER|Soft Tissue Mobilization without Neural Mobilization|"* Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
219567022|NCT00083434|DRUG|Epoetin alfa|
219567023|NCT03076749|OTHER|Creating models for the diagnosis of BL allergy|
219567024|NCT06468722|BEHAVIORAL|Exercise-based rehabilitation|Patients performed regular physical exercise during inpatient rehabilitation
219567025|NCT06350617|DEVICE|High-Frequency, ipsilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
219567026|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
219567027|NCT06350617|DEVICE|High-Frequency, Lt. DLPFC|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
219567028|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
219567029|NCT00325104|PROCEDURE|Parathyroid hormone testing|
219567030|NCT00325104|PROCEDURE|Serum calcium testing|
219567031|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
219567032|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
219755517|NCT05820503|PROCEDURE|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
219755518|NCT05820503|PROCEDURE|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
219406044|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
219406045|NCT07163624|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
219406046|NCT07163624|DRUG|Semaglutide Injection (Ozempic®)|Semaglutide Injection (Ozempic®) once weekly
219406047|NCT07162870|DRUG|Traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).
219406048|NCT07162870|DRUG|Non-traditional Chinese medicine (non-TCM)|All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.
219406049|NCT07161752|DEVICE|Anatomical face mask 1|Providing face mask ventilation in a neonatal manikin using a model of anatomical face mask
219406050|NCT07161752|DEVICE|Anatomical face mask 2|Providing face mask ventilation in a neonatal manikin using another model of anatomical face mask
219406051|NCT07161752|DEVICE|Round face mask|Providing face mask ventilation in a neonatal manikin using a model of round face mask
219406052|NCT07162610|DEVICE|Rejuviel V® with lidocaine|Crosslinked hyaluronic acid (HA) 22 mg/mL + 0.3% lidocaine hydrochloride.
219406053|NCT07162610|DEVICE|JUVEDERM® VOLUMA® with lidocaine|Crosslinked hyaluronic acid (HA) 20 mg/mL + 0.3% lidocaine hydrochloride.
219567033|NCT05568173|OTHER|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
219567034|NCT05568173|OTHER|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
219567035|NCT02636673|PROCEDURE|Sigmoid Resection|
219567036|NCT01047033|BEHAVIORAL|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
219567037|NCT01047033|OTHER|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
219567038|NCT03568604|DRUG|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
219567039|NCT04646694|DRUG|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
219567040|NCT04646694|OTHER|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
219567041|NCT02272894|PROCEDURE|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
219567042|NCT03485027|DRUG|the rechallenge regimen|XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
219567043|NCT04230876|BEHAVIORAL|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
219567044|NCT00268515|DRUG|cyclosporine|
219567045|NCT00268515|DRUG|tacrolimus|
219567046|NCT00268515|DRUG|prednisone|
219567047|NCT00268515|DRUG|azathioprine|
219567048|NCT02369354|BEHAVIORAL|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
219761007|NCT06246305|OTHER|conventional physical therapy training|conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
219406054|NCT07163949|OTHER|Performance-based tests (such as TUG, foot posture measurements, Tandem Gait test) will be administered to children with ASD.|Children with ASD underwent balance and foot measurement tests that they could perform only by following instructions.
219406055|NCT07163936|DEVICE|Citrate dialysate with magensium supplementation|Citrate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 110 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.75 mmol/L, citrate 1 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
219406056|NCT07163936|DEVICE|Acetate dialysate|Acetate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 109 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.5 mmol/L, acetate 3 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
219406057|NCT07161856|PROCEDURE|a novel balloon-assisted EUS-GE|The patients will receive EUS-NBAGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, contrast medium is injected to determine the location and length of the stricture. A guidewire is then placed through the stricture into the jejunum, approximately 15 cm distal to the anal side of the stricture. A double-balloon device is inserted over the guidewire. The anal-side balloon is inflated with about 40 mL of air, and under fluoroscopy, the balloon is confirmed to be well inflated. A mixture of contrast medium and methylene blue in a 1:1 dilution is injected into the proximal small intestine through the water injection channel at the proximal end of the catheter. A linear echoendoscope is inserted into the mid-body of the stomach on the greater curvature side to scan the distended small intestine loop. After identifying the distended small intestine loop, a HOT-AXIOS 1.5×1.0cm LAMS is placed under direct visualization.
219406058|NCT07161856|PROCEDURE|direct EUS-GE|"The patients will receive EUS-DGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, a guidewire and/or nasobiliary catheter is passed through the stricture into the jejunum. A mixture of contrast medium and methylene blue is injected to distend the target intestinal loop. An echoendoscope is introduced into the stomach to select the optimal puncture site.~A 19G or 22G puncture needle is used to puncture the gastric and jejunal walls. Aspiration of fluid confirms the needle tip is in the jejunum, after which the channel is dilated over the guidewire. Using the delivery system of an electrocautery-enhanced fully covered lumen-apposing metal stent (LAMS), the stent is deployed to complete the gastrojejunostomy."
219406059|NCT07163754|DIAGNOSTIC_TEST|Automated Sperm Selection|This group of oocytes will be microinjected with sperm selected by the second version of SID TM (SID V2.0) wich analyses additional sperm parameters than first version of SID TM (SID V1.0).
219406060|NCT07163754|DIAGNOSTIC_TEST|Conventional Sperm Selection|Half of the oocytes will be microinjected with sperm selected by the embryologist without SID assistance, based on the conventional and visual assesment of seminal samples located at ICSI dishes.
219406061|NCT07162935|OTHER|Cigarillo brand 1|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
219406062|NCT07162935|OTHER|Cigarillo brand 2|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
219406063|NCT07162935|OTHER|Cigarillo brand 3|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
219406064|NCT07163039|OTHER|Dual-Task Motor-Cognitive Training|Participants assigned to this group will undergo dual-task motor-cognitive training, which combines physical exercises with simultaneous cognitive tasks. Sessions will last 45-60 minutes, three times per week, for 8 weeks. Exercises will include gait and balance activities performed while engaging in cognitive tasks such as arithmetic, memory recall, or word association.
219406065|NCT07163039|OTHER|Conventional Exercise Training|Participants in this group will receive a conventional exercise program focusing on strength, flexibility, and balance without a cognitive component. Sessions will last 45-60 minutes, three times per week, for 8 weeks, and will be supervised by a physiotherapist.
219406066|NCT07162896|DRUG|Crisaborole 2%|Apply thin layer to affected skin daily for 28 days.
219406067|NCT07162896|DRUG|Tacrolimus 0.1%|Apply thin layer to affected skin daily for 28 days.
219406068|NCT07163871|BEHAVIORAL|Postpartum hygiene, breast milk, and breastfeeding education have been provided for new mothers.|During the first ten days after birth, the first month, and the third month, new mothers received detailed care and education through home visits in addition to routine postnatal education. Information was shared at the mother's request as needed.
219567049|NCT02369354|OTHER|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
219567050|NCT03248986|OTHER|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
219567051|NCT03438006|OTHER|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
219567052|NCT03895229|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
219567053|NCT04646525|DIAGNOSTIC_TEST|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
219755519|NCT05367947|BEHAVIORAL|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
219755520|NCT03156829|OTHER|Splint|Custom made splint
219755521|NCT03156829|DRUG|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
219755522|NCT03156829|COMBINATION_PRODUCT|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
219406069|NCT07161817|BEHAVIORAL|Lateral positioning|Patients allocated to lateral positioning were placed at 90° on a horizontal bed, supported with a pillow to maintain neutral alignment of the spine and avoid hyperextension or forward flexion of the neck. No preference was specified for left or right lateral decubitus positioning, allowing flexibility based on patient comfort and surgical requirements.
219406070|NCT07161817|BEHAVIORAL|Semirecumbent positioning|Patients in the semi-recumbent position were placed in the bed and the head of the bed was raised by 30 °, allowing flexibility based on patient comfort and surgical requirements.
219406071|NCT07163104|BEHAVIORAL|Kaleidoscope|"Immediately before the procedure, children will be given the opportunity to examine the kaleidoscope and asked what shapes they see. The kaleidoscope distraction will begin immediately before the immunotherapy procedure and continue throughout the procedure. Children will be asked detailed questions such as, What shapes do you see in the picture? What colors are there? How many eyes do you see in the picture?, which the child can only accurately answer after careful examination. After the procedure, the kaleidoscope will be wiped with 70% alcohol and preserved by the researcher for the next session. A Zapp Flex Kaleidoscope (31.5 cm) will be used in this study."
219406072|NCT07163104|BEHAVIORAL|Buzzy|The device contains a wing-shaped ice pack on the skin-contact portion. The ice pack is stored in a deep freezer and inserted into the device before application. After application, the ice pack is wiped with 70% alcohol and kept in the freezer until it freezes again. Cold application and vibration begin before the procedure and continue until the end. When vibration is applied, it reduces or eliminates pain by causing numbness, paresthesia, and anesthesia. Cold application reduces pain by slowing or blocking conduction in peripheral nerves. It also reduces pain by activating the gate-control mechanism, stimulating touch receptors, and increasing the release of endogenous opioids.
219429404|NCT04145713|OTHER|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
219429405|NCT02157246|OTHER|Pimonidazole|
219429406|NCT02157246|OTHER|F-MISO PET|
219567054|NCT05542849|DRUG|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
219189944|NCT06488248|PROCEDURE|Ventriculoperitoneal shunt (VPS)|The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.
219189945|NCT03757689|DRUG|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
219189946|NCT03757689|PROCEDURE|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
219429407|NCT02157246|OTHER|pCT|
219189947|NCT03094312|PROCEDURE|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
219189948|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
219189949|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
219189950|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
219189951|NCT01221948|DEVICE|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
219189952|NCT04989556|OTHER|Interview|Participate in interview
219189953|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
219429408|NCT02157246|OTHER|Functional MRI|
219429409|NCT02157246|PROCEDURE|Biopsy|
219429410|NCT02157246|PROCEDURE|Blood sample|
219567055|NCT02720133|BIOLOGICAL|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
219755523|NCT04600284|DRUG|AD-2101|AD-2101 16/5mg
219755524|NCT04600284|DRUG|AD-2102|AD-2102 25mg
219755525|NCT04600284|DRUG|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
219406073|NCT07163104|BEHAVIORAL|Cognitive behavioral intervention|The researcher will suggest various distraction techniques (counting, singing, reading poetry, answering questions, etc.) to shift the child's focus during the procedure. The distraction technique chosen by the child will be used during the procedure. This method will be chosen during the preparation and briefing phases of the procedure. Cognitive behavioral intervention application will begin before subcutaneous application and will last 15-20 minutes, after which subcutaneous application will begin. After subcutaneous administration, children will rate their pain levels during and after the procedure with the Wong Baker Scale, their anxiety levels with the Children's State Anxiety Scale (CSA), and their fear levels with the Children's Fear Scale (CFS). A parent present with the child will observe the child's behavioral state during the procedure and will rate the child's fear level during and after the procedure with the CFS and their anxiety level with the CSA.
219406074|NCT07162376|BEHAVIORAL|Personal Information Disclosure|Each profile also contains non-health related personal information that the patient has disclosed (e.g., nickname, hobbies).
219567056|NCT00440609|DRUG|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
219567057|NCT03026309|OTHER|no intervantion|no intervention is being performed, only observational evaluations.
219755526|NCT06217263|DEVICE|Vibration device|Vibracool vibration device from Pain Care Labs will be used.
219567058|NCT04169555|PROCEDURE|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
219755527|NCT06217263|OTHER|Vibration device&Cold application pack|Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
219406075|NCT07162714|RADIATION|radiotherapy|The patients receive pelvic radiotherapy: Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT), with a total dose of 25 Gy delivered in 5 fractions. Radiotherapy is to start on day 1 and to finish on day 5.
219755528|NCT04745091|PROCEDURE|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
219755529|NCT04966325|DRUG|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
219755530|NCT04966325|DRUG|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
219755531|NCT04966325|DRUG|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
219755532|NCT04966325|DRUG|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
219567059|NCT04169555|OTHER|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
219755533|NCT02434081|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
219755534|NCT00419744|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|
219755535|NCT00419744|DRUG|Formoterol Turbuhaler|
219755536|NCT01668004|BIOLOGICAL|Golimumab|GLM 50 mg subcutaneously once monthly.
219189954|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
219189955|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
219567060|NCT00487331|OTHER|Acupuncture|Acupuncture sessions 1-3 times per week.
219567061|NCT00487331|BEHAVIORAL|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
219567062|NCT04651595|PROCEDURE|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
219567063|NCT04651595|DRUG|Morphine|morphine to control pain and avoid using muscle relaxant
219567064|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
219567065|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
219567066|NCT01447225|DRUG|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
219567067|NCT01447225|DRUG|Carboplatin|administered at AUC 6
219189956|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
219406076|NCT07162714|DRUG|Ivonescimab (20mg/kg Q3W)|The first dose of vonescimab (AK112) was administered 1 week after the completion of radiotherapy. Ivonescimab (AK112) was initiated at a dose of 20 mg/kg via intravenous infusion on Day 1 of each 21-day cycle, for a total of 6 cycles.
219189957|NCT00746096|DRUG|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
219189958|NCT00746096|DRUG|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
219406077|NCT07162714|OTHER|Non-operative Management|Subjects who achieve cCR after radiation and 6 cycles treatment of Ivonescimab can, after discussion with the local investigator, decline surgery and opt for a non-operative management.
219406078|NCT07162714|PROCEDURE|Surgery|For patients who do not achieve cCR at the end of 6 cycles treatment of Ivonescimab, TME surgery is recommended.
219406079|NCT07163897|DEVICE|Cobra Ankle Arthrometer|This is a prototype portable ankle arthrometer designed to measure the laxity of the ankle joint.
219406080|NCT07163390|COMBINATION_PRODUCT|Sideral Folico|Pregnant women will be enrolled from 24 to 32 weeks of gestation whether their hemoglobin levels are comprised between 8.5 and 10.5 g/dl. They start oral supplementation with Sucrosomial iron® 30 mg (Sideral® Folico), 2 sticks for twice a day for 15 days, followed by Sucrosomial iron ® 30 mg (Sideral® Folico), 1 stick for twice a day for the next 15 days
219406081|NCT07163793|DRUG|Azacitidine|Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study
219406082|NCT07163793|DRUG|Decitabine|Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off
219406083|NCT07163793|DRUG|Venetoclax|Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine
219406084|NCT06238466|DRUG|AZD1705|Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
219406085|NCT06238466|OTHER|Placebo|Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
219406086|NCT06525064|OTHER|Health-E You app|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
219429411|NCT06248463|DIAGNOSTIC_TEST|BP measurement in waiting room for 20 minutes|"Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted."
219429412|NCT05269641|OTHER|Food: whole almonds|60g of whole almonds will be consumed daily.
219429413|NCT05269641|OTHER|Food: non-nut snack|A non-nut snack will be consumed daily.
219567068|NCT01447225|DRUG|Pemetrexed|administered IV at 500 mg/m2
219567069|NCT01447225|DRUG|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
219567070|NCT01447225|DRUG|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
219567071|NCT00109486|DRUG|GW685698X|
219567072|NCT05210712|DEVICE|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
219567073|NCT05988424|OTHER|Left atrial mapping|Creation of a left atrial voltage map
219567074|NCT02240004|DEVICE|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
219567075|NCT04691440|DRUG|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
219567076|NCT04108962|DRUG|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
219567077|NCT04118868|COMBINATION_PRODUCT|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
219567078|NCT04718649|DRUG|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
219567079|NCT00230191|DRUG|RK-0202|
219567080|NCT04350008|DEVICE|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
219567081|NCT00905788|PROCEDURE|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
219567082|NCT01000688|DRUG|vildagliptin + acarbose|4 week treatment
219567083|NCT01000688|DRUG|acarbose + vildagliptin|4 week treatment
219567084|NCT02498249|DEVICE|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
219567085|NCT02498249|DEVICE|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
219567086|NCT02737592|DEVICE|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
219567087|NCT05675358|BEHAVIORAL|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
219406087|NCT06525701|OTHER|Execise Group|SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.
219406088|NCT06525701|OTHER|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
219406089|NCT06023680|BEHAVIORAL|Continuous sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days."
219567088|NCT02425501|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
219567089|NCT01784198|DIETARY_SUPPLEMENT|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
219567090|NCT04593303|PROCEDURE|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
219567091|NCT04593303|PROCEDURE|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
219567092|NCT00576303|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
219567093|NCT04452695|DEVICE|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
219567094|NCT03955939|DRUG|LY3295668 Erbumine|Administered orally.
219755537|NCT03462745|DEVICE|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
219755538|NCT05543317|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
219755539|NCT01101126|OTHER|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
219755540|NCT01101126|OTHER|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
219755541|NCT04838652|DRUG|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
219755542|NCT00182650|BIOLOGICAL|aldesleukin|
219755543|NCT00182650|BIOLOGICAL|rituximab|
219429414|NCT04970849|OTHER|observation|IBD doctors who perform the endoscopy perform the questionnaire
219429415|NCT05915936|PROCEDURE|LVMR|laoparoscopic ventral mesh rectopexy
219429416|NCT05915936|PROCEDURE|PSR|perineal stapler resection
219567095|NCT03955939|DRUG|Endocrine therapy|Administered according to label instructions.
219567096|NCT03955939|DRUG|Midazolam|Administered orally.
219567097|NCT05792319|DIAGNOSTIC_TEST|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
219755544|NCT00182650|BIOLOGICAL|therapeutic autologous lymphocytes|
219755545|NCT00182650|DRUG|fludarabine phosphate|
219755546|NCT04902612|DEVICE|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
219755547|NCT04902612|DEVICE|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
219755548|NCT00444314|DRUG|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
219755549|NCT00444314|DRUG|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
219755550|NCT00499044|OTHER|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
219755551|NCT00499044|OTHER|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
219429417|NCT04371627|DRUG|Viaskin Peanut|Daily epicutaneous delivery
219429418|NCT06343025|OTHER|Pilates Exercises Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
219429419|NCT06343025|OTHER|Tai Chi Exercises Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
219429420|NCT01192204|DRUG|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
219429421|NCT01192204|DRUG|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
219406090|NCT06023680|BEHAVIORAL|Bouted sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days."
219567098|NCT00297245|DRUG|cognitive function|
219567099|NCT03684681|BEHAVIORAL|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
219567100|NCT03684681|BEHAVIORAL|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
219406091|NCT04239703|DIAGNOSTIC_TEST|MMDx|Portion of kidney transplant indication biopsy
219406092|NCT04239703|DIAGNOSTIC_TEST|Prospera|Transplant patient blood sample
219406093|NCT04239703|DIAGNOSTIC_TEST|HLA antibody|Transplant patient blood sample
219406094|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
219007187|NCT03001531|DEVICE|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
219007188|NCT03001531|DEVICE|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
219007189|NCT03362073|DRUG|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> … -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
219406095|NCT06826079|DRUG|Sorbitol|During the neoadjuvant treatment week, oral sorbitol 2-4g/ time, three times a day (with meals)
219406096|NCT06826079|OTHER|Placebo|During the neoadjuvant treatment week, oral placebo 2-4g/ time, three times a day (with meals)
219007190|NCT04737083|GENETIC|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
219007191|NCT03459547|DEVICE|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
219007192|NCT00629681|DRUG|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
219406097|NCT04145115|BIOLOGICAL|Ipilimumab|Given IV
219406098|NCT04145115|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219406099|NCT04145115|BIOLOGICAL|Nivolumab|Given IV
219406100|NCT06113445|DRUG|Povorcitinib|Oral, Tablet
219406101|NCT06113445|DRUG|Placebo|Oral, Tablet
219406102|NCT04582383|DRUG|Spironolactone|Dispensation of spironolactone according to the arm description.
219406103|NCT04582383|DRUG|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
219406104|NCT06226571|DRUG|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
219406105|NCT06226571|DRUG|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
219406106|NCT06226571|DRUG|HiDAC|Consolidation: Participants will receive HiDAC IV.
219406107|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
219406108|NCT05031910|OTHER|Best Practice|Receive standard of care
219567101|NCT00061217|DEVICE|Unrectified prosthetic socket|
219567102|NCT00061217|DEVICE|Rectified prosthetic socket|
219567103|NCT02418624|DRUG|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
219567104|NCT06887322|DRUG|Ciplukan|A minimum amount of 20 psoriasis vulgaris lesion treated with the topical formulation containing 20% ciplukan (Physalis angulata Linn.) extract, applied twice a day for 14 days.
219567105|NCT06887322|DRUG|Bethametasone valerate 0,1% cream|A minimum amount of 20 psoriasis vulgaris lesion treated with the bethametasone valerate 0,1% cream, applied twice daily for 14 days.
219567106|NCT06474481|DRUG|Zanubrutinib|Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
219567107|NCT06474481|DRUG|Obinutuzumab|Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
219567108|NCT06474481|DRUG|Prednisone|Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
219002290|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
219002291|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
219406109|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
219567109|NCT06474481|DRUG|Cyclophosphamide|Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
219567110|NCT06474481|DRUG|Vincristine|Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
219567111|NCT06474481|DRUG|Doxorubicin|Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
219567112|NCT00955721|DRUG|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
219567113|NCT00955721|DRUG|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
219567114|NCT00955721|DRUG|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
219567115|NCT01007279|DRUG|ROSUVASTATIN|40 mg before procedure
219567116|NCT02306837|DRUG|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
219755552|NCT00601341|OTHER|lumbosacral joint manipulation|lumbosacral joint manipulation
219002292|NCT04993092|OTHER|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
219002293|NCT04993092|OTHER|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
219002294|NCT04957693|BEHAVIORAL|vegan diet and lifestyle changes|vegan diet and lifestyle changes
219567117|NCT06904716|OTHER|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation
219567118|NCT06905080|DEVICE|Catheter Caps Case (C3)|The nursing team will then assess the participant's catheter, catheter site, and lumens. The C3 device will be placed on the distal lumens and hub caps of the participant's hemodialysis catheter using clean technique and left in place for approximately 15 minutes. During this time, the participant will be asked to lay, sit, and stand while wearing the C3 device. The RN will stay with the participant during the entire time and will write down any comments or requests regarding the C3 made by the participant. After 15 minutes, the nursing team will remove the C3 device and reassess the condition of the catheter site and lumens, noting any changes. Finally, the participant will complete a 10 item post- intervention survey, developed by the study team and evaluated for face validity by all members of the team to provide feedback on the design of the C3 device.
219567119|NCT06185972|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
219567120|NCT06185972|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
219406110|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
219567121|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
219755553|NCT00601341|OTHER|lumbar passive range of motion|lumbar passive range of motion
219755554|NCT00601341|OTHER|No active intervention|Lie on exam table for 3 minutes
219755555|NCT04473001|OTHER|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"
219406111|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
219406112|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
219406113|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
219406114|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
219406115|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
219406116|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
219406117|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
219567122|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
219002295|NCT06359067|OTHER|Treated by bispecific antibodies, teclistamab or elranatamab in usual care|Treated by bispecific antibodies, teclistamab or elranatamab in usual care
219406118|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
219406119|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
219406120|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
219567123|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
219002296|NCT06359067|OTHER|Not treated by bispecific antibodies in usual care|Not treated by bispecific antibodies in usual care
219002297|NCT04069494|OTHER|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
219567124|NCT06322966|OTHER|Air Action Curriculum|"The goal of integrating a new curriculum into classrooms is to improve student knowledge on the health effects of air pollution, specifically of wildfire smoke.~The goal is to implement a student-designed and student-driven air quality study in each school that will lead to improved air quality and health impacts in schools, promote health equity, and train young people to be more informed about their health and proactive citizens in their school community and beyond."
219002298|NCT04921371|OTHER|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
219002299|NCT04921371|OTHER|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
219406121|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
219406122|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
219406123|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
219406124|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
219406125|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
219406126|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
219406127|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
219406128|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
219406129|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
219406130|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
219406131|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
219406132|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
219406133|NCT05973487|BIOLOGICAL|TSC-202-A0201|Escalating doses of TSC-202-A0201 as a monotherapy
219406134|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-202-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-202-A0201
219406135|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-202-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-202-A0201
219406136|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-202-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-202-A0201
219406137|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-202-A0201|Escalating doses of TSC-203-A0201 in combination with TSC-202-A0201
219406138|NCT05973487|BIOLOGICAL|TSC-204-A0101 + TSC-202-A0201|Escalating doses of TSC-204-A0101 in combination with TSC-202-A0201
219406139|NCT05973487|BIOLOGICAL|TSC-201-B0702 + TSC-202-A0201|Escalating doses of TSC-201-B0702 in combination with TSC-202-A0201
219406140|NCT05376345|BIOLOGICAL|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
219406141|NCT06315218|BEHAVIORAL|iTHRIVE 365 HIV care intervention|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
219406142|NCT06195280|RADIATION|Magnetic resonance imaging, 3DT1 sequence|The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
219406143|NCT06195280|PROCEDURE|Laparoscopy|After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
219406144|NCT05183867|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
219406145|NCT04188405|DRUG|Decitabine|Given IV
219406146|NCT04188405|DRUG|Ponatinib|Given PO
219567125|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
219755556|NCT02850588|PROCEDURE|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
219755557|NCT02850588|PROCEDURE|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
219755558|NCT05634486|BEHAVIORAL|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
219755559|NCT05634486|OTHER|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
219007193|NCT02026739|PROCEDURE|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
219406147|NCT04188405|DRUG|Venetoclax|Given PO
219406148|NCT06672458|DEVICE|MyndMove Short Term Therapy|FES therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. FES therapy uses surface electrical stimulation to produce muscle contractions in different combinations to achieve a wide range of reaching and grasping functions. To achieve these movements the single use electrodes will be placed in various combinations on the surface of the different upper arm muscles. Participants will perform hand and finger dexterity tests as well as arm functional mobility tasks while receiving FES.
219406149|NCT06672458|OTHER|Conventional Short Term Therapy|Therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. Conventional therapy will consist of performance hand and finger dexterity tests as well as arm functional mobility tasks
219406150|NCT06672458|DEVICE|MyndMove Long Term Therapy|FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.
219406151|NCT05215769|BEHAVIORAL|Health Education|Participate in a video intervention
219406152|NCT05215769|OTHER|Questionnaire Administration|Complete questionnaires
219406153|NCT06401642|DRUG|Zavegepant|10 mg intranasal
219406154|NCT04369053|DIAGNOSTIC_TEST|Freenome test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.
219406155|NCT06123013|BEHAVIORAL|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
219406156|NCT05299983|OTHER|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
219755560|NCT03573492|OTHER|Education|Type of teaching being assigned to student arms
219755561|NCT02196922|DEVICE|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
219406157|NCT05299983|OTHER|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
219406158|NCT03561220|RADIATION|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
219406159|NCT03561220|RADIATION|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
219567126|NCT04974736|BEHAVIORAL|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
219567127|NCT03581188|DEVICE|Patient-led surveillance|Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.
219567128|NCT03581188|BEHAVIORAL|Clinician-led surveillance|Usual care (scheduled clinician visits)
219755562|NCT02196922|OTHER|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
219755563|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
219406160|NCT03561220|RADIATION|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
219406161|NCT03561220|RADIATION|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
219406162|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMRT
219406163|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMPT
219406164|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
219406165|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
219406166|NCT01629498|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219406167|NCT01629498|RADIATION|Photon Beam Radiation Therapy|Undergo image-guided IMRT
219406168|NCT01629498|RADIATION|Proton Beam Radiation Therapy|Undergo image-guided IMPT
219406169|NCT01629498|OTHER|Questionnaire Administration|Ancillary studies
219406172|NCT06957431|DRUG|Zanzalintinib|Supplied by Exelixis, Inc.
219406173|NCT06957431|DRUG|Eribulin|1.1 mg/m\^2 dose.
219406174|NCT06481904|DRUG|TZIELD (teplizumab-mzwv)|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
219406175|NCT05622864|DRUG|HRS-9821|HRS-9821
219406176|NCT05622864|DRUG|HRS-9821|HRS-9821
219406177|NCT04491877|BIOLOGICAL|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
219406178|NCT04491877|BIOLOGICAL|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
219406179|NCT04491877|BIOLOGICAL|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
219755564|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
219406180|NCT06962891|DIAGNOSTIC_TEST|CKD progression biomarker|We will evaluate the CKD progression biomarker at baseline and evaluate 1-year CKD progression afterwards.
219755565|NCT04937192|OTHER|No intervention|No intervention
219406181|NCT06433128|DRUG|Fosmanogepix solution for infusion|Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
219406182|NCT06433128|DRUG|Fosmanogepix 400 mg tablets|Fosmanogepix 400 mg tablets for oral administration
219406183|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
219406184|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
219406185|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
219755566|NCT02448381|DRUG|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
219755567|NCT02448381|DRUG|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
219761008|NCT06246305|DEVICE|Virtual Reality (VR) training|During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
219761009|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume whole-foods, fiber-rich diet
219406186|NCT05170438|DRUG|Lenvatinib Pill,Paclitaxel|Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
219406187|NCT06068270|PROCEDURE|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
219567129|NCT04757181|OTHER|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
219567130|NCT03938415|PROCEDURE|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
219567131|NCT03938415|OTHER|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
219567132|NCT05692076|DEVICE|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
219567133|NCT02503475|OTHER|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
219567134|NCT02503475|BEHAVIORAL|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
219567135|NCT02503475|DEVICE|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
219567136|NCT03064438|DRUG|ACCU-D1|ACCU-D1
219406188|NCT06370715|DRUG|Insulin Lispro-aabc|Administered SC
219567137|NCT03064438|DRUG|Vehicle|Placebo Comparator
219002300|NCT04921371|OTHER|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
219002301|NCT04921371|OTHER|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
219002302|NCT04921371|OTHER|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
219002303|NCT04921371|OTHER|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
219002304|NCT01635192|BIOLOGICAL|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
219002305|NCT01635192|BIOLOGICAL|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
219406189|NCT06370715|DRUG|Insulin Glargine|Administered SC
219406190|NCT03538652|OTHER|Formative Interviews (not an intervention)|One hour formative-interview session
219406191|NCT03538652|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|In CBT, negative emotional states are viewed as problems to be solved, and the client learns skills to solve them.
219567138|NCT01937351|DEVICE|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
219567139|NCT01961687|DEVICE|Resorbable Mesh|Phasix Mesh
219567140|NCT02107222|DEVICE|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
219567141|NCT03482219|OTHER|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
219002306|NCT03091634|DRUG|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
219002307|NCT03091634|DRUG|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
219406192|NCT03538652|BEHAVIORAL|Acceptance and commitment therapy (ACT)|In ACT, negative emotional states are viewed as a necessary and potentially valuable component of a full life. When they occur, the goal is not to solve them, but to experience them in an observant, curious, nonjudgmental way-a practice referred to as mindfulness.
219406193|NCT03538652|OTHER|No intervention|Control group with no intervention administered
219406194|NCT01988480|PROCEDURE|Image-guided surgery|Placement on residual bone around the implant
219406195|NCT01988480|PROCEDURE|Sinus lift surgery|Allograft bone
219406196|NCT05280379|OTHER|no intervention will take place|no intervention will take place
219406197|NCT05352893|DRUG|Imsidolimab high dose|intravenous
219406198|NCT05352893|DRUG|Imsidolimab low dose|intravenous
219406199|NCT05352893|OTHER|Placebo|intravenous
219406200|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
219406201|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
219406202|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
219406203|NCT05386394|DEVICE|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
219406204|NCT05386394|DEVICE|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
219406205|NCT05790668|BEHAVIORAL|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
219406206|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
219406207|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
219406208|NCT05233631|PROCEDURE|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
219406209|NCT06839976|BIOLOGICAL|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.
219406210|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
219406211|NCT06127407|DRUG|Ivosidenib 500mg|Provided as tablets, taken orally as two 250mg tablets once daily.
219406212|NCT06127407|DRUG|Placebo|Provided as tablets, taken orally once daily.
219406213|NCT04736173|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
219406214|NCT04736173|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
219406215|NCT04736173|DRUG|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
219406216|NCT04736173|DRUG|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
219406217|NCT04736173|DRUG|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
219406218|NCT04736173|DRUG|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
219406219|NCT05420129|DEVICE|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
219406220|NCT05420129|DEVICE|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
219406221|NCT04058457|DEVICE|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
219406222|NCT04802850|OTHER|Mulligan mobilization with movement|
219761010|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
219189959|NCT04059185|OTHER|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
219406223|NCT01415037|PROCEDURE|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
219406224|NCT00532961|DRUG|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
219406225|NCT00532961|DRUG|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
219406226|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
219567142|NCT03482219|OTHER|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
219567143|NCT06616259|DRUG|mCapOX plus Cetuximab|"mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
219567144|NCT06616259|DRUG|mFOLFOX6 plus Cetuximab|"mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
219406227|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
219406228|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
219567145|NCT02376660|OTHER|Oats|
219567146|NCT04828434|OTHER|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
219567147|NCT02806687|DRUG|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
219567148|NCT02806687|DRUG|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
219567149|NCT02997137|DIETARY_SUPPLEMENT|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
219567150|NCT02997137|OTHER|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
219567151|NCT01505361|BIOLOGICAL|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
219567152|NCT01505361|BIOLOGICAL|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
219567153|NCT02284347|DEVICE|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
219567154|NCT04649489|DRUG|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
219761011|NCT03950635|OTHER|Questionnaire Administration|Ancillary studies
219406229|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
219406230|NCT02251444|PROCEDURE|outpatient rehabilitation program|
219406231|NCT02251444|PROCEDURE|physical therapy|
219406232|NCT04237402|OTHER|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
219406233|NCT04611763|DRUG|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
219406234|NCT04611763|DRUG|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
219189960|NCT04059185|OTHER|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
219189961|NCT04059185|OTHER|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
219189962|NCT03756662|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
219189963|NCT05174637|DRUG|FDA018-ADC|FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
219189964|NCT04283045|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
219189965|NCT04283045|BEHAVIORAL|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
219189966|NCT04049851|DRUG|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
219406235|NCT01640990|DRUG|Saline|30mins run-in period
219406236|NCT01640990|DRUG|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
219406237|NCT01640990|DRUG|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
219406238|NCT06346457|DRUG|Tamoxifen|Tamoxifen is 20 mg once daily for two to three weeks.
219406239|NCT06346457|DRUG|Letrozole|Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
219406240|NCT06346457|DRUG|Letrozole + GnRH|When they take Letrozole + GnRh, the GnRh is an injection once a month.
219406241|NCT01113398|DRUG|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
219406242|NCT01113398|DRUG|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
219406243|NCT03280433|OTHER|Aortic valve replacement|
219406244|NCT06266390|DEVICE|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
219406245|NCT02620462|DEVICE|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
219406246|NCT03087825|PROCEDURE|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
219406247|NCT03087825|PROCEDURE|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
219406248|NCT00139334|BIOLOGICAL|Rotavirus|
219406249|NCT00028561|DRUG|ixabepilone|Given IV
219406250|NCT00028561|DRUG|carboplatin|Given IV
219406251|NCT00028561|OTHER|laboratory biomarker analysis|Correlative studies
219406252|NCT00028561|OTHER|pharmacological study|Correlative studies
219406253|NCT01029431|DEVICE|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
219567155|NCT04649489|PROCEDURE|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
219002308|NCT04014842|DEVICE|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
219761012|NCT04207320|DEVICE|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
219406254|NCT02261168|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
219406255|NCT02811536|DEVICE|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
219406256|NCT04684550|DRUG|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
219406257|NCT04684550|DRUG|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
219406258|NCT03824925|DRUG|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
219406259|NCT03824925|DRUG|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
219406260|NCT05848037|DEVICE|cymactive™ catheter device (CCD)|"The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065) and will be available in the UK market, subject to local arrangements.~The cymactive™ catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body except for 2 removal strings, and has an integral, magnetically controlled valve that allows the user to control their own urination. The study participant will each be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical) so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items, i.e. mobile phones, laptops and credit cards. Study participants should also avoid contact with MRI machines."
219406261|NCT05848037|DEVICE|Foley-type catheter device|Routine standard of care. Usually replaced \~ 3 monthly
219406262|NCT06182475|BEHAVIORAL|EPPComm Provider Training|A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
219406263|NCT00492856|DRUG|mercaptopurine|Given orally
219406264|NCT00492856|DRUG|methotrexate|Given orally
219007194|NCT02026739|PROCEDURE|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
219007195|NCT03535610|DEVICE|Uterine Embolization|Uterine Embolization with PVA Microspheres
219406265|NCT00492856|DRUG|tretinoin|Given orally
219406266|NCT06347341|DIETARY_SUPPLEMENT|Clinical study comparing a gluten-containing diet to a gluten-free diet|The study includes a basal period of 2 weeks, 2 test periods of a maximum duration of 1 week and a wash-out period of 2 to 3 weeks.
219406267|NCT02513368|DEVICE|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
219406268|NCT02513368|PROCEDURE|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
219761013|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
219761014|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
219761015|NCT02915497|BEHAVIORAL|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
219761016|NCT06396936|OTHER|Calisthenic exercise program|Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
219761017|NCT01726374|DRUG|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
219007196|NCT04981769|DIAGNOSTIC_TEST|Covid-19 test|PCR Covid-19 test
219007197|NCT01850771|PROCEDURE|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
219007198|NCT01850771|PROCEDURE|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
219007199|NCT03090178|OTHER|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
219761018|NCT05819762|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
219761019|NCT03440008|OTHER|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
219761020|NCT03440008|DEVICE|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
219761021|NCT04700423|DRUG|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
219761022|NCT04700423|DRUG|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
219761023|NCT04700423|DRUG|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
219406269|NCT00857753|DRUG|Fentanyl patch 25 ug/nr Sandoz|
219406270|NCT00857753|DRUG|Duragesic|
219406271|NCT05165511|BEHAVIORAL|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
219406272|NCT06451380|PROCEDURE|orthopaedic surgery|orthopaedic surgery of the upper limb under anaesthesia
219406273|NCT06451380|DRUG|propofol anesthesia|The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.
219406274|NCT01520324|DEVICE|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
219406275|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
219406276|NCT02519049|OTHER|No intervention|This is an observational study
219406277|NCT03488472|DEVICE|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
219406278|NCT03488472|RADIATION|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
219406279|NCT05569304|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
219406280|NCT06405022|OTHER|Brain Endurance Training|Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
219406281|NCT06405022|OTHER|Control|No intervention
219406282|NCT02786732|BIOLOGICAL|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
219406283|NCT02786732|BIOLOGICAL|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
219406284|NCT02786732|BIOLOGICAL|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
219755568|NCT05638074|PROCEDURE|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
219755569|NCT03700229|DRUG|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
219755570|NCT03700229|DRUG|Rituximab|rituximab intravenously 500 mg for one dose
219755571|NCT04778150|DEVICE|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
219755572|NCT06400784|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
219755573|NCT03748914|OTHER|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
219189967|NCT04049851|DRUG|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
219189968|NCT04049851|DRUG|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
219406285|NCT02786732|BIOLOGICAL|Placebo|Placebo administered subcutaneously
219755574|NCT03748914|OTHER|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
219761024|NCT04700423|DRUG|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
219761025|NCT04700423|DRUG|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
219406286|NCT04716166|OTHER|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
219406287|NCT04716166|OTHER|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
219406288|NCT03121222|DRUG|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
219761026|NCT02958345|BIOLOGICAL|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
219761027|NCT02958345|OTHER|Placebo|Injection of 0.65 mL of sterile normal saline
219761028|NCT03735732|BEHAVIORAL|prime|groups be confronted with health or palatability aspects of food items
219406289|NCT03121222|DRUG|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
219406290|NCT06553508|PROCEDURE|Trochanteric bursa repaired|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.
219406291|NCT06553508|PROCEDURE|Trochanteric bursa unrepaired|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
219406292|NCT05431517|PROCEDURE|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
219406293|NCT03635398|DEVICE|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
219755575|NCT04541524|DEVICE|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
219755576|NCT01575574|DRUG|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
219755577|NCT03229538|DRUG|Methylprednisolone|IV Steroid pre-operative and intra-operative
219755578|NCT03229538|DRUG|Isotonic saline|Isotonic saline pre-operative and intra-operative
219755579|NCT02073474|DRUG|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
219755580|NCT02735200|DRUG|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
219755581|NCT02735200|OTHER|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
219755582|NCT00673920|DRUG|Methotrexate|Oral or parenteral repeating dose
219755583|NCT00673920|DRUG|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
219755584|NCT00673920|DRUG|Placebo|Intravenous repeating dose
219755585|NCT04552002|DIETARY_SUPPLEMENT|Synbiotic group|Probiotics and prebiotics
219755586|NCT01164007|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
219755587|NCT01164007|DRUG|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
219755588|NCT01352884|DRUG|AMP-224|Escalating doses of AMP-224
219755589|NCT01352884|DRUG|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
219406294|NCT03635398|DEVICE|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
219406295|NCT03635398|DRUG|midazolam|oral administration of midazolam
219406296|NCT00189241|DRUG|imiquimod|
219406297|NCT04282226|DEVICE|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
219755590|NCT02950337|RADIATION|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
219755591|NCT02950337|RADIATION|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
219755592|NCT02950337|RADIATION|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
219755593|NCT01656577|DRUG|Pexacerfont|
219755594|NCT06078852|OTHER|Diaphragmatic ultrasound|Ultrasound evaluation of diaphragm thickness, contractility, and excursion in semi-supine and sitting positions.
219755595|NCT06078852|OTHER|Pulmonary function test|Routine spirometry, body plethysmography (FRC, TLC), maximal inspiratory/expiratory pressures (MIP, MEP), and nocturnal oximetry.
219755596|NCT04708782|DRUG|Placebo|Placebo administered QID
219406298|NCT04282226|DEVICE|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
219406299|NCT01248234|DRUG|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
219406300|NCT01248234|DRUG|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
219406301|NCT01248234|DRUG|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
219406302|NCT01253681|DRUG|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
219406303|NCT05332912|BEHAVIORAL|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
219406304|NCT01998581|DEVICE|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
219406305|NCT01998581|DEVICE|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
219406306|NCT01251276|BIOLOGICAL|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
219406307|NCT03665376|DIETARY_SUPPLEMENT|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
219406308|NCT03665376|COMBINATION_PRODUCT|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
219567156|NCT03185182|DRUG|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
219002309|NCT02277301|BEHAVIORAL|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
219002310|NCT01318304|OTHER|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
219567157|NCT01562626|DRUG|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
219567158|NCT01562626|DRUG|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
219567159|NCT01562626|DRUG|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
219567160|NCT06617091|DRUG|GRAdHIVNE1 Vaccine|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
219567161|NCT06617091|OTHER|Placebo|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
219567162|NCT03407612|DEVICE|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
219567163|NCT06163872|BEHAVIORAL|survey study|survey study
219002311|NCT05616910|DRUG|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
219002312|NCT05285813|DRUG|Vibecotamab|Given by vein (IV)
219002313|NCT05285813|DRUG|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
219002314|NCT05285813|DRUG|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
219002315|NCT05285813|DRUG|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
219002316|NCT03691792|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
219002317|NCT03691792|OTHER|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
219406309|NCT01345123|BEHAVIORAL|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
219406310|NCT01345123|BEHAVIORAL|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
219406311|NCT04348136|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
219406312|NCT03073681|DEVICE|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
219567164|NCT03489226|DIETARY_SUPPLEMENT|Capsimax|Capsimax
219567165|NCT03489226|DIETARY_SUPPLEMENT|Placebo|Placebo
219567166|NCT03489226|OTHER|Meal|Meal
219567167|NCT02972021|DEVICE|High-flow nasal cannula|
219567168|NCT05172102|OTHER|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
219567169|NCT03442010|OTHER|Detection of adverse drug events|Detection of adverse drug events
219406313|NCT04869904|PROCEDURE|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
219567170|NCT04213209|DRUG|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
219567171|NCT00385788|DRUG|Gemcitabine|800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
219567172|NCT00385788|DRUG|Fludarabine|33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
219567173|NCT00385788|DRUG|Melphalan|70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
219406314|NCT04529551|OTHER|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
219406315|NCT04529551|OTHER|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
219406316|NCT00981383|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
219406317|NCT00981383|OTHER|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
219406318|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219406319|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219406320|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219567174|NCT00385788|DRUG|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
219567175|NCT00385788|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
219755597|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
219755598|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
219567176|NCT00385788|DRUG|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
219567177|NCT00385788|DRUG|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
219567178|NCT00385788|DRUG|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
219567179|NCT01239446|OTHER|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
219567180|NCT03479931|PROCEDURE|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
219567181|NCT03479931|PROCEDURE|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
219567182|NCT01999426|OTHER|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
219567183|NCT02166034|BEHAVIORAL|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
219567184|NCT03925935|BIOLOGICAL|AB-205|Engineered human umbilical vein endothelial cells
219567185|NCT04449224|DRUG|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
219755599|NCT05476991|DRUG|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
219755600|NCT05476991|DRUG|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
219406321|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219406322|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219567186|NCT04449224|DRUG|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
219567187|NCT06290219|COMBINATION_PRODUCT|platelet-rich plasma combined with hyaluronic acid|The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
219567188|NCT06290219|DRUG|Zinc Gluconate 10 MG Oral Tablet|one tablet three times a day for a period of 12 weeks
219567189|NCT06290219|DEVICE|4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil|Sniffing each odorant for 10 seconds, twice a day for 12 weeks
219567190|NCT01812135|BIOLOGICAL|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
219567191|NCT05693818|OTHER|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
219567192|NCT05356936|DIETARY_SUPPLEMENT|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
219567193|NCT05356936|DIETARY_SUPPLEMENT|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
219567194|NCT03104621|DRUG|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
219567195|NCT03104621|DRUG|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
219567196|NCT00609284|DRUG|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
219567197|NCT00609284|DRUG|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
219567198|NCT00609284|RADIATION|Radiotherapy|70 Gy in 7 weeks
219567199|NCT05540821|DIAGNOSTIC_TEST|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
219567200|NCT00384384|DRUG|oral 18B Glycyrrhetinic acid versus placebo|
219567201|NCT02471079|RADIATION|Radiotherapy|
219567202|NCT02533284|DRUG|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
219567203|NCT02533284|DRUG|bupevecaine|US guided TAP using Bupevecaine 0.25 %
219567204|NCT02533284|DRUG|saline|US guided TAP using placebo (saline)
219567205|NCT02065713|DRUG|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
219567206|NCT02065713|DRUG|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
219567207|NCT02065713|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
219567208|NCT04351230|DRUG|Abemaciclib|Given IV
219567209|NCT04351230|BIOLOGICAL|Trastuzumab Emtansine|Given PO
219406323|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
219406324|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
219406325|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
219406326|NCT01883934|OTHER|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
219406327|NCT01883934|OTHER|Control|
219406328|NCT05909254|OTHER|Palatally impacted canine exposure using a surgical guide|Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.
219406329|NCT05909254|OTHER|Palatally impacted canine exposure using the conventional free.hand method|Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
219406330|NCT03798145|PROCEDURE|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
219406331|NCT01712087|DEVICE|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
219406332|NCT02658994|BEHAVIORAL|Thinking Healthy Program Peer Delivered Plus|
219406333|NCT02658994|OTHER|Enhanced Usual Care|
219406334|NCT05966909|DIAGNOSTIC_TEST|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
219406335|NCT02056535|BEHAVIORAL|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
219406336|NCT01013909|DRUG|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
219406337|NCT01013909|DRUG|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
219406338|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
219406339|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
219406340|NCT01013909|DRUG|Lamisil Once|One application of Lamisil Once
219406341|NCT03363243|OTHER|STOP Therapy Treatment group|Testing of the STOP Therapy protocol
219406342|NCT03363243|OTHER|Treatment as usual (TAU) group|Treatment as usual in the community through group therapy
219406343|NCT00441441|DRUG|fluticasone propionate|fluticasone propionate 100mcg HFA
219567210|NCT03399994|DEVICE|device implantation during coronary angioplasty|device implantation during coronary angioplasty
219406344|NCT00441441|DRUG|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
219406345|NCT00262080|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
219406346|NCT00262080|DRUG|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
219406347|NCT04815304|DIAGNOSTIC_TEST|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
219406348|NCT03660813|DIAGNOSTIC_TEST|Follicle measurment|Follicle will be measured before aspiration
219567211|NCT03614494|DRUG|Piroxicam 40 mg|Additional co-treatment
219567212|NCT03614494|DRUG|Levonorgestrel 1.5mg|Standard treatment
219567213|NCT03715322|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
219567214|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
219567215|NCT03715322|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
219567216|NCT05253222|DIAGNOSTIC_TEST|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
219567217|NCT04625322|OTHER|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
219567218|NCT03887416|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
219002318|NCT04165447|BEHAVIORAL|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
219002319|NCT04488068|PROCEDURE|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
219002320|NCT00717132|BEHAVIORAL|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
219002321|NCT00717132|BEHAVIORAL|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
219406349|NCT03660813|DRUG|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
219406350|NCT03660813|DRUG|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
219406351|NCT03443843|DRUG|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
219406352|NCT03443843|DRUG|Placebo tablet|Placebo tablet orally
219406353|NCT03443843|DRUG|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
219406354|NCT03443843|DRUG|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
219406355|NCT03849040|PROCEDURE|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
219406356|NCT00442247|DEVICE|Pelvicol|
219406357|NCT04840654|PROCEDURE|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
219002322|NCT00112060|DRUG|PT-523 for Injection|
219406358|NCT04840654|PROCEDURE|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
219406359|NCT06958653|DEVICE|Brief-BESTest assessment|Uses the traditional Brief-BESTest to assess the balance ability of the participants.
219406360|NCT06958653|DEVICE|Digital balance assessment tool|Uses the digital balance assessment tool, which is the digitalized Brief-BESTest, to assess their balance ability.
219406361|NCT05936385|BEHAVIORAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
219406362|NCT05936385|BEHAVIORAL|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
219406363|NCT05384626|DRUG|Neladalkib (NVL-655)|Oral Tablet of Neladalkib (NVL-655)
219406364|NCT06836401|PROCEDURE|Root scaling|Scaling and root planing is a deep cleaning below the gumline used to remove plaque and tartar that cover the root in the periodontal pockets. This intervention is carried out in both control and experimental sites
219406365|NCT06836401|DRUG|Topical Gel|A gel (experimental: metronidazole VS control: carbopol) is introduced in the recently cleaned periodontal pocket. The allocation of either experimental or control gel was distributed randomly, being masked both the patient and the clinician.
219406366|NCT01762540|DRUG|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
219755601|NCT05476991|DRUG|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
219755602|NCT05884333|DRUG|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
219755603|NCT05884333|BIOLOGICAL|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
219002323|NCT00211809|BEHAVIORAL|Cognitive Behavioral Therapy|standard psychiatric evaluation
219002324|NCT00211809|DRUG|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
219002325|NCT02984748|DEVICE|Cochlear implant|
219002326|NCT05559138|OTHER|no intervention|no intervention
219002327|NCT02513953|PROCEDURE|Laparoscopic|Four Port Laparoscopic cystectomy
219406367|NCT01762540|DRUG|Calcium Supplement|Placebo
219406368|NCT05972070|DEVICE|ROMTech Portable Connect|The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
219406369|NCT04255186|DEVICE|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
219406370|NCT04255186|DEVICE|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
219406371|NCT04255186|DEVICE|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
219406372|NCT02165657|DEVICE|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
219406373|NCT03443726|PROCEDURE|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
219406374|NCT03443726|PROCEDURE|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
219406375|NCT03443726|DRUG|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
219189969|NCT06621849|PROCEDURE|erector spinae plane block|In the erector spinae plane block (group E), an ultrasound-guided block will be performed on the ipsilateral side of the surgery while the patient is in lateral position 3-5 cm from the midline (10). Moving cephalic from the sacrum, we will identify the L5, L4, and L3 transverse processes and erector spinae muscles posteriorly. A 21 G and 70mm length needle will be directed in-plane, and the needle tip will be positioned anterior to the erector spinae muscle at the corner of the transverse process. After the initial saline injection, dissection of the plane will be observed by injecting a total volume of 20 ml composed of 10 micrograms dexmedetomidine in 2ml of normal saline and 18 ml of bupivacaine 0.25%, which is far from the toxic dose (10). Correct placement is defined as the spread of local anesthetic cranially and caudally from the injection point, dissecting the plane between the transverse processes and erector spinae muscles.
219755604|NCT05867953|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
219755605|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
219755606|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
219755607|NCT06100276|DRUG|AMT-162|AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
219755608|NCT06963190|OTHER|Constant Resistance (CR)|Will perform inspiratory muscle training at 30% of MIP. Two daily sessions of 30 breaths or 10 minutes.
219755609|NCT06963190|OTHER|Intermittent Variable Resistance (IVR)|Will perform inspiratory muscle training at 30% of MIP. This will consist of two daily sessions of 30 breaths or 10 minutes. Additionally, the participant will complete 8 sets of 3 repetitions at 60% of the MIP, distributed throughout the day, with a one-minute rest between each repetition.
219755610|NCT05200845|OTHER|Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose|Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
219755611|NCT05200845|OTHER|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose|Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
219755612|NCT05200845|OTHER|High-Fat Test Meal Inside a Metabolic Chamber|A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
219755613|NCT05200845|OTHER|High-Carbohydrate Test Meal Inside a Metabolic Chamber|A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
219755614|NCT05200845|OTHER|fMRI Scan|A subset of participants with BMI \> 25 will be invited to complete an functional magnetic resonance imaging (fMRI) scan as a feasibility measure. fMRI scans will be performed while beverages (without calories) used during the intervention are delivered through a custom manifold fitted to a head coil and connected to a pump system that allows precisely timed and measured delivery of liquids. Because this is feasibility-based measure, the outcome is a count of participants who completed this task.
219755615|NCT00003888|DRUG|cisplatin|
219755616|NCT00003888|DRUG|docetaxel|
219755617|NCT00003888|DRUG|fluorouracil|
219755618|NCT00003888|RADIATION|radiation therapy|
219755619|NCT05746988|OTHER|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
219755620|NCT01486888|DRUG|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
219406376|NCT03443726|PROCEDURE|Third molar extraction|Third molar extraction under local anesthesia.
219406377|NCT03583762|DIAGNOSTIC_TEST|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
219189970|NCT06621849|DRUG|Morphine|patients will receive 5 ml of subcutaneous lidocaine 1% then 3.5 ml of bupivacaine 0.5% and 0.1 mg of morphine in 0.25 ml of normal saline intrathecal
219189971|NCT06106646|DIETARY_SUPPLEMENT|No active intervention in this protocol (previously randomized to Vitamin C)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
219567219|NCT03887416|DRUG|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
219567220|NCT04997395|DRUG|MediCabilis Cannabis sativa 50|Already described
219567221|NCT03013881|BIOLOGICAL|UB-921|150 mg/vial
219567222|NCT03013881|BIOLOGICAL|Herceptin|440 mg/vial
219567223|NCT01652729|DRUG|Exenatide once weekly suspension|
219567224|NCT01652729|DRUG|Sitagliptin|
219567225|NCT01652729|DRUG|Placebo|Placebo oral capsule once daily
219567226|NCT00483548|DRUG|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
219567227|NCT00483548|DRUG|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
219567228|NCT01998386|OTHER|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
219567229|NCT01998386|OTHER|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
219567230|NCT01998386|OTHER|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
219567231|NCT01998386|OTHER|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
219567232|NCT04523324|BIOLOGICAL|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
219189972|NCT06106646|OTHER|No active intervention in this protocol (previously randomized to Placebo)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
219189973|NCT05778838|DRUG|Midodrine Oral Tablet|Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
219189974|NCT06290921|OTHER|Ovulation triggering|Ovulation triggering when women only 2 dominant follicles as opposed to the clinic's standard of 3 follicles or more
219189975|NCT06841185|DRUG|HLX13|HLX13 (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
219567233|NCT04523324|BIOLOGICAL|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
219002328|NCT04294472|DRUG|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
219002329|NCT04294472|OTHER|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
219002330|NCT01191398|DRUG|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
219189976|NCT06841185|DRUG|US-sourced YERVOY®|US-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
219406378|NCT03583762|DIAGNOSTIC_TEST|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
219406379|NCT01797198|DRUG|ASP3652|Oral
219406380|NCT01797198|DRUG|Gemfibrozil|Oral
219406381|NCT01797198|DRUG|Repaglinide|Oral
219406382|NCT03100942|DRUG|Lanraplenib|1 x 30 mg tablet administered orally once daily
219567234|NCT04904016|DEVICE|FlowOx™|The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
219189977|NCT06841185|DRUG|EU-sourced YERVOY®|EU-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
219189978|NCT03801876|DRUG|Carboplatin|Given IV
219189979|NCT03801876|PROCEDURE|Esophagectomy|Undergo esophagectomy
219189980|NCT03801876|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219189981|NCT03801876|DRUG|Paclitaxel|Given IV
219189982|NCT03801876|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
219189983|NCT03801876|OTHER|Quality-of-Life Assessment|Ancillary studies
219406383|NCT03100942|DRUG|Filgotinib|1 x 200 mg tablet administered orally once daily
219406384|NCT03100942|DRUG|Tirabrutinib|1 x 40 mg tablet administered orally once daily
219406385|NCT03100942|DRUG|Lanraplenib placebo|1 x tablet administered orally once daily
219406386|NCT03100942|DRUG|Filgotinib placebo|1 x tablet administered orally once daily
219567235|NCT02418117|OTHER|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
219567236|NCT02980302|PROCEDURE|Cutaneous biopsy|Under local anesthesia
219406387|NCT03100942|DRUG|Tirabrutinib placebo|1 x tablet administered orally once daily
219406388|NCT00264316|PROCEDURE|bone marrow-derived stem cell transfer|
219002331|NCT01191398|DRUG|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
219002332|NCT01191398|DRUG|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
219002333|NCT04086862|PROCEDURE|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
219189984|NCT03801876|OTHER|Questionnaire Administration|Ancillary studies
219189985|NCT03801876|DRUG|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
219189986|NCT03801876|DRUG|CAPOX regimen|Capecitabine combined with oxaliplatin
219189987|NCT03801876|DRUG|Docetaxel|Chemotherapy
219189988|NCT03801876|DRUG|5FU|Chemotherapy
219406389|NCT05992363|DEVICE|ureteral stent\s insertion|ureteral stent\\s insertion in the operating room
219406390|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
219406391|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
219406392|NCT03643822|OTHER|Saline|Control/Placebo intervention
219406393|NCT04009096|BIOLOGICAL|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
219406394|NCT03153215|OTHER|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
219406395|NCT03153215|OTHER|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
219567237|NCT02349243|DRUG|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
219567238|NCT02349243|DRUG|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
219567239|NCT01491308|OTHER|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
219567240|NCT00006108|BIOLOGICAL|trastuzumab|
219567241|NCT00006108|DRUG|capecitabine|
219406396|NCT03084575|PROCEDURE|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
219406397|NCT03084575|DRUG|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
219567242|NCT00006108|DRUG|paclitaxel|
219567243|NCT06405542|BEHAVIORAL|EX-CIPN|"The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals."
219002334|NCT04922437|PROCEDURE|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
219406398|NCT03084575|DEVICE|Thermal RF lesioning is done using Bailys RF generator|
219406399|NCT05151471|DRUG|MT-1186|Oral edaravone
219406400|NCT05151471|DRUG|Placebo|Oral
219406401|NCT04263142|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
219406402|NCT04263142|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
219406403|NCT02679248|DIETARY_SUPPLEMENT|Neo40 Daily®|
219406404|NCT02679248|DIETARY_SUPPLEMENT|Placebo|
219406405|NCT00638326|DRUG|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
219406406|NCT00638326|DRUG|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
219406407|NCT00038701|DRUG|TNP-470|
219406408|NCT04093518|DRUG|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
219406409|NCT04093518|DRUG|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
219406410|NCT02308345|OTHER|Pre-chemotherapy visit summary Video|
219406411|NCT05641792|DEVICE|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
219406412|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
219406413|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
219567244|NCT02382549|DRUG|BRAF inhibitor|BRAF inhibitor
219567245|NCT02382549|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219567246|NCT02382549|DRUG|MEK inhibitor|MEK Inhibitor
219567247|NCT05717270|PROCEDURE|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
219567248|NCT00126126|OTHER|EBAR Program|Evidence Based Amputee Rehabilitation Program
219567249|NCT00288665|DEVICE|Export catheter (Medtronic)|
219567250|NCT00705120|OTHER|Bone Marrow Cell Transplantation|
219002335|NCT04922437|PROCEDURE|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
219406414|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
219406415|NCT00162305|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
219406416|NCT03613415|OTHER|Expansion|non invasive technique to increase thickness of thin ridge
219406417|NCT03925389|PROCEDURE|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
219406418|NCT04156997|OTHER|No intervention is involved in this study|No intervention is involved in this study
219406419|NCT05398003|DEVICE|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)"
219406420|NCT03993691|DEVICE|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
219406421|NCT03993691|DEVICE|Radiograph|Standard of Care radiographic imaging of wrist.
219567251|NCT00705120|RADIATION|Irradiation, Total Body|
219567252|NCT00705120|DRUG|Cyclophosphamide|
219567253|NCT00705120|DRUG|Cyclosporin|
219567254|NCT00705120|PROCEDURE|Mesenchymal Stem Cell Transplantation|
219567255|NCT00705120|DRUG|Busulfan|
219567256|NCT00002351|DRUG|Indinavir sulfate|
219567257|NCT06082297|DEVICE|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
219567258|NCT01435447|DRUG|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
219189989|NCT03795675|DEVICE|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
219406422|NCT02846376|DRUG|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
219406423|NCT02846376|DRUG|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
219406424|NCT02085239|DRUG|Lidocaine Ropivacaine|"* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
219567259|NCT01563926|DRUG|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
219567260|NCT02588066|PROCEDURE|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
219567261|NCT02682186|DRUG|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
219567262|NCT02343757|DEVICE|PET/MRI|
219755621|NCT01763762|BEHAVIORAL|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
219406425|NCT02085239|DRUG|Lidocaine alone|
219406426|NCT03697928|OTHER|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
219406427|NCT04118686|OTHER|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
219406428|NCT04118686|OTHER|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
219406429|NCT04867135|DRUG|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
219406430|NCT01428063|DRUG|Daclatasvir|
219406431|NCT01428063|DRUG|Asunaprevir|
219406432|NCT01428063|DRUG|Pegylated interferon alfa-2a|
219406433|NCT01428063|DRUG|Ribavirin|
219567263|NCT02339610|DEVICE|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
219567264|NCT00685490|PROCEDURE|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
219567265|NCT06063096|DIETARY_SUPPLEMENT|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
219567266|NCT06063096|DIETARY_SUPPLEMENT|Placebo|Fruit-flavoured drink with high fructose corn syrup
219567267|NCT01389934|DRUG|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
219567268|NCT01389934|DRUG|Placebo|Women of this group be infused saline 2 ml / h for 48h.
219567269|NCT01173913|DRUG|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
219567270|NCT01173913|DRUG|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
219002336|NCT01756898|DRUG|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
219002337|NCT01756898|DRUG|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
219189990|NCT05005637|DRUG|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
219406434|NCT01326169|BEHAVIORAL|Brief intervention|Telephone-delivered counseling
219406435|NCT01326169|BEHAVIORAL|Standard care|No intervention
219406436|NCT02004912|OTHER|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
219406437|NCT03793140|DRUG|CPI-613|CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
219189991|NCT05005637|DRUG|Methylprednisolone|Selected participants may be prescribed local or systemic immunosuppressants, including oral methylprednisolone, starting at a dosage of 0.8 mg/kg of body weight per day and tapered gradually (e.g., every three days or weekly) based on the severity of intraocular inflammation observed during presentation and follow-up visits.
219189992|NCT06186830|OTHER|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
219406438|NCT02557971|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
219406439|NCT05279833|DRUG|dronedarone|Pharmaceutical form is tablet and route of administration is oral
219406440|NCT05279833|DRUG|sotalol|Pharmaceutical form is tablet and route of administration is oral
219755622|NCT01763762|BEHAVIORAL|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
219755623|NCT01763762|BEHAVIORAL|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
219755624|NCT02065219|DRUG|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
219755625|NCT02065219|DRUG|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
219755626|NCT01749488|OTHER|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
219755627|NCT01276626|DIETARY_SUPPLEMENT|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
219755628|NCT01276626|OTHER|Maltodextrin|Powder containing only maltodextrin
219002338|NCT01756898|DRUG|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
219002339|NCT01756898|DRUG|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
219002340|NCT02746744|DRUG|Rituximab|Infusion of Mabthera/Rituximab every 6 months
219002341|NCT02746744|DRUG|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
219002342|NCT02746744|DRUG|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
219406441|NCT05806385|DEVICE|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
219406442|NCT05806385|COMBINATION_PRODUCT|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
219406443|NCT00235846|PROCEDURE|vein harvest|Conventional open vein harvest or endoscopic vein harvest
219406444|NCT06037356|DEVICE|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
219406445|NCT06037356|PROCEDURE|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
219755629|NCT05707260|BEHAVIORAL|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
219406446|NCT06370455|PROCEDURE|comparison of septal advancement flap effect on nasal tip in primary rhinoplasty to columellar strut technique|All patients will be operated on under general anesthesia through an open rhinoplasty then will undergo 2 different procedures according to each group.
219002343|NCT00496054|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
219406447|NCT05282953|DRUG|KIO-301|KIO-301 intravitreal injection at ascending doses
219406448|NCT05888090|OTHER|Prone, right lateral, and semi-elevated supine positions|Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.
219567271|NCT01173913|DRUG|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
219567272|NCT00567736|DRUG|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
219002344|NCT02711592|GENETIC|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
219189993|NCT06350266|BEHAVIORAL|Information about healthcare resources|Text messages will be sent following discharge from the emergency department; text may also be modified in the (online and/or printed) discharge summary packet.
219406449|NCT05888090|OTHER|Semi-elevated supine, prone, and right lateral positions|Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.
219406450|NCT05888090|OTHER|Right lateral, semi-elevated supine, and prone positions|Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
219567273|NCT00567736|DRUG|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
219567274|NCT03629613|DIETARY_SUPPLEMENT|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
219755630|NCT02814656|DRUG|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
219406451|NCT06335121|BEHAVIORAL|POWER Up strategies -|Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
219406452|NCT05344508|DRUG|Brensocatib|Brensocatib tablets
219406453|NCT02284906|DRUG|Pioglitazone|Pioglitazone tablets
219755631|NCT02814656|DRUG|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
219755632|NCT00272181|DRUG|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
219755633|NCT05616442|DRUG|Ketotifen|Mast cell stabilizer
219755634|NCT05616442|DRUG|Vitamin E|Dietary supplement
219755635|NCT00153660|DRUG|Celecoxib(drug)|Celecoxib 100 mg bd
219755636|NCT00153660|DRUG|Naproxen(drug)|Naproxen 500 mg bd
219755637|NCT02052973|OTHER|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
219002345|NCT05410691|DEVICE|Handheld US device|Handheld US-guided AVF/AVG cannulation
219406454|NCT02284906|DRUG|Placebo|Pioglitazone placebo-matching tablets
219406455|NCT00461266|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
219406456|NCT00461266|DRUG|Antiretroviral therapy|As prescribed
219406457|NCT03501706|BEHAVIORAL|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
219567275|NCT03629613|OTHER|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
219567276|NCT02694549|DEVICE|CaveoVasc|
219567277|NCT03445299|BEHAVIORAL|Music|Listening to music for 30 minutes at bedtime
219567278|NCT02784678|PROCEDURE|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
219755638|NCT05018364|DIAGNOSTIC_TEST|Serum erythropoietin level|Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
219755639|NCT03255616|OTHER|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
219755640|NCT03255616|OTHER|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
219755641|NCT01259011|BEHAVIORAL|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
219755642|NCT06561139|BEHAVIORAL|Mindfulness|Weekly group sessions of mindfulness, for eight weeks
219755643|NCT01923922|RADIATION|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
219189994|NCT06505356|PROCEDURE|Prostate biopsy|Transrectal prostate biopsy
219406458|NCT03501706|BEHAVIORAL|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
219406459|NCT03501706|BEHAVIORAL|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
219406460|NCT03501706|BEHAVIORAL|Verbal Memory--Visual|word recognition AT memory component
219406461|NCT06555055|OTHER|CT trochlear thickness change|"Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software"
219567279|NCT02784678|DEVICE|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
219567280|NCT01534078|DRUG|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
219567281|NCT01534078|DRUG|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
219406462|NCT02151006|DRUG|DHEA|
219406463|NCT05974735|BEHAVIORAL|Wellness trail|"Setting up wellness trails based on four distinct themes:~* Food, Nutrition and Micronutrition~* Physical activity~* Sleep~* Stress and well-being"
219406464|NCT02407951|BEHAVIORAL|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
219755644|NCT02157428|DRUG|Flumazenil|
219755645|NCT02157428|DRUG|saline|
219755646|NCT05010473|BEHAVIORAL|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
219755647|NCT06172140|DRUG|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
219755648|NCT06172140|DRUG|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
219755649|NCT02464982|PROCEDURE|Tattoo|tattoo device with EC standards, and sterile single-use only needle
219755650|NCT06033534|DEVICE|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
219755651|NCT05583955|DRUG|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
219189995|NCT02658825|DRUG|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
219189996|NCT02658825|DRUG|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
219189997|NCT02658825|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
219002346|NCT01356108|DEVICE|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
219002347|NCT02427022|OTHER|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
219755652|NCT05583955|DRUG|Placebo|Escalating dose levels of matching Placebo will be given
219755653|NCT04395547|DIETARY_SUPPLEMENT|JointAlive™|Combination herbal extract
219755654|NCT04395547|DIETARY_SUPPLEMENT|Placebo|Combination placebo product
219755655|NCT06005402|BIOLOGICAL|CSX-1004|Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
219755656|NCT06005402|BIOLOGICAL|Placebo|Sterile saline for injection
219755657|NCT01960491|DEVICE|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
219755658|NCT02740465|BEHAVIORAL|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
219755659|NCT02740465|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
219755660|NCT02643485|PROCEDURE|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
219755661|NCT01772940|DRUG|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
219755662|NCT01772940|DRUG|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
219755663|NCT01772940|DRUG|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
219755664|NCT01772940|DRUG|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
219755665|NCT01951391|OTHER|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
219755666|NCT01951391|OTHER|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
219002348|NCT00596375|PROCEDURE|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
219002349|NCT00596375|DRUG|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
219755667|NCT01951391|OTHER|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
219755668|NCT03849261|DRUG|CKD-387|Test drug
219755669|NCT03849261|DRUG|D635|Reference drug
219755670|NCT05895994|DRUG|RD13-02 cell infusion|CAR-T cells
219002350|NCT04766398|DRUG|KHK7791|oral administration
219002351|NCT04766398|DRUG|Placebo|oral administration
219002352|NCT05975944|DRUG|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
219002353|NCT00496821|DRUG|ALN-RSV01|
219002354|NCT03798405|BEHAVIORAL|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
219002355|NCT05095545|DRUG|AV5080|Hard gelatin capsules with a white body
219755671|NCT00305396|DRUG|Sirolimus|
219755672|NCT00048984|OTHER|laboratory biomarker analysis|Correlative studies
219002356|NCT05095545|OTHER|Placebo|Hard gelatin capsules with a white body
219002357|NCT05251571|OTHER|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
219755673|NCT01938729|PROCEDURE|Liver resection and placement of hepatic artery infusion pump|
219755674|NCT01938729|DRUG|FLOXURIDINE|
219755675|NCT01938729|DRUG|DEXAMETHASONE|
219755676|NCT01938729|DRUG|GEMCITABINE|
219755677|NCT06490692|OTHER|Blood Flow Restriction Training|The affected limb will have a cuff placed proximally and inflated to occlude the blood flow by 40% attested using a golden standard vascular doppler after which the individuals will perform the strengthening program set forth by the physical therapist. This is preceded by other tennis elbow interventions such as ultrasound, stretching, and deep friction massage at the extensor origin.
219755678|NCT06490692|OTHER|Conventional Strength Training|The individuals in this group will undergo the same conventional physical therapy program as the other group including ultrasound, stretching, and deep friction massage. In addition, they will undergo the same strengthening program set forth by the physical therapist however with no blood flow restriction of any kind.
219755679|NCT00220662|BEHAVIORAL|Readiness and Motivation Therapy|
219755680|NCT05267782|DEVICE|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
219755681|NCT02135484|DRUG|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
219755682|NCT03416894|DEVICE|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
219002358|NCT05251571|OTHER|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
219406465|NCT02407951|BEHAVIORAL|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
219406466|NCT04786873|DRUG|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
219406467|NCT04786873|DIAGNOSTIC_TEST|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
219406468|NCT04786873|DIAGNOSTIC_TEST|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
219406469|NCT01262300|BIOLOGICAL|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
219406470|NCT05420272|BEHAVIORAL|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
219406471|NCT05553431|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
219406472|NCT04591470|DIAGNOSTIC_TEST|Mar test|Study of antisperm antibodies
219567282|NCT05122767|DRUG|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
219406473|NCT04500314|DEVICE|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
219567283|NCT05122767|DRUG|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
219567284|NCT04911465|DEVICE|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
219002359|NCT05636683|PROCEDURE|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
219406474|NCT04500314|OTHER|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
219406475|NCT05605379|BIOLOGICAL|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
219406476|NCT01013948|OTHER|Non-Interventional|Non-Investigational Product (Survey Study)
219406477|NCT02891031|DRUG|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
219406478|NCT02891031|DRUG|Placebo|500 mg twice daily after meal for 6 weeks
219406479|NCT00339014|DRUG|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
219406480|NCT00339014|OTHER|Placebo|Identical placebo
219189998|NCT02658825|DRUG|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
219189999|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
219190000|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
219190001|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
219567285|NCT04026373|BEHAVIORAL|modified Prolonged Exposure|
219567286|NCT04026373|BEHAVIORAL|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
219406481|NCT06262555|PROCEDURE|Transbronchial PDT peripheral lung tumor ablation|Transbronchial lung tumor ablation with Photodynamic therapy
219406482|NCT05655390|BEHAVIORAL|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
219406483|NCT02180503|DRUG|BI 1356 BS PIB - low dose|
219190002|NCT02658825|DRUG|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
219567287|NCT05528640|OTHER|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
219567288|NCT01749748|PROCEDURE|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
219567289|NCT05500092|DRUG|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
219755683|NCT01239550|DRUG|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
219755684|NCT04271293|DRUG|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
219755685|NCT04462575|PROCEDURE|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
219755686|NCT04462575|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
219755687|NCT00202579|DRUG|Ivabradine|
219755688|NCT00226005|DRUG|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
219755689|NCT01656161|DRUG|Triptorelin embonate 22.5 mg|
219755690|NCT00002193|DRUG|Amprenavir|
219755691|NCT05288192|DRUG|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
219755692|NCT00922129|DRUG|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
219567290|NCT05500092|RADIATION|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
219567291|NCT05500092|DRUG|Platinum Doublet|Standard of care doublet platinum therapy
219567292|NCT03532230|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
219567293|NCT02459665|BIOLOGICAL|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
219755693|NCT00922129|DRUG|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
219755694|NCT03510273|DEVICE|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
219755695|NCT00196040|DEVICE|PFX Closure System|
219190003|NCT05199454|OTHER|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
219406484|NCT02180503|DRUG|BI 1356 BS tablet - low dose|
219406485|NCT02180503|DRUG|BI 1356 BS PIB - high dose|
219406486|NCT02180503|DRUG|BI 1356 BS tablet - high dose|
219406487|NCT02180503|DRUG|BI 1356 BS tablet - high dose with food|
219406488|NCT04856436|DRUG|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
219567294|NCT02459665|DRUG|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
219567295|NCT02459665|BIOLOGICAL|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
219567296|NCT02900274|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
219567297|NCT03039348|OTHER|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
219755696|NCT01276106|DRUG|AC-201, 25mg|Capsule, 25mg BID
219755697|NCT01276106|DRUG|AC-201, 50mg|Capsule, 50mg BID
219755698|NCT01276106|DRUG|AC-201, 75mg|Capsule, 75mg BID
219755699|NCT01276106|DRUG|Placebo|Placebo BID
219755700|NCT00050804|DRUG|sertraline|
219190004|NCT05479760|OTHER|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
219190005|NCT06470243|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219190006|NCT06470243|PROCEDURE|Bone Scan|Undergo bone scan
219406489|NCT05426707|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
219406490|NCT05426707|DEVICE|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
219406491|NCT03064776|DEVICE|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
219406492|NCT03064776|DEVICE|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
219406493|NCT00316303|DRUG|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
219406494|NCT00316303|BEHAVIORAL|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
219406495|NCT03023982|DRUG|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
219406496|NCT03023982|DEVICE|Ultrasound|All blocks will be done under ultrasound
219406497|NCT03023982|PROCEDURE|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
219406498|NCT03023982|DRUG|Opioids|standard pain control with opioids
219406499|NCT03023982|DRUG|NSAID|standard pain control with NSAIDs
219406500|NCT00850759|DEVICE|virtual pedestrian environment|a computer-driven virtual pedestrian environment
219406501|NCT00850759|DEVICE|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
219406502|NCT00850759|BEHAVIORAL|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
219406503|NCT05369416|OTHER|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
219406504|NCT05369416|OTHER|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
219406505|NCT03062904|DRUG|Inhaled Bronchodilators +/- Inhaled Methacholine|"1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations"
219406506|NCT00456963|BEHAVIORAL|Diet|total fat \< 5%, saturated fat \< 10%, vegetables, fruit
219406507|NCT00456963|BEHAVIORAL|Moderate exercise|30 min at least 5 times/week
219567298|NCT01349101|RADIATION|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
219567299|NCT01349101|DRUG|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
219406508|NCT00456963|DRUG|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
219567300|NCT01349101|DRUG|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
219567301|NCT01349101|DRUG|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
219567302|NCT01349101|DRUG|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
219567303|NCT01349101|DRUG|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
219567304|NCT01349101|GENETIC|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
219567305|NCT02839668|DRUG|Lidocaine|Continuous infusion of lidocaine
219567306|NCT02839668|DRUG|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
219567307|NCT02839668|DRUG|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
219567308|NCT02839668|DRUG|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
219567309|NCT02839668|DRUG|Tramadol|administration of tramadol for postoperative analgesia
219567310|NCT02839668|DRUG|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
219567311|NCT02839668|DRUG|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
219567312|NCT02839668|DEVICE|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
219567313|NCT04153448|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
219002360|NCT05923437|OTHER|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
219002361|NCT04615481|OTHER|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
219190007|NCT06470243|DRUG|Cabazitaxel|Given IV
219190008|NCT06470243|DRUG|Carboplatin|Given IV
219406509|NCT00456963|DRUG|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
219406510|NCT00456963|DRUG|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
219406511|NCT00065741|DRUG|silymarin|
219406512|NCT00532948|DRUG|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
219406513|NCT00374374|BEHAVIORAL|Administration of probiotic|
219406514|NCT01103817|DIETARY_SUPPLEMENT|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
219406515|NCT06475235|DRUG|Pembrolizumab|Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.
219406516|NCT06475235|DRUG|Methotrexate|Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
219406517|NCT06475235|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.
219406518|NCT06475235|DRUG|Rituximab|Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
219406519|NCT01636024|DRUG|AZD7594|Suspension inhaled via Spira nebuliser
219406520|NCT01636024|DRUG|Placebo to match|Matching placebo inhaled via Spira nebuliser
219406521|NCT02604927|DIETARY_SUPPLEMENT|Beta-alanine|
219190009|NCT06470243|PROCEDURE|Chest Radiography|Undergo chest x-ray
219406522|NCT02604927|DIETARY_SUPPLEMENT|Dextrose|
219406523|NCT02686606|DIETARY_SUPPLEMENT|Vital 1.5|Oral nutritional supplement
219406524|NCT02686606|DIETARY_SUPPLEMENT|Ensure Plus|Oral nutritional supplement
219406525|NCT03535233|DRUG|Triamcinolone Acetonide|
219406526|NCT03535233|DRUG|Minoxidil 5 % Topical Spray|
219406527|NCT03535233|DRUG|clobetasol propionate|
219406528|NCT01753076|DRUG|Ozanezumab|Ozanezumab injection solution
219406529|NCT01753076|DRUG|Placebo|Normal saline (0.9% sodium chloride) infusion
219406530|NCT00678106|DRUG|Dalbavancin|Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
219002362|NCT04615481|OTHER|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
219002363|NCT05079529|DRUG|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
219002364|NCT05079529|DRUG|Placebo Group|Takes placebo capsule 3 times daily for 90 days
219002365|NCT01753505|OTHER|64-slice Multidetector coronary CT angiography|
219406531|NCT06113185|OTHER|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
219406532|NCT02801630|DEVICE|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
219002366|NCT02367937|DRUG|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
219002367|NCT00508716|BEHAVIORAL|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
219002368|NCT05037071|DEVICE|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
219406533|NCT04708652|OTHER|No intervention|No intervention
219406534|NCT02575079|DEVICE|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
219406535|NCT02918266|DRUG|Scopolamine|Scopolamine subcutaneous injection
219406536|NCT02918266|DRUG|TAK-071|TAK-071 DIC
219567314|NCT02358850|DRUG|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
219567315|NCT02358850|DRUG|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
219002369|NCT04051073|DEVICE|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
219002370|NCT00190697|DRUG|arzoxifene|
219406537|NCT02918266|DRUG|Donepezil|Donepezil over-encapsulated tablet
219567316|NCT02358850|DRUG|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
219406538|NCT02918266|DRUG|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
219406539|NCT02918266|DRUG|TAK-071 Placebo|TAK-071 placebo-matching DIC
219406540|NCT02918266|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
219406541|NCT04891991|DRUG|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
219406542|NCT04891991|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy
219406543|NCT03235596|DEVICE|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
219406544|NCT01914419|DRUG|Oxytocin|
219567317|NCT02358850|DRUG|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
219567318|NCT04681196|OTHER|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
219567319|NCT06529939|DRUG|Psilocybin|"Individuals will be given 15 milligrams (mg) of psilocybin orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) brain scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
219002371|NCT05127668|DEVICE|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
219002372|NCT05127668|DEVICE|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
219002373|NCT01408446|DRUG|Menthol|Capsule 48mg three times a day after meals 8 weeks
219002374|NCT01408446|DRUG|Placebo|Capsule 48mg three times a day after meals 8 weeks
219406545|NCT01897961|OTHER|Anticorps anti-PLA2R1|
219406546|NCT00300469|DRUG|ABT-335|135 mg, daily, 12 weeks
219406547|NCT00300469|DRUG|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
219406548|NCT00300469|DRUG|Placebo|daily, 12 weeks, see Arm Description for placebo information
219406549|NCT02405234|DEVICE|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
219406550|NCT02405234|DEVICE|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
219406551|NCT01259856|DRUG|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
219406552|NCT01259856|DRUG|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
219406553|NCT01259856|DRUG|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
219406554|NCT01758393|DRUG|Prednisone|
219406555|NCT02555761|DRUG|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
219567320|NCT06529939|OTHER|Placebo|"Individuals will be given a placebo orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
219567321|NCT04217655|DIAGNOSTIC_TEST|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
219567322|NCT04217655|DIAGNOSTIC_TEST|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
219567323|NCT02573935|DRUG|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
219567324|NCT02573935|DRUG|Placebo|Placebo tablet twice daily for 63 days
219567325|NCT02573935|DRUG|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
219755701|NCT03495401|DIETARY_SUPPLEMENT|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
219755702|NCT03495401|DIETARY_SUPPLEMENT|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
219755703|NCT01777477|DRUG|Chloroquine|Addition of Chloroquine to Gemcitabine
219406556|NCT00412698|DRUG|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
219406557|NCT00412698|DRUG|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
219406558|NCT01636752|BEHAVIORAL|Deprexis|Online self-help with and without e-mail-support
219406559|NCT04405505|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219406560|NCT04405505|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
219406561|NCT04405505|DRUG|Paclitaxel for Injection (albumin bound)|a anti-microtubule drug.
219406562|NCT03988257|DIETARY_SUPPLEMENT|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
219567326|NCT04975321|DEVICE|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
219567327|NCT04975321|DEVICE|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
219567328|NCT04975321|DEVICE|Composite strip crown|Placement of an anterior primary crown restoration
219567329|NCT02207335|DRUG|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
219567330|NCT02207335|DRUG|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
219567331|NCT03286608|OTHER|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
219567332|NCT02044432|OTHER|ginger compress|Kidney ginger compress
219567333|NCT03399617|DIETARY_SUPPLEMENT|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
219567334|NCT03399617|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
219755704|NCT01777477|DRUG|Gemcitabine|
219755705|NCT01082939|DRUG|Fludarabine|25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
219406563|NCT03988257|DIETARY_SUPPLEMENT|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
219406564|NCT04912037|DEVICE|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
219002375|NCT00739791|BEHAVIORAL|exercise intervention|
219002376|NCT00739791|GENETIC|gene expression analysis|
219002377|NCT00739791|GENETIC|polymerase chain reaction|
219406565|NCT04825236|OTHER|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
219406566|NCT06527612|OTHER|Pulmonary rehabilitation exercise programme|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
219755706|NCT01082939|DRUG|Cyclophosphamide|250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
219755707|NCT01082939|DRUG|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
219755708|NCT01082939|DRUG|Rituximab|"Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours"
219755709|NCT02351089|DIETARY_SUPPLEMENT|Capsules placebo|Capsules
219755710|NCT02351089|DIETARY_SUPPLEMENT|Capsules probiotic powder and corn starch|
219755711|NCT02258490|BIOLOGICAL|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
219755712|NCT05230277|OTHER|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.
219755713|NCT05230277|OTHER|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
219755714|NCT03199079|OTHER|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
219755715|NCT03746210|DIAGNOSTIC_TEST|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
219406567|NCT00788775|DRUG|Nilotinib|
219190010|NCT06470243|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219406568|NCT00578864|DRUG|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily"
219002378|NCT00739791|GENETIC|proteomic profiling|
219002379|NCT00739791|GENETIC|reverse transcriptase-polymerase chain reaction|
219190011|NCT06470243|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219567335|NCT03399617|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
219567336|NCT05349578|DIAGNOSTIC_TEST|swab RUT|rapid urease test using swab instead of biopsied tissue
219567337|NCT01030211|PROCEDURE|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
219755716|NCT04079738|DRUG|TAK-659|TAK-659
219755717|NCT04079738|DRUG|Ixazomib|Ixazomib
219002380|NCT00739791|OTHER|laboratory biomarker analysis|
219002381|NCT00739791|OTHER|medical chart review|
219002382|NCT00739791|OTHER|questionnaire administration|
219002383|NCT00739791|PROCEDURE|psychosocial assessment and care|
219002384|NCT00739791|PROCEDURE|quality-of-life assessment|
219002385|NCT00739791|PROCEDURE|support group therapy|
219406569|NCT00578864|DRUG|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes"
219406570|NCT00578864|DRUG|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
219567338|NCT01030211|OTHER|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
219567339|NCT05342311|DIAGNOSTIC_TEST|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
219567340|NCT01088282|PROCEDURE|Cataract surgery|Implantation of multifocal or monofocal IOL
219567341|NCT03144817|OTHER|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
219567342|NCT02262858|DRUG|Telmisartan and HCTZ|
219002386|NCT00739791|PROCEDURE|therapeutic dietary intervention|
219002387|NCT00471328|DRUG|Nilotinib|Nilotinib 400 mg twice daily (bid)
219002388|NCT00471328|OTHER|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
219002389|NCT02983344|DRUG|Ropivacaine|Fascia iliaca compartment block using ropivacaine
219002390|NCT02983344|DRUG|Fentanyl|Intravenous fentanyl
219002391|NCT02983344|DEVICE|Ultrasound|Ultrasound-guided fascia iliaca compartment block
219190012|NCT06470243|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219190013|NCT06470243|DRUG|Prednisone|Given PO
219190014|NCT04618315|DEVICE|Hearing Aids|Receiver-in-the-ear hearing aids.
219190015|NCT06400615|DRUG|AD109|Oral administration at bedtime
219406571|NCT00578864|DRUG|Cisplatin|Cycle 1, 2, and 4
219406572|NCT00578864|DRUG|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
219406573|NCT00578864|DRUG|Mesna|Standard weight-based dosing with cyclophosphamide
219406574|NCT00578864|DRUG|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
219406575|NCT00578864|PROCEDURE|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
219567343|NCT02262858|DRUG|Telmisartan|
219567344|NCT02262858|DRUG|HCTZ|
219567345|NCT00868296|DRUG|pantoprazole|
219567346|NCT06224621|PROCEDURE|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
219567347|NCT01094249|DRUG|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
219567348|NCT04529226|DRUG|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
219567349|NCT04529226|DRUG|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
219567350|NCT05026931|OTHER|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
219567351|NCT05026931|OTHER|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
219755718|NCT06497478|DIAGNOSTIC_TEST|Ultrasonographic examination|"Ultrasonographic examination will be performed using a high-resolution (Epiq Elite Philips Medical Systems, Monza, Italia) and a linear 12-9 MHz transducer.~The patients will be placed in a supine position. Starting with the probe at the base of the neck, the common carotid artery will be explored on the transverse plane and then on the sagittal one, continuing in a cranial sense up to the carotid bifurcation. The medium-intimal thickness will be measured, defined as distance from the first hyperechoic line to the second hyperechoic line.~The femoropopliteal and run-off segments will be continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments will be examined for the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements will be obtained using spectral Doppler imaging and color Doppler imaging."
219761029|NCT04231448|DRUG|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
219406576|NCT05505968|OTHER|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
219002392|NCT05081973|OTHER|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~1. Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~2. Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
219190016|NCT04433338|OTHER|14-day Low Calorie Diet|"Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
219406577|NCT00088868|DRUG|alvespimycin hydrochloride|
219406578|NCT01233401|OTHER|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
219406579|NCT00149656|DIETARY_SUPPLEMENT|Multivitamins|dietary supplement of multivitamins
219406580|NCT00149656|DIETARY_SUPPLEMENT|Selenium|dietary supplement of selenium only
219406581|NCT00149656|OTHER|Placebo|placebo pill
219406582|NCT05111899|BEHAVIORAL|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
219406583|NCT04332029|BEHAVIORAL|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
219406584|NCT04332029|BEHAVIORAL|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
219567352|NCT01264640|DRUG|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
219406585|NCT03796091|BEHAVIORAL|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
219406586|NCT03796091|BEHAVIORAL|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
219406587|NCT03796091|BEHAVIORAL|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
219406588|NCT02796534|OTHER|Diagnosis of sleep apnea by oxymetry|
219567353|NCT05790148|DEVICE|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
219567354|NCT05387148|DRUG|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
219567355|NCT05387148|DRUG|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
219567356|NCT01843686|DEVICE|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
219567357|NCT01843686|OTHER|Placebo Saline Gel and Usual and Customary Standard of Care|
219567358|NCT00750022|BEHAVIORAL|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
219567359|NCT00750022|BEHAVIORAL|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
219567360|NCT05675241|DIAGNOSTIC_TEST|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
219567361|NCT05675241|DIAGNOSTIC_TEST|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
219567362|NCT05675241|DIAGNOSTIC_TEST|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
219002393|NCT05608798|DEVICE|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
219190017|NCT05492175|OTHER|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
219406589|NCT00651976|DRUG|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
219406590|NCT00651976|OTHER|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
219406591|NCT00651976|PROCEDURE|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
219567363|NCT03712241|DRUG|K-285|Topical
219567364|NCT03712241|DRUG|Indomethacin|Capsule
219567365|NCT06309316|BEHAVIORAL|Person-centred care (PCC)|In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
219761030|NCT04231448|DRUG|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
219761031|NCT04231448|DRUG|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
219406592|NCT03167580|PROCEDURE|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
219406593|NCT03167580|PROCEDURE|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
219406594|NCT01860053|BEHAVIORAL|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
219406595|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
219406596|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
219406597|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
219406598|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
219406599|NCT02195791|DRUG|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
219406600|NCT02195791|DRUG|Placebo|Placebo (oral) 1 tab once daily for 7 days
219406601|NCT02858609|OTHER|Nasopharyngeal Swab|
219406602|NCT00426114|DRUG|Administration of an IV glucose-injection|
219406603|NCT00370695|DEVICE|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
219406604|NCT01930812|PROCEDURE|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
219406605|NCT01930812|PROCEDURE|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
219406606|NCT01930812|DRUG|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
219567366|NCT01974024|DRUG|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
219567367|NCT04906317|DRUG|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
219567368|NCT04906317|DRUG|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
219567369|NCT03068650|BIOLOGICAL|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
219567370|NCT01183117|DEVICE|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
219567371|NCT01183117|DEVICE|PTA|balloon angioplasty
219406607|NCT01253044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
219406608|NCT01253044|BEHAVIORAL|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
219406609|NCT00664300|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
219406610|NCT03915899|BEHAVIORAL|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
219406611|NCT06234735|BEHAVIORAL|Physical activity in the community|Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
219406612|NCT06234735|BEHAVIORAL|Conventional intervention|Conventional protocol for lung cancer and PA recommendations.
219406613|NCT00210015|DRUG|INS37217 Nasal Spray|
219406614|NCT03288272|RADIATION|Whole Brain Radiotherapy|Radiotherapy of the whole brain
219406615|NCT03288272|OTHER|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
219406616|NCT04090281|GENETIC|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
219567372|NCT02536235|OTHER|heat|activated heating pad to lower abdomen
219567373|NCT05319834|DRUG|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
219002394|NCT04079608|BEHAVIORAL|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
219406617|NCT01905319|OTHER|Blood collecting for storage of samples|
219406618|NCT04683198|DRUG|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
219406619|NCT04683198|DRUG|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
219406620|NCT04683198|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
219406621|NCT04683198|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
219406622|NCT04151537|BEHAVIORAL|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
219406623|NCT04151537|BEHAVIORAL|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
219406624|NCT02500199|DRUG|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
219406625|NCT01223872|OTHER|interview|"* Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)"
219406626|NCT01223872|OTHER|clinic visit and interview|"* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
219406627|NCT01223872|OTHER|interviews and clinic visit|"* Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
219406628|NCT03450369|BIOLOGICAL|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
219406629|NCT04060667|COMBINATION_PRODUCT|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
219406630|NCT05219617|DRUG|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\])."
219567374|NCT05319834|DRUG|Placebo|group 2: oral placebo once daily at the same time with progesterone
219567375|NCT03829358|DRUG|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
219567376|NCT03829358|DRUG|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
219567377|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
219567378|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
219567379|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
219567380|NCT05156424|OTHER|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
219567381|NCT01057381|DRUG|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
219567382|NCT01057381|DRUG|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
219567383|NCT01057381|DRUG|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
219567384|NCT01057381|DRUG|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
219567385|NCT02947724|DRUG|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
219567386|NCT02434224|PROCEDURE|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
219567387|NCT00541164|DRUG|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
219567388|NCT00541164|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
219761032|NCT05450211|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
219761033|NCT05450211|DEVICE|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
219761034|NCT03419494|DRUG|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
219002395|NCT04079608|BEHAVIORAL|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
219002396|NCT04051008|BEHAVIORAL|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
219406631|NCT03403998|OTHER|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
219406632|NCT03403998|OTHER|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
219761035|NCT03419494|DRUG|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
219761036|NCT05338073|DIAGNOSTIC_TEST|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
219761037|NCT03132987|OTHER|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
219002397|NCT04051008|BEHAVIORAL|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
219761038|NCT01775384|DIETARY_SUPPLEMENT|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
219761039|NCT01775384|DIETARY_SUPPLEMENT|Placebo|
219761040|NCT04605666|BIOLOGICAL|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
219761041|NCT03360994|OTHER|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
219761042|NCT03360994|OTHER|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
219761043|NCT03498716|DRUG|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
219761044|NCT03498716|DRUG|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
219761045|NCT03498716|DRUG|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses"
219761046|NCT03498716|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
219761047|NCT05337566|DRUG|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
219761048|NCT05337566|DRUG|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
219761049|NCT05613816|PROCEDURE|Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
219761050|NCT06029790|OTHER|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
219761051|NCT02702050|OTHER|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
219761052|NCT02702050|OTHER|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
219761053|NCT00265850|BIOLOGICAL|bevacizumab|Given IV
219761054|NCT00265850|BIOLOGICAL|cetuximab|Given IV
219761055|NCT00265850|DRUG|FOLFOX or|Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
219406633|NCT06526858|DEVICE|HyperQureTM Renal Denervation (RDN) System:|"The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA."
219406634|NCT06172777|DIAGNOSTIC_TEST|suspected asthma|enrollment 200 asthma patients
219406635|NCT06172777|DIAGNOSTIC_TEST|suspected COPD|enrollment 200 COPD patients
219406636|NCT06172777|DIAGNOSTIC_TEST|confirmed asthma|enrollment 200 patients
219406637|NCT06172777|DIAGNOSTIC_TEST|confirmed COPD|enrollment 200 patients
219406638|NCT00142012|BEHAVIORAL|Nutrition Intervention|
219406639|NCT06053606|DEVICE|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
219406640|NCT06053606|DEVICE|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
219406641|NCT04472923|PROCEDURE|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
219406642|NCT04472923|DEVICE|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
219002398|NCT01307007|DRUG|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
219406643|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
219755719|NCT05846776|DEVICE|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
219755720|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
219755721|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
219755722|NCT04890184|DIETARY_SUPPLEMENT|grape juice|grape juice
219406644|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement B|4 capsules daily of oral supplement B for 3 days
219406645|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
219406646|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
219406647|NCT03707652|DIETARY_SUPPLEMENT|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
219567389|NCT05532579|OTHER|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
219567390|NCT05532579|OTHER|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
219755723|NCT04890184|OTHER|control|no intervention
219755724|NCT00574015|DRUG|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
219406648|NCT00767156|OTHER|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
219406649|NCT00767156|OTHER|Base cream|The subjects use the base cream on the face, twice per day
219567391|NCT03425487|BEHAVIORAL|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
219755725|NCT00574015|DRUG|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
219755726|NCT03478605|DRUG|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
219755727|NCT03478605|DRUG|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
219755728|NCT03478605|DRUG|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
219755729|NCT03478605|DRUG|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
219755730|NCT03101748|DRUG|Cyclophosphamide|Given IV
219755731|NCT03101748|DRUG|Doxorubicin|Given IV
219567392|NCT03425487|BEHAVIORAL|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
219567393|NCT03425487|OTHER|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
219755732|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
219755733|NCT03101748|DRUG|Neratinib|Given PO
219406650|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
219406651|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
219406652|NCT04989829|DRUG|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
219406653|NCT04005820|OTHER|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
219406654|NCT04005820|OTHER|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
219406655|NCT03057834|BEHAVIORAL|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
219406656|NCT03420378|DIETARY_SUPPLEMENT|vitamin D|Vitamin D replacement
219406657|NCT04490265|BEHAVIORAL|Problem-solving treatment|included in arm descriptions
219406658|NCT04490265|BEHAVIORAL|Supportive Psychotherapy|included in arm descriptions
219406659|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
219406660|NCT03013777|BEHAVIORAL|8-week CBT Program|
219406661|NCT00962000|OTHER|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
219406662|NCT00962000|OTHER|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
219406663|NCT06138795|DRUG|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
219406664|NCT06138795|DRUG|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
219406665|NCT06822010|DRUG|Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)|"Drug: Gemcitabine (endoluminal administration)~Drug: Jelmyto (gel-based mitomycin, endoluminal administration)"
219406666|NCT02702193|BEHAVIORAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
219406667|NCT01016106|GENETIC|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
219406668|NCT00016523|DRUG|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
219406669|NCT00016523|DRUG|Placebo|Started at 5 ppm and could be increased to 10 ppm
219406670|NCT02512003|DEVICE|Fantom Scaffold|
219406671|NCT05517603|DRUG|AJ201|Administered orally
219406672|NCT05517603|DRUG|Placebo|Administered orally
219406673|NCT05462769|DEVICE|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
219406674|NCT02018952|OTHER|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome"
219406675|NCT04516018|OTHER|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
219567394|NCT04746599|PROCEDURE|Autologous Fat Grafting|The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
219567395|NCT03896282|OTHER|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
219567396|NCT03010982|DRUG|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
219567397|NCT00311350|DRUG|MOA-728|
219755734|NCT03101748|DRUG|Paclitaxel|Given IV
219755735|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
219755736|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
219406676|NCT04402268|DEVICE|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
219406677|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
219406678|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
219567398|NCT03914235|COMBINATION_PRODUCT|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
219755737|NCT05196776|DEVICE|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
219406679|NCT04077970|BIOLOGICAL|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
219406680|NCT01201798|DRUG|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
219406681|NCT01201798|DRUG|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
219406682|NCT02198287|DRUG|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
219567399|NCT03914235|DRUG|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
219406683|NCT02198287|DRUG|Placebo|
219567400|NCT03914235|DEVICE|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
219567401|NCT03914235|PROCEDURE|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
219567402|NCT02446834|BEHAVIORAL|intensive lifestyle intervention|3 months low GI diet and exercise
219567403|NCT02446834|DRUG|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
219567404|NCT02446834|DRUG|Metformin|Use metformin 3 months to treat PCOS
219567405|NCT02446834|DRUG|Acarbose|Use acarbose 3 months to treat PCOS
219567406|NCT00288717|DRUG|Candesartan|
219567407|NCT00288717|DRUG|Telmisartan|
219567408|NCT02019082|DEVICE|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
219567409|NCT02019082|DEVICE|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
219567410|NCT05990582|DIAGNOSTIC_TEST|CBCL|A questionnaire on behaviour
219567411|NCT05990582|DIAGNOSTIC_TEST|SDQ|A questionnaire on behaviour
219755738|NCT05196776|DEVICE|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
219755739|NCT06564116|BIOLOGICAL|Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.
219755740|NCT06564116|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
219755741|NCT00867035|DRUG|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
219755742|NCT00867035|DRUG|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
219755743|NCT05023161|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
219755744|NCT02850341|DEVICE|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
219755745|NCT04600973|BEHAVIORAL|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
219755746|NCT02107612|DEVICE|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
219755747|NCT02107612|OTHER|Denture|
219755748|NCT06529484|OTHER|Warm Water Foot Bath Intervention|Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
219755749|NCT06281457|OTHER|Stimulus properties: task-defining feature|The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
219406684|NCT01750398|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
219567412|NCT05990582|DIAGNOSTIC_TEST|CCC-2-NL|A questionnaire on communcational skills
219567413|NCT05990582|DIAGNOSTIC_TEST|MCH Feeding scale|A questionnaire on feeding problems
219567414|NCT05990582|DIAGNOSTIC_TEST|TRF|A questionnaire on behaviour
219567415|NCT05990582|DIAGNOSTIC_TEST|WISC-5-NL|An IQ test for children
219567416|NCT05990582|DIAGNOSTIC_TEST|Movement ABC|A test to assess motor function
219567417|NCT05990582|DIAGNOSTIC_TEST|CELF-5-NL|A test to assess language development
219567418|NCT05990582|DIAGNOSTIC_TEST|Emma Toolbox|Test of executive functions
219567419|NCT03346252|DRUG|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
219567420|NCT00004175|DRUG|cyclophosphamide|
219406685|NCT01750398|DRUG|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
219406686|NCT01750398|DRUG|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
219406687|NCT02683616|DEVICE|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
219406688|NCT00934557|DRUG|ATG Fresenius|
219567421|NCT00004175|DRUG|docetaxel|
219567422|NCT00004175|DRUG|doxorubicin hydrochloride|
219567423|NCT00004175|PROCEDURE|conventional surgery|
219567424|NCT00986570|BIOLOGICAL|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
219567425|NCT05315622|OTHER|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
219567426|NCT05315622|OTHER|Placebo|"Manual tension without reaching the manipulation thrust"
219567427|NCT00724490|PROCEDURE|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
219567428|NCT05182619|PROCEDURE|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
219567429|NCT05685901|DIETARY_SUPPLEMENT|High polyphenolic olive oil. (Early harvest olive oil).|High polyphenolic olive oil is normal olive oil obtained from early harvest olives, this early harvest olive oil has been widely used for culinary purposes for centuries. The investigators wanted to study if oromucosal immunoprophylaxis with small quantities of high polyphenolic olive oil (2 mL of olive oil equivalent to 5 mg of polyphenols) adiministered twice a day could have clinical mitigating effects on the disease caused by SARS-CoV-2 infection.The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity.
219406689|NCT00934557|DRUG|ATG Fresenius|
219406690|NCT00934557|DRUG|ATG Fresenius|
219567430|NCT03780946|PROCEDURE|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
219567431|NCT03780946|PROCEDURE|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
219567432|NCT05775822|DIAGNOSTIC_TEST|CT scan and blood sample collection|"Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan"
219567433|NCT03642522|DEVICE|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
219567434|NCT03119506|BEHAVIORAL|Recess|Recess timing and duration effects on lunch intake
219406691|NCT00934557|DRUG|ATG Fresenius|
219406692|NCT00934557|DRUG|ATG Fresenius|
219406693|NCT00934557|DRUG|ATG Fresenius|
219406694|NCT00934557|DRUG|ATG Fresenius|
219406695|NCT00934557|DRUG|ATG Fresenius|
219406696|NCT00525148|DRUG|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
219406697|NCT02486510|DRUG|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
219406698|NCT03644940|DIAGNOSTIC_TEST|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
219406699|NCT06461611|BEHAVIORAL|Health Diary Program|The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
219406700|NCT06461611|BEHAVIORAL|Traditional Health Education|Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
219406701|NCT05674045|DRUG|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
219406702|NCT05674045|DRUG|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
219406703|NCT00114283|DRUG|lapatinib ditosylate|Given PO
219406704|NCT00114283|OTHER|laboratory biomarker analysis|Correlative studies
219567435|NCT03072199|DRUG|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
219567436|NCT00804141|DRUG|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
219755750|NCT06149585|OTHER|Microbial Sampling|Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
219755751|NCT05452668|DEVICE|Laser Therapy|\- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
219755752|NCT05452668|DEVICE|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
219755755|NCT04866563|DRUG|AX-8, Part 1 of the study|orally disintegrating tablets, BID
219755756|NCT04866563|DRUG|Placebo, Part 1 of the study|orally disintegrating tablets, BID
219755757|NCT04866563|DRUG|AX-8, Part 2 of the study|orally disintegrating tablets, TID
219755758|NCT04866563|DRUG|Placebo, Part 2 of the study|orally disintegrating tablets, TID
219755759|NCT02035657|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
219567437|NCT02148679|OTHER|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
219567438|NCT02148679|OTHER|Usual care|Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
219567439|NCT05417360|DIETARY_SUPPLEMENT|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
219567440|NCT05417360|DIETARY_SUPPLEMENT|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
219567441|NCT01936311|BEHAVIORAL|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
219567442|NCT06351696|DIETARY_SUPPLEMENT|Bromlein|1500 mg/day
219755760|NCT04863404|OTHER|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
219755761|NCT04863404|OTHER|Face mask with conventional bonded RME|Face mask with conventional bonded RME
219755762|NCT04717401|PROCEDURE|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
219755763|NCT04717401|PROCEDURE|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
219755764|NCT00002487|DRUG|dipyridamole|
219755765|NCT00002487|DRUG|methotrexate|
219755766|NCT02996929|DEVICE|LC System|Subjects will undergo CIED lead extraction with the LC system
219406705|NCT02125487|BEHAVIORAL|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
219406706|NCT02125487|BEHAVIORAL|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
219567443|NCT06351696|OTHER|Placebo|Placebo (1500 mg/day)
219567444|NCT00002616|BIOLOGICAL|aldesleukin|
219002399|NCT01307007|DRUG|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
219567445|NCT00002616|BIOLOGICAL|filgrastim|
219755767|NCT02357303|DRUG|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
219755768|NCT02357303|DRUG|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
219406707|NCT01734512|DRUG|Everolimus|Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.
219755769|NCT02357303|OTHER|Placebo|100mL of water
219406708|NCT06053268|DEVICE|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
219406709|NCT00114972|DEVICE|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
219406710|NCT00114972|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
219406711|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
219567446|NCT00002616|DRUG|carboplatin|
219567447|NCT00002616|DRUG|cyclophosphamide|
219567448|NCT00002616|DRUG|thiotepa|
219755770|NCT05613231|BEHAVIORAL|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
219755771|NCT05613231|BEHAVIORAL|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
219755772|NCT02327377|BEHAVIORAL|Online Cognitive Behavior Therapy|
219755773|NCT02327377|BEHAVIORAL|Online Education|
219567449|NCT00002616|PROCEDURE|peripheral blood stem cell transplantation|
219567450|NCT02288494|OTHER|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
219567451|NCT02668042|BIOLOGICAL|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
219567452|NCT03889834|PROCEDURE|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
219406712|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
219406713|NCT05092815|DRUG|HLX208|HLX208 450mg bid po
219567453|NCT03889834|OTHER|No transfusion|no transfusion
219567454|NCT02538835|BEHAVIORAL|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
219567455|NCT02538835|BEHAVIORAL|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
219567456|NCT02538835|BEHAVIORAL|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
219567457|NCT01253928|DRUG|Pioglitazone|45mg qd for 4 months
219406714|NCT02934412|DRUG|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
219567458|NCT00841152|DEVICE|Bioactive glass|Surgical implantation
219567459|NCT00841152|DEVICE|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
219567460|NCT00841152|PROCEDURE|Autograft|Surgical transplantation from iliac crest
219567461|NCT00841152|PROCEDURE|Allograft (frozen femoral head)|Surgical transplantation
219567462|NCT06227117|DRUG|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
219567463|NCT06227117|DRUG|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
219002400|NCT04384211|OTHER|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
219002401|NCT02132130|DRUG|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
219406715|NCT02934412|DRUG|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
219406716|NCT03878017|PROCEDURE|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
219406717|NCT04571008|OTHER|Placebo|Intervention will last at least 16 weeks in the form of two capsules.
219406718|NCT04571008|DIETARY_SUPPLEMENT|Treatment|Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
219406719|NCT05429099|PROCEDURE|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
219567464|NCT06227117|DRUG|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
219567465|NCT06227117|DRUG|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
219567466|NCT06227117|DRUG|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
219567467|NCT06227117|DRUG|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
219567468|NCT06227117|DRUG|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
219567469|NCT00335335|DRUG|iodixanol|
219567470|NCT00028535|BIOLOGICAL|trastuzumab|Given IV
219567471|NCT00028535|DRUG|paclitaxel|Given IV
219567472|NCT00028535|BIOLOGICAL|recombinant interleukin-12|Given SC
219567473|NCT02772952|OTHER|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
219567474|NCT02772952|OTHER|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
219567475|NCT02334111|BEHAVIORAL|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
219406720|NCT05429099|PROCEDURE|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
219429422|NCT06587360|OTHER|fertiShare intervention - sharing bad news eLearning course|"two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.~Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN."
219567476|NCT06324786|BEHAVIORAL|IBMT|IBMT is an effortless mindfulness technique
219567477|NCT06324786|BEHAVIORAL|NF|NF is a mental training technique.
219567478|NCT05155527|DRUG|Ivermectin Tablets|6 mg/tablet
219567479|NCT05155527|OTHER|Placebo|The placebo has same form as Ivermectin.
219567480|NCT00673192|PROCEDURE|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
219567481|NCT02842723|RADIATION|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
219567482|NCT03584217|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
219567483|NCT03584217|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
219567484|NCT03584217|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
219567485|NCT04339595|BIOLOGICAL|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
219567486|NCT04157972|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
219567487|NCT04157972|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
219567488|NCT00466804|PROCEDURE|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
219567489|NCT01309724|OTHER|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
219567490|NCT06535464|DEVICE|Hypotension Prediction Index|Fluid management guided by Hypotension Prediction Index
219567491|NCT06535464|DEVICE|No Hypotension Prediction Index|Fluid management not guided by Hypotension Prediction Index
219567492|NCT00635336|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
219567493|NCT05458037|PROCEDURE|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
219567494|NCT04948671|OTHER|there will be no intervention, this is an observational study|this is an observational study
219567495|NCT03290313|DRUG|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
219567496|NCT03290313|DRUG|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
219567497|NCT03290313|OTHER|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
219567498|NCT03063216|PROCEDURE|intraocular lens implantation|1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
219567499|NCT01109017|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
219567500|NCT00263627|BIOLOGICAL|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
219567501|NCT00263627|OTHER|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
219567502|NCT06077929|OTHER|No intervention done|No interventions done
219567503|NCT05633082|DEVICE|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
219567504|NCT05633082|DEVICE|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
219567505|NCT02349074|PROCEDURE|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
219567506|NCT04479748|DRUG|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
219567507|NCT04479748|DRUG|Prednisolone Acetate 1% Oph Susp|Topical steroid
219406721|NCT06432907|OTHER|motor tasks|"During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes."
219406722|NCT02639793|PROCEDURE|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
219406723|NCT01425190|DRUG|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
219406724|NCT01035255|DRUG|LCZ696 200 mg BID|LCZ696 200 mg BID
219567508|NCT02194140|OTHER|oral iodinated contrast material|diluted in water
219567509|NCT00001873|DEVICE|Isolex 300i plus MoAbs|
219567510|NCT04645940|DRUG|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
219567511|NCT04645940|DRUG|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
219567512|NCT00024388|DRUG|DHA-paclitaxel|
219567513|NCT01501110|DRUG|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
219567514|NCT04250831|DIETARY_SUPPLEMENT|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
219567515|NCT00596206|DRUG|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
219567516|NCT03589131|PROCEDURE|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
219406725|NCT01035255|DRUG|Enalapril 10 mg BID|Enalapril 10 mg BID
219406726|NCT03196297|DRUG|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
219406727|NCT03196297|DRUG|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
219406728|NCT01659944|DRUG|Eliglustat|Capsules for oral administration
219406729|NCT01659944|DRUG|Metoprolol|Tablets for oral administration
219406730|NCT00088010|DRUG|Arzoxifene|20mg, oral, tablet, once a day for 36 months
219002402|NCT00838578|BIOLOGICAL|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
219002403|NCT00838578|DRUG|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
219406731|NCT00088010|DRUG|Placebo|oral, tablet, once a day for 36 months
219406732|NCT04965012|BEHAVIORAL|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
219406733|NCT04965012|BEHAVIORAL|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
219406734|NCT02538666|BIOLOGICAL|Nivolumab|
219406735|NCT02538666|BIOLOGICAL|Ipilimumab|
219406736|NCT02538666|OTHER|Placebo|
219406737|NCT03345836|DRUG|Matching Placebo for Upadacitinib|Matching placebo tablets
219002404|NCT04372030|OTHER|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
219002405|NCT03418415|DEVICE|Renal denervation|multi-electrode catheter-based renal denervation
219002406|NCT05171595|DEVICE|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
219406738|NCT03345836|DRUG|Upadacitinib|Upadacitinib tablets
219406739|NCT00829166|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
219406740|NCT00829166|DRUG|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
219406741|NCT00829166|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
219002407|NCT05171595|DIAGNOSTIC_TEST|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
219002408|NCT00909051|DRUG|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
219002409|NCT04359550|BIOLOGICAL|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
219002410|NCT04359550|OTHER|placebo|placebo
219002411|NCT02421523|PROCEDURE|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
219406742|NCT02188121|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
219406743|NCT02188121|DRUG|Losartan|Angiotensin II receptor antagonist
219406744|NCT02954835|DEVICE|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
219406745|NCT02954835|DEVICE|Traditional Dressing|Sterile gauze dressing secured by tape.
219406746|NCT00002706|PROCEDURE|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
219406747|NCT00002706|OTHER|Quality-of-Life Assessment|Ancillary studies
219406748|NCT00002706|PROCEDURE|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
219406749|NCT00672542|BIOLOGICAL|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
219406750|NCT04652687|OTHER|VIA Disc NP (HCT/P)|VIA Disc NP - Allograft tissue injection
219406751|NCT01892527|DRUG|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
219406752|NCT03312140|DRUG|Choline Chloride|
219406753|NCT03510663|DRUG|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
219406754|NCT03510663|DRUG|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
219567517|NCT03589131|PROCEDURE|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
219002412|NCT02421523|PROCEDURE|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of \~30% of the subject's MVC. Subjects will be asked to perform \~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (\~50% MVC). Similarly, if no damage has occurred at \~50% MVC, four more subjects exercise at \~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
219002413|NCT02421523|PROCEDURE|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
219002414|NCT04047394|DRUG|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
219190018|NCT05492175|OTHER|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
219190019|NCT05492175|OTHER|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
219406755|NCT03510663|DRUG|Moxifloxacin|400mg tablet will be administrated once a week.
219567518|NCT03589131|PROCEDURE|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
219567519|NCT03589131|PROCEDURE|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
219567520|NCT03589131|PROCEDURE|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
219567521|NCT03589131|PROCEDURE|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
219406756|NCT03510663|DRUG|Placebos|Placebo will be intravenously administered once a week.
219406757|NCT05407298|OTHER|Non applicable|Non Applicable
219406758|NCT01924897|BEHAVIORAL|Exercise training|
219406759|NCT00843622|DRUG|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
219567522|NCT01309217|BEHAVIORAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
219761056|NCT00265850|DRUG|FOLFIRI|Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
219761057|NCT01287299|OTHER|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
219761058|NCT01287299|OTHER|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
219761059|NCT00212602|DRUG|ONO-7436|
219761060|NCT04588142|DIETARY_SUPPLEMENT|Probiotic|Non-elite athletes receive probiotic for 6 weeks
219761061|NCT04588142|DIETARY_SUPPLEMENT|Placebo|Non-elite athletes receive placebo for 6 weeks
219761062|NCT03939390|DRUG|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
219761063|NCT04149743|DIAGNOSTIC_TEST|Standard of Care with Hemotag|Comparison of outcomes
219406760|NCT00843622|OTHER|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
219190020|NCT06769282|BEHAVIORAL|Experimental: Intervention (SPARE) plus Treatment as Usual|5 components: (1) Social skills training, including selecting healthy friends and partners, (2) Problem solving with emphasis on positive outcomes of nonaggressive solutions, (3) Awareness of domineering behavior in self and conflict resolution skills, (4) emotion Regulation, and (5) psycho-education on ACEs and trauma. Each session will include 30 minutes of didactic instruction on the component with developmentally engaging activities to illustrate concepts and an individually tailored 15-minute narrative and mindfulness activity, which may address a traumatic memory depending on youth need and receptivity.
219406761|NCT05598996|BEHAVIORAL|COT-Based Intervention|The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
219406762|NCT03491163|DIAGNOSTIC_TEST|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
219406763|NCT01555463|DRUG|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
219406764|NCT01555463|DRUG|Vehicle foam|twice daily topical application
219755774|NCT05478317|PROCEDURE|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
219755775|NCT05478317|PROCEDURE|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
219755776|NCT06545032|PROCEDURE|lumbar fusion|Minimal Invasive Transforaminal Lumbar Interbody Fusion
219755777|NCT06650410|OTHER|Virtual Intervention for Vertebral Fractures (VIVA)|VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
219755778|NCT03666390|DRUG|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
219755779|NCT03666390|DRUG|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
219755780|NCT04273269|GENETIC|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
219755781|NCT00294749|DRUG|Ciprofloxacine|
219755782|NCT07127250|OTHER|Walking sticks|Walking with walking sticks and pedometer Daily walking activity recorded in a logbook
219406765|NCT02491658|BIOLOGICAL|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
219406766|NCT02026271|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"
219406767|NCT02026271|DRUG|veledimex|"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"
219406768|NCT04728971|DRUG|Micafungin Sodium 50 MG Injection|Give Micafungin 150 mg/d within 24 hours after liver transplantation.
219755783|NCT03440801|DEVICE|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
219755784|NCT03440801|DEVICE|Xience|Durable-polymer everolimus-eluting stent Xience
219755785|NCT06708949|DRUG|Drugs Nivolumab|Given by IV Infusion
219406769|NCT04728971|DRUG|Caspofungin Acetate|Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
219406770|NCT02154269|DRUG|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
219406771|NCT02154269|DRUG|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
219406772|NCT00832754|DEVICE|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
219406773|NCT00832754|OTHER|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
219406774|NCT04370028|DRUG|Divaza|Oral administration.
219406775|NCT02965534|DEVICE|Spectacle/Glasses|
219406776|NCT03415724|PROCEDURE|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
219406777|NCT00003019|DRUG|methotrexate|
219406778|NCT00003019|DRUG|vinblastine sulfate|
219406779|NCT05203133|DIETARY_SUPPLEMENT|Energy Balance|Energy balance phase to elicit weight-maintenance
219406780|NCT05203133|DIETARY_SUPPLEMENT|Energy Deficit|Energy deficit phase to elicit weight-loss
219406781|NCT05203133|DIETARY_SUPPLEMENT|Baseline Assessment|Free-living assessment of energy status
219406782|NCT00003859|DRUG|carboplatin|
219406783|NCT00003859|DRUG|cyclophosphamide|
219406784|NCT00003859|DRUG|etoposide|
219406785|NCT00003859|DRUG|vincristine sulfate|
219406786|NCT00003859|PROCEDURE|surgical procedure|
219406787|NCT00003859|RADIATION|radiation therapy|
219755786|NCT06708949|DRUG|Ipilimumab|Given by IV Infusion
219755787|NCT06708949|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV Infusion
219755788|NCT02339051|BEHAVIORAL|Jumping on one leg|
219406788|NCT03175744|DEVICE|Stellarex DCB|Intervention with the Stellarex DCB
219406789|NCT03175744|DEVICE|PTA Catheter|Intervention with an uncoated Standard PTA
219406790|NCT05436938|COMBINATION_PRODUCT|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
219406791|NCT03061123|OTHER|Questionnaire|
219406792|NCT02354170|DRUG|Mifepristone|
219755789|NCT05857748|DRUG|lifitegrast|patient newly started on medication will be followed for 6 months
219406793|NCT02354170|DRUG|Placebo|
219406794|NCT02431585|DIETARY_SUPPLEMENT|gluten|
219406795|NCT02431585|DIETARY_SUPPLEMENT|placebo|
219406796|NCT00606697|DRUG|GR205171|10 milligrams (mg)
219406797|NCT00606697|DRUG|GW597599|15 mg
219406798|NCT02213198|BEHAVIORAL|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
219406799|NCT02213198|BEHAVIORAL|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
219406800|NCT06472505|DEVICE|polyglycolic acid(Neoveil)|This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
219406801|NCT03553329|DRUG|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
219406802|NCT04844047|OTHER|Exercise|refer to arm descriptors
219406803|NCT04844047|OTHER|Exercise|refer to arm descriptors
219406804|NCT00471367|DRUG|AZD4877|intravenous infusion administered twice a week for 2 weeks
219406805|NCT04389476|OTHER|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
219406806|NCT04002440|COMBINATION_PRODUCT|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
219406807|NCT04002440|DEVICE|HomeChoice PRO|Usual care
219406808|NCT05628467|DRUG|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
219406809|NCT01044277|DRUG|Glutathione supplementation|500 mg, two times daily
219755790|NCT05876754|DRUG|Ivosidenib Oral Tablet|Ivosidenib 500 mg
219755791|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
219755792|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
219406810|NCT01044277|DRUG|Gluthathione peroxidases|125 mg, two times daily
219406811|NCT01044277|OTHER|Placebo|2 times daily
219406812|NCT00782925|OTHER|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
219567523|NCT01309217|OTHER|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
219755793|NCT03151564|DIAGNOSTIC_TEST|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
219755794|NCT05464823|OTHER|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
219755795|NCT00055185|DRUG|CD4-IgG2 (PRO 542)|
219406813|NCT00782925|OTHER|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
219406814|NCT00782925|OTHER|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
219567524|NCT02075606|DRUG|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
219567525|NCT01030094|DRUG|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
219567526|NCT01030094|DRUG|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
219567527|NCT01030094|DRUG|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
219567528|NCT01030094|DRUG|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
219567529|NCT01265667|DRUG|CF101|orally q12h
219567530|NCT01265667|DRUG|Placebo|orally q12h
219567531|NCT00877617|BEHAVIORAL|QOL Questionnaire|Mailed survey.
219567532|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
219567533|NCT03314363|DEVICE|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
219567534|NCT03314363|DEVICE|IC|monitor patients during the whole study period with indirect calorimetry
219567535|NCT03314363|DRUG|NaCl predilution|Replace citrate predilution with NaCl
219567536|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
219567537|NCT03314363|DRUG|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
219567538|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
219567539|NCT03314363|DIETARY_SUPPLEMENT|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
219567540|NCT03314363|DIAGNOSTIC_TEST|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
219567541|NCT02674386|DRUG|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
219567542|NCT05504824|OTHER|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
219567543|NCT01413763|DRUG|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
219567544|NCT01413763|DRUG|Placebo cream|placebo cream applied daily for 2 weeks
219567545|NCT02462486|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
219567546|NCT02462486|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
219567547|NCT02462486|OTHER|Sham Procedure|Sham injection.
219755807|NCT06586619|BEHAVIORAL|Tai chi/qigong intervention group|The intervention is a tai chi/qigong intervention for older people living with HIV. This behavioral group-based intervention will be delivered through Zoom twice a week for 12 weeks. Each class lasts 45-60 minutes. Tai chi/qigong is a slow low impact meditative movement.
219406815|NCT03332108|OTHER|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
219406816|NCT03332108|OTHER|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
219406817|NCT05663996|OTHER|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
219406818|NCT05663996|OTHER|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
219406819|NCT03778177|PROCEDURE|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
219406820|NCT04249141|OTHER|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
219406821|NCT04210336|DEVICE|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
219406822|NCT04210336|DEVICE|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
219406823|NCT05557890|BEHAVIORAL|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
219406824|NCT03524677|DIAGNOSTIC_TEST|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
219406825|NCT02915861|OTHER|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
219406826|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
219567548|NCT05568316|DIETARY_SUPPLEMENT|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
219567549|NCT05568316|DIETARY_SUPPLEMENT|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
219755808|NCT06586619|BEHAVIORAL|Health Education group|Participants will be assigned to a health and wellness education group for older people living with HIV. This group will be delivered through Zoom twice a week for 12 weeks, and each class will last 45-60 minutes. Each group will learn about and discuss a health and wellness topic.
219002415|NCT05725109|OTHER|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
219406827|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
219406828|NCT02915861|OTHER|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
219406829|NCT01231633|DRUG|Ozurdex|Ozurdex, 0.7mg dexamethasone
219406830|NCT01231633|DRUG|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
219567550|NCT05103917|DRUG|X4P-001|CXCR4 inhibitor
219567551|NCT01544517|DRUG|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
219406831|NCT04016883|OTHER|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
219406832|NCT04016883|OTHER|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
219406833|NCT06150105|OTHER|Exercise training|Intense endurance training
219406834|NCT00148460|DRUG|TNK-tPA|
219406835|NCT00148460|DRUG|rt-PA|
219406836|NCT02041546|DRUG|Lung lavage with surfactant|
219406837|NCT02041546|DRUG|Bolus surfactant|
219406838|NCT04154267|PROCEDURE|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
219406839|NCT05681741|PROCEDURE|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
219406840|NCT06673069|DRUG|ION269|Administered as intrathecal (IT) injection.
219567552|NCT01692886|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
219567553|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
219567554|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
219567555|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
219567556|NCT04560439|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo METFIT program
219567557|NCT04636541|BEHAVIORAL|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
219567558|NCT04636541|BEHAVIORAL|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
219567559|NCT01439724|DEVICE|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
219567560|NCT01439724|DEVICE|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
219406841|NCT02027298|DRUG|Abatacept|by SC injection of 125 mg weekly for 6 months
219406842|NCT06050863|BIOLOGICAL|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
219406843|NCT06050863|DRUG|Chlorhexidin|chlorhexidine is used
219406844|NCT06050863|BIOLOGICAL|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
219567561|NCT02746419|DEVICE|Vessix|Renal denervation using radio-ablation
219567562|NCT01397955|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
219567563|NCT01767610|DRUG|micronized fenofibrate 160mg|
219567564|NCT01767610|DRUG|pitavastatin Ca 2mg|
219567565|NCT01767610|DRUG|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
219406845|NCT03684161|DIAGNOSTIC_TEST|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
219567566|NCT00944684|DRUG|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
219406846|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
219406847|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
219567567|NCT00944684|DRUG|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
219567568|NCT00307970|DRUG|HFA FP MDI|
219567569|NCT00307970|DEVICE|conventional chamber/mask; anti-static chamber/mask|
219567570|NCT02681406|BEHAVIORAL|ACHESS|Smartphone based additions focused application, encouraging social support
219567571|NCT02681406|BEHAVIORAL|TMC|Brief telephone monitoring and counseling
219567572|NCT04226339|PROCEDURE|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
219567573|NCT04226339|PROCEDURE|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
219567574|NCT02310763|BIOLOGICAL|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
219567575|NCT02310763|DRUG|Placebo|
219567576|NCT04561336|DRUG|Avelumab|avelumab in combination with cetuximab
219567577|NCT04561336|DRUG|Cetuximab|avelumab in combination with cetuximab
219567578|NCT02598245|DEVICE|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
219567579|NCT02598245|DEVICE|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
219567580|NCT03738527|DRUG|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
219567581|NCT03738527|DRUG|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
219567582|NCT04837027|BEHAVIORAL|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
219567583|NCT04837027|BEHAVIORAL|Balance training|Training 5x a week for 30 minutes. Standard of care
219567584|NCT04467320|BEHAVIORAL|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
219567585|NCT04467320|BEHAVIORAL|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
219002416|NCT05725109|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
219002417|NCT05765240|DRUG|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
219002418|NCT05765240|PROCEDURE|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
219190021|NCT06769282|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual consists of individual, family, occupational, and art therapy, social skills and emotion regulation groups, and therapeutic milieu. All staff and clinicians are trained in the Incredible Years Parenting Program, which aims reduce behavioral problems, enhance children's social and emotional competence, and improve child-parent interactions. Children also receive individualized treatment tailored for their needs (e.g., sleep interventions). Behavioral health needs staff (BHS) facilitate children's skill acquisition and generalization, implement individualized behavior contingency programs, and assist caregivers with parenting strategies via daily check-ins
219190022|NCT05332561|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
219755809|NCT06978439|DRUG|Rivaroxaban (Xarelto)|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model-informed dose optimization study
219755810|NCT00404248|DRUG|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
219755811|NCT00404248|OTHER|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
219002419|NCT04633694|DIETARY_SUPPLEMENT|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
219190023|NCT05332561|DRUG|Inavolisib|Arm 2
219190024|NCT05332561|DRUG|Ipatasertib|Arm 3
219190025|NCT05332561|DRUG|Olaparib|Arm 4
219190026|NCT05332561|DRUG|Sacituzumab govitecan|Arm 5
219190027|NCT05332561|DRUG|Trastuzumab/pertuzumab|Arm 6
219190028|NCT06111365|DEVICE|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
219755812|NCT00789555|DRUG|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
219755813|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
219755814|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
219755815|NCT04649645|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
219755816|NCT04649645|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
219755817|NCT04649645|OTHER|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
219755818|NCT06857513|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be interviewed about the current suffering of post-intensive care symptoms
219755819|NCT06857513|DIAGNOSTIC_TEST|EuroQol 5-Dimension 3-Level|to assess health-related quality of life, focusing on the assessment of five key dimensions: mobility, self-care, daily activities, pain/discomfort and anxiety/depression.
219755820|NCT06857513|DIAGNOSTIC_TEST|EuroQol Visual Analogue Scale (EQ-VAS)|"records the patient's self-rated health on a vertical visual analogue scale where endpoints are labelled: 0 best imaginable health - 100 worst imaginable health"
219406848|NCT01135953|OTHER|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
219190029|NCT03941080|DIAGNOSTIC_TEST|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
219190030|NCT03941080|BEHAVIORAL|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
219190031|NCT03941080|DIAGNOSTIC_TEST|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
219406849|NCT03689283|OTHER|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
219406850|NCT03689283|OTHER|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
219190032|NCT05198635|DEVICE|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
219406851|NCT00263302|DRUG|dexamethasone|
219406852|NCT00121355|DEVICE|safety glide|
219190033|NCT05980923|OTHER|Performing blood thyroid test (TSH, FT4, FT3)|Blood test as above
219406853|NCT00121355|DEVICE|autocover needle|
219406854|NCT02689219|DRUG|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
219567586|NCT01749358|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
219567587|NCT01749358|BEHAVIORAL|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
219567588|NCT05140317|PROCEDURE|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
219567589|NCT05777382|OTHER|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
219567590|NCT03767062|DRUG|Topamax|An antiepileptic agent used for migraine prophylaxis.
219567591|NCT03767062|PROCEDURE|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
219567592|NCT03321474|PROCEDURE|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
219567593|NCT06260891|DRUG|25 mg/day zinc|25 mg of zinc as zinc gluconate taken orally once a day
219567594|NCT06260891|DRUG|40 mg/day zinc|40 mg of zinc as zinc gluconate taken orally once a day
219190034|NCT06134440|DIETARY_SUPPLEMENT|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
219190035|NCT05540158|OTHER|Mobile Integrated Health Intervention|"Subjects will have access to on-demand mobile integrated health program for acute symptoms. Subjects will be educated on the nature and capabilities of the MIH community paramedics and will be able to call a hotline for unscheduled visits 24 hours a day, 7 days a week if they wish to be evaluated for acute symptoms or changes in their condition. All visits entail focused history and physical exam with community paramedic, portable diagnostics as indicated, and telehealth visit with a physician"
219406855|NCT04855123|OTHER|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
219406856|NCT04855123|OTHER|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
219406857|NCT05075096|OTHER|No intervention.|No intervention observational study.
219406858|NCT03736746|BEHAVIORAL|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
219406859|NCT01975766|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
219406860|NCT01975766|DEVICE|External beam radiation therapy|
219406861|NCT02292199|DEVICE|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
219567595|NCT00504478|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
219567596|NCT00504478|OTHER|high complex carbohydrate diet|
219002420|NCT01262053|OTHER|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
219002421|NCT01262053|OTHER|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
219002422|NCT01262053|OTHER|Control|Parallel control with no intervention
219190036|NCT05783635|BEHAVIORAL|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
219406862|NCT02292199|DEVICE|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
219406863|NCT02292199|DEVICE|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
219406864|NCT02659683|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
219406865|NCT02659683|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
219406866|NCT03477565|DEVICE|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
219406867|NCT04371731|OTHER|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
219567597|NCT05270486|PROCEDURE|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
219567598|NCT06283121|BIOLOGICAL|BioTTT001 intraperitoneal infusion|Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
219567599|NCT06283121|DRUG|SOX regimen|Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
219567600|NCT06283121|DRUG|toripalimab|Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
219567601|NCT02154802|BEHAVIORAL|video: community member|
219567602|NCT02154802|BEHAVIORAL|video: physician|
219567603|NCT02154802|BEHAVIORAL|video: choice of video|
219567604|NCT00855764|DRUG|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
219567605|NCT01794754|OTHER|Care as usual|
219567606|NCT01794754|OTHER|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
219567607|NCT01275560|DRUG|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
219002423|NCT05139589|OTHER|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
219002424|NCT02343627|DRUG|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
219002425|NCT02343627|DRUG|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
219002426|NCT02273024|BEHAVIORAL|Exercise|
219002427|NCT04966715|PROCEDURE|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
219002428|NCT01408004|DRUG|Pazopanib|Tablet 800mg qd til progression
219002429|NCT01408004|DRUG|Everolimus|tablet 10 mg qd til progression
219002430|NCT01408004|DRUG|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
219002431|NCT01408004|DRUG|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
219406868|NCT02843867|OTHER|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
219002432|NCT01408004|DRUG|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
219406869|NCT02802059|DRUG|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
219406870|NCT02802059|DRUG|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
219406871|NCT00465153|DIETARY_SUPPLEMENT|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
219406872|NCT00465153|BEHAVIORAL|Resistance exercise training|Resistance training
219406873|NCT06146712|OTHER|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
219406874|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
219406875|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
219406876|NCT05158595|OTHER|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
219406877|NCT05158595|OTHER|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
219406878|NCT05158595|OTHER|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
219406879|NCT05158595|OTHER|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
219406880|NCT01259752|DEVICE|compression stockings|compression stockings
219406881|NCT01259752|OTHER|standard non compressive stockings|standard non compressive stockings
219406882|NCT04398017|PROCEDURE|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
219567608|NCT01275560|DRUG|CArbosylane|
219567609|NCT01337726|BEHAVIORAL|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
219002433|NCT01408004|DRUG|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
219002434|NCT01482884|DRUG|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
219002435|NCT01482884|DRUG|placebo|2 sc injections of every 2 weeks for 12 weeks.
219002436|NCT04147208|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
219002437|NCT04147208|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
219002438|NCT04147208|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
219002439|NCT02304172|DEVICE|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
219002440|NCT02304172|DEVICE|Harmonic (Group B)|hemostatic device utilized intraoperatively
219406883|NCT03302416|DRUG|Hydrocortisone|
219406884|NCT03302416|RADIATION|[C-11]NOP-1A|
219406885|NCT04761094|DEVICE|Insulin pump|Treatment with continuous subcutaneous insulin infusion
219406886|NCT00434863|DRUG|botulinum toxin type A|
219406887|NCT02934048|OTHER|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
219406888|NCT02934048|OTHER|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
219406889|NCT02934048|OTHER|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
219567610|NCT01337726|BEHAVIORAL|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
219567611|NCT06615830|DRUG|Standard chemotherapy|Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
219567612|NCT06615830|DRUG|Organoid-guided treatment|Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
219567613|NCT03877926|BIOLOGICAL|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
219567614|NCT03877926|BIOLOGICAL|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
219567615|NCT04155073|BEHAVIORAL|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
219755821|NCT06857461|BEHAVIORAL|Uriclarity Program|"The Uriclarity Program is a behavioral lactation support intervention designed to reduce the perception of insufficient milk supply (PIM) in postpartum women. The program consists of a two-hour hands-on training session delivered within the first 24-48 hours postpartum and a WhatsApp-based follow-up support system.~During the in-person training, participants learn essential breastfeeding techniques, how to recognize normal lactation patterns, and how to use the Uriescala Ashiyama, a self-monitoring tool that evaluates neonatal urine color to assess milk transfer. Right after hospital discharge, participants receive virtual support including educational videos.~This intervention differs from standard lactation counseling by integrating self-monitoring strategies, community-based digital support, and a non-technology-dependent educational approach, making it a scalable and sustainable strategy for breastfeeding promotion."
219755822|NCT04646005|DRUG|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
219755823|NCT04646005|BIOLOGICAL|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
219755824|NCT04410900|BIOLOGICAL|Wistar Rabies Virus Strain PM-1503-3M Vaccine|Given IM
219755825|NCT04410900|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219755826|NCT06313619|COMBINATION_PRODUCT|SmartAMR|"SmartAMR is a digital system including a mobile app that helps keeping record of medicine sales, sending auto-generated messages to the consumers to remind them about medicine taking time and completing doses. It also poses a symptom checker driven by artificial intelligence and a telemedicine service."
219755827|NCT06665165|DRUG|AMX0114|Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
219755828|NCT06665165|OTHER|Placebo|Placebo
219002441|NCT04659304|DRUG|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
219567616|NCT04155073|OTHER|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
219567617|NCT02240186|DEVICE|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
219567618|NCT02240186|DEVICE|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
219567619|NCT05606952|DEVICE|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
219567620|NCT00272649|BIOLOGICAL|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
219755829|NCT06524414|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine
219755830|NCT06524414|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine
219755831|NCT06524414|BIOLOGICAL|15-valent pneumococcal conjugate vaccine (PCV15)|15-valent pneumococcal conjugate vaccine
219755832|NCT06816433|DRUG|Intervention D SLS-002|SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
219406890|NCT04129749|PROCEDURE|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
219406891|NCT00905021|DRUG|Exemestane|Exemestane 25 mg by mouth every day.
219406892|NCT00905021|DRUG|Sutent|Sunitinib 37.5 mg by mouth every day.
219406893|NCT00606762|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
219406894|NCT02893774|OTHER|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)"
219406895|NCT02750657|GENETIC|Molecular Profiling|Whole Genome Sequencing
219567621|NCT04414033|DEVICE|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
219002442|NCT05403905|PROCEDURE|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
219002443|NCT05403905|PROCEDURE|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
219002444|NCT00580606|DRUG|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
219002445|NCT00580606|DRUG|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
219406896|NCT06023173|DIAGNOSTIC_TEST|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
219406897|NCT02058134|DEVICE|cardioPAT cell saver|
219406898|NCT07132385|BEHAVIORAL|Guidelines-based moderate-intensity continuous exercise|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity (total intervention is 6 weeks)
219567622|NCT03554317|DRUG|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
219755833|NCT06816433|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
219755834|NCT06594770|PROCEDURE|Atraumatic Restorative Treatment|"A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds ."
219755835|NCT06594770|PROCEDURE|Hall technique|"The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks."
219755836|NCT06600971|OTHER|acupressure application|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
219755837|NCT03011528|DRUG|VDC-IE x2|"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
219755838|NCT03011528|DRUG|VDC-IE|"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
219755839|NCT03011528|DRUG|TEMIRI|"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"
219755840|NCT03011528|DRUG|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~\- PBSC infusion, D0, at least 3.10\^6 CD34/kg"
219755841|NCT03011528|DRUG|Maintenance|"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"
219755842|NCT03011528|PROCEDURE|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
219755843|NCT03011528|RADIATION|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
219755844|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
219755845|NCT04726592|DRUG|Placebo|Placebo IV
219002446|NCT05376124|OTHER|original therapy|* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
219406899|NCT07132385|BEHAVIORAL|High-intensity interval training|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 75 weekly minutes of high-intensity interval training.
219406900|NCT07132385|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
219406901|NCT06677229|DRUG|Eletriptan HBr 40 mg|Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.
219406902|NCT05513612|BIOLOGICAL|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
219406903|NCT05513612|DRUG|Fludarabine|Administered according to package insert
219406904|NCT05513612|DRUG|Cyclophosphamide|Administered according to package insert
219406905|NCT03312946|DEVICE|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
219406906|NCT05239286|PROCEDURE|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
219406907|NCT05239286|DRUG|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
219567623|NCT03554317|DRUG|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
219567624|NCT00001554|DEVICE|intraoperative infrared (IR) neuroimaging|
219567625|NCT02618226|DEVICE|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
219567626|NCT03795389|DRUG|DM199|Single SC dose
219567627|NCT03345758|OTHER|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
219567628|NCT03427476|DRUG|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
219567629|NCT01352182|DRUG|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
219567630|NCT05445531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
219567631|NCT05445531|DIAGNOSTIC_TEST|Nailfold capillaroscopy|Imaging of nailfold microvasculature
219567632|NCT05445531|DIAGNOSTIC_TEST|Spiroergometry|Cardiopulmonary exercise testing
219567633|NCT05445531|DIAGNOSTIC_TEST|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
219567634|NCT04897191|OTHER|Age|Determination of age-dependence
219567635|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
219567636|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
219567637|NCT01877460|OTHER|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
219567638|NCT00124462|DEVICE|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
219567639|NCT00124462|DEVICE|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
219567640|NCT01816568|PROCEDURE|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
219567641|NCT01816568|PROCEDURE|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
219567642|NCT00965016|PROCEDURE|hypothermia|Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
219406908|NCT05239286|DRUG|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
219406909|NCT06829420|BEHAVIORAL|Mirror speech entrainment|Speech entrainment with the user's own voice using auditory-only and auditory-visual modalities.
219406910|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-only|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-only modality (users only listen and speak along to auditory stimuli)
219406911|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-visual|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-visual modality (users listen and speak along to both auditory and visual stimuli (mouth movements)
219406912|NCT07077902|DRUG|Topical roflumilast 0.3% foam|Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis
219406913|NCT07084740|DIAGNOSTIC_TEST|PeriCam and PeriFlux measurements|PeriCam and PeriFlux measurements
219406914|NCT07083427|OTHER|CAPA-IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
219406915|NCT07083895|BEHAVIORAL|Modified RICHH|"The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads. The program consists of 12 weekly sessions \[30-45 minutes\] that will be held at the caregivers' preferred times. RICHH consists of 6 interactive modules (i.e., self-management for heart health, depressive symptom management, heart healthy eating, physical activity, co-morbid condition management, and adherence to medication and smoking cessation).~The modified RICHH intervention utilizes focus group outcomes to employ modifications needed to target custodial grandparents from varied backgrounds (e.g., high ACEs, SDoH groups)."
219406916|NCT07083895|BEHAVIORAL|Standard of Care (SOC)|Referral to primary care provider
219406917|NCT07085052|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|10-week online MBSR program, involving 10 weekly 2.5-hour group sessions, a day-long online retreat, and approximately 45 minutes of home practice assignments six days per week.
219406918|NCT06635629|DRUG|Desmopressin|Stimulates ACTH release in Cushing disease
219406919|NCT06635629|DRUG|Dexamethasone|Inhibits ACTH release in Cushing disease and healthy volunteers
219406920|NCT06018025|DRUG|CGRP antibody|treatment with CGRP antibody for 4 months
219406921|NCT06892756|DRUG|CHF6001 dry powder inhaler (DPI)|CHF6001 DPI single dose administration followed by a 14 to 17-day wash-out period before Treatment Period 2
219406922|NCT06892756|DRUG|Cyclosporine|Oral cyclosporine single dose administration
219406923|NCT06892756|DRUG|CHF6001 DPI|CHF6001 DPI single dose administration after oral cyclosporine single dose administration
219567643|NCT01906424|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
219755846|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
219755847|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
219406924|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Containing Milk|"Participants will be asked to drink 1% regular milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
219406925|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Free Milk|"Participants will be asked to drink 1% lactose-free milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
219755848|NCT06858735|DRUG|Durvalumab|Given by IV
219755849|NCT06858735|DRUG|Gemcitabine|Given by IV
219755850|NCT06858735|DRUG|Cisplatin|Given by IV
219755851|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
219755852|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
219755853|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
219755854|NCT04398706|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
219755855|NCT04398706|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
219755856|NCT04398706|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
219755857|NCT04398706|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
219755858|NCT04398706|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
219755859|NCT04398706|BIOLOGICAL|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
219755860|NCT04792216|OTHER|Wild Salmon|Wild salmon fillets
219755861|NCT04792216|OTHER|Farmed Salmon|Farm salmon fillets
219755862|NCT07000669|OTHER|Bilateral peribulbar block|Patients undergoing bilateral peribulbar anesthesia for cataract surgery.
219755863|NCT07004348|OTHER|Animation group will receive 4 sessions of animation as education media as intervention.|Wait list group will receive the conventional session of education
219406926|NCT02859545|BEHAVIORAL|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
219406927|NCT02859545|BEHAVIORAL|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
219567644|NCT03669016|BEHAVIORAL|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
219567645|NCT03669016|BEHAVIORAL|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
219567646|NCT03600181|DEVICE|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
219567647|NCT04845516|OTHER|Efficacy of apheresis|Efficacy of apheresis
219567648|NCT00798681|DIETARY_SUPPLEMENT|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
219755864|NCT07003191|DRUG|Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)|First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months
219755865|NCT07003204|PROCEDURE|medical thoracoscopy|pleural fluid aspiration and cellular analysis
219755866|NCT07003854|DEVICE|Mandibular advancement device|Custom made titrable bi-bloc MADs worn during sleep to stabilize airway and treat obstructive sleep apnea
219755867|NCT07004829|BEHAVIORAL|Exercise counselling via instant messaging|The 12 weeks of messages will be sent by a trained counsellor. At baseline, participants will select their desired IM application (WhatsApp/WeChat), timing of messages (morning/noon/afternoon), message format (audio/text), and language style (spoken/written). The message library, established in the HMRF-funded study, consists of messages in text and pre-recorded voice message formats, images, videos, and stickers. Each week starts with messages on factual information and ends with a question to initiate conversations to clear any queries; counsellor will provide real-time replies. The 12-week messages are structured based on the M-PAC framework.
219755868|NCT07003659|OTHER|Tele-Yoga|This program consisted of diaphragmatic breathing, pranayama techniques consisting of nadi sodhana and ujjai, yoga poses consisting of sukhasana, bharadvajasana, marjaryasana - bitilasana, bhujaganasana, salabhasana, kapotasana, hasta uttanasana, virabhadrasana, adho mukha svanasana, bhujangasana. The exercises were carried out in a way that they would be followed up with an exercise diary in which they would take notes on continuing these exercises throughout the tele-yoga practice period, and reminder messages for the exercises were sent by the researchers to the WhatsApp group opened with the participants who participated in the study and were included in the exercise group.
219755869|NCT06543862|OTHER|CADx (AI) system|The CADx system will be used to predict the histopathology of the polyp detected.
219755870|NCT07003945|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|With the real-time guidance of TTE, a radiofrequency electrode needle was percutaneously inserted via the transapical intramyocardial approach into the hypertrophied septum for thermal ablation. Intraoperative TTE and 12-lead electrocardiographic monitoring were employed to assess the ablation extent and prevent vascular and cardiac conduction bundle injury. The success of ablation was confirmed by evaluating contrast medium perfusion defects in the ablated areas and comparing them with the preprocedural hypertrophied septum.
219755871|NCT07003633|PROCEDURE|PENG block with 0.25% bupivacaine guided by ultrasound.|PENG (Pericapsular nerve block) is a peripheral nerve block which is performed for patients with hip fractures aimed to prevent preoperative and postoperative pain. It is performed under sterile conditions under ultrasound guideance.
219755872|NCT06151483|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
219755873|NCT06151483|OTHER|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
219755874|NCT07005050|DEVICE|RPD|Renal Pelvic Denervation
219002447|NCT05376124|OTHER|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
219755875|NCT07005050|DRUG|Active hypertension medical therapy|Prespecified two medication regimen for control of hypertension
219755876|NCT07002879|PROCEDURE|dry needle|"An 18-gauge needle was first used to fenestrate the common extensor tendon and lateral periosteum. Once adequate anesthesia was confirmed, an 18-gauge needle was inserted along the tendon's longitudinal axis (without exiting the skin) and advanced in a peppering motion 40 to 50 passes from superficial to deep layers over approximately two minutes"
219002448|NCT05730751|PROCEDURE|spinal anesthesia|spinal anesthesia
219002449|NCT05730751|PROCEDURE|caesarean section|LSCS
219002450|NCT05489198|PROCEDURE|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
219002451|NCT05489198|PROCEDURE|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
219002452|NCT01831193|DRUG|Curcumin|
219002453|NCT05951504|DRUG|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
219190037|NCT05783635|BEHAVIORAL|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
219406928|NCT06893653|DEVICE|Focal muscle vibration|FMV will be applied to the muscle belly along with the conventional physical therapy
219406929|NCT06893653|DEVICE|tDCS|tDCS will be applied to M1 area of brain along with the conventional physical therapy
219406930|NCT06893653|OTHER|Physical Therapy|Conventional physical therapy will be provided
219406931|NCT06893653|DEVICE|Focal muscle vibration & tDCS|Focal muscle vibration with tDCS and conventional physical therapy will be provided.
219406932|NCT06766500|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet
219406933|NCT06766500|DRUG|Synjardy® 5 mg/850 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets
219406934|NCT07094204|DRUG|ASP5834|Intravenous infusion
219406935|NCT07094204|DRUG|panitumumab|Intravenous infusion
219406936|NCT07102121|PROCEDURE|luting material applaication with Modified Glass Ionomer Cement (RMGIC)|The intervention involves the use of two different types of luting cements-resin-modified glass ionomer cement (RMGIC) and conventional glass ionomer cement (GIC)-for the cementation of fixed dental prostheses. The objective is to compare post-cementation sensitivity between the two materials. All clinical procedures, including tooth preparation, isolation, and cementation, will follow standardized protocols. Sensitivity will be measured using the Visual Analog Scale (VAS) at 24 hours and 7 days post-procedure. The study will maintain consistency across both groups, with the only variable being the type of cement used.
219406937|NCT06911073|DIETARY_SUPPLEMENT|Postbiotic|"Active ingredients:~Vitamin D (as cholecalciferol) - 10 mcg Vitamin B12 (as methylcobalamin) - 200 mcg Chromium (as chromium picolinate) - 600 mcg resM™ Postbiotic (L. plantarum RSB11® HI - 16B cells) - 40 mg White mulberry (Morus alba) leaf extract - 250 mg Fenugreek (Trigonella foenum-graecum) seed extract - 200 mg~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
219190038|NCT05783635|BEHAVIORAL|Usual surgical care (post-operative)|This group will receive standard post-operative care.
219406938|NCT06911073|DIETARY_SUPPLEMENT|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
219406939|NCT06833281|DRUG|SPG302|small synthetic molecule
219406940|NCT01562015|DRUG|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
219406941|NCT06797063|BEHAVIORAL|BEST4Baby|BEST4Baby consists of prenatal and post-delivery breastfeeding education and support for mothers provided by community-based peer counselors who are trained in a modified 5-day WHO/UNICEF Breastfeeding Counselling Course and supported by an mHealth application.
219406942|NCT06797063|BEHAVIORAL|Usual Care|Participants in the control clusters will continue with local practice for antenatal breastfeeding support and referral to facilities. It is expected that they will receive routine health education recommended by the national health system during the prenatal and postnatal period and offered through PHC and community level workers, including ASHAs. ASHAs may visit a woman after delivery to provide lactation support, as needed, with visits ceasing at 42 days post-delivery. Breastfeeding mothers requiring advanced lactation support may be referred to a community subcenter for care with more skilled clinicians.
219406943|NCT07161921|OTHER|lymph node metastasis|Histopathological examination confirmed the presence of at least one lymph node metastasis
219406944|NCT07161843|DRUG|QRX-3|Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
219406945|NCT07162389|DEVICE|Shallow-Threaded Short Implant (SHI)|A 7mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) Macrodesign, surgically placed in the jawbone to restore missing teeth
219406946|NCT07162389|DEVICE|Shallow-Threaded Standard Implant (SDI)|A 11mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) macrodesign, surgically placed in the jawbone to restore missing teeth.
219755877|NCT07002879|PROCEDURE|Platelet Rich Plasma|A 15 mL peripheral blood sample was drawn and centrifuged at 3 000 rpm for 3 minutes. Approximately 2 mL of PRP was aspirated directly from the buffy coat and injected into the epicondylar region under ultrasound guidance.
219755878|NCT06873724|DRUG|SPY003-207|Experimental
219755879|NCT06873724|OTHER|Placebo|Placebo
219406947|NCT07162103|OTHER|GMART|Group Mandala Art Therapy
219406948|NCT05513053|BIOLOGICAL|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
219406949|NCT01107275|BIOLOGICAL|rabies vaccine|intradermal vaccination
219406950|NCT02622100|DEVICE|Bioresorbable Vascular Scaffold|
219406951|NCT02648958|DRUG|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
219406952|NCT02648958|DRUG|normal saline|The control group received the normal saline infusion
219406953|NCT03484923|DRUG|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
219406954|NCT03484923|DRUG|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
219406955|NCT03484923|DRUG|INC280|400 mg of INC280 administered twice daily orally
219406956|NCT03484923|DRUG|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
219406957|NCT03484923|DRUG|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
219567649|NCT00798681|OTHER|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
219002454|NCT02587715|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
219002455|NCT02587715|OTHER|Liberation therapy|
219002456|NCT02352350|OTHER|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
219406958|NCT00556361|DRUG|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
219406959|NCT00556361|DRUG|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
219406960|NCT03430687|OTHER|Laboratory Biomarker Analysis|Correlative studies
219406961|NCT03430687|BIOLOGICAL|Talimogene Laherparepvec|Given intravesically
219406962|NCT00878657|DRUG|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
219406963|NCT00878657|RADIATION|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
219406964|NCT02514928|PROCEDURE|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219406965|NCT02514928|PROCEDURE|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219406966|NCT04569474|DEVICE|Transparent dressing|Use of sterile transparente dressing
219406967|NCT05270538|DEVICE|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
219406968|NCT04861480|BIOLOGICAL|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219002457|NCT02352350|OTHER|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
219406969|NCT03165721|DRUG|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
219406970|NCT02078882|BIOLOGICAL|abatacept|125 mg subcutaneously each week for 24 weeks
219406971|NCT00449111|DRUG|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
219406972|NCT02179528|DRUG|Etoposide|
219567650|NCT00798681|OTHER|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
219567651|NCT05178108|OTHER|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~* 3 sequences with no food~* 3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~* 3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
219406973|NCT04053543|DRUG|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
219406974|NCT01863849|BIOLOGICAL|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
219567652|NCT04922450|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
219406975|NCT01457118|DRUG|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
219406976|NCT01457118|DRUG|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
219406977|NCT01457118|DRUG|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
219406978|NCT01457118|DRUG|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
219002458|NCT02063022|DRUG|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
219190039|NCT05783635|BEHAVIORAL|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
219406979|NCT00200499|DRUG|Nebivolol|
219406980|NCT06092242|DRUG|Tas-102(Suyuan) combined with bevacizumab|Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
219406981|NCT00256048|PROCEDURE|Nasojejunal feeding|
219406982|NCT06423287|DIETARY_SUPPLEMENT|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
219755880|NCT05666609|PROCEDURE|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
219755881|NCT06879210|DEVICE|Mobile device.(phone)|Develop a mobile device \[Disease Assistance Consultation\] to help patients promptly understand their disease and how to care for it. After a 4-week trial period, conduct interviews with participants to determine whether using the mobile device can increase participants' knowledge and improve the quality of healthcare.
219755882|NCT07033195|DEVICE|Skills-based Virtual Reality Therapy|"1. A 34-minute education video session on the science behind chronic pain and the scientific principles of the therapy.~2. VR skills-based therapy: a virtual reality therapy consisting of different psychological training exercises"
219406983|NCT06423287|OTHER|Take placebo in addition to the limited diet.|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
219406984|NCT05274113|DRUG|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
219406985|NCT05274113|DRUG|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
219406986|NCT04761887|DRUG|Cool Ropivacaine Block|Ropivacaine is cooled.
219406987|NCT04761887|DRUG|Room Temp Ropivacaine Block|Room Temp Block
219406988|NCT06198049|OTHER|Pilates Training|This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
219406989|NCT06198049|OTHER|Balance Proprioception Exercises|This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
219406990|NCT01887899|DEVICE|transcranial direct current stimulation|
219406991|NCT01887899|DEVICE|sham stimulation|
219406992|NCT02123160|BEHAVIORAL|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
219567653|NCT04922450|DRUG|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
219567654|NCT04922450|DRUG|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
219567655|NCT06603181|OTHER|conventional treatment|exercise and splint
219567656|NCT06603181|OTHER|phonophoresis|exercise, splint and phonophoresis
219567657|NCT06603181|OTHER|extracorporeal shock wave therapy|exercise, splint and ESWT
219406993|NCT02123160|BEHAVIORAL|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
219406994|NCT05489822|DEVICE|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
219406995|NCT03540134|DEVICE|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
219567658|NCT03225014|DEVICE|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
219406996|NCT04341675|DRUG|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
219406997|NCT04341675|DRUG|Placebo|Matching placebo
219406998|NCT02300415|BIOLOGICAL|blood sample|Dosage of presepsine
219406999|NCT04264455|DEVICE|Biomonitor|Patients receive a Biomonitor only
219407000|NCT04264455|DEVICE|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
219407001|NCT04264455|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
219407002|NCT03456713|BIOLOGICAL|LY3074828|Administered SC
219407003|NCT04792437|PROCEDURE|surgery|surgery
219407004|NCT01405313|DEVICE|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
219407005|NCT01405313|DEVICE|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
219407006|NCT02391090|DEVICE|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
219407007|NCT02391090|DEVICE|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
219407008|NCT02391090|PROCEDURE|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
219567659|NCT03225014|DIAGNOSTIC_TEST|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
219567660|NCT06146855|PROCEDURE|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
219567661|NCT06146855|PROCEDURE|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
219567662|NCT02748655|OTHER|Alkaline ionized water|
219567663|NCT02748655|OTHER|Tap water|
219755883|NCT07033195|DEVICE|Distraction-based Virtual Reality Therapy|1\. A 7-minute education video session on the science behind pain-focused attention and distraction. 2. VR distraction-based therapy: a virtual reality therapy that encourages passive attention and minimizes external cognitive demands.
219755884|NCT07135869|DIAGNOSTIC_TEST|One minute sit-to-stand test|The one minute sit-to-stand test will be used as acute fatigue protocol to generate fatigue.
219755885|NCT06712927|DRUG|Ipilimumab|1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
219407009|NCT02391090|OTHER|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
219407010|NCT02391090|PROCEDURE|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
219407011|NCT02391090|PROCEDURE|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
219407012|NCT02391090|PROCEDURE|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
219407013|NCT03025334|DEVICE|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
219407014|NCT03848221|DRUG|Systane Complete|Systane Complete is an artificial tear.
219407015|NCT03848221|DRUG|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
219407016|NCT03505138|DEVICE|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
219407017|NCT03505138|OTHER|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
219407018|NCT00318903|DRUG|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
219407019|NCT00318903|DRUG|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
219407020|NCT00318903|PROCEDURE|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
219407021|NCT00318903|PROCEDURE|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
219407022|NCT02103790|DEVICE|Home NIV installation|
219407023|NCT00448253|BIOLOGICAL|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
219407024|NCT04281160|DEVICE|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
219407025|NCT01263691|BIOLOGICAL|BioThrax|BioThrax
219407026|NCT01263691|BIOLOGICAL|AV7909 Formulation 1|AV7909 Formulation 1
219407027|NCT01263691|BIOLOGICAL|AV7909 Formulation 2|AV7909 Formulation 2
219407028|NCT01263691|BIOLOGICAL|AV7909 Formulation 3|AV7909 Formulation 3
219407029|NCT01263691|BIOLOGICAL|AV7909 Formulation 4|AV7909 Formulation 4
219407030|NCT01263691|DRUG|Control|Saline control
219407031|NCT00064467|DRUG|Extended-release bupropion (HCl)|
219407032|NCT00948662|DRUG|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
219407033|NCT00948662|DRUG|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
219407034|NCT00948662|DRUG|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
219407035|NCT01111201|BEHAVIORAL|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
219407036|NCT05600192|OTHER|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
219407037|NCT06291116|DRUG|standard care + rotigotine at 4 mg/24h for 24 months.|standard care + rotigotine at 4 mg/24h for 24 months.
219407038|NCT06291116|DRUG|standard care for 24 months.|standard care for 24 months.
219407039|NCT06046716|BEHAVIORAL|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
219407040|NCT02012608|DRUG|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
219407041|NCT02012608|DRUG|Placebo|For subjects undergoing breast conserving therapy
219407042|NCT03546179|OTHER|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
219407043|NCT03546179|OTHER|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
219407044|NCT00637364|PROCEDURE|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
219567664|NCT02629250|PROCEDURE|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
219002459|NCT02063022|DRUG|Intensified chemotherapy|"* Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
219407045|NCT04552379|BIOLOGICAL|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
219407046|NCT00103545|BIOLOGICAL|ACA 125|
219407047|NCT01202227|DRUG|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
219002460|NCT03879226|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
219755886|NCT06712927|DRUG|Nivolumab + Relatlimab FDC|Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
219407048|NCT03625427|DIETARY_SUPPLEMENT|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
219407049|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
219407050|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
219407051|NCT01151592|DRUG|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
219407052|NCT02152592|DRUG|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
219755887|NCT05198557|DRUG|Inebilizumab|Participants will receive IV inebilizumab.
219755888|NCT05198557|DRUG|Placebo|Participants will receive IV placebo matched to inebilizumab.
219755889|NCT06878144|BEHAVIORAL|Mucormycosis|Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).
219755890|NCT06721884|DIETARY_SUPPLEMENT|Artemisia Annua Leaf|"The intervention is Artecinua™ which is an organic Artemisia annua dried leaf powder in a vegan / kosher/ halal capsule. Artemisia annua L is classified as a 'generally regarded as safe' (GRAS) herb. Participants will be instructed to wean up to a full 5g dose by the following schedule.~1. gram (3 caps) 1st day,~2. grams (6 caps) 3/am, 3/pm, for the 3rd day,~3. grams (9 caps) 3/am 3/noon 3/pm for the 5th day,~4. grams (12 caps) 4/am, 4/noon, 4/pm for the 7th day,~5. grams (15 caps) 5/am, 5/noon, 5/pm for rest of intervention period (4 weeks)~Containers of ArtecinuaTM will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.~The justification of the 5g a day dosing is based on empiric experience and is in line with recommended dosages by the pharmacopeia of the People's Republic of China and has been previously used in clinical trials"
219755891|NCT06721884|OTHER|placebo|We have chosen dried-leaf alfalfa of equal weight and dosing to the interventional product (5 grams, 15 caps, 5/am, 5/noon, 5/pm for the 4 weeks of the intervention period plus an additional 1 week dose escalation period to match the dosing of the Artemisia product). We have chosen this as a comparator in consultation with SIBO and herbal medicine content experts as alfalfa matches the texture and color of Artemisia annua and, in the doses used, will provide no meaningful amounts of FODMAPs or antimicrobial phytochemicals. The alfalfa will be sourced from Bulk Apotherapy, LCC, and encapsulated at the same facility as the Artemisia capsules. Containers of placebo capsules will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.
219755892|NCT06894160|DEVICE|Adults EXPLORER|Two sessions with the robotic gait device in patients with neuromuscular diseases.
219755893|NCT06893783|DRUG|Tarlatamab|1 mg step dose on cycle 1 day 1 10 mg target dose starting cycle 1 day 8, cycle 1 day 15, and every 2weeks thereafter
219755894|NCT06893419|OTHER|Geriatric telemanagement|The geriatrician will coordinate, through a telemedicine consultation, a team consisting of the general practitioner and the nursing home staff. The geriatrician will review the diagnoses, treatments, and results of the comprehensive geriatric assessment performed by the nursing home staff. Subsequently, the entire team will conduct a multidisciplinary conference.
219755895|NCT06885957|DRUG|Mab Therapy|Whether receive mab therapy or not.
219755896|NCT03995472|DRUG|SHR-1501|Administered subcutaneously
219407053|NCT02152592|DRUG|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
219407054|NCT06256783|DRUG|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
219755897|NCT03995472|DRUG|SHR-1316|Administered intravenously
219755898|NCT06839261|DIAGNOSTIC_TEST|Intubation Difficulty Scale|The Intubation Difficulty Scale (IDS) is an objective way to classify easy and difficult intubation. A score ≤ 5 indicates an easy or mildly difficult intubation, while IDS \> 5 suggests difficult intubation, requiring additional techniques or attempts.
219407055|NCT00643487|PROCEDURE|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
219407056|NCT06362499|DEVICE|Experimental Group|After the initial assessment, all volunteers will receive a POWERbreathe® classic light resistance device (POWERbreathe®, Nsc, Brazil), to carry out the training, and will be individually guided on how to use it and how to complete the protocol. They will perform a trial session to familiarize themselves with the device that will not be considered for analysis. Every week, volunteers will receive a telephone call from researcher 2, who will not participate in the evaluation, to confirm whether the exercise with the POWERbreathe® will be performed appropriately at the recommended frequency, intensity, and duration and whether there are any questions regarding the protocol. At the end of each week, participants will receive a video call from researcher 2 to adjust the device according to G1's weekly load progression.
219407057|NCT00803010|DRUG|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
219407058|NCT00803010|DRUG|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
219407059|NCT00803010|DRUG|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
219407060|NCT04402008|DRUG|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
219407061|NCT04402008|DRUG|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
219567665|NCT02629250|PROCEDURE|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
219567666|NCT02610270|DIETARY_SUPPLEMENT|2 Gums|760 mg DHA
219567667|NCT02610270|DIETARY_SUPPLEMENT|3 Gums|1140 mg DHA
219567668|NCT00537199|OTHER|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
219567669|NCT00537199|DRUG|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
219567670|NCT02241109|OTHER|no intervention|progression monitoring by echocardiography
219567671|NCT06617377|OTHER|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
219567672|NCT01402154|BIOLOGICAL|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
219567673|NCT01402154|BIOLOGICAL|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
219755899|NCT06839261|OTHER|Artificial Intelligence|The program made with Python 3 programming language using open source libraries. It will be developed to predict difficult intubation with 6 different photo data of patients, this process will be taught with a learning process and then tested.
219407062|NCT04402008|DRUG|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
219407063|NCT00066664|GENETIC|proteomic profiling|
219407064|NCT04346264|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
219567674|NCT01049347|DRUG|amitriptyline|150 mg oral, daily, single evening dose, 35 days
219567675|NCT01049347|DRUG|paroxetine|40 mg oral, single dose, morning, 35 days
219567676|NCT03485482|DRUG|Bisoprolol|bisoprolo 5 mg tablets
219567677|NCT03485482|DRUG|Ivabradine|Ivabradine 10 mg tablet
219567678|NCT03485482|DRUG|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
219567679|NCT02412462|DRUG|AB-16B5|
219567680|NCT03297294|DRUG|EMA401|capsules, oral
219567681|NCT03297294|DRUG|Placebo|Placebo to EMA401 capsules, oral
219567682|NCT02061176|PROCEDURE|Transanal Haemorrhoidal Dearterialization|
219567683|NCT02061176|PROCEDURE|Open Haemorrhoidectomy|
219567684|NCT03367689|DRUG|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
219567685|NCT04424966|DRUG|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
219567686|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
219002461|NCT03879226|DEVICE|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
219407065|NCT01972009|PROCEDURE|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
219407066|NCT02985502|OTHER|pancreatogenic diabetes|pancreatogenic diabetes
219407067|NCT01693133|OTHER|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
219407068|NCT01693133|OTHER|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
219407069|NCT02717065|OTHER|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
219407070|NCT02717065|OTHER|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
219567687|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
219002462|NCT04448574|OTHER|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
219407071|NCT06098209|DRUG|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
219567688|NCT02127073|DRUG|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
219567689|NCT01221831|DRUG|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day"
219567690|NCT01221831|DRUG|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day"
219567691|NCT01221831|DRUG|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day"
219567692|NCT02506231|DRUG|Folinic acid|
219567693|NCT02506231|DRUG|Placebo|
219567694|NCT02621463|DEVICE|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
219567695|NCT02039063|DRUG|E6011 2 mg/kg|
219567696|NCT02039063|DRUG|E6011 5 mg/kg|
219567697|NCT02039063|DRUG|E6011 10 mg/kg|
219567698|NCT02039063|DRUG|E6011 15 mg/kg|
219567699|NCT04575714|OTHER|Data record|Data record
219567700|NCT03241316|BEHAVIORAL|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
219567701|NCT00921284|DRUG|NaCl 9/00|Same volume as in the dexmedetomidine group
219567702|NCT00921284|DRUG|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
219567703|NCT03186599|BEHAVIORAL|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
219567704|NCT03777345|DEVICE|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
219002463|NCT04931745|DEVICE|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
219567705|NCT03777345|DEVICE|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
219567706|NCT04532398|OTHER|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
219407072|NCT06098209|DRUG|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
219567707|NCT04532398|OTHER|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
219407073|NCT03816410|PROCEDURE|LAA amputation|complete surgical amputation of the left atrial appendage
219407074|NCT05800106|DRUG|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
219567708|NCT00467831|DRUG|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
219567709|NCT00467831|DRUG|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
219567710|NCT00467831|DRUG|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
219567711|NCT00467831|DRUG|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
219567712|NCT00467831|DRUG|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
219567713|NCT06596499|DEVICE|CH-VAD|The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
219567714|NCT03259191|PROCEDURE|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
219567715|NCT00005086|DRUG|cisplatin|
219567716|NCT00005086|DRUG|docetaxel|
219567717|NCT00005086|DRUG|gemcitabine hydrochloride|
219567718|NCT00005086|DRUG|methotrexate|
219002464|NCT04931745|DEVICE|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
219407075|NCT05800106|DRUG|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
219407076|NCT01970930|PROCEDURE|Blood specimen|4 green top tube 40 cc of blood draw
219567719|NCT00368563|DRUG|Helioblock SX|
219567720|NCT01884402|DRUG|Peginterferon alfa-2a|Treatment as usual clinical practice
219567721|NCT01884402|DRUG|Ribavirin|Treatment as usual clinical practice
219567722|NCT05321823|DEVICE|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
219567723|NCT05321823|OTHER|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
219567724|NCT05321823|DIAGNOSTIC_TEST|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
219567725|NCT05321823|DIAGNOSTIC_TEST|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
219567726|NCT03309917|OTHER|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
219567727|NCT03309917|OTHER|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
219567728|NCT03309917|OTHER|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
219407077|NCT04300491|OTHER|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
219407078|NCT04503928|DRUG|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
219567729|NCT05592249|OTHER|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
219567730|NCT05592249|OTHER|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
219567731|NCT04580849|OTHER|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
219567732|NCT05814133|DEVICE|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
219755900|NCT05690841|DRUG|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing)."
219755901|NCT07065968|DRUG|Teriflunomide|Teriflunomide 14 mg orally once daily for 24 weeks.
219407079|NCT05880407|PROCEDURE|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
219407080|NCT05880407|PROCEDURE|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
219407081|NCT02637791|DEVICE|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
219407082|NCT00107770|DRUG|sodium phenylbutyrate|histone deacteylase inhibitor
219407083|NCT02260167|OTHER|A mix of natural treatments and medications|
219407084|NCT05821257|OTHER|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
219407085|NCT05821257|OTHER|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
219407086|NCT00900250|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219407087|NCT02773719|OTHER|True Biofield therapy|
219755902|NCT07065968|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days.
219755903|NCT06566079|DRUG|ISM6331|"Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment."
219755904|NCT06654323|BEHAVIORAL|Intensive Behavioral Lifestyle Modification|Participants in all arms will receive visits with their child's primary care provider (4 visits, 1 hour total), on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), and community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total). The difference between arms will be in the frequency and duration of personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional: 16 sessions (60 minutes per session), 12 sessions (60 minutes per session), 9 sessions (60 minutes per session), 8 sessions (45 minutes per session), or 6 sessions (30 minutes per session).
219755905|NCT01613885|OTHER|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
219567733|NCT03902899|OTHER|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
219567734|NCT06322459|BEHAVIORAL|Sport Education Curriculum|The six characteristics of The Sport Education Model include season, affiliation, formal competition, culminating event, Record-keeping, and Festivity. The intensity of the training is increasing in the first 30 minutes, and the intensity is gradually decreasing in the next 10 minutes.
219567735|NCT06322459|BEHAVIORAL|Normal teaching|The intervention content, frequency, and intensity were the same as those in the experimental group, but the type of intervention was different. The most significant difference between the two teaching methods lies in delivering basic content. The Sport Education Model includes Teacher-directed learning (10 minutes) and Team practice (10 minutes); Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
219002465|NCT04931745|OTHER|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
219407088|NCT02773719|OTHER|Fake Biofield therapy|
219407089|NCT06288672|OTHER|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
219407090|NCT06288672|OTHER|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
219407091|NCT05920187|OTHER|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti\_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
219407092|NCT06121700|RADIATION|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
219407093|NCT06121700|RADIATION|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
219407094|NCT06121700|BIOLOGICAL|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
219407095|NCT06121700|BIOLOGICAL|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
219407096|NCT06121700|DRUG|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
219407097|NCT06121700|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
219002466|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
219002467|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
219407098|NCT06121700|PROCEDURE|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
219407099|NCT06121700|PROCEDURE|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
219190040|NCT05783635|BEHAVIORAL|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
219190041|NCT04016545|DEVICE|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
219002468|NCT06502574|OTHER|mobile application|The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
219407100|NCT02930798|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)"
219407101|NCT00861484|DRUG|GSK958108|Coated Tablets 1 mg
219407102|NCT00861484|DRUG|Placebo|Coated tablets
219407103|NCT03633786|PROCEDURE|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
219407104|NCT03633786|PROCEDURE|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
219407105|NCT03633786|DIAGNOSTIC_TEST|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
219407106|NCT03633786|DIAGNOSTIC_TEST|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
219407107|NCT03633786|DIAGNOSTIC_TEST|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
219407108|NCT00411788|DRUG|Rapamycin|oral rapamycin 6 mg daily
219407109|NCT00411788|DRUG|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
219407110|NCT02843334|BIOLOGICAL|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
219407111|NCT02876939|OTHER|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
219407112|NCT02876939|OTHER|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
219407113|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid with no oxytocin will be delivered in 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
219002469|NCT00205790|DEVICE|Vascular graft|
219190042|NCT05152628|DRUG|Tacrolimus granules|Oral
219190043|NCT05152628|DRUG|Tacrolimus granules|Oral
219407114|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Participants weighing less than 40 kg (88 pounds) will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
219407115|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Participants weighing more than 40 kg (880 pounds) will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
219407116|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and Empathy and Theory of Mind task (EmpaTom task will administered pre- and post-administration of oxytocin.
219407117|NCT03783650|BEHAVIORAL|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
219407118|NCT03783650|BEHAVIORAL|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
219407119|NCT03783650|BEHAVIORAL|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
219407120|NCT03783650|BEHAVIORAL|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
219755906|NCT03370315|OTHER|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
219002470|NCT01613729|DRUG|Rosuvastatin 5 mg|Rosuvastatin 5 mg
219190044|NCT06278285|OTHER|Blood GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
219002471|NCT01613729|DRUG|Rosuvastatin 10 mg|
219002472|NCT00439244|DRUG|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
219002473|NCT00439244|DRUG|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
219407121|NCT03783650|BEHAVIORAL|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
219407122|NCT06370936|OTHER|Standardized diet with commercially available animal meats (comparator products)|Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
219407123|NCT06370936|OTHER|Standardized diet with commercially available PBMAs (intervention products)|Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
219407124|NCT04905381|BEHAVIORAL|Usual care|This arm receives usual care (control group)
219407125|NCT04905381|BEHAVIORAL|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
219407126|NCT01332812|DRUG|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
219407127|NCT01332812|OTHER|control group|General anesthesia, without additional interventions
219407128|NCT04855565|DRUG|ALY688-SR|single dose subcutaneous injection
219407129|NCT06154031|BEHAVIORAL|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
219407130|NCT02311855|BIOLOGICAL|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
219407131|NCT01533935|DRUG|Placebo|placebo matching tiotropium + olodaterol
219407132|NCT01533935|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
219407133|NCT01533935|DRUG|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
219407134|NCT01533935|DRUG|Tiotropium|tiotropium
219407135|NCT01533935|DRUG|Olodaterol|Olodaterol 5 mcg once daily
219407136|NCT01533935|DEVICE|Respimat|Respimat inhaler
219755907|NCT03370315|OTHER|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
219190045|NCT06278285|OTHER|Blood No treated GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
219190046|NCT02211859|DRUG|BI 2536|
219407137|NCT03916250|DRUG|PF-06700841 cream|PF-06700841 will be applied topically
219407138|NCT03916250|DRUG|White petrolatum|White petrolatum will be applied topically
219407139|NCT01316601|DRUG|QAX567|
219407140|NCT01600183|DEVICE|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
219407141|NCT01600183|PROCEDURE|cast|casting of the infant legs
219407142|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
219407143|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
219407144|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
219002474|NCT00439244|DRUG|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
219002475|NCT03655691|BIOLOGICAL|Vehicle|Vehicle Formulation
219407145|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
219407146|NCT03258346|OTHER|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
219407147|NCT03258346|DIETARY_SUPPLEMENT|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
219407148|NCT03258346|DIETARY_SUPPLEMENT|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
219407149|NCT01281852|DRUG|Cisplatin|Given IV
219407150|NCT01281852|OTHER|Laboratory Biomarker Analysis|Correlative studies
219407151|NCT01281852|DRUG|Paclitaxel|Given IV
219407152|NCT01281852|DRUG|Veliparib|Given PO
219567736|NCT06616233|DEVICE|Remote Ischaemic Conditioning with exercise|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.
219567737|NCT06616233|DEVICE|Other: Remote Ischaemic Conditioning|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.
219567738|NCT02251977|DRUG|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
219567739|NCT02251977|DRUG|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
219567740|NCT02251977|DRUG|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
219567741|NCT04973098|BIOLOGICAL|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
219567742|NCT02199119|BEHAVIORAL|Exercise|30 min of moderate exercise on a treadmill
219567743|NCT02199119|BEHAVIORAL|TV viewing|watching TV (animated children's programming) for 30 min
219567744|NCT02199119|BEHAVIORAL|Sitting quietly|Sitting quietly for 30 min
219755908|NCT04237584|DRUG|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
219755909|NCT04237584|DRUG|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
219002476|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
219407153|NCT01879670|DEVICE|CircuLite Synergy left ventricular assist device|
219407154|NCT01289626|DRUG|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
219755910|NCT04237584|DRUG|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
219755911|NCT04237584|DRUG|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
219407155|NCT01289626|DRUG|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
219407156|NCT00702156|DRUG|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
219407157|NCT00702156|DRUG|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
219407158|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all participants recorded by a digital thermometer at the time of survey.
219567745|NCT02004067|DRUG|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
219567746|NCT02004067|DRUG|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
219567747|NCT01491633|DRUG|Dasatinib|140 mg orally, daily in 28 day cycles
219567748|NCT05220969|GENETIC|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
219407159|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
219407160|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
219407161|NCT03810209|DRUG|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
219407162|NCT03810209|DRUG|Normal saline|adding normal saline to local anaesthetic in SAP block
219002477|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
219407163|NCT00489840|DRUG|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
219407164|NCT00489840|DRUG|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
219407165|NCT00681538|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
219407166|NCT00681538|DRUG|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
219407167|NCT03587038|DRUG|OKN 007|400 mg OKN-007/mL in a phosphate buffer
219407168|NCT03587038|DRUG|Temozolomide|75 mg/m2
219407169|NCT03587038|RADIATION|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
219407170|NCT05434689|DRUG|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
219407171|NCT05434689|DRUG|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
219002478|NCT00002136|DRUG|Tecogalan sodium|
219002479|NCT00386945|BEHAVIORAL|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
219002480|NCT05218460|DEVICE|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
219002481|NCT04674410|DRUG|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
219002482|NCT03267108|COMBINATION_PRODUCT|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
219002483|NCT03267108|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
219002484|NCT03267108|COMBINATION_PRODUCT|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
219002485|NCT03982628|DIAGNOSTIC_TEST|Abdominal CT imaging|Routine abdominal CT imaging
219002486|NCT06971055|DRUG|Sodium hypochlorite|sodium hypochlorite solution will be used as a root canal irrigant during pulpectomy in primary molars. A volume of 3 mL will be delivered into each canal using a syringe with a side-vented needle. Irrigation will be followed by microbial sampling for blood agar
219407172|NCT05434689|DRUG|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
219407173|NCT05434689|DRUG|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
219407174|NCT00630812|DRUG|inhaled mannitol|400 mg BD for 26 + 26 weeks
219407175|NCT00630812|DRUG|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
219567749|NCT04581876|DRUG|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
219567750|NCT04581876|DRUG|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
219567751|NCT01772355|DEVICE|semi automated core needle biopsy of orbital tumors|
219567752|NCT02676791|DRUG|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
219567753|NCT00625755|BIOLOGICAL|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
219002487|NCT06971055|BIOLOGICAL|Moringa Oleifera Leaf Extract|extract of Moringa oleifera leaves will be used as an intracanal irrigant during pulpectomy. A volume of 3 mL will be used per canal, and post-irrigation microbial samples will be analyzed using the same methods as the control group.
219002488|NCT02061982|DIETARY_SUPPLEMENT|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
219407176|NCT03868709|DRUG|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
219407177|NCT03868709|DRUG|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
219407178|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
219407179|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
219407180|NCT06458439|DRUG|Epcoritamab|"* C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection"
219002489|NCT00221585|BEHAVIORAL|Psychosocial treatment/Psychodynamic treatment|
219002490|NCT00225173|DRUG|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
219002491|NCT00225173|DRUG|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
219002492|NCT00225173|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
219002493|NCT00225173|DRUG|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
219407181|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
219407182|NCT05946395|DEVICE|Hearing aid|Fitting a hearing aid
219407183|NCT05946395|OTHER|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
219567754|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
219567755|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
219567756|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
219002494|NCT00225173|DRUG|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
219002495|NCT00225173|DRUG|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
219002496|NCT00225173|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
219002497|NCT00225173|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
219002498|NCT00225173|DRUG|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
219002499|NCT04138654|DIETARY_SUPPLEMENT|Processed meat product|300 grams per day during 2 weeks
219002500|NCT04138654|DIETARY_SUPPLEMENT|White meat wash-out|300 grams per day during 2 weeks
219002501|NCT04138654|DIETARY_SUPPLEMENT|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
219407184|NCT04824196|OTHER|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
219567757|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
219567758|NCT04813562|BIOLOGICAL|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
219567759|NCT04813562|BIOLOGICAL|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
219567760|NCT04813562|BIOLOGICAL|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
219002502|NCT04138654|DIETARY_SUPPLEMENT|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
219002503|NCT07131423|DEVICE|Standard extracorporeal shock wave therapy|ESWT was performed using the Swiss DolorClast Master ESWT device in accordance with the guidelines of the International Society of Medical Shockwave Therapy. The treatment was carried out by a physical therapist with at least 5 years of ESWT experience. The patient sat with the shoulder abducted at 45°, the elbow flexed at 90°, and the forearm supinated. The shock waves were delivered in a circular motion, targeting the 2-3 most painful tender points within a 3 cm radius centered on the lateral epicondyle. A total of 2,500 pulses were administered per session (0.2 to 2 bar, 8 Hz, 2,500 pulses, with intensity adjusted according to the patient's tolerance). All patients received a total of 4 ESWT sessions, once every 5 days, over a period of 3 weeks.
219190047|NCT05444881|BEHAVIORAL|Mindfulness-based Intervention (Headspace TM)|"A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages)."
219190048|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
219190049|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
219567761|NCT04813562|BIOLOGICAL|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
219567762|NCT02137694|OTHER|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
219567763|NCT00003430|DRUG|L-778,123|
219567764|NCT03321994|DEVICE|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
219567765|NCT03321994|DEVICE|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
219567766|NCT05861219|BEHAVIORAL|water immersion|mild physical activity then water immersion in tub
219567767|NCT05164913|OTHER|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
219567768|NCT03439579|BEHAVIORAL|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
219567769|NCT00467987|DRUG|androgel|androgel 1%
219567770|NCT00467987|DRUG|placebo|placebo
219567771|NCT02776553|OTHER|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
219567772|NCT02776553|BEHAVIORAL|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
219567773|NCT02776553|BEHAVIORAL|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
219567774|NCT01396382|RADIATION|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
219755912|NCT04237584|DRUG|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
219755913|NCT04237584|DRUG|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
219755914|NCT01092221|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, BID
219755915|NCT01092221|DRUG|Placebo|Placebo 1 capsule, 300 mg, BID
219755916|NCT03586973|DRUG|Cabozantinib|Cabozantinib tablet
219755917|NCT06672822|DRUG|Sodium Thiosulfate (STS)|Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
219407185|NCT04824196|OTHER|propriocetion exercise|"1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
219407186|NCT05195333|OTHER|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
219407187|NCT05195333|OTHER|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
219407188|NCT02894047|BIOLOGICAL|blood|measurement of CaSR expression levels on synovial fluid monocytes
219407189|NCT02935634|BIOLOGICAL|Nivolumab|Specified dose on specified days
219407190|NCT02935634|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219407191|NCT02935634|BIOLOGICAL|Relatlimab|Specified dose on specified days
219407192|NCT02935634|BIOLOGICAL|BMS-986205|Specified dose on specified days
219407193|NCT02935634|DRUG|Rucaparib|Specified dose on specified days
219407194|NCT06638021|BEHAVIORAL|Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)|The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
219407195|NCT05647902|DIAGNOSTIC_TEST|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
219407196|NCT02014935|OTHER|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
219407197|NCT06374264|DEVICE|MR-C-014|Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
219567775|NCT03762746|DEVICE|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
219190050|NCT00619879|OTHER|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
219407198|NCT04855201|DRUG|Bocidelpar|Oral
219407199|NCT04855201|DRUG|Placebo|Oral
219567776|NCT03762746|DRUG|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
219567777|NCT05304026|DEVICE|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
219567778|NCT05304026|DEVICE|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
219567779|NCT05304026|DEVICE|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
219567780|NCT05304026|DEVICE|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
219567781|NCT00190580|DRUG|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
219567782|NCT00190580|DRUG|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
219407200|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
219407201|NCT04779229|BEHAVIORAL|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
219407202|NCT04779229|BEHAVIORAL|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions \[community service; detention\] if conditions are not being followed).
219407203|NCT04493411|PROCEDURE|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
219407204|NCT04493411|PROCEDURE|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
219407205|NCT05403944|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
219407206|NCT05403944|BEHAVIORAL|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
219407207|NCT06075706|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
219407208|NCT06075706|BIOLOGICAL|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
219407209|NCT05701904|OTHER|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
219407210|NCT05701904|OTHER|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
219407211|NCT03430245|DEVICE|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
219407212|NCT03430245|DEVICE|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
219407213|NCT01208896|DRUG|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
219407214|NCT05983003|PROCEDURE|endoscopic sinus surgery|Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
219567783|NCT02012231|DRUG|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
219567784|NCT02123420|DEVICE|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium)."
219567785|NCT00171340|DRUG|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
219567786|NCT00171340|DRUG|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
219567787|NCT02235584|DRUG|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
219407215|NCT06129604|DRUG|TPST-1495|Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
219407216|NCT05628181|BEHAVIORAL|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
219407217|NCT05453396|BIOLOGICAL|Loncastuximab Tesirine|Given IV
219407218|NCT04937478|OTHER|Observation|Only observational study, no intervention.
219407219|NCT02532361|DEVICE|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
219407220|NCT02532361|PROCEDURE|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
219407221|NCT00610727|DRUG|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
219407222|NCT00610727|DRUG|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
219407223|NCT00610727|DRUG|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
219407224|NCT00610727|DRUG|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
219407225|NCT00610727|DRUG|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
219407226|NCT00610727|DRUG|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
219407227|NCT00610727|DRUG|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
219407228|NCT00610727|DRUG|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
219407229|NCT06142422|PROCEDURE|stimulation device|"The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation."
219407230|NCT04150822|OTHER|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
219407231|NCT06565338|DRUG|Dexmedetomidine|drug
219407232|NCT06565338|DRUG|Vitamin D3|drug
219407233|NCT05518305|DIAGNOSTIC_TEST|Medical Imaging|magnetic resonance imaging
219407234|NCT05374174|DIAGNOSTIC_TEST|Tardieu Scale for Spasticity|The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
219407235|NCT04301843|DRUG|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
219407236|NCT03656926|DRUG|Liposomal Cyclosporine A|"This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm.~The L-CsA was administered as 10 mg/2.4 mL inhalation via the PARI eFlow device BID (morning/evening, approximately 12 hours apart) for 48 weeks. Nebulization time per inhalation dose was approximately 6 to 17 minutes.~Patients received training on the use of the device and the first dose of L-CsA was self-administered by each patient under the supervision of trained personnel. In addition, during all subsequent scheduled visits the L-CsA inhalation was self-administered by the patient and under the supervision of trained study personnel."
219567788|NCT00006245|DRUG|alvocidib|
219567789|NCT00006245|DRUG|paclitaxel|
219567790|NCT05717244|DEVICE|2WIN-S|Determining pupil diameter by 2WIN-S
219567791|NCT05717244|DEVICE|OPD|Determining pupil diameter by OPD
219567792|NCT00316394|DEVICE|Preventive Care Checklist Form|
219567793|NCT02930629|DEVICE|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~* Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~* The TOF force transducer will be placed on the volar aspect of the thumb.~* The TOF Watch leads will be attached to the ECG electrodes.~* A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~* Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
219567794|NCT02845726|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
219567795|NCT01056640|DEVICE|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
219567796|NCT01056640|OTHER|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
219567797|NCT05601960|OTHER|anti-acne dermocosmetic|Topical application once daily for 2 months
219567798|NCT01720420|DEVICE|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
219567799|NCT03030326|BEHAVIORAL|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
219190051|NCT00619879|RADIATION|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) \< 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~* Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~* Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
219407237|NCT03656926|DRUG|Standard of Care|"Standard of Care Therapy (SoC). The SoC included maintenance immunosuppressive medication including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent; but also a prophylaxis against common opportunistic infections, and all other necessary medications and therapies for the optimal care of the patient.~This also included vaccination against COVID-19 All changes in concurrent treatment or medication were administered according to site's SoC.~The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, should be on a stable regimen for a least 4-weeks prior to randomization and continued to receive azithromycin during the trial as deemed appropriate by the investigator."
219407238|NCT05472233|PROCEDURE|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
219190052|NCT05338606|DRUG|Bimatoprost Sustained Release Implant|Intraocular Implant
219190053|NCT06127459|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
219190054|NCT06127459|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
219407239|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.
219407240|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
219407241|NCT01194557|DEVICE|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
219407242|NCT01194557|DRUG|Lumartem|Presumptive treatment of malaria/fever
219407243|NCT03965663|DEVICE|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
219407244|NCT02114333|BIOLOGICAL|Zostavax|0.65ml, subcutaneous
219407245|NCT02114333|BIOLOGICAL|HZ/su vaccine|0.5ml, intramuscular
219407246|NCT02114333|BIOLOGICAL|Placebo|0.65ml, subcutaneous
219407247|NCT03764202|OTHER|Detection of sufentanil concentration|"* Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point"
219407248|NCT02558816|DRUG|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
219407249|NCT06205147|DEVICE|Elastic Band|Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
219407250|NCT05065801|COMBINATION_PRODUCT|GEMBRAX/FOLFIRINOX Arm A|Patients in the experimental arm received sequential treatment: A maximum of 6 cycles (12 months) of chemotherapy; One cycle = 3 administrations of GEMBRAX followed by 2 administrations of FOLFIRINOX
219407251|NCT05065801|COMBINATION_PRODUCT|FOLFIRINOX Arm B|Patients in this arm received : A maximum of 3 cycles (6 months) of chemotherapy. One cycle = 4 administrations of FOLFIRINOX
219407252|NCT06214910|OTHER|Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)|Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment.
219407253|NCT06214910|OTHER|Clinic-link TPT|Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills).
219407254|NCT04995224|OTHER|Assessment of Psychophysiological factors|Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
219407255|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
219407256|NCT04995224|GENETIC|Assessment of Genetics|Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
219190055|NCT06149663|DRUG|LP352|LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
219407257|NCT04995224|BEHAVIORAL|Assessment of Quality of Life|Investigating QOL by questionnaires.
219407258|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
219407259|NCT05610176|DEVICE|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
219407260|NCT04207619|OTHER|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
219407261|NCT04207619|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
219407262|NCT05929755|DRUG|Depo-Medrol|steroid
219407263|NCT05929755|DRUG|Gel-Flow NT|hemostatic agent
219407264|NCT06549257|BIOLOGICAL|Pfs25-IMX313, Pfs48/45|Two soluble protein vaccines.
219407265|NCT05813431|OTHER|FRENCH grid (classification for emergency nurses in French hospitals)|Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.
219407266|NCT05813431|OTHER|QuickSOFA|Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.
219407267|NCT05813431|OTHER|Capillary lactate assessment|Collect a drop of blood from the fingertip (less than 1 ml)
219407268|NCT01353833|DRUG|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
219407269|NCT06601712|OTHER|Adherence support strategy A|Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs
219407270|NCT06601712|OTHER|Adherence support strategy B|SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs
219407271|NCT06601712|OTHER|Control|No reminders
219407272|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
219407273|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
219407274|NCT01180374|DRUG|Cannabidiol|Active Cannabidiol 5mg.
219407275|NCT01180374|DRUG|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
219407276|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
219567800|NCT05015374|DIETARY_SUPPLEMENT|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
219567801|NCT05015374|DIETARY_SUPPLEMENT|Placebo|Placebo
219567802|NCT00867841|PROCEDURE|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
219567803|NCT01709812|OTHER|individualized patient support program|individualized patient support with compliance supporting tools
219190056|NCT04566237|PROCEDURE|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
219407277|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
219407278|NCT06034938|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Switch previous therapy with DOR/TDF/3TC
219407279|NCT00398541|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
219567804|NCT01709812|OTHER|Standard care|
219567805|NCT04028154|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
219567806|NCT04028154|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
219567807|NCT00668447|DIETARY_SUPPLEMENT|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
219567808|NCT00668447|DIETARY_SUPPLEMENT|Control protein|20 grams of powder mixed in beverages or food daily for one year
219190057|NCT04566237|PROCEDURE|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
219407280|NCT03257072|BIOLOGICAL|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
219407281|NCT03257072|BIOLOGICAL|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
219407282|NCT03257072|BIOLOGICAL|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
219407283|NCT06247592|PROCEDURE|Greater occipital nerve block|Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
219567809|NCT00668447|DIETARY_SUPPLEMENT|Novasoy isoflavones|3 tablets daily for one year
219567810|NCT00668447|DIETARY_SUPPLEMENT|Placebo tablets|3 tablets daily for one year
219407284|NCT06247592|PROCEDURE|Greater occipital nerve pulse radiofrequency|The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
219407285|NCT01375504|BEHAVIORAL|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
219407286|NCT01375504|BEHAVIORAL|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
219407287|NCT02065310|OTHER|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
219002504|NCT07131423|DEVICE|CC points shock wave therapy|The assessment was conducted by a 5-year or more experienced FM therapist, following the standard procedure of the FM organization. The process included conducting interviews, filling out assessment forms, performing movement checks, and conducting palpation. Four CC points covering the entire upper limb, including the shoulder area, were selected. The points were ranked based on the severity of the dense touch. The blackboard pen was used to mark the points on the patient's body. The same ESWT therapist as in Group A used the same shock wave treatment instrument to treat the four CC points. The most severe point received 800 shocks, the second most received 700 shocks, and the remaining two points each received 500 shocks. A total of 2,500 pulses (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity adjusted according to the depth of the point and the patient's tolerance) were administered. This treatment was performed once every 5 days for 3 weeks.
219002505|NCT07131423|DEVICE|Shock wave therapy for the CC points and the lateral epicondyle|Carry out the same process as Group B, but only select the three most severe CC points for shock therapy. Also, rank them according to the severity of the touch examination-induced densification. The most severe point receives 600 pulses, the second most severe receives 500 pulses, and the third most severe receives 400 pulses. At the same time, treat the lateral epicondylitis pain area in the same way as Group A. Apply 1000 pulses to the pain area. The total number of shocks for all treatments is 2500 (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity is adjusted according to the depth of the point and the patient's tolerance). The therapist performing the treatment is the same as those in Group A and Group B. The treatment is carried out once every 5 days for 3 weeks.
219407288|NCT01687738|OTHER|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
219407289|NCT01687738|OTHER|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
219567811|NCT06214416|BEHAVIORAL|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
219567812|NCT06214416|BEHAVIORAL|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
219002506|NCT05353985|DRUG|TAK-062|TAK-062 tablets.
219002507|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
219002508|NCT05353985|DRUG|TAK-062 Placebo|TAK-062 placebo-matching tablets.
219002509|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
219190058|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
219190059|NCT06584721|OTHER|Anti-pronation taping (Low dye taping) + Conventional therapy|"They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week."
219190060|NCT06584721|OTHER|Short Foot Exercises + Conventional PT|"They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week."
219755918|NCT07073781|DIETARY_SUPPLEMENT|Lab4p Probiotic Consortium|"The investigational product in this study is Lab4P, a patented multi-strain probiotic consortium formulated as a food supplement and supplied in capsule form. Each daily dose contains a total of 5 × 10¹⁰ CFU of live bacteria, comprising five strains: Lactobacillus acidophilus CUL60 and CUL21, Lactobacillus plantarum CUL66, Bifidobacterium bifidum CUL20, and Bifidobacterium animalis subsp. lactis CUL34. In addition to probiotics, each capsule also contains three micronutrients at 100-200% of the recommended daily intake: Vitamin D (10 µg; 200%), Vitamin C (80 mg; 100%), and Zinc (10 mg; 100%).~Lab4P is a marketed, human-approved product manufactured by Cultech Ltd. (Port Talbot, UK) and is classified as a food supplement, available for purchase without prescription. Both the active product and placebo will be identically packaged to maintain blinding."
219190061|NCT06585228|DIAGNOSTIC_TEST|Cardiac Computed Tomography|Cardiac CT acquired during the acute stroke imaging protocol
219407290|NCT02327286|BEHAVIORAL|Promote and support healthy behaviors|"* Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
219190062|NCT06585228|DIAGNOSTIC_TEST|Transesophageal echocardiography|Ultrasound through the oesophagus to assess cardiac structures.
219190063|NCT06585228|DIAGNOSTIC_TEST|Repeated Cardiac Computed Tomography|A second cardiac CT performed after the TEE.
219190064|NCT04985955|DRUG|Tofacitinib|Tofacitinib tablet will be administered orally.
219190065|NCT02538809|OTHER|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
219407291|NCT05267353|BEHAVIORAL|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
219002510|NCT07002476|DRUG|guideline-recommended SoC|Guideline-recommended SoC, including but not limited to oral lipid-lowering drugs, antiplatelet aggregation drugs, anticoagulant drugs, antihypertensive drugs, etc. It is to be determined by the investigator based on the subject's treatment needs.
219190066|NCT03911141|BEHAVIORAL|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
219407292|NCT00528346|BEHAVIORAL|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
219407293|NCT00528346|BEHAVIORAL|placebo|Some participants will see simulated data that does not come from their own brains.
219407294|NCT00006222|DRUG|cilengitide|
219755919|NCT07073781|OTHER|Placebo|Placebo capsules are composed of microcrystalline cellulose, and are identical in appearance to the test product.
219002511|NCT07002476|DRUG|Recaticimab (intensive)|Recaticimab is added to the guideline-recommended SoC. After randomization and before endovascular interventional treatment, patients will receive a subcutaneous injection of Recaticimab. The specific method is: Recaticimab 450 mg (3 vials) as a single subcutaneous injection, until the end of the follow-up for this study.
219002512|NCT07002684|DRUG|Esketamine|nasal
219002513|NCT07131085|DRUG|Allogeneic TCR-enhanced γδ T cell(QH101)|dose escalation (3+3) : dose 1 (5×10\^8 enTCR γδ cells) , dose 2 (1.5×10\^9 enTCR γδ cells), dose 3 (3×10\^9 enTCR γδ cells)
219002514|NCT07131085|DRUG|Fludarabine (FLU)|Intravenous fludarabine 20\~30 mg/m\^2/day on days -5, -4, and -3
219002515|NCT07131085|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 300\~500 mg/m\^2/day on days -5, -4, and -3.
219407295|NCT03326219|PROCEDURE|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
219407296|NCT01087528|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
219755920|NCT06752551|BEHAVIORAL|Apprehension-based training|"This intervention is comprised of the 3 phases:~Static phase - Isometric (static) exercises performed in progressively greater shoulder apprehension (instability) provoking conditions Dynamic phase: Isotonic (dynamic) exercises using shoulder apprehension-provoking movement patterns at a gradually increasing pace of movement.~Neurocognitive phase: Dynamic phase exercises are continued at a high pace with the addition of cognitive tasks (distractions).~The intervention is guided by a physical therapist and includes up to 8 individual (one on one) sessions. In each session the physical therapist assesses exercise performance quality and when appropriate progresses exercise intensity and/or phase. Patients are expected to perform home exercises according to their phase of the program on a daily basis in between physical therapy sessions."
219755921|NCT06752551|BEHAVIORAL|Standard physical therapy|Standard physical will be provided based on the assessment and judgment of the physical therapist. Intervention may include active exercises for increased shoulder mobility, muscle strength and neuromuscular control. Intervention may also include manual therapies such as massage, soft-tissue and joint mobilizations, dry needling, and electrophysiological modalities. No more than 8 individual sessions with a physical therapist will be provided over the course of treatment with some form of a home exercise program in between.
219755922|NCT00152438|DRUG|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
219755923|NCT00152438|OTHER|Placebo|3 identical placebo pills daily, no active ingredient.
219755924|NCT06792799|BIOLOGICAL|anti-CD19/BCMA CAR NK cells (KN5601)|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5601) will infused in each group using the 3 + 3 dose-escalation strategy."
219755925|NCT05475366|OTHER|Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC|Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.
219407297|NCT03775018|PROCEDURE|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
219407298|NCT03775018|DRUG|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
219407299|NCT05580172|DRUG|RH324|polymolecular
219407300|NCT01899404|BIOLOGICAL|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
219755926|NCT05475366|OTHER|Biomarkers of tumor signatures (translational studies)|Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
219190067|NCT03911141|BEHAVIORAL|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
219190068|NCT05451979|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
219190069|NCT04657042|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Four-dimensional MRI of torso
219407301|NCT01519622|OTHER|Questionnaire|Questionnaire to be distributed among sick elderly in the community
219407302|NCT01831934|BIOLOGICAL|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
219407303|NCT00436969|DEVICE|Orthovisc|Orthovisc injection
219407304|NCT00436969|DRUG|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
219407305|NCT03020758|DIETARY_SUPPLEMENT|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
219407306|NCT03020758|OTHER|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
219407307|NCT01601054|DEVICE|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
219407308|NCT03838172|OTHER|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
219407309|NCT05749926|BIOLOGICAL|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
219407310|NCT05749926|BIOLOGICAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
219407311|NCT00905307|DRUG|OPC-34712|oral, once daily
219407312|NCT00905307|DRUG|Placebo|Placebo
219407313|NCT00905307|DRUG|Aripiprazole|oral, once daily
219407314|NCT05556733|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
219407315|NCT00005117|DRUG|pravastatin|
219407316|NCT03978819|DEVICE|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
219567813|NCT03142659|OTHER|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
219567814|NCT01930175|DRUG|VAY736|
219567815|NCT01930175|DRUG|Placebo|
219755927|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
219567816|NCT02592759|DEVICE|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
219567817|NCT00834899|DRUG|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
219567818|NCT00834899|DRUG|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
219567819|NCT02820740|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
219567820|NCT01651546|BEHAVIORAL|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
219567821|NCT04507594|PROCEDURE|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
219567822|NCT06278038|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
219567823|NCT06278038|DRUG|Venlafaxine hydrochloride sustained-release tablets|75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
219567824|NCT04301245|OTHER|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
219755928|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
219755929|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
219755930|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
219002516|NCT07132216|DEVICE|Meta Quest 2 VR headset|The Meta Quest 2 VR headset with built-in headphones was used. Patients selected VR environments from a predefined list of five nature scenes (beach, forest, mountain, underwater, and meadow) with identical meditation audio tracks lasting 30 minutes each. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/)featured 360-degree nature environments with standardized calming background music and guided meditation narration. VR was applied immediately after spinal anesthesia and before the surgical incision. Sessions lasted 30 minutes and were discontinued if the patient reported nausea, dizziness, or requested removal.
219002517|NCT06869031|BEHAVIORAL|Standard Interactive Intervention for Hypertension Management|The standard interactive intervention is a doctor-patient interaction intervention conducted by follow-up physicians using an intelligent outbound call system as part of follow-up management. It is implemented once a month and is designed based on the Health Behavior Interaction Model, covering four key aspects: health information (e.g., potential risks of poor self-management behavior), professional skills(e.g., blood pressure measurement, medication guidance), emotional support , and decision-making participation.
219002518|NCT06869031|BEHAVIORAL|Intensified Interactive Intervention for Hypertension Management|The enhanced interactive intervention builds upon the standard interactive intervention by increasing the frequency of interactions. In addition to the monthly intervention, patients receive an additional brief interactive intervention every two weeks via the intelligent outbound call system, reminding them to adhere to self-management behaviors for hypertension control.
219002519|NCT06868719|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
219002520|NCT06868719|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
219002521|NCT06868719|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
219190070|NCT04578249|OTHER|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
219190071|NCT04578249|OTHER|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
219190072|NCT06320171|DEVICE|Non-Invasive neuromodulation|Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.
219407317|NCT03860727|DIAGNOSTIC_TEST|Welch Allyn IExaminer|Fundus Examination
219407318|NCT05255705|OTHER|Observation only|Observation only
219407319|NCT02671695|DRUG|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
219407320|NCT02671695|DRUG|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
219002522|NCT05205421|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
219002523|NCT02656121|DRUG|Vitamin D|6000 IU of vitamin D3
219002524|NCT02656121|DRUG|Ovulatory Agent|only Clomophine Citrate
219002525|NCT02499302|BEHAVIORAL|Mental training|
219407321|NCT01757782|DRUG|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
219407322|NCT01757782|DRUG|Placebo (distilled water)|Distill water oral
219407323|NCT05370599|DRUG|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
219407324|NCT05370599|DRUG|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
219567825|NCT05799027|DIAGNOSTIC_TEST|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
219567826|NCT03409991|BEHAVIORAL|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
219567827|NCT02919826|BEHAVIORAL|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
219567828|NCT03858426|OTHER|no intervention|no intervention
219567829|NCT06180408|OTHER|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
219002526|NCT04953468|DIAGNOSTIC_TEST|expression level of ANXA2 protein|The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
219190073|NCT06320171|OTHER|Placebo|The placebo group followed the same procedure, except that no current was applied during their 20-minute session.
219190074|NCT05724797|DRUG|NRS-033|A single dose of NRS-033 will be administered
219190075|NCT05724797|DRUG|Placebo|A single dose of matching placebo will be administered
219190076|NCT04100408|OTHER|Biospecimen Collection|Undergo saliva or buccal mucosa collection
219190077|NCT04100408|OTHER|Laboratory Biomarker Analysis|Correlative studies
219190078|NCT04100408|OTHER|Questionnaire Administration|Ancillary studies
219407325|NCT05370599|DRUG|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
219002527|NCT04638023|DEVICE|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
219407326|NCT05370599|DEVICE|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
219407327|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
219407328|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
219407329|NCT04898738|OTHER|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
219002528|NCT01113983|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
219002529|NCT05725811|OTHER|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
219002530|NCT03276884|OTHER|Experimental Infant Formula|amino acid-based infant formula powder
219002531|NCT03276884|OTHER|Control Infant Formula|amino acid-based infant formula powder
219002532|NCT05066594|DEVICE|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
219002533|NCT00254813|DRUG|Quetiapine|
219002534|NCT02518828|OTHER|High SpO2|SpO2 range ≥96%
219002535|NCT02518828|OTHER|Low SpO2|SpO2 range 90-92%
219002536|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
219002537|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
219002538|NCT01616524|BIOLOGICAL|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
219567830|NCT06180408|OTHER|lumbar stabilization exercise|core training and myofascial release therapy
219002539|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
219002540|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
219407330|NCT06039761|PROCEDURE|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
219407331|NCT05465733|DRUG|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
219407332|NCT06157502|DRUG|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
219407333|NCT06157502|OTHER|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
219407334|NCT01864018|DRUG|Cyclophosphamide|Given PO
219407335|NCT01864018|DRUG|Dexamethasone|Given PO
219407336|NCT01864018|DRUG|Ixazomib Citrate|Given PO
219567831|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
219567832|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
219567833|NCT03658473|DRUG|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
219567834|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
219567835|NCT03658473|DRUG|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
219567836|NCT00925301|DRUG|migalastat hydrochloride|Oral capsule QOD
219567837|NCT00925301|DRUG|Placebo|Oral capsule QOD
219567838|NCT04062994|BEHAVIORAL|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
219567839|NCT04890080|OTHER|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
219567840|NCT03043560|DRUG|Ezogabine|daily for 5 weeks
219567841|NCT03043560|DRUG|Placebos|placebo pill daily for 5 weeks
219567842|NCT02662166|DEVICE|MR imaging|3 T MRI of the urinary bladder
219567843|NCT01117766|DRUG|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
219567844|NCT01117766|DRUG|Placebo|BID dosing for 28 days
219567845|NCT05310617|OTHER|Survey|Survey on the parental project and its realisation
219567846|NCT00438659|DRUG|mometasone furoate|Applied to treatment area
219567847|NCT00438659|OTHER|placebo|Applied to treatment area
219567848|NCT03195452|DRUG|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
219002541|NCT01616524|DRUG|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
219407337|NCT01864018|OTHER|Laboratory Biomarker Analysis|Correlative studies
219567849|NCT02312479|DEVICE|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
219002542|NCT01616524|DRUG|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
219002543|NCT01617174|BEHAVIORAL|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
219002544|NCT02137733|DRUG|Bisoprolol|
219190079|NCT06100666|BEHAVIORAL|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
219190080|NCT05333393|BEHAVIORAL|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
219190081|NCT02070549|DRUG|Trametinib|Given PO
219567850|NCT05482425|OTHER|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
219567851|NCT00003822|DRUG|apomine|
219407338|NCT01864018|OTHER|Pharmacological Study|Correlative studies
219407339|NCT01864018|OTHER|Quality-of-Life Assessment|Ancillary studies
219567852|NCT01358396|OTHER|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
219567853|NCT00494351|PROCEDURE|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
219567854|NCT00294892|DRUG|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
219567855|NCT00294892|DRUG|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
219567856|NCT05335083|DEVICE|CPAP|A positive CPAP intervention
219567857|NCT01109758|DRUG|Fenofibrate|145 mg
219567858|NCT04771247|PROCEDURE|Cardia Band Ligation|Patients will undergo cardia band ligation at the level of the GEJ.
219567859|NCT00042549|DEVICE|Extracorporeal Shock Wave Lithotripsy|
219567860|NCT00042549|DRUG|ursodiol|
219567861|NCT03069417|BEHAVIORAL|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
219002545|NCT02137733|DRUG|Carvedilol|
219002546|NCT00999583|DRUG|EPOETINE ALPHA|5 injections of 40000 UI of EPO
219002547|NCT00999583|OTHER|Control arm|Usual take care of cardiac arrest
219002548|NCT00275184|DRUG|Senna|
219407340|NCT01864018|OTHER|Questionnaire Administration|Ancillary studies
219407341|NCT03316391|OTHER|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
219567862|NCT03754387|DRUG|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
219567863|NCT03754387|PROCEDURE|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
219567864|NCT02571309|DEVICE|Asthmatuner|Asthmatuner is an app for self-management of asthma.
219567865|NCT00987142|DRUG|CX501|Cultured chimeric skin
219567866|NCT00987142|DEVICE|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
219567867|NCT02317250|PROCEDURE|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
219567868|NCT02317250|PROCEDURE|FDG-PET|\[F-18\] FDG-PET brain scans are administered once to all arms.
219567869|NCT01117987|DRUG|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
219567870|NCT01117987|DRUG|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
219002549|NCT00275184|DRUG|Citramag powder|
219002550|NCT00275184|DRUG|Metoclopramide|
219002551|NCT02056782|DRUG|Dociparstat sodium|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
219407342|NCT02777775|PROCEDURE|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~* The skin area will be cleaned~* The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~* Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~* A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
219407343|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
219407344|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
219407345|NCT05057702|OTHER|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
219407346|NCT05057702|OTHER|Combinations|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
219407347|NCT04906889|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
219407348|NCT04906889|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
219407349|NCT04906889|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
219567871|NCT00615524|DRUG|exemestane and pazopanib|
219567872|NCT04991012|DEVICE|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
219002552|NCT02554266|DEVICE|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
219190082|NCT04819334|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
219407350|NCT01507610|DRUG|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
219407351|NCT06257238|DEVICE|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
219407352|NCT06257238|BEHAVIORAL|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
219407353|NCT06316622|DEVICE|ultrasound|measured by ultrasound
219407354|NCT02379741|BIOLOGICAL|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
219407355|NCT04757779|DRUG|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
219407356|NCT02283606|DEVICE|Accuvix SnonAce UGEO|vaginal ultrasonography
219407357|NCT03264482|PROCEDURE|M-TURP|endoscopic resection of the prostatic adenoma
219407358|NCT03264482|PROCEDURE|THUVAP|vaporization of prostatic adenoma via THULIUM laser
219407359|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
219407360|NCT06502964|DRUG|ALTO-101|ALTO-101 patches
219407361|NCT06502964|DEVICE|ALTO-101 Transdermal Delivery System|ALTO-101 transdermal delivery system
219407362|NCT06502964|DRUG|Placebo|Inactive placebo patches
219407363|NCT06502964|DEVICE|Placebo Transdermal Delivery System|Placebo transdermal delivery system
219407364|NCT05574647|DIAGNOSTIC_TEST|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
219407365|NCT05574647|DIAGNOSTIC_TEST|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
219407366|NCT04342715|DRUG|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
219567873|NCT04991012|DRUG|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
219567874|NCT01850719|PROCEDURE|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
219407367|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
219407368|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
219407369|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
219407370|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
219407371|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
219002553|NCT03965910|OTHER|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
219002554|NCT05012839|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
219002555|NCT00002990|BIOLOGICAL|BCG vaccine|
219002556|NCT03349112|BEHAVIORAL|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
219002557|NCT03349112|BEHAVIORAL|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
219002558|NCT01176669|DRUG|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
219002559|NCT00053053|DIETARY_SUPPLEMENT|Juven|
219002560|NCT00053053|DIETARY_SUPPLEMENT|Non-Juven Supplement|
219002561|NCT05951062|BEHAVIORAL|behavior management for anti-hypertensive medication|five sessions of educational interview and home visiting to improve medication-related self-management skills
219002562|NCT05951062|OTHER|placebo group|treatment as usual
219002563|NCT01770626|OTHER|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
219407372|NCT05735717|BIOLOGICAL|Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells|Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
219190083|NCT05105009|DRUG|Furosemide Injection|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
219190084|NCT05105009|DRUG|Creatinine Powder|5g of creatinine (Sigma) in 250 ml of water was taken orally
219190085|NCT05105009|DRUG|Iohexol|5 ml iohexol (Omnipaque) intravenously
219407373|NCT05735717|DRUG|Thymoglobulin|rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.
219407374|NCT05735717|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2
219407375|NCT05562037|OTHER|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
219190086|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
219407376|NCT04188873|DRUG|Preparation Varenicline and Standard Duration Varenicline|16 weeks of varenicline starting 4 weeks pre-quit
219407377|NCT04188873|DRUG|Preparation Varenicline and Extended Duration Varenicline|28 weeks of varenicline starting 4 weeks pre-quit
219407378|NCT04188873|DRUG|Standard Duration Varenicline|12 weeks of varenicline
219407379|NCT04188873|DRUG|Extended Duration Varenicline|24 weeks of varenicline
219407380|NCT04188873|DRUG|Preparation Combination NRT and Standard Duration Combination NRT|16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
219567875|NCT01850719|OTHER|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
219407381|NCT04188873|DRUG|Preparation Combination NRT and Extended Duration Combination NRT|28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
219407382|NCT04188873|DRUG|Standard Duration Combination NRT|12 weeks of nicotine patch + nicotine mini-lozenge
219407383|NCT04188873|DRUG|Extended Duration Combination NRT|24 weeks of nicotine patch + nicotine mini-lozenge
219407384|NCT04188873|BEHAVIORAL|Intensive Counseling|4 phone or video counseling sessions
219407385|NCT04188873|BEHAVIORAL|Minimal Counseling|2 brief phone or video counseling sessions
219407386|NCT05112458|OTHER|Cope 360 mobile health application|Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
219407387|NCT05112458|OTHER|Usual care|Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
219407388|NCT00660504|DRUG|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
219407389|NCT00660504|DRUG|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
219407390|NCT06286956|DEVICE|Treatment of rectal lesions with UNI-VEC|Polyp resections
219407391|NCT06524999|BEHAVIORAL|Progressive muscle relaxation|This intervention consists of two parts. The first part gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are relaxation exercises accompanied. Both the briefing and the intervention lasted 30 minutes for each patient.
219407392|NCT05750498|OTHER|No interventions|There are no interventions
219407393|NCT05413616|BEHAVIORAL|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
219190087|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
219407394|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 1.0 mg/kg/week
219407395|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 2.0 mg/kg/week
219407396|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 4.0 mg/kg/week
219407397|NCT03919292|DRUG|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
219567876|NCT02244424|BEHAVIORAL|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
219407398|NCT03919292|DRUG|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
219407399|NCT02668237|OTHER|OptiPAC|Molecular and urinary tests.
219407400|NCT02668237|OTHER|Usual care|Antibiotics for prevention.
219407401|NCT04028492|DRUG|Tradipitant|BID
219407402|NCT04028492|DRUG|Placebo|BID
219407403|NCT04028492|DRUG|Open Label Tradipitant|BID
219407404|NCT05153733|DEVICE|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
219407405|NCT04742946|OTHER|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
219407406|NCT05610995|DEVICE|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
219567877|NCT04399265|DIETARY_SUPPLEMENT|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
219567878|NCT04399265|DIETARY_SUPPLEMENT|Maltose|Maltose power
219567879|NCT01594034|PROCEDURE|expired air|collection of expired air from ventilator
219567880|NCT01784237|PROCEDURE|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
219407407|NCT04222439|DEVICE|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
219407408|NCT04278729|DRUG|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
219407409|NCT06556277|DRUG|Metyrapone And Hydrocortisone|"Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7"
219407410|NCT06556277|DRUG|Placebo|"Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7"
219407411|NCT03609359|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
219407412|NCT03609359|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, every 3 weeks (25 minutes to 40 minutes are acceptable).
219407413|NCT06643845|PROCEDURE|arthroplasty|In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
219407414|NCT06643845|OTHER|Medical and non-medical treatments|In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
219567881|NCT01784237|PROCEDURE|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
219407415|NCT06268886|DRUG|BMS-986446|Specified dose on specified days
219567882|NCT04117945|BIOLOGICAL|Cetuximab|Given IV
219567883|NCT04117945|DRUG|Irinotecan|Given IV
219755931|NCT06904027|DRUG|Glycerol phenylbutyrate Oral Liquid|"Administration and dosage: The recommended total daily dose of glycerol phenylbutyrate is calculated based on the patient's body surface area, ranging from 4.5 mL/m2/d to 11.2 mL/m2/d:~1. Recommended initial dose in phenylbutyrate-naïve patients~   * Patients with body surface area (BSA) \< 1.3 m2: 8.5 mL/m2/day~  * Patients with body surface area (BSA) ≥ 1.3 m2: 7 mL/m2/day~2. Initial dose for patients switching from sodium phenylbutyrate to glycerol phenylbutyrate: Total daily dose of glycerol phenylbutyrate (ml) = total daily dose of sodium phenylbutyrate granules (g) ×0.81 Medication Schedule: The daily total dose should be divided into equal amounts and administered with each meal or feeding (such as three to six times daily)."
219002564|NCT01499550|DEVICE|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
219407416|NCT06268886|OTHER|Placebo|Specified dose on specified days
219567884|NCT04117945|BIOLOGICAL|Panitumumab|Given IV
219567885|NCT04117945|DRUG|Regorafenib|Given PO
219567886|NCT02838251|OTHER|No intervention|
219567887|NCT04686994|DRUG|ASC 41|Oral tablets
219567888|NCT04686994|DRUG|ASC 41 Placebo|Oral tablets
219567889|NCT06616519|DEVICE|BenQ Materials MSENCI soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
219567890|NCT06616519|DEVICE|Visco Oxypure Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
219567891|NCT06615999|PROCEDURE|Simple fracture Tension band wiring|OPS 5-793.27
219567892|NCT06615999|PROCEDURE|Simple fracture locked plate fixation|OPS 5-793.k7
219755932|NCT04630769|DRUG|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
219567893|NCT06615999|PROCEDURE|Multi-fragmented tension band wiring|OPS 5-794.17
219567894|NCT06615999|PROCEDURE|Multi-fragmented locked plate fixation|OPS 5-794.k7
219567895|NCT01044134|BEHAVIORAL|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
219567896|NCT02617082|RADIATION|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
219567897|NCT05846256|OTHER|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
219567898|NCT02752386|BEHAVIORAL|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
219567899|NCT00402025|BIOLOGICAL|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
219567900|NCT02128009|OTHER|osteoporosis|
219567901|NCT03529565|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219407417|NCT03897920|OTHER|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
219407418|NCT04950582|DIAGNOSTIC_TEST|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
219407419|NCT00083239|DRUG|talabostat (PT-100) tablets|
219407420|NCT02610400|COMBINATION_PRODUCT|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) \> 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
219407421|NCT02610400|COMBINATION_PRODUCT|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
219407422|NCT02610400|COMBINATION_PRODUCT|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) \> 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
219407423|NCT01123278|DRUG|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
219407424|NCT01123278|DRUG|Placebo|Placebo transdermal gel (5 gr)
219407425|NCT01716468|OTHER|Ketogenic Diet|modified ketogenic diet
219407426|NCT06189001|DRUG|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
219407427|NCT06189001|OTHER|Placebo (saline)|Intravenous saline during experimental days
219407428|NCT02833649|DEVICE|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
219407429|NCT05345834|BEHAVIORAL|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
219567902|NCT03529565|OTHER|Laboratory Biomarker Analysis|Correlative studies
219567903|NCT03529565|OTHER|Quality-of-Life Assessment|Ancillary studies
219567904|NCT03529565|OTHER|Questionnaire Administration|Ancillary studies
219567905|NCT03408431|DEVICE|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
219567906|NCT03408431|PROCEDURE|neck extension|Patients' neck will be maximally extended (\~60°) during blind intubation.
219755933|NCT04630769|DRUG|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
219407430|NCT05345834|BEHAVIORAL|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
219407431|NCT03213613|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
219755934|NCT04630769|DRUG|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
219755935|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
219002565|NCT01499550|OTHER|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
219002566|NCT05830851|OTHER|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
219002567|NCT05830851|OTHER|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
219407432|NCT03213613|BEHAVIORAL|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
219567907|NCT05652309|PROCEDURE|spinal block and obturator nerve block|spinal block and obturator nerve block
219567908|NCT00328484|BEHAVIORAL|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
219567909|NCT00328484|BEHAVIORAL|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
219567910|NCT00120276|DEVICE|Less invasive mitral valve repair|
219567911|NCT02188082|DRUG|IvabRadine hemisulfate Sustained-release Tablets|
219567912|NCT02188082|DRUG|placebo|
219567913|NCT02563821|PROCEDURE|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
219567914|NCT02563821|DRUG|Levobupivacaine|
219567915|NCT02563821|DRUG|sufentanil|
219567916|NCT02563821|DRUG|clonidine|
219567917|NCT02563821|DEVICE|epidural catheter|
219567918|NCT06679764|PROCEDURE|Anterior quadratus lumborum block technique (AQLB)|"AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane."
219755936|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
219755937|NCT06909253|DRUG|Ravulizumab|Ravulizumab, concentrate for solution for infusion
219755938|NCT07089511|OTHER|CB3P-ED + 0.1% cyclosporine eye drops|Combination of CB3P-ED + 0.1% cyclosporine eye drops
219755939|NCT07089511|OTHER|0.15% hyaluronic acid + 0.1% cyclosporine eye drops|Combination of 0.15% hyaluronic acid + 0.1% cyclosporine eye drops
219407433|NCT03213613|BEHAVIORAL|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
219407434|NCT03914820|PROCEDURE|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
219407435|NCT03914820|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
219407436|NCT03914820|DRUG|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
219407437|NCT01912729|BEHAVIORAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
219407438|NCT01912729|BEHAVIORAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
219407439|NCT01418664|DIETARY_SUPPLEMENT|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
219407440|NCT03559244|OTHER|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
219407441|NCT03559244|OTHER|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
219407442|NCT02853734|OTHER|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
219567919|NCT06679764|PROCEDURE|Pericapsular Nerve Group (PENG) block|With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
219567920|NCT06679764|DRUG|Control Group|Pataints received opioid analgesia with genaral anesthesia
219407443|NCT02853734|OTHER|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
219407444|NCT05428072|OTHER|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
219407445|NCT05428072|DRUG|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
219407446|NCT06452628|OTHER|Mulligan mobilizations|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.
219407447|NCT06452628|OTHER|Active Release Technique|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.
219407448|NCT06452628|OTHER|Mulligan mobilizations with active release technique|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
219407449|NCT01107756|DRUG|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
219407450|NCT03262597|OTHER|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
219407451|NCT03262597|OTHER|Pedialyte|Subjects will consume Pedialyte
219407452|NCT03262597|OTHER|Gatorade|Subjects will consume Gatorade
219407453|NCT03262597|OTHER|Water|Subjects will consume water as the control beverage
219407454|NCT00427583|DRUG|imatinib mesylate|
219407455|NCT03206034|BEHAVIORAL|Stylistic Memory Enhancement|
219407456|NCT04276311|DEVICE|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
219407457|NCT02244450|BIOLOGICAL|SCID screening|
219407458|NCT01952834|DIETARY_SUPPLEMENT|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
219407459|NCT01952834|DRUG|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
219190088|NCT06108076|DRUG|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
219190089|NCT05825768|DEVICE|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
219407460|NCT04285346|DRUG|Ganaxolone|titration followed by maintenance and extension period
219407461|NCT06269341|OTHER|No intervention|No intervention
219407462|NCT04749979|DRUG|Agonist (decapeptyl )|giving agonist
219407463|NCT04749979|DRUG|HCG ( eg. Choriomon )|giving HCG
219407464|NCT00610935|DRUG|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
219407465|NCT00610935|DRUG|Placebo|Single intramuscular injection
219407466|NCT04874909|OTHER|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
219407467|NCT04874909|OTHER|Urine sample|Urine sample (500 ml) once time
219407468|NCT02126904|DRUG|IVA group|
219407469|NCT03886727|DEVICE|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
219407470|NCT03886727|DEVICE|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
219407471|NCT04202861|DIAGNOSTIC_TEST|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
219407472|NCT03792776|OTHER|cuff inflation with air|Endotracheal tube cuff inflation with air
219407473|NCT03792776|DRUG|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
219407474|NCT03792776|DRUG|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
219407475|NCT03792776|OTHER|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
219407476|NCT03792776|OTHER|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
219407477|NCT03792776|OTHER|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
219407478|NCT03792776|OTHER|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
219407479|NCT05427825|OTHER|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
219407480|NCT05427825|OTHER|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
219567921|NCT06739304|BEHAVIORAL|Mindfulness-based Relapse Prevention|250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists.
219567922|NCT06904443|OTHER|PsySon is an innovative device that uses music in crisis management in hospitals|"during his hospitalization, the patient can benefit from listening sessions thanks to an original and innovative device, a sort of listening chair equipped with high-quality speakers, thus offering an immersive and enveloping experience (see photo). These sessions aim to anticipate or manage a moment of crisis, of less well, which patients often face in institutions."
219567923|NCT06905548|BEHAVIORAL|climate change awareness training|The climate change training planned for nurse managers consists of 4 sessions of 2 days, each lasting 40 minutes.
219567924|NCT06905782|PROCEDURE|AI chatbot study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
219567925|NCT06905782|PROCEDURE|Traditional counselling study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
219002568|NCT04337606|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
219002569|NCT04337606|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
219002570|NCT04337606|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
219002571|NCT04493281|DRUG|MT-1186|Oral suspension
219002572|NCT04493281|DRUG|MCI-186|Intravenous formulation
219002573|NCT03933189|OTHER|Physical Therapy|Physical therapy modalities to treat chronic pain
219002574|NCT02694874|DRUG|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
219002575|NCT02694874|DRUG|Placebo|This is the placebo control
219407481|NCT02572128|OTHER|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
219407482|NCT04161586|DRUG|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
219407483|NCT04651725|OTHER|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
219407484|NCT06819566|PROCEDURE|Endoscopic variceal ligation (EVL)|"1. EVL for high-risk varices will be performed by experienced endoscopists, certified in gastroenterological endoscopy, within two weeks prior to the initiation of the Atezo/Bev.~2. A follow-up EGD will be conducted one week after the Atezo/Bev #3. If any of the following criteria are met, additional EVL will not be performed, and anticancer treatment will proceed two weeks later. Otherwise, an additional on-demand EVL session will be conducted:~   * The esophageal varices have improved to F1 or less.~  * The red color sign has disappeared.~3. On-demand EVL will be considered after 5th, and 7th consecutive doses of Atezo/Bev, with EGD follow-up performed to assess eligibility. The maximum number of EVL sessions is limited to three sessions."
219407485|NCT06612034|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219407486|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
219407487|NCT03161769|PROCEDURE|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
219407488|NCT03161769|DEVICE|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
219407489|NCT05118958|DRUG|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
219407490|NCT05118958|DRUG|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
219407491|NCT05118958|DRUG|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
219407492|NCT05118958|DRUG|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
219407493|NCT05118958|DRUG|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
219407494|NCT03834571|DRUG|Carboplatin|Given IV
219407495|NCT03834571|DRUG|Cisplatin|Given IV
219407496|NCT03834571|DRUG|Paclitaxel|Given IV
219407497|NCT03834571|PROCEDURE|Patient Monitoring|Undergo active monitoring
219567926|NCT06904898|DEVICE|Cougar LS/Syncage ALIF or CONDUIT LLIF/ALIF cage|Comparison between cages to determine the effectiveness and cost related to the study procedures.
219567927|NCT02331238|BEHAVIORAL|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
219567928|NCT06458244|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
219407498|NCT03834571|RADIATION|Radiation Therapy|Undergo radiation
219407499|NCT00740779|DRUG|Silodosin 8 mg|Silodosin 8 mg daily
219407500|NCT00740779|DRUG|Placebo|Placebo
219407501|NCT00740779|DRUG|Silodosin 4 mg|Silodosin 4 mg daily
219407502|NCT05773716|BEHAVIORAL|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.
219567929|NCT06458244|DRUG|Chemotherapy|Chemotherapy for AML consolidation treatment
219002576|NCT05877833|OTHER|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
219002577|NCT02041286|DEVICE|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
219002578|NCT02257788|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCR5
219190090|NCT05825768|DIAGNOSTIC_TEST|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
219407503|NCT05773716|OTHER|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
219407504|NCT05773716|OTHER|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
219407505|NCT06054035|DRUG|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 6 months. Route of administration: oral.
219407506|NCT06054035|DRUG|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 6 months. Route of administration: oral.
219407507|NCT06054035|BEHAVIORAL|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
219567930|NCT06905418|DIAGNOSTIC_TEST|Clinic|group A will get treatment in clinic
219567931|NCT06905418|COMBINATION_PRODUCT|Mobile App|group B will use mobile application for treatment
219567932|NCT00972907|DRUG|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
219567933|NCT06378788|OTHER|Demographic information form|aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
219567934|NCT06378788|DIAGNOSTIC_TEST|widespread pain index (WPI)|"The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9."
219190091|NCT05086796|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
219190092|NCT04205305|DRUG|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
219190093|NCT04205305|DRUG|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
219190094|NCT06487208|OTHER|Use of a digital cognitive aid in order to anticipate a critical situation|Use of a digital cognitive aid in order to anticipate a critical situation
219190095|NCT06487208|OTHER|Placebo|No intervention
219190096|NCT03295721|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
219190097|NCT03295721|DRUG|Saline Placebo|Saline placebo by instillation
219190098|NCT03295721|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
219190099|NCT03295721|DEVICE|Luer-lock applicator|Applicator for instillation
219407508|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
219755940|NCT07088796|DEVICE|Toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN6AT3-T9) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
219755941|NCT07088796|DEVICE|Non-toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN60WF) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
219755942|NCT07099352|DEVICE|Acupuncture Laser Therapy|Participants will receive low-level laser therapy sessions during dialysis , applied three times per week for 4 weeks to selected treatment areas.
219755943|NCT06889701|DRUG|TNP-2092 for injection|TNP-2092 for injection, 100 mg/vial, Intra-articular administration (IA), 10ml (50 mg) once daily for 14 days. TNP-2092 dose volume, dose, frequency, and duration can be adjusted according to the sentinel group synovial fluid TNP-2092 concentration, PK characteristics, and safety results at the EA visit.
219755944|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IA)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intra-articular administration, 10 mL (0.5 g) once daily for 14 days.
219755945|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IV)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intravenous infusion, 250 mL (1 g) q12h ± 1h per day, for 14 days.
219755946|NCT06889701|DRUG|Oral antibiotics|"Rifampicin capsules: 0.15 g/capsule. 0.45 g (3 capsules) orally once daily within 1 h before breakfast for 8 weeks (56 days).~Levofloxacin Tablets: 0.5 g/tablet. 0.5 g (1 tablet) orally once daily within 1 hour before breakfast for 8 weeks (56 days).~If susceptibility testing results show resistance to rifampicin and/or levofloxacin, or intolerance by the patient 's participant, treatment with oral minocycline hydrochloride capsules will be substituted as follows:Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time for 8 weeks (56 days).~The total duration of oral treatment during the oral administration period was 8 weeks (56 days) regardless of whether oral medication will be changed (eg, intolerance)."
219755947|NCT06889701|DRUG|Background Treatment|Background treatment will be determined by the investigator.
219755948|NCT06872359|DEVICE|KIO017-1|Subcutaneous and/or supraperiostal injections in chin and/or mid-face and/or jawline. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
219755949|NCT06872359|DEVICE|KIO017-2|Subcutaneous injections in temples and/or nasolabial folds and/or marionette lines and/or mid-face. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
219755950|NCT06872359|DEVICE|KIO017-3|Injections in or around labial mucosa for lip volume and contour and/or intradermal injections in perioral lines. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
219190100|NCT03295721|DEVICE|Vial access device|Device for withdrawal of drug product
219190101|NCT02795858|DRUG|Ramucirumab|
219190102|NCT02795858|DRUG|Somatostatin Analog|
219190103|NCT06242756|PROCEDURE|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
219407509|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
219407510|NCT00533637|DRUG|Placebo|Citrate buffer with preservatives
219567935|NCT06378788|DIAGNOSTIC_TEST|symptom severity scale (SSS)|SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
219755951|NCT06761196|OTHER|Questionnaire|The quality of life measured with different scales (BREAST-Q, EORTC QLQ C30 and BR42)
219755952|NCT07095361|DRUG|Fibrinolytic once daily|tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.
219755953|NCT07095361|DRUG|Fibrinolytic twice daily|tissue plasminogen activator (tPA) 10mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
219755954|NCT07095361|DRUG|DNA degradation once daily|Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.
219002579|NCT02950025|DEVICE|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
219002580|NCT02950025|DEVICE|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
219002581|NCT02950025|OTHER|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"* 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
219002582|NCT01349790|DRUG|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
219002583|NCT00597545|PROCEDURE|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
219002584|NCT00597545|DEVICE|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
219002585|NCT04298554|OTHER|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
219190104|NCT05616247|BEHAVIORAL|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
219190105|NCT05616247|BEHAVIORAL|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
219190106|NCT06096103|DIETARY_SUPPLEMENT|placebo|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
219190107|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardized for Iron + Vitamin C|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
219190108|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardised for Iron|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
219190109|NCT02573779|OTHER|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
219190110|NCT04947124|DRUG|QLS-101ophthalmic solution 1%|QLS-101ophthalmic solution 1.0%
219190111|NCT04947124|DRUG|QLS-101ophthalmic solution 2%|QLS-101ophthalmic solution 2.0%
219190112|NCT06547216|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
219190113|NCT03760406|PROCEDURE|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
219190114|NCT01651403|DRUG|Tenofovir DF|"* Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
219190115|NCT01651403|DRUG|TDF Placebo|"* Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
219190116|NCT03435510|BEHAVIORAL|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
219755955|NCT07095361|DRUG|DNA degradation twice daily|Deoxyribonuclease (DNase) 5mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
219755956|NCT07097909|OTHER|LLM-based CBT|An intelligent mobile application that delivers CBT for tinnitus, powered by a LLM. The app provides daily interactive sessions (≥20 minutes per day) over 4 weeks, incorporating cognitive restructuring, relaxation training, attention-shifting, and sleep hygiene guidance. The content dynamically adapts to user input to enhance engagement and personalization.
219002586|NCT04298554|OTHER|Hemp Oil|CBD PURE HEMP OIL
219002587|NCT01250405|DRUG|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
219190117|NCT04752657|OTHER|Delayed administration of survey modules|The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks
219190118|NCT04752657|OTHER|Regular administration of survey modules|The physical function, physical activity, and events survey modules are administered according to the regular pattern
219190119|NCT06799325|BEHAVIORAL|acceptance and commitment therapy based stress management program|The Stress Management Program Based on Acceptance and Commitment Therapy will be applied to the intervention group, consisting of 6 sessions, 1 session per week, and each session lasting 45 minutes.
219190120|NCT06112054|DEVICE|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
219190121|NCT05090683|BEHAVIORAL|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
219755957|NCT07099846|DEVICE|regeneration of post extraction socket with biomaterials|after tooth extraction, in the test group we will place a demineralised bovine bone graft mixed with a gel containing hyaluronic acid and polynucleotide and we will cover the entrance of the socket with a collagen matrix
219002588|NCT01250405|DRUG|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
219002589|NCT06299033|DRUG|hNPC01|hNPC01, human forebrain neural progenitor cell product, intracerebral injection
219002590|NCT05587205|BIOLOGICAL|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
219002591|NCT05587205|OTHER|Sham injection|Sham injection
219002592|NCT02354079|GENETIC|hypobetalipoproteinemia genetic and genotypic screening|
219002593|NCT02085785|BEHAVIORAL|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
219002594|NCT02085785|BEHAVIORAL|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
219002595|NCT02085785|OTHER|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
219755958|NCT06909162|DRUG|INCB123667|single dose administered orally
219002596|NCT04245332|DIETARY_SUPPLEMENT|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
219002597|NCT04245332|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil (4g/d)
219407511|NCT03737318|BEHAVIORAL|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
219755959|NCT07098988|BIOLOGICAL|Visugromab|Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
219755960|NCT07098988|DRUG|Matching placebo for visugromab|Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
219755961|NCT07098988|BIOLOGICAL|Pembrolizumab 200 mg Q3W|Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.
219755962|NCT07098988|DRUG|Pemetrexed 500 mg/m^2|Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
219755963|NCT07098988|DRUG|Carboplatin AUC 5|Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.
219755964|NCT06522386|DRUG|Pirtobrutinib|Given by mouth
219002598|NCT00779467|DRUG|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
219002599|NCT00779467|DRUG|Bupivacaine|
219002600|NCT00779467|DRUG|fentanyl|fentanyl 2 mcg/ml
219002601|NCT00672867|DRUG|Clevudine|30mg
219002602|NCT00672867|DRUG|Adefovir dipivoxil|10mg
219002603|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
219002604|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
219002605|NCT02692703|DRUG|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
219002606|NCT04691453|PROCEDURE|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
219002607|NCT04691453|PROCEDURE|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
219755965|NCT06522386|DRUG|Rituximab|Given by vein (IV)
219002608|NCT04118166|DRUG|Ipilimumab|Ipilimumab 1 mg/kg, injection
219407512|NCT03737318|BEHAVIORAL|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
219407513|NCT03737318|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
219407514|NCT00850460|DRUG|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
219407515|NCT00850460|DRUG|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
219567936|NCT06378788|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
219567937|NCT06378788|DIAGNOSTIC_TEST|Tender Point examination|Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
219567938|NCT06378788|OTHER|Muscle Architecture visualized with ultrasound|The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
219755966|NCT06522386|DRUG|Venetoclax|Given by mouth
219755967|NCT06857903|BEHAVIORAL|Recruitment nudges|Participants who in the intervention condition will receive recruitment materials that contain behavioral nudges
219755968|NCT07101835|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Patients scheduled for LSG will receive a Bilateral ultrasound guided external oblique intercostal block (EOIB) preoperatively, and sensory block status will be evaluated after 30 minutes.
219755969|NCT07101835|DRUG|ıv morphine PCA|ıV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
219755970|NCT07102966|GENETIC|Rapid whole genome sequencing|All consented patients will receive a virtual genetic evaluation and rapid whole genome sequencing
219755971|NCT06147089|BEHAVIORAL|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
219190122|NCT04750252|BIOLOGICAL|StroMel|Autologous MSC
219567939|NCT06378788|OTHER|Sarcopenia assessed by measuring isometric strengths of different parts of the body|Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
219190123|NCT05698355|OTHER|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
219190124|NCT02388048|DRUG|Ibrutinib + ofatumumab|
219190125|NCT06534372|PROCEDURE|Open cardiac surgery with sternotomy|Factors affecting the occurrence of chronic pain in patients undergoing open cardiac surgery with sternotomy will be investigated.
219407516|NCT01474330|DRUG|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
219407517|NCT01474330|DRUG|Placebo|Placebo capsule
219407518|NCT05882604|DRUG|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
219407519|NCT05882604|DRUG|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
219407520|NCT06600165|PROCEDURE|Ex vivo confocal microscopy|The aim is to use AI to assist surgeons in analyzing CLSM tissue slide images obtained during BCC surgeries with the aim to integrate it in real time. We plan to use AI to analyze CLSM images of BCCs and distinguish between tumor tissue, inflammatory tissue, and non-tumor/non-inflammatory tissue. This approach would provide surgeons with real-time feedback and automated image analysis, leading to a more targeted and efficient approach to tissue analysis. By improving the accuracy and speed of tissue analysis, our proposal could ultimately improve operative patient outcomes and benefit healthcare professionals.
219407521|NCT05299502|BEHAVIORAL|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
219567940|NCT06378788|OTHER|Timed Up & Go (TUG)|The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
219567941|NCT05565105|RADIATION|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.
219567942|NCT05565105|DRUG|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
219567943|NCT05565105|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
219567944|NCT05565105|DRUG|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
219567945|NCT05565105|DRUG|Melphalan|Melphalan: 70 mg/m\^2/day x 2
219567946|NCT05565105|DRUG|Fludarabine|Fludarabine: 25 mg/m\^2/day x 5
219567947|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
219407522|NCT02773914|OTHER|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
219567948|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
219567949|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
219567950|NCT03377387|DRUG|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
219567951|NCT03377387|DRUG|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
219567952|NCT03377387|BEHAVIORAL|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
219567953|NCT01901172|DRUG|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
219567954|NCT01901172|DRUG|RO5503781|Daily for 5 days followed by 23 days rest per cycle
219567955|NCT01901172|DRUG|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
219567956|NCT01901172|DRUG|RO5503781|Single doses Days 1 and 11
219567957|NCT01901172|DRUG|posaconazole|Multiple doses Days 8-14
219567958|NCT06063174|BEHAVIORAL|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
219567959|NCT06063174|BEHAVIORAL|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
219567960|NCT06063174|BEHAVIORAL|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
219567961|NCT06063174|BEHAVIORAL|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
219567962|NCT06063174|BEHAVIORAL|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
219567963|NCT06063174|BEHAVIORAL|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
219567964|NCT01086345|RADIATION|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
219567965|NCT01086345|BIOLOGICAL|bevacizumab|Given IV
219567966|NCT01086345|DRUG|irinotecan hydrochloride|Given IV
219567967|NCT05601076|PROCEDURE|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
219567968|NCT05601076|PROCEDURE|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
219407523|NCT04857073|OTHER|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
219407524|NCT04374825|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
219407525|NCT04374825|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
219407526|NCT06666426|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
219407527|NCT06666426|DEVICE|Hollister Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.
219567969|NCT03162068|OTHER|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
219567970|NCT05752708|DIAGNOSTIC_TEST|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
219407528|NCT02399813|DRUG|Axalimogene filolisbac|
219407529|NCT03833674|OTHER|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
219407530|NCT03833674|OTHER|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
219407531|NCT03833674|OTHER|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
219407532|NCT03833674|OTHER|AIH + Strength Training Block|AIH followed by respiratory strength training.
219407533|NCT04111887|BEHAVIORAL|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
219407534|NCT04009174|OTHER|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI"
219407535|NCT00988559|BIOLOGICAL|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
219407536|NCT00988559|DEVICE|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
219755972|NCT06147089|BEHAVIORAL|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
219002609|NCT04118166|PROCEDURE|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
219002610|NCT04118166|DRUG|Nivolumab|Nivolumab 3 mg/kg, injection
219407537|NCT00988559|BIOLOGICAL|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
219407538|NCT00988559|BIOLOGICAL|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
219407539|NCT00988559|PROCEDURE|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
219407540|NCT00988559|DRUG|imiquimod|imiquimod applied to the cervix by the physician
219407541|NCT01658696|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu heterologous prime-boost immunisation
219407542|NCT01658696|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
219407543|NCT06376604|OTHER|Fasting Mimicking Diet|Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
219407544|NCT06376604|DRUG|Chemotherapy|6 cycles of standard chemotherapy for the gynecologic malignancy.
219567971|NCT05886309|DIAGNOSTIC_TEST|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~* 1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~* 1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~* 1 EDTA sample (2,7 ml) for the measurement of hepcidin~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~* 1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~* 1 sample with no anticoagulant (5 ml) for storage"
219407545|NCT05516901|PROCEDURE|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
219407546|NCT05516901|PROCEDURE|Control group|Patients in this group will receive general anesthesia alone.
219407547|NCT06515652|DRUG|rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun|Comparing allopathic and herbal group of drugs for metabolic syndrome
219407548|NCT03223324|DEVICE|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
219407549|NCT00003943|BIOLOGICAL|filgrastim|5 ug/kg
219407550|NCT00003943|DRUG|carboplatin|AUC 5
219567972|NCT06392789|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Receive sleep education
219567973|NCT06392789|OTHER|Internet-Based Intervention|Receive access to website content modules
219567974|NCT06392789|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
219567975|NCT06392789|OTHER|Questionnaire Administration|Ancillary studies
219567976|NCT06392789|OTHER|Text Message-Based Navigation Intervention|Receive sleep compression SMS conversations
219567977|NCT05028062|DRUG|XR-NTX 380 mg, intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
219567978|NCT05028062|BEHAVIORAL|Medical Management|All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
219567979|NCT05028062|DRUG|Placebo intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
219567980|NCT03535857|DEVICE|PTNS|Use of PTNS on the ankle for 30 minutes
219567981|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
219567982|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
219567983|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
219567984|NCT05909059|DRUG|Fludarabine|Received IV on Days -5 to -3 before CAR T cell therapy
219567985|NCT05909059|DRUG|Cyclophosphamide|Received IV on Days -5 to -3 before CAR T cell therapy
219567986|NCT00380757|PROCEDURE|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
219755973|NCT06912646|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
219002611|NCT03247855|PROCEDURE|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
219407551|NCT00003943|DRUG|cyclophosphamide|3 gm/m2
219407552|NCT00003943|DRUG|paclitaxel|250 mg/m2
219407553|NCT00003943|DRUG|topotecan hydrochloride|10 mg/m2
219407554|NCT00003943|PROCEDURE|peripheral blood stem cell transplantation|harvest via apheresis
219407555|NCT02825264|DEVICE|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
219407556|NCT01193192|OTHER|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
219407557|NCT01193192|OTHER|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
219567987|NCT03854344|DRUG|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
219567988|NCT03854344|DRUG|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
219567989|NCT03854344|DRUG|Bupivacaine Hydrochloride|Used for regional nerve block for skin graft harvesting
219567990|NCT06324409|BEHAVIORAL|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
219190126|NCT06799572|OTHER|massage|"Hands will be washed with hand soap and rubbed with disinfectant before the procedure.~* The head of the bed is raised by 30°-45° in the incubator.~* The baby is placed face down.~* Vaseline is applied to the hands.~* The 15 minute session will consist of three 5 minute phases. Phase 1 will be tactile stimulation phase, Phase 2 will be kinesthetic stimulation and Phase 3 will be I Love You technique.~* In the tactile stimulation phase, the infant is turned to the prone position and a stroking motion (12 strokes in approximately 5 seconds) will be applied with moderate pressure in 1-minute intervals, from the top of the head to the neck and back to the top of the head, from the neck to the shoulder, from the neck to the shoulder, from the upper back to the waist and back to the upper back, from the thigh to the foot and both legs, from the shoulder to the hand and from both arms to the shoulder.~* In the kinesthetic stimulation phase, the infant is placed in the supine position and eac"
219190127|NCT06455241|OTHER|HABIT (Hand Activities Behavior Intervention)|A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
219190128|NCT06757036|BEHAVIORAL|Laughter Yoga|the group where Laughter Yoga is performed
219407558|NCT03007953|BEHAVIORAL|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
219407559|NCT05174312|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
219407560|NCT05174312|DRUG|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
219407561|NCT02797041|DRUG|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
219407562|NCT02817542|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
219407563|NCT02224846|DRUG|Tadalafil|Administered orally
219407564|NCT03280550|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
219407565|NCT03280550|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
219407566|NCT03438422|DIETARY_SUPPLEMENT|Pollen extract|1 tablet a day
219407567|NCT04575662|RADIATION|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
219407568|NCT01856634|DRUG|100 mg Delamanid|100 mg Delamanid BID for 10 days
219407569|NCT01856634|DRUG|50 mg Delamanid|50 mg Delamanid BID for 10 days
219407570|NCT01856634|DRUG|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
219407571|NCT01856634|DRUG|10 mg Delamanid Pediatric Formulation|Patients \> 10 kg will receive DPF 10 mg BID for 10 days
219407572|NCT01856634|DRUG|5 mg Delamanid Pediatric Formulation|"Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
219407573|NCT01856634|DRUG|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
219407574|NCT05788068|BEHAVIORAL|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
219407575|NCT06312007|OTHER|Semi seated position|The patient is positioned 45-90 degrees
219407576|NCT06312007|OTHER|side lying position|Side lying position
219407577|NCT06203678|OTHER|Kinesio taping|therapeutic tape application
219407578|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
219002612|NCT01148784|PROCEDURE|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
219407579|NCT06203678|OTHER|Sham taping|patch tape application
219407580|NCT04624893|DRUG|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
219567991|NCT04407299|BEHAVIORAL|self-administered structured questionnaire|It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
219567992|NCT00101842|DRUG|Pemetrexed|
219567993|NCT00101842|DRUG|Gemcitabine|
219567994|NCT00101842|DRUG|Platinol|
219190129|NCT06799975|OTHER|Education|"Patients in the education group will have a meeting with a physiotherapist at the end of the T1 evaluation, which will take place in a suitable room that ensures privacy is maintained. During this meeting, the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercises to activate/maintain the abdominal and lower back muscles, to be performed at home until the next visit, one month after the surgery. These exercises are part of standard clinical practice and should be routinely performed by patients who undergo lumbar spinal fusion in the period following the surgery. Additionally, the patient will have the opportunity to communicate, via email or phone, with the physiotherapist until the follow-up appointment with the spine surgeon (scheduled for one month later)."
219190130|NCT06799975|OTHER|Usual Care|The usual discharge procedures consist of a brief interview with the neurosurgeon during which instructions are provided on how to manage the first month after the surgery.
219190131|NCT06422793|PROCEDURE|No NG tube gastric decompression|Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
219567995|NCT02486913|OTHER|Enhanced Health Check|National Health Service Health Check enhanced by risk report
219567996|NCT04892121|OTHER|Prevention exercises|Participants will have to follow a warm-up prevention program (15 minutes) twice a week
219190132|NCT05022342|OTHER|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
219190133|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
219190134|NCT06230380|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
219567997|NCT05574894|DRUG|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
219567998|NCT05574894|DRUG|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
219567999|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)
219002613|NCT00025766|DEVICE|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
219407581|NCT05942898|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
219407582|NCT05585437|PROCEDURE|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
219407583|NCT03115801|DRUG|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
219407584|NCT03115801|DRUG|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
219568000|NCT06286644|DIETARY_SUPPLEMENT|Iso-alpha-Acids|Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
219568001|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
219568002|NCT05529511|OTHER|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
219568003|NCT05529511|OTHER|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
219568004|NCT06142929|PROCEDURE|Microfasciectomy|Using the microscope in Dupuytren's surgery
219568005|NCT06323551|OTHER|Mother's Smell|The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one).
219568006|NCT06323551|OTHER|Mother's Breast Milk Smell|In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper.
219568007|NCT03363464|DRUG|Empagliflozin|Empagliflozin
219568008|NCT03363464|DRUG|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
219568009|NCT03363464|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
219568010|NCT01730040|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
219568011|NCT01730040|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
219568012|NCT01730040|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
219568013|NCT01730040|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
219002614|NCT00025766|BEHAVIORAL|Optimal Medical Therapy|Participants will receive optimal medical therapy.
219002615|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
219568014|NCT01730040|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
219568015|NCT06615700|DRUG|NA-931|NA-931 is a quadruple receptor agonist for weight loss
219407585|NCT03115801|RADIATION|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
219407586|NCT03115801|DRUG|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
219407587|NCT01312792|OTHER|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
219407588|NCT01312792|OTHER|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
219407589|NCT01073748|DRUG|paracetamol|single dose of paracetamol 15mg/kg.
219407590|NCT05869344|DIETARY_SUPPLEMENT|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
219407591|NCT05869344|OTHER|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
219407592|NCT04688567|BEHAVIORAL|Patient-driven iCBT|1\) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
219407593|NCT04688567|BEHAVIORAL|Standardized iCBT (TAU)|2\) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
219568016|NCT06615700|DRUG|Placebo|Placebo of NA-931
219568017|NCT05477719|DEVICE|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
219568018|NCT00245817|BEHAVIORAL|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
219568019|NCT04328870|OTHER|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
219568020|NCT04328870|OTHER|General anesthsia|General anesthesia alone.
219568021|NCT01684215|DRUG|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
219568022|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
219568023|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
219002616|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
219407594|NCT00722540|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219407595|NCT00722540|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219407596|NCT00722540|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219568024|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
219568025|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
219568026|NCT00835939|DRUG|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
219568027|NCT00835939|DRUG|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
219568028|NCT00835939|PROCEDURE|sclerotherapy|
219002617|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in left side|
219002618|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in right side|
219407597|NCT00722540|DRUG|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219407598|NCT00722540|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219407599|NCT00722540|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219407600|NCT00722540|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219407601|NCT00722540|DRUG|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219407602|NCT00722540|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219407603|NCT00722540|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219568029|NCT02971722|DRUG|JY09|2mg/1ml/bottle
219568030|NCT02971722|DRUG|Placebo|1ml/bottle
219568031|NCT01789957|DRUG|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
219568032|NCT00503230|BEHAVIORAL|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
219568033|NCT00503230|BEHAVIORAL|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
219568034|NCT00401167|DRUG|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
219568035|NCT01301482|DEVICE|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
219568036|NCT01272089|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
219568037|NCT02269956|BEHAVIORAL|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
219568038|NCT06404541|DRUG|Dexamethasone, tobramycin, netilimicin|Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
219568039|NCT05866718|BEHAVIORAL|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
219568040|NCT05866718|BEHAVIORAL|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
219568041|NCT01682642|DRUG|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
219568042|NCT05951348|PROCEDURE|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
219568043|NCT03102151|OTHER|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
219568044|NCT00480324|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
219191855|NCT05389332|BEHAVIORAL|Hispanics Skin Cancer intervention|With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
219407604|NCT05762939|BEHAVIORAL|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
219407605|NCT05762939|BEHAVIORAL|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
219407606|NCT00003210|BIOLOGICAL|recombinant interleukin-12|Given subcutaneously
219407607|NCT00003210|OTHER|laboratory biomarker analysis|Correlative studies
219407608|NCT02203838|DRUG|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
219407609|NCT03223038|OTHER|No intervention|No intervention - exposure is mechanical ventilation in PICU
219407610|NCT03400670|DEVICE|ventilator NCPAP|infants will be randomized into two different NCPAP groups
219568045|NCT00480324|BIOLOGICAL|Placebo|Two-dose oral administration.
219568046|NCT03105934|PROCEDURE|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
219002619|NCT00159536|DRUG|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
219002620|NCT00159536|DRUG|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
219190135|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
219407611|NCT02806778|OTHER|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
219407612|NCT02806778|OTHER|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
219407613|NCT00003356|BIOLOGICAL|aldesleukin|
219407614|NCT00003356|BIOLOGICAL|rituximab|
219407615|NCT01332929|DRUG|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
219755974|NCT07107412|OTHER|Translating the Questionnaire into Turkish and Related Processes|"The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.~Other: Validity The scale will be applied"
219755975|NCT06827262|DEVICE|Intracept™ Intraosseous Nerve Ablation|Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain
219190136|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
219407616|NCT01904877|BEHAVIORAL|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
219407617|NCT02831491|DRUG|Ramucirumab|Administered IV
219407618|NCT02831491|DRUG|Docetaxel|Administered IV
219407619|NCT00002826|DRUG|paclitaxel|
219568047|NCT02009709|DRUG|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
219568048|NCT02009709|DEVICE|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
219407620|NCT00002826|DRUG|valspodar|
219755976|NCT06162572|DRUG|S095018|Via IV infusion on Day 1 of each 21-day cycle
219755977|NCT06162572|DRUG|S095024|Via IV infusion on Day 1 of each 21-day cycle
219407621|NCT04489524|BEHAVIORAL|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
219407622|NCT04489524|BEHAVIORAL|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
219407623|NCT04489524|BEHAVIORAL|NRT|nicotine replacement therapy
219407624|NCT01310595|PROCEDURE|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
219755978|NCT06162572|DRUG|S095029|Via IV infusion on Day 1 of each 21-day cycle
219755979|NCT06162572|DRUG|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
219407625|NCT01310595|PROCEDURE|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
219407626|NCT01554878|PROCEDURE|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
219002621|NCT03702946|OTHER|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
219407627|NCT06302205|OTHER|Physical activity|The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
219407628|NCT06302205|OTHER|Sham intervention|2 times a week, flexibility and balance training
219568049|NCT02009709|DEVICE|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
219568050|NCT04359537|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
219568051|NCT04359537|OTHER|Placebo|Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
219407629|NCT02610088|DRUG|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
219407630|NCT02610088|DRUG|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
219407631|NCT04678167|DIAGNOSTIC_TEST|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
219191856|NCT05389332|BEHAVIORAL|Control group: physical activity and nutrition for Hispanics|Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
219407632|NCT04678167|DIAGNOSTIC_TEST|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
219407633|NCT04678167|DIAGNOSTIC_TEST|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
219568052|NCT03400917|BIOLOGICAL|AV-GBM-1|Investigational treatment with AV-GBM-1
219568053|NCT04403516|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
219568054|NCT04403516|DRUG|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
219568055|NCT00388934|DEVICE|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
219568056|NCT03670134|DEVICE|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
219568057|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
219568058|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
219568059|NCT04079049|PROCEDURE|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
219568060|NCT04079049|DRUG|Control|Oncological treatment in control group
219568061|NCT06389916|DEVICE|Euclid orthokeratology MAX (current design)|The current lens design
219568062|NCT06389916|DEVICE|Euclid orthokeratology MAX Phoenix (new design)|The new lens design
219568063|NCT01552369|DRUG|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
219568064|NCT02329119|OTHER|electrophysiological recordings|
219568065|NCT02234752|DRUG|Galantamine ER|
219568066|NCT02234752|DRUG|Memantine XR|
219568067|NCT00000334|DRUG|Buprenorphine|
219568068|NCT01914523|DEVICE|Macintosh|Laryngeal exposure and tracheal intubation using that device
219568069|NCT01914523|DEVICE|King Vision|Laryngeal exposure and tracheal intubation using that device
219568070|NCT01914523|DEVICE|Glidescope|Laryngeal exposure and tracheal intubation using that device
219568071|NCT01914523|DEVICE|AirTraq|Laryngeal exposure and tracheal intubation using that device
219568072|NCT01582919|OTHER|Neuroimaging|
219568073|NCT02406430|PROCEDURE|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
219568074|NCT02946684|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
219568075|NCT02946684|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
219568076|NCT00110188|DRUG|ridaforolimus|
219568077|NCT02631837|PROCEDURE|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
219568078|NCT02631837|PROCEDURE|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
219568079|NCT05569330|OTHER|Air purification|Aerosol particles are removed from room air by several methods
219568080|NCT03400280|OTHER|Best practice algorithm for postoperative care|See arm/group description
219568081|NCT02776813|BIOLOGICAL|ACTR087|
219568082|NCT02776813|BIOLOGICAL|rituximab|
219568083|NCT06093087|PROCEDURE|SAIF|The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
219755980|NCT06162572|DRUG|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
219755981|NCT06162572|DRUG|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
219568084|NCT06093087|PROCEDURE|BKP|The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
219568085|NCT01559987|OTHER|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
219568086|NCT01559987|OTHER|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
219568087|NCT01559987|OTHER|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
219568088|NCT06026852|DEVICE|Prediction of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
219568089|NCT06026852|DIAGNOSTIC_TEST|Determination of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
219755982|NCT06162572|DRUG|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
219407634|NCT04678167|DIAGNOSTIC_TEST|Alexander's degree of nystagmus|"there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left"
219755983|NCT05871814|DEVICE|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing
219755984|NCT05385978|DRUG|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
219002622|NCT05693779|BEHAVIORAL|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
219002623|NCT04815161|BEHAVIORAL|Adherence|Adherence to medication using an electronic pillbox
219407635|NCT04678167|OTHER|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
219407636|NCT04678167|OTHER|EEV questionnaire|European Vertigo Assessment Questionnaire
219407637|NCT04678167|OTHER|anxiety VAS|visual analog scale of anxiety
219568090|NCT06026852|OTHER|Daily short questionnaire|Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
219568091|NCT06176625|BEHAVIORAL|Communication Signage|Signage regarding effective communication strategies posted on door to patient's room.
219568092|NCT06176625|BEHAVIORAL|Amplifier Use|Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
219568093|NCT04808830|OTHER|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
219568094|NCT04808830|OTHER|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
219568095|NCT04808830|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
219568096|NCT04808830|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
219568097|NCT04711967|BIOLOGICAL|Fecal Microbiota Transplantation|fecal microbiota transplantation
219755985|NCT05385978|DRUG|APHD-012P|Distal jejunal-release placebo beads
219002624|NCT05433714|OTHER|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
219407638|NCT03321292|DRUG|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
219407639|NCT03321292|DRUG|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
219407640|NCT03586843|DRUG|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
219568098|NCT04711967|DRUG|drug|drug
219568099|NCT05082324|OTHER|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
219568100|NCT04027374|PROCEDURE|Fetal surgery for MMC repair|Fetal surgery for MMC repair
219568101|NCT04341259|DRUG|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
219755986|NCT06920160|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to Heart Faillure.
219407641|NCT03934593|BEHAVIORAL|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
219407642|NCT03934593|OTHER|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
219407643|NCT04618393|BIOLOGICAL|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
219568102|NCT05523570|DRUG|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
219568103|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
219568104|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
219568105|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
219568106|NCT00953472|DRUG|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
219002625|NCT03090113|DRUG|Shuxuetong Injection|intravenous drip
219002626|NCT03090113|DRUG|Placebo Injection|intravenous drip
219568107|NCT00953472|OTHER|no-added salt diet|instruction to reduce salt for one week prior to study
219568108|NCT01010022|DRUG|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
219002627|NCT05579821|DIAGNOSTIC_TEST|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
219002628|NCT02708121|BEHAVIORAL|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
219407644|NCT04942483|DIAGNOSTIC_TEST|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
219407645|NCT04942483|DIAGNOSTIC_TEST|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
219407646|NCT04942483|DIAGNOSTIC_TEST|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
219407647|NCT04764123|DIAGNOSTIC_TEST|AVNRT mapping|AV annuli mapping during AVNRT
219407648|NCT04005443|OTHER|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
219568109|NCT01010022|DRUG|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
219568110|NCT04821752|BEHAVIORAL|Avoidance Education|Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
219568111|NCT04070339|OTHER|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
219568112|NCT04935788|DIETARY_SUPPLEMENT|milk protein|milk protein supplement
219568113|NCT04935788|DIETARY_SUPPLEMENT|micellar casein|micellar casein supplement
219568114|NCT04935788|DIETARY_SUPPLEMENT|pea protein|pea protein supplement
219568115|NCT04935788|DIETARY_SUPPLEMENT|milk/pea protein blend|milk/pea protein supplement
219568116|NCT03346070|DRUG|Sugammadex 2 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
219002629|NCT02708121|OTHER|Comparator Intervention|Participants informed that they have access to weight loss treatment.
219002630|NCT01929460|DRUG|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
219002631|NCT01929460|OTHER|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
219002632|NCT02383277|OTHER|Stretching|Stretching of the rib cage muscles
219002633|NCT02383277|OTHER|Control|Rest without stretching (sham)
219002634|NCT02383277|OTHER|Exercise|Constant load exercise on a bike
219407649|NCT05611684|DRUG|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
219407650|NCT01943864|DRUG|Trametinib (single tablet)|The drug substance is blended with inert
219407651|NCT01943864|DRUG|Trametinib (Multiple tablet)|The drug substance is blended with inert
219407652|NCT00110383|BEHAVIORAL|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
219002635|NCT04728074|OTHER|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
219002636|NCT04728074|OTHER|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
219407653|NCT04534426|DRUG|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
219407654|NCT04534426|DRUG|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
219407655|NCT04534426|OTHER|Control group|In Control group, only standard therapy was performed after surgery
219407656|NCT00278265|DRUG|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
219568117|NCT03346070|DRUG|Sugammadex 2 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
219568118|NCT03346070|DRUG|Sugammadex 4 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
219568119|NCT03346070|DRUG|Sugammadex 4 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
219568120|NCT03346070|DRUG|Neostigmine + Glycopyrrolate|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
219755987|NCT06919939|DRUG|Epcoritamab|"Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:~* Cycle 1 Day 1: Step-up dose of 0.16 mg~* Cycle 1 Day 8: Step-up dose of 0.80 mg~* Cycle 1 Day 15: First full dose of 48 mg.~* Cycles 2 through 4 Days 1, 8 and 15: 48 mg~* Cycles 5 through 12 Days 1 and 15: 48 mg"
219755988|NCT06919939|DRUG|Loncastuximab Tesirine|"Loncastuximab will be administered intravenously (IV) at the following dose level and schedule over a total of four cycles:~* Cycles 1 and 2 Day 1: 120 mcg/kg~* Cycles 3 and 4 Day 1: 75 mcg/kg~* Cycle 4 Day 22: 75 mcg/kg"
219755989|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
219407657|NCT04289103|BIOLOGICAL|Inolimomab (Leukotac)|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
219407658|NCT02151500|BEHAVIORAL|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
219407659|NCT03304483|OTHER|246-km running|Spartathlon 2017
219407660|NCT05886647|OTHER|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
219755990|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
219407661|NCT05886647|OTHER|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
219755991|NCT06474013|DEVICE|ExAblate 4000 Type 2.1|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
219002637|NCT01833520|DRUG|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
219002638|NCT03795987|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
219002639|NCT02333877|OTHER|Skinlink|suture using Skinlink
219407662|NCT01167595|OTHER|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
219002640|NCT02333877|OTHER|Nylon|conventional suture using nylon
219002641|NCT03116893|DRUG|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
219002642|NCT03116893|DRUG|Itraconazole|Administration of itraconazole together with BI 685509
219002643|NCT03116893|DRUG|Rifampin|Administration of rifampicin together with BI 685509
219002644|NCT03116893|DRUG|BI 685509 Fasted Conditions|BI 685509, given alone
219002645|NCT03943134|OTHER|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
219568121|NCT03346070|DRUG|Rocuronium or Vecuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW. NMBAs were concomitant medications used per label as adjunct to general anesthesia.
219755992|NCT07114341|OTHER|Cranberry Intervention|30 grams of lyophilized cranberry containing 1187 mg/100 g anthocyanins were given for 7 days.
219755993|NCT02661672|DEVICE|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
219755994|NCT02661672|DEVICE|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
219407663|NCT01915849|DRUG|LIK066|LIK066 15 mg, 50 mg and 150 mg
219407664|NCT01915849|DRUG|Placebo|
219407665|NCT02805218|DRUG|PEG-rhG-CSF|
219755995|NCT02581930|DRUG|Ibrutinib|Given PO
219755996|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
219755997|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
219755998|NCT02581930|OTHER|Pharmacological Study|Correlative studies
219755999|NCT07124923|OTHER|Continuity-of-Care intervention|"The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre.~Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year.~The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation."
219756000|NCT07126977|BEHAVIORAL|Urotherapy training|Standard urotherapy consists of five main components aimed at regulating lower urinary tract (LUT) function in children: education about LUT function and dysfunction, establishing healthy voiding habits and behavioral modifications, lifestyle recommendations such as balanced fluid intake and nutrition, monitoring of symptoms and voiding habits, and consistent caregiver support. In contrast, specific urotherapy focuses on treating particular LUT dysfunctions and includes interventions such as alarm therapy, pelvic floor training, biofeedback, neuromodulation, and clean intermittent catheterization. All children and their caregivers participating in our study will receive urotherapy training prior to the pelvic floor rehabilitation interventions. Each urotherapy session will last approximately 60 minutes.
219756001|NCT07126977|OTHER|Diaphragmatic Breathing Exercise|The exercise will be performed under the supervision of a physiotherapist, twice a week for 8 weeks. After the correct position is established, participants will be instructed to slowly inhale through their nose and focus on feeling the breath move from top to bottom (cranial to caudal). They will be asked to hold their breath for a few seconds, then exhale slowly through pursed lips. Additionally, they will be reminded not to push only their abdomen upward while inhaling, but to feel the intra-abdominal pressure expanding evenly in all directions (360 degrees). This exercise will be performed in 3 sets of 10 repetitions.
219756002|NCT07126977|OTHER|Biofeedback-Assisted Pelvic Floor Muscle Exercises|"No invasive procedures will be performed. The physiotherapist will begin with external palpation of the perineal area to teach correct pelvic floor contractions without using accessory muscles. Once the patient masters this, animation-supported biofeedback exercises will start. If relaxation is insufficient, biofeedback will first target muscle relaxation.~Using the NeuroTrac Myoplus Pro4 device, surface electrodes will be placed at 2 and 7 o'clock on the perineum, and the reference electrode on the right thigh. Exercises will start in a lying position and progress to sitting and standing as control improves. Each session will last about 20 min, with 2-5 s contractions followed by 5-10 s relaxations."
219407666|NCT01147315|PROCEDURE|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
219407667|NCT02361203|BEHAVIORAL|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
219407668|NCT00219765|DRUG|Imatinib mesylate 600 mg|
219407669|NCT00219765|DRUG|Cytarabine|
219002646|NCT03943134|OTHER|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
219002647|NCT02834507|DRUG|Placebo|Matching placebo capsules
219002648|NCT02834507|DRUG|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
219407670|NCT00219765|DRUG|Daunorubicine|
219407671|NCT06459531|BEHAVIORAL|Virtual Reality (VR) Therapy|"Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
219568122|NCT02608970|DRUG|BMS-986177|
219568123|NCT02608970|OTHER|Placebo|
219568124|NCT02253069|DEVICE|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
219568125|NCT02253069|DEVICE|Applying Placebo to tie-over dressings|Placebo control
219568126|NCT00798382|OTHER|soy protein formula|ad lib for 0-35 days of age
219568127|NCT00798382|OTHER|Commercially available soy formula|ad lib for 0-35 days of age
219568128|NCT00798382|OTHER|Soy formula experimental #2|ad lib for 0-35 days of age
219407672|NCT06459531|OTHER|Conservative Treatment|"Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
219407673|NCT05323903|OTHER|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
219407674|NCT05323903|OTHER|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
219407675|NCT03531437|DRUG|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
219407676|NCT03531437|DRUG|15 µg ethinylestradiol and 60 µg gestodene|
219407677|NCT00697047|BEHAVIORAL|Automated Mailing|Usual Care plus Automated mailing
219407678|NCT00697047|BEHAVIORAL|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
219407679|NCT00697047|BEHAVIORAL|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
219407680|NCT00002333|DRUG|Saquinavir|
219407681|NCT00002333|DRUG|Zalcitabine|
219407682|NCT02061722|RADIATION|PET Imaging with [18F]MNI-659|"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
219407683|NCT04956822|OTHER|Basic information|Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
219568129|NCT02948257|DEVICE|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
219756003|NCT07126977|OTHER|Video Game-Based Balance Exercise Training|"In our study, in addition to the standard protocol, virtual reality-supported video game-based balance exercises will be performed twice a week for 8 weeks. Each session will include a 5-minute warm-up, 20 minutes of balance exercises, and a 5-minute cool-down period. All sessions will follow the same protocol, with identical game order and duration. Each game will be played for approximately 5 minutes, and the number of repetitions for each game will vary depending on the participant's performance level.~As a therapeutic tool, the Wii console, Wii Fit Plus game disc, and Wii Balance Board will be used. The selected exercise games will include Hula Hoop Plus, Penguin Slide, Soccer Heading, Table Tilt, Tightrope Walk, Ski Jump, and Step Up."
219407684|NCT04956822|OTHER|Functional scores|depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
219407685|NCT04956822|DEVICE|MINUX|MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
219002649|NCT02834507|DRUG|Comtan®|Capsules containing entacapone 200 mg
219002650|NCT02834507|DRUG|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
219407686|NCT04330755|DRUG|Saline Solution|Placebo
219407687|NCT04330755|DRUG|Levosimendan|Levosimendan
219407688|NCT04330755|DRUG|Magnesium Sulfate|Magnesium Sulfate
219407689|NCT05012319|DRUG|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
219407690|NCT01067508|OTHER|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
219407691|NCT03797040|BIOLOGICAL|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
219407692|NCT06447025|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
219407693|NCT03650348|DRUG|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
219407694|NCT03578848|DEVICE|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
219407695|NCT03578848|DEVICE|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
219568130|NCT04714281|DEVICE|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
219568131|NCT03936179|RADIATION|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
219407696|NCT03578848|DEVICE|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
219407697|NCT00444626|DEVICE|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
219407698|NCT00444626|DEVICE|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
219407699|NCT00444626|DRUG|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
219407700|NCT02276157|DEVICE|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
219407701|NCT01665755|DEVICE|Upstroke Compression Defibrillation|
219407702|NCT01665755|DEVICE|Precompression Defibrillation|
219407703|NCT01822041|DRUG|ARN-509|Single oral dose of 240 mg ARN-509
219407704|NCT03535324|BEHAVIORAL|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
219407705|NCT03535324|OTHER|Control|There will be no intervention
219568132|NCT02370459|OTHER|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
219568133|NCT02370459|OTHER|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
219568134|NCT06456619|OTHER|Tooth restoration|Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
219568135|NCT04955366|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
219568136|NCT04955366|DRUG|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
219568137|NCT04333472|DRUG|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
219568138|NCT04333472|DRUG|Placebo|Placebo orally every 12 hours for up to 28 days
219568139|NCT02551679|BIOLOGICAL|ACP-01|Injection into lower extremity
219568140|NCT02551679|BIOLOGICAL|Placebo|Injection into lower extremity
219568141|NCT06214611|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy in the head and neck region
219568142|NCT05394766|OTHER|Omada Hypertension Program|The Omada Program: an online program that offers comprehensive lifestyle self-management support for hypertension.
219568143|NCT06449872|DEVICE|Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems|Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
219568144|NCT02150772|PROCEDURE|Shear Wave Elastography (SWE)|
219756004|NCT07126977|OTHER|Functional Exercise Training|Our study will include exercises aimed at improving core stabilization, dynamic neuromuscular control, and pelvic mobility. Exercise selection will be tailored to individual needs, and the number of repetitions and duration will be adjusted based on the participant's progress. Preferred exercises will include movements such as bridge, dead bug, bilateral arm and leg lift, bear position, cat-camel, and pelvic clock.
219756005|NCT05185583|DRUG|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
219756006|NCT05185583|DRUG|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
219190137|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
219190138|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
219190139|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
219407706|NCT04507438|DRUG|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
219407707|NCT04507438|DRUG|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
219568145|NCT06617117|OTHER|High-intensity combined exercise|The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.
219756007|NCT06941480|DIAGNOSTIC_TEST|PET/CT|Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT
219756008|NCT06941480|BIOLOGICAL|177Lu-DTPA-SC16.56|177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT
219756009|NCT07143695|DEVICE|Parasternal intercostal thickening fraction|Parasternal intercostal thickening fraction less than 6.5%
219756010|NCT07143695|DEVICE|Sham parasternal intercostal thickening|Ultrasound assessment only for purpose of blinding
219756011|NCT07139483|DEVICE|Trans Direct-Cranial Stimulation (tDCS)|The tDCS electrodes will be inserted into 5×7 cm (35 cm2) sponges soaked with saline (0.9 M) and placed as follows: anode over the M1 contralateral to the amputated limb (adjusted based on lower/upper amputation), and cathode over the forehead, contralateral to the anode (ipsilateral to amputated limb). Total stimulation duration will be 20 min, with a rise and decline time of 30 sec and stimulus intensity of 1.5 mA for the real tDCS real. The intensity of 1.5 mA is in the midrange of recommended intensities (1-2 mA) and supports successful blinding. The sham tDCS will be identical to the real tDCS, except no current will be applied. However, as recommended, during the first and last 30 sec, the current will be ramped up to 1.5 mA and immediately back to 0 to induce scalp sensations similar to those in real tDCS, further supporting blinding. The Mini-CT tDCS Stimulator device has been developed for home use and allows double-blind administration.
219756012|NCT07139483|BEHAVIORAL|Mirror therapy|Participants will be seated with a portable mirror between their limbs so that the unaffected limb is reflected in the mirror. The participants will focus their attention on the reflection in the mirror and perform the following movements: plantarflexion and dorsiflexion and inversion and eversion of the foot, flexion and extension of the wrist and ulnar and radial deviation, for lower and upper limp amputates, respectively. The participants will continue performing the 2 sets of movements for 20 minutes (with short intermissions if needed)
219756013|NCT02556047|DEVICE|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
219756014|NCT07146776|PROCEDURE|open flap debridement with I-prf and xenogeneic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be completely removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. Subsequently, a xenogeneic bone graft mixed with injectable platelet-rich fibrin (i-PRF) will be applied. The flap will then be sutured using 4-0 polypropylene sutures.
219002651|NCT02280785|DRUG|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
219002652|NCT06171763|OTHER|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
219002653|NCT02743520|DEVICE|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
219407708|NCT00169988|DRUG|risperidone|
219407709|NCT00169988|DRUG|sertraline-primary|
219407710|NCT03564171|COMBINATION_PRODUCT|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
219407711|NCT05837078|PROCEDURE|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
219407712|NCT01160055|PROCEDURE|Middle ear fluid and urine.|Middle ear fluid and urine collection.
219407713|NCT00786838|DRUG|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
219407714|NCT00786838|DRUG|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
219407715|NCT03064295|DEVICE|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
219407716|NCT03064295|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
219407717|NCT03064295|DRUG|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
219407718|NCT00276978|DRUG|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
219407719|NCT01176097|DRUG|AZD5658|oral suspension, escalating single doses
219568146|NCT06617117|OTHER|Moderate-intensity combined exercise|The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
219407720|NCT01176097|DRUG|Placebo|oral suspension,single doses
219002654|NCT03489447|OTHER|ICU care|exposure to ICU treatment with or without diagnosed sepsis
219002655|NCT00000534|DRUG|calcium|
219407721|NCT03673241|DEVICE|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
219407722|NCT04897555|DEVICE|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
219407723|NCT01648543|PROCEDURE|lumbar sympathetic ganglion block|
219568147|NCT04801719|DEVICE|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
219568148|NCT00682617|BEHAVIORAL|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
219568149|NCT00682617|BEHAVIORAL|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
219568150|NCT06468306|PROCEDURE|non-invasive ventilation teraphy, NIV|Routine management regimes of NIV
219568151|NCT01679197|DRUG|Metreleptin|
219407724|NCT02746393|OTHER|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
219407725|NCT02746393|OTHER|211 Information Sheet|Receive a printed list of community resources to address social needs.
219568152|NCT00521989|DRUG|CRx-102 (2.7/90)|CRx-102 dose 1
219568153|NCT00521989|DRUG|Prednisolone|Prednisolone
219568154|NCT00521989|DRUG|Placebo|Placebo
219568155|NCT00521989|DRUG|CRx-102 (2.7/180)|CRx-102 dose 2
219568156|NCT00521989|DRUG|CRx-102 (2.7/360)|CRx-102 dose 3
219756015|NCT07146776|PROCEDURE|open flap debridement with saline and xenogenic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be thoroughly removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. A xenogeneic bone graft mixed with physiological saline will then be applied. Finally, the flap will be sutured using 4-0 polypropylene sutures.
219756016|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
219756017|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
219756018|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
219756019|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
219756020|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
219756021|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
219756022|NCT07159529|PROCEDURE|flapless technique|taking a punch of tissue to place dental implant through surgical guide
219756023|NCT07159529|PROCEDURE|flap technique|conventional flap elevation and drilling to place dental implant
219568157|NCT01699919|DRUG|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
219568158|NCT06334419|DRUG|Gaboxadol|Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
219568159|NCT06334419|DRUG|Placebo|Two placebo capsules
219568160|NCT03271606|COMBINATION_PRODUCT|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
219568161|NCT03271606|COMBINATION_PRODUCT|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
219568162|NCT05287152|DEVICE|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
219568163|NCT00143299|DRUG|varenicline (CP-526,555)|
219568164|NCT05842304|DEVICE|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
219568165|NCT05842304|DEVICE|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
219568166|NCT02286973|DRUG|Tranexamic Acid|
219568167|NCT03679273|DIETARY_SUPPLEMENT|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
219568168|NCT03919448|BIOLOGICAL|Bevacizumab|Single-dose infusion
219756024|NCT07159529|PROCEDURE|tissue punching|just a punch of tissue taken to place dental implant
219407726|NCT06295081|OTHER|Exercise exposure|"Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km"
219407727|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
219407728|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
219407729|NCT04594239|DEVICE|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
219407730|NCT04594239|DEVICE|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
219407731|NCT04226859|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
219407732|NCT06671756|DIETARY_SUPPLEMENT|Fructose Ingestion|Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.
219407733|NCT06671756|DIETARY_SUPPLEMENT|Glucose Ingestion|Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.
219407734|NCT06672731|DIAGNOSTIC_TEST|REMS: Radiofrequency Echographic Multi Spectrometry|it is a non invasive ultrasonographic evaluation of bone and muscle quality
219407735|NCT02408146|PROCEDURE|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
219407736|NCT02408146|DRUG|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
219407737|NCT02408146|PROCEDURE|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
219407738|NCT02408146|DRUG|fentanyl citrate+ ondansetron hydrochloride + normal saline|
219407739|NCT02408146|DRUG|celecoxib|
219407740|NCT06693700|OTHER|Indoor Air Quality Monitor AirGradient ONE|Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
219407741|NCT06693219|DIAGNOSTIC_TEST|ultrasonography to confirm the correct placement of a nasogastric tube in the stomach|The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
219407742|NCT00091390|RADIATION|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
219407743|NCT00091390|RADIATION|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
219407744|NCT06692010|DRUG|Bupivacaine with Dexamethasone Solution|10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
219407745|NCT04649528|BEHAVIORAL|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
219407746|NCT04649528|DEVICE|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
219407747|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
219407748|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
219002656|NCT00000534|BEHAVIORAL|dietary supplements|
219002657|NCT03928574|PROCEDURE|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
219002658|NCT03928574|PROCEDURE|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
219002659|NCT03729505|PROCEDURE|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
219407749|NCT04283032|PROCEDURE|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
219407750|NCT06921772|BEHAVIORAL|PNF Stretching Exercise|Proprioceptive Neuromuscular Facilitation (PNF) stretching exercises were applied three times per week for six weeks. The intervention included contract-relax and hold-relax techniques targeting lower extremity muscle groups, conducted in addition to regular volleyball training.
219407751|NCT03662464|OTHER|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
219568169|NCT03704857|OTHER|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
219407752|NCT06924801|BEHAVIORAL|Snipperfingers|Snipperfinger is a self developed engagement focused software platform designed to encourage participation in pediatric physical therapy.
219407753|NCT06922032|DEVICE|Mystics Pet|Participants will receive the game intervention and be instructed to wear a Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in Mystic Pets software game (Stanford Chariot Program, Palo Alto, CA) that is specifically designed to promote overall distraction and emotional distress reduction.
219407754|NCT00436215|DRUG|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
219407755|NCT00436215|DRUG|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
219407756|NCT07128121|BIOLOGICAL|Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)|Formulation for injection
219407757|NCT07128121|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219407758|NCT06929702|DRUG|Beta-lactam antibiotic|amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment
219407759|NCT06929702|DEVICE|Beta-lactam model-informed precision dosing|A dosing calculator is used for the prediction of starting doses (a priori dose predictions) and follow-up doses (a posteriori calculations), using a target 100% fT\>MIC.
219407760|NCT06930118|DRUG|chidamide, regorafenib, and iparomlimab/tuvonralimab|All patients were treated with the following regimen: Chidamide: 30mg per dose, twice a week; Regorafenib: 80mg per dose, once a day, orally for 3 weeks, followed by a 1-week rest, and repeated every 4 weeks; Iparomlimab/Tuvonralimab: 5mg/kg, once every 3 weeks, intravenous infusion.
219407761|NCT01808703|DEVICE|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
219407762|NCT01808703|PROCEDURE|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
219407763|NCT06929585|PROCEDURE|Genicular artery embolization|The patient will receive GAE procedure and sham IA procedure.
219407764|NCT06929585|PROCEDURE|Intra-articular injection with corticosteroids.|The patient will receive IA procedure and sham GAE procedure.
219407765|NCT05437029|DRUG|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
219407766|NCT05437029|DRUG|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
219568170|NCT03704857|OTHER|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
219407767|NCT02279589|BIOLOGICAL|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
219407768|NCT02279589|BIOLOGICAL|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
219407769|NCT02279589|BIOLOGICAL|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
219407770|NCT04416776|DRUG|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
219407771|NCT00309777|DRUG|Pitavastatin|Pitavastatin once daily
219407772|NCT00309777|DRUG|Simvastatin|Simvastatin once daily
219407773|NCT07148063|OTHER|Measurement of Preoperative Inflammatory Biomarkers|Blood samples will be collected preoperatively to measure inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index, monocyte-to-lymphocyte ratio (MLR), and systemic inflammation response index. These values will be analysed in relation to the incidence of postoperative nausea and vomiting within the first 6 hours after pediatric orchiopexy. No experimental drug or device will be administered as part of the study; all procedures will be conducted within the scope of standard perioperative care.
219407774|NCT07162792|DEVICE|bioresorbable scaffold|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of BRS.
219407775|NCT07162792|DEVICE|drug-coated balloon|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of DCB.
219407776|NCT07163143|DRUG|Isoniazid (H)|H, weight based, 150-375mg
219407777|NCT07163143|DRUG|Rifampicin (R)|R, weight based, 300-750mg
219407778|NCT07163143|DRUG|Pyrazinamide (Z)|Z, weight based, 800-2000mg
219407779|NCT07163143|DRUG|Ethambutol (E)|E weight based, 550-1375mg
219407780|NCT07161739|BEHAVIORAL|Behavioural Nudge (Influenza Risk Reduction)|A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.
219407781|NCT07161739|BEHAVIORAL|Behavioural Nudge (Travel Vaccination Benefit)|A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.
219407782|NCT07162077|PROCEDURE|Sodium hypochlorite 5.25%|In the test group, the investigators will be applied sodium hypochlorite 5.25% by using cotton wad on the opacity before treatment, then after the first and second etching cycles (application of the Icon-Etch (ICON® -Etch; DMG, Hamburg, Germany) and Icon-dry (ICON® -Dry; DMG, Hamburg, Germany) according to the manufacturer's recommendations) as irrigation step and following the third -Etch etching cycle Icon-infiltrant (ICON® -Infiltrant; DMG, Hamburg, Germany) will be applied.
219407783|NCT07162077|PROCEDURE|ICON resin infiltration Material group in vivo|In control group, the investigators will be applied the same protocol of test group but without using sodium hypochlorite
219407784|NCT07163364|DRUG|Hydroxocobalamin Chloride Injection|1 - 20 mg per dose, 1 - 5 times per week
219568171|NCT03704857|OTHER|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
219568172|NCT03704857|OTHER|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
219568173|NCT03704857|OTHER|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
219568174|NCT03704857|OTHER|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
219568175|NCT03704857|OTHER|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
219407785|NCT07162597|DEVICE|Pulsed Field Ablation|Pulsed Field Ablation
219407786|NCT07162688|DRUG|Omega-3 Lipid Emulsion|Intravenous Omega-3 lipid emulsion administered at a dose of 2 mL/kg/day (equivalent to 0.2 g/kg of fish oil), starting from the conditioning phase prior to hematopoietic stem cell infusion and continuing daily until neutrophil and platelet engraftment or up to Day +35 post-transplantation. The emulsion is infused over 4-6 hours and combined with medium- and long-chain triglyceride emulsion as part of parenteral nutrition.
219407787|NCT07161804|DRUG|Homoeopathic medicines|Thuja officinalis Vaccininum Causticum Argentum nitricum Tuberculinum Stramonium Staphysagria Arum triphyllum Bacillinum Cina Carcinocin Cuprum Metallicum Ambera grisea Calcarea carbonica Crocus sativus Hepar sulphur Hyoscymus Kali Bromatum Lac Vaccininum Medorrhinum Natrum phosphoricum Thyroidinum
219407788|NCT07161804|BEHAVIORAL|Therapy|Occupational Therapy / Speech Therapy
219407789|NCT07161804|DRUG|Placebo|Saccharum lactis
219407790|NCT07162987|BEHAVIORAL|Prehabilitation|Please refer to arm description
219407791|NCT06795438|DIETARY_SUPPLEMENT|Green tea|Green tea tablets 1000mg 1 x per day
219407792|NCT06795438|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
219407793|NCT05579912|PROCEDURE|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
219407794|NCT01556802|DRUG|Minocicline|Minocicline 100mg oral twice a day for 5 days
219407795|NCT01556802|DRUG|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
219407796|NCT06097767|DRUG|Caffeine citrate|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
219568176|NCT03704857|OTHER|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
219568177|NCT03704857|OTHER|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
219568178|NCT01797926|DRUG|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
219407797|NCT06097767|DRUG|Amikacin|it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
219407798|NCT01430572|DRUG|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
219407799|NCT01430572|DRUG|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
219407800|NCT01923233|BIOLOGICAL|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
219407801|NCT01303809|OTHER|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up"
219407802|NCT03172611|OTHER|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
219407803|NCT01711320|DRUG|Placebo|
219407804|NCT01711320|DRUG|Omeprazole|
219407805|NCT03785496|DRUG|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
219407806|NCT03779035|DRUG|Gemcitabine|1000mg/m2
219407807|NCT03779035|DRUG|Capecitabine|1250mg/m2
219407808|NCT06017583|DRUG|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
219568179|NCT01797926|DRUG|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
219002660|NCT03729505|PROCEDURE|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
219002661|NCT01264588|OTHER|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
219002662|NCT00489021|PROCEDURE|sub-acute hospitalization|
219407809|NCT06017583|DRUG|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
219407810|NCT06017583|DRUG|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
219407811|NCT06017583|RADIATION|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
219407812|NCT06017583|RADIATION|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
219407813|NCT03508765|DIAGNOSTIC_TEST|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
219407814|NCT03508765|DIAGNOSTIC_TEST|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
219407815|NCT03508765|BEHAVIORAL|Digit Span subtest|Evaluates auditory attention and working memory
219407816|NCT03508765|BEHAVIORAL|Brief Test of Attention|Assesses selective auditory attention
219407817|NCT03508765|BEHAVIORAL|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
219407818|NCT03508765|BEHAVIORAL|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
219407819|NCT03508765|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency.
219407820|NCT03508765|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
219407821|NCT03508765|BEHAVIORAL|The Center for Epidemiological Study-Depression|assesses perceived depression
219407822|NCT03508765|BEHAVIORAL|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
219407823|NCT03508765|OTHER|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
219407824|NCT05821153|DRUG|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
219568180|NCT01797926|DRUG|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
219568181|NCT01797926|DRUG|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
219568182|NCT03438539|BEHAVIORAL|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
219568183|NCT03438539|BEHAVIORAL|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
219002663|NCT01749514|DRUG|Luspatercept|Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
219002664|NCT04456660|DIAGNOSTIC_TEST|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
219002665|NCT04456660|DIAGNOSTIC_TEST|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
219002666|NCT04456660|DIAGNOSTIC_TEST|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
219002667|NCT00447460|PROCEDURE|Mesenchymal stem cell (MSC)|
219002668|NCT00004760|BEHAVIORAL|Exercise|
219407825|NCT01814683|DRUG|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
219407826|NCT01814683|DRUG|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
219407827|NCT01814683|DRUG|Placebo|14 days placebo.
219407828|NCT02476682|OTHER|blood or stool samples will be collected|blood or stool samples will be collected
219407829|NCT00660036|DRUG|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
219407830|NCT00660036|DRUG|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
219407831|NCT00660036|DRUG|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
219407832|NCT01830361|DRUG|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
219407833|NCT02728440|DRUG|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
219407834|NCT00211588|DRUG|galantamine|
219407835|NCT03375359|DIAGNOSTIC_TEST|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
219407836|NCT03200873|DEVICE|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
219407837|NCT04185480|DEVICE|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
219407838|NCT00462098|DEVICE|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
219407839|NCT00462098|DEVICE|non-treated control group|no change from routine care, no HBO
219407840|NCT03363048|BEHAVIORAL|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
219002669|NCT03066089|DRUG|Fenfuro|
219002670|NCT03088982|OTHER|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
219002671|NCT06564441|DRUG|Survodutide|Survodutide
219002672|NCT06564441|DRUG|Bupropion|Bupropion
219002673|NCT06564441|DRUG|Caffeine|Caffeine
219002674|NCT06564441|DRUG|Midazolam|Midazolam
219002675|NCT04648631|DEVICE|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
219407841|NCT03363048|BEHAVIORAL|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
219407842|NCT02583802|DRUG|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
219407843|NCT02583802|DRUG|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
219407844|NCT02533518|PROCEDURE|Rigid bronchoscopy with ultraviolet transmission|
219407845|NCT02533518|OTHER|Biopsy|
219407846|NCT00186745|DRUG|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
219407847|NCT02955134|DRUG|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
219568184|NCT03438539|BEHAVIORAL|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
219002676|NCT02851758|OTHER|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
219190140|NCT04072783|DIAGNOSTIC_TEST|MRI,DTI, functional MRI|"1. Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~2. Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~3. Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
219407848|NCT02955134|DRUG|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
219407849|NCT02955134|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
219407850|NCT02955134|DRUG|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
219407851|NCT03015922|DRUG|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
219407852|NCT03015922|BIOLOGICAL|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
219407853|NCT04467177|OTHER|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
219407854|NCT04467177|OTHER|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
219568185|NCT05319613|OTHER|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
219761064|NCT04641832|OTHER|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
219002677|NCT01676389|OTHER|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
219002678|NCT01676389|OTHER|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
219407855|NCT03284294|DRUG|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
219407856|NCT03284294|DRUG|Placebo|Oral placebo daily for 8 weeks
219407857|NCT03863236|DIETARY_SUPPLEMENT|regular diet|The control group (group 1) will continue their regular diet.
219407858|NCT03863236|DIETARY_SUPPLEMENT|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
219407859|NCT03580382|DRUG|Trametinib daily Until PD|1.0 mg daily
219407860|NCT03580382|DRUG|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
219568186|NCT05143203|OTHER|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
219568187|NCT01139749|DRUG|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
219568188|NCT01139749|DRUG|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
219568189|NCT03333499|DRUG|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
219568190|NCT03333499|DRUG|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
219761065|NCT02783833|DRUG|MMV390048 40mg|
219407861|NCT04109235|OTHER|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
219407862|NCT04109235|OTHER|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP\_PAGuidelines\_0-65plus\_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
219407863|NCT04592614|BEHAVIORAL|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
219407864|NCT05619172|DRUG|Nanrilkefusp alfa|Subcutaneous (SC) injection
219407865|NCT05619172|DRUG|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
219407866|NCT00812916|PROCEDURE|RF ablation, using specialized CFAE software|RF ablation
219407867|NCT00450372|BIOLOGICAL|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
219407868|NCT00450372|OTHER|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
219407869|NCT03010423|DRUG|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
219568191|NCT03333499|DRUG|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
219568192|NCT03333499|DRUG|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
219568193|NCT03481413|DEVICE|Ablation|Ablation therapy for cardiac arrhythmias
219568194|NCT05329285|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
219568195|NCT02667678|BIOLOGICAL|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
219568196|NCT01771315|BEHAVIORAL|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
219568197|NCT04684693|DEVICE|Laser|Laser puncture and exercise
219568198|NCT04684693|PROCEDURE|Control|Exercise
219568199|NCT01013428|OTHER|Ultrasound|Ultrasound will be used to evaluate tendons.
219568200|NCT02555293|DRUG|XIFAXAN® (Rifaximin)|
219568201|NCT01208428|BEHAVIORAL|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
219568202|NCT01208428|BEHAVIORAL|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
219568203|NCT06403683|DIAGNOSTIC_TEST|WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test|Case control trial study
219190141|NCT05390281|DIAGNOSTIC_TEST|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
219568204|NCT02283190|DRUG|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
219568205|NCT01002794|PROCEDURE|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
219568206|NCT01002794|OTHER|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
219568207|NCT03451240|BEHAVIORAL|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
219568208|NCT05466344|DEVICE|Herbst Group|"1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used."
219568209|NCT05466344|DEVICE|TFBC Group|"1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient."
219568210|NCT03740620|PROCEDURE|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
219568211|NCT03740620|PROCEDURE|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
219756025|NCT07159776|DEVICE|monitoring of wearable data, shopping data, biomarkers and patient reported outcomes|"1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime.~2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial.~3. biomarkers in blood and feaces will be monitored according to standard of care~4. patient reported outcomes will be monitored according to standard of care"
219756026|NCT07158710|DRUG|HSK42360|Oral administration, QD/BID
219756027|NCT07158931|OTHER|nordic walking|Before the NW program, participants completed a one-week familiarization phase to practice pole use. Training was held three times: 15 minutes on days 1 and 2, and 20 minutes on day 3, at 40-60% heart rate reserve (measured with a pulse oximeter). Warm-up included a 1-minute slow walk, toe raises, seated dorsiflexion, mini squats, scapular adduction, and shoulder/wrist stretches. Each session ended with a cool-down of a 2-minute slow walk and 20-second stretches for major muscle groups (quadriceps, hamstrings, lumbar extensors, gastrocnemius, shoulders, wrists).The walking poles used in this study were the Evolite Ultralite Titanium Antishock Trekking Pole, which has a titanium alloy body and a three-piece telescopic structure, adjustable to the desired length between 68 and 135 cm.
219756028|NCT07158931|OTHER|General walking|The program was performed on concrete or compacted soil surfaces, under the same physiotherapist's supervision. Walking speed was adjusted to remain below 60% of maximal heart rate and to allow participants to converse comfortably during exercise.
219756029|NCT07160543|BEHAVIORAL|Imagination Exposure|Participants were guided to close their eyes and imagine discarding their personal object. The experimenter provided standardized verbal instructions to help participants visualize moving the item from their own space into a trash bin.
219568212|NCT00845325|BEHAVIORAL|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
219568213|NCT00845325|BEHAVIORAL|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
219756030|NCT07160543|DEVICE|Non-immersive Virtual Reality Exposure|Participants used a desktop computer to interact with a virtual household environment. Their personal object, photographed beforehand, was digitally embedded in the scene. Using keyboard and mouse, participants navigated to the virtual garage and dragged the object into a virtual trash bin. The experimenter remained present to provide support.
219756031|NCT07160946|OTHER|AI folow-up system|In AI follow-up group, patients will be followed up by an AI system.
219407870|NCT05445297|DRUG|Pharmacological cardioversion with Amiodarone|"Patients in this group will receive intravenous amiodarone according to the following scheme:~1. administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~2. if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached."
219407871|NCT05445297|DRUG|Pharmacological cardioversion with Refralon|"Patients in this group will receive intravenous refralon according to the following scheme:~1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
219407872|NCT05157672|DIETARY_SUPPLEMENT|Cinnamon (2 g)|oral capsules, 2 g
219407873|NCT05157672|DRUG|Nicotine gum (2.5 mg)|gum, 2.5 mg
219407874|NCT05157672|DRUG|Letrozole (2.5 mg)|tablet, 2.5 mg
219407875|NCT05927389|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
219407876|NCT03555903|OTHER|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
219568214|NCT01674439|PROCEDURE|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
219407877|NCT02236546|DIAGNOSTIC_TEST|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
219407878|NCT02236546|OTHER|Molecular assays on biopsied tissue|Correlative studies
219407879|NCT02236546|DEVICE|positron emission tomography|Undergo FDG-PET/CT
219407880|NCT02236546|DEVICE|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
219407881|NCT00781781|DRUG|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
219407882|NCT03165357|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|
219407883|NCT03165357|DIETARY_SUPPLEMENT|Placebo treatment|
219407884|NCT00335504|DRUG|oligofructose-enriched inulin|Given orally
219407885|NCT00335504|DRUG|sulindac|Given orally
219407886|NCT00335504|DRUG|placebo|Given orally
219407887|NCT00335504|DRUG|atorvastatin calcium|Given orally
219407888|NCT00335504|OTHER|laboratory biomarker analysis|Correlative studies
219407889|NCT02493816|DRUG|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
219407890|NCT04414657|OTHER|blood sampling for biobank|blood sampling for biobank
219407891|NCT06515041|OTHER|brain well-being|Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
219568215|NCT01674439|PROCEDURE|Without supplementation of ADRC|Standard fat graft preparation
219568216|NCT06616935|OTHER|Intervention group one, community activities.|"Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher."
219568217|NCT06616935|OTHER|Intervention group two|Online exercises and activities
219568218|NCT01820858|DRUG|Paclitaxel|175 mg/m(2), intravenously (IV)
219568219|NCT01820858|DRUG|Paraplatin (Carboplatin Injection)|AUC=5, IV
219407892|NCT01980108|OTHER|water|water
219407893|NCT02804412|OTHER|Control group|This is the control group with 14 h treatment over 10 workdays.
219568220|NCT01820858|RADIATION|Pelvic Radiation|45-50 Gy
219568221|NCT01820858|RADIATION|Vaginal Brachytherapy 1|5 Gy, 3 times
219407894|NCT02804412|OTHER|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
219407895|NCT02804412|OTHER|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
219407896|NCT01337531|DRUG|Gonal-F, Fostimon|dosage form
219407897|NCT01337531|DRUG|Gonal-F, Fostimon|injection, daily, 10-15 days
219407898|NCT05263102|DEVICE|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
219407899|NCT01718509|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
219407900|NCT01718509|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
219407901|NCT04823208|DRUG|LY3437943|Administered SC
219407902|NCT04823208|DRUG|Placebo|Administered SC
219407903|NCT05209932|BEHAVIORAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
219407904|NCT05625386|DEVICE|transcranial magnetic stimulation|TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
219407905|NCT01596959|PROCEDURE|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
219407906|NCT01596959|PROCEDURE|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
219407907|NCT04712656|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea.
219407908|NCT05154266|BEHAVIORAL|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
219407909|NCT02940717|OTHER|Vita suprinity|New glass ceramic material
219407910|NCT02940717|OTHER|Emax CAD|standard etchable glass ceramic used for laminate venneers
219407911|NCT04604314|DEVICE|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
219407912|NCT05291871|BIOLOGICAL|HPV vaccine|One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
219407913|NCT06122675|DEVICE|DBS|Implanted in the cerebellum.
219407914|NCT06043700|OTHER|No Intervention|No treatment intervention will be administered.
219407915|NCT01728584|DRUG|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
219407916|NCT01728584|OTHER|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used."
219407917|NCT01728584|DRUG|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
219407918|NCT04699903|DIAGNOSTIC_TEST|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
219407919|NCT06511999|DEVICE|Continuous SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is capable of continuous, indwelling measurement of venous oxygen saturation, which is displayed on a bedside monitor connected by an optical cable. Enrolled participants will undergo continuous SjO2 measurement for 72 hours. Clinical care will not be directed by the continuous SjO2 values.
219407920|NCT06511999|DIAGNOSTIC_TEST|Intermittent SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is also capable of intermittent blood sampling enabling measurement of SjO2 on a laboratory blood gas analyzer. Enrolled participants will undergo intermittent SjO2 measurement every 4-6 hours for 72 hours. Clinical care will be directly by the intermittent values.
219568222|NCT01820858|RADIATION|Vaginal brachytherapy 2|5 Gy, 2-4 times
219568223|NCT05205018|BEHAVIORAL|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
219568224|NCT04104984|DEVICE|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
219568225|NCT04104984|DRUG|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
219568226|NCT04104984|PROCEDURE|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
219568227|NCT04104984|OTHER|digital vaginal exam|vaginal examination to detect short cervix
219568228|NCT04104984|DEVICE|abdominal ultrasound|use abdominal ultrasound to measure cervical length
219568229|NCT04104984|DRUG|Tocolytic Agents|a medication is given to prevent uterine contraction
219002679|NCT03679936|DIAGNOSTIC_TEST|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
219002680|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
219002681|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
219002682|NCT02606604|DEVICE|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
219002683|NCT00468689|DRUG|SB-751689 oral tablets (100 and 400 ng)|
219002684|NCT00468689|DRUG|Ketoconazole (NIZORAL) oral tablets (200 mg)|
219407921|NCT05906732|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
219407922|NCT05906732|DRUG|Placebo|Matching Placebo
219407923|NCT05906732|DRUG|Dofetilide 250 μg Cap|Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
219407924|NCT04821310|DRUG|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
219407925|NCT04821310|DRUG|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
219407926|NCT06095518|DIAGNOSTIC_TEST|DIC markers and Thrombin Generation Parameters|Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
219407927|NCT05415358|OTHER|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.
219407928|NCT02649387|DRUG|Ibrutinib|Given PO
219407929|NCT02649387|OTHER|Laboratory Biomarker Analysis|Correlative studies
219756032|NCT07159477|BEHAVIORAL|Skin to Skin contact|Fathers are briefed on skin-to-skin: what it is/isn't, why it matters, how to do it, and benefits for father, mother, and baby. Keep the room quiet; close windows to avoid drafts. Do not perform if the father is sleeping. Smokers must not perform while smoking and should do it before smoking when possible. After mother-infant skin-to-skin and breastfeeding, start father-infant contact within four hours of birth. If clothing is unsuitable, provide a surgical gown. Place the diapered infant upright on the father's bare chest. The father supports shoulders and back, maintains eye contact, speaks softly, and touches the baby. Cover both with a blanket; only mother, father, and infant remain, with the researcher silent. Continue at least 15 minutes; end if the father requests care or the infant needs care (diapering, dressing, breastfeeding). Repeat once for the early-contact group and at least daily until discharge for the frequent-contact group; on discharge, remind daily home practice.
219756033|NCT07161154|DEVICE|Transcutaneous bone conduction hearing system|The Sentio system is an active transcutaneous bone conduction hearing system (single armed study)
219761066|NCT02783833|DRUG|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
219002685|NCT03966703|BEHAVIORAL|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
219002686|NCT00653250|DRUG|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
219002687|NCT00653250|PROCEDURE|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
219002688|NCT00653250|PROCEDURE|therapeutic conventional surgery|surgery to remove the lung tumor
219002689|NCT04953546|OTHER|No Intervention|This is an observation study, with no intervention
219002690|NCT02509156|BIOLOGICAL|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219002691|NCT02509156|BIOLOGICAL|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219002692|NCT00523354|DRUG|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
219002693|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
219002694|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
219002695|NCT05939986|BEHAVIORAL|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
219407930|NCT06580106|OTHER|Biospecimen samples|Buccal swabs and Blood samples will be collected throughout study.
219407931|NCT05761275|PROCEDURE|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
219407932|NCT05761275|PROCEDURE|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
219407933|NCT05761275|PROCEDURE|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
219407934|NCT05761275|PROCEDURE|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
219761067|NCT03616821|DRUG|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
219761068|NCT03616821|DRUG|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
219761069|NCT01276951|DIETARY_SUPPLEMENT|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
219002696|NCT00935597|BIOLOGICAL|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
219407935|NCT03207022|PROCEDURE|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
219407936|NCT06493825|OTHER|Aurora Mindfulness app versus sham|It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.
219407937|NCT05583474|DRUG|OPC-1085EL|one drop for each eye, once per day
219407938|NCT05583474|DRUG|0.005% Latanoprost|one drop for each eye, once per day
219407939|NCT05627622|BEHAVIORAL|WhatsApp health education message|stone-prevention information on a monthly basis, using personal WhatsApp messages
219407940|NCT00977327|DEVICE|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
219407941|NCT00977327|DEVICE|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
219407942|NCT06331923|DEVICE|Continuous glucose monitoring (CGM) device|Continuous glucose monitoring (CGM) will be prescribed by the attending physician for at least 6 hours before surgery. The supervising nurse will educate the patient and their family on the correct wearing and connection of the CGM device. The calibration frequency and interval of glucose monitoring devices before and after surgery should be determined according to institutional treatment guidelines and the requirements of the monitoring device used. Intraoperative glucose calibration should be done immediately upon entering the operating room, immediately after skin incision, every 2 hours after skin incision, and at the end of wound closure. Glucose monitoring should be continued until the 7th day after surgery or discharge.
219407943|NCT04536740|DEVICE|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
219407944|NCT05544019|DRUG|SGR-1505|SGR-1505 will be administered orally.
219407945|NCT02426372|BIOLOGICAL|QBECO SSI|QBECO Site Specific Immunomodulators
219407946|NCT00636376|PROCEDURE|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
219407947|NCT00138034|PROCEDURE|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
219568230|NCT03662308|DEVICE|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
219568231|NCT03662308|DEVICE|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
219568232|NCT01672359|DIETARY_SUPPLEMENT|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
219002697|NCT01126853|BIOLOGICAL|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
219407948|NCT05509231|BEHAVIORAL|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
219407949|NCT05509231|DEVICE|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
219568233|NCT01672359|DIETARY_SUPPLEMENT|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
219568234|NCT01672359|DIETARY_SUPPLEMENT|Placebo|
219568235|NCT03115528|BEHAVIORAL|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
219568236|NCT00782028|OTHER|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
219568237|NCT00782028|OTHER|Standard Care|
219568238|NCT02217696|OTHER|Computerized reading training|
219568239|NCT03274713|DEVICE|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
219568240|NCT03274713|DEVICE|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
219568241|NCT02875041|DEVICE|Transcranial Magnetic Stimulation (TMS)|
219568242|NCT02875041|DEVICE|MAGSTIM Rapid2|
219407950|NCT04709991|PROCEDURE|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
219407951|NCT06536153|COMBINATION_PRODUCT|Amaranth grain flat bread|The recipe will be produced according to the recommended dietary allowance (RDA); based on RDA, 200 g of flat-bread (30% chickpea and 70% amaranth grain) comprised 30 mg of iron, which can satisfy 50% of RDA supposing 15-20% iron absorption (54). A prior study concluded that the acceptability was satisfactory in the community (55). Also, a study from the Hawassa University Department of Food Sciences reported that amaranth-grain flat-bread was safe for consumption for 48 hours after preparation and improved the nutritional values (56). To lower the phytate levels in the amaranth grain, home-level processing will be used. For 24 hours, amaranth grain will be soaked in water with 5 milliliters of lemon juice per 100 milliliters of water, and it will germinate for 72 hours. It will be sun-dried, roasted, and ground using a nearby electrical mill before fermented bread is made
219407952|NCT05560841|DEVICE|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
219407953|NCT03857763|COMBINATION_PRODUCT|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
219407954|NCT01727713|DRUG|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
219407955|NCT00330655|DRUG|memantine|
219407956|NCT02351245|OTHER|observation|
219407957|NCT00313599|DRUG|lapatinib|
219407958|NCT00313599|DRUG|paclitaxel|
219407959|NCT05474508|OTHER|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
219568243|NCT02862249|BIOLOGICAL|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
219568244|NCT02862249|BIOLOGICAL|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
219756034|NCT07159568|OTHER|Pet dog visit|Pet dog visit will take place during dedicated time slots, following prior verification of the dog's hygiene criteria. The dog may stay in the patient's room for a maximum of 15 minutes. After the visit, an evaluation questionnaire will be completed by the healthcare staff and by the relative who accompanied the dog. The patient's evaluation questionnaire will be completed at ICU discharge if patient is able to respond, or at most 28 days after inclusion if the patient remains in the ICU.
219002698|NCT04267367|BEHAVIORAL|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
219002699|NCT01790256|DEVICE|Cereve Sleep System at 30 degrees C|
219002700|NCT01790256|DEVICE|Cereve Sleep System at 14-16 degrees C|
219002701|NCT04326231|DEVICE|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
219407960|NCT05474508|OTHER|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
219407961|NCT00736710|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
219407962|NCT00736710|PROCEDURE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
219568245|NCT03662256|OTHER|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
219761070|NCT01276951|PROCEDURE|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
219002702|NCT01936688|DRUG|MK-3222 200 mg|MK-3222 200 mg administered SC.
219002703|NCT01936688|DRUG|MK-3222 100 mg|MK-3222 100 mg administered SC.
219002704|NCT01936688|DRUG|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
219002705|NCT01936688|DRUG|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
219002706|NCT01936688|DRUG|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
219407963|NCT03683706|BEHAVIORAL|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
219407964|NCT00455260|DRUG|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
219568246|NCT03662256|OTHER|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
219568247|NCT04017559|BEHAVIORAL|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
219002707|NCT04473014|BEHAVIORAL|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
219002708|NCT01148758|DRUG|RO5323441|cohorts receiving multiple doses iv
219002709|NCT01203150|OTHER|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
219002710|NCT04075058|RADIATION|Hypofractionated Radiation therapy|
219002711|NCT00002144|DRUG|Foscarnet sodium|
219407965|NCT00455260|DEVICE|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
219407966|NCT04758273|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
219002712|NCT00571987|DEVICE|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
219407967|NCT04758273|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
219407968|NCT04758273|BIOLOGICAL|Placebo|placebo
219407969|NCT05977517|BEHAVIORAL|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
219407970|NCT05282264|OTHER|device|closed-loop insulin
219407971|NCT03741894|DRUG|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
219568248|NCT00493454|DRUG|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
219407972|NCT03741894|OTHER|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
219407973|NCT03741894|DRUG|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
219568249|NCT00493454|DRUG|Rituximab|250 mg/m\^2 IV Over 6 to 8 Hours
219568250|NCT00493454|DRUG|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
219568251|NCT06615765|OTHER|Acupuncture|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~* Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~* Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6.~* Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~* Needles are inserted into BL32, BL33, and BL35 with precise angles and depths.~* EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
219568252|NCT06615765|OTHER|Sham acupuncture|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
219568253|NCT01197768|BEHAVIORAL|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
219568254|NCT04627831|DRUG|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
219568255|NCT04627831|DRUG|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
219568256|NCT05650086|DEVICE|Thermalytix|One-time Thermal imaging is performed for this cohort.
219568257|NCT03146637|BIOLOGICAL|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
219002713|NCT00138476|DRUG|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
219002714|NCT00138476|BIOLOGICAL|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
219568258|NCT03146637|BIOLOGICAL|CIK|Traditional CIK were infused for 3 days
219568259|NCT05343221|DEVICE|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
219002715|NCT00426855|DRUG|Bendamustine|starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w
219407974|NCT02028429|DRUG|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
219407975|NCT06206668|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
219407976|NCT01368341|DRUG|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
219407977|NCT01368341|DRUG|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
219407978|NCT01368341|DRUG|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
219568260|NCT05343221|DEVICE|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
219568261|NCT00504803|PROCEDURE|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
219407979|NCT05653206|PROCEDURE|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
219407980|NCT05653206|PROCEDURE|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
219407981|NCT05337813|DEVICE|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
219407982|NCT02197429|OTHER|Acupuncture|
219407983|NCT02336594|DRUG|RDEA3170 10 mg|
219407984|NCT02336594|DRUG|RDEA3170 2.5 mg|
219407985|NCT00471536|DRUG|pazopanib hydrochloride|800 mg Given orally
219407986|NCT00679679|DRUG|Metformin|Metformin 750 mg BID for 4 months
219407987|NCT00679679|DRUG|Placebo|Diet counseling and exercise
219407988|NCT05060666|DRUG|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
219407989|NCT05060666|DRUG|Placebo|"An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
219407990|NCT02651194|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
219407991|NCT00652431|DRUG|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
219407992|NCT00652431|DRUG|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
219568262|NCT06142188|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
219002716|NCT00426855|DRUG|Bortezomib|weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
219002717|NCT06327867|DEVICE|Oro Tracheal Intubation by DL|DL
219002718|NCT06327867|DEVICE|Oro Tracheal Intubation by VL|VL
219002719|NCT05446467|COMBINATION_PRODUCT|pembrolizumab+cisplatin + 5-FU|ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m2 last for 120hours, six circles. Subjects will undergo surgery after receiving neoadjuvant chemotherapy within 3 weeks, followed by adjuvant therapy and pembrolizumab alone maintenance treatment.
219002720|NCT00968656|RADIATION|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
219002721|NCT00968656|OTHER|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
219407993|NCT00652431|DRUG|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
219407994|NCT00301782|BIOLOGICAL|bleomycin sulfate|
219407995|NCT00301782|DRUG|carboplatin|
219407996|NCT00301782|DRUG|cisplatin|
219407997|NCT00301782|DRUG|etoposide phosphate|
219407998|NCT00301782|DRUG|vincristine sulfate|
219407999|NCT05520814|DRUG|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
219408000|NCT05520814|RADIATION|chemoradiotherapy|"Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
219408001|NCT02251054|OTHER|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
219408002|NCT02251054|OTHER|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
219408003|NCT00966758|PROCEDURE|Computed Tomography|1 low dose CT scan is taken
219408004|NCT00966758|PROCEDURE|Single Photon Emission Computed Tomography|1 SPECT scan is taken
219408005|NCT01212172|DEVICE|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
219408006|NCT01212172|DEVICE|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
219408007|NCT06418672|BEHAVIORAL|Go Sun Smart Georgia (GSSG)|"Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups."
219408008|NCT01426399|DRUG|LC15-0444|LC15-0444 50mg qd (8 days once daily)
219408009|NCT01426399|DRUG|Metformin|Metformin 1000 mg bid (8 days twice daily)
219408010|NCT01426399|DRUG|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
219408011|NCT02144454|DIETARY_SUPPLEMENT|Saturated fat|
219568263|NCT02244294|DRUG|FLOMAX® capsules|
219568264|NCT02244294|DRUG|Placebo capsules|
219408012|NCT02144454|DIETARY_SUPPLEMENT|Monounsaturated fat|
219408013|NCT02144454|DIETARY_SUPPLEMENT|n-6 polyunsaturated fat|
219408014|NCT05393817|DRUG|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
219408015|NCT03355287|OTHER|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
219408016|NCT03355287|OTHER|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
219408017|NCT03355287|OTHER|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
219408018|NCT05097053|BIOLOGICAL|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
219408019|NCT05097053|BIOLOGICAL|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
219408020|NCT03885726|DEVICE|Precision Flow Plus|High velocity nasal insufflation
219408021|NCT03885726|DEVICE|Treatment as Usual|Conventional therapy per institution
219408022|NCT01217190|DRUG|Ondansetron (ODFS)|Test Article
219408023|NCT01217190|DRUG|Zofran (ODT)|Comparator
219408024|NCT06291246|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
219408025|NCT06291246|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
219408026|NCT02306993|OTHER|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
219408027|NCT02306993|OTHER|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
219408028|NCT02306993|OTHER|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
219408029|NCT05685368|BEHAVIORAL|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
219408030|NCT03116399|BEHAVIORAL|PRISM 2.0 Condition|Access to the PRISM 2.0 program
219408031|NCT03116399|BEHAVIORAL|Tablet Condition|Access to the tablet
219408032|NCT00320736|DRUG|galantamine|
219408033|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
219408034|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
219408035|NCT01237808|DRUG|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
219408036|NCT01237808|DRUG|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
219408037|NCT01237808|DRUG|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
219408038|NCT02304536|DRUG|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
219408039|NCT02304536|PROCEDURE|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
219408040|NCT05071716|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
219408041|NCT05071716|DRUG|Placebo|Placebo Twice Daily
219408042|NCT04641364|DRUG|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
219408043|NCT04641364|DRUG|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
219408044|NCT04641364|DRUG|human albumin injection|multiple doses of intravenous infusion
219408045|NCT06277154|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.
219408046|NCT06277154|DRUG|Doxorubicin|Commercially approved for cancer treatment
219408047|NCT06277154|DRUG|Ifosfamide|Commercially approved for cancer treatment
219408048|NCT05674747|DEVICE|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
219568265|NCT03893734|DRUG|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
219408049|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
219568266|NCT03893734|DRUG|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
219568267|NCT00103038|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
219568268|NCT00103038|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
219568269|NCT00103038|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
219568270|NCT00103038|DRUG|Ferumoxytol|Given IV
219568271|NCT00103038|DRUG|Gadolinium|Given IV
219568272|NCT00103038|PROCEDURE|MRI-Based Angiogram|Undergo MRA
219568273|NCT03678779|BEHAVIORAL|Incentive|$5 grocery gift card
219568274|NCT03678779|BEHAVIORAL|Education|Video-based brief nutrition education
219568275|NCT03678779|BEHAVIORAL|Combined|Both Incentive and Education interventions received
219190142|NCT06185413|OTHER|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
219408050|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
219408051|NCT01217281|PROCEDURE|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
219408052|NCT04481425|OTHER|SMS intervention|SMS intervention
219408053|NCT05610462|BEHAVIORAL|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
219408054|NCT05610462|BEHAVIORAL|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
219408055|NCT04827238|DIAGNOSTIC_TEST|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
219408056|NCT00675974|DEVICE|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
219568276|NCT03301103|BIOLOGICAL|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
219568277|NCT03301103|DEVICE|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
219568278|NCT06177002|DIAGNOSTIC_TEST|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
219568279|NCT01363141|OTHER|Regular AGE Diet|Regular AGE Diet
219568280|NCT01363141|OTHER|Low AGE Diet|One year reduction in dietary AGE intake.
219568281|NCT06012721|DRUG|ORIC-114|Food effect healthy subjects
219568282|NCT04036149|DEVICE|Intraocular lens|Implantation as part of cataract surgery
219568283|NCT01218984|DRUG|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
219568284|NCT01218984|DRUG|Medisorb naltrexone 150 mg|Single administration via IM injection.
219568285|NCT01218984|DRUG|Medisorb naltrexone 300 mg|Single administration via IM injection.
219568286|NCT01218984|DRUG|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
219568287|NCT01218984|DRUG|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
219568288|NCT03476317|DRUG|Vancomycin|Oral suspension 4 times daily (Day 1-14)
219568289|NCT03476317|DRUG|Neomycin|Oral three times daily (Days 1-3)
219568290|NCT03476317|DRUG|Ciprofloxacin|Oral twice daily (Days 4-14)
219568291|NCT03476317|DRUG|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
219568292|NCT03476317|DRUG|Fluconazole|Orally once daily (Day 1-14)
219761071|NCT01276951|PROCEDURE|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
219761072|NCT01276951|PROCEDURE|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
219408057|NCT00675974|DEVICE|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
219408058|NCT04747483|OTHER|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
219408059|NCT04747483|OTHER|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
219408060|NCT00562003|PROCEDURE|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
219408061|NCT00562003|DRUG|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
219408062|NCT03946423|PROCEDURE|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
219408063|NCT03946423|BEHAVIORAL|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
219408064|NCT06596369|DEVICE|Transcutaneous spinal cord stimulation|Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.
219408065|NCT06596369|OTHER|Upper extremity rehabilitation|Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
219408066|NCT06810843|DRUG|Remazolam combined with afentanil for non-intubated thoracoscopic surgery|Remazolam combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
219408067|NCT06810843|DRUG|Propofol combined with afentanil in non-intubated thoracoscopic surgery|Propofol combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
219408068|NCT03523832|DRUG|Celecoxib and Pregabaline|Single dose versus repetition dose
219408069|NCT03523832|OTHER|Placebo|Placebo
219408070|NCT06469762|OTHER|Dry Cupping|Dry cupping treatment session, using 4 regular plastic cups on the lumbar spine for 10 minutes.
219408071|NCT06469762|OTHER|Placebo Dry Cupping|Dry cupping treatment session, using 4 plastic cups with two 2 mm holes drilled in either side of them, on the lumbar spine for 10 minutes.
219408072|NCT03716232|DEVICE|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~\- Stent will be extracted endoscopically after 6 months."
219568293|NCT03091413|DIAGNOSTIC_TEST|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
219568294|NCT03184259|DEVICE|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
219568295|NCT03184259|DEVICE|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
219568296|NCT02795637|DRUG|dasotraline|dasotraline 8mg capsule/day
219568297|NCT03649412|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
219568298|NCT03649412|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
219002722|NCT00968656|OTHER|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
219002723|NCT00968656|OTHER|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
219002724|NCT00968656|DRUG|F-18-ISO|Patients receive F-18-ISO-1 i.v.
219002725|NCT05740761|OTHER|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
219408073|NCT03716232|DEVICE|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
219408074|NCT00000271|DRUG|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
219408075|NCT00000271|DRUG|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
219408076|NCT03909191|DIAGNOSTIC_TEST|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
219408077|NCT06420648|OTHER|Early passive mobilization|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
219756035|NCT07159438|OTHER|AI-Generated Video Radiology Report Explanation|Participants receive a personalized video explanation of their own radiology imaging results, generated using artificial intelligence technology. The AI converts the participant's existing written radiology report into an easy-to-understand video format featuring an avatar narrator. Each video is approximately 1-5 minutes long and explains the participant's specific imaging findings in plain language. All AI-generated videos are reviewed by qualified medical personnel before delivery to ensure accuracy and prevent misleading information. Participants watch their personalized video and then complete survey to evaluate how well the video helped them understand their radiology results compared to the original written report.
219756036|NCT07159893|DRUG|Inebilizumab + Rapid Steroid Tapering group|"Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-19: 60 mg daily；Day 20: 60 mg every other day (EOD)~；Day 34: 30 mg EOD → Day 48: 15 mg EOD → Day 62: 10 mg EOD → Day 76: 5 mg EOD → Day 90: Discontinue Route: Oral"
219408078|NCT06420648|OTHER|Controlled active motion|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
219408079|NCT00619411|BEHAVIORAL|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
219568299|NCT04570397|DRUG|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
219568300|NCT02865395|DRUG|Belladonna and Opium Suppository|
219568301|NCT02865395|PROCEDURE|Rectal Exam|
219568302|NCT04597398|DEVICE|Evaluation of blood flow with indocyanine green|
219568303|NCT01714349|PROCEDURE|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
219568304|NCT05820867|PROCEDURE|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
219568305|NCT05820867|PROCEDURE|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
219568306|NCT06531915|DRUG|Ciprofol|Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
219568307|NCT06531915|DRUG|Remimazolam|Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
219408080|NCT00399984|BEHAVIORAL|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
219408081|NCT04207957|DRUG|Olorofim|150 mg
219408082|NCT00904826|DRUG|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
219408083|NCT06982937|OTHER|High-Intensity Half-Squat|Participants in the conditioning arm perform a single set of two to three half-squats with a free-weight barbell set at 90% of their one-rep max (1RM). Each squat is taken down until the thigh is parallel to the floor (knee at \~90°) and then driven upward as explosively as possible.
219568308|NCT00292331|PROCEDURE|cyanoacrylate injection to treat gastric variceal hemorrhage|
219568309|NCT06679465|DRUG|Tiotropium (Spiriva®)|2 puffs tiotropium prior to allergen challenge
219568310|NCT06679465|DRUG|Placebo|2 puffs placebo
219568311|NCT03589196|PROCEDURE|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
219568312|NCT03589196|PROCEDURE|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
219568313|NCT03589196|PROCEDURE|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
219408084|NCT06982937|OTHER|Treadmill running|Participants engaged in a standardized 5-minute treadmill warm-up. Participants were instructed to walk at a moderate, self-selected pace of approximately 7-9 km/h, maintaining an incline of 0%. Heart rate and perceived exertion were monitored to ensure that the activity remained within a light-intensity range (Borg scale: 6-11).
219408085|NCT01893190|DRUG|Nimodipine|Based upon Investigator Judgement
219408086|NCT01893190|DRUG|Nimodipine Microparticles|Based upon Investigator Judgement
219408087|NCT02426411|DRUG|EMA401 200 mg|
219408088|NCT02426411|DRUG|EMA401 600 mg|
219408089|NCT02426411|DRUG|Placebo|
219408090|NCT01308320|DRUG|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
219408091|NCT01308320|DRUG|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
219408092|NCT00195260|DRUG|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
219408093|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
219408094|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
219408095|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
219408096|NCT03472378|DRUG|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
219408097|NCT03472378|OTHER|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
219408098|NCT00880672|DRUG|dutasteride|5mg, oral, daily, 2-4 weeks
219408099|NCT06177782|DEVICE|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
219408100|NCT06177782|DEVICE|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
219408101|NCT00226681|BEHAVIORAL|Nursing Telephone Support Protocol|
219408102|NCT00226681|BEHAVIORAL|Usual Care|
219408103|NCT03860311|DEVICE|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
219408104|NCT03860311|OTHER|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
219408105|NCT05841134|DRUG|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
219408106|NCT03119116|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
219408107|NCT03119116|DRUG|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
219408108|NCT03119116|DRUG|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
219408109|NCT03118531|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
219568314|NCT04973813|BEHAVIORAL|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
219408110|NCT06442852|OTHER|exposure|The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
219408111|NCT03930953|DRUG|CC-99282|Specified dose on specified days
219408112|NCT03930953|DRUG|Rituximab|Specified dose on specified days
219408113|NCT03930953|DRUG|Obinutuzumab|Specified dose on specified days
219408114|NCT03930953|DRUG|Tafasitamab|Specified dose on specified days
219408115|NCT03930953|DRUG|Valemetostat|Specified dose on specified days
219408116|NCT02768649|DRUG|RBP-7000|Sequential dosing of each cohort
219408117|NCT02768649|DRUG|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
219408118|NCT02973841|DEVICE|Sono-ease device|insertion of US guided IJV using sono-ease device
219408119|NCT02249234|DRUG|Botox|
219408120|NCT02249234|DRUG|Placebo|
219408121|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
219408122|NCT05057273|DRUG|BT-11|Oral once daily tablet
219408123|NCT05057273|DRUG|Active comparator|Biologic
219568315|NCT04973813|BEHAVIORAL|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
219568316|NCT04973813|BEHAVIORAL|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
219002726|NCT01432860|BEHAVIORAL|In-person counseling|The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
219408124|NCT04229498|DRUG|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
219408125|NCT01778387|PROCEDURE|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
219408126|NCT02277899|OTHER|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
219408127|NCT02277899|OTHER|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
219408128|NCT02277899|OTHER|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
219408129|NCT02277899|OTHER|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
219408130|NCT02277899|OTHER|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
219408131|NCT01599468|DRUG|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
219408132|NCT01599468|DRUG|saline serum|The Placebo group received normal saline with the same volumes
219408133|NCT02153450|DRUG|metformin hydrochloride|Given PO
219408134|NCT02153450|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
219408135|NCT03682510|PROCEDURE|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
219408136|NCT03682510|PROCEDURE|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
219408137|NCT03682510|PROCEDURE|N&H sandwich technique|In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
219408138|NCT03823417|DRUG|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
219408139|NCT03823417|DRUG|Normal saline|Normal saline infusion
219408140|NCT02432287|DRUG|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
219408141|NCT02432287|DRUG|Placebo|there is no other name we used for the placebo
219408142|NCT04427787|DRUG|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
219408143|NCT04427787|DRUG|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
219002727|NCT01432860|BEHAVIORAL|Workbook|Participants will read a workbook and perform skills training exercises.
219002728|NCT01432860|BEHAVIORAL|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
219002729|NCT00006903|DRUG|Fulvestrant|Given intramuscularly
219408144|NCT03041194|OTHER|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
219408145|NCT01975272|DRUG|Ferinject|
219408146|NCT01975272|DRUG|Ferrous fumarate|
219408147|NCT01975272|DRUG|Placebo for ferrous fumarate|
219408148|NCT01975272|DRUG|Placebo for ferinject|
219408149|NCT04661930|DRUG|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
219408150|NCT04661930|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
219408151|NCT04661930|OTHER|Usual care|All participants will otherwise receive usual medical care
219408152|NCT06512467|DRUG|Donafenib|200 mg BID,oral administration will start before the first HAIC treatment .
219408153|NCT06512467|DRUG|Sintilimab|200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
219408154|NCT06512467|OTHER|HAIC|HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
219408155|NCT03369301|DRUG|Gammanorm|Gammanorm given per standard of care
219568317|NCT04973813|BEHAVIORAL|Guideline (G)|Web-based information about the national physical activity guideline.
219568318|NCT02504814|DEVICE|Nasal Highflow (NHF)|changes in breathing physiology in NHF
219568319|NCT05893446|DIETARY_SUPPLEMENT|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
219568320|NCT04073017|DIETARY_SUPPLEMENT|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
219568321|NCT04073017|OTHER|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
219568322|NCT02092337|OTHER|computer-assisted speech training|
219568323|NCT01054352|DRUG|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
219568324|NCT01054352|DRUG|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
219408156|NCT03369301|DRUG|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
219756037|NCT07159893|DRUG|Inebilizumab + Standard Steroid Tapering group|Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-34: 60 mg daily;Day 34: 60 mg EOD → Day 62: 30 mg EOD → Day 90: 15 mg EOD → Day 118: 10 mg EOD → Day 146: 5 mg EOD → Day 174:Discontinue; Route: Oral
219756038|NCT03094143|PROCEDURE|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
219756039|NCT04460781|BIOLOGICAL|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
219756040|NCT04460781|BIOLOGICAL|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
219408157|NCT03695432|BIOLOGICAL|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
219408158|NCT03695432|DIETARY_SUPPLEMENT|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
219408159|NCT03695432|OTHER|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
219408160|NCT03695432|OTHER|Placebo probiotic|Capsul
219408161|NCT01234012|BIOLOGICAL|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
219408162|NCT03392753|PROCEDURE|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
219408163|NCT03392753|PROCEDURE|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
219568325|NCT01054352|DRUG|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
219568326|NCT01054352|DRUG|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
219568327|NCT04394338|OTHER|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
219568328|NCT06326177|PROCEDURE|Spine Posture Assessment|Spine posture will be assessed with double inclinometer method. After determining landmarks for each assessment, inclinometers will be placed and degree will be noted. Both degree which are obtained with different inclinometers will be used to summed up for determining postural alteration degree. Cervical, thoracal, thoracolumbar and lumbar spinal postures will be used. Spine postures are going to be expressed as, cervical lordosis degree, thoracal kyphosis degree, thoracolumbar posture degree and lumbar lordosis degree. Landmarks for cervical lordosis are C2 and C7, for thoracal kyphosis are T1 and T12, for lumbar lordosis are T12 and S1, for thoracolumbar posture C7 and S1.
219568329|NCT06326177|PROCEDURE|Spine Movement Assessment|Spine movement will be assessed via using bubble inclinometer in terms of degree. Bony landmarks will be spotted like done in spine posture assessment after that full spinal flexion and extension wanted in order to record degrees in inclinometers at the end range. As a result the difference between two inclinometer will give the motion of that segment. Lumbar and thoracolumbar spinal movement will be assessed with this method. For thoracal and cervical range of motion values will be recorded separately without substruction from both inclinometer. Thoracal rotation range of motion will be assessed with two landmarks and will be recorded separately according to landmark. Thoracolumbar range of motion will be assessed with two substruction of degrees. Landmarks for cervical range of motion are vertex and C7, for thoracal range of motion are T1 and T12, for lumbar range of motion are T12 and S1, for thoracolumbar range of motion C7 and S1.
219756041|NCT00822094|DRUG|CPX-351|
219756042|NCT00822094|DRUG|Intensive Salvage Therapy|
219756043|NCT02455869|DRUG|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
219756044|NCT02455869|DRUG|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
219756045|NCT02455869|DRUG|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
219408164|NCT00515008|BEHAVIORAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
219408165|NCT00515008|BEHAVIORAL|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
219408166|NCT05823909|DEVICE|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
219408167|NCT05823909|DEVICE|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
219408168|NCT03634605|PROCEDURE|Chemical pleurodesis|
219408169|NCT03634605|DRUG|Tetracycline Topical Ointment|
219408170|NCT03634605|DRUG|Normal saline|
219408171|NCT03634605|DRUG|Lidocaine 2% Injectable Solution|
219408172|NCT01011881|OTHER|pleural level of procalcitonin|no intervention
219408173|NCT04961801|DRUG|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
219408174|NCT05828264|BEHAVIORAL|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
219408175|NCT03611959|OTHER|Non Applicable|
219408176|NCT02444897|DRUG|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
219408177|NCT02444897|DRUG|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
219408178|NCT05091060|DEVICE|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
219408179|NCT04266860|OTHER|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
219408180|NCT04841629|OTHER|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
219408181|NCT04841629|OTHER|Trimosan Gel|Carbomer-based gel
219408182|NCT04841629|OTHER|RepHresh Gel|Carbomer-based gel
219408183|NCT00870272|DRUG|Misoprostol|400mcg misoprostol taken sublingually or buccally
219756046|NCT01269684|DRUG|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
219756047|NCT04648020|DRUG|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
219756048|NCT04648020|DRUG|Placebo Mucoadhesive Buccal Tablet|Placebo
219756049|NCT01534559|OTHER|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
219756050|NCT01621646|OTHER|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
219756051|NCT05878574|DRUG|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
219756052|NCT00022438|BIOLOGICAL|aldesleukin|
219756053|NCT00022438|BIOLOGICAL|incomplete Freund's adjuvant|
219756054|NCT00022438|BIOLOGICAL|recombinant tyrosinase-related protein-2|
219756055|NCT01510093|DRUG|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
219756056|NCT03542617|DRUG|Dexamethasone|
219756057|NCT03542617|DRUG|Normal Saline Solution|
219756058|NCT00906061|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
219756059|NCT03044795|DRUG|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
219756060|NCT05090787|DEVICE|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
219756061|NCT05090787|DEVICE|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
219568330|NCT06326177|PROCEDURE|Core Muscle Endurance Assessment|Core muscle endurance is divided into three components. Trunk anterior flexion test will be used to assess anterior core region endurance. Lateral plank test will be used to determine lateral core muscle endurance. Trunk posterior extensor test will be used to determine endurance of the posterior core musculature. All of these test are calculated in predetermined positions according to literature with static contractions. Maximum duration of maintaining that position is needed. In trunk anterior flexion test participant will sit with 60 degree inclination from the ground while making contact with their feet when hips and knees are flexed. In lateral plank test participants should place their elbow to ground and lift their hip while feet are in contact with ground in side lying position. In trunk extensor endurance test participants will lie prone to the bed while maintaining contact with their ASIS and lower extremity. The upper body should stay outside of the bed.
219002730|NCT05380804|DIAGNOSTIC_TEST|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
219408184|NCT01284179|BEHAVIORAL|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
219002731|NCT05741632|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
219002732|NCT05741632|DRUG|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
219002733|NCT04819074|PROCEDURE|Microsurgery|Microsurgery for unruptured intracranial aneurysm
219408185|NCT01284179|BEHAVIORAL|Educational|Educational recordings regarding FCP and FGIDs.
219408186|NCT01798706|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
219002734|NCT01277263|DEVICE|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
219002735|NCT04833881|OTHER||
219002736|NCT01678911|DRUG|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
219408187|NCT01798706|DRUG|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
219408188|NCT01798706|DRUG|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
219408189|NCT03671759|BEHAVIORAL|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
219408190|NCT03671759|BEHAVIORAL|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
219408191|NCT05666011|DEVICE|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
219002737|NCT04697524|BEHAVIORAL|Support Group Therapy|Virtual group meetings
219408192|NCT02949765|DRUG|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
219002738|NCT04697524|BEHAVIORAL|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
219408193|NCT02949765|DIETARY_SUPPLEMENT|Iron-rich diet|
219002739|NCT04697524|OTHER|Quality of Life (QOL) Questionnaires|Administered at each study visit
219002740|NCT04697524|OTHER|Interview|Virtual exit interview at end of study
219002741|NCT05502757|OTHER|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
219408194|NCT03817593|OTHER|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
219408195|NCT00496873|DRUG|Cytoxan|600 mg/m\^2 on Day 1 of 21-day cycle.
219408196|NCT00496873|DRUG|Nipent|4 mg/m\^2 on Day 1 of 21 Day Cycle.
219408197|NCT00496873|DRUG|Rituxan|375 mg/m\^2 on Day 1 of 21 Day Cycle.
219408198|NCT04201769|DRUG|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
219408199|NCT04201769|DRUG|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
219408200|NCT03769740|DEVICE|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
219408201|NCT02484573|DRUG|Propanolol|
219408202|NCT04652063|OTHER|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
219408203|NCT02979795|PROCEDURE|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
219408204|NCT05162612|DIAGNOSTIC_TEST|abtominal CT|standard basic Abdominal Ct scan
219408205|NCT00942773|DRUG|Voriconazole|
219408206|NCT04146584|DEVICE|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
219408207|NCT02775864|DRUG|Antipsychotic|New initiation of any antipsychotic medication
219408208|NCT02775864|DRUG|Antidepressant|New initiation of any antidepressant medications
219408209|NCT02775864|DRUG|Benzodiazepine|New initiation of any benzodiazepine
219408210|NCT02775864|DRUG|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
219408211|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
219408212|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
219408213|NCT00953550|DRUG|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
219408214|NCT00953550|DRUG|Succinylcholine|1 mg/kg
219408215|NCT01276067|DRUG|Donepezil|10 mg Tablet
219408216|NCT02839967|OTHER|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
219002742|NCT05460845|BEHAVIORAL|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
219568331|NCT06326177|PROCEDURE|Scapular Dyskinesia|Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
219568332|NCT06326177|PROCEDURE|Shoulder Strength|Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
219408217|NCT02839967|OTHER|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
219408218|NCT02826044|DRUG|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
219408219|NCT04194658|DRUG|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
219408220|NCT05215392|BEHAVIORAL|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
219408221|NCT03238235|DRUG|Givinostat|suspension of Givinostat (10 mg/mL)
219408222|NCT03238235|DRUG|Placebo|suspension manufactured to mimic Givinostat
219408223|NCT00096096|DRUG|mycophenolate mofetil|
219408224|NCT00096096|DRUG|tacrolimus|
219408225|NCT03048240|DEVICE|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
219408226|NCT03048240|DRUG|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
219408227|NCT01506414|DRUG|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
219568333|NCT02581878|DRUG|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
219568334|NCT05108844|PROCEDURE|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
219568335|NCT04155827|OTHER|SIT|Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
219568336|NCT05628441|OTHER|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
219568337|NCT06502210|PROCEDURE|Personalized surgical therapy of neuroblastoma|If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
219568338|NCT03319069|RADIATION|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
219568339|NCT03319069|RADIATION|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
219408228|NCT06149312|OTHER|Advance Care Planning Intervention|Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
219568340|NCT00964106|DRUG|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
219568341|NCT00964106|DRUG|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
219568342|NCT00964106|DRUG|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
219568343|NCT00964106|DRUG|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
219568344|NCT00964106|DRUG|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
219568345|NCT00964106|DRUG|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
219002743|NCT01073891|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
219002744|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
219408229|NCT02018614|OTHER|algoplus|
219408230|NCT05896761|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
219568346|NCT00964106|DRUG|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
219568347|NCT00964106|DRUG|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
219568348|NCT00964106|DRUG|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
219568349|NCT00964106|DRUG|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
219408231|NCT05896761|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
219002745|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
219002746|NCT02521610|DRUG|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
219408232|NCT03868228|PROCEDURE|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
219408233|NCT00177541|BEHAVIORAL|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
219408234|NCT03638089|BEHAVIORAL|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
219408235|NCT00178360|BEHAVIORAL|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art"
219568350|NCT00964106|DRUG|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
219568351|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
219568352|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
219568353|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
219568354|NCT00275639|DRUG|Cozaar|
219568355|NCT00489749|PROCEDURE|Protected early weightbearing/Achilles tendon surgery|
219568356|NCT02245698|BIOLOGICAL|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
219408236|NCT04008862|BEHAVIORAL|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
219408237|NCT03189576|DIAGNOSTIC_TEST|blood draw|
219408238|NCT05416229|DRUG|Psilocybin|Psilocybin-assisted therapy
219408239|NCT05416229|DRUG|Maltodextrin|Placebo-assisted therapy
219408240|NCT01191294|OTHER|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
219408241|NCT02740569|OTHER|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
219408242|NCT02112162|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/MRI
219408243|NCT02112162|DEVICE|positron emission tomography|Undergo FDG PET/MRI
219408244|NCT02112162|DEVICE|magnetic resonance imaging|Undergo FDG PET/MRI
219408245|NCT02112162|OTHER|laboratory biomarker analysis|Correlative studies
219408246|NCT01348282|DRUG|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
219408247|NCT01348282|DRUG|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
219408248|NCT03755531|DRUG|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
219408249|NCT03755531|DRUG|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
219408250|NCT04963712|DRUG|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
219408251|NCT03641989|OTHER|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
219408252|NCT03641989|OTHER|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
219568357|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
219568358|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
219756062|NCT04754464|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
219002747|NCT02521610|DRUG|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
219002748|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
219408253|NCT02209233|OTHER|Massage Therapy|
219408254|NCT00619684|DRUG|lenalidomide|Given PO
219408255|NCT00000579|PROCEDURE|Low Tidal Volume Ventilation|
219408256|NCT00000579|PROCEDURE|Positive End-Expiratory Pressure|
219408257|NCT00000579|DRUG|Lysofylline|
219408258|NCT00000579|DRUG|Methylprednisolone|
219408259|NCT00000579|DRUG|Ketoconazole|
219408260|NCT00000579|PROCEDURE|Fluid Management|
219408261|NCT00000579|PROCEDURE|Pulmonary Artery Catheter|
219408262|NCT02028338|COMBINATION_PRODUCT|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
219408263|NCT02028338|COMBINATION_PRODUCT|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
219002749|NCT05972265|BEHAVIORAL|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
219002750|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
219408264|NCT00047281|DRUG|celecoxib|
219408265|NCT00047281|DRUG|cyclophosphamide|
219408266|NCT00047281|DRUG|etoposide|
219408267|NCT00047281|DRUG|thalidomide|
219408268|NCT04617613|DRUG|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
219408269|NCT04617613|DRUG|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
219408270|NCT00843310|DRUG|Lenalidomide (Revlimid)|
219408271|NCT00843310|DRUG|Melphalan|
219408272|NCT00843310|DRUG|Dexamethasone|
219756063|NCT04754464|DIETARY_SUPPLEMENT|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
219408273|NCT05813210|DIAGNOSTIC_TEST|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
219568359|NCT05715476|PROCEDURE|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
219568360|NCT02574338|DEVICE|Foley's Catheter|intracervical extraamniotic Foley's catheter
219568361|NCT02574338|DRUG|prostaglandin E1 analogue|intravaginal misoprostol
219756064|NCT06157021|PROCEDURE|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
219408274|NCT03273075|DRUG|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
219408275|NCT03273075|DRUG|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
219408276|NCT03273075|DRUG|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
219002751|NCT05972265|OTHER|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
219408277|NCT03273075|DRUG|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
219408278|NCT03552549|BIOLOGICAL|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
219408279|NCT03552549|BIOLOGICAL|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
219408280|NCT04224740|DRUG|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
219408281|NCT04224740|DRUG|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
219568362|NCT01540292|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
219568363|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
219568364|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
219568365|NCT01657526|BIOLOGICAL|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
219568366|NCT01613794|DRUG|Rosuvastatin|20 mg od
219568367|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
219756065|NCT06157021|PROCEDURE|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
219756066|NCT01817387|BEHAVIORAL|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
219756067|NCT01817387|BEHAVIORAL|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
219756068|NCT05155111|DIAGNOSTIC_TEST|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
219002752|NCT05972265|OTHER|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
219408282|NCT00363012|BIOLOGICAL|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
219408283|NCT00363012|OTHER|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
219408284|NCT00363012|OTHER|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
219408285|NCT00363012|PROCEDURE|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
219408286|NCT00363012|OTHER|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
219408287|NCT03403504|DRUG|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
219408288|NCT03403504|DRUG|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
219408289|NCT03714113|DIAGNOSTIC_TEST|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
219408290|NCT02796924|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
219408291|NCT04099316|DEVICE|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
219408292|NCT04099316|DEVICE|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
219408293|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
219408294|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219408295|NCT01257217|DEVICE|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
219408296|NCT01257217|DEVICE|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219408297|NCT00467909|BEHAVIORAL|micronutrients|
219408298|NCT06531382|OTHER|Nurses attitudes toward adressing sexual health in patients with cancer|"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.~The aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.~Method: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.~The questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register."
219408299|NCT02421328|DEVICE|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
219408300|NCT02421328|DEVICE|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
219408301|NCT01044173|DEVICE|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
219568368|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
219756069|NCT03220009|PROCEDURE|Conventional Surgery|Undergo surgery
219756070|NCT03220009|BIOLOGICAL|Ipilimumab|Given IV
219756071|NCT03220009|OTHER|Laboratory Biomarker Analysis|Correlative studies
219756072|NCT03220009|BIOLOGICAL|Nivolumab|Given IV
219756073|NCT03220009|OTHER|Patient Observation|Undergo active surveillance
219756074|NCT03220009|RADIATION|Radiation Therapy|Undergo RT
219756075|NCT00556114|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography
219756076|NCT01117779|DEVICE|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
219756077|NCT06142864|OTHER|Data collection|Data collection
219756078|NCT01344148|DRUG|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
219756079|NCT01652313|DRUG|Rasagiline|1 mg/day, tablets for 7 days, orally
219756080|NCT04899765|BIOLOGICAL|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
219756081|NCT04899765|BIOLOGICAL|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
219756082|NCT04899765|OTHER|Placebo|Saline
219002753|NCT05972265|OTHER|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
219002754|NCT05972265|OTHER|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
219408302|NCT06298292|DIETARY_SUPPLEMENT|Zero minis (range of protein substitutes in tablet form)|Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
219408303|NCT01158495|PROCEDURE|Intubation with a cuffed ET Tube|
219408304|NCT01158495|PROCEDURE|CT scan Radiation|
219408305|NCT03756974|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
219408306|NCT03756974|DRUG|Placebo|Placebo of BX-1, oral solution
219408307|NCT00817986|DRUG|Arbaclofen placarbil, 20 mg|tablets
219408308|NCT00817986|DRUG|Placebo|tablets
219408309|NCT00817986|DRUG|Arbaclofen placarbil, 30 mg|tablets
219408310|NCT00817986|DRUG|Arbaclofen placarbil, 40 mg|tablets
219408311|NCT01414816|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
219408312|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
219002755|NCT05972265|OTHER|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
219408313|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
219408314|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
219408315|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
219408316|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
219408317|NCT02995681|OTHER|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
219408318|NCT02995681|OTHER|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
219408319|NCT04883385|OTHER|medical data collection|collection of medical data from patients' medical records
219408320|NCT01442129|BIOLOGICAL|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
219408321|NCT01442129|BIOLOGICAL|Control Solution|Injection of control solution during the LVAD implantation.
219408322|NCT00701740|DRUG|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
219408323|NCT00701740|DRUG|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
219408324|NCT00993603|BEHAVIORAL|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
219408325|NCT02739594|DRUG|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
219408326|NCT02739594|DRUG|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
219408327|NCT03259542|DRUG|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
219408328|NCT03259542|DRUG|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
219408329|NCT03318640|BEHAVIORAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
219408330|NCT00199264|DRUG|Albaconazole oral solution|
219408331|NCT00041717|DRUG|Fampridine-SR|25mg bid (twice daily)
219408332|NCT00041717|OTHER|Placebo|Placebo
219408333|NCT05323786|PROCEDURE|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
219408334|NCT05323786|PROCEDURE|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
219002756|NCT01980992|DRUG|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
219408335|NCT06207500|PROCEDURE|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
219002757|NCT03018509|DRUG|JTE-451|Active drug tablets containing JTE-451
219002758|NCT03018509|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
219002759|NCT05306301|DRUG|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
219002760|NCT01238471|DRUG|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
219408336|NCT03734107|BEHAVIORAL|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
219408337|NCT01350037|DRUG|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
219408338|NCT01350037|DRUG|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
219408339|NCT03774693|OTHER|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
219408340|NCT03774693|PROCEDURE|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
219408341|NCT01465178|DIETARY_SUPPLEMENT|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
219408342|NCT01465178|DIETARY_SUPPLEMENT|Placebo|matching placebo
219408343|NCT00527111|DRUG|Cetuximab|
219408344|NCT00527111|DRUG|5-fluorouracil|
219408345|NCT00527111|RADIATION|Pelvic irradiation|
219408346|NCT06189677|OTHER|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
219408347|NCT03732872|DIAGNOSTIC_TEST|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
219408348|NCT03732872|DIAGNOSTIC_TEST|Saliva analysis|Saliva samples for miRNA 21 expression analysis
219408349|NCT06672094|DIETARY_SUPPLEMENT|NeuroQ|Two (2) capsules of NeuroQ taken once a day for 60 days.
219408350|NCT06672094|OTHER|Placebo|Two (2) capsules of placebo taken once a day for 60 days.
219002761|NCT01238471|DRUG|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
219002762|NCT03042624|DIETARY_SUPPLEMENT|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
219002763|NCT03042624|DIETARY_SUPPLEMENT|Maltodextrins|7 g of maltodextrins powder
219408351|NCT02487849|PROCEDURE|HIPEC|secondary cytoreductive operation
219408352|NCT02487849|DRUG|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
219408353|NCT04806932|PROCEDURE|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
219408354|NCT04806932|PROCEDURE|The conventional approach|The conventional approach
219408355|NCT02916498|DEVICE|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
219408356|NCT00647777|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fed
219408357|NCT00647777|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fed
219408358|NCT03827473|DRUG|Abiraterone Acetate|Given PO
219408359|NCT03827473|DRUG|Antiandrogen Therapy|Given per standard of care
219408360|NCT03827473|DRUG|Docetaxel|Given IV
219408361|NCT03827473|DRUG|Prednisone|Given PO
219408362|NCT03827473|OTHER|Quality-of-Life Assessment|Ancillary studies
219408363|NCT03827473|OTHER|Questionnaire Administration|Ancillary studies
219408364|NCT01395589|DRUG|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
219408365|NCT04081844|DRUG|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
219408366|NCT04081844|DRUG|HGP0904|Amlodipine 5mg(Norvasc)
219408367|NCT04081844|DRUG|HGP0608|Losartan 100mg(Cozaar)
219568369|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
219568370|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
219756083|NCT01624753|DEVICE|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
219756084|NCT04362735|DRUG|Vedolizumab|Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
219756085|NCT03768037|DRUG|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
219756086|NCT03768037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
219756087|NCT06564883|DEVICE|0.20% sodium hyaluronate gel|Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
219756088|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 35mg TID
219756089|NCT00034814|DRUG|Placebo|Enzyme-inducing placebo TID
219756090|NCT00034814|DRUG|Talampanel|Enzyme-inducing Talampanel 35 mg TID
219756091|NCT00034814|DRUG|Talampanel|Enzyme-inducing TLP 50mg TID
219756092|NCT00034814|DRUG|Placebo|Non-enzyme-inducing placebo TID
219756093|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 25mg TID
219756094|NCT01959685|DRUG|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
219756095|NCT01959685|DRUG|Placebo|Placebo, single dose
219756096|NCT05931731|OTHER|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
219756097|NCT05931731|OTHER|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
219756098|NCT05931731|OTHER|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
219756099|NCT02183584|DRUG|Rifampicin|
219756100|NCT02183584|DRUG|Linagliptin|
219756101|NCT04055974|BEHAVIORAL|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
219756102|NCT03527784|DEVICE|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
219408368|NCT02167568|GENETIC|Genetic|
219408369|NCT02674581|DRUG|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
219408370|NCT01477892|DRUG|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
219408371|NCT00409604|DEVICE|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
219408372|NCT00102505|DRUG|Motexafin Gadolinium Injection|
219408373|NCT01476176|DRUG|Experimental paracetamol|experimental paracetamol with caffeine
219408374|NCT01476176|DRUG|Paracetamol marketed formulation|marketed formulation containing caffeine
219408375|NCT00086658|DRUG|mepolizumab|
219408376|NCT00473161|DEVICE|surface EMG biofeedback|
219408377|NCT01921257|DRUG|Cat-PAD|
219408378|NCT01921257|DRUG|Placebo|
219408379|NCT04008589|DEVICE|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
219408380|NCT04008589|DEVICE|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
219408381|NCT03462446|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
219408382|NCT03462446|DRUG|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
219408383|NCT04517617|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
219408384|NCT01996735|DRUG|Ticagrelor 180 mg single dose|
219408385|NCT01996735|DRUG|Placebo|
219002764|NCT06354400|OTHER|Core stabilization training|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control. Breathing control will be coordinated with every exercise.
219002765|NCT05104229|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
219408386|NCT03393364|DRUG|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
219408387|NCT03393364|DRUG|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
219568371|NCT03898531|PROCEDURE|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
219568372|NCT03898531|PROCEDURE|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
219568373|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
219568374|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 350mg|
219568375|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 500mg|
219568376|NCT02930668|DIETARY_SUPPLEMENT|Placebo|
219568377|NCT03302572|OTHER|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
219568378|NCT04744155|BEHAVIORAL|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
219568379|NCT04744155|BEHAVIORAL|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
219568380|NCT06295094|DRUG|Cisplatin|10.5 mg/m2 body surface in 150ml saline
219408388|NCT02187094|DRUG|TC-6499|
219408389|NCT02187094|DRUG|Placebo|
219408390|NCT03154723|DRUG|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
219408391|NCT05881551|DEVICE|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
219568381|NCT06295094|DRUG|Doxorubicin|2.1 mg/m2 body surface in 50ml saline
219568382|NCT00242229|DRUG|DVS-233 SR|
219568383|NCT00464139|PROCEDURE|Laparoscopy|Laparoscopy
219568384|NCT05804435|DEVICE|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
219568385|NCT03322020|RADIATION|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
219568386|NCT03322020|RADIATION|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
219568387|NCT05420116|BEHAVIORAL|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
219002766|NCT05104229|DRUG|Standard of Care|Standard of Care VTE prophylaxis
219002767|NCT03296358|DRUG|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
219408392|NCT05881551|OTHER|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
219408393|NCT00363805|DIETARY_SUPPLEMENT|green tea|Given orally
219408394|NCT00363805|DRUG|Polyphenon E|Given orally
219408395|NCT00363805|OTHER|placebo|Given orally
219408396|NCT05515601|DRUG|Mirikizumab|Administered SC.
219408397|NCT00777491|DRUG|induction cisplatin|15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
219408398|NCT00777491|DRUG|induction 5-fluorouracil|400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
219568388|NCT02276768|DRUG|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
219002768|NCT03296358|DRUG|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
219568389|NCT02276768|DRUG|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
219568390|NCT02276768|DRUG|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
219002769|NCT02232165|OTHER|Hypotension avoidance|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP \>= 65 mmHg is not inferior to induced hypertension.
219002770|NCT02232165|OTHER|Induced hypertension|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
219002771|NCT05775874|DRUG|AZD4547|Initiation dose: 80mg BID,po.
219002772|NCT05775874|DRUG|Tislelizumab|Tislelizumab:200mg Q3W
219002773|NCT05698797|OTHER|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
219002774|NCT05698797|OTHER|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
219002775|NCT05698797|OTHER|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
219002776|NCT05719766|OTHER|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
219408399|NCT00777491|DRUG|induction gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
219408400|NCT00777491|RADIATION|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
219408401|NCT00777491|RADIATION|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
219408402|NCT00777491|RADIATION|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
219408403|NCT00777491|RADIATION|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
219568391|NCT02276768|DRUG|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
219568392|NCT02276768|OTHER|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
219568393|NCT05449782|DIETARY_SUPPLEMENT|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
219568394|NCT05449782|OTHER|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
219568395|NCT04625062|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
219568396|NCT04625062|BEHAVIORAL|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
219568397|NCT05299567|DRUG|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
219568398|NCT01682148|BIOLOGICAL|Botulinum toxin type A|
219568399|NCT03711916|DEVICE|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
219568400|NCT05248984|DRUG|Ketorolac|"Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg"
219568401|NCT05380921|DEVICE|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
219568402|NCT05380921|DEVICE|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
219568403|NCT03466541|BEHAVIORAL|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
219002777|NCT05984966|BEHAVIORAL|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
219002778|NCT02817100|DRUG|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
219002779|NCT02817100|DRUG|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
219002780|NCT02817100|DRUG|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
219002781|NCT01666574|OTHER|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
219002782|NCT01666574|OTHER|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
219408404|NCT00777491|DRUG|consolidation gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
219408405|NCT00777491|DRUG|consolidation 5-fluorouracil|400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
219408406|NCT00777491|DRUG|consolidation cisplatin|15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
219408407|NCT00777491|PROCEDURE|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
219408408|NCT00777491|PROCEDURE|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
219408409|NCT00777491|DRUG|adjuvant gemcitabine|1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
219408410|NCT00777491|DRUG|adjuvant cisplatin|70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
219408411|NCT00398710|DRUG|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
219408412|NCT02353637|DIETARY_SUPPLEMENT|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
219408413|NCT04176432|OTHER|No intervention|Retrospective observational study with no intervention
219408414|NCT01805232|DRUG|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
219408415|NCT01805232|DRUG|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
219756103|NCT03527784|DEVICE|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
219002783|NCT03978338|DIETARY_SUPPLEMENT|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
219408416|NCT04398849|BIOLOGICAL|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
219408417|NCT01801137|DRUG|Everolimus (Afinitor®)|
219408418|NCT03870711|DRUG|lidocaine spray|10% lidocaine spray 4 puffs
219408419|NCT03870711|DRUG|Placebo|Sterile water 4 puffs
219408420|NCT00760227|OTHER|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
219408421|NCT00760227|OTHER|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
219408422|NCT00760227|OTHER|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
219408423|NCT01529476|DRUG|Levofloxacin|levofloxacin 500 mg,QD,7\~10 days
219408424|NCT01529476|DRUG|Nemonoxacin|Nemonoxacin 500mg,QD,7\~10 days
219756104|NCT03527784|DEVICE|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
219756105|NCT00365950|DRUG|Duration of anticoagulation|
219756106|NCT00365950|DRUG|Warfarin duration|
219568404|NCT03466541|BEHAVIORAL|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
219568405|NCT05123781|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
219568406|NCT05123781|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
219568407|NCT04203121|RADIATION|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
219568408|NCT01748955|DRUG|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
219568409|NCT01748955|DRUG|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
219756107|NCT06461780|OTHER|Line-based questionnaire follow-up|The participant will use LINE group to report irAE severity, distress, financial toxicity and change trajectory of quality of life in one-year follow-up. If the severity grade of irAE reach the threshold and require referral, an alarm will appear to notify the research team to conduct and transfer to a clinical specialitst, or refer to the emergency room for treatment. Additionally, the Line group will also provide clinical relevant immunotherapy health education information currently and routinely used in study site. Patients can view it according to their interests, but the APP will not actively promote it.
219002784|NCT03978338|OTHER|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
219002785|NCT03500952|OTHER|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
219408425|NCT02422927|DIETARY_SUPPLEMENT|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
219408426|NCT02422927|OTHER|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
219408427|NCT02422927|OTHER|Placebo|placebo
219408428|NCT00267280|DRUG|torcetrapib/atorvastatin|
219002786|NCT03500952|OTHER|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
219002787|NCT00456560|DRUG|AV650|
219002788|NCT00456560|DRUG|Fluvoxamine|
219002789|NCT00456560|DRUG|Paroxetine|
219408429|NCT00267280|DRUG|simvastatin|
219408430|NCT01912768|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
219408431|NCT01912768|DEVICE|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
219568410|NCT03827018|COMBINATION_PRODUCT|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
219568411|NCT03827018|COMBINATION_PRODUCT|placebo|1 mL of placebo in a pre-filled syringe
219568412|NCT03827018|DRUG|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
219568413|NCT00004079|DRUG|SarCNU|Given PO
219408432|NCT01912768|DEVICE|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
219408433|NCT04160468|DRUG|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
219408434|NCT04160468|DRUG|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
219408435|NCT03505567|DEVICE|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
219408436|NCT03505567|DEVICE|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
219408437|NCT01187901|DRUG|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
219408438|NCT01187901|DRUG|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
219408439|NCT01187901|DRUG|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
219408440|NCT01187901|DRUG|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
219408441|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily
219408442|NCT02150824|DRUG|Placebo|BI 187004 medium dose matching placebo once daily
219408443|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
219568414|NCT00004079|OTHER|pharmacological study|Correlative studies
219568415|NCT00004079|OTHER|laboratory biomarker analysis|Correlative studies
219568416|NCT00727077|BIOLOGICAL|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
219408444|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily add on to background metformin
219408445|NCT02150824|DRUG|Placebo|BI 187004 low dose matching placebo once daily
219408446|NCT02150824|DRUG|BI 187004|BI 187004 medium dose once daily
219408447|NCT02150824|DRUG|BI 187004|BI 187004 low dose once daily
219408448|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily
219408449|NCT03152916|DEVICE|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
219408450|NCT00088634|DRUG|Lurasidone|80 mg AM dosing once daily
219408451|NCT00088634|DRUG|Placebo|Matching Placebo to 40mg lurasidone tablets
219408452|NCT01592279|DRUG|liraglutide|
219408453|NCT01592279|DRUG|Insulin injections|
219568417|NCT00727077|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
219568418|NCT05592353|OTHER|Brace|Brace following hip arthroscopy
219568419|NCT01566526|DRUG|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
219568420|NCT06142669|DEVICE|EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert|Primary knee arthroplasty or a revision knee that requires a revision procedure.
219568421|NCT00746291|OTHER|6 min walk test, Step climbing|walking for 6 minute and climbing steps
219568422|NCT02850172|BEHAVIORAL|Walk, Eat, & Breathe|"1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery"
219408454|NCT06227390|PROCEDURE|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
219408455|NCT01803763|DRUG|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
219408456|NCT01803763|DRUG|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
219568423|NCT00980889|DEVICE|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
219408457|NCT04671914|DRUG|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
219408458|NCT04671914|OTHER|Dilation and curretage|After abortion in II trimester we do D\&C.
219408459|NCT06674096|DRUG|RLC-CRCHOP|"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"
219408460|NCT00540436|DRUG|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
219408461|NCT03948659|PROCEDURE|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
219408462|NCT00849979|BEHAVIORAL|Questionnaire|Day 1 MDASI-GI Questionnaire
219408463|NCT00849979|OTHER|Interview|Open-ended, audiotaped interviews
219408464|NCT06100471|OTHER|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
219408465|NCT03758378|OTHER|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
219408466|NCT00398151|DRUG|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
219408467|NCT00470353|DIETARY_SUPPLEMENT|calcium carbonate|
219408468|NCT00470353|DIETARY_SUPPLEMENT|cholecalciferol|
219408469|NCT00470353|OTHER|immunohistochemistry staining method|
219408470|NCT00470353|OTHER|laboratory biomarker analysis|
219408471|NCT00470353|OTHER|pharmacological study|
219408472|NCT00470353|PROCEDURE|biopsy|
219408473|NCT00040833|PROCEDURE|complementary or alternative medicine procedure|
219408474|NCT00040833|PROCEDURE|pain therapy|
219408475|NCT03611933|OTHER|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
219408476|NCT05362851|DRUG|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
219408477|NCT05362851|DRUG|YYC301 placebo & Celecoxib 200mg|comparator medication
219408478|NCT04292405|DEVICE|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
219408479|NCT01884454|BEHAVIORAL|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
219408480|NCT03255291|BEHAVIORAL|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
219408481|NCT03255291|BEHAVIORAL|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
219408482|NCT03255291|OTHER|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
219408483|NCT03255291|BEHAVIORAL|Audio Recording - Exercise|Participants imagine themselves improving exercise
219408484|NCT03255291|OTHER|Text message reminders|-Reminders to practice mental imagery
219408485|NCT03255291|OTHER|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
219568424|NCT00980889|DEVICE|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
219568425|NCT01017939|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
219408486|NCT01790737|DRUG|Cyclophosphamide|
219408487|NCT01790737|DRUG|Filgrastim|
219408488|NCT03167086|BEHAVIORAL|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
219408489|NCT03167086|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading."
219408490|NCT03167086|BEHAVIORAL|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
219408491|NCT06085846|DEVICE|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
219568426|NCT01017939|DRUG|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
219568427|NCT01017939|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
219568428|NCT01017939|DRUG|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
219568429|NCT00975741|DEVICE|OXIMAX|
219568430|NCT00975741|DEVICE|ASMANEX TWISTHALER|
219568431|NCT02165514|PROCEDURE|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
219568432|NCT03329976|OTHER|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
219568433|NCT04373382|BEHAVIORAL|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
219408492|NCT05348265|OTHER|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
219408493|NCT05348265|OTHER|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
219408494|NCT04898426|OTHER|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
219408495|NCT01401816|OTHER|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
219408496|NCT03243513|OTHER|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
219408497|NCT04355156|DRUG|Axitinib|"* All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
219408498|NCT04355156|DRUG|Placebo|"* All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
219408499|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Behavioral Counseling|
219408500|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Attention Control|
219408501|NCT03929588|DEVICE|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
219408502|NCT03929588|DEVICE|Phoropter|Manual refraction and ETDRS chart
219408503|NCT03929588|DEVICE|Autorefractor|Automated refraction
219568434|NCT04373382|BEHAVIORAL|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
219568435|NCT02087176|DRUG|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
219568436|NCT02087176|DRUG|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
219568437|NCT02087176|DRUG|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
219756108|NCT05464602|OTHER|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
219408504|NCT06336577|OTHER|lower respiratory tract disease|lower respiratory tract disease
219408505|NCT05155475|PROCEDURE|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
219408506|NCT00002533|DRUG|fluconazole|
219408507|NCT00002533|RADIATION|radiation therapy|
219408508|NCT01968096|DEVICE|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
219408509|NCT04993950|OTHER|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
219408510|NCT04993950|OTHER|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
219408511|NCT06608511|OTHER|Blood draw for the laboratory assessment|Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
219408512|NCT05347498|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
219408513|NCT05347498|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
219408514|NCT00471445|DRUG|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
219408515|NCT00471445|OTHER|placebo|Applied topically
219408516|NCT03934086|DRUG|rimegepant|rimegepant 75 mg
219408517|NCT00685620|BEHAVIORAL|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
219568438|NCT02087176|DRUG|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
219190143|NCT06374225|DEVICE|Automated Titration (O2matic)|The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.
219568439|NCT05553782|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
219568440|NCT02266394|DRUG|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
219190144|NCT03085719|DRUG|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
219190145|NCT03085719|RADIATION|Radiation|Radiation is used to shrink the cancer
219190146|NCT04618978|PROCEDURE|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
219190147|NCT06229080|DEVICE|NexGel|When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
219190148|NCT00490516|DRUG|ACP-104|200 mg, tablet, BID, 6 weeks
219190149|NCT00490516|DRUG|ACP-104|100 mg, tablet, BID, 6 weeks
219190150|NCT00490516|DRUG|Placebo|placebo, tablet BID, 6 weeks
219190151|NCT04966299|DIETARY_SUPPLEMENT|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit"
219190152|NCT04966299|DIETARY_SUPPLEMENT|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
219190153|NCT04966299|DIETARY_SUPPLEMENT|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
219568441|NCT02266394|PROCEDURE|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
219568442|NCT04081441|DEVICE|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
219756109|NCT05464602|OTHER|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
219756110|NCT00003561|BIOLOGICAL|recombinant interferon alfa|
219756111|NCT00003561|BIOLOGICAL|sargramostim|
219756112|NCT05427292|OTHER|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
219756113|NCT01170663|BIOLOGICAL|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
219756114|NCT01170663|DRUG|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
219756115|NCT01170663|DRUG|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
219756116|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
219756117|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
219756118|NCT00637910|DRUG|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
219756119|NCT00637910|DRUG|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). \_Until disease progression or unacceptable toxicity develops
219756120|NCT05406973|DEVICE|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
219756121|NCT00208130|DRUG|Topiramate|
219756122|NCT00529295|DRUG|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
219756123|NCT06163339|OTHER|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
219756124|NCT00427037|DRUG|Cholecalciferol|50,000 IU weekly by mouth
219756125|NCT00427037|DRUG|Placebo|identical placebo pill orally by mouth
219190154|NCT04966299|DIETARY_SUPPLEMENT|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
219408518|NCT01794494|PROCEDURE|Bypass surgery|Patients are treated with femoro-popliteal bypass
219408519|NCT01794494|PROCEDURE|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
219408520|NCT02330627|BEHAVIORAL|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
219408521|NCT03591146|DRUG|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
219408522|NCT03591146|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
219408523|NCT00236639|DRUG|topiramate|
219408524|NCT04737031|OTHER|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
219408525|NCT04737031|OTHER|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
219568443|NCT04081441|BEHAVIORAL|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
219568444|NCT02257619|DRUG|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
219568445|NCT02257619|DRUG|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
219568446|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
219568447|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
219568448|NCT05738655|DIETARY_SUPPLEMENT|Placebo|Placeo (300 mg/day)
219568449|NCT03648879|DEVICE|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
219756126|NCT02006927|DEVICE|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
219756127|NCT06513208|DRUG|Ketorolac Tromethamine|IV Ketorolac 15mg every 6 hours, x 4 doses
219190155|NCT04966299|DIETARY_SUPPLEMENT|Xylitol|Xylitol 33.5g dissolved in 300mL water administered once per visit
219190156|NCT04966299|DIETARY_SUPPLEMENT|Water|300mL water administered once per visit
219190157|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
219190158|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
219408526|NCT02572830|BEHAVIORAL|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
219408527|NCT02572830|BEHAVIORAL|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
219408528|NCT04323748|DRUG|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
219408529|NCT03922360|BEHAVIORAL|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
219408530|NCT03922360|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
219568450|NCT02230618|DRUG|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
219756128|NCT06513208|DRUG|Placebo|IV saline as placebo
219756129|NCT02172014|DRUG|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
219756130|NCT02172014|DRUG|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
219756131|NCT04435158|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
219408531|NCT04953650|BEHAVIORAL|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
219408532|NCT04953650|OTHER|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
219408533|NCT02021526|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
219408534|NCT06376214|DRUG|Dratumumab / Hyaluronidase Injection [Darzalex Faspro]|Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
219408535|NCT06376214|DRUG|Pomalidomide 4 MG|Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
219408536|NCT06376214|PROCEDURE|autologous stem cell transplantation (ASCT)|"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."
219408537|NCT01996137|DEVICE|VASST II treadmill|Supervised treadmill training under physiotherapist
219408538|NCT03003780|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
219408539|NCT05397899|OTHER|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
219408540|NCT05397899|OTHER|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
219408541|NCT00962039|DRUG|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
219408542|NCT00962039|DRUG|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
219408543|NCT00526149|DRUG|BI 2536|
219408544|NCT00526149|OTHER|high performance liquid chromatography|
219408545|NCT00526149|OTHER|mass spectrometry|
219408546|NCT00526149|OTHER|pharmacological study|
219408547|NCT00462020|DRUG|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
219568451|NCT06616480|DEVICE|BenQ Materials DSFNC1 soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
219568452|NCT06616480|DEVICE|Visco SiHy Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
219756132|NCT04435158|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
219568453|NCT03812991|DRUG|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
219756133|NCT01501357|BEHAVIORAL|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
219756134|NCT01501357|BEHAVIORAL|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
219756135|NCT02621892|DRUG|Tenapanor|
219756136|NCT02621892|DRUG|Placebo|
219756137|NCT03178409|PROCEDURE|Hepatectomy|Removal of a part of the liver
219756138|NCT00799565|GENETIC|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
219756139|NCT00765414|BIOLOGICAL|Myozyme|30 mg/kg qow f and 40 mg/kg qow
219408548|NCT00462020|DRUG|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
219408549|NCT04889534|PROCEDURE|Analgesia|Patients will be observed during postoperative period,
219408550|NCT01511419|BIOLOGICAL|LAIV H7N3|2 doses of vaccine
219408551|NCT01511419|BIOLOGICAL|placebo|2 doses of placebo
219408552|NCT06692790|OTHER|Venous Sinus Stenting Procedure|"Performed under general or local anesthesia. Targeted stenosis sites included the right transverse sinus, left transverse sinus, bilateral transverse sinuses, and right transverse and sigmoid sinuses.~Stents used included Venous Sinus Stent (CWS), CASPER, PRTCS, and multiple stents where necessary.~Post-procedure care included antiplatelet therapy and routine follow-up assessments"
219408553|NCT06693167|PROCEDURE|chirurgie canal carpien|study compares a group of patients who received a preoperative auriculotherapy session followed by standard analgesic treatment to a group who received only standard analgesic treatment, and this, during the three days following surgery (D1, D2, and D3).
219568454|NCT04740931|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
219568455|NCT04740931|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
219756140|NCT02920320|OTHER|Internet-based self-help program|
219756141|NCT02212860|RADIATION|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
219756142|NCT01358162|OTHER|Placebo|Placebo given orally, daily for 14 consecutive days
219756143|NCT01358162|DRUG|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
219408554|NCT06692023|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
219408555|NCT06692023|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
219408556|NCT06693193|DEVICE|Immersive Virtual Reality|Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.
219408557|NCT05549063|OTHER|Mobility and Stability Exercise|Mobility and stability exercises
219408558|NCT05549063|OTHER|Stretching Exercise|Balance and reaching exercise
219408559|NCT03238092|DRUG|Testosterone|testosterone gel daily during the late luteal phase.
219408560|NCT03238092|DRUG|Estradiol|oral estradiol during the late luteal phase.
219408561|NCT07044700|DRUG|Jardiance|Jardiance
219408562|NCT07044700|DRUG|non-SGLT2 inhibitors|non-SGLT2 inhibitors
219408563|NCT06200116|OTHER|Non-Interventional Study|Non-interventional study
219408564|NCT06742398|OTHER|Carbohydrate Dissolvable Strip|"Participants are provided with a carbohydrate dissolvable strip for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The carbohydrate dissolvable strip (Innsol Health Corp.) is primarily composed of sucrose and glucose; however, the full ingredient list includes pullulan, mannitol, menthol, hydroxyl propyl methyl cellulose, eucalyptol, polysorbate 80, glyceryl oleate, purified water."
219408565|NCT06742398|OTHER|Carbohydrate Mouth Rinse|"Participants are provided with a carbohydrate mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The sucrose solution will consist of 64g of sucrose dissolved in 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
219408566|NCT06742398|OTHER|Water Mouth Rinse|"Participants are provided with a water mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The water solution will consist of 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
219408567|NCT06098261|DRUG|Test (T) Bilastine|Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
219408568|NCT06098261|DRUG|Reference (R) Bilastine|Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
219408569|NCT03229759|DRUG|Octenidine Dihydrocloride in aqueous solution|application of investigational product
219408570|NCT03229759|OTHER|Vehicle Control|application of vehicle control
219408571|NCT03229759|OTHER|Saline Control|application of placebo
219408572|NCT07082790|OTHER|Music intervention|The music was provided to the pregnant women with wireless headphones worn over the head, an electronic acoustic device with sound-enhancing ear pads, and an adjustable headband. These headphones allowed the pregnant women to listen to music in isolation. The music played in the study was determined with the recommendation of the Research and Promotion of Turkish Music (TUMATA), which operates in Turkey and carries out treatment studies with Turkish music. Accordingly, pregnant women were made to listen to Acemashiran maqam, which is thought to have a positive effect on the uterus, the baby in the womb, and facilitate birth. According to TUMATA, Acemashiran Maqam has a fiery nature. It is a dry-hot makam. It is effective on bones and the brain. It helps balance fat in the body. It gives a sense of creativity and inspiration. Revitalizes stagnant thoughts and emotions. Facilitates childbirth in women. Helps to correct the wrong posture of the child in.
219408573|NCT07082790|OTHER|Virtual Reality Intervention|Pregnant women in the VR group were given adaptive three-dimensional (3D) glasses that fit snugly on their heads to optimize image quality and provide full distance adjustment. All pregnant women in the group were allowed to wear the glasses for a few minutes before the application in order to get used to the glasses. The image to be projected on the glasses was provided by placing a smartphone compatible with the glasses on the front of the glasses. Pregnant women in the VR group were shown an image of a green landscape with a relaxing sound accompanying the 3D images. Pregnant women in the VR group were shown an image of green nature due to the proven psychologically relaxing effect of green. Since the content in question is prepared in 360 degrees, the person wearing the glasses finds herself in the virtual world and experiences the feeling of being there, no matter which direction she looks.
219408574|NCT07082504|BEHAVIORAL|Physical Exercise Program|Participants will complete supervised moderate-intensity physical exercise sessions three times per week for 12 weeks (totaling 150 minutes per week). The program includes balance, flexibility, strength, and mobility exercises designed according to WHO and ACSM guidelines for older adults. Sessions are delivered in small groups by trained physiotherapists.
219408575|NCT07082504|BEHAVIORAL|Cognitive Stimulation Program|Participants will attend cognitive stimulation sessions three times per week for 12 weeks. Activities include memory games, attention tasks, puzzles, orientation exercises, and problem-solving strategies. The sessions are led by a psychologist and a trained social educator, in small groups.
219568456|NCT04740931|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
219568457|NCT00304707|DRUG|Bupropion|300 mg QD
219568458|NCT00304707|DRUG|placebo|placebo
219568459|NCT00345215|BEHAVIORAL|High Sodium Diet|250-350 mmol
219408576|NCT07082504|BEHAVIORAL|Combined Physical Exercise and Cognitive Stimulation|Participants will receive both the physical exercise and cognitive stimulation interventions, conducted in parallel, over a 12-week period with three sessions per week. The combined program aims to improve physical and cognitive functions simultaneously and is delivered by a multidisciplinary team.
219408577|NCT07083713|BEHAVIORAL|Group Coaching|Group coaching using a protocol developed with Coaching in Context model
219408578|NCT07084649|DEVICE|TMS|accelerated intermittent theta burst stimulation
219408579|NCT07083778|PROCEDURE|Laser Fistula Surgery (FiLaC - Fistula-tract Laser Closure)|A minimally invasive procedure using a radial fiber diode laser probe to ablate the fistula tract. Laser energy (10W in pulsed mode) is applied circumferentially as the probe is slowly withdrawn, leading to shrinkage and closure of the fistula tract. The internal opening is closed with absorbable sutures. The procedure is done under spinal or general anesthesia.
219408580|NCT07083778|PROCEDURE|Open Fistula Surgery (Fistulotomy, Fistulectomy, or LIFT Procedure)|"Patients in this group will undergo standard open surgical treatment for fistula-in-ano. Based on the type and location of the fistula (intersphincteric or transsphincteric), the surgical procedure may be:~* Fistulotomy: Laying open the fistula tract.~* Fistulectomy: Excision of the entire fistulous tract.~* LIFT Procedure: Ligation of the intersphincteric fistula tract, preserving the sphincter complex. This sphincter-sparing technique is chosen for transsphincteric fistulas when appropriate.~All procedures are performed under spinal anesthesia. The choice of technique is individualized based on MR fistulogram findings and intraoperative assessment. Wounds are managed with regular dressings and allowed to heal by secondary intention. Standard postoperative care includes antibiotics, analgesia, and sitz baths. Follow-up is done at 1 week, 1 month, 3 months, and 6 months."
219408581|NCT06931041|DRUG|insulin lispro|1 UI/ml of insulin added to the autologous serum formulation.
219408582|NCT06931041|OTHER|Autologous serum|Autologous Serum
219408583|NCT06929351|PROCEDURE|otago exercise|"Otago exercise program group 40 min/ thrice a week/ 8 weeks~1st week strengthening of knee flexors( prone lying), extensors ( in sitting) ,abductors( in standing) with 1-2 kg ankle cuff. Dorsi flexors, planter flexors(in standing on weight)/ hold 5-10 sec 5 reps/ 2 sets 2nd week Strengthening same as week 1 balance exercises.Knee bending( standing),tandem stance,sit to stand / with support/ 5-10 reps/2 sets 3rd week strengthening of all above Ms group with increase weight 2-3 kg ankle cuff or participant (The exercises are of moderate intensity; the person should not get unduly tired) balance exercise as 2nd week 4th week strengthening exs as in 3rd week balance exs: Knee bending, tandem stance( without support), forward walk,walking and turning around, side walk, one leg stand,sit to stand, stair climb( all with support)/5-10 reps 5th week strengthening exs of above ms group increase either weight 3-4 kg or repetitions 10-15 or hold time 10-15 sec 6th week strengthening same as 5"
219568460|NCT00345215|BEHAVIORAL|Low Sodium Diet|25-35 mmol
219568461|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
219568462|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
219568463|NCT03153826|OTHER|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
219756144|NCT01217034|DRUG|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
219756145|NCT01217034|PROCEDURE|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
219568464|NCT06677658|DIETARY_SUPPLEMENT|Olive Oil|Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.
219568465|NCT06677658|DRUG|Methylprednisolone|Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
219568466|NCT02812654|DRUG|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
219568467|NCT02812654|DRUG|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
219568468|NCT02812654|RADIATION|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
219568469|NCT03916562|BEHAVIORAL|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
219568470|NCT04099641|DRUG|Bavituximab|Bavituximab IV infusion
219568471|NCT04099641|DRUG|Pembrolizumab Injection|Pembrolizumab IV Infusion
219568472|NCT01391845|DRUG|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
219568473|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
219568474|NCT01391845|DRUG|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
219568475|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
219756146|NCT04065321|PROCEDURE|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
219756147|NCT04065321|PROCEDURE|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
219408584|NCT06929351|PROCEDURE|Dual task exercise|"Balance exercises and secondary cognitive task simultaneously 40 min/ thrice a week/ 8 weeks~1. st week Balance exercises: Narrow-base standing on the floor (firm surface) with eyes open and closed, Tandem standing on the floor with eyes open and closed, Single-leg standing on the floor with eyes open and closed, Wide-base walking on the floor, Chair sitting to standing transfer Cognitive tasks: Naming a group of cities; foodstuff; boy names; or girl names starting with A,I, S, and T sounds/ 3 trails~2. nd week Balance exercise: Narrow-base standing on the floor with open eyes while moving arms, Forward lunge standing on the floor with eyes open, Narrow-base walking on the floor, keeping balance while sitting on a ball and moving arms in different directions Cognitive task: Backward counting from 50,Count by multiple(3,6,9…….)/3trails Week 3 Balance exercises: Narrow-base standing on a foam with eyes open and closed, Tandem standing on a foam with eyes open and closed, Backward walking on"
219408585|NCT06929208|DEVICE|Electrocardiogram (ECG) monitor|"A novel AI-based risk stratification algorithm incorporated into portable platform will be used to monitor and measure patient's ECG, blood pressure, SpO2, and HRV parameters. The platform comprises a tablet application that the clinicians interface with, and coupled with a patient monitoring device with the app that received the real-time patient vital signs to be processed. It requires only a 5-minute 12-lead ECG recording and provides a diagnostic report and risk score on major adverse cardiac events in patients with chest pain complaints. The device is approved as a Class C Medical device by Health Science Authority Singapore for clinical use in Singapore.~Three ECG samples for HRV data will be recorded before, during and after music listening, with a sampling rate of 1000Hz, 5-10-minute duration in the supine position and breathing spontaneously to minimise influence from external factors."
219408586|NCT06929208|OTHER|Music listening|Patients will be given a mobile phone to choose their preferred music to be played during surgery. The music list contains songs across pre-saved playlists spanning different music genres compiled by the institution's music therapist to ensure adequate coverage of the various music genres and to promote relaxation and serenity.
219002790|NCT06311201|OTHER|Abdominal belt|This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
219002791|NCT06311201|OTHER|Pilates exercises|"The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery."
219002792|NCT00000793|DRUG|Mexiletine hydrochloride|
219002793|NCT00000793|DRUG|Benztropine mesylate|
219002794|NCT00000793|DRUG|Amitriptyline hydrochloride|
219002795|NCT02922556|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
219002796|NCT02922556|OTHER|Commercially available computerized training|
219002797|NCT05299281|DEVICE|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
219002798|NCT04694417|OTHER|Compression stocking|Please see the description of the intervention in another section
219002799|NCT04694417|DIETARY_SUPPLEMENT|Magnesium tablet|Please see the description of the intervention in another section
219002800|NCT04694417|OTHER|Placebo tablet|Please see the description of the intervention in another section
219002801|NCT01931124|BEHAVIORAL|High Intensity Training|
219002802|NCT01931124|BEHAVIORAL|Moderate Intensity Training|
219002803|NCT00453882|DEVICE|flostat (TM) System|
219002804|NCT04943094|OTHER|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
219002805|NCT02810860|PROCEDURE|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
219002806|NCT01366209|DRUG|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
219002807|NCT01366209|DRUG|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
219408587|NCT07084376|OTHER|Enhanced Educational Program for Intermittent Catheterization|Participants in this group receive an enhanced educational program for intermittent catheterization (IC), including an informational booklet, a specifically designed video tutorial, and standard clinical practice training. The program aims to improve psychological acceptance, adherence, and self-efficacy by providing comprehensive and patient-centered educational materials in addition to standard care.
219408588|NCT07084376|OTHER|Standard Education Group|Participants in this group will receive standard clinical practice training for intermittent catheterization (IC), as routinely provided in participating healthcare centers. This training focuses on basic procedural skills and practical education necessary to perform IC independently, without additional enhanced educational materials such as booklets or video tutorials.
219756148|NCT02009566|RADIATION|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
219002808|NCT02670837|DEVICE|Cellutome Epidermal Harvesting System|
219408589|NCT07084454|OTHER|GAIN-S Multidisciplinary Telehealth Intervention|This intervention delivers a comprehensive geriatric assessment (GA) via telehealth to older adults with cancer. Based on the GA results, a multidisciplinary team including oncologists, geriatricians, psychiatrists, psychologists, nutritionists, and certified fitness trainers provide personalized supportive care recommendations and consultations remotely. The goal is to improve physical function, reduce depressive symptoms, and enhance quality of life during cancer treatment.
219408590|NCT07084454|OTHER|Standard Oncology Care|Participants receive the usual oncology care provided by their treating physicians without a structured geriatric assessment-driven intervention. Geriatric assessment results are shared with the treating oncologist, who may refer patients to supportive care services based on clinical judgment. No coordinated multidisciplinary telehealth intervention is provided.
219756149|NCT06351514|DEVICE|Accelerated iTBS|Patients will be assigned to receive iTBS over the left dorsolateral prefrontal cortex or Frontal Medea with 5 sessions a day, every weekday for 1 week and total of 25 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 100%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions. All TBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
219756150|NCT05239078|DRUG|local anaesthetic injection|Inferior alveolar nerve block
219002809|NCT04201860|DIAGNOSTIC_TEST|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
219002810|NCT01856413|DRUG|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
219002811|NCT05228262|OTHER|Cohort follow-up|"* Inclusion medical consultation,~* Inclusion clinical examination,~* Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~* Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~* Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~* Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~* Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
219002812|NCT00382460|DRUG|PRAVASTATIN SODIUM|
219408591|NCT07084519|RADIATION|hypofractionated radiotherapy|43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
219756151|NCT01621100|DRUG|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
219002813|NCT00582166|DRUG|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
219002814|NCT05675397|DIETARY_SUPPLEMENT|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
219002815|NCT05063604|DRUG|Citalopram|20 mg tablet one or twice daily for 12 weeks
219408592|NCT07084519|RADIATION|conventional fractionated radiotherapy|50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
219002816|NCT05063604|BEHAVIORAL|Psychotherapy|One session weekly for 12 weeks
219002817|NCT00005571|DRUG|h5G1.1-mAb|
219002818|NCT02532972|DEVICE|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
219002819|NCT01308671|DRUG|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
219002820|NCT01308671|BEHAVIORAL|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
219568476|NCT00895037|DRUG|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
219408593|NCT06926140|DEVICE|Acupuncture|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the acupuncture group is combined with acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
219568477|NCT03460145|OTHER|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
219568478|NCT03460145|OTHER|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
219568479|NCT03460145|DRUG|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
219568480|NCT05822674|DRUG|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
219568481|NCT05822674|DRUG|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
219568482|NCT03467282|DIETARY_SUPPLEMENT|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
219568483|NCT03467282|DIETARY_SUPPLEMENT|Placebo|1g polydextrose/maltodextrin - twice day
219756152|NCT02746809|DEVICE|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
219756153|NCT00374647|DRUG|mycophenolate mofetil|
219756154|NCT00374647|DRUG|sirolimus|
219756155|NCT01071161|DRUG|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
219568484|NCT00298987|DRUG|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
219568485|NCT00142987|DRUG|Tegaserod|
219756156|NCT01071161|DRUG|placebo|placebo
219756157|NCT00004157|BIOLOGICAL|filgrastim|
219756158|NCT00004157|BIOLOGICAL|recombinant interleukin-11|
219756159|NCT04931381|OTHER|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
219756160|NCT05217173|OTHER|telerehabilitation|It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
219756161|NCT00151177|DEVICE|non-invasive continuous positive airway pressure ventilation|
219756162|NCT00151177|DEVICE|CPAP-treatment|night time CPAP-mask ventilation
219756163|NCT03044444|DIETARY_SUPPLEMENT|citrus extract|Participants will receive either a low or high dose citrus extract
219756164|NCT03044444|OTHER|placebo|participants will receive 500mg of maltodextrin
219568486|NCT04263233|OTHER|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates."
219568487|NCT04263233|OTHER|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
219568488|NCT04263233|OTHER|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
219568489|NCT01043926|DRUG|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
219568490|NCT04376359|PROCEDURE|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
219756165|NCT01478984|PROCEDURE|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
219756166|NCT01478984|PROCEDURE|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
219002821|NCT02063620|DRUG|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
219002822|NCT03128554|OTHER|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
219408594|NCT06926140|DEVICE|Sham Comparator|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the sham acupuncture group is combined with sham acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of sham acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the sham press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
219408595|NCT04627428|BIOLOGICAL|RPESC-RPE-4W|RPESC-RPE-4W
219408596|NCT01996345|PROCEDURE|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
219408597|NCT03137394|OTHER|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
219408598|NCT07117734|OTHER|An Evaluation of the Quality and Informational Content of Balance Exercise Training Videos Published on YouTube.|"In the study, there will be no participant groups; YouTube videos searched using the keyword balance exercise will be evaluated based on specific criteria."
219408599|NCT06923358|OTHER|Virtual Nature intervention (VN)|The intervention will consist of a 12-week virtual nature program in which participants will engage in two sessions per week. During each session, they will watch a 10-minute 360° video depicting a natural setting. Participants will select videos from a curated library of nature scenarios filmed by researchers in locations near or within the same region as their nursing homes. The videos will showcase various seasons in Norway (spring, summer, fall, and winter) and include popular activities such as hiking and cross-country skiing. The videos will be played using a Meta Quest 3 headset, with sessions conducted in participants' rooms by nursing home staff-except for the first session, which will be facilitated by the researchers.
219408600|NCT06930482|BEHAVIORAL|Safe early intervention|The SAFE early intervention approach, an activity-focused, sensory intervention program, was applied to the babies in the intervention group in an enriched environment. As part of the intervention, coaching was provided in collaboration with the family on how to support the baby's development. For this purpose, family visits were made 15 days after the initial assessment and once a month. During these visits, the suggestions given to the family were repeated and all questions about the process were answered. It was discussed how the home environment should be structured in a way that is appropriate for the baby's development. The aims of the approaches applied were explained and information was provided about the follow-up process. In order to follow up on whether the family implemented the intervention, the family was interviewed by phone and the family was asked to keep an activity diary.
219408601|NCT06930482|BEHAVIORAL|early intervention approach based on neurodevelopmental treatment|Within the scope of the study, NGT-based applications were applied to the babies included in the control group by their families. After the first assessment, activities were planned to support skills appropriate to the child's developmental level. The treatment movements, how to facilitate the baby's movements, and how to provide hand contact were demonstrated to the families in practice. The applicability of the intervention program was monitored with weekly phone calls. The babies were called to the clinic environment for a check-up every month to revise the intervention program and teach new movements, and an evaluation was made. Two home visits were made to evaluate the families' home environments and parental attitudes (pre- and post-intervention).
219408602|NCT06931067|BEHAVIORAL|OTAGO Exercise Program with motivational interviewing|OTAGO exercise home visits will be offered 7 times with 2 phone-based check-ins during the 6-month period. As part of OTAGO home visits, participants will receive OTAGO exercise instruction and MI. Each home visit will be approximately an hour.
219756167|NCT02791243|DRUG|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
219756168|NCT02791243|DRUG|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
219756169|NCT02791243|DRUG|Negative Control|0.9% aqueous NaCl
219756170|NCT02055508|BEHAVIORAL|Exercise Intervention|
219756171|NCT02055508|OTHER|Care-Management-Phone-Calls|
219756172|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
219756173|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
219756174|NCT00281970|DRUG|cisplatin|
219756175|NCT00281970|DRUG|docetaxel|
219756176|NCT00281970|PROCEDURE|adjuvant therapy|
219756177|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
219756178|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
219002823|NCT02279381|DRUG|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
219002824|NCT02279381|OTHER|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
219408603|NCT06930521|DIAGNOSTIC_TEST|Intervention - Low Risk Group OR Intermediate Risk Group|"Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF.~Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then after the end of HER2TT. This translates to imaging every 6 months for uninterrupted adjuvant HER2TT.~Intermediate Risk (any risk factors): imaging before cycles 1, 6, and 12 of HER2-TT (i.e., at baseline and near the 1/3 and 2/3 marks, corresponding to 1 fewer study than SOC in Year 1), then at end of HER2TT. This translates to imaging every 4 months for uninterrupted adjuvant HER2TT."
219002825|NCT02279381|OTHER|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
219002826|NCT01606436|DRUG|LY2140023|Administered orally.
219002827|NCT01606436|DRUG|Placebo|Administered orally.
219002828|NCT01606436|DRUG|Moxifloxacin|Administered orally.
219002829|NCT00796198|DRUG|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
219408604|NCT06928844|DRUG|Progesterone|Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
219408605|NCT06928844|DRUG|Placebo|Women will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
219568491|NCT06677840|OTHER|probiotic (GKB7/placebo)|The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5
219568492|NCT04093154|DEVICE|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
219568493|NCT02346149|OTHER|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
219568494|NCT00604227|OTHER|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
219568495|NCT01931527|DRUG|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
219756179|NCT02196753|OTHER|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background."
219756180|NCT04764526|OTHER|Protein-enriched ice cream|Offering two protein-enriched ice creams
219756181|NCT02230345|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
219756182|NCT02230345|DIETARY_SUPPLEMENT|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
219002830|NCT00796198|DRUG|Xalatan|Xalatan ophthalmic solution one drop at 10pm
219002831|NCT06139029|DRUG|3% normal saline|nebulization
219002832|NCT06139029|DRUG|steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline|nebulization
219568496|NCT04072315|DRUG|PLN-74809|PLN-74809
219568497|NCT04072315|RADIATION|Knottin tracer|Radiotracer
219002833|NCT02859454|DRUG|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
219568498|NCT05370261|DIETARY_SUPPLEMENT|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
219568499|NCT05370261|DIETARY_SUPPLEMENT|Regular Berberine hard-gels|Total dose of 500 mg of berberine
219568500|NCT02018094|DRUG|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
219568501|NCT02018094|DRUG|Iodine|Intra-operative skin preparation prior to incision to skin.
219568502|NCT02018094|DRUG|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
219568503|NCT02018094|DRUG|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
219756183|NCT05740514|BEHAVIORAL|Exercise|Exercise training.
219756184|NCT05740514|BEHAVIORAL|De-training|Exercise de-training via unilateral knee immobilization.
219756185|NCT00205127|PROCEDURE|Cardiac PET imaging- rest and pharmacological stress|
219756186|NCT02279927|DEVICE|Ureteroscopy|Ureteroscopy with laser stone fragmentation
219002834|NCT05391516|DIAGNOSTIC_TEST|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
219002835|NCT00502645|DEVICE|CS-1 DECISION SUPPORT SYSTEM|
219568504|NCT02018094|DRUG|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
219568505|NCT02018094|DRUG|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
219568506|NCT05178576|DRUG|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
219568507|NCT05178576|DIAGNOSTIC_TEST|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
219408606|NCT07132775|DEVICE|Active full-body stimulation|Participants will receive active stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
219408607|NCT07132775|OTHER|Sham full-body stimulation|Participants will receive sham stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
219408608|NCT01915810|BEHAVIORAL|Exercise Intervention|Complete SCwPA intervention
219408609|NCT01915810|OTHER|Laboratory Biomarker Analysis|Correlative studies
219408610|NCT01915810|DRUG|Nicotine Patch|Receive nicotine patch
219408611|NCT01915810|OTHER|Questionnaire Administration|Ancillary studies
219408612|NCT01915810|OTHER|Tobacco Cessation Counseling|Receive smoking cessation counseling
219568508|NCT05683210|BEHAVIORAL|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
219756187|NCT04518137|DRUG|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
219408613|NCT06930261|DRUG|LBT-999|LBT-999 administration for PET imaging
219408614|NCT06930053|OTHER|Core stability training|"The study group will receive core stability exercises, which consist of three levels. Each level took 4 weeks. The difficulty of each level varies in proprioception, balance, and stability as it started from exercising on a stable surface mat and ended with unstable surface physioball. The first simple level involves supine abdominal draw (3 sets per 20 repetitions), abdominal draw-in with a double knee to chest (3 sets/20 repetitions), and supine twist (3 sets per 20 repetitions). The second medium level involves pelvic bridging (3 sets per 3-5 repetitions) and twists with a medicine ball (3 sets per 10-20 repetitions). The third difficult level involves bridging with head-on physioball holding this position for 3-5 seconds, then slowly relaxing (3 sets per 10-20 repetitions), and prone bridging (3 sets per 3-repetitions). There was a 30-second rest between sets . The program will be applied 30 minutes a day for 3 days a week for 12 weeks. in addition to 30 minutes of a standard"
219408615|NCT06930053|OTHER|Action observation therapy|The examined group got 30 minutes of a standard,selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter infront of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement.The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick. The bimanual tasks were opening a bo
219408616|NCT06930053|OTHER|combination of Action observation therapy and core stability training .|combination of Action observation therapy and core stability training .
219408617|NCT01686503|DRUG|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
219408618|NCT00650429|DRUG|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
219408619|NCT00523822|OTHER|Spinal Manipulative Therapy|
219408620|NCT07161934|BEHAVIORAL|Guided Imagery Training|Participants received guided imagery sessions of 15 minutes after each football training, three times per week for 12 weeks (36 sessions). Sessions included relaxation, visualization of technical movements, and reinforcement of motivation and confidence.
219408621|NCT07161934|BEHAVIORAL|Standard Football Training|Participants received only regular football training three times per week for 12 weeks (36 sessions). Each session lasted 60 minutes and focused on technical skills. To match contact time, a 15-minute team evaluation meeting was held after each practice.
219408622|NCT07163650|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.
219002836|NCT00813735|DRUG|Eszopiclone|Eszopiclone 2mg daily at bedtime
219002837|NCT00813735|DRUG|Placebo|Placebo daily at bedtime
219002838|NCT00813735|DRUG|Escitalopram|Escitalopram 10mg or 20mg
219756188|NCT00734552|DIETARY_SUPPLEMENT|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
219408623|NCT07163650|BEHAVIORAL|Diet and exercise guidelines|Participants followed a science-based diet and exercise program intervention.
219408624|NCT07163455|BEHAVIORAL|Balanced Diet|Participants will receive balanced dietary guidance informed by the Weight Management Manual (developed in line with the Dietary Guidelines for Chinese Residents) along with biweekly consultations with a nutritionist, with an emphasis on weight management education.
219756189|NCT00734552|DIETARY_SUPPLEMENT|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
219756190|NCT01255280|BEHAVIORAL|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
219002839|NCT01841983|OTHER|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors."
219002840|NCT06036212|DEVICE|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
219002841|NCT06036212|DEVICE|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
219002842|NCT00673803|PROCEDURE|cataract surgery|cataract surgery with implantation of an IOL
219002843|NCT01025752|BEHAVIORAL|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
219002844|NCT01025752|BEHAVIORAL|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
219002845|NCT02438098|DRUG|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
219002846|NCT05495516|GENETIC|without Intervention|without Intervention
219002847|NCT03626883|PROCEDURE|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
219408625|NCT07163455|BEHAVIORAL|Artificial Intelligence-Assisted Time-Restricted Eating with Evening Caloric Restriction|"This intervention combines Artificial Intelligence-assisted Time-Restricted Eating (10-hour eating window) with Evening Caloric Restriction (\<20% of total daily energy intake at dinner). The recommended daily energy distribution is 40% for breakfast, 40% for lunch, and 20% for dinner. Al support will be provided via the Weight Manager app, which sends meal reminders ahead of each meal. Participants will log each meal by the app. If no log is recorded for seven consecutive days, the weight management AI will notify a study dietitian to contact the participant for follow-up and provide dietary counseling. Educational infographics and articles on the benefits of restricting the eating window and reducing dinner caloric intake will be pushed once a month via the Weight Manager app or WeChat. Dietary records collected during follow-up visits will be reviewed to reinforce education on lowering the proportion of daily energy consumed at dinner."
219408626|NCT07164144|BEHAVIORAL|Vaccine Communication Training|School personnel receive vaccine communication training + promotional materials
219568509|NCT05683210|BEHAVIORAL|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
219756191|NCT01255280|BEHAVIORAL|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
219756192|NCT01924780|DEVICE|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
219756193|NCT01924780|DEVICE|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
219756194|NCT01924780|DEVICE|NEMOS Device sham stimulation 10 minutes|
219756195|NCT06164158|OTHER|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
219002848|NCT03626883|PROCEDURE|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
219408627|NCT07161869|PROCEDURE|Registration of all findings during preoperative Endoscopic Ultrasound|Using the improved POELH-III EUS format
219408628|NCT07163273|DRUG|NALIRIFOX|NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15
219756196|NCT06164158|OTHER|No procedural videos|No procedural videos
219756197|NCT05453214|DRUG|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
219756198|NCT00894387|DRUG|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
219756199|NCT00894387|DRUG|Placebo|Placebo
219756200|NCT03830580|OTHER|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
219002849|NCT04026308|OTHER|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
219002850|NCT06024356|DRUG|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
219002851|NCT01596400|DRUG|granisetron transdermal system|patch
219002852|NCT01596400|DRUG|Granisetron IV|IV
219002853|NCT05938972|BIOLOGICAL|Mepolizumab|Monoclonal antibodies
219756201|NCT00133627|DRUG|Ketotifen|
219002854|NCT01625702|DEVICE|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
219002855|NCT05177978|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
219002856|NCT05177978|DIETARY_SUPPLEMENT|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
219002857|NCT00905073|DRUG|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
219002858|NCT02528071|OTHER|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
219002859|NCT01417234|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
219002860|NCT04150393|DRUG|MaaT033 capsule|Oral capsule
219408629|NCT07163273|DRUG|Gemcitabine plus nab-Paclitaxel (GnP)|GnP consists of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, given on Days 1, 8, and 15.
219408630|NCT07163247|BEHAVIORAL|Robotic pet (PARO) companionship|"The intervention is composed of the following components:~Duration: Robotic pet companionship lasting 30-120 minutes, depending on clinical goals during each spontaneous breathing trial (SBT).~Preparation and interaction: PARO is introduced 30 minutes before each SBT to establish emotional connection. Study staff will briefly introduce its interactive features, including responding to stroking, gentle tapping, head movements, and eye blinking. Participants may interact freely with PARO during the intervention.~Assessment: Outcome measurements are conducted during the intervention. If extubated successfully, a semi-structured interview is conducted three days later.~Early termination: The intervention is stopped if the participant becomes clinically unsuitable for further SBTs or experiences a serious adverse event (e.g., device dislodgement).~Additional information: After each SBT, PARO is sterilized and stored in a sealed container in the patient's room."
219408631|NCT04924985|OTHER|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
219408632|NCT04924985|OTHER|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
219408633|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
219408634|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
219408635|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
219408636|NCT04909736|OTHER|Music Exposure|Music will be played for participants.
219408637|NCT06811233|DRUG|DMSA|Given PO
219408638|NCT06811233|DRUG|Ca-EDTA|Given by IV
219408639|NCT06811233|DRUG|Magnesium Sulfate|Given by infusion
219408640|NCT06811233|DRUG|Multivitamin|Given PO
219568510|NCT05487768|OTHER|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)"
219002861|NCT04757870|OTHER|frequency|Macro-scale risk factors for the frequency of and mortality of infection
219002862|NCT00023764|DRUG|bortezomib|Given IV
219002863|NCT03550898|DIAGNOSTIC_TEST|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
219002864|NCT01656473|OTHER|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
219002865|NCT01656473|OTHER|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
219408641|NCT05243290|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
219002866|NCT04216771|DRUG|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
219408642|NCT05243290|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
219568511|NCT05095649|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
219002867|NCT04216771|DRUG|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
219408643|NCT05205954|BEHAVIORAL|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
219408644|NCT04966351|BEHAVIORAL|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
219568512|NCT02159287|DRUG|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
219568513|NCT02159287|DRUG|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
219568514|NCT00496028|DRUG|AZD0530|oral tablet
219568515|NCT00496028|DRUG|Carboplatin|intravenous infusion
219002868|NCT05833854|OTHER|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
219002869|NCT05833854|OTHER|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
219408645|NCT04966351|BEHAVIORAL|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
219408646|NCT06030206|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
219408647|NCT06030206|BEHAVIORAL|Publicly available transplant education resource (Attention-control)|Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
219408648|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
219408649|NCT05361122|DIETARY_SUPPLEMENT|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).
219408650|NCT05361122|DIETARY_SUPPLEMENT|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
219408651|NCT06795373|DRUG|Ritlecitinib|Once daily dose of 100mg of ritlecitinib taken orally for 12 weeks
219408652|NCT03890952|DRUG|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
219568516|NCT00496028|DRUG|Paclitaxel|intravenous infusion
219568517|NCT04691700|DRUG|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
219002870|NCT03489824|PROCEDURE|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
219002871|NCT04368767|BEHAVIORAL|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
219002872|NCT03577691|OTHER|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
219002873|NCT03577691|OTHER|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
219002874|NCT03577691|OTHER|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
219568518|NCT04691700|DRUG|Standard Treatment|Standard therapy without Goreisan
219568519|NCT02210052|DEVICE|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
219568520|NCT02851732|BEHAVIORAL|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
219568521|NCT04146831|DRUG|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
219568522|NCT04456933|PROCEDURE|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
219756202|NCT05053061|BEHAVIORAL|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
219756203|NCT03448328|DIETARY_SUPPLEMENT|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
219408653|NCT03890952|DRUG|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
219408654|NCT06076499|DEVICE|NTX100|NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
219408655|NCT06797375|DRUG|RLYB116 for Injection|RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.
219408656|NCT03050359|DRUG|TAK-438|TAK-438 tablets
219408657|NCT03050359|DRUG|Lansoprazole|Lansoprazole capsules
219408658|NCT03050359|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets.
219408659|NCT03050359|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
219408660|NCT03050359|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
219408661|NCT01127126|DRUG|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
219408662|NCT01671969|OTHER|very low calorie diet|medically supervised diet
219408663|NCT01360944|DRUG|LAS41004|once daily, topical, 100 microgram
219408664|NCT01360944|DRUG|reference|once daily, 100 microgram
219408665|NCT00793676|OTHER|spirometry|
219408666|NCT00793676|OTHER|blood test|
219408667|NCT01136668|PROCEDURE|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
219408668|NCT01136668|PROCEDURE|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
219408669|NCT06512948|PROCEDURE|High tibial osteotomy|Surgical treatment for patients with osteoarthritis and indications for high tibial osteotomy
219756204|NCT03448328|DIETARY_SUPPLEMENT|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
219756205|NCT03448328|DIETARY_SUPPLEMENT|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
219756206|NCT00005852|BIOLOGICAL|anti-thymocyte globulin|
219408670|NCT02614287|DRUG|Galcanezumab|Administered SC
219408671|NCT00536042|DRUG|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
219408672|NCT06129318|BEHAVIORAL|Clinical Pharmacist Led Pharmaceutical Care|Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
219408673|NCT03571841|BEHAVIORAL|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
219408674|NCT03571841|BEHAVIORAL|Telephone Booster|One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
219408675|NCT01116219|BIOLOGICAL|bevacizumab, erlotinib|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
219408676|NCT01116219|DRUG|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
219408677|NCT01156597|DRUG|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
219408678|NCT05268315|BEHAVIORAL|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
219408679|NCT04574063|BEHAVIORAL|Lifestyle intervention to reduce breast cancer risk|Women will be educated about lifestyle factors which increase breast cancer risk. They will also be guided through an online goal setting process.
219408680|NCT00582062|OTHER|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
219408681|NCT01814488|PROCEDURE|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
219408682|NCT01392989|DRUG|CIK cells|Standard of care
219408683|NCT01392989|DRUG|Cyclosporine|5 mg/kg, po
219408684|NCT01392989|DRUG|Mycophenolate Mofetil|15 mg/kg, oral
219408685|NCT01392989|DRUG|Thymoglobulin|7.5 mg/kg, IV
219756207|NCT00005852|BIOLOGICAL|filgrastim|
219756208|NCT00005852|BIOLOGICAL|muromonab-CD3|
219408686|NCT01392989|RADIATION|Total Lymphoid Irradiation (TLI)|
219408687|NCT03716817|DEVICE|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
219408688|NCT02417870|BIOLOGICAL|aldesleukin|
219408689|NCT00833248|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
219408690|NCT00833248|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
219002875|NCT03577691|OTHER|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
219002876|NCT01528488|OTHER|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
219408691|NCT00833248|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
219408692|NCT05075148|OTHER|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
219408693|NCT00255684|BIOLOGICAL|graft-versus-tumor induction therapy|
219408694|NCT00255684|DRUG|cyclophosphamide|
219408695|NCT00255684|DRUG|cyclosporine|
219002877|NCT01528488|OTHER|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
219002878|NCT05459675|OTHER|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
219002879|NCT05459675|PROCEDURE|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
219002880|NCT00877253|DRUG|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
219568523|NCT04456933|PROCEDURE|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
219568524|NCT04798482|DRUG|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
219568525|NCT01192399|BIOLOGICAL|Eculizumab|
219568526|NCT01859026|DRUG|MEK162|Treatment as outlined in study arms.
219568527|NCT01859026|DRUG|Erlotinib|Treatment as outlined in study arms.
219568528|NCT06552104|BEHAVIORAL|ACUPRESSURE APPLI ACUPRESSURE APPLICATION|Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
219002881|NCT00877253|DRUG|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
219002882|NCT00877253|DRUG|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
219002883|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
219002884|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using standard method
219568529|NCT01021267|DRUG|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
219408696|NCT00255684|DRUG|fludarabine phosphate|
219408697|NCT00255684|DRUG|mycophenolate mofetil|
219408698|NCT00255684|PROCEDURE|umbilical cord blood transplantation|
219408699|NCT00255684|RADIATION|radiation therapy|
219408700|NCT05394740|DRUG|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy"
219408701|NCT05394740|DRUG|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy
219408702|NCT05394740|DRUG|CapeOX|"For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy"
219408703|NCT05394740|DRUG|FOLFOX regimen|"For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy"
219408704|NCT03545698|OTHER|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
219568530|NCT02438696|DRUG|BI 1060469, iFF, Test|
219568531|NCT02438696|DRUG|BI 1060469, iFF, Test|
219568532|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219568533|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568534|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568535|NCT02438696|DRUG|BI 1060469, iFF, Test|
219568536|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219002885|NCT05113472|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
219002886|NCT01619774|DRUG|GSK2118436|Starting dose 150 mg by mouth twice a day.
219408705|NCT00472472|DEVICE|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
219568537|NCT02438696|DRUG|BI 1060469, iFF, Test|
219568538|NCT02438696|DRUG|BI 1060469, iFF, Test|
219568539|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219568540|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568541|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219568542|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219568543|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568544|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568545|NCT02438696|DRUG|BI 1060469, iFF, Test|
219408706|NCT02006667|DRUG|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
219408707|NCT02006667|DRUG|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
219408708|NCT02006667|DRUG|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
219568546|NCT02438696|DRUG|BI 1060469, TF2, Test|
219568547|NCT02438696|DRUG|BI 1060469, TF1, Reference|
219568548|NCT01779388|PROCEDURE|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
219568549|NCT01029392|DRUG|Vitamin D|2000iu once a day
219568550|NCT06616792|COMBINATION_PRODUCT|Dexamethasone phonophoresis|Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
219568551|NCT06616792|DEVICE|Laser Acupuncture|low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
219568552|NCT06616792|OTHER|Traditional medication|Each participant in this group receive the traditional medication.
219568553|NCT02822196|DRUG|Lidocaine|Local Anesthesia using 1% Lidocaine
219568554|NCT02822196|DRUG|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
219568555|NCT05416463|PROCEDURE|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
219568556|NCT02731963|DRUG|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
219568557|NCT05494216|OTHER|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
219568558|NCT05494216|OTHER|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
219568559|NCT00775788|PROCEDURE|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
219568560|NCT00334256|DRUG|Tenofovir (TDF)|
219568561|NCT00334256|DRUG|Emtricitabine (FTC)|
219568562|NCT01588535|DRUG|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
219568563|NCT01588535|DRUG|placebo|placebo solution, five drops in affected ear canal each hour as needed
219756209|NCT00005852|DRUG|cyclophosphamide|
219756210|NCT00005852|DRUG|cyclosporine|
219756211|NCT00005852|DRUG|methylprednisolone|
219756212|NCT00005852|PROCEDURE|allogeneic bone marrow transplantation|
219756213|NCT04856527|BEHAVIORAL|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
219756214|NCT01816295|DRUG|Testosterone Solution|Administered topically to axillae.
219756215|NCT01816295|DRUG|Placebo Solution|Administered topically to axillae.
219756216|NCT02055846|PROCEDURE|Realisation of blood sample, urinary sample and tumor biopsy|
219756217|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
219756218|NCT05922618|DEVICE|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
219756219|NCT03099122|BIOLOGICAL|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
219756220|NCT03099122|DRUG|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
219756221|NCT03099122|DRUG|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
219568564|NCT04375995|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry test will be applied to all groups.
219568565|NCT04375995|DIAGNOSTIC_TEST|Spirometric pulmonary function test|Spirometric pulmonary function test will be applied to all groups.
219568566|NCT04375995|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|FeNO test will be applied to asthma group.
219568567|NCT04375995|DIAGNOSTIC_TEST|Thorax Computed Tomography|Thorax Computed Tomography will be taken to the asthma group.
219408709|NCT02037802|DEVICE|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
219408710|NCT02037802|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
219408711|NCT02037802|DRUG|Propofol|fentanyl propofol atracurium besylate
219408712|NCT02037802|DRUG|Bupivacaine|
219408713|NCT02037802|DRUG|Fentanyl|
219408714|NCT00000513|BEHAVIORAL|diet, reducing|
219408715|NCT00000513|BEHAVIORAL|diet, sodium-restricted|
219568568|NCT04375995|DIAGNOSTIC_TEST|Blood eosinophil level|The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
219568569|NCT04375995|OTHER|Asthma control test|Asthma control test questions will be applied to the asthma group.
219568570|NCT04375995|OTHER|Asthma quality of life scale|Asthma quality of life scale (AQLQ) will be applied to the asthma group.
219568571|NCT04375995|DIAGNOSTIC_TEST|Chest X Ray|Chest X Ray will be applied to the healthy control group.
219568572|NCT04131231|DRUG|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
219568573|NCT04131231|DRUG|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
219568574|NCT06480604|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
219568575|NCT06480604|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
219568576|NCT01100450|BEHAVIORAL|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
219756222|NCT03099122|DRUG|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
219756223|NCT03099122|DRUG|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
219002887|NCT01619774|DRUG|GSK1120212|2 mg by mouth daily.
219002888|NCT00589563|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
219002889|NCT00589563|DRUG|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
219002890|NCT00589563|DRUG|etoposide|60mg/kg on day -4 from stem cell transplant
219002891|NCT00589563|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
219002892|NCT00589563|DRUG|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
219002893|NCT00589563|DRUG|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
219408716|NCT00000513|DRUG|chlorthalidone|
219756224|NCT03099122|DRUG|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
219756225|NCT00808392|BIOLOGICAL|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
219756226|NCT00808392|BIOLOGICAL|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
219408717|NCT00000513|DRUG|atenolol|
219408718|NCT02939937|DRUG|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
219756227|NCT02976181|DEVICE|IPG|Patient might require IPG device to be implanted under standard of care
219756228|NCT05849766|DRUG|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
219756229|NCT05849766|DRUG|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
219756230|NCT02923154|DRUG|MT-3995|
219756231|NCT02923154|DRUG|Placebo|
219756232|NCT06463184|DRUG|Xevinapant|Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
219756233|NCT04773665|BIOLOGICAL|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
219756234|NCT04773665|BIOLOGICAL|Placebo|0.9% sodium chloride
219756235|NCT04773665|BIOLOGICAL|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
219408719|NCT02939937|DRUG|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
219408720|NCT03458676|PROCEDURE|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
219408721|NCT03458676|PROCEDURE|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
219408722|NCT01087411|BEHAVIORAL|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
219408723|NCT01087411|BEHAVIORAL|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
219568577|NCT05249972|DRUG|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
219568578|NCT05249972|DRUG|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
219568579|NCT05249972|OTHER|Placebo|Placebo cutaneous spray
219568580|NCT02405572|OTHER|infant formula|infant formulas
219568581|NCT06207292|RADIATION|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
219568582|NCT04530279|PROCEDURE|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
219408724|NCT01087411|DIETARY_SUPPLEMENT|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
219408725|NCT01087411|DIETARY_SUPPLEMENT|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
219408726|NCT03994263|DEVICE|ITind device implant|device implanted for 5-7 days
219568583|NCT04395248|PROCEDURE|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
219568584|NCT04395248|PROCEDURE|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
219568585|NCT04395248|DEVICE|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
219756236|NCT02192567|DRUG|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
219756237|NCT04946695|OTHER|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
219756238|NCT03215043|DIETARY_SUPPLEMENT|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
219756239|NCT03215043|OTHER|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
219756240|NCT06559709|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219756241|NCT06559709|OTHER|Dietary Intervention|Receive 3 meals per day and snacks
219002894|NCT00589563|DRUG|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
219756242|NCT06559709|OTHER|Dietary Intervention|Meet with dietitian
219756243|NCT06559709|OTHER|Medical Chart Review|Ancillary studies
219756244|NCT06559709|OTHER|Questionnaire Administration|Ancillary studies
219756245|NCT03574961|BEHAVIORAL|e-Support group|Online (remote), web-based support group via private video link.
219756246|NCT03574961|BEHAVIORAL|e-Journaling placebo|Online journaling activity.
219002895|NCT00589563|DRUG|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
219002896|NCT00589563|PROCEDURE|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
219002897|NCT00589563|PROCEDURE|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
219408727|NCT00107068|PROCEDURE|[A] Aerobic isokinetic cycling exercise|
219408728|NCT00107068|PROCEDURE|[B] Progressive Resistance Training|
219408729|NCT00107068|PROCEDURE|[A] + [B]|
219408730|NCT00856479|DEVICE|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
219408731|NCT00856479|PROCEDURE|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
219408732|NCT01702662|DEVICE|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
219408733|NCT01895816|DIETARY_SUPPLEMENT|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
219408734|NCT05142514|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
219408735|NCT05142514|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
219408736|NCT05598294|PROCEDURE|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
219568586|NCT04395248|DRUG|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
219568587|NCT02965664|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
219568588|NCT02965664|DRUG|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
219568589|NCT00063882|RADIATION|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
219568590|NCT00063882|RADIATION|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
219408737|NCT04606654|OTHER|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
219408738|NCT04606654|OTHER|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
219568591|NCT00063882|RADIATION|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
219756247|NCT05884125|DEVICE|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
219002898|NCT00589563|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
219408739|NCT03503682|RADIATION|standard treatment|3000 cGy in 10 daily fractions
219408740|NCT03503682|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
219756248|NCT03976297|OTHER|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
219756249|NCT06510036|OTHER|The post-processing generated after scanning is converted into energy spectrum image data (SBI)|It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.
219756250|NCT06402162|OTHER|exercise|The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
219756251|NCT06492928|OTHER|Psychomotor Vigilance Task|T0 - at the start of the shift: completion of the 1st PVT / socio-demographic and workstation questionnaire T1 - at the end of the shift: completion of the second PVT and questionnaire on the course of the shift that has just taken place T2 - 1 week after the end of the shift: additional questionnaire sent with scales to assess work-related fatigue (MBI), anxiety (PSS), sleep quality (PSQI) and chronotype (MEQ).
219408741|NCT04961814|OTHER|liberal fasting|preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
219568592|NCT06231459|DRUG|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
219568593|NCT03544359|DEVICE|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
219408742|NCT04961814|OTHER|standard fasting|preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
219568594|NCT01293552|BIOLOGICAL|ANT-1207|single dose application
219408743|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
219568595|NCT01293552|BIOLOGICAL|Vehicle|
219568596|NCT01103479|BEHAVIORAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
219756252|NCT05184556|BEHAVIORAL|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
219756253|NCT05184556|BEHAVIORAL|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
219756254|NCT02041767|DRUG|Ertapenem|One single injection of 1g of ertapenem before surgery
219756255|NCT05514288|PROCEDURE|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
219756256|NCT06746428|BEHAVIORAL|Exercise Coaching|An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.
219756257|NCT05140239|OTHER|No Intervention|Non Interventional
219756258|NCT03232918|DRUG|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
219756259|NCT00216190|DRUG|Dexmedetomidine HCL Injection|
219408744|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
219408745|NCT05216848|OTHER|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
219408746|NCT05216848|OTHER|Clinical data collection|Collection of the standard clinical data during hospitalization
219568597|NCT01103479|BEHAVIORAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
219002899|NCT00589563|PROCEDURE|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
219756260|NCT00216190|DRUG|Midazolam Injection|
219756261|NCT02026167|BEHAVIORAL|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
219568598|NCT06490575|OTHER|Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults|Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
219002900|NCT00589563|RADIATION|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
219002901|NCT00426907|PROCEDURE|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
219002902|NCT04756492|DRUG|sandimmun|follow up for treatment response
219002903|NCT00740701|DEVICE|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
219408747|NCT03007485|OTHER|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
219408748|NCT00792233|OTHER|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
219408749|NCT05738499|OTHER|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
219408750|NCT05738499|OTHER|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
219408751|NCT02634099|DEVICE|blood measurement|Hemoglobin measurement
219408752|NCT02634099|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
219408753|NCT02634099|DEVICE|hemoCue|non invasive method of hemoglobin measurement
219568599|NCT06227520|OTHER|decellularized dermal matrix|Application of Wound bed
219568600|NCT04101695|DEVICE|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
219568601|NCT01534637|DRUG|aprepitant|Given PO
219568602|NCT01534637|DRUG|gemcitabine hydrochloride|Given IV
219568603|NCT01534637|DRUG|capecitabine|Given PO
219568604|NCT01534637|DRUG|fluorouracil|Given IV
219568605|NCT01534637|PROCEDURE|radiation therapy|Undergo radiation therapy
219568606|NCT01534637|OTHER|questionnaire administration|Ancillary studies
219568607|NCT01534637|PROCEDURE|quality-of-life assessment|Ancillary studies
219568608|NCT01534637|PROCEDURE|nausea and vomiting therapy|Receive aprepitant
219568609|NCT01534637|PROCEDURE|management of therapy complications|Receive aprepitant
219568610|NCT02505152|PROCEDURE|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
219568611|NCT06412042|DIETARY_SUPPLEMENT|Probiotic BLa80|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
219568612|NCT06412042|OTHER|Placebo Maltodextrin|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
219568613|NCT01476228|DEVICE|EEG recording|EEG recording
219568614|NCT00605917|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
219568615|NCT04596124|DEVICE|fitostimoline plus|randomized controlled multicentric study
219568616|NCT00881413|DRUG|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
219568617|NCT00881413|DRUG|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
219568618|NCT00757614|GENETIC|DNA analysis|
219568619|NCT00757614|GENETIC|polymorphism analysis|
219568620|NCT00757614|OTHER|laboratory biomarker analysis|
219756262|NCT05601128|DRUG|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
219756263|NCT06572072|DEVICE|Negative Pressure Ventilation|Substitution of positive pressure ventilation by negative pressure ventilation
219756264|NCT04562116|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as SC injections.
219756265|NCT04562116|DRUG|CYP 450 Substrates|CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
219756266|NCT05905172|DRUG|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
219568621|NCT00757614|OTHER|questionnaire administration|
219408754|NCT03913221|DRUG|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
219408755|NCT03913221|DRUG|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
219408756|NCT06285929|OTHER|ACS CARES Student Navigation|Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
219408757|NCT02704494|DRUG|Resveratrol|Resveratrol 500mg daily
219408758|NCT02704494|DRUG|Placebo|Placebo 1 capsule daily
219408759|NCT02704494|DRUG|Losartan|Losartan 12.5mg daily
219408760|NCT04626193|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
219408761|NCT04626193|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
219408762|NCT05249231|DRUG|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
219568622|NCT00240617|DRUG|sumatriptan succinate/naproxen sodium|comparator
219568623|NCT00240617|DRUG|placebo|placebo to match
219568624|NCT00890552|DRUG|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
219568625|NCT00890552|DRUG|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
219408763|NCT05249231|DEVICE|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
219408764|NCT05973643|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
219408765|NCT06457035|DRUG|immunosuppressant|No intervention was performed in this retrospective cohort study.
219408766|NCT00243113|DRUG|docetaxel|
219408767|NCT00243113|RADIATION|radiation therapy|
219408768|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
219408769|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
219568626|NCT00890552|DRUG|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
219568627|NCT00789113|DRUG|Extended Release Lamotrigine|
219568628|NCT05235659|BEHAVIORAL|Basic modules|Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
219756267|NCT05905172|DRUG|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
219408770|NCT04439370|DIAGNOSTIC_TEST|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
219408771|NCT04439370|DIAGNOSTIC_TEST|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
219756268|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
219408772|NCT04439370|DIAGNOSTIC_TEST|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
219408773|NCT04439370|DIAGNOSTIC_TEST|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
219408774|NCT06637865|DRUG|IMP761|intravenous
219408775|NCT06637865|DRUG|Placebo|intravenous
219408776|NCT06637865|OTHER|keyhole limpet haemocyanin (KLH)|intramuscular immunization and intradermal challenge
219408777|NCT05019456|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine (mRNA or J\&J)
219408778|NCT06026254|DRUG|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
219408779|NCT06026254|DRUG|Immune Checkpoint Inhibitor|Administered according to product label
219408780|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
219756269|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
219756270|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
219756271|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
219756272|NCT04258748|BEHAVIORAL|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
219408781|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
219408782|NCT05421832|DEVICE|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
219408783|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
219408784|NCT01284322|DRUG|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
219408785|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
219408786|NCT06702501|DEVICE|PeriCut Catheter System performs minimally invasive pericardiotomy|The PeriCut Catheter System will incise the pericardium to reduce filling pressures of the heart.
219408787|NCT02467803|OTHER|Scapula mobilization|
219408788|NCT02467803|OTHER|Shoulder ROM exercises|
219408789|NCT06467643|PROCEDURE|non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.
219408790|NCT06467643|PROCEDURE|conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
219408791|NCT04813848|PROCEDURE|Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin|"Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air."
219408792|NCT04813848|PROCEDURE|Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin|Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
219408793|NCT04549597|DRUG|Tenapanor|Use of tenapanor
219568629|NCT05235659|BEHAVIORAL|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
219190159|NCT06334991|BIOLOGICAL|CD19 t-haNK|"CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM."
219190160|NCT03213665|DRUG|Tazemetostat|Given PO
219190161|NCT03325985|BEHAVIORAL|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
219568630|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
219408794|NCT04348487|OTHER|Modified cephalica venous access|This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
219408795|NCT00266019|BEHAVIORAL|Weight Management (diet, exercise, and behavior modification)|
219408796|NCT00598195|DRUG|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
219408797|NCT04459702|DRUG|hydroxychloroquine|Treatment with the drug hydroxychloroquine
219408798|NCT04459702|DRUG|Azithromycin|Treatment with the drug azithromycin
219002904|NCT06049290|DRUG|LBL-034 for Injection|Initial dose - MTD; Q2W; intravenous infusion
219002905|NCT05989750|DEVICE|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
219408799|NCT04459702|DRUG|Ritonavir|Treatment with the drug ritonavir
219408800|NCT04459702|DRUG|Lopinavir|Treatment with the drug lopinavir
219408801|NCT03506321|DIAGNOSTIC_TEST|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
219408802|NCT00401622|BEHAVIORAL|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
219408803|NCT00401622|BEHAVIORAL|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
219408804|NCT03874598|PROCEDURE|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
219408805|NCT03874598|BEHAVIORAL|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
219408806|NCT02793167|DEVICE|AKI alert|
219408807|NCT00475280|PROCEDURE|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
219408808|NCT00475280|PROCEDURE|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
219408809|NCT04030052|DRUG|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
219408810|NCT04030052|DRUG|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
219408811|NCT04030052|DRUG|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
219408812|NCT00520676|DRUG|pemetrexed|500 mg/m\^2, IV, q 21 days x 6 cycles maximum
219408813|NCT00520676|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days x 6 cycles maximum
219408814|NCT00520676|DRUG|carboplatin|AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
219408815|NCT00928473|BEHAVIORAL|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
219408816|NCT02152865|DRUG|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
219408817|NCT02152865|DRUG|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
219408818|NCT04705025|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
219568631|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
219568632|NCT05235659|BEHAVIORAL|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
219408819|NCT04705025|OTHER|Interview|Complete interview
219408820|NCT04705025|OTHER|Quality-of-Life Assessment|Ancillary studies
219408821|NCT04705025|OTHER|Questionnaire Administration|Ancillary studies
219408822|NCT02179515|BIOLOGICAL|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
219408823|NCT06554314|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and once a day
219408824|NCT00000748|DRUG|Sulfamethoxazole-Trimethoprim|
219408825|NCT04393584|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
219408826|NCT04393584|DRUG|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
219408827|NCT04393584|DRUG|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
219408828|NCT04393584|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
219408829|NCT04393584|DRUG|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
219408830|NCT02292303|DIETARY_SUPPLEMENT|zinc-enriched yeast|
219408831|NCT02292303|DIETARY_SUPPLEMENT|Zinc references|
219408832|NCT00115349|DRUG|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
219408833|NCT00115349|DRUG|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
219408834|NCT03374514|DRUG|Dexamethasone|instilation of the solution in the middle ear
219408835|NCT03374514|DRUG|Sterile isotonic saline solution|Sterile isotonic saline solution
219408836|NCT02116660|DRUG|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
219408837|NCT02116660|DRUG|Nevirapine|Nevirapine (NVP) 200 mg tablets
219408838|NCT02116660|DRUG|Lamivudine|Lamivudine (3TC) 150 mg tablets
219408839|NCT02116660|DRUG|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
219408840|NCT02116660|DRUG|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
219408841|NCT02116660|DRUG|Lopinavir|Lopinavir (LPV) 200 mg tablets
219408842|NCT02116660|DRUG|Ritonavir|Ritonavir (r) 100 mg tablets
219408843|NCT02116660|DRUG|Atazanavir|Atazanavir (ATV) 300 mg tablets
219408844|NCT02116660|DRUG|Darunavir|Darunavir (DAR) 400 mg tablets
219408845|NCT06400836|OTHER|Carbohydrate timing - carbohydrate intake before or after exercise|The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
219408846|NCT00804258|DRUG|intraperitoneal chemotherapy|
219408847|NCT00804258|OTHER|educational intervention|
219408848|NCT00804258|OTHER|medical chart review|
219408849|NCT00804258|OTHER|questionnaire administration|
219408850|NCT00804258|PROCEDURE|assessment of therapy complications|
219408851|NCT00804258|PROCEDURE|end-of-life treatment/management|
219408852|NCT00804258|PROCEDURE|psychosocial assessment and care|
219408853|NCT00804258|PROCEDURE|quality-of-life assessment|
219408854|NCT04776811|DEVICE|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
219408855|NCT04234126|PROCEDURE|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
219408856|NCT00390416|DRUG|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
219408857|NCT03789604|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
219408858|NCT03789604|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
219408859|NCT06266533|BEHAVIORAL|Conventional Ultra-processed Food Nutrition Education|The participants will receive a conventional nutrition education session with slides, flyers/handouts, and a lecture with discussion.
219408860|NCT06266533|BEHAVIORAL|Arts-based Ultra-processed Food Nutrition Education|The participants will receive an arts-based nutrition education session with video, animation, music, and discussion.
219408861|NCT05355350|DRUG|Piperacillin / Tazobactam Injection|4.5 grams QID
219408862|NCT05355350|DRUG|Meropenem|1 gram TID
219568633|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
219408863|NCT06235476|DIETARY_SUPPLEMENT|whey protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
219408864|NCT06235476|DIETARY_SUPPLEMENT|mixed plant-based protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
219408865|NCT06235476|OTHER|e-health application|Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).
219408866|NCT06235476|DIETARY_SUPPLEMENT|isocaloric carbohydrate control|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
219408867|NCT03893175|DRUG|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
219408868|NCT03893175|DRUG|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
219408869|NCT03893175|DRUG|Placebo|By mouth
219408870|NCT03893175|DRUG|Oxycodone|5 mg by mouth every 6 hours as needed for pain
219408871|NCT02353260|DEVICE|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
219408872|NCT02353260|DRUG|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
219408873|NCT00287326|DRUG|Bupivacaine, Clonidine, Morphine|
219408874|NCT06553313|DEVICE|Micro-Western Array|The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
219408875|NCT04420416|OTHER|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
219408876|NCT00506077|DRUG|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
219408877|NCT00506077|DRUG|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
219408878|NCT00279552|DRUG|Recombinant human intrinsic factor|
219408879|NCT04181567|OTHER|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
219408880|NCT04181567|DRUG|agomelatine|agomelatine
219408881|NCT04181567|DRUG|Placebo|placebo
219408882|NCT03854643|OTHER|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
219756273|NCT04258748|BEHAVIORAL|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
219408883|NCT03854643|OTHER|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
219408884|NCT01594632|DRUG|Jadelle|LNG containing subdermal contraceptive implant
219408885|NCT01594632|DRUG|Sino-implant (II)|LNG containing subdermal contraceptive implant
219408886|NCT05903300|OTHER|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
219408887|NCT00818324|DRUG|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
219408888|NCT02868216|BEHAVIORAL|anger management training|
219756274|NCT04258748|BEHAVIORAL|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
219756275|NCT03525847|DIAGNOSTIC_TEST|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
219756276|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
219756277|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
219756278|NCT02898948|BIOLOGICAL|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
219756279|NCT00534001|DRUG|bupropion hydrochloride|Given orally
219756280|NCT00534001|OTHER|placebo|Given orally
219756281|NCT05964686|COMBINATION_PRODUCT|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
219756282|NCT05964686|COMBINATION_PRODUCT|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
219756283|NCT05964686|COMBINATION_PRODUCT|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
219756284|NCT05831943|DIAGNOSTIC_TEST|Contrast enhanced Kidney CT|"* Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
219756285|NCT00317837|PROCEDURE|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
219756286|NCT00317837|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty
219756287|NCT05439980|OTHER|Knowledge questionnaire|Completion of a questionnaire at baseline
219756288|NCT05439980|OTHER|Focus groups|structured interviews
219756289|NCT02412670|DRUG|Methotrexate|Given IV
219756290|NCT02412670|DRUG|Vinblastine|Given IV
219756291|NCT02412670|DRUG|Doxorubicin|Given IV
219756292|NCT02412670|DRUG|Cisplatin|Given IV
219756293|NCT02412670|DRUG|Gemcitabine|Given IV
219756294|NCT02412670|DRUG|Carboplatin|Given IV
219756295|NCT02412670|DRUG|Pegfilgrastim|Administered subcutaneously
219756296|NCT02412670|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
219756297|NCT01593371|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
219756298|NCT01593371|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
219408889|NCT06084325|DEVICE|Respiration resistance sensitivity task (RRST)|The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
219408890|NCT06084325|BEHAVIORAL|Heartbeat Tracking (HBT)|The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
219568634|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
219756299|NCT00508456|DRUG|Temodar (Temozolomide)|150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
219002906|NCT05989750|DEVICE|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
219002907|NCT03342105|PROCEDURE|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
219002908|NCT03342105|PROCEDURE|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
219756300|NCT00508456|DIETARY_SUPPLEMENT|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
219756301|NCT05746559|DRUG|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion.
219756302|NCT05746559|DRUG|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
219756303|NCT02363166|OTHER|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
219756304|NCT03549325|BIOLOGICAL|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
219756305|NCT00227253|PROCEDURE|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
219756306|NCT00227253|PROCEDURE|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
219756307|NCT00227253|PROCEDURE|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
219756308|NCT00227253|PROCEDURE|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
219756309|NCT00227253|PROCEDURE|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
219756310|NCT00227253|PROCEDURE|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
219756311|NCT00227253|PROCEDURE|Neurology examination|physical examination including observation of balance, coordination and reflexes.
219756312|NCT00227253|PROCEDURE|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
219756313|NCT00227253|PROCEDURE|Speech pathology evaluation|Standardized speech \& language tests and naturalistic assessment procedures.
219756314|NCT00227253|PROCEDURE|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
219756315|NCT00227253|PROCEDURE|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
219756316|NCT00227253|PROCEDURE|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
219756317|NCT00227253|PROCEDURE|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
219408891|NCT06084325|DEVICE|Heartbeat evoked potential (HEP)|The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
219408892|NCT06084325|DEVICE|Libet task|Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
219408893|NCT02496585|DRUG|Nintedanib|
219408894|NCT02496585|DRUG|Prednisone|
219408895|NCT02496585|OTHER|Placebo|
219408896|NCT01051375|BEHAVIORAL|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
219408897|NCT05743478|BEHAVIORAL|Forging Hopeful Futures|Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
219408898|NCT05743478|BEHAVIORAL|Wellness Check-ins|Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
219408899|NCT04751435|OTHER|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
219408900|NCT04751435|BEHAVIORAL|LCAM intervention|"Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic literacy screener and adapted clinical communication materials."
219408901|NCT04751435|BEHAVIORAL|Standard of care|Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
219568635|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
219568636|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
219568637|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
219568638|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
219756318|NCT05385822|BEHAVIORAL|Pelvic Floor Muscle Training|"* Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
219756319|NCT00934921|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
219756320|NCT00934921|DRUG|Zofran®|1 x 8 mg ODT
219756321|NCT04336189|DRUG|Sulfadoxine-pyrimethamine (SP)|SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
219408902|NCT05955170|DRUG|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
219756322|NCT04336189|DRUG|Dihydroartemisinin-piperaquine (DP)|DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
219408903|NCT03136757|OTHER|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~* to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~* to identify new intracellular signaling pathways that could lead to new therapeutic"
219408904|NCT05226819|DRUG|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
219408905|NCT05948410|BEHAVIORAL|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
219408906|NCT05948410|BEHAVIORAL|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
219408907|NCT05948410|BEHAVIORAL|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
219408908|NCT02207699|DRUG|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
219408909|NCT02207699|DRUG|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
219408910|NCT02207699|DRUG|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
219408911|NCT02207699|DRUG|Placebo|8 placebo perles given by mouth once
219408912|NCT03811678|DRUG|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
219408913|NCT03811678|DRUG|placebo|Tablet，administered orally once daily
219408914|NCT03272945|PROCEDURE|Linked-color imaging|Linked-color imaging colonoscopy
219408915|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
219408916|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
219408917|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
219408918|NCT00004993|DRUG|Parathyroid hormone (hPTH 1-34)|
219408919|NCT04891770|DRUG|Tenofovir Alafenamide|Administered as film-coated oral tablets
219408920|NCT04891770|DRUG|VIR-2218|Administered as a sub-cutaneous (SC) injection
219408921|NCT04891770|DRUG|Nivolumab|Administered intravenously
219408922|NCT04891770|DRUG|Selgantolimod|Administered as film-coated oral tablets
219408923|NCT04571710|DRUG|SHR1258|Drug: SHR1258 400mg
219408924|NCT00284778|DRUG|Alimta®|
219408925|NCT00284778|DRUG|Taxotere®|
219408926|NCT06371872|PROCEDURE|total transfixing injury to the rotator cuff|develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
219408927|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
219408928|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
219408929|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
219408930|NCT06169592|PROCEDURE|Liver transplantation|Related transplantation of the right lobe of the liver
219408931|NCT05619497|OTHER|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
219408932|NCT05619497|OTHER|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
219408933|NCT05619497|OTHER|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
219408934|NCT04372576|DIAGNOSTIC_TEST|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
219408935|NCT04819100|DRUG|Selpercatinib|Administered orally.
219408936|NCT04819100|DRUG|Placebo|Administered orally.
219756323|NCT06565273|DRUG|FBL-MTX|Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
219756324|NCT02239003|DRUG|DAOIB|
219756325|NCT02239003|DRUG|Placebo|
219756326|NCT03781479|DRUG|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
219756327|NCT03781479|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219002909|NCT04702334|DRUG|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
219002910|NCT04702334|DRUG|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
219002911|NCT03170401|DIETARY_SUPPLEMENT|Protein supplementation|enteral protein supplementation
219002912|NCT03170401|OTHER|Standard enteral nutrition|Standard enteral nutrition.
219002913|NCT01115634|BIOLOGICAL|Fibroblast|20 million cell in three injection
219002914|NCT01115634|BIOLOGICAL|fibroblast and gel|20 million cell in three injection plus filler
219002915|NCT02589184|OTHER|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
219002916|NCT02589184|OTHER|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
219002917|NCT02589184|OTHER|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
219002918|NCT01598012|DRUG|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
219408937|NCT04813042|BEHAVIORAL|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
219408938|NCT04813042|BEHAVIORAL|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
219002919|NCT01598012|DRUG|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
219002920|NCT06066684|OTHER|n/a, observational|n/a, observational study
219002921|NCT04954703|OTHER|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
219002922|NCT04954703|OTHER|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
219002923|NCT03932721|DRUG|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
219002924|NCT03013478|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
219002925|NCT03013478|BEHAVIORAL|CBT4CBT program|
219408939|NCT04117685|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
219408940|NCT00551824|DRUG|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
219408941|NCT00837512|DEVICE|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
219756328|NCT02921256|DRUG|Capecitabine|Given PO
219756329|NCT02921256|DRUG|Fluorouracil|Given IV
219756330|NCT02921256|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
219002926|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
219002927|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
219408942|NCT00837512|DEVICE|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
219408943|NCT03716986|DIAGNOSTIC_TEST|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
219756331|NCT02921256|DRUG|Leucovorin|Given IV
219756332|NCT02921256|DRUG|Oxaliplatin|Given IV
219756333|NCT02921256|BIOLOGICAL|Pembrolizumab|Given IV
219756334|NCT02921256|DRUG|Veliparib|Given PO
219756335|NCT03152201|DIAGNOSTIC_TEST|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
219756336|NCT00001055|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219756337|NCT00001055|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219756338|NCT00001055|BIOLOGICAL|rgp120/HIV-1 SF-2|
219408944|NCT03065634|BEHAVIORAL|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
219002928|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
219408945|NCT03065634|BEHAVIORAL|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
219408946|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
219408947|NCT01064466|DRUG|ETOPOSIDE - Usual|Etoposide Capsule
219756339|NCT03917615|OTHER|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
219756340|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (1)|"Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
219002929|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
219002930|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
219408948|NCT01064466|DRUG|ETOPOSIDE - Study|China Import Etoposide Capsule
219408949|NCT06973096|DRUG|CART-EGFR-IL13Ra2 cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR epitope 806 and a humanized scFv targeting IL13Ra2; both scFvs are fused to the 4-1BB and CD3ζ signaling domains.
219408950|NCT06973642|DEVICE|Software as a Medical Device (WizeCare)|Telehealth services will be provided through a telerehabilitation platform with AI capabilities and markerless motion capture.
219408951|NCT03644277|OTHER|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
219408952|NCT03644277|PROCEDURE|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve \>100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
219408953|NCT03644277|OTHER|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
219568639|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
219002931|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
219408954|NCT06408025|OTHER|Syrenity App|"Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health."
219408955|NCT06180278|OTHER|Blood tests|Participants will have blood tests done at each scheduled visit (approximately every 6 months).
219756341|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (2)|"Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
219002932|NCT00248989|DRUG|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
219002933|NCT00248989|DRUG|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
219002934|NCT01092104|DRUG|TBR-652|TBR-652 25 mg
219002935|NCT01092104|DRUG|TBR-652 Matching Placebo|Matching Placebo
219002936|NCT01092104|DRUG|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
219002937|NCT01092104|DRUG|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
219002938|NCT01092104|DRUG|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
219002939|NCT01092104|DRUG|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
219756342|NCT05092750|DEVICE|FerroTraceTM|A magnetic
219756343|NCT05092750|DRUG|indocyanine green (ICG)|Given by SC injection
219756344|NCT05459662|DIETARY_SUPPLEMENT|oat based porridge|Consume one preparation per day, orally
219756345|NCT05459662|DIETARY_SUPPLEMENT|plant based preparation|Consume one preparation per day, orally
219756346|NCT05316844|OTHER|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
219756347|NCT02865174|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
219756348|NCT02865174|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
219756349|NCT02865174|DRUG|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
219756350|NCT05121350|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
219756351|NCT05121350|DRUG|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
219756352|NCT05121350|DRUG|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
219756353|NCT03956160|OTHER|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures."
219756354|NCT06146816|DEVICE|photobiomodulation treatment in the infrared (IR) range.|The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
219756355|NCT04026802|OTHER|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
219756356|NCT04026802|OTHER|Standard of Care|Does not include early implementation of physical therapy
219756357|NCT02248571|DRUG|Bevacizumab|administered as combined therapy with Capecitabine
219756358|NCT02248571|DRUG|Capecitabine|administered as combined therapy with Bevacizumab
219756359|NCT02248571|DRUG|Everolimus|administered as combined therapy with Exemestane
219756360|NCT02248571|DRUG|Exemestane|administered as combined therapy with Everolimus
219756361|NCT02248571|OTHER|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
219756362|NCT05932498|PROCEDURE|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
219756363|NCT05547672|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
219756364|NCT04658485|DEVICE|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
219756365|NCT04658485|DEVICE|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
219756366|NCT00003562|DRUG|carboplatin|
219756367|NCT00003562|DRUG|docetaxel|
219756368|NCT00158106|PROCEDURE|Speech and Language therapy for dysarthria and/or aphasia|
219568640|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
219756369|NCT06296680|OTHER|Reiki|The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
219002940|NCT03537898|OTHER|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
219002941|NCT03537898|OTHER|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
219002942|NCT02231723|DRUG|BBI608|Administered continuously twice daily with doses separated by 12 hours
219002943|NCT02231723|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
219002944|NCT02231723|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
219002945|NCT02231723|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
219002946|NCT02231723|DRUG|Leucovorin|Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
219002947|NCT02231723|DRUG|Irinotecan|Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
219002948|NCT02231723|DRUG|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
219002949|NCT02231723|DRUG|MM-398|MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
219190162|NCT03325985|BEHAVIORAL|Facilitated,outpatient specialty palliative care|In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
219190163|NCT05726825|DEVICE|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
219190164|NCT06395779|BEHAVIORAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
219190165|NCT06395779|BEHAVIORAL|Dance Therapy Group|Participants in Group 2 will be given dance training by a dance instructor in the gym for 1 hour a day, 2 days a week, for a total of 12 weeks. In dance therapy practices, simple and basic movements are appropriate to the level of the participants, and special attention will be paid to the rhythm of the music not being fast. Latin dances were applied to the participants; selected rumba, merengue, bachata, and salsa movements. Dance therapy will start with a warm-up exercise (10 minutes), then dance exercises will be applied and the activity will end with a cool-down exercise (10 minutes).
219190166|NCT03056573|DEVICE|Transaortic TAVR Implant|Transaortic TAVR implant
219190167|NCT03056573|DEVICE|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
219190168|NCT05811585|DEVICE|ADEPT|Adhesion Reduction Solution (4% icodextrin solution)
219190169|NCT06444295|BEHAVIORAL|Activity scheduling|"Participants will engage in activity scheduling in the app (i.e., Activities module). On the first day of using the app, users will create a list of valued/important and avoided activities (e.g., spending time with friends, going to the gym), and then have the option to add alcohol protective behavioral strategies (e.g., adding ice to drinks, alternating alcoholic and nonalcoholic beverages) to activities that the user identifies as being likely to involve drinking. On subsequent days, users will be encouraged to complete at least one activity from their list."
219408956|NCT06180278|DRUG|Inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
219002950|NCT01233440|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
219002951|NCT01233440|BIOLOGICAL|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
219002952|NCT03008681|DEVICE|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
219002953|NCT01709890|DEVICE|YO2(R) catheter|
219002954|NCT02214524|DEVICE|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
219408957|NCT06663956|BEHAVIORAL|a patient self-reporting applet|"We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients."
219408958|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
219408959|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
219408960|NCT06552364|DRUG|LABA+LAMA|1 dose per day (AM)
219408961|NCT06552364|DRUG|LABA+LAMA+ICS|1 dose per day (AM)
219408962|NCT06552364|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control
219408963|NCT06552364|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
219408964|NCT02437097|OTHER|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
219408965|NCT02437097|OTHER|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
219408966|NCT02437097|OTHER|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
219408967|NCT02437097|OTHER|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
219408968|NCT06065527|BEHAVIORAL|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
219408969|NCT06065527|BEHAVIORAL|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
219408970|NCT05872971|DEVICE|Dry Needling|Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.
219408971|NCT05872971|DEVICE|Lasertherapy|Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
219408972|NCT06553144|PROCEDURE|control|Canals were irrigated with only10 mL of 5% NaOCl
219002955|NCT04334161|COMBINATION_PRODUCT|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
219002956|NCT02850965|DRUG|BI 695501|
219002957|NCT02850965|DRUG|Humira|
219002958|NCT02152033|BEHAVIORAL|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
219002959|NCT02152033|BEHAVIORAL|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
219002960|NCT02289417|DRUG|Apremilast|
219002961|NCT02289417|DRUG|Placebo|
219002962|NCT01837433|DRUG|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
219002963|NCT01837433|DRUG|Prednisone 6 weeks|Guidelines recommend
219002964|NCT02283385|BEHAVIORAL|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
219002965|NCT04786990|DRUG|SPN-812|Viloxazine extended-release capsule
219002966|NCT00714181|DRUG|hydroxychloroquine|
219408973|NCT06553144|PROCEDURE|methylene blue|0.1 mg/mL methylene blue solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
219408974|NCT06553144|PROCEDURE|erythrosine b|0.3 mg/mL eryrhtosine b solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
219408975|NCT06553144|PROCEDURE|curcumin|5.0 mg/mL curcumin solition delivered into the canal and irradiated with a 200mW diode laser at a wavelength of 450 nm
219408976|NCT05155696|DIETARY_SUPPLEMENT|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
219408977|NCT05155696|DIETARY_SUPPLEMENT|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
219408978|NCT01131221|OTHER|laboratory biomarker analysis|
219002967|NCT00714181|DRUG|temozolomide|
219002968|NCT00714181|GENETIC|TdT-mediated dUTP nick end labeling assay|
219002969|NCT00714181|GENETIC|western blotting|
219190170|NCT06444295|BEHAVIORAL|Cognitive restructuring|"Participants will engage in cognitive restructuring in the app (i.e., Thoughts activities). Users first go through an activity involving the identification of maladaptive cognitions and create a list of their maladaptive cognitions. On subsequent days, they engage in a guided in-app activity involving cognitive restructuring of maladaptive cognitions from their list."
219408979|NCT03737968|DRUG|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
219408980|NCT03737968|DRUG|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
219002970|NCT00714181|OTHER|electron microscopy|
219002971|NCT00714181|OTHER|high performance liquid chromatography|
219002972|NCT00714181|OTHER|immunoenzyme technique|
219002973|NCT00714181|OTHER|immunohistochemistry staining method|
219002974|NCT00714181|OTHER|laboratory biomarker analysis|
219002975|NCT00714181|OTHER|mass spectrometry|
219408981|NCT01245426|DRUG|GW870086 2mg|oral inhalation
219408982|NCT01245426|DRUG|GW870086 4mg|oral inhalation
219408983|NCT01245426|DRUG|GW870086 Placebo|oral inhalation
219408984|NCT01245426|DRUG|GW870086 1mg|oral inhalation
219408985|NCT01245426|DRUG|GW870086 3mg|oral inhalation
219002976|NCT00714181|OTHER|pharmacological study|
219002977|NCT06446167|OTHER|Exercises|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
219408986|NCT00696865|DRUG|AZD2624|oral suspension, 3 doses
219408987|NCT00696865|DRUG|Placebo|
219408988|NCT06661291|OTHER|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
219408989|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
219408990|NCT03220048|DRUG|PrEP-001|
219408991|NCT03220048|OTHER|Placebo Comparator|
219408992|NCT02593747|DRUG|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
219408993|NCT02593747|DRUG|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
219408994|NCT06856005|OTHER|Music intervention|"to evaluate the effectiveness of personalized music playlists in reducing procedural anxiety among young dentists performing crown preparations for porcelain-fused-to-metal (PFM) crowns and to compare the crown preparation performance of students who listened to music with those who did not.~• Experimental Group:~o Participants in the experimental group were asked to use personalized music playlists during the procedure. These playlists were already available on their personal devices (e.g., smartphones) and reflected their individual music preferences. Participants selected music they found relaxing or enjoyable, ensuring the intervention was tailored to their unique tastes."
219408995|NCT00136747|DRUG|Memantine|Two capsules of Memantine twice daily for 12 days.
219408996|NCT00136747|DRUG|bupropion|
219408997|NCT00136747|DRUG|placebo|
219408998|NCT01759329|DIETARY_SUPPLEMENT|test coffee|test coffee with higher alkyl pyridine content
219408999|NCT01759329|DIETARY_SUPPLEMENT|control coffee|control coffee with regular alkyl pyridine content
219409000|NCT00450203|BIOLOGICAL|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
219409001|NCT00450203|DRUG|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
219409002|NCT00450203|DRUG|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
219409003|NCT00450203|DRUG|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
219409004|NCT00450203|PROCEDURE|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
219409005|NCT00450203|PROCEDURE|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
219409006|NCT00450203|PROCEDURE|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
219409007|NCT00450203|DRUG|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
219409008|NCT04051021|BEHAVIORAL|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
219409009|NCT04051021|OTHER|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
219409010|NCT00635947|OTHER|isotonic solution|1.5 L- during 2-4hours
219409011|NCT00635947|OTHER|water|1.5 L- during 2-4hours
219409012|NCT00635947|OTHER|water|200mL- during 2-4hours
219409013|NCT02075762|PROCEDURE|Transbronchial biopsy|
219409014|NCT02075762|PROCEDURE|Cryoprobe biopsy|
219409015|NCT02075762|PROCEDURE|VATS biopsy|
219409016|NCT06862791|DRUG|AZD9550|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP
219409017|NCT06862791|DRUG|AZD6234|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
219409018|NCT06862791|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once weekly.
219409019|NCT06142747|DIAGNOSTIC_TEST|Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)|Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
219409020|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.
219409021|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
219409022|NCT02426242|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
219409023|NCT00118170|DRUG|sorafenib tosylate|Given orally
219409024|NCT00118170|OTHER|pharmacological study|Correlative studies
219409025|NCT00222729|DRUG|Pemetrexed|500 mg/m2 day 1 q 21 days
219409026|NCT00222729|DRUG|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
219409027|NCT06403384|DEVICE|Vibration|Local vibration was applied
219409028|NCT03777956|DRUG|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
219409029|NCT03777956|DRUG|Placebo|Identical placebo are given as capsules and taken orally twice a day.
219409030|NCT03864172|DIETARY_SUPPLEMENT|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
219409031|NCT03864172|DIETARY_SUPPLEMENT|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
219568641|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
219568642|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
219568643|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
219568644|NCT06247501|GENETIC|SNUH-CD19-CAR-T|CD19 CAR-T is a gene therapy that uses genetically modified autologous peripheral blood T-cells to target CD19 on the surface of B-cells. In this approach using CARs, lymphocytes are genetically manipulated, introducing the chimeric antigen receptor gene into the lymphocytes to combine the function of effector T-cells with antibody-like abilities. The chimeric antigen receptor can recognize cell surface antigens without the need for antigen processing. By using a single-chain variable fragment (scFv) antibody, which combines the variable regions of the heavy chain (VH) and light chain (VL) through a peptide linker of approximately 15 amino acids in length, the CAR gains the ability to bind to tumor antigens.
219756370|NCT06296680|OTHER|Sham Reiki|The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
219409032|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
219409033|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
219409034|NCT03222479|BEHAVIORAL|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
219409035|NCT01729364|DRUG|crystalloid|
219409036|NCT01729364|DRUG|colloid|
219409037|NCT00668343|DRUG|simvastatin|40 mg/ day
219409038|NCT00668343|DRUG|placebo|80 mg /day
219409039|NCT01809561|PROCEDURE|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
219409040|NCT04628559|DRUG|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
219409041|NCT04628559|DRUG|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
219409042|NCT04628559|DRUG|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
219409043|NCT05212194|OTHER|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
219409044|NCT01224912|BEHAVIORAL|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
219568645|NCT05262192|OTHER|nutrition education|Nutrition education will be given to the patients in the experimental group.
219568646|NCT01909128|DIETARY_SUPPLEMENT|fermented milk|fermented milk with Lactobacillus CBA-L74
219568647|NCT01909128|DIETARY_SUPPLEMENT|fermented rice|fermented rice wit Lactobacillus CBA-L74
219756371|NCT06296680|OTHER|Progressive Relaxation Exercise|PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
219568648|NCT04714151|DRUG|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
219756372|NCT02943473|DRUG|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
219756373|NCT03822611|BEHAVIORAL|Targeted Subsidy|Voucher
219756374|NCT00969020|PROCEDURE|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
219756375|NCT05392816|OTHER|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
219756376|NCT02103465|DRUG|Rotigotine|transdermal patch
219756377|NCT02103465|DRUG|Placebo|transdermal patch
219756378|NCT06547606|OTHER|Usual Care|Participants in the control group will recieve usual care.
219756379|NCT01891279|OTHER|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
219756380|NCT01891279|OTHER|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
219002978|NCT06446167|OTHER|MLS Laser Treatment|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions
219568649|NCT04714151|DRUG|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
219568650|NCT04714151|DRUG|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
219568651|NCT00078507|BEHAVIORAL|Sensory Re-training|
219568652|NCT00078507|BEHAVIORAL|Sensory Retraining|Facial Exercises
219568653|NCT00078507|BEHAVIORAL|Opening Exercises|
219568654|NCT05814991|DRUG|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
219568655|NCT05814991|DEVICE|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
219568656|NCT03417791|OTHER|no intervention|no intervention
219568657|NCT04079491|OTHER|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
219568658|NCT02562417|DRUG|Normal saline|
219568659|NCT02562417|DRUG|IV dexamethasone|
219756381|NCT03534492|DRUG|Durvalumab|Infusion
219756382|NCT03534492|DRUG|Olaparib|P.O.
219568660|NCT01872702|DRUG|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
219409045|NCT05547373|BEHAVIORAL|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
219409046|NCT00271440|PROCEDURE|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
219409047|NCT02937103|BIOLOGICAL|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
219409048|NCT03342612|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|
219409049|NCT00540969|PROCEDURE|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
219409050|NCT00540969|RADIATION|radiation therapy|Patients undergo radiotherapy for 1 week
219409051|NCT02146989|OTHER|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
219409052|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
219409053|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
219409054|NCT01318083|DRUG|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
219409055|NCT05990660|DEVICE|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
219409056|NCT05041192|DIETARY_SUPPLEMENT|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
219409057|NCT05041192|DIETARY_SUPPLEMENT|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
219409058|NCT01011920|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
219409059|NCT01011920|DRUG|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
219409060|NCT01011920|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
219409061|NCT01011920|DRUG|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
219409062|NCT01011920|RADIATION|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
219409063|NCT01011920|DRUG|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
219409064|NCT01011920|OTHER|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
219409065|NCT01741194|DRUG|AC-1204|AC-1204 taken once daily, by mouth
219409066|NCT01741194|DRUG|Placebo|Placebo taken once daily, by mouth
219409067|NCT04498429|OTHER|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
219568661|NCT03060759|DEVICE|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
219756383|NCT03157947|BEHAVIORAL|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
219756384|NCT03157947|BEHAVIORAL|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
219756385|NCT03157947|BEHAVIORAL|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
219756386|NCT03747055|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
219756387|NCT03747055|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
219756388|NCT06058091|DRUG|RY_SW01 cell injection|Administer basic treatment with an injection of RY\_SW01 cell solution
219756389|NCT06058091|DRUG|Basic treatment|Basic treatment for SSc
219756390|NCT00047034|DRUG|eribulin mesylate|Given IV
219756391|NCT00047034|OTHER|pharmacological study|Correlative studies
219756392|NCT00047034|OTHER|laboratory biomarker analysis|Correlative studies
219756393|NCT05892341|DEVICE|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
219756394|NCT05892341|DEVICE|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
219190171|NCT06444295|BEHAVIORAL|Coaching calls|Participants will receive 10-20 minute weekly coaching calls during the app use period (4 total, including coaching provided in the enrollment call). All coaching calls will, at minimum, include a check-in, troubleshooting of technical issues, check-in about experience with symptom self-monitoring, and offers of referrals. Coaching calls in conditions involving activity scheduling will involve assistance with the Activities module. Coaching calls in conditions involving cognitive restructuring will involve assistance with the Thoughts module.
219568662|NCT03903159|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
219568663|NCT02401477|DRUG|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
219568664|NCT02443545|DRUG|Deferiprone|
219568665|NCT00724373|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
219568666|NCT00724373|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
219568667|NCT03589248|DIAGNOSTIC_TEST|GIF score|assessment by GIF score
219756395|NCT05678426|BEHAVIORAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
219756396|NCT05678426|BEHAVIORAL|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
219409068|NCT04498429|OTHER|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
219409069|NCT01868373|BIOLOGICAL|Microbiota Transplantation (FMT)|Active therapy
219409070|NCT02811133|DRUG|Inositol|Subjects will receive inositol
219409071|NCT06175611|DEVICE|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
219409072|NCT03702205|DIETARY_SUPPLEMENT|Betaine supplementation|Group taking oral betaine supplementation
219409073|NCT03702205|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
219409074|NCT03654547|DRUG|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
219409075|NCT03380117|BEHAVIORAL|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
219409076|NCT04165343|RADIATION|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
219409077|NCT04165343|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
219756397|NCT05678426|BEHAVIORAL|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
219409078|NCT04165343|DIAGNOSTIC_TEST|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
219568668|NCT03589248|DIAGNOSTIC_TEST|US score|assessment by ultrasonography score
219191857|NCT05386563|PROCEDURE|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
219409079|NCT04165343|DIAGNOSTIC_TEST|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
219409080|NCT00382889|DRUG|beclomethasone/salbutamol combination|
219409081|NCT00382889|DRUG|beclomethasone|
219409082|NCT00382889|DRUG|salbutamol|
219409083|NCT02094586|BIOLOGICAL|PXVX0200 Lot A|Lot P700-1CA03
219409084|NCT02094586|BIOLOGICAL|PXVX0200 Lot B|Lot P700-3CA03
219568669|NCT00553592|DRUG|Bicifadine|600mg/day
219568670|NCT00553592|DRUG|Bicifadine|placebo tablet
219568671|NCT00553592|DRUG|Bicifadine|1200 mg
219568672|NCT03399240|DEVICE|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
219568673|NCT03041168|DEVICE|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
219568674|NCT03821363|BIOLOGICAL|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
219568675|NCT00536484|DRUG|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
219568676|NCT00536484|DRUG|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
219568677|NCT01923584|DRUG|EPI-743 400mg|
219568678|NCT01923584|DRUG|EPI-743 200mg|
219568679|NCT05037786|BEHAVIORAL|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
219568680|NCT05037786|BEHAVIORAL|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
219568681|NCT02303314|DRUG|Trigonella Foenum-graecum Seed Extract|
219568682|NCT02303314|DRUG|Drug: Placebo|
219568683|NCT05616403|OTHER|No intervention|This is an observational study without any intervention
219409085|NCT02094586|BIOLOGICAL|PXVX0200 Lot C|Lot P700-6BA03
219409086|NCT02094586|BIOLOGICAL|Placebo|Placebo
219409087|NCT03408496|OTHER|Myofascial release|Manual therapy
219409088|NCT03408496|OTHER|Muscle stretching|Muscle stretching
219409089|NCT03408496|OTHER|Control|Medical appointment
219409090|NCT03242278|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
219409091|NCT02461485|OTHER|Fermented milk product containing Probiotics|2 pots/day during 28 days
219409092|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
219568684|NCT01653795|DEVICE|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
219568685|NCT01653795|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
219568686|NCT01506908|DRUG|oral nicotine|oral nicotine replacement product
219568687|NCT01506908|DRUG|Placebo|no active
219568688|NCT03749954|DIAGNOSTIC_TEST|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
219756398|NCT00593619|DRUG|Iron dextran|300mg in 250cc normal saline given over 2 hours
219756399|NCT00593619|DRUG|Iron sucrose|300mg in 250cc normal saline given over 2 hours
219409093|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
219409094|NCT02461485|OTHER|Non fermented Milk Product|2 pots/day during 28 days
219409095|NCT02761993|BIOLOGICAL|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
219409096|NCT02761993|DRUG|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
219409097|NCT03694574|BEHAVIORAL|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)"
219409098|NCT03694574|BEHAVIORAL|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
219568689|NCT05670145|OTHER|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
219568690|NCT06331117|DIAGNOSTIC_TEST|Diagnostic test|Multiomics profiling
219568691|NCT02155374|DRUG|Sliding scale insulin|
219568692|NCT02155374|DRUG|Intermediate acting insulin|
219568693|NCT02155374|BEHAVIORAL|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
219568694|NCT02155374|DRUG|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
219568695|NCT02155374|DRUG|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
219568696|NCT01368627|DEVICE|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
219568697|NCT01490320|BEHAVIORAL|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
219568698|NCT01490320|BEHAVIORAL|Play Nicely Program|Multimedia program available at www.playnicely.org.
219568699|NCT01490320|OTHER|Control Group|Standard care in primary care clinic.
219568700|NCT04062682|BEHAVIORAL|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
219568701|NCT04417582|PROCEDURE|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
219568702|NCT01229644|DRUG|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
219568703|NCT05676060|COMBINATION_PRODUCT|quasi|block facet joint in back pain due to afacet cause
219568704|NCT05785689|DRUG|Dexmedetomidine|To reduce postoperative agitation
219568705|NCT05785689|DRUG|Placebo|Placebo bolus saline
219756400|NCT03261830|DRUG|Cefazolin|Primary intervention
219409099|NCT03694574|BEHAVIORAL|control|No instruction
219409100|NCT03173820|GENETIC|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
219409101|NCT03173820|GENETIC|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
219409102|NCT01842620|DRUG|Metformin|Oral antidiabetic agent
219568706|NCT02692729|PROCEDURE|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
219568707|NCT02692729|PROCEDURE|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
219568708|NCT03314662|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
219568709|NCT03314662|BIOLOGICAL|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
219756401|NCT03261830|DRUG|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
219756402|NCT03261830|DRUG|Saline|Placebo Intervention
219756403|NCT00897026|DRUG|cyclophosphamide|
219756404|NCT00897026|DRUG|doxorubicin hydrochloride|
219756405|NCT00897026|DRUG|paclitaxel|
219190172|NCT06444295|BEHAVIORAL|Non-core intervention components|"All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues"
219190173|NCT04321551|DRUG|Testosterone Cyp 200Mg/Ml Inj (in Oil)|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
219409103|NCT01647594|BEHAVIORAL|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
219409104|NCT01647594|BEHAVIORAL|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
219409105|NCT06316258|BEHAVIORAL|Compassion focused therapy group|6 session compassion focused therapy group for adults with ABI
219409106|NCT00256867|DRUG|GSK523338|
219409107|NCT04583566|GENETIC|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
219756406|NCT00897026|GENETIC|fluorescence in situ hybridization|
219002979|NCT06446167|OTHER|ESWT treatment|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
219409108|NCT03742336|DRUG|PF-04965842|Single oral 200 mg dose of PF-04965842
219409109|NCT03742336|DRUG|Dabigatran|Single 75 mg dose of dabigatran
219409110|NCT01958736|OTHER|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
219568710|NCT03314662|BIOLOGICAL|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
219568711|NCT00052026|DRUG|carvedilol|low-dose carvedilol administered twice daily for 8 months
219756407|NCT00897026|OTHER|immunohistochemistry staining method|
219756408|NCT05130073|PROCEDURE|Computed Tomography|Undergo PET/CT
219756409|NCT05130073|OTHER|Electronic Health Record Review|Review of medical records
219756410|NCT05130073|PROCEDURE|Follow-Up|Undergo follow-up
219756411|NCT05130073|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219756412|NCT00660218|DRUG|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
219756413|NCT00660218|BIOLOGICAL|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
219756414|NCT00660218|RADIATION|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
219568712|NCT00052026|DRUG|placebo|administered twice daily for 8 months
219568713|NCT00052026|DRUG|carvedilol|high-dose carvedilol administered twice daily for 8 months
219568714|NCT01631526|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
219756415|NCT04211363|DRUG|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
219002980|NCT06347835|DIETARY_SUPPLEMENT|symbiotic|The intervention is made up of multiple probiotics and prebiotics (20g/d) and dietary pattern modification.
219568715|NCT03433131|DRUG|Pitolisant|Tablets
219568716|NCT05382520|DIAGNOSTIC_TEST|Questionares and practice|Questionares and practice
219568717|NCT01393457|DRUG|levodopa/carbidopa|800/200 mg/d
219568718|NCT01393457|DRUG|Ropinirole 2 mg/d|2 mg/d
219568719|NCT01393457|DRUG|Placebo|sugar pill
219568720|NCT01393457|DRUG|Ropinirole 4 mg/d|4 mg/d
219756416|NCT04211363|DRUG|Vehicle Cream|Vehicle cream for topical application.
219409111|NCT01958736|OTHER|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
219190174|NCT04321551|DRUG|Letrozole|Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
219190175|NCT06559007|DRUG|HRS-5041 dose level 1|Single dose of HRS-5041 orally administered
219409112|NCT03223220|DRUG|Ketamine|IV infusion
219409113|NCT03223220|OTHER|Normal Saline|IV infusion
219409114|NCT03223220|DRUG|Midazolam injection|Injection
219409115|NCT00505700|DRUG|velcade|
219002981|NCT06347835|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (20g/d) and dietary pattern modification.
219002982|NCT06347835|DIETARY_SUPPLEMENT|symbiotic placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
219190176|NCT06559007|DRUG|HRS-5041 dose level 2|Single dose of HRS-5041 orally administered
219190177|NCT06158607|BEHAVIORAL|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
219409116|NCT00505700|DRUG|Idarubicin|
219409117|NCT00505700|DRUG|Cytarabine|
219409118|NCT01675219|PROCEDURE|white light TUR-BT|traditional transurethral bladder tumor resection
219409119|NCT01675219|PROCEDURE|blue light TUR-BT|photodynamic transurethral bladder tumor resection
219409120|NCT01675219|DRUG|optimized MMC|six weekly optimized mitomycin-C instillations
219409121|NCT01675219|DRUG|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
219568721|NCT01211782|DRUG|caprylic triglyceride|oral, 20 gm, daily x 6 months
219568722|NCT01211782|DRUG|long-chain triglyceride|oral, 14 gm, daily x 6 months
219568723|NCT03418792|OTHER|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
219568724|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
219409122|NCT05355090|DIETARY_SUPPLEMENT|PP|Protein Pacing three times per day
219568725|NCT02428179|PROCEDURE|StOP? - Control group|Control group - Surgical procedure without Study Intervention
219409123|NCT04339075|OTHER|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
219409124|NCT05818293|DEVICE|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
219409125|NCT03088293|DRUG|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
219756417|NCT03097289|DEVICE|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
219756418|NCT02007941|DRUG|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
219409126|NCT03088293|DRUG|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
219756419|NCT03035630|DRUG|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
219756420|NCT03035630|DRUG|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
219756421|NCT04505488|BEHAVIORAL|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
219409127|NCT00189007|DRUG|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
219409128|NCT00189007|DRUG|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
219756422|NCT02835469|DRUG|Menotrophin|
219409129|NCT04307147|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
219409130|NCT04307147|DRUG|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
219409131|NCT02851680|BIOLOGICAL|blood samples|
219409132|NCT00683358|BIOLOGICAL|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
219409133|NCT06181396|DRUG|Oxytocin|Native oxytocin analog
219756423|NCT02160821|PROCEDURE|Caudal Epidural|Ultrasound Guided Caudal Block
219756424|NCT02160821|PROCEDURE|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
219756425|NCT03522402|DRUG|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
219756426|NCT01302002|DRUG|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
219756427|NCT06155357|BEHAVIORAL|Multicomponent lifestyle intervention program|The multicomponent lifestyle intervention program is targeted at risk factor management, increased exercise capacity, and weight loss. The program will commence upon order/referral for ablation. Ablation would occur during the lifestyle program and the program will be continued after the ablation to complete 12 weeks or up to 36 exercise sessions.
219756428|NCT01823289|DRUG|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
219756429|NCT05957627|PROCEDURE|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
219409134|NCT06864754|OTHER|WashU DIEP Flap Video|Video uses visual cues and graphics to help explain complex procedures in a simplified, comprehensible fashion to patients.
219409135|NCT05029596|DRUG|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
219409136|NCT05029596|DRUG|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
219409137|NCT02993224|DRUG|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
219409138|NCT02993224|DRUG|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
219409139|NCT01834924|OTHER|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
219409140|NCT05122663|BEHAVIORAL|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
219409141|NCT05122663|OTHER|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
219409142|NCT04286412|BIOLOGICAL|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
219409143|NCT05331612|BEHAVIORAL|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
219568726|NCT02428179|PROCEDURE|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
219409144|NCT01032512|DIETARY_SUPPLEMENT|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
219409145|NCT01032512|DIETARY_SUPPLEMENT|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
219409146|NCT01270581|OTHER|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
219409147|NCT01270581|OTHER|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
219409148|NCT05025072|DRUG|Hydroxycarbamide dispersible tablets|Hydroxycarbamide dispersible tablets (20 x 50 mg)
219409149|NCT05025072|DRUG|Hydroxycarbamide film-coated tablet|Hydroxycarbamide film-coated tablet (1000 mg)
219409150|NCT02998437|DRUG|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
219409151|NCT02998437|DRUG|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
219409152|NCT02998437|DRUG|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
219409153|NCT01930799|BEHAVIORAL|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
219409154|NCT04353622|DEVICE|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
219409155|NCT04353622|OTHER|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
219409156|NCT00972400|GENETIC|protein analysis|
219409157|NCT00972400|OTHER|laboratory biomarker analysis|
219409158|NCT00972400|OTHER|mass spectrometry|
219409159|NCT00972400|OTHER|questionnaire administration|
219568727|NCT01207999|PROCEDURE|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
219568728|NCT01207999|OTHER|Data collection|Questionnaire completion
219409160|NCT00972400|PROCEDURE|assessment of therapy complications|
219409161|NCT00972400|PROCEDURE|cognitive assessment|
219409162|NCT00972400|PROCEDURE|quality-of-life assessment|
219409163|NCT04357353|BIOLOGICAL|Platelet rich plasma|PRP will be used in the experimental arm.
219409164|NCT04357353|OTHER|Placebo Sham Injection|sham injection
219409165|NCT01706445|OTHER|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
219568729|NCT00920088|DRUG|darunavir/ritonavir|DRV/RTV 600/100mg
219568730|NCT00920088|DRUG|lopinavir/ritonavir|LPV/RTV 400/100mg
219568731|NCT00920088|DRUG|Midazolam|Midazolam 3mg
219568732|NCT00920088|DRUG|Dextromethorphan|Dextromethorphan 30mg
219568733|NCT00920088|DRUG|Flurbiprofen|Flurbiprofen 50mg
219568734|NCT00920088|DRUG|GSK2248761|NNRTI under investigation
219568735|NCT03353454|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
219568736|NCT03353454|DRUG|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
219568737|NCT00056745|BIOLOGICAL|TBC-3B|
219568738|NCT03544398|OTHER|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
219568739|NCT00772720|DRUG|raltegravir|raltegravir 400 mg BID for 7 days
219568740|NCT00772720|DRUG|Placebo|Placebo BID for 7 days
219568741|NCT02744131|DRUG|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
219568742|NCT02744131|DRUG|Metformin 1500mgs per day|
219756430|NCT01428791|BEHAVIORAL|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
219756431|NCT01428791|BEHAVIORAL|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
219756432|NCT03057756|COMBINATION_PRODUCT|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
219756433|NCT01736917|DRUG|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
219190178|NCT06158607|OTHER|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
219190179|NCT06423339|PROCEDURE|Ultrasound guided Genicular nerve block|Ultrasound guided genicular nerve block
219190180|NCT06423339|PROCEDURE|Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee|Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
219190181|NCT06423339|PROCEDURE|Adductor canal block|Ultrasound guided sub-sartorial Adductor canal block
219568743|NCT02079337|DRUG|Rocuronium|
219568744|NCT02079337|DRUG|sugammadex|
219568745|NCT02079337|DRUG|placebo|
219568746|NCT00211991|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
219756434|NCT01736917|DRUG|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
219756435|NCT01736917|DRUG|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
219568747|NCT02293616|DIETARY_SUPPLEMENT|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
219568748|NCT02293616|DIETARY_SUPPLEMENT|Placebo|
219568749|NCT03844230|OTHER|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
219568750|NCT03844230|OTHER|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
219568751|NCT03844230|OTHER|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
219568752|NCT03844230|OTHER|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
219568753|NCT03844230|OTHER|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
219568754|NCT03844230|OTHER|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
219568755|NCT03844230|OTHER|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
219568756|NCT03825744|DRUG|Hetrombopag Olamine+Standard Therapy|once daily
219568757|NCT03825744|DRUG|Placebo+Standard Therapy|once daily
219568758|NCT04761471|DEVICE|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (\<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
219568759|NCT00238563|DRUG|Triamcinolone injection, sub-tenon|
219568760|NCT00465231|DRUG|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
219568761|NCT00465231|DRUG|preservative free saline|10mL saline solution
219568762|NCT01839695|DEVICE|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
219568763|NCT00440115|BEHAVIORAL|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
219568764|NCT00440115|BEHAVIORAL|Low intensity disease management|Health education mailings, one motivation interview/counseling
219568765|NCT00440115|BEHAVIORAL|Comparison group|Health education mailings
219568766|NCT00440115|DRUG|Bupropion|Buproprion or Nicotine Replacement Therapy
219568767|NCT00206102|DRUG|quetiapine fumarate|flexible dose oral
219568768|NCT00206102|DRUG|risperidone|flexible dose oral
219568769|NCT01332786|DRUG|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest"
219568770|NCT02693431|OTHER|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
219568771|NCT01398202|DIETARY_SUPPLEMENT|vitamin D3|20 micrograms per day for 10 weeks
219568772|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
219568773|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
219568774|NCT01398202|DIETARY_SUPPLEMENT|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
219568775|NCT03204474|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
219568776|NCT03204474|DRUG|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
219568777|NCT06617403|OTHER|non|non
219568778|NCT06616038|OTHER|Data collection|Given the observational nature of the study, the intervention is a simple data collection
219568779|NCT01388452|DEVICE|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
219568780|NCT04325854|PROCEDURE|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
219568781|NCT05907148|OTHER|Sensory integration training|"Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk."
219409166|NCT05609747|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
219002983|NCT06347835|DIETARY_SUPPLEMENT|whey protein placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
219190182|NCT06423339|DRUG|Bupivacaine Hydrochloride|Pupivacaine 0.5% in 20 ml vial
219409167|NCT00952289|DRUG|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
219409168|NCT00952289|DRUG|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
219190183|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
219409169|NCT03091062|DEVICE|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
219756436|NCT05748821|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
219002984|NCT03921671|COMBINATION_PRODUCT|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
219002985|NCT05288244|OTHER|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
219002986|NCT05288244|OTHER|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
219409170|NCT03091062|DEVICE|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
219409171|NCT04356144|DIAGNOSTIC_TEST|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
219409172|NCT04356144|DIAGNOSTIC_TEST|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
219409173|NCT03241758|DIAGNOSTIC_TEST|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
219409174|NCT02142192|DRUG|natalizumab|Administered as specified in the treatment arm
219756437|NCT01392157|DEVICE|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
219756438|NCT01392157|DEVICE|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
219756439|NCT01392157|DEVICE|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
219756440|NCT01392157|DEVICE|LNG-IUS|100 women will receive an LNG-IUS
219002987|NCT05288244|OTHER|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
219002988|NCT03035370|BIOLOGICAL|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
219409175|NCT03468192|OTHER|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
219409176|NCT00469196|PROCEDURE|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
219568782|NCT05907148|OTHER|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
219409177|NCT00875017|DRUG|Lanthanum Carbonate|1 x 1000mg tablet
219568783|NCT05907148|OTHER|General coordination exercise|"In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw"
219002989|NCT03035370|BIOLOGICAL|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
219002990|NCT03035370|BIOLOGICAL|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
219002991|NCT03035370|BIOLOGICAL|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
219409178|NCT00875017|DRUG|Sevelamer|3 x 800mg tablets
219409179|NCT02767141|BEHAVIORAL|Coping Strategies|Coping strategies for households in the US with food insecurity
219409180|NCT03342469|OTHER|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
219409181|NCT03342469|OTHER|Placebo|Placebo chocolate cookies
219409182|NCT00377624|DRUG|sodium hyaluronate|
219409183|NCT02672319|PROCEDURE|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
219190184|NCT04656028|GENETIC|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
219190185|NCT04656028|BEHAVIORAL|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
219409184|NCT04032496|BEHAVIORAL|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
219409185|NCT04032496|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
219409186|NCT01528800|DRUG|Vitamin K1|10mg orally three times a week for 12 months
219409187|NCT01528800|DRUG|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
219409188|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 1|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
219409189|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 2|Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
219409190|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 3|Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
219409191|NCT05336526|DEVICE|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
219409192|NCT02714673|DRUG|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
219409193|NCT00791713|DRUG|Paliperidone ER|
219409194|NCT04559152|DIETARY_SUPPLEMENT|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
219409195|NCT04559152|DIETARY_SUPPLEMENT|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
219409196|NCT02003651|DIETARY_SUPPLEMENT|Quick Defense|Echinacea product from Gaia Herbs.
219190186|NCT04656028|DIAGNOSTIC_TEST|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
219409197|NCT02003651|DIETARY_SUPPLEMENT|Placebo|Placebo
219409198|NCT05513703|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
219409199|NCT02932475|DRUG|Metformin|1000 mg twice a day
219409200|NCT02932475|DRUG|Placebo|Delivered to match active drug
219409201|NCT00367497|DRUG|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
219409202|NCT02686697|DRUG|L-Carnosine|
219409203|NCT02686697|DRUG|Placebo|
219409204|NCT02686697|BEHAVIORAL|Cognitive Training|Cognitive Training for 2 weeks
219409205|NCT04353960|DIAGNOSTIC_TEST|electrocardiograph|electrocardiograph monitor during strabismus surgery
219409206|NCT04836143|DRUG|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
219409207|NCT02322320|DRUG|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
219409208|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
219409209|NCT01323257|DRUG|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
219409210|NCT01323257|DRUG|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
219409211|NCT01323257|DRUG|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
219002992|NCT06175910|PROCEDURE|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
219409212|NCT01323257|DRUG|TMC435|50 mg capsule once daily for 7 days (Trt F)
219409213|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
219409214|NCT01449357|DRUG|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
219409215|NCT01766830|DEVICE|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
219409216|NCT01766830|DEVICE|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
219409217|NCT01766830|DEVICE|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
219409218|NCT01766830|DEVICE|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
219190187|NCT04656028|OTHER|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
219409219|NCT01766830|DEVICE|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
219002993|NCT06175910|PROCEDURE|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
219409220|NCT01766830|DEVICE|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
219409221|NCT01766830|DEVICE|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
219409222|NCT01766830|DEVICE|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
219409223|NCT01766830|DEVICE|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
219409224|NCT01766830|DEVICE|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
219002994|NCT03101683|RADIATION|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
219409225|NCT01452126|DRUG|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
219409226|NCT04575857|DRUG|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
219409227|NCT04575857|DRUG|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
219409228|NCT03762122|DRUG|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
219409229|NCT02385825|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
219409230|NCT04969640|OTHER|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
219409231|NCT01967667|DIETARY_SUPPLEMENT|Liposomal glutathione|Escalating dose steps
219409232|NCT01967667|DIETARY_SUPPLEMENT|Placebo|escalating dose steps
219409233|NCT01290081|OTHER|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
219409234|NCT02538588|DEVICE|Nebulizer 1|
219409235|NCT02538588|DEVICE|Nebulizer 2|
219409236|NCT01506778|DEVICE|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
219409237|NCT05307822|OTHER|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
219409238|NCT05307822|OTHER|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
219409239|NCT05307822|OTHER|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
219409240|NCT05307822|OTHER|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
219409241|NCT03568149|PROCEDURE|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
219409242|NCT03568149|PROCEDURE|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
219409243|NCT01081223|BIOLOGICAL|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
219002995|NCT06332235|DRUG|Silodosin 8 mg|Dosing schedule: Oral, once daily
219002996|NCT06504641|OTHER|Isla for Frailty|"Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
219002997|NCT01782222|DRUG|Rotigotine|"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
219002998|NCT01782222|OTHER|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
219002999|NCT02071914|DRUG|CT-P27|Influenza A treatment drug.
219003000|NCT02071914|DRUG|Placebo|Placebo.
219003001|NCT05469828|DRUG|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
219003002|NCT05469828|OTHER|control|Standard of care
219003003|NCT00903799|DEVICE|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
219003004|NCT00251485|DRUG|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
219003005|NCT01500694|DRUG|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
219409244|NCT02391506|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
219409245|NCT06276608|DIAGNOSTIC_TEST|Iron status|Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
219409246|NCT01727635|OTHER|body-mind-spirit group therapy|8-session therapy
219409247|NCT04212338|OTHER|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
219409248|NCT04212338|OTHER|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
219568784|NCT05904262|OTHER|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
219568785|NCT03699254|DRUG|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
219756441|NCT01911260|DIETARY_SUPPLEMENT|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
219756442|NCT01911260|OTHER|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
219756443|NCT03377660|OTHER|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
219003006|NCT04260152|DEVICE|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
219003007|NCT04260152|PROCEDURE|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
219756444|NCT01669512|BIOLOGICAL|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
219756445|NCT01669512|BIOLOGICAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
219756446|NCT01669512|BIOLOGICAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
219756447|NCT04748887|OTHER|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
219756448|NCT03493646|DRUG|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
219003008|NCT00833794|DRUG|Tramadol Once a day|
219003009|NCT00833794|DRUG|Placebo|
219003010|NCT00663169|BIOLOGICAL|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
219409249|NCT02007785|BEHAVIORAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
219409250|NCT03136185|DRUG|Bomedemstat|Oral (capsule) administration according to dose allocation.
219409251|NCT00466999|DRUG|misoprostol|single dose of 400 mcg misoprostol administered sublingually
219409252|NCT00466999|PROCEDURE|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
219409253|NCT01920620|BEHAVIORAL|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
219409254|NCT01920620|BEHAVIORAL|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
219409255|NCT03972592|DRUG|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
219568786|NCT03699254|DRUG|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
219568787|NCT00260273|BEHAVIORAL|Cognitive Behaviour Therapy|therapy
219568788|NCT04290494|DRUG|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
219003011|NCT00663169|DRUG|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
219003012|NCT00663169|OTHER|placebo matching canakinumab|5% glucose in water intravenous infusion.
219003013|NCT00663169|OTHER|placebo matching dexamethasone|Placebo intravenous infusion.
219191858|NCT05386563|PROCEDURE|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
219191859|NCT05232032|DRUG|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
219409256|NCT03972592|DRUG|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
219409257|NCT00833235|OTHER|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
219409258|NCT04242017|DRUG|Triptoreline|Comparison of the duration of ADT (Triptoreline)
219568789|NCT03366194|DEVICE|SkinStylus Sterilock System|Microneedling device will be used to treat ventral hypertrophic scars.
219568790|NCT00176358|DEVICE|PTCA and Stent Implantation|
219568791|NCT00176358|BEHAVIORAL|Exercise Training|
219568792|NCT01090817|DRUG|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
219568793|NCT06396637|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride: 20mg/kg, qd
219756449|NCT03493646|DRUG|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
219756450|NCT02635295|BEHAVIORAL|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
219756451|NCT02807701|PROCEDURE|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction"
219756452|NCT02807701|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
219756453|NCT02645799|DRUG|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
219756454|NCT02645799|DRUG|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
219756455|NCT01675947|DRUG|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
219756456|NCT01675947|DRUG|Lidocaine|Lidocaine 2%
219756457|NCT00002217|DRUG|Lamivudine/Zidovudine|
219756458|NCT00002217|DRUG|Abacavir sulfate|
219756459|NCT00002217|DRUG|Amprenavir|
219756460|NCT03140618|OTHER|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
219756461|NCT00654732|DRUG|Bleomycin|Given IV
219756462|NCT00654732|DRUG|Dacarbazine|Given IV
219756463|NCT00654732|DRUG|Doxorubicin Hydrochloride|Given IV
219756464|NCT00654732|BIOLOGICAL|Rituximab|Given IV
219756465|NCT00654732|DRUG|Vinblastine|Given IV
219761073|NCT01276951|PROCEDURE|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
219190188|NCT04656028|OTHER|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
219409259|NCT04148924|OTHER|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
219409260|NCT04148924|OTHER|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
219409261|NCT00125658|OTHER|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
219756466|NCT01958086|DEVICE|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
219756467|NCT06479356|BIOLOGICAL|Relma-cel|Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
219756468|NCT05181488|RADIATION|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
219761074|NCT01276951|PROCEDURE|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
219761075|NCT00760552|OTHER|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
219761076|NCT00760552|OTHER|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
219761077|NCT00760552|OTHER|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
219761078|NCT00475098|DRUG|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
219003014|NCT04932278|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
219003015|NCT04932278|PROCEDURE|Usual care|Routine concussion management with healthcare professionals.
219003016|NCT06504797|DEVICE|automatic massage|automatic massage
219003017|NCT03193203|DRUG|Etanercept|50 mg/mL PFS and AI
219003018|NCT01105728|PROCEDURE|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
219003019|NCT05373368|BEHAVIORAL|multi purpose activities|
219003020|NCT03039140|OTHER|Educational Intervention|Attend weekly educational sessions
219756469|NCT05923723|OTHER|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
219003021|NCT03039140|BEHAVIORAL|Exercise Intervention|Participate in CR program
219409262|NCT00125658|OTHER|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
219409263|NCT03055104|OTHER|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
219003022|NCT03039140|OTHER|Quality-of-Life Assessment|Ancillary studies
219003023|NCT03039140|OTHER|Questionnaire Administration|Ancillary studies
219003024|NCT03572062|BIOLOGICAL|Formulation A|RSV vaccine
219756470|NCT05923723|OTHER|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
219003025|NCT03572062|BIOLOGICAL|Formulation B|Adjuvanted RSV vaccine
219409264|NCT02876055|DRUG|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
219756471|NCT06557304|DRUG|BTK inhibitor|patients with treatment naive or R/R CLL who treatment with BTK inhibitor
219003026|NCT03572062|BIOLOGICAL|Formulation C|RSV vaccine
219003027|NCT03572062|BIOLOGICAL|Placebo|Placebo
219756472|NCT02481557|DEVICE|Oxalate Salt Solution|Applied by dentist
219756473|NCT01966146|DEVICE|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
219756474|NCT01734902|DRUG|Hyoscine butylbromide|sugar coated tablets for oral administration
219756475|NCT01734902|DRUG|Hyoscine butylbromide|drops for oral administration
219756476|NCT02647684|BEHAVIORAL|Self-Directed Triple P|10 Week Triple P Self directed workbook
219756477|NCT01959932|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
219003028|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 1|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003029|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 2|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003030|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 3|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003031|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 4|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003032|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 5|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003033|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 6|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003034|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 7|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003035|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 8|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003036|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 9|Liquid formula produced by several food ingredients to provide a balance nutrient intake
219003037|NCT06358716|DIETARY_SUPPLEMENT|Glucose|25 mg of glucose dissolved in 200 mL
219003038|NCT01740947|DRUG|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
219003039|NCT04765956|DEVICE|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
219003040|NCT03390816|OTHER|Nutritional assessment|Observational
219003041|NCT03748888|BEHAVIORAL|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
219003042|NCT03191994|BEHAVIORAL|Exercise|a structured, supervised eight week moderate intensity exercise intervention
219409265|NCT02876055|DRUG|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
219409266|NCT02876055|DRUG|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
219756478|NCT01959932|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
219756479|NCT01959932|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
219003043|NCT01022229|DIETARY_SUPPLEMENT|Compound Natural Health Product|"* 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
219409267|NCT04065477|BEHAVIORAL|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
219190189|NCT04656028|OTHER|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
219568794|NCT02087891|BEHAVIORAL|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
219568795|NCT02087891|BEHAVIORAL|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
219568796|NCT02087891|BEHAVIORAL|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
219568797|NCT02722252|DEVICE|Embryoscope|
219568798|NCT02722252|DEVICE|Embryo culture system without incorporated camera|
219568799|NCT03123783|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
219568800|NCT03123783|DRUG|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
219568801|NCT00000239|DRUG|Buprenorphine|
219568802|NCT00958802|OTHER|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
219568803|NCT00958802|OTHER|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
219409268|NCT02669550|DEVICE|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
219409269|NCT02669550|DEVICE|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
219568804|NCT03643926|PROCEDURE|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
219568805|NCT03643926|PROCEDURE|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
219568806|NCT02664987|OTHER|Patients receiving cancer pain treatment|
219568807|NCT04850248|OTHER|no intervention, this is an observational study|no intervention, this is an observational study
219568808|NCT04678063|OTHER|Exposure to Placebo|Patients are exposed to placebo in the EEC
219568809|NCT04678063|OTHER|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
219756480|NCT04838067|DEVICE|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
219568810|NCT04678063|OTHER|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
219568811|NCT01182662|OTHER|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
219568812|NCT01182662|OTHER|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
219568813|NCT06390566|OTHER|calpaïnopathies|Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A
219568814|NCT04299217|DIETARY_SUPPLEMENT|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
219568815|NCT04299217|OTHER|Placebo|Placebo comparator (carrier)
219003044|NCT01022229|DIETARY_SUPPLEMENT|Placebo|Placebo
219003045|NCT00958750|DRUG|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
219409270|NCT01239186|OTHER|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
219409271|NCT02476981|DRUG|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
219409272|NCT02476981|DRUG|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
219568816|NCT02681484|BEHAVIORAL|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
219568817|NCT06734728|DEVICE|Profilm Cold Sores|The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
219568818|NCT02642237|BIOLOGICAL|Fluenz|intranasal inoculation with Fluenz
219409273|NCT02476981|DRUG|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
219409274|NCT02476981|DRUG|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
219409275|NCT02476981|DRUG|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
219409276|NCT06553274|PROCEDURE|Individualized nutrition intervention|"After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists."
219409277|NCT02280967|BEHAVIORAL|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
219409278|NCT05437224|DRUG|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
219409279|NCT02715960|DRUG|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
219409280|NCT01443455|BEHAVIORAL|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
219409281|NCT01443455|BEHAVIORAL|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
219409282|NCT01443455|BEHAVIORAL|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~\--------------------------------------------------------------------------------"
219409283|NCT02241746|OTHER|no intervention|
219409284|NCT02231255|DRUG|Sifrol®|
219409285|NCT01685632|PROCEDURE|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
219409286|NCT01685632|PROCEDURE|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
219409287|NCT05320770|PROCEDURE|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
219409288|NCT06520176|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
219409289|NCT06520176|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
219409290|NCT06520176|DRUG|Pegfilgrastim|Day 6: 6mg
219409291|NCT06520176|DRUG|Cyclophosphamide|Day 1\~Day 2: 1～2g/m\^2
219409292|NCT06520176|DRUG|G-CSF|Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
219409293|NCT06520176|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
219568819|NCT02642237|OTHER|placebo|
219568820|NCT02642237|OTHER|LPS|
219568821|NCT01370239|BIOLOGICAL|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
219568822|NCT05488886|DIETARY_SUPPLEMENT|Whole Aronia Berry Powder Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
219756481|NCT00758563|DRUG|Fluoride|Brush twice daily
219409294|NCT00364845|DRUG|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
219409295|NCT00364845|DRUG|Placebo|Prefilled syringe placebo, to match active arm
219409296|NCT00843297|DEVICE|Coolgard|invasive Cooling via femoral ICY-catheter
219409297|NCT00843297|DEVICE|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
219409298|NCT00843297|OTHER|Conventional treatment|Intensive care-treatment without cooling
219756482|NCT00758563|DRUG|Triclosan/Fluoride|Brush twice daily
219756483|NCT00060944|DRUG|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
219003046|NCT01082991|OTHER|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
219003047|NCT06318195|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
219003048|NCT03585998|DRUG|Durvalumab|Concurrent radiotherapy Maintenance therapy
219003049|NCT05422196|PROCEDURE|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
219003050|NCT05742100|DRUG|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
219003051|NCT00764647|BEHAVIORAL|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
219409299|NCT03894527|BEHAVIORAL|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
219409300|NCT03894527|BEHAVIORAL|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
219409301|NCT04997889|COMBINATION_PRODUCT|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
219409302|NCT04997889|OTHER|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
219756484|NCT00060944|DRUG|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
219756485|NCT00060944|DRUG|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
219756486|NCT00060944|DRUG|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
219003052|NCT01605877|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
219003053|NCT00458211|DRUG|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
219003054|NCT00052689|DRUG|bortezomib|Given IV
219409303|NCT02884817|DRUG|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
219003055|NCT00052689|DRUG|gemcitabine hydrochloride|Given IV
219190190|NCT04656028|OTHER|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
219409304|NCT02884817|OTHER|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
219568823|NCT05488886|DIETARY_SUPPLEMENT|Aronia Berry Extract Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
219568824|NCT05488886|DIETARY_SUPPLEMENT|Phospholipid-Polyphenol Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
219003056|NCT06505317|DIAGNOSTIC_TEST|AI-based PAD screening intervention|"Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis."
219003057|NCT02818569|DRUG|Dexmedetomidine|Oral form
219409305|NCT02884817|OTHER|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
219409306|NCT01227538|OTHER|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
219409307|NCT00965705|BEHAVIORAL|Therapy|Individual Therapy and Group Therapy
219409308|NCT01926054|DRUG|Acthar gel|
219409309|NCT00488033|PROCEDURE|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
219409310|NCT01784406|BEHAVIORAL|Autonomy supportive counselling|
219568825|NCT05488886|OTHER|Low-Polyphenol Control Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
219568826|NCT06904755|DEVICE|It is loaded with a mesenchymal stem cells reaction device for blood purification|Artificial liver blood purification therapy is performed using a mesenchymal stem cells reactor.
219568827|NCT06904170|DRUG|Durvalumab Plus Tremelimumab|"Systemic infusion of :~Tremelimumab 300 mg, single dose at Cycle 1 Durvalumab 1500 mg at Cycle 1 then every 4 weeks until disease progression or unacceptable toxicity.~Durvalumab and Tremelimumab will be delivered during a single angiography. Implantable catheter is also allowed.~Durvalumab infusion will start 1 hour after the end of the tremelimumab infusion."
219568828|NCT06904170|DRUG|HAIC (GEMOX)|"Hepatic Arterial Infusion of Chemotherapy (HAIC) :~Gemcitabine 1000 mg/m² over 30 minutes, followed by Oxaliplatin 100 mg/m² over 2 hours. Administered every 2 weeks for 4 cycles. When a Durvalumab cycle match with an HAIC infusion, HAIC will be delivered on the same day."
219756487|NCT04268238|PROCEDURE|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
219409311|NCT04019093|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
219409312|NCT04019093|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
219409313|NCT04937582|DIAGNOSTIC_TEST|Cognitive assessment|Complete cognitive and psychological assessment
219409314|NCT04937582|DIAGNOSTIC_TEST|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
219409315|NCT04937582|DIAGNOSTIC_TEST|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
219409316|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary
219409317|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
219409318|NCT03361319|DRUG|Vargatef|small molecule triple kinase inhibitor
219409319|NCT03361319|DRUG|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
219409320|NCT03361319|OTHER|placebo|Placebo in place of Ninedanib
219409321|NCT01769079|DRUG|Nitrate|Two arms: placebo and nitrate
219409322|NCT01769079|DRUG|Placebo|
219409323|NCT03757481|OTHER|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
219409324|NCT06505057|OTHER|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
219568829|NCT06903910|DRUG|Donepezil (Aricept)|Donepezil is a cholinesterase inhibitor tablet taken by mouth once nightly
219568830|NCT06905314|DRUG|HRS-4029|HRS-4029
219568831|NCT06905314|DRUG|Placebo|Placebo
219761079|NCT04883944|OTHER|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice."
219409325|NCT01613014|DRUG|ABT-436|Target dose - 400mg BID
219409326|NCT01613014|DRUG|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
219409327|NCT01218412|BEHAVIORAL|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
219409328|NCT01117688|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
219409329|NCT01187108|DRUG|N-acetylcysteine|NAC 600 mg oral once daily
219409330|NCT01187108|DRUG|Acetazolamide|Acetazolamide 250 mg oral once daily
219409331|NCT01187108|DRUG|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
219409332|NCT04715230|BIOLOGICAL|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
219409333|NCT04715230|DRUG|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
219409334|NCT04715230|DRUG|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
219409335|NCT05261672|DRUG|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
219003058|NCT02818569|OTHER|Saline Placebo|Saline Placebo
219003059|NCT04403477|BIOLOGICAL|Convalescent plasma|Apheretic convalescent plasma from a COVID-19 survivor
219003060|NCT03854305|DRUG|PRV-6527|Treatment
219003061|NCT03854305|DRUG|Placebo|Comparator
219003062|NCT05276193|OTHER|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
219003063|NCT03322878|DRUG|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
219003064|NCT03206528|DEVICE|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
219003065|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
219003066|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
219003067|NCT01918085|OTHER|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
219003068|NCT01918085|OTHER|Strata strip|An adhesive strip made of the Strata adhesive
219190191|NCT04656028|OTHER|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
219190192|NCT02698579|GENETIC|No interventional drug product utilized in this follow-up study|"Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study."
219190193|NCT06000657|DRUG|Vemliver tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)
219190194|NCT06000657|DRUG|Baracross Tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet
219190195|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of liquid biopsy.
219190196|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of tissue biopsy.
219190197|NCT05032092|GENETIC|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
219409336|NCT05261672|DRUG|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
219409337|NCT05630404|DRUG|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
219190198|NCT02821351|DEVICE|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
219003069|NCT04984083|DIETARY_SUPPLEMENT|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
219003070|NCT03761524|PROCEDURE|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
219003071|NCT03761524|PROCEDURE|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
219003072|NCT03637114|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
219003073|NCT03637114|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
219003074|NCT00388778|DRUG|Doxycycline|
219003075|NCT00148018|DRUG|Bortezomib|
219003076|NCT00148018|DRUG|Dexamethasone|
219003077|NCT01207869|BIOLOGICAL|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
219003078|NCT01207869|OTHER|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
219190199|NCT03863457|DRUG|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
219568832|NCT06905457|COMBINATION_PRODUCT|Vojta therapy|Vojta therapy, also known as Reflex Locomotion Therapy, is a specialized physiotherapy technique developed by Czech neurologist Václav Vojta, using sensory stimulation to activate innate movement patterns and improve motor skills, posture, and overall function
219568833|NCT06905457|COMBINATION_PRODUCT|Bobath therapy|Bobath therapy, also known as Neurodevelopmental Treatment (NDT), is a problem-solving approach to neurological rehabilitation, focusing on motor learning and efficient motor control to improve function and participation in daily activities
219409338|NCT05630404|DRUG|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
219409339|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
219409340|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
219409341|NCT05540470|DRUG|PART|"Chloroquine (150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~1. Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A.~   Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~2. OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria."
219409342|NCT05540470|DRUG|Malakit|"delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~* 1 laminated sheet with illustrated instruction~* 1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~  * A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~ * Two 15 mg tablets of primaquine, to be given as a single dose (145)~* 1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~* 3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies."
219409343|NCT05540470|OTHER|CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS|Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample
219409344|NCT05540470|OTHER|QUALITATIVE STUDY|Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
219409345|NCT00277316|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
219409346|NCT02204241|DRUG|Carfilzomib|
219409347|NCT02204241|DRUG|Cyclophosphamide|
219409348|NCT02204241|DRUG|Dexamethasone|
219409349|NCT04913714|BEHAVIORAL|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
219409350|NCT02704221|BEHAVIORAL|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
219409351|NCT02704221|BEHAVIORAL|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
219409352|NCT02704221|BEHAVIORAL|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
219568834|NCT06905184|BEHAVIORAL|Activity PRN|"An Activity PRN plan will be delivered to consenting patients, as described above. The intervention will be communicated to them as a new approach that 'supports the individual to engage in personalised meaningful activities, which they can engage in as and when required'.~Activity Resources are organised within a suitable, accessible location according with the patient's risk management and support plan. Dependent on the plan, resources may be kept on their person, in their bedroom, in a communal area, or in a locked or unlocked accessible cupboard.~Ward staff will facilitate prn activities on an 'as and when required' basis. This can occur when: 1) a patient requests an activity from their card, 2) the patient appears disengaged, or 3) staff deem that the patient may benefit from participation in an activity for the purpose of engagement or distraction."
219568835|NCT06904430|OTHER|Bucket Group|This Bucket Intervention is behavioral and studies the effect of players limiting their throw count during practice to reduce pain occurrence
219568836|NCT06904430|DEVICE|Brace Group|The Brace intervention studies the use of players using an elbow throwing brace during practice to reduce the occurrence of pain
219568837|NCT06905587|DRUG|Methylphenidate (MPH)|"10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.~For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol."
219568838|NCT06905587|DRUG|Placebo|"10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.~Dosage will follow the exact same principles as for the study drug (methylphenidate)."
219568839|NCT06472180|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
219568840|NCT06472180|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
219568841|NCT02953678|DRUG|Ruxolitinib|
219568842|NCT02953678|DRUG|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
219756488|NCT04268238|PROCEDURE|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
219409353|NCT01152164|BEHAVIORAL|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
219409354|NCT03453151|DRUG|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
219409355|NCT01763476|PROCEDURE|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
219409356|NCT01763476|PROCEDURE|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
219409357|NCT01468909|OTHER|Laboratory Biomarker Analysis|Correlative studies
219409358|NCT01468909|DRUG|Paclitaxel|Given IV
219409359|NCT01468909|DRUG|Pazopanib Hydrochloride|Given PO
219409360|NCT01468909|OTHER|Placebo|Given PO
219409361|NCT00704509|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
219409362|NCT00704509|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
219409363|NCT00704509|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
219409364|NCT07006584|OTHER|Experimental|Group B participated in the same workshops and additionally completed functional gait training using the SSM Fisior® program. The intervention period lasted 12 weeks for both groups, with 2 additional weeks allocated for baseline and post-intervention assessments (T1 and T2).
219409365|NCT07006584|OTHER|Active Comparator #1|Group A attended only the physical activity workshops offered by Centro Integral del Adulto Mayor (CIAM), consisting of one weekly class each of gymnastics, dance, swimming, and Tai Chi, held on different days of the week.
219409366|NCT06692946|BEHAVIORAL|Cooperative Parent-Mediated therapy|Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).
219409367|NCT06692946|BEHAVIORAL|Treatement as Usual|"Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD."
219409368|NCT06696001|BEHAVIORAL|Psychoeducation|For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
219409369|NCT06696001|BEHAVIORAL|Behavioral Activation|Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.
219756489|NCT04268238|RADIATION|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
219003079|NCT04080414|BEHAVIORAL|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
219409370|NCT06375811|DRUG|Elagolix 200 MG|Elagolix tablet
219409371|NCT06375811|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
219409372|NCT07026734|PROCEDURE|Deep brain stimulation surgery - GPi|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for GPi DBS will be enrolled in the study prior to their surgery.
219756490|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
219003080|NCT04080414|BEHAVIORAL|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
219409373|NCT07026734|PROCEDURE|Deep Brain Stimulation Surgery - STN|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for STN DBS will be enrolled in the study prior to their surgery.
219409374|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
219409375|NCT06699966|DRUG|Celecoxib|The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
219409376|NCT06699966|DRUG|Minocycline|Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
219756491|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
219756492|NCT01138514|DRUG|Placebo|Placebo
219409377|NCT06692491|DRUG|Albumin-Bound Paclitaxel|Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
219756493|NCT02375074|BEHAVIORAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
219756494|NCT02375074|BEHAVIORAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
219756495|NCT00499525|DRUG|paclitaxel|given IV
219756496|NCT00499525|DRUG|sorafenib tosylate|given orallly
219756497|NCT00499525|OTHER|placebo|given orally
219756498|NCT03791879|DRUG|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
219756499|NCT00776230|BIOLOGICAL|IC51|6 mcg im. at day 0 and day 28
219756500|NCT01228214|DRUG|Placebo|Placebo 5mg/daily for 12 months
219756501|NCT01228214|DRUG|amiloride|5mg/daily for 12 months
219756502|NCT03969173|PROCEDURE|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
219756503|NCT03969173|PROCEDURE|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
219003081|NCT01655472|DEVICE|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
219409378|NCT06692491|DRUG|Epirubicin|Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
219756504|NCT03969173|PROCEDURE|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
219756505|NCT03381989|DEVICE|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
219756506|NCT00458549|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
219756507|NCT00458549|PROCEDURE|biopsy|
219756508|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg twice daily
219756509|NCT01242514|DRUG|Fostamatinib|Fostamatinib 150mg once daily
219756510|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg once daily
219756511|NCT06074432|OTHER|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
219756512|NCT06459440|BEHAVIORAL|Group Task oriented Training|Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
219761080|NCT04883944|OTHER|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding."
219761081|NCT04384614|DIAGNOSTIC_TEST|Test PCR|Viral load (COVID+) testing by PCR
219409379|NCT06692491|DRUG|Gemcitabine|Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
219409380|NCT06692491|DRUG|Vinorelbine|Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
219409381|NCT06692491|DRUG|Cisplatin|Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
219409382|NCT06692491|DRUG|Irinotecan|Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
219190200|NCT05100212|BIOLOGICAL|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 29 weeks of postmenstrual age (29+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
219761082|NCT04384614|GENETIC|TDR|IDR and blood sampling for testing DNA Cheque
219003082|NCT01655472|DEVICE|imaging follow up: Ultrasonographic examination|
219003083|NCT03781596|DIAGNOSTIC_TEST|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
219003084|NCT03781596|OTHER|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
219190201|NCT05100212|BIOLOGICAL|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
219409383|NCT06692491|DRUG|Fluorouracil|Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
219409384|NCT06692491|DRUG|Nivolumab|Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.
219761083|NCT04384614|OTHER|Clinical Examination|COVID 19 symptoms and Physical Examination
219761084|NCT03400423|DRUG|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
219761085|NCT03400423|BEHAVIORAL|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
219761086|NCT04293198|DEVICE|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
219761087|NCT04293198|DEVICE|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
219761088|NCT04915716|OTHER|Peripheral blood glucose levels were monitored|Peripheral blood glucose levels were monitored
219761089|NCT04450732|DRUG|GQ1001|anti-HER2 antibody drug conjugate
219761090|NCT05081362|OTHER|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
219761091|NCT01738243|DRUG|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
219761092|NCT01738243|DRUG|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
219761093|NCT06571344|DRUG|Cholecalciferol|"The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm."
219761094|NCT00467441|DRUG|VSF-173|
219761095|NCT00133133|DRUG|ALGRX 4975|
219761096|NCT05539651|DRUG|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
219761097|NCT05539651|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
219761098|NCT00396617|DEVICE|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
219761099|NCT00396617|PROCEDURE|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
219761100|NCT04723719|BEHAVIORAL|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
219761101|NCT04723719|OTHER|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
219761102|NCT05030584|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
219761103|NCT05030584|DRUG|Placebo|Matching placebo orally once daily.
219761104|NCT01312831|OTHER|Vitamin B12 (cyanocobalamin)|
219761105|NCT02189109|DRUG|NVX-108|0.2% emulsion administered i.v.
219761106|NCT03481348|DEVICE|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
219761107|NCT04001400|DRUG|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
219761108|NCT04001400|DRUG|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
219761109|NCT01306292|DRUG|SonoVue|dose of 4.8 mL administered intravenously one time
219761110|NCT01306292|DRUG|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
219761111|NCT05882396|OTHER|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
219761112|NCT05882396|OTHER|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
219761113|NCT05291754|DEVICE|PEEK Cranioplasty|3D printed PEEK skull implant
219409385|NCT06692491|DRUG|Pembrolizumab|Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
219409386|NCT06692491|DRUG|Durvalumab|Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.
219409387|NCT06692491|DRUG|Atezolizumab|Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.
219409388|NCT06692491|DRUG|Sintilimab|Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
219409389|NCT06692491|DRUG|Tislelizumab|Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.
219409390|NCT06692491|DRUG|Camrelizumab|Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
219568843|NCT03259685|OTHER|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
219568844|NCT03259685|OTHER|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
219409391|NCT06692491|DRUG|Toripalimab|Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.
219409392|NCT06692491|DRUG|Serplulimab|Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
219568845|NCT03259685|OTHER|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
219756513|NCT06459440|OTHER|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)"
219409393|NCT06692491|DRUG|Adebrelimab|Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
219191860|NCT05232032|DEVICE|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
219409394|NCT06692491|DRUG|Envafolimab|Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
219409395|NCT06692491|DRUG|Osimertinib|Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
219409396|NCT06692491|DRUG|Alectinib|Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.
219409397|NCT06692491|DRUG|Vemurafenib|Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.
219756514|NCT02985723|DEVICE|AT LISA tri toric 939MP|
219756515|NCT01485848|DRUG|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
219756516|NCT01485848|DRUG|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
219003085|NCT03781596|OTHER|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
219003086|NCT03781596|DIAGNOSTIC_TEST|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
219409398|NCT06692491|DRUG|Pamiparib|Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
219409399|NCT06692491|DRUG|Pyrotinib|Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
219409400|NCT06692491|DRUG|Imatinib|Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
219409401|NCT06692491|DRUG|Palbociclib|Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
219568846|NCT05859243|BEHAVIORAL|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
219409402|NCT06692491|DRUG|Savolitinib|Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
219409403|NCT06692491|DRUG|Entrectinib|Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
219409404|NCT06692491|DRUG|Other|"Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments."
219409405|NCT06693713|OTHER|Mental Health Youth Series|The Mental Health Youth Series is an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics. The intervention package includes a facilitation guide and a guide for parents and caregivers. The program is intended to be conducted by an experienced facilitator, although there is no specific training provided for facilitators outside of the facilitation guide.
219761114|NCT01657305|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
219761115|NCT01657305|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
219761116|NCT00578097|BIOLOGICAL|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
219003087|NCT03781596|OTHER|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
219409406|NCT06692933|DRUG|Cannabidiol in the form of hemp|Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel
219409407|NCT06692933|DRUG|Clopidogrel|75 mg oral clopidogrel
219761117|NCT00578097|DRUG|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
219003088|NCT03781596|DRUG|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
219003089|NCT03781596|DRUG|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
219761118|NCT03841409|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
219761119|NCT05595746|PROCEDURE|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
219761120|NCT04103450|DRUG|Vibegron|oral administration
219761121|NCT02588885|BEHAVIORAL|Trauma-sensitive Care|"Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills"
219761122|NCT01390623|DRUG|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
219761123|NCT01101607|PROCEDURE|Distal Forearm Fracture Reduction|Fracture reduction
219761124|NCT04342247|DRUG|external testosteron|external testosteron
219761125|NCT00487916|DRUG|AMA1-C1/ISA 720|
219191861|NCT03900221|OTHER|No intervention|No intervention
219409408|NCT06693583|DEVICE|Virtual Reality Headsets|Virtual reality (VR) headsets are used as a form of distraction technique widely throughout healthcare. Women will be assisted to apply the VR prior to their colposcopy examination beginning. They will be shown an immersive video of walking through a forest that reminds them to breath deeply. The aim is that this will relax them during the colposcopy examination.
219409409|NCT07023783|BEHAVIORAL|Transdiagnostic Sleep Health Intervention (TSHI)|"A transdiagnostic sleep health intervention (TSHI) will be delivered across six weekly 50-minute one-on-one sessions with a sleep expert via a HIPAA-compliant videoconference link. The six weekly TSHI sessions are outlined as:~Week 1: Consists of discussing sleep physiology and discussing appropriate bed and wake up times.~Week 2: Consists of discussing how to set/importance of setting, a bedtime routine Week 3: Consists of discussing how to improve daytime function through energy management for daily and weekly tasks.~Week 4: Consists of discussing the sleep beliefs the participant holds and possible corrections of any unhelpful sleep beliefs.~Week 5: Consists of educating participants on sleep hygiene and how it is influenced by environmental, social, and physical factors.~Week 6: Consists of discussing sleep behavior changes observed during the TSHI and collaborating with the participant on plans to maintain their new sleep pattern."
219409410|NCT03492463|DRUG|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
219409411|NCT03492463|OTHER|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
219409412|NCT03492463|OTHER|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
219003090|NCT03781596|DRUG|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
219003091|NCT05778916|PROCEDURE|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
219003092|NCT00346112|PROCEDURE|psycho-educational|
219409413|NCT03492463|OTHER|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
219409414|NCT06876220|BEHAVIORAL|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|MBCT-L is an 8-week group intervention where participants are guided to practice mindfulness and cognitive exercise. The course covers themes such as anchoring, acceptance, and decentering. The course will be provided by mindfulness teachers who have completed the training offered by Oxford Mindfulness Foundation (OMF). Throughout the eight weeks, the course guides the participants through various themes such as anchoring, acceptance, and decentering. The sessions involve guided mindfulness practices, reflection, discussion, inquiry, and weekly home practice. The language of instruction is Cantonese.
219409415|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
219409416|NCT06692816|OTHER|Rehabilitation|As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
219409417|NCT06691906|DRUG|Enlicitide decanoate|Oral tablet
219409418|NCT00484250|DRUG|metronidazole,doxycycline|
219409419|NCT07031089|OTHER|Non-interventional study (RIPH category 3)|The study aims to describe and evaluate an existing care pathway, implemented within the framework of current clinical practice, without modifying the modalities of care or adding specific interventions. No additional procedures are imposed on participants, apart from data collection for evaluation purposes and telephone interviews.
219409420|NCT06168864|DIAGNOSTIC_TEST|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
219409421|NCT04355091|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
219409422|NCT02674607|DIETARY_SUPPLEMENT|Spirulina|
219568847|NCT05859243|BEHAVIORAL|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
219568848|NCT01343875|PROCEDURE|tear of the distal tendon in the biceps muscle|
219003093|NCT05881915|DRUG|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
219003094|NCT05881915|DRUG|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
219003095|NCT03640130|BEHAVIORAL|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
219003096|NCT06370650|PROCEDURE|platelet rich plasma, narrow band UVB|Role of PRP in treating stable vitiligo
219003097|NCT03721601|DEVICE|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
219409423|NCT05507944|DIAGNOSTIC_TEST|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
219003098|NCT03721601|DEVICE|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
219003099|NCT03778762|PROCEDURE|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
219409424|NCT01427569|DRUG|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
219409425|NCT01427569|OTHER|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
219409426|NCT06726018|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion.
219756517|NCT05541848|OTHER|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
219756518|NCT05541848|OTHER|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
219756519|NCT03861338|DRUG|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
219756520|NCT03112902|DEVICE|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
219756521|NCT02274571|DRUG|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
219756522|NCT02274571|OTHER|Placebo|non active
219756523|NCT03213509|OTHER|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
219756524|NCT02847897|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
219756525|NCT03829111|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
219756526|NCT03829111|BIOLOGICAL|Ipilimumab|Given IV
219756527|NCT03829111|BIOLOGICAL|Nivolumab|Given IV
219756528|NCT06449560|OTHER|Practice Group|Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
219756529|NCT06449560|OTHER|Video Feedback Group|Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
219756530|NCT02647671|DRUG|Aquamin®|90 days of Aquamin
219756531|NCT02647671|DRUG|Calcium Carbonate|90 days of Calcium Carbonate
219756532|NCT02647671|DRUG|Placebo|90 days of placebo
219756533|NCT04416958|DEVICE|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
219003100|NCT03778762|PROCEDURE|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
219409427|NCT07046403|DEVICE|High Purity Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
219409428|NCT07046403|DEVICE|Dehydrated Human Amnion / Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
219409429|NCT06925672|OTHER|Questionnaire|"This is an anonymous questionnaire; based upon previous similar studies.~The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:~A. Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.~B. Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.~C. Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.~This questionnaire will be presented in its Arabic version."
219409430|NCT07046793|DIAGNOSTIC_TEST|POCUS|Ultrasound screening of the distal forearm.
219409431|NCT04604106|DIAGNOSTIC_TEST|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
219409432|NCT04604106|DIAGNOSTIC_TEST|Ages & Stages questionnaire|The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
219409433|NCT04604106|DIAGNOSTIC_TEST|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
219409434|NCT01327040|OTHER|light exposure|12-hour light exposure of approximately 200 lux
219568849|NCT05183412|DEVICE|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
219568850|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
219568851|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
219568852|NCT04678817|DEVICE|Etonogestrel contraceptive implant with oral levonorgestrel|Participants who present for emergency contraception and select the Etonogestrel contraceptive implant with oral levonorgestrel
219409435|NCT04105556|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
219409436|NCT06759194|PROCEDURE|Holmium Laser Enucleation of the Prostate|Enucleation of the prostate gland using holmium laser energy
219003101|NCT01914198|OTHER|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
219003102|NCT03585257|BIOLOGICAL|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
219003103|NCT03585257|OTHER|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
219409437|NCT06759194|PROCEDURE|Bipolar Enucleation of the Prostate|Enucleation of the prostate gland using bipolar energy
219409438|NCT07082309|DIETARY_SUPPLEMENT|Ketone Monoester (KE) and whey protein beverage|Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)
219409439|NCT07082309|DIETARY_SUPPLEMENT|Control|Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
219409440|NCT07082556|OTHER|US-guided PNM|Stimulation will be applied for 15 minutes at 4 Hz, using a 250 ms pulse duration.
219409441|NCT06765707|BEHAVIORAL|Pharmacist delivered symptom monitoring and management|Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.
219409442|NCT06894017|DRUG|Ozurdex (dexamethasone)|Intravitreal dexamethasone implant (Ozurdex) given according to the recommendations by the manufacturer.
219409443|NCT07063589|OTHER|Mobile application|Cannabis use patterns and their resulting subjective experiences, along with social and health-related correlates will be collected in real time using a mobile application specifically designed for this study by a local custom software development company (Osedea, Montreal).
219409444|NCT07067801|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|Study of the Standard of care versus Placebo
219003104|NCT03340532|OTHER|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
219003105|NCT03340532|OTHER|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
219003106|NCT03340532|OTHER|Sleep hygiene video|Contain information on better sleep hygiene
219409445|NCT07067801|DRUG|Placebo|Control
219568853|NCT04678817|DEVICE|Levonorgestrel intrauterine device|Participants who present for emergency contraception and select the Levonorgestrel intrauterine device
219568854|NCT04678817|DEVICE|Copper T380A intrauterine device|Participants who present for emergency contraception and select the Copper T380A intrauterine device
219568855|NCT02682147|DRUG|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
219568856|NCT03081728|DEVICE|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
219409446|NCT07084727|OTHER|Arterial stiffness|"Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another.~Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates."
219409447|NCT07084727|OTHER|Flow-meditad dilatation|"This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes.~When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques."
219003107|NCT00313378|DRUG|Hypothetica|
219409448|NCT07084727|OTHER|Dynamic retinal vessel analyzer|Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.
219409449|NCT07082569|OTHER|Volume Control Ventilation|Standard mode of mechanical ventilation delivering a preset tidal volume. Commonly used in ICU patients requiring controlled ventilation.
219568857|NCT03081728|DRUG|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
219568858|NCT03879096|OTHER|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
219568859|NCT00784134|DRUG|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
219003108|NCT01897402|BIOLOGICAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
219003109|NCT01897402|BIOLOGICAL|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
219003110|NCT01647620|DRUG|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
219003111|NCT01647620|DRUG|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
219003112|NCT04367636|BEHAVIORAL|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
219003113|NCT04367636|BEHAVIORAL|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
219003114|NCT04367636|OTHER|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
219409450|NCT07082569|OTHER|Pressure Control Ventilation|Pressure-targeted ventilation mode that delivers breaths at a fixed pressure. Commonly used in critically ill patients.
219409451|NCT07082569|OTHER|Pressure-Regulated Volume Control (PRVC)|Hybrid ventilation mode that automatically adjusts inspiratory pressure to achieve a preset tidal volume.
219409452|NCT07082712|OTHER|Thyroid profile|Thyroid profile in patients with acute coronary syndrome within 24 hour from admission
219003115|NCT00724360|DRUG|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
219003116|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
219409453|NCT07083102|OTHER|Experimental|"* Eligible participants will be randomly assigned to one of the following groups using a computer-generated sequence with allocation concealment via sealed opaque envelopes:~  * Group A: Control group~ * Group B: Full-coverage PFM crowns~ * Group C: Full-coverage Zirconia crowns~* Baseline gingival samples will be collected with the help of sterile swab from the target tooth region prior to prosthesis placement and at the follow-up visits i.e. 1, and 3 months; both for experimental groups and control group.~* Microbial analysis will be conducted through culture techniques to quantify CFUs and identify species.~* Alongside, the same sample from sterile swabs will be smeared by fixating it on a microscopic slide and then Candida albicans will be stained by Periodic Acid Schiff technique, and the bacterial species using Gram staining."
219409454|NCT07082621|DRUG|N-acetylcysteine (NAC) spray|N-acetylcysteine (NAC) mucoadhesive nanoparticles in the form of spray 3 times daily for 6 weeks
219409455|NCT07082621|DRUG|Conventional treatment|"topical anesthetics agents (BBC \[Benzocaine, Benzydamine, and Cetalkonium chloride\] oral spray - oracure gel), topical antifungal agents (Miconaz oral gel)\*, sodium bicarbonate mouth wash (Alkamsir sachets), ice chip,s and anti-inflammatory mouth wash.~(Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology \[MASCC/ISSO\] guidelines) 3 times daily for 6 weeks."
219409456|NCT07084116|DRUG|Tretinoin 0.1% cream|Tretinoin 0.1% cream formulation.
219409457|NCT07084116|DRUG|Bland cream (non-drug)|Bland cream formulation.
219409458|NCT07083986|PROCEDURE|Carotid Artery Stent Placement|Carotid Artery Stent Placement was performed according to the standard technique.
219409459|NCT07083986|PROCEDURE|carotid endarterectomy|Carotid endarterectomy with stenting was performed according to the standard technique. For the purpose of the greatest comparability in the volume of anesthesia, it was decided to use regional anesthesia in all cases, including adequate dynamic observation of neurological status.
219409460|NCT07084636|OTHER|Video Laryngeal Mask|Video laryngeal mask will be used in this group
219409461|NCT07084636|OTHER|Endotracheal intubation|Endotracheal intubation will be performed in this group.
219568860|NCT00784134|OTHER|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
219568861|NCT03785145|DRUG|MT10109L|MT10109L will be injected into the LCL.
219568862|NCT03785145|DRUG|Placebo|Placebo will be injected into the LCL.
219568863|NCT00951184|BEHAVIORAL|telephone-based intervention|
219568864|NCT00951184|OTHER|screening questionnaire administration|
219568865|NCT00951184|OTHER|study of socioeconomic and demographic variables|
219568866|NCT00951184|PROCEDURE|assessment of therapy complications|
219568867|NCT00951184|PROCEDURE|psychosocial assessment and care|
219568868|NCT00561171|DRUG|SPP635|oral once daily
219761126|NCT06184802|BEHAVIORAL|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
219003117|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
219003118|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
219003119|NCT01382095|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
219003120|NCT00795314|DRUG|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
219003121|NCT00795314|DRUG|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
219003122|NCT01064713|DRUG|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
219003123|NCT01118221|BEHAVIORAL|pulmonary rehabilitation|structured exercise program
219003124|NCT00510120|BEHAVIORAL|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
219003125|NCT00510120|BEHAVIORAL|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
219003126|NCT00510120|BEHAVIORAL|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
219191862|NCT03153683|OTHER|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
219191863|NCT05903222|OTHER|Non-Interventional|This study is a non-interventional study of all patients previously enrolled in the PALACS trial
219191864|NCT03758625|BIOLOGICAL|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
219568869|NCT00522990|DRUG|AT9283|Three weekly intravenous administration of AT9283
219191865|NCT03758625|BIOLOGICAL|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
219409462|NCT07083375|DRUG|QL1706 , bevacizumab, etoposide , cisplatin or carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1), bevacizumab (7.5 mg/kg, IV, day 1), etoposide (100 mg/m², IV, days 1-3), plus either cisplatin (75 mg/m² split over days 1-2, IV) or carboplatin (AUC=5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) and bevacizumab (7.5 mg/kg, IV, day 1) every 21 days, continued until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or other protocol-defined criteria. All participants will receive dual-agent maintenance therapy.
219409463|NCT06929897|PROCEDURE|Pulmonary Vein Isolation|"1. Pulmonary vein isolation (PVI) is performed as the primary procedure.~2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group.~3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization."
219409464|NCT06929897|PROCEDURE|Additional Left Atrial Posterior Wall Ablation|"1. Additional left atrial posterior wall ablation is performed.~2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved).~3. Post-procedural rhythm monitoring follows the study protocol."
219409465|NCT06929897|PROCEDURE|Non-PV trigger test|"1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed.~2. Post-procedural rhythm monitoring follows the study protocol."
219409466|NCT04634240|PROCEDURE|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
219409467|NCT06929364|DIETARY_SUPPLEMENT|Omni Biotic Stress|Multistrain probiotic formulation (Omni Biotic Stress), 1 sachet daily for 8 weeks
219409468|NCT06929364|OTHER|Placebo|Inert powder identical in appearance and taste to probiotic, 1 sachet daily for 8 weeks
219409469|NCT06930950|OTHER|Cashew nut oral immunotherapy|Cashew nut oral immunotherapy (OIT) where the aim is desensitizing individuals with cashew nut allergies. The approach involves the gradual administration of increasing doses of cashew nut protein. The goal of OIT is to increase the threshold of tolerance to cashew nuts, thereby reducing the risk of severe allergic reactions upon accidental exposure
219409470|NCT07083167|OTHER|No Interventions.|No interventions.
219409471|NCT06930612|BIOLOGICAL|CM512|Administered subcutaneous injection
219409472|NCT06930612|DRUG|Placebo|Administered subcutaneous injection
219409473|NCT07084194|OTHER|Chitosan Nanoparticles Irrigant|using Chitosan Nanoparticles irrigant as a final irrigation solution.
219409474|NCT07084194|OTHER|aloe vera nanoparticles irrigant|using Aloe Vera Nanoparticles irrigant as a final irrigation solution.
219409475|NCT07084194|DEVICE|Diode Laser Activation|activation of nanoparticles irrigants using diode laser
219409476|NCT07084194|DEVICE|ultrasonic activator|activation of nanoparticles irrigants using ultrasonic activator
219409477|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 1.~Subject will receive placebo at dose level 1."
219568870|NCT01543555|DRUG|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
219409478|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 2.~Subject will receive placebo at dose level 2."
219409479|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 3.~Subject will receive placebo at dose level 3."
219568871|NCT01543555|DRUG|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
219568872|NCT03150355|PROCEDURE|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
219568873|NCT03827941|OTHER|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
219568874|NCT03827941|OTHER|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
219568875|NCT04174716|DRUG|IDX-1197|Until progression or unacceptable toxicity develops
219756534|NCT04951193|BEHAVIORAL|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
219191866|NCT03758625|BIOLOGICAL|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
219191867|NCT03758625|BIOLOGICAL|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
219409480|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 4.~Subject will receive placebo at dose level 4."
219409481|NCT07083570|BEHAVIORAL|Active scapular repositioning|The examiner will first passively position the participant's scapula in a neutral position on the posterior chest wall. The participant will then be instructed to actively maintain that position.
219409482|NCT07083570|PROCEDURE|Passive scapular repositioning|The examiner will passively position and hold the participant's scapula in a neutral position.
219409483|NCT07083570|PROCEDURE|Sham scapular repositioning|The examiner will perform gentle shoulder girdle movements that do not alter scapular positioning.
219409484|NCT07076251|OTHER|Family Box program|Boxes will include approximately five pounds of dry ingredients (e.g., whole grains, legumes, flour), which translates into about 40 servings of food for a family of four per month. Each ingredient box will include culturally relevant recipes and, six times out of the twelve boxes, include a culturally relevant book for the family's child/children.
219568876|NCT00621920|DRUG|FM-601|Dose-escalation, split dosage, liquid
219409485|NCT07074314|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
219409486|NCT07079163|DEVICE|Obturator block|A manually fabricated obturator using a preoperative maxillary cast, retained with clasps and wire. Delivered immediately after maxillectomy.
219409487|NCT07079163|DEVICE|Obturator block|A digitally designed obturator based on fused CBCT and intraoral scan data. Fabricated in resin using 3D-printing, and retained with 3D-printed clasps and palatal screws. Delivered immediately post-maxillectomy
219409488|NCT07079163|DEVICE|Obturator block|A digitally designed and 3D-printed obturator fabricated in metal, using CBCT and intraoral scan data. Retention is provided by metal clasps and palatal screws. Delivered during or immediately after surgery.
219409489|NCT00488618|DRUG|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
219409490|NCT00488618|DRUG|Placebo|Dose-matched placebo oral administration, once per day.
219409491|NCT07083661|BEHAVIORAL|Mindfulness-based intervention on parent empowerment in reducing children's screen time (MORE)|Participants will receive a 6-week MORE group training by integration of mindfulness-based component into a modified Hands-on Parent Empowerment-20 (HOPE-20) programme.
219409492|NCT07083687|DRUG|Lorlatinib 100 mg|After enrollment, patients will receive 100 mg of lorlatinib orally once daily until disease progression, unacceptable toxicity, or withdraw study .
219409493|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria of weaning from mechanical ventilation|Patients will be weaned after fulfilling the conventional clinical criteria of weaning from mechanical ventilation by using spontaneous breathing trials
219409494|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria and ultrasonic criteria for weaning|Patients will be weaned using the conventional clinical criteria and ultrasonic criteria for weaning.
219409495|NCT07082413|OTHER|Nutritional Intervention|This study will follow a randomized controlled trial design aimed at evaluating the impact of nutritional intervention on personal satisfaction and perceived quality of life. The protocol includes two assessment points: a baseline measurement at the start of the intervention (Day 0) and a second measurement after a follow-up period (Day 90), allowing for the analysis of with-in-subject changes associated with the intervention.
219409496|NCT07083258|DEVICE|Progressive Inspiratory Muscle Training (IMT)|The intervention involves the application of inspiratory muscle training using the POWERbreathe Plus device. Training will be conducted at an initial intensity of 50% of the individual's MIP and will be increased weekly by 10%, reaching 80% by week four. Sessions will take place 5 days per week and consist of 2 sets of 30 repetitions per day, with 2-minute rest intervals between sets. This training aims to improve inspiratory muscle strength and endurance, as well as core stability, respiratory function, dynamic balance, and trunk isokinetic strength.
219409497|NCT07083258|OTHER|Placebo Training|The placebo group will perform identical training sessions using the same device but with a constant minimal resistance set at 15% of the initial MIP, insufficient to induce a physiological training effect. This intervention is designed to control for placebo response. Assessment protocols will be identical to those in the experimental group.
219409498|NCT07084324|BEHAVIORAL|Unstuck and On Target|Children will receive the Unstuck and On Target (Unstuck) curriculum, a manualized cognitive-behavioral intervention that teaches executive functioning (EF) skills such as flexibility, emotional regulation, and goal-setting. Caregivers will attend concurrent Spanish-language sessions focused on understanding EF challenges and learning strategies to support their child's skills at home. Weekly home practice sheets in Spanish summarize each session and provide practical tips and activities. The program is designed to be neurodiversity-affirming and accessible to Spanish-speaking families.
219409499|NCT06390982|RADIATION|Radiotherapy|45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
219409500|NCT06390982|DRUG|Tislelizumab|200 mg IV on Day 1 of each 21-day cycle.
219409501|NCT06390982|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
219409502|NCT06390982|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
219409503|NCT06390982|DRUG|Capecitabine|825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
219409504|NCT01468727|DIETARY_SUPPLEMENT|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
219409505|NCT01468727|DIETARY_SUPPLEMENT|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
219409506|NCT03257163|DRUG|Capecitabine|Given PO
219409507|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
219409508|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
219409509|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
219568877|NCT03716531|RADIATION|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
219568878|NCT06182904|DEVICE|Dynamic compression plate|Fixation of fibula in some cases with dynamic compression plate
219568879|NCT00384475|DRUG|Ciclesonide Nasal Spray|
219568880|NCT03008239|DEVICE|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
219568881|NCT03008239|DEVICE|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
219003127|NCT03069547|OTHER|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~\- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
219003128|NCT03069547|OTHER|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~\- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
219003129|NCT03920579|DRUG|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
219003130|NCT03920579|DRUG|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
219003131|NCT03920579|DRUG|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
219003132|NCT00757887|BIOLOGICAL|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
219003133|NCT02943278|BEHAVIORAL|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
219003134|NCT02943278|BEHAVIORAL|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
219409510|NCT07162701|DIAGNOSTIC_TEST|Bioimpedance analysis|Patients' body composition will be assessed using bioimpedance analysis (Akern)
219409511|NCT06389383|OTHER|Nasal Swab|"* Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home"
219568882|NCT03970265|DIAGNOSTIC_TEST|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
219568883|NCT00692146|DRUG|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
219003135|NCT05647655|DEVICE|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
219003136|NCT04557878|DRUG|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
219409512|NCT05922878|DRUG|ALTO-300|ALTO-300 capsule QD
219568884|NCT00692146|DRUG|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
219003137|NCT04557878|BIOLOGICAL|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
219003138|NCT00121745|GENETIC|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
219409513|NCT05922878|DRUG|Placebo|Placebo capsule QD
219568885|NCT03250299|DRUG|Microtubule-Targeted Agent BAL101553|Given PO
219756535|NCT04951193|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
219756536|NCT05791513|OTHER|Using the MAP-Knee Tool|Using the MAP-Knee Tool
219756537|NCT05791513|OTHER|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
219756538|NCT06212817|OTHER|Dietary intervention|Increase dietary fiber intake
219003139|NCT00121745|GENETIC|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
219003140|NCT00121745|GENETIC|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
219409514|NCT06062823|DRUG|Afatinib 40 MG|Afatinib 40mg administered orally daily.
219409515|NCT06781983|DRUG|IPH4502|Part 1 (dose escalation) and Part 2 (dose optimization)
219409516|NCT06017765|BEHAVIORAL|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~1. Education about stress response~2. Elicitation of the Relaxation Response through Mindfulness Training~3. Creating adaptive perspectives~4. Coping strategiest."
219568886|NCT03250299|RADIATION|Radiation Therapy|Undergo radiation therapy
219756539|NCT01841242|DRUG|alcoholic povidone iodine|
219756540|NCT01841242|DRUG|alcoholic chlorhexidine|
219756541|NCT05507242|BIOLOGICAL|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
219756542|NCT05507242|OTHER|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
219756543|NCT04493671|DRUG|TBAJ-876 suspension|TBAJ-876 oral suspension, orally administered
219756544|NCT04493671|DRUG|Placebo suspension|Placebo for TBAJ-876 oral Suspension; orally administered
219756545|NCT04493671|DRUG|TBAJ-876 100 mg tablet|TBAJ-876 100 mg tablets, orally administered
219756546|NCT04493671|DRUG|TBAJ-876 25 mg tablet|TBAJ-876 25 mg tablets, orally administered
219003141|NCT00121745|GENETIC|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
219003142|NCT00387023|DRUG|Rituximab|250 mg/m\^2 IV over 4-6 hours for 2 weeks.
219003143|NCT00387023|DRUG|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
219409517|NCT06017765|BEHAVIORAL|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
219003144|NCT05281939|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
219003145|NCT01096901|BEHAVIORAL|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
219003146|NCT02616055|DRUG|tesevatinib|
219003147|NCT01209260|DEVICE|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
219003148|NCT01209260|DEVICE|Mechanical Needle|Mechanical needle for transseptal access
219003149|NCT06436872|OTHER|informing patients with using a booklet|The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
219003150|NCT05782491|PROCEDURE|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
219003151|NCT05782491|PROCEDURE|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
219003152|NCT05782491|PROCEDURE|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
219003153|NCT04338698|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
219409518|NCT06352372|DEVICE|noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)|The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
219409519|NCT05367063|DRUG|Canagliflozin 100mg or Sitagliptin 100mg|Eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
219409520|NCT06827704|BEHAVIORAL|Enhanced physical activity monitor which is Fitbit watch with mobile App|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). Edit
219409521|NCT06827704|BEHAVIORAL|Bollywood-style group dance|Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
219409522|NCT06827704|BEHAVIORAL|PAMDance|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). In addition, Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
219409523|NCT05786599|DRUG|methadone|"The treatment arm will take methadone 2 mg PO q8h and a placebo called placeboD PO qdaily. PlaceboD and duloxetine will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
219003154|NCT04338698|DRUG|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
219003155|NCT04338698|DRUG|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
219003156|NCT01580618|DRUG|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
219003157|NCT01580618|DRUG|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
219409524|NCT05786599|DRUG|duloxetine|"The control arm will receive duloxetine 30 mg PO qdaily, and a placebo called placeboM PO q8h. PlaceboM and methadone will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
219409525|NCT04294810|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
219409526|NCT04294810|DRUG|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219409527|NCT04294810|DRUG|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219568887|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
219568888|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
219568889|NCT01202071|DRUG|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
219568890|NCT01202071|DRUG|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
219568891|NCT01202071|DRUG|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
219568892|NCT01202071|DRUG|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast."
219003158|NCT03310775|BEHAVIORAL|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
219003159|NCT01179568|DRUG|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
219003160|NCT01179568|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
219003161|NCT01179568|OTHER|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
219003162|NCT05805904|DRUG|BMS-986278|Specified dose on specified days.
219409528|NCT05317429|OTHER|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
219409529|NCT06397690|BEHAVIORAL|My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice) is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
219568893|NCT00031811|DRUG|raloxifene|
219568894|NCT00031811|PROCEDURE|quality-of-life assessment|
219003163|NCT05805904|DRUG|Placebo|Specified dose on specified days
219003164|NCT06214338|DIETARY_SUPPLEMENT|Low dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
219003165|NCT06214338|DIETARY_SUPPLEMENT|High dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
219568895|NCT02087124|OTHER|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
219568896|NCT00977548|DRUG|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
219568897|NCT05151393|DIAGNOSTIC_TEST|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
219003166|NCT04100265|DEVICE|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
219003167|NCT04100265|DEVICE|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
219409530|NCT06397690|BEHAVIORAL|Standard of care (control arm)|Standard of care (control arm) participants will receive comprehensive education on both the advantages and limitations of each PrEP method, including guidance on potential side effects.
219409531|NCT05898750|DIETARY_SUPPLEMENT|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
219409532|NCT00244894|PROCEDURE|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
219409533|NCT00244894|PROCEDURE|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
219409534|NCT00244894|PROCEDURE|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
219409535|NCT00244894|PROCEDURE|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
219409536|NCT00244894|PROCEDURE|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
219409537|NCT04046406|DEVICE|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
219409538|NCT03431324|BEHAVIORAL|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
219409539|NCT03431324|BEHAVIORAL|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
219568898|NCT00633516|DEVICE|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
219568899|NCT04796636|DRUG|Sodium Ascorbate|As previously described
219568900|NCT03529643|DRUG|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
219568901|NCT03529643|OTHER|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
219568902|NCT05085795|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
219568903|NCT04086641|DEVICE|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
219568904|NCT04086641|DEVICE|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
219568905|NCT00555035|DRUG|GSK1349572|
219568906|NCT01317784|DEVICE|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
219568907|NCT01317784|DEVICE|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
219568908|NCT01317784|DEVICE|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
219568909|NCT01317784|DEVICE|HIV only|Choice of 4 different tests for HIV only.
219568910|NCT00067171|BEHAVIORAL|Behavior Therapy|
219568911|NCT01167517|OTHER|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
219568912|NCT01042535|BIOLOGICAL|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
219568913|NCT01042535|DRUG|1-methyl-d-tryptophan|Given orally (PO)
219568914|NCT01042535|OTHER|Laboratory biomarker analysis|Correlative studies
219003168|NCT02876354|DRUG|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
219003169|NCT04753060|PROCEDURE|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
219003170|NCT00679302|DRUG|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
219003171|NCT00679302|DRUG|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
219003172|NCT05028478|DRUG|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
219568915|NCT01546142|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
219568916|NCT01546142|DRUG|Placebo|Phosphate buffered saline placebo for injection
219568917|NCT04531670|BEHAVIORAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
219409540|NCT01044381|DRUG|Luliconazole Solution, 10%|28 days of daily application
219409541|NCT05909605|DEVICE|sphygmomanometer|Comparison to the ultrasound sensor
219409542|NCT05909605|DEVICE|Arterial Line|Comparison to the ultrasound sensor
219409543|NCT05388162|DEVICE|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
219409544|NCT00724724|DRUG|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
219003173|NCT01950507|DRUG|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
219003174|NCT01950507|DRUG|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
219191868|NCT03758625|BIOLOGICAL|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
219191869|NCT03758625|BIOLOGICAL|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
219409545|NCT00724724|DRUG|Aspirin|Aspirin 100mg Qd for 1 year
219409546|NCT05844345|OTHER|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
219409547|NCT05844345|OTHER|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
219409548|NCT03573128|BEHAVIORAL|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
219409549|NCT03573128|OTHER|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
219409550|NCT00663728|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
219409551|NCT00663728|DRUG|Placebo|Matching placebo
219409552|NCT02594397|OTHER|acupoints combination 1|
219409553|NCT02594397|OTHER|acupoints combination 2|
219409554|NCT02594397|OTHER|sham acupoints combination|
219568918|NCT04531670|OTHER|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
219568919|NCT02216799|DRUG|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
219568920|NCT02216799|DRUG|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
219568921|NCT05577806|DRUG|Dydrogesterone|progestin primed ovarian stimulation
219568922|NCT00406588|DRUG|Levodopa (Pardoprunox)|12-42mg
219568923|NCT00406588|DRUG|Placebo Comparator|Placebo
219568924|NCT02855619|PROCEDURE|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
219568925|NCT02855619|PROCEDURE|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
219568926|NCT02855619|PROCEDURE|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
219409555|NCT06004141|BEHAVIORAL|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
219409556|NCT00173251|PROCEDURE|obtain surgical specimen for analysis|
219409557|NCT05494541|OTHER|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
219409558|NCT01827059|DRUG|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
219409559|NCT01827059|DRUG|Placebo|
219409560|NCT03153735|DEVICE|CMDHA0101|Maximum injection dose : 22 ml
219409561|NCT03153735|DEVICE|PowerFill®|Maximum injection dose : 22 ml
219409562|NCT04395352|DEVICE|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
219409563|NCT01534234|DEVICE|PARADYM RF SONR|SonR CRT Optimization
219409564|NCT01534234|DEVICE|PARADYM RF SONR|Echocardiography Optimization
219568927|NCT00389779|DRUG|Darusentan|Darusentan capsules administered orally once daily
219568928|NCT00389779|DRUG|Guanfacine|Guanfacine capsules administered orally once daily
219568929|NCT00389779|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
219568930|NCT00384488|BEHAVIORAL|Interactive Voice Response System (IVR)|
219409565|NCT04972916|OTHER|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
219568931|NCT06471309|DEVICE|Theta burst transcranial magnetic stimulation|The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
219568932|NCT06598293|BEHAVIORAL|PRO-CTCAE, Pain NRS|The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
219568933|NCT01443377|BIOLOGICAL|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
219568934|NCT06329791|DRUG|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5%
219568935|NCT06329791|OTHER|Vehicle|AZR-MD-001 Vehicle
219568936|NCT03224247|PROCEDURE|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
219756547|NCT06320197|OTHER|In situ simulation assessment|Unannounced in situ simulation assessment during working hours
219409566|NCT05141773|DEVICE|Computed adenoma detection system (CADe) plus endocuff|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
219409567|NCT05141773|DEVICE|Endocuff|An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
219409568|NCT04774679|PROCEDURE|Endosonographic fine needle aspiration biopsy|An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
219409569|NCT05172193|BIOLOGICAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
219756548|NCT01706185|OTHER|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
219756549|NCT00811837|DRUG|Midazolam|Intravenous infusion
219409570|NCT04765826|PROCEDURE|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
219409571|NCT03230162|DRUG|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
219409572|NCT03230162|DRUG|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
219409573|NCT02581566|DRUG|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
219191870|NCT02278887|PROCEDURE|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
219409574|NCT02581566|DRUG|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
219409575|NCT02581566|DRUG|Bupivacaine|Intrathecal Bupivacaine
219409576|NCT04822857|DIAGNOSTIC_TEST|AMH|The group was divided according to the level of Anti-Müllerian Hormone
219409577|NCT03347604|DIAGNOSTIC_TEST|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
219409578|NCT02326467|DRUG|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
219409579|NCT00681967|DRUG|Gefitinib|250 mg; oral
219568937|NCT03224247|PROCEDURE|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
219191871|NCT02278887|DRUG|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
219409580|NCT00681967|DRUG|Gefitinib|250mg; oral
219409581|NCT00395408|DRUG|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
219409582|NCT00395408|DRUG|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
219409583|NCT00434512|BIOLOGICAL|HIV vaccine 732461|
219409584|NCT00745186|DRUG|Glucagen|0.2 mg or 1 mg Glucagen single injection
219409585|NCT00745186|DRUG|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
219409586|NCT02526758|DRUG|beclomethasone|
219568938|NCT03416491|DRUG|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
219568939|NCT03416491|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
219568940|NCT04281394|DEVICE|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
219568941|NCT04281394|OTHER|conventional gait training|even level gait training and range of motion exercises
219568942|NCT01747382|PROCEDURE|Renal denervation|
219568943|NCT01886482|OTHER|nutrition intervention|high protein diet
219568944|NCT02130531|DRUG|Emixustat HCl Tablet|Tablet for oral administration
219191872|NCT02278887|DRUG|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
219191873|NCT02278887|DRUG|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
219191874|NCT02278887|DRUG|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
219191875|NCT05636072|BEHAVIORAL|WISER|Participants will engage in one or more positive psychology well-being tool(s).
219409587|NCT02526758|DRUG|formoterol|
219409588|NCT02526758|DRUG|budesonide|
219409589|NCT00004816|DRUG|monoclonal antibody M-T412|
219409590|NCT03570034|DEVICE|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
219409591|NCT00199134|DRUG|Letrozole|Size of the tumor is followed
219409592|NCT06258135|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|Single 7g dose daily for 28 days
219409593|NCT06258135|DIETARY_SUPPLEMENT|Maltodextrin|Single 7g dose daily for 28 days
219409594|NCT05903937|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion (HAI)
219190202|NCT06310252|DIAGNOSTIC_TEST|Opthalmic assessments|"The participants will undergo the following assessments:~1. Pupil size measurement~2. Manifest refraction (no autorefraction)~3. Monocular in both eyes and binocular uncorrected visual acuity (photopic):~   * Distance (4 m)~  * Intermediate (80 cm)~  * Near (40 cm)~4. Monocular best corrected visual acuity (photopic):~   * Distance (4 m)~  * Near (40 cm)~  * Distance-corrected near (40 cm)~5. Monocular and binocular mesopic (with and without glare) and photopic (without glare) contrast sensitivity testing (subgroup)~6. Slit lamp examination~7. Tear breakup time~8. Placido Corneal topography, keratometry and pachymetry~9. Optical coherence tomography including epithelium mapping (subgroup)~10. Applanation intraocular pressure~11. Cycloplegic refraction~12. Dilated fundus examination~13. Wavefront aberrometry (subgroup)~14. Adverse events"
219190203|NCT04593615|PROCEDURE|ICG near-infrared imaging|Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
219190204|NCT05975697|OTHER|Experimental group to be applied FES|"In the first 24 hours after the thrombectomy procedure, the relatives of the patients in the experimental and control groups who meet the inclusion criteria will be informed by the researcher and their consent will be obtained.~FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.Patient information form (Appendix 1), Fugl-meyer upper extremity motor assessment scale (Appendix-2) and Quick DASH (Arm, Shoulder and Hand Injury Questionnaire Short Form) (Appendix-3) were given to both groups within the first 24 hours after the thrombectomy procedure. ) will be applied. All patients will be re-evaluated before and on the 5th day after treatment."
219191876|NCT01866163|DRUG|LEO 90100|
219191877|NCT01866163|DRUG|Vehicle|
219409595|NCT05903937|DRUG|Melphalan|Administered via isolated hepatic perfusion
219409596|NCT05903937|DRUG|Interleukin-2|low-dose, administered s.c.
219409597|NCT03767296|DRUG|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)"
219409598|NCT03767296|DRUG|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)"
219409599|NCT05197478|OTHER|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
219409600|NCT00014378|DRUG|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
219409601|NCT05133193|DRUG|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
219409602|NCT00797797|DRUG|No Treatment Added|No added treatment
219409603|NCT00797797|DRUG|Milnacipran Added|Milnacipran 100 mg/d added
219409604|NCT01397305|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
219409605|NCT01397305|DRUG|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
219409606|NCT02233205|DEVICE|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
219409607|NCT02233205|DRUG|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
219409608|NCT01575197|BIOLOGICAL|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
219409609|NCT04253834|DEVICE|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
219409610|NCT04253834|DEVICE|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
219409611|NCT00698061|BIOLOGICAL|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
219409612|NCT00698061|BIOLOGICAL|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
219409613|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
219409614|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
219568945|NCT02130531|OTHER|Placebo Tablet|Tablet for oral administration
219409615|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
219409616|NCT01630096|DRUG|Nu-Lytely|Bowl prep solution.
219409617|NCT01527227|OTHER|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
219409618|NCT01536002|DRUG|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
219568946|NCT00389220|DEVICE|Coronary stent placement|Coronary stent placement
219756550|NCT00811837|DRUG|Remifentanil|Intravenous infusion
219756551|NCT01784302|DIETARY_SUPPLEMENT|Multivitamins|
219756552|NCT01784302|DIETARY_SUPPLEMENT|Sodium bicarbonate|
219756553|NCT01784302|DRUG|Maalox Plus extra|
219409619|NCT04615702|DIAGNOSTIC_TEST|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis"
219409620|NCT04615702|DEVICE|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
219409621|NCT04615702|DEVICE|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
219409622|NCT04615702|DIAGNOSTIC_TEST|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
219409623|NCT04615702|DEVICE|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
219409624|NCT04615702|DRUG|Ringer lactate|"The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
219409625|NCT04615702|COMBINATION_PRODUCT|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
219409626|NCT04615702|COMBINATION_PRODUCT|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"* Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given."
219409627|NCT04615702|DIETARY_SUPPLEMENT|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs"
219568947|NCT04815382|OTHER|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
219568948|NCT06147531|BIOLOGICAL|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
219568949|NCT06147531|BIOLOGICAL|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
219568950|NCT03136874|OTHER|Interview and questionaires|"* Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
219568951|NCT00707564|DEVICE|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
219568952|NCT00707564|DEVICE|Gauze with pressure|Gauze with pressure
219568953|NCT04776746|DRUG|trofinetide|Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
219568954|NCT02507440|DRUG|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
219568955|NCT02507440|DRUG|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
219756554|NCT01784302|DRUG|Raltegravir 400 mg|
219190205|NCT06296368|BEHAVIORAL|Preference Reporting to Improve Management and Experience (PRIME)|PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities
219190206|NCT05296005|DRUG|Capecitabine|Given PO
219190207|NCT05296005|DRUG|Docetaxel|Given IV
219190208|NCT05296005|DRUG|Fluorouracil|Given IV
219409628|NCT04615702|DEVICE|nasogastric tube|in case of ileus or vomiting
219409629|NCT04615702|PROCEDURE|retroperitoneal necrosectomy|"* General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
219761127|NCT06184802|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
219409630|NCT04615702|PROCEDURE|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
219409631|NCT04615702|PROCEDURE|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
219409632|NCT04615702|PROCEDURE|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
219568956|NCT02507440|DRUG|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
219568957|NCT00025740|DRUG|clonazepam and paroxetine|
219568958|NCT03392740|DRUG|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
219568959|NCT03392740|DRUG|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
219568960|NCT00860366|DRUG|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
219568961|NCT00860366|OTHER|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
219761128|NCT06009302|PROCEDURE|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
219761129|NCT06009302|PROCEDURE|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
219761130|NCT02027792|OTHER|Cabbage leave wraps|
219761131|NCT02027792|DRUG|Diclofenac Gel|
219761132|NCT04426474|DRUG|LY3502970|Administered orally.
219761133|NCT04426474|DRUG|Placebo|Administered orally.
219761134|NCT05388578|DEVICE|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
219761135|NCT05388578|DEVICE|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
219761136|NCT05388578|DEVICE|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
219761137|NCT05388578|DEVICE|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
219761138|NCT01180127|DIETARY_SUPPLEMENT|Flavanol containing food product|12 weeks, 2X/day, 20g serving
219761139|NCT01180127|BEHAVIORAL|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
219761140|NCT01180127|DIETARY_SUPPLEMENT|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
219761141|NCT01180127|BEHAVIORAL|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
219761142|NCT02298621|OTHER|pomegranate juice|Randomized clinical trial or RCT
219761143|NCT02298621|OTHER|placebo|Randomized clinical trial or RCT
219761144|NCT00879489|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
219761145|NCT00160953|PROCEDURE|Endorectal Coil Magnetic Resonance Images|
219409633|NCT04615702|PROCEDURE|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
219409634|NCT04615702|PROCEDURE|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
219409635|NCT05210205|DIETARY_SUPPLEMENT|EAA|EAA-enhanced protein snack bars
219568962|NCT06525272|DRUG|Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
219568963|NCT06525272|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
219568964|NCT03393416|BIOLOGICAL|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
219568965|NCT03393416|DRUG|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
219568966|NCT00563017|DRUG|Long-acting Risperidone microspheres injection|
219756555|NCT00718432|BEHAVIORAL|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
219756556|NCT00718432|BEHAVIORAL|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
219756557|NCT00718432|BEHAVIORAL|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
219756558|NCT02362685|DEVICE|functional test|subjects perform a metabolic exercise testing
219756559|NCT02362685|GENETIC|matching genotype with phenotype|
219756560|NCT00004264|DRUG|amifostine trihydrate|
219756561|NCT00004264|DRUG|cisplatin|
219756562|NCT00004264|DRUG|docetaxel|
219756563|NCT06767956|DRUG|GOLCADOMIDE|Golcadomide (GOLCA, CC-99282) is an oral cereblon E3 ligase modulator (CELMoD®) agent with immunomodulatory and tumor cell-autonomous activities. It is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities.
219761146|NCT03663192|DEVICE|strain echocardiography|strain echocardiography during septic shock
219761147|NCT01696643|DRUG|CB-5945|
219761148|NCT01696643|DRUG|Placebo|
219761149|NCT05562505|OTHER|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
219761150|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
219761151|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
219761152|NCT00363584|DRUG|capecitabine|
219761153|NCT00363584|OTHER|clinical observation|
219761154|NCT00363584|PROCEDURE|adjuvant therapy|
219761155|NCT03942224|DRUG|Bortezomib|Given SC
219003175|NCT01950507|DRUG|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
219409636|NCT05210205|DIETARY_SUPPLEMENT|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
219409637|NCT05210205|DIETARY_SUPPLEMENT|Control|Low energy dense snack bars (same calories in a greater volume of food)
219409638|NCT00111475|DRUG|Romiplostim|Administered by subcutaneous injection
219568967|NCT00440466|DRUG|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
219568968|NCT00440466|DRUG|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
219568969|NCT00440466|DRUG|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
219568970|NCT06446466|DEVICE|PEMF ON-OFF|"In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session."
219761156|NCT03942224|BIOLOGICAL|Daratumumab|Given IV
219761157|NCT03942224|DRUG|Dexamethasone|Given IV and PO
219761158|NCT03942224|DRUG|Ixazomib|Given PO
219409639|NCT00111475|DRUG|Placebo|Administered by subcutaneous injection
219409640|NCT02863367|DRUG|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
219409641|NCT02863367|DRUG|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
219409642|NCT03303092|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
219409643|NCT03303092|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
219409644|NCT03303092|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
219409645|NCT00050986|DRUG|Temozolomide|Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
219409646|NCT00050986|DRUG|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
219756564|NCT06767956|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeted therapy drug that blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system, boosting the immune system's response.
219756565|NCT02498366|OTHER|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
219756566|NCT04549454|BEHAVIORAL|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
219003176|NCT01950507|DRUG|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
219003177|NCT01773785|DRUG|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
219409647|NCT01170117|DRUG|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
219409648|NCT01170117|DRUG|Placebo|Control Group will receive placebo pill
219409649|NCT06459622|DIAGNOSTIC_TEST|Serum IL_25 and eosinophils in nasal polyp tisuee|Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids
219409650|NCT05366972|DEVICE|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
219409651|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
219409652|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
219409653|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
219409654|NCT05220228|DRUG|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
219409655|NCT05220228|DRUG|Placebo|Lactose / sucrose placebo
219409656|NCT04865250|DRUG|Atezolizumab 1200 mg abs day 1 q22 (iv)|Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
219003178|NCT01773785|DRUG|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
219003179|NCT03130361|DEVICE|Non-Invasive Ventilation|
219756567|NCT04549454|BEHAVIORAL|General Parenting Advice|General parenting advice
219003180|NCT03440021|DRUG|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
219003181|NCT03440021|DRUG|Placebo|Identical in appearance to experimental drug, not psycho-active
219409657|NCT01695850|DRUG|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
219409658|NCT01695850|DRUG|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
219409659|NCT01695850|DRUG|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
219409660|NCT01848054|DRUG|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
219409661|NCT01848054|DRUG|Buprenorphine|Buprenorphine sublingual tablets
219409662|NCT00903747|DRUG|prucalopride|2-10 mg prucalopride
219409663|NCT00903747|DRUG|moxifloxacin|400 mg moxifloxacin (Group 2a)
219409664|NCT00903747|DRUG|placebo|placebo (Group 2b)
219409665|NCT01870219|DRUG|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
219409666|NCT01870219|DRUG|Ketamine|ketamine was given to 1mg/kg ıv bolus
219409667|NCT03406286|DRUG|Tolvaptan|
219409668|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
219409669|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
219409670|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
219409671|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
219409672|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
219756568|NCT02446002|DRUG|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
219756569|NCT06532188|PROCEDURE|Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep"
219756570|NCT06532188|PROCEDURE|Sham Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~\- story without trance induction and suggestions"
219756571|NCT04621877|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
219756572|NCT04621877|BEHAVIORAL|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
219756573|NCT05667532|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Screening Modality
219190209|NCT05296005|DRUG|Leucovorin|Given IV
219190210|NCT05296005|DRUG|Oxaliplatin|Given IV
219756574|NCT05880810|DEVICE|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
219756575|NCT06461533|DRUG|Susoctocog Alfa (Genetical Recombination)|Susoctocog Alfa (Genetical Recombination), Intravenous injection
219409673|NCT05217693|DRUG|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
219409674|NCT02693483|DRUG|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
219409675|NCT01361009|DRUG|pramipexole|as prescibed by the investigator
219409676|NCT05603702|DRUG|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
219409677|NCT04446793|DRUG|Onvansertib|15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
219568971|NCT06446466|DEVICE|PEMF OFF-ON|"In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session."
219568972|NCT00717496|OTHER|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
219568973|NCT06468696|PROCEDURE|Suturing the cervical linea alba during endoscopic thyroid surgery.|Suturing the cervical linea alba during endoscopic thyroid surgery.
219568974|NCT06468696|GENETIC|Performing transcriptome sequencing|Performing transcriptome sequencing
219568975|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
219568976|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
219568977|NCT05742919|DRUG|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
219568978|NCT00918918|DIETARY_SUPPLEMENT|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
219568979|NCT00918918|DIETARY_SUPPLEMENT|Orange juice|200 mL orange juice
219568980|NCT02759341|OTHER|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
219568981|NCT02759341|OTHER|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
219568982|NCT02759341|OTHER|State-Trait Anxiety Inventory form Y (STAI-Y)|
219568983|NCT02759341|OTHER|SF-36 Health-Related Quality of Life|
219568984|NCT02759341|OTHER|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
219761159|NCT02209467|OTHER|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
219568985|NCT04085536|PROCEDURE|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
219761160|NCT02866812|OTHER|questionnaires assessing the state of fatigue, depression and anxiety|
219568986|NCT05887219|DRUG|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
219568987|NCT05887219|DRUG|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
219761161|NCT02588469|OTHER|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
219190211|NCT05296005|RADIATION|Radiation Therapy|Undergo radiotherapy
219409678|NCT04446793|BIOLOGICAL|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
219409679|NCT04446793|DRUG|FOLFIRI|FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
219409680|NCT01826422|DIETARY_SUPPLEMENT|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
219409681|NCT01826422|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
219409682|NCT05913960|DEVICE|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219568988|NCT04703621|DRUG|Daratumumab Injection|subcutaneious daratumumab administration
219568989|NCT06427902|OTHER|Periodontal clinical measurements, Saliva sampling|Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
219568990|NCT04727684|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
219568991|NCT04727684|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
219003182|NCT02480023|RADIATION|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
219003183|NCT00646776|DRUG|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
219003184|NCT00646776|DRUG|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
219409683|NCT05913960|DEVICE|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
219409684|NCT05913960|DEVICE|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
219409685|NCT03140930|DIETARY_SUPPLEMENT|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
219409686|NCT03140930|DIETARY_SUPPLEMENT|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
219409687|NCT03140930|DIETARY_SUPPLEMENT|Placebo duodenal|Duodenal infusion of placebo (tap water)
219409688|NCT03140930|DIETARY_SUPPLEMENT|Placebo ileal|Ileal infusion of placebo (tap water)
219409689|NCT01569425|OTHER|Dietary intervention|High Calorie breakfast and high calorie dinner
219409690|NCT01173796|PROCEDURE|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
219003185|NCT03949504|PROCEDURE|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
219003186|NCT03627624|OTHER|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
219003187|NCT01867268|DRUG|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
219003188|NCT01867268|OTHER|prone positioning|prone positioning the patient for 10 days following the surgery
219003189|NCT01867268|OTHER|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
219003190|NCT03673553|OTHER|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
219190212|NCT05296005|PROCEDURE|Surgical Procedure|Undergo surgical resection
219409691|NCT01173796|PROCEDURE|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
219409692|NCT03159377|DEVICE|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
219409693|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
219409694|NCT05329987|OTHER|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
219568992|NCT04727684|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
219761162|NCT02588469|OTHER|Control group|Standard obesity care with physical activity program
219409695|NCT05632458|DEVICE|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
219409696|NCT05847244|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
219409697|NCT03832920|OTHER|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
219761163|NCT02583347|DEVICE|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
219761164|NCT00613431|DRUG|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
219761165|NCT00613431|DRUG|Placebo|Some subjects will receive matching placebo instead of CS-8080.
219761166|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
219761167|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
219761168|NCT00020748|DRUG|epirubicin hydrochloride|
219761169|NCT00020748|DRUG|irinotecan hydrochloride|
219761170|NCT03890510|OTHER|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
219761171|NCT03890510|PROCEDURE|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
219761172|NCT06157593|PROCEDURE|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
219409698|NCT03664284|PROCEDURE|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
219409699|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
219409700|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
219409701|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
219409702|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
219409703|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
219409704|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
219409705|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
219409706|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
219568993|NCT04727684|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
219568994|NCT01206049|DRUG|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
219568995|NCT01206049|DRUG|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
219568996|NCT01206049|DRUG|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
219568997|NCT01206049|DRUG|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
219568998|NCT01206049|DRUG|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
219568999|NCT00002352|DRUG|Lobucavir|
219569000|NCT00956787|DRUG|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
219569001|NCT01421199|PROCEDURE|Myringotomy|tube placement for children with multiple ear infections
219569002|NCT02681744|BEHAVIORAL|Resistance Training|24-weeks of progressive strength training
219756576|NCT06445777|BEHAVIORAL|Mental Health Prevention and Promotion|The Inner Lion Programme is made up of 12 interactive workshops which are based on four key pillars: building confidence by identifying strengths and personal qualities; improving emotional intelligence and self-awareness; establishing adaptive coping strategies and channels of support; and boosting resilience. Professionally created by Child Psychologist Stijn de Leeuw together with an advisory team of psychologists from the Netherlands and South Africa, the programme follows a carefully structured and curated prevention and promotion mental health curriculum with games, crafting activities, psycho-educational stories, dance, movement, and breathing exercises. Workshops are led by local role models (a male-female duo) with lived experience trained to be mental health coaches.
219756577|NCT00016354|DRUG|benzoylphenylurea|
219756578|NCT03110562|DRUG|Selinexor|oral 100 mg dose
219569003|NCT04811365|OTHER|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
219569004|NCT02950142|OTHER|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
219756579|NCT03110562|DRUG|Bortezomib|subcutaneous dose of 1.3 mg/m2
219756580|NCT03110562|DRUG|Dexamethasone|oral dose of 20mg
219190213|NCT05662865|DRUG|SGLT2 inhibitor|SGTL2i (15 mg) once daily
219409707|NCT03201510|OTHER|Observational|HPTN 075 is an observational study in sub-Saharan MSM
219409708|NCT04991454|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
219409709|NCT02561416|BEHAVIORAL|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
219569005|NCT02950142|OTHER|CPOE without order sets for lab testing|CPOE only
219569006|NCT01839370|DEVICE|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
219569007|NCT03472742|DRUG|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
219409710|NCT02561416|BEHAVIORAL|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
219409711|NCT02561416|DRUG|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
219409712|NCT03568539|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks.
219409713|NCT05526170|DEVICE|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
219409714|NCT02666092|OTHER|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
219409715|NCT02666092|BIOLOGICAL|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
219409716|NCT03439748|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
219409717|NCT03439748|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
219409718|NCT01532323|OTHER|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
219569008|NCT00743509|DRUG|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
219569009|NCT04375709|OTHER|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
219569010|NCT04375709|BEHAVIORAL|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
219569011|NCT03416556|PROCEDURE|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
219569012|NCT03416556|PROCEDURE|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
219569013|NCT03416556|OTHER|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
219569014|NCT02563587|OTHER|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
219756581|NCT03409770|OTHER|Therapeutic hypothermia|Whole body cooling using a servo controlled device
219756582|NCT05198570|OTHER|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
219756583|NCT02160808|DRUG|Secretin|Drug to stimulate pancreatic secretion
219756584|NCT02160808|DRUG|Placebo|
219756585|NCT06640439|DEVICE|photobiomodulation|830 nm LED was used to irradiate the post-extraction area
219756586|NCT06640439|DRUG|Antibiotic|ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
219756587|NCT06645184|DIETARY_SUPPLEMENT|Oral nutritional supplement|During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
219409719|NCT05131451|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
219409720|NCT00429065|DRUG|Rituximab|
219409721|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
219409722|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
219409723|NCT00782418|DRUG|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
219409724|NCT06347276|DEVICE|PFO occluder; ASD occluder|Transcatheter closure of atrial septal defect (ASD) and patent foramen ovale (PFO) All cases will be examined with DW-MRI preoperatively, and DW-MRI will be repeated 24 hours and 4 weeks after the transcatheter closure procedure.
219409725|NCT05978830|DEVICE|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
219409726|NCT03927248|DRUG|Nivolumab|See description in Arms/Groups section
219409727|NCT02324842|DRUG|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
219409728|NCT02324842|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
219409729|NCT03537339|OTHER|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
219409730|NCT02805556|DRUG|BMS-663068|Single oral dose of BMS-663068
219409731|NCT02805556|DRUG|BMS-626529|Single intravenous dose of \[13C\]BMS 626529
219569015|NCT02563587|OTHER|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
219569016|NCT02563587|DRUG|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
219756588|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
219409732|NCT05808998|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
219409733|NCT04767256|DRUG|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
219409734|NCT04767256|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
219569017|NCT01891305|DRUG|VT-1161|
219569018|NCT01891305|DRUG|placebo|
219756589|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
219756590|NCT05343988|DEVICE|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
219756591|NCT03314805|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
219756592|NCT03314805|DRUG|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
219409735|NCT04767256|OTHER|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
219409736|NCT04767256|OTHER|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
219409737|NCT01325480|DEVICE|Cardiac Pacing|
219409738|NCT04705727|DRUG|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
219756593|NCT03314805|PROCEDURE|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
219756594|NCT06176547|DIAGNOSTIC_TEST|HbA1c|Blood glucose in last 3 months
219756595|NCT01321580|DEVICE|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
219756596|NCT03435952|DRUG|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
219756597|NCT03435952|BIOLOGICAL|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation."
219756598|NCT03435952|DRUG|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
219190214|NCT05662865|OTHER|Controlled, Adaptive Study Diet|An adaptive study diet combined with SGLT2i, which consists of four sequential, 7-day long phases in which dietary carbohydrates are gradually reduced (50% carbs, 30% carbs, 20% carbs, and 10% carbs) based on safety and tolerability to achieve moderate ketosis. All diet phases are isocaloric. All meals are provided on an inpatient unit.
219190215|NCT05715229|DRUG|Nivolumab|Immunotherapy
219409739|NCT04705727|DRUG|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
219409740|NCT02191787|DRUG|Seresis®|
219409741|NCT02191787|DRUG|Placebo|
219756599|NCT03344705|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
219409742|NCT02750800|BIOLOGICAL|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
219756600|NCT03344705|DRUG|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
219756601|NCT03344705|DRUG|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
219756602|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
219756603|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
219190216|NCT05715229|DRUG|Ipilimumab|Immunotherapy
219190217|NCT05715229|DRUG|Carboplatin|Chemotherapy
219190218|NCT05715229|DRUG|Paclitaxel|Chemotherapy
219190219|NCT05715229|DRUG|Pemetrexed|Chemotherapy
219190220|NCT02470728|OTHER|New Clinical Pathway|
219190221|NCT05906589|DIETARY_SUPPLEMENT|Inulin|The participant will take inulin twice daily over a 14 day period.
219190222|NCT05906589|DIETARY_SUPPLEMENT|Psyllium|The participant will take psyllium twice daily over a 14 day period.
219190223|NCT05906589|DIETARY_SUPPLEMENT|Maltodextrin|The participant will take maltodextrin twice daily over a 14 day period.
219190224|NCT05903482|OTHER|None - observational|Observational
219409743|NCT02750800|BEHAVIORAL|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
219756604|NCT05806190|DEVICE|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
219756605|NCT04139408|DEVICE|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
219756606|NCT06245655|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
219756607|NCT04980157|BEHAVIORAL|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
219756608|NCT06080204|DRUG|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
219756609|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
219756610|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
219756611|NCT02458118|DRUG|Secretin|Secretin 1 IU/kg over 3 min
219756612|NCT00058747|DRUG|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
219756613|NCT00743470|DRUG|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
219756614|NCT00743470|DRUG|rifabutin|rifabutin capsule; see arms for intervention description
219409744|NCT04281745|BIOLOGICAL|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
219409745|NCT03298412|DRUG|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
219756615|NCT02720458|OTHER|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
219756616|NCT02720458|BEHAVIORAL|Short-term simple self-help program|"The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
219756617|NCT02611037|DRUG|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
219756618|NCT02611037|DRUG|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
219756619|NCT02611037|DRUG|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
219756620|NCT02611037|OTHER|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
219756621|NCT06989580|DEVICE|BIOMONITOR IV with study software|Participants are inserted with a BIOMONITOR IV which is then turned into the investigational device by replacing the firmware with the study software.
219756622|NCT07002957|OTHER|Spiritual Music Therapy|In the first session of the spiritual music therapy application, information was given about music, music therapy and its history, and information was given about the Turkish Music makam structure and makam differences and the traces these makams leave on the person's body and soul. In addition, the technique of receiving and giving sound was taught. In the next five sessions, Rast, Uşşak, Segâh, Hüseyni and Hicaz makams were listened to, accompanied by the sound of kanun and water. Information was given about the musical and therapeutic status of the makams, 3 works related to the relevant makam were taught, performed and information was given about the spiritual messages of the piece, its composer and lyricist. At the same time, rhythm studies were done with the bendir to accompany the relevant makam. At the end of each session, the makam of the day was listened to, accompanied by the sound of kanun and water.
219409746|NCT04360616|DIAGNOSTIC_TEST|imaging|perform US and mammography examination
219756623|NCT07004257|DIETARY_SUPPLEMENT|tributyrin|tributyrin (875 mg, BID)
219003191|NCT03673553|OTHER|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
219003192|NCT02590848|DIETARY_SUPPLEMENT|Walnut intake|Nutritional intervention: 30g walnut kernels per day
219003193|NCT03752580|DEVICE|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
219003194|NCT01654029|BEHAVIORAL|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
219409747|NCT05960019|DIETARY_SUPPLEMENT|Fermented milk product|This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
219409748|NCT05960019|DIETARY_SUPPLEMENT|Fermented cereal based product|This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
219409749|NCT05960019|BEHAVIORAL|Behavioural modification counselling|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
219409750|NCT02464397|DEVICE|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
219409751|NCT05471245|DEVICE|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
219756624|NCT07003126|BEHAVIORAL|Circadian Rhythm Intervention Combined with Bladder Training|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and eligible patients will be enrolled. Participants will be randomly assigned to the Bladder Training Combined with Circadian Rhythm Intervention Group, which will receive a 6-month integrated protocol encompassing bladder training and circadian rhythm intervention. The bladder training component includes fluid intake restriction, micturition desire-relaxation training, and sphincter control training. Circadian rhythm interventions involve sleep hygiene education, chronotype-guided bedtime scheduling, and morning bright light therapy.
219003195|NCT01745172|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
219003196|NCT00126568|DRUG|sorafenib tosylate|Given orally
219003197|NCT01717560|OTHER|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
219003198|NCT04464356|DEVICE|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
219003199|NCT06381882|PROCEDURE|Pancreatic resection|Any kind of pancreatic resection will be included
219003200|NCT02520076|DRUG|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"
219761173|NCT03518151|OTHER|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
219761174|NCT03518151|OTHER|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
219761175|NCT03377023|DRUG|Nivolumab|Intravenous nivolumab every 2 weeks.
219761176|NCT03377023|DRUG|Ipilimumab|Intravenous ipilimumab every 6 weeks.
219761177|NCT03377023|DRUG|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
219761178|NCT02692313|DRUG|Epinephrine|Dose response of epinephrine infusion
219761179|NCT02692313|OTHER|Saline infusion|Placebo
219761180|NCT05826912|DRUG|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
219761181|NCT05826912|DRUG|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
219761182|NCT05826912|DRUG|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
219761183|NCT05826912|DRUG|Placebo|Capsule, 2x/day for 28 days
219761184|NCT06165536|BEHAVIORAL|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
219761185|NCT05236192|BEHAVIORAL|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
219761186|NCT05236192|BEHAVIORAL|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
219761187|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
219761188|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
219761189|NCT03354728|OTHER|Laboratory Biomarker Analysis|Correlative studies
219761190|NCT03354728|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219761191|NCT03478514|DRUG|Palbociclib|Taken at 100 mg once daily for 21 days, followed by 7 days off
219761192|NCT03478514|DRUG|Ibrutinib|560 mg taken orally all patients throughout the study
219761193|NCT06834490|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
219761194|NCT06834490|DRUG|Placebo|Placebo IV solution, Placebo tablets
219761195|NCT04269902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219761196|NCT04269902|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219761197|NCT04269902|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219761198|NCT04269902|PROCEDURE|Computed Tomography|Undergo CT
219761199|NCT04269902|BIOLOGICAL|Obinutuzumab|Given IV
219761200|NCT04269902|OTHER|Questionnaire Administration|Ancillary studies
219761201|NCT04269902|DRUG|Venetoclax|Given PO
219761202|NCT05099003|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219761203|NCT05099003|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
219761204|NCT05099003|RADIATION|Radiation Therapy|Undergo radiation therapy
219761205|NCT05099003|DRUG|Selinexor|Given orally
219761206|NCT06041503|DRUG|Pembrolizumab|Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
219761207|NCT06041503|DRUG|Enfortumab vedotin|EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
219761208|NCT06676033|DRUG|epcoritamab|Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
219003201|NCT01658670|BEHAVIORAL|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
219409752|NCT05387252|DIETARY_SUPPLEMENT|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
219409753|NCT03102944|DIAGNOSTIC_TEST|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
219409754|NCT06116877|PROCEDURE|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
219409755|NCT02874404|DRUG|Ibrutinib|Given PO
219409756|NCT02874404|OTHER|Laboratory Biomarker Analysis|Correlative markers
219409757|NCT02874404|DRUG|PI3K-delta Inhibitor TGR-1202|Given PO
219409758|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
219409759|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
219569019|NCT01957345|OTHER|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
219756625|NCT07003126|BEHAVIORAL|Bladder Training (basic treatment for enuresis)|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and those meeting eligibility criteria will be enrolled. Participants will be randomized to the Bladder Training Only Group, which will receive a 6-month intervention comprising fluid intake restriction, micturition desire-relaxation training, and sphincter control training.
219756626|NCT07004140|OTHER|3T MRI research scan|Baseline MRI scan
219003202|NCT01658670|BEHAVIORAL|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
219003203|NCT02048787|DRUG|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
219190225|NCT05356962|BEHAVIORAL|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
219409760|NCT05631548|DEVICE|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
219409761|NCT05631548|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
219409762|NCT04544436|DRUG|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
219409763|NCT04544436|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
219409764|NCT04544436|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
219409765|NCT04544436|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
219409766|NCT05961189|DRUG|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
219003204|NCT00230997|DRUG|Galantamine|
219003205|NCT03032315|DRUG|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
219190226|NCT03776253|BEHAVIORAL|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
219190227|NCT03776253|OTHER|Questionnaire Administration|Ancillary studies
219003206|NCT03032315|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
219409767|NCT01874652|DEVICE|Light Weight Breast Implants|Light Weight Breast Implants
219409768|NCT02310802|DRUG|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
219409769|NCT02310802|DRUG|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
219409770|NCT02310802|DRUG|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
219409771|NCT02310802|DRUG|Placebo|Placebo dispersible tablets for single oral administration
219409772|NCT02730845|DRUG|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
219003207|NCT03032315|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
219003208|NCT00615758|DRUG|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
219003209|NCT00705653|DRUG|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
219003210|NCT05735132|PROCEDURE|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
219003211|NCT05735132|PROCEDURE|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
219003212|NCT05735132|PROCEDURE|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
219409773|NCT02730845|DRUG|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
219409774|NCT06677307|DRUG|KRRO-110|KRRO-110 drug product, IV
219409775|NCT04851678|OTHER|None - observational study|None - observational study
219756627|NCT07004140|OTHER|Field-Cycling Imaging research scan|Baseline FCI scan
219003213|NCT02345694|DEVICE|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
219409776|NCT03875326|DEVICE|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
219409777|NCT03875326|DEVICE|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
219409778|NCT03875326|DEVICE|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
219409779|NCT03875326|DEVICE|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
219409780|NCT01936285|DRUG|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
219409781|NCT01936285|DRUG|Placebo|
219756628|NCT07004140|OTHER|Follow up 3T MRI research scan|Day 30 3T MRI scan
219756629|NCT07004140|OTHER|Follow up Field-Cycling Imaging research scan|Day 30 FCI scan
219756630|NCT07004140|OTHER|Blood samples for clotting experiments in vitro|Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.
219756631|NCT07003009|DIAGNOSTIC_TEST|Malign Lymph Node Washout|During routine axillary lymph node sampling, which is performed as part of standard staging using imaging methods, a washout sample (which is not not routinely applied ) will be obtained by injecting 1 cc of 0.9% saline into axillary lymph nodes suspected to be metastatic. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 1.
219756632|NCT07003009|DIAGNOSTIC_TEST|Benign Lymph Node Washout|Description: During the biopsy performed to histopathologically confirm the benign nature of a radiologically presumed benign axillary lymph node, a washout sampling will also be conducted by injecting 1 cc of 0.9% saline into benign lymph node. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 2.
219756633|NCT07004387|DRUG|Amino acid solution|Adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
219756634|NCT07004387|DRUG|Amino Acid infusion|adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
219756635|NCT07004738|OTHER|Pelvic floor exercises|The bladder should be emptied before the exercise. In order to correctly identify the pelvic floor muscles, it is necessary to initially try to hold urine while emptying the bladder. If the result is successful, it means that the correct muscles have contracted. During the learning phase, the exercise can be done in a supine position with the legs bent at the knees or in a sitting position. Initially, the pelvic floor muscles should be contracted for 5 seconds by pulling them inward as if stopping the passage of urine or gas, and then rested for 5 seconds.
219409782|NCT05805423|PROCEDURE|bilateral superficial cervical plexus blocks and local wound infiltration|10mL bupivacaine at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
219756636|NCT07004738|OTHER|Control group|Women in this group who have been diagnosed with pelvic floor dysfunction will not be given any exercises. Women will continue their routine lives and their evaluations will be made.
219756637|NCT07003607|BEHAVIORAL|Control group (placebo)|Children in the control group received routine health education, which included cancer-related treatment, care, and general health education (e.g., treatment-related, diet, and exercise) without systematic PA health education. Every four weeks, knowledge related to sports activities, the harms of insufficient physical activity, and the benefits of increasing physical activity were pushed through the WeChat platform. During the hospitalization of the child patient, they can voluntarily participate in the activities organized by social workers.
219756638|NCT07003607|BEHAVIORAL|In-Hospital Program|"Researchers will conduct a comprehensive evaluation for each pediatric patient, including:~* Disease status and clinical characteristics~* Patient and family knowledge regarding physical activity (PA)~* Availability of social support systems"
219756639|NCT07003607|BEHAVIORAL|In-Hospital Program|"Based on assessment findings, two structured educational sessions (20-30 minutes each) will be delivered, covering:~* Disease-specific knowledge and PA guidelines~* Practical strategies for safe exercise (e.g., intensity adjustment, injury prevention)~* Interactive demonstrations of age-appropriate movement techniques"
219003214|NCT02345694|DEVICE|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
219190228|NCT04689256|DEVICE|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
219409783|NCT05805423|PROCEDURE|placebo injection and local wound infiltration|10mL normal saline at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
219003215|NCT03833115|OTHER|vaginal gel containing or not sodium lauryl sulfate|Prevention
219003216|NCT05229380|DRUG|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
219409784|NCT04860661|DRUG|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
219409785|NCT04860661|DRUG|Normal saline|10 ml normal saline
219409786|NCT03172221|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
219409787|NCT03609528|DEVICE|CamPROBE|To be completed
219409788|NCT00718757|DRUG|Dexamethasone|5 doses given on Days 6-10
219409789|NCT00718757|DRUG|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
219409790|NCT00718757|DRUG|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"
219409791|NCT01999855|OTHER|Phoniatric tests|
219409792|NCT04447989|DRUG|Sildenafil|Sildenafil citrate injection or powder for suspension
219409793|NCT04447989|DRUG|Placebo|dextrose 5%
219409794|NCT05714098|BEHAVIORAL|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
219409795|NCT02605421|DRUG|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
219409796|NCT02605421|DRUG|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
219409797|NCT02605421|DRUG|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
219409798|NCT02605421|DRUG|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
219409799|NCT02605421|DRUG|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
219409800|NCT02605421|BIOLOGICAL|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
219409801|NCT02605421|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \> 2000/μL for 3 consecutive days.
219409802|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
219409803|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
219409804|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
219409805|NCT01014637|DRUG|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
219409806|NCT01014637|DRUG|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
219190229|NCT04939688|RADIATION|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
219190230|NCT06095375|DRUG|Regorafenib|Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.
219409807|NCT05888792|OTHER|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
219409808|NCT02267863|DRUG|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
219409809|NCT00978861|DRUG|Hydrogen Peroxide|Whitening product syringe type
219409810|NCT05397886|DRUG|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
219409811|NCT05397886|DRUG|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
219409812|NCT05397886|DRUG|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
219409813|NCT02957058|PROCEDURE|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
219409814|NCT00216099|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
219409815|NCT00216099|DIETARY_SUPPLEMENT|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
219409816|NCT00216099|DIETARY_SUPPLEMENT|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
219409817|NCT05495074|OTHER|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
219409818|NCT02544971|BEHAVIORAL|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
219409819|NCT02544971|OTHER|Control|Treatment as usual
219409820|NCT02902172|DRUG|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
219409821|NCT02902172|DRUG|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
219409822|NCT05932511|DRUG|30% ascorbic acid in DMSO|see above
219409823|NCT03419767|DRUG|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
219409824|NCT03419767|OTHER|blank|Patients under carotid revascularization surgery without taking melatonin
219409825|NCT03277950|OTHER|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
219409826|NCT03277950|OTHER|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
219409827|NCT03277950|OTHER|Healthy|Healthy do not play game
219409828|NCT00048594|DRUG|aprepitant|
219409829|NCT00048594|DRUG|Comparator: placebo (unspecified)|
219409830|NCT01412645|DIETARY_SUPPLEMENT|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
219409831|NCT01434472|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
219409832|NCT01434472|DRUG|Cyclosporine|Given PO
219409833|NCT01434472|DRUG|Fludarabine Phosphate|Given IV
219409834|NCT01434472|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
219409835|NCT01434472|DRUG|Mycophenolate Mofetil|Given PO
219409836|NCT01434472|OTHER|Pharmacological Study|Correlative studies
219409837|NCT01434472|BIOLOGICAL|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
219409838|NCT01434472|RADIATION|Total-Body Irradiation|Undergo TBI
219409839|NCT01434472|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
219409840|NCT01434472|DRUG|Fludarabine|Given IV
219409841|NCT00947570|BEHAVIORAL|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
219409842|NCT06391073|BEHAVIORAL|Self-Measured Blood Pressure Monitoring|Prompted SMBP with tailored feedback
219409843|NCT06391073|BEHAVIORAL|Physician appointment and transportation scheduling|Physician appointment and transportation scheduling or none dependent on current BP control
219756640|NCT07003607|BEHAVIORAL|In-Hospital Program|"Patients will co-develop personalized PA plans using the six-step self-regulation framework from the ITHBC (Integrative Theory of Health Behavior Change), including:~* Short/long-term goal formulation~* Progress monitoring tools~* Barrier problem-solving protocols"
219761209|NCT05307328|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
219409844|NCT01240044|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
219569020|NCT05449093|OTHER|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
219756641|NCT07003607|BEHAVIORAL|Post-Discharge Program|Patients will perform PA 3-5 times weekly (20-30 minutes/session) aligned with individualized goals, adhering to oncology-specific safety guidelines
219756642|NCT07003607|BEHAVIORAL|Post-Discharge Program|"Mondays: Curated PA educational content (e.g., home-based exercise videos, fatigue management tips) will be disseminated via the WeChat platform.~Sundays: Scheduled telehealth check-ins with patients and caregivers to:~* Review PA adherence and experiential feedback~* Address knowledge gaps through tailored coaching~* Reinforce behavior change techniques (e.g., self-monitoring logs)"
219756643|NCT07003607|BEHAVIORAL|Post-Discharge Program|Regular monitoring and evaluation will be conducted to assess PA outcomes: comprehensive evaluations will identify barriers (e.g., treatment-related fatigue) and guide real-time adjustments to the exercise plan based on the patient's physical condition and performance. To enhance adherence, families will collaboratively set alarm reminders for PA sessions, and caregivers will be invited to supervise daily activities.
219756644|NCT07004803|OTHER|Virtual reality video watching|The children in the VR experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with virtual reality headset. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Virtual reality headset will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on virtual reality headset. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure
219756645|NCT07004803|OTHER|Tablet video watching|The children in the experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with Tablet. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Tablet will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on tablet. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure.
219756646|NCT07003555|DRUG|Dual-targeting BCMA-CD19 CAR-T cell infusion|Approximately 3-5 days prior to BCMA-CD19 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219756647|NCT07004569|DEVICE|Percutaneous coronary intervention (PCI)|Patients is under Percutaneous coronary intervention (PCI) by using contemporary drug eluting stent (DES). Angiolite is a thin-strut cobalt-chromium durable fluoroacrylate polymer-based, sirolimus-eluting stent that is CE marked and commercially available. Stent sizes 2.0mm to 4.5mm in 9mm to 49mm lengths will be used.
219756648|NCT07004725|DRUG|niacin sustained release capsules|The first stage: the niacin group was given niacin sustained-release capsules for 3 months, and the control group was given placebo for 3 months. The second stage: Both groups were given niacin sustained-release capsules for 3 months. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks
219756649|NCT07004725|DRUG|Placebo|The group was given oral placebo for 3 months in the first stage and niacin sustained-release capsules for 3 months in the second stage. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks.
219756650|NCT07002827|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40 mcg once a week (total 4 doses) for 1 month
219756651|NCT07002827|DRUG|G-CSF|G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
219756652|NCT07002827|DRUG|Lactulose|Standard Medical Tretament part
219756653|NCT07002827|BIOLOGICAL|Albumin|Standard Medical Tretament part
219761210|NCT05307328|DRUG|Placebo|Inactive tablets identical to SPI-62 tablets
219761211|NCT06694454|DRUG|azacytidine|"Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2."
219761212|NCT06694454|DRUG|carboplatin|Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219761213|NCT06694454|DRUG|paclitaxel|Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219409845|NCT01240044|PROCEDURE|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
219409846|NCT04659226|GENETIC|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
219409847|NCT05362643|OTHER|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
219409848|NCT05362643|OTHER|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
219409849|NCT05024123|DIETARY_SUPPLEMENT|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
219569021|NCT03768726|DRUG|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
219569022|NCT03768726|DRUG|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
219569023|NCT03382431|DRUG|PC786|Repeat doses
219756654|NCT06675591|OTHER|Rapid sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
219761214|NCT06694454|DRUG|durvalumab|Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219761215|NCT06694454|DRUG|cisplatin|Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219761216|NCT06694454|DRUG|gemcitabine|Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219003217|NCT04703335|DRUG|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
219003218|NCT03031678|DEVICE|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
219190231|NCT06095375|DRUG|Temozolomide|"Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy)."
219409850|NCT05024123|DIETARY_SUPPLEMENT|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
219409851|NCT01892033|BEHAVIORAL|Aerobic Exercise|12 weeks of brisk walking
219409852|NCT06165484|PROCEDURE|laparoscopy and hysteroscopy|laparoscopy and hysteroscopy for patient with failed IVF
219409853|NCT04652336|PROCEDURE|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
219409854|NCT04652336|PROCEDURE|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
219409855|NCT00000741|DRUG|Methylprednisolone|
219409856|NCT02990637|DIETARY_SUPPLEMENT|OLECOL|Olive leaf extract
219409857|NCT02990637|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219409858|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
219409859|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
219409860|NCT03270696|DRUG|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
219569024|NCT03382431|DRUG|Placebo/vehicle|Repeat doses
219569025|NCT03518892|DIAGNOSTIC_TEST|Resting Metabolic Rate|30 minute test to determine daily caloric needs
219569026|NCT03518892|DIAGNOSTIC_TEST|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
219569027|NCT03518892|BEHAVIORAL|Dietary Assessment|Self administered dietary logs
219569028|NCT01766791|OTHER|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM
219569029|NCT01766791|OTHER|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
219569030|NCT01766791|OTHER|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation
219569031|NCT01766791|OTHER|Control|control group, no intervention, maintenance of physical activity
219569032|NCT02825329|DEVICE|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
219761217|NCT06694454|DRUG|pemetrexed|Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
219409861|NCT02555644|DRUG|Prexasertib|Administered IV
219409862|NCT02555644|DRUG|Cisplatin|Administered IV
219409863|NCT02555644|DRUG|Cetuximab|Administered IV
219409864|NCT02555644|RADIATION|Intensity Modulated Radiation Therapy|
219409865|NCT02515864|DRUG|FYU-981|
219409866|NCT02515864|DRUG|Placebo|
219409867|NCT02515864|DRUG|Moxifloxacin|
219569033|NCT00444093|DRUG|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
219569034|NCT00444093|DRUG|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
219409868|NCT02515864|DRUG|Moxifloxacin Placebo|
219409869|NCT01123122|OTHER|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
219409870|NCT06330662|PROCEDURE|Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only|The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
219409871|NCT03420131|DIAGNOSTIC_TEST|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
219569035|NCT00423683|DRUG|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
219569036|NCT00423683|DEVICE|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
219569037|NCT03769883|BEHAVIORAL|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
219569038|NCT03769883|BEHAVIORAL|Diet|Dietary intervention
219761218|NCT04702880|BIOLOGICAL|BMS-986012|Specified dose on specified days
219761219|NCT04702880|DRUG|Carboplatin|Specified dose on specified days
219761220|NCT04702880|DRUG|Etoposide|Specified dose on specified days
219409872|NCT05357352|OTHER|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
219409873|NCT00995345|DRUG|KRP-104|Tablet
219409874|NCT00995345|DRUG|Placebo|Tablet
219409875|NCT03634358|PROCEDURE|Bipolar scissors|
219569039|NCT06495515|DRUG|Dalpiciclib，Toremifen|"1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs)."
219569040|NCT02601274|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
219569041|NCT03778723|DRUG|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
219569042|NCT03778723|DRUG|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
219569043|NCT03778723|DRUG|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
219569044|NCT01286558|DRUG|40 mg telmisartan|once daily
219569045|NCT01286558|DRUG|5 mg amlodipine|once daily
219569046|NCT01286558|DRUG|5 mg amlodipine|once daily
219756655|NCT06675591|OTHER|Slow sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
219569047|NCT01286558|DRUG|80 mg telmisartan|once daily
219756656|NCT07003750|OTHER|Surgical wound infection prevention bundle|utilization of locally customized surgical wound infection bundle to prevent and or control of infection in patients undergoing CABG surgery
219756657|NCT07004920|OTHER|IPOS-ICU|This is a prospective observational study. Health care providers will be asked to will out the IPOS-ICU for patients in the intensive care unit.
219756658|NCT07002749|DRUG|Tranexamic Acid (TXA)|I would like to see the effect of prophylactic tranexamic acid in women undergoing ELLSCS in preventing PPH in my setup.
219756659|NCT07002749|DEVICE|Placebo|one group will get placebo
219756660|NCT07004530|PROCEDURE|Magnetically Controlled Capsule Endoscopy (MCCE)|. The MCCE used in this study is the magnetically controlled capsule endoscopy (MCE, AnPx USA) which is a capsule measuring 28x12mm, and contains a permanent magnet inside its dome. Images are captured and recorded at 2 frames/s
219756661|NCT07004530|PROCEDURE|Esophageal-gastro-Duodenoscopy (EGD)|Esophageal-gastro-Duodenoscopy (EGD) is commonly performed to look for source of bleeding in patients with anaemia. However, from our own analysis and from retrospective studies of EGD in patients with ACS, EGD finding was normal or non-significant in 20-80% patients14-16. Moreover, EGD was associated with non-negligible periprocedural risks in patients with ACS, including death directly attributed to EGD (9.1%; 95% CI 7.6-10.9%), hypotension (24.1%; 95% CI 17.0-32.9%), arrhythmias (8.3%; 95% CI 4.5-15.1%) and recurrent ACS (6.5%; 95% CI 3.2-12.8%)
219409876|NCT03634358|PROCEDURE|classic scalpel|
219409877|NCT01860534|BEHAVIORAL|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
219409878|NCT05477342|BEHAVIORAL|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
219409879|NCT05477342|BEHAVIORAL|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
219569048|NCT00872924|DRUG|sumatriptan 100mg|
219569049|NCT03037034|DEVICE|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
219569050|NCT00362817|DRUG|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
219569051|NCT00362817|DRUG|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
219409880|NCT05477342|BEHAVIORAL|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
219409881|NCT01504854|DRUG|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
219409882|NCT01504854|DRUG|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
219409883|NCT05927727|DIAGNOSTIC_TEST|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
219409884|NCT04462718|OTHER|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
219409885|NCT04462718|OTHER|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
219409886|NCT05966493|DRUG|lufepirsen high dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
219409887|NCT05966493|DRUG|Vehicle|Matching vehicle without lufepirsen.
219409888|NCT05966493|DRUG|lufepirsen low dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
219409889|NCT03212131|DRUG|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
219409890|NCT06802146|DRUG|Inqovi|Combination of a nucleoside metabolic inhibitor and cytidine deaminase inhibitor, 10mg DEC / 100mg CED tablet, taken orally per protocol.
219409891|NCT05965336|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
219409892|NCT05965336|OTHER|Evaluation of Passive Ankle Stiffness|Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
219569052|NCT01407224|BEHAVIORAL|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
219756662|NCT05788991|DRUG|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
219003219|NCT02793934|OTHER|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
219409893|NCT05965336|OTHER|Gait Biomechanics|Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
219756663|NCT05788991|DRUG|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
219756664|NCT05270863|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
219569053|NCT05650424|OTHER|Abdominal massage training|please refer to group description
219569054|NCT01538836|BEHAVIORAL|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
219569055|NCT01538836|BEHAVIORAL|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
219569056|NCT05557903|BIOLOGICAL|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
219569057|NCT01787279|DRUG|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
219569058|NCT01471899|DRUG|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
219569059|NCT01471899|DRUG|Naproxen|2 tablets every 8 hours for 4 days
219756665|NCT05270863|DRUG|Carbachol PF|A single drop in each eye at a visit.
219756666|NCT05270863|DRUG|Brimonidine tartrate|A single drop in each eye at a visit.
219003220|NCT02793934|OTHER|New model of rehabilitation|
219003221|NCT02793934|OTHER|Old model of rehabilitation|
219003222|NCT02793934|OTHER|ICF reader|
219003223|NCT00948129|OTHER|Laboratory Biomarker Analysis|Correlative studies
219003224|NCT00948129|BEHAVIORAL|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
219409894|NCT05965336|OTHER|Gait Biofeedback|Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
219409895|NCT05965336|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target.
219409896|NCT05965336|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
219409897|NCT02196649|DEVICE|Endoscopic Clip|
219409898|NCT05178992|BEHAVIORAL|Socially Assistive Robot Activity|Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
219409899|NCT03363828|DRUG|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
219409900|NCT05342584|DRUG|Venetoclax Oral Tablet|Given PO
219409901|NCT05342584|DRUG|Daunorubicin|Given IV
219409902|NCT05342584|DRUG|Cytarabine|Given IV
219756667|NCT05509127|DRUG|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
219756668|NCT05509127|DRUG|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
219756669|NCT04464473|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
219003225|NCT00948129|BEHAVIORAL|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
219003226|NCT00948129|OTHER|Tobacco Cessation Counseling|Undergo smoking cessation counseling
219003227|NCT03944460|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
219003228|NCT01385553|BEHAVIORAL|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
219003229|NCT01385553|BEHAVIORAL|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
219003230|NCT01753856|DRUG|Teriparatide|Administered SC
219003231|NCT01753856|DRUG|Denosumab|Administered SC
219003232|NCT01753856|DRUG|Demeclocycline|Administered orally
219409903|NCT00500786|BIOLOGICAL|CYT006-AngQb|
219409904|NCT00001019|BIOLOGICAL|rgp120/HIV-1 SF-2|
219409905|NCT00001019|BIOLOGICAL|MTP-PE/MF59|
219761221|NCT04702880|BIOLOGICAL|Nivolumab|Specified dose on specified days
219003233|NCT01753856|DRUG|Tetracycline|Administered orally
219003234|NCT01753856|DRUG|Calcium Supplement|Administered orally
219003235|NCT01753856|DRUG|Vitamin D|Administered orally
219003236|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
219003237|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
219003238|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
219003239|NCT00864214|DRUG|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
219003240|NCT04386252|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
219003241|NCT05778097|DRUG|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
219003242|NCT05778097|DRUG|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
219409906|NCT04315376|BEHAVIORAL|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
219409907|NCT04315376|BEHAVIORAL|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
219409908|NCT04336397|DIAGNOSTIC_TEST|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
219409909|NCT05138185|DEVICE|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
219409910|NCT01507584|DEVICE|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
219409911|NCT03673748|DRUG|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
219409912|NCT03673748|DRUG|Placebo|Endovenous injection of saline solution without cells
219409913|NCT05122650|DRUG|JZP385|JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
219409914|NCT05122650|OTHER|Placebo|Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
219409915|NCT06622694|BIOLOGICAL|RD13-02|"Before cell infusion (Day 0), subjects will undergo a lymphodepleting chemotherapy based on the Fludarabine + Cyclophosphamide (FC regimen). Prior to the lymphodepleting chemotherapy, subjects must undergo an assessment, and only those meeting the criteria will be eligible for the lymphodepleting chemotherapy. The CAR T infusion should be performed at least 48 hours after the completion of the lymphodepleting chemotherapy. The infusion will be administered intravenously as a single dose. It should be completed within 30 minutes, with continuous cardiac monitoring during the infusion to observe heart rate (HR), blood pressure (BP), respiratory rate (R), and peripheral oxygen saturation (SpO2) for up to 2 hours post-infusion."
219409918|NCT06973005|DRUG|AZD2389|Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.
219569060|NCT03897478|DIAGNOSTIC_TEST|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
219569061|NCT04782128|BIOLOGICAL|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
219003243|NCT05307068|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
219003244|NCT03942848|DRUG|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
219409919|NCT06973005|DRUG|Midazolam|"Single oral dose on:~* Day 1 (co-administered with caffeine)~* Day 14 (co-administered with caffeine and AZD2389)"
219409920|NCT06973005|DRUG|Caffeine|"Single oral dose on:~* Day 1 (co-administered with midazolam)~* Day 14 (co-administered with midazolam and AZD2389)"
219569062|NCT03447340|BEHAVIORAL|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
219409921|NCT06973005|DRUG|Bupropion|"Single oral dose on:~* Day 2 (alone)~* Day 15 (co-administered with AZD2389)"
219409922|NCT04725370|OTHER|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
219409923|NCT06397924|DIETARY_SUPPLEMENT|Chitin Fiber|Dietary fiber isolated from an edible insect (chitin)
219409924|NCT06397924|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219569063|NCT03447340|OTHER|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
219569064|NCT00418522|DRUG|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
219569065|NCT00418522|DRUG|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
219569066|NCT01387425|DRUG|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
219569067|NCT01387425|DRUG|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
219569068|NCT00949455|DRUG|lapatinib ditosylate|Given orally
219569069|NCT00949455|OTHER|Placebo|Given orally
219569070|NCT03331614|DEVICE|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
219569071|NCT00933881|OTHER|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
219569072|NCT00992095|DRUG|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
219569073|NCT03441295|PROCEDURE|Dynamic Intraligamentary Stabilization|DIS, Ligamys
219569074|NCT03441295|PROCEDURE|Internal Brace Ligament Augmentation|IBLA
219191878|NCT05674409|BEHAVIORAL|Brief Family-Involved Treatment (B-FIT)|Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.
219409925|NCT01385423|DRUG|Preparative Regimen|Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
219409926|NCT01385423|BIOLOGICAL|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
219569075|NCT03441295|PROCEDURE|ACL Reconstruction|Conventional
219569076|NCT06193824|DEVICE|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
219569077|NCT01739634|DRUG|CASAD|CASAD is provided in 500mg capsules.
219569078|NCT03781024|COMBINATION_PRODUCT|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
219569079|NCT02695719|DRUG|Placebo|Lubiprostone placebo-matching capsules
219569080|NCT02695719|DRUG|Lubiprostone|Lubiprostone capsules
219569081|NCT03171441|DIAGNOSTIC_TEST|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
219569082|NCT03171441|DIAGNOSTIC_TEST|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
219569083|NCT04357613|DRUG|Experimental drug|Imatinib 800mg/d during 14days
219569084|NCT03717519|DIAGNOSTIC_TEST|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
219569085|NCT05012202|DEVICE|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
219569086|NCT01430793|DRUG|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
219569087|NCT01430793|DRUG|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
219569088|NCT01430793|DRUG|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
219569089|NCT01430793|DRUG|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
219569090|NCT00825552|DRUG|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
219569091|NCT01694017|DRUG|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
219569092|NCT01694017|DRUG|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
219569093|NCT04446988|DEVICE|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
219569094|NCT01991288|PROCEDURE|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
219007200|NCT03975608|BEHAVIORAL|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
219569095|NCT01991288|PROCEDURE|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
219569096|NCT00025129|DRUG|laromustine|
219569097|NCT04009889|DIETARY_SUPPLEMENT|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
219569098|NCT04009889|OTHER|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
219569099|NCT04425889|DIAGNOSTIC_TEST|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
219569100|NCT02857829|DIETARY_SUPPLEMENT|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
219756670|NCT06630156|BIOLOGICAL|Revascularization of Immature Young Permenant Teeth|"An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C"
219569101|NCT02857829|DIETARY_SUPPLEMENT|Caffeine-alone|Caffeine (100 mg)
219569102|NCT02857829|OTHER|Placebo|Rice flour
219569103|NCT01005329|BIOLOGICAL|Bevacizumab|Given IV
219569104|NCT01005329|DRUG|Carboplatin|Given IV
219569105|NCT01005329|DRUG|Cisplatin|Given IV
219569106|NCT01005329|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219569107|NCT01005329|DRUG|Paclitaxel|Given IV
219756671|NCT05919563|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
219756672|NCT05968963|BEHAVIORAL|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
219756673|NCT05968963|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
219756674|NCT06696209|OTHER|Analysis of the withdrawal time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first image of the second portion of the duodenum.
219756675|NCT06696209|OTHER|Analysis of the total time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first esophageal image
219756676|NCT06696209|OTHER|Upper gastrointestinal endoscopy: Common Practices|"Execution of UGE using high-resolution endoscopes, with the option of virtual chromoendoscopy, according with the physician's preference. Possible optimization of visualization with washing and/or the use of simethicone or similar, as pre-medication or during the examination, according with the physician's preference. Patients will be randomised to one of the following measurements-total time versus withdrawal time-in a parallel 1:1 scheme.~The allocation of the randomisation group will be computer-generated. The endoscopist must record the time at which the following three anatomical structures are reached (either by noting during the procedure or based on the information in the photographic documentation), before any biopsies or therapeutic interventions, in the format xxh:xxmin:xxsec:~1. First esophageal image;~2. First image of the second portion of the duodenum;~3. Last esophageal image."
219756677|NCT03246906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
219756678|NCT03246906|DRUG|Cyclophosphamide|Given IV
219756679|NCT03246906|DRUG|Cyclosporine|Given PO
219409927|NCT05107206|DEVICE|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
219003245|NCT03942848|DRUG|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
219409928|NCT05107206|DEVICE|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
219409929|NCT06036927|DRUG|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
219409930|NCT06036927|DRUG|TQC2731 matching placebo|It'a a placebo injection without active substances.
219569108|NCT04652544|DRUG|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
219569109|NCT04652544|OTHER|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
219569110|NCT03651726|DRUG|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
219569111|NCT03651726|DRUG|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
219569112|NCT03432065|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
219003246|NCT03689478|OTHER|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
219003247|NCT00989378|BEHAVIORAL|baseline study|normal bedtimes
219003248|NCT04140591|DRUG|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
219003249|NCT04140591|DRUG|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
219003250|NCT05944874|DEVICE|high definition transcranial direct current stimulation|Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
219003251|NCT02706340|OTHER|No intervention - observational study only|
219003252|NCT03793933|PROCEDURE|Liver resection|Surgery for the liver
219003253|NCT04008615|OTHER|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
219003254|NCT01154764|DRUG|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
219003255|NCT01154764|DRUG|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
219003256|NCT03592108|OTHER|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
219003257|NCT04274842|OTHER|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
219003258|NCT00242489|DRUG|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
219003259|NCT00242489|DRUG|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
219409931|NCT05540899|RADIATION|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
219409932|NCT03340181|OTHER|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
219409933|NCT01542476|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
219409934|NCT01401010|DRUG|Doripenem|500 mg every 8 hours
219409935|NCT01401010|DRUG|doripenem|1000 mg every 8 hours
219409936|NCT06060275|DIAGNOSTIC_TEST|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
219409937|NCT06406777|DIAGNOSTIC_TEST|Spirometry|Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.
219569113|NCT01956448|DEVICE|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
219569114|NCT02997657|BEHAVIORAL|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
219569115|NCT02997657|BEHAVIORAL|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
219569116|NCT01587131|BIOLOGICAL|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
219569117|NCT02190448|DIETARY_SUPPLEMENT|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
219569118|NCT02190448|DIETARY_SUPPLEMENT|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
219569119|NCT01800526|DRUG|N-Acetylcysteine|Oral and Intravenous administration of NAC
219569120|NCT02974491|OTHER|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
219569121|NCT05918757|OTHER|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
219569122|NCT05918757|OTHER|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
219409938|NCT06406777|DIAGNOSTIC_TEST|Contrast Lung Computed Tomography (CT) Scan|CT scan of the lungs using contrast
219409939|NCT06406777|DIAGNOSTIC_TEST|Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan|MRI will be taken while subject is lying on their back breathing 100% oxygen.
219409940|NCT06406777|DRUG|129Xe MRI scans|MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
219409941|NCT06621979|PROCEDURE|Bypass surgery type one anastomosis gastric bypass|Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention.
219409942|NCT05514366|PROCEDURE|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
219409943|NCT05514366|PROCEDURE|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) \< 97% is detected."
219409944|NCT05514366|PROCEDURE|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs \> 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is \>10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
219409945|NCT06579833|RADIATION|Histotripsy|Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.
219409946|NCT05954377|OTHER|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
219409947|NCT06131346|OTHER|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
219409948|NCT00003648|GENETIC|DNA stability analysis|
219409949|NCT00003648|GENETIC|gene rearrangement analysis|
219569123|NCT01583257|BEHAVIORAL|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
219569124|NCT04756596|DIAGNOSTIC_TEST|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
219409950|NCT06983028|DRUG|Atacicept|Atacicept 150 mg SC QW via pre-filled syringe
219007201|NCT02319993|DRUG|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
219409951|NCT01429987|DRUG|plecanatide|Subjects receive experimental study drug for 12 weeks.
219409952|NCT01429987|OTHER|Placebo|Subjects receive experimental study drug for 12 weeks.
219409953|NCT04136561|DEVICE|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
219569125|NCT04756596|DIAGNOSTIC_TEST|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
219569126|NCT05115526|OTHER|PEEP setting|PEEP setting according to various methods
219569127|NCT00908557|OTHER|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
219569128|NCT00908557|OTHER|Control|information based on the classic informed consent document
219756680|NCT03246906|DRUG|Mycophenolate Mofetil|Given PO
219756681|NCT03246906|DRUG|Sirolimus|Given PO
219756682|NCT01681641|OTHER|A psycho-social intervention|
219756683|NCT06868459|OTHER|Data Collection|Subjects with planned PED-TAE delivered via TriNav will receive their treatment following routine standard of care procedures. Post-procedural data obtained by a patient chart review will be collected in a study database. No additional study-specific interventions or visits outside of the routine clinical treatment will be performed.
219756684|NCT07029971|BIOLOGICAL|BB-TL1A-VIAL-HLE|Anti-TL1A monoclonal antibody
219756685|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
219003260|NCT03462264|DEVICE|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
219003261|NCT03462264|OTHER|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
219409954|NCT04826224|BIOLOGICAL|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
219003262|NCT00935753|DRUG|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
219003263|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
219409955|NCT01113021|DEVICE|Photon stimulation by low level laser therapy|
219409956|NCT00100412|DRUG|Graded dobutamine infusions|
219409957|NCT00100412|DRUG|Graded phenylephrine injections|
219409958|NCT00100412|BEHAVIORAL|Psychosocial challenge involving socioevaluative public speaking|
219409959|NCT00235651|DRUG|Amphotericin B|
219409960|NCT03217578|OTHER|SMA Newborn Screening|
219409961|NCT02843373|DEVICE|TMS|
219409962|NCT01125176|DRUG|thalidomide|50 mg oral dosing every other day
219409963|NCT01125176|DRUG|lenalidomide|varying oral doses every other day (max 25 mg/day)
219409964|NCT01125176|BIOLOGICAL|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
219409965|NCT01373567|DRUG|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
219409966|NCT01096082|DRUG|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
219409967|NCT01096082|DRUG|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
219756686|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
219756687|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
219756688|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
219756689|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219756690|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219756691|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
219756692|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
219756693|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
219756694|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
219756695|NCT06612970|DRUG|HB0056|HB0056 Injection
219756696|NCT06612970|DRUG|Placebo|Placebo
219756697|NCT07032376|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
219756698|NCT07032376|BEHAVIORAL|Rectal Expulsion Device use|"During the participant's clinic visit for constipation, the Rectal Expulsion Device will be available for the gastroenterology care provider to use if the decision is made to use this during the clinic visit.~In addition, the care provider will have access to the RED brochure and the Michigan Chart (MICHART) Our Practice Advisory (OPA) - a decision support tool in MiChart to support care navigation using RED."
219756699|NCT07032636|BEHAVIORAL|Crisis Intervention - The First Line Leaders (FLL) program will utilize templated guides developed with stakeholders from the Idaho Army National Guard (ARNG), known as the Total Health Action Plan (T|The Investigators are developing training programs for soldiers and leaders to enhance their communication skills, problem-solving abilities, and approachability. They will be randomized to one of three different groups.
219756700|NCT07117838|OTHER|virtual reality|Virtual reality application were applied to patients during coronary angiography.
219756701|NCT07117838|OTHER|music|Patients will listen to music during coronary angiography.
219756702|NCT05422612|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
219756703|NCT05422612|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
219756704|NCT05422612|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
219756705|NCT05422612|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
219756706|NCT05422612|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily.
219756707|NCT05422612|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
219756708|NCT05422612|DRUG|Intervention D SLS-002|• SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
219003264|NCT01402791|OTHER|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
219409968|NCT04576637|PROCEDURE|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
219409969|NCT00572806|DRUG|insulin aspart|
219003265|NCT05471778|BEHAVIORAL|Watching comedy movie|A 25-minute comedy film created by the researchers was watched.
219409970|NCT04360187|DRUG|Crisaborole Ointment|Crisaborole ointment 2%
219409971|NCT04360187|DRUG|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
219409972|NCT00548080|DRUG|MK0991, caspofungin acetate / Duration of Treatment:|
219409973|NCT02630082|PROCEDURE|Circumcision|
219409974|NCT02630082|PROCEDURE|Flexible sigmoidoscopy|
219409975|NCT04058054|DEVICE|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
219409976|NCT04058054|DEVICE|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
219409977|NCT04058054|DEVICE|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
219409978|NCT04058054|DRUG|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
219003266|NCT05471778|BEHAVIORAL|listening to music|25 minutes of music created by the researchers was played.
219003267|NCT04880525|OTHER|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
219409979|NCT04058054|DRUG|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
219409980|NCT00205725|DRUG|Ziprasidone, Olanzapine|
219569129|NCT03051139|BEHAVIORAL|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
219569130|NCT01706016|PROCEDURE|Thermic destruction of tissue by Laser using the Novilase device|
219569131|NCT04049916|DRUG|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
219569132|NCT04049916|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
219569133|NCT04049916|DRUG|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
219409981|NCT02290054|PROCEDURE|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
219409982|NCT02290054|PROCEDURE|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
219409983|NCT02290054|PROCEDURE|Intra-venous anesthesia|
219409984|NCT01082718|DRUG|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
219409985|NCT05201586|OTHER|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
219409986|NCT05201586|OTHER|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
219409987|NCT01249183|BIOLOGICAL|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
219409988|NCT01249183|BIOLOGICAL|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
219409989|NCT03577093|OTHER|There is no intervention at all.|There is no intervention at all.
219409990|NCT04599205|DRUG|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
219409991|NCT03951961|DRUG|Midostaurin|50mg Midostaurin bid for 12 months
219409992|NCT02124187|DEVICE|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
219409993|NCT02124187|DEVICE|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
219409994|NCT02124187|DEVICE|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
219409995|NCT05106660|PROCEDURE|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
219409996|NCT05106660|PROCEDURE|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
219409997|NCT04592276|DIETARY_SUPPLEMENT|PS128|Participants took two capsules with PS128 after dinner for 30 days.
219569134|NCT00455416|DRUG|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
219569135|NCT00455416|DRUG|Selenium (L-Selenomethionine),|100mcgx2 daily
219569136|NCT00455416|DRUG|Garlic extract (Allicin)|6 garlic pearls daily
219569137|NCT00455416|DRUG|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
219409998|NCT04592276|DIETARY_SUPPLEMENT|placebo|Participants took two capsules without PS128 after dinner for 30 days.
219409999|NCT01913210|DIETARY_SUPPLEMENT|Ginseng|
219410000|NCT05344079|DEVICE|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
219410001|NCT05344079|DEVICE|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
219410002|NCT00364546|DRUG|CG 5503;tapentadol|
219410003|NCT06463769|BEHAVIORAL|8 week predominantly plant-based New Nordic LPF-diet program|An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.
219410004|NCT06463769|BEHAVIORAL|maintenance of the predominantly plant-based New Nordic LPF-diet|Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
219410005|NCT02915367|BEHAVIORAL|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
219410006|NCT00722553|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
219756709|NCT05422612|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
219756710|NCT06240260|DEVICE|TENS (transcutaneous electrical nerve stimulation) unit|"Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of a mild electrical current.~A TENS machine is a small, battery-operated device that has leads connected to sticky pads called electrodes."
219756711|NCT06240260|OTHER|Standard care|Paracervical block only or participant declines analgesia for IUD insertion
219756712|NCT06892093|DIETARY_SUPPLEMENT|Probiotics|Participants in this group will receive a daily dose of probiotics as an adjunct to standard Neratinib therapy. The probiotics will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks (two treatment cycles). Loperamide will be administered prophylactically according to the FDA-recommended schedule to prevent Neratinib-associated diarrhea. The aim is to assess the efficacy of probiotics in reducing Neratinib-induced diarrhea and improving quality of life.
219756713|NCT06892093|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive a daily dose of a placebo that is identical in appearance, taste, and administration method to the probiotic granules, in addition to standard Neratinib therapy. The placebo will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks. Loperamide will also be administered prophylactically to all participants in accordance with FDA recommendations. This group will serve as a control to evaluate the true effect of probiotics on Neratinib-induced diarrhea.
219756714|NCT06892093|DRUG|Loperamide|All participants will receive prophylactic loperamide to reduce the risk of Neratinib-induced diarrhea. Loperamide will be administered according to the FDA-recommended schedule: 4 mg TID for the first 14 days of treatment, then 4 mg BID from Day 15 to Day 42. This intervention is implemented as a standard supportive therapy and not as a randomized variable.
219756715|NCT06574529|DEVICE|Video-observed therapy (vDOT)|All participants are required to send 5 times per week a short video showing they are actually taking their treatment for tuberculosis via a dedicated application on their cellphone
219756716|NCT04558229|OTHER|Additional Standardized Counseling|Research staff will follow a script designed to give unbiased, medically accurate information regarding bleeding changes that may occur with use of a contraceptive ENG implant.
219756717|NCT06762002|OTHER|blood sample|After signature of consent form,blood samples will be collected for full blood cell count;classical autoimmune investigations, immunophenotyping;auto-Abs against type IIFNs, other cytokines, or other target proteins ,Genetic explorations by whole-exome or whole-genome sequencing;Biobanking
219756718|NCT07065617|DRUG|[14C]BI 1819479|\[14C\]BI 1819479
219756719|NCT07065617|DRUG|BI 1819479|BI 1819479
219756720|NCT07065617|DRUG|BI 1819479 (C-14)|BI 1819479 mixed with \[14C\]BI 1819479
219756721|NCT04577404|DRUG|MT-1186|Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
219003268|NCT05600491|DRUG|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
219003269|NCT04718051|DRUG|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
219003270|NCT04718051|DRUG|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
219410007|NCT00722553|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
219410008|NCT00722553|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
219003271|NCT01447095|DRUG|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
219003272|NCT01447095|DRUG|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
219410009|NCT03342391|OTHER|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
219410010|NCT05128253|OTHER|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
219410011|NCT02608437|DRUG|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
219410012|NCT02608437|DRUG|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
219410013|NCT03705962|DRUG|Tobramycin|
219410014|NCT03705962|OTHER|Placebo: normal saline|
219410015|NCT03765801|DRUG|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
219410016|NCT03765801|DRUG|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
219410017|NCT02624401|DRUG|Dexmedetomidine|Intravenous infusion
219410018|NCT02624401|DRUG|Propofol|Intravenous infusion
219410019|NCT02624401|DRUG|S-ketamine|Intravenous infusion
219410020|NCT02624401|DRUG|Sevoflurane|Inhalation
219410021|NCT02624401|DRUG|Placebo|Intravenous infusion of saline (Ringer's Acetate)
219410022|NCT00122005|BIOLOGICAL|GM-CSF gene transduced allogeneic vaccine GVAX|
219410023|NCT06430047|DRUG|EsoDuo® Tablet|QD, PO
219410024|NCT01423617|DIETARY_SUPPLEMENT|Zenoctil|3 tablets 2 times daily
219410025|NCT01423617|OTHER|Placebo|3 tablets 2 times daily
219410026|NCT01515306|BIOLOGICAL|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
219410027|NCT01515306|DRUG|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
219410028|NCT04567966|PROCEDURE|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
219003273|NCT01447095|DRUG|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
219410029|NCT04567966|PROCEDURE|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
219410030|NCT06417931|BEHAVIORAL|Patient education and counselling|The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
219410031|NCT02460926|PROCEDURE|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
219410032|NCT00086957|BIOLOGICAL|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
219410033|NCT00086957|DRUG|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
219410034|NCT00086957|DRUG|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
219410035|NCT02837692|DRUG|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
219410036|NCT02837692|DRUG|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
219410037|NCT02837692|DRUG|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
219410038|NCT02837692|DRUG|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
219410039|NCT02626104|DIETARY_SUPPLEMENT|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
219410040|NCT02626104|DIETARY_SUPPLEMENT|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
219410041|NCT00634244|DRUG|alvocidib|Given IV
219410042|NCT00634244|DRUG|mitoxantrone hydrochloride|Given IV
219003274|NCT02305056|DRUG|C13 N15 Valine|C13 N15 Valine administration
219410043|NCT00634244|DRUG|carboplatin|Given IV
219410044|NCT00634244|DRUG|cytarabine|Given IV
219410045|NCT00634244|DRUG|sirolimus|Given PO
219003275|NCT00064844|BEHAVIORAL|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
219003276|NCT00064844|DRUG|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
219003277|NCT00064844|DRUG|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
219003278|NCT00064844|DRUG|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
219410046|NCT00634244|DRUG|etoposide|Given IV
219410047|NCT00634244|DRUG|topotecan hydrochloride|Given IV
219410048|NCT04158908|BEHAVIORAL|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
219410049|NCT00908206|DRUG|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
219410050|NCT02915406|DEVICE|CliniMACs|
219410051|NCT02166021|BIOLOGICAL|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
219410052|NCT01850784|DIETARY_SUPPLEMENT|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
219410053|NCT01850784|DIETARY_SUPPLEMENT|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
219410054|NCT02499003|DRUG|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
219410055|NCT06291103|DRUG|Conversion to Belatacep|CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
219410056|NCT06291103|DRUG|Standard of care treatment (SOC regimen) with Tacrolimus|Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
219410057|NCT02667990|OTHER|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
219410058|NCT02667990|OTHER|standard stiletto|standard stiletto without insole
219410059|NCT02667990|OTHER|comfy trainer|comfy trainer
219410060|NCT02800564|BEHAVIORAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
219410061|NCT02800564|BEHAVIORAL|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
219410062|NCT01864759|BIOLOGICAL|ICOVIR-5|
219003279|NCT04928040|DIAGNOSTIC_TEST|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
219410063|NCT01672996|DRUG|Ioforminol 160 mgI/mL|Given as s single administration to the subject
219410064|NCT01672996|DRUG|Ioforminol 200 mgI/mL|Given as a single administration to the subject
219410065|NCT01672996|DRUG|Iopamidol 300 mgI/mL|Given as a single administration to the subject
219410066|NCT03880240|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
219410067|NCT03880240|OTHER|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
219410068|NCT00240630|DRUG|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
219410069|NCT00240630|DRUG|placebo|placebo to match
219410070|NCT01924910|DIETARY_SUPPLEMENT|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
219410071|NCT01924910|DIETARY_SUPPLEMENT|Placebo|
219410072|NCT05177952|OTHER|Blood Flow Restriction|Resistance training with BFR
219410073|NCT05177952|OTHER|Standard of Care|Resistance Training with no BFR
219410074|NCT06552559|DRUG|Selinexor|Combination chemotherapy
219410075|NCT00406952|PROCEDURE|electronic diary|
219410076|NCT00406952|DRUG|Sertraline|
219410077|NCT00406952|DRUG|Placebo|
219410078|NCT00406952|PROCEDURE|voice acoustics|
219410079|NCT04279379|DRUG|Sintilimab|200mg d1,ivdrip, repeated every 3 weeks
219410080|NCT04279379|DRUG|Decitabine|10mg d1-5, ivdrip,repeated every 3 weeks
219410081|NCT01341431|DRUG|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
219410082|NCT02435277|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
219569138|NCT00455416|DRUG|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
219003280|NCT00263133|DRUG|Sertraline|
219003281|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
219410083|NCT02435277|DRUG|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
219410084|NCT02435277|DRUG|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
219410085|NCT02435277|DRUG|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
219410086|NCT01915004|OTHER|Educational Intervention|Bladder Training Video
219410087|NCT06554925|PROCEDURE|Cardiac surgery|The difference in males and females undergoing cardiac surgery of all types
219410088|NCT05199350|OTHER|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
219410089|NCT00008138|DRUG|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
219410090|NCT00008138|DRUG|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
219410091|NCT00008138|PROCEDURE|debulking surgery|exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
219410092|NCT06503861|BEHAVIORAL|Food Is Medicine intervention|The intervention provides regular meal kits as well as cooking and nutritional education.
219569139|NCT00455416|DRUG|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
219569140|NCT00643214|DEVICE|Tetrix|Twice daily topical application
219569141|NCT00643214|DEVICE|Tetrix|Twice daily topical application
219410093|NCT06998147|OTHER|correlation and regression analyses|to evaluate the association interplay among balance, functional mobility, cognitive function, psychological well-being, and community participation in addition to identify the anticipated contributing factors that function as predictors of MS features.
219410094|NCT04935060|BEHAVIORAL|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
219410095|NCT04935060|BEHAVIORAL|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
219410096|NCT01251172|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
219410097|NCT01251172|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
219410098|NCT01251172|PROCEDURE|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
219410099|NCT01251172|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
219410100|NCT01251172|OTHER|Laboratory Biomarker Analysis|Correlative studies
219410101|NCT01251172|DRUG|Melphalan|Given IV
219410102|NCT04319562|PROCEDURE|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
219569142|NCT02128555|PROCEDURE|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
219569143|NCT02128555|PROCEDURE|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
219569144|NCT01111214|OTHER|no intervention|There is no intervention. This is a non interventional study.
219569145|NCT03505814|DEVICE|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
219569146|NCT03505814|DEVICE|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
219007202|NCT02319993|DRUG|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
219410103|NCT04319562|DEVICE|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
219410104|NCT03114982|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
219410105|NCT03114982|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
219410106|NCT00385567|DRUG|PEHRG214|
219410107|NCT04543474|OTHER|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
219410108|NCT04543474|OTHER|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
219410109|NCT04284982|BEHAVIORAL|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
219410110|NCT02539082|DEVICE|Regenseal|Regenseal, collagen, injection in the defect area
219410111|NCT02539082|DRUG|normal saline|placebo, normal saline, injection in the defect area
219410112|NCT03445858|DRUG|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
219410113|NCT03445858|DRUG|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
219410114|NCT03445858|RADIATION|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
219569147|NCT02504723|DRUG|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.
219569148|NCT02504723|DRUG|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
219410115|NCT05931523|BEHAVIORAL|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
219410116|NCT00958308|OTHER|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
219569149|NCT05927181|PROCEDURE|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
219569150|NCT04692025|DRUG|ASC41 tablet|Oral tablet
219569151|NCT04385524|BIOLOGICAL|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
219569152|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Placebo|Colored water
219569153|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
219003282|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
219003283|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
219569154|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
219569155|NCT01304758|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
219569156|NCT02244749|OTHER|skin specimen|skin specimen
219569157|NCT02011919|DEVICE|Echopulse|HIFU Under ultrasound guidance
219756722|NCT04066829|BEHAVIORAL|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
219756723|NCT00775671|DRUG|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
219756724|NCT00775671|DRUG|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
219756725|NCT00775671|DRUG|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
219756726|NCT04667962|OTHER|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
219756727|NCT06456541|OTHER|Experimental Extensively Hydrolyzed Formula|Experimental powder formula
219410117|NCT00958308|OTHER|Placebo|Placebo is devoid of microorganisms.
219410118|NCT01214746|DRUG|Placebo|1 tablet Unikalk 1 time pr day for 5 days
219410119|NCT01214746|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
219410120|NCT04158713|DRUG|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
219410121|NCT01720615|DRUG|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
219569158|NCT04109313|DRUG|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
219410122|NCT01720615|DRUG|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
219410123|NCT00654511|DRUG|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
219410124|NCT00654511|DRUG|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
219410125|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
219410126|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
219410127|NCT01264250|DRUG|AZD2927|Single dose of AZD2927
219410128|NCT01264250|DRUG|Placebo|Single dose of placebo
219410129|NCT03828084|DRUG|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
219410130|NCT02368340|OTHER|Pulmonary function test|Pulmonary function testing performed
219410131|NCT02368340|OTHER|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
219410132|NCT02368340|OTHER|Sample collection|Blood and urine sample collections
219410133|NCT05929144|OTHER|MRI sequences testing|Testing different MRI sequences in order to optimize them
219410134|NCT01301560|RADIATION|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
219410135|NCT01301560|RADIATION|Observation|No local treatment
219569159|NCT04119219|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
219569160|NCT01574664|DEVICE|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
219569161|NCT01272921|DRUG|Bupivacaine|Varying doses to determine the duration of analgesia
219569162|NCT01272921|DRUG|Ropivacaine|Varying doses to determine the duration of analgesia
219410136|NCT05924776|BIOLOGICAL|Plasmodium immunotherapy|Inoculation 1-5 × 10\^6 Plasmodium vivax once
219410137|NCT01590680|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
219410138|NCT05594680|DRUG|Cilostazol|Cilostazol 50 MG
219410139|NCT05594680|DRUG|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
219410140|NCT05594680|DRUG|Placebo|Placebo
219410141|NCT02227329|DRUG|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
219410142|NCT02227329|DRUG|Heparin Lock|3 mL of 100 U/ml heparin
219569163|NCT06357949|DEVICE|High-intensity laser|"All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks"
219410143|NCT02227329|DRUG|Normal Saline|
219410144|NCT00161980|DRUG|Fibrin Sealant VH S/D|
219410145|NCT00161980|PROCEDURE|Surgical intervention alone without Fibrin Sealant VH S/D application|
219410146|NCT05228444|BEHAVIORAL|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
219410147|NCT01554540|DRUG|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
219410148|NCT00368134|DRUG|Vildagliptin|
219569164|NCT06357949|DEVICE|Sham laser|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
219569165|NCT01132664|DRUG|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
219003284|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
219003285|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
219003286|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
219410149|NCT05369117|BEHAVIORAL|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
219410150|NCT01984034|BEHAVIORAL|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
219410151|NCT01984034|OTHER|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
219410152|NCT01370096|DRUG|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
219569166|NCT01132664|DRUG|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
219569167|NCT01132664|DRUG|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
219569168|NCT04818437|OTHER|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
219569169|NCT04818437|OTHER|CORE STABILITY EXERCISES|"1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
219569170|NCT00882206|DRUG|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
219569171|NCT00882206|DRUG|decitabine|Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
219569172|NCT00882206|DRUG|doxorubicin hydrochloride|Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
219569173|NCT00882206|DRUG|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.
219756728|NCT06456541|OTHER|Placebo Extensively Hydrolyzed Formula|Placebo powder formula
219756729|NCT06899165|DRUG|Psilocybin|Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
219756730|NCT06899165|BEHAVIORAL|Integration sessions|weekly integration sessions (therapy) for 6 weeks
219756731|NCT06763081|OTHER|Not applicable- observational study|It's an observational study. Participants are not assigned an intervention as part of the study.
219410153|NCT01370096|DRUG|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
219410154|NCT03679663|DEVICE|Ultrasound|Use of ultrasound to identify pre-puncture site
219410155|NCT05913934|BEHAVIORAL|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
219410156|NCT06409078|DEVICE|repeated transcranial magnetic stimulation treatment group|Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.
219410157|NCT06409078|DRUG|Western medicine group|Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
219569174|NCT00882206|DRUG|methotrexate|\*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
219569175|NCT00882206|DRUG|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
219569176|NCT00882206|DRUG|prednisone|40mg/m2/day divided BID (days 5 - 33)
219003287|NCT00708006|DRUG|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
219003288|NCT04461730|DEVICE|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
219003289|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
219569177|NCT00882206|DRUG|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
219569178|NCT00882206|DRUG|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
219569179|NCT01279252|DRUG|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
219569180|NCT00027742|BIOLOGICAL|pegylated interferon alfa|
219569181|NCT00027742|DRUG|temozolomide|
219569182|NCT02936687|DRUG|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
219410158|NCT02730507|DEVICE|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
219410159|NCT02730507|DEVICE|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
219410160|NCT02635737|DEVICE|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
219410161|NCT00300300|PROCEDURE|Computer-assisted surgery|no description
219410162|NCT00347854|OTHER|Systane Free lubricant eye drops|
219410163|NCT00347854|OTHER|Visine Tears Lubricant Eye Drops|
219410164|NCT00347854|OTHER|Refresh Liquigel Lubricant Eye Drops|
219410165|NCT00347854|OTHER|Refresh Plus Lubricant Eye Drops|
219410166|NCT00937768|DRUG|Goserelin Acetate|Given SC
219410167|NCT00937768|OTHER|Laboratory Biomarker Analysis|Correlative studies
219569183|NCT02936687|DRUG|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
219569184|NCT02936687|DRUG|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
219569185|NCT02936687|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
219410168|NCT00937768|DRUG|Leuprolide Acetate|Given IM
219410169|NCT00937768|OTHER|Quality-of-Life Assessment|Ancillary studies
219410170|NCT02117167|DRUG|AZD2014|Target: m-TOR
219410171|NCT02117167|DRUG|AZD4547|Target: FGFR
219569186|NCT02936687|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
219569187|NCT02936687|OTHER|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
219569188|NCT02936687|DRUG|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
219569189|NCT01322971|DRUG|Metronidazole|Metronidazole 500mg orally twice daily for seven days
219569190|NCT01322971|DRUG|Placebo|Placebo will be administered orally twice daily for seven days
219569191|NCT04977609|BEHAVIORAL|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
219410172|NCT02117167|DRUG|AZD5363|Target: AKT
219410173|NCT02117167|DRUG|AZD8931|Target: HER2, EGFR
219410174|NCT02117167|DRUG|Selumetinib|Target: MEK
219410175|NCT02117167|DRUG|Vandetanib|Target : VEGF, EGFR
219410176|NCT02117167|DRUG|Standard maintenance for squamous NSCLC|
219410177|NCT02117167|DRUG|Pemetrexed|Standard maintenance for non squamous NSCLC
219410178|NCT02117167|DRUG|Durvalumab|Target: PD-L1
219410179|NCT02117167|DRUG|savolitinib|target : MET
219410180|NCT02117167|DRUG|Olaparib|target : PARP
219410181|NCT03265509|DIETARY_SUPPLEMENT|glutamine supplementation|30 g/day glutamine supplementation for three months
219410182|NCT03265509|DIETARY_SUPPLEMENT|fantomalt supplementation|30 g/day fantomalt supplementation for three months
219410183|NCT00129805|DRUG|MCI-9042|
219410184|NCT00129805|DRUG|Aspirin|
219410185|NCT03342482|OTHER|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
219410186|NCT01687413|RADIATION|Intensity-modulated radiation therapy (IMRT)|
219410187|NCT01687413|DRUG|Cisplatin|
219410188|NCT03122028|DEVICE|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
219410189|NCT04883580|DEVICE|Navigation and Positioning System for Orthopedic Surgeries|"Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation"
219410190|NCT01574313|PROCEDURE|stellate ganglion block|stellate ganglion block
219410191|NCT01574313|DRUG|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
219569192|NCT04977609|BEHAVIORAL|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
219569193|NCT04977609|BEHAVIORAL|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
219569194|NCT03717493|BEHAVIORAL|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
219569195|NCT00982891|DRUG|Opioid (morphine sulphate) in low dose|individualized titration
219569196|NCT00932945|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
219410192|NCT01574313|DRUG|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
219410193|NCT01574313|DRUG|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
219410194|NCT04357379|BEHAVIORAL|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
219410195|NCT02708043|OTHER|Flexible-Laryngeal Mask Airway|
219410196|NCT00306917|DEVICE|non-coated femoral hip stem|total hip replacement
219410197|NCT00306917|DEVICE|coated femoral hip stem|total hip replacement
219410198|NCT07020273|BEHAVIORAL|ELEVATE|ELEVATE uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools).
219410199|NCT07020273|BEHAVIORAL|ELEVATE-S|ELEVATE-S uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools) and implementation strategies to support patients with chronic care model-informed self-management support (patient centered flexible goals and patient-generated health data).
219756732|NCT06399484|OTHER|Manual mobilizations of the median nerve|"Slippage of the median nerve in the wrist: the subject's starting position (P0) will be recumbent supine with the cervical spine in a neutral position, the shoulder girdle in neutral position, 30º of glenohumeral abduction in neutral rotation, 90º of elbow flexion, prone-supination of the neutral forearm, wrist and fingers in neutral position. From this position the movements will be 1) Glenohumeral abduction up to 90º; 2) Glenohumeral external rotation to the frontal plane; 3) Supination of the forearm; 4) Extension of the wrist and fingers; 5) Elbow extension. This position is will combine with an ipsilateral cervical inclination (distal sliding). The proximal slide is carried out bringing the fingers of the hand towards the flexion while performing a contralateral cervical tilt.~Median nerve tension: the starting position and movements are the same described above but this time it will be done with contralateral cervical tilt."
219756733|NCT06399484|OTHER|Wrist movements|Movements of the wrist joint will be performed as a placebo treatment
219756734|NCT03499743|DRUG|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
219756735|NCT03499743|DRUG|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
219756736|NCT03499743|DRUG|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
219756737|NCT05547867|PROCEDURE|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
219756738|NCT05424705|DIAGNOSTIC_TEST|OCT, NIRS|
219756739|NCT03186820|OTHER|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
219756740|NCT03676387|OTHER|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
219756741|NCT02719509|PROCEDURE|Cardiac Ultrasound|
219756742|NCT06831422|DEVICE|Povidone-Iodine|Following electrocautery opening of the dermal layer, patients in the povidine-iodine group (Group B) will receive application of 10% sterile povidone-iodine along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of betadine, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
219756743|NCT06831422|DEVICE|Hydrogen Peroxide|Following electrocautery opening of the dermal layer, patients in the hydrogen peroxide group (Group A) will receive application of 3% sterile-filtered hydrogen peroxide along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of hydrogen peroxide a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
219756744|NCT06831422|DEVICE|Xperience Antimicrobial Wash|Following electrocautery opening of the dermal layer, patients in the patients in the Xperience group (Group C) will receive application of the Xperience antimicrobial wash (NextScience, Jacksonville, FL) (32.5 g/L citric acid, 31.3 g/L sodium citrate, and 1.00 g/L sodium lauryl sulfate in sterile water) along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of Xperience, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
219410200|NCT05030285|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
219410201|NCT04478682|OTHER|Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application|Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
219410202|NCT02100748|DRUG|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
219410203|NCT02100748|DRUG|Morphine|Morphine 4 mg will be administered every 4 hours
219410204|NCT02100748|DRUG|Placebo|Placebo will be administered every 4 hours
219410205|NCT06116435|BEHAVIORAL|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
219569197|NCT02379780|PROCEDURE|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
219410206|NCT06116435|BEHAVIORAL|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
219410207|NCT06116435|BEHAVIORAL|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
219410208|NCT06116435|BEHAVIORAL|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
219410209|NCT06116435|BEHAVIORAL|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
219410210|NCT01805700|OTHER|Caffeine enhanced energy drink|Comparison of different energy drinks
219569198|NCT02379780|PROCEDURE|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
219569199|NCT01394848|DEVICE|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
219569200|NCT01394848|DEVICE|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
219569201|NCT01394848|DRUG|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
219569202|NCT01394848|DRUG|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
219569203|NCT01552967|DRUG|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
219569204|NCT00024648|DRUG|LErafAON|
219007203|NCT02319993|DRUG|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
219410211|NCT01805700|OTHER|Glucose drink|Glucose drink (containing 84mg glucose alone)
219410212|NCT03047993|DRUG|Azacitidine|Given IV or SC
219410213|NCT03047993|DRUG|Glutaminase Inhibitor CB-839|Given PO
219569205|NCT03676166|DRUG|Cannabis|Inhaled cannabis
219569206|NCT04677855|DRUG|PCUR-101|50 mg capsules
219569207|NCT04677855|DRUG|Dutasteride 0.5 mg|0.5 mg capsules
219569208|NCT04677855|DRUG|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
219569209|NCT04745208|BEHAVIORAL|Simulation based education|high fidelity simulation with moulage
219569210|NCT00655850|DRUG|Paclitaxel|"* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 \_\_\_\_\_\_\_\_80 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_70 mg/m2/weekly"
219569211|NCT00655850|DRUG|Gemcitabine|"Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 \_\_\_\_\_\_\_\_300 mg/m2/weekly~* Dose Level 1 \_\_\_\_\_\_\_\_200 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_150 mg/m2/weekly"
219410214|NCT06693622|BEHAVIORAL|Patient survey|To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
219410215|NCT06874595|OTHER|Cycling exercise at 65% of HRR for 20 minutes followed by HD-tDCS (exercise + HD-tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
219410216|NCT06874595|OTHER|Cycling exercise at 65% of HRR exercise followed by sham HD-tDCS (exercise + sham tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a sham High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
219410217|NCT06874595|OTHER|No exercise followed by HD-tDCS (no exercise + HD-tDCS).|No exercise but a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
219410218|NCT06874595|OTHER|State Anxiety Inventory|"A widely used psychological assessment tool designed to measure both state and trait anxiety. 40 self-report items rated on a 4-point Likert scale (1 = Almost Never to 4 = Almost Always). Higher scores indicate higher levels of anxiety. Scores are compared to normative data to determine if they fall within the range of typical or clinical anxiety."
219410219|NCT06874595|OTHER|Visual Analog Scale for Anxiety|"The Visual Analogue Scale for Anxiety (VASA) is a 100-millimeter line that helps people measure how anxious they feel. The scale has a mark on the left end that indicates not at all anxious and a mark on the right end that indicates very anxious."
219410220|NCT00808327|DRUG|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
219410221|NCT00808327|DRUG|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
219569212|NCT00655850|BIOLOGICAL|Avastin|"* The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions."
219569213|NCT05863624|PROCEDURE|Open hernioplasty|Inguinal hernia is operated using open surgery
219410222|NCT06696365|DEVICE|TMS|The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. MagVenture MagPro X100 is available commercially and has been FDA approved to treat major depressive disorder and obsessive-compulsive disorder.
219410223|NCT02959710|DRUG|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
219410224|NCT02959710|DRUG|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
219410225|NCT02959710|DRUG|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
219410226|NCT07029334|OTHER|Social Prescribing|"The SP intervention consists of a series of intervention components delivered across the SP pathways:~Intervention components~GP:~1. Social prescribing from physician to patient~   Link Worker:~2. Initial phone contact~3. Clarification and follow-up consultations~4. Personalized matching with local services and activities~5. Care coordination~6. Introductory visits to local services and activities~7. Accompanied (if needed)~8. Follow-up conversations~9. Concluding conversations~10. Group-based courses~    GP / Link Worker:~11. Re-prescribing (where appropriate)~Each intervention component is described in detail in the TIDieR checklist"
219410227|NCT07023757|PROCEDURE|Socket preservation|After tooth extraction, the extraction socket will be filled with a collagen plug in one group or a platelet-rich fibrin plug in the other.
219569214|NCT05863624|PROCEDURE|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
219569215|NCT03469817|DIAGNOSTIC_TEST|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
219569216|NCT04507035|DRUG|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
219569217|NCT04429334|DRUG|nangibotide|nangibotide 1.0 mg/kg/h
219569218|NCT04429334|DRUG|placebo|matching placebo
219569219|NCT02165618|OTHER|Medication review, based on but not limited to the RASP list|"Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion"
219569220|NCT04289454|OTHER|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
219569221|NCT01005706|DRUG|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
219569222|NCT01005706|DRUG|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
219007204|NCT02202408|DRUG|SKI2670|Oral, Single Dose
219007205|NCT02202408|DRUG|Placebo|Same shape as the experimental drug
219410228|NCT06692829|PROCEDURE|robotic rehabilitation|In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
219410229|NCT06692829|PROCEDURE|conventional rehabilitation|It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
219410230|NCT06692712|GENETIC|MELPIDA|Gene Therapy agent
219410231|NCT06693440|DRUG|PD-1 Inhibitors|Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
219569223|NCT03919487|PROCEDURE|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
219569224|NCT01567826|DRUG|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]"
219003290|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
219569225|NCT01567826|DRUG|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
219569226|NCT03720574|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
219007206|NCT04134468|DRUG|Pegvorhyaluronidase alfa|IV infusion
219007207|NCT04134468|DRUG|Abraxane|IV infusion
219007208|NCT04134468|DRUG|Gemcitabine|IV infusion
219569227|NCT03720574|DRUG|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
219410232|NCT06692062|RADIATION|Hypofractionated Radiation Therapy|R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
219569228|NCT03023657|OTHER|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
219569229|NCT00040430|DRUG|111In-DAC|
219569230|NCT00040430|PROCEDURE|Diagnostic|
219003291|NCT00615095|OTHER|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
219003292|NCT04567433|DRUG|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
219410233|NCT06692634|OTHER|mechanical ventilation setting|VT reduction, EIP setting, RR reduction, and a new EIP programing.
219756745|NCT06831422|DIAGNOSTIC_TEST|Bacterial Cultures|Four C. Acnes cultures will be obtained for every patient. Once the skin has dried, a culture swab will be applied along the planned incision for all patients (skin culture). Approximately 120 seconds after application of Xperience, hydrogen peroxide or betadine, or after initial incision in the case of the control group, a culture of the dermis will then taken by dragging the culture swab along the length of the exposed dermis (dermis culture). Once the glenohumeral joint is exposed, the surgeon will apply new surgical gloves, and a culture swab will be placed into the joint and along the humeral head (glenohumeral joint culture). An additional culture will then be taken from the air in the operative suite (air culture)
219756746|NCT06831422|PROCEDURE|Shoulder Arthroplasty|All patients will undergo hemiarthroplasty, anatomic total shoulder arthroplasty, or reverse total shoulder arthroplasty in accordance with the appropriate indications and enrollment in this study.
219756747|NCT05243459|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
219756748|NCT05243459|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
219756749|NCT05243459|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
219756750|NCT06581848|DRUG|Elranatamab|According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
219756751|NCT06815575|DRUG|RC220|Administered by intravenous infusion over 60 minutes.
219756752|NCT06815575|DRUG|Doxorubicin (Adriamycin)|60 mg/m2 administered by intravenous infusion over 10 minutes following adminstration of intravenous RC220 on Day 1 of the combination cycles.
219756753|NCT06669754|DRUG|Deucrictibant|Deucrictibant 40mg extended-release tablet for once daily oral use
219756754|NCT06669754|DRUG|Placebo|Placebo
219756755|NCT05442736|DRUG|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
219003293|NCT04567433|DRUG|Hydrocortisone|Hydrocortisone compared to Placebo
219003294|NCT04567433|PROCEDURE|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
219003295|NCT02733068|BIOLOGICAL|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
219003296|NCT02733068|BIOLOGICAL|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
219410234|NCT06112314|DRUG|Brenetafusp|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
219410235|NCT06112314|DRUG|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
219410236|NCT06112314|DRUG|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 16 mg/mL.
219410237|NCT04867655|OTHER|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
219569231|NCT02062801|DRUG|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
219569232|NCT02062801|DRUG|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
219569233|NCT04273919|DEVICE|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
219569234|NCT04273919|DEVICE|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
219569235|NCT01612884|DRUG|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
219569236|NCT01612884|DRUG|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
219569237|NCT01271179|PROCEDURE|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
219569238|NCT01271179|PROCEDURE|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
219569239|NCT04671537|DRUG|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
219569240|NCT01258088|DRUG|AN2728 Ointment|5mg/cm2, BID
219410238|NCT04867655|OTHER|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
219410239|NCT07036952|DRUG|Omega 3 fatty acids|1gm tab twice daily.
219410240|NCT07036952|DRUG|Omega -3 fatty acids|1gm tablet twice daily.
219410241|NCT06880939|DIETARY_SUPPLEMENT|Krill Oil Functional Food|Take 2g of krill oil orally daily, with each krill oil capsule containing 1g, by consuming one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The supplementation period begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
219410242|NCT06880939|DIETARY_SUPPLEMENT|Olive Oil|Instead of taking krill oil orally, use placebo capsules that are visually similar, with the contents being olive oil, each capsule containing 1g. Take one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The duration of intake begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
219410243|NCT07039942|DEVICE|Omnipod 5|"The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.~The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems."
219410244|NCT06704178|DIETARY_SUPPLEMENT|NuBest Tall Growth Protein Powder|NuBest Tall Growth Protein Powder includes a proprietary blend of vitamins, minerals, and probiotics designed to enhance children's health outcomes.
219569241|NCT01258088|DRUG|AN2728 Vehicle|5mg/cm2 BID
219569242|NCT02540499|RADIATION|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
219756756|NCT06262542|OTHER|moxibustion and Chinese herbal medicine group|"Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion."
219756757|NCT06811584|DEVICE|Peanut ball|"Participants will be provided with a mani ball, which will be covered by a cover provided by the investigator. This cover will be changed for each patient. The ball will be placed between the participant's knees, and she will be allowed to use it at least every two hours for a period of 30 minutes. Participants will also have the option to use the balloon more frequently if they wish. Balloon use will be discontinued when the cervical os reaches 10 cm dilation or when the participant is ready to begin the pushing process.~* The positions to be performed with the peanut ball will be:~* Side lying~* Bent position~* Semi-sitting position~* Taylor position."
219756758|NCT00122889|DRUG|Garlic powder with high allicin content|
219003297|NCT00016016|DRUG|cytarabine|Given IV
219003298|NCT00016016|DRUG|mitoxantrone hydrochloride|Given IV
219003299|NCT00016016|DRUG|alvocidib|Given IV
219003300|NCT00016016|OTHER|pharmacological study|Correlative studies
219410245|NCT06704178|DIETARY_SUPPLEMENT|Placebo Powder|The placebo powder is designed to mimic the appearance and taste of the NuBest Tall Growth Protein Powder but does not contain the active ingredients.
219410246|NCT06720922|PROCEDURE|Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
219410247|NCT06720922|PROCEDURE|Open Surgery|Traditional Open Surgery
219410248|NCT00229372|BEHAVIORAL|Prolonged Exposure (PE) therapy|
219756759|NCT00122889|DRUG|Garlic powder with low allicin content|
219756760|NCT00122889|DRUG|Garlic oil|
219756761|NCT00122889|DRUG|Aged garlic|
219756762|NCT06802055|DRUG|Sirolimus (Rapamune®)|Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.
219003301|NCT00016016|OTHER|laboratory procedure|Correlative studies
219003302|NCT06678074|DRUG|Atibuclimab (IC14), 20 mg/kg intravenously, once|monoclonal antibody against CD14
219003303|NCT06678074|OTHER|Placebo, 150 mL intravenously, once|sterile normal saline for injection
219003304|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group I: A total of 20 mL will be injected: 10 mL Ropiclobet (1 ampoule) + 10 mL of 0.9% isotonic saline"
219410249|NCT00187707|DRUG|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
219410250|NCT02472548|BIOLOGICAL|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
219410251|NCT02472548|BIOLOGICAL|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
219410252|NCT02472548|OTHER|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
219410253|NCT05475262|DEVICE|Active white noise|Active white noise of 57 dB - 60 dB from 10 pm to 6 am
219410254|NCT05475262|DEVICE|Inactive white noise|Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
219410255|NCT02687594|DRUG|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
219410256|NCT02532595|PROCEDURE|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
219410257|NCT02532595|PROCEDURE|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
219410258|NCT05741593|OTHER|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
219410259|NCT06724172|BEHAVIORAL|Self-Management|We will universally offer social needs supports (grocery, physical activity, transportation support) widely in use in clinical settings. Patients may elect to receive all, some, or none of the supports. The patient-directed, structured self-management intervention will be provided through mobile health technology (mHealth) and/or mailings, according to patient preference. Participants will receive health information to support health education and behavior change.
219410260|NCT06724172|BEHAVIORAL|Community-Based|As is currently in use broadly by community health workers, participants will complete a detailed social needs assessment and active assistance with referrals to evidence-based home visiting programs; maternal child health services to promote social support and resource access; and services to improve social determinants of health including active enrollment assistance for WIC, SNAP, healthcare and insurance, legal support, housing, job training, mental health and others. Community health workers will deliver group and individual physical activity support and assistance with behavioral goal setting.
219410261|NCT04166045|DEVICE|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
219410262|NCT04166045|DEVICE|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
219410263|NCT06889025|OTHER|Experimental: tASC/CBTp: gamma band electric stimulation for 20 minutes at the beginning of the CBTp session|For the transcranial stimulation we will use the tES device from NeuroMyst,. The gamma pulses are delivered to a study participant via stimulating electrodes positioned at participant's head according to the required technique. The tACS will be applied the first 20 minutes from the classic CBTp session for the experimental group.
219003305|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group II: A total of 20 mL will be injected: 15 mL Ropiclobet (1.5 ampoules) + 5 mL of 0.9% isotonic saline"
219003306|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group III: A total of 20 mL will be injected: 20 mL Ropiclobet (2 ampoules)"
219003307|NCT07031895|COMBINATION_PRODUCT|a bovine-derived graft/xenograft enriched with hyaluronic acid|In study group a bovine-derived graft/xenograft enriched with hyaluronic acid will be placed in the extraction socket after tooth removal.
219003308|NCT07031895|COMBINATION_PRODUCT|a standart bovine-derived graft/xenograft|In comparison group a standard bovine-derived graft/xenograft will be placed in the extraction socket after tooth removal.
219410264|NCT06889025|OTHER|Sham Comparator|For the Sham group the investigators will use the same tES device from NeuroMyst. The Sham stimulation will be applied only for a few seconds in Sham group. The CBTp will follow the same protocol for both arms.
219410265|NCT06734702|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.
219410266|NCT06734702|RADIATION|Hypo-RT and concurrent chemotherapy|Definitive dose of hypofractionated thoracic radiotherapy with concurrent chemotherapy
219410267|NCT06734702|RADIATION|CFRT and concurrent chemotherapy|Definitive dose of conventionally fractionated thoracic radiotherapy with concurrent chemotherapy
219410268|NCT06734702|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
219410269|NCT06891781|DEVICE|Deep Brain Stimulation|AlphaDBS System
219410270|NCT04980846|OTHER|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
219410271|NCT05431140|DEVICE|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
219569243|NCT00156715|DRUG|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
219569244|NCT01680783|DEVICE|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
219569245|NCT01680783|OTHER|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
219569246|NCT03653624|OTHER|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
219569247|NCT04707586|OTHER|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
219569248|NCT05889234|DEVICE|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
219569249|NCT05889234|DRUG|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
219569250|NCT03362996|DIETARY_SUPPLEMENT|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
219569251|NCT03362996|COMBINATION_PRODUCT|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
219569252|NCT03362996|OTHER|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
219569253|NCT02598258|OTHER|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
219569254|NCT05613725|OTHER|Blood sample collection|Blood sample collection
219569255|NCT00057486|DRUG|IL-12|
219410272|NCT07070063|DEVICE|Virtual Reality Therapy|Eight sessions of virtual reality therapy will be administered over a two-week period (four sessions per week, each lasting 20 minutes). The intervention will be delivered using the VRTierOne device (Stolgraf®), which employs a head-mounted display to create a fully immersive environment. Through the integration of visual, auditory, and kinesthetic stimuli, the therapy provides a multi-sensory experience that can have calming and mood-enhancing effects, as well as support psychological engagement and motivation in the rehabilitation process. The virtual environment-designed as a therapeutic garden-is rich in symbols and metaphors derived from Ericksonian psychotherapy. The central element of this environment is the Garden of Revival, a metaphor for the patient's health. Once vibrant and full of life, the garden is now neglected and requires care and effort to be restored. Throughout the therapeutic process, the patient is guided by a symbolic narrative reflecting their individual
219410273|NCT07070063|DEVICE|Pelvic Floor Muscle Electrostimulation with EMG Biofeedback|Eight sessions of pelvic floor muscle electrostimulation combined with EMG biofeedback will be provided over a two-week period (four sessions per week). The intervention will be delivered using a specialized EMG-Biofeedback electrostimulation device equipped with a screen for real-time signal visualization. Vaginal electrodes will be used to ensure precise stimulation and accurate detection of pelvic floor muscle activity. During each 30-minute session, patients will receive symmetrical biphasic rectangular electrical impulses at a frequency of 50 Hz, with a 5-second stimulation phase followed by a 10-second rest period. The intensity of the stimulation will be individually adjusted to ensure both safety and comfort. The integrated biofeedback system will allow participants to observe their muscle activation patterns on the screen, enhancing their awareness and control of pelvic floor function and supporting the learning of correct activation during voluntary contractions.
219410274|NCT05563298|DEVICE|Neuro RX Gamma device|The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
219410275|NCT05563298|DEVICE|Sham Neuro RX Gamma device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
219569256|NCT01819324|BEHAVIORAL|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
219569257|NCT01819324|BEHAVIORAL|Standardized Lifestyle Management|SLM material (every other week for 4 months)
219569258|NCT01129934|DRUG|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
219569259|NCT01129934|DRUG|morphine|Administration of intravenous morphine 0.1 mg/kg
219569260|NCT00573170|DRUG|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
219569261|NCT00573170|DRUG|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
219569262|NCT00573170|DRUG|placebo|placebo
219569263|NCT00167128|DEVICE|hearing aid, Phonak EduLink-FM System|
219003309|NCT06718348|OTHER|Use of the Exoskeleton JAPET.W|Phsysiotherapy sessions with the support of the Exoskeleton JAPET.W
219003310|NCT06741657|DRUG|Litifilimab|Administered as specified in the treatment arm.
219003311|NCT06741657|DEVICE|AI|Administered as specified in the treatment arm.
219003312|NCT06741657|DEVICE|OBI|Administered as specified in the treatment arm.
219003313|NCT06741657|DEVICE|PFS|Administered as specified in the treatment arm.
219569264|NCT03032861|OTHER|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
219569265|NCT04132401|DIAGNOSTIC_TEST|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
219569266|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
219003314|NCT07064200|OTHER|TAP Block|the TAP block is a regional anesthesia technique that targets the somatic nerves supplying the anterior abdominal wall.
219003315|NCT07073417|DRUG|XW003 injection|Subcutaneous injection
219003316|NCT07073417|DRUG|semaglutide injection|Subcutaneous injection
219569267|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
219569268|NCT01060475|DRUG|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
219569269|NCT01060475|DRUG|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
219569270|NCT01565772|RADIATION|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
219569271|NCT01565772|DRUG|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
219410276|NCT00500045|DRUG|nicotinic acid|niacin 1500 mg po qd
219410277|NCT07083700|BEHAVIORAL|Frame Access|FRAME™ provides a collaborative care platform that connects patients with evidence-based resources, education and support from a dedicated care team throughout their reproductive health care journey. More specifically, for patients exploring fertility treatment. Frame supplements the patient experience by providing patients with direct contact to board-certified fertility coaches and resources that can be accessed between appointments in a web-based application. Regular use of Frame's platform may help patients make lifestyle changes that can improve their fertility outcomes as well as boost their emotional health throughout the treatment process and reduce feelings of overwhelm and loneliness which can lead to patients dropping out of care.
219410278|NCT07083531|OTHER|Healthy volunteers without SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
219410279|NCT07083531|OTHER|Healthy volunteers with SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
219410280|NCT07084701|DEVICE|Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD)|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
219410281|NCT07084701|DEVICE|sham-intervention treatment|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
219410282|NCT07082179|DRUG|Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum (cisplatin/carboplatin)|"Induction therapy regimen：Iparomlimab and Tuvonralimab 5 mg/kg, every 3 weeks (q3w), administered via intravenous infusion. Paclitaxel polymer micelles in combination with platinum: In cycle 1, paclitaxel polymer micelles 230 mg/m² administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min. In cycle 2, if the patient's nadir neutrophil count is ≥1.0×10⁹/L and the nadir platelet count is ≥80×10⁹/L after cycle 1, and no grade II-IV non-hematologic toxicities have occurred, then paclitaxel polymer micelles 300 mg/m² will be administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min.~The local treatment regimen is either surgery or standard radiotherapy. The consolidation therapy regimen consists of Iparomlimab and Tuvonralimab for 1 year , with the decision to combine with chemotherapy left to the discretion of the treating physician on an individual basis."
219410283|NCT07082478|DEVICE|in-ear device measuring blood flow|"A small in-ear wearable device will be placed to monitor the blood flow to the head. The investigators will make sure it fits comfortably and show the participant how to use it properly.~Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin of the abdomen to monitor sensor sugar levels.~These sensors will be placed during visit one and will be worn together for 10 days. A followup visit (visit 2) will occur remotely at 4-6 days later. A final visit will occur after 10 days when the device will be removed."
219410284|NCT07084584|DRUG|GB3226|GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles
219410285|NCT07074704|DEVICE|Hi-tACS|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
219410286|NCT07074704|DEVICE|Sham Comparison|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
219410287|NCT06929546|DIAGNOSTIC_TEST|Anti-phospholipid antibodies|Serum samples will be obtained for determination of IgG and IgM isotypes of 4 anti-phospholipid antibodies including anti-cardiolipin (aCL), anti-phosphatidylserine (aPS), anti-phosphatidic acid (aPA) and anti-phosphatidylcholine (aPC) with in-house ELISAs.
219429423|NCT06587360|OTHER|fertiShare control - basic communication skills eLearning course|"self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.~Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying)."
219007209|NCT02648178|DEVICE|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
219007210|NCT02041611|PROCEDURE|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
219007211|NCT00271583|DRUG|CDB-2914|
219007212|NCT00271583|DRUG|levonorgestrel|
219007213|NCT00002602|RADIATION|3D-CRT|3 dimensional conformal radiation therapy
219007214|NCT01840501|DRUG|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
219190232|NCT05401838|BEHAVIORAL|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
219190233|NCT05401838|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
219190234|NCT04512586|PROCEDURE|Conduction System pacing and AV node ablation|See study arm description.
219190235|NCT04512586|PROCEDURE|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
219190236|NCT04004442|DRUG|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
219190237|NCT04004442|DRUG|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
219190238|NCT05104463|DRUG|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
219410288|NCT06930469|BEHAVIORAL|structured team model with shared decision-making|Structured team model based on shared decision-making model: ① Maternal Critical Care Review: Pre-hospital (prenatal checkup): Obstetricians and nurses conduct regular prenatal checkups for mothers, identify high-risk mothers, and set up high-risk maternal health records. Referral: Critically ill pregnant women establish a green channel for timely referral to the obstetrics department or ICU, and contact the relevant personnel of the structured management team. Assessment: The multidisciplinary team conducts a comprehensive assessment of the extent of the maternal condition, vital signs, and laboratory test results. Identification: Identify the main causes of critical maternal illness and potential risks, such as hemorrhage, infection, and organ failure. Rescue plan: according to the assessment results, formulate a personalized rescue plan and clarify the responsibilities and tasks of each department. Monitoring: real-time monitoring of maternal vital signs and changes in condition, a
219410289|NCT06930469|BEHAVIORAL|conventional multidisciplinary resuscitation care|"The observation group implemented a structured team model based on a shared decision-making model, which operated as follows:~(1) Constructing a structured management team: multidisciplinary medical and nursing staff, including obstetricians, ICU doctors, obstetric nurses, ICU nurses, head nurses, anesthesiologists, ultrasonographers, and family members of the patient's main companions, are divided into small teams according to their functions, and each small team has a team leader who is responsible for the coordination of the overall situation and the rapid coordination of information. Obstetricians and ICU doctors are responsible for life support, obstetric evaluation, condition monitoring and development of resuscitation plan for critically ill mothers. Anesthesiologists are responsible for anesthesia management, pain control and intraoperative resuscitation support. The nurse manager coordinates the nursing team to ensure the standardization of rescue care. Obstetrician and ICU nu"
219569272|NCT01565772|DRUG|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
219569273|NCT02993692|DEVICE|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
219569274|NCT00280072|DEVICE|Renal Assist Device|
219756763|NCT06802055|DRUG|Cyclosporin A (CsA)|Cyclosporine A 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function.
219756764|NCT05063786|BIOLOGICAL|Trastuzumab|"6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
219756765|NCT05063786|DRUG|Alpelisib|300 mg oral once daily.
219756766|NCT05063786|DRUG|Fulvestrant|500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
219756767|NCT05063786|DRUG|Vinorelbine|Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
219190239|NCT01885689|DRUG|clofarabine|Given IV
219190240|NCT01885689|DRUG|melphalan|Given IV
219190241|NCT01885689|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
219190242|NCT01885689|DRUG|tacrolimus|Given IV or PO
219190243|NCT01885689|DRUG|sirolimus|Given PO
219190244|NCT01885689|OTHER|Pharmacological Study|Correlative studies
219190245|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
219190246|NCT05267470|DRUG|Docetaxel|IV infusion
219190247|NCT05267470|DRUG|Pembrolizumab|IV infusion
219190248|NCT05267470|DRUG|Carboplatin|IV infusion
219190249|NCT05267470|DRUG|Paclitaxel|IV infusion
219190250|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
219003317|NCT07071363|DRUG|Depigmenting Cosmetic Serum (Applied Morning and Evening)|Participants in Group 1 receive a depigmenting cosmetic serum with non-drug actives applied morning and evening, plus a placebo cream without hydroquinone applied in the evening. Group 2 receives a placebo serum (no active depigmenting ingredients) applied morning and evening, and a hydroquinone 4% cream applied in the evening. All participants apply an SPF50+ sunscreen in the morning throughout the 84-day study. The cosmetic serum is the investigational product; hydroquinone serves as the active comparator. Placebo products are visually matched to their respective actives to ensure blinding. The study distinguishes each intervention by active ingredients, timing of application (morning/evening), and role (test vs. reference vs. supportive care). All products are applied topically, and the regimen remains fixed across the study duration.
219003318|NCT06755060|COMBINATION_PRODUCT|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. Patients in the intervention group will undergo standard ophthalmic examinations, with clinical decisions guided by the recommendations generated by the AI system. In contrast, patients in the control group will receive only standard ophthalmic examinations and treatment, without the support of AI-assisted decision-making tools.
219410290|NCT07082660|DEVICE|High-Frequency Capacitive-Resistive Diathermic Current Therapy (TECAR)|20 minutes per session, 3 times per week for 4 weeks
219410291|NCT07082660|BEHAVIORAL|Lumbal Stabilization Exercise Program|3 sessions per week for 4 weeks, each session includes core stabilization and lumbar control exercises (12 sessions total).
219410292|NCT07082491|BEHAVIORAL|Mindfulness-based stress reduction|The intervention consists of 8 in-person sessions over a period of 8 weeks, with each session lasting about three hours, once per week, with an intensive full-day practice session lasting 7 hours. The instructors provide audio recordings at each session to be used as daily practice. The MBSR program is an introductory pathway to mindfulness practices that works through the systematic and continuous cultivation of specific mental states that foster a different relationship with stress.
219410293|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
219569275|NCT01884922|DRUG|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
219569276|NCT01884922|DRUG|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
219569277|NCT03525730|DRUG|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
219569278|NCT03525730|DRUG|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
219569279|NCT01747122|DEVICE|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
219569280|NCT01747122|DEVICE|Epidural|
219569281|NCT04583748|BEHAVIORAL|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
219569282|NCT04583748|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
219569283|NCT06427525|OTHER|Mobile application-based adolecent obesity education|Mobile application-based adolecent obesity education
219756768|NCT05063786|DRUG|Capecitabine|1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
219003319|NCT06904469|OTHER|Access to a digital clinic|This intervention grants access to a digital clinic that provides chat-based primary care consultations via phone application and website.
219003320|NCT07090655|DRUG|Budoprutug|Subcutaneous or IV administration
219003321|NCT07090655|DRUG|Placebo|Placebo comparator
219007215|NCT01840501|DRUG|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
219410294|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
219569284|NCT04060342|DRUG|GB1275|Oral
219569285|NCT04060342|DRUG|nab-paclitaxel and gemcitabine|IV infusion
219569286|NCT04060342|DRUG|pembrolizumab|IV infusion
219569287|NCT00269542|DRUG|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
219756769|NCT05063786|DRUG|Eribulin|1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
219756770|NCT06696768|BIOLOGICAL|Bevacizumab|Given IV
219410295|NCT07082205|BIOLOGICAL|Antimalarial monoclonal antibodies|L9LS Antimalarial monoclonal antibodies (mMAbs)
219410296|NCT07082205|DRUG|Dihydroartemisinin - Piperaquine (DP)|Post-Discharge Malaria Chemoprevention
219410297|NCT07082205|BIOLOGICAL|Placebo mMAB|Placebo anti malarial monoclonal antibody (placebo mMAB) which is Normal saline
219410298|NCT07082205|DRUG|Placebo PDMC|Placebo PDMC course which comprises placebo DP oral tablets
219410299|NCT00992446|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219410300|NCT00992446|DRUG|Bortezomib|Given IV
219410301|NCT00992446|DRUG|Carmustine|Given IV
219410302|NCT00992446|DRUG|Cytarabine|Given IV
219410303|NCT00992446|DRUG|Etoposide|Given IV
219410304|NCT00992446|DRUG|Melphalan|Given IV
219003322|NCT06734468|BEHAVIORAL|Lifestyle Management|"Each subject will receive a personalized intervention plan, comprised of:~1. An individualized exercise plan guided by a mobile phone app.~2. Healthy diet and nutrition recommendations.~3. Theriome metabolomics testing and individualized recommendations that include dietary supplements.~4. Guidance on healthy sleep patterns, stress management, and maximizing social engagement, as appropriate."
219410305|NCT00992446|DRUG|Rituximab|Given IV
219410306|NCT00992446|DRUG|Vorinostat|Given PO
219410307|NCT06829381|PROCEDURE|Tailored BPL length|Total bowel length measure and BPL will be 40% of total bowel length ensuring at least 250 cm common channel
219410308|NCT06829381|PROCEDURE|Control - BPL 180 cm|Total bowel length measure and BPL will be180 cm
219007216|NCT01840501|DRUG|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
219410309|NCT02931695|OTHER|evaluation of QT interval duration|ECG to evaluation of QT interval duration
219410310|NCT02931695|OTHER|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
219410311|NCT06916754|BEHAVIORAL|Combined Behavioral Intervention|The intervention includes 12 weekly sessions integrating Motivational Interviewing, Cognitive Behavioral Therapy, and relapse prevention strategies. Techniques include enhancing motivation to change, identifying cognitive distortions, managing high-risk situations, and developing alternative coping strategies.
219410312|NCT06916754|BEHAVIORAL|Ericksonian Hypnotherapy|This therapy includes 12 weekly sessions involving individualized trance induction, indirect suggestion, therapeutic metaphor, and ego-strengthening techniques. The sessions follow Ericksonian principles and are delivered by certified hypnotherapists.
219410313|NCT06922552|PROCEDURE|Giomer pit and fissure sealant with etching applied on Permanent Molars Affected by MIH|"* Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel An adequate amount of primer will be dispensed on the enamel surface of the pit and fissure using a brush then will be left undisturbed for 5sec. Gentle air blow for 3 sec and then dryness with stronger stream of air until a thin and uniform bonding layer is obtained.~* The giomer sealant (BeautiSealant, Shofu, Kyoto, Japan) will be applied into the occlusal fissures applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow."
219756771|NCT06696768|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219756772|NCT06696768|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219007217|NCT01840501|DRUG|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
219007218|NCT02205814|DRUG|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
219007219|NCT02205814|DRUG|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
219007220|NCT02205814|DRUG|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
219007221|NCT02205814|DRUG|Placebo comparator|Single intra-articular injection of placebo
219410314|NCT06922552|PROCEDURE|Resin based sealant applied on Permanent Molars Affected by MIH|"Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel~* The resin sealant (UltraSeal XT™ hydro™) will be applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow into the pit and fissures. Photo - curing for the sealant will be done for 20 seconds using LED light curing unit. The tip of the light will be held as close as possible to the sealant, without actually touching the sealant.~the surfaces will be checked with an explorer to ensure that no voids were present."
219410315|NCT06923501|DEVICE|Tools for Coping with Cancer Calm Health mobile app program|"Participants will be asked to use a 13-session self-management program Tools for Coping with Cancer within the Calm Health mobile app."
219410316|NCT06923241|BEHAVIORAL|menu labelling type|Participants will be given a restaurant's menu with calorie information or a menu with calorie information and NS labelling.
219429424|NCT04323150|DEVICE|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
219429425|NCT04323150|DEVICE|Conventional suction system|The using of open (conventional) suctioning
219429426|NCT06330285|OTHER|e-learning|"CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
219429427|NCT06330285|OTHER|face to face learning|"CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
219756773|NCT06696768|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219756774|NCT06696768|BIOLOGICAL|Emavusertib|Given PO
219756775|NCT06696768|DRUG|Fluorouracil|Given IV
219410317|NCT06924879|OTHER|Mindfulness-Based Pregnancy Stress Reduction Program|Mindfulness-Based Pregnancy Stress Reduction Program Training Content Session 1 Introduction to the program Course preparation Orientation process Session 2 Introduction to Mindfulness practices Session 3 Focusing on the moment Session 4 Coping with thoughts Connecting with pregnant women's bodies Becoming aware of their thoughts, feelings and bodily senses Session 5 Releasing emotions and thoughts Session 6 Awareness Session 7 Keeping distance from thoughts Session 8 Accepting Awareness
219410318|NCT06926374|PROCEDURE|Robotic surgery using the Sentire Surgical System|Robotic surgery using the Sentire Surgical System
219410319|NCT06929767|OTHER|biomarker-guided decision making|-recommendations for antibiotic and steroid Rx provided to study physician based on bio-marker (serum CRP, blood eosinophils, sputum colour) results.
219410320|NCT06929767|OTHER|GOLD recommendations|Recommendations provided to study physician for Rx of antibiotics and steroids based on current GOLD recommendations
219410321|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
219410322|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
219410323|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
219410324|NCT06930690|DRUG|Dexamethasone Sodium Phosphate Injection|One time dose of dexamethasone sodium phosphate given intravenously at the time of surgery
219410325|NCT04940936|BEHAVIORAL|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
219410326|NCT06930911|BIOLOGICAL|Antibiotic therapy|Evaluating antibiotic exposure in premature infants before 35 weeks in a tertiary care neonatal unit
219569288|NCT00269542|DRUG|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
219569289|NCT04107155|DIETARY_SUPPLEMENT|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
219569290|NCT04107155|DIETARY_SUPPLEMENT|Placebo|Placebo
219569291|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
219569292|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
219569293|NCT03696355|DRUG|GDC-0084|Given PO
219569294|NCT03696355|RADIATION|radiation therapy|Both photon and proton therapy modalities will be allowed.
219569295|NCT05515016|PROCEDURE|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
219569296|NCT04719104|DEVICE|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
219569297|NCT04628104|RADIATION|cardiac magnetic resonance|"o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation"
219569298|NCT01027741|BEHAVIORAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
219569299|NCT01027741|BEHAVIORAL|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
219569300|NCT01027741|BEHAVIORAL|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
219569301|NCT02196519|DEVICE|Sylys Surgical Sealant|
219569302|NCT02993770|PROCEDURE|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
219569303|NCT02993770|PROCEDURE|External DCR|External DCR
219569304|NCT00276549|DRUG|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219569305|NCT00276549|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219569306|NCT00000674|DRUG|Pyrimethamine|
219569307|NCT00000674|DRUG|Leucovorin calcium|
219569308|NCT00000674|DRUG|Clindamycin|
219410327|NCT06930547|OTHER|Experimental|"In this study, the experimental group will undergo a smoking cessation training program consisting of eight sessions over four weeks, conducted twice a week. Each session is planned to last approximately 40-45 minutes.~During the program, before each session, the previous session will be reviewed to reinforce learning and establish continuity between sessions. Feedback will be collected to ensure engagement and comprehension. At the end of each session, a summary of the session's agenda will be provided.~Before each session, both the experimental and control groups will be evaluated using a smoking cessation status form to assess their progress. Additionally, follow-up assessments will be conducted one month and three months after the program to test the retention of the training's effectiveness."
219410328|NCT06930378|PROCEDURE|Nerve Suture|"Sensory nerve coaptations will be performed~1. either by suturing the donor to the recipient nerve immediately (1 coaptation)~2. or by interposing an autograft originating from the zone of the flap to be discarded (2 coaptations). The anterior cutaneous branch (ACB) of the 3rd or 4th intercostal nerve (ICN) will be connected to the sensory branch of the 10th, 11th or 12th ICN of the flap."
219410329|NCT06929611|OTHER|Combined continous caudal epidural with general anaesthesia|"A 17- or 18-gauge Tuohy-type needle will be inserted in the midline into the caudal canal. An initial dose of 20 ml of 0.25% bupivacaine will be injected in the caudal canal in order to perform sensory block and spare motor power. Then a dose of 10 ml 0.25% bupivacaine will be injected through the epidural catheter every 1-hour intra operatively and at 0-hour and 1-hour post operative then the catheter will be removed 1 hour post operative.~-The following factors will be assessed:~1. Intra operative heart rate and blood pressure.~2. Post operative pain assessment according to numeric pain scale score.~3. Time to rescue analgesia (intravenous analgesia administered after surgery).Patients with numeric pain scale score ≥ 3 at any point of time, will receive intravenous morphine 5mg.~4. Estimated blood loss and surgeon satisfaction of surgical field.~5. Total intra operative and post operative analgesia.~6. Common complications."
219410330|NCT06930859|DRUG|Ribociclib|CDK4/6 inhibitor
219410331|NCT06930859|DRUG|Letrozole|Aromatase inhibitor
219410332|NCT06930859|DRUG|Anastrozole|Aromatase inhibitor
219410333|NCT05511753|DEVICE|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
219003323|NCT06918041|DEVICE|FiberLocker® System (encompassing FiberLocker® Instrument SN & SpeedPatch® PET)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue.
219003324|NCT07114055|DRUG|ebastine|Tab. Ebastine 20mg once daily at night
219003325|NCT07114055|DRUG|Placebo|Tab. Placebo once daily at night
219007222|NCT03766308|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet
219410334|NCT06940388|DRUG|Tislelizumab|During ChemoImmunotherapy: Patients in the investigational arm will receive 8 cycles of tislelizumab 150 mg IV on Day 1, followed by mFOLFOX6 (Q2W).
219410335|NCT06940388|DRUG|Total neoadjuvant therapy (TNT)|Patients will be treated with 6 weeks of capecitabine-based CRT followed 4 weeks later by 16 weeks of chemotherapy with mFOLFOX6, Q2W.
219410336|NCT06939062|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Endoscopic transurethral enucleation of the prostate using bipolar energy
219410337|NCT06939062|PROCEDURE|Bipolar transurethral resection of the prostate (B-TURP)|Endoscopic transurethral resection of the prostate using bipolar energy
219429428|NCT05001061|DRUG|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
219569309|NCT00608517|BIOLOGICAL|anti-thymocyte globulin|Given IV
219569310|NCT00608517|DRUG|cyclophosphamide|Given IV
219569311|NCT00608517|DRUG|fludarabine phosphate|Given IV
219569312|NCT00608517|DRUG|methylprednisolone|Given IV
219569313|NCT00608517|RADIATION|total-body irradiation|Given daily for 1-4 days
219569314|NCT05778955|GENETIC|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
219569315|NCT04862156|DEVICE|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
219569316|NCT03805308|PROCEDURE|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
219569317|NCT04091958|PROCEDURE|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
219569318|NCT05568693|BIOLOGICAL|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
219569319|NCT04686838|BEHAVIORAL|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
219569320|NCT04686838|BEHAVIORAL|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
219569321|NCT03795714|DIAGNOSTIC_TEST|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
219569322|NCT04031638|OTHER|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
219569323|NCT00099710|DIETARY_SUPPLEMENT|Curcumin C3 Complex|
219569324|NCT04783974|DEVICE|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
219569325|NCT03844958|OTHER|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
219569326|NCT03844958|OTHER|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
219569327|NCT05452135|OTHER|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
219569328|NCT01247246|DRUG|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
219569329|NCT01247246|DRUG|Placebo|Placebo
219410338|NCT06937775|OTHER|Periodontal measurements (plaque index, gingival index and probing pocket depth scores )|Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.
219410339|NCT06937775|OTHER|Biochemical Sample Supply (Collection of serum and saliva samples)|"Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses.~For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day.~Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes."
219410340|NCT06937775|PROCEDURE|Rapid maxillary expansion with Hyrax appliance|Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.
219410341|NCT04321694|DRUG|KHK2455|
219410342|NCT06951672|DEVICE|This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.|The ability to deploy the annuloplasty ring in a percutaneous fashion affords an improved safety profile for surgical candidates, as well as surgical style solution for those patients that are at elevated risk for surgery due to comorbidities and advanced age. This early feasibility study allows treatment of higher risk surgical candidates with a surgical- level annuloplasty repair therapy by the AMEND™ Implant.
219410343|NCT06954025|DRUG|High-intensity inpatient MDMA-assisted psychotherapy|"Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg~Psychotherapy: manualized psychotherapy"
219410344|NCT02503176|DRUG|KCT-0809 ophthalmic solution|
219410345|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
219410346|NCT03744546|DRUG|ABBV-8E12|Solution for infusion
219410347|NCT07082634|PROCEDURE|Socket shield concept and immediate implant placement|"Tooth Sectioning: The tooth will be sectioned mesiodistally using a fissure bur, preserving the buccal segment.~Palatal fragment extraction: carefully after sectioning the tooth , the palatal fragment is luxated and extracted with the most important factor is taking care of the buccal part not to become loose , the extraction is done using a periotome to be minimally invasive and to preserve the bone from major damage.~Shield Preparation: The buccal fragment is reduced to bone level using a round bur, a beveled edge is created using a diamond football bur, and the shield is thinned to maintain structural integrity.~Implant Site Preparation: Sequential osteotomy performed under copious irrigation, ensuring primary stability.~Implant Placement: A Megagen implant is inserted"
219410348|NCT06085924|DRUG|SoC|COVID-19 treatment as per government guidance
219410349|NCT06085924|OTHER|Disease description|No intervention
219410350|NCT03906344|DRUG|INCB052793|
219410351|NCT03675737|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
219410352|NCT03675737|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
219410353|NCT03675737|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
219410354|NCT03675737|DRUG|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
219410355|NCT03675737|DRUG|capecitabine|Administered orally BID on Days 1 to 14 Q3W
219410356|NCT03675737|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
219410357|NCT05841680|BEHAVIORAL|SSI Module|Single Session Intervention (SSI) module for youth with anxiety disorders and their parents. The SSI module will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI module will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts.
219410358|NCT05380388|BIOLOGICAL|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
219410359|NCT05380388|BIOLOGICAL|HBV vaccine|HBV Vaccine
219410360|NCT05383235|OTHER|ROUTINE CARE|1\. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
219429429|NCT00981318|DRUG|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
219756776|NCT06696768|DRUG|Leucovorin Calcium|Given IV
219756777|NCT06696768|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219756778|NCT06696768|DRUG|Oxaliplatin|Given IV
219756779|NCT06696768|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219756780|NCT05050084|DRUG|Bicalutamide|Drug
219410361|NCT05383235|DEVICE|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2\. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing."
219410362|NCT01667068|OTHER|Comprehensive non invasive cardiovascular examination|"* Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
219410363|NCT03754933|BIOLOGICAL|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
219410364|NCT03754933|DRUG|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia.
219410365|NCT00213928|DRUG|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
219410366|NCT02964286|DEVICE|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
219410367|NCT02522832|OTHER|Titre 1|Virus infection
219410368|NCT02522832|OTHER|Titre 2|Virus infection
219410369|NCT02522832|OTHER|Titre 3|Virus infection
219410370|NCT06234618|OTHER|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
219410371|NCT00683475|BIOLOGICAL|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
219410372|NCT00683475|DRUG|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
219410373|NCT00683475|DRUG|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
219410374|NCT00683475|BIOLOGICAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
219410375|NCT01524172|BEHAVIORAL|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
219410376|NCT01524172|BEHAVIORAL|Standard Mental Health Treatment|Trauma and evidence informed therapy
219410377|NCT02922634|OTHER|Mini Cog|short cognitive screen, short Frailty screen
219410378|NCT03611517|BEHAVIORAL|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
219410379|NCT04637945|DIETARY_SUPPLEMENT|ACRB|Product will be consumed once daily, preferably with breakfast.
219410380|NCT04637945|OTHER|Placebo|Product will be consumed once daily, preferably with breakfast.
219410381|NCT04485091|COMBINATION_PRODUCT|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
219410382|NCT04485091|OTHER|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
219429430|NCT02624011|BEHAVIORAL|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
219429431|NCT00013455|DEVICE|Hearing|
219429432|NCT00824928|PROCEDURE|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
219007223|NCT03766308|DIETARY_SUPPLEMENT|ADA diet|ADA diet
219003326|NCT07114536|DIETARY_SUPPLEMENT|Calcium-a-ketoglutarate|Description: Participants in the intervention group will receive oral calcium alpha-ketoglutarate (CaAKG) in granular tablet form. Each tablet contains 0.5 grams of CaAKG.Participants will take two tablets twice daily (morning and evening). The total daily dose is 2 grams. The intervention period will last for 12 weeks. CaAKG is a stabilized form of alpha-ketoglutarate that enhances bioavailability and provides supplemental calcium. The tablets are identical in appearance and texture to those in the placebo group to maintain blinding.
219410383|NCT02723604|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
219410384|NCT03191669|OTHER|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
219410385|NCT00696462|DEVICE|forced-air warming|forced-air warming device
219410386|NCT03397927|DEVICE|orthosis|
219410387|NCT03978182|DEVICE|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
219410388|NCT00310570|DEVICE|Circumferential thermoplastic thimble splint|
219410389|NCT00310570|DEVICE|"dorsal aluminium foam Mexican Hat splint"|
219410390|NCT00310570|DEVICE|stack splint (control)|
219410391|NCT01258530|DRUG|over-encapsulated oseltamivir|75 mg once
219410392|NCT01258530|DRUG|oseltamivir|75 mg once
219410393|NCT02130479|BEHAVIORAL|Contingency Management-Family Engagement|
219410394|NCT02130479|BEHAVIORAL|Treatment as Usual|
219410395|NCT00352755|PROCEDURE|Surgical debulking with peritonectomy|
219003327|NCT07114536|OTHER|Placebo(starch)|Participants in the placebo group will receive oral tablets identical inappearance and texture to the CaAKG tablets, but containing starch with no active calciumalpha-ketoglutarate. Each tablet weighs 0.5 grams. Participants will take two tablets twicedaily (morning and evening), for a total daily intake of 2 grams. The placebo tablets arepackaged and administered in the same manner as the CaAKG tablets to ensure blindingthroughout the 12-weekintervention period.
219003328|NCT04847557|DRUG|Tirzepatide|Administered SC
219410396|NCT00352755|DRUG|Intraperitoneal 5FU|
219410397|NCT00352755|DRUG|FOLFOX|
219410398|NCT05293652|OTHER|Iontophoresis|Hydrocortisone iontophoresis
219003329|NCT04847557|OTHER|Placebo|Administered SC
219003330|NCT06932952|DRUG|BYON4228 + Pembrolizumab|BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every three weeks until disease progression or unacceptable toxicity. Different doses. Pembrolizumab IV infusion (200 mg) every three weeks from the second treatment cycle onwards.
219410399|NCT05293652|OTHER|Phonophoresis|Hydrocortisone Phonophoresis
219410400|NCT05293652|OTHER|traditional PT program|Ultrasound and deep friction massage
219410401|NCT04597281|OTHER|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
219410402|NCT04836819|DRUG|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
219429433|NCT02275598|DRUG|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
219429434|NCT02275598|DRUG|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
219756781|NCT05050084|DRUG|Buserelin|Drug
219756782|NCT05050084|DRUG|Darolutamide|Given PO
219756783|NCT05050084|DRUG|Degarelix|Drug
219756784|NCT05050084|DRUG|Flutamide|Drug
219756785|NCT05050084|DRUG|Goserelin|Drug
219756786|NCT05050084|DRUG|Histrelin|Drug
219756787|NCT05050084|DRUG|Leuprolide|Drug
219756788|NCT05050084|RADIATION|Radiation Therapy|Undergo RT
219756789|NCT05050084|DRUG|Relugolix|Drug
219756790|NCT05050084|DRUG|Triptorelin|Drug
219756791|NCT01005290|DRUG|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
219756792|NCT01005290|DRUG|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
219756793|NCT04885621|DIETARY_SUPPLEMENT|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
219410403|NCT04836819|DRUG|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
219410404|NCT04836819|DRUG|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
219410405|NCT01278017|DRUG|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
219410406|NCT00478725|DRUG|GW786034, oral|oral, 800 mg
219569330|NCT05633238|BEHAVIORAL|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
219569331|NCT02193607|PROCEDURE|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
219569332|NCT02193607|PROCEDURE|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
219756794|NCT01920243|BEHAVIORAL|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
219569333|NCT00666887|DRUG|Minocycline|100 mg twice daily to be taken for up to 2 years
219569334|NCT00666887|DRUG|Placebo|placebo twice daily for 2 years
219569335|NCT03029117|PROCEDURE|correction of rheumatic valve lesions|
219756795|NCT06523231|BIOLOGICAL|Shigella4V2|Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.
219756796|NCT06523231|BIOLOGICAL|MenACWY|Control vaccine
219756797|NCT05466383|BEHAVIORAL|Exercise|Exercise rehabilitation with Schroth method
219756798|NCT05466383|DEVICE|Brace|Wear an orthopedic brace
219003331|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 1|Qualia NAD+ version 1 manufactured by Qualia Life Sciences
219003332|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 2|Qualia NAD+ version 2 manufactured by Qualia Life Sciences
219003333|NCT07132801|DIETARY_SUPPLEMENT|Placebo|Rice Flour
219410407|NCT00478725|DRUG|GW786034, IV|IV, 5 mg
219410408|NCT00478725|DRUG|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
219410409|NCT01760993|DRUG|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
219569336|NCT02588079|BEHAVIORAL|Internet-based cognitive behavioral therapy|
219569337|NCT04702763|OTHER|Eye-Tracker®T2 + e-VOG|"* 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
219569338|NCT04702763|OTHER|e-VOG + Eye-Tracker®T2|"* 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
219569339|NCT00457210|PROCEDURE|Brain Radiotherapy/Stereotactic Radiosurgery|
219569340|NCT02988869|DRUG|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
219569341|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
219756799|NCT06735859|BEHAVIORAL|Comparison of eating windows intervention|Participants will be randomized into two groups to follow either eating window for 12 months, with normocaloric meal plans based on the Mediterranean diet adapted to Brazilian culture. After 12 months, a 3-month washout period will follow, during which participants return to their usual eating patterns. The groups will then be swapped to follow the opposite eating window for another 12 months. Finally, a new data collection will be conducted 3 months post-intervention to analyze the stability of behavior.
219756800|NCT06846359|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
219756801|NCT06846359|BEHAVIORAL|Educational module|self-guided online module reviewing chronic GI conditions, pathophysiology, and alternative treatment options.
219756802|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
219003334|NCT07131527|DRUG|Gabapentin|oral Gabapentin will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
219003335|NCT07131527|DRUG|Diclofenac Sodium|oral diclofenac sodium will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
219410410|NCT04366752|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
219003336|NCT07132476|OTHER|No adjuvant therapy|Observe and record hypoglycemia
219003337|NCT07132892|DEVICE|Galaflex Lite Scaffold|The GalaFLEX LITE is a surgical mesh scaffold composed of poly-4-hydroxybutyrate (P4HB) developed to prolong strength retention and reinforce soft tissue in patients undergoing plastic and reconstructive surgery.
219007224|NCT01426373|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
219007225|NCT04341389|BIOLOGICAL|Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Intramuscular injection
219007226|NCT04341389|OTHER|Placebo|Intramuscular injection
219007227|NCT04952402|BIOLOGICAL|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
219007228|NCT04952402|BIOLOGICAL|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
219410411|NCT04366752|OTHER|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
219569342|NCT02988869|DRUG|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
219569343|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
219569344|NCT03541239|DEVICE|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
219569345|NCT01367938|DEVICE|OMNI Apex Ultracongruent Knee Device|
219569346|NCT05701618|OTHER|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
219007229|NCT04952402|BIOLOGICAL|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
219007230|NCT01126450|DRUG|lenalidomide|Given orally
219007231|NCT01126450|BIOLOGICAL|cetuximab|Given IV
219007232|NCT01126450|OTHER|mutation analysis|Correlative studies
219007233|NCT01126450|OTHER|polymerase chain reaction|Correlative studies
219007234|NCT01126450|GENETIC|polymorphism analysis|Correlative studies
219410412|NCT04252612|DRUG|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
219410413|NCT03632252|DEVICE|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
219410414|NCT01928121|OTHER|Care provided by AF expert program|
219569347|NCT05701618|OTHER|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
219569348|NCT06015113|DRUG|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
219410415|NCT04141852|DEVICE|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
219410416|NCT00128700|DRUG|temozolomide|
219410417|NCT00128700|DRUG|vatalanib|
219410418|NCT00128700|PROCEDURE|adjuvant therapy|
219410419|NCT00128700|RADIATION|radiation therapy|
219410420|NCT06163443|DIETARY_SUPPLEMENT|Vitamin B|MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription
219190251|NCT04967248|OTHER|Alpelisib|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
219410421|NCT06163443|DIETARY_SUPPLEMENT|Placebo|MTHFR, MTR, and MTRR polymorphysm based placebo prescription
219410422|NCT01797510|BEHAVIORAL|Web Based Health Coaching|
219410423|NCT01694420|DRUG|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
219410424|NCT04202718|DIAGNOSTIC_TEST|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
219410425|NCT01689402|DEVICE|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
219429435|NCT01714297|DRUG|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
219429436|NCT01661920|OTHER|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
219429437|NCT01661920|OTHER|Control group|Those antibiotic duration treatments which are not modified by their doctors.
219429438|NCT01948141|DRUG|nintedanib|Given PO
219429439|NCT04529421|BEHAVIORAL|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
219429440|NCT04529421|BEHAVIORAL|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
219429441|NCT02022956|DRUG|Lorcaserin|
219429442|NCT03219892|DEVICE|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
219429443|NCT03219892|DEVICE|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
219429444|NCT04297826|BEHAVIORAL|Harvest for Health|Please see previous description
219429445|NCT02697630|DRUG|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
219429446|NCT02697630|DRUG|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
219429447|NCT00192036|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
219429448|NCT00192036|DRUG|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
219429449|NCT00192036|RADIATION|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
219429450|NCT01287481|BEHAVIORAL|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
219410426|NCT05996172|BEHAVIORAL|CAMS Single Session Consultation|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation. CAMS is based around a model of STB which states that youth become suicidal in response to overwhelming pain, and treatment identifies and targets the drivers of suicide as the primary focus of assessment and intervention.
219410427|NCT05996172|BEHAVIORAL|Driver Focused Skills Training|The CAMS approach focuses on therapeutic assessment, collaborative identification and treatment of the patient-defined STB drivers (i.e., the problems that make suicide compelling to the patient) and utilizes problem-focused treatment sessions to address the drivers in order to reduce the wish to die. In the SOARS brief intervention model, specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality.
219410428|NCT05996172|BEHAVIORAL|Caregiver Skills Training|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills adapted from evidence-based treatments for youth suicidality including DBT and CBT.48,49 Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
219190252|NCT04967248|OTHER|Fulvestrant|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
219410429|NCT05996172|BEHAVIORAL|Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means safety over two, 30-minute modules delivered across 2 sessions.
219410430|NCT05784337|DEVICE|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
219569349|NCT06557278|BIOLOGICAL|AlloStim|experimental immunotherapy to prime for checkpoint inhibitor
219569350|NCT06557278|DRUG|Bavencio|anti-PDL1 checkpoint inhibitor
219569351|NCT02402491|DRUG|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
219569352|NCT02402491|DRUG|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
219410431|NCT05053997|BEHAVIORAL|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
219410432|NCT03121833|DRUG|Endostar|Recombinant Human Endostatin Injection
219410433|NCT03121833|DRUG|Placebo|500ml 0.9% sodium chloride
219410434|NCT03121833|DRUG|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
219410435|NCT00000255|DRUG|Nitrous oxide|
219410436|NCT06194175|PROCEDURE|Bariatric surgery|"Participants whose application for bariatric surgery was accepted, regardless of the type of surgical intervention (e.g., sleeve gastrectomy, Roux-en-Y Gastric Bypass).~This longitudinal study includes five measurement times: before surgery and then, 6 months, one year, one and a half years and two years after surgery. At each measurement time, participants are asked to respond to a set of online questionnaires. Responses are anonymous."
219410437|NCT05611099|DEVICE|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
219569353|NCT02402491|DRUG|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
219569354|NCT05444543|DRUG|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
219569355|NCT05444543|DRUG|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
219569356|NCT05659134|OTHER|Alfredson protocol|Alfredson eccentric therapeutical protocol.
219569357|NCT05659134|OTHER|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
219569358|NCT02301858|GENETIC|Genome analysis of tissue samples.|Genome analysis of tissue samples.
219569359|NCT01261624|DRUG|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
219569360|NCT01872624|PROCEDURE|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
219190253|NCT04484428|DRUG|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
219410438|NCT05611099|OTHER|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
219410439|NCT02753036|DRUG|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
219410440|NCT04815551|DRUG|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
219410441|NCT04815551|DRUG|Placebo|Placebo is sterile liquid for IV infusion.
219410442|NCT01682499|DRUG|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
219410443|NCT05297656|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
219410444|NCT05297656|OTHER|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
219410445|NCT05297656|OTHER|Home exercises programe|Only Home exercises programe
219569361|NCT02280187|PROCEDURE|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
219569362|NCT01829815|BEHAVIORAL|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
219569363|NCT02094261|DRUG|AZD9291|Once daily tablet 80 mg
219756803|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
219756804|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
219756805|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
219756806|NCT07094997|OTHER|Guidline-basaed massage therapy|Massage protocol based on guidelines from the Polish Society of Physiotherapy, the Polish Society of Family Medicine, the College of Family Physicians in Poland, and the European Rural and Isolated Practitioners
219756807|NCT07094997|OTHER|Swedish massage|A classical form of therapeutic massage that uses a combination of long, flowing strokes, kneading, friction, tapping, and gentle stretching to promote relaxation, improve circulation, and reduce muscle tension. It is typically performed using oil or lotion to reduce friction on the skin. Techniques are applied with light to moderate pressure and are designed to enhance general well-being and support recovery from muscular discomfort or stress
219756808|NCT07096453|DRUG|Cytogam|Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
219756809|NCT03423979|DEVICE|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
219756810|NCT03423979|DRUG|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
219410446|NCT03987919|DRUG|Tirzepatide|Administered SC
219410447|NCT03987919|DRUG|Semaglutide|Administered SC
219410448|NCT02222389|BEHAVIORAL|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
219410449|NCT02222389|BEHAVIORAL|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
219410450|NCT02222389|BEHAVIORAL|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
219410451|NCT02222389|BEHAVIORAL|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
219410452|NCT05766228|OTHER|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
219410453|NCT03726619|BEHAVIORAL|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
219410454|NCT03726619|BEHAVIORAL|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
219756811|NCT06908577|DRUG|Tozorakimab|Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.
219756812|NCT06908577|DEVICE|Autoinjector (AI) Device|AI device will be used to administer single SC dose of tozorakimab on Day 1.
219756813|NCT06908577|DEVICE|Accessorised Prefilled Syringe (APFS) Device|APFS device will be used to administer single SC dose of tozorakimab on Day 1.
219756814|NCT02760342|DRUG|peficitinib|Oral
219756815|NCT02760342|DRUG|Metformin|Oral
219756816|NCT06934473|OTHER|GIP(3-30)NH2 / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
219756817|NCT06934473|OTHER|Saline (NaCl 0,9 %) (placebo)|Placebo (NaCl 0,9%)
219756818|NCT06934473|OTHER|GIP(1-42)|Agonist of the GIPR, GIP(1-42)
219410455|NCT01194804|DRUG|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
219429451|NCT01287481|BEHAVIORAL|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
219429452|NCT01287481|BEHAVIORAL|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
219429453|NCT04143672|DEVICE|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
219429454|NCT04143672|DIAGNOSTIC_TEST|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
219756819|NCT07145333|DRUG|Topotecan - usual|Topotecan Capsule
219756820|NCT07145333|DRUG|Topotecan - study|China Import Topotecan Capsule
219756821|NCT07140913|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
219756822|NCT07140913|DRUG|Lithium|Specified dose on specified days
219756823|NCT07140913|DRUG|Valproate|Specified dose on specified days
219756824|NCT07140913|DRUG|Lamotrigine|Specified dose on specified days
219756825|NCT07140913|DRUG|Placebo|Specified dose on specified days
219756826|NCT07140172|PROCEDURE|Axillary lymph node dissection (ALND)|Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
219429455|NCT05425719|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
219429456|NCT05425719|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
219429457|NCT02626741|DIETARY_SUPPLEMENT|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
219429458|NCT02626741|BEHAVIORAL|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
219429459|NCT03796182|DRUG|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
219756827|NCT07140172|PROCEDURE|Axillary radiotherapy (ART)|Axillary irradiation
219410456|NCT02883777|BEHAVIORAL|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
219410457|NCT02883777|BEHAVIORAL|Conventional Diet|Conventional diet over 1 year after transplantation.
219410458|NCT04706169|DEVICE|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
219410459|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
219410460|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
219410461|NCT05321095|DIAGNOSTIC_TEST|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
219410462|NCT05321095|DIAGNOSTIC_TEST|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
219410463|NCT05321095|DIAGNOSTIC_TEST|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
219410464|NCT05057546|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
219410465|NCT04987983|OTHER|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
219410466|NCT04987983|OTHER|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
219410467|NCT01060735|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
219410468|NCT06133647|PROCEDURE|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
219410469|NCT00748553|DRUG|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
219410470|NCT00748553|DRUG|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
219410471|NCT01852097|BEHAVIORAL|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
219410472|NCT00315705|DRUG|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
219410473|NCT00315705|DRUG|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
219410474|NCT00315705|DRUG|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
219410475|NCT01021605|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
219410476|NCT02551198|DRUG|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
219429460|NCT03796182|DRUG|PF-04965842|PF 04965842 100 mg tablets
219190254|NCT04484428|DRUG|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
219410477|NCT02551198|DRUG|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
219410478|NCT05094921|OTHER|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
219429461|NCT00000113|OTHER|Progressive Addition Lenses|Varilux comfort with +2.00 addition
219429462|NCT00000113|OTHER|single vision lenses|
219756828|NCT07141082|OTHER|Art therapy combined with Exercise|The intervention program consists of one hour of expressive art intervention followed by one hour of exercise training. Art therapy sessions will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and encouraging them to share their current status. This is followed by a 10-minute mindfulness exercise designed to center participants and promote relaxation, preparing them for the creative activities ahead. The core of each session features a 20-minute art-making process focused on specific themes that guide participants in exploring their pain and personal narratives.
219756829|NCT07141082|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
219756830|NCT07148115|OTHER|Collect data on all pregnancies before and after diagnosis of SLE.|"For participants who are still alive, data are collected from interviews with patients using a prepared questionnaire that asks about all pregnancies and obstetrical events prior to and following the diagnosis of SLE.~For deceased patients, data are taken from the medical records of obstetrical events.~Data will be collected on anthropometric, biological, immunological, and histological features before and after the diagnosis of SLE, if available.~The activity and severity of the disease after diagnosis will be assessed using the recommended tools."
219756831|NCT07147855|BEHAVIORAL|Take your sexuality back|A 12 weeks group program.
219756832|NCT07148076|BEHAVIORAL|Education Program|This intervention consists of a structured educational program specifically designed for educational staff in primary schools and kindergartens, focusing on the care of children with type 1 diabetes. The program includes interactive lectures, practical workshops, and case studies covering diabetes management, symptom recognition, emergency procedures, and day-to-day support for children with type 1 diabetes in educational settings. Unlike standard informational sessions or general health education, this intervention is tailored to address the unique challenges and responsibilities faced by school and kindergarten staff. The program is delivered in-person by certified diabetes educators and includes pre- and post-training assessments to measure changes in knowledge, perceptions, and attitudes. Participants are tracked using unique codes to allow for longitudinal comparison of results before, immediately after, and three months following the intervention.
219756833|NCT07148583|DIETARY_SUPPLEMENT|BioAmicus Complete|Oral liquid probiotic (multistrain) administered by caregivers per protocol/label for 42 days to infants with functional GI symptoms. Given as drops by mouth; dosing and administration instructions per protocol. No other probiotic products allowed during the study. Concomitant medications and routine management may be used as clinically indicated. Adherence is recorded; lot/batch number captured.
219429463|NCT00980421|DIETARY_SUPPLEMENT|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
219429464|NCT03007121|DRUG|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
219429465|NCT03007121|DRUG|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
219429466|NCT03007121|DRUG|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
219429467|NCT04682353|DRUG|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
219429468|NCT04682353|DRUG|Depo-subQ Provera|SC injection of 104 mg/0.65 mL
219429469|NCT04962503|DRUG|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
219429470|NCT03347240|PROCEDURE|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
219429471|NCT03347240|PROCEDURE|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
219429472|NCT03347240|DEVICE|Deep brain stimulation|Bilateral DBS
219429473|NCT03347240|DEVICE|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
219429474|NCT05423002|OTHER|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
219003338|NCT07131176|OTHER|Behavior Change through Education intervention|"The I-Change Model We used behavior alteration theory to identify areas of thinking or conduct that might potentially lead to issues in the process of collecting or consuming medicine. Subsequently, we proceeded to create and improve the substance of the message, and we aligned the messages with a standardized classification of evidence-based strategies for modifying behavior.~Unclear or confusing information in infographics and television videos was revised, while information that was deemed unhelpful or insignificant by both patients and clinicians was eliminated. Patients' feedback was used to create fresh material for television videos and infographics.~1. Encourage patients about routine clinic appointments~2. Provide relevant health-related information.~3. Help participants plan and organize various treatment adherence behaviors including medication collection and taking, diet, and exercise~4. Support positive adherence-related behaviors"
219003339|NCT07131462|PROCEDURE|Direct Composite Restoration|Application of direct composite resin to restore the fractured crown of permanent incisors.
219003340|NCT07131462|PROCEDURE|Cvek Pulpotomy|Partial pulpotomy (Cvek technique) will be performed for complicated crown fractures with vital pulp exposure. The goal is to maintain pulp vitality using biodentin.
219003341|NCT07131462|PROCEDURE|Endodontic Treatment|Root canal treatment will be applied to teeth with necrotic pulp or extensive pulp exposure not suitable for vital pulp therapy. Procedures will follow standard endodontic protocols.
219003342|NCT07131462|PROCEDURE|Pulp Capping|In cases of minimal pulp exposure, a direct pulp capping procedure will be performed using biocompatible materials such as calcium hydroxide to preserve pulp vitality.
219003343|NCT07132580|DEVICE|Re-Timer® light therapy glasses|Participants wore Re-Timer® glasses that emitted bright white light at 506 lux for 30 minutes each morning, over a 4-week intervention period.
219003344|NCT07132580|OTHER|Usual Care|Participants received standard follow-up care with no light therapy intervention during the 4-week period.
219190255|NCT06026488|OTHER|Other|real world treatment and survival of DLBCL patients in China
219410479|NCT05094921|PROCEDURE|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
219410480|NCT00262418|DRUG|Administration of ivermectin or permethrin|
219410481|NCT00355212|PROCEDURE|percutaneous ablation of hepatocellular carcinoma|
219410482|NCT05304910|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
219410483|NCT05304910|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
219410484|NCT05099146|BEHAVIORAL|pictures|pictures with brushing technique demonstrated technique for proper brushing
219410485|NCT05099146|BEHAVIORAL|video|video of brushing technique demonstrated technique for proper brushing
219410486|NCT05099146|BEHAVIORAL|control|oral hygiene instructions provided
219569364|NCT03092882|BEHAVIORAL|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
219569365|NCT04668274|DRUG|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
219569366|NCT04668274|DRUG|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
219569367|NCT04668274|DRUG|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
219003345|NCT07132151|PROCEDURE|AI Controlled General Anesthesia|During painless abortion, anesthesia will be induced using ciprofol, and controlled by an AI model.
219190256|NCT05796154|DEVICE|ear blood pressure monitor|The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
219410487|NCT00948818|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
219410488|NCT00948818|DRUG|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
219410489|NCT01919918|DRUG|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
219410490|NCT02260908|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
219410491|NCT02260908|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
219410492|NCT05591599|DIAGNOSTIC_TEST|calponin 2|serum calponin 2 level
219410493|NCT06552611|COMBINATION_PRODUCT|Transcutaneous electrical spinal cord stimulation + therapy|A two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand therapy sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin as cathodes to stimulate the cervical spinal cord at two vertebral levels. An additional pair of electrodes will be symmetrically positioned over either the iliac crests or shoulders, functioning as anodes. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will range from 0 to 120 milliamperes (mA), with incremental increases of 5 mA until reaching the level that facilitates voluntary movement. The stimulation amplitude will be fine-tuned for each specific activity based on the therapist's observation.
219410494|NCT06552611|OTHER|Occupational Therapy|The hand therapy program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each training session. Activities are chosen according to the participant's ability, interests, and needs and are modified as function progresses over time.
219410495|NCT03355937|PROCEDURE|Sperm Chip|Sperm selection using by conventional or with sperm chip
219410496|NCT00982241|DIETARY_SUPPLEMENT|water|drinking water / normal dietary fluids for oral intake
219569368|NCT04668274|DRUG|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
219569369|NCT06365294|PROCEDURE|Rescue extracranial stenting|Rescue extracranial stenting in tandem occlusions
219569370|NCT03400436|OTHER|No intervention in observational studies|No intervention in observational studies
219569371|NCT05110131|DEVICE|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
219569372|NCT01047891|DRUG|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
219569373|NCT03328429|OTHER|Excision|Bartholin gland will be excised
219569374|NCT03328429|OTHER|Marsupialization|Bartholin gland will be marsupialised
219569375|NCT02363439|DRUG|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
219569376|NCT05644886|BEHAVIORAL|FP Training and Technical Support|Same as in Intervention arm description
219569377|NCT02221063|OTHER|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
219569378|NCT02221063|OTHER|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
219569379|NCT02221063|OTHER|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
219569380|NCT05352724|DIETARY_SUPPLEMENT|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
219569381|NCT04712084|PROCEDURE|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
219569382|NCT04429841|PROCEDURE|Radical gastrectomy with D1 lymphadenectomy|
219569383|NCT04429841|PROCEDURE|Radical gastrectomy with D2 lymphadenectomy|
219569384|NCT01854255|DRUG|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
219569385|NCT02863549|DEVICE|MitraClip in tricuspid valve|MitraClip in tricuspid valve
219569386|NCT06204575|OTHER|Data collection|Data collection
219756834|NCT07148583|OTHER|Usual Care (No Probiotic)|Standard clinical management for infant functional gastrointestinal symptoms per local practice. No probiotic supplementation is provided during the study period. Participants follow the same visit and assessment schedule as the intervention arm. Concomitant medications and supportive care may be used as clinically indicated.
219003346|NCT07132151|PROCEDURE|General Anesthesia|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
219190257|NCT04480736|DRUG|Placebo|Matching placebo will be administered orally.
219569387|NCT01719562|PROCEDURE|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
219569388|NCT01719562|OTHER|Physical Activity|Tailored aerobic exercise program onsite and at home.
219569389|NCT01719562|OTHER|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
219569390|NCT01719562|DEVICE|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
219569391|NCT01719562|OTHER|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
219756835|NCT07147868|BEHAVIORAL|Structured Education Program for Caregivers of Chemotherapy Patients|A structured educational intervention designed for caregivers of cancer patients undergoing chemotherapy, delivered in 30-45 minute sessions to groups of 4-5 participants. The program includes modules on self-efficacy, stress management, healthy lifestyle behaviors, interpersonal relationships, and nutrition based on the Mediterranean diet. Content covers evidence-based strategies for improving family health, psychological well-being, and dietary adherence. Sessions are conducted by a certified practitioner with 480 hours of family counseling training in a university hospital's medical oncology unit seminar room. The intervention aims to reduce caregiver burden, enhance psychological well-being, improve adherence to the Mediterranean diet, and promote family health, as assessed by the Family Health Scale (ASÖ), Mediterranean Diet Adherence Scale (MEDAS), and Psychological Well-Being Scale (PİO) at baseline (t0), post-intervention (t1), and 6 weeks follow-up (t2).
219756836|NCT07150338|DRUG|QRX-3|Compounded new drug regime
219190258|NCT04480736|DRUG|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
219410497|NCT02529241|DRUG|Group 1:LCB01-0371|"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"
219410498|NCT02529241|DRUG|Group 2:LCB01-0371|"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"
219190259|NCT04480736|DRUG|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
219410499|NCT02765178|OTHER|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
219410500|NCT02765178|OTHER|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
219410501|NCT02765178|OTHER|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
219410502|NCT02765178|OTHER|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
219410503|NCT02765178|OTHER|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
219410504|NCT02696915|DRUG|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
219410505|NCT02696915|DRUG|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
219410506|NCT02696915|DEVICE|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
219410507|NCT02696915|DRUG|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
219410508|NCT01794819|DEVICE|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
219410509|NCT01809418|DEVICE|keePAP|
219410510|NCT01490749|DRUG|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
219410511|NCT01490749|DRUG|XELOX|Patients will receive two cycles of XELOX.
219410512|NCT01490749|DRUG|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
219569392|NCT00508027|DRUG|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
219410513|NCT01490749|RADIATION|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
219410514|NCT03242083|OTHER|quality of life questionnaire|quality of life questionnaire
219410515|NCT02052843|BEHAVIORAL|Steps to Success|
219410516|NCT02052843|BEHAVIORAL|Traditional Healthy Families|
219190260|NCT04480736|DRUG|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
219190261|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
219190262|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
219190263|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
219410517|NCT00003444|BIOLOGICAL|recombinant interferon alfa|
219410518|NCT00003444|RADIATION|radiation therapy|
219410519|NCT00745368|DRUG|Raltegravir|400 mg tablets twice daily during duration of trial
219410520|NCT00862316|DEVICE|Oxford Unicompartmental Knee|Knee Arthroplasty
219410521|NCT06554834|PROCEDURE|CV4 + RR|Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
219410522|NCT06554834|PROCEDURE|CV4|Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
219569393|NCT06425367|DIAGNOSTIC_TEST|Antibiotic susceptibility testing|antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
219569394|NCT03485846|DRUG|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
219569395|NCT03485846|DRUG|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
219569396|NCT03485846|DRUG|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
219569397|NCT02036801|OTHER|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
219569398|NCT00338130|DRUG|AZD6244|Oral liquid or Capsule
219756837|NCT07150338|DRUG|Eseronate|Neukidney innovative drug
219756838|NCT07148895|PROCEDURE|Post-surgical drain|During surgery, at the completion of the Sistrunk procedure, participants in the drain cohort will have a suction drain placed, which will be removed based on standard criteria prior to discharge from the hospital. Wound care following drain removal will be standardized, with instructions for patients to allow the area to heal naturally and to follow a regimen of cleaning and applying topical antibiotic ointment for several days.
219756839|NCT07148895|PROCEDURE|No post-surgical drain|Patients will be recovered in SOC manner from Sistrunk surgery without drain placement
219410523|NCT06554834|DEVICE|sham ultrasound transducer|Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
219410524|NCT06554834|DEVICE|Ultrasound Transducer Sham Procedure|Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
219410525|NCT06554834|DEVICE|EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System|Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
219410526|NCT05811767|OTHER|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
219410527|NCT00091143|BIOLOGICAL|gp100 antigen|
219410528|NCT00091143|BIOLOGICAL|incomplete Freund's adjuvant|
219410529|NCT00091143|BIOLOGICAL|keyhole limpet hemocyanin|
219569399|NCT00338130|DRUG|Temozolomide|oral
219569400|NCT01790230|DEVICE|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
219569401|NCT03956589|DRUG|Orkambi|Open label of Orkambi treatment during 3 months
219569402|NCT06463717|DRUG|Transplant, Autologous|High-dose melphalan followed by autologous stem cell transplantation
219756840|NCT07149753|DRUG|MILTEFOSINE gel|Each patient will receive a 30 g tube of G-MTF with instructions and recommendations for use. The first dose will be in the FOSCAL clinical studies unit; subsequent doses will be applied at the patient's site of origin based on their autonomy, once a day (morning or night). Instructions include washing hands thoroughly, cleaning the lesion, applying a thin layer of gel, leaving it uncovered for at least 15 minutes, avoiding contact with water until the next dose, and storing the gel properly during treatment.
219756841|NCT07150663|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 8 weeks (maximum treatment duration: 8 weeks), whichever occurred first.
219756842|NCT07150663|OTHER|Standard Therapy|Standard Therapy
219569403|NCT06463717|DRUG|Chemotherapy drug|Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
219569404|NCT04823819|DEVICE|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
219569405|NCT04823819|DEVICE|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
219569406|NCT01920984|DRUG|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
219569407|NCT01954914|DRUG|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
219569408|NCT06443255|DRUG|Cociane hydrochloride 4%|2 mL of 4% cocaine
219569409|NCT06443255|DRUG|Lidocaine 4%|1.5 mL of 4% lidocaine
219569410|NCT06443255|DRUG|Xylometazoline 0.1%|0.5 mL of xylometazoline 0.1%
219569411|NCT06443255|DRUG|Saline 0.9%|2 mL of saline 0.9%
219569412|NCT06208423|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
219569413|NCT02112279|BIOLOGICAL|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1\. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
219569414|NCT01376206|DRUG|Fluticasone|Collection of safety data
219569415|NCT03945799|DRUG|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
219410530|NCT00091143|DRUG|fludarabine phosphate|
219410531|NCT00091143|PROCEDURE|peripheral blood stem cell transplantation|
219410532|NCT03695640|DRUG|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
219410533|NCT03695640|PROCEDURE|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
219410534|NCT01063816|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
219756843|NCT07150442|PROCEDURE|POP surgery and PRP injection|Patient who undergo POP surgery will receive PRP injection
219410535|NCT01063816|DRUG|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
219410536|NCT01063816|DRUG|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
219410537|NCT03472235|DEVICE|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
219410538|NCT03489616|BIOLOGICAL|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
219410539|NCT03489616|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
219410540|NCT03489616|RADIATION|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
219569416|NCT00663715|OTHER|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
219569417|NCT00510315|OTHER|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
219569418|NCT03187028|BEHAVIORAL|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
219569419|NCT03187028|BEHAVIORAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
219569420|NCT02388698|PROCEDURE|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
219569421|NCT02388698|RADIATION|PET-CT|PET-CT will be completed 3 month post chemoradiation.
219569422|NCT02388698|BIOLOGICAL|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
219569423|NCT01035476|BEHAVIORAL|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
219569424|NCT03680976|DRUG|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
219569425|NCT03680976|DRUG|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
219569426|NCT02026544|DEVICE|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
219569427|NCT02326363|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
219569428|NCT02326363|BEHAVIORAL|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
219569429|NCT04030663|DRUG|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
219569430|NCT04030663|DRUG|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
219569431|NCT04030663|DRUG|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
219410541|NCT03489616|DRUG|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
219410542|NCT01726413|DRUG|GRC 17356|
219569432|NCT03907917|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
219569433|NCT01483014|DRUG|imatinib mesylate|
219569434|NCT06368752|BIOLOGICAL|GIP[3-30]NH2|GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist
219569435|NCT06368752|OTHER|Saline|Sodium chlorid with 0,5% human serum albumin.
219410543|NCT01726413|DRUG|Matching Placebo|
219410544|NCT01290445|DRUG|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
219410545|NCT01290445|BEHAVIORAL|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
219569436|NCT03340987|PROCEDURE|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
219569437|NCT03340987|PROCEDURE|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
219003347|NCT07131189|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
219410546|NCT01290445|OTHER|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
219410547|NCT00414778|DRUG|LHT344|
219410548|NCT03510611|DRUG|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
219410549|NCT00120120|DRUG|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
219003348|NCT07131280|DRUG|Gcsf|G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
219003349|NCT07131280|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month
219003350|NCT07131280|OTHER|Standard Medical Treatment|Standard Medical Treatment
219003351|NCT07131696|DEVICE|Transcutaneous Vagal Nerve Stimulation|Participants will receive up to 4 sessions per day of up to 20-minute stimulation, over the next 10 days of their inpatient hospital stay, following endovascular treatment. Stimulation will be provided by the tVNS device through a small electrode placed around the ear that will send low intensity, pulsed, electrical pulses the vagus nerve.
219003352|NCT07132788|DIAGNOSTIC_TEST|blood draw|Research blood draw
219410550|NCT04521348|DRUG|multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody|Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
219410551|NCT03157973|OTHER|Education intervention|eHealth tool and standardized nurse-led follow-up.
219410552|NCT05078099|DEVICE|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
219410553|NCT03270553|DRUG|plazomicin|single intravenous dose
219410554|NCT03270553|DRUG|metformin|single oral dose
219569438|NCT05487560|DRUG|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
219569439|NCT05369091|DRUG|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
219569440|NCT04031092|DEVICE|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
219569441|NCT04031092|DEVICE|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
219003353|NCT07132788|DIAGNOSTIC_TEST|Short Performance Physical Battery|test of physical performance, which involves measuring movement from sitting to standing, walking speed, and balance
219003354|NCT07132788|DIAGNOSTIC_TEST|Grip strength test|Measures grip strength
219003355|NCT07132788|DIAGNOSTIC_TEST|Six minute walk test|Measures distance walked in 6 minutes
219003356|NCT07132788|RADIATION|Chest CT scan|X-ray and computer technology takes detailed pictures of the organs and structures inside your chest
219003357|NCT07132788|RADIATION|Dual-Energy X-ray Absorptiometry Scan|Uses X-ray technology to measure the mineral density of your bones, and provides a ratio of fat tissue to lean mass (muscle) and bone
219003358|NCT07132788|BEHAVIORAL|Activity monitoring|A device worn on your non-dominant wrist which measures motion/ movement/ activity
219410555|NCT05626517|DIAGNOSTIC_TEST|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
219410556|NCT05626517|OTHER|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
219410557|NCT05480293|DRUG|Ranibizumab|ranibizumab，0.5mg,IVT
219410558|NCT05480293|DRUG|SCT510A|SCT510A，1.25mg,IVT
219410559|NCT02935699|DRUG|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
219410560|NCT02935699|DRUG|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
219569442|NCT04031092|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program.
219569443|NCT05890092|OTHER|Observation|Observing for disease prevalence - actual and self-reported
219569444|NCT04726189|OTHER|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
219569445|NCT04726189|OTHER|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
219569446|NCT03605524|OTHER|Sensory training|12 weeks sensory training
219003359|NCT07132788|BEHAVIORAL|24 hour diet recall|A research dietitian will contact you and ask you to provide details of what you ate over the previous 24 hours
219003360|NCT07132788|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound technology to create moving images of your heart, valves, and chambers
219003361|NCT07132788|BEHAVIORAL|Quality of Life Questionnaire (emPHasis 10)|The emPHasis-10 is a pulmonary hypertension-specific questionnaire which is scored from 0-50 (with higher scores indicating worse quality of life.)
219003362|NCT07132788|BEHAVIORAL|International Physical Activity Questionnaire Short Form (IPAQ-SF)|The IPAQ-SF is a small set of questions to obtain comparable estimates of physical activity.
219003363|NCT07133048|PROCEDURE|Levobupivakain 0.25 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
219410561|NCT02054143|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
219410562|NCT02054143|DRUG|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
219410563|NCT05439460|DRUG|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
219410564|NCT05439460|DRUG|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
219410565|NCT05439460|DRUG|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
219410566|NCT05277688|DRUG|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
219410567|NCT05277688|RADIATION|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
219410568|NCT03446651|DRUG|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
219756844|NCT07150442|PROCEDURE|POP surgery and placebo injection|patient who receive POP surgery and placebo injection
219756845|NCT07149714|DEVICE|iVAC 2L|The goal of this study is to investigate the safety and clinical efficacy of temporary mechanical support system with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention (PCI) in Russia and Belarus. The POTOK trial will include patients with indications for elective, urgent and emergency PCI.
219756846|NCT07150273|DEVICE|UNIVELO Sub-Q 2mL|Test device
219756847|NCT07150273|DEVICE|Restylane Sub-Q 2mL|Comparator Device
219756848|NCT07148349|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219756849|NCT07150910|BEHAVIORAL|Interdental brush|In accordance with the manufacturer's recommendations, the IDBs were stated to be suitable for multiple uses. Participants were advised to replace the IDB once the bristles lost their shape or if the metal wire became damaged.
219756850|NCT07150910|BEHAVIORAL|Rubber bristles interdental cleaner|Two sizes were selected for the study: XS/S - Orange, designed for narrow and very narrow interdental spaces, and M/L - Turquoise, suitable for medium to large spaces. Since the tested RBICs were designed by the manufacturer for single use, participants were instructed to use a new RBIC at each application.
219756851|NCT07156071|OTHER|Serum 1|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group.
219003364|NCT07133048|PROCEDURE|NaCl 0.9 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
219003365|NCT07133022|PROCEDURE|Early Prone Positioning Protocol|A structured protocol in which non-intubated patients with Acute Respiratory Distress Syndrome (ARDS) are positioned prone for 2-4 hours per session, multiple times per day, totaling approximately 8 hours daily for 5 consecutive days. Initiation begins within 24 hours of ARDS diagnosis. Administered by trained Intensive Care Unit (ICU) nurses under medical supervision.
219003366|NCT07133022|OTHER|Standard ICU Care|Participants receive routine Intensive Care Unit (ICU) care for Acute Respiratory Distress Syndrome (ARDS) without the implementation of a structured early prone positioning protocol. Care is provided at the discretion of the treating physicians, following standard ICU management practices.
219003367|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
219003368|NCT06952257|PROCEDURE|Administration of general anaesthesia|The anaesthesia will be administered intravenously
219003369|NCT06952257|PROCEDURE|Neuraxial Analgesia|Will be administered as an epidural
219190264|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 2 stages|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
219190265|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 1 stage|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
219429475|NCT05423002|OTHER|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
219429476|NCT05423002|OTHER|Dim light|This light condition is the baseline (≤10 lux).
219429477|NCT05406557|PROCEDURE|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
219429478|NCT05406557|PROCEDURE|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
219756852|NCT07156071|OTHER|Serum 2|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group.
219003370|NCT06947577|OTHER|pulsed electromagnetic field (PEMF) therapy and a tailored exercise program (TEP)|pulsed electromagnetic field (PEMF) therapy for addressing chemotherapy-induced peripheral neuritis in the lower limb, patients were first prepared by ensuring they were in a relaxed state, free from distractions, and instructed to remove any metallic items while wearing comfortable clothing. The treatment utilized the ASA Easy Terza series PEMF device from Italy, with each patient positioned comfortably in a supine posture. The device was connected to a 220 V electrical supply, and the solenoid was placed over the lower leg, operating at a frequency of 50 Hz and an intensity of 20 G for a duration of 20 minutes. Patients were situated in a position between sitting and lying, with their lower legs and feet positioned within the solenoid. The setup adhered to the manufacturer's guidelines to ensure effective delivery of the magnetic oscillations, with treatment parameters meticulously adjusted
219003371|NCT06947577|OTHER|Tailored Exercise Program|This TEP has been meticulously designed to address the rehabilitation needs of patients dealing with lower limb issues. The program encompasses a comprehensive approach, integrating various types of exercises aimed at enhancing strength, functional mobility, balance, coordination, flexibility, and pain management. The sequence of exercises begins with strengthening exercises targeting key muscle groups such as the gastrocnemius and tibialis anterior, followed by functional training activities that simulate daily movements. This is complemented by balance and coordination drills, coordination drills that challenge stability, and flexibility and stretching exercises to improve range of motion. Additionally, pain management techniques and therapeutic modalities like hot packs are incorporated to alleviate discomfort and enhance relaxation. Finally, the program concludes with low-impact aerobics, such as walking programs, to promote cardiovascular fitness. Prior to commencing the exercise
219190266|NCT06730022|DRUG|MTX-001 (Dermacyte Liquid)|Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
219410569|NCT03446651|OTHER|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
219410570|NCT05553678|DRUG|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
219410571|NCT05553678|DRUG|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
219410572|NCT04317352|PROCEDURE|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
219410573|NCT06164145|OTHER|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
219410574|NCT01766570|OTHER|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
219569447|NCT00860743|DRUG|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
219569448|NCT02208752|OTHER|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
219190267|NCT00709527|DRUG|Avacincaptad Pegol|intravitreal injection
219410575|NCT01766570|OTHER|Placebo|
219410576|NCT05634096|DIAGNOSTIC_TEST|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
219410577|NCT02875821|DRUG|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
219410578|NCT02875821|DRUG|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
219410579|NCT00332514|BEHAVIORAL|telephone call by a pharmacist|
219410580|NCT03397277|BEHAVIORAL|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
219410581|NCT03397277|BEHAVIORAL|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
219410582|NCT04586114|DRUG|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
219410583|NCT00357526|DRUG|OCPs|
219003372|NCT03249727|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
219003373|NCT00955591|OTHER|Papanicolaou test|
219003374|NCT02336711|RADIATION|dose escalation|molecular imaging based radiotherapy dose escalation
219410584|NCT00357526|DEVICE|vaginal ring|
219410585|NCT04738500|PROCEDURE|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
219410586|NCT04738500|PROCEDURE|PCA|PCA will be applied after surgery
219410587|NCT05062616|PROCEDURE|Toenail surgery|modified Winograd procedure
219429479|NCT04284280|DIETARY_SUPPLEMENT|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
219190268|NCT03864601|DRUG|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
219190269|NCT06548646|PROCEDURE|Thoracic Interfascial Plane Block|The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
219410588|NCT04400409|OTHER|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
219410589|NCT04400409|OTHER|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
219410590|NCT04400409|OTHER|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
219410591|NCT04400409|OTHER|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
219410592|NCT04131517|DRUG|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
219410593|NCT04131517|DRUG|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
219410594|NCT02576457|BIOLOGICAL|BMS-936559|
219410595|NCT02576457|OTHER|Placebo|
219410596|NCT03241563|DRUG|Sodium Deoxycholate|
219410597|NCT03241563|DRUG|Triamcinolone|Triamcinolone 40mg/ml
219410598|NCT00918086|DIETARY_SUPPLEMENT|Vitamin D pill|Oral tablet taken for 16 weeks
219410599|NCT00918086|DIETARY_SUPPLEMENT|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
219410600|NCT06168071|DEVICE|taVNS|Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
219410601|NCT05480787|DRUG|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
219410602|NCT05480787|DRUG|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
219410603|NCT05480787|DRUG|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
219410604|NCT02909673|BEHAVIORAL|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
219569449|NCT03072654|PROCEDURE|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
219569450|NCT05593731|BIOLOGICAL|dental implants with melatonin gel|platelet rich fibrin membrane around dental implants
219569451|NCT01353248|DRUG|GS-5885|tablet, 30 mg QD
219569452|NCT01353248|DRUG|Tegobuvir|capsule, 30 mg BID
219569453|NCT01353248|DRUG|GS-9451|tablet, 200 mg QD
219569454|NCT01353248|DRUG|ribavirin tablet|(weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
219569455|NCT01353248|DRUG|GS-5885|tablet, 90 mg QD
219569456|NCT03439631|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
219569457|NCT00941720|DRUG|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
219569458|NCT00941720|DRUG|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
219569459|NCT00941720|PROCEDURE|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
219569460|NCT06193031|DRUG|C16TR|Administered as inhalation using a Philips Micro device inhaler.
219569461|NCT06193031|DRUG|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
219569462|NCT06193031|DRUG|Tyvaso®|Administered as inhalation.
219569463|NCT01685658|DRUG|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
219003375|NCT03853265|BEHAVIORAL|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
219003376|NCT03675607|OTHER|Complementary feeding behaviours|Any kind of complementary feeding practice
219410605|NCT04149899|DRUG|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
219410606|NCT04149899|DRUG|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
219410607|NCT04149899|DRUG|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
219569464|NCT01685658|DRUG|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
219569465|NCT06401967|BEHAVIORAL|Pivot Clear|A mobile app and program for alcohol reduction.
219569466|NCT06401967|DEVICE|BACtrack breathalyzer|Personal breathalyzer device that measures blood alcohol content.
219569467|NCT06327217|RADIATION|Bilateral hip x-ray|Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.
219569468|NCT06327217|OTHER|Questionnaires|Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
219569469|NCT05801302|DEVICE|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
219569470|NCT05801302|DEVICE|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
219569471|NCT04814784|RADIATION|Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum|Study the effect of neoadjuvent radiotherapy in treatment of locally advanced cancer rectum e higher possiblity of preservation of anal sphincter and decreased rate of locoregional recurrence compared to surgery alone
219410608|NCT04149899|DRUG|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
219410609|NCT01935687|DEVICE|Using of instrumented wheel|Using of instrumented wheel
219410610|NCT01935687|DEVICE|Using of ergometer roller|Using of ergometer roller
219410611|NCT00433732|DRUG|sumatriptan|
219410612|NCT00433732|DRUG|naproxen sodium|
219410613|NCT01472172|DEVICE|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
219410614|NCT05295368|OTHER|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
219756853|NCT07149974|DEVICE|EEG and fNIRS|For EEG and fNIRS, EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground). fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
219756854|NCT07149974|DEVICE|EEG|EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground).
219003377|NCT02483728|OTHER|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
219003378|NCT02012998|BIOLOGICAL|HBVAXPRO 5µg|0.5mL intramuscular injection
219003379|NCT01103011|DRUG|ND0611|Continuous delivery of ND0611
219003380|NCT01103011|DRUG|ND0611|Solution of ND0611 delivered continuously
219003381|NCT05924204|RADIATION|Photobiomodulation|Application of photobiomodulation
219003382|NCT05924204|OTHER|Simulation of Photobiomodulation|Simulation of photobiomodulation
219190270|NCT06548646|PROCEDURE|Erector Spinae Plane Block|The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
219190271|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
219410615|NCT02961712|BIOLOGICAL|NK cells|single intravenous injection of NK cells (0.9\~1\*10\^9)
219410616|NCT02961712|BIOLOGICAL|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
219410617|NCT01264094|DRUG|Clevudine|clevudine 30 mg qd
219429480|NCT00102557|DRUG|Hydroxychloroquine|
219429481|NCT01324934|DRUG|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
219429482|NCT01586806|DRUG|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
219429483|NCT01586806|DRUG|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
219429484|NCT01586806|DRUG|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
219429485|NCT01303432|DIETARY_SUPPLEMENT|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
219429486|NCT01303432|DIETARY_SUPPLEMENT|Yogurt|One yogurt (125mL) per day
219429487|NCT05684952|DRUG|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
219429488|NCT01208571|OTHER|"Booster session"|Motivational interview
219429489|NCT05367219|DEVICE|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
219429490|NCT01769469|DRUG|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
219429491|NCT04840017|OTHER|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
219429492|NCT00862654|DRUG|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
219569472|NCT03808584|OTHER|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
219410618|NCT05012852|DEVICE|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
219410619|NCT06371014|DRUG|Ondansetron oral membrane|A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
219410620|NCT00003353|BIOLOGICAL|filgrastim|
219569473|NCT02729779|OTHER|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
219569474|NCT02729779|OTHER|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
219569475|NCT01946984|PROCEDURE|ERCP|endoscopy, retrograde cholangio-pancreaticography.
219569476|NCT01946984|DRUG|Diclofenac hydroxyethylpyrrolidine|
219569477|NCT01946984|DRUG|Normal Saline|
219756855|NCT07149974|DEVICE|fNIRS|fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
219756856|NCT07150403|DRUG|Oxaliplatin intravenous|85 mg/m² IV over 2 hours ; 1 cycle each 15 days
219756857|NCT07150403|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous)
219756858|NCT07150403|DRUG|Folinic acid|400 mg/m² in intravenous
219756859|NCT07150403|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
219756860|NCT07150403|DRUG|Irinotecan|180 mg/m² IV over 1h30
219756861|NCT07150403|DRUG|FRUQUINTINIB|5 mg capsule, taken orally, once daily for 3 weeks, followed by a 7-day break, then resumed (Day 1= Day 29).
219756862|NCT07150403|DRUG|BEVACIZUMAB|5 mg/kg over 90 minutes for the 1st course and in case of good tolerance the 2nd course should be administered over 60 minutes. The next courses should be administered in 30 minutes in case of good tolerance during the 2nd course
219761222|NCT06308081|OTHER|Tailored|Messages will be in the form of high-quality English-language anti-vaping messages comprising static text and imagery designed to resemble social media posts (e.g., image and a caption). We will create 24 messages based on the top-ranked tailoring features and belief themes tested in Aim 2 to comprise SGM-tailored messages. For the non-tailored message condition, we will create 24 anti-vaping social media messages that mirror the SGM-tailored messages but do not contain SGM identity cues. We will match the belief themes used in the tailored and non-tailored messages such that they represent a range of belief targets (e.g., addiction, physical health effects, mental health effects) as indicated in Aims 1 and 2. We do not utilize a social media platform for the delivery of the message to avoid potential contamination across randomized conditions.
219410621|NCT00003353|DRUG|melphalan|
219410622|NCT00003353|PROCEDURE|bone marrow ablation with stem cell support|
219410623|NCT00003353|PROCEDURE|peripheral blood stem cell transplantation|
219410624|NCT01894477|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
219410625|NCT01894477|DRUG|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
219410626|NCT01894477|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
219410627|NCT01894477|RADIATION|Total-Body Irradiation|Undergo TBI
219410628|NCT01894477|DRUG|Treosulfan|Intravenously administered Treosulfan
219410629|NCT01894477|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219410630|NCT04379219|DRUG|Methotrexate|giving methotrexate at least 1 w week before surgery
219410631|NCT02542917|DEVICE|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
219410632|NCT05596903|OTHER|EMDR 2.0 group protocol|EMDR 2.0 group protocol
219190272|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
219756863|NCT07149610|DEVICE|M-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region|"The m-health solution used in the study includes the following interfaces:~1. for the HCPs of the CADs:~   * a section of the EPR currently used (Metaclinic), to set the mobile application and to collect clinical data recorded by the patients;~  * a software to develop and monitor personalised diets (MetaDieta);~2. for the patients: two mobile applications, one for the monitoring of the clinical data and life style (DiaWatch Meteda) and one for the monitoring of the diet (MyDiet), with the latter accessible from a 'button' included in the first one.~The HCPs of the CADs, already having access to the EPR Metaclinic, will access a dedicated section for the setting of the target values and goals (e.g., glycaemia, physical activity, etc.) and for the activation of the app DiaWatch Meteda. After the connection of the app with Metaclinic, the data registered in the apps by the patients will be visible by the HCPs in the EPR dashboard."
219756864|NCT07158073|DEVICE|FiO₂ titration, under the guidance of ORI|In Group R, FiO₂ was titrated between 30% and 50% under the guidance of ORI and SpO₂ values. Accordingly, if SpO₂ was ≥ 98%, FiO₂ was reduced in 5% increments to a minimum of 30%, aiming to achieve an ORI value of 0 or as close to 0 as possible.
219756865|NCT07158073|DEVICE|Conventional oxygen administration|In Group C, FiO₂ was maintained at 50% throughout the surgery, provided that SpO₂ remained ≥ 98%.
219756866|NCT07155161|OTHER|Assesment|assessment
219756867|NCT07159048|DEVICE|Multimodal Tumor Thermal Therapy System|All subjects were treated with a multi-modal thermal therapy system (Shanghai MAaGI Medical Technology Co., Ltd.) following a temperature-controlled tumor ablation protocol. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
219756868|NCT07159048|DEVICE|Radiofrequency Ablation System or Microwave Ablation System|All subjects were treated with a radiofrequency ablation system or microwave ablation System. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
219756869|NCT07160933|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' preferences and recommendations for a psychosocial intervention.
219756870|NCT07159763|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
219756871|NCT07159763|COMBINATION_PRODUCT|Placebo|Placebo to match
219756872|NCT07161453|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
219756873|NCT07161453|DRUG|PD-1 / PD-L1 monoclonal antibody|PD-1/PD-L1 monoclonal antibody
219756874|NCT07161453|DRUG|SOX Chemotherapy|SOX or XELOX
219756875|NCT07161453|DRUG|Tegafur-Ugotex or Capecitabine|Tegafur-Ugotex or Capecitabine
219410633|NCT05596903|OTHER|Mhgap stress module|Mhgap stress module
219410634|NCT04687605|PROCEDURE|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
219410635|NCT01592409|DRUG|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
219410636|NCT01592409|DRUG|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
219410637|NCT01409031|DRUG|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
219410638|NCT01409031|OTHER|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
219410639|NCT05092737|PROCEDURE|Prone positioning|Prone position during invasive mechanical ventilation
219410640|NCT05667155|BIOLOGICAL|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
219410641|NCT01773135|OTHER|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone."
219410642|NCT06124547|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
219410643|NCT02576964|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
219429493|NCT00862654|DRUG|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
219410644|NCT02576964|DRUG|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
219410645|NCT05034484|DRUG|ALPN-303|Multiple dose levels will be evaluated.
219569478|NCT00855075|DEVICE|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
219569479|NCT03359915|BEHAVIORAL|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
219569480|NCT06287437|DRUG|HRS9531|HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
219756876|NCT07159321|OTHER|Comprehensive geriatric assessment|Functional status will be evaluated using Activities of Daily Living (ADL) (assessing bathing, dressing, toileting, transferring, eating, and continence; Katz, 1970) and Instrumental ADL (IADL) (assessing shopping, cooking, medication management, phone use, housework, laundry, transportation, and finances; Lawton \& Brody, 1969). Nutritional status will be measured via the Mini-Nutritional Assessment-Short Form (MNA-SF) (Arabic version; Abd-Al-Atty et al., 2012), a 6-item tool (appetite, weight loss, mobility, illness, neuropsychological issues, BMI) scored 0-14, classifying patients as well-nourished (≥12), at risk (8-11), or malnourished (0-7; Rubenstein et al., 2001). Cognition will be assessed using the Saint Louis University Mental Status (SLUMS) exam (Arabic version; Abdelrahamn et al., 2014), a 30-point test evaluating calculation, orientation, memory, fluency, and visuospatial function, with dementia thresholds at \<20 (\<12 years education) or \<21 (≥12 years; Tariq et al., 2006).
219756877|NCT07159321|OTHER|European Organization for Research and Treatment-Quality of life questionnaire|"Quality of life assessment by European Organization for Research and Treatment-Quality of life questionnaire and breast cancer-specific module (EORTC QLQ-C30)and QLQ-BR23)~EORTC QLQ-C30 is a validated tool designed to measure cancer patients' physical, psychological and social functions. It consists of 30 items measuring Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4).~EORTC-BR23 consists of 23 items which measure two main scales Functional Scale (8 items) and Symptoms scales (15 items). Items measured using 4-point Likert Scale ranging from Not at all (1) to Very much (4)."
219756878|NCT07159321|OTHER|Clinical Frailty Scale|Frailty will be assessed using the Clinical Frailty Scale (CFS), a validated and widely used tool developed by (Rockwood et al., 2005). The CFS is a 9-point ordinal scale that categorizes older adults based on their level of physical fitness, functional independence, and comorbidities, ranging from 1 indicate very fit to 9 indicate terminally ill. Participants were evaluated by trained clinicians based on their clinical judgment, incorporating information from patient interviews. The scale provides a practical and reliable measure of frailty in geriatric populations and has demonstrated strong predictive validity for adverse health outcomes including hospitalization, institutionalization, and mortality.
219756879|NCT07159659|DIETARY_SUPPLEMENT|MCT Diet|MCT diet for patients following lung resection
219756880|NCT07159087|DEVICE|Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB)|Drug Coated Balloon
219756881|NCT07159087|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
219756882|NCT07159542|BEHAVIORAL|listening intervention|Music or podcast listening intervention
219756883|NCT07159542|BEHAVIORAL|Neuropsychology assessment|Neuropsychology assessment
219756884|NCT07159542|OTHER|brain imaging examination|EEG: recording of neural dynamic
219190273|NCT03705078|PROCEDURE|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
219410646|NCT05034484|DRUG|Placebo|Placebo will be administered
219410647|NCT00019500|DRUG|raloxifene|
219410648|NCT00019500|PROCEDURE|evaluation of cancer risk factors|
219410649|NCT03241472|DRUG|Letrozole|oral tablets 5 mg
219410650|NCT03241472|DRUG|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
219410651|NCT00074841|DRUG|Azithromycin/Chloroquine|
219410652|NCT00074841|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
219569481|NCT06287437|DRUG|HRS9531 placebo|HRS9531 placebo low frequency injection for 12 weeks.
219569482|NCT03968497|OTHER|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
219569483|NCT03968497|OTHER|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
219569484|NCT05039476|DIETARY_SUPPLEMENT|Retinol face cream|Retinol face cream
219410653|NCT02555566|PROCEDURE|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
219410654|NCT02555566|PROCEDURE|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
219410655|NCT04125797|OTHER|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
219410656|NCT02918487|DRUG|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
219410657|NCT02918487|DRUG|Placebo|Inactive compound that is similar looking as the intervention
219569485|NCT05039476|DIETARY_SUPPLEMENT|Placebo face cream|Placebo face cream
219569486|NCT00006473|DRUG|oxaliplatin|Given IV
219569487|NCT01726127|OTHER|Broccoli and Brussels Sprouts|
219569488|NCT01726127|DIETARY_SUPPLEMENT|Cruciferous Complete|
219569489|NCT01726127|OTHER|Placebo|
219569490|NCT04845646|DRUG|ASC41|5mg/tablet
219410658|NCT02918188|DRUG|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
219190274|NCT03705078|PROCEDURE|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
219003383|NCT02584335|DRUG|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
219190275|NCT03825588|BEHAVIORAL|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
219190276|NCT03825588|BEHAVIORAL|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
219410659|NCT00916123|DRUG|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
219410660|NCT00916123|DRUG|Prednisone|10 mg per day starting on cycle 1, day 1
219410661|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
219569491|NCT04845646|DRUG|Itraconazole|200mg/capsule
219410662|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
219410663|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
219410664|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
219410665|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
219410666|NCT06840119|DRUG|IMC-R117C|IV infusion
219410667|NCT06840119|DRUG|Chemotherapy drug|IV infusion
219410668|NCT06840119|DRUG|Chemotherapy drug|oral
219410669|NCT06840119|DRUG|Kinase inhibitor|oral
219410670|NCT06840119|DRUG|Antiangiogenic Agent|IV infusion
219410671|NCT06840119|DRUG|Monoclonal antibody|IV infusion
219190277|NCT03825588|BEHAVIORAL|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
219190278|NCT04793646|DRUG|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
219190279|NCT04793646|DRUG|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
219191879|NCT05674409|BEHAVIORAL|Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)|Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
219410672|NCT02500238|OTHER|Saliva sample|All participants will provide a saliva sample.
219410673|NCT02500238|OTHER|Urine Sample|All participants will provide a urine sample.
219410674|NCT02500238|OTHER|Toe nail clippings|All participants will provide toe nail clippings.
219410675|NCT02500238|OTHER|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
219410676|NCT05583435|BEHAVIORAL|One-on-one professional coaching|One-on-one professional coaching
219410677|NCT05583435|BEHAVIORAL|Small-group professional coaching|Small-group professional coaching
219410678|NCT05668312|OTHER|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
219410679|NCT05668312|OTHER|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
219410680|NCT02507193|PROCEDURE|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
219569492|NCT04845646|DRUG|Phenytoin|300mg/capsule
219569493|NCT05839327|DIAGNOSTIC_TEST|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
219569494|NCT05699291|OTHER|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
219569495|NCT05032326|DRUG|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
219569496|NCT05032326|OTHER|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
219569497|NCT06304714|OTHER|Patients suffering from envenomation by Bothrops|"For research purposes, the investigator will collect six additional tubes of blood during a venipuncture. This additional volume of blood will be used for research analysis.~The total volume drawn will be within the maximum volume of blood that can be drawn based on body weight.~Venous sampling is planned as part of routine care and the additional blood volumes collected are not significant. This is a low risk procedure due to the small amount of extra blood taken (25,5 ml)."
219569498|NCT00627081|DRUG|remifentanil|dosage
219569499|NCT00992212|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
219756885|NCT07159672|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving) performed as part of standard clinical care for patients with periampullary malignant neoplasms. This procedure is not assigned by the study protocol, but is the exposure of interest. The study observes nutritional, metabolic, molecular, and imaging outcomes at baseline (preoperative), and at 3 and 6 months after hospital discharge.
219756886|NCT07159165|PROCEDURE|Minimally invasive surgical treatment for benign prostatic obstruction|"Surgical management of BPO using contemporary minimally invasive procedures, including but not limited to: Transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), Thulium laser enucleation of the prostate (ThuLEP), Rezum® water vapor thermal therapy.~Procedures are performed according to standard clinical practice at each participating center, with perioperative and follow-up data prospectively recorded in the MIUS registry."
219756887|NCT07160010|DIAGNOSTIC_TEST|Sophia Herditary Cancer Solution|To compare the performance of MGI's DNBSEQ-G400 sequencing instrument with the gold standard Illumina instruments (MiSeq and NextSeq 550) using the same capture DNA libraries constructed with Sophia Genetics assays.
219756888|NCT07160556|OTHER|Observational|no intervention was required for this cross sectional study
219756889|NCT07161232|BEHAVIORAL|Standardized Postoperative Rehabilitation Protocol|"This intervention is a standardized, progressive rehabilitation protocol for patients after lumbar disc herniation surgery, delivered under the guidance of a senior physical therapist. The protocol aims to improve pain, restore function, and prevent complications through core stability exercises and neurodynamic techniques. The exercises are performed once daily and progressed based on patient tolerance. The protocol consists of two phases:~Initial Phase ( commencing postoperatively): Includes: 1) Transverse abdominis activation; 2) Sit-to-stand training with abdominal bracing; 3) Four-point kneeling rockbacks for spinal mobility; 4) Neural mobilization techniques (performed in sitting); 5) Neural sliding techniques (performed in sitting).~Progressive Phase: Builds upon the initial exercises by increasing the range of motion, adding isometric hold times, and integrating cervical movement with neural techniques to increase difficulty and intensity."
219756890|NCT07158619|DIETARY_SUPPLEMENT|OIT with cashew nut protein|After 8 months of continued oral immunotherapy (OIT) with cashew nuts, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to assess desensitization. Patients who had a negative OFC after 3 months in the initial phase-confirming desensitization-will skip the pre-break OFC and proceed directly to the next stage. Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to evaluate sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed during this visit.
219756891|NCT07160842|BEHAVIORAL|Hand hygiene intervention|The educational intervention consisted of a two-part training session: (i) a thirty-minute didactic session introducing the 7-step alcohol-based hand rub (ABHR) technique (14), the importance of proper hand hygiene for infection prevention; and (ii) a practical component on hand hygiene with real-time feedback.
219756892|NCT07159191|DRUG|Envafolimab Injection, Axitinib Tablets|"Envafolimab + Axitinib~* Envafolimab 400 mg, subcutaneous injection, day 1, every 3 weeks;~* Axitinib 5 mg, orally, twice daily"
219569500|NCT01625481|DEVICE|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
219003384|NCT02584335|DRUG|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
219003385|NCT05816512|DRUG|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
219003386|NCT05816512|DRUG|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
219003387|NCT02500888|RADIATION|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
219003388|NCT02326961|DEVICE|Celution Device|ADRCs Prepared using the Celution Device
219410681|NCT02507193|PROCEDURE|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
219410682|NCT02913222|OTHER|Rehabilitation|Comparison of two rehabilitation approaches
219410683|NCT01945424|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
219410684|NCT04151355|DRUG|Atorvastatin 20mg|atorvastatin (20 mg once daily)
219003389|NCT02326961|OTHER|Placebo|Inactive Placebo
219191880|NCT04715893|OTHER|Ostomy belt|Stealth ostomy belt continuous for eight weeks
219191881|NCT05920148|PROCEDURE|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
219410685|NCT00694954|DEVICE|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
219410686|NCT00694954|OTHER|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
219410687|NCT06400316|DIETARY_SUPPLEMENT|Amino Acid Supplement|The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
219410688|NCT05415150|DRUG|Thrombolytic Agent|Subjects may receive one or more of the treatment options
219410689|NCT06313177|PROCEDURE|syndesmosis fixation with screws|syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
219410690|NCT00736866|DRUG|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
219410691|NCT00736866|DRUG|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
219429494|NCT00862654|DRUG|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
219429495|NCT00862654|DRUG|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
219429496|NCT01476748|DEVICE|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
219429497|NCT02750267|DEVICE|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
219429498|NCT01750944|PROCEDURE|Ankle first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured."
219410692|NCT06365515|DRUG|Levodopa administration|To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
219410693|NCT06365515|DRUG|Placebo administration|Placebo tablets will be administered as the placebo-controlled condition.
219410694|NCT02652312|DRUG|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
219410695|NCT02652312|DRUG|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
219410696|NCT02652312|PROCEDURE|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
219410697|NCT02652312|PROCEDURE|fentanyl|1.5 μg/kg intraoperative
219410698|NCT02652312|PROCEDURE|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
219410699|NCT02652312|PROCEDURE|Atracurium|0.5 mg/kg IV for endotracheal intubation
219410700|NCT02652312|PROCEDURE|diclofenac sodium|1 mg/kg for postoperative analgesia
219410701|NCT02652312|PROCEDURE|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
219756893|NCT07159022|PROCEDURE|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
219756894|NCT07159022|PROCEDURE|Face Mask Oxygenation|conventional oxygen therapy will be administered through common mask with a flow up to 6 Liters per minute
219756895|NCT07160816|DRUG|Insulin icodec|Participants with T1D will be treated with commercially available insulin icodec.
219756896|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule
219756897|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule placebo|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule placebo
219756898|NCT07158996|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
219756899|NCT07161375|DEVICE|Infrared Thermography|Infrared thermography will be used to predict the success of an erector spinae block by measuring the temperature difference between the blocked and unblocked sides.
219756900|NCT07159464|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
219756901|NCT07159282|OTHER|XWRAP|Application of XWRAP + standard of care for up to 12 weeks.
219756902|NCT07161544|BIOLOGICAL|AAVB-039|Single subretinal administration
219756903|NCT07159204|DRUG|Paclitaxel polymer micelle immunocombination|Paclitaxel polymer micelle immunocombination
219756904|NCT07159516|DIAGNOSTIC_TEST|Diagnostic interview|SCID-5 Clinician Version (SCID-5-CV) was used as gold standard method for determining if diagnostic criteria of PTSD was met or not (First, 2023). SCID-5-CV has been validated for use via telephone with good results for PTSD (Osorio et al., 2019). Only the PTSD-chapter was used, and exclusively birth-related traumatic experiences were considered. This was done achieved by adding a question to the interview guide, addressing potentially traumatic experiences associated with healthcare during a physical examination, operation, intensive care or childbirth.
219756905|NCT07160374|PROCEDURE|Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)|Transarterial chemoembolization performed through the radial artery using HepaSphere drug-eluting microspheres in patients with hepatocellular carcinoma.
219756906|NCT07160166|OTHER|Prototype 1|Subjects will brush and rinse with their assigned mouthwash twice daily.
219756907|NCT07160166|OTHER|Prototype 2|Subjects will brush and rinse with their assigned mouthwash twice daily.
219756908|NCT07160166|OTHER|Marketed Comparator|Subjects will brush and rinse with their assigned mouthwash twice daily.
219756910|NCT07159360|DEVICE|CLINICAL EXPLORER|8 sessions of use of the device in the rehabilitation center
219756911|NCT07161297|DRUG|Intravenous remimazolam (5 mg initially, with optional 2.5 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Remimazolam + Fentanyl IV fentanyl 100 mcg is given first, followed after 1 minute by IV remimazolam 5 mg over 1 minute. Additional 2.5 mg boluses may be given every 2 minutes as needed. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
219756912|NCT07161297|DRUG|Intravenous midazolam (3 mg initially, with optional 3 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Midazolam + Fentanyl (≤1000 caratteri) IV fentanyl 100 mcg is given first, followed after 1 minute by IV midazolam 3 mg over 1 minute. Additional midazolam may be administered based on clinical judgment. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
219756913|NCT07160881|BEHAVIORAL|Pillow maniquin training|In this initiative, participants will be trained with a low-cost mannequin in addition to standard training.
219756914|NCT07160686|DRUG|Apixaban|apixaban 2.5mg twice a day for 6 months
219756915|NCT07160686|OTHER|Placebo|Placebo twice a day for 6 months
219756916|NCT07161635|DEVICE|Clareon PanOptix Pro/Pro Toric Trifocal IOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
219756917|NCT07161635|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for IOL implantation.
219756918|NCT06152107|PROCEDURE|BTVA treatment plus optimal medical therapy (GOLD guidelines)|"Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments(unless the two most severe subsegments are located in the same segment). Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will receive ipsilateral hemithorax treatment per procedure, with a treatment volume (air + tissue) of ≤1700 mL per procedure and ≥1000 mL cumulatively across two procedures. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded."
219410702|NCT01091987|BEHAVIORAL|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
219410703|NCT05663736|DRUG|Gemigliptin|DPP-4 inhibitor
219410704|NCT05663736|DRUG|Glimepiride|Glimepiride
219410705|NCT00809458|DRUG|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
219569501|NCT02910414|DRUG|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
219569502|NCT02910414|DEVICE|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
219569503|NCT00128037|DRUG|mitomycin C, vindesine, cisplatin and radiotherapy|
219569504|NCT02523937|OTHER|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
219756919|NCT06160427|BIOLOGICAL|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
219756920|NCT06160427|BIOLOGICAL|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
219569505|NCT02501551|DRUG|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
219569506|NCT01202877|DRUG|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
219756921|NCT03419234|DRUG|Abiraterone Acetate|Given PO
219756922|NCT03419234|DRUG|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
219756923|NCT03419234|DRUG|Cabazitaxel|Given IV
219756924|NCT03419234|OTHER|Laboratory Biomarker Analysis|Correlative studies
219756925|NCT03419234|PROCEDURE|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
219756926|NCT03419234|OTHER|Pharmacological Study|Correlative studies
219756927|NCT03419234|DRUG|Prednisone|Given PO
219756928|NCT04817189|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
219756929|NCT04817189|DRUG|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
219756930|NCT04817189|DRUG|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
219191882|NCT05833867|DRUG|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
219410706|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
219410707|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
219410708|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
219410709|NCT04216927|DRUG|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
219410710|NCT04216927|DRUG|Oxygen|Oxygen alone will be entrained for placebo arm
219756931|NCT05056896|DRUG|Aspirin|Capsule taken orally
219756932|NCT05056896|OTHER|Placebo|Capsule taken orally
219191883|NCT05833867|RADIATION|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
219410711|NCT05972759|OTHER|Forced and voluntary exercise|Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
219569507|NCT01202877|DRUG|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
219569508|NCT01362426|DRUG|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
219569509|NCT00396331|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
219410712|NCT04491786|DRUG|Gabapentin|Gabapentin plus nefopam
219410713|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
219410714|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
219410715|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
219191884|NCT05843188|DRUG|Hydroxychloroquine|Anti-Inflammatory - antimalarial - aminoquinolines
219410716|NCT03977285|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
219410717|NCT02568917|PROCEDURE|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
219410718|NCT02568917|PROCEDURE|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
219410719|NCT04145830|DEVICE|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
219410720|NCT05442463|DRUG|Captopril Tablets|Captorpril challenge to each participant
219410721|NCT05442463|DRUG|Iohexol|Iohexol infusion to evaluate measured GFR
219410722|NCT06600048|DRUG|Hyperbaric prilocaine|Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.
219410723|NCT06600048|DRUG|Hyperbaric bupivacaine|Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
219410724|NCT01054677|BEHAVIORAL|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
219410725|NCT05414617|DEVICE|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
219410726|NCT05414617|DEVICE|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
219410727|NCT02654106|RADIATION|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
219410728|NCT02654106|DRUG|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
219410729|NCT00748540|DEVICE|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
219410730|NCT03803761|DRUG|Copanlisib|Given IV
219569510|NCT06617130|DIETARY_SUPPLEMENT|Corn soy bean blended flour porridge plus indispensable amino acid|"Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids."
219569511|NCT06616922|DRUG|RD03/2016 eye drops|1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
219410731|NCT03803761|DRUG|Fulvestrant|Given IM
219410732|NCT00720239|OTHER|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
219410733|NCT03765346|DRUG|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
219410734|NCT03765346|DRUG|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
219191885|NCT05843188|DRUG|Irinotecan|Antineoplastic agent
219191886|NCT05843188|DRUG|Leucovorin|Folic acid derivative
219191887|NCT05843188|DRUG|Fluorouracil|Antineoplastic agent
219191888|NCT05843188|DRUG|Bevacizumab|Antineoplastic agent
219410735|NCT03765346|DRUG|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
219410736|NCT03765346|DRUG|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
219410737|NCT02824380|DRUG|DA-4001 H|5% minoxidil / high dose of finasteride
219410738|NCT02824380|DRUG|DA-4001 L|5% minoxidil / low dose of finasteride
219003390|NCT03615976|PROCEDURE|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)"
219003391|NCT04220450|DIAGNOSTIC_TEST|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
219003392|NCT05252000|DEVICE|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
219191889|NCT05110989|DEVICE|AtriCure Cryo Nerve Block (cryoNB) Device Family|Use of Atricure Cryo Nerve Block Device Family to generate cryoanalgesia for the management of post operative pain.
219410739|NCT03604471|DRUG|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
219410740|NCT05715541|OTHER|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
219410741|NCT00308425|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
219410742|NCT04208867|BEHAVIORAL|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
219410743|NCT01668563|PROCEDURE|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
219410744|NCT01668563|PROCEDURE|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
219410745|NCT01814800|BIOLOGICAL|RI-002|Immune Globulin Intravenous (IGIV)
219410746|NCT02030145|PROCEDURE|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
219410747|NCT02030145|PROCEDURE|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
219410748|NCT01333982|OTHER|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
219410749|NCT01333982|OTHER|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
219410750|NCT05009823|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
219410751|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
219410752|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
219410753|NCT05009823|DIETARY_SUPPLEMENT|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
219410754|NCT05009823|DIETARY_SUPPLEMENT|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
219410755|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
219410756|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
219410757|NCT02938065|PROCEDURE|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
219569512|NCT06616922|DRUG|Levofloxacin 0.5% eye drops solution (Oftaquix®)|1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
219569513|NCT06415214|DRUG|Placebo|Placebo
219569514|NCT06415214|DRUG|HRS-7535|HRS-7535
219569515|NCT01884584|DRUG|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
219569516|NCT06605625|BIOLOGICAL|Influenza vaccination|one annual dose of inactivated influenza vaccine
219410758|NCT02938065|OTHER|2% milk|16 participants will drink 10 ounces of 2% milk
219410759|NCT02938065|OTHER|apple juice|16 participants will drink 10 ounces of apple juice
219410760|NCT02938065|OTHER|ensure clear|16 participants will drink 10 ounces of ensure clear
219410761|NCT05522335|BIOLOGICAL|BBV154(Intranasal) & covaxin|Intervention Covaxin
219410762|NCT01515176|DRUG|Dinaciclib|Given IV
219410763|NCT01515176|OTHER|Laboratory Biomarker Analysis|Correlative studies
219410764|NCT01515176|BIOLOGICAL|Ofatumumab|Given IV
219410765|NCT01515176|OTHER|Pharmacological Study|Correlative studies
219410766|NCT00362063|DRUG|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
219410767|NCT03727321|COMBINATION_PRODUCT|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
219410768|NCT03727321|DIETARY_SUPPLEMENT|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
219569517|NCT06605625|BIOLOGICAL|SARS-CoV-2 vaccine|dose of SARS CoV2 vaccine
219410769|NCT03727321|DIETARY_SUPPLEMENT|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
219410770|NCT02586636|DRUG|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
219410771|NCT02586636|DRUG|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
219569518|NCT06605625|BIOLOGICAL|Zoster Vaccine Recombinant|first and/or second vaccination for shingles (Herpes zoster)
219410772|NCT02586636|DRUG|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
219410773|NCT01896037|DIETARY_SUPPLEMENT|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
219569519|NCT05631821|PROCEDURE|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
219569520|NCT00775528|DRUG|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
219569521|NCT02377180|PROCEDURE|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
219569522|NCT02377180|PROCEDURE|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
219569523|NCT02377180|PROCEDURE|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
219569524|NCT06050876|PROCEDURE|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
219756933|NCT06433700|OTHER|BAS|NOMESCO (Nordic Medico-Statistical Committee) Classification of Surgical Procedures (KJDF10 \& KJDF11 \[gastric bypass\]; KJDF20 \& KJDF21 \[gastric banding\]; KJDF40, KJDF41, KJDF96 \& KJDF97 \[gastric sleeve\]).
219756934|NCT06433700|OTHER|Non-BAS|Patients without BAS codes
219756935|NCT00561990|DRUG|Nimotuzumab|
219756936|NCT00492453|PROCEDURE|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
219410774|NCT02371759|DRUG|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
219410775|NCT02371759|DRUG|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
219410776|NCT02371759|DRUG|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
219569525|NCT04010916|OTHER|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
219756937|NCT01334918|DRUG|regadenoson|Administered by intravenous bolus.
219756938|NCT01334918|RADIATION|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
219756939|NCT01334918|RADIATION|Contrast|Administered by intravenous infusion.
219756940|NCT01334918|PROCEDURE|Single Photon Emission Computed Tomography|Procedure/Surgery
219756941|NCT01334918|PROCEDURE|Multidetector Computed Tomography|Procedure/Surgery
219756942|NCT00414375|PROCEDURE|Operation on Admission|Laparoscopic appendectomy on admission
219756943|NCT00414375|PROCEDURE|Drainage and Interval Appendectomy|drainage with interval appendectomy
219756944|NCT02273089|DEVICE|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
219756945|NCT03172143|PROCEDURE|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
219191890|NCT04900350|DRUG|AK117|Subjects receive AK117 intravenously.
219756946|NCT03172143|PROCEDURE|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
219756947|NCT02842593|BEHAVIORAL|Lower-repetition, heavier-load|8-12 reps/set at \~80% 1 repetition maximum
219756948|NCT02842593|BEHAVIORAL|Higher-repetition, lighter-load|20-25 reps/set at \~30% 1 repetition maximum
219756949|NCT02200601|DEVICE|Seipher Wellness|
219410777|NCT02371759|DRUG|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
219410778|NCT00454064|BEHAVIORAL|cognitive-behavioral treatment|
219410779|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 200 mL tap water via nasogastric tube|
219410780|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
219569526|NCT04010916|OTHER|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
219569527|NCT04010916|OTHER|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
219569528|NCT04855448|DEVICE|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
219569529|NCT04855448|DEVICE|da Vinci robot|The surgeries are performed with the da Vinci robot
219569530|NCT01058551|DEVICE|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
219756950|NCT06718738|BIOLOGICAL|IM96 CAR-T Cells|IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
219003393|NCT05252000|DEVICE|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
219003394|NCT05252000|DEVICE|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
219003395|NCT05323942|OTHER|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
219003396|NCT00574509|RADIATION|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
219410781|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
219410782|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
219410783|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
219410784|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
219410785|NCT03190720|DEVICE|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
219410786|NCT05304182|DEVICE|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
219410787|NCT05304182|DEVICE|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
219410788|NCT04676750|BEHAVIORAL|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
219410789|NCT01403740|DRUG|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
219410790|NCT00430625|BIOLOGICAL|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
219569531|NCT04776954|DEVICE|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
219003397|NCT00574509|DRUG|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
219410791|NCT03649958|DEVICE|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
219410792|NCT03649958|DEVICE|Cereset 2x|Cereset 2x for five 90 minute sessions
219410793|NCT03605810|OTHER|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
219410794|NCT00243230|DRUG|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
219410795|NCT00243230|DRUG|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
219410796|NCT00243230|DRUG|Placebo|Three tablets of placebo once daily for 48 weeks.
219410797|NCT00243230|DRUG|Placebo|Two tablets of placebo once daily for 48 weeks.
219410798|NCT00243230|DRUG|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
219410799|NCT04933305|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
219410800|NCT04188340|BEHAVIORAL|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
219410801|NCT02159963|OTHER|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
219410802|NCT02159963|OTHER|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
219410803|NCT02159963|OTHER|Optional training|8 weeks of optional home based, unsupervised training.
219410804|NCT02159963|OTHER|Control|8 weeks of control period. Participants are doing daily living.
219410805|NCT03072017|BEHAVIORAL|MBAT|Breathing-based intervention
219410806|NCT03003143|DRUG|Vigabatrin 500 MG|
219410807|NCT01680094|DRUG|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
219410808|NCT00333268|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
219410809|NCT00333268|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
219410810|NCT01137331|DRUG|K301|Liquid- applied once daily prior to bed
219410811|NCT01137331|DRUG|Placebo|Liquid- applied once daily prior to bed
219410812|NCT02029404|PROCEDURE|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
219569532|NCT04776954|DEVICE|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
219003398|NCT02371109|OTHER|selftaken versus clinically taken swabs|
219410813|NCT02029404|PROCEDURE|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
219191891|NCT04900350|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
219191892|NCT06543303|DRUG|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
219191893|NCT06543303|DRUG|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
219410814|NCT03975868|OTHER|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
219410815|NCT00540553|DRUG|placebo|
219410816|NCT00540553|DRUG|GSK971086|
219410817|NCT01064453|DRUG|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
219410818|NCT02249286|BEHAVIORAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
219410819|NCT02249286|OTHER|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
219410820|NCT01470573|PROCEDURE|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
219410821|NCT01516164|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
219410822|NCT01188382|PROCEDURE|CSF dynamic investigation|
219410823|NCT03828006|DIETARY_SUPPLEMENT|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
219410824|NCT03828006|OTHER|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
219410825|NCT01689207|DRUG|Avibactam (AVI)|PART A: AVI IV infusion
219410826|NCT01689207|DRUG|Aztreonam (ATM)|PART A: ATM IV infusion
219410827|NCT01689207|DRUG|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
219410828|NCT01689207|DRUG|Placebo|PART A, PART B, PART C: matching placebo IV infusions
219410829|NCT05118386|DRUG|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"
219410830|NCT05118386|OTHER|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
219410831|NCT05130333|OTHER|No intervention|No intervention
219410832|NCT00004013|BIOLOGICAL|trastuzumab|
219410833|NCT00004013|DRUG|paclitaxel|
219410834|NCT03176940|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
219410835|NCT04640324|DRUG|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
219410836|NCT00294008|DRUG|Risperdal Consta|flexible dosage for 24 months
219410837|NCT02244723|OTHER|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
219410838|NCT02844023|BEHAVIORAL|Clinical evaluation|With questionnaire.
219410839|NCT02844023|OTHER|Paraclinical evaluation|Symptom inflammatory, biomarkers.
219410840|NCT02844023|DEVICE|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
219191894|NCT06543303|DRUG|BTV100 High dose|4% Cevimeline Ophthalmic Solution
219410841|NCT02844023|OTHER|Ophthalmologic examination|
219410842|NCT02844023|BIOLOGICAL|Dosage of biomarkers|Control patients.
219410843|NCT01150955|DIETARY_SUPPLEMENT|Resveratrol|500 mg three times a day for five weeks.
219410844|NCT01150955|OTHER|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
219410845|NCT00303108|DRUG|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
219410846|NCT00303108|DRUG|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
219410847|NCT00303108|DRUG|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
219410848|NCT02954003|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
219410849|NCT01769690|OTHER|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
219410850|NCT01769690|OTHER|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
219191895|NCT06543303|DRUG|Placebo|Placebo
219410851|NCT03542071|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
219429499|NCT01750944|PROCEDURE|Toe first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured."
219429500|NCT06356948|DRUG|Tranexamic Acid (TXA)|Study drug administration
219429501|NCT04702048|DRUG|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
219429502|NCT04702048|DRUG|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
219429503|NCT03089658|DRUG|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
219429504|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219429505|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219190280|NCT05845931|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
219410852|NCT03542071|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
219410853|NCT03076047|DEVICE|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
219410854|NCT01588145|DRUG|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
219569533|NCT05612282|DIAGNOSTIC_TEST|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
219756951|NCT01583673|OTHER|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
219756952|NCT01583673|OTHER|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
219756953|NCT05807568|OTHER|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
219191896|NCT05130814|DEVICE|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
219569534|NCT05612282|OTHER|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
219569535|NCT05612282|OTHER|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
219569536|NCT05612282|DIAGNOSTIC_TEST|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
219569537|NCT05612282|DIAGNOSTIC_TEST|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
219569538|NCT05612282|OTHER|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
219569539|NCT04621916|DRUG|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
219569540|NCT04621916|DRUG|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
219569541|NCT00350402|BEHAVIORAL|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
219569542|NCT00419887|DRUG|Vildagliptin (LAF237)|
219569543|NCT02331693|BIOLOGICAL|anti-EGFR CAR T|
219191897|NCT05130814|PROCEDURE|cleansing|cleaning of the wound area with saline or ringer's lactate
219191898|NCT05130814|COMBINATION_PRODUCT|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
219191899|NCT05130814|DRUG|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
219191900|NCT05130814|PROCEDURE|topical treatment|topical treatment indicated for that stage of the lesion
219410855|NCT03201198|BEHAVIORAL|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
219410856|NCT03201198|BEHAVIORAL|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
219191901|NCT05130814|PROCEDURE|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
219191902|NCT06561061|DRUG|zinc sulfate|Dispersible (20 mg) tablet
219191903|NCT06561061|DRUG|Placebo|Dispersible tablet
219410857|NCT00149604|DRUG|conjugated estrogens|
219410858|NCT00149604|DRUG|Raloxifene|
219410859|NCT00149604|BEHAVIORAL|exercise plus mild caloric restriction for weight loss|
219410860|NCT04901065|DRUG|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
219410861|NCT04901065|DRUG|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
219410862|NCT02142179|BEHAVIORAL|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
219410863|NCT03649100|PROCEDURE|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
219410864|NCT02912806|PROCEDURE|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
219410865|NCT03816306|DRUG|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
219410866|NCT03855137|DRUG|Atogepant 30 mg|Tablets containing 30 mg atogepant
219410867|NCT03855137|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
219410868|NCT03855137|DRUG|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
219410869|NCT02674737|DRUG|dexmedetomidine, tramadol and flurbiprofen|
219410870|NCT02674737|DRUG|tramadol and flurbiprofen|
219410871|NCT01579981|PROCEDURE|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
219410872|NCT01105416|BEHAVIORAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
219410873|NCT01105416|BEHAVIORAL|ESC|Enhanced standard care
219410874|NCT02427477|DEVICE|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
219410875|NCT02427477|DEVICE|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
219410876|NCT02335216|DEVICE|Implantation with the commercially available Axium neurostimulator|
219410877|NCT02406547|DEVICE|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
219410878|NCT02406547|DEVICE|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
219569544|NCT06236568|DEVICE|D-HOPE machine perfusion|use of the device
219569545|NCT06236568|PROCEDURE|Liver transplantation|Liver transplantation for HCC within Milan criteria
219569546|NCT01884688|DRUG|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
219569547|NCT02938013|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
219569548|NCT02938013|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
219756954|NCT01317303|PROCEDURE|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
219756955|NCT01317303|PROCEDURE|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
219756956|NCT01317303|PROCEDURE|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
219756957|NCT01317303|PROCEDURE|iTBS|190 seconds of intermittent theta-burst stimulation
219756958|NCT00765219|BEHAVIORAL|CBT|10-12 weekly sessions of CBT in person or over the telephone.
219756959|NCT00765219|OTHER|Usual Care|Treatment as usual provided by participants' physician(s)
219003399|NCT05484518|BEHAVIORAL|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
219410879|NCT04369430|DRUG|AKST4290|Oral AKST4290
219410880|NCT04369430|DRUG|Placebo|Oral Placebo
219410881|NCT06115434|PROCEDURE|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
219410882|NCT04748224|DRUG|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
219410883|NCT04748224|DRUG|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
219410884|NCT04827836|PROCEDURE|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
219410885|NCT02994069|DRUG|Cisplatin|Cisplatin
219410886|NCT02994069|RADIATION|XRT|Radiation Therapy
219410887|NCT06273657|OTHER|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
219410888|NCT02065622|DRUG|Adalimumab|
219410889|NCT02065622|OTHER|Placebo|
219410890|NCT05866471|DRUG|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
219410891|NCT05866471|DEVICE|Transcutaneous auricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
219410892|NCT05866471|BEHAVIORAL|Psychosocial Support Alone|Participants assigned to Psychosocial Support Alone will not receive taVNS following psilocybin dosing.
219410893|NCT05866471|OTHER|Sham taVNS|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
219410894|NCT04349306|DRUG|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
219410895|NCT02349334|DEVICE|Percutaneous Tibial Nerve Stimulation|
219429506|NCT05314881|GENETIC|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
219429507|NCT03451500|DRUG|carbidopa-levodopa|See previous
219429508|NCT03258697|DRUG|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
219429509|NCT00356395|DRUG|ramipril, candesartan|
219429510|NCT02392494|DRUG|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
219429511|NCT04736329|DRUG|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
219429512|NCT06372886|PROCEDURE|portal/superior vein resection|portal/superior vein resection
219429513|NCT05202223|BEHAVIORAL|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
219429514|NCT05208723|BEHAVIORAL|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
219429515|NCT04152642|DEVICE|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
219429516|NCT04152642|OTHER|Water control|negative control
219429517|NCT04152642|DEVICE|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
219429518|NCT04911699|BEHAVIORAL|breast adenocarcinoma receiving chemotherapy|for chemotherapy
219429519|NCT04911699|BEHAVIORAL|Control-for|hormonal drug treatment
219429520|NCT02443571|RADIATION|Fluciclovine (18F)|Not applicable. This is an observational study.
219429521|NCT00361894|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
219429522|NCT00361894|DRUG|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
219429523|NCT06224972|DEVICE|Vlab|The study is observational, there is no intervention.
219429524|NCT05161312|BEHAVIORAL|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
219429525|NCT00643357|DRUG|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
219429526|NCT00643357|DRUG|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
219429527|NCT04081376|DRUG|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
219429528|NCT00984880|DRUG|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
219429529|NCT01382199|DRUG|Lactoferrin|
219429530|NCT03579992|BEHAVIORAL|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
219410896|NCT03769935|DRUG|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
219410897|NCT02307721|DRUG|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
219756960|NCT05981326|PROCEDURE|Biopsy|biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
219410898|NCT02307721|DRUG|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
219756961|NCT05981326|PROCEDURE|Blood samples|Centralized blood samples will be performed at inclusion + evaluation visits
219756962|NCT05981326|BEHAVIORAL|Questionnaires|Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
219756963|NCT05188638|DRUG|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
219756964|NCT05188638|DRUG|Placebo|Sterile isotonic saline
219410899|NCT02307721|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
219410900|NCT02307721|DEVICE|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
219410901|NCT01693458|BEHAVIORAL|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
219410902|NCT01787643|OTHER|Height-Adjustable Desk Intallation in Office|
219410903|NCT00267332|DRUG|Modafinil|
219429531|NCT03579992|BEHAVIORAL|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
219429532|NCT03579992|BEHAVIORAL|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
219429533|NCT05677295|DRUG|duloxetine|Duloxetine 30 mg per day
219429534|NCT05677295|DRUG|Imipramine|Imipramine 25 mg per day
219429535|NCT03129412|RADIATION|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
219429536|NCT00587769|DRUG|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
219429537|NCT03467295|PROCEDURE|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
219429538|NCT03467295|PROCEDURE|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
219429539|NCT01055418|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
219429540|NCT00350311|DRUG|nicotine transdermal patch/lozenge|
219429541|NCT02031432|DRUG|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
219429542|NCT01617187|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
219429543|NCT01617187|DRUG|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
219429544|NCT01617187|DRUG|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
219429545|NCT01617187|DRUG|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
219429546|NCT03923439|DEVICE|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
219429547|NCT06710158|DRUG|SC-102|SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.
219429548|NCT00503178|PROCEDURE|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
219429549|NCT04430283|DRUG|FDY-5301|FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
219429550|NCT04430283|OTHER|Placebo|Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
219429551|NCT01905670|DEVICE|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
219429552|NCT04396743|PROCEDURE|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
219410904|NCT05422352|DIETARY_SUPPLEMENT|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
219410905|NCT06519552|GENETIC|JWK008 Single intravenous infusion administration|"Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant."
219410906|NCT00077337|DRUG|romidepsin|
219410907|NCT05420688|OTHER|Heart Failure Group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
219410908|NCT05833893|DRUG|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
219410909|NCT01947244|BEHAVIORAL|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
219410910|NCT01947244|BEHAVIORAL|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
219410911|NCT04115696|DEVICE|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
219410912|NCT02276235|DEVICE|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
219410913|NCT02276235|DEVICE|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
219410914|NCT03496363|DIAGNOSTIC_TEST|TSH , T4|Thyroid stimulating hormone
219410915|NCT01192750|OTHER|immunohistochemistry staining method|
219410916|NCT01192750|OTHER|laboratory biomarker analysis|
219756965|NCT02275507|DEVICE|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
219756966|NCT01619917|DEVICE|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
219756967|NCT02025998|DRUG|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
219756968|NCT02025998|OTHER|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
219756969|NCT01082848|DRUG|aripiprazole|10 mg QD during 26 weeks
219756970|NCT01082848|DRUG|placebo|QD during 26 weeks
219756971|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
219756972|NCT03362268|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
219756973|NCT03362268|DRUG|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
219756974|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
219756975|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
219756976|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
219756977|NCT05949879|OTHER|Pecan LOW|Participants are provided with a quantity of pecans that delivers 6% of the participant's estimated energy needs for 28 days.
219756978|NCT05949879|OTHER|Pecan MID|Participants are provided with a quantity of pecans that delivers 13% of the participant's estimated energy needs for 28 days.
219756979|NCT05949879|OTHER|Pecan HIGH|Participants are provided with a quantity of pecans that delivers 20% of the participant's estimated energy needs for 28 days.
219756980|NCT05949879|OTHER|CONTROL|Participants are asked to maintain their current habitual diet and to avoid any tree nut/peanut consumption for the entire 28-day intervention period.
219756981|NCT04948112|DEVICE|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
219756982|NCT04948112|DEVICE|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
219756983|NCT06102655|DRUG|Jiajian Guishen Formulation|Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
219190281|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
219190282|NCT03576612|BIOLOGICAL|AdV-tk|Given IT
219410917|NCT01192750|OTHER|medical chart review|
219569549|NCT05450484|DRUG|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
219190283|NCT03576612|DRUG|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
219569550|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
219569551|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
219410918|NCT04408859|DRUG|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
219410919|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
219429553|NCT04396743|PROCEDURE|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
219429554|NCT06159829|BEHAVIORAL|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
219429555|NCT07057986|DEVICE|Trans cervical or abdominal ultrasound|ultrasound assessment before the scheduled upper endoscopy.
219756984|NCT06403449|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
219756985|NCT06403449|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
219756986|NCT06261255|PROCEDURE|ATT + EMD|All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
219756987|NCT03381599|DRUG|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
219756988|NCT04372485|BEHAVIORAL|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
219756989|NCT03292237|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
219429556|NCT06762366|BEHAVIORAL|Additional Incentive|During this behavioral intervention, participants will be given additional compensation for correct answers.
219756990|NCT05918848|DEVICE|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
219756991|NCT01295489|OTHER|Laboratory Biomarker Analysis|Correlative studies
219190284|NCT03576612|RADIATION|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
219190285|NCT03576612|DRUG|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
219190286|NCT03576612|BIOLOGICAL|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
219410920|NCT01458509|BEHAVIORAL|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
219410921|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
219410922|NCT01458509|BEHAVIORAL|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
219410923|NCT01767194|BIOLOGICAL|Dinutuximab|Given IV
219756992|NCT01068184|DRUG|AZD6553|Single or multiple oral dose
219410924|NCT01767194|DRUG|Irinotecan Hydrochloride|Given IV
219569552|NCT02268539|PROCEDURE|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
219410925|NCT01767194|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219410926|NCT01767194|BIOLOGICAL|Sargramostim|Given SC or IV
219410927|NCT01767194|DRUG|Temozolomide|Given PO
219410928|NCT01767194|DRUG|Temsirolimus|Given IV
219410929|NCT00066625|DRUG|oxaliplatin|Given IV
219410930|NCT00066625|DRUG|bortezomib|Given IV
219410931|NCT00066625|OTHER|laboratory biomarker analysis|Correlative studies
219410932|NCT00066625|OTHER|pharmacological study|Correlative studies
219410933|NCT00001439|BIOLOGICAL|gp100 human melanoma peptide|
219410934|NCT02474667|DRUG|ANG-3777|
219410935|NCT02474667|OTHER|Placebo|
219410936|NCT05846997|DIAGNOSTIC_TEST|Liquid biopsy and imaging|Liquid biopsy and imaging
219410937|NCT02317406|DRUG|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
219410938|NCT02317406|DRUG|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
219410939|NCT04072354|DRUG|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
219410940|NCT04072354|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
219569553|NCT00712244|DEVICE|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
219569554|NCT00712244|DEVICE|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
219569555|NCT00712244|DEVICE|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
219569556|NCT00712244|DEVICE|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
219569557|NCT02063087|OTHER|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
219569558|NCT02560428|BEHAVIORAL|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
219756993|NCT01068184|DRUG|Placebo|single or multiple oral dose
219410941|NCT04072354|DRUG|Placebo|Placebo tablet dosed once daily
219410942|NCT05165576|BEHAVIORAL|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
219756994|NCT04368208|OTHER|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
219410943|NCT02946710|BIOLOGICAL|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
219410944|NCT00495664|DEVICE|Titan stent and Taxus-Liberte stent|
219410945|NCT01444495|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
219410946|NCT01444495|PROCEDURE|Surgery|Total mesorectal excision of rectal cancer
219410947|NCT02920684|OTHER|Passive legs mobilisation|A physiotherapist performs a passive leg movement
219410948|NCT02920684|OTHER|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
219410949|NCT02920684|OTHER|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
219410950|NCT02920684|OTHER|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
219756995|NCT03185221|DEVICE|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
219756996|NCT03185221|DEVICE|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
219761223|NCT05904769|DEVICE|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
219410951|NCT05831059|RADIATION|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
219756997|NCT01051245|BEHAVIORAL|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
219410952|NCT05831059|OTHER|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
219410953|NCT02764632|PROCEDURE|Digital facilitation|
219410954|NCT06679621|BEHAVIORAL|Telehealth intervention|This telehealth intervention will be made using human centered design methods
219410955|NCT05104099|DRUG|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
219410956|NCT04973228|DRUG|Roflumilast Foam|Roflumilast 0.3% foam for topical application
219410957|NCT04973228|DRUG|Vehicle Foam|Vehicle foam for topical application
219410958|NCT04237207|DEVICE|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
219410959|NCT04237207|DEVICE|301-M062 sound processor & software|New cochlear implant sound processor
219410960|NCT02490150|DRUG|Corifollitropin alfa|
219410961|NCT06421246|BEHAVIORAL|Staff-facing screen|Activity will be monitored before and after the introduction of a staff-facing screen
219569559|NCT03099629|BEHAVIORAL|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
219569560|NCT02860182|OTHER|measure the elastic properties of aortic wall|
219569561|NCT00591331|DRUG|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
219569562|NCT00591331|DRUG|placebo|
219756998|NCT01051245|OTHER|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
219003400|NCT03026452|PROCEDURE|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
219410962|NCT06681623|DRUG|Ublituximab|Drug: ublituximab
219410963|NCT06684535|DRUG|Dexmedetomidine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
219410964|NCT06684535|DRUG|Saline|Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
219410965|NCT06684431|BIOLOGICAL|N-pVAX1|Crimean Congo Hemorrhagic Fever Vaccine
219410966|NCT06684626|DRUG|Sodium Hyaluronate|Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
219410967|NCT06684626|DRUG|Levofloxacin 500mg|Treatment typically involves fluoroquinolones alone, such as levofloxacin.
219410968|NCT07013890|DRUG|FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium|"FICOXPEA® is a phytoterapic compound made of:~* phycocyanin (spirulina platensis extract) 250 mg~* palmitoylethanolamide 200 mg~* L-selenometionine 11 mg"
219410969|NCT02318914|DRUG|gevokizumab|
219410970|NCT00319852|BIOLOGICAL|DTaP-IPV combined vaccine|0.5 mL, IM
219569563|NCT02549573|DRUG|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
219569564|NCT02549573|BEHAVIORAL|Physical Therapy|All subjects will participate in a standardized PT intervention
219003401|NCT02310568|DRUG|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
219569565|NCT02197026|DRUG|Hylan G-F 20|
219569566|NCT02197026|DRUG|Standard treatment|Standard drug treatment at the discretion of the investigator
219569567|NCT02197026|PROCEDURE|Physiotherapy|
219569568|NCT02197026|PROCEDURE|Hydrotherapy|
219569569|NCT00161382|BEHAVIORAL|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
219190287|NCT03576612|OTHER|Laboratory Biomarker Analysis|correlative studies
219190288|NCT05810012|DRUG|PENG block|10ml of 0.125% isobaric bupivacaine injected
219190289|NCT05810012|DRUG|FICB Block|20ml of 0.125% isobaric bupivacaine injected
219410971|NCT00319852|BIOLOGICAL|DTaP vaccine|0.5 mL, IM
219410972|NCT06691100|BEHAVIORAL|Aerobic Exercise|30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).
219756999|NCT00805389|BIOLOGICAL|Engerix-B™|2 doses intramuscular injections
219757000|NCT00805389|BIOLOGICAL|Fendrix™|2 doses intramuscular injections
219757001|NCT00805389|BIOLOGICAL|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
219410973|NCT06688032|OTHER|Jarlsberg cheese|Jarlsberg cheese contains Propionebacterium freudenreichii (PF) producing the K2-vitamer MK-9(4H) and DHNA in addition to the K2-vitamers found in Norvegia cheese
219410974|NCT06688032|OTHER|Norvegia|Cheese with different content of K2 vitamers
219410975|NCT06691308|COMBINATION_PRODUCT|WL276 CAR-T cells|This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
219429557|NCT06762366|BEHAVIORAL|Response Delay|During this behavioral intervention, participants will not be allowed to respond with their judgements until after a certain amount of time has passed.
219429558|NCT06762366|BEHAVIORAL|Baseline Performance|In this intervention, the participant completes the task as it is typically administer for a baseline performance measure. The participant can respond at will and does not receive incentive for correct responses.
219429559|NCT07071376|OTHER|cold dialysis|Patients who meet the inclusion criteria will receive 3 sessions of cold dialysis treatment by reducing the dialysate temperature from 36.5°C to 36°C. Patients will receive this treatment for 1 week, i.e. 3 dialysis sessions. Each dialysis session will last 4 hours. During each dialysis session, the thermal comfort status of the patients will be evaluated by applying the Temperature Comfort Perception Scale at the beginning of dialysis, at the 1st, 2nd and 3rd hours of dialysis and at the end of dialysis. In addition, the day after each session, the patients will be called by phone and the Postdialysis Fatigue Scale will be re-administered and their fatigue levels will be evaluated.
219429560|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- low risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the low risk of overdiagnosis arm will view a version of the decision aid the describes a low risk of overdiagnosis.
219429561|NCT07071415|BEHAVIORAL|Breast cancer decision aid -- moderate risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the moderate risk of overdiagnosis arm will view a version of the decision aid the describes a moderate risk of overdiagnosis.
219429562|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- high risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the high risk of overdiagnosis arm will view a version of the decision aid the describes a high risk of overdiagnosis.
219429563|NCT07071415|OTHER|Control condition|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the control arm will view a version of the decision aid that does not contain any information about overdiagnosis.
219429564|NCT06901258|BEHAVIORAL|Genius Pillbox|Participants will be mailed a Genius Pillbox to their home address. Along with the pillbox, they will also receive a detailed written description to orient them to the Genius Pillbox. Participants will be expected to use the Genius pill box organizer daily for four weeks as part of their usual medication routine. Participants are also expected to fill the designated compartments with their daily pills.
219429565|NCT03862131|DEVICE|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
219429566|NCT06765161|DRUG|efgartigimod administration|efgartigimod infusion
219429567|NCT07091721|BEHAVIORAL|Mentalization based therapy (MBT)|Mentalization based therapy for conduct disorder
219429568|NCT07091721|OTHER|Support as usual|Support usually provided by FCAMHS which may include advice/guidance to the professional network around the child/adolescent, psychoeducation, other mental health treatment e.g. CBT
219429569|NCT07092423|DIETARY_SUPPLEMENT|Semi-elemental formula|Treatment: Semi-elemental enteral nutrition Objective: To assess the efficacy of semi-elemental enteral nutrition in enhancing gastrointestinal tolerance in patients with severe traumatic brain injury.
219429570|NCT07092423|DIETARY_SUPPLEMENT|Standard formula|Treatment: Standard enteral nutrition Objective: To serve as the control for evaluating the efficacy and safety of semi-elemental enteral nutrition versus standard nutritional therapy
219429571|NCT07091812|DEVICE|Ultrasound Vagus Nerve Stimulation (U-VNS)|Ultrasound stimulation of the auricular branch of the vagus nerve using the ZenBud device manufactured by NeurGear (Rochester, New York, USA), a CE-compliant over-the-ear headset. It delivers low-intensity focused ultrasound to the auricular branch of the vagus nerve through several layers of skin (centre frequency 5.3 MHz, pulse repetition rate 41 hertz, 50% duty cycle, average intensity of 1.03 MPa).
219429572|NCT07091812|DEVICE|Sham U-VNS|Sham device, also produced by NeurGear, which is identical in appearance to the true ZenBud device, emits the same sound and warms up slightly where the transducer sits on the skin.
219429573|NCT07091084|DIETARY_SUPPLEMENT|MZRW|MZRW herbal formula consists of a 7:1 extract of Huo Ma Ren \[Hemp Seed 33.4%\]; Da Huang (Sheng) \[Rhubarb (Fresh) 22.2%\]; Bai Shao \[Peony (White) 11.1%\]; Zhi Shi \[Aurantium Immaturus 11.1%\]; Hou Po \[Magnolia Bark 11.1%\]; and Xing Ren \[Apricot Kernel 11.1%\] - Taken for 2 weeks intervention and 2 weeks follow-up
219429574|NCT07090031|DRUG|TAS-102 in combination with oxaliplatin|"Induction : TAS102 35mg/m2, twice a day for 5 days, on 1st, 3rd, 5th week; Oxliplatin 85mg/m2 on 1st and 2nd week; Rectal radiotherapy 50GY/25f in 5 weeks. 2 weeks no treatment.~Consolidation: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 3 cycles. 4 weeks no treatment.~Surgery Adjuvant chemotherapy: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 16 cycles."
219429575|NCT07090265|PROCEDURE|non-surgical periodontal therapy|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes
219429576|NCT07090265|PROCEDURE|non-surgical periodontal therapy + I-PRF|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes following by subgingival application of I-PRF
219410976|NCT07017595|BEHAVIORAL|Visual-acoustic biofeedback: experimental|Visual-acoustic biofeedback treatment incorporates elements of traditional voice training, including auditory models, verbal descriptions of articulator placement, and cues for repetitive motor practice using images and diagrams of the vocal tract as visual aids. Our experimental software will provide several options for visualizing the fundamental frequency of the voice (for targets involving vocal pitch) and for visualizing vocal tract resonances. Custom targets for pitch and resonance will be created for each participant based on their baseline voice characteristics and personal voice goals. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments influence the proximity of their output to the target.
219410977|NCT07017023|DRUG|Losartan with BA|7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA
219410978|NCT07017023|OTHER|Placebo with BA|7-day placebo (oral; microcellulose in identical capsules) with 7-day BA
219410979|NCT02678780|DRUG|Lenvatinib|
219410980|NCT02034357|OTHER|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
219410981|NCT02034357|OTHER|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
219410982|NCT06108427|OTHER|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
219410983|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
219410984|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
219410985|NCT06693375|DEVICE|Rectal Magnetomotoric ultrasound (MMUS)|MMUS examination of lymphnodes in rectum
219410986|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
219410987|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
219410988|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
219410989|NCT06687161|DEVICE|Transcranial Magnetic Stimulation (TMS) therapy|Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC
219410990|NCT06687161|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)
219410991|NCT06728566|DEVICE|Inmersive virtual reality|"In addition to conventional training, IVR training aims to provide a detailed preview of the tasks and procedures required in the standard training with selected virtual scenarios:~Scenario 1: Inspection and Use of Personal Protective Equipment (PPE):~In this scenario, the worker will inspect the equipment to ensure it is in good condition and properly used: Harness, Helmet, Lanyards, Carabiners, Lifelines, Energy Absorbers~Scenario 2: Working on an Elevated Metal Structure:~Structure Ascent: Ascent Method: Use specific ascent systems, ensuring you are always connected to an anchor point.~Positioning on the Structure: Secure Anchorage: Once the working position is reached, secure the anchor to a fixed and reliable point.~Structure Descent: Unanchoring and Reanchoring: Unanchor and re-anchor at secure points as you descend.~Additional Safety Measures: Weather Conditions, signage and delimitation:~Scenario 3: Rescue at Heights: Accessing the Person in Danger, rescue Techniques."
219410992|NCT06728566|OTHER|Conventional training|"The working at heights training provided by the National Learning Service (SENA) in Colombia includes key steps to ensure safety and proper equipment use:~* Harness Use: Inspect for damage, wear it like a vest, and ensure correct orientation. Adjust shoulder and leg straps for comfort and secure the chest strap.~* Final Check: Verify D-rings are correctly positioned, and all buckles are securely fastened.~* Helmet: Inspect for damage and adjust for a secure fit.~* Lanyards: Select in good condition, connect properly, keep tension, and avoid overloading.~* Carabiners: Use certified carabiners with functioning locks, connected to proper points.~* Lifelines and Energy Absorbers: Install and tension lifelines properly; check energy absorbers before use.~* Climbing/Descending: Maintain three contact points and secure tools to avoid accidents."
219569570|NCT00161382|BEHAVIORAL|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
219569571|NCT02732691|DEVICE|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
219569572|NCT05237440|BIOLOGICAL|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
219569573|NCT00847106|DRUG|Daclizumab|
219569574|NCT00847106|BIOLOGICAL|Dendritic cells|
219569576|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
219569577|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
219569578|NCT02162355|DRUG|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
219569579|NCT02162355|DRUG|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
219569580|NCT02162355|DRUG|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
219569581|NCT02162355|DRUG|Placebo|1 or 2 matching placebo tablets once daily for 10 days
219569582|NCT03794518|DRUG|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
219569583|NCT03794518|DRUG|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
219569584|NCT04239118|COMBINATION_PRODUCT|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
219569585|NCT04239118|PROCEDURE|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
219190290|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
219410993|NCT06777654|OTHER|Robotic therapy (RT)|The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.
219410994|NCT06777654|OTHER|Mirror therapy (MT)|The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.
219410995|NCT06777654|OTHER|Dose-matched control intervention|Participants in the control group will receive therapist-mediated rehabilitation per session.
219410996|NCT01454401|DEVICE|LeucoPatch treatment|weekly
219410997|NCT04614545|DRUG|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
219410998|NCT04614545|BEHAVIORAL|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
219410999|NCT04614545|BEHAVIORAL|Exercise program|Patients will be provided with a personalized exercise program
219569586|NCT01473121|OTHER|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
219569587|NCT01158352|DIETARY_SUPPLEMENT|Nutritional supplementation formula|Nutritional supplementation formula
219569588|NCT01158352|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
219569589|NCT06604195|PROCEDURE|Modified sciatic nerve mobility exercises|Each participant was made to lie down in a supine position on the treatment couch. The participant's leg was moved to about 30-45 degrees hip flexion with knee extension. The ankle was then moved to maximum dorsiflexion with inversion and hip internal rotation within the participant's tolerance, and this position was maintained for 30 seconds. While the therapist performed dorsiflexion with inversion and hip internal rotation in the supported straight leg raise position, the participant was instructed to actively flex the cervical spine slowly until they perceived a tolerable stretch sensation in the hamstring muscle and lower leg. The synchronous alternating movements were performed rhythmically for 10-15 repetitions. This maneuver was repeated 3 times in a single session, 3 days per week, and continued for 3 consecutive weeks.
219569590|NCT06604195|PROCEDURE|Dynamic hamstring muscle stretching|"The participant was instructed to stand straight with the unaffected foot supported on the floor and the toes pointing forward. The heel of the testing leg was placed on an 18 high step with the toes directed upwards with knee extension. Once cued, the participant was asked to flex forward at the hip while maintaining the spine in a neutral position and reaching the arms forward. The knee joint remained fully extended as the participant continued to flex the hip until a gentle stretch was felt in the posterior thigh. Once the position was achieved, the participants were asked to hold it for 20-30 seconds. The same procedure was repeated 3 times daily, 3 days a week for three consecutive weeks."
219569591|NCT06824012|BEHAVIORAL|Growth Mindset Intervention|"A structured, daily-activity-based intervention program designed to foster a growth mindset among adolescents in youth custody frameworks and their staff. The intervention involves:~Guided engagement in practical, meaningful daily activities tailored to individual and group needs.~Reflective feedback sessions to reinforce principles of a growth mindset. Pre- and post-intervention assessments using standardized tools, including the Canadian Occupational Performance Measure (COPM) and structured questionnaires."
219569592|NCT06590376|OTHER|midwifery care based on swanson care theory|All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
219569593|NCT02194569|DRUG|Citrate|
219569594|NCT00759434|PROCEDURE|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
219569595|NCT00759434|PROCEDURE|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
219569596|NCT05542979|DRUG|HH-003 injection|HH-003 injection is administrated via I.V. infusion
219569597|NCT05542979|DRUG|Placebo|Placebo is administrated via I.V. infusion
219569598|NCT02506608|PROCEDURE|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
219757002|NCT00805389|BIOLOGICAL|HBsAg (Booster injection)|Single dose intramuscular injection
219757003|NCT03893526|DRUG|Entresto|Single dose administration of entresto
219757004|NCT03893526|DRUG|Sitagliptin|Single dose administration of sitagliptin
219190291|NCT07056959|PROCEDURE|Soft tissue substitute for peri-implant phenotype modification|XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when
219411000|NCT05167500|DRUG|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
219411001|NCT07053670|DRUG|CAR T cells|chimeric antigen receptor T cells
219003402|NCT01989078|DRUG|Losartan|"Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
219003403|NCT02085317|DRUG|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
219411002|NCT07054060|PROCEDURE|carotid endarterectomy|Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke due to carotid artery stenosis. During an endarterectomy, the surgeon opens the artery and removes the plaque.
219411003|NCT07054060|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an endovascular procedure in which a stent is deployed in the lumen of the carotid artery to treat narrowing of the carotid artery and reduce the risk of stroke.
219411004|NCT07060300|OTHER|Agree to Pharmacogenetic Testing|Caregivers agree to receive pharmacogenetic testing for their child.
219411005|NCT04748783|OTHER|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
219411006|NCT04748783|OTHER|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
219411007|NCT04748783|DRUG|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
219411008|NCT04748783|OTHER|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
219411009|NCT00544128|DRUG|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
219411010|NCT00544128|DRUG|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
219411011|NCT05800444|DRUG|BAY3283142|Oral administration as tablet.
219411012|NCT05800444|OTHER|Placebo|Oral administration as tablet.
219411013|NCT05468944|PROCEDURE|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
219411014|NCT05468944|PROCEDURE|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
219411015|NCT00521092|DRUG|sunitinib malate|Given orally
219190292|NCT07056959|PROCEDURE|Control Group - Free gingival graft for soft tissue augmentation|Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification
219411016|NCT00521092|PROCEDURE|laboratory biomarker analysis|Correlative study
219411017|NCT00521092|PROCEDURE|pharmacological study|Correlative study
219411018|NCT06897826|OTHER|Proprioceptive neuromuscular facilitation|The reason for choosing the proprioceptive neuromuscular facilitation technique is that it increases the hip flexion angle more than static stretching. Participants first lay down on the stretcher in a supine position. Then, the participant's lower extremity was lifted straight until the physiotherapist felt resistance. After reaching this position, the participant was asked to try to extend his lower extremity straight with half of his strength. After 10 seconds, the participant was given time to relax and after the participant relaxed, the lower extremity was brought to the new range of motion. This process was applied 3 times.
219411019|NCT06897462|DIETARY_SUPPLEMENT|SRW Ndo1|The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).
219411020|NCT06898619|BEHAVIORAL|Crisis Management Training for Third-Year Nursing Students|"Crisis management is essential for nurses, who often work on the front lines during emergencies. This training program for third-year nursing students equips them with the skills and knowledge required to handle crises effectively. The program includes nine stages: raising awareness, assessing baseline knowledge, reinforcing foundational concepts, introducing advanced techniques, practicing through simulations, reflecting on learning, providing feedback, summarizing key points, and enhancing learning with additional resources.~Participants explore critical topics such as disaster response, triage, communication strategies, and teamwork. Simulated scenarios help develop practical skills like decision-making and prioritization under pressure. Feedback and reflective discussions reinforce learning, while additional resources encourage ongoing professional growth.~By bridging theoretical knowledge with practical application, the training prepares nursing students to respond confidently t"
219569599|NCT06857058|DEVICE|NOVA DES|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
219569600|NCT05356143|DRUG|Rupatadine|Oral single dose 10 mg tablet
219569601|NCT06766721|DEVICE|Ultrasound (USG)|The intervention involves the use of a portable ultrasound (USG) device to assess costochondral joint separation in patients with blunt thoracic trauma. The ultrasound examination will focus on detecting disruptions in the connection between the ribs and cartilage, providing a non-invasive, radiation-free diagnostic method. A 12-MHz linear transducer will be used to scan the rib area for fractures or separations. The findings will be compared to those of computed tomography (CT), considered the gold standard. This intervention is designed to evaluate the accuracy, sensitivity, and specificity of ultrasound as a diagnostic tool in this context.
219569602|NCT00000963|DRUG|Didanosine|
219757005|NCT03893526|DRUG|Valsartan|single doses administration of valsartan
219190293|NCT07057609|DRUG|Tested Propofol Medium and Long Chain Fat Emulsion Injection (T)|Single-dose intravenous infusion of the test formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
219757006|NCT03893526|DRUG|Placebo|placebo day
219757007|NCT02036346|DIETARY_SUPPLEMENT|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
219757008|NCT02036346|OTHER|Advise on calculated oral fluid requirements|
219757009|NCT02036346|OTHER|No nutritional advice will be given|
219757010|NCT06413732|OTHER|Conventional physiotherapy|Conventional physiotherapy was applied for approximately 1 hour, 5 days a week.
219411021|NCT06899347|PROCEDURE|Total Thyroidectomy + Central Compartment Neck Dissection|"Thyroidectomy will be performed with the patient in the supine position with the neck hyperextended. A 3 to 6 cm transverse cervicotomy, two fingers above the sternal notch, will be performed, and the midline will be opened. After the inferior laryngeal nerve and parathyroids are visualized, the thyroidectomy will be achieved.~When performed, pCCND will aim at removing the nodes of Level VI, which has been reported to contain the thyroid gland and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the brachiocephalic artery, and laterally on each side by the carotid sheaths"
219411022|NCT05612672|OTHER|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
219411023|NCT06899243|DIETARY_SUPPLEMENT|CL22205|200 mg, Route : Oral, One capsule a day after breakfast for 360 days
219411024|NCT06899243|OTHER|Placebo|Route : Oral, One capsule a day after breakfast for 360 days
219411025|NCT07063316|DRUG|SGLT2 inhibitor|SGLT2 inhibitor
219411026|NCT07062588|DRUG|AGA2115|Subcutaneous injection
219411027|NCT07062588|OTHER|Placebo|Subcutaneous injection
219411028|NCT06899321|OTHER|Cosmetic product M68|Cosmetic skin brightening product to be applied to defined test site
219411029|NCT06899321|OTHER|Cosmetic product Z15|Cosmetic skin brightening product to be applied to defined test site
219569603|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
219569604|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
219569605|NCT01644422|OTHER|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
219569606|NCT01776567|DEVICE|Everolimus eluting stents|
219411030|NCT06899321|OTHER|Cosmetic product R52|Cosmetic skin brightening product to be applied to defined test site
219411031|NCT06899321|OTHER|Cosmetic product J61|Cosmetic skin brightening product to be applied to defined test site
219411032|NCT06899321|OTHER|Cosmetic product U36|Cosmetic skin brightening product to be applied to defined test site
219411033|NCT06898684|BEHAVIORAL|Exercise|Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.
219411034|NCT06898879|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
219411035|NCT06898879|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation, befriending, and Veteran to Veteran support. Each session is 60 minutes long.
219569607|NCT03490474|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
219569608|NCT03490474|OTHER|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
219411036|NCT07063030|GENETIC|LX107 Injection|Subjects will receive subretinal injection of LX107 on Day 0.
219569609|NCT03490474|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
219569610|NCT02926781|DEVICE|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
219569611|NCT02624726|DRUG|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
219569612|NCT02624726|DRUG|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
219569613|NCT02624726|DRUG|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
219569614|NCT02624726|DRUG|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
219757011|NCT05962944|DEVICE|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
219757012|NCT02670902|BEHAVIORAL|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
219757013|NCT02670902|BEHAVIORAL|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
219757014|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
219003404|NCT02085317|DRUG|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
219003405|NCT01327105|DEVICE|TVU|Use of transvaginal ultrasound to determine location of micro-insert
219411037|NCT07067749|DIAGNOSTIC_TEST|multiparametric magnetic resonance imaging (mpMRI) of the bladder|"This study will investigate the role of bladder mpMRI as a tool to expedite treatment in patients with muscle invasive bladder cancer.~mpMRIs will be investigated as a possible replacement of standard TURBt, a planned surgical procedure for cancer local staging.~mpMRis will be reported according to the Vesical Imaging - Reporting and Data System Stanrdars (VI-RADS) to provide a score indicating probability of muscle invasion."
219411038|NCT07067749|PROCEDURE|Transurethral resection of bladder tumour (TURBt)|This is a planned endoscopic surgical procedure consisting in resection of the bladder tumour through a electrified loop manouvred with an endoscope. In muscle invasive bladder cancer, this procedure allows histological confirmation of presence of detrusor muscle invasion.
219411039|NCT07067749|GENETIC|Circulating tumour DNA levels assessment|"Blood samples will be collected from each enrolled patient at pre-planned time points:~1. Cystoscopy, both arms~2. mpMRI (experimental arm) or TURBt (control arm)~3. Definite cancer treatment, both arms~ctDNA levels will be measured on the collected blood samples."
219411040|NCT02725073|PROCEDURE|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
219411041|NCT04604249|DIAGNOSTIC_TEST|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
219411042|NCT02362711|DRUG|NPC-16 Standard Dosing Regimen Group|
219411043|NCT02362711|DRUG|NPC-16 Continuous Dosing Regimen Group|
219411044|NCT02362711|DRUG|Placebo Group|
219411045|NCT05911009|DRUG|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
219569615|NCT03748355|GENETIC|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
219569616|NCT00562120|DRUG|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
219569617|NCT00562120|DRUG|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
219569618|NCT00562120|DRUG|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
219569619|NCT00562120|DRUG|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
219569620|NCT05598164|OTHER|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
219569621|NCT00707421|DRUG|ketorolac acetate|
219569622|NCT00707421|DRUG|fluorometholone|
219569623|NCT00707421|DRUG|artificial lacrimal tears|
219569624|NCT05872464|OTHER|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
219003406|NCT03379532|DEVICE|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
219003407|NCT03379532|DEVICE|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
219569625|NCT05872464|OTHER|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
219569626|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
219569627|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
219569628|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
219569629|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
219569630|NCT00952276|BIOLOGICAL|Normal saline solution|0.5 mL, Intramuscular on Day 0
219569631|NCT05329818|DEVICE|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
219569632|NCT03431064|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
219569633|NCT03431064|OTHER|Fluid Administration|Administration of IV Fluid by Anesthesiologist
219569634|NCT06190886|DRUG|PTX-912|Investigation Product Monotherapy
219569635|NCT04824144|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
219003408|NCT03376022|OTHER|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
219411046|NCT06809166|DRUG|Contrave|"CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule).~Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events."
219411047|NCT06809166|DRUG|Placebo|"Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention.~Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave."
219411048|NCT06809166|BEHAVIORAL|Diet Program|All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.
219411049|NCT06898203|DEVICE|SkinScan3D|A handheld, simple, low-cost, and user-friendly technology that combines liquid lens technology and artificial intelligence (AI).
219411050|NCT05943938|OTHER|Epic Sepsis Model Version - 1|The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
219411051|NCT05943938|OTHER|Epic Sepsis Model Version - 2|The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
219411052|NCT05943938|OTHER|Emory Sepsis Model|Emory internal algorithm
219411053|NCT06854627|PROCEDURE|Daily prone position sessions|Prone position sessions will be extended at least 16 hours, but no longer than 24 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
219411054|NCT06854627|PROCEDURE|Prolonged prone position sessions|Prone position sessions will be extended at least 48 hours AND until PaO2/FiO2 ratio is ≥ 200, but no longer than 120 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
219411055|NCT06864949|DEVICE|AMCOP appliance|"The device measure will be determined with OrthoCad program on digital models, taking the distance between the vestibular cusps of the upper first molars, at the level of the most prominent point. AMCOPs are preformed devices and there are five different measures based on transverse diameter: 1 (45mm), 2 (50mm), 3 (55mm), 4 (60mm), 5 (65mm).~Requiring expansion, we will choose an higher AMCOP measure than the transverse distance measured on the digital models at T0.~The clinical indications for use of the AMCOP device will be as follow:~* in the first week, wear the appliance during the night and for 30 minutes during the day~* from the second week onward, wear the appliance for one hour during the day and throughout the night During this time, every month we will visit patients and we will expand the device by soaking it in hot water at about 70 °C for 30 s and then in cold water to stabilize it in its new shape."
219411056|NCT06896240|DIETARY_SUPPLEMENT|Assigned Interventions|"The Green Smoothie Guide from the American College of Lifestyle Medicine contains guidelines for a 6-step smoothie to include whole and high fiber foods."
219411057|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
219411058|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
219411059|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
219003409|NCT02655939|DIETARY_SUPPLEMENT|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
219003410|NCT02655939|DIETARY_SUPPLEMENT|Placebo|Fructose,Orange flavor and sucralose
219003411|NCT02432014|BEHAVIORAL|PMTO-PTC Group clinic-based|
219003412|NCT02432014|BEHAVIORAL|PMTO Individual home-based|
219003413|NCT02432014|BEHAVIORAL|PMTO Individual clinic-based|
219003414|NCT02432014|BEHAVIORAL|Services as Usual|
219003415|NCT00001105|DRUG|F105 Monoclonal Antibody (Human)|
219003416|NCT00441883|DRUG|PF-03187207 and Latanoprost Vehicle|
219411060|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
219411061|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
219411062|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
219411063|NCT07074964|OTHER|Autonomic nervous system intervention|Manual therapy applied to structures adjacent to the vagus nerve along its pathway. Head: CV4 tecnique and Jugular foramen tecnique; Neck: stretching and mobilization of the superficial and deep layers; Thorax: Longitudinal and transverse translations of the mediastinum; Diaphragm tecniques, Abdomen: Stretching of the gastro-phrenic ligament with lowering of the stomach and general treatment of the small intestine and the mesentery. Stretching, compression and traction movements will be carried out on these structures.
219411064|NCT07074964|OTHER|Slight finger pressure|The hands will be placed on areas similar to those in the intervention group, with the fingertips in contact with the skin of the area. A slight finger pressure will be applied, which would not have the same effect as the proposed techniques, since those techniques require a greater intensity of manipulation of the described tissues and structures.
219411065|NCT07075380|BEHAVIORAL|online questionnaire|Online questionnaire assessing physical activity level, completed twice at a 6-month interval.
219411066|NCT07075848|PROCEDURE|vaginal delivery|follow up of progress of labour
219411067|NCT07076966|DEVICE|3D device|Use 3D machine to generate the 3D image
219429577|NCT07091136|DRUG|manidipine|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
219757015|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
219757016|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
219757017|NCT03054714|DEVICE|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
219757018|NCT02550145|DRUG|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
219757019|NCT02550145|OTHER|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
219757020|NCT03721250|OTHER|epidural|thoracic epidural analgesia
219757021|NCT04209556|DRUG|PF-06826647 100 mg QD|Investigational Product
219757022|NCT04209556|DRUG|PF-06826647 300 mg QD|Investigational Product
219429578|NCT07091136|DRUG|Placebo|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
219429579|NCT07092449|DRUG|Neoadjuvant chemo-immunotherapy|Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)
219429580|NCT07090434|DEVICE|Mobile App + psychoeducation program|"Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation. In addition to that, participants will receive access to the BEI mobile app, designed to reinforce education and exercise strategies outside clinical sessions. Participants will be instructed to use the app daily, guided by a to-do list including:~* 1 educational module (interactive format) + 3 questions self-exam~* 1 physical activity (video-guided, adapted by fatigue and pain level)~* 1 gamified cognitive task (for memory, attention, speed processing and/or executive function)~* Daily mood and symptom check-in"
219757023|NCT04209556|DRUG|PF-06826647 600 mg QD|Investigational Product
219757024|NCT04209556|DRUG|Placebo|Matched Placebo
219757025|NCT04209556|DRUG|PF-6826647 400 mg QD|Investigational Product
219757026|NCT05324241|DIETARY_SUPPLEMENT|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
219757027|NCT02605902|BEHAVIORAL|(i)Comprehensive Behavioral Intervention for Tics|
219757028|NCT02605902|BEHAVIORAL|internet-delivered psychoeducation and relaxation training|
219757029|NCT06131658|OTHER|Functional motor control excercise|This include functional motor control thrice a week for six weeks
219757030|NCT06131658|OTHER|convectional excercise|This include convectional exercise thrice a week for six weeks
219757031|NCT01409096|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
219757032|NCT01409096|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
219757033|NCT05050903|OTHER|Rhinovirus infection|Inoculation with rhinovirus-16
219757034|NCT03348124|BEHAVIORAL|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
219757035|NCT04726995|OTHER|CHOP and BFM regiments|used CHOP and BFM regiments
219411068|NCT07078747|BEHAVIORAL|To compare the effectiveness of video- and model-based training methods in improving Leopold maneuver skills among midwifery students.|"This study involves two educational interventions aimed at improving Leopold maneuver skills among midwifery students. Both intervention groups receive a standardized 2-hour theoretical lecture about the purpose, application, and clinical relevance of the Leopold maneuvers.~In the Video-Based Training Group, students watch an instructional video developed by the research team that visually demonstrates each step of the maneuver.~In the Model-Based Training Group, students perform the maneuvers on anatomical models under the supervision of an instructor.~These interventions are conducted in separate sessions to prevent cross-group contamination."
219411069|NCT04941378|DRUG|OTL38|One time infusion of OTL38
219569636|NCT05824819|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
219411070|NCT04941378|DEVICE|intraoperative imaging camera system|intraoperative imaging camera system
219569637|NCT05477459|DRUG|LSD tartrate|LSD tartrate equivalent to 25 microgram LSD base
219569638|NCT05477459|DRUG|Placebo|Placebo with equal appearance
219569639|NCT05535855|DRUG|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
219569640|NCT04567576|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
219569641|NCT00095433|DRUG|rhuFab V2 (ranibizumab)|
219569642|NCT01792414|DEVICE|Sham TES|Neuroconn Eldith device
219569643|NCT01792414|DEVICE|Active TES|Neuroconn Eldith device
219569644|NCT04685551|BEHAVIORAL|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
219569645|NCT01010126|BIOLOGICAL|Bevacizumab|Given IV
219569646|NCT01010126|DRUG|Temsirolimus|Given IV
219569647|NCT04698772|DRUG|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
219569648|NCT04698772|DRUG|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
219569649|NCT00635830|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
219757036|NCT00099255|DRUG|SGN-30|
219757037|NCT01180283|DRUG|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
219757038|NCT05061030|BIOLOGICAL|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
219003417|NCT00441883|DRUG|Latanoprost 0.005% and PF-03187207 Vehicle|
219411071|NCT07082114|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 52 weeks
219411072|NCT07082114|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 52 weeks
219411073|NCT07082114|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 52 weeks
219569650|NCT00214331|DRUG|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
219569651|NCT00214331|DRUG|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
219757039|NCT06026150|OTHER|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
219569652|NCT00214331|DRUG|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
219569653|NCT02919241|BEHAVIORAL|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
219569654|NCT02919241|BEHAVIORAL|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
219569655|NCT04587102|OTHER|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
219569656|NCT04587102|OTHER|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
219569657|NCT01150162|DRUG|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
219569658|NCT01150162|DRUG|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
219757040|NCT01599884|DRUG|N-acetylcysteine|1800 mg twice daily for 8 weeks
219757041|NCT01599884|DRUG|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
219757042|NCT00093366|BIOLOGICAL|etanercept|
219757043|NCT00093366|DRUG|arsenic trioxide|
219757044|NCT02282228|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
219757045|NCT05091411|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219757046|NCT02270658|DEVICE|CPAP|
219757047|NCT04003298|DEVICE|Electric toothbrush|Electric toothbrush and power interdental device
219757048|NCT04003298|DEVICE|Control|Oscillating-rotating
219757049|NCT04375436|DRUG|NTRX-07-SDD|NTRX-07-SDD for oral administration
219569659|NCT03883555|DEVICE|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
219569660|NCT03883555|DEVICE|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
219757050|NCT06316726|COMBINATION_PRODUCT|full bed silicone mattress plus other measures|full bed silicone mattress plus put silicone pads on the head and shoulders, cotton rolls wraps bony prominence (elbows and heels), petrissage every two hours on shoulders to fingers and lower legs to heels, change location of ankle pads, use round gel full of air sit pad, a pillow on the knees
219757051|NCT00498992|DIETARY_SUPPLEMENT|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
219757052|NCT03578250|OTHER|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
219757053|NCT03680885|DRUG|Lidocaine gel|Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
219411074|NCT07082114|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg will be provided
219411075|NCT07082764|DRUG|Brimonidine gel|TAR-0520 gel
219411076|NCT07082764|OTHER|No intervantion|No treatment
219411077|NCT07082985|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 14 days (4 capsules per day)
219411078|NCT07082985|OTHER|Maca (Maca trial)|The Maca capsule supplement was taken for 14 days, with a daily dosage of 1600 mg of Maca (equivalent to 4 capsules per day, each containing 400 mg of Maca).
219411079|NCT07082647|BEHAVIORAL|Mixed feedback method|Feedback (technical correction) method in which both visual and verbal feedback are predominantly used in the feedback given to the participants throughout the training program.
219411080|NCT07082647|BEHAVIORAL|Visual feedback method|Feedback (technical correction) method in which visual feedback is predominantly used in the feedback given to gymnasts throughout the training program.
219569661|NCT04060914|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
219569662|NCT04060914|DRUG|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
219569663|NCT04060914|DRUG|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
219569664|NCT04238637|DRUG|Durvalumab|Durvalumab IV (intravenous Infusion)
219569665|NCT04238637|DRUG|Tremelimumab|Tremelimumab IV (intravenous Infusion)
219757054|NCT03680885|DRUG|Placebo|PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
219757055|NCT03680885|DRUG|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
219757056|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
219757057|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
219757058|NCT03908203|PROCEDURE|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
219411081|NCT07082647|BEHAVIORAL|Verbal feedback method|Feedback (technical correction) method in which verbal feedback is predominantly used in the feedback given to gymnasts throughout the training program.
219411082|NCT07083739|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
219411083|NCT07074236|DRUG|QLC7401 injection|QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.
219411084|NCT07074236|DRUG|RBD7022 injection|RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.
219411085|NCT07075874|OTHER|PDPH|Observational analysis of preoperative inflammatory markers (e.g., NLR, PLR, SIRI) in relation to PDPH development following spinal anesthesia.
219411086|NCT07077187|DIAGNOSTIC_TEST|computerized dynamic posturography|Patients in each arm will have computerized dynamic posturography performed at baseline prior to taking first tablet as well as at 4 weeks and 8 weeks. In the adjuvant therapy arm, subjects will be evaluated on rasagiline but in a functional OFF state for their other Parkinson disease medications.
219569666|NCT05218109|DEVICE|tVNS|transcutaneous vagus nerve stimulation
219569667|NCT05218109|BEHAVIORAL|Mindfulness|Brightmind mobile mindfulness application
219569668|NCT05218109|DEVICE|sham tVNS|sham transcutaneous vagus nerve stimulation
219757059|NCT01798888|PROCEDURE|Implantation of Deep Brain Stimulation|
219757060|NCT00212836|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
219757061|NCT00212836|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
219411087|NCT07077187|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral tablet daily will be administered to study participants.
219411088|NCT07077187|DRUG|Placebo|Placebo 1 mg oral tablet daily will be administered to study participants.
219411089|NCT07083882|BIOLOGICAL|freezedried autologous encapsulated fecal microbiota transplantation|The freezedried autologous encapsulated microbiota transplantation increases the exposure of the small intestine to the microbiota residing in the colon. Prior evidence was found that this has strong immunomodulatory effects leading to potential preservation of beta cell function in type 1 diabetes.
219411090|NCT07083882|OTHER|placebo matching capsule without microbial content|this is the matching placebo capsule that looks from the outside identical to the actual treatment but does not contain the fecal microbiota.
219411091|NCT07083141|OTHER|Peer Mentoring Program|A 13-week peer mentoring program in which trained third-year midwifery students supported first-year students through regular meetings aimed at enhancing academic adaptation, confidence, and professional understanding.
219411092|NCT07082517|OTHER|Percentage analysis|Analysis the percentage of the population with risk factors that may lead to a PAD.
219411093|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
219411094|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
219411095|NCT07084623|DRUG|Pre-procedure lignocaine spray (PPL)|Administration of 2 mL of 4% lignocaine spray in the oropharynx before the fiberoptic bronchoscopy procedure, followed by additional 2% lignocaine spray according to body weight (3 mg/kg)
219411096|NCT07084623|DRUG|Lignocaine Spray (Spray-as-you-go)|Administration of 2% lignocaine spray via oral scope insertion during the fiberoptic bronchoscopy procedure, according to body weight (3 mg/kg), with standard procedural sedation with midazolam and initial 2 mL of 4% lignocaine spray in the oropharynx for gag reflex suppression
219411097|NCT07083908|DEVICE|THD® Anopress (Sensyprobe) first|Anorectal manometry with THD® Anopress (Sensyprobe) first then with High Resolution Anorectal Manometry (Laborie)
219411098|NCT07083908|DEVICE|High Resolution Anorectal Manometry first|Anorectal manometry with High Resolution Anorectal Manometry (Laborie) first followed by THD® Anopress (Sensyprobe)
219411099|NCT07082192|DRUG|Test drug CB03-154 5mg group|One CB03-154 tablet (5mg/tablet) once daily.
219411100|NCT07082192|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
219411101|NCT07082192|DRUG|Test drug CB03-154 15mg group|Three CB03-154 tablets (5mg/tablet) once daily.
219411102|NCT07082192|DRUG|Placebo Group|Three Placebo tablets once daily.
219411103|NCT07083674|BEHAVIORAL|Multi-level communication intervention|The intervention will target multiple levels (provider, unit, hospital) and will respond to identified modifiable communication challenges. Aim 2 intervention mapping will finalize the specific intervention; we anticipate it will involve training and education of staff members and new unit protocols for communication.
219411104|NCT07083466|DIAGNOSTIC_TEST|complete blood count|blood test
219411105|NCT07083466|DIAGNOSTIC_TEST|serum albumin|blood test
219411106|NCT07082907|OTHER|intervention group|Before using the nebulizer, children were given 2 fish in a bowl accompanied by their parents. The child patient was in the fowler/semifowler position, the movements of the fish were monitored during the nebulization period, and the fish was fed by the child during this process (Communication was provided for at least 5 minutes.)
219411107|NCT07083128|DEVICE|Parasternal intercostal thickening|Temporal change in parasternal intercostal thickening fraction at initiation and 30 minutes of spontaneous breathing trial
219411108|NCT07083622|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
219411109|NCT07083622|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
219411110|NCT07083037|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)|The BRIDGE intervention includes 12 weeks of 20-60-minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use).
219569669|NCT05218109|OTHER|Number Puzzle|Control number puzzle task delivered via mobile device
219411111|NCT07082023|PROCEDURE|V-NOTES Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via vaginal natural orifice transluminal endoscopic surgery (V-NOTES).
219411112|NCT07082023|PROCEDURE|Laparoscopic Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via conventional laparoscopy.
219411113|NCT07083973|BEHAVIORAL|Prone position|"Patients were ventilated based on the ARDS-Net recommendations . Patients were kept in a supine position. The process of lung ventilation and perfusion assessment was as follows:~1. PEEP was determined by the attending doctor and was kept the same during the supine and prone period.~2. 3D-EIT was used to monitor the ventilation and perfusion of ARDS patients at three timepoints: T1: supine position, T2: prone position at 30min, T3: prone position over 10 hours."
219411114|NCT07083921|DEVICE|plantar pressure|Healthy individuals carry loads with their dominant and non-dominant hands.
219429581|NCT07090434|BEHAVIORAL|Psychoeducation program|Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation.
219429582|NCT07091071|DEVICE|CochSyn device|The CochSyn device is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn device records and analyses biopotential waveforms that can be used for hearing screening and diagnostic applications.
219429583|NCT07092007|BIOLOGICAL|NWRD09 administered by intramuscular injection|NWRD09 administered by intramuscular injection according to the study protocol.
219429584|NCT07090044|DRUG|Bromfenac Sodium 0.07%|Bromfenac sodium 0.07% is a nonsteroidal anti-inflammatory drug to be administered as one topical drop, one time 5 minutes prior to the regularly scheduled standard of care intravitreal injection.
219411115|NCT07082153|DEVICE|the coronary sinus balloon pump|The coronary sinus balloon pump comprises a coronary sinus balloon pump catheter system and a coronary sinus balloon pump therapeutic device. This product is indicated for the treatment of ST-segment elevation myocardial infarction (STEMI) with or without coronary microvascular dysfunction (CMD), by intermittently occluding coronary sinus blood flow during percutaneous coronary intervention (PCI) procedures to reduce myocardial infarction size.
219411116|NCT07083505|DRUG|HB1801|HB1801 \[administered according to the clinical trial protocol\]
219411117|NCT07083505|DRUG|Taxotere®|Taxotere® 75 mg/ m\^2 \[administered according to the clinical trial protocol\]\]
219411118|NCT06930222|DIAGNOSTIC_TEST|blood sampling|blood samples obtained for 3 different days, limited to 5cc
219411119|NCT07082062|DIETARY_SUPPLEMENT|GLP-1 formula Group|Participants in the intervention group will consume a single dose of GLP-1 formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
219411120|NCT04315649|OTHER|3D movie viewing|3D movie viewing
219411121|NCT03042013|DRUG|ASP8273|Oral
219411122|NCT07083388|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
219411123|NCT07083388|DRUG|Dapagliflozin 10 mg|Orally administered once per day
219411124|NCT07083388|DRUG|Pioglitazone 30 mg|Orally administered once per day
219411125|NCT07083388|DRUG|Metformin HCl 1000 mg|Orally administered once per day
219411126|NCT07082933|OTHER|Standard medical treatment|Standard medical treatment
219411127|NCT06825884|BIOLOGICAL|Extracellular micro vesicles (EV)|Extracellular micro vesicles (EV) as direct perilesional injection into the diabetic chronic foot ulcers (DFU) which have not healed after using standard of care.
219411128|NCT07084259|DRUG|PCSK9 inhibitor|Single dose of subcutaneous administration of PCSK9 inhibitors (evolocumab) after PCI in patients with coronary artery disease and elevated post-PCI lipid core burden (maxLCBI4mm ≥ 200).
219569670|NCT05721651|DRUG|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
219569671|NCT04193319|DRUG|Fluzoparib|PARP inhibitor
219569672|NCT04193319|DRUG|Fluconazole|inhibitor
219569673|NCT00595335|DRUG|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
219569674|NCT00595335|DRUG|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
219569675|NCT00595335|DRUG|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
219411129|NCT07084259|DRUG|Standard Lipid-Lowering Therapy|Lipid-lowering therapy with high-intensity or maximally tolerated statins with or without ezetimibe, as per current clinical guidelines, excluding the use of PCSK9 inhibitors.
219411130|NCT07082881|OTHER|Colostrum|The treatment group will undergo the following treatment protocol within the initial 48-72 h: Investigators will select storage bags with the closest lactation time to the current time while wearing sterile gloves for the entire procedure. Next, using two 1-mL sterile syringes, investigators will draw 0.1 mL of colostrum from each bag and tightly cap the needle hubs to ensure hygiene and safety. Each syringe will be labeled with the hospitalization number, the infant's name, and the date of the mother's colostrum expression. The bags will be then left to sit at room temperature for 5 min to reach an appropriate temperature for oropharyngeal administration of the colostrum. Subsequently, the tip and cap of the first syringe will be removed, and the colostrum will be slowly injected along the right oral mucosa of the participants, lasting at least 20 s. After injection, a sterile cotton swab will be used to gently wipe the right buccal mucosa for at least 10 s.
219411131|NCT07082881|OTHER|Normal Saline|For the control group, normal saline will be used instead of colostrum. The rest of the procedure will be the same as that for the treatment group.
219411132|NCT07083180|OTHER|Recreative activity|Patients practice a leisure activity before surgery (20 minutes)
219411133|NCT07083180|OTHER|Medical Hypnosis by virtual reality|Patients benefit from a medical hypnosis session using virtual reality (20 minutes)
219569676|NCT01959490|BIOLOGICAL|trastuzumab|Given IV
219569677|NCT01959490|BIOLOGICAL|Pertuzumab|Given IV
219569678|NCT01959490|DRUG|docetaxel|Given IV
219569679|NCT01959490|DRUG|carboplatin|Given IV
219569680|NCT01959490|DRUG|doxorubicin|Given IV
219569681|NCT01959490|DRUG|cyclophosphamide|Given IV
219569682|NCT01959490|DRUG|paclitaxel|Given IV
219569683|NCT01959490|DRUG|Bevacizumab|
219761224|NCT06246526|DEVICE|Evoke|The Saluda Medical Evoke® CL-SCS System (Evoke System). The Evoke System measures and records spinal cord (SC) activation resulting from stimulation via evoked compound action potentials (ECAPs). The Evoke System can be programmed to provide ECAP-controlled, closed-loop SCS or open-loop, fixed-output (traditional) SCS; ECAPs may be measured and recorded in either stimulation mode.
219761225|NCT05835466|DRUG|reparixin|reparixin at 1200mg TID three times per day.
219761226|NCT03808610|DRUG|Cyclophosphamide|Given IV
219761227|NCT03808610|DRUG|Cytarabine|Given IV
219761228|NCT03808610|DRUG|Dexamethasone|Given IV or PO
219761229|NCT03808610|DRUG|Methotrexate|Given IV
219761230|NCT03808610|DRUG|Nelarabine|Given IV
219411134|NCT07083934|DEVICE|Peripheral nerve stimulator|Peripheral nerve stimulator along with ultrasound
219411135|NCT07083934|DEVICE|No peripheral nerve stimulator|No peripheral nerve stimulator with ultrasound. Only ultrasound will be used
219003418|NCT03063567|DEVICE|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
219003419|NCT00002096|DRUG|Zidovudine|
219003420|NCT00002096|DRUG|Didanosine|
219003421|NCT00002096|DRUG|Ganciclovir|
219190294|NCT07057609|DRUG|Reference Propofol Medium and Long Chain Fat Emulsion Injection (R)|Single-dose intravenous infusion of the reference formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
219411136|NCT07083557|OTHER|Endothelial cell collection|Participants may opt to have testing performed including blood sampling, urine sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS, having adipose (fat) or muscle biopsies, or non-invasive endothelial function testing to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
219411137|NCT07083401|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
219411138|NCT07083401|DRUG|Dapagliflozin 10 mg|Orally administered once per day
219411139|NCT07083401|DRUG|Pioglitazone 30 mg|Orally administered once per day
219411140|NCT07083401|DRUG|Metformin HCl 1000 mg|Orally administered once per day
219569684|NCT04553835|BEHAVIORAL|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
219757062|NCT05975658|DEVICE|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
219411141|NCT07082296|BEHAVIORAL|iCBT-Academia|iCBT-Academia is a brief, self-guided, internet-based cognitive behavioral therapy (iCBT) program specifically tailored to address the real-life challenges faced by the university and research community. It consists of four modules, each designed to be completed over a week.
219757063|NCT06345768|OTHER|Stress Ball|It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
219757064|NCT05000983|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
219757065|NCT05000983|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
219757066|NCT04504955|OTHER|Observational Non-Interventional Registry|Observational Non-Interventional Registry
219757067|NCT06090344|OTHER|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
219757068|NCT06090344|OTHER|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
219757069|NCT06389058|OTHER|Recommendation for the diagnoses and treatment of Severe Asthma|No intervention planned in this phase for the patients. Recommendations to be developed for healthcare and condition.
219757070|NCT06070662|DIAGNOSTIC_TEST|Coronary microvascular disease testing during coronary angiography|During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
219757071|NCT06070662|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan including exercise|Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
219757072|NCT06070662|DIAGNOSTIC_TEST|Additional analysis of already acquired CT scan|Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
219757073|NCT04083417|DRUG|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
219757074|NCT04083417|OTHER|No antibiotic treatment|No prescription of antibiotics
219757075|NCT05484128|DIETARY_SUPPLEMENT|Gastrus|"Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus."
219757076|NCT05484128|OTHER|Placebo|placebo has an identical preparation to Gastrus
219757077|NCT06068504|OTHER|Arm-cranking exercise|Arm-cranking exercise
219003422|NCT04173468|OTHER|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
219411142|NCT07082348|BEHAVIORAL|Herbs and Spices Nutrition Education Program|Participants will attend two group visits at the UNLV Nutrition Center (weeks 0 and 3 of the 6-week intervention), where trained RDs will deliver the HSNP, covering the principles and health benefits of the Dietary Guidelines for Americans (DGA), recommended food group intake, and practical, budget-friendly strategies for incorporating herbs and spices into the diet. Sessions will include education, supporting materials, and a sensory evaluation of 20 foods (spanning fruits, vegetables, grains, dairy, and proteins) prepared with various herbs and spices, rated using a 9-point hedonic scale to identify preferred flavor profiles and promote long-term DGA adherence through enhanced taste and acceptability.
219003423|NCT04173468|OTHER|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
219429585|NCT07090044|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Loteprednol etabonate 0.38% ophthalmic gel is a steroidal drug to be administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
219429586|NCT07090044|DRUG|Propylene Glycol Preservative-free Artificial Tears|Propylene Glycol Preservative-free Artificial Tears is a placebo compartor administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
219429587|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 60-70% HR reserve for 30 minutes.
219003424|NCT00988611|OTHER|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
219003425|NCT05699499|OTHER|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
219429588|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 20-30% HR reserve for 30 minutes.
219411143|NCT07083544|BEHAVIORAL|Written Sleep Hygiene Strategies (W-SHS)|Participants assigned to the W-SHS group received a printed handout containing general sleep hygiene strategies. These strategies were designed to improve sleep quality and included recommendations on maintaining a consistent sleep-wake schedule, minimizing light exposure before bedtime, avoiding screens and heavy meals in the evening, optimizing the sleep environment (e.g., room temperature, noise), and managing nap timing. Participants were instructed to apply these strategies consistently for 10 consecutive days. No individual guidance was provided.
219411144|NCT07083544|BEHAVIORAL|Verbal Sleep Hygiene Strategies (V-SHS)|Participants in the V-SHS group received the same general sleep hygiene strategies as the W-SHS group, but delivered through a one-on-one verbal education session. A trained researcher in sleep and sport science conducted a 40-minute session with each athlete, explaining each strategy and offering personalized clarifications and suggestions. Participants were then instructed to implement these strategies over a 10-day period.
219411145|NCT07083089|OTHER|Thorough Hearing assessment|Otoscopy Tympanometry Tonal audiometry (air and bone conduction) Vocal audiometry (in silence and in noise) Distorsion Products of OtoAcoustic Emissions (DPOAE) Middle Ear Muscle Reflex (MEMR) Auditory Brainstem Response (ABR) Electrocochleography (EcochG)
219411146|NCT05185882|OTHER|Single leg squat|Single leg squat exercise in different circumstances
219411147|NCT07083518|DEVICE|Anodal transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes.
219411148|NCT07083518|DEVICE|Sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219569685|NCT04553835|BEHAVIORAL|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
219757078|NCT06068504|OTHER|Heating|Immersion of the foot in warm water
219757079|NCT02549066|PROCEDURE|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
219761231|NCT03808610|DRUG|Pegaspargase|Given IV
219761232|NCT03808610|DRUG|Prednisone|Given PO
219411149|NCT07082426|DEVICE|Balloon expandable TAVI|Prospective, single-arm, multi-center early experience study.
219411150|NCT06930404|OTHER|facial scans, videos and heart rate variability measurements|Ignite app to collect data (videos, photos and heart rate variability)
219411151|NCT04562064|DEVICE|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
219411152|NCT02222012|DEVICE|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
219411153|NCT02222012|DEVICE|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
219411154|NCT07082751|BEHAVIORAL|Lifestyle Guidance|Lifestyle Guidance
219411155|NCT07083492|DIAGNOSTIC_TEST|non-invasive measurement of zink protoporphyrin|validation of non-invasive measurement of zink protoporphyrin
219411156|NCT05497778|DRUG|Gemcitabine|Given by IV (vein)
219411157|NCT05497778|DRUG|Nab paclitaxel|Given by IV (vein)
219411158|NCT05497778|DRUG|IM156|Given by PO
219761233|NCT03808610|BIOLOGICAL|Rituximab|Given IV
219761234|NCT03808610|DRUG|Venetoclax|Given PO
219761235|NCT03808610|DRUG|Vincristine|Given IV
219761236|NCT06474195|BEHAVIORAL|Cue based intervention|The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.
219761237|NCT06474195|BEHAVIORAL|Treatment as Usual|This group will not get any intervention but the usual treatment all assessments will continue
219761238|NCT05300503|BEHAVIORAL|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
219761239|NCT02386800|DRUG|ruxolitinib|ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
219761240|NCT02386800|DRUG|panobinostat|panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
219761241|NCT04870762|OTHER|Best Practice|Receive standard of care
219761242|NCT04870762|OTHER|Medical Device Usage and Evaluation|Wear 3D printed oral stent
219761243|NCT06347016|DRUG|Plozasiran Injection|ARO-APOC3 Injection
219761244|NCT06347016|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219761245|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
219761246|NCT02502786|DRUG|GM-CSF|
219761247|NCT05215236|OTHER|Opiate Sparing|Subjects will receive non-opiate medications for pain control
219761248|NCT05215236|OTHER|Opiate Based|Subjects will receive opiate based medications for pain control
219761249|NCT05206331|DEVICE|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
219411159|NCT05032053|DRUG|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
219411160|NCT06920719|DRUG|YHP2406|Test drug: YHP2406, Comparator: YHR2501
219411161|NCT06920719|DRUG|YHR2501|Test drug: YHP2406, Comparator: YHR2501
219757080|NCT02549066|DRUG|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."
219003426|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo strength training classes
219003427|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo tai chi classes
219003428|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo stretching and relaxation classes
219003429|NCT01635413|OTHER|Questionnaire Administration|Ancillary studies
219003430|NCT00760578|DRUG|Placebo|Once daily, oral
219003431|NCT00760578|DRUG|Pioglitazone|Once daily, oral
219003432|NCT00760578|DRUG|MSDC-0160 90 mg|Once daily, oral
219411162|NCT05809011|DRUG|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
219411163|NCT05809011|DRUG|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
219429589|NCT07092163|DEVICE|QLF Imaging (Qraypen C®)|Fluorescence-based assessment of restoration margins using Qraypen C® device to measure autofluorescence loss (ΔF) and red fluorescence (ΔR). Imaging was performed during routine 18-month follow-up to detect micro-leakage or marginal biofilm activity.
219429590|NCT07092163|PROCEDURE|Clinical evaluation|Restorations were evaluated both at baseline (1-week recall) and at 18-month follow-up using the FDI World Dental Federation Clinical Evaluation Criteria, which allow structured and sensitive assessment of indirect restorations across three domains: Functional properties (e.g., marginal adaptation, fracture, retention, occlusion), Biological properties (e.g., recurrent caries, hypersensitivity, pulp status), Esthetic properties (e.g., marginal discoloration, surface texture, shade matching). Each criterion was scored on a 5-point ordinal scale: 1 = Clinically excellent / very good, 2 = Good (minor corrections), 3 = Satisfactory (acceptable with no significant clinical impact), 4 = Unsatisfactory (repair required), 5 = Clinically poor (replacement required). Scores of 1-3 were considered clinically acceptable, while scores of 4 or 5 indicated restorative failure.
219429591|NCT07092358|OTHER|None of intervention|No specific intervention was implemented in this study.
219757081|NCT00624845|DRUG|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
219757082|NCT00624845|DRUG|Vehicle|Maximum of 6 bags of vehicle irrigation solution
219757083|NCT05871957|DRUG|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
219757084|NCT03323957|DIAGNOSTIC_TEST|nutritional screening tool|screening of disease associated malnutrition in sick infants
219757085|NCT03763578|OTHER|Licorice|Natural herbal product
219757086|NCT02168556|BEHAVIORAL|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
219757087|NCT02168556|BEHAVIORAL|Video|Subject watches an informational video prior to undergoing urodynamic testing.
219757088|NCT02168556|OTHER|Standard of care|Standard of care
219757089|NCT03387956|DRUG|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
219757090|NCT03387956|DRUG|dexamethasone|intravenous 8 mg dexamethasone (2ml).
219757091|NCT04682665|DRUG|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
219757092|NCT04682665|OTHER|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
219757093|NCT02235324|BIOLOGICAL|ziv-aflibercept|Given IV
219757094|NCT02235324|DRUG|leucovorin calcium|Given IV
219757095|NCT02235324|DRUG|fluorouracil|Given IV
219757096|NCT02235324|OTHER|laboratory biomarker analysis|Correlative studies
219757097|NCT02136992|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
219757098|NCT02136992|DRUG|placebo|placebo will be taken two tablets 3 times a day during the whole study process
219757099|NCT02063451|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
219757100|NCT01701882|DRUG|tenofovir/emtricitabine/rilpivirine|
219757101|NCT00193024|DRUG|Docetaxel|
219757102|NCT00193024|DRUG|Epirubicin|
219757103|NCT00240851|DRUG|acetaminophen extended release|
219757104|NCT02704208|BEHAVIORAL|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
219757105|NCT02704208|BEHAVIORAL|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
219761250|NCT05206331|DRUG|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
219761251|NCT06399263|DRUG|Psilocybin|The psilocybin will include two dose administration sessions, first a 20mg administration, and second an administration of up to 30mg.
219003433|NCT00760578|DRUG|MSDC-0160 220 mg|Once daily, oral
219003434|NCT04932551|OTHER|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
219003435|NCT04647578|DEVICE|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
219190295|NCT07063550|OTHER|exposure to microplastic|Microplastic content in cancerous and paracancerous tissues
219411164|NCT05104671|OTHER|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:"
219411165|NCT05104671|OTHER|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
219761252|NCT06399263|BEHAVIORAL|Preparation and Integration Sessions|The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.
219761253|NCT06001320|DRUG|Letermovir 480 mg once daily|We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
219761254|NCT06001320|OTHER|Historical/Control|The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
219761255|NCT05303519|DRUG|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
219003436|NCT00812578|DRUG|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
219003437|NCT01920789|RADIATION|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
219190296|NCT07063355|OTHER|Stripping Massage Technique:|"* The back of the neck and shoulder were uncovered.~* Controlled and steady pressure was administered using the thumb along the entirety of the tense trapezius muscle, moving from origin to insertion and perpendicular to the muscle fibers, for approximately 3 minutes, twice weekly over a period of 4 weeks.~* The pressure was progressively raised with each subsequent stroke, based on tolerance level."
219190297|NCT07063355|OTHER|Post-Isometric Relaxation (PIR)|"* During the PIR intervention, the patients rested in a supine position with their necks tilted to the side, away from the affected side, placing the upper trapezius muscle fibers in a stretched position.~* A moderate isometric contraction, around 75% of the patient's maximum effort, was performed by the upper trapezius and maintained for 5 seconds, followed by a 3-second relaxation phase.~* The therapist then gently mobilized the cervical spine to a new range of motion barrier.~* This sequence was repeated four times per session."
219761256|NCT05303519|DRUG|Placebo|Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
219761257|NCT00696124|BIOLOGICAL|VM202 2 mg|2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
219761258|NCT00696124|BIOLOGICAL|VM202 4 mg|4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
219761259|NCT00696124|BIOLOGICAL|VM202 8 mg|8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
219761260|NCT00696124|BIOLOGICAL|VM202 16 mg|16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
219761261|NCT05617677|DRUG|Deucravacitinib|Specified dose on specified days
219761262|NCT05617677|OTHER|Placebo|Specified dose on specified days
219761263|NCT04428008|DRUG|Thymalfasin|Synthetic 28 amino acid peptide
219761264|NCT05047172|DRUG|Ticagrelor + Aspirin|ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
219761265|NCT05047172|DRUG|Rivaroxaban + Aspirin|low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
219761266|NCT05047172|DRUG|Clopidogrel + Aspirin|clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
219761267|NCT05047172|OTHER|Risk Factor Management|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
219761268|NCT04462302|BEHAVIORAL|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
219761269|NCT02255435|DRUG|Omaveloxolone Capsules, 2.5 mg|
219761270|NCT02255435|DRUG|Omaveloxolone Capsules, 5 mg|
219761271|NCT02255435|DRUG|Omaveloxolone Capsules, 10 mg|
219761272|NCT02255435|DRUG|Placebo|
219761273|NCT02255435|DRUG|Omaveloxolone Capsules, 20 mg|
219761274|NCT02255435|DRUG|Omaveloxolone Capsules, 40 mg|
219003438|NCT01920789|RADIATION|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
219003439|NCT04550390|DIAGNOSTIC_TEST|Saliva collection|2 saliva samples are self-collected by participants
219003440|NCT00173082|PROCEDURE|Glucose tolerance test|
219003441|NCT06382584|PROCEDURE|Femoral fracture surgery|Hip fracture surgery
219411166|NCT05104671|OTHER|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
219411167|NCT06929637|DRUG|Infusion Therapy|Infusion of amino acids once daily - dose 1g/kg, maximum 100 g daily for 3 consecutive days starting D1 after kidney transplantation procedure
219411168|NCT06929637|DRUG|Saline solution infusion|Infusion of saline solution a s standard rehydration therapy after kidney transplantation
219411169|NCT06929793|DIETARY_SUPPLEMENT|Multiple Micronutrients|"1. Multiple micronutrient~2. Calcium Carbonat 766 mg~3. Vitamin D3 5000 IU~4. DHA 300 mg"
219411170|NCT06929793|DRUG|Standard Antenatal Vitamin|Standard Antenatal Vitamin given in Community Health Centers
219411171|NCT06929078|OTHER|Protective lung ventilation methods with different positive end-expiratory pressure during Laparoscopic Surgeries|Protective lung ventilation methods with positive end-expiratory pressure help in prevention of atelectasis and improvement of intraoperative ventilator parameters e.g low driving pressure and improved dynamic compliance resulting in better oxygenation of lungs ere will be three groups in this study. Individualized positive end-expiratory pressure with recruitment maneuver and fixed positive end-expiratory pressure will be interventional groups. They will be compared with conventional ventilation group in which no additional positive end-expiratory pressure will be applied. The effects on respiratory parameters and oxygenation of patients will be compared for each group. This study will determine which method of positive end-expiratory pressure is superior and how it differs from conventional ventilation for prevention of atelectasis induced by pneumoperitonium and improvement of respiratory mechanical parameters and oxygenation in Mechanical ventilation during laparoscopic surgeries.
219411172|NCT06930807|OTHER|Adaptive postoperative management based on minimal residual disease|participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.
219411173|NCT05366413|OTHER|Early Referral|Directing a patient for a pain specialist consult earlier than standardly occurs.
219411174|NCT05366413|OTHER|Pain Management Strategies|Specialized plan with procedures to ease pain
219411175|NCT06939140|PROCEDURE|Bipolar prostatectomy|Endoscopic transurethral bipolar enucleation or reaction of the prostate
219569686|NCT04553835|BEHAVIORAL|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
219569687|NCT04553835|BEHAVIORAL|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
219569688|NCT05637853|DRUG|GDMT|Predifined fast uptitration of GDMT for HFrEF with support of home monitoring.
219569689|NCT00146380|DRUG|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
219569690|NCT00146380|BEHAVIORAL|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
219569691|NCT05984602|DRUG|Canakinumab|250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
219757106|NCT00527228|DRUG|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
219757107|NCT00527228|DRUG|placebo|
219411176|NCT05170659|DRUG|Relatlimab|
219411177|NCT07082452|DRUG|Venetoclax|Venetoclax 400 mg orally once Daily
219411178|NCT07082452|DRUG|Azacitidine|75 mg/m2 Subcutaneous (SC) or intravenous (IV) Daily with a continuous 7-day scheme or on a 5-on/2-off \[weekend\]/2-on schedule (5-0-2) in 28-day cycle
219761275|NCT02255435|DRUG|Omaveloxolone Capsules, 80 mg|
219411179|NCT07082400|PROCEDURE|right heart catheter|measurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction
219411180|NCT06337812|DIETARY_SUPPLEMENT|Potato Starch|"Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study."
219411181|NCT05487417|DRUG|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
219411182|NCT05617898|BEHAVIORAL|Motivational Interviewing|Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
219411183|NCT05617898|BEHAVIORAL|Nutrition Didactic Training|The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
219411184|NCT06104228|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490
219411185|NCT06077292|BEHAVIORAL|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
219569692|NCT05984602|DRUG|Tislelizumab|300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
219569693|NCT05984602|DRUG|Nab-Paclitaxel|125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
219411186|NCT06077292|BEHAVIORAL|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
219411187|NCT00228969|DRUG|RWJ-333369|
219411188|NCT06195501|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)|"Flexible Endoscopic Evaluation of Swallowing (FEES):~FEES is performed for analysis of swallowing ability according to the same methodology as in the initial trial: one day before a TEE and max. 4 hours after TEE. Before the FEES anticongestive nose drops are applied and the nostrils are anaesthetized by applying a lidocaine gel via cotton sticks. During the FEES examination the participants sit upright and are asked to swallow various consistencies: FEES is aborted in case of aspiration of any of the consistencies during the examination.~Transesophageal Ecocardiography (TEE):~For the TEE anesthesia is applied via intravenous injection of propofol or a combined anesthesia, through intravenous application of propofol and local anesthesia, using lidocaine spray. All patients undergoing a TEE are sober before and at least two to four hours after TEE."
219411189|NCT00755846|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
219411190|NCT00755846|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
219411191|NCT00755846|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
219411192|NCT00755846|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
219411193|NCT00755846|DRUG|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
219411194|NCT00755846|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
219411195|NCT06283784|OTHER|Yovis Capsules|Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
219569694|NCT05984602|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
219569695|NCT02753517|DEVICE|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
219569696|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
219569697|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
219569698|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
219569699|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
219757108|NCT05428644|BEHAVIORAL|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
219757109|NCT00565565|DRUG|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
219190298|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin|Administered as a single regimen every 2weeks
219757110|NCT00506623|DRUG|Capecitabine, Irinotecan|
219757111|NCT04347421|DIETARY_SUPPLEMENT|Krill oil group|This group takes 500 mg/day Krill oil for 12 weeks.
219757112|NCT04347421|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks.
219757113|NCT02315092|DEVICE|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
219757114|NCT01069913|DRUG|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."
219757115|NCT00284180|DRUG|Vinflunine|Novel second generation vinca alkaloid
219757116|NCT00284180|DRUG|Trastuzumab|Anti-HER2 monoclonal antibody
219757117|NCT05140356|DEVICE|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
219757118|NCT05140356|DEVICE|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
219757119|NCT01899547|PROCEDURE|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
219757120|NCT01899547|PROCEDURE|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
219757121|NCT03421184|OTHER|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219757122|NCT03421184|OTHER|urine sample|10 ml
219757123|NCT03421184|OTHER|food questionnaire|dietary habit enquiry and a 48h dietary
219411196|NCT06283784|OTHER|Placebo|Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
219411197|NCT03522350|DEVICE|EmbryoScope|Standard of care arm
219411198|NCT03522350|DEVICE|EmbryoScope+|Experimental arm
219190299|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,|Administered alternately every 2weeks
219411199|NCT00786032|DEVICE|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
219411200|NCT04783532|BEHAVIORAL|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
219411201|NCT03835000|PROCEDURE|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
219411202|NCT00775502|DRUG|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
219411203|NCT05386654|DEVICE|imPulse™ Tor System|Self-directed blood pressure data capture
219411204|NCT03830814|PROCEDURE|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
219411205|NCT00133900|PROCEDURE|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
219411206|NCT05160558|DRUG|BIIB132|Administered as specified in the treatment arm
219411207|NCT05160558|DRUG|BIIB132-Matching Placebo|Administered as specified in the treatment arm
219411208|NCT04573127|OTHER|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
219411209|NCT03924141|BEHAVIORAL|Training in de-escalation|Will receive one hour of de-escalation training
219411210|NCT05747131|BEHAVIORAL|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
219411211|NCT05747131|BEHAVIORAL|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
219411212|NCT01865435|GENETIC|cord blood sample|
219411213|NCT02307669|BEHAVIORAL|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
219411214|NCT02307669|BEHAVIORAL|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
219411215|NCT00304265|BIOLOGICAL|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
219411216|NCT04436809|PROCEDURE|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
219411217|NCT04436809|PROCEDURE|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
219411218|NCT04104906|OTHER|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
219411219|NCT04104906|OTHER|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
219757124|NCT03421184|OTHER|hair|lock of hair
219757125|NCT04585308|DEVICE|transShield Embolic Protection System|Used for embolic protection during TAVR.
219761276|NCT02255435|DRUG|Omaveloxolone Capsules, 160 mg|
219190300|NCT07062146|OTHER|reiki|Reiki sessions for 30 minutes, on Day-7 before the surgery and on D15 after the surgery
219003442|NCT03432754|BEHAVIORAL|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
219003443|NCT03432754|BEHAVIORAL|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
219411220|NCT05408312|BIOLOGICAL|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
219411221|NCT05408312|BIOLOGICAL|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
219003444|NCT02989194|DRUG|VIS410 low dose|Single intravenous fixed low dose of VIS410
219003445|NCT02989194|DRUG|VIS410 high dose|Single intravenous fixed high dose of VIS410
219003446|NCT02989194|DRUG|Placebo|Single intravenous infusion of placebo
219003447|NCT01033266|DIAGNOSTIC_TEST|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
219003448|NCT00765050|BIOLOGICAL|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
219003449|NCT00686192|DIETARY_SUPPLEMENT|Calcium Carbonate|1500 mg per day
219003450|NCT05711953|OTHER|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
219003451|NCT01439191|DRUG|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
219411222|NCT05408312|BIOLOGICAL|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
219411223|NCT05408312|BIOLOGICAL|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
219411224|NCT01820078|DRUG|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
219411225|NCT01820078|OTHER|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
219411226|NCT04486963|DRUG|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
219411227|NCT04486963|DRUG|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
219411228|NCT03363334|DRUG|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
219411229|NCT03363334|DRUG|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
219411230|NCT04092244|DIAGNOSTIC_TEST|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
219411231|NCT03021434|OTHER|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
219411232|NCT03021434|OTHER|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
219411233|NCT03021434|OTHER|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
219411234|NCT05483621|DRUG|Beta-hCG|Treatment of spermatogenesis
219757126|NCT03516721|OTHER|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
219757127|NCT03564886|DRUG|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
219003452|NCT01439191|DRUG|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
219003453|NCT04022902|OTHER|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
219003454|NCT01549860|DEVICE|MIST Therapy|Non-contact low frequency ultrasound therapy
219003455|NCT03742934|OTHER|Short peptide|Short peptide formula during bowel preparation
219003456|NCT03742934|OTHER|Liquid diet|Liquid diet during bowel preparation
219003457|NCT00275769|DEVICE|Pacemaker|
219003458|NCT01129609|DEVICE|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
219190301|NCT07062146|OTHER|Sham (No Treatment)|Sham sessions for 30 minutes, on D-7 before the surgery and on D15 after the surgery,
219190302|NCT07062939|OTHER|postural drainage with ACBT|postural drainage and ACBT for 2 times a day for 30 min for 4 weeks.
219411235|NCT04538092|OTHER|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
219757128|NCT03564886|DRUG|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
219411236|NCT06412419|DIAGNOSTIC_TEST|Magnifying Endoscopy and Endoscopic Ultrasonography|The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
219411237|NCT01672021|PROCEDURE|PET/MRI|PET/MRI
219411238|NCT00311181|DEVICE|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
219411239|NCT03000374|DRUG|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
219411240|NCT03000374|DRUG|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
219411241|NCT03000374|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
219411242|NCT03000374|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
219411243|NCT00444509|DRUG|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
219411244|NCT00444509|DRUG|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
219411245|NCT02669862|DRUG|A-101 Solution 40|
219411246|NCT02669862|DRUG|A-101 Solution 45|
219411247|NCT02669862|DRUG|Vehicle Solution|
219411248|NCT02567617|DIETARY_SUPPLEMENT|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
219569700|NCT04930666|OTHER|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
219569701|NCT06689592|DEVICE|Transcranial Magnetic Stimulation|Intermittent theta burst stimulation
219569702|NCT05857631|RADIATION|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
219569703|NCT05857631|DRUG|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
219569704|NCT05857631|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
219411249|NCT02567617|DIETARY_SUPPLEMENT|Placebo controlled|Starch capsules
219411250|NCT01907984|DRUG|Diclofenac|
219411251|NCT01907984|DRUG|Midazolam|
219411252|NCT05138783|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
219411253|NCT05138783|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
219411254|NCT02566252|DRUG|PUL-042 Inhalation Solution|PUL-042
219569705|NCT05671822|DRUG|SHR-A1811 and SHR-1701|(Arm 1A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion;
219569706|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
219569707|NCT05671822|DRUG|SHR-A181, SHR-1701, and capecitabine|(Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally；
219411255|NCT02566252|DRUG|Cromolyn Sodium|Pre-treatment
219411256|NCT02566252|DRUG|Albuterol sulfate|Pre-treatment
219411257|NCT02264899|OTHER|in Memento-VASCOD|"* Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement"
219411258|NCT03746223|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
219411259|NCT03746223|DRUG|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
219411260|NCT03746223|DRUG|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
219411261|NCT05731843|DRUG|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
219411262|NCT05731843|DRUG|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
219411263|NCT05890118|DRUG|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
219411264|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
219411265|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
219411266|NCT00878631|DRUG|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
219569708|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally；
219569709|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
219411267|NCT00878631|DRUG|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
219411268|NCT02294318|BEHAVIORAL|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
219411269|NCT02294318|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
219411270|NCT03187912|DRUG|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
219411271|NCT02429258|DRUG|Farxiga|Farxiga 10mg/day
219411272|NCT02429258|DRUG|Placebo|Placebo
219411273|NCT02429258|DRUG|Metformin|Metformin background therapy \>/= 1500mg/day
219411274|NCT02429258|DRUG|Insulin|Insulin \>/= 30 units
219411275|NCT06394518|DRUG|TNP-2092 for injection|The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
219411276|NCT06394518|DRUG|placebo|The placebo for TNP-2092 active drug
219411277|NCT04825119|DRUG|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
219411278|NCT02723266|BEHAVIORAL|STOPPING-GDM|Educational counseling and skills building Intervention
219411279|NCT02397694|DRUG|BIC|75 mg tablet administered orally once daily
219411280|NCT02397694|DRUG|F/TAF|200/25 mg FDC tablet administered orally once daily
219411281|NCT02397694|DRUG|DTG|50 mg tablet administered orally once daily
219411282|NCT02397694|DRUG|BIC Placebo|Tablet administered orally once daily
219411283|NCT02397694|DRUG|DTG Placebo|Tablet administered orally once daily
219411284|NCT02397694|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
219411285|NCT04274166|DRUG|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
219569710|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
219411286|NCT06019936|DRUG|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
219411287|NCT06019936|DRUG|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
219411288|NCT00078559|DRUG|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
219411289|NCT00078559|DRUG|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
219411290|NCT00078559|DRUG|Tacrolimus|2mg orally twice daily, on days 1-60
219411291|NCT00078559|PROCEDURE|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
219411292|NCT00078559|DRUG|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
219411293|NCT00078559|DRUG|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
219411294|NCT00078559|DRUG|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
219411295|NCT00078559|DRUG|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
219411296|NCT00078559|DRUG|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
219411297|NCT00078559|DRUG|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
219411298|NCT00078559|DRUG|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
219411299|NCT00078559|DRUG|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
219411300|NCT00078559|DRUG|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
219411301|NCT00887146|DRUG|concomitant temozolomide (TMZ)|75 mg/m\^2, orally daily
219411302|NCT00887146|RADIATION|radiotherapy|
219411303|NCT00887146|DRUG|procarbazine|Days 8-21: 60 mg/m\^2 orally
219411304|NCT00887146|DRUG|adjuvant temozolomide (TMZ)|150 or 200 mg/m\^2 orally
219411305|NCT00887146|DRUG|CCNU|Day 1: 110 mg/m\^2 orally
219411306|NCT00887146|DRUG|vincristine|Days 8 and 29: 1.4 mg/m\^2 IV
219411307|NCT04478149|DEVICE|SafelyYou|technology to detect and prevent falls
219411308|NCT04478149|OTHER|Control|technology present but not activated
219569711|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug：capecitabine, administered orally；
219569712|NCT05671822|DRUG|SHR-1316 and SHR-A1811|(Arm 2B) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion
219569713|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
219569714|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
219761277|NCT02255435|DRUG|Omaveloxolone Capsules, 300 mg|
219411309|NCT04765436|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
219411310|NCT04765436|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219411311|NCT03617133|RADIATION|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
219411312|NCT03617133|RADIATION|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
219411313|NCT03617133|RADIATION|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
219190303|NCT07062939|OTHER|flutter with ACBT|flutter with active cycle breathing technique for 30 min. for 4 week and 2 times a day.
219411314|NCT03617133|RADIATION|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
219429592|NCT07091994|DRUG|edaravone dexborneol injection|The experimental intervention involved twice-daily administration of edaravone dexborneol injection at a dose of 37.5 mg (containing 30 mg edaravone and 7.5 mg dexborneol), with doses spaced exactly 12 hours apart. For each infusion, the study medication was first diluted in 100 mL of normal saline (0.9% sodium chloride solution) and then administered as a controlled intravenous infusion over a precisely timed 30-minute period. This standardized dosing regimen was maintained consistently throughout the 10-14 day treatment course for all participants in the experimental group.
219569715|NCT05671822|DRUG|SHR-A1811and 5-FU|(Arm 2E) Drug: SHR-A1811, administered as an IV infusion Drug：5-FU，administered as an IV infusion
219569716|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 2F) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
219569717|NCT05617625|DRUG|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
219569718|NCT05617625|DRUG|Melphalan|70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
219569719|NCT05617625|DRUG|Fludarabine|25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
219569720|NCT05617625|DEVICE|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
219569721|NCT04718545|PROCEDURE|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
219569722|NCT04317872|DRUG|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
219569723|NCT04317872|DRUG|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
219569724|NCT03632135|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
219569725|NCT03632135|DRUG|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
219569726|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
219569727|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
219569728|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
219569729|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
219761278|NCT02255435|DRUG|Omaveloxolone Capsules, 150 mg|
219761279|NCT05645718|DRUG|Cyclophosphamide|Given by (IV) vein
219411315|NCT03617133|RADIATION|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
219411316|NCT03617133|RADIATION|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
219411317|NCT03617133|RADIATION|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or \>2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
219411318|NCT03617133|DRUG|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
219411319|NCT03617133|OTHER|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (\>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
219411320|NCT03136133|DIETARY_SUPPLEMENT|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
219411321|NCT04859335|RADIATION|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
219411322|NCT03808038|OTHER|None- Observational Study|None- Observational Study
219569730|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
219569731|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
219569732|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
219569733|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
219569734|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
219569735|NCT04379635|DRUG|Carboplatin|administered via IV infusion
219569736|NCT05213169|DRUG|Apomorphine Hydrochloride 5mg/ml|Product administered using an external continuous subcutaneous infusion pump.
219569737|NCT05213169|OTHER|Sodium chloride 9mg/ml|Product administered using an external continuous subcutaneous infusion pump.
219569738|NCT06231563|DRUG|Ketamine|intravenous ketamine infusion 0.5 mg/kg
219569739|NCT06231563|DRUG|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
219569740|NCT05645471|BEHAVIORAL|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
219569741|NCT00688298|DEVICE|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
219569742|NCT00688298|DEVICE|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
219569743|NCT04474431|OTHER|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
219569744|NCT03594825|DRUG|Valsartan|Different time of taking medicine
219757129|NCT01658046|OTHER|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
219757130|NCT01658046|OTHER|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
219190304|NCT06783933|DIAGNOSTIC_TEST|surgical or interventional validation|surgical or interventional validation
219569745|NCT05336435|DIAGNOSTIC_TEST|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
219569746|NCT06473402|DIAGNOSTIC_TEST|Muscle Strength Test|Hamstring muscle strength of the participants was measured with a dynamometer (Microfet 2, Hoggan Health Industries, HHD) with the knee flexed at 90 degrees. After the physiotherapist fixes and positions the dynamometer 5 cm proximal to the calcaneus with a belt, the participant will be asked to accelerate to maximum isometric strength by trying to bring his heel closer to his hip against this resistance. The isometric strength of the hamstring muscle will be measured in Newtons (N) by being asked to wait at maximum force level for three seconds. Measurements were made in 2 repetitions and the highest value was noted. There will be a 30-second rest period between attempts.
219569747|NCT06473402|DIAGNOSTIC_TEST|Hamstring Flexibility|The Sit and Reach Test will be administered to evaluate flexibility. Measurements will be made with a test stand with a length of 35 cm, a width of 45 cm and a height of 32 cm. The measurement of the participant who cannot reach the zero point of the sole of the foot on this tripod will be recorded as minus (-), while the measurement of the participant who can pass the zero point will be recorded as plus (+). Participants will be seated in a long sitting position with the soles of their feet resting on the testing apparatus, and the measurement will begin with their knee joints fully extended. While leaning his body forward, he will be asked to lie forward as far as he can, with his hands in front of his body, without bending his knees. The test will be repeated 2 times and the best value will be recorded in cm.
219569748|NCT06473402|DIAGNOSTIC_TEST|Knee Range of Motion|Joint range of motion measurement of the participants was made with a universal goniometer. Degree was used as the measurement unit. The measurement was made in the prone position. The pivot point of the goniometer is placed on the lateral epicondyle of the femur, and the fixed arm is kept parallel to the lateral midline of the femur, while the movable arm will follow the fibula. The joint range of motion of the participants was measured before and after manual therapy. AAOS (American of Orthopedic Surgeons) was taken as the reference value.
219569749|NCT06473402|DEVICE|Percussion Therapy|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
219757131|NCT01658046|OTHER|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
219757132|NCT00785720|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
219757133|NCT02005744|DRUG|CKD-501|CKD-501 0.5mg, PO(per oral), once
219190305|NCT07063121|BEHAVIORAL|Shadow's Edge mobile app|A mobile application adapted for Colombian youth that uses interactive storytelling, journaling, and emotional regulation activities to promote subjective well-being and resilience.
219411323|NCT05454202|DEVICE|ANI|Pain measurement during care procedures in palliative care
219411324|NCT01796262|DIETARY_SUPPLEMENT|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
219411325|NCT01796262|DIETARY_SUPPLEMENT|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
219411326|NCT02168933|DEVICE|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
219411327|NCT02168933|DEVICE|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
219411328|NCT01483898|BIOLOGICAL|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
219411329|NCT01483898|OTHER|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
219411330|NCT05915494|OTHER|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
219411331|NCT05915494|OTHER|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
219411332|NCT04689594|COMBINATION_PRODUCT|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
219411333|NCT01554839|BEHAVIORAL|"Family of Heroes"|One hour online educational tool
219411334|NCT01554839|BEHAVIORAL|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
219411335|NCT04977154|OTHER|Primary prevention|The primary prevention that the trainers put in place for the hockey players
219190306|NCT07063121|BEHAVIORAL|Guide to Self-Awareness (GSEA)|A printed guide developed to promote emotional insight, mindfulness, self-awareness, and social-emotional skills through structured reflection activities. Designed to be used alongside the Shadow's Edge app.
219411336|NCT01480479|DRUG|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
219411337|NCT01480479|DRUG|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
219411338|NCT01480479|DRUG|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
219411339|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
219411340|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
219411341|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
219411342|NCT00518921|DRUG|Placebo|Placebo, double dummy
219411343|NCT05015166|BEHAVIORAL|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
219411344|NCT05015166|BEHAVIORAL|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
219411345|NCT05484180|OTHER|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
219411346|NCT00866892|PROCEDURE|Irrigation|irrigation
219411347|NCT00866892|PROCEDURE|No irrigation|no irrigation
219411348|NCT05958758|DRUG|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
219411349|NCT01235169|DEVICE|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
219411350|NCT01985373|DRUG|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
219411351|NCT03945032|OTHER|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
219411352|NCT01225757|DEVICE|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
219411353|NCT03725202|DRUG|Upadacitinib|Administered orally once a day
219411354|NCT03725202|DRUG|Corticosteroid (CS)|At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
219761280|NCT05645718|DRUG|Vincristine|Given by (IV) vein
219411355|NCT03725202|OTHER|Placebo|Administered orally once a day
219411356|NCT02557386|DRUG|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
219411357|NCT02557386|DRUG|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
219411358|NCT02557386|DRUG|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
219411359|NCT02557386|DRUG|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
219411360|NCT02557386|DRUG|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
219411361|NCT02557386|DRUG|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
219761281|NCT05645718|DRUG|Blinatumomab|Given by (IV) vein
219761282|NCT05645718|DRUG|Methotrexate|Given by (IV) vein
219761283|NCT05645718|DRUG|Cytarabine|Given by (IV) vein
219761284|NCT05645718|DRUG|Mercaptopurine|Given by (IV) vein
219761285|NCT05645718|DRUG|Prednisone|Given by PO
219761286|NCT05645718|DRUG|Pegfilgrastim|Given by (IV) vein
219761287|NCT05645718|DRUG|Inotuzumab ozogamicin|Given by (IV) vein
219761288|NCT05645718|DRUG|Rituximab|Given by (IV) vein
219761289|NCT05645718|DRUG|Dexamethasone|Given by (IV) vein
219761290|NCT03943511|OTHER|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
219761291|NCT03943511|OTHER|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
219761292|NCT04551430|DRUG|Cabozantinib|Cabozantinib will be supplied by Exelixis.
219761293|NCT04551430|DRUG|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
219761294|NCT04551430|DRUG|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
219761295|NCT06297629|DRUG|ASTX727|Given by PO
219761296|NCT06297629|DRUG|Donor Lymphocyte Infusion|Given by Infusion
219761297|NCT05667142|DRUG|XEN1101|XEN1101 capsules
219761298|NCT05667142|DRUG|Placebo|Placebo capsules
219761299|NCT06643481|BIOLOGICAL|VHB937|VHB937 solution for infusion
219761300|NCT06643481|OTHER|Placebo|Solution for infusion
219761301|NCT06604871|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
219411362|NCT00376987|DIETARY_SUPPLEMENT|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
219411363|NCT04093817|DEVICE|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
219411365|NCT05975775|PROCEDURE|Laparoscopic radical prostatectomy|Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
219411366|NCT03130023|DEVICE|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
219411367|NCT01247220|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
219411368|NCT01247220|PROCEDURE|Peripheral Laser|Angiography-directed peripheral laser
219411369|NCT02783794|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
219411370|NCT02783794|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
219411371|NCT01328249|DRUG|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
219411372|NCT03226080|DRUG|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
219569750|NCT06473402|OTHER|Manual Therapy Technique|Anterior and posterior innominate muscle energy techniques were performed on patients. In the anterior technique, the patient lay on their back with their leg on the diagonal shoulder. The clinician flexed the hip and knee, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and applied pressure against a new barrier. In the posterior technique, the patient lay on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. The patient then pulled the leg towards themselves, applying equal counterforce for eight seconds before inhaling and exhaling. Finally, the clinician extended the leg and pushed it against a new barrier.
219569751|NCT06239714|DRUG|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
219569752|NCT06239714|OTHER|Atorvastatin|The dosage of atorvastatin was determined by the investigator
219569753|NCT06239714|OTHER|Placebo|Normal saline 0.9%
219569754|NCT00804206|DRUG|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
219569755|NCT00804206|DRUG|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
219569756|NCT02136303|DIETARY_SUPPLEMENT|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
219411373|NCT03226080|DRUG|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
219411374|NCT03226080|DRUG|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
219411375|NCT06054022|DEVICE|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
219411376|NCT06054022|DEVICE|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
219411377|NCT01215734|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
219411378|NCT01215734|BIOLOGICAL|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
219411379|NCT02294409|BEHAVIORAL|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
219429593|NCT07091994|DRUG|Standard therapeutic protocol|The standard treatment regimen, which may include antiplatelet therapy, anticoagulation (if indicated), blood pressure management, and other evidence-based interventions, will be administered continuously for 10 to 14 days according to current clinical guidelines.
219429594|NCT07092176|OTHER|Steady Strides|"Participants in the control arm will receive a one-time assessment by a trained research assistant at baseline and once more at 2 month follow up. Research assistant will measure and document the specified demographic and clinical variables to be compared between the control and intervention groups.~Participants in the intervention arm will receive a multifactorial intervention, including: Medical Intervention: Provided by physician(s) and/or nurse practitioners (NPs) or physician assistants (PAs) trained in the Steady Strides fall prevention protocol via the hybrid online and in person course on the Steady Strides fall prevention protocol . Rehabilitation Intervention: Provided by occupational therapists (OTs) and physical therapists (PTs) trained through a hybrid online and in person course on the Steady Strides fall prevention protocol"
219569757|NCT02136303|OTHER|S2: Kale extract versus kale purée|
219569758|NCT02136303|OTHER|S3: Kale extract: AMD-patients|
219569759|NCT03800225|PROCEDURE|Repair|Anterior ligament repair with internal brace.
219569760|NCT04204031|BEHAVIORAL|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
219569761|NCT01647958|DEVICE|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
219569762|NCT01647958|DRUG|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
219569763|NCT03190772|OTHER|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
219569764|NCT03190772|OTHER|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
219569765|NCT02440035|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
219569766|NCT02440035|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
219569767|NCT02440035|DRUG|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
219569768|NCT00005090|BIOLOGICAL|bleomycin sulfate|10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
219569769|NCT00005090|DRUG|carmustine|150/m\^2 on days -6 to -4 (4-6 days before transplant).
219569770|NCT00005090|DRUG|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
219569771|NCT00005090|DRUG|dacarbazine|375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
219569772|NCT00005090|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
219569773|NCT00005090|DRUG|etoposide|60 mg/kg on day -4 (4 days before transplant).
219569774|NCT00005090|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
219569775|NCT00005090|PROCEDURE|peripheral blood stem cell transplantation|2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
219569776|NCT03572842|OTHER|quantiferon monitor test|different blood test with quantiferon monitor
219569777|NCT00544817|RADIATION|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
219569778|NCT00544817|DRUG|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
219569779|NCT00544817|DRUG|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
219003459|NCT03125343|PROCEDURE|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA"
219569780|NCT05765799|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
219569781|NCT01131299|OTHER|Placebo|2 tablets PO 3 times a day for 12-14 weeks
219569782|NCT01131299|DRUG|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
219569783|NCT00949728|PROCEDURE|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
219569784|NCT03012659|BEHAVIORAL|Contraceptive Counseling Training|"Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
219757134|NCT01741961|PROCEDURE|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
219411380|NCT02294409|BEHAVIORAL|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
219411381|NCT05658185|BEHAVIORAL|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:"
219411382|NCT05476185|BEHAVIORAL|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
219411383|NCT01406847|OTHER|Spinal Manipulation|High velocity low amplitude joint-biased intervention
219411384|NCT01406847|OTHER|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
219411385|NCT01406847|OTHER|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
219411386|NCT00623454|BEHAVIORAL|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
219411387|NCT03273205|DEVICE|Anodal tDCS|This group gets a real stimulation
219411388|NCT03273205|DEVICE|Sham tDCS|This group gets a sham stimulation
219411389|NCT06254105|OTHER|HANDY programme|The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
219411390|NCT05130164|RADIATION|CBCT|Cone beam computed tomographic images selected for age estimation
219411391|NCT03761043|BEHAVIORAL|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
219411392|NCT01642524|BIOLOGICAL|hypertonic saline mixed Dextran|single dose administered intravenously
219411393|NCT01642524|BIOLOGICAL|Saline solution|placebo - saline solution
219411394|NCT03233412|PROCEDURE|Control|Exertion of the cervix transformation zone
219757135|NCT02724839|BEHAVIORAL|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
219757136|NCT02724839|DEVICE|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
219757137|NCT03007771|DEVICE|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
219411395|NCT03233412|DRUG|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
219411396|NCT01716533|PROCEDURE|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
219411397|NCT01716533|OTHER|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
219411398|NCT02140359|BEHAVIORAL|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
219411399|NCT02701803|DEVICE|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
219411400|NCT05900193|DIETARY_SUPPLEMENT|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
219429595|NCT07090291|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is used to examine the inner lining of the colon and rectum. During the procedure, if suspicious growths (e.g., polyps) are detected, they will be biopsied and sent for pathological examination.
219411401|NCT05948371|OTHER|High Intensity interval Training|"High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
219411402|NCT05948371|OTHER|Continuous Aerobic training|"Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling."
219569785|NCT04877587|DRUG|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)"
219569786|NCT04877587|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
219569787|NCT01682629|OTHER|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
219411403|NCT02474524|BEHAVIORAL|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
219411404|NCT02474524|BEHAVIORAL|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
219411405|NCT02330549|DRUG|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
219411406|NCT02330549|DRUG|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
219411407|NCT01393171|DEVICE|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
219411408|NCT01393171|PROCEDURE|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
219411409|NCT01393171|PROCEDURE|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
219411410|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
219411411|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
219411412|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
219411413|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
219757138|NCT03773809|OTHER|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
219411414|NCT03408951|OTHER|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
219411415|NCT05590741|BEHAVIORAL|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
219411416|NCT02295735|DEVICE|Mepilex® Border Sacrum and Mepilex® Border Heel|
219411417|NCT00495495|DEVICE|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
219411418|NCT00495495|DEVICE|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
219411419|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
219411420|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
219411421|NCT01511835|DRUG|Folic Acid|Folic Acid 400mcg; 1 cp/die
219411422|NCT02536170|DRUG|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
219411423|NCT02536170|DRUG|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
219411424|NCT02536170|OTHER|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
219411425|NCT03061370|PROCEDURE|Esophagectomy or Gastrectomy|Surgical resection
219411426|NCT04923919|DRUG|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
219411427|NCT03331666|DRUG|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
219411428|NCT03144583|BIOLOGICAL|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
219569788|NCT01682629|OTHER|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
219411429|NCT02694627|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
219411430|NCT01938690|DEVICE|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
219411431|NCT00380211|BIOLOGICAL|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
219411432|NCT00380211|BIOLOGICAL|Fluarix|
219411433|NCT03448978|BIOLOGICAL|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
219411434|NCT03448978|DRUG|Fludarabine|intravenous fludarabine
219411435|NCT03448978|DRUG|Cyclophosphamide|intravenous cyclophosphamide
219411436|NCT06226688|PROCEDURE|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
219569789|NCT00002194|DRUG|Erythromycin|
219569790|NCT00002194|DRUG|Nevirapine|
219569791|NCT00002194|DRUG|Clarithromycin|
219569792|NCT05925244|OTHER|Control Condition|Control (no alteration to body mass).
219569793|NCT05925244|OTHER|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
219569794|NCT05925244|OTHER|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
219569795|NCT02105311|DEVICE|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
219411437|NCT06226688|PROCEDURE|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
219411438|NCT02236728|DRUG|Pramipexole|
219411439|NCT02178293|DRUG|Benzidamine hydrochloride|
219411440|NCT02178293|DRUG|Ketoprofen lysine salt|
219411441|NCT01062568|DRUG|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
219411442|NCT01062568|DRUG|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
219411443|NCT04498819|BEHAVIORAL|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
219411444|NCT05258708|BIOLOGICAL|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
219411445|NCT01026389|DRUG|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
219411446|NCT01026389|DRUG|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
219411447|NCT02512744|PROCEDURE|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
219411448|NCT02512744|DEVICE|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
219411449|NCT01995136|DRUG|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
219411450|NCT03402152|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
219411451|NCT03402152|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
219411452|NCT03402152|DRUG|Placebo|Placebo oral capsule
219569796|NCT02105311|DRUG|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
219757139|NCT03773809|OTHER|placebo|oral administration of placebo
219757140|NCT00163644|PROCEDURE|aereobic plus resisted exercise|
219757141|NCT00163644|PROCEDURE|aerobic plus active exercise|
219757142|NCT00163644|OTHER|No formal exercise plus phone calls|
219757143|NCT00992550|DRUG|Cigarette|
219757144|NCT00992550|DRUG|Hookah|
219003460|NCT03125343|PROCEDURE|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
219003461|NCT03125343|DEVICE|MRI|
219003462|NCT04432194|DIETARY_SUPPLEMENT|Nutritional supplementation and Pulmonary Rehabilitation|Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
219003463|NCT04937491|DEVICE|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
219003464|NCT01148823|OTHER|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
219411453|NCT01480492|DRUG|Telbivudine|600mg,1/d,one year
219411454|NCT01791699|DRUG|Moxonidine|
219003465|NCT01148823|OTHER|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
219003466|NCT02588807|DRUG|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
219003467|NCT05067829|DEVICE|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
219190307|NCT07062302|DEVICE|photobiomodulation|"The output of the photobiomodulation device is listed as below:~* Irradiation size: 15 cm × 10 cm~* Dual-wavelength: 660 nm + 850 nm~* Optical power density: 10 - 15 mW/cm2~* Dose density: 6J/cm2"
219411455|NCT01791699|DRUG|Placebo|
219411456|NCT00012896|BEHAVIORAL|Telephone Care + Educational (AV Materials)|
219411457|NCT04410198|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
219411458|NCT03222076|BIOLOGICAL|Ipilimumab|Given IV
219411459|NCT03222076|BIOLOGICAL|Nivolumab|Given IV
219569797|NCT00686244|OTHER|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
219757145|NCT01081392|BIOLOGICAL|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
219757146|NCT02143284|DEVICE|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
219757147|NCT01636284|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
219190308|NCT07062523|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of Sjögren's syndrome by PET/ CT.
219411460|NCT05310994|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
219411461|NCT05310994|DIETARY_SUPPLEMENT|Wasabi Leaf Extract Drink|consume 1 bottle per day
219411462|NCT01044420|DRUG|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
219411463|NCT05690334|DRUG|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219411464|NCT05690334|DRUG|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219411465|NCT05690334|DRUG|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219411466|NCT02543398|PROCEDURE|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
219411467|NCT06091020|BIOLOGICAL|IncobotulinumtoxinA|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
219569798|NCT03050034|DEVICE|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
219569799|NCT03050034|OTHER|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
219569800|NCT01398059|OTHER|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
219569801|NCT01398059|OTHER|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
219569802|NCT01398059|OTHER|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
219569803|NCT02309853|OTHER|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space"
219190309|NCT07063108|DRUG|Esketamine hydrochloride|Intravenous infusion of esketamine: after induction, a single dose of 0.25 mg/kg before skin incision，and continuous 0.125 mg/kg/h until 30 min before surgery was stopped.
219411468|NCT06091020|BIOLOGICAL|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219411469|NCT01830543|DRUG|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
219411470|NCT01830543|DRUG|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
219411471|NCT01830543|DRUG|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
219411472|NCT01830543|DRUG|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
219411473|NCT01830543|DRUG|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
219411474|NCT01830543|DRUG|clopidogrel|One 75 mg tablet once daily for up to twelve months
219411475|NCT01830543|DRUG|prasugrel|One 10 mg tablet once daily for up to twelve months
219411476|NCT01830543|DRUG|ticagrelor|One 90 mg tablet twice daily for up to twelve months
219411477|NCT01566643|DRUG|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
219411478|NCT01566643|DRUG|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
219411479|NCT01566643|DRUG|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
219411480|NCT03487900|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
219411481|NCT04513834|OTHER|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
219411482|NCT04513834|OTHER|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
219411483|NCT05806047|DRUG|chidamide combined with fulvestrant|chidamide combined with fulvestrant
219411484|NCT01321931|DRUG|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
219411485|NCT01321931|DRUG|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
219411486|NCT01321931|DRUG|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
219411487|NCT02059213|DRUG|Ibrance|
219411488|NCT02059213|DRUG|Bicalutamide|
219411489|NCT02059213|DRUG|Zoladex|
219411490|NCT02059213|DRUG|Lupron Depot|
219411491|NCT03605719|DRUG|Carfilzomib|Given IV
219003468|NCT00458198|BEHAVIORAL|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
219190310|NCT07063108|DRUG|Saline|after induction, a single intravenous infusion of an equal amount of 0.9% saline before skin incision, followed by a continuous infusion at the same rate as the test group until 30 min before surgical cessation.
219411492|NCT03605719|DRUG|Dexamethasone|Given IV
219411493|NCT03605719|BIOLOGICAL|Nivolumab|Given IV
219411494|NCT03605719|BIOLOGICAL|Pelareorep|Given IV
219411495|NCT02572258|OTHER|Nutritional cookie|
219411496|NCT06317233|BEHAVIORAL|Chronic Pelvic Pain Treatment Guide|The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
219411497|NCT06553677|PROCEDURE|Tunneled coronal advanced flap with connective tissue graft|Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
219411498|NCT06553677|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
219411499|NCT06433518|DRUG|recombinant hCG|"Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups."
219411500|NCT01313806|DEVICE|Resonator|Treatment group vs. Placebo group
219411501|NCT01313806|DEVICE|Placebo|Inactive Resonator Device
219411502|NCT00455130|DRUG|Inhaled mannitol|
219411503|NCT03009201|DRUG|Doxorubicin Hydrochloride|Given IV
219569804|NCT02309853|OTHER|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
219411504|NCT03009201|OTHER|Laboratory Biomarker Analysis|Correlative studies
219411505|NCT03009201|OTHER|Pharmacological Study|Correlative studies
219411506|NCT03009201|DRUG|Ribociclib|Given PO
219411507|NCT01062620|DRUG|AXL1717|Phase I study with increasing dosage and treatment duration
219411508|NCT01021072|DRUG|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
219411509|NCT03285074|OTHER|No intervention|No intervention
219411510|NCT02024191|DIETARY_SUPPLEMENT|Glutamine|
219411511|NCT03583372|DRUG|Vibegron|single daily dose 75 mg
219411512|NCT03583372|DRUG|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
219411513|NCT03583372|DRUG|Tolterodine Tartrate ER|single daily dose of 4 mg
219411514|NCT02685891|OTHER|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
219411515|NCT02685891|OTHER|sham condition|in the sham condition, no tones will be played
219411516|NCT01151046|DRUG|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
219411517|NCT01151046|DRUG|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
219411518|NCT01151046|DRUG|Exemestane|Exemestane (25 mg) administered orally once per day
219411519|NCT05837052|PROCEDURE|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
219411520|NCT05836519|OTHER|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
219411521|NCT00272636|PROCEDURE|Radiofrequency catheter ablation|
219411522|NCT00272636|DRUG|Amiodarone and cardioversion|
219429596|NCT07090291|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
219429597|NCT07090291|DIAGNOSTIC_TEST|Blood test|Blood test based on cfDNA methylation will be performed.
219429598|NCT07090525|DRUG|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled
219429599|NCT07090525|DRUG|cisplatin 40mg/m2 intracavity injection|cisplatin 40mg/m2 intracavity injection
219411523|NCT02025491|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
219569805|NCT06332313|PROCEDURE|erector spina plane block|ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
219411524|NCT03585699|DIAGNOSTIC_TEST|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
219411525|NCT03585699|DIAGNOSTIC_TEST|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
219757148|NCT03577899|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
219757149|NCT03577899|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
219757150|NCT03577899|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
219569806|NCT05016934|BIOLOGICAL|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
219757151|NCT01155050|DEVICE|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
219757152|NCT01155050|BEHAVIORAL|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
219757153|NCT01155050|DEVICE|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
219757154|NCT01340456|DRUG|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
219757155|NCT03070678|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219757156|NCT03070678|DRUG|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
219757157|NCT05456048|DRUG|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
219757158|NCT05456048|DRUG|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
219757159|NCT04120207|BEHAVIORAL|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
219757160|NCT04120207|OTHER|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
219757161|NCT05878067|DRUG|ABBV-444|Lubricant Eye drops
219757162|NCT00241150|DRUG|VALSARTAN|
219757163|NCT00433485|DRUG|sirolimus|
219757164|NCT00433485|GENETIC|comparative genomic hybridization|
219757165|NCT00433485|GENETIC|gene expression analysis|
219757166|NCT00433485|GENETIC|microarray analysis|
219757167|NCT00433485|GENETIC|protein expression analysis|
219757168|NCT00433485|GENETIC|proteomic profiling|
219757169|NCT00433485|OTHER|laboratory biomarker analysis|
219757170|NCT00433485|OTHER|mass spectrometry|
219757171|NCT00433485|PROCEDURE|biopsy|
219757172|NCT04612426|DEVICE|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
219757173|NCT04612426|DEVICE|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
219757174|NCT00949533|DRUG|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
219757175|NCT05024513|DRUG|oxaliplatin and 5-fluorouracil|Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.
219757176|NCT05024513|PROCEDURE|Biliary Drainage|External biliary drainage, or biliary stent placement; Biliary stent placement plus Iodine-125 seed strands is allowed
219757177|NCT05024513|OTHER|Best Supportive Care|Nutrition support, symptomatic treatment, and other supportive treatments
219757178|NCT05024513|PROCEDURE|External biliary drainage|External biliary drainage
219757179|NCT02030626|DEVICE|active or placebo rTMS or active or placebo tDCS|
219190311|NCT07063524|DEVICE|Electrical stimulation|Electrical stimulation with controlled heat during the intervention
219190312|NCT07062263|DRUG|Trastuzumab|Inj Trastuzumab given in a dose of 8mg/kg intravenously over 90 mins as first dose and subsequent doses at a dose of 6mg/kg intravenously over 30-60 minutes in 3 weekly cycle along with standard of care chemotherapy
219190313|NCT07062263|DRUG|Chemotherapy|Gemcitabine + cisplatin OR Gemcitabine-cisplatin-Nab-Paclitaxel given as a standard of care, chemotherapy as per the institutional guidlines
219190314|NCT07062016|OTHER|Non-Interventional Study|Non-interventional study
219411526|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
219757180|NCT03183310|DRUG|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
219757181|NCT03183310|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
219757182|NCT03183310|DRUG|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
219757183|NCT01959529|DRUG|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
219757184|NCT01959529|DRUG|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
219757185|NCT03896191|PROCEDURE|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
219757186|NCT03896191|OTHER|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
219757187|NCT02428426|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
219757188|NCT01440764|DRUG|Furosemide|
219003469|NCT00088985|BIOLOGICAL|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
219003470|NCT00088985|BIOLOGICAL|trastuzumab|4 mg/kg intravenously, every 14 days
219190315|NCT04230681|DRUG|Hydromorphone|Patients will be randomized to one of two opioids for the treatment of post-operative pain.
219190316|NCT04230681|DRUG|Fentanyl|Fentanyl
219411527|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
219757189|NCT01440764|DRUG|Saline|
219411528|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
219003471|NCT00088985|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
219411529|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
219411530|NCT06070740|DRUG|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
219411531|NCT03145194|DRUG|Ticagrelor|2 x 90mg Ticagrelor tablets
219411532|NCT03145194|OTHER|Placebo|2 x matching placebo tablets
219569807|NCT00810862|DRUG|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
219569808|NCT00810862|OTHER|placebo base cream|apply to affected study area twice daily for 21 days
219569809|NCT05981287|OTHER|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
219411533|NCT03170583|DEVICE|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
219411534|NCT05597059|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
219411535|NCT03623334|RADIATION|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
219411536|NCT04624035|PROCEDURE|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
219569810|NCT05981287|OTHER|Gross motor task training and Conventional physical therapy (CPT)|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
219757190|NCT01597817|OTHER|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
219757191|NCT01597817|OTHER|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
219757192|NCT03082924|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
219757193|NCT03082924|DEVICE|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
219757194|NCT03082924|DEVICE|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
219757195|NCT03082924|DEVICE|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
219757196|NCT05964569|OTHER|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
219757197|NCT05964569|OTHER|standard treatment plan, no optimization|original treatment plans are not optimized
219757198|NCT00668629|DRUG|Lactic acid (Dermacid)|
219757199|NCT00406861|DRUG|montelukast in treatment of ENL reaction|
219757200|NCT00618761|OTHER|hyperglycemic clamp test|hyperglycemic clamp test
219757201|NCT00070304|BIOLOGICAL|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
219757202|NCT00070304|DRUG|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
219757203|NCT00070304|DRUG|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
219757204|NCT02283034|DEVICE|The CPRmeter|Feedback device - 1
219757205|NCT02283034|DEVICE|The PocketCPR|Feedback device - 2
219757206|NCT02283034|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
219757207|NCT02283034|DEVICE|The CPREazy|Feedback device - 3
219757208|NCT02283034|DEVICE|The CPR PRO APP|Feedback device - 4
219757209|NCT02283034|DEVICE|The CardioPump|Feedback devices - 5
219757210|NCT02283034|DEVICE|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
219757211|NCT05951426|PROCEDURE|1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage|"1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium"
219757212|NCT00557193|DRUG|Asparaginase|Given IV, IM, or PO
219757213|NCT00557193|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219757214|NCT00557193|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219757215|NCT00557193|DRUG|Cyclophosphamide|Given IV
219757216|NCT00557193|DRUG|Cytarabine|Given IV or IT
219757217|NCT00557193|DRUG|Daunorubicin Hydrochloride|Given IV
219757218|NCT00557193|DRUG|Dexamethasone|Given IV or PO
219757219|NCT00557193|PROCEDURE|Echocardiography|Undergo ECHO
219757220|NCT00557193|DRUG|Etoposide|Given IV
219757221|NCT00557193|BIOLOGICAL|Filgrastim|Given IV or SC
219757222|NCT00557193|OTHER|Laboratory Biomarker Analysis|Correlative studies
219411537|NCT04624035|PROCEDURE|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
219003472|NCT01595698|OTHER|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
219411538|NCT00192439|BEHAVIORAL|High Risk Respiratory Disease|
219569811|NCT02536469|DRUG|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
219569812|NCT00274885|DRUG|oxaliplatin|
219569813|NCT00274885|PROCEDURE|management of therapy complications|
219003473|NCT01595698|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
219003474|NCT02775721|OTHER|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
219003475|NCT02775721|OTHER|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
219003476|NCT02775721|OTHER|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
219003477|NCT02775721|OTHER|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
219003478|NCT02775721|OTHER|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
219003479|NCT03208855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
219003480|NCT03132376|DIETARY_SUPPLEMENT|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
219003481|NCT03132376|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
219003482|NCT03132376|DIETARY_SUPPLEMENT|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
219003483|NCT03132376|DIETARY_SUPPLEMENT|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
219003484|NCT03132376|DIETARY_SUPPLEMENT|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
219003485|NCT04946838|DEVICE|DS5 electrical stimulator|TENS
219003486|NCT00031057|DRUG|Thiamine hydrochloride|
219003487|NCT00031057|DRUG|Riboflavin|
219003488|NCT01586676|BEHAVIORAL|SAU|Supervision-as-usual
219757223|NCT00557193|DRUG|Lestaurtinib|Given PO
219757224|NCT00557193|DRUG|Leucovorin Calcium|Given IV
219757225|NCT00557193|DRUG|Mercaptopurine|Given PO
219757226|NCT00557193|DRUG|Methotrexate|Given IV, IT, or PO
219757227|NCT00557193|DRUG|Methylprednisolone|Given IV
219757228|NCT00557193|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219757229|NCT00557193|DRUG|Pegaspargase|Given IM
219757230|NCT00557193|OTHER|Pharmacological Study|Correlative studies
219757231|NCT00557193|DRUG|Prednisone|Given PO
219757232|NCT00557193|DRUG|Therapeutic Hydrocortisone|Given IT
219757233|NCT00557193|DRUG|Vincristine Sulfate|Given IV
219757234|NCT02815163|OTHER|Empowerment education|"1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback"
219757235|NCT00284128|DRUG|AVE7688|oral administration (capsules)
219757236|NCT00284128|DRUG|Losartan-potassium|oral administration (capsules)
219757237|NCT00652834|PROCEDURE|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
219757238|NCT00652834|DRUG|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
219757239|NCT02983409|RADIATION|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
219190317|NCT06844526|OTHER|Hoping Exercise|Week 1 Hopping to the sides on two legs (hands-free) 3 × 10 repetitions Hopping to front and back on two legs (hands-free) 3 × 10 repetitions Hopping to the front on two legs (hands-free) 3 × 10 repetitions Week 2 Hopping to the sides on two legs (hands on the chest) 2 × 15 repetitions Hopping to front and back on two legs (hands-free) 2 × 10 repetitions Hopping to the sides on one leg (hands-free) 5 × 4 repetitions Week 3 Hopping to the sides on one leg (hands on the chest) 3 × 10 repetitions Hopping zig-zag on two legs (hands-free) 2 × 10 repetitions Week 4 Hopping zig-zag on one leg (hands-free) 2 × 10 repetitions Hopping through squares on two legs (hands-free) 2 × 10 repetitions Week 5 Hopping in 8-shape on two legs (hands-free) 2 × 10 repetitions Hopping through squares on one leg (hands-free) 2 × 10 repetitions Week 6 Hopping through squares on one leg (hands on the chest) 2 × 10 repetitions Hopping in 8-shape on one leg (hands-free) 2 × 10 repetitions
219411539|NCT03372668|OTHER|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
219411540|NCT01030458|DRUG|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
219411541|NCT01030458|DRUG|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
219411542|NCT02420223|DRUG|Propranolol|
219411543|NCT04785079|PROCEDURE|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
219411544|NCT01836744|DEVICE|Survival rate dental implant (OsseoSpeed™)|
219411545|NCT00985556|DRUG|capecitabine|Given orally
219411546|NCT00985556|DRUG|oxaliplatin|Given IV
219411547|NCT00985556|DRUG|tegafur-gimeracil-oteracil potassium|Given orally
219411548|NCT04466501|DEVICE|ACR LAB|"The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
219411549|NCT02353039|DRUG|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
219757240|NCT00320606|DRUG|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
219757241|NCT00633841|BIOLOGICAL|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
219411550|NCT02353039|DRUG|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
219411551|NCT02353039|DRUG|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
219411552|NCT02353039|DRUG|Placebo|Administer placebo t.i.d for 2 weeks
219411553|NCT06100484|DIAGNOSTIC_TEST|Echocardiography|Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
219411554|NCT02325947|DEVICE|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
219411555|NCT02325947|DEVICE|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
219411556|NCT03173482|OTHER|questionnaire|asking about details of indication of cesarean section
219411557|NCT00980785|DRUG|Ramipril|Ramipril 5 mg/day
219411558|NCT00980785|DRUG|Placebo|Matching Placebo
219411559|NCT05024877|DRUG|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
219411560|NCT05024877|DRUG|Stanozolol Tablets|Stanozolol would be given 2mg tid.
219411561|NCT01540461|DRUG|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
219411562|NCT00330863|DRUG|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
219757242|NCT03984825|DRUG|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
219757243|NCT03984825|DRUG|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
219757244|NCT04109300|GENETIC|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
219757245|NCT04109300|OTHER|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
219757246|NCT02892370|DRUG|SHR0302|SHR0302 tablets (10 mg)
219757247|NCT02332811|DRUG|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
219757248|NCT02332811|DRUG|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
219757249|NCT00095550|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
219757250|NCT00095550|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
219757251|NCT00095550|DRUG|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
219757252|NCT04906694|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
219757253|NCT04906694|DRUG|Placebo|Diluent solution
219411563|NCT00330863|DRUG|Risperidone|Target dose is 4 mg/day.
219411564|NCT00330863|DRUG|Olanzapine|Target dose is 15 mg/day.
219411565|NCT00330863|DRUG|Quetiapine|Target dose is 600 mg/day.
219411566|NCT00330863|DRUG|Ziprasidone|Target dose is 120 mg/day.
219411567|NCT00330863|DRUG|Aripiprazole|Target dose is 20 mg/day.
219411568|NCT00330863|DRUG|Paliperidone|Target dose is 6 mg/day.
219411569|NCT05565976|DRUG|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
219411570|NCT05565976|DRUG|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
219411571|NCT05565976|DRUG|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
219411572|NCT05565976|DRUG|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
219411573|NCT05917626|BEHAVIORAL|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
219411574|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
219411575|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
219569814|NCT00642421|DRUG|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
219569815|NCT00642421|DRUG|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
219569816|NCT01215071|PROCEDURE|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
219569817|NCT01215071|PROCEDURE|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
219411576|NCT00312884|DEVICE|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
219003489|NCT01586676|BEHAVIORAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
219411577|NCT00882726|DRUG|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
219411578|NCT00882726|DRUG|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
219411579|NCT00882726|DRUG|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
219411580|NCT00882726|DRUG|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
219411581|NCT05142332|OTHER|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
219411582|NCT05277870|DEVICE|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
219411583|NCT05277870|DEVICE|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
219411584|NCT01818050|OTHER|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
219411585|NCT04474899|DRUG|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
219411586|NCT04474899|DRUG|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
219569818|NCT02647528|DEVICE|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
219569819|NCT02647528|DEVICE|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
219411587|NCT05801809|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
219411588|NCT05148585|OTHER|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
219411589|NCT05148585|OTHER|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
219411590|NCT03226223|DRUG|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
219411591|NCT03535038|DIAGNOSTIC_TEST|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
219411592|NCT03535038|DIAGNOSTIC_TEST|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
219569820|NCT02365948|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"
219411593|NCT01963299|DRUG|5 ml Ropivacaine 10% + physiological saline|
219411594|NCT01963299|DRUG|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
219569821|NCT02365948|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
219569822|NCT00982501|DRUG|WS® 1442 900 mg/d|
219569823|NCT00982501|DRUG|WS® 1442 1800 mg/d|
219569824|NCT00982501|BEHAVIORAL|Nordic walking training 2 x 30 min/week|
219569825|NCT00982501|BEHAVIORAL|Nordic walking training 4x45 min/week|
219569826|NCT03554252|OTHER|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
219411595|NCT03317275|DEVICE|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
219411596|NCT03317275|PROCEDURE|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
219411597|NCT03317275|OTHER|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
219411598|NCT02233400|DRUG|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
219411599|NCT04585295|DIETARY_SUPPLEMENT|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
219569827|NCT03554252|OTHER|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
219411600|NCT04585295|DIETARY_SUPPLEMENT|BCAA Big 6|1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
219411601|NCT04585295|DIETARY_SUPPLEMENT|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
219411602|NCT05856825|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
219411603|NCT01495338|DRUG|AC-170 0.17%|1 drop in one eye at one timepoint
219569828|NCT00543452|OTHER|Oxygen|4 liters of oxygen a minute
219569829|NCT00543452|OTHER|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
219569830|NCT05665959|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
219757254|NCT02818517|OTHER|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
219757255|NCT02818517|OTHER|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
219757256|NCT02975960|BIOLOGICAL|injection of autologous stromal vascular fraction|"1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously."
219757257|NCT02668666|DRUG|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
219411604|NCT01495338|DRUG|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
219411605|NCT01495338|DRUG|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
219569831|NCT05887349|OTHER|Neck Stabilization Exercise|"1\. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
219757258|NCT02668666|DRUG|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
219411606|NCT01495338|DRUG|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
219003490|NCT04818281|BIOLOGICAL|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
219003491|NCT04818281|BIOLOGICAL|Placebo|0.9% NaCl
219003492|NCT05187715|DRUG|Simvastatin 40mg|Simvastatin 40mg OD
219411607|NCT00150670|DRUG|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
219411608|NCT00150670|DRUG|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
219411609|NCT06082752|PROCEDURE|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
219411610|NCT02780765|DEVICE|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
219411611|NCT02780765|DEVICE|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
219411612|NCT02919124|DEVICE|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
219411613|NCT06195826|PROCEDURE|Gravity infusion|hysteroscopic myomectomy with the gravity infusion method
219569832|NCT05887349|OTHER|Neck Stabilization Exercise + Rocabado Exercises|"2\. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
219411614|NCT06195826|PROCEDURE|Pump infusion|hysteroscopic myomectomy with the pump infusion method
219411615|NCT03298152|PROCEDURE|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
219569833|NCT00053235|GENETIC|Comparative Genomic Hybridization|Correlative studies
219569834|NCT00053235|OTHER|Laboratory Biomarker Analysis|Correlative studies
219569835|NCT00053235|GENETIC|Polymerase Chain Reaction|Correlative studies
219569836|NCT03686150|DIETARY_SUPPLEMENT|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
219411616|NCT03298152|PROCEDURE|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
219569837|NCT03694808|DRUG|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
219569838|NCT03694808|DRUG|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
219569839|NCT03421366|DRUG|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
219569840|NCT02113371|BEHAVIORAL|Intervention|
219757259|NCT01483170|DRUG|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
219003493|NCT05187715|OTHER|Placebo|Placebo
219003494|NCT05187715|OTHER|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
219411617|NCT04899713|OTHER|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
219411618|NCT01006720|DRUG|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
219411619|NCT01006720|DRUG|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
219411620|NCT01006720|DRUG|Saline|Saline 0.9% (Saline)
219411621|NCT02916030|DIETARY_SUPPLEMENT|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
219411622|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
219411623|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
219411624|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
219411625|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
219411626|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
219411627|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
219411628|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
219411629|NCT04868006|PROCEDURE|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
219569841|NCT04520776|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
219569842|NCT04520776|DEVICE|Mobi-C® Cervical Disc|surgery
219569843|NCT00320567|DRUG|norgestimate/ethinyl estradiol|
219569844|NCT00500552|DRUG|Perhexiline/Placebo|
219569845|NCT00207948|DRUG|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
219569846|NCT04194684|DRUG|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
219569847|NCT01530594|DRUG|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
219569848|NCT01530594|DRUG|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
219569849|NCT01530594|DRUG|Lenalidomide|Lenalidomide/Low dose Dex (LLD
219569850|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
219569851|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
219569852|NCT03660241|DRUG|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
219569853|NCT03698266|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
219569854|NCT00117741|BEHAVIORAL|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
219569855|NCT00117741|BEHAVIORAL|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
219569856|NCT05698706|DEVICE|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
219569857|NCT00441350|DRUG|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
219757260|NCT01483170|DRUG|Placebo|Placebo fexinidazole
219757261|NCT02656056|OTHER|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
219757262|NCT05630456|OTHER|Receving feedback|Receving regular feedback from a health provider
219757263|NCT05630456|OTHER|No regular feedback|No regular feedback from a health provider
219411630|NCT04868006|PROCEDURE|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
219411631|NCT04868006|PROCEDURE|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
219569858|NCT00441350|DRUG|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
219569859|NCT01213836|DRUG|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
219569860|NCT01213836|DRUG|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
219569861|NCT01213836|DRUG|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
219569862|NCT01213836|DRUG|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
219761302|NCT06404047|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
219411632|NCT00869765|DRUG|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
219411633|NCT00869765|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
219411634|NCT05306158|OTHER|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
219569863|NCT05150756|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
219569864|NCT05150756|DRUG|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
219569865|NCT02450877|DRUG|Azacitidine|
219003495|NCT03611764|BEHAVIORAL|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
219569866|NCT02450877|OTHER|Control Arm|
219411635|NCT05306158|OTHER|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
219411636|NCT05306158|OTHER|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
219411637|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
219569867|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
219569868|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
219569869|NCT00255151|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
219569870|NCT00021060|DRUG|paclitaxel|Given IV
219569871|NCT00021060|DRUG|carboplatin|Given IV
219569872|NCT00021060|BIOLOGICAL|bevacizumab|Given IV
219569873|NCT00021060|OTHER|laboratory biomarker analysis|Correlative studies
219569874|NCT05332834|BIOLOGICAL|SM17|Peripheral intravenous injection
219569875|NCT05332834|OTHER|Placebo|Peripheral intravenous injection
219569876|NCT00909584|DRUG|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
219569877|NCT02676284|DEVICE|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
219569878|NCT05177159|OTHER|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
219569879|NCT05177159|OTHER|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
219569880|NCT05177159|OTHER|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
219569881|NCT01685073|DRUG|Zolpidem extended-release|nightly administration of zolpidem extended-release
219569882|NCT01685073|BEHAVIORAL|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
219569883|NCT00934596|PROCEDURE|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
219003496|NCT03611764|OTHER|Rotterdam Symptom Checklist|"* 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
219003497|NCT03611764|OTHER|Practice Logs|-Describe frequency of the Zen Den
219411638|NCT03460067|RADIATION|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
219411639|NCT02052778|DRUG|Futibatinib|oral once daily dosing, 21-day cycle
219569884|NCT00934596|DRUG|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
219569885|NCT01332578|DRUG|Paracetamol|Present in both test and active comparator
219569886|NCT01332578|DRUG|Phenylephrine|Test product
219569887|NCT01332578|DRUG|Ascorbic Acid|Test product
219569888|NCT01355718|DRUG|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
219569889|NCT01007747|OTHER|Geranium oil|Daily topical application over neuropathic pain
219569890|NCT00107042|BIOLOGICAL|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
219569891|NCT00107042|BIOLOGICAL|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
219569892|NCT02848911|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
219569893|NCT05210452|BIOLOGICAL|Follicular stem cells|Cultured autologous follicular stem cells
219569894|NCT05210452|OTHER|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
219569895|NCT01431352|DRUG|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
219411640|NCT05811676|DRUG|Tranexamic acid|Intravenous administration of 10 mL (1 g of tranexamic acid), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
219411641|NCT05811676|OTHER|0.9% sodium chloride|Intravenous administration of 10 mL placebo(0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
219569896|NCT01431352|DRUG|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
219569897|NCT04294342|BEHAVIORAL|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
219569898|NCT04047537|OTHER|Medical Food Formulation 1|WBF-0011
219569899|NCT04047537|OTHER|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
219569900|NCT04047537|OTHER|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
219569901|NCT05865808|OTHER|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
219569902|NCT05865808|OTHER|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
219569903|NCT00523328|DRUG|BG9924|dosage administered as per Biogen-idec protocol
219569904|NCT00152191|DRUG|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
219411642|NCT04168593|PROCEDURE|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
219411643|NCT06422494|DRUG|hyperinsulinaemic hypoglycaemic clamp|Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
219569905|NCT00152191|DRUG|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
219569906|NCT01764867|DRUG|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
219569907|NCT01764867|DRUG|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
219569908|NCT01764867|OTHER|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
219569909|NCT01764867|OTHER|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
219569910|NCT01764867|DRUG|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569911|NCT01764867|DRUG|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569912|NCT01764867|DRUG|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569913|NCT01764867|DRUG|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569914|NCT01764867|DRUG|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219411644|NCT06422494|DRUG|Propranolol Hydrochloride 1 MG/ML|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
219411645|NCT06422494|DRUG|Phentolamine|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
219569915|NCT01764867|DRUG|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219757264|NCT01190527|RADIATION|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
219411646|NCT06159868|OTHER|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
219411647|NCT06159868|OTHER|Standard care|Standard ward based care provided by usual care teams
219411648|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
219411649|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
219757265|NCT03769688|DRUG|Cervicovaginal secretions|Same as arm descriptions
219757266|NCT03769688|DRUG|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
219411650|NCT03533725|OTHER|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
219411651|NCT06350227|COMBINATION_PRODUCT|the absorbable hemostat and suture|The hemostasis method of the experimental group is to use both the absorbable hemostat and suture.
219411652|NCT06350227|COMBINATION_PRODUCT|electrocoagulation and suture|The active comparator group is to use electrocoagulation and suture simultaneously to stop bleeding.
219411653|NCT06350227|OTHER|suture|The placebo comparator is to use suture alone for hemostasis.
219411654|NCT04451655|DRUG|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
219411655|NCT04004624|DEVICE|Ablation|Cardiac Ablation
219411656|NCT05744115|DRUG|Ga-68-PSMA-11|Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
219411657|NCT02131948|DRUG|Intranasal insulin|Intranasal spray
219411658|NCT02131948|DRUG|Intranasal placebo|Intranasal spray
219411659|NCT02222454|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
219411660|NCT01870024|DRUG|Clonazepam|clonazepam 0,015 mg/kg
219411661|NCT01870024|DRUG|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
219411662|NCT01870024|DRUG|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
219569916|NCT01764867|DRUG|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569917|NCT01764867|DRUG|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569918|NCT01764867|DRUG|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219757267|NCT03769688|DIAGNOSTIC_TEST|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
219757268|NCT03769688|BEHAVIORAL|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
219569919|NCT01764867|DRUG|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219757269|NCT03769688|OTHER|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
219757270|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
219757271|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
219757272|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
219757273|NCT00399035|DRUG|Cediranib|oral tablet
219757274|NCT00399035|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
219411663|NCT01870024|DRUG|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
219411664|NCT06254352|DIAGNOSTIC_TEST|scoring system|Clinical Risk Scores in Prediction of Outcome of Acute Upper Gastrointestinal Bleeding in Non Cirrhotic Patients.
219411665|NCT01196624|DEVICE|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
219411666|NCT01196624|DEVICE|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
219411667|NCT06242067|DRUG|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
219411668|NCT06163456|OTHER|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
219411669|NCT00069420|BEHAVIORAL|Cognitive Motivational Behavior Therapy|
219411670|NCT01752582|DEVICE|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
219411671|NCT01752582|DEVICE|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
219411672|NCT05066828|OTHER|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
219411673|NCT01980706|DRUG|Baclofen|Baclofen is a GABA-B agonist
219411674|NCT01980706|DRUG|Placebo|Pill containing no pharmacologically active substance.
219411675|NCT06295016|OTHER|High-intensity intensive training|"Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume."
219411676|NCT06295016|OTHER|Taper|"Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%."
219411677|NCT04753814|DIAGNOSTIC_TEST|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
219411678|NCT01515995|DRUG|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
219411679|NCT03972644|PROCEDURE|Aortic valve replacement|Open heart surgery or transcatheter surgery
219411680|NCT02481726|RADIATION|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
219411681|NCT03314220|BEHAVIORAL|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
219411682|NCT05249088|OTHER|Protocolised reduction of non-resuscitation fluids|"* Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
219569920|NCT01764867|DRUG|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
219569921|NCT00000374|DRUG|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
219569922|NCT00000374|DRUG|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
219569923|NCT02712801|DRUG|Zidovudine|Dose will be adjusted according to the child's weight.
219569924|NCT02712801|DRUG|Nevirapine|Dose will be adjusted according to the child's weight.
219569925|NCT02712801|DRUG|Lamivudine|Dose will be adjusted according to the child's weight.
219569926|NCT02712801|DRUG|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
219569927|NCT03341546|OTHER|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
219569928|NCT05828355|OTHER|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
219569929|NCT04156412|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
219569930|NCT00883623|DRUG|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
219411683|NCT05249088|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol"
219411684|NCT00005986|DRUG|busulfan|
219411685|NCT00005986|DRUG|cyclophosphamide|
219411686|NCT00005986|DRUG|filgrastim|
219411687|NCT00005986|DRUG|recombinant interferon alfa|
219411688|NCT00005986|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219411689|NCT00005986|PROCEDURE|peripheral blood stem cell transplantation|
219411690|NCT00005986|PROCEDURE|radiation therapy|
219411691|NCT03902743|OTHER|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
219411692|NCT03925818|DRUG|Bismuth Subcitrate Potassium|Pylera capsules
219411693|NCT03925818|DIETARY_SUPPLEMENT|Gastrus|Gastrus 1 tablet
219411694|NCT03379610|DIAGNOSTIC_TEST|Nasopharngeal brush|"1. Baseline nasopharngeal brush before treatment~2. Post-treatment reassessment of residual NPC"
219411695|NCT05682820|DIAGNOSTIC_TEST|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
219411696|NCT00001261|DRUG|Gamma Globulin|
219569931|NCT01622608|BEHAVIORAL|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
219569932|NCT00031850|DRUG|goserelin acetate|
219569933|NCT00031850|DRUG|raloxifene|
219411697|NCT03404596|DRUG|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
219411698|NCT03404596|BEHAVIORAL|Counseling|Brief counseling sessions, 10-15 minutes each.
219411699|NCT03404596|BEHAVIORAL|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
219411700|NCT03404596|OTHER|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
219411701|NCT05591898|BEHAVIORAL|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
219411702|NCT04899791|OTHER|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
219569934|NCT04663438|DRUG|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
219411703|NCT04899791|OTHER|Wheat bread|Wheat bread
219411704|NCT01094730|DEVICE|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
219411705|NCT01094730|DEVICE|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
219411706|NCT01980121|DEVICE|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
219411707|NCT05804409|DIAGNOSTIC_TEST|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
219411708|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
219411709|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via non-rebreather
219411710|NCT04171037|OTHER|Questionnaire Administration|Ancillary studies
219411711|NCT04171037|DEVICE|Optiflow THRIVE|Oxygen Administration
219411712|NCT04209777|DRUG|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
219411713|NCT04209777|DRUG|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
219569935|NCT04004117|DRUG|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
219569936|NCT04004117|DRUG|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
219569937|NCT01758419|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
219569938|NCT06077734|OTHER|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
219569939|NCT01221090|BEHAVIORAL|PDA|Technological assistance
219569940|NCT01221090|BEHAVIORAL|CDSMP|6-week classes
219569941|NCT01221090|BEHAVIORAL|PDA/CDSMP|Combined technology and education
219569942|NCT05246696|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
219569943|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
219569944|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
219569945|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
219569946|NCT01613664|DRUG|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
219569947|NCT01613664|OTHER|no tisseel|the surgeon does not applied tissucol during the surgery
219569948|NCT04260321|DEVICE|AI|Artificial intelligence colonoscopy
219757275|NCT00399035|DRUG|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
219757276|NCT00399035|DRUG|Cediranib Placebo|oral tablet
219757277|NCT00716001|DRUG|N-acetylcysteine|
219757278|NCT01848093|OTHER|sputum collection|collecting of spontaneous sputum from the patient
219757279|NCT00976456|DRUG|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
219757280|NCT00976456|DRUG|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
219757281|NCT06087380|PROCEDURE|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
219757282|NCT06087380|OTHER|standard ward care|standard ward care
219757283|NCT01631968|PROCEDURE|Cement without antibiotic.|
219757284|NCT01631968|PROCEDURE|Cement with erytromycin and colistin.|
219757285|NCT02474810|DRUG|Alteplase|Alteplase for CVC dysfunction.
219757286|NCT02037529|DRUG|Eribulin Mesylate|Given IV
219757287|NCT02037529|OTHER|Laboratory Biomarker Analysis|Correlative studies
219757288|NCT02037529|DRUG|Paclitaxel|Given IV
219757289|NCT02037529|OTHER|Quality-of-Life Assessment|Ancillary studies
219757290|NCT05523908|RADIATION|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f
219757291|NCT05523908|RADIATION|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
219757292|NCT02131766|DEVICE|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
219757293|NCT02131766|OTHER|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
219757294|NCT02474121|DEVICE|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
219757295|NCT00718315|DRUG|erlotinib [Tarceva]|150mg po daily
219757296|NCT00718315|DRUG|fusidic acid [Verutex]|topical, daily for 30 days.
219757297|NCT00718315|DRUG|erythromycin [Eritex]|topical, daily for 30 days.
219757298|NCT00718315|DRUG|Fisiogel|topical, daily for 30 days
219757299|NCT05177250|DEVICE|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
219757300|NCT03152448|BEHAVIORAL|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
219757301|NCT04586933|DIETARY_SUPPLEMENT|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
219757302|NCT04586933|DIETARY_SUPPLEMENT|Placebo (soya)|Placebo (soya)
219757303|NCT04586933|BEHAVIORAL|Dietary guidance|Dietary guidance
219757304|NCT02526914|DRUG|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
219757305|NCT02526914|DRUG|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
219757306|NCT02526914|DRUG|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
219757307|NCT02188966|DEVICE|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
219757308|NCT04562415|DEVICE|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
219757309|NCT04562415|DEVICE|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
219411714|NCT00132821|DRUG|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
219411715|NCT00132821|DRUG|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
219411716|NCT00132821|DRUG|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
219411717|NCT00132821|DRUG|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
219411718|NCT03973684|DEVICE|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
219411719|NCT03973684|OTHER|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
219411720|NCT01413984|BEHAVIORAL|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
219411721|NCT02444819|DRUG|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
219411722|NCT00490763|BEHAVIORAL|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
219411723|NCT01934894|DRUG|cabazitaxel|
219003498|NCT05084274|BEHAVIORAL|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
219411724|NCT01934894|DRUG|lapatinib|
219757310|NCT04562415|DEVICE|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
219757311|NCT01927913|DRUG|SPD602|32, 50 or 75 mg/kg/day BID, capsule
219757312|NCT01927913|DRUG|Deferasirox|Per approved country specific label
219003499|NCT05744154|BEHAVIORAL|Audit & feedback with educational outreach and facilitation|As in arm descriptions
219411725|NCT00786136|DRUG|rosuvastatin|rosuvastatin
219411726|NCT04406051|PROCEDURE|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
219411727|NCT04406051|PROCEDURE|norepinephrine infusion and crystalloid co-loading (NOR-CRYST)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
219411728|NCT02857114|OTHER|massage|
219411729|NCT02426593|DEVICE|IMED-4|Non-invasive novel lung hydration status sensor.
219569949|NCT00708708|DRUG|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219569950|NCT02429375|DRUG|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
219569951|NCT04625075|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
219569952|NCT04625075|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to assess coronaries
219569953|NCT04625075|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|ECG to assess rhythm
219569954|NCT04625075|DIAGNOSTIC_TEST|Blood samples|renal function liver function full blood count, hematocrit glucose
219411730|NCT03585322|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
219569955|NCT04417049|DRUG|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
219569956|NCT00873106|DEVICE|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
219569957|NCT03934749|DEVICE|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
219757313|NCT00711373|PROCEDURE|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
219411731|NCT03248947|DRUG|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
219411732|NCT03248947|OTHER|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
219411733|NCT06301841|OTHER|experimental|"At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days."
219190318|NCT06844526|OTHER|Core Stability Exercises|Week 1 Bridging in face-down position 3 × 20 s Bridging in the supine position 3 × 20 s Side bridging (right and left) 3 × 20 s Week 2 Lifting the leg in supine position (knee bent) 3 × 20 repetitions Rising opposite hand and foot in quadriceps 3 × 20 repetitions Cross-crunch abdominal muscles 3 × 20 repetitions Week 3 Bridging on a physioball 3 × 20 repetitions Cobra exercise on a physioball 3 × 20 repetitions Superman exercise 3 × 20 repetitions Week 4 Sit-up on a physioball 3 × 20 repetitions Rotating the trunk in a sitting position using a physioball 3 × 20 repetitions Week 5 Lunge exercise with trunk rotation using a medicine ball 3 × 20 repetitions Bridging on a physioball (leg raising alternately) 3 × 10 repetitions on each leg Week 6 Lunge exercise (back leg on a physioball) 3 × 10 repetitions on each leg Superman exercise (alternately) 3 × 10 repetitions on each side
219411734|NCT03160105|DRUG|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
219411735|NCT03160105|OTHER|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
219411736|NCT01100307|DRUG|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
219411737|NCT01100307|OTHER|sham injection|sham injection every 6 weeks
219411738|NCT05135130|DRUG|ON101 Cream|Not applicable in this retrospective study
219411739|NCT02437448|OTHER|No intervention|
219411740|NCT06367790|OTHER|Experimental group|"The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied."
219411741|NCT06367790|OTHER|Control group|The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
219411742|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
219411743|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
219411744|NCT01473251|DRUG|Lucentis|0.5 mg monthly for 4 months
219411745|NCT02951611|PROCEDURE|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
219411746|NCT02951611|PROCEDURE|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
219411747|NCT01201070|DRUG|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
219411748|NCT04017533|PROCEDURE|GMK Sphere TKR|Se earlier
219411749|NCT05606679|GENETIC|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
219411750|NCT06560645|DRUG|PRT7732|PRT7732 capsules will be self-administered once daily at the dose-level assigned
219411751|NCT03398746|PROCEDURE|LOOP Technique|Placement of subcutaneous loop drain
219411752|NCT03398746|PROCEDURE|Standard incision and drainage|Incise and drain with placement of packing
219569958|NCT04424849|DIAGNOSTIC_TEST|CT-Scan|Chest CT scan on admission to the intensive care unit
219569959|NCT04733209|OTHER|TENS, US, exercise|Physiotherapy
219569960|NCT03050697|DEVICE|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
219569961|NCT03050697|PROCEDURE|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
219569962|NCT02597582|PROCEDURE|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
219569963|NCT02440516|OTHER|Early treatment group|Physical- and occupational Therapy
219569964|NCT02440516|OTHER|Late treatment group|Waiting list - then Physical- and occupational Therapy
219569965|NCT00799916|DRUG|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
219569966|NCT00799916|DRUG|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
219569967|NCT06108258|DRUG|IV iron administration|IV iron administration during pregnancy
219411753|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
219411754|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
219411755|NCT05324826|DEVICE|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
219411756|NCT03794141|BEHAVIORAL|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
219411757|NCT03794141|BEHAVIORAL|life style advise|all test persons were given information on healthy diet and life style
219411758|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
219411759|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
219411760|NCT02348411|DEVICE|ExAblate|
219569968|NCT06468423|DRUG|Deferasirox (DFX)|Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
219569969|NCT06468423|DRUG|Deferoxamine (DFO)|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
219569970|NCT04594915|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
219569971|NCT06364332|BEHAVIORAL|Social Media campaign|Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
219569972|NCT04691375|DRUG|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
219569973|NCT04691375|DRUG|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
219569974|NCT01164306|BEHAVIORAL|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
219569975|NCT01164306|BEHAVIORAL|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
219569976|NCT01164306|BEHAVIORAL|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
219569977|NCT02280720|PROCEDURE|Stenting using Optimax™|
219569978|NCT02280720|PROCEDURE|Stenting using PROMUS Element™ Plus|
219761303|NCT06404047|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
219761304|NCT06404047|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
219003500|NCT05744154|BEHAVIORAL|Simple audit & feedback (usual practice)|As in arm descriptions
219411761|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
219411762|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
219411763|NCT05125536|OTHER|Music therapy|rutin
219411764|NCT03966105|DIAGNOSTIC_TEST|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
219411765|NCT04144452|OTHER|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
219411766|NCT04144452|OTHER|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
219411767|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
219411768|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
219411769|NCT06603662|DRUG|Prednisone|Subjects assigned to the Intervention A group will receive oral prednisone 50 mg once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours for 5 days.
219411770|NCT06603662|DRUG|Dexamethasone|Subjects assigned to the Intervention B group will receive a single oral dose of dexamethasone 10 mg, plus standard ibuprofen 600 mg every 8 hours for 5 days.
219411771|NCT06603662|DRUG|Placebo|Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
219411772|NCT06378073|DIAGNOSTIC_TEST|Incentive Spirometer|"Specificity and sensitivity: Incentive spirometry is a specific type of spirometry that aims to encourage people to breathe deeply intentionally but does not provide a measurement or inform management of chronic lung diseases. Less than 5 repetitions per day (sensitivity 93%, specificity 77%) and less than 2 balls per repetition (sensitivity 93%, specificity 77%) were predictive of postoperative pulmonary complications. (1) Validity and reliability: Incentive spirometry can be used as a simple mean to follow lung function, especially VC, in the postoperative period in spontaneously breathing patients. Incentive spirometry is noninvasive and can be performed repeatedly at the bedside in the intensive care setting. (2)~Interpretation:~There are only three numeric values that are required to interpret spirometry:~* Forced Vital Capacity (FVC)~* Forced Expiratory Volume (FEV1)~* FEV1/FVC ratio."
219411773|NCT06378073|DIAGNOSTIC_TEST|Numeric Pain Rating Scale|"Sensitivity: The area under the receiver operator characteristic curve for the NRS as a test for pain that interferes with functioning was 0.76, indicating fair accuracy. A pain screening NRS score of 1 was 69% sensitive for pain that interferes with functioning. (4) he diagnostic value of different NRS cut-off values for administering analgesics is determined by an ROC curve. Sensitivity of NRS \> 3 for 'unbearable' pain in older patients was 72% with a specificity of 97·2%. With a cut-off point NRS \> 4, sensitivity increased to 83%, while specificity was 96·7%. (5) Validity and reliability: The numerical rating scale is a reliable and valid tool for pain assessment in patients with musculoskeletal impairments. (3)~Measurement (circle): Categorical /Numerical /Both:~Numerical:~The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable)"
219757314|NCT05140343|DIAGNOSTIC_TEST|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
219761305|NCT06404047|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
219761306|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
219761307|NCT05666518|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
219761308|NCT05666518|DRUG|Standard of care|Dosage at the discretion of the treating physician
219411774|NCT05121077|OTHER|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
219411775|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
219411776|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
219411777|NCT05020938|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
219411778|NCT03135028|DRUG|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
219411779|NCT03135028|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
219411780|NCT03135028|DRUG|Cytarabine|"100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle"
219411781|NCT02464787|DIETARY_SUPPLEMENT|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
219569979|NCT04539626|DRUG|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
219569980|NCT03046498|BEHAVIORAL|Evidence-Based Program|DSMP and DPP
219569981|NCT01633294|DRUG|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
219569982|NCT02215148|DRUG|Tolvaptan|
219569983|NCT01152866|DRUG|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
219411782|NCT04747808|DRUG|LL-BMT1|Drug-printed contact lens in both eyes
219411783|NCT01791868|DRUG|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
219569984|NCT03537157|DRUG|Rifaximin delayed release tablets|Active intervention
219569985|NCT03537157|OTHER|Placebo|Comparator placebo
219569986|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
219569987|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
219569988|NCT01976455|OTHER|20% fewer calories|
219569989|NCT01976455|OTHER|40% fewer calories|
219003501|NCT06036667|PROCEDURE|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
219003502|NCT06369376|DIAGNOSTIC_TEST|New nerve conduction protocol|We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
219411784|NCT01791868|DRUG|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
219411785|NCT04757935|BEHAVIORAL|Yoga|Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
219411786|NCT02532634|DRUG|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
219411787|NCT02532634|DRUG|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
219411788|NCT05960344|PROCEDURE|Spirometry|Supervised v unsupervised spirometry
219569990|NCT05628558|DRUG|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
219411789|NCT00530322|PROCEDURE|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
219411790|NCT04436224|DRUG|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
219411791|NCT04436224|DRUG|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
219569991|NCT06013917|DEVICE|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
219569992|NCT02231424|DRUG|Drug: Berodual®|
219569993|NCT01307839|DRUG|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
219569994|NCT01307839|DRUG|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
219569995|NCT00140413|DRUG|Nutropin AQ|Daily injection. Dosage dependent on weight.
219190319|NCT01266096|DRUG|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
219411792|NCT04436224|DRUG|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
219411793|NCT04436822|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
219411794|NCT03463616|RADIATION|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
219411795|NCT03463616|RADIATION|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
219411796|NCT02347241|OTHER|Educational intervention|Educational Debriefings and High frequency training and team reflection
219411797|NCT00011765|DRUG|Fluoxetine|
219411798|NCT05300867|OTHER|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
219411799|NCT05300867|OTHER|Physiotherapy|Physiotherapy 3-week-long
219411800|NCT03375112|PROCEDURE|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
219411801|NCT03375112|DRUG|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
219411802|NCT03375112|DRUG|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
219411803|NCT04310163|OTHER|Natural history|Parent interview and video capture
219411804|NCT03695991|PROCEDURE|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
219569996|NCT03044236|PROCEDURE|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
219569997|NCT04751539|DRUG|AND017 single dose|AND017 administrated as oral single-dose on Day 1 in Part A
219569998|NCT04751539|DRUG|AND017 multiple dose|AND017 administrated once daily from Day 1 to Day 10 in Part B
219569999|NCT04751539|DRUG|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
219570000|NCT01046630|DRUG|AZD6765|single infusion
219570001|NCT01046630|DRUG|Ketamine|single infusion
219570002|NCT01046630|DRUG|Placebo|single infusion
219570003|NCT04832048|OTHER|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
219570004|NCT04832048|OTHER|No physical exercise|No programmed physical exercise
219570005|NCT01466322|DRUG|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
219570006|NCT00865098|DRUG|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
219570007|NCT06070805|OTHER|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
219570008|NCT03634345|DRUG|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
219570009|NCT03634345|DRUG|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
219570010|NCT03634345|DRUG|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
219570011|NCT04457453|OTHER|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
219570012|NCT04457453|OTHER|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
219570013|NCT04457453|OTHER|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
219570014|NCT05513287|OTHER|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
219570015|NCT01007474|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
219570016|NCT01007474|DEVICE|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
219570017|NCT01007474|DEVICE|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
219761309|NCT06788990|DRUG|Ficerafusp alfa|Investigational
219003503|NCT03916198|DRUG|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
219411805|NCT06419868|BEHAVIORAL|"Universal preventive intervention for depression and anxiety for university students"|"This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning."
219411806|NCT04044391|DIAGNOSTIC_TEST|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
219411807|NCT05807334|OTHER|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
219190320|NCT07061938|DRUG|ACE1831|ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
219570018|NCT01007474|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
219570019|NCT01007474|DEVICE|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
219570020|NCT03623620|BEHAVIORAL|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
219570021|NCT04092920|DEVICE|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
219570022|NCT00811434|DRUG|Lactulose|1.5cc/kg/day po for three months
219570023|NCT00811434|DRUG|placebo|1.5 ml sugar water/kg day for three months
219003504|NCT03916198|DRUG|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
219190321|NCT07061938|DRUG|Lymphodepleting chemotherapy|Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.
219570024|NCT00197522|BIOLOGICAL|CD34+ derived DCs|
219570025|NCT02790034|DRUG|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
219570026|NCT02790034|DRUG|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
219570027|NCT02790034|DRUG|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
219570028|NCT01084434|DIETARY_SUPPLEMENT|probiotic|Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
219570029|NCT01084434|DIETARY_SUPPLEMENT|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
219570030|NCT01084434|DIETARY_SUPPLEMENT|Synbiotic|(Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
219570031|NCT01084434|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
219570032|NCT02658916|DRUG|BIIB092|Same dose as corresponding CN002003 study panel.
219570033|NCT02135120|DRUG|Combined spinal epidural anesthesia technique with intrathecal morphine|
219570034|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
219570035|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
219570036|NCT00793026|DRUG|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
219570037|NCT04747704|BEHAVIORAL|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
219570038|NCT01360866|DRUG|OPC-34712|Tablet
219570039|NCT01360866|DRUG|Escitalopram|Tablet
219570040|NCT01360866|DRUG|Fluoxetine|Capsule
219570041|NCT01360866|DRUG|Paroxetine CR|Controlled-release tablets
219570042|NCT01360866|DRUG|Sertraline|Tablets
219570043|NCT01360866|DRUG|Duloxetine|Delayed-release capsules
219570044|NCT01360866|DRUG|Venlafaxine XR|Extended-release capsules
219570045|NCT02126930|OTHER|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
219570046|NCT02126930|OTHER|Routine care|Patients randomized to this arm will receive care in the habitual manner.
219411808|NCT05807334|OTHER|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
219411809|NCT04301882|DRUG|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
219411810|NCT04301882|DRUG|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
219570047|NCT04102241|DRUG|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
219570048|NCT04102241|DRUG|Placebos|Placebos are the same as drugs, but contain no Hemay005.
219757315|NCT03859076|BEHAVIORAL|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
219757316|NCT03859076|OTHER|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
219757317|NCT03534882|OTHER|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
219757318|NCT04792385|DRUG|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
219757319|NCT00409955|PROCEDURE|Lamellar transplant with lyophilized corneas|
219757320|NCT00085527|DRUG|depsipeptide|
219757321|NCT05940350|BEHAVIORAL|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
219757322|NCT01093014|BEHAVIORAL|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
219757323|NCT01093014|BEHAVIORAL|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
219757324|NCT01093014|BEHAVIORAL|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
219761310|NCT06788990|DRUG|Pembrolizumab (KEYTRUDA®)|Immunotherapy agent used in combination with investigational agent
219761311|NCT06788990|DRUG|Placebo|Placebo Control
219003505|NCT02940145|OTHER|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
219411811|NCT00538876|DRUG|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
219411812|NCT02058927|DRUG|Measles vaccine|measles revaccination administered at 12 months from start of ART
219411813|NCT03744780|BEHAVIORAL|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
219411814|NCT01438567|DRUG|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
219411815|NCT01438567|DRUG|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
219570049|NCT02499224|DRUG|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
219411816|NCT05959772|RADIATION|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
219411817|NCT04261634|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
219411818|NCT04261634|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
219411819|NCT03566693|DEVICE|Dexcom G6 CGM System|continuous glucose monitor
219411820|NCT03566693|DEVICE|Blood glucose meter|Blue-tooth enabled blood glucose meter
219411821|NCT00335946|DEVICE|HANS non-needle acupuncture|
219411822|NCT00335946|PROCEDURE|Stimulation of two acupuncture points bi-lateral|
219411823|NCT02523326|DEVICE|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
219411824|NCT03943758|DIETARY_SUPPLEMENT|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
219411825|NCT03943758|DIETARY_SUPPLEMENT|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
219411826|NCT02963714|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
219411827|NCT02963714|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
219411828|NCT05048823|OTHER|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
219411829|NCT05048823|OTHER|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
219411830|NCT00894413|DRUG|Tadalafil|20 mg once daily for 10 - 14 days
219411831|NCT00894413|OTHER|Placebo Pill|Placebo
219411832|NCT02253706|DEVICE|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
219411833|NCT02253706|DEVICE|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
219411834|NCT05056467|PROCEDURE|Induction of Labor|Induction of Labor at 39 weeks of gestation
219757325|NCT01151657|DIETARY_SUPPLEMENT|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
219757326|NCT01151657|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing maltodextrin
219757327|NCT01649193|OTHER|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
219757328|NCT01128569|DRUG|Fluticasone Furoate|FF
219757329|NCT01128569|DRUG|FF/Vilanterol (VI; GW642444M)|FF/VI
219757330|NCT01128569|DRUG|Placebo|Placebo Inhaler
219411835|NCT02390336|OTHER|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
219411836|NCT02390336|OTHER|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
219411837|NCT03112213|DRUG|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
219411838|NCT03112213|DRUG|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
219411839|NCT04719338|DIAGNOSTIC_TEST|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
219411840|NCT02467387|DRUG|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
219411841|NCT02467387|DRUG|Lactated Ringer's Solution|One time infusion 1.5mL/kg
219411842|NCT05950477|DIAGNOSTIC_TEST|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
219757331|NCT04753775|DRUG|Aloe vera gel|
219757332|NCT02805140|BEHAVIORAL|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
219757333|NCT02805140|BEHAVIORAL|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
219757334|NCT02805140|BEHAVIORAL|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
219757335|NCT02768207|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
219003506|NCT01224431|DRUG|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
219003507|NCT05480085|BEHAVIORAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
219003508|NCT03186222|DIAGNOSTIC_TEST|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
219003509|NCT00894569|DRUG|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
219003510|NCT00894569|DRUG|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
219003511|NCT00004224|DRUG|cyclophosphamide|
219003512|NCT00004224|DRUG|etoposide|
219411843|NCT03661268|OTHER|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
219411844|NCT01811849|DRUG|Insulin LISPRO|
219411845|NCT01811849|DRUG|Insulin LISPRO|
219411846|NCT01811849|DRUG|Insulin LISPRO|
219411847|NCT03027804|PROCEDURE|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
219411848|NCT05233696|DRUG|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
219411849|NCT05233696|DRUG|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
219411850|NCT05233696|RADIATION|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
219411851|NCT05233696|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
219411852|NCT01868178|DEVICE|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
219570050|NCT04702724|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
219570051|NCT03440424|DRUG|Lemborexant|oral tablet
219570052|NCT02110017|OTHER|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
219003513|NCT00004224|DRUG|vincristine sulfate|
219003514|NCT00004224|PROCEDURE|adjuvant therapy|
219003515|NCT00004224|PROCEDURE|conventional surgery|
219003516|NCT00004224|RADIATION|radiation therapy|
219003517|NCT05385393|PROCEDURE|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
219003518|NCT04811391|BIOLOGICAL|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
219003519|NCT02240251|OTHER|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
219003520|NCT06336850|PROCEDURE|Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement|The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
219003521|NCT04056689|DRUG|DNL151|Oral repeating dose
219003522|NCT04056689|DRUG|Placebo|Oral repeating dose
219003523|NCT00827424|BEHAVIORAL|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
219003524|NCT02705495|OTHER|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
219411853|NCT00093093|DRUG|Viramidine|
219411854|NCT00093093|DRUG|Ribavirin|
219411855|NCT00093093|DRUG|pegylated interferon alfa-2a|
219411856|NCT03213626|DRUG|Cabozantinib 40 MG|To be taken orally once daily
219411857|NCT03213626|DRUG|Erlotinib 100Mg Tab|To be taken orally once daily
219411858|NCT04422665|OTHER|Resistance exercise|Single-legged resistance exercise
219003525|NCT02705495|DRUG|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
219003526|NCT02257944|BEHAVIORAL|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
219411859|NCT04363489|DEVICE|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
219411860|NCT04363489|DIAGNOSTIC_TEST|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
219411861|NCT04363489|DIAGNOSTIC_TEST|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
219411862|NCT01249872|DRUG|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219411863|NCT01249872|DRUG|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219411864|NCT01249872|DRUG|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219570053|NCT06094907|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
219570054|NCT06023849|DEVICE|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
219570055|NCT03702049|BEHAVIORAL|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
219570056|NCT06094049|OTHER|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
219570057|NCT06094049|OTHER|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
219570058|NCT02439203|DRUG|JM-010|
219570059|NCT02439203|DRUG|Placebo|
219570060|NCT00049699|DRUG|laromustine|
219570061|NCT04528199|DRUG|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
219570062|NCT03392675|BEHAVIORAL|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
219570063|NCT01304693|BIOLOGICAL|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
219570064|NCT01304693|BIOLOGICAL|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
219570065|NCT01272115|BEHAVIORAL|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
219570066|NCT03738176|DRUG|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
219411865|NCT01249872|DRUG|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219570067|NCT03738176|DRUG|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
219570068|NCT05408182|PROCEDURE|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
219570069|NCT00006182|PROCEDURE|Blood Transfusion|
219570070|NCT02129647|DRUG|Axitinib|
219570071|NCT03444272|DRUG|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
219411866|NCT01249872|DRUG|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219411867|NCT01249872|DRUG|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
219411868|NCT02848690|BEHAVIORAL|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
219411869|NCT02848690|OTHER|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
219411870|NCT04335266|DRUG|SHR2554|SHR2554
219411871|NCT03302793|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
219570072|NCT01715896|BIOLOGICAL|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
219570073|NCT01715896|BIOLOGICAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
219570074|NCT02164734|DEVICE|Endotracheal intubation|
219570075|NCT02164734|DEVICE|Laryngeal mask airway|
219570076|NCT02164734|DRUG|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
219757336|NCT02768207|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
219757337|NCT02236676|BEHAVIORAL|Nap after rehearsal trials|Behavioral
219757338|NCT06341894|DRUG|Dalpiciclib|CDK4/6 inhibitor dalpiciclib, 100mg orally qd
219411872|NCT03302793|DEVICE|tDCS|tDCS will be applied for 20 minutes.
219570077|NCT04773717|DRUG|Ascorbic acid|200mg/kg/24h in four equal parts
219757339|NCT06341894|DRUG|Endocrine therapy|Fulvestrant/AI
219757340|NCT00563732|DRUG|Lecozotan|
219003527|NCT02257944|OTHER|Treatment as Usual|treatment as usual
219411873|NCT03302793|DEVICE|tDCS sham|
219411874|NCT01272297|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
219570078|NCT04773717|DRUG|Placebo|The same regimen as ascorbic acid.
219570079|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
219570080|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
219757341|NCT02519842|DRUG|Fosaprepitant|
219757342|NCT02519842|DRUG|Placebo for fosaprepitant|
219757343|NCT02519842|DRUG|Ondansetron|
219757344|NCT02519842|DRUG|Dexamethasone|
219757345|NCT02519842|DRUG|5-HT3 antagonist|
219570081|NCT04226235|BEHAVIORAL|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
219757346|NCT04907071|DEVICE|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
219411875|NCT05818527|DEVICE|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
219411876|NCT03524833|DRUG|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
219411877|NCT03524833|DRUG|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
219411878|NCT00121511|DRUG|Efudex (5-fluorouracil)|
219411879|NCT00883480|DRUG|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
219411880|NCT00883480|DRUG|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
219411881|NCT00883480|DRUG|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
219757347|NCT04767711|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
219411882|NCT00883480|DRUG|Erlotinib|Erlotinib 150 mg/day x 21 days
219411883|NCT03081286|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
219411884|NCT03081286|PROCEDURE|Fat graft|The harvested lipoaspirate is injected at the site of pain.
219411885|NCT03081286|PROCEDURE|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
219411886|NCT03532555|DIETARY_SUPPLEMENT|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
219411887|NCT03532555|OTHER|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
219570082|NCT00953108|DRUG|quetiapine|300 mg per day
219570083|NCT00953108|DRUG|escitalopram|escitalopram 10 mg per day
219570084|NCT04031612|DRUG|Neoadjuvant therapy|Neoadjuvant therapy
219570085|NCT03923699|DEVICE|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
219570086|NCT00209846|DRUG|Gaboxadol|
219757348|NCT04767711|DRUG|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
219411888|NCT07010822|BIOLOGICAL|nOPV2|nOPV2 will be administered at birth and Wk 14 of age depending on the study arm.
219411889|NCT06625723|PROCEDURE|Standard postoperative care|This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
219411890|NCT06625723|DEVICE|Surgical Recovery Systems Sleep Aid|Sleep assistive device
219411891|NCT00755352|DRUG|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
219411892|NCT00755352|DRUG|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
219411893|NCT03394170|OTHER|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
219411894|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
219411895|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
219570087|NCT01276717|DRUG|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
219570088|NCT01276717|DRUG|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
219570089|NCT05089929|DEVICE|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
219570090|NCT05089929|PROCEDURE|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
219570091|NCT04761705|DRUG|JV-GL1|Experimental Treatment
219570092|NCT04761705|DRUG|Latanoprost 0.005% Ophthalmic Solution|Active Control
219411896|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
219411897|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
219411898|NCT02017678|BIOLOGICAL|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
219411899|NCT02126111|BIOLOGICAL|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
219570093|NCT03863483|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
219570094|NCT03863483|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
219570095|NCT03863483|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
219570096|NCT03863483|DRUG|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
219411900|NCT02126111|BIOLOGICAL|DEPIGOID Placebo|Placebo for subcutaneous administration
219411901|NCT03175003|OTHER|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
219411902|NCT05729217|OTHER|SBQ-LC survey|Symptom burden questionnaires of Long COVID
219411903|NCT04215081|DEVICE|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
219411904|NCT06687174|DRUG|MY008211A tablets|MY008211A BID
219411905|NCT06687174|DRUG|MY008211A tablets matched placebo|Matching placebo to MY008211A taken twice a day.
219411906|NCT06686914|DRUG|Cannabidiol (CBD) Oil 300mg|Cannabidiol (CBD) Oil 300mg, 1 dose
219411907|NCT06686914|DRUG|Cannabidiol (CBD) Oil 150mg|Cannabidiol (CBD) Oil 150mg, 1 dose
219411908|NCT06686914|DRUG|Placebo Oil|Placebo Oil, 1 dose
219411909|NCT05998616|BEHAVIORAL|Exercise Training Program|The intervention group will be encouraged to complete aerobic and resistance training exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment for monitoring walking and complete resistance training will be provided to the intervention group. The exercise training prescription involves 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and resistance training consisting of 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.
219411910|NCT05998616|BEHAVIORAL|Flexibility Program|The control group will be encouraged to complete stretching and range of motion exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment (yoga mat) for monitoring walking and complete flexibility training will be provided to the control group. The flexibility training prescription involves stretches from the Stretching for People with MS: An Illustrated Manual from the National MS Society.
219411911|NCT05650450|DEVICE|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
219411912|NCT06693102|BEHAVIORAL|Digital intervention targeting cancer-related cognitive impairments|The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.
219411913|NCT06693102|BEHAVIORAL|Crossword and sudoku taks|Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.
219411914|NCT06693778|OTHER|electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI|eCDS tool for risk stratification of pediatric mTBI patients
219411915|NCT06692751|BIOLOGICAL|Blood sampling|2 tubes of 5 mL
219411916|NCT06692751|PROCEDURE|Ophthalmological examination|"angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A."
219570097|NCT05748119|DRUG|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
219570098|NCT05748119|DRUG|Placebo|Equivalent number and size of capsules containing placebo
219570099|NCT00472121|DEVICE|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
219570100|NCT04393090|OTHER|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
219411917|NCT06692751|OTHER|angina severity questionnaire|at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
219411918|NCT01344811|PROCEDURE|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
219411919|NCT01344811|OTHER|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
219411920|NCT00444223|PROCEDURE|fluorine F 18 FEQA + positron emission tomography|
219570101|NCT00772135|DRUG|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
219570102|NCT00302549|DRUG|FK506|FK506,0.1mg/kg/d
219757349|NCT03737552|OTHER|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
219411921|NCT06052735|OTHER|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
219757350|NCT03912870|OTHER|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
219757351|NCT05786287|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
219757352|NCT05786287|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
219757353|NCT00008086|DIETARY_SUPPLEMENT|calcitriol|
219757354|NCT00008086|DRUG|carboplatin|
219003528|NCT04161989|DRUG|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
219003529|NCT04161989|DRUG|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
219003530|NCT02069301|BEHAVIORAL|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
219003531|NCT02069301|OTHER|Treatment as Usual|National Guideline for antidepressant care
219003532|NCT02069301|OTHER|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
219003533|NCT01635101|DRUG|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
219003534|NCT01635101|DRUG|IV Control|IV Control q6h; 4 doses, in 24 hours
219003535|NCT02275650|RADIATION|nbUVB|2 SED nbUVB exposure will be given every other week
219003536|NCT02659306|DRUG|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
219003537|NCT02569723|DRUG|Carbon C 14 Oxaliplatin|Intravenous infusion
219003538|NCT02569723|DRUG|Oxaliplatin|Intravenous infusion
219411922|NCT06693401|OTHER|Intervention group: PD rehabilitation complemented with Occupational Therapy programme|"In intervention group both Physiotherapy and Occupational Therapy programmes were implemented.~Occupational Therapy programme consisted in trainning the amplitude of the movements involved in the realization of each letter of the alphabet separately and through fine motor exercises. Specifically the tasks consisted of performing:~1. 2 types of handwriting exercises, namely for tracing the upper and lower-case letters of the alphabet guided by dotted lines and writing a sentence with and without spatial boundaries, in Portuguese language (to be performed for about 45 minutes, three times a week) and;~2. 4 groups of fine motor tasks exercises, namely for hand manipulation (2 exercises), finger isolation (3 exercises), finger flexion and extension (2 exercises) and coordination (1 exercise). All exercises were performed 10 times, in triplicate, for each hand on a regular basis of 2-3 times per week."
219411923|NCT06693401|OTHER|Control Group: conventional physiotherapy programme|In this group only the conventional physiotherapy programme was implemented. This programme has the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support. In this regard, participants were guided and supervised in each physiotherapy session by a Parkinson's disease healthcare specialist.
219003539|NCT02263794|PROCEDURE|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
219003540|NCT02263794|PROCEDURE|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
219003541|NCT01327885|DRUG|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
219003542|NCT01327885|DRUG|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
219003543|NCT01516931|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
219003544|NCT01516931|BEHAVIORAL|counseling|Placebo monthly by general counseling for 12 months.
219003545|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
219411924|NCT07034963|DRUG|Determine the ED50 and ED95 of esketamine|According to Dixon's up-and-down sequential design, esketamine will be initiated at 0.3 mg∙kg-1 intravenously, followed by dose adjustments (0.02 mg∙kg-1 increments/decrements) based on somatic responses to cervical dilation (positive: any movement; negative: no movement). The tests will continued until six crossover pairs are achieved.
219411925|NCT07034963|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
219003546|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
219003547|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
219003548|NCT03015012|GENETIC|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
219411926|NCT07034963|DRUG|Intravenous remifentanil 1μg∙kg-1|The control group will be injected with remifentanil 1μg∙kg-1.
219411927|NCT06712420|DRUG|neoadjuvant chemotherapy|NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0. PAtients will undergo curative surgery after neoadjuvant chemotherapy
219411928|NCT06712420|PROCEDURE|curative surgery|Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification
219411929|NCT05838833|DRUG|INV-001|Patient will be assigned to one of three arms.
219411930|NCT06517953|DRUG|Icotinib|An orally first-generation EGFR inhibitior.
219411931|NCT06517953|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
219411932|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
219411933|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
219570103|NCT05223491|PROCEDURE|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
219570104|NCT05223491|PROCEDURE|Conventional TURB|Tumour is resected piecemeal.
219570105|NCT01946776|DEVICE|implantable heart rate monitor|Implantation of Reveal XT
219570106|NCT01478737|DRUG|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
219570107|NCT01478737|PROCEDURE|Vitrectomy|Vitrectomy only
219570108|NCT01764295|DRUG|DWJ1276|
219570109|NCT01764295|DRUG|Olmesartan|
219570110|NCT01764295|DRUG|Rosuvastatin|
219570111|NCT01764295|DRUG|Placebo|
219570112|NCT01820351|OTHER|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
219570113|NCT02630836|DRUG|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
219570114|NCT02630836|PROCEDURE|Surgical treatment|Isolated endomedullary nailing
219411934|NCT06715709|DRUG|Dexamethasone IV|Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.
219411935|NCT06715709|DRUG|Dexamethasone IV+Oral|Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
219411936|NCT06715709|DRUG|Dexamethasone IV+Oral 2 Day|Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
219411937|NCT04207567|BEHAVIORAL|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
219411938|NCT00406640|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
219411939|NCT00406640|DRUG|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
219411940|NCT06926192|COMBINATION_PRODUCT|Surgery combined with secukinumab|Surgery combined with secukinumab
219411941|NCT00443339|DRUG|Darbepoetin|
219411942|NCT04645017|BEHAVIORAL|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
219570115|NCT01746264|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
219570116|NCT03566264|OTHER|Non-Interventional|Non-Interventional
219570117|NCT02283164|BEHAVIORAL|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
219570118|NCT04841018|DRUG|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
219570119|NCT04841018|DRUG|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
219570120|NCT04056871|DIAGNOSTIC_TEST|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
219570121|NCT00476632|BEHAVIORAL|Questionnaire|50 Minute Interview
219570122|NCT01833533|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219570123|NCT01833533|DRUG|Ribavirin|Capsule
219570124|NCT01833533|DRUG|Placebo for Ribavirin|Capsule
219570125|NCT02710097|DRUG|Active inhaled cannabis|"\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
219757355|NCT04904835|DIAGNOSTIC_TEST|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
219411943|NCT06889870|PROCEDURE|Pectoral Nerve Block|In the PEC group, the PECS II block will be performed by the same anesthesiologist and will be performed before the skin incision, using the technique described by Blanco at al, 2012. 10 ml of ropivacaine solution (0.3%) will be administered into the fascia between the pectoralis major and pectoralis minor muscles and 20 ml of the same anesthetic solution between the pectoralis minor and serratus muscles.
219411944|NCT06889870|PROCEDURE|Local Anesthesia|In the LOC group, local infiltration will be carried out by the surgeon before the surgical incision. Adrenaline 1:20000 will be added to the anesthetic solution in the LOC group for the surgeon's convenience in order to better control per operative bleeding. In the PEC group, a solution of adrenaline in the same concentration in 0.9% saline will be infiltrated, also just to control bleeding in the surgical field.
219411945|NCT04183842|DIETARY_SUPPLEMENT|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6)."
219411946|NCT04183842|OTHER|Placebo|"Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~\- Carrot juice"
219411947|NCT06754982|OTHER|Myofascial release|Nine myofascial release techniques will be applied to each group: Transverse hamstring play; Transverse hamstring and adductor magnus play: posterior to anterior pressure; Transverse gastrocnemius-soleus play; Tibia bone clearing: posterior tibia; Tibia bone clearing: prone grip with half chisel; Lateral fascial distraction of the tibia; Lateral elongation of the peroneal tissue; Cross-friction of the gastrocnemius-soleus musculotendinous junction; Manipulation of the plantar fascia.
219190322|NCT06149338|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope has been the gold standard for endotracheal intubation since the middle of 20th century. During laryngoscopy and direct vision of the vocal cords, an endotracheal tube is passed into the trachea, establishing the airway.
219411948|NCT06758128|GENETIC|Evaluation of HS1,2 polymorphisms|"Echocardiograms will be performed by experienced operators of the echocardiography service.~Inflammatory profile. A single additional blood sample (3 cc) will be collected. Plasma will be isolated from whole blood to determine pro-inflammatory cytokines.~Immunoprofile: Circulating lymphocytes will be separated according to Ficoll gradient (into the two different components of immunity (B and T lymphocytes) with different inflammatory phenotypes.~Evaluation of HS1,2 polymorphisms and estrogen levels: DNA purifications and amplifications will be performed from an aliquot of the single whole blood sample. Genomic DNA will be isolated using the QIAamp DNA Mini and Blood Mini kit (QIAGEN Hilden, Germany) according to the manufacturer's protocol. 9 single nucleotide polymorphisms (SNPs) in four specific polymorphic regions of the 3'-1 Regulatory Region (3'RR-1) of the human immunoglobulin (IgH) heavy chain locus will be sequenced."
219757356|NCT01295710|BIOLOGICAL|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
219757357|NCT01295710|BIOLOGICAL|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
219190323|NCT06149338|DEVICE|Vie Scope|Vie Scope is a laryngoscope, whose function is relied on Seldinger technique. Firstly, bougie is passed through the translucent barrel of Vie Scope under direct vision between the vocal cords and into the trachea. Then, Vie Scope is removed and an endotracheal tube is passed over the bougie, which will be finally removed. The inflation of the endotracheal tube's cuff is followed by ventilation and confirmation of the tube placement.
219411949|NCT06898190|BEHAVIORAL|Learning Early Infant Feeding Cues (LEIFc)|Coaching sessions using SS-OO-PP-RR are conducted at infant age of 2 and 3 months. This occurs during an infant feeding session between mother and infant with the interventionists offering coaching specific to responsive feeding during the session. At the conclusion of the visit, the interventionists and mother develop specific strategies to practices prior to the next visit. At the following visit, a discussion of reflection and review occurs prior to the infant feeding session to identify what is going well and what still needs work.
219411950|NCT06897956|OTHER|Oral health educational program|Oral health educational program about oral hygiene, prevention of dental caries and techniques of tooth brushing
219411951|NCT06769646|OTHER|No tretament given|No treatment given
219411952|NCT03437538|DEVICE|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
219411953|NCT03437538|DEVICE|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
219570126|NCT02710097|DRUG|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
219570127|NCT02710097|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
219570128|NCT02710097|DRUG|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
219411954|NCT06814340|DEVICE|ECMO + near apneic ventilation|"Near apneic ventilation will be use during the first 3 days of ECMO. Patients will be ventilated in BIPAP/APRV or pressure-controlled ventilation. PEEP will be set to maintain the same mean airway pressure obtained during the standardized ventilation period pre-randomization to prevent lung derecruitment (PEEP ≥15cmH2O). If BIPAP/APRV is used, an RR of 2-4/min will be set with high pressure set at 30cmH20 for 3 sec. If pressure-controlled ventilation is selected, a respiratory rate of two sigh breaths/min with 30 cmH2O plateau pressure will be applied. Each sigh breath will be of three seconds duration.~Neuromuscular blockade and sedation could be used at the discretion of the attending physician. After 3 days on ECMO, apneic ventilation could be pursued (at the physician's discretion). If not, ultra-protective lung ventilation will be applied (i.e standard of care). Prone positioning on ECMO will be left to the physicians' discretion."
219411955|NCT06814340|DEVICE|ECMO + ultra-protective lung ventilation|"Ultra-protective lung ventilation will be used up to the ECMO weaning. This group will receive ultra-protective lung ventilation with BIPAP/APRV or VCV mode setting a PEEP \>10 cmH2O, ΔP 14-15 cmH2O, RR 15-20/min, Vt 3-4ml/kg and lowest FiO2 to maintain SpO2\>92%.~The use of prone positioning during ECMO will be left at the physician's discretion."
219570129|NCT04124666|BIOLOGICAL|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
219570130|NCT03192241|OTHER|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
219570131|NCT03192241|OTHER|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
219570132|NCT05792124|PROCEDURE|Erector spina area block|After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.
219570133|NCT05792124|PROCEDURE|Retrolaminar block|The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
219570134|NCT04680234|PROCEDURE|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
219570135|NCT04680234|DEVICE|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
219570136|NCT02844517|DEVICE|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
219411956|NCT07070674|DRUG|AC-003|AC-003 capsules will be administered orally.
219570137|NCT02377635|DIETARY_SUPPLEMENT|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
219570138|NCT02377635|DIETARY_SUPPLEMENT|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
219411957|NCT07072455|OTHER|Scales|"This observational study consists of data collection using a structured questionnaire based on an e-CRF, distributed by e-mail.~Four questionnaires were administered : the Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS) and the State-Trait Anxiety Inventory (STAI-Y).~Socio-demographic and treatments were collected."
219411958|NCT07072455|OTHER|High Intellectual Potential Scale|For participants with High Intellectual Potential, the total Intelligence Quotient (IQ) or General Ability Index (GAI), along with the index scores from the Wechsler scales (Verbal Comprehension Index, Perceptual Reasoning Index, Working Memory Index, and Processing Speed Index), will be extracted from the cognitive assessment previously completed by the participant prior to study enrollment.
219411959|NCT00380354|DRUG|GSK256066|
219411960|NCT07082595|OTHER|TASS Intervention (Sham)|Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. No auditory stimuli will be delivered.
219411961|NCT07082595|OTHER|TASS Intervention (Verum)|TASS: Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. Auditory stimuli will be delivered through the integrated headphones when non-rapid-eye-movement (NREM) sleep is detected during the night to induce TASS.
219570139|NCT05558475|BEHAVIORAL|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
219570140|NCT04067388|OTHER|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
219570141|NCT03083977|OTHER|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
219570142|NCT01048502|DRUG|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
219570143|NCT01048502|DRUG|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
219570144|NCT01048502|DRUG|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
219570145|NCT01485484|DEVICE|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
219757358|NCT04147273|DEVICE|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
219757359|NCT00003616|DRUG|irinotecan hydrochloride|
219757360|NCT04883268|OTHER|Expand Your Horizon|Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
219757361|NCT04044963|BEHAVIORAL|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
219757362|NCT01493414|DRUG|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
219757363|NCT04926116|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
219757364|NCT04926116|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
219757365|NCT01072526|DRUG|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
219757366|NCT01072526|DRUG|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
219757367|NCT03443635|BEHAVIORAL|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
219757368|NCT05589454|DRUG|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
219757369|NCT05589454|DRUG|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
219757370|NCT04402710|BEHAVIORAL|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
219757371|NCT04402710|BEHAVIORAL|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
219757372|NCT02336061|BEHAVIORAL|Evaluation of gender differences on the psychosocial and economic impact.|
219190324|NCT06682130|DRUG|Group A：Patients with PR or ctDNA positivity after salvage treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15."
219190325|NCT06682130|PROCEDURE|Group B: Patients with CR and ctDNA negative after salvage treatment|Group B patients initiated ASCT treatment directly after evaluating the efficacy of salvage treatment
219411962|NCT07084714|BEHAVIORAL|Moderate Aerobic Exercise|"Participants will complete moderate intensity aerobic exercise for 30 minutes per session, progressing from three to five days per week to meet the minimum recommended aerobic physical activity guideline of 150 minutes per week set by the American College of Sports Medicine (ACSM) over two menstrual cycles. Moderate intensity is defined as maintaining a heart rate within 40-59% heart rate reserve and a rate of perceived exertion of 11-14 light to somewhat hard on the Borg 6-20 scale."
219411963|NCT07082829|DRUG|ORX142 Tablets|ORX142 Tablets
219411964|NCT07082829|OTHER|Placebo Tablets|Placebo Tablets
219411965|NCT07083440|DRUG|Remimazolam|Intravenous bolus administered over 1 minute (prepared as a 1 mg/mL solution). Doses: 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg according to group allocation.
219411966|NCT07083440|DRUG|Propofol|Intravenous (10 mg/mL emulsion), initial titrated dose ranging from 0.5 to 2 mg/kg, administered slowly until MOAA/S ≤ 2. Supplemental 0.5 mg/kg boluses as needed.
219411967|NCT07083440|DRUG|Sufentanil|Intravenous dose of 0.1 µg/kg administered approximately 30 minutes before the start of the procedure.
219411968|NCT07083635|DRUG|Transdermal Ethinyl Estradiol/Norelgestromin Patch|Transdermal contraceptive patch containing ethinyl estradiol 600 micrograms and norelgestromin 6 milligrams per patch, manufactured by GEDEON RICHTER PLC and imported by Abbott.
219411969|NCT07083635|DRUG|Placebo Patch|Identical-appearing transdermal patches without active hormonal ingredients , manufactured and imported by Convatec.
219411970|NCT07082842|DRUG|HEC585|HEC585 tablet, taken once daily
219411971|NCT07082842|DRUG|Placebo|HEC585 Simulation Board, taken once daily
219411972|NCT07082842|DRUG|Pirfenidone|Pirfenidone, taken three times a day
219411973|NCT07083453|OTHER|Comparator 1|$10 rebate offered with an online caries and periodontal risk assessment
219411974|NCT07083453|OTHER|Comparator 2|20 rebate offered without risk assessment
219411975|NCT07083453|OTHER|Comparator 3|$30 rebate offered without risk assessment
219411976|NCT07083453|OTHER|Comparator 4|$50 rebate offered without risk assessment
219411977|NCT07083453|OTHER|Control|$10 rebate offered with no risk assessment
219570146|NCT05797584|DRUG|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
219570147|NCT05797584|OTHER|Passive leg raising|Passive leg raising for acute volume load
219570148|NCT00104091|DRUG|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
219757373|NCT00414570|DRUG|[18]F-FLT PET scan|Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
219411978|NCT07083245|BEHAVIORAL|Psychosocial care|Psychosocial support to chemotherapy patients during their treatment sessions through conversations, board games, movies, and gift baskets
219411979|NCT07083869|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
219411980|NCT07083869|BEHAVIORAL|Sleep Well|Sleep Well is a website that is mobile enabled that provides psychoeducation about healthy sleep habits that is based on NIH Health Guide to Health Sleep and VA's Whole Health Change Your Habits to Sleep Better.
219411981|NCT07082855|DRUG|Minocycline 100mg|Capsules Minocycline 100mg po per day and placebo 100mg po per day for 12 months
219411982|NCT07082855|DRUG|Minocycline 200mg|Capsules Minocycline 100mg po twice a day for 12 months
219411983|NCT07082855|DRUG|Placebo|Capsules placebo 100mg po twice a day for 12 months
219411984|NCT07082010|DEVICE|MBPS App|A MBPS web application designed and built on a customizable case management platform (CommCare) to support non-specialist providers will be used by study participants for approximately 3 months.
219411985|NCT07084155|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
219570149|NCT03861663|DEVICE|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
219570150|NCT03365544|OTHER|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
219570151|NCT03122340|DRUG|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
219570152|NCT03122340|OTHER|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
219570153|NCT01138826|DRUG|Amlodipine - reference|10 mg tablet, single dose, with water
219570154|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
219570155|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
219570156|NCT06337825|BEHAVIORAL|Activity Tracker (Fitbit)|Wearable, activity tracker
219570157|NCT06337825|DIAGNOSTIC_TEST|HbA1C|Average blood glucose (sugar) levels reported as a percentage
219570158|NCT06337825|BEHAVIORAL|The PROMPT Questionnaire|The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
219570159|NCT05462730|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
219570160|NCT05462730|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
219570161|NCT03507478|DEVICE|BPI1000013|Foam insole
219570162|NCT02302521|DEVICE|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
219411986|NCT07083609|DRUG|Dabigatran|Dabigatran will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
219411987|NCT07083609|DRUG|Rivaroxaban|Rivaroxaban will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
219411988|NCT07083856|BEHAVIORAL|Reiki|Reiki
219411989|NCT07083856|BEHAVIORAL|Self-Acupressure|Self-Acupressure
219570163|NCT06387680|OTHER|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial
219570164|NCT06123182|BEHAVIORAL|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
219570165|NCT06123182|BEHAVIORAL|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
219570166|NCT06123182|BEHAVIORAL|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
219570167|NCT06123182|BEHAVIORAL|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
219570168|NCT06123182|BEHAVIORAL|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
219570169|NCT03921060|DRUG|Denosumab|treatment with denosumab every 6 months for up to 5 years
219570170|NCT06700122|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D
219411990|NCT07082049|PROCEDURE|Prostate surgery|Including but not limited to open radical prostatectomy, laparoscopic radical prostatectomy (LapRP) and robot-assisted radical prostatectomy (RARP).
219411991|NCT07082049|BEHAVIORAL|LLM-assisted communication|Preoperatively, patients will communicate with the LLM, which will provide direct answers to their various questions, including but not limited to diagnosis, treatment options, operative risks, and complication management. To ensure the accuracy of LLM-generated responses in real-world clinical settings, all answers will undergo verification by the researchers before being provided to patients.
219411992|NCT07082049|BEHAVIORAL|Routine preoperative communication|Preoperatively, patients will attend a consultation with the attending surgeon and surgical team. This physician-led communication will comprehensively discuss, current disease status, treatment options, operative risks, potential complication. The surgical team will subsequently address patient inquiries, followed by executing the informed consent form.
219570171|NCT03360916|DRUG|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
219411993|NCT07084415|OTHER|Postural correction exercise|Each participant will be given cervical thoracic spine correction exercises in the form of thoracic Roll Stretching Exercises, shoulder Bracing (Shoulder Retraction), superman Pose, chin Tuck (Cervical Retraction), five days a week for 4 weeks
219570172|NCT03360916|DRUG|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
219570173|NCT03360916|DRUG|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
219570174|NCT03360916|BEHAVIORAL|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
219570175|NCT01402180|BIOLOGICAL|Nimotuzumab|
219570176|NCT01402180|RADIATION|Radiation therapy|
219570177|NCT01402180|RADIATION|radiation therapy|
219570178|NCT01402180|DRUG|chemotherapy|
219570179|NCT01402180|DRUG|chemotherapy|
219003549|NCT03015012|OTHER|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
219003550|NCT02441777|DEVICE|Polarization-Sensitive OFDI|OCT Imaging of the eye
219003551|NCT06000514|DRUG|Sm29 Protein, Schistosoma Mansoni|Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
219003552|NCT06000514|DRUG|Pentavalent antimony (Sbv)|Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
219003553|NCT06276439|PROCEDURE|Surgical removal of breast cancer and lymph nodes|The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
219003554|NCT02003612|OTHER|Not applicable - observational study|No intervention exists as this is a retrospective observational study
219003555|NCT05346341|PROCEDURE|Minimally invasive techniques|"All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy."
219003556|NCT03232801|BEHAVIORAL|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
219003557|NCT03232801|BEHAVIORAL|general health education group|A general health and aging education group
219411994|NCT07084415|DEVICE|Laser acupuncture|"A dermatograph pencil (COLOURED®) will be used to draw circles with diameters of 2 cm around the application points. Each point will be stimulated for 30 seconds.~The laser will be placed at the specific acupuncture points in shoulder and cervical regions.~Each woman in the study group will be treated by laser acupuncture for 7 minutes twice a week for 4 weeks.~Acupuncture points of the neck:~B10 (Tianzhu), GB 20 (Fengchi), GB 21 (jianjing), and EX-HN15 (jianzhongsgu). Acupuncture points of shoulder: LI 14 (Binao), LI 15 (Jianyu), TE 14 (Jianlio), LI 4 (Hegu),LI16 (Jugu), ST 38 (Tiaoko), SI 10 (Naoshu),LI 11 (Quchi),TE 15 (Tianliao),LU 1 (Zhongfu),~Parameter of laser:~wavelength: 808\[nm\], Operating mode: Continuous wave, Output power: 100 \[mW\], Power density: 333\[mW/cm\], area irradiated:0.3 cm2, Total time per point: 30\[s\], Angle of application:90 degree."
219411995|NCT07084207|DEVICE|Symani® Surgical System|"Robotic-assisted surgery consists of participants who undergo nerve coaptation with the Symani Surgical System, according to the Instruction for Use (IFU). In order for the surgery to be considered a robotic assisted surgery, the participants must be randomized to the RAS group which will include:~* Participants where all nerve coaptations were performed entirely with Symani.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using Symani but a switch to manual suturing occurred during the procedure"
219411996|NCT07084207|PROCEDURE|Manual Surgery|"Manual surgery consists of participants who undergo nerve coaptation through manual techniques by a surgeon using handheld instruments without robotic assistance. In order for the surgery to be considered a manual surgery, the participants must be randomized to the MS group which will include:~* Participants where all nerve coaptations were performed entirely manually.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using manual suturing but a switch to Symani occurred during the procedure."
219570180|NCT03914768|BIOLOGICAL|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
219003558|NCT03824912|DRUG|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
219003559|NCT03824912|DRUG|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
219003560|NCT03824912|DRUG|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
219003561|NCT05036551|DIAGNOSTIC_TEST|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
219003562|NCT02511184|DRUG|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
219003563|NCT02511184|DRUG|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
219003564|NCT03657706|PROCEDURE|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
219003565|NCT03657706|PROCEDURE|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
219003566|NCT05741320|OTHER|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
219003567|NCT04462003|DRUG|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
219003568|NCT04462003|DRUG|Enoxaparin|1mg/Kg/sc/12h
219003569|NCT00774150|BEHAVIORAL|Cognitive Behavioral Therapy|16 sessions of CBT
219003570|NCT00774150|BEHAVIORAL|Client Centered Therapy|16 sessions of CCT
219003571|NCT02634684|DRUG|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
219003572|NCT02634684|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
219003573|NCT05948254|PROCEDURE|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
219003574|NCT03704454|DIETARY_SUPPLEMENT|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
219003575|NCT03704454|DIETARY_SUPPLEMENT|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
219003576|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
219003577|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
219003578|NCT05571241|BEHAVIORAL|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
219003579|NCT01053728|DRUG|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
219003580|NCT01053728|DRUG|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
219570181|NCT04862884|DRUG|HRS4800 tablets|"1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration"
219003581|NCT01963403|DRUG|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
219003582|NCT01963403|DRUG|Placebo|1 pill per day; daily during study participation (up to 84 days)
219003583|NCT03395886|DRUG|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
219003584|NCT03395886|DRUG|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
219003585|NCT00004443|DRUG|NTBC|
219003586|NCT01580189|DIETARY_SUPPLEMENT|Whey protein|18g protein, immediately after training, 9 weeks
219003587|NCT01580189|DIETARY_SUPPLEMENT|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
219411997|NCT07075900|OTHER|Dynamic Neuromuscular Stabilization Training|"According to the principles of Dynamic Neuromuscular Stabilization (DNS), proper activation of the integrated spinal stabilization system requires that the abdominal muscles expand not only in the caudal direction but also posteriorly and laterally.Therefore, firstly, the physiotherapist will assess the expansion of the entire abdominal wall and teach the patient to regulate intra-abdominal pressure through correct breathing techniques. During training and exercises, a belt will be used. Participants will be instructed to maintain abdominal expansion toward the belt during exercises performed in positions supported by proper alignment. A four-phase exercise protocol based on developmental kinesiology principles will be implemented for the DNS group, beginning with supine-position exercises appropriate for the 3-month developmental stage.~They will be instructed to repeat the exercises at least three times per day.Patients will record their home exercise program using an exercise diary."
219411998|NCT07075900|OTHER|Pelvic Floor Muscle Training|"Participants in the PFMT group will undergo a structured pelvic floor muscle training program supervised by a physiotherapist. The training will include verbal and manual instructions to ensure correct identification and isolated activation of the pelvic floor muscles without compensatory movements from the gluteal, abdominal, or thigh muscles using a NeuroTrac Simplex EMG-Biofeedback device.~The exercise protocol will consist of both slow and fast contractions, focusing on endurance, strength, and coordination.~The exercises will be performed in various positions (e.g., supine, sitting, standing) and will gradually progress in intensity and complexity over time, following the principles of motor learning stages. They will be instructed to repeat the exercises at least three times per day. Patients will record their home exercise program using an exercise diary."
219411999|NCT06926179|DRUG|neoadjuvant immunotherapy|"Patients in the cohort received neoadjuvant immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors, as part of routine clinical care. The specific regimens included monotherapy or combination with chemotherapy. The agents used may include nivolumab, camrelizumab, sintilimab, atezolizumab, or others.~This is a retrospective observational study. All interventions (neoadjuvant immunotherapy ± chemotherapy, surgery, or other treatments) were determined by treating physicians as part of standard care. The study aims to evaluate perioperative and survival outcomes across different treatment paths in real-world clinical settings."
219412000|NCT07082140|OTHER|Social media based education|"Participants in the intervention group will be required to follow the Instagram account created specifically for the training. The Instagram account will be made private to prevent women in the control group from accessing Instagram posts. The training provided via Instagram will last 2 weeks, including the process of sharing all posts and videos. After the completion of the training, the Healthy Lifestyle Behaviors Scale and the Preconceptional Knowledge and Attitude Scale will be applied as a post-test."
219412001|NCT07083193|DRUG|AC-101|AC-101 tablets will be administered orally.
219412002|NCT03752853|BEHAVIORAL|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
219412003|NCT07084753|DRUG|Levobupivacaine|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
219412004|NCT07084753|DRUG|Dexamethasone contained in the solution for thoracic paravertebral block|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
219412005|NCT07084753|DRUG|Adrenaline|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
219412006|NCT07084753|DRUG|Dexmedetomidin|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
219412007|NCT07084753|DRUG|ketamine|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
219003588|NCT01580189|DIETARY_SUPPLEMENT|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
219003589|NCT01514812|DRUG|YM150|oral - modified release formulation of YM150
219003590|NCT01514812|DRUG|placebo|oral
219003591|NCT01514812|DRUG|digoxin|oral
219003592|NCT02630550|DEVICE|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
219412008|NCT07084753|DRUG|Lidocain|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
219412009|NCT07084753|DRUG|Sufentanil|Following three-minute preoxygenation, sufentanil (5 to 15 micrograms), propofol (1 to 2 mg/kg ideal body weight), and rocuronium (0.8 to 1 mg/kg ideal body weight) are administered intravenously during induction of anesthesia. Anesthesia is sustained with sevoflurane maintained at 0.6-1.3 MAC. Sufentanil is added at the assessment of the anesthesiologist in the operating room.
219190326|NCT06682130|DRUG|Group C: Patients with SD/PD after posterior treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial."
219190327|NCT05727761|DRUG|pioglitazone-metformin|Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
219190328|NCT06554847|DRUG|611|subcutaneous injection
219190329|NCT06554847|DRUG|Placebo|subcutaneous injection
219190330|NCT06554847|DRUG|Topical corticosteroid|Topical
219412010|NCT07084753|PROCEDURE|Opioid free anesthesia based on thoracic paravertebral block|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized without the use of opioids, with general anesthesia and pain blockade using a thoracic paravertebral block
219412011|NCT07084753|PROCEDURE|Opioid based Anesthesia|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized with opioids and general anesthesia
219412012|NCT07084753|PROCEDURE|Opioid free anesthesia, Opioid free anesthesia based on intravenous dexmedetomidine, ketamine and lidocainedexmedetomidine, ketamine and lidocaine|Patients who are scheduled for laparoscopic gastrectomy will be anesthetized without the use of opioids and under general anesthesia, with analgesia by intravenous administration of dexmedetomidine, ketamine and lidocaine.
219412013|NCT07084753|DEVICE|Ultrasound guided thoracic paravertebral block|"Patients are positioned prone, with the identification of the 1st rib achieved using a convex XX Hz ultrasound probe. The left and right transverse processes of the 5th, 7th, and 9th thoracic vertebrae are marked accordingly. TPVB is executed in a paramedian sagittal oblique scan utilizing an in-plane needle insertion approach at the Th5, Th7, and Th9 levels bilaterally. An insulated echogenic needle, sized between 10-15 cm and 22-20 G, is employed. The skin and subcutaneous tissue at each level are infiltrated with 1.5 ml of 1% lidocaine.~Ultrasound guidance combined with nerve stimulation (dual monitoring) is utilized at each corresponding paravertebral space. Verification of the paravertebral space is established through visualization of pleural displacement, as observed via the ultrasound probe following the injection of 1 ml of 5% glucose, as well as via a motor response at a current intensity of 0.3-0.5 mA."
219412014|NCT07084753|DEVICE|Nerve stimulator for peripheral nerve blocks|During the application of the thoracic paravertebral block, verification of the distance of the insulated echogenic needle tip from the thoracic spinal nerve is monitored using via a motor response at a current intensity of 0.3-0.5 mA.
219412015|NCT07084753|DRUG|Metoclopramide 10mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and metoclopramide (10 mg) intraoperatively
219412016|NCT07084753|DRUG|Ondasetron 4mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intraoperatively.
219412017|NCT07084753|DRUG|Thiethylperazine|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and thiethylperazine (6.5 mg) intravenously.
219412018|NCT07084753|DRUG|Dexamethasone, 8 mg intravenously|To prevent postoperative nausea and vomiting (PONV), patients receive intraoperatively dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intravenously.
219412019|NCT07083219|BEHAVIORAL|Aerobic High Intensity Interval Training|"HIIT Protocol (Individualization of Exercise Program): Peak power will be calculated with Graded Exercise Test (GXT), with 90% of peak power used as the target range for the intervention.~Total Training Time: 35 minutes.~Warm-Up Phase:~1. Duration: 10 minutes~2. Intensity: 40-50% of peak power~HIIT Work and Rest Cycles:~Each session includes 20 minutes of intervals with the following pattern:~Work: 1 minute at 90% of peak power Rest: 3 minutes at 40% of peak power Repeat for five cycles. 5 minute cool down at 40% of peak power~Monitoring:~VO₂ and heart rate will be continuously measured.~Lactate levels will be measured at the following points:~1. Before the warm-up~2. After completing the warm-up (1st-minute intervention)~3. During the second minute of each rest period"
219190331|NCT06904612|DIETARY_SUPPLEMENT|Micronutrient fortified iodized salt|addition of folic acid, B12 and iron to iodized salt to be consumed daily and assess rise in serum levels.
219190332|NCT06934642|DRUG|Tirzepatide|The drug is being studied to better understand the biological effects of tirzepatide on MASLD.
219412020|NCT07083804|DIAGNOSTIC_TEST|Gastric biopsies|"After obtaining informed consent, patients receive routine endoscopic procedures with an additional biopsy taken for research purposes.~Invasive screening method used in routine care."
219412021|NCT07083804|DIAGNOSTIC_TEST|Stool sampling|"Stool samples are taken and sent within 10 days of the endoscopy. Self-collected stool samples are analyzed using antigen testing and molecular techniques to detect H. pylori and associated resistance mutations.~Experimental diagnosis."
219412022|NCT07082218|BEHAVIORAL|Sleep Intervention|The investigators will randomly assign participants (adolescents with concussion) to a personalized sleep schedule and sleep health recommendation, based on a meeting with an administrator after enrollment and randomization. They will undergo testing prior to the intervention, after the intervention (2 weeks after the initial visit, intervention length=2 weeks), and 6 weeks after intervention completion.
219412023|NCT06330844|BEHAVIORAL|Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)|RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.
219570182|NCT04862884|DRUG|placebo|"1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration"
219570183|NCT01333072|DRUG|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
219190333|NCT04362644|DRUG|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
219190334|NCT06628778|DRUG|Dalteparin|Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
219190335|NCT05619367|DRUG|Odronextamab|
219190336|NCT05727670|PROCEDURE|exposure of the tooth crown|surgical exposure of the crown of a retentive tooth
219190337|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
219190338|NCT05819710|DRUG|TS-142|Single dose of 5 mg of TS-142
219190339|NCT05819710|DRUG|TS-142|Single-dose of 10 mg of TS-142
219412024|NCT06330844|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)|"ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations."
219412025|NCT04042571|DEVICE|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
219412026|NCT02457182|OTHER|Mindfulness-based Stress Reduction (MBSR)|
219412027|NCT02457182|OTHER|Usual medical therapy|
219412028|NCT01895491|BIOLOGICAL|VM206DNA|
219412029|NCT01895491|BIOLOGICAL|VM206Ad|
219412030|NCT03440255|DEVICE|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
219003593|NCT02630550|DEVICE|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
219190340|NCT05819710|DRUG|Zopiclone|Single-dose of 7.5 mg of zopiclone
219190341|NCT05819710|DRUG|Placebo|Single-dose of placebo
219190342|NCT05911724|OTHER|Group I Healthy|Healthy Subjects
219412031|NCT06239506|OTHER|no intervention|no intervention
219412032|NCT05632029|DEVICE|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
219412033|NCT05632029|DEVICE|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
219412034|NCT00917085|BEHAVIORAL|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
219412035|NCT00554463|DRUG|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
219412036|NCT00554463|DRUG|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
219412037|NCT00554463|DRUG|Etoposide|Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
219412038|NCT00554463|DRUG|Cisplatin|Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
219412039|NCT00554463|RADIATION|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
219412040|NCT03863067|PROCEDURE|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
219412041|NCT00215436|DRUG|Formoterol Fumarate|
219412042|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
219570184|NCT01333072|DRUG|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
219412043|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
219570185|NCT04441099|DRUG|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
219412044|NCT05152017|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
219412045|NCT04839536|DRUG|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
219412046|NCT00425711|DRUG|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
219412047|NCT05079867|DEVICE|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
219412048|NCT00762372|DRUG|desflurane|volatile liquid for inhalation
219412049|NCT00762372|DRUG|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
219412050|NCT00762372|DRUG|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
219570186|NCT03121014|DRUG|Fludarabine|40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
219570187|NCT03121014|DRUG|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
219570188|NCT03121014|DRUG|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
219570189|NCT03121014|RADIATION|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
219570190|NCT03121014|PROCEDURE|Stem Cell Product Infusion|Day 0 according to BMT unit policy
219570191|NCT03121014|DRUG|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
219570192|NCT03121014|DRUG|Methotrexate|5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
219570193|NCT06301087|DEVICE|Web Application|web application for monitoring children's development and postnatal depression of mothers
219412051|NCT03364335|DRUG|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
219570194|NCT01557842|DRUG|Drug Treatment|Class I and III antiarrhythmic drug treatment.
219003594|NCT03836612|OTHER|No intervention|Observation of routine clinical practice
219003595|NCT04700982|OTHER|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
219003596|NCT00948623|BEHAVIORAL|physical activity counseling program|
219003597|NCT00948623|BEHAVIORAL|sham counseling program|
219003598|NCT03171623|DRUG|globalagliatin hydrochloride|orally administration, single dose
219412052|NCT03364335|DRUG|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
219412053|NCT03364335|DRUG|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
219570195|NCT01557842|DEVICE|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
219412054|NCT03364335|DRUG|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
219412055|NCT03364335|DRUG|Placebo|Placebo
219412056|NCT00728312|DRUG|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
219412057|NCT00728312|DRUG|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
219412058|NCT02030444|PROCEDURE|PET-MRI and EBUS-TBNA|
219412059|NCT04406935|DEVICE|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
219761312|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
219412060|NCT05066035|DRUG|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
219412061|NCT05066035|DRUG|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
219412062|NCT01445106|DRUG|Nelfinavir|
219412063|NCT01445106|DRUG|Nelfinavir Mesylate|
219412064|NCT05812469|BEHAVIORAL|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
219412065|NCT05812469|BEHAVIORAL|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
219412066|NCT02440295|PROCEDURE|Lower Extremity Amputation|
219761313|NCT06171724|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
219003599|NCT03171623|DRUG|placebo|orally administration, single dose
219190343|NCT05911724|DRUG|CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group II: Stable Angina Patients
219190344|NCT05911724|DRUG|HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group III: Heart Failure Patients
219412067|NCT02440295|DEVICE|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
219761314|NCT06785038|BEHAVIORAL|EMPOWER Strategy|The EMPOWER Strategy will: 1) identify women in primary care; 2) deliver understandable, actionable, and non-stigmatizing PrEP education, in multiple formats and languages, directly and securely to women via the patient portal; 3) enable women to discreetly self-schedule a visit to discuss PrEP options via the patient portal, with either their own PCP or with a female PCP who has years of experience in PrEP delivery; and 4) support PCP counseling via clinical decision support that provides standardized, patient-centered language to guide PrEP discussions and via 'smart sets' to facilitate PrEP prescribing, when desired and appropriate.
219761315|NCT06785038|BEHAVIORAL|Attention Control|Women in this arm will be sent, via the patient portal, a CDC patient education material on benefits of physical activity. The material will be in English or Spanish based on patient's language.
219761316|NCT06406465|DRUG|Belinostat|400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status
219761317|NCT06406465|DRUG|Cisplatin|60 mg/m\^2 IV over 60 minutes on day 2
219761318|NCT06406465|DRUG|Etoposide|80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
219761319|NCT03918837|OTHER|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
219761320|NCT03918837|OTHER|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
219761321|NCT05918211|DRUG|Udenafil|Active drug
219761322|NCT05918211|DRUG|Placebo|Matching Placebo
219761323|NCT06789757|DRUG|Memantine Hydrochloride|Memantine (5mg) is an N-methyl-D-aspartate (NMDA) receptor antagonist given in 21-day cycles over six months in combination with Bevacizumab and Atezolizumab. Each week memantine will be escalated by 5mg as tolerated
219761324|NCT06789757|DRUG|Bevacizumab|Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.
219761325|NCT06789757|DRUG|Atezolizumab|Atezolizumab (1200mg) is a programmed death-ligand 1 (PD-L1) blocking antibody given in 21-day cycles over six months in combination with Memantine and Bevacizumab
219761326|NCT06262477|DRUG|BIIB800|Administered as specified in the treatment arm.
219761327|NCT06262477|DRUG|Actemra|Administered as specified in the treatment arm.
219412068|NCT02440295|DRUG|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
219412069|NCT02211183|PROCEDURE|Best Repair of torn Rotator Cuff|
219412070|NCT02211183|DEVICE|InSpace™ system|
219412071|NCT04753138|DEVICE|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
219412072|NCT04753138|DEVICE|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
219412073|NCT02670915|DRUG|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
219412074|NCT02670915|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
219412075|NCT02670915|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
219570196|NCT02914249|OTHER|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
219570197|NCT03053583|DEVICE|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
219570198|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
219570199|NCT05655156|DEVICE|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
219570200|NCT01469507|DEVICE|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
219570201|NCT01469507|DRUG|Hyaluronan|3 weekly injections
219570202|NCT02457611|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219570203|NCT05391711|BEHAVIORAL|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth"
219570204|NCT01911806|DEVICE|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
219570205|NCT01911806|PROCEDURE|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
219412076|NCT01225367|DEVICE|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
219412077|NCT02022072|DEVICE|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
219412078|NCT02573376|BEHAVIORAL|Directly Observed Therapy|
219412079|NCT02573376|BEHAVIORAL|Wirelessly Observed Therapy|
219412080|NCT02546427|RADIATION|Helical TomoTherapy (HT)|
219412081|NCT02546427|RADIATION|CyberKnife SBRT|
219570206|NCT00957619|DRUG|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
219003600|NCT01779739|PROCEDURE|Perineorrhaphy|Procedure to build up the vaginal opening
219190345|NCT06839118|DRUG|Botox 200 UNT Injection|A concentration of 50U/mL BTX-A is prepared using saline in four syringes: one with 1 mL, one with 0.8 mL, one with 0.7 mL, one with 0.6 mL. This equals a total administration dose of 155U. A total of 155U BTX-A will be injected at day 1 (first day in week 1) by subcutaneous injections according to the PREEMPT protocol.
219412082|NCT02546427|RADIATION|Permanent Prostate Implant (PPI)|
219190346|NCT01957735|DRUG|BP31510 monotherapy|
219412083|NCT02546427|RADIATION|HDR brachytherapy|
219412084|NCT06078787|DRUG|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
219412085|NCT02807064|DRUG|Bifidobacteria|0.5 ml per os all days for 2 months
219412086|NCT02807064|DRUG|placebo|0,5 ml per os all days for 2 months
219412087|NCT01142609|BEHAVIORAL|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
219412088|NCT05871021|RADIATION|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
219412089|NCT03499080|BEHAVIORAL|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
219412090|NCT03499080|BEHAVIORAL|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
219412091|NCT03499080|BEHAVIORAL|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
219412092|NCT00228150|DRUG|SR57667B|
219412093|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
219412094|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
219412095|NCT05364229|RADIATION|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
219412096|NCT02494778|DRUG|Pridopidine|45 mg BID
219412097|NCT02616185|BIOLOGICAL|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
219412098|NCT02616185|BIOLOGICAL|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
219412099|NCT02616185|DEVICE|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
219412100|NCT02616185|BIOLOGICAL|Tremelimumab|PF-06753388 will be administered every 28 days.
219412101|NCT02616185|BIOLOGICAL|PF-06801591|PF-06801591 will be administered every 28 days.
219412102|NCT02616185|BIOLOGICAL|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
219412103|NCT01303380|DRUG|Canakinumab|
219412104|NCT02077985|BEHAVIORAL|Sensory Adapted Dental Environment|See study arm description.
219412105|NCT03617029|DEVICE|Microcoil|Needle localization with microcoil
219412106|NCT03617029|DRUG|Lipiodol|Needle localization with contrast injection
219412107|NCT05610917|COMBINATION_PRODUCT|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
219412108|NCT05610917|COMBINATION_PRODUCT|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
219412109|NCT02963896|DRUG|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
219190347|NCT01957735|DRUG|BP31510 in combination with chemotherapy|
219412110|NCT01617512|DEVICE|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
219412111|NCT02827994|OTHER|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
219412112|NCT04117568|OTHER|Blood sampling|Blood sampling at 3-5 occasions per admission
219412113|NCT02168881|DRUG|Misoprostol|
219412114|NCT02168881|DRUG|Dinoprostone|
219412115|NCT00418730|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
219190348|NCT06322667|OTHER|No Intervention|This is a non-interventional study.
219412116|NCT03705312|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
219190349|NCT05268510|DRUG|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
219190350|NCT05268510|DRUG|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
219570207|NCT00957619|DRUG|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
219412117|NCT03705312|OTHER|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
219190351|NCT05268510|DRUG|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
219190352|NCT05268510|DRUG|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
219190353|NCT06836700|PROCEDURE|Mini PCNL|90 Participants underwent MINI PCNL in MIN PCNL arm and 90 Participants underwent Standard PCNL in Standard PCNL arm.
219190354|NCT05846334|DEVICE|mindfulHeart|'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
219190355|NCT06259279|BEHAVIORAL|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~\- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
219412118|NCT01992666|GENETIC|Blood sampling|Immunologic and genetic analysis from a single blood sample.
219412119|NCT02376595|DRUG|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
219412120|NCT02366741|RADIATION|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
219412121|NCT03871140|OTHER|diagnosis|therre is no intervention diagnosis or treatment for patients
219412122|NCT00735124|DRUG|Gabapentin|1200 mg single dose gabapentin
219412123|NCT00735124|OTHER|placebo|Injection of placebo/sham
219412124|NCT04913961|OTHER|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
219412125|NCT04913961|OTHER|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
219412126|NCT01346371|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|
219412127|NCT01346371|DRUG|Bepreve 1.5% Ophthalmic Solution|
219412128|NCT04224896|DIAGNOSTIC_TEST|UPPER ENDOSCOPY|UPPER ENDOSCOPY
219190356|NCT04079218|DRUG|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
219412129|NCT00200252|DRUG|oxytocin|
219412130|NCT02320695|DRUG|Saline|
219412131|NCT02320695|DRUG|Isopropyl Alcohol|
219412132|NCT02320695|DRUG|Pain Relieving Cream|
219412133|NCT02320695|DRUG|Antibiotic/Pain Relieving Ointment|
219412134|NCT02320695|DRUG|Original Ointment|
219412135|NCT02320695|DRUG|Pain Relief Ointment|
219412136|NCT06552858|DRUG|Fluzoparib|150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
219412137|NCT06552858|DRUG|Dalpiciclib|150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
219412138|NCT03056495|DRUG|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
219412139|NCT01432197|OTHER|ADL intervention|1\) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
219412140|NCT02456545|OTHER|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
219412141|NCT02456545|OTHER|depressive syndrome|in- and outpatients with depressive syndrome
219412142|NCT02456545|OTHER|ADHD|in- and outpatients with ADHD
219412143|NCT06238245|DRUG|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
219570208|NCT06364254|DIETARY_SUPPLEMENT|Cannabidiol Capsules|300 mg of cannabidiol administered 2 hours before 2 mile run
219570209|NCT04290234|OTHER|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
219570210|NCT04977661|DRUG|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
219570211|NCT04977661|DRUG|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
219412144|NCT00239187|DRUG|E1 and G1|
219190357|NCT05744024|DEVICE|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.
219412145|NCT02004587|DRUG|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
219412146|NCT01670656|DRUG|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
219412147|NCT01670656|DRUG|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
219412148|NCT01670656|DRUG|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
219412149|NCT01670656|DRUG|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
219412150|NCT00789958|DRUG|capecitabine|"Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
219412151|NCT00789958|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
219412152|NCT00789958|RADIATION|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
219412153|NCT00789958|RADIATION|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
219412154|NCT00074724|PROCEDURE|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
219412155|NCT00074724|DRUG|Modern medical management|Therapies with evidence-based recommendations.
219412156|NCT00074724|DEVICE|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
219412157|NCT00074724|DRUG|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
219412158|NCT05151679|DRUG|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
219412159|NCT05151679|DRUG|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
219570212|NCT04977661|DRUG|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
219570213|NCT00384293|DRUG|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
219570214|NCT00384293|DRUG|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
219570215|NCT04553224|OTHER|Clinical evaluations|SCORAD and target SCORAD
219190358|NCT05744024|OTHER|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
219412160|NCT02737735|DRUG|standard chemotherapy medicine combined with Chinese herbs|
219412161|NCT02737735|DRUG|standard chemotherapy medicine|
219412162|NCT00132236|DRUG|nicotine sublingual tablets|
219412163|NCT00132236|BEHAVIORAL|low and high behavior support|
219190359|NCT06505187|DRUG|Celecoxib|200mg every 12 hours
219412164|NCT03481127|BEHAVIORAL|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
219412165|NCT03481127|OTHER|Surveys|"* NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey"
219412166|NCT03481127|PROCEDURE|Blood draw|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment"
219412167|NCT03481127|PROCEDURE|Fresh tissue from ovary|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery"
219412168|NCT03137121|DRUG|Olanzapine|Olanzapine is used as an anti-emetic.
219412169|NCT03137121|OTHER|Placebo|The placebo is a non-anti-emetic.
219412170|NCT00048399|DRUG|Fludarabine|
219412171|NCT00048399|DRUG|CAMPATH 1H|
219412172|NCT00048399|DRUG|FK506|
219570216|NCT04553224|OTHER|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
219570217|NCT04553224|OTHER|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
219570218|NCT00688428|DRUG|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
219570219|NCT00688428|DRUG|Esomeprazole|40mg capsule, administered as a single dose
219570220|NCT00688428|DRUG|ASA|325mg tablet, administered as a single oral dose
219570221|NCT02269644|DRUG|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
219570222|NCT02269644|DRUG|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
219412173|NCT00048399|PROCEDURE|Stem Cell Transplantation|
219412174|NCT01308723|DRUG|RO5323441|escalating doses iv
219412175|NCT01308723|DRUG|RO5323441|iv every 2 weeks
219412176|NCT01308723|DRUG|sorafenib|400 mg orally twice daily to once every other day
219412177|NCT04350229|DRUG|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
219412178|NCT04350229|OTHER|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
219412179|NCT00836277|DRUG|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
219412180|NCT00836277|DRUG|Irinotecan|125mg/m2 IV Day 1 and Day 8
219412181|NCT04627116|DRUG|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
219412182|NCT06079957|PROCEDURE|Ergonomic training|"1\. Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
219412183|NCT06079957|PROCEDURE|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
219412184|NCT06215222|OTHER|Microbiota Sampling|We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
219412185|NCT00509496|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
219412186|NCT00509496|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenous
219412187|NCT00509496|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219412188|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
219412189|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
219412190|NCT05617404|DIAGNOSTIC_TEST|CT scan|Polytrauma patients with thoracic CT-scan
219412191|NCT02437058|OTHER|preidictive model|
219412192|NCT01705197|DRUG|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
219412193|NCT01354353|DRUG|LY2140023|Administered orally
219412194|NCT01354353|DRUG|Aripiprazole|Administered orally
219412195|NCT05175937|DEVICE|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
219570223|NCT02269644|DRUG|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
219570224|NCT02269644|DRUG|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
219570225|NCT06115304|OTHER|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
219003601|NCT06017440|BEHAVIORAL|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
219003602|NCT06017440|BEHAVIORAL|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
219003603|NCT03963362|DRUG|GLA5PR tablet 75 mg|GLARS-NF3 tablet
219412196|NCT05175937|DEVICE|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
219570226|NCT03005067|DRUG|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
219570227|NCT03005067|OTHER|Placebo|Reference product containing vehicle without carbomer 980 gel
219570228|NCT02560779|DRUG|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
219003604|NCT03963362|DRUG|GLA5PR tablet 150 mg|GLARS-NF3 tablet
219190360|NCT06505187|DRUG|Tylenol|650mg q6h
219412197|NCT03117166|DRUG|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
219412198|NCT03117166|DRUG|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
219570229|NCT02560779|DRUG|Sorafenib|400 mg of sorafenib will be given twice daily.
219570230|NCT02782091|BEHAVIORAL|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
219570231|NCT01176643|OTHER|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
219412199|NCT03712501|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
219412200|NCT01206478|DRUG|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
219570232|NCT00619359|DRUG|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
219190361|NCT06505187|DRUG|Oxycodone|5mg every 6 hours as needed
219190362|NCT06505187|DRUG|placebo|every 12 hours
219190363|NCT06415955|OTHER|None, pure observationnal study|None, pure observationnal study
219412201|NCT01206478|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
219412202|NCT01206478|DRUG|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
219412203|NCT01467648|DRUG|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
219412204|NCT01467648|DRUG|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
219570233|NCT00619359|DRUG|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
219570234|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
219570235|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
219570236|NCT00619359|DRUG|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
219570237|NCT02296853|DRUG|TAF|25 mg tablet administered orally
219412205|NCT01248910|BEHAVIORAL|Alpine Skiing|
219412206|NCT04143620|PROCEDURE|Procedure|Triple procedure
219412207|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
219412208|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
219412209|NCT03563456|BEHAVIORAL|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
219412210|NCT03563456|BEHAVIORAL|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
219412211|NCT02066753|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
219412212|NCT05732844|DEVICE|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
219190364|NCT04942626|DRUG|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
219190365|NCT04942626|DRUG|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
219190366|NCT04942626|RADIATION|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
219190367|NCT04942626|PROCEDURE|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W\&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
219190368|NCT04169893|DRUG|Placebo (fasting)|Participants will receive placebo once in fasting condition
219190369|NCT04169893|DRUG|Placebo (feeding)|Participants will receive placebo once after meal condition
219190370|NCT04169893|DRUG|1 mg of TS-142|Participants will receive 1 mg of TS-142 once in fasting condition
219412213|NCT05732844|OTHER|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
219412214|NCT04343313|DEVICE|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
219570238|NCT03128684|OTHER|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
219412215|NCT04095806|OTHER|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
219412216|NCT02683694|DEVICE|iOCT|the number of subjects that can be peeled without dye are assessed
219412217|NCT05611840|PROCEDURE|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
219412218|NCT05611840|PROCEDURE|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
219412219|NCT00905723|DRUG|estradiol|1 mg daily for 6 months
219570239|NCT03128684|OTHER|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
219570240|NCT03128684|OTHER|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
219570241|NCT03128684|OTHER|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
219412220|NCT00905723|DRUG|isoflavone|150 mg isoflavone daily for 6 months
219412221|NCT00905723|DRUG|Placebo|sugar pill daily for six months
219003605|NCT01693926|BEHAVIORAL|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
219003606|NCT01693926|BEHAVIORAL|placebo|
219412222|NCT01493986|DRUG|Ropivacaine|Dosage. Onset time
219412223|NCT00236119|DRUG|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
219412224|NCT00236119|DRUG|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
219412225|NCT00236119|DRUG|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
219412226|NCT00236119|DRUG|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
219412227|NCT00498238|DRUG|Levothyroxine|
219412228|NCT04831515|DEVICE|Lens A|daily disposable soft contact lens - test lens
219412229|NCT04831515|DEVICE|Lens B|daily disposable soft contact lens - control lens
219412230|NCT06463548|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
219412231|NCT06463548|DRUG|Capecitabine|Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
219412232|NCT06463548|DRUG|Lenvatinib|Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
219412233|NCT02698618|PROCEDURE|Diagnostic|"Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
219412234|NCT02698618|DRUG|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
219412235|NCT02698618|PROCEDURE|PCI|"1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
219412236|NCT05016869|DRUG|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
219412237|NCT06220630|OTHER|Breast cancer|Male patients who were microscopically diagnosed as primary breast cancer.
219570242|NCT03128684|OTHER|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
219570243|NCT03128684|OTHER|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
219761328|NCT02531880|DRUG|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
219761329|NCT01581580|DEVICE|Medtronic Activa Tremor Control System|Medtronic DBS Therapy delivers electrical stimulation to an area in the brain to help treat Parkinson's Disease, dystonia, and essential tremor.
219761330|NCT01581580|PROCEDURE|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
219761331|NCT05473429|DEVICE|TSA2 Thermosensory Stimulator|TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
219761332|NCT05509582|DRUG|fostamatinib|Subjects will receive fostamatinib at the same dose as the dose they receive at the time of rollover. The dose could be reduced to 100mg daily, 150 mg daily, 100 mg twice a day if a dose-limiting adverse event occurred. After the initial 12 weeks on the extended access (total of 24 weeks of treatment), subjects will have the option to start tapering fostamatinib if they are maintaining hematologic recovery. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response, defined as Hb\<9g/dL and/or PLT\< 30 X 10\^9/L can increase their dose to next higher dose. Once count stabilization again occurs, a slow dose reduction to next lowest dose (100mg or 150mg) can be performed to identify the lowest dose necessary to keep counts over these thresholds.
219761333|NCT06953505|DIAGNOSTIC_TEST|Ammonia Study Device|Ammonia study device for capillary ammonia measurement
219761334|NCT06257875|DRUG|Lutikizumab|Subcutaneous (SC) Injection
219761335|NCT06257875|DRUG|Lutikizumab|Intravenous (IV) Infusion
219761336|NCT06257875|DRUG|Adalimumab|SC Injection
219412238|NCT03338114|DRUG|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
219412239|NCT01819311|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
219412240|NCT01819311|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
219412241|NCT03059719|BIOLOGICAL|Exenatide injection(Byetta)|
219412242|NCT03059719|BIOLOGICAL|PB-119 injection|
219412243|NCT01640925|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
219412244|NCT01640925|OTHER|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
219412245|NCT01679093|DRUG|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
219412246|NCT01679093|DRUG|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
219412247|NCT01679093|DRUG|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
219412248|NCT00731263|DRUG|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
219412249|NCT00180141|DRUG|Elidel-Creme|
219412250|NCT03441893|DIAGNOSTIC_TEST|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
219412251|NCT03441893|DRUG|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
219412252|NCT03441893|DRUG|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
219412253|NCT03441893|DRUG|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
219412254|NCT03441893|DRUG|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
219412255|NCT03102359|DRUG|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
219412256|NCT03102359|DEVICE|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
219412257|NCT01319110|DRUG|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
219412258|NCT01319110|DIETARY_SUPPLEMENT|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
219412259|NCT05464862|DRUG|Popliteal Plexus Block with 10 ml|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
219412260|NCT05464862|DRUG|Popliteal Plexus Block with 20 ml|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
219412261|NCT05464862|DRUG|Popliteal Plexus Block with 30 ml|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
219761337|NCT01961557|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
219761338|NCT05828069|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219412262|NCT05464862|DRUG|Femoral Nerve Block|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
219412263|NCT05464862|DRUG|Sciatic Nerve Block|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
219412264|NCT03837353|DRUG|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
219412265|NCT03837353|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
219412266|NCT00442013|DRUG|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
219412267|NCT00442013|DRUG|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
219412268|NCT05641038|OTHER|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
219003607|NCT01681732|OTHER|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
219003608|NCT01681732|OTHER|Control Standard Care|This is the standard care arm
219412269|NCT05641038|OTHER|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
219003609|NCT04894773|OTHER|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
219003610|NCT04894773|OTHER|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
219003611|NCT02069990|DRUG|Cholecalciferol|
219003612|NCT05743179|DRUG|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
219003613|NCT03181087|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
219003614|NCT05513079|BEHAVIORAL|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
219412270|NCT03604237|DIAGNOSTIC_TEST|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
219412271|NCT00503360|DRUG|SAD448|
219412272|NCT01332019|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
219412273|NCT04791267|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
219412274|NCT02791087|OTHER|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
219412275|NCT02791087|OTHER|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
219412276|NCT00165061|PROCEDURE|Esophagectomy|
219412277|NCT00165061|PROCEDURE|Chemoradiation|
219412278|NCT04781569|OTHER|data collection|Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
219412279|NCT04781569|DIAGNOSTIC_TEST|blood draw|2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
219412280|NCT04781569|DIAGNOSTIC_TEST|nose swabs|2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
219412281|NCT04781569|DIAGNOSTIC_TEST|Intraoperative tissue samples|Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
219412282|NCT05828732|OTHER|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
219412283|NCT01724112|DRUG|LY2940094|Administered orally
219570244|NCT05992831|DEVICE|Accelerated iTBS|The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
219570245|NCT05992831|DEVICE|Sham Comparator|To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
219003615|NCT04106986|COMBINATION_PRODUCT|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
219412284|NCT01724112|DRUG|Placebo|Administered orally
219761339|NCT05828069|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219761340|NCT05828069|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219761341|NCT05828069|PROCEDURE|Computed Tomography|Undergo CT
219761342|NCT05828069|PROCEDURE|Echocardiography Test|Undergo ECHO
219761343|NCT05828069|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET imaging
219761344|NCT05828069|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219761345|NCT05828069|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219761346|NCT05828069|DRUG|Tovorafenib|Given PO
219761347|NCT06754501|DRUG|Atezolizumab|Given by vein
219761348|NCT06754501|DRUG|Tiragolumab|Given by vein
219761349|NCT06664801|BIOLOGICAL|Sotatercept|SC administered every 3 weeks.
219761350|NCT06664801|BIOLOGICAL|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
219761351|NCT06444412|PROCEDURE|Computed Tomography|Undergo PET/CT
219761352|NCT06444412|OTHER|Electronic Health Record Review|Ancillary studies
219761353|NCT06444412|DRUG|Ga 68 PSMA-11|Contrast dye given IV
219761354|NCT06444412|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219761355|NCT05886036|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219761356|NCT05886036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761357|NCT05886036|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219761358|NCT05886036|PROCEDURE|Computed Tomography|Undergo PET/CT
219761359|NCT05886036|OTHER|Fludeoxyglucose F-18|Receive FDG
219761360|NCT05886036|BIOLOGICAL|Mosunetuzumab|Given SC
219761361|NCT05886036|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219761362|NCT05886036|BIOLOGICAL|Rituximab|Given IV
219412285|NCT04050813|BEHAVIORAL|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
219412286|NCT03737604|DRUG|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
219412287|NCT03737604|DRUG|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
219412288|NCT01536977|OTHER|quality-of-life assessment|Ancillary studies
219412289|NCT01536977|OTHER|questionnaire administration|Ancillary studies
219412290|NCT01536977|BEHAVIORAL|management of therapy complications|Undergo BBT-I
219412291|NCT01536977|BEHAVIORAL|cognitive assessment|Ancillary studies
219761363|NCT05886036|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219761364|NCT01861821|DEVICE|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
219761365|NCT01861821|DEVICE|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
219190371|NCT04169893|DRUG|3 mg of TS-142|Participants will receive 3 mg of TS-142 once in fasting condition
219190372|NCT04169893|DRUG|10 mg of TS-142 (fasting)|Participants will receive 10 mg of TS-142 once in fasting condition
219190373|NCT04169893|DRUG|10 mg of TS-142 (feeding)|Participants will receive 10 mg of TS-142 once after meal condition
219190374|NCT04169893|DRUG|30 mg of TS-142|Participants will receive 30 mg of TS-142 once in fasting condition
219412292|NCT01536977|BEHAVIORAL|educational intervention|Undergo BBT-I
219412293|NCT06444243|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.
219412294|NCT06444243|DRUG|Niacin|"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control."
219761366|NCT05987241|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
219761367|NCT05987241|OTHER|cfDNA or ctDNA Measurement|Undergo ctDNA surveillance
219761368|NCT05987241|PROCEDURE|Computed Tomography|Undergo CT
219761369|NCT05987241|PROCEDURE|Cystoscopy|Undergo cystoscopy
219412295|NCT06270355|PROCEDURE|Risk based screening|Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
219412296|NCT02867449|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
219003616|NCT04106986|OTHER|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
219412297|NCT02867449|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
219412298|NCT02134327|DRUG|Combination of Dexmedetomidine with Midazolam|
219412299|NCT02405585|DRUG|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
219412300|NCT02405585|BIOLOGICAL|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
219412301|NCT02405585|RADIATION|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
219412302|NCT02405585|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
219412303|NCT00288860|BEHAVIORAL|Telephone monitoring|Three months of biweekly telephone monitoring and support
219412304|NCT00288860|OTHER|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
219003617|NCT01170754|DRUG|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
219003618|NCT01170754|DRUG|Golytely 4 liters|Golytely 4 liters
219003619|NCT00910312|DEVICE|Ice-Sense|Ice-Sense Cryoprobe
219412305|NCT05014048|DIETARY_SUPPLEMENT|Vitamin D3|20 mikrog vitamin D3 daily
219412306|NCT05014048|DIETARY_SUPPLEMENT|Placebo|Placebo
219412307|NCT05161351|DRUG|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
219412308|NCT05161351|DRUG|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
219412309|NCT04329611|DRUG|Hydroxychloroquine|COVID19
219412310|NCT02711709|OTHER|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~1. muscle weakness~2. fatigue~3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
219412311|NCT02711709|OTHER|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
219412312|NCT02711709|OTHER|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
219761370|NCT05987241|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761371|NCT05987241|BIOLOGICAL|Nivolumab|Given IV
219761372|NCT05987241|OTHER|Questionnaire Administration|Ancillary studies
219761373|NCT05987241|BIOLOGICAL|Relatlimab|Given IV
219761374|NCT06236724|DRUG|Asciminib|Given by PO
219761375|NCT00873951|OTHER|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
219412313|NCT02711709|OTHER|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
219570246|NCT03233958|BEHAVIORAL|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
219570247|NCT06424106|OTHER|Glucagon|a variable rate glucagon infusion
219570248|NCT06424106|OTHER|Glucose|a variable rate glucose infusion
219570249|NCT06475625|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
219570250|NCT06475625|DEVICE|Orsiro™ or Orsiro_Mission™ stent|Percutaneous coronary intervention with Orsiro™ or Orsiro\_Mission™ stents
219570251|NCT00992563|DRUG|AL-39324 ophthalmic suspension|
219570252|NCT00992563|DRUG|Ranibizumab 10 mg/mL|
219757374|NCT01977365|BEHAVIORAL|Growth promotion based on child centered approach|"\- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~\- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
219761376|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
219761377|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
219761378|NCT00873951|DIETARY_SUPPLEMENT|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
219412314|NCT05154149|OTHER|Neck Disability Pain Index|Single time collection of the data
219412315|NCT03969797|DEVICE|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
219412316|NCT06457984|DIETARY_SUPPLEMENT|Selenium nutritional supplementation|Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
219412317|NCT03072719|DRUG|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
219412318|NCT03072719|DRUG|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
219412319|NCT06203730|BEHAVIORAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
219412320|NCT00279968|DEVICE|ICD|
219412321|NCT04361643|DRUG|Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
219412322|NCT04361643|DRUG|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
219412323|NCT03791437|DEVICE|Digital chest drainage system|patients who received Digital chest drainage system
219570253|NCT02584088|OTHER|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
219570254|NCT02989298|OTHER|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
219761379|NCT01399385|DEVICE|MR Imaging Techniques - 1|Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
219412324|NCT03791437|DEVICE|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
219570255|NCT00203541|DEVICE|TELFA™ A.M.D. Island dressing|
219570256|NCT00478049|DRUG|Gefitinib|250 mg oral tablet
219570257|NCT00478049|DRUG|Docetaxel|intravenous infusion
219570258|NCT04686513|OTHER|Observation|observational study
219570259|NCT02433119|DRUG|OROSARTAN® 5/160mg|
219570260|NCT02433119|DRUG|CODIOVAN® 160/12.5mg|
219570261|NCT04792879|DIAGNOSTIC_TEST|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
219570262|NCT00363402|PROCEDURE|PET-CT|
219570263|NCT02152202|OTHER|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
219570264|NCT02152202|OTHER|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
219570265|NCT00553449|DRUG|rabeprazole|
219761380|NCT01399385|DEVICE|MR Imaging Techniques - 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
219412325|NCT05337527|DIETARY_SUPPLEMENT|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
219761381|NCT01399385|DEVICE|MR Imaging Techniques - 3|Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
219003620|NCT05792891|OTHER|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
219003621|NCT05526820|BIOLOGICAL|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
219570266|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
219570267|NCT05681754|PROCEDURE|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
219570268|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
219761382|NCT01399385|DEVICE|MR Imaging Techniques - 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
219761383|NCT06433349|OTHER|Survey and interviews|Questionnaires and interviews
219761384|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
219003622|NCT00161083|DRUG|ursodeoxycholic acid|
219190375|NCT06051227|DRUG|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
219412326|NCT04043182|PROCEDURE|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
219412327|NCT02218814|PROCEDURE|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
219570269|NCT05681754|PROCEDURE|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
219570270|NCT05646628|BEHAVIORAL|Qualitative Interviews|Semi-structured Qualitative Interviews
219570271|NCT04722328|DIAGNOSTIC_TEST|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
219570272|NCT05212883|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionnaires
219570273|NCT00132054|DRUG|amrubicin hydrochloride|
219570274|NCT00132054|DRUG|irinotecan hydrochloride|
219570275|NCT02253602|DRUG|Ferumoxytol|maximum rate of administration 1 ml/sec
219761385|NCT06168305|DEVICE|GENOSS® DES Sirolimus Eluting Coronary Stent System|The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
219761386|NCT06088043|DRUG|TAK-279|Specified drug on specified days.
219761387|NCT06088043|DRUG|Placebo|Specified drug on specified days.
219761388|NCT06088043|DRUG|Apremilast|Specified drug on specified days.
219761389|NCT06067828|DRUG|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
219761390|NCT06067828|DRUG|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
219761391|NCT06067828|DRUG|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
219761392|NCT05642026|DRUG|Ropivacaine|Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
219761393|NCT05642026|DRUG|Non steroidal anti-inflammatory drug and opioids|Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
219412328|NCT02218814|PROCEDURE|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
219412329|NCT04115046|DEVICE|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
219412330|NCT04115046|DEVICE|FibroScan|manufactured by Echosens
219412331|NCT04115046|DEVICE|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
219412332|NCT00209599|DRUG|fospropofol disodium|
219412333|NCT00337376|DRUG|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
219412334|NCT00337376|DRUG|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
219412335|NCT04137276|DRUG|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
219570276|NCT04121117|OTHER|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
219570277|NCT02502734|DRUG|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
219570278|NCT02502734|DRUG|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
219570279|NCT02502734|DRUG|Salbutamol|Salbutamol will be provided as a inhaler.
219757375|NCT01977222|DEVICE|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
219761394|NCT05624359|DRUG|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
219761395|NCT05624359|DRUG|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
219761396|NCT01064440|BIOLOGICAL|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
219003623|NCT05714813|BEHAVIORAL|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
219003624|NCT05714813|BEHAVIORAL|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
219003625|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
219412336|NCT04137276|DRUG|vitamin B1|thiamine 200 mg/12 hours for 3 days
219412337|NCT06288776|DIAGNOSTIC_TEST|Herbal based mouthwash|Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
219412338|NCT02976376|OTHER|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
219412339|NCT05094999|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
219412340|NCT05094999|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
219412341|NCT02645383|DEVICE|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
219761397|NCT01064440|BIOLOGICAL|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
219761398|NCT01064440|OTHER|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
219761399|NCT06963827|DRUG|Mezagitamab|Mezagitamab injections administered SC.
219761400|NCT06963827|DRUG|Placebo|Mezagitamab-matching placebo injections administered SC.
219761401|NCT06958211|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219761402|NCT06958211|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
219761403|NCT05672316|BIOLOGICAL|Balstilimab|Given IV
219412342|NCT02645383|DEVICE|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
219412343|NCT05479409|RADIATION|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
219412344|NCT01901731|PROCEDURE|transjugular coil embolisation of pelvic veins|
219570280|NCT04390802|DRUG|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
219570281|NCT03720769|BEHAVIORAL|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
219570282|NCT03720769|BEHAVIORAL|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
219570283|NCT00682214|DRUG|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
219570284|NCT00682214|DRUG|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
219570285|NCT03338348|DRUG|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
219570286|NCT03338348|DRUG|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
219570287|NCT04128202|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
219412345|NCT01901731|PROCEDURE|endovenous treatment of leg varicose veins|
219412346|NCT05524441|OTHER|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
219412347|NCT02600325|DRUG|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
219412348|NCT01027208|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
219412349|NCT03201146|DRUG|Apatinib|Doses to be determined following the completion of Phase I of the study.
219412350|NCT03201146|DRUG|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
219412351|NCT03201146|DRUG|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
219412352|NCT03201146|DRUG|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
219412353|NCT03201146|DRUG|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
219412354|NCT00264602|DRUG|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
219412355|NCT01863407|DRUG|DAM|composed of dexamethasone, allantoin and metronidazole
219412356|NCT01863407|DRUG|Normal Saline|Normal Saline 250ml
219412357|NCT02689232|BIOLOGICAL|Fresh Frozen Plasma|
219003626|NCT01101646|DRUG|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
219003627|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
219412358|NCT02689232|BIOLOGICAL|Platelets Concentrate|
219412359|NCT02689232|BIOLOGICAL|Cryo Precitipitate|
219003628|NCT03519932|DEVICE|comfilcon A toric lens|Contact lens
219412360|NCT00882999|DRUG|LY2127399|Administered via Injection
219412361|NCT00882999|DRUG|Placebo|Administered via Injection
219412362|NCT03271385|DIAGNOSTIC_TEST|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
219412363|NCT06312449|OTHER|The side-lying position with the peanut ball during the second stage of labor.|"The usage of the peanut ball is divided into two stages:~Stage one: The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The peanut ball is placed between the legs, allowing for leg separation. The parturient can choose to lie on either the left or right side according to preference.~Stage two: When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides. The peanut ball is then positioned between the legs with the knees bent together, for pushing"
219412364|NCT06312449|OTHER|During the second stage, the patient is placed in a lateral position|The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The parturient can choose to lie on either the left or right side according to preference.When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides, for pushing
219412365|NCT02132234|DRUG|Etanercept|biological treatment according to rheumatologic indication
219412366|NCT02132234|DRUG|Adalimumab|biological treatment according to rheumatologic indication
219412367|NCT02132234|DRUG|Certolizumab|biological treatment according to rheumatologic indication
219412368|NCT02132234|DRUG|Infliximab|biological treatment according to rheumatologic indication
219412369|NCT06139679|PROCEDURE|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
219412370|NCT02456870|OTHER|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
219412371|NCT04685070|DRUG|HS-10296 (Almonertinib)|Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
219003629|NCT03519932|DEVICE|samfilcon A toric lens|Contact lens
219003630|NCT01658891|DRUG|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
219003631|NCT01658891|DRUG|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
219412372|NCT00741143|OTHER|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
219412373|NCT01104584|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
219412374|NCT00904540|DRUG|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
219412375|NCT01833767|DRUG|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
219412376|NCT03247660|OTHER|PFM training|See information included in arm/group descriptions.
219412377|NCT03247660|OTHER|HE|See information included in arm/group descriptions.
219412378|NCT03247660|BEHAVIORAL|Educational strategy|See information included in arm/group descriptions.
219412379|NCT03918603|OTHER|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
219412380|NCT02887833|OTHER|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
219412381|NCT04017442|DRUG|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
219003632|NCT04745429|OTHER|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
219003633|NCT03099421|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
219190376|NCT06051227|DRUG|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
219003634|NCT02254486|DRUG|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
219003635|NCT02254486|DRUG|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
219003636|NCT01612481|PROCEDURE|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
219003637|NCT01612481|PROCEDURE|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
219412382|NCT04017442|DRUG|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
219412383|NCT04182698|DRUG|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
219412384|NCT01153191|PROCEDURE|Normal saline pressurized irrigation|same
219412385|NCT01153191|DRUG|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
219412386|NCT00144755|DRUG|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
219412387|NCT06555211|PROCEDURE|MRI|MRI will be performed
219412388|NCT06555211|PROCEDURE|PET/CT|PET/CT will be performed
219412389|NCT02586233|DRUG|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
219412390|NCT02586233|DRUG|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
219412391|NCT03287752|DEVICE|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
219412392|NCT03287752|DEVICE|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
219003638|NCT01911871|BIOLOGICAL|Blood sample|a blood sample was taken on the day of inclusion
219412393|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using ND:YAG laser|A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
219412394|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using diode laser|"Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing"
219412395|NCT06358937|PROCEDURE|Scaling and Root Planing using ultrasonic and curettes|Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
219003639|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
219003640|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
219003641|NCT06062511|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
219003642|NCT00468182|DRUG|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
219003643|NCT02263989|DRUG|Telmisartan film coated tablet|
219003644|NCT02263989|DRUG|Telmisartan conventional tablet|
219003645|NCT01444118|BIOLOGICAL|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
219003646|NCT01350414|DEVICE|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
219003647|NCT04016285|DEVICE|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
219412396|NCT04922788|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
219412397|NCT04922788|BIOLOGICAL|Placebo|0,5 mg Aluminum adjuvant
219412398|NCT05311644|OTHER|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
219412399|NCT04235257|BIOLOGICAL|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
219412400|NCT01358877|DRUG|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
219412401|NCT01358877|DRUG|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
219412402|NCT01358877|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
219412403|NCT01358877|DRUG|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
219570288|NCT04128202|BEHAVIORAL|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
219003648|NCT04016285|DEVICE|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
219003649|NCT01177592|DEVICE|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
219003650|NCT01445561|DRUG|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
219003651|NCT01247740|DRUG|NuTRIflex Lipid peri|parenteral nutrition
219003652|NCT01247740|DRUG|compounded monobag|parenteral nutrition
219003653|NCT01374620|DRUG|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90"
219003654|NCT01374620|DRUG|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
219003655|NCT01374620|DRUG|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
219003656|NCT01374620|BIOLOGICAL|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
219003657|NCT00038857|PROCEDURE|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
219003658|NCT00038857|DRUG|Melphalan|140 mg/m\^2 on day -8
219003659|NCT00038857|DRUG|Thiotepa|10 mg/kg on day -7
219003660|NCT00038857|DRUG|Fludarabine|160 mg/m\^2 over 4 days on days -6, -5, -4, -3
219003661|NCT00038857|DRUG|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
219003662|NCT00742534|DRUG|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
219003663|NCT01572454|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
219003664|NCT01572454|DRUG|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
219412404|NCT01358877|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
219412405|NCT01358877|DRUG|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
219412406|NCT01358877|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
219412407|NCT01358877|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
219412408|NCT01358877|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
219412409|NCT01358877|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
219412410|NCT04769635|DEVICE|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
219757376|NCT01713439|BIOLOGICAL|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10\^7/kg, 10\^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10\^4/kg and rising to 10\^7/kg (10\^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10\^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be \<1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
219757377|NCT02146443|OTHER|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
219412411|NCT05296850|OTHER|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
219757378|NCT02146443|OTHER|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
219757379|NCT02146443|DEVICE|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
219757380|NCT04124627|PROCEDURE|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
219757381|NCT02514343|DRUG|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
219757382|NCT02514343|DRUG|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
219757383|NCT04330976|BEHAVIORAL|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
219757384|NCT04330976|BEHAVIORAL|Control|Messages sent on general health during pregnancy
219003665|NCT05360511|DRUG|particulate xenograft + erythropoietin gel.|"1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
219003666|NCT05360511|COMBINATION_PRODUCT|particulate xenograft|"* All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
219412412|NCT05296850|OTHER|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
219757385|NCT05378412|BEHAVIORAL|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
219761404|NCT05672316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219761405|NCT05672316|BIOLOGICAL|Botensilimab|Given IV
219761406|NCT05672316|PROCEDURE|Computed Tomography|Undergo CT
219761407|NCT05672316|DRUG|Regorafenib|Given PO
219761408|NCT06127030|BEHAVIORAL|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
219761409|NCT06127030|BEHAVIORAL|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
219761410|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
219412413|NCT06093282|BEHAVIORAL|ARCH|"ARCH is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* A 12-session adaptation of Behavioral Activation Treatment for Depression~* Weekly contacts from an outreach worker~* Optional resources aimed at promoting physical activity and weight management"
219412414|NCT06093282|BEHAVIORAL|Traditional Health Outreach|"The Traditional Health Outreach comparator is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* Support calls from an outreach worker at least once every 3 weeks"
219412415|NCT04183179|BEHAVIORAL|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
219570289|NCT02712437|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
219570290|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
219570291|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
219570292|NCT04745715|PROCEDURE|craniectomy|craniectomy outcomes and survival
219570293|NCT04854252|DRUG|Fentanyl|TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
219570294|NCT01356784|OTHER|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
219570295|NCT01356784|BEHAVIORAL|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
219570296|NCT01356784|BEHAVIORAL|Health counselling|Health guidance (1,5h)
219570297|NCT03071328|DRUG|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
219412416|NCT03575884|BEHAVIORAL|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
219412417|NCT06097650|OTHER|cold snare polypectomy|Histological analyses suggest that cold snare polypectomy causes less damage to blood vessels in the submucosal layers, which results in a reduced incidence of hemorrhage
219412418|NCT06097650|OTHER|hot snare polypectomy|According to current clinical guidelines, hot snare polypectomy is the recommended standard technique for the resection of pedunculated colorectal polyps.
219412419|NCT05935215|DRUG|Iptacopan|Open Label
219412420|NCT06368622|DEVICE|Surpass Evolve Flow Diverter System|Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
219412421|NCT05613049|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
219412422|NCT05585645|BIOLOGICAL|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
219412423|NCT06376916|DRUG|Magnesium Sulfate 2 G|Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
219412424|NCT06376916|DRUG|Magnesium Sulfate 4 G|Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
219412425|NCT06376916|DRUG|Saline|The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
219412426|NCT05967468|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
219412427|NCT05967468|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
219412428|NCT05967468|OTHER|Relaxation and Mentorship|Relaxation based treatment
219412429|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
219412430|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
219412431|NCT05872152|DIAGNOSTIC_TEST|FTIR results|Weekly transmission of FTIRS typing of ESBL-E to centers
219412432|NCT06470685|BEHAVIORAL|Qualitative Research Interviews|Research Interviews
219412433|NCT05457933|DRUG|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
219412434|NCT05457933|DRUG|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
219412435|NCT06060223|OTHER|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
219412436|NCT04431661|PROCEDURE|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
219412437|NCT04431661|PROCEDURE|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
219412438|NCT04431661|PROCEDURE|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
219757386|NCT00680628|DRUG|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg"
219757387|NCT00680628|DRUG|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
219757388|NCT00641264|DRUG|Omeprazole|
219757389|NCT00641264|BEHAVIORAL|Quality of Life questionnaire|
219757390|NCT03383042|DRUG|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
219570298|NCT04531995|DEVICE|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
219570299|NCT04487743|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
219412439|NCT01911845|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
219757391|NCT03383042|DRUG|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
219412440|NCT01911845|DRUG|ABT-333|Tablet
219412441|NCT01911845|DRUG|Ribavirin (RBV)|Tablet
219412442|NCT04005898|DEVICE|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
219412443|NCT01994226|DRUG|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
219412444|NCT01994226|DRUG|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
219412445|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
219570300|NCT04487743|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
219570301|NCT02794259|DEVICE|tDCS|
219570302|NCT02794259|DEVICE|sham-tDCS|
219570303|NCT05015335|DRUG|Adalimumab|ADA 40mg q2w
219570304|NCT05015335|DRUG|Methotrexate|MTX 10mg qw
219570305|NCT05558995|OTHER|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
219570306|NCT06240689|DRUG|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
219570307|NCT06240689|DRUG|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
219570308|NCT05021887|DRUG|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
219570309|NCT05021887|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
219757392|NCT03383042|DRUG|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
219757393|NCT03383042|DRUG|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
219757394|NCT03383042|DRUG|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
219757395|NCT03383042|DRUG|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
219757396|NCT03383042|DRUG|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
219757397|NCT03383042|DRUG|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
219757398|NCT03383042|DRUG|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
219757399|NCT05460182|OTHER|CAF+CTG|Coronally Advanced Flap + Connective Tissue Graft
219757400|NCT05460182|OTHER|CAF|Coronally Advanced Flap
219757401|NCT06105866|DIAGNOSTIC_TEST|Tricuspid Annular Plane Systolic Excursion|Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
219757402|NCT01605669|OTHER|Tranthoracic Echocardiogram|standard measurement
219757403|NCT01605669|DEVICE|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
219757404|NCT04675827|DRUG|Pertuzumab and tratuzumab fixed dose combination|Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
219757405|NCT04675827|DRUG|Trastuzumab emtansine|Treatment administration: adjuvant T-DM1 for 14 cycles.
219757406|NCT01554098|PROCEDURE|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
219761411|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
219003667|NCT03414619|BEHAVIORAL|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
219412446|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
219412447|NCT03223857|PROCEDURE|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
219570310|NCT03220113|COMBINATION_PRODUCT|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
219570311|NCT03752398|BIOLOGICAL|XmAb®23104|Monoclonal bispecific antibody
219570312|NCT03752398|BIOLOGICAL|Yervoy® (ipilimumab)|Monoclonal antibody
219570313|NCT02438982|DRUG|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
219570314|NCT02438982|DRUG|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
219570315|NCT04783194|DRUG|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
219570316|NCT04783194|DRUG|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
219003668|NCT03729960|OTHER|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
219003669|NCT02573350|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
219412448|NCT04209647|OTHER|REHIT Exercise|"-Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
219412449|NCT04209647|OTHER|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
219412450|NCT03075176|DEVICE|Wavefront optimized LASIK|Wavefront optimized laser vision correction
219570317|NCT04217148|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
219570318|NCT04217148|DRUG|ATRA|ATRA, po,10mg bid, for 12 weeks
219570319|NCT04982367|DEVICE|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
219570320|NCT04982367|DEVICE|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
219570321|NCT03324217|OTHER|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
219570322|NCT01483625|DRUG|tiotropium|18mcg
219003670|NCT02573350|DRUG|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
219003671|NCT02786342|PROCEDURE|blood sample collection|
219003672|NCT00064194|DIETARY_SUPPLEMENT|selenium|
219003673|NCT00064194|DIETARY_SUPPLEMENT|soy protein isolate|
219003674|NCT00064194|DIETARY_SUPPLEMENT|vitamin E|
219570323|NCT01483625|DRUG|Placebo|placebo
219570324|NCT00337974|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
219570325|NCT00337974|OTHER|Educational DVDs|
219570326|NCT01402973|OTHER|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
219570327|NCT02010294|GENETIC|DNA samples, GAS strains|DNA samples,GAS strains
219570328|NCT04625673|DEVICE|OsciPulse|OsciPulse device and standard IPC device
219003675|NCT03186560|DEVICE|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
219412451|NCT03075176|DEVICE|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
219412452|NCT03075176|DEVICE|Topography-guided LASIK|Topography-guided laser vision correction
219412453|NCT03075176|DEVICE|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
219412454|NCT03217773|PROCEDURE|ESD|Refer to arm description
219412455|NCT03217773|PROCEDURE|TAMIS|Refer to arm description
219412456|NCT01929655|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
219412457|NCT03520816|OTHER|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
219412458|NCT05700955|DRUG|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
219412459|NCT06018610|OTHER|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
219412460|NCT06018610|OTHER|Control|Conventional rehabilitation will be applied to the control group.
219412461|NCT06252259|BEHAVIORAL|Choose to Move|As described under study arm description
219412462|NCT05503654|BEHAVIORAL|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
219412463|NCT00139685|DRUG|Depo-Provera Contraceptive Injection - DP150CI|
219412464|NCT02841319|OTHER|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
219412465|NCT04333121|OTHER|weight|we can monitoring the growth of the infants by weight gain degree
219412467|NCT06204068|DEVICE|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
219412468|NCT06204068|DEVICE|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
219412469|NCT04427761|BEHAVIORAL|Measurement of Transitions in Cancer Scale (MOT-CA) Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
219412470|NCT04427761|BEHAVIORAL|Distress Thermometer Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
219412471|NCT04322994|DEVICE|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
219412472|NCT02306603|PROCEDURE|Endoscopic Mucosal Resection|
219412473|NCT02669004|DRUG|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
219412474|NCT02669004|DRUG|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
219570329|NCT05864924|BIOLOGICAL|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
219570330|NCT05864924|BIOLOGICAL|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
219570331|NCT05864924|BIOLOGICAL|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
219003676|NCT00958152|DRUG|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
219003677|NCT00958152|DRUG|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
219003678|NCT00958152|DRUG|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
219003679|NCT00958152|DRUG|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
219003680|NCT01979016|DRUG|Dupilumab|
219412475|NCT03346369|DRUG|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
219412476|NCT04548687|PROCEDURE|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
219412477|NCT04548687|PROCEDURE|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
219412478|NCT01435239|DEVICE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
219412479|NCT01435239|DEVICE|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
219412480|NCT06197945|OTHER|Mulligan bent leg raise|Mulligan bent leg raise
219412481|NCT06197945|OTHER|Mulligan bent leg raise with Bowen therapy|Mulligan bent leg raise with Bowen therapy
219412482|NCT05820100|OTHER|Observational|"The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel."
219412483|NCT04322630|OTHER|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
219570332|NCT02595827|OTHER|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
219412484|NCT00375115|DRUG|Sambucol|
219412485|NCT03664193|RADIATION|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
219412486|NCT01938781|DRUG|entecavir|antiviral therapy
219412487|NCT01938781|DRUG|Peg-IFN|antiviral and antifibrosis therapy
219570333|NCT03080376|OTHER|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
219570334|NCT03080376|OTHER|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
219570335|NCT03080376|OTHER|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
219570336|NCT05990231|DRUG|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
219570337|NCT05708482|OTHER|Sling-Swing Position|The device is hammock which look likes a rope
219570338|NCT01669031|OTHER|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
219570339|NCT02497131|DRUG|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
219003681|NCT01979016|DRUG|Placebo|Matching placebo
219003682|NCT01979016|OTHER|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
219003683|NCT00494078|DEVICE|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
219003684|NCT00494078|DRUG|intensive insulin therapy|intensive insulin therapy according to an algorithm
219412488|NCT02125006|BEHAVIORAL|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
219412489|NCT03625362|DIETARY_SUPPLEMENT|Hydrogen|Hydrogen-rich water
219412490|NCT03625362|DIETARY_SUPPLEMENT|Placebo|Tap water
219412491|NCT03367130|BEHAVIORAL|Mobile phone reminder|Intervention described already in arm/group descriptions.
219412492|NCT03047148|OTHER|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
219412493|NCT00407264|DRUG|Fluticasone propionate|
219412494|NCT01676402|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
219412495|NCT01676402|BIOLOGICAL|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
219412496|NCT06335368|OTHER|Nutrition and Growth Status|Nutrition and Growth Status
219412497|NCT04087421|DEVICE|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
219412498|NCT04087421|DRUG|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
219412499|NCT01157416|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
219412500|NCT01157416|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
219412501|NCT01157416|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
219412502|NCT02345252|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
219412503|NCT02345252|DRUG|FTC/RPV/TDF Placebo|Tablets administered orally once daily
219412504|NCT02345252|DRUG|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
219412505|NCT02345252|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
219412506|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
219412507|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
219412508|NCT00661401|BIOLOGICAL|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
219412509|NCT00084916|DRUG|temsirolimus|Given IV
219412510|NCT00084916|OTHER|laboratory biomarker analysis|Correlative studies
219570340|NCT02142231|DEVICE|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
219761412|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
219761413|NCT06956235|DRUG|Tulisokibart|Solution in autoinjector for subcutaneous (SC) injection
219761414|NCT06956235|DRUG|Placebo|Solution in autoinjector for SC injection
219761415|NCT06956690|BIOLOGICAL|ENV-501|ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.
219761416|NCT04108130|OTHER|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
219761417|NCT04108130|PROCEDURE|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
219761418|NCT04108130|OTHER|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
219761419|NCT04108130|PROCEDURE|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
219761420|NCT04108130|BEHAVIORAL|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
219761421|NCT06099769|DRUG|Enzalutamide|mouth once daily (160 mg/day)
219761422|NCT06099769|DRUG|Mifepristone|mouth once daily 300-mg tablet
219761423|NCT06099769|DRUG|TPC|"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
219761424|NCT03656562|DRUG|VAY736|150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
219761425|NCT03656562|DRUG|VAY736 Placebo|solution for injection; 0 mg/mL administered as 2 mL s.c. injection
219761426|NCT03656562|DRUG|CFZ533|150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
219761427|NCT03656562|DRUG|CFZ533 Placebo|Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
219761428|NCT06136741|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
219412511|NCT04026152|BEHAVIORAL|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
219412512|NCT04026152|BEHAVIORAL|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
219412513|NCT03616665|OTHER|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
219412514|NCT02036593|BEHAVIORAL|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
219412515|NCT02167841|BEHAVIORAL|Knee-Chest Position|
219412516|NCT02991157|DRUG|Nimodipine|
219412517|NCT06210191|PROCEDURE|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
219412518|NCT03959449|BEHAVIORAL|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
219412519|NCT03959449|BEHAVIORAL|Motor imagery|Motor imagery of running
219570341|NCT02142231|DEVICE|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
219570342|NCT01110044|BIOLOGICAL|251154 vaccine|Intramuscular, single dose
219570343|NCT01110044|BIOLOGICAL|Infanrix hexa™|Intramuscular, four doses
219757407|NCT01554098|PROCEDURE|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
219412520|NCT03959449|BEHAVIORAL|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
219412521|NCT01643759|DRUG|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
219570344|NCT01110044|BIOLOGICAL|Synflorix™|Intramuscular, four doses
219570345|NCT01110044|BIOLOGICAL|Rotarix™|Oral, two doses
219570346|NCT05231369|BIOLOGICAL|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
219570347|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
219570348|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
219570349|NCT02904538|DRUG|Dexamethasone|
219570350|NCT02904538|DRUG|isotonic saline|
219570351|NCT05661461|DRUG|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
219570352|NCT04159194|OTHER|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
219570353|NCT04159194|OTHER|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
219570354|NCT00056381|DRUG|Anidulafungin|
219570355|NCT05190523|DRUG|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
219757408|NCT04589897|DEVICE|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
219757409|NCT04589897|DEVICE|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
219412522|NCT02403830|DRUG|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
219412523|NCT02403830|OTHER|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
219412524|NCT02403830|DRUG|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
219412525|NCT02403830|DRUG|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
219412526|NCT01261806|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
219570356|NCT05190523|DRUG|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
219412527|NCT01261806|BEHAVIORAL|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
219412528|NCT01288898|DRUG|ASP1941|Oral
219412529|NCT01288898|DRUG|Placebo|Oral
219412530|NCT01858155|DRUG|Melatonin|
219570357|NCT05190523|DRUG|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
219412531|NCT02417909|OTHER|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
219412532|NCT01078701|BIOLOGICAL|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
219570358|NCT05190523|DRUG|Placebo|Placebo tablets orally once daily for 12 weeks.
219003685|NCT02657174|DEVICE|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
219003686|NCT02657174|DEVICE|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
219412533|NCT01078701|BIOLOGICAL|Placebo|SPGN buffer
219412534|NCT05290142|OTHER|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
219570359|NCT02023008|PROCEDURE|yoga therapy|Undergo integral yoga intervention with videoconferencing
219570360|NCT02023008|OTHER|internet-based intervention|Undergo integral yoga intervention with videoconferencing
219570361|NCT02023008|OTHER|questionnaire administration|Ancillary studies
219570362|NCT01143649|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
219570363|NCT01143649|PROCEDURE|constraint induced movement therapy (CIMT)|
219570364|NCT01143649|DEVICE|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
219412535|NCT05290142|OTHER|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
219412536|NCT04345926|DRUG|Propofol|Stepped propofol concentration after 20 min of LOS
219412537|NCT04345926|DEVICE|Electroencephalogram recording|Acquisition of EEG activity
219412538|NCT00570752|OTHER|Placebo|
219412539|NCT00570752|DRUG|BMS-582949|
219412540|NCT00570752|DRUG|Atorvastatin|
219412541|NCT00570752|DRUG|Statin|
219412542|NCT03102320|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
219412543|NCT03102320|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
219412544|NCT03102320|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
219412545|NCT03416738|BEHAVIORAL|Semantically focused treatment|"Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
219412546|NCT03416738|BEHAVIORAL|Phonologically focused treatment|"Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
219412547|NCT01790971|DRUG|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
219412548|NCT01790971|DRUG|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
219412549|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
219412550|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
219412551|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
219570365|NCT00707447|BEHAVIORAL|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
219570366|NCT00707447|BEHAVIORAL|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
219570367|NCT05791747|OTHER|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
219570368|NCT04061577|DEVICE|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
219570369|NCT00175097|OTHER|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
219570370|NCT00175097|OTHER|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
219570371|NCT00175097|OTHER|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
219570372|NCT00175097|OTHER|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
219570373|NCT01684527|OTHER|Respiratory secretions obtained|
219570374|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
219570375|NCT05276076|BIOLOGICAL|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
219570376|NCT05276076|BIOLOGICAL|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
219570377|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly"
219003687|NCT04983264|DRUG|GBT021601|Tablets and capsules which contain GBT021601 drug substance
219003688|NCT04022044|BEHAVIORAL|Observational group|
219003689|NCT04579185|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
219190377|NCT03916276|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
219190378|NCT03916276|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
219190379|NCT03916276|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
219190380|NCT05433662|BEHAVIORAL|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
219190381|NCT06094062|OTHER|App-based treatment support|The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
219190382|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
219190383|NCT05712759|OTHER|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever \> 37,8°C or/and cough or sore throat."
219190384|NCT03299959|DEVICE|Agili-C implant|Agili-C implant
219190385|NCT03299959|PROCEDURE|SSOC|microfracture and/or debridement
219190386|NCT05256940|BEHAVIORAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
219190387|NCT05256940|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
219003690|NCT05519410|DRUG|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
219003691|NCT05519410|DRUG|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
219190388|NCT02052882|BIOLOGICAL|romiplostim|
219412552|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
219412553|NCT05792670|PROCEDURE|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
219412554|NCT02021448|OTHER|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
219412555|NCT05047159|DEVICE|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
219412556|NCT05047159|DEVICE|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
219412557|NCT05047159|DEVICE|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
219412558|NCT05047159|DEVICE|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
219412559|NCT05047159|DRUG|drug therapy|There is no restriction on the choice of therapeutic drugs.
219412560|NCT04496440|OTHER|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
219412561|NCT01563640|OTHER|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
219412562|NCT01563640|OTHER|washing|normal washing of school uniforms, without permethrin insecticide impregnation
219412563|NCT04273399|OTHER|High-impact exercise intervention|"* Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading"
219412564|NCT04273399|OTHER|Acute response to high-impact exercise|"* First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise"
219412565|NCT00364494|PROCEDURE|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not
219412566|NCT01842308|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
219412567|NCT01842308|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
219412568|NCT01842308|DRUG|Carfilzomib|Given IV
219570378|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly"
219412569|NCT01842308|OTHER|Laboratory Biomarker Analysis|Correlative studies
219412570|NCT01842308|DRUG|Melphalan|Given IV
219570379|NCT00043576|DRUG|calcitriol|
219761429|NCT06136741|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
219190389|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
219190390|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
219190391|NCT05613478|PROCEDURE|Radical surgery|Radical surgery
219412571|NCT03237988|DRUG|CPI-444 Capsules|100mg Capsule
219412572|NCT03237988|DRUG|CPI-444 Tablets|100mg Tablets
219412573|NCT03892330|DRUG|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219570380|NCT00043576|DRUG|docetaxel|
219570381|NCT03208673|DEVICE|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
219570382|NCT05799716|DRUG|IVIG|0.5g/Kg
219570383|NCT01008514|PROCEDURE|adjuvant therapy|
219570384|NCT01008514|RADIATION|accelerated partial breast irradiation|
219570385|NCT01008514|RADIATION|intracavitary balloon brachytherapy|
219570386|NCT00768118|DIETARY_SUPPLEMENT|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
219570387|NCT00768118|GENETIC|electrophoretic mobility shift assay|
219761430|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761431|NCT04550481|DRUG|Lisinopril|Given PO
219761432|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
219761433|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
219761434|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
219761435|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
219761436|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
219761437|NCT05688475|DRUG|CC-122|Specified dose on specified days
219761438|NCT05688475|DRUG|Dexamethasone|Specified dose on specified days
219761439|NCT05897125|OTHER|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
219761440|NCT05897125|BEHAVIORAL|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
219412574|NCT03892330|DRUG|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219412575|NCT03892330|DRUG|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219412576|NCT03892330|DRUG|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219412577|NCT03892330|DRUG|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219190392|NCT05613478|PROCEDURE|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
219412578|NCT03892330|DRUG|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
219412579|NCT02850991|RADIATION|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
219412580|NCT02850991|RADIATION|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
219412581|NCT03349541|OTHER|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
219412582|NCT01971489|DRUG|Buparlisib|Given PO
219190393|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (at least 6 cycles) after radical surgery
219412583|NCT01971489|DRUG|Cisplatin|Given IV
219412584|NCT01971489|DRUG|Gemcitabine Hydrochloride|Given IV
219412585|NCT01971489|OTHER|Laboratory Biomarker Analysis|Correlative studies
219412586|NCT01971489|OTHER|Pharmacological Study|Correlative studies
219412587|NCT01971489|OTHER|Questionnaire Administration|Ancillary studies
219412588|NCT03363412|DEVICE|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
219412589|NCT00779324|DRUG|Amantadine Hydrochloride|100 mg every morning and noon
219412590|NCT00779324|DRUG|Placebo|one placebo tablet every morning and 12 Noon
219412591|NCT05945901|DRUG|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
219570388|NCT00768118|OTHER|laboratory biomarker analysis|
219190394|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (at least 6 cycles) after radical surgery
219412592|NCT05945901|DRUG|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
219412593|NCT04774042|DIETARY_SUPPLEMENT|Infloran probiotic|Infloran
219412594|NCT04774042|DIETARY_SUPPLEMENT|HAC probiotic|HAc probiotic
219412595|NCT04774042|DIETARY_SUPPLEMENT|Infloran placebo|Infloran placebo
219412596|NCT04774042|DIETARY_SUPPLEMENT|HAC placebo|HAC placebo
219412597|NCT03665350|DRUG|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
219412598|NCT02919488|OTHER|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
219412599|NCT02919488|OTHER|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
219412600|NCT00617409|DRUG|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
219570389|NCT04082936|DRUG|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
219570390|NCT06842602|OTHER|gum|chewed gum within 2 hours before the procedure
219570391|NCT06842602|OTHER|candy|consumed candy within 2 hours before the procedure
219570392|NCT06842602|OTHER|strict fasting rules|followed strict fasting rules
219412601|NCT00617409|BIOLOGICAL|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
219412602|NCT00617409|DRUG|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
219412603|NCT04121429|OTHER|Observation|No intervention will be performed
219412604|NCT00864422|BEHAVIORAL|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
219412605|NCT00864422|BEHAVIORAL|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
219412606|NCT02565771|OTHER|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
219412607|NCT05275621|DEVICE|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
219412608|NCT05275621|PROCEDURE|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
219412609|NCT01226355|DEVICE|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
219412610|NCT01800006|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
219412611|NCT02776410|BEHAVIORAL|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
219412612|NCT04736706|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
219412613|NCT04736706|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
219412614|NCT04736706|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
219412615|NCT04736706|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
219412616|NCT01928108|BEHAVIORAL|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
219412617|NCT01928108|BEHAVIORAL|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
219757410|NCT04389073|DRUG|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219757411|NCT04389073|BIOLOGICAL|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219757412|NCT04389073|BIOLOGICAL|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219757413|NCT04389073|DRUG|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219761441|NCT05897125|OTHER|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
219003692|NCT03571152|OTHER|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
219412618|NCT06426199|DRUG|Chitosan-Hyaluronate Gel Mixture|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
219003693|NCT04661540|DRUG|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
219003694|NCT04661540|DRUG|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
219003695|NCT03752632|DEVICE|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
219003696|NCT03752632|DEVICE|Tourniquet|A tourniquet alone will be used.
219570393|NCT01868282|PROCEDURE|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
219761442|NCT05897125|OTHER|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
219761443|NCT05897125|OTHER|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
219761444|NCT05897125|OTHER|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
219761445|NCT03017820|PROCEDURE|Biopsy Procedure|Undergo tumor or lymph node biopsy
219003697|NCT01690208|OTHER|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
219003698|NCT01690208|OTHER|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
219003699|NCT02344485|PROCEDURE|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
219003700|NCT06193720|DRUG|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
219003701|NCT06193720|OTHER|Placebo|Patients will take placebo drug after surgeries
219003702|NCT00184691|DRUG|somatropin|
219003703|NCT02875483|OTHER|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
219003704|NCT02875483|OTHER|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
219190395|NCT05305495|DRUG|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
219761446|NCT03017820|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761447|NCT03017820|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219761448|NCT03017820|PROCEDURE|Computed Tomography|Undergo SPECT/CT
219761449|NCT03017820|DRUG|Cyclophosphamide|Given IV
219761450|NCT03017820|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219761451|NCT03017820|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
219761452|NCT03017820|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219761453|NCT03017820|BIOLOGICAL|Cemiplimab|Given IV
219761454|NCT03017820|DRUG|Ruxolitinib|Given PO
219761455|NCT03017820|BIOLOGICAL|ipilimumab|Given IV
219761456|NCT03017820|BIOLOGICAL|Nivolumab|Given IV
219761457|NCT03017820|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219761458|NCT03017820|PROCEDURE|Echocardiography Test|Undergo echocardiography
219761459|NCT03017820|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219761460|NCT06118281|DRUG|Ziltivekimab|Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
219761461|NCT06118281|DRUG|Placebo|Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
219570394|NCT01868282|PROCEDURE|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
219003705|NCT04519684|DRUG|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
219003706|NCT04519684|OTHER|Placebo|Normal Saline
219003707|NCT01690247|DRUG|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
219003708|NCT01690247|DRUG|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
219003709|NCT03435744|DRUG|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
219003710|NCT03435744|OTHER|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
219757414|NCT04389073|DRUG|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219412619|NCT06426199|DRUG|Hyaluronic Acid|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
219003711|NCT03905187|BEHAVIORAL|Modified CR|Stress management involved modified cardiac rehabilitation
219003712|NCT03905187|BEHAVIORAL|Traditional CR|Traditional cardiac rehabilitation
219003713|NCT03905187|BEHAVIORAL|Education|Education
219003714|NCT01716351|BEHAVIORAL|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
219757415|NCT04389073|DRUG|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219757416|NCT00107276|DRUG|capecitabine|
219757417|NCT00107276|DRUG|cyclophosphamide|
219757418|NCT06476678|DEVICE|Speedboat™ Ultraslim|Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.
219757419|NCT04846231|DIETARY_SUPPLEMENT|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
219757420|NCT04846231|DRUG|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
219003715|NCT00340080|DRUG|Abacavir|
219003716|NCT01348945|OTHER|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
219003717|NCT03748160|OTHER|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
219757421|NCT04846231|OTHER|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
219757422|NCT02980107|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
219757423|NCT02980107|OTHER|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
219757424|NCT06353815|OTHER|4% articaine infiltration|Two injections using short needle and dental syringe will be given , the first injection is 1.5 ml out of 1.8 ml of 4% articaine with 1:100,000 epinephrine (ARTINIBSA 4% 1:100,000) in the mucobuccal fold adjacent to the mandibular first Molar, the second injection is 0.3 ml in the lingual side for lingual soft and hard tissues .
219757425|NCT00945659|DEVICE|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
219412620|NCT02731118|DIETARY_SUPPLEMENT|Salovum|AF-enriched egg yolk
219412621|NCT02731118|DIETARY_SUPPLEMENT|Placebo|egg yolk
219757426|NCT00945659|OTHER|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
219761462|NCT06239974|DRUG|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
219761463|NCT06239974|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
219761464|NCT03075696|DRUG|Glofitamab|Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
219412622|NCT02352792|RADIATION|radiochemotherapy with 70 Gy|
219412623|NCT02352792|RADIATION|radiochemotherapy with 77 Gy|
219412624|NCT02864966|DEVICE|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
219412625|NCT03021291|DEVICE|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
219412626|NCT06483516|PROCEDURE|Open repair|Open repair via median laparotomy or lumbotomy
219412627|NCT06483516|PROCEDURE|Endovascular repair|EVAR if AAA simple F-BEVAR if Complex AAA
219412628|NCT05038748|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219412629|NCT05038748|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
219412630|NCT05931744|DRUG|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
219412631|NCT05931744|DRUG|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
219412632|NCT05931744|DRUG|Saline|saline intrapolyp injection
219412633|NCT04356417|OTHER|- Synthetic anti-malarial drugs|Prevalent users will be those with at least one dispensing of AMD or ARBs/ACEi's from 01/01/2019 to 01/01/2020. Exposed users will be those among prevalent users who still received AMD or ARBs/ACEi's on 31/12/2019. The inclusion period will be from 01/01/2019 to 01/01/2020. The study end date will be 30/06/2020. For each treatment AMD or ARB/ACRi's, the persistence of treatment will be defined as the length of time from initiation to discontinuation. Initiation will be the date of the first reimbursement of AMD or ARB/ACRi's during the inclusion period. We will define the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription i.e 30 days. Exposure to a combination of drugs will be defined as a period shorter than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
219570395|NCT01868282|PROCEDURE|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
219570396|NCT03891329|DEVICE|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
219570397|NCT03891329|DEVICE|Plexa S DX|Implantation, measurements and follow-up schedule
219570398|NCT00487929|DEVICE|nasal CPAP|Nocturnal
219003718|NCT05975515|PROCEDURE|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
219003719|NCT02368431|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
219003720|NCT02368431|DRUG|Placebo|Placebo
219412634|NCT03670069|DRUG|Itacitinib|Given PO
219412635|NCT03670069|OTHER|Laboratory Biomarker Analysis|Correlative studies
219412636|NCT00011713|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
219412637|NCT04385147|OTHER|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
219412638|NCT00987623|DEVICE|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
219412639|NCT00987623|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
219412640|NCT03995628|DRUG|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
219412641|NCT03995628|DRUG|Placebo|One dose of placebo on post-operative day 3 after tonsillectomy
219412642|NCT05019040|DRUG|PA1010|TDF as control
219412643|NCT03314558|OTHER|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
219412644|NCT01140854|PROCEDURE|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
219412645|NCT01140854|OTHER|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
219412646|NCT06579196|DRUG|Trabedersen|Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).
219412647|NCT06579196|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
219412648|NCT03284242|DRUG|Treg|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
219570399|NCT00487929|DEVICE|Sham CPAP|Nocturnal
219570400|NCT05305768|DRUG|IncobotulinumtoxinA|Injection of glabellar rhytids
219570401|NCT04382430|PROCEDURE|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
219570402|NCT04382430|PROCEDURE|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
219570403|NCT06602492|DRUG|Lower nicotine e-liquid|A 3% nicotine concentration eliquid.
219412649|NCT02509598|DRUG|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
219412650|NCT02509598|DRUG|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
219412651|NCT02509598|PROCEDURE|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
219412652|NCT04056455|DRUG|Mobocertinib|Mobocertinib capsule.
219570404|NCT06602492|DRUG|Higher nicotine eliquid|A 5% nicotine concentration eliquid.
219570405|NCT01293266|DRUG|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
219003721|NCT04827329|OTHER|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
219003722|NCT05550402|DRUG|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
219003723|NCT05550402|DRUG|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
219412653|NCT02196038|BEHAVIORAL|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
219570406|NCT02740179|DRUG|Eplerenone|Eplerenone 50mg by mouth twice daily
219570407|NCT02740179|DRUG|Placebo|Placebo by mouth twice daily
219412654|NCT02196038|BEHAVIORAL|Attention Control|Usual care with bi-weekly contact from study staff
219412655|NCT02697513|BEHAVIORAL|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
219412656|NCT02191241|DRUG|Red Vine Leaf Extract|
219412657|NCT01055808|DRUG|Insulins|Individual dose and frequency and duration as determined by the treating physician
219412658|NCT05621824|DEVICE|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
219412659|NCT05621824|PROCEDURE|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
219412660|NCT05931016|DIAGNOSTIC_TEST|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
219412661|NCT05931016|DIAGNOSTIC_TEST|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
219412662|NCT00422838|PROCEDURE|fine-needle aspiration biopsy|aspiration of intrahepatic cells
219570408|NCT02740179|BEHAVIORAL|Lifestyle Modification|Counseling regarding diet and healthy activity
219570409|NCT02414373|DRUG|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
219003724|NCT05550402|DRUG|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
219412663|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
219412664|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
219412665|NCT04801342|DRUG|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
219412666|NCT04392102|DRUG|ZL-2306(Niraparib）|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
219412667|NCT00590018|DRUG|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
219412668|NCT00590018|DRUG|Placebo|Placebo for 5 days intravenously.
219412669|NCT01005537|BIOLOGICAL|aldesleukin|Given IV and orally
219412670|NCT01005537|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219412671|NCT01005537|DRUG|cyclophosphamide|Given IV
219412672|NCT01172587|OTHER|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
219412673|NCT03399175|DRUG|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
219412674|NCT02362087|OTHER|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
219412675|NCT04365985|DRUG|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
219412676|NCT04365985|DRUG|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
219412677|NCT04365985|OTHER|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
219412678|NCT02364167|DRUG|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
219570410|NCT02414373|DRUG|Bupivacaine|local anesthetics, which will epidurally administered
219570411|NCT02414373|DEVICE|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
219570412|NCT02414373|DEVICE|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
219570413|NCT06678204|OTHER|Optimized illustrated pamphlets|Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
219761465|NCT03075696|DRUG|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
219761466|NCT03075696|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
219761467|NCT01169259|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
219761468|NCT01169259|DRUG|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219761469|NCT01169259|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
219761470|NCT01169259|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219761471|NCT06720415|DRUG|Oral methadone, immediately prior to transport|Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room
219761472|NCT06720415|DRUG|Intravenous methadone|Patients will receive 0.3mg/kg IV methadone after induction of general anesthesia
219761473|NCT00097474|DRUG|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
219761474|NCT00097474|DRUG|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
219761475|NCT00097474|DRUG|Placebo|Placebo
219761476|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
219412679|NCT02364167|DEVICE|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
219003725|NCT05550402|OTHER|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
219003726|NCT05337007|OTHER|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
219412680|NCT02364167|OTHER|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
219412681|NCT00979446|BEHAVIORAL|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
219412682|NCT00979446|BEHAVIORAL|Self-directed|Received study materials but no phone coaching
219412683|NCT01276457|DRUG|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
219412684|NCT01276457|DRUG|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
219412685|NCT01276457|DRUG|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
219412686|NCT03134508|OTHER|treated by antiTNFα|pregnant IBD women treated by antiTNFα
219412687|NCT03134508|OTHER|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
219003727|NCT05337007|OTHER|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
219190396|NCT05713942|DIAGNOSTIC_TEST|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
219412688|NCT05519371|DRUG|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
219412689|NCT05519371|DRUG|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
219412690|NCT01040208|DRUG|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
219412691|NCT01040208|DRUG|flibanserin 100 mg qhs|100mg qhs
219757427|NCT00945659|BEHAVIORAL|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
219757428|NCT03064828|RADIATION|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
219757429|NCT03064828|RADIATION|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
219412692|NCT01040208|DRUG|placebo 2 tablets qhs|50 mg placebo
219757430|NCT00082121|DRUG|TP10|
219761477|NCT05621538|DEVICE|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
219761478|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
219761479|NCT05621538|DEVICE|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
219761480|NCT05663710|DRUG|177Lu girentuximab|Given by IV (vein)
219761481|NCT05663710|DRUG|Nivolumab|Given by IV (vein)
219761482|NCT05663710|DRUG|Cabozantinib|Given by PO
219412693|NCT01985633|BIOLOGICAL|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
219412694|NCT01985633|BIOLOGICAL|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
219412695|NCT04877314|OTHER|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
219412696|NCT03589105|DRUG|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
219412697|NCT03589105|DRUG|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
219412698|NCT02991937|DRUG|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
219412699|NCT02991937|PROCEDURE|Surgical Treatment|Appendectomy
219412700|NCT00643591|OTHER|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
219412701|NCT03508635|DRUG|CORT125134|Oral capsules
219412702|NCT03508635|DRUG|Matching Placebo of CORT125134|Placebo
219412703|NCT03508635|DRUG|Mifepristone|Active comparator
219412704|NCT03508635|DRUG|Prednisone|Challenge agent
219190397|NCT05713942|DIAGNOSTIC_TEST|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
219412705|NCT03508635|DRUG|Glucose|
219412706|NCT04550611|OTHER|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
219412707|NCT04550611|OTHER|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
219412708|NCT02582021|PROCEDURE|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
219412709|NCT02582021|PROCEDURE|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
219412710|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
219412711|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
219412712|NCT02582021|PROCEDURE|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
219412713|NCT02582021|PROCEDURE|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
219412714|NCT02582021|PROCEDURE|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
219412715|NCT04100798|PROCEDURE|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
219412716|NCT04100798|PROCEDURE|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
219412717|NCT02042495|DRUG|Metformin|
219412718|NCT00063583|DRUG|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
219570414|NCT01832402|DRUG|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
219570415|NCT01832402|DRUG|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
219757431|NCT04626102|BEHAVIORAL|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
219757432|NCT04626102|BEHAVIORAL|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
219757433|NCT06568419|BEHAVIORAL|Transdiagnostic, work-focused Cognitive Behavioural Therapy|Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
219757434|NCT03108196|PROCEDURE|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
219412719|NCT06531083|BEHAVIORAL|Early physical therapy intervention|Physical therapy including manual therapy, home exercises for the neck and jaw, and use of a jaw stretching device.
219412720|NCT03506698|OTHER|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
219412721|NCT03847155|DRUG|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
219412722|NCT03847155|OTHER|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
219412723|NCT02958397|BIOLOGICAL|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
219412724|NCT00039195|BIOLOGICAL|filgrastim|
219412725|NCT00039195|BIOLOGICAL|rituximab|
219412726|NCT00039195|DRUG|carboplatin|
219412727|NCT00039195|DRUG|cyclophosphamide|
219412728|NCT00039195|DRUG|doxorubicin hydrochloride|
219412729|NCT00039195|DRUG|etoposide|
219412730|NCT00039195|DRUG|ifosfamide|
219412731|NCT00039195|DRUG|prednisone|
219412732|NCT00039195|DRUG|vincristine sulfate|
219412733|NCT00039195|PROCEDURE|peripheral blood stem cell transplantation|
219412734|NCT00039195|RADIATION|radiation therapy|
219570416|NCT01832402|OTHER|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
219570417|NCT01832402|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
219570418|NCT01832402|BEHAVIORAL|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
219570419|NCT01445418|DRUG|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
219570420|NCT00823381|DIETARY_SUPPLEMENT|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
219570421|NCT00823381|OTHER|placebo|one placebo pill taken once a day with breakfast
219570422|NCT00823381|BEHAVIORAL|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
219570423|NCT04944082|DRUG|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
219570424|NCT00688402|DRUG|AZD3355|Single dose
219570425|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
219570426|NCT02898103|DEVICE|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
219570427|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
219570428|NCT01803269|DRUG|topotecan hydrochloride|Given IV
219570429|NCT01803269|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
219570430|NCT05931120|DEVICE|Dry needling|"dry needling using 50mm or 60mm sized needles based on individual muscle bulk. Targeted dry needling will be performed on the muscles presenting with tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
219570431|NCT05931120|DEVICE|IASTM|"Instrument assisted soft tissue mobilization tools targeting tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
219570432|NCT04952831|OTHER|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
219570433|NCT03793920|OTHER|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
219570434|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops|
219570435|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops placebo|
219570436|NCT02288208|DRUG|Antiviral Therapy (tenofovir or entecavir)|
219570437|NCT02288208|DRUG|Birinapant|
219570438|NCT02288208|DRUG|Placebo (for birinapant)|
219570439|NCT00606138|DRUG|ranibizumab|One 0.5 mg intravitreal injection
219570440|NCT00606138|PROCEDURE|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
219570441|NCT02080507|DEVICE|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
219570442|NCT02080507|DEVICE|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
219570443|NCT06193447|OTHER|None intervention|None intervention
219761483|NCT05663710|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
219761484|NCT06797973|DRUG|Intrathecal Morphine|80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
219761485|NCT06797973|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
219761486|NCT05548556|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
219761487|NCT05548556|DRUG|RO7204239|Participants will receive SC RO7204239 Q4W
219761488|NCT04990128|COMBINATION_PRODUCT|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
219761489|NCT04990128|DRUG|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
219761490|NCT02400190|OTHER|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
219412735|NCT03516019|OTHER|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
219412736|NCT03516019|OTHER|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
219412737|NCT03516019|OTHER|am notices|notifications sent at 7 am.
219412738|NCT03516019|OTHER|pm notices|notifications sent at 7 pm.
219412739|NCT03516019|OTHER|weekday notices|notifications sent on Wednesday
219412740|NCT03516019|OTHER|weekend notices|notifications sent on Saturday
219412741|NCT06108869|OTHER|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis"
219412742|NCT06108869|OTHER|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
219412743|NCT04308512|DEVICE|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
219412744|NCT00658372|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
219412745|NCT00658372|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
219412746|NCT00658372|DRUG|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
219412747|NCT00658372|DRUG|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
219412748|NCT00003662|BIOLOGICAL|anti-thymocyte globulin|
219412749|NCT00003662|DRUG|busulfan|
219412750|NCT00003662|DRUG|cyclophosphamide|
219412751|NCT00003662|DRUG|cyclosporine|
219570444|NCT01584531|DRUG|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
219570445|NCT00266240|DRUG|GK Activator (2)|Escalating doses po bid
219570446|NCT00266240|DRUG|Placebo|po bid
219757435|NCT03108196|PROCEDURE|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
219412752|NCT00003662|DRUG|melphalan|
219757436|NCT05978934|BEHAVIORAL|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
219412753|NCT00003662|DRUG|methylprednisolone|
219412754|NCT00003662|PROCEDURE|umbilical cord blood transplantation|
219412755|NCT00003662|RADIATION|radiation therapy|
219412756|NCT04006743|BEHAVIORAL|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
219412757|NCT04006743|BEHAVIORAL|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
219412758|NCT04006743|BEHAVIORAL|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
219412759|NCT04006743|BEHAVIORAL|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
219570447|NCT00164541|BEHAVIORAL|Arts Based Program|
219570448|NCT00164541|BEHAVIORAL|Curriculum|
219570449|NCT01918579|PROCEDURE|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
219761491|NCT04362839|BIOLOGICAL|Ipilimumab|Given IV
219412760|NCT04006743|BEHAVIORAL|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
219412761|NCT02065869|BIOLOGICAL|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
219412762|NCT02065869|DRUG|Rimiducid|0.4mg/kg administered IV to treat GVHD
219412763|NCT01583322|DRUG|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
219412764|NCT01583322|DRUG|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
219412765|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
219412766|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
219412767|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
219412768|NCT03712163|DRUG|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
219412769|NCT03712163|DRUG|Placebo Oral Capsule|Placebo
219412770|NCT03437772|BEHAVIORAL|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
219412771|NCT02021058|OTHER|Experimental Formula|Experimental formula
219412772|NCT02021058|OTHER|Standard control formula|Standard Infant formula
219412773|NCT04371172|OTHER|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
219412774|NCT01053546|BEHAVIORAL|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
219412775|NCT01053546|OTHER|questionnaire administration|Ancillary study
219412776|NCT01053546|PROCEDURE|quality-of-life assessment|Ancillary study
219412777|NCT02830841|DEVICE|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
219412778|NCT02830841|DEVICE|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
219412779|NCT00269191|DRUG|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
219757437|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
219412780|NCT00269191|DRUG|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
219412781|NCT00252486|DRUG|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
219412782|NCT03901612|DRUG|Ropivacaine 0.2%|Continuous post operative regional analgesia
219412783|NCT03901612|DRUG|saline 09%|Continuous post operative regional analgesia
219412784|NCT04755296|DEVICE|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
219412785|NCT04755296|OTHER|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
219412786|NCT04755296|OTHER|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
219757438|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
219757439|NCT04256655|DRUG|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
219412787|NCT00429377|DRUG|tacrolimus|
219761492|NCT04362839|BIOLOGICAL|Nivolumab|Given IV
219412788|NCT03020901|DRUG|Teicoplanin for Injection|Use Teicoplanin for Injection
219412789|NCT02402218|OTHER|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
219412790|NCT02402218|OTHER|Usual care plus incentives|Participants are given incentives after completing treatment goals.
219412791|NCT02402218|OTHER|Usual Care|Participants receive standard of care in the clinic from their health care team.
219412792|NCT05916833|OTHER|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
219412793|NCT05916833|OTHER|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
219412794|NCT03184909|DRUG|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
219412795|NCT03184909|DRUG|Placebo|Placebo capsules of look alike inert substance for control
219412796|NCT00592397|OTHER|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
219412797|NCT03614091|PROCEDURE|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
219412798|NCT03614091|PROCEDURE|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
219412799|NCT03807739|DRUG|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
219412800|NCT03807739|DRUG|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
219412801|NCT03807739|DRUG|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
219412802|NCT04720508|DIAGNOSTIC_TEST|blood sample collection.|venipuncture procedure
219412803|NCT01186146|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
219412804|NCT01186146|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
219412805|NCT03417180|DRUG|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
219570450|NCT05129254|DEVICE|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
219570451|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
219412806|NCT03417180|DEVICE|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
219412807|NCT03442335|DIAGNOSTIC_TEST|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
219412808|NCT03442335|DIAGNOSTIC_TEST|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
219412809|NCT04601142|DRUG|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
219412810|NCT00296959|DRUG|topiramate (drug)|
219412811|NCT00501566|DRUG|satavaptan (SR121463B)|
219412812|NCT05464446|DEVICE|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
219412813|NCT01831973|DRUG|Lipotecan|
219412814|NCT02329522|DEVICE|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
219412815|NCT02329522|DEVICE|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
219412816|NCT03587558|DRUG|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
219412817|NCT03587558|DRUG|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
219412818|NCT05616767|OTHER|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
219412819|NCT02284958|BEHAVIORAL|Standard|Back care advice
219412820|NCT02284958|BEHAVIORAL|Walking|Back care advice, individualized 12 week pedometer-driven walking program
219412821|NCT04288804|DEVICE|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
219412822|NCT04288804|DEVICE|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
219412823|NCT03136081|DIAGNOSTIC_TEST|Candidiasis infection occurence|Candidiasis infection occurence
219412824|NCT04296500|OTHER|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
219412825|NCT01300897|PROCEDURE|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
219412826|NCT01300897|PROCEDURE|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
219412827|NCT01300897|PROCEDURE|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
219412828|NCT04015947|DEVICE|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
219412829|NCT01544777|DEVICE|Study IOL|Aspheric IOL for correction of aphakia
219412830|NCT01544777|DEVICE|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
219412831|NCT01544777|DEVICE|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
219412832|NCT03956953|DRUG|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
219412833|NCT03956953|OTHER|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
219412834|NCT01952197|OTHER|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
219412835|NCT05746351|DRUG|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
219412836|NCT05746351|DRUG|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
219412837|NCT05746351|DRUG|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
219412838|NCT02634879|BEHAVIORAL|Incentive Change|
219412839|NCT05769842|DRUG|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
219412840|NCT05769842|DRUG|normal saline|Same dose as propofol.
219412841|NCT02774226|DRUG|Tetrahydrobiopterin (BH4)|12 week intervention
219412842|NCT02774226|DIETARY_SUPPLEMENT|Antioxidant Cocktail|12 week intervention
219412843|NCT05302739|OTHER|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
219412844|NCT03572270|DIAGNOSTIC_TEST|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
219412845|NCT03572270|DIAGNOSTIC_TEST|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
219412846|NCT02496637|BEHAVIORAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
219412847|NCT02496637|BEHAVIORAL|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
219412848|NCT04673526|PROCEDURE|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
219412849|NCT04673526|PROCEDURE|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
219761493|NCT04362839|DRUG|Regorafenib|Given PO
219412850|NCT02081339|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|
219412851|NCT02072317|DRUG|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
219412852|NCT02072317|DRUG|taxol|taxol 135 mg/m2, every three weeks for a cycle
219412853|NCT04042610|BEHAVIORAL|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
219412854|NCT03169010|OTHER|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
219412855|NCT03169010|GENETIC|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
219412856|NCT06554392|DIAGNOSTIC_TEST|Blood sample|Blood sample from each subject to detect Glutathione Peroxidase 4.
219412857|NCT03440216|DRUG|blood sampling|"* temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
219412858|NCT03440216|DRUG|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
219412859|NCT03440216|DRUG|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
219003728|NCT03835611|OTHER|Game based treadmill Platform|"The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
219412860|NCT02597023|DRUG|MitoQ|Mitoquinone pill, 20 mg/day
219412861|NCT02597023|DRUG|Placebo|Placebo pill with inert excipient, 1 time/day
219412862|NCT03264508|BEHAVIORAL|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
219412863|NCT03264508|BEHAVIORAL|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
219412864|NCT03054077|OTHER|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
219412865|NCT04091282|OTHER|No intervention|No intervention
219412866|NCT03596359|BEHAVIORAL|Education with Teach-Back method|
219412867|NCT03596359|OTHER|Received routine treatment|
219412868|NCT05391984|OTHER|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
219412869|NCT05391984|OTHER|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
219412870|NCT02642887|PROCEDURE|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
219412871|NCT06088316|DRUG|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
219412872|NCT06088316|DRUG|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
219412873|NCT00163150|DRUG|Atorvastatin|
219412874|NCT03570281|DRUG|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
219570452|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
219570453|NCT03379155|OTHER|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
219412875|NCT03570281|DRUG|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
219412876|NCT05323968|DIAGNOSTIC_TEST|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
219412877|NCT05323968|DIAGNOSTIC_TEST|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
219412878|NCT00003117|DRUG|carboplatin|
219412879|NCT00003117|DRUG|paclitaxel|
219412880|NCT04020484|BEHAVIORAL|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
219412881|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
219412882|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
219412883|NCT04574297|BEHAVIORAL|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
219412884|NCT04574297|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
219412885|NCT00870831|OTHER|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
219412886|NCT04705558|OTHER|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
219412887|NCT04705558|OTHER|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
219412888|NCT07083648|RADIATION|Magnetic resonance Imaging-guided online adaptive radiotherapy|On each day of treatment, a new MRI scan in the treatment position will be acquired using the dedicated MR simulator, co-registered with the original one. The original target and organ at risk (OAR) contours will be propagated to the new image set using rigid and deformable image registration. The contours will be adapted to changes detected with MRI of the day. The original SBRT treatment plan will be adapted to the changed and hence adapted anatomy of targets and OARs by plan optimization. Dose calculation will be performed on the newly generated synthetic CT (preferred) or, if there is a contra-indication for synthetic CT, on the original image.
219412889|NCT07084441|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
219412890|NCT07084441|OTHER|Supportive Care|\*Please see description for supportive care arm.
219412891|NCT05676528|OTHER|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
219412892|NCT07084311|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
219412893|NCT07083752|DRUG|Botulinum toxin application|Hemiplegic stroke patients who received upper extremity botulinum toxin will be evaluated retrospectively. Information regarding upper extremity motor recovery, spasticity levels, and muscle thickness measured by ultrasound before and one month after botulinum toxin administration will be obtained from file records.
219412894|NCT07082101|OTHER|temporal interference|In this intervertion, patients with SEEG operation will take temporal interference (TI) stimulation and the deep brain EEG will be monitorated through the entire experiment.
219412895|NCT06509789|DEVICE|Transcranial magnetic stimulation (TMS) - Theta burst stimulation (TBS) protocol|This procedure uses magnetic fields to stimulate nerve cells in the brain involved in various neurological functions, such as motor control. Theta burst stimulation is a patterned form of TMS protocol.
219412896|NCT05145244|OTHER|NO intervention|No intervention
219412897|NCT01187784|BEHAVIORAL|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
219412898|NCT05841264|BEHAVIORAL|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
219412899|NCT00789191|DRUG|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
219412900|NCT00789191|DRUG|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
219412901|NCT00789191|DRUG|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
219412902|NCT00789191|DRUG|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
219570454|NCT01856439|DRUG|ProSavin|Long term follow up of patients who received ProSavin in a previous study
219761494|NCT06427811|DRUG|Asciminib|Film-coated tablets with 40 mg dose strength taken orally
219761495|NCT06161532|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
219761496|NCT06161532|DRUG|Atezolizumab|Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
219761497|NCT06790121|DRUG|Lunsekimig|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
219761498|NCT06790121|DRUG|Placebo|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
219761499|NCT03216187|DRUG|Pregabalin|pregabalin 150 mg capsules
219761500|NCT03216187|DRUG|Placebos|capsules identical to pregabalin but without active drug
219761501|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
219761502|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
219003729|NCT03835611|OTHER|Control Group|"* Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
219412903|NCT04158089|BEHAVIORAL|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
219412904|NCT01009983|BIOLOGICAL|panitumumab|Given IV
219412905|NCT01009983|DRUG|paclitaxel|Given IV
219412906|NCT01009983|DRUG|carboplatin|Given IV
219412907|NCT01009983|PROCEDURE|laboratory biomarker analysis|Correlative study
219412908|NCT01009983|PROCEDURE|immunohistochemistry staining method|Correlative study
219412909|NCT03497429|DRUG|Niraparib|Niraparib capsule
219412910|NCT05522894|DRUG|AK104|10mg/kg IV every 3 weeks (Q3W)
219412911|NCT05522894|DRUG|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
219412912|NCT05522894|DRUG|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
219412913|NCT02101840|DRUG|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
219412914|NCT02101840|DRUG|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
219412915|NCT02101840|DRUG|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
219412916|NCT00506948|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
219412917|NCT00506948|DRUG|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
219757440|NCT04256655|DRUG|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
219412918|NCT00506948|DRUG|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
219412919|NCT00506948|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
219412920|NCT04775472|PROCEDURE|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
219412921|NCT04775472|PROCEDURE|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
219412922|NCT03258047|COMBINATION_PRODUCT|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
219412923|NCT04370964|OTHER|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
219412924|NCT04370964|OTHER|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
219412925|NCT00695708|BEHAVIORAL|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
219190398|NCT05091879|GENETIC|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
219412926|NCT00695708|BEHAVIORAL|Cogpack|Computer-aided cognitive program for cognitive abilities
219412927|NCT02884830|DEVICE|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
219757441|NCT04256655|DRUG|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
219412928|NCT02962219|BEHAVIORAL|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
219412929|NCT02962219|BEHAVIORAL|Home Exercise Programme (HEP)|Written advice on exercise at home
219412930|NCT02483702|OTHER|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
219412931|NCT02483702|OTHER|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
219412932|NCT01059396|DRUG|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
219412933|NCT01059396|DRUG|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
219412934|NCT01059396|DRUG|placebo|placebo propranolol / carvedilol
219412935|NCT05271903|BEHAVIORAL|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
219412936|NCT00450164|PROCEDURE|esofagic varices ligation|
219412937|NCT00450164|DRUG|Nadolol|
219412938|NCT00450164|DRUG|Isosorbide mononitrate|
219412939|NCT00450164|DRUG|Prazosin|
219412940|NCT02174861|DRUG|Erenumab|Administered by subcutaneous injection once a month
219003730|NCT01189214|DRUG|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
219190399|NCT05267873|DRUG|Duloxetine, Vortioxetine|Medications for major depressive disorder
219190400|NCT04959552|DEVICE|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
219412941|NCT01915108|DRUG|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
219412942|NCT04006912|PROCEDURE|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
219412943|NCT00218140|DRUG|nicotine transdermal system|
219412944|NCT01539278|PROCEDURE|Adenotonsillectomy|Tonsils and adenoids are surgically removed
219412945|NCT01539278|OTHER|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
219412946|NCT05446623|DRUG|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
219412947|NCT05446623|DRUG|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
219412948|NCT01122628|DEVICE|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
219412949|NCT01469806|DEVICE|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
219412950|NCT03309787|BEHAVIORAL|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
219412951|NCT00130806|DRUG|MK0478 (muraglitazar)|
219412952|NCT00130806|DRUG|Comparator: placebo|
219412953|NCT03710941|DRUG|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
219412954|NCT03710941|DRUG|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
219412955|NCT00488579|DRUG|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
219003731|NCT01313936|DRUG|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
219412956|NCT05510778|DIETARY_SUPPLEMENT|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
219412957|NCT05510778|OTHER|Placebo|capsules containing \~250 mg cellulose
219412958|NCT00914602|DRUG|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
219412959|NCT00914602|DRUG|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
219003734|NCT05560997|DIAGNOSTIC_TEST|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
219003735|NCT05808491|RADIATION|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
219412960|NCT00914602|DRUG|Carbidopa Pill|
219412961|NCT03555084|DEVICE|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
219412962|NCT03555084|DEVICE|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
219412963|NCT05765695|PROCEDURE|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
219412964|NCT00849251|DRUG|cyclophosphamide|Given IV or PO
219412965|NCT00849251|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
219412966|NCT00849251|DRUG|bortezomib|Given IV
219412967|NCT00849251|DRUG|dexamethasone|Given IV or PO
219412968|NCT00314652|DRUG|Buprenorphine transdermal delivery system|
219412969|NCT05446025|DIAGNOSTIC_TEST|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
219412970|NCT04980352|OTHER|real world treatment by doctors|real world treatment by doctors
219412971|NCT02702518|DRUG|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
219412972|NCT02702518|DRUG|Vehicle|Drug vehicle 4 times a day for 8 weeks
219003736|NCT04035928|DEVICE|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
219003737|NCT06493721|PROCEDURE|Clear Aligner Treatment|Clear aligner therapy to treat incisors crowding
219003738|NCT06493721|PROCEDURE|Low level laser|Apply clear aligner therapy with low level laser application on incisors
219003739|NCT02551731|DRUG|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
219003740|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
219003741|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT) + Air Stacking|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
219003742|NCT00971854|PROCEDURE|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
219003743|NCT00817024|DRUG|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
219003744|NCT00817024|DRUG|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
219003745|NCT00817024|DRUG|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
219003746|NCT00729989|PROCEDURE|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
219003747|NCT05259696|BIOLOGICAL|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
219003748|NCT05259696|BIOLOGICAL|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
219003749|NCT06468397|DEVICE|iSeelr™|The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear
219412973|NCT04004559|OTHER|No interventions|As this is a patient registry, there are no interventions.
219757442|NCT05414799|OTHER|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
219003750|NCT06412848|DRUG|Avelumab|This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
219003751|NCT04771520|DRUG|Avapritinib|Given PO
219003752|NCT05149807|DRUG|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
219003753|NCT05149807|DRUG|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
219757443|NCT05414799|OTHER|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
219757444|NCT05414799|OTHER|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
219757445|NCT01836757|DRUG|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
219757446|NCT01836757|DRUG|Placebo|
219757447|NCT05951907|PROCEDURE|Maxillary extraction without palatal injection|Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)
219757448|NCT05951907|PROCEDURE|Maxillary extraction with buccal and palatal injection|Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
219757449|NCT04770207|DRUG|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
219757450|NCT04349969|DRUG|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
219757451|NCT04349969|DRUG|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
219757452|NCT03652155|PROCEDURE|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
219757453|NCT05210816|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
219757454|NCT04361279|DRUG|SIBP-02|Injection，100mg/10ml
219757455|NCT04361279|DRUG|Rituximab|Injection，100mg/10ml
219757456|NCT01495013|DRUG|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
219757457|NCT01495013|DRUG|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
219757458|NCT01495013|DRUG|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
219757459|NCT01495013|DRUG|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
219757460|NCT01495013|DRUG|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
219757461|NCT01495013|DRUG|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
219757462|NCT01495013|DRUG|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
219757463|NCT01495013|DRUG|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
219757464|NCT01495013|DRUG|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
219003754|NCT04696445|DRUG|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
219003755|NCT01287689|OTHER|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
219003756|NCT06200233|DRUG|Rivoceranib|700mg once daily
219003757|NCT03012347|DRUG|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
219003758|NCT03012347|DRUG|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
219003759|NCT06030557|DRUG|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
219003760|NCT03857243|DEVICE|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
219003761|NCT03765918|BIOLOGICAL|Pembrolizumab 200 mg|200 mg administered IV infusion on Day 1 of each 21-day cycle
219570455|NCT05878379|BEHAVIORAL|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
219570456|NCT03658187|DIETARY_SUPPLEMENT|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
219570457|NCT03658187|DIETARY_SUPPLEMENT|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
219003762|NCT03765918|RADIATION|Radiotherapy 60 Gray|Low risk participants administered 2 Gray in 30 fractions. Administered using intensity modulated radiation therapy.
219003763|NCT03765918|RADIATION|Radiotherapy 66 Gray|High risk participants administered 2 Gray in 33 fractions. Administered using intensity modulated radiation therapy.
219003764|NCT03765918|RADIATION|Radiotherapy 70 Gray|Participants with gross residual disease administered 2 Gray in 35 fractions. Administered using intensity modulated radiation therapy.
219003765|NCT03765918|DRUG|Cisplatin 100 mg/m^2|100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
219003766|NCT06480747|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
219003767|NCT04202965|DRUG|PTG-300|Active treatment with PTG-300 injected subcutaneously.
219570458|NCT02377921|DRUG|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
219003768|NCT01589744|DEVICE|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
219003769|NCT03628560|DEVICE|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
219003770|NCT03628560|DEVICE|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
219412974|NCT02123563|OTHER|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
219412975|NCT02123563|OTHER|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
219412976|NCT01782794|OTHER|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
219412977|NCT05140954|DRUG|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
219412978|NCT01146249|OTHER|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
219412979|NCT05267912|PROCEDURE|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
219412980|NCT02288624|DIETARY_SUPPLEMENT|Processed orange juice|3 different formulation of edible orange drinks
219412981|NCT01648452|BIOLOGICAL|NT-501 CNTF-releasing implant|20 ng/day released into the eye
219412982|NCT01396993|PROCEDURE|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
219412983|NCT01396993|PROCEDURE|Breast Surgery|Breast conserving therapy without defect correction
219412984|NCT01000727|DRUG|Darapladib 160 mg|Lp-PLA2 inhibitor
219412985|NCT01000727|DRUG|Placebo|Placebo administered
219412986|NCT01000727|OTHER|Standard Therapy|Guideline mandated therapy for individual's condition
219003771|NCT03628560|DEVICE|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
219003772|NCT03628560|DEVICE|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
219412987|NCT02207478|PROCEDURE|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
219412988|NCT02207478|PROCEDURE|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
219412989|NCT02998424|DRUG|Propofol|Continuous infusion
219412990|NCT02998424|DEVICE|Pupillary diameter measurement|Instantaneous measure
219412991|NCT00000417|PROCEDURE|Counseling intervention|
219570459|NCT02377921|DRUG|Placebo|tablets for oral use
219412992|NCT00000417|DEVICE|Informational film|
219412993|NCT03586245|DIETARY_SUPPLEMENT|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
219412994|NCT03586245|DIETARY_SUPPLEMENT|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
219570460|NCT01615887|DRUG|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
219757465|NCT01495013|DRUG|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
219003773|NCT03628560|DEVICE|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
219003774|NCT00356369|BIOLOGICAL|meningococcal ACWY (vaccine)|One intramuscular dose.
219570461|NCT01615887|DRUG|placebo|sugar pill
219757466|NCT01495013|DRUG|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
219757467|NCT01495013|DRUG|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
219757468|NCT01495013|DRUG|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
219757469|NCT01495013|DRUG|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
219570462|NCT06617442|PROCEDURE|Pulmonary vein isolation|First pulmonary vein isolation performed for atrial fibrillation.
219570463|NCT00017459|DRUG|cisplatin|
219570464|NCT00017459|DRUG|tirapazamine|
219570465|NCT00017459|DRUG|vinorelbine tartrate|
219570466|NCT04859036|DIAGNOSTIC_TEST|24 hours ambulatory Holter monitoring|
219412995|NCT03586245|DIETARY_SUPPLEMENT|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
219412996|NCT03711006|OTHER|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
219412997|NCT04812418|DIETARY_SUPPLEMENT|Noctesia|3 tablets every day at bedtime with a large glass of water
219412998|NCT04812418|DIETARY_SUPPLEMENT|Placebo|3 tablets every day at bedtime with a large glass of water
219412999|NCT04482699|BIOLOGICAL|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
219413000|NCT04482699|OTHER|Placebo|RAPA-501-Allo cell placebo
219413001|NCT00970528|DRUG|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
219570467|NCT05286840|DIAGNOSTIC_TEST|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
219570468|NCT04211142|PROCEDURE|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
219570469|NCT04211142|PROCEDURE|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
219570470|NCT00074750|DRUG|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
219570471|NCT05426616|DEVICE|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
219413002|NCT00970528|DRUG|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
219413003|NCT03544268|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
219570472|NCT05426616|DEVICE|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
219570473|NCT04689347|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
219570474|NCT04689347|DRUG|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
219570475|NCT04689347|DRUG|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
219570476|NCT04689347|DRUG|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
219570477|NCT04689347|DRUG|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
219570478|NCT00638833|DRUG|Memantine|Memantine 30 mg/day (20-10-0)
219570479|NCT00638833|DRUG|Placebo|Placebo pills
219570480|NCT03669068|PROCEDURE|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy."
219570481|NCT03630094|DRUG|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
219003775|NCT00356369|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
219413004|NCT03544268|DRUG|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
219570482|NCT05861635|DRUG|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
219570483|NCT04184999|DRUG|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
219570484|NCT04184999|DRUG|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
219570485|NCT00545688|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
219570486|NCT00545688|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
219570487|NCT00545688|DRUG|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
219570488|NCT00813826|DRUG|SLC022|SLC022 150 mg capsule, 900mg daily dose
219570489|NCT00813826|DRUG|Placebo|Placebo capsule, TID
219570490|NCT05655247|PROCEDURE|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
219003776|NCT04674384|DIETARY_SUPPLEMENT|Optifast meal replacement shakes|Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
219413005|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for control|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
219413006|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for patients|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
219413007|NCT05866653|DRUG|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
219413008|NCT00084812|DRUG|cisplatin|
219413009|NCT00084812|DRUG|safingol|
219413010|NCT01690689|DEVICE|Implant surgery|surgery
219413011|NCT01818388|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
219413012|NCT00214968|DRUG|Modafinil|maximum dosage 400 mg/day (4 tablets)
219413013|NCT00084942|DRUG|capecitabine|
219413014|NCT00084942|DRUG|gemcitabine hydrochloride|
219413015|NCT04908241|OTHER|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
219413016|NCT04908241|OTHER|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
219413017|NCT01193816|DRUG|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
219413018|NCT01193816|DRUG|Placebo|Placebo
219413019|NCT00931580|DIETARY_SUPPLEMENT|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
219413020|NCT03969043|OTHER|MRI|"The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
219413021|NCT01593163|DRUG|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
219413022|NCT01593163|DRUG|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
219413023|NCT03480607|DRUG|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
219413024|NCT03480607|DRUG|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
219570491|NCT05655247|PROCEDURE|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
219570492|NCT05992948|DEVICE|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
219570493|NCT00932282|DRUG|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
219003777|NCT01910090|DRUG|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
219003778|NCT01910090|DRUG|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
219413025|NCT02704676|OTHER|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
219413026|NCT00375817|PROCEDURE|Myoblasts injection with MyoCath catheter|
219413027|NCT00297362|DRUG|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
219413028|NCT04766502|OTHER|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
219413029|NCT04846751|BEHAVIORAL|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
219413030|NCT02152670|DRUG|Methylphenidate|
219413031|NCT02152670|DRUG|Alpha Methyl Para Tyrosine (AMPT)|
219413032|NCT02152670|OTHER|[11C]PHNO|
219413033|NCT02152670|OTHER|[11C]raclopride|
219413034|NCT00362791|BEHAVIORAL|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
219413035|NCT00362791|BEHAVIORAL|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
219413036|NCT00362791|BEHAVIORAL|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
219570494|NCT00932282|DRUG|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
219003779|NCT05916014|DIAGNOSTIC_TEST|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
219570495|NCT05589038|OTHER|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
219757470|NCT02630641|DRUG|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
219413037|NCT01573507|OTHER|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
219413038|NCT04745793|OTHER|Hyperspectral and Fluobeam acquisition|"Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations."
219413039|NCT00568958|BEHAVIORAL|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
219413040|NCT00568958|DRUG|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
219570496|NCT05589038|OTHER|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
219570497|NCT02883478|DEVICE|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
219570498|NCT02883478|PROCEDURE|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
219570499|NCT02883478|DRUG|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
219757471|NCT05049863|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
219757472|NCT05049863|DRUG|Allopurinol|Allopurinol is commercially available.
219757473|NCT05049863|DRUG|Irinotecan|Irinotecan is commercially available.
219413041|NCT00568958|DRUG|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
219570500|NCT05468372|DRUG|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
219757474|NCT00143884|PROCEDURE|Reduced intensity conditioning|
219003780|NCT02116296|BEHAVIORAL|ToyBox-intervention|
219003781|NCT05549570|DRUG|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
219003782|NCT03639298|DEVICE|Intendu|intensive training with Motion Based Cognitive Video Games Software
219757475|NCT00143884|PROCEDURE|Prophylactic donor leukocyte infusions|
219757476|NCT04165837|DRUG|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
219757477|NCT04165837|DRUG|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
219413042|NCT01709136|DRUG|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
219413043|NCT02607254|DRUG|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
219413044|NCT02607254|DRUG|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
219413045|NCT00651404|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
219413046|NCT00651404|DRUG|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
219413047|NCT01057069|DRUG|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
219413048|NCT01057069|DRUG|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
219413049|NCT01057069|DRUG|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
219413050|NCT02929849|DIETARY_SUPPLEMENT|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
219413051|NCT02929849|DIETARY_SUPPLEMENT|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
219570501|NCT05468372|DRUG|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
219570502|NCT06286657|DIETARY_SUPPLEMENT|Xanthohumol|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
219413052|NCT02929849|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
219413053|NCT04895163|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
219413054|NCT02939924|DEVICE|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
219570503|NCT06286657|DIETARY_SUPPLEMENT|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
219570504|NCT01983514|DRUG|8IU intranasal oxytocin|
219003783|NCT06124144|DRUG|Oleylphosphocholine|The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
219413055|NCT05958095|DEVICE|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
219413056|NCT05958095|DEVICE|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
219413057|NCT04876703|DEVICE|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
219413058|NCT04876703|OTHER|Standard motor training|Standard motor training is the conventional rehabilitation treatment
219570505|NCT01983514|DRUG|24 IU intranasal oxytocin|
219413059|NCT02932189|DEVICE|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
219413060|NCT02119884|DRUG|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
219413061|NCT02119884|DRUG|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
219413062|NCT03001154|BEHAVIORAL|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
219413063|NCT03001154|BEHAVIORAL|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
219413064|NCT03001154|OTHER|Waiting-list|Weekly assessments of public speaking
219413065|NCT02231450|DRUG|Lu AE58054 encapsulated film-coated tablets|
219413066|NCT00483275|DRUG|Alfacalcidol|
219413067|NCT00483275|BEHAVIORAL|Balance, gait and strength training|
219413068|NCT00483275|BEHAVIORAL|Patient education|
219570506|NCT01983514|DRUG|1 IU intravenous oxytocin|
219757478|NCT04951349|DRUG|GX-03|Same dosage used in Bactroban Nasal studies.
219003784|NCT02408315|DRUG|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
219003785|NCT02117648|DRUG|Abemaciclib|Administered orally
219413069|NCT03916172|BEHAVIORAL|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
219413070|NCT06087042|DIAGNOSTIC_TEST|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
219413071|NCT00377611|BIOLOGICAL|Fluarix™|
219413072|NCT05738694|DRUG|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
219003786|NCT02117648|DRUG|Clarithromycin|Administered orally
219413073|NCT05738694|PROCEDURE|nephrectomy|nephrectomy
219413074|NCT03986775|DIETARY_SUPPLEMENT|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
219413075|NCT03986775|DIETARY_SUPPLEMENT|sucrose|conventional beverage with sucrose
219413076|NCT04949906|DRUG|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
219413077|NCT04949906|DRUG|No nourishing serum brain granules are used|No nourishing serum brain granules are used
219413078|NCT02854904|DRUG|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
219413079|NCT02854904|DRUG|Placebo|Placebo controlled
219413080|NCT06153082|DIAGNOSTIC_TEST|ROTEM|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
219570507|NCT01983514|DRUG|Placebo|
219570508|NCT02966184|DRUG|preservative free albuterol|Preservative free albuterol for nebulization
219570509|NCT03860207|BIOLOGICAL|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
219570510|NCT03860207|OTHER|Blood draw|In cycle 1, blood is drawn for PK studies.
219570511|NCT05877079|DRUG|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
219413081|NCT06153082|DIAGNOSTIC_TEST|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
219413082|NCT03639012|DIETARY_SUPPLEMENT|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
219413083|NCT01844622|OTHER|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
219413084|NCT03721393|DEVICE|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
219413085|NCT02343276|DRUG|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
219413086|NCT02343276|OTHER|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
219413087|NCT05004142|DRUG|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
219413088|NCT05004142|DRUG|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
219413089|NCT00003026|DRUG|bicalutamide|
219413090|NCT00003026|DRUG|flutamide|
219413091|NCT00003026|DRUG|triptorelin|
219413092|NCT00003026|RADIATION|radiation therapy|
219413093|NCT01000779|DRUG|Propranolol|upto 320mg/day maximum
219413094|NCT01000779|DEVICE|multi band ligator for esophageal varices|to obliterate esophageal varices
219413095|NCT00900172|BIOLOGICAL|bevacizumab|
219413096|NCT00900172|DRUG|carboplatin|
219570512|NCT05877079|DRUG|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
219570513|NCT04542850|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
219413097|NCT00900172|DRUG|paclitaxel|
219413098|NCT00900172|GENETIC|gene expression analysis|
219413099|NCT00900172|GENETIC|polymerase chain reaction|
219413100|NCT00900172|GENETIC|polymorphism analysis|
219413101|NCT00900172|OTHER|laboratory biomarker analysis|
219413102|NCT00839878|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
219413103|NCT05852678|OTHER|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
219413104|NCT04010890|BEHAVIORAL|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
219413105|NCT02156492|DRUG|Evacetrapib|Administered orally.
219413106|NCT02156492|DRUG|Simvastatin|Administered orally.
219413107|NCT02156492|DRUG|Atorvastatin|Administered orally.
219413108|NCT04388098|OTHER|Diagnosis of caries experience and periodontal health|
219413109|NCT01523314|DRUG|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
219413110|NCT01523314|OTHER|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
219413111|NCT04703127|DRUG|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
219413112|NCT04703127|DRUG|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
219413113|NCT05610358|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
219413114|NCT03489993|DIAGNOSTIC_TEST|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
219757479|NCT04951349|DRUG|Petrolatum ointment|Viscous ointment similar in form to study drug.
219757480|NCT01742884|OTHER|Thealoz|Instillation of 1 drop of Thealoz
219757481|NCT01742884|OTHER|Vehicle|1 drop of the vehicle will be instillated in the eye
219757482|NCT02575144|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
219757483|NCT02575144|DRUG|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
219757484|NCT02575144|DRUG|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
219757485|NCT00404807|DEVICE|CPAP(Continuous Positive Airway Pressure)|
219757486|NCT03573050|DRUG|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
219757487|NCT03573050|DRUG|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
219757488|NCT05748002|OTHER|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
219003787|NCT06237660|PROCEDURE|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
219413115|NCT03489993|DIAGNOSTIC_TEST|FGF23 and klotho|Measured using ELISA's.
219413116|NCT04903964|OTHER|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
219413117|NCT04673136|DEVICE|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
219757489|NCT05455892|OTHER|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
219757490|NCT06030518|DIAGNOSTIC_TEST|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
219413118|NCT04673136|OTHER|Colonoscopy|Standard colonoscopy
219413119|NCT04625894|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
219413120|NCT04625894|DRUG|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
219757491|NCT03342560|DEVICE|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
219757492|NCT01879007|DRUG|Factive® Tab / Factive IV|
219413121|NCT01262612|DRUG|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
219413122|NCT01262612|DRUG|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
219413123|NCT03179280|DRUG|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
219413124|NCT02823678|PROCEDURE|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
219413125|NCT01978158|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
219413126|NCT04043715|DEVICE|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
219413127|NCT04043715|DEVICE|Epidural spinal stimulation|Physical therapy to improve standing and walking
219413128|NCT05436886|DRUG|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
219413129|NCT05436886|DRUG|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
219003788|NCT06237660|DIAGNOSTIC_TEST|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
219413130|NCT05684601|DEVICE|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
219413131|NCT04868370|OTHER|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
219413132|NCT00089453|DRUG|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
219413133|NCT00089453|DRUG|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
219413134|NCT00089453|DRUG|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.
219413135|NCT00089453|DRUG|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
219413136|NCT00089453|DRUG|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
219413137|NCT00089453|PROCEDURE|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
219413138|NCT00089453|DRUG|Interleukin|2 at 3x10x6 IU on days +1 to 13.
219413139|NCT00089453|PROCEDURE|Infusion #1|Infusion of donor NK Cells #1 on day 0
219413140|NCT00089453|PROCEDURE|Leukapheresis #2|on day +2
219413141|NCT00089453|PROCEDURE|Infusion #2|on day +2
219413142|NCT00089453|PROCEDURE|Auto Graft|on day +14
219413143|NCT00871377|DRUG|Placebo|corn oil (n-6 fatty acids)
219413144|NCT00871377|DRUG|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
219413145|NCT00871377|DRUG|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
219413146|NCT03698188|PROCEDURE|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
219413147|NCT03698188|PROCEDURE|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
219413148|NCT04428658|BEHAVIORAL|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
219413149|NCT04428658|BEHAVIORAL|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
219413150|NCT04428658|BEHAVIORAL|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
219570514|NCT04082728|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
219570515|NCT04082728|DRUG|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
219570516|NCT01997294|DRUG|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
219570517|NCT02632734|DEVICE|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
219570518|NCT02632734|DEVICE|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
219570519|NCT05224284|OTHER|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
219570520|NCT02813421|DEVICE|CGM Informed|
219570521|NCT01915719|PROCEDURE|Early non invasive ventilation|
219570522|NCT01915719|PROCEDURE|Oxygen therapy only|
219570523|NCT05763706|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
219570524|NCT04731402|OTHER|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
219570525|NCT02759770|OTHER|no intervention|This is a clinical observational study, no intervention was included.
219570526|NCT00003517|DRUG|antineoplaston A10|
219570527|NCT00003517|DRUG|antineoplaston AS2-1|
219570528|NCT00003517|DRUG|bicalutamide|
219570529|NCT00003517|DRUG|flutamide|
219570530|NCT00003517|DRUG|leuprolide acetate|
219570531|NCT00003517|PROCEDURE|alternative product therapy|
219570532|NCT00003517|PROCEDURE|antiandrogen therapy|
219570533|NCT00003517|PROCEDURE|biological therapy|
219570534|NCT00003517|PROCEDURE|biologically based therapies|
219570535|NCT00003517|PROCEDURE|cancer prevention intervention|
219570536|NCT00003517|PROCEDURE|complementary and alternative therapy|
219570537|NCT00003517|PROCEDURE|differentiation therapy|
219570538|NCT00003517|PROCEDURE|endocrine therapy|
219570539|NCT00003517|PROCEDURE|hormone therapy|
219570540|NCT05457517|DRUG|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
219570541|NCT01452594|DRUG|Diphenylcyclopropenone|Topical administration
219570542|NCT01452594|DRUG|Placebo|Placebo
219570543|NCT02548312|OTHER|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
219570544|NCT06125496|OTHER|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
219413151|NCT06240494|PROCEDURE|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
219413152|NCT01590394|DEVICE|Large plastic biliary stent|Stent placement for bile duct obstruction.
219413153|NCT00658710|BEHAVIORAL|physical therapy sessions|two physical therapy sessions per week for two months
219413154|NCT05257577|PROCEDURE|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
219413155|NCT00930605|DRUG|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
219413156|NCT00930605|DRUG|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
219413157|NCT00810056|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
219413158|NCT00810056|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
219413159|NCT03474406|OTHER|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
219413160|NCT00922194|DRUG|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
219413161|NCT04423900|DIAGNOSTIC_TEST|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
219413162|NCT01993862|OTHER|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
219413163|NCT01321840|PROCEDURE|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
219413164|NCT03831802|DEVICE|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
219413165|NCT03831802|DEVICE|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
219413166|NCT04966195|RADIATION|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
219413167|NCT03428412|DRUG|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
219413168|NCT03428412|DRUG|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
219413169|NCT06395428|DRUG|Haloperidol|Intramuscular injection of drug
219413170|NCT06395428|DRUG|Ketorolac Tromethamine|Intramuscular injection of drug
219570545|NCT01856036|PROCEDURE|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
219570546|NCT00003034|DRUG|doxorubicin hydrochloride|Given IV
219570547|NCT00003034|DRUG|ranpirnase|Given IV
219570548|NCT06411340|OTHER|Observation|Observation
219570549|NCT01006941|BIOLOGICAL|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
219570550|NCT04766541|OTHER|no intervention|There is no intervention.
219570551|NCT02109536|DEVICE|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
219570552|NCT03574922|OTHER|Balance exercises|Balance Exercises
219003789|NCT06237660|DIAGNOSTIC_TEST|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
219003790|NCT06237660|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
219003791|NCT06237660|PROCEDURE|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
219413171|NCT01374776|DRUG|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
219413172|NCT04829019|RADIATION|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
219003792|NCT06237660|DIAGNOSTIC_TEST|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
219003793|NCT05268900|DEVICE|Volume control ventilation group|Volume control ventilation mode
219413173|NCT04829019|DRUG|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
219413174|NCT03860545|DIAGNOSTIC_TEST|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
219570553|NCT03574922|OTHER|Core Stabilization exercises|Core Stabilization exercises
219570554|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
219413175|NCT05514652|DRUG|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
219413176|NCT00207259|BEHAVIORAL|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
219413177|NCT04755712|DRUG|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
219570555|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
219570556|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
219570557|NCT00856830|DRUG|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
219570558|NCT04927026|BEHAVIORAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
219570559|NCT03580174|OTHER|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
219570560|NCT03580174|OTHER|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
219570561|NCT01025674|BEHAVIORAL|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
219570562|NCT03131622|BEHAVIORAL|Digital Therapeutics|
219413178|NCT04755712|DRUG|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
219413179|NCT04755712|DRUG|Morphine|Morphine via pump (patient controlled analgesia)
219413180|NCT02912728|BEHAVIORAL|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
219413181|NCT02912728|DEVICE|Standard CGM|use of CGM alone to assess CGM adherence
219413182|NCT02082145|DEVICE|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
219413183|NCT00970957|DRUG|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
219413184|NCT00970957|DRUG|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
219190401|NCT05219175|DRUG|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
219413185|NCT04903184|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
219413186|NCT04903184|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
219413187|NCT02326207|DEVICE|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
219413188|NCT04191291|BEHAVIORAL|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
219190402|NCT04766892|DRUG|mavacamten|mavacamten capsules
219190403|NCT05111613|DEVICE|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
219190404|NCT05111613|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
219413189|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
219413190|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
219413191|NCT04089813|DRUG|Metformin|Patients use metformin to control blood sugar
219413192|NCT04447703|OTHER|Interview|Attend Interview
219413193|NCT04447703|OTHER|Internet Based Intervention|Use web-based genetic education tool online
219413194|NCT04447703|OTHER|Survey Administration|Ancillary Studies
219570563|NCT01922752|DRUG|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
219413195|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
219413196|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
219413197|NCT04447703|OTHER|Survey Administration|Ancillary Studies
219413198|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
219413199|NCT04447703|OTHER|Internet-Based Intervention|Use web-based genetic education tool online
219413200|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
219413201|NCT04447703|OTHER|Survey Administration|Ancillary Studies
219413202|NCT01434641|OTHER|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
219413203|NCT05910541|BEHAVIORAL|Mindful breathing|30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
219413204|NCT05910541|OTHER|Standard care (control)|Standard care such as pain control, oxygen supplement.
219413205|NCT00996021|DRUG|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
219413206|NCT00996021|DRUG|Placebo Suspension|Placebo is a liquid with no drug in it.
219413207|NCT00996021|DRUG|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
219413208|NCT00082758|BIOLOGICAL|hu14.18-Interleukin-2 fusion protein|Given IV
219413209|NCT02598518|BEHAVIORAL|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
219413210|NCT02598518|BEHAVIORAL|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
219413211|NCT02767453|PROCEDURE|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
219570564|NCT01914068|OTHER|Supervised exercise in hospital|
219413212|NCT02767453|PROCEDURE|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
219413213|NCT00238303|DRUG|vorinostat|Given orally
219413214|NCT00238303|PROCEDURE|conventional surgery|Patients undergo surgery to remove tumor
219413215|NCT02090192|PROCEDURE|WBV training|
219413216|NCT02090192|PROCEDURE|PRT training|
219413217|NCT04876989|PROCEDURE|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
219413218|NCT04876989|PROCEDURE|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
219413219|NCT01235286|PROCEDURE|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
219413220|NCT02351843|DEVICE|MECTA Spectrum 5000Q|
219413221|NCT02623595|RADIATION|Stereotactic body radiotherapy|A type of radiation therapy
219413222|NCT02623595|DRUG|rhGM-CSF|Immune modulating agents
219413223|NCT03983928|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219413224|NCT03983928|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219413225|NCT06215456|DEVICE|Virtual reality therapy|VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.
219413226|NCT05329779|DRUG|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
219413227|NCT05329779|DRUG|placebo|The placebo is a 0.45% sodium chloride infusion.
219413228|NCT01833741|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
219570565|NCT01941888|DRUG|Propofol|
219570566|NCT01941888|DRUG|Midazolam|
219003794|NCT05268900|DEVICE|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
219003795|NCT00247091|BIOLOGICAL|standard-titer measles vaccine|
219190405|NCT06766890|BEHAVIORAL|WeJoy+WeHop|School-based CBT (WeJoy) comprises six weekly sessions on psychoeducation, cognitive restructuring, behavioural activation, emotional regulation, and self-monitoring. Exergaming on the interactive floor (WeHop) can gain a sense of autonomy, competence, and relatedness to help them regulate their emotions and maintain positive behaviours according to the Self-Determination Theory. Children participate in the interactive floor games by stepping on various targets and moving in response to the game's rules. Combining task division, cooperation, and taking turns constitutes the collaboration mechanism.
219413229|NCT04875949|PROCEDURE|Immunoabsorption/plasmapheresis procedure|
219413230|NCT00208494|DEVICE|Total Hip Replacement|Total hip replacement
219413231|NCT00208494|DEVICE|Total hip replacement|Total hip replacement
219413232|NCT04365816|OTHER|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
219413233|NCT05853523|COMBINATION_PRODUCT|Gas ozone|The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
219570567|NCT01941888|DEVICE|Target Controlled Infusion|
219570568|NCT04377048|DRUG|Nivolumab|"as described in NGS Arm"
219570569|NCT04377048|DRUG|Gemcitabine|"as described in NGS Arm"
219570570|NCT04377048|DRUG|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
219570571|NCT01294566|DRUG|GSK1322888|1 mg, 5 mg or 25 mg capsule
219570572|NCT01294566|DRUG|Placebo|matching placebo capsules
219413234|NCT05853523|COMBINATION_PRODUCT|Diode laser and desensitized gel|"The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel."
219413235|NCT00121069|DRUG|Escitalopram|
219413236|NCT03435172|DEVICE|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
219413237|NCT03105206|PROCEDURE|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
219413238|NCT05929417|OTHER|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
219413239|NCT02561299|DEVICE|Peripheral Orbital Atherectomy System|Orbital Atherectomy
219190406|NCT04613505|BEHAVIORAL|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
219190407|NCT04613505|BEHAVIORAL|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
219413240|NCT02561299|DEVICE|014 Drug Coated Balloon|Drug Coated Balloon
219190408|NCT06765343|DEVICE|Plaque disclosing agent|Dye agent binding to oral biofilm and plaque for visual detection
219570573|NCT05443269|DIETARY_SUPPLEMENT|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
219570574|NCT03580564|DRUG|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
219570575|NCT04062149|OTHER|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
219757493|NCT05032586|DEVICE|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
219190409|NCT06765343|DEVICE|Guided Biofilm Therapy|Utilisation of a air-polishing device conveying a jet of air, water and erythritol powder for plaque debridement on dental surfaces, followed by calculus removal with an ultrasonic scaler
219413241|NCT03508141|DRUG|Fibrinogen Concentrate|Experimental
219413242|NCT03508141|DRUG|Cryoprecipitate|Comparator
219413243|NCT05312710|DRUG|APG-157|Treatment
219413244|NCT01955850|BEHAVIORAL|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
219413245|NCT00501046|DRUG|Placebo|9g /day (3 times a day)
219413246|NCT00501046|DRUG|AST-120|9g /day (3 times a day)
219413247|NCT04638712|OTHER|Microbiopsy sample|before and after chemotherapy
219413248|NCT04638712|OTHER|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
219413249|NCT02311699|BEHAVIORAL|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
219570576|NCT04062149|OTHER|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
219570577|NCT04119999|DEVICE|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
219570578|NCT04119999|DEVICE|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
219413250|NCT01609179|DRUG|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
219413251|NCT02426060|DRUG|Imrecoxib|
219413252|NCT02426060|DRUG|Warfarin|
219413253|NCT03014167|DRUG|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
219413254|NCT04799236|DRUG|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
219413255|NCT04799236|DRUG|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
219413256|NCT04799236|DRUG|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
219413257|NCT06553183|PROCEDURE|immersive virtual reality|Exercise based on virtual reality video games. Immersive type will be used.
219413258|NCT06553183|PROCEDURE|traditional physicaltherapy|pneumatic compression, exercise and skin care
219190410|NCT06765343|DEVICE|Ultrasonic debridement and polishing|Removal of plaque and calculus with an ultrasonic scaler, followed by surface polishing with a rubber cup and abrasive paste
219570579|NCT04986852|DRUG|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
219570580|NCT04869709|DRUG|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
219570581|NCT02668094|DRUG|Lidocaine|
219570582|NCT02668094|DRUG|Pregabalin|
219570583|NCT02668094|DRUG|propofol|
219757494|NCT02872038|DRUG|Cefepime|Cefepime intraperitoneal continuous dosing
219003796|NCT03406572|DEVICE|HFHO Group|"* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2"
219003797|NCT03406572|DEVICE|Standard O2|Standard oxygen therapy
219003798|NCT01985867|DIETARY_SUPPLEMENT|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)
219003799|NCT01985867|DIETARY_SUPPLEMENT|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
219003800|NCT03546192|BIOLOGICAL|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
219757495|NCT02872038|DRUG|Cefazolin plus Ceftazidime|
219757496|NCT01229124|GENETIC|RNA analysis|
219757497|NCT01229124|GENETIC|nucleic acid sequencing|
219757498|NCT01229124|GENETIC|reverse transcriptase-polymerase chain reaction|
219757499|NCT01229124|OTHER|laboratory biomarker analysis|
219757500|NCT00725088|BEHAVIORAL|Exercise training|Exercise training
219757501|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
219757502|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
219757503|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
219757504|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
219757505|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
219757506|NCT04554004|DIAGNOSTIC_TEST|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
219757507|NCT00833521|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
219757508|NCT00833521|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
219757509|NCT03832985|GENETIC|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
219757510|NCT03832985|GENETIC|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
219757511|NCT03832985|GENETIC|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
219757512|NCT06643091|DRUG|Nintedanib|Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
219413259|NCT04507867|DIETARY_SUPPLEMENT|Nutritional support system (NSS)|"1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
219761503|NCT05599269|DEVICE|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
219413260|NCT04507867|OTHER|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
219413261|NCT00228306|BEHAVIORAL|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
219413262|NCT04894786|OTHER|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
219413263|NCT04894786|OTHER|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
219413264|NCT06402812|OTHER|Interview|A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
219413265|NCT04124536|BEHAVIORAL|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
219413266|NCT03164512|DRUG|Oral or vaporized cannabidiol|Acute drug exposure
219413267|NCT03164512|DRUG|Placebo|Placebo capsule/vapor
219413268|NCT04281342|DRUG|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
219413269|NCT04281342|DRUG|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
219413270|NCT04281342|DRUG|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
219413271|NCT04281342|OTHER|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
219413272|NCT03314441|BEHAVIORAL|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
219570584|NCT03095898|DEVICE|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
219570585|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
219570586|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
219413273|NCT00459485|DIETARY_SUPPLEMENT|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
219570587|NCT06389006|DRUG|Disitamab Vedotin for Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
219570588|NCT06389006|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
219761504|NCT06798298|GENETIC|Non-interventional|No study drug administered. Long-term follow-up only.
219761505|NCT06784752|RADIATION|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)
219761506|NCT06784752|DRUG|Octreotide LAR|"Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W."
219761507|NCT06335264|DEVICE|Watch HOP|A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)
219761508|NCT04269265|BIOLOGICAL|Yellow Fever Vaccine|YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
219761509|NCT05104723|DRUG|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
219761510|NCT05728502|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
219761511|NCT05728502|DRUG|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
219761512|NCT05757102|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
219003801|NCT01813591|DRUG|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
219003802|NCT04419584|DRUG|Modified Qing-Ying Decoction|Herbal granules
219003803|NCT04419584|DRUG|Identical looking placebo|Placebo granules
219413274|NCT00459485|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 3 weeks
219413275|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
219413276|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
219413277|NCT03038243|OTHER|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
219413278|NCT02843646|DEVICE|Walk Aide training|
219413279|NCT01879176|DEVICE|CytoSorb|
219413280|NCT01763021|DRUG|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
219413281|NCT01763021|DRUG|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
219413282|NCT03357146|DEVICE|Optical coherence tomography angiography|OCTA scans per built-in device protocol
219413283|NCT04596280|PROCEDURE|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
219413284|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
219413285|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
219413286|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
219413287|NCT02918409|DRUG|Colistin|
219413288|NCT02918409|DRUG|Tobramycin|
219413289|NCT05236881|DEVICE|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
219413290|NCT04758429|DEVICE|Machine-learning Algorithm|System technology/Software
219413291|NCT00139425|BEHAVIORAL|Disease Management Assessment|
219413292|NCT03192072|DIAGNOSTIC_TEST|Host Gene Expression|comparison to retrospective clinical adjudication
219413293|NCT00677690|OTHER|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
219413294|NCT00677690|OTHER|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
219413295|NCT03704441|DRUG|Bupivacaine|bupivacaine dose
219413296|NCT00209521|DRUG|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
219413297|NCT00209521|DRUG|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
219413298|NCT06330597|DIAGNOSTIC_TEST|Echocardiography and lung ultrasound|All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
219413299|NCT00275925|DRUG|Oxcarbazepine|
219413300|NCT00781599|DRUG|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
219413301|NCT00781599|BEHAVIORAL|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
219003804|NCT00553514|DRUG|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
219003805|NCT00553514|DRUG|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
219003806|NCT00553514|DRUG|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
219413302|NCT00781599|BEHAVIORAL|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
219413303|NCT04090905|OTHER|Standard clinical monitoring|Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
219413304|NCT04090905|DIAGNOSTIC_TEST|Holter monitoring|Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
219413305|NCT03741725|OTHER|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
219413306|NCT03741725|OTHER|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
219413307|NCT06498752|DRUG|PD-1 monoclonal antibody consolidation therapy|PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
219413308|NCT01106625|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
219413309|NCT01106625|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
219413310|NCT01106625|DRUG|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
219413311|NCT01106625|DRUG|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
219413312|NCT05271422|DEVICE|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
219413313|NCT05271422|DEVICE|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
219757513|NCT06642077|DRUG|LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
219413314|NCT06027931|PROCEDURE|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
219757514|NCT06644443|BIOLOGICAL|BCMA-GPRC5D CAR-T cells|patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
219413315|NCT03822871|DRUG|CTT1403|Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
219413316|NCT03822871|DRUG|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
219570589|NCT06389006|DRUG|Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
219570590|NCT06389006|DRUG|Cyclophosphamide|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
219570591|NCT05685277|DRUG|Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg|Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
219570592|NCT05685277|DRUG|Tritace® Plus tablet 10 mg/25 mg|Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
219570593|NCT04995757|DEVICE|Stent Retriever|Stent Retriever for acute ischemic stroke
219757515|NCT06293781|DEVICE|Web-based ACT|ACT program delivered online
219757516|NCT06293781|BEHAVIORAL|Treatment as usual|Treatment as usual for major depressive disorder
219757517|NCT06545006|OTHER|isometric contractions|Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
219413317|NCT03822871|DRUG|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
219413318|NCT03489135|DEVICE|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
219413319|NCT01088438|BEHAVIORAL|Contextualization workshop|A four-hour course on contextualization.
219413320|NCT03212846|OTHER|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
219413321|NCT01053117|OTHER|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
219413322|NCT04665791|BIOLOGICAL|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
219413323|NCT06569147|DRUG|Elranatamab|Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
219413324|NCT05848830|DIETARY_SUPPLEMENT|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
219413325|NCT05848830|DIETARY_SUPPLEMENT|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
219413326|NCT05848830|BEHAVIORAL|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
219413327|NCT05917366|OTHER|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
219413328|NCT05917366|OTHER|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
219761513|NCT05757102|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
219761514|NCT05757102|DRUG|FF/VI|FF/VI will be administered.
219761515|NCT04257578|DRUG|Acalabrutinib|Given PO
219761516|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
219761517|NCT06456463|DRUG|Tagraxofusp|Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.
219413329|NCT02276716|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
219413330|NCT03106194|OTHER|case management|
219757518|NCT06545006|OTHER|stroboscopic glasses|"This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport."
219413331|NCT00511342|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
219413332|NCT00511342|DRUG|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
219413333|NCT00403312|BEHAVIORAL|Smoking Cessation Behavioral Program|
219413334|NCT00403312|DRUG|Nicotine Patch|
219413335|NCT00403312|BEHAVIORAL|Physical Activity|
219413336|NCT02836535|BEHAVIORAL|qualitative interviews|
219413337|NCT02797691|OTHER|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
219413338|NCT02797691|OTHER|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
219413339|NCT03579524|PROCEDURE|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
219413340|NCT03579524|PROCEDURE|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
219413341|NCT00503880|BIOLOGICAL|filgrastim|subcutaneously one day prior to treatment
219413342|NCT00503880|DRUG|clofarabine|single IV dose over 1 hour daily for 5 days
219413343|NCT00503880|DRUG|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
219757519|NCT06545006|OTHER|Quick Release|"The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement"
219413344|NCT00503880|GENETIC|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
219757520|NCT00646230|DRUG|fenretinide|
219757521|NCT00646230|OTHER|high performance liquid chromatography|
219757522|NCT00646230|OTHER|pharmacological study|
219757523|NCT01280942|BEHAVIORAL|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
219413345|NCT00503880|PROCEDURE|biopsy|bone marrow biopsy
219413346|NCT01611350|OTHER|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
219413347|NCT01611350|OTHER|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
219757524|NCT01280942|DEVICE|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
219413348|NCT01611350|OTHER|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
219413349|NCT05259267|BEHAVIORAL|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
219413350|NCT05259267|BEHAVIORAL|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
219413351|NCT05273840|DIETARY_SUPPLEMENT|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
219413352|NCT05273840|BEHAVIORAL|lifestyle intervention|Patients will receive lifestyle interventions.
219413353|NCT01793519|DRUG|Etanercept|Subcutaneous
219413354|NCT01793519|DRUG|Infliximab|Infusion
219413355|NCT01793519|DRUG|Adalimumab|Subcutaneous
219413356|NCT01793519|DRUG|Placebo|Matching Placebo
219413357|NCT01891422|OTHER|Non-interventional.|
219413358|NCT05662228|DRUG|Lorazepam|Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
219413359|NCT05662228|DRUG|Intravenous immunoglobulin (IVIG)|IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
219413360|NCT05662228|DRUG|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
219413361|NCT01496430|DRUG|Placebo|
219413362|NCT01496430|DRUG|Azilsartan medoxomil|
219413363|NCT01496430|DRUG|Azilsartan medoxomil|
219413364|NCT04982120|DEVICE|Repris Needle|Injection of Botox
219570594|NCT00300326|PROCEDURE|Computer assist|same implant using a computer-assisted surgical technique.
219003807|NCT00553514|DRUG|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
219190411|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
219190412|NCT05879536|DRUG|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
219413365|NCT03772938|BIOLOGICAL|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
219413366|NCT05110040|DRUG|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
219413367|NCT00997321|DRUG|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
219413368|NCT00997321|DRUG|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
219413369|NCT00188877|PROCEDURE|intensity modulated radiation therapy|
219413370|NCT00188877|DRUG|cisplatinium and fluorouracil - standard treatment|
219413371|NCT00932529|DRUG|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
219413372|NCT00932529|DRUG|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
219413373|NCT00932529|DRUG|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
219413374|NCT00932529|DRUG|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
219413375|NCT01806246|BEHAVIORAL|integrative rehabilitation program|
219413376|NCT04229550|BEHAVIORAL|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
219413377|NCT01545908|OTHER|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
219413378|NCT01545908|OTHER|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
219413379|NCT02217319|DRUG|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
219413380|NCT02217319|DRUG|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
219413381|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 25 mg b.i.d
219413382|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg qhs
219413383|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg b.i.d.
219413384|NCT00360243|DRUG|placebo|placebo
219413385|NCT02512068|DRUG|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
219413386|NCT02512068|DRUG|Placebo|Placebo Tablets
219413387|NCT02316756|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
219413388|NCT02316756|DRUG|Placebo|Placebo which will be given as oral suspension
219413389|NCT02569411|OTHER|Financial Incentive|money
219413390|NCT02528097|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
219413391|NCT02528097|DRUG|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
219570595|NCT03282968|DEVICE|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
219570596|NCT03282968|OTHER|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
219570597|NCT05714566|DIAGNOSTIC_TEST|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
219190413|NCT05879536|DRUG|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
219757525|NCT05283889|PROCEDURE|Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
219761518|NCT06456463|DRUG|Venetoclax|Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.
219761519|NCT06456463|DRUG|Azacitidine|Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
219761520|NCT04305431|BEHAVIORAL|Cooking Intervention|90-minute culinary education sessions.
219761521|NCT06578104|DEVICE|PulseSelect™ PFA system|Ablation using the PulseSelect™ PFA system
219413392|NCT03168256|DRUG|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
219413393|NCT03168256|DRUG|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
219413394|NCT03168256|DRUG|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
219413395|NCT03168256|DRUG|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
219413396|NCT01133431|DRUG|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
219413397|NCT01133431|DRUG|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
219413398|NCT03521687|DRUG|Apremilast|30 mg BID
219413399|NCT01962714|BEHAVIORAL|Loving-Kindness Meditation|12-week loving-kindness meditation course
219413400|NCT01962714|BEHAVIORAL|Cognitive Processing Therapy|12-week CPT course
219413401|NCT03498781|OTHER|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
219413402|NCT03498781|OTHER|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
219413403|NCT02951390|OTHER|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
219413404|NCT05344144|OTHER|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
219413405|NCT05344144|OTHER|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
219413406|NCT02458690|BEHAVIORAL|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
219413407|NCT02458690|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
219413408|NCT02458690|DRUG|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
219413409|NCT02458690|OTHER|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
219413410|NCT01151579|DRUG|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
219413411|NCT01151579|DRUG|Albuterol|Nebulized albuterol 2.5mg
219413412|NCT00437333|DRUG|Metformin cloridrate|
219413413|NCT02456181|BEHAVIORAL|JumpMath|
219413414|NCT01333839|OTHER|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
219413415|NCT02200471|DEVICE|VeinViewer|
219190414|NCT04070469|DRUG|Amoxicillin|dosage of plasma concentration of amoxicillin
219413416|NCT01924052|DRUG|CGRP|Calcitonin-gene-related-peptide (CGRP)
219413417|NCT04809389|BIOLOGICAL|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
219413418|NCT04809389|BIOLOGICAL|Matching placebo|0.9% NaCl solution
219413419|NCT02559154|DRUG|Bortezomib|
219413420|NCT02559154|DRUG|Dexamethasone|
219413421|NCT02559154|DRUG|Doxorubicin|
219413422|NCT02559154|DRUG|Cyclophosphamide|
219413423|NCT02559154|DRUG|Mitoxsnteone|
219413424|NCT02559154|DRUG|Thalidomide|
219413425|NCT02019524|BIOLOGICAL|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
219413426|NCT02019524|BIOLOGICAL|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
219413427|NCT02019524|BIOLOGICAL|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
219413428|NCT03524105|BEHAVIORAL|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
219413429|NCT03524105|BEHAVIORAL|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
219413430|NCT04358042|OTHER|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
219413431|NCT04358042|OTHER|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
219413432|NCT04358042|OTHER|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
219413433|NCT04358042|OTHER|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
219413434|NCT06441812|DRUG|SHR-1703 Injection|SHR-1703 Injection
219570598|NCT00918463|DRUG|dasatinib|100 mg daily dosing
219570599|NCT01784666|DRUG|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
219570600|NCT01784666|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
219570601|NCT01321281|DIETARY_SUPPLEMENT|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
219570602|NCT01321281|DIETARY_SUPPLEMENT|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
219413435|NCT02953392|DEVICE|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
219413436|NCT02953392|DEVICE|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
219413437|NCT02953392|DEVICE|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
219413438|NCT02953392|DEVICE|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
219413439|NCT05256875|OTHER|chemical adherence test, medication adherence questionnaire, pharmacy refill rate|Urine/blood samples will be collected from participants, also they will be asked to complete a medication adherence questionnaire, medication records will also be examined to determine the pharmacy refill rate.
219413440|NCT05289804|DEVICE|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
219413441|NCT05289804|DRUG|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
219413442|NCT05289804|DEVICE|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
219413443|NCT05289804|DEVICE|Sham NITESGON|Sham NITESGON
219413444|NCT03615469|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
219413445|NCT03615469|DEVICE|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
219413446|NCT01925859|DRUG|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
219413447|NCT04041388|OTHER|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
219413448|NCT01153763|DRUG|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
219570603|NCT01014624|DRUG|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
219570604|NCT01014624|DRUG|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
219570605|NCT00836017|OTHER|No Intervention|No intervention was administered as part of the study.
219570606|NCT01824134|OTHER|Klean & Klear The Dandy Day Corp|
219570607|NCT01824134|OTHER|The Skin Gel Herbal Answers, Inc|
219003808|NCT00553514|DRUG|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
219413449|NCT05942937|OTHER|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
219757526|NCT05283889|PROCEDURE|Sham Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
219413450|NCT06297343|PROCEDURE|Creation of an arteriovenous fistula|Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.
219413451|NCT05986643|BEHAVIORAL|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
219413452|NCT05986643|BEHAVIORAL|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
219413453|NCT04960345|DEVICE|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
219413454|NCT03674203|BIOLOGICAL|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
219413455|NCT01474746|DRUG|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
219413456|NCT01474746|DRUG|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
219413457|NCT00400829|DRUG|eribulin mesylate|Given IV
219413458|NCT02742922|BEHAVIORAL|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
219413459|NCT00396708|DEVICE|myomo e100 neurorobotic elbow brace|
219413460|NCT01766336|DRUG|Group 1 ELND005|
219413461|NCT01766336|DRUG|Group 2 ELND005|
219570608|NCT02954159|DRUG|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
219570609|NCT02954159|DRUG|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
219570610|NCT02954159|OTHER|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
219570611|NCT01311752|PROCEDURE|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
219570612|NCT02834806|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
219570613|NCT05695092|BEHAVIORAL|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
219570614|NCT05695092|OTHER|control|control group will not receive any intervention
219757527|NCT06455904|PROCEDURE|Training sessions|The training program will be performed during 15 weeks, with one session per week.
219570615|NCT02596321|DRUG|Mitizax|Allergen extract
219570616|NCT02596321|DRUG|Placebo|Placebo tablet
219003809|NCT00553514|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
219757528|NCT06278051|DRUG|Rivaroxaban granules for oral suspension|Treatment dose and period decided by its prescription
219757529|NCT06278051|DRUG|Warfarin|Treatment dose and period decided by its prescription
219757530|NCT04336826|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
219413462|NCT00901537|DRUG|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
219413463|NCT02605447|DRUG|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
219413464|NCT02605447|DEVICE|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
219413465|NCT02110121|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
219413466|NCT02110121|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
219570617|NCT01780779|OTHER|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
219570618|NCT06414239|DEVICE|Use of a VR mask|Virtual reality mask
219570619|NCT06414239|OTHER|Standard of care|Without any premedication or anesthesia
219570620|NCT03946020|PROCEDURE|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
219570621|NCT06304935|OTHER|Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control|Compare both sides of tonsillar beds in post operative healing, pain and hemostasis
219570622|NCT05378919|RADIATION|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
219570623|NCT05378919|DRUG|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
219757531|NCT04332783|BEHAVIORAL|psychophysics of sequential biases (no drug or patient work)|Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
219413467|NCT02303951|DRUG|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
219413468|NCT02303951|DRUG|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
219413469|NCT02303951|DRUG|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
219413470|NCT00944606|DIETARY_SUPPLEMENT|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
219413471|NCT00944606|OTHER|Placebo candy|candy gum drops
219413472|NCT03979105|DRUG|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
219413473|NCT04382859|PROCEDURE|Transversus abdominis plane (TAP) block with liposomal bupivacaine|Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
219413474|NCT01503073|DEVICE|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
219413475|NCT04544709|DRUG|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
219413476|NCT04482491|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
219413477|NCT02045212|DRUG|RPh201|SC injection twice a week during 13/26 weeks
219413478|NCT02045212|DRUG|Placebo|SC injection twice a week during 13/26 weeks
219413479|NCT04591795|DRUG|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
219570624|NCT05378919|DRUG|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
219570625|NCT05378919|RADIATION|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
219570626|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
219570627|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
219413480|NCT04591795|DRUG|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
219413481|NCT00145249|DRUG|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
219413482|NCT00145249|DRUG|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
219413483|NCT00403858|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
219413484|NCT00403858|DRUG|Lactulose|
219413485|NCT03224975|OTHER|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
219413486|NCT04056364|BIOLOGICAL|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
219413487|NCT03188679|DEVICE|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
219413488|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
219413489|NCT03005977|PROCEDURE|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
219413490|NCT02512692|DEVICE|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
219413491|NCT02512692|DRUG|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
219413492|NCT02512692|DRUG|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
219413493|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
219413494|NCT01707212|BEHAVIORAL|Pain management education|Education about pain management during infant immunization
219413495|NCT01707212|BEHAVIORAL|No pain management education|Control - no education about pain management during infant immunization
219413496|NCT05311280|OTHER|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
219413497|NCT05311280|OTHER|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
219413498|NCT00899743|GENETIC|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
219413499|NCT00899743|GENETIC|western blotting|western blotting
219413500|NCT00899743|OTHER|immunologic technique|immunologic technique
219570628|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
219003810|NCT03658655|BIOLOGICAL|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
219003811|NCT04464889|DRUG|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
219003812|NCT04464889|DRUG|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
219003813|NCT04464889|DRUG|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
219413501|NCT00899743|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219413502|NCT05146232|OTHER|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
219413503|NCT05146232|OTHER|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
219413504|NCT05146232|OTHER|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
219570629|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
219570630|NCT01117337|PROCEDURE|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
219190415|NCT05069168|DIAGNOSTIC_TEST|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
219190416|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
219190417|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
219190418|NCT06053619|OTHER|GaitTrainer and Virtual Reality|"Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR)."
219190419|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
219190420|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
219190421|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
219190422|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
219190423|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
219190424|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
219190425|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
219190426|NCT06780241|DIAGNOSTIC_TEST|CMR|CMR (with contrast at baseline and non-contrast at follow-up)
219190427|NCT06780241|OTHER|Quality of Life Questionnaire|Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
219190428|NCT06780748|PROCEDURE|Identification rate of sentinel lymph node|To evaluate the identification rate of sentinel lymph nodes (SLNs). The study will compare the identification rates based on different localization techniques for SLN mapping
219190429|NCT04294641|DRUG|Ibrutinib|140 mg capsules for a dose of 420 mg daily by mouth for up to 12 months.
219190430|NCT04294641|DIAGNOSTIC_TEST|ECG|At screening.
219190431|NCT04294641|DIAGNOSTIC_TEST|PFT's|"Participants should have PFTs if not performed ≤3 months prior to start of study treatment and Cycle 7, Day 1 (6 months).~Optional at Cycle 12, Day 28 (12 months) and Cycle 24, Day 28 (24 months)."
219190432|NCT04294641|DIAGNOSTIC_TEST|CT|Non-contrast CT at baseline and later during the study if clinically indicated.
219190433|NCT04294641|DRUG|Steroid pulse (prednisone)|0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
219190434|NCT04294641|DRUG|Voriconazole|At any dose.
219190435|NCT04294641|DRUG|Posaconazole|"As clinically indicated. At doses less than or equal to suspension 200 mg twice a day (BID) if ibrutinib dose modified to 280 mg once daily.~OR Posaconazole suspension 200 mg three times a day (TID) or 400 mg BID if Ibrutinib dose modified to 140 mg once daily.~OR Posaconazole injection intravenous (IV) injection 300 mg once daily; or delayed-release capsules 300 mg once daily if Ibrutinib dose modified to 140 mg once daily.."
219190436|NCT04294641|DRUG|Azithromycin|Treat or prevent bronchiolitis obliterans.
219190437|NCT04294641|DRUG|Montelukast|Treat or prevent bronchiolitis obliterans.
219190438|NCT04294641|DRUG|Budesonide|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
219190439|NCT04294641|DRUG|Beclomethasone|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
219190440|NCT04294641|OTHER|Filgrastim|Neutrophil growth factor permitted per institutional policy
219190441|NCT04294641|OTHER|Pegfilgrastim|Neutrophil growth factor permitted per institutional policy.
219190442|NCT04294641|OTHER|Erythropoietin|Red cell growth factor permitted per institutional policy.
219190443|NCT04294641|OTHER|Transfusions|According to institutional policy.
219413505|NCT05146232|OTHER|First postoperative analgesia|IV acetaminophen will be administered every 6 h
219413506|NCT05146232|OTHER|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
219413507|NCT05723549|DRUG|HCP1803-3|Take it once per period
219413508|NCT05723549|DRUG|RLD2002|Take it once per period
219413509|NCT05723549|DRUG|HCP1904-1|Take it once per period
219413510|NCT01661400|DRUG|Metronomic Cyclophosphamide|
219413511|NCT01661400|DRUG|Thalidomide|
219190444|NCT04294641|PROCEDURE|Oral/Skin biopsy|Optional. Baseline, Cycle 7, Day 1 (6 months), Cycle 12, Day 28 (12 months) and Cycle 24, Day 28.
219190445|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
219190446|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
219413512|NCT01855542|OTHER|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
219413513|NCT01855542|OTHER|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
219757532|NCT03158831|DRUG|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
219757533|NCT02419495|DRUG|Capecitabine|Given PO
219757534|NCT02419495|DRUG|Carboplatin|Given IV
219757535|NCT02419495|DRUG|Cyclophosphamide|Given IV
219757536|NCT02419495|DRUG|Doxorubicin|Given IV
219757537|NCT02419495|DRUG|Eribulin|Given IV
219757538|NCT02419495|DRUG|Fluorouracil|Given IV
219757539|NCT02419495|BIOLOGICAL|Ipilimumab|Given IV
219757540|NCT02419495|DRUG|Irinotecan Hydrochloride|Given IV
219003814|NCT04464889|DRUG|MDG1021 optimal dose|20 patients to receive the selected optimal dose
219003815|NCT04564729|OTHER|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
219190447|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
219190448|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
219190449|NCT05752461|DRUG|SHR-2004 injection|low dose subcutaneous injection once
219190450|NCT05752461|DRUG|SHR-2004 injection|medium dose subcutaneous injection once
219190451|NCT05752461|DRUG|SHR-2004 injection|high dose subcutaneous injection once
219413514|NCT03651193|DIAGNOSTIC_TEST|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
219413515|NCT01291329|GENETIC|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
219413516|NCT02334332|OTHER|Educational Intervention|Receive educational brochure
219413517|NCT02334332|PROCEDURE|Standard Follow-Up Care|Receive standard post-operative care
219413518|NCT02334332|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219413519|NCT05941949|DIETARY_SUPPLEMENT|Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E|2 softgels per day
219413520|NCT05941949|DIETARY_SUPPLEMENT|Placebo|2 softgels per day
219413521|NCT00331370|BEHAVIORAL|GP training and Health Education|
219413522|NCT05005741|DRUG|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
219413523|NCT05005741|DRUG|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
219413524|NCT01574222|BIOLOGICAL|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
219413525|NCT00695591|OTHER|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
219413526|NCT03992768|DEVICE|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
219413527|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
219413528|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
219413529|NCT00369668|BEHAVIORAL|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
219413530|NCT04068558|DEVICE|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
219757541|NCT02419495|DRUG|Leucovorin Calcium|Given IV
219757542|NCT02419495|BIOLOGICAL|Nivolumab|Given IV
219757543|NCT02419495|DRUG|Olaparib|Given PO
219757544|NCT02419495|DRUG|Oxaliplatin|Given IV
219757545|NCT02419495|DRUG|Paclitaxel|Given IV
219757546|NCT02419495|BIOLOGICAL|Pembrolizumab|Given IV
219413531|NCT04068558|DEVICE|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
219413532|NCT00321100|DRUG|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
219570631|NCT03232099|DIETARY_SUPPLEMENT|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
219570632|NCT03232099|OTHER|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
219570633|NCT03575871|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
219570634|NCT03575871|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
219570635|NCT03575871|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
219570636|NCT03236142|PROCEDURE|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
219570637|NCT03236142|PROCEDURE|Standard Duodenal Switch Operation|
219757547|NCT02419495|DRUG|Pemetrexed|Given IV
219757548|NCT02419495|DRUG|Selinexor|Given PO
219570638|NCT02537847|DRUG|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
219413533|NCT00321100|DRUG|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
219413534|NCT00321100|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
219413535|NCT00321100|DRUG|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
219413536|NCT05525767|DRUG|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
219570639|NCT02537847|DRUG|Ertapenem|Control group will be given ertapenem only for 10 days.
219570640|NCT06227624|DRUG|Oral zinc sulfate and standard phototherapy|study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
219570641|NCT00325208|DEVICE|partial-vacuum milk bottle|
219570642|NCT00325208|DEVICE|anti-vacuum milk bottle|
219570643|NCT04238832|OTHER|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
219570644|NCT04238832|OTHER|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
219570645|NCT03174106|DEVICE|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
219570646|NCT01610739|DRUG|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
219570647|NCT05964192|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
219570648|NCT03394755|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
219570649|NCT02467608|DRUG|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
219570650|NCT02467608|DRUG|HRZE|the same as experimental group,without the excipient of HUEXC030 only
219570651|NCT01612039|DRUG|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
219570652|NCT01612039|DRUG|Placebo|Matching placebo tablets
219757549|NCT02419495|DRUG|Topotecan|Given IV
219757550|NCT06421350|DEVICE|Spinal Cord Stimulation Device|The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
219757551|NCT05261711|DRUG|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
219570653|NCT03880799|BEHAVIORAL|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
219570654|NCT03604107|GENETIC|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
219570655|NCT01744093|DRUG|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
219570656|NCT01744093|DRUG|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
219570657|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
219757552|NCT06422247|DRUG|Systemic therapy|Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
219757553|NCT05273567|DRUG|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
219757554|NCT05273567|OTHER|Placebo|placebo will be dispensed similar to the active arm.
219757555|NCT05965700|DRUG|NVG-291|A once daily injection
219413537|NCT02290535|PROCEDURE|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
219413538|NCT02290535|PROCEDURE|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
219570658|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
219570659|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
219413539|NCT00920608|DRUG|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
219413540|NCT00920608|DRUG|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
219570660|NCT04051463|DRUG|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
219570661|NCT04051463|DRUG|Placebo|Placebo eye drops instilled once daily
219570662|NCT04883970|OTHER|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
219570663|NCT02527499|BEHAVIORAL|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
219570664|NCT02527499|BEHAVIORAL|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
219570665|NCT02527499|BEHAVIORAL|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
219570666|NCT02756247|DRUG|Buparlisib|
219570667|NCT02756247|DRUG|Ibrutinib|
219570668|NCT06406660|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
219413541|NCT00218036|DRUG|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
219413542|NCT00218036|DRUG|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
219570669|NCT06322394|DRUG|high-dose BXOS110|3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
219570670|NCT06322394|DRUG|low-dose BXOS110|2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.
219570671|NCT06322394|DRUG|Placebo|Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
219570672|NCT06290518|DIETARY_SUPPLEMENT|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9.5 log10 cfu of the strain.
219570673|NCT06290518|DIETARY_SUPPLEMENT|Placebo|Oral administration of a capsule containing maltodextrin.
219570674|NCT02524587|DEVICE|standard polyethylene acetabular irradiated at 3 Mrad|
219570675|NCT02524587|OTHER|radio stereometric analysis (RSA) of the acetabular|
219570676|NCT02524587|DEVICE|acetabular polyethylene vitamys®|
219570677|NCT05434377|OTHER|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
219570678|NCT05434377|OTHER|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
219570679|NCT05434377|OTHER|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
219570680|NCT05690087|DRUG|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
219413543|NCT00218036|DRUG|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
219413544|NCT00218036|DRUG|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
219413545|NCT00218036|DRUG|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
219190452|NCT05752461|DRUG|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
219413546|NCT06282900|OTHER|University students|A cross-sectional study (Level IV evidence) will be conducted at the university (Acibadem University, Turkey). All students at the university will be invited to respond to a self-administered online survey. The survey will be prepared via Google Forms.
219413547|NCT01606592|BEHAVIORAL|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
219413548|NCT01606592|BEHAVIORAL|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
219413549|NCT01606592|OTHER|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
219413550|NCT03126539|DRUG|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
219413551|NCT03126539|RADIATION|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
219413552|NCT03126539|PROCEDURE|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
219413553|NCT03864263|OTHER||
219570681|NCT05690087|DRUG|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
219570682|NCT06332287|DRUG|combination of Trilaciclib and Pemetrexed|This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
219570683|NCT00558909|DRUG|BI 44847|
219570684|NCT00558909|DRUG|placebo for BI 44847|
219570685|NCT00704093|DEVICE|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
219570686|NCT04583020|DRUG|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
219570687|NCT04583020|RADIATION|radiation|60Gy/30
219003816|NCT05303636|DRUG|LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet|LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
219413554|NCT03352414|DRUG|Alvimopan|alvimopan pill
219413555|NCT03352414|DRUG|Placebo|placebo pill
219413556|NCT01266655|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
219413557|NCT01266655|DRUG|Placebo|Placebo
219570688|NCT04583020|DRUG|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
219570689|NCT05857826|OTHER|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
219757556|NCT05605249|DEVICE|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
219003817|NCT04219553|BEHAVIORAL|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
219003818|NCT04219553|OTHER|Comparator (no intervention)|No active intervention
219003819|NCT03767816|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
219003820|NCT03767816|DRUG|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
219003821|NCT03957720|DRUG|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
219003822|NCT03957720|DRUG|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
219413558|NCT02632110|DRUG|ALA|20% ALA applied to face prior to light treatment
219413559|NCT02632110|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
219413560|NCT02632110|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
219413561|NCT02632110|PROCEDURE|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
219413562|NCT02632110|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
219570690|NCT05857826|OTHER|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
219570691|NCT02251873|DRUG|TPV + RTV (low dose)|
219570692|NCT02251873|DRUG|TPV + RTV (high dose)|
219570693|NCT02251873|DRUG|ddl|
219570694|NCT05243186|DEVICE|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
219570695|NCT05243186|DRUG|Methylphenidate|Using prescription drug
219413563|NCT03699787|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
219413564|NCT02473133|RADIATION|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
219413565|NCT02473133|RADIATION|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
219413566|NCT03645408|DRUG|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
219413567|NCT03645408|OTHER|Sham injection|Subjects received a sham injection with no study drug.
219413568|NCT00846079|DEVICE|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
219413569|NCT04970771|BEHAVIORAL|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
219413570|NCT05067062|DIETARY_SUPPLEMENT|New Zealand blackcurrant extract|Capsules taken daily or intermittent
219413571|NCT05213468|DEVICE|PainDrainerTM|Self management digital tool for chronic pain
219413572|NCT01907594|DRUG|D-cycloserine|
219413573|NCT01907594|DRUG|Nicotine Replacement Therapy (patch)|
219413574|NCT01907594|BEHAVIORAL|Smoking Cue Exposure|
219413575|NCT01907594|BEHAVIORAL|Progressive Muscle Relaxation|
219413576|NCT01907594|DRUG|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
219413577|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
219413578|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
219413579|NCT00516269|DRUG|Methylphenidate|18 mg by mouth daily for 2 weeks
219413580|NCT00516269|DRUG|Placebo|Capsule by mouth daily for 2 weeks
219413581|NCT00734786|OTHER|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
219413582|NCT00142519|DRUG|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
219413583|NCT00142519|DRUG|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
219413584|NCT00006708|BIOLOGICAL|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
219413585|NCT00006708|BIOLOGICAL|rituximab|
219570696|NCT03203135|BEHAVIORAL|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
219570697|NCT01415219|OTHER|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
219413586|NCT00006708|DRUG|carboplatin|
219413587|NCT00006708|DRUG|etoposide|
219413588|NCT00006708|DRUG|ifosfamide|
219413589|NCT02731703|DEVICE|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
219413590|NCT03072121|DRUG|Shexiang Baoxin pill|Conventional western medicine \& shexiang baoxin pill
219413591|NCT03072121|DRUG|SBP placebo|Conventional western medicine \& placebo (for shexiang baoxin pill)
219413592|NCT03072121|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
219413593|NCT03072121|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
219413594|NCT03072121|DRUG|Atorvastatin Calcium|10 mg tablet, two tablets each night.
219413595|NCT03072121|DRUG|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
219413596|NCT03072121|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
219413597|NCT03072121|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
219413598|NCT04178681|OTHER|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
219413599|NCT04178681|OTHER|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
219413600|NCT04178681|OTHER|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
219570698|NCT05495035|DRUG|Olverembatinib, APG-2575, Dexamethasone|"* Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2\) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3\) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
219003823|NCT03957720|DRUG|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
219003824|NCT03957720|DRUG|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
219003825|NCT04021940|PROCEDURE|ULOD|ULOD
219003826|NCT02755558|BEHAVIORAL|Low energy density|Low energy density milk served
219003827|NCT02755558|BEHAVIORAL|High energy density|High energy density milk served
219003828|NCT02755558|BEHAVIORAL|Small portion|Small portion of milk served
219003829|NCT02755558|BEHAVIORAL|Large portion|Large portion of milk served
219190453|NCT04179773|OTHER|Current care study|"Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
219190454|NCT04466488|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
219190455|NCT04870307|OTHER|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
219190456|NCT02442115|OTHER|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
219190457|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
219190458|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
219413601|NCT00184106|DRUG|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
219413602|NCT03108144|BEHAVIORAL|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
219413603|NCT06199440|DRUG|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
219413604|NCT06199440|DRUG|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
219570699|NCT01046799|DRUG|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
219570700|NCT01173471|DRUG|AZD4017|tablet, oral, one tablet once daily, 28 days
219003830|NCT04090450|RADIATION|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
219003831|NCT03041402|OTHER|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
219413605|NCT06199440|DRUG|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
219570701|NCT01173471|DRUG|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
219570702|NCT01173471|DRUG|AZD4017|tablet, oral 2 tablets twice daily, 28 days
219570703|NCT01173471|DRUG|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
219570704|NCT04952077|DEVICE|MRI|Magnetic Resonance Imaging (MRI)
219570705|NCT03564301|DRUG|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
219570706|NCT03564301|DRUG|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
219003832|NCT03041402|OTHER|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
219413606|NCT04406246|DRUG|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
219413607|NCT05478044|DRUG|Ascorbic acid|Ascorbic acid IV ampoules (20%).
219413608|NCT05478044|OTHER|saline|saline (0.9%)
219413609|NCT04068467|OTHER|Smartphone App|The application consists of content areas focused on mental health.
219413610|NCT04068467|OTHER|Waitlist Control|Waitlist control
219413611|NCT01201096|RADIATION|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
219413612|NCT01201096|PROCEDURE|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
219413613|NCT04561635|DIETARY_SUPPLEMENT|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
219413614|NCT00234858|DRUG|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
219413615|NCT00234858|DRUG|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
219413616|NCT05518734|DRUG|VX-708|Solution for intravenous (IV) administration.
219413617|NCT05518734|DRUG|Itraconazole|Solution for oral administration.
219570707|NCT06288022|OTHER|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
219757557|NCT06975800|BEHAVIORAL|Low social feedback|Social information is provided to participants signaling that the upcoming trial will be low in negative affect and cognitive effort.
219003833|NCT03041402|OTHER|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
219003834|NCT00697762|DRUG|RWJ-333369|200 mg tablet twice daily for 12 weeks
219003835|NCT00697762|DRUG|RWJ-333369|100 mg tablet twice daily for 12 weeks
219413618|NCT05518734|DRUG|Midazolam|Solution for oral administration.
219413619|NCT05518734|DRUG|Placebo|Placebo matched to VX-708 for IV administration.
219413620|NCT01005732|DEVICE|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and \<5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
219413621|NCT02596711|DRUG|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
219413622|NCT02596711|BEHAVIORAL|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
219413623|NCT02596711|OTHER|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
219570708|NCT06288022|OTHER|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
219570709|NCT04636359|BEHAVIORAL|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
219757558|NCT06975800|BEHAVIORAL|High social feedback|Social information is provided to participants signaling that the upcoming trial will be high in negative affect and cognitive effort.
219757559|NCT03874559|DIAGNOSTIC_TEST|Blood Draw|Serum samples will be obtained from each patient enrolled
219003836|NCT00697762|DRUG|Placebo|Placebo tablet twice daily for 12 weeks
219413624|NCT02596711|BEHAVIORAL|Health Education and Handouts|Participants receive general health education and handouts.
219413625|NCT02596711|BEHAVIORAL|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
219413626|NCT02596711|BEHAVIORAL|Counseling Sessions|Participants attend 3 counseling sessions during the study.
219413627|NCT03218254|DRUG|Methylphenidate|Titration of MTP for treatment of fatigue
219413628|NCT03218254|DRUG|Placebo|Placebo
219413629|NCT02558153|DEVICE|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
219413630|NCT02558153|DEVICE|standard PTA|Percutaneous angioplasty performed with a standard balloon
219413631|NCT01552928|DRUG|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
219413632|NCT01552928|DRUG|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
219413633|NCT01552928|DRUG|Moxifloxacin|400 mg Moxifloxacin single oral dose
219413634|NCT01552928|DRUG|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
219413635|NCT01395095|OTHER|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
219413636|NCT01395095|OTHER|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
219413637|NCT01395095|OTHER|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
219413638|NCT04030104|DEVICE|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
219413639|NCT04030104|DEVICE|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
219413640|NCT04030104|DEVICE|Mammography|Mammography as available per standard of care
219413641|NCT02270892|DEVICE|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
219413642|NCT03105596|DRUG|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
219413643|NCT05126524|OTHER|NO INTERVENTION|Observational study, no intervention performed
219413644|NCT06553417|OTHER|Aqua posae and microresyl|"* This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
219413645|NCT06553417|OTHER|Urea 10%|"Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
219413646|NCT03563703|DEVICE|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
219413647|NCT03563703|DEVICE|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
219570710|NCT06062849|DEVICE|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
219570711|NCT06062849|DEVICE|double J stent|we will investigate if a JJ stent really necessary after PNL operations
219570712|NCT06062849|PROCEDURE|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
219757560|NCT04267445|PROCEDURE|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
219570713|NCT05089474|DEVICE|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
219570714|NCT03487783|DRUG|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
219570715|NCT03487783|DRUG|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
219570716|NCT02908282|DEVICE|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
219570717|NCT02908282|DEVICE|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
219757561|NCT00860600|DRUG|PG2|500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
219570718|NCT03433144|DRUG|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
219570719|NCT03433144|OTHER|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
219570720|NCT03028740|DRUG|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
219570721|NCT03028740|DRUG|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
219757562|NCT06220318|DRUG|C019199|The C019199 will be taken orally, once a day
219757563|NCT06220318|DRUG|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
219570722|NCT02583386|BEHAVIORAL|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
219413648|NCT00330720|DEVICE|Emergency Response System (Device)|
219413649|NCT04413435|OTHER|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
219413650|NCT00563836|DRUG|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
219413651|NCT04435145|BEHAVIORAL|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
219413652|NCT01079962|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
219413653|NCT01079962|DRUG|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
219413654|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
219413655|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
219413656|NCT04840992|BIOLOGICAL|Placebo for Inhalation|Aerogen Solo
219413657|NCT04840992|BIOLOGICAL|Placebo|Intramuscular administration
219570723|NCT02583386|OTHER|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
219570724|NCT04628520|PROCEDURE|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
219570725|NCT04628520|PROCEDURE|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
219570726|NCT04628520|PROCEDURE|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
219570727|NCT05015881|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|Drink a single dose of ketone ester 1.9 kcal/kg
219570728|NCT05015881|DRUG|FDG|Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
219570729|NCT03903926|BIOLOGICAL|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
219570730|NCT05850988|OTHER|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
219003837|NCT03530098|DEVICE|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
219413658|NCT01331239|DRUG|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
219413659|NCT01887249|DRUG|Clarithromycin|
219413660|NCT01887249|DRUG|metronidazole|
219413661|NCT01887249|DRUG|esomeprazole|
219413662|NCT00850018|PROCEDURE|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
219413663|NCT00850018|BEHAVIORAL|Usual care|Participants will receive usual care for the treatment of SCD.
219413664|NCT05253313|OTHER|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
219413665|NCT00207766|DRUG|infliximab or placebo|
219413666|NCT02390115|OTHER|Elastic tape application in shoulder|
219413667|NCT00480922|BEHAVIORAL|Low glycemic load diet|Outpatient behavioral counseling
219413668|NCT00480922|BEHAVIORAL|Low fat diet|Outpatient behavioral counseling
219413669|NCT00946530|DEVICE|Bright light|Participants uses bright light
219413670|NCT00946530|DEVICE|Control|Participants uses dim light
219413671|NCT02366663|RADIATION|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
219413672|NCT02366663|DRUG|Carmustine|Given IV
219413673|NCT02366663|DRUG|Etoposide|Given IV
219413674|NCT02366663|DRUG|Cytarabine|Given IV
219413675|NCT02366663|DRUG|Melphalan|Given IV
219413676|NCT02366663|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
219413677|NCT02366663|BIOLOGICAL|Rituximab|Given IV
219413678|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 0 and 4
219413679|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
219413680|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 12
219413681|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
219413682|NCT05212155|BEHAVIORAL|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
219413683|NCT02062528|DIETARY_SUPPLEMENT|omega-3 fatty acids|highly dosed in EPA
219413684|NCT02062528|DIETARY_SUPPLEMENT|placebo|
219413685|NCT01469494|PROCEDURE|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
219570731|NCT05850988|OTHER|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
219570732|NCT00259168|DRUG|Nateglinide|
219413686|NCT01469494|PROCEDURE|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
219413687|NCT01255046|DRUG|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
219413688|NCT01255046|DRUG|STA-1|300mg/tab, 2 tab/tid for 72 weeks
219413689|NCT01255046|DRUG|placebo|2 tab/tid for 72 weeks
219413690|NCT06692595|DIAGNOSTIC_TEST|digital PCR|digital PCR quantification of subgingival plaque samples
219413691|NCT04871633|DRUG|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
219413692|NCT04871633|DRUG|Conventional|IV Steroids Antibiotics
219413693|NCT06691945|COMBINATION_PRODUCT|Saline delivered using an intrauterine pressure catheter (IUPC)|An intrauterine pressure catheter (IUPC) will be placed in participants after membrane rupture, or at 4 cm if membranes previously ruptured. A 300cc bolus of normal saline will be administered. A continuous rate of 100 cc/hr of normal saline will continue until delivery to prevent Postpartum Hemorrhage. If the IUPC is dislodged, it will be replaced by a trained clinician.
219413694|NCT02197039|DRUG|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
219413695|NCT02197039|PROCEDURE|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
219570733|NCT00413686|DRUG|AZD7762|intravenous infusion
219570734|NCT00413686|DRUG|Gemcitabine|weekly intravenous infusion
219570735|NCT04060719|DRUG|BI 894416|tablet
219570736|NCT04060719|DRUG|Rifampicin|tablet
219570737|NCT03853018|DEVICE|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
219570738|NCT03853018|DEVICE|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
219570739|NCT04706962|DRUG|TH1902|Intravenous infusion
219413696|NCT06692582|OTHER|Electrolysed saline rinse|EOS ph = 7, 200 ppm free available Chlorine
219413697|NCT06753383|OTHER|To the Virtual Reality Based Exercise|After posterior fusion surgery, a rehabilitation program will be applied to individuals with AIS using Kinect Sports Ultimate for 30 minutes per day for a total of 6 weeks, 2 days a week.
219413698|NCT06753383|OTHER|Routine physiotherapy and rehabilitation program|14 patients with posterior fusion AIS routinely in the postoperative clinic for 6 weeks. the physiotherapy program used will be applied.
219413699|NCT06898892|DIAGNOSTIC_TEST|Fetal MRI|all participant will undergo MRI fetal weight estimation
219570740|NCT00207454|BEHAVIORAL|Social Cognitive Counseling|
219570741|NCT02472535|OTHER|Run-In Period: Placebo|2 capsules, once a day for two weeks
219570742|NCT02472535|DRUG|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
219413700|NCT06898541|DEVICE|Coronary sinus reducer|Implantation of a Coronary Sinus Reducer device
219570743|NCT02472535|DRUG|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
219570744|NCT02472535|DRUG|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
219570745|NCT04578886|DRUG|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
219570746|NCT04578886|DRUG|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
219570747|NCT04802408|COMBINATION_PRODUCT|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
219570748|NCT04802408|COMBINATION_PRODUCT|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
219570749|NCT04802408|COMBINATION_PRODUCT|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
219570750|NCT04802408|COMBINATION_PRODUCT|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
219413701|NCT06898541|OTHER|Sham CSR procedure|Patients will undergo a complete sham CSR implantation procedure without actual deployment of the CSR.
219570751|NCT00894517|BIOLOGICAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
219570752|NCT00894517|DRUG|Placebo (saline)|Saline injected into the prostate on Day 1.
219570753|NCT05274672|DRUG|Nitrofurantoin|Prophylactic postoperative antibiotic use
219570754|NCT05274672|DRUG|Cephalexin|Prophylactic postoperative antibiotic use
219570755|NCT05274672|DRUG|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
219570756|NCT05274672|DRUG|Ciprofloxacin|Prophylactic postoperative antibiotic use
219570757|NCT05274672|PROCEDURE|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
219413702|NCT06899100|BEHAVIORAL|Primary Services|Participants receive 26 hours of Next Level Fatherhood curriculum, 2 hours of child maltreatment workshops, 2 hours of anger management workshops, and 2 hours of optional legitimation workshops. Participants also receive ongoing case management and support services.
219413703|NCT06899256|OTHER|Horticultural Activity Program|Prior to the commencement of the horticultural intervention program, the nursing home was visited to assess its physical environment and to inform staff about the program's objectives. Participants were recruited, and baseline data was collected. The program was structured around weekly activities and visits, with a three-day interval between each session. Activities included plant identification, gardening tasks, and nature-based art projects. The program was designed to foster social interaction, cognitive stimulation, and physical activity, while promoting a sense of accomplishment and well-being among participants. Throughout the program, regular assessments were conducted to monitor participants' progress and satisfaction.
219413704|NCT03754608|DIAGNOSTIC_TEST|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
219413705|NCT07073664|PROCEDURE|The surgical side of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES)|Surgery was performed by Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) . Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
219413706|NCT07073664|PROCEDURE|The surgical side of Endoscopic Sinus Surgery (ESS)|Description: Surgery was performed by Endoscopic Sinus Surgery (ESS). Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
219413707|NCT06898294|DIAGNOSTIC_TEST|EIT kidney function assessment|The product under investigation is named Gense EIT-kidney device. This kidney device is a portable and non-invasive imaging modality capable of capturing the cross-sectional bioelectrical impedance distribution of the kidney at multiple current injection frequencies using electrical impedance tomography (EIT). Currently, the kidney device employs a band consisting of 16 equally distributed electrodes around the abdomen. The electrode band is connected to a control unit that switches the electrode stimulation and measurement pairs, then sends the collected measurement to a computational unit for image reconstruction. The images are then post-processed to extract functional kidney images for diagnosis. This kidney device has a large LED screen, allowing the functional images to be produced and visualized.
219413708|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in GCF|The primary intervention will involve the non-invasive collection of GCF samples using Periopaper strips. The strips will be placed into the gingival sulcus for 30 seconds and then stored at -80°C until analysis. The analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
219413709|NCT06897722|DIAGNOSTIC_TEST|IL-17A analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
219413710|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
219413711|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
219413712|NCT06897722|DIAGNOSTIC_TEST|İL-17A analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
219413713|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
219413714|NCT06897722|DIAGNOSTIC_TEST|Periodontal assesment|Comprehensive periodontal assessments will be conducted, including Plaque Index (PI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL).
219413715|NCT03273738|DIAGNOSTIC_TEST|folate level measurement|the level of folate measured in plasma with homocysteine
219413716|NCT03273738|DIAGNOSTIC_TEST|B12|B12 measurement in blood
219413717|NCT07080125|DRUG|Ofev®|Ofev®
219413718|NCT07084103|BEHAVIORAL|Psychosocial Support Intervention|Participants in the intervention arm will receive a structured psychosocial support program designed for women diagnosed with fetal anomaly. The program includes individual counseling sessions, stress management techniques, emotional support, and educational materials addressing coping strategies and mental well-being. The intervention will be delivered by trained healthcare professionals over sessions during the prenatal period.
219413719|NCT07082699|OTHER|antegrade enema|Introduce saline at a flow rate of 40 ml/minute through the distal end of the ileostomy. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
219413720|NCT07082699|OTHER|retrograde enema|Introduce saline at a flow rate of 40 ml/minute through the anus. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
219003838|NCT05825521|OTHER|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
219003839|NCT03483051|DRUG|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
219413721|NCT07081997|COMBINATION_PRODUCT|Palopegteriparatide|Palopegteriparatide is supplied as a solution with a concentration of 0.3 mg/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
219413722|NCT07082231|OTHER|Blood sample|3 blood samples
219413723|NCT07082231|PROCEDURE|biopsy|3 pairs of biopsy realised during the coloscopy
219413724|NCT07083310|BEHAVIORAL|Health Education|Structured group education focused on breast cancer awareness, risk reduction, and early detection.
219413725|NCT07083310|BEHAVIORAL|Motivational Interviewing|Individual counseling sessions using motivational interviewing to enhance screening behavior.
219413726|NCT07084363|DEVICE|Quantitative monitoring|The TetraGraph TOF monitor will be used to quantitatively assess the TOF-ratio. Quantitative monitoring includes objective measurement of the TOF-ratio, as defined by the ratio between the first and the fourth muscular responses and is quantified by acceleromyography. A TOF twitch response ratio equal or greater to 95% (TOF0.95) will be targeted prior to extubation. If TOF0.95 is not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
219413727|NCT07084363|OTHER|Qualitative monitoring|Clinicians will assess the TOF-ratio. Qualitative monitoring includes subjective assessment of the count and the amplitude of the muscular responses related to neuromuscular block depth. A TOF twitch response count of 4 similarly strong twitches will be targeted prior to extubation. If 4 similarly strong TOF twitch responses are not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
219413728|NCT07084545|DEVICE|CT LUCIA 621P Intraocular Lens Implantation|The intervention consists of bilateral implantation of the CT LUCIA 621P intraocular lens (IOL) during routine cataract surgery in patients with a history of myopic corneal laser vision correction. The CT LUCIA 621P IOL is an approved, single-piece, hydrophobic acrylic lens designed to provide improved visual quality and refractive stability. Implantation is performed following each investigator's standard surgical procedures, including preoperative preparation, operative technique, and postoperative care. IOL power calculation uses the ZEISS Cataract Workflow platform with the VERACITY system and Barrett True-K with TK formula, incorporating the VERION Optical Coherence (VOC) technology.
219413729|NCT07083336|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
219413730|NCT07082088|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
219413731|NCT07084662|DRUG|Xinlikang capsules|Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks
219413732|NCT07084662|DRUG|mimic capsules|mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.
219413733|NCT03732391|DRUG|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
219413734|NCT01086046|DRUG|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
219413735|NCT05693090|DRUG|Tipifarnib|Oral administration
219413736|NCT05693090|DRUG|Osimertinib|Oral administration
219413737|NCT03750071|BIOLOGICAL|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
219413738|NCT03750071|BIOLOGICAL|Avelumab|Monoclonal anti-PD-L1 Antibody
219413739|NCT00040547|DRUG|Farnesyl Protein Transferase Inhibitor|
219413740|NCT00171028|DRUG|valsartan|
219413741|NCT02214485|BEHAVIORAL|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
219570758|NCT06617637|OTHER|Aerobic Based Virtual Reality Exercise Training|"With Aerobic Based Virtual Reality Exercise Training, participants will perform aerobic exercise training with the Xbox Kinect 360 game Your Shape Fitness Evolved 2012. Your Shape Fitness Evolved 2012 is a game that requires basic coordination and is designed to improve the fitness levels of individuals. The game is used as an entertaining aerobic training tool that includes many aerobic activities such as boxing, yoga, dancing, etc. with adjustable difficulty levels."
219413742|NCT02214485|BEHAVIORAL|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
219413743|NCT03201367|DRUG|Rivaroxaban|Rivaroxaban 10 mg/12 hour
219413744|NCT03201367|OTHER|symptomatic therapy for ascites, abdominal pain|
219413745|NCT02604810|BIOLOGICAL|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
219413746|NCT02604810|BIOLOGICAL|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
219413747|NCT05718206|DEVICE|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
219413748|NCT01125657|DRUG|YM150|oral
219413749|NCT03297307|BEHAVIORAL|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
219413750|NCT02458157|DRUG|Furosemide (Furix)|"* Loading dose: 40 mg I.V.~* Infusion rate 40 mg/h~* Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
219413751|NCT02458157|OTHER|Continuous renal replacement therapy (CRRT)|"* Initiated in case of contraindications or inadequate effect of furosemide.~* Fluid removal is started at 2 ml/kg/h~* The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
219003840|NCT03483051|DRUG|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
219003841|NCT06406283|BEHAVIORAL|High-Intensity Functional Training (HIFT)|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements."
219413752|NCT02458157|OTHER|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~* Mottling beyond the edge of kneecaps~* Hypotension (MAP \< 50) resistant to inotropes and vasopressors~* Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~1. Fluid removal is paused~2. A crystalloid fluid bolus of 250-500 ml is given~3. Circulatory status is reevaluated within 30 minutes~4. Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~5. Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
219413753|NCT02458157|OTHER|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~* Hyperkalaemia (p-K+ \> 6 mmol/l)~* Severe metabolic acidosis attributable to AKI (pH \< 7.25 and standard base excess \< -10 mmol/l) resistant to IV bicarbonate infusion~* Severe respiratory failure with PaO2/FiO2 \< 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~* Progressive azotaemia and a blood urea nitrogen (BUN) \> 25 mmol/l."
219413754|NCT06249256|BIOLOGICAL|Fast CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
219413755|NCT02389712|DRUG|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
219413756|NCT02389712|DRUG|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
219413757|NCT02909998|OTHER|Blood sample|Conservation at the end of the blood sample
219413758|NCT05286073|PROCEDURE|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
219413759|NCT02625324|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
219413760|NCT05331950|OTHER|Office Workers|Office Workers which will be observed/exposed with different task and different factors
219413761|NCT01828918|GENETIC|microRNAs|
219413762|NCT01446679|DRUG|atrovastatin|oral
219413763|NCT06209814|DEVICE|Conventional denture|Patients in this group received conventional maxillary and mandibular complete dentures. The patients used these dentures for 45 days. Then, the conventional maxillary denture was replaced by open faced denture with soft acryl resin wing.
219413764|NCT06209814|DEVICE|Maxillary open-faced denture|Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
219413765|NCT05665621|OTHER|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
219413766|NCT02337595|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
219413767|NCT05585086|OTHER|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
219413768|NCT00823524|BIOLOGICAL|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
219413769|NCT05875558|PROCEDURE|M-TACE|Lipiodol combined with microspheres
219413770|NCT01196650|DRUG|IN 10 003 formulation A|
219413771|NCT01196650|DRUG|IN 10 003 formulation B|
219413772|NCT01196650|DRUG|Placebo capsules|
219003842|NCT06406283|BEHAVIORAL|Mindfulness-Based Stress Reduction Program (MBSR)|This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
219413773|NCT03534063|GENETIC|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
219413774|NCT00834704|DRUG|PEGPH20|PEGylated recombinant human hyaluronidase
219413775|NCT00734344|DRUG|Raltegravir|Raltegravir 400 mg. BID
219413776|NCT00734344|DRUG|Efavirenz|600 mg once daily
219413777|NCT00734344|DRUG|Emtricitibine|200mg once daily
219570759|NCT06617637|OTHER|Traditional Aerobic Exercise Training|Using a treadmill, participants will be put through an exercise training consisting of a 10-minute warm-up at 0 degree incline, a 20-30-minute (by increasing the walking time by 5 minutes at the end of the first four weeks and the beginning of the last four weeks) walking at 40-80% of the heart rate reserve (moderate-vigorous intensity) and a 10-minute cool-down period. Treadmill walking levels will be changed if necessary to ensure the targeted exercise intensity.
219570760|NCT04490226|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
219570761|NCT04490226|DIETARY_SUPPLEMENT|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
219570762|NCT04490226|DIETARY_SUPPLEMENT|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
219570763|NCT04490226|DIETARY_SUPPLEMENT|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
219570764|NCT06494800|DIAGNOSTIC_TEST|True cut needle biobsy|The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
219570765|NCT06033157|BEHAVIORAL|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
219570766|NCT01826461|DRUG|PDI-192|
219570767|NCT01826461|DRUG|Vehicle|
219570768|NCT03594409|DIAGNOSTIC_TEST|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
219570769|NCT02327507|BEHAVIORAL|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
219570770|NCT01651611|BEHAVIORAL|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
219570771|NCT01651611|BEHAVIORAL|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
219413778|NCT00734344|DRUG|Tenofovir disoproxil once daily|300mg once daily
219413779|NCT00734344|DRUG|Tenofovir disoproxil twice daily|300mg twice daily
219570772|NCT01651611|BEHAVIORAL|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
219570773|NCT01651611|BEHAVIORAL|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
219570774|NCT02173652|DRUG|BI 1356, high dose|
219570775|NCT02173652|DRUG|BI 1356, low dose|
219570776|NCT00733031|DRUG|AZD6918|liquid suspension, daily, oral dose
219570777|NCT00733031|DRUG|gemcitabine|intravenous, doses are on an intermittent schedule
219413780|NCT04342182|BIOLOGICAL|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
219570778|NCT00733031|DRUG|pemetrexed|intravenous, dose administered every 21-days
219570779|NCT00256776|DRUG|Velcade (Bortezomib)|
219413781|NCT00000585|DRUG|penicillin|
219413782|NCT01832012|OTHER|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
219413783|NCT01832012|OTHER|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
219570780|NCT00256776|DRUG|Thalidomide|
219570781|NCT00256776|DRUG|Dexamethasone|
219570782|NCT01039194|DRUG|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
219570783|NCT01039194|DRUG|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
219570784|NCT01039194|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
219570785|NCT00431782|DRUG|ATI-5923|
219413784|NCT01116687|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219413785|NCT01116687|OTHER|laboratory biomarker analysis|Correlative studies
219413786|NCT04265170|DEVICE|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
219413787|NCT03294408|DIAGNOSTIC_TEST|multimodal imaging|
219413788|NCT00506571|DRUG|S-1, irinotecan, oxaliplatin|
219413789|NCT02201381|DRUG|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
219413790|NCT01975077|DRUG|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
219413791|NCT00371111|DRUG|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
219413792|NCT00371111|DRUG|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
219413793|NCT00484536|DRUG|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
219413794|NCT00484536|DRUG|placebo|capsules, once daily
219413795|NCT00484536|DRUG|CDP323|250 mg Capsules, 500 mg, once daily
219413796|NCT00165841|DRUG|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
219413797|NCT05208203|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
219413798|NCT06129396|OTHER|Aerobic exercise|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with HR at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
219413799|NCT06129396|OTHER|Video-watching|The video-watching group will be asked to watch a nature documentary for 30 mins
219413800|NCT00796094|OTHER|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
219413801|NCT03874624|DIAGNOSTIC_TEST|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
219413802|NCT01925638|DRUG|BAY86-9766|
219413803|NCT01925638|DRUG|Ketoconazole|
219413804|NCT05566652|DEVICE|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
219413805|NCT05566652|DRUG|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
219413806|NCT05248971|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
219413807|NCT01487096|DRUG|Teriflunomide|"film-coated tablet~oral administration"
219413808|NCT01487096|DRUG|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
219413809|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
219413810|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
219413811|NCT03933423|DEVICE|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
219413812|NCT04768335|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
219413813|NCT05015205|OTHER|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
219413814|NCT05015205|OTHER|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
219413815|NCT02860845|DEVICE|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
219413816|NCT02860845|DRUG|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
219413817|NCT02860845|DRUG|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
219413818|NCT02791971|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
219570786|NCT03382249|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
219570787|NCT03382249|COMBINATION_PRODUCT|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
219413819|NCT02791971|BEHAVIORAL|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
219413820|NCT02638896|DRUG|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
219413821|NCT02638896|DRUG|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
219413822|NCT02638896|DRUG|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
219413823|NCT02638896|DRUG|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
219413824|NCT05123898|PROCEDURE|Soft tissue augmentation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
219570788|NCT04924374|DIETARY_SUPPLEMENT|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
219570789|NCT04924374|DRUG|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
219413825|NCT06018935|OTHER|No intervention|No intervention
219413826|NCT03196193|PROCEDURE|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
219413827|NCT03196193|DEVICE|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
219413828|NCT03196193|DEVICE|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
219570790|NCT00751738|DRUG|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
219413829|NCT03925961|OTHER|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
219413830|NCT02709083|DRUG|Dasatinib|Given orally
219413831|NCT02709083|DRUG|Imatinib Mesylate|Given orally
219413832|NCT02709083|DRUG|Nilotinib|Given orally
219413833|NCT05551598|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
219413834|NCT02029352|DRUG|Sinecatechins 10%|
219413835|NCT02029352|DRUG|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
219413836|NCT04262401|BEHAVIORAL|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
219413837|NCT04262401|BEHAVIORAL|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
219413838|NCT00061919|DRUG|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
219413839|NCT00061919|DRUG|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
219413840|NCT00143975|DRUG|Cytarabine|3 g/m2 bid. i.v day 1-3
219413841|NCT00143975|DRUG|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
219413842|NCT00143975|DRUG|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
219413843|NCT00143975|DRUG|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
219413844|NCT04018196|OTHER|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
219413845|NCT04018196|OTHER|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
219413846|NCT04018196|OTHER|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
219413847|NCT04018196|OTHER|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
219413848|NCT03498417|DIAGNOSTIC_TEST|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
219413849|NCT01697267|BIOLOGICAL|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
219413850|NCT01697267|DRUG|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
219413851|NCT03311399|OTHER|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
219570791|NCT01555827|OTHER|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~* Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~* Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~* Wide-field colour and autofluorescence imaging (Optomap)~* Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~* Age, gender~* educational level~* smoking~* cardiovascular diseases, current medications~* scores at neuropsychological tests"
219413852|NCT03311399|OTHER|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
219413853|NCT03677310|DRUG|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
219413854|NCT03677310|DRUG|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
219413855|NCT00333619|BEHAVIORAL|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
219413856|NCT00333619|BEHAVIORAL|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
219413857|NCT02031822|PROCEDURE|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
219413858|NCT04311801|DIAGNOSTIC_TEST|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
219413859|NCT01240512|DRUG|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
219413860|NCT02909842|DIETARY_SUPPLEMENT|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
219413861|NCT02909842|DIETARY_SUPPLEMENT|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
219570792|NCT03815968|OTHER|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
219413862|NCT02909842|BIOLOGICAL|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
219413863|NCT05874687|DRUG|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
219413864|NCT04446026|DRUG|teneligliptin|teneligliptin 20mg PO qd for 24weeks
219413865|NCT04446026|DRUG|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
219413866|NCT03076866|OTHER|observational follow-up:clinical, radiological et biological|
219413867|NCT02871193|DRUG|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
219413868|NCT02871193|DRUG|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
219413869|NCT02871193|OTHER|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
219413870|NCT04780958|OTHER|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
219413871|NCT03915236|DEVICE|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
219413872|NCT03915236|OTHER|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
219413873|NCT04031404|DEVICE|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
219413874|NCT01650792|DRUG|Aspirin|
219413875|NCT04826458|DEVICE|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
219413876|NCT04826458|OTHER|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
219413877|NCT02042729|DRUG|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
219413878|NCT02042729|DRUG|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
219570793|NCT04259255|DRUG|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
219570794|NCT00911755|PROCEDURE|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
219570795|NCT00911755|PROCEDURE|Endotracheal Intubation|
219003843|NCT06406283|BEHAVIORAL|Qigong|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition."
219003844|NCT00395369|DRUG|intraoperative aprotinin administration|
219003845|NCT06021145|DRUG|Empagliflozin|26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
219413879|NCT02042729|DRUG|E2022 Matching Placebo- Current Formula Tape|
219413880|NCT02042729|DRUG|E2022 Matching Placebo- New Formula Tape|
219570796|NCT00685802|DRUG|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
219570797|NCT00685802|DRUG|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
219570798|NCT03204071|DRUG|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
219570799|NCT03204071|DRUG|Aloevera|Oral prophylaxis followed by placement of aloevera gel
219570800|NCT03204071|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
219570801|NCT04966364|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
219413881|NCT02834546|BIOLOGICAL|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
219413882|NCT03496467|COMBINATION_PRODUCT|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
219413883|NCT03496467|COMBINATION_PRODUCT|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
219413884|NCT04762147|DRUG|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
219413885|NCT04762147|DRUG|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
219413886|NCT02150473|DRUG|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
219570802|NCT04966364|DEVICE|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
219757564|NCT05721079|DEVICE|ECP (Extracorporeal Photopheresis System)|Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
219757565|NCT06068192|OTHER|no intervention|no intervention
219757566|NCT05150626|DRUG|DBPR108 tablets|Drug: DBPR108, tablets, oral
219757567|NCT02625779|DRUG|Valproate and Placebo|
219413887|NCT02150473|DRUG|Placebo|Placebo the same amount as adalimumab
219413888|NCT05583981|OTHER|Interview|Participate in interview
219413889|NCT01206010|DRUG|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
219413890|NCT01206010|DRUG|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
219413891|NCT01206010|DRUG|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
219413892|NCT00062634|BEHAVIORAL|Female condom skills training|
219570803|NCT06390202|OTHER|no intervention|there is no intervention in this study
219570804|NCT03878888|DRUG|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
219570805|NCT02708888|OTHER|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
219570806|NCT02708888|OTHER|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
219570807|NCT03998436|DRUG|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
219190459|NCT04142866|DEVICE|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
219190460|NCT04142866|DEVICE|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
219190461|NCT04142866|BEHAVIORAL|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
219190462|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
219190463|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
219190464|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
219190465|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
219190466|NCT02668692|DRUG|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
219190467|NCT02668692|DRUG|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
219190468|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
219190469|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
219190470|NCT03562832|DRUG|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
219570808|NCT03998436|OTHER|Only Standard of Care|Only Standard of Care treatment
219570809|NCT03998436|OTHER|Vehicle Gel|Vehicle gel application along with Standard of Care
219570810|NCT00964288|DRUG|GSK1014802 low dose|oral tablet
219570811|NCT00964288|DRUG|Lidocaine|positive control
219570812|NCT00964288|DRUG|GSK1014802 high dose|oral tablet
219570813|NCT00964288|DRUG|Placebo|To match GSK drug and positive control
219570814|NCT03650959|OTHER|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
219757568|NCT02625779|DRUG|Valproate and Cytidine-containing Drug|
219757569|NCT02625779|DRUG|Valproate and Creatine-containing Drug|
219757570|NCT06530459|DRUG|Menopausal hormone therapy|Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month
219757571|NCT06530459|BEHAVIORAL|Exercise training|Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.
219757572|NCT06530459|COMBINATION_PRODUCT|Menopausal hormone therapy + exercise training|"1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month~2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week."
219757573|NCT03713801|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
219757574|NCT03713801|DRUG|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
219757575|NCT06376825|BEHAVIORAL|MyLife: An internet-based self-help program to reduce burnout|MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
219757576|NCT01296165|BEHAVIORAL|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
219757577|NCT02565459|BIOLOGICAL|Mesenchymal Stromal Cells|
219757578|NCT06109727|DEVICE|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
219413893|NCT01064193|PROCEDURE|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative."
219413894|NCT01064193|PROCEDURE|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
219413895|NCT01734486|DRUG|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
219413896|NCT01734486|DRUG|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
219413897|NCT02673892|OTHER|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
219413898|NCT03791645|BEHAVIORAL|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
219570815|NCT02447159|BEHAVIORAL|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
219413899|NCT06196957|COMBINATION_PRODUCT|pursed lip breathing|pursed lip breathing
219413900|NCT03904524|BEHAVIORAL|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
219413901|NCT02796391|DRUG|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
219570816|NCT03336242|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219570817|NCT00514969|DRUG|Imatinib (STI571)|
219003846|NCT06021145|DRUG|Placebo|26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
219413902|NCT02796391|BEHAVIORAL|One on One Counseling|All participants will receive One on One Counseling.
219413903|NCT02681055|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
219413904|NCT02695524|OTHER|Scapula-focused exercises|
219413905|NCT02695524|OTHER|Motor control exercises|
219413906|NCT05582265|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219413907|NCT05582265|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219570818|NCT03014193|DEVICE|Semiquantitative Multi-Level Pregnancy Test|
219570819|NCT02964819|OTHER|exercise|
219570820|NCT02964819|DEVICE|Interferential current therapy|
219570821|NCT02964819|DEVICE|Therapeutic Ultrasound|
219570822|NCT05421793|OTHER|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
219190471|NCT04027140|DEVICE|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
219190472|NCT01585805|PROCEDURE|Biopsy|Undergo biopsy
219190473|NCT01585805|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
219190474|NCT01585805|DRUG|Cisplatin|Given IV
219190475|NCT01585805|PROCEDURE|Computed Tomography|Undergo CT
219190476|NCT01585805|DRUG|Gemcitabine|Given IV
219190477|NCT01585805|DRUG|Gemcitabine Hydrochloride|Given IV
219190478|NCT01585805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219413908|NCT05582265|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219413909|NCT05582265|PROCEDURE|Surgical resection|Standard of care
219413910|NCT05582265|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219413911|NCT05582265|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219413912|NCT05582265|RADIATION|Radiation|Recommended, standard of care
219413913|NCT05582265|DRUG|Carboplatin (neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219413914|NCT05582265|DRUG|Carboplatin (adjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219190479|NCT01585805|DRUG|Veliparib|Given PO
219190480|NCT03514069|DRUG|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
219190481|NCT03514069|RADIATION|radiation|60gy for 6 weeks
219190482|NCT03514069|DRUG|temozolomide|75mg/m2
219190483|NCT06079775|DRUG|Xeruborbactam Oral Prodrug|Experimental
219190484|NCT06079775|DRUG|Ceftibuten|Experimental
219190485|NCT06079775|DRUG|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
219190486|NCT06079775|DRUG|Ceftibuten Placebo|Placebo Comparator
219190487|NCT00595049|DRUG|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
219190488|NCT05640479|DRUG|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
219190489|NCT05640479|DRUG|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
219190490|NCT01957722|PROCEDURE|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
219190491|NCT01957722|BIOLOGICAL|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
219190492|NCT04567238|BEHAVIORAL|Mobile contingency management|Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
219190493|NCT04736121|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
219190494|NCT04631744|DRUG|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
219413915|NCT00396240|DRUG|Rosuvastatin|
219413916|NCT00396240|PROCEDURE|Initiatives to improve compliance|
219413917|NCT02155764|DEVICE|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
219413918|NCT02155764|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
219413919|NCT02155764|DEVICE|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
219413920|NCT01427283|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
219413921|NCT01427283|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
219413922|NCT01427283|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
219413923|NCT00831441|DRUG|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
219413924|NCT00831441|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
219413925|NCT05674344|DEVICE|Masimo Temperature device|Non-invasive temperature device
219413926|NCT00169117|BEHAVIORAL|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
219413927|NCT02483104|DRUG|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
219413928|NCT02483104|DRUG|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
219413929|NCT02483104|DRUG|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
219413930|NCT04719676|OTHER|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
219413931|NCT04719676|OTHER|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
219413932|NCT00111917|DRUG|Infliximab|anti-TNF
219413933|NCT00111917|OTHER|Placebo|Placebo infusion
219413934|NCT01728753|DRUG|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
219413935|NCT01728753|DRUG|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
219570823|NCT01017419|BEHAVIORAL|Counseling|Informational Counseling provided after hearing aid fitting
219191928|NCT06587906|OTHER|Pulmonary ultrasound examination|All ultrasound scans were performed by the same anaesthetists. Pulmonary ultrasound examination was performed at two time points for each patient: 20 min before starting mechanical ventilation of the lungs when patients were placed in the supine position(preoperative), 20 min after after surgery end at the time the patient was placed in the supine position (postoperative), before Intubation and after extubation Patientswere scanned in the supine position following the pulmonary ultrasound examination method The thorax was divided by the anterior axillary line, the posterior axillary line, and a horizontal line beneath nipple. Twelve intercostal spaces of each area were scanned and analysed. Aeration loss was assessedby calculating the modified LUS score that is calculated mainly using the amount of B-line The pulmonary ultrasound score of the hemithorax (0-18).
219413936|NCT01728753|DRUG|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
219413937|NCT01728753|DRUG|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
219413938|NCT00798655|DRUG|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
219413939|NCT00798655|DRUG|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
219413940|NCT00798655|RADIATION|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
219413941|NCT03119844|OTHER|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
219413942|NCT03119844|OTHER|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
219413943|NCT03119844|OTHER|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
219413944|NCT03754062|DRUG|Placebo - Cap|Administration of Placebo by pill.
219413945|NCT03754062|DRUG|L-dopa|Administration of L-dopa by pill.
219413946|NCT03754062|DRUG|Haloperidol|Administration of Haloperidol by pill.
219413947|NCT04600050|OTHER|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
219413948|NCT04600050|OTHER|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
219413949|NCT03720821|BEHAVIORAL|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
219413950|NCT00960934|DRUG|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
219413951|NCT00960934|DRUG|Placebo|Dose-matched oral placebo to MK-5442
219413952|NCT00960934|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
219570824|NCT04774341|DRUG|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
219570825|NCT03494114|DRUG|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
219570826|NCT03421782|BEHAVIORAL|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
219570827|NCT03421782|BEHAVIORAL|Exercise Intervention|Undergo POWER exercise intervention
219570828|NCT00251225|DRUG|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
219570829|NCT00251225|DRUG|Docetaxel|60 mg/m\^2 administered IV on day 0
219413953|NCT00960934|DIETARY_SUPPLEMENT|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
219413954|NCT04958421|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
219413955|NCT00748085|DEVICE|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
219413956|NCT02363270|PROCEDURE|Ketamine|IV Push or or IV Drip
219413957|NCT02311309|OTHER|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.
219413958|NCT02311309|OTHER|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
219413959|NCT01354041|BEHAVIORAL|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
219413960|NCT05254613|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
219413961|NCT05254613|DRUG|Placebo|Placebo will be administered as SC infusion(s).
219413962|NCT06371651|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing creatine and guanidinoacetic acid
219413963|NCT06371651|DIETARY_SUPPLEMENT|Placebo|Inert substance
219570830|NCT02904668|OTHER|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
219191929|NCT06793306|OTHER|Age|Breast cancer patients were divided into young breast cancer and non-young breast cancer by age 35
219191930|NCT06793306|OTHER|combination therapy|To observe and compare the difference in diagnosis, combined treatment and prognosis between young and non-young breast cancer
219413964|NCT02413619|PROCEDURE|Vitrectomy|Vitrectomy
219413965|NCT02413619|PROCEDURE|Cataract surgery|Cataract surgery
219413966|NCT02413619|PROCEDURE|Combined surgery|Combined vitrectomy and cataract surgery at the same time
219191931|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
219413967|NCT06187116|OTHER|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
219413968|NCT06187116|OTHER|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
219413969|NCT03408652|DRUG|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
219413970|NCT04973033|DRUG|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
219413971|NCT05524870|OTHER|Mobilization|Movement with mobilization plus exercise
219413972|NCT06102252|DRUG|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
219570831|NCT03177382|RADIATION|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
219570832|NCT03177382|RADIATION|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
219570833|NCT03177382|PROCEDURE|TME|The TME operation will be given after the end of the neoadjuvant treatment.
219570834|NCT03177382|DRUG|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
219757579|NCT05137158|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
219191932|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
219191933|NCT06827145|DRUG|Vebreltinib|Vebreltinib 100mg oral BID
219191934|NCT06827145|DRUG|Osimertinib|Osimertinib 80mg oral once daily.
219413973|NCT06102252|DRUG|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
219413974|NCT01085058|DRUG|lenograstim|
219413975|NCT06175962|BEHAVIORAL|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
219413976|NCT03598569|OTHER|dyspnea|dyspnea assessment
219413977|NCT06248905|OTHER|Rehabilitation program based on the strengthening of gluteal muscles|Physiotherapy program (8 weeks)
219413978|NCT06248905|OTHER|Extracorporeal shock wave therapy|Focused shock wave therapy (3 weeks)
219413979|NCT05835245|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
219413980|NCT05835245|DRUG|Sintilimab|a PD-1 immune check inhibitor
219413981|NCT05835245|DRUG|Lenvatinib|Lenvatinib capsules
219413982|NCT02387372|DRUG|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
219570835|NCT02224573|DRUG|GWP42003-P|
219757580|NCT05137158|DEVICE|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
219757581|NCT03202173|DIAGNOSTIC_TEST|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
219413983|NCT02387372|DRUG|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
219413984|NCT05570045|DIETARY_SUPPLEMENT|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
219413985|NCT04133805|DIETARY_SUPPLEMENT|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
219413986|NCT00848549|DRUG|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
219190495|NCT04817761|DRUG|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
219413987|NCT00848549|DRUG|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
219413988|NCT05740449|DRUG|Decitabine|intravenous
219413989|NCT05740449|DRUG|Venetoclax|oral
219413990|NCT05740449|DRUG|Navitoclax|oral
219413991|NCT05740449|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
219413992|NCT06361264|COMBINATION_PRODUCT|Karanahan|During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
219413993|NCT02961686|RADIATION|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
219413994|NCT03916471|DEVICE|Solyx™ SIS System|Single-incision sling system
219413995|NCT03916471|DEVICE|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
219413996|NCT04136080|OTHER|vasopressors|control the mean arterial pressure with vasopressors
219413997|NCT00039442|DRUG|Capecitabine|Given orally
219413998|NCT00039442|OTHER|Laboratory Biomarker Analysis|Correlative studies
219413999|NCT03921138|OTHER|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
219414000|NCT02600000|RADIATION|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
219414001|NCT02600000|DEVICE|Cardiopulmonary test|Assessment of maximal functional capacity
219414002|NCT02600000|DEVICE|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
219570836|NCT05749679|OTHER|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance"
219414003|NCT02600000|DEVICE|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
219414004|NCT05338281|DEVICE|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
219414005|NCT01013168|PROCEDURE|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
219414006|NCT00544011|BIOLOGICAL|bevacizumab|
219570837|NCT05749679|OTHER|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
219414007|NCT00544011|DRUG|capecitabine|
219570838|NCT00003020|BIOLOGICAL|LMB-7 immunotoxin|
219003847|NCT00492908|DEVICE|Helistent Titan2 (Titanium coated stent)|Titan2
219003848|NCT00492908|DEVICE|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
219414008|NCT00544011|DRUG|fluorouracil|
219414009|NCT00544011|DRUG|irinotecan hydrochloride|
219003849|NCT06261203|DRUG|Aspirin|To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
219414010|NCT00544011|OTHER|diagnostic laboratory biomarker analysis|
219414011|NCT03996109|BEHAVIORAL|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 6 months. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
219414012|NCT03996109|BEHAVIORAL|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 6 months. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
219414013|NCT01842841|DRUG|velaglucerase alfa|15-60 U/kg, EOW
219414014|NCT01418053|DRUG|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
219414015|NCT01418053|DRUG|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
219003850|NCT01442675|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
219003851|NCT04059978|DRUG|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
219003852|NCT04059978|DRUG|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
219003853|NCT04059978|DRUG|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
219003854|NCT00006361|DRUG|semaxanib|
219003855|NCT01919723|DRUG|Ticagrelor|Ticagrelor loading dose
219414016|NCT05963048|DRUG|Rituximab|IV infusion 1000 mg
219414017|NCT05963048|DRUG|IL6 inhibitor|6 mg/kg I V infusion monthly
219414018|NCT04185883|DRUG|Sotorasib|Sotorasib administered orally as a tablet.
219414019|NCT04185883|DRUG|Trametinib|Trametinib administered orally as a tablet.
219414020|NCT04185883|DRUG|RMC-4630|RMC-4630 administered orally as a capsule.
219414021|NCT04185883|DRUG|Afatinib|afatinib administered orally as a tablet.
219414022|NCT04185883|DRUG|Pembrolizumab|pembrolizumab administered as an intravenous (IV) infusion.
219414023|NCT04185883|DRUG|Panitumumab|Panitumumab administered as an IV infusion.
219414024|NCT04185883|DRUG|Carboplatin, pemetrexed, docetaxel, paclitaxel|Carboplatin, pemetrexed, docetaxel administered as an IV infusion.
219414025|NCT04185883|DRUG|Atezolizumab|Atezolizumab administered as an IV injection.
219414026|NCT04185883|DRUG|Palbociclib|Palbociclib administered orally as a tablet.
219414027|NCT04185883|DRUG|MVASI® (bevacizumab-awwb)|MVASI® (bevacizumab-awwb) administered as an IV infusion.
219414028|NCT04185883|DRUG|TNO155|TNO155 administered orally as a capsule.
219414029|NCT04185883|DRUG|IV Chemotherapy (Regimen 1)|Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
219003856|NCT01919723|DRUG|Eptifibatide|i.v. infusion
219414030|NCT04185883|DRUG|IV Chemotherapy (Regimen 2)|IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
219414031|NCT04185883|DRUG|BI 1701963|BI 1701963 administered orally
219414032|NCT04185883|DRUG|AMG 404|AMG 404 administered as an IV infusion.
219570839|NCT05179694|DIAGNOSTIC_TEST|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
219570840|NCT01456091|BEHAVIORAL|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
219570841|NCT03132194|DRUG|DPSG 7.5%|topical gel
219570842|NCT03132194|DRUG|Aczone|topical gel
219570843|NCT03132194|DRUG|Placebo|topical gel
219570844|NCT02546362|DEVICE|Cefaly|
219570845|NCT01828944|DIETARY_SUPPLEMENT|olive oil|
219570846|NCT00386126|DRUG|Iron Sucrose IV 200mg, once a week, for 5 weeks|
219570847|NCT00386126|DRUG|Ferrous sulfate 200mg PO TID, for 8 weeks|
219570848|NCT05036395|OTHER|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
219570849|NCT05036395|OTHER|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
219570850|NCT05206448|DRUG|Letrozole|Letrozole tablet
219570851|NCT05206448|DRUG|Clomiphene Citrate|Clomiphene Citrate tablet
219570852|NCT01481857|OTHER|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
219570853|NCT01481857|OTHER|Segmental trunk exercise|Segmental trunk exercise
219003857|NCT01699282|BEHAVIORAL|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
219003858|NCT01699282|BEHAVIORAL|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
219003859|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
219003860|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
219003861|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
219003862|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
219414033|NCT04185883|DRUG|Everolimus|Everolimus administered orally.
219414034|NCT02860637|OTHER|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
219414035|NCT01902953|DRUG|Lymphoseek and VBD Sln dissection|See detailed description of study design
219414036|NCT03809221|DRUG|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
219414037|NCT02094053|DRUG|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
219414038|NCT02094053|DRUG|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
219414039|NCT02094053|DRUG|Placebo|placebo (oral) once daily, for 24 weeks
219414040|NCT05352906|DIAGNOSTIC_TEST|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
219414041|NCT04629898|BEHAVIORAL|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
219414042|NCT01248130|DRUG|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
219414043|NCT05041478|PROCEDURE|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
219414044|NCT05041478|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
219414045|NCT06205225|BEHAVIORAL|Text4HF|Behavioral text messages about heart failure self-care
219414046|NCT06205225|BEHAVIORAL|MyApps|consumer mobile health apps and devices for heart failure self-care
219414047|NCT06205225|BEHAVIORAL|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
219414048|NCT06205225|BEHAVIORAL|Enhanced Usual Care|Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
219414049|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
219414050|NCT00305643|DRUG|Capecitabine|Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
219414051|NCT00305643|DRUG|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
219414052|NCT00305643|PROCEDURE|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
219414053|NCT00305643|DRUG|Placebo|Oral placebo twice daily on days 1-21
219414054|NCT05086185|DIAGNOSTIC_TEST|Kalemic Response to Orange Juice|100% pulp-free orange juice
219414055|NCT05086185|DIETARY_SUPPLEMENT|Kalemic Response to Orange Juice with Fiber|100% pulp-free orange juice with psyllium-based fiber added
219414056|NCT04087343|BEHAVIORAL|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
219414057|NCT04087343|BEHAVIORAL|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
219414058|NCT06683365|PROCEDURE|Sural Nerve Graft to the Substantia Nigra|Participants assigned to this arm will have the sural nerve biopsied from one of their ankles. This cellular tissue will be deposited bilaterally into the substantia nigra area of their brain by a specialized cannula via bilateral scalp incisions and skull burr holes.
219414059|NCT06683365|PROCEDURE|Sham surgery|Participants assigned to this arm will have the sural nerve from one of their ankles biopsied in the same fashion as the experimental arm. Bilateral incisions will be made on the participants scalp but no burr holes into the skull and no cannula passes into the brain will occur.
219570854|NCT05748197|BIOLOGICAL|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
219570855|NCT05748197|DRUG|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
219570856|NCT06513585|PROCEDURE|Superselective adrenal artery embolization or adrenalectomy|Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.
219570857|NCT06260813|DIAGNOSTIC_TEST|Radiography|X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
219570858|NCT06260813|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
219570859|NCT06260813|DIAGNOSTIC_TEST|MRI|MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
219570860|NCT06260813|DIAGNOSTIC_TEST|CT-scan|CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
219003863|NCT00752232|OTHER|PBS|IM injection, Day 1, month 3, 6, 9, 12
219003864|NCT01103648|DRUG|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
219003865|NCT01103648|DRUG|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
219570861|NCT06260813|DIAGNOSTIC_TEST|Gait analysis|This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
219570862|NCT05346354|DRUG|Ravulizumab|"Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight."
219414060|NCT05456204|DRUG|Pharmacological cardioversion with Refralon|"1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
219414061|NCT04980976|DEVICE|Blind insertion technique|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
219414062|NCT04980976|DEVICE|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique
219414063|NCT04064320|BEHAVIORAL|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
219414064|NCT03134651|DEVICE|Monitoring brain function|
219414065|NCT03134651|DRUG|propofol|
219414066|NCT02974387|DRUG|Fluorometholone(FML)|
219414067|NCT02974387|DRUG|Loteprednol (Lotemax)|
219414068|NCT03398122|PROCEDURE|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
219414069|NCT03398122|DRUG|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
219414070|NCT00541138|DRUG|carboplatin|CBDCA AUC=3
219414071|NCT00541138|DRUG|tamoxifen citrate|Tamoxifen 100mg bid
219414072|NCT00541138|DRUG|topotecan hydrochloride|Topotecan 0.75 g/m2/d
219414073|NCT00541138|OTHER|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
219414074|NCT02106455|DRUG|Sodium risedronate|Sodium risedronate tablets
219414075|NCT02382341|DEVICE|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
219570863|NCT04685655|OTHER|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
219003866|NCT01103648|DRUG|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
219414076|NCT00718289|OTHER|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
219414077|NCT00718289|OTHER|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
219414078|NCT05166746|DRUG|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
219003867|NCT02324894|PROCEDURE|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
219003868|NCT02764515|DRUG|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
219003869|NCT02764515|DRUG|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
219003870|NCT05787457|OTHER|Clinical examination|
219414079|NCT05166746|OTHER|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
219414080|NCT01478438|DEVICE|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
219414081|NCT06490198|DRUG|OBI-833/OBI-821|"OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy."
219414082|NCT00316342|DEVICE|Back supports|
219414083|NCT01293149|DRUG|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
219414084|NCT01293149|DRUG|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
219570864|NCT01122316|DRUG|Metformin|3\. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
219570865|NCT06267794|DRUG|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
219570866|NCT06267794|DRUG|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
219414085|NCT02531464|OTHER|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
219414086|NCT02190747|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
219414087|NCT02190747|DRUG|Placebo|
219414088|NCT04906408|DEVICE|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
219414089|NCT04906408|DEVICE|Prineo|Incisions will be dressed with Prineo
219414090|NCT04906408|DRUG|Traditional|Incisions will be dressed with bacitracin/xeroform
219414091|NCT06388993|DEVICE|Bone Marrow Collection|Comparing the two collection systems for bone marrow aspirate
219414092|NCT01480141|DRUG|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
219414093|NCT06133634|DIETARY_SUPPLEMENT|Fisetin|Fisetin dietary supplement
219414094|NCT06133634|OTHER|Placebo|Placebo capsules identical in appearance to fisetin capsules
219414095|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
219414096|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
219414097|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
219414098|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
219414099|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
219414100|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
219414101|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
219414102|NCT05188612|COMBINATION_PRODUCT|Observational (registry)|Observational (Patient Registry)
219414103|NCT02318732|BEHAVIORAL|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
219414104|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
219414105|NCT06583876|DEVICE|Coriofix System|Treatment of functional mitral regurgitation by reducing the mitral valve annular area through ablation of the posterior annulus.
219414106|NCT02000141|PROCEDURE|Endoscopic Mucosal Resection|
219570867|NCT06267794|DRUG|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
219570868|NCT02835963|OTHER|Data collection|Usual data collection
219414107|NCT04906902|DRUG|Acalabrutinib|Tablet taken by mouth twice daily
219414108|NCT05800431|DEVICE|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
219414109|NCT04786951|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
219414110|NCT04786951|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
219414111|NCT04786951|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
219414112|NCT00312299|DEVICE|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
219414113|NCT00312299|DEVICE|Round edge PMMA IOL|Round edge PMMA IOL
219414114|NCT00312299|DEVICE|Acrysof IOL|Acrysof IOL
219414115|NCT00312299|DEVICE|square Edge PMMA IOL|Square edge PMMA intra ocular lens
219414116|NCT00312299|DEVICE|Square Edge PMMA IOL|Square Edge PMMA IOL lens
219414117|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
219414118|NCT04352322|DIETARY_SUPPLEMENT|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
219414119|NCT04352322|DIETARY_SUPPLEMENT|Placebo|oral solution with no active ingredients
219414120|NCT00187239|DEVICE|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
219414121|NCT02315287|DRUG|Pioglitazone|Comparison of two different thiazolidinediones
219414122|NCT02315287|DRUG|Lobeglitazone|Comparison of two different thiazolidinediones
219414123|NCT04718181|DRUG|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
219414124|NCT04718181|DRUG|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
219414125|NCT05834803|PROCEDURE|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
219414126|NCT05834803|PROCEDURE|Sham treatment|Optimal medical therapy and sham treatment.
219570869|NCT01661881|DRUG|Rituximab|
219570870|NCT01661881|DRUG|Bendamustine|
219570871|NCT01661881|DRUG|Cytarabine|
219570872|NCT06834568|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|t:slim X2 insulin pump with Tandem Freedom System consists of the Tandem t:slim X2 insulin pump and the Freedom algorithm embedded in the pump. Participants will also use the Dexcom G6 continuous glucose monitoring system.
219570873|NCT01560884|DRUG|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
219570874|NCT01560884|DRUG|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
219414127|NCT01241838|DEVICE|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
219414128|NCT03963245|BEHAVIORAL|Meaningful Activities and Recovery|"MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
219414129|NCT03963245|BEHAVIORAL|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
219414130|NCT01390116|DIETARY_SUPPLEMENT|Aged garlic extract|2 aged garlic extract capsules taken twice daily
219414131|NCT01390116|DIETARY_SUPPLEMENT|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
219414132|NCT02488551|DEVICE|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
219570875|NCT01560884|DRUG|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
219570876|NCT01560884|DRUG|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
219570877|NCT01958515|OTHER|research blood draw and tissue biopsy|research blood draw and tissue biopsy
219570878|NCT01626651|DRUG|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
219570879|NCT01626651|DRUG|Ketoconazole|Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
219570880|NCT06117943|OTHER|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
219570881|NCT05061914|PROCEDURE|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
219570882|NCT01359748|DEVICE|Reference sphygmomanometer|\* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
219570883|NCT01359748|DEVICE|Sphygmomanometer under test|Electronic Oscillometric method.
219570884|NCT00949988|DRUG|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
219003871|NCT05787457|OTHER|Blood testing|
219570885|NCT00730951|DIETARY_SUPPLEMENT|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
219003872|NCT05787457|OTHER|MRI|
219003873|NCT05776589|DEVICE|The mechanical ventilation mode|Changing the mechanical ventilation mode
219003874|NCT03234686|DRUG|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
219003875|NCT03234686|DRUG|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
219414133|NCT02488551|OTHER|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
219003876|NCT04938193|DIAGNOSTIC_TEST|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
219003877|NCT04502589|DRUG|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
219414134|NCT05999474|DRUG|Topical tioconazole|Laser
219570886|NCT00730951|DIETARY_SUPPLEMENT|Corn Starch|500mg Capsulated Corn Starch
219570887|NCT02249221|BIOLOGICAL|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
219570888|NCT02249221|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
219570889|NCT02651142|PROCEDURE|Patients receive SLNB|Patients receive sentinel lymph node biopsy
219570890|NCT01450241|OTHER|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
219570891|NCT01450241|OTHER|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
219570892|NCT00604084|DRUG|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
219570893|NCT00604084|DRUG|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
219570894|NCT03783988|COMBINATION_PRODUCT|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
219003878|NCT04502589|DRUG|Disulfiram|Disulfiram will be kept at 250mg daily
219003879|NCT00555321|DRUG|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
219003880|NCT00555321|DRUG|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
219190496|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
219190497|NCT05140434|DIAGNOSTIC_TEST|Exercise test|exercise test on an exercise bike with increasing load
219190498|NCT05140434|DIAGNOSTIC_TEST|Cardiac CT|cardiac CT scan
219190499|NCT04832854|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
219190500|NCT04832854|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
219190501|NCT04832854|DRUG|Carboplatin|Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
219190502|NCT04832854|DRUG|Cisplatin|Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
219190503|NCT04832854|DRUG|Pemetrexed|Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
219190504|NCT04832854|DRUG|Gemcitabine|Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
219190505|NCT04832854|DRUG|Paclitaxel|Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
219003881|NCT00555321|DRUG|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])"
219003882|NCT00555321|DRUG|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
219003883|NCT00555321|DRUG|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
219003884|NCT02235480|DRUG|Experimental Tazarotene Gel|
219003885|NCT02235480|DRUG|Placebo|
219003886|NCT00160251|DRUG|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
219003887|NCT00160251|BIOLOGICAL|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
219003888|NCT00160251|DRUG|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
219003889|NCT03178981|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
219003890|NCT03298594|DIAGNOSTIC_TEST|specific cervicograph|
219003891|NCT05571098|BEHAVIORAL|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process."
219003892|NCT05571098|BEHAVIORAL|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey"
219003893|NCT05571098|BEHAVIORAL|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
219003894|NCT05451160|DEVICE|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
219003895|NCT05451160|DEVICE|RF Ablation System|RF Ablation System
219003896|NCT03782272|DIETARY_SUPPLEMENT|Enterade|enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
219190506|NCT04889495|DRUG|Zirabev|Bevacizumab biosimilar
219190507|NCT05128903|DRUG|[18F]DPA714|"Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy"
219190508|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
219190509|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
219190510|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
219414135|NCT05405296|DEVICE|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
219414136|NCT05962996|DEVICE|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
219414137|NCT06029712|DRUG|Heart failure polypill|Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
219414138|NCT06029712|DRUG|Control Rx|GDMT delivered as individual tablets
219414139|NCT03637192|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219414140|NCT03637192|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
219414141|NCT03709810|COMBINATION_PRODUCT|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
219414142|NCT03709810|OTHER|No Adhesive|No adhesive will be applied.
219414143|NCT03065504|DIETARY_SUPPLEMENT|Turmeric|
219570895|NCT06369649|DEVICE|Coolsense and Buzzy|Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
219570896|NCT02506218|DIETARY_SUPPLEMENT|10 + 20 g protein consumption|whey isolate
219570897|NCT02506218|OTHER|30 g protein breakfast|30 g mixed meal breakfast
219414144|NCT03065504|DIETARY_SUPPLEMENT|Turmeric-containing combination tablet|
219414145|NCT03065504|DIETARY_SUPPLEMENT|Placebo tablets|
219414146|NCT05238467|OTHER|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
219414147|NCT02191423|DRUG|Oxytocin|administered pre-fMRI assessment
219570898|NCT02506218|OTHER|10 g protein breakfast|10 g mixed meal breakfast
219757582|NCT05913674|DRUG|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
219414148|NCT02191423|DRUG|placebo|administered pre-fMRI assessment
219414149|NCT02191423|BEHAVIORAL|Dyadic psychotherapy|
219414150|NCT03169452|DEVICE|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
219414151|NCT03935087|DIAGNOSTIC_TEST|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
219414152|NCT04622787|OTHER|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
219414153|NCT03364608|DRUG|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
219414154|NCT03364608|DRUG|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
219414155|NCT03364608|OTHER|Placebo MDI|Placebo MDI (2 actuations)
219414156|NCT03364608|DRUG|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
219414157|NCT03364608|DRUG|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
219414158|NCT00002358|DRUG|Sorivudine|
219414159|NCT02982304|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation Electrode
219570899|NCT01956708|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
219570900|NCT01191528|DEVICE|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
219757583|NCT02993263|DEVICE|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
219757584|NCT06565143|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
219414160|NCT02517827|DEVICE|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
219414161|NCT02517827|PROCEDURE|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
219414162|NCT03071549|DRUG|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
219570901|NCT00719979|BEHAVIORAL|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
219570902|NCT00719979|BEHAVIORAL|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
219570903|NCT00719979|BEHAVIORAL|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
219570904|NCT01905059|DRUG|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
219757585|NCT06565143|DEVICE|Sham transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
219003897|NCT03782272|DIETARY_SUPPLEMENT|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
219003898|NCT02055014|DRUG|Liraglutide|
219003899|NCT02055014|DEVICE|Duodenal-jejunal bypass liner - Endobarrier device|
219003900|NCT05083364|DRUG|ARO-C3|ARO-C3 for sc injection
219003901|NCT05083364|DRUG|Placebo|sterile normal saline (0.9% NaCl) for sc injection
219003902|NCT02840370|DEVICE|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
219003903|NCT02840370|DEVICE|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
219003904|NCT04243681|COMBINATION_PRODUCT|CD 34 and MSC infusion|Combination of stem cells
219003905|NCT04243681|DRUG|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
219414163|NCT03071549|DRUG|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
219570905|NCT01905059|DRUG|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
219570906|NCT05307406|BIOLOGICAL|Experimental|Participants will receive a single IV infusion in a double blind manner
219570907|NCT03207958|DRUG|Belimumab|-Given over 1 hour
219570908|NCT00908219|DRUG|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
219570909|NCT04154358|DIAGNOSTIC_TEST|HPV testing|will perform HPV testing with self-collected specimen
219570910|NCT03988517|OTHER|timing of receiving the drug|each group took levothyroxine in different timing
219570911|NCT00314431|PROCEDURE|Care coordination by telephone contacts with a nurse|
219570912|NCT04353024|DRUG|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
219570913|NCT04353024|DRUG|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
219570914|NCT01668121|DRUG|Symbicort Turbohaler|
219570915|NCT01668121|DRUG|Budesonide/formoterol Easyhaler|
219570916|NCT00004150|DRUG|fluorouracil|
219570917|NCT00004150|DRUG|leucovorin calcium|
219570918|NCT00004150|PROCEDURE|adjuvant therapy|
219570919|NCT00201916|PROCEDURE|5250 cGy/20 fractions over 28 days|see above
219757586|NCT01364831|BEHAVIORAL|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
219757587|NCT04035031|DRUG|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
219757588|NCT04035031|DRUG|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
219757589|NCT01221116|DRUG|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
219757590|NCT00545779|DRUG|Ibandronate|150 mg orally once monthly for 6 months
219757591|NCT01616147|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
219757592|NCT01616147|BEHAVIORAL|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
219757593|NCT02076711|DRUG|Metoprololsuccinate|
219757594|NCT02076711|DRUG|Placebo|Placebo
219757595|NCT02149966|DRUG|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
219757596|NCT02149966|DRUG|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
219757597|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
219757598|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
219414164|NCT05441137|BEHAVIORAL|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
219570920|NCT00201916|PROCEDURE|6600 cGy/33 fractions over 45 days|see above
219414165|NCT05441137|BEHAVIORAL|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
219414166|NCT02239770|DRUG|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
219570921|NCT02593396|DRUG|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
219570922|NCT02593396|DRUG|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
219570923|NCT01868763|DEVICE|telemedical devices (weighing machine and step counter)|
219570924|NCT01868763|BEHAVIORAL|care calls once per week for 12 weeks|
219570925|NCT03399578|BIOLOGICAL|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
219570926|NCT03123757|OTHER|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
219570927|NCT03123757|OTHER|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
219570928|NCT03123757|OTHER|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
219570929|NCT01345526|DEVICE|Reconval K1 Cream|
219570930|NCT01345526|DEVICE|Reconval Cream|
219570931|NCT02229565|DEVICE|Biopsy or prostatectomy|
219757599|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
219757600|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
219003906|NCT02792972|OTHER|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
219570932|NCT00913198|DRUG|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219757601|NCT05540483|DRUG|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
219757602|NCT04321655|OTHER|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
219003907|NCT02792972|OTHER|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
219570933|NCT04829760|DIETARY_SUPPLEMENT|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
219414167|NCT02239770|DRUG|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
219570934|NCT04829760|DIETARY_SUPPLEMENT|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
219570935|NCT04829760|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
219757603|NCT04321655|OTHER|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
219414168|NCT01438749|DRUG|Placebo|Single dose
219757604|NCT04321655|OTHER|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
219757605|NCT04321655|OTHER|Conventional Physiotherapy (CPT)|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
219414169|NCT01438749|DRUG|RO4917838|Single doses (3 dose levels)
219414170|NCT01438749|DRUG|diazepam|Single dose
219414171|NCT04866303|DIAGNOSTIC_TEST|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
219414172|NCT03668691|DEVICE|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
219414173|NCT00436566|BIOLOGICAL|trastuzumab|
219414174|NCT00436566|DRUG|cyclophosphamide|
219570936|NCT04317313|OTHER|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
219570937|NCT03964519|OTHER|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
219757606|NCT05221892|DRUG|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
219757607|NCT05221892|DRUG|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
219757608|NCT03732469|DRUG|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
219414175|NCT00436566|DRUG|doxorubicin hydrochloride|
219414176|NCT00436566|DRUG|lapatinib ditosylate|
219757609|NCT03732469|DRUG|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
219757610|NCT03732469|DRUG|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
219757611|NCT02434861|DRUG|Rolapitant|
219757612|NCT02434861|DRUG|Digoxin|P-gp substrate
219414177|NCT00436566|DRUG|paclitaxel|
219414178|NCT00436566|GENETIC|gene expression analysis|
219757613|NCT02434861|DRUG|Sulfasalazine|BCRP substrate
219757614|NCT02434861|DRUG|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
219757615|NCT01480778|DRUG|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
219757616|NCT01480778|DRUG|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
219757617|NCT05695105|DEVICE|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
219414179|NCT00436566|GENETIC|reverse transcriptase-polymerase chain reaction|
219414180|NCT00436566|OTHER|fluorophotometry|
219414181|NCT00436566|OTHER|laboratory biomarker analysis|
219414182|NCT00436566|OTHER|mass spectrometry|
219414183|NCT00436566|PROCEDURE|adjuvant therapy|
219414184|NCT00436566|PROCEDURE|quality-of-life assessment|
219414185|NCT04377594|PROCEDURE|Radio frequency ablation|Two different radio frequency ablation procedures
219414186|NCT00783211|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
219414187|NCT00783211|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
219570938|NCT03964519|OTHER|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
219570939|NCT03964519|OTHER|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
219414188|NCT00783211|DRUG|placebo|placebo, once daily for 15 days
219414189|NCT00923234|DRUG|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
219414190|NCT00923234|DRUG|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
219414191|NCT03077126|OTHER|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
219414192|NCT03077126|DEVICE|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
219414193|NCT03077126|DIAGNOSTIC_TEST|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
219414194|NCT03077126|PROCEDURE|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
219414195|NCT00064129|BIOLOGICAL|Ipilimumab|Given IV
219414196|NCT00064129|OTHER|Laboratory Biomarker Analysis|Correlative studies
219414197|NCT00064129|OTHER|Pharmacological Study|Correlative studies
219414198|NCT00064129|BIOLOGICAL|Sargramostim|Given SC
219414199|NCT01053845|OTHER|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
219414200|NCT02697084|OTHER|anal cancer|Anal cancer patients with TEP TDM
219414201|NCT03209635|DIETARY_SUPPLEMENT|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
219414202|NCT03209635|DIETARY_SUPPLEMENT|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
219414203|NCT02857335|BEHAVIORAL|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
219414204|NCT02983630|OTHER|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
219003908|NCT04542785|OTHER|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
219414205|NCT00698789|DRUG|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
219414206|NCT00698789|DRUG|INCB019602|20 mg in AM with placebo administration in PM
219570940|NCT00617370|DRUG|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
219570941|NCT04784884|DEVICE|HSI|diagnostic hyperspectral imaging
219570942|NCT05790954|OTHER|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
219757618|NCT05695105|DEVICE|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
219757619|NCT04594993|DEVICE|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
219414207|NCT00698789|DRUG|INCB019602|5 mg in PM with placebo administration in AM
219414208|NCT00698789|DRUG|INCB019602|20 mg in PM with placebo administration in AM
219414209|NCT00698789|DRUG|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
219414210|NCT00698789|DRUG|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
219414211|NCT00698789|DRUG|Metformin|Stable dose metformin monotherapy
219414212|NCT00510328|DEVICE|Whole Body Vibration|
219414213|NCT05649618|BIOLOGICAL|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
219414214|NCT05649618|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
219570943|NCT04015960|OTHER|no intervention|qualitative research and patient reported outcome measure (PROm) development
219757620|NCT05311423|DIAGNOSTIC_TEST|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
219570944|NCT03551873|DRUG|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
219570945|NCT02555982|DRUG|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
219570946|NCT02555982|DRUG|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
219414215|NCT05649618|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219414216|NCT05649618|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
219414217|NCT01188564|DRUG|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
219414218|NCT01188564|DRUG|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
219414219|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
219414220|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
219570947|NCT04412486|BIOLOGICAL|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
219757621|NCT02990702|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
219757622|NCT02990702|OTHER|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
219757623|NCT02990702|DRUG|Bupivacaine|
219414221|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
219414222|NCT02492997|DEVICE|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
219414223|NCT02492997|OTHER|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
219414224|NCT02892565|OTHER|Blood sample|
219414225|NCT00588250|OTHER|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
219414226|NCT04357119|PROCEDURE|One-anastomosis gastric bypass|"Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision."
219414227|NCT04886999|BEHAVIORAL|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
219414228|NCT03147274|BEHAVIORAL|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
219757624|NCT02990702|DEVICE|Ultrasound|
219757625|NCT00572559|DRUG|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
219757626|NCT00572559|DRUG|Linezolid|600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
219414229|NCT02520518|DRUG|Dapagliflozin|
219414230|NCT02520518|DRUG|Placebo|
219414231|NCT02520518|BEHAVIORAL|Weight maintenance|
219757627|NCT06644092|OTHER|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation|The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
219757628|NCT03181984|DRUG|Hemoporfin|Hemoporfin mediated photodynamic therapy
219414232|NCT02520518|BEHAVIORAL|Ad libitum dietary intake|
219414233|NCT02520518|BEHAVIORAL|Dietary restriction|
219414234|NCT04657952|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
219414235|NCT04657952|DRUG|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
219570948|NCT03768284|OTHER|Saliva or buccal sample|Saliva or buccal sample
219570949|NCT02605213|DRUG|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
219570950|NCT02605213|DRUG|Placebo|Placebo for control Group of primary sclerosing vhlangitis
219570951|NCT02605252|DRUG|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
219570952|NCT00141661|DRUG|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
219757629|NCT01356147|DRUG|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
219570953|NCT00141661|DRUG|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
219570954|NCT00141661|DRUG|Placebo Comparator|Matching placebo.
219570955|NCT02959476|DRUG|Ropivacaine|Anesthetic
219570956|NCT02959476|DRUG|Placebos|Inactive comparator
219414236|NCT01518426|DEVICE|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
219414237|NCT00000875|DRUG|Indinavir sulfate|
219414238|NCT00000875|DRUG|Diphenhydramine hydrochloride|
219414239|NCT00000875|DRUG|Lymphocytes, Activated|
219414240|NCT00000875|DRUG|Lamivudine|
219414241|NCT00000875|DRUG|Zidovudine|
219414242|NCT00000875|DRUG|Acetaminophen|
219414243|NCT00000875|DRUG|Aldesleukin|
219414244|NCT00580944|PROCEDURE|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
219414245|NCT02215408|BEHAVIORAL|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
219414246|NCT02665364|BIOLOGICAL|IFNα-Kinoid|
219414247|NCT02665364|OTHER|Placebo|
219570957|NCT01513031|OTHER|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
219570958|NCT04309526|DRUG|NCO-48 Fumarate|NCO-48 Fumarate
219003909|NCT03648268|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
219003910|NCT04405947|PROCEDURE|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
219003911|NCT02911753|OTHER|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
219414248|NCT02665364|OTHER|ISA 51 VG|
219414249|NCT03888391|DEVICE|Active TNS|
219414250|NCT00301028|BIOLOGICAL|Cetuximab|Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
219414251|NCT00301028|DRUG|Carboplatin|AUC 2 weekly for 6 courses.
219414252|NCT00301028|DRUG|Paclitaxel|135 mg/m\^2 weekly for 6 courses.
219414253|NCT00301028|PROCEDURE|Conventional Surgery|Following induction in second part of study.
219414254|NCT00301028|RADIATION|Radiation Therapy|Following induction in second part of study.
219414255|NCT00000150|PROCEDURE|Subfoveal Choroidal Neovascularization Removal|
219414256|NCT02040818|DRUG|tigecycline, N-acetylcysteine, heparin combination|
219414257|NCT02040818|DEVICE|guide-wire exchange|
219414258|NCT05487053|PROCEDURE|Single-shot adductor canal block|Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
219414259|NCT05487053|PROCEDURE|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
219414260|NCT01954251|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219414261|NCT01954251|BIOLOGICAL|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
219414262|NCT01899859|DRUG|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
219414263|NCT01899859|DRUG|Placebo|GR-MD-02 Placebo
219414264|NCT00877669|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
219414265|NCT00877669|PROCEDURE|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
219414266|NCT05108220|DIETARY_SUPPLEMENT|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
219414267|NCT01345344|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
219414268|NCT01345344|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
219414269|NCT01413841|DRUG|Nasal oxygen|3 l oxygen
219414270|NCT01413841|DRUG|Regular nasal air|3 l nasal air
219414271|NCT02701686|BEHAVIORAL|quit immediately (QI)|advise to quit immediately using the AWARD model
219570959|NCT04309526|DRUG|Placebo|Placebo
219570960|NCT01856387|BIOLOGICAL|high neutrophil to lymphocyte ratio|
219570961|NCT01856387|OTHER|normal neutrophil-to Lymphocyte ratio|
219570962|NCT04751474|OTHER|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
219570963|NCT01351350|DRUG|MLN0128|MLN0128 capsules
219570964|NCT01351350|DRUG|paclitaxel|paclitaxel intravenous infusion
219570965|NCT01351350|DRUG|trastuzumab|trastuzumab intravenous infusion
219570966|NCT00919984|DRUG|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
219003912|NCT02911753|OTHER|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
219003913|NCT02911753|OTHER|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
219003914|NCT01503944|DRUG|18F-AV-133|185 MBq
219414272|NCT02701686|BEHAVIORAL|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
219414273|NCT00104078|DRUG|MYO-029|
219414274|NCT02175771|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
219414275|NCT02175771|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
219414276|NCT02175771|DRUG|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
219414277|NCT02175771|DRUG|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
219414278|NCT02175771|DRUG|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
219414279|NCT01450046|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
219414280|NCT00469404|DRUG|Buprenorphine|
219570967|NCT05589350|OTHER|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
219570968|NCT00028379|PROCEDURE|Transcranial magnetic stimulation (TMS)|
219570969|NCT01974128|PROCEDURE|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
219414281|NCT00568880|DRUG|bortezomib|bortezomib 1.0-1.3mg/m2 IV
219570970|NCT04647383|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
219570971|NCT04647383|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
219414282|NCT00568880|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg pill
219414283|NCT01549743|DRUG|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
219414284|NCT01549743|DRUG|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
219570972|NCT04647383|DRUG|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
219757630|NCT01356147|DRUG|Placebo|No therapy will be given to placebo arm
219757631|NCT03741270|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
219757632|NCT00741078|DRUG|statin, amlodipine|
219003915|NCT01503944|DRUG|18F-AV-45|185-370 MBq
219003916|NCT03504150|BEHAVIORAL|SPHERE|Comprehensive Internet-based CBT program with no human support
219570973|NCT04647383|DRUG|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
219570974|NCT01176019|DEVICE|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
219570975|NCT06011382|DEVICE|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
219570976|NCT06011382|DEVICE|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
219414285|NCT01549743|DRUG|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
219414286|NCT04818814|BEHAVIORAL|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
219414287|NCT04818814|BEHAVIORAL|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
219414288|NCT03191006|DEVICE|MEI BIN insoles|insoles
219414289|NCT02232087|DRUG|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
219414290|NCT02232087|DRUG|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
219414291|NCT00620971|DRUG|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
219414292|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
219414293|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
219570977|NCT00254020|DRUG|Citalopram|Patients who are found to have major depression will be referred to a psychologist
219570978|NCT01099631|BIOLOGICAL|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
219570979|NCT04483531|DRUG|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
219570980|NCT05472116|DEVICE|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
219570981|NCT02602834|OTHER|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
219757633|NCT05983705|BEHAVIORAL|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
219003917|NCT03504150|BEHAVIORAL|PRISM|Brief Internet-based CBT program with no human support
219003918|NCT04464915|OTHER|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
219414294|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
219414295|NCT00620971|DRUG|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
219414296|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
219570982|NCT02602834|OTHER|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
219570983|NCT00873119|DRUG|belinostat, carboplatin, paclitaxel|
219003919|NCT03334448|DRUG|LY900014-U200|Administered SC
219003920|NCT03334448|DRUG|LY900014-U100|Administered SC
219414297|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
219414298|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
219003921|NCT04919850|DIETARY_SUPPLEMENT|Saccharomyces boulardii and SOD|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
219414299|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
219414300|NCT04069156|DEVICE|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
219414301|NCT04069156|DRUG|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
219414302|NCT04069156|DRUG|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
219414303|NCT03864718|PROCEDURE|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
219414304|NCT04215523|DRUG|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
219414305|NCT04215523|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
219414306|NCT01426607|DEVICE|AMO|
219570984|NCT00873119|DRUG|carboplatin, paclitaxel|
219570985|NCT00127517|DRUG|peptide-nucleic acid solution AVR118|
219570986|NCT03803033|OTHER|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
219757634|NCT01729039|BEHAVIORAL|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
219414307|NCT06160869|BEHAVIORAL|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
219414308|NCT06160869|COMBINATION_PRODUCT|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
219414309|NCT02596152|OTHER|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
219414310|NCT02596152|OTHER|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
219414311|NCT03957655|BIOLOGICAL|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
219414312|NCT05126706|BEHAVIORAL|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
219570987|NCT01367717|DIETARY_SUPPLEMENT|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
219570988|NCT01367717|DIETARY_SUPPLEMENT|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
219570989|NCT01418677|DRUG|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
219570990|NCT01418677|DRUG|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
219757635|NCT01729039|BEHAVIORAL|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
219757636|NCT01729039|BEHAVIORAL|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
219414313|NCT05667792|DEVICE|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
219414314|NCT05667792|OTHER|Pediatric Rehabilitation|Bobath therapy
219414315|NCT02207556|DRUG|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."
219414316|NCT06070116|DRUG|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
219414317|NCT06070116|DRUG|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
219414318|NCT06070116|DRUG|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
219570991|NCT01418677|DRUG|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
219570992|NCT00285584|DRUG|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
219757637|NCT06592079|PROCEDURE|Immediate implant and connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
219003922|NCT04919850|COMBINATION_PRODUCT|Placebo|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
219003923|NCT04746261|BEHAVIORAL|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
219003924|NCT04746261|OTHER|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
219414319|NCT06070116|DRUG|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
219414320|NCT03712332|BEHAVIORAL|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
219414321|NCT01405118|DRUG|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
219414322|NCT03558555|DRUG|Acetaminophen IV Soln|1000mg of IV acetaminophen
219414323|NCT03558555|DRUG|Oral Acetaminophen|oral acetaminophen 975mg pills
219414324|NCT03558555|DRUG|Placebo Pills|placebo match to acetaminophen
219414325|NCT03558555|DRUG|Saline|Intravenous saline
219414326|NCT01958125|DEVICE|gammaCore|Vagal stimulation
219414327|NCT03925311|PROCEDURE|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
219570993|NCT00285584|DRUG|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
219570994|NCT02378051|BEHAVIORAL|Staying Strong with Schools Intervention|"1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
219003925|NCT04940689|DRUG|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
219414328|NCT01073280|PROCEDURE|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
219414329|NCT02352610|PROCEDURE|LRTI|
219414330|NCT02352610|DEVICE|Biotenodesis Screw|
219414331|NCT04987853|DIAGNOSTIC_TEST|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire"
219414332|NCT04987853|DIAGNOSTIC_TEST|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2\. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3\. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4\. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
219414333|NCT04987853|DIAGNOSTIC_TEST|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
219414334|NCT04987853|DIAGNOSTIC_TEST|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
219414335|NCT05532098|PROCEDURE|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
219414336|NCT05532098|PROCEDURE|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
219414337|NCT00204997|PROCEDURE|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
219414338|NCT04019275|BEHAVIORAL|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
219003926|NCT04940689|DRUG|Remifentanil|The patient will be anesthetized with morphin.
219003927|NCT02684266|DRUG|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
219414339|NCT01182948|BEHAVIORAL|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
219414340|NCT01182948|BEHAVIORAL|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
219414341|NCT03338517|OTHER|Helium Neon Laser|
219414342|NCT05093413|BEHAVIORAL|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
219570995|NCT02378051|OTHER|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
219757638|NCT06592079|PROCEDURE|Immediate implant with connective tissue graft and bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will placed to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
219003928|NCT03613012|DIAGNOSTIC_TEST|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
219003929|NCT03775629|DRUG|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
219003930|NCT03775629|DRUG|Polmacoxib|Polmacoxib
219570996|NCT00427674|DRUG|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
219570997|NCT04517929|OTHER|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
219570998|NCT00466726|BIOLOGICAL|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
219570999|NCT00466726|BIOLOGICAL|sargramostim|
219757639|NCT06074263|DRUG|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
219757640|NCT06074263|OTHER|Placebo|Placebo capsule which looks identical to dexamethasone capsule
219757641|NCT06596642|DRUG|Luspatercept|As per product label
219757642|NCT06982105|DRUG|Trimethoprim Sulfamethoxazole|"* For osteoarticular infections- 4-5 mg/kg/dose (based on TMP) PO every 8 hours (max dose 320mg/dose)~* For head and neck infections- 5-6 mg/kg/dose (based on TMP PO every 12 hours (max dose 320mg/dose)~Duration will be at the discretion of the treating provider"
219003931|NCT03775629|DRUG|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
219003932|NCT02988843|DRUG|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
219003933|NCT02988843|DRUG|Bevacizumab|15 mg/kg every 21 days
219003934|NCT01683383|DEVICE|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
219003935|NCT01683383|OTHER|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
219003936|NCT05329701|OTHER|Individualized treatment duration strategy|As listed under arm description.
219757643|NCT01772251|DRUG|Oshadi Icp|
219757644|NCT03624556|DIETARY_SUPPLEMENT|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
219757645|NCT03624556|OTHER|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
219757646|NCT06650384|DRUG|Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin|Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
219757647|NCT06650384|DRUG|Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin|Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
219757648|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
219757649|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|
219414343|NCT05632627|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
219414344|NCT05632627|DRUG|Placebo|Placebo arm
219414345|NCT03638661|DIETARY_SUPPLEMENT|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
219414346|NCT03638661|DIETARY_SUPPLEMENT|soybean oil|soybean oil used formula
219414347|NCT01070602|PROCEDURE|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
219414348|NCT00673478|DRUG|Tiotropium+Salmeterol|
219414349|NCT00673478|DRUG|Salmeterol|
219414350|NCT00673478|DRUG|Tiotropium|
219414351|NCT00407914|DEVICE|Aquamid|Subcutaneous injection
219414352|NCT00407914|DEVICE|Restylane|Injection in dermis
219414353|NCT05311293|DIAGNOSTIC_TEST|Endoscopy|Observe the extent of colonic lesions and obtain intestinal mucosal samples
219414354|NCT01831206|PROCEDURE|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
219414355|NCT04399512|PROCEDURE|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
219414356|NCT03013244|BEHAVIORAL|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
219414357|NCT02129335|OTHER|stress|stress level and survival
219414358|NCT02236949|BEHAVIORAL|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
219414359|NCT00542724|DRUG|VIAject™|Dosage as individually required
219757650|NCT06569810|DEVICE|Repeated Low-Level Red Light (RLRL) therapy|In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
219414360|NCT00542724|DRUG|Regular Human Insulin|Dosage as individually required
219414361|NCT01244347|DRUG|folic acid|
219414362|NCT01244347|DRUG|folic acid|
219414363|NCT00668200|DRUG|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
219414364|NCT00668200|DIETARY_SUPPLEMENT|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
219414365|NCT00668200|DIETARY_SUPPLEMENT|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
219414366|NCT02646267|DRUG|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
219414367|NCT02646267|DRUG|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
219414368|NCT02646267|DRUG|dabigatran etexilate|110mg, twice a day, oral
219414369|NCT03943979|OTHER|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
219414370|NCT03943979|DEVICE|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
219414371|NCT05630430|PROCEDURE|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
219414372|NCT00103805|DRUG|levodopa|
219414373|NCT02979730|OTHER|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
219414374|NCT02979730|OTHER|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
219414375|NCT01100996|OTHER|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
219414376|NCT01100996|OTHER|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
219414377|NCT06522581|DRUG|Citicoline Sodium|one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
219414378|NCT05662254|BEHAVIORAL|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
219757651|NCT00698841|DRUG|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
219757652|NCT01348893|BEHAVIORAL|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
219757653|NCT03490565|BEHAVIORAL|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
219757654|NCT06984510|OTHER|Observational|Observational
219757655|NCT06605209|DEVICE|Peripheral Balloon-Expandable Covered Stent System|The intervention in this clinical trial involves the Peripheral Balloon-Expandable Covered Stent System. This stent system is specifically designed for the treatment of stenosis and/or occlusion in the common and external iliac arteries.
219757656|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - fast|Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
219003937|NCT05846204|BEHAVIORAL|Progressive Muscle Relaxation|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught."
219003938|NCT05846204|BEHAVIORAL|Deep Breathing Exercise Group-DBE|Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
219414379|NCT02537314|DRUG|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
219757657|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - slow|Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions
219757658|NCT06817603|DEVICE|Procedural Oxygen Mask|Procedural Oxygen Mask will be used
219414380|NCT02537314|OTHER|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
219414381|NCT06145685|PROCEDURE|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
219003939|NCT04081974|OTHER|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
219414382|NCT06145685|PROCEDURE|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
219414383|NCT06323915|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
219414384|NCT05137509|DEVICE|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
219414385|NCT00121303|DRUG|cytarabine|
219414386|NCT00121303|DRUG|daunorubicin hydrochloride|
219414387|NCT00121303|DRUG|gemtuzumab ozogamicin|
219003940|NCT05204238|DIAGNOSTIC_TEST|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
219003941|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
219414388|NCT03305094|PROCEDURE|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
219414389|NCT02221180|DRUG|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
219414390|NCT02221180|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
219414391|NCT02221180|DRUG|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
219414392|NCT05738902|OTHER|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
219414393|NCT04729920|DEVICE|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
219414394|NCT01887028|DEVICE|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
219414395|NCT00463658|OTHER|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
219414396|NCT03007017|PROCEDURE|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
219414397|NCT03007017|PROCEDURE|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
219414398|NCT01204255|DRUG|lorazepam|Given topically
219414399|NCT01204255|DRUG|diphenhydramine hydrochloride|Given topically
219414400|NCT01204255|DRUG|haloperidol|Given topically
219414401|NCT01204255|OTHER|questionnaire administration|Ancillary studies
219414402|NCT01204255|OTHER|laboratory biomarker analysis|Correlative studies
219414403|NCT01098461|BIOLOGICAL|albiglutide|subcutaneous injection of albiglutide
219414404|NCT01098461|BIOLOGICAL|placebo|subcutaneous injection of placebo to match albiglutide
219414405|NCT06400563|DEVICE|MRg-NIRS|The trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
219414406|NCT06399640|DRUG|Eltanexor|Eltanexor will be taken by mouth
219414407|NCT06399640|DRUG|Venetoclax|Venetoclax will be taken by mouth
219414408|NCT06399640|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219414409|NCT06399640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219414410|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
219414411|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
219414412|NCT00252122|DRUG|Ketamine|Ketamine. 0.2 mg/kg, intravenously
219414413|NCT01425073|OTHER|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
219414414|NCT05475821|DRUG|ABBV-990|Oral Tablet
219414415|NCT05475821|DRUG|Placebo for ABBV-990|Oral Tablet
219414416|NCT02172079|OTHER|Real mobilization-with-movement (MWM)|
219414417|NCT02172079|OTHER|Sham mobilization-with-movement (MWM)|
219414418|NCT03628508|OTHER|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
219414419|NCT05304871|DRUG|Cefazolin|infusion
219414420|NCT05304871|OTHER|saline|infusion
219414421|NCT02742077|DEVICE|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
219414422|NCT03023644|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
219414423|NCT05145504|DIAGNOSTIC_TEST|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
219003942|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)|Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
219414424|NCT05678413|PROCEDURE|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
219414425|NCT05678413|PROCEDURE|DVIU|DVIU
219414426|NCT00190203|PROCEDURE|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
219414427|NCT00190203|PROCEDURE|hemicraniectomy|hemicraniectomy
219414428|NCT02733614|DRUG|SRX246|novel V1a receptor antagonist
219414429|NCT02733614|DRUG|Placebo|matching placebo
219414430|NCT06065267|DRUG|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
219414431|NCT06065267|DRUG|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
219414432|NCT03323918|OTHER|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
219414433|NCT03323918|OTHER|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
219414434|NCT03029416|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
219414435|NCT04950881|PROCEDURE|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
219414436|NCT04950881|DRUG|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
219571000|NCT04909541|OTHER|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
219003943|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)|Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
219414437|NCT04570657|BIOLOGICAL|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
219414438|NCT04570657|DRUG|Placebo|Participants will receive multiple doses of placebo
219003944|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
219003945|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
219003946|NCT05362097|OTHER|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
219003947|NCT02626546|PROCEDURE|Major surgical procedure|observation of postoperative outcomes
219003948|NCT00855920|DRUG|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
219414439|NCT02786589|BIOLOGICAL|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
219414440|NCT04961372|OTHER|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
219414441|NCT01731301|DRUG|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
219571001|NCT05603455|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
219571002|NCT05603455|DIETARY_SUPPLEMENT|Placebo|Placebo
219571003|NCT00004481|PROCEDURE|genetic testing|
219571004|NCT03060850|DRUG|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
219003949|NCT00855920|DRUG|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
219003950|NCT00855920|OTHER|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
219003951|NCT00855920|OTHER|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
219003952|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
219003953|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
219003954|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
219003955|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
219571005|NCT01376310|DRUG|GSK1120212|up to 2 mg/day
219571006|NCT01376310|DRUG|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
219571007|NCT01376310|DRUG|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
219571008|NCT01376310|DRUG|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
219571009|NCT01376310|DRUG|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
219571010|NCT01376310|DRUG|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
219571011|NCT01376310|DRUG|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
219571012|NCT01376310|DRUG|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
219414442|NCT01731301|DRUG|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
219414443|NCT01731301|DRUG|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
219414444|NCT00437606|DRUG|GK Activator (2)|100mg po
219414445|NCT00437606|DRUG|Ethanol|40g po
219414446|NCT04873024|DEVICE|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
219414447|NCT03862690|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
219414448|NCT05006898|COMBINATION_PRODUCT|PBO to control presbyopia symptoms|Low dose PBO to control presbyopia symptoms
219414449|NCT01754220|DRUG|Montelukast|Montelukast is a leukotriene receptor antagonist
219414450|NCT01072539|DRUG|tigecycline|As prescribed by physician in usual clinical practice
219414451|NCT00134225|DEVICE|Muscle Pattern Recognition (MPR)|
219414452|NCT00348582|DRUG|Ketorolac, Nepafenac|
219414453|NCT02577250|DRUG|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
219414454|NCT04931316|OTHER|antiglaucoma|use antiglaucoma in ocular hypertension
219414455|NCT05685641|DIAGNOSTIC_TEST|Histoplasma Urine Antigen Lateral Flow Antigen test|Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
219414456|NCT05685641|DIAGNOSTIC_TEST|Cryptococcal Lateral Flow Antigen test|Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
219414457|NCT05685641|DIAGNOSTIC_TEST|Tuberculosis-lipoarabinomannan Lateral Flow Antigen test|Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
219414458|NCT03446937|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
219414459|NCT03446937|DRUG|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
219414460|NCT03446937|DRUG|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
219571013|NCT02610764|PROCEDURE|Blood Test for CTC evaluation|
219003956|NCT05886829|COMBINATION_PRODUCT|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
219414461|NCT06053827|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
219414462|NCT02856269|DIETARY_SUPPLEMENT|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
219414463|NCT01679080|DRUG|Zoledronic acid|antiresorptive and calcium and vitamin D
219414464|NCT01679080|DRUG|Teriparatide|anabolic and calcium and vitamin D
219414465|NCT01679080|OTHER|No active treatment|Calcium and vitamin D
219414466|NCT00080366|DRUG|1-Octanol|
219414467|NCT06179550|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219571014|NCT04844021|BEHAVIORAL|Nudge|"EHR-based nudge"
219571015|NCT04844021|BEHAVIORAL|Nudge+|"EHR-based nudge plus facilitation"
219571016|NCT06502652|OTHER|hippotherapy|A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
219571017|NCT06502652|OTHER|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
219571018|NCT06467552|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols.
219571019|NCT06467552|DIETARY_SUPPLEMENT|Nucare Curact group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
219571020|NCT03184532|DIAGNOSTIC_TEST|ultrasound|ultrasound examination of pyloric antrum
219190511|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
219190512|NCT01627574|BEHAVIORAL|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
219190513|NCT01627574|BEHAVIORAL|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
219190514|NCT05541029|BEHAVIORAL|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
219190515|NCT05541029|BEHAVIORAL|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
219190516|NCT05541029|OTHER|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of \>1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
219190517|NCT04970446|DRUG|Antibiotics|All patients will receive a one week course of antibiotic therapy.
219190518|NCT04970446|DIETARY_SUPPLEMENT|Dietician designed diet|All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
219190519|NCT04970446|DRUG|FMT|Anaerobically prepared stool. Dosing will vary according to mode of administration.
219190520|NCT04970446|OTHER|Placebo|Placebo will contain food colourant, 0.9% normal saline and glycerol.
219190521|NCT05725564|BEHAVIORAL|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
219190522|NCT05725564|BEHAVIORAL|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
219190523|NCT05725564|BEHAVIORAL|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
219190524|NCT03048331|DEVICE|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
219190525|NCT06485479|BEHAVIORAL|Intervention ads|The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
219190526|NCT06485479|BEHAVIORAL|Control ads|The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
219190527|NCT02608359|DRUG|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
219190528|NCT04892940|DEVICE|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
219190529|NCT04892940|DRUG|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
219190530|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
219190531|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
219414468|NCT06179550|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219414469|NCT01389622|OTHER|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
219571021|NCT04825015|DEVICE|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
219757659|NCT06817603|DEVICE|High-Flow Nasal Cannula|High-Flow Nasal Cannula (HFNC) will be used.
219003957|NCT05886829|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
219003958|NCT03262909|DEVICE|GelrinC|Patients will undergo GelrinC implantation.
219003959|NCT03262909|OTHER|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
219003960|NCT05409456|OTHER|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
219003961|NCT05409456|OTHER|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
219003962|NCT04603690|DIETARY_SUPPLEMENT|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
219003963|NCT04603690|DRUG|Standard of care|This arm will receive standard of care as per the hospital guidelines
219003964|NCT04891874|RADIATION|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
219003966|NCT01845493|DIETARY_SUPPLEMENT|Alpha Sprout Homogenate|Alpha Sprout Homogenate
219414470|NCT01389622|OTHER|acupuncture|random points + digital pressure
219757660|NCT06817642|OTHER|Data recovery from language and cognitive assessment|Data recovery from language assessment: Core Assessment of LAnaguage Processing, and from neuropsychological assessment : Montreal Cognitive Assessment, Trail Making Test, Batterie Rapide d'Efficience Frontale (BREF), animal fluency, 5 words of Dubois, Ne
219757661|NCT06662279|DEVICE|Removable Rapid Palatal Expander|Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
219757662|NCT06662279|DEVICE|Banded Palatal Expander|Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
219757663|NCT06655740|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
219757664|NCT06453772|PROCEDURE|Liposuction|Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
219757665|NCT06603493|OTHER|Assessment of sleep disorders|: Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index
219003967|NCT01845493|DIETARY_SUPPLEMENT|Sulforaphane Homogenate|Active
219003968|NCT05639426|BEHAVIORAL|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
219757666|NCT06603493|OTHER|Assessment of Central Sensitization|Central sensitization will be assessed with the Central Sensitization Inventory
219757667|NCT06603493|OTHER|Assessment of depression, anxiety and stress levels|Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
219757668|NCT00697385|DRUG|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
219757669|NCT05751577|PROCEDURE|TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
219757670|NCT05751577|PROCEDURE|TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
219757671|NCT00650507|PROCEDURE|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
219757672|NCT00650507|PROCEDURE|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
219414471|NCT00325286|DRUG|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
219414472|NCT00115804|DRUG|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
219414473|NCT06376266|COMBINATION_PRODUCT|nutritional supplements|a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
219414474|NCT02226042|BEHAVIORAL|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
219414475|NCT02683915|PROCEDURE|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
219414476|NCT01300611|DRUG|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
219414477|NCT01300611|DRUG|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
219414478|NCT04234815|BEHAVIORAL|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
219414479|NCT04234815|BEHAVIORAL|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
219414480|NCT05399238|DEVICE|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
219414481|NCT02294721|DEVICE|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
219414482|NCT02294721|DEVICE|The CPREazy|feedback device-1
219414483|NCT02294721|DEVICE|TrueCPR|feedback device -2
219571022|NCT01267006|DRUG|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
219571023|NCT01267006|DRUG|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
219571024|NCT00809315|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
219571025|NCT00809315|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
219571026|NCT03984045|DRUG|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
219414484|NCT02294721|DEVICE|The CPR PRO APP|feedback device -3
219571027|NCT03984045|DRUG|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
219757673|NCT05574881|DRUG|Dalpiciclib|150 mg qd
219757674|NCT05574881|DRUG|Fulvestrant|500mg d1, 15, 29, and then q4w
219757675|NCT05574881|DRUG|Pertuzumab|840mg q3w, and then 420 mg q3w
219757676|NCT05574881|DRUG|Trastuzumab|8 mg/kg q3w, and then 6 mg/kg q3w
219757677|NCT06992024|COMBINATION_PRODUCT|Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody|Electroacupuncture (EA) Combined With Paclitaxel Protein-bound (Chemo) and PD-1 Antibody (IO) for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer. Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1, d7, d8 + Paclitaxel Protein-bound (125mg/m2) d1, d8 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W. If the diseases are well controlled after 6 cycles, maintenance treatment, namely Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W, will be continually conducted until the diseases progress.
219757678|NCT06988735|PROCEDURE|Nonrobotic TCRAT|Nonrobotic TCRAT for CABG
219757679|NCT06988735|PROCEDURE|Robotic TCRAT|Robotic TCRAT for CABG
219757680|NCT02976805|DRUG|4L PegLyte + 15 mg bisacodyl|Randomized
219757681|NCT02976805|DRUG|6L PegLyte + 15 mg bisacodyl|Randomized
219757682|NCT06994416|DEVICE|novel fluorescent localization marker needle|novel fluorescent localization needle, which features a controllable shedding quantum dot chiral nanofluorescent coating
219757683|NCT06994416|DEVICE|conventional localization marker needle|conventional localization marker needle, without any coating
219757684|NCT00829998|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
219757685|NCT00829998|DRUG|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
219414485|NCT02294721|DEVICE|The CardioPump|feedback device- 4
219414486|NCT05241015|OTHER|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
219414487|NCT05241015|OTHER|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
219414488|NCT01132989|DRUG|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
219571028|NCT06061783|DRUG|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
219571029|NCT06061783|DRUG|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
219190532|NCT04721041|OTHER|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension delivered through mid-gut and lower-gut
219414489|NCT05941858|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resource document
219414490|NCT05941858|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
219414491|NCT05941858|OTHER|Internet-Based Intervention|Receive access to WaQi/Tai Chi program
219414492|NCT05941858|OTHER|Survey Administration|Ancillary studies
219571030|NCT00914979|DEVICE|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
219571031|NCT04812574|PROCEDURE|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
219571032|NCT04812574|DRUG|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
219571033|NCT02339740|DRUG|Arsenic Trioxide|Given IV
219571034|NCT02339740|DRUG|Cytarabine|Given IV
219571035|NCT02339740|DRUG|Dexamethasone|Given PO or IV
219190533|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
219414493|NCT05941858|OTHER|Tai Chi|Practice Tai Chi
219414494|NCT06217536|DRUG|Lurbinectedin|Given intravenously (IV)
219414495|NCT06217536|RADIATION|Radiotherapy|Conventionally fractionated radiotherapy or external beam radiation
219414496|NCT06217536|PROCEDURE|Non-investigational surgery|Non-investigational surgical procedure on tumor tissue
219414497|NCT02098460|DRUG|Atorvastatin, Probucol, Cilostazol|
219414498|NCT03484000|BEHAVIORAL|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
219414499|NCT01752842|DRUG|Fenofibrate|
219414500|NCT01752842|DRUG|Placebo for fenofibrate|
219571036|NCT02339740|DRUG|Idarubicin|Given IV
219571037|NCT02339740|OTHER|Laboratory Biomarker Analysis|Correlative studies
219571038|NCT02339740|DRUG|Mitoxantrone Hydrochloride|Given IV
219571039|NCT02339740|OTHER|Quality-of-Life Assessment|Ancillary studies
219757686|NCT03159988|DRUG|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
219757687|NCT03159988|BEHAVIORAL|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
219190534|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
219190535|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
219414501|NCT04169334|BEHAVIORAL|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
219414502|NCT06203496|DIAGNOSTIC_TEST|Blood sample|Blood sample
219414503|NCT01683071|DRUG|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
219414504|NCT01683071|DRUG|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
219414505|NCT01683071|DRUG|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
219414506|NCT01683071|DRUG|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
219414507|NCT03121183|DEVICE|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
219414508|NCT03121183|BEHAVIORAL|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
219414509|NCT01625598|PROCEDURE|Photography of the retina|Every subject will undergo photography of the retina in both eyes
219414510|NCT01625598|PROCEDURE|Retinal photography|"Device~Subjects will have photography of both eyes"
219414511|NCT06866028|DEVICE|Real-time fNIRS neurofeedback from Turbo-Satori|Activity in the target brain region measured by fNIRS in real-time will undergo processing on Turbo-Satori (BrainVoyager; Maastricht, Netherlands) to infer changes in oxygenated blood activity in the target brain region and relayed to the task program for visual feedback.
219414512|NCT06866028|DEVICE|Yoked sham feedback from Turbo-Satori|Previous data acquired from another individual in the experimental group will be loaded into Turbo-Satori (BrainVoyager; Maastricht, Netherlands) software for preprocessing in real-time and relayed to the task program for visual feedback.
219414513|NCT06626139|DRUG|Psilocybin|Healthy participants will receive up to 25 mg psilocybin.
219414514|NCT06626139|BEHAVIORAL|Context 1|Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
219414515|NCT06626139|BEHAVIORAL|Context 2|Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
219414516|NCT06626139|DRUG|Placebo|Healthy participants will receive an inactive placebo.
219414517|NCT02558738|DEVICE|ear spray|
219414518|NCT03166436|PROCEDURE|Radiofrequency ablation|radiofrequency ablation
219414519|NCT03166436|PROCEDURE|Biliary stenting|biliary stenting
219414520|NCT05092971|DEVICE|Shock or startle device|Shock and startle devices were used as aversive stimulus (shock and startle)
219414521|NCT03216551|DIAGNOSTIC_TEST|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
219414522|NCT02306187|DRUG|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
219414523|NCT06260072|DRUG|magnesium and riboflavin supplement|Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
219414524|NCT06108323|BEHAVIORAL|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
219414525|NCT06108323|BEHAVIORAL|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
219414526|NCT05549141|OTHER|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
219414527|NCT05549141|OTHER|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
219414528|NCT00798213|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
219414529|NCT00798213|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
219414530|NCT03571620|DRUG|Q301 Cream|1.0% or 1.4% Q301 Cream
219190536|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive dietary counseling
219414531|NCT03571620|DRUG|Vehicle|Vehicle Control
219414532|NCT06692257|BEHAVIORAL|Observation|To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
219571040|NCT02339740|OTHER|Questionnaire Administration|Ancillary studies
219571041|NCT02339740|DRUG|Tretinoin|Given PO
219571042|NCT01353846|OTHER|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
219571043|NCT01353846|DRUG|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
219571044|NCT03699033|RADIATION|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
219571045|NCT03699033|DRUG|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
219571046|NCT03699033|DRUG|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
219571047|NCT03617627|BEHAVIORAL|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
219757688|NCT06459804|PROCEDURE|Electro Dry Needling|"Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest."
219190537|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive guidelines for low-fat diet
219571048|NCT00147160|DRUG|Temozolomide, Cisplatinum|
219571049|NCT00755378|DRUG|AZD8529|Oral
219571050|NCT00755378|DRUG|Placebo|Oral
219571051|NCT00374582|DEVICE|Bodystat Quadscan 4000|device determining body composition and nutritional status
219571052|NCT00374582|DEVICE|bodystat quadscan 400|device determining body composition and nutritional status
219571053|NCT05550220|DIAGNOSTIC_TEST|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
219571054|NCT02096588|DRUG|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
219571055|NCT02096588|DRUG|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
219190538|NCT02176902|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
219190539|NCT02176902|OTHER|laboratory biomarker analysis|Correlative studies
219190540|NCT03528928|DEVICE|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
219190541|NCT06565793|DEVICE|Non Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).
219571056|NCT01694082|BEHAVIORAL|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
219757689|NCT06459804|PROCEDURE|Dry Needling|Dry Needling
219414533|NCT06693063|OTHER|Data collection|Some data will be collected for all patients included: medical and family history, chest pain data and medical care data
219414534|NCT06692231|BEHAVIORAL|Pharmacist intervention|Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
219414535|NCT06692777|DIETARY_SUPPLEMENT|Bergavit|Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
219414536|NCT06692777|DIETARY_SUPPLEMENT|Placebo|Subjects will take capsule equivalent amount of maltodextrin for 4 months.
219414537|NCT06692049|PROCEDURE|Gonadectomy|Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
219571057|NCT01694082|BEHAVIORAL|Brief brochure and assessment control|
219571058|NCT00017394|BIOLOGICAL|bevacizumab|Given IV
219571059|NCT00017394|DRUG|vinorelbine tartrate|Given IV
219571060|NCT00017394|OTHER|laboratory biomarker analysis|Correlative studies
219571061|NCT01795248|DRUG|Liraglutide|1.8 mg liraglutide
219571062|NCT01795248|DRUG|Placebo|Liraglutide without the GLP-1 analogue
219571063|NCT00653016|DRUG|norelgestromin; ethinyl estradiol|
219571064|NCT01216657|DRUG|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
219571065|NCT03418168|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
219571066|NCT02389101|OTHER|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
219571067|NCT01684059|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
219757690|NCT00933478|DEVICE|Clay|Small dime sized piece of clay.
219757691|NCT05132296|BEHAVIORAL|Behavioral Intervention|Undergo behavioral counseling
219757692|NCT05132296|OTHER|Best Practice|Receive usual care supportive services
219757693|NCT05132296|DEVICE|FitBit|Receive FitBit
219757694|NCT05132296|BEHAVIORAL|Nutrition Education|Receive nutrition education
219414538|NCT05112016|PROCEDURE|Total mesorectal excision for rectal cancer|
219414539|NCT00382096|DRUG|Vildagliptin|
219571068|NCT00303667|BIOLOGICAL|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
219571069|NCT00303667|BIOLOGICAL|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
219571070|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
219571071|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
219571072|NCT00303667|PROCEDURE|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
219571073|NCT00303667|RADIATION|total body irradiation|Administered on Day -13, 200 cGy two times.
219571074|NCT00303667|BIOLOGICAL|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
219757695|NCT05132296|OTHER|Physical Activity|Undergo physical activity
219757696|NCT05132296|OTHER|Questionnaire Administration|Ancillary studies
219757697|NCT06996808|DEVICE|Bakri Baloon|Bakri Balloon Standard insertion and inflation as per hospital protocol following delivery.
219757698|NCT06996808|DEVICE|Celox gauze|Celox gauze will be placed intrauterine according to manufacturer instructions, post-vaginal or cesarean delivery. Duration and removal will follow standardized clinical guidelines
219757699|NCT06675721|OTHER|Study Questionnaire|A survey questionnaire to assess factors related to vaccination adherence, including factors such as vaccine novelty, cost, and prior knowledge among vulnerable populations.
219757700|NCT06675201|BIOLOGICAL|neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)|"Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause."
219003969|NCT05639426|BEHAVIORAL|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
219414540|NCT00382096|DRUG|Metformin|
219414541|NCT00382096|DRUG|Vildagliptin + Metformin|
219414542|NCT05928806|DRUG|Botensilimab|Botensilimab 75mg IV
219414543|NCT05928806|DRUG|Balstilimab|Balstilimab 450mg IV
219757701|NCT06998485|BEHAVIORAL|Arm Basis Training|This program is a systematic training regimen specifically designed to improve proximal motor control for patients with severe upper extremity hemiparesis. The core principles of the Arm Basis Training Program focus on rebuilding the fundamental capacity for specific and selective motor control before progressing to more complex motor patterns.
219414544|NCT05928806|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV
219414545|NCT05928806|DRUG|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
219414546|NCT06490354|DEVICE|Lightback group|Use of the patented Lightback device to relax the gluteal musculature and prevent hamstring injuries.
219414547|NCT06490354|OTHER|Conventional treatment|Conventional treatment to relax the gluteal musculature and prevent hamstring injuries.
219414548|NCT04588883|BEHAVIORAL|Kuja Pamoja - HIV|Information has been provided in the treatment arm description.
219414549|NCT06692647|DRUG|MK-4318|Oral administration
219414550|NCT06692647|DRUG|Diltiazem|Oral administration
219571075|NCT00303667|DRUG|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
219571076|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
219571077|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
219571078|NCT00414349|DRUG|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
219571079|NCT00414349|DRUG|oral intake|300 to 600 mg per day taken orally
219571080|NCT00414349|DRUG|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
219571081|NCT05724446|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
219571082|NCT05724446|DRUG|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
219414551|NCT06898762|OTHER|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.
219414552|NCT06898060|DRUG|QLG2128|Recommended dosage is 80 μg subcutaneously once daily，52week
219414553|NCT06898060|DRUG|Teriparatide Injection|Recommended dosage is 20μg subcutaneously once daily，52week
219414554|NCT06899178|DRUG|Atomoxetine|Initial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose)
219414555|NCT06899178|DRUG|Placebo|Matching placebo oral capsule
219414556|NCT01739777|BIOLOGICAL|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
219414557|NCT01739777|OTHER|Controls|Autologous Serum will administrated as placebo
219414558|NCT00202631|DEVICE|Surface Functional Electrical Stimulation|
219414559|NCT01968187|DRUG|FE 992097|"Each spray pump actuation delivered a 50 μL volume of solution that contained 1.6 mg carbetocin (FE 992097); each dose consisted of 3 spray pump actuations in each nostril that delivered a total of 9.6 mg carbetocin.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
219414560|NCT01968187|DRUG|Placebo|"Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
219414561|NCT06898801|OTHER|Just-in-time video training|"A Just-in-time educational video was designed and produced by the investigating team. Content of the video includes;~* Environmental set up and patient positioning~* Equipment preparation including stylet insertion~* Description of internal anatomy of airway~* Suggested instructional language for supervisors~* Example footage of an intubation~* Tips and common pitfalls~* Guidance for intubation assistant on how to perform cricoid pressure"
219414562|NCT02813798|DRUG|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
219414563|NCT07084532|OTHER|Chewing gum|Dry mouth was diagnosed in the initial assessment of diabetic individuals assigned to the intervention group. Following the assessment, they were asked to chew gum for 15 minutes before each main meal for seven days. Dry mouth was re-evaluated with the Xerostomia Scale seven days later.
219414564|NCT07084532|OTHER|Standart therapy group|The control group was informed about the study. They were then assessed for dry mouth. They were asked to follow their standard treatment. They were warned not to chew gum. A day later, dry mouth was assessed again without any treatment.
219414565|NCT07078643|PROCEDURE|Superior Hypogastric Plexus Block (SHPB)|Laparoscopic superior hypogastric plexus block with bupivacaine and lidocaine injection near sacral promontory.
219414566|NCT07078643|PROCEDURE|Erector Spinae Plane Block (ESPB)|Erector spinae plane block with ultrasound-guided injection of bupivacaine and lidocaine at T10 level.
219414567|NCT07082972|DRUG|Botulinum toxin injection|Patients will receive a total of 20 units of botulinum toxin type A (Botox) injected into each masseter muscle. The injections will be administered at three standardized sites on each side using a fine needle to ensure accurate delivery. Muscle activity will be recorded using electromyography (EMG) before the injection, and follow-up EMG measurements will be taken at one month and four months post-treatment to evaluate changes in muscle activity and treatment efficacy.
219414568|NCT07082972|DEVICE|Occlusal splint|Patients with myofascial pain syndrome will receive custom-made occlusal splints to wear during sleep. These splints help reduce abnormal muscle activity and relieve pain by redistributing bite forces. EMG measurements will be taken before and during treatment to monitor changes in muscle activity.
219414569|NCT07082972|COMBINATION_PRODUCT|Botulinum toxin + Occlusal splint combined|Patients will receive both botulinum toxin injections (20 units per masseter muscle, injected at three standardized points per side) and will use occlusal splints during sleep. EMG measurements will be conducted before treatment, and at follow-up visits to assess the combined effect of pharmacological and mechanical therapy on muscle activity.
219414570|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 without Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
219414571|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 with Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
219414572|NCT06831344|DRUG|Vonoprazan (Reference)|Vonoprazan will be administered orally as a tablet
219414573|NCT06929754|OTHER|Lip bumper|Lip bumper appliance will be given as intervention to Lip bumper group
219414574|NCT00052169|DRUG|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
219414575|NCT06929247|PROCEDURE|Pulpotomy using Neoputty Mineral Trioxide Aggregate|Pulpotomy (Test Group): Removal of coronal pulp followed by Neoputty MTA placement and restoration.
219414576|NCT06929247|PROCEDURE|single visit pulpectomy using metapex|pulpectomy: removal of radicular pulp followed by metapex placement and final restoration
219414577|NCT04095286|DRUG|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
219414578|NCT04095286|DRUG|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
219414579|NCT06392256|PROCEDURE|Non surgical therapy|Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.
219414580|NCT06392256|PROCEDURE|Free gingival Grafting|In the PM-NS-FGG group, soft tissue augmentation using a free gingival graft will be performed.
219414581|NCT02310633|BEHAVIORAL|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
219414582|NCT02310633|BEHAVIORAL|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
219003970|NCT02496611|DRUG|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
219414583|NCT02310633|BEHAVIORAL|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
219414584|NCT03766087|PROCEDURE|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
219414585|NCT02020031|DRUG|Vancomycin|
219571083|NCT02610920|PROCEDURE|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
219571084|NCT02610920|DRUG|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
219571085|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
219571086|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
219571087|NCT01258101|DRUG|ribavirin|800 mg orally daily
219571088|NCT01258101|DRUG|ribavirin|400 mg orally daily
219571089|NCT00958867|BEHAVIORAL|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
219571090|NCT00958867|BEHAVIORAL|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
219571091|NCT00958867|BEHAVIORAL|Exercise training (S & R; control)|Six-month, twice-weekly stretch \& relax (S \& R; control) program
219571092|NCT01807117|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
219571093|NCT01807117|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
219571094|NCT01807117|PROCEDURE|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
219571095|NCT01807117|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
219003971|NCT02496611|DRUG|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
219414586|NCT05006521|DRUG|KN-002|KN-002 dry powder inhaler
219003972|NCT04226001|OTHER|Quality of life questionnaire|Quality of life questionnaire
219003973|NCT00524784|BIOLOGICAL|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
219414587|NCT02397603|DRUG|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
219414588|NCT02397603|DRUG|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
219414589|NCT02210104|DRUG|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
219571096|NCT05393063|DRUG|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
219571097|NCT06234319|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
219571098|NCT05396664|BEHAVIORAL|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
219571099|NCT00603863|BIOLOGICAL|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
219571100|NCT00577148|DRUG|Rimonabant|Tablet, oral administration
219571101|NCT00577148|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219571102|NCT00992368|PROCEDURE|reduction mammaplasty|patients submitted to reduction mammaplasty
219571103|NCT04136418|DEVICE|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
219571104|NCT04136418|OTHER|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
219571105|NCT03349359|DRUG|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
219571106|NCT03560687|DRUG|Sucrosomial Iron|CardioSideral 2 caps per day
219571107|NCT01215799|DRUG|Bafetinib|Bafetinib 240 mg bid
219571108|NCT02224066|DRUG|Ticagrelor 90 mg twice per day during three months following TAVI|
219571109|NCT02224066|DRUG|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
219571110|NCT04647617|BEHAVIORAL|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
219571111|NCT03474029|DRUG|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
219571112|NCT03474029|DRUG|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
219757702|NCT06998615|OTHER|shoulder impingement group|"the Patients with shoulder impingement syndrome in this group had at least 3 out of the following 6 criteria 1) positive Neer's sign; 2) positive Hawkins' sign; 3) pain on active shoulder elevation in the scapular plane, 4) pain on the C5-C6 dermatome; 5) pain on palpation of the rotator cuff tendons and 6) pain with resisted isometric abduction."
219414590|NCT02210104|DRUG|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
219414591|NCT02210104|BIOLOGICAL|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
219414592|NCT02243917|DRUG|CB-5083|
219414593|NCT00810459|DEVICE|Trilogy Ventilator|Exposure to one hour on the Trilog ventilator
219414594|NCT00810459|DEVICE|Standard of Care|Exposure of one hour on the Participants prescribed ventilator
219414595|NCT05274828|DEVICE|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
219414596|NCT03992209|OTHER|Standard care|Usual operating room practice
219414597|NCT03992209|OTHER|Protocolized care|Hand washing per protocol
219414598|NCT02906956|BEHAVIORAL|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
219414599|NCT05517356|PROCEDURE|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
219414600|NCT01159509|BEHAVIORAL|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
219414601|NCT04282070|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
219414602|NCT04282070|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
219414603|NCT04282070|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
219414604|NCT04282070|DRUG|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
219414605|NCT00796042|OTHER|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
219414606|NCT00796042|OTHER|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
219414607|NCT04438772|OTHER|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
219414608|NCT00488995|DRUG|CP-675,206|
219003974|NCT02551978|OTHER|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
219414609|NCT01047046|OTHER|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
219414610|NCT05000814|DEVICE|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
219414611|NCT04084938|PROCEDURE|Prostate operation or prostate artery embolization|As described above.
219757703|NCT06998615|OTHER|normal subjects|the subjects in this group had no pain or disability in shoulder
219757704|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
219757705|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
219757706|NCT06245434|BEHAVIORAL|Repeated behavioural assessment|"One CRS-R per visit~* 4 SECONDs~* Eye tracking during every clinical assessment~* Recording every 2-4h of the Glasgow Coma Score~* Recording every 2h of the temperature and pupillometer reactivity to light"
219757707|NCT06245434|BEHAVIORAL|Act-Pass paradigm|Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).
219414612|NCT02823041|BEHAVIORAL|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
219414613|NCT02823041|BEHAVIORAL|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
219414614|NCT02823041|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
219414615|NCT02823041|BEHAVIORAL|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
219414616|NCT04848454|DRUG|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
219414617|NCT04092816|BEHAVIORAL|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
219414618|NCT01124201|OTHER|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
219571113|NCT03474029|DRUG|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
219571114|NCT03474029|DRUG|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
219571115|NCT02375217|DRUG|Sugammadex|half dose
219571116|NCT02375217|DRUG|Sugammadex|full dose
219571117|NCT02375217|DRUG|Neostigmine|IV = 50mcg/kg
219571118|NCT02375217|DRUG|glycopyrrolate|
219757708|NCT06245434|BEHAVIORAL|Biological measures of circadian and monoamines biomarkers|Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites
219003975|NCT03682666|DEVICE|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
219571119|NCT00399737|DRUG|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
219571120|NCT01577693|DRUG|dutasteride|novel dutasteride
219571121|NCT01577693|DRUG|dutasteride|dutasteride soft gel capsule
219571122|NCT04959383|OTHER|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
219571123|NCT04959383|OTHER|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
219571124|NCT04959383|OTHER|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
219571125|NCT04959383|OTHER|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
219571126|NCT05656079|DRUG|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
219571127|NCT05656079|DRUG|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
219571128|NCT05656079|DRUG|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
219757709|NCT06245434|BEHAVIORAL|Transcriptomic and genomic analysis|Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery
219757710|NCT06245434|BEHAVIORAL|Polysomnography with concomitant environment recording|"One 48h polysomnography for the first visit~\+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms"
219757711|NCT06245434|BEHAVIORAL|Actimetry|Continuous recording of movements at the wrist during 7 days after sedation withdrawal
219757712|NCT06245434|BEHAVIORAL|Morphological MRI|Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal
219571129|NCT05656079|DRUG|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
219571130|NCT05656079|DRUG|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
219571131|NCT05656079|DRUG|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
219571132|NCT01298778|DRUG|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
219571133|NCT01298778|DRUG|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
219003976|NCT03682666|BEHAVIORAL|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
219003977|NCT03682666|DEVICE|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
219414619|NCT06483763|OTHER|SmokerFace App from the Education Against Tobacco (EAT) program|The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
219414620|NCT06483763|OTHER|The use of standardized school-based educational module|This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
219414621|NCT00316381|PROCEDURE|Autologous bone marrow-derived stem cells|
219414622|NCT02307539|PROCEDURE|Psychosocial Assessment and Care|Undergo PCPI
219414623|NCT02307539|OTHER|Palliative Therapy|Undergo PCPI
219414624|NCT02307539|OTHER|Quality-of-Life Assessment|Undergo QOL assessment
219414625|NCT02307539|OTHER|Questionnaire Administration|Undergo questionnaire administration
219414626|NCT04982510|DEVICE|complete denture|3D printed complete denture
219414627|NCT05602012|BEHAVIORAL|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
219414628|NCT04377334|BIOLOGICAL|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
219414629|NCT02065596|DRUG|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
219414630|NCT02065596|PROCEDURE|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
219414631|NCT05025735|DRUG|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
219414632|NCT00625898|DRUG|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
219571134|NCT01298778|DRUG|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
219571135|NCT03155737|OTHER|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
219571136|NCT03155737|OTHER|Knee health education|A course regarding knee health will be offered to the subjects in this group.
219571137|NCT03135652|RADIATION|adjuvant SBRT|adjuvant SBRT of liver lesions
219571138|NCT03135652|DRUG|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
219414633|NCT00625898|DRUG|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
219414634|NCT00625898|DRUG|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
219414635|NCT00625898|DRUG|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
219414636|NCT00625898|DRUG|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
219414637|NCT00625898|DRUG|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
219414638|NCT00625898|DRUG|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
219414639|NCT01374763|DRUG|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
219414640|NCT01374763|DRUG|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
219414641|NCT04923620|DRUG|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
219414642|NCT04923620|RADIATION|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
219414643|NCT00424528|DRUG|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
219414644|NCT00424528|DRUG|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
219414645|NCT00424528|DRUG|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
219414646|NCT00424528|DRUG|Placebo|Placebo inhalation solution and placebo inhalation powder
219757713|NCT06245434|BEHAVIORAL|Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.|Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
219414647|NCT01734980|PROCEDURE|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
219414648|NCT02278640|DEVICE|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
219414649|NCT04082468|DIAGNOSTIC_TEST|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T \& B lymphocyte panel at above time points
219414650|NCT04389398|DEVICE|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
219414651|NCT01159626|DRUG|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
219414652|NCT01159626|DRUG|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
219414653|NCT01159626|DRUG|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
219414654|NCT01159626|DRUG|Placebo|Oral single dose as matching placebo
219414655|NCT01159626|DRUG|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
219414656|NCT01159626|DRUG|Placebo|Oral multiple doses as matching placebo for 7 days
219414657|NCT01313520|DRUG|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
219414658|NCT01313520|DRUG|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
219414659|NCT04824417|DRUG|Itraconazole 200 mg|Control
219414660|NCT04824417|DRUG|Voriconazole 200mg|Comparator
219757714|NCT07002866|BEHAVIORAL|HIV Risk Reduction (HIVRR)|This is an intervention comprised of 5 sessions of an evidence-based, HIV/STI risk reduction with PrEP to strengthen HIV prevention knowledge and behavioral skills intervention. Session content cover harm reduction, social support networks, HIV knowledge, transmission risks and testing procedures for HIV/STIs, build enthusiasm for condom use, alternatives to unsafe sex, importance of safer sex negotiations, strategies to negotiate safer sex, setting appropriate risk reduction goals, introduction to PrEP, PrEP screening and eligibility; monitoring and managing PrEP side effects and stigma, recognizing and understanding consequences of abusive behavior by any sexual partners or others; build safety plan skills; review and identify ways to increase social support; build skill in communication with health care professionals.
219757715|NCT07002866|BEHAVIORAL|PrEP Peer Supporters (PS)|PrEP peer supporter are women currently on PrEP willing to share their lived experiences. Women will meet with peer supporters in a group at least 8 times during the intervention period (every 2-3 months). Sessions with peers will involve unstructured, in-depth discussions that integrate peers' own lived experiences and emerging PrEP-related issues as raised by participants. These may include, how to mitigate PrEP stigma and disclosure, creating PrEP adherence strategies, navigating family and intimate relationship issues, and navigating provider attitudes. At each stage of the facility visit (waiting space, consultation, and pharmacy), peer supporters will explain facility protocols, and strategies women can use to overcome facility-level barriers to care.
219761522|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
219414661|NCT04534036|DIETARY_SUPPLEMENT|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
219414662|NCT04534036|OTHER|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
219414663|NCT00148850|DRUG|Pioglitazone|
219414664|NCT02221271|DRUG|NPB-01|
219414665|NCT00109304|BIOLOGICAL|VEE 3526|
219414666|NCT03824548|OTHER|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
219414667|NCT01208701|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
219414668|NCT01208701|DRUG|Unikalk|1 tablet Unikalk pr day for 5 days
219414669|NCT00223691|DRUG|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
219414670|NCT00223691|DRUG|Acarbose|25-100 mg, PO. Single dose.
219414671|NCT00223691|DRUG|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
219414672|NCT00223691|DRUG|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
219414673|NCT00223691|DRUG|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
219414674|NCT00223691|DRUG|placebo|PO.Single dose.
219414675|NCT00223691|DRUG|Modafinil|50-400 mg PO. Single dose
219414676|NCT00223691|DRUG|Octreotide|5-50 µg, S.C. Single dose.
219414677|NCT00223691|OTHER|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
219414678|NCT00223691|DRUG|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
219571139|NCT03910660|DRUG|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
219414679|NCT00223691|DRUG|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
219414680|NCT00223691|DRUG|Tranylcypromine|5 - 40 mg PO. Single dose
219414681|NCT00223691|DRUG|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
219414682|NCT00223691|DRUG|Celecoxib|50-200 mg PO. Single dose
219414683|NCT00223691|DRUG|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
219414684|NCT00223691|DRUG|Methylphenidate|5 or 10 mg PO. Single dose.
219414685|NCT00223691|DRUG|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
219414686|NCT00223691|DRUG|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
219414687|NCT00223691|DRUG|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
219414688|NCT00223691|DIETARY_SUPPLEMENT|Bovril|6-10 g, PO. Single dose.
219414689|NCT00223691|DRUG|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
219414690|NCT00223691|DRUG|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
219414691|NCT00223691|DRUG|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
219414692|NCT00223691|DEVICE|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
219414693|NCT00223691|DEVICE|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
219414694|NCT04083898|BIOLOGICAL|Isatuximab|Isatuximab will be administered on a 28-day cycle
219414695|NCT04083898|DRUG|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
219414696|NCT04083898|DRUG|Prednisone|Prednisone will be administered on a 28-day cycle as follows
219414697|NCT01825980|DRUG|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
219414698|NCT01825980|DRUG|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
219414699|NCT01825980|DRUG|Placebo|Placebo
219414700|NCT04470128|DRUG|Stage I: HSK21542 0.5 μg/kg|intravenous injection
219414701|NCT04470128|DRUG|Stage I: HSK21542 1 μg/kg|intravenous injection
219414702|NCT04470128|DRUG|HSK21542 0.5 μg/kg|intravenous injection
219414703|NCT04470128|DRUG|HSK21542 1 μg/kg|intravenous injection
219414704|NCT04470128|DRUG|HSK21542 2 μg/kg|intravenous injection
219414705|NCT04470128|DRUG|Placebo|intravenous injection
219414706|NCT00609453|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
219414707|NCT00247260|DEVICE|32P BioSilicon|
219414708|NCT02395653|DRUG|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
219414709|NCT00040014|DRUG|exemestane|
219003978|NCT03928600|COMBINATION_PRODUCT|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
219003979|NCT03928600|DRUG|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
219003980|NCT03928600|DRUG|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
219003981|NCT01767155|DRUG|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
219003982|NCT01767155|DRUG|doxorubicin|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
219003983|NCT02518750|DRUG|Dexamethasone|Given orally (PO).
219414710|NCT03308162|BEHAVIORAL|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
219414711|NCT02469532|DEVICE|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
219414712|NCT02469532|DEVICE|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
219414713|NCT01757756|DRUG|Pf-05175157|200-mg administered twice daily for 14 days
219414714|NCT01757756|DRUG|placebo|placebo administered twice daily for 14 days
219414715|NCT01757756|DRUG|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
219414716|NCT02021825|DRUG|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
219414717|NCT05069805|PROCEDURE|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
219414718|NCT05069805|PROCEDURE|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
219414719|NCT00234819|DRUG|Bazedoxifene/Conjugated Estrogen|
219003984|NCT02518750|DRUG|Panobinostat|Given PO.
219003985|NCT02518750|DRUG|Liposomal vincristine|For intravenous (IV) use only.
219003986|NCT02518750|DRUG|Mitoxantrone|Given IV.
219003987|NCT02518750|DRUG|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
219414720|NCT02453438|OTHER|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
219414721|NCT00483158|DRUG|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
219414722|NCT02776956|DRUG|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
219414723|NCT02776956|DRUG|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
219414724|NCT00151125|DRUG|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
219414725|NCT00151125|DRUG|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
219414726|NCT00151125|DRUG|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
219414727|NCT03736629|DRUG|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
219414728|NCT03736629|DRUG|Placebo|Placebo
219414729|NCT06293677|DRUG|Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 40 mg/kg q6 h eGFR 150-199 : 30 mg/kg q4h eGFR 200-299 : 40 mg/kg q4h eGFR \&amp;gt;/= 300 : 40 mg/kg q4h~Piperacillin-tazobatam dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 150 mg/kg q6 h eGFR 150-199 : 120 mg/kg q4h eGFR 200-299 : 150 mg/kg q4h eGFR \&amp;gt;/= 300 : 180 mg/kg q4h~The maximum doses for the antibiotic prescription before the first drug monitoring will be 2gr of MER every 4 hours and 4gr of PIP every 4 hours.~The duration of infusion will be set to 2 h."
219414730|NCT06293677|DRUG|Standard dosages of piperacillin-tazobactam or meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR\> 50 : 40mg/kg q8h eGFR 25-49 : 40mg/kg q12h eGFR 15-24 : 20mg/kg q12h~Piperacillin-tazobactam :~eGFR \>50 : 100mg/kg q6h eGFR 20-49 : 50mg/kg q6h eGFR 15-29 : 50 mg/kg q8h"
219414731|NCT03522194|DRUG|Sevoflurane|Anesthesia maintenance with Sevoflurane
219761523|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
219003988|NCT02518750|DRUG|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
219003989|NCT02518750|DRUG|Intrathecal Triples|Given IT as ITMHA.
219003990|NCT02518750|DRUG|High-dose methotrexate|Given intrathecally (IT) or IV.
219003991|NCT02518750|DRUG|6-Mercaptopurine|Given PO at consistent time each day.
219003992|NCT02518750|DRUG|High-dose cytarabine|Given IT or IV.
219003993|NCT02518750|DRUG|Nelarabine|Given IV
219003994|NCT02518750|DRUG|Cyclophosphamide|Given IV.
219003995|NCT02518750|DRUG|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
219003996|NCT02518750|DRUG|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
219003997|NCT02788357|DRUG|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
219003998|NCT02788357|DRUG|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
219003999|NCT01365910|DRUG|linifanib|Given PO
219004000|NCT01401270|BEHAVIORAL|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
219414732|NCT03522194|DRUG|Propofol|Anesthesia maintenance with Propofol
219414733|NCT03900806|BEHAVIORAL|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
219414734|NCT00129194|DRUG|KP-1461|
219414735|NCT00003809|BIOLOGICAL|cetuximab|
219414736|NCT00003809|DRUG|cisplatin|
219414737|NCT03853512|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
219414738|NCT03853512|OTHER|Semisolid vaseline|Product is applied to the other side of the inguinal region.
219414739|NCT00825019|DRUG|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
219414740|NCT00825019|DRUG|placebo|oral administration in 12h intervals
219414741|NCT00825019|DRUG|paroxetine|oral administration of 20 mg/day
219414742|NCT04676542|OTHER|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
219414743|NCT02320968|OTHER|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
219414744|NCT00967226|DRUG|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
219414745|NCT00967226|DRUG|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
219414746|NCT03476382|DEVICE|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
219414747|NCT01768338|DRUG|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
219414748|NCT00505804|DRUG|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
219414749|NCT00505804|DRUG|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
219414750|NCT06342570|OTHER|There is no Intervention name to describe.|There is no Intervention name to describe.
219414751|NCT00714298|OTHER|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
219414752|NCT01541527|BIOLOGICAL|blood test|One blood test entering in the usual follow-up of the patient
219414753|NCT05275296|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
219414754|NCT03516955|DRUG|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
219414755|NCT00605722|DRUG|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
219414756|NCT00605722|DRUG|erlotinib (Tarceva)|150 mg orally (po) daily.
219414757|NCT03300219|BEHAVIORAL|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
219414758|NCT03909932|OTHER|Observational study : no intervention|Observational study : only exporting data
219414759|NCT00210080|DRUG|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
219757716|NCT07002866|BEHAVIORAL|Matched Savings Accounts + Financial Literacy (FL)|A matched savings account (MSA) is a savings account held at a local bank whereby deposits made by the participants are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce participants to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each participant will receive an account held in her own name, and will be allowed to save an equivalent of US$10 a month or US$200 for the 20-months intervention period. During the intervention period, participants will have direct access to both their personal savings deposited in the accounts and the match provided by the study. In addition, participants will also receive six 1-2-hour financial literacy (FL) workshop sessions that cover components on saving, and financial management.
219757717|NCT07004166|OTHER|Z-track method|Z-track method, the skin will be pulled laterally by 2.5-3.5 cm before needle insertion at a 90-degree angle. After aspiration and injection, the needle will be withdrawn and the skin released immediately.
219757718|NCT07004166|OTHER|TPR method|TPR method, while the needle is inserted at a 90-degree angle, deep pressure will be applied to the muscle, then rapidly released to create a snapping motion that facilitates the injection. This technique relies on rapid muscle relaxation rather than needle movement by the dominant hand.
219757719|NCT07005024|DRUG|Apixaban 2.5 mg twice daily|Apixaban, a direct oral anticoagulant (DOAC), will be administered at a prophylactic dose of 2.5 mg by mouth twice daily for 6 months. This dose is guideline-recommended for VTE prevention in high-risk ambulatory cancer patients. Participants will continue their cancer-directed therapy during this time. No study-mandated visits or labs are required beyond standard care.
219757720|NCT07005024|DRUG|Apixaban 5 mg once daily|Apixaban will be administered at 5 mg by mouth once daily for 6 months. This alternative prophylactic schedule is being studied to assess its effectiveness and adherence in patients with a Khorana Risk Score of 2. Participants will continue their usual cancer treatment. This arm evaluates a simplified dosing strategy in a real-world, pragmatic design.
219414760|NCT02530606|PROCEDURE|Photoacoustic Imaging|Undergo PAI
219414761|NCT01155297|BEHAVIORAL|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
219414762|NCT01155297|BEHAVIORAL|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
219414763|NCT02156232|PROCEDURE|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
219414764|NCT02156232|PROCEDURE|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
219414765|NCT01042613|PROCEDURE|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
219414766|NCT01042613|PROCEDURE|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
219414767|NCT00487084|DRUG|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
219414768|NCT00487084|DRUG|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
219414769|NCT00487084|DRUG|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
219414770|NCT04583111|DRUG|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
219414771|NCT04583111|DRUG|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
219414772|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
219414773|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
219414774|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
219414775|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
219414776|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
219414777|NCT00254293|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
219414778|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
219414779|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
219414780|NCT02230878|DRUG|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
219414781|NCT02230878|DRUG|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
219414782|NCT02230878|DRUG|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
219414783|NCT02230878|DRUG|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
219414784|NCT02230878|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
219004001|NCT05950932|DIETARY_SUPPLEMENT|Melissa phytosome|Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.
219004002|NCT05950932|OTHER|Placebo|2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
219004003|NCT00480298|DRUG|Administration of oral methylprednisolone|
219004004|NCT01780818|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
219004005|NCT01780818|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
219414785|NCT01602926|PROCEDURE|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
219004006|NCT01780818|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
219004007|NCT05466877|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
219004008|NCT05466877|DRUG|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
219190542|NCT06565793|DEVICE|Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
219190543|NCT06282523|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
219414786|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
219004009|NCT00691821|OTHER|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
219004010|NCT00691821|DEVICE|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
219004011|NCT00371137|DRUG|Xyrem®|two doses
219004012|NCT00371137|DRUG|Placebo|Oral Solution
219190544|NCT06282523|BEHAVIORAL|HMRP web app|The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
219190545|NCT05748015|DIAGNOSTIC_TEST|quantification of sensory and autonomic small nerve fibers by punch skin biopsy|We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.
219190546|NCT05748015|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
219414787|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
219414788|NCT03986008|DRUG|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
219414789|NCT03986008|DRUG|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
219414790|NCT04717193|DRUG|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
219414791|NCT04717193|PROCEDURE|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
219414792|NCT01161082|DRUG|REGN727(SAR236553)|subcutaneous
219414793|NCT02814864|DRUG|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
219414794|NCT02568345|DRUG|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
219414795|NCT03170479|DIETARY_SUPPLEMENT|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
219414796|NCT03170479|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
219414797|NCT00852189|DRUG|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
219414798|NCT00852189|DRUG|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
219414799|NCT00852189|DRUG|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
219757721|NCT07005024|DRUG|No anticoagulation|Participants randomized to this arm will not receive apixaban or any other anticoagulant for VTE prevention. This reflects current standard care for many cancer outpatients with moderate risk (Khorana Score = 2). Outcomes will be monitored through routine care and medical record abstraction.
219414800|NCT00697658|DRUG|Paliperidone ER|6 mg tablet once daily, variable treatment length.
219414801|NCT02640144|DRUG|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
219414802|NCT02640144|DRUG|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
219414803|NCT03209440|BEHAVIORAL|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
219757722|NCT07003958|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
219757723|NCT07004933|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|Rapid antiretroviral treatment initiation with BIC/FTC/TAF
219757724|NCT07002944|OTHER|Brachial plexus pulsed radiofrequency|Patients will receive pulsed radiofrequency of brachial plexus with steroids injection.
219757725|NCT07002944|OTHER|Sholder individual nerves pulsed radiofrequency|Patients will receive shoulder individual nerves pulsed radiofrequency with steroids injection.
219757726|NCT07002944|OTHER|Control|Patients will receive conservative treatment (paracetamol 1000 tid and pregabalin 75 mg bid; can be increased to 150 mg bid , oxycodone 10 mg oral every 12 hrs .
219757727|NCT07002840|OTHER|Cross- legged sitting position|CLS in which the legs were crossed with hip and knee joints flexed
219757728|NCT07002840|OTHER|Physical Therapy Rehabilitation Program|Strengthening Exercises Stretching Exercises Range of Motion Exercises
219757729|NCT07004101|OTHER|virtual reality|virtual reality and biodex training
219757730|NCT07004101|OTHER|biodex training|biodex training
219757731|NCT07004101|OTHER|conventional balance exercises|conventional balance exercises
219757732|NCT07003880|DRUG|Methoxyflurane anesthesia|A single Penthrox (3mL) self-inhaler will be administered 5-minutes prior to the onset of the procedure, before local anesthesia. Patients will undergo the procedure, have post-procedural vital signs, and remain in clinic for observation for 30 minutes post-procedure per our usual post-procedure monitoring.
219757733|NCT07003646|PROCEDURE|Catheter directed intervention, any device|Catheter directed intervention for treatment of pulmonary embolism
219757734|NCT07003646|DRUG|Alteplase|Systemic thrombolysis
219414804|NCT03209440|BEHAVIORAL|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
219414805|NCT03209440|BEHAVIORAL|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
219414806|NCT03493867|DEVICE|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
219414807|NCT02658344|BIOLOGICAL|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
219414808|NCT02658344|DRUG|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
219414809|NCT04273126|BEHAVIORAL|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
219414810|NCT00743457|DEVICE|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
219757735|NCT07003568|DRUG|Dual-targeting BCMA-GPRC5D CAR-T cell infusion|Approximately 3-5 days prior to BCMA-GPRC5D CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219004013|NCT05954806|DRUG|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
219004014|NCT00536198|DRUG|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
219004015|NCT00536198|DRUG|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
219414811|NCT00845546|DRUG|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
219757736|NCT07002892|DRUG|Ozon treatment|Each patient will receive 2 ml 10 μg/ml ozon perineural injection into the median nerve under US guidance, for 1 session.
219757737|NCT07002892|DRUG|Steroid treatment|Each patient will receive 2 ml:(1 ml betamethasone dipropionate+1ml saline) perineural injection into the median nerve under US guidance, for 1 session.
219004016|NCT02013791|DRUG|Vehicle|Vehicle of cyclosporine administered as per protocol
219004017|NCT02013791|OTHER|Sham|Sham administered to non-study eye as per protocol on Day 1
219004018|NCT02013791|DRUG|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
219757738|NCT07002892|DRUG|Dextrose 5%|Each patient will receive 2 ml %5 dextrose perineural injection into the median nerve under US guidance, for 1 session.
219414812|NCT01864824|DRUG|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
219414813|NCT01864824|DRUG|Placebo|Placebo
219190547|NCT05748015|OTHER|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score
219190548|NCT06568094|DRUG|HRS-5041 tablets|HRS-5041 tablets
219414814|NCT00390247|DRUG|thalidomide|
219414815|NCT01807195|OTHER|contrast medium usage|
219414816|NCT04762407|DRUG|HGP1910|Take it once per period.
219414817|NCT04762407|DRUG|HGP1909|Take it once per period.
219414818|NCT04762407|DRUG|HCP1903|Take it once per period.
219414819|NCT03333330|DRUG|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
219414820|NCT01507844|DEVICE|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
219414821|NCT04874467|PROCEDURE|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
219414822|NCT01002053|PROCEDURE|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
219414823|NCT02712177|BIOLOGICAL|4CMenb|
219414824|NCT02712177|BIOLOGICAL|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
219414825|NCT02712177|BIOLOGICAL|conjugated pneumococcal vaccine|
219414826|NCT02712177|BIOLOGICAL|MMRV|
219414827|NCT00484965|PROCEDURE|Coronary stenting|
219414828|NCT06355401|DRUG|Tamoxifen 20mg|maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
219414829|NCT05747755|BEHAVIORAL|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
219414830|NCT03768531|DRUG|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
219414831|NCT03768531|DRUG|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
219414832|NCT04850716|OTHER|non-intervention|non-intervention
219414833|NCT01626352|DRUG|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
219414834|NCT01626352|DRUG|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
219414835|NCT02797704|DRUG|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
219414836|NCT04825145|OTHER|Pregnancy|Pregnancies complicated by preeclampsia
219757739|NCT07003867|OTHER|Ventilator inspiratory trigger sensitivity adjustment , threshold device training|Ventilator inspiratory trigger sensitivity adjustment threshold device training
219757740|NCT07004517|DIAGNOSTIC_TEST|peri-implant probing before and after crown removal|"Before removal of the prosthetic reconstruction:~* Measurement of PPD-1: The PPDs at 6 site were measured as the distance from the mucosal margin to the base of the peri-implant pocket.~* Measurement of BOP-1：Bleeding sites after gentle probing within 15s were recorded as BOP scores. A positive score (1 point) was recorded if bleeding was observed during either of probing assessment by two researchers.~After removal of the prosthetic reconstruction, PPD-2 and BOP-2 were recorded following the same protocol."
219190549|NCT06568094|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
219190550|NCT06568094|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
219414837|NCT00052884|BIOLOGICAL|filgrastim|
219414838|NCT00052884|DRUG|amifostine trihydrate|
219414839|NCT00052884|DRUG|melphalan|
219414840|NCT00052884|PROCEDURE|bone marrow ablation with stem cell support|
219414841|NCT00052884|PROCEDURE|peripheral blood stem cell transplantation|
219414842|NCT06552715|DEVICE|Placement of resorbable HAp-based composite|The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
219571140|NCT03910660|DRUG|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
219190551|NCT06568094|DRUG|Docetaxel Injection|Docetaxel Injection
219414843|NCT02341118|GENETIC|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
219414844|NCT00127530|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
219414845|NCT00127530|DRUG|Placebo|sugar pill, twice a day (b.i.d.)
219414846|NCT00621452|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219414847|NCT00621452|DRUG|cyclophosphamide|Given IV
219414848|NCT00621452|BIOLOGICAL|aldesleukin|Given subcutaneously
219414849|NCT00621452|GENETIC|polymerase chain reaction|Correlative studies
219414850|NCT00621452|GENETIC|gene rearrangement analysis|Correlative studies
219414851|NCT00621452|PROCEDURE|lymph node biopsy|Optional correlative studies
219571141|NCT02804282|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
219571142|NCT03883282|OTHER|Not Provided|Not Provided
219571143|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
219571144|NCT01037582|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
219571145|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
219571146|NCT01037582|DRUG|placebo|Subjects will be randomized to receive a single dose of placebo.
219571147|NCT01037582|DRUG|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
219757741|NCT07003113|DEVICE|Ischemic Preconditioning|The intervention arm will include full blood flow occlusion in one thigh for 5 minutes followed by 5 minutes of reperfusion for a cycle of 50 minutes.
219757742|NCT07003113|DEVICE|Sham Intervention|This intervention includes 25mmHg of pressure, which is not sufficient for blodo flow occlusion.
219757743|NCT07004114|OTHER|Neurocognitive training group|Neurocognitive training is a rehabilitation approach that, unlike traditional treatment methods which primarily focus on improving physical performance, emphasizes cognitive functions and psychometric skills. It is a program developed by integrating motor learning strategies and cognitive challenges into neuromuscular training. These cognitive challenges include tasks requiring quick reactions, motor-motor or cognitive-motor tasks (dual-task), congruent and incongruent tasks, exercises involving mathematical calculations (working memory), and response inhibition tasks.
219190552|NCT06568094|DRUG|HRS-1167 tablets|HRS-1167 tablets
219190553|NCT06568094|DRUG|SHR2554 tablets|SHR2554 tablets
219190554|NCT05647564|DIAGNOSTIC_TEST|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
219571148|NCT01037582|DRUG|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
219190555|NCT05647564|DIAGNOSTIC_TEST|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
219190556|NCT04858009|DRUG|Cisplatin|Given via HIPEC
219190557|NCT04858009|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with mitomycin and cisplatin
219190558|NCT04858009|DRUG|Nab-paclitaxel|Given via HIPEC
219190559|NCT04858009|PROCEDURE|Computed Tomography|Undergo CT scan
219414852|NCT00621452|BIOLOGICAL|genetically engineered lymphocyte therapy|Receive genetically modified T cells
219414853|NCT00621452|PROCEDURE|bone marrow aspiration|Optional correlative studies
219414854|NCT00621452|OTHER|flow cytometry|Correlative studies
219414855|NCT00621452|OTHER|laboratory biomarker analysis|Correlative studies
219414856|NCT00621452|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219414857|NCT05059951|DRUG|Immune checkpoint inhibitor|Chemotherapy follow the guild line.
219414858|NCT05138874|BEHAVIORAL|Trending Feedback|Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
219414859|NCT05138874|BEHAVIORAL|Benchmark Peer Comparison Feedback|Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
219414860|NCT05138874|BEHAVIORAL|Private Commitment|Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
219414861|NCT05138874|BEHAVIORAL|Public Commitment|Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
219414862|NCT05250830|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
219414863|NCT05250830|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
219414864|NCT03689413|DRUG|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
219414865|NCT06324279|DEVICE|Transvaginal ultrasound|Transvaginal ultrasound will be used to see the presence of cervical sliding sign
219414866|NCT06324279|DRUG|Misoprostol 200mcg Tab|Induction of labor by misoprostol
219414867|NCT02338492|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
219414868|NCT05097248|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
219414869|NCT05097248|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
219414870|NCT05097248|DRUG|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
219571149|NCT01123317|DRUG|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
219571150|NCT02356991|DRUG|Famitinib|
219571151|NCT02356991|DRUG|Placebo|
219571152|NCT03243929|BEHAVIORAL|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
219571153|NCT03243929|BEHAVIORAL|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
219571154|NCT06616129|DIAGNOSTIC_TEST|Geriatric assessment|At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
219571155|NCT06616129|OTHER|Shared decision-making conversation|"The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally."
219757744|NCT07004855|OTHER|30 hr Respite Service|Caregivers will be provided with 30 hours of respite service within 6 months. Trained substitute caregivers will provide in-home elderly-sitting service.
219571156|NCT04965389|DRUG|BMS-986177 Oral Solution|Specified dose on specified days
219571157|NCT04965389|DRUG|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days
219571158|NCT04965389|DRUG|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
219571159|NCT00261131|DRUG|Botulinum Toxin A|
219571160|NCT02138292|DRUG|Trametinib (2mg)/Digoxin (.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
219571161|NCT03938129|OTHER|Blood sample|1st trimester blood sample for bio-bank
219571162|NCT03938129|OTHER|Urine sample|1st trimester urine sample for bio-bank
219571163|NCT03938129|OTHER|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
219571164|NCT04322578|DRUG|Crizotinib|Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
219571165|NCT04322578|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt erery 21day.
219571166|NCT00027859|DRUG|docetaxel|
219571167|NCT00027859|DRUG|estramustine phosphate sodium|
219571168|NCT00027859|DRUG|ketoconazole|
219571169|NCT00027859|DRUG|therapeutic hydrocortisone|
219757745|NCT07004855|OTHER|Case follow-up|Case follow-up service provided by social workers. Social workers will call the caregiver regularly to see if situation changes.
219757746|NCT07004855|OTHER|Crisis management|Crisis management and councelling provided by social workers and professionals.
219757747|NCT07004855|OTHER|Phone Check-in|Regular phone check-in and on-demand services (e.g., escort to hospital) provided by volunteers.
219757748|NCT07002736|OTHER|The Biodex training|Participants will undergo balance training using the Biodex Balance System plus Traditional balance training
219757749|NCT07002736|OTHER|Traditional balance training|Traditional balance training only
219414871|NCT00884052|DRUG|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
219414872|NCT00884052|DRUG|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
219414873|NCT00839423|DRUG|Placebo|capsules, daily, orally
219414874|NCT00839423|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
219414875|NCT00839423|DRUG|Venlafaxine XL|capsules, daily, orally
219414876|NCT03569306|DEVICE|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
219414877|NCT03569306|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
219571170|NCT01509521|DRUG|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
219414878|NCT03831815|DRUG|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
219571171|NCT01509521|DRUG|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
219571172|NCT05600205|BEHAVIORAL|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
219571173|NCT01057927|DRUG|OC000459|OC000459 capsules 2x100mg BID for 28 days
219571174|NCT01057927|DRUG|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
219571175|NCT06308172|PROCEDURE|Hysterotomy closure|Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.
219571176|NCT03968198|DRUG|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
219757750|NCT07002775|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in different position with the same person
219757751|NCT07002970|OTHER|aerobic exercise program|All study group patients performed aerobic exercise on a treadmill. approved by the American College of Sports Medicine.
219757752|NCT07002970|OTHER|Mediterranean diet|received a Mediterranean diet for 12 weeks tailored according to patients caloric needs
219757753|NCT07004959|PROCEDURE|Vaginal ultrasound-guided ethanol sclerotherapy|Use of an endovaginal ultrasound probe combined with a puncture guide. The technique involves locating the endometriosis cyst, echo-guided drainage via the endovaginal route, sclerotherapy (replacement of 60% of the punctured volume with 95% ethanol left in place for 10 minutes) and then reaspiration of the ethanol.
219757754|NCT07004959|PROCEDURE|Laparoscopic cystectomy|Conventional laparoscopy, with the laparoscope introduced through a 10mm incision at the umbilicus, and the laparoscopic instruments used through two or three 5mm incisions (suprapubic and right and left fossa iliaca). The surgical technique may vary according to the patient and the surgeon's preferences or habits, but must necessarily include a cystectomy (cyst wall sent for anatomopathology).
219757755|NCT07003152|DIAGNOSTIC_TEST|diagnosis of endolymphatic hydrops in hydrocephalus patients|the hydrocephalus could be associated with endolymphatic hydrops, this study designed to show the relationship between both of these diseases by special tests for diagnosis
219757756|NCT07003087|OTHER|Shoe's sole modification|Shoe's sole modification by insertion of supporting materials
219757757|NCT07003737|DRUG|Blinatumomab|"Blinatumomab is administered starting approximately one month before allogeneic hematopoietic stem cell transplantation (allo-HSCT).~For participants weighing ≥45 kg: 9 μg/day is administered on Days 1-3, followed by 28 μg/day on Days 4-14.~For participants weighing \<45 kg: 5 μg/m²/day (based on body surface area) is administered on Days 1-3, followed by 15 μg/m²/day on Days 4-14. The total dose must not exceed the dosage used for participants ≥45 kg."
219757758|NCT07003737|OTHER|Consolidation Chemotherapy or Direct Allogeneic HSCT|Participants in the Non-BiTE group will either proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) or receive one additional cycle of consolidation chemotherapy prior to
219757759|NCT07003243|DRUG|Local melatonin powder|A single topical dose of 3 mg of pure melatonin powder was mixed with particulate bone graft and normal saline, then packed into the jumping gap around immediately placed dental implants. The intervention was performed at the time of surgery following atraumatic tooth extraction. The aim was to enhance osseointegration and minimize crestal bone loss over a 6-month healing period.
219757760|NCT07004985|BEHAVIORAL|Kahoot Reinforcement|"Students in this group will complete four interactive reinforcement sessions using the Kahoot platform, following the theoretical content of the Normal Birth and Postpartum Period course. Each session includes 25 multiple-choice questions delivered in a gamified format, with real-time feedback and scoring. The intervention aims to increase motivation, focus, and retention of knowledge."
219414879|NCT05871229|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
219571177|NCT04332016|OTHER|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
219414880|NCT05871229|OTHER|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
219414881|NCT05435144|DIETARY_SUPPLEMENT|Elderberry|European black elderberry extract
219414882|NCT05435144|OTHER|Placebo|Inactive placebo
219571178|NCT02709486|DRUG|Tanezumab|2.5 mg
219571179|NCT02709486|DRUG|Tanezumab|5 mg
219190560|NCT04858009|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219414883|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
219414884|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
219414885|NCT04303793|DEVICE|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
219414886|NCT04348656|BIOLOGICAL|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
219414887|NCT06352099|DIETARY_SUPPLEMENT|Dietary supplement with micronised diosmin, hesperidin and herbal extracts|Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
219414888|NCT01935362|DIETARY_SUPPLEMENT|Citrus supplement|
219571180|NCT02709486|DRUG|Placebo|Placebo
219571181|NCT04267263|BEHAVIORAL|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
219757761|NCT07004985|BEHAVIORAL|Google Forms Reinforcement|Students in this group will complete four structured reinforcement sessions using Google Forms, after participating in the same theoretical course content. Each session consists of 25 multiple-choice questions, delivered in a self-paced online format. The intervention supports repetition and reflection, aiming to improve academic performance and motivation.
219757762|NCT07003971|BEHAVIORAL|counselling|After the participants in the experimental group signed the 'Informed Consent Form', the Instagram addresses actively used by the pregnant women participating in the study will be taken, the Instagram account created by the researcher will be shared with the pregnant women in the experimental group, the participants will be ensured to follow the Instagram address created by the researcher and join the Instagram DM group. After the participation to the platform is completed, the visibility of the participants in the account will be checked. After the visibility of all participants is ensured, pre-tests created in Google Forms and uploaded to WhatsApp and Instagram DM group will be applied.
219761524|NCT03533283|DRUG|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
219761525|NCT03533283|DRUG|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
219761526|NCT03533283|DRUG|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
219190561|NCT04858009|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219190562|NCT02369406|DRUG|Nevirapine|
219190563|NCT02369406|DRUG|Kaletra|
219190564|NCT02369406|DRUG|Lamivudine|
219190565|NCT02369406|DRUG|Zidovudine|
219190566|NCT05758493|DIAGNOSTIC_TEST|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
219190567|NCT05418998|BEHAVIORAL|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
219414889|NCT01935362|DIETARY_SUPPLEMENT|Placebo|
219414890|NCT03248245|OTHER|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
219414891|NCT03248245|OTHER|TAU|Ordinary practices related to interprofessional team collaboration
219414892|NCT05764356|GENETIC|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
219571182|NCT00572117|DRUG|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
219571183|NCT00209586|DRUG|fospropofol disodium|
219571184|NCT00888784|PROCEDURE|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
219190568|NCT06105567|BEHAVIORAL|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
219190569|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
219190570|NCT05738408|BEHAVIORAL|Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)|: In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
219757763|NCT07003971|OTHER|Control|After the 'Informed Consent Form' is signed by the pregnant women in the control group, the telephone numbers of the participants will be taken and recorded in the directory. Participants will also be asked to save the researcher's phone number. After being registered in the phone book, questionnaires and scales will be shared via WhatsApp and asked to answer the pre-tests prepared in Google Forms. Pregnant women who answer will be asked to return with a WhatsApp message in the form of 'I answered' or 'I sent'. The control group will not be trained on Instagram, but will be provided with standardised medical care established by the Turkish Ministry of Health during the follow-up period.
219190571|NCT06567548|OTHER|control group|An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
219190572|NCT06567548|OTHER|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
219190573|NCT06567548|OTHER|Albumin Platelet Rich- Fibrin|is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
219190574|NCT04039581|OTHER|Kinesio Taping|Kinesio Taping (Space Correction).
219190575|NCT04039581|OTHER|Conventional treatment|Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
219190576|NCT06429527|BEHAVIORAL|WHOeyes combined with a questionnaire.|The WHOeyes app (a self-administered visual acuity testing app) plus a questionnaire (to ask the patients to go to the hospital if they ever experience ocular discomfort including eye redness, discharge, etc.) will be used for 1-week follow-up after cataract surgery, and only those with significant vision loss based on WHOeye test or with ocular discomfort are advised to return to the hospital for follow-up.
219190577|NCT06346470|OTHER|Web-based breast self examination education|Students in this group will receive web-based breast self-examination education for 6 hours .
219190578|NCT03308877|BEHAVIORAL|BMI|Four 45-minute, brief motivational sessions for substance use
219190579|NCT03308877|BEHAVIORAL|Stadard Care (SC)|Standard procedures at pretrial program + assessement
219190580|NCT02219633|DRUG|LEO 39652 cream|Applied for 21 days
219190581|NCT05233800|BEHAVIORAL|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
219190582|NCT05233800|BEHAVIORAL|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
219190583|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
219190584|NCT06283719|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219190585|NCT06218485|PROCEDURE|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
219190586|NCT06218485|PROCEDURE|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05"
219190587|NCT05823922|BEHAVIORAL|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
219190588|NCT05823922|BEHAVIORAL|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
219190589|NCT05823311|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
219761527|NCT03533283|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
219761528|NCT03533283|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
219414893|NCT05764356|OTHER|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
219004019|NCT03798483|OTHER|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
219004020|NCT02923960|OTHER|Standard ONS|One serving (237 ml) standard oral nutritional beverage
219190590|NCT05823311|DRUG|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
219190591|NCT06313489|PROCEDURE|Biopsy of EPL tendon and muscle during the operation|Biopsy of EPL tendon and muscle
219414894|NCT05764356|OTHER|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
219414895|NCT00757770|BIOLOGICAL|Rotarix|Two oral doses.
219414896|NCT00757770|BIOLOGICAL|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
219414897|NCT02529293|DRUG|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
219414898|NCT02529293|DRUG|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
219414899|NCT04030780|DIETARY_SUPPLEMENT|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
219414900|NCT04030780|OTHER|Placebo|similar capsules administered twice daily
219414901|NCT04959253|COMBINATION_PRODUCT|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
219414902|NCT04959253|COMBINATION_PRODUCT|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
219414903|NCT03817567|DRUG|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
219414904|NCT04003077|DEVICE|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
219414905|NCT00941954|BEHAVIORAL|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
219414906|NCT00941954|BEHAVIORAL|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
219414907|NCT06555614|OTHER|Acellular Dermal Matrix(ADM)|A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
219414908|NCT03470649|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
219190592|NCT03726047|BEHAVIORAL|Exercise|Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
219414909|NCT01453569|DRUG|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
219414910|NCT01453569|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
219414911|NCT01453569|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
219414912|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
219414913|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
219757764|NCT07004088|BEHAVIORAL|Mandala coloring|"Female patients undergoing dialysis treatment in the dialysis unit were informed about the study. After women are informed about the effects of mandala application on health and how to paint mandala; voluntary consent form, personal information form, Dialysis Symptom Index Scale, Self-Care Power Scale for Chronic Dialysis Patients were filled. One hour after the start of each dialysis session, the patients were given mandalas for 20-30 minutes and asked to paint. The women's own paints and mandalas were preserved for the next session. After the sixth dialysis session , the patients were asked to refill the scales with one-on-one interviews, and the verbal opinions and feedback of the patients about the application were taken."
219757765|NCT07004478|OTHER|Translating the Generic Functional Index into Turkish and Related Processes|The translation process will follow a specific protocol in accordance with the guidelines. It will include two independent forward translations and one back-translation, conducted after obtaining written permission from the original authors. Discrepancies between translations will be reviewed by an expert committee to resolve terminological and cultural differences. The process will ensure conceptual and cultural equivalence between the original English version and the Turkish version. The final version of the questionnaire will be adapted to the target population and finalized in consultation with the original authors.
219414914|NCT00723411|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
219414915|NCT02252237|BIOLOGICAL|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
219757766|NCT07004478|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Generic Functional Index.
219757767|NCT07004478|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
219757768|NCT00834197|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
219757769|NCT00834197|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
219757770|NCT06545617|DRUG|BAT8006 for Injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
219757771|NCT05889507|PROCEDURE|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.
219757772|NCT05889507|PROCEDURE|Targeted normothermia|The axillary temperature will be maintained at 37±0.5°C for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
219414916|NCT00937560|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
219414917|NCT00937560|DRUG|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
219414918|NCT00937560|DRUG|Carboplatin|Carboplatin was supplied locally in commercial batches.
219757773|NCT05889507|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
219761529|NCT03533283|DRUG|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
219761530|NCT04046523|DEVICE|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
219761531|NCT03173937|BIOLOGICAL|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn(TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn(TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
219761532|NCT03173937|DEVICE|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
219761533|NCT06522373|DRUG|MT-0169|Given by Vein (IV)
219761534|NCT03486873|DRUG|Pembrolizumab|200 or 400 mg IV infusion
219761535|NCT03486873|DRUG|Standard of Care (SOC)|IV infusion or oral tablets
219761536|NCT03486873|DRUG|Lenvatinib|Oral capsules
219761537|NCT03486873|DRUG|Olaparib|300mg or 250mg or 100mg oral tablers
219761538|NCT03486873|DRUG|MK-4280|IV Infusion
219761539|NCT03486873|BIOLOGICAL|MK-4280A|800mg favezelimab + 200mg pembrolizumab IV Infusion
219761540|NCT04340141|DRUG|Oxaliplatin|Given IV
219761541|NCT04340141|DRUG|Irinotecan Hydrochloride|Given IV
219761542|NCT04340141|DRUG|Leucovorin Calcium|Given IV
219761543|NCT04340141|DRUG|Fluorouracil|Given IV
219761544|NCT04340141|PROCEDURE|Resection|Undergo surgical resection
219761545|NCT04340141|OTHER|Questionnaire Administration|Ancillary studies
219761546|NCT05746169|OTHER|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
219761547|NCT05746169|OTHER|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
219761548|NCT05953480|BIOLOGICAL|Redasemtide|Lyophilized white powder reconstituted in 0.9% saline for injection
219761549|NCT05953480|DRUG|Placebo|Lyophilized white powder reconstituted in 0.9% saline for injection
219761550|NCT04963296|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
219761551|NCT04963296|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
219761552|NCT04963296|DRUG|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
219761553|NCT04963296|DRUG|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
219761554|NCT04963296|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
219761555|NCT05507333|DEVICE|pHyph generation II|Daily administration of the Gedea pessary during 6 days
219761556|NCT06233461|DRUG|TAK-279|TAK-279 capsules.
219761557|NCT06233461|DRUG|Placebo|TAK-279 placebo-matching capsules.
219761558|NCT06269055|OTHER|Interview|Telephone interview and questionnaires about the results and side effects experienced
219761559|NCT06092034|GENETIC|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
219761560|NCT04189445|DRUG|Futibatinib|Futibatinib tablets were dosed orally every day on a continuous 28-day cycle
219414919|NCT05912309|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
219414920|NCT05912309|BEHAVIORAL|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
219414921|NCT05912309|BEHAVIORAL|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
219414922|NCT00005050|DRUG|ethynyluracil|
219414923|NCT00005050|DRUG|fluorouracil|
219414924|NCT00005050|DRUG|oxaliplatin|
219414925|NCT01911299|DIETARY_SUPPLEMENT|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
219414926|NCT01911299|DIETARY_SUPPLEMENT|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
219414927|NCT02373241|DRUG|Losartan|Standard dosing
219757774|NCT05889507|DIAGNOSTIC_TEST|Follow up assessment at 2 years of age|The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
219757775|NCT05622942|BIOLOGICAL|PBPV|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
219757776|NCT05622942|BIOLOGICAL|PPV23|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
219757777|NCT06863753|OTHER|Kangoroo mother care|Kangaroo mother care will be practiced once, when the service, mother and baby are available, and then the training will be given. For skin-to-skin contact, the newborn will be laid naked on the mother's bare chest in the prone position, the newborn's abdomen and chest will be in contact with the mother's skin. Subsequently, the newborn's head will be turned to the side so that the airway remains open. The newborn will stay in this position for at least 45 minutes.
219757778|NCT06673498|DRUG|Lusutrombopag combined with recombinant human thrombopoietin|After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
219757779|NCT06674174|OTHER|lower limb strength training|Experimental group will receive lower limb strength training treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
219757780|NCT06674174|OTHER|endurance training|Control group will receive endurance training, treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
219757781|NCT05790356|DRUG|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
219757782|NCT05790356|OTHER|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
219757783|NCT07004543|PROCEDURE|Standard Silicone Toe Separator Application|Participants will be instructed to wear standard, commercially available silicone toe separators during a single evaluation session. The intervention consists of applying the separators between the toes while the participant is barefoot, both in static standing and while walking on a treadmill equipped with a Zebris pressure analysis system. Measurements will be taken immediately before and after the application, including plantar pressure distribution, intermetatarsal spacing (via imaging), digital circulation (via thermography and visual assessment), foot posture (using the Foot Posture Index - FPI-6), and subjective comfort levels (via Visual Analog Scale). The toe separators are not customized and reflect common consumer-grade devices marketed for podiatric or wellness purposes.
219757784|NCT06681272|OTHER|Questionnaire|sleep quality assessment using the PROMIS (Patient-Reported Outcomes Measurement Information System) item Bank score
219757785|NCT06681272|OTHER|Questionnaire|assessment of emotional state using the Neuropathic Pain Symptom Inventory score (NPSI)
219414928|NCT02373241|DRUG|Losartan|Experimental dosing
219414929|NCT03719326|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
219414930|NCT03719326|DRUG|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
219414931|NCT03719326|DRUG|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
219414932|NCT03719326|DRUG|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
219414933|NCT00451750|DRUG|Cortisol|20 mg for 3 times
219414934|NCT06169371|DRUG|Abemaciclib|Week 1 50mg orally BID
219414935|NCT06169371|DRUG|Abemaciclib|Week 2 100mg orally BID
219414936|NCT06169371|DRUG|Abemaciclib|Week 3+ 150mg orally BID
219414937|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
219414938|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
219414939|NCT00229203|DRUG|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
219414940|NCT02756975|DEVICE|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
219414941|NCT02756975|DEVICE|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
219414942|NCT03102216|DIAGNOSTIC_TEST|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
219414943|NCT03102216|DIAGNOSTIC_TEST|CBC|Complete Blood Count
219414944|NCT03102216|DIAGNOSTIC_TEST|ECG|ElectroCardioGram
219414945|NCT03102216|DIAGNOSTIC_TEST|Lodox|Low dose x-ray
219414946|NCT04159077|DRUG|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
219414947|NCT04159077|DRUG|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
219414948|NCT00095368|DRUG|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
219414949|NCT04804891|BIOLOGICAL|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
219414950|NCT03607838|DRUG|SI-6603|SI-6603 will be injected into an intervertebral disc.
219414951|NCT03607838|DRUG|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
219414952|NCT04023513|OTHER|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
219414953|NCT04023513|OTHER|Control, no intervention|No Intervention, control
219414954|NCT04023513|OTHER|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
219414955|NCT04023513|OTHER|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
219414956|NCT01266434|DRUG|Simvastatin|10 mg once daily for 8 weeks
219414957|NCT01266434|DRUG|B1-6-12|1 tablet once daily for 8 weeks
219757786|NCT06681272|OTHER|Questionnaire|To assess whether pain measured by a Numercial rating scale (NRS) predicts chronic postoperative pain.
219757787|NCT06623201|DRUG|aminolevulinic acid HCL (ALA)|Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
219757788|NCT06623201|DEVICE|BLU-U device model 4170E|Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
219757789|NCT07003230|DIETARY_SUPPLEMENT|vegan and omnivorous diet|Participants underwent a 2-week omnivorous diet intervention, followed by a 2-week vegan diet intervention
219004021|NCT02923960|OTHER|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
219004022|NCT02923960|OTHER|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
219004023|NCT00450684|DEVICE|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
219004024|NCT00450684|DEVICE|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
219004025|NCT01678430|DRUG|Ofatumumab|
219414958|NCT05629533|DEVICE|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
219414959|NCT04393636|OTHER|Digital cardiac Counseling|"* Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling."
219414960|NCT01576016|DEVICE|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
219414961|NCT01576016|DEVICE|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
219414962|NCT02191709|DRUG|Dextromethorphan syrup|
219414963|NCT02191709|DRUG|Dextromethorphan soft pastilles|
219414964|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414965|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414966|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414967|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219757790|NCT07004816|OTHER|Uncover mutation profiles|Uncover mutation profiles
219757791|NCT07003828|DIAGNOSTIC_TEST|CEUS examinations|CEUS examinations were performed at three predetermined time points during each HD session: immediately before, 3 hours after HD initiation, and 15 minutes post-dialysis.
219757792|NCT01325233|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
219757793|NCT01325233|DRUG|Placebo|500 ml normal saline, tiw, 2 weeks
219757794|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose A|Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
219757795|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose B|Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
219004026|NCT01678430|DRUG|Chlorambucil|
219757796|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose C|Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
219757797|NCT06194656|OTHER|HER3 Monoclonal antibodies-Dose D|The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
219004027|NCT01678430|DRUG|Bendamustine|
219004028|NCT04602455|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
219004029|NCT03425747|DRUG|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
219414968|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219571185|NCT00888784|DRUG|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
219414969|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414970|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414971|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219757798|NCT06194656|OTHER|Placebo|SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
219757799|NCT06194656|COMBINATION_PRODUCT|Cetuximab injection|Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
219004030|NCT03425747|DRUG|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
219004031|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
219004032|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
219004033|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
219004034|NCT00632242|DRUG|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
219004035|NCT00632242|DRUG|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
219004036|NCT03900351|PROCEDURE|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
219004037|NCT03900351|PROCEDURE|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
219004038|NCT02231333|DRUG|S-adenosylmethionine (SAMe)|
219004039|NCT02231333|DRUG|pentoxiphylline (PTX)|
219414972|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414973|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
219414974|NCT02667860|PROCEDURE|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
219414975|NCT02667860|PROCEDURE|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
219414976|NCT02667860|DEVICE|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
219571186|NCT04916496|BEHAVIORAL|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
219571187|NCT04916496|BEHAVIORAL|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
219571188|NCT05082363|COMBINATION_PRODUCT|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
219571189|NCT03226119|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
219571190|NCT04588441|DRUG|Adenosine|Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
219414977|NCT02667860|DEVICE|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
219414978|NCT04834973|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
219414979|NCT04834973|DRUG|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
219414980|NCT05851508|DRUG|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
219414981|NCT05851508|DRUG|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
219414982|NCT00410501|DRUG|Indacaterol (QAB149)|
219571191|NCT02214719|BEHAVIORAL|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
219571192|NCT01369602|DRUG|PF-04991532|single dose 300-mg
219571193|NCT01369602|DRUG|PF-04991532|single dose 300-mg
219571194|NCT01369602|DRUG|PF-04991532|single dose 300-mg
219571195|NCT01369602|DRUG|PF-04991532|single dose 300-mg
219571196|NCT05322902|DRUG|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
219004040|NCT02704871|OTHER|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
219414983|NCT03195855|OTHER|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
219414984|NCT05120960|DRUG|tepotinib|Given by PO
219414985|NCT05120960|DRUG|tepotinib plus osimertinib|Given by PO
219571197|NCT05322902|DRUG|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
219571198|NCT05407506|DIAGNOSTIC_TEST|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
219571199|NCT06233019|OTHER|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
219571200|NCT00052416|DRUG|thalidomide|
219571201|NCT00589849|PROCEDURE|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
219004041|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
219004042|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
219004043|NCT02205632|DEVICE|MPS II|
219004044|NCT03657511|BEHAVIORAL|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
219004045|NCT06094595|DIAGNOSTIC_TEST|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
219414986|NCT02546674|DRUG|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
219414987|NCT01163253|DRUG|CP-690,550|5 mg oral BID
219414988|NCT01163253|DRUG|CP-690,550|10 mg oral BID
219571202|NCT05813938|DEVICE|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
219571203|NCT05760352|DEVICE|Eccentric bike|Received eccentric cycling exercise
219571204|NCT05760352|DEVICE|Helmet ventilation|Using helmet ventilation during eccentric cycling exercise
219571205|NCT00737737|DRUG|MS Contin|
219414989|NCT03670394|DIAGNOSTIC_TEST|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
219414990|NCT03972358|DRUG|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
219414991|NCT03972358|DRUG|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
219414992|NCT05315232|OTHER|survey and interview|qualitative assessment
219414993|NCT02656758|BEHAVIORAL|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
219571206|NCT00737737|DRUG|Placebo|
219571207|NCT01481870|DRUG|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
219004046|NCT01116583|DRUG|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
219004047|NCT01116583|DRUG|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
219414994|NCT06373172|OTHER|virtual simulation-based education program|"We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module."
219571208|NCT01481870|DRUG|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
219571209|NCT03024047|DEVICE|Pacemaker|
219571210|NCT06504147|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
219571211|NCT03517254|DIETARY_SUPPLEMENT|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
219757800|NCT05493657|DRUG|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
219757801|NCT05493657|DRUG|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
219757802|NCT06941857|DRUG|Oxaliplatin|65mg/m2 will be administered as a 120 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757803|NCT06941857|DRUG|Irinotecan|150 mg/m2 will be administered as a 90 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219004048|NCT01918930|BIOLOGICAL|MGA271|MGA271 anti-B7-H3 monoclonal antibody
219571212|NCT03517254|OTHER|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
219571213|NCT03517254|OTHER|Placebo|Maltodextrin powder to mimic glutamine,
219571214|NCT03517254|OTHER|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
219757804|NCT06941857|DRUG|Folinic Acid|50 mg will be administered as a 15 minute IV infusion (-5/+20 min) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. Folinic acid can be given concurrent with irinotecan. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757805|NCT06941857|DRUG|5-Fluorouracil (5-FU)|2400 mgm2 will be administered as a continuous IV Infusion (-120/+ 120 minutes) over approximately 46 hours on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757806|NCT06941857|DRUG|NC410|100 mg will be administered as a 60 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757807|NCT06941857|DRUG|Nivolumab|400 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757808|NCT06941857|DRUG|Ipilimumab|50 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
219757809|NCT07143617|BIOLOGICAL|STR-P004|STR-P004 Intravenous infusion
219757810|NCT07149506|OTHER|Epicatechin|A comparison will be made between oral catechin (epicatechin) from two approaches: a preventive approach and a therapeutic approach.
219757811|NCT07149506|OTHER|Epigallocatechin Gallate (EGCG)|A comparison will be made between topical catechin (EGCG) from two approaches: a preventive approach and a therapeutic approach.
219757812|NCT07149506|OTHER|Microcrystalline Cellulose NF (placebo)|A comparison will be made between oral placebo (microcrystalline cellulose) from two approaches: a preventive approach and a therapeutic approach.
219757813|NCT07149506|OTHER|Saline (0.9% NaCl)|A comparison will be made between topical placebo (0.9% saline solution) from two approaches: a preventive approach and a therapeutic approach.
219571215|NCT05336305|DIETARY_SUPPLEMENT|Polydextrose|Administration of 3g polydextrose per day, for 2 months
219757814|NCT05530733|PROCEDURE|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
219757815|NCT05530733|PROCEDURE|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
219757816|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
219757817|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
219414995|NCT02521688|PROCEDURE|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
219757818|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
219757819|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
219757820|NCT05498584|BEHAVIORAL|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
219757821|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given IV
219414996|NCT00987922|DEVICE|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
219414997|NCT02848339|DRUG|aspirin|aspirin desensitization
219414998|NCT03736954|BEHAVIORAL|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
219757822|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
219757823|NCT02146924|OTHER|Laboratory Biomarker Analysis|Correlative studies
219761561|NCT06957769|OTHER|heat stress|"Heat stress (exposure) will be quantified using validated environmental heat stress indices, including the Universal Thermal Climate Index (UTCI), Wet Bulb Globe Temperature (WBGT) and heat index (HI). The former two indices integrate four key environmental parameters, ambient temperature, relative humidity, solar radiation, and wind speed, to provide a quantified measure of thermal stress. The heat index represents the apparent temperature or how hot it feels to the human body when air temperature is combined with relative humidity.~Indoor heat exposure will be assessed using wearable temperature and humidity loggers, while outdoor environmental data, including temperature, humidity, radiation, and wind speed, will be captured using Kestrel WBGT devices installed in the study area."
219414999|NCT00423735|DRUG|Dasatinib|Given PO
219415000|NCT00423735|OTHER|Pharmacological Study|Correlative studies
219415001|NCT05839431|BEHAVIORAL|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
219415002|NCT00446485|DRUG|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
219415003|NCT00446485|DRUG|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
219415004|NCT00446485|DRUG|placebo|placebo during 6 months
219415005|NCT04996472|BEHAVIORAL|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
219415006|NCT04996472|BEHAVIORAL|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
219415007|NCT02864940|DEVICE|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
219415008|NCT02864940|DEVICE|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
219415009|NCT02581111|DRUG|Naloxone|Naloxone 8-mg IV bolus
219415010|NCT02581111|DRUG|Normal saline|
219190593|NCT04804293|DEVICE|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
219190594|NCT03643744|DRUG|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
219190595|NCT03643744|DRUG|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
219190596|NCT05806021|DRUG|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
219190597|NCT04895033|BEHAVIORAL|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
219190598|NCT03787173|DEVICE|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
219190599|NCT03787173|DEVICE|Automated|Inspiratory trigger and Expiratory trigger settings automatized
219190600|NCT06537596|DRUG|89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)|Single administration of 89Zr-TLX300-CDx
219190601|NCT06536647|DIAGNOSTIC_TEST|Contactless measurement of patient vital signs using the VitalsTM system|Contactless measurement of the patient blood pressure, heart rate, respiratory rate, body temperature and SpO2 will be carried out using the VitalsTM platform based on facial video data.
219190602|NCT06419855|DEVICE|Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
219190603|NCT06419855|DEVICE|Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
219190604|NCT03397706|COMBINATION_PRODUCT|VRx-3996 and valganciclovir|second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)
219415011|NCT01722487|DRUG|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
219757824|NCT04104347|OTHER|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
219190607|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
219190608|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
219190609|NCT05742399|DRUG|Hyaluronic acid NanoGel|Hyaluronic acid nanoparticles (2%)
219190610|NCT05742399|DRUG|Placebo gel|conventional gel having the same color, form and packaging
219190611|NCT06271382|OTHER|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
219415012|NCT01722487|DRUG|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
219757825|NCT04104347|OTHER|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
219415013|NCT00579501|DRUG|Trabectedin|Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
219415014|NCT00579501|DRUG|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
219415015|NCT01370057|DEVICE|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
219415016|NCT03364673|OTHER|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
219415017|NCT03364673|OTHER|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
219415018|NCT02446353|DRUG|Apetrol ES / Megace|Sequences of administered drugs
219415019|NCT06296433|OTHER|VR rehabilitation|VR software application containing education, exergames, therapeutic exercises and relaxation sections.
219415020|NCT06296433|OTHER|VR video application|VR software application that plays 2D nature videos
219415021|NCT01897181|DEVICE|Hearing aids|Using hearing aids for 12 months
219415022|NCT06261099|OTHER|control + working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
219415023|NCT03025217|BEHAVIORAL|Total Lifestyle Coaching (TLC)|
219415024|NCT04585217|PROCEDURE|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
219571216|NCT02540447|PROCEDURE|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
219571217|NCT02794935|OTHER|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
219571218|NCT02794935|OTHER|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
219571219|NCT00649727|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
219571220|NCT00649727|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
219571221|NCT04776057|OTHER|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
219571222|NCT00110344|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
219571223|NCT00110344|DRUG|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
219004049|NCT00923247|DRUG|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
219004050|NCT00923247|DRUG|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
219004051|NCT03438344|BIOLOGICAL|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
219004052|NCT03438344|OTHER|Laboratory Biomarker Analysis|Correlative studies
219415025|NCT01165593|OTHER|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
219415026|NCT01953536|DRUG|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
219415027|NCT01953536|DRUG|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m\^2.
219415028|NCT01953536|DRUG|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
219415029|NCT01953536|DRUG|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
219415030|NCT01953536|DRUG|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
219415031|NCT03689062|PROCEDURE|induction of labor|oxytocin intravenous drip
219415032|NCT03689062|PROCEDURE|follow up|hospitalization and antibiotics
219415033|NCT04875338|DRUG|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
219415034|NCT04875338|DRUG|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
219415035|NCT04875338|DRUG|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
219415036|NCT05143762|DRUG|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
219415037|NCT05143762|DRUG|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
219415038|NCT05143762|DRUG|normal Saline|patients will receive placebo 10 ml normal saline IV.
219415039|NCT00692510|DRUG|AZD3480|Capsule, oral, dose once daily, 7 days
219415040|NCT00692510|DRUG|Placebo|Capsule, oral, dose once daily, 7 days
219415041|NCT00692510|DRUG|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
219571224|NCT00604201|BIOLOGICAL|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
219761562|NCT06794177|OTHER|Variable priority dual task training|Variable priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
219004053|NCT03438344|OTHER|Placebo|Given IM
219004054|NCT06504823|OTHER|Light level|light application
219415042|NCT03379012|DRUG|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
219415043|NCT01254513|DRUG|Docetaxel every 3 weeks + Prednisone|"* Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
219415044|NCT01254513|DRUG|Docetaxel weekly+ Prednisone|"* Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
219004055|NCT06505655|DIAGNOSTIC_TEST|trehalase levels|We think that in surgical patients requiring hypotensive anesthesia, acute kidney injury, which may occur due to intraoperative renal hypoperfusion, can be diagnosed early by evaluating the urine trehalase value using the ELISA method
219004056|NCT00023504|BIOLOGICAL|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
219415045|NCT00893048|DRUG|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
219415046|NCT00893048|DRUG|Placebo Oral Tablet|Placebo
219415047|NCT01670409|RADIATION|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
219415048|NCT01670409|DRUG|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
219415049|NCT05133804|DRUG|Methylphenidate|Ritalin 10mg
219415050|NCT05133804|DRUG|Reboxetine|Reboxetine 4mg
219415051|NCT05133804|DRUG|Placebo|Placebo matched to Reboxetine
219415052|NCT05133804|DRUG|Placebo|Placebo matched to Ritalin
219415053|NCT02208024|RADIATION|Stereotactic Body Radiation Therapy|
219415054|NCT03475576|OTHER|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
219415055|NCT00229164|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|
219415056|NCT04677621|OTHER|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
219415057|NCT04677621|OTHER|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
219415058|NCT05075967|OTHER|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks \[BTAN\]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
219415059|NCT05075967|BEHAVIORAL|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~* HIV/sexually transmitted infections (STI) testing promotion~* PrEP (and general HIV prevention) awareness and promotion~* Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
219415060|NCT05075967|BEHAVIORAL|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
219415061|NCT05075967|BEHAVIORAL|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~* HIV, PrEP, nPEP, other HIV prevention options and ART education~* Adherence to PrEP, ART and medical care~* HIV/STI testing~* New HIV diagnosis~* Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~* Self-care~* Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~* Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
219415062|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
219415063|NCT04096326|DRUG|AGN-151586|AGN-151586 solution for injection.
219415064|NCT04096326|DRUG|Placebo|Placebo solution for injection.
219571225|NCT05202041|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
219571226|NCT05202041|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
219571227|NCT00789763|DRUG|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
219571228|NCT00789763|RADIATION|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
219004057|NCT00023504|BIOLOGICAL|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
219004058|NCT00023504|BIOLOGICAL|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
219004059|NCT00023504|BIOLOGICAL|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
219004060|NCT03714867|DRUG|Pregabalin 150mg|150 mg concealed pregabalin capsule
219004061|NCT03714867|OTHER|Placebo|Concealed placebo capsule
219004062|NCT03558178|PROCEDURE|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
219571229|NCT00789763|DRUG|Sorafenib|200-800 mg/day p.o. during 5 weeks
219571230|NCT01659164|BEHAVIORAL|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
219571231|NCT01626963|PROCEDURE|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
219571232|NCT01626963|PROCEDURE|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
219571233|NCT04719741|OTHER|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
219571234|NCT04951414|DIAGNOSTIC_TEST|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
219757826|NCT05198258|OTHER|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
219757827|NCT05198258|OTHER|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
219757828|NCT04446403|PROCEDURE|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
219757829|NCT04446403|PROCEDURE|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
219761563|NCT06794177|OTHER|Fixed priority dual task training|Fixed priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
219415065|NCT01800279|OTHER|Physiotherapy Protocol|"Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
219415066|NCT01800279|OTHER|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
219415067|NCT06269289|OTHER|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
219415068|NCT06269289|OTHER|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
219415069|NCT02004782|DRUG|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
219415070|NCT02004782|DRUG|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
219415071|NCT00194025|DRUG|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
219415072|NCT00004418|DRUG|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
219415073|NCT05877651|BIOLOGICAL|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
219415074|NCT05782296|DEVICE|TrueLabor|Non invasive monitoring device
219571235|NCT00706355|DRUG|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
219571236|NCT04799613|OTHER|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
219571237|NCT04799613|OTHER|visual loading|visual loading (walking through narrow pathway using VR)
219757830|NCT04446403|PROCEDURE|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
219757831|NCT04446403|PROCEDURE|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
219571238|NCT04799613|OTHER|dual task|dual task (serial subtraction using VR)
219571239|NCT04799613|OTHER|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
219571240|NCT06445218|OTHER|Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
219571241|NCT00530543|PROCEDURE|Robot-assisted gait training|
219571242|NCT00549952|OTHER|no intervention study|
219571243|NCT02463799|DRUG|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
219571244|NCT02463799|BIOLOGICAL|Sipuleucel-T|3 infusions of sipuleucel-T alone
219571245|NCT01020799|DRUG|AZD7268|15 mg, oral, twice daily (BID)
219571246|NCT01020799|DRUG|Escitalopram|20 mg, oral, once daily (QD)
219571247|NCT01020799|DRUG|Placebo capsules|Placebo capsules to match AZD7268
219571248|NCT01020799|DRUG|Placebo tablets|Placebo tablets to match encapsulated escitalopram
219757832|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
219757833|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
219757834|NCT06289465|OTHER|Observation|Seasonal workers will be assessed in the assessment area established in the hazelnut field and healthy controls will be assessed in their homes.
219757835|NCT02207543|OTHER|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
219757836|NCT04055753|DRUG|Doxil|Doxil 50 mg/m2, as per institutional standard
219757837|NCT04055753|DRUG|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
219757838|NCT05731271|DRUG|TST003|IV humanized anti-GREM1 monoclonal antibody
219415075|NCT04732819|BEHAVIORAL|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team."
219415076|NCT01318473|DEVICE|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
219415077|NCT04804033|DRUG|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
219415078|NCT04804033|DRUG|Placebo|Matching placebo softgel capsule.
219415079|NCT06177184|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
219415080|NCT05239949|OTHER|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
219757839|NCT05544721|DRUG|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
219757840|NCT03801512|OTHER|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
219004063|NCT03558178|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
219004064|NCT03791489|DEVICE|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
219004065|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
219004066|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
219004067|NCT00534391|DRUG|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
219004068|NCT00534391|DRUG|Artificial tear|4 times daily
219004069|NCT02447042|PROCEDURE|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
219415081|NCT05239949|OTHER|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
219571249|NCT01932099|DEVICE|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
219571250|NCT03504761|DEVICE|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
219757841|NCT03801512|OTHER|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
219757842|NCT03801512|OTHER|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
219757843|NCT04122378|OTHER|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
219757844|NCT03838744|DRUG|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
219571251|NCT01784354|OTHER|Acupressure|
219571252|NCT01784354|OTHER|Acupressure dilatation|
219571253|NCT01784354|BEHAVIORAL|education|
219004070|NCT02447042|DEVICE|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
219004071|NCT01798511|PROCEDURE|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
219004072|NCT01798511|OTHER|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
219004073|NCT01691781|DRUG|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
219571254|NCT05349747|BIOLOGICAL|Biologic drugs|Assess the results of treatment with biologic drugs
219757845|NCT03838744|DRUG|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
219004074|NCT02165969|PROCEDURE|endoscopic endonasal surgery with UPSIT|
219004075|NCT00655044|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
219004076|NCT00662805|DRUG|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
219004077|NCT02088281|DRUG|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
219415082|NCT04917835|DEVICE|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
219415083|NCT05974085|DRUG|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
219415084|NCT00209170|BEHAVIORAL|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
219415085|NCT00209170|DRUG|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
219415086|NCT00209170|DRUG|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
219415087|NCT06554470|DRUG|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
219415088|NCT06554470|DRUG|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
219415089|NCT02310971|BIOLOGICAL|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
219415090|NCT04719169|DIAGNOSTIC_TEST|Dynamic MRI enema|Dynamic MRI enema
219415091|NCT04719169|DIAGNOSTIC_TEST|Fluoroscopic enema|Fluoroscopic enema
219415092|NCT04648423|DRUG|Sodium Oxybate|solution for oral administration
219415093|NCT04648423|DRUG|Placebo|solution for oral administration
219415094|NCT04958863|OTHER|Surgical mask|Use of a surgical mask during test
219415095|NCT04958863|OTHER|Polyester reusable mask|Use of a polyester reusable mask during test
219415096|NCT05589116|OTHER|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
219415097|NCT00543569|DRUG|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
219415098|NCT00543569|DRUG|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
219571255|NCT04179019|DRUG|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
219571256|NCT05369078|DRUG|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
219571257|NCT05369078|DRUG|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
219415099|NCT00543569|DRUG|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
219415100|NCT00543569|DRUG|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
219415101|NCT00543569|DRUG|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
219415102|NCT03097224|BEHAVIORAL|Prehabilitation|Four weeks of tele-supervised prehabilitation
219415103|NCT03194152|DIETARY_SUPPLEMENT|Peanut|Dietary Supplement: Peanut
219415104|NCT03194152|DIETARY_SUPPLEMENT|Control|Dietary Supplement: High carbohydrate snacks
219415105|NCT02020096|PROCEDURE|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
219415106|NCT02020096|PROCEDURE|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
219415107|NCT03259997|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
219415108|NCT03259997|DIETARY_SUPPLEMENT|Placebo|Placebo
219415109|NCT03169023|BEHAVIORAL|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
219415110|NCT03169023|BEHAVIORAL|Enhanced Usual Care Packets|-From the American Cancer Society Website
219415111|NCT03169023|OTHER|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
219415112|NCT03169023|OTHER|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
219415113|NCT03169023|OTHER|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
219415114|NCT03169023|OTHER|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
219415115|NCT03169023|OTHER|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
219415116|NCT03169023|BEHAVIORAL|iOTA|-Washington University based intervention
219415117|NCT03374384|OTHER|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
219415118|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
219571258|NCT00788229|DRUG|AT01|eye drop for 12 weeks
219571259|NCT00788229|DRUG|AT02|eye drop for 12 weeks
219571260|NCT00788229|DRUG|AT03|eye drop for 12 weeks
219571261|NCT00788229|DRUG|AT04|eye drop for 12 weeks
219571262|NCT02382926|OTHER|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
219571263|NCT00705692|DRUG|Levamisole|
219571264|NCT00705692|DRUG|Placebo|
219571265|NCT06583850|OTHER|The Neck Disability Index|The Neck Disability Index (NDI) is the most widely used self-report tool to assess neck pain status, and provides information not only about pain experiences but also about a person\&#39;s functional status. The NDI consists of 10 questions related to pain, functional activities, self-care, and quality of life that are measured on a 6-point scale (0, no disability; 5, full disability). The numeric score for each item is summed for a score ranging from 0 to 50; 0-4 points are defined as no disability, 5-14 points as mild disability, 15-24 points as moderate disability, 25-34 points as severe disability and above 35 points as complete disability.
219571266|NCT06583850|OTHER|Visual analog scale (VAS)|A 10 cm VAS numbered from 0 to 10 was used for the assessment. 0 indicates no pain and 10 indicates unbearable pain. Participants were asked to mark a point between 0-10 according to their pain status
219571267|NCT06583850|OTHER|Pittsburgh Sleep Quality Index|Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire
219004078|NCT05930977|PROCEDURE|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
219004079|NCT04085809|OTHER|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
219004080|NCT02535988|RADIATION|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
219415119|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
219415120|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
219415121|NCT06142461|DEVICE|PharmaJet Stratis® Needle-Free Injection System|0.5mL dose injection
219415122|NCT06142461|DEVICE|PharmaJet Tropis® Needle-Free Injection System|0.1mL dose injection
219415123|NCT02124707|DRUG|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
219415124|NCT02124707|DRUG|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
219571268|NCT06583850|OTHER|Cervical Range of Motion Assessment|Active Cervical Range Of Motion was measured with a universal goniometer in all three planes of motion in the cervical region: lateral flexion (frontal plane), axial rotation to both right and left sides (horizontal plane), and flexion-extension (sagittal plane).
219571269|NCT04531657|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
219571270|NCT02610816|OTHER|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
219571271|NCT02610816|OTHER|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
219571272|NCT02610816|OTHER|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
219761564|NCT06794177|OTHER|Single task training|Single task training with balance and walking exercises, twice a week for six weeks
219415125|NCT02124707|DRUG|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
219415126|NCT00037635|DRUG|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
219415127|NCT00037635|DRUG|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
219415128|NCT01692353|OTHER|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
219415129|NCT04753242|OTHER|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C\&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C\&L services in the context of pandemics, especially the COVID-19 pandemic.
219415130|NCT00123916|DRUG|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
219415131|NCT00123916|DRUG|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
219415132|NCT01268423|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
219415133|NCT01268423|PROCEDURE|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
219415134|NCT06357260|DRUG|Pregabalin and Carbamazepine|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
219415135|NCT06357260|DRUG|Carbamazepine|Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
219571273|NCT02610816|DRUG|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
219757846|NCT05906771|DIETARY_SUPPLEMENT|Metabolaid(R)|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~The nutraceutical has been elaborated by Monteloeder, S.L. It is a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves. The dose that the participants of the experimental group will receive will be 300mg plus 20mg of microcrystalline cellulose. The product is presented in an unflavored capsule, it is a reddish-brown powder with a characteristic odor and a slightly bitter taste. The manufacturing date of the product was 01/12/2022 and the expiration date was 30/11/2024."
219757847|NCT05906771|DIETARY_SUPPLEMENT|Nutraceutical placebo|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~Nutraceutical placebo contains microcystalline cellulose (185mg) and maltodextrin (185mg)."
219415136|NCT03117062|OTHER|occlusal reduction|relief of occlusion following endodontic treatment
219415137|NCT01593501|DIETARY_SUPPLEMENT|vitamin D3|pharmaceutical grade D3
219415138|NCT06531070|DIETARY_SUPPLEMENT|Nitrate|"A four-day supplementation period, separated by one week including a 3-day washout period between conditions will be applied before conducting strength and endurance assessments~Days 1 to 3 the randomly assigned supplement (N, NC, or PLA) will be ingested 2 hr before a standard low-volume training session including 3 sets of 8 to 10 reps of squat and deadlift using a very light load (e.g., own body mass) and flexibility exercises following by 5 min of running at self-paced intensity rated as light (12) with the rating of perceived exertion Borg Scale.~Day 4: the assigned supplement will be ingested 2.5 h before the assessments~Assessment of strength and endurance will be conducted"
219415139|NCT04054843|DIAGNOSTIC_TEST|Afamin|Plasma maternal afamin levels
219415140|NCT05729425|DEVICE|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
219415141|NCT03653403|DRUG|IDP-126 Gel|Component A
219415142|NCT03653403|DRUG|Control Gel|gel
219415143|NCT04790266|DIAGNOSTIC_TEST|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
219415144|NCT02815176|OTHER|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
219571274|NCT05684146|DEVICE|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
219571275|NCT05684146|DEVICE|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
219571276|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
219571277|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
219571278|NCT04516408|BIOLOGICAL|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
219571279|NCT04516408|BIOLOGICAL|Placebo|Sterilized water
219571280|NCT04419623|DRUG|TL-895|TL-895, administered by mouth
219190612|NCT06271382|OTHER|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
219415145|NCT05528874|DIETARY_SUPPLEMENT|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
219415146|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
219415147|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
219415148|NCT04888234|DRUG|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
219415149|NCT05640674|DRUG|Ibuprofen|Non-opioid
219415150|NCT05640674|DRUG|Hydrocodone/acetaminophen|Opioid
219415151|NCT05640674|DRUG|Acetaminophen|Non-opioid
219415152|NCT02626845|DRUG|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
219415153|NCT02626845|OTHER|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
219415154|NCT01202721|DRUG|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
219415155|NCT01202721|DRUG|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
219571281|NCT05678855|BEHAVIORAL|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
219190613|NCT06271382|OTHER|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
219415156|NCT00551538|DRUG|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
219415157|NCT00551538|DRUG|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
219415158|NCT00261248|BIOLOGICAL|Immunization with inactivated bacteria|
219415159|NCT00974051|DRUG|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
219415160|NCT00974051|OTHER|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
219415161|NCT00974051|OTHER|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
219415162|NCT01403701|BEHAVIORAL|Physical therapy|pelvic floor physical therapy
219415163|NCT05360355|PROCEDURE|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
219415164|NCT06409091|DEVICE|Medium weight or Heavy weight mesh|Patients received a hernia repair with one of the two groups
219415165|NCT01650818|OTHER|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
219415166|NCT01650818|OTHER|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
219415167|NCT00089479|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
219190614|NCT02523222|DIETARY_SUPPLEMENT|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
219190615|NCT04491617|OTHER|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
219190616|NCT04491617|OTHER|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
219190617|NCT03125928|DRUG|Atezolizumab|Monoclonal antibody
219415168|NCT00089479|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
219415169|NCT00089479|DRUG|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
219415170|NCT06410599|DRUG|Ketamine|Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
219571282|NCT00780923|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
219571283|NCT03975413|OTHER|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
219571284|NCT02919813|BEHAVIORAL|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
219571285|NCT02919813|BEHAVIORAL|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
219571286|NCT02335515|DEVICE|Soctec|Gastroretentive Drug Delivery System
219571287|NCT04765527|DIETARY_SUPPLEMENT|Turmeric Strength for Joint|Turmeric-based tablets
219571288|NCT04765527|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219571289|NCT03665948|OTHER|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
219571290|NCT03665948|OTHER|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
219190618|NCT03125928|DRUG|Paclitaxel|Chemotherapy
219190619|NCT03125928|DRUG|Trastuzumab|Monoclonal antibody
219415171|NCT06410599|DRUG|Placebo|Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
219415172|NCT06410599|BEHAVIORAL|CBASP|In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
219415173|NCT06410599|BEHAVIORAL|TAU|Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
219415174|NCT01547468|PROCEDURE|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
219415175|NCT01547468|PROCEDURE|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
219415176|NCT01094717|DRUG|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
219415177|NCT01094717|DEVICE|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
219415178|NCT01094717|DRUG|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
219415179|NCT01094717|DEVICE|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
219571291|NCT02164630|BEHAVIORAL|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
219571292|NCT02164630|OTHER|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
219571293|NCT03236948|BEHAVIORAL|Women for Women International Intervention|
219571294|NCT05518630|BEHAVIORAL|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
219571295|NCT04012372|OTHER|ROSA Water|Ad libitum hydration with ROSA oligomineral water
219571296|NCT04012372|OTHER|Control water|Ad libitum hydration with other waters
219571297|NCT02394691|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
219571298|NCT01704430|DIETARY_SUPPLEMENT|Glutamine|Enteric L-Glutamine
219571299|NCT01704430|DIETARY_SUPPLEMENT|Maltodextrin|Enteric Maltodextrin
219571300|NCT01855048|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
219571301|NCT01855048|OTHER|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
219571302|NCT00542763|DRUG|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
219190620|NCT03125928|DRUG|Pertuzumab|Monoclonal antibody
219190621|NCT04677738|DIETARY_SUPPLEMENT|B. breve strain|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve strain in the morning before breakfast for 12 weeks.
219190622|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
219190623|NCT04707469|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
219571303|NCT02212340|DRUG|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
219004081|NCT02535988|DRUG|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
219004082|NCT05609006|DIETARY_SUPPLEMENT|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
219004083|NCT05609006|DIETARY_SUPPLEMENT|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
219415180|NCT00126399|DRUG|doxycycline|
219415181|NCT03529136|BIOLOGICAL|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
219571304|NCT02212340|DRUG|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
219571305|NCT03927924|PROCEDURE|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
219571306|NCT02139124|DRUG|Placebo|Oral placebo capsule
219571307|NCT02139124|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
219571308|NCT02139124|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
219571309|NCT02139124|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
219571310|NCT02139124|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
219571311|NCT02596386|PROCEDURE|sialometry|potassium evaluation
219571312|NCT02596386|PROCEDURE|blood test|potassium evaluation
219571313|NCT02691741|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
219004084|NCT02555072|BIOLOGICAL|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
219004085|NCT04691505|DRUG|Methotrexate|Methotrexate is used as the reference group.
219004086|NCT04691505|DRUG|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
219190624|NCT05021497|OTHER|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
219190625|NCT05021497|OTHER|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
219415182|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
219415183|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
219415184|NCT00950079|DRUG|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
219415185|NCT00950079|DRUG|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
219571314|NCT02691741|DEVICE|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
219571315|NCT01371084|BEHAVIORAL|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
219571316|NCT01371084|BEHAVIORAL|Pedal@Work|Worksite wellness program.
219571317|NCT00255255|DRUG|Budesonide/Formoterol|
219571318|NCT04523402|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
219004087|NCT00687323|DRUG|temozolomide|
219415186|NCT04429685|DRUG|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
219571319|NCT03465436|DRUG|Lasmiditan|100 mg administered orally (PO)
219571320|NCT03465436|DRUG|Lasmiditan|400 mg administered PO
219571321|NCT03465436|DRUG|Placebo|Placebo administered for lasmiditan or moxifloxacin
219571322|NCT03465436|DRUG|Moxifloxacin|400 mg moxifloxacin administered PO
219571323|NCT04867421|OTHER|No intervention|No intervention
219571324|NCT04912336|DIAGNOSTIC_TEST|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
219004088|NCT01772108|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
219004089|NCT04984720|BEHAVIORAL|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
219004090|NCT06417294|OTHER|3D health education model|explanation combined with 3D printed health education model
219004091|NCT06417294|OTHER|traditional education|Regular education
219004092|NCT05745584|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
219190626|NCT06505512|DIAGNOSTIC_TEST|No intervention|No intervention
219190627|NCT06504836|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
219415187|NCT04429685|DRUG|Saline (placebo)|Saline (placebo)
219415188|NCT02882763|OTHER|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
219190628|NCT06504836|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
219415189|NCT05528224|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
219415190|NCT05528224|OTHER|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
219571325|NCT04912336|DIAGNOSTIC_TEST|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
219571326|NCT04912336|OTHER|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
219571327|NCT00379990|DRUG|GW274150|60 mg /day
219190629|NCT06265688|DRUG|CX-2051|Investigational drug monotherapy
219415191|NCT05528224|DRUG|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
219571328|NCT00379990|DRUG|Prednisolone|7.5 mg/day
219571329|NCT00379990|OTHER|Placebo|Placebo
219571330|NCT01069952|DEVICE|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
219571331|NCT03167593|DIETARY_SUPPLEMENT|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
219571332|NCT03167593|OTHER|Control placebo|Maltodextrin
219571333|NCT05848778|DEVICE|Acute Intermittent Hypoxia|The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
219571334|NCT05848778|DEVICE|Normoxia|The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
219571335|NCT06783140|DRUG|Nab paclitaxel|Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity.
219571336|NCT06783140|DRUG|Gemcitabine|Gemcitabine is a hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.
219571337|NCT06783140|DRUG|Cisplatin|Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.
219571338|NCT04974619|BEHAVIORAL|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
219190630|NCT04443530|DRUG|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
219190631|NCT04904146|DIAGNOSTIC_TEST|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
219571339|NCT04974619|BEHAVIORAL|Focus groups or Individual Interviews|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
219571340|NCT04974619|BEHAVIORAL|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
219571341|NCT04335188|OTHER|Prospective oberservational registry|Non interventional study.
219004093|NCT02589756|OTHER|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
219004094|NCT02589756|OTHER|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
219004095|NCT02589756|OTHER|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
219004096|NCT01929915|PROCEDURE|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
219415192|NCT00555048|BIOLOGICAL|alemtuzumab|
219004097|NCT01929915|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
219004098|NCT03331003|DEVICE|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
219004099|NCT03331003|DEVICE|non-LLLT wavelength group|A LED light device is non-curative for the patients.
219004100|NCT01422317|DRUG|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
219004101|NCT01422317|DRUG|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
219004102|NCT01161862|DEVICE|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
219004103|NCT03251300|DRUG|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
219004104|NCT03251300|DRUG|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
219415193|NCT00555048|DRUG|busulfan|
219415194|NCT00555048|DRUG|cyclophosphamide|
219415195|NCT00555048|DRUG|methotrexate|
219415196|NCT00555048|DRUG|tacrolimus|
219415197|NCT00555048|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219415198|NCT00555048|PROCEDURE|peripheral blood stem cell transplantation|
219415199|NCT04766138|DEVICE|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
219415200|NCT03395275|BEHAVIORAL|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
219415201|NCT03395275|BEHAVIORAL|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
219415202|NCT05821621|OTHER|no intervention|observational study : there is no intervention
219004105|NCT01152242|DRUG|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
219004106|NCT01152242|DRUG|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
219004107|NCT02310061|PROCEDURE|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
219004108|NCT02310061|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
219004109|NCT00598832|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
219004110|NCT00598832|DRUG|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
219415203|NCT03198754|DEVICE|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
219415204|NCT03198754|DEVICE|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
219415205|NCT00986310|DRUG|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
219415206|NCT00986310|DRUG|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
219415207|NCT00943982|DRUG|Interferon Gamma 1-b|
219415208|NCT03190096|PROCEDURE|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
219571342|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
219571343|NCT06234878|DEVICE|REEV SENSE|Gait analysis with an Inertial Measurement Unit (IMU) sensor
219571344|NCT06234878|DEVICE|Motion capture system|Gait analysis with reflective markers and pressure sensors
219415209|NCT03090373|DEVICE|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
219415210|NCT00790738|DRUG|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
219415211|NCT00790738|DRUG|placebo|placebo
219571345|NCT05466032|OTHER|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
219571346|NCT05251324|OTHER|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
219571347|NCT04279964|BEHAVIORAL|Boot Camp Translation|Practices in the intervention arm will participate in the Boot Camp Translation process, where BCT Community Advisory group members will come together to develop and implement practice relevant materials to promote adolescent vaccination.
219190632|NCT05724433|OTHER|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
219190633|NCT05724433|OTHER|Routine HF Care|Care as determined by the treating physician
219415212|NCT00240552|DRUG|fosamprenavir|
219415213|NCT00240552|DRUG|Telzir®|
219415214|NCT00305253|DEVICE|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
219571348|NCT04279964|OTHER|Control|No intervention. Practices will continue to behave as usual.
219571349|NCT02520687|DIETARY_SUPPLEMENT|Beetroot juice|70mls daily for seven days
219571350|NCT02520687|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls daily for seven days
219757848|NCT05578066|OTHER|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
219415215|NCT02393573|DRUG|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
219415216|NCT02393573|DRUG|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
219415217|NCT02800473|DEVICE|Strorz (commercial)|
219190634|NCT02851095|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
219190635|NCT02851095|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
219190636|NCT02851095|DRUG|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
219415218|NCT02800473|DEVICE|CyPaM2 (experimental)|
219415219|NCT02819115|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
219415220|NCT01785810|DRUG|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
219415221|NCT02923752|DEVICE|MRI|Contrast-enhanced MRI
219415222|NCT01750632|PROCEDURE|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
219415223|NCT04289246|DEVICE|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
219415224|NCT03429816|PROCEDURE|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
219415225|NCT01737567|OTHER|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
219004111|NCT05381116|DEVICE|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
219004112|NCT05381116|DEVICE|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
219004113|NCT05138497|OTHER|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
219004114|NCT02760069|DRUG|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
219004115|NCT02760069|DRUG|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
219004116|NCT02760069|DRUG|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
219004117|NCT02760069|DRUG|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
219004118|NCT01429753|OTHER|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
219004119|NCT01429753|DEVICE|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
219004120|NCT00439660|BIOLOGICAL|Oral Rotavirus Vaccine 116E Live Attenuated|
219004121|NCT02465216|OTHER|Placebo|Placebo
219004122|NCT02465216|BIOLOGICAL|ID93 + GLA-SE|ID93 + GLA-SE
219415226|NCT01737567|OTHER|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
219415227|NCT02077387|BEHAVIORAL|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
219415228|NCT02077387|BEHAVIORAL|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
219415229|NCT04213287|DRUG|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
219415230|NCT04213287|OTHER|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
219415231|NCT04213287|OTHER|IPACK|Drug: bupivacaine 20 ml 0,025%
219415232|NCT04213287|OTHER|PAI|Drug: bupivacaine 30 ml 0,025%
219415233|NCT04213287|OTHER|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
219415234|NCT00666133|DEVICE|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
219415235|NCT04838106|OTHER|Not applicable as observational study|Not applicable as observational study.
219415236|NCT02214199|OTHER|Manipulative Therapy Techniques|
219415237|NCT02214199|OTHER|Home Exercises|
219415238|NCT04654000|PROCEDURE|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
219415239|NCT04654000|PROCEDURE|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
219415240|NCT03587480|PROCEDURE|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
219415241|NCT03587480|PROCEDURE|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
219415242|NCT04667806|BEHAVIORAL|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
219415243|NCT03134313|DEVICE|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
219415244|NCT04115618|RADIATION|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
219415245|NCT05913284|DRUG|Methadone|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
219415246|NCT05913284|DRUG|Morphine|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
219415247|NCT00823849|DRUG|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
219415248|NCT00823849|DRUG|Probucol|250 mg Bid, PO after breakfast and dinner.
219415249|NCT00823849|DRUG|Cilostazol+Probucol|
219415250|NCT00823849|OTHER|Control Group|Routine treatment
219415251|NCT05373706|BEHAVIORAL|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
219415252|NCT04729491|DRUG|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
219415253|NCT04729491|DRUG|Azithromycin|Azithromycin 500mg/day for 05 days
219415254|NCT04729491|DRUG|Nitazoxanide|500mg twice daily for 06 days
219415255|NCT04729491|DRUG|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
219415256|NCT05553626|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
219415257|NCT05553626|DEVICE|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
219415258|NCT02981277|DRUG|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
219415259|NCT02981277|DRUG|Spray as you go|Lignocaine delivery using Spray as you go method
219415260|NCT04684914|BIOLOGICAL|HepTcell|Intramuscular injection
219415261|NCT04684914|DRUG|Placebo|Intramuscular injection
219415262|NCT03144323|BEHAVIORAL|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
219415263|NCT06313437|DRUG|Revumenib|Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
219415264|NCT06313437|DRUG|Midostaurin|Kinase inhibitor, capsule taken orally per protocol.
219415265|NCT06313437|DRUG|Cytarabine|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
219415266|NCT06313437|DRUG|Daunorubicin|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
219415267|NCT03410927|DRUG|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
219415268|NCT02566330|DEVICE|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
219415269|NCT03125655|DIAGNOSTIC_TEST|Inflammatory markers|
219415270|NCT01521234|BEHAVIORAL|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
219415271|NCT04253977|BEHAVIORAL|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
219415272|NCT04253977|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
219415273|NCT01657448|DRUG|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
219415274|NCT01657448|DRUG|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
219415275|NCT05151328|DRUG|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
219415276|NCT00498108|DRUG|Rotigotine|
219415277|NCT00853333|DRUG|dexmedetomidine|
219415278|NCT00853333|DRUG|midazolam|
219415279|NCT00853333|DRUG|propofol|
219571351|NCT06456372|BEHAVIORAL|Digital Health Intervention Group|Our digital health intervention (DHI) uses Patient-Centered Digital Healthcare Technologies (PC-DHT) to promote co-regulation (child/parent), capture patient data, support efficient healthcare delivery, enhance patient engagement, and facilitate shared decision-making, thereby improving access to timely and targeted mental health intervention for children at great risk for poor outcomes. This system will integrate treatment across multiple points of care and will enable health care providers and caregivers to share reliable and targeted information that will facilitate collaborative decision-making (e.g., making decisions about changing or titrating medications/dosages or shifting behavioral therapy and educational intervention targets) and improve patient experiences and outcomes.
219571352|NCT06051968|BEHAVIORAL|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
219571353|NCT06051968|BEHAVIORAL|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
219757849|NCT05578066|OTHER|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO \& OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
219415280|NCT00917306|DRUG|PEP005 Gel|0.05% two day treatment
219415281|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with investigational device
219415282|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with reference device
219415283|NCT04770987|OTHER|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
219415284|NCT01614236|DRUG|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
219415285|NCT01614236|DRUG|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
219415286|NCT05280431|DEVICE|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects (on a plane or in the space)~* exergames.~A subset of exercises is defined based on the patient's capability."
219571354|NCT06483282|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
219571355|NCT06483282|DRUG|Apatinib Mesylate|This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
219571356|NCT06483282|DRUG|Etoposide|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
219571357|NCT06483282|DRUG|Carboplatin|This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
219190637|NCT04487860|DRUG|AS012|oral administration
219415287|NCT05280431|DEVICE|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
219415288|NCT05280431|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Occupational therapy exercises~* Constraint-induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training"
219415289|NCT04709302|BIOLOGICAL|COVID-19|Patients diagnosed with a COVID-19 infection
219415290|NCT04709302|BIOLOGICAL|HIV|Patients diagnosed HIV-positive
219415291|NCT04709302|DRUG|ART|Patients on ART
219415292|NCT05971004|DEVICE|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
219415293|NCT05971004|DRUG|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
219415294|NCT02985268|DEVICE|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
219415295|NCT02985268|DRUG|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
219415296|NCT02985268|DEVICE|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
219415297|NCT03734367|BEHAVIORAL|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
219415298|NCT04523441|OTHER|Focus group|Holding of a focus group by a sociologist
219415299|NCT04523441|OTHER|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
219415300|NCT00157937|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
219571358|NCT02658487|DRUG|Cytarabine|Given IV
219571359|NCT02658487|DRUG|Vosaroxin|Given IV
219571360|NCT06147440|OTHER|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
219571361|NCT04237623|DRUG|Sargramostim|250mcg/m2/day IV starting Day +5
219571362|NCT04237623|OTHER|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
219571363|NCT00493779|PROCEDURE|Blood Collection|4 weeks
219004123|NCT04830774|DEVICE|ILR, PMK, ICD|"* Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
219571364|NCT03055741|DRUG|Donepezil|5mg or 10mg, once a day, 24 weeks
219571365|NCT03055741|DRUG|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
219571366|NCT03055741|DRUG|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
219571367|NCT03216109|BEHAVIORAL|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
219415301|NCT00157937|DRUG|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
219415302|NCT05918874|OTHER|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
219571368|NCT02075034|DRUG|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
219571369|NCT04734834|DIETARY_SUPPLEMENT|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
219415303|NCT00256087|DRUG|Probiotic Lactobacillus|
219415304|NCT00256087|OTHER|Lactose Powder|
219415305|NCT02987348|DRUG|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
219415306|NCT02987348|DRUG|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
219415307|NCT02987348|DRUG|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
219415308|NCT04289415|BEHAVIORAL|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
219004124|NCT04606082|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
219004125|NCT04606082|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
219004126|NCT05015465|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
219004127|NCT00078637|DRUG|E7820|
219004128|NCT02733939|DEVICE|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home."
219004129|NCT02292602|BEHAVIORAL|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
219004130|NCT01691001|DRUG|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
219415309|NCT03432052|PROCEDURE|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
219004131|NCT01691001|DRUG|normal saline|
219004132|NCT02892071|DRUG|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
219415310|NCT00230529|DRUG|infliximab|
219415311|NCT01479374|DRUG|AL-4943A ophthalmic solution|
219415312|NCT01479374|DRUG|AL-4943A vehicle|Inactive ingredients used as placebo
219415313|NCT01479374|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
219415314|NCT00091702|BIOLOGICAL|Cold-adapted live attenuated influenza vaccine (FluMist)|
219415315|NCT00091702|BIOLOGICAL|Inactivated influenza vaccine (IAIV)|
219415316|NCT03616327|DEVICE|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
219415317|NCT05086289|DRUG|LY3526318|Administered orally
219415318|NCT05086289|DRUG|Placebo|Administered orally
219415319|NCT01045772|DRUG|rilonacept|160mg of rilonacept 1x/week
219415320|NCT04777643|DRUG|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
219415321|NCT04777643|OTHER|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
219571370|NCT06308133|OTHER|apheresis procedure|collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
219571371|NCT01508819|OTHER|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
219571372|NCT01885182|DRUG|Oxycodone/Naloxone|
219004133|NCT02892071|DEVICE|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
219190638|NCT04487860|DRUG|Placebo|oral administration
219571373|NCT01885182|DRUG|Oxycodone|
219571374|NCT00444236|DRUG|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
219571375|NCT00444236|DRUG|Placebo|matching placebo for active drug
219190639|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
219004134|NCT02892071|DEVICE|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
219004135|NCT03064451|PROCEDURE|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
219004136|NCT02401438|OTHER|5D ultrasound|
219004137|NCT02401438|OTHER|2D ultrasound|
219004138|NCT00462267|BEHAVIORAL|Enriched lifestyle intervention|Multi-component lifestyle intervention
219004139|NCT00844688|DRUG|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason."
219004140|NCT00844688|DRUG|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
219415322|NCT05071560|OTHER|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
219415323|NCT05407090|DIETARY_SUPPLEMENT|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
219415324|NCT05407090|DIETARY_SUPPLEMENT|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
219415325|NCT02621879|PROCEDURE|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
219415326|NCT02456376|PROCEDURE|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
219415327|NCT02456376|PROCEDURE|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
219415328|NCT05146583|PROCEDURE|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
219415329|NCT05146583|PROCEDURE|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
219415330|NCT01562366|DEVICE|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
219571376|NCT03707041|DRUG|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
219571377|NCT03707041|DRUG|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
219571378|NCT03707041|DRUG|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
219571379|NCT03707041|BIOLOGICAL|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
219004141|NCT06445192|OTHER|Best Practice|Receive usual care
219004142|NCT06445192|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219004143|NCT06445192|OTHER|Exercise Counseling|Attend group counseling
219004144|NCT06445192|OTHER|Exercise Intervention|Receive aerobic and resistance exercise intervention via telehealth
219004145|NCT06445192|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
219004146|NCT06445192|OTHER|Physical Performance Testing|Ancillary studies
219004147|NCT06445192|OTHER|Questionnaire Administration|Ancillary studies
219004148|NCT06445192|OTHER|Telemedicine|Receive aerobic and resistance exercise intervention via telehealth
219571380|NCT03245034|BEHAVIORAL|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
219571381|NCT02696941|DRUG|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
219571382|NCT02696941|DRUG|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
219004149|NCT05188950|DEVICE|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
219004150|NCT04356274|OTHER|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
219004151|NCT04356274|OTHER|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
219415331|NCT01562366|PROCEDURE|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
219415332|NCT05923489|DIAGNOSTIC_TEST|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
219415333|NCT05923489|DIAGNOSTIC_TEST|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
219415334|NCT04222933|DEVICE|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
219415335|NCT04222933|DEVICE|Classical cryotherapy|application of an ice bag
219415336|NCT03150108|DRUG|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
219415337|NCT03150108|DRUG|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
219757850|NCT05578066|OTHER|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
219004152|NCT04542135|DRUG|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
219004153|NCT04542135|DRUG|Placebo|placebo pills twice daily
219761565|NCT05785962|OTHER|Vojta Therapy|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
219761566|NCT06959225|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219004154|NCT01731392|DIETARY_SUPPLEMENT|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
219004155|NCT01731392|DIETARY_SUPPLEMENT|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
219004156|NCT01731392|DIETARY_SUPPLEMENT|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
219190640|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
219190641|NCT04511364|OTHER|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
219415338|NCT03150108|DRUG|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
219415339|NCT05804006|OTHER|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
219415340|NCT03293277|DRUG|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
219415341|NCT03293277|DRUG|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
219415342|NCT03293277|DRUG|Intranasal Placebo|Intranasal Placebo
219415343|NCT03293277|DRUG|Intravenous Placebo|Intravenous Placebo
219415344|NCT06317857|OTHER|Centio Forte|A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
219415345|NCT01368159|DEVICE|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
219415346|NCT01975935|DRUG|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
219415347|NCT01975935|DRUG|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
219415348|NCT05111496|RADIATION|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
219415349|NCT02388061|DRUG|Tenecteplase|
219415350|NCT02388061|DRUG|Tissue Plasminogen Activator|
219415351|NCT00102453|DRUG|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
219415352|NCT03698604|PROCEDURE|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
219415353|NCT02358330|OTHER|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
219571383|NCT05409521|OTHER|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
219757851|NCT05578066|OTHER|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
219761567|NCT06959225|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
219761568|NCT06959095|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
219190642|NCT06543368|BIOLOGICAL|Intra articular PRP Injection|A total of 20 joints (estimated 10-15 patients) will receive injections, performed at day 0 and 3 weeks, for a total of two injections - two injections have demonstrated superior outcomes to one, and will increase our number of injections to improve the proof of feasibility. All subjects will receive ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort.
219190643|NCT06413654|DRUG|B001|The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP
219190644|NCT06413654|OTHER|Placebo|The subjects will receive IV dose of placebo matched to B001 on Day 1 and Day 15 of the RCP
219415354|NCT05103319|OTHER|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
219415355|NCT03599141|BEHAVIORAL|Trust-building Self-management Together|Trust building plus depression self-management
219415356|NCT03599141|BEHAVIORAL|Depression Management|Traditional depression self-management
219415357|NCT05670964|DEVICE|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
219415358|NCT05670964|DEVICE|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
219415359|NCT01280890|BEHAVIORAL|Staff training using VIPS|Staff training using the VIPS framework
219415360|NCT01280890|BEHAVIORAL|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
219415361|NCT01280890|BEHAVIORAL|Control group|Filmed traditional Lectures will be given to care staff
219415362|NCT02274584|GENETIC|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
219415363|NCT04032743|OTHER|ICU treatment|any treatment available by ICU
219415364|NCT03126929|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
219571384|NCT05409521|OTHER|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
219571385|NCT00614926|DRUG|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
219571386|NCT00614926|DRUG|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
219571387|NCT06198530|BEHAVIORAL|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
219761569|NCT06959095|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.
219761570|NCT05648968|BIOLOGICAL|Ianalumab|i.v. infusion, prepared from concentrate solution
219761571|NCT05648968|DRUG|Placebo|i.v. infusion, prepared from matching placebo
219761572|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
219761573|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Dasatanib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
219761574|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
219761575|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
219761576|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
219415365|NCT04615962|DRUG|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
219415366|NCT04615962|DRUG|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
219415367|NCT04615962|DRUG|SNG100|A combination of low potency steroid and skin barrier repair agent
219415368|NCT00807846|DRUG|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
219415369|NCT00807846|DRUG|Naproxen|Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
219415370|NCT01081873|DRUG|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
219415371|NCT05224401|DRUG|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
219415372|NCT05224401|DRUG|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
219415373|NCT03011840|OTHER|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
219415374|NCT02580916|OTHER|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
219415375|NCT02491073|OTHER|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
219415376|NCT01165021|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
219415377|NCT01165021|DRUG|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
219415378|NCT01165021|DRUG|Folic Acid|Administered orally.
219415379|NCT01165021|DRUG|Vitamin B12|Administered Intramuscular injection.
219190645|NCT06483035|DEVICE|Intensive Visual Simulation (IVS)|The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.
219415380|NCT01165021|DRUG|Dexamethasone|Administered orally.
219415381|NCT02274324|DIETARY_SUPPLEMENT|different diets|3 different diets: A\\B\\C
219415382|NCT02681380|OTHER|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
219415383|NCT02681380|OTHER|Control group|No session will be planned for the participants.
219415384|NCT00175084|BEHAVIORAL|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
219415385|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
219415386|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
219415387|NCT00924976|BEHAVIORAL|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
219415388|NCT03192982|DEVICE|A-V impulse 6000 Series|foot pad and pump
219415389|NCT03192982|DEVICE|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
219415390|NCT01419665|BIOLOGICAL|GP2013|Type: Biological/Vaccine
219415391|NCT01419665|BIOLOGICAL|rituximab|Type: Biological/Vaccine
219415392|NCT02934776|DEVICE|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
219415393|NCT04527354|DRUG|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
219415394|NCT04527354|DRUG|Placebo|Participants will receive Placebo once a day during 4 weeks
219571388|NCT06198530|BEHAVIORAL|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
219415395|NCT00975702|PROCEDURE|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
219415396|NCT06889714|DEVICE|ultrasonography|Right thigh length (between the right femur greater trochanter and patella) was measured and recorded while the patients were lying supine. A linear transducer (Philips Affiniti 50, Philips Medical Systems, Seattle, WA, United States) was used for ultrasonographic measurements. The rectus femoris (RF) and vastus intermedius (VI) were visualized with the feather-touch technique after a generous amount of ultrasound gel was sprayed in the center of the right thigh, and the thickness of the muscles was determined and recorded using ultrasonography software. After these measurements, the rectus femoris-to-thigh length ratio (RF/B), vastus intermedius-to-thigh length ratio (VI/B), and total muscle thickness-to-thigh length ratio (T/B) were calculated and recorded.
219415397|NCT06892938|DIAGNOSTIC_TEST|Atrial Fibrillation Identification|Identification of atrial fibrillation by device.
219415398|NCT06897761|DEVICE|Interactive Digital Respiratory Game|With the development of technology and digitalization, Digital Respiratory Games (DRG) offer an alternative solution. DRGs, with their difficulty levels, provide a platform for progression, offering a fun and engaging experience that enhances patient adherence to therapy through storytelling and user interaction. The absence of a locally made DRG in Turkey, despite the chronic respiratory diseases impact, has led to the need for an interactive DRG with personalized features. The developed interactive DRG and device will be Turkey first interactive DRG example, designed to respond to different respiratory maneuvers. The developed DRG and device will detect the lung volume and flow rates and allow for the real-time execution of maneuvers within the Active Cycle of Breathing Techniques (ACBT) in a playful environment.
219415399|NCT06897761|OTHER|home-based exercise training|Patients in the home-based exercise training group will be asked to perform the active breathing techniques cycle, which is an airway clearance technique, twice a day, 7 days a week, for 20 minutes each, for 8 weeks and to follow the program that includes physical activity recommendations. Patients who use mucolytic and/or nebulized drugs such as hypertonic saline or mannitol will be instructed to perform nebulization before performing the active breathing techniques cycle.
219415400|NCT06898372|DRUG|JAK Inhibitor|The retrospective analysis will examine the effects of Janus Kinase 1/2 (JAK1/2) inhibitors, such as Baricitinib and Ruxolitinib, on neurological symptoms and brain MRI.
219415401|NCT06898008|OTHER|Assessment of socio-demographic, anthropometric, psychometric and clinical characteristics|age, sex and place of residence, socioeconomic level, education, anthropometric data, first-degree family history, screen time, physical activity time, sleep time, comorbidity, drug treatments, education, total IQ, results of Epworth, CDI, ISI, ADHD, CONNERS, SCSC, Horne and Ostberg questionnaires, hearing aids, referring professional, melatonin dosage, ferritinemia, etiology of sleepiness
219415402|NCT03120780|DRUG|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
219415403|NCT03120780|DRUG|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
219415404|NCT05265845|BEHAVIORAL|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
219415405|NCT05265845|BEHAVIORAL|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
219571389|NCT06198530|BEHAVIORAL|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
219571390|NCT02932020|DRUG|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
219190646|NCT06483035|OTHER|Usual Care (UC)|"After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor or other health professionals. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period."
219415406|NCT04260022|DRUG|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
219415407|NCT04260022|DRUG|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
219415408|NCT06111053|OTHER|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
219415409|NCT06111053|OTHER|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
219415410|NCT06111053|OTHER|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
219415411|NCT06111053|OTHER|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
219415412|NCT04211155|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
219415413|NCT04211155|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
219571391|NCT02932020|DRUG|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
219571392|NCT02932020|DEVICE|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
219571393|NCT02932020|DRUG|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
219571394|NCT00809237|DRUG|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
219571395|NCT06132633|DEVICE|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
219190647|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
219190648|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
219415414|NCT06898840|OTHER|Fruit drink|Commercially available fruit drinks or smoothies
219415415|NCT06897891|COMBINATION_PRODUCT|Acupuncture combined with core stability training|All patients were given routine health education guidance and core stability training. Acupuncture group combined with core stability training
219415416|NCT06897891|COMBINATION_PRODUCT|Dragon Tank joint core stability training|All patients were given routine health education guidance and core stability training. Huolong Tank group adopts Huolongcan combined core stability training
219415417|NCT06899139|OTHER|Orthokeratology Lens Wear|"Orthokeratology Lens Wear~Intervention Type:~Device~Description:~Participants will wear gas-permeable orthokeratology (OK) lenses overnight for a minimum of 8 hours per night. Lenses are designed to reshape the cornea temporarily to reduce refractive error and slow axial elongation. This intervention is administered to both the experimental and control groups."
219415418|NCT06899139|DEVICE|Repeated Low-Level Red-Light Therapy Intervention Type: Device Description: Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a no|"Description:~Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a non-invasive light-emitting device. Each session will last no more than 3 minutes, with a minimum interval of 4 hours between sessions. The therapy is administered under parental supervision and aims to enhance myopia control in conjunction with orthokeratology."
219415419|NCT05803889|OTHER|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
219415420|NCT05803889|OTHER|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
219415421|NCT06898138|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
219190649|NCT04246671|BIOLOGICAL|TAEK-VAC-HerBy|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
219190650|NCT06536491|DRUG|EC-104 high dose|Intravitreal injection
219415422|NCT01877382|DRUG|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
219415423|NCT01877382|DRUG|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
219415424|NCT00649467|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
219415425|NCT00649467|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
219415426|NCT06930326|OTHER|intradermal exosome|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
219571396|NCT05430945|BIOLOGICAL|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
219571397|NCT01207440|DRUG|Ponatinib|Ponatinib tablets.
219571398|NCT03447886|OTHER|Phone interview|Collecting clinical and socio-demographic information.
219571399|NCT02544542|DEVICE|Rectum cooling system|
219571400|NCT02544542|DEVICE|Hyper-hypothermia blanket|
219571401|NCT03341000|DEVICE|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
219761577|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
219190651|NCT06536491|DRUG|EC-104 low dose|Intravitreal injection
219190652|NCT06536491|DRUG|Dexamethasone intravitreal implant|Marketed product intravitreal injection
219190653|NCT06045416|PROCEDURE|venous blood puncture|"Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons."
219190654|NCT06522919|BIOLOGICAL|Autologous Dendritic Cell (DC) Vaccine|Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
219415427|NCT06930326|OTHER|0.9 % NaCl|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
219415428|NCT05050721|OTHER|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
219415429|NCT02808533|DRUG|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
219415430|NCT02808533|OTHER|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
219415431|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
219415432|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
219004157|NCT05319145|BEHAVIORAL|Intervention group|1\) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
219415433|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
219415434|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
219415435|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
219415436|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
219415437|NCT06304675|OTHER|no intervention|no intervention
219190655|NCT06527235|DRUG|ultrasound-guided betamethasone infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 megahertz (MHz) linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of lidocaine injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
219415438|NCT02526719|PROCEDURE|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
219415439|NCT02690207|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
219415440|NCT00828334|DEVICE|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
219415441|NCT04972734|BIOLOGICAL|premature newborns developing a NEC|weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
219415442|NCT04972734|BIOLOGICAL|premature newborns without NEC|weekly Blood sample and daily Stools sample during 12 weeks
219415443|NCT00517335|PROCEDURE|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
219415444|NCT00801853|DRUG|Aerovant|Aerovant 1mg bid (dry powder)
219415445|NCT00801853|DRUG|Aerovant|Aerovant 3mg bid (dry powder)
219415446|NCT00801853|DRUG|Aerovant|Aerovant 10mg bid (dry powder)
219415447|NCT00801853|OTHER|placebo|placebo control (dry powder)
219415448|NCT05940727|OTHER|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
219415449|NCT05940727|OTHER|No macroalgae consumption|The participants exclude any macroalgae products from their diet
219571402|NCT00601757|BEHAVIORAL|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
219571403|NCT00601757|BEHAVIORAL|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
219571404|NCT02242318|DRUG|Telmisartan|
219571405|NCT02242318|DRUG|Valsartan|
219415450|NCT00590915|DRUG|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
219415451|NCT06482554|DRUG|Lumateperone 42 mg|Standard treatment with lumateperone
219415452|NCT06482554|DRUG|Risperidone 2 mg|Standard treatment with other antipsychotic drugs
219415453|NCT01216592|OTHER|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
219761578|NCT06840873|DEVICE|wearable device|Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation, including 3 aerobic and 2 strengthening exercise sessions per week at a moderate intensity, 30 min/session.
219415454|NCT04068064|PROCEDURE|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
219415455|NCT04068064|PROCEDURE|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
219415456|NCT04061681|BEHAVIORAL|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
219415457|NCT03424889|DRUG|Xylometazoline|Nasal administration of Xylometazoline
219415458|NCT03424889|DRUG|Saline|Nasal administration of 0.9% Saline
219415459|NCT00343291|BIOLOGICAL|Cetuximab|Administered intravenously
219415460|NCT00343291|BIOLOGICAL|Bevacizumab|Administered intravenously
219415461|NCT00343291|DRUG|Paclitaxel|Administered intravenously
219415462|NCT00343291|DRUG|Carboplatin|Administered intravenously
219415463|NCT03712345|DRUG|IFX-1 low dose|Single IV infusions of IFX-1
219415464|NCT03712345|DRUG|IFX-1 high dose|Single IV infusions of IFX-1
219415465|NCT03712345|DRUG|Placebo|Placebo
219415466|NCT02765633|DRUG|Cangrelor|
219415467|NCT06375980|OTHER|Intraoperative Mechanical Ventilation Strategies|The intervention involves the management of mechanical ventilation during major abdominal surgery. This includes the adjustment of ventilation parameters such as tidal volume, respiratory rate, peak pressure, positive end-expiratory pressure (PEEP), and inspiratory flow rate. The aim is to optimize ventilation strategies to reduce the risk of postoperative pulmonary complications
219415468|NCT02842112|OTHER|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
219415469|NCT02943265|OTHER|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
219415470|NCT01479959|DEVICE|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
219415471|NCT00000993|DRUG|Zidovudine|
219761579|NCT06840873|BEHAVIORAL|Healthy consulation|Participants received routine outpatient health education.
219415472|NCT03294668|BEHAVIORAL|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
219415473|NCT03294668|OTHER|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
219415474|NCT02853006|BIOLOGICAL|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
219415475|NCT02853006|PROCEDURE|Biopsy|
219761580|NCT05652504|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 Pf sporozoites (PfSPZ) produced by Sanaria Inc. PfSPZ Vaccine is manufactured in compliance with Good Manufacturing Practice (GMP) regulations (21 Code of Federal Regulations \[CFR\] 21), that is described in detail in Investigational New Drug (IND) 13969. Manufacture of PfSPZ Vaccine is performed in Sanaria s Clinical Manufacturing Facility (CMF) in Rockville, Maryland, USA.
219761581|NCT05652504|OTHER|PfSPZ Diluent|The diluent for PfSPZ Vaccine is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA) and is termed PfSPZ Diluent (or Diluent). The PfSPZ Diluent was manufactured in compliance with GMP by Sanaria, Inc. (9800 Medical Center Dr., Rockville, MD, USA), or Sanaria s contractor Emergent Biosolutions (https://www.emergentcdmo.com/). Each lot of PfSPZ Diluent is issued a Certificate of Analysis (CoA) and is also placed on a stability program. HSA used in PfSPZ Diluent is a licensed product which is approved for parenteral, IV administration to humans and is purchased by Sanaria, Inc. from CSL Behring, Bern, Switzerland.
219415476|NCT02853006|PROCEDURE|Excised tissues|
219415477|NCT01071096|DRUG|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
219415478|NCT01071096|DRUG|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
219415479|NCT05265143|OTHER|bolus/intermittant feeding|sequential randomization
219415480|NCT02003729|DEVICE|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
219415481|NCT05429229|DRUG|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
219415482|NCT05429229|DRUG|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
219415483|NCT05429229|DRUG|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
219415484|NCT00485589|DRUG|Methotrexate|Oral repeating dose
219415485|NCT00485589|DRUG|Ocrelizumab|Intravenous repeating dose
219415486|NCT00485589|DRUG|Placebo|Intravenous repeating dose
219004158|NCT05319145|OTHER|Control group|General recommendations (written and videos) will be offered.
219004159|NCT02176876|DRUG|GS-5745|GS-5745 400 mg administered intravenously
219004160|NCT02176876|DRUG|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
219415487|NCT02585999|DEVICE|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
219415488|NCT02104999|DEVICE|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
219415489|NCT00249639|BEHAVIORAL|Contingency management|Rewards valued $1-$100
219415490|NCT00003856|DRUG|temoporfin|
219415491|NCT01922778|PROCEDURE|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
219415492|NCT01954069|DEVICE|Semi-quantitative pregnancy test|
219415493|NCT04633057|DRUG|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
219415494|NCT04633057|DRUG|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
219415495|NCT00066118|DEVICE|Dental amalgam restorations|
219415496|NCT02637440|PROCEDURE|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
219415497|NCT02637440|PROCEDURE|Angio guided PCI|Patients receive PCI without FFR measurement
219415498|NCT01369849|DRUG|Akt Inhibitor MK2206|Given PO
219415499|NCT01369849|DRUG|Bendamustine Hydrochloride|Given IV
219415500|NCT01369849|OTHER|Laboratory Biomarker Analysis|Correlative studies
219415501|NCT01369849|BIOLOGICAL|Rituximab|Given IV
219571406|NCT02242318|DRUG|Placebo|
219571407|NCT00312819|DRUG|chemotherapy +/- disulfiram|
219571408|NCT02969772|OTHER|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
219571409|NCT02969772|OTHER|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
219571410|NCT03442881|PROCEDURE|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
219415502|NCT02262884|DEVICE|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
219415503|NCT02262884|DEVICE|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
219004161|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
219415504|NCT03687138|OTHER|24h urin sample|The samples will analyzed by proteomic techniques
219415505|NCT03377244|BEHAVIORAL|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
219415506|NCT03377244|BEHAVIORAL|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
219415507|NCT03377244|BEHAVIORAL|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
219415508|NCT00756886|DRUG|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
219415509|NCT00756886|DRUG|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
219415510|NCT00174785|DRUG|dronedarone (SR33589)|oral administration (tablets)
219415511|NCT00174785|DRUG|placebo|oral administration (tablets)
219415512|NCT01314976|DRUG|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
219415513|NCT01314976|DRUG|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
219415514|NCT00274768|DRUG|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
219415515|NCT00120289|DRUG|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
219415516|NCT00120289|DRUG|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
219415517|NCT02285712|DEVICE|Vascular ultrasound system|
219415518|NCT03214926|DEVICE|Moving Through Glass intervention|
219415519|NCT03619291|OTHER|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
219415520|NCT03619291|OTHER|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
219415521|NCT03619291|OTHER|control|physical inactivity, reading sports science literature, total duration 15 minutes
219415522|NCT01932931|DIETARY_SUPPLEMENT|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
219415523|NCT00651612|DRUG|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
219415524|NCT00651612|DRUG|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
219415525|NCT05551338|OTHER|Serious games|The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.
219415526|NCT00099788|DRUG|Ranolazine|IV to oral transition.
219415527|NCT00099788|DRUG|Placebo|IV to oral transition.
219415528|NCT02664207|PROCEDURE|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
219415529|NCT05357326|DRUG|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
219415530|NCT05357326|DEVICE|Orthokeratology|wear orthokeratology at night while sleeping
219415531|NCT05357326|DRUG|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
219415532|NCT01944969|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
219415533|NCT02560831|BEHAVIORAL|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
219415534|NCT02560831|BEHAVIORAL|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
219415535|NCT01864798|DRUG|Denosumab|
219415536|NCT01587573|OTHER|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
219415537|NCT03279302|DRUG|Glepaglutide|Solution for injection
219415538|NCT03411707|DIAGNOSTIC_TEST|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
219415539|NCT04203563|BEHAVIORAL|Strong People Strength Training|A community-based progressive strength training program
219571411|NCT02662231|PROCEDURE|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
219571412|NCT06465732|DRUG|Dupilumab|the active comparator arm receive dupilumab only
219571413|NCT06465732|DRUG|Tofacitinib|the experimental arm receive dupilumab plus tofacitinib.
219571414|NCT02053129|OTHER|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
219571415|NCT02053129|OTHER|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
219415540|NCT03341897|PROCEDURE|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
219415541|NCT05781971|DIETARY_SUPPLEMENT|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
219415542|NCT05781971|BEHAVIORAL|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
219415543|NCT05781971|DIETARY_SUPPLEMENT|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
219415544|NCT04453696|BEHAVIORAL|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
219415545|NCT04759014|OTHER|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
219415546|NCT00961337|BIOLOGICAL|Trivalent inactivated influenza vaccine|one dose
219004162|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
219004163|NCT01092754|DRUG|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
219004164|NCT03405506|DEVICE|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
219004165|NCT05505903|DIAGNOSTIC_TEST|Temerature measurement|Temerature measurement on admission to WBN or NICU
219004166|NCT02726646|DRUG|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
219004167|NCT02726646|PROCEDURE|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
219004168|NCT02726646|DRUG|Placebo|The application of 1 mg of microspheres placebo
219415547|NCT03501745|BEHAVIORAL|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
219415548|NCT03948308|BIOLOGICAL|blood sample|blood sample before, during and after infection treatment
219415549|NCT01490762|DRUG|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
219415550|NCT01490762|DRUG|Regular Human Insulin|Subcutaneous injection
219415551|NCT04512469|DEVICE|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
219415552|NCT03038659|DEVICE|Penile Duplex|Measuring intima media thickness
219415553|NCT00418964|PROCEDURE|Single bundle hamstring|Single bundle hamstring
219415554|NCT00418964|PROCEDURE|Double bundle hamstring|Double bundle hamstring
219415555|NCT00418964|PROCEDURE|Bone patellar tendon bone|Bone patellar tendon bone
219415556|NCT05511675|DEVICE|cold application|ISO-BALL
219415557|NCT01044680|DIETARY_SUPPLEMENT|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
219415558|NCT01044680|DIETARY_SUPPLEMENT|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
219415559|NCT04284943|PROCEDURE|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
219415560|NCT04284943|PROCEDURE|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
219415561|NCT04284943|PROCEDURE|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
219415562|NCT05516693|OTHER|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
219415563|NCT05831618|OTHER|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
219415564|NCT05831618|OTHER|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
219415565|NCT02367534|PROCEDURE|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
219415566|NCT03677817|DRUG|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
219415567|NCT03677817|DRUG|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
219415568|NCT05102149|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
219004169|NCT06265727|DRUG|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
219415569|NCT05102149|DRUG|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
219415570|NCT05102149|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
219415571|NCT05102149|DRUG|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
219415572|NCT05402098|PROCEDURE|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
219415573|NCT05402098|PROCEDURE|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
219415574|NCT05108610|OTHER|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
219415575|NCT05108610|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
219415576|NCT00941889|DRUG|Saline|0.5 ml
219415577|NCT00941889|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
219415578|NCT02590523|DRUG|Vancomycin|Intracameral vancomycin injection during cataract surgery
219004170|NCT06265727|DRUG|Anti-PD-1|checkpoint inhibitor
219004171|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
219415579|NCT02590523|DRUG|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
219415580|NCT02590523|DRUG|Placebo|Intracameral placebo injection with BSS during cataract surgery
219571416|NCT03677791|OTHER|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
219415581|NCT03497442|DRUG|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
219190656|NCT06527235|DRUG|ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
219415582|NCT03497442|DRUG|Placebo Vehicle Gel|Vehicle Gel
219415583|NCT05628025|OTHER|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
219190657|NCT05295602|RADIATION|CT scan|CT of lower leg
219415584|NCT03072641|DIETARY_SUPPLEMENT|ProBion Clinica|
219415585|NCT04342039|DRUG|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
219415586|NCT04342039|OTHER|Placebo|2 sprays each nostril daily on days as indicated in the timeline
219190658|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
219415587|NCT03657914|PROCEDURE|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
219415588|NCT03517683|OTHER|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
219415589|NCT03517683|OTHER|High speed|speed of intrathecal injection will be 1ml in 5 seconds
219415590|NCT05521932|OTHER|endometrium collected|endometrium tissue collected following adhesiolysis surgery
219415591|NCT02938585|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
219415592|NCT02938585|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
219415593|NCT03993964|DRUG|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
219415594|NCT01850745|OTHER|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
219415595|NCT03427905|PROCEDURE|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
219415596|NCT03427905|PROCEDURE|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
219415597|NCT00703833|DRUG|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
219415598|NCT00703833|DRUG|Placebo (unspecified)|matching placebo
219415599|NCT02511951|PROCEDURE|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
219415600|NCT00288834|BEHAVIORAL|dysphagia rehabilitation|
219415601|NCT00377533|DEVICE|wheelchair rear anti-tip device|assistive device
219415602|NCT06390254|OTHER|Resilience-Enhancing Nursing Suppor|The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
219415603|NCT02287012|OTHER|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
219004172|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
219415604|NCT04058262|OTHER|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
219415605|NCT04058262|OTHER|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
219415606|NCT04058262|OTHER|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
219415607|NCT04058262|OTHER|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
219004173|NCT01317030|OTHER|Non-Contact Lens Wear|No intervention
219415608|NCT03192527|DRUG|KN015|experimental drug
219415609|NCT03192527|DRUG|Placebo|Comparator.
219415610|NCT03192527|DRUG|Triptorelin|The drug is used for down-regulation of endogenous FSH.
219571417|NCT03677791|OTHER|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
219415611|NCT04698213|DRUG|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
219415612|NCT04698213|DRUG|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
219571418|NCT01252719|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
219571419|NCT01252719|DRUG|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
219571420|NCT01252719|DRUG|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
219571421|NCT04815421|OTHER|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
219571422|NCT04815421|OTHER|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
219571423|NCT03766490|DRUG|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
219571424|NCT03766490|DRUG|Gefitinib|Tablet, P.O. 250mg qd
219757852|NCT05578066|OTHER|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
219757853|NCT06032884|PROCEDURE|continuous renal replacement therapy (CRRT)|renal replacement therapy (RRT).
219757854|NCT06032884|PROCEDURE|Intermittent hemodialysis (IHD)|renal replacement therapy (RRT).
219757855|NCT04533945|DEVICE|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
219415613|NCT02411201|DRUG|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
219571425|NCT03766490|DRUG|Icotinib|Tablet, P.O. 125mg tid
219571426|NCT05439811|PROCEDURE|Swan-Ganz Catheter|Swan-Ganz Catheter
219571427|NCT02769884|DEVICE|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
219571428|NCT01475253|DRUG|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
219571429|NCT01475253|OTHER|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
219571430|NCT01475253|PROCEDURE|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
219757856|NCT06563960|OTHER|carbonated water|Participants will drink carbonated water during videofluoroscopy.
219757857|NCT01585025|DRUG|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
219757858|NCT00890760|BIOLOGICAL|AdCh63 ME-TRAP|5 x 10\*10 vp IM
219757859|NCT00890760|BIOLOGICAL|MVA ME-TRAP|2 x 10\*8 pfu ID
219757860|NCT00890760|OTHER|Sporozoite challenge|Infected mosquito bite
219757861|NCT00890760|BIOLOGICAL|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
219757862|NCT04801576|OTHER|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
219757863|NCT04801576|OTHER|Placebo mouthrinse|Mouthrinses without flouride
219004174|NCT06198868|PROCEDURE|Operable|Enrolled patients capable of surgical treatment
219757864|NCT00503984|DRUG|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
219004175|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
219004176|NCT06130579|DRUG|IFN-Α|Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
219004177|NCT04204668|PROCEDURE|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
219004178|NCT04204668|PROCEDURE|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
219415614|NCT04929340|OTHER|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
219415615|NCT04929340|OTHER|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
219415616|NCT01260467|DRUG|memantine|10 milligrams orally twice a day
219415617|NCT02005848|BIOLOGICAL|Alpha-1 Antitrypsin|
219415618|NCT02005848|OTHER|Placebo|Placebo
219757865|NCT00503984|DRUG|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
219757866|NCT00503984|DRUG|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
219757867|NCT00503984|GENETIC|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
219004179|NCT04204668|PROCEDURE|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
219004180|NCT06423911|DRUG|olverembatinib|olverembatinib QOD
219004181|NCT06423911|DRUG|Bosutinib|Bosutnib QD
219004182|NCT06227910|DRUG|Vedolizumab|Vedolizumab IV infusion.
219004183|NCT06227910|DRUG|Upadacitinib|Upadacitinib over-encapsulated tablets.
219004184|NCT06227910|DRUG|Placebo|Upadacitinib matched placebo capsules.
219004185|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
219004186|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
219004187|NCT05109442|DRUG|AFM24|intravenous infusion
219004188|NCT05109442|DRUG|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
219004189|NCT06562894|DRUG|SYHX1901|Administered orally, once daily (QD)
219004190|NCT06562894|DRUG|Placebo|Administered orally, once daily (QD)
219190659|NCT05690685|DEVICE|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period."
219190660|NCT06368479|DEVICE|iStatis HBsAg Test|Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
219004193|NCT04853225|OTHER|Prospective observational cohort study|Prospective observational cohort study
219004194|NCT06119685|DRUG|IDP-023|NK cell therapy
219004195|NCT06119685|DRUG|Rituximab|Anti-CD20 antibody therapy
219004196|NCT06119685|DRUG|Daratumumab|Anti-CD38 antibody therapy
219004197|NCT06119685|DRUG|Interleukin-2|Immune cytokine
219004198|NCT06119685|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219004199|NCT06119685|DRUG|Fludarabine|Lymphodepleting chemotherapy
219004200|NCT06119685|DRUG|Mesna|Chemoprotectant
219004201|NCT06119685|DRUG|Isatuximab|Anti-CD38 antibody therapy
219190661|NCT06131281|PROCEDURE|E-TORe|The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.
219415619|NCT05678192|DRUG|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
219415620|NCT05678192|DRUG|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
219415621|NCT04251689|DRUG|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
219415622|NCT04251689|DRUG|Placebo|0.9% normal saline 100 ml
219757868|NCT00503984|DRUG|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
219757869|NCT00503984|DRUG|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
219757870|NCT02282748|OTHER|No intervention|
219757871|NCT01246960|BIOLOGICAL|Ramucirumab|Administered intravenously
219757872|NCT01246960|DRUG|Placebo|Administered intravenously
219757873|NCT01246960|DRUG|Oxaliplatin|Administered intravenously
219757874|NCT01246960|DRUG|Leucovorin|Administered intravenously
219415623|NCT06179615|OTHER|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
219415624|NCT06179615|OTHER|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
219415625|NCT00654784|DRUG|idebenone|idebenone 450 mg/day (150 mg three times a day)
219415626|NCT00654784|DRUG|placebo|
219415627|NCT01367301|DRUG|paclitaxel|Given IV
219415628|NCT01367301|DRUG|carboplatin|Given IV
219415629|NCT01367301|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
219415630|NCT01367301|RADIATION|brachytherapy|Undergo HDR brachytherapy
219415631|NCT01367301|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219415632|NCT01367301|OTHER|laboratory biomarker analysis|Correlative studies
219571431|NCT03734887|BEHAVIORAL|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
219571432|NCT03734887|BEHAVIORAL|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
219757875|NCT01246960|DRUG|5-Fluorouracil|Administered intravenously
219757876|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
219757877|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
219415633|NCT01628094|DRUG|RO5024048|
219415634|NCT01628094|DRUG|RO5190591|
219415635|NCT01628094|DRUG|RO5466731|
219415636|NCT01628094|DRUG|ribavirin [Copegus]|
219415637|NCT01628094|DRUG|ritonavir|
219415638|NCT02598466|DRUG|Abatacept|
219415639|NCT02504268|DRUG|Abatacept|
219415640|NCT02504268|DRUG|Methotrexate|
219415641|NCT02504268|OTHER|Abatacept Placebo|
219415642|NCT02504268|OTHER|Methotrexate Placebo|
219415643|NCT01672437|OTHER|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
219571433|NCT05010824|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
219571434|NCT01328236|DRUG|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
219415644|NCT02548572|DEVICE|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
219415645|NCT00126178|BIOLOGICAL|HSPPC-96|
219415646|NCT02296437|OTHER|Transcranial direct current stimulation combined with cognitive training|
219415647|NCT02503774|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
219415648|NCT02503774|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
219415649|NCT04114513|DIETARY_SUPPLEMENT|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
219415650|NCT04114513|DIETARY_SUPPLEMENT|Inulin|BENEO-Orafti, white powder 5 weeks intervention
219415651|NCT04114513|DIETARY_SUPPLEMENT|Pectin|BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention
219415652|NCT04114513|DIETARY_SUPPLEMENT|Beta-glucan|Tate \& Lyle, white powder 5 weeks intervention
219415653|NCT04114513|DIETARY_SUPPLEMENT|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
219415654|NCT00956215|DRUG|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
219415655|NCT00956215|DRUG|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
219415656|NCT04141215|BIOLOGICAL|BIOBank bone paste|BIOBank bone paste (PPT322)
219415657|NCT04141215|BIOLOGICAL|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
219571435|NCT01328236|DRUG|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
219571436|NCT01328236|DRUG|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
219004202|NCT04553523|DEVICE|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
219004203|NCT04553523|PROCEDURE|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
219004204|NCT04553523|DEVICE|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
219004205|NCT05659641|DEVICE|PerMed Stent Graft System In Surgical Operation|PerMed Branch Stent Graft
219004206|NCT05659641|DEVICE|Endovastec CRONUS® Intraoperative stent system|CRONUS® Branch Stent Graft
219004207|NCT05073120|OTHER|Piqray Prescriber's/HCP guide for hyperglycemia|oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
219004208|NCT06071377|OTHER|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
219004209|NCT03567304|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
219004210|NCT06521294|OTHER|Mulligan SNAG mobilization tecnique|Mulligan SNAG mobilization tecnique
219004211|NCT06521294|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
219004212|NCT02700815|DRUG|Diclofenac|
219004213|NCT02700815|DRUG|Capsaicin|
219004214|NCT02700815|DRUG|Placebo|
219004215|NCT03592199|DRUG|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
219004216|NCT04716569|DRUG|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
219004217|NCT01850550|BEHAVIORAL|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
219004218|NCT02384408|PROCEDURE|Endometrial Biopsy|Histological assessment
219004219|NCT02384408|DEVICE|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
219004220|NCT02384408|PROCEDURE|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
219004221|NCT03021408|OTHER|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
219004222|NCT03021408|OTHER|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
219004223|NCT03021408|OTHER|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
219004224|NCT02233816|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
219004225|NCT02233816|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
219004226|NCT02233816|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
219004227|NCT02233816|BIOLOGICAL|Placebo|A single dose of placebo
219004228|NCT04351321|PROCEDURE|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
219004229|NCT04351321|PROCEDURE|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
219004230|NCT04907721|DIAGNOSTIC_TEST|Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon|"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."
219004231|NCT03048565|BEHAVIORAL|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
219004232|NCT02154490|DRUG|Docetaxel|Given IV
219004233|NCT02154490|BIOLOGICAL|Durvalumab|Given IV
219004234|NCT02154490|DRUG|Erlotinib Hydrochloride|Given PO
219571437|NCT00005918|DRUG|Efavirenz|
219004235|NCT02154490|DRUG|FGFR Inhibitor AZD4547|Given PO
219004236|NCT02154490|BIOLOGICAL|Ipilimumab|Given IV
219004237|NCT02154490|OTHER|Laboratory Biomarker Analysis|Correlative studies
219004238|NCT02154490|BIOLOGICAL|Nivolumab|Given IV
219004239|NCT02154490|DRUG|Palbociclib|Given PO
219004240|NCT02154490|OTHER|Pharmacological Study|Correlative studies
219571438|NCT00005918|DRUG|Lamivudine|
219571439|NCT00005918|DRUG|Stavudine|
219571440|NCT01790035|DRUG|LGG|
219571441|NCT01790035|DRUG|Placebo|
219415658|NCT06230835|BEHAVIORAL|Intervention Group|Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
219415659|NCT03768141|PROCEDURE|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
219415660|NCT05848050|PROCEDURE|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
219415661|NCT00861861|DRUG|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
219415662|NCT00861861|DRUG|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
219415663|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
219415664|NCT05378607|BEHAVIORAL|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
219415665|NCT05378607|BEHAVIORAL|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
219415666|NCT05378607|BEHAVIORAL|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
219415667|NCT05378607|BEHAVIORAL|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
219415668|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
219415669|NCT05378607|BEHAVIORAL|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
219571442|NCT03053336|BEHAVIORAL|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
219571443|NCT03418506|BEHAVIORAL|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
219004241|NCT02154490|BIOLOGICAL|Rilotumumab|Given IV
219004242|NCT02154490|DRUG|Talazoparib|Given PO
219004243|NCT02154490|DRUG|Taselisib|Given PO
219415670|NCT05378607|BEHAVIORAL|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
219571444|NCT03135899|DRUG|BI 443651|Three doses, each 12 hours apart
219571445|NCT03135899|DRUG|Placebo|Three doses, each 12 hours apart
219004244|NCT02154490|BIOLOGICAL|Tremelimumab|Given IV
219415671|NCT05746884|PROCEDURE|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
219415672|NCT05746884|PROCEDURE|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
219757878|NCT00754884|DRUG|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
219415673|NCT00307515|DRUG|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
219415674|NCT00307515|DEVICE|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
219004245|NCT03746873|BEHAVIORAL|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
219415675|NCT04772664|DIETARY_SUPPLEMENT|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
219415676|NCT04772664|DIETARY_SUPPLEMENT|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
219415677|NCT00836680|DEVICE|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
219415678|NCT00308438|DRUG|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
219415679|NCT03866863|OTHER|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
219415680|NCT00025532|OTHER|iodine I 131 monoclonal antibody CC49-deltaCH2|
219415681|NCT02130427|DIAGNOSTIC_TEST|CT scan|Weekly 3D/4D CT scan
219415682|NCT00258427|BIOLOGICAL|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
219415683|NCT00258427|BIOLOGICAL|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
219415684|NCT00258427|DRUG|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
219415685|NCT00258427|DRUG|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
219415686|NCT00258427|DRUG|fludarabine phosphate|35 mg/m\^2 intravenously (IV) on Days -5 through -2.
219415687|NCT00258427|DRUG|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
219415688|NCT00258427|BIOLOGICAL|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
219415689|NCT04010786|DRUG|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
219415690|NCT04010786|DRUG|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
219415691|NCT00409201|DRUG|reboxetine adjuvant therapy|
219415692|NCT01175967|OTHER|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
219415693|NCT01175967|OTHER|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
219415694|NCT01175967|OTHER|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
219415695|NCT01175967|OTHER|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
219415696|NCT05096871|GENETIC|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
219415697|NCT01389648|OTHER|Pre Operative|Pre operative chest physiotherapy treatment
219757879|NCT00754884|DRUG|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
219757880|NCT05809947|OTHER|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
219004246|NCT05236569|DRUG|Tranexamic acid injection|The tranexamic acid injection was given intradermally to the facial skin
219004247|NCT05236569|DRUG|Injection Water|The 0.9% normal saline injection was given intradermally to the facial skin
219415698|NCT03150095|BEHAVIORAL|Health coaching|Patients will work with a health coach by telephone
219415699|NCT02506296|DRUG|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
219415700|NCT02506296|DEVICE|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
219415701|NCT01143168|BIOLOGICAL|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
219415702|NCT02815241|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
219415703|NCT05176431|DEVICE|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
219004248|NCT01157949|DRUG|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
219415704|NCT05176431|DEVICE|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
219415705|NCT05176431|DEVICE|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
219415706|NCT06554028|DRUG|chemotherapy TP regimen combined with Tislelizumab|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel"
219415707|NCT06473493|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
219415708|NCT00213252|DRUG|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
219415709|NCT00213252|DRUG|Prednisolone|Six daily doses of oral prednisolone
219415710|NCT01238315|BIOLOGICAL|HuCNS-SC|Surgery to implant human CNS stem cells
219415711|NCT02700100|DEVICE|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
219415712|NCT01951235|DRUG|Imeglimin|
219415713|NCT01951235|DRUG|Placebo|
219415714|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
219415715|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
219415716|NCT04032171|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
219004249|NCT06125353|DIETARY_SUPPLEMENT|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
219415717|NCT04032171|DRUG|Avonex®|Participants received avonex® IM injection once a week.
219415718|NCT04032171|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
219415719|NCT04032171|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
219004250|NCT01252108|DRUG|SQ109|300 mg SQ109 daily for 14 days
219004251|NCT03757897|DRUG|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
219004252|NCT02422511|GENETIC|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
219415720|NCT03147339|OTHER|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
219415721|NCT02822534|DRUG|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
219415722|NCT02428530|OTHER|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
219415723|NCT01869751|DRUG|Prucalopride|Treatment with prucalopride for slow-transit constipation
219415724|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
219415725|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
219415726|NCT02299063|DRUG|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
219415727|NCT02299063|DRUG|0.9% NaCl|
219415728|NCT01362686|DRUG|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
219415729|NCT01362686|DRUG|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
219415730|NCT01362686|DRUG|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
219415731|NCT01613547|DRUG|Amoxicillin|80 mg/kg/day for 7 days
219571446|NCT00212576|BEHAVIORAL|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
219571447|NCT00212576|BEHAVIORAL|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
219415732|NCT01613547|DRUG|Placebo|7 days
219415733|NCT01767870|PROCEDURE|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
219571448|NCT04146363|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
219571449|NCT04146363|OTHER|Placebo|Subcutaneous Injection
219571450|NCT03521063|DRUG|Budesonide|Drug: Budesonide inhalation suspension
219757881|NCT00716820|DRUG|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
219757882|NCT04324281|OTHER|Investigation|cadaveric dissection
219757883|NCT00886730|BEHAVIORAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
219004253|NCT02422511|OTHER|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
219004254|NCT05160220|DRUG|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
219004255|NCT05160220|DRUG|Placebo|0.5 g dried edible non-psychoactive mushroom material.
219190662|NCT06131281|PROCEDURE|c-TORe|The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
219190663|NCT05157282|DEVICE|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
219415734|NCT01767870|PROCEDURE|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
219415735|NCT00311558|BIOLOGICAL|recombinant interferon alfa-2b|SSG x 5 week
219415736|NCT00311558|DRUG|sodium stibogluconate|SSG \& IFN
219415737|NCT00311558|DRUG|SSG & interferon|1 arm study with SSG \& interferon
219415738|NCT03477526|PROCEDURE|Pulmonary rehabilitation program|3 weeks, ...
219415739|NCT03096223|DRUG|KHK4083|IV administration
219415740|NCT02108951|DRUG|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
219415741|NCT04247750|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
219415742|NCT00718666|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
219415743|NCT04779671|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
219415744|NCT04779671|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
219415745|NCT06576102|OTHER|Persisting SARS-CoV-2 infection|Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients defined as the persistence or the recurrence of symptoms and signs (fever, dyspnea, hypoxemia, changes on chest-X ray or CT scan) and positive SARS-CoV-2 PCR ≥ 21 days after the time 0 (day of the first test positive for SARS-CoV-2 infection)
219415746|NCT00516425|BIOLOGICAL|pegfilgrastim|
219415747|NCT00516425|DRUG|cyclophosphamide|
219415748|NCT00516425|DRUG|doxorubicin hydrochloride|
219757884|NCT00886730|BEHAVIORAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
219757885|NCT00886730|BEHAVIORAL|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
219415749|NCT00516425|DRUG|epirubicin hydrochloride|
219415750|NCT00516425|GENETIC|proteomic profiling|
219415751|NCT00516425|OTHER|diagnostic laboratory biomarker analysis|
219757886|NCT02475421|BIOLOGICAL|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
219757887|NCT02267434|BIOLOGICAL|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
219757888|NCT02267434|BIOLOGICAL|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
219757889|NCT02267434|BIOLOGICAL|Adjuvant without active component|s.c. injection
219190664|NCT05157282|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
219415752|NCT00516425|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
219415753|NCT00516425|OTHER|pharmacological study|
219415754|NCT00516425|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
219415755|NCT00516425|PROCEDURE|adjuvant therapy|
219415756|NCT00670397|DRUG|HPPH|IV
219415757|NCT04510350|OTHER|Biomarkers analysis|Genetic analysis of regions of interest
219415758|NCT02298478|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
219415759|NCT01652248|PROCEDURE|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
219415760|NCT01467908|DEVICE|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
219415761|NCT05449496|BEHAVIORAL|Dietary Education Curriculum|Curriculum of dietary education and group-based counseling to encourage whole-food plant-based eating
219415762|NCT02690233|PROCEDURE|Elective Surgery|Elective laparoscopic inguinal hernia repair
219415763|NCT00932152|DRUG|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
219415764|NCT00932152|DRUG|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
219415765|NCT00932152|DRUG|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
219415766|NCT00932152|DRUG|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
219415767|NCT05434247|DEVICE|Needle choice|The type of needle use was the only intervention
219415768|NCT00783341|DRUG|GAP-134|
219415769|NCT00783341|DRUG|placebo|
219415770|NCT03591679|DRUG|Oxytocin|20 units by slow intravenous drip injection
219415771|NCT03591679|PROCEDURE|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
219415772|NCT00421343|DRUG|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
219415773|NCT00421343|DRUG|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
219415774|NCT00421343|BEHAVIORAL|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
219415775|NCT01580592|DRUG|Omalizumab|150mg, s.c., every 4 weeks
219415776|NCT01580592|DRUG|Omalizumab|300mg, s.c., every 4 weeks
219415777|NCT01580592|DRUG|Placebo|Placebo, s.c., every 4 weeks
219415778|NCT06516666|BEHAVIORAL|Music|"Participants went through four stages. In the rest stage, they were instructed to relax. In the neutral control stage, they watched an informative video about plastic injection molding. In the sadness induction stage, they viewed sad clips from either Hachi: A Dog's Tale or My Brother and Sister, with the order randomized across participants. In the music intervention stage, they listened to the cheerful Cuckoo Waltz. Each stage lasted for about 6 minutes.~The interventions for the two groups were exactly same.~PS: On the basis of the PHQ-9, this HAMD interview was conducted to further group the participants. So, following the experimental protocol, participants who scored ≥ 5 on the PHQ-9 measure underwent the HAMD interview, while the remaining individuals were simply interviewed about their feelings during the experiment."
219190665|NCT05157282|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
219415779|NCT01205672|DRUG|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
219415780|NCT04043338|DRUG|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
219415781|NCT04043338|DRUG|Placebo|Placebo supplied as matching capsules or tablets
219415782|NCT04619121|DEVICE|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
219415783|NCT04619121|DEVICE|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
219571451|NCT03521063|DRUG|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
219571452|NCT03521063|DRUG|Saline|Sodium chloride injection 0.9%
219571453|NCT01479257|BEHAVIORAL|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
219571454|NCT01479257|DEVICE|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
219757890|NCT00445094|DRUG|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
219757891|NCT00445094|DRUG|Comparator: amikacin / Duration of Treatment: 3 Days|
219757892|NCT00445094|DRUG|Comparator: tazocin / Duration of Treatment: 3 Days|
219190666|NCT05157282|DEVICE|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
219190667|NCT06085547|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
219415784|NCT03471767|DRUG|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
219415785|NCT03471767|DRUG|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
219415786|NCT00564954|DRUG|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
219415787|NCT00564954|DRUG|Placebo|orally once a day for 7 days
219571455|NCT01479257|DEVICE|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
219571456|NCT00165386|PROCEDURE|Magnetic Resonance Imaging|
219571457|NCT00165386|PROCEDURE|Bone Marrow Biopsy|
219571458|NCT04016792|DRUG|Placebo|Placebo will be administered once daily
219571459|NCT04016792|DRUG|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
219571460|NCT02914236|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
219571461|NCT00594113|OTHER|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
219571462|NCT00594113|OTHER|Touch screen intervention|Touch screen intervention
219571463|NCT04340999|DIAGNOSTIC_TEST|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
219571464|NCT03113578|DEVICE|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
219757893|NCT00445094|DRUG|Comparator: vancomycin / Duration of Treatment: 3 Days|
219757894|NCT02022709|DRUG|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
219757895|NCT02022709|DRUG|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
219757896|NCT02022709|DRUG|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
219757897|NCT02022709|DRUG|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
219757898|NCT02022709|DRUG|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
219757899|NCT02022709|BEHAVIORAL|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
219757900|NCT03789981|GENETIC|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
219190668|NCT06085547|BEHAVIORAL|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
219415788|NCT00657852|DRUG|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
219415789|NCT00657852|DRUG|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
219415790|NCT05371990|OTHER|Determination of Eating habits|Questionnaire
219415791|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
219415792|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
219415793|NCT00678587|DRUG|Eltrombopag|75 mg, once daily, oral
219415794|NCT00678587|DRUG|Placebo|placebo, once daily, oral
219415795|NCT02763878|PROCEDURE|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
219415796|NCT02763878|PROCEDURE|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
219415797|NCT01747278|DRUG|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
219415798|NCT02002806|OTHER|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
219415799|NCT02002806|OTHER|Placebo Injection|
219415800|NCT00895518|BEHAVIORAL|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
219415801|NCT03650686|OTHER|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
219415802|NCT03650686|OTHER|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
219415803|NCT03650686|OTHER|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
219415804|NCT03806179|DRUG|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
219415805|NCT03806179|DRUG|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
219415806|NCT02310828|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
219415807|NCT02310828|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
219415808|NCT00116857|DRUG|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
219415809|NCT00116857|DRUG|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
219415810|NCT04507477|BIOLOGICAL|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
219415811|NCT02375633|DRUG|DW-330SR2|
219415812|NCT02375633|DRUG|Pelubiprofen|
219415813|NCT03998475|BEHAVIORAL|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
219415814|NCT01952730|BIOLOGICAL|GVAX|
219415815|NCT00003539|BIOLOGICAL|trastuzumab|
219415816|NCT00003539|DRUG|paclitaxel|
219415817|NCT03703830|DEVICE|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
219415818|NCT03703830|OTHER|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
219415819|NCT03703830|DEVICE|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
219415820|NCT03703830|DEVICE|Cerebello-spinal direct current stimulation|Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
219415821|NCT03703830|DEVICE|Sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
219415822|NCT04217889|OTHER|Questionnaire|Short questionnaire that can be completed during the usual consultation.
219415823|NCT02076321|DRUG|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
219415824|NCT02076321|DRUG|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
219415825|NCT06502756|DEVICE|SOBER, mobile Application providing digital CBT|SOBER is a software application (Android) that delivers cognitive behavioral therapy (CBT) in a structured and interactive manner. It analyzes patterns in participants\&#39; lifestyles to identify problematic behaviors related to their alcohol consumption. By providing tailored guidance and support, the app aims to help individuals make sustainable changes, ultimately reducing hazardous drinking. This approach combines the principles of CBT with the convenience and accessibility of digital technology, offering a personalized experience to support the reduction of alcohol consumption.
219415826|NCT05564286|DRUG|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
219571465|NCT03507348|DRUG|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
219571466|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
219571467|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
219571468|NCT03507348|OTHER|Transplant Day-0|TRANSPLANTATION
219571469|NCT01677923|DRUG|Metformin|Metformin 500 mg BID for 12 months
219571470|NCT00891748|GENETIC|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
219571471|NCT05311917|OTHER|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
219571472|NCT05311917|OTHER|base in prism prescription|base in prism prescription according to sheards criterion
219571473|NCT05311917|OTHER|conventional placebo|using near glasses with aimless eye training
219571474|NCT01476735|OTHER|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
219571475|NCT02961166|DRUG|IgM enriched Immunoglobulins|Treatment for 3 days
219571476|NCT00500279|DRUG|Celecoxib|
219415827|NCT05564286|DRUG|tropisetron|All patients received tropisetron 5mg on day 1.
219415828|NCT05564286|DRUG|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
219571477|NCT01139684|BEHAVIORAL|Repeated sprint test|
219571478|NCT02976259|DRUG|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
219571479|NCT03036241|DEVICE|Conventional angioplasty|Angioplasty with conventional balloon
219571480|NCT03036241|DEVICE|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
219571481|NCT01731899|DRUG|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
219571482|NCT02273687|DEVICE|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
219571483|NCT05154812|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
219571484|NCT05154812|DRUG|Routine medical care|Routine medical care
219571485|NCT03441724|DIAGNOSTIC_TEST|Mechanocardiography|Mechanocardiographic recording
219190669|NCT05534945|DRUG|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219415829|NCT04767633|DRUG|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
219415830|NCT05622383|OTHER|aromatherapy|aromatherapy,
219415831|NCT05622383|OTHER|music concert|music concert
219415832|NCT05622383|OTHER|aromatherapy and music concert,|aromatherapy and music concert,
219571486|NCT04030182|DIAGNOSTIC_TEST|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
219415833|NCT04419285|BEHAVIORAL|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
219415834|NCT04419285|BEHAVIORAL|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
219415835|NCT04419285|BEHAVIORAL|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
219415836|NCT01366066|DEVICE|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
219415837|NCT01449201|DRUG|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
219415838|NCT06411119|DEVICE|Meta Oculus Quest 2™ Virtual Reality Exergaming|Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
219415839|NCT05683652|DEVICE|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
219415840|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
219415841|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
219415842|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
219415843|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
219415844|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
219415845|NCT02145091|DRUG|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
219415846|NCT02145091|DRUG|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
219415847|NCT02145091|DRUG|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
219415848|NCT02145091|DRUG|Placebo|An oral placebo (lactose pill).
219415849|NCT02237157|DRUG|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
219415850|NCT01996748|DRUG|DF277|Two administrations daily for 7 days
219415851|NCT01996748|DRUG|Placebo|Two administrations daily for 7 days
219415852|NCT06102642|BIOLOGICAL|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
219415853|NCT01220986|PROCEDURE|Liver biopsy|0, 30, 60, 90 min post inflow-division
219415854|NCT01341379|DRUG|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
219415855|NCT02082314|PROCEDURE|RFA Vertebroplasty|
219415856|NCT00307060|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
219415857|NCT00307060|DRUG|losartan / Duration of Treatment: 6 weeks|
219415858|NCT01951014|OTHER|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
219415859|NCT04152525|OTHER|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
219415860|NCT05745896|OTHER|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
219415861|NCT05745896|OTHER|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
219415862|NCT03340792|DEVICE|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
219415863|NCT00441558|DRUG|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
219415864|NCT04426123|DRUG|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
219415865|NCT04426123|OTHER|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
219415866|NCT05275153|OTHER|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
219415867|NCT03738566|DEVICE|Esophageal self-dilation therapy|Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
219415868|NCT03738566|PROCEDURE|Endoscopic therapy with esophageal dilation|A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
219415869|NCT06473337|DIAGNOSTIC_TEST|Blood sample|Serum blood sample for Vitamin D testing
219571487|NCT01599130|DRUG|Entecavir|entecavir 0.5mg per day
219004256|NCT03896776|BEHAVIORAL|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
219415870|NCT02583945|PROCEDURE|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
219415871|NCT05169645|OTHER|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale"
219415872|NCT04834882|OTHER|Data collection (|online survey
219415873|NCT02302794|PROCEDURE|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
219415874|NCT02302794|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
219004257|NCT02633644|DEVICE|Harmony System|Percutaneous neuromodulation of the aortic wall
219004258|NCT02961751|DRUG|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
219004259|NCT03770442|DEVICE|Cycling with FES|As described already
219415875|NCT00093080|DRUG|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
219415876|NCT05320458|OTHER|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
219415877|NCT01229488|DEVICE|Intervention|Project was withdrawn before starting. There were no interventions
219415878|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
219415879|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
219415880|NCT05990764|OTHER|Placebo|"placebo~Once a day"
219415881|NCT01982604|DRUG|TI-Inhalation Powder A|Inhaled Insulin
219571488|NCT01599130|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
219571489|NCT04311151|PROCEDURE|own seizures visualization|At the hospital discharge, patients
219004260|NCT03770442|OTHER|Routine physiotherapy|As described already
219004261|NCT04827550|OTHER|STUDY|Fibromyalgia Patient
219004262|NCT00939250|BEHAVIORAL|Diabetes and depression intervention|Disease self management for diabetes and depression
219004263|NCT00939250|BEHAVIORAL|Diabetes intervention|Disease self management for diabetes
219415882|NCT01982604|DRUG|TI-Inhalation Powder B|Inhaled Insulin
219415883|NCT01540916|OTHER|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
219415884|NCT01540916|OTHER|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
219415885|NCT06006858|BIOLOGICAL|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
219415886|NCT01655823|DRUG|Placebo|Sham treatment acting as control arm
219415887|NCT01655823|DRUG|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
219415888|NCT04539249|DRUG|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
219571490|NCT03393455|OTHER|not accurate|not accurate
219571491|NCT01305148|DEVICE|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
219571492|NCT01087632|DIETARY_SUPPLEMENT|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
219571493|NCT03952611|PROCEDURE|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
219571494|NCT03952611|DEVICE|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
219571495|NCT03952611|DEVICE|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
219757901|NCT00692887|DEVICE|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
219757902|NCT03583229|DRUG|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
219757903|NCT03583229|OTHER|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
219757904|NCT00003873|DRUG|fluorouracil|Given IV or orally
219757905|NCT00003873|DRUG|eniluracil|Given orally
219415889|NCT04539249|DRUG|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
219415890|NCT04798885|BEHAVIORAL|GAIN 2.0|1\) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
219415891|NCT02462304|PROCEDURE|End-Point-Management grid laser|
219415892|NCT02462304|DRUG|ranibizumab|
219415893|NCT02462304|DRUG|Bevacizumab|
219415894|NCT05300100|BEHAVIORAL|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
219415895|NCT00187837|PROCEDURE|SW|Stepwise removal of carious tissue in 2 stages
219415896|NCT00187837|PROCEDURE|DCE|one complete excavation
219415897|NCT04799405|DEVICE|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
219415898|NCT05430451|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
219415899|NCT05430451|BEHAVIORAL|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
219415900|NCT05430451|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
219571496|NCT01342536|BEHAVIORAL|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
219415901|NCT05430451|BEHAVIORAL|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
219571497|NCT03840499|DRUG|Optimal medical therapy|Optimal medical therapy
219571498|NCT04642859|BEHAVIORAL|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
219757906|NCT02466724|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
219757907|NCT05889325|PROCEDURE|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
219004264|NCT06087666|PROCEDURE|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
219004265|NCT00822250|OTHER|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
219757908|NCT06405386|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
219415902|NCT05430451|BEHAVIORAL|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
219415903|NCT05430451|BEHAVIORAL|SMS|SMS on follow-up survey reminders
219415904|NCT04612062|DRUG|CEE321|CEE321 administered to all subjects
219415905|NCT01957826|OTHER|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
219415906|NCT01957826|OTHER|placebo intervention|placebo administration
219415907|NCT02434627|DRUG|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
219415908|NCT04946136|OTHER|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
219415909|NCT02683525|DRUG|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
219415910|NCT01660087|DEVICE|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
219415911|NCT06117800|OTHER|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
219415912|NCT01064024|DRUG|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
219415913|NCT01064024|DRUG|Placebo|Tablets, every 8 hours for 48 hours
219415914|NCT03476785|BEHAVIORAL|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
219415915|NCT03476785|BEHAVIORAL|Yoga|Subjects will perform strength and flexibility exercises.
219415916|NCT04265586|BEHAVIORAL|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
219415917|NCT04265586|BEHAVIORAL|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
219415918|NCT02114567|OTHER|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
219415919|NCT06377800|OTHER|navicular mobilization along conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
219415920|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
219415921|NCT00158548|DRUG|SP, chloroquine, amodiaquine, primaquine, artesunate|
219415922|NCT01912430|BEHAVIORAL|ICC (Integrated Care Coaching) Intervention Group|
219415923|NCT04972344|DIAGNOSTIC_TEST|Ionized magnesium|Assessment of ionized magnesium level
219004266|NCT03281681|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
219004267|NCT06037291|DIETARY_SUPPLEMENT|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
219004268|NCT06037291|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
219415924|NCT01633996|PROCEDURE|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
219415925|NCT01700517|OTHER|Spinal anesthesia|spinal anesthesia
219415926|NCT01700517|OTHER|Femoral nerve block|Femoral nerve block
219415927|NCT01700517|OTHER|sciatic nerves block|sciatic nerves block
219415928|NCT01849835|PROCEDURE|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
219415929|NCT01849835|PROCEDURE|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
219415930|NCT00537550|DRUG|Vincristine|Steroids pre-treatment
219415931|NCT00537550|DRUG|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
219004269|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
219004270|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
219190670|NCT05534945|DRUG|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219571499|NCT02978820|OTHER|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
219571500|NCT02978820|OTHER|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
219571501|NCT00336765|DRUG|XL647|Tablets supplied in 50-mg strength administered orally daily
219571502|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
219571503|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
219571504|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
219571505|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
219571506|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
219571507|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
219571508|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
219004271|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
219004272|NCT02526745|BIOLOGICAL|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
219004273|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
219571509|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
219004274|NCT02526745|BIOLOGICAL|placebo|
219004275|NCT01069107|OTHER|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
219004276|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
219571510|NCT02904499|DRUG|Dabigatran|
219571511|NCT04344197|OTHER|global survey|surgery questionnaire
219571512|NCT00207194|BEHAVIORAL|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
219571513|NCT00207194|BEHAVIORAL|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
219571514|NCT03935022|OTHER|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
219571515|NCT03274622|BEHAVIORAL|Impact Parent Training|
219571516|NCT03274622|BEHAVIORAL|No Impact|
219004277|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
219004278|NCT00694213|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
219004279|NCT00694213|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
219004280|NCT00147888|PROCEDURE|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
219190671|NCT05534945|DRUG|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219415932|NCT05056454|BEHAVIORAL|Online therapy with coaching within STAND|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
219415933|NCT05056454|BEHAVIORAL|Clinical care within STAND|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
219415934|NCT05056454|OTHER|Perinatal Psychiatric Care|Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
219571517|NCT03142035|DRUG|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
219571518|NCT03142035|DRUG|gonapeptyl|gonadotropic releasing hormone agonist
219571519|NCT03142035|PROCEDURE|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
219571520|NCT00836719|DRUG|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
219190672|NCT05534945|DRUG|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219190673|NCT05534945|DRUG|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219190674|NCT05534945|DRUG|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
219190675|NCT02368041|DEVICE|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
219190676|NCT06184984|DIETARY_SUPPLEMENT|Metabolic availability of methionine in mung beans|Each participant will randomly receive 7 different levels of methionine provided as free amino acids and cooked mung beans.
219190677|NCT04110522|OTHER|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
219190678|NCT06849492|DRUG|Camrelizumab|PD-1 inhibitor
219190679|NCT06849492|DRUG|Nab-paclitaxel|chemotherapy
219190680|NCT06849492|DRUG|SKB264|Trop2-ADC
219190681|NCT06849492|DRUG|Lenvatinib|Anti-angiogenic TKI
219190682|NCT06852989|OTHER|Shared book reading intervention|The study group participated in a parent training program focusing on shared interactive reading practices and attended nine read-aloud meetings with their children under the supervision of a trained librarian.
219190683|NCT06850935|OTHER|Centella asiatica extracellular vesicle formulation|Water-based formulation containing purified Centella asiatica extracellular vesicle as main active ingredient. Applied twice daily at two drops per use to the face after face cleansing for 28 consecutive days.
219190684|NCT06851221|DIAGNOSTIC_TEST|beta3 expression|the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor
219190685|NCT04098874|DRUG|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
219190686|NCT04098874|DRUG|Placebo oral tablet|12 weeks postpartum of blinded placebo
219190687|NCT06786611|DIAGNOSTIC_TEST|MRI|Based on the different manifestations of facet joints under MRI, and with the help of the characteristic manifestations of the gray value curve of facet joints under different subtypes, the curve of facet joints under the same level is fitted, and finally the accurate evaluation of different subtypes of small joints is achieved.
219190688|NCT06851975|OTHER|blood sampling|36ml of blood will be taken during a blood sampling performed in standard practice
219571521|NCT02589158|DRUG|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
219571522|NCT02589158|DRUG|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
219190689|NCT06847984|DIETARY_SUPPLEMENT|Curcumin|"Participants were instructed to rinse with 10 mL of mouthwash for~1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year."
219415935|NCT02215993|DRUG|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
219415936|NCT02215993|DRUG|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
219415937|NCT04062851|OTHER|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
219415938|NCT02504476|DRUG|AMG 581|Active drug
219415939|NCT02504476|DRUG|Placebo|Placebo
219415940|NCT02504476|DRUG|Midazolam|Interaction
219415941|NCT00926796|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
219415942|NCT00926796|DRUG|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
219415943|NCT00926796|DRUG|Gemifloxacin|One 320 mg tablet administered orally.
219415944|NCT05414708|BEHAVIORAL|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
219571523|NCT02148913|DRUG|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
219571524|NCT02148913|DRUG|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
219571525|NCT02148913|DRUG|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
219571526|NCT02148913|DRUG|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
219571527|NCT02572349|DRUG|IW-1701|
219571528|NCT02572349|DRUG|Matching Placebo|
219415945|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler|
219415946|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
219571529|NCT03192852|OTHER|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
219571530|NCT03192852|PROCEDURE|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
219571531|NCT04832126|GENETIC|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
219571532|NCT05904249|OTHER|Internet Based Synchronized Telerehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
219190690|NCT06847984|OTHER|Chlorohexidine|Participants were instructed to rinse with 10 mL of mouthwash for 1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year
219415947|NCT02162485|DRUG|Seretide Diskus|
219415948|NCT02162485|DRUG|Seretide Diskus with charcoal|
219415949|NCT01628016|BEHAVIORAL|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
219415950|NCT01341652|BIOLOGICAL|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
219415951|NCT01341652|BIOLOGICAL|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
219190691|NCT05066854|PROCEDURE|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
219415952|NCT06263634|OTHER|Hand exercises|30-45 minutes of home exercises consisting of stretching, mobility and strengthening
219415953|NCT01160952|DRUG|itraconazole|the two groups are defined by different treatment duration
219415954|NCT03502252|BEHAVIORAL|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
219415955|NCT04975971|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
219415956|NCT02410707|DRUG|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
219415957|NCT02410707|DRUG|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
219415958|NCT02410707|DRUG|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
219415959|NCT01260766|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
219571533|NCT05904249|OTHER|Face-to-Face Rehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
219571534|NCT04526392|OTHER|Questionnaire|Pubertal course questionnaire
219571535|NCT00780260|BEHAVIORAL|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
219571536|NCT00027794|PROCEDURE|conventional surgery|
219571537|NCT05175924|OTHER|Nanpharmacological method|Virtual Reality
219571538|NCT01494935|BEHAVIORAL|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
219571539|NCT01494935|BEHAVIORAL|Control diet|Normal fat, normal fat diet
219571540|NCT02623452|DRUG|Insulin Lispro|Administered subcutaneously (SC)
219415960|NCT01260766|DEVICE|Placebo Patch|same as active patch
219415961|NCT03798912|COMBINATION_PRODUCT|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
219415962|NCT04926194|BIOLOGICAL|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
219415963|NCT02460757|OTHER|Laryngoscopy|Observation of glottic width in different arms
219415964|NCT06266273|OTHER|No intervention|No intervention
219571541|NCT00478452|BIOLOGICAL|DC-Ova|
219571542|NCT00478452|BIOLOGICAL|DC Ova with Cyclophosphamide|
219571543|NCT02340494|BEHAVIORAL|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
219190692|NCT05066854|PROCEDURE|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
219190693|NCT06544187|DIAGNOSTIC_TEST|MRS scan|Magnetic Resonance Spectroscopy scan on the thigh
219190694|NCT06544187|DIAGNOSTIC_TEST|CPET|Cardiopulmonary Exercise Test
219571544|NCT05386524|DRUG|sintilimab|sintilimab 200mg, ivgtt，d1
219571545|NCT05386524|DRUG|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
219571546|NCT05386524|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
219571547|NCT00431158|OTHER|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
219571548|NCT05602402|OTHER|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
219571549|NCT05602402|OTHER|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
219571550|NCT02678442|DEVICE|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
219571551|NCT02678442|DEVICE|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
219415965|NCT00632463|BIOLOGICAL|RI-001|Dose 1
219415966|NCT00632463|BIOLOGICAL|RI-001|Dose 2
219415967|NCT00632463|BIOLOGICAL|RI-001|Placebo
219415968|NCT00626912|PROCEDURE|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
219415969|NCT02849912|OTHER|questionnaire|
219415970|NCT03483506|DRUG|BI 1467335|Film-coated tablet
219571552|NCT02490306|DEVICE|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
219571553|NCT03647046|DEVICE|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
219571554|NCT06302972|OTHER|Traditional treatment|Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
219571555|NCT06302972|OTHER|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
219571556|NCT04336839|PROCEDURE|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
219571557|NCT01906086|OTHER|nutritional intervention|
219571558|NCT01906086|OTHER|life style intervention|
219571559|NCT01805726|DRUG|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
219571560|NCT01805726|DRUG|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
219415971|NCT03483506|DRUG|BI 1467335 (C-14) intravenous solution|Intravenous solution
219415972|NCT05381376|DIAGNOSTIC_TEST|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
219415973|NCT05381376|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
219415974|NCT00002157|DRUG|Thalidomide|
219415975|NCT02088684|DRUG|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
219415976|NCT02088684|DRUG|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
219415977|NCT02088684|DRUG|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
219415978|NCT02088684|DRUG|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
219415979|NCT01609803|OTHER|laboratory biomarker analysis|Correlative studies
219415980|NCT02074579|DRUG|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
219415981|NCT02074579|DRUG|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
219415982|NCT02473159|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
219571561|NCT01805726|DRUG|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
219415983|NCT04752579|OTHER|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
219415984|NCT05602259|DIAGNOSTIC_TEST|induced sputum|After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
219415985|NCT05602259|DIAGNOSTIC_TEST|lung biopsy|As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
219571562|NCT02979457|BEHAVIORAL|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
219571563|NCT04420338|BIOLOGICAL|Blood sample|rapid serological tests carried out
219571564|NCT04420338|BIOLOGICAL|Serum tube collection|SARS-COV2 seroconversion assay
219571565|NCT04289506|DIAGNOSTIC_TEST|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
219571566|NCT00303875|BEHAVIORAL|behavioral dietary and exercise intervention|
219571567|NCT03176368|OTHER|Coconut Oil|Coconut Oil
219571568|NCT04815330|OTHER|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
219571569|NCT04815330|OTHER|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
219571570|NCT04891965|BIOLOGICAL|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
219571571|NCT04891965|DRUG|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
219571572|NCT05404412|PROCEDURE|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
219571573|NCT00004748|DRUG|colchicine|
219571574|NCT00004748|DRUG|methotrexate|
219571575|NCT00004748|DRUG|ursodiol|
219757909|NCT06405386|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
219571576|NCT03465748|DEVICE|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
219571577|NCT04094948|DRUG|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
219571578|NCT04094948|DRUG|Placebos|dextrose-filled capsules
219571579|NCT01699386|OTHER|Control Study Formula|feed as lib
219571580|NCT01699386|OTHER|Experimental Study Formula|feed as lib
219571581|NCT03074539|DRUG|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
219757910|NCT00693550|OTHER|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
219757911|NCT06564662|DEVICE|Rapid Response EEG|The Ceribell(R) Rapid Response EEG is a relatively new device that is becoming standard of care in the adult critical care. In this pediatric study the device will be placed by trained ICU physicians
219757912|NCT04779099|BEHAVIORAL|Brief 4-session intervention for borderline personality disorder|Intervention consists of weekly 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support. This intervention is detailed in a published manual.
219757913|NCT04779099|BEHAVIORAL|Treatment as usual|TAU comprises access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
219757914|NCT05345483|DEVICE|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
219757915|NCT03326245|DRUG|Methylphenidate Pill|Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
219571582|NCT03074539|PROCEDURE|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
219415986|NCT05602259|DIAGNOSTIC_TEST|bronchoalveolar lavage|When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
219415987|NCT05602259|DIAGNOSTIC_TEST|blood draw|As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
219571583|NCT03074539|PROCEDURE|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
219571584|NCT05518448|DIETARY_SUPPLEMENT|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
219571585|NCT02221908|DEVICE|Mespere Venus 1000 CVP System|
219757916|NCT03326245|DRUG|Oral Placebo|Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
219757917|NCT03326245|DRUG|Intravenous Placebo|Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
219415988|NCT05250271|OTHER|15 g dextrose|15 g dextrose tablets
219757918|NCT03326245|DRUG|Intravenous methylphenidate|Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
219757919|NCT01144000|DRUG|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
219757920|NCT01792167|BEHAVIORAL|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
219757921|NCT06426979|DRUG|Methotrexate|Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
219757922|NCT06426979|DRUG|Letrozole|FEMARA 2.5 mg tablets two tablets daily
219757923|NCT00140140|DRUG|ABI-007|Weekly intravenous infusions over 30 minutes.
219757924|NCT00140140|DRUG|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
219757925|NCT00140140|DRUG|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
219761582|NCT05652504|DRUG|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
219190695|NCT06851000|PROCEDURE|ultrasound-guided pulsed radiofrequency|Medication: 0-3months; Pulsed radiofrequency: week 2, 6, 10;
219190696|NCT06851000|PROCEDURE|ultrasound-guided dry needling|Medication: 0-3 months; Dry needling: week 2; Pulsed radiofrequency: week 6, 10;
219415989|NCT05250271|OTHER|5 g dextrose|5 g dextrose tablets
219415990|NCT05250271|OTHER|Protein bar|5 g carbohydrates + 10 g protein
219415991|NCT02315937|PROCEDURE|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
219415992|NCT01778088|DRUG|I-131-CLR1404 Injection|
219415993|NCT00952237|DRUG|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
219415994|NCT00952237|DRUG|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
219571586|NCT00859001|DRUG|FM+R|Fludarabine-Mitoxantrone-Rituximab
219571587|NCT00859001|DRUG|Zevalin (Ibritumomab Tiuxetan)|
219571588|NCT04244201|DEVICE|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
219571589|NCT02314572|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
219571590|NCT04595916|DRUG|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
219571591|NCT04595916|DRUG|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
219571592|NCT03612739|BIOLOGICAL|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
219761583|NCT06274671|OTHER|Magnetic Resonance Imaging|A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
219571593|NCT01231750|DRUG|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
219190697|NCT06851832|BIOLOGICAL|Recombinant zoster vaccine(CHO cell)(low adjuvant)|The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
219190698|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|"The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle.~Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose.~Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\]."
219415995|NCT06156111|DEVICE|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
219415996|NCT06156111|DEVICE|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
219415997|NCT05140005|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
219415998|NCT00123851|DRUG|Tarceva (OSI-774)|
219415999|NCT00123851|DRUG|Capecitabine|
219416000|NCT00123851|DRUG|Oxaliplatin|
219416001|NCT02998554|DRUG|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
219416002|NCT02998554|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
219571594|NCT01231750|OTHER|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
219571595|NCT01261741|DRUG|Memantine|Each subject will receive memantine 10mg tablets once daily
219571596|NCT01261741|DRUG|Placebo|Each subject will receive matching placebo tablets once daily
219571597|NCT05632341|DIETARY_SUPPLEMENT|Lactococcus lactis|1 capsule once a day
219571598|NCT05632341|OTHER|maltodextrin|1 capsule once a day
219571599|NCT03064321|BEHAVIORAL|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
219571600|NCT03064321|OTHER|Information Control|Information on websites that are general health promoting
219571601|NCT00004402|DRUG|calcitriol|
219571602|NCT00004402|DRUG|interferon gamma|
219571603|NCT00725478|DRUG|Piribedil|
219571604|NCT02818387|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
219571605|NCT02818387|DRUG|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
219571606|NCT02818387|DRUG|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
219571607|NCT01045993|DEVICE|Heat Device|8-Hour Heatwrap
219571608|NCT01045993|DEVICE|Sham Device|Inactive wrap worn for 8 hours
219571609|NCT01045993|DRUG|marketed analgesic|2 x 200 mg ibuprofen tablets
219571610|NCT01045993|DRUG|Placebo|2 x placebo tablets
219571611|NCT01827124|DRUG|Carbetocin|
219571612|NCT01827124|DRUG|oxytocin|
219571613|NCT02025010|DRUG|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
219571614|NCT03547973|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously.
219571615|NCT03547973|DRUG|Pembrolizumab|Administered per package insert
219571616|NCT03547973|DRUG|Cisplatin|Administered per package insert
219571617|NCT03547973|DRUG|Avelumab|Administered per package insert
219571618|NCT03547973|DRUG|Zimberelimab|Administered intravenously
219571619|NCT03547973|DRUG|Carboplatin|Administered per package insert
219571620|NCT03547973|DRUG|Gemcitabine|Administered per package insert
219571621|NCT03547973|DRUG|Domvanalimab|Administered intravenously
219571622|NCT03547973|DRUG|Enfortumab Vedotin|Administered intravenously
219571623|NCT06534320|DRUG|DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 6 subjects receive DA-302168S tablets.
219571624|NCT06534320|DRUG|Placebo of DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.
219571625|NCT06534320|DRUG|DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 8 subjects receive study DA-302168S tablets.
219571626|NCT06534320|DRUG|Placebo of DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
219571627|NCT01644487|DEVICE|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
219571628|NCT01644487|DEVICE|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
219571629|NCT04769752|OTHER|collection of the allocated treatment|collection of the allocated treatment
219571630|NCT04769752|OTHER|collection of medical complications|collection of medical complications
219571631|NCT03714555|DIAGNOSTIC_TEST|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
219571632|NCT03714555|OTHER|AE Assessment|Assessment of Adverse Events (AE)
219416003|NCT06553534|OTHER|SAMURAI PICU Bundle|"The proposed multifaceted SAMURAI PICU Bundle is an intervention with the following core elements: 1) PICU Warning Tool: an automated clinical decision support (CDS) tool to provide a non-interruptive interprofessional predictive alert, 2) twice daily safety huddles with unit leadership, and 3) bedside assessment including the care team and patient's family to complete and display a bedside mitigation plan to prevent deterioration. This intervention combines the automated accurate prediction of the PICU Warning Tool with the use of provider intuition or a gut feeling from huddles to improve decision making at the bedside. Peripheral elements and possible adaptations will be suggested during Aim 1 and additional peripheral elements may be added by local sites after discussion with the PI through a user-centered design approach."
219416004|NCT06187844|PROCEDURE|Inguinal exploration|Inguinal exploration will be done for all the included patients.
219416005|NCT06187844|PROCEDURE|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
219416006|NCT05742672|OTHER|ABDOMINAL MASSAGE APPLICATION|"* Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue."
219416007|NCT02069496|BIOLOGICAL|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
219416008|NCT06553196|BEHAVIORAL|MATAspire Web-app|Substance misuse prevention education and adaptive coping skills
219416009|NCT04496596|DRUG|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
219571633|NCT03714555|OTHER|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
219571634|NCT03714555|OTHER|Concomitant Medication Review|Prior and Concomitant Medication Review
219416010|NCT04496596|DRUG|Placebo|Placebo
219416011|NCT02010216|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
219416012|NCT01717664|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
219416013|NCT01999413|DRUG|OMEGAVEN|AML Study treatment induction phase
219416014|NCT01999413|DRUG|Daunorubicin|AML Study treatment induction phase
219416015|NCT01999413|DRUG|Cytarabine|AML Study treatment induction phase
219416016|NCT02000713|OTHER|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
219571635|NCT03714555|DIAGNOSTIC_TEST|Tumor Imaging|Tumor CT or MRI
219571636|NCT03714555|DRUG|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
219571637|NCT03714555|DRUG|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
219571638|NCT03714555|DRUG|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
219571639|NCT01980342|DRUG|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
219571640|NCT01157715|BIOLOGICAL|intravitreal injection of KH902|
219761584|NCT06654050|DRUG|alrizomadlin|Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.
219761585|NCT01266577|OTHER|NSR MAGNETOM 7T|The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
219761586|NCT01266577|OTHER|1Tx x 32Rx Head Coil|Used to perform proton imaging and spectroscopy in the human heads.
219761587|NCT06836284|DEVICE|Digi-physical treatment tool, Evira|A digi-physical treatment tool named Evira will be used to provide behavioral treatment.
219761588|NCT06836284|DRUG|Anti-obesity medication with liraglutide or semaglutide|Anti-obesity medication with liraglutide or semaglutide according to the clinic's standard procedure
219761589|NCT01672255|DRUG|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
219761590|NCT01672255|DRUG|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
219761591|NCT06836232|DRUG|VTX2735|Dose A, daily
219761592|NCT06836232|DRUG|VTX2735|Dose B, Daily
219761593|NCT06836232|DRUG|VTX2735|Dose C, daily
219761594|NCT06203600|PROCEDURE|Biospecimen Collection|Undergo optional blood sample collection
219761595|NCT06203600|PROCEDURE|Computed Tomography|Undergo CT scan
219761596|NCT06203600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761597|NCT06203600|BIOLOGICAL|Nivolumab|Given IV
219761598|NCT06203600|DRUG|Paclitaxel|Given IV
219761599|NCT06203600|OTHER|Questionnaire Administration|Ancillary studies
219761600|NCT06203600|BIOLOGICAL|Ramucirumab|Given IV
219761601|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
219761602|NCT05609968|BIOLOGICAL|Sacituzumab Govitecan|IV infusion
219761603|NCT05609968|BIOLOGICAL|Pembrolizumab|IV infusion
219761604|NCT05785624|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
219761605|NCT05785624|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
219761606|NCT05612035|DRUG|Frespaciguat|Frespaciguat 380 µg administered as dry powder inhalation once daily.
219761607|NCT05612035|DRUG|Placebo|Placebo administered as dry powder inhalation once daily.
219761608|NCT06516965|DRUG|Povorcitinib|Oral Tablet
219190699|NCT06851832|BIOLOGICAL|Zoster Vaccine, Live|"The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm.~A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60."
219416017|NCT02000713|OTHER|Clinical Exam|Brief neurological exam will be performed.
219416018|NCT06081998|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
219416019|NCT06081998|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
219416020|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
219416021|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
219416022|NCT03407196|DRUG|Forxiga|Oral antidiabetics
219416023|NCT04915677|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
219416024|NCT04915677|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
219416025|NCT06033339|OTHER|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
219416026|NCT06516939|DRUG|bFGF|Half-face randomized control
219416027|NCT06516939|DRUG|Bovine Basic Gel|Bovine Basic Gel
219416028|NCT00997048|PROCEDURE|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
219416029|NCT00997048|PROCEDURE|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
219571641|NCT04917081|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
219571642|NCT04917081|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
219416030|NCT04610034|BEHAVIORAL|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
219416031|NCT04610034|OTHER|Care as usual|The control arm will receive usual care, which implies no systematic support.
219416032|NCT01656681|DIETARY_SUPPLEMENT|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
219416033|NCT01656681|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
219571643|NCT00365287|DRUG|anti-thymocyte globulin|
219571644|NCT00365287|DRUG|cyclophosphamide|
219571645|NCT00365287|DRUG|cyclosporine|
219571646|NCT00365287|DRUG|fludarabine phosphate|
219571647|NCT00365287|DRUG|mycophenolate mofetil|
219571648|NCT00365287|PROCEDURE|radiation therapy|
219571649|NCT00365287|PROCEDURE|umbilical cord blood transplantation|
219571650|NCT03885219|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
219571651|NCT02941510|DRUG|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
219571652|NCT02941510|OTHER|Placebo|Subject(s) will participate in all study activities but will receive placebo.
219416034|NCT05580055|DIAGNOSTIC_TEST|Affinity|Blood Analyser
219416035|NCT04167306|DRUG|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
219416036|NCT04167306|DRUG|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
219416037|NCT04167306|OTHER|Placebo for varenicline|Capsules for oral use
219416038|NCT04167306|OTHER|Placebo for bupropion|Capsules for oral use
219416039|NCT00129350|PROCEDURE|Pulmonary rehabilitation programme|
219416040|NCT05688579|DRUG|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
219416041|NCT05688579|OTHER|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
219571653|NCT00484419|DRUG|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
219571654|NCT00484419|DRUG|rosiglitazone maleate|rosiglitazone tablets 4mg
219571655|NCT00484419|DRUG|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
219571656|NCT03360357|PROCEDURE|Guided drills|"These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)"
219190700|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
219416042|NCT00896987|DRUG|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
219416043|NCT00896987|DRUG|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
219416044|NCT00127062|OTHER|Oxford street|2 h walk around Oxford street
219571657|NCT06111079|DRUG|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
219416045|NCT00127062|OTHER|Hyde park|2 h walk around Hyde park
219416046|NCT03132480|OTHER|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
219416047|NCT01727050|DEVICE|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
219416048|NCT01727050|DEVICE|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
219416049|NCT02641366|DEVICE|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
219416050|NCT02641366|PROCEDURE|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
219571658|NCT06111079|DRUG|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
219571659|NCT03349528|BIOLOGICAL|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
219571660|NCT03349528|BIOLOGICAL|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
219571661|NCT03998579|OTHER|The CanMoRe programme|An exercise intervention in Primary Health Care
219416051|NCT02641366|PROCEDURE|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
219416052|NCT04048525|PROCEDURE|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
219416053|NCT04048525|PROCEDURE|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
219416054|NCT06484439|DRUG|Ketorolac|10 mg PO q 6h scheduled
219416055|NCT06484439|DRUG|Oxycodone|5 mg PO PRN
219416056|NCT06484439|DRUG|Acetaminophen|650 mg q 6h scheduled
219571662|NCT03998579|OTHER|Home exercise|An active control group
219757926|NCT00140140|BIOLOGICAL|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
219757927|NCT01761578|DEVICE|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
219416057|NCT06484439|DRUG|Ibuprofen|600 mg PO scheduled q6h
219571663|NCT04623021|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
219571664|NCT03186703|BEHAVIORAL|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
219757928|NCT00772759|DRUG|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
219416058|NCT06484439|DRUG|Hydrocodone|5 mg hydrocodone PO PRN q6h
219416059|NCT03689504|DIETARY_SUPPLEMENT|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
219416060|NCT03689504|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
219416061|NCT03689504|BEHAVIORAL|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
219416062|NCT02202096|OTHER|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
219416063|NCT02202096|OTHER|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
219416064|NCT02202096|OTHER|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
219416065|NCT02202096|OTHER|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
219416066|NCT02202096|OTHER|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
219416067|NCT02202096|OTHER|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
219416068|NCT02202096|OTHER|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
219416069|NCT02202096|OTHER|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
219416070|NCT02202096|OTHER|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
219416071|NCT02202096|OTHER|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
219416072|NCT02202096|OTHER|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
219416073|NCT06185218|OTHER|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
219190701|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)|The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
219190702|NCT06851832|BIOLOGICAL|Normal Saline|"The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial).~To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial)."
219190703|NCT06388434|BEHAVIORAL|Protective Arm Balance Response Training|Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
219190704|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
219190705|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
219416074|NCT04103255|OTHER|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
219416075|NCT03731364|DRUG|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
219416076|NCT03731364|DRUG|Placebo|Placebo
219416077|NCT03780556|DRUG|Lornoxicam and mepridine|compare the effect of each to control pain
219416078|NCT01368393|PROCEDURE|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
219416079|NCT01368393|PROCEDURE|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
219571665|NCT00283322|OTHER|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
219571666|NCT00898534|DEVICE|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
219190706|NCT06346067|DRUG|Naporafenib|Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
219190707|NCT06346067|DRUG|Dacarbazine|Dacarbazine IV - Day 1
219190708|NCT06346067|DRUG|Temozolomide|Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
219190709|NCT06346067|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
219416080|NCT06425783|PROCEDURE|Warmed Blood Transfusion|"The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K."
219416081|NCT01914705|PROCEDURE|Landmark Procedure|Using Landmarks to guide SCVC placement
219416082|NCT01914705|PROCEDURE|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
219416083|NCT01934192|DRUG|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
219416084|NCT01934192|DRUG|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
219416085|NCT01934192|DRUG|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
219190710|NCT04359654|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
219416086|NCT01934192|DRUG|Placebo IV|Placebo will be administered IV every 6 hours
219416087|NCT03354819|BEHAVIORAL|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
219416088|NCT03354819|BEHAVIORAL|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction"
219416089|NCT05689658|BEHAVIORAL|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
219190711|NCT05089877|DEVICE|Surgical Ablation|The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.
219571667|NCT01321021|DRUG|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
219757929|NCT00772759|DRUG|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
219757930|NCT03376516|DRUG|Wilate|von Willebrand factor / Factor VIII (plasma derived)
219757931|NCT01359956|DRUG|Dacarbazine|900 mg / m2 every 3 weeks
219190712|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
219190713|NCT06851247|DRUG|Toripalimab|"Fixed dose: 240mg/ time, add 100ml normal saline, intravenous infusion for 30 minutes (not less than 20 minutes, not more than 60 minutes).~The first course of induction chemotherapy (D1) is used on the first day of each cycle, and every 21 days is a course of treatment up to 18 courses or one year.~After intravenous infusion of triplelizumab, GP regimen induction chemotherapy was administered at an interval of 30-60 minutes."
219416090|NCT05689658|BEHAVIORAL|Diet|Hypocaloric diet prescription
219416091|NCT02357849|DRUG|Aripiprazole|see arm description
219757932|NCT01359956|DRUG|Fotemustine|100 mg / m2 every 3 weeks
219757933|NCT01359956|DRUG|Interferon Alfa-2b|5 M units every 3 weeks
219416092|NCT02357849|DRUG|Fluoxetine|see arm description
219757934|NCT04108650|OTHER|Fit & Strong! group|Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
219757935|NCT03968874|DEVICE|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
219757936|NCT03968874|DEVICE|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
219757937|NCT05123326|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
219757938|NCT05123326|DIAGNOSTIC_TEST|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
219190714|NCT06851247|DRUG|Anlotinib|"Oral administration before breakfast, 10mg/ time/day, once a day (d1-14), repeated every 3 weeks, using three courses, one week before radiotherapy discontinuation.~Use on the day the first course of induction chemotherapy begins (D1)."
219416093|NCT04887103|OTHER|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
219416094|NCT03641209|DRUG|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
219416095|NCT03641209|OTHER|Placebo|Half physiological saline solution as the non-active placebo solution
219416096|NCT05072717|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
219416097|NCT04508673|OTHER|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
219416098|NCT01600768|DRUG|Beta-Lactams|infusion time: 30 mins or 1 hr
219416099|NCT01600768|DRUG|Beta-Lactams|infusion time 4 hrs
219416100|NCT01597427|DRUG|Clonidine|Administration of 2 μg/kg of intravenous clonidine
219416101|NCT01597427|DRUG|Placebo|Injection of placebo solution.
219416102|NCT01605591|PROCEDURE|the DLT bending to the right|bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
219416103|NCT01605591|PROCEDURE|the DLT bending to the left|bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
219416104|NCT02831075|BIOLOGICAL|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
219416105|NCT02831075|BIOLOGICAL|saline|
219416106|NCT04691752|OTHER|Audit|Audit from clinical records
219416107|NCT06495307|DRUG|rhPRG4|Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
219416108|NCT02399839|DRUG|lomitapide|As prescribed by Physician.
219416109|NCT05844800|PROCEDURE|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
219416110|NCT05844800|DRUG|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
219416111|NCT04095988|PROCEDURE|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
219416112|NCT04095988|PROCEDURE|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
219416113|NCT01121159|PROCEDURE|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
219416114|NCT03468699|COMBINATION_PRODUCT|Autologous BMMC transplantation|Stem cell transplantation
219416115|NCT00043875|DRUG|lamotrigine|
219416116|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
219416117|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
219416118|NCT04901403|OTHER|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
219416119|NCT04901403|OTHER|Home visiting|Parents as Teachers home visiting program
219571668|NCT06616168|DIAGNOSTIC_TEST|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
219571669|NCT06616168|DRUG|Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)|Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
219757939|NCT05123326|DIAGNOSTIC_TEST|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
219757940|NCT06544044|BEHAVIORAL|Brief Mindfulness' Self compassion|session includes mindfulness exercises like breath awareness and body scans, self-compassion practices like self-kindness meditations, and emotional regulation strategies such as cognitive reappraisal and response modulation. Discussions focus on applying mindfulness and self-compassion to manage difficult emotions, improve interpersonal interactions, and reduce aggression. Home practice assignments encourage students to integrate mindfulness and self-compassion into their daily lives. The program curriculum is based on existing evidence-based interventions, including mindfulness-based stress reduction for teens.
219757941|NCT05544253|PROCEDURE|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
219190715|NCT06851247|DRUG|Gemcitabine|"1000mg/m2, D1, D8, add 0.9% normal saline 500ml, intravenous infusion. Every 21 days is a treatment cycle. If the recovery of toxicity in the subject is not sufficient for the next course of chemotherapy, the start of the next course of chemotherapy may be appropriately delayed, but the delay cannot exceed 21 days.~The treatment was continued for 3 courses."
219416120|NCT05280041|BEHAVIORAL|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
219416121|NCT03367065|RADIATION|Dynamic contrast enhanced computerised tomography|
219416122|NCT06118567|DRUG|Nitrous oxide|Nitrous oxide gas.
219416123|NCT06118567|DRUG|Room Air|Room Air
219416124|NCT05678985|BEHAVIORAL|Choose to Move|As described under study arm description.
219571670|NCT06616168|COMBINATION_PRODUCT|Suppositoria for vaginal microflora recovery (Giynoflor)|Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
219571671|NCT06616168|DRUG|Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)|Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
219571672|NCT02623049|OTHER|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
219571673|NCT01453413|OTHER|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
219190716|NCT06851247|DRUG|Cisplatin|"Induction Chemotherapy: 80mg/m2, D1, add 1000ml 0.9% normal saline, intravenous infusion for 3 hours.~Concurrent Chemoradiotherapy100mg/m2, add 5% glucose 500ml, intravenous drip. Use on the first day of each cycle, every 21 days for a treatment cycle"
219416125|NCT05989490|OTHER|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
219416126|NCT03095521|DRUG|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
219416127|NCT03095521|DRUG|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
219416128|NCT05239559|DEVICE|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
219416129|NCT03675438|OTHER|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
219416130|NCT02822404|DIETARY_SUPPLEMENT|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
219416131|NCT05298696|DRUG|Cilostazol|Cilostazol 100 mg twice daily
219416132|NCT05298696|DRUG|Placebo|Placebo twice daily
219571674|NCT04075019|BEHAVIORAL|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
219004281|NCT02324374|DEVICE|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
219571675|NCT00273741|DRUG|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
219190717|NCT06851247|RADIATION|radiation|IMRT, 33Fx
219190718|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
219190719|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
219416133|NCT01691352|PROCEDURE|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
219571676|NCT00273741|DRUG|placebo comparator|placebo capsules
219571677|NCT03969199|BEHAVIORAL|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
219571678|NCT02191475|DRUG|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
219571679|NCT02191475|DRUG|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
219757942|NCT00626080|DRUG|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
219757943|NCT00626080|DRUG|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
219757944|NCT03344341|DRUG|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
219757945|NCT03344341|DRUG|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
219757946|NCT00582907|DRUG|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
219757947|NCT00582907|DRUG|Placebo|placebo by subcutaneous injection weekly for 3 months
219757948|NCT02024412|DRUG|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
219757949|NCT02024412|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
219757950|NCT04129307|BEHAVIORAL|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
219757951|NCT04129307|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
219757952|NCT04129307|BEHAVIORAL|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
219757953|NCT01737866|DRUG|AMG 423|omecamtiv mecarbil
219757954|NCT01149746|DRUG|Tamsulosin|Test 0.4 mg Capsule
219757955|NCT01149746|DRUG|Tamsulosin|Reference Listed 0.4 mg Capsule
219761609|NCT06516965|DRUG|Placebo|Oral Tablet
219761610|NCT06832618|DRUG|Ruxolitinib|The study cream will be applied topically as defined in the protocol for each period.
219761611|NCT06832618|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically as defined in the protocol for each period.
219416134|NCT01691352|PROCEDURE|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
219416135|NCT01536119|BEHAVIORAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
219416136|NCT06678347|BEHAVIORAL|Leadership for recovery|The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
219571680|NCT00845975|DEVICE|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
219571681|NCT00845975|DEVICE|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
219571682|NCT04221607|OTHER|Sensate Focus exercise|Structured exercise to enhance intimacy
219571683|NCT02477241|PROCEDURE|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
219571684|NCT02477241|DEVICE|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
219571685|NCT02122718|DRUG|Allopurinol|
219571686|NCT02122718|DRUG|Placebo|
219571687|NCT02884323|DEVICE|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
219571688|NCT00359242|BEHAVIORAL|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
219571689|NCT00359242|BEHAVIORAL|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
219757956|NCT06078826|OTHER|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
219757957|NCT06078826|OTHER|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
219757958|NCT05287750|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
219757959|NCT01150292|DIETARY_SUPPLEMENT|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
219757960|NCT01150292|DIETARY_SUPPLEMENT|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
219571690|NCT05690126|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
219571691|NCT05690126|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
219757961|NCT04628130|OTHER|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
219757962|NCT01482858|DIETARY_SUPPLEMENT|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
219571692|NCT00102687|DRUG|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
219571693|NCT00949611|BEHAVIORAL|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
219571694|NCT00949611|BEHAVIORAL|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
219571695|NCT01713426|DRUG|Qutenza|Cutaneous patch
219571696|NCT01713426|DRUG|Pregabalin|Oral capsule
219571697|NCT00355472|DRUG|KW-0761|IV administration at 4 escalating dose levels.
219190720|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
219416137|NCT03266666|BEHAVIORAL|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
219416138|NCT03266666|OTHER|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
219416139|NCT00470652|DEVICE|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
219416140|NCT05986032|DIAGNOSTIC_TEST|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
219416141|NCT03900754|DRUG|Oxytocin|Intranasal administration of oxytocin
219416142|NCT03900754|DRUG|Placebo|Placebo
219416143|NCT06184269|DRUG|BR1017-1|One tablet administered alone
219416144|NCT06184269|DRUG|BR1017-1A|One tablet administered alone
219571698|NCT03421704|DEVICE|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
219571699|NCT00903552|BIOLOGICAL|Influenza VLP Vaccine|
219571700|NCT00903552|BIOLOGICAL|Placebo|phosphate-buffered saline (PBS)
219571701|NCT04799652|OTHER|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
219571702|NCT03500042|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
219416145|NCT06184269|DRUG|BR1017-1B|One tablet administered alone
219571703|NCT00878696|PROCEDURE|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
219571704|NCT03357081|DRUG|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
219757963|NCT01482858|OTHER|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
219757964|NCT00370292|DRUG|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
219757965|NCT00370292|DRUG|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
219416146|NCT01810042|DRUG|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
219416147|NCT06689059|OTHER|Multimodal Data Integration and Multi-Task Learning|This study utilizes a multimodal data integration and multi-task learning approach to predict perioperative events after hip replacement surgery. By combining various data types, including demographics, surgical details, medical history, and lab results, the model enhances prediction accuracy for outcomes like AKI, blood transfusion needs, and ICU transfers. The use of ensemble learning algorithms such as CatBoost optimizes the platform's performance, offering a unique method for clinical decision support.
219416148|NCT04304755|DRUG|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
219757966|NCT03089060|DEVICE|Silicone Finger cap|Treatment with silicone finger cap
219757967|NCT03089060|DEVICE|Film Dressing|Treatment with conventional film dressing
219757968|NCT00003614|DRUG|estramustine phosphate sodium|
219757969|NCT00003614|DRUG|paclitaxel|
219757970|NCT05412992|DRUG|DMTS Patch|DMTS applied before surgery and worn for 96 hours
219757971|NCT05412992|DRUG|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
219757972|NCT01843530|DRUG|Berinert|
219757973|NCT01843530|DRUG|Clemastin|
219757974|NCT01843530|DRUG|Cortisone acetate|
219757975|NCT01843530|DRUG|NaCl|
219757976|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
219757977|NCT05361460|OTHER|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
219757978|NCT06049914|BEHAVIORAL|Experimental group|"1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks"
219757979|NCT04971928|DRUG|GSK3228836|GSK3228836 will be administered
219757980|NCT01853709|BEHAVIORAL|Education|
219757981|NCT01853709|OTHER|Fiber free diet|
219757982|NCT01853709|DIETARY_SUPPLEMENT|Adjuvants|
219416149|NCT04304755|DRUG|Placebos|NaCl 0.9%
219416150|NCT06693414|OTHER|Tailored health promotion education|14 weeks tailored education
219571705|NCT00003621|DRUG|carmustine|
219416151|NCT06693414|OTHER|Routine nursing education|14 weeks nursing education
219416152|NCT06691334|DEVICE|PRP injection|Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
219416153|NCT06691334|DEVICE|Hifu procedure and PRP injection|Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
219416154|NCT06693466|OTHER|Facial expression block|Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.
219416155|NCT06693466|OTHER|Conditioned pain modulation block|The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).
219416156|NCT06693466|OTHER|Pain facilitation block|Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.
219571706|NCT00003621|DRUG|cisplatin|
219571707|NCT00003621|DRUG|etoposide|
219571708|NCT00003621|RADIATION|radiation therapy|
219571709|NCT06177314|OTHER|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
219571710|NCT02733952|DRUG|Tranexamic Acid|
219571711|NCT02733952|PROCEDURE|Pericervical Tourniquet|
219571712|NCT03095118|DRUG|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
219571713|NCT04730089|DEVICE|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
219571714|NCT05705817|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
219571715|NCT03015714|OTHER|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
219571716|NCT03015714|OTHER|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
219757983|NCT01853709|DRUG|Polyethylene glycol (PEG)|
219757984|NCT01853709|DRUG|Bisacodyl|
219757985|NCT04714593|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
219416157|NCT06692465|DRUG|GT20029 Tincture|5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
219416158|NCT06692465|DRUG|GT20029 matching placebo|5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
219416159|NCT06696820|DRUG|PCSK9 inhibitors combined with atorvastatin/rosuvastatin|A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
219416160|NCT06696820|DRUG|Atorvastatin/Rosuvastatin|Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
219416161|NCT02773238|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219416162|NCT02773238|PROCEDURE|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
219571717|NCT04551820|PROCEDURE|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
219571718|NCT04551820|PROCEDURE|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
219571719|NCT04551820|DEVICE|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
219757986|NCT00276419|DRUG|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
219190721|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
219190722|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
219190723|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
219190724|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
219416163|NCT02773238|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
219416164|NCT02773238|OTHER|Laboratory Biomarker Analysis|Correlative studies
219416165|NCT02773238|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219416166|NCT02773238|RADIATION|Radiation Therapy|Undergo functional avoidance radiation therapy
219416167|NCT02773238|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
219416168|NCT02773238|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
219416169|NCT02773238|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
219416170|NCT07027228|OTHER|Using virtual reality glasses or listening to music|Donors in the intervention group will be randomly assigned and shown relaxing nature images through virtual reality glasses.
219416171|NCT07027228|OTHER|Using listening to music|Donors in the intervention group will be randomly assigned and will listen to relaxing music.
219571720|NCT00093184|DRUG|Angiomax (bivalirudin) anticoagulant|
219571721|NCT05215093|OTHER|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
219571722|NCT05215093|OTHER|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
219571723|NCT02513836|OTHER|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
219571724|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
219571725|NCT01862393|DEVICE|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
219571726|NCT01862393|DEVICE|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
219571727|NCT01862393|DEVICE|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
219571728|NCT05917691|PROCEDURE|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
219571729|NCT05917691|DRUG|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
219571730|NCT05917691|DEVICE|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
219571731|NCT03066791|DIETARY_SUPPLEMENT|Turmeric tablets|
219571732|NCT03066791|DIETARY_SUPPLEMENT|Curcumin and Bioperine tablets|
219571733|NCT03066791|DIETARY_SUPPLEMENT|Placebo tablets|
219571734|NCT01604369|PROCEDURE|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
219757987|NCT00276419|DRUG|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
219757988|NCT04627129|DRUG|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
219757989|NCT01706484|DRUG|BNO 1016|comparison of different dosages of drug and placebo
219757990|NCT02483364|OTHER|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
219757991|NCT06073522|OTHER|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
219757992|NCT02208219|BEHAVIORAL|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
219761612|NCT05505513|DEVICE|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
219761613|NCT06735209|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
219761614|NCT06735209|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) Challenge consists of cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ Challenge (7G8) contains a laboratory malaria clone derived from Brazil.
219761615|NCT06735209|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
219416172|NCT06693245|PROCEDURE|VAS scores of the puncture|All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
219416173|NCT06693297|DEVICE|Immediate loading of early placed implants|Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.
219416174|NCT06693297|DEVICE|Conventional loading of early placed implants|Definitive loading of early placed implants upon successful osteointegration (after 8 weks)
219416175|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
219416176|NCT02487901|DEVICE|drill|making gutter with drill
219416177|NCT01073696|DRUG|granisetron IV|IV
219416178|NCT01073696|DRUG|granisetron patch|patch
219416179|NCT06419517|DEVICE|EMG-triggered ES|The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
219416180|NCT06419517|OTHER|Pelvic Floor Muscle Training|Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
219416181|NCT04850703|DEVICE|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
219416182|NCT04850703|DRUG|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
219416183|NCT04850703|COMBINATION_PRODUCT|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
219416184|NCT04850703|DIAGNOSTIC_TEST|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
219416185|NCT06717282|BEHAVIORAL|visual rehabilitation for ophthalmic compliance|contextual, behavioral, and cognitive-based program for ophthalmic compliance
219416186|NCT06717282|BEHAVIORAL|Using contextual, behavioral, and cognitive-based stragegies to develop training programs|"Key Features of the Intervention:~1. Contextual Adaptation: Participants practice ophthalmic examination procedures in a simulated clinical environment to familiarize themselves with real-world conditions.~2. Behavioral Strategies: Positive reinforcement, such as rewards (snacks, toys, or videos), is used to encourage participation and cooperation during sessions.~3. Cognitive Support: Animated materials and interactive exercises are employed to teach the concepts required for visual tests, with take-home tasks for generalization.~4. Individualized Goals: Individualized training plans and objectives are established collaboratively with caregivers based on participants' cognitive and behavioral profiles.~Duration and Frequency:~Six sessions, each lasting one hour, are conducted biweekly, with flexibility based on caregiver availability."
219571735|NCT04421976|PROCEDURE|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
219416187|NCT06892119|DRUG|Celrixafor|Use a reduced-dose of generic plerixafor
219416188|NCT06890624|DRUG|cmFOLFOXIRI plus PD-1 inhibitor|cmFOLFOXIRI: oxaliplatin 85 mg/m² , irinotecan 150 mg/m², folinic acid 400 mg/m², 5-FU 2400 mg/m² continuous 46h infusion, repeat once every 2 weeks. PD-1 inhibitor 200mg, repeat once every 2 weeks.
219416189|NCT06890624|DRUG|mFOLFOX6|mFOLFOX6: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hours, repeat once every 2 weeks.
219416190|NCT00002340|DRUG|Atovaquone|
219416191|NCT00002340|DRUG|Pentamidine isethionate|
219416192|NCT04255550|DIAGNOSTIC_TEST|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
219571736|NCT03847194|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
219761616|NCT06828861|DRUG|Placebo|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
219761617|NCT06828861|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
219761618|NCT06264167|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound surveillance|Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
219761619|NCT06628362|DRUG|Placebo|Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
219416193|NCT05745402|BEHAVIORAL|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
219571737|NCT01561794|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2\) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
219571738|NCT04766229|COMBINATION_PRODUCT|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
219571739|NCT04219787|PROCEDURE|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
219571740|NCT04219787|PROCEDURE|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
219571741|NCT02408120|DRUG|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
219571742|NCT02408120|DRUG|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
219571743|NCT02408120|DRUG|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart"
219004282|NCT02324374|DEVICE|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
219004283|NCT02373202|DRUG|Sarilumab|Pharmaceutical form:solution
219004284|NCT02373202|DRUG|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
219004285|NCT02373202|DRUG|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
219004286|NCT02373202|DRUG|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
219004287|NCT02373202|DRUG|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
219004288|NCT02373202|DRUG|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
219004289|NCT04992455|OTHER|Older Patients Receiving Chemotherapy|No Intervention
219190725|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
219190726|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
219004290|NCT02884674|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
219416194|NCT06898216|DEVICE|Steerable FANS|This device is designed for flexible ureteroscopy procedures in patients with lower pole renal stones ≤2 cm. It features an active deflection mechanism that enables independent adjustment to enhance access into the lower pole calyx. The description focuses solely on the device and does not include procedural details already provided in the arm description.
219416195|NCT06898216|DEVICE|Conventional FANS|This device is intended for use in flexible ureteroscopy for lower pole renal stone management. It relies on passive deflection provided by the flexible ureteroscope for navigation into the lower pole calyx. The description is limited to the device characteristics without duplicating procedural details from the arm description.
219416196|NCT06898567|OTHER|Right Lateral Position|Participants rested for 10 minutes in a fully seated position, leaning their backs on a chair, without crossing their legs and placing their feet parallel to the floor. During this time, the arm to be measured was kept at heart level.
219416197|NCT06898567|OTHER|Left Lateral Position|Left Lateral Position
219004291|NCT02884674|DEVICE|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
219004292|NCT03936543|OTHER|Position change|Different position during central line catheterization
219416198|NCT06898567|OTHER|Semi Fowler Position (45° Fowler)|Semi Fowler Position (45° Fowler)
219416199|NCT06899269|DEVICE|robotic resection with Da Vinci Xi|robotic resection with Da Vinci Xi
219416200|NCT06897449|BEHAVIORAL|Positive psychological intervention|Each week consists of two modules, focusing on different techniques and methods from positive psychology, aimed at improving athletes' mental health and performance.
219416201|NCT06897449|OTHER|Introduction to Positive Psychology Poster|The poster serves as an introductory resource, summarizing key concepts of positive psychology in an accessible format.
219416202|NCT06898021|DIAGNOSTIC_TEST|3DStent|Coronary interventions will be performed according to the standard of care, which includes IVUS guidance. In patients undergoing stent implantation, a 3DStent image acquisition will be done followed by IVUS.
219571744|NCT02419625|BEHAVIORAL|questionnaires|questionnaires , serum samples will be used
219571745|NCT05227131|DRUG|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
219004293|NCT03936543|OTHER|Conventional position|Conventional position during central line catheterization
219004294|NCT00055263|DRUG|DN-101|
219416203|NCT04689750|DIAGNOSTIC_TEST|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
219416204|NCT06897865|OTHER|survey|SURVEY
219416205|NCT06898827|PROCEDURE|IVR using the Morpheus Programme|Patients in the intervention group will receive 20 mins of immersive therapy during cardiac rehabilitation
219416206|NCT06898827|PROCEDURE|Cardiac Rehabilitation control group|Cardiac rehabilitation but no IVR
219571746|NCT05227131|DRUG|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
219004295|NCT06024057|DRUG|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
219416207|NCT03829332|BIOLOGICAL|Pembrolizumab|IV infusion
219416208|NCT03829332|DRUG|Lenvatinib|oral capsule
219416209|NCT03829332|DRUG|Placebo for lenvatinib|oral capsule
219571747|NCT05227131|DRUG|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
219416210|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
219416211|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
219416212|NCT01448291|DRUG|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
219416213|NCT04552535|DRUG|Second line (2L) afatinib|Afatinib
219416214|NCT04552535|DRUG|Second line chemotherapy|Chemotherapy
219571748|NCT04657250|BEHAVIORAL|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
219571749|NCT04657250|BEHAVIORAL|Passive quitline referral|Single text message with contact information for the Quitline
219571750|NCT03810573|DEVICE|NB1|rhNELL-1/DBX
219571751|NCT02023840|DRUG|metronidazole gel|
219571752|NCT02023840|PROCEDURE|ultrasonics|
219571753|NCT02023840|PROCEDURE|erythritol|
219416215|NCT05085028|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
219416216|NCT02592603|DEVICE|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
219416217|NCT00746031|DRUG|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
219416218|NCT00746031|DRUG|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
219416219|NCT06355557|OTHER|AI enabled ultrasound system for self-directed learning|use of the AI enabled ultrasound system for self-directed learning
219416220|NCT06355557|OTHER|Simulator for self-directed learning|use of the simulator for self-directed learning
219416221|NCT06355557|OTHER|traditional with human instructors|Medical students who are randomised to this arm
219416222|NCT05906641|DIETARY_SUPPLEMENT|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
219416223|NCT02115113|DRUG|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
219416224|NCT02115113|DRUG|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
219571754|NCT02023840|DRUG|placebo|
219571755|NCT04626752|DRUG|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
219571756|NCT04626752|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
219571757|NCT04626752|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
219571758|NCT03818386|DRUG|AGuIX®|"3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session"
219571759|NCT03818386|RADIATION|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
219571760|NCT01913717|RADIATION|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
219571761|NCT05051878|DEVICE|T-scan|occlusal analysis T-scan
219571762|NCT05051878|OTHER|articulating paper|articulating paper occlusal analysis
219571763|NCT04917627|DRUG|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
219571764|NCT01104428|DRUG|Placebo|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
219571765|NCT01104428|DRUG|"ziying granules"|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
219571766|NCT01341587|DEVICE|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
219571767|NCT00744172|PROCEDURE|laparoscopy|laparoscopic hysterectomy
219416225|NCT01011036|DRUG|clobazam|test substance
219416226|NCT01011036|DRUG|clonazepam|positive control
219416227|NCT01011036|DRUG|tolterodine|active placebo
219571768|NCT00744172|PROCEDURE|vaginal|vaginal hysterectomy
219571769|NCT00744172|PROCEDURE|abdominal|abdominal hysterectomy
219190727|NCT06845748|OTHER|Physical activity Group|"This intervention consists of a 48-week structured physical activity program designed to counteract age-related muscle decline. Participants assigned to this group will engage in a home-based exercise program, including muscle-strengthening exercises (bodyweight exercises targeting major muscle groups; progressive difficulty based on individual capacity; designed for feasibility in daily life, requiring no specialized equipment) and aerobic exercise (moderate-intensity cardiovascular activity (e.g., brisk walking, cycling); target heart rate between 65-75% of the estimated maximum heart rate).~The program follows guidelines from the American College of Sports Medicine (ACSM) and aims to improve muscle strength, function, and quality of life. It is distinct from other studies as it specifically targets preventing sarcopenia and muscle loss through a practical, home-based, and scalable intervention.~Participants will be monitored through periodic assessments."
219416228|NCT01967524|DRUG|botulinum toxin A + ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
219416229|NCT01967524|DRUG|Ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
219416230|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
219416231|NCT00383578|DRUG|Vildagliptin 100 mg qd|
219416232|NCT00383578|DRUG|Metformin 1500 mg daily|
219416233|NCT05246241|DEVICE|magnetic resonance imaging|Preoperative magnetic resonance imaging
219416234|NCT01708707|DRUG|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
219416235|NCT01708707|DRUG|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
219416236|NCT02485548|DRUG|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
219416237|NCT02485548|DRUG|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
219416238|NCT02485548|DRUG|Cisplatin|All patients will receive concurrent cisplatin.
219416239|NCT02485548|RADIATION|IMRT|All patients will receive IMRT
219416240|NCT00089271|DRUG|alvespimycin hydrochloride|Given IV
219416241|NCT00089271|OTHER|laboratory biomarker analysis|Correlative studies
219416242|NCT01313364|DEVICE|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
219416243|NCT03700788|DRUG|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
219416244|NCT03700788|DRUG|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
219416245|NCT02622724|DRUG|Interferon beta-1a|Investigational drug
219416246|NCT02622724|DRUG|Placebo|Placebo for investigational drug
219416247|NCT00296725|DRUG|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
219004296|NCT04055142|PROCEDURE|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
219190728|NCT06844448|PROCEDURE|with Biodentine|After the bleeding has stopped, the cavity is flushed with sterile saline and Biodentine (Septodont, Saint-Maur-des-Fossés, France) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and then the entire cavity is filled with it. One week later the superficial 2-3 mm is removed and replaced it with permanent restoration.
219416248|NCT00296725|DRUG|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
219416249|NCT02345824|DRUG|Ribociclib|CDK4/6 INHIBITOR
219416250|NCT05098548|PROCEDURE|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
219416251|NCT04367025|DRUG|Camrelizumab|Camrelizumab: 200mg,iv drip for 1h,d1,q3w
219416252|NCT04367025|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
219416253|NCT04367025|DRUG|S1|S-1:40\~60mg Bid, d1\~14, q3w;
219416254|NCT04745286|DRUG|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
219416255|NCT04745286|DRUG|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
219416256|NCT05734326|DEVICE|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA \[18\].
219416257|NCT05478330|DRUG|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
219416258|NCT05478330|DRUG|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
219416259|NCT02997384|OTHER|Information|information of women about their risk of breast cancer and the screening methods recommended for them
219416260|NCT02199106|DEVICE|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
219416261|NCT02199106|DEVICE|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
219416262|NCT05425875|PROCEDURE|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure \<100 mmHg
219416263|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
219571770|NCT02116894|BIOLOGICAL|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
219416264|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
219416265|NCT00356863|BEHAVIORAL|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
219416266|NCT01850862|OTHER|Collective group exercise program in patients with KOA|
219416267|NCT01850862|OTHER|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
219416268|NCT02462733|BEHAVIORAL|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
219416269|NCT02462733|BEHAVIORAL|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
219416270|NCT01954472|BEHAVIORAL|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
219416271|NCT01954472|BEHAVIORAL|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
219416272|NCT03294928|OTHER|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
219761620|NCT06628362|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
219761621|NCT02210078|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
219761622|NCT05034835|DEVICE|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
219761623|NCT05034835|OTHER|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
219761624|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
219761625|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
219761626|NCT05075759|BEHAVIORAL|Behavioral Intervention|Remote sessions with a health coach
219761627|NCT05075759|OTHER|Survey Administration|Ancillary studies
219761628|NCT05075759|OTHER|Interview|Ancillary studies
219761629|NCT06236919|BEHAVIORAL|VR cognitive training|The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
219761630|NCT06236919|BEHAVIORAL|VR nature exposure relaxation|The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
219761631|NCT06050070|OTHER|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
219761632|NCT06050070|OTHER|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
219190729|NCT06844448|PROCEDURE|with MTA|After the bleeding has stopped, the cavity is flushed with sterile saline and MTA+ (Cercamed, Stalowa Wola, Poland) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and after its initial setting the cavity is filled with glass ionomer cement. One week later the glass ionomer cement is removed and replaced it with permanent restoration.
219416273|NCT03101059|PROCEDURE|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
219416274|NCT00394238|PROCEDURE|Ultrasonographic imaging|
219416275|NCT06048926|DRUG|Carrelizumab|200 mg/time, iv, Q3W
219416276|NCT06048926|DRUG|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
219416277|NCT06048926|DRUG|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
219416278|NCT06048926|RADIATION|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
219416279|NCT02572895|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
219416280|NCT05674201|COMBINATION_PRODUCT|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
219416281|NCT02637024|RADIATION|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
219416282|NCT02637024|RADIATION|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
219416283|NCT06041646|DRUG|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
219416284|NCT05283863|DEVICE|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
219416285|NCT05283863|DEVICE|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
219416286|NCT03520439|DRUG|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
219416287|NCT03520439|DRUG|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
219416288|NCT02241044|DEVICE|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
219416289|NCT02241044|DEVICE|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
219416290|NCT04044209|DRUG|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
219416291|NCT04044209|DRUG|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
219416292|NCT05754697|OTHER|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
219416293|NCT05754697|OTHER|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
219190730|NCT06189508|DRUG|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
219416294|NCT05754697|OTHER|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
219571771|NCT02116894|DRUG|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
219416295|NCT02640066|OTHER|acupuncture|
219416296|NCT05089344|DRUG|Growth Hormone|growth hormone
219416297|NCT05089344|DRUG|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
219761633|NCT06465719|PROCEDURE|Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System|Basal ganglion hemorrhage patients will be operated on hematoma puncture and aspiration with Tract-based AI Robot Guiding System
219761634|NCT06465719|DRUG|Patients will be managed with guideline-based medications|Patients will be managed with guideline-based medications without surgery
219761635|NCT03959527|DRUG|zoliflodacin|Dose: 3g, oral administration
219761636|NCT03959527|DRUG|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
219757993|NCT02208219|BEHAVIORAL|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
219757994|NCT02208219|BEHAVIORAL|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements."
219571772|NCT00542360|BEHAVIORAL|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
219757995|NCT05117814|DRUG|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
219416298|NCT04020094|COMBINATION_PRODUCT|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
219416299|NCT02535832|DRUG|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
219416300|NCT02535832|DRUG|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
219416301|NCT00246948|PROCEDURE|Active conservative treatment of sciatica|
219416302|NCT01236742|DEVICE|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
219571773|NCT02293473|DEVICE|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
219416303|NCT01236742|DEVICE|single-vision glasses|daily wear of spectacle glasses to correct vision
219416304|NCT04969497|DRUG|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
219416305|NCT04969497|DRUG|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
219571774|NCT02293473|DEVICE|BIS-Bispectral Index Monitor|Depth of anaesthesia
219571775|NCT02293473|DEVICE|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
219571776|NCT02293473|OTHER|Standard of care|Using standard of care
219571777|NCT00006331|PROCEDURE|renal transplant|
219571778|NCT05559463|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
219571779|NCT02540837|DRUG|Bupivacaine|Obturator nerve block
219416306|NCT04969497|DRUG|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
219004297|NCT04055142|DRUG|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
219416307|NCT05515822|DRUG|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
219416308|NCT05515822|DRUG|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
219416309|NCT05515822|DRUG|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
219416310|NCT03277144|DEVICE|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
219416311|NCT03277144|OTHER|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
219416312|NCT00213980|DRUG|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
219416313|NCT05798169|OTHER|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
219416314|NCT01313026|PROCEDURE|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
219416315|NCT03129581|BEHAVIORAL|Dietary Counseling|Counseling to only eat during a restricted amount of time.
219416316|NCT00798694|DRUG|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
219416317|NCT00798694|DRUG|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
219416318|NCT05117229|DEVICE|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
219416319|NCT04169724|BEHAVIORAL|Calm Meditation|10 minutes per day of meditation via the Calm app.
219416320|NCT02256332|DIETARY_SUPPLEMENT|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
219416321|NCT02256332|DIETARY_SUPPLEMENT|High dose plant based ingredient|Reference food with high dose of plant based ingredient
219416322|NCT02256332|DIETARY_SUPPLEMENT|Reference food format|Reference food without plant-based ingredient
219416323|NCT01774344|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
219416324|NCT01774344|DRUG|Placebo|Placebo tablets matching in appearance
219416325|NCT00258089|DRUG|Levofloxacin|
219416326|NCT05618496|DEVICE|Sodium Hyaluronate Lyophilizate|Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
219571780|NCT02540837|DRUG|Saline|Obturator nerve block with saline(placebo)
219416327|NCT05905211|OTHER|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
219416328|NCT04424355|DIAGNOSTIC_TEST|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
219416329|NCT00734773|BIOLOGICAL|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
219416330|NCT00734773|DRUG|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
219571781|NCT01838382|DEVICE|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
219571782|NCT02281682|DRUG|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
219571783|NCT02281682|DRUG|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
219571784|NCT02281682|DRUG|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
219571785|NCT02281682|PROCEDURE|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
219571786|NCT03989531|BIOLOGICAL|Adrecizumab|Drip infusion over 60 minutes
219571787|NCT03989531|DRUG|Placebo|Drip infusion over 60 minutes
219004298|NCT04055142|DRUG|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
219416331|NCT00734773|DRUG|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
219416332|NCT00734773|DRUG|Motexafin gadolinium|"* Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
219416333|NCT00734773|DRUG|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
219416334|NCT00734773|DRUG|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
219416335|NCT00734773|RADIATION|Radiation therapy|Given at weeks 11 through 16.
219416336|NCT00228254|DRUG|Zinc (12.5 mg/day)|
219416337|NCT00228254|DRUG|vitamin A 10,000 IU per week|
219416338|NCT05491057|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
219416339|NCT04343079|DIAGNOSTIC_TEST|PET CT|measurement of surgical margins during lumpectomy
219416340|NCT02370355|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
219416341|NCT02370355|OTHER|Laboratory Biomarker Analysis|Correlative studies
219416342|NCT05233449|DEVICE|NoL monitor|NoL monitor : non invasive, adhesive digital device
219416343|NCT05233449|PROCEDURE|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
219416344|NCT06093763|PROCEDURE|Group without bone grafting|Open wedge corrective osteotomy and plate fixation without bone grafting.
219416345|NCT06093763|PROCEDURE|Group with bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
219416346|NCT03777371|OTHER|Anti HIV Seropositive Pregnant Women|
219416347|NCT01442740|PROCEDURE|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
219416348|NCT03730883|PROCEDURE|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
219004299|NCT03019302|DEVICE|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
219416349|NCT03730883|PROCEDURE|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
219416350|NCT06534814|DIAGNOSTIC_TEST|AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)|The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.
219416351|NCT06105424|PROCEDURE|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
219416352|NCT02351258|DEVICE|70% Isopropyl alcohol embedded caps|Protective cap on central lines
219416353|NCT02351258|OTHER|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care"
219416354|NCT01724125|OTHER|personal electronic medical record|
219571788|NCT04553991|PROCEDURE|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
219571789|NCT04553991|PROCEDURE|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
219571790|NCT02640365|DRUG|MM-398|unresectable Advanced non-colorectal cancer
219571791|NCT02640365|DRUG|Irinotecan|unresectable metastatic colorectal cancer
219416355|NCT00285974|DEVICE|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
219416356|NCT01353937|DRUG|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
219416357|NCT03939806|DRUG|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
219416358|NCT03939806|DRUG|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
219416359|NCT00611897|DRUG|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
219416360|NCT00611897|DRUG|placebo and ketamine|placebo N-acetylcysteine
219416361|NCT04995328|OTHER|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
219416362|NCT05508438|DEVICE|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
219757996|NCT01042314|DRUG|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
219416363|NCT01023412|DIETARY_SUPPLEMENT|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
219416364|NCT04114500|DIAGNOSTIC_TEST|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
219416365|NCT01699620|PROCEDURE|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
219571792|NCT02640365|DRUG|Leucovorin (LV)|unresectable metastatic colorectal cancer
219571793|NCT02640365|DRUG|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
219571794|NCT02640365|DRUG|bevacizumab|unresectable metastatic colorectal cancer
219571795|NCT02640365|DRUG|MM-398|unresectable metastatic colorectal cancer
219757997|NCT01042314|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
219416366|NCT02488096|DEVICE|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
219416367|NCT02488096|DEVICE|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI."
219416368|NCT00674830|BEHAVIORAL|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
219416369|NCT00674830|BEHAVIORAL|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
219416370|NCT00674830|BEHAVIORAL|placebo|usual care
219416371|NCT00456729|DRUG|Metronidazole|
219416372|NCT00456729|PROCEDURE|Blood tests|
219416373|NCT05825209|DRUG|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
219416374|NCT05825209|DRUG|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
219416375|NCT03768830|BEHAVIORAL|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
219416376|NCT02393118|DEVICE|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
219416377|NCT05209412|DEVICE|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
219416378|NCT05209412|DEVICE|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
219416379|NCT05209412|DRUG|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
219416380|NCT05209412|DRUG|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
219416381|NCT05209412|DRUG|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
219004300|NCT00829946|BEHAVIORAL|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
219416382|NCT04905199|PROCEDURE|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
219004301|NCT04078477|OTHER|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
219004302|NCT02855216|OTHER|Manual technique of sub-occipital inhibition|
219416383|NCT01397552|DRUG|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
219416384|NCT01397552|DRUG|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
219416385|NCT05966844|BEHAVIORAL|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
219416386|NCT00286390|PROCEDURE|Acupuncture|
219416387|NCT00001940|DRUG|Voriconazole|
219571796|NCT01434576|BIOLOGICAL|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
219571797|NCT01434576|BIOLOGICAL|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
219571798|NCT01434576|DRUG|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
219761637|NCT03959527|DRUG|azithromycin|Dose: 1g, oral administration
219761638|NCT05379322|DRUG|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
219761639|NCT05379322|DRUG|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
219761640|NCT05416515|DRUG|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
219761641|NCT01815749|BIOLOGICAL|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
219004303|NCT02855216|OTHER|Self-treatment by way of Occipivot®|
219757998|NCT01819740|OTHER|"determine the levels of the HEM substance in seminal plasma"|
219757999|NCT03545672|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
219758000|NCT03015493|OTHER|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
219416388|NCT05653297|DEVICE|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
219416389|NCT04441736|DEVICE|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
219416390|NCT06186635|OTHER|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
219758001|NCT03015493|OTHER|Traction|Traction techniques for the cervical spine
219416391|NCT06186635|OTHER|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
219416392|NCT03096002|BEHAVIORAL|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
219416393|NCT03934892|DIAGNOSTIC_TEST|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
219416394|NCT03184857|PROCEDURE|open maxillary sinus lifting|biopsy of the region 6 months later
219416395|NCT00110318|PROCEDURE|Manual therapy and therapeutic exercise|
219416396|NCT00110318|PROCEDURE|Corticosteroid injections|
219416397|NCT05851339|OTHER|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
219416398|NCT00439673|DRUG|5-Azacytidine|
219416399|NCT00439673|DRUG|Valproic Acid|
219416400|NCT00439673|DRUG|ATRA|
219416401|NCT05271396|OTHER|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
219416402|NCT04185441|DRUG|Tanzânia association|Tanzânia association capsule
219416403|NCT04185441|DRUG|Omnic Ocas|Tamsulosin 0,4 mg
219416404|NCT04185441|OTHER|Omnic Ocas placebo|Tamsulosin placebo
219416405|NCT04185441|OTHER|Tanzânia association placebo|EMS association placebo
219416406|NCT02070406|DRUG|cyclophosphamide|Given IV
219416407|NCT02070406|DRUG|fludarabine phosphate|Given IV
219758002|NCT01628913|DRUG|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
219758003|NCT01628913|DRUG|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
219758004|NCT00508521|DEVICE|Functional Electrical Stimulation|commercially available surface electrical stimulator
219758005|NCT00508521|OTHER|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
219758006|NCT04032821|DRUG|Alkotinib（300mg)|1\. First empty stomach, after the meal.2. After eating first, after fasting.
219416408|NCT02070406|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
219416409|NCT02070406|BIOLOGICAL|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
219416410|NCT02070406|BIOLOGICAL|aldesleukin|Given SC
219416411|NCT02070406|RADIATION|fludeoxyglucose F 18|Correlative studies
219416412|NCT02070406|PROCEDURE|positron emission tomography|Correlative studies
219416413|NCT02070406|OTHER|laboratory biomarker analysis|Correlative studies
219416414|NCT02877355|DRUG|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
219416415|NCT02665923|OTHER|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
219416416|NCT02731807|DIETARY_SUPPLEMENT|Dose A: TA-65 24mg, powder|
219416417|NCT02731807|DIETARY_SUPPLEMENT|Dose B: TA-65, 8mg, powder|
219416418|NCT02731807|DIETARY_SUPPLEMENT|Dose C: TA-65 3.2mg, capsule|
219416419|NCT02731807|DIETARY_SUPPLEMENT|Dose D: TA-65 8mg, capsule|
219416420|NCT02731807|DIETARY_SUPPLEMENT|Dose E: TA-65 32mg, capsule|
219416421|NCT01089582|OTHER|No intervention|
219416422|NCT00375635|PROCEDURE|mFPSA treatment|
219416423|NCT05474690|DRUG|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|"Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle."
219758007|NCT05790447|DRUG|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
219758008|NCT05790447|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
219758009|NCT05790447|DRUG|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
219758010|NCT05790447|DRUG|GM-CSF|subcutaneous injection daily for 7 consecutive days
219758011|NCT05365100|DRUG|BN102|oral tablets: BN102, BID
219758012|NCT04601129|PROCEDURE|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
219758013|NCT04937725|DIAGNOSTIC_TEST|eye tracking|Eye tracker will be used to evaluate study parameters
219758014|NCT00905229|DRUG|Phytonadione|2.5 mg po
219758015|NCT00905229|DRUG|Phytonadione|0.5 mg IV
219004304|NCT02938689|OTHER|Exercise|
219758016|NCT00456573|PROCEDURE|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
219004305|NCT01619345|DRUG|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
219416424|NCT05474690|DRUG|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)|Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
219416425|NCT02346500|DEVICE|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
219416426|NCT02108600|DRUG|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
219416427|NCT02425007|DEVICE|Incentive spirometry|
219416428|NCT05500924|OTHER|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
219416429|NCT03377010|OTHER|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
219416430|NCT03377010|OTHER|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
219416431|NCT00862849|DRUG|Insulin Lispro|
219416432|NCT00862849|DRUG|Regular Human Insulin|
219416433|NCT00862849|DRUG|rHuPH20|
219416434|NCT01621672|DRUG|Revlimid|10 mg/day in the morning same time each day
219416435|NCT05696171|PROCEDURE|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
219416436|NCT05696171|PROCEDURE|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
219416437|NCT04138030|PROCEDURE|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
219416438|NCT04138030|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
219416439|NCT02423434|OTHER|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
219416440|NCT05211011|DRUG|Fosfomycin|Infectofos 5 g
219571799|NCT02278458|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
219571800|NCT02278458|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
219571801|NCT01144403|DRUG|Cyclophosphamide|as prescribed, 6 cycles
219571802|NCT01144403|DRUG|Fludarabine|as prescribed, 6 cycles
219571803|NCT01144403|DRUG|Mitoxantrone|as prescribed, 6 cycles
219571804|NCT01144403|DRUG|Rituximab|375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
219758017|NCT03070093|DRUG|gilteritinib|oral
219758018|NCT00057161|BEHAVIORAL|Coordinated Representative Payeeship with Case Management|
219758019|NCT04778592|DRUG|ETX-018810|Study Drug
219004306|NCT02786147|OTHER|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
219758020|NCT04778592|DRUG|Placebo|Placebo
219758021|NCT03568747|DEVICE|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
219758022|NCT03568747|DEVICE|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
219761642|NCT01815749|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
219761643|NCT01815749|OTHER|laboratory biomarker analysis|Correlative studies
219761644|NCT03737669|BIOLOGICAL|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
219416441|NCT04004533|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
219416442|NCT04820543|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
219416443|NCT04941352|BEHAVIORAL|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
219416444|NCT00300651|BEHAVIORAL|Cognitive Behavioral Therapy|
219416445|NCT00734734|BIOLOGICAL|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
219416446|NCT01735617|DRUG|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
219416447|NCT06063408|BEHAVIORAL|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
219571805|NCT02931292|PROCEDURE|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
219571806|NCT01459263|DEVICE|ClariVein|Using the ClariVein device, the GSV will be occluded.
219571807|NCT03176784|DRUG|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
219571808|NCT03176784|DRUG|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
219571809|NCT03176784|OTHER|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
219571810|NCT03176784|OTHER|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
219004307|NCT02786147|OTHER|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
219571811|NCT01935479|DRUG|AK159|transdermal administration of teriparatide acetate
219571812|NCT01935479|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
219571813|NCT01935479|DRUG|Placebo|Placebo AK159
219571814|NCT02788799|OTHER|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
219571815|NCT02788799|OTHER|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
219571816|NCT06655194|DRUG|Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)|Chewable tablet, 81mg, oral
219571817|NCT06655194|DRUG|Acetylsalicylic Acid (BAYE004465, UI1615160)|Chewable tablet, 81 mg, oral
219571818|NCT03959995|OTHER|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
219571819|NCT03959995|OTHER|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
219004308|NCT02786147|OTHER|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
219004309|NCT02786147|OTHER|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
219004310|NCT04329169|OTHER|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
219416448|NCT06063408|BEHAVIORAL|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
219416449|NCT02344407|BIOLOGICAL|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
219416450|NCT02344407|BIOLOGICAL|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
219416451|NCT02344407|BIOLOGICAL|Placebo|
219416452|NCT03348111|DEVICE|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
219571820|NCT06467565|DRUG|Liposomal irinotecan|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
219571821|NCT06616220|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
219571822|NCT06616220|DRUG|0.9%NaCl|0.9% NaCl
219571823|NCT00138957|PROCEDURE|Laparoscopic parastomal hernia repair with mesh|
219571824|NCT01847365|DEVICE|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
219571825|NCT04214665|DRUG|Alpha Lipoic acid 600 mg HR film coated tablets|
219571826|NCT01526460|DRUG|Atorvastatin|80 mg
219571827|NCT01526460|DRUG|Rosuvastatin|40 mg
219571828|NCT01526460|DRUG|Placebo|no statin loading dose
219571829|NCT03901391|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing
219571830|NCT00003130|DRUG|paclitaxel|
219571831|NCT00381823|BEHAVIORAL|Cognitive Behavioral Therapy|
219571832|NCT02269631|BEHAVIORAL|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
219004311|NCT06392503|DIAGNOSTIC_TEST|different diagnostic models|the patients were screened by different diagnostic models
219004312|NCT00113217|DRUG|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
219761645|NCT03737669|BIOLOGICAL|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
219416453|NCT04853524|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
219571833|NCT02269631|BEHAVIORAL|Control diet group|no legumes in lunch or dinner meals
219571834|NCT02269631|DEVICE|Smartpill|to assess how long food takes to pass through the digestive system
219571835|NCT02269631|OTHER|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
219571836|NCT01974882|OTHER|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
219571837|NCT05688397|DIETARY_SUPPLEMENT|Experimental 1|L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
219571838|NCT05688397|DIETARY_SUPPLEMENT|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
219571839|NCT05688397|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
219571840|NCT06306092|BEHAVIORAL|Sleep on Schedule|Sleep education at school
219416454|NCT04853524|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
219416455|NCT05181319|OTHER|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
219571841|NCT06306092|BEHAVIORAL|Technology restriction|Reduction of electronic media use before bedtime
219571842|NCT02646917|PROCEDURE|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
219571843|NCT00680186|DRUG|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
219571844|NCT00680186|DRUG|Dabigatran etexilate|150mg bid
219571845|NCT05766020|BEHAVIORAL|Listen training|Auditory skills with the inclusion of cognitive control.
219571846|NCT00373191|DRUG|chemotherapy|N/A- not dictated by study
219571847|NCT00373191|DRUG|endocrine therapy|N/A- not dictated by study
219571848|NCT00373191|GENETIC|DNA methylation analysis|laboratory analysis
219571849|NCT00373191|GENETIC|protein analysis|laboratory analysis
219571850|NCT00373191|OTHER|laboratory biomarker analysis|laboratory analysis
219571851|NCT00373191|OTHER|questionnaire administration|questionnaire
219571852|NCT00373191|PROCEDURE|adjuvant therapy|N/A- not dictated by study
219571853|NCT00373191|PROCEDURE|conventional surgery|N/A- not dictated by study
219571854|NCT00373191|RADIATION|radiation therapy|N/A- not dictated by study
219571855|NCT01373060|DRUG|ASP1941|oral
219416456|NCT05346913|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
219416457|NCT00992784|BIOLOGICAL|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
219416458|NCT00992784|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
219416459|NCT02498756|BIOLOGICAL|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
219416460|NCT02498756|DRUG|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
219416461|NCT04228692|PROCEDURE|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
219416462|NCT04228692|DEVICE|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
219416463|NCT02570763|DEVICE|Active tDCS stimulation|
219416464|NCT02570763|DEVICE|Sham tDCS stimulation|
219416465|NCT01231360|OTHER|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
219571856|NCT01373060|DRUG|Placebo|oral
219571857|NCT00452608|DRUG|amido pill|one pill of amido/d by mouth for 10 days
219571858|NCT00452608|DRUG|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
219571859|NCT00645944|DRUG|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
219571860|NCT00645944|DRUG|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
219571861|NCT01823276|OTHER|Tyrosine-Containing Bar|
219571862|NCT01823276|OTHER|Placebo Bar|
219416466|NCT01231360|OTHER|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
219416467|NCT05415046|PROCEDURE|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
219416468|NCT03861546|BEHAVIORAL|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
219571863|NCT00817947|DEVICE|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
219571864|NCT00990847|DRUG|Procaterol, Salbultamol|
219571865|NCT02947620|DRUG|Metformin/Atorvastatin 1500mg/40mg, QD|
219571866|NCT02947620|DRUG|Metformin 1500mg, QD|
219571867|NCT02947620|DRUG|Atorvastatin 40mg, QD|
219571868|NCT02036450|DEVICE|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
219571869|NCT04126616|DIAGNOSTIC_TEST|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
219571870|NCT05854459|OTHER|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
219571871|NCT05854459|OTHER|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
219571872|NCT00933959|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
219571873|NCT00933959|BEHAVIORAL|Sleep Hygiene|Treatment as usual
219571874|NCT01523587|DRUG|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
219571875|NCT01523587|DRUG|erlotinib|erlotinib taken once daily
219571876|NCT05150418|DRUG|Oxygen gas|Oxygen 15 l/min
219571877|NCT05150418|DRUG|Air|Room air 15 l/min
219571878|NCT01931228|PROCEDURE|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
219416469|NCT04654091|PROCEDURE|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
219416470|NCT04654091|PROCEDURE|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
219416471|NCT04561921|DRUG|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
219416472|NCT04561921|DRUG|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
219416473|NCT03453021|DRUG|Mepolizumab|
219416474|NCT02035982|DRUG|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
219416475|NCT02035982|DRUG|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
219416476|NCT05186766|DEVICE|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
219416477|NCT02432248|DRUG|Dehydroepiandrosterone|75mg/day, PO for 90 days
219416478|NCT02432248|OTHER|placebo(medical starch)|75mg/day, PO for 90 days
219571879|NCT01931228|PROCEDURE|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
219571880|NCT05904275|DRUG|caudal epidural injection|Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
219416479|NCT00398957|DRUG|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
219416480|NCT02795546|DRUG|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
219416481|NCT02795546|BIOLOGICAL|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
219416482|NCT01363713|DRUG|DE-114 ophthalmic solution|
219416483|NCT03173586|OTHER|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
219416484|NCT02051725|OTHER|Active life-style intervention|
219416485|NCT03798249|OTHER|Gluten|Tereos
219571881|NCT05414864|DRUG|Ramelteon (RozeremR)|8mg daily
219571882|NCT05414864|BEHAVIORAL|sleep hygiene|sleep behavioral guidelines
219571883|NCT02306057|PROCEDURE|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
219571884|NCT02306057|PROCEDURE|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
219571885|NCT02306057|PROCEDURE|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
219571886|NCT02306057|PROCEDURE|TCPC|Surgical procedure Total CavoPulmonary Connection
219571887|NCT03680079|OTHER|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
219571888|NCT03384433|BIOLOGICAL|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
219571889|NCT04920526|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
219571890|NCT04477551|PROCEDURE|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
219571891|NCT04477551|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
219571892|NCT04625452|BEHAVIORAL|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
219571893|NCT05298787|DRUG|RLS-0071|RLS-0071 is administered as an IV infusion
219571894|NCT05298787|DRUG|Saline Placebo|Placebo is administered as an IV infusion
219416486|NCT03798249|OTHER|Placebo|Nestlé Health Science
219416487|NCT00399594|PROCEDURE|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
219571895|NCT06304909|DRUG|Dexmedetomidine injection|Dexmedetomidine group will receive 0.5 mcg/kg
219416488|NCT00399594|PROCEDURE|B|LV lead placement in standard (lateral / posterolateral) position.
219416489|NCT01102218|DRUG|Erythropoietin|Standard of Care
219416490|NCT01102218|DRUG|Erythropoietin|Standard of Care
219416491|NCT01102218|DRUG|Pentoxifylline|400 mg qd po for 6 months
219416492|NCT00803543|DRUG|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
219416493|NCT00803543|DRUG|Placebo|Dosage: Two tablets once a day for 24 weeks
219416494|NCT03299738|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
219571896|NCT04070287|COMBINATION_PRODUCT|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
219571897|NCT04070287|COMBINATION_PRODUCT|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
219758023|NCT04670861|PROCEDURE|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
219416495|NCT03747744|OTHER|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
219416496|NCT00289185|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
219416497|NCT00289185|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
219416498|NCT00289185|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
219416499|NCT01152736|DRUG|Nicotine|2 mg Single-dose
219416500|NCT02930369|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
219416501|NCT05603507|OTHER|inspiratory muscle training|training done with a pressure threshold-loading device
219416502|NCT05603507|OTHER|pulmonary rehabilitation|Circuit training of aerobic and resistive exercise
219416503|NCT02297113|DEVICE|Macintosh blade|conventional endotracheal intubation
219416504|NCT02297113|DEVICE|C-MAC videolaryngoscope|
219758024|NCT04513782|DIAGNOSTIC_TEST|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
219758025|NCT01192126|DEVICE|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
219416505|NCT05046678|DIAGNOSTIC_TEST|Control|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
219416506|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontally healthy|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
219416507|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
219758026|NCT01192126|DEVICE|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
219758027|NCT05952050|DRUG|Dexmedetomidine|Different Administration Routes of Dexmedetomidine
219758028|NCT04556344|BEHAVIORAL|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
219758029|NCT04556344|BEHAVIORAL|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
219758030|NCT04102007|DRUG|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
219758031|NCT01115907|DEVICE|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
219758032|NCT03669796|DIETARY_SUPPLEMENT|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
219758033|NCT03669796|DIETARY_SUPPLEMENT|Control|Maltodextrin/Casein
219758034|NCT00818090|DRUG|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
219758035|NCT00537043|DRUG|SK&F-105517 (COREG CR FDC)|
219758036|NCT01126073|DRUG|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
219761646|NCT05313334|BEHAVIORAL|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
219416508|NCT05046678|DIAGNOSTIC_TEST|Smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
219416509|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
219416510|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
219416511|NCT04157647|DEVICE|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
219416512|NCT04157647|DEVICE|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
219416513|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
219416514|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
219416515|NCT05417659|OTHER|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
219416516|NCT05398276|BEHAVIORAL|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
219416517|NCT05398276|BEHAVIORAL|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
219416518|NCT01658579|DRUG|HOE901-U300 (new formulation of insulin glargine)|
219416519|NCT01658579|DRUG|Lantus (insulin glargine)|
219416520|NCT01260376|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
219416521|NCT01908959|BEHAVIORAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
219416522|NCT02040883|DRUG|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
219416523|NCT02040883|DRUG|Tandospirone|Tandospirone，30mg per day
219416524|NCT01410266|OTHER|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
219761647|NCT04095364|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219190731|NCT05912608|PROCEDURE|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
219190732|NCT05912608|PROCEDURE|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
219761648|NCT04095364|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761649|NCT04095364|DRUG|Carboplatin|Given IV
219190733|NCT06128915|OTHER|vaccine|Vaccination against 20 serotypes of S. pneumoniae
219190734|NCT04530032|OTHER|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
219416525|NCT03702530|BIOLOGICAL|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
219571898|NCT04070287|COMBINATION_PRODUCT|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
219571899|NCT04070287|COMBINATION_PRODUCT|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
219571900|NCT04070287|COMBINATION_PRODUCT|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
219571901|NCT00792519|BEHAVIORAL|HIV support group|group support
219416526|NCT03702530|OTHER|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
219416527|NCT03702530|BIOLOGICAL|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
219416528|NCT00576251|DRUG|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
219416529|NCT00576251|DRUG|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
219416530|NCT01717703|DIETARY_SUPPLEMENT|Water|
219416531|NCT01717703|DIETARY_SUPPLEMENT|Fruit drink|
219571902|NCT00792519|BEHAVIORAL|CBT|group cognitive behavioral treatment
219416532|NCT01717703|DIETARY_SUPPLEMENT|Cola|
219571903|NCT00489281|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
219416533|NCT01717703|DIETARY_SUPPLEMENT|1% chocolate milk|
219571904|NCT00489281|DRUG|Fludarabine|Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
219571905|NCT00489281|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
219571906|NCT00489281|DRUG|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
219571907|NCT00489281|PROCEDURE|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
219571908|NCT00489281|RADIATION|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
219571909|NCT00489281|DRUG|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
219571910|NCT00489281|BIOLOGICAL|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
219190735|NCT04530032|OTHER|Standard diet|standard (normal) diet use
219416534|NCT00423618|RADIATION|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
219416535|NCT02432040|DRUG|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
219416536|NCT02432040|DRUG|Placebo|Placebo tablets, made to look like the interventional drug
219416537|NCT05682586|BIOLOGICAL|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
219416538|NCT05682586|DRUG|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
219416539|NCT03026335|BEHAVIORAL|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
219571911|NCT00489281|RADIATION|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
219571912|NCT04471402|DRUG|Precedex|Intranasal Precedex 3mcg/kg
219571913|NCT00606502|DRUG|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
219571914|NCT00606502|DRUG|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
219571915|NCT00606502|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
219571916|NCT00606502|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
219571917|NCT04133649|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
219190736|NCT06849739|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|This study compares the detection of blood samples from IBD patients after biologic therapy(eg:IFX,ADA,UST,VDZ) using different methods
219416540|NCT03026335|BEHAVIORAL|Control|Business as usual with students in non-itervened schools
219416541|NCT01368666|DEVICE|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
219416542|NCT00183950|DRUG|Noscapine|
219416543|NCT01889654|OTHER|Venous blood sampling|
219416544|NCT04460417|BEHAVIORAL|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
219416545|NCT04460417|BEHAVIORAL|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
219416546|NCT01552187|DRUG|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
219416547|NCT01552187|DRUG|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
219416548|NCT04042675|DIAGNOSTIC_TEST|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
219416549|NCT02566941|DEVICE|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
219416550|NCT02176395|DRUG|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
219416551|NCT02176395|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
219416552|NCT02176395|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
219416553|NCT01434381|BIOLOGICAL|Pfs25-EPA/Alhydrogel|
219416554|NCT00920036|DEVICE|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
219571918|NCT00641784|DRUG|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
219571919|NCT00641784|DRUG|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
219571920|NCT01096979|DRUG|LIPO-102|subcutaneous injection
219758037|NCT01126073|DRUG|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
219758038|NCT04156139|DEVICE|HFNC|The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
219758039|NCT04156139|DEVICE|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
219190737|NCT06852040|DEVICE|Intraoral induction electrical stimulation therapy|Intraoral induction electrical stimulation therapy (specific method\[13\]: hand-held electrode rods were used to stimulate the mandibular hyoid muscle, digastric muscle, anterior abdomen, and other muscles of the three groups. Parameter setting: the frequency is 80Hz, the wave width is 1ms, the intensity is set to the muscle contraction, each electrical stimulation is 3s, intermittent 10s, 20min/time, 1 time/day, 5 days/week, 4 weeks is limited.
219416555|NCT03326830|DEVICE|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
219416556|NCT03326830|DEVICE|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
219416557|NCT02636348|DIETARY_SUPPLEMENT|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
219416558|NCT02636348|DIETARY_SUPPLEMENT|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
219571921|NCT01096979|DRUG|Placebo|Placebo
219571922|NCT04462484|BEHAVIORAL|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
219571923|NCT03513042|RADIATION|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
219571924|NCT02854059|BIOLOGICAL|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
219571925|NCT02854059|BIOLOGICAL|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
219571926|NCT05329506|OTHER|patient population|questionnaires, standard of care
219571927|NCT05767736|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
219571928|NCT05767736|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
219758040|NCT05834049|BEHAVIORAL|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
219761650|NCT04095364|PROCEDURE|Imaging Procedure|Undergo medical imaging
219004313|NCT02165774|DEVICE|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
219190738|NCT06852040|DEVICE|tDCS treatment|tDCS treatment (specific method: microcurrent stimulator, stimulation electrode (3 cm×4 cm gelatin sponge), anodic stimulation site is the pharyngeal sensorimotor cortex area (between C3/T3 on the left\[14\], between C4/T4 on the right); the supraorbital area is the site of cathodic stimulation. The direct current intensity is 2.0 mA (20 min/time, 2 times/day) for two treatments (respectively, yin and yang alternating treatment), with an interval of at least 1 h, 5 days/week, and 4 weeks.
219416559|NCT03342196|DRUG|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
219416560|NCT03342196|DRUG|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
219416561|NCT03342196|DRUG|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
219416562|NCT01769417|DRUG|Placebo|Placebo
219416563|NCT01769417|DRUG|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
219416564|NCT01987167|DRUG|ACTHAR|Injectable Gel
219416565|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
219416566|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
219416567|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
219416568|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
219416569|NCT05383729|OTHER|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
219416570|NCT05383729|OTHER|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
219416571|NCT05607940|PROCEDURE|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
219416572|NCT05607940|PROCEDURE|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
219571929|NCT05767736|DRUG|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
219571930|NCT02057445|DRUG|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
219571931|NCT02057445|OTHER|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
219571932|NCT03897647|DEVICE|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
219571933|NCT03116321|DRUG|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
219571934|NCT03260075|OTHER|cat|Cat living at the ward
219571935|NCT02801552|DEVICE|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
219571936|NCT00921037|PROCEDURE|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
219761651|NCT04095364|DRUG|Letrozole|Given PO
219761652|NCT04095364|DRUG|Paclitaxel|Given IV
219761653|NCT03213652|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219761654|NCT03213652|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
219761655|NCT03213652|PROCEDURE|Bone Scan|Undergo a bone scan
219761656|NCT03213652|PROCEDURE|Computed Tomography|Undergo a CT scan
219761657|NCT03213652|DRUG|Ensartinib|Given PO
219761658|NCT03213652|OTHER|Laboratory Biomarker Analysis|Correlative studies
219761659|NCT03213652|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761660|NCT03213652|OTHER|Pharmacological Study|Correlative studies
219004314|NCT02165774|DEVICE|Turning ON the neuromodulator|
219004315|NCT06334471|OTHER|no intervention needed|no intervention needed
219416573|NCT01434888|DRUG|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
219416574|NCT01434888|DRUG|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
219416575|NCT01434888|DRUG|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
219416576|NCT06022978|PROCEDURE|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
219416577|NCT06022978|PROCEDURE|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
219416578|NCT04715308|PROCEDURE|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
219416579|NCT04526756|PROCEDURE|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
219416580|NCT00240188|PROCEDURE|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
219416581|NCT00240188|PROCEDURE|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
219416582|NCT03013205|PROCEDURE|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
219571937|NCT04816747|BIOLOGICAL|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
219571938|NCT06110247|DEVICE|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
219571939|NCT06110247|OTHER|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
219571940|NCT05354089|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
219571941|NCT05354089|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
219571942|NCT05354089|DRUG|Placebo|Placebo IM on day 0 and day 21.
219571943|NCT02083926|DRUG|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
219571944|NCT02083926|OTHER|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
219571945|NCT00988936|DRUG|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
219571946|NCT04998578|DEVICE|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
219571947|NCT03438227|DRUG|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
219571948|NCT03438227|DRUG|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
219571949|NCT02582372|DRUG|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
219571950|NCT02582372|DRUG|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
219416583|NCT03013205|PROCEDURE|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
219416584|NCT03013205|PROCEDURE|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
219416585|NCT03013205|PROCEDURE|Physiotherapy|
219416586|NCT04051151|BEHAVIORAL|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
219571951|NCT04438590|DIETARY_SUPPLEMENT|Kelulut Honey|The Substance being tested to be used as an alternative
219416587|NCT01147575|DIETARY_SUPPLEMENT|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
219416588|NCT01147575|DIETARY_SUPPLEMENT|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
219416589|NCT02136199|OTHER|Active Implementation of ShareEBM Toolkit|
219416590|NCT02136199|OTHER|Passive Dissemination of Share EBM|
219416591|NCT00220766|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
219416592|NCT00220766|DRUG|Dextrose, 5% in Water|
219416593|NCT01357915|PROCEDURE|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
219416594|NCT01357915|BIOLOGICAL|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
219416595|NCT03298191|DRUG|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
219416596|NCT03298191|DRUG|Ritodrine|Those women will be given Ritodrine for tocolysis
219416597|NCT03298191|DRUG|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
219416598|NCT02068131|DRUG|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
219416599|NCT02068131|DRUG|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
219416600|NCT00247182|BEHAVIORAL|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
219416601|NCT00247182|BEHAVIORAL|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
219416602|NCT00247182|BEHAVIORAL|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
219416603|NCT00671580|DRUG|PZ-601|750 mg
219416604|NCT00671580|DRUG|PZ-601|1000 mg
219416605|NCT00671580|DRUG|Standard of Care|as directed
219416606|NCT03140995|BEHAVIORAL|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
219416607|NCT02310139|PROCEDURE|Colonoscopy|
219416608|NCT01919905|DIETARY_SUPPLEMENT|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
219416609|NCT04050098|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
219416610|NCT04050098|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
219416611|NCT04245527|DEVICE|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
219416612|NCT03574935|DRUG|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
219416613|NCT03574935|DRUG|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
219416614|NCT01514188|DRUG|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
219571952|NCT04438590|DIETARY_SUPPLEMENT|Carborie|The commercially available substance
219571953|NCT03994549|DRUG|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
219571954|NCT04176588|DRUG|Etrasimod|Drug:Etrasimod Tablet other name:APD334
219571955|NCT04176588|DRUG|Placebo|Drug:placebo Tablet
219416615|NCT01514188|DRUG|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
219416616|NCT02379754|DRUG|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
219416617|NCT05624684|DIAGNOSTIC_TEST|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
219416618|NCT04081597|DRUG|Star-101|Administered orally
219416619|NCT04081597|DRUG|Placebo|Administered orally
219416620|NCT01019486|DRUG|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
219416621|NCT01019486|DRUG|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
219416622|NCT03026413|PROCEDURE|pulmonary vein antrum modification|
219416623|NCT05203276|DRUG|Envafolimab|300mg，SC，Q3W，d1
219416624|NCT05203276|DRUG|Endostar|210mg，CIV，Q3W，d1-3
219416625|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
219416626|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
219416627|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
219416628|NCT01277341|DRUG|Placebo Nasal Spray|nasal spray
219416629|NCT03590522|GENETIC|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
219416630|NCT03440853|BEHAVIORAL|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
219571956|NCT01813071|BIOLOGICAL|WRSS1|
219571957|NCT05613751|BEHAVIORAL|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
219758041|NCT05834049|BEHAVIORAL|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
219758042|NCT06414083|DEVICE|Diathermy|Diathermy will be used to ablate the randomized sample.
219416631|NCT03440853|OTHER|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
219571958|NCT04636593|DRUG|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
219416632|NCT03226132|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
219416633|NCT03226132|BEHAVIORAL|Repeated Contact|Repeated Contact
219416634|NCT02932332|OTHER|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
219416635|NCT02932332|OTHER|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
219416636|NCT02932332|OTHER|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
219416637|NCT02932332|OTHER|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
219416638|NCT05344976|BIOLOGICAL|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
219416639|NCT01351402|PROCEDURE|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
219416640|NCT04021394|DIAGNOSTIC_TEST|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
219416641|NCT04021394|DIAGNOSTIC_TEST|Parsortix CTC platform|EMT-independent platform
219416642|NCT03216317|BEHAVIORAL|Intervention Group|Isometric handgrip training consisting of four series
219416643|NCT04416126|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
219571959|NCT04476628|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
219571960|NCT04476628|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
219758043|NCT06414083|DEVICE|CO2 Laser|CO2 Laser will be used to ablate the randomized sample.
219571961|NCT04476628|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
219758044|NCT06414083|DEVICE|Argon Beam Coagulator|Argon Beam Coagulator will be used to ablate the randomized sample.
219004316|NCT00187876|PROCEDURE|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
219004317|NCT00187876|PROCEDURE|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
219004318|NCT02550249|DRUG|Nivolumab|Intravenous administration of nivolumab
219004319|NCT03223597|DRUG|Radium-223 dichloride|Registry of patients who receive Radium-223.
219416644|NCT04416126|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
219416645|NCT00003450|BIOLOGICAL|Ad5CMV-p53 gene|
219416646|NCT02705508|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
219416647|NCT02705508|DRUG|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
219416648|NCT02705508|DRUG|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
219416649|NCT02705508|RADIATION|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
219416650|NCT06471998|DRUG|Sodium Chloride injection|"Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard treatment including stage I and II analgesics and physiotherapy in line with the recommendations of the French National Authority for Health.~At each session, 250ml to 500ml of physiological serum will be injected subcutaneously using a Meso-Kit-Perfuser\* or injection octopus positioned by the nurse according to the injection points defined by the investigating physician during the inclusion visit, with a dermographic tracer for surgical use."
219416651|NCT02671942|DRUG|Roflumilast|
219416652|NCT02671942|DRUG|Placebo|
219416653|NCT05843110|OTHER|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
219416654|NCT02841787|BEHAVIORAL|iCBT for late life depression|
219416655|NCT00239772|BEHAVIORAL|Cognitive Processing Therapy|
219416656|NCT00239772|BEHAVIORAL|Prolonged Exposure Therapy|
219416657|NCT00607958|DRUG|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
219416658|NCT06418776|OTHER|Intensive therapy|Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
219416659|NCT06418776|OTHER|Low intensity therapy|Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
219416660|NCT01763268|BIOLOGICAL|Trivivac vaccine|Trivalent MMR vaccine
219416661|NCT00207103|DRUG|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
219416662|NCT00207103|DRUG|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
219416663|NCT00207103|DRUG|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
219416664|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
219416665|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
219416666|NCT00207103|DRUG|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
219416667|NCT01276665|PROCEDURE|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
219416668|NCT01276665|PROCEDURE|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
219416669|NCT03633227|DRUG|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
219416670|NCT03633227|DRUG|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
219416671|NCT03965832|DEVICE|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
219416672|NCT03965832|DEVICE|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
219416673|NCT01419483|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
219416674|NCT00348634|DRUG|Tegaserod|
219416675|NCT01043354|BEHAVIORAL|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
219416676|NCT01043354|BEHAVIORAL|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
219416677|NCT01043354|BEHAVIORAL|attention placebo intervention|6 monthly counseling sessions about general health topics
219416678|NCT05525338|DRUG|Alectinib|In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
219416679|NCT01205555|DEVICE|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day."
219416680|NCT04836455|BEHAVIORAL|The FDA's The REal Cost vaping prevention ads - Health harms theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
219416681|NCT04836455|BEHAVIORAL|The FDA's The Real Cost vaping prevention ads - Addiction theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.
219416682|NCT04836455|BEHAVIORAL|Neutral vaping ads|Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
219416683|NCT04811248|OTHER|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
219416684|NCT01986634|PROCEDURE|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
219416685|NCT00580177|PROCEDURE|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
219416686|NCT00580177|PROCEDURE|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
219416687|NCT00580177|PROCEDURE|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
219416688|NCT03029650|DRUG|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
219416689|NCT03029650|DRUG|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
219416690|NCT01875367|DRUG|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
219416691|NCT01875367|DRUG|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
219416692|NCT01875367|DRUG|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
219416693|NCT05900011|BEHAVIORAL|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
219416694|NCT05418062|BEHAVIORAL|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
219416695|NCT05059548|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
219416696|NCT03623126|OTHER|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
219416697|NCT04711876|BIOLOGICAL|Cytokine level in blood and CSF|Measure of cytokine level
219758045|NCT00638729|DRUG|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
219571962|NCT04989777|DEVICE|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
219416698|NCT04533815|BEHAVIORAL|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
219416699|NCT06041295|BEHAVIORAL|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
219416700|NCT02130258|DEVICE|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
219416701|NCT02130258|PROCEDURE|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
219416702|NCT03312712|RADIATION|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
219416703|NCT03312712|OTHER|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
219416704|NCT03312712|OTHER|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
219416705|NCT03312712|DIAGNOSTIC_TEST|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
219416706|NCT05609123|DIAGNOSTIC_TEST|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
219416707|NCT02951988|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
219416708|NCT02951988|DRUG|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
219416709|NCT04615689|OTHER|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
219416710|NCT03053596|DEVICE|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
219571963|NCT05144347|DRUG|XL114|Tablets of XL114
219190739|NCT06852040|DEVICE|tDCS combined with intraoral induction electrical stimulation|tDCS combined with intraoral induction electrical stimulation. The patients were first treated with tDCS (the method is the same as that of the control group B) for 20 people twice a day and then given intraoral induction stimulation (the specific method is the same as that of the control group A) for 20 minutes, once a day, for 4 weeks.
219190740|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
219571964|NCT02399098|BEHAVIORAL|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
219758046|NCT00638729|DRUG|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
219004320|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
219004321|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
219004322|NCT03268720|OTHER|FODMAP low diet|2 week FODMAP low diet
219004323|NCT03268720|OTHER|gluten-free diet|2 week gluten-free diet
219416711|NCT02955654|BEHAVIORAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
219416712|NCT02955654|DRUG|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
219416713|NCT02955654|BEHAVIORAL|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
219416714|NCT03253991|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
219416715|NCT03218423|DEVICE|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
219416716|NCT00041613|GENETIC|INGN 201|
219416717|NCT04702555|DRUG|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
219571965|NCT02180698|OTHER|Laboratory Biomarker Analysis|Correlative studies
219571966|NCT02180698|RADIATION|Radiation Therapy|Undergo radiation therapy
219571967|NCT02180698|DRUG|TLR4 Agonist GLA-SE|Given intratumorally
219571968|NCT02923882|OTHER|'$100Kitchen and improved cookstove'|
219758047|NCT00638729|DRUG|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
219416718|NCT03551301|OTHER|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
219416719|NCT03977727|DRUG|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
219416720|NCT03977727|DRUG|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
219416721|NCT03977727|DEVICE|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
219416722|NCT00918476|DRUG|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
219416723|NCT04355312|DIAGNOSTIC_TEST|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
219416724|NCT03448718|DRUG|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
219416725|NCT06499545|OTHER|Pressure release|Release of pre-pressure at the latent trigger point of flexor digitorum brevis
219416726|NCT06499545|OTHER|Non emision Laser|Non emision laser in Flexor digitorum brevis latent trigger point
219416727|NCT00862966|OTHER|citrate|comparison of different catheter lock solutions
219416728|NCT00862966|OTHER|heparin|comparison of different lock solutions
219416729|NCT03037658|OTHER|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
219416730|NCT04190784|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
219416731|NCT04190784|OTHER|Placebo stretching|The therapist maintains the same manual contact without stretching force.
219416732|NCT05080179|BEHAVIORAL|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
219416733|NCT05080179|BEHAVIORAL|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
219416734|NCT05080179|BEHAVIORAL|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
219416735|NCT05080179|BEHAVIORAL|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
219416736|NCT02848300|DRUG|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
219571969|NCT02035020|DRUG|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
219190741|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
219416737|NCT02848300|DRUG|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
219416738|NCT00143221|DRUG|Viagra|
219416739|NCT00143221|DRUG|Placebo|
219416740|NCT03986346|DEVICE|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
219416741|NCT03986346|OTHER|standardized care|the scar will receive standardized care such as scar massage.
219416742|NCT00603980|DRUG|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
219416743|NCT00603980|DRUG|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
219416744|NCT00603980|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
219416745|NCT00603980|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
219416746|NCT00603980|DRUG|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
219416747|NCT00603980|DRUG|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
219416748|NCT00603980|DRUG|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
219416749|NCT00603980|DRUG|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
219416750|NCT00603980|DRUG|Oral placebo qualifying session|Qualifying control session (oral placebo)
219416751|NCT06208982|DIAGNOSTIC_TEST|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
219416752|NCT01627067|DRUG|Everolimus|10 mg by mouth once daily.
219416753|NCT01627067|DRUG|Exemestane|25 mg by mouth once daily.
219416754|NCT01627067|DRUG|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
219571970|NCT04793074|COMBINATION_PRODUCT|Transforming nanoparticle dressing|Transforming nanoparticle dressing
219571971|NCT04793074|COMBINATION_PRODUCT|Conventional compression dressing|Conventional compression dressing
219571972|NCT05717582|DRUG|apalutamide|Patients receive apalutamide 240mg,qd,po.
219571973|NCT05717582|DRUG|androgen deprivation therapy|Patients receive systemic ADT.
219416755|NCT02801162|DEVICE|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
219416756|NCT02801162|DEVICE|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
219416757|NCT02260102|DRUG|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
219416758|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416759|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416760|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416761|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416762|NCT00586924|DRUG|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416763|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
219416764|NCT03185455|OTHER|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
219416765|NCT04186000|BIOLOGICAL|Ad26.ZEBOV vaccine|The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
219571974|NCT05717582|PROCEDURE|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
219571975|NCT05717582|RADIATION|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
219571976|NCT02215668|PROCEDURE|Physical exercise|Exercise muscle stretching and body warming.
219571977|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
219571978|NCT00105573|BEHAVIORAL|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
219571979|NCT00105573|BEHAVIORAL|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
219571980|NCT00105573|BEHAVIORAL|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
219416766|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
219416767|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
219416768|NCT03060603|DRUG|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
219416769|NCT05596968|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
219416770|NCT00840944|DRUG|somatropin|somatropin 0.050 mg/kg/day
219190742|NCT06568406|PROCEDURE|Physiotherapy|Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
219571981|NCT01478282|DRUG|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
219571982|NCT01478282|DRUG|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
219571983|NCT06026774|BIOLOGICAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
219571984|NCT02697773|OTHER|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
219571985|NCT02697773|BIOLOGICAL|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
219571986|NCT02697773|BIOLOGICAL|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
219571987|NCT02405663|PROCEDURE|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
219571988|NCT02405663|PROCEDURE|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
219571989|NCT06000735|DEVICE|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above
219571990|NCT00613834|DRUG|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
219571991|NCT00613834|DRUG|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
219571992|NCT01995968|OTHER|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
219571993|NCT01843309|DRUG|Spironolactone 100mg|
219571994|NCT01843309|DRUG|Spironolactone 200mg|
219571995|NCT01843309|DRUG|Placebo|
219571996|NCT02404077|DRUG|Clonidine|
219571997|NCT05893316|DIAGNOSTIC_TEST|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
219571998|NCT05265221|PROCEDURE|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
219571999|NCT00842530|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
219572000|NCT00842530|BIOLOGICAL|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
219572001|NCT00842530|BIOLOGICAL|Placebo|Sodium chloride 0.9%
219572002|NCT01251978|DRUG|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
219572003|NCT01251978|DRUG|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
219761661|NCT03213652|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219761662|NCT03213652|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
219761663|NCT03213652|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219416771|NCT00840944|DRUG|triptorelin|triptorelin 3.75 mg each month
219416772|NCT06244940|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
219416773|NCT01513226|OTHER|Cycled light|lights on at daytime, lights off at nighttime
219416774|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
219416775|NCT00383422|DRUG|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
219416776|NCT00383422|DRUG|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
219416777|NCT02520622|BEHAVIORAL|Digital photographs loaded onto a mobile device|
219416778|NCT02520622|BEHAVIORAL|Skin exam reminders|
219416779|NCT02520622|BEHAVIORAL|Social support network|
219190743|NCT06568406|DIAGNOSTIC_TEST|Urogynaecology|Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
219190744|NCT06852937|DEVICE|da Vinci SP Surgery System|da Vinci SP Surgery System
219416780|NCT02562248|OTHER|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
219416781|NCT02562248|OTHER|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
219416782|NCT03798444|RADIATION|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
219416783|NCT03798444|RADIATION|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
219416784|NCT01463904|PROCEDURE|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
219416785|NCT05054673|OTHER|universal adhesive|PALFIQUE universal adhesive
219416786|NCT05054673|OTHER|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
219572004|NCT01414751|BEHAVIORAL|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
219416787|NCT02902744|DRUG|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
219572005|NCT01414751|BEHAVIORAL|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
219572006|NCT00944112|BIOLOGICAL|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
219572007|NCT00944112|BIOLOGICAL|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
219572008|NCT01692314|OTHER|Resistance training|
219572009|NCT06011616|OTHER|Sensory training|sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.
219572010|NCT06011616|OTHER|Motor training|Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.
219572011|NCT06011616|OTHER|Conventional exercises|stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning
219761664|NCT04838626|DRUG|[18F]CTT1057|PET/CT imaging with \[18F\]CTT1057
219761665|NCT06843408|DRUG|INCA034176|IV infusion
219761666|NCT03873467|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
219761667|NCT03873467|OTHER|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
219761668|NCT06844214|BIOLOGICAL|SAR446268|Pharmaceutical form: Solution for infusion; Route of administration: IV infusion
219761669|NCT05224505|BIOLOGICAL|ATA-100 (AAV9 encoding FKRP gene)|Single intravenous infusion on Day 0
219761670|NCT06847854|DRUG|RO7497372|RO7497372 will be administered as IVT injection as per the schedule specified in the arms.
219761671|NCT02792270|OTHER|Caloric Restriction Diet|"Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein."
219761672|NCT05762367|DIAGNOSTIC_TEST|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
219416788|NCT04146467|DEVICE|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
219416789|NCT01269372|DEVICE|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
219416790|NCT01269372|DEVICE|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
219416791|NCT01114958|DRUG|Cisplatin, Thiosulfate|Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
219416792|NCT02163304|OTHER|Sucrose|
219416793|NCT02163304|OTHER|Artificial Sweetner|
219416794|NCT02163304|OTHER|Tasteless Solution|
219416795|NCT02136121|DEVICE|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
219416796|NCT02537379|DRUG|SOF|SOF 400 mg tablets administered orally once daily
219572012|NCT06354855|OTHER|Group is doing breathing exercises while watching videos|Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
219572013|NCT06354855|OTHER|Medium pace walking group|Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
219572014|NCT02939950|DEVICE|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
219572015|NCT02939950|DEVICE|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
219758048|NCT00686673|BEHAVIORAL|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
219758049|NCT00686673|BEHAVIORAL|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
219758050|NCT06117007|DIETARY_SUPPLEMENT|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
219758051|NCT06117007|OTHER|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
219758052|NCT01453166|OTHER|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
219190745|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
219416797|NCT02537379|DRUG|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
219416798|NCT03179514|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
219416799|NCT03179514|DRUG|Lipid Regulating Drugs|Mainly including statins
219416800|NCT03179514|DRUG|Coronary Vasodilator|Mainly including nitrates
219416801|NCT03179514|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
219416802|NCT05557955|OTHER|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
219572016|NCT03130114|DRUG|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
219416803|NCT03670914|DIAGNOSTIC_TEST|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
219416804|NCT02029508|PROCEDURE|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
219416805|NCT02029508|PROCEDURE|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
219416806|NCT02029508|PROCEDURE|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
219416807|NCT00340314|PROCEDURE|Circumferential Pulmonary Vein Ablation|
219416808|NCT00340314|DRUG|Antiarrhythmic Drug Therapy|
219416809|NCT05829616|DRUG|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
219416810|NCT04284956|PROCEDURE|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
219416811|NCT06281886|DRUG|Induction Immunotherapy-Toripalimab|Toripalimab 240mg iv. drip, Q3W, 2 cycles
219416812|NCT06281886|DRUG|Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
219416813|NCT06281886|RADIATION|Radiotherapy|Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
219416814|NCT06281886|DRUG|Apatinib|Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
219416815|NCT06281886|DRUG|Capecitabine|Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
219416816|NCT02626572|DRUG|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
219416817|NCT02626572|DRUG|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
219416818|NCT02626572|DRUG|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
219416819|NCT02626572|DRUG|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
219416820|NCT00233259|BEHAVIORAL|Mediterranean Diet|Mediterranean dietary program
219416821|NCT00233259|BEHAVIORAL|Physical Activity|Physical activity program
219416822|NCT00233259|BEHAVIORAL|Stress Management|Stress management program
219416823|NCT00233259|BEHAVIORAL|Social Support|Social support
219416824|NCT00233259|BEHAVIORAL|Smoking Cessation|Smoking cessation program
219416825|NCT00233259|OTHER|Control group|Usual Diabetes Care Control group
219416826|NCT03262532|OTHER|Web-base simulator|Training manipulation of TEE using a Web-based simulator
219572017|NCT03130114|OTHER|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
219572018|NCT06128694|DIETARY_SUPPLEMENT|NUTRICAN|Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
219758053|NCT01453166|OTHER|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
219572019|NCT06862713|BEHAVIORAL|pulmonary rehabilitation exercise|pulmonary rehabilitation exercise + standard protocol
219572020|NCT00486018|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
219416827|NCT03262532|OTHER|No web-base simulator|Training manipulation of TEE with out a web-base simulator
219758054|NCT01453166|OTHER|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
219758055|NCT04636996|OTHER|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
219416828|NCT01250093|DEVICE|acupuncture|
219416829|NCT03247205|BEHAVIORAL|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
219416830|NCT00946777|OTHER|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
219758056|NCT02429817|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
219758057|NCT02429817|DEVICE|Aeroneb Solo|
219758058|NCT02429817|DEVICE|Jet Nebulizer|
219758059|NCT02429817|OTHER|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
219758060|NCT02429817|OTHER|Spirometry|FEV1, FVC assessment
219758061|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
219758062|NCT03004885|DEVICE|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
219758063|NCT04944771|DRUG|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
219758064|NCT04944771|DRUG|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
219758065|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
219758066|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
219190746|NCT06852885|OTHER|Meals|The intervention of the Solid'Africa Gemura selective feeding program will be administered as usual for study participants in the two intervention sites. Eligible hospital inpatients will receive three meals a day during their hospital stay, as prescribed by hospital nutritionists for their specific conditions and ordered from Solid'Africa. The Solid'Africa team will prepare the ordered meals in their off-site kitchen in Rusororo and deliver them daily to the hospitals where the meals will be distributed to the study participants. Meal caloric and nutritional content information is standardized except upon request. The normal meal is 575g of food consisting of 2300kCal with 300g of carbohydrates, 175g of protein, and 100g vitamins/minerals. In addition, Solid'Africa will adjust meal content per nutritionist request for specific needs like low salt/sugar, etc.
219758067|NCT05007964|DEVICE|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
219758068|NCT06244589|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
219758069|NCT06244589|PROCEDURE|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
219758070|NCT03144167|OTHER|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
219758071|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
219416831|NCT00006054|DRUG|anti-thymocyte globulin|
219758072|NCT01161771|PROCEDURE|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
219416832|NCT00006054|DRUG|busulfan|
219416833|NCT00006054|DRUG|cyclophosphamide|
219416834|NCT00006054|DRUG|cyclosporine|
219416835|NCT00006054|DRUG|etoposide|
219416836|NCT00006054|DRUG|methotrexate|
219758073|NCT06460376|OTHER|Wurn Technique|"Treatment:~Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left.~To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat.~Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment."
219758074|NCT06460376|OTHER|Mercier Therapy|"Treatment:~The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles.~Manual poking, pressing, and massage actions do three things:~Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment"
219416837|NCT00006054|DRUG|methylprednisolone|
219416838|NCT00006054|DRUG|prednisone|
219416839|NCT00006054|PROCEDURE|Allogeneic Bone Marrow Transplantation|
219416840|NCT02426554|DIETARY_SUPPLEMENT|DDU-supplement|DDU: Vitamin D, DHA, Uridine
219416841|NCT02426554|DIETARY_SUPPLEMENT|Placebo supplement|
219572021|NCT00486018|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
219004324|NCT06410820|DEVICE|Procedure/Surgery: Ultrasound method group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
219190747|NCT03703167|DRUG|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
219190748|NCT03703167|DRUG|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
219416842|NCT02467647|DRUG|Thalidomide|
219416843|NCT02467647|DRUG|HLJDT|
219416844|NCT05249816|BIOLOGICAL|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
219416845|NCT05249816|BIOLOGICAL|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
219416846|NCT01760824|DRUG|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
219416847|NCT01760824|DRUG|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
219416848|NCT01189435|DRUG|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
219572022|NCT00486018|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
219572023|NCT02243293|DRUG|ABT-493|Tablet
219572024|NCT02243293|DRUG|ABT-530|Tablet
219572025|NCT02243293|DRUG|ribavirin (RBV)|Tablet
219572026|NCT02243293|DRUG|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
219572027|NCT00893451|DRUG|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
219190749|NCT03703167|DRUG|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
219190750|NCT00140322|BEHAVIORAL|Exercise, fall risk reduction|
219190751|NCT03818620|DEVICE|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
219416849|NCT00347763|PROCEDURE|10% permethrin in water applied as low volume spray|
219416850|NCT03714035|OTHER|no intervention|no intervention
219416851|NCT04208763|DRUG|Imipenem|Inj Imipenem 1gm i.v. TDS
219416852|NCT04208763|DRUG|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
219190752|NCT03818620|DEVICE|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
219190753|NCT06201390|BEHAVIORAL|Sleep consistency|Participants will be asked to maintain a consistent bed- and wake-time.
219190754|NCT04314778|BEHAVIORAL|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
219190755|NCT05807048|DRUG|Daratumumab and Hyaluronidase-fihj|DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
219190756|NCT05807048|DRUG|Pre-Intervention Medication|"The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously"
219190757|NCT05807048|DRUG|Post-Intervention Medication|"The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment."
219190758|NCT06104605|OTHER|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
219416853|NCT04208763|DRUG|GMCSF|Inj GM-CSF 500mcg s.c. OD
219416854|NCT04208763|DRUG|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
219572028|NCT00893451|DRUG|Placebo|Placebo orally twice daily
219572029|NCT00333723|DRUG|Rosiglitazone|
219572030|NCT00785681|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
219572031|NCT06461117|OTHER|Beetroot Juice|Beetroot juice (8 mmol NO3-) consumption before training at 6 days
219572032|NCT06461117|OTHER|Plesabo Drink|Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
219572033|NCT01118117|DEVICE|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
219758075|NCT04934267|OTHER|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
219758076|NCT04934267|OTHER|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
219758077|NCT04949009|DRUG|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
219758078|NCT00998257|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
219758079|NCT03610048|DRUG|ALKS 5461|samidorphan + buprenorphine administered sublingually
219758080|NCT02900430|OTHER|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
219758081|NCT02900430|DRUG|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
219758082|NCT00085748|DRUG|paliperidone ER|
219416855|NCT02787434|OTHER|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
219416856|NCT02118610|DRUG|L-tetrahydropalmatine (30mg)|Active comparator
219416857|NCT02118610|DRUG|Sugar pill|Placebo
219416858|NCT04989010|DRUG|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
219416859|NCT03627910|DIETARY_SUPPLEMENT|symbiotic|Feed supplementation
219416860|NCT03627910|DIETARY_SUPPLEMENT|zinc and arginine|Feed supplementation
219416861|NCT01758666|DRUG|Methotrexate,Calcium folinate|
219416862|NCT00504335|DRUG|BIO 300 Capsules|
219416863|NCT02771249|DRUG|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
219416864|NCT02771249|DRUG|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
219416865|NCT02771249|DRUG|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
219416866|NCT02771249|DIETARY_SUPPLEMENT|Pyridoxine|
219416867|NCT05277649|OTHER|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
219416868|NCT05328921|DRUG|Antihypertensive Agents|Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
219416869|NCT05328921|DRUG|Antihistaminics|Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
219416870|NCT01641549|PROCEDURE|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
219416871|NCT01641549|DRUG|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
219416872|NCT04070352|DRUG|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
219416873|NCT04619875|OTHER|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
219416874|NCT04619875|OTHER|SG1|SG1 is a novel glycan
219416875|NCT04619875|OTHER|Lactulose|Lactulose is a synthetic dissacharide
219416876|NCT06197932|OTHER|Routine exercise and running training|impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
219416877|NCT06197932|OTHER|Big Toe Strengthening Exercise|impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
219416878|NCT03057457|DEVICE|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
219416879|NCT00100633|DRUG|CpG7909 oligodeoxynucleotides (ODN)|
219416880|NCT00100633|BIOLOGICAL|Hepatitis B virus vaccine|
219416881|NCT02711215|DIAGNOSTIC_TEST|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
219416882|NCT02711215|DRUG|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
219416883|NCT02711215|DRUG|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
219416884|NCT02711215|DRUG|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
219572034|NCT00961454|DEVICE|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
219572035|NCT04881734|OTHER|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
219416885|NCT02952326|PROCEDURE|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
219416886|NCT02952326|PROCEDURE|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
219416887|NCT05775744|OTHER|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
219416888|NCT00389740|DRUG|MK0217, /Duration of Treatment : 12 Months|
219572036|NCT03327090|OTHER|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
219572037|NCT01380249|DRUG|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
219572038|NCT00403182|DRUG|chemotherapy|
219572039|NCT00403182|DRUG|letrozole|
219416889|NCT00389740|DRUG|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
219572040|NCT01660022|DRUG|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
219416890|NCT06521957|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
219416891|NCT00058734|BIOLOGICAL|Dendritic Cells Pulsed with HIV antigens|
219416892|NCT03745196|DRUG|PC945|Study drug under investigation
219572041|NCT01660022|DRUG|Placebo|Placebo
219572042|NCT01660022|DRUG|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
219572043|NCT01660022|DRUG|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
219572044|NCT01660022|DRUG|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
219416893|NCT03745196|DRUG|Placebo|Placebo control
219572045|NCT01660022|DRUG|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
219572046|NCT01660022|DRUG|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
219572047|NCT01448356|PROCEDURE|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
219572048|NCT00379509|DRUG|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
219572049|NCT00379509|GENETIC|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
219572050|NCT00379509|GENETIC|gene expression analysis|Genetic analysis of tumor tissue.
219572051|NCT00379509|GENETIC|microarray analysis|Genetic analysis of tumor tissue.
219572052|NCT00379509|OTHER|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
219572053|NCT00379509|PROCEDURE|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
219572054|NCT00379509|RADIATION|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
219416894|NCT01473810|BIOLOGICAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
219416895|NCT01473810|BIOLOGICAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
219572055|NCT06616376|OTHER|Anti-Embolism Stocking|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
219572056|NCT05585931|DRUG|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
219572057|NCT05585931|DRUG|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
219572058|NCT03913260|DRUG|LY3375880|Administered SC
219572059|NCT03913260|DRUG|Buffer Matrix (No LY3375880)|Administered SC
219572060|NCT03913260|DEVICE|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
219572061|NCT03913260|DEVICE|Manual Syringe|Manual syringe used to inject LY3375880
219572062|NCT04969159|OTHER|no intervention|standard treatment in the clinical routine
219572063|NCT04785508|DEVICE|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
219572064|NCT04785508|BEHAVIORAL|antigravity arm position|antigravity arm position
219004325|NCT06410820|DEVICE|Landmark method group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
219190759|NCT06104605|OTHER|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local doctors of chiropractic (DCs), information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
219190760|NCT06104605|OTHER|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
219190761|NCT05977621|OTHER|Transrectal ultrasound (TRUS)|Transrectal ultrasound (TRUS) images of the female pelvis
219190762|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
219190763|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
219416896|NCT01473810|BIOLOGICAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
219416897|NCT01473810|BIOLOGICAL|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
219416898|NCT04200716|BEHAVIORAL|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
219416899|NCT04200716|BEHAVIORAL|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
219416900|NCT00832546|DRUG|Placebo|
219416901|NCT00832546|DRUG|Oral NGX426 (Powder in solution)|
219416902|NCT02223455|OTHER|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
219572065|NCT04805619|DEVICE|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
219004326|NCT01761331|OTHER|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
219416903|NCT03817255|OTHER|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
219416904|NCT03817255|OTHER|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
219416905|NCT04423614|OTHER|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
219416906|NCT04423614|OTHER|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
219416907|NCT02408055|DRUG|TA-8995|
219416908|NCT01948284|PROCEDURE|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
219416909|NCT01948284|PROCEDURE|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
219416910|NCT01948284|DEVICE|Suction Unit|
219416911|NCT01477190|DRUG|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
219416912|NCT01477190|DRUG|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
219572066|NCT00872326|PROCEDURE|Autologous Bone Marrow Mononuclear Cells|Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
219758083|NCT03526263|PROCEDURE|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
219416913|NCT03386656|DRUG|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
219416914|NCT03386656|OTHER|Saline Solution|Placebo
219416915|NCT01155648|DEVICE|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
219572067|NCT04741529|BEHAVIORAL|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
219572068|NCT02409329|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
219572069|NCT02409329|BEHAVIORAL|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
219572070|NCT02409329|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
219572071|NCT05412524|BEHAVIORAL|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
219572072|NCT01764243|DRUG|MT-4666|low dose, high dose
219572073|NCT01764243|DRUG|Placebo|
219004327|NCT00720434|DRUG|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
219004328|NCT00720434|DRUG|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
219004329|NCT00720434|DRUG|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
219004330|NCT00720434|DRUG|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
219004331|NCT04202692|DEVICE|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
219004332|NCT04202692|DEVICE|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
219004333|NCT00075179|DRUG|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
219572074|NCT00831636|DRUG|CP-4055|D1-5 and D8(+2)-12(+2) q4w
219572075|NCT00831636|DRUG|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
219758084|NCT00006384|BIOLOGICAL|recombinant interferon alfa|
219004334|NCT00075179|PROCEDURE|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
219004335|NCT01577329|BEHAVIORAL|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
219004336|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
219004337|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
219004338|NCT02642289|OTHER|Placebo|Innocuous substance
219004339|NCT05919381|DRUG|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
219416916|NCT01155648|DEVICE|Chest wall compression for ten minutes in chest|
219416917|NCT06555237|DRUG|Trametinib tablet|Trametynib orally once daily in 0,025mg/kg dose
219416918|NCT06555237|DRUG|Standard therapy|Disopiramide and Beta blockers orally
219416919|NCT02515617|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
219572076|NCT06263062|BEHAVIORAL|Awareness-Based Coping with Fear of Cancer Programme|The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
219758085|NCT00006384|DRUG|semaxanib|
219758086|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
219758087|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
219758088|NCT04510207|BIOLOGICAL|Placebo|The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
219004340|NCT05919381|DRUG|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
219004341|NCT00568074|DRUG|repaglinide|
219004342|NCT00568074|DRUG|Glurenorm®|
219004343|NCT00568074|DRUG|Glucobay®|
219004344|NCT05859789|PROCEDURE|kegel exercise|"* Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
219004345|NCT05859789|OTHER|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
219004346|NCT04140799|DEVICE|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
219004347|NCT00166673|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|
219004348|NCT02144051|DRUG|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
219004349|NCT00260494|OTHER|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
219416920|NCT02515617|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
219416921|NCT05439694|DRUG|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
219416922|NCT04378920|DRUG|LEAF-4L6715|LEAF-4L6715
219416923|NCT00511524|DRUG|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
219416924|NCT00511524|DRUG|[carbonyl-^11C]GW842166|\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
219416925|NCT05291949|DEVICE|ATLASense RAPHAEL PolyMonitor|All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
219416926|NCT04839770|DEVICE|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
219416927|NCT01621152|OTHER|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
219416928|NCT01621152|OTHER|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
219416929|NCT06224881|DRUG|Ascorbic acid|2 gm every 8hrs for 4 days
219758089|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
219758090|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
219004350|NCT00260494|OTHER|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
219004351|NCT03103633|PROCEDURE|mean artery pressure|mean artery pressure declined with less than 20% of baseline
219004352|NCT03103633|PROCEDURE|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
219758091|NCT02854163|DRUG|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
219758092|NCT02232360|DRUG|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
219758093|NCT02232360|DRUG|Rosuvastatin alone|Rosuvastatin 10mg per day
219758094|NCT04862754|OTHER|interval training exercise|interval training exercise
219758095|NCT00729950|BIOLOGICAL|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
219758096|NCT00506467|PROCEDURE|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
219758097|NCT01920490|DEVICE|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
219758098|NCT01920490|DEVICE|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
219758099|NCT01186757|DRUG|PF-03715455|PF-03715455 1.6 mg BID
219758100|NCT01186757|DRUG|PF-03715455|PF-03715455 4mg BID
219758101|NCT01186757|DRUG|PF-03715455|PF-03715455 10 mg BID
219758102|NCT01186757|DRUG|Placebo|Placebo
219758103|NCT02113319|DRUG|dasatinib|dasatinib 50 mg and 20 mg During one year
219416930|NCT01770873|BEHAVIORAL|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
219416931|NCT02278289|DEVICE|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
219004353|NCT03103633|PROCEDURE|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
219416932|NCT02278289|PROCEDURE|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
219416933|NCT01982773|BEHAVIORAL|Virtual Hope Box Smartphone App|Smartphone app
219416934|NCT01982773|BEHAVIORAL|Enhanced Treatment as Usual|Printed materials
219416935|NCT04434820|DEVICE|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
219416936|NCT05542329|DEVICE|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
219416937|NCT02388022|DEVICE|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
219416938|NCT01029886|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly
219416939|NCT01029886|DRUG|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
219572077|NCT03900117|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
219572078|NCT03900117|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
219572079|NCT02776527|DRUG|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
219572080|NCT03001752|DEVICE|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
219572081|NCT03001752|DEVICE|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
219572082|NCT03001752|DEVICE|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
219572083|NCT03195673|DRUG|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
219572084|NCT03195673|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
219572085|NCT03443817|BEHAVIORAL|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
219572086|NCT00014391|BIOLOGICAL|palivizumab|
219572087|NCT00014391|DRUG|ribavirin|
219572088|NCT05496673|DIAGNOSTIC_TEST|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
219572089|NCT05496673|DIAGNOSTIC_TEST|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
219572090|NCT05496673|DIAGNOSTIC_TEST|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
219572091|NCT00050882|DRUG|GM-611|
219572092|NCT06690138|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
219572093|NCT06690138|DRUG|Itraconazole|Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
219572094|NCT05998551|DRUG|Dexmedetomidine|intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine
219572095|NCT05998551|DRUG|Fentanyl|intrathecal injection of fentanyl added to hyperbaric bupivacaine
219416940|NCT05415540|OTHER|Questionnaires|Subjects included in the study will answer questionnaires
219416941|NCT01952457|DEVICE|Zilver PTX|
219572096|NCT05998551|DRUG|Bupivacaine Hcl 0.5% Inj|intrathecal injection of hyperbaric bupivacaine only
219572097|NCT03291041|DRUG|Tasimelteon|capsule
219572098|NCT03291041|DRUG|Placebo|capsule
219572099|NCT05064267|DIAGNOSTIC_TEST|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
219572100|NCT06085339|BEHAVIORAL|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
219572101|NCT06297655|DRUG|Recombinant human activated coagulation factor VIII for injection|Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
219416942|NCT01952457|DEVICE|prosthetic bypass|
219416943|NCT03936517|DRUG|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
219416944|NCT03936517|DRUG|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
219572102|NCT00774943|DRUG|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
219572103|NCT06060184|GENETIC|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
219572104|NCT04735731|DIAGNOSTIC_TEST|Echography|Echography of diaphragma and other respiratory muscles
219572105|NCT03755089|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
219572106|NCT03755089|DRUG|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
219572107|NCT01398839|DEVICE|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
219572108|NCT01398839|DRUG|Riboflavin|Both treatment and sham groups will receive riboflavin
219572109|NCT06269354|DEVICE|3D printed prostheses|3D printed prostheses
219416945|NCT04922619|DEVICE|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
219416946|NCT04922619|DEVICE|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
219416947|NCT00093860|DRUG|Propranolol|
219416948|NCT01778127|BEHAVIORAL|Activity Monitor|Measurement of physical activity.
219416949|NCT01778127|BEHAVIORAL|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
219416950|NCT01778127|BEHAVIORAL|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
219416951|NCT01218789|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
219416952|NCT00668304|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
219416953|NCT00007904|BIOLOGICAL|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.
219416954|NCT00007904|DRUG|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
219416955|NCT00007904|DRUG|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
219416956|NCT00007904|DRUG|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
219416957|NCT00007904|DRUG|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
219416958|NCT00007904|PROCEDURE|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
219416959|NCT00007904|RADIATION|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
219416960|NCT04347317|PROCEDURE|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
219416961|NCT04347317|PROCEDURE|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
219416962|NCT04915924|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
219416963|NCT03430817|DRUG|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
219416964|NCT03430817|DRUG|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
219416965|NCT03722784|DEVICE|Invigor A (test)|silicone hydrogel lens
219416966|NCT03722784|DEVICE|Invigor B (control)|silicone hydrogel lens
219416967|NCT04286542|DIAGNOSTIC_TEST|Cold, dry air|Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
219572110|NCT03695055|DRUG|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
219572111|NCT00508040|DRUG|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
219416968|NCT03497026|DEVICE|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
219416969|NCT04469374|OTHER|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
219416970|NCT04469374|OTHER|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
219416971|NCT04377061|DIAGNOSTIC_TEST|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
219416972|NCT03259490|DRUG|Empagliflozin/linagliptin/metformin HCl|Once daily
219416973|NCT03259490|DRUG|Empagliflozin|Once daily
219416974|NCT03259490|DRUG|Linagliptin|Once daily
219416975|NCT03259490|DRUG|Metformin HCl|Once daily
219416976|NCT01963208|DRUG|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
219416977|NCT01963208|DRUG|Placebo|placebo
219416978|NCT00448916|DRUG|Pregabalin|Orally-administered pregabalin
219416979|NCT03521193|DEVICE|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
219416980|NCT06348407|DRUG|IgE monoclonal antibody|omalizumab
219416981|NCT03707158|BEHAVIORAL|Therapist-Led CBT (telehealth, office-based, or hybrid)|Participants receiving therapist-led CBT will participate in therapist-led (telehealth or office-based) CBT treatment for up to 20 weeks. Weekly therapist-led treatment sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
219416982|NCT03707158|BEHAVIORAL|Guided Online CBT|Participants receiving guided online CBT will complete an online, self-paced, standardized and digitalized CBT program for up to 20 weeks with 8 modules, with adjunctive therapist phone support for supportive accountability. The self-administered treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
219416983|NCT06874374|DEVICE|Closed-loop tACS|Individual alpha tACS
219416984|NCT06874374|DEVICE|Sham Comparator|Sham stimulation
219758104|NCT06280248|PROCEDURE|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|"The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent."
219758105|NCT03792516|DRUG|artesunate ointment 40%|artesunate formulated as an ointment to be applied topically to the vulva
219758106|NCT06199414|DEVICE|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
219416985|NCT05790811|OTHER|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
219416986|NCT05790811|OTHER|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
219416987|NCT06693232|PROCEDURE|Mobile micro-learning|Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
219416988|NCT06897540|DEVICE|Upper endoscopy|View mucosa of esophagus with upper endoscope
219416989|NCT06898359|RADIATION|Radioimmunotherapy|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles)
219416990|NCT02362308|OTHER|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
219416991|NCT02362308|DRUG|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
219416992|NCT05301322|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine
219416993|NCT05301322|OTHER|Placebo|Placebo
219416994|NCT05301322|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV
219416995|NCT03059563|DRUG|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
219416996|NCT03059563|OTHER|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
219416997|NCT05917457|OTHER|balance coordination and strengthening training|"The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group.~Study group: Low vision children were given balance, coordination training and general strengthening training with sandbags for 70 minutes 3 days a week (5-minute warm-up phase, 20-minute balance training, 20-minute coordination training, 20-minute strengthening training and 5-minute cooling phase) for 8 weeks."
219416998|NCT06816420|OTHER|Cold Application|The effects of local cold application on pain and vital signs during port catheter needle insertion will be studied in this group.
219416999|NCT06892652|OTHER|Supportive care measures|shared decision making with patients and families to receive specialist palliative care
219417000|NCT06898697|DRUG|Epidural fentanyl|Fentanyl will be injected in the epidural space by the surgeon one or two levels above the surgical site.
219417001|NCT06898697|DRUG|epidural midazolam|midazolam will be injected in the epidural space by the surgeon one or two levels above the surgical site.
219758107|NCT05900752|DIETARY_SUPPLEMENT|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
219758108|NCT05900752|DIETARY_SUPPLEMENT|Placebo product|consume one sachet of the assigned product, once a day after meals.
219758109|NCT02892240|OTHER|No intervention. Observational study|
219758110|NCT05804721|DRUG|Apipe (Aripiprazole10 mg)|Test drug
219758111|NCT05804721|DRUG|Abilify (Aripiprazole10 mg)|Reference drug
219417002|NCT02471664|DEVICE|Mitral Loop Cerclage Annuloplasty|
219417003|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation active stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
219417004|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation sham stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
219417005|NCT04939077|BIOLOGICAL|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
219417006|NCT02678988|DEVICE|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
219417007|NCT02678988|DEVICE|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
219417008|NCT02678988|DRUG|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
219417009|NCT02551133|DRUG|dexamethasone|1 hour before surgery
219417010|NCT03872583|OTHER|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
219417011|NCT03872583|OTHER|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
219417012|NCT06898931|BEHAVIORAL|Dialect Interpreting Training|The intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments.
219417013|NCT06701331|DRUG|Placebo|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
219572112|NCT00508040|DRUG|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
219417014|NCT06701331|DRUG|Upadacitinib|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
219417015|NCT06898034|OTHER|Ultrasound|Postpartum ultrasound exam
219417016|NCT01620632|PROCEDURE|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
219417017|NCT06898268|DRUG|Metoclopramide|Patients were prescribed metoclopramide twice a day for one week.
219417018|NCT06898268|DRUG|Ondansetron|Patients were put on oral ondansetron in BD doses for one week.
219417019|NCT06899048|DIAGNOSTIC_TEST|residual neuromuscular block risk prediction score|it is a clinical tool designed to estimate the likelihood of residual neuromuxcular blockade in postoperative patients
219417020|NCT06898554|OTHER|The structured balance training protocol|The structured balance training protocol consists of 7 exercises including balance and hop stabilization exercises for athletes with chronic ankle instability.
219417021|NCT04611711|DRUG|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
219417022|NCT04611711|DRUG|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
219417023|NCT05756673|DRUG|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
219417024|NCT05756673|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
219417025|NCT05756673|DRUG|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
219417026|NCT05756673|DEVICE|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
219417027|NCT02973464|DRUG|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
219572113|NCT01950676|DEVICE|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
219572114|NCT00922324|DRUG|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
219572115|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
219417028|NCT02973464|DRUG|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
219572116|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
219572117|NCT01680874|DIETARY_SUPPLEMENT|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
219572118|NCT01680874|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
219417029|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner (NP) located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, heart rate (HR), respiration rate (RR), SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
219417030|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
219417031|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
219417032|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
219417033|NCT05108805|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleuce given by IV
219417034|NCT05108805|DRUG|Cyclophosphamide|Given IV
219417035|NCT05108805|DRUG|Fludarabine|Given IV
219572119|NCT01810094|DEVICE|Fracture Fixation|Thoracolumbar Fracture Fixation
219572120|NCT02823847|BEHAVIORAL|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
219417036|NCT05687695|OTHER|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
219572121|NCT02823847|DEVICE|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
219572122|NCT02823847|BEHAVIORAL|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation."
219572123|NCT02823847|PROCEDURE|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
219572124|NCT02823847|PROCEDURE|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
219572125|NCT02823847|PROCEDURE|Oral Biopsy|Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
219572126|NCT01782287|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
219572127|NCT01782287|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
219572128|NCT02946216|GENETIC|ctDNA analysis|
219572129|NCT03206567|DIETARY_SUPPLEMENT|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
219572130|NCT03206567|OTHER|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
219572131|NCT03829007|DIAGNOSTIC_TEST|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
219572132|NCT03829007|DRUG|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
219572133|NCT03492658|DRUG|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
219572134|NCT03492658|DRUG|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
219572135|NCT04329416|OTHER|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
219417037|NCT05687695|OTHER|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
219417038|NCT04134325|BIOLOGICAL|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
219417039|NCT04134325|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
219417040|NCT05083156|OTHER|Diet Change|Observation Cohort will be observed for treatment response to elimination of cow's milk
219417041|NCT00847938|DRUG|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
219417042|NCT00847938|DRUG|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
219572136|NCT04329416|OTHER|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
219572137|NCT04329416|OTHER|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
219572138|NCT03839277|DEVICE|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
219572139|NCT01100879|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
219758112|NCT05839925|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
219758113|NCT06230809|BEHAVIORAL|Web-based self-help|Web-based self-help with 5 modules, lasting 5 weeks.
219758114|NCT06370390|BEHAVIORAL|swallowing function training|"The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training"
219758115|NCT00827957|DEVICE|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
219758116|NCT00827957|DEVICE|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
219758117|NCT01987414|BEHAVIORAL|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
219758118|NCT01987414|DEVICE|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
219417043|NCT00847938|DRUG|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
219417044|NCT00795353|DRUG|Amevive exposure|Commercial alefacept prescribed by Physician
219417045|NCT00216775|DRUG|interferon-alfa-2b and ribavirin|
219417046|NCT02198651|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
219417047|NCT02198651|OTHER|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
219417048|NCT02595047|PROCEDURE|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
219417049|NCT04231955|DIAGNOSTIC_TEST|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
219417050|NCT04231955|OTHER|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
219417051|NCT04231955|OTHER|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
219417052|NCT04231955|OTHER|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
219417053|NCT05719051|DRUG|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
219572140|NCT02278419|DRUG|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
219572141|NCT02278419|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
219572142|NCT02774486|DEVICE|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
219572143|NCT00131755|DRUG|diazoxide|
219417054|NCT04718584|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
219417055|NCT05724017|BEHAVIORAL|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
219417056|NCT00587444|DRUG|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
219417057|NCT00587444|DRUG|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
219572144|NCT05472402|BEHAVIORAL|LADIES online intervention (R33 phase)|Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
219572145|NCT05472402|BEHAVIORAL|LADIES online control (R33 phase)|Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
219758119|NCT01987414|OTHER|No treatment|Participants will maintain their daily routines during the no treatment period.
219758120|NCT02054637|DRUG|Lanreotide|
219758121|NCT00503490|DRUG|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
219758122|NCT00503490|DRUG|placebo|BID
219758123|NCT06179979|DIAGNOSTIC_TEST|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
219758124|NCT01999192|DRUG|Tregalizumab|humanized anti-CD4 mAb
219758125|NCT01999192|DRUG|Placebo|identical end formulation buffer
219758126|NCT06441279|PROCEDURE|intra-articular injection with Platelet lysate (PL).|2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
219758127|NCT06441279|PROCEDURE|intra-articular injection with Hyaluronic Acid.|2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
219758128|NCT00827229|DEVICE|Labor Monitor|
219758129|NCT02169648|DRUG|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
219758130|NCT00854360|DRUG|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
219758131|NCT00854360|DRUG|Placebo|HFA Vehicle Aerosol
219758132|NCT05309525|DRUG|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
219758133|NCT05309525|DRUG|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
219758134|NCT03894085|DRUG|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
219758135|NCT06639789|DIETARY_SUPPLEMENT|Vitamin B12 (B12)|The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
219758136|NCT06639789|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
219758137|NCT06564805|DRUG|Candida Albicans Antigen Injection|subcutaneous administration of Candida albicans antigen
219758138|NCT06564233|BEHAVIORAL|care.coach Avatar™|"care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings."
219758139|NCT03410654|DRUG|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
219758140|NCT05961098|DRUG|RBD1016|RBD1016 with NAs background treatment will be explored.
219758141|NCT05957042|DRUG|Lumason|Up to 4.8mL administered intravenously
219758142|NCT06563843|PROCEDURE|Robotic-assisted TKA|Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
219758143|NCT06563843|PROCEDURE|Conventional TKA|Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
219758144|NCT06400082|DRUG|Insulin|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
219758145|NCT06400082|DRUG|Povidone-Iodine|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
219761673|NCT05121012|OTHER|Study procedures|"All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up."
219417058|NCT00587444|DRUG|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
219417059|NCT03525457|PROCEDURE|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
219004354|NCT03103633|OTHER|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
219004355|NCT03828357|OTHER|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
219004356|NCT02985554|DRUG|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
219004357|NCT01720992|OTHER|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
219004358|NCT02670954|DRUG|Dexmedetomidine, tramadol and flurbiprofen|
219004359|NCT02670954|DRUG|tramadol and flurbiprofen|
219004360|NCT04534023|DRUG|Idebenone|trial group
219004361|NCT04534023|DRUG|Placebo|control group
219417060|NCT00000248|DRUG|Pergolide|
219417061|NCT01891760|DEVICE|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
219417062|NCT01891760|DEVICE|Profore|Four-layer compression bandaging therapy.
219417063|NCT02312076|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
219758146|NCT05298930|OTHER|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
219758147|NCT06565130|OTHER|Attention skills training|Attention skills program planned with occupational therapy principles
219758148|NCT03297658|DEVICE|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
219758149|NCT03297658|DEVICE|sham|Micro electrodes will be placed but there will be no stimulation
219758150|NCT03192436|DEVICE|Ultrasound|Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
219758151|NCT05694247|DEVICE|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
219758152|NCT03952845|OTHER|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
219758153|NCT06560333|DRUG|N0892|1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
219758154|NCT06560333|DRUG|Januvia® + Glifage XR® + Placebo|1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
219758155|NCT06560333|DRUG|Forxiga® + Glifage XR® + Placebo|1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
219758156|NCT05081830|BEHAVIORAL|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
219758157|NCT05081830|BEHAVIORAL|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
219758158|NCT04049500|OTHER|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
219758159|NCT01651468|DIETARY_SUPPLEMENT|HEMOFIX|unique complex herbal mixture
219417064|NCT00267371|DEVICE|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
219758160|NCT05119010|DIETARY_SUPPLEMENT|Continuous ketogenic diet|ARM A : continuous ketogenic diet
219758161|NCT05119010|DIETARY_SUPPLEMENT|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
219758162|NCT05119010|DIETARY_SUPPLEMENT|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
219758163|NCT05390788|OTHER|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
219758164|NCT01889914|DRUG|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
219758165|NCT04754490|DIAGNOSTIC_TEST|Speech Recognition|Speech Recognition
219758166|NCT02441218|DRUG|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
219758167|NCT02441218|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
219417065|NCT00267371|DRUG|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
219417066|NCT02494388|PROCEDURE|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
219417067|NCT06187623|OTHER|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
219417068|NCT06187623|OTHER|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
219417069|NCT05398393|DRUG|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
219417070|NCT05398393|DRUG|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
219417071|NCT03839017|DEVICE|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
219417072|NCT06138327|DRUG|BMN 255|Oral Capsule
219417073|NCT06138327|DRUG|Placebo|Oral Capsule
219417074|NCT03018912|OTHER|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?"
219417075|NCT03034759|OTHER|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
219417076|NCT00374855|DRUG|PPAR alpha|
219417077|NCT00374855|DRUG|Hydrochlorothiazide|
219417078|NCT00374855|DRUG|Placebo|
219417079|NCT05194046|DRUG|JP-1366 20mg 1capsule|will be orally administered
219758168|NCT01541371|DRUG|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
219417080|NCT05194046|DRUG|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
219758169|NCT03781674|DRUG|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
219758170|NCT03781674|DRUG|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
219758171|NCT03781674|DRUG|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
219417081|NCT05194046|DRUG|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
219417082|NCT03264794|DRUG|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
219417083|NCT03264794|DRUG|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
219417084|NCT03264794|DRUG|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
219417085|NCT02581358|OTHER|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
219417086|NCT01734096|OTHER|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
219417087|NCT01734096|DRUG|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
219417088|NCT00000118|DEVICE|Sustained-Release Intraocular Drug Delivery System|
219417089|NCT03550287|DIETARY_SUPPLEMENT|Experimental product|10 g/day
219417090|NCT03550287|DIETARY_SUPPLEMENT|Placebo product|10 g/day
219417091|NCT03532581|OTHER|Indocyanine Green Solution|Given Subcutaneous injection
219417092|NCT03532581|PROCEDURE|Lymphangiography|Undergo lymphangiography
219417093|NCT03286712|DRUG|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
219417094|NCT00111579|BIOLOGICAL|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
219417095|NCT00111579|OTHER|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
219417096|NCT03082989|DEVICE|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
219417097|NCT03082989|OTHER|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
219758172|NCT03781674|DRUG|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
219758173|NCT04454515|DRUG|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
219758174|NCT04454515|DRUG|placebo|normal saline infusion
219758175|NCT06453031|PROCEDURE|Gastric Ischemic Preconditioning Before Esophagectomy|Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
219758176|NCT02128087|BEHAVIORAL|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
219758177|NCT02128087|BEHAVIORAL|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
219758178|NCT04747301|DEVICE|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
219758179|NCT04747301|DRUG|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
219758180|NCT03290352|OTHER|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
219758181|NCT03248323|RADIATION|dyna-pbv|
219758182|NCT04946604|BEHAVIORAL|Ashtangayoga|This is an active and intense type of yoga, focused on physical activity and breath control
219758183|NCT06325787|PROCEDURE|thyroid lobectomy|thyroid lobectomy
219758184|NCT06325787|PROCEDURE|image-guided thermal ablation|radiofrequency ablation or microwave ablation or laser ablation
219758185|NCT01131052|DRUG|Insulin Glargine|glargine once a day
219572146|NCT04978116|DIAGNOSTIC_TEST|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
219572147|NCT04978116|DIAGNOSTIC_TEST|Low-dose CT scan (LDCT)|See above in CXR paragraph
219572148|NCT04978116|DIAGNOSTIC_TEST|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
219572149|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of Gpi|
219572150|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of STN|
219758186|NCT01131052|DRUG|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
219572151|NCT00302302|DRUG|L-arabinose|
219572152|NCT06928740|OTHER|Music Care® device|Installation of the Music Care® device, selection of the sequence based on the patient's musical taste, listening to at least 20-minute sequence in the preparation room. Once placed on the scanner table, the patient listens to the same sequence as in the preparation room.
219572153|NCT06928740|OTHER|EMONO|Equimolar mixture of oxygen and nitrous oxide given as usual care
219572154|NCT02406794|DRUG|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
219572155|NCT06453525|OTHER|intubation|Tracheal intubation using one of the three existing videolaryngoscopes
219572156|NCT02709629|BEHAVIORAL|Individualized and adaptive computerized cognitive training|
219572157|NCT02709629|BEHAVIORAL|Active control|
219572158|NCT03016338|DRUG|Niraparib|200 or 300 mg daily PO, for 21 day cycle
219572159|NCT03016338|DRUG|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
219572160|NCT00635518|BEHAVIORAL|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
219572161|NCT00656968|DRUG|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
219572162|NCT00656968|DRUG|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
219572163|NCT02262195|OTHER|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
219572164|NCT05424250|BEHAVIORAL|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
219572165|NCT05424250|BEHAVIORAL|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
219572166|NCT02985879|DRUG|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
219572167|NCT02985879|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
219572168|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
219572169|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
219572170|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
219572171|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
219572172|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
219572173|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
219572174|NCT06415279|DRUG|Winlevi (clascoterone) 1% cream|Twice daily (BID) dosing
219572175|NCT06029491|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
219572176|NCT05555706|DRUG|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
219758187|NCT01131052|DRUG|Insulin glulisine|glulisine given as needed before meals
219758188|NCT02404714|DEVICE|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
219758189|NCT03609424|DRUG|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"
219417098|NCT03508661|OTHER|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
219417099|NCT01807260|PROCEDURE|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
219417100|NCT03933514|OTHER|Plaque control|Children were instructed about the hygiene procedures
219417101|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
219417102|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
219417103|NCT02155361|DRUG|Topical Citrullus colocynthis fruit oil (1%)|
219417104|NCT02155361|DRUG|Topical vehicle oil|
219417105|NCT05126745|DEVICE|color flow Doppler ultrasonography|Doppler ultrasonography
219572177|NCT05368012|DRUG|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
219417106|NCT06057636|BEHAVIORAL|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
219417107|NCT06057636|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
219417108|NCT00799929|OTHER|in vitro fertilization (IVF/ICSI)|
219572178|NCT02403661|PROCEDURE|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
219572179|NCT03929809|DEVICE|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
219004362|NCT06197854|PROCEDURE|Hernioplasty|Surgical hernioplasty
219417109|NCT03661450|DIAGNOSTIC_TEST|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
219417110|NCT02924688|DRUG|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
219572180|NCT06272292|DIAGNOSTIC_TEST|EOS|Every subject in this study will undergo a radiographic analysis of the hip and spine using a low-dose, full-body biplanar X-ray acquisition (in standing, sitting and squatting position, EOS imaging).
219758190|NCT01426802|DRUG|vildagliptin|Drug 50mg vildagliptin bid
219758191|NCT02497105|OTHER|Ketogenic Diet|Dietary
219758192|NCT03690245|PROCEDURE|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
219758193|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
219758194|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
219758195|NCT00969423|DEVICE|5mm videoscope|use of 5mm videoscope
219758196|NCT00969423|DEVICE|10mm videoscope|use of 10mm videoscope
219758197|NCT06250764|DIAGNOSTIC_TEST|Clinical periodontal measuremenets|The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
219758198|NCT06250764|DIAGNOSTIC_TEST|ELISA test from gingival crevicular fluid (GCF)|GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
219758199|NCT01127919|BEHAVIORAL|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
219758200|NCT01127919|OTHER|Cognitive Component|Provide general information about health and fitness
219758201|NCT02867137|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
219758202|NCT00744744|OTHER|informational intervention|Patient educational information
219758203|NCT00744744|OTHER|questionnaire administration|Survey
219758204|NCT00744744|PROCEDURE|management of therapy complications|Survey
219758205|NCT00744744|PROCEDURE|psychosocial assessment and care|Survey
219758206|NCT00744744|PROCEDURE|quality-of-life assessment|Survey
219758207|NCT00470015|BIOLOGICAL|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
219758208|NCT00470015|BIOLOGICAL|IL-2|0.5x10\^6/m\^2
219758209|NCT00470015|BIOLOGICAL|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
219417111|NCT02924688|DRUG|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
219417112|NCT02924688|DRUG|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
219417113|NCT02924688|DRUG|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
219417114|NCT02924688|DRUG|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
219417115|NCT02924688|DRUG|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
219417116|NCT02924688|DRUG|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
219004363|NCT01832376|PROCEDURE|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
219417117|NCT02924688|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
219417118|NCT02924688|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
219417119|NCT02924688|DEVICE|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
219417120|NCT02924688|DEVICE|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
219417121|NCT02790554|DEVICE|Moyo strap-on|Continous monitoring
219417122|NCT02790554|DEVICE|Hand-held Doppler|Intermittent monitoring
219417123|NCT01661166|DRUG|Fesoterodine|4 mg
219417124|NCT01661166|DRUG|Placebo oral tablet|Placebo
219417125|NCT05871593|GENETIC|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
219758210|NCT00470015|BIOLOGICAL|GM-CSF|300mcg
219004364|NCT05340608|OTHER|Smart, non-invasive shirt - Physiological parameters|Observation Group One and Control Group - Participants in these groups will be asked to wear a smart, non-invasive shirt while watching two different five-minute videos. One video will show relaxing images and will emit relaxing music (relaxing video). The second video will present impressive human body deformities accompanied by anxious music (disturbing video). Both videos will be presented with the participant in a sitting position. The duration of the entire session will be approximately 15 minutes. For the whole duration of the session, the smart shirt will collect data on participants' physiological parameters (electrocardiogram, heart rate, heart rate variability, respiration rate, minute ventilation, and body movement). Collected data will be used to develop an ad-hoc algorithm to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
219417126|NCT03677895|DRUG|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
219417127|NCT00882102|DRUG|Decitabine|Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
219758211|NCT00470015|BIOLOGICAL|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
219417128|NCT00882102|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.
219417129|NCT00310388|DRUG|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
219758212|NCT05015231|DIAGNOSTIC_TEST|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
219758213|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
219758214|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
219758215|NCT01528592|DRUG|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
219758216|NCT00146744|BIOLOGICAL|Mtb72F/AS02A|
219758217|NCT03825705|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219758218|NCT03825705|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
219417130|NCT03518099|BIOLOGICAL|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
219417131|NCT00868959|DRUG|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
219417132|NCT04302103|BIOLOGICAL|RC18 160mg|subcutaneous injection
219417133|NCT04302103|BIOLOGICAL|RC18 240 mg|subcutaneous injection
219417134|NCT04479917|DRUG|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
219417135|NCT04479917|DRUG|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
219417136|NCT02558556|DEVICE|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
219417137|NCT02558556|OTHER|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
219417138|NCT02205827|OTHER|Single-arm|collection of blood for assessment of whole blood clotting time
219417139|NCT01933165|DEVICE|LipiView|
219417140|NCT00848250|DRUG|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
219417141|NCT00848250|OTHER|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
219417142|NCT03277300|DIETARY_SUPPLEMENT|dietary supplement|good dietary supplement for critically ill patients
219417143|NCT01010711|DIETARY_SUPPLEMENT|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
219417144|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
219417145|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
219417146|NCT02331615|DEVICE|SHAM|no meaningful stimulation will be given
219417147|NCT00304317|DRUG|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
219417148|NCT00304317|OTHER|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
219417149|NCT06175650|PROCEDURE|Cardiac surgery|Cardiac surgery of all types
219417150|NCT04641312|DRUG|LY3457263|Administered SC
219572181|NCT06272292|DIAGNOSTIC_TEST|3D motion lab analysis|"A hip-specific 3D motion analysis will be performed. The 3D motion protocol will be divided into 2 main sections.~First section: Consist of movements categorized within the activities of daily living (walking at self-selected speed, uphill walking, standardized deep squat and non-standardized deep squat)~Second section: Consists of movements that are categorized within athletic training and have been specifically chosen to induce large hip ranges of motion (Sumo squats, dead lifts, forward lunges, running uphill and downhill)~Each movements will be repeated 6 times. Three times with the dominant foot/opposite leg on the force plate to collect kinetic data. All data will be captured using two 10-15 camera 3D motion capture systems and one capturing an instrumented treadmill (M-gait)"
219417151|NCT04641312|DRUG|Dulaglutide|Administered SC
219758219|NCT01334255|DRUG|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
219758220|NCT04116255|OTHER|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
219758221|NCT04116255|OTHER|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
219758222|NCT01088685|DEVICE|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
219417152|NCT04641312|DRUG|Placebo|Administered SC
219417153|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
219572182|NCT05473624|DRUG|HRS-1167|Participants will receive HRS-1167.
219758223|NCT01088685|DEVICE|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
219758224|NCT05303883|OTHER|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
219758225|NCT01935388|OTHER|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
219758226|NCT02487511|OTHER|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
219758227|NCT00338637|DEVICE|APOS shoe kit|
219758228|NCT01914588|PROCEDURE|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
219417154|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
219417155|NCT04497298|BIOLOGICAL|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
219417156|NCT04497298|OTHER|Placebo|Physiological saline solution (0.9% NaCl)
219417157|NCT05469477|BEHAVIORAL|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
219417158|NCT05469477|BEHAVIORAL|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
219417159|NCT05469477|BEHAVIORAL|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
219417160|NCT05469477|BEHAVIORAL|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
219417161|NCT05469477|BEHAVIORAL|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
219417162|NCT05469477|BEHAVIORAL|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
219417163|NCT05469477|BEHAVIORAL|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
219417164|NCT04274660|BEHAVIORAL|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
219417165|NCT05334680|DEVICE|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
219758229|NCT01914588|OTHER|Standard care|"* Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits"
219758230|NCT04345055|OTHER|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
219758231|NCT04345055|OTHER|Placebo intervention|Introduce in a machine off
219758232|NCT05245903|DEVICE|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
219758233|NCT00806585|DRUG|MK-0736|
219758234|NCT00806585|DRUG|Comparator: Placebo|
219758235|NCT00806585|DRUG|Comparator: HCTZ|
219758236|NCT03985735|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
219758237|NCT00474903|DRUG|acetylsalicylic acid|Given orally
219758238|NCT00474903|DRUG|esomeprazole magnesium|Given orally
219758239|NCT00474903|OTHER|placebo|Given orally
219758240|NCT04863742|DRUG|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
219758241|NCT04863742|DRUG|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
219758242|NCT02599116|OTHER|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
219758243|NCT02599116|OTHER|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
219758244|NCT02847403|DRUG|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
219758245|NCT02847403|OTHER|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
219758246|NCT04843280|PROCEDURE|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
219758247|NCT04843280|PROCEDURE|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
219758248|NCT00399529|BIOLOGICAL|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
219761674|NCT04347759|BEHAVIORAL|Coaching Messages|Participants receive real-time self-management coaching messages based on the severity of their symptoms. When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad.
219417166|NCT04619264|DRUG|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
219417167|NCT04619264|PROCEDURE|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
219417168|NCT03832439|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
219572183|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
219572184|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
219572185|NCT05576623|OTHER|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
219572186|NCT00176540|DRUG|dextromethorphan hydrobromide|
219572187|NCT00010166|DRUG|gemcitabine hydrochloride|
219572188|NCT00010166|PROCEDURE|adjuvant therapy|
219572189|NCT00010166|RADIATION|radiation therapy|
219572190|NCT06154694|RADIATION|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane"
219572191|NCT01675024|DRUG|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
219572192|NCT01675024|DRUG|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
219417169|NCT03832439|DIETARY_SUPPLEMENT|microcrystalline cellulose|Placebo
219417170|NCT05861804|PROCEDURE|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
219417171|NCT03268694|BEHAVIORAL|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
219572193|NCT04625192|PROCEDURE|Trephine osteotomy|"* Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
219572194|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
219572195|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
219572196|NCT04669717|DRUG|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
219572197|NCT02619136|PROCEDURE|Transfusion|Red Blood Cell Transfusion
219572198|NCT00118378|DRUG|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
219572199|NCT00118378|DRUG|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
219572200|NCT04969042|DEVICE|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
219572201|NCT02516410|DRUG|VX-661 plus ivacaftor combination|
219572202|NCT02516410|DRUG|Ivacaftor|
219572203|NCT02516410|DRUG|Placebo (matched to VX-661 plus ivacaftor combination)|
219572204|NCT02516410|DRUG|Placebo (matched to ivacaftor)|
219572205|NCT01834781|DEVICE|Pulsed electromagnetic fields|
219572206|NCT01834781|DEVICE|w/o pulsed electromagnetic fields|
219572207|NCT06429839|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
219572208|NCT01432574|BIOLOGICAL|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
219572209|NCT02894866|DEVICE|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
219761675|NCT04347759|BEHAVIORAL|Automated Daily Monitoring|Participants report daily symptoms and symptom severity. There are three categories of severity based on a numeric scale of 1 to 3 for mild symptoms, 4 to 7 for moderate symptoms, and 8 to 10 for severe symptoms.
219761676|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
219761677|NCT04663347|DRUG|rituximab and lenalidomide|rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
219761678|NCT04663347|DRUG|rituximab and bendamustine|6 cycles (28-day cycles)
219004365|NCT05340608|OTHER|Smart, non-invasive shirt - Relation with challenging behaviors|Observation Group Two - Each participant in this group will be asked to wear the smart, non-invasive shirt for seven consecutive days during waking hours, performing his usual daily activities. During the same seven days, the caregivers who care for the participant will be asked to accurately report the participant's status in a behavioral diary. Each evening, the data collected by the smart shirt will be uploaded to an online cloud along with the behavioral diary of the day. Collected data will be used to develop an ad-hoc algorithm able to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
219572210|NCT00996931|DRUG|lenalidomide|2.5 mgs per day orally for 12 weeks
219572211|NCT00345020|PROCEDURE|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
219572212|NCT04461132|OTHER|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
219572213|NCT04461132|OTHER|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
219758249|NCT00399529|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
219572214|NCT04461132|OTHER|Exercise|breathing and foot pump exercise was prescribed
219572215|NCT04461132|OTHER|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
219572216|NCT05017779|BEHAVIORAL|Unstuck & On Target: High School|Unstuck \& On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
219572217|NCT05017779|OTHER|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
219572218|NCT00209287|BEHAVIORAL|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
219572219|NCT01032772|BEHAVIORAL|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
219572220|NCT01032772|BEHAVIORAL|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
219572221|NCT05707143|OTHER|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
219572222|NCT05707143|OTHER|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
219572223|NCT01582984|OTHER|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
219572224|NCT03824990|BEHAVIORAL|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
219572225|NCT03145402|BIOLOGICAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
219572226|NCT03145402|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
219758250|NCT00399529|DRUG|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
219758251|NCT01936831|DRUG|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
219758252|NCT01936831|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
219758253|NCT04457024|OTHER|classification statistics|Without any intervention
219758254|NCT01103414|DRUG|Mitoglitazone|50 mg capsules, once daily for 84 days
219758255|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
219758256|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
219758257|NCT01103414|DRUG|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
219758258|NCT01103414|DRUG|Placebo|Placebo, once daily for 84 days
219758259|NCT03435380|BEHAVIORAL|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
219758260|NCT03435380|BEHAVIORAL|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
219758261|NCT03435380|BEHAVIORAL|Control|Mailed educational materials.
219761679|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|3 cycles (21-day cycles)
219761680|NCT04663347|DRUG|gemcitabine and oxaliplatin|4 cycles (28-day cycles)
219761681|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
219004366|NCT05340608|OTHER|Smart, non-invasive shirt - Proof of Concept|Proof of Concept - The participant with autism spectrum disorder enrolled in the proof-of-concept phase of this study will wear the smart, non-invasive shirt for seven days during all hours of attendance at the special school. At the end of the seven days, the healthcare professional and teacher who interacted with the developed system at the special school will participate in a focus group to analyze their experiences and opinions related to the system use.
219004367|NCT03445572|OTHER|Best Practice|Receive standard supportive care
219004368|NCT03445572|PROCEDURE|Meditation Therapy|Perform MSB
219004369|NCT03445572|PROCEDURE|Meditation Therapy|Perform IK meditation
219004370|NCT03445572|OTHER|Questionnaire Administration|Ancillary studies
219004371|NCT06167044|OTHER|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
219417172|NCT03268694|BEHAVIORAL|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
219417173|NCT03268694|BEHAVIORAL|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
219417174|NCT03214692|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
219417175|NCT00514202|DRUG|Placebo|matched placebo
219417176|NCT00514202|DRUG|Dextroamphetamine SR|60 mg/day
219417177|NCT03357809|PROCEDURE|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
219417178|NCT04022174|BEHAVIORAL|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
219417179|NCT04022174|BEHAVIORAL|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
219417180|NCT04022174|BIOLOGICAL|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
219572227|NCT05964790|DRUG|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
219004372|NCT01824901|DRUG|docetaxel|Given IV
219004373|NCT01824901|DRUG|AZD4547|Given PO
219004374|NCT06398535|DEVICE|magenetic resonance and ultrasound|examination of patient using magentic resonace coil for imaging of knee and comapring the results obtaines by ultrasound examination using the ulatrsound tarsnsducer .
219004375|NCT00607412|BEHAVIORAL|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
219004376|NCT00607412|BEHAVIORAL|12-step based supportive therapy|supportive psychotherapy based on 12-step model
219004377|NCT06122129|PROCEDURE|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
219004378|NCT06122129|PROCEDURE|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
219004379|NCT04980690|BIOLOGICAL|IBC0966|IBC0966 is an investigational product.
219417181|NCT04022174|BEHAVIORAL|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
219417182|NCT06282497|RADIATION|Optimised neck CTV|neck CTV delineation extends from the lateral process of C1
219417183|NCT06282497|RADIATION|standard neck CTV|neck CTV delineation extends from skull base
219417184|NCT01069523|DRUG|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
219417185|NCT01069523|DRUG|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
219417186|NCT02724774|BEHAVIORAL|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
219417187|NCT06130852|BEHAVIORAL|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
219417188|NCT00863837|DRUG|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
219417189|NCT00863837|DRUG|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
219417190|NCT02860806|DRUG|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
219417191|NCT02860806|DRUG|Placebo|Intravenous infusion of matching placebo.
219417192|NCT04698590|DEVICE|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
219004380|NCT02520050|BEHAVIORAL|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
219004381|NCT02520050|BEHAVIORAL|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
219417193|NCT04698590|DEVICE|Traditional Scleral Lenses|Traditional scleral lenses
219417194|NCT00473837|DRUG|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
219417195|NCT00473837|DRUG|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
219417196|NCT00720421|DRUG|AZD7325|AZD7325 10 mg oral 2 capsules
219572228|NCT05964790|DRUG|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
219572229|NCT02988479|OTHER|Out of pocket payments in patients|
219572230|NCT05626699|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
219572231|NCT05492370|DIETARY_SUPPLEMENT|EpiCor|2 gummies daily
219572232|NCT05492370|DIETARY_SUPPLEMENT|Placebo|2 gummies daily
219572233|NCT03629600|DRUG|Lactated Ringer|High-volume Lactated Ringer Solution
219572234|NCT03629600|DRUG|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
219761682|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
219761683|NCT04663347|DRUG|Lenalidomide|12 cycles (28-day cycles)
219761684|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|3 cycles (21-day cycles)
219761685|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
219761686|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
219761687|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
219761688|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
219761689|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
219761690|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
219761691|NCT04663347|BIOLOGICAL|Epcoritamab|"Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules.~Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years.~In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years."
219761692|NCT04663347|DRUG|Rituximab and Lenalidomide|Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
219761693|NCT04663347|BIOLOGICAL|Epcoritamab|Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
219761694|NCT04716452|DRUG|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
219761695|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program A) intervention
219761696|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program B) intervention
219761697|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program A)
219761698|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program B)
219761699|NCT06386432|OTHER|Biospecimen Collection|Complete at-home saliva sample collection
219761700|NCT06386432|OTHER|Questionnaire Administration|Ancillary studies
219761701|NCT06029309|DRUG|Zanubrutinib|"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1."
219004382|NCT02520050|BEHAVIORAL|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
219004383|NCT00662610|DRUG|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
219417197|NCT00720421|DRUG|AZD7325|AZD7325 1 mg oral 2 capsules
219417198|NCT00720421|DRUG|AZD7325|AZD7325 Placebo oral 2 capsules
219417199|NCT00720421|DRUG|Lorazepam|Lorazepam 1 mg oral 2 tablets
219417200|NCT00720421|DRUG|Lorazepam|Lorazepam Placebo oral 2 tablets
219417201|NCT02019394|DRUG|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
219417202|NCT03914495|DIETARY_SUPPLEMENT|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
219417203|NCT03914495|DIETARY_SUPPLEMENT|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
219417204|NCT06195384|BIOLOGICAL|Neoantigen mRNA Vaccine|Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
219417205|NCT05600647|DEVICE|Electromagnetic Field therapy with an exercise program|"1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
219572235|NCT01120652|BEHAVIORAL|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
219572236|NCT01120652|BEHAVIORAL|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
219004384|NCT00662610|DRUG|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
219004385|NCT01685931|DRUG|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
219417206|NCT05600647|OTHER|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
219417207|NCT05393076|DRUG|Linerixibat|Linerixibat dose and administration as per study intervention.
219417208|NCT03707964|OTHER|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
219417209|NCT03707964|OTHER|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
219417210|NCT00327548|BEHAVIORAL|guided imagery|
219417211|NCT04930211|DRUG|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
219572237|NCT01224028|DRUG|Tacrolimus|oral
219572238|NCT01224028|DRUG|Placebo|oral
219004386|NCT03211689|OTHER|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
219417212|NCT03672877|BEHAVIORAL|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
219417213|NCT05895227|PROCEDURE|Oocyte retrieval|
219417214|NCT05903391|DEVICE|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
219417215|NCT05903391|DEVICE|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
219417216|NCT06250517|DEVICE|EVLP|The right lung will be perfused for 3h with EVLP
219417217|NCT06250517|DEVICE|Cold preservation|The left lung will be cold preserved as usual protocol
219417218|NCT06616766|DRUG|YH42946|YH42946
219417219|NCT05836818|OTHER|Question (Q)|Flu vaccine acceptance question: a question asked of participants about their willingness to accept a flu vaccine
219417220|NCT05836818|OTHER|Messaging (M)|Flu vaccine educational materials -videos and flyers containing flu vaccine educational information
219417221|NCT02692339|DRUG|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
219004387|NCT03736317|DEVICE|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
219004388|NCT03736317|DEVICE|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
219417222|NCT02692339|DRUG|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
219417223|NCT05930392|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
219417224|NCT05930392|PROCEDURE|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
219417225|NCT01595737|DRUG|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
219417226|NCT01595737|DRUG|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
219417227|NCT02661607|PROCEDURE|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
219417228|NCT02661607|DEVICE|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
219417229|NCT02661607|PROCEDURE|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
219417230|NCT00150371|DRUG|atorvastatin|
219417231|NCT03945045|PROCEDURE|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
219417232|NCT03945045|PROCEDURE|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
219572239|NCT01857648|OTHER|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
219004389|NCT03736317|DEVICE|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
219004390|NCT03736317|DEVICE|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
219417233|NCT01662700|DRUG|Artesunate|
219417234|NCT01662700|DRUG|Chloroquine|
219417235|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
219417236|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
219417237|NCT00711269|DRUG|Placebo|
219417238|NCT00711269|DRUG|Risperidone|
219417239|NCT00374153|BEHAVIORAL|Feedback|Online personal feedback report
219417240|NCT00374153|BEHAVIORAL|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
219417241|NCT00374153|BEHAVIORAL|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
219417242|NCT03930212|DRUG|Progesterone|received rectal progesterone suppositories 400 mg once daily
219417243|NCT03930212|DRUG|Placebos|received placebo suppositories rectally once daily.
219417244|NCT04593940|DRUG|Infliximab|study drug or matching placebo
219417245|NCT04593940|DRUG|Abatacept|study drug or matching placebo
219417246|NCT04593940|DRUG|Remdesivir|Standard of Care
219417247|NCT04593940|DRUG|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
219417248|NCT00180596|DEVICE|Contak heart failure devices|
219417249|NCT02645058|PROCEDURE|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
219417250|NCT02645058|PROCEDURE|ESWL|Treatment by extracorporeal shock waves lithotripsy
219417251|NCT02645058|DEVICE|Rigid and flexible ureteroscope|
219417252|NCT02645058|DEVICE|Lithotripter|
219417253|NCT02645058|DEVICE|Holmium laser|
219417254|NCT02645058|DEVICE|Basket for fragment removal|
219417255|NCT02645058|PROCEDURE|General or spinal anesthesia|
219572240|NCT00826579|PROCEDURE|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
219004391|NCT03921086|DRUG|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
219417256|NCT02645058|DRUG|Intravenous pain medication|If required by the patient
219417257|NCT02645058|DEVICE|X-ray|To focus the stone
219417258|NCT02645058|DEVICE|Ultrasound|To focus the stone
219417259|NCT02077634|DRUG|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
219417260|NCT02077634|DRUG|abiraterone acetate + prednisone|ormon therapy will be stopped
219417261|NCT03739463|DIETARY_SUPPLEMENT|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
219417262|NCT03739463|DIETARY_SUPPLEMENT|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
219417263|NCT05339724|OTHER|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
219417264|NCT03989219|PROCEDURE|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
219417265|NCT03010995|DRUG|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
219417266|NCT00347555|BIOLOGICAL|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
219417267|NCT00347555|DRUG|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
219417268|NCT00347555|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
219417269|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
219417270|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
219572241|NCT00826579|PROCEDURE|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
219572242|NCT04051684|PROCEDURE|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
219572243|NCT04051684|DRUG|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
219572244|NCT00618202|DRUG|Balsalazide|
219417271|NCT04671316|DRUG|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
219417272|NCT02634918|OTHER|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
219417273|NCT00002207|DRUG|Stavudine|
219417274|NCT00002207|DRUG|Didanosine|
219417275|NCT00392262|DRUG|valsartan + amlodipine|
219417276|NCT04892758|DRUG|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
219417277|NCT04892758|DRUG|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
219417278|NCT01743339|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
219417279|NCT01743339|BEHAVIORAL|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
219417280|NCT00217867|BEHAVIORAL|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
219417281|NCT03104335|DRUG|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
219572245|NCT06141824|DEVICE|Lucira COVID-19 & Flu Test|The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
219572246|NCT04440319|BEHAVIORAL|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
219572247|NCT03995017|DRUG|Rucaparib|Rucaparib tablet
219572248|NCT03995017|DRUG|Ramucirumab|Ramucirumab intravenous solution
219572249|NCT03995017|DRUG|Nivolumab|Nivolumab intravenous solution
219004392|NCT04359433|BEHAVIORAL|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week"
219004393|NCT03258151|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219004394|NCT03498690|BEHAVIORAL|Integrative|Stakeholder groups: a-b
219417282|NCT06182813|OTHER|Beta auditory beats (Group A)|Beta auditory beats for 25 min and then perform alternate wall toss test.
219417283|NCT06182813|OTHER|white noise (Group B)|Involves participants receiving White noise for 25 min and then perform alternate wall toss test.
219417284|NCT04136613|DEVICE|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
219417285|NCT05162950|DIAGNOSTIC_TEST|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
219417286|NCT05162950|BEHAVIORAL|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
219417287|NCT03071536|DRUG|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
219417288|NCT02986893|BEHAVIORAL|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
219417289|NCT02986893|BEHAVIORAL|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
219417290|NCT02817815|DEVICE|Electrocardiogram (ECG)|
219572250|NCT02785536|BEHAVIORAL|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
219761702|NCT06029309|DRUG|Tafasitamab|"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15"
219761703|NCT04497779|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
219004395|NCT03498690|BEHAVIORAL|Role specific|Stakeholder groups: a or b
219004396|NCT03498690|BEHAVIORAL|Consecutive|Stakeholder groups: a=\> b
219417291|NCT02817815|BIOLOGICAL|Blood sampling from the cephalic vein|
219417292|NCT02817815|BIOLOGICAL|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
219417293|NCT02817815|BIOLOGICAL|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
219417294|NCT02817815|PROCEDURE|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
219417295|NCT02817815|BIOLOGICAL|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
219417296|NCT05506592|OTHER|dermatological product|cosmetic shampoo
219417297|NCT00621855|DRUG|placebo|matched placebo
219417298|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
219417299|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
219417300|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
219417301|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
219417302|NCT02953782|DRUG|Magrolimab|Administered intravenously
219417303|NCT02953782|DRUG|Cetuximab|Administered intravenously
219761704|NCT04497779|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219761705|NCT04497779|OTHER|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
219761706|NCT04497779|OTHER|Questionnaire Administration|Ancillary studies
219761707|NCT05980546|DRUG|Bupivacaine Injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
219761708|NCT05980546|DRUG|Dexamethasone injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
219761709|NCT05980546|DRUG|Fentanyl|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
219761710|NCT05980546|DRUG|Mepivacaine|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
219761711|NCT06579222|OTHER|Primary Care Rheumatology Family Physician Consultation|The participant will be booked with a primary care rheumatology family physician for rheumatoid arthritis comorbidity screening. They will complete weight, height, blood pressure measurement, assess for risk factors for dyslipidemia, type 2 diabetes, hypertension, bone mineral density loss and vaccine preventable infectious diseases.
219761712|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
219417304|NCT04743700|PROCEDURE|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
219417305|NCT04743700|PROCEDURE|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
219572251|NCT02785536|BEHAVIORAL|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
219572252|NCT05364996|DIAGNOSTIC_TEST|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
219572253|NCT05364996|DIAGNOSTIC_TEST|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
219572254|NCT00727519|DIETARY_SUPPLEMENT|Pomegranate juice|
219572255|NCT00727519|DIETARY_SUPPLEMENT|Placebo|
219572256|NCT00393536|BEHAVIORAL|Educational outreach visiting|
219417306|NCT00323505|DRUG|Pegylated Interferon|
219417307|NCT00323505|DRUG|Interferon-alpha2a|
219417308|NCT03579953|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
219417309|NCT03579953|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219417310|NCT03972124|DRUG|CBD 100 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
219417311|NCT03972124|DRUG|CBD 200 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
219417312|NCT03972124|DRUG|Placebo|Soft-gel capsules containing placebo
219417313|NCT02678234|DRUG|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
219417314|NCT01737840|DRUG|Pantoprazole|33 patients
219417315|NCT01737840|DRUG|Ranitidine|33 patients
219417316|NCT01006863|DRUG|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
219417317|NCT01006863|DRUG|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
219417318|NCT01006863|DRUG|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
219417319|NCT00813514|GENETIC|VEGF genotyping|blood sample for gene analysis
219417320|NCT03105700|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
219572257|NCT06091228|OTHER|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
219572258|NCT01962181|DRUG|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
219572259|NCT01962181|DRUG|Placebo|
219004397|NCT05281445|BEHAVIORAL|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
219417321|NCT00432952|BEHAVIORAL|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
219417322|NCT05924906|DRUG|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
219417323|NCT03637699|BEHAVIORAL|Positive Psychology|5-week positive psychology intervention
219417324|NCT02510170|OTHER|no intervention|
219417325|NCT01237106|OTHER|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
219417326|NCT04773899|DIAGNOSTIC_TEST|Procedure : Multimodal microvascular assessment at study inclusion|"* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy."
219417327|NCT03791359|OTHER|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
219417328|NCT04662242|DRUG|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
219572260|NCT06037226|BEHAVIORAL|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
219417329|NCT04662242|DRUG|normal saline|normal saline 100ml iv infusion for 7 days
219417330|NCT00403559|DRUG|Elidel|
219417331|NCT00403559|DRUG|Ketoconazole Cream|
219572261|NCT00180076|DRUG|Budesonide|
219417332|NCT00127504|DRUG|Rifampin|
219417333|NCT00127504|DRUG|Azithromycin|
219417334|NCT03553433|DRUG|Apremilast 30mg|Anti-psoriatic drug
219417335|NCT03553433|DRUG|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
219417336|NCT01253421|DRUG|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
219417337|NCT01253421|DRUG|placebo|single-dose placebo capsule
219417338|NCT00929734|DRUG|Rosuvastatin|10mg tablets, once daily in three months
219572262|NCT04902625|DRUG|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
219572263|NCT00666848|DRUG|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
219572264|NCT00666848|DRUG|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
219417339|NCT00929734|DRUG|Placebo|1 tablet, once daily in three months
219417340|NCT03584854|DRUG|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
219572265|NCT00666848|DRUG|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
219572266|NCT00666848|DRUG|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
219004398|NCT05851781|DRUG|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219004399|NCT05851781|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219004400|NCT00119002|DRUG|dexamethasone|1mg/kg dexamethasone
219004401|NCT00119002|DRUG|Placebo|1mg/kg placebo
219190764|NCT05099874|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
219190765|NCT06016764|DEVICE|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia, intellectual disability, and social-emotional impairment in autism
219190766|NCT04428541|OTHER|Questionnaire for visual function assessment of preverbal children|18 items questionnaire
219417341|NCT03584854|DRUG|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
219190767|NCT03523572|DRUG|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
219417342|NCT04270994|DRUG|Misoprostol|
219417343|NCT00100724|BIOLOGICAL|rPA102|
219417344|NCT00516633|BEHAVIORAL|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
219417345|NCT00059722|DRUG|ZD6474|
219417346|NCT00059722|DRUG|Placebo|
219761713|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
219004402|NCT03542968|PROCEDURE|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
219004403|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
219417347|NCT00059722|DRUG|ZD1839|
219417348|NCT00135486|BIOLOGICAL|MenC-TT|
219417349|NCT00135486|BIOLOGICAL|Hib-MenC-TT|
219417350|NCT03172520|DEVICE|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
219417351|NCT03172520|DEVICE|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
219417352|NCT00980980|DRUG|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
219761714|NCT00098072|PROCEDURE|Heart Catheterization|Heart Catheterization and collection of samples
219761715|NCT01688466|DRUG|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
219761716|NCT04972721|OTHER|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
219761717|NCT05963568|DRUG|Polycap|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
219761718|NCT06231238|BEHAVIORAL|Balance Acceptance and Commitment Therapy|Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.
219761719|NCT05989451|BEHAVIORAL|Dialectical behavior therapy (DBT)|The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
219761720|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab Prefilled Syringe|Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
219004404|NCT03989557|DEVICE|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
219190768|NCT03523572|DRUG|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
219190769|NCT04845893|OTHER|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
219417353|NCT02200367|BEHAVIORAL|e-mental health collaborative programme|
219417354|NCT02200367|OTHER|Usual Care|
219417355|NCT04073940|BEHAVIORAL|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
219417356|NCT03331094|PROCEDURE|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
219417357|NCT03331094|PROCEDURE|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
219417358|NCT06336551|BEHAVIORAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
219417359|NCT02085876|OTHER|2 additional MRI sequences|
219417360|NCT02085876|OTHER|An additional blood sample|
219417361|NCT00121992|DRUG|Docetaxel|
219417362|NCT00121992|DRUG|5-fluorouracil|
219417363|NCT00121992|DRUG|Doxorubicin|
219572267|NCT05709041|OTHER|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
219004405|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
219004406|NCT05076526|BIOLOGICAL|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat"
219417364|NCT00121992|DRUG|Cyclophosphamide|
219417365|NCT00024076|PROCEDURE|radiofrequency ablation|
219417366|NCT05671601|DIAGNOSTIC_TEST|Automatic picture recognition|A machine that processes photographs automatically taken
219417367|NCT05671601|DIAGNOSTIC_TEST|Manual Assessment Group|Manual recognition of pictures
219417368|NCT06011746|DRUG|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
219417369|NCT06011746|DRUG|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
219417370|NCT02410850|DEVICE|Oral Appliance|Mandibular Advancement Splints
219417371|NCT06473285|DRUG|Drug: Esketamine (Continuous infusion)|Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.
219004407|NCT05076526|BIOLOGICAL|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)"
219572268|NCT05709041|OTHER|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
219572269|NCT03832881|DIAGNOSTIC_TEST|ADAMTS13, VWF assay|
219572270|NCT04206514|BEHAVIORAL|Person Centered Care - Post Abortion Support|Post abortion phone based support
219572271|NCT05805735|OTHER|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
219572272|NCT05468788|BEHAVIORAL|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
219572273|NCT05468788|BEHAVIORAL|Control: Improvisational Theatre|Participants play improvisational theatre games.
219572274|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
219572275|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
219572276|NCT00301847|DRUG|sorafenib tosylate|
219572277|NCT00761449|DRUG|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
219572278|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
219572279|NCT01029158|DRUG|RN1006 (Avotermin)|250 ng, intradermal injection, twice
219572280|NCT01029158|DRUG|RN1006 (Avotermin)|205 ng, Intradermal injection, once
219758262|NCT02133573|DRUG|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
219572281|NCT01029158|DRUG|RN1006 (Avotermin)|500ng, intradermal injection, once
219572282|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, intradermal injection, twice
219572283|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
219572284|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
219572285|NCT01029158|DRUG|RN1006 (Avotermin)|500 ng, intradermal injection, twice
219572286|NCT01029158|DRUG|Placebo|Placebo
219572287|NCT00735917|DRUG|saracatinib|Given PO
219572288|NCT00735917|OTHER|pharmacogenomic studies|Optional correlative studies
219572289|NCT00735917|OTHER|pharmacological study|Optional correlative studies
219572290|NCT00735917|PROCEDURE|positron emission tomography|Optional correlative studies
219572291|NCT00735917|RADIATION|fludeoxyglucose F 18|Optional correlative studies
219572292|NCT00735917|OTHER|laboratory biomarker analysis|Optional correlative studies
219572293|NCT05436704|PROCEDURE|EUS-FNB|EUS-FNB
219572294|NCT03321162|DIAGNOSTIC_TEST|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
219572295|NCT00690976|BEHAVIORAL|Proyecto SOL|Group intervention
219758263|NCT02133573|DRUG|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
219758264|NCT00788112|DRUG|vorinostat|
219758265|NCT00788112|GENETIC|protein expression analysis|
219572296|NCT00690976|BEHAVIORAL|HCT|Offer of HIV counseling and testing
219572297|NCT04790123|PROCEDURE|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
219572298|NCT04790123|PROCEDURE|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
219758266|NCT00788112|OTHER|immunohistochemistry staining method|
219758267|NCT00788112|OTHER|laboratory biomarker analysis|
219758268|NCT00788112|PROCEDURE|neoadjuvant therapy|
219758269|NCT00788112|PROCEDURE|therapeutic conventional surgery|
219758270|NCT03687281|OTHER|Survey|"The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex."
219758271|NCT02825108|DRUG|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
219417372|NCT01912937|DEVICE|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
219417373|NCT00087737|DRUG|DVS-233 SR|
219417374|NCT00087737|DRUG|Venlafaxine ER|
219417375|NCT05346601|DRUG|Chiauranib|50mg po only once
219417376|NCT03092869|OTHER|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
219417377|NCT03092869|OTHER|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
219417378|NCT03218982|BEHAVIORAL|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
219417379|NCT02237976|BEHAVIORAL|Self-hypnosis|
219417380|NCT02237976|BEHAVIORAL|Routine practice|
219417381|NCT05604469|DIAGNOSTIC_TEST|Isolation of skin microbiota|Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
219417382|NCT00740168|DRUG|bevacizumab treatment|single infusion 10 mg/kg
219417383|NCT00414960|DRUG|Enzastaurin|500 mg po QD for 6 months
219417384|NCT00414960|DRUG|Placebo|po QD for 6 months
219417385|NCT03227562|DRUG|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
219417386|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
219417387|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
219417388|NCT04897282|DIAGNOSTIC_TEST|UCRI|Biomarker panel and algorithm
219417389|NCT01062594|OTHER|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
219417390|NCT01062594|OTHER|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
219417391|NCT01062594|OTHER|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
219417392|NCT02266082|OTHER|No intervention|There is no intervention in this study.
219417393|NCT02675894|DEVICE|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
219417394|NCT02675894|DEVICE|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
219417395|NCT03768791|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
219417396|NCT03768791|OTHER|SCS is switched on|Spinal cord stimulator is on
219417397|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
219417398|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
219417399|NCT02753829|OTHER|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
219758272|NCT02825108|DRUG|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
219758273|NCT02825108|PROCEDURE|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
219758274|NCT04494789|DRUG|Fludrocortisone Acetate|50mcg
219758275|NCT04494789|DRUG|Fludrocortisone Acetate|100mcg
219417400|NCT02618980|OTHER|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
219417401|NCT01763281|DRUG|CRH|
219417402|NCT01763281|DRUG|Placebo|
219417403|NCT02649543|PROCEDURE|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
219417404|NCT02649543|PROCEDURE|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
219758276|NCT04494789|DRUG|Fludrocortisone Acetate|200mcg
219758277|NCT04494789|OTHER|Standard Therapy|NO Fludrocortisone
219761721|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab AI|AI for SC injection self-administration of rocatinlimab.
219190770|NCT05058924|DRUG|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
219190771|NCT05058924|DRUG|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
219190772|NCT06040125|BEHAVIORAL|Supervised Circuit Training|16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
219190773|NCT05110508|BEHAVIORAL|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
219758278|NCT04041193|BEHAVIORAL|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
219190774|NCT05575219|DRUG|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
219190775|NCT05575219|DRUG|Clonidine (protocolized initiation)|"* Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of \>/= 168 hours or with infusion time of 120-167 hours at doses \>/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
219190776|NCT03967002|PROCEDURE|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors."
219190777|NCT05661604|OTHER|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
219190778|NCT06508632|BEHAVIORAL|Mandala group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).
219190779|NCT05709249|DRUG|XLJDOD compound granule|Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.
219190780|NCT05709249|DRUG|placebo (XLJDOD mimetic agent)|The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
219758279|NCT04041193|BEHAVIORAL|Usual Care Program|Usual Care program activities (paper and pencil at home)
219758280|NCT06486402|OTHER|participation rate|participation rate
219758281|NCT04088903|DRUG|Daratumumab|\>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
219761722|NCT04939090|DRUG|Olanzapine|Given PO
219761723|NCT04939090|DRUG|Megestrol Acetate|Given PO
219761724|NCT04939090|OTHER|Questionnaire Administration|Ancillary studies
219761725|NCT06770582|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219761726|NCT06770582|DRUG|Cisplatin|Given IV
219761727|NCT06770582|PROCEDURE|Computed Tomography|Undergo CT
219761728|NCT06770582|DRUG|Fluorouracil|Given IV
219761729|NCT06770582|DRUG|Gemcitabine|Given IV
219761730|NCT06770582|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219004408|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
219761731|NCT06770582|DRUG|Mitomycin|Given IV
219761732|NCT06770582|BIOLOGICAL|Pembrolizumab|Given IV
219761733|NCT06770582|OTHER|Questionnaire Administration|Ancillary studies
219761734|NCT06770582|RADIATION|Radiation Therapy|Undergo radiation therapy
219761735|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
219761736|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
219004409|NCT03138889|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
219004410|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
219190781|NCT05566470|DIAGNOSTIC_TEST|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
219190782|NCT05870046|PROCEDURE|Power training in women older than 65 years with pre-sarcopenia|resistance training based on muscle power training, perform the exercises at high speed.
219190783|NCT05870046|PROCEDURE|Multimodal and nonspecific exercises in women older than 65 years with pre-sarcopenia|different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
219417405|NCT02649543|PROCEDURE|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
219417406|NCT03711994|OTHER|Alkantis|cold therapy pack placed on the wound post operatively
219417407|NCT01316991|DIETARY_SUPPLEMENT|Chewing Gum|chewing gum will be provided
219417408|NCT01316991|DIETARY_SUPPLEMENT|No Gum|no chewing gum will be provided
219417409|NCT03164226|DEVICE|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
219417410|NCT02779192|DRUG|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
219758282|NCT04859998|BEHAVIORAL|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
219758283|NCT05162248|DIAGNOSTIC_TEST|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
219758284|NCT05790694|DRUG|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
219758285|NCT05790694|DRUG|Placebo|Strength: 225 mg (1.5 mL)/vial
219758286|NCT03641196|DEVICE|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
219758287|NCT03641196|PROCEDURE|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
219758288|NCT06399055|DRUG|CKD-387|1 Tablet
219758289|NCT06399055|DRUG|D484|1 Tablet
219758290|NCT03070626|DIETARY_SUPPLEMENT|PreOp®|No preoperative drink.
219758291|NCT02523950|PROCEDURE|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
219758292|NCT02523950|PROCEDURE|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
219758293|NCT02523950|DEVICE|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
219758294|NCT04225858|PROCEDURE|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
219758295|NCT03928925|OTHER|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
219758296|NCT03928925|OTHER|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
219758297|NCT02234349|PROCEDURE|pancreas kidney transplantation|
219758298|NCT02234349|PROCEDURE|kidney transplantation|
219758299|NCT04435314|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days
219758300|NCT04435314|DRUG|Placebo|Subjects will receive placebo TID for 7 days.
219758301|NCT02468830|DRUG|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
219758302|NCT02268643|OTHER|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
219758303|NCT03563547|BEHAVIORAL|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
219761737|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
219004411|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
219004412|NCT03138889|DRUG|Cisplatin|Cisplatin will be dosed per the pharmacy manual
219758304|NCT03563547|BEHAVIORAL|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
219758305|NCT03745950|DRUG|Olaparib Oral Capsule|\- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
219758306|NCT03745950|DRUG|Placebo oral capsule|\- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
219190784|NCT01805609|BEHAVIORAL|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
219758307|NCT00700206|DRUG|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
219758308|NCT01362101|BEHAVIORAL|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
219758309|NCT02922946|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
219758310|NCT02319486|DRUG|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
219758311|NCT02319486|DRUG|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
219758312|NCT02220634|DRUG|Regadenoson|Injection for intravenous administration
219758313|NCT04794933|OTHER|Conventional therapy|
219758314|NCT04794933|OTHER|CT+ PNF in extremity pattern|
219758315|NCT04794933|OTHER|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
219758316|NCT04089514|DRUG|Adalimumab|Administered as specified in the treatment arm
219758317|NCT00413348|DRUG|Lactobacillus acidophilus NCFM|
219004413|NCT03138889|DRUG|Carboplatin|Carboplatin will be dosed per the pharmacy manual
219004414|NCT03138889|DRUG|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
219190785|NCT01805609|BEHAVIORAL|questionnaires|
219758318|NCT05589987|DEVICE|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
219004415|NCT03138889|DRUG|Paclitaxel|Paclitaxel will be dosed per local practice and label
219190786|NCT04267120|DRUG|Lenvatinib|Lenvatinib will be provided by Merck.
219190787|NCT04267120|DRUG|Pembrolizumab|Merck will provide pembrolizumab
219758319|NCT00671086|DRUG|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
219004416|NCT03138889|DRUG|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
219004417|NCT03138889|DRUG|Atezolizumab|Atezolizumab will be dosed per current label indication
219004418|NCT04590261|OTHER|Blood sampling|Peripheral Blood sampling, 25 mL
219004419|NCT04590261|OTHER|Nasal Brushing|Nasal Brushing, facultative
219004420|NCT01524510|RADIATION|CT scan|low dose radiation scan without contrast without and with MRA
219004421|NCT01524510|DEVICE|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
219004422|NCT00551733|DRUG|carboplatin|Given IV
219004423|NCT00551733|DRUG|paclitaxel|Given IV
219004424|NCT00551733|DRUG|paclitaxel poliglumex|Given IV
219004425|NCT04120831|DRUG|Abatacept Injection|Drug
219004426|NCT02557698|OTHER|Balneum oil bath|
219004427|NCT00403442|DEVICE|Verteporfin Therapy/ Drug: Bevacizumab|
219004428|NCT02289690|DRUG|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
219004429|NCT02289690|DRUG|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
219417411|NCT02779192|DRUG|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
219417412|NCT02779192|DRUG|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
219417413|NCT05881772|OTHER|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
219572299|NCT02043613|OTHER|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
219572300|NCT02043613|OTHER|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
219572301|NCT02698865|DEVICE|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
219572302|NCT02698865|DEVICE|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
219572303|NCT03394911|BIOLOGICAL|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
219572304|NCT01323465|DRUG|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
219572305|NCT01323465|DRUG|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
219572306|NCT01323465|DRUG|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
219572307|NCT01323465|DRUG|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
219572308|NCT01323465|DRUG|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
219572309|NCT01323465|DRUG|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
219572310|NCT04341857|DRUG|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
219572311|NCT05587114|DIAGNOSTIC_TEST|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
219572312|NCT00773734|DRUG|Apremilast 10mg|
219572313|NCT00773734|DRUG|Apremilast 20mg|
219758320|NCT00671086|DRUG|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
219004430|NCT02289690|DRUG|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
219004431|NCT02289690|DRUG|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
219417414|NCT05855317|OTHER|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
219417415|NCT05691634|PROCEDURE|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
219417416|NCT05691634|OTHER|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
219417417|NCT01412658|DIETARY_SUPPLEMENT|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
219572314|NCT00773734|DRUG|Apremilast 30 mg|
219572315|NCT00773734|DRUG|Placebo|
219572316|NCT00773734|DRUG|Apremilast 30mg|
219572317|NCT00773734|DRUG|Apremilast 20mg|
219572318|NCT03605511|DIAGNOSTIC_TEST|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
219572319|NCT00033904|DRUG|autologous human tumor-derived HSPPC-96|
219572320|NCT06226922|OTHER|No intervention|No intervention
219572321|NCT01758822|OTHER|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
219572322|NCT03477019|DRUG|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
219572323|NCT03477019|PROCEDURE|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
219572324|NCT05208658|OTHER|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
219572325|NCT05208658|OTHER|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
219758321|NCT00794092|DRUG|Sinerem administration|Single dose
219758322|NCT00713011|DRUG|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
219761738|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
219572326|NCT04303650|DEVICE|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
219758323|NCT00713011|DRUG|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
219758324|NCT02115321|DRUG|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
219004432|NCT03687853|DEVICE|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
219004433|NCT01427504|DRUG|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
219004434|NCT04166435|DRUG|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
219004435|NCT01327521|DEVICE|CyberKnife|Standard of Care
219004436|NCT01327521|PROCEDURE|TACE|Standard of Care
219004437|NCT01327521|DRUG|CT Contrast|Standard of Care
219417418|NCT01412658|DIETARY_SUPPLEMENT|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
219417419|NCT01683110|DRUG|cabozantinib|
219417420|NCT06430112|DRUG|Liposomal Bupivacaine|After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
219417421|NCT06430112|DRUG|Ropivacaine|Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
219417422|NCT05180110|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
219417423|NCT05180110|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
219417424|NCT04863014|DRUG|evinacumab|Intravenous infusion every 4 weeks (Q4W)
219417425|NCT04863014|OTHER|Placebo|Intravenous infusion Q4W
219417426|NCT03464123|OTHER|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
219004438|NCT01327521|DRUG|doxorubicin|Standard of Care
219004439|NCT01327521|DRUG|Epirubicin|Standard of Care
219004440|NCT01327521|DRUG|5-fluorouracil|Standard of Care
219004441|NCT01327521|DRUG|Mitomycin C|Standard of Care
219004442|NCT01327521|DRUG|Gemcitabine|Standard of Care
219004443|NCT01327521|DRUG|Cisplatin|Standard of Care
219417427|NCT02602938|DRUG|Aspirin|Take aspirin (100mg) orally once a day for 2 months
219417428|NCT04301921|OTHER|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
219004444|NCT01327521|DEVICE|SMANCS|Standard of Care
219004445|NCT05442320|DEVICE|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
219190788|NCT04267120|PROCEDURE|Research blood collection|-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
219417429|NCT04301921|OTHER|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
219417430|NCT01889966|DRUG|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
219417431|NCT00632190|OTHER|fluorophotometry|
219417432|NCT00632190|PROCEDURE|colposcopic biopsy|
219417433|NCT00632190|PROCEDURE|colposcopy|
219417434|NCT00632190|PROCEDURE|light-scattering spectroscopy|
219417435|NCT04633473|BEHAVIORAL|SIB-Time Web-Application Tool|Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
219417436|NCT03166865|BIOLOGICAL|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
219758325|NCT02115321|DRUG|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
219758326|NCT02115321|DRUG|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
219758327|NCT00551083|OTHER|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
219417437|NCT03166865|OTHER|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
219417438|NCT02683226|DRUG|Vipdomet|
219417439|NCT02683226|DRUG|Incresync|
219417440|NCT05059418|DRUG|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
219761739|NCT05081492|BIOLOGICAL|Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody|Given IT
219417441|NCT05059418|DRUG|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
219417442|NCT05059418|OTHER|Placebo|Mouth rinse with no capsaicin
219417443|NCT01757613|DRUG|AK 3012|cutaneous use twice a day
219417444|NCT05618899|OTHER|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
219417445|NCT05618899|OTHER|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
219417446|NCT06043206|PROCEDURE|Bariatric Surgery|Bariatric Surgery
219417447|NCT04679259|DIAGNOSTIC_TEST|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
219417448|NCT04679259|DIAGNOSTIC_TEST|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
219417449|NCT04679259|DIAGNOSTIC_TEST|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
219417450|NCT05197673|BEHAVIORAL|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
219417451|NCT01097473|PROCEDURE|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
219417452|NCT04724382|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
219417453|NCT04724382|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
219417454|NCT04569331|PROCEDURE|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
219417455|NCT04569331|PROCEDURE|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
219417456|NCT03733873|DRUG|Desmopressin|take desmopressin for 3 months
219417457|NCT03733873|DRUG|Suoquan|take Suoquan mixture for 3 months
219417458|NCT01424826|DRUG|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
219417459|NCT01424826|DRUG|Rifampicin|\< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days \> 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
219417460|NCT01424826|DRUG|Raltegravir|800 mg bd for 4 days
219417461|NCT03408548|PROCEDURE|Scaling root planning|Periodontal treatment
219417462|NCT03408548|DIETARY_SUPPLEMENT|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
219417463|NCT03408548|OTHER|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
219417464|NCT01804322|OTHER|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
219417465|NCT01804322|OTHER|usual care|usual care according to the participating Epilepsy Centers
219417466|NCT03734081|DEVICE|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
219417467|NCT03734081|DEVICE|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
219417468|NCT03294681|DEVICE|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
219572327|NCT06172413|DEVICE|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
219417469|NCT01553916|DRUG|Lithium Carbonate|
219417470|NCT01553916|RADIATION|Prophylactic cranial irradiation|
219417471|NCT02569619|BEHAVIORAL|Activity Intervention|
219417472|NCT02569619|BEHAVIORAL|Healthy Diet Intervention|
219004446|NCT00774319|RADIATION|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
219004447|NCT00774319|RADIATION|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
219004448|NCT01626560|DRUG|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
219417473|NCT04123717|DRUG|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
219417474|NCT06520319|DRUG|68Ga-MGS5|Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
219417475|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
219417476|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
219417477|NCT04626843|OTHER|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
219417478|NCT00583323|DRUG|Lomotil|Orally 10ml of Lomotil
219417479|NCT00583323|OTHER|Normal saline|10 ml orally
219417480|NCT06273306|DEVICE|IMIDOC|Patient´s Mobile App for recording clinical data
219417481|NCT01948388|DRUG|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
219417482|NCT01959737|PROCEDURE|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
219190789|NCT05427253|DRUG|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
219417483|NCT02260245|BEHAVIORAL|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
219417484|NCT01836887|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
219417485|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
219417486|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
219417487|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
219417488|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
219417489|NCT03089216|PROCEDURE|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
219417490|NCT03089216|PROCEDURE|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
219417491|NCT03089216|PROCEDURE|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
219417492|NCT03089216|PROCEDURE|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
219417493|NCT03089216|DRUG|8% arginine and calcium carbonate|using during all the treatment.
219417494|NCT03280641|DRUG|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
219417495|NCT03280641|DRUG|Warfarin Sodium|Target INR:1.6-3.0
219572328|NCT06172413|DEVICE|Sham tACS|Sham tACS
219572329|NCT04818749|DRUG|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
219004449|NCT01626560|DRUG|Vancomycin|Vancomycin 1g q12h 10 - 14 days
219190790|NCT05427253|DRUG|Placebo|Placebo for C106 solution
219004450|NCT02461563|DRUG|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
219004451|NCT02461563|DRUG|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
219004452|NCT02461563|DRUG|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
219004453|NCT01366560|DRUG|Active|GSK962040 125mg
219004454|NCT01366560|DRUG|Placebo|Matching Placebo
219004455|NCT00126841|PROCEDURE|CT and MR fusion|
219004456|NCT00332033|DRUG|Pirfenidone|
219004457|NCT05460117|DEVICE|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
219190791|NCT02240238|DRUG|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
219190792|NCT02240238|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
219190793|NCT03519178|DRUG|PF-06873600|PF-06873600 tablet for oral dosing
219190794|NCT03519178|DRUG|Endocrine Therapy 1|Endocrine Therapy 1
219417496|NCT05341505|BEHAVIORAL|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
219417497|NCT06080776|DRUG|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
219417498|NCT06080776|DRUG|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
219417499|NCT02263482|OTHER|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
219417500|NCT02263482|OTHER|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
219004458|NCT03852355|DRUG|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
219190795|NCT03519178|DRUG|Endocrine Therapy 2|Endocrine Therapy 2
219190796|NCT02315703|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
219417501|NCT02263482|OTHER|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
219572330|NCT04818749|DRUG|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
219572331|NCT04818749|DRUG|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
219572332|NCT00795808|DRUG|Metformin|500mg tds for 6 months
219004459|NCT03852355|DRUG|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
219190797|NCT02315703|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
219572333|NCT00795808|DRUG|Placebo|One tablet tds for 6 months
219004460|NCT05039645|BEHAVIORAL|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
219572334|NCT00795808|DRUG|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
219572335|NCT00795808|DRUG|Metformin|500mg tds for 6 months
219417502|NCT00001165|DRUG|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
219417503|NCT00417976|DRUG|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
219417504|NCT00417976|DRUG|Bevacizumab|10 mg/kg every 2 weeks.
219417505|NCT00417976|DRUG|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
219417506|NCT01022567|PROCEDURE|Appendicectomy|Standard appendicectomy
219417507|NCT01022567|DRUG|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
219417508|NCT04348591|BEHAVIORAL|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
219417509|NCT04348591|DEVICE|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
219417510|NCT00032968|DRUG|Buprenorphine/naloxone|
219417511|NCT00706667|DRUG|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
219417512|NCT05753280|DRUG|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
219417513|NCT04547894|DRUG|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
219417514|NCT00143260|DRUG|Viagra (Sildenafil Citrate) 100 mg|
219004461|NCT02749071|PROCEDURE|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
219004462|NCT02749071|DEVICE|EndoStim stimulation for first six months of study|Lower esophageal stimulation
219004463|NCT02749071|DEVICE|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
219004464|NCT02749071|DEVICE|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
219004465|NCT00260403|PROCEDURE|Photodynamic therapy versus Transpupillary thermotherapy|
219004466|NCT04412824|DRUG|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
219572336|NCT00795808|DRUG|Clomiphene|Ovulatory dose for 6 months
219572337|NCT06394726|BEHAVIORAL|Exercise İntervention|Aerobic and Core Stabilization Exercise Intervention
219572338|NCT04414839|DEVICE|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
219572339|NCT04414839|DEVICE|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
219004467|NCT03545165|DRUG|177Lu-PSMA-617|\[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\]
219004468|NCT03545165|DRUG|177Lu-J591|\[1.35 GBq/m2 or 36.5 mCi/m2\]
219004469|NCT03545165|DRUG|68Ga-PSMA-HBED-CC|\[185 ±74MBq or 5 ±2 mCi\]
219004470|NCT00869453|OTHER|test meal|Mixed meal containing bread, butter, beef
219004471|NCT00869453|OTHER|glucose|administration of a glucose meal
219004472|NCT00869453|OTHER|fat|administration of a lipid meal
219004473|NCT00869453|OTHER|protein|administration of a protein meal
219004474|NCT00869453|OTHER|control|no meal
219004475|NCT04173078|BEHAVIORAL|Computerized Distress Intolerance Intervention|
219004476|NCT04173078|BEHAVIORAL|Computerized Healthy Behaviors Intervention|
219004477|NCT02669732|DRUG|DS-8500a|tablets
219572340|NCT05506358|DIAGNOSTIC_TEST|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
219004478|NCT02669732|DRUG|placebo|tablets
219004479|NCT01694589|DRUG|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
219417515|NCT00991380|BEHAVIORAL|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
219417516|NCT00991380|BEHAVIORAL|Usual Care|Control
219417517|NCT04246580|PROCEDURE|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
219417518|NCT01003080|DEVICE|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
219417519|NCT01003080|OTHER|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
219417520|NCT02104804|DRUG|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
219417521|NCT02104804|DRUG|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
219417522|NCT03509272|DEVICE|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
219417523|NCT04482868|PROCEDURE|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
219417524|NCT01348425|DEVICE|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
219417525|NCT01348425|DEVICE|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
219572341|NCT05506358|DEVICE|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
219572342|NCT05506358|DIAGNOSTIC_TEST|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
219572343|NCT05506358|DEVICE|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
219572344|NCT05506358|DEVICE|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
219572345|NCT05506358|DEVICE|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
219572346|NCT01659736|DEVICE|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
219758328|NCT00551083|OTHER|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
219417526|NCT00603434|DRUG|OROS-MPH|18 mg bid on days 1 and 2
219417527|NCT00603434|DRUG|OROS-MPH|27mg bid on days 3 and 4
219417528|NCT00603434|DRUG|OROS-MPH|35 mg bid on days 5-9
219417529|NCT04793763|OTHER|traditional therapeutic exercises|group A will receive traditional exercises
219417530|NCT04793763|OTHER|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
219417531|NCT04793763|OTHER|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
219417532|NCT00354263|BIOLOGICAL|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
219417533|NCT00354263|BIOLOGICAL|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
219417534|NCT02720016|BEHAVIORAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
219572347|NCT00391079|DRUG|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
219572348|NCT00391079|DRUG|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
219572349|NCT02809170|DIETARY_SUPPLEMENT|Arginine|Arginine is an amino acids
219572350|NCT02809170|DIETARY_SUPPLEMENT|Citrulline|Citrulline is an amino acid
219758329|NCT05407701|DIETARY_SUPPLEMENT|Cranberry Juice|100% cranberry juice
219758330|NCT05407701|DIETARY_SUPPLEMENT|Placebo|Placebo juice
219758331|NCT00248924|BEHAVIORAL|Social Services|
219758332|NCT02999607|OTHER|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
219761740|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
219417535|NCT02720016|BEHAVIORAL|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
219417536|NCT02720016|BEHAVIORAL|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
219417537|NCT02038218|DRUG|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
219417538|NCT02049749|BEHAVIORAL|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
219417539|NCT02942849|DRUG|r-hFSH|As per standard clinical practice
219417540|NCT03740412|BEHAVIORAL|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
219417541|NCT00389103|BIOLOGICAL|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
219417542|NCT05890287|DRUG|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
219417543|NCT03282708|OTHER|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
219417544|NCT05444478|PROCEDURE|Microwave ablation|only microwave ablation for tumor
219417545|NCT05444478|DRUG|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
219417546|NCT00647868|DRUG|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
219417547|NCT04086069|DEVICE|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
219417548|NCT00067314|DRUG|Edotecarin|
219417549|NCT06082648|DEVICE|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
219417550|NCT06082648|DEVICE|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
219572351|NCT01004042|DRUG|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
219572352|NCT00338052|DRUG|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
219572353|NCT03165877|OTHER|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.
219572354|NCT03165877|OTHER|Control|Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
219758333|NCT05098314|OTHER|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
219761741|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
219761742|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
219004480|NCT05145530|PROCEDURE|selective anterior cervical discectomy and fusion (ACDF)|selective anterior cervical discectomy and fusion (ACDF)
219758334|NCT02785328|OTHER|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
219758335|NCT02785328|OTHER|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
219758336|NCT02785328|OTHER|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
219758337|NCT04501432|OTHER|No intervention|This study does not include an intervention
219758338|NCT02493764|DRUG|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
219758339|NCT02493764|DRUG|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
219758340|NCT02493764|DRUG|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
219758341|NCT02493764|DRUG|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
219758342|NCT02493764|DRUG|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
219758343|NCT02493764|DRUG|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
219758344|NCT00512564|OTHER|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
219758345|NCT00859833|DRUG|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
219758346|NCT00859833|DRUG|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
219758347|NCT04929964|PROCEDURE|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
219758348|NCT01307449|BIOLOGICAL|PNEUMOVAX|1 dose of PNEUMOVAX
219758349|NCT01307449|BIOLOGICAL|Prevnar|1 dose of Prevnar
219758350|NCT01561976|DRUG|Metformin hydrochloride prolonged release|1000mg in fasting state
219758351|NCT01561976|DRUG|metformin hydrochloride prolonged release|1000mg in fed state
219758352|NCT01561976|DRUG|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
219758353|NCT02468583|DRUG|FX006 32 mg|Experimental
219758354|NCT02468583|DRUG|TCA IR 40 mg|Comparator
219758355|NCT03218917|DRUG|Brensocatib 10 mg|Administered once per day for 24 weeks
219758356|NCT03218917|DRUG|Brensocatib 25 mg|Administered once per day for 24 weeks
219758357|NCT03218917|DRUG|Placebo|Administered once per day for 24 weeks
219758358|NCT00863161|DRUG|AZD3355|capsule, oral, single dose
219758359|NCT04528589|OTHER|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
219758360|NCT01507701|DRUG|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
219758361|NCT00427193|BEHAVIORAL|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
219758362|NCT00427193|BEHAVIORAL|Control|Participants continue their current diet for 24 months
219758363|NCT05508828|PROCEDURE|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
219758364|NCT06544915|DIETARY_SUPPLEMENT|Synbiotic, Probiotic, Placebo|Use of dietary supplements to improve gut microbiome and cardiometabolic health
219758365|NCT05136170|DRUG|Cenegermin|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
219758366|NCT05136170|OTHER|Vehicle|Vehicle was instilled with the same scheme of the test product
219758367|NCT01463527|DEVICE|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
219758368|NCT03420365|BEHAVIORAL|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
219758369|NCT05194150|DEVICE|non-diffractive monofocal IOL|Rayone EMV
219758370|NCT05194150|DEVICE|standard EDOF IOL|Acrysof IQ Vivity
219758371|NCT00748631|DEVICE|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
219758372|NCT00337038|DRUG|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
219758373|NCT06021808|PROCEDURE|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
219572355|NCT06341049|PROCEDURE|Intraperitoneal local anasthetic application + local anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
219572356|NCT06341049|PROCEDURE|Intrathecal morphine application|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
219572357|NCT06341049|PROCEDURE|Quadratus lumborum block tip 1 application|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
219572358|NCT00110006|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
219572359|NCT00110006|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
219572360|NCT00110006|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
219572361|NCT00110006|DRUG|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
219572362|NCT00110006|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
219572363|NCT00110006|PROCEDURE|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat \^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
219572364|NCT00110006|RADIATION|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV.
219572365|NCT00397306|DEVICE|Bioimpedance Analysis|
219572366|NCT04529447|OTHER|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
219572367|NCT01144728|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
219572368|NCT03301532|DRUG|Triheptanoin|Dietary supplementation with triheptanoin
219572369|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
219572370|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
219572371|NCT04463498|OTHER|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
219572372|NCT00006091|DRUG|arsenic trioxide|
219572373|NCT00002199|DRUG|Indinavir sulfate|
219572374|NCT00002199|DRUG|Lamivudine/Zidovudine|
219758374|NCT06021808|DRUG|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
219758375|NCT00051077|DRUG|Adefovir dipivoxil|
219572375|NCT00002199|DRUG|Abacavir sulfate|
219572376|NCT05051059|OTHER|Functional outcome|3D-motion analysis and strength assessment
219572377|NCT05051059|OTHER|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
219572378|NCT02751970|PROCEDURE|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
219572379|NCT02751970|PROCEDURE|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
219572380|NCT02751970|PROCEDURE|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
219572381|NCT02751970|PROCEDURE|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
219572382|NCT02751970|PROCEDURE|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
219572383|NCT00351598|RADIATION|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
219572384|NCT05160753|PROCEDURE|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
219572385|NCT03861793|BIOLOGICAL|ALKS 4230|SC injection administered in the back of the arm or the abdomen
219572386|NCT03861793|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
219572387|NCT00474851|DRUG|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
219758376|NCT00051077|DRUG|Peginterferon-alfa-2A|
219758377|NCT00051077|DRUG|Ribavirin|
219758378|NCT00051077|PROCEDURE|Liver Biopsy|
219572388|NCT00474851|DRUG|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
219572389|NCT01922167|DIETARY_SUPPLEMENT|Leucine|
219572390|NCT01922167|DIETARY_SUPPLEMENT|Alanine|
219572391|NCT02581163|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
219572392|NCT02581163|DRUG|Dasabuvir|Tablet
219572393|NCT02581163|DRUG|Ribavirin|Tablet
219417551|NCT01941524|DRUG|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
219417552|NCT01941524|DRUG|Beractant instillation|aEEG and NRs monitoring during beractant instillation
219417553|NCT05007249|PROCEDURE|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
219417554|NCT01390961|DRUG|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
219417555|NCT04593693|DEVICE|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
219417556|NCT05941351|PROCEDURE|flap fixation|flap fixation using running or interrupted sutures
219417557|NCT04123756|BEHAVIORAL|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
219417558|NCT03615911|BIOLOGICAL|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
219417559|NCT03455309|BIOLOGICAL|NDV-3A|Single dose administered by intramuscular injection
219417560|NCT03455309|BIOLOGICAL|Placebo|Single dose administered by intramuscular injection
219417561|NCT01287533|DRUG|Ibandronate|monthly dosage of ibandronate 150mg
219417562|NCT01287533|DRUG|Placebo|monthly dosage of placebo
219417563|NCT03832153|PROCEDURE|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
219417564|NCT02385877|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
219572394|NCT01370135|DRUG|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
219572395|NCT04689763|BEHAVIORAL|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
219761743|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 2 months
219417565|NCT02385877|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
219417566|NCT03374553|DEVICE|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
219417567|NCT03374553|DEVICE|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
219417568|NCT01337063|OTHER|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
219417569|NCT00644254|PROCEDURE|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
219417570|NCT03713931|DIAGNOSTIC_TEST|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
219761744|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
219761745|NCT03963518|DRUG|nivolumab monotherapy|nivolumab monotherapy
219761746|NCT03963518|DRUG|nivolumab plus ipilimumab|nivolumab plus ipilimumab
219761747|NCT06108544|DRUG|TAK-279|Specified drug on specified days.
219761748|NCT06108544|DRUG|Placebo|Specified drug on specified days.
219761749|NCT06108544|DRUG|Apremilast|Specified drug on specified days.
219417571|NCT03411265|OTHER|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
219417572|NCT01968954|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
219004481|NCT05145530|PROCEDURE|SNRB+ selective anterior cervical discectomy and fusion (ACDF)|US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
219004482|NCT00967772|DRUG|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
219004483|NCT03455920|OTHER|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
219004484|NCT03455920|OTHER|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
219004485|NCT01929434|OTHER|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
219004486|NCT01929434|BIOLOGICAL|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
219417573|NCT01968954|OTHER|Placebo|subcutaneous injection, every 2 weeks for 12 months
219417574|NCT04202653|DRUG|ETV|entecavir 0.5 mg qd
219417575|NCT04202653|DRUG|TQ-A3334|TQ-A3334 po qw
219417576|NCT04202653|DRUG|TQ-B2450|TQ-B2450 q3w iv
219417577|NCT03939351|DIAGNOSTIC_TEST|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
219417578|NCT03518814|OTHER|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
219004487|NCT02727023|OTHER|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
219190798|NCT02315703|BIOLOGICAL|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
219417579|NCT05350566|DIETARY_SUPPLEMENT|Olive leaf extract|A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water before exercise.
219417580|NCT05350566|DIETARY_SUPPLEMENT|Placebo|A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water before exercise.
219417581|NCT00751114|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
219417582|NCT00751114|DRUG|Sitagliptin|Oral administration. 100 mg film-coated tablets.
219417583|NCT00751114|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
219417584|NCT03825094|DEVICE|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
219417585|NCT02476591|BEHAVIORAL|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
219417586|NCT05491694|DRUG|Toripalimab|Toripalimab 240mg
219417587|NCT05491694|DRUG|Epirubicin|90mg/m2，IVD，q3w
219417588|NCT05491694|PROCEDURE|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
219417589|NCT05491694|DRUG|Cyclophosphamide|600mg/m2，IVD，q3w
219417590|NCT05491694|DRUG|Carboplatin|AUC 5，IVD，q3w
219572396|NCT01563419|DEVICE|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
219572397|NCT02629913|DEVICE|mementor somnium|
219572398|NCT02629913|OTHER|wait list|delayed access to mementor somnium
219417591|NCT05491694|DRUG|Nab-paclitaxel|260mg/m2，IVD，q3w
219572399|NCT02341950|BEHAVIORAL|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
219572400|NCT02791893|DEVICE|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
219572401|NCT02791893|DEVICE|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
219572402|NCT04553861|DEVICE|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
219572403|NCT04553861|DEVICE|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
219758379|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
219417592|NCT00465491|DRUG|picoplatin|IV picoplatin 150mg/m2 q3wk
219417593|NCT00465491|OTHER|best supportive care|best supportive care
219417594|NCT05360420|DIAGNOSTIC_TEST|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
219417595|NCT00239486|DRUG|Pramipexole|
219417596|NCT05319080|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
219758380|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
219758381|NCT00005590|DRUG|levofloxacin|
219758382|NCT02129712|BEHAVIORAL|Cognitive training|
219758383|NCT03593174|DEVICE|Ossur Rigid Dressing|Removable Rigid Dressing
219758384|NCT03593174|DEVICE|Elastic Bandage|Usual modality: Elastic bandage
219758385|NCT01119287|DRUG|Dexamethasone 0.1% ophthalmic suspension|Maxidex
219758386|NCT01119287|DRUG|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
219758387|NCT01119287|OTHER|Inactive ingredients, used as placebo|Tears Naturale II
219758388|NCT04086355|OTHER|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
219758389|NCT00689806|DRUG|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
219758390|NCT00689806|DRUG|Placebo|Placebo by mouth once daily for weeks 1-4.
219758391|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
219758392|NCT03612024|BEHAVIORAL|questionnaire|a standardized questionnaire was sent to all participants
219758393|NCT05203380|DRUG|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
219758394|NCT04851574|DRUG|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
219758395|NCT00041028|DRUG|EF5|
219758396|NCT00041028|OTHER|flow cytometry|
219758397|NCT00041028|OTHER|immunohistochemistry staining method|
219758398|NCT00383071|BIOLOGICAL|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
219758399|NCT00383071|PROCEDURE|Apheresis|Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
219758400|NCT04795375|BEHAVIORAL|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
219758401|NCT06084351|DRUG|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
219758402|NCT06084351|OTHER|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
219758403|NCT03240107|PROCEDURE|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
219758404|NCT03240107|PROCEDURE|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
219004488|NCT03856164|DRUG|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
219004489|NCT03856164|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
219004490|NCT01453114|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
219417597|NCT03569865|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
219417598|NCT01571648|DRUG|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
219417599|NCT00292448|DRUG|Ba 679 BR Respimat|
219417600|NCT00292448|DRUG|Tiotropium (Spiriva) inhalation capsule 18 ug|
219417601|NCT04212286|DIAGNOSTIC_TEST|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
219417602|NCT01755468|DRUG|Intermittent insulin therapy|
219417603|NCT01755468|DRUG|Continuous metformin|
219004491|NCT05520944|DRUG|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
219004492|NCT04181502|PROCEDURE|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
219004493|NCT04181502|OTHER|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
219004494|NCT01230905|RADIATION|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
219417604|NCT01423773|DEVICE|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
219417605|NCT01423773|DEVICE|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
219417606|NCT01423773|DEVICE|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
219417607|NCT04465396|DRUG|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
219417608|NCT04465396|DEVICE|Syringe Injection|Teduglutide was administered using syringe.
219417609|NCT04465396|DEVICE|Pen injector|Teduglutide was administered using pen injector.
219417610|NCT00747396|OTHER|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
219004495|NCT00226161|PROCEDURE|Inguinal herniorrhaphy|
219004496|NCT05769439|OTHER|No intervention in an observational study|This study is an observational study only.
219417611|NCT02648724|DRUG|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
219004497|NCT05252117|DRUG|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
219417612|NCT00042484|PROCEDURE|Community-level intervention & policy change|
219417613|NCT00547638|DEVICE|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
219417614|NCT00547638|DEVICE|cyanoacrylate|Topical Skin Adhesive
219417615|NCT01378936|BEHAVIORAL|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
219417616|NCT01378936|BEHAVIORAL|Motivational Interview only|45 minute Motivational Interview session
219417617|NCT01665521|OTHER|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
219417618|NCT01642836|BEHAVIORAL|MMM|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
219417619|NCT01642836|BEHAVIORAL|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
219572404|NCT03161548|DRUG|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
219572405|NCT03161548|PROCEDURE|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
219572406|NCT03161548|RADIATION|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
219572407|NCT01953822|OTHER|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
219572408|NCT03858166|DRUG|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
219572409|NCT03438396|DRUG|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
219572410|NCT02806258|RADIATION|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
219572411|NCT02806258|DRUG|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
219572412|NCT01509742|DRUG|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
219572413|NCT01509742|DRUG|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
219572414|NCT06073535|PROCEDURE|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
219572415|NCT06073535|DEVICE|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
219572416|NCT03286478|BEHAVIORAL|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
219572417|NCT03286478|BEHAVIORAL|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
219572418|NCT03286478|BEHAVIORAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
219758405|NCT05321329|DRUG|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
219758406|NCT03027674|DRUG|10% nifedipine cream|Topical treatment for Raynaud
219417620|NCT02461836|DRUG|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
219417621|NCT02461836|RADIATION|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
219758407|NCT03027674|DRUG|5% sildenafil cream|Topical treatment for Raynaud
219758408|NCT04403919|DEVICE|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
219004498|NCT05252117|DRUG|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
219004499|NCT04541550|DRUG|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
219004500|NCT04541550|DRUG|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
219004501|NCT04541550|DRUG|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
219190799|NCT02315703|BIOLOGICAL|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
219417622|NCT03076190|BEHAVIORAL|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
219417623|NCT00434122|DRUG|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
219417624|NCT00434122|DRUG|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
219417625|NCT00881855|DRUG|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
219417626|NCT00881855|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
219758409|NCT04403919|DEVICE|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
219758410|NCT04403919|DEVICE|Conventional Closure: Hip|"1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson)."
219758411|NCT04403919|DEVICE|Barbed suture closure: Hip|"1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson)."
219758412|NCT03630146|BEHAVIORAL|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
219758413|NCT03630146|OTHER|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
219758414|NCT06303427|OTHER|Modified constraint-induced movement therapy|"The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver."
219758415|NCT06303427|OTHER|Electrical stimulation|The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
219758416|NCT03109405|DEVICE|Stimulation-assisted venous access|Stimulation-assisted venous access
219758417|NCT03109405|OTHER|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
219758418|NCT03243773|OTHER|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
219758419|NCT00579644|DRUG|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
219758420|NCT00579644|DRUG|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
219758421|NCT00000389|DRUG|Fluvoxamine|
219758422|NCT01612676|DRUG|FE 202158|
219004502|NCT02695498|OTHER|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
219004503|NCT02695498|OTHER|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
219004504|NCT04717115|GENETIC|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
219004505|NCT05070598|DRUG|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
219004506|NCT03791840|DIAGNOSTIC_TEST|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
219004507|NCT01214811|DEVICE|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
219004508|NCT05279443|OTHER|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
219004509|NCT06505369|DRUG|Daratumumab|Daratumumab will be administered by SC injection
219004510|NCT06505369|DRUG|Bortezomib|Bortezomib will be administered by SC injection
219004511|NCT06505369|DRUG|Lenalidomide|Lenalidomide will be administered by oral route
219004512|NCT06505369|DRUG|Dexamethasone|Dexamethasone will be administered by oral route
219004513|NCT06505369|DRUG|Talquetamab|Talquetamab will be administered by SC injection
219004514|NCT06505369|DRUG|Teclistamab|Teclistamab will be administered by SC injection
219004515|NCT00222794|DRUG|Atomoxetine (Strattera)|
219004516|NCT02312661|DRUG|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
219572419|NCT05181332|OTHER|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
219758423|NCT03923868|DRUG|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
219758424|NCT02743741|DRUG|Lutetium-177 Octreotate|Radiopharmaceutical
219758425|NCT04319809|DEVICE|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
219758426|NCT01156844|DRUG|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
219758427|NCT01156844|DRUG|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
219758428|NCT04831671|OTHER|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
219758429|NCT04831671|OTHER|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
219758430|NCT05064722|DEVICE|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
219758431|NCT06446583|OTHER|Chewing sugar-free gum|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
219758432|NCT03264144|BEHAVIORAL|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
219758433|NCT03679104|PROCEDURE|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
219758434|NCT03679104|PROCEDURE|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
219758435|NCT05214352|OTHER|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
219572420|NCT03483207|DRUG|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
219417627|NCT04474119|DRUG|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
219417628|NCT04474119|DRUG|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
219572421|NCT03483207|PROCEDURE|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
219758436|NCT03147183|DRUG|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
219758437|NCT03231553|OTHER|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
219758438|NCT05859113|DEVICE|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
219758439|NCT05859113|DEVICE|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
219004517|NCT02312661|DRUG|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
219004518|NCT02312661|DRUG|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
219004519|NCT02268604|DRUG|BIIB 722 CL|
219004520|NCT02268604|DRUG|Placebo|
219190800|NCT02315703|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
219417629|NCT01288508|DIETARY_SUPPLEMENT|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
219417630|NCT01288508|DIETARY_SUPPLEMENT|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
219417631|NCT03911336|DRUG|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
219417632|NCT03911336|DRUG|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
219417633|NCT03911336|DRUG|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
219758440|NCT04824833|PROCEDURE|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
219758441|NCT05124730|DRUG|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
219758442|NCT05124730|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
219758443|NCT01726764|OTHER|St John's Wort|
219758444|NCT01726764|DRUG|Metformin|
219758445|NCT00024934|DRUG|B-Lymphocyte Stimulator (BLyS)|
219758446|NCT05697718|BIOLOGICAL|MSC|a single injection dose i.v.
219758447|NCT02249078|DRUG|E6011|E6011 solution for injection
219758448|NCT02249078|DRUG|Placebo|Placebo 2-mL vial solution for injection
219758449|NCT01204788|PROCEDURE|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
219758450|NCT01204788|PROCEDURE|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
219758451|NCT05525962|BEHAVIORAL|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~* M0: cognitive test, psychiatric classification and psychologic assessments~* M12 and M24: psychiatric classification and psychologic assessments"
219758452|NCT03892317|BEHAVIORAL|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
219417634|NCT06359743|PROCEDURE|Quadratus Lamborum versus superior hypogatric|Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
219417635|NCT04070170|DEVICE|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
219758453|NCT05880147|DEVICE|Consent App|Family will receive their study information and consent form in an app on a tablet
219758454|NCT05880147|OTHER|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
219758455|NCT02049411|DRUG|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
219758456|NCT02049411|DRUG|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
219758457|NCT05361174|BIOLOGICAL|IOV-4001|A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
219758458|NCT06186232|PROCEDURE|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
219004521|NCT04913402|OTHER|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
219417636|NCT04070170|PROCEDURE|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
219417637|NCT01336556|PROCEDURE|Oral appliance|Anterior mandibular repositioner: used for two months
219417638|NCT03594487|DRUG|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
219417639|NCT03594487|PROCEDURE|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
219417640|NCT03594487|OTHER|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
219417641|NCT05982223|PROCEDURE|Acupuncture|The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219758459|NCT06163287|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen
219758460|NCT06163287|DIETARY_SUPPLEMENT|Placebo|Inert substance
219758461|NCT04972851|BEHAVIORAL|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan"
219758462|NCT03325504|BIOLOGICAL|Cultured Mesenchymal Stem Cells|Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
219758463|NCT03325504|PROCEDURE|Autologous iliac crest graft|Autologous iliac crest grafting
219758464|NCT03352765|DRUG|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
219758465|NCT03352765|DRUG|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
219758466|NCT03352765|DRUG|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
219417642|NCT05982223|PROCEDURE|Mind-body therapy|The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219417643|NCT05982223|PROCEDURE|Touch therapy|The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219417644|NCT05982223|PROCEDURE|Movement therapy|The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219417645|NCT05982223|DIETARY_SUPPLEMENT|Herbal supplements|The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219417646|NCT05982223|BEHAVIORAL|Emotional treatment|The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
219417647|NCT06600178|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10mg oral
219417648|NCT06600178|DRUG|Placebo|Placebo tablet given to subject vs. active drug.
219417649|NCT00497016|DRUG|atorvastatin 80 mg|
219417650|NCT02675153|DRUG|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
219417651|NCT04191577|DRUG|CVN424 Low Dose|CVN424
219417652|NCT04191577|DRUG|CVN424 High Dose|CVN424
219417653|NCT04191577|DRUG|Placebo|Placebo
219417654|NCT03488121|BEHAVIORAL|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
219417655|NCT03488121|BEHAVIORAL|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
219417656|NCT01185249|PROCEDURE|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
219417657|NCT05896618|DEVICE|TPA|1\. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
219417658|NCT05896618|DEVICE|Nance appliance|2\. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
219417659|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
219572422|NCT03483207|DRUG|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
219572423|NCT05589961|DRUG|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
219758467|NCT03352765|PROCEDURE|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
219758468|NCT04401462|PROCEDURE|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
219758469|NCT04401462|BEHAVIORAL|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
219758470|NCT06638476|OTHER|Perturbation Induced Step training|A sudden lateral displacement of the treadmill.
219417660|NCT00634959|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
219417661|NCT00634959|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
219417662|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
219417663|NCT00634959|OTHER|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
219417664|NCT05518175|DEVICE|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
219417665|NCT05518175|DEVICE|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
219417666|NCT05518175|DEVICE|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
219417667|NCT00332800|DRUG|Nutritional Supplementation|
219417668|NCT04452227|OTHER|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
219417669|NCT01471704|DRUG|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
219417670|NCT01471704|DRUG|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
219758471|NCT06638476|OTHER|Voluntary step training|Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
219572424|NCT04936828|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
219572425|NCT03982563|BEHAVIORAL|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
219758472|NCT06642727|BEHAVIORAL|laughter yoga|Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
219758473|NCT04299984|PROCEDURE|Open Conversion after EVAR|"See Open Conversions group description."
219758474|NCT04299984|PROCEDURE|SemiConversion after EVAR|"See SemiConversions group description."
219758475|NCT06644820|DIAGNOSTIC_TEST|radiology|"Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules."
219572426|NCT03982563|BEHAVIORAL|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
219572427|NCT03982563|BEHAVIORAL|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
219572428|NCT03982563|BEHAVIORAL|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
219572429|NCT03893474|DIAGNOSTIC_TEST|OCT|Optical Coherence Tomography of study eye.
219572430|NCT03893474|DIAGNOSTIC_TEST|Visual Acuity|Visual acuity measured by ETDRS
219417671|NCT01471704|DRUG|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
219572431|NCT06224166|DIAGNOSTIC_TEST|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
219572432|NCT00002922|DRUG|paclitaxel|
219572433|NCT05810558|PROCEDURE|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
219572434|NCT05810558|PROCEDURE|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
219572435|NCT01618136|DRUG|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
219572436|NCT01618136|DRUG|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
219572437|NCT01618136|DRUG|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
219572438|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
219572439|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
219572440|NCT00262041|BIOLOGICAL|MenACWY polysaccharide vaccine|
219572441|NCT01098864|DEVICE|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
219758476|NCT01136369|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
219758477|NCT03501628|DIETARY_SUPPLEMENT|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
219758478|NCT03501628|DIETARY_SUPPLEMENT|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
219758479|NCT03501628|DIETARY_SUPPLEMENT|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
219758480|NCT03501628|DIETARY_SUPPLEMENT|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
219758481|NCT03501628|DIETARY_SUPPLEMENT|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
219758482|NCT01503320|DIETARY_SUPPLEMENT|Enteral glutamine|Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
219417672|NCT00422409|PROCEDURE|Endoscopic stenting|
219417673|NCT04363437|DRUG|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
219417674|NCT04363437|DRUG|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
219417675|NCT00406783|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
219417676|NCT00406783|DRUG|Placebo|Placebo tablet, once daily for 15 days
219417677|NCT02787330|BEHAVIORAL|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
219417678|NCT02787330|BEHAVIORAL|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
219417679|NCT00808730|PROCEDURE|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
219758483|NCT01503320|DIETARY_SUPPLEMENT|Placebo|Similar appearing nutritional supplement without glutamine.
219417680|NCT00012012|DRUG|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
219417681|NCT00012012|DRUG|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
219417682|NCT00012012|RADIATION|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
219417683|NCT00012012|RADIATION|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
219417684|NCT03069846|DEVICE|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
219190801|NCT04901078|DRUG|KNX100|KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
219190802|NCT05496036|DRUG|Pembrolizumab|400mg IV
219190803|NCT02932176|DEVICE|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
219190804|NCT02932176|DEVICE|machine-learning algorithm|
219417685|NCT04785391|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
219417686|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
219417687|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
219417688|NCT01391819|OTHER|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
219417689|NCT01391819|PROCEDURE|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
219417690|NCT00001251|DRUG|Mafosfamide|
219417691|NCT00050791|DRUG|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
219417692|NCT00050791|BEHAVIORAL|Very Low Calorie Diet|placebo injections
219417693|NCT00691262|DRUG|tacrolimus ointment|transdermal
219417694|NCT01522040|DRUG|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
219417695|NCT01522040|DRUG|Placebo|Simple saline drip, without active drug
219417696|NCT01890070|DIETARY_SUPPLEMENT|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
219417697|NCT01890070|DIETARY_SUPPLEMENT|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
219417698|NCT01890070|DIETARY_SUPPLEMENT|Red wine|Italian Organic Red Wine
219417699|NCT01890070|DIETARY_SUPPLEMENT|Olive Oil|Italian Organic Olive Oil
219417700|NCT01890070|DIETARY_SUPPLEMENT|Wild mixed greens|Italian organic wild mixed greens
219417701|NCT01890070|DIETARY_SUPPLEMENT|Chestnut|Italian Organic Chestnut
219417702|NCT01890070|OTHER|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
219417703|NCT04475822|BEHAVIORAL|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
219417704|NCT04475822|BEHAVIORAL|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
219417705|NCT04475822|BEHAVIORAL|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
219417706|NCT04291872|OTHER|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
219417707|NCT04914741|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
219417708|NCT04914741|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
219417709|NCT04914741|DRUG|Doxorubicin|Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
219417710|NCT04914741|DRUG|Vincristine|Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
219417711|NCT04914741|DRUG|Prednisolone|Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
219758484|NCT02341066|DEVICE|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
219758485|NCT02117102|OTHER|Bladder and lumbar stimulation technic|
219758486|NCT02832570|DRUG|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
219417712|NCT04914741|DRUG|Glofitamab|Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
219417713|NCT04914741|DRUG|Polatuzumab vedotin|Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
219417714|NCT04597619|OTHER|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
219417715|NCT04015414|DRUG|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
219417716|NCT04015414|DRUG|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
219417717|NCT03172858|DEVICE|Intracervical balloon catheter|cervical ripening balloon
219417718|NCT03172858|DRUG|Oxytocin|medication used to induce contractions
219758487|NCT02832570|DRUG|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
219758488|NCT04306328|DEVICE|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
219758489|NCT01946334|DEVICE|anorectal manometry and high-resolution three-dimensional|
219761750|NCT05456295|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
219572442|NCT05484843|BEHAVIORAL|telenursing training based on self-care theory|"* A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~* Identification of the study/control group (randomization)~* Patients were informed and consents were obtained.~* Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~* All patients included in the sample group were pre-tested before discharge.~* Training was offered for the study group patients in line with the guide prepared based on self-care theory.~* Tele-nursing training was applied to the study group patients.~* Control group patients were followed up~* Post-tests were administered at the end of the 12-week period~* The training of the control group patients was completed~* Your data has been evaluated"
219417719|NCT04359082|DIETARY_SUPPLEMENT|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
219417720|NCT04359082|OTHER|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
219417721|NCT01290120|DRUG|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
219417722|NCT02633995|PROCEDURE|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
219417723|NCT01388582|DEVICE|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
219417724|NCT01388582|DEVICE|Implanon|60 mcg/day contraceptive implant
219417725|NCT01388582|DRUG|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
219417726|NCT01388582|DEVICE|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
219417727|NCT01388582|DEVICE|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
219417728|NCT06434103|DRUG|SHR-A1921；Adebrelimab；SHR-8068；carboplatin|SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
219572443|NCT05484843|BEHAVIORAL|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
219572444|NCT05633108|OTHER|No Intervention|No intervention will be administered.
219572445|NCT01421342|DRUG|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
219572446|NCT01421342|DRUG|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
219572447|NCT01421342|DRUG|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
219417729|NCT04152005|OTHER|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
219572448|NCT06457399|DRUG|Heliox|Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
219417730|NCT00920595|DRUG|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
219572449|NCT06457399|DRUG|Oxygen|Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
219417731|NCT05522712|DEVICE|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
219417732|NCT05522712|DEVICE|Incentive spirometer user|"1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets."
219572450|NCT05484453|DIAGNOSTIC_TEST|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
219572451|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
219572452|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
219572453|NCT04214925|OTHER|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
219572454|NCT00273481|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
219758490|NCT04152239|PROCEDURE|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
219758491|NCT06241300|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
219417733|NCT05522712|PROCEDURE|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
219572455|NCT00273481|DRUG|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
219572456|NCT00273481|DRUG|timolol maleate 0.5%|
219004522|NCT04913402|OTHER|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
219190805|NCT06244654|DEVICE|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones|After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
219572457|NCT00273481|DRUG|placebo|
219572458|NCT02831218|PROCEDURE|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
219572459|NCT02831218|PROCEDURE|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
219572460|NCT02831218|PROCEDURE|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
219572461|NCT02831218|PROCEDURE|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
219572462|NCT03702361|DRUG|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
219758492|NCT00476645|DRUG|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
219758493|NCT05944692|DEVICE|Tripolar electroencephalography|We will record physiological signals with the tripolar electroencephalography
219758494|NCT01448616|DRUG|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
219761751|NCT06308588|DRUG|Blinatumomab|Given by Infusion
219761752|NCT06308588|DRUG|Asciminib|Given by PO
219761753|NCT06140836|DRUG|Repotrectinib|Specified dose on specified days
219761754|NCT06140836|DRUG|Crizotinib|Specified dose on specified days
219761755|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
219417734|NCT03577912|PROCEDURE|TAP block administered by Surgery|TAP block administered by Surgery
219417735|NCT03577912|PROCEDURE|TAP block administered by Anesthesia|TAP block administered by Anesthesia
219761756|NCT06157879|DEVICE|WVI-MIS-01-2022|Microwave scans
219761757|NCT06161441|DRUG|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
219761758|NCT06161441|DRUG|Cemiplimab|Administered IV Q3W
219761759|NCT06161441|DRUG|Pemetrexed|Administered IV Q3W
219761760|NCT06161441|DRUG|Paclitaxel|Administered IV Q3W
219761761|NCT06161441|DRUG|Carboplatin|Administered IV Q3W
219761762|NCT06161441|DRUG|Cisplatin|Administered IV Q3W
219004523|NCT02003820|BEHAVIORAL|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
219004524|NCT02063360|DRUG|BMS-663068|BMS-663068
219417736|NCT06692387|BEHAVIORAL|Step count increase with the use of a motivational application|The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
219417737|NCT01208038|DRUG|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
219417738|NCT06692478|BEHAVIORAL|Exercise regimen|"Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups."
219417739|NCT06693791|DRUG|Romiplostim N01|Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
219417740|NCT02300077|DRUG|methadone|Escalating dose of methadone up to .3mg/kg.
219417741|NCT02300077|DRUG|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
219417742|NCT05824637|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
219417743|NCT05824637|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
219417744|NCT02304315|BIOLOGICAL|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
219417745|NCT02304315|BIOLOGICAL|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
219417746|NCT05998954|PROCEDURE|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
219572463|NCT06205017|DIETARY_SUPPLEMENT|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
219572464|NCT02384941|DRUG|Placebo|Placebo once daily, before first meal of the day.
219004525|NCT02063360|DRUG|Darunavir (DRV)|Darunavir (DRV)
219417747|NCT05998954|PROCEDURE|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
219417748|NCT06712511|OTHER|Caffeine content|Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.
219417749|NCT00486538|DRUG|ABT-869|One oral dose daily.
219572465|NCT02384941|DRUG|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
219572466|NCT00124995|DRUG|terbutaline|
219572467|NCT02107820|BEHAVIORAL|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
219761763|NCT06161441|DRUG|Placebo|Administered IV Q3W
219417750|NCT04250740|OTHER|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
219417751|NCT04250740|OTHER|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
219417752|NCT04250740|OTHER|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
219417753|NCT05669534|BEHAVIORAL|community-friendly health recovery program|Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
219417754|NCT05669534|DRUG|Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis|Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
219417755|NCT06888843|DRUG|Capecitabine|Capecitabine 2000mg/m2 from day 1 to 14
219417756|NCT06888843|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on day 1, cycle of 21 days
219417757|NCT06795399|DRUG|OPC-131461|OPC-131461 will be administered as oral tablets.
219761764|NCT06569368|DRUG|Metronidazole|Given by PO
219761765|NCT06405633|DRUG|WVE-006|RNA editing oligonucleotide
219761766|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
219761767|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
219761768|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
219761769|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
219761770|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered Intravenously over 60 minutes (weekly)
219761771|NCT02867384|DRUG|Obinutuzumab|B cell depletion
219761772|NCT02867384|DRUG|Placebo|Placebo
219761773|NCT05414994|OTHER|Eye swab|This is a simple swab under the eyelids of both eyes
219004526|NCT02063360|DRUG|Ritonavir (RTV)|Ritonavir (RTV)
219004527|NCT02063360|DRUG|Etravirine (ETR)|Etravirine (ETR)
219004528|NCT05602181|BEHAVIORAL|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
219417758|NCT06795399|DRUG|Placebo|OPC-131461 matched placebo will be administered as oral tablets.
219417759|NCT01966575|DRUG|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
219417760|NCT00002057|DRUG|Nystatin|
219417761|NCT02170805|DRUG|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
219417762|NCT02170805|DRUG|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
219417763|NCT02170805|DRUG|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
219417764|NCT02170805|DRUG|Pantoprazole|Pantoprazole 40 mg
219417765|NCT03260205|DRUG|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
219417766|NCT03260205|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
219417767|NCT03260205|DRUG|SPD489|SPD489
219417768|NCT01743963|BEHAVIORAL|Decision support|Clinical pharmacists mediated computerized decision support
219417769|NCT01743963|BEHAVIORAL|Usual Care|clinicians typical apporach for GID monitering
219417770|NCT06898086|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation using the CE-certified Myval™ transcatheter heart valve series
219417771|NCT06897995|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participants in the exercise groups were trained five times a week for six weeks. The regimen began with a 5-min warm-up and ended with a 5-min cool-down, both at 40% of heart rate reserved (HRR). The circuit training participants were trained for three bouts of 10-min moderate-intensity exercise (60% of HRR) with 1-min rest intervals at a stationary ergometer, a rowing machine, and an elliptical trainer, respectively. The cycling training group was trained on an ergometer for three bouts of 10-min cycling on a stationary ergometer.
219417772|NCT06897917|DRUG|Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets|"1. Calculate the total opioid dosage administered to the patient in the previous 24 hours and convert it to an equivalent dose of oxycodone/naloxone sustained-release tablets(Mimeixin).~2. Based on the principle of incremental dosing, calculate the total dosage to be administered on the day of enrollment, divide it into two portions, and administer one portion every 12 hours (q12h).~3. In case of breakthrough pain during treatment, administer an equivalent dose of immediate-release morphine or other medications equivalent to 10%-20% of the 24-hour background dosing for relief.~4. If the number of breakthrough pain events exceeds 2 in a day after dosing, adjust the dosage again based on the incremental dosing principle. Adjustments should be made every 1-2 days, with each adjustment increasing the dose by a gradient of 5 mg/2.5 mg or 10 mg/5 mg of oxycodone/naloxone sustained-release tablets, twice daily, and so on. The maximum daily dose of oxycodone should not exceed 160 mg."
219417773|NCT06898164|OTHER|This study does not involve any interventions|This study does not involve any interventions
219417774|NCT01345097|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty
219758495|NCT01448616|DRUG|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
219004529|NCT05602181|BEHAVIORAL|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
219004530|NCT06374641|DIETARY_SUPPLEMENT|Mitochondrial Substrate Supplement|Mitochondrial Substrate supplement, 2xdaily 65 mL drink
219417775|NCT06897553|BEHAVIORAL|ACT-based group therapy|"ACT-based group therapy based on the manual Living Well with Neurological Conditions published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members."
219417776|NCT01369316|PROCEDURE|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
219417777|NCT01369316|PROCEDURE|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
219417778|NCT06755125|OTHER|Kinesio Taping|Patients in Group A was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with kinesio taping. Kinesio tape was applied directly to the muscle with 50% stretching.During the treatment, kinesio tape will be applied to the patients twice a week, eight times in total.
219417779|NCT06755125|OTHER|Dry Needling|Patients in Group B was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with dry needling.During the treatment, dry needling was applied to the patients twice a week, eight times in total.
219417780|NCT06898723|DRUG|Shenfu Injection|The treatment will utilize Ginseng and Aconite Injection, which primarily consists of Red Ginseng and Aconite
219417781|NCT06898645|DEVICE|navigated iTBS (Intermittent theta-burst stimulation) targeting the cerebellum|1,800 pulses per session for unilateral cerebellum, 50-minute intersession interval, 80% resting motor threshold, total 75600 pulse number.
219572468|NCT02107820|DEVICE|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
219572469|NCT03716635|PROCEDURE|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
219572470|NCT03716635|PROCEDURE|normal saline|a room temperature saline is used as a final flush after mechanical preparation
219572471|NCT05040308|OTHER|Integrating PrEP delivery|Integration of PrEP delivery services in NSP and MAT programs
219572472|NCT00971737|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
219004531|NCT06374641|DIETARY_SUPPLEMENT|Placebo Supplement|Placebo supplement, 2xdaily 65 mL drink
219417782|NCT05902754|DIETARY_SUPPLEMENT|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
219572473|NCT00971737|BIOLOGICAL|trastuzumab|Given IV
219572474|NCT00971737|DRUG|cyclophosphamide|Given IV
219417783|NCT05902754|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
219572475|NCT06027138|OTHER|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
219417784|NCT06346028|DEVICE|Brainsway H4 deep rTMS coil and Brainsway stimulator system|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC."
219417785|NCT05022771|DRUG|PMG1015 Dose 1|Dose level 1 of PMG1015
219417786|NCT05022771|DRUG|PMG1015 Dose 2|Dose level 2 of PMG1015
219417787|NCT05022771|DRUG|PMG1015 Dose 3|Dose level 3 of PMG1015
219190806|NCT06244654|OTHER|No VR|After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
219417788|NCT05022771|DRUG|PMG1015 Dose 4|Dose level 4 of PMG1015
219417789|NCT05022771|DRUG|PMG1015 Dose 5|Dose level 5 of PMG1015
219190807|NCT05586061|DRUG|Disitamab vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
219190808|NCT05586061|DRUG|Tislelizumab|Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
219190809|NCT05586061|DRUG|S1|S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
219190810|NCT04073498|DRUG|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
219417790|NCT05022771|DRUG|PMG1015 Dose 6|Dose level 6 of PMG1015
219417791|NCT05022771|DRUG|Placebo|Placebo to match
219417792|NCT05022771|DRUG|PMG1015 Dose 7|Dose level 7 of PMG1015
219758496|NCT01448616|DRUG|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
219758497|NCT01448616|DRUG|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
219758498|NCT05486767|DIAGNOSTIC_TEST|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
219004532|NCT01596868|DRUG|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
219004533|NCT01596868|DRUG|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
219417793|NCT00657631|BEHAVIORAL|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999)."
219417794|NCT00088803|GENETIC|molecular genetic technique|
219417795|NCT00088803|GENETIC|polymerase chain reaction|
219417796|NCT00088803|GENETIC|polymorphism analysis|
219417797|NCT06899334|DRUG|LSD|A moderate to high oral dose of 150 µg LSD will be administered followed by 20 mg intravenous ketanserin after 3 h
219417798|NCT06899334|DRUG|Psilocybin|A moderate to high oral dose of 30 mg psilocybin will be administered followed by 20 mg intravenous ketanserin after 3 h
219417799|NCT06899334|DRUG|DMT|A moderate to high, dose-escalating, intravenous infusion up to 2 mg/min DMT will be administered followed by 20 mg intravenous ketanserin after 3 h
219417800|NCT06899334|DRUG|Placebo|An oral and an intravenous placebo will be administered followed by 20 mg intravenous ketanserin after 3 h
219417801|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
219417802|NCT02763904|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
219417803|NCT02763904|OTHER|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
219417804|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
219417805|NCT06381414|BEHAVIORAL|Observation|"Identify the prevalence of early wear in primary dentition, using Childhood Early Oral Aging Syndrome (CEOAS) index.~The CEOAS index involves scores of 0 to 3 for the assessment of tooth wear and dental management, whereas scores of I, II and III are used concomitantly in cases of the presence of enamel defects."
219417806|NCT06068361|DIAGNOSTIC_TEST|EEG|32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap
219417807|NCT01196169|DRUG|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
219417808|NCT01196169|DRUG|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
219758499|NCT06120322|OTHER|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
219758500|NCT00628381|DIETARY_SUPPLEMENT|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
219761774|NCT05734560|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
219004534|NCT05524155|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
219004535|NCT05524155|DRUG|Sintilimab|200mg IV d1,Q3W
219004536|NCT05524155|DRUG|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
219004537|NCT00254449|DRUG|NGX-4010|
219004538|NCT02245308|DRUG|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
219190811|NCT04073498|DRUG|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
219417809|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
219417810|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
219417811|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
219417812|NCT00808249|DRUG|Placebo|2 tablets taken twice a day for 28 days
219417813|NCT00002058|DRUG|Clofazimine|
219417814|NCT04691063|DRUG|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
219417815|NCT04691063|DRUG|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
219190812|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
219761775|NCT05734560|DRUG|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
219190813|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
219190814|NCT03291652|DIAGNOSTIC_TEST|DSA/3DRA|DSA/3DRA
219417816|NCT06826976|OTHER|sensory electrical stimulation|peripheral sensory electrical stimulation on median, ulnar, and radial nerves of affected upper limb, simultaneously with Task Specific Training program which included four subtests of Action Research Arm Test scale.
219417817|NCT06826976|OTHER|task specific training program|received task specific training program only. Patients were tested pre and post treatment by Grip dynamometer, Pinch dynamometer, Digital goniometer and Action Research Arm Test Scale (ARAT).
219417818|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
219417819|NCT04054349|OTHER|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
219417820|NCT05834764|DRUG|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
219417821|NCT04065880|OTHER|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
219004539|NCT02245308|BEHAVIORAL|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
219190815|NCT05861921|OTHER|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
219190816|NCT04524416|DEVICE|Minimally invasive glaucoma surgery (MIGS)|MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
219190817|NCT05112809|DEVICE|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
219417822|NCT04065880|OTHER|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
219417823|NCT01996202|DRUG|Ipilumimab|
219758501|NCT00628381|DIETARY_SUPPLEMENT|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
219417824|NCT01996202|RADIATION|Radiation|
219417825|NCT02814357|OTHER|Control (market standard)|
219417826|NCT02814357|OTHER|wheat flour|
219417827|NCT02814357|OTHER|chickpea flour|
219417828|NCT02814357|OTHER|guar gum|
219417829|NCT02814357|OTHER|barley|
219758502|NCT03808571|OTHER|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
219758503|NCT01991860|DRUG|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
219758504|NCT01991860|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
219758505|NCT01775540|DRUG|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
219758506|NCT01775540|DRUG|Saline solution|Saline solution,1 drop used QID for 4 weeks
219758507|NCT01775540|DRUG|Maxidex|Eyedrop-1 drop QID for 4 weeks
219758508|NCT03281213|OTHER|Thoracotomy|
219758509|NCT05334940|OTHER|not applicable, observational study|Patients do not receive intervention
219758510|NCT00172367|DRUG|Lycopene|
219758511|NCT04847882|BEHAVIORAL|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
219758512|NCT02900014|PROCEDURE|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
219758513|NCT00397540|PROCEDURE|PEIT|Percutaneous Ethanol Injection Therapy
219758514|NCT00397540|PROCEDURE|RFTA|Radiofrequency Thermal Ablation
219758515|NCT00116571|DRUG|Lemuteporfin for injection|
219758516|NCT00116571|DEVICE|Transurethral drug delivery system|
219758517|NCT00116571|DEVICE|Transurethral light delivery system|
219758518|NCT05600413|DIETARY_SUPPLEMENT|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
219758519|NCT05600413|DIETARY_SUPPLEMENT|Placebo|4 weeks of Placebo (crystalline cellulose)
219758520|NCT04651530|PROCEDURE|Phaco|phacoemulsification of cataract only
219758521|NCT04651530|PROCEDURE|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
219758522|NCT01129206|DRUG|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
219758523|NCT01129206|DRUG|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
219758524|NCT01129206|RADIATION|fludeoxyglucose F 18|Correlative studies
219758525|NCT01129206|PROCEDURE|positron emission tomography|Correlative studies
219758526|NCT05244161|BEHAVIORAL|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
219758527|NCT06033625|PROCEDURE|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
219758528|NCT00090506|BEHAVIORAL|Yoga|
219758529|NCT01119638|DRUG|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
219758530|NCT01119638|DRUG|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
219758531|NCT02373904|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
219758532|NCT01800786|DEVICE|CPAP|
219004540|NCT02245308|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
219004541|NCT02245308|DRUG|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
219004542|NCT02245308|DRUG|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
219004543|NCT02687945|PROCEDURE|Outpatient physiotherapy|
219004544|NCT02687945|PROCEDURE|Self-guided physiotherapy|
219004545|NCT03661632|DRUG|BMS-986310|Specified dose on specified days
219004546|NCT03661632|BIOLOGICAL|Nivolumab|Specified dose on specified days
219004547|NCT06254404|DRUG|Low dose protamine|Administration of 70% of the normal dose of protamine
219004548|NCT05557799|RADIATION|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
219004549|NCT05557799|RADIATION|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
219004550|NCT02407704|DRUG|Venlafaxine XR|
219004551|NCT02407704|OTHER|Aerobic Exercise|
219417830|NCT06897709|PROCEDURE|Classic Approach in Laparoscopic Appendectomy|underwent laparoscopic appendectomy using the standard approach
219417831|NCT06897709|PROCEDURE|Stump first Approach in Laparoscopic Appendectomy|Stump first Approach in Laparoscopic Appendectomy
219417832|NCT04838925|DEVICE|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
219417833|NCT05641818|OTHER|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
219417834|NCT06137521|PROCEDURE|Coronary angiography|
219417835|NCT00479557|BIOLOGICAL|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
219417836|NCT00479557|BIOLOGICAL|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
219417837|NCT00479557|BIOLOGICAL|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
219417838|NCT00479557|DRUG|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
219417839|NCT04524286|OTHER|Interviews only.|Interviews will be conducted with childbearing women and midwives.
219417840|NCT00259220|DRUG|erythomycin|erythomycin
219417841|NCT00259220|PROCEDURE|gastric lavage alone|gastric lavage alone
219004552|NCT02407704|DRUG|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
219004553|NCT03687489|DEVICE|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
219004554|NCT05318599|DEVICE|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
219004555|NCT05318599|DEVICE|Lung ultrasound|Lung ultrasonography
219417842|NCT00259220|PROCEDURE|erythromycine and gastric lavage|erythromycine and gastric lavage
219417843|NCT00061126|DRUG|ABX-EGF|
219417844|NCT05864443|PROCEDURE|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
219758533|NCT00242606|DRUG|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
219758534|NCT00242606|DRUG|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
219758535|NCT00485173|DEVICE|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
219758536|NCT03006055|DEVICE|Circulating tumor cells|
219758537|NCT00746811|DRUG|P-OM3|4 grams/day - 4 one gram capsules
219758538|NCT00746811|DRUG|Placebo|4 grams/day - 4 one gram capsules
219758539|NCT05479370|BIOLOGICAL|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219758540|NCT05479370|BIOLOGICAL|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219758541|NCT05479370|BIOLOGICAL|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219758542|NCT03050710|DEVICE|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
219758543|NCT03374306|DRUG|Atropine (0.01%)|tropical application
219758544|NCT03374306|DRUG|Artificial tear|tropical application
219758545|NCT04756453|DEVICE|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
219758546|NCT01370551|DRUG|Estriol 0.03 mg, lyophylized lactobacillus|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
219758547|NCT04466358|PROCEDURE|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
219758548|NCT04466358|PROCEDURE|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
219758549|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Low Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 2 consecutive minutes for each side, only once for the experiment duration.
219758550|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
219761776|NCT01445509|DRUG|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
219761777|NCT01445509|DRUG|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
219761778|NCT06526702|DEVICE|High-flux hemodialysis|FX CorDiax 100 dialyzer
219761779|NCT06526702|DEVICE|Post-dilution hemodiafiltration|FX CorDiax 1000 dialyzer
219004556|NCT05318599|OTHER|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
219004557|NCT05318599|DIAGNOSTIC_TEST|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
219004558|NCT03747328|DRUG|ABI-009|nanoparticle albumin bound sirolimus
219004559|NCT05718128|PROCEDURE|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
219004560|NCT06039826|DRUG|LY3437943|Administered SC.
219417845|NCT03180359|BIOLOGICAL|Recommended vaccine scheme according to French Vaccine Schedule 2015|"* BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
219417846|NCT01745991|DEVICE|CoSeal spray|
219417847|NCT04752189|BEHAVIORAL|Enhanced Replicating Effective Programs (Enhanced REP)|Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.
219572476|NCT06027138|OTHER|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
219758551|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (High Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
219758552|NCT06541808|OTHER|Sham mechanical Vagus Nerve Stimulation|Participants will be treated with a fake vagus stimulation by letting the operator hold the neck of the participant in one hand and placing the other hand on the abdomen without any stretch on the vagus nerve
219758553|NCT03524599|OTHER|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
219758554|NCT03602508|DRUG|mirabegron|oral
219758555|NCT03602508|DRUG|solifenacin|oral
219758556|NCT03602508|DRUG|darifenacin|oral
219758557|NCT03602508|DRUG|imidafenacin|oral
219758558|NCT03602508|DRUG|tolterodine|oral
219758559|NCT03602508|DRUG|oxybutynin|oral
219758560|NCT03602508|DRUG|trospium|oral
219758561|NCT03602508|DRUG|fesoterodine|oral
219758562|NCT03602508|DRUG|propiverine|oral
219758563|NCT04941885|DRUG|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
219758564|NCT05218161|DRUG|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
219758565|NCT01659502|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
219758566|NCT06674902|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
219758567|NCT07003048|BEHAVIORAL|Singing, dancing in small groups and active listening to live music at the Berlin Philharmony building|"Pregnant women are invited from 12 gestational weeks onwards to participate in active and passive interventions following a protocol derived from our feasibility study. The following interventions take place:~LIVE GROUP~1. concerts customized for pregnant women by professionals. They talk before and in between the concerts about the meaning of the music with the study attendants. The sessions take around one hour.~2. workshops in singing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn melodies of songs which they can repeat at home on a daily basis.~3. workshops in dancing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn to move with music which they can repeat at home on a daily basis.~DIGITAL GROUP The described interventions are all digitalized with interviews encouraging the second group to participate from home."
219758568|NCT00840333|DRUG|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
219758569|NCT06997107|OTHER|Health promotional messages generated by Artificial Intelligence|Short (850 characters) and long (1 page) messages will be generated by a Generative Artificial Intelligence (ChatGPT 4.0) on different health-related topics
219758570|NCT06997107|OTHER|Health promotional messages generated by humans|Short (850 characters) and long (1 page) messages will be generated by a primary care and/or public health human expert on different health-related topics
219417848|NCT04752189|BEHAVIORAL|Standard implementation|The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
219572477|NCT05511220|BEHAVIORAL|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
219572478|NCT05511220|BEHAVIORAL|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
219572479|NCT00488930|OTHER|Observational|data collection ONLY
219572480|NCT06132620|DRUG|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
219572481|NCT06132620|DRUG|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
219572482|NCT00252174|DRUG|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
219572483|NCT00252174|DRUG|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
219572484|NCT00252174|BEHAVIORAL|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
219417849|NCT03761719|OTHER|No intervention|No intervention
219417850|NCT03422133|OTHER|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
219572485|NCT00252174|DRUG|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
219758571|NCT07003477|DIAGNOSTIC_TEST|Detection of peripheral blood biomarkers|Peripheral blood samples were collected from patients suffering from acute stroke. The concentration of the biomarker glial fibrillary acidic protein (GFAP) was then detected. This was aimed at differentiating between hemorrhagic stroke and non - hemorrhagic stroke. Time - concentration curves were constructed, thereby offering a novel potential approach for the rapid identification of stroke types within ambulances.
219572486|NCT05925504|DRUG|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
219572487|NCT04529330|PROCEDURE|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
219572488|NCT02784782|DEVICE|Orthesis|
219572489|NCT02784782|BEHAVIORAL|No orthesis|
219572490|NCT02443584|OTHER|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
219572491|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
219572492|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
219572493|NCT05179239|DRUG|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
219758572|NCT02561962|DRUG|AMG 224|Administered as an IV infusion.
219758573|NCT01580787|DEVICE|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
219758574|NCT01580787|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
219190818|NCT03878407|OTHER|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
219190819|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
219417851|NCT05374551|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
219417852|NCT03003403|BEHAVIORAL|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
219417853|NCT06302309|OTHER|Psychological intervention|The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
219417854|NCT02151799|PROCEDURE|Abdominoplasty and liposuction|
219417855|NCT00251277|DRUG|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
219417856|NCT04589962|OTHER|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
219417857|NCT02560493|BEHAVIORAL|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
219417858|NCT02670460|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
219417859|NCT05668468|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
219417860|NCT05668468|OTHER|Placebo cellulose capsule|Daily cellulose capsule
219417861|NCT04205578|DRUG|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
219417862|NCT04205578|DRUG|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
219417863|NCT04307836|DEVICE|Renal Denervation|Renal Denervation: DENEX system
219417864|NCT02319096|OTHER|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
219417865|NCT04290481|OTHER|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
219417866|NCT05204511|OTHER|endurance training|endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 30-60 minutes per session
219417867|NCT05204511|OTHER|concurrent training|combination of endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 20-40 minutes per session and resistance training of moderate intensity performing 2-3 sets of leg press, leg curls, chest press and seated horizontal rows
219417868|NCT00280150|BIOLOGICAL|bevacizumab|Given IV
219417869|NCT00280150|DRUG|carboplatin|Given IV
219417870|NCT00280150|DRUG|erlotinib hydrochloride|Given orally
219417871|NCT00280150|DRUG|paclitaxel|Given IV
219417872|NCT00280150|RADIATION|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
219417873|NCT02370940|OTHER|High phytate intake|
219417874|NCT02370940|OTHER|Low phytate intake|
219417875|NCT05020093|PROCEDURE|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
219004561|NCT06039826|DRUG|Ethinyl Estradiol|Administered orally
219004562|NCT06039826|DRUG|Drospirenone|Administered orally
219004563|NCT03703765|DEVICE|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
219004564|NCT01336920|DRUG|carfilzomib|Given IV
219004565|NCT03117101|DRUG|Lucitanib|
219004566|NCT02093845|DEVICE|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
219004567|NCT02093845|DEVICE|SYNERGY stent|Percutaneous coronary intervention involving use of stent
219004568|NCT01806948|DRUG|Ramosetron|
219004569|NCT04334408|DRUG|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
219004570|NCT04334408|DRUG|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
219004571|NCT03357159|DRUG|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
219004572|NCT03357159|DRUG|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
219004573|NCT03557463|DIETARY_SUPPLEMENT|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
219004574|NCT03944954|DEVICE|Placebo TMS Sham|Individuals will receive placebo dose and sham TMS.
219004575|NCT03944954|DRUG|Marinol 10Mg Capsule TMS Sham|Individuals will receive 10mg dose and sham TMS.
219417876|NCT05020093|PROCEDURE|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
219417877|NCT03303040|OTHER|Electrical stimulation of hemidiaphragm|Electrical impulses
219417878|NCT02607332|DRUG|Paclitaxel|
219417879|NCT04438252|DIAGNOSTIC_TEST|ICDAS II|Index for caries detection
219417880|NCT04438252|DEVICE|CariScan Pro|Device for early caries detection
219417881|NCT04438252|RADIATION|Digital Radiograpgy|Device for digital x-ray imaging
219417882|NCT03227965|BIOLOGICAL|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
219572494|NCT02752841|DIETARY_SUPPLEMENT|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
219572495|NCT05824117|OTHER|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
219004576|NCT03944954|DRUG|Marinol 30Mg Capsule TMS Sham|Individuals will receive 30mg dose and sham TMS.
219004577|NCT03944954|DEVICE|Placebo TMS Real|Individuals will receive placebo and real TMS.
219004578|NCT03944954|OTHER|Marinol 10Mg Capsule TMS Real|Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
219572496|NCT05628779|DEVICE|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
219004579|NCT03944954|OTHER|Marinol 30Mg Capsule TMS Real|Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
219572497|NCT05628779|DEVICE|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
219572498|NCT03606421|RADIATION|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
219572499|NCT03606421|RADIATION|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
219417883|NCT00020566|BIOLOGICAL|dactinomycin|Given IV
219417884|NCT00020566|DRUG|busulfan|Given orally and IV
219417885|NCT00020566|DRUG|doxorubicin hydrochloride|Given IV
219417886|NCT00020566|DRUG|etoposide|Given IV
219417887|NCT00020566|DRUG|ifosfamide|Given IV
219417888|NCT00020566|DRUG|melphalan|Given orally and IV
219417889|NCT00020566|DRUG|vincristine sulfate|Given IV
219417890|NCT00020566|PROCEDURE|autologous hematopoietic stem cell transplantation|Given IV
219417891|NCT00020566|PROCEDURE|conventional surgery|Given to patients deemed to require it
219417892|NCT00020566|RADIATION|radiation therapy|Given to patients deemed to require it
219417893|NCT02915107|DEVICE|BioFreedom|PCI with BioFreedom
219417894|NCT02915107|DEVICE|Orsiro|PCI with BioFreedom
219417895|NCT00565656|DRUG|BEVACIZUMAB|Administration of Bevacizumab
219417896|NCT03006471|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
219417897|NCT03006471|DRUG|Placebo - Cap|one per day before breakfast during 12 weeks.
219417898|NCT02477293|DRUG|Hyeonggaeyeongyo-tang|
219190820|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
219190821|NCT03324477|DRUG|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
219190822|NCT05888025|BEHAVIORAL|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
219417899|NCT00556192|DRUG|rituximab|"1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
219417900|NCT00474162|DRUG|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
219417901|NCT00474162|DRUG|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
219417902|NCT02534194|OTHER|Image acquisition|Images of baby's face (including ear) and feet
219417903|NCT02480894|DRUG|BMS-663068|BMS-663068
219417904|NCT02480894|DRUG|Maraviroc|Maraviroc
219417905|NCT05577091|GENETIC|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
219417906|NCT02871401|DRUG|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
219417907|NCT02871401|DRUG|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
219417908|NCT04375241|OTHER|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
219417909|NCT01120379|DEVICE|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
219190823|NCT06143215|BEHAVIORAL|4 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 4-8-12 weeks revision times could change diabetic foot reulceration rate.
219572500|NCT05510024|PROCEDURE|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
219004580|NCT04426981|BEHAVIORAL|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
219190824|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
219190825|NCT02905422|BEHAVIORAL|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
219417910|NCT06047899|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
219417911|NCT06047899|OTHER|Placebo|mannitol formulated for oral administration (capsules)
219417912|NCT01590862|DEVICE|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
219417913|NCT02334670|DRUG|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
219417914|NCT03699449|DRUG|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
219417915|NCT03699449|DRUG|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
219758575|NCT01484249|DEVICE|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
219758576|NCT05729087|BEHAVIORAL|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
219758577|NCT00004682|DRUG|immune globulin|
219758578|NCT00244192|DRUG|infliximab (Remicade)|
219758579|NCT00373542|DRUG|ropinirole CR-RLS|
219758580|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
219758581|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
219758582|NCT04312945|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
219758583|NCT04312945|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
219758584|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
219758585|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
219758586|NCT05471986|DEVICE|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
219761780|NCT05616650|DRUG|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
219761781|NCT05616650|RADIATION|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
219761782|NCT04160910|DRUG|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
219417916|NCT03699449|DRUG|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
219417917|NCT03699449|DRUG|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
219417918|NCT03699449|DRUG|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
219417919|NCT03699449|DRUG|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
219417920|NCT03162055|DRUG|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
219417921|NCT03162055|DRUG|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
219417922|NCT03560635|BEHAVIORAL|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
219190826|NCT05822635|DEVICE|SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System|Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
219417923|NCT00606814|DRUG|IPI-504, docetaxel|"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
219417924|NCT03852914|DEVICE|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
219417925|NCT04417114|DRUG|Rosuvastatin|Statin
219417926|NCT04248400|OTHER|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
219572501|NCT05510024|PROCEDURE|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
219572502|NCT03936049|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group
219572503|NCT03936049|DRUG|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
219572504|NCT02770105|OTHER|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
219572505|NCT02770105|OTHER|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
219572506|NCT02770105|OTHER|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
219572507|NCT02770105|OTHER|Placebo|Oral administration of 200ml of distilled water
219572508|NCT03581214|OTHER|No oxygen|No facemask, room air only
219572509|NCT03581214|OTHER|Oxygen|10Liters/minute oxygen by facemask
219572510|NCT06806878|OTHER|Progressive muscle relaxation|We will apply progressive muscle relaxation exercises to reduce nursing students' anxiety about intramuscular injection administration
219572511|NCT00351351|DEVICE|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
219572512|NCT00351351|DEVICE|single probe ultrasonic|FDA-approved - single probe ultrasonic
219572513|NCT00314782|DRUG|ZD4054 (Zibotentan)|oral tablet
219572514|NCT00314782|DRUG|Docetaxel|intravenous infusion
219572515|NCT00314782|DRUG|Placebo|
219572516|NCT03553563|DRUG|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
219572517|NCT03553563|DRUG|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
219572518|NCT04715776|DIETARY_SUPPLEMENT|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
219572519|NCT04715776|DIETARY_SUPPLEMENT|placebo|Uptake of 1650 mg placebo twice daily
219572520|NCT05127694|OTHER|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
219572521|NCT01975194|DRUG|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
219761783|NCT04160910|DRUG|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
219004581|NCT01849224|OTHER|Pelvic and lower extremity exercise|
219417927|NCT04248400|OTHER|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
219417928|NCT06027073|BIOLOGICAL|omalizumab|adding omalizumab to anti asthmatic therapy
219417929|NCT06197048|BEHAVIORAL|Nutritional counseling|"The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments.~The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases."
219417930|NCT03450525|OTHER|No intervention|No intervention
219417931|NCT02581865|DRUG|NBI-98854|
219417932|NCT02581865|DRUG|Placebo|
219417933|NCT00855257|DRUG|Acid Nicotinique|
219417934|NCT00855257|DRUG|Placebo|
219417935|NCT02493322|DRUG|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
219417936|NCT02493322|DRUG|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
219417937|NCT02493322|DRUG|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
219417938|NCT03480958|DEVICE|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
219417939|NCT03480958|OTHER|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
219417940|NCT03480958|OTHER|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
219417941|NCT01993615|PROCEDURE|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
219417942|NCT01993615|PROCEDURE|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
219417943|NCT01617655|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
219417944|NCT01617655|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
219417945|NCT01617655|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
219417946|NCT00254735|DRUG|quetiapine fumarate|
219417947|NCT00254735|DRUG|SSRI/Clomipramine|
219417948|NCT03224585|DRUG|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
219417949|NCT03224585|DRUG|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
219417950|NCT03483766|DEVICE|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
219417951|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
219417952|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
219417953|NCT01175213|BIOLOGICAL|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
219417954|NCT00813618|DRUG|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
219417955|NCT00813618|DRUG|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
219417956|NCT00813618|DRUG|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
219417957|NCT00438893|DIETARY_SUPPLEMENT|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
219417958|NCT01252641|BIOLOGICAL|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
219417959|NCT01113996|BEHAVIORAL|Protein supplementation and strength training|Protein supplementation and strength training
219417960|NCT01113996|DIETARY_SUPPLEMENT|Protein supplementation|Protein supplementation
219417961|NCT00891163|DRUG|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
219417962|NCT00891163|DRUG|Placebo Patch|placebo
219417963|NCT02897869|DRUG|POL7080|7 doses of POL7080 alone over 2.5 days
219417964|NCT02897869|DRUG|Amikacin|3 doses of Amikacin alone over 2.5 days
219417965|NCT02897869|DRUG|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
219417966|NCT03036423|BEHAVIORAL|Online video education|
219417967|NCT03036423|BEHAVIORAL|Computerized mental exercises|
219417968|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
219417969|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
219572522|NCT02488668|DEVICE|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
219572523|NCT01117467|OTHER|Simulation scenario|Students performing their scenario will be paired, not solo
219572524|NCT01117467|OTHER|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
219572525|NCT04598360|PROCEDURE|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
219417970|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
219417971|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
219417972|NCT03235817|OTHER|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
219417973|NCT03235817|DEVICE|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
219417974|NCT03235817|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
219417975|NCT01921634|OTHER|Modified Pathologic Analysis|
219417976|NCT00388258|DRUG|Alvimopan|
219572526|NCT06600750|PROCEDURE|Arteriovenous fistula|Patients who underwent Radiocephalic arteriovenous fistula surgery
219572527|NCT06472544|BEHAVIORAL|Culturally Grounded Intervention|Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
219417977|NCT05388019|OTHER|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
219572528|NCT00062101|DRUG|erlotinib hydrochloride|Given orally (PO)
219572529|NCT00062101|DRUG|celecoxib|Given PO
219417978|NCT05388019|BEHAVIORAL|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
219572530|NCT00062101|OTHER|laboratory biomarker analysis|Correlative studies
219572531|NCT02990806|DRUG|NI-071|IV infusion.
219417979|NCT01965418|DRUG|Fufang Biejia Ruangan Tablet|
219572532|NCT02990806|DRUG|Remicade|IV infusion.
219572533|NCT01142531|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
219572534|NCT06031220|OTHER|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
219572535|NCT00610324|DRUG|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
219572536|NCT00610324|DRUG|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
219572537|NCT03588052|PROCEDURE|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
219572538|NCT03588052|PROCEDURE|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
219572539|NCT01652976|DRUG|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
219572540|NCT01652976|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
219572541|NCT00113724|DRUG|TPI 287 Injection|
219004582|NCT01906203|DEVICE|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
219004583|NCT04334551|DRUG|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
219004584|NCT03223246|OTHER|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
219417980|NCT01965418|DRUG|Placebo|
219417981|NCT01245764|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
219417982|NCT01245764|BIOLOGICAL|Placebo|
219417983|NCT00003476|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
219417984|NCT04493957|BEHAVIORAL|ACCOMPAGNE Education Program|"The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop"
219572542|NCT05540379|DEVICE|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
219572543|NCT00783887|OTHER|Blood sample|Blood sample of 5 ml
219572544|NCT01825837|DRUG|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
219572545|NCT01825837|DRUG|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
219572546|NCT01825837|DRUG|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
219572547|NCT01825837|DRUG|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
219572548|NCT04007471|OTHER|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
219417985|NCT04493957|BEHAVIORAL|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
219417986|NCT02500368|DEVICE|silicone hydrogel lens (test)|contact lens
219417987|NCT02500368|DEVICE|enfilcon A lens (control)|contact lens
219417988|NCT03674658|DRUG|Propafenone|oral, TID
219417989|NCT02621619|DRUG|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
219417990|NCT02621619|DRUG|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
219572549|NCT05171894|DRUG|Hemopfin+Green Light|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
219572550|NCT05171894|DEVICE|Vehicle+Green Light|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
219004585|NCT02730455|DRUG|natalizumab|Administered as specified in the treatment arm
219004586|NCT02730455|DRUG|Placebo|Matched placebo
219417991|NCT04568018|DRUG|Surfactant|Inhalation of surfactant emulsion at 150 mg
219417992|NCT05566288|DRUG|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
219417993|NCT05566288|DRUG|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
219417994|NCT05566288|DRUG|Moxifloxacin|400 mg tablets
219417995|NCT05381558|DRUG|Triamcinolone Injection|local injection in sinus tarsi
219572551|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
219572552|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
219572553|NCT00904748|DRUG|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
219572554|NCT03579134|DEVICE|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
219004587|NCT02356744|OTHER|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
219004588|NCT03209687|DRUG|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
219004589|NCT04540029|OTHER|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
219004590|NCT00424671|DRUG|Licarbazepine|
219417996|NCT03956329|OTHER|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
219417997|NCT03956329|OTHER|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
219417998|NCT03663140|DIAGNOSTIC_TEST|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
219417999|NCT00745381|OTHER|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
219418000|NCT02911623|DEVICE|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
219418001|NCT06028425|DRUG|LOXO-783|Administered orally.
219572555|NCT03579134|OTHER|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
219572556|NCT02221596|DIETARY_SUPPLEMENT|vitamin D|50,000IU/wk of vitamin D3
219572557|NCT02221596|OTHER|aerobic training|7 days of treadmill training during the 13th week of study
219572558|NCT03302377|BEHAVIORAL|physical activity counseling & Fitbit|Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
219572559|NCT00038831|DRUG|Mylotarg|Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.
219572560|NCT00038831|DRUG|Fludarabine|30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
219572561|NCT00038831|DRUG|Melphalan|140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
219572562|NCT00038831|DRUG|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
219572563|NCT00038831|PROCEDURE|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
219572564|NCT03990480|DRUG|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
219418002|NCT04137419|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic strains
219758587|NCT05017558|DIAGNOSTIC_TEST|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
219758588|NCT06932835|DRUG|Transversus Abdominis Plane (TAP) Block|Transversus Abdominis Plane (TAP) Block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
219758589|NCT06932835|DRUG|Modified Thoracoabdominal Nerve Block (M-TAPA)|Modified Thoracoabdominal Nerve Block (M-TAPA) is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
219758590|NCT04838704|DRUG|Ruxolitinib+Calcineurin inhibitor+Methotrexate|low-dose ruxolitinib combine with calcineurin inhibitor and short course of methotrexate.
219758591|NCT04838704|DRUG|Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil|calcineurin inhibitor and short course of methotrexate and mycophenolate mofetil
219758592|NCT06934681|BEHAVIORAL|Usual Care Group|Participants will receive the standard intervention provided by the healthcare service, which includes recommendations for physical exercise, physical activity, and healthy eating. This intervention is delivered by the Endocrinology and Nutrition Department at Hospital Universitario y Politécnico La Fe and consists of periodic individual follow-ups (at least three in-person visits per year, both pre- and post-bariatric surgery) by specialized medical staff in Endocrinology and licensed Nutrition and Dietetics professionals. Additionally, it includes five preoperative group sessions focusing on various aspects of healthy nutrition, physical exercise, and physical activity.
219758593|NCT06934681|BEHAVIORAL|Controlled exercise with telerehabilitation|Participants will receive the same standard care as the control group, including the same number of visits with the physician and nutritionist and participation in group sessions. Additionally, they will follow a structured physical exercise program, tailored to individual capabilities, combining aerobic and strength exercises, which will primarily be carried out at home with the assistance of telerehabilitation. Physical exercise will be structured in different phases: prior to surgery (prehabilitation), after surgery (rehabilitation), with maintenance periods in between.
219758594|NCT01589614|DRUG|PH-797804|Tablet, 6mg, single
219758595|NCT01589614|DRUG|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
219190827|NCT04898075|BEHAVIORAL|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
219190828|NCT04898075|OTHER|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
219190829|NCT04622683|PROCEDURE|Ultrasound|To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
219190830|NCT04136132|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
219190831|NCT03617445|DRUG|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
219418003|NCT04137419|OTHER|Placebo|Similar to ProlacSan lozenges in taste in colour
219418004|NCT03626740|OTHER|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
219418005|NCT03626740|OTHER|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
219418006|NCT00351169|DRUG|Quetiapine SR|
219418007|NCT00351169|DRUG|Escitalopram|
219418008|NCT00781963|BEHAVIORAL|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
219572565|NCT03990480|DRUG|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
219572566|NCT05088031|DEVICE|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
219418009|NCT00781963|BEHAVIORAL|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
219418010|NCT04656392|DIAGNOSTIC_TEST|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
219418011|NCT03098524|PROCEDURE|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
219418012|NCT03098524|PROCEDURE|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
219572567|NCT01067716|DEVICE|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
219572568|NCT03630419|DIETARY_SUPPLEMENT|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
219758596|NCT04826237|DRUG|Statin|Oral dose to be taken with methylprednisolone
219758597|NCT04826237|DRUG|methylprednisolone|oral dose, standard of care
219758598|NCT04826237|DRUG|dexamethasone|Drug for intratympanic administration
219758599|NCT04826237|DRUG|Placebo|Capsule the same as for statins but without statin
219758600|NCT01566240|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.
219758601|NCT01566240|DRUG|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.
219418013|NCT03098524|PROCEDURE|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
219418014|NCT05855395|DRUG|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
219418015|NCT05278286|BEHAVIORAL|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
219418016|NCT05278286|BEHAVIORAL|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
219418017|NCT00680953|DRUG|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
219572569|NCT03630419|OTHER|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
219572570|NCT04540055|PROCEDURE|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
219572571|NCT04540055|PROCEDURE|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
219572572|NCT02948725|OTHER|Cross-education + standard rehabilitation|
219572573|NCT03978312|OTHER|Nominal consensus group|NLit-UK linguistic and cultural adaptation (NLit-UK) 2 x nominal consensus groups evidence review and topic expert engagement
219572574|NCT03978312|OTHER|Observational cohort (validity and reliability testing)|Nutrition Literacy Measurement Tool validation (NLit-UK). Target sample 366 on treatment cancer patients confirmatory binary analysis for validity and reliability.
219572575|NCT02493920|OTHER|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).
219572576|NCT02493920|DEVICE|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
219572577|NCT01761669|DRUG|Vitamin D|
219572578|NCT00860691|PROCEDURE|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
219572579|NCT00860691|PROCEDURE|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
219418018|NCT00680953|DRUG|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
219418019|NCT00680953|DRUG|Alendronate sodium hydrate|Oral tablet once a week for 24 months
219572580|NCT00860691|OTHER|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
219572581|NCT06127017|PROCEDURE|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
219572582|NCT06127017|PROCEDURE|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
219418020|NCT02064205|DIETARY_SUPPLEMENT|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
219418021|NCT02064205|DIETARY_SUPPLEMENT|glucose syrup|Glucose syrup is used a control product for the polydextrose
219418022|NCT03057951|DRUG|Empagliflozin|once daily
219418023|NCT03057951|DRUG|Placebo|once daily
219418024|NCT03904784|BEHAVIORAL|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
219418025|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
219418026|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
219418027|NCT00696436|DRUG|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
219418028|NCT00696436|DRUG|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
219418029|NCT00696436|DRUG|Placebo|Matching placebo, orally, once daily for up to six weeks.
219418030|NCT01967472|DRUG|amodiaquine-artesunate (AQAS) fixed-dose|
219418031|NCT01967472|DRUG|Artemether-lumefantrine combination (AL) dispersable|
219418032|NCT03405493|BEHAVIORAL|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
219418033|NCT03405493|BEHAVIORAL|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
219418034|NCT04859478|DIAGNOSTIC_TEST|Dual energy / spectral portal venous chest computed tomography|Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
219418035|NCT03095716|OTHER|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
219418036|NCT02062463|DRUG|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
219418037|NCT02062463|DRUG|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
219418038|NCT01605344|DRUG|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
219418039|NCT01605344|DRUG|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
219418040|NCT01911013|PROCEDURE|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
219418041|NCT01911013|DEVICE|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
219418042|NCT01911013|DEVICE|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
219418043|NCT01079533|BEHAVIORAL|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
219418044|NCT01079533|BEHAVIORAL|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
219418045|NCT03937258|DRUG|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
219418046|NCT03937258|DRUG|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
219418047|NCT00307424|DEVICE|AutoCPAP|
219418048|NCT00307424|DEVICE|FixCPAP|
219418049|NCT01889628|DIETARY_SUPPLEMENT|Liquid-based Nutritional Formulae and liquid glucose|
219418050|NCT04520828|OTHER|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
219418051|NCT04124692|DEVICE|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
219572583|NCT02842463|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|
219418052|NCT05034471|DEVICE|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
219418053|NCT00050999|DRUG|ONTAK|
219418054|NCT06160037|BEHAVIORAL|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
219418055|NCT06160037|BEHAVIORAL|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
219418056|NCT02294149|DRUG|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
219418057|NCT02294149|DRUG|placebo|
219418058|NCT04471064|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
219418059|NCT02370498|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
219418060|NCT02370498|DRUG|paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
219418061|NCT03391687|DIAGNOSTIC_TEST|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
219418062|NCT05941169|PROCEDURE|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
219418063|NCT04494464|OTHER|No intervention|
219418064|NCT02156869|OTHER|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
219418065|NCT00367198|DIETARY_SUPPLEMENT|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
219418066|NCT01399749|OTHER|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
219418067|NCT01122030|DRUG|Naldemedine|Tablets or solution for oral administration
219418068|NCT01122030|DRUG|Placebo|Tablets or solution for oral administration
219418069|NCT06155760|DRUG|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
219418070|NCT06155760|OTHER|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
219418071|NCT06155760|DRUG|Placebo|Placebo
219418072|NCT02275767|DEVICE|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
219418073|NCT02275767|DEVICE|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
219418074|NCT02275767|DEVICE|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
219418075|NCT00914043|GENETIC|gene expression analysis|
219418076|NCT00914043|GENETIC|microarray analysis|
219418077|NCT00914043|GENETIC|polymerase chain reaction|
219418078|NCT00914043|GENETIC|polymorphism analysis|
219418079|NCT00914043|GENETIC|reverse transcriptase-polymerase chain reaction|
219418080|NCT00914043|OTHER|biologic sample preservation procedure|
219418081|NCT00914043|OTHER|enzyme-linked immunosorbent assay|
219418082|NCT00914043|OTHER|laboratory biomarker analysis|
219758602|NCT01566240|RADIATION|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
219418083|NCT00914043|PROCEDURE|fatigue assessment and management|
219418084|NCT05875220|OTHER|No intervention|No intervention
219004591|NCT05350111|BEHAVIORAL|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
219418085|NCT06118580|DRUG|Alcohol (Ethanol)|95% Ethanol diluted in Grape-flavored drink
219418086|NCT06118580|DRUG|Placebo|Grape-flavored drink
219418087|NCT04323761|DRUG|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
219418088|NCT05433194|BIOLOGICAL|ABO1009-DP|Vaccine
219418089|NCT01893658|DRUG|Omalizumab|administration of a single dose together with the standard treatment
219418090|NCT01893658|DRUG|Prednisone|standard treatment
219418091|NCT03457103|DEVICE|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
219418092|NCT03457103|DEVICE|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
219758603|NCT01566240|DRUG|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
219572584|NCT04403763|DRUG|AGN-241622|Topical eye drop
219004592|NCT05564429|DRUG|18F-SF12051|Injected intravenously followed by PET scanning
219418093|NCT01922284|BIOLOGICAL|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
219418094|NCT01922284|BIOLOGICAL|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
219418095|NCT01922284|BIOLOGICAL|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
219418096|NCT01922284|BIOLOGICAL|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
219418097|NCT05779579|DRUG|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
219418098|NCT05779579|DRUG|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
219418099|NCT05779579|DRUG|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
219418100|NCT05779579|DRUG|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
219418101|NCT05779579|DRUG|Placebo|Dose level A of placebo
219418102|NCT05911815|RADIATION|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
219418103|NCT06419647|BEHAVIORAL|Intervention|Daily mood tracking tasks
219418104|NCT00195767|DRUG|divalproex sodium|
219418105|NCT04715256|BEHAVIORAL|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
219418106|NCT04715256|GENETIC|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
219418107|NCT04715256|DIAGNOSTIC_TEST|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
219418108|NCT03055403|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
219418109|NCT03055403|DRUG|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
219418110|NCT05051865|DRUG|camrelizumab|camrelizumab combined with SHR1020 for advanced melanoma
219418111|NCT05051865|DRUG|SHR1020|camrelizumab combined with SHR1020 for advanced melanoma
219418112|NCT05157451|OTHER|Quality of Life|Ancillary studies
219418113|NCT05157451|OTHER|Questionnaire Administration|Ancillary studies
219418114|NCT05157451|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219418115|NCT05157451|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Given via injection
219418116|NCT02225873|OTHER|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
219418117|NCT02225873|OTHER|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
219418118|NCT04915664|DEVICE|Pessary|Use of Pessary as treatment of POP
219418119|NCT05102396|DRUG|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
219418120|NCT05102396|DRUG|Topical placebo spray|Participants will receive topical placebo spray.
219418121|NCT05102396|DRUG|Oral oxybutynin|Participants will receive oxybutynin (tablets).
219418122|NCT05535127|DIAGNOSTIC_TEST|"Palpation with  laryngeal handshake technique"|Information alredy included
219418123|NCT05535127|DIAGNOSTIC_TEST|Palpation strategy plus sequential ultrasound|Information alredy included
219418124|NCT05535127|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
219418125|NCT03943953|BEHAVIORAL|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners."
219418126|NCT01835613|OTHER|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
219572585|NCT04403763|DRUG|Vehicle|Topical eye drop
219418127|NCT01154179|OTHER|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
219418128|NCT01199055|DRUG|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
219572586|NCT01174524|DRUG|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
219572587|NCT01174524|DRUG|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
219572588|NCT05827484|BIOLOGICAL|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
219572589|NCT05827484|COMBINATION_PRODUCT|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
219572590|NCT00749502|DRUG|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
219418129|NCT01199055|DRUG|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
219418130|NCT01199055|DRUG|Paclitaxel|Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
219418131|NCT00505232|DRUG|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy."
219418132|NCT06065358|PROCEDURE|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
219758604|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
219758605|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
219418133|NCT04109872|DRUG|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
219418134|NCT02011126|DRUG|Imetelstat Sodium|Given IV
219418135|NCT02011126|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219418136|NCT04798391|DRUG|Dexamethasone|Steroids and analgesics
219418137|NCT04472364|DEVICE|HemoPill Acute ®|Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
219572591|NCT02453633|OTHER|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
219572592|NCT02453633|OTHER|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
219572593|NCT05836415|PROCEDURE|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
219572594|NCT02857647|BEHAVIORAL|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
219572595|NCT01098994|DIETARY_SUPPLEMENT|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
219572596|NCT01098994|OTHER|Dummy pills|Daily placebo administration for 8 weeks
219572597|NCT02470091|BIOLOGICAL|Denosumab|Given SC
219572598|NCT02470091|OTHER|Laboratory Biomarker Analysis|Correlative studies
219572599|NCT02470091|OTHER|Pharmacological Study|Correlative studies
219572600|NCT01320020|DRUG|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
219572601|NCT00176631|DIETARY_SUPPLEMENT|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
219572602|NCT00176631|DRUG|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
219572603|NCT04480801|OTHER|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
219572604|NCT04480801|OTHER|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
219572605|NCT04290286|OTHER|i2TransHealth|i2TransHealth: online intervention for TGD people
219572606|NCT05795348|DIAGNOSTIC_TEST|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
219572607|NCT06616558|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
219758606|NCT04747288|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
219758607|NCT04747288|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
219761784|NCT06534983|DRUG|Autogene Cevumeran|Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
219761785|NCT06534983|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
219761786|NCT06534983|DRUG|Saline|Saline solution for IV infusion
219418138|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
219418139|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
219418140|NCT01156610|BEHAVIORAL|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
219418141|NCT02820376|OTHER|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
219418142|NCT00131040|DRUG|Aprotinin|
219418143|NCT02864537|OTHER|Training|Patients were trained to measure INR and dose warfarin
219418144|NCT03886142|PROCEDURE|radiofrequency|radiofrequency of the genicular nerves
219190832|NCT03617445|DRUG|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
219190833|NCT03617445|DRUG|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
219572608|NCT06616558|OTHER|Sunscreen SPF 70|On the randomized side of the half-face, the product will be applied by a qualified technician
219572609|NCT02521077|DRUG|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
219572610|NCT02521077|OTHER|Normal Saline|Saline 0.9%
219572611|NCT02240563|PROCEDURE|Low-level laser therapy|
219572612|NCT02240563|PROCEDURE|Non laser ordinary red light|
219572613|NCT00896194|BEHAVIORAL|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
219758608|NCT04747288|DIAGNOSTIC_TEST|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
219758609|NCT04747288|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
219758610|NCT04747288|DIAGNOSTIC_TEST|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
219418145|NCT03886142|PROCEDURE|platelet rich plasma injection|intra articular injection of platelet rich plasma
219572614|NCT00896194|BEHAVIORAL|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
219572615|NCT02087917|DRUG|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
219572616|NCT02087917|DRUG|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
219758611|NCT03693495|DIAGNOSTIC_TEST|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
219572617|NCT01829919|DRUG|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
219572618|NCT03744221|DIETARY_SUPPLEMENT|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
219572619|NCT03744221|DIETARY_SUPPLEMENT|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
219572620|NCT03744221|DIETARY_SUPPLEMENT|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
219572621|NCT02457884|OTHER|Temporal Group|Visual Processing Training
219004593|NCT00469183|DRUG|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
219004594|NCT02480439|DRUG|TAK-648 Tablet|Tak-648 tablet
219004595|NCT02480439|DRUG|TAK-648 Oral Solution|TAK-648 oral solution
219004596|NCT02268084|DEVICE|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
219004597|NCT02268084|DEVICE|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
219004598|NCT05227027|BEHAVIORAL|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
219004599|NCT05227027|BEHAVIORAL|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
219004600|NCT03415217|OTHER|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
219004601|NCT00114946|DRUG|Avastin|
219004602|NCT01890551|OTHER|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
219572622|NCT02457884|OTHER|Spatial Group|Spatial visual span training
219572623|NCT02457884|OTHER|Combined Group|Visual processing speed and spatial visual span training
219572624|NCT02457884|OTHER|Control Group|Leisure reading activities
219572625|NCT01453621|OTHER|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
219572626|NCT02083419|DEVICE|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
219572627|NCT00168116|PROCEDURE|radiation treatment and surgery|
219572628|NCT00168116|PROCEDURE|radiation alone|
219572629|NCT02135965|DRUG|2mg of Albuterol|2mg of Albuterol on metabolic rate
219572630|NCT02135965|DRUG|4mg of Albuterol|4mg of Albuterol on metabolic rate
219572631|NCT02135965|DRUG|100mg of Caffeine|100mg of caffeine on metabolic rate
219572632|NCT02135965|DRUG|200mg of Caffeine|200mg of Caffeine on metabolic rate
219572633|NCT02135965|DRUG|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
219572634|NCT02135965|DRUG|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
219572635|NCT02135965|DRUG|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
219572636|NCT02135965|DRUG|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
219572637|NCT01090375|OTHER|Exercise|
219572638|NCT01090375|OTHER|Non Exercise|
219572639|NCT01690975|DRUG|Placebo|Placebo - single dose at start of each treatment period
219572640|NCT01690975|DRUG|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
219572641|NCT01690975|DRUG|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
219572642|NCT02549846|DRUG|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
219572643|NCT03508869|DRUG|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
219572644|NCT03508869|DRUG|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
219572645|NCT03508869|DRUG|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
219572646|NCT01661634|DRUG|Ularitide|
219572647|NCT01661634|DRUG|Placebo|
219572648|NCT02153892|DEVICE|GDS Accucinch System|Percutaneous Coronary Intervention
219572649|NCT05876728|GENETIC|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
219572650|NCT04916483|OTHER|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
219572651|NCT04916483|OTHER|usual care|The control group maintains the unit routine treatment.
219572652|NCT02903238|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
219572653|NCT02903238|DRUG|Placebo Oral Tablet|Lactose capsule
219572654|NCT05209906|DRUG|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
219572655|NCT05327855|DRUG|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
219572656|NCT05327855|DRUG|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
219572657|NCT05327855|DRUG|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
219572658|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
219572659|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
219572660|NCT03571659|PROCEDURE|Laser|
219572661|NCT01426737|DRUG|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
219572662|NCT01353807|DIETARY_SUPPLEMENT|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
219572663|NCT01353807|DIETARY_SUPPLEMENT|Olive oil|4 1-g gelatine capsules with virgin olive oil
219572664|NCT04787770|OTHER|non-intervention|non-intervention
219418146|NCT01886131|OTHER|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
219418147|NCT01594138|OTHER|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
219418148|NCT02941913|DRUG|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
219418149|NCT04703348|DIAGNOSTIC_TEST|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities."
219418150|NCT01165151|BEHAVIORAL|behavioral weight loss program|weekly, group-based lifestyle weight loss program
219418151|NCT02754830|DRUG|LY3303560 - IV|Administered IV
219004603|NCT03817307|DIAGNOSTIC_TEST|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
219004604|NCT03763591|BEHAVIORAL|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
219418152|NCT02754830|DRUG|Saline Solution - IV|Administered IV
219418153|NCT02754830|DRUG|LY3303560 - SC|Administered SC
219004605|NCT05908695|DRUG|GV-971|Administered PO
219004606|NCT05908695|DRUG|Placebo|Administered PO
219418154|NCT04365439|BIOLOGICAL|Blood plasma|Convalescent plasma after COVID-19
219418155|NCT05585892|OTHER|Elaboration and individual mailed feedback|see above
219418156|NCT03184298|OTHER|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
219418157|NCT03184298|OTHER|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
219418158|NCT03184298|OTHER|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
219418159|NCT04729582|BIOLOGICAL|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
219004607|NCT05673512|COMBINATION_PRODUCT|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
219418160|NCT04729582|OTHER|Placebo|Placebo is the injection solution without muscle stem cells.
219418161|NCT02497157|DRUG|Oxaliplatin (L-OHP)|
219418162|NCT02497157|DRUG|Irinotecan hydrochloride hydrate (CPT-11)|
219418163|NCT02497157|DRUG|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
219758612|NCT03693495|DIAGNOSTIC_TEST|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
219418164|NCT02497157|DRUG|Levofolinate calcium (l-LV)|
219418165|NCT02497157|DRUG|Bevacizumab (Bmab)|
219572665|NCT01553201|DRUG|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
219572666|NCT01553201|DRUG|Placebo|Saline, 4cc, one time intramuscular administration
219572667|NCT02166320|DEVICE|Partially covered SEMS|
219572668|NCT02166320|DEVICE|Fully covered SEMS|
219572669|NCT02743728|DEVICE|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
219572670|NCT02743728|DEVICE|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
219572671|NCT02743728|BEHAVIORAL|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
219572672|NCT00020267|DRUG|interleukin-2|
219572673|NCT00020267|DRUG|MAGE-12 peptide vaccine|
219572674|NCT00020267|DRUG|Montanide ISA-51|
219418166|NCT02634931|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
219418167|NCT04650958|PROCEDURE|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
219572675|NCT02291471|DRUG|T0001，10mg|
219572676|NCT02291471|DRUG|T0001，20mg|
219572677|NCT02291471|DRUG|T0001，35mg|
219572678|NCT02291471|DRUG|T0001，50mg|
219572679|NCT02291471|DRUG|T0001，65mg|
219572680|NCT02291471|DRUG|T0001，75mg|
219572681|NCT00003242|DRUG|bryostatin 1|
219572682|NCT00003242|DRUG|cisplatin|
219572683|NCT00003242|DRUG|paclitaxel|
219572684|NCT04149028|PROCEDURE|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
219572685|NCT00396461|DRUG|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
219572686|NCT00396461|DRUG|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
219572687|NCT06616428|OTHER|Bike group fitness class|Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
219572688|NCT06616428|OTHER|Pump Power|Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
219758613|NCT03693495|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
219758614|NCT01819272|DRUG|Met DR|metformin delayed-release tablets
219758615|NCT01819272|DRUG|Met XR|metformin extended-release tablets
219758616|NCT01819272|DRUG|Placebo|placebo delayed-release tablets
219572689|NCT06616428|OTHER|Global Training|Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
219572690|NCT02182167|DRUG|IV N-acetylcysteine (NAC)|
219572691|NCT02182167|DRUG|Water|
219572692|NCT01245036|DRUG|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
219418168|NCT00488592|BIOLOGICAL|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
219572693|NCT00483587|DRUG|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
219572694|NCT03845413|BEHAVIORAL|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
219572695|NCT03845413|BEHAVIORAL|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
219572696|NCT00155233|DRUG|Nalbuphine and morphine|
219572697|NCT00700817|DRUG|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
219572698|NCT00700817|DRUG|sitagliptin|Tablets, 100 mg daily
219572699|NCT00700817|DRUG|metformin|Tablets, minimum 1500 mg daily
219572700|NCT00700817|DRUG|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
219572701|NCT04291807|BEHAVIORAL|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
219572702|NCT00325832|DEVICE|BpTRU|
219758617|NCT03929003|BEHAVIORAL|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
219418169|NCT00488592|BIOLOGICAL|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
219418170|NCT00488592|DRUG|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
219572703|NCT00325832|DEVICE|Conventional mercury sphygmomanometry|
219572704|NCT05914545|DRUG|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
219572705|NCT04686227|DIAGNOSTIC_TEST|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
219572706|NCT03500497|DIAGNOSTIC_TEST|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
219758618|NCT06028828|DRUG|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
219572707|NCT00722631|DRUG|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
219572708|NCT00722631|DRUG|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
219572709|NCT00767520|DRUG|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
219572710|NCT00767520|DRUG|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
219572711|NCT04274582|DIETARY_SUPPLEMENT|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
219572712|NCT00594620|DIETARY_SUPPLEMENT|Flav-ein capsules|Soy/isoflavone supplementation
219572713|NCT00594620|DRUG|Placebo|Placebo
219572714|NCT05973682|OTHER|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~\+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
219572715|NCT05973682|OTHER|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
219758619|NCT06028828|DRUG|Melphalan|Given Day-5
219758620|NCT06028828|RADIATION|Total Body Irradiation|Given Day-1
219758621|NCT02868424|DRUG|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
219418171|NCT00488592|BIOLOGICAL|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
219418172|NCT03628430|PROCEDURE|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
219418173|NCT03628430|PROCEDURE|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
219418174|NCT03628430|PROCEDURE|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
219418175|NCT05651217|DEVICE|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
219418176|NCT05651217|DEVICE|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
219418177|NCT02074774|DEVICE|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
219572716|NCT04729647|PROCEDURE|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
219572717|NCT00775541|DIETARY_SUPPLEMENT|Vitamin C|One IV infusion of 2 gm vitamin C
219572718|NCT04175743|DRUG|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
219418178|NCT02074774|OTHER|Manual control|Standard practice of manually titrating FiO2 as needed.
219418179|NCT00135837|DRUG|Verteporfin for injection|
219572719|NCT03166553|DRUG|Elemene|
219572720|NCT01700478|DRUG|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
219572721|NCT01700478|DRUG|Vasopressin|Vasopressin was used in all patients during surgery.
219572722|NCT06166784|DEVICE|Mectascrew B|reconstruction of ACL or PCL rupture
219761787|NCT05722769|BEHAVIORAL|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
219418180|NCT05475912|OTHER|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
219418181|NCT00825955|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
219418182|NCT00825955|OTHER|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
219418183|NCT00825955|PROCEDURE|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
219418184|NCT01453309|PROCEDURE|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
219418185|NCT01453309|PROCEDURE|No Cell Saver|Cell Saver will not be available during surgery
219418186|NCT03384225|DRUG|Cladribine|
219572723|NCT03543345|DIAGNOSTIC_TEST|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~* Written consent.~* Complete history.~* Complete physical examination.~* Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~* Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
219572724|NCT00121147|DRUG|Travatan|
219572725|NCT00121147|DRUG|Azopt|
219572726|NCT00121147|DRUG|Alphagan P|
219572727|NCT04882982|BEHAVIORAL|Caria app|App to improve symptoms of menopause
219572728|NCT04882982|BEHAVIORAL|Menopause Education|Educational materials about symptoms of menopause
219572729|NCT02971982|DRUG|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
219572730|NCT02971982|DRUG|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
219761788|NCT05722769|BEHAVIORAL|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
219418187|NCT03384225|DRUG|Fludarabine|
219418188|NCT03384225|DRUG|Busulfan|
219418189|NCT03384225|DRUG|Cytarabine|
219418190|NCT05008588|BIOLOGICAL|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
219572731|NCT02780427|DRUG|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
219572732|NCT06615791|BEHAVIORAL|FIT FIRST Teen|High intensity sports drills and games.
219572733|NCT03313882|OTHER|no intervention is involved|
219572734|NCT05440331|OTHER|Training with AnesList©|Training with AnesList© as tool
219572735|NCT00485927|BEHAVIORAL|stress|
219572736|NCT01487382|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
219190834|NCT03617445|DRUG|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
219190835|NCT02578550|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
219190836|NCT02578550|DRUG|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
219190837|NCT02578550|DRUG|Darunavir|A single tablet containing darunavir 800 mg will be administered.
219190838|NCT02578550|DRUG|Cobicistat|A single table containing cobistat 150 mg will be administered.
219190839|NCT05216406|DIETARY_SUPPLEMENT|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
219418191|NCT05008588|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
219418192|NCT05008588|PROCEDURE|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
219418193|NCT02377271|DRUG|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
219418194|NCT02377271|DRUG|placebo|treatment by bosentan or placebo is randomized
219758622|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
219758623|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
219418195|NCT02210871|DRUG|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
219418196|NCT05739812|DEVICE|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
219418197|NCT06293664|OTHER|α-MSH infusion|Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
219418198|NCT06293664|OTHER|Placebo solutions|Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
219418199|NCT00305851|PROCEDURE|Music Therapy|Undergo therapeutic music video therapy
219758624|NCT01626742|OTHER|Ready to Drink Flavored Beverage|2 servings a day
219758625|NCT01626742|OTHER|Ready to drink flavored beverage w/ AN 777|2 servings a day
219758626|NCT02202564|PROCEDURE|LT|Orthotopic LT
219758627|NCT02202564|DRUG|ADV-TK|
219758628|NCT02202564|DRUG|ganciclovir|
219758629|NCT02612246|DRUG|GLPG1972 single ascending doses|single dose, oral solution
219758630|NCT02612246|DRUG|Placebo single dose|single dose, oral solution, matching placebo
219758631|NCT02612246|DRUG|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
219758632|NCT02612246|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
219758633|NCT01216488|DRUG|Xylocaine|40 ml or 25 ml of Xylocaine injection
219758634|NCT04707092|DRUG|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
219758635|NCT03825627|DEVICE|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
219758636|NCT05162690|DRUG|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
219758637|NCT05162690|OTHER|Placebo|Metformin DPP4 inhibitors
219758638|NCT00639951|BIOLOGICAL|A|20 vials up front in a Single Dose of Antivipmyn
219758639|NCT00639951|BIOLOGICAL|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
219758640|NCT05874089|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billions/sachets
219758641|NCT05874089|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
219758642|NCT02764411|DRUG|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
219758643|NCT03528317|OTHER|Alternate day fasting|Alternate day fasting with a high protein diet
219758644|NCT01265485|DRUG|coated suppository|Dose escalating study
219758645|NCT05247203|BIOLOGICAL|Telitacicept|subcutaneous injection
219758646|NCT05247203|DRUG|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
219758647|NCT01622296|DRUG|Sodium bicarbonate|8.4% neutralizing solution
219190840|NCT05216406|OTHER|Placebo|Maltodextrin capsule
219190841|NCT05485584|DRUG|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
219190842|NCT05485584|DRUG|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
219190843|NCT05485584|DRUG|Placebo Nasal Spray|Once daily
219418200|NCT00305851|PROCEDURE|Psychosocial Assessment and Care|Undergo books on tape therapy
219418201|NCT00305851|OTHER|Quality-of-Life Assessment|Ancillary studies
219418202|NCT02344069|DRUG|Fibrinogen|Human fibrinogen concentrate as a injection
219418203|NCT02344069|DRUG|Placebo|Saline 0.9% as a injection
219418204|NCT02660333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin - 11g/day
219418205|NCT02660333|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharide - 11g/day
219418206|NCT02660333|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
219418207|NCT03348852|DEVICE|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
219418208|NCT00005096|DRUG|docetaxel|
219418209|NCT01035242|BEHAVIORAL|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
219418210|NCT01035242|BEHAVIORAL|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
219418211|NCT03420716|DIETARY_SUPPLEMENT|yogurt|
219418212|NCT05943327|DRUG|Lu AG06474|Oral Solution
219418213|NCT05943327|DRUG|Placebo|Oral Solution
219418214|NCT05943327|DRUG|Lu AG06474|Capsule
219572737|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
219572738|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
219572739|NCT00958126|BIOLOGICAL|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
219572740|NCT04339426|DRUG|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
219418215|NCT01726920|DRUG|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
219418216|NCT01726920|DRUG|naratriptan|Tablets containing naratriptan 2,5 mg
219418217|NCT01726920|DRUG|naproxen|Tablets containing naproxen 500 mg
219418218|NCT04196361|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound as part of routine physical examination
219418219|NCT06422351|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
219572741|NCT06208826|DRUG|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
219572742|NCT06208826|RADIATION|Radiation Therapy|Radiation Therapy
219572743|NCT06208826|DRUG|Cisplatin|Chemotherapy agent
219004608|NCT05673512|COMBINATION_PRODUCT|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
219004609|NCT02402439|DRUG|Islet cells|Transplantation of islets into the gastrointestinal submucosa
219190844|NCT05485584|DRUG|Placebo Nasal Spray|Twice daily
219190845|NCT04266431|BEHAVIORAL|EMPOWER|Behavioral weight loss intervention
219190846|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery|Esthetic crown lengthening surgery using mock-up based guide
219190847|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery using Digital guide|Esthetic crown lengthening surgery using digital guide based on DSD and CBCT
219572744|NCT00720226|DRUG|Losartan|Losartan 100 mg daily
219572745|NCT00720226|DRUG|Placebo|Placebo pill daily
219572746|NCT01497626|DRUG|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
219572747|NCT01481740|DRUG|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
219572748|NCT01481740|DRUG|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
219572749|NCT03401073|DRUG|Intravenous immunoglobulin|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
219572750|NCT03401073|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
219572751|NCT05223257|OTHER|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
219004610|NCT02402439|PROCEDURE|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
219004611|NCT03668912|BEHAVIORAL|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
219190848|NCT04869631|OTHER|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
219418220|NCT05342129|OTHER|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
219418221|NCT03670641|DRUG|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
219418222|NCT03670641|DRUG|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
219418223|NCT03670641|DEVICE|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
219418224|NCT04331873|DIAGNOSTIC_TEST|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
219418225|NCT03246217|BEHAVIORAL|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
219418226|NCT03246217|BEHAVIORAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
219418227|NCT03246217|BEHAVIORAL|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
219418228|NCT03759457|DEVICE|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
219418229|NCT01319643|DRUG|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
219418230|NCT03018626|DRUG|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
219418231|NCT03018626|DRUG|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
219004612|NCT06189651|DEVICE|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
219190849|NCT04690582|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
219190850|NCT04690582|BEHAVIORAL|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
219418232|NCT03018626|DRUG|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
219418233|NCT03018626|DRUG|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
219418234|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
219418235|NCT03018626|DRUG|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
219418236|NCT03018626|DRUG|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
219418237|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
219418238|NCT03018626|DRUG|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
219572752|NCT00733369|DEVICE|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
219572753|NCT00733369|DEVICE|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
219572754|NCT02529202|DRUG|Dexmedetomidine|Dexmedetomidine infusion
219572755|NCT01334684|DRUG|Metformin|Metformin, pills, 850 mg three times a day for three months
219572756|NCT00279955|DEVICE|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
219572757|NCT01470612|DRUG|CP-690,550|5 mg tablets, BID, for at least 12 months
219572758|NCT01470612|DRUG|CP-690,550|10 mg tablets, BID, for at least 12 months
219758648|NCT01622296|DRUG|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
219758649|NCT04946058|PROCEDURE|hyebrid Mathieu Urethroplasty|incision of the urethral plate during the procedure
219190851|NCT04690582|BEHAVIORAL|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
219418239|NCT03018626|DRUG|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
219418240|NCT02960048|DEVICE|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
219418241|NCT02960048|DEVICE|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
219418242|NCT02007330|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
219418243|NCT02007330|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
219418244|NCT04229589|OTHER|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
219418245|NCT01449591|DRUG|BFH772 1% ointment|
219418246|NCT01449591|DRUG|Vehicle ointment|
219418247|NCT01449591|DRUG|Noritate® 1% cream|
219418248|NCT01096849|DRUG|levofloxacin|
219418249|NCT01096849|DRUG|plazomicin|
219418250|NCT01096849|DRUG|placebo|
219418251|NCT03412318|DEVICE|Twisted file|Use of twisted file during cleaning and shaping of root canals
219418252|NCT03412318|DEVICE|Mpro|Use of Mpro during cleaning and shaping of root canals
219418253|NCT03571334|DRUG|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
219418254|NCT03571334|DRUG|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
219418255|NCT03744884|BEHAVIORAL|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
219418256|NCT04460690|DEVICE|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
219418257|NCT01542359|OTHER|Yogic practice|breathing, meditation, physical postures
219418258|NCT01542359|OTHER|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
219418259|NCT01457859|DRUG|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
219572759|NCT00065455|DRUG|Vitamin A|
219572760|NCT01397708|BIOLOGICAL|INXN-2001|"* approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles"
219572761|NCT01397708|DRUG|INXN-1001|"* 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
219572762|NCT01343095|DEVICE|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
219572763|NCT01343095|DEVICE|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
219572764|NCT02510014|DRUG|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
219572765|NCT02510014|DRUG|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
219418260|NCT01457859|OTHER|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
219418261|NCT05145075|OTHER|Survey|Patients are asked to fill in a survey concerning teleconsultations
219418262|NCT03154632|DEVICE|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
219418263|NCT03154632|DEVICE|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
219572766|NCT01913236|OTHER|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
219572767|NCT05206487|DIETARY_SUPPLEMENT|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
219572768|NCT04714970|DEVICE|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
219572769|NCT04714970|DEVICE|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
219572770|NCT02896777|OTHER|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
219572771|NCT02896777|OTHER|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
219572772|NCT02896777|OTHER|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
219572773|NCT00654654|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments"
219572774|NCT03083626|OTHER|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
219572775|NCT01770431|DRUG|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
219572776|NCT02328950|DRUG|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
219758650|NCT01731795|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
219758651|NCT01652781|DRUG|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
219758652|NCT01281111|DRUG|Dimethyl Fumarate (BG00012)|
219758653|NCT01281111|DRUG|Aspirin|
219758654|NCT01281111|DRUG|BG00012 matching placebo|
219758655|NCT01281111|DRUG|ASA matching placebo|
219758656|NCT05003193|DEVICE|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
219418264|NCT05115500|DRUG|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
219418265|NCT02024893|OTHER|Observational study|"Observation and type of data collected are listged in detail under 'description"
219758657|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
219572777|NCT04948957|DRUG|Esmolol|
219572778|NCT04948957|DRUG|Nitroglycerin|
219572779|NCT00674401|PROCEDURE|Radiofrequency catheter ablation|"* In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
219572780|NCT04462016|OTHER|Calamansi|250 ml of a commercially sourced calamansi drink
219572781|NCT04462016|OTHER|Glucose|75 g of glucose dissolved in 250 ml of drinking water
219572782|NCT01095419|OTHER|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
219572783|NCT01095419|OTHER|Control|no intervention
219572784|NCT01221246|DRUG|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
219418266|NCT04445493|DEVICE|MindRhythm Harmony|Passive recording of the head pulse
219418267|NCT05717452|DIETARY_SUPPLEMENT|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
219418268|NCT05717452|DIETARY_SUPPLEMENT|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
219418269|NCT00174707|DRUG|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
219418270|NCT00174707|DRUG|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
219418271|NCT00174707|DRUG|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
219418272|NCT00118482|DRUG|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
219418273|NCT06151366|OTHER|non interventional|non interventional
219418274|NCT03870126|OTHER|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
219418275|NCT00242580|DRUG|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
219418276|NCT00242580|DRUG|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
219418277|NCT00242580|DRUG|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
219418278|NCT05745324|PROCEDURE|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
219418279|NCT01241669|DRUG|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
219418280|NCT01241669|DRUG|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
219418281|NCT04791683|OTHER|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
219758658|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
219758659|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
219758660|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
219758661|NCT05351528|OTHER|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
219758662|NCT00090376|DRUG|GPI 1485|
219758663|NCT06400667|DEVICE|Upper limb Kinematic Assessment with Optoelectronic system|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
219758664|NCT01528579|OTHER|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
219758665|NCT01528579|BEHAVIORAL|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
219758666|NCT01528579|OTHER|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
219758667|NCT01561833|DRUG|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
219758668|NCT00372957|DRUG|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
219758669|NCT00372957|DRUG|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
219758670|NCT00372957|DRUG|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
219758671|NCT05444738|DRUG|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
219758672|NCT05444738|DRUG|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
219758673|NCT01750853|DRUG|LY3045697|Administered orally
219758674|NCT01750853|DRUG|Placebo|Administered orally
219758675|NCT02660229|DRUG|Oxycodone Hydrochloride|Oxycodone injection
219758676|NCT02660229|DRUG|Morphine Sulphate|Morphine sulphate injection
219758677|NCT01110057|DRUG|Placebo|Placebo to match GW856553
219758678|NCT01110057|DRUG|GS856553|GW586553 7.5mg bid
219758679|NCT00938262|DRUG|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
219758680|NCT02271880|OTHER|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
219758681|NCT02271880|OTHER|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
219758682|NCT00966108|DEVICE|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
219418282|NCT05201183|COMBINATION_PRODUCT|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
219418283|NCT00029991|DRUG|Gingko Biloba (Herb)|
219418284|NCT03513965|BEHAVIORAL|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
219418285|NCT03513965|BEHAVIORAL|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
219418286|NCT02328989|DEVICE|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
219418287|NCT00235339|BEHAVIORAL|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
219418288|NCT00235339|BEHAVIORAL|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
219418289|NCT03720730|OTHER|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
219418290|NCT01795222|DRUG|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
219418291|NCT01795222|DRUG|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
219418292|NCT02643186|DRUG|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
219418293|NCT02643186|PROCEDURE|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
219758683|NCT03423511|DEVICE|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
219758684|NCT03423511|DEVICE|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
219758685|NCT05165706|BEHAVIORAL|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
219758686|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
219758687|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
219758688|NCT06249464|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
219758689|NCT06249464|DRUG|Lidocaine hydrochloride|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
219758690|NCT01402310|OTHER|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
219418294|NCT04720586|PROCEDURE|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
219418295|NCT04720586|PROCEDURE|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
219418296|NCT04546386|PROCEDURE|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
219572785|NCT01221246|DRUG|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
219572786|NCT01974908|PROCEDURE|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
219572787|NCT02516423|DRUG|ixazomib|oral
219572788|NCT02516423|DRUG|lenalidomide|oral
219572789|NCT02516423|DRUG|dexamethasone|oral
219572790|NCT02516423|DRUG|zoledronic acid|IV
219572791|NCT00065013|BEHAVIORAL|strength training|
219572792|NCT06437418|DIAGNOSTIC_TEST|abdominal ultrasonography.|Evaluate the gallbladder ejection fraction (EF)
219572793|NCT04971213|DEVICE|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
219572794|NCT04971213|DEVICE|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
219418297|NCT00753935|DRUG|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
219418298|NCT00753935|DRUG|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
219418299|NCT05314218|DEVICE|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~* Exploration procedures for diagnosis alone~* Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
219418300|NCT03970395|OTHER|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
219418301|NCT03970395|OTHER|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
219572795|NCT00911599|DIAGNOSTIC_TEST|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
219572796|NCT02691832|DEVICE|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
219572797|NCT02556307|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
219572798|NCT02556307|DRUG|Ribavirin|Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
219572799|NCT03329807|DEVICE|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
219572800|NCT03329807|BEHAVIORAL|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
219572801|NCT01510652|PROCEDURE|BiP Group|Implantation of standard Left Ventricular (LV) lead
219572802|NCT01510652|DEVICE|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
219572803|NCT04574115|DEVICE|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
219572804|NCT04574115|DEVICE|FDA approved Intraocular Lens|FDA approved Intraocular Lens
219572805|NCT04008537|DEVICE|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
219572806|NCT03913897|OTHER|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
219572807|NCT06603987|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
219572808|NCT06603987|DIAGNOSTIC_TEST|［18F］FBPA|Intravenous injection of ［18F］FBPA and radiation exposure from PET-CT scan.
219572809|NCT04191798|BEHAVIORAL|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
219572810|NCT04191798|BEHAVIORAL|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
219418302|NCT03970395|OTHER|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
219418303|NCT00062114|BIOLOGICAL|rituximab|
219418304|NCT00062114|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219418305|NCT04257955|BEHAVIORAL|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
219418306|NCT03482323|BEHAVIORAL|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
219418307|NCT03482323|BEHAVIORAL|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
219418308|NCT00469755|DRUG|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
219418309|NCT00469755|DRUG|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
219418310|NCT00469755|DRUG|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
219418311|NCT04788108|DRUG|Dydrogesterone|Dydrogesterone tablet
219418312|NCT04788108|DRUG|Placebo|Placebo tablet
219572811|NCT04079127|DEVICE|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
219572812|NCT01344382|BEHAVIORAL|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
219758691|NCT06048458|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
219758692|NCT06048458|DIAGNOSTIC_TEST|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
219758693|NCT06048458|DIAGNOSTIC_TEST|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
219418313|NCT03927508|DRUG|r-tPA|Pulse spray and infusion
219418314|NCT03927508|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
219418315|NCT00125190|DRUG|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
219758694|NCT06048458|DIAGNOSTIC_TEST|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
219758695|NCT06048458|DIAGNOSTIC_TEST|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
219758696|NCT02345239|DRUG|Pantoprazole|proton pump inhibitor
219758697|NCT06547736|DRUG|SHR-A2102 or/and HRS-4642|"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
219758698|NCT06547736|DRUG|SHR-A1904 or/and HRS-4642|"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
219758699|NCT06547736|DRUG|SHR-A1811 or/and HRS-4642|"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
219758700|NCT00738296|DRUG|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
219758701|NCT00738296|DRUG|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
219758702|NCT00738296|DRUG|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
219758703|NCT02431325|DRUG|Teduglutide|
219758704|NCT02431325|DRUG|Placebo|
219758705|NCT05206903|OTHER|Questionnaires|Questionnaires about pandemia process
219761789|NCT05552664|GENETIC|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
219761790|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
219418316|NCT04076150|DEVICE|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
219418317|NCT02734719|DEVICE|Bonestim|Bonestim is the multipad electrical stimulation device.
219418318|NCT00334932|DRUG|bortezomib|
219418319|NCT00334932|DRUG|melphalan|
219418320|NCT00334932|DRUG|pegylated liposomal doxorubicin hydrochloride|
219418321|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
219418322|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
219418323|NCT02817152|PROCEDURE|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
219418324|NCT02817152|DEVICE|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
219418325|NCT01441921|DIETARY_SUPPLEMENT|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
219418326|NCT01441921|OTHER|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
219418327|NCT02242825|DRUG|Micardis®|
219418328|NCT02242825|DRUG|MicardisPlus®|
219418329|NCT02266186|BEHAVIORAL|Traditional Cognitive behavioural therapy|Therapist supported live therapy
219418330|NCT02266186|BEHAVIORAL|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
219418331|NCT01015482|DRUG|Remifentanil|Remifentanil Infusion
219418332|NCT01015482|DRUG|Midazolam|Midazolam Infusion
219418333|NCT06281782|OTHER|topical retinoids and platalet rich plasma|We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
219418334|NCT05198752|DRUG|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
219418335|NCT00575952|DRUG|Cisplatin|Given IV or IP
219418336|NCT00575952|DRUG|Doxorubicin Hydrochloride|Given IV
219418337|NCT00575952|BIOLOGICAL|Filgrastim|Given SC
219572813|NCT01344382|BEHAVIORAL|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
219572814|NCT00384176|DRUG|Cediranib|oral tablet once daily
219572815|NCT00384176|DRUG|Bevacizumab|intravenous infusion
219418338|NCT00575952|DRUG|Paclitaxel|Given IV or IP
219418339|NCT00575952|BIOLOGICAL|Pegfilgrastim|Given SC
219418340|NCT00578799|DIETARY_SUPPLEMENT|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
219418341|NCT00578799|DIETARY_SUPPLEMENT|placebo|placebo capsules (potato starch
219418342|NCT03319615|BEHAVIORAL|Dietary energy restriction|
219758706|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
219758707|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
219418343|NCT05595785|BEHAVIORAL|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
219418344|NCT05595785|BEHAVIORAL|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
219572816|NCT00384176|DRUG|5-fluorouracil ( in FOLFOX)|intravenous infusion
219572817|NCT00384176|DRUG|Leucovorin (in FOLFOX)|intravenous infusion
219572818|NCT00384176|DRUG|Oxaliplatin (in FOLFOX)|intravenous infusion
219572819|NCT04810520|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
219572820|NCT04810520|OTHER|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
219572821|NCT02409394|DRUG|Hetrombopag Olamine|
219572822|NCT02999594|DRUG|Tramadol Hydrochloride|50mg intramuscularly
219572823|NCT02999594|DRUG|Distilled Water|2ml intramuscularly
219758708|NCT05157087|DRUG|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
219418345|NCT01892098|DIETARY_SUPPLEMENT|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
219572824|NCT05754229|DEVICE|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
219418346|NCT01892098|DIETARY_SUPPLEMENT|Placebo|Cellulose pill given as placebo
219418347|NCT04793386|DIAGNOSTIC_TEST|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
219418348|NCT05242549|BEHAVIORAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
219418349|NCT04868591|OTHER|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
219418350|NCT04868591|OTHER|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
219572825|NCT04387682|DIETARY_SUPPLEMENT|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
219572826|NCT05941273|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
219418351|NCT05449613|DRUG|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
219418352|NCT05449613|OTHER|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
219418353|NCT04102878|DRUG|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
219572827|NCT06048289|OTHER|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
219572828|NCT04854564|BEHAVIORAL|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
219572829|NCT04854564|BEHAVIORAL|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
219572830|NCT00946049|DEVICE|Vicryl Plus|
219572831|NCT00946049|DEVICE|Vicryl|
219418354|NCT04102878|PROCEDURE|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
219418355|NCT04102878|PROCEDURE|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
219418356|NCT04102878|OTHER|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
219418357|NCT04102878|OTHER|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
219418358|NCT04102878|PROCEDURE|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
219418359|NCT03206242|OTHER|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
219418360|NCT02921919|DRUG|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
219418361|NCT06162260|PROCEDURE|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
219418362|NCT03790462|OTHER|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected."
219418363|NCT03612180|DRUG|Metoprolol Succinate|Pharmacokinetics
219418364|NCT04079894|OTHER|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
219418365|NCT04079894|DEVICE|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
219418366|NCT04635072|DRUG|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
219418367|NCT03282357|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
219418368|NCT03282357|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection
219418369|NCT04353921|OTHER|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
219418370|NCT05894473|OTHER|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
219418371|NCT00642655|DRUG|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
219418372|NCT06365814|OTHER|enhanced recovery after surgery|ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
219418373|NCT06365814|OTHER|conventional perioperative management|conventional perioperative management
219418374|NCT04922515|OTHER|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
219418375|NCT05041452|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameters
219418376|NCT01586156|DRUG|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
219418377|NCT01586156|DRUG|placebo|Placebo will be taken twice daily for 6 months
219572832|NCT04656730|DRUG|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
219572833|NCT01785121|BEHAVIORAL|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
219572834|NCT01785121|BEHAVIORAL|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
219572835|NCT00102830|DRUG|AMG 386|
219418378|NCT06063252|BEHAVIORAL|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
219418379|NCT00547378|DEVICE|InterStim|
219418380|NCT00547378|DRUG|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
219418381|NCT02508688|PROCEDURE|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
219418382|NCT02871115|OTHER|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
219418383|NCT02871115|OTHER|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
219418384|NCT04096352|BEHAVIORAL|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
219418385|NCT04096352|BEHAVIORAL|Indirect Method|Information on voice function and voice hygiene.
219418386|NCT04105244|BEHAVIORAL|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
219418387|NCT02112994|DRUG|Sebelipase Alfa|IV infusion of sebelipase alfa
219418388|NCT01525927|DRUG|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
219418389|NCT01525927|RADIATION|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
219418390|NCT01525927|RADIATION|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
219418391|NCT02768194|DEVICE|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
219572836|NCT04432675|DRUG|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
219418392|NCT02768194|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
219418393|NCT02768194|OTHER|Mineral water|Commercially available mineral water
219418394|NCT03684291|PROCEDURE|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
219418395|NCT06553066|DRUG|Deep neuromascular blockage|"maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
219418396|NCT06553066|DRUG|Moderate neuromascular blockage|maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
219418397|NCT03926767|OTHER|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
219418398|NCT03926767|OTHER|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
219418399|NCT03926767|OTHER|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
219572837|NCT04432675|DRUG|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
219572838|NCT03407521|DRUG|Misoprostol|induction of abortion using misoprostol
219572839|NCT03407521|DRUG|isosorbide mononitrate|isosorbide mononitrate
219572840|NCT03407521|DRUG|Placebo|Placebo
219572841|NCT05307159|DIETARY_SUPPLEMENT|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
219418400|NCT03926767|OTHER|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
219418401|NCT05787912|DEVICE|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
219418402|NCT05787912|OTHER|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
219418403|NCT00747838|PROCEDURE|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
219418404|NCT06128590|DEVICE|Photobiomodulation|"Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups."
219418405|NCT06128590|DRUG|Mepivacaine hydrochloride in combination with epinephrine|"The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure."
219572842|NCT04108559|PROCEDURE|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
219572843|NCT04108559|PROCEDURE|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
219572844|NCT04108559|OTHER|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
219572845|NCT05418075|OTHER|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
219572846|NCT03293173|COMBINATION_PRODUCT|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
219572847|NCT03293173|COMBINATION_PRODUCT|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
219572848|NCT01330667|DIETARY_SUPPLEMENT|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
219572849|NCT01612416|DEVICE|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
219572850|NCT06420414|OTHER|Virtual Reality|"Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance."
219572851|NCT06420414|OTHER|Traditional HIIT|"Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency."
219572852|NCT04127955|OTHER|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
219572853|NCT04798235|BIOLOGICAL|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
219004613|NCT06189651|PROCEDURE|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
219004614|NCT02834208|OTHER|MRI (Magnetic resonance imaging)|
219418406|NCT06128590|DEVICE|Photobiomodulation simulation|The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
219418407|NCT01321502|DRUG|famciclovir|500 mg tablet
219418408|NCT04873284|DRUG|fosaprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV"
219418409|NCT04873284|DRUG|aprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg)."
219418410|NCT04873284|DRUG|Granisetron plus dexamethasone|Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
219418411|NCT02137590|DIETARY_SUPPLEMENT|Spanish Black Radish product|
219572854|NCT03643679|OTHER|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
219418412|NCT06015802|OTHER|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
219418413|NCT05611359|PROCEDURE|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
219418414|NCT05611359|DRUG|Chemotherapy|Chemotherapy
219418415|NCT03754283|DEVICE|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
219418416|NCT00975195|DRUG|tiotropium inhalation|
219418417|NCT00975195|DRUG|salmeterol xinafoate|
219190852|NCT04690582|BEHAVIORAL|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
219418418|NCT00975195|DRUG|fluticasone propionate|
219418419|NCT00975195|DRUG|placebo matched for fluticasone propionate|
219418420|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
219418421|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
219418422|NCT03509337|DIAGNOSTIC_TEST|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
219418423|NCT01782456|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
219418424|NCT04108585|PROCEDURE|HFO therapy|HFO therapy from mechanical ventilation
219418425|NCT04108585|PROCEDURE|CPAP therapy|CPAP therapy from mechanical ventilation
219572855|NCT03603938|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
219572856|NCT00049842|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
219758709|NCT02901886|BEHAVIORAL|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
219758710|NCT02185300|DRUG|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
219758711|NCT02185300|DRUG|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
219758712|NCT06041321|DEVICE|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
219758713|NCT06041321|DEVICE|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
219758714|NCT01641484|PROCEDURE|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
219758715|NCT03857776|OTHER|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
219004615|NCT02834208|GENETIC|Polymorphism (SNP in DNA)|
219004616|NCT02834208|GENETIC|quantitative measures of mRNA|
219004617|NCT02834208|OTHER|Neuropsychological assessment|
219004618|NCT01504945|OTHER|RBC transfusion|1 bag of packed red blood cells
219004619|NCT01504945|OTHER|Normal saline infusion|500 mL of normal saline infusion
219418426|NCT01343134|DEVICE|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
219418427|NCT00002833|BIOLOGICAL|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
219418428|NCT00002833|DRUG|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
219418429|NCT00002833|DRUG|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
219418430|NCT00002833|DRUG|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
219758716|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about CAM
219758717|NCT02045602|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
219758718|NCT02045602|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
219758719|NCT02045602|DRUG|Abraxane®|125 mg/m2 intravenous administration
219758720|NCT01818687|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
219758721|NCT00049361|DRUG|temozolomide|
219758722|NCT00049361|DRUG|thalidomide|
219758723|NCT00049361|RADIATION|radiation therapy|
219758724|NCT05524831|OTHER|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
219758725|NCT05524831|OTHER|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
219758726|NCT05185076|DEVICE|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
219758727|NCT02353962|OTHER|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
219418431|NCT00002833|DRUG|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
219418432|NCT00002833|DRUG|Idarubicin|IV Days -6, -5 and -4.
219418433|NCT00002833|DRUG|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
219418434|NCT00002833|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
219418435|NCT03251287|DRUG|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
219418436|NCT03251287|DRUG|Placebo|Single dose of oral matching placebo
219418437|NCT03251287|DIAGNOSTIC_TEST|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
219418438|NCT03251287|DIAGNOSTIC_TEST|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
219418439|NCT00764959|DEVICE|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
219418440|NCT00077519|DRUG|tipifarnib|
219418441|NCT00077519|RADIATION|radiation therapy|
219418442|NCT01611129|BEHAVIORAL|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
219418443|NCT05637723|OTHER|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
219418444|NCT05637723|OTHER|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
219418445|NCT00426517|DRUG|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
219418446|NCT00426517|DRUG|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
219418447|NCT00426517|DRUG|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
219418448|NCT00426517|DRUG|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
219418449|NCT00426517|DRUG|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
219418450|NCT01989234|DRUG|YKP10811|
219418451|NCT01989234|DRUG|Placebo|
219418452|NCT01608724|DRUG|Saxagliptin|oral, 5 mg once a day (Q.D.)
219418453|NCT00004038|BIOLOGICAL|Ad5CMV-p53 gene|
219418454|NCT00004038|DRUG|chemotherapy|
219418455|NCT06447324|DEVICE|Fender Mate matrix system|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
219418456|NCT06447324|DEVICE|T-band matrix|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
219758728|NCT01885988|DRUG|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
219758729|NCT01885988|DRUG|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
219418457|NCT01824173|OTHER|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
219418458|NCT01824173|OTHER|Aerobic exercise|Moderate intensity for 45 minutes
219418459|NCT00211718|DRUG|intra-articular botulinum toxin type a|
219418460|NCT00873808|DRUG|clodronate disodium|
219418461|NCT00873808|DRUG|demeclocycline hydrochloride|
219418462|NCT00873808|DRUG|ibandronate sodium|
219418463|NCT00873808|DRUG|tetracycline hydrochloride|
219418464|NCT00873808|DRUG|zoledronic acid|
219418465|NCT00873808|OTHER|laboratory biomarker analysis|
219758730|NCT02507986|DEVICE|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
219190853|NCT06051760|BIOLOGICAL|NV-001|NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
219418466|NCT00873808|PROCEDURE|adjuvant therapy|
219418467|NCT00873808|PROCEDURE|computed tomography|
219418468|NCT00873808|PROCEDURE|dual x-ray absorptiometry|
219418469|NCT02421744|BEHAVIORAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
219418470|NCT02421744|BEHAVIORAL|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
219758731|NCT02507986|DEVICE|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
219758732|NCT05746858|OTHER|no intervention (observational study)|No intervention (observational study)
219418471|NCT05391568|OTHER|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
219418472|NCT05391568|OTHER|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
219418473|NCT06146296|BIOLOGICAL|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
219572857|NCT04731311|DEVICE|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
219418474|NCT06146296|BIOLOGICAL|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
219418475|NCT00022035|BIOLOGICAL|trivalent influenza vaccine|
219572858|NCT01072266|DRUG|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
219572859|NCT02778503|OTHER|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
219572860|NCT02778503|OTHER|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
219572861|NCT03326674|DRUG|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
219572862|NCT03326674|DRUG|Capecitabine|Capecitabine alone at approved dose
219572863|NCT00231257|DEVICE|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
219572864|NCT00231257|PROCEDURE|Brachytherapy|Brachytherapy
219572865|NCT04133766|BEHAVIORAL|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
219190854|NCT03711474|DRUG|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
219190855|NCT03711474|DRUG|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
219418476|NCT06148896|BEHAVIORAL|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
219418477|NCT06148896|BEHAVIORAL|GrEx|Group physiotherapy exercise
219418478|NCT04837534|BEHAVIORAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
219418479|NCT04837534|BEHAVIORAL|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
219418480|NCT04387136|DRUG|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
219418481|NCT05255913|DRUG|Nanosilver|preventive material for arresting caries
219418482|NCT05255913|DRUG|Silver diamine fluoride|preventive material for arresting caries
219572866|NCT00307931|BIOLOGICAL|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
219572867|NCT00854373|DRUG|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
219572868|NCT00854373|OTHER|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
219572869|NCT02161120|OTHER|Traditional Finnish rye bread|
219572870|NCT02161120|OTHER|Low FODMAP rye bread|
219572871|NCT03249740|DRUG|GB-102|Intravitreal injection of GB-102
219572872|NCT03249740|DRUG|Aflibercept|Intravitreal injection of Aflibercept.
219572873|NCT00293202|DRUG|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
219572874|NCT00293202|DRUG|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
219418483|NCT03106506|PROCEDURE|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
219004620|NCT03648060|DEVICE|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
219004621|NCT02747589|PROCEDURE|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
219004622|NCT00816985|PROCEDURE|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
219004623|NCT00816985|OTHER|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
219418484|NCT00815906|DRUG|SBI-087|IV, Single dose
219418485|NCT00815906|DRUG|SBI-087|IV, Single dose
219418486|NCT00815906|DRUG|SBI-087|SC, Single dose
219418487|NCT00815906|DRUG|SBI-087|SC, Single dose
219418488|NCT00264849|DRUG|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
219418489|NCT00264849|OTHER|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
219418490|NCT04255836|DRUG|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
219418491|NCT04255836|DRUG|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
219418492|NCT04255836|RADIATION|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
219418493|NCT03019770|BEHAVIORAL|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
219418494|NCT00099359|DRUG|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
219418495|NCT00099359|DRUG|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams"
219418496|NCT00099359|DRUG|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams"
219572875|NCT00717184|DRUG|Interleukin, NK cells|
219572876|NCT05715554|OTHER|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
219572877|NCT02442271|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219004624|NCT02303288|DEVICE|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
219004625|NCT02015871|DRUG|Degarelix|
219418497|NCT00099359|DRUG|Nelfinavir (NFV)|200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
219418498|NCT03614442|OTHER|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
219418499|NCT01788306|DRUG|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
219418500|NCT05138406|OTHER|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
219572878|NCT02442271|DRUG|ribavirin|Tablet
219572879|NCT01508754|PROCEDURE|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
219572880|NCT05123677|DIAGNOSTIC_TEST|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
219572881|NCT05123677|DIAGNOSTIC_TEST|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
219572882|NCT06206083|GENETIC|Descriptive and analytical|Patients with EC endometroid
219572883|NCT02227654|PROCEDURE|Abnormal Ovarian Ultrasound|Ultrasound
219572884|NCT03531801|OTHER|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
219572885|NCT05955495|OTHER|Food|Post-operative feeding includes water, liquid diet, soft diet.
219572886|NCT04764955|DIETARY_SUPPLEMENT|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
219758733|NCT00401076|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
219418501|NCT05138406|OTHER|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
219418502|NCT01123577|OTHER|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
219004626|NCT06474052|DRUG|Gelofusine 4%|Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
219004627|NCT06451601|DEVICE|Intermittent hypoxia-hyperoxia therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, occupation, environment, body mass index, nutritional status, abdominal circumference, hip circumference, smoking, alcohol. Also, the patients performed a 6-minute walking test.~Other Names:~* Hydrokinetotherapy~* Hydrothermotherapy~* Electrotherapy~* Massage therapy~* Kinetotherapy"
219418503|NCT04627298|BEHAVIORAL|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
219418504|NCT01485926|DRUG|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
219418505|NCT01485926|DRUG|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
219418506|NCT01463865|DRUG|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
219418507|NCT01463865|DRUG|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
219418508|NCT05392894|PROCEDURE|Haploidentical stem cell transplantation|Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
219418509|NCT05392894|OTHER|Standard medical care|Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
219418510|NCT02713191|DRUG|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
219418511|NCT02713191|DRUG|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
219190856|NCT06813846|PROCEDURE|Mid-Crestal Sulcular Incision|A long incision over the crest and midway between buccolingual aspect through the gingiva from the site of the distal implant in mesial direction with intra-sulcular incisions in the teeth adjected to the implant site · Following a full or partial thickness flap is raised to establish access to cover screw.
219418512|NCT02713191|OTHER|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
219418513|NCT02713191|DRUG|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
219418514|NCT02713191|DRUG|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
219418515|NCT02756650|DRUG|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
219418516|NCT01822691|DRUG|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
219418517|NCT05902546|OTHER|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
219418518|NCT05902546|OTHER|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
219418519|NCT01546389|BIOLOGICAL|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
219418520|NCT01546389|DRUG|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
219418521|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with less ≤ 3mm from each other.|Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.
219418522|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with > 3mm from each other.|Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
219418523|NCT01897922|OTHER|An investigational infant formula containing a probiotic source|
219418524|NCT01897922|OTHER|Control: Marketed routine infant formula|
219418525|NCT04872816|DEVICE|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
219418526|NCT01015664|DRUG|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
219418527|NCT01015664|DRUG|cisplatin|75 mg/m2 IV over 60 minutes on day 1
219418528|NCT01015664|DRUG|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
219418529|NCT01156038|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
219190857|NCT06813846|PROCEDURE|Split-Finger Procedure|"The surgical technique first designs 3 interlacing fingers over and adjacent to each implant site and will be extended around each adjacent tooth. · A sulcular incision will be made 2 to 3 mm to the palatal side from each tooth with a loop design (at least 2.0-2.5 mm) adjacent to the implant location. · The incisions will then be joined facially with a semicircular incision at the preplanned free tissue margin of the implant crown. · The facial fingers will be elevated to the desired interimplant height for the papillae. The middle palatal finger will then be split and reflected to the respective mesial and distal sides (each is at least 2.0-2.5 mm wide). · The soft tissue maintains its elevated position with a permucosal extension or a final prosthetic abutment that is extended through the soft tissue. · A modified vertical mattress suture will then be used to suture each papilla using 4-0 or 5-0 Gut or Vicryl sutures."
219190858|NCT06813846|PROCEDURE|"I shaped incision"|A Labial horizontal incision with a #15c blade will be performed mesiodistally 0.5-1.0 mm inside from the labial border of the implant. A horizontal incision will also be performed, parallel to the buccal side, on the palatal side, which is in contact with the palatal border line of the implant different from the labial side. Another incision will be done bucco-lingually over the implant midline perpendicular to the horizontal incision lines performed on the labial and palatal sides. The flap will be reflected with care and the implant will be exposed to remove the cover screw. The healing abutment will be connected and both flaps will be folded up alongside the healing abutment intending them to heal without suture.
219418530|NCT05415852|DEVICE|Laser|Laser
219418531|NCT04972487|DRUG|Tofersen|Administered as intrathecal bolus injection
219418532|NCT03920826|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
219418533|NCT03920826|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
219418534|NCT04757909|DIAGNOSTIC_TEST|Monthly Haemoglobinometry|"Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary."
219418535|NCT02727270|OTHER|No Intervention - Observational Study|No Intervention - Observational Study
219418536|NCT05942157|OTHER|Therapeutic Drug Monitoring (TDM)|Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
219418537|NCT01260935|PROCEDURE|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
219418538|NCT01260935|PROCEDURE|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
219418539|NCT01985009|DEVICE|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
219418540|NCT05763160|DRUG|RZL-012|Ready to use drug product for injection into the subcutaneous fat
219418541|NCT06254027|DEVICE|Forte|One application per day for a complete treatment period.
219418542|NCT06254027|DEVICE|Active Cover Light|One application per day for a complete treatment period.
219418543|NCT06254027|DRUG|Loceryl|One application per week for a complete treatment period.
219190859|NCT05487404|DRUG|ADX-629|3 oral doses of ADX-629 600 milligrams
219418544|NCT03365427|OTHER|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
219418545|NCT02742350|DEVICE|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
219418546|NCT02998060|PROCEDURE|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
219418547|NCT02998060|DEVICE|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
219418548|NCT02998060|DEVICE|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
219418549|NCT03858062|DEVICE|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
219418550|NCT03858062|DEVICE|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
219418551|NCT04078672|PROCEDURE|NOTAL-OCT V3.0|AMD and DR patients
219418552|NCT00780169|DRUG|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"
219418553|NCT03371160|DEVICE|Nutriplace™ System|The Nutriseal™ Nutriplace™ System is an electromagnetic tracking system for feeding tube placement designed to aid qualified operators in the placement of the Nutriseal™ Enteral Feeding Tube™ into the stomach or small intestine.
219761791|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
219761792|NCT06222606|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
219761793|NCT04314401|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
219761794|NCT04314401|PROCEDURE|Computed Tomography|Undergo CT
219761795|NCT04314401|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761796|NCT04314401|OTHER|Medical Chart Review|Medical charts are reviewed and data is collected
219761797|NCT04314401|PROCEDURE|Paracentesis|Undergo paracentesis
219761798|NCT04314401|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219761799|NCT02018692|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
219761800|NCT02018692|DIETARY_SUPPLEMENT|Placebo:Starch|Starch powder
219761801|NCT06807268|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
219761802|NCT06807268|OTHER|Placebo|Placebo administered as liquid oral suspension.
219761803|NCT03981445|BEHAVIORAL|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
219761804|NCT03981445|BEHAVIORAL|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
219761805|NCT06270719|GENETIC|Delandistrogene Moxeparvovec|No study medication will be provided by the sponsor during this study.
219761806|NCT06270719|DRUG|Standard of Care|No study medication will be provided by the sponsor during this study.
219761807|NCT05807594|BEHAVIORAL|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
219418554|NCT03177980|DRUG|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
219418555|NCT03177980|DRUG|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
219418556|NCT05272527|BEHAVIORAL|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
219418557|NCT01317667|BIOLOGICAL|RVEc|
219418558|NCT02381496|DRUG|ACT-453859 1 mg|Capsule
219418559|NCT02381496|DRUG|ACT-453859 3 mg|Capsule
219418560|NCT02381496|DRUG|ACT-453859 10 mg|Capsule
219418561|NCT02381496|DRUG|ACT-453859 30mg|Capsule
219418562|NCT02381496|DRUG|ACT-453859 100 mg|Capsule
219418563|NCT02381496|DRUG|ACT-453859 300 mg|Capsule
219418564|NCT02381496|DRUG|ACT-453859 800 mg|Capsule
219418565|NCT02381496|OTHER|Placebo|Matching ACT-453859 placebo capsule
219418566|NCT02381496|DRUG|Setipiprant 500 mg|Capsule
219418567|NCT02381496|DRUG|Setipiprant 1000 mg|Capsule
219418568|NCT00394290|DEVICE|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
219418569|NCT05607017|DRUG|Losartan|Taken Orally
219418570|NCT05607017|RADIATION|Radiation Therapy|Photon Radiation Therapy
219418571|NCT05403749|BIOLOGICAL|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
219418572|NCT05403749|DRUG|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
219418573|NCT05403749|BIOLOGICAL|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
219418574|NCT00605410|DRUG|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
219418575|NCT00605410|DRUG|placebo|Matched placebo
219418576|NCT04374110|OTHER|Clinical data|Clinical characteristics from medical records
219418577|NCT03752606|BIOLOGICAL|TACHOSIL GROUP|
219418578|NCT03696303|OTHER|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
219418579|NCT02213302|DRUG|placebo administration|
219418580|NCT02213302|DRUG|midazolam intravenous administration|
219418581|NCT04515043|DRUG|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
219418582|NCT02862821|OTHER|HR-EEG|
219418583|NCT04501679|DRUG|Nemolizumab|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
219190860|NCT05487404|DRUG|Placebo|3 oral doses of placebo
219190861|NCT04889716|DRUG|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
219418584|NCT04501679|DRUG|Placebo|Participants received matching placebo as SC injection.
219418585|NCT01977079|OTHER|procalcitonin|
219418586|NCT03365479|DRUG|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
219418587|NCT01032993|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
219418588|NCT01032993|OTHER|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
219418589|NCT04979832|DRUG|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
219418590|NCT00978809|OTHER|Epley maneuver|
219418591|NCT00978809|OTHER|Semont maneuver|
219418592|NCT00186056|DRUG|Mifepristone|Glucocorticoid antagonist
219418593|NCT00186056|DRUG|Placebo Oral Tablet|Inactive placebo tab
219418594|NCT05872594|DIAGNOSTIC_TEST|Online questionnaire|data will be collected remotely on the online platform Qualtrics
219418595|NCT04412382|DIAGNOSTIC_TEST|NETosis markers|"NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed."
219418596|NCT02128282|DRUG|CX-4945|API powder-in-capsule in 200 mg strength.
219418597|NCT02128282|DRUG|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
219418598|NCT02128282|DRUG|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
219418599|NCT03998020|OTHER|scale of severity|assessment of the severity of the sleep disorders by scale
219418600|NCT03998020|GENETIC|blood sample|Genetical study, serum and sample
219418601|NCT02273557|DRUG|Asasantin ER (new formulation I - low)|
219418602|NCT02273557|DRUG|Asasantin ER (new formulation III - medium)|
219418603|NCT02273557|DRUG|Asasantin ER (new formulation II - high)|
219418604|NCT02273557|DRUG|Asasantin ER (present commercial formulation)|
219418605|NCT03543306|DRUG|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
219572887|NCT04764955|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
219572888|NCT04878614|DRUG|Levothyroxine Tablet|Standard clinical management
219004628|NCT01377532|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
219418606|NCT04110418|DRUG|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
219418607|NCT00053261|PROCEDURE|management of therapy complications|
219418608|NCT05764278|OTHER|exercise|exercise group: first bed exercise after 0\~24hr onset ; sit at bed after 24\~48hr onset control group: first bed exercise after 24\~48hr onset ; sit at bed after 48\~72hr onset
219418609|NCT04511026|DRUG|Lymphoseek|Radioactive diagnostic agent
219418610|NCT04511026|DEVICE|Single Photon Emission Computed Tomography (SPECT)|Imaging test
219418611|NCT04511026|DRUG|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
219004629|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
219418612|NCT04511026|DEVICE|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
219572889|NCT04878614|DRUG|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
219418613|NCT01502982|DRUG|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
219418614|NCT05217992|OTHER|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
219418615|NCT05766865|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
219418616|NCT05766865|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
219418617|NCT02358369|DRUG|Bimatoprost|Bimatoprost sustained release Ocular Insert
219418618|NCT02358369|DRUG|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
219418619|NCT02358369|DEVICE|Placebo Ocular Insert|Placebo ocular insert OU.
219418620|NCT02358369|DRUG|Placebo Eye Drops|Placebo eye drops BID OU.
219418621|NCT04872335|OTHER|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
219418622|NCT04872335|OTHER|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included\_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
219418623|NCT02607358|OTHER|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
219004630|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
219004631|NCT06208033|DRUG|SMET12|"1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
219004632|NCT03902288|OTHER|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
219004633|NCT00189150|DRUG|Mycophenolate mofetil|
219004634|NCT00189150|DRUG|Valganciclovir|
219004635|NCT02336971|BEHAVIORAL|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
219004636|NCT02336971|BEHAVIORAL|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
219004637|NCT01294267|DEVICE|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
219004638|NCT00848471|DEVICE|Quark RMR|Quark RMR calorimeter (Cosmed)
219004639|NCT00848471|DEVICE|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
219418624|NCT01783717|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
219418625|NCT02821455|PROCEDURE|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
219418626|NCT04198324|PROCEDURE|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
219418627|NCT04198324|PROCEDURE|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
219418628|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
219418629|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
219418630|NCT05751486|BIOLOGICAL|Toripalimab /JS001|JS001 IV (if applicable) .
219418631|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
219418632|NCT02357641|OTHER|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
219004640|NCT04581161|DEVICE|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
219418633|NCT04224285|OTHER|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
219418634|NCT00274872|DRUG|fluorouracil|
219418635|NCT00274872|DRUG|leucovorin calcium|
219004641|NCT04856189|BIOLOGICAL|Pembrolizumab|Given IV
219004642|NCT04856189|DRUG|Selinexor|Given PO
219004643|NCT02742480|DRUG|Dabigatran|
219004644|NCT02742480|DRUG|Acenocoumarol|
219190862|NCT04889716|DRUG|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
219190863|NCT04889716|DRUG|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
219190864|NCT06016062|DRUG|RC148 Monotherapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
219190865|NCT06016062|DRUG|RC148+docetaxel Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
219418636|NCT00274872|DRUG|oxaliplatin|
219418637|NCT00306774|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
219418638|NCT00306774|DIETARY_SUPPLEMENT|Placebo|Placebo capsule per day for 2 years
219418639|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (low dose)|The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
219418640|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (high dose)|The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
219418641|NCT06350058|BIOLOGICAL|Placebo|Aluminum hydroxide adjuvant.
219418642|NCT01184716|OTHER|Vitamin D fortification|Bread and milk fortified with vitamin D3
219418643|NCT00885417|DRUG|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
219418644|NCT01838967|DRUG|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
219418645|NCT01838967|DRUG|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
219418646|NCT01838967|DRUG|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
219418647|NCT01838967|DRUG|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
219418648|NCT01838967|DRUG|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
219572890|NCT00025636|BIOLOGICAL|filgrastim|
219004645|NCT06404502|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants;~PRISMA has four sessions."
219418649|NCT01838967|DRUG|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
219418650|NCT00796601|DRUG|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
219418651|NCT00796601|DRUG|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
219418652|NCT03054467|DRUG|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
219004646|NCT03899571|DRUG|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
219004647|NCT03899571|DRUG|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
219418653|NCT03054467|DRUG|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
219418654|NCT01892319|DRUG|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
219418655|NCT01892319|DRUG|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
219418656|NCT00119730|DRUG|Fludarabine|Given on days 1-3 of each 28-day cycle
219418657|NCT00119730|DRUG|Mitoxantrone|Given on day 1 of each 28-day cycle
219418658|NCT00119730|DRUG|Rituximab|Given on day 1 of each 28-day cycle
219418659|NCT00119730|DRUG|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
219418660|NCT02523820|DRUG|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
219418661|NCT02523820|DRUG|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
219418662|NCT05027516|DRUG|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
219418663|NCT05027516|DRUG|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
219004648|NCT03312478|DRUG|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
219418664|NCT03655717|DRUG|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
219004649|NCT05881928|DRUG|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
219004650|NCT05881928|DRUG|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
219004651|NCT05881928|DEVICE|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
219004652|NCT01202292|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
219190866|NCT06016062|DRUG|RC148+RC48 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle； RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.
219418665|NCT03655717|DRUG|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
219418666|NCT03655717|DRUG|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
219418667|NCT03655717|DRUG|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
219418668|NCT02470052|DEVICE|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
219418669|NCT03030911|DRUG|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
219418670|NCT03030911|DRUG|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
219418671|NCT03030911|DRUG|Fentanyl|The drug will be administered in both groups
219572891|NCT00025636|DRUG|carmustine|
219572892|NCT00025636|DRUG|cisplatin|
219572893|NCT00025636|DRUG|cyclophosphamide|
219572894|NCT00025636|DRUG|cytarabine|
219572895|NCT00025636|DRUG|dexamethasone|
219572896|NCT00025636|DRUG|etoposide|
219572897|NCT00025636|DRUG|melphalan|
219572898|NCT00025636|DRUG|methotrexate|
219572899|NCT00025636|DRUG|vincristine sulfate|
219572900|NCT00025636|PROCEDURE|bone marrow ablation with stem cell support|
219572901|NCT00025636|PROCEDURE|peripheral blood stem cell transplantation|
219572902|NCT04254835|DRUG|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
219418672|NCT03030911|DEVICE|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
219418673|NCT03329651|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
219418674|NCT03329651|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
219418675|NCT06553430|BEHAVIORAL|aerobics exercises|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
219418676|NCT03360539|BEHAVIORAL|Nurse-Family Partnership|
219418677|NCT00278772|DRUG|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
219418678|NCT00278772|OTHER|Placebo|oral dose, placebo
219004653|NCT03985514|DRUG|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
219418679|NCT01547910|DIETARY_SUPPLEMENT|Fish Oil|Fish oil given in supplementary dose
219418680|NCT01745601|DRUG|escitalopram 10 mg|Reference product
219418681|NCT01745601|DRUG|escitalopram 10 mg|Test product
219418682|NCT04433624|OTHER|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
219418683|NCT01656317|OTHER|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
219418684|NCT04682834|DRUG|Sulopenem Etzadroxil/Probenecid|Individual Patients
219418685|NCT03912025|OTHER|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
219418686|NCT00607438|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
219004654|NCT03985514|OTHER|Active observation|In-hospital observation without antibiotics
219004655|NCT02725710|DRUG|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
219004656|NCT02725710|DRUG|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
219004657|NCT00946699|BIOLOGICAL|MEDI-551|0.1 mg/kg
219004658|NCT00946699|BIOLOGICAL|Placebo|0.3 mg/kg
219004659|NCT00946699|BIOLOGICAL|MEDI-551|1.0 mg/kg
219418687|NCT00607438|DRUG|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
219418688|NCT00383214|DRUG|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
219004660|NCT00946699|BIOLOGICAL|MEDI-551|3.0 mg/kg
219004661|NCT00946699|BIOLOGICAL|MEDI-551|10.0 mg/kg
219004662|NCT00946699|OTHER|Placebo|Placebo
219004663|NCT03502980|DEVICE|Bard PowerPICC|PICC Insertion
219004664|NCT03502980|DEVICE|Bard PowerMidline catheter|Midline Insertion
219004665|NCT02784275|DRUG|Cyclo-Z|
219004666|NCT02784275|DRUG|Placebo|
219004667|NCT00640601|DRUG|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
219004668|NCT04946188|DEVICE|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
219004669|NCT00941785|DRUG|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
219418689|NCT00383214|OTHER|Placebo|Intravenous
219418690|NCT00206895|PROCEDURE|Photodynamic therapy|
219418691|NCT06532253|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
219418692|NCT05680194|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
219418693|NCT05680194|DRUG|Bisphosphonate|Bisphosphonate
219418694|NCT05507645|DRUG|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
219418695|NCT05507645|DRUG|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
219418696|NCT00088569|DRUG|0-15 Water|
219418697|NCT00313027|RADIATION|PET scan|
219418698|NCT06051981|DRUG|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
219418699|NCT06051981|DRUG|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
219418700|NCT06051981|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
219418701|NCT06051981|DRUG|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
219418702|NCT01019772|BIOLOGICAL|LBVH0101 (Hib vaccine)|
219418703|NCT01019772|BIOLOGICAL|Hiberix™ Vaccine|
219418704|NCT01540968|BEHAVIORAL|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
219418705|NCT06171672|OTHER|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
219418706|NCT06332027|DIAGNOSTIC_TEST|Hystro-Salpingo-Foam-Sonography (HYFOSY)|antibiotic prophylaxis oral azithromycin 500 mg per day 3 days the patient lie in dorsal lithotomy cervix visualized by Cusco speculum, cleaned with betadine 7% 6-Fr pediatric Foley's balloon catheter will be introduced into the cervical canal inflated with 2 ml of saline to prevent backflow of contrast through the cervix TV-US probe will be introduced,The foam will be created by mixing 3-4ml of 2% rialocaine gel (lidocaine hydrochloride 2%, Riadh Pharma,Saudi Arabia) with 16-17 ml of saline shaking the mixture between two syringes until a whitish suspension 20ml of lidocaine foam infused into uterine cavity observing the flow in each fallopian tube using greyscale and power Doppler (PD) 2D ultrasound Foam flow over the whole length of the tube fimbrial outflow, or peritoneal spillage of contrast provided evidence of tubal patency Patients observed for15-30 min for any complication or increase in pain Comparison between results and that of laparoscopy in operative list
219418707|NCT01570933|DEVICE|NivNava|Non-invasive Nava ventilation mode on nasal cannula
219418708|NCT01570933|DEVICE|Cpap|nasal Cpap on nasal cannula
219418709|NCT01031485|DIETARY_SUPPLEMENT|Milk peptides and plant sterols|
219418710|NCT01031485|OTHER|Placebo|
219418711|NCT03424577|DRUG|H3B-6527|Oral capsule
219418712|NCT02142257|PROCEDURE|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
219418713|NCT02142257|DEVICE|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
219418714|NCT03036111|DRUG|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
219418715|NCT03036111|PROCEDURE|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
219418716|NCT05496218|DIAGNOSTIC_TEST|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
219418717|NCT03807076|OTHER|GIP-A|GIP-A
219572903|NCT04254835|DRUG|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
219572904|NCT05318209|OTHER|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
219758734|NCT05201651|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
219758735|NCT05201651|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
219418718|NCT03807076|OTHER|Placebo|Placebo
219418719|NCT01005056|DRUG|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
219418720|NCT01481909|DRUG|Rupatadin|20 mg, 28 days over 60 days
219418721|NCT03682939|BIOLOGICAL|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
219418722|NCT03682939|BIOLOGICAL|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
219418723|NCT00003595|BIOLOGICAL|filgrastim|
219418724|NCT00003595|BIOLOGICAL|rituximab|
219418725|NCT00003595|DRUG|CHOP regimen|
219418726|NCT00003595|DRUG|cyclophosphamide|
219418727|NCT00003595|DRUG|doxorubicin hydrochloride|
219418728|NCT00003595|DRUG|prednisone|
219572905|NCT01560507|DRUG|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
219572906|NCT01560507|DRUG|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
219572907|NCT01560507|DRUG|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
219572908|NCT02080832|DRUG|Citalopram|20 mg or 40 mg daily for 8 weeks
219418729|NCT00003595|DRUG|vincristine sulfate|
219418730|NCT05128526|BEHAVIORAL|exercise|Short foot exercises without respiratory exercises
219418731|NCT05128526|BEHAVIORAL|respiratory|Short foot exercises with respiratory exercises
219418732|NCT05578768|OTHER|No intervention|Patients will receive standard of care.
219418733|NCT00067821|DRUG|2-Flourodeoxyglucose|
219418734|NCT00582699|BEHAVIORAL|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
219418735|NCT03182413|DRUG|Placebo|
219418736|NCT03182413|DRUG|Modafinil|
219418737|NCT03182413|DRUG|THN102|
219418738|NCT04575831|BEHAVIORAL|Exercise, Nutrition, and Palliative Symptom Management|"1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
219418739|NCT06402903|OTHER|Observation|"The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties)."
219418740|NCT03305757|DRUG|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
219418741|NCT03305757|PROCEDURE|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
219418742|NCT03305757|PROCEDURE|Conventional|Conventional closure after mastectomy
219418743|NCT04415619|PROCEDURE|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
219418744|NCT02277340|PROCEDURE|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
219418745|NCT06017778|DEVICE|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
219418746|NCT06017778|OTHER|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
219418747|NCT00647257|DRUG|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
219418748|NCT00647257|DRUG|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
219418749|NCT02066519|BEHAVIORAL|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
219418750|NCT00425126|DRUG|Epoetin Alfa|
219418751|NCT04560140|BEHAVIORAL|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
219004670|NCT00941785|DRUG|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
219418752|NCT02800772|DIETARY_SUPPLEMENT|acetic acid|
219418753|NCT02800772|DIETARY_SUPPLEMENT|saline|
219418754|NCT02299713|DEVICE|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
219418755|NCT03073213|DRUG|Ixekizumab|Administered as subcutaneous (SC) injection
219418756|NCT00961662|DRUG|D-Tagatose|powder to be dissolved in water prior to dosage.
219418757|NCT01560897|DRUG|Oral C13|Ingestion of C13 and follow up of the ureogenesis
219418758|NCT05539105|PROCEDURE|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
219418759|NCT05539105|PROCEDURE|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
219004671|NCT04038684|BEHAVIORAL|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
219004672|NCT04038684|BEHAVIORAL|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
219004673|NCT04138121|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
219004674|NCT03194607|OTHER|Functional walk tests|
219418760|NCT05539105|PROCEDURE|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
219418761|NCT02517593|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
219418762|NCT02286492|DRUG|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
219418763|NCT05271110|PROCEDURE|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
219418764|NCT02732340|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
219418765|NCT03379506|DRUG|EBR/GZR FDC Tablet|Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
219418766|NCT03379506|DRUG|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
219418767|NCT03379506|DRUG|Grazoprevir Oral Granules|Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
219418768|NCT03379506|DRUG|Elbasvir Oral Granules|Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
219418769|NCT03309592|DRUG|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
219418770|NCT03309592|DRUG|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
219418771|NCT04758598|DEVICE|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
219418772|NCT04758598|DEVICE|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
219418773|NCT01974986|OTHER|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
219418774|NCT01974986|OTHER|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
219572909|NCT02080832|DRUG|Placebo|Placebo daily for 8 weeks
219572910|NCT03173053|DRUG|Doxycycline|tablet
219572911|NCT03173053|DRUG|Trimethoprim|tablet
219572912|NCT03173053|DRUG|Sulfamethoxazole/trimethoprim|tablet
219572913|NCT03173053|DRUG|Clindamycin|tablet
219572914|NCT03173053|DRUG|Clarithromycin|tablet
219572915|NCT03173053|DRUG|Ciprofloxacin|tablet
219572916|NCT03173053|DRUG|Fusidic Acid|tablet or ointment
219572917|NCT03173053|DRUG|Rifampin|tablet
219572918|NCT03173053|DRUG|Chlorhexidine|Mouthwash or bodywash
219572919|NCT03173053|DRUG|Mupirocin|Nasal ointment
219758736|NCT05584579|PROCEDURE|laparoscopic surgery|laparoscopic surgery
219758737|NCT03212352|DRUG|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
219572920|NCT03173053|DRUG|Betadine|Shampoo
219572921|NCT04758663|BEHAVIORAL|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
219758738|NCT03212352|DRUG|Misoprostol|Regular treatment with Misoprostol 800 mcg.
219758739|NCT01252615|BEHAVIORAL|patient only|education, behavioral strategies, psychological interventions
219418775|NCT01974986|OTHER|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
219418776|NCT05136378|DRUG|Low Dose Selenious Yeast Tablets|Low dose of Selenious Yeast Tablets
219418777|NCT05136378|DRUG|High Dose Selenious Yeast Tablets|High Dose Selenious Yeast Tablets
219418778|NCT00649441|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
219572922|NCT04758663|BEHAVIORAL|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
219572923|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg on alternate weeks
219572924|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg every other week
219572925|NCT04865913|OTHER|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
219572926|NCT05729919|PROCEDURE|Free gingival graft technique|"A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface"
219572927|NCT03917511|BEHAVIORAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
219572928|NCT03917511|BEHAVIORAL|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
219572929|NCT06367036|OTHER|Topical hypericum perforatum oil intervention|The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
219572930|NCT02728011|OTHER|Scientific Brain Training (SBT)|Cognitive training
219004675|NCT03194607|OTHER|3D analysis of locomotion and posture|
219004676|NCT03194607|OTHER|questionnaires|
219004677|NCT01784159|DRUG|Aspirin|Aspirin administration for 7 days
219418779|NCT00649441|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
219418780|NCT04350190|DRUG|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
219572931|NCT02728011|OTHER|Tetris|
219572932|NCT00312676|PROCEDURE|Rapid versus slow conversion|
219572933|NCT03026855|BIOLOGICAL|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
219572934|NCT03352895|DIETARY_SUPPLEMENT|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
219418781|NCT04350190|DRUG|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
219418782|NCT03427541|PROCEDURE|Surgeries|Surgeries
219418783|NCT05923476|DRUG|Lithium|Placebo + ECT
219418784|NCT03656120|DRUG|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
219418785|NCT03656120|DRUG|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
219418786|NCT03656120|DRUG|placebo control group|Participants only take placebos for 12 weeks during the research.
219572935|NCT03352895|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
219572936|NCT04400760|DRUG|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
219572937|NCT02507817|OTHER|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
219572938|NCT02181296|DRUG|ropivacaine|
219572939|NCT00141141|DRUG|Atorvastatin|
219572940|NCT00141141|DRUG|Simvastatin|
219758740|NCT01252615|BEHAVIORAL|patient and partner intervention|education, psychological support, behavioral strategies
219758741|NCT01385592|DRUG|AFQ056|
219758742|NCT01385592|DRUG|Placebo|
219758743|NCT02746302|DRUG|HS-20004|
219758744|NCT02746302|DRUG|Placebo|
219758745|NCT06263036|OTHER|Men|Laryngeal cartilages
219758746|NCT06263036|OTHER|Women|Laryngeal cartilages
219758747|NCT00795028|OTHER|Standard Care for people after hip fracture|
219758748|NCT00795028|OTHER|Standard Care + exercise intervention|
219758749|NCT05739266|BEHAVIORAL|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
219758750|NCT03103854|BEHAVIORAL|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
219418787|NCT00319228|DRUG|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
219004678|NCT04229563|DEVICE|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
219190867|NCT06016062|DRUG|RC148+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.
219190868|NCT06016062|DRUG|RC148/Bevacizumab+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
219190869|NCT05507814|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will generate descriptions of vivid positive future events.
219190870|NCT05507814|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive future events.
219418788|NCT02488616|OTHER|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
219418789|NCT02488616|OTHER|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
219418790|NCT02488616|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
219418791|NCT02488616|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
219418792|NCT02488616|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
219418793|NCT04411212|DRUG|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
219418794|NCT04411212|OTHER|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
219418795|NCT03812523|DRUG|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
219418796|NCT03812523|DRUG|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
219418797|NCT03466021|DRUG|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
219418798|NCT03466021|DRUG|Placebo|Matching injection
219418799|NCT01908517|BEHAVIORAL|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
219418800|NCT02909569|DRUG|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
219418801|NCT05250193|DEVICE|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
219418802|NCT05250193|DEVICE|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
219004679|NCT00719420|DRUG|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
219004680|NCT00719420|DRUG|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
219004681|NCT06255106|OTHER|cast treatment|Surgical intervention vs cast treatment
219190871|NCT05366712|DEVICE|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
219190872|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
219190873|NCT03845790|OTHER|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
219190874|NCT06823089|DEVICE|ReNew Hip Implant|Surgical Intervention
219190875|NCT05834712|DEVICE|mobile platform or not mobile platform|Intervention using WeChat
219190876|NCT04220684|DRUG|Cytarabine Hydrochloride|Given IV
219190877|NCT04220684|DRUG|Fludarabine|Given IV
219418803|NCT00190983|DRUG|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
219418804|NCT02856685|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
219418805|NCT01284270|OTHER|Cardiac MRI|Cardiac MRI
219418806|NCT03600948|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
219418807|NCT00637715|DRUG|Alfuzosin|
219572941|NCT06489938|BEHAVIORAL|Mirror therapy|In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
219572942|NCT06489938|BEHAVIORAL|Task-oriented approach|The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
219572943|NCT06489938|BEHAVIORAL|Impairment-oriented approach|The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
219572944|NCT00378716|DRUG|5-fluorouracil|
219572945|NCT00378716|DRUG|leucovorin calcium|
219572946|NCT00378716|DRUG|tegafur|
219572947|NCT00378716|DRUG|uracil|
219572948|NCT01019863|DRUG|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
219572949|NCT01762124|DEVICE|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
219572950|NCT01736436|DRUG|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
219572951|NCT01736436|PROCEDURE|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
219572952|NCT01736436|PROCEDURE|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
219572953|NCT02149121|BIOLOGICAL|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
219190878|NCT04220684|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
219418808|NCT04197544|PROCEDURE|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
219572954|NCT02149121|DRUG|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
219572955|NCT02149121|DRUG|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
219572956|NCT02545855|DEVICE|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
219572957|NCT02545855|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
219572958|NCT04043936|BEHAVIORAL|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
219572959|NCT04043936|BEHAVIORAL|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
219572960|NCT04043936|BEHAVIORAL|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
219572961|NCT06338735|OTHER|Ultra-High Frequency Ultrasound scan of minor salivary glands|Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
219572962|NCT00472875|DRUG|Glibenclamide|
219572963|NCT04955015|PROCEDURE|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
219572964|NCT03187496|DRUG|Midazolam|Each subject will receive midazolam on Days 1 and 12.
219572965|NCT03187496|DRUG|Caffeine|Each subject will receive caffeine on Days 1 and 12.
219572966|NCT03187496|DRUG|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
219572967|NCT03187496|DRUG|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
219572968|NCT06416917|DEVICE|bubble inclinometer|to measure range of motion
219572969|NCT04316325|DRUG|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
219190879|NCT04744506|DEVICE|Tissue Marker Clip|Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
219190880|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
219418809|NCT06085261|BEHAVIORAL|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
219418810|NCT06085261|BEHAVIORAL|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
219418811|NCT02182141|DRUG|BIBF 1120 ES|
219418812|NCT04518982|DRUG|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
219572970|NCT05993715|DIETARY_SUPPLEMENT|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
219572971|NCT05993715|DIETARY_SUPPLEMENT|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
219572972|NCT03297671|DRUG|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
219572973|NCT03297671|DEVICE|ELDONCARD|ELDONCARD point-of-care test.
219572974|NCT03297671|DIAGNOSTIC_TEST|ELDONCARD Test|LHVs will perform ELDONCARD test.
219572975|NCT00622687|DRUG|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
219572976|NCT00622687|DRUG|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
219572977|NCT00622687|DRUG|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
219572978|NCT05486832|DEVICE|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
219572979|NCT02761603|BEHAVIORAL|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
219572980|NCT02761603|BEHAVIORAL|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
219758751|NCT03103854|BEHAVIORAL|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
219758752|NCT03103854|BEHAVIORAL|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
219758753|NCT04763434|DRUG|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
219758754|NCT05855018|DRUG|Atropine sulfate eye drops|One drop once daily
219758755|NCT04416113|PROCEDURE|photobiomodulation and photodynamic therapy|antiviral treatment
219758756|NCT05242601|OTHER||no intervention
219758757|NCT00678730|DRUG|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
219758758|NCT04507906|DRUG|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
219758759|NCT03763734|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
219758760|NCT06211712|DRUG|Experimental: Human Urinary Kallidinogenase|Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
219758761|NCT06211712|DRUG|Placebo Comparator: Placebo|Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
219190881|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
219418813|NCT04518982|DRUG|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
219418814|NCT02525419|BEHAVIORAL|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
219190882|NCT06818799|PROCEDURE|Thulium laser en-bloc resection of bladder mass|En-bloc laser technique
219418815|NCT02525419|BEHAVIORAL|HP-IF|High Protein, Intermittent Fast
219418816|NCT02525419|BEHAVIORAL|HH|Heart Healthy
219418817|NCT05859048|DIAGNOSTIC_TEST|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
219418818|NCT05859048|DIAGNOSTIC_TEST|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
219190883|NCT06818799|PROCEDURE|Trans-urethral en-bloc resection of bladder mass|En-bloc technique
219190884|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
219418819|NCT05859048|DIAGNOSTIC_TEST|electrocardiogram|tracing of electrical cardiac activity of the heart
219418820|NCT05859048|OTHER|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
219418821|NCT06323694|BEHAVIORAL|quality of life|data collection through questionnaire and interview
219572981|NCT04178382|DIAGNOSTIC_TEST|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
219572982|NCT06688695|BEHAVIORAL|Neurodevelopmental support|The Intervention for Neurodevelopmental Support in Preterm Infants using Responsive parenting and E-health (INSPIRE) aims to support the infant's neurodevelopment by supporting the parents to develop a responsive approach. The intervention will enhance the infant's social and environmental interactions, focusing on developing both the infant's and parent's strengths, seeking opportunities instead of problems in behaviour, enhancing mutually satisfying interaction and parental empowerment.
219572983|NCT03166124|DRUG|LY900014|Administered SC
219572984|NCT03166124|DRUG|Insulin Lispro|Administered SC
219572985|NCT00766831|DRUG|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
219572986|NCT02666391|BIOLOGICAL|umbilical cord mesenchymal stem cells|
219572987|NCT01980160|DEVICE|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
219572988|NCT01980160|DEVICE|Unactivated Nometex Device|
219418822|NCT03685552|OTHER|Prog: Purify-2|"Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
219418823|NCT01916616|BEHAVIORAL|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
219418824|NCT00348842|PROCEDURE|Newcastle Virus|
219418825|NCT00502320|DRUG|Ramelteon|one 8 mg tablet at bed for up to 4 months
219418826|NCT00502320|DRUG|Placebo|one tablet at bedtime for up to 4 months
219572989|NCT05719337|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
219572990|NCT02105155|DRUG|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
219572991|NCT02105155|DRUG|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
219758762|NCT04513808|DRUG|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
219758763|NCT04513808|DRUG|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
219418827|NCT05061797|DIETARY_SUPPLEMENT|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
219418828|NCT05061797|DIETARY_SUPPLEMENT|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
219418829|NCT02692170|BIOLOGICAL|CVI-HBV-001|Investigational Product
219418830|NCT02692170|BIOLOGICAL|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
219418831|NCT03685045|PROCEDURE|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
219418832|NCT01887782|DEVICE|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
219418833|NCT01887782|DEVICE|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
219418834|NCT00286364|DRUG|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
219418835|NCT06289842|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
219418836|NCT04011124|DRUG|Fluzoparib|single dose on Day 1 and Day 12
219418837|NCT04011124|DRUG|Rifampicin|QD on Day 5-14 for 10 days
219418838|NCT01453998|BIOLOGICAL|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
219418839|NCT01453998|BIOLOGICAL|Prevenar 13|Single co-administered dose, intramuscular into left thigh
219418840|NCT01453998|BIOLOGICAL|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
219758764|NCT04802603|RADIATION|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
219758765|NCT05592548|DEVICE|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
219418841|NCT03734952|RADIATION|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
219418842|NCT03734952|DRUG|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
219418843|NCT03734952|PROCEDURE|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
219418844|NCT03734952|RADIATION|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
219004682|NCT01721655|DRUG|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
219418845|NCT04761172|PROCEDURE|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
219418846|NCT03737422|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
219418847|NCT03737422|OTHER|control|no supplementation
219418848|NCT02277522|BIOLOGICAL|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
219418849|NCT02173392|DRUG|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
219418850|NCT05137730|DRUG|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
219418851|NCT00080886|BIOLOGICAL|rituximab|
219418852|NCT00080886|DRUG|carmustine|
219418853|NCT00080886|DRUG|cytarabine|
219418854|NCT00080886|DRUG|etoposide|
219418855|NCT00080886|DRUG|melphalan|
219418856|NCT00080886|PROCEDURE|autologous bone marrow transplantation|
219418857|NCT00080886|PROCEDURE|peripheral blood stem cell transplantation|
219758766|NCT06012851|BEHAVIORAL|Mobile behavioral parent training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
219758767|NCT06012851|BEHAVIORAL|In the moment feedback|In-the-moment feedback will include parenting feedback.
219758768|NCT06012851|BEHAVIORAL|In the moment suggestions|In-the-moment feedback will include suggestions for parenting strategies.
219758769|NCT05023460|DEVICE|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
219758770|NCT05023460|DEVICE|Placebo|ONS system deactivated
219190885|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
219190886|NCT05870761|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219004683|NCT01721655|DRUG|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
219004684|NCT02817308|OTHER|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
219190887|NCT05870761|PROCEDURE|Computed Tomography|Undergo MRI/CT
219190888|NCT05870761|BIOLOGICAL|Dostarlimab|Given IV
219190889|NCT05870761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
219190890|NCT05870761|DRUG|Niraparib|Given PO
219418858|NCT00796133|DRUG|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
219418859|NCT03654755|DRUG|ASN002|Daily dose of ASN002 for up to 110 weeks
219004685|NCT01462097|BEHAVIORAL|Aerobic exercise training|12 months of aerobic exercise
219004686|NCT01462097|BEHAVIORAL|Health Education|12 months of health education sessions
219004687|NCT02364752|PROCEDURE|Blood Draw|
219004688|NCT02364752|PROCEDURE|Loop Diuretic Withdrawal/Salt Load|
219004689|NCT03798496|PROCEDURE|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
219418860|NCT03058172|OTHER|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
219418861|NCT03058172|OTHER|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
219004690|NCT06387095|PROCEDURE|1. no block|After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
219004691|NCT06387095|PROCEDURE|2. superficial parasternal block|After induction, the patient will undergo an ultrasound-guided superficial parasternal plan block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
219004692|NCT06387095|PROCEDURE|3. deep parasternal block|After induction, the patient will undergo an ultrasound-guided deep parasternal plane block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
219004693|NCT03231605|BIOLOGICAL|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
219004694|NCT03092921|DEVICE|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
219004695|NCT03092921|DEVICE|F&P Mask|Investigative Mask to be used for OSA therapy
219418862|NCT05511818|DIETARY_SUPPLEMENT|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
219418863|NCT03111355|DIETARY_SUPPLEMENT|Brazil nut|one nut a day for 2 months, no intervention for 2 months
219418864|NCT04810585|DRUG|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
219418865|NCT02854553|PROCEDURE|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
219418866|NCT02854553|PROCEDURE|rectus sheath block|ultrasound guided rectus sheath block
219758771|NCT03407768|BEHAVIORAL|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
219758772|NCT05162586|DRUG|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
219758773|NCT05162586|DRUG|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
219758774|NCT05162586|DRUG|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
219758775|NCT05162586|DRUG|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
219758776|NCT05373472|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
219758777|NCT05373472|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
219758778|NCT06637657|OTHER|No intervention (observational study)|No intervention, only guideline implementation (observational study)
219418867|NCT03213977|DRUG|R-DA-EPOCH|R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
219418868|NCT03213977|DRUG|R-CEOP90|R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
219418869|NCT01508494|DRUG|Galantamine|16 mg galantamine daily P/O
219418870|NCT01508494|DRUG|placebo|placebo
219418871|NCT01932281|DIETARY_SUPPLEMENT|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
219418872|NCT01932281|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
219418873|NCT02394808|DEVICE|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
219418874|NCT02394808|DEVICE|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
219418875|NCT00344955|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
219418876|NCT05479266|OTHER|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
219418877|NCT05479266|OTHER|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
219418878|NCT04220385|OTHER|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
219418879|NCT04220385|OTHER|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
219418880|NCT06152419|DEVICE|Questionnaire|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
219418881|NCT04605939|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
219418882|NCT04605939|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
219418883|NCT03453190|COMBINATION_PRODUCT|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
219418884|NCT02705768|DRUG|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
219418885|NCT02705768|DRUG|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
219418886|NCT03755284|OTHER|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
219418887|NCT05468723|DEVICE|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses \[which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)\] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
219418888|NCT06120959|OTHER|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
219758779|NCT04661033|DRUG|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
219418889|NCT06120959|OTHER|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
219418890|NCT05124795|DRUG|IMU-935|IMU-935 capsules
219572992|NCT05488717|OTHER|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
219572993|NCT02801084|BEHAVIORAL|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
219758780|NCT06191445|PROCEDURE|Conventional Landmark Technique|The investigator will perform spinal anesthesia using the conventional landmark technique.
219004696|NCT03695120|OTHER|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
219004697|NCT03002766|PROCEDURE|Breast conservative surgery|
219418891|NCT03445897|DRUG|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
219418892|NCT01219517|OTHER|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
219572994|NCT02689999|DRUG|Dexrabeprazole 10 mg Enteric-Coated Tablets|
219572995|NCT02479373|OTHER|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
219758781|NCT06191445|PROCEDURE|Ultrasound Assisted Technique|The investigator will perform spinal anesthesia using the ultrasound assisted technique.
219758782|NCT06191445|PROCEDURE|Real-Time Ultrasound Guided Technique|The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
219004698|NCT01848691|OTHER|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
219004699|NCT06296966|DRUG|VSJ-110|ophthalmic solution
219004700|NCT06296966|DRUG|Placebo|ophthalmic solution
219418893|NCT04415567|DRUG|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
219418894|NCT03182400|BEHAVIORAL|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
219418895|NCT03182400|BEHAVIORAL|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
219418896|NCT05545579|OTHER|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
219758783|NCT05276674|DEVICE|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
219758784|NCT06117059|RADIATION|3 fractions of prostate SBRT|Radical radiotherapy using only 3 fractions of prostate SBRT over 3 consecutive days
219758785|NCT03811470|OTHER|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
219758786|NCT04562311|DRUG|Chidamide|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
219758787|NCT06557759|BEHAVIORAL|Listening to Calming Music|Participants will listen to calming music, which may enhance health and wellness by reducing autonomic reactivity and improving bodily awareness, brain-body connection, and emotional wellbeing.
219004701|NCT00525330|DRUG|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
219004702|NCT00525330|DRUG|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
219418897|NCT05545579|OTHER|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
219572996|NCT02479373|OTHER|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
219572997|NCT02479373|OTHER|Biodex dynamometer|To study muscle strength
219572998|NCT02479373|OTHER|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
219572999|NCT02479373|OTHER|Quality of life questionnaires|
219573000|NCT05745792|OTHER|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
219573001|NCT01699763|DEVICE|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219573002|NCT01699763|DEVICE|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219573003|NCT01699763|DEVICE|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219573004|NCT03373136|DEVICE|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
219573005|NCT00094094|DRUG|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
219573006|NCT01088919|DRUG|ASP1941|oral tablet
219573007|NCT01088919|DRUG|pioglitazone hydrochloride|oral tablet
219418898|NCT05091294|OTHER|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
219418899|NCT03269890|PROCEDURE|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
219418900|NCT03269890|PROCEDURE|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
219573008|NCT00965055|DRUG|Ezetimibe|10 mg
219004703|NCT00525330|DRUG|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
219004704|NCT03932110|DIAGNOSTIC_TEST|omentin, visfatin|diagnostic blood test
219004705|NCT01666782|BIOLOGICAL|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
219418901|NCT04422106|DIAGNOSTIC_TEST|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
219418902|NCT02473003|BEHAVIORAL|high intensity exercise|high intensity exercise 80-90%
219418903|NCT02473003|BEHAVIORAL|low/medium intensity exercise|low/medium intensity exercise 40-50%
219418904|NCT02473003|BEHAVIORAL|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
219418905|NCT02769351|DEVICE|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
219418906|NCT03886831|DRUG|PRT543|PRT543 will be administered orally
219758788|NCT05891899|OTHER|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
219758789|NCT04087356|GENETIC|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
219758790|NCT02304159|DRUG|daclatasvir|
219758791|NCT02304159|DRUG|Sofosbuvir, Sovaldi|
219758792|NCT02304159|DRUG|Ribavirin|
219758793|NCT02711501|PROCEDURE|Laser-assisted surgery.|laser-assisted surgery
219758794|NCT02711501|PROCEDURE|conventional surgery by blade|conventional surgery
219190891|NCT06529393|PROCEDURE|SHAC block|with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .
219418907|NCT01180114|BEHAVIORAL|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
219418908|NCT01180114|OTHER|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
219418909|NCT01758965|OTHER|PPI|monotherapy of PPI
219418910|NCT01758965|OTHER|H2RA and surgicel|combination therapy of H2RA and surgicel
219418911|NCT02922192|DRUG|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
219573009|NCT00965055|DRUG|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
219573010|NCT06920407|DEVICE|Breathing training device (Inspiratory Muscle Training)|Daily inspiratory muscle training (IMT) using the PowerBreathe IMT K3 device at varying resistance levels (15% for Sham and 65% for Experimental group) for 12 weeks. Participants will perform breathing exercises designed to assess the effects of different resistance levels on overall physical and emotional well-being, with a focus on how varying resistance impacts both respiratory strength and well-being.
219573011|NCT06920407|DEVICE|Oura Ring|The Oura ring measures daily biometrics such as heart rate, sleep, and blood oxygen levels, providing personalized health data and insights. Participants have access to this data through a mobile app, allowing researchers to assess whether increased access to health data and awareness has an impact on overall physical and emotional well-being.
219573012|NCT00683982|DRUG|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
219573013|NCT00683982|DRUG|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
219573014|NCT00683982|OTHER|Oral hydration solutions|Oral hydration solutions as needed
219573015|NCT02350582|DEVICE|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
219573016|NCT03536494|BEHAVIORAL|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention."
219573017|NCT03779568|OTHER|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
219573018|NCT00765011|DRUG|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
219573019|NCT00765011|PROCEDURE|H&N surgery|Rescue surgery
219573020|NCT04141696|DRUG|Ketamine|Given intravenously over 40 minutes
219573021|NCT04141696|DRUG|Midazolam|Used as placebo comparator; given intravenously over 40 minutes
219573022|NCT00669981|BEHAVIORAL|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
219573023|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
219573024|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
219573025|NCT02960087|RADIATION|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
219573026|NCT02960087|RADIATION|High dose rate brachytherapy|27 Gy in 2 fractions
219418912|NCT06157047|PROCEDURE|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
219418913|NCT00947752|DRUG|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
219418914|NCT00947752|DRUG|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
219418915|NCT04973410|DIAGNOSTIC_TEST|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
219418916|NCT04973410|DIAGNOSTIC_TEST|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
219418917|NCT03265743|OTHER|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
219418918|NCT02789605|DRUG|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
219418919|NCT02789605|DRUG|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
219573027|NCT06084052|DEVICE|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). All participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
219418920|NCT04683107|OTHER|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
219418921|NCT04683107|OTHER|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
219418922|NCT02881983|OTHER|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
219418923|NCT04786132|OTHER|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
219418924|NCT04786132|OTHER|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
219573028|NCT06084052|OTHER|Control Group|Control Group will receive care as usual.
219573029|NCT05640414|OTHER|Weekly Family Food Packages|Families receive weekly family food packages for 6 months
219573030|NCT05640414|BEHAVIORAL|Family Health Group Sessions|Families with children aged 6-17 years attend 6 monthly group sessions with cooking demonstrations
219573031|NCT05626803|DRUG|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
219573032|NCT05626803|DRUG|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
219573033|NCT05626803|DRUG|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
219573034|NCT05626803|DRUG|Placebo|25 subjects will receive matching placebo
219573035|NCT04583163|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
219573036|NCT02553525|PROCEDURE|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
219573037|NCT02553525|PROCEDURE|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
219573038|NCT05854238|DEVICE|TIRA-VoM|"treat persistent atrial fibrillation~* The ablation temperature range is 50-60℃~* About 2 minutes per ablation"
219418925|NCT03341923|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
219418926|NCT03341923|DEVICE|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
219573039|NCT05867329|DRUG|Cyclosporine Injection (IV)|"Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers."
219573040|NCT05867329|DRUG|Cyclosporine Oral Product|"Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician."
219573041|NCT05867329|DRUG|Upadacitinib Extended Release Oral Tablet|"This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital."
219573042|NCT05867329|DRUG|Intravenous Methylprednisolone|Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
219573043|NCT05867329|DRUG|Prednisone Oral Product|Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
219573044|NCT06511167|DEVICE|TIGR® Matrix|bioresorbable, synthetic, surgical mesh
219573045|NCT03943537|DRUG|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
219418927|NCT05501288|DRUG|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
219758795|NCT02622191|DEVICE|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
219758796|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
219758797|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
219758798|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
219758799|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
219758800|NCT00565409|DRUG|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
219758801|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
219418928|NCT05501288|DRUG|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
219573046|NCT05674526|BIOLOGICAL|WU-NK-101 - Dose Escalation|WU-NK-101 administered on Days 1, 15, 30 and 44
219758802|NCT00294034|DEVICE|Pacemaker|
219418929|NCT04580394|DRUG|AD109|Oral administration before bed
219418930|NCT04580394|DRUG|Atomoxetine|Oral administration before bed
219418931|NCT04580394|DRUG|R-oxybutynin|Oral administration before bed
219418932|NCT04580394|DRUG|Placebo|Oral administration before bed
219418933|NCT04580394|DIAGNOSTIC_TEST|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
219418934|NCT02276521|BIOLOGICAL|Cervarix®|All groups will received one dose of Cervarix® vaccine
219758803|NCT06010680|DRUG|[14C]SHR2554|Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
219758804|NCT05884372|DRUG|Eldecalcitol|the same as arm descriptions.
219758805|NCT05884372|DRUG|Native Vitamin D|the same as arm descriptions.
219758806|NCT05884372|DRUG|Denosumab|the same as arm descriptions.
219758807|NCT05884372|DRUG|Calcium|the same as arm descriptions.
219418935|NCT05521217|DIAGNOSTIC_TEST|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
219418936|NCT02010437|DRUG|Sodium Tetradecyl Sulphate (STS)|
219418937|NCT04380974|PROCEDURE|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
219573047|NCT05674526|DRUG|Cetuximab - Dose Escalation|Cetuximab 500mg/m2 administered on Days 29 and 43
219573048|NCT05674526|BIOLOGICAL|WU-NK-101 - Cohort Expansion|WU-NK-101 administered on Days 2 and 16
219573049|NCT05674526|BIOLOGICAL|Cetuximab - Cohort Expansion|Cetuximab 500mg/m2 administered on Days 1 and 15
219573050|NCT06679374|DRUG|Placebo|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
219573051|NCT06679374|DRUG|Varenicline|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
219573052|NCT06427915|OTHER|OLIPOP prebiotic soda|12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)
219573053|NCT06427915|OTHER|Traditional sugar-sweetened cola|12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
219573054|NCT01790802|DEVICE|2RT nanosecond laser|active laser therapy
219573055|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autologous cartilage|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous auricular cartilage graft spacer.
219573056|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autogenous dermis graft spacer.|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous dermis graft spacer.
219573057|NCT05017649|BIOLOGICAL|Blood sample|Blood sampling.
219573058|NCT06837246|DIETARY_SUPPLEMENT|Cognitive Nutritional Supplement|Pills of cognitive nutritional supplement
219573059|NCT06837246|OTHER|Placebo|Matching placebo to active
219573060|NCT06281509|PROCEDURE|Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.|Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)
219573061|NCT06281509|PROCEDURE|Ultrasound|A small mobile ultrasound device will be used to further asses the presence of the tendon.
219573062|NCT05866380|OTHER|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
219573063|NCT05564117|DRUG|Semaglutide|Semaglutide tablets orally once daily for 64 weeks.
219573064|NCT05564117|DRUG|Placebo semaglutide|Semaglutide placebo-matching tablets orally once daily for 64 weeks.
219573065|NCT06164951|DRUG|Infigratinib 0.25 mg/kg/day|Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
219573066|NCT06164951|DRUG|Placebo Comparator 0.25 mg/kg/day|Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
219573067|NCT05712382|BEHAVIORAL|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
219573068|NCT05712382|BEHAVIORAL|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
219573069|NCT05712382|BEHAVIORAL|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
219573070|NCT05712382|BEHAVIORAL|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
219573071|NCT06216574|OTHER|Internet-based Intervention|Receive access to SHINE modules
219573072|NCT05064280|DRUG|Pembrolizumab|Given by IV (200 mg IV D1 Q3W)
219758808|NCT05973162|OTHER|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
219761808|NCT05807594|BEHAVIORAL|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
219418938|NCT04380974|PROCEDURE|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
219004706|NCT01666782|BIOLOGICAL|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
219418939|NCT04380974|DRUG|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
219004707|NCT05157230|BEHAVIORAL|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
219004708|NCT03228927|OTHER|comparison of twin A to twin B|Comparison of Twin A to Twin B
219418940|NCT04675606|BEHAVIORAL|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
219418941|NCT04675606|BEHAVIORAL|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
219418942|NCT02307071|DEVICE|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
219004709|NCT06169696|DEVICE|Intervention/Treatment|Non-invasive EEG headband device
219004710|NCT03971214|DRUG|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
219004711|NCT04031391|OTHER|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
219004712|NCT05533684|DRUG|Gabapentin|single preoperative dose of 600 mg gabapentin
219004713|NCT00041483|DRUG|Anecortave Acetate 15 mg sterile suspension|
219418943|NCT06443476|PROCEDURE|Tenting abutment technique|To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible.
219418944|NCT06443476|PROCEDURE|Tent pole technique|using the Tent pole technique to gain bone vertical and horizontal loss
219418945|NCT00913133|DRUG|Desirudin|Desirudin SC 15mg q12h
219418946|NCT00642746|DRUG|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
219418947|NCT00642746|DRUG|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
219418948|NCT00642746|DRUG|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
219418949|NCT00642746|DRUG|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
219418950|NCT00642746|DRUG|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
219004714|NCT00041483|OTHER|Photodynamic Therapy (PDT)|
219004715|NCT02393170|OTHER|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
219004716|NCT02393170|OTHER|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
219004717|NCT04764903|OTHER|No intervention|There is no intervention in this study
219004718|NCT03560232|DRUG|Ceftriaxone|See arm description
219418951|NCT05249985|DEVICE|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
219418952|NCT05249985|DIETARY_SUPPLEMENT|Protein|Participants will consume a daily protein supplement
219418953|NCT01204333|DRUG|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
219418954|NCT01204333|DRUG|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
219004719|NCT03560232|DRUG|Ampicillin/sulbactam|See arm description
219418955|NCT00507598|OTHER|No intervention|Correlative study collecting serum and tissue samples
219418956|NCT04352595|DRUG|Hemay808|Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
219418957|NCT01811355|DRUG|Mexiletine|Sodium channel blocker
219418958|NCT01811355|DRUG|Placebo|Placebo
219418959|NCT05728671|DRUG|IP2015|Test drug
219418960|NCT05380934|DRUG|TQH3821 tablets|TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
219573073|NCT05064280|DRUG|Lenvatinib|Given by PO (20 mg PO QD)
219573074|NCT06357286|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
219573075|NCT05618353|DRUG|Colchicine|0.6 mg tablets
219573076|NCT05618353|DRUG|Placebo|Matching placebo
219573077|NCT03702634|BEHAVIORAL|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
219573078|NCT02027870|DEVICE|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
219573079|NCT06406569|DEVICE|H-Man Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
219004720|NCT03560232|DRUG|Piperacillin/tazobactam|See arm description
219004721|NCT03560232|DRUG|Cefazolin + Gentamicin|See arm description
219004722|NCT03560232|DRUG|Clindamycin + Gentamicin|See arm description
219004723|NCT03681405|OTHER|Informational Intervention|Given information about mindful movement and breathing
219004724|NCT03681405|OTHER|Questionnaire Administration|Ancillary studies
219004725|NCT03681405|BEHAVIORAL|Telephone-Based Intervention|Receive caring attention phone call
219004726|NCT03809052|DRUG|GB1211|Hard capsules for oral use
219004727|NCT03809052|DRUG|Placebo|Hard capsules for oral use
219004728|NCT04397783|PROCEDURE|construction of an end colostomy|longitudinal incision in the construction of an end colostomy
219418961|NCT05380934|DRUG|TQH3821 tablets (Placebo)|TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
219418962|NCT05380934|DRUG|Methotrexate tablets|Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
219418963|NCT02175173|DRUG|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
219418964|NCT06490419|DEVICE|Electrolipolysis|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute."
219418965|NCT06490419|DEVICE|ultrasound cavitation|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes."
219418966|NCT04020146|OTHER|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
219418967|NCT03337152|DRUG|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
219418968|NCT03337152|DRUG|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
219758809|NCT05973162|OTHER|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
219758810|NCT00654537|DRUG|Rosuvastatin|
219758811|NCT00654537|DRUG|Atorvastatin|
219758812|NCT00654537|DRUG|Pravastatin|
219758813|NCT00654537|DRUG|Simvastatin|
219758814|NCT01158859|DRUG|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
219758815|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
219758816|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
219758817|NCT03134326|DEVICE|R1-25 and R2-25 Pulse Oximeter Sensor|
219758818|NCT04750161|OTHER|No intervention|No intervention will be given to participants. It is purely observational.
219758819|NCT06256055|BIOLOGICAL|UCMYM802 Injection|1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
219758820|NCT06384170|DEVICE|Spinal Cord Stimulation- Closed loop|This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
219758821|NCT05622578|OTHER|QST, CPM and Paisudoscan|Quantified pain tests
219758822|NCT01006395|DRUG|Zoledronic acid|yearly infusion
219758823|NCT01006395|DRUG|Placebo|yearly infusion
219758824|NCT03350464|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
219758825|NCT02287779|DRUG|SHP626|
219758826|NCT02287779|DRUG|Placebo|
219758827|NCT01936558|OTHER|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
219758828|NCT01150032|OTHER|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
219004729|NCT03328312|DRUG|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR \>0.9
219190892|NCT06529393|PROCEDURE|suprascapular nerve block|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
219190893|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - curved 11508AAK|11508AAK Miniature straight forward telescope 0-degree set, curved, diameter 3.3 millimeter, length 30 centimeter, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 French., remote eyepiece, fiber optic light transmission incorporated.
219190894|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - straight 11506AAK|11506AAK Miniature straight forward telescope 0-degree, straight, diameter 3.3 millimeter, length 30 cm, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 french, remote eyepiece, fiber optic light transmission incorporated.
219190895|NCT06547294|DEVICE|Osprey IV|Utilization of novel needle over catheter commercial insertion device
219190896|NCT06547294|OTHER|Historical Controls|Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
219190897|NCT06703151|BEHAVIORAL|CMDs (Cardiometabolic Diseases) Self-Care Manual|1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
219758829|NCT04900298|DEVICE|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
219758830|NCT06266546|DRUG|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
219758831|NCT05886478|DRUG|No intervention|As this is an observational study, no intervention will be administered.
219758832|NCT06563908|PROCEDURE|Lipiodol® uterine treatment prior to IVF/ICSI|Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. One millilitre of Lipiodol Ultra Fluide® contains 0.48g iodine. Women will lie in the left lateral or supine position. Radiologists will use a 'no touch' technique after applying antiseptic solution to the cervix. Uterine cannulation using the Cook HSG catheter will be applied to conduct Lipiodol® treatment. Prewarmed (37oC) Lipiodol® will be slowly instilled, with intermittent fluoroscopic X-ray guidance. Up to 10 ml of Lipiodol® will be slowly injected into the uterus and directly monitored by fluoroscopy. If intravasation was observed on X-ray (contrast apparent in the venous system), instillation will be stopped immediately.
219758833|NCT05140421|BEHAVIORAL|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
219758834|NCT04849897|DEVICE|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
219758835|NCT04849897|OTHER|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
219758836|NCT05554679|DRUG|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
219758837|NCT04064905|BIOLOGICAL|mRNA-1893|Zika vaccine
219190898|NCT05285943|DRUG|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
219190899|NCT05285943|DRUG|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
219418969|NCT03645772|OTHER|Exercise intervention|12-week progressive training intervention
219758838|NCT04064905|OTHER|Placebo|0.9% sodium chloride
219190900|NCT05285943|OTHER|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
219190901|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
219418970|NCT00777231|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
219418971|NCT02118857|OTHER|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
219418972|NCT01548898|DEVICE|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
219418973|NCT00398385|DRUG|cisplatin|
219418974|NCT00398385|DRUG|gemcitabine hydrochloride|
219758839|NCT06505226|BEHAVIORAL|in person meditation|in person guided meditation
219418975|NCT00398385|PROCEDURE|adjuvant therapy|
219418976|NCT00398385|PROCEDURE|conventional surgery|
219418977|NCT00398385|PROCEDURE|neoadjuvant therapy|
219418978|NCT04233359|PROCEDURE|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
219418979|NCT04233359|PROCEDURE|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
219758840|NCT06505226|BEHAVIORAL|in person meditation using headphones|in person meditation using headphones
219758841|NCT06505226|BEHAVIORAL|virtual meditation|virtually guided meditation via Zoom
219758842|NCT00114348|PROCEDURE|R-Blocks|
219758843|NCT00114348|PROCEDURE|Protocol II-Ida|
219758844|NCT06274957|OTHER|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
219758845|NCT06274957|DEVICE|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
219758846|NCT06274957|DEVICE|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
219758847|NCT04970914|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
219758848|NCT04970914|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
219758849|NCT02257684|DRUG|pegcrisantaspase|
219758850|NCT02128776|OTHER|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
219758851|NCT02128776|OTHER|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
219758852|NCT04313582|BEHAVIORAL|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
219758853|NCT02587910|DIETARY_SUPPLEMENT|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
219758854|NCT02587910|DIETARY_SUPPLEMENT|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
219190902|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
219190903|NCT05663047|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
219190904|NCT05663047|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
219190905|NCT03449264|BIOLOGICAL|biological collection|"* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out."
219190906|NCT06823895|DRUG|Maixuekang capsule|"Single dose group: Participants will be given Maixuekang capsules once, 1g, orally.~Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day."
219418980|NCT06515769|DIAGNOSTIC_TEST|TERMOGRAPHY|Obtaining an image of the foot using a thermographic camera
219418981|NCT05055167|DRUG|Envafolimab|single agent, 300mg Q3W IH until disease progressed
219418982|NCT00077610|DRUG|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
219418983|NCT00077610|DRUG|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
219573080|NCT06406569|DEVICE|ReHandyBot|ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.
219190907|NCT06286722|OTHER|Progressive, individualized and structured exercise program|See description under Arms
219190908|NCT06433739|OTHER|standardized algorithm|standardized algorithm for the correct selection of peripheral venous catheters
219190909|NCT06822764|OTHER|observational|observational
219573081|NCT06406569|DEVICE|MyoPanda|MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
219573082|NCT06308640|DEVICE|Insertion of the device intraorally|"* The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance"
219573083|NCT04300413|OTHER|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
219573084|NCT05113459|DRUG|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
219190910|NCT06822595|DEVICE|Blood flow restriction (BFR) training|Both groups followed an identical 8-week isokinetic training protocol twice weekly. The BFR group performed exercises with arterial occlusion pressure set to 80% of the measured occlusion pressure.
219418984|NCT00077610|DRUG|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
219418985|NCT05256056|DRUG|Bupivacain|efficacy of bupivacaine in different volumes
219418986|NCT05673473|RADIATION|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
219418987|NCT03284008|OTHER|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
219573085|NCT06226701|DEVICE|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
219573086|NCT06580704|DRUG|Lumbosacral Erector Spinae Plane Block|Patients will receive ultrasound-guided lumbosacral erector spinae plane block.
219573087|NCT06580704|DRUG|Psoas Muscle Compartment With Sciatic Nerve Block|Patients will receive ultrasound-guided psoas muscle compartment with sciatic nerve block.
219573088|NCT01000610|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
219758855|NCT04434755|OTHER|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
219758856|NCT05478278|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
219418988|NCT03284008|OTHER|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
219418989|NCT03953261|DRUG|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
219418990|NCT01634321|DRUG|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
219758857|NCT05478278|DRUG|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
219758858|NCT05478278|DRUG|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
219761809|NCT05716945|DRUG|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
219761810|NCT05716945|DRUG|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
219761811|NCT05716945|OTHER|Stop steroids|Half the patients in each study arm will discontinue steroids.
219573089|NCT01000610|DRUG|methotrexate|10-25 mg weekly (oral or parenteral)
219573090|NCT01000610|DRUG|methylprednisolone|100 mg iv prior to each rituximab infusion
219573091|NCT00576641|BIOLOGICAL|autologous dendritic cells|
219573092|NCT00002473|PROCEDURE|conventional surgery|
219190911|NCT06822595|DEVICE|Isokinetic training|Both groups followed an identical 8-week isokinetic training protocol twice weekly.
219573093|NCT00678626|DRUG|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
219190912|NCT06078761|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
219190913|NCT06805500|DEVICE|REACTION|Combination of a exoskeleton and gait trainer
219190914|NCT06805500|DEVICE|ABLE Regain|Exoskeleton
219418991|NCT03921255|OTHER|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
219418992|NCT04068311|OTHER|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
219418993|NCT04004078|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
219418994|NCT00361127|DRUG|isotonic saline infusion|
219418995|NCT00994656|DEVICE|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
219573094|NCT00678626|DRUG|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
219573095|NCT02917226|OTHER|Clinical decision support and monitoring system|
219573096|NCT04808882|DRUG|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
219573097|NCT04808882|DRUG|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
219573098|NCT04808882|DRUG|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
219573099|NCT00667082|DRUG|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
219573100|NCT03216694|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
219573101|NCT02645344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
219573102|NCT02645344|BEHAVIORAL|Sensory Cueing (SC)|
219573103|NCT02645344|BEHAVIORAL|Conventional Rehabilitation|
219573104|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
219190915|NCT06805500|DEVICE|GABLE Core|Gait trainer
219190916|NCT06311175|BEHAVIORAL|Dietary Tracking Prescription|Dietary tracking prescriptions to follow during a digital weight loss intervention.
219190917|NCT03836066|DRUG|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
219418996|NCT05312931|OTHER|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
219418997|NCT02245451|DRUG|Tipranavir|
219418998|NCT02245451|DRUG|Ritonavir|
219573105|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
219573106|NCT03898674|DRUG|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
219573107|NCT05392374|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
219758859|NCT06133023|PROCEDURE|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
219758860|NCT06133023|PROCEDURE|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
219758861|NCT01570387|DRUG|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
219758862|NCT01570387|DRUG|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
219758863|NCT03325231|OTHER|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
219758864|NCT02499744|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
219758865|NCT02499744|DEVICE|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
219004730|NCT03328312|DRUG|neostigmine+atropine|Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation
219004731|NCT03328312|DRUG|neostigmine+atropine+sugammadex|4\. Time of extubation
219418999|NCT02245451|DRUG|Methadone|
219419000|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
219573108|NCT01741779|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
219419001|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
219419002|NCT00071422|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
219419003|NCT00656734|BIOLOGICAL|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
219419004|NCT00976950|DRUG|Tipranavir|
219419005|NCT00976950|DRUG|ritonavir|low-dose
219419006|NCT04722484|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
219419007|NCT05862558|DEVICE|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
219419008|NCT02674672|DEVICE|VenaTech® (VenaTech Retrievable Filter)|
219004732|NCT04238702|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
219190918|NCT06446193|DEVICE|NDTx-01|NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
219190919|NCT06446193|BEHAVIORAL|TAU|TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
219190920|NCT05156320|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 was administered every 4 weeks by intravenous (IV) infusion.
219419009|NCT05044585|OTHER|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
219419010|NCT00126789|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
219419011|NCT01921946|DRUG|Fimasartan|
219573109|NCT01741779|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
219419012|NCT01921946|DRUG|Rosuvastatin|
219419013|NCT01943422|DRUG|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
219419014|NCT01943422|DRUG|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
219573110|NCT01741779|OTHER|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
219573111|NCT05476419|OTHER|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
219419015|NCT04325945|DEVICE|Low level laser therapy|808nm low level laser therapy on acupuncture points
219573112|NCT00368095|BEHAVIORAL|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
219573113|NCT04299659|DIAGNOSTIC_TEST|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
219190921|NCT05156320|DRUG|Placebo|Placebo was administered every 4 weeks by intravenous (IV) infusion.
219190922|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
219004733|NCT04238702|DRUG|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
219004734|NCT04238702|OTHER|Placebo|Placebo 7 days intervention period
219004735|NCT05540405|DIETARY_SUPPLEMENT|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
219004736|NCT05540405|DIETARY_SUPPLEMENT|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
219004737|NCT05540405|DIETARY_SUPPLEMENT|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
219190923|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
219190924|NCT05270005|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
219190925|NCT06816797|OTHER|Cog Fun Ageing intervention|Cog Fun Aging is a group-based intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 10 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
219190926|NCT06816797|OTHER|Cog-Fun Aging Crossover|"In the initial phase of the study (between T0 and T1) this group will receive usual care. Participants are users of regional services where activities for healthy older adults are available. This group will continue going to activities as normal during the initial phase and then participate in the Cog-Fun Aging intervention."
219190927|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
219190928|NCT03004547|OTHER|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
219190929|NCT03382938|DRUG|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
219190930|NCT03382938|DRUG|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
219190931|NCT03382938|DRUG|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
219190932|NCT03382938|OTHER|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
219190933|NCT06823453|BEHAVIORAL|Peer Harm Reduction Support Champion Intervention|This intervention will recruit non-substance-using friends and family members of people who use opioids and live on the West side of Chicago, educate them on harm reduction (HR) tools and services, and train them to become peer HR support champions. They will be asked to recruit one friend or family member who uses opioids to the study, who will also be provided with an educational training on overdose risk reduction and available HR tools and services. The intervention will then facilitate a counselor-led initial conversation between peer HR support champions and their friend or family member who uses opioids, to help establish HR-related support, and will provide all participants with naloxone and fentanyl test strip kits. This intervention will not only provide another mechanism through which people who use opioids can access HR tools and services, thereby reducing logistical barriers to access and preventing overdose, but it should also reduce stigma and increase social support.
219190934|NCT06823505|OTHER|structured questionnaire|Using the Depression Scale (CES-D), Cancer Self-Efficacy Scale (CASE), Family Peer Relationship Questionnaire (FPRQ), Family Resilience Scale (FRAS) and Parent-Child Relationship Quality Scale
219190935|NCT00179465|DRUG|Tiagabine|Up to 36 mg daily
219190936|NCT00179465|DRUG|Placebo|Placebo
219419016|NCT00304915|BEHAVIORAL|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
219419017|NCT04008901|DRUG|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
219419018|NCT04008901|DRUG|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
219419019|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to starchy meal|
219419020|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to liquid|
219419021|NCT02168296|DIETARY_SUPPLEMENT|No Plant-based ingredient|
219419022|NCT00160992|BIOLOGICAL|Melan-A analog peptide|
219573114|NCT03812705|BIOLOGICAL|fecal microbiome transplantation|"1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation."
219419023|NCT03411577|OTHER|Behavioral Intervention|
219419024|NCT05984810|PROCEDURE|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
219419025|NCT06271928|DRUG|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
219419026|NCT05282446|DRUG|INV-202|tablet
219419027|NCT05282446|DRUG|Placebo|matching tablet
219419028|NCT03925194|DRUG|Anakinra|Application of Anakinra once daily for 28 days
219419029|NCT01853111|BIOLOGICAL|Interleukin-2|
219419030|NCT02660619|OTHER|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
219573115|NCT01758133|BEHAVIORAL|Exposure to medical clown activities|
219004738|NCT04923191|OTHER|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
219004739|NCT05221515|BEHAVIORAL|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
219004740|NCT05221515|BEHAVIORAL|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
219004741|NCT03978520|DRUG|Elsubrutinib|Capsule; Oral
219004742|NCT03978520|DRUG|Placebo for elsubrutinib|Capsule; Oral
219004743|NCT03978520|DRUG|Upadacitinib|Film-coated tablet; Oral
219004744|NCT03978520|DRUG|Placebo for upadacitinib|Film-coated tablet; Oral
219004745|NCT05725967|PROCEDURE|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
219419031|NCT03882346|COMBINATION_PRODUCT|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
219419032|NCT00598169|BIOLOGICAL|rituximab|375mg/m2 on Day 1
219419033|NCT00598169|DRUG|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
219419034|NCT00598169|DRUG|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
219419035|NCT00598169|DRUG|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
219419036|NCT00598169|DRUG|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
219419037|NCT00598169|DRUG|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
219419038|NCT00598169|GENETIC|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
219004746|NCT05725967|PROCEDURE|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
219004747|NCT05725967|PROCEDURE|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
219004748|NCT05725967|DEVICE|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
219004749|NCT05725967|DEVICE|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
219004750|NCT05725967|DEVICE|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
219004751|NCT05725967|DEVICE|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
219419039|NCT00598169|GENETIC|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
219419040|NCT04124042|BIOLOGICAL|XT-150|plasmid DNA
219419041|NCT04124042|DRUG|Placebo|Placebo is a sterile phosphate-buffered saline
219419042|NCT04895605|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
219419043|NCT04895605|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
219190937|NCT06086951|BEHAVIORAL|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
219573116|NCT05979077|OTHER|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
219004752|NCT05725967|DEVICE|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
219004753|NCT06394297|RADIATION|SBRT|SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
219190938|NCT06086951|OTHER|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
219190939|NCT06760455|DRUG|BPR-30221616 Injection|BPR-30221616 will be administered by subcutaneous (SC) injection
219190940|NCT06760455|DRUG|Sodium Chloride Injection|Sodium Chloride Injection will be administered by SC injection
219419044|NCT02662985|DRUG|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
219419045|NCT02662985|DRUG|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
219419046|NCT01807715|OTHER|survey|Survey before procedure to obtain demographic information and contraceptive information
219419047|NCT02628249|DIETARY_SUPPLEMENT|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
219419048|NCT02628249|DIETARY_SUPPLEMENT|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
219419049|NCT02628249|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
219419050|NCT02628249|DIETARY_SUPPLEMENT|Essential amino acids|Essential amino acids modeled after egg protein.
219419051|NCT02628249|DIETARY_SUPPLEMENT|Non essential amino acids|Non essential amino acids modeled after egg protein.
219419052|NCT02143193|BEHAVIORAL|Skin-to-Skin Contact|
219419053|NCT00139139|BIOLOGICAL|Hepatitis A vaccine|
219419054|NCT04172753|RADIATION|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
219419055|NCT04172753|DIAGNOSTIC_TEST|Imaging on the MR Linac|Only imaging performed on the MR Linac
219419056|NCT01228942|DEVICE|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
219419057|NCT03676153|OTHER|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
219573117|NCT05259501|OTHER|RMIST|"RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
219573118|NCT04637035|OTHER|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
219004754|NCT00188669|DRUG|pentoxifylline|
219004755|NCT00188669|DRUG|alpha-Tocopherol|
219419058|NCT03676153|OTHER|Integrative medicine treatment program|Integrative medicine treatment program
219419059|NCT02480179|DEVICE|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
219419060|NCT01947959|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
219419061|NCT01947959|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
219419062|NCT05572827|BEHAVIORAL|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
219419063|NCT02056717|DRUG|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
219419064|NCT02056717|DRUG|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
219419065|NCT01486004|DRUG|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
219573119|NCT06270628|BEHAVIORAL|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
219004756|NCT03758352|PROCEDURE|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
219004757|NCT03758352|OTHER|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
219190941|NCT05319821|BEHAVIORAL|Receive ECHO training|Active Intervention
219190942|NCT05319821|BEHAVIORAL|Offered ECHO training in year 5|Delayed Intervention
219190943|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
219419066|NCT01486004|DRUG|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
219419067|NCT06382363|PROCEDURE|POC-cHbA1c testing|The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
219419068|NCT04782037|DRUG|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
219419069|NCT04301687|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
219419070|NCT04301687|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
219573120|NCT03740113|BEHAVIORAL|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
219573121|NCT04673448|BIOLOGICAL|Dostarlimab|Given IV
219573122|NCT04673448|DRUG|Niraparib|Given PO
219573123|NCT04673448|PROCEDURE|Biopsy|Undergo biopsy
219573124|NCT04673448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219758866|NCT04204824|OTHER|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
219573125|NCT04673448|PROCEDURE|Computed Tomography|Undergo CT
219573126|NCT04673448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219573127|NCT04843566|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
219573128|NCT04843566|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
219573129|NCT04843566|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
219573130|NCT03349827|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
219573131|NCT03349827|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
219758867|NCT03332030|DIAGNOSTIC_TEST|Collection of Stem Cells|One time collection of a 20 ml blood sample
219758868|NCT04629742|OTHER|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
219758869|NCT04629742|OTHER|Standard pizza|A standard pizza administered to 12 healthy subjects
219758870|NCT01852981|BEHAVIORAL|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
219758871|NCT01852981|BEHAVIORAL|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
219419071|NCT05279989|OTHER|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
219573132|NCT03349827|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
219573133|NCT03349827|DRUG|Apatinib|500mg, once daily, day 1 to day 21.
219573134|NCT06857227|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
219573135|NCT06857227|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
219573136|NCT01951287|OTHER|Acute beverage (water) consumption|Acute beverage consumption includes water.
219573137|NCT01951287|OTHER|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
219573138|NCT01951287|OTHER|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
219573139|NCT01951287|OTHER|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
219573140|NCT01951287|OTHER|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
219419072|NCT05279989|OTHER|Health Information Videos|Participants will receive videos of health information.
219419073|NCT03442829|BEHAVIORAL|Sweet food consumption|Sweet food consumption at breakfast
219419074|NCT03442829|BEHAVIORAL|Non-sweet food consumption|Non-sweet food consumption at breakfast
219419075|NCT01134757|BIOLOGICAL|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
219419076|NCT02862223|DIETARY_SUPPLEMENT|Neoprinol|
219573141|NCT01951287|OTHER|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
219573142|NCT02915926|BEHAVIORAL|occupational performance coaching|
219419077|NCT01066195|DRUG|iressa|iressa 250mg per day every day
219419078|NCT01066195|DRUG|alimta|alimta 500mg/m2 every 3 weeks
219419079|NCT01486784|DRUG|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
219419080|NCT04886193|DRUG|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"* FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
219573143|NCT02915926|BEHAVIORAL|standard OT|
219573144|NCT01300624|BEHAVIORAL|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
219573145|NCT02354911|BIOLOGICAL|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
219573146|NCT02354911|OTHER|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
219573147|NCT03804164|OTHER|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
219573148|NCT03804164|OTHER|Quality-of-Life Assessment|Ancillary studies
219573149|NCT03804164|OTHER|Survey Administration|Ancillary studies
219573150|NCT06451718|DEVICE|Intracorneal implantation|Intracorneal implantation of the nitinol investigational device
219573151|NCT03659084|DRUG|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
219573152|NCT01592721|BIOLOGICAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
219419081|NCT00156910|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
219419082|NCT00156910|OTHER|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
219573153|NCT02483143|DRUG|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
219573154|NCT02483143|DRUG|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
219573155|NCT02483143|DRUG|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
219419083|NCT06804304|BEHAVIORAL|Music-based telerehabilitation|The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).
219573156|NCT04244669|DEVICE|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
219573157|NCT04244669|DEVICE|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
219419084|NCT06809933|OTHER|Digital Health Mobile App|"A digital health technology (DHT) called Move by Sword Health, which utilizes a mobile app displaying tailored and recommended exercise options, wearable technology (Move wearable or equivalent), and a web-based platform monitored by a physical therapist who will provide individual support"
219419085|NCT06809933|OTHER|Virtual Support Group|An institutional, virtual peer support group session will include a maximum of 5 participant per group
219419086|NCT06809933|OTHER|Health Coaching|The facilitated group and discussions sessions will be led by a University of California, San Francisco (UCSF) certified health coach (CHC), following a pre-specified agenda and provided virtually
219573158|NCT02839148|DIETARY_SUPPLEMENT|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
219573159|NCT04725448|DRUG|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
219573160|NCT04725448|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
219573161|NCT04725448|DRUG|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
219573162|NCT04725448|DRUG|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
219573163|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
219573164|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
219573165|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
219573166|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
219419087|NCT06809933|OTHER|Wearable Activity Tracker|A wearable device to track participant activity
219419088|NCT06809933|OTHER|Handouts|A handout with exercise recommendations for those with cancer in accordance with national guidelines
219419089|NCT01021852|DRUG|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
219419090|NCT01021852|DRUG|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
219419091|NCT03985072|DRUG|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
219419092|NCT04137133|DIAGNOSTIC_TEST|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
219419093|NCT04693442|OTHER|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling \& scar assessment questionnaires
219419094|NCT00776399|DEVICE|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
219758872|NCT05495022|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
219758873|NCT01987557|BEHAVIORAL|rate group|walking with a high cadence (steps per minute)
219419095|NCT01763463|DRUG|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
219419096|NCT01763463|DRUG|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
219758874|NCT01987557|BEHAVIORAL|magnitude treadmill group|
219758875|NCT01987557|BEHAVIORAL|regular treadmill walking|
219758876|NCT05266547|DEVICE|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
219758877|NCT03164161|DEVICE|Cold pressor test|Described before.
219419097|NCT03631862|DRUG|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
219419098|NCT03631862|DRUG|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
219419099|NCT01740037|OTHER|Specialized outpatient AF Clinic|
219004758|NCT04597788|OTHER|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
219419100|NCT01740037|OTHER|Usual Care|
219004759|NCT04597788|OTHER|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
219004760|NCT00138996|DEVICE|automated direct feedback on CPR from defibrillator|
219004761|NCT02481232|BIOLOGICAL|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
219419101|NCT02493426|DRUG|Intranasal Oxytocin|
219419102|NCT02493426|DRUG|Placebo|
219419103|NCT03491553|DRUG|Selgantolimod|Tablet(s) administered orally once weekly
219004762|NCT01119417|DRUG|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
219004763|NCT01119417|DRUG|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
219004764|NCT01119417|DRUG|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
219004765|NCT01119417|DRUG|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
219004766|NCT01119417|DRUG|Saline|2-3 IV saline infusions for 15 min each.
219004767|NCT03116971|DRUG|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
219004768|NCT03116971|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.
219004769|NCT03116971|DRUG|Etoposide|Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
219004770|NCT01939743|DRUG|Diclofenac suppository plus lidocaine gel|
219419104|NCT03491553|DRUG|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
219573167|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
219573168|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
219573169|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
219758878|NCT03164161|OTHER|β-endorphins evaluation in saliva|Described before.
219758879|NCT03164161|OTHER|β-endorphins evaluation in blood plasma|Described before.
219004771|NCT01939743|DRUG|Lidocaine gel only|
219419105|NCT03491553|DRUG|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
219419106|NCT05673863|BEHAVIORAL|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
219573170|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
219573171|NCT03861481|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
219573172|NCT03861481|OTHER|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
219573173|NCT03118388|BEHAVIORAL|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
219573174|NCT03118388|BEHAVIORAL|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
219573175|NCT02473783|DRUG|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
219573176|NCT02473783|OTHER|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
219758880|NCT05683366|DEVICE|No Intervention|There is no intervention in this study
219758881|NCT03398330|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
219758882|NCT03398330|DRUG|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
219758883|NCT02347605|DRUG|Nicotine lozenge 4 mg|
219758884|NCT02347605|DRUG|Placebo lozenge|
219758885|NCT00773084|DRUG|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
219758886|NCT02083978|OTHER|MRI scanning|
219758887|NCT05732038|BEHAVIORAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
219758888|NCT05732038|BEHAVIORAL|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
219758889|NCT00317811|DIETARY_SUPPLEMENT|ascorbic acid|
219758890|NCT00317811|DRUG|bortezomib|
219758891|NCT00317811|DRUG|melphalan|
219758892|NCT02876731|DEVICE|PET-CT|NaF PET-CT
219758893|NCT02876731|DEVICE|MRI|DWMRI
219758894|NCT05515744|PROCEDURE|Childbirth|Induction or planned cesarean
219758895|NCT02759133|DEVICE|Metal wire|Localization technique for breast surgery using metal wire
219004772|NCT05544604|DEVICE|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
219419107|NCT02581319|PROCEDURE|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
219419108|NCT06450691|PROCEDURE|biopsy|skin biopsy and blood sampling
219758896|NCT02759133|DEVICE|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
219004773|NCT02032810|DRUG|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
219419109|NCT04428684|DRUG|Pepti 3.6 mg|Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
219419110|NCT04195269|DRUG|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
219419111|NCT04802980|DRUG|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
219419112|NCT04802980|DRUG|Oxaliplatin|Oxaliplatin is an anti-tumor drug
219419113|NCT04802980|DRUG|Capecitabine|Capecitabine is an anti-tumor drug
219419114|NCT04802980|DRUG|Paclitaxel|Paclitaxel is an anti-tumor drug
219419115|NCT04802980|DRUG|Gemcitabine|Gemcitabine is an anti-tumor drug
219419116|NCT04802980|DRUG|Cisplatin|Cisplatin is an anti-tumor drug
219758897|NCT00805584|DRUG|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
219758898|NCT02272127|DRUG|icotinib|
219004774|NCT02032810|DRUG|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
219004775|NCT04124276|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
219004776|NCT04124276|DIETARY_SUPPLEMENT|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
219004777|NCT05914805|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
219004778|NCT05914805|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
219758899|NCT02256995|DEVICE|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
219758900|NCT06645795|COMBINATION_PRODUCT|Robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
219004779|NCT00000489|PROCEDURE|coronary artery bypass|
219004780|NCT03273595|DRUG|Lapatinib|
219004781|NCT03273595|BIOLOGICAL|Trastuzumab|
219004782|NCT03273595|DRUG|Paclitaxel|
219419117|NCT04802980|DRUG|Carboplatin|Carboplatin is an anti-tumor drug
219419118|NCT04176055|DRUG|Haloperidol|haloperidol intervention
219419119|NCT02242994|DEVICE|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
219419120|NCT02242994|DEVICE|Experimental App|Participant receives experimental app to test speed and error rate of communication.
219419121|NCT05102708|OTHER|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
219004783|NCT03273595|DRUG|Epirubicin|
219004784|NCT03273595|DRUG|Cyclophosphamide|
219004785|NCT02260700|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
219004786|NCT02260700|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
219419122|NCT03838068|BIOLOGICAL|Biodentine|Biodentine is considered a calcium silicate cement
219419123|NCT03838068|BIOLOGICAL|mineral trioxide aggregate|calcium based silicate cement
219419124|NCT03838068|PROCEDURE|cervical pulpotomy|coronal pulp tissue was removed till the orifice
219419125|NCT03838068|DRUG|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
219419126|NCT01755494|DRUG|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
219419127|NCT01755494|DRUG|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
219419128|NCT01755494|DRUG|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
219419129|NCT01755494|DRUG|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
219419130|NCT01755494|DRUG|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
219419131|NCT02017236|DRUG|Volitinib|600mg Volitinib ,single dose,oral
219419132|NCT01025817|DRUG|Everolimus and tacrolimus|"Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels"
219419133|NCT01025817|DRUG|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
219419134|NCT01769261|OTHER|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
219419135|NCT01769261|OTHER|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
219419136|NCT01769261|OTHER|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
219419137|NCT00817401|DEVICE|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
219419138|NCT01136421|DRUG|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
219419139|NCT01136421|DRUG|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
219419140|NCT05779332|OTHER|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
219573177|NCT04158661|PROCEDURE|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
219573178|NCT04158661|PROCEDURE|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
219573179|NCT04158661|PROCEDURE|no thymectomy (control)|routine medical care
219758901|NCT06645795|OTHER|Conventional pjysical therapy|Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
219758902|NCT02051192|BEHAVIORAL|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
219419141|NCT01821820|OTHER|Pistachios|
219419142|NCT04261387|DRUG|LUT014 Gel|Topical application qd for 28 days
219758903|NCT02051192|OTHER|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
219419143|NCT04261387|DRUG|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
219419144|NCT00173693|BEHAVIORAL|exercise for strength, balance, health education|
219573180|NCT04722159|DEVICE|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
219573181|NCT00005809|PROCEDURE|computed tomography|
219573182|NCT00005809|PROCEDURE|diagnostic colonoscopy|
219573183|NCT00236067|DRUG|Gabitril|
219573184|NCT00002360|DRUG|Didanosine|
219419145|NCT00731848|DIETARY_SUPPLEMENT|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
219419146|NCT04182256|DEVICE|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
219419147|NCT06414538|OTHER|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application."
219419148|NCT06414538|OTHER|Classic Method Group|After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
219419149|NCT00005023|BIOLOGICAL|HER-2/neu peptide vaccine|
219419150|NCT00005023|BIOLOGICAL|sargramostim|
219419151|NCT02107430|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
219419152|NCT02107430|RADIATION|Standard radiotherapy|radiotherapy
219419153|NCT04735367|DRUG|palbociclib plus letrozole|palbociclib plus letrozole
219419154|NCT05010993|DIAGNOSTIC_TEST|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
219419155|NCT05010993|DIAGNOSTIC_TEST|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
219419156|NCT05010993|DIAGNOSTIC_TEST|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
219419157|NCT02528968|BEHAVIORAL|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
219419158|NCT04059445|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
219419159|NCT04059445|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
219419160|NCT02296996|DRUG|Dabrafenib + Trametinib|
219419161|NCT02804880|BEHAVIORAL|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
219419162|NCT02804880|BEHAVIORAL|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
219419163|NCT02804880|BEHAVIORAL|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
219419164|NCT02804880|OTHER|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
219419165|NCT02804880|OTHER|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
219419166|NCT02804880|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
219419167|NCT02804880|OTHER|12-page booklet|12-page smoking cessation self-help booklet
219419168|NCT00475462|DRUG|metoprolol|
219419169|NCT00475462|DRUG|conventional treatment|
219419170|NCT00101192|BIOLOGICAL|cetuximab|
219419171|NCT00101192|DRUG|cisplatin|
219419172|NCT06064786|DIAGNOSTIC_TEST|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
219419173|NCT02840058|OTHER|Biological samples|blood and tumor tissue samples
219419174|NCT02840058|DRUG|Anti PD1/PDL1 treatment|
219419175|NCT04604236|BEHAVIORAL|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
219419176|NCT04604236|BEHAVIORAL|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
219419177|NCT01465711|PROCEDURE|All abdominal surgical procedures|Laparotomy, Laparoscopy
219419178|NCT01465711|PROCEDURE|Intubation|Ventilatory support
219419179|NCT01465711|RADIATION|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
219419180|NCT05528497|OTHER|VR+|Use of a virtual reality helmet during ovocyte retrieval
219419181|NCT00672529|DIETARY_SUPPLEMENT|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
219419182|NCT02657668|BEHAVIORAL|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
219573185|NCT01220297|DRUG|Sirolimus|"Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
219573186|NCT01220297|DRUG|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
219573187|NCT01220297|DRUG|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
219573188|NCT01220297|DRUG|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
219573189|NCT01220297|DRUG|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
219573190|NCT01220297|DRUG|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
219573191|NCT00085306|BIOLOGICAL|recombinant interferon beta|recombinant interferon beta
219573192|NCT01989988|PROCEDURE|LMGB|
219573193|NCT01989988|PROCEDURE|LRYGB|
219573194|NCT01989988|PROCEDURE|SADJB|
219573195|NCT01287039|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
219573196|NCT01287039|DRUG|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
219573197|NCT04437888|DRUG|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
219573198|NCT04528888|DRUG|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
219004787|NCT02260700|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
219004788|NCT01157260|DRUG|Kremezin|AST-120 2g three times a day
219004789|NCT03405129|BEHAVIORAL|Phoenix|Phoenix cessation app
219004790|NCT03405129|BEHAVIORAL|NRT order button|Ability to order NRT through smartphone app
219004791|NCT03405129|BEHAVIORAL|Factoid|Factoid app
219004792|NCT01183156|BEHAVIORAL|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
219419183|NCT05686616|DRUG|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
219004793|NCT01183156|BEHAVIORAL|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
219573199|NCT04528888|DRUG|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
219573200|NCT04528888|DRUG|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
219573201|NCT00417404|DRUG|Aquasol A|IM Aquasol A 10,000IU three times weekly
219573202|NCT00417404|DRUG|aquasol A|10,000 IU three times weeks, by intramuscular injection
219419184|NCT05232422|BEHAVIORAL|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
219419185|NCT02702427|BIOLOGICAL|virus-specific T-Cells|infusion
219419186|NCT05799443|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
219004794|NCT02071121|DRUG|BIIB061|BIIB061 capsules for oral administration
219419187|NCT05799443|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
219004795|NCT02071121|DRUG|Placebo|BIIB061 matching placebo capsules
219004796|NCT02071121|DRUG|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
219419188|NCT05799443|DRUG|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
219419189|NCT05799443|RADIATION|SBRT|8-10Gy×5F，QOD
219004797|NCT00088517|DRUG|[11C]NNC-112|
219004798|NCT02868320|OTHER|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
219419190|NCT01232894|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
219419191|NCT01232894|DRUG|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
219573203|NCT00417404|OTHER|sham injection|sham injection
219419192|NCT03364426|OTHER|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
219419193|NCT02149056|BEHAVIORAL|observation|
219419194|NCT02149056|OTHER|Impaired Glucose Tolerance|Impaired Glucose Tolerance
219419195|NCT02128763|DRUG|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
219419196|NCT02128763|DRUG|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
219419197|NCT02776657|OTHER|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
219573204|NCT02843594|PROCEDURE|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
219004799|NCT02868320|OTHER|Instruction booklet|General detailed instructions addressing the same SMS categories.
219004800|NCT02090244|DRUG|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
219004801|NCT01322178|DRUG|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
219419198|NCT02776657|DEVICE|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
219419199|NCT02776657|PROCEDURE|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
219419200|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
219419201|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
219419202|NCT01892618|DRUG|Prevenar 13|13-valent pneumococcal conjugated vaccine
219419203|NCT01892618|DRUG|Pneumovax|23-valent pneumococcal polysaccharide vaccine
219419204|NCT00717366|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
219419205|NCT04476355|OTHER|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
219573205|NCT02843594|PROCEDURE|Standard Phaco Control|
219573206|NCT00217269|DEVICE|Coronary Artery Stenting|Endeavor Drug eluting stent
219573207|NCT00217269|DEVICE|Coronary Artery Stenting|Taxus Drug Eluting Stent
219004802|NCT03240614|DEVICE|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
219004803|NCT03240614|DEVICE|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
219004804|NCT03240614|DEVICE|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
219190944|NCT05049239|BEHAVIORAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
219419206|NCT03936816|OTHER|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
219419207|NCT02141802|BEHAVIORAL|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
219419208|NCT02141802|BEHAVIORAL|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
219419209|NCT00235690|PROCEDURE|Blood draws|PK samples obtained around a clinical dosing of colistin
219419210|NCT00235690|OTHER|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
219419211|NCT01879956|OTHER|Craft Activities|There is no intervention method used to perform the task.
219419212|NCT01879956|BEHAVIORAL|OGI Method|metacognitive approach to assess executive functions.
219419213|NCT01446601|DEVICE|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
219419214|NCT03661489|DRUG|Remimazolam|For induction and maintenance of general anesthesia
219419215|NCT03661489|DRUG|Propofol|For induction and maintenance of general anesthesia
219419216|NCT00910429|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
219419217|NCT01182389|PROCEDURE|Robotic VT Ablation|Robotic VT Ablation
219419218|NCT01182389|OTHER|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
219419219|NCT03378726|DIETARY_SUPPLEMENT|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
219419220|NCT03378726|BEHAVIORAL|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
219573208|NCT00099268|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
219004805|NCT06372002|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|"The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games…) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation."
219419221|NCT03378726|BEHAVIORAL|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
219419222|NCT03378726|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
219419223|NCT03378726|BEHAVIORAL|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
219419224|NCT05672966|BIOLOGICAL|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
219419225|NCT05672966|BIOLOGICAL|Placebo|0.5mL, Intramuscular
219419226|NCT01167465|OTHER|Moussik Diaper Rash Mousse|To be used as instructed
219419227|NCT01167465|OTHER|Desitin Creamy Ointment|To be used as instructed
219419228|NCT04846348|COMBINATION_PRODUCT|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
219419229|NCT04417725|OTHER|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
219419230|NCT02121756|DRUG|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
219419231|NCT02121756|DRUG|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
219419232|NCT03976115|DRUG|DDO-3055|Oral
219419233|NCT03976115|DRUG|Placebos|Oral
219004806|NCT03623802|OTHER|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
219419234|NCT03120481|OTHER|no intervation|no intervention
219419235|NCT02749877|BEHAVIORAL|Working Memory Training|(Training Details already described above)
219419236|NCT02749877|BEHAVIORAL|Physical Training|(Training Details already described above)
219573209|NCT00099268|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
219573210|NCT05016622|BIOLOGICAL|BNT162b2 vaccine|Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
219758904|NCT06176209|DIAGNOSTIC_TEST|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
219004807|NCT03623802|OTHER|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
219004808|NCT01525368|BEHAVIORAL|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
219004809|NCT04451239|DRUG|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
219419237|NCT00154167|DRUG|NV-101 (phentolamine mesylate solution)|
219419238|NCT01322646|DEVICE|CarChipPro|On board driving monitor
219419239|NCT01322646|BEHAVIORAL|Driver's Education|10 Session License to Learn Program.
219419240|NCT01322646|BEHAVIORAL|STEER Program|8-session behavioral parent training and teen social skills/communication training program
219419241|NCT01322646|OTHER|Driving Simulator Practice|Practice Driving on a driving simulator
219419242|NCT00283530|PROCEDURE|Tumor biopsy|
219419243|NCT02047630|DRUG|Generic latanoprost|
219419244|NCT02047630|DRUG|Brand-name latanoprost|
219419245|NCT02049801|DRUG|MEK inhibitor MEK162|Given PO
219419246|NCT02049801|DRUG|idarubicin|Given IV
219419247|NCT02049801|DRUG|cytarabine|Given IV
219419248|NCT02049801|OTHER|pharmacological study|Correlative studies
219758905|NCT03961126|DRUG|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
219419249|NCT02049801|OTHER|laboratory biomarker analysis|Correlative studies
219419250|NCT03627858|DRUG|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
219419251|NCT00204334|DRUG|darbopoeitin|
219419252|NCT04982159|OTHER|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
219419253|NCT04813536|OTHER|the Standard Shiftwork Index questionnaire|"1. Biographical information: This includes personal data (e.g., age, sex, marital status, and domestic situations), shift details (e.g., shift start and end times), organization of shiftwork, and general job satisfaction~2. Sleep and fatigue: Measures the effect of shiftwork on perceived sleep quality and quantity and fatigue"
219419254|NCT04813536|OTHER|complete blood picture|5ml blood to estimate changes of total leucocytic count, Hemoglobin, eosinophilic, monocyte
219419255|NCT04813536|OTHER|lipid profile|5ml blood to estimate changes of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and HDL-C
219419256|NCT06168500|PROCEDURE|Test group|3.0mm diameter implant
219419257|NCT06168500|PROCEDURE|Control group|4.0 diameter implant + guided bone regeneration
219419258|NCT04147871|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
219419259|NCT04147871|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
219573211|NCT03894241|BEHAVIORAL|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
219573212|NCT03892213|DRUG|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
219573213|NCT03892213|DRUG|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
219573214|NCT05002413|DIAGNOSTIC_TEST|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
219573215|NCT05723419|PROCEDURE|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
219573216|NCT04822571|OTHER|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
219573217|NCT04284514|DRUG|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
219573218|NCT04284514|DRUG|Placebo Ophthalmic Solution|Matched vehicle-control
219573219|NCT00999180|PROCEDURE|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
219573220|NCT00999180|PROCEDURE|Saline and Kinesiotherapy|Saline and Kinesiotherapy
219573221|NCT00046449|DRUG|Investigational Seasonal Affective Disorder (SAD) Drug|
219573222|NCT04686656|OTHER|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
219573223|NCT04686656|OTHER|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
219573224|NCT01237353|DIETARY_SUPPLEMENT|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
219573225|NCT01237353|DRUG|Rabeprazole|rabeprazole po daily x 5 days
219573226|NCT05703243|DIAGNOSTIC_TEST|Comprehensive liquid molecular panel test|Lab test
219573227|NCT05703243|OTHER|EORTC QLQ-30|Quality of life questionnaire
219004810|NCT00044278|DRUG|lamotrigine|
219419260|NCT05601024|BEHAVIORAL|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
219419261|NCT03309267|PROCEDURE|Intercostal block|Intercostal block +patient controlled analgesia
219419262|NCT03309267|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
219419263|NCT00255086|DRUG|Memantine|10mg Memantine
219419264|NCT00255086|DRUG|Placebo pill|10mg placebo pill
219419265|NCT00321425|PROCEDURE|brachial plexus block|
219419266|NCT00321425|PROCEDURE|ultrasound guidance|
219419267|NCT00321425|PROCEDURE|electrical nerve stimulation|
219419268|NCT03878524|DRUG|Abemaciclib|Given PO
219419269|NCT03878524|DRUG|Abiraterone|Given PO
219419270|NCT03878524|DRUG|Afatinib|Given PO
219419271|NCT03878524|BIOLOGICAL|Bevacizumab|Given IV
219419272|NCT03878524|DRUG|Bicalutamide|Given PO
219419273|NCT03878524|PROCEDURE|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
219419274|NCT03878524|DRUG|Bortezomib|Given IV
219419275|NCT03878524|DRUG|Cabazitaxel|Given IV
219419276|NCT03878524|DRUG|Cabozantinib|Given PO
219419277|NCT03878524|DRUG|Capecitabine|Given PO
219419278|NCT03878524|DRUG|Carboplatin|Given IV
219419279|NCT03878524|DRUG|Celecoxib|Given PO
219419280|NCT03878524|DRUG|Cobimetinib|Given PO
219419281|NCT03878524|DRUG|Copanlisib|Given IV
219419282|NCT03878524|DRUG|Dabrafenib|Given PO
219573228|NCT02765217|DRUG|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
219573229|NCT02765217|DRUG|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
219573230|NCT02765217|DRUG|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
219419283|NCT03878524|DRUG|Dacomitinib|Given PO
219573231|NCT02328222|DRUG|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
219573232|NCT01880125|DRUG|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
219004811|NCT01755013|PROCEDURE|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
219004812|NCT01997632|BIOLOGICAL|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
219573233|NCT00358748|DRUG|Hydrocortisone|See detailed description above.
219004813|NCT01997632|BIOLOGICAL|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
219004814|NCT01927367|OTHER|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
219573234|NCT03744871|OTHER|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
219004815|NCT01164982|DEVICE|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
219419284|NCT03878524|DRUG|Darolutamide|Given PO
219419285|NCT03878524|DRUG|Dasatinib|Given PO
219419286|NCT03878524|DRUG|Doxorubicin|Given IV
219419287|NCT03878524|BIOLOGICAL|Durvalumab|Given IV
219419288|NCT03878524|DRUG|Enasidenib|Given PO
219419289|NCT03878524|DRUG|Entrectinib|Given PO
219419290|NCT03878524|DRUG|Enzalutamide|Given PO
219419291|NCT03878524|DRUG|Erlotinib|Given PO
219573235|NCT02880748|OTHER|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
219004816|NCT04995991|BEHAVIORAL|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
219419292|NCT03878524|DRUG|Everolimus|Given PO
219573236|NCT02880748|OTHER|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
219573237|NCT05033366|DIAGNOSTIC_TEST|Proov Test|Rapid response urine PdG, FSH, E1G and LH test strips, Proov
219419293|NCT03878524|DRUG|Fluorouracil|Given IV
219419294|NCT03878524|DRUG|Idelalisib|Given PO
219419295|NCT03878524|DRUG|Imatinib|Given PO
219419296|NCT03878524|BIOLOGICAL|Ipilimumab|Given IV
219419297|NCT03878524|DRUG|Lenvatinib|Given PO
219419298|NCT03878524|DRUG|Leucovorin|Given IV
219419299|NCT03878524|DRUG|Lorlatinib|Given PO
219419300|NCT03878524|DRUG|Losartan|Given PO
219419301|NCT03878524|DRUG|Nab-paclitaxel|Given IV
219419302|NCT03878524|DRUG|Neratinib|Given PO
219419303|NCT03878524|BIOLOGICAL|Nivolumab|Given IV
219419304|NCT03878524|DRUG|Olaparib|Given PO
219419305|NCT03878524|DRUG|Oxaliplatin|Given IV
219419306|NCT03878524|DRUG|Palbociclib|Given PO
219419307|NCT03878524|DRUG|Panobinostat|Given PO
219419308|NCT03878524|BIOLOGICAL|Pembrolizumab|Given IV
219419309|NCT03878524|BIOLOGICAL|Pertuzumab|Given IV
219419310|NCT03878524|DRUG|Ponatinib|Given PO
219419311|NCT03878524|OTHER|Quality-of-Life Assessment|Ancillary studies
219419312|NCT03878524|DRUG|Regorafenib|Given PO
219004817|NCT04995991|BEHAVIORAL|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
219004818|NCT01218230|DRUG|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
219004819|NCT02547454|DRUG|Methoxy polyethylene glycol-epoetin beta|
219419313|NCT03878524|DRUG|Ruxolitinib|Given PO
219419314|NCT03878524|DRUG|Sirolimus|Given PO
219419315|NCT03878524|DRUG|Sorafenib|Given PO
219419316|NCT03878524|DRUG|Sunitinib|Given PO
219419317|NCT03878524|DRUG|Trametinib|Given PO
219004820|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
219004821|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
219419318|NCT03878524|BIOLOGICAL|Trastuzumab Emtansine|Given IV
219419319|NCT03878524|DRUG|Tretinoin|Given PO
219419320|NCT03878524|DRUG|Vemurafenib|Given PO
219419321|NCT03878524|DRUG|Venetoclax|Given PO
219419322|NCT03878524|DRUG|Vismodegib|Given PO
219419323|NCT03878524|DRUG|Vorinostat|Given PO
219419324|NCT04741334|DRUG|direct anticoagulant|exposure to direct anticoagulant
219419325|NCT04741334|DRUG|antiplatelet drugs|exposure to antiplatelet drugs
219419326|NCT04741334|DRUG|Dicumarols|exposure to dicumarols
219573238|NCT03822507|DRUG|KHK7580|oral administration
219419327|NCT04260334|OTHER|Preoperative Education|The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
219419328|NCT02619318|BEHAVIORAL|Balancing Everyday Life (BEL)|
219419329|NCT02619318|BEHAVIORAL|Care as usual (generally standard occupational therapy)|
219419330|NCT02176590|BEHAVIORAL|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
219419331|NCT02176590|OTHER|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
219573239|NCT03822507|DRUG|Cinacalcet Hydrochloride|oral administration
219573240|NCT02239107|DRUG|N-Acetyl cysteine|
219573241|NCT02239107|PROCEDURE|laparoscopic ovarian drilling|
219419332|NCT05534204|PROCEDURE|Silk suture|Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
219419333|NCT05534204|PROCEDURE|Polyester suture|Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
219419334|NCT02640352|DIETARY_SUPPLEMENT|Probi Defendum|
219419335|NCT02640352|DIETARY_SUPPLEMENT|Placebo|
219419336|NCT03783052|DEVICE|SmartPill in fasted state|SmartPill administration in fasted state
219419337|NCT03783052|DEVICE|SmartPill in fed state|SmartPill administration in fed state
219573242|NCT02006628|DRUG|Placebo|Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
219190945|NCT05049239|BEHAVIORAL|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
219419338|NCT03783052|OTHER|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
219419339|NCT03783052|OTHER|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
219419340|NCT02072720|DRUG|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
219419341|NCT03719482|DRUG|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
219419342|NCT03420326|BEHAVIORAL|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
219419343|NCT00583440|BEHAVIORAL|12-step facilitation|12 weekly individual 12-step facilitation sessions
219419344|NCT00583440|BEHAVIORAL|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
219419345|NCT03374748|OTHER|N/A - observational study|N/A - observational study
219419346|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
219573243|NCT02006628|DRUG|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
219190946|NCT05911308|DRUG|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
219419347|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
219419348|NCT02472119|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-free diet
219419349|NCT02935114|DRUG|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
219004822|NCT01411111|DRUG|Rosuvastatin 10 mg|days 1-14
219004823|NCT01411111|DRUG|GSK2190915 30mg|1x30mg tablet, days 8-14
219004824|NCT01411111|DRUG|GSK2190915 100mg|1x100mg tablet, days 8-14
219190947|NCT05911308|DRUG|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
219190948|NCT05911308|DRUG|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
219004825|NCT01331798|DEVICE|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
219004826|NCT01331798|PROCEDURE|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
219004827|NCT03945578|OTHER|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
219004828|NCT03945578|OTHER|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
219004829|NCT03945578|OTHER|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
219004830|NCT04107610|DEVICE|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
219419350|NCT02935114|DRUG|35% hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
219004831|NCT05333146|PROCEDURE|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
219004832|NCT05633420|DRUG|Pyramax|"Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)"
219419351|NCT02207595|DRUG|UCB5857|"* Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
219573244|NCT04569448|DRUG|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
219573245|NCT00343239|DRUG|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
219419352|NCT02207595|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
219419353|NCT02693795|OTHER|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
219004833|NCT02164812|DRUG|Moxifloxacin|
219004834|NCT02164812|DRUG|Placebo|
219004835|NCT02164812|DRUG|Efavirenz|
219004836|NCT03329950|DRUG|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
219004837|NCT03329950|DRUG|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
219190949|NCT05911308|DRUG|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
219419354|NCT02693795|OTHER|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
219419355|NCT05913141|OTHER|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
219573246|NCT00343239|DRUG|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
219419356|NCT01970514|DEVICE|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
219573247|NCT00343239|DRUG|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
219573248|NCT05841290|PROCEDURE|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
219573249|NCT05841290|PROCEDURE|Supplemental local anesthesia|if needed
219573250|NCT05841290|PROCEDURE|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
219573251|NCT05841290|PROCEDURE|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
219190950|NCT05911308|DRUG|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
219004838|NCT03329950|DRUG|pembrolizumab|pembrolizumab will be administered every 3 weeks.
219004839|NCT03329950|DRUG|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
219004840|NCT05174897|BEHAVIORAL|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
219004841|NCT00540826|DRUG|Atomoxetine|in-label use
219004842|NCT00540826|DRUG|stimulants (any approved ADHD medication)|in-label use
219004843|NCT03694821|DRUG|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
219573252|NCT05841290|PROCEDURE|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
219573253|NCT05841290|PROCEDURE|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
219419357|NCT04254783|DRUG|Risankizumab|Intravenous (IV) infusion
219573254|NCT05841290|PROCEDURE|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
219573255|NCT05841290|PROCEDURE|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
219758906|NCT03961126|DRUG|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
219758907|NCT01567722|GENETIC|DNA analysis|This sample will be used for germline DNA analysis.
219419358|NCT04254783|DRUG|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
219419359|NCT03215654|OTHER|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
219419360|NCT00379197|DRUG|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
219419361|NCT00379197|PROCEDURE|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
219419362|NCT06099691|BEHAVIORAL|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
219419363|NCT03490357|PROCEDURE|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
219419364|NCT03490357|PROCEDURE|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
219419365|NCT01451034|PROCEDURE|WHYX cancer group|WHYX cancer diagnosed by pathologic report
219419366|NCT05235217|DRUG|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
219419367|NCT05235217|DRUG|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
219758908|NCT01567722|GENETIC|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
219758909|NCT01567722|GENETIC|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
219758910|NCT01567722|GENETIC|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
219419368|NCT02370017|BIOLOGICAL|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
219419369|NCT01557218|OTHER|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
219419370|NCT01557218|OTHER|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
219419371|NCT01557218|OTHER|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
219004844|NCT03694821|DRUG|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
219758911|NCT01567722|OTHER|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
219004845|NCT03694821|DRUG|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
219004846|NCT04316923|DIAGNOSTIC_TEST|ECG|ECG will be performed during each visit in the study group.
219419372|NCT01557218|OTHER|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
219419373|NCT01557218|OTHER|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
219419374|NCT01557218|OTHER|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
219419375|NCT01557218|OTHER|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
219419376|NCT01557218|OTHER|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
219419377|NCT02365584|DRUG|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
219419378|NCT00523406|PROCEDURE|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
219419379|NCT03548038|OTHER|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
219004847|NCT04316923|DIAGNOSTIC_TEST|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
219004848|NCT04316923|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
219419380|NCT01973452|DRUG|Dexmedetomidine|
219419381|NCT01973452|DRUG|Placebo|
219419382|NCT04504370|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
219419383|NCT04504370|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
219758912|NCT01567722|OTHER|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
219758913|NCT01567722|OTHER|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
219004849|NCT04316923|DIAGNOSTIC_TEST|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
219419384|NCT04371952|DRUG|Doxycycline|comparison of doxycycline 200 mg/day to placebo
219419385|NCT04371952|DRUG|Placebo|Placebo : lactose, 380 mg/gélule
219419386|NCT03052842|DRUG|C16G2 Strip|Antimicrobial Peptide
219419387|NCT03052842|OTHER|Placebo Strip|Placebo
219419388|NCT00349752|BIOLOGICAL|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
219419389|NCT00349752|OTHER|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
219004850|NCT03181568|DEVICE|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
219004851|NCT03181568|PROCEDURE|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
219004852|NCT02888444|DRUG|Varenicline|Two 0.5mg tablets taken twice daily
219004853|NCT02888444|BEHAVIORAL|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
219004854|NCT02888444|DRUG|Placebo|Two 0.5mg tablets taken twice daily
219004855|NCT01747798|DRUG|auranofin|Given PO
219004856|NCT01747798|OTHER|laboratory biomarker analysis|Correlative studies
219004857|NCT00018200|DRUG|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
219004858|NCT00018200|DRUG|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
219004859|NCT00018200|DRUG|Benztropine|Daily dose 0.125 to 0.5mg
219004860|NCT02805101|DRUG|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
219419390|NCT03136770|DIETARY_SUPPLEMENT|CK-30|Compound K 600 mg
219419391|NCT03136770|DIETARY_SUPPLEMENT|Red ginseng extracts|Red ginseng extracts 2.94 g
219419392|NCT02193815|DRUG|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
219419393|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 4% solution
219419394|NCT02193815|DRUG|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
219419395|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 2% Ointment
219419396|NCT02193815|DRUG|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
219419397|NCT02193815|DRUG|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
219573256|NCT05841290|PROCEDURE|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
219573257|NCT05841290|PROCEDURE|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
219573258|NCT05841290|PROCEDURE|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
219573259|NCT05841290|PROCEDURE|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
219573260|NCT05841290|PROCEDURE|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
219573261|NCT05841290|PROCEDURE|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
219573262|NCT05841290|PROCEDURE|Master cone check|Master cone check Clinically and confirmatory radiograph
219758914|NCT03179878|DRUG|Placebo|Placebo
219573263|NCT05841290|DRUG|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
219573264|NCT05841290|DIAGNOSTIC_TEST|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
219758915|NCT03179878|DRUG|SYNB1020|Investigational Product
219758916|NCT00344981|DRUG|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
219758917|NCT00344981|DRUG|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches \>400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
219758918|NCT03234634|PROCEDURE|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
219758919|NCT04162834|DRUG|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
219758920|NCT04162834|DRUG|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
219573265|NCT05841290|PROCEDURE|Obturation|done by lateral condensation technique
219004861|NCT02805101|DRUG|MTA|MTA is going to be used as the sealing agent for the perforation.
219004862|NCT06046391|BIOLOGICAL|LP-003 dose 1|Liquid in vial
219419398|NCT01320111|DRUG|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
219419399|NCT01320111|DRUG|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
219419400|NCT00854178|DRUG|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
219419401|NCT06206278|DRUG|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
219419402|NCT00016198|DRUG|FOLFOX regimen|
219419403|NCT00016198|DRUG|fluorouracil|
219419404|NCT00016198|DRUG|leucovorin calcium|
219419405|NCT00016198|DRUG|oxaliplatin|
219419406|NCT02990897|BEHAVIORAL|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
219419407|NCT04365998|DEVICE|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
219419408|NCT04580251|PROCEDURE|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
219419409|NCT01789853|BEHAVIORAL|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
219419410|NCT01789853|BEHAVIORAL|Conventional Physical Therapy|Regular physical therapy for 8 weeks
219419411|NCT00661245|DEVICE|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
219419412|NCT00661245|DEVICE|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
219419413|NCT02725827|OTHER|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
219573266|NCT05841290|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
219004863|NCT06046391|BIOLOGICAL|LP-003 dose 2|Liquid in vial
219004864|NCT06046391|BIOLOGICAL|Placebo|Liquid in vial
219419414|NCT02725827|OTHER|Control medium|The usual embryo transfer medium used in the study centres.
219419415|NCT05246176|DEVICE|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
219419416|NCT02472691|DRUG|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
219419417|NCT02472691|DRUG|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
219419418|NCT02472691|BIOLOGICAL|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
219004865|NCT05013593|DIETARY_SUPPLEMENT|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
219573267|NCT05483803|BEHAVIORAL|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
219573268|NCT03055442|OTHER|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
219573269|NCT03055442|OTHER|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
219573270|NCT06044532|OTHER|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
219573271|NCT00834652|DRUG|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
219573272|NCT00834652|DRUG|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
219758921|NCT00431964|DRUG|azithromycin 250 mg tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
219004866|NCT05013593|OTHER|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
219004867|NCT06177587|OTHER|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
219758922|NCT00431964|DRUG|placebo tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
219758923|NCT03991585|BEHAVIORAL|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
219758924|NCT06362109|BEHAVIORAL|Routine rehabilitation|"Routine rehabilitation consists of:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219419419|NCT03896880|DIAGNOSTIC_TEST|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar"
219419420|NCT03896880|OTHER|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
219419421|NCT03896880|OTHER|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
219419422|NCT03896880|OTHER|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
219419423|NCT02027168|OTHER|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
219419424|NCT00234572|DRUG|Lanreotide (Autogel formulation)|
219419425|NCT00002386|DRUG|Indinavir sulfate|
219419426|NCT00002386|DRUG|Lamivudine|
219419427|NCT00002386|DRUG|Stavudine|
219419428|NCT00002386|DRUG|Zidovudine|
219573273|NCT03578237|DEVICE|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
219004868|NCT05045014|OTHER|Balance assessment|Romberg test and one-leg standing test will be used.
219004869|NCT05045014|OTHER|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
219004870|NCT05045014|OTHER|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
219419429|NCT00002386|DRUG|Zalcitabine|
219419430|NCT00002386|DRUG|Didanosine|
219419431|NCT01527019|DRUG|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
219419432|NCT01527019|DRUG|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
219573274|NCT03578237|DEVICE|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
219004871|NCT05045014|OTHER|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
219004872|NCT05045014|OTHER|Cobb angle measurement|It will be evaluated with the help of X-ray.
219004873|NCT05045014|OTHER|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
219004874|NCT06112262|DRUG|Heparin|Comparison between heparin and hirudin
219004875|NCT04074460|DRUG|Propofol|General Anaesthesia
219004876|NCT04074460|DRUG|isoflurane, sevoflurane or desflurane|General Anaesthesia
219419433|NCT01527019|DRUG|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
219419434|NCT05294211|DEVICE|M•care™ System|The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
219004877|NCT02789202|OTHER|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
219004878|NCT02789202|OTHER|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
219190951|NCT05615389|DRUG|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
219190952|NCT05615389|DRUG|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
219419435|NCT05294211|DEVICE|Cardiotocography (CTG)|A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
219419436|NCT05759845|DRUG|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
219758925|NCT06362109|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
219419437|NCT05759845|DRUG|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
219419438|NCT05759845|DRUG|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
219419439|NCT00064350|DRUG|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
219419440|NCT00064350|DRUG|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
219419441|NCT03751592|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
219419442|NCT00608439|DRUG|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
219419443|NCT00608439|OTHER|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
219419444|NCT02927340|DRUG|Lorlatinib|
219419445|NCT00939224|DEVICE|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
219419446|NCT00838916|BIOLOGICAL|albiglutide|albiglutide weekly injection
219758926|NCT01918189|BEHAVIORAL|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
219758927|NCT00382174|DRUG|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
219758928|NCT00382174|DRUG|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
219190953|NCT05409573|OTHER|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
219190954|NCT06126224|DRUG|KarXT|KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
219190955|NCT06126224|DRUG|Placebo|Placebo Capsules
219419447|NCT00838916|DRUG|insulin glargine|insulin glargine
219758929|NCT03868358|DEVICE|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
219004879|NCT02554487|DEVICE|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
219419448|NCT04696458|DIETARY_SUPPLEMENT|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
219419449|NCT04696458|OTHER|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
219419450|NCT03769324|DIAGNOSTIC_TEST|Osmolarity Test|Osmolarity Test
219419451|NCT04961099|DRUG|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
219419452|NCT04558788|DIAGNOSTIC_TEST|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
219419453|NCT05038033|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
219419454|NCT05038033|BEHAVIORAL|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
219419455|NCT02518152|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
219419456|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
219419457|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
219419458|NCT02880397|DRUG|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
219419459|NCT02880397|DRUG|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
219758930|NCT02108288|DRUG|OPC-1085EL ophthalmic solution|
219758931|NCT02108288|DRUG|Carteolol long-acting ophthalmic solution|
219758932|NCT02108288|DRUG|Latanoprost ophthalmic solution|
219004880|NCT00203996|DEVICE|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
219419460|NCT06317077|OTHER|PAP therapy setting|Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
219419461|NCT06317077|OTHER|exclusive use of Löwenstein Medical full face masks|Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
219419462|NCT04224428|DRUG|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
219419463|NCT04224428|DRUG|Placebo oral tablet|lactose oral tablet
219419464|NCT02547116|DRUG|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
219419465|NCT01884857|DRUG|Metoprolol Succinate ER Tablets 50 mg|1\* 50 mg tablet once a day
219004881|NCT00203996|DRUG|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
219419466|NCT01884857|DRUG|'TOPROL-XL®' ER Tablets 50 mg|1 \* 50 mg tablet per day
219419467|NCT02034474|DRUG|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
219419468|NCT02034474|DRUG|Placebo|intravenously via iv drip over 60 min
219419469|NCT01795287|PROCEDURE|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
219419470|NCT01795287|PROCEDURE|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
219419471|NCT05651893|BEHAVIORAL|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
219573275|NCT03762551|OTHER|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
219573276|NCT00006472|DRUG|carboplatin|Carboplatin AUC 6 days 1 and 22
219573277|NCT00006472|DRUG|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
219419472|NCT05651893|BEHAVIORAL|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
219419473|NCT01965236|DIETARY_SUPPLEMENT|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
219419474|NCT01965236|DIETARY_SUPPLEMENT|Placebo|
219419475|NCT03600714|DRUG|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
219419476|NCT03600714|DRUG|Lonafarnib|Oral prenylation inhibitor
219419477|NCT03600714|DRUG|Ritonavir|Booster of lonafarnib action
219419478|NCT00675103|DRUG|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
219419479|NCT00261170|DRUG|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
219419480|NCT00261170|OTHER|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
219419481|NCT00391417|DRUG|estradiol gel|
219419482|NCT02117596|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
219419483|NCT06150690|OTHER|No intervention|The participants did not receive any study-specific intervention
219419484|NCT00245193|BEHAVIORAL|Motivationally-Enhanced Interpersonal Psychotherapy|
219419485|NCT02164513|DRUG|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
219419486|NCT02164513|DRUG|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
219419487|NCT02164513|DRUG|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
219419488|NCT00945074|OTHER|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
219419489|NCT00945074|OTHER|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
219419490|NCT00945074|OTHER|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
219419491|NCT02969434|OTHER|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
219419492|NCT01185145|RADIATION|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
219419493|NCT01185145|RADIATION|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
219419494|NCT03503149|OTHER|no intervention|observational study
219419495|NCT06467604|BEHAVIORAL|Surveys|Participants will be provided electronic surveys at 3 timepoints throughout study.
219419496|NCT06467604|OTHER|Indirect Calorimetry|Participants will receive indirect calorimetry at 3 time points throughout the study.
219419497|NCT06467604|OTHER|Body composition|Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.
219419498|NCT06467604|OTHER|Anthropometrics|Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.
219419499|NCT05841602|OTHER|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
219419500|NCT01510808|PROCEDURE|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
219419501|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT - Active comparator|Consumation of 200 mL of tea infusion (VitalPLANT) in the morning 30 min before breakfast for one week
219419502|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT + Helichrysum Italicum - Experimental product|Consumation of 200 mL of tea infusion VitalPLANT + Helichrysum Italicum in the morning 30 min before breakfast for one week
219419503|NCT03201952|DRUG|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
219419504|NCT03201952|DRUG|Placebos|Ileostomy administration of 5cc saline placebo once
219419505|NCT01987388|OTHER|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
219419506|NCT01987388|OTHER|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
219419507|NCT01987388|OTHER|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
219419508|NCT01987388|OTHER|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
219419509|NCT03308981|DEVICE|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
219419510|NCT03308981|OTHER|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
219419511|NCT00092066|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
219573278|NCT00006472|DRUG|paclitaxel|taxol
219573279|NCT00006472|PROCEDURE|conventional surgery|
219573280|NCT00006472|RADIATION|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
219004882|NCT00203996|DRUG|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
219419512|NCT01628250|PROCEDURE|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
219419513|NCT01628250|PROCEDURE|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
219419514|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
219419515|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
219419516|NCT06824064|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
219573281|NCT00044668|DRUG|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
219573282|NCT06434922|DEVICE|Prevention Strategies|Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.
219573283|NCT06434922|DEVICE|Standard Strategiies|Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
219573284|NCT00349726|DRUG|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
219573285|NCT00349726|DRUG|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
219573286|NCT00349726|DRUG|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
219573287|NCT00349726|DRUG|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
219573288|NCT01956617|OTHER|lumbar plexus block|
219573289|NCT04095949|DIETARY_SUPPLEMENT|Artichokes|Approximately 200 g of cooked artichokes
219573290|NCT03053219|DRUG|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
219573291|NCT00788502|BEHAVIORAL|Healing Touch|
219573292|NCT00788502|BEHAVIORAL|Desensitization Therapy|
219004883|NCT00203996|PROCEDURE|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
219004884|NCT00203996|PROCEDURE|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
219004885|NCT05544916|DRUG|XC221|200 mg/day, for 5 days
219004886|NCT05544916|DRUG|Placebo|2 tablets/day, for 5 days
219419517|NCT06824064|DRUG|Placebo|Placebo to Match RBS2418
219573293|NCT04131543|DRUG|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
219573294|NCT04131543|DRUG|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
219573295|NCT04131543|DRUG|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
219573296|NCT03625518|DRUG|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
219573297|NCT03625518|DEVICE|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
219419518|NCT04008407|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
219419519|NCT04008407|PROCEDURE|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
219419520|NCT06897631|DEVICE|Robot-Assisted Tai Chi Training|This intervention involves robot-assisted Tai Chi training for upper limb rehabilitation, delivered in a seated position to ensure participant safety and comfort. Each 60-minute session consists of a 5-minute warm-up/preparation phase, followed by three 15-minute segmented functional training phases incorporating Tai Chi-inspired movements to target upper limb coordination, range of motion, and strength recovery, interspersed with two 5-minute rest intervals. The protocol is administered 5 times per week over 4 weeks, with robotic assistance tailored to guide functional upper limb trajectories while minimizing compensatory movements.
219419521|NCT06897631|BEHAVIORAL|Conventional rehabilitation training|This intervention follows evidence-based clinical guidelines for post-stroke upper limb rehabilitation, focusing on therapist-guided task-oriented training that integrates activities of daily living (ADL) such as table wiping and clothes hanging. Sessions emphasize progressive functional integration, with exercises adjusted weekly based on patient performance. Training is delivered in 60-minute sessions (1 session/day), 5 days per week over 4 weeks, under direct therapist supervision to ensure proper movement patterns and safety.
219419522|NCT06898489|COMBINATION_PRODUCT|Yu-Tone Music Intervention|SLE patients undergo a structured Yu-tone music listening program (30 minutes daily, 5 days per week, with each cycle lasting 8 weeks, for a total of 3 cycles
219419523|NCT06898489|DRUG|Conventional pharmacotherapy|Standard SLE medications (e.g., hydroxychloroquine, glucocorticoids).
219419524|NCT03637842|DRUG|Lorcaserin|Lorcaserin XR 20mg per day
219419525|NCT03637842|DRUG|Placebo oral capsule|Placebo
219419526|NCT02860533|DEVICE|cuff device|Measurement of blood pressure during stress testing with cuff device
219419527|NCT02860533|DEVICE|iphone|Measurement of blood pressure during stress testing with iPhone
219419528|NCT00002344|DRUG|Azithromycin|
219419529|NCT01594294|DEVICE|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
219419530|NCT01594294|DEVICE|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
219419531|NCT01594294|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
219573298|NCT04943159|DRUG|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
219190956|NCT06823687|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 1-2 minute before the start of the procedure, the patients will be watched (5-10 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
219419532|NCT01594294|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
219419533|NCT01594294|DEVICE|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
219419534|NCT01422278|OTHER|Rehabilitation|Three weeks of rehabilitation in Hospital.
219419535|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
219419536|NCT05136248|PROCEDURE|intraarticular injection|Ultrasound-guided intraarticular injection
219419537|NCT05136248|PROCEDURE|peng block|Ultrasound-guided PENG block
219419538|NCT01869166|BIOLOGICAL|CART-EGFR|
219419539|NCT02509494|BIOLOGICAL|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
219419540|NCT02509494|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
219419541|NCT02509494|BIOLOGICAL|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
219419542|NCT02509494|BIOLOGICAL|Placebo|0.9% saline for injection.
219419543|NCT02623036|DRUG|Equivalent dose enalapril|Chronotherapy with enalapril.
219419544|NCT02623036|DRUG|Equivalent dose lisinopril|Chronotherapy with lisinopril
219573299|NCT01011075|DRUG|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
219419545|NCT06039917|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
219419546|NCT06039917|OTHER|Manually remind the patients|Medical staff remind patients to review manually.
219419547|NCT04900480|OTHER|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
219419548|NCT01450956|DRUG|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
219573300|NCT01011075|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
219758933|NCT02566863|DRUG|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
219758934|NCT02160288|DRUG|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
219758935|NCT02160288|DRUG|Normal Saline|Dispensed in a 5 cc syringe
219758936|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM)."
219758937|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT)."
219758938|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
219758939|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
219758940|NCT02450825|DEVICE|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
219758941|NCT02690142|DRUG|Placebo|Single dose i.v.
219004887|NCT05950490|DRUG|Intravitreal injection of methotrexate|"Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years"
219004888|NCT02551276|DRUG|Salbutamol|
219419549|NCT01450956|OTHER|Control|Patients will receive only oxygen and air through oxygenator
219758942|NCT02690142|DRUG|ABY-035 i.v.|Single dose i.v.
219758943|NCT02690142|DRUG|ABY-035 s.c.|Single dose s.c.
219758944|NCT02170064|DRUG|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
219004889|NCT02551276|DRUG|Placebo|
219004890|NCT02551276|OTHER|Resistance training|
219419550|NCT00305747|DRUG|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
219419551|NCT01179347|DRUG|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
219419552|NCT01179347|DRUG|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
219419553|NCT02692456|DEVICE|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
219419554|NCT02692456|DEVICE|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
219419555|NCT04616495|PROCEDURE|Liver transplantation|Chemotherapy and liver transplantation
219419556|NCT00369967|DRUG|NuvaRing|Initiation of NuvaRing for contraception
219419557|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
219419558|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg|
219419559|NCT03536598|DRUG|Valsartan 160 mg + Rosuvastatin 20 mg|
219419560|NCT02829866|DEVICE|AMIStem-H|
219419561|NCT00866268|DEVICE|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
219419562|NCT00866268|DEVICE|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
219419563|NCT02344420|PROCEDURE|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
219419564|NCT02344420|BEHAVIORAL|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
219419565|NCT02344420|PROCEDURE|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
219419566|NCT02344420|BEHAVIORAL|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
219419567|NCT05336006|OTHER|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
219419568|NCT05336006|OTHER|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
219419569|NCT02586077|DRUG|Exparel|
219419570|NCT03117530|DRUG|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
219004891|NCT06463327|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
219004892|NCT00005794|DRUG|perifosine|
219004893|NCT05664737|BIOLOGICAL|Luspatercept|Specified dose on specified days
219419571|NCT04342520|OTHER|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
219419572|NCT01376726|BIOLOGICAL|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
219419573|NCT01376726|BIOLOGICAL|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
219419574|NCT04973891|DRUG|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
219419575|NCT04973891|DRUG|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
219419576|NCT05289206|OTHER|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
219419577|NCT05994586|DIETARY_SUPPLEMENT|AP029 mix|Polyphenol-rich plant extracts Twice a day
219419578|NCT05994586|OTHER|Placebo|Twice a day
219419579|NCT03363217|DRUG|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
219419580|NCT01743872|PROCEDURE|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
219573301|NCT04899193|DRUG|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
219419581|NCT01743872|PROCEDURE|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
219419582|NCT01743872|PROCEDURE|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
219419583|NCT01743872|PROCEDURE|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
219419584|NCT00921882|PROCEDURE|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
219419585|NCT00707655|DRUG|Zalutumumab|Eight weekly infusions
219419586|NCT02733406|OTHER|Target Controlled Infusion|
219419587|NCT02733406|OTHER|Velocity Controlled Infusion|
219419588|NCT02925663|BEHAVIORAL|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
219419589|NCT03016026|PROCEDURE|ERAS|Undergo an ERAS program
219419590|NCT03353753|DRUG|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
219419591|NCT03353753|DRUG|Placebo Oral Tablet|Placebo
219419592|NCT02858154|OTHER|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
219419593|NCT02858154|OTHER|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
219419594|NCT02979301|DRUG|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
219573302|NCT04899193|DRUG|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
219573303|NCT04899193|DRUG|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
219573304|NCT04899193|DRUG|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
219573305|NCT04124198|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
219573306|NCT04124198|DRUG|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
219573307|NCT04124198|DRUG|Nimorazole.|Concurrent nimorazole
219573308|NCT04124198|PROCEDURE|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
219573309|NCT05991128|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
219573310|NCT05991128|DRUG|Placebo|n the placebo group, patients will receive the equivalent number of normal saline injections.
219573311|NCT06217861|BIOLOGICAL|VGM-R02b|Administered as specified in the treatment arm.
219419595|NCT01733901|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
219419596|NCT01733901|PROCEDURE|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
219419597|NCT00983840|OTHER|Family Eats|8-session web-based program on healthy eating for African American families
219419598|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared calcium hydroxide in to the root canals|Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.
219419599|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared double antibiotic paste in to the root canals|Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.
219419600|NCT05581706|DIAGNOSTIC_TEST|Taking standart periapical radiography with film holder|"Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up."
219419601|NCT05581706|OTHER|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
219419602|NCT05207306|PROCEDURE|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
219419603|NCT00055536|DRUG|natalizumab|
219419604|NCT00709917|DRUG|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
219419605|NCT03444194|PROCEDURE|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
219419606|NCT04536649|RADIATION|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
219419607|NCT00611221|PROCEDURE|Massage|Massage therapy by an RMT during labour
219419608|NCT00611221|PROCEDURE|Massage|Massage by anyone else, eg. husband, nurse, doula
219419609|NCT03148626|OTHER|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
219419610|NCT03148626|OTHER|Control|Usual Education
219419611|NCT03179579|PROCEDURE|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
219419612|NCT03179579|PROCEDURE|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
219419613|NCT04994652|DEVICE|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
219419614|NCT04994652|DEVICE|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
219419615|NCT04535154|OTHER|No interventions|No interventions
219419616|NCT00518232|DRUG|OROS-methylphenidate|
219419617|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
219419618|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
219419619|NCT03106948|DRUG|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
219419620|NCT03106948|DRUG|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
219419621|NCT03106948|DRUG|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
219419622|NCT06118164|BEHAVIORAL|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
219419623|NCT06118164|BEHAVIORAL|pursing- lip breathing|pursing- lip breathing
219419624|NCT06118164|BEHAVIORAL|aerobic walking exercise|aerobic walking exercise
219573312|NCT01131793|DEVICE|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
219573313|NCT02017860|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
219573314|NCT02488330|DRUG|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
219573315|NCT02488330|DRUG|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
219573316|NCT02488330|DRUG|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
219573317|NCT06213467|DEVICE|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
219004894|NCT05664737|DRUG|Placebo|Specified dose on specified days
219419625|NCT00131677|DRUG|tenofovir disoproxil fumarate|study product taken daily
219419626|NCT00131677|DRUG|placebo|study product taken daily
219419627|NCT00280319|BEHAVIORAL|interpersonal psychotherapy for groups|psychotherapy
219419628|NCT00280319|BEHAVIORAL|creative play therapy|consisted of play activities
219419629|NCT06024213|PROCEDURE|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
219419630|NCT06024213|DRUG|indocyanine green|Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
219419631|NCT06024213|DRUG|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
219419632|NCT06024213|DRUG|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
219419633|NCT02720653|PROCEDURE|Endoscopic sinus surgery|
219419634|NCT06183632|BIOLOGICAL|blood sampling|3 x 7mL EDTA blood tubes
219419635|NCT03711877|DEVICE|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
219419636|NCT03711877|DEVICE|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
219419637|NCT03703687|BEHAVIORAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
219419638|NCT00205699|DRUG|risperidone|randomized to begin 12 week trial of risperidone
219419639|NCT00205699|DRUG|olanzapine|randomized to begin 12 week trial of olanzapine
219419640|NCT00205699|DRUG|aripiprazole|randomized to 12 week trial of aripiprazole
219419641|NCT02644837|DEVICE|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
219419642|NCT02644837|DEVICE|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
219419643|NCT02644837|DEVICE|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
219419644|NCT02644837|DEVICE|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
219419645|NCT02644837|DEVICE|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
219419646|NCT02644837|DEVICE|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
219419647|NCT02644837|DEVICE|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
219419648|NCT02644837|DEVICE|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
219419649|NCT02521909|DEVICE|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
219419650|NCT02521909|DEVICE|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
219419651|NCT02521909|DEVICE|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
219419652|NCT02970227|OTHER|Observation|None, observation only
219419653|NCT03945734|BEHAVIORAL|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
219419654|NCT05340322|DEVICE|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
219573318|NCT03242460|DRUG|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
219573319|NCT03242460|DRUG|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
219573320|NCT03242460|DRUG|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
219573321|NCT00794391|BEHAVIORAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
219573322|NCT00794391|BEHAVIORAL|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
219758945|NCT04683705|DIAGNOSTIC_TEST|Ultrasound|"1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
219419655|NCT02574858|DRUG|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
219419656|NCT05924516|BEHAVIORAL|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
219419657|NCT01726712|OTHER|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
219419658|NCT00635557|DRUG|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
219419659|NCT02357953|OTHER|Measurement of cardiac index|
219419660|NCT06191120|RADIATION|[18F]-ALF-FAPI-74 PET/CT scan|Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.
219419661|NCT04917497|DRUG|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
219419662|NCT00992732|DRUG|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
219419663|NCT00992732|DRUG|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
219419664|NCT05619679|OTHER|Kidney Transplantation|Kidney transplantation
219419665|NCT01541267|DRUG|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
219419666|NCT05491655|DEVICE|High Intensity His Bundle pacing|All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
219419667|NCT01192217|PROCEDURE|Modified thoracoscopic technique|Two-port thoracoscopic technique
219419668|NCT01192217|PROCEDURE|Axillary mini-thoracotomy|Axillary mini-thoracotomy
219419669|NCT04922749|BEHAVIORAL|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
219419670|NCT06290947|DEVICE|BFR Cuffs for Intervention Group|"The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes."
219419671|NCT06290947|OTHER|Standard Walking Training Program|"The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention."
219419672|NCT03337555|DEVICE|McGrath|McGrath videolaryngoscope
219419673|NCT03337555|DEVICE|Pentax|Pentax videolaryngoscope
219419674|NCT03337555|DEVICE|Macintosh|Macintosh direct laryngoscope
219419675|NCT02093234|BEHAVIORAL|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
219419676|NCT02093234|BEHAVIORAL|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
219419677|NCT02093234|BEHAVIORAL|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
219419678|NCT06390917|DEVICE|PVA recognition function|Ventilator with the function of identify and judge PVAs
219419679|NCT01866878|DEVICE|equipment rehabilitation stereognosis|
219419680|NCT01866878|DEVICE|TENS|
219419681|NCT00286130|DRUG|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
219419682|NCT00286130|DRUG|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
219419683|NCT00286130|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
219419684|NCT04258046|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
219419685|NCT01690169|DRUG|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
219419686|NCT01690169|DRUG|placebo|A single dose of oral placebo administered.
219004895|NCT03918447|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
219419687|NCT05883553|DEVICE|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
219419688|NCT03284255|DEVICE|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
219419689|NCT03284255|DEVICE|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
219419690|NCT00789269|DRUG|rhubarb|14 days of rhubarb
219419691|NCT00789269|DRUG|placebo|14 days of placebo
219573323|NCT04712721|DRUG|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
219573324|NCT03738020|DEVICE|HA IDF (YVOIRE classic)|Treatment with HA IDF
219419692|NCT00613418|DEVICE|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
219419693|NCT01962519|DIETARY_SUPPLEMENT|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
219573325|NCT03738020|DEVICE|Restylane|Treatment with Restylane
219573326|NCT05579574|DRUG|BMS-986322|Specified dose on specified days
219573327|NCT05579574|DRUG|Loestrin|Specified dose on specified days
219004896|NCT03918447|DRUG|Placebo oral capsule|Capsule containing an inert placebo
219004897|NCT03278613|DEVICE|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
219004898|NCT04777071|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219004899|NCT04777071|DRUG|Gallium Ga 68 Gozetotide|Given IV
219004900|NCT04777071|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219004901|NCT04777071|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR scan
219004902|NCT04777071|PROCEDURE|Bone Scan|Undergo bone scan
219004903|NCT04777071|OTHER|Electronic Health Record Review|Ancillary studies
219419694|NCT02462941|DRUG|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
219419695|NCT02462941|PROCEDURE|Cardiac catheterization|(non-experimental) standard procedure
219419696|NCT02095236|BEHAVIORAL|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
219419697|NCT02404883|OTHER|Online Decision-Aid Tool|
219419698|NCT03225716|DRUG|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
219573328|NCT00946348|DRUG|Dronabinol|Dronabinol 10 mg or 15 mg
219573329|NCT00946348|DRUG|Cannabis|Cannabis cigarette
219573330|NCT04671030|DRUG|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
219573331|NCT04671030|DEVICE|Iontophoresis|Application of direct current to skin using an FDA-approved device
219573332|NCT03743792|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
219573333|NCT03743792|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
219419699|NCT03225716|DRUG|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
219419700|NCT04574388|OTHER|open label placebo|open label placebo pill
219419701|NCT03665428|DRUG|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
219419702|NCT03665428|DRUG|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
219573334|NCT01678001|DRUG|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
219573335|NCT01242930|DRUG|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
219573336|NCT01242930|DRUG|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
219573337|NCT01242930|DRUG|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
219758946|NCT00987350|DEVICE|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
219758947|NCT00987350|DEVICE|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
219758948|NCT00987350|BIOLOGICAL|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
219758949|NCT03323164|DRUG|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
219758950|NCT03323164|DRUG|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
219758951|NCT03195569|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
219758952|NCT03195569|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
219758953|NCT03195569|DRUG|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
219758954|NCT03195569|DRUG|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
219758955|NCT01130792|DIETARY_SUPPLEMENT|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
219758956|NCT01130792|DIETARY_SUPPLEMENT|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
219758957|NCT00164281|DRUG|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
219758958|NCT06071676|OTHER|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
219758959|NCT06071676|OTHER|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
219758960|NCT04301648|OTHER|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~1. To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~2. Make education to the patient and family.~3. Make communication bridge with cardiologists.~4. Establish specific patient-centered care processes.~5. Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
219758961|NCT04301648|OTHER|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
219758962|NCT02144467|DEVICE|MRI|fMRI, sMRI, ASL and DTI
219758963|NCT04756830|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
219758964|NCT01732614|PROCEDURE|Topcon Endpoint Management laser|
219758965|NCT05408780|DRUG|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
219758966|NCT03794973|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
219758967|NCT03794973|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
219758968|NCT05791214|OTHER|score|Creation and validation of new nurse' score in ICU
219758969|NCT01337570|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
219758970|NCT01337570|OTHER|Placebo|Vaginal Ring containing no drug substance
219758971|NCT01337570|DRUG|Dapivirine|
219758972|NCT05945888|DRUG|BI 3000202|BI 3000202
219758973|NCT05945888|DRUG|Placebo matching BI 3000202|Placebo matching BI 3000202
219758974|NCT03268564|BEHAVIORAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
219758975|NCT02638909|DRUG|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
219419703|NCT01157052|OTHER|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)"
219419704|NCT01866761|PROCEDURE|Periodontal treatment|
219419705|NCT02284685|BEHAVIORAL|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
219419706|NCT03335956|DRUG|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
219419707|NCT03335956|DRUG|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
219419708|NCT03335956|DRUG|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
219419709|NCT03335956|DRUG|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
219419710|NCT03335956|DRUG|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
219419711|NCT03335956|DRUG|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
219419712|NCT03335956|DRUG|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
219419713|NCT03335956|DRUG|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
219419714|NCT03335956|DRUG|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
219419715|NCT03335956|DRUG|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
219419716|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
219419717|NCT03335956|DRUG|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
219419718|NCT03335956|DRUG|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
219758976|NCT04753489|DRUG|Rivaroxaban film-coated tablet 10 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
219758977|NCT04753489|DRUG|Xarelto® film-coated tablet 10 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
219758978|NCT03434834|DEVICE|optical coherence tomography|OCT measurements of 5 locations in the esophagus
219758979|NCT04397380|DEVICE|Thermography|Measure Temperature using Thermal Camera
219758980|NCT04397380|DEVICE|Tympanic Temperature|Measure Temperature using Tympanic Temperature
219758981|NCT01082302|DRUG|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
219419719|NCT03335956|DRUG|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
219419720|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
219419721|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
219419722|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
219419723|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
219419724|NCT00046176|DRUG|abacavir/lamivudine|
219419725|NCT00046176|DRUG|abacavir|
219419726|NCT00046176|DRUG|lamivudine|
219419727|NCT04248790|BEHAVIORAL|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
219419728|NCT03090464|OTHER|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
219419729|NCT02912598|DEVICE|Mallinckrodt™ Endobronchial Tube|
219419730|NCT02912598|DEVICE|Fuji Uniblocker™|
219419731|NCT02912598|DEVICE|ETView VivaSight™-SL+EB|
219419732|NCT02912598|DEVICE|COOK© Arndt Endobronchial Blocker|
219419733|NCT05263817|BIOLOGICAL|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
219419734|NCT06061042|BEHAVIORAL|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
219419735|NCT06061042|BEHAVIORAL|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
219419736|NCT01583985|OTHER|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
219419737|NCT01583985|OTHER|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
219419738|NCT06554002|OTHER|Control|Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
219419739|NCT06554002|OTHER|Treatment|Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
219419740|NCT05261880|OTHER|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
219758982|NCT01082302|OTHER|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
219758983|NCT06254066|DRUG|Adebrelimab plus Fluzoparib|Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
219758984|NCT02098135|DEVICE|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
219758985|NCT04786054|DIAGNOSTIC_TEST|BED Questionnaire|BED Questionnaire
219419741|NCT05261880|OTHER|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
219419742|NCT06110299|DIAGNOSTIC_TEST|air injection|delination of the ureter and pelvis by injecting air under C-ARM
219419743|NCT03598738|DRUG|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
219419744|NCT04198103|DEVICE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
219419745|NCT00101491|BEHAVIORAL|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
219419746|NCT00701155|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
219758986|NCT02333448|BIOLOGICAL|Blood sample taken on the day the treatment is initiated|
219758987|NCT02333448|BIOLOGICAL|Blood sample taken on day 3 after initiation of treatment|
219758988|NCT02333448|BIOLOGICAL|Blood sample taken on day 5 after initiation of|
219758989|NCT02333448|BIOLOGICAL|Blood sample taken on day 7 after initiation of treatment|
219758990|NCT02333448|BIOLOGICAL|Blood sample taken on day 10 after initiation of treatment|
219758991|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
219419747|NCT05677191|DEVICE|Proximal Femoral Nail|open reduction
219419748|NCT05677191|COMBINATION_PRODUCT|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
219419749|NCT01170702|DRUG|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
219419750|NCT01170702|DRUG|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
219758992|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
219758993|NCT00814255|DRUG|Adalimumab|Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
219758994|NCT00814255|DRUG|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
219758995|NCT00814255|DRUG|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
219573338|NCT01206816|DRUG|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
219758996|NCT01901692|RADIATION|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
219419751|NCT01170702|DRUG|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
219419752|NCT01170702|DRUG|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
219573339|NCT03525743|DEVICE|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
219419753|NCT01682577|DRUG|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
219419754|NCT01682577|DRUG|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
219419755|NCT01951690|DRUG|defactinib (VS-6063)|
219419756|NCT02729948|OTHER|Survey Administration|Ancillary studies
219419757|NCT02729948|DEVICE|Tethered Capsule Endoscope|Undergo TCE
219419758|NCT00560222|DIETARY_SUPPLEMENT|bovine lactoferrin|1gm of lactoferrin will be given each day
219419759|NCT00560222|DIETARY_SUPPLEMENT|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
219419760|NCT02732353|DIETARY_SUPPLEMENT|Minced beef|Cow meat protein supplement
219419761|NCT02732353|DIETARY_SUPPLEMENT|Hydrolyzed beef|Cow meat protein supplement
219419762|NCT03798184|PROCEDURE|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
219419763|NCT01677507|DRUG|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
219419764|NCT00005812|DRUG|temozolomide|
219419765|NCT00571688|DRUG|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
219573340|NCT04963595|DRUG|Pyrotinib|400 mg once daily
219573341|NCT04963595|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
219758997|NCT01901692|DRUG|Sorafenib|Sorafenib 800 mg/day orally
219758998|NCT01731925|DRUG|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
219758999|NCT01731925|DRUG|Placebo (for sunitinib)|
219419766|NCT00571688|DRUG|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
219419767|NCT02825147|DRUG|Pegaspargase|
219419768|NCT02825147|DRUG|Methotrexate|
219419769|NCT02825147|DRUG|Dexamethasone|
219419770|NCT02825147|DRUG|Etoposide|
219419771|NCT02825147|RADIATION|radiotherapy|
219419772|NCT04362449|COMBINATION_PRODUCT|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
219419773|NCT04362449|COMBINATION_PRODUCT|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
219419774|NCT04761029|OTHER|RIIS|unilateral Rhomboid intercostal and subserratus block
219419775|NCT04761029|DRUG|Tramadol|intravenous patient-controlled analgesia (tramadol)
219573342|NCT04963595|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
219573343|NCT03050203|OTHER|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
219573344|NCT03050203|OTHER|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
219573345|NCT02310243|DRUG|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
219573346|NCT01836406|DRUG|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
219573347|NCT00014625|DRUG|indisulam|
219759000|NCT01731925|DRUG|Sunitinib|Sunitinib 37.5 mg daily
219759001|NCT03848780|DRUG|Desflurane|
219759002|NCT03026179|BEHAVIORAL|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
219004904|NCT04180579|DEVICE|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
219004905|NCT05459038|DIAGNOSTIC_TEST|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
219004906|NCT01405456|DRUG|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
219004907|NCT01405456|OTHER|placebo and lifestyle|placebo pill daily and lifestyle counseling
219004908|NCT06501833|OTHER|FIFA 11+ KIDS PROGRAM|The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
219190957|NCT06821763|DRUG|Calcium Hydroxide Intracanal medication|non setting calcium hydroxide(CH) mixed with normal saline and placed as intra canal medicament during first visit of root canal treatment. effectiveness measured after 48hrs, 72hrs and 96hrs
219190958|NCT06821763|DRUG|triple antibiotic paste (TAP)|mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.
219573348|NCT03217396|PROCEDURE|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
219573349|NCT03000218|DRUG|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
219573350|NCT03000218|DRUG|Metformin|Day 29 to 56: Metformin 500mg bid
219573351|NCT03000218|DRUG|Placebo|Day 1 to 56: Placebo bid
219573352|NCT05515393|DRUG|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
219573353|NCT05515393|DRUG|XY03-EA Placebo|XY03-EA Placebo
219573354|NCT02914093|OTHER|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
219573355|NCT01087671|DRUG|tafluprost|prostaglandin analogue
219573356|NCT00485628|DRUG|Atomoxetine Hydrochloride|
219573357|NCT02493777|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
219573358|NCT02493777|DRUG|Placebo|
219573359|NCT00378183|DRUG|risperidone|
219759003|NCT05152602|PROCEDURE|Bilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
219759004|NCT05152602|PROCEDURE|Unilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
219759005|NCT01126957|DRUG|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
219759006|NCT01126957|DRUG|Placebo|Placebo given as an bolus to control group.
219759007|NCT01126957|DRUG|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
219759008|NCT01126957|DRUG|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
219759009|NCT03196830|BIOLOGICAL|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
219759010|NCT03166748|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
219759011|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
219759012|NCT00518180|BIOLOGICAL|Tdap Vaccine|One dose of vaccine administered intramuscularly
219759013|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
219759014|NCT05260749|PROCEDURE|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
219759015|NCT05260749|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
219759016|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
219759017|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
219759018|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
219759019|NCT01564017|BIOLOGICAL|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
219759020|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
219759021|NCT01564017|BIOLOGICAL|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
219759022|NCT02526784|DRUG|degarelix|
219759023|NCT03662061|OTHER|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
219759024|NCT04734314|OTHER|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
219419776|NCT03154151|BEHAVIORAL|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
219419777|NCT03154151|BEHAVIORAL|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
219419778|NCT00870285|RADIATION|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
219419779|NCT06169930|OTHER|This was an observational study without any intervention|This was an observational study without any intervention
219419780|NCT05221788|PROCEDURE|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
219419781|NCT05957497|BIOLOGICAL|Biological samples transport and analysis|Biological samples transport and analysis
219419782|NCT01921933|DEVICE|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
219419783|NCT02603354|DRUG|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
219419784|NCT06446414|BEHAVIORAL|Choose to Move|As described under study arm description
219419785|NCT04343209|DIAGNOSTIC_TEST|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
219419786|NCT04343209|DRUG|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
219419787|NCT03428802|OTHER|Laboratory Biomarker Analysis|Correlative studies
219419788|NCT03428802|BIOLOGICAL|Pembrolizumab|Given IV
219419789|NCT01684475|DRUG|CJH1 (CLR4001)|
219419790|NCT02331524|BEHAVIORAL|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
219004909|NCT06501833|OTHER|REGULAR TRAINING|The control group will be continuing their regular training
219419791|NCT02331524|OTHER|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
219419792|NCT00790179|PROCEDURE|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
219419793|NCT00030615|DRUG|decitabine|Given IV
219419794|NCT00030615|OTHER|pharmacological study|Correlative studies
219419795|NCT00030615|OTHER|laboratory biomarker analysis|Correlative studies
219004910|NCT01163045|PROCEDURE|thyroidectomy|total thyroidectomy and lobectomy
219004911|NCT04783480|OTHER|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
219004912|NCT04783480|OTHER|Standard of care|Subjects will participate in childbirth education at their own discretion.
219004913|NCT03529851|OTHER|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
219004914|NCT00000350|PROCEDURE|radioactive substance|
219004915|NCT00850564|DRUG|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
219419796|NCT03908710|OTHER|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
219419797|NCT05480254|OTHER|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
219419798|NCT00546793|BIOLOGICAL|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
219004916|NCT02303301|DIETARY_SUPPLEMENT|Probiotics|Cultures from the oropharynx
219004917|NCT02303301|DIETARY_SUPPLEMENT|Placebo|Cultures from the oropharynx
219004918|NCT06440408|DRUG|Ferumoxytol|Ferumoxytol will be used as a contrast agent for the cMRI
219004919|NCT07131449|OTHER|This is observational studies, participants are not assigned an intervention as part of the study.|This is observational studies, participants are not assigned an intervention as part of the study.
219419799|NCT04584853|DRUG|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
219419800|NCT04584853|DRUG|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
219759025|NCT04734314|OTHER|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
219759026|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
219759027|NCT02917005|DRUG|Palbociclib|CDK 4/6 inhibitor
219759028|NCT02917005|DRUG|Exemestane|Aromatase inhibitor
219004920|NCT07132697|DRUG|L-Amino acid mixture|Continuous infusion of a L-amino acids mixture in a dose of 2 g/kg dry body weight/day (to a maximum 100 g/day) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation
219004921|NCT07132697|OTHER|Standard of care|Standard peri tranplant care as per out institution including intra operative and post operative care. Its includes starting of immunosuppression after serial blood investigation monitoring.
219419801|NCT05960110|DRUG|Fluoride varnish|Fluoride varnish 26200 ppm
219419802|NCT05960110|DRUG|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
219759029|NCT02917005|DRUG|Goserelin|LHRH agonist
219004922|NCT07131397|DEVICE|Inspiratory Muscle Traing|IMT will be performed by applying resistance at 40% of the maximum inspiratory pressure (1 set of 30 repetitions 30 breaths per session). Each week there will be a gradual increase in resistance by 10% of the initial maximum inspiratory pressure.
219004923|NCT07131397|DEVICE|Sham Inspiratory Muscle Training|Inspiratory muscle training will be applied with a constant resistance load of 7cmH20
219004924|NCT07131098|OTHER|Early Enteral Feeding Protocol|Early enteral nutrition was initiated within 24-48 hours of ICU admission based on a structured protocol aligned with ASPEN and ESPEN guidelines. The protocol defined target caloric goals, methods of tube feeding initiation, rate advancement, and monitoring procedures. Nurses and ICU staff were trained in protocol implementation. The goal was to optimize nutrition early in critical illness to improve clinical outcomes such as ICU length of stay, ventilator dependence, and physiological stability.
219004925|NCT07131098|OTHER|Standard Nutritional Care|Patients in the control group received standard nutritional care per routine hospital practices. Initiation and progression of feeding were left to the discretion of the attending physician and nursing staff, without the use of a structured protocol or defined early feeding timeline.
219190959|NCT03625115|BEHAVIORAL|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
219190960|NCT06822270|PROCEDURE|open surgery|open surgical methods for treating Pelvi-ureteric Junction Obstruction
219190961|NCT06822270|PROCEDURE|Laparoscopic Pyeloplasty|minimally invasive laparoscopic techniques.
219190962|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
219190963|NCT06823414|OTHER|Video assisted mastectomy|Nipple Skin sparing mastectomy assisted by endoscopic or robotic
219419803|NCT05743751|DEVICE|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
219419804|NCT05743751|DEVICE|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
219759030|NCT00529360|DRUG|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
219759031|NCT00529360|DRUG|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
219759032|NCT04858581|DIAGNOSTIC_TEST|Virological and serological tests|Survey, RT-PCR test and blood test
219759033|NCT05298475|DRUG|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
219759034|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
219759035|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
219759036|NCT03060902|BEHAVIORAL|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
219759037|NCT03347630|DIAGNOSTIC_TEST|MRI|Thoraco-abominal MRI
219190964|NCT06823258|DRUG|HS-10365|HS-10365 administered orally once at D1
219190965|NCT05815745|DEVICE|Pacemaker - Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
219190966|NCT05815745|DEVICE|Pacemaker - Right Ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
219190967|NCT06823102|OTHER|tDCS|Transcranial direct current stimulation
219759038|NCT04565730|OTHER|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
219004926|NCT07132398|DRUG|Slow-tapering glucocorticoids + Inebilizumab|Slow-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab. The prednisone dose will be tapered as follows: a reduction of 5 mg every 2 weeks until reaching 20 mg/day(Week 16); thereafter, a reduction of 5 mg every 4 weeks until discontinuation (a total duration of 32 weeks for combined inebilizumab and glucocorticoids therapy).
219419805|NCT03874754|OTHER|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
219419806|NCT01174953|DRUG|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
219004927|NCT07132398|DRUG|Rapid-tapering glucocorticoids + Inebilizumab|Rapid-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab, with a tapering schedule of 5 mg reduction per week until discontinuation (a total duration of 12 weeks for combined inebilizumab and glucocorticoids therapy).
219004928|NCT07125521|OTHER|GERCCare mobile app|Using the smartphone application GERDCare (with detailed instructions provided during recruitment)
219004929|NCT07133217|DEVICE|Root canal preparation with Hand Files (Dentsply Sirona)|Root canal treatments were performed with hand files
219004930|NCT07133217|DEVICE|Root canal preparation with the WaveOne Gold file system (Dentsply Sirona, Ballaigues, Switzerland)|Root canal treatments were performed with WaveOne Gold Files
219004931|NCT07133217|DEVICE|Root canal preparation with the ProTaper Ultimate file system (Dentsply Sirona)|Root canal treatments were performed with ProTaper Ultimate Files
219004932|NCT00054145|DRUG|perifosine|
219004933|NCT01378078|DEVICE|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
219004934|NCT01378078|DEVICE|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
219004935|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
219419807|NCT00282269|PROCEDURE|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
219004936|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
219004937|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
219419808|NCT02524756|PROCEDURE|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
219419809|NCT02524756|PROCEDURE|laparoscopic radical hysterectomy (type III/C2).|
219419810|NCT02449408|OTHER|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
219419811|NCT00368498|DRUG|teicoplanin|
219419812|NCT04321252|DRUG|KAE609|"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
219419813|NCT04321252|DRUG|Placebo|matching placeo for iv administration
219419814|NCT03004469|DRUG|P-3074|
219419815|NCT03004469|DRUG|Finasteride|
219419816|NCT03004469|DRUG|P-3074 Vehicle|
219419817|NCT03004469|DRUG|Finasteride Placebo|
219419818|NCT05429177|DRUG|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
219419819|NCT02325817|DEVICE|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
219419820|NCT02325817|DEVICE|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
219419821|NCT04161274|PROCEDURE|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
219419822|NCT04161274|PROCEDURE|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
219419823|NCT04161274|PROCEDURE|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
219573360|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
219573361|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
219573362|NCT00267943|DRUG|telmisartan 80 mg + hydrochlorothiazide 25 mg|
219573363|NCT02264288|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
219573364|NCT02264288|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
219573365|NCT02264288|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
219573366|NCT02264288|OTHER|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
219573367|NCT03130218|OTHER|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
219573368|NCT01642914|DRUG|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
219573369|NCT01642914|DRUG|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
219573370|NCT01642914|DRUG|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
219573371|NCT01832935|DRUG|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
219573372|NCT01832935|DRUG|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
219573373|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
219759039|NCT04565730|OTHER|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
219004938|NCT06657235|OTHER|Transitional Care Program|Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
219573374|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
219573375|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
219573376|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
219759040|NCT00138684|PROCEDURE|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
219004939|NCT00321945|PROCEDURE|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
219573377|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
219759041|NCT02092181|DRUG|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
219759042|NCT02092181|DRUG|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
219004940|NCT06591741|DIETARY_SUPPLEMENT|Oral PCA|PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
219004941|NCT06590896|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
219004942|NCT04322461|DIETARY_SUPPLEMENT|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
219419824|NCT04161274|PROCEDURE|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
219573378|NCT01705236|DRUG|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
219573379|NCT05348980|DRUG|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
219573380|NCT05348980|DRUG|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
219004943|NCT06990009|BEHAVIORAL|exercise|In line with the Puerperium and Newborn Care Guide, an exercise implementation protocol will be prepared by obtaining the opinion of a group of 10 experts on the appropriateness of the exercises and when they should be started. In this direction, a brochure and a video will be created for the participants to practice the exercises. A pilot study will be conducted in a group of 10 people on the use of the brochure and video, and the brochure and video will be finalized. Participants will be asked to do these exercises for 30 minutes a day, five days a week for eight weeks. A reminder message will be sent to the exercise group by the researchers to remind them of the exercises and provide motivation for eight weeks.
219004944|NCT06357754|BIOLOGICAL|Idecabtagene vicleucel|As per product label
219004945|NCT06357754|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
219004946|NCT05965505|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
219004947|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). In the standard condition, the remaining retrieval trials for each word will be spaced - occurring only after 3 other words have intervened. This practice schedule is repeated the next day (Day 2).
219573381|NCT01344174|DRUG|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
219573382|NCT04363840|DRUG|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
219573383|NCT04363840|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
219573384|NCT06319937|DIAGNOSTIC_TEST|Ultrasound|Ultrasound
219573385|NCT02442674|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
219573386|NCT02442674|OTHER|Placebo|Placebo tablet matching active drug
219004948|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Adaptive retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). For the remainder of the session, there will be spaced retrieval trials for each word - occurring after 3 words have intervened. In the Adaptive condition, children will have additional retrieval opportunities throughout. These will be provided whenever the child does not remember the word form, whether it is an immediate (initial) or space retrieval trial. This practice schedule is repeated the next day (Day 2).
219004949|NCT05355805|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219004950|NCT05355805|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219004951|NCT04676282|OTHER|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
219004952|NCT07002580|PROCEDURE|IPACK and adductor canal block with Bupivacaine 0.25%|iPACK block is infiltration between the Popliteal Artery and the Capsule of the Knee. iPACK and adductor canal blocks are performed with ultrasound guidence under sterile conditions.
219004953|NCT07002580|PROCEDURE|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia is a basic anesthesia method used for years to grant anesthesia for surgeries for lower extremities and lower torso surgeries.
219004954|NCT07000773|BEHAVIORAL|Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) Exercise|Participants perform the Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) exercise using a resistance band. The exercise is conducted under various conditions including stable and unstable surfaces (using BOSU® balance trainer) and in three different lower limb positions: standing, lunge, and squat. Each condition is randomized, and participants complete all conditions in a crossover design. The intervention aims to evaluate trapezius muscle activation patterns during these exercises using surface electromyography (EMG).
219004955|NCT07001176|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
219004956|NCT07001176|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg)
219004957|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
219419825|NCT00259740|DRUG|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
219419826|NCT04538885|BIOLOGICAL|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
219419827|NCT03051087|DRUG|Ganirelix acetate|
219419828|NCT02287402|DRUG|AO-128|AO-128 tablet
219419829|NCT05432674|COMBINATION_PRODUCT|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
219419830|NCT01844830|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
219419831|NCT01844830|DRUG|Placebo|Inactive ingredients supplied in identical nasal sprayer
219419832|NCT04247815|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
219419833|NCT04247815|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
219419834|NCT04247815|DRUG|Methotrexate|7.5 mg to 25 mg weekly
219573387|NCT00171301|DRUG|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
219419835|NCT02170649|DRUG|BIA 2-093|
219573388|NCT04319159|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
219573389|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
219573390|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
219573391|NCT02987023|PROCEDURE|uterus transplantation|Uterus transplantation from live donor
219759043|NCT00956293|DRUG|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
219419836|NCT03411057|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
219419837|NCT03411057|OTHER|Control|Standard of care including an educational video.
219419838|NCT00041691|DRUG|hMN14 (labetuzumab)|
219419839|NCT04092998|PROCEDURE|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
219419840|NCT04354779|DIAGNOSTIC_TEST|a specifically designed self-administered questionnaire|The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
219419841|NCT03296293|OTHER|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
219419842|NCT03296293|OTHER|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
219419843|NCT03296293|OTHER|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
219419844|NCT00838006|DEVICE|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
219419845|NCT00838006|DEVICE|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
219419846|NCT00838006|DEVICE|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
219419847|NCT04849819|DRUG|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
219573392|NCT02100319|DRUG|Azilsartan|Azilsartan tablets
219573393|NCT01913379|DRUG|MDV3100|Oral
219573394|NCT01913379|DRUG|Gemfibrozil|Oral
219573395|NCT01913379|DRUG|Itraconazole|Oral
219004958|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
219004959|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
219419848|NCT05301023|OTHER|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
219419849|NCT05301023|OTHER|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
219419850|NCT02000518|RADIATION|external beam radiotherapy|
219419851|NCT04663984|BEHAVIORAL|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
219419852|NCT00032838|DRUG|Yohimbine|
219419853|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
219419854|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
219419855|NCT02882815|DEVICE|IrisFIT PFO Occluder|
219419856|NCT00307242|DRUG|Adefovir Dipivoxil|
219419857|NCT01792245|DEVICE|Phototherapy|
219004960|NCT07002138|DEVICE|Digital Dental Impression|Digital dental impressions were performed using the Medit i700 intraoral scanner (Medit, Seoul, South Korea). The scanner utilizes 3D-in-motion video technology with UV-C and LED light sources and adaptive anti-fogging. Scans were taken of both upper and lower arches following manufacturer-recommended protocols. Two tip sizes were used (normal and small), and scanning included occlusal, lingual, and buccal surfaces. Moisture control was maintained with cheek retractors and saliva ejectors. Impression time was recorded using a chronometer. This procedure was used to evaluate patient comfort, anxiety, and preference.
219419858|NCT02835677|BEHAVIORAL|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
219419859|NCT03332901|OTHER|this is an observational study, no intervention required|this is an observational study, no intervention required
219419860|NCT03792165|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
219419861|NCT03792165|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
219419862|NCT05821348|DIAGNOSTIC_TEST|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
219419863|NCT00722709|DRUG|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
219419864|NCT00722709|DRUG|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
219419865|NCT02994095|BEHAVIORAL|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
219419866|NCT06168370|RADIATION|CT guided strategy|"1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
219419867|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419868|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419869|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419870|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419871|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419872|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419873|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419874|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419875|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419876|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419877|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419878|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419879|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
219419880|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
219419881|NCT03685370|PROCEDURE|LOS|placement of epidural catheters with LOS technique
219419882|NCT03685370|PROCEDURE|X-ray placement|placement of epidural catheters with x-ray guide
219419883|NCT04116476|DRUG|MT-7117|Single Dose of MT-7117
219419884|NCT00257491|DRUG|Telmisartan|
219419885|NCT00257491|DRUG|Telmisartan/HCTZ|
219419886|NCT02863939|DEVICE|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
219419887|NCT02863939|OTHER|exercise|
219419888|NCT04556370|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
219419889|NCT04556370|DRUG|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
219419890|NCT05425485|BEHAVIORAL|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
219419891|NCT05068193|DRUG|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
219419892|NCT05068193|DRUG|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
219419893|NCT04779944|OTHER|other|questionnaire
219419894|NCT03647436|OTHER|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
219419895|NCT03696706|RADIATION|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
219573396|NCT03875014|DEVICE|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
219573397|NCT02370914|DEVICE|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
219573398|NCT02370914|BEHAVIORAL|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
219573399|NCT02485002|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
219573400|NCT02485002|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
219573401|NCT02664857|DRUG|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
219573402|NCT02664857|DRUG|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
219573403|NCT06051084|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
219573404|NCT06051084|BEHAVIORAL|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
219573405|NCT00675636|OTHER|study of socioeconomic and demographic variables|database, no intervention
219573406|NCT00675636|PROCEDURE|evaluation of cancer risk factors|database, no intervention
219573407|NCT00675636|PROCEDURE|study of high risk factors|database, no intervention
219573408|NCT05742698|DRUG|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
219573409|NCT05742698|DRUG|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
219573410|NCT02721836|BEHAVIORAL|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
219573411|NCT02721836|BEHAVIORAL|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
219004961|NCT07002138|PROCEDURE|Conventional Dental Impression|Conventional impressions were taken using extra-fast setting flavored alginate (Hydrogum 5, Zhermack SpA, Italy) for both upper and lower arches. The impression material was manually mixed according to the manufacturer's instructions and applied using standard perforated plastic trays suitable for pediatric arches. Children were seated upright, and the impression sequence followed lower arch first, then upper arch. Comfort was evaluated using VAS scores and anxiety using the Venham Clinical Anxiety Scale (VCAS). The procedure was timed with a chronometer.
219419896|NCT03696706|RADIATION|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
219419897|NCT00259441|DRUG|Simvastatin|
219419898|NCT03723005|DEVICE|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
219573412|NCT03898830|DEVICE|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
219573413|NCT03113448|DRUG|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
219573414|NCT03113448|DRUG|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
219573415|NCT05907330|DRUG|CU104|CU104 will administer the study drug once a day after a meal
219573416|NCT05907330|DRUG|Placebo|Placebo will administer the study drug once a day after a meal
219573417|NCT01009671|DRUG|ART 44|
219573418|NCT01009671|DRUG|ART 50|
219573419|NCT02349971|DEVICE|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
219573420|NCT04109586|BEHAVIORAL|Personalized nutritional therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
219573421|NCT05599022|DEVICE|Magnetic Stimulation|Transcutaneous Magnetic Stimulation
219573422|NCT00754442|DRUG|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
219573423|NCT05230732|DEVICE|neuromodulation device|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
219759044|NCT00956293|DRUG|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
219759045|NCT00956293|DRUG|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
219759046|NCT00956293|DRUG|Cyclosporin A (CsA)|Dosage was based according to blood level
219759047|NCT00956293|DRUG|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
219759048|NCT03383666|DEVICE|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
219759049|NCT04405817|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
219004962|NCT07002541|PROCEDURE|PECS II block|The PECS-II block is an ultrasound-guided interfascial plane block designed to provide analgesia for surgeries involving the anterolateral chest wall, particularly breast surgery. It is an extension of the PECS-I block, which targets the medial and lateral pectoral nerves. In the PECS-II technique, a high-frequency linear ultrasound probe is used to identify the fascial planes. A 22G, 50 mm regional block needle is advanced in-plane under sterile conditions. A total of 30 mL of 0.25% bupivacaine is administered: 10 mL is injected between the pectoralis major and minor muscles (targeting the pectoral nerves), and 20 mL between the pectoralis minor and serratus anterior muscles (to block the lateral branches of intercostal nerves and intercostobrachial nerve).
219419899|NCT03723005|DEVICE|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
219419900|NCT04154696|PROCEDURE|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
219419901|NCT02418533|DRUG|menotropin|Menopur is used for controlled ovarian stimulation (COH)
219419902|NCT02418533|DRUG|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
219419903|NCT04627012|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219419904|NCT04627012|DRUG|Opdivo|3mg/mg intravenously every 3 weeks
219419905|NCT04627012|DRUG|Camrelizumab|200mg intravenously every 3 weeks
219419906|NCT04627012|DRUG|Keytruda|200mg intravenously every 3 weeks
219419907|NCT04627012|DRUG|Toripalimab|240mg intravenously every 3 weeks
219759050|NCT04243148|COMBINATION_PRODUCT|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
219759051|NCT04243148|COMBINATION_PRODUCT|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
219419908|NCT04627012|DRUG|Sintilimab|200mg intravenously every 3 weeks
219419909|NCT04627012|DRUG|Tislelizumab|200mg intravenously every 3 weeks
219419910|NCT05723315|DRUG|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
219419911|NCT03841487|DEVICE|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
219419912|NCT02196987|OTHER|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
219419913|NCT02196987|OTHER|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
219419914|NCT00799500|OTHER|Screening|Weekly vaginal pH
219419915|NCT00467025|DRUG|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
219419916|NCT00467025|DRUG|Sorafenib|400 mg PO BID
219419917|NCT00467025|DRUG|AMG 386 placebo IV|AMG 386 placebo IV
219419918|NCT01940510|DRUG|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
219419919|NCT01940510|DRUG|rifampin|Multiple doses Days 8-16 and Days 17-20
219419920|NCT04694105|DRUG|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
219419921|NCT04694105|DRUG|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
219004963|NCT07002541|PROCEDURE|ESP block|The erector spinae plane (ESP) block is a fascial plane block performed under ultrasound guidance to provide multimodal analgesia for thoracic and abdominal surgeries, including breast procedures. In this technique, a high-frequency linear ultrasound probe is used to visualize the transverse process of the thoracic vertebra, typically at the T4-T5 level. With the patient in a seated position and under standard sterile conditions, a 22G, 50 mm regional block needle is inserted in-plane until the tip reaches the fascial plane between the erector spinae muscle and the transverse process. After negative aspiration, 1-2 mL of test dose is injected to confirm correct needle placement by observing separation of fascial layers. Then, 20 mL of 0.25% bupivacaine is injected incrementally.
219004964|NCT07001813|DEVICE|socket preserved|(8 cases): was treated by immediate socket preservation with S1-XB xenograft augmentation after extraction.
219004965|NCT07001813|DEVICE|non preserved socket|(8 cases): was not exposed to any type of socket preservation after the extraction procedure.
219004966|NCT07002606|OTHER|medication errors reporting guidelines|the intervention is designed to reduce the medication errors and develop the culture of reporting the Medication errors in clinical settings.
219004967|NCT07000500|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants in this arm will receive a daily dose of a nutritional supplement for 90 consecutive days. The supplement is administered orally and aims to improve cognitive performance in older adults with signs of cognitive decline. Participants will also complete cognitive assessments before and after the intervention.
219004968|NCT07000500|OTHER|Placebo|Participants in this arm will receive a daily dose of an inert placebo that matches the supplement in appearance, taken orally for 90 consecutive days. The placebo is used as a control to compare the effects of the nutritional supplement on cognitive performance. Participants will undergo the same cognitive assessments as the experimental group.
219419922|NCT04694105|DRUG|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
219419923|NCT03855748|OTHER|Healthy group|"Subjects undergo the following activities:~1. Walking~2. Jogging (8-11 km/h)~3. Maximal 5 meters sprint acceleration~4. Single leg drop jump from 35 cm height~5. Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~6. Maximal change of direction at 45, 135, 180 degrees~7. Single-leg cross-country skiing exercise"
219419924|NCT01404026|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
219419925|NCT00679718|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
219419926|NCT03522493|DEVICE|"Yaalom Katom"|Full face Gas mask
219419927|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
219419928|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
219419929|NCT04195100|DRUG|Pilocarpine Ophthalmic Solution|"1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
219419930|NCT02982538|BEHAVIORAL|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
219419931|NCT02982538|BEHAVIORAL|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
219419932|NCT01728883|DEVICE|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
219419933|NCT06678867|DRUG|5-ALA (Gliolan)|Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery
219573424|NCT05230732|DEVICE|SHAM|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
219573425|NCT05169073|PROCEDURE|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
219419934|NCT03327753|BEHAVIORAL|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
219573426|NCT05169073|PROCEDURE|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
219573427|NCT05279313|DRUG|Centanafadine Hydrochloride|Capsule
219004969|NCT07001878|DRUG|Metformin|Metformin will be prescribed, reaching 1000mg/day (a standard dose). This will be done under the principal investigator's care and the patient's clinical team, including assessment of metformin adherence. Metformin will be prescribed for 6 months. Antipsychotic treatment will continue as per standard of care (metformin as adjunct therapy), as well as routine follow up.
219004970|NCT07002411|OTHER|Innovative hospital reception service with social robot NAO|The robot NAO welcomes the user and asks how it can assist them. At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take.
219004971|NCT07002411|OTHER|Innovative hospital reception service with social robot PEPPER|"The robot PEPPER welcomes the user and asks how it can assist them, stating the following phrase: Good morning and welcome to INRCA. I am PEPPER and I am here to provide directions to help you reach your desired location within the hospital. Which department do you need to reach or which exam do you need to take?  At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user as follows: Thank you for your participation. Have a good day. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take."
219004972|NCT07001761|RADIATION|Ultrasound/ x rays|"* The MSK Ultrasound (US) will be performed using a General Electric LOGIQ P9 unit / Toshiba Applio 500 unit using a 7-13 MHz linear array transducer.~* Conventional Radio-graphic examination bi-plane weight-bearing semi-flexed (15) radiograms will be taken of the target knee; one in the posteroanterior view, and one in the lateral medial view"
219419935|NCT03327753|BEHAVIORAL|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
219419936|NCT03506399|DRUG|Lanabecestat|Administered orally
219419937|NCT03506399|DRUG|Oral Contraceptive|Administered orally
219419938|NCT04717141|OTHER|Selective nerve block|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~\- Clinical and instrumental post-botulinum toxin injection evaluation."
219419939|NCT03108651|OTHER|Case|Motivational message will be administrated.
219419940|NCT02408796|DRUG|OTO-201|
219419941|NCT00846261|DEVICE|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
219419942|NCT04716192|OTHER|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
219573428|NCT05197777|DEVICE|tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.
219573429|NCT05197777|OTHER|Conservative physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
219004973|NCT07001098|DRUG|Amino Acids|The participants receive a continuous infusion of a balanced mixture of amino acids (Trophamine) in a dose of 2g/kg/day (max 100g/day) starting at the time of cardiac surgery up to 3 days
219004974|NCT07001098|DRUG|Placebo|The participants receive a continuous infusion of a lactated ringers (placebo), equivalent volume to amino acids, starting at the time of cardiac surgery up to 3 days
219004975|NCT07000617|DRUG|DAPT regimen plus radiotherapy|Patients receive 6 cycles of DAPT regimen plus concurrent radiotherapy. The DAPT regimen is administered as follows: dexamethasone 10mg intravenously on days1-3, azacitidine 100mg subcutaneously on days 1-5, pegaspargase 2500IU/m2 intramuscularly on day 1, and tislelizumab 200mg intravenously on day 6, repeated every 21 days. Concurrent radiotherapy given to the tumor sites is started after 2 cycles of DAPT regimen. The specific doses and methods of radiotherapy are in accordance with the clinical guidelines for NK/T-cell lymphoma.
219007235|NCT06088706|PROCEDURE|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
219419943|NCT04716192|OTHER|Myofascial release technique & Ultrasound|"Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
219419944|NCT05300243|DIAGNOSTIC_TEST|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
219419945|NCT00014664|BIOLOGICAL|apolizumab|
219419946|NCT03820037|DRUG|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
219419947|NCT03820037|DRUG|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
219419948|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
219419949|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
219419950|NCT00987233|DRUG|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
219419951|NCT01947608|DRUG|LDK378|750 mg. orally
219573430|NCT00296491|DRUG|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
219573431|NCT00296491|DRUG|montelukast (MON)|montelukast capsule
219573432|NCT00296491|DRUG|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
219573433|NCT00296491|DRUG|placebo nasal|vehicle placebo nasal spray
219573434|NCT00296491|DRUG|ADVAIR DISKUS|ADVAIR DISKUS
219007236|NCT01723592|DIETARY_SUPPLEMENT|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
219007237|NCT01723592|DIETARY_SUPPLEMENT|Oral lactose placebo|Placebo
219573435|NCT00296491|DRUG|placebo capsule|placebo capsule
219573436|NCT00296491|DRUG|placebo DISKUS|placebo DISKUS
219573437|NCT01183325|DEVICE|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
219573438|NCT01300052|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
219419952|NCT02775552|BEHAVIORAL|A&T community-based interventions|"1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   \- Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   \- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families"
219419953|NCT02775552|BEHAVIORAL|Mass media|Radio campaign - radio drama series, spots, and jingles
219419954|NCT00073814|DRUG|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
219573439|NCT01300052|DRUG|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
219419955|NCT00073814|DRUG|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
219419956|NCT00073814|DRUG|Placebo|Placebo MDI QID
219419957|NCT06365671|OTHER|autologous stem-cell transplantation|high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
219419958|NCT06365671|DRUG|Relmacabtagene autoleucel (relma-cel)|relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
219419959|NCT05202093|DEVICE|Oclean electric toothbrush A|Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks
219573440|NCT04695756|OTHER|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
219573441|NCT01231373|DRUG|polidocanol injectable foam, 0.125%|active placebo for blinding
219573442|NCT01231373|DRUG|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
219573443|NCT01231373|DRUG|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
219573444|NCT01231373|DRUG|Vehicle|injection of vehicle comparator
219573445|NCT05642169|BEHAVIORAL|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
219573446|NCT05642169|BEHAVIORAL|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
219573447|NCT05642169|BEHAVIORAL|CON|This group will not suffer any changes in their lifestyle
219759052|NCT04243148|COMBINATION_PRODUCT|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
219419960|NCT05202093|DEVICE|Oral B manual toothbrush|Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks
219419961|NCT05202093|DEVICE|Oclean electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
219419962|NCT01498237|DEVICE|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
219573448|NCT03446599|DRUG|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
219573449|NCT03446599|DRUG|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
219573450|NCT03446599|DRUG|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
219573451|NCT03451006|DRUG|Metformin|Oral metformin (up to 2gm) will be given in divided doses
219419963|NCT01498237|PROCEDURE|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
219573452|NCT03451006|DRUG|Placebo|Oral Placebo will be given in divided doses
219573453|NCT03660215|OTHER|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
219759053|NCT04243148|COMBINATION_PRODUCT|No specific intervention.|Follow up as a clinical practice
219759054|NCT00105664|PROCEDURE|Collaborative care model|
219759055|NCT00105664|PROCEDURE|Group interventions|
219759056|NCT00105664|PROCEDURE|Facilitated consultation|
219759057|NCT04063813|BEHAVIORAL|Experimental: 40 minute up trial|
219759058|NCT04063813|BEHAVIORAL|Experimental: 40 minute down trial|
219759059|NCT04063813|BEHAVIORAL|Experimental: Two 20 minute up trials|
219759060|NCT04063813|BEHAVIORAL|Experimental: Two 20 min down trials|
219759061|NCT04063813|BEHAVIORAL|Active Comparator: Sedentary trial|
219419964|NCT00712322|DRUG|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
219419965|NCT03608553|DEVICE|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
219419966|NCT01294891|OTHER|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
219419967|NCT06226506|DRUG|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
219419968|NCT06226506|DRUG|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
219419969|NCT02001116|OTHER|Quality Improvement intervention|"1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
219419970|NCT03523221|DRUG|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
219419971|NCT00205296|BEHAVIORAL|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
219419972|NCT03240393|DRUG|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
219419973|NCT01711684|DRUG|Diphenylcyclopropenone (DPCP)|Topical application of study drug
219419974|NCT04880538|PROCEDURE|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
219419975|NCT06061887|OTHER|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
219419976|NCT04694547|OTHER|There is no intervention, as this is a survey study|Survey
219419977|NCT01674244|BEHAVIORAL|Integrative Exercise|
219419978|NCT01674244|BEHAVIORAL|Monitor Only Waitlist|
219419979|NCT05725382|DEVICE|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
219419980|NCT04629612|PROCEDURE|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
219419981|NCT05171582|PROCEDURE|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
219419982|NCT05171582|PROCEDURE|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
219419983|NCT01016691|DRUG|High Dose Drug Device|device inserted for 4 days
219419984|NCT01016691|DRUG|Low Dose Drug Device|device inserted for 4 days
219419985|NCT01016691|DRUG|Placebo Device|device inserted for 4 days
219419986|NCT01016691|DRUG|bimatoprost 0.03%|one drop in each eye on one day only
219419987|NCT00057460|DRUG|Talampanel|
219419988|NCT01974726|OTHER|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
219419989|NCT01974726|OTHER|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
219419990|NCT01974726|OTHER|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
219573454|NCT02650141|DRUG|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
219573455|NCT02650141|DRUG|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
219573456|NCT00004810|DRUG|-aminosalicylic acid|
219573457|NCT06651294|DIETARY_SUPPLEMENT|Neorenal Forte|This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
219573458|NCT06651294|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
219419991|NCT01974726|OTHER|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
219573459|NCT00437190|DEVICE|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
219573460|NCT00437190|DEVICE|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
219573461|NCT06052787|DRUG|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
219573462|NCT06052787|DRUG|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
219573463|NCT03865537|PROCEDURE|Cold snare EMR|Participants will have their large polyp removed without electrocautery
219573464|NCT03865537|PROCEDURE|Hot snare EMR|Participants will have their large polyp removed with electrocautery
219573465|NCT03865537|PROCEDURE|Eleview injection|Participants will have their polyp submucosally injected with Eleview
219573466|NCT03865537|PROCEDURE|Placebo injection|Participants will have their polyp submucosally injected with placebo
219573467|NCT01643226|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
219573468|NCT01643226|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
219573469|NCT01643226|DEVICE|KXL System|30 mW/cm2
219573470|NCT00974948|PROCEDURE|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
219573471|NCT04491357|DRUG|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
219573472|NCT04491357|DRUG|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
219573473|NCT00638794|DEVICE|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
219573474|NCT01929395|DEVICE|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
219573475|NCT01863056|OTHER|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
219573476|NCT02547766|DRUG|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
219573477|NCT05802108|DRUG|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
219573478|NCT05802108|DRUG|Statin|the control group was treated with statin only for lipid-lowering
219573479|NCT03693534|DIAGNOSTIC_TEST|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
219573480|NCT06311669|PROCEDURE|iliac vein stenting|patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.
219573481|NCT06311669|PROCEDURE|pelvic vein embolization|embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
219573482|NCT03104348|DIAGNOSTIC_TEST|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
219573483|NCT04372290|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
219573484|NCT04372290|OTHER|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
219573485|NCT04372290|OTHER|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
219573486|NCT04372290|OTHER|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
219573487|NCT04372290|OTHER|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
219759062|NCT03807583|DRUG|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
219419992|NCT01974726|OTHER|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
219419993|NCT01974726|OTHER|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
219419994|NCT01974726|OTHER|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
219419995|NCT01974726|OTHER|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
219419996|NCT01974726|OTHER|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
219419997|NCT01731613|DIETARY_SUPPLEMENT|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
219419998|NCT01398072|DRUG|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
219419999|NCT01398072|DRUG|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
219420000|NCT01398072|DRUG|Doxycycline|An oral dose of 100 mg once daily.
219573488|NCT03452618|DIAGNOSTIC_TEST|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
219573489|NCT02521818|OTHER|Modified Atkins Diet|
219573490|NCT02521818|OTHER|NIA Diet for Seniors|
219573491|NCT03604341|DRUG|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
219573492|NCT03604341|OTHER|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
219573493|NCT00850226|BEHAVIORAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
219573494|NCT00850226|BEHAVIORAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
219573495|NCT03786419|DRUG|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
219759063|NCT03807583|DIETARY_SUPPLEMENT|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
219007238|NCT05508191|DEVICE|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
219420001|NCT01398072|DRUG|Placebo|Oral dose of one table once daily.
219420002|NCT06067412|DRUG|Levetiracetam|Efficacy in fits
219420003|NCT06067412|DRUG|Phenytoin|Efficacy in fits
219420004|NCT01794247|DRUG|Magnesium sulfate|
219420005|NCT01794247|DRUG|Fentanyl|
219420006|NCT01794247|DRUG|Lidocaine|
219420007|NCT03482141|DEVICE|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
219420008|NCT02793895|DEVICE|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
219420009|NCT02793895|OTHER|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
219420010|NCT02793895|DEVICE|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
219420011|NCT02635152|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
219420012|NCT02635152|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
219573496|NCT05385848|PROCEDURE|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
219573497|NCT04963387|OTHER|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
219573498|NCT04963387|OTHER|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
219573499|NCT04375839|DEVICE|Zirconia implant|Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
219573500|NCT04375839|DEVICE|Titanium implant|Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
219573501|NCT03563846|DRUG|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
219573502|NCT05916521|DRUG|0.454% stannous fluoride|Brush two times daily
219573503|NCT05916521|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
219573504|NCT05916521|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
219573505|NCT01653613|GENETIC|DNA analysis|
219573506|NCT01653613|GENETIC|fluorescence in situ hybridization|
219573507|NCT01653613|GENETIC|gene expression analysis|
219573508|NCT01653613|GENETIC|microarray analysis|
219573509|NCT01653613|GENETIC|mutation analysis|
219573510|NCT01653613|GENETIC|polymorphism analysis|
219573511|NCT01653613|GENETIC|reverse transcriptase-polymerase chain reaction|
219573512|NCT01653613|OTHER|laboratory biomarker analysis|
219573513|NCT02312713|BEHAVIORAL|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
219573514|NCT02312713|BEHAVIORAL|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
219420013|NCT02438215|DRUG|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
219573515|NCT02676713|DRUG|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
219573516|NCT02676713|DRUG|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
219573517|NCT02676713|DRUG|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
219573518|NCT02676713|DRUG|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
219573519|NCT03153618|OTHER|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
219573520|NCT05880121|DIAGNOSTIC_TEST|MRI|brain MRI
219573521|NCT03627234|BEHAVIORAL|Same Day Discharge|Patients will be randomized to same day discharge
219573522|NCT03627234|BEHAVIORAL|Overnight Stay|Patients will be randomized to stay overnight
219573523|NCT01829113|DRUG|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
219573524|NCT01829113|DRUG|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
219573525|NCT04754334|DRUG|ORMD-0801|Oral Insulin
219420014|NCT03354702|OTHER|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
219420015|NCT03354702|OTHER|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
219420016|NCT03471481|OTHER|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
219420017|NCT06166355|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
219420018|NCT06166355|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
219420019|NCT06166355|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
219420020|NCT03375905|DEVICE|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
219420021|NCT01422811|BEHAVIORAL|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
219420022|NCT01422811|OTHER|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
219420023|NCT01688167|BEHAVIORAL|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
219420024|NCT00435032|PROCEDURE|early appendectomy|Appendectomy within 24 hours of admission
219420025|NCT00435032|PROCEDURE|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
219573526|NCT04754334|OTHER|Placebo|Fish Oil
219573527|NCT03736759|BEHAVIORAL|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
219573528|NCT03250390|DEVICE|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
219573529|NCT02010255|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
219573530|NCT02010255|DRUG|RBV|RBV tablets administered orally in a divided daily dose
219420026|NCT02802878|DEVICE|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
219573531|NCT04703543|DEVICE|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
219420027|NCT02802878|DEVICE|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
219420028|NCT01599754|DRUG|Axitinib|Axitinib 5 mg twice daily
219420029|NCT01599754|DRUG|Placebo|Placebo twice daily
219420030|NCT02028546|PROCEDURE|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
219420031|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
219420032|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
219420033|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
219420034|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
219420035|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
219420036|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
219420037|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
219420038|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
219420039|NCT03002116|OTHER|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
219420040|NCT04498533|OTHER|forearm strap (counterforce brace)|
219420041|NCT04498533|OTHER|Kinesio tape application|
219420042|NCT03286088|DIAGNOSTIC_TEST|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
219420043|NCT03286088|DIAGNOSTIC_TEST|Cardiac Magnetics Resonance|imaging as standard practice
219573532|NCT03226171|DRUG|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
219420044|NCT03286088|DIAGNOSTIC_TEST|MitraClip|imaging as standard practice
219420045|NCT03233100|OTHER|FMT|fecal microbiota transplantation
219420046|NCT03036332|BEHAVIORAL|Aerobic interval training|Carried out 3 times per week for 16 weeks
219420047|NCT05459389|OTHER|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
219420048|NCT01029002|DRUG|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
219573533|NCT04688047|BEHAVIORAL|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
219573534|NCT05815368|DEVICE|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
219573535|NCT05815368|OTHER|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
219420049|NCT01029002|OTHER|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
219420050|NCT03623139|BEHAVIORAL|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
219420051|NCT03623139|BEHAVIORAL|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
219420052|NCT03696264|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
219573536|NCT03304340|DEVICE|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
219420053|NCT00702052|DRUG|Everolimus|Everolimus tablets
219420054|NCT01577160|DRUG|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
219420055|NCT01551758|DRUG|FF/VI|FF/VI
219420056|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
219420057|NCT03000816|RADIATION|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
219420058|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review.
219420059|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review
219420060|NCT02421367|BIOLOGICAL|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
219420061|NCT02623634|BEHAVIORAL|Position, waveform|different positions and waveform
219420062|NCT02027116|BIOLOGICAL|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
219420063|NCT03562585|DIAGNOSTIC_TEST|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
219573537|NCT03304340|DEVICE|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
219573538|NCT03304340|OTHER|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
219573539|NCT02568709|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
219420064|NCT01334372|BEHAVIORAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
219420065|NCT00239317|DRUG|Tamusulosin|
219420066|NCT01380158|DEVICE|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
219420067|NCT02325635|OTHER|Educational Training|Intervention/Training offered to endoscopists only.
219420068|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
219573540|NCT02568709|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
219573541|NCT05818982|DRUG|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
219573542|NCT05818982|DRUG|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
219573543|NCT06616974|DRUG|TX000045- Dose A|The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
219573544|NCT06616974|DRUG|TX000045- Dose B|The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
219573545|NCT06616974|DRUG|Placebo|The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
219004976|NCT07001722|OTHER|TÜBSİS Web-based Psycho-education Programme|The theoretical infrastructure of the TÜBSİS Program, which consists of a total of 8 modules lasting 1 month, is supported by the integration of two different frameworks: Mindfulness Approach and HAPA Health Action Approach. While the progress process in the TÜBSİS Program was created with the HAPA Model, the module contents of it were created within the framework of the Mindfulness Approach. Each participant receives reminder emails during this asynchronous and distance learning process and can open each new module at least 3 days later. Participants in the intervention (as well as control group) were asked about sociodemographic and tobacco use characteristics at baseline. Health Action Process Approach (HAPA) Model Change Question Form, Warwick Edinburgh Mental Well-Being Scale, Fagerström Nicotine Dependence Test and Informed Consent Form were administered to the intervention group at the beginning, in the middle and at the end of the intervention study.
219420069|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
219420070|NCT02638805|DRUG|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
219420071|NCT02638805|DRUG|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
219420072|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
219420073|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
219420074|NCT02238496|PROCEDURE|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
219420075|NCT02238496|DRUG|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
219573546|NCT03261362|DIETARY_SUPPLEMENT|Branched-chain amino acids reduced intake|
219573547|NCT06318039|OTHER|Novel program|Applying new training method; the Nordic hamstring exercise
219420076|NCT02238496|DRUG|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
219420077|NCT05755334|DRUG|Ropivacaine|Administration of Ropivacaine
219420078|NCT03477617|OTHER|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
219420079|NCT03477617|COMBINATION_PRODUCT|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
219420080|NCT04807543|DRUG|17-hydroxyprogesterone caproate|intramuscular injection weekly
219420081|NCT04807543|DRUG|Castor Oil|intramuscular injection weekly
219573548|NCT06318039|OTHER|Traditional program|Conventional rehabilitation training administered
219573549|NCT02466802|DRUG|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
219573550|NCT02466802|DRUG|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
219420082|NCT04228120|BEHAVIORAL|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
219420083|NCT02852148|DEVICE|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
219420084|NCT00916370|DEVICE|Core size Xience Prime|Core size includes a range of stent sizes.
219420085|NCT00916370|DEVICE|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
219420086|NCT01344837|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219420087|NCT01344837|OTHER|Immunohistochemistry Staining Method|Correlative studies
219420088|NCT01344837|OTHER|Medical Chart Review|Correlative studies
219420089|NCT01344837|GENETIC|Microarray Analysis|Correlative studies
219420090|NCT01344837|OTHER|Study of Socioeconomic and Demographic Variables|Correlative studies
219420091|NCT01344837|GENETIC|Western Blotting|Correlative studies
219420092|NCT05120999|DEVICE|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
219420093|NCT01604304|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
219420094|NCT01604304|PROCEDURE|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
219420095|NCT03898869|DIAGNOSTIC_TEST|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
219420096|NCT04669314|PROCEDURE|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
219420097|NCT03311490|DEVICE|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
219420098|NCT05339243|OTHER|ES 1|Two capsules orally once daily after breakfast for 84 days
219420099|NCT05339243|OTHER|HT ES1|Two capsules orally once daily after breakfast for 84 days
219420100|NCT05339243|OTHER|Placebo|Two capsules orally once daily after breakfast for 84 days
219420101|NCT00610376|BEHAVIORAL|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
219420102|NCT00610376|BEHAVIORAL|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
219420103|NCT06288958|OTHER|Quality of Life and social participation in Italian children with CP|CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
219420104|NCT06553950|DRUG|Botox injection|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle."
219420105|NCT06553950|DRUG|Mandibular stabilization splint|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
219420106|NCT06553950|DRUG|Muscle relaxant|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
219420107|NCT00230100|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
219420108|NCT00230100|BEHAVIORAL|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
219420109|NCT04727502|DRUG|Duloxetine|duloxetine
219420110|NCT04727502|DRUG|Pregablin|Pregablin
219420111|NCT01200615|BEHAVIORAL|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
219420112|NCT01317615|DRUG|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
219573551|NCT00139438|BEHAVIORAL|Disease Management Assessment|
219420113|NCT01317615|DRUG|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
219420114|NCT01317615|DRUG|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
219420115|NCT00005847|BIOLOGICAL|recombinant interferon alfa|
219573552|NCT02593487|DRUG|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
219573553|NCT02593487|DRUG|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
219573554|NCT03389087|DRUG|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
219573555|NCT01010750|DRUG|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
219573556|NCT01010750|DRUG|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
219573557|NCT01010750|DRUG|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
219573558|NCT03288402|OTHER|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
219573559|NCT01076556|DRUG|Alvocidib Hydrochloride|Given IV
219573560|NCT01076556|DRUG|Cyclophosphamide|Given IV
219573561|NCT01076556|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219573562|NCT01076556|OTHER|Pharmacological Study|Correlative studies
219573563|NCT01076556|BIOLOGICAL|Rituximab|Given IV
219573564|NCT03700645|DRUG|Allopurinol|Allopurinol
219759064|NCT01790373|BEHAVIORAL|Suubi+Adherence|"* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
219759065|NCT01790373|BEHAVIORAL|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
219759066|NCT01221506|DRUG|Pazopanib|800 mg PO QD x 28 days
219420116|NCT00005847|DRUG|estramustine phosphate sodium|
219420117|NCT00005847|DRUG|isotretinoin|
219420118|NCT00005847|DRUG|mitoxantrone hydrochloride|
219420119|NCT00005847|DRUG|paclitaxel|
219420120|NCT00005847|DRUG|vinorelbine ditartrate|
219420121|NCT02859493|DEVICE|Saccharomyces cerevisiae|
219420122|NCT02859493|DEVICE|Placebo|
219420123|NCT01380444|PROCEDURE|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
219420124|NCT01380444|PROCEDURE|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
219420125|NCT00191074|DRUG|somatropin, rDNA origin, for injection|
219420126|NCT05770050|OTHER|No intervention|No intervention
219573565|NCT03739138|BIOLOGICAL|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
219573566|NCT03739138|BIOLOGICAL|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
219573567|NCT01194102|BEHAVIORAL|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
219573568|NCT01194102|OTHER|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
219573569|NCT01194102|OTHER|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
219573570|NCT02654587|BIOLOGICAL|OSE2101|
219573571|NCT02654587|DRUG|Docetaxel|
219573572|NCT02654587|DRUG|Pemetrexed|
219573573|NCT01419587|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
219573574|NCT03381937|OTHER|speech trial|speech trial during different ventilation conditions
219573575|NCT04702347|DIAGNOSTIC_TEST|Urine biomarker|Bladder urine samples (\> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
219573576|NCT05519657|OTHER||
219573577|NCT06305520|DEVICE|Investigational medical device (SkinPlus-HYAL Implant Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
219759067|NCT01221506|DEVICE|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
219573578|NCT06305520|DEVICE|Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
219004977|NCT07000487|BEHAVIORAL|Yoga|Hatha yoga will be applied in this study. Yoga practice will be carried out by the researcher for 6 weeks, 1 day face-to-face and 1 day online, and each practice will be 60 minutes, in total 12 sessions, considering the studies done. It will be applied by a researcher with a yoga certificate. Pre-test and post-test nausea and pain measurements will be made.
219004978|NCT07002164|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography ≤2 hours after randomization
219573579|NCT02497794|OTHER|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
219573580|NCT02399631|OTHER|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
219573581|NCT04593212|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
219420127|NCT02969850|DIETARY_SUPPLEMENT|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
219420128|NCT02969850|OTHER|Placebo|Subjects in this group will receive a placebo.
219420129|NCT02969850|DIETARY_SUPPLEMENT|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
219573582|NCT00699478|DRUG|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
219573583|NCT03979833|GENETIC|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
219759068|NCT03339596|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
219759069|NCT03339596|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
219759070|NCT01873105|OTHER|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
219759071|NCT02343315|DEVICE|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes"
219004979|NCT07002164|PROCEDURE|Delayed coronary angiography|Delayed coronary angiography after stabilization
219004980|NCT07000799|BEHAVIORAL|CBT|The EMOTION Intervention is based on cognitive-behavioral therapy, which has been shown to be effective in both the treatment and prevention of anxiety and depression in children. The EMOTION intervention has been developed as a school-based program and consists of an intensive course lasting eight weeks, using a hybrid model with eight face-to-face group meetings at school and eight hours of digital sessions completed by the child at home. Additionally, it is desirable for parents to support their children; hence, guardians will be offered the opportunity to attend an informational meeting. They will also receive a brochure detailing how they can support and assist their child. A group leader manual and a workbook for the children have been developed (Martinsen et al., 2017).
219420130|NCT05830513|DEVICE|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
219420131|NCT03270150|DEVICE|BTL-899|BTL-899
219420132|NCT01670214|PROCEDURE|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
219420133|NCT06553443|DEVICE|Angioplasty of all peripheral AVF stenosis|All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
219420134|NCT01906866|DRUG|Circadin 2/5/10 mg|Circadin 2/5/10 mg. Active arm
219420135|NCT01906866|DRUG|Placebo|Control arm
219420136|NCT04045236|OTHER|Registry|Data collection
219420137|NCT02977013|DIAGNOSTIC_TEST|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
219420138|NCT02913352|PROCEDURE|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
219420139|NCT02913352|PROCEDURE|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
219420140|NCT00438399|DRUG|C. propionate - Corticosteroid 1|Twice daily application
219573584|NCT03069677|OTHER|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
219573585|NCT03069677|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
219004981|NCT07001267|PROCEDURE|Anesthesia drugs during the surgery|During treatment for acute ischemic stroke, patients will be given either inhalation or intravenous anesthesia.
219004982|NCT07000890|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial tissue and blood samples will be collected and processed for bulk and scRNAseq; serum, plasma, DNA, RNA and PBMCs as per below flow chart. Biomarker exploratory analysis will be performed.
219004983|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days."
219004984|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
219004985|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
219420141|NCT00438399|DRUG|C. propionate- Corticosteroid 2|Twice daily application
219420142|NCT00438399|DRUG|C. propionate -Corticosteroid 3|Twice daily application
219420143|NCT00438399|DRUG|Corticosteroid 1- C. propionate|Twice daily application
219420144|NCT00438399|DRUG|Corticosteroid 2 - C. propionate|Twice daily application
219420145|NCT00438399|DRUG|Corticosteroid 3 - C. propionate|Twice daily application
219420146|NCT02851433|DRUG|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
219420147|NCT02851433|DRUG|total intravenous anaesthesia with Propofol.|
219420148|NCT04729556|DEVICE|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
219420149|NCT00231244|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
219420150|NCT02568124|DRUG|Tranexamic Acid|
219420151|NCT02568124|DRUG|Placebo|
219420152|NCT05739877|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
219420153|NCT05739877|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
219420154|NCT06679517|PROCEDURE|TAVI|Clinical follow-up up to 10 years of patients undergoing TAVI
219420155|NCT00004363|DRUG|chlorpropamide|
219420156|NCT00004363|DRUG|desmopressin|
219420157|NCT04653818|DRUG|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
219420158|NCT01530438|OTHER|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
219420159|NCT02604862|OTHER|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
219420160|NCT02604862|OTHER|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
219420161|NCT00070980|PROCEDURE|Massage therapy|
219420162|NCT00632541|DRUG|Sorafenib|Sorafenib 200mg po daily
219420163|NCT00632541|DRUG|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
219573586|NCT04669548|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
219573587|NCT05044728|DRUG|Anti-PD-1 antibody combined with Paclitaxel and carboplatin.|"Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy."
219573588|NCT05044728|PROCEDURE|Surgical treatment stage|After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
219420164|NCT00632541|OTHER|Imaging|Imaging every third cycle
219420165|NCT05807386|BEHAVIORAL|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
219420166|NCT01333696|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
219004986|NCT07132411|BEHAVIORAL|Patients in Talk With Me Baby Clinics|Parent-child participants in TWMB clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule.
219004987|NCT07132411|BEHAVIORAL|Patients in Care-As-Usual Clinics|Parent-child participants in Care-As-Usual clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule. Measures will be completed at five time points.
219420167|NCT01012505|OTHER|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
219420168|NCT03902782|PROCEDURE|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
219420169|NCT03902782|PROCEDURE|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
219420170|NCT03902782|PROCEDURE|Sham ESP block|As described earlier
219420171|NCT03902782|PROCEDURE|Sham Intercostal block|As described earlier
219420172|NCT03902782|DRUG|Bupivacaine-epinephrine|As described earlier
219420173|NCT03902782|DRUG|Dexamethasone injection|As described earlier
219004988|NCT07132528|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
219420174|NCT03902782|DRUG|Normal saline|As described earlier
219420175|NCT03946826|DRUG|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
219420176|NCT03946826|DRUG|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
219420177|NCT03946826|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
219420178|NCT03256474|OTHER|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
219004989|NCT07132528|DRUG|SOX Chemotherapy|SOX or XELOX
219420179|NCT00804739|OTHER|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
219420180|NCT04668001|DEVICE|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
219420181|NCT04668001|DEVICE|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
219420182|NCT04398199|DRUG|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
219420183|NCT04398199|RADIATION|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
219420184|NCT04134585|OTHER|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
219420185|NCT02193256|DRUG|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
219420186|NCT02193256|DRUG|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
219420187|NCT02193256|DRUG|Placebo|
219420188|NCT01842607|BIOLOGICAL|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
219420189|NCT01945333|BEHAVIORAL|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
219420190|NCT01398033|DEVICE|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
219420191|NCT01398033|DEVICE|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
219420192|NCT00379262|DRUG|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
219420193|NCT00379262|DRUG|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
219420194|NCT00379262|DRUG|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
219420195|NCT00972127|DRUG|Neramexane|25 mg or 2x25mg tablets
219420196|NCT06250894|DRUG|PD-1inhibitor|Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
219004990|NCT07015138|RADIATION|TRT|"Comprehensive metastasis-directed radiotherapy:~* Targets: Primary prostate tumor + all metastatic lesions (≤10 sites confirmed by PSMA PET)~* Concurrent therapy: Standard systemic treatment (ADT + novel hormonal agents)"
219004991|NCT07015138|RADIATION|NTRT|"Standard primary radiotherapy:~* Targets: Prostate primary tumor only~* Concurrent therapy: Same systemic treatment as experimental arm"
219573589|NCT01130779|DRUG|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
219573590|NCT00004876|DRUG|carboplatin|
219190968|NCT06609642|BEHAVIORAL|Art application|"First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application."
219420197|NCT05231174|OTHER|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
219420198|NCT00003817|DRUG|dolasetron mesylate|
219420199|NCT00003817|DRUG|granisetron hydrochloride|
219420200|NCT00003817|DRUG|ondansetron|
219420201|NCT00003817|DRUG|tropisetron|
219420202|NCT00003817|PROCEDURE|quality-of-life assessment|
219420203|NCT04966884|DRUG|JAK Inhibitor|"1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months."
219420204|NCT01858610|DRUG|Irbeasartan/hydrochlorothiazide|
219420205|NCT01858610|DRUG|Irbesartan|
219420206|NCT01858610|DRUG|Hydrochlorothiazide|
219420207|NCT01927419|DRUG|Nivolumab|
219420208|NCT01927419|DRUG|Ipilimumab|
219420209|NCT01927419|DRUG|Placebo|Matching nivolumab
219573591|NCT00004876|DRUG|thalidomide|
219573592|NCT01128582|DRUG|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
219420210|NCT06056349|DRUG|Midazolam oral solution|Buccal administration
219420211|NCT06056349|DRUG|ClonazePAM Oral Product|Orodispersable
219420212|NCT06056349|OTHER|Usual medication/ traditional|Medication that is usually used in the emergency department
219420213|NCT03107455|DEVICE|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
219420214|NCT00393913|DEVICE|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
219420215|NCT03991364|OTHER|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
219420216|NCT03991364|OTHER|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
219420217|NCT03488251|DRUG|MT-3724|MT-3724 will be administered.
219420218|NCT03488251|DRUG|Gemcitabine|Gemcitabine will be administered.
219420219|NCT03488251|DRUG|Oxaliplatin|Oxaliplatin will be administered.
219420220|NCT06303947|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219573593|NCT01128582|DRUG|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
219573594|NCT04047563|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
219573595|NCT04047563|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
219573596|NCT04432519|PROCEDURE|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
219573597|NCT05420779|DRUG|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
219573598|NCT05420779|DRUG|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
219573599|NCT05420779|DRUG|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
219420221|NCT06303947|DEVICE|Nasogastric tube|The group is given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219420222|NCT06303947|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219420223|NCT04044092|OTHER|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
219420224|NCT04044092|OTHER|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
219420225|NCT03019744|DEVICE|MeCFES-assisted task-oriented upper limb rehabilitation|
219420226|NCT03019744|OTHER|Usual Care task-oriented upper limb rehabilitation|
219420227|NCT04448262|OTHER|data collection|collection of data about bronchial and systemic inflammation, quality of life, lung function
219420228|NCT00274157|BEHAVIORAL|Behavior|
219420229|NCT00274157|BEHAVIORAL|diet control, smoking cessation, exercize|
219420230|NCT04564430|DRUG|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
219420231|NCT04564430|OTHER|Saline|controlgroup receiving saline
219420232|NCT00757926|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
219420233|NCT00757926|OTHER|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
219573600|NCT05039437|DIETARY_SUPPLEMENT|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
219573601|NCT05039437|DIETARY_SUPPLEMENT|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
219420234|NCT04153617|DIETARY_SUPPLEMENT|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
219420235|NCT04153617|DIETARY_SUPPLEMENT|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
219420236|NCT02001675|DEVICE|magnetic resonance imaging (MRI)|
219420237|NCT02001675|DEVICE|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
219420238|NCT04280887|DEVICE|MyPad|Ultrasound bed wetting alarm
219420239|NCT05674500|OTHER|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
219420240|NCT05674500|OTHER|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
219420241|NCT02895256|DRUG|Any treatment for cluster headache|
219420242|NCT03215082|OTHER|Vestibular-Visual Intervention|vestibular-visual exercises
219420243|NCT03215082|BEHAVIORAL|standard care|standard care
219420244|NCT02366754|DEVICE|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
219573602|NCT00670033|DRUG|Travoprost ophthalmic solution (new formulation)|
219573603|NCT00670033|DRUG|Travoprost ophthalmic solution, 0.004%|
219573604|NCT00670033|DRUG|Vehicle|Inactive ingredients used as a placebo
219573605|NCT00802282|DRUG|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
219573606|NCT00802282|BEHAVIORAL|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
219573607|NCT00802282|BEHAVIORAL|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
219573608|NCT01473576|DIETARY_SUPPLEMENT|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
219573609|NCT01473576|DIETARY_SUPPLEMENT|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
219004992|NCT03773692|BEHAVIORAL|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
219004993|NCT07021976|DRUG|HRS-1893 Tablets|HRS-1893 tablets.
219004994|NCT07021976|DRUG|HRS-1893 Placebo Tablets|HRS-1893 placebo tablets.
219004995|NCT04315909|DRUG|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
219004996|NCT04315909|DIETARY_SUPPLEMENT|Vitamin E and C|Vitamin E and vitamin C
219004997|NCT04315909|OTHER|Placebo|Placebo
219004998|NCT07018297|COMBINATION_PRODUCT|Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor|Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.
219004999|NCT01461941|DRUG|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
219005000|NCT01461941|DRUG|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
219005001|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
219005002|NCT07031219|OTHER|provider order set/order panel|Triple testing order panels will be built specifically for this study. An order for a screening blood test for any of the three bloodborne viruses (BBVs; i.e. HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)) will be coupled with orders for the respective screening blood tests for the other two BBVs to be selected by default in a single order panel. These order panels will only be available to participating providers during their participation in the intervention arm.
219420245|NCT02366754|DEVICE|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
219420246|NCT00822484|BIOLOGICAL|ILV-095|
219420247|NCT00822484|OTHER|Placebo|
219005003|NCT06880263|DEVICE|use 360 degree VR training|Participants will use Virtual Reality (VR) training
219005004|NCT07030673|DRUG|antibiotic withdrawal|stop antibiotics on viral or negative results
219005005|NCT07030673|DRUG|Antibiotics|"standard of care~Antibiotics are :~Amoxicilline-acide clavulanique : 1g x3/j, 7j or Ceftriaxone : 1g/j, 7j or Pipéracilline-Tazobactam : 4g x3/j, 7j or Pristinamycine : 1g x 3/j, 7j"
219420248|NCT03230474|DRUG|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
219420249|NCT03230474|DRUG|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
219420250|NCT03041909|DRUG|GBT440|Oral drug
219420251|NCT02518308|BEHAVIORAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
219420252|NCT06342323|RADIATION|SBRT|the fiducial marker was implanted with 3D template assistance under CT guidance
219420253|NCT04453904|OTHER|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
219420254|NCT03894774|BEHAVIORAL|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
219420255|NCT03894774|OTHER|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
219420256|NCT02999568|OTHER|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
219420257|NCT00003466|DRUG|temozolomide|
219420258|NCT06131125|OTHER|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
219420259|NCT06131125|OTHER|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
219420260|NCT00328965|DRUG|Lacidipine|Lacidipine 2, 4, 6mg
219420261|NCT06170801|BEHAVIORAL|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
219420262|NCT06170801|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
219420263|NCT03431701|OTHER|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
219420264|NCT03431701|OTHER|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
219573610|NCT02074267|DRUG|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
219005006|NCT07133035|DIAGNOSTIC_TEST|Pulmonary function test|Participants' respiratory functions will be assessed in different positions with the Cosmed Pony Fx Digital Spirometer (11). Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC), and peak expiratory flow rate (PEF) will be determined during the pulmonary function test.
219573611|NCT02074267|DRUG|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
219005007|NCT07133035|DIAGNOSTIC_TEST|Fonseca Anamnestic Index|The questionnaire consists of 10 questions covering headaches, neck pain, temporomandibular joint pain, pain during chewing, parafunctional habits, malocclusion, and stress, and is scored as 10 (yes), 5 (sometimes), and 0 (no). The total score ranges from 0 to 100. A higher total score indicates an increased risk of temporomandibular joint problems.
219420265|NCT03431701|OTHER|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
219420266|NCT02612441|DEVICE|real Acupuncture Needles|Acupuncture needles
219420267|NCT02612441|DEVICE|sham Acupuncture Needles|sham Acupuncture Needles
219005008|NCT07133035|OTHER|Jenkins Sleep Scale|The Jennkis Sleep Scale consists of four questions that assess sleep problems over a 4-week period. Each question is scored from 0 to 5. The total score ranges from 0 to 20 and indicates increasing sleep disturbance.
219420268|NCT03111264|BEHAVIORAL|CHAMP|"The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
219420269|NCT03111264|BEHAVIORAL|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
219420270|NCT02719236|PROCEDURE|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
219420271|NCT02719236|PROCEDURE|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
219420272|NCT01853436|DEVICE|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
219420273|NCT03326154|OTHER|No intervention, observational|Observation
219420274|NCT06441851|PROCEDURE|Videolaparoscopic Partial Nephrectomy|Videolaparoscopic partial nephrectomy
219573612|NCT02787317|DRUG|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
219573613|NCT02787317|DRUG|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
219573614|NCT01967693|PROCEDURE|Retrospective analysis of data|Retrospective data analysis
219573615|NCT02172482|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
219420275|NCT06441851|PROCEDURE|Robot-assisted Partial Nephrectomy|Robot-assisted partial nephrectomy
219420276|NCT00592553|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
219573616|NCT06053762|BEHAVIORAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
219573617|NCT06053762|BEHAVIORAL|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
219573618|NCT00416026|BEHAVIORAL|Educational/Counseling/Training|
219005009|NCT07133035|OTHER|Berlin Questionnaire|Berlin Questionnaire: The Berlin Questionnaire is a three-part assessment tool that assesses individuals' predisposition to sleep apnea. The first part contains five questions investigating snoring, the second part contains four questions investigating daytime sleepiness, and the third part contains two questions investigating hypertension and obesity. Each section is evaluated independently. Individuals who score 2 or higher in the first and second sections, and those who score 1 in the third section, are considered predisposed to sleep apnea. If two or more categories are positive, the participant is considered high risk for obstructive sleep apnea. If the participant scores two or more in the first and second categories, they are considered high risk. If blood pressure is high or BMI is above 30 kg/m2, the participant is considered high risk.
219005010|NCT07133035|OTHER|Headache Impact Test-6|"Headache Impact Test-6: The Headache Impact Test-6 (HIT-6) is administered to identify activities individuals are unable to perform due to headaches and to determine the extent to which headaches impact daily life. This six-question questionnaire includes columns with increasing scores, from never to always. Participants are asked to mark the box closest to their response. A high total score indicates that headaches negatively impact daily life."
219005011|NCT01937559|BIOLOGICAL|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
219005012|NCT01937559|DRUG|Normal saline|
219005013|NCT07033364|OTHER|Functional liver imaging using hepatobiliary scintigraphy (HEBIS)|The Hepatobiliary scintigraphy (HEBIS) or HIDA scan is a nuclear imaging technique that uses \[99mTc\]Tc-mebrofenin, a iminodiacetic acid (IDA) agent, which is a lidocaine analogue that is taken up by hepatocytes and is eliminated in the biliary tract (Arntz, 2023). This functional liver scan quantitatively assesses liver function of which the potential will be tested to measure liver function before and after radiotherapy.
219005014|NCT06925984|RADIATION|SBRT|SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.
219420277|NCT00592553|DRUG|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
219420278|NCT05429554|DRUG|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
219420279|NCT03596658|DRUG|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
219420280|NCT00004929|BIOLOGICAL|MUC-2-KLH vaccine|
219420281|NCT00004929|BIOLOGICAL|QS21|
219420282|NCT03449316|BEHAVIORAL|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
219573619|NCT04711720|DEVICE|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
219573620|NCT01882920|DRUG|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
219573621|NCT01882920|DRUG|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
219573622|NCT00616174|PROCEDURE|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
219005015|NCT07048756|BEHAVIORAL|Imagery Rescripting|Imagery Rescripting (Regular)
219005016|NCT07048756|BEHAVIORAL|Imagery Exposure|Imagery Exposure
219005017|NCT07048756|BEHAVIORAL|Imagery Rescripting with Disruption of Reconsolidation|Imagery Rescripting with Disruption of Reconsolidation
219005018|NCT07048756|BEHAVIORAL|Compassion-Focused Therapy Imagery Rescripting|Imagery Rescripting in Compassion-Focused Therapy
219005019|NCT02167893|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
219005020|NCT06729294|OTHER|Binaural beat music recital|Binaural beats music is therapeutic music that provides auditory stimuli at different frequencies to each ear. However, the maximum sound levels are 60 dB, which helps to relax and reduce stress.
219005021|NCT06741072|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219420283|NCT02300896|OTHER|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
219420284|NCT02006264|DRUG|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
219420285|NCT02006264|DRUG|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
219420286|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
219005022|NCT06741072|DRUG|Dulbecco''s Phosphate-Buffered Saline|Given SC
219005023|NCT06741072|BIOLOGICAL|Peptide Vaccine|Given OSU-2131 SC
219420287|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
219420288|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
219420289|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|control biscuit on a daily basis for 8 months
219420290|NCT04127734|PROCEDURE|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
219573623|NCT00216645|DRUG|doxorubicin hydrochloride|
219573624|NCT01338987|PROCEDURE|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
219573625|NCT01338987|DRUG|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
219759072|NCT02343315|OTHER|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
219420291|NCT00657124|DIETARY_SUPPLEMENT|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
219420292|NCT00657124|DIETARY_SUPPLEMENT|Placebo|placebo
219005024|NCT06741072|BIOLOGICAL|QS21|Given SC
219005025|NCT06890338|DRUG|Carboplatin|Intravenous (IV) infusion
219005026|NCT06890338|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
219420293|NCT05846295|OTHER|ESTIMATE|An online educational module consisting of a video tutorial and feedback during a questionnaire
219420294|NCT00609219|BIOLOGICAL|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"
219420295|NCT04961918|PROCEDURE|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
219573626|NCT01338987|DRUG|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
219573627|NCT01338987|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
219573628|NCT01338987|DRUG|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
219573629|NCT01338987|DRUG|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
219005027|NCT06890338|DRUG|Bevacizumab|Intravenous (IV) infusion (per investigator's discretion)
219005028|NCT06745388|DRUG|Magnesium sulfate|Receive intravenous magnesium intra-operatively
219005029|NCT06745388|DRUG|Ketamine|Receive IV push ketamine intra-operatively
219005030|NCT06745388|DRUG|Placebo|Receives no additional medication or infusion
219005031|NCT06555328|DRUG|CSU lower dose treatment|CSU lower dose treatment
219005032|NCT06555328|DRUG|CSU high dose treatment|CSU high dose treatment
219005033|NCT06555328|DRUG|CSU non responders IgE - high dose treatment|CSU non responders IgE - high dose treatment
219005034|NCT06555328|DRUG|HS low dose treatment|HS low dose treatment
219005035|NCT06555328|DRUG|HS medium dose treatment|HS medium dose treatment
219420296|NCT06366295|DEVICE|subgingival mechanotherapy with perioscopy|Subgingival mechanotherapy using a machine scaler, curettes and a perioscope
219420297|NCT06366295|DEVICE|classical subgingival mechanotherapy|Subgingival mechanotherapy using a machine scaler and curettes
219420298|NCT05782166|BEHAVIORAL|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
219573630|NCT01338987|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
219573631|NCT01338987|DRUG|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
219573632|NCT01338987|DRUG|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
219573633|NCT01338987|PROCEDURE|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
219759073|NCT02343315|OTHER|UHEP|"All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
219759074|NCT03055091|OTHER|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
219005036|NCT06555328|DRUG|HS high dose treatment|HS high dose treatment
219573634|NCT06205433|OTHER|IHSS Basic Training|The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
219573635|NCT03985787|BEHAVIORAL|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
219573636|NCT00632086|DRUG|PA32540|
219573637|NCT00632086|DRUG|aspirin component of PA32540|The 325 mg aspirin component of PA32540
219573638|NCT00632086|DRUG|Ecotrin|325 mg Ecotrin
219573639|NCT02815202|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
219005037|NCT07062159|OTHER|the psychoeducation intervention program|The content of the psychoeducation intervention program based on the Watson Human Caring Model will consist of the postpartum process and care, maternal blues, postpartum psychosis, postpartum depression, frequency, causes, predisposing factors, symptoms, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support, adaptation to the role of motherhood, mother and baby bonding, practices that will strengthen mother-baby bonding, breast milk and breastfeeding, nutrition and baby care, problems encountered in baby care and solution suggestions.
219005038|NCT07062159|OTHER|routine care|routine care
219005039|NCT07065331|DRUG|AZD8630|Single inhaled dose of AZD8630 via dry powder inhaler.
219005040|NCT07065331|DEVICE|Dry powder inhaler|Single inhaled dose of AZD8630 via dry powder inhaler.
219573640|NCT06601621|COMBINATION_PRODUCT|electroacupuncture+ self-acupressure|"Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes."
219759075|NCT03055091|OTHER|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
219759076|NCT03576235|DRUG|PG102P|Daily dose of 1.5g
219759077|NCT03576235|DRUG|Placebo|Daily dose of placebo
219759078|NCT00098995|DRUG|cisplatin|
219005041|NCT06777485|PROCEDURE|Procedure/Surgery treatment|Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
219005042|NCT06777485|DRUG|Anti-Tumor Drugs|Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
219005043|NCT06442397|BEHAVIORAL|Anti-Inflammatory Lifestyle Intervention|Content includes training in empirically-supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with evidence-based behavior change content adapted to meet the needs of EACS. Participants will also receive digital tools to facilitate daily self-monitoring (Fitbit activity monitor, wireless scales, self-monitoring app) and generate information for tailored weekly e-coaching
219005044|NCT06840444|BEHAVIORAL|Firefly Mobile App: A Digital Health Solution for Healthy Sleep in Teens|A six week cognitive behavioral therapy for insomnia program delivered via a mobile app.
219005045|NCT06820476|DRUG|NNC0487-0111|Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
219005046|NCT06820476|DRUG|Placebo (NNC0487-0111)|Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.
219420299|NCT05782166|BEHAVIORAL|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
219420300|NCT02085213|DRUG|Glyceryl Trinitrate|
219420301|NCT02085213|DRUG|Matched Placebo|Matched placebo
219420302|NCT02451436|BEHAVIORAL|Sleep and Media Use Intervention|
219420303|NCT02451436|BEHAVIORAL|Study Skills Control Group|
219420304|NCT05107349|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
219420305|NCT02379390|DRUG|Cabazitaxel XRP6258|
219420306|NCT02379390|DRUG|Ezalutamide|
219420307|NCT02379390|DRUG|Abiraterone acetate|
219420308|NCT02379390|DRUG|Prednisone|
219420309|NCT03079349|OTHER|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
219420310|NCT03079349|OTHER|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
219420311|NCT05164679|BEHAVIORAL|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
219005047|NCT06858150|DIAGNOSTIC_TEST|Ultrasound-Guided Needle Depth and Angle Measurement|This study utilizes ultrasound imaging to measure the needle insertion depth at Jianzhongshu (SI15) and an electronic goniometer to assess insertion angles. The aim is to collect anatomical reference data for acupuncture needling precision, focusing on the relationship between SI15 and the insertion point of the levator scapulae muscle. This is an observational study designed to collect anatomical reference data for acupuncture needling, without evaluating therapeutic effects.
219005048|NCT04818840|DEVICE|Resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
219005049|NCT04818840|PROCEDURE|Un-resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
219573641|NCT06601621|COMBINATION_PRODUCT|sham electroacupuncture + sham self-acupressure|"Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
219573642|NCT06616350|DEVICE|esTOCma: an app to fight stigma associated with OCD|The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
219573643|NCT05283603|DIAGNOSTIC_TEST|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
219573644|NCT04608799|DRUG|Perampanel|Efficacy of epilepsy drugs
219420312|NCT05780593|OTHER|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
219420313|NCT05780593|OTHER|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
219420314|NCT00234728|DEVICE|Occlusive dressing|
219420315|NCT01079429|GENETIC|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
219420316|NCT02687750|DEVICE|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
219573645|NCT04478461|DRUG|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
219573646|NCT00135382|DRUG|Videx EC|
219573647|NCT00135382|DRUG|Epivir|
219759079|NCT00098995|DRUG|tirapazamine|
219759080|NCT00098995|RADIATION|brachytherapy|
219759081|NCT00098995|RADIATION|radiation therapy|
219759082|NCT02522039|DRUG|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
219759083|NCT02522039|DRUG|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
219759084|NCT02522039|DRUG|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
219759085|NCT01455480|DRUG|RPh201, botanical drug product|topical
219759086|NCT05119530|DIAGNOSTIC_TEST|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
219759087|NCT00790673|DRUG|CF 102|Oral capsules
219759088|NCT00790673|DRUG|Placebo|Matching placebo capsules
219759089|NCT05811325|OTHER|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
219759090|NCT05811325|OTHER|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
219759091|NCT02412150|DRUG|Desflurane|Anesthesia is maintained with desflurane
219759092|NCT02412150|DRUG|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
219759093|NCT02412150|PROCEDURE|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
219759094|NCT02412150|OTHER|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
219759095|NCT02412150|BEHAVIORAL|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
219420317|NCT00004278|DRUG|ganciclovir|
219420318|NCT01244191|DRUG|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
219420319|NCT01244191|DRUG|Placebo|Tivantinib Placebo tablets given twice a day
219420320|NCT01244191|DRUG|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
219420321|NCT03160664|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219420322|NCT03160664|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
219420323|NCT03160664|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
219420324|NCT06270693|PROCEDURE|Endodontic treatment|Root canal treatment
219420325|NCT00006248|DRUG|cisplatin|
219420326|NCT00006248|DRUG|fluorouracil|
219420327|NCT00006248|DRUG|paclitaxel|
219420328|NCT03984331|DEVICE|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
219420329|NCT03984331|DEVICE|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
219420330|NCT06233734|DEVICE|The Lokomat (Hocoma, Zurich, Switzerland).|The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
219420331|NCT01667393|DEVICE|IDEV SUPERA Stent|
219420332|NCT01667393|DEVICE|Percutaneous Transluminal Angioplasty|
219420333|NCT04786041|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
219420334|NCT02582580|OTHER|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
219420335|NCT02582580|DEVICE|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
219420336|NCT02582580|OTHER|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
219420337|NCT00810719|DRUG|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
219420338|NCT00810719|DRUG|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
219420339|NCT04344379|DRUG|hydroxychloroquine|200 mg BID per day
219420340|NCT04344379|DRUG|azithromycin|250 mg per day
219420341|NCT04344379|DRUG|hydroxychloroquine placebo|200 mg BID per day
219420342|NCT00598715|DEVICE|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
219420343|NCT00598715|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
219420344|NCT00176670|DRUG|midazolam or GameBoy or parental presence|
219573648|NCT00135382|DRUG|Sustiva|
219573649|NCT05698927|PROCEDURE|Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)|Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
219573650|NCT00522340|BEHAVIORAL|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
219420345|NCT03082495|BEHAVIORAL|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
219420346|NCT04614116|OTHER|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
219420347|NCT04614116|DIAGNOSTIC_TEST|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
219420348|NCT04614116|DIAGNOSTIC_TEST|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
219573651|NCT00286819|DRUG|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
219573652|NCT01949714|PROCEDURE|Removal of adrenal tumor|
219573653|NCT01166555|DRUG|PF-04236921|single subcutaneous dose
219573654|NCT02112721|DIETARY_SUPPLEMENT|Vitamin D|
219573655|NCT02112721|DIETARY_SUPPLEMENT|Placebo|
219573656|NCT04053413|OTHER|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
219573657|NCT05106543|DEVICE|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
219573658|NCT02332408|RADIATION|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
219573659|NCT02332408|RADIATION|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
219573660|NCT00247299|DEVICE|IPL Quantum Product manufactured by Luminis Ltd.|
219573661|NCT01606852|DRUG|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
219573662|NCT00455442|DRUG|Mifepristone|
219573663|NCT03856593|BEHAVIORAL|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking \> 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
219759096|NCT02412150|BEHAVIORAL|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus"
219420349|NCT04316663|BEHAVIORAL|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
219759097|NCT02412150|OTHER|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
219759098|NCT02412150|BEHAVIORAL|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
219759099|NCT02412150|OTHER|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
219759100|NCT02412150|OTHER|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
219759101|NCT02412150|OTHER|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
219759102|NCT02412150|DRUG|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
219759103|NCT02412150|DRUG|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
219759104|NCT01918137|DIETARY_SUPPLEMENT|chocolate bar|
219759105|NCT01918137|DIETARY_SUPPLEMENT|Porridge|
219759106|NCT02803905|BIOLOGICAL|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
219759107|NCT06050980|DRUG|HSK40118|Oral administration, QD
219759108|NCT02972996|OTHER|Blueberry|22 g freeze-dried whole blueberry powder
219759109|NCT02972996|OTHER|Placebo|22 g placebo blueberry powder
219759110|NCT05812326|DRUG|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
219759111|NCT03508050|DEVICE|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
219759112|NCT02625181|PROCEDURE|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
219759113|NCT02625181|PROCEDURE|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
219759114|NCT02625181|PROCEDURE|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
219759115|NCT02625181|PROCEDURE|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
219759116|NCT02625181|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
219759117|NCT02625181|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
219759118|NCT02625181|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
219759119|NCT02625181|PROCEDURE|Elective surgery|Surgical procedures that are scheduled and not an emergency.
219759120|NCT02625181|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
219759121|NCT02625181|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
219759122|NCT02625181|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
219759123|NCT02625181|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
219420350|NCT04316663|BEHAVIORAL|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
219573664|NCT03856593|BEHAVIORAL|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
219573665|NCT02159937|OTHER|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
219759124|NCT02625181|DRUG|Scopolamine|Prophylactic antiemetic
219759125|NCT02625181|DRUG|Droperidol|Prophylactic antiemetic \& rescue antiemetic
219759126|NCT02625181|DRUG|Haloperidol|Prophylactic antiemetic \& rescue antiemetic
219759127|NCT02625181|DRUG|Dexamethasone|Prophylactic antiemetic \& rescue antiemetic
219759128|NCT02625181|DRUG|Promethazine|Prophylactic antiemetic \& rescue antiemetic
219759129|NCT02625181|DRUG|Meclizine|Prophylactic antiemetic \& rescue antiemetic
219759130|NCT02625181|DRUG|Aprepitant|Prophylactic antiemetic \& rescue antiemetic
219759131|NCT02625181|DRUG|Metoclopramide|Rescue antiemetic
219759132|NCT02625181|DRUG|Fentanyl|Analgesic drug / Opioid
219759133|NCT02625181|DRUG|Sufentanil|Analgesic drug / Opioid
219759134|NCT02625181|DRUG|Alfentanil|Analgesic drug / Opioid
219759135|NCT02625181|DRUG|Remifentanil|Analgesic drug / Opioid
219759136|NCT02625181|DRUG|Morphine|Analgesic drug / Opioid
219759137|NCT02625181|DRUG|Meperidine|Analgesic drug / Opioid
219759138|NCT02625181|DRUG|Hydromorphone|Analgesic drug / Opioid
219005050|NCT07131592|DRUG|IV TXA|Patients randomized to the IV TXA group will receive intravenous Tranexamic acid during the procedure. The dose will be 1g IV infused over approx. 10 minutes prior to skin closure (dosing of approx. 15 mg/kg, capped at 1 g, which is within safe limits).
219005051|NCT07131592|DRUG|Topical TXA|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized topical TXA intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the TXA to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
219420351|NCT06692569|OTHER|Conventional Physical Therapy|The conventional Physical Therapy, the treatment will be based on the client's capabilities. It included functional reeducation, muscle strengthening and stretching, muscle tone regulation methods, and training for activities of daily living
219573666|NCT04954378|DIAGNOSTIC_TEST|radiomics|
219573667|NCT04299451|OTHER|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
219573668|NCT06148545|DRUG|Elemental iron|Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
219759139|NCT02625181|DRUG|Methadone|Analgesic drug / Opioid
219759140|NCT02625181|DRUG|Oxycodone|Analgesic drug / Opioid
219759141|NCT02625181|DRUG|Oxymorphone|Analgesic drug / Opioid
219759142|NCT02625181|DRUG|Hydrocodone|Analgesic drug / Opioid
219759143|NCT02625181|DRUG|Ketamine|Analgetic / Analgesic drug
219759144|NCT02625181|DRUG|Ondansetron|Prophylactic antiemetic \& rescue antiemetic
219759145|NCT02625181|DRUG|Granisetron|Prophylactic antiemetic \& rescue antiemetic
219759146|NCT02625181|DRUG|Dolasetron mesylate|Prophylactic antiemetic \& rescue antiemetic
219759147|NCT02625181|DRUG|Palonosetron|Prophylactic antiemetic \& rescue antiemetic
219759148|NCT02625181|DRUG|Tropisetron|Prophylactic antiemetic \& rescue antiemetic
219759149|NCT02625181|DRUG|Ramosetron|Prophylactic antiemetic \& rescue antiemetic
219759150|NCT01542970|DIETARY_SUPPLEMENT|Placebo|Olive oil
219759151|NCT01542970|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
219759152|NCT01542970|DIETARY_SUPPLEMENT|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
219759153|NCT01542970|DIETARY_SUPPLEMENT|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
219759154|NCT03710889|DRUG|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
219573669|NCT06148545|DRUG|Elemental iron and Vit D|Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
219573670|NCT01464554|BEHAVIORAL|Usual care|alcohol and drug education
219573671|NCT01464554|BEHAVIORAL|Project Free Talk|motivational interviewing alcohol and drug program
219573672|NCT01129453|BIOLOGICAL|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
219573673|NCT01129453|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
219573674|NCT04768894|PROCEDURE|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
219573675|NCT02350374|OTHER|carbohydrate counting|"patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner"
219573676|NCT01949116|DRUG|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
219573677|NCT01949116|DRUG|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
219573678|NCT01949116|DIETARY_SUPPLEMENT|Folic acid|1-mg tablet of folic acid by mouth once a day
219573679|NCT05667636|RADIATION|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
219573680|NCT01997021|OTHER|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
219573681|NCT01997021|OTHER|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
219573682|NCT01997021|OTHER|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
219573683|NCT04652284|DRUG|Rifabutin|150 mg
219573684|NCT04652284|DRUG|Amoxicillin|1000 mg
219573685|NCT04652284|DRUG|Esomeprazole|40 mg
219573686|NCT04652284|DRUG|Clarithromycin|500 mg
219573687|NCT04652284|DRUG|Tinidazole|500 mg
219573688|NCT02059330|DRUG|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
219005052|NCT07131592|DRUG|Topical saline|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized saline intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the saline to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
219005053|NCT07131137|BEHAVIORAL|The Life Balance Training Intervention|The Life Balance Training intervention is administering as an individualized, therapist-guided program over a period of eight weeks, comprising two 45-minute sessions per week conducted via videoconferencing platforms. The program's objective was to enhance engagement in meaningful daily activities, promote a sense of life balance, and improve participation in instrumental activities of daily living (IADLs). Each session focused on fundamental components, including goal setting, skills training, activity planning, and problem solving. Caregiver involvement is encouraging when appropriate to support the generalization of skills to the home environment. The sessions commenced with a collaborative goal-setting process, centred on participants' desired modifications to their daily routines and occupational balance. The curriculum encompassed a range of pertinent subjects, including meal preparation, financial management, and time management.
219005054|NCT01804075|DRUG|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
219420352|NCT06692569|OTHER|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy (mCIMT) which involves trunk constraint along with conventional Physical Therapy treatment. Under the attentive guidance of a physiotherapist, the patient engages in specific hand activities aligned with personalized goals. These activities encompass tasks such as picking up marbles, flipping cards, stacking blocks, combing hair, writing, and other actions relevant to daily life. The difficulty level is dynamically adjusted according to the patient's abilities and progress during the training sessions.Tasks may vary from one patient to another, and each session introduces fresh, goal-oriented challenges to further enhance rehabilitation outcomes, along with the conventional physical therapy treatment. The patients were wearing a trunk west which had a Velcro strap on the non-effected side part of the west, and it was attached to the Velcro straps on the non-affected part on the back support of the treatment chair.
219420353|NCT06693323|DRUG|AHCC®capsules|Given PO
219420354|NCT06339333|BEHAVIORAL|ACT Now GAIN Later|ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.
219420355|NCT06339333|OTHER|Control Group|Waitlist Group
219420356|NCT00440427|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
219420357|NCT01883323|DRUG|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
219420358|NCT01883323|DRUG|Fludarabine|i.v., 25mg/m2 per day for 5 days
219420359|NCT01883323|BIOLOGICAL|Tumor-Infiltrating Lymphocytes|i.v., 1x10\^10 - 1.6x10\^11 cells
219420360|NCT01883323|BIOLOGICAL|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
219420361|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
219005055|NCT01804075|DRUG|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
219420362|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
219420363|NCT03699852|RADIATION|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
219420364|NCT03699852|OTHER|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
219420365|NCT01511107|DRUG|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
219420366|NCT01511107|DRUG|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
219420367|NCT01016548|BIOLOGICAL|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
219420368|NCT00078988|BIOLOGICAL|filgrastim|Given IV
219420369|NCT00078988|DRUG|carboplatin|Given IV
219420370|NCT00078988|DRUG|etoposide|Given IV
219420371|NCT00078988|DRUG|isotretinoin|Given IV
219420372|NCT00078988|DRUG|thiotepa|Given IV
219420373|NCT00078988|PROCEDURE|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
219420374|NCT00078988|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
219420375|NCT05349942|DEVICE|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
219420376|NCT01106482|OTHER|Serology blood draw|Blood draw only, no vaccine
219420377|NCT04178135|DRUG|rLH|rLH supplement from day 1 of stimulation
219420378|NCT04178135|DRUG|rLH|rLH supplement from day 6 of stimulation
219420379|NCT05670405|OTHER|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R."
219420380|NCT04080869|DRUG|retinyl palmitate|topical retinyl palmitate loaded ethosomes
219420381|NCT04080869|DRUG|Tretinoin|topical tretinoin
219420382|NCT01830816|DRUG|Ixazomib|Ixazomib capsules
219420383|NCT04437030|DEVICE|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
219420384|NCT05043246|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
219420385|NCT00484549|PROCEDURE|Blood sample|Ischemic stroke hospitalized
219420386|NCT02539355|OTHER|Diet A|12-week diet
219420387|NCT02539355|OTHER|Diet B|12-week Diet
219420388|NCT04173871|DEVICE|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
219420389|NCT00511953|DRUG|Gabapentin Extended Release tablets|1800mg
219420390|NCT00511953|DRUG|Gabapentin|1800mg
219420391|NCT06481657|OTHER|train with oxygen and without oxygen enrichment (placebo).|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
219420392|NCT05186909|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
219420393|NCT05186909|OTHER|Placebo|Placebo
219420394|NCT03054987|PROCEDURE|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
219420395|NCT03054987|PROCEDURE|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
219420396|NCT01372371|BIOLOGICAL|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
219573689|NCT02059330|DRUG|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
219573690|NCT02059330|DRUG|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
219573691|NCT02059330|DRUG|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
219573692|NCT02059330|DRUG|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
219573693|NCT00331071|DRUG|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
219573694|NCT00331071|DRUG|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
219573695|NCT01778153|BEHAVIORAL|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
219420397|NCT01372371|BIOLOGICAL|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
219420398|NCT01372371|BIOLOGICAL|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
219420399|NCT00363051|DRUG|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
219420400|NCT00363051|DRUG|Octreotide Depot|
219420401|NCT02028585|DIETARY_SUPPLEMENT|Low-fat milk group|
219420402|NCT02411383|DEVICE|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
219420403|NCT04509804|OTHER|non-interventional|non-interventional
219420404|NCT00648141|DRUG|Celecoxib|200 mg oral capsule once daily for 12 weeks
219420405|NCT00648141|DRUG|Celecoxib|200 mg oral capsule twice daily for 12 weeks
219420406|NCT00648141|DRUG|Diclofenac|75 mg oral capsule twice daily for 12 weeks
219420407|NCT02384772|OTHER|Survey|
219420408|NCT03768895|RADIATION|MRI|"The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI."
219420409|NCT06051825|DIAGNOSTIC_TEST|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
219420410|NCT03053726|PROCEDURE|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
219420411|NCT06348953|OTHER|selective caries removal and conventional non-bioactive restorative system|conventional dental restorative adhesive and resin based composite
219420412|NCT06348953|OTHER|selective caries removal and bioactive restorative system|bioactive dental restorative resin based system
219005056|NCT02175498|DRUG|Homoeopathic medicines|4 pills once a week of the indicated Similimum
219005057|NCT07132346|OTHER|AGING ANXIETY SCALE|This study was conducted as descriptive research to determine the mediating role of aging anxiety in the relationship between maternal ambivalence and pregnancy avoidance in women.
219420413|NCT02433860|BEHAVIORAL|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery."
219420414|NCT02409056|BEHAVIORAL|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
219420415|NCT02409056|BEHAVIORAL|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
219573696|NCT00234455|DEVICE|drug eluting-stent|PCI
219573697|NCT00234455|DEVICE|drug-eluting stent|PCI
219573698|NCT00408564|BIOLOGICAL|cetuximab|
219573699|NCT00408564|DRUG|capecitabine|
219573700|NCT00408564|DRUG|oxaliplatin|
219573701|NCT00408564|PROCEDURE|conventional surgery|
219573702|NCT00408564|RADIATION|radiation therapy|
219573703|NCT00408564|DRUG|Gemcitabine|
219573704|NCT03261479|DIAGNOSTIC_TEST|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
219573705|NCT05040178|DRUG|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
219573706|NCT03446352|OTHER|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
219005058|NCT05305105|DRUG|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
219005059|NCT07124624|DEVICE|AI-Assisted CTA Interpretation|A locked, independently validated deep learning model was used to assist radiologists in interpreting head CTA scans. The model was trained on 16,546 CTA cases and externally validated on an independent set of 900 DSA-verified CTA cases, achieving a patient-level sensitivity of 0.943 and an average of 0.187 false positives per case.
219005060|NCT07124624|DIAGNOSTIC_TEST|Standard CTA Interpretation|Head CTA interpretation performed by radiologists using local routine diagnostic workflows without AI support.
219005061|NCT07124949|OTHER|No intervention|no intervention
219005062|NCT07126834|BEHAVIORAL|VIH|During the experimental session, they additionally performed a 5-minute VIH session (20 breaths/minute) after 1 hour of hypoxic exposure. Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc., Kelowna, British Columbia, Canada) equipped with 6-liter breathing bags were employed to perform VIH. The accompanying Isocapnic mobile app was used to guide breathing rhythm and monitor session duration.
219420416|NCT03342456|DRUG|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
219420417|NCT03342456|DRUG|Amoxicillin Capsules|group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
219420418|NCT03342456|DRUG|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
219420419|NCT03342456|DRUG|Furazolidone Tablets|group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
219420420|NCT03342456|DRUG|Potassium Citrate Tablets|group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
219420421|NCT04169685|PROCEDURE|bronchoscopy|during flexible bronchoscopy
219420422|NCT03678376|OTHER|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
219420423|NCT00129792|DRUG|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
219420424|NCT00129792|BEHAVIORAL|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
219420425|NCT03746808|BEHAVIORAL|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
219420426|NCT00830115|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
219420427|NCT00139607|DRUG|Paracoxib|
219420428|NCT02928380|DEVICE|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
219420429|NCT02928380|DEVICE|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
219420430|NCT01861145|DEVICE|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
219759155|NCT02648945|OTHER|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
219759156|NCT00133445|BIOLOGICAL|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
219759157|NCT00133445|BIOLOGICAL|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
219759158|NCT00133445|DRUG|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
219759159|NCT03700177|DRUG|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
219759160|NCT03700177|DRUG|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
219759161|NCT03700177|DRUG|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
219759162|NCT01159093|BEHAVIORAL|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
219759163|NCT01159093|BEHAVIORAL|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
219759164|NCT01159093|OTHER|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
219759165|NCT01159093|OTHER|Control|Usual care
219759166|NCT00894595|BEHAVIORAL|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
219759167|NCT05725122|PROCEDURE|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
219759168|NCT05725122|PROCEDURE|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
219759169|NCT04098705|OTHER|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
219759170|NCT05758324|DIETARY_SUPPLEMENT|Nutri PNEA|4 sequences of 10 tablets (one intake)
219759171|NCT05758324|DIETARY_SUPPLEMENT|Placebo|4 sequences of 10 tablets (one intake)
219759172|NCT04034888|BEHAVIORAL|HEX|HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
219759173|NCT03643081|DEVICE|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
219759174|NCT03254784|DRUG|BMS-986165 Capsule|Oral capsule
219759175|NCT03254784|DRUG|BMS-986165 Tablet|Oral tablet
219759176|NCT00180284|DEVICE|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
219420431|NCT01861145|DRUG|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
219420432|NCT04779632|DIETARY_SUPPLEMENT|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
219420433|NCT04779632|DIETARY_SUPPLEMENT|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
219420434|NCT00352950|DRUG|AMG 954/Panitumumab|
219573707|NCT03446352|OTHER|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
219573708|NCT03347552|BEHAVIORAL|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
219573709|NCT03199313|DRUG|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
219420435|NCT05720273|DRUG|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
219420436|NCT04826913|DEVICE|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
219420437|NCT05897112|DRUG|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
219420438|NCT05897112|DRUG|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
219573710|NCT03199313|DRUG|Placebo|Matching Sutezolid placebo
219573711|NCT02485821|DRUG|Estradiol|
219573712|NCT02485821|DRUG|Placebo|
219573713|NCT02485821|DRUG|Misoprostol|
219573714|NCT02427984|OTHER|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
219573715|NCT02427984|OTHER|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
219573716|NCT02427984|OTHER|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
219573717|NCT05530473|DEVICE|capsular tension ring|To insert a capsular tension ring during the cataract surgery
219573718|NCT00549016|DEVICE|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
219573719|NCT06402682|PROCEDURE|Right approach|Right approach of the management of esophageal atresia with a right aortic arch
219573720|NCT06402682|PROCEDURE|Left approach|Left approach of the management of esophageal atresia with a right aortic arch
219573721|NCT04948229|OTHER|Blood serum samples|Blood serum samples will be taken.
219573722|NCT03443518|PROCEDURE|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
219573723|NCT03443518|PROCEDURE|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
219573724|NCT03443518|DRUG|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
219573725|NCT03443518|DRUG|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
219573726|NCT04474782|DIAGNOSTIC_TEST|There is not an intervention|There is not an intervention
219573727|NCT01524913|DRUG|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
219573728|NCT01524913|DRUG|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
219573729|NCT01524913|DRUG|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
219573730|NCT02560441|OTHER|chemotherapy followed by radiotherapy|
219573731|NCT02560441|OTHER|radiotherapy followed by chemotherapy|
219573732|NCT02560441|DRUG|IPGDP regimen chemotherapy|
219573733|NCT03257150|PROCEDURE|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
219573734|NCT03257150|DEVICE|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
219573735|NCT04706923|DRUG|BCV|Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
219573736|NCT04334655|OTHER|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
219573737|NCT05859321|OTHER|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
219573738|NCT05859321|OTHER|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
219573739|NCT01783002|RADIATION|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
219573740|NCT01783002|RADIATION|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
219573741|NCT01783002|RADIATION|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
219573742|NCT00005823|DRUG|cytarabine|
219573743|NCT00005823|DRUG|daunorubicin hydrochloride|
219573744|NCT00005823|DRUG|etoposide|
219573745|NCT00005823|DRUG|hydroxyurea|
219573746|NCT00005823|DRUG|idarubicin|
219573747|NCT00005823|DRUG|mitoxantrone hydrochloride|
219573748|NCT00005823|DRUG|thioguanine|
219573749|NCT00005823|DRUG|tretinoin|
219573750|NCT00005823|DRUG|valspodar|
219573751|NCT04363749|OTHER|hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint|the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
219573752|NCT03596736|PROCEDURE|Elbow Hemiarthroplasty|
219573753|NCT03596736|PROCEDURE|Total Elbow Arthroplasty|
219573754|NCT00644384|DRUG|acitretin|
219573755|NCT00644384|GENETIC|gene expression analysis|
219573756|NCT00644384|GENETIC|northern blotting|
219573757|NCT00644384|GENETIC|polymerase chain reaction|
219573758|NCT00644384|GENETIC|protein expression analysis|
219573759|NCT00644384|OTHER|laboratory biomarker analysis|
219573760|NCT04667702|BEHAVIORAL|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
219573761|NCT03339505|DIETARY_SUPPLEMENT|Salovum|Dietary supplement with high concentration of anti-secretory factor
219573762|NCT03339505|DIETARY_SUPPLEMENT|Placebo|Placebo for Salovum
219573763|NCT04566705|OTHER|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
219573764|NCT04054128|DRUG|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
219573765|NCT04054128|DRUG|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
219573766|NCT01870245|DRUG|ACHN-975|Intravenous multiple dose
219573767|NCT01870245|DRUG|placebo|Intravenous multiple dose
219573768|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (low dose)|
219573769|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (high dose)|
219573770|NCT00794976|DRUG|Dexamethasone Passive Patch|
219573771|NCT00794976|DRUG|Placebo Patch|
219573772|NCT04871516|OTHER|Quality-of-Life Assessment|Ancillary studies
219573773|NCT04871516|OTHER|Questionnaire Administration|Ancillary studies
219573774|NCT04871516|RADIATION|Radiation Boost|Undergo radiation therapy boost
219573775|NCT04871516|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard surgery
219573776|NCT04871516|RADIATION|Whole Breast Irradiation|Undergo standard WBI
219573777|NCT04871516|OTHER|Breast MRI|A baseline breast MRI
219573778|NCT03126422|DRUG|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
219420439|NCT03050216|BIOLOGICAL|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
219420440|NCT03310437|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
219420441|NCT06060756|OTHER|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire"
219420442|NCT01207388|DRUG|Blinatumomab|Continuous intravenous infusion
219420443|NCT01885078|DRUG|Baricitinib|Administered orally
219420444|NCT01885078|DRUG|Placebo|Administered orally
219420445|NCT04146571|DRUG|Ensartinib|Oral, ALK inhibitor
219420446|NCT01885858|BEHAVIORAL|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
219420447|NCT01885858|BEHAVIORAL|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
219420448|NCT00155454|PROCEDURE|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
219420449|NCT03115112|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
219420450|NCT03115112|DRUG|Sitagliptin|tablets containing 100 mg sitagliptin
219420451|NCT03115112|DRUG|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
219420452|NCT03115112|DRUG|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
219420453|NCT04622085|DEVICE|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
219420454|NCT04622085|DEVICE|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
219420455|NCT01680978|DRUG|aleglitazar|150 mcg orally daily, 6 weeks
219420456|NCT01680978|DRUG|placebo|orally daily, 6 weeks
219420457|NCT05027256|DEVICE|Entia Liberty|Home Monitoring solution
219420458|NCT02466568|DRUG|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
219420459|NCT02466568|BIOLOGICAL|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
219420460|NCT03662633|DIAGNOSTIC_TEST|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
219420461|NCT03662633|DIAGNOSTIC_TEST|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
219420462|NCT05415345|BIOLOGICAL|Cecolin|Bivalent HPV Vaccine
219420463|NCT05415345|BIOLOGICAL|Hecolin|Hepatitis E vaccine
219420464|NCT03554070|PROCEDURE|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
219420465|NCT03554070|DEVICE|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
219573779|NCT05654194|DRUG|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
219573780|NCT02305173|DRUG|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
219573781|NCT02305173|DRUG|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
219420466|NCT00624728|RADIATION|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
219005063|NCT07131501|PROCEDURE|Radical surgery|Radical surgery
219005064|NCT07131501|PROCEDURE|TACE treatment|TACE treatment (cTACE, Idarubicin): Preoperative: 1 session; Postoperative: 1 session.
219420467|NCT01546285|DEVICE|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
219420468|NCT04689672|DIAGNOSTIC_TEST|Lung ultrasound|Bedside lung ultrasound
219420469|NCT01755312|DEVICE|Medication reminder|Medication reminder
219420470|NCT05843071|DEVICE|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
219420471|NCT05353101|DRUG|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
219420472|NCT05353101|DRUG|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
219420473|NCT03979027|DIETARY_SUPPLEMENT|Breakfast: ready-to-eat-cereal and milk|
219420474|NCT03317249|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram
219420475|NCT03317249|DIAGNOSTIC_TEST|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
219420476|NCT03317249|DIAGNOSTIC_TEST|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
219420477|NCT03317249|DIAGNOSTIC_TEST|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
219420478|NCT03317249|OTHER|Echocardiogram|optional (for non-IST participants only)
219420479|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
219420480|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
219420481|NCT05889351|DRUG|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
219420482|NCT05889351|DRUG|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
219420483|NCT05889351|DRUG|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
219420484|NCT04019795|DEVICE|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
219420485|NCT04019795|DEVICE|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
219420486|NCT04019795|DEVICE|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
219420487|NCT04019795|DEVICE|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
219420488|NCT05396313|DEVICE|CRT/ICD|The patients received implantation of CRT/ICD.
219420489|NCT06436729|PROCEDURE|Splinting|The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices
219420490|NCT06436729|PROCEDURE|MINST alone|Minimally invasive non surgical therapy alone
219420491|NCT03492645|BEHAVIORAL|Telephone-and technology-facilitated treatment protocol|"1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
219420492|NCT03492645|BEHAVIORAL|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
219420493|NCT05189158|DIAGNOSTIC_TEST|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
219573782|NCT01783652|BEHAVIORAL|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
219573783|NCT04430127|OTHER|No supplementary intervention is performed|No supplementary intervention will be applied
219573784|NCT01038037|DRUG|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
219573785|NCT01038037|DRUG|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
219573786|NCT01038037|DRUG|panitumumab|i.v. day 1: 9 mg/kg q3w
219573787|NCT00788593|DRUG|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
219573788|NCT00788593|DRUG|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
219573789|NCT00788593|DRUG|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
219573790|NCT03653494|PROCEDURE|phrenic block|phrenic block by 1% ropivacaine 5ml
219573791|NCT03653494|PROCEDURE|no phrenic block|no phrenic block
219573792|NCT05361291|DRUG|Lidocaine Hydrochloride|Inferior alveolar nerve block
219573793|NCT02671682|PROCEDURE|Immunoadsorption|
219573794|NCT02671682|PROCEDURE|Plasmapheresis|
219573795|NCT00745719|PROCEDURE|parathyroidectomy|total parathyroidectomy with forearm autografting
219573796|NCT04226131|OTHER|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
219759177|NCT03425955|DEVICE|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
219573797|NCT04226131|OTHER|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
219573798|NCT04226131|OTHER|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
219573799|NCT04226131|OTHER|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
219573800|NCT04226131|OTHER|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
219420494|NCT05189158|DIAGNOSTIC_TEST|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
219759178|NCT03425955|DEVICE|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
219759179|NCT03076684|OTHER|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
219759180|NCT03076684|DRUG|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
219759181|NCT00570713|DRUG|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
219759182|NCT00570713|DRUG|Placebo|As per package insert.
219759183|NCT00570713|DRUG|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
219759184|NCT04982952|BEHAVIORAL|Contingency Management - Increasing|Increasing incentive payment for abstinent participant
219759185|NCT04982952|BEHAVIORAL|Fixed payments|Fixed payments for attending study visits
219759186|NCT02431156|OTHER|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
219759187|NCT01649713|DRUG|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
219759188|NCT00776360|DRUG|oxytocin|80mIE/min as continuous infusion for 70 minutes
219759189|NCT00776360|DRUG|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
219759190|NCT03498573|OTHER|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
219759191|NCT04881760|DRUG|LY3437943|Administered SC
219759192|NCT04881760|DRUG|Placebo|Administered SC
219759193|NCT06513533|OTHER|Placebo|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
219759194|NCT06513533|DRUG|Dimethyl fumarate|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
219759195|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
219759196|NCT04769869|DRUG|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
219759197|NCT04769869|DRUG|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
219759198|NCT04769869|DRUG|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
219759199|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
219759200|NCT05873088|DIAGNOSTIC_TEST|Isometric|Effects of Isometric Exercise in Female Patients With Osteoarthritis
219759201|NCT05873088|DIAGNOSTIC_TEST|Isotonic Exercise|Effects of Isotonic Exercise in Female Patients With Osteoarthritis
219759202|NCT00240266|DRUG|Rosuvastatin|
219759203|NCT05495581|DRUG|pudexacianinium chloride|Intravenous
219759204|NCT02133079|BIOLOGICAL|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
219759205|NCT05993741|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
219759206|NCT05994352|OTHER|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
219759207|NCT02081586|BEHAVIORAL|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
219759208|NCT02081586|DEVICE|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
219759209|NCT02081586|OTHER|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
219759210|NCT02460276|DRUG|Lenalidomide|
219759211|NCT02460276|DRUG|Ibrutinib|
219759212|NCT02460276|DRUG|Rituximab|
219420495|NCT04430660|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
219420496|NCT04430660|DEVICE|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
219420497|NCT03071705|DRUG|Metformin|500 mg PO BID
219420498|NCT03071705|DRUG|TKI|standard dose
219420499|NCT01518712|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
219420500|NCT01518712|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
219420501|NCT02750904|BEHAVIORAL|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
219420502|NCT02750904|BEHAVIORAL|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
219420503|NCT03019224|PROCEDURE|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
219759213|NCT02118155|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
219759214|NCT04017234|OTHER|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
219759215|NCT05513963|BEHAVIORAL|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
219759216|NCT03904160|BEHAVIORAL|Weight management|Please see the arm descriptions.
219759217|NCT03393104|BEHAVIORAL|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
219759218|NCT03393104|BEHAVIORAL|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
219759219|NCT03722810|OTHER|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
219759220|NCT03722810|OTHER|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
219759221|NCT03601299|OTHER|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
219759222|NCT05802901|PROCEDURE|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
219759223|NCT05802901|PROCEDURE|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
219759224|NCT05802901|PROCEDURE|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
219759225|NCT04146155|DRUG|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
219759226|NCT04146155|OTHER|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
219759227|NCT04613388|OTHER|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
219759228|NCT00951392|DRUG|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
219573801|NCT04226131|OTHER|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
219573802|NCT04226131|OTHER|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
219573803|NCT04226131|OTHER|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
219573804|NCT04226131|OTHER|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
219573805|NCT06236256|DEVICE|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
219573806|NCT06236256|OTHER|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
219573807|NCT03020719|DRUG|Oral Glutathione|Oral Glutathione oral powder
219573808|NCT03020719|DRUG|Placebo|Placebo oral powder
219573809|NCT00339872|DRUG|IMA-638|
219005065|NCT07131501|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. Neoadjuvant: 2 cycles; Adjuvant: up to 17 cycles.
219005066|NCT07131501|DRUG|Lenvatinib|Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), orally (PO), once daily (QD), Q3W. Consistent daily timing. Neoadjuvant: 2 cycles.
219005067|NCT07132229|OTHER|Cervical High-Intensity Resistive Exercises|The patient will wear a neck harness, and a weight equivalent to 90% of the patient's measured maximum voluntary isometric contraction (MVIC) will be attached to it.
219005068|NCT07132229|OTHER|Conventional physical therapy|Conventional physical therapy consisting of TENS for pain control, soft tissue release for the cervical and associated muscles, activation and strengthening exercises for the deep neck flexors, extensors, and scapular muscles, as well as diaphragmatic breathing exercises.
219420504|NCT03019224|PROCEDURE|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
219420505|NCT03019224|PROCEDURE|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
219420506|NCT03019224|PROCEDURE|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
219420507|NCT03019224|PROCEDURE|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
219420508|NCT03019224|DRUG|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
219420509|NCT03019224|PROCEDURE|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
219420510|NCT02942316|DEVICE|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure"
219420511|NCT04102735|DEVICE|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
219420512|NCT04102735|DEVICE|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
219420513|NCT02417467|OTHER|Nicotine E-Cigarette|
219420514|NCT02417467|OTHER|Non-Nicotine E-Cigarette|
219420515|NCT02417467|BEHAVIORAL|Counseling|
219420516|NCT02043405|BEHAVIORAL|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
219420517|NCT02043405|BEHAVIORAL|Weight loss Only Intervention|Weight loss Only Intervention
219420518|NCT05638763|DRUG|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
219420519|NCT05638763|DRUG|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
219420520|NCT02035150|DIETARY_SUPPLEMENT|Oatmeal|A breakfast consisting of oatmeal
219420521|NCT02035150|DIETARY_SUPPLEMENT|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
219420522|NCT02035150|DIETARY_SUPPLEMENT|No Breakfast|A breakfast consisting of plain water
219573810|NCT04497272|OTHER|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
219573811|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
219573812|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
219573813|NCT00515034|DRUG|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
219573814|NCT00515034|DRUG|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
219420523|NCT00091845|DRUG|AVI-4020 Injection|
219420524|NCT02875847|DIETARY_SUPPLEMENT|HMO1|
219420525|NCT02875847|DIETARY_SUPPLEMENT|HMO2|
219420526|NCT02875847|DIETARY_SUPPLEMENT|Dextropur|
219420527|NCT02168803|DRUG|Evacetrapib|Administered orally
219420528|NCT05904184|DRUG|Epoxy resin-based sealers (ERS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
219420529|NCT05904184|DRUG|Calcium silicate-based sealers (CSS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
219420530|NCT01806636|DEVICE|PneumRx Coil System|
219190969|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
219420531|NCT04314479|BEHAVIORAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
219420532|NCT04807036|DEVICE|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
219190970|NCT06822556|DIETARY_SUPPLEMENT|Placebo|14 days of supplementation with 25 mg/day hemicellulose crystalline
219190971|NCT06822556|DIETARY_SUPPLEMENT|Tetraselmis chuii|14 days of supplementation with 25 mg/day tetraselmis chuii
219420533|NCT03579550|PROCEDURE|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
219420534|NCT02808741|DRUG|F901318 SDD|Pharmacokinetics area under curve
219420535|NCT02808741|DRUG|F901318 IR|Pharmacokinetics area under curve
219420536|NCT02808741|DRUG|F901318 IR Fasting|Pharmacokinetics area under curve
219420537|NCT02808741|DRUG|F901318 IR Fed|Pharmacokinetics area under curve
219420538|NCT01310816|DRUG|IPI-926|Oral
219420539|NCT01310816|DRUG|Placebo Arm|oral placebo
219420540|NCT03448861|DEVICE|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
219420541|NCT00283998|PROCEDURE|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
219420542|NCT00120653|DRUG|Metoclopramide|
219005069|NCT07133243|OTHER|testicular ultrasound|each patient will receive an testicular ultrasound to confirm diagnostic of testicular torsion
219190972|NCT03016156|OTHER|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
219420543|NCT00377910|DRUG|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
219190973|NCT03016156|OTHER|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
219190974|NCT06281834|DRUG|Rifapentine|Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
219420544|NCT05122195|OTHER|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
219420545|NCT02484612|BEHAVIORAL|acute exercise|
219573815|NCT05154552|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
219573816|NCT05154552|OTHER|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
219573817|NCT05482204|OTHER|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
219573818|NCT05482204|OTHER|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
219573819|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
219573820|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
219190975|NCT06281834|DRUG|Dolutegravir|All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
219190976|NCT05377957|OTHER|Quality of life questionnaires|Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
219190977|NCT05377957|OTHER|Discrete choice experiment|Assessment of patient preferences for outcomes of proton therapy and enucleation
219190978|NCT05377957|OTHER|Shared decision-making analysis|Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
219190979|NCT05377957|OTHER|Impact of side-effects analysis|Assessment of the impact of side-effects by questionnaire
219190980|NCT04098250|DRUG|Erenumab|a CGRP receptor monoclonal antibody
219190981|NCT04098250|OTHER|Placebo|Placebo
219573821|NCT01965184|BEHAVIORAL|Cognitive-Behavioral Therapy for Anger and Aggression|
219573822|NCT01965184|BEHAVIORAL|Supportive Psychotherapy (SPT)|
219420546|NCT03016546|BEHAVIORAL|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
219420547|NCT03016546|BEHAVIORAL|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
219420548|NCT01114373|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
219420549|NCT01114373|DRUG|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
219759229|NCT00951392|PROCEDURE|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip"
219420550|NCT03709524|DEVICE|Airtraq + fiberoptic|video laryngoscope with a monitor
219420551|NCT03709524|DEVICE|Airtraq|video laryngoscope with a monitor
219420552|NCT03709524|DEVICE|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
219759230|NCT00951392|DEVICE|indirect calorimetry|energy expenditure measurement
219759231|NCT05296161|DRUG|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
219759232|NCT04033692|DEVICE|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
219759233|NCT01677988|DRUG|Neo-adjuvant Chemotherapy|"1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
219759234|NCT01677988|RADIATION|Chemoradiation|"1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection"
219759235|NCT01677988|PROCEDURE|Surgical Resection|"1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
219759236|NCT00928772|DEVICE|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
219759237|NCT00928772|DRUG|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
219759238|NCT00928772|OTHER|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
219759239|NCT00544206|OTHER|standard enteral feeding product|16 hrs daily x 5 days
219759240|NCT00544206|OTHER|Diabetes specific feeding product|16 hrs daily for 5 days
219759241|NCT01332656|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
219759242|NCT01332656|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
219759243|NCT01332656|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
219759244|NCT01332656|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
219759245|NCT00499837|DRUG|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
219759246|NCT04955184|DEVICE|non-invasive monitoring|non-invasive measurements of cardiac output
219759247|NCT05687370|PROCEDURE|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
219759248|NCT05687370|PROCEDURE|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
219759249|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219759250|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219759251|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219759252|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219005070|NCT07132710|OTHER|Semi-structured interviews|Patients and caregivers will be interviewed about the barriers and facilitators to the use of VR masks in the management of pain and anxiety, in order to propose organizational changes that encourage their use.
219420553|NCT00934427|DRUG|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
219420554|NCT00934427|DRUG|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
219420555|NCT02527122|DIAGNOSTIC_TEST|Allergen extracts|
219420556|NCT04091230|DEVICE|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
219759253|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219759254|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219005071|NCT07131150|BIOLOGICAL|SC01009 injection|Menstrual Blood-Derived Mesenchymal Stem Cell (Product Code: SC01009) Injection is a cell therapy product developed by Zhejiang Sinocord Precision Medicine Technology Co., Ltd. The active component consists of mesenchymal stem cells (MSCs) derived from menstrual blood.
219005072|NCT07131150|BIOLOGICAL|Placebo Group(Vehicle)|The placebo consists of the SC01009 Injection formulation solution, containing all components identical to the active product except for the absence of mesenchymal stem cells.
219005073|NCT07132554|OTHER|Combined 1:1 MICT and HIIT aerobic cardiac rehabilitation|Combining 1:1 MICT and HIIT in short (4 weeks) high-volume (32 sessions) early-to-very-early phase program post heart transplantation
219190982|NCT03221309|OTHER|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
219190983|NCT06313957|BIOLOGICAL|LUCAR-20SP cells|Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219190984|NCT04101357|DRUG|BNT411|intravenous
219190985|NCT04101357|DRUG|Atezolizumab|intravenous
219759255|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219420557|NCT05991674|DIAGNOSTIC_TEST|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
219420558|NCT01504386|PROCEDURE|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
219420559|NCT01504386|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
219420560|NCT03110146|DEVICE|EnSite Precision|Ablation procedure
219759256|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
219759257|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
219759258|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
219759259|NCT02361892|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
219759260|NCT03888560|DEVICE|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
219759261|NCT05364450|BEHAVIORAL|Enhanced Usual Care|"Interventionists will provide a brief explanation of the intervention and coaching to the group on how to utilize the resources provided. Prior to the single session group, EUC participants will have received a workbook with the National Cancer Institute's Facing Forward: Life After Cancer Treatment booklet on maximizing quality of life during cancer survivorship and the American Society of Clinical Oncology's Guide to Cancer Survivorship."
219190986|NCT04101357|DRUG|Carboplatin|intravenous
219759262|NCT05364450|BEHAVIORAL|Acceptance Commitment Therapy|Interventionists will support participants in adopting a psychologically flexible posture toward FCR through six interdependent processes of change - acceptance, cognitive defusion, mindfulness, perspective taking, values, and committed action. During ACT sessions, participants will learn to respond adaptively to FCR by being more fully aware of thoughts, feelings, and bodily sensations without judging or attempting to control or avoid them. Participants will also clarify their deeply-held values and set action goals in alignment with their values.
219759263|NCT05364450|BEHAVIORAL|Cognitive Behavioral Therapy|Interventionists will provide psycho-education on the cognitive behavioral model of FCR and assist participants in changing unhelpful thinking patterns and maladaptive behaviors linked to FCR. Session topics will include FCR triggers, behavioral experiments to reduce FCR-perpetuating safety behaviors, and pleasant events scheduling. Interventionists will also provide evidence-based information on behaviors that may reduce recurrence risk (e.g., achieving a healthy weight, physical activity, cancer surveillance).
219759264|NCT03634956|DRUG|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
219759265|NCT00271544|DEVICE|Pacing Lead|implant and follow-up of study device
219759266|NCT05663684|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
219759267|NCT05663684|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
219759268|NCT05754866|PROCEDURE|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
219759269|NCT05754866|PROCEDURE|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
219759270|NCT06564064|DEVICE|abdominal binder|study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
219759271|NCT05700409|BEHAVIORAL|Intensive lifestyle consultations|detailed above
219759272|NCT05595109|DRUG|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
219759273|NCT05595109|DRUG|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
219759274|NCT03358030|DRUG|ISIS 416858|Subcutaneous injection
219759275|NCT03358030|DRUG|Placebo|Subcutaneous injection
219759276|NCT02445209|OTHER|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
219759277|NCT02445209|OTHER|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
219759278|NCT04887532|DRUG|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
219759279|NCT03445312|BEHAVIORAL|not processing urine cultures|microbiology lab will not process culture unless called
219759280|NCT04894682|BIOLOGICAL|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
219759281|NCT02433938|PROCEDURE|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
219759282|NCT02433938|PROCEDURE|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
219759283|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
219759284|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
219759285|NCT06324032|PROCEDURE|EUS Elastography (EUS-E)|All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
219759286|NCT00652171|DRUG|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
219759287|NCT00652171|DIETARY_SUPPLEMENT|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
219759288|NCT04487509|OTHER|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
219759289|NCT03361878|DRUG|Metformin Hydrochloride|Single dose of 500mg oral metformin
219759290|NCT04314622|DRUG|Supaglutide|Administered SC
219759291|NCT04314622|DRUG|Placebo|Administered SC
219759292|NCT00158093|DRUG|Nebivolol|
219759293|NCT00158093|DRUG|Atenolol|
219759294|NCT00158093|DRUG|Moxifloxacin|
219759295|NCT03973957|DEVICE|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
219759296|NCT03973957|DRUG|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
219759297|NCT03973957|DRUG|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
219759298|NCT03973957|DEVICE|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
219759299|NCT02623244|PROCEDURE|Laparoscopic oophorocystectomy or oophorectomy|
219759300|NCT01472731|OTHER|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
219759301|NCT01472731|DRUG|GC1008|5 mg/kg intravenous use
219190987|NCT04101357|DRUG|Etoposide|intravenous
219190988|NCT05015348|OTHER|fish oil with omega-3 PUFA|3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
219190989|NCT05015348|OTHER|placebo|palm oil as placebo
219190990|NCT05868382|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219420561|NCT01396239|DRUG|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
219005074|NCT07131774|OTHER|Filling in a symptom diary|"Each patient will receive a diary form in which they are asked to record their symptoms, body temperature, and body weight on a daily basis. This approach is intended to provide a comprehensive overview of the disease course and the impact of treatment over time.~Depending on hospitalization status, disease severity, treatment progress, and national treatment guidelines, clinical, microbiological, and radiological follow-up assessments will be performed as part of routine care at intervals ranging from weekly to monthly. No additional study visits or microbiological or radiological diagnostics outside of standard clinical care will be conducted."
219005075|NCT00221273|PROCEDURE|ACL surgery|
219005076|NCT02367677|OTHER|Method comparison|
219420562|NCT01396239|OTHER|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
219420563|NCT01107405|DRUG|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
219420564|NCT01107405|DRUG|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
219420565|NCT01107405|DRUG|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
219420566|NCT01107405|DRUG|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
219420567|NCT01107405|DRUG|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
219420568|NCT03255993|DRUG|SPH3127 50mg|SPH3127 50mg
219420569|NCT03255993|DRUG|SPH3127 100mg|SPH3127 100mg
219420570|NCT03255993|DRUG|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
219420571|NCT03255993|DRUG|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
219420572|NCT01404442|DRUG|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
219005077|NCT03542981|DEVICE|Interferential Current|
219005078|NCT03542981|DEVICE|Sham Interferential Current|
219005079|NCT04784949|PROCEDURE|portland cement|pulpotomy with PRF and white Portland cement
219420573|NCT01404442|DRUG|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
219420574|NCT01404442|DRUG|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
219420575|NCT01827930|DRUG|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
219005080|NCT04784949|PROCEDURE|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
219005081|NCT04784949|PROCEDURE|Biodentine|pulpotomy with PRF and Biodentine
219005082|NCT04016753|DRUG|BMS-986256|30 mg(6ml)
219005083|NCT04016753|DRUG|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
219420576|NCT01827930|DRUG|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
219420577|NCT01827930|DRUG|Imatinib Mesylate|Imatinib Mesylate for CP CML
219420578|NCT01608399|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
219420579|NCT05140395|DIAGNOSTIC_TEST|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
219420580|NCT03991884|DRUG|Etoposide|Given IV
219420581|NCT03991884|DRUG|Doxorubicin|Given IV
219420582|NCT03991884|DRUG|Vincristine|Given IV
219420583|NCT03991884|DRUG|Prednisone|Given PO or IV
219420584|NCT03991884|DRUG|Cyclophosphamide|Given IV
219420585|NCT03991884|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219759302|NCT02727608|DRUG|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
219759303|NCT02009579|DRUG|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
219759304|NCT02009579|DRUG|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
219759305|NCT04069442|OTHER|This is a non-interventional study|This is a non-interventional study
219759306|NCT00755170|DRUG|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
219759307|NCT00755170|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
219759308|NCT01298336|DRUG|Clarithromycin|500 mg twice a day seven days a week
219759309|NCT01298336|DRUG|Moxifloxacin|400 mg per day seven days a week
219759310|NCT04597749|DIAGNOSTIC_TEST|PSG|In-lab sleep polysomnography test
219759311|NCT04597749|DIAGNOSTIC_TEST|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
219759312|NCT04597749|OTHER|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
219759313|NCT05415488|OTHER|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
219759314|NCT04400825|OTHER|Dry needling|Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
219759315|NCT02604511|DRUG|Ibrutinib|
219005084|NCT00524368|DRUG|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
219005085|NCT00524368|DRUG|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
219190991|NCT05868382|BIOLOGICAL|mRNA-1010.4|Sterile liquid for injection
219420586|NCT06192953|OTHER|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
219420587|NCT01895452|DRUG|ALKS 9072, Low Dose|Intramuscular injection, given monthly
219420588|NCT01895452|DRUG|ALKS 9072, High Dose|Intramuscular injection, given monthly
219190992|NCT05868382|BIOLOGICAL|mRNA-1010.6|Sterile liquid for injection
219190993|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Active|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
219420589|NCT04799951|OTHER|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
219190994|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Sham|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
219190995|NCT03574649|DRUG|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219190996|NCT03574649|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219190997|NCT03574649|DRUG|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219190998|NCT03574649|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219190999|NCT03574649|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
219759316|NCT06305208|DEVICE|Endoscopic gastric suturing|Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
219759317|NCT06305208|DEVICE|Endoscopic gastric plication|Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
219759318|NCT06305208|DEVICE|Revisional gastroplasty|Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
219759319|NCT06305208|DEVICE|Transoral outlet reduction endoscopy (TORe)|Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
219759320|NCT06305208|DEVICE|Duodenal mucosal resurfacing (DMR)|Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
219759321|NCT06305208|DEVICE|Intragastric balloon(s)|The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
219759322|NCT03770286|DEVICE|5% Fluoride Varnish|Topical varnish
219759323|NCT03770286|DEVICE|38% Silver diamine fluoride|Topical varnish
219759324|NCT03770286|DEVICE|Super Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
219759325|NCT03571490|DRUG|Ropivacaine|Single shot of ropivacaine 0.325%
219759326|NCT03571490|DRUG|Saline|Single shot of saline 0.9%
219759327|NCT02505425|BEHAVIORAL|Behavioral Support|"ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
219759328|NCT02505425|BEHAVIORAL|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
219759329|NCT02297412|DRUG|Minocycline Hydrochloride|Given PO
219759330|NCT02297412|OTHER|Placebo|Given PO
219759331|NCT02297412|OTHER|Quality-of-Life Assessment|Ancillary studies
219759332|NCT02297412|OTHER|Questionnaire Administration|Ancillary studies
219759333|NCT01596114|OTHER|Stopping treatment with TKI|stopping until loss of MMR
219759334|NCT02031302|DEVICE|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
219759335|NCT06645197|DRUG|SNUG01|Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
219759336|NCT06395558|BEHAVIORAL|Lifestyle intervention|Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
219759337|NCT05432609|DIAGNOSTIC_TEST|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
219759338|NCT04482127|OTHER|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
219759339|NCT04329767|DEVICE|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
219759340|NCT05175014|BIOLOGICAL|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
219759341|NCT05175014|BIOLOGICAL|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
219759342|NCT05470166|DRUG|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
219759343|NCT05470166|OTHER|saline IV|saline infusion same volume as lidocaine
219759344|NCT06152848|OTHER|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
219759345|NCT06272890|BEHAVIORAL|motivational interviewing|motivational interviewing
219759346|NCT05348967|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement with D-chiro-inositol and alpha-lactalbumin
219005086|NCT00311610|DRUG|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
219005087|NCT02201654|OTHER|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
219005088|NCT03683108|DRUG|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
219005089|NCT03683108|OTHER|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
219005090|NCT06293755|DEVICE|Microneedle patch|with 20 units botulinum toxin
219005091|NCT06293755|DEVICE|Intradermal injection|with 20 units botulinum toxin
219005092|NCT01876160|OTHER|Transcutaneous electrical nerve stimulation|
219420590|NCT01784952|DIETARY_SUPPLEMENT|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
219420591|NCT01365377|OTHER|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
219759347|NCT05465655|OTHER|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
219759348|NCT04337151|DEVICE|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
219759349|NCT04337151|DIAGNOSTIC_TEST|Titanium blood test|A blood test captured to measure the level of titanium
219759350|NCT03699865|OTHER|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
219759351|NCT05154734|DRUG|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
219759352|NCT05036135|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
219759353|NCT05036135|DRUG|Placebo|Placebo administered via dry powder inhalation
219759354|NCT05456087|DRUG|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
219759355|NCT05869747|BEHAVIORAL|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
219759356|NCT05869747|BEHAVIORAL|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
219759357|NCT05869747|BEHAVIORAL|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
219759358|NCT05869747|BEHAVIORAL|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
219759359|NCT05869747|BEHAVIORAL|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
219759360|NCT04411992|DEVICE|Vibrating Device|The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
219759361|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
219759362|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
219759363|NCT01442987|DRUG|Irbesartan/Atorvastatin A|once daily, P.O. 8week
219759364|NCT01442987|DRUG|Irbesartan|once daily, P.O. 8week
219759365|NCT01442987|DRUG|Atorvastatin A|once daily, P.O. 8week
219759366|NCT01442987|DRUG|Placebo|once daily, P.O. 8week
219759367|NCT01442987|DRUG|Irbesartan/Atorvastatin B|once daily, P.O. 8week
219759368|NCT01442987|DRUG|Atorvastatin B|once daily, P.O. 8week
219759369|NCT06429787|DRUG|Balfaxar|BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure
219759370|NCT06429787|DRUG|Kcentra|"KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with:~* acute major bleeding or~* need for an urgent surgery/invasive procedure"
219759371|NCT04194554|DRUG|Niraparib|given PO per dose escalation schedule
219759372|NCT04194554|DRUG|Leuprolide|22.5 mg q3 month
219759373|NCT04194554|DRUG|Abiraterone Acetate|1000 mg daily
219759374|NCT04194554|RADIATION|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
219759375|NCT06490367|BEHAVIORAL|Time-Restricted Eating Diet|Participants engage in a time-restricted eating diet, specifically maintaining a 6-8-hour eating window every day for 12 weeks. Participants are allowed to self-select the timing of the eating window, but once selected, they are asked to maintain that schedule daily. Outside of that window, for the remaining 16-18 hours of day/night, participants are asked not to consume calorie-containing food or drink. Beverages without calories are allowed.
219759376|NCT00949039|DRUG|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
219759377|NCT00949039|RADIATION|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
219759378|NCT00949039|PROCEDURE|Surgery|
219759379|NCT03517358|OTHER|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
219759380|NCT05438121|DEVICE|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
219005093|NCT05194592|DRUG|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
219759381|NCT06570252|DEVICE|activated Light Source (aPDT)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes"
219759382|NCT06570252|DEVICE|non activated Light Source (Control)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes"
219759383|NCT06569823|BIOLOGICAL|Z-1018|Formulation for injection
219759384|NCT06569823|BIOLOGICAL|Shingrix|Formulation for injection
219759385|NCT06570200|PROCEDURE|PMPR+iPRF|locally applied iPRF in the periodontal pocket
219759386|NCT06570200|DRUG|PMPR+iPRF+Vit.D|locally applied iPRF plus vitamin D in the periodontal pocket
219759387|NCT06570200|PROCEDURE|PMPR only|scaling and root planing only will be done for the periodontal pocket for the control group
219759388|NCT00561379|DRUG|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
219759389|NCT00561379|DRUG|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
219759390|NCT05007158|OTHER|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
219759391|NCT01064726|DRUG|Ibuprofen|800 mg oral
219759392|NCT01064726|DRUG|Fluticasone propionate|200 mcg intra-nasal
219759393|NCT01064726|DRUG|Placebo|Placebo
219759394|NCT02781558|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
219759395|NCT02781558|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219759396|NCT01356368|DRUG|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
219759397|NCT03240328|BIOLOGICAL|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
219759398|NCT00380146|DRUG|sulfadoxine-pyrimethamine|
219759399|NCT06539481|DRUG|fluocinolone acetonide 190 micrograms|ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
219759400|NCT03906084|PROCEDURE|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
219759401|NCT03906084|PROCEDURE|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
219005094|NCT05194592|DRUG|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
219005095|NCT05891262|DRUG|BMS-986196|Specified dose on specified days
219759402|NCT05516121|DRUG|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
219759403|NCT06171061|DRUG|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
219759404|NCT06171061|OTHER|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
219005096|NCT05891262|DRUG|Loestrin|Specified dose on specified days
219191000|NCT03574649|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219759405|NCT04082130|PROCEDURE|(XCM)+(CAF)|The description of this intervention has been already given before.
219759406|NCT04082130|PROCEDURE|(SCTG)+(CAF)|The description of this intervention has been already given before.
219759407|NCT03540680|OTHER|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
219759408|NCT06645418|DIAGNOSTIC_TEST|relative Hand grip strength|To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
219759409|NCT06645418|DIAGNOSTIC_TEST|senior fitness test|The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
219759410|NCT04171895|OTHER|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
219420592|NCT04659434|DRUG|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
219420593|NCT03585192|OTHER|Skin Group|"1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
219420594|NCT03585192|OTHER|Warmer Group|"1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
219420595|NCT01653158|DRUG|CP-751,871|"CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
219420596|NCT01653158|DRUG|Docetaxel|Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
219420597|NCT02469792|PROCEDURE|Liposuction|
219420598|NCT02469792|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
219420599|NCT02469792|PROCEDURE|Arthroscopic surgery|
219420600|NCT02469792|OTHER|Intraarticular administration of autologous ADRC|
219420601|NCT01933750|DEVICE|PresVIEW Device Implantation|
219420602|NCT03497234|DIAGNOSTIC_TEST|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
219420603|NCT02435550|GENETIC|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
219420604|NCT06322524|DEVICE|Gamma sensory flicker|participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
219420605|NCT03415763|DRUG|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
219420606|NCT03415763|DRUG|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
219573823|NCT05976724|OTHER|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
219573824|NCT05976724|OTHER|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
219005097|NCT02740777|BIOLOGICAL|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
219005098|NCT00793598|DRUG|Placebo|
219420607|NCT03212664|OTHER|exercise|physical therapy exercises
219573825|NCT03912402|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
219573826|NCT03912402|BIOLOGICAL|Bevacizumab|IV infusion
219573827|NCT03912402|DRUG|Paclitaxel|IV infusion
219005099|NCT00793598|DRUG|Brincidofovir|
219005100|NCT01759030|DRUG|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
219191001|NCT03574649|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
219573828|NCT03912402|DRUG|Cisplatin (or carboplatin)|IV infusion
219573829|NCT01392326|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
219420608|NCT00980343|DRUG|vismodegib|Given orally
219420609|NCT00980343|PROCEDURE|therapeutic conventional surgery|undergo surgery
219420610|NCT00980343|OTHER|laboratory biomarker analysis|correlative studies
219420611|NCT00980343|OTHER|pharmacological study|correlative studies
219420612|NCT00421603|DRUG|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
219420613|NCT00421603|DRUG|Placebo|Placebo
219420614|NCT00965783|OTHER|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
219420615|NCT00965783|OTHER|Extension|Bedtime is extended by 2 hours per night for 4 nights
219005101|NCT02773355|DRUG|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
219005102|NCT00531232|DRUG|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
219005103|NCT00840346|DRUG|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
219005104|NCT04085068|OTHER|cranioscaral treatment|dural release
219005105|NCT04386421|OTHER|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
219420616|NCT00765128|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
219420617|NCT00765128|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
219420618|NCT02709928|DRUG|TD-0714|
219420619|NCT02709928|DRUG|Placebo|
219420620|NCT05582161|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
219420621|NCT03060083|OTHER|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
219420622|NCT03060083|OTHER|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
219420623|NCT01523561|BEHAVIORAL|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
219420624|NCT02217228|DEVICE|Sebacia microparticles and laser|
219420625|NCT02217228|DEVICE|Vehicle suspension and laser|
219420626|NCT02217228|DEVICE|Sebacia microparticles without laser|
219420627|NCT00828685|PROCEDURE|CRPP|Closed reduction, percutaneous pinning
219005106|NCT04386421|DRUG|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
219191002|NCT03574649|BIOLOGICAL|GI-4000|RAS yeast vaccine
219191003|NCT03574649|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219420628|NCT00828685|PROCEDURE|ORIF|Open reduction, internal fixation
219420629|NCT03444870|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
219420630|NCT03444870|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
219420631|NCT03555188|DRUG|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
219420632|NCT03783728|DRUG|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
219420633|NCT03783728|DRUG|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
219573830|NCT01392326|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
219573831|NCT01392326|DRUG|Placebo Comparator|Placebo Comparator
219573832|NCT03527004|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
219573833|NCT03527004|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
219420634|NCT03783728|DRUG|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
219420635|NCT02209311|PROCEDURE|Oral mucosa biopsy|
219420636|NCT02209311|PROCEDURE|Sinus lift with implantation of tissue engineered construction|
219420637|NCT02209311|DEVICE|Dental implant|
219420638|NCT02090985|PROCEDURE|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
219573834|NCT05429697|DRUG|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
219573835|NCT05429697|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219191004|NCT03574649|DRUG|Aldoxorubicin|INNO-206
219191005|NCT03574649|DRUG|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219420639|NCT05783193|DRUG|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
219420640|NCT05783193|DRUG|Placebo|Placebo capsules
219420641|NCT03591094|DRUG|PTI-428|Active
219420642|NCT03591094|DRUG|Placebo|Placebo
219420643|NCT01560221|BEHAVIORAL|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
219420644|NCT01560221|DRUG|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
219573836|NCT01972035|DRUG|Valacyclovir|Experimental Arm
219573837|NCT01972035|DRUG|Valganciclovir|Standard of care
219573838|NCT04094740|DEVICE|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
219420645|NCT01560221|DRUG|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
219420646|NCT01608490|DEVICE|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
219191006|NCT03574649|DRUG|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
219420647|NCT06386809|DEVICE|TAVNS|TAVNS is a recently introduced treatment involving transcutaneous electrical stimulation of the auricular branch of the vagus nerve with VAGUSTIM device.
219420648|NCT06386809|OTHER|Exercise program|Rocabado 6x6 exercises will be applied in our study. Rocabado exercise, which is the most commonly used exercise method in the literature, is a set of exercises for the craniocervical and craniomandibular system.
219005107|NCT02652520|PROCEDURE|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
219005108|NCT04508868|BEHAVIORAL|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
219005109|NCT04508868|BEHAVIORAL|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
219005110|NCT02152696|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
219005111|NCT02152696|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
219005112|NCT02152696|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
219005113|NCT00797472|DRUG|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
219005114|NCT00797472|DRUG|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
219005115|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
219005116|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is turned off.
219420649|NCT04902534|DRUG|Naoqingzhiming Tablets (contains echinacoside 180mg)|Single dose escalation and multiple dose escalation
219573839|NCT01862419|OTHER|Alert|
219005117|NCT05611879|DRUG|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
219420650|NCT04902534|DRUG|placebo of Naoqingzhiming Tablets (without echinacoside)|Single dose escalation and multiple dose escalation
219420651|NCT02466165|BEHAVIORAL|Physical exercise|
219573840|NCT00233987|DRUG|carmustine|150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
219573841|NCT00233987|DRUG|cyclophosphamide|100 mg/kg IV 2 days before transplant.
219573842|NCT00233987|DRUG|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
219573843|NCT00233987|DRUG|melphalan|150 mg/m\^2 IV 1 day before transplant.
219573844|NCT00233987|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
219573845|NCT00233987|RADIATION|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
219573846|NCT03358043|DEVICE|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
219573847|NCT04778293|OTHER|Diacutaneous fibrolysis|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
219005118|NCT05611879|DRUG|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
219005119|NCT05611879|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
219005120|NCT02867189|OTHER|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
219420652|NCT05654766|DIAGNOSTIC_TEST|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
219420653|NCT05654766|DIAGNOSTIC_TEST|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
219420654|NCT03581929|DIETARY_SUPPLEMENT|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
219005121|NCT03316664|BEHAVIORAL|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
219420655|NCT03581929|OTHER|Placebo|Placebo comparator
219420656|NCT06461312|PROCEDURE|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
219420657|NCT04037917|DEVICE|CorNeat EverPatch|Covering Ophthalmic Implants
219420658|NCT04498572|OTHER|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
219420659|NCT04498572|OTHER|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
219573848|NCT02194023|DRUG|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
219573849|NCT02194023|DRUG|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
219573850|NCT02194023|DRUG|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
219573851|NCT02194023|DRUG|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
219573852|NCT02508259|DRUG|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
219573853|NCT02508259|DRUG|Saline|50 ml IV over 30 minutes
219573854|NCT03743610|OTHER|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
219573855|NCT03743610|OTHER|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
219420660|NCT01848639|DRUG|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
219420661|NCT01848639|DRUG|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
219573856|NCT03856905|OTHER|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
219573857|NCT03856905|DEVICE|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
219005122|NCT03316664|BEHAVIORAL|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
219420662|NCT05096013|OTHER|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
219420663|NCT06299579|DRUG|GD-11 for injection test group|The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
219420664|NCT06299579|DRUG|Placebo control group|The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
219420665|NCT05341570|DRUG|BPI-21668|Subjects will receive BPI-21668 until disease progression
219420666|NCT00004207|DRUG|liposomal daunorubicin citrate|
219420667|NCT03280069|DEVICE|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
219420668|NCT05557669|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
219420669|NCT05133544|DEVICE|Endocuff with AI|Use of endocuff with computer assisted polyp detection
219420670|NCT05133544|DEVICE|AI alone|Use of computer assisted polyp detection
219420671|NCT04379934|DIETARY_SUPPLEMENT|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
219420672|NCT02658201|DEVICE|MRI|Ultrafast MRI to assess constipation
219420673|NCT02333591|DRUG|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
219573858|NCT03856905|DEVICE|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
219573859|NCT00518622|DRUG|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
219573860|NCT00518622|DRUG|Comparator: Placebo|MK7009 Placebo
219005123|NCT03316664|OTHER|COGPACK|Information already included in arm/group description.
219005124|NCT03952000|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
219005125|NCT00042770|OTHER|talc|Given intrapleurally
219420674|NCT02333591|DRUG|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
219420675|NCT02333591|DRUG|Saline|Infused intravenously for 2,5 hours.
219005126|NCT00042770|PROCEDURE|dyspnea management|No talc
219420676|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
219420677|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
219420678|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
219420679|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
219420680|NCT04003753|OTHER|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
219420681|NCT01205451|DRUG|Botulinum toxin type A|Botulinum toxin type A
219191007|NCT03574649|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
219191008|NCT03574649|DRUG|Docetaxel|Docetaxel
219191009|NCT03574649|DRUG|carboplatin|carboplatin
219420682|NCT03777202|PROCEDURE|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
219573861|NCT01058928|OTHER|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
219573862|NCT01941108|BEHAVIORAL|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
219573863|NCT01594359|OTHER|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
219573864|NCT01594359|OTHER|BEAN|Placebo
219420683|NCT03777202|PROCEDURE|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
219573865|NCT01996059|PROCEDURE|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
219420684|NCT02590887|DIETARY_SUPPLEMENT|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
219420685|NCT05279105|BEHAVIORAL|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
219420686|NCT02383680|BIOLOGICAL|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
219420687|NCT01499719|BEHAVIORAL|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
219420688|NCT03409419|DRUG|[18F] CFA|pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
219420689|NCT02762019|DEVICE|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
219420690|NCT02762019|DEVICE|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
219420691|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
219420692|NCT02131545|DRUG|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
219420693|NCT02131545|DRUG|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
219420694|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
219573866|NCT01996059|PROCEDURE|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
219573867|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
219573868|NCT03284502|DRUG|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
219420695|NCT01040338|DRUG|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
219420696|NCT01194869|DRUG|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
219420697|NCT01194869|DRUG|Cisplatin|75 mg/m² given IV
219420698|NCT01194869|DRUG|Paclitaxel|175 mg/m² given IV
219420699|NCT04859972|DIAGNOSTIC_TEST|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
219420700|NCT00900445|DRUG|Daunorubicin Hydrochloride|Given IV
219420701|NCT00900445|OTHER|Pharmacological Study|Correlative studies
219420702|NCT00900445|DRUG|Prednisolone|Given orally
219420703|NCT00900445|DRUG|Prednisone|Given orally
219420704|NCT00900445|DRUG|Vincristine Sulfate|Given IV
219573869|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
219573870|NCT03284502|DRUG|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
219573871|NCT04235972|OTHER|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
219573872|NCT01688726|OTHER|SYSTANE® BALANCE eyedrops|
219573873|NCT01688726|OTHER|Minims® Saline 0.9% eyedrops|
219573874|NCT03567525|PROCEDURE|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
219573875|NCT03567525|PROCEDURE|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
219420705|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
219573876|NCT06490887|OTHER|Use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
219573877|NCT00258375|DRUG|custirsen sodium|
219759411|NCT04171895|OTHER|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
219759412|NCT04171895|OTHER|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
219759413|NCT04171895|OTHER|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
219759414|NCT04667156|DRUG|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
219005127|NCT06479798|DIAGNOSTIC_TEST|Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)|Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
219191010|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
219191011|NCT04421222|DRUG|EPI-7386 (QD)|Once daily oral dose of EPI-7386
219420706|NCT00313950|BIOLOGICAL|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
219759415|NCT04171960|DIAGNOSTIC_TEST|Blood draw|Venous whole blood collection within 12 hours and 12-24 hours following injury.
219759416|NCT04171960|OTHER|Outcome assessments|Administered at baseline.
219759417|NCT07004907|DEVICE|Treatment with the pedriatic mode of the APD cycler|Patients weighing less than 20 kg will be treated for 4 weeks with APD using the PAED mode of the Silencia PD cycler
219420707|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
219420708|NCT05971953|OTHER|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
219573878|NCT00258375|DRUG|docetaxel|
219573879|NCT02456649|DEVICE|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
219573880|NCT00648024|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
219573881|NCT00648024|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fasting
219573882|NCT00003972|BIOLOGICAL|filgrastim|
219573883|NCT00003972|BIOLOGICAL|sargramostim|
219573884|NCT00003972|DRUG|busulfan|
219573885|NCT00003972|DRUG|carboplatin|
219573886|NCT00003972|DRUG|cyclophosphamide|
219573887|NCT00003972|DRUG|melphalan|
219759418|NCT06370208|DIETARY_SUPPLEMENT|Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)|Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
219759419|NCT03830398|DRUG|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
219759420|NCT03830398|DRUG|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
219759421|NCT03830398|DRUG|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
219759422|NCT06675760|DEVICE|The intervention group|The intervention group received training through a mobile augmented reality application in the laboratory.
219759423|NCT04612140|PROCEDURE|Radiosurgery|The study subjects randomized in this study arm will undergo a radiosurgery procedure.
219759424|NCT04612140|PROCEDURE|Repeated catheter ablation|The study subjects randomized in this study arm will undergo repeated catheter ablation.
219759425|NCT07002931|PROCEDURE|khoury block graft|Bone blocks will be harvested from the retromolar area after measuring of the size required and measuring of the donor site anatomy. Piezoelectric device will be used to perform the graft osteotomy. The osteotomy lines will be connected and the graft will be mobilized using a bibeveled chisel and mallet. Sharp bony edges will be smoothened and the donor defect was packed with gelatin sponges. The bone block margins will be smoothened and separated into two thinner bone shells using titanium disk with copious saline irrigation. The blocks will be fixed into the recipient site buccally using at least two microscrews leaving a gap to be filled with bone graft. Particulate xenogenic bone graft will be mixed with the autogenous bone chips (50% Xenograft: 50% Autogenous graft) to fill the gap.
219759426|NCT07002931|PROCEDURE|urban sausage technique|: A resorbable pericardium membrane will be fixed with titanium pins on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption. The membrane will be stretched over the graft ensuring maximum immobilization of the graft.
219759427|NCT07002931|PROCEDURE|non resorbable membrane|A non-resorbable polytetrafluoroethylene (PTFE) membrane (Permamem membrane, Botiss Biomaterials, Germany) will be fixed with titanium tacks on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption.
219759428|NCT06225206|BEHAVIORAL|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX
219759429|NCT07004582|PROCEDURE|HDR brachytherapy|High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer
219759430|NCT07004582|DIAGNOSTIC_TEST|Diagnostic biopsy|Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer
219759431|NCT07003373|DRUG|hormone replacement therapy (HRT) group|Estradiol valerate is initiated at 4 mg/day on day 2 of the menstrual cycle and is adjusted to 8 mg/day based on endometrial thickness. Once the endometrial thickness reaches ≥8 mm, progesterone supplementation is started (400 mg vaginal suppositories twice daily and 50 mg intramuscular injections daily) for 5 days before blastocyst transfer.
219759432|NCT06625372|DIETARY_SUPPLEMENT|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
219759433|NCT06625372|DIETARY_SUPPLEMENT|INTRALIPIDS|The Intralipid will be given to the patient as fat component of total parenteral nutrition.
219759434|NCT06621277|OTHER|No intervention|No intervention
219759435|NCT06621277|OTHER|Tailored counseling programs (Phase 2)|Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
219759436|NCT04701242|DRUG|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
219759437|NCT00861549|DRUG|Phencynonate hydrochloride|2mg/tablet
219759438|NCT04712669|DRUG|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
219759439|NCT04712669|DRUG|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
219759440|NCT04712669|DRUG|Placebo|2 matching placebo tablets on top of standard of care
219759441|NCT06623019|DIAGNOSTIC_TEST|Validation and reliability|As this is a cross-sectional validation study, there is no intervention.
219759442|NCT03802396|DRUG|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
219759443|NCT03802396|DRUG|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
219759444|NCT06629961|PROCEDURE|abutment placement|Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
219759445|NCT06629961|PROCEDURE|Ti-base placement|Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
219759446|NCT06698640|BEHAVIORAL|Automated SMS|Participants will receive automated SMS messages reminding them of their Well-Child Visits. These messages will be standardized and sent at intervals designed to prompt appointment attendance.
219759447|NCT06698640|BEHAVIORAL|Automated SMS + Scheduling Assistance|Participants will receive the same automated SMS messages as in Arm 2, but with the added component of proactive appointment scheduling assistance. This may include options for scheduling directly through the SMS platform or follow-up messages encouraging appointment setting.
219759448|NCT06707922|DRUG|Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate|Peginterferon α-2b Injection, subcutaneous injection, once a week. Tenofovir Alafenamide Fumarate, Oral administration, once a day.
219759449|NCT06715358|BEHAVIORAL|Reintervention|"* SI! Program environment intervention from 2nd grade through all Elementary Education.~* SI! Program classroom intervention in 2nd grade.~* SI! Program classroom intervention in 5th grade."
219573888|NCT00003972|DRUG|paclitaxel|
219573889|NCT00003972|DRUG|tamoxifen citrate|
219573890|NCT00003972|DRUG|thiotepa|
219191012|NCT04421222|DRUG|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
219573891|NCT00003972|PROCEDURE|peripheral blood stem cell transplantation|
219573892|NCT00003972|RADIATION|radiation therapy|
219573893|NCT02056067|BEHAVIORAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
219573894|NCT02056067|BEHAVIORAL|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
219573895|NCT05045313|DRUG|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
219573896|NCT05045313|DRUG|Digoxin tablet|Drug: Digoxin, tablet, oral
219573897|NCT05045313|DRUG|Probenecid tablets|Drug: Probenecid, tablet, oral
219573898|NCT05045313|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
219420709|NCT05971953|OTHER|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
219420710|NCT00002545|DRUG|carmustine|
219573899|NCT03103074|DRUG|Botulinum B Toxin|Intradermal injections
219573900|NCT03103074|OTHER|Placebo Saline|Intradermal injections
219573901|NCT03036774|PROCEDURE|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
219573902|NCT00128934|DRUG|levonorgestrel/ethinyl estradiol|
219573903|NCT04216420|DEVICE|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
219573904|NCT00231218|DRUG|dietary supplement--echinacea, propolis, and vitamin c|
219573905|NCT00210899|DRUG|ceftobiprole medocaril|
219573906|NCT00210899|DRUG|Vancomycin plus Ceftazidime|
219573907|NCT06444321|BEHAVIORAL|INTERCARE-HF|Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
219573908|NCT01522079|PROCEDURE|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
219573909|NCT06412211|DEVICE|Photoacoustic finder|Sentinel lymph node detector using photoacoustic signal
219573910|NCT05506930|DRUG|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
219573911|NCT05506930|DRUG|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
219573912|NCT04107402|OTHER|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
219573913|NCT02631876|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
219573914|NCT02631876|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
219573915|NCT02631876|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
219573916|NCT02631876|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
219005128|NCT04834427|DRUG|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg."
219191013|NCT04421222|DRUG|Abiraterone acetate|Once daily dose of abiraterone acetate
219191014|NCT04421222|DRUG|Apalutamide|Once daily dose of apalutamide
219420711|NCT00002545|RADIATION|low-LET photon therapy|
219420712|NCT03368131|DRUG|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
219420713|NCT03368131|DRUG|Capecitabine|825\~1000mg/m2 bid d1-14
219420714|NCT03368131|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
219420715|NCT03368131|RADIATION|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
219420716|NCT00530530|DRUG|ASP8825|oral
219420717|NCT00530530|DRUG|Placebo|oral
219420718|NCT03773926|DEVICE|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
219420719|NCT01707329|DRUG|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
219420720|NCT01707329|DRUG|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
219420721|NCT02941341|DRUG|r-hFSH|As per standard practice
219420722|NCT04574921|OTHER|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
219420723|NCT04574921|OTHER|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
219420724|NCT03445754|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
219420725|NCT03445754|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
219420726|NCT01918787|DEVICE|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
219420727|NCT02017613|DRUG|RP6530|Escalating doses starting at 25 mg BID
219420728|NCT02356146|DRUG|Tacrolimus C12|
219420729|NCT03494426|PROCEDURE|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
219420730|NCT03494426|DRUG|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
219420731|NCT03934710|DRUG|Placebo|Drug will be administered in solution form
219420732|NCT03934710|DRUG|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
219420733|NCT03934710|DRUG|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
219420734|NCT02471001|BIOLOGICAL|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
219420735|NCT06259773|DIAGNOSTIC_TEST|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
219420736|NCT00059618|DRUG|PS-341 (Bortezomib)|Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
219573917|NCT04212377|BIOLOGICAL|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
219573918|NCT02785653|DRUG|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
219420737|NCT00059618|DRUG|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
219420738|NCT03084718|DRUG|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
219420739|NCT03084718|DRUG|Placebo pMDI|Placebo Control
219420740|NCT03084718|DRUG|Beclomethasone Dipropionate (BDP)|Active Control
219420741|NCT00262977|BEHAVIORAL|Electronic prompt plus patient-directed intervention|
219420742|NCT00262977|BEHAVIORAL|Electronic prompt to clinician to prescribe aspirin|
219420743|NCT00740324|DRUG|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
219420744|NCT00740324|DRUG|NPO-11|NPO-11 after administration of NPO-11
219420745|NCT00740324|DRUG|NPO-11|1 mg glucagons after administration of NPO-11
219420746|NCT01742078|DRUG|LY2541546 - IV|Administered IV
219420747|NCT01742078|DRUG|LY2541546 - SC|Administered SC
219420748|NCT01742078|DRUG|Placebo|Administered IV or SC
219420749|NCT06006910|BEHAVIORAL|Column-based nudge in the EHR|The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
219005129|NCT04834427|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
219005130|NCT04040478|DEVICE|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
219005131|NCT03218033|BEHAVIORAL|Social Media|
219005132|NCT02036463|DRUG|Prednisone|
219005133|NCT02036463|DRUG|Placebo|
219005134|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
219005135|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
219005136|NCT00378274|BEHAVIORAL|Observation|
219005137|NCT02299479|DEVICE|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
219005138|NCT02299479|DEVICE|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
219420750|NCT06006910|BEHAVIORAL|No column-based nudge in the EHR|No intervention control period prior to nudge deployment.
219420751|NCT00163072|DRUG|transdermal Megace|oral vs transdermal levels
219420752|NCT03083509|OTHER|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
219420753|NCT03083509|OTHER|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
219759450|NCT06715358|BEHAVIORAL|Late intervention|"* SI! Program environment intervention from 5th grade through all Elementary Education.~* SI! Program classroom intervention in 5th grade."
219759451|NCT06719089|DEVICE|Biodegradable double loop ureteral stent|This ureteral stent is based on natural polymers and degrades inside the human body without causing obstruction, avoiding the need of a second surgery for stent removal and minimizing complications related to encrustation and bacterial infections.
219759452|NCT06719089|DEVICE|PolyUrethane Double Loop Ureteral Stent|This ureteral stent is a double J made of 100% polyurethan, heat-sensitive and radiopaque for excellent patient tolerance and high incrustation resistance.
219420754|NCT03083509|OTHER|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
219759453|NCT06717360|DRUG|AG2304T|AG2304T, QD, PO
219759454|NCT06717360|DRUG|AG2304R|AG2304R, QD, PO
219759455|NCT05578209|DEVICE|intermittent theta burst stimulation|stimulatory protocol
219759456|NCT04955041|OTHER|MRI|T2\* MRI
219759457|NCT02798003|OTHER|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
219759458|NCT00163293|DRUG|Ciclesonide|Ciclesonide metered-dose inhaler
219759459|NCT00163293|DRUG|Placebo|Ciclesonide placebo-matching metered-dose inhaler
219420755|NCT03756740|OTHER|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
219573919|NCT02785653|DRUG|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
219573920|NCT01805635|OTHER|No intervention|No intervention
219573921|NCT00785096|OTHER|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
219759460|NCT01821755|BEHAVIORAL|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
219420756|NCT03756740|OTHER|control|subjects will receive the LBP exercises as printed pictures on paper
219420757|NCT00003225|DRUG|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
219420758|NCT00003225|DRUG|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
219573922|NCT03877341|PROCEDURE|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
219573923|NCT03877341|PROCEDURE|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
219420759|NCT02287701|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
219420760|NCT05397483|BEHAVIORAL|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
219573924|NCT05704972|OTHER|the operating room environment risk|in determining the risks they face in the operating room environment.
219759461|NCT05042206|BIOLOGICAL|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
219759462|NCT01150357|DRUG|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
219759463|NCT01150357|DRUG|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
219005139|NCT03494309|PROCEDURE|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
219005140|NCT03494309|PROCEDURE|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
219420761|NCT05397483|BEHAVIORAL|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
219573925|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
219759464|NCT01150357|DRUG|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
219005141|NCT03108833|DRUG|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
219005142|NCT03108833|DRUG|Alteplase|The drug is used for intravenous thrombolysis therapy
219420762|NCT00084929|PROCEDURE|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
219005143|NCT03909295|DRUG|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
219005144|NCT01411228|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
219005145|NCT02177045|DRUG|Sonovue, Bracco|Intravenous injection
219420763|NCT03849976|BEHAVIORAL|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
219420764|NCT03930641|DRUG|RTH258|6 mg in prefilled syringe
219759465|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
219759466|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
219759467|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
219759468|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
219759469|NCT06116175|PROCEDURE|60 degree thermal radiofequency of tennis elbow|under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
219759470|NCT06932276|BEHAVIORAL|"Some things a re better outside"|"Some Things Are Better Outside interventionis designed to encourage participants to voluntarily create a smoke-free home by accepting a norm of never smoking at home, whether indoors or outdoors, such as on balconies. The intervention is delivered over six weeks and consists of four components: an initial mailing of printed materials, a coaching call, and two additional mailings. It is based on five steps to adopting a smoke-free home: 1) deciding on the reasons for creating one, 2) discussing it with family members, 3) choosing a date to go smoke-free, 4) making the home a smoke-free environment, and 5) maintaining it as smoke-free."
219759471|NCT06937307|DRUG|Droxidopa capsules|Droxidopa is an oral synthetic amino acid that is directly metabolized to norepinephrine by dopa-decarboxylase. It will be administered at an initial dose of 100 mg three times daily, titrated in 100 mg increments every 24 hours based on blood pressure response, up to a maximum of 300 mg three times daily. Doses will be given approximately 4 hours apart during daytime hours, at least 3 hours apart, with a maximum total daily dose of 900 mg. The treatment duration is 28 days. The drug will be over-encapsulated using opaque capsules to maintain the double-blind design.
219759472|NCT06937307|OTHER|Placebo|Matching placebo capsules containing microcrystalline cellulose (from Millipore Sigma) will be over-encapsulated using identical opaque capsules to maintain blinding. Placebo will be administered following the same schedule as the active treatment: three times daily with the same titration protocol based on blood pressure response, for a treatment duration of 28 days. The Columbia University Research Pharmacy will perform over-encapsulation of both active drug and placebo to ensure they are identical in appearance.
219759473|NCT06944639|DEVICE|Membrane Jason MB GmbH Non-cross-linked (NCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
219759474|NCT06944639|DEVICE|Membrane BioMend Extend Glutaraldehyde cross-linked|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
219759475|NCT06944639|DEVICE|Membrane OSSIX Agile Ribose cross-linked (RCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
219759476|NCT04175184|OTHER|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
219759477|NCT04175184|OTHER|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
219759478|NCT06305390|DIAGNOSTIC_TEST|PET/MRI|18F-PSMA PET/MRI
219573926|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
219420765|NCT02181010|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
219420766|NCT02060318|DRUG|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
219420767|NCT03247413|DRUG|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
219420768|NCT03247413|DRUG|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
219420769|NCT00513097|BEHAVIORAL|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
219420770|NCT00513097|BEHAVIORAL|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
219420771|NCT00513097|BEHAVIORAL|Survey|On-line evaluations and questionnaires
219420772|NCT06003257|OTHER|stainless steel crown|stainless steel full coverage crown for deciduous teeth
219573927|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
219420773|NCT06003257|OTHER|zirconia crown|zirconia full coverage crown for deciduous teeth
219420774|NCT06003257|OTHER|fiberglass crown|fiberglass full coverage crown for deciduous teeth
219573928|NCT05580952|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
219573929|NCT04661592|DEVICE|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
219573930|NCT00726102|OTHER|Meat|2 0z of locally available meat per day
219573931|NCT00726102|OTHER|Cereal|Daily provision of cereal to infants from 6-18 mos
219005146|NCT03120546|DEVICE|rigid video stylet intubation|intubation using rigid video stylet
219005147|NCT03120546|DEVICE|video laryngoscope intubation|intubation using video laryngoscope
219005148|NCT03600974|PROCEDURE|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
219005149|NCT03600974|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
219005150|NCT03600974|DRUG|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
219420775|NCT00804375|DRUG|2PX|cutaneous solution to be applied twice daily for 84 days
219420776|NCT00804375|DRUG|Placebo|cutaneous solution to be applied twice daily for 84 days
219573932|NCT00726102|OTHER|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
219005151|NCT03600974|DRUG|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
219005152|NCT03600974|DRUG|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
219420777|NCT02892838|DEVICE|mobile bearing knee system for total knee arthroplasty|
219005153|NCT03600974|DRUG|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
219573933|NCT00567437|OTHER|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
219573934|NCT00784524|BIOLOGICAL|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
219005154|NCT06468631|BEHAVIORAL|Complex Nursing Intervention|"Training prepared as an expert opinion on patient handover, starting to use the standard patient handover form for each patient, ensuring standardization in handover and supporting this improvement work by managers were expressed as interventions.~Training offered; It includes the importance of patient handover, how to ensure standardization and why we should use the standard patient handover form."
219005155|NCT05455788|DRUG|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
219005156|NCT00004984|DRUG|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
219005157|NCT00004984|OTHER|Close Observation|Study visits every 6 months including an oral glucose tolerance test
219005158|NCT00004984|DRUG|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
219005159|NCT00004984|DRUG|Placebo|Placebo for oral insulin
219005160|NCT03780868|PROCEDURE|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
219005161|NCT03780868|PROCEDURE|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
219005162|NCT01907880|DRUG|Pamidronate|90mg IV once every 4 weeks for 3 cycles
219005163|NCT01907880|DRUG|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
219005164|NCT01907880|DRUG|placebo|
219005165|NCT02569216|DEVICE|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
219005166|NCT01974375|DRUG|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
219005167|NCT01974375|DRUG|Fluconazole|Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
219573935|NCT00784524|BIOLOGICAL|aldesleukin|Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
219573936|NCT03570450|DRUG|Adipose derived Stem Cell|4 doses
219005168|NCT00469989|PROCEDURE|Infection with hookworm larvae|
219573937|NCT03570450|OTHER|placebo|placebo
219005169|NCT04812054|PROCEDURE|Hypothermic oxygenated machine perfusion|Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.
219005170|NCT04812054|PROCEDURE|Simple cold storage|Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
219420778|NCT02892838|DEVICE|fixed bearing total knee prosthesis|
219420779|NCT00424294|DRUG|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
219420780|NCT00424294|DRUG|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
219420781|NCT00424294|DRUG|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
219420782|NCT03831308|DIAGNOSTIC_TEST|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
219573938|NCT00494624|DRUG|prednisolone|
219005171|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219005172|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219005173|NCT04672447|DIETARY_SUPPLEMENT|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219005174|NCT04672447|DIETARY_SUPPLEMENT|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219005175|NCT02566083|DEVICE|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
219005176|NCT02566083|DEVICE|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
219573939|NCT01852734|PROCEDURE|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
219573940|NCT01852734|PROCEDURE|embolizations|comparison between the two microspheres
219573941|NCT00107718|DRUG|SB-485232|
219573942|NCT02277704|DRUG|TNX-102 SL|
219573943|NCT02277704|DRUG|Placebo|
219005177|NCT05605392|OTHER|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
219191015|NCT05485727|OTHER|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
219191016|NCT05485727|OTHER|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
219191017|NCT02497950|DEVICE|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
219191018|NCT06310551|DRUG|Oral VH4524184|VH4524184 to be taken orally.
219573944|NCT01408563|DRUG|Fludarabine|30 mg/m2/day IV x 6 days
219573945|NCT01408563|DRUG|Melphalan|100 mg/m2/day IV x 1 day
219573946|NCT01408563|RADIATION|Total Body Radiation|200 cGy on Day 0
219573947|NCT01408563|BIOLOGICAL|Cord Blood|2 cord blood units IV
219573948|NCT03142516|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
219573949|NCT03142516|DRUG|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
219573950|NCT03142516|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
219191019|NCT06310551|DRUG|VH4524184 Formulation A SC|Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.
219191020|NCT06310551|DRUG|Placebo Formulation A SC|Starting dose of Placebo Formulation A administered subcutaneously.
219191021|NCT06310551|DRUG|rHuPH20|Dose of rHuPH20 administered subcutaneously.
219573951|NCT03142516|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
219573952|NCT04227938|DRUG|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
219573953|NCT04172519|OTHER|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
219573954|NCT04172519|OTHER|Unsupervised PMFT|intervention after surgery, unsupervised exercises
219573955|NCT04172519|OTHER|Supervised PMFT|intervention after surgery and supervised exercise
219573956|NCT03695848|DEVICE|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
219420783|NCT05688501|OTHER|descriptiv group|no intervention
219420784|NCT00554892|PROCEDURE|bowel preparation|oral laxatives, retrograde enemas
219420785|NCT00554892|PROCEDURE|no preparation bowel|no preparation bowel
219420786|NCT03346447|OTHER|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
219420787|NCT00731393|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
219420788|NCT00731393|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
219420789|NCT04397718|DRUG|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
219420790|NCT04397718|OTHER|Saline|09% Saline
219420791|NCT03714906|PROCEDURE|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
219420792|NCT01693055|DEVICE|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
219420793|NCT01797965|DRUG|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
219420794|NCT02327221|DRUG|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
219420795|NCT02327221|DRUG|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
219573957|NCT03181698|DIAGNOSTIC_TEST|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
219573958|NCT04525638|DRUG|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
219573959|NCT04525638|DRUG|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
219573960|NCT03659461|DRUG|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
219573961|NCT05017974|BEHAVIORAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
219573962|NCT05017974|OTHER|Treatment as Usual|TAU
219573963|NCT04104555|OTHER|Birthday card|Birthday card sent to participants in the post
219573964|NCT04104555|DEVICE|Prefabricated orthoses|Prefabricated insole
219573965|NCT04104555|OTHER|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
219420796|NCT05865873|BEHAVIORAL|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
219005178|NCT01752907|OTHER|General Education DVD|A general chemotherapy side effects education DVD
219005179|NCT01752907|OTHER|Bone Pain Education DVD|
219191022|NCT06310551|DRUG|VH4524184 Formulation B SC|Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
219420797|NCT02557412|DEVICE|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
219420798|NCT02557412|BEHAVIORAL|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
219420799|NCT02557412|OTHER|Conventional treatment|Hygiene and diet recommendations on sleep
219420800|NCT00646841|DRUG|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
219420801|NCT05424991|BEHAVIORAL|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
219420802|NCT04069741|OTHER|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
219420803|NCT04069741|BEHAVIORAL|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
219420804|NCT05950347|DEVICE|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
219420805|NCT05950347|DEVICE|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
219420806|NCT04991844|BEHAVIORAL|Intervention Group|Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
219420807|NCT03611322|DRUG|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
219420808|NCT03611322|DRUG|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
219420809|NCT03611322|DRUG|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
219573966|NCT04104555|OTHER|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
219005180|NCT06358365|DEVICE|The AquaPass System|The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
219420810|NCT03611322|DEVICE|DV3372|DV3372 device will be used for administration of semaglutide
219420811|NCT03611322|DEVICE|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
219420812|NCT02154126|DEVICE|Continuous Glucose Monitoring Device (Senseonics)|
219420813|NCT03760848|DRUG|Aramchol|Aramchol 600 mg
219420814|NCT03760848|DRUG|Midazolam|Midazolam 2 mg
219420815|NCT03760848|DRUG|Atorvastatin|atorvastatin 40 mg
219420816|NCT03054948|DRUG|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
219420817|NCT03054948|DRUG|Standard therapy|In most cases standard therapy will be IntraLipid.
219420818|NCT02687230|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
219420819|NCT02687230|DRUG|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
219420820|NCT01887587|DRUG|MLN9708|
219420821|NCT01887587|DRUG|Vincristine|
219420822|NCT01887587|DRUG|Doxorubicin|
219573967|NCT00396799|DRUG|bazedoxifene/conjugated estrogens|
219573968|NCT02512536|DRUG|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
219005181|NCT06142045|DEVICE|RespirACT RA-MR System|RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
219005182|NCT01950650|BEHAVIORAL|No treatment given|Survey conducted through computer-assisted telephone interviewing.
219005183|NCT01950650|BEHAVIORAL|survey|Survey conducted via the Internet.
219005184|NCT02024633|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
219005185|NCT02024633|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
219420823|NCT01887587|DRUG|Dexamethasone|
219420824|NCT05630170|DEVICE|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
219420825|NCT05562024|BIOLOGICAL|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
219420826|NCT05225220|DEVICE|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
219420827|NCT05430711|DRUG|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
219420828|NCT03593863|BEHAVIORAL|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
219420829|NCT02670330|DRUG|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
219420830|NCT01689376|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
219420831|NCT03359694|DRUG|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
219420832|NCT03359694|DRUG|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
219420833|NCT03359694|DRUG|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
219420834|NCT00032994|BEHAVIORAL|Behavior Therapy|
219420835|NCT01766882|BEHAVIORAL|Lower sodium intervention|"1\. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
219420836|NCT01766882|OTHER|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
219420837|NCT03216083|DRUG|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
219420838|NCT03216083|OTHER|Placebo|67mL IV normal saline
219420839|NCT03111017|OTHER|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
219420840|NCT05412537|OTHER|MI|How to motivate people
219420841|NCT05412537|OTHER|CAU|consult as usual
219420842|NCT04324918|DRUG|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
219420843|NCT04324918|DRUG|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
219420844|NCT05152277|DRUG|HRS9531|Administered SC once
219420845|NCT05152277|OTHER|placebo|Administered SC once
219420846|NCT05152277|DRUG|HRS9531|Administered SC for multiple dose
219420847|NCT05152277|OTHER|placebo|Administered SC for multiple dose
219420848|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|patient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
219420849|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|peripheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
219420850|NCT00218790|PROCEDURE|Cool Dialysate|Decreased temperature of the dialysis bath
219005186|NCT04371991|DIAGNOSTIC_TEST|blood test|blood test (serum samples) for biochemical examination
219005187|NCT00107445|DRUG|EF5|Given IV
219005188|NCT02696473|DIETARY_SUPPLEMENT|Carrot|
219005189|NCT03912285|DRUG|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
219005190|NCT03912285|DRUG|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
219005191|NCT03912285|DRUG|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
219005192|NCT00333814|DRUG|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
219005193|NCT00333814|DRUG|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
219005194|NCT00333814|DRUG|Sham injection|Sham injection at Day 0
219005195|NCT02670083|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
219005196|NCT02670083|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
219005197|NCT00713050|BEHAVIORAL|Imitate Therapy|Imitation-based computer therapy
219191023|NCT06310551|DRUG|Placebo Formulation B SC|Starting dose of Placebo Formulation B administered subcutaneously.
219191024|NCT06310551|DRUG|VH4524184 Formulation C SC|Starting dose of VH4524184 LAI Formulation C administered subcutaneously.
219191025|NCT06310551|DRUG|Placebo Formulation C SC|Dose of Placebo Formulation C administered subcutaneously.
219573969|NCT00120536|DRUG|vildagliptin|
219005198|NCT04982887|OTHER|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
219005199|NCT04687878|DRUG|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
219005200|NCT04687878|DRUG|Normal saline|twice a day, intranasally, every day for 12 weeks
219005201|NCT04590365|DEVICE|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
219005202|NCT04590365|DEVICE|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
219005203|NCT01780636|DRUG|botulinum toxin|
219420851|NCT05497895|BIOLOGICAL|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
219573970|NCT02054130|DRUG|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
219005204|NCT01279278|OTHER|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
219005205|NCT01279278|OTHER|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
219005206|NCT05954026|DEVICE|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
219005207|NCT00603993|BIOLOGICAL|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
219005208|NCT05531084|DEVICE|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
219005209|NCT05118503|BEHAVIORAL|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
219573971|NCT02054130|DRUG|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
219005210|NCT05118503|BEHAVIORAL|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
219005211|NCT01708681|DIETARY_SUPPLEMENT|Lean seafood|
219005212|NCT01708681|DIETARY_SUPPLEMENT|Meat, egg, milk|
219005213|NCT00464087|DRUG|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
219005214|NCT05534997|OTHER|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
219573972|NCT02054130|DRUG|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
219573973|NCT02054130|DRUG|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
219573974|NCT02060474|DRUG|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
219573975|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
219573976|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
219759479|NCT05985239|PROCEDURE|VI|Laparoscopic or robotic surgery with virtual ileostomy
219759480|NCT05985239|PROCEDURE|DI|Laparoscopic or robotic surgery with virtual ileostomy
219759481|NCT02622035|BEHAVIORAL|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
219759482|NCT02622035|BEHAVIORAL|Emotion induction|Film clip designed to induce anger or fear
219759483|NCT02622035|BEHAVIORAL|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
219759484|NCT03243864|DRUG|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
219759485|NCT06715228|BEHAVIORAL|shitali pranayama respiratory rehabilitation training|in this group, patients (n=20) with obstructive sleep apnea will participate and will administer six cycles of 5-min shitali respiratory pranayama exercise rehabilitation training (the rehabilitation will be repeated or applied at morning, afternoon, and also at evening) for 12 week as a daily performance
219759486|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
219759487|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
219759488|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
219759489|NCT02562781|DRUG|Oxygen|Oxygen in sufficient quantity to maintain SpO2 \> 98%
219759490|NCT02562781|OTHER|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
219759491|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
219759492|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
219420852|NCT05497895|BIOLOGICAL|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
219420853|NCT05497895|PROCEDURE|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
219420854|NCT01226212|DIETARY_SUPPLEMENT|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
219420855|NCT01226212|DIETARY_SUPPLEMENT|Placebo|maltodextrose
219573977|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
219005215|NCT02442362|DRUG|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
219420856|NCT00160394|DRUG|Duac® Gel / Differin® Gel|
219420857|NCT00959530|PROCEDURE|lingualized occlusion|occlusal surface arranged by lingualized occlusion
219420858|NCT00959530|PROCEDURE|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
219420859|NCT02615067|DRUG|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
219420860|NCT02615067|DIAGNOSTIC_TEST|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
219420861|NCT03805581|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
219420862|NCT02268006|RADIATION|IMRT-SIB|
219420863|NCT02268006|DRUG|Capecitabine|
219420864|NCT02268006|PROCEDURE|Surgery|
219573978|NCT00015769|DRUG|levetiracetam|
219573979|NCT00094458|BIOLOGICAL|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
219573980|NCT00094458|OTHER|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
219420865|NCT04404010|OTHER|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
219420866|NCT04404010|OTHER|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
219573981|NCT00094458|DRUG|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
219005216|NCT02442362|DRUG|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
219005217|NCT04218305|DIAGNOSTIC_TEST|Serum Level Of Fetuin A|
219420867|NCT06281145|BEHAVIORAL|Heart-rate variability biofeedback intervention|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
219420868|NCT05414305|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
219420869|NCT00133835|PROCEDURE|Extracorporeal shock wave lithotripsy|
219420870|NCT00133835|PROCEDURE|Endoscopic drainage of the main pancreatic duct|
219420871|NCT02120157|DRUG|Cyclophosphamide|Chemotherapy administration
219420872|NCT02120157|RADIATION|TBI|Radiation Therapy
219420873|NCT02120157|DRUG|Busulfan|Chemotherapy Administered
219420874|NCT02120157|OTHER|Unmanipulated Bone Marrow|Bone Marrow Transplant
219573982|NCT04171713|BEHAVIORAL|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
219005218|NCT00814190|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
219005219|NCT01779102|BIOLOGICAL|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219005220|NCT01779102|BIOLOGICAL|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219005221|NCT01779102|BIOLOGICAL|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
219420875|NCT02120157|DRUG|Tacrolimus|Immunosuppressive Drug Administered
219420876|NCT02120157|DRUG|Mycophenolate mofetil|Immunosuppressive Drug Administered
219005222|NCT00609492|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
219005223|NCT00609492|BIOLOGICAL|Infanrix™-IPV/Hib|Single dose, intramuscular injection
219005224|NCT00275054|DRUG|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
219420877|NCT05970744|BIOLOGICAL|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
219420878|NCT05970744|BIOLOGICAL|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
219420879|NCT05970744|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of Placebo
219420880|NCT02195817|DRUG|Selincro® 18 mg with continuous psychosocial support: Cohort A|
219420881|NCT02195817|OTHER|Initial psychosocial support: Cohort B|
219420882|NCT04368455|BEHAVIORAL|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
219005225|NCT00275054|DRUG|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
219005226|NCT00275054|BIOLOGICAL|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
219005227|NCT02737189|PROCEDURE|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
219420883|NCT04368455|BEHAVIORAL|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
219759493|NCT01658059|OTHER|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
219759494|NCT01658059|OTHER|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
219759495|NCT01597739|DRUG|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
219759496|NCT01597739|DRUG|Placebo|Form=capsule; route=oral use; twice daily.
219759497|NCT02916264|PROCEDURE|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
219759498|NCT03198871|DRUG|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
219759499|NCT03198871|DRUG|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
219759500|NCT00332618|DEVICE|OXYGENATED GLYCEROL TRIESTERS|
219759501|NCT02552797|BEHAVIORAL|Shared Decision Making tool|
219759502|NCT06259357|OTHER|Protocolized protective mechanical ventilation in prone position|Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
219759503|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
219759504|NCT00984503|DRUG|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
219759505|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
219759506|NCT00984503|DRUG|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
219759507|NCT06154018|DRUG|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
219759508|NCT01254448|DRUG|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
219759509|NCT01254448|DRUG|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
219759510|NCT01250054|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
219759511|NCT01250054|DEVICE|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
219759512|NCT03886467|OTHER|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
219759513|NCT02559648|DRUG|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
219005228|NCT02737189|DRUG|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
219420884|NCT00780702|DRUG|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
219420885|NCT00780702|DRUG|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
219005229|NCT04817371|DEVICE|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
219005230|NCT04817371|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
219005231|NCT04817371|DEVICE|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
219005232|NCT04817371|DEVICE|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
219005233|NCT01564797|BEHAVIORAL|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
219005234|NCT00836290|BEHAVIORAL|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
219005235|NCT00836290|BEHAVIORAL|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
219191026|NCT06310551|DRUG|VH4524184 Formulation A IM|Starting dose VH4524184 LAI Formulation A administered intramuscularly.
219420886|NCT05432102|DIAGNOSTIC_TEST|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
219420887|NCT05432102|DIAGNOSTIC_TEST|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
219420888|NCT04653142|DRUG|BI 765063|BI 765063
219420889|NCT04653142|DRUG|BI 754091|BI 754091
219420890|NCT01238406|DEVICE|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
219420891|NCT01238406|DEVICE|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
219420892|NCT05931185|OTHER|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
219420893|NCT05931185|OTHER|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
219420894|NCT05931185|OTHER|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
219420895|NCT03263156|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
219420896|NCT04509323|DRUG|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
219420897|NCT02491398|DRUG|Bendamustine + Rituximab|
219420898|NCT01372449|DRUG|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
219420899|NCT01372449|DRUG|Placebo|
219420900|NCT02623296|DRUG|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
219420901|NCT02623296|DRUG|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
219420902|NCT02623296|DRUG|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
219420903|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
219573983|NCT04171713|BEHAVIORAL|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
219573984|NCT04171713|BEHAVIORAL|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
219420904|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (6 wk postpartum)|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
219420905|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
219420906|NCT02043223|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation, both at \<3-day and 6-wk postpartum.
219420907|NCT00269737|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
219420908|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
219420909|NCT00441103|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
219420910|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
219420911|NCT03852121|BEHAVIORAL|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
219420912|NCT02098057|DIETARY_SUPPLEMENT|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
219420913|NCT02098057|DRUG|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
219573985|NCT02322619|DRUG|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
219759514|NCT02559648|DRUG|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
219420914|NCT04935047|OTHER|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
219420915|NCT04436874|DEVICE|endoscopy|transplant infusion of feces from healthy donors into affected subjects
219420916|NCT03529383|DEVICE|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
219420917|NCT03529383|BEHAVIORAL|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
219420918|NCT04612153|OTHER|Epidemiologic|Epidemiologic study. Observational, transverse study
219420919|NCT00400439|DRUG|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
219420920|NCT00400439|DRUG|placebo|po daily for 24 weeks
219573986|NCT05881902|BEHAVIORAL|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
219420921|NCT00223288|DRUG|Lexapro|
219573987|NCT05881902|BEHAVIORAL|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
219573988|NCT03557359|DRUG|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
219573989|NCT03596619|DEVICE|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
219573990|NCT01046552|PROCEDURE|preoperative ERCP and LC|preoperative ERCP followed by LC
219573991|NCT01046552|PROCEDURE|Intraoperative ERCP and LC|LC and intraoperative ERCP
219573992|NCT05695872|PROCEDURE|subtarsal approach|surgical approach
219573993|NCT05695872|PROCEDURE|conventional transconjunctival approach|surgical approach
219573994|NCT05695872|PROCEDURE|transconjunctival approach with Y- modification|surgical approach
219573995|NCT03421756|DRUG|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
219573996|NCT03421756|RADIATION|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
219573997|NCT03421756|DRUG|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
219420922|NCT02584465|DRUG|Tamoxifen|Tamoxifen: 40 mg/day
219573998|NCT03443193|OTHER|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
219005236|NCT02399501|PROCEDURE|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
219191027|NCT06310551|DRUG|Placebo Formulation A IM|Dose of Placebo Formulation A administered intramuscularly.
219191028|NCT06310551|DRUG|VH4524184 Formulation B IM|Starting dose VH4524184 LAI Formulation B administered intramuscularly.
219420923|NCT02584465|DRUG|Regorafenib|Stivarga; 120mg/day
219420924|NCT00835107|DRUG|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
219420925|NCT00835107|DRUG|placebo|placebo comparator, oral capsules, BID, for one month
219573999|NCT03056261|PROCEDURE|Combined general and epidural|Combined general and epidural anaesthesia
219574000|NCT03056261|PROCEDURE|General anaesthesia|General anaesthesia
219574001|NCT02276898|DRUG|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
219574002|NCT02276898|DRUG|Isotonic Saline 0.9% (Placebo)|
219191029|NCT06310551|DRUG|Placebo Formulation B IM|Dose of Placebo Formulation B administered intramuscularly.
219574003|NCT04856124|DRUG|Intranasal esketamine|Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
219574004|NCT03735134|DRUG|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
219574005|NCT03735134|DRUG|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
219574006|NCT05927272|PROCEDURE|SKIN SAMPLES|"At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq)."
219420926|NCT00239837|BEHAVIORAL|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
219420927|NCT04035265|PROCEDURE|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
219420928|NCT01153893|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
219420929|NCT01153893|BIOLOGICAL|InfanrixTM|Intramuscular injection, 1dose
219574007|NCT05927272|PROCEDURE|BLOOD SAMPLES|Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
219574008|NCT05927272|DEVICE|narrowband UVB|narrowband UVB (Nb-UVB) 2 times a week
219574009|NCT05927272|DRUG|Systemic Steroids|Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
219574010|NCT01400386|OTHER|Coffee bioavailability trial|Coffee bioavailability trial
219574011|NCT00973765|DRUG|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
219574012|NCT00973765|DRUG|placebo|placebo 2 pills po BID x 7 days
219191030|NCT01236781|DEVICE|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
219191031|NCT01236781|DEVICE|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
219420930|NCT03056807|OTHER|25° head-up position|Angle person is positioned for procedure.
219420931|NCT03056807|OTHER|55° head-up position|Angle person is positioned for procedure.
219420932|NCT05939271|PROCEDURE|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
219420933|NCT01838590|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219420934|NCT01838590|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219420935|NCT03162341|PROCEDURE|ultrasonography|The tophus volume will be assess using ultrasonography.
219574013|NCT00000396|BEHAVIORAL|Patient self-care education|
219191032|NCT05951023|DRUG|Eszopiclone 2 mg|Eszopiclone tablet (encapsulated)
219574014|NCT02011113|DRUG|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
219574015|NCT02011113|DRUG|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
219574016|NCT02964949|DRUG|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
219191033|NCT05951023|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Eszopiclone
219191034|NCT05377281|PROCEDURE|Peripheral Nerve Tissue Implantation|At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
219420936|NCT03162341|PROCEDURE|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
219191035|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
219191036|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
219191037|NCT05394935|OTHER|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest
219191038|NCT05394935|OTHER|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
219420937|NCT00219388|DRUG|Levosimendan|
219420938|NCT02469727|BEHAVIORAL|Fitbit|Participants will use the FitBit device to track their physical activity
219420939|NCT02469727|BEHAVIORAL|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
219420940|NCT02683304|BIOLOGICAL|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
219005237|NCT02399501|DEVICE|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
219005238|NCT02399501|DEVICE|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
219005239|NCT02399501|DEVICE|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
219005240|NCT02057406|DRUG|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
219005241|NCT02057406|DRUG|High EPA|
219005242|NCT02057406|OTHER|Placebo|
219005243|NCT02562794|BEHAVIORAL|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
219005244|NCT00099853|DRUG|Vildagliptin|Vildagliptin 50 mg tablets
219005245|NCT00099853|DRUG|pioglitazone|pioglitazone 45 mg qd
219005246|NCT00099853|DRUG|Placebo|Vildagliptin matching placebo
219005247|NCT01514929|DRUG|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
219005248|NCT01514929|DRUG|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
219005249|NCT01514929|DRUG|Moxifloxacin|400mg oral pill given once
219005250|NCT01514929|DRUG|Placebo|Placebo oral pill given once
219005251|NCT00756860|DRUG|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
219005252|NCT00756860|DRUG|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
219005253|NCT02187185|OTHER|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
219005254|NCT02187185|OTHER|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
219005255|NCT05162131|DRUG|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
219420941|NCT02683304|DEVICE|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
219574017|NCT05992818|DIAGNOSTIC_TEST|comparing DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium) tests to assess postoperative delirium|determine the test that is more effective and practical in the assessment of POD
219005256|NCT05162131|DRUG|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
219005257|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
219420942|NCT04467632|OTHER|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
219420943|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
219574018|NCT05754307|PROCEDURE|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
219574019|NCT05754307|PROCEDURE|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
219574020|NCT02583893|DRUG|Sirolimus|Given PO
219574021|NCT02583893|DRUG|Mitoxantrone|Given IV
219574022|NCT02583893|DRUG|Etoposide|Given IV
219574023|NCT02583893|DRUG|Cytarabine|Given IV
219574024|NCT02262793|DRUG|telmisartan|
219574025|NCT02262793|DRUG|ASA/ER-DP|
219574026|NCT04327856|PROCEDURE|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
219574027|NCT00815256|PROCEDURE|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
219005258|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
219005259|NCT05162131|DRUG|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
219005260|NCT05162131|DRUG|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
219005261|NCT05162131|DRUG|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
219005262|NCT04566211|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
219191904|NCT05166850|BEHAVIORAL|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
219574028|NCT06204211|DIAGNOSTIC_TEST|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
219005263|NCT04566211|DRUG|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
219574029|NCT03361384|DRUG|Alcohol|
219574030|NCT03361384|OTHER|Placebo (non-alcoholic beverage)|
219574031|NCT02816866|OTHER|empowered primary care model|mode of survivorship care
219574032|NCT02816866|OTHER|specialty survivor clinic|mode of survivorship care
219574033|NCT02274844|BEHAVIORAL|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
219574034|NCT01251029|DRUG|N-acetylcysteine|1200 mg orally; 600mg i.v.
219574035|NCT01251029|DRUG|Siran (N-acetylcysteine)|
219574036|NCT01892657|DRUG|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
219574037|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
219574038|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
219574039|NCT01507155|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
219574040|NCT04779541|OTHER|observation|observation of the mechanisms of acceptance or rejection of the vaccine
219574041|NCT00017719|DRUG|Lamivudine|
219574042|NCT00017719|DRUG|Lamivudine/Zidovudine|
219574043|NCT00017719|DRUG|Nelfinavir mesylate|
219574044|NCT00017719|DRUG|Nevirapine|
219574045|NCT00017719|DRUG|Zidovudine|
219005264|NCT05212649|DIAGNOSTIC_TEST|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
219005265|NCT01640145|DIETARY_SUPPLEMENT|Protein|Whey protein intake
219005266|NCT01640145|OTHER|Exercise|Unilateral low intensity exercise
219005267|NCT03654651|DRUG|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
219005268|NCT03654651|DRUG|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
219191905|NCT05166850|OTHER|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
219420944|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A."
219420945|NCT01697904|PROCEDURE|Titration of oxygen during newborn resuscitation in delivery room|
219420946|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
219420947|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
219420948|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
219420949|NCT03530202|DRUG|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
219420950|NCT03530202|DRUG|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
219420951|NCT03110198|DRUG|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
219420952|NCT03110198|DRUG|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
219005269|NCT03982927|OTHER|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
219005270|NCT02938871|DIETARY_SUPPLEMENT|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
219574046|NCT00299936|DRUG|Ribavirin, PEG-Intron|
219005271|NCT02938871|DIETARY_SUPPLEMENT|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
219191906|NCT05159219|DRUG|Colchicine Pill|Anti-inflammatory
219191907|NCT05159219|OTHER|Placebo|Inert ingredients
219191908|NCT06336122|BEHAVIORAL|Peer Coach Training - Weekly|Peer participants will be contacted by peer coaches on a weekly basis.
219191909|NCT06336122|BEHAVIORAL|Peer Coach Training - Biweekly|Peer participants will be contacted by peer coaches on a bi-weekly basis
219005272|NCT03147365|BEHAVIORAL|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
219005273|NCT03147365|BEHAVIORAL|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
219005274|NCT00846131|DRUG|Sorafenib|Randomized to Y-90 ± Sorafenib
219005275|NCT00846131|DRUG|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
219005276|NCT05352334|DIAGNOSTIC_TEST|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
219420953|NCT03110198|DRUG|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
219420954|NCT06194981|DRUG|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
219574047|NCT05284396|RADIATION|IFRT vs NFRT|involved field irradiation versus nodal field irradiation
219005277|NCT05713721|DEVICE|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
219005278|NCT05713721|OTHER|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
219005279|NCT05713721|OTHER|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
219005280|NCT05713721|OTHER|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
219005281|NCT06066658|DEVICE|cranial electrotherapy stimulation (Alpha-Stim AID)|Alpha-Stim AID
219191910|NCT03826901|DRUG|delgocitinib|Cream for topical application
219420955|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
219574048|NCT00169819|DRUG|Abciximab|
219574049|NCT00468728|DRUG|PAR-101/OPT-80|capsules
219574050|NCT00468728|DRUG|Vancomycin|Capsules
219759515|NCT04815798|COMBINATION_PRODUCT|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
219759516|NCT04815798|COMBINATION_PRODUCT|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
219759517|NCT04815798|PROCEDURE|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
219759518|NCT04470388|DRUG|EDP-514|Oral Capsule
219759519|NCT04470388|DRUG|Placebo|Placebo to match EDP-514
219759520|NCT02777086|BEHAVIORAL|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
219759521|NCT02982629|BEHAVIORAL|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
219759522|NCT05257382|PROCEDURE|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
219759523|NCT03372161|DRUG|SP-102|injection
219759524|NCT03372161|DRUG|Placebo|injection
219759525|NCT00403325|DRUG|rhuFab V2 [ranibizumab] ( Lucentis )|
219759526|NCT06353477|DRUG|EPs® 7630|EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
219759527|NCT00626535|DRUG|Esomeprazole|20mg Oral Once Daily
219759528|NCT00626535|DRUG|Matching placebo|Oral Once Daily
219759529|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
219759530|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
219005282|NCT01571427|BEHAVIORAL|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
219005283|NCT01571427|BEHAVIORAL|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
219191911|NCT05874362|OTHER|Diagnosis of depressive episode or post traumatic stress disorder|Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
219191912|NCT05874362|OTHER|No diagnosis of depressive episode or post traumatic stress disorder|No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
219191913|NCT06828094|DIETARY_SUPPLEMENT|enteral nutrition|Nutritionally complete liquid diet used in the study to replace all (exclusive enteral nutrition) or half (partial enteral nutrition) of a participants daily energy intake
219420956|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
219420957|NCT00736086|DEVICE|Vessel Closure (StarClose™)|
219420958|NCT02128620|BEHAVIORAL|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
219420959|NCT02787993|BEHAVIORAL|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
219420960|NCT00536978|DRUG|ARA-C|100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
219420961|NCT00536978|DRUG|BCNU|300 mg/m\^2 IV Over 1 Hour for 1 Day
219420962|NCT00536978|DRUG|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
219005284|NCT02068833|PROCEDURE|Gastrectomy|
219005285|NCT02068833|PROCEDURE|BPD-DS|
219005286|NCT01702454|BIOLOGICAL|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
219005287|NCT03989453|OTHER|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
219005288|NCT02093754|PROCEDURE|MRI and biopsy|
219005289|NCT00001008|DRUG|Methadone hydrochloride|
219005290|NCT00001008|DRUG|Zidovudine|
219420963|NCT00536978|DRUG|Cyclophosphamide|1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
219420964|NCT00536978|DRUG|Etoposide|100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
219420965|NCT00536978|DRUG|Fludarabine|30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
219420966|NCT00536978|DRUG|Melphalan|100 mg/m\^2 IV Over 30 Minutes for 1 Day.
219420967|NCT00536978|DRUG|Rituximab|375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
219420968|NCT00536978|OTHER|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
219420969|NCT00536978|RADIATION|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
219420970|NCT00536978|DRUG|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
219420971|NCT00536978|DRUG|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
219420972|NCT00536978|PROCEDURE|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
219005291|NCT04981743|DIETARY_SUPPLEMENT|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
219005292|NCT00221728|DEVICE|Radiofrequency|
219005293|NCT00221728|PROCEDURE|conservative surgery|
219005294|NCT00845689|DRUG|placebo|NaCl 0,9 %
219005295|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0, 2 %
219420973|NCT04200105|DEVICE|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
219420974|NCT04200105|DEVICE|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
219005296|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0,2 %
219005297|NCT00845689|PROCEDURE|Liver resection|Liver resection with Pringle maneuver
219005298|NCT03274401|DEVICE|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
219005299|NCT03274401|DEVICE|5 day ECG patch|Selection of device for monitoring clinicians' choice
219005300|NCT00224315|DRUG|ziprasidone|
219005301|NCT00224315|DRUG|risperidone|
219420975|NCT03215394|BEHAVIORAL|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
219420976|NCT03215394|BEHAVIORAL|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
219420977|NCT03215394|OTHER|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
219420978|NCT03215394|BEHAVIORAL|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
219420979|NCT00538980|DRUG|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
219420980|NCT03924791|DRUG|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
219420981|NCT03924791|DRUG|Methylprednisolone Acetate|In combination with lidocaine
219420982|NCT03924791|DRUG|Dexamethasone|In combination with lidocaine
219005302|NCT02061267|DIETARY_SUPPLEMENT|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
219005303|NCT02061267|DIETARY_SUPPLEMENT|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
219005304|NCT02061267|DIETARY_SUPPLEMENT|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
219005305|NCT02061267|DIETARY_SUPPLEMENT|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
219005306|NCT04774107|DRUG|P1101 + Ribavirin|P1101 400 µg SC
219005307|NCT02000973|DRUG|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
219005308|NCT02000973|DRUG|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
219005309|NCT02000973|DRUG|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
219005310|NCT02000973|DRUG|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
219005311|NCT05641051|DRUG|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
219005312|NCT05641051|DRUG|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
219191914|NCT03069326|DRUG|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
219191915|NCT03069326|DRUG|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
219005313|NCT06144489|DIETARY_SUPPLEMENT|Tart Cherry|Tart cherry supplementation in two doses
219005314|NCT06144489|DIETARY_SUPPLEMENT|Placebo|Control group
219005315|NCT03510884|DRUG|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
219005316|NCT03510884|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
219005317|NCT03510884|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
219005318|NCT03510884|DRUG|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
219005319|NCT03510884|DRUG|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
219005320|NCT03510884|DRUG|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
219005321|NCT03510884|DRUG|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
219005322|NCT03510884|DRUG|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
219005323|NCT03510884|DRUG|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
219005324|NCT03510884|DRUG|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
219005325|NCT03510884|DRUG|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
219005326|NCT03510884|DRUG|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
219005327|NCT03510884|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
219005328|NCT02198742|DEVICE|Miller blade|To participate in the study the subjects must have \>500 intubations with the miller blade.
219005329|NCT02198742|DEVICE|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
219005330|NCT02198742|DEVICE|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
219191916|NCT05728138|BEHAVIORAL|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
219420983|NCT05935904|OTHER|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
219420984|NCT05935904|OTHER|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
219420985|NCT04705324|PROCEDURE|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
219420986|NCT04705324|PROCEDURE|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
219420987|NCT04705324|PROCEDURE|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
219420988|NCT04505696|OTHER|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
219420989|NCT06406686|PROCEDURE|Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter|Durable block across the cavotricuspid isthmus by radiofrequency ablation.
219420990|NCT01592890|DRUG|RO4917523|\[14C\]-labeled RO4917523, single oral dose
219420991|NCT01592890|DRUG|RO4917523|\[13C\]-labeled RO4917523, single intravenous tracer dose
219420992|NCT03698513|DRUG|BMS-986177|BMS-986177 capsule
219420993|NCT03698513|OTHER|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
219420994|NCT03698513|DRUG|Clopidogrel|Clopidogrel tablet
219420995|NCT03698513|DRUG|Aspirin|Aspirin tablet
219420996|NCT01076842|DRUG|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
219420997|NCT01076842|DRUG|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
219420998|NCT01076842|DRUG|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
219420999|NCT01076842|DEVICE|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
219421000|NCT01076842|DEVICE|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
219421001|NCT03176797|DIAGNOSTIC_TEST|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
219421002|NCT02087384|BIOLOGICAL|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
219421003|NCT02087384|DRUG|Placebo|injection of 0.9% saline
219421004|NCT05912855|DEVICE|qNOX|Non
219421005|NCT01376713|BIOLOGICAL|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
219421006|NCT01376713|BIOLOGICAL|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
219421007|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
219005331|NCT00856284|DRUG|Alogliptin|Alogliptin tablets
219005332|NCT00856284|DRUG|Metformin|Metformin tablets
219005333|NCT00856284|DRUG|Glipizide|Glipizide tablets
219421008|NCT00501215|BEHAVIORAL|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
219005334|NCT01036035|DRUG|Tolterodine|Comparison of different dosages of drug
219005335|NCT01036035|DRUG|Pilocarpine|Comparison of different dosages of drug
219005336|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
219005337|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
219005338|NCT01036035|DRUG|placebo capsule|Comparison of different dosages of drug
219005339|NCT02374554|DEVICE|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
219421009|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
219421010|NCT00501215|BEHAVIORAL|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
219421011|NCT06017947|PROCEDURE|Music care|20 min music listening during transportation to hospital
219005340|NCT02374554|DEVICE|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
219421012|NCT03586882|DEVICE|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
219759531|NCT01294852|OTHER|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
219759532|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
219759533|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
219759534|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
219759535|NCT03117647|PROCEDURE|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
219759536|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
219759537|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
219759538|NCT05745610|DRUG|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
219759539|NCT05745610|DRUG|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
219759540|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
219759541|NCT00002395|DRUG|Topotecan|
219759542|NCT04691388|DRUG|sintilimab combined with anlotinib|All patients will receive sintilimab combined with anlotinib every 3 weeks
219759543|NCT05192915|DEVICE|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
219759544|NCT05812885|DEVICE|TENS|Active TENS
219005341|NCT04862364|OTHER|Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.
219421013|NCT05633134|PROCEDURE|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
219759545|NCT05912621|DRUG|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
219759546|NCT06477627|OTHER|change of environment|The participants will change from inland to coastal environment to see the effect. We will take VAMS blood samples and nose swabs from the participant to measure this effect.
219759547|NCT06477627|OTHER|no intervention|reference groups, stay in their coastal or inland environment
219759548|NCT06064487|DIAGNOSTIC_TEST|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
219005342|NCT02043249|OTHER|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
219005343|NCT05744544|PROCEDURE|External Oblique Block|Patients will be followed after EOIB which are routinely performed in our clinic.
219759549|NCT01732536|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
219759550|NCT01732536|PROCEDURE|Sham procedure|In-office bilateral sham procedure
219005344|NCT05744544|PROCEDURE|m-TAPA block|m-TAPA block
219005345|NCT01728701|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
219005346|NCT01728701|BIOLOGICAL|Normal Saline (NS)|Normal saline
219005347|NCT02560584|DRUG|Hexaminolevulinate hydrochloride|Instillation in bladder
219005348|NCT02560584|DEVICE|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
219191917|NCT04000971|OTHER|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
219421014|NCT05633134|PROCEDURE|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
219421015|NCT00005612|BIOLOGICAL|filgrastim|
219421016|NCT00005612|DRUG|carboplatin|
219421017|NCT00005612|DRUG|cyclophosphamide|
219421018|NCT00005612|DRUG|etoposide|
219421019|NCT00005612|DRUG|paclitaxel|
219421020|NCT00005612|DRUG|topotecan hydrochloride|
219421021|NCT00005612|PROCEDURE|peripheral blood stem cell transplantation|
219421022|NCT05642013|PROCEDURE|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
219759551|NCT01732536|DRUG|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
219759552|NCT03906526|DRUG|VTX-2337|Motolimod
219759553|NCT03906526|DRUG|Nivolumab|IV Nivolumab
219759554|NCT02122380|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
219759555|NCT02122380|DRUG|Placebo|1 placebo pill by mouth per day for 30 days
219759556|NCT04127318|BEHAVIORAL|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
219759557|NCT00786162|OTHER|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
219759558|NCT00786162|OTHER|BP cuff at workplace|Provided BP cuff for communal use at the worksite
219759559|NCT02212665|BEHAVIORAL|High intense interval training|
219759560|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer|
219421023|NCT05642013|OTHER|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
219574051|NCT05949671|OTHER|mediterranean, gluten-free and mediterranean gluten-free diet intervention|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
219759561|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+HIIT|
219421024|NCT01290133|DRUG|GW597599|Single dose IV infusion
219421025|NCT01290133|DRUG|Placebo|Single dose IV infusion
219574052|NCT00792870|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
219574053|NCT01168206|DIETARY_SUPPLEMENT|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
219574054|NCT01168206|DIETARY_SUPPLEMENT|1 capsule, 3 times per day|Placebo
219574055|NCT04648332|DRUG|Bupivacaine Hydrochloride|compartment psoas block
219574056|NCT03055663|OTHER|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
219759562|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+group intervention|
219759563|NCT03753048|PROCEDURE|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
219759564|NCT03753048|PROCEDURE|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
219421026|NCT04389580|DRUG|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
219421027|NCT04389580|DRUG|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
219574057|NCT03055663|PROCEDURE|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
219574058|NCT03055663|DRUG|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
219574059|NCT00140621|DRUG|Agalsidase beta|
219574060|NCT05738759|DRUG|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
219574061|NCT05738759|DRUG|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
219759565|NCT00165828|DRUG|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
219421028|NCT04586868|BEHAVIORAL|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
219421029|NCT04586868|BEHAVIORAL|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
219421030|NCT04586868|BEHAVIORAL|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
219421031|NCT03550131|BEHAVIORAL|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
219421032|NCT03550131|BEHAVIORAL|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
219421033|NCT00118027|DRUG|sulphadoxine-pyrimethamine intermittent preventive treatment|
219421034|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
219421035|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
219421036|NCT02738996|BEHAVIORAL|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
219421037|NCT04540081|OTHER|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
219421038|NCT02008838|DIETARY_SUPPLEMENT|Synbiotic|
219421039|NCT02008838|DIETARY_SUPPLEMENT|Placebo|
219421040|NCT04832919|BEHAVIORAL|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
219191918|NCT04000971|OTHER|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
219191919|NCT05717530|PROCEDURE|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
219005349|NCT05277701|DRUG|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
219574062|NCT03373734|DEVICE|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
219759566|NCT03345277|OTHER|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
219759567|NCT06354673|PROCEDURE|Stellate ganglion block|Sympathectomy by using combination of regional nerve block and systemic drugs
219759568|NCT06354673|DRUG|Dexmedetomidine|intravenous Dexmedetomidine infusion
219759569|NCT06354673|DRUG|Ketamine|intravenous ketamine infusion
219759570|NCT06255405|BEHAVIORAL|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
219759571|NCT00530881|DRUG|PHX1149|
219759572|NCT00558818|DRUG|Clevudine|clevudine 30 mg qd
219759573|NCT05987124|DRUG|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
219759574|NCT00888225|PROCEDURE|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
219759575|NCT00888225|PROCEDURE|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
219759576|NCT01510873|OTHER|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
219759577|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
219005350|NCT03063554|PROCEDURE|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
219421041|NCT03321214|OTHER|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
219421042|NCT04359355|DEVICE|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
219421043|NCT05939596|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
219421044|NCT05939596|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
219421045|NCT01928043|DRUG|Curcumin|
219005351|NCT03063554|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
219005352|NCT00664976|PROCEDURE|Electroconvulsive therapy|Electroconvulsive therapy
219005353|NCT00664976|OTHER|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
219005354|NCT00617045|DRUG|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
219005355|NCT02266745|DRUG|PT-112 Injection|
219005356|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 1|Mango (pulp/flesh) (500 g)
219005357|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
219005358|NCT03365739|DIETARY_SUPPLEMENT|Control Comparator|Vitamin C (100 mg)
219005359|NCT03848650|DEVICE|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
219005360|NCT03848650|PROCEDURE|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
219005361|NCT02904512|DEVICE|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
219005362|NCT02904512|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
219005363|NCT00227435|DRUG|val-mCyd|
219574063|NCT02712333|BEHAVIORAL|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
219574064|NCT02712333|BEHAVIORAL|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
219005364|NCT00269282|BEHAVIORAL|Self-Management Training|Asthma education and self-monitoring strategies
219005365|NCT00269282|BEHAVIORAL|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
219005366|NCT02942394|DEVICE|sinus-Obliquus Stent System|
219005367|NCT01705184|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
219005368|NCT01705184|DRUG|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
219005369|NCT01705184|DRUG|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
219191039|NCT06255288|OTHER|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
219421046|NCT01175278|PROCEDURE|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
219421047|NCT01175278|OTHER|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
219574065|NCT02199678|DRUG|Placebo|placebo
219574066|NCT02199678|DRUG|ketamine 25 mg|ketamine
219574067|NCT02199678|DRUG|ketamine 35 mg|ketamine
219574068|NCT02199678|DRUG|ketamine 50 mg|ketamine
219005370|NCT01522989|DRUG|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
219191040|NCT06082323|DRUG|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
219574069|NCT03463993|DRUG|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
219005371|NCT01522989|DRUG|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
219005372|NCT01522989|DRUG|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
219005373|NCT03372811|DRUG|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
219005374|NCT03372811|DRUG|Vehicle|Vehicle
219005375|NCT02533830|BIOLOGICAL|sugarless gum|"One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
219005376|NCT02533830|OTHER|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
219005377|NCT03578991|DEVICE|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
219191041|NCT04028284|DEVICE|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
219191042|NCT04028284|OTHER|US-guided epidural|traditional thoracic epidural procedure
219191043|NCT00949598|DRUG|letrozole|Given orally
219191044|NCT00949598|DRUG|tamoxifen citrate|Given orally
219191045|NCT03190538|OTHER|No intervention|There will be no specific intervention to these paediatric NASH patient
219191046|NCT05229822|DIAGNOSTIC_TEST|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
219191047|NCT05229822|DIAGNOSTIC_TEST|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
219191048|NCT05229822|DIAGNOSTIC_TEST|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
219191049|NCT06077214|DRUG|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
219191050|NCT06077214|DRUG|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
219191051|NCT05176470|DRUG|Cyclophosphamide|Given IV
219191052|NCT05176470|DRUG|Fludarabine|Given IV
219191053|NCT05176470|BIOLOGICAL|Lifileucel|Given by IV infusion
219191054|NCT05176470|BIOLOGICAL|Pembrolizumab|Given IV
219005378|NCT03578991|OTHER|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
219191055|NCT05176470|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219191056|NCT04075461|PROCEDURE|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
219191057|NCT04075461|PROCEDURE|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
219191058|NCT06045299|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine+Brimonidine combination ophthalmic solution
219191059|NCT06045299|DRUG|Aceclidine ophthalmic solution|Aceclidine ophthalmic solution
219421048|NCT04680078|PROCEDURE|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
219574070|NCT03463993|DRUG|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
219574071|NCT03725865|BIOLOGICAL|Induction of neural stem cells|Brain injection iNSC
219005379|NCT00844051|BIOLOGICAL|School-based influenza vaccination program|School-based influenza vaccination program
219005380|NCT06255314|PROCEDURE|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
219005381|NCT02050074|DRUG|Colesevelam|
219005382|NCT02050074|DRUG|Metformin|
219005383|NCT02050074|OTHER|Placebo|
219005384|NCT00462774|PROCEDURE|Intramyocardial injection of autologous CD133+ marrow cells|
219574072|NCT04975074|DRUG|Iron|One of each type of iron was taken orally according to the instructions and followed every two weeks
219191060|NCT06045299|DRUG|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution
219574073|NCT03659474|OTHER|compression|compression by Game Ready
219421049|NCT04680078|PROCEDURE|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
219421050|NCT00195689|BIOLOGICAL|Human anti-TNF monoclonal antibody/adalimumab|
219421051|NCT01357304|BEHAVIORAL|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
219421052|NCT04338516|DEVICE|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
219421053|NCT04338516|DEVICE|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
219421054|NCT04000555|DRUG|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
219421055|NCT04000555|OTHER|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
219421056|NCT00539916|BEHAVIORAL|Regular orange juice consumption|600 mL /day.
219421057|NCT02074306|DEVICE|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
219421058|NCT02074306|DEVICE|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
219421059|NCT01984879|OTHER|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
219421060|NCT02730936|DEVICE|Antimicrobial Hernia Repair Device|hernia repair
219421061|NCT02235987|DRUG|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
219421062|NCT02235987|DRUG|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
219421063|NCT00396149|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
219421064|NCT00396149|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
219421065|NCT01428518|DRUG|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
219421066|NCT02745236|OTHER|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
219421067|NCT02745236|OTHER|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
219421068|NCT06373042|DRUG|Intraarterial and intravenous tirofiban|Intraarterial and intravenous tirofiban after endovascular thrombectomy
219421069|NCT06373042|DRUG|Intraarterial and intravenous placebo|Intraarterial and intravenous placebo after endovascular thrombectomy
219421070|NCT00878215|DEVICE|Explorer Liver Image Guided System|
219421071|NCT00878215|DEVICE|Explorer Liver Passive Tracking|
219421072|NCT00878215|PROCEDURE|Liver surgery|-Standard of care
219421073|NCT00878215|PROCEDURE|Liver abalation|-Standard of care
219421074|NCT01911000|RADIATION|RT and hyperthermia after TACE|
219421075|NCT01364233|DEVICE|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
219421076|NCT01961843|DRUG|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
219421077|NCT01961843|DRUG|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
219421078|NCT05355727|OTHER|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
219421079|NCT04575272|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
219421080|NCT05522673|DRUG|11(R)-rolipram|Injected IV followed by PET scanning
219421081|NCT00302718|BEHAVIORAL|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
219421082|NCT00302718|BEHAVIORAL|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
219421083|NCT00302718|BEHAVIORAL|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
219421084|NCT03280342|DRUG|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
219005385|NCT01816633|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
219005386|NCT03244345|BEHAVIORAL|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
219421085|NCT03280342|DRUG|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
219421086|NCT00819585|DRUG|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
219421087|NCT00819585|DRUG|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
219005387|NCT04945902|BEHAVIORAL|Synchronous Intervention|Weekly one-hour support groups. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connection and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
219005388|NCT04945902|BEHAVIORAL|Asynchronous Intervention|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include: (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
219005389|NCT05791266|DEVICE|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
219005390|NCT00358228|DRUG|Rimonabant|
219005391|NCT02480842|OTHER|Alloplastic free ROM|
219005392|NCT02480842|OTHER|Alloplastic limited ROM|
219005393|NCT02480842|OTHER|Oncoplastic free ROM|
219005394|NCT02480842|OTHER|Oncoplastic limited ROM|
219005395|NCT02742584|PROCEDURE|Cough Stress Test|Varying bladder volumes during cough stress test.
219005396|NCT04416464|OTHER|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
219005397|NCT06520852|OTHER|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials|Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.
219005398|NCT05181683|DRUG|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
219005399|NCT04107194|DRUG|Pantoprazole 40mg|Proton pump inhibitor
219005400|NCT04107194|DRUG|Amoxicillin 1000 MG|Antibiotic
219191061|NCT03915262|BIOLOGICAL|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
219005401|NCT04107194|DRUG|Clarithromycin 500mg|Antibiotic
219005402|NCT04107194|DRUG|Metronidazole|Antibiotic
219005403|NCT04107194|DRUG|Tetracycline 125 MG|Antibiotic
219574074|NCT03659474|OTHER|ice pack|cryotherapy for ice pack
219005404|NCT04107194|DRUG|Bismuth Subcitrate|Antibiotic adjuvant
219005405|NCT04107194|DRUG|Rifabutin 150 MG|Antibiotic
219005406|NCT04107194|DRUG|Levofloxacin 500mg|Antibiotic
219574075|NCT03659474|OTHER|immersion|immersion therapy
219574076|NCT00932230|OTHER|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
219574077|NCT06285630|OTHER|Observational, no intervation will be made|No intervention will be made, only longitudinal sample collection.
219574078|NCT00683267|DRUG|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
219574079|NCT00683267|DRUG|Placebo|One dose administered by direct instillation into the surgical site
219191062|NCT06536517|DRUG|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
219191063|NCT06541184|DRUG|Ziconotide [Prialt]|Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
219421088|NCT00819585|DRUG|Allopurinol|100-300 mg orally once daily for 24 weeks.
219191064|NCT01804985|DRUG|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
219421089|NCT00819585|DRUG|Placebo Matching Canakinumab|Subcutaneous injection.
219421090|NCT00819585|DRUG|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
219421091|NCT04640207|DEVICE|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
219421092|NCT06525545|PROCEDURE|early mobilizzation of the ankle|perform flexion-extension exercises of the operated ankle
219421093|NCT01108497|PROCEDURE|Bone Marrow Aspiration|
219421094|NCT00738374|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
219421095|NCT00738374|DRUG|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
219005407|NCT04763798|OTHER|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
219421096|NCT03370991|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
219421097|NCT03370991|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder for 12 weeks
219421098|NCT00645294|DRUG|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
219421099|NCT00645294|DRUG|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
219421100|NCT00645294|DRUG|Adefovir Dipivoxil|ADV 10 mg on Day 1
219421101|NCT01286948|DRUG|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
219421102|NCT01665248|OTHER|18-F Sodium Fluoride Uptake in Positron emission tomography|
219421103|NCT05149248|BIOLOGICAL|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
219759578|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
219005408|NCT04763798|OTHER|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
219421104|NCT05149248|BIOLOGICAL|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
219421105|NCT05149248|OTHER|Control group|HPV vaccination at 12 months
219191065|NCT01804985|DRUG|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
219421106|NCT05149248|BIOLOGICAL|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
219421107|NCT04171648|OTHER|Roasted Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
219421108|NCT04171648|OTHER|Boiled Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
219421109|NCT06509724|RADIATION|Conventional Fractionated IMRT|"* Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions"
219421110|NCT06509724|RADIATION|Hypofractionated IMRT|"* Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions"
219421111|NCT05868096|OTHER|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
219421112|NCT05868096|OTHER|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
219421113|NCT01260363|PROCEDURE|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
219421114|NCT01260363|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
219421115|NCT01981278|DRUG|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
219421116|NCT01981278|DRUG|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
219421117|NCT05636371|OTHER|Written Communication|Written patient care updates provided to families of ICU patients each day
219759579|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
219005409|NCT04763798|OTHER|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
219421118|NCT02428452|BEHAVIORAL|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
219421119|NCT00022971|BIOLOGICAL|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
219421120|NCT00022971|BIOLOGICAL|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
219574080|NCT06464497|BEHAVIORAL|Whole Foods MyPlate Group|Families will receive 4-weeks of rotating menus that have been designed as a part of our preliminary work and will be adapted to support adherence with the adolescent in mind (e.g., school lunch options, on-the-go snacks). Menus and diet recommendations will align with the current macronutrient nutritional goals outlined by the 2020-2025 DGA for age-sex groups. Participants will be encouraged to eat ad libitum (i.e., as desired until full) without calorie restrictions. MyPlate will be used by participants to implement the diet. During the study, adolescents and adults in the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs.
219574081|NCT00004230|DRUG|captopril|
219574082|NCT00004230|DRUG|cyclophosphamide|
219574083|NCT00004230|PROCEDURE|autologous bone marrow transplantation|
219574084|NCT00004230|PROCEDURE|peripheral blood stem cell transplantation|
219574085|NCT00004230|RADIATION|radiation therapy|
219574086|NCT02709954|DRUG|Active inhaled delta-9-THC|"Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
219574087|NCT02709954|DRUG|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
219574088|NCT02709954|DRUG|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
219759580|NCT01024348|DRUG|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
219759581|NCT01024348|DRUG|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
219759582|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
219759583|NCT02359006|DRUG|Minocycline|Minocycline will be compared with placebo
219759584|NCT02359006|DRUG|Placebo|Placebo will be compared with minocycline
219759585|NCT05323890|DRUG|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
219005410|NCT03256214|PROCEDURE|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
219759586|NCT03855566|BEHAVIORAL|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
219759587|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
219759588|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
219759589|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
219759590|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
219759591|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
219759592|NCT05373485|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
219759593|NCT05373485|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
219759594|NCT06088173|OTHER|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
219759595|NCT06088173|OTHER|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
219421121|NCT04574609|DEVICE|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~* for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~* during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
219421122|NCT04949178|OTHER|No intervention|This is an observational study.
219574089|NCT02709954|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
219574090|NCT01478828|DRUG|Lovastatin|oral qd varying dose escalations/de-escalations
219574091|NCT00328679|DEVICE|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
219574092|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
219574093|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
219574094|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
219574095|NCT06465485|DRUG|Benralizumab|Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
219421123|NCT02822911|BEHAVIORAL|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
219421124|NCT02822911|PROCEDURE|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
219421125|NCT02822911|PROCEDURE|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
219421126|NCT02822911|PROCEDURE|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
219574096|NCT06346340|DRUG|Miebo|Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
219574097|NCT06091280|DEVICE|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
219759596|NCT03916809|OTHER|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
219759597|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
219759598|NCT01581684|DRUG|Placebo|Solution for oral administration
219759599|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
219421127|NCT02067091|DEVICE|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
219421128|NCT05657782|BIOLOGICAL|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
219191066|NCT01804985|DRUG|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
219574098|NCT04664868|PROCEDURE|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
219574099|NCT04583696|DIETARY_SUPPLEMENT|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
219759600|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
219759601|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
219191067|NCT03314688|BEHAVIORAL|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
219759602|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
219759603|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
219759604|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
219759605|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
219759606|NCT06095895|OTHER|venipuncture|An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed
219759607|NCT03728933|DRUG|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
219759608|NCT03728933|DRUG|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
219421129|NCT06399731|DEVICE|High-frequency (10Hz) rTMS|High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
219421130|NCT06399731|DEVICE|Anodal tDCS|Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
219421131|NCT04116450|PROCEDURE|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
219574100|NCT00343434|BEHAVIORAL|behavioral dietary intervention|
219574101|NCT00343434|BEHAVIORAL|exercise intervention|
219574102|NCT00343434|DIETARY_SUPPLEMENT|soy isoflavones|
219191068|NCT03314688|BEHAVIORAL|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
219421132|NCT04822272|DEVICE|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
219421133|NCT03046940|OTHER|Patient-centered style of communication|Different doctor-patient communication
219421134|NCT03046940|OTHER|Doctor-centered style of communication|Different doctor-patient communication
219574103|NCT00343434|DIETARY_SUPPLEMENT|soy protein isolate|
219574104|NCT00343434|OTHER|counseling intervention|
219574105|NCT00343434|OTHER|educational intervention|
219574106|NCT00343434|PROCEDURE|psychosocial assessment and care|
219574107|NCT00343434|PROCEDURE|quality-of-life assessment|
219574108|NCT00287300|DRUG|Sulfadoxine-Pyrimethamine|
219574109|NCT00287300|DRUG|Azithromycin|
219574110|NCT00287300|DRUG|Artesunate|
219574111|NCT04579315|OTHER|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
219574112|NCT01264549|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
219574113|NCT02430805|OTHER|dna extraction and genotyping|blood and urine sample
219574114|NCT00897949|DRUG|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
219574115|NCT00897949|DRUG|Comparator: placebo|Placebo to rizatriptan
219574116|NCT01712919|RADIATION|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
219421135|NCT03334396|DRUG|Baricitinib|Administered orally.
219574117|NCT01712919|DRUG|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
219005411|NCT03256214|PROCEDURE|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
219421136|NCT03334396|DRUG|Placebo|Administered orally.
219421137|NCT01070524|DRUG|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
219421138|NCT01070524|DRUG|Budesonide extrafine pMDI|Budesonide extrafine pMDI
219421139|NCT01070524|DRUG|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
219421140|NCT04212858|GENETIC|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
219421141|NCT05381012|OTHER|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
219421142|NCT05381012|OTHER|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
219421143|NCT05366270|DEVICE|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
219421144|NCT05366270|DEVICE|Sham|Sham (mild heating) using Heckel Hyperthermia Device
219421145|NCT01149642|DIETARY_SUPPLEMENT|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
219574118|NCT01712919|BIOLOGICAL|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
219574119|NCT00114621|DRUG|Anthrax Vaccine|
219574120|NCT00114621|PROCEDURE|Blood Chemistry|
219005412|NCT02908555|OTHER|No intervention|This is a descriptive study with no intervention
219005413|NCT00642577|DRUG|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
219005414|NCT00642577|DRUG|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
219005415|NCT00642577|DRUG|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
219005416|NCT00642577|DRUG|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
219005417|NCT01073709|DRUG|Acetaminophen|
219421146|NCT01149642|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
219421147|NCT01969799|DRUG|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
219421148|NCT01969799|DRUG|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
219421149|NCT04914377|DRUG|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
219421150|NCT04026854|BEHAVIORAL|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
219421151|NCT05123651|BIOLOGICAL|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
219574121|NCT00114621|PROCEDURE|Hematology|
219574122|NCT00114621|PROCEDURE|Urinalysis|
219574123|NCT01553747|DRUG|Eluxadoline|Oral tablets twice daily
219574124|NCT01553747|DRUG|Placebo|Oral tablets twice daily
219574125|NCT06242561|BEHAVIORAL|Data collection from sepsis management|observational study
219574126|NCT04574128|PROCEDURE|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
219574127|NCT06097793|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
219759609|NCT03728933|DRUG|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
219005418|NCT00449020|DRUG|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
219005419|NCT00449020|DRUG|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
219005420|NCT00449020|DRUG|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
219005421|NCT00449020|RADIATION|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
219574128|NCT06301061|DEVICE|Equistasi®|Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
219574129|NCT06301061|DEVICE|Sham|Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
219759610|NCT04236999|BEHAVIORAL|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~* Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~* Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~* Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
219005422|NCT01391559|DRUG|arformoterol|15 mcg administered via nebulizer
219005423|NCT01391559|DRUG|salmeterol|50 mcg delivered vis Diskus
219421152|NCT05405036|OTHER|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
219421153|NCT05044260|PROCEDURE|Direct sinus lift with titanium reinforced PTFE membrane|Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
219421154|NCT03195062|OTHER|Test meal|Liquid test meal (fructose+glucose)
219005424|NCT03262818|DEVICE|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
219005425|NCT03262818|DEVICE|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
219005426|NCT00267046|DRUG|Palifermin|180 mcg/kg 3 days prior to chemotherapy
219421155|NCT02159469|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
219421156|NCT02338791|DEVICE|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
219421157|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
219759611|NCT04551300|DRUG|VS-505|4 dosages of experimental drug
219759612|NCT04551300|DRUG|Sevelamer Carbonate|Active Comparator
219759613|NCT02838641|DEVICE|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
219005427|NCT00267046|DRUG|Placebo|Single dose 3 days prior to chemotherapy
219005428|NCT00267046|DRUG|Adriamycin (Doxorubicin)|30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
219005429|NCT00267046|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
219005430|NCT00267046|DRUG|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
219005431|NCT00267046|DRUG|Cisplatin|120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
219005432|NCT05277740|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219005433|NCT03421392|OTHER|non interventional study|non interventional study
219005434|NCT05485597|DEVICE|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
219191069|NCT00179400|DRUG|Pioglitazone|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
219191070|NCT00179400|DRUG|Placebo|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
219191071|NCT00179400|PROCEDURE|Pancreatic Clamp Study|During the clamp procedure, glucose (a sugar) and insulin were infused with an IV catheter, and blood samples were collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism.
219191072|NCT03765619|DRUG|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
219191073|NCT05572684|DRUG|NC410|NC410 will be given intravenously (IV) every 2 weeks
219191074|NCT05572684|DRUG|pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
219191075|NCT06288360|DRUG|Camrelizumab|200 mg, intravenously, 20-60 min. 2 times, every 21 days
219191076|NCT06288360|DRUG|Paclitaxel-albumin|260 mg/m² over 30 min, 3 times, every 21 days
219191077|NCT06288360|DRUG|Cisplatin|4 h, 75-80 mg/m², 3 times, every 21 days
219574130|NCT06301061|DRUG|Gabapentin; Pregabalin; Duloxetine; Amitriptyline|Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
219191078|NCT06288360|PROCEDURE|radical surgery|Radical hysterectomy + pelvic lymphadenectomy 士 para-aortic lymphadenectomy
219191079|NCT05874453|OTHER|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
219191080|NCT04243070|DIAGNOSTIC_TEST|3-channel Holter ECG recording|3-channel Holter ECG recording for patients undergoing an EPS
219191081|NCT04243070|DIAGNOSTIC_TEST|12-channel Holter ECG recording|12-channel Holter ECG recording for patients undergoing a routine follow-up
219191082|NCT06235190|DEVICE|Felix NeuroAI Wristband|The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
219191083|NCT06235190|DEVICE|Sham Device|The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
219191084|NCT06258681|OTHER|Incentive spirometer|The incentive spirometry group will continue training with Volumetric Triflo. It is asked to exhale at first and then hold their breath for at least 3 seconds after taking as deep a breath as possible.
219191085|NCT06258681|OTHER|Individualized respiratory training group|Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle.
219191086|NCT01009788|DRUG|ABT-888|Capsules (30-40 mg) taken orally twice a day on days 1-7 of each 28 day cycle
219191087|NCT01009788|DRUG|temozolomide|Capsules (150 mg/m\^2 initially, and 200 mg/m\^2 starting cycle 2 if tolerated) taken orally once a day on days 1 through 5 of a 28 day cycle
219191088|NCT06350669|DEVICE|Vestibular rehabilitation phone application|The standard vestibular rehabilitation process, with the support of a phone app throughout the process
219191089|NCT06514963|DRUG|HRS-9813|Specified dose on specified days
219191090|NCT06514963|DRUG|Placebo|Specified dose on specified days
219191091|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
219191092|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
219191093|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
219191094|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
219191095|NCT05253586|PROCEDURE|Laparoscopic|Surgeon
219191096|NCT05253586|PROCEDURE|Robotic|Versius system
219191097|NCT05832047|DRUG|Plasma solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
219191098|NCT05832047|DRUG|Lactated Ringer solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
219574131|NCT01570348|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
219574132|NCT01570348|DRUG|Cyclophosphamide|Given IV
219005435|NCT06315439|PROCEDURE|Endoscopic ultrasound fine needle biopsy|"EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging."
219421158|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
219421159|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
219421160|NCT02927873|DRUG|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
219421161|NCT05040789|BIOLOGICAL|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
219421162|NCT02910544|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
219421163|NCT06243341|DIETARY_SUPPLEMENT|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
219421164|NCT01519284|DRUG|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
219421165|NCT01519284|DRUG|Entacapone|Entacapone 200 mg
219421166|NCT01519284|DRUG|Placebo|placebo (four times a day)
219421167|NCT01519284|DRUG|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
219421168|NCT01519284|DRUG|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
219421169|NCT01519284|DRUG|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
219421170|NCT03629041|DEVICE|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
219421171|NCT03629041|DEVICE|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
219421172|NCT01262755|BEHAVIORAL|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
219421173|NCT03531333|PROCEDURE|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
219421174|NCT04986020|DIAGNOSTIC_TEST|MRI|Identification of novel biomarkers from MRI
219421175|NCT00503542|DRUG|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
219421176|NCT00503542|DRUG|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
219421177|NCT00503542|DRUG|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
219421178|NCT00503542|OTHER|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
219421179|NCT03771456|PROCEDURE|Colorectal resections|Colorectal resections
219421180|NCT04823767|OTHER|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
219421181|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
219421182|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
219421183|NCT00383721|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
219421184|NCT00383721|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
219421185|NCT00383721|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
219421186|NCT00663455|DRUG|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
219421187|NCT00607568|DRUG|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
219574133|NCT01570348|DRUG|Fludarabine Phosphate|Given IV
219574134|NCT01570348|OTHER|Laboratory Biomarker Analysis|Correlative studies
219574135|NCT01570348|DRUG|Mycophenolate Mofetil|Given PO
219574136|NCT01570348|DRUG|Mycophenolic Acid|Given PO
219574137|NCT01570348|OTHER|Quality-of-Life Assessment|Ancillary studies
219574138|NCT01570348|DRUG|Tacrolimus|Given IV or PO
219574139|NCT01570348|RADIATION|Total-Body Irradiation|Undergo TBI
219574140|NCT05166681|PROCEDURE|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
219574141|NCT02011750|DRUG|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
219421188|NCT01271387|DRUG|tasimelteon|20 mg tasimelteon capsules, PO single dose
219574142|NCT02011750|DRUG|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
219574143|NCT05611450|OTHER|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
219574144|NCT04666519|DIAGNOSTIC_TEST|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
219574145|NCT02255682|DRUG|Simvastatin|
219574146|NCT02255682|DIETARY_SUPPLEMENT|Q10|
219574147|NCT01524250|DRUG|corticosteroids|1250mg of oral prednisone daily for 3 days
219574148|NCT01524250|DRUG|corticosteroids|1000mg IV methylprednisolone daily for 3 days
219574149|NCT02563717|DEVICE|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
219421189|NCT00251407|DRUG|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
219421190|NCT00251407|DRUG|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
219421191|NCT00251407|DRUG|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
219574150|NCT02563717|DEVICE|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
219574151|NCT02909738|OTHER|Volunteer to pedal a bicycle|
219574152|NCT03552094|OTHER|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
219574153|NCT03552094|OTHER|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
219574154|NCT01490931|DRUG|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
219574155|NCT04293094|DRUG|AMG 650|AMG 650 administered orally as a tablet.
219574156|NCT06531369|DRUG|Flumazenil Injection（F1 group）|Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
219574157|NCT06531369|DRUG|Flumazenil Injection（F2 group）|Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
219574158|NCT06531369|DRUG|Saline（C group）|Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
219574159|NCT03453840|DRUG|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
219574160|NCT06330181|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart"
219574161|NCT06330181|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
219574162|NCT06612918|DEVICE|high-intensity laser acupuncture and the exercise program|The experimental group will receive high-intensity lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises.
219574163|NCT06612918|OTHER|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
219574164|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
219574165|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
219574166|NCT05322837|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
219574167|NCT05536830|OTHER|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
219574168|NCT05004350|DRUG|Encorafenib|oral hard capsule
219759614|NCT01784029|DRUG|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
219759615|NCT03496116|OTHER|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
219759616|NCT01317992|DRUG|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
219421192|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
219421193|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
219421194|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
219421195|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
219421196|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
219574169|NCT05004350|DRUG|Cetuximab|intravenous infusion
219574170|NCT05004350|DRUG|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
219574171|NCT02371421|DRUG|Allopurinol|
219574172|NCT01089621|DRUG|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
219574173|NCT03729154|BEHAVIORAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
219574174|NCT04736108|DRUG|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
219574175|NCT04736108|DRUG|Prednisolone|5 mg oral low dose prednisone, once daily
219574176|NCT04736108|DRUG|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
219574177|NCT06577051|DIAGNOSTIC_TEST|Eustachian tube function test with 226 and 1000 Hz probes|In children undergoing tonsillectomy ± adenoidectomy without eustachian dysfunction, tympanometry with 226 Hz and 1000 Hz probes, ipsi and contralateral acoustic reflexes with 226 Hz probe, eustachian function test with 226 Hz probe (automatic Williams test) and play audiometry in young children and pure tone audiometry in older children are aimed to control tubal functions in preoperative period, postoperative day 1 and week 2.
219759617|NCT01317992|DRUG|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
219759618|NCT01155557|DEVICE|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
219759619|NCT01155557|BEHAVIORAL|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
219574178|NCT05730907|DRUG|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
219759620|NCT00639457|DRUG|Pioglitazone|Oral 30mg/day for 16 weeks
219421197|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
219421198|NCT00703755|DRUG|Placebo|Placebo
219421199|NCT04068324|DIETARY_SUPPLEMENT|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
219574179|NCT02603978|BEHAVIORAL|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
219574180|NCT02603978|BEHAVIORAL|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
219759621|NCT00639457|BEHAVIORAL|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
219759622|NCT03324789|OTHER|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
219759623|NCT03324789|OTHER|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
219759624|NCT02403544|RADIATION|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
219759625|NCT02403544|DRUG|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
219759626|NCT02403544|DRUG|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
219421200|NCT04501198|DEVICE|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
219421201|NCT04501198|DEVICE|Moxibustion combined with lifestyle intervention.|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
219421202|NCT04501198|DEVICE|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
219421203|NCT04613102|DRUG|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
219421204|NCT04873076|DEVICE|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
219421205|NCT01279304|RADIATION|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
219421206|NCT01279304|RADIATION|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
219421207|NCT01279304|RADIATION|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
219421208|NCT00436319|PROCEDURE|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
219421209|NCT05360823|OTHER|Birth ball|Exercises for childbirth
219421210|NCT05360823|OTHER|Squatting|Exercises for childbirth
219421211|NCT01283997|OTHER|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
219421212|NCT01283997|DRUG|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
219421213|NCT06041685|PROCEDURE|local warming|local warming on the site for arterial catheterization using forced air warmer
219421214|NCT04617899|DIAGNOSTIC_TEST|Intravascular imaging|Use of imaging catheter
219421215|NCT02017899|BIOLOGICAL|S. sonnei 1790GAHB|
219421216|NCT02017899|BIOLOGICAL|Placebo|
219421217|NCT03367442|OTHER|no intervention|no intervention
219421218|NCT04890106|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
219421219|NCT04890106|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
219421220|NCT00961870|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
219421221|NCT05453448|DRUG|tenofovir alafenamide|Antiviral therapy
219421222|NCT05453448|DRUG|Entecavir|entecavir
219421223|NCT02299648|OTHER|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
219574181|NCT02603978|BEHAVIORAL|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
219574182|NCT00650988|PROCEDURE|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
219574183|NCT00232271|DRUG|Clexane|
219574184|NCT03808740|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day.
219574185|NCT03808740|DRUG|Placebo|sugar pill
219574186|NCT06234774|PROCEDURE|Robot-assisted laparoscopic surgery|
219005436|NCT02715414|BEHAVIORAL|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
219421224|NCT04907422|DIAGNOSTIC_TEST|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
219421225|NCT04907422|DIAGNOSTIC_TEST|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
219421226|NCT06376838|DEVICE|DLMR01|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
219421227|NCT06376838|DEVICE|Rejuran|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
219421228|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
219421229|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
219421230|NCT02967484|DEVICE|acupuncture|"1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
219421231|NCT02533661|OTHER|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
219421232|NCT03969836|DEVICE|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
219421233|NCT02020460|DEVICE|Subdural trial lead|
219421234|NCT02020460|DEVICE|Epidural trial lead|
219421235|NCT05533333|BEHAVIORAL|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
219421236|NCT01812486|RADIATION|dose de escalation|
219421237|NCT01812486|RADIATION|standard dose|
219421238|NCT02541448|DEVICE|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
219421239|NCT02858687|OTHER|Nasopharyngeal swab|
219421240|NCT00241163|PROCEDURE|Fibrinogen (human) + thrombin (human) (TachoSil)|
219421241|NCT00168324|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
219421242|NCT00168324|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
219421243|NCT00168324|OTHER|Sham Injection|Sham injection on Day 0.
219421244|NCT01619592|DEVICE|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
219421245|NCT01187836|DRUG|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
219759627|NCT03235050|DRUG|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
219421246|NCT01187836|DRUG|Placebo|Placebo administered for 14 hours.
219421247|NCT04781452|OTHER|standard treatment|there ist no Intervention but our standart Treatment in the center
219421248|NCT03342937|DRUG|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
219421249|NCT03372629|DRUG|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
219421250|NCT03372629|DRUG|Placebo oral capsule|Placebo capsules matching ID-085 capsules
219421251|NCT00142402|DRUG|Modafinil|
219759628|NCT03235050|DRUG|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
219759629|NCT03235050|DRUG|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
219759630|NCT03235050|DRUG|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
219421252|NCT01677624|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
219421253|NCT05518669|DEVICE|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
219421254|NCT03296852|DIAGNOSTIC_TEST|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
219574187|NCT06234774|PROCEDURE|Conventional (non-robotic) laparoscopic surgery|
219574188|NCT01404052|DEVICE|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
219574189|NCT00754494|DRUG|erlotinib hydrochloride|Given PO
219574190|NCT00754494|OTHER|placebo|Given PO
219421255|NCT03296852|DRUG|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
219421256|NCT00377585|BIOLOGICAL|Fluarix|
219421257|NCT00377585|BIOLOGICAL|adjuvanted influenza vaccine|
219421258|NCT03181841|DRUG|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
219421259|NCT03181841|DRUG|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
219421260|NCT01747811|DEVICE|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
219421261|NCT01747811|DEVICE|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
219421262|NCT03393468|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
219421263|NCT03012633|DEVICE|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
219574191|NCT00754494|OTHER|laboratory biomarker analysis|Correlative studies
219574192|NCT00867048|DRUG|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
219574193|NCT03662763|DRUG|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
219574194|NCT03662763|DRUG|Placebo oral capsule|
219759631|NCT03235050|DRUG|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
219759632|NCT03852030|BEHAVIORAL|Text or email message|Text or email messages sent to research participants
219421264|NCT04004377|OTHER|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
219421265|NCT00812240|DRUG|Masitinib|
219421266|NCT00812240|DRUG|Imatinib|imatinib 400 mg or 600 mg per day, per os
219574195|NCT01914172|OTHER|online questionairres|see group descriptions
219759633|NCT02823002|PROCEDURE|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
219759634|NCT02823002|PROCEDURE|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
219759635|NCT02823002|PROCEDURE|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
219759636|NCT02823002|PROCEDURE|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
219759637|NCT02823002|PROCEDURE|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
219759638|NCT02823002|PROCEDURE|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
219759639|NCT02823002|DRUG|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
219759640|NCT02823002|DRUG|Buffer|Sodium Bicarbonate
219759641|NCT02870465|PROCEDURE|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
219759642|NCT03995160|PROCEDURE|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
219759643|NCT03995160|PROCEDURE|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
219759644|NCT01171911|DRUG|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
219759645|NCT05390164|DIAGNOSTIC_TEST|skin biopsy|skin biopsy to be analyzed by ELISA
219759646|NCT04101097|OTHER||
219005437|NCT02715414|BEHAVIORAL|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
219005438|NCT00460408|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
219005439|NCT00853801|BEHAVIORAL|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
219421267|NCT05378022|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
219421268|NCT05378022|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
219421269|NCT01337167|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
219421270|NCT01337167|BIOLOGICAL|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
219421271|NCT01337167|BIOLOGICAL|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
219421272|NCT01337167|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
219421273|NCT01337167|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
219421274|NCT01337167|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
219421275|NCT01337167|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
219421276|NCT01337167|BIOLOGICAL|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
219421277|NCT03833817|BEHAVIORAL|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
219421278|NCT03713957|DRUG|GRF6021|GRF6021 for IV infusion
219421279|NCT03713957|OTHER|Placebo|Placebo for IV infusion
219421280|NCT02504177|DRUG|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
219421281|NCT02504177|DRUG|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
219574196|NCT01620723|OTHER|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
219005440|NCT00865124|DRUG|Spironolactone|25 mg capsule daily for 6 months
219005441|NCT00865124|DRUG|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
219005442|NCT00865124|OTHER|Placebo|Placebo capsule daily
219005443|NCT01380873|DRUG|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
219574197|NCT01620723|OTHER|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
219005444|NCT01380873|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
219421282|NCT00884221|DRUG|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
219421283|NCT00884221|DRUG|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
219421284|NCT02757092|OTHER|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
219421285|NCT03363919|DEVICE|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
219421286|NCT03363919|DEVICE|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
219421287|NCT01771536|OTHER|Decision Aid|
219421288|NCT00989404|DRUG|Zanamivir|Rotahaler placebo 10mg BID 5 days
219421289|NCT00989404|DRUG|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
219421290|NCT00989404|DRUG|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
219421291|NCT03230617|DEVICE|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
219421292|NCT01565434|OTHER|CR1 impact|
219421293|NCT02627833|OTHER|observation|Record lung function, Lung clearance index, inflammatory status
219421294|NCT01367314|DRUG|NVC-422|Dermal Gel applied 3 times per day for 7 days
219574198|NCT06815601|OTHER|rTMS|Intermittent theta burst stimulation (iTBS) will be utilized since they have been reported to have a cortical neuromodulatory effect. The iTBS protocol will be applied over primary motor cortex to investigate its effect on corticospinal excitability and functional outcome. Theta burst stimulation (TBS) consists of bursts of pulses containing 3 pulses at 50 Hz (3 pulses per second) repeated at 200 ms intervals (5 Hz). During iTBS, a 2 second train of TBS is repeated every 10 seconds (600 pulses in 190 seconds).
219759647|NCT02896946|RADIATION|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
219005445|NCT01380873|DRUG|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
219005446|NCT02212392|DRUG|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
219421295|NCT03717116|DIAGNOSTIC_TEST|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
219421296|NCT02255617|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
219421297|NCT01646398|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
219574199|NCT06815601|OTHER|Sham rTMS|Sham iTBS protocols will be applied with the same parameters as in iTBS protocol. However, sham coil will be used.
219005447|NCT03287440|BEHAVIORAL|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
219005448|NCT03287440|BEHAVIORAL|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
219005449|NCT01654367|DRUG|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
219005450|NCT01674270|DRUG|Degarelix|
219005451|NCT01674270|DRUG|Casodex|
219005452|NCT01674270|DRUG|LHRH Agonist|
219005453|NCT06507982|DEVICE|EWL|the working length determination with EAL method
219005454|NCT06507982|DEVICE|SWL|In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
219005455|NCT06507982|DEVICE|RWL|Radiographic method was used for determining the working length
219005456|NCT00001830|DRUG|Th2 cells in allo HSCTT|
219005457|NCT00001830|DRUG|Th2 Cells|
219421298|NCT01646398|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
219421299|NCT01051115|DRUG|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
219421300|NCT02174016|DIETARY_SUPPLEMENT|Ketogenic diet|
219421301|NCT03357666|DRUG|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
219421302|NCT03357666|DRUG|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
219421303|NCT03357666|DRUG|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
219421304|NCT03357666|DRUG|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
219421305|NCT03357666|DRUG|Placebo|Vaginal administration, two tablets once a day for 7 days
219421306|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
219421307|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
219421308|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
219421309|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
219421310|NCT02185248|BEHAVIORAL|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
219421311|NCT04625361|DRUG|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
219421312|NCT03943108|DIAGNOSTIC_TEST|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
219421313|NCT05459792|PROCEDURE|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
219421314|NCT05459792|PROCEDURE|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
219759648|NCT01808378|DRUG|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
219005458|NCT02829515|PROCEDURE|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
219421315|NCT05459792|PROCEDURE|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
219421316|NCT03125161|DRUG|HAI|HAI
219421317|NCT03125161|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
219421318|NCT01039818|RADIATION|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
219421319|NCT01039818|RADIATION|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
219421320|NCT02559557|OTHER|Educational Intervention|Participate in focus groups
219421321|NCT02559557|OTHER|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
219421322|NCT02559557|OTHER|Quality-of-Life Assessment|Answer questionnaires
219759649|NCT00598650|DRUG|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
219759650|NCT02015247|PROCEDURE|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
219759651|NCT02315222|DIETARY_SUPPLEMENT|Regenium|
219759652|NCT02315222|DIETARY_SUPPLEMENT|Placebo|
219759653|NCT02315222|PROCEDURE|Full Mouth Disinfection|
219759654|NCT06306001|DRUG|Methylene Blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
219759655|NCT06306001|OTHER|Placebo|Subjects in the placebo arm will receive normal saline in the same volumetric dose as methylene blue in the intervention arm
219759656|NCT05017623|DRUG|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
219759657|NCT02912819|OTHER|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
219005459|NCT03028714|BEHAVIORAL|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
219005460|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
219005461|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
219421323|NCT02559557|OTHER|Questionnaire Administration|Answer questionnaires
219421324|NCT06280612|OTHER|Pet therapy|The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
219421325|NCT01144195|DRUG|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
219574200|NCT06815601|BEHAVIORAL|Motor training|The motor training will be focused on participant's hand motor function such as grasping function.
219574201|NCT04789967|BEHAVIORAL|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
219421326|NCT03327519|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
219421327|NCT03327519|BEHAVIORAL|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
219421328|NCT01913171|OTHER|Exercise|
219574202|NCT04789967|BEHAVIORAL|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
219574203|NCT04789967|OTHER|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
219574204|NCT04387071|BIOLOGICAL|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
219574205|NCT04387071|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
219421329|NCT05494983|OTHER|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
219574206|NCT05981495|DEVICE|NanoDetect-TB|This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
219574207|NCT00977431|DRUG|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
219005462|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
219574208|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
219005463|NCT04207970|OTHER|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
219005464|NCT05657314|DIETARY_SUPPLEMENT|Active Comparator|Consists of 15 grams of pea protein
219005465|NCT00777478|DRUG|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
219005466|NCT04478955|DIAGNOSTIC_TEST|Schirmer test|Tear tests Meibomian gland grading test
219421330|NCT05494983|OTHER|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
219759658|NCT00023335|DRUG|Rifapentine|
219759659|NCT00023335|DRUG|Isoniazid|
219759660|NCT05935956|DEVICE|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
219759661|NCT00415090|DRUG|Nevirapine|Switch one of ARV drugs to Nevirapine
219759662|NCT03606577|DRUG|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
219005467|NCT00481000|BEHAVIORAL|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
219005468|NCT01417273|DIETARY_SUPPLEMENT|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
219421331|NCT05494983|OTHER|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
219421332|NCT04595357|PROCEDURE|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
219421333|NCT01933204|OTHER|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
219421334|NCT01933204|DRUG|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
219574209|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
219005469|NCT01417273|DRUG|Drug: placebo|1 cap placebo/day for 12 month
219005470|NCT04390945|DRUG|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
219005471|NCT05841394|DRUG|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
219574210|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
219574211|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
219574212|NCT01897623|OTHER|ultrasound of aorta|
219574213|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10\^9 virus particles.
219574214|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10\^10 virus particles.
219574215|NCT01151319|BIOLOGICAL|pSG2.HIVconsv|DNA at 4mg per dose.
219574216|NCT01151319|BIOLOGICAL|MVA.HIVconsv|Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
219759663|NCT03606577|DRUG|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
219759664|NCT03606577|DRUG|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
219005472|NCT05841394|DRUG|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
219005473|NCT05841394|DRUG|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
219574217|NCT01151319|OTHER|Placebo|Phosphate buffered saline
219574218|NCT05883033|DEVICE|VAC|Vacuum Assisted Closure device
219574219|NCT04701034|DRUG|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
219574220|NCT04701034|DRUG|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
219759665|NCT03606577|DRUG|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
219759666|NCT02415556|DRUG|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
219759667|NCT02415556|DRUG|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
219759668|NCT04885101|PROCEDURE|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
219005474|NCT05841394|DRUG|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
219005475|NCT00294268|BEHAVIORAL|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
219191099|NCT05832047|DRUG|8-hour aggressive hydration|If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
219421335|NCT04154995|DIAGNOSTIC_TEST|Venipuncture|Blood testing at 3, 6 and 12 months
219759669|NCT04885101|PROCEDURE|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
219421336|NCT04154995|DIAGNOSTIC_TEST|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
219421337|NCT01033604|PROCEDURE|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
219421338|NCT01033604|PROCEDURE|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
219421339|NCT01603979|BIOLOGICAL|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
219421340|NCT00574119|DRUG|spironolactone|spironolactone 50 mg daily for 6 months
219421341|NCT02860754|OTHER|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
219421342|NCT04084132|PROCEDURE|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
219421343|NCT05359406|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
219421344|NCT03008733|OTHER|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
219421345|NCT03008733|OTHER|Electro myography surface nerves|Electro myography surface nerves
219421346|NCT01780909|DRUG|Paromomycin Sulfate Fasted State|
219421347|NCT01780909|DRUG|Paromomycin Sulfate Fed State|
219421348|NCT01780909|DRUG|Paromomycin Sulfate w/ domperidone|
219421349|NCT01780909|DRUG|Paromomycin Sulfate w/ loperamide HCl|
219574221|NCT04701034|DRUG|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
219574222|NCT04701034|DRUG|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
219759670|NCT04885101|PROCEDURE|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
219759671|NCT04699344|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
219759672|NCT06434558|PROCEDURE|Cryosa Procedure|The Cryosa Procedure is part of the ARCTIC-3 protocol (IRB #854182). Therefore, all patients enrolled in this study are expected to undergo the Cryosa Procedure. Undergoing the Cryosa Procedure is not a part of this protocol.
219759673|NCT02781441|BEHAVIORAL|Question prompt list (QPL)|
219759674|NCT02781441|BEHAVIORAL|Education brochure of Groupe Français des Myélodysplasies|
219759675|NCT01041430|OTHER|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
219759676|NCT01041430|OTHER|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
219759677|NCT00105534|DRUG|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
219759678|NCT00105534|OTHER|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
219191100|NCT01988883|DRUG|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
219191101|NCT01988883|DRUG|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
219421350|NCT04256304|BEHAVIORAL|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
219421351|NCT01353144|DRUG|aspirin|aspirin, 100 mg, qd x 8 weeks
219421352|NCT00438789|DRUG|eculizumab|600mg IV every week and 900mg IV every 2 weeks
219421353|NCT01615796|DRUG|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
219421354|NCT01615796|DRUG|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
219191102|NCT01988883|DRUG|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
219191103|NCT06451835|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
219421355|NCT02905942|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
219421356|NCT02905942|DRUG|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
219421357|NCT03114878|OTHER|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
219421358|NCT03114878|BEHAVIORAL|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
219574223|NCT01758341|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
219574224|NCT01758341|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
219574225|NCT01758341|DEVICE|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
219574226|NCT03143387|OTHER|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
219574227|NCT03143387|OTHER|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
219574228|NCT04676815|PROCEDURE|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
219574229|NCT05470933|DRUG|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
219574230|NCT00005119|PROCEDURE|Measures of calcium and bone turnover|
219574231|NCT02138981|PROCEDURE|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
219574232|NCT02138981|PROCEDURE|Immediate Resection|patients received immediate surgical resection.
219574233|NCT01094028|DRUG|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
219574234|NCT00933283|DRUG|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
219574235|NCT00933283|DRUG|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
219574236|NCT02641002|DRUG|CC-90002|Monoclonal Ab to CD47
219574237|NCT04826068|BEHAVIORAL|Emotional Processing|Processing Emotions of others based on photographs of faces
219574238|NCT00308126|DRUG|Hydroxyethyl Starch 130/0.4 (Voluven)|
219574239|NCT04588688|DRUG|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
219005476|NCT03750604|DIAGNOSTIC_TEST|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
219005477|NCT03247530|DRUG|Placebo|Placebo was administered once daily
219005478|NCT03247530|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
219005479|NCT03247530|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
219005480|NCT00635960|DRUG|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
219005481|NCT00635960|DRUG|Placebo|Same as for Growth hormone group
219005482|NCT05263323|OTHER|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
219005483|NCT05263323|OTHER|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
219421359|NCT03786198|BEHAVIORAL|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
219005484|NCT05953220|OTHER|Exclusive tobacco smoking|No intervention, participants own tobacco products
219005485|NCT05953220|OTHER|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
219005486|NCT05953220|OTHER|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
219005487|NCT05953220|OTHER|No use of e-cigarettes or tobacco smoking|No intervention
219421360|NCT03786198|BEHAVIORAL|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
219421361|NCT05795010|OTHER|MRD test|ctDNA detection based on tumor whole exon sequencing
219421362|NCT00604435|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
219421363|NCT00604435|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
219421364|NCT03582735|OTHER|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
219421365|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
219421366|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
219421367|NCT02592395|DRUG|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
219574240|NCT04597489|PROCEDURE|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
219574241|NCT04597489|PROCEDURE|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
219574242|NCT02346851|PROCEDURE|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
219574243|NCT06616207|DRUG|Placebo|Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
219574244|NCT06616207|DRUG|Povidone-iodine solution|Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
219574245|NCT06502587|OTHER|blood flow restriction training|"we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes"
219421368|NCT02592395|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
219421369|NCT04843826|PROCEDURE|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
219421370|NCT00004938|DRUG|fluconazole|
219421371|NCT06429423|BEHAVIORAL|Acute exercise low intensity|"A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
219574246|NCT06502587|OTHER|ultrasound therapy|All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
219574247|NCT05009732|DRUG|GT0918|300mg once daily orally
219574248|NCT05009732|DRUG|Standard of care|Local standard of care per written policies or guidelines
219574249|NCT05009732|DRUG|Matching placebo|Matching placebo
219421372|NCT06429423|BEHAVIORAL|Acute exercise moderate intensity|"A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
219421373|NCT05467462|DRUG|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
219421374|NCT05467462|DRUG|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
219421375|NCT05467462|DRUG|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
219421376|NCT05467462|DRUG|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
219421377|NCT04781907|PROCEDURE|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
219421378|NCT00303615|DRUG|Fluoxymesterone 10 mg|
219421379|NCT00303615|DRUG|Anastrozole 1 mg|
219421380|NCT03939611|OTHER|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
219421381|NCT03939611|OTHER|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
219421382|NCT05195268|PROCEDURE|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
219421383|NCT03701646|DEVICE|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
219421384|NCT02667457|RADIATION|99mTc-rhAnnexin V-128|
219421385|NCT02475850|OTHER|Evidence-based tailored fall prevention|
219421386|NCT02475850|OTHER|Usual care|
219421387|NCT01930929|PROCEDURE|Bariatric surgery|
219421388|NCT01653002|OTHER|No intervention|
219421389|NCT02766595|OTHER|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
219421390|NCT03058822|DRUG|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
219421391|NCT03917225|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
219421392|NCT03917225|DRUG|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
219421393|NCT02017821|BEHAVIORAL|high intensity aerobic training|
219574250|NCT04606836|DRUG|Bupivacaine Hydrochloride|See group descriptions
219574251|NCT06074302|DEVICE|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
219005488|NCT00936585|OTHER|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
219421394|NCT01746940|DRUG|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
219421395|NCT01746940|DRUG|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
219421396|NCT01746940|DRUG|Placebo Topical Solution|Placebo Topical Solution
219421397|NCT05723458|COMBINATION_PRODUCT|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
219421398|NCT05723458|DRUG|Placebo|Placebo cream containing vaseline
219421399|NCT01332604|DRUG|GDC-0980|Oral escalating dose
219421400|NCT01332604|DRUG|bevacizumab|Intravenous repeating dose
219421401|NCT01332604|DRUG|capecitabine|Oral repeating dose
219421402|NCT01332604|DRUG|mFOLFOX6|Intravenous repeating dose
219421403|NCT02562872|DRUG|DSM265|DSM265 400 mg single oral dose
219421404|NCT02562872|DRUG|Placebo|Placebo to match DSM265, single oral dose
219421405|NCT02562872|BIOLOGICAL|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
219421406|NCT02562872|BIOLOGICAL|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
219421407|NCT03297216|DRUG|17P|Synthetic progestin
219421408|NCT03297216|OTHER|Placebo|Non-active placebo comparator
219574252|NCT05198388|DIAGNOSTIC_TEST|βeta endorphins, interleukin 6 and interleukin 38|"* \- Collection of peripheral blood samples in gel tube.~* \- Creparation of samples in centrifuge to obtain serum.~* \- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
219421409|NCT05295745|BEHAVIORAL|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
219421410|NCT02700919|DRUG|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
219421411|NCT02700919|DRUG|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
219421412|NCT00003635|DRUG|nelarabine|
219421413|NCT03973203|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
219421414|NCT04771143|DRUG|AFQ056|oral administration
219421415|NCT04771143|DRUG|Placebo|matching placebo for oral administration
219421416|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
219421417|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
219421418|NCT00730626|DIETARY_SUPPLEMENT|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
219421419|NCT04374266|DIAGNOSTIC_TEST|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
219574253|NCT02593227|BIOLOGICAL|Low dose FRα vaccine|165ug per peptide ID injection
219574254|NCT02593227|DRUG|Cyclophosphamide|IV infusion over 1 hour
219421420|NCT02752724|DRUG|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
219421421|NCT02752724|DRUG|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
219421422|NCT03434418|DRUG|osimertinib|80 mg oral administration daily
219421423|NCT06392750|BEHAVIORAL|Collection of tumor tissue specimens|Collection of tumor tissue specimens during surgery
219574255|NCT02593227|BIOLOGICAL|High dose FRα vaccine|500ug per peptide ID injection
219574256|NCT01671982|OTHER|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
219191104|NCT05408975|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
219421424|NCT00067613|OTHER|Benchmarking Management Practices|"The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center"
219421425|NCT00067613|OTHER|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
219421426|NCT04197518|DIAGNOSTIC_TEST|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
219421427|NCT05343585|DEVICE|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
219421428|NCT00085488|BIOLOGICAL|autologous tumor cell vaccine|
219421429|NCT00085488|BIOLOGICAL|therapeutic autologous dendritic cells|
219421430|NCT00833807|DRUG|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
219421431|NCT06447571|OTHER|Trunk Rehabilitation|Activating and strengthening the trunk muscles.
219421432|NCT06447571|OTHER|Core Stability|Standard core stability fucus on lower trunk.
219421433|NCT01383109|DRUG|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
219421434|NCT04089436|DIAGNOSTIC_TEST|CSF sampling|CSF sampling by lumbar puncture
219421435|NCT04089436|DIAGNOSTIC_TEST|Blood sampling|Blood sampling by blood test
219421436|NCT04089436|DIAGNOSTIC_TEST|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
219421437|NCT00944216|DRUG|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
219421438|NCT03320538|OTHER|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
219421439|NCT03320538|OTHER|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
219421440|NCT03320538|DRUG|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
219421441|NCT04226287|DEVICE|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
219574257|NCT02777918|BEHAVIORAL|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
219421442|NCT00104156|PROCEDURE|External Qigong therapy|
219421443|NCT02755025|OTHER|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
219421444|NCT03649516|DEVICE|iCKD APP|Use iCKD APP to upload home bio-information data
219574258|NCT00841360|OTHER|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
219574259|NCT00841360|OTHER|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
219574260|NCT01744119|DEVICE|Vascutek Anaconda™ Stent Graft System|
219421445|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
219421446|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
219421447|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
219421448|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
219574261|NCT00976794|DRUG|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
219574262|NCT00976794|DRUG|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
219574263|NCT00757848|DRUG|AZD9668|60 mg, oral tablet, twice daily for 28 days
219574264|NCT00757848|DRUG|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
219005489|NCT01413529|BEHAVIORAL|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
219005490|NCT01413529|BEHAVIORAL|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
219005491|NCT01442493|OTHER|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
219421449|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
219421450|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
219421451|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
219421452|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
219421453|NCT02938546|RADIATION|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
219421454|NCT01517412|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
219421455|NCT01517412|DEVICE|Self-injector pen device (OptiClik®)|
219421456|NCT01517412|DRUG|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
219421457|NCT02851368|DEVICE|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
219421458|NCT02851368|DRUG|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
219005492|NCT01442493|OTHER|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
219005493|NCT05885204|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
219005494|NCT05885204|PROCEDURE|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
219005495|NCT00002079|DRUG|Butyldeoxynojirimycin|
219005496|NCT00002079|DRUG|Zidovudine|
219421459|NCT00169910|DRUG|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
219421460|NCT04018703|DRUG|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
219421461|NCT04018703|DRUG|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
219421462|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
219005497|NCT05211791|PROCEDURE|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
219421463|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
219421464|NCT01253187|DRUG|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
219421465|NCT01991405|DEVICE|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
219421466|NCT01566058|DEVICE|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
219421467|NCT01566058|OTHER|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
219421468|NCT03434704|DRUG|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.
219421469|NCT03434704|PROCEDURE|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
219421470|NCT03434704|DRUG|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
219421471|NCT03434704|DRUG|Primary antifungal prophylaxis|Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
219421472|NCT03484351|OTHER|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
219421473|NCT02388841|RADIATION|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
219421474|NCT01509872|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
219421475|NCT01509872|BEHAVIORAL|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
219005498|NCT05211791|PROCEDURE|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
219005499|NCT05211791|PROCEDURE|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
219574265|NCT03542084|OTHER|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
219574266|NCT02071953|DEVICE|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
219421476|NCT04777578|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
219421477|NCT01221688|PROCEDURE|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
219421478|NCT01221688|PROCEDURE|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
219421479|NCT04851002|PROCEDURE|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
219574267|NCT02071953|DEVICE|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
219574268|NCT02116517|DIETARY_SUPPLEMENT|green tea extract|500 mg three times per day
219574269|NCT02116517|DIETARY_SUPPLEMENT|Placebo|cellulose 500mg three times a day for 6 weeks
219574270|NCT00488813|DRUG|Third generation cephalosporins|
219574271|NCT00058214|DRUG|perifosine|Given orally
219574272|NCT00058214|OTHER|laboratory biomarker analysis|Correlative studies
219574273|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
219574274|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
219574275|NCT04352608|BIOLOGICAL|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
219574276|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
219574277|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
219574278|NCT04352608|BIOLOGICAL|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
219574279|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
219574280|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
219574281|NCT04352608|BIOLOGICAL|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
219421480|NCT04851002|PROCEDURE|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
219574282|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
219574283|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
219574284|NCT04352608|BIOLOGICAL|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
219574285|NCT05279508|BEHAVIORAL|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
219574286|NCT01906359|OTHER|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
219574287|NCT01906359|OTHER|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
219574288|NCT01906359|OTHER|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
219574289|NCT00442754|BIOLOGICAL|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
219574290|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
219574291|NCT02191007|DRUG|Calcipotriol Betamethasone ointment|
219574292|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Urea Cream|
219574293|NCT00411398|DRUG|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
219574294|NCT02480582|OTHER|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
219574295|NCT02480582|OTHER|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
219574296|NCT03757780|OTHER|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
219191105|NCT05408975|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
219191106|NCT05298748|OTHER|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
219421481|NCT04851002|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied
219421482|NCT04851002|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
219421483|NCT05720442|DRUG|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
219421484|NCT05720442|DRUG|Mosapride Citrate|The mosapride citrate tablets will be administrated.
219421485|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 1|
219421486|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 2|
219421487|NCT02317536|OTHER|Placebo|Placebo
219421488|NCT04276129|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
219421489|NCT04276129|OTHER|post-surgical CHX mouth-rinses indication|CHX mouth-rinses (0.12%) will be indicated 2 times/day after the surgical procedure
219421490|NCT01956240|PROCEDURE|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
219421491|NCT01956240|PROCEDURE|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
219421492|NCT06243822|DRUG|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
219421493|NCT06243822|DRUG|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
219421494|NCT02540096|OTHER|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
219421495|NCT02540096|OTHER|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
219421496|NCT04195659|PROCEDURE|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
219421497|NCT02168894|PROCEDURE|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
219421498|NCT02168894|PROCEDURE|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
219421499|NCT02168894|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
219421500|NCT03252314|DEVICE|Second-generation hydrogel coils|Hydrogel coils 90% by length
219421501|NCT01836211|OTHER|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
219421502|NCT01836211|OTHER|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
219421503|NCT03329417|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
219421504|NCT02092441|OTHER|Alcohol prep pad group|Subjects inhale scent of alcohol pad
219191107|NCT04308681|OTHER|BMS-986278 Placebo|Specified Dose on Specified Days
219191108|NCT04308681|DRUG|BMS-986278|Specified Dose on Specified Days
219191109|NCT03844750|PROCEDURE|Hepatectomy|Undergo liver resection.
219421505|NCT02092441|OTHER|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
219421506|NCT02705118|DEVICE|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
219421507|NCT02705118|DEVICE|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
219421508|NCT02321618|BEHAVIORAL|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
219421509|NCT02321618|BEHAVIORAL|BP educational materials|Exposure to hypertension educational materials
219421510|NCT02982486|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
219421511|NCT02982486|DRUG|Nivolumab|Ninolumab 240 mg IV every 2 weeks
219421512|NCT03609736|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|"* A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~* After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~* Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~* At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
219421513|NCT03001336|OTHER|no intervention|This is a cross-sectional study
219421514|NCT01543139|DRUG|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
219421515|NCT01543139|DRUG|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
219421516|NCT01543139|DRUG|Valproate|Valproate: Week0-8: 300mg/day
219421517|NCT05365009|DIAGNOSTIC_TEST|Multidisciplinary aproach|regular tests
219421518|NCT04485117|DEVICE|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
219421519|NCT04485117|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
219421520|NCT04485117|DRUG|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
219421521|NCT04485117|DRUG|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
219421522|NCT00600028|DRUG|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
219421523|NCT00600028|DRUG|Placebo|Placebo 50-100 mg by mouth per day
219421524|NCT05962918|OTHER|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
219421525|NCT05175209|DIAGNOSTIC_TEST|EMG|Electromyelography
219421526|NCT03256734|OTHER|Policy intervention|Incentive payment for physicians
219421527|NCT04658420|DRUG|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
219421528|NCT04658420|OTHER|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
219421529|NCT05990036|OTHER|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
219421530|NCT00218426|DRUG|naltrexone implant|naltrexone implant is 1000 mg naltrexone
219759679|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
219421531|NCT00218426|DRUG|oral naltrexone|oral naltrexone 50 mg/day
219421532|NCT00218426|DRUG|oral placebo naltrexone|oral placebo naltrexone resembles active medication
219421533|NCT00218426|DRUG|placebo implant|placebo implant resembles active medication
219421534|NCT02952703|BEHAVIORAL|brief pre-delivery smoking cessation counseling|
219421535|NCT02952703|BEHAVIORAL|additional pre-delivery smoking cessation counseling|
219421536|NCT02952703|BEHAVIORAL|post- delivery smoking cessation counseling|
219421537|NCT02952703|BEHAVIORAL|incentives|
219421538|NCT06375252|OTHER|Central Jugular Vein Catheter Lumen Holder Apparatus|Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
219421539|NCT03172481|DRUG|PRC-063 oral capsules|Daily dose
219421540|NCT03172481|DRUG|Placebo oral capsules|Daily dose
219421541|NCT02679196|DRUG|KA2237|PI3 Kinase p110β/δ inhibitor
219421542|NCT01699412|DRUG|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
219421543|NCT01699412|DRUG|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
219421544|NCT01957709|OTHER|Laboratory Biomarker Analysis|Correlative studies
219421545|NCT01957709|BIOLOGICAL|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
219421546|NCT00382213|DRUG|Olmesartan medoxomil|
219421547|NCT00382213|DRUG|Placebo|
219421548|NCT03028584|BEHAVIORAL|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
219421549|NCT01969669|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
219421550|NCT01969669|DRUG|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
219421551|NCT02831842|DRUG|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
219421552|NCT02831842|DRUG|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
219421553|NCT02831842|DRUG|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
219421554|NCT04260919|PROCEDURE|Chest physiotherapy|
219421555|NCT04387318|DEVICE|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
219421556|NCT04387318|DEVICE|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
219005500|NCT01986985|DEVICE|PET/MRI system|Compared to PET CT
219005501|NCT00125801|DRUG|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
219421557|NCT04387318|DEVICE|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
219421558|NCT04387318|DEVICE|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
219421559|NCT04072185|OTHER|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
219421560|NCT02069236|OTHER|G6PD Test|All subjects are tested by multiple G6PD tests
219759680|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
219759681|NCT02258802|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
219759682|NCT01621178|DRUG|Dulaglutide|Administered SC
219759683|NCT01621178|DRUG|Insulin glargine|Administered SC
219759684|NCT01621178|DRUG|Insulin lispro|Administered SC
219191110|NCT03844750|BIOLOGICAL|Pembrolizumab|Given IV
219421561|NCT02128984|DIETARY_SUPPLEMENT|Symbiotic Formula with DHA and antioxidants|6 months intervention.
219421562|NCT02128984|DIETARY_SUPPLEMENT|Standard Formula|6 months intervention.
219421563|NCT02310906|DRUG|Placebo|SRP-4053 placebo-matching solution for IV infusion.
219421564|NCT02310906|DRUG|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
219421565|NCT04238884|DRUG|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
219421566|NCT04238884|DRUG|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
219421567|NCT02667548|PROCEDURE|PCI|percutaneous coronary intervention
219421568|NCT04315493|DRUG|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
219421569|NCT04315493|DRUG|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
219421570|NCT05287607|DIAGNOSTIC_TEST|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
219421571|NCT06248697|BIOLOGICAL|αPD1/CTLA4-MSLN-CAR T cells|BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
219421572|NCT05380674|BEHAVIORAL|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
219005502|NCT03042533|DEVICE|Conventional Compression|Method of Nail fitting
219005503|NCT03042533|DEVICE|Standard Backslapping|Method of Nail fitting
219005504|NCT03042533|DEVICE|Dynamic Locking with Backslapping|Method of Nail fitting
219005505|NCT00182377|DRUG|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
219005506|NCT06159712|OTHER|Blood samples|Extra blood samples
219005507|NCT03578029|DRUG|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
219005508|NCT03578029|DRUG|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
219421573|NCT04702217|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
219421574|NCT01023438|OTHER|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
219421575|NCT01023438|OTHER|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
219421576|NCT03827590|DRUG|Test|three times a day for five days
219421577|NCT03827590|DRUG|Active Comparator Control 1|three times a day for five days
219421578|NCT03827590|DRUG|Active Comparator Control 2|three times a day for five days
219421579|NCT03827590|DRUG|Placebo|three times a day for five days
219421580|NCT03350178|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
219421581|NCT02567214|DRUG|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
219421582|NCT02567214|DRUG|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
219421583|NCT02928926|OTHER|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
219421584|NCT05644379|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
219421585|NCT05644379|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
219421586|NCT01471860|DEVICE|BAROSTIM NEO System|
219574297|NCT04038086|DIAGNOSTIC_TEST|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
219574298|NCT04038086|OTHER|circadian rhythm|Blood and CSF will be collected five times throughout the day.
219574299|NCT04038086|DRUG|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
219574300|NCT04649450|OTHER|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
219574301|NCT03314818|DEVICE|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
219759685|NCT03502564|BEHAVIORAL|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
219421587|NCT01471860|DRUG|Medical Management|
219421588|NCT01204697|DRUG|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
219759686|NCT03502564|BEHAVIORAL|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
219759687|NCT05863455|DRUG|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
219421589|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
219421590|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally as monotherapy
219421591|NCT01010854|DRUG|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
219421592|NCT04107558|DEVICE|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
219421593|NCT02655445|PROCEDURE|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
219421594|NCT02655445|PROCEDURE|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
219421595|NCT02655445|PROCEDURE|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
219421596|NCT02791880|PROCEDURE|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
219421597|NCT02430428|DEVICE|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
219421598|NCT05533255|OTHER|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
219421599|NCT05533255|OTHER|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
219421600|NCT00664755|DRUG|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
219421601|NCT00664755|DEVICE|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
219421602|NCT04094766|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
219421603|NCT01841957|PROCEDURE|ISBCS|same-day cataract surgery
219421604|NCT01841957|PROCEDURE|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
219421605|NCT02500602|DRUG|doxazosin|active medication
219421606|NCT02500602|DRUG|placebo|placebo pill
219421607|NCT00799344|DEVICE|Catania Stent|coronary stent implantation
219421608|NCT04841720|DRUG|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
219421609|NCT04841720|DRUG|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
219421610|NCT04841720|DRUG|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
219421611|NCT02271867|PROCEDURE|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
219421612|NCT00098020|DRUG|Isotretinoin|
219421613|NCT01840228|DRUG|Micronized progesterone suppository|
219421614|NCT04731623|DRUG|ION904|ION904 will be administered by SC injection.
219421615|NCT04731623|DRUG|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
219421616|NCT04027101|DRUG|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
219421617|NCT04027101|DRUG|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
219421618|NCT03703271|DRUG|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
219421619|NCT03703271|PROCEDURE|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
219421620|NCT06317922|DEVICE|Thealoz Duo;|THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
219421621|NCT06317922|DEVICE|sham (Hydrabak)|Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
219421622|NCT00386490|DRUG|larazotide acetate|capsule for oral administration
219759688|NCT05863455|DRUG|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
219759689|NCT03665259|PROCEDURE|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
219759690|NCT03665259|PROCEDURE|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
219005509|NCT04421729|BEHAVIORAL|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
219005510|NCT04421729|BEHAVIORAL|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
219191111|NCT03844750|DRUG|Vactosertib|Given orally
219191112|NCT05664217|DRUG|NKTR-255 at 1.5 µg/kg|NKTR-255 at 1.5 µg/kg
219191113|NCT05664217|DRUG|NKTR-255 at 3.0 μg/kg|NKTR-255 at 3.0 μg/kg
219421623|NCT03915912|BEHAVIORAL|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
219421624|NCT01954888|PROCEDURE|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
219421625|NCT01954888|PROCEDURE|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
219421626|NCT05331456|DEVICE|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
219421627|NCT01790789|BEHAVIORAL|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
219421628|NCT01790789|OTHER|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
219421629|NCT01560442|DRUG|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
219759691|NCT02176915|BEHAVIORAL|Group program|
219759692|NCT02176915|BEHAVIORAL|Print Materials|
219759693|NCT04464239|DRUG|TS-142|TS-142 tablets
219759694|NCT04464239|DRUG|TS-142 Placebo|TS-142 matching placebo tablets
219421630|NCT04668092|OTHER|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
219574302|NCT05470764|DRUG|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
219421631|NCT02336139|DRUG|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
219421632|NCT00712933|DRUG|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
219421633|NCT05126940|DIAGNOSTIC_TEST|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
219421634|NCT03475901|OTHER|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
219421635|NCT06335498|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
219421636|NCT06335498|DEVICE|Periodic ECG triggered measurement|Subject triggers AFGen1 to perform an extended measurement during wear period
219421637|NCT00047307|DRUG|alvocidib|Given IV
219421638|NCT00047307|DRUG|gemcitabine hydrochloride|Given IV
219421639|NCT00047307|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
219421640|NCT00047307|OTHER|laboratory biomarker analysis|Correlative studies
219574303|NCT05470764|DRUG|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
219759695|NCT02935192|BIOLOGICAL|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
219759696|NCT02935192|OTHER|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
219759697|NCT01606579|DRUG|PRI-724|PRI-724
219759698|NCT01606579|DRUG|PRI-724|PRI-724 in combination with dasatinib
219005511|NCT04384328|OTHER|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
219005512|NCT06135701|DIAGNOSTIC_TEST|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
219005513|NCT04130126|BEHAVIORAL|Taking cold showers|Showering behaviour
219421641|NCT06015412|DIAGNOSTIC_TEST|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
219421642|NCT04250376|DEVICE|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
219421643|NCT02476357|DEVICE|Harmonic scalpel|
219421644|NCT01295580|DEVICE|ARTZ|Hyaluronic acid (five 2.5 mL injections)
219421645|NCT01295580|DEVICE|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
219421646|NCT02482441|DRUG|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
219421647|NCT02482441|DRUG|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
219759699|NCT01606579|DRUG|PRI-724|PRI-724 in combination with low dose ara-C therapy
219759700|NCT02896257|OTHER|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
219191114|NCT05664217|DRUG|NKTR-255 at 3.0/6.0 μg/kg|NKTR-255 at 3.0/6.0 μg/kg
219191115|NCT05664217|OTHER|Placebo Comparator|Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
219191116|NCT05565820|OTHER|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
219191117|NCT05565820|DRUG|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
219191118|NCT03209609|DEVICE|VEST|External support for vein grafts, cobalt chrome braid
219421648|NCT01222572|RADIATION|Stereotactic boost|
219421649|NCT01222572|RADIATION|Conventional RT|
219421650|NCT01222572|DRUG|Etoposide|
219421651|NCT01222572|DRUG|Cisplatin|
219421652|NCT00303758|DRUG|cisplatin|
219421653|NCT00303758|DRUG|fluorouracil|
219421654|NCT00303758|DRUG|gemcitabine hydrochloride|
219421655|NCT00303758|DRUG|leucovorin calcium|
219574304|NCT03808870|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
219191119|NCT03209609|PROCEDURE|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
219191120|NCT06281041|DRUG|Antiplatelet Agents|Aspirin or clopidogrel
219191121|NCT06021353|DEVICE|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
219191122|NCT06021353|DEVICE|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
219191123|NCT06021353|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
219191124|NCT06430333|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness-based sleep program for pregnant women.
219191125|NCT06430333|OTHER|Treatment-as-usual (TAU)|Usual practices from real-world care experiences.
219421656|NCT01481090|PROCEDURE|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
219421657|NCT04353336|DRUG|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
219421658|NCT04946799|BEHAVIORAL|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
219421659|NCT04946799|BEHAVIORAL|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
219421660|NCT04946799|BEHAVIORAL|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
219421661|NCT04733846|OTHER|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
219421662|NCT00432094|DRUG|carboplatin|Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
219421663|NCT00432094|DRUG|etoposide|600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
219421664|NCT00432094|DRUG|ifosfamide|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
219421665|NCT00432094|DRUG|paclitaxel|225 mg/m\^2 intravenous over 3 hours on Day -7.
219421666|NCT00432094|DRUG|thiotepa|150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
219421667|NCT00432094|PROCEDURE|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
219421668|NCT00432094|DRUG|Mesna|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
219421669|NCT00432094|BIOLOGICAL|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
219421670|NCT05374148|BEHAVIORAL|health education|health education to prevent respiratory diseases among workers
219421671|NCT04315480|DRUG|Tocilizumab|single intravenous administration 8mg/Kg
219421672|NCT01160653|DEVICE|FES-IM|implantable Functional Electrical Stimulation
219421673|NCT01160653|OTHER|Cognitive training|training of impaired cognitive processes
219421674|NCT01261546|DRUG|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
219421675|NCT01261546|DRUG|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
219421676|NCT05938777|BEHAVIORAL|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
219421677|NCT02022033|DRUG|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
219421678|NCT00200018|DEVICE|Enterra Therapy System (H9900014)|
219574305|NCT05151575|BEHAVIORAL|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
219574306|NCT04223999|PROCEDURE|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
219574307|NCT04223999|OTHER|Control|Tumor treating fields combined with best medical treatment.
219574308|NCT05423470|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
219574309|NCT05423470|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
219574310|NCT05451732|PROCEDURE|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
219574311|NCT01155778|BIOLOGICAL|Recombinant human heparan N-sulfatase (rhHNS)|
219191126|NCT00898638|OTHER|biologic sample preservation procedure|
219421679|NCT04591041|DEVICE|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
219421680|NCT04591041|OTHER|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
219421681|NCT00889993|DIETARY_SUPPLEMENT|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
219421682|NCT05071352|DRUG|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
219421683|NCT05071352|DRUG|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
219574312|NCT01875471|DEVICE|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
219574313|NCT01875471|DEVICE|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
219574314|NCT00962988|DRUG|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
219574315|NCT00962988|OTHER|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
219574316|NCT02121561|BEHAVIORAL|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
219191127|NCT00898638|OTHER|medical chart review|
219191920|NCT05717530|PROCEDURE|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
219421684|NCT02279121|DEVICE|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
219574317|NCT01838928|DRUG|Bupivacaine|
219759701|NCT02465931|OTHER|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
219191921|NCT06453850|DEVICE|Use of FLEXIGO delivery catheter|Use of FLEXIGO delivery catheter for implantation of ventricular pacing lead
219191922|NCT04165720|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
219191923|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Gadovist for MRI investigation|Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis
219421685|NCT02279121|DRUG|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
219421686|NCT00759746|BEHAVIORAL|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
219421687|NCT00759746|BEHAVIORAL|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
219421688|NCT00759746|BEHAVIORAL|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
219421689|NCT05669300|PROCEDURE|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
219421690|NCT05689138|OTHER|Oral and Fecal Sample Collection|No interventions
219574318|NCT03996551|BEHAVIORAL|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
219574319|NCT03686020|DIAGNOSTIC_TEST|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
219574320|NCT03252327|OTHER|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
219574321|NCT00792727|DRUG|ketoprofen Patch|2 topical patches applied once daily for 28 days
219574322|NCT00792727|OTHER|Placebo Patch|2 topical placebo patches applied once daily for 28 days
219191128|NCT06190223|PROCEDURE|Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique|A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
219421691|NCT04991883|OTHER|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
219421692|NCT05364983|DEVICE|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
219421693|NCT05364983|DEVICE|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
219421694|NCT02415764|BEHAVIORAL|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
219421695|NCT04357990|DEVICE|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
219421696|NCT04357990|OTHER|Placebo|The placebo will be a similar spray containing saline only.
219421697|NCT02861755|BEHAVIORAL|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
219421698|NCT02861755|BEHAVIORAL|5-week Emotion Reporting|
219421699|NCT03398733|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
219421700|NCT06348810|BEHAVIORAL|Dual-task training|The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
219421701|NCT06348810|BEHAVIORAL|Cognitive training|Participants only receive cognitive tasks
219421702|NCT06348810|BEHAVIORAL|Motor training|Participants only receive motor tasks
219421703|NCT06348810|OTHER|Usual care|assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
219421704|NCT01595659|BEHAVIORAL|Passenger|Driving with risk accepting or risk averse passenger
219421705|NCT04000919|DRUG|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
219421706|NCT04000919|DRUG|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
219421707|NCT04000919|DRUG|Placebo oral tablet|Placebo
219421708|NCT04000919|DRUG|Carbidopa|Carbidopa (50mg)
219421709|NCT02813759|OTHER|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
219421710|NCT02813759|OTHER|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
219421711|NCT03051724|OTHER|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
219421712|NCT01148563|DEVICE|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
219421713|NCT04184115|DRUG|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
219421714|NCT04184115|DRUG|Placebos|Placebo Nasal Gel and placebo patch
219421715|NCT04846166|DIAGNOSTIC_TEST|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
219421716|NCT04846166|DIAGNOSTIC_TEST|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
219574323|NCT00773682|OTHER|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
219574324|NCT03182894|DRUG|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
219574325|NCT04399876|COMBINATION_PRODUCT|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
219574326|NCT05012865|DRUG|avelumab|as provided in real world practice
219421717|NCT05240638|DEVICE|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
219421718|NCT00442676|DRUG|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
219421719|NCT00442676|DRUG|Placebo|Gelatin capsules of lactose
219421720|NCT05129995|OTHER|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
219421721|NCT01933256|DRUG|HIP2B|
219421722|NCT01933256|DRUG|Placebo|
219421723|NCT01879319|BIOLOGICAL|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
219759702|NCT02465931|OTHER|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
219759703|NCT01160809|OTHER|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
219191129|NCT02393885|DEVICE|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
219191130|NCT01976182|DRUG|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
219191131|NCT01976182|DRUG|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
219421724|NCT01879319|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
219421725|NCT05750134|OTHER|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
219421726|NCT05750134|OTHER|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
219421727|NCT03763903|OTHER|3D training|Skills (FLS tasks) training using 3D visualization
219421728|NCT03763903|OTHER|2D training|Skills (FLS tasks) training using 2D visualization
219421729|NCT00854256|PROCEDURE|Canaloplasty|Canaloplasty surgery
219421730|NCT00854256|PROCEDURE|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
219421731|NCT02611063|DRUG|fostamatinib|100mg qd, 150mg qd, or 100mg bid
219421732|NCT00566449|DRUG|Placebo|one dose daily for 4 weeks
219421733|NCT00566449|DRUG|JNJ-31001074|10 mg daily for 4 weeks
219421734|NCT00566449|DRUG|JNJ-31001074|30 mg daily for 4 weeks
219421735|NCT02357797|DRUG|Vortioxetine|
219421736|NCT02357797|OTHER|Placebo|
219421737|NCT05739760|BEHAVIORAL|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
219421738|NCT05739760|BEHAVIORAL|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
219421739|NCT01164592|DEVICE|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
219421740|NCT00469846|PROCEDURE|L-arginine supplementation in a medical food|
219421741|NCT00469846|PROCEDURE|Vitamin C and E supplementation in a medical food|
219421742|NCT04392336|OTHER|Trust/Respect feedback|This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
219421743|NCT06119451|BEHAVIORAL|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
219421744|NCT01500018|DRUG|TC-5214|Single oral dose of 2 mg
219574327|NCT05012865|DRUG|axitinib|as provided in real world practice
219574328|NCT02906865|OTHER|Proximal hamstring tendons repair|Proximal hamstring tendons repair
219574329|NCT01900496|BIOLOGICAL|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
219574330|NCT01900496|BIOLOGICAL|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
219574331|NCT00208117|DRUG|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
219574332|NCT00208117|DRUG|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
219574333|NCT03407118|DRUG|LY900014|Administered SC.
219574334|NCT03407118|DRUG|Insulin Lispro|Administered SC.
219574335|NCT02761213|DRUG|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
219574336|NCT02761213|DRUG|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
219759704|NCT02394821|DRUG|Polihexanide 2%|
219191132|NCT02658279|DRUG|Pembrolizumab|
219574337|NCT00190242|DRUG|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
219574338|NCT00190242|DRUG|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
219574339|NCT00729131|DRUG|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
219574340|NCT05575635|DRUG|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
219574341|NCT02254018|DRUG|bivatuzumab mertansine|
219574342|NCT01362465|PROCEDURE|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
219574343|NCT03050918|BEHAVIORAL|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
219574344|NCT03353402|PROCEDURE|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
219574345|NCT00592202|DEVICE|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
219574346|NCT01995721|BIOLOGICAL|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
219574347|NCT02972502|DRUG|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
219574348|NCT02972502|DRUG|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
219759705|NCT02394821|DRUG|Metronidazole 0.8%|
219759706|NCT00492557|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
219759707|NCT00492557|BIOLOGICAL|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
219759708|NCT02441842|DRUG|atenolol|administered 60 minutes pre procedure
219759709|NCT02441842|DRUG|lisinopril|administered 60 minutes pre procedure
219759710|NCT02441842|OTHER|glucose|administered 60 minutes pre procedure
219759711|NCT00403156|DRUG|Imatinib Mesylate /Ranibizumab|
219759712|NCT01574144|DEVICE|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
219759713|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
219759714|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
219759715|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
219759716|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
219759717|NCT05958914|DIAGNOSTIC_TEST|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
219759718|NCT05958914|DIAGNOSTIC_TEST|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
219759719|NCT05958914|DIAGNOSTIC_TEST|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
219759720|NCT05958914|DIAGNOSTIC_TEST|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
219759721|NCT05384314|DEVICE|RespiraSense|The use of continuous electronic monitoring of respiratory rate
219759722|NCT05816824|OTHER|Symptom monitoring software via visual feedback|With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
219574349|NCT02972502|OTHER|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
219574350|NCT02972502|DRUG|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
219421745|NCT01500018|DRUG|TC-5214 Placebo|Single oral dose
219421746|NCT01500018|DRUG|Ketamine|Single oral dose of 100 mg
219421747|NCT01500018|DRUG|Phentermine|Single oral dose of 45 mg
219421748|NCT01500018|DRUG|TC-5214|Single oral dose of 8 mg
219421749|NCT01500018|DRUG|TC-5214|Single oral dose of 16 mg
219421750|NCT01500018|DRUG|Phentermine|Single oral dose of 90 mg
219421751|NCT00128583|BIOLOGICAL|polyvalent melanoma vaccine|
219421752|NCT02742857|BIOLOGICAL|BQ-A Peptide Extract|BQ-A Peptide Extract
219574351|NCT05895721|OTHER|Virtual Reality|Virtual Reality as adjunct treatment
219574352|NCT05767203|OTHER|Biological samplings|Blood and/or skin samples
219574353|NCT04076670|OTHER|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
219574354|NCT01774279|OTHER|Tissue, blood and clinical data collection|
219574355|NCT01933464|DRUG|Cromolyn Sodium|
219759723|NCT04618029|OTHER|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
219759724|NCT04618029|OTHER|Education|"Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home"
219191133|NCT06350175|COMBINATION_PRODUCT|Nicotine Replacement Therapy Agent|The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (\~210).
219421753|NCT02742857|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells
219421754|NCT02742857|DEVICE|Transcranial Laser Therapy|Transcranial Laser Therapy
219421755|NCT02742857|DEVICE|Median Nerve Stimulator|Median Nerve Stimulator
219421756|NCT01360762|DRUG|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
219421757|NCT03985748|DEVICE|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
219421758|NCT03985748|DEVICE|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
219421759|NCT04432844|PROCEDURE|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
219421760|NCT01103778|DRUG|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
219421761|NCT01839175|BIOLOGICAL|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
219421762|NCT01839175|BIOLOGICAL|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
219421763|NCT01839175|BIOLOGICAL|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
219421764|NCT01839175|BIOLOGICAL|RotaTeq|2 mL oral administration at 2, 3 and 4 months
219421765|NCT01839175|BIOLOGICAL|Nimenrix|0.5 mL intramuscular injection at 12 months
219421766|NCT01839175|BIOLOGICAL|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
219574356|NCT01933464|DRUG|Normal Saline|
219574357|NCT03351387|COMBINATION_PRODUCT|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
219574358|NCT01047579|DRUG|Rivastigmine transdermal|
219574359|NCT04269733|DEVICE|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
219574360|NCT00442000|PROCEDURE|Prostatectomy|Patients undergoing prostatectomy.
219574361|NCT04794387|BIOLOGICAL|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
219574362|NCT01888575|DRUG|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
219574363|NCT01352728|DRUG|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
219574364|NCT01801683|OTHER|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
219574365|NCT00468078|PROCEDURE|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
219421767|NCT04740099|OTHER|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
219191134|NCT06350175|OTHER|West Virginia Quit Line|Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.
219421768|NCT04740099|OTHER|Standard of Care|A handout including a map and list of locations offering this service.
219421769|NCT04724733|BEHAVIORAL|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
219421770|NCT04724733|BEHAVIORAL|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
219421771|NCT03420443|DIETARY_SUPPLEMENT|Oat bran|45 g oat bran.
219421772|NCT03420443|DIETARY_SUPPLEMENT|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
219421773|NCT03420443|DIETARY_SUPPLEMENT|No oral supplementation|No oral supplementation.
219574366|NCT00468078|DRUG|F-18 FPCIT|5mCi, intravenous injection
219574367|NCT04912882|DIAGNOSTIC_TEST|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
219574368|NCT05734131|OTHER|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up\&Go test (TUG).
219759725|NCT03423121|DRUG|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
219759726|NCT03423121|DRUG|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
219191135|NCT04047602|RADIATION|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
219191136|NCT02684227|DRUG|Carboplatin|Given IV
219191137|NCT02684227|DRUG|Enzalutamide|Given PO
219421774|NCT01193140|DRUG|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
219421775|NCT01193140|DRUG|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
219421776|NCT01408667|DRUG|TRC150094|50 mg Tablets once a day
219421777|NCT01408667|OTHER|Placebo|Tablets once daily
219421778|NCT04266106|DRUG|SuperBio probiotic|One capsule po BID for 28 days
219574369|NCT00227331|DRUG|Oral amoxicillin|
219574370|NCT03520868|DIAGNOSTIC_TEST|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
219574371|NCT02046668|DRUG|spironolactone|spironolactone 25mg daily for 12 weeks
219421779|NCT04266106|DRUG|Placebo|One capsule po BID for 28 days
219759727|NCT03173014|DEVICE|EEG|EEG monitoring
219759728|NCT02474979|DEVICE|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
219759729|NCT02474979|OTHER|Control|
219759730|NCT00149786|BEHAVIORAL|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
219759731|NCT00149786|BEHAVIORAL|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
219759732|NCT03917030|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.
219421780|NCT03963713|RADIATION|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
219421781|NCT03963713|RADIATION|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
219421782|NCT01809925|DIETARY_SUPPLEMENT|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
219421783|NCT01809925|DIETARY_SUPPLEMENT|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
219421784|NCT05613842|DRUG|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
219421785|NCT06314165|OTHER|music medicine practice|Music medicine will be applied
219421786|NCT05108688|DRUG|Mirtazapine|Mirtazapine 30 mg tablet once daily for 3 successive days
219421787|NCT05108688|DRUG|Sumatriptan|Sumatriptan 50 mg tablet once daily for 3 successive days
219421788|NCT05108688|OTHER|Placebo|Placebo tablets once daily for 3 successive days.
219574372|NCT03983694|OTHER|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
219574373|NCT02249676|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
219574374|NCT01569776|OTHER|Amino Acid formula|Amino Acid baby formula
219574375|NCT01569776|OTHER|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
219574376|NCT01762826|DIETARY_SUPPLEMENT|Myo-inositol|Dietary control plus Myo-inositol
219005514|NCT01354951|OTHER|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
219005515|NCT01266954|DRUG|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
219191138|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
219191139|NCT02684227|DRUG|Paclitaxel|Given IV
219574377|NCT01762826|DIETARY_SUPPLEMENT|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
219574378|NCT01762826|DIETARY_SUPPLEMENT|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
219574379|NCT01762826|DIETARY_SUPPLEMENT|Placebo|Dietary control plus folic acid 400 mcg daily
219005516|NCT01096524|OTHER|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
219191140|NCT02684227|OTHER|Pharmacological Study|Correlative studies
219191924|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Imeron for B-CT investigation|Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
219421789|NCT03986190|BEHAVIORAL|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
219421790|NCT04511819|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
219759733|NCT03917030|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
219759734|NCT03059784|OTHER|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
219005517|NCT01096524|DEVICE|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
219191925|NCT04544007|DRUG|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
219421791|NCT04511819|DRUG|Placebo oral tablet|Placebo will be administered with food when possible.
219421792|NCT02978209|DEVICE|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
219421793|NCT05194501|OTHER|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
219421794|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
219421795|NCT04953117|DEVICE|Restore DEB|subjects receiving Restore DEB
219421796|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
219421797|NCT01924156|BIOLOGICAL|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
219421798|NCT04929613|BEHAVIORAL|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
219421799|NCT03957356|DEVICE|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
219421800|NCT02116816|DIETARY_SUPPLEMENT|Polyphenol|Polyphenol
219421801|NCT05790473|DIAGNOSTIC_TEST|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
219421802|NCT04448093|PROCEDURE|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
219421803|NCT03522701|BEHAVIORAL|CBTI|Refer to the arm description
219421804|NCT06509711|OTHER|PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)|First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
219421805|NCT06509711|OTHER|PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
219421806|NCT00602719|DRUG|Zolpidem|
219421807|NCT04468334|DEVICE|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
219421808|NCT03428841|PROCEDURE|Audiometry|
219421809|NCT00844649|DRUG|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m\^2 administered by intravenous infusion
219421810|NCT00844649|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
219421811|NCT02767856|DEVICE|IO-therapy Glasses|
219421812|NCT04611178|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
219421813|NCT00988260|DRUG|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
219759735|NCT00560508|DRUG|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
219759736|NCT00560508|DRUG|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
219759737|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
219759738|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
219759739|NCT03323684|OTHER|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
219574380|NCT04946565|DIAGNOSTIC_TEST|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
219574381|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
219574382|NCT01347866|DRUG|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
219574383|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
219574384|NCT01347866|DRUG|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
219574385|NCT01817465|DRUG|Motilitone ®|
219574386|NCT01817465|DRUG|Pantoline®|
219574387|NCT01817465|DRUG|Motilitone® and Pantoline®|
219574388|NCT01389466|BIOLOGICAL|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
219574389|NCT01389466|BIOLOGICAL|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
219005518|NCT02288559|OTHER|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
219005519|NCT02288559|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
219005520|NCT00525460|BEHAVIORAL|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
219005521|NCT03629067|DRUG|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
219005522|NCT03629067|DRUG|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
219574390|NCT06496074|DIAGNOSTIC_TEST|Head-up Tilt Test|Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
219574391|NCT00430950|DRUG|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
219574392|NCT00430950|DRUG|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
219574393|NCT01791231|DRUG|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
219574394|NCT00266526|BIOLOGICAL|Recombinant birch pollen|
219574395|NCT05160467|DIAGNOSTIC_TEST|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
219574396|NCT05874440|DRUG|Tenofovir Disoproxil Fumarate and Entcavir|Regular registration of side effects of the drugs, cause of non-compliance to treatment
219574397|NCT03265067|DEVICE|autoRIC|Application of the autoRIC device
219574398|NCT02199340|OTHER|iStep exercise test|newly developed submaximal exercise test
219574399|NCT02199340|OTHER|CPET exercise test|maximal gold standard exercise test
219574400|NCT02537873|DRUG|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
219574401|NCT02537873|DRUG|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
219574402|NCT02537873|DRUG|Placebo comparator|Dextrose in gelatin capsule
219574403|NCT00005586|DRUG|L-leucovorin|
219574404|NCT00005586|DRUG|fluorouracil|
219574405|NCT00005586|PROCEDURE|adjuvant therapy|
219759740|NCT03323684|OTHER|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
219759741|NCT03323684|OTHER|Control group (C)|No intervention will be done
219759742|NCT03323684|DRUG|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
219759743|NCT03323684|DRUG|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
219759744|NCT03323684|DRUG|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
219759745|NCT03150381|BEHAVIORAL|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
219191141|NCT06406075|DEVICE|Lab demo 1.0|During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
219191142|NCT06509984|DRUG|Apremilast treatment|treatment of apremilast
219421814|NCT00988260|DRUG|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
219421815|NCT00988260|DRUG|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
219421816|NCT01398267|DRUG|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
219421817|NCT01398267|DRUG|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
219421818|NCT01398267|DRUG|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
219421819|NCT03537352|PROCEDURE|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
219421820|NCT03537352|DRUG|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
219421821|NCT01392053|OTHER|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
219421822|NCT05698121|DEVICE|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
219421823|NCT01464788|DRUG|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
219421824|NCT01464788|DRUG|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
219421825|NCT01464788|DRUG|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
219421826|NCT04394455|BEHAVIORAL|Brief cognitive behavioral therapy|9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
219421827|NCT04394455|BEHAVIORAL|Crisis intervention therapy|3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
219421828|NCT03411772|PROCEDURE|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
219759746|NCT03150381|BEHAVIORAL|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
219759747|NCT03150381|BEHAVIORAL|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
219759748|NCT01490034|BEHAVIORAL|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
219759749|NCT01490034|BEHAVIORAL|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
219759750|NCT01490034|BEHAVIORAL|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
219759751|NCT01490034|BEHAVIORAL|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
219759752|NCT03246087|DEVICE|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
219759753|NCT03246087|OTHER|Standard of care|standard of care home exercise program
219759754|NCT00586794|DRUG|Sildenafil|3x per day 20 mg TID
219759755|NCT00586794|DRUG|Placebo|3x per day, 20 mg TID
219759756|NCT04734457|DRUG|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
219759757|NCT03816189|DIAGNOSTIC_TEST|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
219759758|NCT03816189|DIAGNOSTIC_TEST|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
219759759|NCT03714607|DEVICE|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
219759760|NCT02481193|DRUG|Cisatracurium|Different doses of cisatracurium pretreatment
219759761|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
219759762|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
219759763|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
219759764|NCT02987608|DEVICE|Power Up|Smartphone phone app
219759765|NCT00362492|PROCEDURE|Bilateral ultrasound examination 7+/- 2 after surgery|
219759766|NCT05130593|DIETARY_SUPPLEMENT|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
219759767|NCT03218280|DRUG|Vitamin C|
219759768|NCT01936233|DRUG|Aspirin|Aspirin 0.1 QD po
219759769|NCT01936233|DRUG|Lamivudine|LAminvudine 0.1 QD po
219759770|NCT04286152|DRUG|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
219759771|NCT04286152|DRUG|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
219574406|NCT05905263|OTHER|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
219574407|NCT01583517|PROCEDURE|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
219574408|NCT01583517|PROCEDURE|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
219421829|NCT03411772|PROCEDURE|Bariatric surgery|Bariatric surgery will be conducted
219421830|NCT00091026|BIOLOGICAL|cetuximab|Given IV
219574409|NCT01583517|PROCEDURE|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
219574410|NCT02554734|DRUG|levodopa, carbidopa, ODM-104|
219574411|NCT02554734|DRUG|levodopa, carbidopa, entacapone|
219574412|NCT02429934|BIOLOGICAL|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
219574413|NCT02429934|DRUG|Placebo|
219574414|NCT00971984|OTHER|Medical records summary|Summary of Medical files and laboratory results.
219574415|NCT04729465|DRUG|Propofol|Propofol
219574416|NCT04729465|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor
219574417|NCT00734201|DRUG|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
219574418|NCT01176110|DEVICE|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
219574419|NCT05793814|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri 3613|Daily for 6 month
219574420|NCT05793814|DIETARY_SUPPLEMENT|Placebo|Daily for 6 month
219574421|NCT00283413|DEVICE|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
219574422|NCT00283413|DEVICE|Bare metal stent|Any commercially available bare metal stent for coronary indication
219005523|NCT01443754|PROCEDURE|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
219421831|NCT00091026|DRUG|gemcitabine hydrochloride|Given IV
219421832|NCT00091026|BIOLOGICAL|bevacizumab|Given IV
219421833|NCT00091026|DRUG|erlotinib hydrochloride|Given orally
219421834|NCT01896388|DRUG|Ifenprodil Tartrate|
219421835|NCT01896388|DRUG|Placebo|
219421836|NCT04286464|OTHER|No intervention|No intervention
219421837|NCT05262582|PROCEDURE|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
219574423|NCT01763749|DRUG|Closone|Closone 75mg/100mg, 4weeks, PO
219574424|NCT01763749|DRUG|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
219574425|NCT03626506|DRUG|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
219574426|NCT03626506|DRUG|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
219574427|NCT03626506|DRUG|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
219574428|NCT03525418|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
219574429|NCT04135521|DRUG|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
219574430|NCT03277209|DRUG|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
219574431|NCT03547726|OTHER|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
219421838|NCT05262582|PROCEDURE|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
219421839|NCT02763293|OTHER|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
219574432|NCT03547726|OTHER|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
219574433|NCT04900909|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
219421840|NCT00589979|DRUG|Lidoderm (Lidocaine 5% Patch)|Topical Patch
219421841|NCT00589979|DRUG|Placebo Patch|Topical Patch
219421842|NCT00250991|DRUG|activase|
219574434|NCT05970419|OTHER|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
219574435|NCT05970419|OTHER|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
219574436|NCT05970419|OTHER|Sham laser|sham laser (Not active)
219005524|NCT01443754|PROCEDURE|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
219005525|NCT01174927|DRUG|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
219005526|NCT01174927|OTHER|Placebo|Saline
219005527|NCT03055351|BEHAVIORAL|Stop&Go Intervention|Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
219005528|NCT01111149|OTHER|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
219421843|NCT00250991|DRUG|integrilin|
219421844|NCT00101621|DRUG|M40403|
219421845|NCT03146221|OTHER|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
219421846|NCT01756872|PROCEDURE|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
219421847|NCT05191355|BIOLOGICAL|blood test|Blood spot collection for sampling
219421848|NCT01497535|DRUG|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
219421849|NCT01497535|DRUG|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
219421850|NCT00217516|DRUG|selenium|Given orally
219421851|NCT00217516|OTHER|placebo|Given orally
219421852|NCT05308615|DIETARY_SUPPLEMENT|Rhea® Health Tone|Rhea® Health Tone
219421853|NCT04103398|COMBINATION_PRODUCT|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
219421854|NCT04103398|PROCEDURE|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
219421855|NCT00003157|DRUG|cisplatin|
219421856|NCT00003157|DRUG|gemcitabine hydrochloride|
219421857|NCT00003157|RADIATION|radiation therapy|
219421858|NCT03688945|PROCEDURE|Art Therapy|Attend art viewing sessions
219421859|NCT03688945|OTHER|Best Practice|Receive standard of care
219421860|NCT03688945|OTHER|Questionnaire Administration|Ancillary studies
219421861|NCT02617017|DRUG|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
219421862|NCT02617017|DRUG|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
219421863|NCT03886701|DRUG|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
219421864|NCT03886701|DRUG|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
219421865|NCT03886701|DRUG|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
219421866|NCT01397448|DRUG|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
219421867|NCT01397448|DRUG|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
219421868|NCT01397448|DRUG|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
219421869|NCT04065087|BIOLOGICAL|GX-I7|Investigational drug
219421870|NCT04065087|OTHER|Placebo|Placebo drug
219421871|NCT00931476|DRUG|somatropin|
219421872|NCT00931476|DRUG|placebo|
219421873|NCT04156828|DRUG|Copanlisib|Given IV
219421874|NCT04156828|DRUG|Gemcitabine|Given IV
219421875|NCT04156828|DRUG|Carboplatin|Given IV
219421876|NCT04156828|DRUG|Dexamethasone|Given PO
219421877|NCT04156828|BIOLOGICAL|Rituximab|Given IV
219421878|NCT04156828|BIOLOGICAL|Pegfilgrastim|Given SC
219421879|NCT03809832|DIAGNOSTIC_TEST|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
219574437|NCT02494050|BEHAVIORAL|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
219574438|NCT02494050|BEHAVIORAL|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
219574439|NCT02494050|BEHAVIORAL|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
219574440|NCT05982821|OTHER|Artificial Intelligent|Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
219421880|NCT04031053|OTHER|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
219421881|NCT05688072|OTHER|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
219421882|NCT05688072|OTHER|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
219421883|NCT01797991|DRUG|Dexamethasone per os|
219421884|NCT01797991|DRUG|Matching placebo for dexamethasone IV|
219421885|NCT01797991|DRUG|Dexamethasone IV|
219421886|NCT01797991|DRUG|Matching placebo for dexamethasone per os|
219421887|NCT01868776|DRUG|buffered lidocaine|
219421888|NCT01868776|DRUG|nonbuffered lidocaine|
219421889|NCT00091936|DRUG|Didanosine|
219421890|NCT00091936|DRUG|Efavirenz|
219421891|NCT00091936|DRUG|Lamivudine|
219421892|NCT00091936|DRUG|Standard TB treatment|
219574441|NCT06347991|BEHAVIORAL|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
219421893|NCT04799067|OTHER|observational study|no study drug involved, observational study.
219574442|NCT06918015|DRUG|ZGCVP|"Patients receive the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles at the following dose:~1. Zanubrutinib: 160mg orally twice daily;~2. Obinutuzumab: 1000mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of subsequent 5 cycles;~3. Cyclophosphamide: 750m/m2 intravenously on days 1 of every cycle;~4. Vindesine: 3 mg/m2 (maximum dose 4 mg) intravenously on days 1 of every cycle;~5. Prednisolone: 30mg orally three times daily on day 1-5 of every cycle. Patients achieving CR at stage II underwent observation directly; those at stage III/IV receive obinutuzumab maintenance every 8 weeks for 2 years (1000mg intravenously) until disease progression or withdrawal. Patients with disease progression during treatment switch to second-line therapy."
219574443|NCT01125020|DRUG|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
219574444|NCT01125020|DRUG|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
219421894|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|DDD+/-R pacing
219421895|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|ODO pacing
219574445|NCT05061576|BEHAVIORAL|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
219574446|NCT05061576|BEHAVIORAL|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
219574447|NCT03913182|DRUG|apatinib|500mg po Qd
219574448|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique + PRF|
219574449|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique|
219574450|NCT01077882|BEHAVIORAL|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
219574451|NCT01077882|BEHAVIORAL|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
219574452|NCT01077882|BEHAVIORAL|Lifestyle factors and psycho-education|by dietician and psychiatrist
219574453|NCT01077882|OTHER|no educational program|standard care without educational program
219574454|NCT00398931|DRUG|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
219005529|NCT01111149|DRUG|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
219005530|NCT01111149|DRUG|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
219421896|NCT01481168|DEVICE|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
219421897|NCT05399550|DRUG|Balovaptan|Intravenous Solution
219421898|NCT05399550|DRUG|Placebo|Matching Intravenous Solution
219421899|NCT04504435|DRUG|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
219421900|NCT04504435|DRUG|Placebo|Matching placebo capsules will be provided
219421901|NCT02180217|DRUG|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
219421902|NCT02180217|DRUG|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
219421903|NCT04278508|DRUG|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
219574455|NCT00398931|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
219574456|NCT04579276|PROCEDURE|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
219574457|NCT04579276|PROCEDURE|thoracic epidural analgesia|locoregional analgesia under ultrasound control
219574458|NCT05402982|DEVICE|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
219574459|NCT05402982|OTHER|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
219574460|NCT01293760|OTHER|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
219574461|NCT01293760|OTHER|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
219421904|NCT05534035|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
219421905|NCT05534035|BIOLOGICAL|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
219421906|NCT04894812|OTHER|Neurodevelopmental technique|"1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
219421907|NCT05242445|DRUG|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
219421908|NCT05242445|DRUG|Placebo|Placebo will be administered via SC injection or as an IV infusion.
219421909|NCT03528889|PROCEDURE|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
219421910|NCT03472599|OTHER|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
219421911|NCT06113497|DRUG|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
219421912|NCT04753047|OTHER|No intervention|No intervention
219574462|NCT05402462|DIAGNOSTIC_TEST|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
219574463|NCT03545191|DRUG|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
219574464|NCT03545191|DRUG|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
219574465|NCT03545191|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
219574466|NCT01400620|DRUG|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
219574467|NCT01769274|DRUG|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
219574468|NCT01769274|DRUG|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
219574469|NCT04694326|DIAGNOSTIC_TEST|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
219574470|NCT00196131|DRUG|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
219574471|NCT03795831|DEVICE|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
219574472|NCT04765774|OTHER|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
219574473|NCT04765774|OTHER|Music|The music chosen by the patient will be played in the music group.
219574474|NCT02059720|PROCEDURE|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
219574475|NCT00949689|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
219574476|NCT02504346|DRUG|AZD9291|
219421913|NCT03685526|DEVICE|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
219421914|NCT06081673|DRUG|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
219421915|NCT06081673|DRUG|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
219421916|NCT06081673|DRUG|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
219421917|NCT05005091|DIETARY_SUPPLEMENT|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
219421918|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
219421919|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
219421920|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
219421921|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
219421922|NCT06120309|DIAGNOSTIC_TEST|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
219421923|NCT06120309|DIAGNOSTIC_TEST|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
219421924|NCT01229241|DRUG|local anesthetic|"postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
219421925|NCT05190536|PROCEDURE|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
219421926|NCT05190536|PROCEDURE|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
219191143|NCT04946032|OTHER|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
219191144|NCT03598894|OTHER|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
219191145|NCT03606408|DRUG|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
219191926|NCT05402813|OTHER|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
219191927|NCT05402813|OTHER|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
219421927|NCT05843305|DRUG|BPI-452080|Subjects will receive BPI-452080 until disease progression
219421928|NCT00753961|OTHER|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
219421929|NCT00753961|OTHER|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
219421930|NCT05218057|PROCEDURE|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
219421931|NCT02399904|OTHER|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
219421932|NCT00694694|DRUG|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
219421933|NCT00694694|DRUG|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
219421934|NCT05239312|DRUG|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
219421935|NCT02492685|DEVICE|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
219421936|NCT03666975|DEVICE|LIV 30 Hz|LivMD LIV platform
219421937|NCT06553846|DRUG|Lutetium [177Lu]-FAP-75|Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
219421938|NCT04791033|PROCEDURE|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
219421939|NCT03201887|BEHAVIORAL|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
219421940|NCT03201887|BEHAVIORAL|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
219421941|NCT00671814|DRUG|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
219421942|NCT00671814|DRUG|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
219574477|NCT00960830|DRUG|mirtazapine|mirtazapine 15 mg daily tablets
219005531|NCT03535870|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
219005532|NCT03535870|DRUG|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
219421943|NCT00671814|DRUG|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
219421944|NCT02240745|OTHER|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
219421945|NCT00160576|DRUG|Levetiracetam|
219421946|NCT03365804|DEVICE|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
219421947|NCT01811901|OTHER|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
219421948|NCT04727606|DRUG|Ure-Na|"* Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month."
219421949|NCT05084794|PROCEDURE|Internal fixation|Fixation of posterior malleolus with either plate or screws.
219421950|NCT01017809|DRUG|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
219574478|NCT00960830|DRUG|mirtazapine|15 mg daily
219574479|NCT05981248|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219574480|NCT05818748|DEVICE|virtual reality|virtual reality distraction
219574481|NCT01507974|DRUG|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
219574482|NCT01507974|DRUG|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
219574483|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
219005533|NCT03535870|DRUG|Placebo|placebo dry powder administered via the LOMI inhaler device
219421951|NCT04968340|PROCEDURE|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
219421952|NCT04968340|PROCEDURE|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
219421953|NCT04148599|DRUG|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
219574484|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
219421954|NCT04148599|DRUG|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
219421955|NCT04148599|DRUG|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
219421956|NCT03537820|OTHER|questionnaire|questionnaire EVAN-G
219421957|NCT01680588|DRUG|[18F]NAV4694|
219421958|NCT02782871|DEVICE|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
219421959|NCT02403193|DRUG|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
219421960|NCT02403193|DRUG|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
219421961|NCT02403193|DRUG|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
219421962|NCT02403193|DRUG|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
219574485|NCT01507974|DRUG|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
219574486|NCT01507974|DRUG|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
219574487|NCT06392204|PROCEDURE|CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
219574488|NCT06392204|PROCEDURE|Champy's techqniue|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
219574489|NCT03602040|BEHAVIORAL|PISICC|"PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
219005534|NCT04539847|DEVICE|High-end hearing aid|hearing aid with premium level of technology
219005535|NCT04539847|DEVICE|Basic hearing aid|hearing aid with basic level of technology
219574490|NCT05759117|PROCEDURE|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
219574491|NCT01491035|DRUG|Vortioxetine|5 mg tablets for 14 days; orally; once daily
219574492|NCT01491035|DRUG|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
219005536|NCT00061880|DRUG|forodesine hydrochloride|
219005537|NCT00759954|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
219005538|NCT00759954|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
219421963|NCT02403193|DRUG|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
219421964|NCT02403193|DRUG|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
219421965|NCT02403193|DRUG|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
219421966|NCT02403193|DRUG|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
219421967|NCT02403193|DRUG|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
219421968|NCT01085305|BEHAVIORAL|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
219421969|NCT01085305|BEHAVIORAL|TAU|Usual treatment for behavioral disorders
219421970|NCT03039127|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
219421971|NCT01694576|DRUG|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
219421972|NCT01662297|DRUG|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
219421973|NCT01662297|DRUG|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
219005539|NCT01890850|OTHER|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
219005540|NCT00422175|DRUG|BAF 312|
219421974|NCT06011330|DRUG|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
219421975|NCT02055430|PROCEDURE|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
219421976|NCT02055430|PROCEDURE|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
219421977|NCT02055430|PROCEDURE|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
219421978|NCT06156358|OTHER|No intervention|No intervention
219421979|NCT04129606|DIAGNOSTIC_TEST|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
219421980|NCT00995670|DRUG|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
219421981|NCT00995670|DRUG|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
219421982|NCT00995670|DRUG|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
219421983|NCT00995670|DRUG|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
219421984|NCT05614713|PROCEDURE|Selected physical therapy program|Gait training and balance training
219421985|NCT05614713|PROCEDURE|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
219421986|NCT04390568|DRUG|Spesolimap|Spesolimap
219421987|NCT00338468|DRUG|epoetin alfa|
219421988|NCT00289562|DRUG|forodesine hydrochloride (BCX-1777)|
219421989|NCT03828149|COMBINATION_PRODUCT|Drug:OP0201|Drug: OP0201
219421990|NCT03828149|COMBINATION_PRODUCT|Drug: Placebo|Drug: Placebo
219421991|NCT04568941|BEHAVIORAL|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
219421992|NCT04568941|BEHAVIORAL|Core Needle Biopsy|Core Needle Biopsy
219421993|NCT04568941|BEHAVIORAL|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
219421994|NCT04486924|DEVICE|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
219421995|NCT00941616|BIOLOGICAL|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
219421996|NCT00941616|BIOLOGICAL|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
219421997|NCT02652507|DRUG|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
219421998|NCT02652507|DRUG|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
219421999|NCT03784027|DEVICE|CamAPS FX|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
219422000|NCT03784027|OTHER|Sensor augmented therapy|Study insulin pump and study CGM.
219005541|NCT03124875|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
219005542|NCT03220516|PROCEDURE|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
219005543|NCT03220516|PROCEDURE|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
219005544|NCT03220516|PROCEDURE|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
219005545|NCT03741179|DRUG|ASA-withdrawn group|Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
219005546|NCT00456131|BEHAVIORAL|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
219005547|NCT02320149|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
219005548|NCT02320149|DRUG|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
219422001|NCT06898229|BEHAVIORAL|Education|The intervention program aimed to increase participation in breast cancer screenings and reduce fear among illiterate women. The three-month training was structured in three phases. In the first month, awareness was raised through visual-audio materials about breast cancer, risk factors, and the importance of early diagnosis. In the second month, practical training was provided on breast self-examination (BSE), and clinical breast examination (CBE) and mammography procedures were introduced. In the final month, group discussions and success stories supported behavioral change, reinforcing knowledge. The program's effectiveness was evaluated through pre-test and post-test comparisons.
219422002|NCT02632695|DEVICE|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
219422003|NCT06416059|BEHAVIORAL|Mobile Application|The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
219574493|NCT01491035|DRUG|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
219574494|NCT01491035|DRUG|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
219005549|NCT01342146|DRUG|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
219005550|NCT01342146|DRUG|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
219191146|NCT06110273|BEHAVIORAL|Fit for Duty-mobile|Fit for Duty-mobile participants will receive self-regulatory support and behavior change techniques via an initial core intervention delivered through a native smartphone app (includes connected device data, 10 weekly lessons, weekly tailored feedback) and 4 coaching calls (weeks 1, 4, 8, and 16). App based tailored feedback and messaging will continue through 2 years. Optional 4-week refresher e-campaigns are offered every 6 mos. after the initial core intervention. Participants choose to follow either a Small Changes approach or a Large Changes approach and may choose to switch approaches over the 2 years, if desired.
219422004|NCT06899035|OTHER|Intervention Group (water-based and conventional exercise)|Patients in the study group will undergo individualized water-based exercises (including standing, balance, weight shifting, breathing exercises, range of motion, stretching, and strengthening exercises) under the supervision of an experienced physiotherapist, 2-3 times per week for six weeks. Additionally, routine conventional exercises will be continued daily for six weeks.
219422005|NCT06899035|OTHER|control group (conventional exercise)|Patients in the control group will continue passive, active, active-assisted, or resistance-based upper and lower extremity conventional exercises appropriate to their functional level and muscle strength. They will be instructed to perform these exercises 2-3 times per week, with each session lasting no more than 45 minutes, for six weeks.
219422006|NCT05824455|COMBINATION_PRODUCT|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
219005551|NCT01342146|DRUG|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
219005552|NCT00473642|DRUG|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
219422007|NCT05267613|DRUG|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
219422008|NCT05267613|DRUG|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
219005553|NCT00473642|DRUG|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
219005554|NCT00473642|DRUG|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
219005555|NCT00539331|DRUG|AZD2171|oral tablet
219005556|NCT00539331|DRUG|Paclitaxel|intravenous infusion
219191147|NCT06110273|BEHAVIORAL|m-Health Control|Participants receive digital tools and education on weight gain prevention behaviors at baseline.
219422009|NCT05643157|DEVICE|Adaptive Optics - Optical Coherence Tomography (AO-OCT) retinal imaging|AO-OCT used in this study is an investigational OCT imaging system. . In this instrument, ocular aberration sensing and correction is achieved with a Shack-Hartmann wavefront sensor (SHWS) and deformable mirror, respectively. A pupil camera and fixation target are used to position the participant's head and eye for scanning a particular retinal region within 15 degrees of the fovea. Data collected generally includes AO-OCT volume videos and SHWS measurements of ocular aberrations.
219422010|NCT01255306|OTHER|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day"
219422011|NCT01255306|DRUG|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
219422012|NCT04224818|DRUG|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
219422013|NCT04224818|DRUG|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
219422014|NCT00039468|DRUG|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
219422015|NCT00039468|DRUG|thalidomide|400mg/day oral
219422016|NCT04724304|DIAGNOSTIC_TEST|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
219422017|NCT04724304|DIAGNOSTIC_TEST|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
219422018|NCT03608891|DEVICE|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
219422019|NCT03608891|DEVICE|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
219422020|NCT05820009|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
219422021|NCT05820009|DEVICE|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
219422022|NCT05594212|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
219759772|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
219005557|NCT00539331|DRUG|Carboplatin|intravenous injection
219759773|NCT03280693|DIAGNOSTIC_TEST|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
219005558|NCT00055081|BEHAVIORAL|Critical Time Intervention|
219005559|NCT03012958|OTHER|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
219005560|NCT00226954|DRUG|zoledronic acid|
219005561|NCT03695107|DRUG|Nifedipine controlled released tablets|lower blood pressure
219005562|NCT02118844|DRUG|rocuronium|
219005563|NCT01741701|DRUG|Oxaloacetate (OAA)|
219005564|NCT01741701|DRUG|Placebo|
219422023|NCT01812070|BEHAVIORAL|ACT|
219422024|NCT01812070|BEHAVIORAL|CBT|
219422025|NCT01146951|DRUG|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
219422026|NCT01146951|DRUG|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
219422027|NCT02269384|PROCEDURE|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
219422028|NCT02269384|BEHAVIORAL|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
219422029|NCT02269384|BEHAVIORAL|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
219422030|NCT02269384|PROCEDURE|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
219422031|NCT01160861|DRUG|MEMP1972A|Repeating ascending dose
219422032|NCT01160861|DRUG|placebo|Repeating ascending dose
219422033|NCT03563261|DIETARY_SUPPLEMENT|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
219422034|NCT03563261|DIETARY_SUPPLEMENT|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
219422035|NCT02311790|DIETARY_SUPPLEMENT|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
219422036|NCT02311790|DIETARY_SUPPLEMENT|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
219422037|NCT03345940|DRUG|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
219759774|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
219759775|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
219759776|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
219759777|NCT01092884|DIETARY_SUPPLEMENT|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
219759778|NCT01092884|OTHER|Placebo|This placebo capsule will be taken orally three times daily
219422038|NCT03345940|DRUG|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
219422039|NCT01232751|DIETARY_SUPPLEMENT|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
219422040|NCT03312868|RADIATION|SBRT|Stereotactic Body Radiotherapy
219422041|NCT02915068|BEHAVIORAL|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
219422042|NCT05601908|OTHER|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
219422043|NCT05444010|BEHAVIORAL|mandala painting|nurse painted mandala for relaksing
219422044|NCT01141218|OTHER|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
219422045|NCT05281848|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
219422046|NCT01329289|DRUG|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
219422047|NCT01329289|DRUG|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
219422048|NCT01329289|DRUG|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
219422049|NCT01299610|DRUG|GW870086 2.0%|White to slightly colored opaque cream
219422050|NCT01299610|DRUG|GW870086 0.2%|White to slightly colored opaque cream
219422051|NCT01299610|DRUG|FP 0.05%|White cream
219422052|NCT01299610|DRUG|Placebo|White to slightly colored opaque cream
219422053|NCT00804843|DRUG|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
219422054|NCT00804843|DRUG|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
219422055|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
219422056|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
219422057|NCT00536848|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
219422058|NCT00536848|DIETARY_SUPPLEMENT|Placebo|
219422059|NCT00536848|DRUG|Metronidazole|
219422060|NCT00003129|DRUG|valrubicin|
219574495|NCT05991596|BEHAVIORAL|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
219422061|NCT05979714|OTHER|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
219422062|NCT05979714|BEHAVIORAL|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
219191148|NCT05390268|BEHAVIORAL|Mobile app-assisted behavioral treatment|"The app-assisted training group has access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\["
219422063|NCT05979714|OTHER|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
219422064|NCT05979714|BEHAVIORAL|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
219422065|NCT04291924|DIAGNOSTIC_TEST|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
219422066|NCT02223429|DRUG|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
219422067|NCT02223429|DRUG|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
219422068|NCT02223429|DRUG|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
219422069|NCT04457570|OTHER|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
219422070|NCT04378257|BEHAVIORAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
219422071|NCT04378257|BEHAVIORAL|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
219422072|NCT01926470|PROCEDURE|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
219422073|NCT01926470|PROCEDURE|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
219422074|NCT02567357|BEHAVIORAL|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
219422075|NCT02567357|BEHAVIORAL|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
219422076|NCT04426994|DRUG|proton pump inhibitor use|Patients using long term proton pump inhibitor
219422077|NCT02517853|DEVICE|Posterior tibial nerve stimulation|
219422078|NCT02517853|DEVICE|Sham posterior tibial nerve stimulation|
219422079|NCT03978104|DIETARY_SUPPLEMENT|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
219422080|NCT03978104|DIETARY_SUPPLEMENT|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
219422081|NCT03978104|DIETARY_SUPPLEMENT|Control biscuits|Consumption of control biscuits together with habitual diet.
219422082|NCT00978679|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
219422083|NCT00978679|DEVICE|Spectacles|Daily use of single vision lenses to correct refractive errors
219422084|NCT02097485|DRUG|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
219422085|NCT02097485|DRUG|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
219422086|NCT03607474|OTHER|Questionnaires of life quality for patients|"* the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale"
219574496|NCT05991596|BEHAVIORAL|Self-help activities|"The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
219574497|NCT01731717|BEHAVIORAL|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
219574498|NCT01731717|BEHAVIORAL|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
219574499|NCT01731717|BEHAVIORAL|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
219574500|NCT01731717|BEHAVIORAL|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
219574501|NCT01731717|PROCEDURE|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
219574502|NCT01731717|BEHAVIORAL|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
219574503|NCT01731717|OTHER|Control group: treatment as usual|treatment as usual
219005565|NCT04931355|OTHER|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
219005566|NCT04931355|OTHER|Western medicine|Western medicine
219422087|NCT03607474|OTHER|Questionnaires of life quality for caregivers|"* the WhoQoL~* The Beck II scale~* HAD scale"
219422088|NCT05317702|OTHER|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
219422089|NCT02748122|OTHER|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
219574504|NCT02527239|OTHER|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
219759779|NCT05021939|OTHER|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
219422090|NCT05535101|DEVICE|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
219422091|NCT05535101|DEVICE|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
219422092|NCT02126670|DRUG|ACT01|
219422093|NCT02126670|DRUG|Comp01|
219422094|NCT02126670|DRUG|Comp02|
219422095|NCT02126670|DRUG|Comp03|
219574505|NCT05978739|DRUG|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
219574506|NCT05978739|DRUG|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
219574507|NCT03179163|DRUG|Captopril Pill|ACEi+SH
219574508|NCT03179163|DRUG|Enalapril Pill|ACEi
219574509|NCT03179163|DRUG|Hydrochlorothiazide|diuretic
219574510|NCT04918641|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
219005567|NCT00006488|DRUG|recombinant-methionyl human glial cell line-derived neurotrophic factor|
219005568|NCT03134287|PROCEDURE|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
219005569|NCT02093481|OTHER|Test meal|
219005570|NCT02093481|OTHER|Reference|
219005571|NCT02093481|OTHER|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
219005572|NCT02093481|OTHER|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
219191149|NCT05390268|OTHER|Mobile app-assisted psychoeducation|The app-assisted educational group has access to a newly developed app in which they receive psychoeducation on tics.
219422096|NCT02126670|DRUG|Comp04|
219422097|NCT04318379|BIOLOGICAL|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
219422098|NCT04172701|DRUG|Long-acting Muscarinic Antagonists (LAMA)|drug
219422099|NCT04172701|DRUG|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
219422100|NCT03836352|OTHER|DPX-Survivac|SubQ injection (q9w)
219422101|NCT03836352|DRUG|Cyclophosphamide|PO (BID)
219422102|NCT03836352|DRUG|Pembrolizumab|IV Infusion (q3w)
219422103|NCT02472015|PROCEDURE|telemedicine|psycho-behavioural care by telemedicine
219422104|NCT02700139|DEVICE|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
219422105|NCT06048653|OTHER|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~* Patients will receive training for four weeks, two sessions per week.~* Each patient will assume a comfortable sitting position on a chair in front of the screen.~* A report will be generated at the end of the session. It will be used for follow up.~* Session duration will range from 45 to 60 min. including rest period."
219191150|NCT06138470|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
219422106|NCT06048653|DEVICE|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
219422107|NCT00313248|DRUG|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
219422108|NCT00313248|DRUG|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
219422109|NCT03437317|BEHAVIORAL|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
219422110|NCT03437317|BEHAVIORAL|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
219422111|NCT01286116|DEVICE|Parachute Implant|Mechanical ventricular partitioning
219422112|NCT00453856|DRUG|Sulfadoxine Pyrimethamine|
219422113|NCT02079051|BEHAVIORAL|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
219422114|NCT02079051|BEHAVIORAL|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
219422115|NCT03842956|PROCEDURE|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
219422116|NCT03039920|OTHER|Electronic cigarette|Smoking of electronic cigarette
219422117|NCT03039920|OTHER|Conventional cigarette|Smoking tobacco cigarette
219422118|NCT00360048|DRUG|oxytocin|
219422119|NCT05862948|DEVICE|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
219422120|NCT04077229|BEHAVIORAL|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
219422121|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
219422122|NCT01975246|DRUG|hydrochlorothiazide|tablet
219422123|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
219422124|NCT01975246|DRUG|Placebo|placebo matching hydrochlorothiazide tablet
219422125|NCT01263093|DRUG|Clopidogrel|
219422126|NCT01263093|DRUG|LY2216684|
219191151|NCT06138470|DIETARY_SUPPLEMENT|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
219422127|NCT02571608|DRUG|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
219422128|NCT02571608|DRUG|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
219422129|NCT00424346|DRUG|Canakinumab|
219422130|NCT00424346|DRUG|Placebo|
219422131|NCT04907864|COMBINATION_PRODUCT|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
219422132|NCT02855645|DRUG|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
219422133|NCT02855645|DRUG|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
219422134|NCT04464577|DRUG|Fluconazole|Specified Dose on Specified Days
219422135|NCT04464577|DRUG|Bupropion|Specified Dose on Specified Days
219422136|NCT04464577|DRUG|Itraconazole|Specified Dose on Specified Days
219422137|NCT04464577|DRUG|BMS-986235|Specified Dose on Specified Days
219422138|NCT02653313|DRUG|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
219422139|NCT00571519|DRUG|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
219422140|NCT00571519|DRUG|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
219422141|NCT00571519|DRUG|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
219422142|NCT00571519|DRUG|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
219422143|NCT00571519|DRUG|pioglitazone HCl|15 mg capsules administered orally, once daily
219422144|NCT00571519|DRUG|pioglitazone HCl|30 mg capsules administered orally, once daily
219422145|NCT00571519|DRUG|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
219422146|NCT00571519|DRUG|placebo|placebo capsules for pioglitazone administered orally, once daily
219422147|NCT00571519|DRUG|metformin|Oral tablets. Rescue medication.
219422148|NCT01924962|DEVICE|revascularisation|revascularisation of chronic occluded coronary artery
219422149|NCT03771690|BEHAVIORAL|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
219422150|NCT02522650|DRUG|Amiloride|5mg twice a day for 8 weeks
219422151|NCT02522650|DRUG|Triamterene|50mg twice a day for 8 weeks
219422152|NCT06376929|OTHER|oral carbohydrate containing fluid|administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
219422153|NCT04740060|OTHER|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
219422154|NCT04740060|OTHER|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
219422155|NCT04740060|OTHER|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
219422156|NCT00005018|DRUG|Hydroxyurea|
219422157|NCT00005018|DRUG|Abacavir sulfate|
219422158|NCT00005018|DRUG|Efavirenz|
219422159|NCT00005018|DRUG|Didanosine|
219422160|NCT03549468|DEVICE|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
219422161|NCT01902537|DRUG|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
219422162|NCT04919746|OTHER|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
219422163|NCT04539691|DEVICE|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
219422164|NCT06338046|OTHER|Corthellus Shiitake(Mushroom) Extract|topical treatment with Corthellus Shiitake(Mushroom) Extract
219422165|NCT06338046|OTHER|Placebo|topical treatment with a placebo cosmetic formula
219422166|NCT02407314|PROCEDURE|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
219574511|NCT02377063|DIETARY_SUPPLEMENT|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
219422167|NCT02407314|DEVICE|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
219422168|NCT02407314|OTHER|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
219422169|NCT02407314|OTHER|Six minute walk distance|Assessment of the walking distance in 6 minutes.
219422170|NCT02407314|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
219422171|NCT02407314|DRUG|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
219422172|NCT02401802|DIETARY_SUPPLEMENT|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
219422173|NCT02401802|DIETARY_SUPPLEMENT|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
219422174|NCT01109069|DRUG|PCI-32765|Dose based on parent protocol
219422175|NCT05151224|DIAGNOSTIC_TEST|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
219422176|NCT03246555|DRUG|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
219422177|NCT03246555|DRUG|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
219422178|NCT03457766|DEVICE|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
219422179|NCT02953613|DEVICE|NIRS/IVUS|Cardiac catheterization using infraredx
219422180|NCT05709314|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
219422181|NCT00562640|BIOLOGICAL|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
219422182|NCT00562640|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
219422183|NCT00562640|DRUG|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
219422184|NCT00562640|OTHER|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
219574512|NCT03282734|OTHER|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
219574513|NCT03282734|OTHER|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
219191152|NCT06138470|DIETARY_SUPPLEMENT|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
219191153|NCT06138470|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
219422185|NCT05369624|OTHER|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
219422186|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
219005573|NCT01291758|DIAGNOSTIC_TEST|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
219422187|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
219005574|NCT03125317|OTHER|Music|a kind of music which the participant likes will be listened using speakers
219005575|NCT03125317|OTHER|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
219005576|NCT03125317|OTHER|control|No intervention
219191154|NCT06244992|DRUG|PTT-936|Eligible patients will receive single-agent PTT-936 administered per orally (PO).
219422188|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
219422189|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
219422190|NCT00848770|DRUG|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
219422191|NCT00848770|DRUG|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
219422192|NCT00848770|DRUG|manipulation of SAP|Esmolol or NPS or NOR
219422193|NCT05193851|DRUG|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
219574514|NCT01418716|OTHER|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
219574515|NCT01418716|OTHER|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
219574516|NCT05368441|DRUG|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
219574517|NCT05368441|DRUG|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
219574518|NCT00306163|DRUG|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
219574519|NCT00306163|DRUG|Fluticasone|inhaled Fluticasone 100 µg, twice daily
219422194|NCT06398093|BEHAVIORAL|Self-Compassion Tool Kit|Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
219422195|NCT02919735|DRUG|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
219422196|NCT02919735|DRUG|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
219422197|NCT02787603|OTHER|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
219422198|NCT00272545|BEHAVIORAL|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
219422199|NCT00272545|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
219422200|NCT06136455|DRUG|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
219574520|NCT02900963|OTHER|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
219574521|NCT02139917|BEHAVIORAL|Transitional community based palliative care|"transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support"
219005577|NCT02209389|DEVICE|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
219005578|NCT01296620|DRUG|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
219005579|NCT01296620|DRUG|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
219005580|NCT01296620|DRUG|5% dextrose in water|Placebo
219422201|NCT06136455|DRUG|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
219422202|NCT06136455|OTHER|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
219422203|NCT06136455|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
219422204|NCT03672669|GENETIC|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
219422205|NCT03672669|GENETIC|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
219422206|NCT01852630|DRUG|cefepime + Albumin|cefepime + Albumin will be given for 2 days
219422207|NCT01852630|DRUG|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
219422208|NCT02499575|DRUG|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
219422209|NCT02499575|DRUG|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
219422210|NCT03203590|DRUG|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
219574522|NCT00775684|DRUG|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
219574523|NCT00775684|DRUG|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
219005581|NCT03949374|DRUG|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
219422211|NCT03203590|DRUG|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
219422212|NCT06347965|BEHAVIORAL|Low load blood flow restriction training|Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
219422213|NCT06347965|BEHAVIORAL|Progressive resistance training group|The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
219422214|NCT01952704|BEHAVIORAL|Aerobic exercise|
219422215|NCT01952704|BEHAVIORAL|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
219574524|NCT00775684|DRUG|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
219574525|NCT01709279|BIOLOGICAL|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
219574526|NCT01277718|DRUG|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
219574527|NCT01277718|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
219574528|NCT01598519|BEHAVIORAL|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
219574529|NCT00195013|DRUG|glutamine|10 grams three times a day (orally) for four days and then stop
219574530|NCT00195013|DRUG|Placebo|10 grams three times a day (orally) for four days and then stop
219574531|NCT02902718|DEVICE|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
219574532|NCT02925806|OTHER|Non-interventional study - retrospective database review|
219574533|NCT06030349|DEVICE|Non-invasive ventilation|Non-invasive ventilation
219574534|NCT04061642|DEVICE|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
219574535|NCT05094752|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
219574536|NCT05094752|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
219574537|NCT03237533|DRUG|Dexamethasone|Dexamethasone will be applied locally on the lesion
219574538|NCT00280878|DRUG|gemcitabine|
219005582|NCT03949374|DRUG|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
219422216|NCT02658968|DRUG|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
219422217|NCT05118711|DIAGNOSTIC_TEST|Cardiorespiratory fitness|Cardiopulmonary exercise testing
219422218|NCT05118711|DIAGNOSTIC_TEST|Lung function|Body plethysmography
219574539|NCT00280878|DRUG|vinorelbine|
219574540|NCT00280878|DRUG|ifosfamide|
219574541|NCT00280878|DRUG|rituximab|
219574542|NCT02397005|DRUG|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
219574543|NCT02397005|DRUG|Placebo matching ZL-2102|
219574544|NCT01754506|DIETARY_SUPPLEMENT|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
219574545|NCT02459145|BEHAVIORAL|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)\_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
219574546|NCT01940328|DEVICE|Transchoracic ultrasound Doppler|
219574547|NCT01911663|DIETARY_SUPPLEMENT|KRG|500 mg Korea red ginseng (KRG)
219574548|NCT01911663|DIETARY_SUPPLEMENT|Placebo|500 mg placebo
219574549|NCT04722601|DRUG|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
219574550|NCT04722601|DRUG|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
219759780|NCT05021939|OTHER|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
219574551|NCT04722601|DRUG|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
219574552|NCT03196674|OTHER|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
219574553|NCT00869986|DRUG|dirucotide|500mg, intravenous, every 6 months for 15 months
219574554|NCT00869986|DRUG|placebo|intravenous, once every six months for 15 months
219574555|NCT04336124|DRUG|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
219759781|NCT02136914|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
219759782|NCT02136914|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
219759783|NCT02312648|OTHER|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
219759784|NCT02312648|OTHER|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
219759785|NCT00004466|DRUG|Atorvastatin|
219759786|NCT00004466|DRUG|Placebo|
219759787|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
219759788|NCT04136145|DRUG|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
219759789|NCT04136145|DRUG|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
219759790|NCT01148667|DIETARY_SUPPLEMENT|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
219759791|NCT01148667|DIETARY_SUPPLEMENT|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
219759792|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
219759793|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
219759794|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
219759795|NCT06395116|OTHER|Denture base material|Denture base material constructed with different techniques for completely edentulous populations
219759796|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
219759797|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
219759798|NCT04389697|DIETARY_SUPPLEMENT|Clear fluids and food up to up to 1 hour before the procedure|Clear fluids and food up to up to 1 hour before the start of the procedure
219759799|NCT02665325|DRUG|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
219574556|NCT00695435|DRUG|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
219574557|NCT00695435|DRUG|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
219574558|NCT00695435|DRUG|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
219574559|NCT04944134|BIOLOGICAL|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
219574560|NCT02776514|DRUG|Triamcort|Fluoroscopic guided injection in the knee joint
219574561|NCT02776514|DRUG|Platelet-rich-plasma|
219422219|NCT05118711|DIAGNOSTIC_TEST|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
219574562|NCT02776514|DRUG|Suplasyn1|
219574563|NCT02776514|DRUG|Placebo|
219574564|NCT05649449|BEHAVIORAL|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
219574565|NCT05649449|BEHAVIORAL|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
219574566|NCT04464993|BEHAVIORAL|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
219574567|NCT04464993|BEHAVIORAL|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
219574568|NCT04464993|BEHAVIORAL|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
219574569|NCT04464993|BEHAVIORAL|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
219422220|NCT05118711|DIAGNOSTIC_TEST|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
219574570|NCT00038337|PROCEDURE|Health Literacy|
219574571|NCT04263428|BEHAVIORAL|Irregular sleep|Experimental-induced sleep variability
219574572|NCT04527328|DEVICE|AKST1210|AKST1210
219574573|NCT04527328|OTHER|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
219574574|NCT04527328|PROCEDURE|Hemodialysis|Hemodialysis
219422221|NCT05118711|DIAGNOSTIC_TEST|Blood sampling and analysis|Blood sampling by venepuncture
219422222|NCT05118711|DIAGNOSTIC_TEST|Physical activity|Physical activity surveillance using accelerometers
219422223|NCT05118711|DIAGNOSTIC_TEST|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
219422224|NCT05118711|DIAGNOSTIC_TEST|Body composition|Dual-energy x-ray absorptiometry (DXA)
219422225|NCT04644965|DIAGNOSTIC_TEST|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
219422226|NCT04644965|DIAGNOSTIC_TEST|Blood Taking|Sampling of blood of the finger pad to assess liver function
219574575|NCT02680418|DRUG|FDL169|
219574576|NCT03964610|DIAGNOSTIC_TEST|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
219574577|NCT00336115|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
219759800|NCT01493089|DRUG|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
219759801|NCT01493089|DRUG|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
219422227|NCT04644965|DIAGNOSTIC_TEST|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
219422228|NCT04644965|DIAGNOSTIC_TEST|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
219422229|NCT04644965|DIAGNOSTIC_TEST|Ultrasound|Ultrasound for abdominal wall muscles
219422230|NCT04644965|DIAGNOSTIC_TEST|Stance and gait analyses|Stance and gait analyses for measuring the core stability
219422231|NCT06440265|OTHER|AM-PAC inpatient short form (low function)|"The Activity Measure for Post-Acute Care(AM-PAC) 6-clicks instruments have advantages in that they are simple and quick to complete, easy to use within usual care and has been validated in the entire hospital population. It has gained broad adoption in acute care hospital and, although it includes items for people at lower levels of function, there is a concern of a floor effect in ICU measurement. So, new AM-PAC items are developed to measure physical function at the lowest level and added 2 new items to AM-PAC inpatient mobility short form. It lowered the floor effect and increased statistical power, measurement breath, and sensitivity.~2 new items~* Turning head~* Following simple instructions"
219422232|NCT02025803|DRUG|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
219422233|NCT00384826|DRUG|erlotinib|Erlotinib 150 mg/day (until progression)
219422234|NCT00384826|DRUG|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
219422235|NCT01635010|PROCEDURE|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
219422236|NCT05431049|PROCEDURE|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
219422237|NCT01546844|OTHER|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
219422238|NCT02134067|DRUG|TAS-119|
219422239|NCT02134067|DRUG|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
219422240|NCT03794752|DEVICE|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
219422241|NCT01621724|GENETIC|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
219422242|NCT03292952|DRUG|KP415 oral capsule|Daily dose
219422243|NCT03292952|DRUG|Placebo oral capsule|Daily dose
219422244|NCT01206452|DRUG|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
219422245|NCT01206452|OTHER|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
219422246|NCT01206452|PROCEDURE|Ablation Procedure|Atrial Fibrillation (AF) ablation
219422247|NCT00972842|DRUG|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
219422248|NCT01362946|BEHAVIORAL|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
219005583|NCT04785976|PROCEDURE|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
219005584|NCT02875756|PROCEDURE|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
219005585|NCT02875756|PROCEDURE|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
219005586|NCT02866552|DRUG|Stromal Vascular fraction|
219005587|NCT02866552|DRUG|Ringer lactate|
219005588|NCT03033394|DRUG|Beta-lactam antibiotic|Routine clinical dosing
219005589|NCT02036294|OTHER|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
219005590|NCT02036294|OTHER|Usual Care|Standard Healthcare Services
219005591|NCT03325283|DEVICE|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
219005592|NCT05318170|PROCEDURE|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
219005593|NCT06093698|BIOLOGICAL|Recombinant Anti-EpCAM-CD3 Antibody Injection|Intravenous Infusion
219422249|NCT01362946|BEHAVIORAL|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
219422250|NCT00709358|OTHER|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
219422251|NCT00709358|OTHER|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
219422252|NCT03302897|BIOLOGICAL|LEP-F1 + GLA-SE|Investigational vaccine
219422253|NCT04603040|DRUG|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
219422254|NCT00671216|DRUG|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
219422255|NCT00671216|DRUG|GW642444|Subjects will receive 50 mcg once daily as a single dose
219422256|NCT00671216|DRUG|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
219422257|NCT00671216|DRUG|Placebo|Placebo matching study medication will be inhaled by subjects
219422258|NCT01948895|DRUG|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
219422259|NCT03634904|DRUG|Drug bood sampling|"Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
219422260|NCT02131012|DRUG|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
219422261|NCT00627835|DRUG|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
219422262|NCT00627835|DRUG|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
219422263|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
219422264|NCT00627835|DRUG|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
219422265|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
219422266|NCT05386121|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
219422267|NCT05386121|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
219422268|NCT05386121|DEVICE|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
219422269|NCT05386121|DEVICE|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
219422270|NCT05386121|DRUG|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
219422271|NCT05386121|DRUG|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
219422272|NCT03185104|DRUG|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
219422273|NCT03185104|DRUG|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
219422274|NCT05244499|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
219422275|NCT05244499|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
219422276|NCT03355794|DRUG|ribociclib|Oral capsule or liquid formula
219422277|NCT03355794|DRUG|Everolimus|Oral tablets or dispersible tablets
219422278|NCT01595165|PROCEDURE|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
219005594|NCT05623098|DIETARY_SUPPLEMENT|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
219005595|NCT01169974|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
219422279|NCT01595165|PROCEDURE|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
219422280|NCT02267226|DRUG|Octafibrin|
219422281|NCT00445250|DRUG|Calcipotriol|
219422282|NCT03882398|OTHER|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
219005596|NCT06505616|DEVICE|Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it|The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
219422283|NCT03882398|OTHER|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
219422284|NCT04693520|DRUG|ALZ-801|ALZ-801 265 mg twice daily (BID)
219422285|NCT01883869|DRUG|ticagrelor|
219422286|NCT01883869|DRUG|placebo|placebo
219574578|NCT05606588|BEHAVIORAL|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
219574579|NCT01627925|DEVICE|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
219574580|NCT01469741|BEHAVIORAL|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
219574581|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
219422287|NCT03330041|DEVICE|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
219422288|NCT05399108|PROCEDURE|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
219422289|NCT05399108|PROCEDURE|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
219422290|NCT00397878|DRUG|saracatinib|Given orally
219422291|NCT00397878|OTHER|laboratory biomarker analysis|Correlative studies
219574582|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
219574583|NCT00026052|DRUG|riluzole|
219422292|NCT00912340|DRUG|Everolimus|
219422293|NCT00912340|BIOLOGICAL|Trastuzumab|
219422294|NCT04084249|DIAGNOSTIC_TEST|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
219422295|NCT04084249|OTHER|Intensified Follow-up Schedule|PET/CT-scans every 3. month
219422296|NCT00216541|DRUG|epoetin alfa|
219422297|NCT02236741|DRUG|Mirapexin® (Sifrol®)|
219422298|NCT04060810|OTHER|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
219422299|NCT03027388|DRUG|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
219422300|NCT04234763|BEHAVIORAL|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
219422301|NCT04234763|BEHAVIORAL|Control group|Assess nutritional status and no active intervention is conducted.
219005597|NCT01200602|DRUG|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
219005598|NCT01200602|OTHER|clinical observation|No treatment is given.
219422302|NCT05969912|OTHER|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
219422303|NCT05969912|OTHER|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
219422304|NCT00292747|DRUG|Drotaverine|
219422305|NCT00292747|DRUG|Drotaverine Placebo|
219422306|NCT00292747|DRUG|Ibuprofen|
219422307|NCT00292747|DRUG|Ibuprofen Placebo|
219574584|NCT05049031|OTHER|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
219574585|NCT00810628|BEHAVIORAL|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
219574586|NCT04878237|OTHER|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
219574587|NCT04690569|DIAGNOSTIC_TEST|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
219574588|NCT01010815|PROCEDURE|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
219574589|NCT01010815|OTHER|stool collection|Stool will be collected from participants at study entry
219574590|NCT01010815|PROCEDURE|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
219574591|NCT01010815|OTHER|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
219574592|NCT04544137|BEHAVIORAL|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
219574593|NCT05208879|BIOLOGICAL|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
219005599|NCT00438984|DRUG|cyclophosphamide|Given IV
219005600|NCT00438984|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219005601|NCT00438984|BIOLOGICAL|aldesleukin|Given IV or SC
219005602|NCT00438984|OTHER|immunohistochemistry staining method|Correlative studies
219005603|NCT00438984|PROCEDURE|biopsy|Optional correlative studies
219005604|NCT00438984|OTHER|laboratory biomarker analysis|Correlative studies
219005605|NCT00438984|OTHER|immunologic technique|Correlative studies
219005606|NCT00438984|GENETIC|polymerase chain reaction|Correlative studies
219005607|NCT04821921|OTHER|No intervention|Care as usual
219005608|NCT04887714|OTHER|Mask|Mask wearing
219005609|NCT00686660|BEHAVIORAL|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
219005610|NCT00686660|BEHAVIORAL|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
219422308|NCT05766293|DEVICE|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
219574594|NCT05208879|OTHER|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
219574595|NCT06257316|DRUG|EPHEDrine Hydrochloride 5 mg/ml|"In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable."
219574596|NCT00682552|PROCEDURE|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
219422309|NCT05766293|OTHER|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
219422310|NCT03946293|DIETARY_SUPPLEMENT|White Bread|White bread made with commercial white flour with bran/fibre removed
219422311|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
219422312|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
219422313|NCT00671723|DRUG|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
219422314|NCT00671723|DRUG|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
219422315|NCT00671723|DRUG|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
219422316|NCT00474825|DRUG|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
219422317|NCT00474825|DRUG|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
219422318|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
219574597|NCT00280176|DRUG|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
219574598|NCT00280176|DRUG|fluorouracil|225mg/m2 given weekly, up to 6 weeks
219574599|NCT00280176|RADIATION|radiation therapy|180 cGy, every 5 days, up to six weeks
219574600|NCT03351231|DRUG|BMS-986242|Specified dose on specified days
219574601|NCT03351231|BIOLOGICAL|Nivolumab|Specified dose on specified days
219574602|NCT01370486|DRUG|melatonin|melatonin cp 2 mg 1x/d for 1 month
219574603|NCT01370486|DRUG|placebo|placebo cp 1x/d for 1 month
219574604|NCT01745354|DRUG|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
219574605|NCT01745354|RADIATION|Local Radiation|
219574606|NCT05029934|PROCEDURE|use of EndoClot|deployment of EndoClot adhesive spray
219422319|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
219422320|NCT01969942|BIOLOGICAL|allogeneic stem cell transplantation|
219422321|NCT01969942|DRUG|Clyclophosphamide|
219422322|NCT01969942|DRUG|Fludarabina|
219422323|NCT01969942|DRUG|Busulfan|
219422324|NCT01969942|DRUG|Melphalan|
219422325|NCT00390494|PROCEDURE|Hysterectomy|
219422326|NCT00390494|PROCEDURE|Myomectomy|
219422327|NCT00390494|PROCEDURE|Uterine Fibroid Embolization|
219422328|NCT00502528|DRUG|Placebo|Peri-interventional
219422329|NCT00502528|DRUG|BQ-123|Peri-interventional
219422330|NCT01061736|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219422331|NCT01061736|DRUG|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219422332|NCT01061736|DRUG|Methotrexate|Same weekly dose as received prior to enrollment
219422333|NCT01061736|DRUG|Folic Acid|According to local standard
219422334|NCT05682313|DIAGNOSTIC_TEST|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
219422335|NCT04051476|OTHER|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
219005611|NCT00686660|BEHAVIORAL|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
219005612|NCT00686660|BEHAVIORAL|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
219005613|NCT05040321|DRUG|MIB-626|Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
219005614|NCT05040321|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000 mg MIB-626 twice daily orally.
219191155|NCT06244992|DRUG|Combination of PTT-936 and anti-PD-1/L1 therapy|Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
219574607|NCT02198924|DRUG|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
219574608|NCT02198924|DRUG|placebo|control patients are supplied with the corresponding placebo with the same instructions.
219191156|NCT05995496|OTHER|Fasting state|16 hours of fasting
219422336|NCT04051476|OTHER|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
219422337|NCT04051476|OTHER|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
219422338|NCT04051476|OTHER|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
219422339|NCT05032417|OTHER|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
219422340|NCT00002783|DRUG|cisplatin|
219422341|NCT00002783|DRUG|floxuridine|
219422342|NCT00002783|DRUG|fluorouracil|
219422343|NCT00002783|DRUG|leucovorin calcium|
219422344|NCT00002783|PROCEDURE|conventional surgery|
219422345|NCT03424317|BEHAVIORAL|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
219422346|NCT03424317|BEHAVIORAL|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
219005615|NCT01634815|PROCEDURE|The Edge|measuring blood lactate
219191157|NCT05995496|OTHER|Fed state|Fed a standardized meal
219191158|NCT05995496|OTHER|Magnetic Resonance Imaging|Neuroimaging with computational modeling
219191159|NCT01593241|DRUG|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
219191160|NCT01593241|RADIATION|Involved node RT|Involved node RT
219191161|NCT04218318|DEVICE|phototherapy|Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
219191162|NCT03556293|BEHAVIORAL|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
219422347|NCT01768468|DRUG|LAYLA tablet|1 tablet twice a day
219422348|NCT01768468|DRUG|JOINS tablet|1 tablet at each time, 3 times a day
219574609|NCT00000202|DRUG|Buprenorphine|
219574610|NCT01711749|DRUG|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
219574611|NCT01711749|DRUG|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
219574612|NCT02130778|DRUG|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
219574613|NCT02130778|OTHER|500 ml 0.9% saline|infusion of saline
219574614|NCT00764231|BEHAVIORAL|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
219422349|NCT04992039|OTHER|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling."
219422350|NCT01532713|PROCEDURE|oxygen administration|nasal O2 5L/min via nasal cannula
219005616|NCT02461303|OTHER|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
219191163|NCT03556293|BEHAVIORAL|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
219422351|NCT03388996|DIAGNOSTIC_TEST|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
219422352|NCT01362218|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
219422353|NCT01362218|DRUG|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
219422354|NCT04735965|DRUG|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
219422355|NCT04735965|DRUG|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
219422356|NCT04735965|DRUG|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
219422357|NCT01610076|OTHER|Code Status Video|"10 minute video about Code Status"
219422358|NCT04899960|DRUG|Clinical Pharmacist Intervention|Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
219422359|NCT03817840|PROCEDURE|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
219422360|NCT05023850|PROCEDURE|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
219422361|NCT05023850|PROCEDURE|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
219422362|NCT05875389|OTHER|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
219422363|NCT04264767|PROCEDURE|Blood collection|Peripheral blood collection via routine venipuncture
219422364|NCT01759498|DIETARY_SUPPLEMENT|HYDRO|
219422365|NCT01759498|DIETARY_SUPPLEMENT|ACTIVE|
219422366|NCT01759498|DIETARY_SUPPLEMENT|HYDRO 2|
219422367|NCT03998917|DIAGNOSTIC_TEST|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
219422368|NCT00326222|BEHAVIORAL|Lifestyle counseling|Self-management group education
219422369|NCT05270642|PROCEDURE|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
219422370|NCT00284739|DRUG|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
219422371|NCT00284739|OTHER|saline|saline injection twice daily for three days
219422372|NCT03629691|OTHER|lung cavitation|apatinib treated patients developed lung cavitation
219422373|NCT06114394|PROCEDURE|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
219422374|NCT06114394|PROCEDURE|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
219422375|NCT04182789|DRUG|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
219422376|NCT06517862|DRUG|Zinc sulfate|Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
219422377|NCT06517862|DRUG|Ursodeoxycholic acid|Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
219422378|NCT00111930|DRUG|DHEA|
219422379|NCT02680587|RADIATION|SBRT|SBRT (1-5 fractions) will be administered.
219422380|NCT03461432|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
219422381|NCT02899377|RADIATION|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
219422382|NCT02899377|RADIATION|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
219422383|NCT02899377|PROCEDURE|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
219422384|NCT02899377|PROCEDURE|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
219422385|NCT04759677|OTHER|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
219422386|NCT05668676|DRUG|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
219422387|NCT05668676|OTHER|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
219422388|NCT05145712|DIAGNOSTIC_TEST|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
219422389|NCT02786108|PROCEDURE|left gastric artery embolization|
219422390|NCT02786108|BEHAVIORAL|healthy diet and exercise|
219422391|NCT02424006|DEVICE|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
219422392|NCT02424006|DEVICE|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
219422393|NCT01371448|DRUG|Paroxetine|
219422394|NCT03084289|BIOLOGICAL|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
219422395|NCT03084289|BIOLOGICAL|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
219422396|NCT03600493|DRUG|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
219422397|NCT03600493|DRUG|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
219422398|NCT05572788|PROCEDURE|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
219422399|NCT03779633|DRUG|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
219422400|NCT03779633|OTHER|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
219422401|NCT03022513|OTHER|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
219191164|NCT03556293|BEHAVIORAL|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
219422402|NCT02382783|OTHER|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
219422403|NCT01892449|OTHER|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
219422404|NCT01892449|OTHER|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
219422405|NCT03987334|OTHER|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
219422406|NCT03987334|OTHER|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
219422407|NCT06177119|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
219422408|NCT06177119|DRUG|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
219422409|NCT06177119|DRUG|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
219422410|NCT06177119|DRUG|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
219422411|NCT06177119|DRUG|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
219422412|NCT06177119|DRUG|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
219422413|NCT06177119|DRUG|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
219422414|NCT03222219|PROCEDURE|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
219422415|NCT05409768|PROCEDURE|Short axis out of plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
219422416|NCT05409768|PROCEDURE|Anteroposterior short axis in plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
219422417|NCT00363441|PROCEDURE|Intensity Modulated Radiotherapy|
219422418|NCT02818140|PROCEDURE|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
219422419|NCT02818140|PROCEDURE|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
219422420|NCT02818140|DRUG|Ropivacaine|
219422421|NCT02818140|DRUG|Saline|
219422422|NCT02818140|DEVICE|Ultrasound|
219422423|NCT04532073|OTHER|Eurythmy Therapy|A mindfulness-oriented movement therapy
219422424|NCT04532073|OTHER|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
219422425|NCT04532073|OTHER|Standard Care|Treatment process that a clinician should follow for a certain type of patient
219422426|NCT00469209|DRUG|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
219422427|NCT00469209|DRUG|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
219422428|NCT00469209|DRUG|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
219422429|NCT00469209|DRUG|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
219422430|NCT04562545|DEVICE|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
219422431|NCT04562545|DEVICE|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
219422432|NCT01333306|PROCEDURE|Transcranial direct current stimulation (tDCS)|
219422433|NCT04995471|BEHAVIORAL|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
219005617|NCT03789045|DIAGNOSTIC_TEST|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
219005618|NCT03764501|DEVICE|Image fusion system|Image fusion system for the 3D preoperative planning
219005619|NCT01832987|DRUG|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
219005620|NCT01887873|DEVICE|Hyaluronan Thiomer i.o. implant|
219005621|NCT00279240|DRUG|Metformin|
219005622|NCT00150722|DRUG|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
219005623|NCT04848545|OTHER|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
219005624|NCT05577481|COMBINATION_PRODUCT|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
219005625|NCT05577481|COMBINATION_PRODUCT|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
219005626|NCT01171339|OTHER|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
219005627|NCT02592174|OTHER|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
219422434|NCT04995471|BEHAVIORAL|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
219422435|NCT04995471|BEHAVIORAL|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
219422436|NCT04995471|BEHAVIORAL|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
219422437|NCT01949727|OTHER|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
219422438|NCT04646473|BEHAVIORAL|SweetGoals app|App offers goal setting and feedback
219422439|NCT04646473|BEHAVIORAL|Coaching|Web health coaching
219422440|NCT04646473|BEHAVIORAL|Incentives|Financial incentives for meeting goals
219422441|NCT02858973|DRUG|Q203|
219005628|NCT02592174|OTHER|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
219005629|NCT02592174|RADIATION|cerebral images sub-study|Standard magnetic resonance imaging
219005630|NCT02408640|BEHAVIORAL|Cannabishjalpen.se|
219005631|NCT00876629|DEVICE|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
219005632|NCT03053414|DIETARY_SUPPLEMENT|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
219005633|NCT04360954|DIAGNOSTIC_TEST|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
219005634|NCT01624454|OTHER|Laxabon|4 l PEG solution split dose cleansing
219005635|NCT01624454|OTHER|CitraFleet|Small volume osmotic bowelcleansing
219005636|NCT00913367|DRUG|glimepiride + insulin glargine (Amaryl + Lantus)|"* Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
219422442|NCT02858973|DRUG|Placebo|
219422443|NCT01666691|DRUG|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
219422444|NCT01666691|DRUG|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
219422445|NCT00347035|DRUG|brimonidine|
219005637|NCT00913367|DRUG|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"* Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
219005638|NCT00331279|DRUG|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
219422446|NCT03668535|PROCEDURE|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
219422447|NCT03668535|PROCEDURE|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
219422448|NCT01926847|DRUG|Riociguat (Adempas, BAY63-2521)|
219422449|NCT01926847|DRUG|Placebo|
219422450|NCT01115075|OTHER|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
219422451|NCT01115075|BEHAVIORAL|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
219422452|NCT02823600|DEVICE|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
219422453|NCT02943018|OTHER|anovaginal distance variation|Kappa calculation
219422454|NCT00041353|OTHER|cytology specimen collection procedure|
219422455|NCT00041353|PROCEDURE|comparison of screening methods|
219422456|NCT00041353|PROCEDURE|study of high risk factors|
219422457|NCT01309867|DEVICE|Investigational Toric Lens|Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
219422458|NCT01309867|DEVICE|PureVision Toric Lens|Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
219422459|NCT04975542|OTHER|Osteopathic Manipulative Medicine|Manipulative therapies based on Osteopathic principles.
219422460|NCT04975542|OTHER|Sham|Light touch techniques to mimic to osteopathic treatment.
219422461|NCT00943488|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
219005639|NCT00331279|DRUG|Placebo|Placebo pills in likeness of the cinnamon extract
219005640|NCT04737343|DRUG|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
219005641|NCT04737343|DRUG|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
219005642|NCT06219850|OTHER|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
219005643|NCT01564381|DIETARY_SUPPLEMENT|ResA|90mg of resveratrol conjugated with arginine.
219005644|NCT01564381|DIETARY_SUPPLEMENT|Resveratrol|90mg of resveratrol.
219005645|NCT01564381|DIETARY_SUPPLEMENT|Placebo|Made up of cellulose.
219005646|NCT05193864|DEVICE|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
219422462|NCT02556424|DRUG|Dexamethasone|Intravitreal implant at D0
219422463|NCT02556424|DRUG|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
219422464|NCT05825196|DIAGNOSTIC_TEST|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
219422465|NCT00430963|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|
219422466|NCT00430963|DRUG|Placebo|
219422467|NCT04291976|PROCEDURE|Back-to-back high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
219422468|NCT04291976|PROCEDURE|single-pass high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
219422469|NCT04291976|PROCEDURE|chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
219422470|NCT00783172|DRUG|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
219574615|NCT00764231|BEHAVIORAL|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
219574616|NCT02304068|OTHER|Home monitoring|
219574617|NCT02304068|OTHER|Hospital assessment|
219574618|NCT02004184|DRUG|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
219574619|NCT02004184|DRUG|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
219574620|NCT02858726|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
219574621|NCT02858726|DRUG|CR845 1 mcg/kg|IV medication delivered three times/week
219574622|NCT02858726|DRUG|CR845 1.5mcg/kg|IV medication delivered three times/week
219574623|NCT02858726|DRUG|Placebo|IV medication delivered three times/week
219574624|NCT00190879|DRUG|Atomoxetine hydrochloride|
219574625|NCT00190879|DRUG|placebo|
219574626|NCT04126954|OTHER|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
219574627|NCT02340221|DRUG|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
219005647|NCT02774525|BEHAVIORAL|Reinforcement for drug & alcohol abstinence|
219422471|NCT00783172|BIOLOGICAL|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
219422472|NCT02080156|DEVICE|CPAP|
219422473|NCT00865189|DRUG|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
219422474|NCT00865189|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
219422475|NCT00865189|DRUG|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.
219422476|NCT00865189|DRUG|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
219422477|NCT00865189|RADIATION|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
219422478|NCT00865189|PROCEDURE|Surgery|Radical rectal excision based on the TME technique.
219422479|NCT00289744|BIOLOGICAL|TWINRIX™ ADULT|2 doses IM injection in primary study
219422480|NCT00289744|BIOLOGICAL|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
219422481|NCT01708616|DRUG|RO5285119|multiple doses
219422482|NCT01708616|DRUG|RO5285119 placebo|multiple doses
219422483|NCT01708616|DRUG|risperidone|single dose
219574628|NCT02340221|DRUG|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
219574629|NCT02340221|DRUG|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
219574630|NCT01358149|OTHER|cocoa-based food|single intake of cocoa-based food
219574631|NCT01358149|OTHER|cocoa-based food|Single intake of cocoa-based food
219574632|NCT03256422|DRUG|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
219574633|NCT00279539|GENETIC|Vascular Endothelial Growth Factor (VEGF1)|
219574634|NCT02008708|BEHAVIORAL|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
219574635|NCT02008708|OTHER|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
219574636|NCT03705949|DRUG|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
219574637|NCT03705949|DRUG|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
219574638|NCT01742559|PROCEDURE|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
219422484|NCT01708616|DRUG|risperidone placebo|single dose
219422485|NCT04913441|OTHER|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
219422486|NCT04913441|OTHER|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
219422487|NCT04913441|OTHER|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
219422488|NCT01978509|DRUG|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
219422489|NCT01978509|DRUG|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
219422490|NCT01978509|DRUG|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
219422491|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
219422492|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
219422493|NCT01327872|DRUG|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
219422494|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
219422495|NCT04083001|DEVICE|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
219422496|NCT05239377|OTHER|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
219422497|NCT02513784|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
219422498|NCT05398419|OTHER|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
219422499|NCT05398419|OTHER|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
219422500|NCT01475864|PROCEDURE|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
219422501|NCT05923450|PROCEDURE|Colorectal Resection|Radical resection of colorectal cancer
219422502|NCT05363670|DRUG|ARS-1|ARS-1
219422503|NCT05363670|DRUG|Albuterol MDI|180 mcg
219422504|NCT05363670|DRUG|Placebo|Placebo
219422505|NCT00843843|DEVICE|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
219422506|NCT03594253|BEHAVIORAL|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
219422507|NCT01035008|PROCEDURE|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
219422508|NCT04545398|OTHER|Food. Beef, Pasture-raised|Pasture-raised beef
219422509|NCT04545398|OTHER|Food. Beef, Grain-fed|Grain-fed beef
219422510|NCT04545398|OTHER|Food. Meat alternative|Meat alternative
219422511|NCT04545398|OTHER|Food, Lamb|Lamb
219574639|NCT01742559|PROCEDURE|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
219005648|NCT02774525|BEHAVIORAL|Parenting intervention|
219422512|NCT04914078|DRUG|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
219422513|NCT01594333|DRUG|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
219422514|NCT01594333|DRUG|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
219422515|NCT02085057|PROCEDURE|Functional Magnetic Resonance Imaging|
219422516|NCT03335787|OTHER|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
219422517|NCT03335787|OTHER|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
219422518|NCT01480557|PROCEDURE|liquefaction|Cataract extraction surgery type
219422519|NCT01480557|PROCEDURE|Torsional ip|A type cataract surgery using torsional ip technology
219422520|NCT05539586|OTHER|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
219422521|NCT05539586|OTHER|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
219422522|NCT05678075|BEHAVIORAL|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
219422523|NCT02985905|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
219422524|NCT04240288|OTHER|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
219422525|NCT04240288|OTHER|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
219574640|NCT03499119|DRUG|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
219574641|NCT03499119|DRUG|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
219574642|NCT03499119|DRUG|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
219574643|NCT05296876|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
219574644|NCT03163433|BEHAVIORAL|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
219574645|NCT05160714|RADIATION|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
219005649|NCT02774525|BEHAVIORAL|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug \& alcohol screening plus support for personal goal setting
219005650|NCT00013429|PROCEDURE|Visual|
219422526|NCT02612389|OTHER|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
219422527|NCT02694211|BEHAVIORAL|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
219422528|NCT01790711|PROCEDURE|FMT through mid-gut|
219574646|NCT05213260|OTHER|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
219574647|NCT02870036|DRUG|Simmitecan|
219574648|NCT02870036|DRUG|5-fluorouracil and Leucovorin Calcium|
219574649|NCT02870036|DRUG|Thalidomide|
219574650|NCT04873180|DIAGNOSTIC_TEST|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
219005651|NCT02660502|DRUG|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
219005652|NCT02660502|DRUG|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
219422529|NCT02834234|GENETIC|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
219422530|NCT06454851|BEHAVIORAL|Prosocial VR intervention|A four-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include four weekly sessions, each lasting between 15 to 20 minutes. Each session will depict a different daily life scenario-campus, lecture hall, canteen, and library, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
219422531|NCT06454851|OTHER|No intervention|The waitlist control group will not receive the intervention during the study.
219422532|NCT05656898|DEVICE|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
219422533|NCT05656898|DEVICE|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
219422534|NCT05656898|DEVICE|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
219422535|NCT00749164|PROCEDURE|MSC transplantation|1-2X10\^6 MSC per kg
219422536|NCT02786940|DEVICE|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
219422537|NCT00355849|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
219422538|NCT00355849|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
219422539|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
219422540|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
219422541|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
219422542|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
219422543|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
219422544|NCT04771988|RADIATION|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
219422545|NCT06103448|DEVICE|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
219422546|NCT04970394|BEHAVIORAL|Cervical Screening Reminder|Verbal reminder and if seen face-to-face, a written appointment booking slip.
219422547|NCT00565058|BIOLOGICAL|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
219422548|NCT05768425|DIAGNOSTIC_TEST|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
219422549|NCT05768425|DIAGNOSTIC_TEST|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
219422550|NCT05768425|DIAGNOSTIC_TEST|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
219422551|NCT00869388|BIOLOGICAL|rBBX-01|
219422552|NCT03155633|OTHER|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
219422553|NCT03155633|OTHER|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
219422554|NCT03360045|DRUG|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
219005653|NCT02660502|DRUG|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
219005654|NCT02660502|DRUG|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
219574651|NCT06045520|BEHAVIORAL|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
219574652|NCT00027508|DRUG|trabectedin|
219422555|NCT03360045|DRUG|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
219422556|NCT03360045|DEVICE|Merocel|Merocel packing is applied.
219422557|NCT04496648|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
219422558|NCT04496648|PROCEDURE|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
219422559|NCT01992848|OTHER|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
219574653|NCT04553913|DEVICE|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
219005655|NCT05940207|DEVICE|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
219005656|NCT00220870|BEHAVIORAL|Decision aid|
219005657|NCT03640845|OTHER|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan"
219005658|NCT06501482|DRUG|Postoperative reintroduction of FOLFIRI based chemotherapy|Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
219422560|NCT01992848|OTHER|4-day food diary|
219422561|NCT01992848|OTHER|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
219422562|NCT01992848|RADIATION|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
219422563|NCT05731232|DIETARY_SUPPLEMENT|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
219422564|NCT06122987|DRUG|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
219574654|NCT02029781|PROCEDURE|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
219574655|NCT03003260|OTHER|CBD chewing gum|
219574656|NCT03003260|OTHER|Placebo|
219574657|NCT04841330|DEVICE|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
219005659|NCT00911053|DRUG|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
219422565|NCT02776501|DRUG|Coppertone (BAY987521)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
219422566|NCT04861948|DRUG|IBI188|intravenous
219422567|NCT04861948|DRUG|GM-CSF|subcutaneous injection
219422568|NCT04861948|DRUG|Cisplatin/Carboplatin|intravenous
219422569|NCT04861948|DRUG|Bevacizumab|intravenous
219422570|NCT04861948|DRUG|Sintilimab|intravenous
219422571|NCT04861948|DRUG|Pemetrexed|intravenous
219422572|NCT04562142|DEVICE|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
219422573|NCT00863980|DRUG|Micardis (Telmisartan)|40-80 mg/day oral administration
219422574|NCT00863980|DRUG|Blopress (Candesartan)|8-12 mg/day oral administration
219422575|NCT03428256|DEVICE|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
219422576|NCT03428256|DEVICE|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
219422577|NCT03948126|OTHER|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
219422578|NCT02072512|DRUG|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
219422579|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
219422580|NCT02072512|DRUG|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
219422581|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
219422582|NCT02879981|DRUG|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
219422583|NCT02879981|DRUG|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
219422584|NCT02879981|DRUG|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
219422585|NCT00391781|PROCEDURE|Temperature of contrast medium|
219422586|NCT04712357|DRUG|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
219422587|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
219422588|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
219422589|NCT02666508|OTHER|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
219422590|NCT02666508|OTHER|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
219005660|NCT00911053|BEHAVIORAL|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
219422591|NCT06207695|BEHAVIORAL|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
219422592|NCT06182540|DIETARY_SUPPLEMENT|Mango puree|Mango puree 300g
219422593|NCT00830804|DRUG|Raltegravir|400 mg tablet taken orally twice daily
219422594|NCT00830804|DRUG|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
219422595|NCT03248050|BEHAVIORAL|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
219422596|NCT00002707|DRUG|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
219422597|NCT00002707|DRUG|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
219422598|NCT00002707|DRUG|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
219422599|NCT00002707|DRUG|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
219422600|NCT00018018|DRUG|CD34+ cells transduced with ADA retrovir|
219422601|NCT02792049|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
219422602|NCT02792049|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
219422603|NCT00779311|DRUG|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
219422604|NCT00779311|DRUG|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
219422605|NCT00779311|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
219005661|NCT00911053|BEHAVIORAL|Light|Subjects will be exposed to light.
219005662|NCT02366520|DEVICE|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
219005663|NCT00137046|DRUG|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
219005664|NCT00137046|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
219005665|NCT04334629|DRUG|Ibuprofen|Lipid ibuprofen 200 mg
219005666|NCT06123104|DEVICE|Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
219422606|NCT03963934|OTHER|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
219422607|NCT05605483|OTHER|Salad bar|Schools where the school district has installed salad bars
219422608|NCT05605483|OTHER|Waitlisted control|Schools where the school district has not yet installed salad bars
219422609|NCT05605483|OTHER|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
219574658|NCT04205396|BEHAVIORAL|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
219574659|NCT04205396|BEHAVIORAL|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
219574660|NCT04205396|OTHER|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
219574661|NCT03046134|BIOLOGICAL|PCV13|Conjugated pneumococcal vaccine
219574662|NCT02420418|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
219574663|NCT02420418|OTHER|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
219574664|NCT01804218|DRUG|Nadolol|
219574665|NCT01804218|DRUG|Placebo|
219574666|NCT01036490|OTHER|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
219574667|NCT04860050|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
219574668|NCT04860050|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
219574669|NCT01172821|DRUG|placebo|Placebo that represents BI drug
219574670|NCT01172821|DRUG|placebo|Placebo that represents comparator
219574671|NCT01172821|DRUG|placebo|Placebo that represents comparator
219574672|NCT01172821|DRUG|tiotropium Respimat® low dose|IMP
219574673|NCT01172821|DRUG|placebo|Placebo that represents BI drug
219574674|NCT01172821|DRUG|tiotropium Respimat® high dose|IMP
219422610|NCT01794481|PROCEDURE|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
219574675|NCT01172821|DRUG|50 mcg salmeterol HFA MDI|Active comparator
219574676|NCT01172821|DRUG|placebo|Placebo that represents comparator
219574677|NCT01066949|BEHAVIORAL|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
219574678|NCT01066949|BEHAVIORAL|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
219191165|NCT03556293|BEHAVIORAL|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
219422611|NCT01160341|DRUG|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
219422612|NCT03302208|DRUG|Pregabalin|Pregabalin capsule 150 mg oral
219422613|NCT03302208|DRUG|Placebo|Placebo
219422614|NCT00794014|PROCEDURE|Conservative strategy|"* Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup."
219422615|NCT00794014|PROCEDURE|Aggressive strategy|"* Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup."
219422616|NCT01319916|DRUG|ATX-101|ATX-101 2mg/cm2
219422617|NCT01747785|OTHER|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
219422618|NCT01747785|OTHER|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
219574679|NCT03245645|OTHER|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
219422619|NCT01747785|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
219422620|NCT01158729|DRUG|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
219422621|NCT01158729|OTHER|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
219422622|NCT00216177|DRUG|Infliximab|Remicade
219422623|NCT00216177|DRUG|Adalimumab|Humira
219422624|NCT04700852|DEVICE|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
219422625|NCT01769703|DRUG|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
219422626|NCT03271788|OTHER|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
219422627|NCT00364325|OTHER|Acute Decompensated Heart Failure|Standard of Care
219422628|NCT05830188|BEHAVIORAL|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
219422629|NCT05830188|OTHER|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
219422630|NCT04095754|PROCEDURE|Head-Up Position|Anti-Trendelenburg Position
219422631|NCT04095754|DRUG|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
219422632|NCT04095754|DRUG|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
219422633|NCT03130712|DRUG|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
219422634|NCT04305886|OTHER|Discussion Guide|Written list of prompts to facilitate discussion
219422635|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
219422636|NCT03691610|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
219005667|NCT02345382|DRUG|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
219005668|NCT03959566|DRUG|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
219005669|NCT03959566|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
219005670|NCT03959566|DRUG|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
219005671|NCT06478355|DRUG|Immunotherapy|Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
219005672|NCT06478355|DRUG|Chemotherapy drug|TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
219191166|NCT04867278|PROCEDURE|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
219191167|NCT04867278|PROCEDURE|Debridement|Gluteus minimus debridement in the OR
219422637|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
219422638|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
219422639|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
219422640|NCT03691610|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
219422641|NCT03691610|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
219422642|NCT03691610|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
219422643|NCT03691610|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
219422644|NCT03691610|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
219422645|NCT03691610|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
219422646|NCT00122356|DRUG|Alendronate sodium|70mg tablets, once weekly
219422647|NCT04183699|DIAGNOSTIC_TEST|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
219422648|NCT02938052|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
219422649|NCT03146052|DRUG|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
219422650|NCT02681952|DRUG|Renamezin capsule|
219191168|NCT05981040|DRUG|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
219191169|NCT05981040|DRUG|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
219191170|NCT05981040|DRUG|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
219422651|NCT02681952|DRUG|Kremezin granule|
219422652|NCT00202111|PROCEDURE|Laparoscopic-assisted colectomy|
219422653|NCT00202111|PROCEDURE|Conventional open colectomy|
219422654|NCT00679731|DRUG|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
219574680|NCT06142123|OTHER|3-D Ankle Mobility Exercises(A)|"The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist."
219574681|NCT06142123|OTHER|Eccentric Heel Drop Training(B)|": Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening"
219005673|NCT06478355|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
219422655|NCT00679731|DRUG|Methotrexate|5.0 to 25 mg weekly
219422656|NCT02022696|GENETIC|Lentiviral Gene Transfer|
219422657|NCT00208312|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
219422658|NCT00208312|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
219422659|NCT04121312|BEHAVIORAL|Facilitation Intervention|"See arm description"
219422660|NCT00454155|DRUG|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
219574682|NCT02707133|OTHER|No intervention|
219422661|NCT06048237|DIAGNOSTIC_TEST|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
219422662|NCT00669916|BIOLOGICAL|AIN457|single infusion of 3 mg/kg
219422663|NCT00669916|DRUG|Placebo|single infusion of placebo
219422664|NCT04296526|BEHAVIORAL|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
219422665|NCT04296526|BEHAVIORAL|Exercise Education|To organize sessions for how to proper exercise.
219422666|NCT04296526|BEHAVIORAL|Social Support|Supports such as peer influence or reminder phone messages
219422667|NCT00535015|DRUG|Betamarc|2 tabs BID
219422668|NCT05463042|BEHAVIORAL|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
219422669|NCT05463042|BEHAVIORAL|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
219422670|NCT05109819|RADIATION|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
219422671|NCT03775772|PROCEDURE|Oral Health|"* test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
219422672|NCT03775772|PROCEDURE|Bite Force|"* test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training"
219422673|NCT04108013|DRUG|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
219422674|NCT04108013|DRUG|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
219422675|NCT05228106|DIAGNOSTIC_TEST|[68Ga]-PSMA-617|The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
219422676|NCT01199250|OTHER|Laboratory Biomarker Analysis|Correlative studies
219422677|NCT05685667|DEVICE|needless laser injector (Mirajet)|Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.
219422678|NCT05685667|DEVICE|needle injection|For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
219422679|NCT01013896|BEHAVIORAL|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
219422680|NCT01013896|OTHER|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
219574683|NCT03997214|DEVICE|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
219574684|NCT01930318|DRUG|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
219574685|NCT00462059|BEHAVIORAL|Treatment|
219574686|NCT02427295|DRUG|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
219574687|NCT02731014|OTHER|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
219422681|NCT00601796|BIOLOGICAL|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
219422682|NCT00601796|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
219574688|NCT02731014|OTHER|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
219574689|NCT02731014|OTHER|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
219759802|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
219759803|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
219759804|NCT03202394|DRUG|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
219759805|NCT03202394|DRUG|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
219422683|NCT00601796|DRUG|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
219422684|NCT01414712|OTHER|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
219422685|NCT06518200|BEHAVIORAL|Individualised health recommentations|Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
219422686|NCT06518200|BEHAVIORAL|General health recommendations|Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
219422687|NCT06518200|BEHAVIORAL|Individualised physical exercise program|Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
219422688|NCT02449954|DRUG|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
219574690|NCT02731014|OTHER|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
219574691|NCT03512184|BEHAVIORAL|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
219574692|NCT00710749|DEVICE|Disposable device|Disposable urine flow meter
219574693|NCT00710749|DEVICE|Digital device|Digital urine flowmeter
219574694|NCT00710749|DEVICE|Clinic flow measurement|Clinic gold standard flow measurement
219574695|NCT04208269|OTHER|postcard campaign|Post card sent to parent only
219574696|NCT04208269|OTHER|Health Information Technology system|Accessed by adolescent and provider only
219759806|NCT00329030|DRUG|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
219759807|NCT00329030|DRUG|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
219759808|NCT02347592|DEVICE|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
219759809|NCT02347592|DEVICE|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
219759810|NCT03012334|DRUG|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
219759811|NCT03012334|DRUG|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
219759812|NCT03012334|OTHER|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
219759813|NCT00368524|BEHAVIORAL|contingency management and behavioral day treatment|
219759814|NCT02167789|DEVICE|Paradym CRT 8770|
219759815|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
219759816|NCT00325143|BIOLOGICAL|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
219759817|NCT00325143|BIOLOGICAL|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
219422689|NCT02449954|DRUG|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
219422690|NCT02449954|DRUG|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
219422691|NCT01464463|BEHAVIORAL|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
219422692|NCT01464463|BEHAVIORAL|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
219422693|NCT01464463|BEHAVIORAL|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
219422694|NCT00699101|DEVICE|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
219422695|NCT02499341|DRUG|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
219422696|NCT02499341|DRUG|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
219422697|NCT01461512|DRUG|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
219422698|NCT01461512|DRUG|Placebo administration|NaCl isotonic
219422699|NCT02475395|DEVICE|TRAK device|Use of TRAK to attain sperm concentration measurement
219422700|NCT02387619|DRUG|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
219422701|NCT02387619|DRUG|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
219422702|NCT02387619|DRUG|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
219422703|NCT02075749|DRUG|Triamcinolone Acetonide|
219422704|NCT02075749|DRUG|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
219422705|NCT01098838|DRUG|LCL161|
219574697|NCT02358733|PROCEDURE|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
219574698|NCT02358733|PROCEDURE|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
219574699|NCT00791141|DRUG|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
219574700|NCT01709994|DRUG|Aspirin|100 mg/day of aspirin
219574701|NCT06882655|PROCEDURE|PIFB group|A pecto-intercostal-fascial plane block (PIFB) will be performed bilaterally in a supine position after induction of anaesthesia. The in-plane needle approach will be applied under the guidance of a high-frequency Hockey Stick Linear-Array US transducer probe (SONOSITE M-TURBO). Under strict aseptic precautions, the transducer will be placed 1-2 cm lateral to and parallel to the sternum to count the ribs from the second to the sixth rib. A 22-gauge, 50-mm short bevel echogenic needle will be advanced in a caudal-to-cranial direction until the tip of the needle will be in the targeted fascial plane, a test bolus of normal saline (1-2 mL) will be injected (in real-time) to confirm that the tip was correctly placed, as shown by separation of the fascial layers. After excluding intravascular, the dose of local anaesthetic (0.4 mL/kg 0.25% bupivacaine) will be deposited into the fascial plane visualised in real-time.
219422706|NCT04507620|DEVICE|cervical neck collar|devices used for cervical immobilization
219422707|NCT05675891|OTHER|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
219574702|NCT06882655|PROCEDURE|Intrathecal fentanyl(IT fentanyl)|IT fentanyl group (Group IT; n = 30) will be placed in lateral decubitus position immediately after intubation and catheterisation and receive an IT injection of 2 µg/kg of fentanyl in 0.2 mL/kg of normal saline through a 2-in., 25-gauge Quincke spinal needle inserted at L3-4 or L4-5. The dose of IT fentanyl will be based on a previous study. (15) with this route of fentanyl administration to provide intraoperative analgesia and blunt the stress response in pediatric cardiac anaesthesia. Successful dural puncture will be confirmed by observation of a free flow of cerebrospinal fluid, and the injection will be performed with the bevel of the needle oriented in the cephalic direction.
219574703|NCT06882655|PROCEDURE|IT + PIFB|Patients assigned to the combined IT fentanyl and PIFB (Group IT + PIFB; n = 30) will receive both a PIFB and IT fentanyl, with the use of the methods described for the other two groups.
219005674|NCT00495183|DRUG|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
219005675|NCT00495183|DRUG|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
219005676|NCT00495183|DRUG|Placebo|Placebo
219005677|NCT03362008|DRUG|Zeropix|administration of Zeropix
219005678|NCT03362008|DRUG|Champix®|administration of Champix®
219422708|NCT02178176|BEHAVIORAL|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
219422709|NCT02178176|BEHAVIORAL|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
219422710|NCT03730194|DIETARY_SUPPLEMENT|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
219574704|NCT06846853|DRUG|Gadopiclenol|The enhanced images by Gadopiclenol and Gadobutrol will be compared.
219574705|NCT06846853|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Gadobutrol will be used as a comparator
219574706|NCT06927427|PROCEDURE|fiberoptic endoscopic evaluation of swallowing (FEES)|Using flexible endoscopy, the patient will be given a colored thin fluid to keep in their mouth and then swallow following the instructions of the examiner, then the examination will be repeated using semisolids (1 teaspoon of yogurt) and using solids (piece of bread). The evaluation of swallowing will involve four items: early spill of food (delayed triggering), aspiration, penetration, and retention (residue). And the results will be recorded.
219574707|NCT06927791|OTHER|Machine learning based development of a diagnostic tool for acute cardiovascular disease|MALBEC will be delivered through five integrated work packages (WP) encompassing: (0) platform development and implementation, (1) data pooling, (2) model development, (3) performance comparison, (4) performance validation, and (5) platform plugin
219574708|NCT06927401|DEVICE|Flower|"Flower is a single-use capsule endoscope designed for timely visualization of the human stomach. The patient drinks water to fill the stomach before swallowing the Flower capsule, which transmits wireless video, through an external dongle placed near the patient's abdomen, to a physician's computer or smartphone. Flower is weighted to orientationally bias the capsule upward, meaning that with a few simple position adjustments a complete viewing of the stomach can be achieved approximately 10 minutes.~The procedure requires no sedation or equipment other than the Flower System (capsule and dongle). As a simple means of screening, Flower functions equivalent to comparable technologies, but offers advantages of being less invasive and burdensome. Flower has fewer potentially adverse consequences than traditional endoscopy (EGD), and it does not require capital equipment as magnetic endoscopy does. Flower offers the identification and location of bleeding sources in the stomach."
219422711|NCT03730194|BEHAVIORAL|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
219422712|NCT05237180|OTHER|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
219422713|NCT00845494|BEHAVIORAL|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
219422714|NCT00115765|DRUG|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
219574709|NCT05711342|BEHAVIORAL|Aggression|"The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
219574710|NCT05711342|BEHAVIORAL|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
219574711|NCT05865977|DEVICE|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
219574712|NCT06928649|DIAGNOSTIC_TEST|Blood sampling|Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission
219574713|NCT02218307|DRUG|Mupirocin|
219005679|NCT04686071|OTHER|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
219005680|NCT04686071|OTHER|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
219005681|NCT03067168|DRUG|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
219422715|NCT00115765|DRUG|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
219574714|NCT02218307|DRUG|Placebo|
219191171|NCT05981040|DRUG|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
219191172|NCT05122793|BEHAVIORAL|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
219574715|NCT02332980|DRUG|Ibrutinib|Given PO
219574716|NCT02332980|DRUG|Idelalisib|Given PO
219574717|NCT02332980|OTHER|Laboratory Biomarker Analysis|Correlative studies
219574718|NCT02332980|BIOLOGICAL|Pembrolizumab|Given IV
219574719|NCT05355038|BEHAVIORAL|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
219574720|NCT05355038|BEHAVIORAL|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
219574721|NCT05355038|BEHAVIORAL|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
219574722|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in peripheral blood|Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
219574723|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in endometrium|Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
219574724|NCT03697330|DRUG|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
219574725|NCT06616662|PROCEDURE|MAF|use mucosal advancement flap to treat PAF
219005682|NCT03067168|DRUG|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
219005683|NCT02658929|BIOLOGICAL|bb2121|bb2121
219191173|NCT06224712|BEHAVIORAL|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
219191174|NCT06196203|DRUG|AK117|AK117 IV injection
219191175|NCT06196203|DRUG|Placebo|Placebo IV injection
219191176|NCT06196203|DRUG|Azacitidine|Azacitidine SC injection
219574726|NCT06616662|PROCEDURE|LIFT|use LIFT surgery for treating PAF
219574727|NCT00554320|PROCEDURE|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
219574728|NCT00554320|PROCEDURE|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
219574729|NCT06924528|OTHER|using toy during inhaler treatment|The mask application on the toy will be performed only during the first inhaler treatment that the children receive in the emergency department.
219574730|NCT06928974|PROCEDURE|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition to restore the function of underdeveloped or absent rectus abdomini muscles
219574731|NCT05087862|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
219574732|NCT05087862|PROCEDURE|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
219422716|NCT00115765|DRUG|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
219574733|NCT04495283|DRUG|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
219574734|NCT04495283|DRUG|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
219574735|NCT04495283|OTHER|Placebo 1|Placebo for APAP
219574736|NCT04495283|OTHER|Placebo 2|Placebo for combination
219005684|NCT00642876|DEVICE|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
219191177|NCT04246138|PROCEDURE|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
219191178|NCT03822793|DRUG|Placebo|Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
219422717|NCT00115765|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
219422718|NCT03014440|DRUG|Cannabidiol|
219574737|NCT01752647|PROCEDURE|Low dose computed tomography|Low dose computed tomography scan
219574738|NCT03383237|DRUG|Apatinib|500mg/d,q.d.,p.o.
219574739|NCT06645444|OTHER|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
219574740|NCT01792934|DRUG|XELOX regimen according to standard procedures|
219574741|NCT01792934|DRUG|FOLFOX regimen according to standard procedures|
219574742|NCT01792934|PROCEDURE|Surgery|
219574743|NCT01792934|OTHER|radiofrequency ablation (RFA)|
219574744|NCT01792934|OTHER|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
219574745|NCT01792934|RADIATION|stereotactic body radiation therapy (SBRT)|
219574746|NCT01792934|DRUG|Bevacizumab|may be added to both regimens according to standard procedures
219191179|NCT03822793|DRUG|Group 1: perfusion of 300 mg Exacyl|Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
219191180|NCT03822793|DRUG|Group 2: perfusion of 500 mg Exacyl|Patient will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
219191181|NCT03822793|DRUG|Group 3: perfusion of 1000 mg Exacyl|Patient will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
219574747|NCT01792934|PROCEDURE|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
219759818|NCT02725333|PROCEDURE|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
219422719|NCT00781248|DEVICE|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
219422720|NCT06068322|OTHER|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
219422721|NCT04084626|DRUG|PD1 antibody|2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
219422722|NCT04084626|DRUG|lenalidomide|5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
219759819|NCT04224519|BIOLOGICAL|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
219422723|NCT06179030|DIAGNOSTIC_TEST|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
219422724|NCT06179030|DRUG|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
219422725|NCT00111150|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily|
219422726|NCT05751057|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
219759820|NCT04224519|BIOLOGICAL|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
219759821|NCT04224519|BIOLOGICAL|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
219005685|NCT00642876|DEVICE|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
219005686|NCT03851068|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
219759822|NCT04340154|BIOLOGICAL|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
219759823|NCT03419429|DRUG|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
219759824|NCT03419429|OTHER|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
219759825|NCT03419429|DEVICE|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
219759826|NCT03419429|DEVICE|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
219191182|NCT03822793|DRUG|Group 4: perfusion of 3000 mg Exacyl|Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
219422727|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
219422728|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
219422729|NCT06350565|DRUG|Dexamethasone|This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
219574748|NCT05864287|BEHAVIORAL|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
219574749|NCT02058082|PROCEDURE|Intracytoplasmic sperm injection|
219574750|NCT03028948|OTHER|Internet-Based Intervention|Access ITW
219574751|NCT03028948|OTHER|Questionnaire Administration|Ancillary studies
219574752|NCT03028948|OTHER|Survey Administration|Ancillary studies
219574753|NCT05200624|DEVICE|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
219574754|NCT01751542|BEHAVIORAL|Mindfulness + Residential Treatment|
219574755|NCT01751542|BEHAVIORAL|Residential treatment alone|
219574756|NCT03993249|BIOLOGICAL|Nivolumab|standard of care chemoradiotherapy + Nivolumab
219574757|NCT03993249|OTHER|chemoradiotherapy|standard of care chemoradiotherapy
219574758|NCT00419549|DRUG|Glyceryl - trinitrate|Transdermal Patch once only
219574759|NCT00419549|DRUG|Valdecoxib|Single parenteral administration
219574760|NCT00474604|PROCEDURE|diffusion-weighted magnetic resonance imaging|A scan will be performed.
219574761|NCT00474604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
219574762|NCT00474604|PROCEDURE|magnetic resonance spectroscopic imaging|A scan will be performed.
219574763|NCT05421104|OTHER|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
219759827|NCT06338111|DIAGNOSTIC_TEST|ELISA Sepsis Biomarkers dosage|Observational
219759828|NCT01752218|DEVICE|arcuate incision|
219759829|NCT02640300|DRUG|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
219759830|NCT00468091|DRUG|exendin(9-39)amide|
219759831|NCT00468091|DRUG|atropine|
219759832|NCT02320188|OTHER|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
219759833|NCT02320188|OTHER|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
219759834|NCT02449525|PROCEDURE|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
219759835|NCT03838835|BEHAVIORAL|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
219759836|NCT03838835|BEHAVIORAL|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
219005687|NCT01414010|DIETARY_SUPPLEMENT|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
219574764|NCT05410158|DRUG|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
219574765|NCT03030716|DIETARY_SUPPLEMENT|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
219574766|NCT04612517|DRUG|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
219422730|NCT04939025|PROCEDURE|Multi-interventional program|"1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
219422731|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
219422732|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
219422733|NCT02649530|DRUG|WNT974|
219422734|NCT01951248|DEVICE|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
219574767|NCT04612517|DRUG|Placebo|Placebo; corresponding volume
219574768|NCT05753670|DRUG|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
219422735|NCT04237740|DRUG|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
219574769|NCT05753670|DRUG|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
219574770|NCT02104336|DRUG|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
219574771|NCT00618930|DRUG|Moviprep®|use of Moviprep®
219574772|NCT00618930|DRUG|Fleet|Use of Fleet
219574773|NCT00380692|DRUG|Atomoxetine|
219574774|NCT00380692|DRUG|Placebo|
219422736|NCT05078073|DEVICE|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
219422737|NCT01522625|DRUG|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
219422738|NCT01522625|DRUG|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
219422739|NCT05298644|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
219422740|NCT05298644|DRUG|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
219422741|NCT03935165|DRUG|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~\- Indocyanine Green is administered Intravenously"
219422742|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
219574775|NCT00219583|DRUG|UK-390,957|
219574776|NCT03898518|OTHER|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
219574777|NCT02018926|DRUG|Mocetinostat|Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
219574778|NCT02018926|DRUG|Azacitidine|Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
219574779|NCT05727072|DRUG|LY3848575|Administered IV.
219574780|NCT05727072|DRUG|LY3848575|Administered SC.
219574781|NCT05727072|DRUG|Placebo|Administered IV.
219574782|NCT05727072|DRUG|Placebo|Administered SC.
219574783|NCT00446836|DRUG|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
219574784|NCT03715998|DRUG|Ramipril|1 or 2 capsules administered orally, twice daily
219574785|NCT03715998|DRUG|Firibastat|1 or 2 capsules administered orally, twice daily
219759837|NCT03838835|OTHER|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
219759838|NCT03423407|DEVICE|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
219422743|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
219422744|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
219422745|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
219422746|NCT04674839|DRUG|MS-20|fermented soymilk product
219422747|NCT04674839|OTHER|Placebo|No active ingredient
219422748|NCT00000639|DRUG|Itraconazole|
219422749|NCT00000639|DRUG|Flucytosine|
219422750|NCT00000639|DRUG|Fluconazole|
219422751|NCT00000639|DRUG|Amphotericin B|
219422752|NCT01506050|DRUG|Desloratadine|Desloratadine ODT 5 mg
219422753|NCT00211250|DRUG|Valproic Acid and Depakote ER|
219422754|NCT01568424|DEVICE|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
219422755|NCT00567541|DEVICE|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
219574786|NCT03641391|PROCEDURE|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
219759839|NCT01021800|BIOLOGICAL|MIS|Cell infusion
219759840|NCT03085680|DRUG|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
219191183|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
219191184|NCT03223090|BEHAVIORAL|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
219005688|NCT01414010|DIETARY_SUPPLEMENT|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
219005689|NCT01414010|DRUG|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
219191185|NCT03223090|BEHAVIORAL|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
219422756|NCT03348241|DRUG|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
219422757|NCT03348241|DRUG|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
219422758|NCT03348241|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
219422759|NCT01147081|BIOLOGICAL|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
219422760|NCT02849314|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
219422761|NCT02849314|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219422762|NCT03519516|DRUG|PRO-174|"Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
219422763|NCT03519516|DRUG|Sophixín Ofteno®|"* Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
219422764|NCT01935336|DRUG|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
219422765|NCT00735085|DRUG|SLV334|1000mg SLV334 as a single dose
219422766|NCT00735085|DRUG|SLV334|1000mg SLV334 b.i.d. for one day
219422767|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for one day
219422768|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for three days
219422769|NCT00735085|DRUG|Placebo|SLV334 Placebo arm
219422770|NCT05321485|OTHER|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
219422771|NCT01975233|DEVICE|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
219422772|NCT01773096|DRUG|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
219422773|NCT01773096|DRUG|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
219422774|NCT00450047|DEVICE|Speed-feedback therapy system with a bicycle ergometer|
219422775|NCT00450047|DEVICE|Ergometer at conventional settings|
219422776|NCT05369026|OTHER|Single leg immobilization|2 weeks of single-leg immobilization
219759841|NCT03085680|DRUG|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
219574787|NCT03641391|PROCEDURE|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
219574788|NCT02177136|DRUG|Obeticholic Acid (OCA)|
219574789|NCT02177136|DRUG|Placebo|
219574790|NCT01660191|DRUG|Pitavastin 4mg|
219422777|NCT01213069|OTHER|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
219422778|NCT06319001|OTHER|Low-volume high intensity exercise|This intervention will consist of 10 x 10-second interval sprints on a stationary bicycle interspersed with 50-second breaks between repetitions. The cycle resistance will be adjusted to the level equaling the highest power output, which will be determined during warm-up sprints.
219422779|NCT06319001|OTHER|Combined intermittent sauna and cold water bath (sauna+cold bath).|This intervention will consist of 3x10 min bouts in the dry sauna interspersed with 2x 60 seconds of cold water immersion up to the neck.
219422780|NCT00321269|BEHAVIORAL|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
219422781|NCT00321269|BEHAVIORAL|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
219422782|NCT06127706|DEVICE|twin vaginal delivery simulation|skill test after formal lecture and simulation in group 1 and after digital learning only
219422783|NCT00844064|DRUG|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
219422784|NCT06687122|DIETARY_SUPPLEMENT|3 whole eggs|Participants will be free-living and will not be supplied with any other food except for the eggs during the intervention period with no restrictions of energy intake.
219422785|NCT03337139|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
219422786|NCT03337139|BEHAVIORAL|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
219422787|NCT03337139|BEHAVIORAL|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
219422788|NCT03288493|BIOLOGICAL|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
219422789|NCT03288493|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
219422790|NCT04419324|DEVICE|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
219422791|NCT04260828|DRUG|Aspirin 100mg|Daily active drug administered orally for 3 months.
219422792|NCT04260828|OTHER|Placebo|Sugar pill administered orally for 3 months.
219422793|NCT01238133|DRUG|Carboplatin|Given IV
219422794|NCT01238133|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219574791|NCT01660191|DRUG|Atorvastatin 20mg|
219574792|NCT01660191|DRUG|Rosuvastatin 5mg|
219574793|NCT02350244|BEHAVIORAL|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
219574794|NCT00870649|BIOLOGICAL|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
219574795|NCT00870649|BIOLOGICAL|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
219422795|NCT01238133|OTHER|Laboratory Biomarker Analysis|Correlative studies
219422796|NCT01238133|DRUG|Paclitaxel|Given IV
219422797|NCT01238133|OTHER|Pharmacological Study|Ancillary studies
219422798|NCT01238133|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219422799|NCT03190226|PROCEDURE|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
219574796|NCT06125574|OTHER|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
219574797|NCT04146311|DRUG|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
219574798|NCT04146311|DRUG|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
219422800|NCT03190226|PROCEDURE|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
219574799|NCT04146311|OTHER|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
219574800|NCT01032018|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
219422801|NCT03529123|DRUG|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
219422802|NCT03529123|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
219422803|NCT03529123|DRUG|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
219422804|NCT03529123|DRUG|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
219422805|NCT05847491|DIAGNOSTIC_TEST|IGRA/Tuberculin skin test|"All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible"
219422806|NCT04295200|OTHER|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
219422807|NCT04480697|DRUG|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
219422808|NCT06011291|DRUG|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
219422809|NCT06011291|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
219422810|NCT01144078|BEHAVIORAL|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
219422811|NCT01144078|BEHAVIORAL|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
219422812|NCT04061252|DRUG|KHK4827|brodalumab 210mg Q2W, SC
219422813|NCT04061252|DRUG|Placebo|Q2W, SC
219574801|NCT01032018|DRUG|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
219574802|NCT01032018|OTHER|Standard care|Participants will receive standard of care from the current physicians
219574803|NCT05506410|DRUG|Rituximab|Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
219574804|NCT02402114|DRUG|Hydrocortisone|120 mg Hydrocortisone given orally one time.
219574805|NCT04882631|DRUG|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
219574806|NCT04882631|DRUG|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
219574807|NCT04882631|OTHER|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
219574808|NCT04882631|OTHER|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
219422814|NCT06890741|OTHER|exercise test|Participant perforemed 6000m ergometer test.
219422815|NCT06758518|OTHER|No Interventions|there will be no intervention
219422816|NCT06898671|BEHAVIORAL|Eye-Tracking in Visual World Paradigm|Participants complete six eye tracking tasks. They see images on a computer screen are tasked with finding a specific picture or saying a specific word (target). We track their eye movements to the visual representations of the target compared with their eye movements to visual representations of items that are similar to the target.
219422817|NCT00016393|DRUG|ixabepilone|
219422818|NCT00818285|DEVICE|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
219422819|NCT06898112|DRUG|PrEP|oral PrEP
219422820|NCT06897592|BEHAVIORAL|Enneagram|The training will be offered to students as 10 modules, 2 hours per week, for 8 weeks. The training content will consist of the Enneagram basic level and relationships.
219422821|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of esophageal pressure Peso (cmH2O)|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia.
219422822|NCT06899295|DIAGNOSTIC_TEST|Measurement of impedance variation with each respiratory cycle (EIT), Z in ohm|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
219574809|NCT04047524|OTHER|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
219574810|NCT02783430|DRUG|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
219422823|NCT06899295|DIAGNOSTIC_TEST|Measurement of regional respiratory compliance (EIT), Ohm/cmH2O|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
219574811|NCT02783430|DRUG|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
219574812|NCT02783430|DRUG|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
219574813|NCT00170794|DRUG|Everolimus (RAD001)|
219574814|NCT04161846|BEHAVIORAL|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
219574815|NCT04161846|BEHAVIORAL|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
219574816|NCT06273826|DIAGNOSTIC_TEST|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
219422824|NCT06899295|DIAGNOSTIC_TEST|Measurement of lung volumes (EELV or CRF) mL, (ml/kg)|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
219422825|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of multiparametric monitoring data in place (hemodynamics, depth of sedation, respiratory data, temperature).|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
219422826|NCT06899295|DIAGNOSTIC_TEST|Quantification of delivered doses of hypnotics, morphine and paralytics|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
219422827|NCT06899295|DIAGNOSTIC_TEST|Demographic criteria: age, sex, height, weight, BMI, theoretical ideal weight, ASA. - Procedure-related criteria: type of surgery, technique (laparoscopic, endoscopic, laparoscopic), position, duratio|These parameters will be recorded during the perioperative hospitalization
219422828|NCT06898710|PROCEDURE|z mini plate with lingual extension|patient with class III mandible fracture will be treated with patient specific z mini plate with lingual extension
219422829|NCT06898710|PROCEDURE|conventional 2 mini plates|patient with class III mandible fracture will be treated with conventional 2 mini plates
219422830|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
219574817|NCT03265288|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
219574818|NCT03265288|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
219574819|NCT03197558|COMBINATION_PRODUCT|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
219574820|NCT02970435|BEHAVIORAL|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
219574821|NCT02970435|BEHAVIORAL|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
219574822|NCT02970435|BEHAVIORAL|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
219574823|NCT01618188|DRUG|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
219574824|NCT01618188|DRUG|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
219574825|NCT00001007|DRUG|Zidovudine|
219574826|NCT00822393|DRUG|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
219574827|NCT00822393|DRUG|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
219574828|NCT02088190|PROCEDURE|Sleeve gastrectomy|Type of bariatric surgery
219574829|NCT04660890|DRUG|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
219422831|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
219422832|NCT02541006|DRUG|Tiotropium 18 mcg|tiotropium 18 mcg once a day
219422833|NCT00825383|OTHER|High Fiber and Moderate Fiber Diets|Dietary
219574830|NCT04660890|DRUG|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
219574831|NCT04660890|DRUG|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
219574832|NCT04660890|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
219574833|NCT02041936|DEVICE|NanoKnife IRE System|
219574834|NCT03181321|BEHAVIORAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
219422834|NCT06508320|BIOLOGICAL|mRNA-1083|IM injection in a deltoid muscle.
219422835|NCT04253041|BEHAVIORAL|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
219422836|NCT02494739|OTHER|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
219574835|NCT03141879|OTHER|HUR equipment resistance training intervention|Resistance training intervention
219574836|NCT04910659|OTHER|acupuncture|P6, LI4 and LI 11 stimulation
219574837|NCT04235699|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
219574838|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
219574839|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
219759842|NCT00516282|DRUG|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
219759843|NCT00516282|DRUG|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
219759844|NCT06108570|OTHER|Cosmetic Product TOPIALYSE Baume Protect+|One or two application.s of TOPIALYSE Baume Protect+ daily on one side for 28±3 days and the Neutral Product daily on the other side for 28±3 days. The side will be decided before by randomisation.
219422837|NCT02494739|OTHER|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
219422838|NCT04890574|DEVICE|CellMist™ System|Open Label, Safety and Feasibility
219422839|NCT03629392|BEHAVIORAL|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
219422840|NCT03629392|BEHAVIORAL|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
219574840|NCT03648242|BEHAVIORAL|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines"
219574841|NCT06341387|OTHER|Breath, urine and blood analysis|"breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube."
219574842|NCT00726154|BEHAVIORAL|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
219574843|NCT00726154|BEHAVIORAL|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
219574844|NCT04306237|DRUG|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
219574845|NCT04306237|DRUG|Placebo oral tablet|Matched placebo tablet for oral administration
219574846|NCT00466908|DEVICE|Pentacam and IOL Master|Pentacam and IOL Master
219574847|NCT00350649|BEHAVIORAL|Standard CBT|Manualized delivery of CBT by trained clinicians
219759845|NCT06005909|OTHER|Cawthorne-Cooksey Exercises|"A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed."
219759846|NCT06005909|OTHER|Mechanical Hippotherapy Exercises|"From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance."
219422841|NCT03629392|BEHAVIORAL|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
219422842|NCT00937794|BEHAVIORAL|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
219422843|NCT00937794|OTHER|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
219759847|NCT02748681|DEVICE|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
219422844|NCT05524740|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
219422845|NCT04777214|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
219422846|NCT04777214|DEVICE|Sham TMS|Sham TMS will be administered
219422847|NCT02199301|PROCEDURE|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
219422848|NCT00597935|PROCEDURE|SSLF|sacrospinous ligament fixation (SSLF)
219422849|NCT00597935|PROCEDURE|ULS|uterosacral vaginal vault ligament suspension (ULS)
219422850|NCT00597935|BEHAVIORAL|PMT|Pelvic muscle training and exercises (PMT)
219422851|NCT01064076|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
219422852|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
219759848|NCT03333603|DRUG|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
219422853|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
219759849|NCT03557866|DIAGNOSTIC_TEST|running|individuals will be asked to run for 5 km in self selected speed
219759850|NCT01760070|DEVICE|Hybrid knife|Use Hybrid knife in ESD procedure
219759851|NCT01760070|DEVICE|IT knife|Use IT knife in ESD procedure.
219005690|NCT01441206|DRUG|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
219191186|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Sulfasalazine enteric-coated tablets Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA(13-15mg/kg), 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. (2) Newly treated PBC patients: 30 patients took UDCA(13- 15mg/kg) and 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
219422854|NCT00676936|DRUG|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
219759852|NCT04868344|DRUG|MRG003|Administered intravenously
219759853|NCT03410069|DEVICE|IKORUS UP system|Continuous assessment of the urethral microcirculation
219759854|NCT01008618|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
219759855|NCT01008618|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
219759856|NCT04931238|DRUG|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
219759857|NCT01603017|DEVICE|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
219759858|NCT01603017|DEVICE|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
219759859|NCT00744861|DEVICE|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
219005691|NCT01648205|DRUG|Placebo|Matching Placebo will be given for first month.
219005692|NCT01648205|DRUG|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
219005693|NCT06074315|DEVICE|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
219005694|NCT06074315|DEVICE|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
219422855|NCT00676936|DRUG|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
219422856|NCT01738737|DEVICE|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
219422857|NCT01738737|OTHER|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
219422858|NCT01738737|DEVICE|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
219422859|NCT01670175|DRUG|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
219422860|NCT04638868|DEVICE|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
219422861|NCT04638868|DEVICE|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
219422862|NCT05220241|BIOLOGICAL|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
219759860|NCT00744861|DEVICE|Exospine|Active Exospine LIPUS device (dual transducers)
219422863|NCT02572011|OTHER|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
219422864|NCT04744610|DIAGNOSTIC_TEST|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
219422865|NCT04095442|DEVICE|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
219422866|NCT04095442|DEVICE|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
219422867|NCT00083343|DRUG|MK0991, caspofungin acetate/Duration of Treatment: variable|
219422868|NCT05725330|OTHER|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
219574848|NCT00350649|BEHAVIORAL|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
219422869|NCT04374201|OTHER|2 zirconia FDPs|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
219422870|NCT04374201|OTHER|1 zirconia FDP|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
219422871|NCT05340101|BEHAVIORAL|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
219422872|NCT01374672|OTHER|laboratory biomarker analysis|Correlative studies
219574849|NCT00350649|BEHAVIORAL|CM/abstinence|Contingency Management
219574850|NCT00350649|BEHAVIORAL|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
219574851|NCT01991665|OTHER|Digital examination|
219574852|NCT01991665|OTHER|Sonography evaluation|
219574853|NCT03263039|DRUG|Pembrolizumab|Pembrolizumab 200 mg Q3W
219574854|NCT03499418|OTHER|modified Silverman scale|Clinical assessment of severity of respiratory failure
219574855|NCT03499418|DIAGNOSTIC_TEST|echocardiography|echocardiographic evaluation of haemodynamic problems
219574856|NCT02899832|DEVICE|NIRS|Near Infra Red Spectroscopy
219574857|NCT04999033|OTHER|no intervention|This is a cross-sectional study, and no intervention will be included
219574858|NCT03533374|DIAGNOSTIC_TEST|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
219574859|NCT02466230|DEVICE|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
219574860|NCT02072148|PROCEDURE|PET/CT|PET scan or CT scan q 4 months for 5 years
219574861|NCT02072148|RADIATION|Radiotherapy|Postoperative XRT 5000 cGy
219574862|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
219574863|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
219574864|NCT04132895|OTHER|observational only, no interventions are prescribed in protocol.|"* Treatment will be given as per usual standard of care.~* No treatments are specified by this protocol."
219574865|NCT03456895|OTHER|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
219574866|NCT03456895|OTHER|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
219574867|NCT03456895|OTHER|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
219574868|NCT03456895|OTHER|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
219574869|NCT03456895|OTHER|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
219191187|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort B:60 cases with hepatitis B cirrhosis were collected from each group, 30 cases continued the current treatment, and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
219574870|NCT00177502|BEHAVIORAL|behavioral exercise intervention|
219574871|NCT00061243|BIOLOGICAL|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
219574872|NCT02129296|DEVICE|Air filled balloon|Balloon filled with air according to the manufacturing company orders
219574873|NCT02129296|DEVICE|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
219574874|NCT05218382|DEVICE|Virtual reality|immersive virtual reality technology
219422873|NCT02726126|DRUG|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
219422874|NCT04938271|DEVICE|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
219422875|NCT04087408|DRUG|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
219422876|NCT05986825|OTHER|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
219422877|NCT03019705|OTHER|Observation|
219422878|NCT00567060|DRUG|Piracetam|
219422879|NCT03508544|PROCEDURE|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
219422880|NCT03508544|PROCEDURE|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
219422881|NCT03508544|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
219422882|NCT01620697|PROCEDURE|Colorectal surgery|Colorectal surgery
219574875|NCT05218382|DEVICE|No virtual reality|Virtual reality with blank screen
219574876|NCT04729192|OTHER|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
219574877|NCT02915965|DRUG|DCX|docetaxel, cisplatin and capecitabine
219574878|NCT02915965|PROCEDURE|surgery|Ivor Lewis Esophagectomy
219574879|NCT01350843|DIETARY_SUPPLEMENT|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
219574880|NCT03393871|DIAGNOSTIC_TEST|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
219422883|NCT04489537|BIOLOGICAL|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
219422884|NCT04625985|DRUG|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
219422885|NCT04625985|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
219574881|NCT04614493|DEVICE|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~\+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
219759861|NCT00744861|DEVICE|Exogen 4000+|Active Exogen LIPUS device (single transducer)
219005695|NCT04748120|PROCEDURE|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
219422886|NCT01141127|DRUG|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
219759862|NCT00744861|DEVICE|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
219759863|NCT01627691|DEVICE|Lotus Valve System|"* bioprosthetic bovine pericardial aortic valve~* delivery system"
219574882|NCT04614493|DRUG|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
219574883|NCT02793570|OTHER|observational|
219422887|NCT03159013|OTHER|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
219422888|NCT01343355|DRUG|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
219422889|NCT01304472|DRUG|Prasugrel|Prasugrel 10mg per day
219422890|NCT01304472|DRUG|Clopidogrel|Clopidogrel 150mg per day
219422891|NCT00369746|DRUG|citalopram|tablets, 60 mg maximum, daily, 12 weeks
219422892|NCT05959304|OTHER|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
219422893|NCT06330974|OTHER|No intervention|No intervention
219422894|NCT01674816|DEVICE|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
219422895|NCT01674816|DEVICE|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
219574884|NCT05578365|OTHER|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
219574885|NCT05578365|OTHER|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
219574886|NCT04567914|DIAGNOSTIC_TEST|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
219574887|NCT02932514|DEVICE|Eversense (Senseonics) Continuous Glucose Monitoring System|"* Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days."
219574888|NCT04744350|PROCEDURE|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
219422896|NCT03947255|DRUG|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
219422897|NCT04682678|PROCEDURE|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
219422898|NCT02774044|DRUG|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
219422899|NCT02774044|DRUG|Survanta|
219422900|NCT06362395|RADIATION|Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)|Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
219422901|NCT00898404|OTHER|laboratory biomarker analysis|Correlative studies
219422902|NCT04717076|BEHAVIORAL|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
219422903|NCT04717076|BEHAVIORAL|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
219422904|NCT04717076|BEHAVIORAL|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
219422905|NCT02282176|DRUG|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
219422906|NCT02282176|DRUG|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
219574889|NCT05847439|DRUG|[14C]BMS-986419|Specified dose on specified days
219574890|NCT03820934|DIAGNOSTIC_TEST|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
219422907|NCT00700531|DEVICE|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
219574891|NCT06000917|DRUG|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
219422908|NCT00700531|PROCEDURE|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
219422909|NCT00673686|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
219422910|NCT00673686|DRUG|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
219574892|NCT00405613|DRUG|Aspirin|
219574893|NCT04361903|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
219574894|NCT02756936|DRUG|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
219574895|NCT02756936|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
219574896|NCT04390321|OTHER|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
219574897|NCT03560349|DRUG|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
219574898|NCT03560349|DRUG|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
219574899|NCT01939496|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
219574900|NCT01939496|DRUG|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
219574901|NCT05223296|DEVICE|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
219574902|NCT05396131|DEVICE|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
219574903|NCT05396131|DEVICE|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
219574904|NCT00948727|BEHAVIORAL|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
219574905|NCT00948727|DRUG|Cyclosporine (CsA)|Cyclosporine (CsA)
219422911|NCT04656418|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
219422912|NCT04656418|DRUG|Placebo|Buffer without active ingredient
219422913|NCT01128335|DRUG|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
219422914|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
219422915|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
219422916|NCT01128335|DRUG|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
219422917|NCT02770313|BEHAVIORAL|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
219422918|NCT01094951|BEHAVIORAL|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
219422919|NCT02779673|OTHER|Yoghurt drink containing plant stanol as esters|
219422920|NCT02779673|OTHER|Yoghurt drink without plant stanol as esters|
219422921|NCT04765748|DEVICE|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
219422922|NCT01611766|PROCEDURE|Secondary Cytoreductive Surgery|Complete Cytoreduction
219422923|NCT01611766|DRUG|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
219422924|NCT01641757|PROCEDURE|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
219422925|NCT04811001|DRUG|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
219422926|NCT04811001|DRUG|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
219422927|NCT05382988|DRUG|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
219574906|NCT05225974|DRUG|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
219574907|NCT05225974|DRUG|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
219422928|NCT00989612|BIOLOGICAL|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
219422929|NCT05248555|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
219422930|NCT00388323|OTHER|blood and biopsies|blood and biopsies
219422931|NCT00525239|DRUG|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
219422932|NCT02839824|PROCEDURE|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
219422933|NCT05482035|DEVICE|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
219574908|NCT04547530|DIETARY_SUPPLEMENT|Vitamin D|as above
219574909|NCT04547530|DIETARY_SUPPLEMENT|Placebo|as above
219759864|NCT04653974|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
219759865|NCT04130412|PROCEDURE|open release|Open release of lateral retinaculae
219422934|NCT03261063|DEVICE|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
219422935|NCT06279663|PROCEDURE|Revascularization|revascularization
219422936|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
219422937|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet
219422938|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
219422939|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
219422940|NCT06000436|OTHER|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
219422941|NCT06000436|OTHER|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
219759866|NCT02035514|BIOLOGICAL|Bone marrow autologous mesenchymal stem cells transplantation|
219759867|NCT06454656|OTHER|MOBILE|"Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback"
219422942|NCT06000436|OTHER|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases."
219422943|NCT06000436|OTHER|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
219422944|NCT02623387|PROCEDURE|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
219422945|NCT02035579|BEHAVIORAL|Aerobic Training Intervention|
219422946|NCT02035579|BEHAVIORAL|Stretching Intervention|
219422947|NCT00605696|DRUG|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
219422948|NCT01842646|DRUG|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
219422949|NCT01057134|DEVICE|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
219422950|NCT00556335|PROCEDURE|manual aspiration|air aspiration
219422951|NCT00556335|PROCEDURE|conventional drainage|drainage, pneumocath
219422952|NCT04197024|DEVICE|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
219422953|NCT04197024|DEVICE|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
219422954|NCT02474823|OTHER|polysomnogram|all participants will undergo PSG for assessment of OSA
219422955|NCT02474823|OTHER|home sleep test|all participants will undergo HST for assessment of OSA
219422956|NCT02474823|OTHER|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
219422957|NCT00352313|DRUG|ATN-161|Given IV
219422958|NCT00352313|DRUG|carboplatin|Given IV
219422959|NCT04521309|BIOLOGICAL|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
219422960|NCT05359809|BEHAVIORAL|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
219422961|NCT02854007|DEVICE|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
219422962|NCT01875913|BEHAVIORAL|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
219422963|NCT01875913|BEHAVIORAL|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
219422964|NCT02482012|OTHER|Survey|This was a survey
219422965|NCT00751179|DRUG|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
219422966|NCT00751179|DRUG|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
219422967|NCT00751179|DRUG|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
219422968|NCT02670018|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day
219422969|NCT02670018|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
219422970|NCT00606853|BEHAVIORAL|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
219422971|NCT02406053|GENETIC|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
219422972|NCT01297309|DRUG|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
219422973|NCT03039738|DEVICE|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
219422974|NCT03039738|DEVICE|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
219422975|NCT01798017|DRUG|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
219422976|NCT04241146|DEVICE|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
219422977|NCT04241146|DEVICE|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
219422978|NCT00915538|DRUG|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
219422979|NCT00915538|DEVICE|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
219422980|NCT04445350|OTHER|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
219422981|NCT04445350|OTHER|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
219422982|NCT03555240|OTHER|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
219422983|NCT04190212|BEHAVIORAL|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
219574910|NCT01007565|PROCEDURE|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
219574911|NCT01612026|PROCEDURE|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
219574912|NCT05075720|DIETARY_SUPPLEMENT|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
219574913|NCT05075720|DIETARY_SUPPLEMENT|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
219422984|NCT00003194|BIOLOGICAL|filgrastim|
219422985|NCT00003194|DRUG|carboplatin|
219422986|NCT00003194|DRUG|cyclophosphamide|
219422987|NCT00003194|DRUG|etoposide|
219422988|NCT00003194|DRUG|thiotepa|
219422989|NCT00003194|DRUG|topotecan hydrochloride|
219574914|NCT05075720|DIETARY_SUPPLEMENT|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
219574915|NCT03703648|RADIATION|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
219574916|NCT02922101|BEHAVIORAL|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
219759868|NCT04054362|DRUG|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
219759869|NCT04054362|DRUG|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
219422990|NCT00003194|PROCEDURE|peripheral blood stem cell transplantation|
219422991|NCT01149343|BIOLOGICAL|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
219422992|NCT01093755|DRUG|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
219422993|NCT01093755|DRUG|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
219422994|NCT03056976|DEVICE|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
219422995|NCT03056976|DEVICE|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
219422996|NCT03056976|DEVICE|Fixed mandibular denture|A fixed mandibular denture retained by four implants
219422997|NCT02542436|OTHER|No intervention|No intervention administered in this study
219422998|NCT01216449|DRUG|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
219422999|NCT01216449|DRUG|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
219423000|NCT01902862|DRUG|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
219423001|NCT01902862|DRUG|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
219574917|NCT02922101|BEHAVIORAL|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
219574918|NCT00045669|DRUG|imatinib mesylate|
219574919|NCT03052322|DRUG|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
219759870|NCT04054362|DRUG|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
219759871|NCT04054362|DRUG|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
219759872|NCT02126163|BEHAVIORAL|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
219191188|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort C：Patients with HCV were treated with sulfasalazine Cohort C: 60 cases with hepatitis C cirrhosis were collected，30 cases continued the current treatment(people with hepatitis C cirrhosis continue to take antivirals), and30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
219423002|NCT06257329|OTHER|register|Multicentre prospective observational register
219423003|NCT05841108|DEVICE|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
219423004|NCT05841108|OTHER|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
219423005|NCT04152148|BIOLOGICAL|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
219423006|NCT04152148|BIOLOGICAL|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
219423007|NCT04152148|BIOLOGICAL|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
219759873|NCT03736148|OTHER|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
219759874|NCT03736148|OTHER|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
219574920|NCT03052322|DRUG|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
219574921|NCT05783648|DRUG|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
219574922|NCT03712839|OTHER|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
219574923|NCT06168565|DEVICE|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
219574924|NCT04920916|BIOLOGICAL|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
219574925|NCT04920916|DRUG|Placebo|Normal Saline.
219574926|NCT03660358|DEVICE|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
219574927|NCT05727917|DRUG|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
219574928|NCT05727917|OTHER|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
219574929|NCT05818618|DRUG|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
219574930|NCT05818618|DRUG|Placebo|Placebo oral gel applied locally on OLP lesions.
219574931|NCT03018808|OTHER|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
219574932|NCT03018808|OTHER|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
219574933|NCT03018808|OTHER|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
219574934|NCT03018808|PROCEDURE|Blood test|Blood samples will be collected at indicated time points
219759875|NCT03736148|OTHER|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
219191189|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine 60 cases with alcoholic cirrhosis were collected , 30 cases continued the current treatment and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
219191190|NCT05311085|DRUG|Cytisine|"Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
219574935|NCT03018808|OTHER|anthropometric measures|Anthropologic measures will be performed.
219574936|NCT03018808|OTHER|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
219574937|NCT01093664|BIOLOGICAL|AFFITOPE AD02|s.c. injection
219574938|NCT03832309|BEHAVIORAL|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
219574939|NCT03832309|BEHAVIORAL|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
219574940|NCT00003093|BIOLOGICAL|filgrastim|
219574941|NCT00003093|BIOLOGICAL|sargramostim|
219574942|NCT00003093|DRUG|carboplatin|
219574943|NCT00003093|DRUG|cyclophosphamide|
219574944|NCT00003093|DRUG|doxorubicin hydrochloride|
219574945|NCT00003093|DRUG|etoposide|
219574946|NCT00003093|PROCEDURE|conventional surgery|
219574947|NCT00003093|PROCEDURE|neoadjuvant therapy|
219574948|NCT03660293|DRUG|Atorvastatin|cardio-protective agents
219574949|NCT03660293|DRUG|Captopril|cardio-protective agents
219574950|NCT03660293|DRUG|L-carnitine|cardio-protective agents
219574951|NCT01703884|DRUG|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
219574952|NCT01574482|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
219759876|NCT01482130|BEHAVIORAL|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
219574953|NCT01574482|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
219574954|NCT06420544|BEHAVIORAL|JAPI: Cognitive, Emotional and Social Stimulation for Preschool Children|"Those children in the intervention group will play with the gaming platform Japi using a tablet device in a designated time given from schools' authorities. Early Year Educators will be present to help with the discipline and motivation of the students and Research Assistants will be there as well to provide technical support for the use of the equipment.~The intervention has 24 sessions, and the dosage will be two sessions of 15 minutes each per week for 12 weeks. Sessions number 1 to number 8 are focused on emotional regulation and inhibitory control. Sessions number 9 to 16 work on working memory and problem-solving. Sessions number 17 to 24 promote empathy and planification skills. Each session will have eight activities with increasing levels of difficulty."
219574955|NCT04360044|DRUG|THC ~5%|4 puffs of vaporized flower containing THC \~5%
219574956|NCT04360044|DRUG|CBD ~12%|4 puffs of vaporized flower containing CBD \~12%
219574957|NCT04360044|DRUG|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC \~5% and CBD \~12%
219574958|NCT04360044|DRUG|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
219574959|NCT04008966|DRUG|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
219574960|NCT04008966|DRUG|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
219423008|NCT04152148|BIOLOGICAL|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
219423009|NCT05955157|BIOLOGICAL|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
219423010|NCT05955157|DRUG|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
219423011|NCT01768312|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
219423012|NCT01712217|DRUG|AT13387|HSP90 inhibitor
219423013|NCT01712217|DRUG|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
219423014|NCT03886441|DRUG|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
219423015|NCT04172311|OTHER|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
219423016|NCT04172311|DRUG|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
219423017|NCT03999541|OTHER|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
219423018|NCT03086538|DRUG|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
219574961|NCT04008966|DRUG|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
219574962|NCT04008966|DRUG|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
219574963|NCT04008966|DRUG|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
219423019|NCT03086538|DRUG|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
219574964|NCT04008966|DRUG|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
219574965|NCT04008966|PROCEDURE|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
219574966|NCT04008966|PROCEDURE|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
219574967|NCT04008966|DRUG|natural Progesterone|400 mg twice daily per vagina
219191191|NCT05311085|DRUG|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
219423020|NCT04372342|DRUG|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
219423021|NCT04372342|DRUG|remifentanil|remifentanil
219423022|NCT00797069|OTHER|standard nutritional product (medical food)|once during crossover
219423023|NCT00797069|OTHER|nutritional product for diabetes (medical food)|once during crossover
219423024|NCT00797069|OTHER|diabetes specific experimental nutritional product (medical food)|once during crossover
219423025|NCT03182465|DIAGNOSTIC_TEST|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
219423026|NCT06071637|PROCEDURE|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
219423027|NCT02307838|OTHER|Assessments arm|Protocol required assessments not provided in standard of care
219423028|NCT05545904|BEHAVIORAL|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
219423029|NCT05545904|BEHAVIORAL|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
219423030|NCT01098825|OTHER|web-based survey|Anonymous web-based survey
219423031|NCT03605199|DRUG|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
219574968|NCT03317665|DEVICE|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
219574969|NCT01829841|DRUG|Famitinib|Famitinib 25 mg p.o. qd
219574970|NCT01829841|DRUG|Sunitinib|Sunitinib 50 mg p.o. qd
219423032|NCT05200156|DIETARY_SUPPLEMENT|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
219574971|NCT05657236|OTHER|medical treatment|traditional medical treatment and regular follow-up
219574972|NCT05657236|OTHER|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
219574973|NCT03840616|DRUG|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
219423033|NCT06199622|OTHER|music|20 minutes of classical Turkish musicor classical western music
219423034|NCT06379438|COMBINATION_PRODUCT|Photodynamic therapy (indocyanine green+laser)|Photodynamic therapy with indocyanine green
219423035|NCT01015729|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
219423036|NCT01015729|DRUG|Esomeprazole|oral, single dose
219423037|NCT01015729|DRUG|ASA|Tablet, oral, single dose
219423038|NCT01882777|BEHAVIORAL|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
219423039|NCT00085917|DRUG|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
219423040|NCT00085917|DRUG|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
219423041|NCT03636568|OTHER|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
219574974|NCT03840616|DRUG|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
219574975|NCT03840616|DRUG|Placebo|Administered once weekly starting on Day 14.
219574976|NCT03949803|BEHAVIORAL|Chocolate 100gr|"Evening/Night Chocolate:~Eating 100gr of milk chocolate within 1 hours of habitual bedtime~Control Chocolate:~Eating no milk chocolate or other chocolate~Chocolate Morning:~Eating chocolate within one hour of habitual waketime."
219574977|NCT03166683|OTHER|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
219574978|NCT03166683|OTHER|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
219574979|NCT06062797|DEVICE|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
219574980|NCT06062797|DEVICE|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
219574981|NCT00302120|PROCEDURE|Contrast-enhanced MR mammography|
219423042|NCT05424185|BEHAVIORAL|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
219423043|NCT00397709|DRUG|I ( isoniazid), II (isoniazid + rifampin )|
219423044|NCT01641965|DEVICE|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
219423045|NCT02234557|BEHAVIORAL|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
219423046|NCT00348413|DRUG|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
219574982|NCT03163004|BEHAVIORAL|Implementation of standing desks|Three standing desks will be introduced to the classroom
219574983|NCT04057469|DRUG|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
219574984|NCT04057469|DRUG|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
219574985|NCT03251963|DRUG|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
219759877|NCT01482130|BEHAVIORAL|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved"
219759878|NCT04524988|PROCEDURE|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
219759879|NCT03847584|OTHER|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
219423047|NCT01022151|DRUG|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219423048|NCT01022151|DRUG|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219423049|NCT01022151|DRUG|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219423050|NCT01022151|DRUG|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219423051|NCT01022151|DRUG|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219423052|NCT01022151|DRUG|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
219574986|NCT03251963|DRUG|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
219574987|NCT05444686|DIAGNOSTIC_TEST|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
219191192|NCT05311085|COMBINATION_PRODUCT|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
219191193|NCT05062330|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
219191194|NCT05062330|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
219423053|NCT03770195|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
219423054|NCT00002434|DRUG|Trimetrexate glucuronate|
219423055|NCT00002434|DRUG|Leucovorin calcium|
219423056|NCT03905395|BEHAVIORAL|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
219423057|NCT03825263|DEVICE|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
219423058|NCT04965129|DRUG|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
219423059|NCT04965129|DRUG|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
219759880|NCT05551468|BEHAVIORAL|StayFine guided app-based personalised intervention modules|Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
219759881|NCT05551468|BEHAVIORAL|StayFine app-based monitoring|Monitoring six times per day for two weeks in the StayFine app.
219423060|NCT02071264|BEHAVIORAL|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
219574988|NCT03308539|RADIATION|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
219574989|NCT00653952|DRUG|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
219574990|NCT00653952|DRUG|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
219574991|NCT03867799|DRUG|Nivolumab|Immunotherapy
219574992|NCT00290836|DRUG|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
219423061|NCT05270850|PROCEDURE|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
219191195|NCT05105906|DIAGNOSTIC_TEST|cognitive tests performed|cognitive tests performed
219191196|NCT05451875|DEVICE|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
219191197|NCT05785546|OTHER|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
219191198|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
219191199|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
219423062|NCT05270850|PROCEDURE|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
219423063|NCT06483165|OTHER|BE FAST Educational video|A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
219423064|NCT06483165|OTHER|F.A.S.T. Educational Video|A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
219423065|NCT00151749|DRUG|Colesevelam hydrochloride|
219423066|NCT05142540|PROCEDURE|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
219423067|NCT01429077|DRUG|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
219423068|NCT01429077|DRUG|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
219423069|NCT03838445|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
219423070|NCT00178048|DRUG|paroxetine|
219423071|NCT00280241|DRUG|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
219423072|NCT00280241|DRUG|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
219574993|NCT05913466|DRUG|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
219574994|NCT05913466|DRUG|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
219574995|NCT00149188|DRUG|Lanreotide (Autogel formulation)|
219574996|NCT03577483|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
219759882|NCT06389175|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|"Participants receive tVNS during the neuroimaging sessions and the extended stimulation period. To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established, conventional stimulation protocol (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany). To improve blinding, the stimulations intensities will be adjusted to correspond to a mild pricking sensation for tVNS and sham.~The extended stimulation period in the experimental group involves six sessions with at least 1.5h of stimulation (stimulation in the lab or at home with home device using the same stimulation protocol as during the neuroimaging sessions; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
219423073|NCT00280241|DRUG|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
219423074|NCT02495740|BEHAVIORAL|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
219423075|NCT01894464|BEHAVIORAL|Teacher led intervention|
219423076|NCT04335604|DRUG|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
219423077|NCT05911464|DRUG|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
219423078|NCT04945213|DRUG|Biperiden|5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
219423079|NCT04945213|OTHER|Placebo|1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
219423080|NCT03260972|DRUG|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
219423081|NCT03260972|DRUG|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
219574997|NCT05308264|DRUG|R906289 Monosodium (R289 Na)|Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)
219574998|NCT06079697|OTHER|Electronic Health Record Review|Ancillary studies
219574999|NCT06079697|OTHER|Exercise Intervention|Receive prehabilitation exercise intervention
219575000|NCT06079697|OTHER|Medical Device Usage and Evaluation|Wear Fitbits
219575001|NCT06079697|OTHER|Survey Administration|Ancillary studies
219575002|NCT03026907|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
219575003|NCT03026907|DRUG|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
219575004|NCT06324799|OTHER|phototherapy treatment|The newborns in the study group will be subjected to position changes (supine, prone, lateral) every 2 hours
219575005|NCT06294236|BIOLOGICAL|SC291|SC291 is an allogeneic CAR T cell therapy
219575006|NCT05118087|PROCEDURE|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
219575007|NCT05118087|PROCEDURE|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
219005696|NCT04748120|PROCEDURE|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
219005697|NCT05950009|OTHER|No intervention (observational studies)|No intervention (observational studies)
219005698|NCT01700777|OTHER|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
219191200|NCT06033599|OTHER|MORE and MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
219423082|NCT01119157|BIOLOGICAL|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
219423083|NCT04980313|DEVICE|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
219423084|NCT04980313|DEVICE|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
219423085|NCT05688319|BEHAVIORAL|Problem-Solving Training|Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
219423086|NCT03562754|PROCEDURE|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
219423087|NCT03562754|PROCEDURE|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
219575008|NCT05496387|OTHER|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
219575009|NCT03654664|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
219575010|NCT03654664|BIOLOGICAL|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
219575011|NCT01091272|DRUG|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
219575012|NCT01091272|DRUG|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
219575013|NCT01091272|DRUG|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
219423088|NCT03067129|DRUG|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
219423089|NCT03067129|DRUG|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
219423090|NCT03372603|DRUG|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
219575014|NCT01091272|DRUG|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
219575015|NCT02707926|DRUG|Anti-HIV Agents|Therapy to treat HIV infection
219575016|NCT02686203|DEVICE|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
219575017|NCT01835379|DEVICE|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
219575018|NCT01835379|OTHER|Standard|
219423091|NCT03372603|DRUG|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
219423092|NCT04673487|DIAGNOSTIC_TEST|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
219423093|NCT00943085|BEHAVIORAL|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
219423094|NCT00943085|BEHAVIORAL|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
219423095|NCT01313481|BEHAVIORAL|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
219423096|NCT01313481|BEHAVIORAL|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
219575019|NCT00136318|DRUG|Escitalopram|
219423097|NCT03330600|BEHAVIORAL|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
219423098|NCT03330600|BEHAVIORAL|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
219423099|NCT06528899|BEHAVIORAL|Physical Therapy|Assessment and/or treatment by physitoherapist during the visit
219575020|NCT00136318|DRUG|Placebo|
219575021|NCT00136318|DRUG|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
219575022|NCT00136318|DRUG|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
219575023|NCT04845906|DEVICE|StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)|Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
219575024|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
219423100|NCT04902898|DEVICE|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
219423101|NCT04902898|PROCEDURE|Circumcision in adults|Circumcision in adults
219423102|NCT04693923|PROCEDURE|Fluid challenge|Fluid challenge according to the assigned group
219423103|NCT04668794|PROCEDURE|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
219423104|NCT02014727|BIOLOGICAL|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
219423105|NCT02014727|BIOLOGICAL|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
219423106|NCT02014727|BIOLOGICAL|Group B2 : Placebo|
219423107|NCT00049218|BIOLOGICAL|Autologous dendritic cell-adenovirus p53 vaccine|
219423108|NCT00049218|DRUG|Carboplatin|
219423109|NCT00049218|DRUG|Etoposide|
219423110|NCT05816694|DRUG|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
219423111|NCT05816694|DRUG|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
219423112|NCT03526315|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
219423113|NCT03526315|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
219423114|NCT03526315|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
219423115|NCT02422082|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
219423116|NCT02422082|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo twice daily for 12 months
219423117|NCT01608282|BEHAVIORAL|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
219423118|NCT04828356|OTHER|Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
219423119|NCT01889888|OTHER|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
219423120|NCT03109756|DRUG|OV101|Single-dose 5 mg OV101
219423121|NCT02806947|DRUG|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
219423122|NCT02806947|DRUG|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
219423123|NCT04635761|BEHAVIORAL|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
219423124|NCT04635761|BEHAVIORAL|Questionnaire Administration|Ancillary studies
219423125|NCT00000384|BEHAVIORAL|Cognitive Behavior Therapy|
219423126|NCT00000384|BEHAVIORAL|Educational Support|
219423127|NCT00000384|DRUG|Sertraline|
219423128|NCT05057741|BEHAVIORAL|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
219423129|NCT00032617|PROCEDURE|Prolonged Exposure|trauma-focused exposure therapy
219423130|NCT00032617|PROCEDURE|Present Centered Therapy|therapy that focuses on current problems
219423131|NCT02750579|PROCEDURE|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
219423132|NCT02674165|BEHAVIORAL|HART|Skills based sexual education intervention plus PTSD awareness
219423133|NCT02995213|BEHAVIORAL|Accelerometer based feedback about paretic arm use|
219423134|NCT02359695|DRUG|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
219423135|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
219423136|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
219423137|NCT03031548|DEVICE|Point-of-care ultrasound exam|No intervention
219423138|NCT03031548|RADIATION|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
219423139|NCT02293356|DRUG|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
219423140|NCT05508685|OTHER|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
219423141|NCT05508685|OTHER|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
219423142|NCT05508685|OTHER|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
219423143|NCT05508685|OTHER|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
219423144|NCT04324138|DRUG|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
219423145|NCT04324138|DRUG|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
219423146|NCT02471911|DRUG|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
219423147|NCT02471911|DRUG|Rituximab|IV Rituximab 375 mg/m2 on D1
219423148|NCT02471911|DRUG|Etoposide|IV Etoposide 100 mg/m2 on D1-3
219423149|NCT02471911|DRUG|Carboplatin|IV Carboplatin AUC 5 on D2
219423150|NCT02471911|DRUG|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
219423151|NCT02471911|DRUG|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
219423152|NCT03141268|DIAGNOSTIC_TEST|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
219423153|NCT06391944|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
219423154|NCT06391944|DRUG|Osimertinib tablet|Osimertinib 80 or 160mg po everyday
219423155|NCT05399030|DRUG|ICP-332|ICP-332 will be administered as tablet
219423156|NCT05399030|OTHER|Placebo|Matching placebo will be administered as tablet
219423157|NCT05217953|DEVICE|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
219423158|NCT00002392|DRUG|Thalidomide|
219423159|NCT01504048|PROCEDURE|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
219423160|NCT00664209|DRUG|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
219423161|NCT00664209|DRUG|placebo|placebo therapy
219423162|NCT03641547|DRUG|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
219423163|NCT03641547|DRUG|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
219423164|NCT03641547|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
219423165|NCT03641547|RADIATION|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
219423166|NCT01500928|DEVICE|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
219423167|NCT02097433|DRUG|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
219423168|NCT03181074|OTHER|Non-Interventional|Non-Interventional
219423169|NCT01326117|DRUG|tadalafil|7 days of Cialis for Daily Use (5mg)
219423170|NCT02368080|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
219423171|NCT01078714|DRUG|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
219423172|NCT00148421|DRUG|Darbepoetin alfa and Epoetin alfa|
219423173|NCT02943512|OTHER|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
219423174|NCT00418379|DRUG|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
219423175|NCT00418379|DRUG|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
219423176|NCT00418379|DRUG|Placebo|Placebo tablet
219423177|NCT03345433|BEHAVIORAL|interactive group drumming sessions|interactive group drumming sessions
219423178|NCT01847898|PROCEDURE|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
219423179|NCT01847898|PROCEDURE|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
219423180|NCT00680290|PROCEDURE|Exercise|Exercise x 8 weeks
219423181|NCT00065442|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
219423182|NCT00065442|BIOLOGICAL|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
219423183|NCT00082329|DRUG|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
219423184|NCT00082329|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
219423185|NCT03743233|DEVICE|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
219423186|NCT03743233|DEVICE|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
219423187|NCT03061045|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
219423188|NCT02098694|OTHER|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
219423189|NCT02488525|DRUG|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
219423190|NCT04162535|DRUG|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
219423191|NCT04162535|BIOLOGICAL|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
219423192|NCT04162535|DRUG|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
219423193|NCT04162535|DRUG|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
219423194|NCT06445894|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
219423195|NCT06445894|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
219423196|NCT04268095|OTHER|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
219423197|NCT02029638|BIOLOGICAL|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
219191201|NCT06033599|OTHER|MORE and No MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
219191202|NCT06033599|OTHER|Support Group and MI and NRT|Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
219191203|NCT06033599|OTHER|Support Group and No MI and NRT|Eight group support group sessions and and nicotine replacement therapy.
219575025|NCT05272982|DIAGNOSTIC_TEST|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
219575026|NCT05272982|DIAGNOSTIC_TEST|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
219575027|NCT06046248|DRUG|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
219575028|NCT06046248|DRUG|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
219575029|NCT03284866|OTHER|Laboratory Biomarker Analysis|Correlative studies
219575030|NCT03284866|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219575031|NCT03284866|OTHER|Saline|Given IM
219423198|NCT02029638|DRUG|Fludarabine|Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
219575032|NCT06849648|DEVICE|The Buzzy Device|In essence, the Buzzy device offers a multi-sensory approach (vibration + cold) in conjunction with a hygienic protocol, which is a key differentiator from other non-pharmacological interventions such as distraction through toys, videos, or verbal techniques. Currently, there is no studies evaluating the use of the Buzzy device and finger puppets, which are nonpharmacologic methods, in relation to the levels of pain, fear, and anxiety in children aged 4-7 years undergoing venipuncture procedures in emergency department settings.
219423199|NCT02029638|DRUG|Cyclophosphamide|"1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
219423200|NCT02029638|RADIATION|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
219575033|NCT06849648|DEVICE|Finger Puppet|Finger puppets were used to distract the participants during venepuncture procedure. Children are allowed to pick their favourite animals. These soft in various shaped finger puppets can be placed on adult's fingers. One minute before the venipuncture procedure, the researcher (K.O.) engaged the participants in finger puppet play and initiated conversation by asking; 'Hello, how are you? What is this figure? Do you know where this animal/figure live in? Have you previously seen this animal/figure alive? Have you been in a zoo? Additionally, techniques such as having the animals 'sing' or 'interact' with each other were employed to capture the child's attention on the finger puppets. Children in this group were not given any distraction techniques prior to the procedure. All groups' parents accompanied over their children during the process, but they were not permitted to comfort them.
219575034|NCT02172196|DRUG|BI 10773|
219575035|NCT02172196|DRUG|Sitagliptin|
219575036|NCT01884064|DEVICE|rTMS|rTMS
219575037|NCT01884064|DEVICE|Sham rTMS|Sham rTMS
219575038|NCT01164215|DRUG|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
219423201|NCT02029638|DRUG|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
219423202|NCT02029638|DRUG|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
219423203|NCT02029638|DRUG|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
219423204|NCT02029638|BIOLOGICAL|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
219423205|NCT02029638|DRUG|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
219575039|NCT01164215|DRUG|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
219575040|NCT01164215|DRUG|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
219575041|NCT06617572|GENETIC|Non-conforming afamitresgene autoleucel|Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
219575042|NCT00466895|DRUG|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
219575043|NCT03910764|OTHER|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
219575044|NCT03758573|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
219005699|NCT00790855|DRUG|Bendamustine|Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
219005700|NCT05339737|DEVICE|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values \>25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
219005701|NCT00461162|BEHAVIORAL|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
219005702|NCT00461162|BEHAVIORAL|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
219191204|NCT05493241|BEHAVIORAL|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
219191205|NCT05493241|OTHER|Usual care|"In this study, both arms will have access to usual care as part of their routine clinical care. Recognizing the heterogeneity of primary care services provided to patients at risk for functional decline, we will minimally standardize the usual care arm by providing a booklet of educational information on maintaining activity to support independence in aging (e.g., an NIH handout Participating in Activities you Enjoy as you Age and information on VA and community recreation programs to stay active) that will be mailed to participants after randomization."
219191206|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
219191207|NCT04446351|DRUG|GSK6097608|GSK6097608 will be administered as an IV infusion.
219191208|NCT04446351|DRUG|Dostarlimab|Dostarlimab will be administered as an IV infusion.
219191209|NCT04446351|DRUG|Cobolimab|Cobolimab will be administered as an IV infusion.
219191210|NCT04446351|DRUG|Belrestotug|Belrestotug will be administered as an IV infusion.
219575045|NCT03758573|OTHER|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
219575046|NCT04000243|DIAGNOSTIC_TEST|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
219005703|NCT00461162|BEHAVIORAL|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
219005704|NCT02350790|PROCEDURE|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
219191211|NCT06487104|DEVICE|TrachPhone HME|"Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients."
219191212|NCT06487104|DEVICE|External Humidifier (Usual Care)|Usual care routines using an External Humidifier for humidification of inhaled air in tracheostomized patients.
219575047|NCT05342649|PROCEDURE|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
219575048|NCT05342649|PROCEDURE|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
219575049|NCT00172419|DRUG|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
219575050|NCT00284804|DRUG|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
219191213|NCT05127980|OTHER|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
219191214|NCT05127980|OTHER|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
219191215|NCT05127980|OTHER|Data collection: Patient reported outcome (Fatigue questionnaires)|Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.
219191216|NCT06840067|RADIATION|carbon ion radiotherapy (CIRT)|1.CIRT: GTV: Primary tumor visible on imaging and clinical examination, and involved regional lymph nodes identified by CT/MRI (≥1.0 cm) or PET/CT scan. CTV: GTV plus 5mm margin, include posterior peritoneal plexus area and elective node irradiation around the pancreas (ENI). PTV: CTV plus 2.5-5mm margin (depending on the system error of each unit; When pancreatic head cancer is close to the stomach and intestines, the gastrointestinal direction does not expand). ITV: delineated on 4D-CT considering the influence of respiratory activity. Prescription dose: Stratification by measuring the nearest distance between PTV and gastrointestinal tract (≥5mm or \< 5mm); Pancreatic head cancer (distance \< 5mm) : 52.8Gy(RBE)/4.4Gy/12Fx; Pancreatic head, body and tail cancer (≥5mm) : 57.2Gy(RBE)/4.4Gy/13Fx. CIRT was once a day, four or five times a week. 2.Chemotherapy:Gemcitabine 1000mg/m2, intravenous infusion, dl, d8; Q3w . 3.Targeted therapyNituzumab injection 400mg, Qw，at least 4-6 cycles.
219191217|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
219191218|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
219423206|NCT02029638|DRUG|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
219423207|NCT02029638|DRUG|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
219423208|NCT02029638|DRUG|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
219423209|NCT02992834|BIOLOGICAL|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
219575051|NCT02488031|BEHAVIORAL|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
219005705|NCT02350790|PROCEDURE|Robotic excision|Robotic excision of endometriosis
219005706|NCT03466008|BEHAVIORAL|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
219575052|NCT02488031|BEHAVIORAL|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
219005707|NCT02142959|DRUG|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
219005708|NCT02142959|DRUG|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
219005709|NCT02142959|DRUG|Vehicle Lotion|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
219005710|NCT02142959|RADIATION|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
219005711|NCT01777100|DRUG|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
219005712|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
219005713|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
219005714|NCT05925660|DIAGNOSTIC_TEST|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
219005715|NCT01201382|BEHAVIORAL|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
219005716|NCT01201382|BEHAVIORAL|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
219005717|NCT04495348|DRUG|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
219005718|NCT00954070|DEVICE|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
219005719|NCT03358121|DIAGNOSTIC_TEST|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
219191219|NCT04093167|DRUG|Pembrolizumab|Per current Product Monograph/U.S. Drug Label and/or local guidelines.
219191220|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
219191221|NCT04590196|DRUG|Longvida curcumin|longvida curcumin verdure sciences formulation
219191222|NCT04590196|OTHER|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
219191223|NCT03703908|DRUG|CCX140-B|Orally administered tablet
219191224|NCT06851546|PROCEDURE|Nasal 180° Selective Laser Trabeculoplasty (SLT)|The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
219191225|NCT06851546|PROCEDURE|Inferior 180° Selective Laser Trabeculoplasty (SLT)|The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
219423210|NCT02992834|BIOLOGICAL|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
219423211|NCT04374812|OTHER|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
219423212|NCT04374812|OTHER|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
219423213|NCT05379894|PROCEDURE|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
219423214|NCT02570646|BEHAVIORAL|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
219423215|NCT03427450|DIAGNOSTIC_TEST|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
219423216|NCT06140277|PROCEDURE|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
219423217|NCT06140277|PROCEDURE|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
219423218|NCT06140277|PROCEDURE|tooth extraction only|hopeless tooth will be extracted without any intervention
219423219|NCT01153841|BIOLOGICAL|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
219423220|NCT01153841|BIOLOGICAL|Infanrix hexa™|Intramuscular, 3 doses
219423221|NCT04134741|OTHER|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
219423222|NCT03823807|DRUG|SH-1028|Oral,100mg or 200mg ,QD, fasted
219423223|NCT00781872|BIOLOGICAL|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
219423224|NCT01867866|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219423225|NCT01867866|DRUG|Trifluridine|35 mg/m2, orally, single dose
219423226|NCT00947843|DRUG|aspirin + pregrel (Clopidogrel resinate)|
219423227|NCT00947843|DRUG|aspirin + placebo|
219423228|NCT00947843|DRUG|aspirin + plavix (Clopidogrel bisulfate)|
219423229|NCT01127295|DRUG|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
219423230|NCT03428997|DEVICE|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
219423231|NCT03428997|OTHER|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
219423232|NCT02431130|OTHER|low-fidelity instructor driven simulation training|
219423233|NCT00443235|DRUG|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
219423234|NCT00443235|DRUG|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
219423235|NCT02424812|BEHAVIORAL|Lifebuoy School of Five Handwashing Intervention|
219423236|NCT03304327|BEHAVIORAL|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
219575053|NCT02488031|BEHAVIORAL|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
219575054|NCT02488031|BEHAVIORAL|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
219575055|NCT02488031|BEHAVIORAL|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
219575056|NCT02488031|BEHAVIORAL|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
219575057|NCT02488031|BEHAVIORAL|Brief Test of Attention|A cognitive test assessing focus and attention.
219575058|NCT02488031|BEHAVIORAL|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
219575059|NCT02488031|BEHAVIORAL|Hand Grip Dynamometer|This tests measures hand grip strength.
219575060|NCT02488031|BEHAVIORAL|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
219575061|NCT02488031|BEHAVIORAL|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
219575062|NCT02488031|BEHAVIORAL|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
219575063|NCT02488031|BEHAVIORAL|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
219575064|NCT02488031|BEHAVIORAL|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
219575065|NCT02278718|DRUG|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
219575066|NCT02278718|PROCEDURE|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
219575067|NCT00111358|BEHAVIORAL|Lifestyle Modification|
219575068|NCT00111358|OTHER|No lifestyle modification|
219575069|NCT01546649|DRUG|TAP-144-SR(6M)|
219575070|NCT01546649|DRUG|TAP-144-SR(3M)|
219575071|NCT00380549|DIAGNOSTIC_TEST|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
219575072|NCT05732259|OTHER|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
219575073|NCT05732259|OTHER|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
219575074|NCT03645499|DRUG|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
219575075|NCT03645499|DRUG|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
219575076|NCT03645499|DRUG|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
219575077|NCT03645499|DRUG|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
219575078|NCT03645499|DRUG|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
219575079|NCT04440449|BEHAVIORAL|Lifestyle App|A mobile app used to assist with lifestyle changes
219575080|NCT04440449|BEHAVIORAL|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
219575081|NCT04440449|BEHAVIORAL|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
219575082|NCT02439632|DRUG|prulifloxacin|
219575083|NCT02439632|DRUG|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
219575084|NCT02439632|DRUG|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
219575085|NCT02439632|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
219575086|NCT04546932|PROCEDURE|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
219575087|NCT05442242|PROCEDURE|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
219575088|NCT05442242|PROCEDURE|High tibial osteotomy|Medial open wedge high tibial osteotomy
219575089|NCT04428099|BEHAVIORAL|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
219575090|NCT04428099|BEHAVIORAL|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
219575091|NCT04428099|BEHAVIORAL|Written Information|Written information about lifestyle change suggestions
219575092|NCT01763918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219575093|NCT01763918|DRUG|Placebo|Administered by subcutaneous injection
219575094|NCT00767338|BEHAVIORAL|Timed intercourse|Timed intercourse
219423237|NCT05506969|BIOLOGICAL|rF1V-1018|rF1V vaccine and CpG 1018® adjuvant
219423238|NCT05506969|BIOLOGICAL|rF1V vaccine|rF1V vaccine
219423239|NCT04915326|PROCEDURE|rectal resection|every patients will undergo to the appropriate rectal resection
219423240|NCT01630759|DEVICE|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
219423241|NCT01630759|OTHER|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
219423242|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
219423243|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
219423244|NCT04655209|BEHAVIORAL|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
219423245|NCT06089954|OTHER|private web-portal eHealth disclosure of genetic results|The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
219423246|NCT06089954|OTHER|eHealth education intervention (web or chatbot)|The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
219575095|NCT00767338|PROCEDURE|Microsurgical varicocelectomy|Microsurgical varicocelectomy
219575096|NCT00767338|PROCEDURE|Intrauterine insemination|Intrauterine insemination
219575097|NCT03185403|OTHER|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
219575098|NCT03185403|OTHER|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
219575099|NCT03185403|DRUG|ropivacaine|
219575100|NCT03185403|DRUG|Sufentanil|
219575101|NCT03100734|BIOLOGICAL|Benepali|As specified in the treatment arm
219575102|NCT03100734|BIOLOGICAL|Enbrel|As specified in the treatment arm
219575103|NCT03295695|DIAGNOSTIC_TEST|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
219575104|NCT03295695|BIOLOGICAL|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
219575105|NCT03295695|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
219575106|NCT00833352|DEVICE|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
219575107|NCT04414436|BEHAVIORAL|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
219575108|NCT01408095|DRUG|LY2608204|Administered orally
219575109|NCT01408095|DRUG|Glimepiride|Administered orally
219575110|NCT06367595|DRUG|Magnesium sulfate|IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
219575111|NCT04934150|DEVICE|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
219575112|NCT00004997|DRUG|Leucovorin|
219575113|NCT00732433|PROCEDURE|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
219575114|NCT04560348|OTHER|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
219575115|NCT01969292|OTHER|Colometer|Real time software based image analysis tool.
219575116|NCT01969292|OTHER|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
219575117|NCT05331157|DEVICE|ultrasound|the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
219575118|NCT04710511|OTHER|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
219575119|NCT02494817|BEHAVIORAL|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
219575120|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
219423247|NCT06517641|DRUG|Haploidentical donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant."
219423248|NCT06517641|DRUG|Unrelated donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant."
219423249|NCT01259635|DEVICE|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
219423250|NCT01181440|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
219423251|NCT01181440|OTHER|Conventional care|Weekly application of conventional care
219575121|NCT01064141|BIOLOGICAL|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
219005720|NCT06234657|BEHAVIORAL|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
219575122|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
219575123|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
219005721|NCT03172455|DRUG|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
219005722|NCT06386250|PROCEDURE|regional block|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
219423252|NCT00510068|DRUG|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
219423253|NCT00510068|DRUG|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
219423254|NCT01896739|BIOLOGICAL|Eutravac|
219423255|NCT05433636|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
219423256|NCT05433636|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
219423257|NCT05433636|BEHAVIORAL|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
219005723|NCT06386250|PROCEDURE|Caudal block|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
219005724|NCT06386250|PROCEDURE|Epidural|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
219423258|NCT05433636|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
219423259|NCT05433636|BEHAVIORAL|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
219423260|NCT04935970|DIAGNOSTIC_TEST|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
219423261|NCT04935970|DIAGNOSTIC_TEST|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
219423262|NCT04763590|BEHAVIORAL|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
219423263|NCT02563925|RADIATION|Brain radiotherapy or Stereotactic Radiosurgery|
219423264|NCT02563925|DRUG|Tremelimumab|
219575124|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
219005725|NCT03598556|DIETARY_SUPPLEMENT|Vitamin D3|180,000IU Vitamin D3 oral emulsion
219423265|NCT02563925|DRUG|HER2 directed therapy|
219423266|NCT02563925|DRUG|Durvalumab|
219423267|NCT06423872|DRUG|ZT002|Participants will receive a single subcutaneous (SC) ZT002 injection.
219423268|NCT06423872|OTHER|Placebo|Participants will receive same volume as of the study drug.
219423269|NCT04395534|PROCEDURE|Complete mesocolic excision|
219423270|NCT03771404|OTHER|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
219423271|NCT03220711|DEVICE|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
219423272|NCT03220711|DRUG|Fluorescein|Fluorescent dye used for imaging contrast only.
219423273|NCT00400712|BEHAVIORAL|physical rehabilitation|two weeks intensive physical rehabilitation
219423274|NCT01996891|OTHER|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
219423275|NCT03741296|PROCEDURE|Single stage revision|One-stage exchange hip joint replacement surgery
219005726|NCT03598556|OTHER|Placebo|Placebo
219005727|NCT00981734|OTHER|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
219005728|NCT04742296|DEVICE|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
219423276|NCT03741296|PROCEDURE|Two-stage revision|Two-stage exchange hip joint replacement surgery
219423277|NCT01619605|PROCEDURE|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
219423278|NCT04172909|OTHER|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
219423279|NCT04172909|OTHER|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
219423280|NCT04857749|OTHER|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
219423281|NCT04857749|OTHER|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
219423282|NCT03624218|BEHAVIORAL|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
219423283|NCT05125107|DEVICE|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
219423284|NCT05085431|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
219423285|NCT00570531|DRUG|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
219423286|NCT00570531|DRUG|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
219423287|NCT00570531|DRUG|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
219423288|NCT00570531|DRUG|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
219423289|NCT00570531|RADIATION|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
219423290|NCT00570531|PROCEDURE|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
219423291|NCT00425477|BIOLOGICAL|sargramostim|
219423292|NCT00425477|DRUG|bexarotene|
219423293|NCT00425477|GENETIC|cytogenetic analysis|
219423294|NCT00425477|GENETIC|fluorescence in situ hybridization|
219423295|NCT00425477|OTHER|flow cytometry|
219423296|NCT00425477|OTHER|laboratory biomarker analysis|
219423297|NCT00425477|PROCEDURE|biopsy|
219423298|NCT04207268|BEHAVIORAL|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
219005729|NCT05945043|OTHER|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
219005730|NCT05945043|OTHER|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
219005731|NCT05945043|OTHER|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
219005732|NCT05945043|OTHER|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
219005733|NCT05832398|DRUG|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
219005734|NCT05832398|DRUG|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
219423299|NCT04207268|BEHAVIORAL|Nutrition Advice|Participate in only nutrition advice
219423300|NCT00960258|DRUG|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
219423301|NCT00672360|DIETARY_SUPPLEMENT|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
219423302|NCT00672360|DIETARY_SUPPLEMENT|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
219423303|NCT00044486|DRUG|Posaconazole oral suspension|
219423304|NCT05220761|DIAGNOSTIC_TEST|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
219423305|NCT02292992|DEVICE|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
219423306|NCT04511442|OTHER|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
219575125|NCT05822245|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
219575126|NCT05822245|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
219575127|NCT05822245|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
219575128|NCT06387173|OTHER|Non-Interventional Study|Non-interventional study
219005735|NCT04397224|DIAGNOSTIC_TEST|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
219005736|NCT02568085|DEVICE|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
219005737|NCT01161147|DRUG|Meloxicam|Meloxicam Tablets 15 mg
219005738|NCT00088478|DRUG|Intramuscular Olanzapine Depot|
219005739|NCT00088478|DRUG|Placebo|
219005740|NCT03341949|BIOLOGICAL|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
219005741|NCT03674996|OTHER|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
219005742|NCT03674996|OTHER|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
219005743|NCT03674996|OTHER|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
219005744|NCT04689633|PROCEDURE|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
219005745|NCT03642405|DIAGNOSTIC_TEST|Electrocardiogram examination|12-lead ECG monitored by Holter
219005746|NCT03642405|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
219005747|NCT03642405|PROCEDURE|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
219005748|NCT03642405|BEHAVIORAL|Questionnaire|Questionnaire regarding patients quality of life
219423307|NCT02438995|DRUG|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
219423308|NCT05338957|DRUG|MRG002+HX008|Administrated intravenously
219423309|NCT05349058|DRUG|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
219423310|NCT05833321|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
219423311|NCT02289482|DRUG|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
219423312|NCT02289482|DRUG|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
219423313|NCT02289482|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
219423314|NCT02289482|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
219575129|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
219575130|NCT00865631|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
219575131|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
219575132|NCT00378950|BEHAVIORAL|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
219575133|NCT00378950|BEHAVIORAL|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
219575134|NCT04273282|DRUG|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
219005749|NCT02052674|DEVICE|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
219005750|NCT02052674|DEVICE|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
219005751|NCT01050426|OTHER|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
219005752|NCT01050426|OTHER|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
219005753|NCT04023604|OTHER|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
219005754|NCT04023604|OTHER|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
219005755|NCT03547687|DEVICE|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
219423315|NCT05692648|BEHAVIORAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
219423316|NCT05692648|BEHAVIORAL|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
219423317|NCT05692648|BEHAVIORAL|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
219423318|NCT00622869|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
219423319|NCT00622869|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
219423320|NCT00622869|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
219423321|NCT00622869|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
219423322|NCT00622869|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
219423323|NCT00622869|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
219423324|NCT02472925|BEHAVIORAL|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
219423325|NCT04534569|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
219423326|NCT03230344|PROCEDURE|open flap debridement|open flap debridement simultaneously with root canal treatment
219423327|NCT03230344|PROCEDURE|open flap debridement|open flap debridement and delayed root canal treatment
219423328|NCT03487640|PROCEDURE|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
219423329|NCT03487640|PROCEDURE|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
219423330|NCT02695706|DEVICE|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
219423331|NCT03378154|PROCEDURE|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
219423332|NCT03378154|PROCEDURE|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
219423333|NCT00645567|DEVICE|Unassisted Manual Transfer|No device assistance
219423334|NCT00645567|DEVICE|Standard Transfer Board|Flat surface board
219423335|NCT00645567|DEVICE|Glide n' Go|Flip down power lift chair
219423336|NCT00645567|DEVICE|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
219423337|NCT00645567|DEVICE|Ryno lift|Lift for the wheelchair
219423338|NCT05602610|OTHER|No intervention|No intervention
219423339|NCT00353964|DRUG|rEV131|
219423340|NCT00353964|DRUG|Prenisolone sodium phosphate 1.0%|
219423341|NCT00353964|DRUG|rEV131 vehicle|
219423342|NCT00422708|PROCEDURE|Local anesthesia|
219423343|NCT06429878|DIAGNOSTIC_TEST|Biparametric prostatic MRI|
219575135|NCT04273282|DRUG|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
219575136|NCT06123260|DIAGNOSTIC_TEST|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
219575137|NCT01134627|DRUG|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
219575138|NCT01134627|DRUG|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
219575139|NCT05524428|BEHAVIORAL|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
219423344|NCT00103467|BIOLOGICAL|rPA102 Vaccine|
219423345|NCT00153894|BEHAVIORAL|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
219423346|NCT00153894|BEHAVIORAL|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
219423347|NCT04811469|DRUG|CBP-174|CBP-174 oral solution, given once
219423348|NCT04811469|DRUG|Placebo|Placebo oral solution, given once
219423349|NCT03093961|DEVICE|IASD implant|Single arm for implant
219423350|NCT00282789|DEVICE|bilevel positive airway pressure|
219423351|NCT00282789|DEVICE|bilevel positive airway pressure (Device)|
219423352|NCT01632735|BEHAVIORAL|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
219423353|NCT02760017|DRUG|B. forficata|
219423354|NCT02760017|DRUG|Placebo|
219423355|NCT00900913|DRUG|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
219423356|NCT00001906|BIOLOGICAL|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
219423357|NCT04840706|DEVICE|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
219423358|NCT04840706|OTHER|Standard care|No HFNC treatment
219423359|NCT02352805|DEVICE|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
219423360|NCT02300428|DIETARY_SUPPLEMENT|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
219423361|NCT04742426|OTHER|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
219575140|NCT04883424|BEHAVIORAL|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
219423362|NCT04742426|OTHER|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
219423363|NCT05679973|DEVICE|Polybutester suture|After third molar surgery this suture used for primary closure.
219423364|NCT05679973|DEVICE|Polypropylene suture|After third molar surgery this suture used for primary closure.
219423365|NCT03097796|DRUG|PUL-042|PUL-042 Inhalation Solution
219423366|NCT05762874|DRUG|Ruxolitinib|JAK inhibitor
219423367|NCT03543358|DRUG|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
219423368|NCT03543358|DRUG|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
219423369|NCT00695240|DEVICE|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
219423370|NCT05606224|BEHAVIORAL|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
219423371|NCT05985434|PROCEDURE|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
219423372|NCT06101524|PROCEDURE|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
219423373|NCT04521335|DRUG|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
219423374|NCT04521335|DRUG|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
219423375|NCT00546039|DRUG|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
219423376|NCT00546039|DRUG|Placebo|Capsule
219423377|NCT03204435|PROCEDURE|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
219423378|NCT03204435|PROCEDURE|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
219423379|NCT03204435|PROCEDURE|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
219423380|NCT03204435|PROCEDURE|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
219423381|NCT04427917|DRUG|PF-06835919|PF-06835919 300 mg repeated doses
219423382|NCT04427917|DRUG|Placebo|Placebo repeated doses
219575141|NCT05665517|DEVICE|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
219575142|NCT02382367|OTHER|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
219423383|NCT04413643|DEVICE|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
219423384|NCT00004095|DRUG|gemcitabine hydrochloride|
219423385|NCT00004095|DRUG|irinotecan hydrochloride|
219423386|NCT06441110|DRUG|Tislelizumab in Combination with Bacillus Calmette-Guérin|Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
219575143|NCT06297525|DRUG|STP938|Small molecule
219575144|NCT02592772|OTHER|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
219423387|NCT01257919|DRUG|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
219423388|NCT01257919|DRUG|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
219423389|NCT01240655|DRUG|LCL161|
219423390|NCT01240655|DRUG|Paclitaxel|
219423391|NCT03085355|PROCEDURE|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
219423392|NCT03085355|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
219423393|NCT05202769|OTHER|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
219423394|NCT00870818|DIAGNOSTIC_TEST|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
219423395|NCT00870818|BEHAVIORAL|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
219575145|NCT02592772|OTHER|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
219575146|NCT02592772|OTHER|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
219575147|NCT05212441|DEVICE|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
219575148|NCT05212441|BEHAVIORAL|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
219575149|NCT05212441|PROCEDURE|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
219423396|NCT00870818|DIAGNOSTIC_TEST|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
219423397|NCT06446206|DRUG|Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib|Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
219423398|NCT00178464|DRUG|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
219423399|NCT03503214|DIAGNOSTIC_TEST|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
219423400|NCT03503214|DIAGNOSTIC_TEST|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
219423401|NCT02723136|DEVICE|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
219423402|NCT02281903|DEVICE|The TrueCPR feedback device|feedback devices
219423403|NCT02281903|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
219423404|NCT00243100|DRUG|vorinostat|Given orally
219423405|NCT00243100|DRUG|gemcitabine hydrochloride|Given IV
219423406|NCT02227108|DRUG|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
219423407|NCT04060264|BIOLOGICAL|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
219423408|NCT04060264|BIOLOGICAL|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
219423409|NCT02486952|DRUG|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
219423410|NCT02486952|DRUG|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
219423411|NCT02486952|DRUG|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
219423412|NCT02486952|DRUG|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
219423413|NCT02486952|DRUG|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
219423414|NCT00530556|DRUG|zolpidem|
219423415|NCT04259385|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
219423416|NCT04259385|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
219423417|NCT02679209|BIOLOGICAL|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
219423418|NCT02679209|BIOLOGICAL|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
219423419|NCT04450056|OTHER|No intervention|No intervention
219005756|NCT03547687|DEVICE|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
219423420|NCT01464242|DRUG|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
219423421|NCT01464242|DRUG|Placebo|Placebo 400mg orally 3 times a day for 20 days
219423422|NCT01464242|DRUG|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
219423423|NCT03512977|PROCEDURE|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
219423424|NCT03512977|DRUG|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
219423425|NCT03132168|BEHAVIORAL|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
219423426|NCT03132168|PROCEDURE|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
219575150|NCT05212441|OTHER|Therapeutic Exercises|"1. Passive ROM (PROM).~2. Active ROM (AROM) \& Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~3. Stretching exercises: A low-load (low-intensity), long-duration stretch~4. Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
219575151|NCT03527654|OTHER|Observational|Surveys, blood and urine collected prospectively over 24 months.
219423427|NCT03132168|OTHER|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
219423428|NCT03637907|OTHER|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
219423429|NCT04385615|OTHER|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
219423430|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
219423431|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423432|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
219423433|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423434|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423435|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423436|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219575152|NCT06843356|PROCEDURE|Endovascular Treatment|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
219575153|NCT03645382|DIETARY_SUPPLEMENT|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
219575154|NCT03645382|DIETARY_SUPPLEMENT|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
219005757|NCT03667924|BEHAVIORAL|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
219575155|NCT04528576|DEVICE|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
219575156|NCT03405376|DRUG|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
219575157|NCT05637476|OTHER|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance ."
219005758|NCT01126476|OTHER|Proton Radiotherapy|
219005759|NCT02128178|DRUG|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
219423437|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
219423438|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423439|NCT03814590|DRUG|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
219423440|NCT05225051|OTHER|skin biopsy|skin biopsy
219423441|NCT03011450|DRUG|K-877|
219423442|NCT03011450|DRUG|Fenofibrate|
219423443|NCT03011450|DRUG|Placebo (for K-877)|
219423444|NCT03180827|PROCEDURE|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
219423445|NCT00679068|DRUG|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
219423446|NCT04209894|DIAGNOSTIC_TEST|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
219423447|NCT03623282|DRUG|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
219423448|NCT04065373|DEVICE|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
219423449|NCT02204826|DRUG|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
219423450|NCT02204826|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
219423451|NCT04084340|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
219423452|NCT04084340|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
219423453|NCT01825655|DRUG|Cetirizine|
219423454|NCT01825655|DRUG|Placebo or sugar pill|
219423455|NCT01529385|DEVICE|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
219423456|NCT01529385|DEVICE|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
219423457|NCT05496894|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
219423458|NCT00964158|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
219423459|NCT02961517|OTHER|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
219423460|NCT02137759|RADIATION|Standard Radiation Therapy|Radiation therapy to 60 Gy
219423461|NCT02137759|DRUG|Standard Temozolomide|Temozolomide given orally
219423462|NCT02137759|DRUG|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
219423463|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
219423464|NCT01666678|DRUG|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
219423465|NCT01666678|DRUG|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
219423466|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
219423467|NCT03658993|DRUG|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
219423468|NCT01077388|BEHAVIORAL|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
219423469|NCT04910763|BEHAVIORAL|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
219575158|NCT05637476|OTHER|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
219423470|NCT06006312|DIAGNOSTIC_TEST|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
219423471|NCT06006312|DIAGNOSTIC_TEST|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
219575159|NCT02067767|DRUG|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
219575160|NCT04830917|OTHER|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
219575161|NCT05054218|BIOLOGICAL|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
219575162|NCT00759278|PROCEDURE|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
219423472|NCT06006312|DIAGNOSTIC_TEST|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
219575163|NCT02669160|DEVICE|PC Innowalk|
219575164|NCT02669160|DEVICE|Conventional passive stander|
219575165|NCT05528861|DRUG|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
219575166|NCT05528861|OTHER|Placebo|Placebo
219575167|NCT01602172|BEHAVIORAL|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
219575168|NCT01602172|OTHER|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
219575169|NCT04448496|DRUG|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
219575170|NCT04526652|DRUG|Dexmedetomidine|Evaluating anxiety score in both arms
219423473|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
219005760|NCT02128178|DRUG|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
219423474|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
219423475|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
219575171|NCT04526652|DRUG|Placebo|Evaluating anxiety score in both arms
219575172|NCT03223454|BIOLOGICAL|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
219575173|NCT03223454|BIOLOGICAL|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
219575174|NCT05308680|BIOLOGICAL|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
219575175|NCT00161681|DRUG|Levonorgestrel/Ethinyl Estradiol|
219575176|NCT02983032|BEHAVIORAL|BBTI|3 group sessions over 4 weeks
219575177|NCT00036647|DRUG|Tarceva (erlotinib HCl, OSI-774 )|
219575178|NCT00469053|DRUG|Buprenorphine|
219575179|NCT04659551|DRUG|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
219575180|NCT04659551|DRUG|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
219575181|NCT04659551|DRUG|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
219575182|NCT04659551|DRUG|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
219575183|NCT04659551|DRUG|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
219575184|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
219575185|NCT05331183|DRUG|IVA|Tablets for oral administration.
219575186|NCT00518882|DRUG|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
219575187|NCT00518882|DRUG|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
219575188|NCT06768580|DRUG|Melatonin|Patients will receive one capsule of melatonin (5mg) orally the night before surgery at 9 pm, the night of the operation, and two nights after the surgical operation at 9 pm, also the patients will receive 10 ml bolus of saline intravenous (IV) over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) until the end of surgery.
219575189|NCT06768580|DRUG|Lidocaine|Patients will receive a bolus (10 ml) of intravenous lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. Continuous infusion of 1.5 mg/kg/hr of intravenous lidocaine diluted with saline (20 ml/hr) will be administered until the end of the surgery, also will receive placebo capsule the night before surgery at 9 pm, the night of operation and two nights after the surgical operation at 9 pm.
219423476|NCT03011580|DIETARY_SUPPLEMENT|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
219423477|NCT03011580|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
219423478|NCT02389140|OTHER|Trigger point release|Trigger point therapy
219423479|NCT02389140|OTHER|Ultrasound|sham ultrasound
219575190|NCT06768580|DRUG|Placebo|Patients will receive a bolus (10 ml) of saline over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) and placebo capsule the night before surgery at 9 pm, the night of the operation and two nights after the surgical operation at 9 pm.
219423480|NCT04564326|PROCEDURE|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
219423481|NCT04564326|PROCEDURE|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
219423482|NCT04564326|DRUG|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
219423483|NCT03385382|DRUG|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
219005761|NCT01593215|DRUG|Yohimbine|Yohimbine capsule
219005762|NCT01033591|BEHAVIORAL|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
219005763|NCT01033591|BEHAVIORAL|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
219423484|NCT03385382|DRUG|Ranibizumab Injection|Injection of ranibizumab
219423485|NCT02247674|PROCEDURE|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
219423486|NCT03633565|DRUG|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
219423487|NCT03633565|DRUG|Prednisolone (Steroids)|tablet 20 mg
219575191|NCT01295086|DRUG|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
219575192|NCT01295086|DRUG|Oxaliplatin|100 mg/m² day 1 every 3. week
219575193|NCT01295086|DRUG|Capecitabine|1250 mg/² continuously
219005764|NCT04160897|DRUG|Entecavir|entecavir naive for chronic hepatitis B patients
219005765|NCT04160897|DRUG|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
219423488|NCT03633565|PROCEDURE|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
219423489|NCT01363557|OTHER|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
219423490|NCT01363557|DRUG|Gefitinib (IRESSA)|250 mg/day
219423491|NCT00261326|DRUG|simvastatin|80 mg once daily
219423492|NCT00261326|DRUG|placebo|calcium tablets once daily
219575194|NCT01295086|DRUG|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
219575195|NCT03395639|DRUG|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
219575196|NCT03395639|DRUG|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
219575197|NCT05271136|OTHER|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
219575198|NCT05271136|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
219575199|NCT05271136|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants
219575200|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
219575201|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
219575202|NCT05373381|DIETARY_SUPPLEMENT|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
219575203|NCT00186823|DEVICE|Miltenyi Biotec CliniMACS|A stem cell selection device.
219575204|NCT00186823|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
219575205|NCT00186823|DRUG|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
219575206|NCT05540873|DRUG|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
219575207|NCT03221231|DRUG|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
219575208|NCT03221231|DRUG|Placebo Oral Tablet|twice daily, placebo
219575209|NCT03221231|OTHER|Magnetic Resonance Imaging|
219575210|NCT03221231|OTHER|Neurocognitive measures|
219575211|NCT03221231|OTHER|Neuro-inflammatory measures|
219575212|NCT00942331|BIOLOGICAL|Bevacizumab|Given IV
219575213|NCT00942331|DRUG|Cisplatin|Given IV
219575214|NCT00942331|DRUG|Gemcitabine Hydrochloride|Given IV
219423493|NCT02160886|BEHAVIORAL|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
219423494|NCT02160886|BEHAVIORAL|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
219423495|NCT04395963|DEVICE|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
219423496|NCT00295217|DEVICE|ExAblate 2000|
219423497|NCT03077763|DRUG|Sodium Nitrite|
219423498|NCT01606735|DRUG|IBI-10090|dexamethasone
219575215|NCT00942331|OTHER|Laboratory Biomarker Analysis|Correlative studies
219575216|NCT00942331|OTHER|Placebo Administration|Given IV
219575217|NCT01849016|DRUG|N-Acetylcysteine|
219575218|NCT01849016|DRUG|Placebo|
219575219|NCT01397617|DEVICE|NobelActive Internal implant|Dental implant
219575220|NCT01397617|DEVICE|NobelActive External implant|Dental implant
219575221|NCT01397617|DEVICE|NobelReplace Tapered Groovy implant|Dental implant
219575222|NCT00006263|BIOLOGICAL|filgrastim|
219575223|NCT00006263|DRUG|carboplatin|
219759883|NCT06389175|DEVICE|Sham stimulation|"The control intervention consists of a sham stimulation. In the neuroimaging session the electrode will be placed upside down to stimulate the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.~During the extended stimulation period, the electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA). To ensure blinding, participants will be instructed that the extended stimulation period will examine the effects of a low- vs. high-intensity tVNS protocol. Each repeated stimulation period will involve six sessions with at least 1.5h of low-intensity stimulation (stimulation in the lab or at home with home device; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
219575224|NCT00006263|DRUG|temozolomide|
219575225|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
219575226|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
219575227|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
219575228|NCT03699241|BIOLOGICAL|Placebo|Tris-NaCl Diluent
219759884|NCT00181844|DRUG|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
219759885|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
219759886|NCT06637098|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
219575229|NCT02994251|DRUG|gemcitabine|1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
219575230|NCT02994251|DRUG|Cisplatin|25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
219575231|NCT02994251|DRUG|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
219575232|NCT04858659|DRUG|PK101|1 tablet at each time, 2 times a day
219575233|NCT04858659|DRUG|PK101-002|1 tablet at each time, 2 times a day
219575234|NCT04858659|DRUG|PK101 placebo|1 tablet at each time, 2 times a day
219575235|NCT04858659|DRUG|PK101-002 placebo|1 tablet at each time, 2 times a day
219575236|NCT01702077|PROCEDURE|Neurofeedback|
219575237|NCT01702077|PROCEDURE|Sham feedback|
219575238|NCT00168090|DRUG|Blood coagulation Factor VIII and vWF, human|
219759887|NCT06637098|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219759888|NCT06637098|BEHAVIORAL|Gastrostomy feeding|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
219759889|NCT06165991|DRUG|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
219759890|NCT05321563|BEHAVIORAL|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
219759891|NCT01958749|PROCEDURE|Fat graft with Platelet Rich Plasma|
219005766|NCT02135302|DRUG|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
219005767|NCT02822768|PROCEDURE|Packing|The patient will receive packing as part of their wound care
219005768|NCT02822768|OTHER|No packing|The patient will not receive packing as part of their wound care
219005769|NCT00881582|DRUG|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
219005770|NCT00709930|DEVICE|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
219005771|NCT00709930|DEVICE|Placebo magnetic field generator|Placebo device with no magnetic fields
219005772|NCT03972553|PROCEDURE|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
219005773|NCT03972553|PROCEDURE|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
219005774|NCT00400751|BEHAVIORAL|FAMCON (Family Consultation)|
219005775|NCT01112241|DRUG|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
219423499|NCT04758858|OTHER|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
219423500|NCT04758858|DEVICE|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
219423501|NCT04758858|OTHER|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
219423502|NCT04758858|OTHER|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
219423503|NCT04758858|OTHER|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
219423504|NCT04758858|OTHER|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
219423505|NCT04758858|OTHER|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
219423506|NCT04758858|OTHER|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
219423507|NCT04758858|OTHER|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
219005776|NCT03305653|DEVICE|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
219423508|NCT04758858|DEVICE|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
219423509|NCT04758858|OTHER|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
219423510|NCT04758858|OTHER|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
219423511|NCT04758858|OTHER|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
219423512|NCT04758858|OTHER|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
219423513|NCT04758858|OTHER|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
219423514|NCT04758858|OTHER|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
219423515|NCT04758858|OTHER|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
219423516|NCT04758858|OTHER|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
219575239|NCT06817538|BEHAVIORAL|Physiotherapy/Exercise Program|"Arm 1: Scoliosis-Specific Exercises Combined with Dual-Task Cognitive Training Participants with idiopathic scoliosis in this group received scoliosis-specific physiotherapeutic exercises combined with dual-task cognitive training. The intervention included motor exercises performed on balance boards and stability trainers to enhance postural control. While engaging in these motor exercises, participants simultaneously performed cognitive tasks such as word recall, identifying cities or countries starting with a given letter, and other memory-based games. This dual-task approach aimed to improve both motor and cognitive functions.~Arm 2: Scoliosis-Specific and Motor Exercises Only~Participants with idiopathic scoliosis in this group performed scoliosis-specific physiotherapeutic exercises along with motor exercises aimed at improving postural stability. The motor exercises were conducted using balance boards and stability trainers, focusing solely on physical performance without the"
219575240|NCT05125562|DRUG|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
219423517|NCT04908917|DEVICE|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
219423518|NCT04908917|DEVICE|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
219423519|NCT02290886|OTHER|Intravenous administration of placebo|
219423520|NCT02290886|DRUG|Intravenous administration of 1 million of MSC|
219423521|NCT02290886|DRUG|Intravenous administration of 2 million of MSC|
219423522|NCT02290886|DRUG|Intravenous administration of 4 million of MSC|
219423523|NCT02491502|DEVICE|Echopulse|HIFU Under ultrasound guidance
219423524|NCT02063919|OTHER|the mucosal microbiome in the biopsy specimen was analysed|
219423525|NCT04752124|OTHER|Exercise Therapy|High intensity speed based interval treadmill training
219423526|NCT04752124|OTHER|conventional therapy|conventional physical therapy
219575241|NCT04224727|BEHAVIORAL|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
219423527|NCT02496481|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
219005777|NCT01550302|PROCEDURE|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
219423528|NCT02496481|BEHAVIORAL|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
219423529|NCT01623141|PROCEDURE|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
219423530|NCT00413335|DRUG|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
219423531|NCT00413335|DRUG|Placebo|Subject receives placebo.
219423532|NCT04009213|DEVICE|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
219423533|NCT04009213|DEVICE|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
219423534|NCT00966303|OTHER|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
219575242|NCT04224727|BEHAVIORAL|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
219575243|NCT04224727|BEHAVIORAL|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
219575244|NCT04224727|OTHER|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
219005778|NCT01550302|DRUG|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
219005779|NCT03403660|OTHER|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
219423535|NCT00922350|OTHER|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
219423536|NCT00922350|OTHER|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
219423537|NCT00922350|OTHER|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
219575245|NCT05025280|OTHER|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
219423538|NCT00922350|OTHER|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
219423539|NCT03716518|DRUG|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
219423540|NCT03716518|DRUG|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
219005780|NCT02042378|DRUG|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
219005781|NCT01133483|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
219423541|NCT05529290|DRUG|Dexketoprofen Trometamol + Thiocolchicoside|Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
219423542|NCT05529290|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
219423543|NCT05529290|DRUG|Dexketoprofen Trometamol (25mg)|Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
219423544|NCT05529290|DRUG|Paracetamol|Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
219423545|NCT00545987|DEVICE|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
219423546|NCT00545987|DEVICE|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
219423547|NCT02545842|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219423548|NCT01252342|DRUG|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
219575246|NCT00567476|DRUG|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
219575247|NCT00567476|DRUG|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
219575248|NCT00567476|DRUG|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
219575249|NCT00567476|DRUG|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
219575250|NCT02758860|PROCEDURE|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
219575251|NCT00443482|DRUG|formoterol|
219575252|NCT04475250|DEVICE|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
219423549|NCT01252342|DRUG|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
219423550|NCT05414370|DRUG|Liquid oxygen|Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
219423551|NCT05414370|DRUG|medical air|Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.
219423552|NCT00997178|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
219423553|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
219423554|NCT01991938|DRUG|VS-5584|
219423555|NCT04105569|PROCEDURE|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
219423556|NCT04545788|DRUG|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
219575253|NCT05273931|OTHER|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
219575254|NCT04845620|DRUG|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
219575255|NCT04845620|DRUG|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
219575256|NCT02696031|DRUG|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
219575257|NCT02696031|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
219575258|NCT04658316|BEHAVIORAL|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
219575259|NCT00597116|DRUG|Vinorelbine|
219575260|NCT00597116|DRUG|Vandetanib|once daily oral dose
219575261|NCT05339646|DRUG|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
219575262|NCT05339646|DRUG|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
219575263|NCT05339646|DRUG|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
219005782|NCT00076284|DRUG|GW873140|
219005783|NCT03242057|OTHER|NAVA|Infant will be extubated to NAVA, settings based per protocol
219423557|NCT01259973|DRUG|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
219423558|NCT01259973|DRUG|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
219423559|NCT01259973|DRUG|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
219423560|NCT06069011|OTHER|Interdisciplinary management|assessment and treatment in an interdisciplinary model
219423561|NCT06069011|OTHER|usual care|assessment and treatment in usual care model
219423562|NCT01011452|DRUG|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
219423563|NCT01011452|DRUG|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
219423564|NCT04973215|OTHER|no intervention|this is not an intervention study
219423565|NCT04944888|DRUG|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
219423566|NCT04944888|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
219575264|NCT05339646|DRUG|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
219575265|NCT05339646|DRUG|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
219575266|NCT04272203|DRUG|ABBV-184|Intravenous (IV) infusion
219575267|NCT03758482|OTHER|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
219575268|NCT04948294|DEVICE|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
219575269|NCT04948294|DEVICE|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
219575270|NCT00183586|BEHAVIORAL|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
219423567|NCT04782193|BIOLOGICAL|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
219575271|NCT00183586|BEHAVIORAL|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
219575272|NCT04303702|DRUG|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
219005784|NCT03242057|OTHER|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
219005785|NCT00240162|DRUG|PTK787/ZK 222584|
219005786|NCT06248892|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219423568|NCT03450915|BIOLOGICAL|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
219423569|NCT03450915|BIOLOGICAL|Saline|0.9% sodium chloride (NaCl)
219423570|NCT03565848|PROCEDURE|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
219423571|NCT00684125|DEVICE|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
219423572|NCT00684125|DEVICE|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
219423573|NCT02812446|OTHER|IAI infection|
219575273|NCT04303702|OTHER|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
219423574|NCT02812446|OTHER|Staphylococcus aureus nasal carriage infection|
219423575|NCT02766790|DIETARY_SUPPLEMENT|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
219423576|NCT02766790|OTHER|Placebo|Placebo, an inactive formulation
219575274|NCT02480231|DEVICE|Retropubic Midurethral Sling|
219575275|NCT04699526|OTHER|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
219575276|NCT06388837|OTHER|Injectable Platelet Rich Fibrin|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
219575277|NCT06388837|OTHER|Xenograft|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
219423577|NCT02793323|OTHER|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
219423578|NCT02793323|OTHER|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
219423579|NCT02793323|OTHER|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
219423580|NCT02793323|OTHER|IV placebo|100 ml IV saline
219423581|NCT02793323|OTHER|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
219423582|NCT01709981|DRUG|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
219423583|NCT01709981|DRUG|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
219423584|NCT03299855|OTHER|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
219423585|NCT03307954|DEVICE|Ekso Therapy (Exoskeleton Suit)|
219423586|NCT03307954|OTHER|Usual Physiotherapy|
219423587|NCT04090047|DRUG|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
219423588|NCT04090047|DRUG|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
219423589|NCT03558451|OTHER|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
219423590|NCT03558451|OTHER|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
219423591|NCT04901533|PROCEDURE|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
219423592|NCT04901533|PROCEDURE|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
219423593|NCT04249505|DEVICE|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
219575278|NCT00253981|DEVICE|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
219575279|NCT01163448|RADIATION|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
219575280|NCT01677013|OTHER|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
219575281|NCT02135406|BIOLOGICAL|CART-19 T cells|
219575282|NCT03352752|DEVICE|HTC Vive|Wearing VR helmet before operation
219575283|NCT03352752|OTHER|Without HTC Vive|Wearing a blindfold before operation
219575284|NCT04828798|DEVICE|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
219575285|NCT03978091|DRUG|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
219423594|NCT04249505|DEVICE|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
219423595|NCT04249505|DEVICE|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
219423596|NCT04870827|DRUG|13N Amonia|Administered during PET/CT scans
219423597|NCT01054976|DRUG|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
219575286|NCT03978091|DRUG|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
219423598|NCT00744016|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
219423599|NCT00744016|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
219423600|NCT02661841|OTHER|LI-Guided Therapy|Preemptive treatment according to LI monitoring
219423601|NCT02661841|OTHER|Heart Failure Guidelines|Treatment according to clinical signs
219423602|NCT01763866|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219423603|NCT01763866|DRUG|Ezetimibe|Administered orally once a day
219423604|NCT01763866|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
219423605|NCT01763866|DRUG|Placebo to Ezetimibe|Administered orally once a day
219423606|NCT01763866|DRUG|Atorvastatin|Administered orally once a day
219423607|NCT01763866|DRUG|Rosuvastatin|Administered orally once a day
219423608|NCT01763866|DRUG|Simvastatin|Administered orally once a day
219423609|NCT00514436|BEHAVIORAL|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
219423610|NCT02058485|DRUG|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
219423611|NCT02058485|DRUG|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
219575287|NCT01197157|DRUG|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
219575288|NCT01197157|DRUG|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
219423612|NCT01106742|DIETARY_SUPPLEMENT|AndoSan|AndoSan, 20mlx3, 12 days
219423613|NCT05157399|DEVICE|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
219423614|NCT05157399|DEVICE|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
219423615|NCT05055570|OTHER|No intervention|No intervention
219423616|NCT02825433|OTHER|No intervention, only ventilation monitoring|
219423617|NCT00847756|OTHER|questionnaire|Identification of risk factors
219423618|NCT00847756|PROCEDURE|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
219423619|NCT00847756|PROCEDURE|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
219423620|NCT00847756|PROCEDURE|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
219423621|NCT00187629|BEHAVIORAL|dietary phosphorus|varying amts dietary phosphorus
219423622|NCT00750165|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
219423623|NCT04275050|DRUG|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
219423624|NCT02545491|BEHAVIORAL|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
219423625|NCT02545491|BEHAVIORAL|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
219423626|NCT03308565|BIOLOGICAL|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
219423627|NCT03556748|OTHER|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
219423628|NCT01559064|DEVICE|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
219423629|NCT02603185|DRUG|Hemay007|
219423630|NCT02603185|DRUG|placebo|
219575289|NCT04352465|DRUG|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
219575290|NCT04352465|DRUG|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
219575291|NCT04352465|DRUG|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
219005787|NCT06248892|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219423631|NCT03128216|PROCEDURE|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
219423632|NCT03128216|PROCEDURE|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
219423633|NCT03128216|PROCEDURE|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
219423634|NCT03128216|DRUG|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
219423635|NCT03128216|DRUG|Bupivacaine|Local anesthetic used for Spinal Anesthesia
219423636|NCT02833116|DRUG|Betamethasone|
219575292|NCT02324673|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219575293|NCT03463486|BEHAVIORAL|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
219575294|NCT05796063|DIAGNOSTIC_TEST|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
219575295|NCT01602016|DRUG|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
219575296|NCT01602016|DRUG|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
219575297|NCT05820386|PROCEDURE|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
219575298|NCT05820386|PROCEDURE|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
219575299|NCT05732896|DEVICE|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
219575300|NCT04328519|OTHER|observation|observation
219575301|NCT01685541|OTHER|Maximum After Visit Summary Content|
219423637|NCT02833116|DRUG|Dexamethasone|
219575302|NCT01685541|OTHER|Intermediate After Visit Summary Content|
219575303|NCT01685541|OTHER|Minimum After Visit Summary Content|
219575304|NCT01685541|OTHER|Usual AVS|
219759892|NCT06564558|OTHER|Spinal Strengthening Exercises|Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).
219423638|NCT03320291|DEVICE|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
219423639|NCT03850327|DEVICE|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
219423640|NCT01146041|DRUG|Rivastigmine|Rivastigmine 1.5 mg Capsules
219423641|NCT05978687|DRUG|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
219575305|NCT01815112|OTHER|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
219575306|NCT01815112|OTHER|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
219575307|NCT02591212|BEHAVIORAL|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
219575308|NCT02591212|BEHAVIORAL|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
219575309|NCT02595008|DRUG|DSXS|Active treatment
219575310|NCT02667002|PROCEDURE|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
219575311|NCT02667002|PROCEDURE|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
219575312|NCT02667002|OTHER|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
219575313|NCT04209335|OTHER|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
219423642|NCT05978687|DRUG|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
219423643|NCT03826355|PROCEDURE|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
219575314|NCT05772806|DEVICE|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
219575315|NCT05077956|DIAGNOSTIC_TEST|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
219575316|NCT02341833|DRUG|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
219575317|NCT03522571|BEHAVIORAL|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
219575318|NCT00136578|DRUG|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
219575319|NCT00136578|DRUG|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
219005788|NCT06248892|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219005789|NCT04104945|RADIATION|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
219005790|NCT04203784|OTHER|Plasma concentration measurements|Plasma concentration measurements
219575320|NCT03695705|DRUG|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
219575321|NCT02032251|DRUG|oral administration of ginger|Oral administration of ginger in patients with infertility.
219575322|NCT02032251|DRUG|Placebo|
219575323|NCT04660305|DRUG|AT278|Concentrated rapid acting insulin aspart
219575324|NCT04660305|DRUG|NovoRapid|Rapid acting insulin aspart
219575325|NCT02214420|DRUG|Simeprevir|
219575326|NCT02214420|DRUG|Sofosbuvir|
219575327|NCT02214420|DRUG|Ribavirin|
219575328|NCT01739920|OTHER|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
219005791|NCT02740764|OTHER|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
219423644|NCT03826355|PROCEDURE|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
219423645|NCT04981574|OTHER|Massage and stretching on neck area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
219423646|NCT04981574|OTHER|Massage and stretching on low back area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
219423647|NCT01669811|DRUG|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
219423648|NCT01669811|DRUG|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
219423649|NCT02730442|DRUG|F901318|Administration of F901318 intravenously
219423650|NCT02730442|DRUG|Fluconazole|Oral administration
219423651|NCT02723110|OTHER|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
219423652|NCT02723110|OTHER|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
219423653|NCT00101803|DRUG|vildagliptin|
219423654|NCT02571751|DEVICE|UNIGEL Silicone Gel-Filled Breast Implant|
219423655|NCT04627142|DRUG|BI 1701963|Tablet
219423656|NCT04627142|DRUG|Camptosar®|Solution for infusion
219423657|NCT00313534|DRUG|masoprocol|
219423658|NCT04794556|DEVICE|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
219423659|NCT02663479|DIETARY_SUPPLEMENT|Cardiopressin|
219423660|NCT02663479|DIETARY_SUPPLEMENT|Placebo|
219423661|NCT06366828|OTHER|retrospective|follow up
219423662|NCT02214316|OTHER|Hypertonic Saline|
219575329|NCT01739920|OTHER|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
219759893|NCT06564558|OTHER|Thoracic Spine Stretching|Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.
219005792|NCT05196165|OTHER|No Intervention|No investigational product (IP) will be administered in this study
219005793|NCT03806140|BEHAVIORAL|text messages|receive about one health-related text message a day for 16 weeks
219005794|NCT05849389|DRUG|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
219005795|NCT04019665|OTHER|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
219423663|NCT05864183|DIAGNOSTIC_TEST|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
219423664|NCT05864183|DIAGNOSTIC_TEST|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
219423665|NCT05864183|DIAGNOSTIC_TEST|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
219423666|NCT05864183|DIAGNOSTIC_TEST|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
219423667|NCT05864183|DIAGNOSTIC_TEST|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
219423668|NCT05864183|DIAGNOSTIC_TEST|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
219423669|NCT05864183|DIAGNOSTIC_TEST|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
219423670|NCT05864183|DIAGNOSTIC_TEST|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
219005796|NCT04019665|OTHER|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
219191226|NCT06851286|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
219423671|NCT05864183|DIAGNOSTIC_TEST|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
219423672|NCT06372054|OTHER|Biological sample collection|Collection of biological samples (blood, urine, saliva) and clinical data
219423673|NCT03758430|OTHER|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
219423674|NCT03758430|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
219423675|NCT03201172|DEVICE|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
219423676|NCT03245723|PROCEDURE|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
219423677|NCT03245723|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
219423678|NCT03245723|PROCEDURE|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
219423679|NCT03245723|PROCEDURE|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
219423680|NCT00519493|PROCEDURE|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
219423681|NCT00519493|DEVICE|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
219423682|NCT02240537|DRUG|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
219423683|NCT02240537|DRUG|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
219423684|NCT02240537|DRUG|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
219423685|NCT02612961|OTHER|3mL of normal saline from the pink sodium chloride bullet|
219423686|NCT02612961|OTHER|Sham Comparator of 3mL normal saline|
219423687|NCT00154141|DRUG|Fibrin sealant (FS2)|
219423688|NCT00835419|DRUG|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
219759894|NCT06564558|OTHER|Thoracic Spine Mobilization|The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.
219759895|NCT06564558|OTHER|Sham Postural Correction|comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
219759896|NCT06399224|DEVICE|Local Plantar vibrator|A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
219423689|NCT06885125|DIETARY_SUPPLEMENT|anti-inflammatory diet|The anti-inflammatory diet consists of a 12-week plant-based diet, followed by guidance and monitoring from a nutritionist.
219423690|NCT00077376|BIOLOGICAL|trastuzumab|Given IV
219423691|NCT00077376|DRUG|ixabepilone|Given IV
219423692|NCT00077376|DRUG|carboplatin|Given IV
219423693|NCT00077376|OTHER|laboratory biomarker analysis|Correlative studies
219423694|NCT06076148|DEVICE|Virtual reality games|three individual games (physical, cognitive and relaxation) and two multiplayer games will be tested.
219423695|NCT04020055|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
219423696|NCT00860418|BEHAVIORAL|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
219423697|NCT00860418|BEHAVIORAL|Standard asthma education|Standard asthma education during 2 home visits.
219423698|NCT00653913|DRUG|SCH 58235|SCH 58235 10 mg (once daily)
219423699|NCT00653913|DRUG|pitavastatin|Pitavastatin 2 mg (once daily)
219423700|NCT01726283|DEVICE|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
219423701|NCT01726283|DRUG|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
219575330|NCT05253274|DEVICE|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
219575331|NCT03078582|DRUG|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
219759897|NCT06399224|OTHER|Otago exercise|Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
219759898|NCT06432465|DEVICE|active tDCS|The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered for 20 minutes via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus).
219759899|NCT06432465|DEVICE|sham tDCS|Same device and procedures as active tDCS with the exception that the device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.
219575332|NCT03112980|DEVICE|Transcatheter aortic valve implantation|(TAVI)
219759900|NCT01165034|OTHER|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
219759901|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
219759902|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
219759903|NCT03251521|OTHER|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
219759904|NCT02213029|DRUG|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg
219759905|NCT02213029|DRUG|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
219759906|NCT02213029|DRUG|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
219759907|NCT02213029|DRUG|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
219759908|NCT02797821|DRUG|Asfotase alfa|
219759909|NCT03144284|OTHER|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
219759910|NCT01057979|BEHAVIORAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
219423702|NCT00412906|DRUG|Escherichia Coli Endotoxin|
219423703|NCT04923698|OTHER|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
219423704|NCT01645865|BEHAVIORAL|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
219575333|NCT03112980|PROCEDURE|Surgical aortic valve replacement|(SAVR)
219575334|NCT00750126|DRUG|Fludarabine, Busulfan, Thymoglobulin|"study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival"
219575335|NCT06188130|OTHER|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
219575336|NCT06188130|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
219575337|NCT06188130|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
219423705|NCT01645865|BEHAVIORAL|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
219423706|NCT02801422|OTHER|fMRI|
219423707|NCT03429322|BEHAVIORAL|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
219423708|NCT03429322|OTHER|Usual Care|Participants will receive and provide usual and customary care in their communities.
219423709|NCT03724617|DRUG|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
219575338|NCT06188130|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
219575339|NCT01843348|DRUG|Everolimus|
219759911|NCT01057979|BEHAVIORAL|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
219575340|NCT01843348|DRUG|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
219575341|NCT01843348|DRUG|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
219759912|NCT00353002|DRUG|Ametop (4% Amethocaine cream )|
219759913|NCT00353002|DRUG|Maxilene (4% Liposomal Lidocaine)|
219759914|NCT04039932|BEHAVIORAL|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
219759915|NCT04391920|DEVICE|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
219759916|NCT01249001|DRUG|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
219759917|NCT01249001|DRUG|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
219759918|NCT03130686|DEVICE|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
219423710|NCT04675736|PROCEDURE|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
219423711|NCT04697602|DRUG|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
219575342|NCT01843348|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
219575343|NCT01843348|DRUG|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
219575344|NCT01843348|DRUG|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
219575345|NCT01843348|DRUG|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
219575346|NCT02823730|OTHER|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
219575347|NCT02046525|BIOLOGICAL|Autologous fecal microbiota therapy|
219575348|NCT02046525|OTHER|Placebo|Saline enema
219759919|NCT06564415|PROCEDURE|Transperineal Laser Ablation of Prostate|Transperineal Laser Ablation of the Prostate is an ultra minimally-invasive procedure that consists in the insertion trough the perineum skin of laser fibers into the prostatic adenoma, under US guidance. Laser energy generates an area of coagulative necrosis that will bring to a reduction of the prostatic volume.
219759920|NCT04442893|BEHAVIORAL|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
219759921|NCT04442893|OTHER|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
219423712|NCT04697602|DRUG|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
219423713|NCT05294341|DRUG|Norethindrone Acetate 5 MG|As specified in arm design
219423714|NCT05294341|DRUG|Norethindrone 0.35 MG|As specified in arm design
219423715|NCT00889811|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
219423716|NCT05718661|BEHAVIORAL|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
219423717|NCT05718661|BEHAVIORAL|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
219423718|NCT00646113|DEVICE|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
219423719|NCT01773798|DRUG|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
219423720|NCT01773798|DRUG|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
219423721|NCT01773798|DRUG|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
219423722|NCT01773798|DRUG|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
219423723|NCT01773798|DRUG|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
219423724|NCT05355935|DRUG|Brensocatib|Oral tablet.
219423725|NCT05355935|DRUG|Moxifloxacin|Oral tablet.
219423726|NCT05355935|DRUG|Placebo|Oral tablet.
219423727|NCT02109744|DRUG|Decitabine|
219423728|NCT03099980|BIOLOGICAL|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
219423729|NCT03604068|DEVICE|RecoveryRx|A pulsed shortwave therapy medical device
219423730|NCT03604068|DEVICE|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
219423731|NCT06580730|PROCEDURE|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
219423732|NCT06580730|OTHER|Standard medical treatment|Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
219423733|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
219423734|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
219423735|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
219423736|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
219423737|NCT04768699|DRUG|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
219575349|NCT01633502|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
219575350|NCT01633502|DEVICE|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
219575351|NCT03313648|PROCEDURE|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
219575352|NCT03313648|PROCEDURE|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
219575353|NCT01048216|RADIATION|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
219575354|NCT05895734|DEVICE|NDS-Powerball®,|Rehabilitation using the Powerball system
219575355|NCT05895734|OTHER|Conventional treatment|Rehabilitation by conventional treatment
219575356|NCT04719234|DEVICE|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
219423738|NCT04768699|DRUG|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
219423739|NCT04768699|DRUG|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
219423740|NCT03827668|DRUG|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
219575357|NCT02689063|DRUG|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
219575358|NCT02689063|DRUG|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
219575359|NCT02689063|DRUG|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
219575360|NCT02689063|DRUG|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
219575361|NCT00480623|DRUG|Satraplatin plus radiation therapy|
219575362|NCT04997655|DIAGNOSTIC_TEST|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
219575363|NCT06166316|DEVICE|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
219191227|NCT06199089|DRUG|CM313 Injection|"Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
219423741|NCT03827668|DRUG|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
219423742|NCT03827668|DRUG|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
219423743|NCT03287245|DRUG|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
219423744|NCT02701192|OTHER|Coccygectomy|Patient receiving coccygectomy surgery.
219423745|NCT03097614|DEVICE|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
219575364|NCT02994355|OTHER|Systems Analysis and Improvement Approach|"1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)"
219575365|NCT00350155|DRUG|Lumiracoxib|
219575366|NCT04704349|RADIATION|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
219575367|NCT01592136|DRUG|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
219575368|NCT02546349|DRUG|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
219575369|NCT02788149|DEVICE|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
219423746|NCT00444470|DRUG|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
219423747|NCT00444470|DRUG|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
219575370|NCT02788149|DEVICE|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
219575371|NCT03832738|DRUG|JTE-451 Tablets|Active drug tablets containing JTE-451
219575372|NCT03832738|DRUG|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
219005797|NCT04997434|BEHAVIORAL|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
219005798|NCT01756547|DRUG|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
219005799|NCT01756547|DRUG|Placebo|
219005800|NCT06969651|BEHAVIORAL|Black-Food|Ads featuring a Black person with a food product
219005801|NCT06969651|BEHAVIORAL|White-Food|Ads featuring a White person with a food product
219005802|NCT06969651|BEHAVIORAL|Black-Non Food|Ads featuring a Black person with a non-food product
219005803|NCT06969651|BEHAVIORAL|White-Non Food|Ads featuring a White person with a non-food product
219005804|NCT06969651|BEHAVIORAL|Food-Many Likes|"Ads with Many likes featuring a food product"
219575373|NCT01405287|DEVICE|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
219575374|NCT03290287|DRUG|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
219005805|NCT06969651|BEHAVIORAL|Non Food-Many Likes|"Ads with Many likes featuring a non-food product"
219005806|NCT06969651|BEHAVIORAL|Food-Few Likes|"Ads with Few likes featuring a food product"
219423748|NCT03029949|BEHAVIORAL|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
219575375|NCT03290287|DRUG|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
219575376|NCT03580291|OTHER|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
219423749|NCT03029949|BEHAVIORAL|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
219575377|NCT03580291|DRUG|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
219575378|NCT03580291|OTHER|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
219575379|NCT03580291|DRUG|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
219423750|NCT03029949|OTHER|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
219423751|NCT02150213|PROCEDURE|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
219423752|NCT02150213|PROCEDURE|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
219423753|NCT02150213|PROCEDURE|Sonogram|Sonogram of the uterus (females only)
219423754|NCT02150213|PROCEDURE|Biopsy|Uterine endometrial biopsy (females only)
219423755|NCT02150213|DRUG|BGG492|No study-drug was administered in this study
219423756|NCT04048538|OTHER|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
219423757|NCT04048538|OTHER|usual standard of care|individuals will receive treatment as per the usual standard of care
219423758|NCT03667508|PROCEDURE|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
219423759|NCT03667508|PROCEDURE|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
219575380|NCT03977701|BEHAVIORAL|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
219423760|NCT00833677|BEHAVIORAL|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
219423761|NCT01666145|DEVICE|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
219423762|NCT01345370|DRUG|Temozolomide|According to sites procedures
219423763|NCT01345370|RADIATION|Radiation Therapy|According to sites procedures
219423764|NCT00122421|BEHAVIORAL|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
219575381|NCT03977701|BEHAVIORAL|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
219575382|NCT05240131|DRUG|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
219423765|NCT00122421|OTHER|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
219423766|NCT01993056|BEHAVIORAL|"FIFA 11+"|
219423767|NCT01993056|BEHAVIORAL|"no FIFA 11+"|
219423768|NCT03025893|DRUG|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
219423769|NCT03025893|DRUG|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
219423770|NCT00324688|DRUG|Viread|
219423771|NCT00024193|BIOLOGICAL|filgrastim|
219423772|NCT00024193|DRUG|busulfan|
219423773|NCT00024193|DRUG|cisplatin|
219423774|NCT00024193|DRUG|cyclophosphamide|
219423775|NCT00024193|DRUG|doxorubicin hydrochloride|
219423776|NCT00024193|DRUG|etoposide|
219423777|NCT00024193|DRUG|melphalan|
219423778|NCT00024193|DRUG|vincristine sulfate|
219423779|NCT00024193|PROCEDURE|conventional surgery|
219423780|NCT00024193|PROCEDURE|peripheral blood stem cell transplantation|
219423781|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
219423782|NCT02678312|DRUG|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
219423783|NCT02678312|DRUG|Placebo of LCZ696|
219423784|NCT02678312|DRUG|Placebo of Enalapril|
219423785|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
219423786|NCT01646801|DEVICE|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
219423787|NCT02527187|BIOLOGICAL|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
219423788|NCT02527187|BIOLOGICAL|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
219423789|NCT02527187|BIOLOGICAL|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
219575383|NCT05240131|DRUG|Placebo|Placebo is administered orally twice a day.
219423790|NCT02527187|BIOLOGICAL|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
219423791|NCT02335203|DRUG|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
219423792|NCT02335203|OTHER|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
219423793|NCT06506838|DRUG|Anlotinib|For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
219423794|NCT05158179|DEVICE|Sensation testing|Sensation testing tactile aesthesiometer.
219423795|NCT01207284|OTHER|Physical Therapy|strengthening passive and active stretching balance training gait training
219423796|NCT00683813|BEHAVIORAL|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
219423797|NCT04059471|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
219423798|NCT03081598|DRUG|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
219423799|NCT03081598|OTHER|Placebo|Placebo soft gelatine capsule
219423800|NCT06380764|PROCEDURE|Greater Occipital Nerve Block|"The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance."
219423801|NCT06380764|PROCEDURE|Bilateral suboccipital intramuscular injection|Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
219423802|NCT06380764|PROCEDURE|Epidural Blood Patch|Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
219423803|NCT06380764|DRUG|Normal Saline 10 mL Injection|Placebo drug
219423804|NCT06380764|DRUG|Lidocaine 2% Injectable Solution|Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
219423805|NCT04154657|PROCEDURE|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
219423806|NCT05739357|DEVICE|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
219575384|NCT05240131|DRUG|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
219575385|NCT04744324|BEHAVIORAL|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
219575386|NCT04744324|BEHAVIORAL|Home health education|Individualized home health education
219575387|NCT00337441|DRUG|Epoetin Alfa (drug)|
219575388|NCT02577341|DRUG|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
219575389|NCT02577341|DRUG|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
219575390|NCT02577341|RADIATION|daily RT to the chest|Patients received daily RT to the chest
219575391|NCT04648124|DEVICE|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
219575392|NCT00869024|BIOLOGICAL|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
219575393|NCT04054284|DIETARY_SUPPLEMENT|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
219575394|NCT04054284|DIETARY_SUPPLEMENT|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
219423807|NCT06418568|DEVICE|Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
219423808|NCT02057367|DRUG|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
219423809|NCT02057367|DRUG|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
219575395|NCT06231719|OTHER|Cold Spray|Using cold spray for injection site before the Anti-D immunglobulin injection. 2 sprays of cold spray are applied from a distance of 25 cm.
219423810|NCT00278941|DRUG|Quetiapine Fumarate Sustained Release|
219423811|NCT03392441|OTHER|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
219423812|NCT02281968|DRUG|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
219423813|NCT02281968|DRUG|Placebo|
219423814|NCT05143567|OTHER|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
219423815|NCT05143567|OTHER|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
219423816|NCT05143567|OTHER|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
219423817|NCT04807101|DRUG|midazolam alone|elimination of fentanyl from conscious sedation
219423818|NCT02254551|DRUG|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
219423819|NCT02254551|DRUG|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
219423820|NCT02539719|DRUG|SC-003|
219423821|NCT02539719|DRUG|SC-003 in combination with ABBV-181|
219575396|NCT06231719|OTHER|Manuel Pressure|Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
219575397|NCT06231719|OTHER|Standard Injection Procedure|Using any special method for injection
219575398|NCT01079884|DRUG|esomeprazole 40 mg|40 mg daily for 4 weeks
219575399|NCT06138119|BEHAVIORAL|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
219005807|NCT06969651|BEHAVIORAL|Non Food-Few|"Ads with Few likes featuring a non-food product"
219423822|NCT01598207|DRUG|Marinol|5mg BID, orally for 1 month
219423823|NCT01598207|DRUG|Placebo|5mg BID, orally for 1 month
219423824|NCT04678297|BEHAVIORAL|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
219575400|NCT00377936|DRUG|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
219575401|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
219575402|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
219575403|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
219575404|NCT04248348|DRUG|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
219575405|NCT02213952|DRUG|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
219575406|NCT02213952|OTHER|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
219575407|NCT04293549|DRUG|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
219575408|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
219423825|NCT04678297|BEHAVIORAL|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
219575409|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
219575410|NCT01828710|DIETARY_SUPPLEMENT|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
219575411|NCT02216019|OTHER|Whole blood|preoparatoire whole blood and postoperative whole blood
219575412|NCT03023514|DIETARY_SUPPLEMENT|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
219575413|NCT03023514|DRUG|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
219575414|NCT01023295|DRUG|fosbretabulin|single dose, intravenous infusion
219575415|NCT01023295|DRUG|Saline|single dose, intravenous infusion
219575416|NCT03657108|RADIATION|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
219575417|NCT03657108|RADIATION|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
219575418|NCT03657108|RADIATION|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
219575419|NCT00922558|OTHER|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
219575420|NCT05070702|DRUG|CT-1500|Hard Capsule
219575421|NCT05070702|DRUG|Placebo|Hard Capsule
219575422|NCT00703508|DRUG|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
219575423|NCT01064323|DEVICE|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
219575424|NCT00831623|RADIATION|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
219575425|NCT00831623|RADIATION|Proton|As above
219575426|NCT01252849|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
219575427|NCT01252849|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
219575428|NCT01252849|DEVICE|iStent|Implantation of Three iStents through a small temperal clear corneal incision
219575429|NCT05342207|PROCEDURE|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
219423826|NCT05399849|BEHAVIORAL|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
219423827|NCT05451472|DIAGNOSTIC_TEST|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
219423828|NCT05451472|DIAGNOSTIC_TEST|complete blood count|complete blood count
219423829|NCT05451472|DIAGNOSTIC_TEST|serum creatinine|serum creatinine
219423830|NCT05451472|DIAGNOSTIC_TEST|blood urea|blood urea
219575430|NCT01758146|DRUG|Tamoxifen|20 mg once daily for 5 years
219575431|NCT01758146|DRUG|Letrozole|Letroz, Femara, Letronat
219575432|NCT01443559|GENETIC|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
219575433|NCT01443559|GENETIC|homogenic cornea|homogenic corneas were sterilised by radiation
219575434|NCT03621319|DEVICE|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
219575435|NCT03621319|DEVICE|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
219575436|NCT03357887|OTHER|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
219575437|NCT05307887|DEVICE|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
219575438|NCT00998972|DRUG|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
219575439|NCT01564459|DRUG|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
219575440|NCT01564459|DRUG|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
219005808|NCT04073069|DRUG|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219005809|NCT04073069|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219005810|NCT04557371|OTHER|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
219423831|NCT05451472|DIAGNOSTIC_TEST|serum electrolyte|serum electrolyte
219423832|NCT05451472|DIAGNOSTIC_TEST|serum calcium|serum calcium
219575441|NCT01988168|PROCEDURE|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
219575442|NCT01988168|PROCEDURE|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
219423833|NCT05451472|DIAGNOSTIC_TEST|serum phosphorus|serum phosphorus
219423834|NCT05451472|DIAGNOSTIC_TEST|parathyroid hormone level|parathyroid hormone level
219423835|NCT05451472|DIAGNOSTIC_TEST|liver function test|ALT\_AST\_Total biliruin\_total protein \_serum albumin
219423836|NCT05451472|DIAGNOSTIC_TEST|arterial blood gases|PH\_PCO2\_PO2\_HCO3\_base deficit
219423837|NCT05451472|DIAGNOSTIC_TEST|complete urine analysis|complete urine analysis
219423838|NCT06482580|OTHER|PNF exercise|Ankle and foot exercises practiced for 6 weeks.
219423839|NCT06482580|OTHER|Clam exercise|Hip exercise practiced for 6 weeks.
219423840|NCT06482580|OTHER|Short-foot exercise|Foot exercise practiced together for 6 weeks.
219575443|NCT03951584|OTHER|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
219575444|NCT06374966|DRUG|Zonisamide|This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
219575445|NCT02957266|RADIATION|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
219575446|NCT02957266|RADIATION|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
219575447|NCT02957266|DRUG|Cisplatin|Weekly Cisplatin
219575448|NCT02957266|DRUG|Gemcitabine|Weekly Gemcitabine
219575449|NCT02957266|GENETIC|PIK3CA|PIK3CA mutations rate
219575450|NCT02957266|GENETIC|KRAS|KRAS mutations rate
219575451|NCT02957266|GENETIC|BRAF|BRAF mutations rate
219575452|NCT02957266|GENETIC|RRM1|RRM1 mutations rate
219575453|NCT00106938|DEVICE|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
219575454|NCT00106938|PROCEDURE|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
219575455|NCT00278187|BIOLOGICAL|volociximab|
219575456|NCT00278187|DRUG|erlotinib hydrochloride|
219575457|NCT03096275|DRUG|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
219423841|NCT02771652|BEHAVIORAL|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
219423842|NCT02771652|OTHER|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
219423843|NCT02591004|DRUG|Magesium sulphate|\*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
219423844|NCT02591004|DRUG|Nifedipine|\*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
219423845|NCT02591004|RADIATION|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
219423846|NCT04573205|DRUG|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
219423847|NCT04157868|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
219423848|NCT04157868|DRUG|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
219423849|NCT04865185|DIAGNOSTIC_TEST|Xylocaine spray 100mg/ml|Topical application
219423850|NCT04865185|DIAGNOSTIC_TEST|Ethanol|Topical application
219423851|NCT04404023|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
219423852|NCT01028833|OTHER|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
219423853|NCT03989752|DEVICE|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
219423854|NCT04641819|DRUG|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
219423855|NCT04641819|OTHER|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
219575458|NCT03096275|DRUG|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
219575459|NCT03096275|DRUG|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
219575460|NCT03096275|DRUG|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
219575461|NCT03096275|DRUG|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
219575462|NCT00070538|DRUG|cytarabine|
219005811|NCT04557371|OTHER|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
219005812|NCT04557371|OTHER|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
219005813|NCT02356224|DRUG|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
219005814|NCT02356224|DRUG|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
219005815|NCT01217840|DRUG|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
219423856|NCT02716194|BIOLOGICAL|BAX 826|
219423857|NCT02716194|BIOLOGICAL|Octocog alfa|
219423858|NCT02325687|PROCEDURE|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
219423859|NCT00648661|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
219423860|NCT00648661|DRUG|Lexapro® Tablets 20 mg|20mg, single dose fed
219423861|NCT03585673|DRUG|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
219423862|NCT03585673|DRUG|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
219423863|NCT01053702|DRUG|R475|IV
219423864|NCT01053702|DRUG|Placebo|Placebo
219423865|NCT01684683|DRUG|Theophylline|Theophylline 0.1 bid
219423866|NCT01684683|DRUG|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
219575463|NCT00070538|DRUG|laromustine|
219423867|NCT05414149|PROCEDURE|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
219423868|NCT06068179|DRUG|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
219423869|NCT06068179|DRUG|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
219423870|NCT00971425|BIOLOGICAL|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
219423871|NCT00971425|BIOLOGICAL|Fluarix™|1 dose intramuscular injection
219423872|NCT00971425|BIOLOGICAL|Placebo|1 dose intramuscular injection
219423873|NCT00171106|DRUG|valsartan|
219423874|NCT00966810|PROCEDURE|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
219423875|NCT06418126|BIOLOGICAL|blood sampling before radiotherapy|A blood sample (20 ml) will be taken prior to radiotherapy
219423876|NCT06418126|BIOLOGICAL|blood sampling after the fourth radiotherapy session|A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
219575464|NCT04109859|DRUG|Saline|When using saline, if found mean arterial pressure \<65mmHg, Cardic Output\>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
219575465|NCT04109859|DRUG|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
219575466|NCT02416011|BEHAVIORAL|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
219575467|NCT02416011|BEHAVIORAL|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
219575468|NCT00366041|DRUG|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
219005816|NCT01217840|DRUG|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
219423877|NCT06418126|OTHER|collection of acute toxicity (radiodermatitis)|for the entire duration of radiotherapy
219423878|NCT06418126|OTHER|collection of late toxicity|every year for 5 years
219423879|NCT06418126|OTHER|collection of disease status|throughout the study
219423880|NCT06418126|RADIATION|Radiotherapy - Breast +/- lymph node areas|40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
219423881|NCT06418126|RADIATION|Radiotherapy - Boost operating bed|10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
219423882|NCT01811381|DRUG|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
219423883|NCT01811381|BEHAVIORAL|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
219423884|NCT01811381|BEHAVIORAL|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
219423885|NCT01811381|DIETARY_SUPPLEMENT|Placebo|Subjects will take 4 capsules x BID of placebo
219423886|NCT03573440|OTHER|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
219423887|NCT04469803|BEHAVIORAL|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
219423888|NCT04101448|OTHER|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
219423889|NCT00425568|DRUG|AndroGel (Transdermal Testosterone Gel)|
219423890|NCT02297737|BEHAVIORAL|Tai Chi|
219423891|NCT02297737|OTHER|Health Education|
219423892|NCT03067194|DRUG|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
219423893|NCT03067194|DRUG|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
219423894|NCT05197140|OTHER|food: cooked 85% lean ground beef|see arm description
219423895|NCT05197140|OTHER|food: Impossible Burger (R)|see arm description
219423896|NCT00407173|DRUG|HCV-796|HCV-796 1000mg single dose
219423897|NCT05066633|DRUG|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
219575469|NCT00366041|DEVICE|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
219575470|NCT03794791|BEHAVIORAL|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
219575471|NCT03794791|BEHAVIORAL|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
219575472|NCT02030483|DRUG|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
219575473|NCT02030483|DRUG|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
219575474|NCT02030483|DRUG|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
219575475|NCT01431443|OTHER|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
219575476|NCT01431443|OTHER|Placebo Chocolate|Placebo intervention
219575477|NCT00068081|DRUG|Capsaicin Dermal Patch|
219423898|NCT05066633|DRUG|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
219423899|NCT02294422|DEVICE|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
219423900|NCT02294422|DEVICE|LOR|
219423901|NCT02294422|DEVICE|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
219423902|NCT04255017|DRUG|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
219575478|NCT05278572|BEHAVIORAL|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
219423903|NCT04255017|DRUG|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
219423904|NCT04255017|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
219423905|NCT02030587|PROCEDURE|Radiofrequency Ablation|
219423906|NCT02030587|PROCEDURE|Laparoscopic Adrenalectomy|
219423907|NCT06064903|BIOLOGICAL|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
219423908|NCT01705964|DRUG|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
219423909|NCT01705964|OTHER|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
219423910|NCT04944381|BIOLOGICAL|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
219575479|NCT00706992|BIOLOGICAL|ALVAC-MART-1 vaccine|Given subcutaneously
219575480|NCT00706992|BIOLOGICAL|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
219575481|NCT00706992|BIOLOGICAL|Aldesleukin|Given subcutaneously
219575482|NCT00706992|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
219575483|NCT00706992|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
219575484|NCT00702208|DEVICE|Delphi Screener|Self-sampling device for cervical vaginal lavage
219575485|NCT00839059|DRUG|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
219575486|NCT03848169|OTHER|Radiofrequency|See previous page
219575487|NCT06371144|DRUG|Paracetamol|Analgestic
219575488|NCT02746627|BEHAVIORAL|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
219575489|NCT02746627|BEHAVIORAL|Education|Educational materials on diabetes management
219005817|NCT04358120|DEVICE|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
219005818|NCT00897104|DRUG|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
219423911|NCT04944381|BIOLOGICAL|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
219423912|NCT00627770|DEVICE|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
219005819|NCT00897104|DRUG|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
219191228|NCT06199089|DRUG|Placebo Injection|"Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration."
219575490|NCT06316713|BEHAVIORAL|One MORE (Spanish Adaptation)|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
219575491|NCT04117737|OTHER|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
219423913|NCT01753830|DEVICE|Durolane|4.5 mL
219423914|NCT01753830|DEVICE|PBS|4.5 mL
219423915|NCT02045251|DRUG|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
219423916|NCT01697852|OTHER|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
219423917|NCT01697852|OTHER|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
219575492|NCT01122589|BEHAVIORAL|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
219575493|NCT01122589|OTHER|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
219191229|NCT04674826|DRUG|Tralokinumab administered as 1 × X mL with Device A|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
219423918|NCT04698109|OTHER|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
219575494|NCT00697840|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 doses
219575495|NCT00697840|BIOLOGICAL|HBV-MPL 208129|Intramuscular injection, 2 doses
219575496|NCT00697840|BIOLOGICAL|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
219423919|NCT04698109|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219423920|NCT04698109|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
219423921|NCT01322451|DRUG|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
219423922|NCT01322451|DRUG|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
219423923|NCT00502632|DRUG|Urokinase and Dornase alfa|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
219423924|NCT00502632|DRUG|Urokinase|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
219423925|NCT03336762|DIAGNOSTIC_TEST|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
219423926|NCT03336762|DIAGNOSTIC_TEST|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
219423927|NCT03587584|DRUG|liposomal bupivacaine|Experimental
219423928|NCT03587584|DRUG|Bupivacaine|Active Comparator
219575497|NCT04596397|OTHER|Inpatient setting|These women stay at the hospital.
219575498|NCT04596397|OTHER|Outpatient setting|These women can leave the hospital.
219575499|NCT04812639|OTHER|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
219423929|NCT04230798|OTHER|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
219423930|NCT04142749|DRUG|Oltipraz|Total 90mg, By mouth, TID
219423931|NCT04142749|DRUG|Placebos|Total 90mg, By mouth, TID
219423932|NCT02152358|DRUG|Aciclovir|Intravenous 15 mg/kg/d during 14 days
219005820|NCT00897104|DRUG|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
219423933|NCT02152358|DRUG|Ganciclovir|intravenous 10 mg/kg/d for 14 days
219423934|NCT02152358|DRUG|Placebo|
219423935|NCT01001858|OTHER|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
219423936|NCT00387348|DRUG|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
219423937|NCT00387348|DRUG|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
219423938|NCT05094895|PROCEDURE|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
219423939|NCT05094895|PROCEDURE|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
219423940|NCT03010722|DRUG|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
219423941|NCT04579796|OTHER|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
219423942|NCT04579796|PROCEDURE|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
219575500|NCT04812639|OTHER|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
219575501|NCT04847596|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
219575502|NCT04847596|OTHER|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
219575503|NCT05294835|DRUG|Ketamine|ketamine infusion
219575504|NCT02498535|DRUG|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
219575505|NCT03052972|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
219005821|NCT03649750|DRUG|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
219423943|NCT05905757|PROCEDURE|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
219423944|NCT05905757|DRUG|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
219423945|NCT06180668|PROCEDURE|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
219575506|NCT03052972|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
219575507|NCT05296382|DRUG|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
219005822|NCT06350825|PROCEDURE|Cytoreductive prostatectomy or brachytherapy|local treatment+SOC for metastatic prostate cancer
219005823|NCT06350825|DRUG|ADT+second-generation antiandrogens ± chemotherapy|SOC(Triplet or doublet therapy) for mHSPC
219005824|NCT05776199|DIAGNOSTIC_TEST|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
219423946|NCT02501837|DRUG|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
219423947|NCT01755741|COMBINATION_PRODUCT|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
219423948|NCT01755741|DEVICE|Condom|Male condom
219423949|NCT00278863|DRUG|S-1|
219423950|NCT00278863|DRUG|Capecitabine|
219423951|NCT03421509|OTHER|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
219423952|NCT05066867|OTHER|Smart sharps bin - collects data on compliance|collects compliance data
219423953|NCT02349737|OTHER|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
219575508|NCT05296382|OTHER|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
219575509|NCT00919178|BIOLOGICAL|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
219191230|NCT04674826|DEVICE|Tralokinumab administered as 2 × Y mL with Device B|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
219423954|NCT00505752|DRUG|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
219575510|NCT00919178|BIOLOGICAL|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
219575511|NCT06293443|OTHER|Lower extremity unilateral amputee|To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
219575512|NCT06368557|BEHAVIORAL|CoolMinds: Internet-based cognitive behavioral therapy (iCBT)|The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
219575513|NCT00236249|DRUG|Lidocaine|
219575514|NCT05946902|DRUG|tolterodine|tolterodine 4 mg per day
219575515|NCT05946902|DRUG|mirabegron|mirabegron 25 mg per day
219575516|NCT05946902|DRUG|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
219005825|NCT03336047|BEHAVIORAL|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
219005826|NCT03336047|BEHAVIORAL|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
219005827|NCT04834076|DIAGNOSTIC_TEST|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
219005828|NCT04834076|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
219005829|NCT04834076|DIAGNOSTIC_TEST|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
219005830|NCT00671892|BIOLOGICAL|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
219423955|NCT00505752|DRUG|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
219423956|NCT00505752|DRUG|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
219759922|NCT06098326|DRUG|cyclophosphamide, fludarabine, and antithymocyte globulin|"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"
219759923|NCT06101810|BEHAVIORAL|COMET|information already included in arm/group descriptions.
219759924|NCT06101810|BEHAVIORAL|CBT|information already included in arm/group descriptions.
219005831|NCT06472063|OTHER|pre- or perioperative treatment and D2 gastrectomy|pre- or perioperative treatment and D2 gastrectomy
219423957|NCT00505752|DRUG|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
219423958|NCT00505752|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
219575517|NCT06232239|DRUG|Empagliflozin-Test product|Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand
219575518|NCT06232239|DRUG|Empagliflozin-Reference product|Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
219575519|NCT05098002|BEHAVIORAL|Mindfulness program|6 week class designed to improve psychological well-being
219575520|NCT05466175|DRUG|Olverembatinib|Given PO
219575521|NCT05466175|DRUG|Prednisone|Given Intravenous
219575522|NCT05466175|DRUG|Vincristine|Given Intravenous
219759925|NCT01465841|DEVICE|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
219759926|NCT05905562|OTHER|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
219423959|NCT05525312|PROCEDURE|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
219575523|NCT04940702|OTHER|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
219575524|NCT04940702|OTHER|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
219423960|NCT05525312|PROCEDURE|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
219423961|NCT03046017|DEVICE|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
219423962|NCT03046017|OTHER|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
219423963|NCT03046017|OTHER|Control cream|A neutral cream will be applied as a control.
219423964|NCT04163107|DRUG|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
219423965|NCT04163107|DRUG|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
219423966|NCT04163107|DRUG|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
219423967|NCT00022958|DRUG|Iodine-131 Anti-B1 Antibody|
219423968|NCT04618926|DEVICE|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
219423969|NCT06308146|DIETARY_SUPPLEMENT|Bacillus subtilis ATCC 122264|One capsule (5 billion CFU) per day for 8 weeks.
219423970|NCT06308146|DIETARY_SUPPLEMENT|Placebo|One capsule per day for 8 weeks.
219423971|NCT05987345|DEVICE|PEF|PEF device treated in the trial.
219423972|NCT05987345|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
219575525|NCT04940702|OTHER|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
219575526|NCT02336620|DRUG|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
219423973|NCT01925612|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
219423974|NCT01925612|DRUG|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
219423975|NCT01925612|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
219423976|NCT01925612|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
219423977|NCT01925612|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
219423978|NCT01925612|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
219423979|NCT01925612|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
219423980|NCT02591888|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
219423981|NCT02591888|DRUG|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
219423982|NCT02778945|DRUG|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
219423983|NCT02778945|DRUG|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
219423984|NCT03331224|DEVICE|OTSC|OTSC placement
219575527|NCT02336620|DRUG|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
219575528|NCT03010618|OTHER|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
219575529|NCT01233843|DRUG|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
219575530|NCT01233843|DRUG|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
219575531|NCT01233843|RADIATION|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
219575532|NCT03163849|DRUG|Sofosbuvir , daclatasvir|Tablets
219575533|NCT03163849|DRUG|Placebos|oral tablets
219575534|NCT01876849|DRUG|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
219423985|NCT03331224|DEVICE|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
219423986|NCT01009918|DRUG|Coreg CR®|Given orally
219423987|NCT01009918|DRUG|lisinopril|Given orally
219423988|NCT01009918|OTHER|placebo|Given orally
219423989|NCT05848180|OTHER|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
219423990|NCT05848180|OTHER|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
219423991|NCT06020573|DEVICE|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
219423992|NCT04229069|DIETARY_SUPPLEMENT|alkaline salt mixture|blood and tissue alkalinisation
219423993|NCT04229069|DIETARY_SUPPLEMENT|placebo|no blood and tissue alkalinisation
219423994|NCT01537094|DIETARY_SUPPLEMENT|Placebo|
219423995|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 250 mg once daily|
219423996|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 1,000 mg once daily|
219423997|NCT02547519|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
219423998|NCT02547519|DRUG|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
219575535|NCT02858648|BEHAVIORAL|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
219575536|NCT02858648|BEHAVIORAL|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
219575537|NCT00588640|DRUG|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
219005832|NCT04981951|DRUG|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
219575538|NCT00588640|DRUG|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
219575539|NCT00588640|DRUG|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
219575540|NCT02744599|DEVICE|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
219575541|NCT05114759|DRUG|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
219575542|NCT03898895|COMBINATION_PRODUCT|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
219005833|NCT03730246|PROCEDURE|cesarean sectio|consecutive parturients due for cesarean sectio
219423999|NCT00634465|DEVICE|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
219424000|NCT04624672|DRUG|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
219424001|NCT04624672|DRUG|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
219424002|NCT01216904|DRUG|nicotine patch|7 mg patches to be worn for 16 hours per day
219424003|NCT01216904|DRUG|placebo|placebo patch to be worn 16 hours per day
219424004|NCT03472040|DRUG|BCX7353|BCX7353 mg oral capsules administered once daily
219424005|NCT02072694|OTHER|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
219424006|NCT02072694|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
219424007|NCT04669145|DRUG|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
219424008|NCT02932150|DRUG|TAF|Administered orally once daily
219424009|NCT02932150|DRUG|Placebo|Administered orally once daily
219424010|NCT03064568|DRUG|Misoprostol 200Mcg Tab|4 tablets will be inserted rectally
219424011|NCT03064568|DRUG|Placebo|
219424012|NCT04473781|PROCEDURE|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
219424013|NCT06226103|OTHER|Aerobic Exercise and Computerized Cognitive Training|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function."
219424014|NCT06226103|OTHER|Conventional Exercises and Brain health lectures|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
219424015|NCT04874480|DRUG|Decitabine|Given IV
219424016|NCT04874480|DRUG|Tegavivint|Given IV
219424017|NCT04568317|BEHAVIORAL|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
219424018|NCT04568317|DEVICE|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
219424019|NCT04308473|OTHER|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
219424020|NCT04308473|OTHER|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
219424021|NCT01596530|DRUG|Drug-AZD8931|Active drug for biological activity
219424022|NCT01596530|DRUG|Drug-Placebo|Placebo comparator for biological activity comparison
219424023|NCT06042530|DIAGNOSTIC_TEST|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
219424024|NCT06042530|DIAGNOSTIC_TEST|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
219575543|NCT03606720|OTHER|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
219424025|NCT06042530|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
219424026|NCT06042530|DIAGNOSTIC_TEST|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
219424027|NCT04568187|DEVICE|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
219424028|NCT04568187|DEVICE|placebo|radiofrequency with 3000 Hz
219424029|NCT02204813|DRUG|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
219424030|NCT02204813|DRUG|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
219424031|NCT02204813|DRUG|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
219424032|NCT02204813|DRUG|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
219424033|NCT02765503|RADIATION|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
219424034|NCT03874351|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
219424035|NCT01510223|DIETARY_SUPPLEMENT|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
219424036|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
219424037|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
219424038|NCT01510223|DIETARY_SUPPLEMENT|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
219424039|NCT00004696|DRUG|morphine|
219759927|NCT05905562|OTHER|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
219424040|NCT00225147|DRUG|Recombinant Human C1 Inhibitor|IV
219424041|NCT00225147|DRUG|placebo|saline solution
219424042|NCT03522883|DIETARY_SUPPLEMENT|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
219424043|NCT01867645|DRUG|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
219759928|NCT02536664|DRUG|Rituximab|
219759929|NCT04780139|DIAGNOSTIC_TEST|Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area|Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia.
219759930|NCT00549159|DEVICE|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
219759931|NCT00549159|DEVICE|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
219759932|NCT04265131|OTHER|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
219759933|NCT04655157|DRUG|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
219424044|NCT01867645|DRUG|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
219424045|NCT05060796|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
219424046|NCT00222742|PROCEDURE|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
219424047|NCT01121003|BEHAVIORAL|weight maintenance, low sugar diet|
219424048|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet|
219424049|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet+ exercise|
219424050|NCT01729572|OTHER|Tele-medicine monitoring of medication adherence|
219424051|NCT03713216|DRUG|Naldebain|150 mg Nalbuphine sebacate
219424052|NCT03713216|DRUG|Morphine|Morphine
219424053|NCT04169113|OTHER|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
219424054|NCT04169113|OTHER|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
219424055|NCT01285063|OTHER|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
219424056|NCT02685995|DEVICE|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
219424057|NCT02685995|DEVICE|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
219424058|NCT03823040|DRUG|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
219424059|NCT03823040|DRUG|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
219424060|NCT03625141|DRUG|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
219424061|NCT03625141|DRUG|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
219424062|NCT03625141|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
219424063|NCT04429152|DRUG|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
219424064|NCT05558241|DEVICE|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
219424065|NCT03937193|DIAGNOSTIC_TEST|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
219424066|NCT00193219|DRUG|Bevacizumab|5 mg/kg IV
219759934|NCT04655157|DRUG|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
219759935|NCT04655157|DRUG|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
219759936|NCT04655157|DRUG|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
219759937|NCT02728024|OTHER|Missing items, Errors in Completion, Difficulties|
219759938|NCT03507127|DRUG|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
219759939|NCT03507127|DRUG|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
219759940|NCT03655067|BEHAVIORAL|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
219759941|NCT04534673|DRUG|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
219424067|NCT00193219|DRUG|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
219424068|NCT00193219|DRUG|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
219424069|NCT00193219|DRUG|Leucovorin|350 mg IV
219424070|NCT00193219|DRUG|Oxaliplatin|85 mg/m2 IV
219424071|NCT03151252|DIAGNOSTIC_TEST|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
219424072|NCT05167461|OTHER|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of \>95% compared to human assessment
219424073|NCT01900678|DEVICE|VytronUS Ablation System|Pulmonary vein isolation.
219424074|NCT02580994|DRUG|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
219424075|NCT02580994|DRUG|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
219424076|NCT00868166|DRUG|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
219424077|NCT00868166|DRUG|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
219759942|NCT04051177|BEHAVIORAL|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
219759943|NCT04051177|BEHAVIORAL|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
219759944|NCT00335166|DRUG|Pardaprunox|12-42 mg
219759945|NCT00335166|DRUG|pramipexole|1.5-4.5 mg
219759946|NCT00335166|DRUG|Placebo Comparator|Placebo
219424078|NCT00868166|DRUG|Riluzole|Riluzole given as add-on therapy 50mg bid
219424079|NCT04121520|OTHER|Questionnaire|"1. Comprehensive perioperative assessment~2. Questionnaire administration"
219424080|NCT04191603|DEVICE|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
219424081|NCT04191603|DEVICE|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
219424082|NCT03803592|BEHAVIORAL|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
219424083|NCT06134791|OTHER|No intervention|No intervention
219424084|NCT06014294|BEHAVIORAL|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
219424085|NCT06014294|BEHAVIORAL|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
219424086|NCT06014294|BEHAVIORAL|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
219424087|NCT00240539|PROCEDURE|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
219759947|NCT01497756|DEVICE|CAPP use|Any abdominal pelvic pressure
219759948|NCT06077877|DRUG|GSK4524101|GSK452101 will be administered.
219759949|NCT06077877|DRUG|Niraparib|Niraparib will be administered.
219424088|NCT05519618|PROCEDURE|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
219575544|NCT03606720|OTHER|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
219575545|NCT00522444|DRUG|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
219424089|NCT00031499|DRUG|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
219424090|NCT00031499|DRUG|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
219424091|NCT00031499|DRUG|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
219424092|NCT02147496|OTHER|Dietary Intervention|
219424093|NCT04173052|DEVICE|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
219424094|NCT03089970|DIAGNOSTIC_TEST|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
219424095|NCT03108209|OTHER|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
219424096|NCT03108209|OTHER|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
219424097|NCT05833685|OTHER|no intervention|no intervention
219424098|NCT04856956|OTHER|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
219424099|NCT02203669|OTHER|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
219424100|NCT02203669|OTHER|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
219424101|NCT03121118|OTHER|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
219424102|NCT02625675|OTHER|Ultrasound scan|
219424103|NCT04219969|DRUG|Fludeoxyglucose F-18|Given IV
219424104|NCT04219969|DEVICE|Magnetic Resonance Imaging|Undergo PET-MRI
219424105|NCT04219969|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
219424106|NCT05093998|DRUG|AV5080|oral hard gelatin capsules
219575546|NCT00522444|OTHER|Nebulized normal saline|standard of care
219424107|NCT05093998|OTHER|Placebo|Hard gelatin capsules with a white body
219424108|NCT02819505|DIETARY_SUPPLEMENT|beta-alanine|
219424109|NCT02819505|DIETARY_SUPPLEMENT|Placebo|
219575547|NCT06071819|DIAGNOSTIC_TEST|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
219575548|NCT02614963|DRUG|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
219575549|NCT02614963|DRUG|placebo|Irritable bowel syndrome patients treated with placebo
219575550|NCT01001260|DRUG|No ASA|Alternative antiplatelet therapy instead of aspirin
219575551|NCT01001260|DRUG|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
219575552|NCT01001260|DRUG|325 mg ASA|high dose of aspirin prior to PTCA
219575553|NCT00003598|DRUG|tretinoin|
219424110|NCT00074802|DRUG|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
219424111|NCT00074802|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
219424112|NCT04331990|OTHER|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
219575554|NCT03544151|DEVICE|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
219575555|NCT00906113|DRUG|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
219575556|NCT00906113|DRUG|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
219424113|NCT04331990|OTHER|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
219424114|NCT04331990|OTHER|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
219424115|NCT00433446|BIOLOGICAL|CNTO 328|
219424116|NCT03819218|DRUG|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
219424117|NCT00225680|DEVICE|drug eluting coronary stent|
219424118|NCT02375269|DEVICE|RIPC with a tourniquet|
219424119|NCT02999880|PROCEDURE|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
219424120|NCT00456794|DRUG|Istradefylline (KW-6002)|
219424121|NCT00221429|DRUG|Lithium|lithium
219424122|NCT00221429|DRUG|sodium divalproex|Depakote
219424123|NCT00221429|OTHER|Placebo|Placebo
219424124|NCT04164329|DRUG|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
219424125|NCT05996380|DRUG|SHR-3167|SHR-3167, Single administration
219424126|NCT05996380|DRUG|SHR-3167 Placebo|SHR-3167 Placebo Single administration
219424127|NCT02267278|DRUG|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
219424128|NCT02267278|DRUG|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
219424129|NCT02267278|BEHAVIORAL|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
219424130|NCT00103571|DRUG|Olanzapine|
219424131|NCT00103571|DRUG|Aripiprazole|
219424132|NCT00650091|DRUG|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
219575557|NCT04013113|DRUG|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
219424133|NCT00650091|DRUG|Placebo|Participants will receive placebo each day.
219424134|NCT05008068|DRUG|Simvastatin|Simvastatin with PRF at site of osteotome
219424135|NCT00329134|DRUG|Administration of quinine sulphate taste-masked pellets|
219424136|NCT04319419|DIETARY_SUPPLEMENT|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
219424137|NCT04319419|OTHER|Nutrition education|Group received nutrition education program during 6 months
219424138|NCT01784588|DEVICE|Solyx Single Incision Sling System|Solyx Single Incision Sling System
219424139|NCT01784588|DEVICE|Obtryx II Sling System|Standard outside-in transobturator sling
219424140|NCT04950205|DRUG|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
219424141|NCT02645279|OTHER|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
219424142|NCT02645279|DRUG|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
219424143|NCT00255879|DRUG|Quetiapine|
219424144|NCT00255879|DRUG|Risperidone|
219424145|NCT00255879|DRUG|Olanzapine|
219424146|NCT05511025|DRUG|AZD6234|Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
219424147|NCT05511025|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC or IV injection
219575558|NCT04013113|DRUG|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
219575559|NCT04013113|OTHER|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
219424148|NCT05511025|COMBINATION_PRODUCT|Acetaminophen|Participants will receive a single dose of acetaminophen as part of a meal
219424149|NCT05006339|DEVICE|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
219424150|NCT05006339|OTHER|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
219424151|NCT02257164|PROCEDURE|Femoral nerve block|2 mg/ml
219575560|NCT02879110|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
219759950|NCT01273571|DRUG|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
219759951|NCT03368066|DRUG|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
219424152|NCT02257164|PROCEDURE|obturator nerve block|
219424153|NCT02257164|PROCEDURE|intraarticular injection|
219424154|NCT00001735|PROCEDURE|Gene therapy|
219424155|NCT04729062|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219424156|NCT02335580|DRUG|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
219424157|NCT02335580|PROCEDURE|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
219424158|NCT00258388|DRUG|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
219424159|NCT00258388|DRUG|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
219424160|NCT00258388|DRUG|prednisone|5mg PO BID
219424161|NCT04387526|DRUG|(SOF and DCV)|
219424162|NCT04387526|DRUG|(SOF, DCV, and RBV)|
219424163|NCT03176173|RADIATION|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
219424164|NCT03176173|DRUG|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
219424165|NCT02466412|OTHER|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
219424166|NCT02466412|OTHER|mCC|Single use of subject's own menthol conventional cigarette (mCC)
219575561|NCT02879110|OTHER|Placebo|Placebo tablet is composed of starch.
219575562|NCT00794482|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
219575563|NCT01920542|DRUG|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
219575564|NCT01920542|DRUG|no dexmedetomidine|no administration of dexmedetomidine on control group
219575565|NCT02021253|DIETARY_SUPPLEMENT|Probiotic|Lactibiane TOLERANCE vs Placebo
219575566|NCT02021253|DIETARY_SUPPLEMENT|Placebo|
219575567|NCT06331520|DRUG|Netupitant / Palonosetron Oral Capsule [Akynzeo]|Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
219759952|NCT00079313|DRUG|Imatinib|
219759953|NCT05407103|OTHER|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
219424167|NCT00237445|DRUG|telithromycin|
219424168|NCT00237445|DRUG|azithromycin|
219424169|NCT05928676|DIETARY_SUPPLEMENT|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
219575568|NCT06331520|DRUG|Olanzapine|Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
219424170|NCT04198233|DRUG|Diazepam|Diazepam 10 mg compounded suppository
219424171|NCT04198233|DRUG|Placebos|Placebo suppository
219424172|NCT05058898|OTHER|blood samples|5 mL
219424173|NCT05058898|OTHER|Scabs and pus samples|if available
219424174|NCT02709772|BEHAVIORAL|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
219424175|NCT03509987|DEVICE|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
219424176|NCT03620812|DIETARY_SUPPLEMENT|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
219575569|NCT06331520|DRUG|Dexamethasone Oral|synthetic glucocorticoids
219575570|NCT01198834|DRUG|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
219575571|NCT01198834|DRUG|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
219575572|NCT01198834|DRUG|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
219575573|NCT01198834|DRUG|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
219575574|NCT02726919|DRUG|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
219575575|NCT02429141|PROCEDURE|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
219424177|NCT00553137|DRUG|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
219575576|NCT02429141|PROCEDURE|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
219575577|NCT03521648|PROCEDURE|PAE|Prostatic artery embolization
219424178|NCT00553137|DRUG|fluconazole|150 mg fluconazole tablets once daily for 14 days
219424179|NCT02553317|BIOLOGICAL|Caplacizumab|"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
219575578|NCT03521648|PROCEDURE|TURP|Transurethral resection of the prostate
219575579|NCT03521648|PROCEDURE|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
219759954|NCT05407103|OTHER|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
219759955|NCT03961308|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
219759956|NCT04561856|DRUG|Dexamethasone|Intravenous 4mg
219759957|NCT04561856|DRUG|Dexamethasone|Perineural 4mg
219424180|NCT02553317|BIOLOGICAL|Placebo|"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
219424181|NCT03092349|DEVICE|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
219424182|NCT01965912|DRUG|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
219424183|NCT05521100|PROCEDURE|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
219424184|NCT05521100|PROCEDURE|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
219424185|NCT00188266|DRUG|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
219424186|NCT00406991|DRUG|aspirin|
219424187|NCT00406991|DRUG|clopidogrel|
219424188|NCT01492699|DRUG|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
219424189|NCT03070561|BIOLOGICAL|sublingual film with peanut extract|
219424190|NCT03125876|DRUG|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
219424191|NCT02204514|PROCEDURE|Surgery for external snapping hip|
219424192|NCT02439944|DRUG|Nicotine patch|
219424193|NCT02439944|DRUG|Nicotine mouthspray|
219424194|NCT00225056|DRUG|docetaxel and capecitabine|
219424195|NCT03700632|OTHER|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
219424196|NCT03661827|DIAGNOSTIC_TEST|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
219424197|NCT04597255|DEVICE|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
219424198|NCT00764400|BEHAVIORAL|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
219424199|NCT00756496|DEVICE|Mammography screening and diagnosis|Mammography screening and diagnosis
219424200|NCT02416362|OTHER|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
219424201|NCT02416362|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
219424202|NCT01869062|DEVICE|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
219424203|NCT01869062|DEVICE|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
219424204|NCT00000944|DRUG|Indinavir sulfate|
219424205|NCT00000944|DRUG|Lamivudine|
219575580|NCT06177106|OTHER|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
219424206|NCT00000944|DRUG|Zidovudine|
219424207|NCT04958616|DIAGNOSTIC_TEST|Skin prick test.|Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
219424208|NCT02678663|PROCEDURE|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
219424209|NCT02678663|PROCEDURE|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
219424210|NCT04664855|OTHER|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
219424211|NCT00057590|BEHAVIORAL|Care manager outreach and monitoring|
219424212|NCT02219087|DRUG|Liposomal bupivacaine|
219424213|NCT02219087|DRUG|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
219424214|NCT00156299|DRUG|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
219424215|NCT00156299|DRUG|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
219575581|NCT03056079|DRUG|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
219575582|NCT03811626|PROCEDURE|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
219575583|NCT01872052|DEVICE|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
219424216|NCT02477228|PROCEDURE|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
219424217|NCT02477228|PROCEDURE|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
219424218|NCT02389673|DEVICE|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
219424219|NCT01912716|DRUG|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
219424220|NCT01912716|DRUG|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
219424221|NCT00118508|DRUG|risedronate (including placebo)|risedronate 35mg weekly
219424222|NCT03829865|DIAGNOSTIC_TEST|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
219424223|NCT04387994|OTHER|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
219424224|NCT05696262|BEHAVIORAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
219575584|NCT01025219|GENETIC|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
219575585|NCT00093951|DRUG|SGS742|
219575586|NCT02428686|DRUG|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
219575587|NCT02882672|OTHER|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
219575588|NCT02882672|OTHER|Control|They did not do ant exercise training during 8 weeks.
219575589|NCT03257904|PROCEDURE|intracranial pressure monitoring|measurement of intracranial pressure
219575590|NCT04177563|OTHER|whole body cryostimulation|Whole-body cryotherapy
219575591|NCT01795742|DEVICE|Human-Powered Nebulizer|
219575592|NCT04075552|BEHAVIORAL|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
219424225|NCT03435263|OTHER|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
219424226|NCT01714752|PROCEDURE|measure of left ventricular and diastolic pressure at exercise|
219424227|NCT05412472|DRUG|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
219424228|NCT01833104|BEHAVIORAL|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
219424229|NCT01833104|BEHAVIORAL|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
219575593|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
219575594|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
219575595|NCT00603291|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
219575596|NCT00603291|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
219191231|NCT05995054|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
219191232|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
219424230|NCT01833104|BEHAVIORAL|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
219759958|NCT04561856|DRUG|Placebo|Normal Saline 2ml
219575597|NCT00603291|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
219575598|NCT00261963|DEVICE|ultraviolet light|
219575599|NCT05783661|OTHER|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
219191233|NCT04954677|OTHER|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
219424231|NCT04803968|OTHER|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
219424232|NCT04803968|OTHER|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
219424233|NCT03064958|OTHER|Herbs and spices|Mix of commonly used herbs and spices
219575600|NCT05783661|OTHER|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
219575601|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
219759959|NCT05690425|DRUG|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
219759960|NCT00000857|DRUG|Interleukin-12|
219424234|NCT03064958|OTHER|High fat meal|Meal containing 1000kcal and 45g fat
219424235|NCT01230736|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
219424236|NCT02292316|BEHAVIORAL|gait and cognitive assessments|several tests are given in each domain
219424237|NCT02292316|BIOLOGICAL|blood sample|routine analyses in rheumatology such blood count and 25OH-D
219424238|NCT02292316|OTHER|osteodensitometry|Looking for osteoporosis
219424239|NCT00005060|DRUG|Taxotere-Cisplatin-5FU|Preoperatively
219424240|NCT00005060|DRUG|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
219424241|NCT00935519|DEVICE|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
219424242|NCT03454412|PROCEDURE|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
219424243|NCT03360136|BEHAVIORAL|Multi-professional CBT-rehabilitation|"See Detailed description"
219424244|NCT00490659|DRUG|gemcitabine|
219424245|NCT00490659|DRUG|cisplatin|
219424246|NCT00490659|PROCEDURE|radical surgery|
219424247|NCT00490659|PROCEDURE|chemoradiotherapy|
219575602|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
219575603|NCT03967951|OTHER|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
219575604|NCT00003138|BIOLOGICAL|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
219575605|NCT00003138|BIOLOGICAL|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
219575606|NCT00003138|PROCEDURE|Transfusion|Red cell and platelet transfusions
219575607|NCT00102518|DRUG|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
219575608|NCT00107705|BIOLOGICAL|Tree MATA MPL|
219575609|NCT03093818|OTHER|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
219005834|NCT00959309|BEHAVIORAL|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
219005835|NCT00959309|BEHAVIORAL|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
219005836|NCT00572585|DRUG|AEB071|
219424248|NCT04793854|OTHER|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…)."
219424249|NCT02836860|OTHER|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
219424250|NCT03441568|DEVICE|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
219424251|NCT03267992|BEHAVIORAL|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
219575610|NCT05142566|DEVICE|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
219759961|NCT03150537|BIOLOGICAL|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
219759962|NCT06154603|PROCEDURE|Surgical treatment type|This observational design will study the clinical outcome for each type of upper gastrointestinal perforation in relation to surgical or non-surgery treatment and in relation to treatment centre.
219759963|NCT04179422|OTHER|anthropometric measurement|weight, height, BMI
219005837|NCT00572585|DRUG|Placebo|
219424252|NCT01839201|OTHER|control|No psychological intervention
219424253|NCT01839201|OTHER|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
219759964|NCT04179422|OTHER|nutritional questionnaire|24hs food recall, presence of feeding disorders
219759965|NCT06008977|OTHER|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
219759966|NCT05207384|PROCEDURE|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
219759967|NCT05207384|PROCEDURE|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
219759968|NCT06168396|DEVICE|Somatosensation Device|The somatosensation device will be worn on the lower limb (either the residual limb for an amputee, or limb with decreased sensation for a participant with diabetic neuropathy) while performing outcome measures.
219759969|NCT06168396|OTHER|Baseline|Participants will perform outcome measures without wearing the somatosensation device.
219424254|NCT01839201|OTHER|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
219424255|NCT01518244|DRUG|Brinzolamide/timolol maleate fixed combination|
219424256|NCT00955292|DRUG|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
219575611|NCT00969319|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
219005838|NCT00636142|BIOLOGICAL|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
219005839|NCT01144923|OTHER|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
219005840|NCT01144923|PROCEDURE|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
219424257|NCT01144234|BEHAVIORAL|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
219424258|NCT01144234|BEHAVIORAL|Information letter|In this arm the pregnant women got an information letter
219575612|NCT02710513|DIETARY_SUPPLEMENT|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
219191234|NCT04621643|BEHAVIORAL|digital cognitive behavioral therapy (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
219424259|NCT04119817|DIETARY_SUPPLEMENT|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
219424260|NCT04119817|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
219424261|NCT02902913|OTHER|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
219424262|NCT02902913|OTHER|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
219424263|NCT02902913|OTHER|D2i0|No oleocanthal and no oleacein
219424264|NCT02902913|DRUG|Ibuprofen|400 mg of Ibuprofen
219575613|NCT03732261|OTHER|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
219575614|NCT00400621|DRUG|acetaminophen|
219575615|NCT04180553|DIAGNOSTIC_TEST|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
219575616|NCT04180553|OTHER|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
219575617|NCT04718194|BEHAVIORAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
219575618|NCT04718194|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
219759970|NCT06220084|BEHAVIORAL|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
219424265|NCT00674518|BEHAVIORAL|One on one counseling|Motivational Interviewing
219424266|NCT00674518|BEHAVIORAL|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
219424267|NCT00674518|BEHAVIORAL|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
219424268|NCT01766817|DRUG|BMS-986020|
219424269|NCT01766817|DRUG|Placebo matching with BMS-986020|
219424270|NCT01236313|PROCEDURE|TEE report|Information will be collected during cardiac surgery.
219424271|NCT04900038|DRUG|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
219424272|NCT04900038|DRUG|Dolutegravir|DTG was available as 50 mg tablets administered orally.
219424273|NCT04900038|DRUG|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
219424274|NCT04900038|DRUG|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
219424275|NCT05166759|DEVICE|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
219424276|NCT00094887|DRUG|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
219424277|NCT00094887|DRUG|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
219424278|NCT02878733|DRUG|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
219424279|NCT00004799|BIOLOGICAL|whole-cell pertussis vaccine|
219424280|NCT00004799|BIOLOGICAL|diphtheria-tetanus vaccine|
219759971|NCT00135083|DRUG|insulin glulisine|"* Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
219424281|NCT04810299|OTHER|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
219424282|NCT04810299|OTHER|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
219424283|NCT04675359|PROCEDURE|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
219424284|NCT00258206|BIOLOGICAL|rituximab|
219424285|NCT00258206|DRUG|cyclophosphamide|
219424286|NCT01843400|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
219424287|NCT01333852|DRUG|metformin up to 2500mg/d|metformin up to 2500mg/d
219575619|NCT05124561|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
219575620|NCT05124561|BIOLOGICAL|Placebo|Nebulized inhalation through the mouth
219575621|NCT01108666|DRUG|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
219575622|NCT00564226|DRUG|SSR240600C|oral administration
219575623|NCT00564226|DRUG|tolterodine|oral administration
219575624|NCT00564226|DRUG|placebo|oral administration
219575625|NCT04064619|DRUG|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
219575626|NCT05461118|PROCEDURE|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
219575627|NCT06168318|DRUG|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
219575628|NCT06168318|DRUG|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
219759972|NCT00867139|DRUG|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
219759973|NCT00867139|DRUG|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
219005841|NCT01144923|OTHER|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
219005842|NCT01059799|DRUG|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
219005843|NCT01059799|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
219005844|NCT03839745|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
219005845|NCT05008497|OTHER|Questionnaire|Questionnaire
219424288|NCT01333852|DRUG|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
219424289|NCT01333852|DRUG|placebo|placebo
219575629|NCT06168318|DRUG|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
219575630|NCT06168318|DRUG|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
219575631|NCT06168318|DRUG|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
219575632|NCT05228496|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
219005846|NCT00821977|DRUG|Vildagliptin|
219424290|NCT02099942|DEVICE|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~* as stand-alone intervention~* as a bridge to transcatheter aortic valve replacement (TAVR)~* as a bridge to surgical aortic valve replacement (SAVR)~* as an intraprocedural predilatation prior to TAVR"
219424291|NCT01393756|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
219424292|NCT06472388|DRUG|Everolimus 5 MG|oral everolimus 5 mg/daily
219424293|NCT05907993|DRUG|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
219424294|NCT01928485|OTHER|active surveillance|Undergo active surveillance
219424295|NCT01928485|DRUG|Sunphenon|Given PO
219424296|NCT01928485|OTHER|laboratory biomarker analysis|Correlative studies
219424297|NCT01928485|OTHER|Questionnaire Administration|Ancillary studies
219424298|NCT03179007|BIOLOGICAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
219424299|NCT04764409|PROCEDURE|Chemoembolization|Transarterial Chemoembolization (TACE)
219424300|NCT04764409|PROCEDURE|Chemoinfusion|Transarterial Infusion (TAI)
219575633|NCT05228496|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
219424301|NCT04111107|DRUG|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
219424302|NCT04111107|OTHER|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
219575634|NCT03602443|BEHAVIORAL|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
219575635|NCT03602443|BEHAVIORAL|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
219424303|NCT04111107|DIAGNOSTIC_TEST|Next Gen Sequencing Report|1\) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
219424304|NCT03215524|BIOLOGICAL|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
219575636|NCT03755479|DEVICE|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
219575637|NCT05417503|OTHER|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
219575638|NCT05417503|OTHER|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
219575639|NCT02091141|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575640|NCT02091141|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575641|NCT02091141|DRUG|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219424305|NCT03215524|BIOLOGICAL|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
219424306|NCT04287101|OTHER|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
219424307|NCT03905629|OTHER|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
219424308|NCT03110419|OTHER|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
219575642|NCT02091141|DRUG|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575643|NCT02091141|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575644|NCT02091141|DRUG|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575645|NCT02091141|DRUG|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219005847|NCT00821977|DRUG|Vildagliptin|
219424309|NCT01756066|BEHAVIORAL|Different levels of cost sharing|
219424310|NCT06252857|DRUG|Imiquimod Topical|Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
219424311|NCT00002903|DRUG|docetaxel|
219424312|NCT04005950|DEVICE|Scalpel Bougie technique|ScalpelCric Set
219424313|NCT04005950|DEVICE|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
219424314|NCT02329002|DEVICE|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
219424315|NCT03714282|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
219424316|NCT03714282|DEVICE|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
219424317|NCT03714282|OTHER|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
219424318|NCT02834091|PROCEDURE|Hypnoanalgesia|
219575646|NCT02091141|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
219575647|NCT01939041|DEVICE|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
219575648|NCT01939041|DEVICE|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
219575649|NCT01939041|BEHAVIORAL|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
219575650|NCT01598441|DRUG|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
219575651|NCT01598441|DRUG|distilled water|1-2 ml aerosolized distilled water inhalation per session
219575652|NCT02246439|DRUG|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
219575653|NCT02246439|DRUG|Placebo Oral Tablet|Placebo
219575654|NCT03178721|DIAGNOSTIC_TEST|blood sample|study B regulatory in blood and its correlation with atherosclerosis
219575655|NCT01553279|BIOLOGICAL|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
219575656|NCT01553279|BIOLOGICAL|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
219575657|NCT01553279|BIOLOGICAL|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
219575658|NCT01553279|BIOLOGICAL|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
219575659|NCT01553279|BIOLOGICAL|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
219575660|NCT01553279|BIOLOGICAL|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
219575661|NCT03819621|DEVICE|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
219575662|NCT05055895|DRUG|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
219575663|NCT02754908|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
219575664|NCT02754908|BEHAVIORAL|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
219759974|NCT00867139|OTHER|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
219759975|NCT01203397|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
219424319|NCT03107676|OTHER|trunk extensors endurance training|endurance training
219424320|NCT04039191|BEHAVIORAL|SMS education|Patients will receive additional educational SMS messages post-operatively
219424321|NCT04039191|BEHAVIORAL|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
219759976|NCT03272555|OTHER|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
219759977|NCT02525198|DIETARY_SUPPLEMENT|fatty acid/flavonoid blend|see arm description
219759978|NCT02525198|DIETARY_SUPPLEMENT|Placebo|see arm description
219005848|NCT00821977|DRUG|Placebo|
219005849|NCT00003596|DRUG|cisplatin|
219005850|NCT00003596|DRUG|fluorouracil|
219424322|NCT01417065|DRUG|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
219424323|NCT00946569|DRUG|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
219424324|NCT00946569|DRUG|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
219424325|NCT03126331|DRUG|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
219424326|NCT03126331|DRUG|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
219424327|NCT05760820|BEHAVIORAL|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini \& SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
219424328|NCT03975374|DRUG|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
219575665|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
219575666|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
219575667|NCT05410366|OTHER|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
219424329|NCT03975374|DRUG|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
219424330|NCT02089620|DRUG|Yasmin|will be used every 21 days for three months by the patient
219424331|NCT02089620|DIETARY_SUPPLEMENT|Calver|Calver will be given daily for 3 months
219575668|NCT05000086|DRUG|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
219575669|NCT03676517|RADIATION|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
219575670|NCT00400361|DRUG|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
219575671|NCT03955471|DRUG|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
219575672|NCT03955471|DRUG|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
219575673|NCT03012672|DRUG|Cladribine|Given IV
219575674|NCT03012672|DRUG|Cytarabine|Given IV
219005851|NCT00003596|DRUG|mitomycin C|
219005852|NCT00003596|RADIATION|radiation therapy|
219005853|NCT01168531|DRUG|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
219005854|NCT01168531|DRUG|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
219005855|NCT01168531|DRUG|placebo|vitamin B complex formula
219424332|NCT02089620|DRUG|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
219424333|NCT02089620|DRUG|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
219005856|NCT02697812|PROCEDURE|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
219424334|NCT02260648|DRUG|Evacetrapib|Administered orally
219424335|NCT02260648|DRUG|Ezetimibe|Administered orally
219424336|NCT02260648|DRUG|Atorvastatin|Administered orally
219424337|NCT02260648|DRUG|Placebo|Administered orally
219424338|NCT03956225|DEVICE|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
219424339|NCT03956225|DEVICE|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
219575675|NCT03012672|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Given SC
219575676|NCT03012672|DRUG|Mitoxantrone Hydrochloride|Given IV
219759979|NCT06327711|OTHER|Control: CHO Blend|2 servings as a snack or between meals morning and evening
219759980|NCT06327711|OTHER|Experimental: CHO Blend plus AN100|2 servings as a snack or between meals morning and evening
219424340|NCT05331430|OTHER|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
219424341|NCT01240148|DRUG|AZD3161|Single dose, intradermal injection
219424342|NCT01240148|DRUG|Lidocaine|Single dose, intradermal injection
219424343|NCT01240148|DRUG|AZD3161 Placebo|
219424344|NCT05454722|DEVICE|ADEX Gel|Emollient Gel with added anti-inflammatory
219424345|NCT04755465|DEVICE|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
219424346|NCT04755465|OTHER|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
219424347|NCT04093258|DEVICE|Dailies Total 1® Multifocal Contact Lenses|TEST
219424348|NCT04093258|DEVICE|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
219424349|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
219424350|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
219424351|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
219424352|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
219424353|NCT01477372|BEHAVIORAL|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
219575677|NCT03012672|OTHER|Quality-of-Life Assessment|Ancillary studies
219575678|NCT03012672|OTHER|Questionnaire Administration|Ancillary studies
219575679|NCT05320601|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
219575680|NCT05320601|PROCEDURE|Dry needling|Dry needling at trigger point of upper trapezius muscle
219575681|NCT00055133|DRUG|Micellar Paclitaxel for Injection|
219575682|NCT02115217|DEVICE|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
219575683|NCT02115217|DEVICE|Sham kinesiotape|KT put with no effects
219191235|NCT04621643|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
219191236|NCT06356558|OTHER|Educational intervention (VISACT)|The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
219424354|NCT05091892|OTHER|Hydrotherapy programm|Treatment
219424355|NCT00594204|DRUG|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
219424356|NCT00594204|DRUG|Placebo|matching placebo 1 tablet twice a day for 12 weeks
219424357|NCT00176241|DRUG|gemcitabine|2000-3000mg/m2 IV on days 1 \& 15
219424358|NCT00176241|DRUG|paclitaxel|150 mg/m2 IV on days 1 \& 15
219424359|NCT00176241|RADIATION|radiation|50-80 cGy on days 1,2,15,16
219424360|NCT01213095|DRUG|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
219424361|NCT02757781|BEHAVIORAL|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
219424362|NCT02335112|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
219424363|NCT02335112|DEVICE|NanoKnife|
219424364|NCT03691753|DEVICE|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
219424365|NCT03691753|DEVICE|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
219424366|NCT01830296|DRUG|Remifentanil+morphine|Morphine, Remifentanil+Morphine
219424367|NCT03785795|DEVICE|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
219424368|NCT03314714|PROCEDURE|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
219424369|NCT01401465|DRUG|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
219424370|NCT01401465|DRUG|mometasone|200 mcg mometasone aqueous nasal spray once daily
219424371|NCT00986427|DRUG|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
219424372|NCT00986427|DRUG|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
219424373|NCT03497260|DIETARY_SUPPLEMENT|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
219424374|NCT03497260|OTHER|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
219575684|NCT05925673|OTHER|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
219575685|NCT05925673|OTHER|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
219575686|NCT05925673|OTHER|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
219424375|NCT04597892|DIAGNOSTIC_TEST|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
219424376|NCT05155657|BIOLOGICAL|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)
219424377|NCT05155657|BIOLOGICAL|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)
219424378|NCT05155657|BIOLOGICAL|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
219424379|NCT01115738|DRUG|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
219424380|NCT01115738|DRUG|Clopidogrel|Loading dose administered once orally.
219424381|NCT01115738|DRUG|Placebo|Loading dose administered once orally
219424382|NCT01552824|PROCEDURE|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
219424383|NCT01552824|PROCEDURE|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
219424384|NCT00011479|DRUG|Abacavir sulfate|
219191237|NCT06093217|DEVICE|Artificial Intelligence|AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
219424385|NCT01022346|DRUG|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
219424386|NCT01022346|DRUG|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
219424387|NCT02721251|BEHAVIORAL|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
219575687|NCT04566341|DEVICE|OCT - TCE|Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
219575688|NCT00793494|OTHER|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
219424388|NCT02721251|BEHAVIORAL|Weight Loss|16 week. the goal is 10% weight loss.
219424389|NCT02721251|BEHAVIORAL|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
219575689|NCT00793494|OTHER|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
219575690|NCT03785392|PROCEDURE|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
219424390|NCT03001583|BEHAVIORAL|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
219424391|NCT03001583|BEHAVIORAL|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
219424392|NCT00599261|PROCEDURE|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
219424393|NCT06314529|OTHER|Assessments|Safety and efficacy assessments
219424394|NCT04005196|DIAGNOSTIC_TEST|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
219424395|NCT01714817|BIOLOGICAL|BMS-188667|
219424396|NCT01714817|DRUG|Mycophenolate mofetil|
219575691|NCT03785392|PROCEDURE|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
219575692|NCT04732481|PROCEDURE|passive leg lift test|passive leg lift test
219575693|NCT06423638|BEHAVIORAL|Virtual Tai Chi Easy|"The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions"
219575694|NCT03805100|BIOLOGICAL|Ranibizumab|Intravitreal injection
219575695|NCT00522171|DEVICE|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
219575696|NCT03254030|OTHER|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
219191238|NCT03368625|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
219424397|NCT01714817|DRUG|Prednisone|
219424398|NCT01714817|BIOLOGICAL|Placebo matching with BMS-188667|
219575697|NCT00289757|BIOLOGICAL|Havrix™|2 doses at 6 months interval
219575698|NCT06306235|OTHER|Questionnaire|Part A: 30 patients will be interviewed. Part B: 300 patients will complete written questionnaire on tablet.
219424399|NCT00131820|BIOLOGICAL|Typhoid Vi vaccine|
219424400|NCT00131820|BIOLOGICAL|Hepatitis A (control)|
219575699|NCT04749472|OTHER|Sling|Participants wore six different shoulder slings in a randomized order.
219424401|NCT02916095|DRUG|Kanitinib|Oral administration of Kanitinib tablets.
219424402|NCT02527655|BEHAVIORAL|Choice-Based Physical Activity and Active Transportation|
219424403|NCT02921763|DRUG|Dydrogesterone|
219424404|NCT06051851|DRUG|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
219424405|NCT06051851|DRUG|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
219424406|NCT06051851|DRUG|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
219424407|NCT06051851|DRUG|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
219424408|NCT05454930|OTHER|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
219424409|NCT01737658|OTHER|Exercise Program|Exercise Program for Obese Adolescents
219575700|NCT03081234|DRUG|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
219575701|NCT03081234|DRUG|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
219424410|NCT01338883|DRUG|Cenicriviroc 100 mg|100 mg CVC plus Truvada
219424411|NCT01338883|DRUG|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
219424412|NCT01338883|DRUG|Sustiva + Truvada|Sustiva plus Truvada
219424413|NCT01582971|OTHER|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
219424414|NCT02746354|OTHER|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
219424415|NCT06101082|BIOLOGICAL|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
219424416|NCT04965376|PROCEDURE|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
219424417|NCT04965376|PROCEDURE|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
219424418|NCT04928495|DRUG|Vitamin C|Vitamin C 500 mg / day for ten days
219424419|NCT04928495|DRUG|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
219424420|NCT04928495|DRUG|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
219424421|NCT00000341|DRUG|Buprenorphine|
219424422|NCT03665012|OTHER|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
219424423|NCT01178736|PROCEDURE|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
219424424|NCT01178736|PROCEDURE|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
219424425|NCT01178736|PROCEDURE|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
219424426|NCT01178736|PROCEDURE|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
219424427|NCT02396342|GENETIC|AAV5-hFIX|AAV5hFIX gene therapy
219424428|NCT03700970|DRUG|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
219424429|NCT03700970|DRUG|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
219424430|NCT00434499|DRUG|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
219424431|NCT04362904|OTHER|acupressure|
219424432|NCT02246023|DEVICE|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
219424433|NCT02246023|DEVICE|Oxygen saturation|Continuous measurement of oxygen saturation;
219424434|NCT02246023|DEVICE|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
219424435|NCT02246023|DEVICE|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
219575702|NCT03081234|DRUG|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
219575703|NCT04766736|PROCEDURE|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
219575704|NCT03011736|OTHER|Laboratory Biomarker Analysis|Correlative studies
219424436|NCT02246023|DEVICE|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
219424437|NCT00854555|OTHER|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
219424438|NCT00854555|OTHER|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
219424439|NCT02993913|DRUG|Simmiparib|Simmiparib Tablets, oral administration
219424440|NCT06287944|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
219424441|NCT06287944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219424442|NCT06287944|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219424443|NCT06287944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219424444|NCT06287944|PROCEDURE|Computed Tomography|Undergo CT
219424445|NCT06287944|BIOLOGICAL|Daratumumab|Given IV
219424446|NCT06287944|PROCEDURE|Echocardiography|Undergo echocardiography
219424447|NCT06287944|DRUG|Fludarabine|Given IV
219424448|NCT06287944|PROCEDURE|Hematopoietic Cell Transplantation|Undergo SCT
219424449|NCT06287944|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
219424450|NCT06287944|DRUG|Melphalan|Given IV
219424451|NCT06287944|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219424452|NCT06287944|PROCEDURE|Radionuclide Imaging|Undergo nuclear scan
219424453|NCT06287944|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT scan
219424454|NCT06287944|DRUG|Sirolimus|Given sirolimus
219424455|NCT06287944|DRUG|Tacrolimus|Given tacrolimus
219424456|NCT06287944|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
219424457|NCT01524367|DRUG|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
219424458|NCT01524367|DRUG|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
219424459|NCT01754077|BEHAVIORAL|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
219424460|NCT01754077|BEHAVIORAL|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
219424461|NCT01754077|BEHAVIORAL|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
219424462|NCT02554253|DRUG|Ketamine|Ketamine used for induction
219424463|NCT02554253|DRUG|Propofol|Propofol for induction
219424464|NCT05507060|DEVICE|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
219424465|NCT05507060|DEVICE|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
219424466|NCT03558191|DRUG|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
219424467|NCT00042250|DRUG|Chemotherapy for hematologic malignancy|
219424468|NCT05657704|DRUG|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
219424469|NCT04748406|DEVICE|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
219575705|NCT03011736|PROCEDURE|Parathyroidectomy|Undergo parathyroidectomy
219575706|NCT00506649|OTHER|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
219575707|NCT02483832|BEHAVIORAL|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
219191239|NCT04687865|OTHER|Biobank|"For each patient included in the study the following samples will be collected at the indicated time points after transplantation:~* Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.~* Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.~* Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.~* Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction."
219191240|NCT05037461|RADIATION|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
219424470|NCT04748406|OTHER|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
219575708|NCT03474432|DEVICE|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
219759981|NCT01538199|DEVICE|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
219191241|NCT04382079|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
219575709|NCT03291353|DRUG|pembrolizumab|200 mg IV given every three weeks
219575710|NCT03744663|DRUG|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
219575711|NCT03744663|DRUG|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
219575712|NCT01233648|OTHER|rate control via CRT-D and AVN ablation|rate control
219575713|NCT01233648|OTHER|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
219759982|NCT01538199|DEVICE|Sham device|The sham device does not emit near-infrared radiation.
219575714|NCT05916261|BIOLOGICAL|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
219424471|NCT04748406|OTHER|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
219424472|NCT04748406|OTHER|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
219424473|NCT05556551|OTHER|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
219424474|NCT05556551|OTHER|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
219424475|NCT05049447|DRUG|Pascoflair|1 x 2 tablets (single-dose)
219424476|NCT05049447|OTHER|Placebo|1 x 2 tablets (single-dose)
219424477|NCT04699214|DRUG|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
219424478|NCT04699214|DRUG|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
219424479|NCT01671722|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
219424480|NCT01736254|DRUG|Evacetrapib|
219575715|NCT02130583|BEHAVIORAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
219575716|NCT02130583|BEHAVIORAL|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
219191242|NCT04382079|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
219424481|NCT01736254|DRUG|Gemfibrozil|
219575717|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + Regenfast + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
219575718|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
219424482|NCT00165581|DEVICE|High Dose Intracavitary Brachytherapy|
219424483|NCT01478152|OTHER|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
219424484|NCT01647659|DRUG|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
219424485|NCT01647659|DRUG|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
219424486|NCT06460636|OTHER|progressive muscle relaxation therapy|Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
219424487|NCT06460636|OTHER|aquatic therapy|participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
219424488|NCT02559206|DRUG|Linaclotide|Oral, once daily
219424489|NCT02559206|DRUG|Matching Placebo|Oral, once daily
219424490|NCT00754728|DEVICE|JACTAX DES|Drug Eluting Stent
219424491|NCT00093678|DRUG|celecoxib|
219424492|NCT00093678|PROCEDURE|anticachectic therapy|
219424493|NCT00093678|PROCEDURE|nutritional support|
219424494|NCT00093678|PROCEDURE|pain therapy|
219424495|NCT00093678|PROCEDURE|supportive care/therapy|
219575719|NCT04113824|PROCEDURE|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
219424496|NCT01561560|DEVICE|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
219759983|NCT05965219|DRUG|Emraclidine|Emraclidine tablets.
219424497|NCT01561560|DEVICE|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
219424498|NCT06754189|DEVICE|Time Limited stimulation|The participant self-administer 30 min. of electrical stimulation using Time Limited stimulation to the dorsal genital nerve (DGN) for 6 weeks using UCon with the UCon-Patch electrode.
219191243|NCT03899649|DRUG|SOC|Standard of Care treatment
219191244|NCT03899649|DEVICE|NanoKnife System|Irreversible Electroporation
219424499|NCT06754189|DEVICE|Sham stimulation|The participant self-administer 30 min. of sham stimulation to the dorsal genital nerve (DGN) for 6 weeks using a sham device with the UCon-Patch electrode.
219424500|NCT00004986|DRUG|Nitazoxanide|
219424501|NCT06812520|BEHAVIORAL|Educational intervention in adherence|An educational intervention of 4 face-to-face sessions will be carried out as a complement to the care provided by professionals to users with venous ulcers, which consists of the advanced healing procedure that includes compressive bandaging of the venous ulcer.
219424502|NCT07091162|OTHER|CTCA results|Participants who are assigned to CTCA group will receive their CTCA results
219424503|NCT07091162|OTHER|PRS results|Participants who are assigned to PRS group will receive their PRS results
219424504|NCT04643223|OTHER|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
219424505|NCT04643223|OTHER|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
219424506|NCT05506553|DEVICE|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
219424507|NCT05506553|DEVICE|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
219575720|NCT04113824|PROCEDURE|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
219575721|NCT02045992|DIETARY_SUPPLEMENT|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
219575722|NCT05325073|DRUG|Erythropoietin|Erythropoietin
219191245|NCT03500731|BIOLOGICAL|CD3/CD19 negative hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
219424508|NCT03170557|OTHER|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
219424509|NCT03170557|OTHER|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
219424510|NCT03203889|BEHAVIORAL|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
219424511|NCT03203889|BEHAVIORAL|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
219424512|NCT01017822|BIOLOGICAL|conatumumab|
219424513|NCT01017822|DRUG|capecitabine|
219424514|NCT01017822|DRUG|gemcitabine hydrochloride|
219424515|NCT01017822|RADIATION|3-dimensional conformal radiation therapy|
219424516|NCT02415439|DRUG|VBP15|
219424517|NCT02415439|DRUG|Placebo|
219424518|NCT05466266|DEVICE|ICE|All patients received ICE examination.
219424519|NCT05466266|DEVICE|TEE|All patients received TEE examination.
219424520|NCT04557254|DEVICE|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
219424521|NCT01917110|DEVICE|omafilcon A|
219424522|NCT01917110|DEVICE|Spectacle|
219424523|NCT05912920|PROCEDURE|gastric band|gastric band
219759984|NCT05965219|DRUG|Itraconazole|Itraconazole oral solution.
219191246|NCT03500731|DRUG|Rituximab|Transplantation Conditioning
219191247|NCT03500731|DRUG|Alemtuzumab|Transplantation Conditioning
219424524|NCT02497872|PROCEDURE|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
219424525|NCT01806376|DRUG|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
219424526|NCT03630978|PROCEDURE|Liver resection|Major or minor, open or laparoscopic liver resection
219424527|NCT06088407|DRUG|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
219424528|NCT04782804|DRUG|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
219424529|NCT04782804|DRUG|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
219575723|NCT01793818|BIOLOGICAL|Tat Oyi|Three injections in the arm
219575724|NCT00854802|DRUG|Debio 025|Debio 025 supplied in soft gel capsules
219575725|NCT00854802|DRUG|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
219575726|NCT00854802|DRUG|Ribavirin|Ribavirin supplied in tablets
219575727|NCT00854802|DRUG|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
219759985|NCT05965219|DRUG|Carbamazepine|Carbamazepine tablets.
219759986|NCT05965219|DRUG|Metformin|Metformin tablets.
219424530|NCT02102984|DEVICE|covered biliary stents|endoscopic placement of covered biliary stents
219424531|NCT02102984|DEVICE|uncovered biliary stents|endoscopic placement of uncovered biliary stents
219575728|NCT02237742|DRUG|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
219575729|NCT06004778|BEHAVIORAL|Motivational Support Program|In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.
219575730|NCT06004778|BEHAVIORAL|Educational support|educational support
219575731|NCT06616909|BEHAVIORAL|ACP GAME|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
219575732|NCT06616909|BEHAVIORAL|acp manual|acp manual
219424532|NCT01248494|DRUG|BEZ235|"* Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID"
219759987|NCT04845256|DEVICE|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
219424533|NCT01248494|DRUG|BKM 120|"* Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily"
219575733|NCT05631834|PROCEDURE|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
219575734|NCT05631834|PROCEDURE|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
219575735|NCT04333238|OTHER|New progress note template|Residents assigned to document with new progress note template
219759988|NCT02951260|DRUG|Metformin|17 days treatment with metformin
219759989|NCT02951260|OTHER|Placebo|17 days treatment with placebo
219759990|NCT04844333|OTHER|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
219759991|NCT00571883|OTHER|questionnaire administration|
219759992|NCT00571883|PROCEDURE|psychosocial assessment and care|
219759993|NCT00571883|PROCEDURE|quality-of-life assessment|
219759994|NCT00571883|PROCEDURE|regional lymph node dissection|
219759995|NCT00571883|PROCEDURE|therapeutic conventional surgery|
219759996|NCT05290532|OTHER|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
219759997|NCT05064228|BEHAVIORAL|Mobile Rewarding Activity Centered Treatment (m-ReACT)|Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
219424534|NCT01248494|DRUG|Letrozole|All levels: 2.5mg/day PO
219759998|NCT05671250|COMBINATION_PRODUCT|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
219575736|NCT04333238|OTHER|Standard progress note template|Residents assigned to document with standard progress note template
219575737|NCT00003521|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219575738|NCT02709252|DEVICE|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
219575739|NCT00131378|DRUG|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
219759999|NCT05671250|COMBINATION_PRODUCT|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
219760000|NCT05671250|PROCEDURE|Standard of Care|Sharp debridement, saline washing and regular saline dressing
219760001|NCT05390684|OTHER|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
219760002|NCT02382354|DRUG|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
219760003|NCT02382354|DEVICE|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
219760004|NCT02382354|DEVICE|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
219760005|NCT02382354|DRUG|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
219191248|NCT03500731|DRUG|Fludarabine|Transplantation Conditioning
219191249|NCT03500731|DRUG|Thiotepa|Transplantation Conditioning
219191250|NCT03500731|DRUG|G-CSF|Transplantation conditioning
219191251|NCT03500731|DRUG|Hydroxyurea|Transplantation Conditioning
219424535|NCT01248494|DRUG|BKM120|"* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
219424536|NCT01046383|DIETARY_SUPPLEMENT|IMN1207|20 grams of IMN1207 per day for 40 weeks.
219424537|NCT01046383|DIETARY_SUPPLEMENT|Casein|20 grams of Casein per day for 40 weeks
219575740|NCT00131378|DRUG|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
219575741|NCT04896411|OTHER|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
219575742|NCT04896411|OTHER|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
219575743|NCT04340349|DRUG|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
219424538|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
219424539|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
219424540|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
219424541|NCT05901285|COMBINATION_PRODUCT|Nivolumab or pembrolizumab|VAX014 will be given in combination with Investigator's choice of nivolumab or pembrolizumab.
219424542|NCT05894070|OTHER|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~* Standardized, phonetically balanced text~* Sustained, modulated production of five vowels~* Picture description~* Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~* Health barometer~* Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
219424543|NCT05958615|BEHAVIORAL|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
219424544|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over 12 weeks. Eight core modules discussing essential elements (such as main problems of solid waste management, health effects of exposure to burning plastic, sustainable alternatives to plastic litter) and four periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize one task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as:~* engaging in a community clean-up~* starting an organic compost pile free of plastic waste~* training on community recycling, focusing on plastics recycling~* making organic soaps, to use for personal grooming or washing clothes, eliminating plastic packaging~* creating materials out of plastic, like bottle planters"
219424545|NCT05456256|DRUG|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
219424546|NCT05456256|DRUG|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
219424547|NCT05456256|DRUG|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
219424548|NCT05844865|OTHER|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
219424549|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
219424550|NCT06025396|DRUG|Cohort 1 - TMP-301|50 mg BID Fasted
219575744|NCT04340349|DRUG|Bromhexine 8 MG|TMPRSS2 blocker
219575745|NCT03250949|PROCEDURE|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
219575746|NCT02291770|BIOLOGICAL|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
219575747|NCT03122067|DRUG|oxytocin treatment|intranasal administration of oxytocin
219575748|NCT03122067|DRUG|placebo treatment|intranasal administration of placebo
219575749|NCT03247517|DRUG|Placebo|Placebo was administered once daily
219575750|NCT03247517|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
219575751|NCT03247517|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
219575752|NCT02399930|OTHER|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
219575753|NCT01996332|DRUG|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
219424551|NCT06025396|DRUG|Placebo|Multiple ascending dose comparator
219424552|NCT06025396|DRUG|Cohort 2 - TMP-301|50 mg QD Fasted
219424553|NCT06025396|DRUG|Cohort 3 - TMP-301|50 mg QD Fed
219424554|NCT06025396|DRUG|Cohort 4 - TMP-301|25 mg QD Fed
219424555|NCT06234059|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
219424556|NCT06234059|BEHAVIORAL|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
219575754|NCT03049605|DEVICE|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
219575755|NCT03049605|DEVICE|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
219575756|NCT03049605|DRUG|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
219575757|NCT03690661|BEHAVIORAL|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
219575758|NCT03690661|BEHAVIORAL|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
219760006|NCT02441894|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
219760007|NCT02441894|DRUG|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
219760008|NCT02441894|DRUG|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
219760009|NCT02441894|DRUG|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
219191252|NCT04415866|BEHAVIORAL|Paced Auditory Serial Addition task (PASAT)|Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
219424557|NCT05691829|DRUG|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
219424558|NCT05691829|RADIATION|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
219424559|NCT05691829|DRUG|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
219424560|NCT05876208|OTHER|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
219424561|NCT05876208|OTHER|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
219424562|NCT05821556|DRUG|Valproic acid|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219575759|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
219575760|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
219575761|NCT00548951|OTHER|Control|Receive no sessions in a Snoezelen Room.
219575762|NCT02113189|OTHER|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
219575763|NCT02113189|OTHER|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
219760010|NCT02441894|DRUG|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
219760011|NCT02441894|DRUG|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
219760012|NCT02441894|DRUG|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
219760013|NCT05215002|OTHER|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
219760014|NCT05215002|OTHER|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
219424563|NCT05821556|DRUG|Simvastatin 20mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219424564|NCT05821556|DRUG|Gemcitabine 1000 mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219424565|NCT05821556|DRUG|Nab paclitaxel|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219424566|NCT05821556|DRUG|Cisplatin|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219424567|NCT05821556|DRUG|Capecitabine|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
219760015|NCT05730842|DRUG|EDG-5506 Tablet|Single Oral Dose - Tablet
219760016|NCT05730842|DRUG|Radiolabeled EDG-5506 Suspension|Single Oral Dose
219760017|NCT05730842|DRUG|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
219760018|NCT02406222|DRUG|Pomalidomide|Chemotherapy
219760019|NCT02406222|DRUG|Dexamethasone|Chemotherapy
219760020|NCT02406222|DRUG|Cyclophosphamide|Chemotherapy
219760021|NCT04068805|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
219760022|NCT03703505|DRUG|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
219760023|NCT03703505|DRUG|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
219760024|NCT03872115|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
219760025|NCT05085132|BEHAVIORAL|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
219760026|NCT05085132|BEHAVIORAL|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
219760027|NCT04476992|DRUG|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
219424568|NCT06588660|BIOLOGICAL|Vevoctadekin|Given SC
219424569|NCT06588660|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219424570|NCT06588660|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219424571|NCT06588660|OTHER|Medical Chart Review|Ancillary studies
219424572|NCT06588660|DRUG|Teclistamab|Given SC
219191253|NCT05333029|BIOLOGICAL|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10\^6 cells/kg (+/- 20%)
219424573|NCT06588660|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219424574|NCT05867212|DRUG|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
219424575|NCT00949910|DRUG|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
219424576|NCT00271271|DRUG|oxaliplatine / gemcitabine / Vinorelbine|
219191254|NCT05333029|BIOLOGICAL|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
219424577|NCT02759562|DRUG|Andecaliximab|Administered via subcutaneous injection
219424578|NCT02759562|DRUG|Placebo|Administered via subcutaneous injection
219424579|NCT03015025|GENETIC|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
219424580|NCT02401087|PROCEDURE|Anaesthesiological procedure|
219424581|NCT03487328|PROCEDURE|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
219424582|NCT03515018|DRUG|hydroxyurea|pulse therapy
219424583|NCT03515018|DRUG|Imatinib|400mg qd PO per day
219424584|NCT00944788|OTHER|qi-gong|Physical activity similar to tai-chi
219575764|NCT02113189|OTHER|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
219575765|NCT06160505|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
219575766|NCT04053361|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
219575767|NCT05070000|DIAGNOSTIC_TEST|Radiologic examination|Patients underwent US, CT or CT after US
219575768|NCT02044406|DRUG|BI 1181181|single dose (low to high dose)
219575769|NCT02044406|DRUG|BI 1181181, R|powder for oral solution
219575770|NCT02044406|DRUG|BI 1181181, T2|tablet, fasted
219575771|NCT02044406|DRUG|Placebo to BI 1181181|Placebo to BI 1181181
219575772|NCT02044406|DRUG|BI 1181181, T1|tablet, fed
219575773|NCT00207675|DRUG|infliximab|
219424585|NCT05304572|DIAGNOSTIC_TEST|Multi-Detector CT angiography|Multiphasic CT within 4 weeks interval prior to TACE will be done including non-enhanced, arterial, portal and venous phases using IV bolus injection of a 75-100-mLiodinated contrast material iopamidol at a rate of 3.0 mL/s. The images of arterial phase will be transferred to workstation to produce 3D angiographic reconstruction images .
219424586|NCT05304572|PROCEDURE|Trans-arterial chemoembolization and DSA|Percutaneous arterial access is achieved through the common femoral artery (19 G needle) under local anesthesia with placement of a 5-Fr sheath. A 5-Fr Cobra (C2) or sidewinder (SIM1) catheter was used for catheterizing the coeliac trunk and SMA. Then celiac and superior mesenteric angiography was done by injecting 24 mL of iopamidol using forced manual injection method or using a pump at a rate of 6 mL/s according to the operator preferences.Then a microcatheter was used for selective and super-selective access of the hepatic arteries. The micro-catheter was placed in the feeding artery as close as possible to the tumor.The chemotherapeutic drugs (Doxorubicin 50 mg) solved within 5 ml of iodinated non-ionic contrast media and then mixed with 10 ml of iodized oil (lipiodol) will be delivered through the feeding hepatic artery and then embolized using Poly-vinyl Alcohol (PVA) particles.
219424587|NCT05138341|DEVICE|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
219005857|NCT04305483|PROCEDURE|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
219005858|NCT04305483|PROCEDURE|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
219424588|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
219424589|NCT04645823|DRUG|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
219424590|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
219424591|NCT01351311|OTHER|Exercise|Resistance Training exercise with swiss ball
219424592|NCT01351311|OTHER|Drug treatment|Drug treatment
219424593|NCT04145869|PROCEDURE|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
219575774|NCT00166907|BEHAVIORAL|Balance and Exercise|
219575775|NCT00353652|DRUG|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
219424594|NCT03288740|DRUG|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
219424595|NCT03288740|DRUG|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
219424596|NCT03288740|DRUG|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
219424597|NCT03288740|DRUG|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
219424598|NCT04662411|DIETARY_SUPPLEMENT|Placebo|acute intake of 0 mg butyrate and hexanoate
219575776|NCT00353652|DRUG|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
219575777|NCT00353652|DRUG|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
219575778|NCT00353652|DRUG|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
219575779|NCT00353652|DRUG|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
219575780|NCT04693338|OTHER|Quality-of-Life Assessment|Ancillary studies
219424599|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
219575781|NCT04693338|OTHER|Questionnaire Administration|Ancillary studies
219575782|NCT04693338|OTHER|Supportive Care|Receive ICP tasks
219575783|NCT01947478|DEVICE|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
219575784|NCT01947478|DEVICE|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
219575785|NCT05253924|DIAGNOSTIC_TEST|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
219191255|NCT03501524|DEVICE|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
219191256|NCT03501524|DEVICE|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
219424600|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
219575786|NCT05253924|DIAGNOSTIC_TEST|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
219575787|NCT00537108|BEHAVIORAL|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
219575788|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
219575789|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
219575790|NCT00812422|DRUG|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
219191257|NCT05259150|BEHAVIORAL|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
219191258|NCT05259150|BEHAVIORAL|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
219191259|NCT05259150|BEHAVIORAL|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
219191260|NCT05259150|OTHER|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
219424601|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
219424602|NCT03989856|DEVICE|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
219575791|NCT01426035|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
219575792|NCT06441461|OTHER|Primary informal caregiver at work.|Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
219575793|NCT03336320|DEVICE|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
219575794|NCT06223217|OTHER|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
219191261|NCT05191121|BEHAVIORAL|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
219424603|NCT03989856|DEVICE|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
219575795|NCT03858595|DEVICE|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
219424604|NCT03206112|OTHER|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
219424605|NCT03206112|OTHER|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
219424606|NCT03206112|OTHER|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
219424607|NCT00933192|DEVICE|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
219424608|NCT00232505|BIOLOGICAL|cetuximab|Given IV
219424609|NCT00232505|DRUG|carboplatin|Given IV
219424610|NCT01646463|BEHAVIORAL|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
219424611|NCT01646463|BEHAVIORAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
219424612|NCT02051738|DRUG|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
219424613|NCT02051738|DRUG|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
219424614|NCT03457480|OTHER|Computer-Assisted Intervention|Read computer messages
219424615|NCT03457480|BEHAVIORAL|Focus Group|Attend focus group
219424616|NCT03457480|OTHER|Informational Intervention|Receive text messages
219575796|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
219575797|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
219575798|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
219424617|NCT03457480|OTHER|Survey Administration|Complete surveys about experience
219424618|NCT05129761|DRUG|Syrup Hydryllin|( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
219424619|NCT04121572|DEVICE|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
219575799|NCT00430495|DRUG|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
219575800|NCT02857738|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219575801|NCT02857738|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219575802|NCT03858738|DEVICE|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
219575803|NCT01376817|DRUG|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
219575804|NCT01376817|DRUG|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
219575805|NCT00782821|DRUG|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
219575806|NCT00782821|DRUG|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
219575807|NCT00782821|DRUG|Rituxan|Given via IV per group assignment.
219575808|NCT00158756|BIOLOGICAL|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
219575809|NCT00158756|BIOLOGICAL|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
219575810|NCT00158756|BIOLOGICAL|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
219575811|NCT00158756|BIOLOGICAL|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
219575812|NCT00158756|BIOLOGICAL|Engerix™-B|GSK Biologicals' hepatitis B vaccine
219575813|NCT00158756|DRUG|Placebo|Placebo for the Rotarix™ vaccine
219575814|NCT05726461|DEVICE|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
219575815|NCT05726461|DEVICE|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
219575816|NCT04957420|DRUG|Neupro|Rotigotine Patches
219424620|NCT02791867|DRUG|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
219424621|NCT03373318|DRUG|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
219424622|NCT03373318|DRUG|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
219424623|NCT01489761|DEVICE|percutaneous coronary intervention|drug eluting stent implantation
219424624|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
219575817|NCT02796131|DRUG|RDX5791|
219760028|NCT04476992|DRUG|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
219760029|NCT02383784|DIETARY_SUPPLEMENT|Low GI index diet|Low glycemic index diet
219760030|NCT02383784|DIETARY_SUPPLEMENT|High GI diet|High glycemic index diet
219760031|NCT04708522|BEHAVIORAL|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
219424625|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
219760032|NCT04708522|BEHAVIORAL|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
219760033|NCT04708522|BEHAVIORAL|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
219760034|NCT03950856|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
219760035|NCT03950856|DRUG|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
219760036|NCT01533545|DRUG|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
219424626|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
219760037|NCT01533545|DRUG|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
219760038|NCT01389687|BIOLOGICAL|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
219760039|NCT03150264|DEVICE|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
219424627|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
219424628|NCT01309490|DRUG|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
219424629|NCT04658199|DRUG|UCB0107 (bepranemab)|UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
219424630|NCT05810844|DIAGNOSTIC_TEST|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
219575818|NCT02796131|DRUG|Placebo|Placebo
219575819|NCT03234894|DEVICE|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
219575820|NCT01485666|OTHER|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
219575821|NCT05555368|OTHER|Quality of Recovery Score|Descriptive
219424631|NCT05810844|DIAGNOSTIC_TEST|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
219424632|NCT00834886|DIETARY_SUPPLEMENT|Melatonin|Capsules, 3 mg, once every night
219575822|NCT06323486|DEVICE|active accelerated bilateral sequential theta burst stimulation and sham treatment|"We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions."
219424633|NCT00834886|OTHER|Bright light|Bright light therapy 10.000 lux by Miljølys AS
219424634|NCT00834886|OTHER|Placebo red light|Red light 400 lux as placebo light
219424635|NCT00834886|OTHER|Placebo capsule|Capsules containing 3 mng rice flour, once every night
219575823|NCT02145026|DRUG|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
219575824|NCT02935166|OTHER|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
219575825|NCT01799863|DRUG|Ketorolac trometamol 0.45% with carboxymethylcellulose|
219005859|NCT03081065|DIETARY_SUPPLEMENT|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
219575826|NCT01799863|DRUG|Preservative free artificial tear|
219575827|NCT03207841|OTHER|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
219575828|NCT01799317|DRUG|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
219760040|NCT03150264|DEVICE|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
219760041|NCT00000621|DRUG|all trans retinoic acid|
219191262|NCT05191121|BEHAVIORAL|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
219424636|NCT05521464|OTHER|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
219424637|NCT05521464|OTHER|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
219424638|NCT00453843|DEVICE|rehabilitation robotics|sequence of intervention
219424639|NCT00453843|PROCEDURE|Movement therapy|sequence of intervention
219424640|NCT02739256|PROCEDURE|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
219760042|NCT00000621|DRUG|13 cis retinoic acid|
219760043|NCT00000621|DRUG|placebo|
219760044|NCT00753532|DIETARY_SUPPLEMENT|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
219760045|NCT00678522|DRUG|Atorvastatin|80 mg atorvastatin daily on two following days
219760046|NCT05958602|BEHAVIORAL|Technology|See previous response.
219760047|NCT05958602|BEHAVIORAL|Standard DSMES Only|See previous response.
219760048|NCT05958602|BEHAVIORAL|Traditional Recruitment Methods|See previous response.
219760049|NCT05958602|BEHAVIORAL|CHW-Led Recruitment Methods|See previous response.
219760050|NCT06157073|DEVICE|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
219760051|NCT06157073|DEVICE|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
219760052|NCT00188214|PROCEDURE|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
219760053|NCT04174352|DRUG|Tamoxifen|estrogen modulator
219760054|NCT04174352|DIAGNOSTIC_TEST|FES PET/CT|Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
219760055|NCT05899829|DRUG|Camlipixant|Camlipixant will be administered
219760056|NCT05899829|DRUG|Rabeprazole|Rabeprazole will be administered
219760057|NCT05899829|DRUG|Rifampin|Rifampin will be administered.
219424641|NCT03465176|OTHER|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219424642|NCT03465176|OTHER|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
219424643|NCT02467023|DEVICE|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
219424644|NCT02467023|DEVICE|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
219424645|NCT02467023|PROCEDURE|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
219424646|NCT02467023|DRUG|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
219424647|NCT02467023|DRUG|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
219424648|NCT02467023|DRUG|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
219424649|NCT02467023|OTHER|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
219424650|NCT02467023|DEVICE|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
219424651|NCT01778400|PROCEDURE|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
219424652|NCT01778400|PROCEDURE|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
219424653|NCT03532776|DRUG|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
219424654|NCT03532776|DRUG|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
219424655|NCT03532776|DRUG|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
219575829|NCT02501434|DRUG|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
219575830|NCT02152735|PROCEDURE|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
219575831|NCT02590835|PROCEDURE|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
219760058|NCT01855893|OTHER|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
219760059|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
219424656|NCT06314997|DRUG|panitumumab (EGFR inhibitors)|Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
219424657|NCT03967756|DEVICE|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
219424658|NCT05779800|DEVICE|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
219424659|NCT05779800|DEVICE|periodontal pack|Non eugenol containing dressing supplied in two tubes
219424660|NCT04560673|DRUG|Duloxetine|Given PO
219424661|NCT04560673|BEHAVIORAL|Neurofeedback|Receive neurofeedback training
219424662|NCT04560673|OTHER|Quality-of-Life Assessment|Ancillary studies
219424663|NCT04560673|OTHER|Questionnaire Administration|Ancillary studies
219424664|NCT01274455|GENETIC|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
219424665|NCT05273658|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
219424666|NCT05273658|DRUG|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
219424667|NCT02322268|DIETARY_SUPPLEMENT|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
219424668|NCT05605977|BEHAVIORAL|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
219424669|NCT05605977|BEHAVIORAL|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
219424670|NCT01030380|DEVICE|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
219760060|NCT01578161|DRUG|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
219424671|NCT04801394|PROCEDURE|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
219424672|NCT01108562|DRUG|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
219424673|NCT01108562|OTHER|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
219424674|NCT00110578|PROCEDURE|Adoptive transfer of HIV-specific CD8+ T cells|
219424675|NCT00110578|DRUG|Aldesleukin|
219424676|NCT01823770|DRUG|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
219424677|NCT01823770|DRUG|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
219424678|NCT05100433|PROCEDURE|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
219424679|NCT05812937|PROCEDURE|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
219424680|NCT01188538|DRUG|Epiduo gel|Once daily application on the face in the evening for 12 weeks
219424681|NCT01188538|DRUG|BPO|Once daily application on the face in the evening for 12 weeks
219424682|NCT00654953|DRUG|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
219575832|NCT02590835|PROCEDURE|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
219575833|NCT01409590|BEHAVIORAL|Exercise program|Homogenous exercise program in local fitness centers
219760061|NCT01578161|DRUG|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
219760062|NCT03479983|DIETARY_SUPPLEMENT|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
219424683|NCT00654953|DRUG|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
219575834|NCT01409590|BEHAVIORAL|Diet|Weigh loss diet program prescribed by a professional nutritionist
219424684|NCT00654953|DRUG|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
219424685|NCT00489372|DRUG|Se-methyl-seleno-L-cysteine|Given orally
219424686|NCT00489372|OTHER|placebo|Given orally
219424687|NCT00489372|OTHER|pharmacological study|Correlative studies
219424688|NCT00489372|OTHER|laboratory biomarker analysis|Correlative studies
219424689|NCT03213483|PROCEDURE|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
219424690|NCT03213483|PROCEDURE|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
219760063|NCT03479983|DIETARY_SUPPLEMENT|Placebo|500 mg roasted rice powder in visually identical capsules
219424691|NCT05460650|BEHAVIORAL|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
219424692|NCT02174783|OTHER|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
219575835|NCT02138942|DEVICE|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
219575836|NCT01915693|RADIATION|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
219424693|NCT02174783|OTHER|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
219424694|NCT02174783|OTHER|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
219424695|NCT01231607|DRUG|1mg Finasteride active|1mg finasteride active, by mouth once daily
219575837|NCT01429051|DRUG|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
219575838|NCT01429051|DRUG|Placebo|Matching intranasal placebo spray
219575839|NCT03008486|DEVICE|Real soft splint (6 cm)|
219575840|NCT03008486|DEVICE|Placebo soft splint (1 cm)|
219575841|NCT00852566|DRUG|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
219575842|NCT00852566|DRUG|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
219575843|NCT05739214|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
219760064|NCT04487405|DEVICE|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
219760065|NCT01520181|DRUG|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
219760066|NCT03062943|DRUG|Nintedanib|
219575844|NCT05355714|DEVICE|Sofwave|High-Frequency Non-Focused Ultrasound Device
219575845|NCT05355714|DEVICE|Ultherapy|Microfocused Ultrasound with Visualization
219575846|NCT02091323|PROCEDURE|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
219760067|NCT04811690|BEHAVIORAL|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
219424696|NCT01231607|DRUG|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
219424697|NCT01231607|DRUG|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
219424698|NCT01231607|DRUG|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
219424699|NCT01231607|DRUG|Finasteride placebo|finasteride placebo, by mouth once daily
219424700|NCT01231607|DRUG|Dutasteride placebo|dutasteride placebo, by mouth once daily
219760068|NCT04443088|DRUG|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
219191263|NCT05191121|BEHAVIORAL|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
219424701|NCT04320277|DRUG|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
219424702|NCT02846805|PROCEDURE|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
219424703|NCT05082298|BEHAVIORAL|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
219424704|NCT05082298|BEHAVIORAL|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
219424705|NCT00370877|DRUG|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
219424706|NCT00370877|PROCEDURE|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
219424707|NCT01917708|DRUG|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
219424708|NCT02501902|DRUG|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
219424709|NCT02501902|DRUG|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
219424710|NCT04943666|OTHER|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
219424711|NCT05852730|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
219424712|NCT05852730|DRUG|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
219424713|NCT04771026|DRUG|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
219424714|NCT01877785|DRUG|MHAA4549A|Single-ascending dose of MHAA4549A
219424715|NCT01877785|DRUG|Placebo|Placebo to MHAA4549A
219424716|NCT04016688|PROCEDURE|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
219424717|NCT01261598|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
219424718|NCT02513771|DRUG|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
219424719|NCT02513771|DRUG|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
219424720|NCT01972854|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
219424721|NCT01972854|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
219424722|NCT01972854|DEVICE|KXL System|30mW/cm2
219424723|NCT00561613|OTHER|SILCS and lubricant|
219424724|NCT00561613|OTHER|SILCS and spermicide|
219575847|NCT04132336|DRUG|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
219575848|NCT04132336|DRUG|Naproxen sodium (Aleve)|Tablet, oral, single dose
219575849|NCT04132336|DRUG|Caffeine|Tablet, oral, single dose
219575850|NCT04132336|DRUG|Placebo|Tablet, oral, single dose
219575851|NCT03532113|BEHAVIORAL|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
219575852|NCT03532113|BEHAVIORAL|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
219760069|NCT04443088|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
219760070|NCT05172297|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
219760071|NCT03659825|DIETARY_SUPPLEMENT|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
219760072|NCT03659825|DIETARY_SUPPLEMENT|Taste Matched Placebo|Placebo that tastes similar to active intervention
219191264|NCT04564183|OTHER|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
219191265|NCT04564183|OTHER|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
219424725|NCT02770118|BEHAVIORAL|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
219760073|NCT03659825|OTHER|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
219760074|NCT00713193|DRUG|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
219760075|NCT00713193|DRUG|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
219760076|NCT03131193|OTHER|Physician|Study primary health centers will be staffed with an additional physician
219760077|NCT03131193|OTHER|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
219760078|NCT03131193|BEHAVIORAL|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
219005860|NCT00750204|DEVICE|APRV|"APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
219005861|NCT00750204|DEVICE|Conventional MV|Low tidal-volume mechanical ventilation
219424726|NCT02770118|BEHAVIORAL|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
219424727|NCT02770118|BEHAVIORAL|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
219424728|NCT00511849|DRUG|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
219424729|NCT03007719|DRUG|Fluorine F 18 Ara-G|Given IV
219424730|NCT03007719|PROCEDURE|Positron Emission Tomography|Undergo PET/MR imaging
219424731|NCT03007719|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR imaging
219424732|NCT03140683|DEVICE|non-stress test|antepartum fetal monitoring
219424733|NCT01797445|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
219424734|NCT01797445|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
219424735|NCT01797445|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
219424736|NCT01797445|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
219424737|NCT03908905|DIAGNOSTIC_TEST|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
219424738|NCT04606368|DEVICE|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
219424739|NCT01157546|PROCEDURE|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
219005862|NCT02701439|DEVICE|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms"
219005863|NCT01922128|DRUG|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
219191266|NCT04564183|RADIATION|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
219424740|NCT01157546|PROCEDURE|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
219424741|NCT06306326|DIAGNOSTIC_TEST|3dMD technology|By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
219424742|NCT02397590|DRUG|Fimasartan|
219424743|NCT02397590|DRUG|Atorvastatin|
219424744|NCT06200285|OTHER|Registry of patients with accidental hypothermia|
219424745|NCT04547998|DEVICE|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
219424746|NCT04547998|DEVICE|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
219424747|NCT04745312|DEVICE|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
219424748|NCT01595438|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
219424749|NCT01595438|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
219424750|NCT01595438|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
219575853|NCT03532113|BEHAVIORAL|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
219575854|NCT06195696|BEHAVIORAL|employs questionnaires|The first phase is a quantitative study that employs a questionnaire to investigate the current state of illness perception and the distribution of coping styles in kidney transplant recipients, and to explore the differences in illness perception between positive coping and negative coping patients after kidney transplantation; The second phase involves a descriptive qualitative study that utilizes face-to-face, semi-structured, in-depth interviews to investigate the causes of differences in illness perceptions of different coping styles in kidney transplant recipients who experience idiosyncrasies.
219575855|NCT00940836|DRUG|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
219575856|NCT00940836|DRUG|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
219424751|NCT01595438|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
219424752|NCT05621590|DRUG|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
219424753|NCT05621590|DRUG|Placebo|placebo capsules filled with stevia sweetened powder
219424754|NCT01960426|OTHER|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
219424755|NCT01960426|OTHER|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
219424756|NCT01022385|DIETARY_SUPPLEMENT|24-hour low-residual diet|
219424757|NCT05306184|PROCEDURE|Electroconvulsive therapy (ECT)|ECT
219424758|NCT00930709|DRUG|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
219424759|NCT00930709|BEHAVIORAL|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
219424760|NCT01452724|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
219424761|NCT01452724|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
219424762|NCT01452724|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
219424763|NCT01452724|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
219424764|NCT06962631|BIOLOGICAL|5% (5g/100 ml) intravenous immunoglobin|"A 5% human normal immunoglobulin I.P. (5 g/100 mL) V-IMMUNE® will be administered at a dose of 1 g/kg, intravenously, once daily for 2 consecutive days (Day 1 and Day 2). The infusion rate starts at 0.01 mL/kg/min during the first 30 minutes and is gradually increased up to 0.06 mL/kg/min if no adverse events occur. This will constitute the first cycle of V-IMMUNE® treatment. The dose of 1 g/kg/day on 2 consecutive days is consistent with recommendations for the use of other IVIG products in Immune Thrombocytopenia.~If the platelet count is not maintained for the desired duration after the first V-IMMUNE® cycle, and at the discretion of the investigator and the patient/legal representative, participants may receive up to one additional cycle of V-IMMUNE®-at the same dosing regimen used in Cycle 1-between Day 15 and Day 30"
219424765|NCT04707378|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
219424766|NCT05167188|OTHER|no intervention|no intervention
219424767|NCT03625297|OTHER|shelter cat|families will adopt a shelter cat
219424768|NCT01620008|PROCEDURE|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
219424769|NCT01444872|DRUG|TRV120027|IV infusion
219424770|NCT01444872|DRUG|Normal Saline|IV infusion
219424771|NCT05133206|OTHER|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
219424772|NCT04790539|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
219424773|NCT01000519|OTHER|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
219424774|NCT01000519|OTHER|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
219424775|NCT03932019|DRUG|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
219424776|NCT03932019|DRUG|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
219005864|NCT01847794|DEVICE|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
219424777|NCT03932019|DRUG|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
219424778|NCT01113788|DEVICE|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
219005865|NCT04671550|DIAGNOSTIC_TEST|questionnaire|"Questionnaire on Driving performances and Visual Field"
219191267|NCT04564183|DIAGNOSTIC_TEST|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
219191268|NCT06174181|DEVICE|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
219424779|NCT04925518|DEVICE|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
219424780|NCT04925518|DEVICE|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
219424781|NCT01003353|BEHAVIORAL|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
219424782|NCT02252575|DEVICE|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
219424783|NCT03128385|OTHER|Intensive CIT Model Program|"Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
219424784|NCT03128385|OTHER|Distributed CIT Model Program|"Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
219424785|NCT04072172|DEVICE|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
219424786|NCT01147406|DRUG|N6022|This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
219424787|NCT01147406|DRUG|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
219424788|NCT04689841|OTHER|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
219575857|NCT00940836|DRUG|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
219575858|NCT00204958|DRUG|nutritional supplement|
219005866|NCT06087107|OTHER|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
219191269|NCT06174181|OTHER|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
219424789|NCT04689841|OTHER|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
219424790|NCT04105413|DIAGNOSTIC_TEST|Blood culturs|CBC, Blood culture and CRP
219424791|NCT01817647|PROCEDURE|Colorectal surgery|
219424792|NCT04374279|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily for 7 days
219424793|NCT00797485|BIOLOGICAL|bevacizumab|Given IV
219424794|NCT00797485|DRUG|capecitabine|Given orally
219424795|NCT00797485|DRUG|fluorouracil|Given IV
219424796|NCT00797485|DRUG|irinotecan hydrochloride|Given IV
219575859|NCT00204958|DRUG|glutamine popsicle|
219575860|NCT05288036|OTHER|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
219575861|NCT05288036|OTHER|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
219760079|NCT01143636|DEVICE|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
219760080|NCT04815174|OTHER|Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.
219760081|NCT01044719|DRUG|Ceftazidime|Ceftazidime 2g TDS IV
219760082|NCT01044719|DRUG|Tobramycin|Tobramycin 7mg/kg/day OD IV
219760083|NCT01044719|DRUG|Meropenem|Meropenem 2g TDS IV
219005867|NCT06087107|OTHER|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
219191270|NCT04939038|PROCEDURE|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
219191271|NCT04939038|PROCEDURE|Standard wound care|Standard wound care according to guidelines
219191272|NCT06840652|DRUG|Baclofen|Safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease. The investigators will administer baclofen in increasing doses up to a maximum dose of 10 mg every 8 hours, evaluating the drug's tolerance and its effectiveness in achieving alcohol abstinence. Baclofen will be administered during the patient's hospitalization for decompensation of their liver disease, in patients followed up as outpatients in hepatology clinics, and in those managed as outpatients by psychiatrists specializing in addiction
219191273|NCT03924414|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
219760084|NCT02227745|DRUG|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
219760085|NCT02227745|DRUG|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
219760086|NCT05773469|OTHER|Exercise|Ski traverse of Greenland polar Icecap
219760087|NCT05773469|OTHER|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
219760088|NCT01174563|DRUG|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
219005868|NCT04692571|DEVICE|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
219424797|NCT00797485|DRUG|leucovorin calcium|Given IV
219424798|NCT00408759|BEHAVIORAL|hypnosis|
219424799|NCT04403529|DRUG|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
219424800|NCT04403529|DRUG|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
219424801|NCT06145152|PROCEDURE|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
219424802|NCT06145152|PROCEDURE|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
219424803|NCT01691287|BEHAVIORAL|Michael Method|
219424804|NCT01280266|DRUG|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
219424805|NCT05931133|OTHER|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
219424806|NCT04818528|OTHER|Constraint Induced Movement Therapy and Routine Physical Therapy|"Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization."
219005869|NCT02044705|BEHAVIORAL|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
219191274|NCT03924414|OTHER|Placebo|Normal Saline 100 ml (placebo) IV infusion
219191275|NCT03403257|OTHER|No interventions|No intervention
219191276|NCT05257759|OTHER|Usual care|Standard management offered in the intensive care unit
219424807|NCT04818528|OTHER|Routine Physical Therapy|As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
219424808|NCT01913860|BEHAVIORAL|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
219575862|NCT05288036|OTHER|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
219575863|NCT02023736|OTHER|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
219575864|NCT02023736|OTHER|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
219424809|NCT01734707|DIETARY_SUPPLEMENT|Allicor|
219424810|NCT01734707|DRUG|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
219424811|NCT01274117|PROCEDURE|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
219424812|NCT05244538|DEVICE|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
219424813|NCT05244538|DRUG|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
219424814|NCT00175162|DEVICE|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
219005870|NCT00477971|BIOLOGICAL|filgrastim|No administration information given
219424815|NCT05843812|DRUG|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
219424816|NCT02505815|PROCEDURE|Surgery|
219424817|NCT02505815|PROCEDURE|Cortisol Level Measurement|
219424818|NCT02505815|PROCEDURE|Neurocognitive Testing|
219424819|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
219424820|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
219424821|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
219424822|NCT00778726|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
219424823|NCT04263779|BEHAVIORAL|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
219424824|NCT04263779|BEHAVIORAL|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
219424825|NCT02084069|DRUG|Atorvastatin|
219424826|NCT00861588|DRUG|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
219424827|NCT00861588|DRUG|placebo|starch placebo
219575865|NCT03256084|PROCEDURE|Blood and tumor samples|Blood and tumor samples
219005871|NCT00477971|DRUG|dexamethasone|Given orally
219005872|NCT00477971|DRUG|melphalan|Given IV or orally
219005873|NCT00477971|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
219191277|NCT05257759|OTHER|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
219424828|NCT04655703|DEVICE|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
219424829|NCT02452112|DRUG|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
219424830|NCT02452112|DRUG|Placebo|Placebo patch to be placed on the site of pain
219424831|NCT03273231|DRUG|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
219424832|NCT03273231|DRUG|Saline|0.9% saline solution
219424833|NCT00515580|PROCEDURE|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
219424834|NCT01933321|BIOLOGICAL|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
219424835|NCT02178072|DRUG|5-Azacitadine|
219424836|NCT04499846|OTHER|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
219424837|NCT00215241|DRUG|sertraline and risperidone|
219424838|NCT01422512|BIOLOGICAL|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
219424839|NCT01661309|DIETARY_SUPPLEMENT|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
219424840|NCT01661309|DIETARY_SUPPLEMENT|Methylcobalamin|Aimed at reducing plasma tHcy.
219424841|NCT00280605|DRUG|Alfuzosin|
219424842|NCT02268136|DRUG|BIII 890 CL|
219424843|NCT02268136|DRUG|Placebo|
219424844|NCT06279637|BEHAVIORAL|Joint Home-DM-BAT Intervention|8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.
219424845|NCT06279637|BEHAVIORAL|Usual Care|Diabetes education materials will be mailed weekly and monthly according to the booster schedule
219424846|NCT04062370|DRUG|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
219575866|NCT04426279|OTHER|questionnaire assesment|15-minute face-to-face questionnaire
219575867|NCT02908737|DEVICE|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
219575868|NCT02719106|DEVICE|Ultimaster stent|
219575869|NCT04561687|DRUG|Montelukast|Montelukast and nasal budesonide
219005874|NCT03700671|OTHER|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
219005875|NCT03700671|OTHER|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
219005876|NCT01774968|DRUG|Human Regular U-500 Insulin|
219005877|NCT04984798|DRUG|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
219005878|NCT02044393|DRUG|itraconazole|multiple doses of itraconazole given as capsules
219424847|NCT04062370|DEVICE|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
219575870|NCT04561687|DRUG|Azelastine|Azelastine and nasal budesonide
219575871|NCT04561687|DRUG|Budesonide|To all groups
219575872|NCT04561687|DRUG|Placebo|Placebo and nasal budesonide
219760089|NCT02427932|DRUG|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
219760090|NCT02427932|DRUG|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
219005879|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
219424848|NCT04116073|DRUG|INCMGA00012 (PD-1 antibody)|INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days)
219424849|NCT03200795|OTHER|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017)."
219575873|NCT05001711|DEVICE|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
219760091|NCT02427932|DRUG|Gentamicin|Prescribed to non-pregnant participants
219760092|NCT01761149|DRUG|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
219760093|NCT04670484|OTHER|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
219005880|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
219575874|NCT00857792|DRUG|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
219575875|NCT01310673|DRUG|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
219575876|NCT01310673|DRUG|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
219575877|NCT01566357|OTHER|Toothpaste|
219575878|NCT01566357|DIETARY_SUPPLEMENT|Milk|
219575879|NCT01566357|DIETARY_SUPPLEMENT|Fluoridated Milk|
219575880|NCT01566357|DRUG|Tooth Mousse|
219575881|NCT01566357|DRUG|MI Paste Plus|
219575882|NCT01566357|DRUG|Elmex Erosion Protection|
219575883|NCT03564041|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
219005881|NCT00115687|DRUG|placebo|
219005882|NCT00115687|DRUG|2 mg nicotine polacrilex|
219005883|NCT07000760|DRUG|Ultrasonic atomization of lidocaine|After induction of general anesthesia and before the end of the surgery, 100mg of 2% lidocaine was nebulized and inhaled respectively, and the nebulization time was 15-20 minutes each time.
219005884|NCT07000760|DRUG|Ultrasonic atomization of normal saline|After anesthesia induction and before the end of the surgery, the same volume of normal saline (5ml of 0.9% NaCl) was ultrasonically atomized, and the atomization time was 15-20 minutes each time.
219005885|NCT07000968|OTHER|Virtual Reality Training Group|Virtual Reality Training Procedure; In general, virtual reality training will be developed taking into account neurorehabilitation principles; Type of game and specificity (there will be exercises specific to the disease), Intensity (will be gradually increased), Progress (exercises will be gradually progressed, variability (the environment will be changed) and Feedback (visual and auditory feedback will be provided). The virtual reality training to be applied will also be fun, It will include attention and problem-solving ability. The difficulty and skill level will gradually increase in order to ensure continuity of motivation and motor learning in individuals. It will be aimed to perform the exercises at moderate to severe intensity. The intensity level of the exercises will be at moderate intensity, and the perceived effort according to the Borg Scale will be 12- It will be checked by asking for 15 points.
219575884|NCT03564041|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
219575885|NCT01797835|BEHAVIORAL|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
219575886|NCT01797835|BEHAVIORAL|usual care|Youth receive a brochure with information on AOD use.
219575887|NCT03932123|DRUG|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
219575888|NCT00008151|DRUG|cyclosporine|
219575889|NCT00008151|DRUG|fludarabine phosphate|
219760094|NCT01395745|DRUG|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
219424850|NCT03200795|OTHER|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
219005886|NCT07000968|OTHER|Task-Oriented Training Group|ask Oriented Training Procedure; Task-oriented training focusing on improving balance and walking will consist of 8 different exercise stations. Individuals will continue the exercise at each station for 4 minutes and rest for 1 minute before moving on to the next station. The training completed in this way will consist of a total of 40 minutes and the exercise stations will be applied following the determined order: The exercises will first be demonstrated by the physiotherapist. The aim is to perform exercises at moderate to vigorous intensity. It will be checked that the intensity level of the exercises is moderate and that the perceived effort is 12-15 points according to the Borg Scale. Perception of perceived exertion; It will be controlled by asking to increase the speed, changing the ground, giving double tasks and using obstacles made of wooden blocks. Individuals will be given visual and auditory positive feedback during the exercises.
219424851|NCT05041491|BEHAVIORAL|BREAK|The BREAK intervention is a physical activity regimen.
219424852|NCT05041491|BEHAVIORAL|ONE|The ONE intervention is a physical activity regimen.
219424853|NCT02103036|PROCEDURE|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
219424854|NCT02103036|PROCEDURE|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
219424855|NCT02103036|DEVICE|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
219424856|NCT02103036|DEVICE|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
219424857|NCT01110772|DEVICE|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
219424858|NCT01110772|DEVICE|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
219424859|NCT06281574|PROCEDURE|Questionnaires|"To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)"
219424860|NCT02919137|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
219424861|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
219424862|NCT06701188|BEHAVIORAL|Virtual Coaching and social support|The investigators propose a randomized clinical trial (RCT) of a virtual coaching and social support intervention that integrates evidence- and theory-based approaches to build self-efficacy, self-regulation, and perceived social support after cardiac rehabilitation (CR) to improve physical activity, psychosocial, social cognitive, and clinical outcomes, delivered via a social networking platform (Trainerize). Our intervention will also include goal setting for exercise and tailored feedback by our qualified intervention team.
219424863|NCT05929352|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
219424864|NCT06799234|BIOLOGICAL|ChAdOx1 RVF|One 0.36mL dose contains 5x10\^10vp ChAdOx1 RVF.
219424865|NCT06799234|BIOLOGICAL|Rabies Vaccine|1mL per dose
219424866|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
219424867|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
219424868|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
219575890|NCT00008151|DRUG|gemtuzumab ozogamicin|
219575891|NCT00008151|DRUG|methotrexate|
219575892|NCT00008151|DRUG|mycophenolate mofetil|
219575893|NCT00008151|PROCEDURE|allogeneic bone marrow transplantation|
219575894|NCT00008151|PROCEDURE|peripheral blood stem cell transplantation|
219575895|NCT00008151|RADIATION|radiation therapy|
219005887|NCT07000968|OTHER|Conventional Training Group|Individuals in this group will continue classical physiotherapy exercises. There will be no intervention by us in the traditional training group.
219424869|NCT04871139|OTHER|Radioactive Iodine|Given IV
219424870|NCT00695214|DRUG|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
219424871|NCT06263699|PROCEDURE|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
219575896|NCT02528123|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
219575897|NCT02528123|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
219575898|NCT02528123|DRUG|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
219005888|NCT07000838|DEVICE|Medially wedged ortheses|3 month long wear of medially wedged ortheses. Ortheses have to be worn for 6 to 8 hours daily during work shifts.
219005889|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
219424872|NCT05799079|DRUG|Venetoclax|Given by mouth
219424873|NCT05799079|DRUG|Decitabine|Given by mouth
219424874|NCT05799079|DRUG|Cedazuridine|Given by mouth
219424875|NCT05799079|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy
219424876|NCT05799079|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219191278|NCT05257759|OTHER|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
219424877|NCT06256029|PROCEDURE|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
219575899|NCT02528123|DRUG|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
219575900|NCT02528123|DRUG|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
219575901|NCT00687310|BEHAVIORAL|Educational intervention|Tailored asthma education based on needs assessment
219575902|NCT01598350|DEVICE|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
219575903|NCT03728634|DRUG|ION-682884|ION-682884 administered SC
219575904|NCT03728634|DRUG|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
219575905|NCT03728634|DIETARY_SUPPLEMENT|Vitamin A|Oral supplement
219760095|NCT01395745|DRUG|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
219760096|NCT03402841|DRUG|Olaparib|300 mg twice daily - oral
219424878|NCT03894098|PROCEDURE|Nerve block|High ankle nerve block
219424879|NCT04041908|OTHER|Experimental Product|2 sachets per day
219424880|NCT02330913|PROCEDURE|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
219424881|NCT01927393|OTHER|palliative care|Receive PCPI
219424882|NCT01927393|BEHAVIORAL|educational intervention|Receive education sessions
219424883|NCT01927393|PROCEDURE|quality-of-life assessment|Ancillary studies
219424884|NCT01927393|OTHER|questionnaire administration|Ancillary studies
219424885|NCT01927393|BEHAVIORAL|telephone-based intervention|Receive telephone contacts
219760097|NCT03174067|DRUG|Buprenorphine|The participant receives buprenorphine
219424886|NCT04365894|OTHER|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
219424887|NCT01241123|PROCEDURE|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
219424888|NCT01241123|DRUG|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
219424889|NCT01241123|RADIATION|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
219424890|NCT01241123|DEVICE|pedometers|to record the amount of ambulation
219424891|NCT05814471|DEVICE|Cable fastening system and 3d printed straps(14 days)|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
219575906|NCT03185234|DEVICE|anodal tDCS|2 mA, 10 min, 5 sessions
219575907|NCT03185234|DEVICE|sham tDCS|sham stimulation, 10 min, 5 sessions
219575908|NCT01345435|PROCEDURE|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
219575909|NCT01345435|PROCEDURE|Telemonitoring & Telemedicine|The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
219575910|NCT01345435|OTHER|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
219575911|NCT02148341|OTHER|Community of Practice Facilitation|
219575912|NCT02148341|OTHER|Usual Care|
219760098|NCT03174067|DRUG|Clonidine|The participant receives clonidine
219424892|NCT05814471|DEVICE|Velcro straps system(14 days)|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
219424893|NCT05814471|DEVICE|Adjustment period(Velcro-14 days)|The participants will wear a new Odra knee brace held in place with by a velcro straps system for 2 weeks.
219424894|NCT04904614|DRUG|Letermovir|Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
219424895|NCT02816879|PROCEDURE|Cytology Specimen Collection Procedure|Undergo anal cytology collection
219424896|NCT02816879|OTHER|Laboratory Biomarker Analysis|Correlative studies
219424897|NCT03241732|OTHER|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
219424898|NCT03241732|DIETARY_SUPPLEMENT|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
219424899|NCT03241732|BEHAVIORAL|Neuro Emotive Technique|Neuro Emotive Technique sessions
219424900|NCT04906135|OTHER|Experimental manipulation of stimulation parameters|This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
219424901|NCT04702165|DEVICE|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
219424902|NCT05840614|BEHAVIORAL|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
219424903|NCT04459052|DIETARY_SUPPLEMENT|N acetyl cysteine|Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
219424904|NCT04459052|DRUG|[F-18] Fluorodopa Positron Emission Tomography|FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
219424905|NCT05625828|BEHAVIORAL|Cognitive-motor Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of cognitive-motor exercises where participants have to perform two tasks consequently (for example, walking while answering math questions or throwing a ball while reverse walking) and 5 minutes of stretching exercises.
219424906|NCT05625828|BEHAVIORAL|Multifactorial Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of multifactorial exercises that consists of high speed walking, resistance training and balance training in single task condition and 5 minutes of stretching exercises.
219424907|NCT01383642|OTHER|No intervention, observational study|
219424908|NCT05256082|DIAGNOSTIC_TEST|six-minutes-walking test|Patients conducting a six-minutes-walking test
219424909|NCT00881361|DRUG|systemic chemotherapy|
219575913|NCT02158611|OTHER|Lifestyle counseling|
219575914|NCT00198653|BEHAVIORAL|Newborn Thermal Care Practice|
219575915|NCT04505293|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
219575916|NCT05172466|DEVICE|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
219760099|NCT01198665|DRUG|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
219191279|NCT03743532|BEHAVIORAL|E-cigarette Switching|Participants provided with e-cigarette device and nicotine pods and advised to switch from combustible cigarettes to e-cigarettes.
219424910|NCT00881361|PROCEDURE|axillary lymph node dissection|
219424911|NCT00881361|PROCEDURE|neoadjuvant therapy|
219424912|NCT00881361|PROCEDURE|sentinel lymph node biopsy|
219424913|NCT00881361|PROCEDURE|therapeutic conventional surgery|
219424914|NCT00881361|PROCEDURE|ultrasound imaging|
219424915|NCT02445599|DRUG|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
219424916|NCT02445599|DRUG|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
219424917|NCT02445599|DRUG|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
219424918|NCT02445599|DRUG|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
219424919|NCT02445599|DRUG|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
219424920|NCT02445599|DRUG|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
219424921|NCT02445599|DRUG|Metamizole-sodium|Additional rescue analgetic 2g intravenously
219424922|NCT02445599|DRUG|Tramadol|Additional rescue analgetic 100mg intravenously
219424923|NCT03101046|DRUG|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
219424924|NCT03101046|DRUG|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
219424925|NCT00957255|DEVICE|OrthoADAPT|soft tissue augmentation device
219424926|NCT00957255|PROCEDURE|Standard of care|Standard of care rotator cuff repair
219424927|NCT00012883|BEHAVIORAL|Homewalking exercise program|
219424928|NCT02585726|DEVICE|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
219424929|NCT04765618|PROCEDURE|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
219424930|NCT00365768|DRUG|Glutamine|Administered orally twice daily for 21 days
219424931|NCT00365768|OTHER|Placebo|Administered orally twice daily for 21 days
219424932|NCT02467829|DEVICE|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
219424933|NCT01930526|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
219424934|NCT01413542|DRUG|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
219424935|NCT01413542|DRUG|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
219424936|NCT01413542|DRUG|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
219424937|NCT01413542|DRUG|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
219424938|NCT01413542|DRUG|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
219424939|NCT01413542|DRUG|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
219424940|NCT00993395|BEHAVIORAL|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
219760100|NCT01347060|DRUG|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
219760101|NCT01347060|DRUG|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
219760102|NCT00309283|DRUG|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
219424941|NCT03281447|OTHER|Nurse navigation|
219424942|NCT03281447|OTHER|Current care coordination|
219424943|NCT03685487|PROCEDURE|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
219424944|NCT03685487|OTHER|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
219424945|NCT04782986|DIAGNOSTIC_TEST|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
219424946|NCT03748277|PROCEDURE|Decompression|Bilateral decompression
219424947|NCT03748277|PROCEDURE|PLIF|Traditional open surgery
219424948|NCT03748277|PROCEDURE|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
219424949|NCT03748277|PROCEDURE|Screw Fixation|Transpedicular Screw Fixation
219424950|NCT03795818|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
219424951|NCT02806466|PROCEDURE|Fiberoptic bronchoscopy|
219424952|NCT02505542|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
219424953|NCT02505542|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
219424954|NCT02681185|OTHER|Virtual Care|"Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
219424955|NCT02681185|OTHER|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
219760103|NCT00309283|OTHER|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
219760104|NCT00178009|BEHAVIORAL|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
219760105|NCT00100425|PROCEDURE|Viceral Perception Testing|
219760106|NCT02666560|DEVICE|Auditory Cueing|Auditory cueing set at different frequency rates
219760107|NCT00293176|DRUG|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
219760108|NCT00293176|DRUG|Placebo|Subjects will receive matching placebo tablets.
219760109|NCT05358002|PROCEDURE|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
219424956|NCT02764983|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
219424957|NCT02764983|BEHAVIORAL|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
219424958|NCT02764983|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
219424959|NCT02764983|BEHAVIORAL|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
219424960|NCT02764983|BEHAVIORAL|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
219424961|NCT02764983|BEHAVIORAL|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
219424962|NCT02764983|PROCEDURE|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
219424963|NCT02764983|OTHER|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
219424964|NCT02570282|DRUG|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
219424965|NCT02570282|DRUG|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
219424966|NCT03895112|DRUG|AVID200|dose cohorts of 21-day cycles
219424967|NCT01668030|DRUG|Enzymatic agent|Enzymatic agent
219760110|NCT01737892|DRUG|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
219760111|NCT01737892|DRUG|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
219005890|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet) +RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days."
219005891|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~RIF: 600 mg (4 capsules), 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
219005892|NCT07000929|DIAGNOSTIC_TEST|Videonystagmography|In the regular examination of patients with vertigo, videonystagmography with thermal testing (caloric) is already an established and necessary examination procedure that is used to diagnose many different vertigo disorders.
219191280|NCT03743532|BEHAVIORAL|Financial Incentives|Participants earned incentives for carbon monoxide-verified combustible cigarette abstinence.
219424968|NCT01668030|DRUG|Bacitracin|
219424969|NCT02651792|DRUG|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
219424970|NCT02651792|DRUG|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
219424971|NCT02783144|PROCEDURE|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
219424972|NCT02783144|OTHER|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
219424973|NCT02783144|DRUG|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
219760112|NCT03732755|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
219760113|NCT00006379|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
219760114|NCT00006379|BIOLOGICAL|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
219760115|NCT00006379|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
219760116|NCT00006379|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
219760117|NCT00006379|PROCEDURE|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
219760118|NCT00645502|DRUG|risperidone|
219760119|NCT01542788|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219760120|NCT01542788|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
219760121|NCT01542788|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
219760122|NCT01542788|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
219005893|NCT06876103|OTHER|Religiously-integrated Cognitive Behavioral Therapy|"This study aims to assess the efficacy and feasibility of a newly developed online intervention for death anxiety based on Religiously Integrated Cognitive Behavioral Therapy (RCBT). Building upon the framework of Furer and Walker's 2008 intervention protocol, this adaptation incorporates beliefs in an afterlife, aligning with Turkish society's cultural and religious values.~The RCBT intervention consists of seven structured group therapy sessions, each lasting 90 minutes. The program is designed to help participants identify and challenge unhelpful thoughts related to death anxiety while integrating religious resources to promote cognitive restructuring. Key components of the intervention include psychoeducation, cognitive restructuring, exposure exercises, the concept of repentance in the context of trust and belief in the afterlife, gratitude, and value-oriented behaviors."
219424974|NCT00895648|DRUG|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
219424975|NCT00895648|DRUG|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
219424976|NCT00526461|DRUG|HPPH|IV
219424977|NCT03645889|OTHER|PLTG|A combination of 13 herbal granules
219424978|NCT03645889|OTHER|Placebo|90% starch filler and 10% PLTG
219424979|NCT00618995|DRUG|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
219424980|NCT00618995|DRUG|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
219424981|NCT00618995|DRUG|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
219575917|NCT04657926|DRUG|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
219575918|NCT04657926|DRUG|Placebo|Placebo capsules
219424982|NCT00618995|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
219424983|NCT02420301|OTHER|Tuina exercises|
219424984|NCT02420301|OTHER|Placebo Tuina exercises|
219424985|NCT01503580|DRUG|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
219424986|NCT00367029|BEHAVIORAL|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
219191281|NCT03643107|DRUG|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
219424987|NCT01428999|DIETARY_SUPPLEMENT|probiotics|probiotics 1 pack (2g) bid for three weeks
219424988|NCT05825599|DEVICE|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
219424989|NCT03634917|DRUG|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
219424990|NCT03634917|DRUG|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
219424991|NCT03634917|DRUG|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
219424992|NCT03634917|DRUG|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
219424993|NCT03316677|PROCEDURE|Intraoperative testing of colorectal anastomoses|"1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
219424994|NCT03316677|PROCEDURE|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
219424995|NCT01701219|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
219424996|NCT02988219|DRUG|Bupivacaine-fentanyl|Local anesthetic
219575919|NCT04295135|BEHAVIORAL|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
219575920|NCT02327416|DRUG|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
219575921|NCT02327416|DRUG|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
219424997|NCT02988219|DEVICE|Holter ECG monitor|3-chanel, CM5 leads
219424998|NCT02988219|PROCEDURE|Open kidney cancer surgery|Lateral position
219424999|NCT02988219|PROCEDURE|General anesthesia|
219425000|NCT02988219|PROCEDURE|Epidural Anaesthesia|
219425001|NCT00870974|DRUG|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
219425002|NCT06365476|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
219425003|NCT05420194|OTHER|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
219425004|NCT05420194|OTHER|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
219575922|NCT02327416|DRUG|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
219575923|NCT01517659|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219425005|NCT02538367|DRUG|YH12852 IR 0.05mg|
219425006|NCT02538367|DRUG|YH12852 IR 0.1mg|
219005894|NCT06876103|OTHER|Classical Cognitive Behavioral Therapy|"The standard CBT intervention follows the structured protocol developed by Furer and Walker (2008), which targets cognitive distortions, avoidance behaviors, and excessive safety-seeking behaviors contributing to death anxiety. The researcher has adapted the session content to fit the protocol's core components while maintaining fidelity to the original intervention model. Sessions last 90 minutes and are conducted in an online group format.~Session Structure: Session 1: Treatment Rationale, Session 2: Reducing Excessive Checking, Reassurance Seeking, and Safety Behaviors, Session 3: Exposure, Session 4: Cognitive Reappraisal, Session 5: Enhancing Enjoyment of Life, Session 6: Healthy Lifestyle, and Session 7: Relapse Prevention."
219005895|NCT07035457|DRUG|Vicadrostat|Vicadrostat
219425007|NCT02538367|DRUG|YH12852 IR 0.3mg|
219425008|NCT02538367|DRUG|YH12852 IR 0.5mg|
219425009|NCT02538367|DRUG|YH12852 IR 1mg|
219575924|NCT05177874|DEVICE|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
219575925|NCT05177874|DEVICE|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
219005896|NCT07035457|DRUG|Jardiance®|Jardiance®
219425010|NCT02538367|DRUG|YH12852 IR 2mg|
219425011|NCT02538367|DRUG|YH12852 IR 3mg|
219425012|NCT02538367|DRUG|YH12852 DR1 0.5mg|
219425013|NCT02538367|DRUG|YH12852 DR1 1mg|
219425014|NCT02538367|DRUG|YH12852 DR1 2mg|
219425015|NCT02538367|DRUG|YH12852 DR1 4mg|
219425016|NCT02538367|DRUG|YH12852 DR2 8mg|
219425017|NCT02538367|DRUG|Prucalopride 2mg|
219425018|NCT02538367|DRUG|Placebo|
219425019|NCT01057914|DIETARY_SUPPLEMENT|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
219425020|NCT01057914|OTHER|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
219575926|NCT00474474|PROCEDURE|Virtual patient is NOT introduced|
219575927|NCT00048204|DRUG|GW597599B|
219575928|NCT00048204|DRUG|paroxetine|
219575929|NCT00376025|DIETARY_SUPPLEMENT|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
219575930|NCT00698893|BIOLOGICAL|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
219575931|NCT03525925|DRUG|Ibrutinib|Given PO
219575932|NCT03525925|OTHER|Laboratory Biomarker Analysis|Correlative studies
219425021|NCT01057914|OTHER|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
219425022|NCT01522443|DRUG|cabozantinib|Tablets taken orally once daily.
219425023|NCT01522443|DRUG|mitoxantrone|Given by IV once every 3 weeks.
219425024|NCT01522443|DRUG|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
219425025|NCT01256983|BEHAVIORAL|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
219425026|NCT01256983|BEHAVIORAL|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
219425027|NCT01444313|DEVICE|narafilcon A contact lens|Soft contact lenses with UV protection
219425028|NCT01444313|DEVICE|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
219425029|NCT04744636|DRUG|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
219575933|NCT03525925|BIOLOGICAL|Nivolumab|Given IV
219575934|NCT03484117|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
219575935|NCT00002752|RADIATION|iodine I 131 monoclonal antibody 81C6|
219575936|NCT00054600|DRUG|Methoxsalen|
219575937|NCT00054600|PROCEDURE|Extracorporeal Photopheresis|
219575938|NCT04578652|DRUG|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
219425030|NCT04744636|DRUG|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
219425031|NCT00403819|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
219425032|NCT05590767|PROCEDURE|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
219425033|NCT00233818|DEVICE|Sirolimus-coated Bx VELOCITY Stent|
219425034|NCT00228930|DRUG|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
219425035|NCT01866345|PROCEDURE|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
219425036|NCT01866345|PROCEDURE|Conventional orthodontic treatment|Conventional orthodontic Procedure
219425037|NCT06965907|OTHER|Kinesio Taping|The participant will be seated upright in a chair with the elbow flexed at 90 degrees. The forearm under examination will be placed in a pronated position, and the wrist will be maintained in a neutral position. I-shaped kinesio taping will be applied as described by Mohammadi et al. Prior to taping, the extensor surface will be cleaned using a cotton swab moistened with alcohol. The tape length will be measured from a point 2 cm distal to the lateral epicondyle to the radial styloid process. Each end of the tape will be 2 cm in length (totaling 4 cm for both ends). To achieve 35% tension, the following formula will be used: (L - 4) / 1.35 + 4. In this formula, L represents the total length of the tape, 4 is the combined length of the two tape ends, and 1.35 corresponds to the factor required to achieve the desired 35% tension.
219425038|NCT06965907|OTHER|Sham Taping|The participant will be seated in a chair with the forearm resting comfortably. The tape will be applied to the middle of the forearm without any tension. The taping will be performed from the medial to the lateral direction.
219425039|NCT01764256|BIOLOGICAL|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
219425040|NCT01764256|OTHER|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
219425041|NCT03102177|DRUG|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
219425042|NCT01874249|OTHER|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
219425043|NCT01874249|OTHER|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
219425044|NCT01874249|OTHER|Transient elastography|Transient elastography values greater than 8 kPa
219425045|NCT02067741|DRUG|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
219425046|NCT02451202|PROCEDURE|Deep Neuromuscular Blockade|"* During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
219575939|NCT04578652|DIETARY_SUPPLEMENT|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
219575940|NCT03403166|BEHAVIORAL|DASH diet|Diet intervention
219575941|NCT03403166|BEHAVIORAL|Fruits and vegetables diet|Diet intervention
219575942|NCT03403166|BEHAVIORAL|Control diet|Diet intervention
219575943|NCT00930254|PROCEDURE|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
219575944|NCT01138865|DEVICE|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
219575945|NCT01138865|DEVICE|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
219425047|NCT02451202|PROCEDURE|Moderate Neuromuscular Blockade|\- During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
219425048|NCT02451202|DRUG|Sugammadex|
219425049|NCT02451202|DRUG|Rocuronium|
219425050|NCT04717778|DIETARY_SUPPLEMENT|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
219575946|NCT03325465|DRUG|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
219575947|NCT03325465|DRUG|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
219425051|NCT04328922|OTHER|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
219575948|NCT00281606|DRUG|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
219575949|NCT00289874|DRUG|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
219005897|NCT06912919|OTHER|BFR-Aerobic Training|Low-intensity cycling exercise with BFR (pressure of 160-180 mmHg) for 20 minutes, 3 days a week for 6 weeks.
219425052|NCT04328922|OTHER|Placebo capsuls|capsules of glycerol and saline (placebo).
219425053|NCT04131985|PROCEDURE|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
219425054|NCT03373110|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy|see arm description
219425055|NCT03373110|BEHAVIORAL|Online Cognitive Behavioral Therapy|see arm description
219425056|NCT03373110|BEHAVIORAL|Fitbit Alone|see arm description
219425057|NCT05096494|DRUG|SP-103|SP-103 topical system is worn daily for 12 hours per day for 28 days
219575950|NCT00289874|DRUG|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
219005898|NCT06912919|OTHER|Aerobic Training Without BFR|Low-intensity cycling exercise (without BFR) for 20 minutes, 3 days a week for 6 weeks.
219005899|NCT05094622|OTHER|Physical exercise program|A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
219005900|NCT02148692|PROCEDURE|Higher PEEP|
219005901|NCT02148692|PROCEDURE|Lower PEEP|
219005902|NCT00998660|DEVICE|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
219425058|NCT05096494|DRUG|Placebo|Placebo topical system is worn daily for 12 hours per day, for 28 days
219425059|NCT04871230|DIAGNOSTIC_TEST|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
219425060|NCT04871230|DIAGNOSTIC_TEST|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
219425061|NCT04871230|DIAGNOSTIC_TEST|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
219425062|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
219425063|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
219425064|NCT03407508|DIETARY_SUPPLEMENT|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
219425065|NCT00305812|DRUG|dexamethasone|
219425066|NCT00305812|DRUG|lenalidomide|
219425067|NCT00305812|DRUG|melphalan|
219425068|NCT02452268|DRUG|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
219425069|NCT02452268|DRUG|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
219425070|NCT05185648|BEHAVIORAL|standard trauma care taining|trauma care training
219425071|NCT03329599|DRUG|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
219425072|NCT03917082|DRUG|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
219425073|NCT05976932|DRUG|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
219425074|NCT02755142|BIOLOGICAL|Gliolan|
219425075|NCT03876145|OTHER|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
219425076|NCT04161612|OTHER|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
219425077|NCT01827241|OTHER|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
219425078|NCT03063853|OTHER|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
219425079|NCT03063853|PROCEDURE|Elective cesarean delivery|non emergent elective cesarean delivery
219425080|NCT06318221|DIETARY_SUPPLEMENT|Experimental (Immunonutrition) Group|"Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group."
219425081|NCT06318221|DIETARY_SUPPLEMENT|Active Comparator Group ( Standard enteral nutrition)|"Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group."
219425082|NCT03419936|DIAGNOSTIC_TEST|Endoscopic biopsy|"1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
219425083|NCT01056419|PROCEDURE|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
219425084|NCT01056419|DRUG|Propylthiouracil|150-600 mg in two-three divided doses
219425085|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
219425086|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
219425087|NCT06263231|DRUG|INT230-6|INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
219575951|NCT05594303|BIOLOGICAL|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
219005903|NCT04738344|DEVICE|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
219005904|NCT00973739|DRUG|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
219425088|NCT06263231|DRUG|Eribulin|Eribulin IV
219425089|NCT06263231|DRUG|Trabectedin|Trabectedin infusion
219425090|NCT06263231|DRUG|Pazopanib|Pazopanib pill
219425091|NCT01274312|PROCEDURE|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
219425092|NCT06642610|DEVICE|CGM Dynamic Index (CDI)|Participants will undergo one-time oral glucose tolerance test (OGTT) and a one-time use of a CGM device, which will be worn for up to 10 days.
219425093|NCT03745300|DRUG|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
219425094|NCT03745300|DRUG|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
219425095|NCT03745300|DRUG|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
219425096|NCT00335998|DRUG|triapine|Given IV
219425097|NCT00335998|OTHER|laboratory biomarker analysis|Correlative studies
219425098|NCT00335998|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
219425099|NCT00335998|RADIATION|brachytherapy|Undergo intracavitary or interstitial brachytherapy
219425100|NCT00335998|DRUG|cisplatin|Given IV
219425101|NCT00335998|OTHER|pharmacological study|Correlative studies
219425102|NCT04875403|OTHER|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
219425103|NCT04875403|OTHER|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
219425104|NCT03630484|OTHER|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
219425105|NCT03630484|OTHER|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
219425106|NCT01833325|RADIATION|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
219425107|NCT01804036|DRUG|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
219425108|NCT01804036|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
219425109|NCT00164736|DRUG|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
219005905|NCT03475537|DEVICE|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
219005906|NCT05937191|DRUG|Leflunomide|Leflunomide+Glucocorticoids treatment Group
219005907|NCT05937191|DRUG|Steroid Drug|Steroid Treatment
219005908|NCT03401424|PROCEDURE|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
219425110|NCT00164736|DRUG|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
219425111|NCT00164736|DIETARY_SUPPLEMENT|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
219425112|NCT03962556|OTHER|bimanual palpation|bimanual palpation....i..
219425113|NCT02199613|DRUG|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
219575952|NCT06258603|OTHER|oral care bundle|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
219425114|NCT05708937|BEHAVIORAL|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body \& Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
219425115|NCT03297437|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
219425116|NCT05161182|OTHER|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
219425117|NCT05161182|OTHER|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
219425118|NCT05265130|DRUG|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
219425119|NCT05265130|DRUG|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
219425120|NCT03452891|OTHER|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
219425121|NCT03452891|DRUG|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
219425122|NCT00776555|DRUG|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
219425123|NCT00776555|DRUG|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
219425124|NCT00002212|DRUG|Bexarotene|
219575953|NCT06258603|OTHER|clinical oral care|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
219760123|NCT02112084|BEHAVIORAL|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
219760124|NCT02972307|OTHER|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
219425125|NCT04744701|DIAGNOSTIC_TEST|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
219425126|NCT04776421|PROCEDURE|Diverting ileostomy|Diverting ileostomy
219005909|NCT03401424|PROCEDURE|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
219005910|NCT03780283|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
219005911|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
219005912|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
219425127|NCT02711904|DRUG|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h."
219575954|NCT06058286|OTHER|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
219425128|NCT02711904|DRUG|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h."
219425129|NCT02086721|DRUG|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
219425130|NCT02878512|PROCEDURE|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
219425131|NCT02878512|PROCEDURE|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
219575955|NCT05500196|DEVICE|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
219575956|NCT05597735|DRUG|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
219575957|NCT05597735|DRUG|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
219575958|NCT02924636|BEHAVIORAL|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
219760125|NCT05572294|BEHAVIORAL|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
219760126|NCT03315585|DEVICE|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
219760127|NCT03419182|PROCEDURE|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
219760128|NCT03419182|PROCEDURE|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
219760129|NCT05781581|OTHER|no intervention|no intervention
219760130|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
219760131|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
219191282|NCT03643107|COMBINATION_PRODUCT|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
219005913|NCT02492347|PROCEDURE|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
219575959|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
219575960|NCT00505648|DRUG|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
219760132|NCT03537703|COMBINATION_PRODUCT|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
219760133|NCT02092714|OTHER|laboratory biomarker analysis|Correlative studies
219760134|NCT05772871|DRUG|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
219760135|NCT05772871|DRUG|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
219760136|NCT05772871|DRUG|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
219760137|NCT05772871|DRUG|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
219425132|NCT02330107|OTHER|MAT & LAT|"For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
219425133|NCT06275243|DIAGNOSTIC_TEST|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
219425134|NCT06275243|OTHER|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
219425135|NCT06275243|OTHER|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
219425136|NCT06016140|OTHER|Medication plan|Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
219575961|NCT00210613|DRUG|Dapoxetine|
219760138|NCT05772871|DRUG|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
219760139|NCT04445948|DRUG|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
219760140|NCT04445948|DRUG|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
219760141|NCT04445948|DRUG|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
219760142|NCT04445948|DRUG|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
219760143|NCT04445948|DRUG|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
219005914|NCT00428896|DRUG|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
219425137|NCT04206527|BEHAVIORAL|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
219425138|NCT04206527|BEHAVIORAL|Enhanced FP training|Participation in an enhanced FP training including PCC
219425139|NCT03000387|DRUG|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
219575962|NCT04247152|OTHER|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
219575963|NCT00313456|DRUG|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
219005915|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
219005916|NCT05565651|OTHER|Fecal microbiota analysis|Data analysis
219425140|NCT03000387|DRUG|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
219425141|NCT02830035|PROCEDURE|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
219425142|NCT02830035|PROCEDURE|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
219425143|NCT05341635|DIAGNOSTIC_TEST|Swab sampling|Collection of three nose-pharyngeal and oral swabs
219425144|NCT03671382|BEHAVIORAL|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
219575964|NCT06166238|PROCEDURE|Millard and Tension Randal Technique|Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
219425145|NCT04260061|DEVICE|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
219425146|NCT05816967|PROCEDURE|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
219425147|NCT02308176|BEHAVIORAL|APP + health advice|health advice and reinforcement to it
219425148|NCT02308176|BEHAVIORAL|health advice|health advice
219425149|NCT01478399|DRUG|PB1023 Injection|90 mg Dose
219425150|NCT03223493|OTHER|No treatment given|Completion of a questionnaire
219425151|NCT03483116|BIOLOGICAL|RV3-BB|Oral administration
219425152|NCT03483116|BIOLOGICAL|Placebo|Oral administration
219425153|NCT01181102|DRUG|edoxaban|
219425154|NCT01181102|DRUG|enoxaparin sodium|
219425155|NCT03120728|DRUG|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
219425156|NCT00866515|DRUG|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
219425157|NCT00866515|DRUG|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
219425158|NCT04776564|OTHER|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
219425159|NCT03119818|DEVICE|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
219575965|NCT03939325|RADIATION|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
219575966|NCT04218500|OTHER|Niacinamide 4%|cream moisturizer
219575967|NCT04218500|OTHER|Virgin Coconut oil 30%|cream moisturizer
219760144|NCT04069988|BEHAVIORAL|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
219760145|NCT06652295|OTHER|Complex decongestive physiotherapy (CDP)|CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
219425160|NCT03119818|OTHER|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
219425161|NCT06086756|BEHAVIORAL|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
219425162|NCT06086756|BEHAVIORAL|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
219425163|NCT04846894|DIAGNOSTIC_TEST|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
219425164|NCT03548974|BEHAVIORAL|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
219425165|NCT03548974|BEHAVIORAL|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
219425166|NCT03438578|DEVICE|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
219425167|NCT04990661|BEHAVIORAL|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
219425168|NCT00000361|DRUG|Corticosteroids|
219425169|NCT00000361|DRUG|Methotrexate|
219425170|NCT05831527|DRUG|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
219425171|NCT03945903|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
219425172|NCT03743207|OTHER|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
219425173|NCT03743207|OTHER|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
219425174|NCT05459766|BEHAVIORAL|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
219575968|NCT04414306|OTHER|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
219575969|NCT04414306|OTHER|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
219760146|NCT06652295|OTHER|Self-administered Complex Decongestive Physiotherapy (CDP)|The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
219760147|NCT01280968|BIOLOGICAL|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
219425175|NCT05459766|BEHAVIORAL|Usual care|Participants will be educated about the postoperative rehabilitation program
219425176|NCT04819581|DRUG|SP-103|lidocaine topical system 5.4%
219425177|NCT04819581|DRUG|ZTlido|lidocaine topical system 1.8%
219425178|NCT04226963|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
219005917|NCT02315781|DEVICE|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
219005918|NCT02315781|DEVICE|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
219191283|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
219191284|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
219575970|NCT04414306|OTHER|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
219005919|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
219005920|NCT02345850|PROCEDURE|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
219191285|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
219191286|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
219425179|NCT05840341|DRUG|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
219425180|NCT04685499|DRUG|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
219425181|NCT04685499|DRUG|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
219425182|NCT03176277|DRUG|ONO-7475 3mg once daily|Part A initial dose level
219425183|NCT03176277|DRUG|ONO-7475 6mg once daily|Part A 2nd dose level
219425184|NCT03176277|DRUG|ONO-7475 10mg once daily|Part A 3rd dose level
219425185|NCT03176277|DRUG|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax Combination
219425186|NCT05015738|OTHER|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
219425187|NCT05015738|DEVICE|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
219425188|NCT04508062|PROCEDURE|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
219425189|NCT04508062|PROCEDURE|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
219575971|NCT04414306|OTHER|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
219575972|NCT05559775|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
219575973|NCT01131572|DRUG|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
219575974|NCT05854082|DRUG|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
219005921|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
219191287|NCT02424617|DRUG|Erlotinib|Participants received erlotinib 150 mg for the 21-day cycle.
219191288|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 600 mg on Days 1 and 2 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
219425190|NCT04565600|DRUG|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
219425191|NCT00634114|DRUG|Esomeprazole|10mg once daily oral administration
219425192|NCT00634114|DRUG|Esomeprazole|20mg once daily oral administration
219425193|NCT00634114|DRUG|Omeprazole|10mg once daily oral administration
219425194|NCT02598505|DRUG|Indacaterol|
219425195|NCT02598505|DRUG|Placebo|
219425196|NCT04895098|DRUG|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
219760148|NCT01280968|BIOLOGICAL|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
219760149|NCT02181920|DRUG|Metamizole|
219760150|NCT02181920|DRUG|Diclofenac|
219425197|NCT04895098|DRUG|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
219425198|NCT01442532|DRUG|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
219425199|NCT01442532|DRUG|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
219425200|NCT01442532|DRUG|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
219425201|NCT01442532|DRUG|Placebo|Form=tablet, route=oral use, for 14 days
219425202|NCT01442532|DRUG|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
219425203|NCT04742049|OTHER|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
219425204|NCT04742049|OTHER|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
219425205|NCT06999993|DRUG|Sodium hyaluronate jell|sodium hyaluronate gel was used to decrease or prevent tissue lyres adhesion after surgery
219425206|NCT06999993|DRUG|Sodium Bicarbonate|sodium bicarbonate decreases tissue acidosis and so it decreases fibrosis
219425207|NCT06999993|DRUG|Saline|saline 0.9% is a placebo
219425208|NCT00344149|DRUG|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
219425209|NCT03292679|PROCEDURE|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
219425210|NCT02940626|DRUG|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
219425211|NCT02940626|DRUG|Placebo|Placebo
219425212|NCT01364350|OTHER|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
219425213|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
219425214|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
219425215|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425216|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
219425217|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
219425218|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425219|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
219425220|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
219425221|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425222|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
219425223|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
219425224|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
219425225|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425226|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
219425227|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
219425228|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
219425229|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425230|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
219425231|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
219425232|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
219425233|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
219425234|NCT01996904|PROCEDURE|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
219425235|NCT01996904|PROCEDURE|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
219425236|NCT00648193|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
219760151|NCT02181920|DRUG|Diclofenac placebo|
219760152|NCT02181920|DRUG|Metamizole placebo|
219760153|NCT04692389|DEVICE|Jalosome soothing gel|This study has not got other intervention
219760154|NCT00097279|DRUG|biphasic insulin aspart|
219760155|NCT00097279|DRUG|pioglitazone|
219760156|NCT00097279|DRUG|metformin|
219005922|NCT02345850|DRUG|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
219005923|NCT02345850|DRUG|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
219425237|NCT00648193|DRUG|Paxil® 40 mg Table|40mg, single dose fasting
219425238|NCT00198445|DRUG|Bromfenac|One drop in study eye every 12 hours for 14 days
219425239|NCT00198445|DRUG|Placebo|One drop in study eye every 12 hours for 14 days
219425240|NCT01047761|OTHER|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
219425241|NCT02205606|DRUG|HGP0816 5mg|P.O.
219425242|NCT02205606|DRUG|HGP0816 10mg|P.O.
219575975|NCT02404688|DRUG|Active delta-9-THC|"Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes."
219575976|NCT02404688|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
219005924|NCT02345850|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
219191289|NCT02424617|DRUG|Bemcentinib|"Participants received starting loading dose of bemcentinib 600 mg (200 mg on Days 1, 2 and 3) and bemcentinib 100 mg as daily maintenance dose for the 21-day cycle.~Depending on tolerability and DLT, the loading dose of bemcentinib was escalated to 800mg (400 mg on Days 1 and 2) and bemcentinib 100 mg as daily maintenance for the 21- day cycle and to 1200 mg daily (600 mg on Days 1 and 2, or 400 mg on Days 1, 2 and 3) and bemcentinib 200 mg as daily maintenance for the 21- day cycle)."
219191290|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 400 mg on Days 1, 2 and 3 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
219191291|NCT02694822|DRUG|Zalifrelimab|An anti-CTLA-4 monoclonal antibody.
219425243|NCT02205606|DRUG|HGP0816 20mg|P.O.
219425244|NCT02205606|DRUG|HCP1306 5/10mg|P.O.
219425245|NCT02205606|DRUG|HCP1306 10/10mg|P.O.
219425246|NCT02205606|DRUG|HCP1306 20/10mg|P.O.
219425247|NCT00585923|DEVICE|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
219425248|NCT00585923|DEVICE|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
219425249|NCT02840890|PROCEDURE|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
219425250|NCT02840890|PROCEDURE|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
219425251|NCT05322057|DRUG|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
219425252|NCT04345406|DRUG|ACEIs|Captopril or enalapril
219575977|NCT02404688|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
219575978|NCT02404688|DRUG|Placebo|Control: no alcohol, administered for a total of 80 minutes.
219575979|NCT00576654|DRUG|Irinotecan Hydrochloride|Given IV
219575980|NCT00576654|OTHER|Laboratory Biomarker Analysis|Correlative studies
219425253|NCT04345406|DRUG|Conventional treatment|alexoquine
219425254|NCT00923819|PROCEDURE|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
219425255|NCT00923819|BEHAVIORAL|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
219425256|NCT03447613|PROCEDURE|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
219425257|NCT02051894|DRUG|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
219575981|NCT00576654|OTHER|Pharmacological Study|Correlative studies
219575982|NCT00576654|DRUG|Veliparib|Given PO
219575983|NCT03835325|DIETARY_SUPPLEMENT|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
219760157|NCT00557037|DRUG|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
219760158|NCT02987738|DRUG|Dapagliflozin|two administrations in the evening and 12 hours later
219425258|NCT01791114|OTHER|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
219575984|NCT06321991|DRUG|Vitamin E-creme (Remederm®) vs Vaseline (Placebo)|Louis Widmer Remederm® Face Cream Without Perfume 50 ml is a skin care product that contains vitamin E as an active ingredient. Before applying Remederm®, the following are advised: On dry clean skin thoroughly before applying Remederm®, apply a layer of cream cutaneous to the hand palm, twice a day: morning and evening, massage cream into skin until absorbed. This procedure is applied by the patient treated with Vaseline or Remederm®.
219575985|NCT06321991|PROCEDURE|Ultrasound measurement|Nodule evolution will be measured with ultrasound.
219575986|NCT06003751|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
219575987|NCT06003751|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
219575988|NCT06003751|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
219575989|NCT05020314|BEHAVIORAL|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
219575990|NCT06583018|BEHAVIORAL|In-Person Mindfulness-based Group Sessions|The 3-hour group-based session in week 1 focuses on experiential mindfulness practices, and a booster session in week 5 further consolidates these mindfulness techniques, reinforces mindful, healthy lifestyle, and provides peer support. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity.
219575991|NCT06583018|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.
219575992|NCT06583018|BEHAVIORAL|In-person Lifestyle Education Session|A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.
219575993|NCT06583018|DEVICE|Activity Monitoring|All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
219575994|NCT06439602|DRUG|AR882 50 mg|Solid Oral Capsule
219575995|NCT06439602|DRUG|AR882 75 mg|Solid Oral Capsule
219575996|NCT06439602|DRUG|Placebo|Matching Solid Oral Capsule Placebo
219575997|NCT04725058|OTHER|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
219575998|NCT04725058|OTHER|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
219575999|NCT06414954|DRUG|NMD670|Tablets taken twice a day for 21 days
219576000|NCT06414954|DRUG|Placebo|Tablets taken twice a day for 21 days
219576001|NCT04890093|DRUG|PEN-866|PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
219576002|NCT04890093|DRUG|Vincristine|Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
219576003|NCT04890093|DRUG|Temozolomide|temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
219760159|NCT02987738|DRUG|Placebo Oral Tablet|two administrations in the evening and 12 hours later
219760160|NCT00001066|DRUG|Lamivudine|
219760161|NCT00001066|DRUG|Zidovudine|
219760162|NCT00001066|DRUG|Didanosine|
219760163|NCT03688971|DRUG|Omiganan|Omiganan Topical Gel
219760164|NCT03688971|DRUG|Ketoconazole|Ketoconazole Cream
219760165|NCT03688971|DRUG|Placebo|Vehicle
219760166|NCT01627886|DRUG|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
219425259|NCT01791114|OTHER|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
219576004|NCT02117388|BEHAVIORAL|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
219425260|NCT01791114|OTHER|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
219425261|NCT01791114|OTHER|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
219425262|NCT01791114|OTHER|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
219425263|NCT01791114|OTHER|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
219425264|NCT01791114|OTHER|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
219425265|NCT03016299|PROCEDURE|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
219425266|NCT00972829|DRUG|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
219425267|NCT00972829|DRUG|Ezetimibe|Ezetimibe 5 or 10 milligrams
219425268|NCT05625854|BEHAVIORAL|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
219425269|NCT05625854|BEHAVIORAL|Blow a fan to the face|Blow a fan to the face
219425270|NCT05625854|BEHAVIORAL|Blow a fan to the feet|Blow a fan to the feet
219425271|NCT03800862|DEVICE|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
219425272|NCT02541474|OTHER|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
219576005|NCT02117388|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
219576006|NCT02117388|BEHAVIORAL|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
219576007|NCT05201638|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
219760167|NCT03507725|BEHAVIORAL|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
219005925|NCT03898141|OTHER|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
219005926|NCT03898141|OTHER|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
219005927|NCT03898141|OTHER|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
219425273|NCT02399592|DRUG|Bevacizumab|10 mg/kg q3w
219425274|NCT02399592|DRUG|Tocotrinol|300 mg tid
219425275|NCT01592669|PROCEDURE|passive leg raising|bilateral PLR was achieved by raising the legs of patient
219425276|NCT00041769|PROCEDURE|Therapeutic Drug Monitoring (TDM)|
219425277|NCT00424333|DRUG|Inhaled human insulin|
219425278|NCT00618449|DRUG|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
219425279|NCT00618449|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
219425280|NCT05127421|DRUG|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
219425281|NCT05127421|DRUG|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
219425282|NCT01441115|PROCEDURE|Radiation Therapy|
219425283|NCT01441115|DRUG|ECI301|
219425284|NCT02709473|DRUG|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
219576008|NCT05201638|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
219576009|NCT06035484|OTHER|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
219576010|NCT06035484|OTHER|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
219576011|NCT04593342|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
219425285|NCT02709473|DRUG|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
219576012|NCT04593342|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
219760168|NCT03507725|PROCEDURE|Prostate Biopsy|Prostate needle biopsy under local anesthesia
219425286|NCT02709473|DRUG|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
219425287|NCT01589055|DRUG|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
219425288|NCT02787642|DRUG|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
219425289|NCT02787642|RADIATION|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
219425290|NCT06019910|OTHER|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
219425291|NCT03488914|BEHAVIORAL|YMHP Intervention|
219425292|NCT03488914|BEHAVIORAL|Enhanced Treatment as Usual|
219425293|NCT06310096|OTHER|TLF fascial stretching exercise|"Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF"
219425294|NCT06310096|OTHER|conventional physiotherapy program.|hotpack, ultrasound ,Tens
219425295|NCT05619562|DIAGNOSTIC_TEST|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
219425296|NCT02503631|DEVICE|Stool Sample Collection Kit|Stool sample collection kit
219425297|NCT00000524|DRUG|cyclosporine|
219576013|NCT04063982|OTHER|none, only assessment at different time points|assessment at different time points
219425298|NCT00000524|DRUG|prednisone|
219425299|NCT03811717|OTHER|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
219425300|NCT03811717|OTHER|FAST|Participants will complete an 8-hour fast.
219425301|NCT00208741|DRUG|Gabitril|
219425302|NCT01743014|DRUG|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
219425303|NCT01743014|DRUG|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
219425304|NCT00258102|DRUG|Levofloxacin|
219425305|NCT02843581|DEVICE|Cryosurgery|Argon-helium cryosurgical system
219576014|NCT01012141|DIETARY_SUPPLEMENT|phytochemical|
219576015|NCT01012141|DRUG|Docetaxel|
219576016|NCT00775606|DRUG|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
219576017|NCT00775606|DRUG|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
219760169|NCT03507725|BEHAVIORAL|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
219760170|NCT05262569|OTHER|ileus|retrospectively allocation according to a postoperative outcome-ileus
219760171|NCT05231863|DRUG|TKIs|tyrosine kinase inhibitors based therapy
219760172|NCT00451230|DRUG|cocaine|
219760173|NCT00451230|DRUG|hydrocortisone|
219760174|NCT00087217|DRUG|tanespimycin|Given IV
219760175|NCT00087217|DRUG|paclitaxel|Given IV
219760176|NCT00087217|OTHER|laboratory biomarker analysis|Correlative studies
219760177|NCT00087217|OTHER|pharmacological study|Correlative studies
219191292|NCT05869539|DRUG|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
219425306|NCT02843581|BIOLOGICAL|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
219425307|NCT01498081|DRUG|AZD2115|AZD2115 administered via inhalation
219576018|NCT01033578|OTHER|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
219760178|NCT06643273|OTHER|Robotic rehabilitation|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
219760179|NCT06643273|OTHER|Conventional rehabilitation|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
219760180|NCT02247128|DRUG|Aspirin + clopidogrel|
219760181|NCT02247128|DRUG|Aspirin monotherapy|
219760182|NCT02247128|DRUG|OAC + clopicogrel|
219760183|NCT02247128|DRUG|OAC monotherapy|
219760184|NCT05411497|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
219760185|NCT05411497|DRUG|Cyclophosphamide|Given IV
219760186|NCT04704193|OTHER|Survey of Decision Aid|The decision aid will be evaluated by a survey administered to those who have used the tool.
219425308|NCT01498081|DRUG|Placebo|Placebo administered via inhalation
219425309|NCT01498081|DRUG|Indacaterol|Indacaterol administered via inhalation
219425310|NCT01498081|DRUG|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
219425311|NCT03901261|PROCEDURE|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
219425312|NCT01492283|OTHER|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
219425313|NCT01492283|OTHER|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
219425314|NCT02521961|OTHER|Informational Intervention|Watch a Chair-robics DVD
219760187|NCT01202084|DRUG|Formoterol/Fluticasone|
219760188|NCT01202084|DRUG|Foraseq®|
219425315|NCT02521961|OTHER|Informational Intervention|Receive community resource booklet
219425316|NCT02521961|OTHER|Quality-of-Life Assessment|Ancillary studies
219425317|NCT02521961|OTHER|Questionnaire Administration|Ancillary studies
219425318|NCT02521961|PROCEDURE|Support Group Therapy|Attend support group sessions
219425319|NCT01802554|BEHAVIORAL|Pleasant Events Program (PEP)|Behavioral Activation Therapy
219760189|NCT01202084|DRUG|Fluticasone|
219005928|NCT05296759|DRUG|botulinum toxin A|botulinum toxin A injection
219005929|NCT05296759|DRUG|Gabapentin|Gabapentin oral intake
219005930|NCT05296759|DRUG|Duloxetine|Duloxetine oral drug intake
219005931|NCT00720837|PROCEDURE|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
219005932|NCT02590653|DRUG|Atorvastatin|Lipid-lowering therapy
219005933|NCT04801160|PROCEDURE|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
219005934|NCT04801160|PROCEDURE|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
219005935|NCT01110954|DRUG|PD L 506|Two different doses will be compared
219005936|NCT01045889|OTHER|Rituximab and CHOP regimen + PBSCT|
219425320|NCT01802554|BEHAVIORAL|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
219005937|NCT06084403|DRUG|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
219425321|NCT06271447|OTHER|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
219425322|NCT04813939|DEVICE|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
219425323|NCT05310513|OTHER|Whether the patient needs to be admitted to the ICU|According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
219425324|NCT00999219|DRUG|FK199B|oral
219425325|NCT00999219|DRUG|Zolpidem|oral
219425326|NCT04156932|PROCEDURE|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
219425327|NCT00574496|DRUG|cyclophosphamide|
219005938|NCT06084403|DRUG|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
219425328|NCT00574496|DRUG|cyclosporine|
219576019|NCT04884061|OTHER|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
219005939|NCT06084403|DRUG|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
219425329|NCT00574496|DRUG|fludarabine phosphate|
219425330|NCT00574496|DRUG|gemcitabine hydrochloride|
219425331|NCT00574496|DRUG|ifosfamide|
219425332|NCT00574496|DRUG|mechlorethamine hydrochloride|
219576020|NCT03212794|BEHAVIORAL|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
219576021|NCT02551393|BEHAVIORAL|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
219576022|NCT06324058|PROCEDURE|Transurethral cryoablation|Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
219425333|NCT00574496|DRUG|melphalan|
219425334|NCT00574496|DRUG|methotrexate|
219576023|NCT06324058|PROCEDURE|Transurethral resection of bladder tumor|Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
219576024|NCT06324058|DRUG|Bcg Intravesical|Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
219576025|NCT02316158|OTHER|Web-based support|Comparison between the efficacy between webb-based support and informational support
219576026|NCT00371306|DRUG|Insulin versus glucovance (glyburide/metformin)|
219425335|NCT00574496|DRUG|mycophenolate mofetil|
219425336|NCT00574496|DRUG|prednisone|
219425337|NCT00574496|DRUG|procarbazine hydrochloride|
219425338|NCT00574496|DRUG|vincristine sulfate|
219425339|NCT00574496|DRUG|vinorelbine tartrate|
219425340|NCT00574496|PROCEDURE|allogeneic bone marrow transplantation|
219425341|NCT00574496|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219425342|NCT00574496|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219425343|NCT00574496|PROCEDURE|peripheral blood stem cell transplantation|
219425344|NCT00574496|PROCEDURE|umbilical cord blood transplantation|
219425345|NCT00574496|RADIATION|total-body irradiation|
219425346|NCT02946541|DRUG|evogliptin 5mg|evogliptin 5mg, QD
219425347|NCT02946541|DRUG|Placebo|Placebo, QD
219425348|NCT01005511|DEVICE|Grindcare|Active treatment
219425349|NCT01005511|DEVICE|Grindcare - inactive|Placebo treatment
219425350|NCT04284020|BEHAVIORAL|Therapeutic educational program|See arm/group descriptions
219425351|NCT04284020|OTHER|PFMT|See arm/group descriptions
219425352|NCT04284020|OTHER|TTNS|See arm/group descriptions
219425353|NCT01018719|DEVICE|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
219425354|NCT05127070|DEVICE|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
219425355|NCT05062941|OTHER|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
219576027|NCT04090970|DEVICE|Briagen|Natural complex carbohydrate wound dressing for skin wounds
219576028|NCT00498342|DRUG|N-acetylcysteine|
219576029|NCT01973023|OTHER|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
219576030|NCT00426010|DRUG|caffeine/placebo|caffeine or placebo, either overt or covert
219576031|NCT04904159|PROCEDURE|Thyroidectomy|total thyroidectomy
219576032|NCT04904159|PROCEDURE|Lobectomy|Lobectomy
219576033|NCT02725775|DIETARY_SUPPLEMENT|100% Florida OJ|
219576034|NCT02725775|DIETARY_SUPPLEMENT|Placebo Equicaloric Orange Drink|
219576035|NCT03304028|DEVICE|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
219576036|NCT03304028|BEHAVIORAL|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
219576037|NCT03304028|DEVICE|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
219425356|NCT05062941|DEVICE|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
219425357|NCT05316090|PROCEDURE|Core stability exercises program|Strengthening to the trunk muscles
219425358|NCT05316090|PROCEDURE|Traditional physical therapy program|Neurodevelopmental training excercises
219425359|NCT03766802|BEHAVIORAL|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
219425360|NCT03766802|BEHAVIORAL|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
219425361|NCT03766802|BEHAVIORAL|Supervised exercise training group|3/week training supervised by a physical therapist
219425362|NCT05819736|OTHER|Monitoring|Monitoring
219425363|NCT04790552|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
219425364|NCT04790552|OTHER|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
219425365|NCT04790552|OTHER|Fast Bar|Subjects will be asked to consume a Fast Bar.
219425366|NCT04790552|OTHER|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
219005940|NCT01089959|DRUG|Esomeprazole|40 mg daily for 7 days
219005941|NCT01089959|DRUG|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
219005942|NCT01347450|DIETARY_SUPPLEMENT|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
219425367|NCT04790552|OTHER|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
219425368|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
219425369|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
219425370|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
219425371|NCT02247284|DEVICE|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
219576038|NCT03304028|OTHER|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
219576039|NCT03304028|BEHAVIORAL|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
219576040|NCT00454519|PROCEDURE|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
219576041|NCT00454519|PROCEDURE|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
219576042|NCT01566019|PROCEDURE|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
219425372|NCT00901147|DRUG|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
219425373|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
219425374|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
219425375|NCT02303873|DRUG|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
219576043|NCT03674502|DRUG|ADU-1604|anti-CTLA-4 monoclonal antibody
219576044|NCT05886231|OTHER|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
219005943|NCT01347450|DIETARY_SUPPLEMENT|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
219005944|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
219425376|NCT04060576|PROCEDURE|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
219425377|NCT04060576|PROCEDURE|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
219576045|NCT00215449|DRUG|Formoterol Fumarate|
219576046|NCT04142619|BIOLOGICAL|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
219425378|NCT04060576|PROCEDURE|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
219425379|NCT02231294|DRUG|Sifrol®|
219425380|NCT02723292|BEHAVIORAL|TOP|
219425381|NCT02723292|BEHAVIORAL|Control intervention|
219425382|NCT02033772|PROCEDURE|Thoracoscopic surgery|
219425383|NCT00004992|BEHAVIORAL|Intensive lifestyle|
219425384|NCT00004992|DRUG|Metformin|
219425385|NCT00004992|DRUG|Placebo|
219425386|NCT00736580|OTHER|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
219425387|NCT00736580|OTHER|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
219425388|NCT02557360|DIETARY_SUPPLEMENT|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
219425389|NCT03074994|DRUG|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
219425390|NCT03074994|DRUG|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
219425391|NCT03074994|PROCEDURE|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
219425392|NCT03074994|PROCEDURE|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
219425393|NCT01681576|DRUG|Valsartan|Valsartan 320mg tablet once daily
219425394|NCT01681576|DRUG|LCZ696|LCZ696 400mg tablet once daily
219576047|NCT00962884|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
219576048|NCT00962884|DEVICE|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
219576049|NCT01216098|BEHAVIORAL|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
219576050|NCT04030494|DIAGNOSTIC_TEST|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
219576051|NCT04030494|DIAGNOSTIC_TEST|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
219005945|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
219425395|NCT02225574|DRUG|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
219425396|NCT02225574|DRUG|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
219425397|NCT02225574|BEHAVIORAL|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
219425398|NCT02172092|DRUG|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
219425399|NCT05072665|DEVICE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
219425400|NCT03386331|BEHAVIORAL|diet and exercise|Diet and lifestyle intervention
219425401|NCT00574431|OTHER|Data Collection|Collection of patient data before implementation of a nutritional management protocol
219425402|NCT00574431|OTHER|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
219425403|NCT05536193|DRUG|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
219425404|NCT05536193|DIAGNOSTIC_TEST|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
219425405|NCT03095053|PROCEDURE|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
219425406|NCT02659605|PROCEDURE|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
219425407|NCT02659605|PROCEDURE|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
219576052|NCT04030494|DIAGNOSTIC_TEST|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
219576053|NCT04392557|DRUG|Metformin / alogliptin Oral Product|850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
219576054|NCT04392557|DRUG|Metformin / Pioglitazone Pill|(850 mg/15 mg every 12 hours) for 12 months
219576055|NCT04392557|DRUG|triple therapy|Metformin / Alogliptin/ Pioglitazone
219576056|NCT04762940|DEVICE|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
219576057|NCT04762940|DEVICE|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
219576058|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
219576059|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
219576060|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
219760190|NCT05181228|BEHAVIORAL|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
219760191|NCT02281045|DEVICE|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
219760192|NCT02281045|DEVICE|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
219760193|NCT00542178|DRUG|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
219760194|NCT00542178|DRUG|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
219425408|NCT00460447|DRUG|Gemtuzumab Ozogamicin|
219760195|NCT00542178|DRUG|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
219760196|NCT00542178|DRUG|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
219760197|NCT00542178|DRUG|Fenofibrate|Blinded fenofibrate
219760198|NCT00542178|DRUG|Simvastatin|Simvastatin 20-40 mg/d
219760199|NCT00542178|DRUG|Placebo|Placebo
219005946|NCT04602832|OTHER|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
219005947|NCT02415881|DRUG|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
219005948|NCT02415881|DEVICE|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
219005949|NCT02415881|DEVICE|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
219005950|NCT06539559|DRUG|Eribulin|Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
219191293|NCT02766322|OTHER|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
219576061|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
219425409|NCT00218920|BEHAVIORAL|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
219425410|NCT00218920|BEHAVIORAL|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
219425411|NCT00218920|BEHAVIORAL|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
219425412|NCT06079866|DEVICE|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
219425413|NCT06079866|DEVICE|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
219576062|NCT01072786|BIOLOGICAL|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
219576063|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
219576064|NCT06273020|DRUG|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
219576065|NCT06273020|PROCEDURE|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
219576066|NCT05610592|PROCEDURE|total mesorectal exicision|
219576067|NCT04953416|DEVICE|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
219576068|NCT05920564|OTHER|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
219576069|NCT05920564|OTHER|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
219760200|NCT01099488|PROCEDURE|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
219191294|NCT02766322|OTHER|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
219191295|NCT02766322|OTHER|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
219425414|NCT01195363|DRUG|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
219425415|NCT01195363|DRUG|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
219425416|NCT01589510|DRUG|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
219425417|NCT00729313|DRUG|Lanreotide microparticles|
219425418|NCT00729313|DRUG|Placebo|
219425419|NCT02556593|RADIATION|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
219576070|NCT05841147|DRUG|Tirofiban|Intravenous administration of tirofiban
219576071|NCT05841147|DRUG|normal saline|Intravenous administration of normal saline
219576072|NCT02025231|RADIATION|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
219425420|NCT02556593|RADIATION|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
219425421|NCT02556593|DRUG|erlotinib|erlotinib 150mg daily
219576073|NCT02422914|BEHAVIORAL|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
219576074|NCT02422914|BEHAVIORAL|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
219576075|NCT02422914|BEHAVIORAL|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
219576076|NCT05173870|DEVICE|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
219005951|NCT06539559|DRUG|Bevacizumab|Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
219425422|NCT00538824|DRUG|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
219425423|NCT00538824|DRUG|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
219425424|NCT00538824|DRUG|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*"
219425425|NCT05580861|DRUG|Sulfasalazine|Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
219425426|NCT02664532|OTHER|Miller group|Miller blade was used for laryngoscopy
219425427|NCT02664532|OTHER|Macintosh group|Macintosh blade was used for laryngoscopy
219425428|NCT03838770|DEVICE|Active tDCS|Active target 2.0mA tDCS (n=60)
219425429|NCT03838770|DEVICE|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
219576077|NCT01615042|DRUG|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
219576078|NCT00965770|DEVICE|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
219425430|NCT04767919|PROCEDURE|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
219005952|NCT01430091|DRUG|Prasugrel (clinical formulation)|Administered orally
219005953|NCT01430091|DRUG|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
219005954|NCT02715076|OTHER|Ambient Temperature 19°C|Ambient Temperature 19°C
219005955|NCT02715076|OTHER|Ambient Temperature 21°C|Ambient Temperature 21°C
219005956|NCT02715076|OTHER|Ambient Temperature 23°C|Ambient Temperature 23°C
219425431|NCT04767919|PROCEDURE|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
219425432|NCT02024204|DRUG|Fluticasone propionate 230mcg for 3 Months|
219425433|NCT02024204|DRUG|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
219425434|NCT02024204|DRUG|Salmeterol 21mcg for 3 Months|
219425435|NCT00184782|PROCEDURE|FDG-PET|
219425436|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
219576079|NCT04894071|DRUG|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
219576080|NCT04894071|DRUG|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
219576081|NCT00560027|OTHER|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
219576082|NCT04508920|OTHER|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
219576083|NCT01901874|DEVICE|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
219425437|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
219425438|NCT03522272|OTHER|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
219425439|NCT00717262|DRUG|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
219425440|NCT00717262|DRUG|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
219425441|NCT05174130|DEVICE|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
219425442|NCT01871896|DEVICE|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
219425443|NCT04829955|OTHER|Eccentric manual resistance training|Eccentric bodyweight resistance training
219425444|NCT04829955|OTHER|Concentric manual resistance resistance training|Concentric bodyweight resistance training
219425445|NCT05603039|DRUG|QL1706|5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
219425446|NCT05603039|DRUG|QL1604|200mg#D1#Q3W IV
219425447|NCT05603039|DRUG|Bevacizumab|15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
219425448|NCT02306174|BEHAVIORAL|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
219425449|NCT05220410|DRUG|Psilocybin|Open-Label
219425450|NCT05524597|BEHAVIORAL|Writing Intervention|Participants will be asked to write about different kinds of experiences.
219576084|NCT03218891|BEHAVIORAL|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation."
219576085|NCT03718741|RADIATION|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
219576086|NCT01269281|DRUG|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
219576087|NCT05526859|OTHER|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
219576088|NCT05526859|OTHER|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
219576089|NCT04632706|DRUG|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
219576090|NCT04632706|DRUG|Placebo|Matching Placebo to the Active IMP.
219576091|NCT00003014|DRUG|carboplatin|
219576092|NCT00003014|RADIATION|radiation therapy|
219576093|NCT03661606|OTHER|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
219576094|NCT04158349|DRUG|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
219576095|NCT04158349|DRUG|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
219576096|NCT02234206|DRUG|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940"
219760201|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
219425451|NCT06362005|DRUG|Triamcinolone Acetonide 0.1% Oint|RCT
219425452|NCT06362005|DRUG|Tacrollimus Topical|RCT
219425453|NCT06362005|DRUG|Selenium|RCT
219425454|NCT06362005|DRUG|Selenium & Triamcinolone Acetonide 0.1% Oint|RCT
219576097|NCT00506818|OTHER|Multifactorial vascular-risk-factor-intervention|
219425455|NCT06362005|DRUG|Selenium& Tacrollimus topical|RCT
219425456|NCT06074068|BEHAVIORAL|Fathers for Change|18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
219425457|NCT06074068|BEHAVIORAL|Duluth BIP|18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
219576098|NCT03347513|DRUG|triple attack therapy|eradication of H-pylori using triple attack therapy.
219576099|NCT03347513|DRUG|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
219425458|NCT01512108|DRUG|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
219425459|NCT01512108|DRUG|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
219425460|NCT04469764|DRUG|Abemaciclib|Given PO
219425461|NCT04469764|DRUG|Anastrozole|Given PO
219425462|NCT04469764|DRUG|Letrozole|Given PO
219425463|NCT06382064|DEVICE|Biweekly replacement contact lenses|Biweekly replacement reusable contact lenses.
219425464|NCT06382064|DEVICE|One week replacement contact lenses|One week replacement reusable contact lenses.
219425465|NCT03488628|OTHER|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours
219425466|NCT03488628|OTHER|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.
219425467|NCT05984199|BIOLOGICAL|VCAR33|Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
219425468|NCT04368559|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
219576100|NCT01976013|DEVICE|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
219576101|NCT02247219|BEHAVIORAL|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
219576102|NCT04439084|OTHER|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
219576103|NCT00117403|DRUG|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
219576104|NCT00117403|DRUG|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
219576105|NCT00117403|DRUG|Placebo capsules|one placebo capsule three times per day with meals
219576106|NCT00117403|DRUG|Placebo wafers|two placebo wafers three times per day with meals
219576107|NCT03763760|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
219576108|NCT05877391|BEHAVIORAL|SGM Communication Intervention|Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
219576109|NCT04167176|PROCEDURE|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
219576110|NCT04167176|PROCEDURE|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
219576111|NCT04167176|DEVICE|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
219576112|NCT04167176|DRUG|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
219576113|NCT04167176|DRUG|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
219760202|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
219760203|NCT01916473|OTHER|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
219576114|NCT00770692|DRUG|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
219576115|NCT00770692|DRUG|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
219425469|NCT04368559|DRUG|Posaconazole|Oral antifungal therapy
219576116|NCT00770692|DRUG|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
219425470|NCT04368559|DRUG|Fluconazole|Oral antifungal therapy
219425471|NCT04368559|DRUG|Trimethoprim-sulfamethoxazole (TMP/SMX)|Oral antibacterial therapy
219425472|NCT04368559|DRUG|Intravenous Placebo|Normal saline
219425473|NCT04368559|DRUG|Oral Placebo|Microcrystalline cellulose
219425474|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
219425475|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
219425476|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
219425477|NCT02373371|DRUG|Metvix®|
219425478|NCT02373371|PROCEDURE|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
219425479|NCT02373371|PROCEDURE|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
219576117|NCT00770692|DRUG|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
219576118|NCT00773695|DRUG|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
219576119|NCT00773695|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
219425480|NCT05455190|BEHAVIORAL|Fit Together|Fit Together intervention follows a clinic and community partnership model for childhood obesity treatment. Children with obesity will receive standard of care obesity treatment from their usual provider and will also receive a referral to an activity program run out of the local community center. Each session delivers a combination of high-intensity individual exercises, sports and games, and unstructured playtime to help children reach the US Physical Activity guidelines of 60min moderate-to-vigorous physical activity daily. There will also be a nutrition activity session offered regularly.
219576120|NCT00773695|DRUG|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
219576121|NCT00773695|DRUG|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
219576122|NCT00773695|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
219576123|NCT00773695|DRUG|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
219576124|NCT00773695|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
219576125|NCT05559112|OTHER|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
219760204|NCT01916473|OTHER|Continuous wound infusion|Continuous wound infusion via catheter
219760205|NCT03449576|OTHER|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
219760206|NCT03449576|OTHER|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
219760207|NCT06058416|BIOLOGICAL|Healive (hepatitis A vacine(human diploid cell), inactivated)|"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."
219760208|NCT06988748|OTHER|Assigned Interventions (diet training)|"Pain and bleeding will be evaluated at 4 hours, 8 hours, 24 hours and 7 days after adenotonsillectomy by using Wong-Baker Faces Pain Rating Scale and Follow-up and Evaluation Form for Children After Adenotonsillectomy in Children."
219760209|NCT05896202|OTHER|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
219425481|NCT05455190|BEHAVIORAL|Educational materials|Participants will receive a child-friendly cooking magazine mailed quarterly and a local Parks and Recreation program guide.
219760210|NCT05896202|OTHER|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
219425482|NCT05726305|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
219425483|NCT05726305|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
219760211|NCT05896202|OTHER|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
219425484|NCT04690205|OTHER|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
219425485|NCT06474364|DRUG|Long-acting Cabotegravir injection|Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.
219576126|NCT05559112|OTHER|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
219576127|NCT00453817|DRUG|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
219576128|NCT00453817|PROCEDURE|Islet transplantation|intraportal percutaneous islet transplantation
219576129|NCT00453817|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
219576130|NCT00004313|DRUG|dehydroepiandrosterone|
219576131|NCT00821366|BEHAVIORAL|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
219576132|NCT00821366|DIETARY_SUPPLEMENT|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
219191296|NCT02766322|OTHER|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
219191297|NCT05814159|DRUG|Anakinra|sub cutaneous daily injection
219191298|NCT05814159|DRUG|Placebo|sub cutaneous daily injection
219191299|NCT01722812|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
219425486|NCT06474364|OTHER|SEARCH-YOUTH|It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
219425487|NCT04756388|OTHER|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
219191300|NCT01722812|DRUG|Placebo|Twice daily topical treatment for 14 days
219425488|NCT04756388|OTHER|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
219425489|NCT05446298|DRUG|ONC-392|ONC-392 will be given by IV infusion, q3w.
219425490|NCT05446298|DRUG|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
219425491|NCT06147713|DEVICE|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
219425492|NCT00219518|PROCEDURE|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
219425493|NCT01539811|PROCEDURE|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
219425494|NCT01539811|DRUG|Short course antibiotics|Short course (\<2 weeks) of antibiotics will be prescribed
219425495|NCT01539811|DRUG|Long course antibiotics|Long course (\>2 weeks) of antibiotics will be prescribed
219425496|NCT04752449|BEHAVIORAL|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
219425497|NCT03135886|OTHER|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
219425498|NCT03135886|OTHER|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
219425499|NCT03135886|OTHER|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
219425500|NCT04669782|DIETARY_SUPPLEMENT|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
219425501|NCT04669782|DRUG|Teriparatide|Teriparatide will be administered as standard of care
219425502|NCT06422377|DRUG|Soticlestat|Soticlestat tablets or mini-tablets
219425503|NCT06794125|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy
219425504|NCT06794125|RADIATION|Radiation Therapy|standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy
219425505|NCT06030362|DIETARY_SUPPLEMENT|Probiotic|Dietary Supplement taken once daily for 3 months (90 days).
219425506|NCT06030362|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement taken once daily for 3 months (90days).
219425507|NCT05536713|DEVICE|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
219425508|NCT03086681|DRUG|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
219425509|NCT03086681|DRUG|DDP|DDP: 40mg /m2，per week, for 5 cycles
219425510|NCT04796025|DRUG|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
219576133|NCT00821366|DRUG|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
219425511|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
219425512|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
219425513|NCT06109519|PROCEDURE|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
219425514|NCT05157711|DRUG|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
219425515|NCT05157711|DRUG|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
219425516|NCT05157711|DRUG|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
219425517|NCT02843178|BEHAVIORAL|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
219425518|NCT01985971|RADIATION|PET/CT Imaging|
219576134|NCT03532633|PROCEDURE|cord blood|collection of cord blood
219576135|NCT03532633|PROCEDURE|blood sample infant|collection of remnant of clinically indicated blood sample
219576136|NCT03532633|PROCEDURE|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
219576137|NCT03532633|PROCEDURE|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
219576138|NCT05590156|PROCEDURE|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
219760212|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
219425519|NCT04104061|OTHER|iron profile|blood test
219425520|NCT03271060|PROCEDURE|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
219425521|NCT03271060|PROCEDURE|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
219760213|NCT06995612|BEHAVIORAL|SMART-CPT|SMART-CPT T is a psychotherapy that combines Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) and Cognitive Symptom Management and Rehabilitation Training (CogSMART) for neurobehavioral and neurocognitive symptoms to simultaneously target persistent postconcussive symptoms and PTSD
219425522|NCT01002898|DRUG|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
219576139|NCT05590156|DEVICE|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
219576140|NCT05590156|PROCEDURE|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
219005957|NCT02715076|DEVICE|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
219425523|NCT05912036|BEHAVIORAL|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
219425524|NCT00539318|PROCEDURE|Blood drawing|Once when enroll in study
219425525|NCT00554255|DRUG|SB751689|
219425526|NCT00289861|DRUG|Risperidone|
219425527|NCT00289861|DRUG|placebo|
219425528|NCT00873145|PROCEDURE|HMRS|Modular prosthetic replacement of the humerus and elbow.
219576141|NCT02713815|RADIATION|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
219576142|NCT02713815|RADIATION|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
219576143|NCT00560937|DRUG|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
219576144|NCT00560937|DRUG|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
219576145|NCT01138111|DRUG|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
219425529|NCT03453970|BEHAVIORAL|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
219425530|NCT05041153|DRUG|Lenvatinib|Given by PO
219425531|NCT05041153|BIOLOGICAL|Pembrolizumab|Given by IV
219425532|NCT06580184|BEHAVIORAL|LEARN 2 Platform|The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.
219425533|NCT04112732|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
219425534|NCT04112732|OTHER|Placebo|Placebo
219576146|NCT03676751|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
219576147|NCT03676751|DRUG|Placebo|Oral suspension of placebo for azithromycin
219576148|NCT00378651|PROCEDURE|Neck Auscultation|
219576149|NCT00256711|DRUG|Gefitinib|
219576150|NCT00256711|DRUG|Vinorelbine|
219425535|NCT03452202|DEVICE|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
219425536|NCT03452202|DEVICE|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
219425537|NCT02762799|BIOLOGICAL|Leucostim®|Leucostim® is filgrastim biosimilar.
219425538|NCT02762799|BIOLOGICAL|Neupogen®|
219425539|NCT00453180|DRUG|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
219425540|NCT00453180|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
219425541|NCT06067893|DRUG|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
219425542|NCT06067893|DRUG|Normal Saline|Patient receives normal saline for 48 hours post-operatively
219576151|NCT04785157|BIOLOGICAL|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
219576152|NCT04785157|BIOLOGICAL|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
219576153|NCT04785157|OTHER|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
219576154|NCT04785157|OTHER|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
219576155|NCT04785157|BEHAVIORAL|neurocognitive assessment|multi-domains neurocognitive assessment
219576156|NCT03694366|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
219576157|NCT05667350|OTHER|Blood drawing|Blood drawing before anti-cancer therapy
219576158|NCT05667350|OTHER|Blood drawing|Blood drawing before radical treatment
219576159|NCT02168725|DRUG|briciclib|
219576160|NCT03858218|OTHER|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
219576161|NCT03823235|OTHER|Human embryo culture|humidifed or dry incubator
219191301|NCT05912634|PROCEDURE|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
219191302|NCT05912634|PROCEDURE|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
219191303|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
219191304|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
219191305|NCT01868997|DRUG|teprotumumab|
219191306|NCT01868997|DRUG|normal saline|
219191307|NCT06521866|DRUG|Serplulimab|IV 3 mg/kg on Day 1, q2w
219191308|NCT06521866|DRUG|Chemotherapy|"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
219191309|NCT06521866|RADIATION|SABR|SABR: 25-60 Gy/5 Fx
219191310|NCT06521866|DRUG|Targeted therapy|Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly ; Bevacizumab: 5 mg/kg IV on Day 1
219191311|NCT04742075|DRUG|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
219191312|NCT03592693|DRUG|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
219191313|NCT03592693|DRUG|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
219191314|NCT06789315|DRUG|Mycophenolate Mofetil|MMF at a dose of 750 mg twice daily for a period of 28 days,
219191315|NCT06789315|DRUG|Prednisone|Prednisone at a dose of 40 mg for 28 days.
219191316|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
219191317|NCT04533737|BIOLOGICAL|Brodalumab|Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
219191318|NCT04533737|OTHER|Placebo|The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
219191319|NCT04533737|BIOLOGICAL|Guselkumab|Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
219191320|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
219191321|NCT06557512|RADIATION|Hypofractionated Stereotactic Radiosurgery (SRS)|Undergo Hypofractionated Stereotactic Radiosurgery
219191322|NCT06557512|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
219191323|NCT06557512|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
219191324|NCT05753215|DRUG|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
219191325|NCT05753215|DRUG|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
219191326|NCT06528184|DIAGNOSTIC_TEST|Self-sampled HPV DNA testing|Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
219191327|NCT06528184|DIAGNOSTIC_TEST|Clinician-sampled HPV DNA test|Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
219191328|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
219191329|NCT06132685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219191330|NCT06132685|PROCEDURE|Computed Tomography|Undergo CT scan
219425543|NCT05817955|DRUG|Azacitidine (AZA) with Ruxolitinib|"1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
219191331|NCT06132685|DRUG|Dexamethasone|Given dexamethasone or IV
219191332|NCT06132685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219191333|NCT06132685|OTHER|Questionnaire Administration|Ancillary studies
219191334|NCT03802799|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
219425544|NCT05363709|DRUG|Balstilimab|Given by Vein (IV)
219576162|NCT01566864|BEHAVIORAL|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
219760214|NCT06995612|BEHAVIORAL|CPT|CPT is a cognitive behavioral treatment specifically targeting PTSD and other corollary symptoms following traumatic events (Resick \& Schnicke, 1992). Based on a social cognitive theory of PTSD and trauma, CPT focuses on identifying the content of trauma-related thoughts, examining whether these thoughts are consistent or inconsistent with a patient's prior beliefs about the world, and addressing the impact these thoughts have on emotions and behaviors. Patients are taught to recognize and challenge thought patterns such as, assimilation (distorting the memory of the traumatic event to fit prior world beliefs), over-accommodation (excessively altering world beliefs to be consistent with the trauma), or the reinforcement of previously held distorted world beliefs.
219760215|NCT06995469|PROCEDURE|Chairless Chair® 2.0 Passive Lower-Limb Exoskeleton|"Participants used a passive lower-limb exoskeleton (Chairless Chair® 2.0) during their regular work tasks involving prolonged standing. The device enables a semi-seated posture without the need for external power, aiming to reduce lower limb strain.~The intervention involved each participant performing their typical standing tasks once with the exoskeleton and once without it, in a within-subject repeated-measures design. Each participant served as their own control.~Objective data were collected using a plantar pressure platform (Podoprint S4, Namrol) to measure:~Plantar pressure distribution~Postural stability~Body sway"
219760216|NCT06669871|OTHER|Shirt-A|A dress shirt of a specific design will be provided to the participants, in which weight of the front side will be double than the back side.
219191335|NCT03825107|OTHER|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
219425545|NCT05411328|DEVICE|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
219425546|NCT04183387|DRUG|Simvastatin 40mg|
219425547|NCT00665678|DRUG|paroxetine|treatment for three months with paroxetine
219425548|NCT00665678|DRUG|placebo|treatment for three months with placebo
219760217|NCT06669871|OTHER|Shirt-B|A dress shirt of a simple design will be provided to the participants, in which weight of the front side will be equal to the back side.
219760218|NCT06994715|OTHER|Acupressure|The patient will be placed in a suitable position (supine) or alternatively in a side-lying position, and the patient's privacy will be taken into account to determine the pressure points. The patient's own finger measurement will be taken into account when determining the pressure points. Acupressure points will be marked using a surgical marking pen. The pressure will be applied manually. The thumb will be used for this. Before applying direct pressure to the point, a light rubbing movement will be made for approximately 15 seconds on the point area to reduce tension and tissue sensitivity, to warm, relax and prepare. Approximately 2 minutes of pressure will be applied to each point in a circular manner. Each application will last approximately 18 minutes. The patient will be measured 9 times in total during 4 sessions.
219191336|NCT03825107|OTHER|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
219191337|NCT06568432|DEVICE|CRP+SAA POCT|CRP+SAA POCT will be provided in 20 village clinics in the intervention group
219191338|NCT06506734|OTHER|Questionnaires|"*  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia."
219191339|NCT00306215|DRUG|CCX282-B|CCX282-B or placebo capsules
219191340|NCT06569056|DRUG|HRS-8427|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
219425549|NCT00547898|DRUG|Crofelemer 125 mg|Crofelemer 125 mg
219425550|NCT00547898|DRUG|Crofelemer 250 mg|Crofelemer 250 mg
219425551|NCT00547898|DRUG|Crofelemer 500 mg|Crofelemer 500 mg
219425552|NCT00547898|DRUG|Placebo|Placebo
219191341|NCT06569056|DRUG|Imipenem and Cilastatin Sodium|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
219191342|NCT06569056|DRUG|HRS-8427 placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
219191343|NCT06569056|DRUG|Imipenem and Cilastatin Sodium placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
219191344|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
219191345|NCT03027102|BIOLOGICAL|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
219191346|NCT05754177|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
219191347|NCT05754177|OTHER|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
219425553|NCT03406364|DRUG|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
219576163|NCT01566864|BEHAVIORAL|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
219191348|NCT02852538|BEHAVIORAL|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
219191349|NCT05872204|DRUG|Abemaciclib|150 mg tablet twice daily
219760219|NCT06994715|OTHER|pseudo acupressure|A pseudo acupressure will be applied to the patients in the supine or side-lying position. The researcher will perform this application by wearing gloves. Wearing gloves will reduce the therapeutic interaction with the patient. Since applying pressure or circular rubbing movements to patients may enter the area where other meridians pass and create a different effect, it will be waited for 2 minutes without applying any pressure or rubbing movements on the bone protrusions where the meridian does not pass and where there are no active pressure points. The application will be determined to be approximately 2 cm away from the acupressure points. The application will again be done manually with the thumb. Each application will take approximately 18 minutes. 4 sessions of application and a total of 9 measurements will be made to the patients.
219760220|NCT06996366|OTHER|Outreach to encourage Annual Wellness Visit completion|Mailed and telephone outreach to patient.
219760221|NCT06997276|DRUG|Mirdametinib (MEK Inhibitor)|Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.
219191350|NCT05872204|DRUG|Letrozole|2.5 mg tablet once daily
219760222|NCT06624800|PROCEDURE|Shoulder chuna treatment(posterior displacement, anterior displacement, or lateral displacement)|The Shoulder Chuna therapy for the shoulder joint will be performed on the affected shoulder from the second day of hospitalization until the day before discharge.
219191351|NCT05673759|DEVICE|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
219760223|NCT06624800|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
219191352|NCT05673759|BEHAVIORAL|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
219191353|NCT05673759|BEHAVIORAL|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) \[37\] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) \[38\] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) \[39\] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
219191354|NCT02622217|BEHAVIORAL|Sleep deprivation|
219425554|NCT01082978|DEVICE|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
219425555|NCT01082978|DEVICE|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
219425556|NCT02420795|DRUG|Akt/ERK Inhibitor ONC201|Given PO
219425557|NCT02420795|OTHER|Laboratory Biomarker Analysis|Correlative studies
219425558|NCT02420795|OTHER|Pharmacological Study|Correlative studies
219425559|NCT04833868|OTHER|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
219425560|NCT04833868|OTHER|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
219425561|NCT01874119|DRUG|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
219576164|NCT01566864|BEHAVIORAL|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
219576165|NCT01993602|PROCEDURE|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
219576166|NCT05692284|OTHER|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
219576167|NCT05692284|OTHER|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
219576168|NCT00287859|DRUG|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
219760224|NCT05992376|BEHAVIORAL|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
219005958|NCT02715076|OTHER|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
219191355|NCT04785300|DRUG|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
219005959|NCT04099927|DRUG|SHR0410|SHR0410 monotherapy,given intravenously
219005960|NCT00131833|BIOLOGICAL|Typhoid Vi vaccine|
219005961|NCT00131833|BIOLOGICAL|Meningococcal A (control)|
219005962|NCT00888251|OTHER|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
219005963|NCT01382056|OTHER|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
219005964|NCT01382056|OTHER|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
219005965|NCT01382056|OTHER|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
219005966|NCT03240796|PROCEDURE|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
219005967|NCT03240796|PROCEDURE|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
219005968|NCT05219656|DRUG|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
219005969|NCT03395912|DRUG|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
219005970|NCT03566927|COMBINATION_PRODUCT|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
219005971|NCT03011398|PROCEDURE|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
219005972|NCT00653146|BEHAVIORAL|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
219005973|NCT00653146|BEHAVIORAL|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
219005974|NCT01991067|BIOLOGICAL|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
219005975|NCT02406976|OTHER|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
219760225|NCT04586075|DIAGNOSTIC_TEST|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
219005976|NCT02406976|BEHAVIORAL|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
219005977|NCT02406976|OTHER|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
219005978|NCT01075204|DRUG|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
219005979|NCT00969176|DRUG|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
219005980|NCT01132404|DRUG|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
219005981|NCT01132404|DRUG|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
219005982|NCT05745558|BEHAVIORAL|Prehabilitation|"The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist."
219005983|NCT03715218|OTHER|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
219005984|NCT03715218|OTHER|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
219425562|NCT03457740|DIETARY_SUPPLEMENT|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
219425563|NCT03457740|DIETARY_SUPPLEMENT|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
219425564|NCT03457740|DIETARY_SUPPLEMENT|Placebo|Placebo comparison
219425565|NCT02318069|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 5 arms
219425566|NCT02671955|DRUG|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
219425567|NCT06203483|DRUG|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
219425568|NCT06203483|DRUG|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
219425569|NCT04401397|PROCEDURE|Intensive early mobilization techniques|"Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques."
219425570|NCT05750238|OTHER|no intervention|no intervention, survey was applied to the participants
219425571|NCT01646567|DRUG|SHP-141C|Topical Cream
219425572|NCT01646567|DRUG|Placebo to SHP-141C|Placebo Topical Cream
219425573|NCT01646567|DRUG|Betamethasone Valerate|Topical cream, 0.02%
219425574|NCT01646567|DRUG|Calcipotriol|Topical cream, 0.005%
219425575|NCT01238913|PROCEDURE|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
219005985|NCT01012518|DEVICE|Standard PCT|The standard technique, performed without video guidance
219005986|NCT01012518|DEVICE|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
219005987|NCT00543348|PROCEDURE|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
219005988|NCT00543348|PROCEDURE|Balloon angioplasty|HIGH PRESSURE BALLOON
219425576|NCT04568811|BIOLOGICAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
219425577|NCT06229483|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
219760226|NCT06699251|BEHAVIORAL|Chat|Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.
219425578|NCT06229483|OTHER|Placebo|0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
219425579|NCT01002742|DRUG|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
219425580|NCT01002742|DRUG|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
219425581|NCT00154219|DRUG|Lumiracoxib (drug)|
219425582|NCT00786097|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
219425583|NCT02438046|PROCEDURE|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
219425584|NCT01001728|RADIATION|Imaging investigations (with radiation)|
219425585|NCT02818413|OTHER|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
219425586|NCT03780413|BEHAVIORAL|PR-ESSENCE treatment|
219576169|NCT05582252|OTHER|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
219576170|NCT01709734|DRUG|galeterone|
219576171|NCT02996045|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
219005989|NCT02189746|OTHER|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
219005990|NCT02189746|OTHER|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
219191356|NCT04785300|DRUG|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
219191357|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
219425587|NCT03780413|BEHAVIORAL|Control (TAU)|
219425588|NCT03532724|DEVICE|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
219425589|NCT01158066|PROCEDURE|CT Cardiac|the patient will undergo cardiac CT
219425590|NCT04863313|DIETARY_SUPPLEMENT|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
219425591|NCT04863313|DIETARY_SUPPLEMENT|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
219425592|NCT04904380|OTHER|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
219425593|NCT00702260|DRUG|Ramipril|10 mg capsule
219425594|NCT06441747|DRUG|Durvalumab|Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
219576172|NCT06868420|BEHAVIORAL|Play therapy with transport cart|he intervention consisted of allowing pediatric patients to engage in five minutes of play with a toy transport cart, after which they were transported to the operating room in the same cart.
219760227|NCT06699251|BEHAVIORAL|Enhanced Usual Care|An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
219760228|NCT06701461|DEVICE|Electrodermal Activity signal|Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
219760229|NCT04928547|DIAGNOSTIC_TEST|Test|Different test
219760230|NCT04809233|DRUG|Tipifarnib|
219760231|NCT06764615|DRUG|Zasocitinib|Zasocitinib capsules.
219760232|NCT06766968|DEVICE|Graduated Compression Stocking: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
219760233|NCT06766968|DEVICE|Graduated Compression Stocking: 1 week using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
219760234|NCT03424733|DRUG|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
219760235|NCT03424733|DRUG|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
219760236|NCT03424733|DRUG|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
219760237|NCT04925427|BEHAVIORAL|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
219760238|NCT04925427|BEHAVIORAL|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
219760239|NCT02618941|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
219760240|NCT00208338|DEVICE|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
219760241|NCT00208338|PROCEDURE|Rotator cuff repair|Standard surgical repair of torn rotator cuff
219425595|NCT06441747|DRUG|Olaparib|Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
219425596|NCT01187134|BEHAVIORAL|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
219425597|NCT05241938|PROCEDURE|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
219425598|NCT05241938|DRUG|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
219425599|NCT00271791|DRUG|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
219425600|NCT00271791|DRUG|Prednisone|PO, Placebo, 17 days
219425601|NCT03064165|DRUG|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
219760242|NCT04133415|RADIATION|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
219425602|NCT03064165|PROCEDURE|Sham block|Injection as for obturator nerve block, but with placebo
219425603|NCT03064165|PROCEDURE|Obturator nerve block|Postoperative obturator nerve block
219425604|NCT03064165|DRUG|Sodium Chloride 9mg/mL|Placebo
219425605|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
219425606|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
219425607|NCT04306900|COMBINATION_PRODUCT|TTX-030 and mFOLFOX6|Dose and schedule per protocol
219425608|NCT04306900|COMBINATION_PRODUCT|TTX-030 and budigalimab|Dose and schedule per protocol
219425609|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
219425610|NCT04306900|COMBINATION_PRODUCT|TTX-030 and pembrolizumab|Dose and schedule per protocol
219425611|NCT04306900|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
219425612|NCT04306900|COMBINATION_PRODUCT|Budigalimab and mFOLFOX6|Dose and schedule per protocol
219760243|NCT04133415|PROCEDURE|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
219760244|NCT04549467|DRUG|Lamivudine 300 MG|Experimental arm
219760245|NCT04549467|DRUG|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
219760246|NCT00399022|DRUG|Duloxetine|
219760247|NCT02501421|BIOLOGICAL|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
219760248|NCT02501421|BIOLOGICAL|Placebo|Buffer
219760249|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Non-invasive MRI will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
219760250|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy|Non-invasive MRS will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
219760251|NCT06819475|OTHER|Physical function assessment|As part of the SJLIFE visit in the Human Performance Lab, the participant's physical health will be assessed by testing muscle strength, physical function, and lean muscle mass.
219760252|NCT06819475|OTHER|Peripheral blood sample|Peripheral blood sample will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in the muscles of survivors and age/sex-matched healthy controls.
219760253|NCT06819475|OTHER|Skeletal muscle biopsy|Muscle biopsy will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in muscles of survivors and age/sex-matched healthy controls.
219760254|NCT06819475|DIAGNOSTIC_TEST|Muscle Ultrasound|Bilateral quadriceps and calf muscle ultrasound will be used to measure muscle volume by calculating the cross-sectional area using the Cavalieri method.
219760255|NCT00630617|BEHAVIORAL|Diet, Physical activity, Physical inactivity|Community based participatory research design
219576173|NCT04918160|OTHER|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
219425613|NCT00300612|BIOLOGICAL|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
219425614|NCT03513289|OTHER|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
219425615|NCT03654079|OTHER|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
219425616|NCT04300790|DRUG|Alpelisib|Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
219425617|NCT04300790|DRUG|Metformin|500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
219576174|NCT00356980|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
219576175|NCT00356980|OTHER|pharmacological study|
219576176|NCT04788160|OTHER|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position."
219576177|NCT04788160|OTHER|Conventional Therapy|"* Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
219760256|NCT02051426|OTHER|D-serine|single P.O. administration of D-serine (2.1g)
219425618|NCT04300790|DRUG|Fulvestrant|"fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)"
219425619|NCT04300790|DRUG|Letrozole|Letrozole 2.5 mg tablets, once daily, orally
219425620|NCT04300790|DRUG|Exemestane|Exemestane 25 mg tablets, once daily, orally
219425621|NCT04300790|DRUG|Vildagliptin|Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
219425622|NCT04300790|DRUG|Tamoxifen|Tamoxifen 20 mg tablets, once daily, orally
219425623|NCT03776162|PROCEDURE|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
219425624|NCT03776162|DEVICE|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
219425625|NCT02269150|BIOLOGICAL|fecal microbiota transplantation (FMT)|
219425626|NCT02269150|OTHER|No fecal microbiota transplantation (FMT), routine management|
219425627|NCT04920136|PROCEDURE|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
219576178|NCT01576094|DRUG|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
219760257|NCT02051426|OTHER|Placebo|single P.O. administration of Placebo
219760258|NCT00946595|DRUG|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
219760259|NCT00946595|DRUG|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
219760260|NCT06047938|RADIATION|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
219760261|NCT00916448|DRUG|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
219760262|NCT00916448|DRUG|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
219760263|NCT00946933|DIETARY_SUPPLEMENT|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
219760264|NCT00946933|DIETARY_SUPPLEMENT|placebo|0.025 g/kg/day of NaCl (sodium chloride)
219425628|NCT04920136|PROCEDURE|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
219760265|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
219760266|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
219760267|NCT03238053|PROCEDURE|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
219425629|NCT04175301|DRUG|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
219425630|NCT04175301|DRUG|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
219425631|NCT06356155|DRUG|Enfortumab vedotin|1.25 mg/kg IV
219425632|NCT06356155|DRUG|Pembrolizumab|200 mg IV
219425633|NCT03421574|DEVICE|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
219425634|NCT01705548|RADIATION|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
219425635|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
219425636|NCT05387577|DRUG|Transdermal patch|Estradiol patch therapy for 8 weeks
219425637|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
219425638|NCT02862548|DRUG|TAF|Tablet administered orally
219425639|NCT02862548|DRUG|TDF|Tablet administered orally
219425640|NCT02862548|DRUG|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
219425641|NCT00880763|DRUG|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
219425642|NCT00880763|DRUG|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
219425643|NCT00880763|DRUG|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
219576179|NCT01576094|DRUG|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
219576180|NCT00653991|BEHAVIORAL|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
219576181|NCT03757273|PROCEDURE|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
219425644|NCT00880763|DRUG|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
219425645|NCT03865511|DRUG|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
219425646|NCT03865511|GENETIC|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
219425647|NCT03865511|GENETIC|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations"
219425648|NCT02849249|BIOLOGICAL|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
219425649|NCT05710965|DEVICE|FRx-001|Wearable digital therapy
219425650|NCT05710965|DEVICE|FRx-003|Wearable digital therapy
219576182|NCT03757273|PROCEDURE|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
219576183|NCT01947231|OTHER|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
219576184|NCT01947231|OTHER|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
219576185|NCT01846273|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
219760268|NCT03238053|DEVICE|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
219760269|NCT03238053|DEVICE|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
219760270|NCT06907407|OTHER|Diaphragmatic Myofascial Release|six technique will be applied; 1-Diaphragmatic transverse plane, 2-Anteroposterior equilibrium technique, 3-Supra and infrahyoid fascial induction, 4-Psoas fascial induction,5-Diaphragm stretching technique and 6-Phrenic centre inhibition. diaphragmatic breathing, Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
219760271|NCT06907407|OTHER|visceral mobilization techniques|Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
219760272|NCT06907407|OTHER|irritable bowel syndrome medication|the patients will receive irritable bowel syndrome medication
219760273|NCT06534775|OTHER|Questionnary|"The patients were included in a previous study (PABLOS) - These patients received locoregional anesthesia (LRA) by deep parasternal intercostal block (Deep-PIP) or bilateral superficial parasternal intercostal block (Superficial-PIP), compared with standard management (general anesthesia without LRA) for chronic postoperative pain after cardiac surgery by sternotomy.~In PABLOS 2.0 study, the evaluation focuses on the presence of chronic pain between 12 and 24 months postoperatively. There is no intervention in PABLOS 2.0 study but only a questionnary."
219760274|NCT06505460|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
219425651|NCT05710965|DEVICE|FRx-004|Wearable digital therapy
219760275|NCT04473833|PROCEDURE|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
219425652|NCT03678584|OTHER|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
219425653|NCT05307445|DEVICE|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
219425654|NCT05203627|OTHER|Best Practice|Receive standard nutritional support
219425655|NCT05203627|OTHER|Questionnaire Administration|Ancillary studies
219425656|NCT05203627|OTHER|Telemedicine Visit|Receive telehealth sessions
219425657|NCT01223326|DRUG|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
219425658|NCT01223326|DRUG|Saline|Na Cl 0.9% infusion
219425659|NCT00966069|OTHER|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
219425660|NCT00966069|OTHER|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
219425661|NCT04327518|DEVICE|TECNIS® Toric II|Toric Intraocular Lens
219425662|NCT03920878|DRUG|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
219576186|NCT01846273|DRUG|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
219576187|NCT01846273|DRUG|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
219576188|NCT00165230|DRUG|Thalidomide|
219576189|NCT00165230|DRUG|Temodar|
219576190|NCT01298713|DRUG|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
219576191|NCT01298713|DRUG|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
219576192|NCT04715360|COMBINATION_PRODUCT|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
219576193|NCT04715360|DRUG|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
219576194|NCT03431974|DRUG|LD-Aminopterin oral capsule|anti-folate treatment
219425663|NCT03920878|DRUG|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
219425664|NCT06315244|PROCEDURE|US Guided Perineural Injection and Neuroprolotherapy|Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
219576195|NCT03431974|DRUG|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
219576196|NCT05183295|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
219576197|NCT03436914|DRUG|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
219576198|NCT03440541|COMBINATION_PRODUCT|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
219576199|NCT02939014|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
219576200|NCT03515902|DEVICE|mouthguard|mouthguard
219576201|NCT03515902|DEVICE|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
219576202|NCT00555802|OTHER|exercise|exercise
219576203|NCT03014336|DEVICE|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
219425665|NCT04387929|DIAGNOSTIC_TEST|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
219425666|NCT03620435|DRUG|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
219425667|NCT01966263|PROCEDURE|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
219425668|NCT01966263|PROCEDURE|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
219425669|NCT01966263|PROCEDURE|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
219425670|NCT01966263|PROCEDURE|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
219576204|NCT01806038|OTHER|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
219576205|NCT01806038|OTHER|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
219576206|NCT02599259|DEVICE|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
219576207|NCT05128370|OTHER|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
219576208|NCT01252875|PROCEDURE|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
219425671|NCT02675725|DEVICE|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
219576209|NCT01252875|PROCEDURE|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
219576210|NCT03864042|DRUG|losartan|taken orally
219576211|NCT03864042|DRUG|dextromethorphan|taken orally
219425672|NCT05259930|OTHER|Amino MP9|Name used by Nualtra for their product of BCAA
219425673|NCT04501835|OTHER|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
219425674|NCT01984736|DRUG|Experimental: EVP-6124|
219425675|NCT04868136|BEHAVIORAL|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
219425676|NCT05561712|OTHER|Laboratory method validation|Test several sampling conditions
219425677|NCT03287869|DRUG|Brexpiprazole|Brexpiprazole tablets
219425678|NCT04229108|DEVICE|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
219425679|NCT03488238|DEVICE|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
219425680|NCT06085287|DEVICE|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
219760276|NCT05229614|RADIATION|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.
219425681|NCT05860998|DIAGNOSTIC_TEST|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
219425682|NCT02884518|DEVICE|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
219425683|NCT02884518|BEHAVIORAL|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
219425684|NCT06210438|DRUG|SHR-A1921 + Bevacizumab|SHR-A1921 + Bevacizumab
219425685|NCT03524911|BEHAVIORAL|CHFFF nutrition education|
219425686|NCT02670928|BEHAVIORAL|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
219425687|NCT00443937|DRUG|enteric-coated mycophenolate sodium|oral
219425688|NCT00443937|DRUG|everolimus|oral
219425689|NCT05906992|BIOLOGICAL|CT-P53|Intravenous(IV) infusion
219425690|NCT05906992|BIOLOGICAL|US-Ocrevus|Intravenous(IV) infusion
219425691|NCT05906992|BIOLOGICAL|EU-Ocrevus|Intravenous(IV) infusion
219425692|NCT03199508|DIAGNOSTIC_TEST|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
219425693|NCT03199508|DIAGNOSTIC_TEST|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
219425694|NCT05671315|DRUG|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
219425695|NCT05671315|DRUG|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
219425696|NCT00950976|OTHER|citrulline|TID for 5 days
219425697|NCT00950976|OTHER|Lemonade|TID for 5 days
219425698|NCT00334646|DRUG|Oral GW679769|150mg oral, once daily on days 1-3
219576212|NCT03864042|DRUG|caffeine|taken orally
219576213|NCT03864042|DRUG|omeprazole|taken orally
219576214|NCT03864042|DRUG|midazolam|taken orally
219576215|NCT03864042|DRUG|rosuvastatin|taken orally
219576216|NCT03864042|DRUG|bupropion immediate release (IR)|taken orally
219576217|NCT03864042|DRUG|encorafenib|taken orally
219576218|NCT03864042|DRUG|binimetinib|taken orally
219576219|NCT03864042|DRUG|modafinil|taken orally
219576220|NCT00377507|DIETARY_SUPPLEMENT|catechin extracts|catechin extracts solution
219576221|NCT04407078|DRUG|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
219576222|NCT04407078|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
219425699|NCT00334646|DRUG|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
219425700|NCT06527508|OTHER|Non-Interventional|This study has a observational design
219425701|NCT02660866|DRUG|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
219425702|NCT02660866|DRUG|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
219425703|NCT02889757|DRUG|Acteylcysteine|randomized into three arms
219576223|NCT02139371|OTHER|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
219576224|NCT05344651|DEVICE|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
219576225|NCT00810173|BEHAVIORAL|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
219760277|NCT05229614|DRUG|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
219576226|NCT02220725|BIOLOGICAL|Andexanet|
219005991|NCT02189746|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
219005992|NCT02189746|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
219425704|NCT05610657|DRUG|Mitapivat|Mitapivat tablets
219425705|NCT06456138|DRUG|Trametinib|Trametinib will be administrated orally every day.
219425706|NCT06456138|DRUG|Anlotinib|Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
219425707|NCT06456138|DRUG|Tislelizumab|Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
219425708|NCT02591238|OTHER|non-smoker oral placebo|Participants oral placebo last 2 weeks.
219576227|NCT02220725|OTHER|Placebo|
219576228|NCT05099523|PROCEDURE|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
219576229|NCT01858987|PROCEDURE|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
219576230|NCT01858987|PROCEDURE|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
219576231|NCT01858987|DEVICE|Ligasure|
219760278|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
219425709|NCT02591238|DRUG|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
219425710|NCT02591238|OTHER|smoker oral placebo|Participants oral placebo last 2 weeks.
219576232|NCT01858987|OTHER|vascular staple|
219576233|NCT03370822|DEVICE|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
219760279|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
219760280|NCT06904313|DRUG|Piflufolastat F18|Participants will be injected with Piflufolastat F18 and imaged for up to 3 hours on a PET scanner
219425711|NCT02591238|DRUG|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
219425712|NCT04394143|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
219425713|NCT04394143|DRUG|Mannitol|Oral administration of two capsules before sleep for 7 days.
219425714|NCT01268033|DRUG|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
219425715|NCT01268033|DRUG|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
219576234|NCT00132834|DEVICE|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
219576235|NCT00004135|BIOLOGICAL|filgrastim|
219576236|NCT00004135|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219576237|NCT00004135|DRUG|cyclophosphamide|
219576238|NCT00004135|DRUG|fludarabine phosphate|
219576239|NCT00004135|PROCEDURE|peripheral blood stem cell transplantation|
219576240|NCT03801941|DEVICE|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
219576241|NCT03801941|OTHER|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
219576242|NCT05069155|BEHAVIORAL|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
219576243|NCT00655278|DRUG|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
219576244|NCT01987726|OTHER|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
219576245|NCT01987726|OTHER|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
219425716|NCT04173039|DIAGNOSTIC_TEST|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
219425717|NCT04549415|DRUG|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
219576246|NCT03466359|BEHAVIORAL|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
219576247|NCT03466359|BEHAVIORAL|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
219760281|NCT06927674|BEHAVIORAL|Consumption of vegetables|DELIVER is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. DELIVER aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables. The project also includes a livelihood component that will increase market connections and access to finance for smallholder farmers.
219760282|NCT06507540|OTHER|No intervention (observational study)|Retrospective description of diagnostics and treatements of dental emergencies
219760283|NCT06943209|OTHER|Creation of a contraception education program and post on social networks for high school students|Training of peer influencers and program design.
219760284|NCT06943209|OTHER|Education program|View videos/messages created by peer influencers on social networks
219760285|NCT06943209|OTHER|Survey and questionnaires|Respond to the sexual health and contraception knowledge survey and the education program satisfaction survey
219760286|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
219425718|NCT04549415|OTHER|lifestyle modification|Lifestyle modification Standard Principles
219425719|NCT01293006|DRUG|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
219425720|NCT01293006|DRUG|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
219425721|NCT04639843|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.
219760287|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
219425722|NCT04639843|DRUG|Duvelisib|Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).
219425723|NCT04639843|DRUG|Romidepsin|Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.
219425724|NCT04639843|DRUG|Doxorubicin|Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
219425725|NCT04099706|PROCEDURE|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
219425726|NCT03350971|OTHER|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
219425727|NCT03350971|OTHER|Control|chest physical therapy exercises
219425728|NCT04297293|DRUG|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
219425729|NCT01189799|BEHAVIORAL|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
219425730|NCT01189799|BEHAVIORAL|Dual Recovery Anonymous/Tx as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
219425731|NCT06339606|OTHER|Biospecimen collection|Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
219425732|NCT04712487|DIAGNOSTIC_TEST|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
219425733|NCT06195098|OTHER|Nutritional educational intervention|The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
219425734|NCT02771457|DRUG|Infliximab at weeks 0,2, and 6|
219425735|NCT02771457|DRUG|Infliximab at weeks 0,4, and 8|
219425736|NCT02771457|DRUG|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
219425737|NCT05730374|BEHAVIORAL|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
219425738|NCT05730374|BEHAVIORAL|Music therapy|"* The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~* This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
219425739|NCT00436982|DEVICE|Cemented Triathlon total knee system|Orthopaedic implant
219425740|NCT00436982|DEVICE|Duracon total knee system|Orthopaedic implant
219425741|NCT00425074|DRUG|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
219425742|NCT00425074|DRUG|ASA|normal release acetylsalicylic acid
219425743|NCT00425074|DRUG|SR-ASA|slow release acetylsalicylic acid 150 mg
219425744|NCT04225390|DRUG|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
219425745|NCT00953225|DRUG|vitamin D3|4,000 IU daily for one year
219425746|NCT00953225|DRUG|Placebo daily for one year|Placebo
219425747|NCT01855113|DEVICE|Invisalign|
219425748|NCT04991064|OTHER|Complete denture base modified by Titanium dioxide nanoparticles.|Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
219425749|NCT02821091|OTHER|Interactive Dynamic Balance Training|
219425750|NCT05446974|OTHER|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
219425751|NCT01804257|OTHER|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
219425752|NCT02661620|DEVICE|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
219425753|NCT00609804|DRUG|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
219425754|NCT00609804|DRUG|Erlotinib|Erlotinib 150 mg once daily by mouth
219576248|NCT03940482|BEHAVIORAL|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
219576249|NCT04834739|OTHER|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
219005993|NCT03486132|PROCEDURE|repair of episiotomy|Different techniques for repair of episiotomy incsicion
219760288|NCT06421649|RADIATION|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
219425755|NCT04992637|BEHAVIORAL|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
219425756|NCT04992637|OTHER|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
219425757|NCT02215616|DRUG|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
219425758|NCT02215616|DRUG|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
219425759|NCT06295601|OTHER|Traditional rehabilitation|The program consists of a joint treatment in which lower extremity strengthening and balance exercises are carried out synchronously. The program will include a total of 5 minutes of warm-up, 5 minutes of cool-down and 30 minutes of exercises related to the program. The difficulty of the program will increase by changing the number of exercises and increasing the weight in strengthening exercises. Progress in balance and coordination exercises will vary by changing the ground, increasing the standing time, and keeping the eyes open and closed.
219425760|NCT06295601|OTHER|Action observation therapy and motor imagery|In the experimental group, in addition to traditional telerehabilitation, action observation and motor imagery of 4 exercises will be performed in each session. A video will be prepared for 4 exercises. Then, the participant will perform 2 minutes of action observation of each movement, followed by 1 minute of motor imagery. In addition to the traditional telerehabilitation program, a 12-minute combination of action observation and motor imagery will be performed in each session. Exercises will be changed every two weeks, gradually increasing the difficulty.
219425761|NCT00357149|DRUG|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
219425762|NCT00357149|DRUG|Concomitant cisplatin, 5-FU and radiotherapy|
219425763|NCT02769078|DRUG|dabigatran|
219425764|NCT02769078|DRUG|rivaroxaban|
219425765|NCT02769078|DRUG|apixaban|
219425766|NCT02769078|DRUG|warfarin|
219425767|NCT02319213|OTHER|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
219425768|NCT02319213|OTHER|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
219425769|NCT02319213|OTHER|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
219576250|NCT04834739|OTHER|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
219576251|NCT04834739|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
219425770|NCT05510609|DEVICE|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
219425771|NCT05031429|OTHER|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
219425772|NCT00004916|DRUG|ifosfamide|
219425773|NCT00004916|DRUG|paclitaxel|
219425774|NCT00004916|DRUG|teniposide|
219425775|NCT00004916|PROCEDURE|peripheral blood stem cell transplantation|
219425776|NCT00880880|OTHER|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
219576252|NCT04834739|OTHER|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
219576253|NCT04834739|OTHER|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
219760289|NCT04860466|DRUG|CC-96673|IV Infusion
219760290|NCT06954454|OTHER|prenatal physical exercise intervention|Multicomponent prenatal exercise program including aerobic, coordination, strength, stretching, balance, postural, and pelvic floor muscle training exercises. Delivered either in person or online by qualified exercise physiologists. Duration and frequency: two sessions of 60 minutes per week for 12 weeks. Moderate intensity: According to the Borg scale of perceived exertion, from six to 20, moderate exercise is rated between 13 and 14. Each pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. Settings: home or healthcare, university, or fitness centers. Following international guidelines for physical activity during pregnancy (ACOG-USA, ACSM-USA, CSEP-Canada, PSOG-Poland, SEGO-Spain).
219760291|NCT05722223|COMBINATION_PRODUCT|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
219760292|NCT03984188|DRUG|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
219760293|NCT03984188|DRUG|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
219005994|NCT01951742|BIOLOGICAL|ANT-1401|Active
219005995|NCT01951742|BIOLOGICAL|Vehicle|Vehicle
219425777|NCT05549089|DEVICE|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
219425778|NCT05549089|DEVICE|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
219425779|NCT05549089|DEVICE|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
219425780|NCT01511432|DRUG|telaprevir formulation A|A single 1125-mg dose administered orally
219425781|NCT01511432|DRUG|telaprevir Formulation B|A single 1125-mg dose administered orally
219425782|NCT01511432|DRUG|telaprevir Formulation C|A single 1125-mg dose administered orally
219425783|NCT01511432|DRUG|telaprevir Formulation D|A single 1125-mg dose administered orally
219425784|NCT01754207|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
219425785|NCT01754207|DEVICE|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
219425786|NCT05069285|OTHER|self-help book|information and advice given in the self-help book
219425787|NCT05069285|OTHER|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
219425788|NCT03728140|PROCEDURE|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
219425789|NCT03188432|DRUG|Carboplatin|Given IV and IP
219425790|NCT03188432|OTHER|Quality-of-Life Assessment|Ancillary studies
219425791|NCT03188432|OTHER|Questionnaire Administration|Ancillary studies
219425792|NCT03188432|PROCEDURE|Cytoreductive Surgery|Undergo CRS
219425793|NCT04243252|BEHAVIORAL|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
219425794|NCT04243252|OTHER|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
219425795|NCT00003219|DRUG|perillyl alcohol|
219425796|NCT02079558|DRUG|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
219425797|NCT02079558|DRUG|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
219425798|NCT05119088|OTHER|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
219425799|NCT03519672|OTHER|No intervention|This is a non-interventional study.
219425800|NCT01381718|DRUG|modafinil|Given PO
219425801|NCT01381718|OTHER|placebo|Given PO
219425802|NCT01027572|DEVICE|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
219425803|NCT01906957|OTHER|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
219425804|NCT01906957|OTHER|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
219576254|NCT04834739|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
219576255|NCT04834739|OTHER|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
219760294|NCT03984188|OTHER|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
219760295|NCT04111354|DEVICE|Pacemaker implantation|Pacemaker implantation
219760296|NCT03508674|DEVICE|Levita Magnetic Surgical System|use of surgical tool
219760297|NCT04902209|PROCEDURE|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
219760298|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
219760299|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
219760300|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
219760301|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
219760302|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
219760303|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
219760304|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
219760305|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
219760306|NCT01283438|DEVICE|Barricaid|Annular closure device
219760307|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
219760308|NCT01173679|DRUG|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
219760309|NCT01173679|DRUG|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
219760310|NCT01173679|DRUG|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
219760311|NCT01031888|DRUG|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
219005996|NCT02066740|DEVICE|EverFlex™ stent with Entrust™ delivery system|
219005997|NCT00937443|OTHER|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
219425805|NCT01668381|PROCEDURE|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
219425806|NCT00703170|DRUG|Temsirolimus|
219425807|NCT00703170|DRUG|Pegylated liposomal doxorubicin|
219425808|NCT04503850|DRUG|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
219425809|NCT04503850|DRUG|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
219425810|NCT04015440|BEHAVIORAL|HBMT|Individual is presented with words with some letters missing and told to complete the word.
219425811|NCT04015440|BEHAVIORAL|Other Training|Alternative to HBMT training
219425812|NCT04309669|DRUG|TOT'HEMA|three ampoules per day during 12 weeks
219760312|NCT01031888|DRUG|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
219760313|NCT00848263|PROCEDURE|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
219760314|NCT00848263|PROCEDURE|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
219760315|NCT05174585|BIOLOGICAL|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
219760316|NCT05174585|BIOLOGICAL|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
219760317|NCT01978483|DRUG|Denosumab|
219760318|NCT01978483|RADIATION|UVB exposure|
219760319|NCT01978483|DRUG|Diphenylcyclopropenone|
219760320|NCT01978483|DRUG|Normal Saline|
219760321|NCT04106115|DRUG|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
219760322|NCT04106115|BIOLOGICAL|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
219760323|NCT02026011|DRUG|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
219760324|NCT02026011|DRUG|Placebo|Sugar pill, matched to the active study medication in capsule size and color
219760325|NCT01577602|OTHER|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
219760326|NCT01577602|OTHER|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
219760327|NCT01577602|OTHER|Combined intervention|Combines the printed medication list with the open ended question
219576256|NCT04834739|OTHER|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
219576257|NCT04834739|OTHER|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
219576258|NCT06698445|OTHER|Short film video|The short film training video will be prepared by researchers based on literature and appropriate for the level of children aged 7-12. The content will include topics such as preparation for KİAB, KİAB environment and the process after KİAB. Since the short film will be shot in a realistic manner, the scenario will include a doctor, a nurse, a child patient and a parent. The short film will be shot in the clinic where the data will be collected, at the appropriate time for the clinic. After the short film is shot, the editing process will be done and the final version will be given.
219425813|NCT05326217|OTHER|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
219425814|NCT05326217|OTHER|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
219425815|NCT04922697|OTHER|Educational Intervention|Watch educational videos and use wearable air pollution sensor
219425816|NCT04922697|OTHER|Questionnaire Administration|Complete questionnaires
219425817|NCT02662413|OTHER|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
219425818|NCT03516409|DIETARY_SUPPLEMENT|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
219425819|NCT03516409|DIETARY_SUPPLEMENT|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
219425820|NCT04285944|OTHER|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
219425821|NCT01403467|DEVICE|Continuous positive airway pressure|CPAP 8 cmH2O
219576259|NCT05181826|DIAGNOSTIC_TEST|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
219576260|NCT00290394|DRUG|rosiglitazone(drug), blood pressure lowering effect|
219425822|NCT04563819|GENETIC|Genom-wide association study (GWAS) and biological pathway analyses|
219760328|NCT01400009|DRUG|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
219760329|NCT01400009|DRUG|Placebo|Standard Placebo made of Lactose 100 mg
219760330|NCT05626933|PROCEDURE|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
219760331|NCT02252315|OTHER|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
219760332|NCT02252315|OTHER|Verbal education module|A structured in-person education module about mild traumatic brain injury.
219005998|NCT00937443|BIOLOGICAL|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
219425823|NCT01058733|OTHER|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
219425824|NCT01388868|OTHER|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
219425825|NCT01388868|OTHER|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
219425826|NCT01388868|OTHER|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
219425827|NCT04809272|BEHAVIORAL|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
219425828|NCT04225884|OTHER|DTx for pain software|Software with active intervention
219425829|NCT04225884|OTHER|Control software|Software without active intervention
219425830|NCT04225884|OTHER|Standard care|Pain medication
219425831|NCT02759861|DRUG|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
219425832|NCT00570440|DRUG|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
219425833|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
219425834|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
219425835|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
219425836|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
219425837|NCT05836363|PROCEDURE|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
219425838|NCT00002247|DRUG|Ganciclovir|
219576261|NCT04209010|PROCEDURE|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
219576262|NCT06142149|PROCEDURE|ultrasonographic evaluation|Screen the front of neck using ultrasound
219576263|NCT03487848|DRUG|Daclatasvir|Specified dose on specified days for specified duration
219576264|NCT03487848|DRUG|Sofosbuvir|Specified dose on specified days for specified duration
219576265|NCT00731549|DRUG|Aripiprazole IM Depot|300mg or 400mg
219576266|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
219576267|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
219576268|NCT06020001|OTHER|Placebo|Twice a day
219576269|NCT04072549|BEHAVIORAL|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
219576270|NCT01845402|BIOLOGICAL|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
219576271|NCT05563818|OTHER|WinterLight Mobile Phone Speech Analysis|N/A- observational study
219576272|NCT03365999|DRUG|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
219760333|NCT01770743|BIOLOGICAL|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
219760334|NCT01770743|BIOLOGICAL|BioThrax|
219760335|NCT00000906|DRUG|Ritonavir|
219760336|NCT00000906|DRUG|Saquinavir|
219760337|NCT00000906|DRUG|Methadone hydrochloride|
219425839|NCT05405907|OTHER|PuraBond haemostatic agent|Application of Purabond to surgical field
219425840|NCT04402853|DIAGNOSTIC_TEST|Tears swab|rtPCR on tears swabs samples
219425841|NCT00899210|OTHER|laboratory biomarker analysis|
219425842|NCT00899210|PROCEDURE|cryosurgery|
219425843|NCT00899210|PROCEDURE|radiofrequency ablation|
219425844|NCT00899210|PROCEDURE|therapeutic conventional surgery|
219576273|NCT03365999|DRUG|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
219576274|NCT01946074|DRUG|paclitaxel|Paclitaxel will be administered by intravenous infusion.
219576275|NCT01946074|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
219576276|NCT01946074|DRUG|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
219425845|NCT00285103|DRUG|SPC2996|
219425846|NCT06076200|DRUG|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
219425847|NCT01504971|OTHER|symptom questionaire|GerdQ questionaire
219425848|NCT01504971|PROCEDURE|pH monitoring|24-hour pH monitoring
219425849|NCT01504971|PROCEDURE|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
219425850|NCT01504971|DRUG|rabeprazole|10mg, bid, p.o.
219425851|NCT00936117|DRUG|Posaconazole|200 mg (liquid) by mouth 3 times per day.
219425852|NCT04979949|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
219425853|NCT04979949|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
219425854|NCT02360553|BEHAVIORAL|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
219425855|NCT02360553|BEHAVIORAL|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
219425856|NCT01142453|DRUG|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
219425857|NCT01315002|DRUG|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
219425858|NCT01315002|DRUG|Placebo patch|Placebo patch
219425859|NCT01577784|DRUG|Pazopanib|800 mg / day of pazopanib in monotherapy.
219425860|NCT06980077|PROCEDURE|Biopsy Procedure|Undergo biopsy
219425861|NCT06980077|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219576277|NCT01946074|DRUG|ABBV-181|ABBV-181 will be administered by intravenous infusion.
219576278|NCT01393730|DRUG|Abiraterone acetate|
219576279|NCT01393730|DRUG|Dutasteride|
219425862|NCT06980077|PROCEDURE|Computed Tomography|Undergo CT
219425863|NCT06980077|BIOLOGICAL|Ivonescimab|Given IV
219425864|NCT06980077|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219425865|NCT06980077|OTHER|Questionnaire Administration|Ancillary studies
219425866|NCT04369755|OTHER|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
219425867|NCT03267771|DRUG|Progesterone Suppositories Vaginal|progesterone vaginal suppository
219425868|NCT03267771|DRUG|Dydrogesterone Oral Tablet|oral progesterone drug
219576280|NCT01393730|DRUG|Prednisone|
219576281|NCT00103402|DRUG|Alfuzosin|
219576282|NCT00103402|DRUG|Placebo|
219576283|NCT01404117|DRUG|Laquinimod 0.6|Laquinimod 0.6 capsule
219576284|NCT01404117|DRUG|Laquinimod 1.2|Placebo
219576285|NCT01404117|OTHER|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
219576286|NCT05730504|OTHER|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
219576287|NCT02987803|OTHER|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
219576288|NCT02333487|DRUG|Lu AF35700|5 mg tablets for oral administration
219760338|NCT05067205|PROCEDURE|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
219760339|NCT01312519|DEVICE|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
219760340|NCT01312519|DEVICE|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
219760341|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
219760342|NCT05389748|OTHER|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
219760343|NCT05389748|BIOLOGICAL|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
219425869|NCT03267771|DEVICE|doppler ultrasound|pulsed doppler ultrasound
219425870|NCT05053126|DRUG|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
219425871|NCT05053126|DRUG|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
219425872|NCT05053126|DRUG|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
219425873|NCT05053126|DRUG|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
219425874|NCT05053126|DRUG|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
219425875|NCT05053126|DRUG|Placebo|Participant will receive an oral dose of placebo
219425876|NCT04334915|DRUG|Cenicriviroc Mesylate (CVC)|Administered orally
219425877|NCT04334915|DRUG|Placebo|Administered orally
219425878|NCT03673696|DRUG|HEC74647PA Capsule|Capsule administered orally once daily
219425879|NCT03673696|DRUG|placebo|Matching Placebo Capsule
219425880|NCT00057395|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
219425881|NCT00769808|DEVICE|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
219425882|NCT02238288|DRUG|Aminocaproic acid|Crushed tablet in the dental socket
219425883|NCT02238288|OTHER|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
219425884|NCT02238288|DRUG|lidocaine and epinephrine|2%
219576289|NCT04212533|DIETARY_SUPPLEMENT|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
219576290|NCT04212533|DIETARY_SUPPLEMENT|rice starch tablets|rice starch tablets as placebo
219576291|NCT03405558|OTHER|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
219576292|NCT02677259|DRUG|17-beta estradiol|
219576293|NCT02677259|DRUG|Micronized progesterone|
219576294|NCT05064774|OTHER|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
219576295|NCT05064774|OTHER|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
219576296|NCT02758249|DRUG|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
219576297|NCT02758249|DRUG|propofol|patients are anesthetized by using propofol infusion
219576298|NCT03997071|OTHER|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
219576299|NCT01297322|OTHER|Manual compression|Standard of Care
219760344|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219760345|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219760346|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219576300|NCT01297322|DEVICE|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
219576301|NCT03898921|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
219576302|NCT03898921|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
219425885|NCT02238288|DRUG|Paracetamol|750 mg
219425886|NCT00497354|DRUG|Variation in volume of local anesthetic|
219425887|NCT00497354|PROCEDURE|Ultrasound-guided interscalene brachial plexus block|
219425888|NCT06139536|DRUG|BAT4706 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
219425889|NCT06139536|DRUG|BAT1308 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
219425890|NCT02814695|DIETARY_SUPPLEMENT|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
219425891|NCT02814695|DIETARY_SUPPLEMENT|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
219425892|NCT02814695|DIETARY_SUPPLEMENT|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
219425893|NCT02814695|DIETARY_SUPPLEMENT|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
219576303|NCT04219735|DRUG|Minocycline|Minocycline 100mg BID
219576304|NCT04219735|DRUG|Placebos|Placebo
219576305|NCT04736563|DEVICE|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
219576306|NCT04487002|PROCEDURE|surgical resection|
219576307|NCT03516084|DRUG|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
219576308|NCT03516084|DRUG|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
219425894|NCT02814695|DIETARY_SUPPLEMENT|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
219425895|NCT03931395|DIETARY_SUPPLEMENT|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
219425896|NCT03931395|OTHER|Standard of Care|Patients will receive standard post operative medications per surgeon
219576309|NCT03964636|DIAGNOSTIC_TEST|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
219576310|NCT05333484|OTHER|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
219576311|NCT01111019|DRUG|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
219576312|NCT01524302|DRUG|Ceftaroline|600 mg Q12h
219576313|NCT01524302|DRUG|Levofloxacin|750 mg QD
219576314|NCT01583218|DRUG|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
219576315|NCT01583218|DRUG|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
219576316|NCT00986453|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
219576317|NCT00986453|PROCEDURE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
219425897|NCT00879983|DRUG|azithromycin (Zithromax)|"1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg"
219425898|NCT00879983|DRUG|azithromycin (Zithromax)|"1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g"
219425899|NCT02718391|BIOLOGICAL|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
219425900|NCT00225212|DRUG|Rituximab 375 mg/m2|
219425901|NCT03052439|OTHER|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
219425902|NCT01519063|DRUG|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
219425903|NCT01519063|DRUG|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
219425904|NCT02745132|OTHER|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
219425905|NCT01309841|DRUG|NKTR-118|12.5 mg oral tablet once daily
219425906|NCT01309841|DRUG|NKTR-118|25 mg oral tablet once daily
219425907|NCT01309841|DRUG|Placebo|Oral tablet once daily
219425908|NCT02356640|PROCEDURE|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
219425909|NCT02356640|PROCEDURE|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
219425910|NCT02356640|DEVICE|Olympus UM 2000|
219425911|NCT02356640|DEVICE|B-D Quincke Type Point|
219425912|NCT02356640|DRUG|Levobupivacaine|
219425913|NCT01459770|OTHER|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
219425914|NCT01459770|OTHER|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
219425915|NCT01330641|PROCEDURE|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
219425916|NCT01153308|OTHER|Observational Study|This is an Observational study
219425917|NCT03530618|DEVICE|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
219425918|NCT03530618|DEVICE|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
219425919|NCT02448004|DRUG|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
219425920|NCT03379480|BEHAVIORAL|Yoga arm|Yoga module developed for patients with Schizophrenia
219576318|NCT05514236|OTHER|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
219576319|NCT05514236|OTHER|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
219576320|NCT03168321|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
219576321|NCT03168321|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
219576322|NCT04690036|DRUG|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
219576323|NCT01436565|DRUG|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
219576324|NCT01436565|DRUG|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
219425921|NCT03315728|OTHER|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
219576325|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
219576326|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
219576327|NCT04508036|DIAGNOSTIC_TEST|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
219576328|NCT03983252|DRUG|[F-18]PBR06|PET radiopharmaceutical
219576329|NCT00375570|DRUG|ME-609|Topical treatment 5 times daily for 5 days
219576330|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
219576331|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
219576332|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
219576333|NCT05045352|DEVICE|echogenic needles for intravenous access|echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
219576334|NCT03829137|DEVICE|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
219576335|NCT03829137|DEVICE|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
219576336|NCT02925585|OTHER|Pre/post imaging|
219576337|NCT05377593|DEVICE|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
219576338|NCT00712985|DRUG|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
219576339|NCT02674061|BIOLOGICAL|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
219576340|NCT02700711|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
219576341|NCT02700711|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
219576342|NCT02700711|DRUG|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
219576343|NCT01856361|DRUG|Ramipril|Angiotensin Converting Enzyme Inhibitor
219576344|NCT01856361|DRUG|Placebo|Placebo pill that will match the treatment pill
219576345|NCT01299805|DRUG|Vortioxetine|Encapsulated tablet
219576346|NCT01299805|DRUG|Placebo|Vortioxetine placebo-matching capsules.
219576347|NCT01753947|OTHER|Deliberate Practice|
219576348|NCT05080647|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
219576349|NCT04463290|OTHER|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
219760347|NCT01133665|DRUG|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
219760348|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
219760349|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
219760350|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
219760351|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
219191358|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
219576350|NCT03182582|DEVICE|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
219425922|NCT05445011|DRUG|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
219425923|NCT03699631|DRUG|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
219425924|NCT03699631|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
219576351|NCT03182582|PROCEDURE|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
219576352|NCT03235869|DRUG|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
219576353|NCT03235869|RADIATION|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
219760352|NCT03429738|DRUG|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
219760353|NCT03429738|DRUG|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
219191359|NCT06775613|GENETIC|Long-read sequencing|The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.
219425925|NCT03699631|DRUG|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
219576354|NCT03631082|OTHER|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
219576355|NCT03631082|OTHER|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
219576356|NCT00266357|DRUG|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
219576357|NCT00266357|DRUG|Placebo / Duration of Treatment: 2 days for screening period|
219576358|NCT00449826|PROCEDURE|Computed Tomographic Angiography|CT scan
219576359|NCT03814330|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
219760354|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
219760355|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
219760356|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
219760357|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
219760358|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
219760359|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
219760360|NCT00918606|DRUG|LIPO-102|LIPO-102
219760361|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
219760362|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
219760363|NCT04001842|OTHER|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
219760364|NCT04790500|OTHER|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
219760365|NCT04790500|OTHER|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
219425926|NCT06440369|OTHER|Training group|"The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR."
219005999|NCT02201706|PROCEDURE|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
219006000|NCT04565431|DRUG|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
219191360|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
219191361|NCT06144281|BEHAVIORAL|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
219576360|NCT03814330|DIAGNOSTIC_TEST|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
219576361|NCT03814330|OTHER|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
219576362|NCT03814330|DEVICE|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
219576363|NCT03218163|DRUG|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
219576364|NCT00933517|DRUG|vectibix|9mg/kg at D1 of each 21-days cycle
219576365|NCT00933517|DRUG|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
219576366|NCT00933517|DRUG|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
219006001|NCT03900767|OTHER|Electronic Health Record intervention|AAC
219006002|NCT03900767|BEHAVIORAL|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
219006003|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
219191362|NCT06083662|DRUG|Neratinib Maleate|"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"
219576367|NCT00933517|DRUG|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
219576368|NCT00933517|DRUG|docetaxel|100 mg/m2 at D1 of each 21 days cycle
219576369|NCT04309214|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
219576370|NCT04461119|DRUG|Evenamide|oral capsules for 4 weeks of treatment
219576371|NCT04461119|DRUG|Placebo|oral capsules for 4 weeks of treatment
219006004|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
219006005|NCT01014520|DRUG|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
219006006|NCT03625791|BIOLOGICAL|blood sample|1 tube with 4 ml of blood per patient
219576372|NCT04378517|OTHER|psychosocial education in parents groups|psychosocial education
219576373|NCT04378517|OTHER|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
219576374|NCT05789719|BIOLOGICAL|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
219576375|NCT04739150|DRUG|nintedanib|nintedanib
219576376|NCT00123955|DRUG|Spironolactone|25mg tablet daily for 9 months
219425927|NCT06440369|OTHER|Physical activity orientation group|Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
219576377|NCT00123955|DRUG|Placebo|Placebo tablet daily for 9 months
219425928|NCT05737173|DRUG|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
219425929|NCT05737173|DRUG|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
219425930|NCT05737173|DRUG|Corticosteroid|Intra-articular knee injection
219425931|NCT02430662|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
219425932|NCT02430662|DEVICE|NanoKnife|
219425933|NCT00382980|BIOLOGICAL|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
219425934|NCT00382980|BIOLOGICAL|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
219425935|NCT00382980|DRUG|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
219576378|NCT00270049|DRUG|epoetin alfa|
219425936|NCT06391957|DIETARY_SUPPLEMENT|Spirulina supplement|Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
219425937|NCT06391957|PROCEDURE|Eccentric exercise|On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
219425938|NCT06391957|DIETARY_SUPPLEMENT|Placebo supplement|Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
219425939|NCT00054249|DRUG|T900607|
219425940|NCT01457001|DRUG|25-OH-D vitamin|
219576379|NCT04356118|DRUG|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
219576380|NCT04356118|DRUG|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
219576381|NCT04356118|DRUG|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
219576382|NCT00692718|DRUG|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
219576383|NCT05983913|BEHAVIORAL|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
219425941|NCT01324622|DEVICE|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
219425942|NCT01324622|PROCEDURE|laminectomy|standard procedure
219425943|NCT04566822|BEHAVIORAL|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
219425944|NCT04566822|BEHAVIORAL|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
219425945|NCT04566822|BEHAVIORAL|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
219425946|NCT04566822|BEHAVIORAL|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
219425947|NCT00234416|DRUG|Gefitinib|
219425948|NCT00234416|DRUG|Gemcitabine|
219576384|NCT05983913|BEHAVIORAL|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
219576385|NCT02405949|GENETIC|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
219576386|NCT05262036|DIETARY_SUPPLEMENT|Anti-aging Supplement|Mixture of different vitamins and nutrients
219576387|NCT05262036|DIETARY_SUPPLEMENT|Placebo|Excipient powder
219576388|NCT00679536|DRUG|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
219576389|NCT00679536|DRUG|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
219576390|NCT00679536|DRUG|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
219576391|NCT00679536|RADIATION|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
219576392|NCT04341649|OTHER|Manual Head Massage|Duration 10 minutes.
219576393|NCT04341649|DEVICE|BREO Helmet Massager|Duration 10 minutes.
219576394|NCT04341649|DEVICE|Low Laser Therapy (LLT)|Duration 7 minutes.
219425949|NCT04223700|PROCEDURE|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
219425950|NCT02530957|DEVICE|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
219425951|NCT02530957|DEVICE|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
219425952|NCT01798940|DRUG|Torrent's Pioglitazone|
219425953|NCT00138424|DRUG|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
219576395|NCT04341649|DEVICE|Sham LLT|Duration 7 minutes.
219576396|NCT04341649|DEVICE|TENS ear stimulation|Duration 7 minutes.
219576397|NCT04341649|BEHAVIORAL|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
219576398|NCT04341649|BEHAVIORAL|Relaxed Reading time|Duration 10 minutes.
219576399|NCT01649466|DRUG|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
219006007|NCT03564847|BEHAVIORAL|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
219425954|NCT00138424|DRUG|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
219425955|NCT04311177|DRUG|Losartan|Losartan; 25 mg daily; oral administration
219425956|NCT04311177|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
219425957|NCT02517151|DRUG|Ferric carboxymaltose|
219425958|NCT02517151|DRUG|Placebo|
219425959|NCT01172834|BEHAVIORAL|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
219425960|NCT01911234|BIOLOGICAL|TNF-Kinoid|IM administration
219425961|NCT01911234|OTHER|Placebo|IM administration
219425962|NCT04370717|OTHER|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
219576400|NCT01649466|DRUG|Protaphane|Protaphane will be used as commercially available injection pens
219576401|NCT03334721|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
219576402|NCT03334721|DRUG|Placebo Oral Capsule|5 day trial of matched placebo
219576403|NCT00569790|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
219576404|NCT03771937|OTHER|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
219576405|NCT05709977|OTHER|Acupuncture|Fixed set of acupuncture points
219576406|NCT05709977|DRUG|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
219576407|NCT06015477|DRUG|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
219576408|NCT06015477|DRUG|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
219760366|NCT02151929|DEVICE|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
219760367|NCT02151929|DEVICE|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
219760368|NCT03547427|OTHER|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
219760369|NCT03547427|OTHER|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
219760370|NCT03547427|OTHER|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
219425963|NCT02391350|BEHAVIORAL|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
219425964|NCT02391350|PROCEDURE|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
219576409|NCT04183647|DEVICE|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
219760371|NCT03547427|OTHER|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
219576410|NCT03716245|PROCEDURE|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
219576411|NCT03716245|RADIATION|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
219576412|NCT00304720|DRUG|Tacrolimus and MMF|
219760372|NCT03547427|OTHER|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
219760373|NCT03547427|OTHER|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
219760374|NCT02710539|DRUG|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
219006008|NCT03247075|BEHAVIORAL|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
219006009|NCT03247075|BEHAVIORAL|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
219006010|NCT01554423|OTHER|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
219425965|NCT05378516|OTHER|no intervention|no intervention
219425966|NCT04045717|RADIATION|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
219425967|NCT00912899|DRUG|Noscapine HCl|Escalating doses given twice per day
219425968|NCT00062699|DRUG|Zemplar (paricalcitol injection)|
219425969|NCT00062699|DRUG|Calcijex|
219425970|NCT04621669|DRUG|SHR3680|240 mg
219425971|NCT04621669|DRUG|digoxin|0.25 mg
219425972|NCT04621669|DRUG|Rosuvastatin calcium|10 mg
219425973|NCT04621669|DRUG|metformin hydrochloride|500 mg
219425974|NCT00413062|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
219576413|NCT02706782|DRUG|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
219576414|NCT01624441|DRUG|Dinaciclib|Given IV
219576415|NCT01624441|DRUG|Epirubicin Hydrochloride|Given IV
219576416|NCT01624441|OTHER|Laboratory Biomarker Analysis|Correlative studies
219576417|NCT00878514|DRUG|Alprazolam|Alprazolam 1 mg tablet
219576418|NCT00878514|DRUG|Xanax|Xanax 1 mg tablet
219576419|NCT01418482|DEVICE|Mepilex Border Ag|a silver dressing
219576420|NCT03145831|DRUG|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
219576421|NCT00979381|BIOLOGICAL|influenza vaccine|influenza vaccination
219576422|NCT00016276|DRUG|dexrazoxane hydrochloride|Given IV
219576423|NCT00016276|DRUG|doxorubicin hydrochloride|Given IV
219576424|NCT00016276|DRUG|cyclophosphamide|Given IV
219576425|NCT00016276|DRUG|paclitaxel|Given IV
219576426|NCT00016276|BIOLOGICAL|trastuzumab|Given IV
219760375|NCT02710539|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
219425975|NCT00413062|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
219425976|NCT02893527|BEHAVIORAL|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
219425977|NCT04935125|PROCEDURE|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
219576427|NCT00016276|PROCEDURE|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
219576428|NCT00016276|RADIATION|radiation therapy|Undergo radiation therapy
219576429|NCT00016276|DRUG|tamoxifen citrate|Given orally
219576430|NCT00016276|OTHER|laboratory biomarker analysis|Correlative studies
219576431|NCT02475382|DRUG|Nivolumab|Specified dose on specified days
219576432|NCT01696136|DEVICE|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
219576433|NCT06895161|OTHER|Remotely supervised exercise at home or outdoors|Aerobic exercise at home/outdoors 30 minutes each session,five days a week for three weeks using a Polar H9 heart rate monitor.
219425978|NCT04935125|PROCEDURE|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
219576434|NCT06895161|OTHER|Hospital-based exercise program|The aerobic exercise ,30 minutes each session,five days a week for three weeks at cardiopulmonary rehabilitation unit under supervision.
219576435|NCT06895161|OTHER|Phone calls with reinforcement feedback|Calls twice a week that include symptom inquiries and encouraging feedback on exercise
219576436|NCT06802224|DRUG|Norepinephrine|Intravenous Norepinephrine for both infusion and bolus dosing
219576437|NCT06802224|DRUG|Phenylephrine|Intravenous Phenylephrine for both infusion and bolus dosing
219576438|NCT02006368|OTHER|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
219576439|NCT01121341|PROCEDURE|Vein harvesting|Endoscopic versus conventional vein harvesting
219576440|NCT02287909|DRUG|Clopidogrel|Swiching from ticagrelor to clopidogrel
219576441|NCT02287909|DRUG|Ticagrelor|Continue treatment with ticagrelor
219576442|NCT04749836|PROCEDURE|His bundle pacing implantation, Left bundle branch area pacing implantation, Bachmann bundle pacing|"Different active fixation leads and the dedicated delivery sheaths are introduced via standard transvenous approach under fluoroscopic guidance. His bundle potential mapping is performed in a unipolar setting with the use of the electrophysiological system for His bundle pacing. After localizing the His bundle potential, the pacing is attempted before the lead fixation to confirm HB capture. The lead is then screwed into position. Acute HBP threshold ≤ 2.5V at 1ms is considered acceptable. On the other hand, the initial site for LBBP is approximately 1-1.5 cm distal to the HBP lead position in the RV septum along the line between the HBP site and RV apex in the right anterior oblique (30°) fluoroscopic view. Bachmann bundle pacing (upper atrial septum) will be performed with the J-stylet modification technique or with specialized catheter method using the SelectSecure active fixation lead.~Stepwise approach for conduction pacing will also be tested."
219576443|NCT00297726|BEHAVIORAL|Self-Management Program|
219576444|NCT01192984|BIOLOGICAL|KW-0761|Intravenously 8 times at 1-week intervals
219760376|NCT05160948|OTHER|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
219425979|NCT02176291|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
219760377|NCT04016857|PROCEDURE|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
219760378|NCT04016857|PROCEDURE|Control|deflated cuff placed on the left arm for 40 min
219760379|NCT02875470|DEVICE|Intensiv Perio Set|Diamond burs for root planing
219425980|NCT02176291|DRUG|Placebo|matched placebo
219425981|NCT04237324|PROCEDURE|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
219425982|NCT04237324|PROCEDURE|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
219425983|NCT01669941|DRUG|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
219576445|NCT01681602|OTHER|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
219576446|NCT01908413|DRUG|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
219576447|NCT02613741|OTHER|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
219576448|NCT03914118|DRUG|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
219425984|NCT01669941|DRUG|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
219425985|NCT01669941|DRUG|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
219425986|NCT04658381|GENETIC|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
219425987|NCT04658381|PROCEDURE|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
219425988|NCT01881971|DRUG|Placebo|suger pill manufactured to mimic crestor pills
219760380|NCT02875470|DEVICE|Gracey curette|
219576449|NCT03914118|DRUG|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
219760381|NCT00272792|DRUG|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
219760382|NCT00272792|DRUG|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
219760383|NCT06447766|BEHAVIORAL|Feeding Families Your Way Program|Feeding Families Your Way is a video-based education program delivered by the University of Rhode Island Supplemental Nutrition Assistance Program - Education (SNAP-Ed).
219760384|NCT00112892|DIETARY_SUPPLEMENT|selenium|
219760385|NCT00112892|DRUG|irinotecan hydrochloride|
219760386|NCT02718235|OTHER|Overall survival|Observation of overall and disease free survival
219760387|NCT02255539|DEVICE|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
219425989|NCT01881971|DRUG|Rouvastatin calcium|
219425990|NCT00740883|DRUG|warfarin|18 months of warfarin therapy, once daily
219425991|NCT00740883|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
219760388|NCT06513000|DIAGNOSTIC_TEST|Dry eye diagnostic system|"following tests:~1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.~2. Non-invasive tear meniscus height.~3. Evaluation of Meibomian glands function.~4. Lipid layer thickness.~5. Eyelid margin.~6. Analysis of conjunctival hyperemia.~7. Cornea sodium fluorescein staining.~8. Schirmer I test"
219760389|NCT00873925|BIOLOGICAL|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
219760390|NCT00873925|DIETARY_SUPPLEMENT|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
219760391|NCT00873925|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
219576450|NCT03914118|DRUG|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
219576451|NCT05545618|DIAGNOSTIC_TEST|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
219576452|NCT04556552|DEVICE|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
219425992|NCT03506022|OTHER|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
219425993|NCT04473144|DRUG|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
219576453|NCT04556552|DRUG|Oxygen (15-O) Water|Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.
219576454|NCT04556552|DEVICE|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
219576455|NCT04102813|BEHAVIORAL|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
219576456|NCT03439852|BEHAVIORAL|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
219576457|NCT05962502|DRUG|Cetuximab and irinotecan|chemotherapy plus targeted therapy
219576458|NCT01215513|DRUG|Degarelix|
219576459|NCT04774887|BIOLOGICAL|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
219576460|NCT05892484|DEVICE|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
219576461|NCT05892484|DIAGNOSTIC_TEST|X-RAY|Routine X-RAY
219576462|NCT05732974|OTHER|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
219576463|NCT04009538|OTHER|Rehabilitation program|exercise program twice a week
219576464|NCT05016687|DRUG|CUR-N399|CUR-N399 will be administered as oral capsules.
219576465|NCT05016687|DRUG|Placebo|Placebo capsules matching CUR-N399 will administered.
219576466|NCT00616044|PROCEDURE|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
219576467|NCT00616044|PROCEDURE|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
219576468|NCT00616044|PROCEDURE|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
219576469|NCT00605865|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
219576470|NCT05352165|DRUG|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
219576471|NCT05352165|DRUG|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
219576472|NCT05352165|DRUG|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
219576473|NCT05352165|DRUG|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
219576474|NCT05352165|DRUG|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
219576475|NCT05352165|DRUG|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
219576476|NCT05174117|COMBINATION_PRODUCT|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
219576477|NCT05174117|COMBINATION_PRODUCT|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
219576478|NCT00959361|BEHAVIORAL|pharmaceutical care|consultation with the pharmacists and usual care
219576479|NCT03972449|BEHAVIORAL|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
219760392|NCT02921789|DRUG|Bleselumab|Intravenous infusion
219760393|NCT02921789|DRUG|Basiliximab|Bolus injection
219760394|NCT02921789|DRUG|Mycophenolate Mofetil (MMF)|Oral Intravenous
219760395|NCT02921789|DRUG|Tacrolimus Capsules|Oral Capsule
219760396|NCT02921789|DRUG|Methylprednisone|Oral or Intravenous
219760397|NCT02921789|DRUG|Prednisone|Oral Tablet
219760398|NCT03681756|BEHAVIORAL|WALK|Walking program
219760399|NCT02028845|DEVICE|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
219760400|NCT02028845|DEVICE|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
219760401|NCT04099277|DRUG|LY3435151|Administered IV
219760402|NCT04099277|DRUG|Pembrolizumab|Administered IV
219760403|NCT04304560|DRUG|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
219760404|NCT04304560|DRUG|Placebo oral tablet|Similar Placebo oral tablet
219760405|NCT04995172|PROCEDURE|Computed Tomography|Undergo mobile CT-assisted bronchoscopy
219576480|NCT03972449|BEHAVIORAL|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
219576481|NCT00044109|DEVICE|Magnets|
219576482|NCT04524052|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
219576483|NCT04524052|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
219576484|NCT02858492|DRUG|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
219576485|NCT02858492|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
219576486|NCT01211704|DRUG|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
219006011|NCT01554423|BEHAVIORAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
219425994|NCT01318772|DEVICE|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
219576487|NCT01211704|DRUG|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
219576488|NCT03365167|RADIATION|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
219576489|NCT03365167|RADIATION|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
219191363|NCT03976154|OTHER|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
219576490|NCT04404946|OTHER|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
219576491|NCT04404946|OTHER|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
219576492|NCT04404946|OTHER|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
219576493|NCT05199168|PROCEDURE|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
219576494|NCT01428050|DRUG|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
219576495|NCT01428050|DRUG|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
219576496|NCT02718508|BEHAVIORAL|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
219425995|NCT02713763|DRUG|Sunitinib|Sunitinib 37.5 mg/day
219576497|NCT00926224|DEVICE|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
219576498|NCT04425538|DRUG|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
219576499|NCT03111914|DIAGNOSTIC_TEST|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
219576500|NCT05311748|DIAGNOSTIC_TEST|Ultrasound and doppler|Penile echocolour doppler ultrasound
219576501|NCT04030065|DRUG|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
219576502|NCT02119286|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
219576503|NCT02119286|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
219576504|NCT02119286|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
219760406|NCT04995172|OTHER|Electronic Health Record Review|Patients' medical records are reviewed
219760407|NCT04995172|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo radial probe EBUS
219760408|NCT02838667|PROCEDURE|Standard of Care plus Nephrology Care|
219760409|NCT04212663|PROCEDURE|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
219760410|NCT04212663|PROCEDURE|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
219760411|NCT04212663|PROCEDURE|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
219425996|NCT00360919|BEHAVIORAL|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
219425997|NCT02699242|DEVICE|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
219425998|NCT06552806|DIETARY_SUPPLEMENT|SLAB51|One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
219425999|NCT01848899|DRUG|Iodixanol|contrast media used during coronary angiography
219426000|NCT01848899|DRUG|Ioxaglate|contrast media used during coronary angiography
219426001|NCT01848899|DRUG|Bivalirudin|A direct thrombin inhibitor
219576505|NCT02119286|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
219576506|NCT04259463|PROCEDURE|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
219576507|NCT03512132|BIOLOGICAL|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
219576508|NCT03512132|BIOLOGICAL|Urine sample|Urine sample on an empty stomach
219576509|NCT00998478|OTHER|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
219576510|NCT06180265|DIAGNOSTIC_TEST|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
219576511|NCT01271751|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
219006012|NCT01554423|BEHAVIORAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
219006013|NCT00128947|DRUG|Mycophenolic Acid|
219426002|NCT00628953|DRUG|Esomeprazole|40mg twice a day
219426003|NCT00628953|DRUG|Placebo|40mg twice a day
219426004|NCT05947747|DRUG|EXO-CD24|Twice a day for 5 days, dose 10\^10
219426005|NCT05947747|OTHER|Placebo|Twice a day for 5 days
219426006|NCT02815293|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
219426007|NCT02815293|DRUG|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
219426008|NCT01129180|DRUG|azacitidine|Given SC
219426009|NCT01129180|DRUG|bortezomib|Given IV
219426010|NCT01129180|PROCEDURE|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
219426011|NCT02752568|PROCEDURE|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
219760412|NCT04212663|PROCEDURE|Fascial release|To cut off the metatarsal fascia in the middle part.
219426012|NCT02752568|PROCEDURE|assisted hatching|using Octax laser 20120644-laser 5452
219760413|NCT01766102|PROCEDURE|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
219426013|NCT02752568|PROCEDURE|controlled ovarian hyperstimulation|using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
219426014|NCT00118729|DRUG|GW685698X Aqueous Nasal Spray|
219576512|NCT01271751|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
219576513|NCT01418963|DRUG|RO5285119|single and multiple ascending oral doses
219576514|NCT01418963|DRUG|placebo|single and multiple oral doses
219576515|NCT00276822|OTHER|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
219576516|NCT00619112|DRUG|temozolomide|single arm study
219760414|NCT01766102|PROCEDURE|Standard Mammography|There is not an added device associated with this arm.
219760415|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
219760416|NCT05198401|OTHER|covid-19|viral infection
219006014|NCT00128947|DRUG|Mycophenolate 7-O-Phenolic Glucuronide|
219006015|NCT06486090|BEHAVIORAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
219426015|NCT03414762|DEVICE|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
219426016|NCT03414762|DEVICE|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
219426017|NCT00006604|DRUG|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
219426018|NCT00006604|DRUG|Ritonavir|Administered as 100 mg capsules or oral solution.
219426019|NCT03180489|DRUG|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
219426020|NCT03180489|DRUG|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
219426021|NCT01881841|BEHAVIORAL|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
219576517|NCT03044717|OTHER|Nutrition survey|Survey will be done prior to the initiation of the education
219576518|NCT03044717|OTHER|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
219576519|NCT03044717|OTHER|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
219576520|NCT03149939|DRUG|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
219006016|NCT02123355|DRUG|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
219006017|NCT02123355|PROCEDURE|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
219006018|NCT02123355|DRUG|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
219006019|NCT02123355|DRUG|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
219006020|NCT02123355|DRUG|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
219006021|NCT02141282|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
219006022|NCT02323230|BIOLOGICAL|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
219006023|NCT02323230|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
219006024|NCT06083272|DEVICE|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
219006025|NCT05773508|DEVICE|Video regulation and emergency kit|Video regulation and emergency kit
219191364|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
219191365|NCT03627728|OTHER|placebo|regorafenib/placebo
219426022|NCT01056341|DRUG|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
219576521|NCT02188511|OTHER|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
219576522|NCT02188511|OTHER|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
219576523|NCT02188511|OTHER|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
219576524|NCT02188511|OTHER|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
219426023|NCT01056341|DRUG|Placebo|Treatment with placebo for 6 months
219426024|NCT01476384|DIETARY_SUPPLEMENT|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
219760417|NCT06361134|BEHAVIORAL|SAFE Early İntervention|As part of the intervention, sensory-based intervention was applied in an enriched environment. In the home setting, physiotherapists collaborated with the family to advance the intervention. The intervention was revised by making monthly home visits to infants with a corrected age of 42 weeks.
219760418|NCT06361134|BEHAVIORAL|NDT based therapy|Neuromotor evaluations of the babies were performed in a clinical setting. The rehabilitation program to be implemented was given to the family as a booklet. The programs of the children examined in the clinic every month were revised.
219426025|NCT01476384|DIETARY_SUPPLEMENT|Placebo|250 ml water
219426026|NCT00987012|DIETARY_SUPPLEMENT|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
219426027|NCT00987012|DIETARY_SUPPLEMENT|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
219426028|NCT00661349|DRUG|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
219426029|NCT00661349|DRUG|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
219426030|NCT01086150|PROCEDURE|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
219426031|NCT01086150|DRUG|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
219426032|NCT05685576|DEVICE|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
219426033|NCT01167582|BIOLOGICAL|Red blood cell transfusion|Liberal versus restrictive transfusion
219426034|NCT00693680|DIETARY_SUPPLEMENT|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
219426035|NCT00693680|DIETARY_SUPPLEMENT|Placebo|placebo + imipramine (100-200mg/day)
219426036|NCT04493294|RADIATION|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
219576525|NCT02188511|OTHER|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
219576526|NCT02936011|DEVICE|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
219576527|NCT02833545|DEVICE|Ozone gas|Injection of ozone gas intra articularly
219576528|NCT02833545|DRUG|Steroid injection|Injection of steroids (diprospan) intra articularly
219760419|NCT01697111|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
219006026|NCT06334783|BIOLOGICAL|Autologous tumor-infiltrating lymphocyte cells|On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
219426037|NCT01431729|OTHER|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
219426038|NCT01578057|DRUG|tasimelteon|20mg, once
219426039|NCT01578057|DRUG|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
219426040|NCT01578057|OTHER|Placebo tasimelteon|once
219426041|NCT01578057|DRUG|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
219760420|NCT01697111|DRUG|Placebo|One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
219760421|NCT01697111|DRUG|Dienogest|Dienogest 1mg twice a day (bid)
219426042|NCT05368129|PROCEDURE|Balloon dilation|Balloon dilation was performed after DES implantation.
219426043|NCT02289404|DRUG|NVP-1203|Oral
219426044|NCT02289404|DRUG|NVP-1203|Oral
219426045|NCT04426370|OTHER|Observational|Physical examination and questionnaires
219426046|NCT05080959|DRUG|CPL-01|Subjects will receive a single dose
219426047|NCT05080959|DRUG|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
219426048|NCT05080959|DRUG|Placebo|Subjects will receive a single dose
219760422|NCT04391712|DEVICE|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
219760423|NCT04391712|OTHER|Regular Inpatient Medical Care|Regular inpatient medical care
219760424|NCT02886130|DIETARY_SUPPLEMENT|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
219760425|NCT02886130|DIETARY_SUPPLEMENT|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
219760426|NCT01426061|OTHER|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
219426049|NCT03765255|OTHER|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
219426050|NCT01583452|OTHER|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
219426051|NCT01182337|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
219426052|NCT01182337|DRUG|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
219426053|NCT00033033|DRUG|Reserpine|
219426054|NCT02819895|OTHER|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
219426055|NCT02810652|OTHER|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
219426056|NCT02810652|OTHER|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
219426057|NCT00152074|BEHAVIORAL|Reduce salt intake|
219576529|NCT01529398|OTHER|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
219006027|NCT04849455|DRUG|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
219576530|NCT01529398|OTHER|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
219576531|NCT01529398|OTHER|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
219576532|NCT03778398|OTHER|Neurologic music therapy|Customized piano training
219576533|NCT01352130|DRUG|Ondansetron|Intravenous Ondansetron 8 mgs
219576534|NCT01352130|DRUG|Granisetron|Intravenous Granisetron 1 mgs
219576535|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|As a experimental vaccine for 6 months to 5 years old.
219576536|NCT06314685|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 6-11 months and 12-23 months.
219006028|NCT04849455|DRUG|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
219006029|NCT04849455|DRUG|Spinal Morphine|200-300 mcg of spinal morphine
219426058|NCT03448224|OTHER|Questionnaire Administration|Questionnaire
219426059|NCT03448224|OTHER|Internet-Based Intervention|Intervention
219426060|NCT02266758|OTHER|GDM Screening Methods|
219426061|NCT02679443|DIETARY_SUPPLEMENT|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
219576537|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 2-5 years.
219576538|NCT01327144|DRUG|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
219576539|NCT01327144|DRUG|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
219576540|NCT03376230|OTHER|Collect of blood, urines, and intestinal biopsies|
219576541|NCT04590066|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
219576542|NCT00002639|DRUG|chemotherapy|
219576543|NCT00002639|DRUG|suramin|
219576544|NCT01749917|OTHER|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
219576545|NCT01749917|OTHER|Control intervention|Active upper limb range of movement exercises for 15 minutes.
219576546|NCT03768518|DIAGNOSTIC_TEST|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
219576547|NCT01445210|PROCEDURE|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
219426062|NCT00325338|BIOLOGICAL|Ragweed MATAMPL|
219426063|NCT01898364|DRUG|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
219426064|NCT06483490|OTHER|This is a cross-sectional, non pharmacological study|Measurement of immune checkpoint levels, mitochondrial dysfunction, pollutant concentrations and G-quadruplex levels and their correlation in all enrolled subjects.
219426065|NCT03991559|DRUG|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
219426066|NCT03991559|DRUG|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
219426067|NCT03991559|COMBINATION_PRODUCT|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
219426068|NCT01644942|OTHER|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
219426069|NCT02297542|BIOLOGICAL|Flu Vaccine|
219426070|NCT01654042|OTHER|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
219426071|NCT03103906|OTHER|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
219426072|NCT03103906|OTHER|Cleanser (Reference Product)|Moisturizing facial cleanser
219426073|NCT03103906|OTHER|Sunscreen (Reference Product)|SPF 50 sunscreen
219426074|NCT03571256|DRUG|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
219426075|NCT03571256|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
219426076|NCT03477071|PROCEDURE|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
219426077|NCT05685888|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
219426078|NCT02899117|OTHER|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
219426079|NCT01461408|BEHAVIORAL|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
219426080|NCT06410079|PROCEDURE|total hip replacement|Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
219426081|NCT00575094|DRUG|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
219426082|NCT01788982|DRUG|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
219426083|NCT01788982|DRUG|Placebo|
219426084|NCT02290964|PROCEDURE|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
219426085|NCT03390712|DRUG|Paliperidone Palmitate|Monthly injections
219426086|NCT03390712|DRUG|Risperidal Consta|Bi-weekly injection
219426087|NCT03390712|DRUG|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
219426088|NCT00868452|DRUG|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
219426089|NCT00868452|DRUG|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
219426090|NCT04223401|OTHER|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention"
219426091|NCT00906867|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
219426092|NCT00906867|PROCEDURE|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
219426093|NCT04186468|OTHER|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
219576548|NCT01445210|PROCEDURE|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
219576549|NCT00105300|DRUG|Adalimumab|
219576550|NCT00719771|DEVICE|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
219576551|NCT06211608|DIAGNOSTIC_TEST|Two-dimensional and three-dimensional ultrasound of the female reproductive organ|Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer
219576552|NCT04044911|BEHAVIORAL|Task model (CogWatch)|
219576553|NCT02438852|OTHER|Placebo|Given IV
219576554|NCT02438852|OTHER|Questionnaire Administration|Ancillary studies
219576555|NCT02438852|DRUG|Ropivacaine Hydrochloride|Given IV
219576556|NCT06456736|OTHER|None, non-interventional study|Not applicable, non-interventional study
219576557|NCT02040779|DRUG|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
219576558|NCT02040779|DRUG|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
219576559|NCT02040779|DRUG|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
219576560|NCT02132637|DRUG|Insulin Peglispro|Administered SQ
219576561|NCT02132637|DRUG|Insulin Glargine|Administered SQ
219760427|NCT01426061|OTHER|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
219760428|NCT01426061|OTHER|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
219760429|NCT05810519|BEHAVIORAL|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
219760430|NCT05810519|BEHAVIORAL|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
219576562|NCT00929890|BEHAVIORAL|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
219576563|NCT00929890|BEHAVIORAL|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
219576564|NCT02084602|DRUG|Artesunate|Orally administration of artesunate 4mg/Kg by three days
219760431|NCT03997032|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
219760432|NCT04259216|BEHAVIORAL|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
219760433|NCT04259216|OTHER|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
219760434|NCT03590886|OTHER|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
219760435|NCT03239457|BIOLOGICAL|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
219760436|NCT03730584|DRUG|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
219760437|NCT03730584|BIOLOGICAL|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
219760438|NCT00371371|PROCEDURE|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
219760439|NCT00371371|PROCEDURE|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
219576565|NCT02084602|DRUG|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
219576566|NCT03717714|DIETARY_SUPPLEMENT|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
219006030|NCT02425046|BEHAVIORAL|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
219006031|NCT02425046|BEHAVIORAL|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
219576567|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
219426094|NCT05128682|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
219426095|NCT01673191|DRUG|Dexamethasone intravitreal implant|
219576568|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
219006032|NCT00139009|DRUG|Cyclosporine A|
219006033|NCT00891254|DEVICE|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
219426096|NCT01673191|DRUG|Steroid plus NSAID eye drop combination therapy|
219576569|NCT03065595|DIETARY_SUPPLEMENT|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
219576570|NCT03065595|OTHER|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
219576571|NCT03648034|PROCEDURE|ropivacaine|To perform scalp nerve blocks with ropivacaine
219576572|NCT03648034|PROCEDURE|saline|To perform scalp nerve blocks with saline
219576573|NCT05828121|BEHAVIORAL|POINT1|Receiving treatment
219576574|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Analerg|
219576575|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Bronchi|
219426097|NCT00772382|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
219426098|NCT02833220|DEVICE|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
219426099|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
219426100|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219426101|NCT00643604|DRUG|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
219426102|NCT02763072|DEVICE|Enlighten Laser|
219426103|NCT02763072|DEVICE|Excel V Laser|
219426104|NCT03608904|OTHER|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
219426105|NCT03608904|OTHER|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
219426106|NCT00760604|PROCEDURE|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
219426107|NCT05796804|PROCEDURE|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
219426108|NCT05796804|PROCEDURE|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
219426109|NCT05796804|PROCEDURE|spinal anesthesia|bupivacaine 0.5% 2.2 ml
219006034|NCT00017498|DRUG|gemcitabine hydrochloride|
219006035|NCT03958721|DRUG|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
219006036|NCT03958721|RADIATION|Radiotherapy|Once daily (Monday through Friday) for six weeks
219006037|NCT04998474|BIOLOGICAL|FRAME-001 personalized vaccine|Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
219006038|NCT05552950|BIOLOGICAL|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
219006039|NCT04189211|DRUG|BAT8001|IV infusions.
219006040|NCT03696511|DEVICE|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
219006041|NCT03386682|DEVICE|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
219426110|NCT01644955|DRUG|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
219426111|NCT01644955|PROCEDURE|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
219426112|NCT03591055|OTHER|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
219426113|NCT05931055|DIAGNOSTIC_TEST|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
219426114|NCT04426838|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
219426115|NCT01225471|BIOLOGICAL|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
219576576|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
219576577|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
219191366|NCT06851273|BEHAVIORAL|Guided Self Help Family Based Therapy (GSH FBT)|Each family will participate in ten virtual sessions of GSH FBT with a trained GSH practitioner local to their provincial study site. Parents will meet their coach for a 60-minute onboarding session where the parents/caregivers are familiarized with the video platform used in treatment. Then, the treatment consists of ten virtual 20-minute sessions over 6 months. In GSH FBT, the parents weigh the adolescent patient prior to the session, on the same day as the session, and report the weight to the coach. Throughout treatment, parents have access to an online platform with a series of videos that outline the core components of FBT: the urgency to act, parental empowerment, medical complications, strategies to use during and after mealtime, and how to externalize the illness. In line with GSH approaches, coach-therapists direct parents to watch or review videos and text content rather than directly affecting behavioral change.
219426116|NCT03550638|DEVICE|Coil system(Ton-bridgeMT)|1\. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
219426117|NCT03550638|DEVICE|Axium Detachable Coil(Medtronic)|2\. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
219426118|NCT03843736|BEHAVIORAL|Lifestyle intervention|"1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation."
219426119|NCT03843736|DRUG|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
219426120|NCT03843736|DRUG|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
219426121|NCT05594108|DIAGNOSTIC_TEST|ultrasonography|transabdominal ultrasonography
219426122|NCT02165033|DRUG|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
219576578|NCT04803188|DIAGNOSTIC_TEST|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
219576579|NCT02264093|DRUG|Propranolol|
219576580|NCT02264093|DRUG|Talsaclidine|
219576581|NCT00886041|PROCEDURE|laparoscopy|subjected to laparoscopy
219191367|NCT06851468|DRUG|Keverprazan|Keverprazan ：Dosage form: tablet；dose：20mg；dosage: 2 times a day；duration: 14 days
219191368|NCT06851468|DRUG|Esomeprazole|Esomeprazole：Dosage form: capsule；dose：40mg；dosage: 2 times a day；duration: 14 days
219576582|NCT00886041|OTHER|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
219576583|NCT06402201|BIOLOGICAL|CDR404|IV infusions
219576584|NCT02316249|DRUG|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
219576585|NCT02316249|OTHER|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
219426123|NCT03203954|BEHAVIORAL|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
219191369|NCT06851468|DRUG|Amoxicillin|Amoxicillin：Dosage form: capsule；dose：1g；dosage: 3 times a day；duration: 14 days。
219191370|NCT05803473|DEVICE|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
219191371|NCT05803473|DEVICE|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
219576586|NCT01297374|BEHAVIORAL|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
219576587|NCT00054041|BIOLOGICAL|HspE7|Given subcutaneously
219576588|NCT00054041|PROCEDURE|therapeutic conventional surgery|Undergo large loop excision
219576589|NCT00054041|OTHER|laboratory biomarker analysis|Correlative studies
219576590|NCT05689593|OTHER|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
219576591|NCT05689593|OTHER|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
219760440|NCT00371371|PROCEDURE|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
219426124|NCT03203954|BEHAVIORAL|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
219426125|NCT03203954|BEHAVIORAL|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
219426126|NCT02000453|DRUG|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
219426127|NCT02702011|DRUG|empagliflozin medium dose|
219426128|NCT02702011|DRUG|empagliflozin low dose|
219426129|NCT02702011|DRUG|empagliflozin high dose|
219426130|NCT02702011|DRUG|placebo|
219426131|NCT03017365|OTHER|Stable Resistance Training|traditional machine-based resistance training
219426132|NCT03017365|OTHER|Unstable Resistance Training|free weight resistance training using unstable devices
219426133|NCT03017365|OTHER|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
219426134|NCT04143763|OTHER|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
219426135|NCT02930616|DEVICE|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
219426136|NCT02930616|DEVICE|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
219426137|NCT04208334|DIETARY_SUPPLEMENT|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
219426138|NCT04208334|OTHER|Placebo|We give a control arm to consume placebo for 60 consecutive days.
219426139|NCT06251219|DIAGNOSTIC_TEST|PCR|PCR test for EV71, CA16, CA10, or CA6
219426140|NCT00874679|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
219426141|NCT03546790|DRUG|Marijuana|Marijuana smoked via blunts with different cigar wrappers
219426142|NCT02407041|DRUG|GR-MD-02|IV infusion
219426143|NCT01703611|OTHER|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
219426144|NCT01703611|OTHER|Usual Nutrition Care|Usual nutrition care in India
219426145|NCT05022745|OTHER|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
219426146|NCT04944329|PROCEDURE|Hip fracture surgery|Hip fracture surgery
219191372|NCT06850194|PROCEDURE|vertical ramus osteotomy with iliac graft|in the VRO group all patient will undergo vertical ramus osteotomy surgery with iliac graft to correct the sever mandibular defficiency
219191373|NCT06850194|PROCEDURE|bilateral sagittal splitting osteotomy|all patients in this group will undergo to bilateral sagittal split osteotomy to correct the sever mandibular deficiency
219426147|NCT01422590|DRUG|Sitagliptin|Single oral administration of sitagliptin 100 mg
219426148|NCT01422590|DRUG|Mitiglinide|Single oral administration of mitiglinide 10 mg
219426149|NCT01422590|DRUG|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
219426150|NCT06050967|COMBINATION_PRODUCT|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
219426151|NCT00005848|DRUG|chemotherapy|
219426152|NCT00005848|DRUG|tipifarnib|
219426153|NCT00778986|DEVICE|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
219426154|NCT04142216|DIETARY_SUPPLEMENT|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
219426155|NCT02615795|DEVICE|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
219426156|NCT02007954|DEVICE|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
219426157|NCT01156207|DRUG|Aliskiren|300mg Aliskiren qd for 6 month
219426158|NCT06205394|OTHER|Non-Interventional Study|Non-interventional study
219426159|NCT00475540|DEVICE|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
219426160|NCT02013089|DRUG|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
219426161|NCT02013089|DRUG|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
219426162|NCT02013089|DRUG|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
219006042|NCT05634304|BEHAVIORAL|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
219191374|NCT06850948|OTHER|Qualitative|Interviews collected with participants concerning their experience of gender identity healthcare
219426163|NCT02013089|DRUG|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
219426164|NCT02013089|DRUG|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
219426165|NCT00377429|DRUG|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
219426166|NCT05589480|OTHER|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
219426167|NCT03114566|OTHER|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
219426168|NCT01718626|DRUG|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
219426169|NCT01718626|DRUG|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
219426170|NCT01692223|BEHAVIORAL|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
219426171|NCT03729934|DIETARY_SUPPLEMENT|Ketone Ester|This arm receives 25 g ketone ester.
219426172|NCT03729934|DIETARY_SUPPLEMENT|Ketone Salt|This arm receives 25 g ketone salt.
219426173|NCT00904995|DRUG|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
219426174|NCT00904995|DRUG|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
219426175|NCT05291416|DIAGNOSTIC_TEST|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
219426176|NCT04485234|DIAGNOSTIC_TEST|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
219426177|NCT01584258|PROCEDURE|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
219426178|NCT01584258|RADIATION|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
219426179|NCT01584258|RADIATION|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
219426180|NCT04718324|OTHER|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
219426181|NCT04718324|OTHER|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
219576592|NCT05689593|OTHER|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
219576593|NCT00652028|DRUG|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
219006043|NCT02175589|OTHER|Colchicine Cessation|Colchicine Cessation
219006044|NCT05855460|DIAGNOSTIC_TEST|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
219006045|NCT02692716|DRUG|semaglutide|For oral use once daily.
219006046|NCT02692716|DRUG|placebo|For oral use once daily.
219426182|NCT05741086|DRUG|Evolocumab|evolocumab (140 mg every 2 weeks)
219426183|NCT05741086|DRUG|Atorvastatin|Atorvastatin 20-40mg
219426184|NCT02067416|DRUG|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
219576594|NCT03924011|DEVICE|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
219576595|NCT03924011|DEVICE|Sham laser|Sham laser sessions will be applied 2x/week after RT.
219006047|NCT02508402|DRUG|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
219006048|NCT02508402|DRUG|Placebo|two milliliters of normal saline given to placebo group .
219426185|NCT02067416|DRUG|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
219426186|NCT02827279|OTHER|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
219576596|NCT01031966|BIOLOGICAL|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
219426187|NCT01033487|DRUG|placebo|oral inhaled formulation, single dose
219426188|NCT01033487|DRUG|active comparator|oral inhaled formulation, single dose
219576597|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
219760441|NCT02399644|BEHAVIORAL|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
219760442|NCT02399644|OTHER|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
219760443|NCT04286178|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
219760444|NCT04286178|DIETARY_SUPPLEMENT|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
219760445|NCT04286178|DIETARY_SUPPLEMENT|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
219760446|NCT04286178|DIETARY_SUPPLEMENT|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
219760447|NCT04286178|BEHAVIORAL|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
219760448|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
219191375|NCT05244278|DEVICE|Medtronic-GI genius (CADe system for detecting colorectal polyps)|Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
219191376|NCT06851637|BEHAVIORAL|PoET|Participants in the PoET group completed two online training sessions (3 hours each) via Zoom. Group size was about 25-30 people. The sessions included the following positive psychology constructs: happiness, humour, optimism, loving kindness and gratitude on the first day, and hope, self-efficacy, meaningfulness, forgiveness and resilience on the second day.
219426189|NCT01033487|DRUG|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
219576598|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
219576599|NCT03716076|DRUG|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
219576600|NCT01385306|DEVICE|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
219426190|NCT01033487|DRUG|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
219426191|NCT01033487|DRUG|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
219426192|NCT00675558|PROCEDURE|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) \& fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
219426193|NCT00675558|PROCEDURE|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
219426194|NCT00255099|DRUG|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
219576601|NCT05645770|COMBINATION_PRODUCT|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
219576602|NCT03106558|DEVICE|Total Knee Arthroplasty using Manual Instrumentation|
219760449|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
219760450|NCT01720030|DRUG|Levosimendan|Verum therapy
219760451|NCT01720030|DRUG|Conventional therapy|Placebo therapy to safeguard blinding
219760452|NCT06048211|OTHER|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
219576603|NCT03106558|DEVICE|Total Knee Arthroplasty using Robotic Arm|
219576604|NCT03854786|DIETARY_SUPPLEMENT|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
219426195|NCT00255099|DRUG|Placebo|2 tablets b.i.d. / 96 weeks
219426196|NCT04090437|PROCEDURE|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
219426197|NCT02939599|DRUG|QCC374|0.015mg and 0.06mg
219426198|NCT04011748|COMBINATION_PRODUCT|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
219426199|NCT05820620|PROCEDURE|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
219426200|NCT05820620|PROCEDURE|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
219426201|NCT05820620|OTHER|Control Group|Control Group + Patient Control Analgesia (PCA)
219426202|NCT04260659|DRUG|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
219426203|NCT04260659|DRUG|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
219426204|NCT04260659|DRUG|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
219426205|NCT04260659|DRUG|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
219426206|NCT04260659|DRUG|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
219426207|NCT04260659|DRUG|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
219426208|NCT01762306|DRUG|Diclofenac Potassium|
219426209|NCT01762306|DRUG|Folic Acid|
219426210|NCT05796882|BEHAVIORAL|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
219426211|NCT05796882|BEHAVIORAL|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
219426212|NCT03104998|DRUG|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
219426213|NCT02209649|DRUG|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
219426214|NCT02209649|DRUG|Lacidipine|
219426215|NCT02209649|DRUG|Telmisartan|
219426216|NCT04965506|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219576605|NCT03854786|DIETARY_SUPPLEMENT|Pacebo|Methyl Crystalline Cellulose
219006049|NCT04478474|DRUG|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
219426217|NCT04965506|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
219426218|NCT04965506|OTHER|Dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
219426219|NCT05918588|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
219426220|NCT05918588|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
219426221|NCT02148211|OTHER|Data collection|Initial and follow-up data was collected using questionnaires.
219576606|NCT06305130|OTHER|No intervention|No intervention
219576607|NCT02192008|BIOLOGICAL|Salmonella Typhi|
219426222|NCT05227482|RADIATION|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
219426223|NCT05227482|RADIATION|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
219426224|NCT04673604|DIAGNOSTIC_TEST|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
219426225|NCT04673604|DRUG|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
219576608|NCT02192008|BIOLOGICAL|Salmonella Paratyphi|
219576609|NCT03331237|PROCEDURE|scalene block|scalene block using 5ml of ropivacaine
219006050|NCT03061838|DRUG|MabThera®|1000 mg intravenously
219426226|NCT03036449|BEHAVIORAL|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~\- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
219426227|NCT02436733|PROCEDURE|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
219426228|NCT02436733|DRUG|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
219426229|NCT02726113|DRUG|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
219426230|NCT02726113|OTHER|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
219426231|NCT05588180|PROCEDURE|FVD/FAD ratio guided|Ultrasound-guided ratio
219426232|NCT05588180|PROCEDURE|PPV|PPV
219426233|NCT00250406|DEVICE|Ureteral Stent|triclosan-eluting ureteral stent
219426234|NCT00250406|DEVICE|Ureteral Stent|Percuflex Plus Stent as the control
219426235|NCT01376362|DRUG|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
219426236|NCT01690104|DRUG|Rifampicin|
219426237|NCT01690104|DRUG|Placebo|
219426238|NCT02905916|DRUG|PEG-rhG-CSF|
219426239|NCT04644016|DRUG|Clofarabine|Clofarabine
219426240|NCT04644016|DRUG|Fludarabine|Fludarabine
219426241|NCT04644016|DRUG|Busulfan|Busulfan per PK
219426242|NCT04644016|DRUG|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
219426243|NCT04644016|DRUG|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
219426244|NCT04644016|BIOLOGICAL|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
219426245|NCT06375967|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
219426246|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm."
219426247|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
219576610|NCT03331237|PROCEDURE|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
219576611|NCT00872885|DRUG|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
219006051|NCT03061838|DRUG|Ritumax®|1000 mg intravenously
219006052|NCT05784064|BEHAVIORAL|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
219006053|NCT03980106|OTHER|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
219426248|NCT06028750|PROCEDURE|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
219426249|NCT06028750|PROCEDURE|Freehand|Freehand implant placement
219426250|NCT06392724|GENETIC|GEN6050X intravenous injection|GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.
219426251|NCT06065202|DIETARY_SUPPLEMENT|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
219426252|NCT04421963|DRUG|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
219426253|NCT03722472|BIOLOGICAL|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
219426254|NCT05038852|DEVICE|smartphone applications|app is designed to help you learn relaxation skills.
219426255|NCT05038852|DEVICE|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
219426256|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
219576612|NCT00872885|DRUG|Morphine|60 mg
219576613|NCT00872885|DRUG|Placebo|single dosage
219576614|NCT04436978|DRUG|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
219576615|NCT04436978|DRUG|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
219576616|NCT00031083|GENETIC|Interferon-beta|
219576617|NCT01722565|PROCEDURE|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
219576618|NCT04190030|BEHAVIORAL|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
219576619|NCT04190030|BEHAVIORAL|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
219576620|NCT01047930|BEHAVIORAL|Exercise|"Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary."
219576621|NCT00003748|DRUG|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
219576622|NCT04310839|PROCEDURE|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
219576623|NCT04375930|OTHER|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
219426257|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
219426258|NCT04435561|OTHER|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
219576624|NCT04375930|OTHER|Control|It consists of only skills and discharge education
219576625|NCT04111848|DRUG|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
219576626|NCT04111848|DRUG|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
219576627|NCT00750646|DEVICE|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
219760453|NCT03454230|PROCEDURE|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
219576628|NCT00931268|DEVICE|Macrolane VRF 30|One administration
219426259|NCT04435561|OTHER|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
219760454|NCT05465525|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
219191377|NCT06851897|OTHER|perforated 3D printed metal fixed retainer|The key of modification is digitally designing fixed metal retainer which will be custom made for each patient, and 3D metal printing of the fixed retention wire using Metal printer instead of using generic metal wire for all patients.
219576629|NCT01388166|PROCEDURE|Education|Education
219576630|NCT04929938|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
219576631|NCT01112813|DRUG|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
219576632|NCT05236920|DEVICE|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
219576633|NCT05046665|DRUG|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
219576634|NCT01587586|BIOLOGICAL|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
219576635|NCT01587586|BIOLOGICAL|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
219426260|NCT04721938|BEHAVIORAL|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
219426261|NCT00656084|DRUG|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
219426262|NCT00656084|DRUG|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
219426263|NCT00656084|DRUG|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
219426264|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
219426265|NCT05054179|OTHER|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
219426266|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
219426267|NCT06360471|OTHER|fertility preservation|If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
219426268|NCT01494987|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
219426269|NCT01494987|DRUG|Placebo|Placebo to match ranolazine for the duration of the study
219426270|NCT01494987|DRUG|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
219426271|NCT01494987|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
219426272|NCT01494987|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
219426273|NCT04329000|DRUG|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
219426274|NCT04329000|DRUG|Esomeprazole|Continuous Esomeprazole 40 mg QD
219426275|NCT02490943|OTHER|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
219426276|NCT02490943|OTHER|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
219426277|NCT01250652|DRUG|Levocetirizine|20 mg levocetirizine for 5 days
219426278|NCT01250652|DRUG|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
219426279|NCT00105209|DRUG|Aspirin|
219426280|NCT00105209|DRUG|clopidogrel|
219426281|NCT01184456|DIETARY_SUPPLEMENT|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
219426282|NCT01184456|DRUG|Placebo|1 capsule per day for 90 days.
219426283|NCT04600687|OTHER|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
219426284|NCT00004226|RADIATION|radiation therapy|
219426285|NCT04310865|DRUG|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
219576636|NCT01587586|BIOLOGICAL|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
219576637|NCT01587586|BIOLOGICAL|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
219576638|NCT02138019|PROCEDURE|Fibrin Glue assisted external eye surgery|
219426286|NCT04310865|DRUG|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
219426287|NCT04310865|OTHER|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
219426288|NCT05004519|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
219426289|NCT05004519|DRUG|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
219426290|NCT03864536|BEHAVIORAL|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
219426291|NCT02181036|OTHER|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
219426292|NCT00672295|DRUG|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
219576639|NCT02138019|DEVICE|Fibrin glue|
219191378|NCT06851897|OTHER|conventional fixed retainer|Conventional fixed metal retainer will be used. Multi strand wire will be used
219576640|NCT00376974|BEHAVIORAL|American Academy of Ophthalmology Glaucoma Educational Tape|
219576641|NCT05404074|DRUG|Cobitolimod 500mg|Rectal administration
219426293|NCT06269718|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
219426294|NCT06269718|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
219426295|NCT01410162|DRUG|Tacrolimus|tacrolimus extended release capsules vs Prograf
219426296|NCT01261260|DRUG|Uridine|1 gram tablets BID for 7 days
219576642|NCT01272362|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
219576643|NCT02541162|BEHAVIORAL|Oral information and interviews|interviews about sexuality and self experience during the disease
219426297|NCT03609489|DRUG|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
219426298|NCT03609489|DRUG|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
219426299|NCT01092026|OTHER|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
219576644|NCT02273791|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
219576645|NCT02273791|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
219576646|NCT00115557|OTHER|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
219576647|NCT00115557|OTHER|Practice intervention 2|Performance feedback only.
219760455|NCT05465525|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
219760456|NCT05465525|OTHER|No Block|The patients will receive general anesthesia.
219760457|NCT04467814|BEHAVIORAL|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
219760458|NCT04467814|BEHAVIORAL|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
219760459|NCT02487953|DRUG|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
219760460|NCT02487953|OTHER|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
219760461|NCT02487953|OTHER|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
219760462|NCT02487953|OTHER|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
219191379|NCT06096623|BEHAVIORAL|Weekly Survey|Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
219191380|NCT06231706|OTHER|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients.
219191381|NCT06231706|OTHER|Bread Crouton|A commercially available bread crouton product.
219191382|NCT06231706|DIETARY_SUPPLEMENT|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
219191383|NCT06231706|OTHER|White bread and low fat spread|Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
219191384|NCT04783766|DRUG|CK-3773274|CK-3773274- Tablets
219191385|NCT04783766|DRUG|Placebo|Placebo- Tablets
219760463|NCT03423602|DEVICE|PerQseal®|Large hole closure system
219760464|NCT04444089|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
219760465|NCT03249363|PROCEDURE|Group A - Pulsed PVP-I Irrigation|
219760466|NCT00419692|DRUG|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
219426300|NCT01727557|PROCEDURE|regional anesthesia|Regional anesthesia will be compared to local anesthesia
219426301|NCT01727557|PROCEDURE|local anesthesia|Regional anesthesia will be compared to local anesthesia
219426302|NCT04600843|OTHER|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
219426303|NCT04600843|OTHER|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
219426304|NCT03437291|PROCEDURE|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
219191386|NCT06484140|BEHAVIORAL|Financial Navigation|During hospitalization, participants will receive needs assessment, and one-on-one cost-related health education with a material booklet. Resource and service referral will be delivered face-to-face or by phone when the navigator identifies unaddressed problems. Within three months after discharge, participants will receive monthly follow-up phone calls and personalized counseling via WeChat.
219426305|NCT03437291|DEVICE|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
219426306|NCT03437291|DEVICE|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
219426307|NCT03219801|BIOLOGICAL|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
219426308|NCT06252246|DEVICE|Phacoemulsification machine|type of phacoemulsification machine is different
219426309|NCT00640146|DRUG|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
219426310|NCT00640146|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
219426311|NCT03926637|OTHER|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
219426312|NCT04836507|BIOLOGICAL|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
219006054|NCT03980106|OTHER|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
219006055|NCT03421821|DRUG|Ropivacaine|Subfascial injection OR extrafascial injection
219006056|NCT03902197|BIOLOGICAL|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
219006057|NCT05445986|PROCEDURE|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
219006058|NCT05445986|PROCEDURE|gap filling|to use biomaterials to fill the jumping gap
219006059|NCT05445986|PROCEDURE|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
219006060|NCT01024803|DEVICE|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
219006061|NCT02669381|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
219426313|NCT04836507|DRUG|Fludarabine|Administered according to package insert
219426314|NCT04836507|DRUG|Cyclophosphamide|Administered according to package insert
219426315|NCT05308160|DRUG|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
219426316|NCT05308160|DRUG|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
219426317|NCT02448017|DEVICE|The Herbst appliance|Orthodontic functional appliance
219426318|NCT02448017|DEVICE|Twin block appliance|Orthodontic functional appliance
219426319|NCT05168852|OTHER|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
219426320|NCT02967770|OTHER|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
219426321|NCT02967770|DRUG|Standard of Care Second Line Therapy|
219426322|NCT02485613|DRUG|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
219426323|NCT05808023|OTHER|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
219426324|NCT00371813|DRUG|Varenicline tartrate|
219426325|NCT00371813|DRUG|Placebo|
219576648|NCT05384717|OTHER|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
219576649|NCT05384717|OTHER|Control group|No intervention
219426326|NCT05645653|BEHAVIORAL|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
219426327|NCT01894334|DRUG|Ulinastatin|
219426328|NCT01894334|DRUG|Tranexamic acid|
219426329|NCT01894334|DRUG|Edaravone|
219426330|NCT04142710|DEVICE|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
219426331|NCT04058158|DRUG|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
219426332|NCT04058158|DRUG|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
219426333|NCT04847141|BIOLOGICAL|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
219426334|NCT04847141|DRUG|0.9% Sodium chloride|C19-IG 20% matching placebo
219426335|NCT01634113|DRUG|tiotropium-bromide|IMP
219426336|NCT01634113|DRUG|tiotropium-bromide|IMP
219426337|NCT01634113|DRUG|placebo|placebo matching tiotropium
219426338|NCT05255341|PROCEDURE|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
219426339|NCT00565019|DRUG|Triamcinolone Acetonide|"* Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg"
219426340|NCT00324740|DRUG|vorinostat|Given orally
219426341|NCT00324740|DRUG|isotretinoin|Given orally
219426342|NCT00141934|DRUG|AD 452|
219426343|NCT00080184|PROCEDURE|Low Energy Neurofeedback System|
219426344|NCT01052831|DRUG|Naltrexone|50-100 mg qd for 8 weeks
219426345|NCT01052831|DRUG|Placebo|50-100 mg qd for 8 weeks
219426346|NCT01594346|DRUG|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
219426347|NCT01594346|DRUG|Sugar Pill|
219426348|NCT01689766|DRUG|Technetium Tc 99m EC20|
219426349|NCT04463238|COMBINATION_PRODUCT|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
219426350|NCT04463238|PROCEDURE|Microfracture|Operate in accordance with the clinical microfracture surgery method.
219576650|NCT06067321|OTHER|abdominal ultrasound, insertion of naso-gastric tube|measurement antral cross sectional area, volume and pH of residual stomach contents
219006062|NCT02284594|BEHAVIORAL|text message|series of text messages regarding influenza vaccination
219426351|NCT00520299|DRUG|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
219006063|NCT04252456|PROCEDURE|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
219006064|NCT05983276|DRUG|Decitabine|Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
219006065|NCT05983276|DRUG|Carboplatin|Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
219006066|NCT05983276|DRUG|Paclitaxel|"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."
219006067|NCT05983276|DRUG|Selinexor|Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
219426352|NCT01352845|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
219426353|NCT01352845|OTHER|Placebo|0.5 mL dose, given at 0, 2 and 6 months
219426354|NCT01807091|DRUG|Chemotherapy|Receive outpatient induction chemotherapy
219426355|NCT03267589|DRUG|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
219426356|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121 without MF59®
219426357|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241 without MF59®
219426358|NCT05664334|BIOLOGICAL|Placebo|Diluent
219426359|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, without MF59®
219426360|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, without MF59®
219426361|NCT05664334|BIOLOGICAL|IVX-241|225 mcg of IVX-241, without MF59®
219426362|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, with MF59®
219426363|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241, with MF59®
219426364|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, with MF59®
219426365|NCT05664334|OTHER|MF59®|MF59® as an adjuvant
219576651|NCT01739621|DRUG|Proellex 12 mg|
219576652|NCT01739621|DRUG|Proellex 24 mg|
219576653|NCT03514654|PROCEDURE|Mastectomy|Removal of the whole breast.
219576654|NCT03514654|PROCEDURE|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
219576655|NCT04993300|DEVICE|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
219426366|NCT01081821|DRUG|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
219426367|NCT01081821|DRUG|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
219191387|NCT06484140|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
219576656|NCT03257475|RADIATION|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
219576657|NCT02751359|DRUG|Cannabidiol|200, 400, or 800 mg Cannabidiol
219576658|NCT02751359|DRUG|Placebo|0 mg Cannabidiol
219191388|NCT04170881|OTHER|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
219191389|NCT03079921|DRUG|Phentolamine|Physiologic receptor blockade (α1-receptor).
219191390|NCT03079921|DRUG|Propranolol|Physiologic receptor blockade (β2-receptor).
219191391|NCT03079921|DRUG|Placebo|100mL bag of Normal Saline Solution (NSS).
219191392|NCT04805658|DIAGNOSTIC_TEST|Clinical examinations|Clinical examinations
219426368|NCT06059300|DIAGNOSTIC_TEST|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
219426369|NCT01354613|DRUG|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
219426370|NCT01354613|DRUG|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
219426371|NCT03255265|OTHER|no interventions|no interventions
219426372|NCT00250185|DRUG|Sodium Nitrate|
219426373|NCT00250185|DRUG|Acetylcholine|
219426374|NCT01047748|DRUG|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
219426375|NCT01047748|DRUG|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
219426376|NCT02271009|DRUG|AllerT|Ultrafast immunotherapy
219426377|NCT02271009|DRUG|Placebo|placebo control
219426378|NCT03579225|DEVICE|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
219426379|NCT01525940|DEVICE|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
219576659|NCT06091852|DIETARY_SUPPLEMENT|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
219426380|NCT02427750|BIOLOGICAL|Aggripal®|TIV
219576660|NCT01558336|DRUG|praziquantel|praziquantel 40 mg/kg oral tablets
219576661|NCT02400671|BEHAVIORAL|SMS messaging|
219576662|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
219006068|NCT00672412|DRUG|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
219006069|NCT00672412|DRUG|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
219006070|NCT00672412|DRUG|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
219006071|NCT00672412|DRUG|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
219006072|NCT02364973|OTHER|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
219006073|NCT04859023|DIAGNOSTIC_TEST|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
219191393|NCT02482337|PROCEDURE|POEM|POEM procedure in the OR
219191394|NCT05325099|DRUG|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
219191395|NCT05325099|DRUG|Placebo|Placebo (subcutaneous injection) QOD x 3 times
219006074|NCT04859023|DIAGNOSTIC_TEST|saliva sample (Self-sample)|Tested by RT-PCR.
219191396|NCT05163496|DRUG|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
219426381|NCT03749798|PROCEDURE|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
219426382|NCT00716638|BEHAVIORAL|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
219426383|NCT00716638|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
219426384|NCT05516160|DIAGNOSTIC_TEST|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
219426385|NCT00454272|DRUG|Teicoplanin|
219426386|NCT00454272|DRUG|Vancomycin|
219426387|NCT02128594|BEHAVIORAL|Serosorting Intervention|Single session, behavioral intervention
219426388|NCT03623425|DRUG|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
219426389|NCT03623425|DRUG|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
219426390|NCT00643344|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
219426391|NCT05535309|DRUG|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
219576663|NCT05777161|BEHAVIORAL|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
219576664|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
219576665|NCT05550883|OTHER|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
219426392|NCT01593579|BEHAVIORAL|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
219426393|NCT01593579|OTHER|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
219426394|NCT06796985|DRUG|Botulinum neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm). Participants will receive this drug twice throughout the duration of the study. Approximately 200 units of botulinum neurotoxin will be administered per injection.
219576666|NCT05550883|DRUG|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
219576667|NCT01748331|OTHER|Fluid restriction|Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
219576668|NCT03949244|DRUG|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
219576669|NCT03949244|DRUG|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
219576670|NCT03949244|DRUG|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
219576671|NCT03949244|DIAGNOSTIC_TEST|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
219191397|NCT05163496|DRUG|Active placebo|PAP + niacin 250mg
219576672|NCT03124862|DEVICE|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
219576673|NCT02370225|OTHER|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
219576674|NCT04646486|BEHAVIORAL|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
219576675|NCT03687658|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
219006075|NCT04859023|OTHER|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
219006076|NCT04859023|OTHER|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
219006077|NCT02964351|BIOLOGICAL|High PSA levels|
219426395|NCT06796985|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management. The device will be used five times during the study. Each use will last approximately ten minutes.
219426396|NCT03201848|DRUG|Placebo|Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
219426397|NCT03201848|DRUG|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
219426398|NCT00003828|DRUG|vinorelbine|
219426399|NCT04578015|DRUG|Metronidazole|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
219006078|NCT00468416|DEVICE|Compression Anastomosis Ring (CAR)|
219426400|NCT04578015|DRUG|Placebo|Participants in this arm will receive placebo
219576676|NCT04126421|DEVICE|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
219576677|NCT04126421|DEVICE|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
219576678|NCT02613325|DEVICE|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
219576679|NCT02613325|PROCEDURE|Standard of care surgical excision|
219576680|NCT02613325|DEVICE|Single cell photoacoustic microscopy|
219576681|NCT00626717|PROCEDURE|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
219576682|NCT00626717|PROCEDURE|Sham treatment|Fluorescein eye drops. Exposure with blue light
219576683|NCT03656874|OTHER|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
219006079|NCT00972569|DRUG|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
219006080|NCT00972569|DRUG|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
219006081|NCT01012960|DRUG|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
219006082|NCT05431452|OTHER|Pain management|Nonpharmacological pain management during blood collection in preterm infants
219006083|NCT02782780|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
219006084|NCT03562481|DRUG|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
219006085|NCT03562481|DRUG|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
219426401|NCT03143556|DEVICE|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
219426402|NCT02528253|BIOLOGICAL|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
219426403|NCT02528253|BIOLOGICAL|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
219426404|NCT02528253|BIOLOGICAL|Tanezumab 5 mg SC|Tanezumab 5 mg SC
219006086|NCT01602874|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
219006087|NCT01602874|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
219006088|NCT01602874|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
219006089|NCT01602874|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
219006090|NCT02075229|DEVICE|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
219006091|NCT04857242|DIAGNOSTIC_TEST|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
219006092|NCT01994460|DRUG|Linezolid|
219006093|NCT01994460|DRUG|Ethambutol|
219006094|NCT00353561|DRUG|Boric|Gelatin capsules filled with 600 mg of boric acid
219006095|NCT00353561|DRUG|Fluconazole|150 mg oral fluconazole gives once in 14 days
219006096|NCT01413191|BIOLOGICAL|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
219006097|NCT01413191|OTHER|Laboratory biomarker analysis|Correlative studies
219006098|NCT03942627|BEHAVIORAL|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
219006099|NCT03942627|BEHAVIORAL|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
219006100|NCT04023786|PROCEDURE|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
219006101|NCT01280916|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
219006102|NCT02319746|BEHAVIORAL|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
219006103|NCT02319746|BEHAVIORAL|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
219006104|NCT03051035|DRUG|KO-947|Intravenous administration
219006105|NCT05456464|OTHER|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
219006106|NCT01308346|DEVICE|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
219006107|NCT01308346|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
219426405|NCT02528253|BIOLOGICAL|Tanezumab 10 mg SC|Tanezumab 10 mg SC
219576684|NCT00584844|BIOLOGICAL|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
219760467|NCT06447909|BEHAVIORAL|Treatment App|"The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers."
219426406|NCT02528253|BIOLOGICAL|Tramadol PR oral|Tramadol PR oral
219426407|NCT01357980|BIOLOGICAL|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
219426408|NCT01357980|DRUG|Placebo|Intra detrusor injection on Day 1 (single dose)
219426409|NCT03078023|DEVICE|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
219426410|NCT00259246|DRUG|Peptide YY infusion|
219426411|NCT00523653|OTHER|blood test|looking at DNA
219426412|NCT05220371|DIETARY_SUPPLEMENT|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
219426413|NCT05220371|OTHER|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
219426414|NCT06291506|OTHER|Radiofrequency ablation of heart atrial tissue.|Ablation with radiofrequency, advances techniques: contact force-guided, improved tissue temperature sensors, automark algorithms.
219426415|NCT05953571|PROCEDURE|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
219426416|NCT03194620|OTHER|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
219426417|NCT03194620|OTHER|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
219426418|NCT03194620|OTHER|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
219426419|NCT03194620|OTHER|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
219426420|NCT03194620|OTHER|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
219426421|NCT03194620|OTHER|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
219426422|NCT03194620|OTHER|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
219006108|NCT02338414|DRUG|Romiplostim|Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
219006109|NCT02533427|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
219426423|NCT03194620|OTHER|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
219576685|NCT00797329|OTHER|chart review|"* cholesterol~* cognitive profiles~* violent behavior"
219576686|NCT01124357|DEVICE|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
219006110|NCT02533427|DRUG|VOX|100 mg tablet administered orally once daily
219006111|NCT02533427|DRUG|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
219426424|NCT00406211|BIOLOGICAL|MMRV|
219426425|NCT00406211|BIOLOGICAL|MMR (Priorix®)|
219426426|NCT00406211|BIOLOGICAL|Varicella (Varilrix®)|
219426427|NCT04507776|DRUG|Etanercept|Patients with spondyloarthrosis as provided in real world practice
219426428|NCT02781350|OTHER|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
219426429|NCT02781350|DIETARY_SUPPLEMENT|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
219426430|NCT03994393|DRUG|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
219426431|NCT03994393|DRUG|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
219426432|NCT00838721|OTHER|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
219426433|NCT00393068|DRUG|Erlotinib|Erlotinib
219426434|NCT00393068|DRUG|Bevacizumab|Bevacizumab
219426435|NCT00393068|DRUG|Paclitaxel|Paclitaxel
219426436|NCT00393068|DRUG|Carboplatin|Carboplatin
219426437|NCT00393068|DRUG|5-FU|5-FU
219426438|NCT00393068|PROCEDURE|Radiation therapy|Radiation therapy
219426439|NCT00393068|PROCEDURE|Surgery|Surgery
219426440|NCT06046547|OTHER|Pulmonary rehabilitation integrating education about palliative care|"PR will include exercise training twice a week, and education and psychosocial support once per week during 12 weeks.~The intervention will include an education session on palliative care, a Peer-to-peer session, a Get-apart session and online sessions.~The education session on palliative care will be facilitated by two specialist healthcare professionals. The main topics that will be discussed are: concept of palliative care, symptom control, disease impact, psychosocial support and planning for the future.~Participants will be the primary communicators in the Peer-to-peer session, and the dialogue will be based on their suggestions. Those who feel more reluctant to reveal private thoughts in front of their loved ones will have the opportunity to discuss their issues in a Get-apart environment.~Individual cases will be referred to a specialist palliative care team or to any other health/social care professional according to the unmet needs identified."
219426441|NCT06046547|OTHER|Pulmonary rehabilitation|"Participants will receive the same PR program as the experimental group besides the education session on palliative care, the Peer-to-peer session, the Get-apart session and the online sessions (i.e. traditional pulmonary rehabilitation)."
219426442|NCT02293993|DRUG|SGI-110|
219426443|NCT04849910|BIOLOGICAL|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
219426444|NCT04849910|DRUG|Mylotarg|Infusion of Mylotarg
219426445|NCT06641765|DEVICE|Continous Glucose Monitoring|10 days of real time open access to Continous Glucose Monitoring - either at defined time intervals (Group 2) or continuously for 9 months (Group 3).
219576687|NCT01124357|DEVICE|thermachoice|ThermachoiceTM III thermal balloon ablation
219191398|NCT03871712|BEHAVIORAL|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
219426446|NCT00094835|BIOLOGICAL|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
219426447|NCT00094835|DRUG|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
219426448|NCT00094835|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
219426449|NCT00094835|DRUG|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
219426450|NCT06565325|BEHAVIORAL|Exercise + Audible Cues|Combined Terminal Knee Extension Exercise with Audible Cues
219426451|NCT06565325|BEHAVIORAL|Exercise|Terminal Knee Extension Exercise
219426452|NCT00734812|PROCEDURE|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
219426453|NCT00734812|PROCEDURE|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
219426454|NCT04048629|DEVICE|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
219576688|NCT00085774|DRUG|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
219576689|NCT00085774|DRUG|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
219576690|NCT00085774|DRUG|placebo aerosol by HFA|placebo HFA
219576691|NCT03983174|PROCEDURE|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
219576692|NCT03983174|PROCEDURE|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
219576693|NCT01254474|DEVICE|Cardiac chambers mapping with MAP 4|
219576694|NCT03187366|OTHER|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
219426455|NCT04048629|OTHER|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
219426456|NCT05367557|PROCEDURE|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
219426457|NCT01271413|BEHAVIORAL|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
219426458|NCT01178723|DIETARY_SUPPLEMENT|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
219426459|NCT01632176|BEHAVIORAL|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
219426460|NCT05979233|PROCEDURE|staged managment|staged management
219426461|NCT05979233|PROCEDURE|one session ERCP then LC|one session ERCP then LC
219426462|NCT05979233|PROCEDURE|one session LC then ERCP|one session LC then ERCP
219426463|NCT00873288|OTHER|Usual care mailing intervention|routine colposcopy reminder letter
219426464|NCT00873288|OTHER|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
219426465|NCT05037669|BIOLOGICAL|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
219426466|NCT00329394|DRUG|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
219426467|NCT02693327|OTHER|Biological Sample|A one time sample will be collected.
219426468|NCT02693327|OTHER|Blood Sample|A one time blood sample will be collected.
219426469|NCT02001363|DRUG|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
219576695|NCT02319395|GENETIC|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
219576696|NCT03667014|DRUG|Dupilumab|Dupilumab treatment
219576697|NCT03001219|DRUG|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
219006112|NCT04800705|OTHER|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
219191399|NCT03871712|BEHAVIORAL|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
219426470|NCT02001363|DRUG|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
219426471|NCT05172037|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
219426472|NCT05172037|BIOLOGICAL|Placebo|Saline
219576698|NCT03001219|DRUG|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
219576699|NCT03001219|DRUG|Placebo|Participants will receive intravenous infusion of placebo.
219576700|NCT03001219|DRUG|RO7123520|Participants will receive intravenous infusion of RO7123520.
219576701|NCT01781819|PROCEDURE|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
219576702|NCT00001993|DRUG|Butyldeoxynojirimycin|
219576703|NCT00001993|DRUG|Zidovudine|
219576704|NCT02860065|DRUG|CPC-201|solifenacin and donepezil
219576705|NCT02860065|OTHER|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
219576706|NCT05033574|DIAGNOSTIC_TEST|Biochemical study of hormone levels|Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
219576707|NCT05033574|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
219576708|NCT05033574|RADIATION|Radiography of the hands|Determination of bone age using radiography of the hands
219426473|NCT01270230|BEHAVIORAL|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
219426474|NCT01270230|BEHAVIORAL|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
219426475|NCT03712800|OTHER|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
219426476|NCT03712800|BEHAVIORAL|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
219426477|NCT03024255|DRUG|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
219426478|NCT03024255|DRUG|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
219426479|NCT03024255|DRUG|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
219426480|NCT03024255|DRUG|Vehicle (Placebo)|Placebo, applied once to each axilla daily
219426481|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
219426482|NCT02521298|OTHER|Strength Training|
219426483|NCT02521298|PROCEDURE|Placebo|
219426484|NCT02521298|DRUG|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
219426485|NCT02521298|PROCEDURE|Dry Needling|
219426486|NCT02169804|DRUG|Androxal 25 mg|
219426487|NCT03583606|BIOLOGICAL|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).
219426488|NCT03583606|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).
219426489|NCT03583606|OTHER|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
219426490|NCT00207012|DRUG|BMS-599626|
219426491|NCT03101527|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
219426492|NCT05402722|DRUG|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
219426493|NCT05402722|DRUG|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
219426494|NCT01526681|OTHER|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
219426495|NCT01526681|OTHER|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
219426496|NCT01526681|OTHER|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
219426497|NCT01526681|DEVICE|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
219426498|NCT01526681|PROCEDURE|Autologous Breast Reconstruction with Neurotization|
219426499|NCT01526681|PROCEDURE|Autologous Breast Reconstruction without Neurotization|
219426500|NCT00126581|DRUG|Carboplatin|Given IV
219426501|NCT00126581|DRUG|Erlotinib|Given PO
219426502|NCT00126581|DRUG|Erlotinib Hydrochloride|Given PO
219426503|NCT00126581|DRUG|Paclitaxel|Given IV
219426504|NCT02570529|DRUG|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
219426505|NCT02570529|DRUG|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
219426506|NCT00793182|DRUG|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
219426507|NCT00793182|DRUG|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
219426508|NCT02700295|DEVICE|Orthokeratology lens|
219426509|NCT00251875|DEVICE|online health information journal|
219576709|NCT05033574|BEHAVIORAL|Consultation of a medical psychologist|Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
219576710|NCT01043120|DRUG|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
219576711|NCT01043120|DRUG|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
219576712|NCT01195103|DRUG|Fospropofol disodium|10 mg/kg bolus
219426510|NCT02043236|BEHAVIORAL|Healthy bones pamphlet|written educational material
219426511|NCT02043236|BEHAVIORAL|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
219576713|NCT01195103|DRUG|Fospropofol disodium|6.5 mg/kg bolus
219426512|NCT02043236|BEHAVIORAL|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
219426513|NCT06198075|OTHER|Control Group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
219426514|NCT06198075|DEVICE|Experimental Group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
219426515|NCT00114270|DRUG|letrozole|
219426516|NCT00114270|DRUG|zoledronic acid|
219426517|NCT03396978|OTHER|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
219426518|NCT00001777|DRUG|Sertraline|
219426519|NCT03628521|DRUG|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
219426520|NCT05646654|PROCEDURE|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
219426521|NCT05646654|PROCEDURE|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
219006113|NCT05288075|DRUG|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
219006114|NCT04593563|DRUG|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
219006115|NCT04094363|OTHER|Product A|Usual Brand, filtered combustible cigarette
219426522|NCT01853098|BEHAVIORAL|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
219426523|NCT02197897|DRUG|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
219426524|NCT00418210|RADIATION|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
219426525|NCT03553550|OTHER|biospecimen collection|Peripheral blood collection Archival tissue collection
219426526|NCT04188002|BEHAVIORAL|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
219426527|NCT04188002|OTHER|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
219426528|NCT02685657|DRUG|Drug: Selumetinib|
219426529|NCT02685657|DRUG|Doxorubicin|
219426530|NCT02685657|DRUG|Cyclophosphamide|
219426531|NCT02685657|DRUG|Docetaxel|
219426532|NCT06304519|DEVICE|Dynamic ankle-foot orthosis|customized, carbon fiber, passive ankle-foot orthosis
219576714|NCT01195103|DRUG|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
219576715|NCT01195103|DRUG|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
219576716|NCT03760250|DRUG|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
219426533|NCT05506917|PROCEDURE|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
219426534|NCT02384395|DRUG|Dolutegravir 50 mg|Initial therapy for AHI
219426535|NCT02384395|DRUG|Lamivudine 300 mg|Initial therapy for AHI
219426536|NCT02384395|DRUG|Abacavir 600 mg|Initial therapy for AHI
219426537|NCT02904525|DEVICE|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
219426538|NCT03202745|OTHER|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
219426539|NCT03202745|OTHER|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
219426540|NCT00606528|OTHER|No intervention|None. This is an observational study.
219426541|NCT01254578|OTHER|Laboratory Biomarker Analysis|Correlative studies
219576717|NCT03733210|DRUG|Panitumumab-IRDye800|30 mg administered intravenously (IV)
219006116|NCT04094363|OTHER|Product B|CSD1902-11, an electronic nicotine delivery system
219760468|NCT06447909|BEHAVIORAL|Sham app|As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
219006117|NCT04094363|OTHER|Product C|CSD1902-21, an electronic nicotine delivery system
219426542|NCT01254578|DRUG|Lenalidomide|Given orally
219426543|NCT01254578|OTHER|Pharmacological Study|Correlative studies
219426544|NCT00430898|DRUG|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
219426545|NCT02785146|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
219426546|NCT02785146|DRUG|Oxaliplatin|85 mg/m², ivdrip, D1
219576718|NCT03733210|DRUG|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
219576719|NCT03733210|DEVICE|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
219576720|NCT03733210|DEVICE|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
219576721|NCT03733210|DEVICE|Explorer Air camera|Fluorescence camera manufactured by SurgVision
219760469|NCT04841954|DIAGNOSTIC_TEST|hemp prick-test|hemp seed and flower prick-test
219426547|NCT02785146|DRUG|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
219426548|NCT02785146|DRUG|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
219426549|NCT03351010|BEHAVIORAL|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
219426550|NCT03351010|DEVICE|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
219426551|NCT03669406|PROCEDURE|Autograft fat|autograft fat
219426552|NCT00189787|DRUG|tacrolimus|
219426553|NCT05448989|DRUG|1% atropine 5+3|A method for myopia control using high-concentration atropine
219426554|NCT01525056|RADIATION|ct and mri scans|ct and mri scan preradiation and postradiation
219426555|NCT01525056|RADIATION|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
219576722|NCT03733210|DEVICE|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
219576723|NCT03733210|DEVICE|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
219576724|NCT03733210|DEVICE|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
219576725|NCT03733210|DEVICE|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
219426556|NCT01525056|RADIATION|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
219576726|NCT03733210|DEVICE|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
219576727|NCT03733210|DEVICE|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
219426557|NCT00550277|DRUG|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
219426558|NCT04644055|DIAGNOSTIC_TEST|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
219426559|NCT02321683|DEVICE|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
219426560|NCT02473224|BIOLOGICAL|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
219426561|NCT02473224|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
219426562|NCT04673669|DIAGNOSTIC_TEST|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
219426563|NCT00617318|DIETARY_SUPPLEMENT|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
219576728|NCT03733210|DEVICE|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
219426564|NCT00617318|DIETARY_SUPPLEMENT|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
219576729|NCT03733210|DEVICE|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
219576730|NCT01237925|DRUG|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
219576731|NCT01237925|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
219576732|NCT02302313|DEVICE|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
219576733|NCT04990596|BIOLOGICAL|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
219576734|NCT03951896|BIOLOGICAL|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
219576735|NCT03951896|OTHER|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
219576736|NCT03538119|OTHER|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
219006118|NCT04094363|OTHER|Product D|4mg Nicotine gum
219576737|NCT03538119|OTHER|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
219006119|NCT01224067|DRUG|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
219426565|NCT06531226|OTHER|Fill in personality questionnaires|For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
219426566|NCT03911778|OTHER|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
219426567|NCT04713579|OTHER|No intervention - observational study|There is no intervention in this study as it is purely observational.
219426568|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
219426569|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
219426570|NCT02850497|DEVICE|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
219426571|NCT00992004|DIETARY_SUPPLEMENT|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
219426572|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
219426573|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
219426574|NCT01929213|DRUG|Udenafil|Udenafil is administered
219426575|NCT01929213|DRUG|Bosentan|Bosentan is administered
219426576|NCT01929213|DRUG|Udenafil/Bosentan|Udenafil and Bosentan are administered
219426577|NCT03103880|DEVICE|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
219426578|NCT03842215|DEVICE|smart physical exam|Use smart physical exam to collect functional performance
219760470|NCT01322256|PROCEDURE|Bone scintigraphy|Bone scintigraphy of the affected area
219760471|NCT01322256|PROCEDURE|Leukoscan|Scintigraphy with labeled neutrophils
219426579|NCT01136863|DRUG|Felodipine|
219426580|NCT01136863|DRUG|Placebo|
219426581|NCT04884672|DEVICE|SMILE|Small incision lenticule extraction, a refractive surgery procedure for the corrcetion of myopia with or without astigmatism
219426582|NCT05099536|DRUG|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
219426583|NCT00886106|DRUG|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
219760472|NCT01322256|PROCEDURE|PET / CT|PET / CT of the affected area
219760473|NCT01322256|PROCEDURE|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
219760474|NCT01322256|BIOLOGICAL|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
219760475|NCT00272220|BEHAVIORAL|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
219760476|NCT01781884|DRUG|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
219760477|NCT01781884|DRUG|Placebo|
219760478|NCT01354223|DEVICE|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
219760479|NCT01354223|DEVICE|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219760480|NCT01035502|DRUG|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
219760481|NCT00569322|PROCEDURE|BG Test|
219760482|NCT05794607|OTHER|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
219576738|NCT06014918|DEVICE|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
219576739|NCT03880760|OTHER|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
219426584|NCT00886106|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
219426585|NCT00343109|BIOLOGICAL|HER-2/neu intracellular domain protein|Given ID
219426586|NCT00343109|PROCEDURE|leukapheresis|Optional correlative studies
219426587|NCT00343109|OTHER|laboratory biomarker analysis|Correlative studies
219426588|NCT00343109|BIOLOGICAL|sargramostim|Given ID
219426589|NCT00343109|OTHER|immunologic technique|Correlative studies
219426590|NCT00343109|BIOLOGICAL|synthetic tumor-associated peptide vaccine therapy|Given ID
219426591|NCT04373018|PROCEDURE|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
219426592|NCT04373018|PROCEDURE|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
219426593|NCT04373018|PROCEDURE|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
219426594|NCT00438919|DEVICE|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
219426595|NCT02701179|DRUG|Lignocaine 1% concentration solution|
219426596|NCT02701179|DRUG|Lignocaine 2% concentration solution|
219426597|NCT01106391|DEVICE|"Cordis AAA stent graft system INCRAFT TM"|
219426598|NCT06643390|DRUG|MK-2225|Subcutaneous administration
219426599|NCT06643390|OTHER|Placebo|Subcutaneous administration
219426600|NCT04220138|PROCEDURE|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
219426601|NCT06470555|OTHER|A figure-of-eight suture secured with a three-way tap|Femoral haemostasis using a figure-of-eight suture technique
219426602|NCT06470555|OTHER|Shortened bed rest duration of 2-hours|Bed rest duration of 2-hours after initial haemostasis
219426603|NCT06470555|OTHER|Manual compression|Femoral haemostasis using manual compression
219426604|NCT06470555|OTHER|Conventional bed rest duration of 4-hours|Bed rest duration of 4-hours after initial haemostasis
219426605|NCT04426890|BIOLOGICAL|CT-P39|Prefilled syringe (PFS) of 1 mL solution
219426606|NCT04426890|BIOLOGICAL|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
219426607|NCT04798248|BEHAVIORAL|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
219426608|NCT04798248|BEHAVIORAL|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
219760483|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab|Administration of Lilly Bamlanivimab to COVID positive patients
219426609|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
219426610|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
219426611|NCT06789432|DRUG|Atorvastatin 10 mg and ezetimibe 10 mg|Atorvastatin/Ezetimibe 10/10mg once daily
219426612|NCT06789432|DRUG|Atorvastatin 20 mg|Atorvastatin (20 mg) Monotherapy once daily
219426613|NCT06665256|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
219426614|NCT06665256|OTHER|Active Comparator Option|Investigator choice of treatment as per protocol
219426615|NCT04353973|OTHER|Pre-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
219426616|NCT04353973|OTHER|Standard of Care|Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
219576740|NCT03880760|OTHER|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
219760484|NCT04790786|BIOLOGICAL|Regeneron Casirivimab + Imdevimab|Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients
219760485|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab + Etesevimab|Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients
219760486|NCT04790786|BIOLOGICAL|Sotrovimab|Administration of Sotrovimab to COVID positive patients
219760487|NCT04790786|BIOLOGICAL|Bebtelovimab|Administration of Bebtelovimab to COVID positive patients
219760488|NCT01082627|DRUG|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
219426617|NCT04353973|OTHER|Post-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
219426618|NCT05162781|BEHAVIORAL|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
219426619|NCT05162781|BEHAVIORAL|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
219426620|NCT05162781|BEHAVIORAL|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
219426621|NCT05162781|BEHAVIORAL|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
219426622|NCT05162781|BEHAVIORAL|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 5 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
219426623|NCT05162781|BEHAVIORAL|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
219426624|NCT05162781|BEHAVIORAL|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
219426625|NCT01772836|DRUG|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
219426626|NCT01772836|DRUG|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
219426627|NCT01772836|DRUG|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
219426628|NCT05236036|DRUG|Mycophenolate Mofetil|Given PO
219576741|NCT04683666|PROCEDURE|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. \^Postoperative complications were assessed.
219576742|NCT01554826|BIOLOGICAL|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
219426629|NCT05236036|OTHER|Quality-of-Life Assessment|Ancillary studies
219426630|NCT05236036|RADIATION|Radiation Therapy|Receive radiation therapy
219426631|NCT05236036|DRUG|Temozolomide|Given Orally (PO)
219426632|NCT00635245|BIOLOGICAL|figitumumab|
219426633|NCT00635245|OTHER|imaging biomarker analysis|
219426634|NCT00635245|OTHER|laboratory biomarker analysis|
219426635|NCT00635245|OTHER|pharmacological study|
219426636|NCT00635245|PROCEDURE|conventional surgery|
219426637|NCT00635245|PROCEDURE|magnetic resonance spectroscopic imaging|
219426638|NCT00635245|PROCEDURE|neoadjuvant therapy|
219426639|NCT01673269|OTHER|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
219426640|NCT00954057|DRUG|LIPO-102|intraorbital injection
219426641|NCT00954057|DRUG|Placebo|intraorbital injection
219426642|NCT06249022|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
219426643|NCT06249022|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
219576743|NCT01554826|BIOLOGICAL|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
219576744|NCT00999765|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
219576745|NCT00937820|DRUG|YM150|oral
219576746|NCT06026020|OTHER|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
219576747|NCT00727948|DRUG|Aspirin|325 mg tablets, once daily for 45 days
219576748|NCT04629768|DEVICE|PuraStat|Purastat is applied to the EMR defect
219576749|NCT04421586|BEHAVIORAL|VISTA|VISTA will be an educational intervention.
219576750|NCT05451186|OTHER|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
219760489|NCT01082627|OTHER|common daily practice|common daily practice
219760490|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
219760491|NCT01973868|DRUG|Regorafenib (Stivarga, BAY73-4506)|
219760492|NCT01973868|DRUG|Cetuximab (ERBITUX)|
219760493|NCT00948688|RADIATION|Radiation therapy|Once per day, 5 days a week for 6 weeks
219760494|NCT00948688|DRUG|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
219760495|NCT00948688|DRUG|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
219426644|NCT06249022|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
219426645|NCT03582852|PROCEDURE|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
219426646|NCT06269575|BEHAVIORAL|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
219426647|NCT00972972|DIETARY_SUPPLEMENT|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
219426648|NCT00972972|DIETARY_SUPPLEMENT|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
219426649|NCT03646760|BEHAVIORAL|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
219426650|NCT03646760|BEHAVIORAL|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
219426651|NCT04227327|DRUG|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
219426652|NCT04227327|DRUG|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
219426653|NCT02091245|DRUG|KPT-330|
219426654|NCT05351333|OTHER|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
219426655|NCT00742807|DRUG|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
219760496|NCT04093232|DRUG|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
219760497|NCT00563758|DRUG|tegaserod|
219426656|NCT00742807|DRUG|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
219426657|NCT05007015|PROCEDURE|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
219426658|NCT03939637|DRUG|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
219760498|NCT02629926|OTHER|GH Replacement (NutropinAq®)|GH Replacement continued.
219760499|NCT02629926|OTHER|No additional treatment|GH Replacement not continued.
219760500|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
219760501|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
219760502|NCT01963988|PROCEDURE|Transurethral Coagulation (TUC)|
219760503|NCT01963988|PROCEDURE|Transurethral Resection(TUR)|
219760504|NCT03571932|BEHAVIORAL|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
219760505|NCT03180229|DRUG|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
219760506|NCT03601390|DEVICE|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
219760507|NCT03407092|OTHER|ADAPT cohort|Thrombectomy with distal aspiration technique
219760508|NCT03407092|OTHER|Stentriever Cohort|Thrombectomy with stent retriever
219760509|NCT04420858|BEHAVIORAL|Enhanced (experimental) education|See arm description.
219760510|NCT04420858|BEHAVIORAL|Standard (control) education.|See arm description.
219760511|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water|
219760512|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate|
219426659|NCT03939637|DRUG|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
219576751|NCT02398357|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
219426660|NCT03939637|DRUG|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
219426661|NCT03939637|DRUG|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
219426662|NCT05886348|DEVICE|Model-A Novel spectacle lens|Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months
219426663|NCT05886348|DEVICE|Model-B Novel spectacle lens|Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months
219426664|NCT05886348|DEVICE|Single vision spectacle lens|Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months
219426665|NCT06549218|DIAGNOSTIC_TEST|newborn genetic screening and whole genome sequencing|newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
219426666|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
219426667|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
219426668|NCT03733457|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
219576752|NCT02694471|BEHAVIORAL|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
219426669|NCT01631292|DIETARY_SUPPLEMENT|600 IU Vitamin D3|Once daily
219426670|NCT01631292|DIETARY_SUPPLEMENT|2000 IU Vitamin D3|Once daily
219426671|NCT01631292|DIETARY_SUPPLEMENT|4000 IU Vitamin D3|Once daily
219426672|NCT01350713|DRUG|povidone iodine|one local application of 10% povidone iodine ointment
219426673|NCT01353755|DRUG|Grass pollen specific immunotherapy|"* Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
219426674|NCT01353755|DRUG|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
219426675|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
219426676|NCT06172127|DRUG|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
219426677|NCT06172127|DRUG|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
219426678|NCT06172127|DRUG|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
219426679|NCT05380453|BIOLOGICAL|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
219426680|NCT05380453|DRUG|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
219576753|NCT00967044|DRUG|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
219576754|NCT00967044|DRUG|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
219576755|NCT02715544|OTHER|Healthy lifestyle|The families will receive a designed for these purposes intervention
219576756|NCT02715544|OTHER|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
219576757|NCT00469157|DRUG|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
219576758|NCT03823014|DEVICE|Elator|Measurement for device, use of device
219760513|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate + protein|
219760514|NCT00006004|DRUG|carboplatin|
219760515|NCT00006004|DRUG|cisplatin|
219760516|NCT00006004|DRUG|gemcitabine hydrochloride|
219760517|NCT00006004|DRUG|paclitaxel|
219760518|NCT02859974|BEHAVIORAL|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
219760519|NCT04242706|DEVICE|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
219760520|NCT04242706|DEVICE|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
219576759|NCT03382314|COMBINATION_PRODUCT|HDDO-1614|"* Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product"
219426681|NCT05204407|DIETARY_SUPPLEMENT|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
219426682|NCT05204407|DIETARY_SUPPLEMENT|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
219426683|NCT06295107|DIAGNOSTIC_TEST|Ankle Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
219426684|NCT06295107|DIAGNOSTIC_TEST|Knee Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
219426685|NCT05879250|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219426686|NCT05879250|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219426687|NCT05879250|RADIATION|Radiation Therapy|Undergo routine radiation therapy
219426688|NCT05879250|DRUG|STAT3 Inhibitor WP1066|Given PO
219426689|NCT05879250|PROCEDURE|Surgical Procedure|Undergo removal or biopsy of tumor
219576760|NCT03382314|DRUG|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
219576761|NCT04310813|DIAGNOSTIC_TEST|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
219576762|NCT00753818|OTHER|DHA and ARA|various levels of DHA and ARA
219576763|NCT00753818|OTHER|Control|
219576764|NCT02774096|DRUG|xenon|
219426690|NCT03814967|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
219426691|NCT04268004|BEHAVIORAL|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
219426692|NCT05558696|DRUG|Bomedemstat|Oral tablet
219426693|NCT03995108|DRUG|Mavorixafor|Mavorixafor provided as 100 mg capsules.
219426694|NCT03995108|DRUG|Placebo|Placebo matching to mavorixafor capsules
219426695|NCT06135415|DRUG|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
219426696|NCT06135415|OTHER|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
219426697|NCT04946084|PROCEDURE|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
219426698|NCT04946084|OTHER|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
219426699|NCT04946084|OTHER|Blood Draw|Venipuncture
219426700|NCT01743170|OTHER|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
219426701|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
219426702|NCT03783442|DRUG|Cisplatin|Cisplatin 60-80 mg/m² administered by intravenous infusion every 3 weeks. Cisplatin was used as the platinum agent in China, Taiwan, and Japan.
219426703|NCT03783442|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m² administered by intravenous infusion every 3 weeks.
219426704|NCT03783442|DRUG|Fluorouracil (5-FU)|Fluorouracil 750-800 mg/m² administered by intravenous infusion on Days 1-5 of each treatment cycle.
219426705|NCT03783442|DRUG|Capecitabine|Capecitabine 1000 mg/m² administered orally twice daily on Days 1-14 of each treatment cycle
219426706|NCT03783442|DRUG|Paclitaxel|Paclitaxel 175 mg/m² administered by intravenous infusion every 3 weeks.
219576765|NCT00006235|DRUG|carboplatin|
219576766|NCT00006235|DRUG|pegylated liposomal doxorubicin hydrochloride|
219576767|NCT03449836|COMBINATION_PRODUCT|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
219576768|NCT03449836|COMBINATION_PRODUCT|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
219576769|NCT03449836|OTHER|placebo|nasal spray based on isotonic solution
219576770|NCT04205019|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
219576771|NCT04004143|OTHER|No intervention|No intervention.
219576772|NCT04192279|DIAGNOSTIC_TEST|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
219576773|NCT04852900|OTHER|Decompression with 30%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
219576774|NCT04852900|OTHER|Decompression with 40%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
219576775|NCT04852900|OTHER|Decompression with 50%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
219426707|NCT03783442|BIOLOGICAL|Tislelizumab|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks.
219576776|NCT05194878|DRUG|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
219576777|NCT05194878|PROCEDURE|Colectomy|Radical colectomy
219576778|NCT05194878|DRUG|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
219426708|NCT03783442|DRUG|Placebo|Placebo to match tislelizumab administered by intravenous infusion every 3 weeks.
219426709|NCT06605430|DRUG|Medical Cannabis|The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.
219426710|NCT06394804|DRUG|Avutometinib|Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks
219426711|NCT06394804|DRUG|Defactinib|Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks
219426712|NCT06394804|DRUG|Letrozole|2.5 mg PO daily
219426713|NCT05818865|DEVICE|CLG|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
219426714|NCT06145464|BEHAVIORAL|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
219426715|NCT06145464|BEHAVIORAL|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
219426716|NCT06145464|BEHAVIORAL|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
219426717|NCT06145464|BEHAVIORAL|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
219426718|NCT04130828|DRUG|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
219426719|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
219426720|NCT01267604|DRUG|Recombinant FSH (rFSH)|225IU
219426721|NCT01267604|DIETARY_SUPPLEMENT|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
219576779|NCT00601809|OTHER|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
219760521|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
219760522|NCT02852967|DRUG|Belumosudil|
219426722|NCT03025152|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
219426723|NCT03025152|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
219426724|NCT00630708|DRUG|Benazepril|20 mg per day
219426725|NCT00630708|DRUG|Losartan|100 mg per day
219426726|NCT00630708|DRUG|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
219426727|NCT05386472|DRUG|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
219426728|NCT05386472|DRUG|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
219426729|NCT02453009|DRUG|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
219426730|NCT02453009|DRUG|Prednisone|Pharmaceutical form:tablet Route of administration: oral
219426731|NCT02453009|DRUG|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
219426732|NCT02317341|DRUG|Ketamine|Single intravenous dose
219426733|NCT02317341|DRUG|Placebo (saline)|Given intravenously over 40 minutes
219426734|NCT02317341|DRUG|Ketamine|Single intravenous dose given over 40 minutes
219426735|NCT02317341|DRUG|Midazolam|Given intravenously over 40 minutes
219426736|NCT02317341|DRUG|Midazolam(placebo)|Given intravenously over 40 minutes
219576780|NCT00601809|DRUG|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
219576781|NCT01327261|DRUG|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
219576782|NCT05065983|BIOLOGICAL|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
219426737|NCT03935607|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
219426738|NCT00823940|DRUG|GSK1362885|5 - 100mg of GSK1362885 or placebo
219426739|NCT00823940|DRUG|GSK1362885|100 - 600mg or placebo
219426740|NCT00823940|DRUG|Glucagon|0.5mg IV bolus
219576783|NCT03318276|DRUG|SID142|SID142 is administrated to patients with PAD for 12 weeks
219426741|NCT00823940|DRUG|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
219426742|NCT00000450|DRUG|Naltrexone Tablet|
219426743|NCT00000450|DRUG|Matched Placebo Tablet|
219426744|NCT02976727|DRUG|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
219576784|NCT03318276|DRUG|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
219576785|NCT01765582|DRUG|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
219426745|NCT02976727|DRUG|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
219426746|NCT02976727|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
219576786|NCT01765582|DRUG|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
219576787|NCT01765582|DRUG|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
219760523|NCT02852967|DRUG|Placebo|Placebo tablets matching belumosudil
219760524|NCT05556486|DEVICE|GlioStem|GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.
219760525|NCT02898922|BIOLOGICAL|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
219760526|NCT03853044|DRUG|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
219426747|NCT02976727|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
219576788|NCT01765582|DRUG|irinotecan|Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
219576789|NCT01765582|DRUG|folinic acid|Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
219576790|NCT01765582|DRUG|oxaliplatin|Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
219576791|NCT01074762|BEHAVIORAL|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
219576792|NCT00986180|DRUG|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
219760527|NCT03853044|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
219760528|NCT03853044|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
219760529|NCT03853044|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
219006120|NCT03182101|BEHAVIORAL|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
219006121|NCT05627960|DRUG|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
219006122|NCT00150449|DRUG|Pregabalin|
219426748|NCT02976727|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
219426749|NCT02976727|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
219426750|NCT02976727|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
219426751|NCT00645918|DRUG|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
219426752|NCT00645918|DRUG|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
219426753|NCT00645918|DRUG|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
219426754|NCT04766151|DRUG|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
219576793|NCT00986180|DRUG|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
219576794|NCT00729274|DRUG|normal saline solution|Two 4ml nebulizations with 30 minute interval
219576795|NCT01691820|PROCEDURE|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
219576796|NCT01691820|PROCEDURE|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
219576797|NCT01691820|PROCEDURE|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
219760530|NCT03853044|DRUG|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
219006123|NCT01974349|DRUG|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
219426755|NCT04766151|DRUG|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
219576798|NCT03710720|BEHAVIORAL|TIPS app|Psycho-educational electronic application
219576799|NCT03710720|BEHAVIORAL|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
219576800|NCT00074776|DRUG|Lithium|Participants will receive lithium.
219426756|NCT06480188|DEVICE|deep brain stimulation|Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
219426757|NCT04372043|OTHER|Questionnaire|"Sleep Hygiene Index and demographic questions."
219576801|NCT00074776|DRUG|Lamotrigine|Participants will receive lamotrigine.
219760531|NCT05171153|OTHER|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
219760532|NCT05171153|OTHER|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
219006124|NCT01124422|DRUG|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
219006125|NCT01124422|DRUG|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
219576802|NCT05757882|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
219576803|NCT05757882|OTHER|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
219576804|NCT05467046|DEVICE|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
219576805|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane blend|1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
219576806|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane and reishi blend|1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
219576807|NCT06406946|DIETARY_SUPPLEMENT|Placebo|1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
219576808|NCT05885191|OTHER|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
219576809|NCT02668926|DRUG|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
219426758|NCT06382337|OTHER|Group A : ice cream cone technique|collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
219576810|NCT02668926|DRUG|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
219426759|NCT06382337|OTHER|Group B : the vestibular socket therapy|cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
219426760|NCT04150562|DRUG|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
219426761|NCT04150562|BIOLOGICAL|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
219426762|NCT04392869|BEHAVIORAL|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
219576811|NCT02668926|DRUG|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
219576812|NCT03261960|DRUG|BLI4700|Oral bowel preparation
219576813|NCT03261960|DRUG|Magnesium bowel preparation|Oral bowel preparation
219576814|NCT04768166|DRUG|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
219576815|NCT06431165|DRUG|Lidocaine IV|After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
219576816|NCT05746065|DRUG|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
219576817|NCT00004218|DRUG|chlorambucil|
219576818|NCT00004218|DRUG|cyclophosphamide|
219576819|NCT00004218|DRUG|doxorubicin hydrochloride|
219191400|NCT05161117|BEHAVIORAL|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
219576820|NCT00004218|DRUG|fludarabine phosphate|
219576821|NCT00004218|DRUG|prednisolone|
219576822|NCT00004218|DRUG|vincristine sulfate|
219576823|NCT02453906|OTHER|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
219576824|NCT02453906|OTHER|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
219426763|NCT04392869|BEHAVIORAL|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
219426764|NCT03409029|DIAGNOSTIC_TEST|MRI Scan|Additional imaging using MRI scan
219426765|NCT00992186|DRUG|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
219426766|NCT00333697|OTHER|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
219426767|NCT01178346|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
219426768|NCT01178346|BIOLOGICAL|Placebo|Placebo vaccine given 6 times over 6 months
219426769|NCT03002103|DRUG|EndoTAG-1|
219426770|NCT03002103|DRUG|Paclitaxel|
219426771|NCT03002103|DRUG|Gemcitabine Hydrochloride|
219426772|NCT05961800|BEHAVIORAL|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
219426773|NCT05961800|BEHAVIORAL|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
219426774|NCT05961800|BEHAVIORAL|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
219426775|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
219426776|NCT04713787|DRUG|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
219576825|NCT02453906|OTHER|Control 2|stimulation at 5 control points
219576826|NCT02453906|OTHER|Control 3|no stimulation at 5 control points
219576827|NCT04642937|DRUG|Treatment with hP1A8|Treatment with hP1A8
219576828|NCT01268605|PROCEDURE|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
219576829|NCT01268605|PROCEDURE|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
219576830|NCT00500747|BIOLOGICAL|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
219576831|NCT00500747|DRUG|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
219576832|NCT02870387|OTHER|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
219426777|NCT04713787|DRUG|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
219426778|NCT04929418|OTHER|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
219426779|NCT04929418|OTHER|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
219426780|NCT02751021|OTHER|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
219426781|NCT02751021|OTHER|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
219426782|NCT00684112|DRUG|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
219426783|NCT00684112|DRUG|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
219426784|NCT02726529|BEHAVIORAL|Brighter Bites|
219426785|NCT02726529|BEHAVIORAL|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
219426786|NCT06458257|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
219426787|NCT06458257|DRUG|Chemotherapy|Chemotherapy
219426788|NCT06311110|OTHER|Vancouver symptom score for dysfunctional elimination symptoms Questionnaire|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
219426789|NCT06311110|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.
219426790|NCT06311110|OTHER|Questionnaire concerning impaired toilettraining and comorbities|Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
219426791|NCT03933280|DRUG|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
219426792|NCT03933280|DRUG|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
219426793|NCT03933280|DRUG|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
219426794|NCT03933280|DRUG|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
219426795|NCT04965168|PROCEDURE|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
219426796|NCT04166656|BIOLOGICAL|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
219426797|NCT04166656|BIOLOGICAL|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
219426798|NCT00612989|DRUG|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose."
219426799|NCT05703698|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
219426800|NCT06853496|DRUG|RK-582|"Dosing Frequency:~Do single dose of RK-582 at the dose level specified for the cohort. Seven days after the first dose, Start repeated daily dose and continue until discontinuation criteria were met.~Dose level per dose:~Dose Level 1: 5 mg BID Dose level 2: 10 mg QD Dose level 3: 20 mg QD Dose level 4: 40 mg QD Dose Level 5: 60 mg QD Dose Level 6: 80 mg QD Dose Level 7: 100 mg QD Dose Level 8: 200 mg QD"
219426801|NCT06813014|PROCEDURE|Oral Glucose Tolerance Test|Three hour glucose tolerance test
219426802|NCT02193672|DRUG|[18F] Fluciclatide|\[18F\] Fluciclatide given by vein before PET/CT scan.
219576833|NCT02870387|OTHER|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
219576834|NCT02218970|BEHAVIORAL|strength training|
219576835|NCT02218970|BEHAVIORAL|no training (control)|
219576836|NCT04370951|PROCEDURE|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
219576837|NCT01011244|BIOLOGICAL|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
219426803|NCT02193672|PROCEDURE|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
219426804|NCT02193672|BEHAVIORAL|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
219426805|NCT03334474|OTHER||no intervention
219426806|NCT05902429|DRUG|Cladribine 10 mg oral tablet|Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
219426807|NCT02677220|DEVICE|CI532 cochlear implant|
219426808|NCT00965146|DEVICE|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
219426809|NCT00553553|DRUG|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
219426810|NCT00553553|DRUG|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
219426811|NCT01847261|DIETARY_SUPPLEMENT|Soy Dairy Protein Blend|
219426812|NCT01847261|DIETARY_SUPPLEMENT|Positive Control (Dairy Whey Protein)|
219426813|NCT00543621|OTHER|daily enteral nutritional product and/or behavioral changes|
219426814|NCT01244958|BIOLOGICAL|Rituximab|1000 mg Rituximab infusion
219426815|NCT01244958|DRUG|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
219426816|NCT02913742|PROCEDURE|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
219426817|NCT06371664|DRUG|Conventional Tray (1 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
219426818|NCT06371664|DRUG|Extended Tray (3 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
219426819|NCT02853981|DEVICE|Harmonic scalpel|a method for liver parenchymal transection
219426820|NCT02853981|DEVICE|Kelly clamp crush technique|a method for liver parenchymal transection
219191401|NCT05161117|BEHAVIORAL|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
219191402|NCT05263583|DRUG|Sepantronium Bromide|continuous intravenous infusion
219426821|NCT06013267|OTHER|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
219426822|NCT02448316|PROCEDURE|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
219426823|NCT02448316|DRUG|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
219426824|NCT02448316|DRUG|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
219426825|NCT02448316|BEHAVIORAL|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
219426826|NCT04213937|DRUG|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
219006126|NCT03762421|BEHAVIORAL|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
219426827|NCT04213937|DRUG|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
219426828|NCT05930990|BEHAVIORAL|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
219426829|NCT00685529|DRUG|Racemic formoterol|12 µg of racemic formoterol fumarate BID
219426830|NCT00685529|DRUG|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
219426831|NCT00685529|DRUG|Racemic formoterol|24 µg of racemic formoterol fumarate BID
219426832|NCT03285906|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
219426833|NCT00830960|DRUG|Prasugrel|Oral, daily, 90 days
219426834|NCT00830960|DRUG|Clopidogrel|Oral, daily, 90 days
219426835|NCT02855450|DRUG|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
219426836|NCT02855450|DRUG|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
219426837|NCT03383978|BIOLOGICAL|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
219426838|NCT03383978|DRUG|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
219576838|NCT04492865|DEVICE|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~* Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~* MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
219191403|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
219426839|NCT05767710|BEHAVIORAL|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
219426840|NCT05767710|BEHAVIORAL|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
219426841|NCT05767710|BEHAVIORAL|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
219576839|NCT00076804|BEHAVIORAL|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
219576840|NCT04677881|OTHER|Intervention group|intervention group: bread with sourdough control group: bread with yeast
219576841|NCT01284296|DRUG|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
219576842|NCT01284296|DEVICE|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
219006127|NCT03762421|BEHAVIORAL|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
219006128|NCT02086994|DRUG|misoprostol|given after the delivery of the anterior shoulder of the baby.
219006129|NCT02086994|DRUG|carbetocin|given after delivery of anterior shoulder
219006130|NCT05657834|DRUG|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
219006131|NCT01261689|DRUG|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
219006132|NCT01261689|OTHER|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
219006133|NCT04671407|DRUG|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
219006134|NCT02133287|DEVICE|AVI® Arsenic trioxide drug eluting stent delivery system|
219006135|NCT02133287|DEVICE|Firebird2® sirolimus eluting stent system|
219426842|NCT05767710|BEHAVIORAL|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
219426843|NCT05767710|BEHAVIORAL|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
219426844|NCT05767710|BEHAVIORAL|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
219576843|NCT03573960|DRUG|Lenvatinib|Lenvatinib capsules.
219006136|NCT00650624|DRUG|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
219006137|NCT00650624|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
219006138|NCT00650624|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
219006139|NCT00650624|DRUG|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
219006140|NCT03038334|DIETARY_SUPPLEMENT|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
219576844|NCT02828592|DRUG|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
219006141|NCT01631578|PROCEDURE|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
219006142|NCT06155409|DEVICE|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
219006143|NCT05004753|DIETARY_SUPPLEMENT|Artemisinin|a herbal supplement
219006144|NCT05004753|DRUG|Dexamethasone|corticosteroids
219576845|NCT02828592|DRUG|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
219576846|NCT02828592|RADIATION|Total Body Irradiation|300 cGy x1 dose (Day -1)
219576847|NCT02828592|DRUG|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
219576848|NCT02828592|DRUG|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
219576849|NCT05741645|OTHER|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
219576850|NCT05741645|OTHER|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
219576851|NCT05483387|DEVICE|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
219576852|NCT04355949|DIAGNOSTIC_TEST|Serum vitamin D, vitamin B12, folic acid|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
219576853|NCT05146349|OTHER|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
219191404|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
219191405|NCT04024020|OTHER|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
219426845|NCT05767710|BEHAVIORAL|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
219426846|NCT05767710|BEHAVIORAL|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
219426847|NCT05767710|BEHAVIORAL|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
219576854|NCT01095679|DRUG|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
219576855|NCT01095679|DRUG|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
219576856|NCT05291455|DRUG|Lacosamide|lacosamide will be given
219576857|NCT05291455|DRUG|Phenobarbital|phenobarbital will be given
219576858|NCT01227655|DRUG|BIA 9-1067|Capsules will be used.
219576859|NCT01227655|DRUG|Placebo|comparator
219576860|NCT01227655|DRUG|Levodopa|
219576861|NCT01227655|DRUG|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
219576862|NCT01227655|DRUG|Benserazide|DOPA decarboxylase inhibitor
219576863|NCT04445220|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
219006145|NCT00528385|DRUG|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
219576864|NCT05351814|OTHER|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
219760533|NCT05171153|OTHER|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
219760534|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
219760535|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
219760536|NCT00080574|PROCEDURE|Skin Biopsy|
219760537|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
219006146|NCT00053040|BIOLOGICAL|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
219006147|NCT00053040|PROCEDURE|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
219006148|NCT02520843|DRUG|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
219576865|NCT05747521|DRUG|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
219576866|NCT04297995|DRUG|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
219576867|NCT04297995|DRUG|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
219576868|NCT04297995|DRUG|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
219576869|NCT04297995|DRUG|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
219576870|NCT04297995|DRUG|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
219576871|NCT02496819|OTHER|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
219576872|NCT02496819|OTHER|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
219760538|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
219760539|NCT02343848|DEVICE|smart bracelet.|Physical activity will be evaluated using smart bracelet.
219426848|NCT06144242|BEHAVIORAL|Feedback on RTD metric|Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
219426849|NCT00426556|DRUG|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
219426850|NCT00426556|DRUG|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
219426851|NCT00426556|DRUG|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
219426852|NCT03442348|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
219576873|NCT02496819|OTHER|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
219576874|NCT04272476|OTHER|acupuncture and moxibustion|
219576875|NCT04272476|DRUG|Fluoxetine|
219576876|NCT02856009|OTHER|completion of a quality of life questionnaire|
219576877|NCT03528785|DRUG|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"* Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
219576878|NCT01274806|OTHER|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
219576879|NCT06304649|DEVICE|Cast or brace alternative|Waterproof alternative to a cast or brace for broken bones
219576880|NCT02006537|DRUG|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
219576881|NCT01405131|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
219576882|NCT01405131|DRUG|methylprednisolone|tablets 32 mg single dose
219576883|NCT04960319|DEVICE|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
219576884|NCT04068974|DRUG|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
219576885|NCT04068974|DRUG|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
219576886|NCT02159170|BIOLOGICAL|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
219576887|NCT05994820|BEHAVIORAL|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
219576888|NCT05994820|BEHAVIORAL|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
219576889|NCT05750147|OTHER|Blood Sample Collection|Blood for DNA and biomarker analysis
219576890|NCT02980250|DRUG|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
219576891|NCT02980250|DRUG|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
219576892|NCT02980250|DRUG|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
219576893|NCT02980250|DRUG|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
219576894|NCT00164749|DRUG|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
219576895|NCT00164749|DRUG|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
219576896|NCT00164749|DRUG|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
219576897|NCT00465049|OTHER|PRIMARY CLOSRE|SUTURE
219576898|NCT00465049|OTHER|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
219576899|NCT00465049|OTHER|SPONTANEOUS HALING|SECONDARY HEALING AFTER I\&D
219576900|NCT06052488|BEHAVIORAL|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
219576901|NCT03475628|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
219576902|NCT05264961|BEHAVIORAL|voice therapy|sessions of voice therapy
219576903|NCT00402220|DRUG|TMS|Active Transcranial Magnetic Stimulation
219426853|NCT03442348|DIETARY_SUPPLEMENT|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
219426854|NCT02604615|DRUG|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
219191406|NCT05646355|BEHAVIORAL|Proactive CRC Screening Outreach|Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
219426855|NCT02604615|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
219426856|NCT02604615|RADIATION|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
219426857|NCT04591496|BEHAVIORAL|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
219426858|NCT04591496|BEHAVIORAL|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
219426859|NCT05966246|DRUG|Arm I : Experimental (Prucalopride succinate group)|Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
219426860|NCT05966246|DRUG|Arm II : Control (Mosapride citrate group)|Control gourp taking mosapride citrate from day 1 day 5 after surgery
219426861|NCT04273009|DEVICE|Renew VS PTNS|These will be prescribed and applied as described above.
219426862|NCT05184127|DRUG|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
219426863|NCT05184127|COMBINATION_PRODUCT|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
219426864|NCT04180800|OTHER|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
219426865|NCT01597037|BEHAVIORAL|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
219426866|NCT01415856|DEVICE|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
219426867|NCT01415856|DEVICE|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
219576904|NCT00402220|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
219576905|NCT01056094|DRUG|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
219006149|NCT02959944|DRUG|ibrutinib|Ibrutinib capsules administered orally daily
219006150|NCT02959944|DRUG|Placebo|Placebo capsules administered orally daily
219006151|NCT02959944|DRUG|Prednisone|Prednisone administered daily
219191407|NCT05646355|BEHAVIORAL|Usual Care|Participants will not receive additional outreach from the study team regarding CRC screening.
219191408|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
219426868|NCT05735509|DEVICE|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
219426869|NCT00354497|OTHER|physiologic testing|
219426870|NCT00354497|OTHER|study of socioeconomic and demographic variables|
219426871|NCT00354497|PROCEDURE|evaluation of cancer risk factors|
219426872|NCT00354497|PROCEDURE|mutation carrier screening|
219426873|NCT00354497|PROCEDURE|study of high risk factors|
219426874|NCT03242005|DEVICE|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
219426875|NCT03242005|DEVICE|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
219426876|NCT05096702|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
219426877|NCT05096702|DRUG|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
219426878|NCT05096702|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
219426879|NCT01191905|DRUG|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
219426880|NCT01191905|DRUG|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
219426881|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
219426882|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
219426883|NCT02288065|DRUG|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
219426884|NCT04907591|DEVICE|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
219426885|NCT06213129|DEVICE|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
219426886|NCT02066194|PROCEDURE|Electroacupuncture|
219426887|NCT05243394|OTHER|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
219576906|NCT02283450|DRUG|Qiliqiangxin Capsule|
219576907|NCT02114957|DIETARY_SUPPLEMENT|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
219576908|NCT01184248|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
219576909|NCT00177463|DRUG|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
219191409|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
219191410|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
219426888|NCT05243394|OTHER|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
219426889|NCT05243394|OTHER|Treadmill gait training|Progressive treadmill gait training
219426890|NCT04810234|DEVICE|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
219426891|NCT04047758|DRUG|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
219426892|NCT04047758|DRUG|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
219426893|NCT00507416|DRUG|Bortezomib|Bortezomib bolus intravenous (IV) injection
219426894|NCT00507416|DRUG|Dexamethasone|Dexamethasone for oral administration
219426895|NCT00507416|DRUG|Melphalan|Melphalan for oral administration
219426896|NCT00507416|DRUG|Prednisone|Prednisone for oral administration
219426897|NCT00507416|DRUG|Thalidomide|Thalidomide for oral administration
219426898|NCT04883658|DRUG|CKD-348(2)|QD, PO
219426899|NCT04883658|DRUG|CKD-828, D097, D337|QD, PO
219426900|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood"
219426901|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample"
219426902|NCT00773565|DIETARY_SUPPLEMENT|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
219426903|NCT04428359|DRUG|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
219576910|NCT03581513|PROCEDURE|Deferred or Immediate Stent Implantation|IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
219576911|NCT02171390|DRUG|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
219576912|NCT02171390|DRUG|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
219760540|NCT01078948|DEVICE|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
219426904|NCT04428359|DRUG|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
219426905|NCT00150059|DRUG|Pimecrolimus Cream 1%|
219426906|NCT02719470|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
219426907|NCT04742270|DEVICE|SIMEOX+ respiratory physiotherapy telecare|"Every 10 days, the patient's expert physiotherapist will contact the patient by video-transmission or telephone call for motivational reinforcement and technical support in the use of the device.~During these phone calls, a quick 3-question questionnaire will be administered to the patient to monitor events of hemoptysis, chest pain and clinical symptoms of gastroesophageal reflux disease: pyrosis.If patients report this type of event, the physiotherapist will inform the patient's physician for management at his/her discretion.~The expert physiotherapist will also conduct this sessions in order to increase the patient's motivation and compliance to the device. In order to do this, he will identify (in collaboration with the patient), the patient's difficulties and obstacles and he will try to find solutions with him."
219426908|NCT02350933|PROCEDURE|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
219426909|NCT03304470|DRUG|ATx201 2% Cream|Anhydrous Cream
219426910|NCT03304470|DRUG|ATx201 Cream Vehicle|Anhydrous Cream
219760541|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
219006152|NCT01521208|DEVICE|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
219006153|NCT01521208|OTHER|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
219006154|NCT00203177|DRUG|rasagiline mesylate|0.5 rasagiline mesylate
219006155|NCT00203177|DRUG|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
219006156|NCT06182189|OTHER|Observation of patients with a benign prostatic hyperplasia condition|Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
219426911|NCT02157506|DRUG|CXL-1427|
219426912|NCT02157506|DRUG|Placebo|
219426913|NCT02680886|DEVICE|Novosyn® Quick|Skin closure
219426914|NCT02252692|DRUG|Enalapril|oral administration
219426915|NCT03101514|DRUG|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
219426916|NCT03101514|DRUG|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
219426917|NCT04314596|OTHER|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
219006157|NCT03507894|BEHAVIORAL|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
219191411|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
219426918|NCT04314596|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
219426919|NCT03273517|PROCEDURE|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
219426920|NCT04662216|PROCEDURE|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
219760542|NCT01693367|DEVICE|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
219760543|NCT01693367|DEVICE|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
219760544|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
219760545|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
219006158|NCT00740844|DEVICE|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
219006159|NCT00003081|BIOLOGICAL|filgrastim|
219426921|NCT04662216|PROCEDURE|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
219426922|NCT01021813|DRUG|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
219426923|NCT01021813|DRUG|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
219426924|NCT04578106|BIOLOGICAL|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
219426925|NCT03771599|OTHER|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
219426926|NCT03771599|OTHER|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
219426927|NCT02103452|PROCEDURE|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
219426928|NCT04905875|PROCEDURE|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
219426929|NCT02790671|DRUG|DS-8500a|DS-8500a 25mg tablet
219426930|NCT02790671|DRUG|Itraconazole|200mg itraconazole
219006160|NCT00003081|DRUG|busulfan|
219006161|NCT00003081|DRUG|melphalan|
219006162|NCT00003081|DRUG|thiotepa|
219006163|NCT00003081|PROCEDURE|peripheral blood stem cell transplantation|
219006164|NCT00003081|RADIATION|radiation therapy|
219006165|NCT02775162|DEVICE|Normothermic Machine Perfusion (NMP)|
219006166|NCT02775162|OTHER|Standard of Care (Ice)|
219006167|NCT01810354|DRUG|Cefazolin|
219006168|NCT06049784|DEVICE|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
219006169|NCT06049784|DEVICE|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
219426931|NCT03624764|PROCEDURE|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
219760546|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
219760547|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
219426932|NCT03624764|PROCEDURE|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
219760548|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
219760549|NCT05850767|OTHER|Sleep deprivation|Participants will stay fully awake for 24 hours
219426933|NCT05101460|DEVICE|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
219006170|NCT03325361|OTHER|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
219426934|NCT05580471|DEVICE|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
219426935|NCT00879606|DRUG|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
219426936|NCT00879606|DRUG|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
219426937|NCT00977015|DRUG|Treatment A|Inhaled, 750/150, single dose
219426938|NCT00977015|DRUG|Treatment B|Inhaled, 750/150, single dose
219426939|NCT00764478|DRUG|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
219426940|NCT00764478|DRUG|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
219426941|NCT00764478|DRUG|Placebo|placebo sublingual tablet, administered BID for 21 days
219426942|NCT02322684|DEVICE|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
219426943|NCT04065191|OTHER|High-intensity interval training|Heart rate based high-intensity interval training
219426944|NCT04904965|DRUG|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
219426945|NCT04904965|DRUG|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
219426946|NCT04904965|DRUG|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
219006171|NCT03886350|OTHER|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
219006172|NCT03454893|DRUG|AVR-RD-01|Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
219191412|NCT05928013|DIAGNOSTIC_TEST|Neurothesiometer|The 'gold standard' device for Vibration Perception Threshold testing
219426947|NCT04904965|DRUG|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
219426948|NCT04257084|DIAGNOSTIC_TEST|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
219426949|NCT00019721|BIOLOGICAL|MART-1 antigen|
219426950|NCT00019721|BIOLOGICAL|aldesleukin|
219426951|NCT00019721|BIOLOGICAL|gp100 antigen|
219426952|NCT00019721|BIOLOGICAL|incomplete Freund's adjuvant|
219426953|NCT02986685|DRUG|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
219426954|NCT02986685|DRUG|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
219426955|NCT05184309|OTHER|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
219576913|NCT01484184|DRUG|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
219426956|NCT05184309|OTHER|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
219426957|NCT03648307|DIAGNOSTIC_TEST|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
219426958|NCT00213161|DRUG|iron supplement, iron drops|
219426959|NCT05052528|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
219426960|NCT05052528|DRUG|Cyclophosphamide|Given IV
219426961|NCT05052528|DRUG|Fludarabine Phosphate|Given IV
219426962|NCT05052528|BIOLOGICAL|Rituximab|Given IV
219426963|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
219426964|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
219426965|NCT04462757|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
219426966|NCT05557734|PROCEDURE|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
219426967|NCT05557734|PROCEDURE|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
219426968|NCT00883220|BEHAVIORAL|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
219426969|NCT03823092|DIAGNOSTIC_TEST|polarization sensitivity|test of polarization vision as described in Study Description
219426970|NCT02450734|PROCEDURE|Ultrasound-guided intermediate cervical plexus block|
219426971|NCT01740388|DRUG|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
219426972|NCT01740388|DRUG|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
219576914|NCT05212064|DEVICE|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
219006173|NCT04876274|BEHAVIORAL|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
219426973|NCT05344625|DRUG|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
219426974|NCT04490317|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients"
219426975|NCT04490317|PROCEDURE|Hyperbaric oxygen therapy|"1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients"
219426976|NCT01025258|BEHAVIORAL|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
219426977|NCT01025258|BEHAVIORAL|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
219426978|NCT01369212|DRUG|Tenofovir|300 mg daily for 192 weeks (4 years)
219426979|NCT01369212|DRUG|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
219426980|NCT01309438|DRUG|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
219426981|NCT01309438|DRUG|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
219426982|NCT01309438|DRUG|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
219426983|NCT01309438|DRUG|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
219426984|NCT00862121|DRUG|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
219426985|NCT00862121|DRUG|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
219426986|NCT04007601|DEVICE|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
219426987|NCT04007601|DEVICE|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
219426988|NCT04358198|DIAGNOSTIC_TEST|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
219426989|NCT04345497|OTHER|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
219426990|NCT04345497|OTHER|Standard Of Care|Standard of Care
219426991|NCT02943005|PROCEDURE|Rotator cuff repair|
219426992|NCT03077113|DIAGNOSTIC_TEST|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
219426993|NCT03077113|DIAGNOSTIC_TEST|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
219426994|NCT03051841|DRUG|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
219426995|NCT00895193|OTHER|Apple pectin|Apple pectin 2000mg
219426996|NCT00895193|DRUG|Aspirin 325 mg|Aspirin 325 mg
219576915|NCT05212064|OTHER|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
219576916|NCT03507413|DRUG|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
219576917|NCT03507413|DRUG|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
219576918|NCT04130659|COMBINATION_PRODUCT|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
219576919|NCT04130659|DRUG|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
219576920|NCT04130659|DEVICE|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
219576921|NCT03338179|BEHAVIORAL|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
219426997|NCT00895193|OTHER|Placebo|Placebo
219426998|NCT02637726|DRUG|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
219426999|NCT02637726|DRUG|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
219427000|NCT02637726|DRUG|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
219427001|NCT02637726|DEVICE|EEG Monitoring|Maintaining a bispectral index between 45 and 55
219427002|NCT02637726|DRUG|Remifentanil|Remifentanil at discretion of the anesthesiologist
219427003|NCT03283618|BEHAVIORAL|Video Conferencing Group|
219427004|NCT02084784|DRUG|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
219427005|NCT02084784|DRUG|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
219427006|NCT00171314|DRUG|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
219427007|NCT00171314|DRUG|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
219427008|NCT05508672|OTHER|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
219427009|NCT05508672|OTHER|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
219427010|NCT04284904|DIAGNOSTIC_TEST|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
219427011|NCT05638906|DEVICE|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
219427012|NCT04949724|OTHER|translation and adaptation study|translation and adaptation study
219576922|NCT01430975|DRUG|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
219576923|NCT01430975|DRUG|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
219576924|NCT05727475|PROCEDURE|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
219576925|NCT05727475|PROCEDURE|Fluoride gel application|Fluoride gel application 1.23%
219576926|NCT03511170|DRUG|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
219576927|NCT03511170|DRUG|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
219427013|NCT02978664|PROCEDURE|Air insufflation|Air insufflation during colonoscopy including insertion phase
219427014|NCT02978664|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
219427015|NCT02978664|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
219427016|NCT01692912|OTHER|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
219427017|NCT04924010|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
219427018|NCT04924010|BEHAVIORAL|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
219427019|NCT06092632|OTHER|Pigmented rice|Cooked black rice
219427020|NCT06092632|OTHER|White Rice|Cooked white rice
219427021|NCT04982835|DEVICE|M6-C Artificial Cervical Disc|An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.
219427022|NCT04982835|DEVICE|ACDF|One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.
219427023|NCT07011901|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD. It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).
219427024|NCT00638924|OTHER|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
219427025|NCT01325324|DEVICE|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
219427026|NCT07017933|DEVICE|Renal assist device|The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.
219427027|NCT02259127|DRUG|Dolutegravir|
219427028|NCT02259127|DRUG|Standard of Care|PI or non nucleoside transcriptase inhibitors
219427029|NCT06695026|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
219427030|NCT06695026|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
219191413|NCT05928013|DIAGNOSTIC_TEST|NERVE|The experimental device for Vibration Perception Threshold testing developed by the project team
219427031|NCT06695026|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
219427032|NCT04896190|OTHER|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
219576928|NCT00838942|BEHAVIORAL|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
219191414|NCT03676894|DEVICE|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
219191415|NCT03676894|DEVICE|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
219191416|NCT03676894|DEVICE|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
219760550|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
219760551|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
219760552|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
219427033|NCT03395756|DRUG|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
219760553|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
219427034|NCT01809678|BEHAVIORAL|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
219427035|NCT01809678|BEHAVIORAL|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
219427036|NCT01809678|OTHER|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
219427037|NCT02178501|DIETARY_SUPPLEMENT|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
219427038|NCT02336412|OTHER|SMS reminder|Daily SMS medication reminder
219427039|NCT04093687|OTHER|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
219427040|NCT01005446|DEVICE|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
219427041|NCT07047365|DRUG|TQB2930+ chemotherapy|TQB2930 injection is a HER2 bispecific antibody drug； Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
219427042|NCT07047365|DRUG|Trastuzumab+ chemotherapy|Trastuzumab is a HER2-specific targeted drug； Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
219427043|NCT05945329|DEVICE|GalaFLEX LITE™ Scaffold|Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue
219427044|NCT05945329|OTHER|Standard surgery|Surgery performed without the use of a scaffold
219427045|NCT01635634|OTHER|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
219427046|NCT06762275|DIAGNOSTIC_TEST|Diagnostic strategy|GPs' use of an externally validated cPR followed by CRP-POCT in the medium risk group. See for details: Detailed description - Intervention.
219427047|NCT07072195|DRUG|AMC6156 0.1mg|Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
219427048|NCT07072195|DRUG|AMC6156 0.3mg|Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
219427049|NCT07072195|DRUG|AMC6156 1.0mg|Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
219427050|NCT07072195|DRUG|Placebo|Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
219427051|NCT05266794|DRUG|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
219427052|NCT05266794|DRUG|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
219576929|NCT01520636|PROCEDURE|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
219576930|NCT01520636|PROCEDURE|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
219576931|NCT04016337|DIETARY_SUPPLEMENT|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
219576932|NCT02790307|DEVICE|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
219576933|NCT03866915|DIAGNOSTIC_TEST|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
219576934|NCT03866915|DIAGNOSTIC_TEST|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
219427053|NCT04007666|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
219427054|NCT04007666|BEHAVIORAL|Control Group|Coping-focused treatment.
219427055|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
219427056|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
219427057|NCT07080021|DRUG|Standard Reagents, Pancreatic Cancer|This is a non-interventional study. Neoadjuvant therapy regimens and surgical approaches are determined solely by attending physicians according to clinical treatment standards.
219427058|NCT07084870|OTHER|High flow nasal oxygen|Patients in group I then received HFNO. The initial flow rate was adjusted to 50L/min and gradually reduced as tolerated by the patient. The humidification chamber temperature was set at 37°C and gradually reduced to the patient comfort. FiO2 was 100% and then gradually reduced over time according to improvement in oxygenation.
219427059|NCT07084870|OTHER|non invasive BIPAP|Patients in group II received oxygen therapy via intermittent non- invasive positive pressure ventilation, BiPAP mode ventilator using a face mask. BiPAP settings were adjusted as follows: P (low) of 5cm H2O to 10cm H2O and an inspiratory pressure P (high) of 10-20cm H2O . FiO2 was adjusted to 100% and then gradually reduced over time according to improvement in oxygen saturation and PaO2/Fio2 ratio. Respiratory rate was adjusted from 10-12 at then changed according to patient´s respiratory effort and according to ABG.
219576935|NCT06107478|OTHER|Self-report questionnaires (only for parents)|"Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2."
219760554|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
219191417|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
219427060|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
219427061|NCT03196427|DRUG|Vedolizumab|Vedolizumab intravenous infusion
219427062|NCT07088380|DRUG|Ketamine Hydrochloride|Ketamine will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
219427063|NCT07088380|DRUG|Placebo|Placebo will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
219427064|NCT06906367|DRUG|migalastat HCl|Non-interventional study of participants receiving migalastat HCl 150 mg
219427065|NCT06906367|DRUG|ERT|Non-interventional study of participants receiving enzyme replacement therapy
219427066|NCT07091890|DEVICE|Fluoride gel|After non-surgical therapy, 6-8 g of a gel containing 12,500 ppm of fluoride was applied for 4 min using a disposable tray appropriately sized for the patient's mouth. As per the guidelines, the patient was asked to briefly rinse their mouth with water. The aim was to remineralize the dental enamel to make it less susceptible to acid attacks caused by low salivary pH and the byproducts of bacterial metabolism
219427067|NCT07091890|DEVICE|Fluoride varnish|After non-surgical therapy, a fluoride varnish containing 7,700 ppm of fluoride in a homogeneous solution was evenly distributed over the dental surfaces using a micro-brush. Patients were instructed to spit out excess saliva but not to rinse their mouth with water, and to refrain from eating or drinking for at least 60 min afterward. After drying, the varnish formed a fluoride-rich layer on the enamel, increasing the concentration by up to four times. Despite the high concentration of fluoride, the resin component of the varnish allowed for a slow, controlled release of fluoride over time, thus preventing its immediate loss and minimizing the amount ingested by the patient. The purpose was to prevent mineral loss from the enamel and promote its restoration, making the dental tissue more resistant to the acidic pH of saliva caused by the production of organic acids through bacterial metabolism.
219427068|NCT07090408|BEHAVIORAL|Artificial intelligence support|Each student in the intervention group will be asked to solve a given case example using ChatGPT support. However, students in the control group will be asked to analyze the case using their own academic knowledge without ChatGPT support.
219427069|NCT07092293|OTHER|occupational therapy|N/A as there is no intervention for this study
219427070|NCT07090993|BEHAVIORAL|sustainable nutrition education|"The educational intervention applied to the experimental group was carried out in 12 sessions. The knowledge-attitude-behavior education model was adopted in the education sessions. The education program, which was created by obtaining expert opinions, consists of five basic topics and was carried out with the interactive education method.~Sessions;~1. Environmental effects during the production of animal and plant foods~2. Production and environmental effects of processed foods~3. Foods with low environmental impact and nutrition models~4. What are food losses and wastes?~5. Workshops~6. Processing and storage of foods~7. Consumption of local, regional and seasonal fruits, vegetables and fish~8. The importance of sustainable nutrition and alternative protein sources~9. Mediterranean diet model~10. Preparing a shopping list~11. Reading labels and nutritional content~12. Watching a documentary on the harms of packaged foods on living beings and the environment"
219427071|NCT07091188|BEHAVIORAL|Health education, capacity building and economic incentives|"1. Social media platform-based for health education. Pregnant women in the same gestational month will be invited to join specific WeChat group chats tailored to their similar health education and management needs.~2. Capacity building. ANC providers at township hospitals will participate in short-term, small-class training courses designed to cover essential aspects of antenatal care prior to the intervention with the pregnant women.~3. Economic incentives. To encourage ANC attendance, a monetary reward system will be implemented for village doctors every time they successfully identify and invite a newly pregnant woman to initiate her ANC visit."
219427072|NCT07090304|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
219427073|NCT07090304|DIAGNOSTIC_TEST|FIT-sDNA|FIT-sDNA test combines Fecal Immunochemical Test (FIT) and stool DNA (sDNA) analysis. It detects hemoglobin in stool through FIT to identify occult blood in the gastrointestinal tract and simultaneously analyzes specific DNA mutations or epigenetic alterations (such as methylation changes) in stool DNA to assess the risk of colorectal neoplasms.
219427074|NCT07091305|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|"Induction: QL1706 5 mg/kg IV on Day 1, Etoposide: 100 mg/m² IV on Days 1-3, Cisplatin or Carboplatin: Cisplatin 75 mg/m² IV on Day 1 or Cisplatin 25 mg/m² IV on Days 1-3, Or Carboplatin AUC = 5 IV on Day 1, Q3W, for a total of 2 cycles.~Chemoradiotherapy：Thoracic Radiotherapy（60 Gy in 30 fractions, once daily (2 Gy/fraction), or 45 Gy in 30 fractions, twice daily (1.5 Gy/fraction)），Etoposide 100 mg/m² IV on Days 1-3, Cisplatin either 75 mg/m² IV on Day 1, or 25 mg/m² IV on Days 1-3, Or Carboplatin AUC=5 IV on Day 1 PCI: Patients achieving or approaching complete response, per investigator assessment, 25Gy in 10 fractions.~Consolidation: QL1706 5 mg/kg IV on Day 1, Q3W"
219427075|NCT07091240|BEHAVIORAL|Behavioral Parent Training|Family Check-Up® Online is delivered through a secure website that can be accessed via computer or phone at participating caregivers' convenience. Caregivers will complete the Developmental Early Childhood Instrument for Deciding Effectively about Mental Health (DECIDE) tool, a risk calculator that screens for early signs of future mental health challenges, at their child's 24- or 30-month well-check visit with their pediatrician. Clinicians will use the DECIDE tool risk calculator score to refer caregivers of at-risk children to FCU-O. Caregivers may use FCU-O independently, or they may work with a trained coach who will facilitate their use of the program. Participation is open to caregivers who are referred to FCU-O based on their DECIDE risk calculator score by their child's pediatrician and is available in English or Spanish. Participants will also complete assessments via survey and direct observation before beginning FCU-O, and 6- and 12-months after their referral to FCU-O.
219427076|NCT07091175|BIOLOGICAL|Dupilumab|Subcutaneous injection of Dupilumab for 24 weeks (weight based dosing)
219576936|NCT06107478|OTHER|Interview (only for parents)|"Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances."
219576937|NCT06107478|OTHER|Clinical data collection (only concerning Children)|The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
219427077|NCT07091175|DRUG|Placebo|Subcutaneous injection of normal saline placebo (matching dupilumab subcutaneous injection dosing) for 24 weeks
219427078|NCT07091175|DRUG|Co-intervention of Prednisolone wean during randomised controlled phase|"The Prednisolone wean will commence 2 weeks after receiving the loading dose of Dupilumab/placebo, with each weaning step 2 weeks apart. Prednisolone will be first weaned to the same dose every other day, if the current dosing is daily (or more frequent). The dose will subsequently weaned to 4 pre-determined levels of 30mg/m2, 15mg/m2, 10mg/m2 and 5mg/m2 every other day, rounding up to the nearest 5mg. For instance, if the current dose of prednisolone is 12mg/m2 every other day, the patient will decrease the dose to 10mg/m2 every other day for 2 weeks, followed by 5mg/m2 every other day for 2 weeks, before discontinuing the drug.~If patients enter the trial on Mycophenolate or Levamisole, this will be continued for the duration of the trial at the same dose."
219427079|NCT07091175|BIOLOGICAL|Dupilumab open label extension phase|Upon nephrotic relapse, participants will be unmasked. If they were given placebo, they will be invited to enrol in an open label extension phase to receive dupilumab for 24 weeks (with dosing identical to the experimental arm).
219427080|NCT07091175|DRUG|Co-intervention of Prednisolone wean during open label extension phase|Patients will also receive prednisolone 60mg/m2/day as a single daily dose (max 80mg OD) until in remission for 3 days, before prednisolone is weaned to 40mg/m2 every other day for 2 weeks. Doses should be rounded up to nearest 5mg where possible. Prednisolone will then be weaned in steps as per the randomised controlled phase. If patients do not enter full remission after 2 weeks from enrolment into the extension phase, they will be removed from the study. Additional agents, e.g. Mycophenolate, Levamisole, Calcineurin inhibitors should not be started during this time unless there is strong clinical indication.
219427081|NCT07091682|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
219576938|NCT03501537|PROCEDURE|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
219576939|NCT04710537|OTHER|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
219576940|NCT04710537|OTHER|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
219576941|NCT05607251|OTHER|No intervention|There is no intervention as this is an observational study
219576942|NCT04888676|PROCEDURE|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
219576943|NCT03987594|PROCEDURE|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
219576944|NCT03987594|PROCEDURE|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
219576945|NCT04316130|DEVICE|Uincare Homeplus|Interactive digital healthcare system
219576946|NCT04316130|OTHER|Brochure|Brochure
219576947|NCT01348984|DRUG|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
219576948|NCT01348984|DRUG|placebo patch|group 2 = placebo patch
219576949|NCT02760706|DEVICE|Computed Tomography scan|
219006174|NCT05841251|DRUG|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
219006175|NCT05841251|DRUG|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
219006176|NCT02051608|DRUG|Placebo|Participants received Placebo SC injection Q4W.
219427082|NCT03143972|DRUG|Dexmedetomidine|Single drug administration
219427083|NCT03143972|DRUG|Remifentanil|Single drug administration
219427084|NCT00805922|OTHER|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
219576950|NCT03852459|DRUG|S-Ibuprofen|Topical Gel 5%
219576951|NCT03852459|DRUG|Vehicle|Vehicle Gel
219576952|NCT00697606|DEVICE|Seprafilm®|Seprafilm® placed at time of primary cesarean
219576953|NCT00697606|OTHER|Control|no Seprafilm® used at primary cesarean
219576954|NCT01981499|DRUG|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
219576955|NCT01981499|DRUG|Placebo|Placebo tablets
219576956|NCT01981499|DRUG|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
219576957|NCT01981499|DRUG|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
219576958|NCT01981499|DRUG|10 mg cetirizine|Single 10 mg dose of cetirizine
219576959|NCT01981499|DRUG|Placebo|Placebo tablets
219006177|NCT02051608|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
219576960|NCT05310799|OTHER|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
219760555|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
219427085|NCT02578823|DEVICE|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
219427086|NCT02578823|DEVICE|Arcticgel™|
219427087|NCT02578823|PROCEDURE|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
219427088|NCT04407455|DIAGNOSTIC_TEST|Karaduman Chewing Performance Scale|For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
219427089|NCT07091149|BEHAVIORAL|CBT-I|Cognitive behavioral therapy for insomnia
219427090|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for pretest genetic education
219427091|NCT07091617|OTHER|Genetic Testing|Complete standard of care genetic testing
219427092|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for disclosure of results
219427093|NCT07091617|OTHER|Internet-Based Intervention|Receive access to Genetic Journey Chatbot
219427094|NCT07091617|OTHER|Educational Intervention|Complete digital pre-test genetic education
219427095|NCT07091617|BEHAVIORAL|Patient Navigation|Utilize chatbot to answer questions, assess barriers, and provide reminders for next steps during the testing period
219427096|NCT07091617|OTHER|Interview|Complete interview
219427097|NCT07091617|OTHER|Survey Administration|Ancillary studies
219427098|NCT07092085|DIAGNOSTIC_TEST|AI model|An AI model provides an objective and rapid assessment of potential mental health risks in students by holistically analyzing their facial expressions, vocal characteristics, and linguistic content from data.
219427099|NCT01987349|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
219427100|NCT01987349|BIOLOGICAL|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
219427101|NCT05481203|BEHAVIORAL|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
219427102|NCT05481203|BEHAVIORAL|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
219427103|NCT05018117|DRUG|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
219427104|NCT05018117|OTHER|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
219427105|NCT04151095|OTHER|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
219427106|NCT04151095|OTHER|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
219576961|NCT05333237|DIETARY_SUPPLEMENT|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
219576962|NCT05333237|DIETARY_SUPPLEMENT|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
219576963|NCT05333237|DIETARY_SUPPLEMENT|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
219576964|NCT04458493|BEHAVIORAL|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
219576965|NCT04458493|DIETARY_SUPPLEMENT|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
219427107|NCT03897868|DRUG|HCP1803|HCP1803
219427108|NCT03897868|DRUG|Amlodipine|Amlodipine
219427109|NCT03897868|DRUG|Losartan|Losartan
219427110|NCT03897868|DRUG|Placebo|Placebo
219427111|NCT00961922|OTHER|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
219427112|NCT00961922|OTHER|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
219427113|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
219427114|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
219427115|NCT00397176|DRUG|desvenlafaxine succinate sustained release (DVS SR)|
219427116|NCT06026007|OTHER|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
219427117|NCT06026007|OTHER|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
219427118|NCT06026007|OTHER|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
219427119|NCT02452801|DRUG|ALKS 5461|Single dose, given orally
219576966|NCT05010733|DEVICE|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
219576967|NCT05010733|DEVICE|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
219576968|NCT00578071|DRUG|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
219427120|NCT03728712|DIAGNOSTIC_TEST|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
219427121|NCT05452772|DRUG|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
219427122|NCT05452772|DRUG|Niacin|Participants will received two niacin sessions, 1 week apart
219427123|NCT03521661|PROCEDURE|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
219427124|NCT06554717|DRUG|Tesamorelin|Tesamorelin WR 1.28 mg given subcutaneously daily
219427125|NCT06554717|DRUG|Placebo|Identical placebo injection given subcutaneously daily
219427126|NCT06554717|BEHAVIORAL|Exercise|Home-based semi-supervised exercise program
219427127|NCT06120465|OTHER|Yoga|Yoga classes
219427128|NCT03326869|DEVICE|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
219427129|NCT01630798|DRUG|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
219427130|NCT03788967|DRUG|TBPM-PI-HBr|TBPM-PI-HBr tablets administered orally.
219006178|NCT02829450|OTHER|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
219006179|NCT03441776|OTHER|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
219576969|NCT00578071|DRUG|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
219576970|NCT00578071|DRUG|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
219576971|NCT00578071|RADIATION|Radiation Therapy (RT)|Daily for 6 weeks
219760556|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
219760557|NCT01555060|DIETARY_SUPPLEMENT|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
219760558|NCT06000930|DIAGNOSTIC_TEST|Troponin fragmentation|laboratory test from blood sample
219427131|NCT03788967|DRUG|Ertapenem|Antibiotic Therapy for cUTI.
219427132|NCT03788967|DRUG|Dummy Infusion|Dummy intravenous infusion.
219427133|NCT03788967|DRUG|Dummy tablets|Dummy tablets orally.
219576972|NCT03605251|DRUG|TAS5315 low dose|Oral administration for 12 or 36 weeks
219576973|NCT03605251|DRUG|TAS5315 high dose|Oral administration for 12 or 36 weeks
219760559|NCT03488329|DIETARY_SUPPLEMENT|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
219760560|NCT03946969|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
219760561|NCT03946969|DRUG|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
219760562|NCT01870869|DEVICE|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
219006180|NCT03441776|OTHER|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
219427134|NCT03927911|DRUG|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
219576974|NCT03605251|DRUG|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
219576975|NCT06310928|OTHER|Thermal Blanket|Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
219427135|NCT03927911|DRUG|Standard of Care|Standard of Care
219427136|NCT04432376|DRUG|miconazole 2% oil|Drug treatment of otomycosis for 14 days
219427137|NCT04432376|DRUG|vehicle oil|Placebo treatment of otomycosis for 14 days
219427138|NCT03122249|BEHAVIORAL|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
219427139|NCT01025687|DIETARY_SUPPLEMENT|water with noncalorie sweetener|
219427140|NCT01025687|DIETARY_SUPPLEMENT|water with glucose|
219427141|NCT01025687|BEHAVIORAL|TV program showed while feeding|
219427142|NCT01025687|BEHAVIORAL|TV program showed while feeding|
219427143|NCT01824693|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
219427144|NCT01824693|DRUG|Busulfan|Given IV
219427145|NCT01824693|DRUG|Cyclophosphamide|Given IV
219427146|NCT01824693|DRUG|Fludarabine Phosphate|Given IV
219427147|NCT01824693|OTHER|Laboratory Biomarker Analysis|Correlative studies
219427148|NCT01824693|DRUG|Melphalan|Given IV
219427149|NCT01824693|DRUG|Mycophenolate Mofetil|Given IV or PO
219427150|NCT01824693|OTHER|Pharmacological Study|Correlative studies
219427151|NCT01824693|DRUG|Tacrolimus|Given IV or PO
219427152|NCT00211874|BEHAVIORAL|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
219427153|NCT01376401|DRUG|Bendamustine|
219427154|NCT01376401|DRUG|Velcade|
219427155|NCT01376401|DRUG|Prednisone|
219427156|NCT04147507|OTHER|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
219427157|NCT04147507|BEHAVIORAL|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
219427158|NCT00498849|DEVICE|CPAP|
219576976|NCT00336128|BEHAVIORAL|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
219576977|NCT00336128|BEHAVIORAL|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
219760563|NCT00712517|DRUG|propofol|propofol anesthesia 3-5mg/kg
219427159|NCT02979366|DRUG|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
219427160|NCT02979366|DRUG|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
219427161|NCT06527677|DRUG|ANT3310|ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
219427162|NCT06527677|DRUG|Meropenem|meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
219427163|NCT06638541|RADIATION|Prostate radical radiotherapy|Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
219427164|NCT05189132|DIAGNOSTIC_TEST|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
219427165|NCT05189132|DIAGNOSTIC_TEST|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
219427166|NCT05189132|DIAGNOSTIC_TEST|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
219427167|NCT02533687|PROCEDURE|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
219427168|NCT02533687|PROCEDURE|Bipolar TURP-2|Bipolar TURP
219427169|NCT02533687|PROCEDURE|Monopolar TURP|Monopolar TURP
219760564|NCT00712517|DRUG|sevoflurane|sevoflurane anesthesia
219427170|NCT02760160|OTHER|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
219427171|NCT03628599|DEVICE|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
219427172|NCT03628599|DEVICE|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
219427173|NCT06553365|DRUG|FCN-159|FCN-159 8mg qd po
219427174|NCT04745078|OTHER|Caboxy30|carboxy30 to periorbital dark halos
219427175|NCT04745078|OTHER|Caboxy60|carboxy60 to periorbital dark halos
219427176|NCT04019210|PROCEDURE|MODIFIED TRABECULECTOMY|Rectangular scleral flap
219427177|NCT01573403|DRUG|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
219427178|NCT01573403|DRUG|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
219427179|NCT01573403|DRUG|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
219427180|NCT04101669|DEVICE|RESET Liner|The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
219427181|NCT04101669|OTHER|Sham|Patient receives upper endoscopy but no treatment
219427182|NCT00908622|PROCEDURE|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
219427183|NCT00908622|PROCEDURE|Cardiac revascularization|Cardiac revascularization
219427184|NCT02931526|DRUG|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
219427185|NCT01248403|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
219427186|NCT01248403|DRUG|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
219427187|NCT03228706|BEHAVIORAL|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
219427188|NCT05072756|OTHER|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
219427189|NCT06014957|DRUG|spinal anesthesia|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
219427190|NCT06014957|DRUG|saddle block|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
219427191|NCT03771807|DIETARY_SUPPLEMENT|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
219427192|NCT03771807|OTHER|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
219427193|NCT03771807|OTHER|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
219427194|NCT05779345|PROCEDURE|surgery|short implant placement
219427195|NCT05246488|DIAGNOSTIC_TEST|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
219427196|NCT02468206|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
219427197|NCT02468206|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
219427198|NCT02468206|DRUG|N-butyl-2-cyanoacrylate|
219427199|NCT02468206|DRUG|Lauromacrogol|
219427200|NCT05450744|DRUG|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
219427201|NCT04246125|PROCEDURE|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
219427202|NCT06094972|BEHAVIORAL|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
219576978|NCT03987347|OTHER|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
219006181|NCT05061810|BEHAVIORAL|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
219427203|NCT06094972|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
219427204|NCT04798846|PROCEDURE|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
219427205|NCT06415162|OTHER|Cooling Pillowcases|No intervention will be given to the patients in the control group.
219427206|NCT00962754|PROCEDURE|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
219427207|NCT00323024|DRUG|NX1011|
219427208|NCT04984460|DIAGNOSTIC_TEST|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
219427209|NCT03716687|DEVICE|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
219427210|NCT05461183|OTHER|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
219427211|NCT00132314|DRUG|IM risperidone|long-acting injectable risperidone
219427212|NCT00132314|DRUG|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
219427213|NCT00832312|OTHER|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
219427214|NCT00832312|OTHER|placebo (saline)|Injection of 1cc of saline into the knee joint
219427215|NCT06087523|OTHER|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~* Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~* Systemic Lupus Activity Questionnaire~* Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
219427216|NCT03690947|DRUG|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
219427217|NCT03690947|PROCEDURE|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
219427218|NCT03690947|DRUG|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
219427219|NCT06443749|PROCEDURE|appendectomy|the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
219427220|NCT06221956|BEHAVIORAL|relevis|Participants will receive access to the digital health intervention relevis in addition to TAU.
219427221|NCT03602989|DEVICE|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
219576979|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator flaps|closure of myelomeningocele defect by perforator island flap after complete incision of the flap all around based on perforator vessel .
219006182|NCT00047814|DRUG|FK788|
219427222|NCT03514238|BEHAVIORAL|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
219427223|NCT03514238|BEHAVIORAL|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
219427224|NCT03514238|BEHAVIORAL|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
219427225|NCT03422640|DRUG|Apremilast|Open label treatment with apremilast
219576980|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator-plus flaps|closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
219576981|NCT01609621|DEVICE|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
219427226|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
219427227|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
219427228|NCT02391974|DEVICE|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
219427229|NCT00707460|BEHAVIORAL|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
219427230|NCT04748913|DEVICE|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
219427231|NCT04748913|DEVICE|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
219427232|NCT04748913|DEVICE|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
219427233|NCT04748913|DIAGNOSTIC_TEST|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
219427234|NCT02802072|DEVICE|Enterprise stent implantation|Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
219006183|NCT02071251|PROCEDURE|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
219006184|NCT06224101|BEHAVIORAL|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
219006185|NCT00741637|BIOLOGICAL|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
219006186|NCT00741637|BIOLOGICAL|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
219006187|NCT01830699|DRUG|Rilonacept|160 mg intra-bursal once
219427235|NCT02802072|DRUG|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
219427236|NCT04939532|BEHAVIORAL|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
219427237|NCT04939532|BEHAVIORAL|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
219427238|NCT04773704|DIAGNOSTIC_TEST|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
219427239|NCT04961476|DIETARY_SUPPLEMENT|1-MNA|1-MNA supplementation
219427240|NCT00926666|DRUG|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
219427241|NCT00719524|DRUG|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
219576982|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
219576983|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
219576984|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
219427242|NCT00105755|DEVICE|personal dermal thermometer (DT)|
219427243|NCT00105755|DEVICE|Device|
219427244|NCT02347462|DEVICE|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
219427245|NCT02347462|OTHER|Standard care|Standard care according to the hospital severe asthma protocol
219427246|NCT00987636|DRUG|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
219427247|NCT00987636|DRUG|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW
219427248|NCT00987636|DRUG|Treosulfan|12 g/m² d-5 to d-3
219427249|NCT06066359|DRUG|Fludarabine phosphate|Given by (IV) vein
219427250|NCT06066359|DRUG|Cyclophosphamide|Given by (IV) vein
219427251|NCT06066359|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
219427252|NCT03639922|DRUG|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
219427253|NCT03639922|DRUG|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
219427254|NCT03162094|DRUG|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
219427255|NCT03162094|DRUG|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
219427256|NCT03162094|DRUG|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
219427257|NCT01226589|PROCEDURE|MRS|
219006188|NCT01830699|DRUG|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
219191418|NCT03768960|DRUG|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
219427258|NCT05010772|DRUG|Decitabine and Cedazuridine|Given PO
219427259|NCT05010772|DRUG|Enasidenib|Given PO
219427260|NCT05010772|DRUG|Gilteritinib|Given PO
219427261|NCT05010772|DRUG|Ivosidenib|Given PO
219427262|NCT05010772|DRUG|Venetoclax|Given PO
219427263|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
219427264|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
219427265|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
219427266|NCT02098499|DRUG|Haloperidol|5mg IV
219427267|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
219576985|NCT06859853|DRUG|Placebo|Sub cutaneous injection on the abdomen by a qualified member of study staff.
219576986|NCT06859853|DRUG|Subcutaneous single and mutiple dose|Sub cutaneous injection on the abdomen by a qualified member of study staff.
219576987|NCT04072276|BIOLOGICAL|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
219576988|NCT06617273|DEVICE|Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation|Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
219427268|NCT02098499|DRUG|Diphenhydramine|25mg IV
219427269|NCT06248723|OTHER|Nutritional intervention|"The objectives of the dietary intervention will be in accordance with the principles of the Mediterranean diet. Weekly menus will be provided that ensure a balanced intake of the various nutrients, according to the objectives outlined in the study protocol, including a reduction in saturated fatty acids (with proportionately more mono- and polyunsaturated fatty acids), promotion of fiber sources and reduction of sugars, adequate protein and micronutrient intake. They will be accompanied by specific dietary patterns that can be individualized based on weight, comorbidities and personal preferences.~The need for weight loss or gain will be assessed on an individual basis. Dietary interventions will include group and individual sessions, and will be conducted by dietitians and nutritionists in a harmonized manner among the centers. The first meeting will be in-person and will be held at the subject's clinical center of enrollment. Follow-up will be conducted through online meetings."
219427270|NCT06248723|OTHER|Physical exercise|The physical activity protocol will be geared to the principles of progressive and individualized loading, in group sessions supervised by a physical therapist within gyms for the strength and balance training portion, and in moderate to intense aerobic activities based on individual preferences and characteristics. The physiotherapist will conduct an individual assessment and develop personalized programs for all participants. Exercise sessions will be held 2-3 times a week.
219576989|NCT00257920|DRUG|Zemplar® injection|6 mcg QOD
219576990|NCT00257920|DRUG|Hectorol® injection|3.6 mcg QOD
219576991|NCT00449982|DRUG|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
219576992|NCT04544020|DIETARY_SUPPLEMENT|NG feeding|NG feeding
219576993|NCT01757574|DRUG|Alemtuzumab infusion|
219427271|NCT06248723|OTHER|Cognitive training|Participants will be evaluated through a Cognitive and Psychological Assessment, which will allow measurement of each participant's cognitive functioning and well-being. Computerized cognitive training (CCT) using Brain HeadQuarter (BrainHQ) or similar software will be used as a cognitive intervention. The CCT includes game-based adaptive exercises that target attention, intelligence, memory, navigation, processing speed and social skills. The training will consist of 72 sessions for 24 weeks (about six months), at least three times a week.
219427272|NCT06248723|OTHER|Oral hygiene|"Participants will be referred for evaluation at dental hygiene offices. As part of the study, participants will also undergo anticholinergic burden calculation, screening for risk factors for oral diseases (smoking, alcohol), and reduction in the frequency of sugar intake through dietary intervention will be sought.~Participants will also undergo the Oral Health Assessment Tool rating scale."
219427273|NCT06248723|OTHER|Sleep quality|"During the visits, participants' sleep will be assessed, either by clinical interview or by scales. Participants will also have the opportunity to assess their own sleep via wearable devices.~If sleep hygiene issues are detected, advice based on currently available scientific evidence will be provided. If, on the other hand, a suspicion of sleep disorders, including, for example, obstructive sleep apnea syndrome, restless legs syndrome, insomnia, or Rapid Eye Movement (REM) sleep disorder, is raised from the medical history, participants will be referred to the relevant specialists for diagnosis and treatment of such problems."
219427274|NCT06248723|OTHER|Control of cardiovascular, metabolic, and infectious risk factors|Measurements of blood pressure, weight, BMI, abdominal circumference, and advice on health promotion and healthy lifestyle will be provided. Recommendations on adherence to the Piano Nazionale di Prevenzione Vaccinale (PNPV) will also be provided.
219427275|NCT06248723|OTHER|Pharmacological evaluation|Evaluation of prescriptive appropriateness (STOP\&START and Beers criteria) and calculation of anticholinergic burden (ACB calculator) will be carried out by a geriatrician, with rationalization of therapy and, where possible, de-prescribing.
219427276|NCT06248723|BEHAVIORAL|Socializing|"To encourage socialization, proposed activities will be carried out as much as possible in groups of 10-12 people, and outdoor group activities will be suggested on a biweekly basis (e.g., walks in parks). On a monthly basis, the nurse and psychologist will organize motivational and check-up meetings (in recreation centers/via telematics) in order to promote adherence to the protocol, collect questions and stimulate participants.~Social activity will also be implemented in the context of all interventions, for example through:~* Physical activity in groups or pairs, including dance or choir activities where possible~* Opportunities for further cognitive stimulation in groups through games (e.g., chess, cards, etc.)~* Proposal to cook, eat or shop together~* Group sessions with dietitian"
219191419|NCT06683391|BEHAVIORAL|Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment|The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
219427277|NCT06248723|OTHER|Self-administered interventions|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website. Such advice and information will be timed to encourage adherence. In addition, participants randomized to the self-guided intervention will receive an initial counseling session of 30-60 minutes on all domains covered by the study, where guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
219427278|NCT02966353|DRUG|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
219427279|NCT03013257|DEVICE|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
219427280|NCT06062342|BEHAVIORAL|FPI|The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
219427281|NCT04632407|DIETARY_SUPPLEMENT|"Flax milk"|See above
219427282|NCT04632407|DIETARY_SUPPLEMENT|"Oat fibre milk"|See above
219427283|NCT01320956|BEHAVIORAL|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
219427284|NCT01320956|OTHER|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
219427285|NCT01029015|PROCEDURE|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
219427286|NCT01029015|PROCEDURE|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
219427287|NCT00445731|BEHAVIORAL|exercise intervention|
219427288|NCT00445731|PROCEDURE|management of therapy complications|
219006189|NCT03683446|PROCEDURE|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
219006190|NCT03683446|PROCEDURE|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
219006191|NCT02309489|BEHAVIORAL|Partner involvement|Partner is involved in maternity care
219006192|NCT04579731|DRUG|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
219760565|NCT04279743|DIETARY_SUPPLEMENT|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
219006193|NCT03992157|DEVICE|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
219006194|NCT01845350|OTHER|M2 macrophage introduction|"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"
219006195|NCT01948050|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|
219006196|NCT02734446|DRUG|Reuterin D3 drops|5 drops/day for 3 months
219427289|NCT00445731|PROCEDURE|observation|
219427290|NCT06123390|OTHER|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
219006197|NCT02734446|OTHER|Placebo|5 drops/day for 3 months
219006198|NCT05693246|DRUG|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
219006199|NCT05693246|OTHER|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
219427291|NCT03385499|BIOLOGICAL|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
219006200|NCT01550640|DRUG|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
219006201|NCT00054314|DRUG|ortataxel|
219006202|NCT03294057|BEHAVIORAL|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
219427292|NCT04777474|DIAGNOSTIC_TEST|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
219427293|NCT04777474|DIAGNOSTIC_TEST|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
219427294|NCT04777474|DIAGNOSTIC_TEST|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
219427295|NCT03418272|DIAGNOSTIC_TEST|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis"
219427296|NCT00093470|PROCEDURE|Clinical Observation|Undergo observation
219427297|NCT00093470|DRUG|Tipifarnib|Given PO
219427298|NCT05905601|BEHAVIORAL|"NORTH Full"|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
219006203|NCT03294057|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
219006204|NCT03294057|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
219006205|NCT03927664|OTHER|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
219006206|NCT04597827|OTHER|Metacognition tests|Test on episodic or semantic memory
219006207|NCT05098925|OTHER|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
219006208|NCT04728581|DRUG|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
219006209|NCT04728581|DRUG|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
219006210|NCT04728581|DRUG|Placebo|a gelatinous capsule without an active ingredient
219427299|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
219427300|NCT00293150|DRUG|Eplerenone|
219427301|NCT04270617|BEHAVIORAL|Yoga program|The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
219427302|NCT05289076|DRUG|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
219427303|NCT02514772|BIOLOGICAL|GP2013 - A Proposed biosimilar rituximab|
219427304|NCT02514772|BIOLOGICAL|Originator rituximab - Rituxan ® or MabThera ®|
219427305|NCT04397926|DRUG|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
219427306|NCT06270563|OTHER|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
219427307|NCT06270563|OTHER|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
219427308|NCT06270563|OTHER|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
219427309|NCT06270563|OTHER|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
219427310|NCT01945268|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
219427311|NCT01945268|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
219006211|NCT02651298|DEVICE|Fractional Co2-laser|laser treatment
219006212|NCT00909116|PROCEDURE|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
219006213|NCT01971411|DRUG|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
219427312|NCT00381719|DRUG|AGN 203818|3 mg Capsule twice daily for 4 weeks
219427313|NCT00381719|DRUG|AGN 203818|20 mg Capsule twice daily for 4 weeks
219427314|NCT00381719|DRUG|AGN 203818|60 mg Capsule twice daily for 4 weeks
219427315|NCT00381719|DRUG|placebo capsule|Capsule twice daily for 4 weeks
219427316|NCT05076097|DRUG|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
219427317|NCT05106595|DEVICE|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
219427318|NCT01415908|DEVICE|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
219006214|NCT01971411|PROCEDURE|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
219006215|NCT01971411|BEHAVIORAL|Usual sun exposure documentation|
219006216|NCT01971411|BEHAVIORAL|Dietary intake of calcium, vitamin D, magnesium|
219006217|NCT02099357|DIETARY_SUPPLEMENT|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
219006218|NCT02099357|DIETARY_SUPPLEMENT|Placebo|
219006219|NCT02099357|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
219006220|NCT03231865|DIAGNOSTIC_TEST|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
219006221|NCT02187250|DRUG|metformin|
219006222|NCT02187250|DRUG|liraglutide|
219006223|NCT02187250|DRUG|roflumilast|
219006224|NCT03303079|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
219006225|NCT03303079|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
219006226|NCT03303079|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
219427319|NCT01415908|OTHER|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
219427320|NCT04518345|DRUG|Azacitidine|Given IV
219427321|NCT04518345|DRUG|Dubermatinib|Given PO
219427322|NCT06337162|DRUG|INCB099280|400 mg Tablet
219427323|NCT05693688|DRUG|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
219427324|NCT05942170|DRUG|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
219427325|NCT05595551|BEHAVIORAL|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
219427326|NCT01770041|OTHER|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
219427327|NCT03825172|DIAGNOSTIC_TEST|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
219427328|NCT05337904|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
219427329|NCT05337904|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
219427330|NCT03250377|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg and 50 mg~* Route of administration: Oral use"
219427331|NCT04302272|DEVICE|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
219427332|NCT06042478|DRUG|Remibrutinib|Active treatment
219427333|NCT06042478|DRUG|Placebo to remibrutinib|Placebo followed by active treatment
219427334|NCT06042478|DRUG|Placebo to omalizumab|Placebo followed by active comparator
219427335|NCT06042478|DRUG|Omalizumab|Active comparator
219427336|NCT00817206|DRUG|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
219427337|NCT00817206|DRUG|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
219006227|NCT02005445|DEVICE|CPAP|Continuous positive airway pressure
219006228|NCT02005445|BEHAVIORAL|HLSE|Healthy living and sleep education
219427338|NCT02189590|DEVICE|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
219427339|NCT02189590|DEVICE|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
219427340|NCT00859989|BEHAVIORAL|behavioral dietary intervention|
219427341|NCT00859989|BEHAVIORAL|exercise intervention|
219427342|NCT00859989|BEHAVIORAL|telephone-based intervention|
219427343|NCT00859989|OTHER|counseling intervention|
219427344|NCT00859989|OTHER|educational intervention|
219006229|NCT06476457|BEHAVIORAL|STAIR Coach|STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
219006230|NCT01010386|PROCEDURE|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
219006231|NCT01010386|PROCEDURE|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
219006232|NCT00240903|BIOLOGICAL|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
219006233|NCT01156311|DRUG|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
219427345|NCT00859989|OTHER|immunoenzyme technique|
219427346|NCT00859989|OTHER|laboratory biomarker analysis|
219427347|NCT00859989|OTHER|questionnaire administration|
219427348|NCT00859989|OTHER|study of socioeconomic and demographic variables|
219427349|NCT00859989|PROCEDURE|evaluation of cancer risk factors|
219427350|NCT00859989|PROCEDURE|support group therapy|
219576994|NCT00521274|BIOLOGICAL|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
219576995|NCT00521274|DRUG|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
219006234|NCT01288248|DEVICE|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
219427351|NCT04720495|PROCEDURE|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
219427352|NCT04720495|PROCEDURE|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
219427353|NCT06264349|OTHER|Lifestyle Educational Intervention|The Lifestyle Educational Intervention (LEI) consists of promoting a healthy lifestyle during pregnancy and breastfeeding. In particular, the contents concern: i). macro- and micronutrient requirements during pregnancy/breastfeeding; ii). definition of the concept of the food pyramid and healthy plate also considering aspects of food sustainability; iii). definition of the principles of food safety during pregnancy; iv). importance of maternal and infant sleep quality; v). importance of maternal physical activity during pregnancy and lactation; vi). psychological aspects regarding the mother-child dyad.
219427354|NCT02601443|DEVICE|Cervical Pessary|
219427355|NCT02034552|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
219427356|NCT02034552|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
219427357|NCT02034552|DRUG|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
219427358|NCT02034552|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
219427359|NCT02405806|DIETARY_SUPPLEMENT|low carbohydrate food|low carbohydrate food
219427360|NCT02405806|DIETARY_SUPPLEMENT|standard food|standard food
219427361|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
219427362|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
219427363|NCT03278652|OTHER|Consumption of drugs for analgesic use|"* Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)"
219427364|NCT00698035|DRUG|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
219427365|NCT00698035|DRUG|Estring|2mg ring inserted vaginally once every 12 weeks
219427366|NCT05678842|OTHER|Descriptive|Descriptive
219427367|NCT02278991|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
219427368|NCT00003810|DRUG|docetaxel|
219427369|NCT00003810|DRUG|gemcitabine hydrochloride|
219427370|NCT01916707|DRUG|Dosing of enoxaparin for VTE prophylaxis|
219427371|NCT00723671|PROCEDURE|MRI|
219427372|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
219427373|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
219427374|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
219427375|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
219427376|NCT00291499|DRUG|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
219427377|NCT00291499|OTHER|Placebo|800 mg placebo/day for 6 months
219427378|NCT05474872|DEVICE|BIS monitoring|The depth of anesthesia will be monitored using Bispectral Index values.
219427379|NCT05989308|BEHAVIORAL|Email|Email message sent to guardian with proxy information.
219427380|NCT05989308|BEHAVIORAL|Text|Text message sent to guardian with proxy information.
219427381|NCT05989308|BEHAVIORAL|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
219427382|NCT06247267|DRUG|Fortesta|Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
219427383|NCT06247267|DRUG|Estradiol|Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
219427384|NCT06247267|DRUG|Fortesta|Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
219427385|NCT06134414|DRUG|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
219427386|NCT00002391|DRUG|Abacavir sulfate|
219427387|NCT00002391|DRUG|Lamivudine|
219427388|NCT00002391|DRUG|Zidovudine|
219427389|NCT00289549|DRUG|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
219427390|NCT01532570|DRUG|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
219427391|NCT03858270|DRUG|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
219427392|NCT03858270|OTHER|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
219427393|NCT05976243|DRUG|Remibrutinib|Remibrutinib treated groups and arms
219427394|NCT05976243|OTHER|Placebo|Placebo treated groups and arms
219427395|NCT01082367|DRUG|TOBI|TOBI (tobramycin inhaled solution)
219427396|NCT01082367|DRUG|Placebo|Placebo
219427397|NCT04965870|DRUG|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
219427398|NCT02016898|PROCEDURE|Placement of the sponge|
219427399|NCT02016898|DRUG|Mitomycin-C|
219427400|NCT03472794|OTHER|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
219427401|NCT00159718|DRUG|amlodipine|
219427402|NCT00159718|DRUG|atorvastatin|
219576996|NCT03508687|DRUG|300mg Gemcabene|300mg Gemcabene
219427403|NCT06411249|DRUG|Belimumab (GSK1550188)|GSK1550188 will be administered subcutaneously.
219427404|NCT01817114|DEVICE|Auto Remote Ischemic Conditioning (AutoRIC) device|
219427405|NCT03771443|DRUG|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
219427406|NCT04757922|PROCEDURE|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
219427407|NCT01287546|DRUG|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
219427408|NCT01287546|DRUG|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
219427409|NCT01287546|DRUG|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
219427410|NCT01287546|DRUG|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
219427411|NCT05425095|OTHER|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
219427412|NCT05425095|OTHER|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
219427413|NCT03794713|DEVICE|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
219427414|NCT04277832|DIAGNOSTIC_TEST|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
219427415|NCT06380790|PROCEDURE|Laser-aided csf|Laser-aided csf before leveling and alignment
219427416|NCT06380790|OTHER|placebo laser-aided csf|placebo laser-aided csf before leveling and alignment
219427417|NCT00925145|PROCEDURE|Single Incision Laparoscopic Appendectomy|
219427418|NCT01545024|DRUG|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
219427419|NCT01656811|DRUG|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
219427420|NCT01656811|DRUG|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
219427421|NCT01656811|DRUG|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
219576997|NCT03508687|DRUG|600mg Gemcabene|600mg Gemcabene
219427422|NCT01656811|DRUG|Placebo|Placebo 2 actuations QID
219427423|NCT02565498|RADIATION|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
219427424|NCT02565498|RADIATION|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
219427425|NCT01594567|OTHER|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
219427426|NCT06300567|OTHER|data collection|"collection of data of generated by real world follow up"
219427427|NCT04503512|PROCEDURE|removal of fat pad|Removal removal of fat pad
219427428|NCT04503512|PROCEDURE|non removal of fat pad|non removal of fat pad
219427429|NCT05265962|DRUG|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
219427430|NCT05410197|DRUG|Envofolimab|400mg by subcutaneous injection every 3 weeks
219427431|NCT05410197|DRUG|Lenvatinib|8 mg orally once a day
219427432|NCT05410197|DRUG|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
219427433|NCT05410197|DRUG|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
219427434|NCT05873699|DRUG|Hyperpolarized 13-C-pyruvate|Given by Injection
219427435|NCT00226278|DRUG|ORG 34517|
219427436|NCT01665768|DRUG|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
219427437|NCT01665768|BIOLOGICAL|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
219427438|NCT01329341|OTHER|Service Dogs|Service dogs will be trained to help Veterans with PTSD
219427439|NCT03116373|OTHER|mandible fixation|Intubation device will be fixed on mandible
219427440|NCT03116373|OTHER|Maxilla fixation|Intubation device will be fixed on maxilla
219427441|NCT03621423|PROCEDURE|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
219006235|NCT01288248|DEVICE|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
219006236|NCT04876443|DIAGNOSTIC_TEST|Study questionnaire|Study questionnaire related to drinking behaviour
219006237|NCT05955950|BEHAVIORAL|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
219427442|NCT05017714|DRUG|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
219006238|NCT05955950|BEHAVIORAL|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
219006239|NCT04500210|DIETARY_SUPPLEMENT|Placebo|Placebo in gelatin capsules
219006240|NCT04500210|DIETARY_SUPPLEMENT|Turmeric|Turmeric in gelatin capsules
219006241|NCT03762109|DRUG|Dantrolene|muscle relaxant
219427443|NCT03177265|BEHAVIORAL|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
219427444|NCT03177265|BEHAVIORAL|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
219427445|NCT03177265|BEHAVIORAL|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
219427446|NCT03177265|BEHAVIORAL|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
219576998|NCT01727687|BEHAVIORAL|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
219427447|NCT03017846|DRUG|Cantharidin|Application of topical cantharidin
219427448|NCT03539913|BIOLOGICAL|Probiotic : Saccharomyces boulardii|Treatment for 5 days
219427449|NCT03539913|BIOLOGICAL|Probiotic : Bacillus clausii|Treatment for 5 days
219427450|NCT01524237|DRUG|LY2979165|Capsules administered orally
219427451|NCT01524237|DRUG|LY2140023|Tablets administered orally
219427452|NCT01524237|OTHER|Placebo|Administered orally
219427453|NCT01524237|OTHER|Ketamine|Administered intravenously (IV)
219427454|NCT01959399|DRUG|ASP015K|oral tablet
219427455|NCT01959399|DRUG|Rosuvastatin|oral tablet
219427456|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
219006242|NCT03762109|DRUG|Placebo Oral Tablet|inactive pill
219427457|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
219427458|NCT01079286|DRUG|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
219427459|NCT04616404|DIETARY_SUPPLEMENT|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
219427460|NCT04616404|OTHER|Placebo|Tablets with no active ingredient
219427461|NCT03384628|DEVICE|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
219427462|NCT03384628|DEVICE|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
219427463|NCT03384628|DEVICE|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
219427464|NCT02780479|DRUG|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
219427465|NCT02780479|DRUG|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
219427466|NCT02465346|DEVICE|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
219427467|NCT02465346|DEVICE|Control stroke management|Conventional stroke management
219427468|NCT02316626|DRUG|Subcutaneous progesterone|25 mg daily for 14 days
219006243|NCT04431648|DRUG|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
219006244|NCT04431648|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
219427469|NCT02316626|DRUG|Vaginal progesterone|90 mg daily for 14 days
219427470|NCT00518401|BIOLOGICAL|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
219427471|NCT05118542|DRUG|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
219427472|NCT05118542|DRUG|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
219427473|NCT02151682|DRUG|Tapentadol prolonged release|
219427474|NCT02151682|DRUG|Morphine prolonged release|
219427475|NCT04298190|BEHAVIORAL|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
219006245|NCT03271112|OTHER|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
219006246|NCT01025791|DRUG|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
219760566|NCT04279743|DIETARY_SUPPLEMENT|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
219427476|NCT04298190|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
219427477|NCT05121831|DRUG|DGX-001Dose 1|Dose level 1 of DGX-001
219427478|NCT05121831|DRUG|DGX-001 Dose 2|Dose level 2 of DGX-001
219427479|NCT05121831|DRUG|DGX-001 Dose 3|Dose level 3 of DGX-001
219427480|NCT05121831|DRUG|DGX-001 Dose 4|Dose level 4 of DGX-001
219760567|NCT02286895|BIOLOGICAL|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
219006247|NCT01025791|DRUG|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
219427481|NCT05121831|DRUG|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
219427482|NCT01306032|DRUG|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
219427483|NCT01306032|DRUG|Cyclophosphamide|
219427484|NCT02375984|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
219427485|NCT04787211|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
219427486|NCT04787211|DRUG|Placebo|Placebo given by intravenous administration
219006248|NCT01025791|DRUG|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
219006249|NCT04470674|DRUG|Durvalumab|Durvalumab 1500 mg
219006250|NCT04470674|DRUG|Carboplatin|carboplatin AUC 5
219427487|NCT04789863|DEVICE|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
219427488|NCT04789863|OTHER|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
219576999|NCT00563680|DRUG|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
219577000|NCT05177562|OTHER|No intervention|There is no intervention in this study
219577001|NCT03749629|OTHER|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
219006251|NCT04470674|DRUG|Pemetrexed|pemetrexed 500 mg/m2
219427489|NCT04477915|OTHER|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
219427490|NCT04477915|OTHER|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
219427491|NCT02654275|OTHER|Proprioceptive Intervention|
219427492|NCT02995122|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)"
219427493|NCT02995122|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219427494|NCT06054503|DEVICE|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
219427495|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
219427496|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
219427497|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
219427498|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
219427499|NCT04516655|DRUG|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
219427500|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
219427501|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
219427502|NCT00168064|DRUG|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
219427503|NCT00003077|DIETARY_SUPPLEMENT|omega-3 fatty acid|
219427504|NCT03779893|COMBINATION_PRODUCT|BioCoat® by Premier®.|Bioactive pits and fissure sealant
219427505|NCT03779893|COMBINATION_PRODUCT|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
219427506|NCT00821665|DIETARY_SUPPLEMENT|Sucrose consumption|Sucrose
219427507|NCT00821665|DIETARY_SUPPLEMENT|water consumption|water
219427508|NCT03488394|GENETIC|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously."
219427509|NCT06976944|DRUG|Pembrolizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Pembrolizumab: Intravenous infusion(400 mg/body, every 6 weeks starting on Day 1 of Cycle 1)"
219427510|NCT06976944|DRUG|Paclitaxel|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Paclitaxel: Intravenous infusion(90 mg/m\^2, on Days 1, 8, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
219427511|NCT06976944|DRUG|Bevacizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Bevacizumabl: Intravenous infusion(10 mg/kg, on Days 1, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
219427512|NCT00318565|DEVICE|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
219427513|NCT01113840|BEHAVIORAL|Exercise|Exercise classes three times per week in a controlled, supervised environment.
219427514|NCT01113840|BEHAVIORAL|Control|Control group continues daily life as prior to randomization.
219427515|NCT06212570|DEVICE|KeySuite|KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
219427516|NCT01707368|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
219427517|NCT02578472|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
219427518|NCT02578472|DRUG|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
219427519|NCT02578472|DRUG|Placebo|Matching Placebo will be administered orally.
219427520|NCT05603754|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
219427521|NCT05603754|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
219427522|NCT01017887|DEVICE|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
219427523|NCT01017887|DEVICE|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
219427524|NCT01896856|DRUG|SGI-110 Dose Escalation|"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"
219427525|NCT01896856|DRUG|Regorafenib|160 mg taken orally
219427526|NCT01896856|DRUG|TAS-102|35 mg/m\^2 taken orally
219427527|NCT01896856|DRUG|SGI-110|45 mg/m\^2 administered as a subcutaneous injection
219427528|NCT01896856|DRUG|Irinotecan|125 mg/m\^2 administered IV
219427529|NCT06043245|PROCEDURE|Duodenal Switch|Classic Duodenal Switch
219427530|NCT06043245|PROCEDURE|SADI-S|SADI-S with a 300cm common channel
219427531|NCT06043245|PROCEDURE|Minigastric Bypass|Classic minigastric bypass
219427532|NCT01879813|DIETARY_SUPPLEMENT|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
219427533|NCT01879813|DIETARY_SUPPLEMENT|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
219427534|NCT06854484|DEVICE|AVEIR™leadless pacemaker|AVEIR™ leadless pacemaker implantation
219427535|NCT00282867|DRUG|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
219427536|NCT00282867|OTHER|standard care|usual care
219427537|NCT00141180|DRUG|CP-481,715|
219427538|NCT02306239|DRUG|Terlipressin|
219427539|NCT02306239|DRUG|Norepinephrine|
219427540|NCT02881710|OTHER|contrast product used to assess biomarkers variations|
219427541|NCT02262234|OTHER|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
219427542|NCT02262234|OTHER|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
219427543|NCT03997929|DIAGNOSTIC_TEST|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
219427544|NCT02703987|OTHER|Fermented infant milk formula|
219427545|NCT02703987|OTHER|Non-fermented infant milk formula|
219427546|NCT03436771|GENETIC|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
219427547|NCT03436771|GENETIC|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
219427548|NCT03883490|DIAGNOSTIC_TEST|ECG|A 12-lead ECG will be taken for each participant.
219427549|NCT03883490|DIAGNOSTIC_TEST|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
219427550|NCT03883490|DIAGNOSTIC_TEST|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
219427551|NCT03883490|DIAGNOSTIC_TEST|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
219427552|NCT03883490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
219427553|NCT04576247|BEHAVIORAL|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
219760568|NCT02286895|BIOLOGICAL|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
219427554|NCT05100108|BEHAVIORAL|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
219427555|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg|
219006252|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
219427556|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg X 2|
219427557|NCT01785108|DRUG|Vitamin D|
219427558|NCT01785108|DRUG|Ibuprofen|
219427559|NCT00139620|DRUG|Tarceva, erlotinib, OSI-774|
219006253|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
219427560|NCT01376245|DRUG|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
219427561|NCT01376245|DRUG|Placebo|matching placebo
219427562|NCT05159362|OTHER|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
219427563|NCT04149847|PROCEDURE|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
219427564|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
219427565|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
219427566|NCT03454204|OTHER|Pharmacokinetic|Analysis of blood samples
219427567|NCT01335698|DRUG|Atazanavir Sulphate|
219427568|NCT01335698|DRUG|Ritonavir|
219427569|NCT01879254|DEVICE|Deep Brain Stimulation|
219427570|NCT00473044|BEHAVIORAL|Sisters in Motion|
219427571|NCT05564442|DRUG|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
219006254|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
219006255|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
219006256|NCT05502601|PROCEDURE|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
219006257|NCT05699395|DIAGNOSTIC_TEST|Non interventional|No intervention
219427572|NCT05564442|DEVICE|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
219427573|NCT05564442|DRUG|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
219427574|NCT05564442|OTHER|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
219427575|NCT03970824|BIOLOGICAL|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
219427576|NCT03970824|BIOLOGICAL|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
219427577|NCT03970824|BIOLOGICAL|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
219427578|NCT00054236|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
219427579|NCT00054236|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
219427580|NCT00054236|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
219427581|NCT00054236|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
219427582|NCT00054236|PROCEDURE|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
219427583|NCT00054236|DRUG|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
219427584|NCT04066946|DEVICE|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
219427585|NCT04066946|OTHER|Standard of care|"Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
219427586|NCT00416312|DEVICE|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7."
219427587|NCT00416312|DEVICE|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
219427588|NCT05587634|BEHAVIORAL|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
219427589|NCT05764460|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
219006258|NCT01965275|DRUG|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
219006259|NCT05002855|OTHER|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
219006260|NCT01830972|DRUG|SA-ER 500 mg|oral tablets
219006261|NCT01830972|DRUG|SA-IR 500 mg|oral capsules
219577002|NCT03749629|OTHER|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
219577003|NCT05196360|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
219006262|NCT00380497|DRUG|PEG-Lyte®|
219006263|NCT00380497|DRUG|Pico-Salax®|
219427590|NCT00004014|DRUG|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
219006264|NCT01050972|BEHAVIORAL|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
219006265|NCT00933374|DRUG|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
219006266|NCT00933374|DRUG|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
219006267|NCT05935852|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
219427591|NCT02593968|DRUG|Recombinant Human Interferon a-2b Gel|
219427592|NCT02593968|DRUG|Placebo|
219427593|NCT00086736|DRUG|bicalutamide|
219427594|NCT00086736|DRUG|eflornithine|
219427595|NCT00086736|DRUG|oral eflornithine placebo|
219427596|NCT00086736|DRUG|oral bicalutamide placebo|
219427597|NCT03797508|DIAGNOSTIC_TEST|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
219427598|NCT02907671|PROCEDURE|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
219427599|NCT03498976|PROCEDURE|pulsed radiofrequency|Echoguided technic
219427600|NCT00198458|DRUG|Vitrase|
219427601|NCT02309814|DEVICE|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
219427602|NCT02147509|DRUG|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
219427603|NCT02147509|DRUG|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
219427604|NCT02147509|OTHER|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
219427605|NCT02147509|DRUG|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
219427606|NCT06233214|DEVICE|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
219427607|NCT06249009|DEVICE|Non invasive ventilation|CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
219427608|NCT03005041|OTHER|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
219427609|NCT03005041|OTHER|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
219427610|NCT05987189|DIAGNOSTIC_TEST|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
219427611|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
219427612|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
219427613|NCT00162708|DRUG|CDDP, 5 Fu|
219427614|NCT02670850|OTHER|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
219427615|NCT05297799|DEVICE|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
219427616|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
219427617|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
219427618|NCT06218199|DRUG|Furosemide|oral administration
219427619|NCT06218199|DRUG|Torsemide|oral administration
219427620|NCT06218199|DRUG|Bumetanide|oral administration
219427621|NCT06218199|DRUG|sacubitril/valsartan|oral administration
219427622|NCT06218199|DRUG|Hydralazine|oral administration
219427623|NCT06218199|DRUG|Isosorbide Dinitrate|oral administration
219427624|NCT02727660|DRUG|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
219427625|NCT02727660|DRUG|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
219427626|NCT02727660|DRUG|FF MDI (PT005) 9.6 μg|Blinded Treatment
219006268|NCT06204744|OTHER|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
219427627|NCT00050960|DRUG|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
219427628|NCT00050960|DRUG|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
219760569|NCT02286895|BIOLOGICAL|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
219006269|NCT06204744|OTHER|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
219427629|NCT03601793|BEHAVIORAL|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
219427630|NCT03601793|BEHAVIORAL|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
219427631|NCT04749576|DIETARY_SUPPLEMENT|saffron supplement for IBD|anti inflammatory effect
219427632|NCT05702970|DRUG|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
219427633|NCT05702970|DRUG|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
219427634|NCT05702970|DRUG|Ferric Carboxymaltose 50 MG/ML|Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
219006270|NCT01743053|DEVICE|Standard Care plus ReCell|
219006271|NCT01743053|OTHER|Standard Care|
219427635|NCT02327156|DRUG|dexmedetomidine|adding dexmedetomidine to the local anesthetic
219427636|NCT01812122|DRUG|Glimepiride|
219427637|NCT01812122|DRUG|Vildagliptin|
219427638|NCT04020406|BIOLOGICAL|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
219427639|NCT00105560|RADIATION|radiation therapy|Radiation therapy with proton beam to standard doses
219427640|NCT00305604|DRUG|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
219427641|NCT00305604|DRUG|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
219427642|NCT00006234|PROCEDURE|peripheral blood stem cell transplantation|
219427643|NCT00006234|RADIATION|holmium Ho 166 DOTMP|
219427644|NCT03460925|RADIATION|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
219427645|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
219427646|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
219427647|NCT02171819|OTHER|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
219427648|NCT03684941|DEVICE|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
219427649|NCT03684941|DEVICE|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
219427650|NCT01248364|DRUG|BI 10773|BI 10773 tablets once daily high dose
219427651|NCT04814472|DRUG|BLD-0409|Randomized to active product.
219427652|NCT02428972|DRUG|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
219427653|NCT02428972|DRUG|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
219427654|NCT01200160|DRUG|Niacin|
219427655|NCT01567891|BIOLOGICAL|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
219427656|NCT02227472|OTHER|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
219427657|NCT02227472|OTHER|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
219427658|NCT05733260|BEHAVIORAL|Exercise|10 weeks of resistance training.
219577004|NCT03915665|DRUG|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
219577005|NCT03915665|DEVICE|Air-powder|Erythritol powder using air-powder device
219577006|NCT02447926|PROCEDURE|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
219577007|NCT01528020|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
219577008|NCT01528020|BEHAVIORAL|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
219577009|NCT05623631|OTHER|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
219577010|NCT02235220|OTHER|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
219760570|NCT02286895|BIOLOGICAL|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
219760571|NCT01093313|BEHAVIORAL|Cognitive therapy|
219760572|NCT01093313|BEHAVIORAL|attention training|
219760573|NCT04747262|BEHAVIORAL|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
219760574|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
219760575|NCT06279611|DRUG|LY007|FC and LY007 infusion
219760576|NCT02791464|BEHAVIORAL|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
219760577|NCT04167943|DRUG|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
219760578|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
219760579|NCT01073293|BIOLOGICAL|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
219760580|NCT01073293|BIOLOGICAL|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
219760581|NCT01073293|BIOLOGICAL|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
219760582|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
219577011|NCT01200940|OTHER|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
219427659|NCT04140604|OTHER|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
219427660|NCT04140604|OTHER|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
219427661|NCT04140604|OTHER|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
219427662|NCT06294041|BEHAVIORAL|Sleep Restriction Therapy (SRT)|SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
219427663|NCT06294041|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
219427664|NCT04514588|DIETARY_SUPPLEMENT|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
219427665|NCT02920281|OTHER|Polysomnography|
219427666|NCT02418767|DRUG|MOD-4023|
219427667|NCT02418767|DRUG|Placebo|
219427668|NCT03801811|PROCEDURE|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
219427669|NCT00764946|DRUG|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
219427670|NCT03388086|DRUG|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
219577012|NCT01200940|OTHER|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
219577013|NCT01200940|OTHER|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
219577014|NCT01200940|OTHER|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
219427671|NCT06305221|DRUG|Opioid-free Analgesics (esketamine, dexmedetomidine)|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
219427672|NCT06305221|DRUG|Opioid Anesthetics (sufentanil and remifentanil)|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
219577015|NCT05587335|BEHAVIORAL|PREP|Relationship intervention to improve communication and conflict resolution for couples
219577016|NCT05587335|BEHAVIORAL|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
219577017|NCT06449755|DIAGNOSTIC_TEST|Radiologic examination|Posoperative first week, month and third month On the x-ray of Hand AP view: metacarpal shortening On the x-ray of Hand 30 degree pronation view: dorsal angulation
219577018|NCT06449755|PROCEDURE|Grip Strength|Postoperative first month and third month grip streng compare with Cambry hand dinamometer.
219577019|NCT06449755|OTHER|Quick DASH Questionnaire|Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
219577020|NCT03668821|OTHER|Questionnaire|Quality of life and frailty questionnaires
219577021|NCT03166813|PROCEDURE|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
219577022|NCT03166813|OTHER|Control|Placement of blood pressure cuff without inflation for 30 minutes.
219577023|NCT06326502|DRUG|ETN101|Oral administration
219006272|NCT05553002|OTHER|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
219427673|NCT03552627|DRUG|Oxygen|Medical Oxygen
219427674|NCT03590704|DEVICE|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
219427675|NCT04569799|DRUG|Lumason|2.4 mL per lesion
219427676|NCT00000937|DRUG|Antibiotics|
219427677|NCT00206011|PROCEDURE|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
219427678|NCT05766436|DRUG|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
219427679|NCT05766436|DRUG|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
219427680|NCT05766436|DRUG|Placebo|placebo ODF and 0.9% normal saline nebulizer
219427681|NCT06367972|PROCEDURE|Local Consolidation Therapy|Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
219427682|NCT06367972|PROCEDURE|Next-line Systemic Therapy|The specific next-line systemic therapy will be determined by your doctor.
219427683|NCT00903253|DRUG|LNK-754|
219427684|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
219427685|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
219427686|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
219006273|NCT05553002|OTHER|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
219427687|NCT03903744|PROCEDURE|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
219427688|NCT00979017|DRUG|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
219427689|NCT00979017|DRUG|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
219427690|NCT00979017|DRUG|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
219427691|NCT03086317|DEVICE|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
219427692|NCT03086317|DEVICE|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
219427693|NCT02843295|OTHER|blood samples|
219427694|NCT05699317|OTHER|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
219427695|NCT00702585|DRUG|Org 36286|Org 36286 single-dose subcutaneous injection
219427696|NCT00702585|DRUG|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
219427697|NCT00194272|DRUG|Methotrexate|Two dose methotrexate
219427698|NCT00945802|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
219427699|NCT00945802|DRUG|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
219427700|NCT01361919|PROCEDURE|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
219427701|NCT01361919|PROCEDURE|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
219427702|NCT01361919|PROCEDURE|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
219427703|NCT03001843|DRUG|Ketamine|Anesthesia of only Ketamine
219427704|NCT03001843|DRUG|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
219427705|NCT03001843|BEHAVIORAL|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
219427706|NCT00212303|BEHAVIORAL|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
219427707|NCT06379867|DRUG|HSK3486|0.4 mg/kg, IV bolus administration
219427708|NCT06379867|DRUG|Placebo|IV bolus administration
219427709|NCT06379867|DRUG|Moxifloxacin|0.4 g, Oral administration with 240 mL
219427710|NCT01770691|DEVICE|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
219427711|NCT05233982|DRUG|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
219427712|NCT03472274|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
219427713|NCT03472274|DRUG|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
219427714|NCT03472274|DRUG|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"
219427715|NCT04149639|DIETARY_SUPPLEMENT|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
219427716|NCT00790101|DRUG|Risedronate|
219427717|NCT00790101|DRUG|Raloxifene|
219427718|NCT00790101|OTHER|Placebo|
219760583|NCT03261895|BEHAVIORAL|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
219006274|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
219427719|NCT02263495|DRUG|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
219427720|NCT02263495|DRUG|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
219427721|NCT02263495|DRUG|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
219427722|NCT00039741|DRUG|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
219427723|NCT00039741|DRUG|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
219427724|NCT00039741|DRUG|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
219427725|NCT01767519|BIOLOGICAL|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
219427726|NCT01767519|DRUG|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
219427727|NCT01767519|DRUG|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
219427728|NCT01767519|DRUG|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
219427729|NCT02898519|OTHER|cohort|Blood sampling
219427730|NCT00946881|DRUG|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
219427731|NCT00293423|BIOLOGICAL|HSPPC-96|25 mcg
219427732|NCT00293423|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
219427733|NCT06134713|DRUG|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
219427734|NCT06134713|DRUG|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
219427735|NCT00411736|DRUG|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
219427736|NCT00411736|DRUG|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
219427737|NCT04427436|OTHER|No Intervention|No Intervention
219427738|NCT00123149|DRUG|Epoetin alfa|
219427739|NCT04697433|DEVICE|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
219427740|NCT03659370|OTHER|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
219427741|NCT03659370|OTHER|Acupuncture|Acupuncture
219427742|NCT02632500|OTHER|Quality of chest compressions|
219427743|NCT05005988|BEHAVIORAL|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
219427744|NCT05978856|OTHER|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~* All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~* Through the use of software, the initial cephalogram and the initial photograph will be linked.~* Then, the final values of some angles will be tracted from the post-treatment cephalogram.~* These values will be inserted in the treatment simulationsection of the software.~* A post-treatment projected image of the patient will be simulated by the software.~* Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~* From the pupil , real horizontal and vertical reference lines will be drawn.~* Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
219427745|NCT03870256|DRUG|misoprostol|Patient receive 600mic gm sublingual misoprostol
219427746|NCT03870256|DRUG|Carbetocin|Patient receive 100 mic gm carbetocin IV
219427747|NCT03870256|DRUG|TA|The patient receives 1gm oral tranexamic acid
219427748|NCT02270684|DEVICE|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
219427749|NCT06197542|OTHER|Active Release Technique|active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
219427750|NCT06197542|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
219427751|NCT05239364|PROCEDURE|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
219427752|NCT03141372|DEVICE|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
219427753|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 48 weeks
219427754|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 24 weeks
219427755|NCT03539861|DEVICE|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
219427756|NCT00006454|DRUG|carboplatin|
219427757|NCT00006454|DRUG|paclitaxel|
219427758|NCT00006454|DRUG|topotecan hydrochloride|
219427759|NCT00466583|DRUG|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
219427760|NCT01555905|DEVICE|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
219427761|NCT05293574|DRUG|norethisterone acetate|Norethindrone, a progesterone agonist
219427762|NCT00380276|DRUG|MPC-7869|800 mg BID Oral dosing
219577024|NCT03288974|DRUG|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
219577025|NCT03201679|PROCEDURE|Repair of hip fracture|Patients undergoing hip fracture surgery
219577026|NCT02469779|BEHAVIORAL|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
219577027|NCT02469779|BEHAVIORAL|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
219577028|NCT02469779|BEHAVIORAL|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
219577029|NCT02469779|BEHAVIORAL|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
219577030|NCT06194006|OTHER|Follow-up|Follow-up grafted patients as long as their condition allows
219577031|NCT03957187|DIAGNOSTIC_TEST|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
219577032|NCT03840252|DIAGNOSTIC_TEST|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
219577033|NCT03840252|DIAGNOSTIC_TEST|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
219577034|NCT03840252|DIAGNOSTIC_TEST|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
219577035|NCT00562770|DRUG|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
219427763|NCT05753098|DRUG|estrogen therapy|oral estradiol valerate
219427764|NCT05753098|DRUG|Sildenafil|PDE5 inhibitor
219427765|NCT05753098|DRUG|Clomiphene Citrate 50mg|used for ovulation induction
219427766|NCT03866148|DEVICE|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
219427767|NCT02682030|DEVICE|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
219427768|NCT02682030|DEVICE|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
219427769|NCT02029495|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
219427770|NCT02029495|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
219427771|NCT02029495|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
219577036|NCT00562770|DRUG|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
219577037|NCT06358287|PROCEDURE|cryogenic auriculotherapy|Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
219577038|NCT01861236|DRUG|Firmagon® (degarelix)|Monthly subcutaneous injections
219577039|NCT01147978|BEHAVIORAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
219577040|NCT05110807|DRUG|TQB3617|TQB3617 is a BET inhibitor.
219577041|NCT01698437|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
219427772|NCT04441879|BEHAVIORAL|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
219427773|NCT04441879|BEHAVIORAL|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
219427774|NCT04609995|BEHAVIORAL|Incentives|No financial incentive
219427775|NCT01545609|OTHER|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
219427776|NCT03498287|DEVICE|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
219427777|NCT03498287|DEVICE|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
219427778|NCT02058758|DEVICE|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
219427779|NCT01374217|DRUG|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
219427780|NCT01374217|DRUG|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
219427781|NCT01374217|DRUG|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
219427782|NCT01374217|DRUG|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
219427783|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
219427784|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
219427785|NCT01578785|DRUG|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
219427786|NCT01578785|DRUG|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
219427787|NCT03977350|DEVICE|EEG monitoring|EEG monitoring under general anesthesia
219427788|NCT00410449|DRUG|Alpha tocopherol|
219577042|NCT01868711|BEHAVIORAL|Cognitive Behavior Therapy|
219577043|NCT03486054|DEVICE|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
219006275|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
219427789|NCT01873443|DRUG|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
219427790|NCT03371732|BEHAVIORAL|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
219427791|NCT03371732|BEHAVIORAL|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
219427792|NCT02581982|OTHER|Laboratory Biomarker Analysis|Correlative studies
219427793|NCT02581982|DRUG|Paclitaxel|Given IV
219427794|NCT02581982|BIOLOGICAL|Pembrolizumab|Given IV
219427795|NCT02034604|DRUG|Naftofidil|
219427796|NCT02034604|DRUG|Tamsulosin|
219427797|NCT05511831|DRUG|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
219427798|NCT05511831|DRUG|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
219427799|NCT06159348|DIAGNOSTIC_TEST|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
219427800|NCT06159348|DIAGNOSTIC_TEST|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
219427801|NCT02307656|DRUG|Atazanavir|
219427802|NCT02307656|DRUG|Cobicistat|
219427803|NCT02307656|DRUG|Active Pharmaceutical Ingredient|
219427804|NCT01403831|OTHER|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
219427805|NCT00603213|PROCEDURE|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
219427806|NCT05566821|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
219427807|NCT05485259|DIETARY_SUPPLEMENT|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
219427808|NCT05485259|OTHER|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
219427809|NCT05948852|PROCEDURE|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
219427810|NCT05341674|OTHER|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
219427811|NCT06123910|DIETARY_SUPPLEMENT|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
219427812|NCT06123910|OTHER|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
219427813|NCT04830228|DEVICE|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
219427814|NCT03807115|OTHER|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
219427815|NCT05984797|OTHER|Integrated Short-term Palliative Rehabilitation|"Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians."
219427816|NCT00003091|BIOLOGICAL|aldesleukin|
219427817|NCT00003091|BIOLOGICAL|recombinant interferon alfa|
219427818|NCT05596786|DRUG|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
219006276|NCT03551860|PROCEDURE|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
219427819|NCT05596786|OTHER|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
219427820|NCT02839941|DRUG|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
219427821|NCT02839941|DRUG|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
219427822|NCT02839941|DRUG|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
219427823|NCT02839941|DRUG|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
219427824|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
219427825|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
219577044|NCT03486054|DEVICE|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
219577045|NCT05023577|DRUG|Rabeprazole|20mg bid
219577046|NCT05023577|DRUG|Bismuth potassium citrate|0.6g bid
219577047|NCT05023577|DRUG|Metronidazole|0.4g qid
219577048|NCT05023577|DRUG|Clarithromycin|0.5g bid
219427826|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
219427827|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
219427828|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
219427829|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
219577049|NCT05023577|DRUG|Levofloxacin|0.5g qd
219427830|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection
219577050|NCT01026259|OTHER|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
219577051|NCT01026259|OTHER|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
219577052|NCT03629028|DIAGNOSTIC_TEST|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
219577053|NCT03629028|DIAGNOSTIC_TEST|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
219427831|NCT04007913|BEHAVIORAL|teleCBIT|Eight sessions of individual behavior therapy
219427832|NCT04929756|BEHAVIORAL|Visual Feedback|Gaze-contingent visual feedback
219427833|NCT00676793|DRUG|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
219577054|NCT03629028|DIAGNOSTIC_TEST|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
219577055|NCT03629028|DIAGNOSTIC_TEST|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
219577056|NCT04637633|DRUG|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
219577057|NCT00793741|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
219577058|NCT00384007|PROCEDURE|Hydrodiscectomy with Spinejet|
219577059|NCT03046719|DRUG|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
219427834|NCT06055127|PROCEDURE|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
219427835|NCT06055127|PROCEDURE|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
219427836|NCT02665078|OTHER|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
219427837|NCT01922245|DEVICE|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
219427838|NCT04328233|BEHAVIORAL|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
219577060|NCT03046719|DRUG|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
219577061|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle intervention program employs a structured, multi-component approach under professional supervision to achieve and sustain 15% weight reduction from baseline. This 12-month intervention features:~1. A weight loss phase (months 1-5) incorporating:~   Individualized calorie restriction using partial meal replacement (carbohydrate energy supply ratio is 20\~25%, and the daily calorie intake is 22.5\*70% kcal/kg/d); exercise recommends at least 150 min of moderate intensity and 2 to 3 resistance training per week; with monthly follow-ups；~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20-25 kcal/kg/d; exercise recommends at least 150 minutes of moderate intensity and 2-3 resistance training per week; with follow-ups every 2 months；~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
219760584|NCT03849105|RADIATION|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
219760585|NCT01926132|DRUG|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
219760586|NCT01926132|DRUG|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
219760587|NCT00639288|OTHER|modified CPT-C|modified CPT-C
219760588|NCT04435743|DRUG|Lenalidomide|"Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
219760589|NCT00991809|DRUG|Alfentanil|15 mcg/kg IM
219760590|NCT00991809|DRUG|Diphenhydramine|25 mg IM
219760591|NCT02478151|DEVICE|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
219760592|NCT03569943|DEVICE|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
219760593|NCT02422329|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline and after intervention.
219006277|NCT03551860|PROCEDURE|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
219006278|NCT01574326|DRUG|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
219006279|NCT01574326|DRUG|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
219006280|NCT00523003|DIETARY_SUPPLEMENT|high protein|2.2 g protein/kg of LBM per day
219006281|NCT00523003|DIETARY_SUPPLEMENT|standard protein|1.1 g protein/kg LBM/day standard protein diet
219006282|NCT03971890|OTHER|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
219006283|NCT03971890|OTHER|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
219006284|NCT03232021|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
219427839|NCT01553071|DRUG|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
219427840|NCT05578482|DRUG|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
219427841|NCT05578482|DRUG|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
219427842|NCT00532428|DRUG|Raloxifene|60 mg QD
219427843|NCT00532428|DRUG|Raloxifene|120 mg QD
219427844|NCT00532428|DRUG|Placebo|Placebo
219427845|NCT04564716|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
219191420|NCT05362435|BEHAVIORAL|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
219427846|NCT04564716|OTHER|Placebo|placebo comparator
219427847|NCT06259864|OTHER|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
219427848|NCT06511440|DEVICE|Vision-700|OCT machines used for diagnostic purposes
219427849|NCT04595396|PROCEDURE|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
219427850|NCT07007780|DRUG|Sacituzumab Tirumotecan|Sacituzumab Tirumotecan monotherapy before surgery at a dose of 5mg/kg, with a dosing schedule of once every 2 weeks for a total of 12 weeks
219427851|NCT05092880|DEVICE|radioembolization|holmium-166 microspheres
219427852|NCT05092880|DRUG|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
219427853|NCT03071380|DRUG|Repatoxaban|1 tablet contains 10 mg rivaroxaban
219427854|NCT03071380|DRUG|Xarelto|1 tablet contains 10 mg rivaroxaban
219427855|NCT03479216|DRUG|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
219427856|NCT03479216|DRUG|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
219427857|NCT05466734|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
219427858|NCT05466734|DRUG|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
219427859|NCT00124241|DRUG|telbivudine|
219427860|NCT00124241|DRUG|lamivudine|
219577062|NCT04116905|BEHAVIORAL|Conventional Treatment|"The conventional treatment arm receive standardized metabolic syndrome management through monthly group education sessions and peer support, with a target of 7% weight reduction from baseline. The program incorporates:~1. A weight loss phase (months 1-5) incorporating:~   Structured lifestyle education; limit the total energy diet (total daily calorie intake is 22.5\*85% kcal/kg/d), with carbohydrates, fat, proteins accounting for 45-55%, 20-30%, and 20-30%, respectively, for the daily energy intake.; physical activity(150 min medium intensity exercise and 2 to 3 resistance training); with monthly follow-ups;~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20\~25 kcal/kg/d; physical activity(150 min medium intensity exercise and 2 to 3 resistance training);with follow-ups every 2 months;~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
219427861|NCT03693118|BEHAVIORAL|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
219427862|NCT03858608|DIETARY_SUPPLEMENT|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
219427863|NCT03858608|OTHER|Usual asthma care|Usual asthma management
219427864|NCT03073408|DRUG|Propofol|Closed loop control for propofol administration guided by the BIS.
219427865|NCT03073408|DRUG|Propofol|Manual control group: Propofol administration adjusted manually.
219427866|NCT03276013|DRUG|Pembrolizumab|pembrolizumab in combination with doxorubicin
219427867|NCT06204302|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
219427868|NCT06204302|DRUG|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
219427869|NCT06204302|DRUG|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
219427870|NCT06868290|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
219427871|NCT06868290|OTHER|Active Comparator|Active comparator option as per protocol
219427872|NCT06868290|DRUG|Glucocorticoids|Concomitant glucocorticoids as per protocol
219427873|NCT02800720|BEHAVIORAL|Meditation Awareness Training|8 Week Meditation Intervention
219427874|NCT02800720|BEHAVIORAL|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
219427875|NCT06526806|OTHER|Kahoot game strategy|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course."
219427876|NCT00798577|DRUG|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
219427877|NCT00798577|DRUG|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
219427878|NCT04546464|BEHAVIORAL|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
219427879|NCT03919838|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
219427880|NCT03919838|DIETARY_SUPPLEMENT|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
219427881|NCT01565590|DRUG|Dexmedetomidine|0.2-1.5 mcg/kg/hr
219427882|NCT01565590|DRUG|propofol|5-80 mcg/kg/min
219427883|NCT01599702|DRUG|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
219427884|NCT04904003|OTHER|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
219427885|NCT00082043|DRUG|Dutasteride|
219427886|NCT00082043|DRUG|Placebo oral capsule|
219427887|NCT02027415|DIETARY_SUPPLEMENT|Beet juice|2 cups of beet juice will be given before the car ride
219427888|NCT02027415|DIETARY_SUPPLEMENT|Orange juice|2 cups of orange juice will be given before the car ride
219427889|NCT00385463|DRUG|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
219427890|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
219427891|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
219427892|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
219427893|NCT00685841|DRUG|Salmeterol MDI|Salmeterol MDI 42 mcg BID
219427894|NCT00685841|DRUG|Placebo|Placebo BID MDI
219427895|NCT02103881|DRUG|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
219577063|NCT00492765|DRUG|Interferon-beta-1a|dosage and frequency as per label
219427896|NCT02103881|DRUG|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
219427897|NCT03870685|PROCEDURE|TAP Block|Transversus Plane block
219427898|NCT03870685|PROCEDURE|Surgical Site Infiltration|Surgical Site Infiltration
219427899|NCT03870685|DRUG|Exparel|liposomal bupivacaine
219427900|NCT04169854|DRUG|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
219427901|NCT04169854|DRUG|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
219006285|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
219006286|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
219006287|NCT04296305|DRUG|Hydromorphone|Given IV after
219006288|NCT04296305|DRUG|Placebo Administration|Given IV after
219006289|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
219006290|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
219006291|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
219006292|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
219577064|NCT00492765|DRUG|Simvastatin|dosage and frequency as per Biogen Idec protocol
219427902|NCT04125173|OTHER|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
219191421|NCT06089837|DRUG|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
219427903|NCT04125173|OTHER|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
219427904|NCT04125173|OTHER|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
219427905|NCT00719225|DRUG|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
219577065|NCT00492765|DRUG|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
219577066|NCT02359201|DRUG|V0018|Oromucosal - Single dose
219427906|NCT01305213|BIOLOGICAL|Bevacizumab|Given IV
219577067|NCT02359201|DRUG|Placebo|Oromucosal - Single dose
219577068|NCT03043118|OTHER|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
219577069|NCT06204419|DRUG|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
219577070|NCT06204419|OTHER|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
219577071|NCT03822364|DRUG|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
219577072|NCT03822364|DRUG|active comparator|commercially available apomorphine injector
219577073|NCT03822364|DRUG|009-0|Inhaled placebo via Staccato device
219577074|NCT03822364|DRUG|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
219577075|NCT03822364|DRUG|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
219006293|NCT04997161|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
219006294|NCT04997161|OTHER|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
219006295|NCT04997161|OTHER|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
219427907|NCT01305213|DRUG|Fosbretabulin Tromethamine|Given IV
219427908|NCT01305213|OTHER|Laboratory Biomarker Analysis|Correlative studies
219427909|NCT01511510|DRUG|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
219427910|NCT01511510|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
219577076|NCT03822364|DRUG|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
219577077|NCT03822364|DRUG|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
219577078|NCT03866018|OTHER|Adapted physical activity|12 sessions of one hour of adapted physical activity.
219577079|NCT02728752|DRUG|Octagam 10%|Patients to be treated with Octagam 10%
219577080|NCT02728752|OTHER|Placebo|Patients to be treated with a Placebo
219577081|NCT05465642|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
219577082|NCT02025751|DRUG|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
219577083|NCT02025751|DRUG|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
219577084|NCT02546843|DRUG|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
219577085|NCT02546843|DRUG|Cisatracurium|cisatracurium 0.15mg/kg intravenously
219577086|NCT02546843|DRUG|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
219577087|NCT02546843|DRUG|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
219577088|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
219577089|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
219577090|NCT00817076|DRUG|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
219577091|NCT01978210|DEVICE|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
219577092|NCT03146182|BEHAVIORAL|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
219577093|NCT03146182|BEHAVIORAL|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
219427911|NCT01511510|DRUG|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
219427912|NCT01511510|DRUG|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
219427913|NCT01511510|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
219427914|NCT01693718|DRUG|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
219427915|NCT01693718|DRUG|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
219427916|NCT01693718|DRUG|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.
219427917|NCT05371470|DEVICE|Ellipsis Health Voice Application|Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
219427918|NCT01431261|OTHER|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
219427919|NCT01431261|BEHAVIORAL|Pain management|Educational sessions in pain management 4 times
219427920|NCT02969447|DRUG|Administration of 10 units of intra venous oxytocin after fetal expulsion|
219427921|NCT02547636|OTHER|Observational study|No intervention will be used in this study.
219427922|NCT05010525|DRUG|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
219006296|NCT01500161|DRUG|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
219427923|NCT01575405|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
219427924|NCT01575405|DRUG|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
219427925|NCT01575405|DRUG|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
219427926|NCT07014267|DEVICE|Intervention Group (Virtual Reality intervention)|"Patients will experience the VR mindfulness intervention using the Tripp App or comparable applications.~Anxiety levels will be measured using the STAI before the VR experience, immediately after the VR experience, and after the procedure."
219427927|NCT06875765|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
219427928|NCT06875765|OTHER|18F-PE2I PET-CT|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I.
219427929|NCT06875765|DIAGNOSTIC_TEST|MRI brain|Magnetic resonance imaging of brain volume.
219427930|NCT00897325|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219427931|NCT00897325|OTHER|Laboratory Biomarker Analysis|Correlative studies
219006297|NCT01500161|DRUG|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
219006298|NCT01500161|DRUG|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
219006299|NCT01500161|DRUG|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
219006300|NCT01500161|DRUG|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
219006301|NCT01500161|DRUG|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
219006302|NCT01500161|DRUG|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
219006303|NCT05261256|DIAGNOSTIC_TEST|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
219006304|NCT00680381|BEHAVIORAL|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
219006305|NCT00680381|BEHAVIORAL|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
219427932|NCT06627777|BEHAVIORAL|Laboratory tasks in early adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
219427933|NCT04465123|DRUG|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
219427934|NCT04465123|DRUG|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
219427935|NCT02550314|DRUG|fiblast,gelatin sponge,fibrin glue|
219427936|NCT03509571|OTHER|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
219427937|NCT03509571|OTHER|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
219427938|NCT07026162|DRUG|Oliceridine|For gynecological laparoscopic surgery, general anesthesia was induced with Oliceridine at a dose of 0.06 mg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was administered with a total dose of Oliceridine ranging from 0.1 to 0.15 mg/kg. Postoperatively, Oliceridine was administered through a patient-controlled analgesia (PCA) system.
219427939|NCT07026162|DRUG|Sufentanil|For gynecological laparoscopic surgery, general anesthesia was induced with Sufentanil at a dose of 0.3 µg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was provided with a total dose of Oliceridine ranging from 0.5 to 0.8 µg/kg. Postoperatively, Sufentanil was administered through a patient-controlled analgesia (PCA) system.
219427940|NCT06127966|PROCEDURE|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
219427941|NCT06127966|PROCEDURE|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
219427942|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
219427943|NCT01413048|DRUG|Carvedilol 25mg|Tablet, q.d.
219427944|NCT01413048|DRUG|AGSCT101 12.5mg|Tablet, q.d.
219427945|NCT03861195|PROCEDURE|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
219427946|NCT02769806|PROCEDURE|MRI|
219427947|NCT05009030|DRUG|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
219427948|NCT04707872|DIAGNOSTIC_TEST|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
219427949|NCT04707872|DIAGNOSTIC_TEST|Prospera|Donor derived cell-free DNA in patient blood
219427950|NCT04707872|DIAGNOSTIC_TEST|HLA antibody|Centralized measurement of HLA antibodies in patient blood
219427951|NCT07090057|PROCEDURE|Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy|Participants undergo Tendoachilles (TA) lengthening or gastrocnemius (GN) recession surgery before Plantaris tenotomy.
219427952|NCT07090057|PROCEDURE|Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession|Participants undergo plantaris tenotomy surgery before Tendoachilles (TA) lengthening or gastrocnemius (GN) recession.
219427953|NCT01234857|DRUG|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
219427954|NCT01234857|DRUG|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
219427955|NCT01234857|DRUG|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
219427956|NCT01234857|DRUG|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
219577094|NCT03021694|DIETARY_SUPPLEMENT|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
219577095|NCT03200691|RADIATION|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
219577096|NCT03200691|DRUG|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
219577097|NCT05387174|BEHAVIORAL|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
219006306|NCT00680381|BEHAVIORAL|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
219577098|NCT04429529|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
219577099|NCT04429529|OTHER|0.9% Saline|Placebo
219577100|NCT04851431|BEHAVIORAL|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
219577101|NCT02794857|DRUG|NP001|
219577102|NCT02794857|DRUG|Placebo|
219760594|NCT02422329|BEHAVIORAL|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
219760595|NCT02422329|BEHAVIORAL|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
219577103|NCT05467163|DEVICE|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
219760596|NCT04591119|PROCEDURE|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
219760597|NCT04591119|PROCEDURE|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
219760598|NCT05317130|OTHER|Athlete health monitoring|Observational study
219427957|NCT05108480|OTHER|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
219427958|NCT04417504|OTHER|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood\_PPS4.
219427959|NCT04417504|OTHER|Control isocaloric breakfast|White bread, butter and milk.
219427960|NCT04622670|OTHER|Media Intervention|Receive DVD
219427961|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
219006307|NCT03750799|DEVICE|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
219006308|NCT03750799|DEVICE|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
219006309|NCT05693441|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
219006310|NCT05693441|OTHER|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
219006311|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
219006312|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
219006313|NCT04403971|DRUG|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
219006314|NCT04403971|DRUG|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
219427962|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
219427963|NCT04622670|OTHER|Survey Administration|Ancillary studies
219427964|NCT04622670|PROCEDURE|Yoga|Attend yoga class
219006315|NCT04403971|OTHER|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
219006316|NCT00192205|BIOLOGICAL|CAIV-T or TIV|
219006317|NCT00748683|OTHER|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
219427965|NCT06549972|OTHER|Acute Ischemic Stroke|first-ever anterior circulation AIS (Acute Ischemic Stroke)
219577104|NCT05467163|DEVICE|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
219006318|NCT05760833|PROCEDURE|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
219006319|NCT04068090|OTHER|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
219006320|NCT04068090|OTHER|Blood Collection|biomarker analysis
219006321|NCT06286904|DEVICE|Skiin Garment system|Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
219427966|NCT02596828|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
219427967|NCT02596828|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
219427968|NCT02596828|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
219577105|NCT05467163|PROCEDURE|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
219577106|NCT02947074|BEHAVIORAL|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
219577107|NCT00891839|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
219006322|NCT05329272|OTHER|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
219006323|NCT03240250|PROCEDURE|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
219577108|NCT00891839|DRUG|Rituximab|Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
219427969|NCT02596828|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
219427970|NCT04884945|PROCEDURE|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
219427971|NCT04884945|DEVICE|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
219427972|NCT00062205|DRUG|imatinib mesylate|
219427973|NCT02332798|DRUG|PF-04958242|Administered as specified in the treatment arm
219427974|NCT02332798|DRUG|Placebo|Administered as specified in the treatment arm
219427975|NCT05406440|DRUG|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
219427976|NCT05406440|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
219427977|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
219427978|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
219427979|NCT01221818|DRUG|E6007|E6007 25mg single dose or matching placebo
219427980|NCT01221818|DRUG|E6007|E6007 50mg single dose or matching placebo
219427981|NCT01221818|DRUG|E6007|E6007 100mg single dose or matching placebo
219427982|NCT01221818|DRUG|E6007|E6007 200mg single dose or matching placebo
219427983|NCT01221818|DRUG|E6007|E6007 400mg single dose or matching placebo
219427984|NCT01221818|DRUG|E6007|E6007 600 mg single dose or matching placebo
219427985|NCT00151541|DRUG|Dapsone Topical Gel + adapalene gel 0.1%|
219006324|NCT03240250|PROCEDURE|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
219006325|NCT03634462|OTHER|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
219006326|NCT02904330|DRUG|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
219427986|NCT00151541|DRUG|Dapsone Topical Gel + benzoyl peroxide gel 4%|
219427987|NCT00151541|DRUG|Dapsone Topical Gel + vehicle control|
219427988|NCT04285372|PROCEDURE|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
219427989|NCT04285372|PROCEDURE|No side branch protection/ballooning|No intervention on the side branch
219427990|NCT02071641|DRUG|Sunitinib|
219427991|NCT02297646|BEHAVIORAL|Endurance Training|
219427992|NCT05810389|COMBINATION_PRODUCT|Fluoride|Application methods of delivery of topical fluoride
219577109|NCT04774952|DRUG|RMC-5552|RMC-5552 for IV administration
219577110|NCT05419115|DRUG|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
219006327|NCT01610544|DRUG|3'-deoxy-3'-18F fluorothymidine (FLT)|
219006328|NCT01610544|OTHER|PET/CT scan|
219191422|NCT06089837|DRUG|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
219427993|NCT00805818|DRUG|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
219427994|NCT00805818|DRUG|Placebo|Sodium Chloride 0.9% Injection
219427995|NCT00259389|BEHAVIORAL|Directly observed therapy (DOT)|
219427996|NCT01340404|PROCEDURE|Stem cell transplantation|Stem cell transplantation
219427997|NCT01340404|PROCEDURE|Transfusion program|Transfusion program
219427998|NCT05223699|BIOLOGICAL|MGTA-117|MGTA-117 will be administered as an IV infusion
219427999|NCT03751969|DRUG|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
219428000|NCT00628225|BEHAVIORAL|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
219428001|NCT00628225|BEHAVIORAL|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
219428002|NCT00947934|DEVICE|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
219428003|NCT04797312|DRUG|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
219428004|NCT04797312|DRUG|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
219428005|NCT06066840|DRUG|Basiliximab|Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
219428006|NCT06066840|DRUG|Vedolizumab|Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
219428007|NCT03983460|DRUG|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
219428008|NCT03983460|DRUG|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
219428009|NCT03983460|PROCEDURE|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion"
219428010|NCT03983460|PROCEDURE|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm"
219428011|NCT03983460|PROCEDURE|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
219577111|NCT05419115|DEVICE|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
219577112|NCT06126965|DRUG|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
219577113|NCT06126965|OTHER|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
219577114|NCT01520974|OTHER|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
219577115|NCT01520974|OTHER|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
219577116|NCT00005765|DRUG|nicotine|
219577117|NCT00005765|DRUG|alcohol|
219577118|NCT00532935|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
219428012|NCT06156891|PROCEDURE|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
219428013|NCT06156891|PROCEDURE|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
219428014|NCT03027219|DRUG|Alprostadil|Vasodilator for anastomosis-site of free flap
219577119|NCT00532935|DRUG|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
219577120|NCT02379286|OTHER|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
219577121|NCT03738514|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
219577122|NCT03738514|OTHER|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
219577123|NCT03738514|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
219577124|NCT00456495|DRUG|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
219006329|NCT04044716|DEVICE|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
219006330|NCT04044716|OTHER|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
219006331|NCT01645696|DEVICE|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
219006332|NCT01645696|DEVICE|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
219006333|NCT01645696|DEVICE|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
219006334|NCT00594984|DRUG|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
219006335|NCT00594984|DRUG|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
219006336|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
219006337|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
219006338|NCT00594984|DRUG|Brivanib Placebo|Oral, tablet, QD, until progression
219191423|NCT05269966|BIOLOGICAL|Injection Brolucizumab|"Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing."
219191424|NCT04821141|DRUG|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
219191425|NCT05309616|DRUG|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
219577125|NCT01474902|DRUG|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
219577126|NCT01124708|DRUG|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
219577127|NCT01124708|DRUG|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
219577128|NCT03244423|DRUG|Normal saline at induction|0.5 ml/kg
219577129|NCT03244423|DRUG|Normal saline infusion|1ml/kg/hr. during surgery for six hours
219577130|NCT03244423|DRUG|Intravenous tranexamic acid|50 mg/kg
219577131|NCT03244423|DRUG|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
219577132|NCT03244423|DRUG|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
219577133|NCT03244423|DRUG|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
219191426|NCT06156072|DIAGNOSTIC_TEST|Ultrasound-guided venipuncture|Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
219428015|NCT04055467|DRUG|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
219428016|NCT04055467|BEHAVIORAL|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
219428017|NCT00525785|DRUG|5-Fluorouracil|"2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
219428018|NCT00525785|DRUG|Folinic Acid|200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
219006339|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
219428019|NCT00525785|DRUG|Oxaliplatin|"100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
219428020|NCT00525785|RADIATION|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
219428021|NCT00525785|PROCEDURE|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
219428022|NCT02455388|DIETARY_SUPPLEMENT|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
219428023|NCT02455388|DIETARY_SUPPLEMENT|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
219428024|NCT03263741|DRUG|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
219428025|NCT04005807|DRUG|BPN-14967|BPN-14967 oral capsules
219428026|NCT04005807|DRUG|Placebo|Oral capsules
219428027|NCT01011088|OTHER||Not any artificial interventions were given
219428028|NCT02747407|BIOLOGICAL|Hepatitis A Vaccine|
219428029|NCT02747407|OTHER|Laboratory Biomarker Analysis|Correlative studies
219428030|NCT02747407|BIOLOGICAL|Tetanus Toxoid Vaccine|
219428031|NCT02747407|BIOLOGICAL|Trivalent Influenza Vaccine|
219577134|NCT05147038|DEVICE|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
219428032|NCT03872193|OTHER|Exercise|Virtual Reality Exercies
219428033|NCT02471209|DRUG|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
219428034|NCT01541111|DRUG|Magnesiun|75mg pills; each 12h; 12wk
219428035|NCT02205164|DRUG|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
219428036|NCT02205164|DRUG|Palonosetron|Aloxi 0.25mg
219428037|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams once daily
219428038|NCT01316939|DRUG|Placebo|Placebo
219428039|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams twice daily
219428040|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
219428041|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219428042|NCT03039049|DRUG|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
219428043|NCT02150512|DEVICE|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
219428044|NCT02150512|DEVICE|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
219428045|NCT02156752|BEHAVIORAL|ACT|Treatment is based on Acceptance and Commitment Therapy
219428046|NCT02156752|BEHAVIORAL|SR|Treatment is based on Self-Regulation theory.
219428047|NCT02156752|BEHAVIORAL|WLO|Treatment is based on cooking tips and demonstrations.
219428048|NCT01291706|DEVICE|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
219428049|NCT00929136|BIOLOGICAL|USP endotoxin|Continuous intra-arterial infusion
219428050|NCT05351463|PROCEDURE|papila suture technique|simple interupted vs internal horoizontal matress suture
219428051|NCT00888212|PROCEDURE|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
219428052|NCT01729663|BIOLOGICAL|CSF470 vaccine, BCG, Molgramostim|
219428053|NCT01729663|DRUG|interferon alpha 2b|
219428054|NCT03624439|DEVICE|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
219577135|NCT06142370|OTHER|Descriptive|The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
219577136|NCT01366378|DRUG|methylnaltrexone|
219577137|NCT01869478|DRUG|Intravenous Thrombolysis|
219577138|NCT01869478|DEVICE|Endovascular Arterial Reperfusion|
219577139|NCT01663727|DRUG|Bevacizumab [Avastin]|Intravenous repeating dose
219577140|NCT01663727|DRUG|Paclitaxel|Intravenous repeating dose
219577141|NCT01663727|DRUG|Placebo|Intravenous repeating dose
219577142|NCT04150198|DEVICE|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
219577143|NCT06898437|DRUG|177Lu-LNC1004 Injection|Intravenous administration: a single dose of 80 mCi per Cycle
219577144|NCT06821191|DRUG|clopidogrel 75 mg|Clopidogrel 75 mg od for 30 ± 5 days
219428055|NCT03624439|DEVICE|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
219428056|NCT04379960|OTHER|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
219428057|NCT02463136|BEHAVIORAL|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
219428058|NCT02463136|DEVICE|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
219577145|NCT06821191|DRUG|Prasugrel 5 mg|Prasugrel 5 mg od for 30 ± 5 days
219428059|NCT01760759|BEHAVIORAL|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
219428060|NCT01760759|BEHAVIORAL|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
219428061|NCT04733001|DRUG|HSG4112|Once-daily oral administration
219428062|NCT01629901|DEVICE|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
219428063|NCT05247385|DRUG|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
219428064|NCT05247385|DRUG|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
219428065|NCT00745953|DRUG|Valsartan|Valsartan 320mg PO daily for 8 months
219428066|NCT00745953|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
219428067|NCT01234896|DRUG|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
219577146|NCT06798571|DRUG|Elagolix Oral Tablet|2 x 200 mg tablet
219577147|NCT06798571|DRUG|Estradiol patch|0.05 mg/day patch
219577148|NCT06798571|OTHER|cellulose placebo|placebo tablet
219577149|NCT06798571|OTHER|placebo patch|placebo patch
219577150|NCT06927882|OTHER|WBV Therapy Group|"* Frequency: 3 sessions per week for 12 weeks.~* Duration: 25 minutes per session.~* Vibration Parameters: Participants will undergo whole body vibration therapy at a frequency of 30 Hz, for 25 minutes per session, 3 times a week, with an amplitude of 1-2 mm, over a duration of 12 weeks."
219577151|NCT06927882|OTHER|Placebo Group:|• Participants will stand on a non-vibrating platform and perform similar static and dynamic exercises for the same duration. The platform will mimic the active intervention's noise and display settings to maintain blinding.
219577152|NCT06927882|OTHER|Control|Only assessment at baseline, after 12 weeks and 6 months.
219577153|NCT06928207|COMBINATION_PRODUCT|Provide the diagnostic (RDT) for free to clients suspected of having malaria and provide a subsidized ACT to only those testing positive|To promote the use of the recommended first line drug, we implement a conditional subsidy. The retail provider is given the malaria diagnostic for free and is instructed to test clients suspected of having malaria. Only if the test is positive, the provider is instructed to provide the ACT at a low cost.
219577154|NCT06928909|OTHER|Intensity-adapted pediatric acute myeloid treatment guidelines|This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.
219577155|NCT06927388|DEVICE|freeform myopia control spectacles|The open ring freeform myopia control spectacle lens designs incorporate positively powered cylindrical annular refractive elements (CARE) on the back surface with a superiorly positioned opening in each CARE. The CARE provides an effective optical myopic defocus signal for myopia control and the ring opening facilitates a defocus free zone to aid a smoother visual free transition from downgaze through to upgaze (far) vision for the wearer. The OR designs provide a difference in area and strength of myopia defocus by altering design parameters i.e. zone widths and zone powers. The OR2 and OR3 designs have wider zones and/or higher zone powers than OR1.
219428068|NCT01234896|DRUG|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
219577156|NCT06927388|DEVICE|Commercial myopia control spectacle lens (CML)|Myoless freeform peripheral plus myopia control spectacle lens by IOT
219577157|NCT06928870|OTHER|MAP 55-65 mmHg|MAP will be maintained between 55-65 mmHg during anesthesia.
219428069|NCT01234896|DRUG|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
219428070|NCT01234896|DRUG|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
219428071|NCT02679794|BEHAVIORAL|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
219428072|NCT02679794|BEHAVIORAL|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
219428073|NCT04909216|OTHER|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
219428074|NCT01788280|DRUG|Fluciclitite , PET imaging, and Bevacizumab|\[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
219428075|NCT03466307|DEVICE|Ultrasonography|Ultrasonographic examination of shoulder
219428076|NCT05063617|DEVICE|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
219428077|NCT00801892|DEVICE|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
219428078|NCT00801892|DEVICE|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
219428079|NCT06167278|OTHER|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
219428080|NCT01521806|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to snack foods
219428081|NCT00647972|DRUG|Olanzapine Tablets 20 mg|20mg, single dose fasting
219428082|NCT00647972|DRUG|Zyprexa® Tablets 20 mg|20mg, single dose fasting
219577158|NCT06928870|OTHER|MAP 66-75 mmHg|MAP will be maintained between 66-75 mmHg during anesthesia.
219191427|NCT04734080|DRUG|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
219191428|NCT04734080|OTHER|Placebo oral tablet|Non-active placebo
219191429|NCT05739955|OTHER|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
219191430|NCT05739955|OTHER|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
219428083|NCT01016678|DRUG|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
219428084|NCT01016678|DRUG|Placebo|Dummy pill comparator
219428085|NCT01610908|OTHER|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
219577159|NCT06928987|OTHER|Touch Massage|"The practitioner performs the touch-massage for 15 minutes on clothed personnel in a seated position on an ergonomic massage chair. The massage focuses on the back, neck and arm areas. It's a precise, technical sequence of pressure, stretching and sweeping movements that follows the following pattern:~* Basic anti-stress maneuvers to relieve tension,~* Relaxation of the upper torso with weightless movements to loosen shoulders and arms,~* Stretching,~* Redynamization through rapid friction on the back.~Burnout, anxiety, affect, and musculoskeletal disorders (MSDs) will be assessed in participants using the following questionnaires at different times of the study."
219760599|NCT05348811|DRUG|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
219760600|NCT00002766|BIOLOGICAL|dactinomycin|
219760601|NCT00002766|BIOLOGICAL|sargramostim|
219760602|NCT00002766|DRUG|carmustine|
219760603|NCT00002766|DRUG|cyclophosphamide|
219760604|NCT00002766|DRUG|cytarabine|
219760605|NCT00002766|DRUG|daunorubicin hydrochloride|
219760606|NCT00002766|DRUG|doxorubicin hydrochloride|
219760607|NCT00002766|DRUG|etoposide|
219191431|NCT05739955|OTHER|Routine Disinfection|Routine disinfection at the study hospital
219191432|NCT06233253|OTHER|Best Practice|Receive usual care
219191433|NCT06233253|OTHER|Medical Chart Review|Ancillary studies
219428086|NCT01610908|OTHER|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
219428087|NCT03185416|OTHER|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
219428088|NCT01233700|BEHAVIORAL|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
219428089|NCT01233700|BEHAVIORAL|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
219428090|NCT01766219|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219428091|NCT01126684|DRUG|Atorvastatin|10 mg of atorvastatin once daily for six months
219428092|NCT01126684|DRUG|Placebo|placebo once daily for six months
219428093|NCT03550365|OTHER|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
219428094|NCT03550365|OTHER|Rye bread intervention|4 week dietary intervention rich in rye bread
219428095|NCT03550365|OTHER|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
219428096|NCT02691481|DIETARY_SUPPLEMENT|Oatmeal breakfast|
219428097|NCT02691481|DIETARY_SUPPLEMENT|Glucerna formula|
219428098|NCT02691481|DIETARY_SUPPLEMENT|Ultra Glucose Control formula|
219428099|NCT00541736|DRUG|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
219428100|NCT06376188|OTHER|communication training|The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
219428101|NCT05557097|DIAGNOSTIC_TEST|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
219428102|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, two days treatment
219428103|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, two days treatment
219428104|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, two days treatment
219428105|NCT00700063|DRUG|Vehicle gel|two days treatment
219428106|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, three days treatment
219760608|NCT00002766|DRUG|mercaptopurine|
219760609|NCT00002766|DRUG|methotrexate|
219760610|NCT00002766|DRUG|mitoxantrone hydrochloride|
219760611|NCT00002766|DRUG|pegaspargase|
219760612|NCT00002766|DRUG|prednisone|
219760613|NCT00002766|DRUG|vincristine sulfate|
219428107|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, three days treatment
219428108|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, three days treatment
219428109|NCT00700063|DRUG|Vehicle gel|three days treatment
219760614|NCT00002766|RADIATION|radiation therapy|
219760615|NCT01451411|DRUG|Conivaptan hydrochloride|Intravenous
219760616|NCT01451411|DRUG|Placebo|Intravenous
219760617|NCT03483389|DRUG|Alcohol, Ethyl|Randomized within-subjects design
219760618|NCT03483389|OTHER|Alcohol, Ethyl - placebo|Randomized within-subjects design
219760619|NCT00020254|BIOLOGICAL|aldesleukin|
219760620|NCT00020254|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
219760621|NCT00020254|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
219760622|NCT00020254|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
219760623|NCT00020254|BIOLOGICAL|sargramostim|
219760624|NCT00020254|DRUG|nilutamide|
219760625|NCT00077974|DRUG|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
219006340|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
219006341|NCT04268810|PROCEDURE|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
219191434|NCT06233253|BEHAVIORAL|Online Mindfulness Meditation|Receive an online mindfulness intervention
219191435|NCT06233253|OTHER|Survey Administration|Ancillary studies
219191436|NCT04661397|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
219428110|NCT04511780|OTHER|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
219760626|NCT00256126|DRUG|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
219760627|NCT00256126|DRUG|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
219760628|NCT03674983|BEHAVIORAL|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
219760629|NCT04161664|DRUG|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
219760630|NCT02652221|DEVICE|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
219760631|NCT01877304|DEVICE|AKITA|
219760632|NCT00003816|BIOLOGICAL|anti-thymocyte globulin|Given IV
219760633|NCT00003816|DRUG|busulfan|Given IV
219760634|NCT00003816|DRUG|carboplatin|Given IV
219760635|NCT00003816|DRUG|cyclophosphamide|Given IV
219760636|NCT00003816|DRUG|etoposide|Given IV
219191437|NCT04661397|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
219191438|NCT04661397|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
219191439|NCT04661397|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
219428111|NCT00546429|DEVICE|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
219428112|NCT01188096|DRUG|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
219428113|NCT03728504|DRUG|ASN002|Daily dose of ASN002 for 32 weeks
219760637|NCT00003816|DRUG|fludarabine phosphate|Given IV
219760638|NCT00003816|DRUG|melphalan|Given IV
219760639|NCT00003816|DRUG|thiotepa|Given IV
219760640|NCT00003816|RADIATION|total-body irradiation|Given twice daily for 3 days
219760641|NCT00312286|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
219760642|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
219006342|NCT01516554|DRUG|Testosterone undecanoate|40 mg twice daily
219006343|NCT01516554|DRUG|placebo|twice daily
219006344|NCT01965496|DRUG|PEX168|A injection administered subcutaneously
219006345|NCT02431234|OTHER|serum RANKL|
219191440|NCT05941182|OTHER|online questionnaires|Before and after online questionnaires
219191441|NCT06451627|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .
219191442|NCT06451627|DRUG|saline|Saline will be infused at a speed of 0.3mg / kg / h during surgery .
219191443|NCT05199051|COMBINATION_PRODUCT|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
219191444|NCT06145620|OTHER|Physiotherapy|The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
219428114|NCT03728504|DRUG|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
219428115|NCT04235439|DRUG|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
219428116|NCT06282419|OTHER|USE OF MOBILE ULTRASOUND|"First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth."
219760643|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
219760644|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
219760645|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
219760646|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
219760647|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
219428117|NCT06282419|OTHER|ultrasound image taken from the internet|First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
219428118|NCT06377722|DRUG|Cabozantinib|This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
219760648|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
219760649|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
219760650|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
219760651|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
219760652|NCT06068517|DEVICE|Closed incision negative pressure wound therapy|After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.
219760653|NCT06068517|DEVICE|Standard dressing|After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
219428119|NCT01273493|DRUG|Trabectedin|Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
219428120|NCT01273493|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
219428121|NCT06376370|OTHER|Application of computer-assisted cognitive rehabilitation program|Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
219428122|NCT04799353|DRUG|Budigalimab|Subcutaneous (SC)
219760654|NCT01404247|OTHER|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
219760655|NCT01404247|PROCEDURE|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
219760656|NCT02141009|BIOLOGICAL|Prevnar 13|
219428123|NCT04799353|DRUG|Placebo|Subcutaneous (SC)
219428124|NCT04799353|DRUG|Budigalimab|Intravenous (IV)
219760657|NCT02250417|OTHER|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
219760658|NCT02874729|PROCEDURE|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
219428125|NCT04799353|DRUG|Placebo|Intravenous (IV)
219760659|NCT02874729|PROCEDURE|Urine collection|Urine will be collected in appropriate sterile holders provided.
219760660|NCT02874729|PROCEDURE|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
219760661|NCT02874729|PROCEDURE|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
219760662|NCT00899912|GENETIC|microarray analysis|
219760663|NCT00899912|OTHER|diagnostic laboratory biomarker analysis|
219428126|NCT00851253|RADIATION|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
219428127|NCT04698512|DEVICE|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
219428128|NCT05616169|DEVICE|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
219428129|NCT05473104|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Social training targeting adolescents with ASD and focused on making and keeping friends
219428130|NCT00043212|DRUG|Dendritic cell immunotherapy|
219428131|NCT03909555|OTHER|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
219428132|NCT00565214|DIETARY_SUPPLEMENT|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
219428133|NCT00565214|DIETARY_SUPPLEMENT|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
219428134|NCT03625154|PROCEDURE|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
219428135|NCT03625154|OTHER|non operative management|closed reduction and splinting followed by progressive weight bearing
219428136|NCT01621854|DRUG|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
219428137|NCT03385174|OTHER|Carbon monoxide|Carbon monoxide inhalation
219428138|NCT02062398|DEVICE|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
219428139|NCT01277497|DRUG|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
219428140|NCT01277497|DRUG|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
219428141|NCT03924310|DEVICE|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
219428142|NCT03924310|DEVICE|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
219428143|NCT03230513|OTHER|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
219428144|NCT03230513|OTHER|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
219428145|NCT02646150|PROCEDURE|Magnetic Resonance Perfusion Imaging|
219428146|NCT01779648|DEVICE|DVT-3000|
219428147|NCT01779648|DEVICE|SCD Express|
219428148|NCT02099487|RADIATION|Radiation|hypofractionated IMRT
219428149|NCT00415519|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
219428150|NCT00415519|DRUG|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
219428151|NCT03154307|DEVICE|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
219428152|NCT02416778|DRUG|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
219428153|NCT03485222|DRUG|Empagliflozin|6 months
219428154|NCT03485222|DRUG|Placebos|placebo equivalent for 6 months
219428155|NCT01618422|OTHER|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
219760664|NCT05579652|DIAGNOSTIC_TEST|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
219760665|NCT01711528|DRUG|Bortezomib|Given SC
219760666|NCT01711528|DRUG|Dexamethasone|Given PO
219760667|NCT01711528|DRUG|Dinaciclib|Given IV
219760668|NCT01711528|OTHER|Laboratory Biomarker Analysis|Correlative studies
219760669|NCT00002366|DRUG|Ritonavir|
219760670|NCT02405299|OTHER|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
219428156|NCT01618422|OTHER|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
219428157|NCT03657810|DRUG|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
219428158|NCT03657810|DRUG|Norco|hydrocodone 5 mg/APAP 325 mg
219428159|NCT03657810|DRUG|Placebo|Placebo matching CL-108
219428160|NCT02157012|DRUG|The effectiveness of Xeljanz in rheumatoid arthritis patients|
219428161|NCT03983226|PROCEDURE|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
219428162|NCT03983226|DRUG|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
219428163|NCT03983226|DRUG|Niraparib|Niraparib maintenance therapy
219428164|NCT00688545|DRUG|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
219428165|NCT00688545|DRUG|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
219428166|NCT02699853|OTHER|Questionnaire Administration|Ancillary studies
219428167|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo RRC
219428168|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo ORC
219428169|NCT03514888|PROCEDURE|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
219428170|NCT01886885|BEHAVIORAL|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
219428171|NCT05599113|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
219428172|NCT02691364|PROCEDURE|Blood withdrawal|
219428173|NCT03554850|DEVICE|Trevo® Retriever|Stent retriever procedure
219428174|NCT00577915|OTHER|Radiology/MRI scan|MRI spectroscopy
219577160|NCT06926907|BEHAVIORAL|The Teacher Education and Classroom Habits (T.E.A.C.H.) Program|The T.E.A.C.H. Program utilized essential constructs of the Social Cognitive Theory to deliver virtual nutrition education to Montessori teachers over a 6-week period. The intervention consisted of four program components: 1. An interactive online nutrition education platform with 6 modules was developed using a WordPress website. Each module contained 5 topics including adult nutrition, child nutrition, classroom food practices, cultural practices, and teacher-parent communication. Teachers were provided login information via email containing a unique identifier to be used as their username and were prompted to complete one module per week for 6 weeks; 2. Live weekly virtual education sessions were held via Zoom to supplement and reinforce the online learning experience; 3. A Montessori-based nutrition curriculum with 6 weekly lessons to utilize in the classroom was provided to each participant; 4. Educational handouts to be disseminated to parents.
219577161|NCT06927050|BEHAVIORAL|Visual Communication Tool|MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.
219760671|NCT03376932|DRUG|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
219428175|NCT00263250|PROCEDURE|watchful waiting or tension-free hernia repair|
219428176|NCT05441943|PROCEDURE|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
219428177|NCT00533611|DRUG|MK0524A, /Duration of Treatment : 4 Weeks|
219428178|NCT00533611|DRUG|Comparator : niacin /Duration of Treatment : 1 Weeks|
219428179|NCT04801641|DRUG|Placebo|Six placebo capsules taken orally twice daily
219760672|NCT03376932|DRUG|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
219760673|NCT03376932|DRUG|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
219760674|NCT03376932|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
219760675|NCT03376932|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
219760676|NCT03376932|DEVICE|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
219760677|NCT03376932|DEVICE|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
219760678|NCT03376932|DEVICE|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
219428180|NCT04801641|DRUG|Nabilone|Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
219577162|NCT03496857|DEVICE|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
219577163|NCT03496857|OTHER|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
219577164|NCT06175247|OTHER|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
219577165|NCT00951626|BEHAVIORAL|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
219577166|NCT00951626|BEHAVIORAL|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
219428181|NCT06195943|BEHAVIORAL|Exercise Intervention with use of El-Fit App|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
219428182|NCT01155596|BEHAVIORAL|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
219428183|NCT04489927|DEVICE|Tcore|Temperature Measurement of standard care versus the Tcore measurement
219577167|NCT00951626|DIETARY_SUPPLEMENT|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
219577168|NCT00951626|OTHER|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
219577169|NCT00951626|OTHER|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
219428184|NCT05456152|DRUG|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
219428185|NCT01705587|DRUG|teriparatide|20 microgram once-daily subcutaneous injection
219428186|NCT02487277|DRUG|PEGPH20|
219428187|NCT02487277|DRUG|Gemcitabine|
219428188|NCT02487277|DRUG|Nab-paclitaxel|
219428189|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
219428190|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
219428191|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
219577170|NCT00951626|PROCEDURE|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
219577171|NCT00951626|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
219577172|NCT00951626|PROCEDURE|assessment of therapy complications|Collected throughout the 12 month study period
219577173|NCT00951626|PROCEDURE|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
219428192|NCT04324788|OTHER|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
219428193|NCT04324788|OTHER|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
219428194|NCT01373918|DRUG|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
219428195|NCT01373918|DRUG|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
219428196|NCT00461422|DRUG|Ganirelix|sc injection of Ganirelix 0.25 mg per day
219428197|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
219428198|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
219428199|NCT06027944|OTHER|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
219428200|NCT05859971|DRUG|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
219428201|NCT05859971|DEVICE|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
219428202|NCT06045728|OTHER|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
219428203|NCT06045728|BEHAVIORAL|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
219428204|NCT03004976|BIOLOGICAL|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
219428205|NCT03004976|OTHER|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
219428206|NCT01609725|DEVICE|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
219428207|NCT01609725|DEVICE|Oral prophylaxis|One session of supraginigval calculus removal
219428208|NCT02194556|DRUG|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
219428209|NCT02194556|DRUG|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
219428210|NCT04687488|OTHER|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
219577174|NCT00951626|PROCEDURE|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
219428211|NCT04687488|OTHER|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
219428212|NCT02539524|OTHER|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
219428213|NCT02539524|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
219428214|NCT01939093|DRUG|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
219428215|NCT01939093|DIETARY_SUPPLEMENT|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
219428216|NCT01939093|DRUG|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
219428217|NCT02892201|DRUG|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
219428218|NCT05438251|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
219428219|NCT03277508|DEVICE|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
219428220|NCT03277508|DEVICE|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
219428221|NCT00209326|DRUG|FE200440|
219428222|NCT02428907|BEHAVIORAL|simulation training|teamtraining of endoscopy staff
219428223|NCT01458496|BEHAVIORAL|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
219428224|NCT03119246|OTHER|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
219428225|NCT03337425|BEHAVIORAL|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
219428226|NCT03337425|BEHAVIORAL|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
219428227|NCT03337425|OTHER|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
219428228|NCT06528730|DIAGNOSTIC_TEST|DCM|Confirm degenerative cervical myelopathy by Orthopaedic surgeon and MRI
219006346|NCT02495441|OTHER|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
219191445|NCT06223451|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
219191446|NCT06223451|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
219428229|NCT02866734|OTHER|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
219428230|NCT02866734|OTHER|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
219191447|NCT04088838|OTHER|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
219428231|NCT02866734|OTHER|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
219428232|NCT00102934|DRUG|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
219428233|NCT05034614|DIAGNOSTIC_TEST|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
219428234|NCT05034614|DIAGNOSTIC_TEST|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
219428235|NCT01385319|DEVICE|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
219428236|NCT01385319|DEVICE|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
219428237|NCT02293824|DRUG|Caffeine|Given per standard of care.
219428238|NCT01890317|PROCEDURE|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
219428239|NCT03892707|DRUG|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
219577175|NCT00951626|PROCEDURE|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
219577176|NCT00951626|PROCEDURE|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
219006347|NCT04811989|BEHAVIORAL|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
219428240|NCT01612377|DRUG|Prednisolone-Dipyridamole|Oral, QD
219428241|NCT01612377|DRUG|Prednisone|Oral QD Prednisone 5mg
219428242|NCT01612377|DRUG|prednisone|Oral, QD prednisone 7.5mg
219428243|NCT04263363|DRUG|Sugammadex 100 MG/ML [Bridion]|Sugammadex administered to patients within the clinical best practice pathway.
219428244|NCT02428712|DRUG|FORE8394|
219428245|NCT01807949|DRUG|Placebo|Matching placebo tablet
219428246|NCT01807949|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
219577177|NCT06928896|PROCEDURE|This interventional trial enrolled a total of 42 patients, dividing them into two age groups: group 1. Using the friction and group 2. Using the frictionless|Cone beam computed tomography (CBCT) was conducted before and after retraction to evaluate alveolar changes and speed.
219577178|NCT06928935|BEHAVIORAL|d-DBT|d-DBT is an 8-week self-led online intervention that teaches mindfulness, emotional regulation, distress tolerance, and interpersonal effectiveness skills. Participants receive weekly digital navigator check-ins.
219760679|NCT03376932|DEVICE|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
219006348|NCT04811989|BEHAVIORAL|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
219006349|NCT04811989|BEHAVIORAL|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
219006350|NCT04811989|BEHAVIORAL|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
219006351|NCT01733602|DEVICE|transcranial direct current stimulation|
219191448|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1\. Sleep, through the Pediatric Sleep Questionnaire."
219428247|NCT01807949|DRUG|Ivacaftor|Film-coated tablet
219577179|NCT06927908|PROCEDURE|Partial Cardiac Denervation|Expose the ligament of Marshall (LOM) between the left atrial appendage and left pulmonary veins, and transect it using an electrocautery knife. Expose the fatty pad along the Waterston groove between the right pulmonary veins and the right atrium, and completely resect it down to the myocardial surface, extending the superior margin beyond the ostium of the right superior pulmonary vein and the inferior margin to the inferior vena cava.
219577180|NCT06927596|PROCEDURE|Interventional therapy|The fistula was occluded by coil and NBCA glue.
219760680|NCT02949011|DRUG|Baloxavir Marboxil|Tablets taken orally
219760681|NCT02949011|DRUG|Placebo to Baloxavir Marboxil|Matching tablets taken orally
219760682|NCT02949011|DRUG|Oseltamivir|Capsules taken orally
219760683|NCT02949011|DRUG|Placebo to Oseltamivir|Matching placebo capsules taken orally
219760684|NCT05829876|OTHER|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
219760685|NCT05829876|OTHER|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
219577181|NCT06461481|DEVICE|Withings Scanwatch|Data captured by the used smartwatches (Withings Scanwatch) includes activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep efficiency and quality etc.).
219577182|NCT02605798|DRUG|Elbanovir|1 tablet contains 400 mg sofosbuvir
219577183|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
219428248|NCT03029858|OTHER|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
219428249|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
219428250|NCT03819764|BEHAVIORAL|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
219428251|NCT03819764|BEHAVIORAL|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
219428252|NCT04325906|DEVICE|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
219577184|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
219428253|NCT04325906|PROCEDURE|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
219577185|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 8g protein/100kcal|Enteral feed containing 8g protein/100kcal
219191449|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
219191450|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3\. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4\. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5\. Tongue peak pressure during 3 sec. of tongue protrusion."
219577186|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 5g protein/100kcal|Enteral feed containing 5g protein/100kcal
219577187|NCT04064814|DRUG|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
219577188|NCT04064814|DRUG|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
219577189|NCT03083821|DRUG|Baraclude|Specified dose on specified day
219577190|NCT04969861|DRUG|Bempegaldesleukin|Specified dose on specified days
219577191|NCT04969861|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
219577192|NCT06920615|BEHAVIORAL|Fading and chaining combined with differential reinforcement|Intervention Treatment will involve backward chaining, fading and differential reinforcement.
219577193|NCT06920615|BEHAVIORAL|Differential reinforcement of high rate|This will be identical to baseline, except a DRH will be introduced: The participant will be instructed to complete his whole meal within set time criteria to receive an identified reinforcer.
219577194|NCT06920615|BEHAVIORAL|Response interruption with redirection|RIRD involves physically blocking a movement from occurring using the least amount of physical contact for max 3 s, and then redirecting behavior to an ongoing activity or movement. Stereotypi that is verbal or not possible to block physically will involve a demand to answer a verbal question or a motor task that sufficiently interrupts the behavior and then redirecting.
219760686|NCT05014152|DEVICE|Q-temp-w1|Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.
219760687|NCT05014152|DEVICE|Omron thermometer(MC-171W)|Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
219760688|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
219760689|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
219760690|NCT02489084|OTHER|Blood sampling|
219191451|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6\. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7\. The tongue endurance during tongue protrusion."
219428254|NCT04932044|BEHAVIORAL|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
219191452|NCT06166680|OTHER|Orofacial praxis assessment|\- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
219428255|NCT04932044|OTHER|Routine care|Receives routine care and provide general discharge care and nursing guidance.
219428256|NCT05711199|DRUG|Glyceroltrinitrat|transdermal patch
219006352|NCT03608592|BIOLOGICAL|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
219428257|NCT06364761|PROCEDURE|Bag in the lens cataract surgery|Cataract surgery using the Morcher 89A intraocular lens
219428258|NCT00614653|DRUG|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
219428259|NCT00614653|DRUG|Erlotinib|100 mg by mouth Once Daily on days with radiation.
219428260|NCT00614653|DRUG|Capecitabine|400 mg/m\^2 PO Twice Daily on days with radiation.
219428261|NCT00614653|RADIATION|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
219428262|NCT05914883|DIAGNOSTIC_TEST|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
219428263|NCT01113554|OTHER|questionnaire administration|
219428264|NCT01113554|BEHAVIORAL|exercise intervention|
219006353|NCT03608592|BIOLOGICAL|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
219428265|NCT01113554|PROCEDURE|quality-of-life assessment|
219428266|NCT01113554|OTHER|survey administration|
219428267|NCT01113554|PROCEDURE|management of therapy complications|
219428268|NCT01113554|PROCEDURE|psychosocial assessment and care|
219428269|NCT01841918|BIOLOGICAL|Avian Flu Vaccine|
219428270|NCT03381209|DRUG|Sugammadex|sugammadex given based on 3 measurements of body weights
219428271|NCT06067308|DIAGNOSTIC_TEST|Performance of CTPA|Exposure to CT scan and injection of IV contrast
219428272|NCT06213610|DRUG|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
219428273|NCT06213610|DRUG|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
219428274|NCT04254432|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
219428275|NCT05847933|DEVICE|rTMS (cTBS 50Hz experiment)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
219577195|NCT06920615|BEHAVIORAL|Chained schedules|"The following procedures are based on Slaton et al. (2016): At the start of each session, the candidate or therapist will hold up the red card, prompt the participant to touch the card, while saying we are in red now, time to work. The participant will have to perform age- or function appropriate tasks without stereotypi to gain access to the green phase. Demand will be designated with a token economy, where each token represents completion of a certain amount of task-related responses. The participant will not be prompted to perform the tasks. If the participant makes an error in a task (e.g. answer a math question incorrectly), this will lead to an error correction and no token will be presented. If stereotypi occurs, it will be blocked for up to 3 s, and then all demands will be reset by removing all earned tokens."
219577196|NCT01021241|BIOLOGICAL|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
219577197|NCT02804230|DEVICE|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
219006354|NCT01018186|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
219006355|NCT01018186|DRUG|Fluticasone propionate|Inhaled corticosteroid
219006356|NCT02356068|OTHER|ROTEM analysis|3 blood samples for ROTEM analysis
219006357|NCT01931852|PROCEDURE|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
219006358|NCT01931852|OTHER|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
219191453|NCT05364307|OTHER|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
219191454|NCT06031610|PROCEDURE|carotid artery stenting|Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
219428276|NCT05847933|DEVICE|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 0%~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
219428277|NCT05847933|DEVICE|rTMS (cTBS 50 Hz active control)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: Right superior frontal cortex~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
219428278|NCT05847933|DEVICE|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics:~* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
219428279|NCT05847933|DEVICE|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 30 minutes, continuously~* Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
219428280|NCT05847933|DEVICE|rTMS (high frequency sham)|"* Frequency: 20 Hz~* Intensity: 10% of MSO~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
219428281|NCT05847933|DEVICE|rTMS (high frequency active control)|"* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: right superior frontal cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
219428282|NCT05847933|DEVICE|rTMS (low frequency active control )|"* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: Right superior frontal cortex of the dominant brain hemisphere~* Duration: 6 minutes~* Timing: Starting 1 minutes before and continuing during the memory task (Online)"
219428283|NCT05847933|DEVICE|rTMS ( cTBS 30 Hz active control)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on right superior frontal cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
219428284|NCT05847933|DEVICE|rTMS (cTBS 30 Hz)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
219428285|NCT06216587|DIETARY_SUPPLEMENT|BLa80|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
219428286|NCT02137837|DRUG|Fulvestrant|
219428287|NCT02137837|DRUG|Anastrozole|
219428288|NCT02137837|DRUG|Everolimus|
219191455|NCT06031610|DRUG|drug therapy|Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
219191456|NCT06105190|DEVICE|Implantation of premium monofocal IOL, LuxSmart (device under investigation)|Patients will be implanted with study IOL in both eyes
219191457|NCT06105190|DEVICE|Implantation of monofocal IOL, LuxGood (control device)|Patients will be implanted with Control IOL in both eyes
219428289|NCT02137837|DRUG|Placebo - Anastrozole|
219191458|NCT03325946|BEHAVIORAL|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
219191459|NCT03935971|DRUG|Dupilumab|See arm/group description
219191460|NCT06278753|DIAGNOSTIC_TEST|carbon dioxide cystoscopy|Using carbon dioxide medium for filling bladder
219191461|NCT05863156|DIAGNOSTIC_TEST|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
219191462|NCT05863156|DIAGNOSTIC_TEST|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
219191463|NCT05863156|DIAGNOSTIC_TEST|left side lying position|In the study, 120 participants in the left side lying position (control group).
219428290|NCT02137837|DRUG|Placebo - Everolimus|
219428291|NCT02141217|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
219428292|NCT02141217|DRUG|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
219428293|NCT02232594|DRUG|Berodual®|
219577198|NCT06928285|OTHER|Technology Enriched Rehabilitation|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants should attend a minimum of two times per week and can more frequently for the two hour group based circuit class.
219577199|NCT06929065|PROCEDURE|HIFU vs Cryoablation|HIFU vs cryoablation
219577200|NCT06927531|OTHER|sacral massage|During labor, pregnant women will be given effleurage (stroking) and vibration (vibration) techniques to the sacral region in a comfortable position during contractions, once an hour for a maximum of 10 minutes.
219577201|NCT06927531|OTHER|pilates ball|During labor, pregnant women will be given pelvic oscillation movements (a full rotation of the hips, going right/left, coming forward and backward, lightly bouncing on a ball while holding onto the headboard) once an hour during the active phase of labor.
219577202|NCT06928532|BEHAVIORAL|Seated TC|3-month seated Tai Chi training (24 sessions in total) given to Parkinson's disease patients
219191464|NCT03433742|OTHER|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
219428294|NCT03845049|OTHER|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
219428295|NCT03845049|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
219428296|NCT03845049|DRUG|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
219577203|NCT06928363|DRUG|KY-0301|KY-0301 is an antibody-drug conjugate (ADC) targeting both EGFR and c-Met, developed independently by Novatim Immune Therapeutics (Zhejiang) Co., Ltd
219577204|NCT06928441|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)|The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
219577205|NCT06927063|DIAGNOSTIC_TEST|blood-based protein biomarker assessments|Assessment of multiple blood-based biomarkers of different cellular origin and inflammatory mediators
219428297|NCT03845049|OTHER|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
219577206|NCT06927063|DIAGNOSTIC_TEST|blood-based metabolomic/lipidomic biomarker assessments|Assessment of multiple blood-based TBI-related metabolomic and lipidomic biomarkers
219577207|NCT06927063|DIAGNOSTIC_TEST|Diffusion-weighted magnetic resonance imaging (brain)|Diffusion-weighted magnetic resonance imaging
219577208|NCT06927063|DIAGNOSTIC_TEST|Structural magnetic resonance imaging (brain)|Structural magnetic resonance imaging
219577209|NCT06927063|DIAGNOSTIC_TEST|PET imaging (brain)|Positron emission tomography imaging
219577210|NCT06927063|PROCEDURE|Standard colonoscopy with pinch biopsies|Standard colonoscopy including pinch biopsies from the bowel wall at several levels (terminal ileum, ascending colon, transverse colon, descending colon, and rectosigmoideum) for histology, microbiome analysis and metabolomics
219428298|NCT03515213|DRUG|Fenofibrate|145mg of fenofibrate
219428299|NCT03515213|DRUG|Placebo|Placebo
219428300|NCT04806633|DRUG|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
219428301|NCT04806633|DRUG|Placebo|Patients randomized in this arm will receive placebo.
219577211|NCT06927063|DIAGNOSTIC_TEST|Fecal microbiome assessments|Fecal microbiome assessments (DNA)
219577212|NCT02646449|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
219760691|NCT00163189|DRUG|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
219760692|NCT01995097|BEHAVIORAL|Scheduled Gradual Reduction Text Messages|
219760693|NCT01995097|BEHAVIORAL|Support Text Messages|
219760694|NCT06348095|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
219760695|NCT06348095|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
219760696|NCT05035888|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
219760697|NCT05035888|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
219191465|NCT04466865|OTHER|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
219191466|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
219191467|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
219428302|NCT03506100|OTHER|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
219428303|NCT02187341|DIETARY_SUPPLEMENT|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
219428304|NCT02187341|DIETARY_SUPPLEMENT|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
219428305|NCT05651841|DRUG|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
219428306|NCT05651841|OTHER|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
219428307|NCT01978600|DRUG|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
219428308|NCT01978600|DRUG|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
219577213|NCT02646449|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
219191468|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
219191469|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
219191470|NCT03170206|DRUG|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
219428309|NCT00203255|DRUG|Soy Isoflavones|
219428310|NCT03114423|OTHER|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
219428311|NCT03114423|OTHER|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
219428312|NCT06119425|DIAGNOSTIC_TEST|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
219577214|NCT00551382|DRUG|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
219577215|NCT00551382|DRUG|Placebo|Look alike tablets or granules 1 per day for 12 weeks
219577216|NCT00586482|DRUG|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
219577217|NCT00586482|DRUG|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
219428313|NCT02284945|PROCEDURE|Open fixation|
219428314|NCT02284945|PROCEDURE|Keyhole surgery|
219428315|NCT01877590|DRUG|alpha-lipoic acid|
219428316|NCT05936593|DEVICE|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
219428317|NCT05936593|DEVICE|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
219428318|NCT04342416|BEHAVIORAL|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
219428319|NCT01181141|DRUG|DU-176b (edoxaban)|
219428320|NCT01181141|DRUG|Enoxaparin sodium 20mg|
219428321|NCT02343419|OTHER|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
219428322|NCT03714061|OTHER|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
219428323|NCT03714061|OTHER|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
219428324|NCT04848584|BIOLOGICAL|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
219428325|NCT04848584|BIOLOGICAL|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
219428326|NCT04848584|BIOLOGICAL|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
219428327|NCT02482649|BEHAVIORAL|EAA/T|bi-weekly for 12weeks
219428328|NCT02482649|DRUG|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
219577218|NCT00586482|BEHAVIORAL|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
219428329|NCT02482649|DRUG|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
219428330|NCT05786534|DIETARY_SUPPLEMENT|Green Seaweed|400 mg per day
219428331|NCT02323399|DRUG|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
219428332|NCT06382948|DRUG|Everolimus|Patients will receive 7.5 mg of everolimus orally once daily.
219577219|NCT02932228|OTHER|ImPACT|"The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
219428333|NCT06382948|DRUG|Elacestrant|Patients will receive elacestrant 345 mg orally once daily
219428334|NCT06382948|DRUG|Placebo|Patients will receive placebo orally once daily
219428335|NCT06382948|DRUG|Auxiliary Medicinal Product - Dexamethasone|10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
219428336|NCT06382948|DRUG|Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues|According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
219428337|NCT04938388|DRUG|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
219428338|NCT04938388|DIETARY_SUPPLEMENT|Fresh organic vegetables|Prescriptions of organic vegetables
219428339|NCT00707343|RADIATION|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
219428340|NCT00290589|DRUG|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
219428341|NCT00290589|DRUG|Placebo|Normal saline intramuscular injection
219428342|NCT04800120|OTHER|Hyperbaric Oxygen Therapy|Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
219428343|NCT06136819|COMBINATION_PRODUCT|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
219428344|NCT05014542|PROCEDURE|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
219428345|NCT05014542|DRUG|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
219428346|NCT06226714|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
219428347|NCT06226714|BIOLOGICAL|MPSV4|1 dose of MSPV4 on Day 0
219428348|NCT03604510|PROCEDURE|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
219428349|NCT06968962|DRUG|Tadalafil|Target dose 40 mg OD
219428350|NCT06968962|DRUG|Ambrisentan|Target dose 10 mg OD
219428351|NCT06968962|DRUG|Ambrisentan mimic|Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.
219428352|NCT06968962|DRUG|Tadalafil mimic|Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.
219428353|NCT06433375|PROCEDURE|Growth hormone application|Growth hormone application during non-surgical root canal treatment
219428354|NCT06433375|PROCEDURE|Root canal treatment|Teeth undergo conventional root canal treatment without any additional intervention
219006359|NCT03649464|DRUG|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
219006360|NCT05984160|OTHER|Paragastric neural block|A block method used to control patients' symptoms of pain, nausea and vomiting after surgery.
219006361|NCT03049280|DEVICE|Transoral robotic surgery|Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
219006362|NCT04216095|DEVICE|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
219428355|NCT06252311|BEHAVIORAL|Mindfulness-Based Breastfeeding Programme|Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
219577220|NCT01068379|PROCEDURE|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
219577221|NCT01068379|PROCEDURE|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
219577222|NCT04451603|PROCEDURE|Surgery|Surgical resection of the liver
219577223|NCT04451603|RADIATION|Radiation therapy|Y-90 radioembolization therapy is the main treatment
219577224|NCT04451603|DRUG|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
219577225|NCT00072072|DRUG|celecoxib|
219428356|NCT06000501|DRUG|Serdexmethylphenidate/dexmethylphenidate|Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
219428357|NCT03427866|DRUG|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
219191471|NCT03170206|DRUG|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
219191472|NCT05831072|BEHAVIORAL|Mindfulness-cognitive oriented group program|Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
219428358|NCT02715999|PROCEDURE|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
219428359|NCT02715999|PROCEDURE|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
219428360|NCT04990102|DRUG|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
219428361|NCT04879654|PROCEDURE|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
219428362|NCT01372644|DRUG|SOM 230 / Pasireotide|
219428363|NCT02146248|DRUG|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
219428364|NCT02146248|DRUG|DepoProvera|injectable hormonal contraceptive
219428365|NCT05090358|DIETARY_SUPPLEMENT|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
219428366|NCT05090358|DIETARY_SUPPLEMENT|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
219428367|NCT05090358|DRUG|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
219428368|NCT05090358|DRUG|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
219428369|NCT05090358|DRUG|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
219428370|NCT04003337|OTHER|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
219428371|NCT00086944|BIOLOGICAL|oblimersen sodium|Given IV
219428372|NCT00086944|BIOLOGICAL|rituximab|Given IV
219428373|NCT00086944|DRUG|ifosfamide|Given IV
219428374|NCT00086944|DRUG|carboplatin|Given IV
219428375|NCT00086944|DRUG|etoposide|Given IV
219428376|NCT00086944|BIOLOGICAL|filgrastim|Given SC
219428377|NCT00086944|BIOLOGICAL|pegfilgrastim|Given SC
219428378|NCT00086944|OTHER|laboratory biomarker analysis|Correlative studies
219428379|NCT01066884|DRUG|erlotinib [Tarceva]|150mg po daily
219428380|NCT03228498|DRUG|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
219428381|NCT03228498|DRUG|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
219428382|NCT01315847|DRUG|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
219760698|NCT04955288|PROCEDURE|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
219428383|NCT01315847|DRUG|[11C]MK-4232|Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
219428384|NCT01105221|DEVICE|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
219428385|NCT01105221|DRUG|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
219428386|NCT03034408|DRUG|Nalmefene|
219428387|NCT03034408|DRUG|Baclofen|
219428388|NCT03034408|DRUG|Placebo Oral Capsule|
219428389|NCT02790710|DRUG|Propanolol|Active treatment
219428390|NCT02790710|DRUG|Placebo|
219428391|NCT06613100|DRUG|Xaluritamig|Intravenous (IV) infusion
219428392|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
219428393|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
219428394|NCT07000058|DRUG|Hyaluronidase and Lidocaine 1% mixture|in group A hyaluronidase is expected to shorten the onset of action and prolong the duration of action of lidocaine 1% mixture than in group B where lidocaine 1% mixture only will be given
219428395|NCT07000058|DRUG|lidocaine 1 % mixture|lidocaine 1 % mixture includes; A mixture of ( epinephrine 1:200,000 and lidocaine 1% ) buffered by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.
219428396|NCT06998576|BEHAVIORAL|Animated educational video on antibiotic use|The intervention features a concise animated video on antibiotic use and AMR. The video's content and format will be developed based on the results of a survey conducted among the community residents in the two neighborhoods. Through the survey, the participants evaluated multiple message options including the various delivery formats. The animated video was designed incorporating the community's preferred key message and delivery method. The resulting video uses graphics, voice-overs, captions \[in all 4 official national languages\] to convey key messages about appropriate antibiotic use and AMR.
219428397|NCT02575573|OTHER|Factors influencing resuscitation decisions of patients|
219428398|NCT02575573|OTHER|Factors leading to not asking patients about resuscitation preference|
219428399|NCT06138561|BEHAVIORAL|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
219428400|NCT06138561|BEHAVIORAL|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
219428401|NCT06138561|BEHAVIORAL|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
219428402|NCT00186654|PROCEDURE|Acupuncture|
219428403|NCT00186654|PROCEDURE|Perinatal massage|
219577226|NCT00072072|DRUG|erlotinib hydrochloride|
219577227|NCT04945772|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
219577228|NCT04945772|PROCEDURE|Sham Injection|Sham Injection
219577229|NCT00608192|BEHAVIORAL|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
219577230|NCT00608192|BEHAVIORAL|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
219577231|NCT06394674|DRUG|Furmonertinib|Drug: Furmonertinib
219577232|NCT04542265|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
219577233|NCT04337684|DRUG|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
219760699|NCT04955288|PROCEDURE|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
219760700|NCT04955288|PROCEDURE|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
219191473|NCT04680715|RADIATION|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
219428404|NCT04699305|DEVICE|ActiGraft|Whole blood clot (WBC) gel
219191474|NCT01725763|OTHER|Cardiac MRI|
219191475|NCT06074120|DEVICE|Low-level laser therapy|Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.
219428405|NCT00027456|DRUG|Leptin A-100|
219428406|NCT02431468|DRUG|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
219428407|NCT02431468|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
219428408|NCT05073965|DIETARY_SUPPLEMENT|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
219428409|NCT05073965|OTHER|Placebo|Subject were assigned to receive a placebo
219191476|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia
219428410|NCT04385914|OTHER|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
219428411|NCT03155295|OTHER|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
219428412|NCT03155295|OTHER|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
219428413|NCT01721031|PROCEDURE|DPNB|Patients receive DPNB 30min before extubation at the end of operation
219428414|NCT01721031|DRUG|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
219428415|NCT05778019|OTHER|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
219428416|NCT03589885|DRUG|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
219428417|NCT03589885|DRUG|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
219428418|NCT03589885|DRUG|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
219428419|NCT03589885|DRUG|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
219428420|NCT03017482|DEVICE|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~* Questionnaires about the utility and impact of the device~* Use of the device in children younger than the current FDA approval range"
219428421|NCT04199208|OTHER|Prehabilitation and Immunonutrition|See study synopsis
219428422|NCT04199208|OTHER|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
219428423|NCT02907320|DRUG|CYCLO 3 ® FORT|
219577234|NCT03016221|OTHER|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
219577235|NCT03016221|OTHER|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
219577236|NCT03016221|OTHER|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
219006363|NCT04216095|DEVICE|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
219006364|NCT01382823|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
219006365|NCT04386980|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
219006366|NCT04386980|DRUG|Placebo|Diluent in normal saline
219191477|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia
219428424|NCT02907320|DRUG|MPFF|
219428425|NCT02907320|DRUG|placebo CYCLO 3 ® FORT|
219577237|NCT03016221|OTHER|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
219006367|NCT03235076|DRUG|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
219006368|NCT03590106|BEHAVIORAL|Peer Recovery Support Program|See above
219006369|NCT00633386|DRUG|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
219006370|NCT00633386|OTHER|Placebo|Matched placebo
219006371|NCT00929318|PROCEDURE|blood sampling|
219006372|NCT00929318|PROCEDURE|blood sampling|
219428426|NCT02907320|DRUG|placebo MPFF|
219428427|NCT03029481|DRUG|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
219428428|NCT02491697|BIOLOGICAL|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
219428429|NCT02491697|DRUG|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
219577238|NCT03016221|OTHER|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
219577239|NCT03016221|OTHER|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
219577240|NCT03016221|OTHER|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
219577241|NCT03016221|OTHER|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
219577242|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
219577243|NCT03261102|BIOLOGICAL|Adalimumab|
219577244|NCT03755336|OTHER|Administered Slip Perturbations|Participants will be exposed to a series of 12 unannounced slip perturbations while walking overground. These perturbations will be delivered at 3 different times within the gait cycle - early phase, middle phase, and late phase.
219577245|NCT01777919|DRUG|Temozolomide|already included
219577246|NCT01777919|DRUG|Disulfiram|already included
219428430|NCT03403894|BEHAVIORAL|Asking caregivers in their practice|A questionary is given to caregivers
219577247|NCT01777919|DRUG|Copper|already included
219428431|NCT01995279|DEVICE|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
219428432|NCT01995279|OTHER|Sham Ultrasound|Ultrasound turned off.
219428433|NCT04198896|OTHER|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
219428434|NCT01872091|OTHER|cryotherapy by immersion|
219428435|NCT01872091|OTHER|Control group|
219428436|NCT00808782|DEVICE|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
219428437|NCT00808782|DEVICE|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
219428438|NCT04528797|DRUG|Levothyroxine|
219428439|NCT04528797|DRUG|Methylprednisolone|
219428440|NCT04325776|DRUG|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
219428441|NCT04325776|DRUG|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
219428442|NCT00553345|DRUG|selenium|
219428443|NCT00553345|DRUG|vitamin E|
219428444|NCT00553345|PROCEDURE|chemoprevention|
219428445|NCT03638882|BEHAVIORAL|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
219428446|NCT03638882|BEHAVIORAL|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
219428447|NCT03638882|BEHAVIORAL|Passive Control|No Intervention.
219577248|NCT06436404|OTHER|Hammock intervention|It is a hammock made of 100% cotton fabric that prevents heat loss and has an internal apparatus to support the position, which can be adapted to the incubator by the researchers.
219577249|NCT06436404|OTHER|Kangaroo care intervention|In the clinic, the baby will receive kangaroo care with his mother in a quiet room with reduced lighting.
219428448|NCT04663139|DRUG|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
219428449|NCT04663139|DRUG|Placebo|Matching placebo
219428450|NCT02995330|PROCEDURE|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
219428451|NCT02995330|DRUG|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
219428452|NCT02995330|DRUG|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
219428453|NCT05109130|PROCEDURE|Surgical approach|Different surgical methods for rectal cancer resection
219428454|NCT00740922|DRUG|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
219428455|NCT02816125|DIETARY_SUPPLEMENT|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
219428456|NCT01603030|DRUG|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
219428457|NCT01603030|DRUG|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
219428458|NCT02489565|OTHER|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
219428459|NCT04488848|OTHER|bolus glucose|bolus Glucose
219428460|NCT04488848|OTHER|continuous clucose|continuous clucose
219428461|NCT02119234|DRUG|Beclometasone/formoterol/glycopyrrolate|
219428462|NCT02119234|DRUG|Placebo|
219428463|NCT00641524|PROCEDURE|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
219428464|NCT03722914|DRUG|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
219428465|NCT03722914|DRUG|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
219577250|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
219577251|NCT06422130|OTHER|Pregnant women and their offspring without intervention|Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
219760701|NCT04955288|PROCEDURE|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
219760702|NCT02154061|DRUG|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
219760703|NCT02154061|DRUG|Metronidazole|This is a standard antibiotic
219577252|NCT03821935|DRUG|Livmoniplimab|Liquid for intravenous infusion.
219577253|NCT03821935|DRUG|Budigalimab|Lyophilized powder for solution for intravenous infusion.
219191478|NCT01130025|DRUG|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
219428466|NCT02435641|OTHER|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
219428467|NCT04686019|OTHER|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
219428468|NCT06432556|GENETIC|scRNAseq|A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
219428469|NCT06432556|PROCEDURE|two Skin biopsies|2 skin biopsies from a lesional area
219428470|NCT06432556|PROCEDURE|one Skin biopsies|1 skin biopsies from a lesional area
219428471|NCT03136952|DEVICE|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
219428472|NCT00928356|PROCEDURE|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
219760704|NCT02154061|DRUG|Neomycin|This is a standard antibiotic.
219760705|NCT02154061|DRUG|Vancomycin|This is a standard antibiotic.
219191479|NCT01130025|DRUG|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
219191480|NCT04285814|DIAGNOSTIC_TEST|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
219428473|NCT00928356|PROCEDURE|Off Pump CABG|Standard of Care Off Pump CABG
219577254|NCT04989803|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
219577255|NCT04989803|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
219577256|NCT04989803|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
219577257|NCT04989803|BIOLOGICAL|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
219577258|NCT05633706|DEVICE|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
219577259|NCT00285948|DEVICE|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
219760706|NCT00477984|DRUG|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
219006373|NCT04217876|DIAGNOSTIC_TEST|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
219428474|NCT03848611|DRUG|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
219428475|NCT03910647|DRUG|pantoprazole|effect of this drug on renal function
219428476|NCT04179435|BEHAVIORAL|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
219428477|NCT04179435|OTHER|brain MRI|Brain MRI scans
219428478|NCT04179435|OTHER|TMS|Measure of the cortical inhibitory capacity using TMS measures
219428479|NCT05549648|OTHER|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
219428480|NCT01925651|RADIATION|No Bolus|no bolus use
219428481|NCT01925651|RADIATION|Alternate Bolus|0.5cm bolus use in alternate days
219428482|NCT01925651|RADIATION|Continuous Bolus|0.5 cm bolus use in continuous days
219428483|NCT03583320|DIAGNOSTIC_TEST|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
219428484|NCT05515952|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
219428485|NCT05515952|DEVICE|Transcranial Magnetic Stimulation (Sham)|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used.
219428486|NCT04985331|DEVICE|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
219428487|NCT06390631|DEVICE|Continuous Positive Airway Pressure|Patients with COPD were recruited to breath under the atmosphere pressure and different levels of CPAP (4, 6, 8 and 10 cm H2O).
219428488|NCT04569916|RADIATION|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
219428489|NCT04569916|DRUG|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
219428490|NCT04569916|DRUG|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
219428491|NCT04569916|DRUG|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
219428492|NCT01452555|BEHAVIORAL|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
219428493|NCT04306055|OTHER|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
219428494|NCT04306055|OTHER|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
219428495|NCT06161155|COMBINATION_PRODUCT|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
219428496|NCT04091334|DEVICE|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
219428497|NCT04091334|OTHER|Standard care|Standard care and evaluation and monitoring
219428498|NCT01795586|DRUG|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2"
219577260|NCT03664648|BIOLOGICAL|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
219006374|NCT03552198|BEHAVIORAL|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
219577261|NCT02418143|DEVICE|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
219428499|NCT01795586|DRUG|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
219428500|NCT04605536|OTHER|animation videos|watch animation videos about capsule endoscopy
219428501|NCT04605536|OTHER|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
219428502|NCT03411850|BIOLOGICAL|Orencia|FDA approved biologic
219428503|NCT03411850|OTHER|Placebo|
219428504|NCT04408118|DRUG|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
219428505|NCT04408118|DRUG|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
219428506|NCT04408118|DRUG|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
219428507|NCT05627700|DEVICE|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
219428508|NCT05946759|DEVICE|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
219428509|NCT01913808|DRUG|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
219428510|NCT01913808|DRUG|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
219577262|NCT04041622|DIAGNOSTIC_TEST|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
219006375|NCT02916342|PROCEDURE|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
219006376|NCT02916342|PROCEDURE|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
219428511|NCT03889600|OTHER|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
219428512|NCT05165979|OTHER|Hospitalization due to COVID-19|Hospitalization due to COVID-19
219428513|NCT01766479|RADIATION|CT colonography|
219428514|NCT03428685|DRUG|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
219428515|NCT03428685|DRUG|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
219428516|NCT04240171|DRUG|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
219428517|NCT04240171|DRUG|Glimepiride 4Mg Tab|Glimepiride Tablets daily
219428518|NCT00531245|DRUG|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
219428519|NCT02746848|BIOLOGICAL|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
219428520|NCT04113148|OTHER|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
219428521|NCT01241396|OTHER|Any MMY treatment|Any line of treatment for MMY
219428522|NCT01117012|DRUG|Ivacaftor|
219428523|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
219428524|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
219428525|NCT02486211|DRUG|Amantadine|100mg twice per day for 7 days at 0600 and 1200
219428526|NCT02486211|DRUG|Placebo|Placebo comparator
219577263|NCT04845074|PROCEDURE|TSA-group|Anatomical total shoulder arthroplasty followed by standard rehabilitation.
219760707|NCT00506142|DRUG|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
219760708|NCT02946203|OTHER|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
219760709|NCT02946203|OTHER|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
219760710|NCT00346723|BIOLOGICAL|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
219760711|NCT04106245|BEHAVIORAL|Behavioral Intervention|Participate in PACK Health
219760712|NCT04106245|OTHER|Survey Administration|Complete survey
219760713|NCT02862119|PROCEDURE|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
219760714|NCT02862119|OTHER|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
219760715|NCT05443529|OTHER|Adaptive sports|Participation in community adaptive sports programs
219760716|NCT03319576|OTHER|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
219760717|NCT01399853|BIOLOGICAL|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
219760718|NCT01399853|BIOLOGICAL|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
219760719|NCT01399853|BIOLOGICAL|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
219760720|NCT01399853|BIOLOGICAL|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
219760721|NCT01399853|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
219428527|NCT03695393|BEHAVIORAL|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
219428528|NCT04141553|DRUG|Diltiazem Injection|Randomization to one of to active comparator groups
219428529|NCT02500394|PROCEDURE|Ionosteril|biomarker guided volume substitution with Ionosteril
219428530|NCT00673894|DRUG|Sitagliptin|Glutamine 30g +sitagliptin 100mg
219428531|NCT00673894|DRUG|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
219428532|NCT02555657|BIOLOGICAL|pembrolizumab|
219428533|NCT02555657|DRUG|capecitabine|
219428534|NCT02555657|DRUG|eribulin|
219428535|NCT02555657|DRUG|gemcitabine|
219428536|NCT02555657|DRUG|vinorelbine|
219428537|NCT02411526|DRUG|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
219428538|NCT02411526|DRUG|Risperdal Consta|Risperdal Consta administered as a IM injection
219428539|NCT02411526|DRUG|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
219428540|NCT02636920|OTHER|Therapeutic Education to the Patient (TEP)|"* Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients."
219577264|NCT04845074|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
219428541|NCT04282057|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
219428542|NCT04282057|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
219428543|NCT04282057|DEVICE|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
219428544|NCT05650931|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
219428545|NCT05650931|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
219428546|NCT05650931|PROCEDURE|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
219428547|NCT00493974|DRUG|Zileuton|Zyflo tablets, 600 mg, 4 times a day
219428548|NCT00493974|DRUG|Placebo|Placebo 4 x daily
219428549|NCT06141941|DEVICE|CGM|Continuous glucose monitoring
219428550|NCT03701217|DRUG|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
219428551|NCT03463096|OTHER|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
219428552|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
219191481|NCT06646250|DEVICE|NeoDoppler - CE certified|The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
219428553|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
219428554|NCT02807363|DRUG|Leuprolide Depot|3.75 mg intramuscular depot injection
219428555|NCT02807363|DRUG|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
219428556|NCT00001449|DRUG|gemcitabine|
219428557|NCT00001449|DRUG|fluorodeoxyuridine|
219428558|NCT00001449|DRUG|leucovorin|
219428559|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
219428560|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
219428561|NCT02188719|BIOLOGICAL|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is \<50/mm\^3 or when the maximal dose of 4.5/mg/kg has been given.
219428562|NCT02188719|BIOLOGICAL|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
219428563|NCT02188719|DRUG|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
219428564|NCT02188719|DRUG|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
219428565|NCT02188719|DRUG|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
219428566|NCT02188719|DRUG|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
219191482|NCT04797195|OTHER|CKD-PD app with home monitoring equipment|use home monitoring equipment to measure blood pressure, body weight, and dialysate fluid volume and record in CKD-PD app
219428567|NCT02188719|DRUG|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
219428568|NCT02188719|DRUG|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
219428569|NCT02188719|DRUG|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
219428570|NCT02188719|PROCEDURE|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level \>/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
219428571|NCT02188719|PROCEDURE|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
219428572|NCT02188719|PROCEDURE|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
219428573|NCT02188719|PROCEDURE|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
219428574|NCT04367441|DRUG|608|recombinant humanized anti-IL17A monoclonal antibody injection
219428575|NCT04367441|DRUG|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
219428576|NCT01214941|DRUG|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
219428577|NCT01214941|DRUG|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
219428578|NCT01214941|DRUG|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
219428579|NCT03780036|DEVICE|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
219428580|NCT04144075|BEHAVIORAL|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
219428581|NCT04144075|BEHAVIORAL|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
219428582|NCT04144075|OTHER|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
219191483|NCT06348329|OTHER|Birth Preparation Training|Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
219428583|NCT05717959|BEHAVIORAL|Oropharyngeal Exercises|Oropharyngeal Exercises
219428584|NCT00966693|DRUG|Dexamethasone|Given PO
219428585|NCT00966693|DRUG|Lenalidomide|Given PO
219428586|NCT00966693|DRUG|Thalidomide|Given PO
219428587|NCT03517306|OTHER|No Interventions|No Interventions
219428588|NCT03922633|DRUG|E3112|Intravenous infusion.
219428589|NCT03922633|OTHER|Placebo|Intravenous infusion.
219428590|NCT01164865|DEVICE|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
219428591|NCT01164865|DEVICE|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
219428592|NCT01164865|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
219428593|NCT01089829|OTHER|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
219428594|NCT00347412|DRUG|Paclitaxel|"Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first."
219428595|NCT00347412|DRUG|NOV-002|"* Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
219428596|NCT00347412|DRUG|Carboplatin|"Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
219428597|NCT00255294|DRUG|Cellulose sulfate vaginal gel|
219428598|NCT04696874|PROCEDURE||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
219428599|NCT04046757|OTHER|Mechanical thrombectomy|Neuroradiological endovascular treatment
219428600|NCT06017648|DEVICE|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
219428601|NCT06017648|DEVICE|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
219428602|NCT04715048|DRUG|PrabotulinumtoxinA|Glabellar line correction
219428603|NCT04715048|DRUG|Onabotulinum toxin A|Glabellar line correction
219428604|NCT05894044|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
219428605|NCT05894044|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
219577265|NCT03174951|DRUG|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
219428606|NCT05894044|OTHER|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
219428607|NCT05894044|OTHER|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
219428608|NCT02633839|DRUG|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
219428609|NCT02633839|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
219428610|NCT04209257|DEVICE|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
219428611|NCT06182930|OTHER|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.|They will receive routine home health care follow-up.
219428612|NCT05457348|PROCEDURE|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
219760722|NCT00454116|DRUG|Vandetanib|once daily oral tablet two doses
219760723|NCT00454116|DRUG|FOLFIRI|Intravenous infusion
219760724|NCT02213250|DRUG|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
219760725|NCT03186339|PROCEDURE|TAVI|transfemoral transcatheter aortic valve implantation
219760726|NCT03186339|PROCEDURE|SAVR|isolated surgical valve replacement
219760727|NCT03186339|OTHER|MM|management of aortic stenosis by medical treatment only
219006377|NCT06051929|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
219006378|NCT03587012|OTHER|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
219006379|NCT03587012|OTHER|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
219006380|NCT01329731|DRUG|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
219006381|NCT01329731|DRUG|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
219006382|NCT03235154|DRUG|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
219006383|NCT05875090|DIAGNOSTIC_TEST|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
219006384|NCT03610022|DRUG|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
219006385|NCT01953055|RADIATION|Stereotactic ablative radiotherapy|
219006386|NCT01962805|DRUG|Proellex Formulation A|
219006387|NCT01962805|DRUG|Proellex Formulation B|
219006388|NCT02781493|DRUG|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
219006389|NCT02781493|DRUG|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
219006390|NCT03012802|PROCEDURE|Colorectal Surgery|Postoperative Audit
219006391|NCT04975685|BEHAVIORAL|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
219428613|NCT01852695|BEHAVIORAL|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
219428614|NCT02789449|OTHER|assessment of DLNO and DLCO|
219760728|NCT01917318|DRUG|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
219006392|NCT04975685|BEHAVIORAL|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
219006393|NCT02326025|DRUG|Olaratumab|Administered IV
219006394|NCT02326025|DRUG|Doxorubicin|Administered IV
219428615|NCT05886179|OTHER|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
219428616|NCT04180995|DRUG|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
219006395|NCT03236740|DRUG|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
219006396|NCT03236740|DRUG|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
219006397|NCT00001723|DRUG|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
219006398|NCT00001723|DRUG|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
219006399|NCT01622790|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
219006400|NCT01622790|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
219006401|NCT01622790|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
219006402|NCT01265290|DEVICE|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
219428617|NCT05652413|BEHAVIORAL|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
219006403|NCT01265290|DEVICE|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
219006404|NCT04367220|DIAGNOSTIC_TEST|Diagnostic testing performed as per routine care|
219428618|NCT00861679|PROCEDURE|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided."
219428619|NCT01310218|OTHER|extended postoperative dressing|2 weeks of bulky dressing
219191484|NCT05675735|BEHAVIORAL|Clinic-Level Multidimensional Intervention|The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
219428620|NCT01310218|OTHER|short postoperative dressing|2 days bulky dressing followed by bandaid
219191485|NCT05772520|DRUG|TLL018 tablets|oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
219760729|NCT01917318|DRUG|Placebo|During 8 weeks subjects will receive oral placebo
219760730|NCT01306747|BEHAVIORAL|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
219006405|NCT06384040|PROCEDURE|platelet-rich plasma knee injection|platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
219006406|NCT01454622|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
219191486|NCT06402851|DRUG|Anticoagulant Oral|Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
219191487|NCT03127189|DRUG|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
219191488|NCT03127189|DRUG|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
219191489|NCT06558994|PROCEDURE|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
219428621|NCT01943318|PROCEDURE|Liver biopsy|Histologic evaluation
219428622|NCT01943318|DEVICE|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
219428623|NCT00608452|OTHER|Symptom Assessment Scale|"* Memorial Symptom Assessment Scale~* History and neurologic examination"
219191490|NCT06558994|PROCEDURE|Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
219191491|NCT04731376|OTHER|Best Practice|Receive standard peri-operative care
219191492|NCT04731376|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219191493|NCT04731376|OTHER|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
219191494|NCT04731376|DRUG|Testosterone Cypionate|Given IM
219191495|NCT02296684|BIOLOGICAL|MK-3475 (neoadjuvant)|
219191496|NCT02296684|PROCEDURE|Surgery|Standard of care
219191497|NCT02296684|RADIATION|Intensity modulated radiation therapy|Recommended, standard of care
219191498|NCT02296684|RADIATION|Image-guided radiation therapy|Recommended, standard of care
219191499|NCT02296684|DRUG|Cisplatin|Standard of care
219191500|NCT02296684|BIOLOGICAL|MK-3475 (adjuvant)|
219428624|NCT02492087|DRUG|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
219428625|NCT02492087|DRUG|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
219428626|NCT05424887|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
219428627|NCT05424887|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
219428628|NCT01754675|BEHAVIORAL|Soccer|Watching the soccer match at the time that the favorite team is playing
219428629|NCT01754675|BEHAVIORAL|Movie|Watching a movie at the time that the favorite team is playing
219428630|NCT03116308|DRUG|Opicapone (OPC)|50 mg OPC capsules; oral route
219428631|NCT04632537|DRUG|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
219428632|NCT04632537|DRUG|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
219760731|NCT00151450|DRUG|Pregabalin|
219760732|NCT00151450|DRUG|Venlafaxine XR|
219577266|NCT04626453|BEHAVIORAL|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
219577267|NCT06520579|BEHAVIORAL|Proactive pharyngeal-laryngeal Exercise Program|This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.
219577268|NCT06520579|DIETARY_SUPPLEMENT|Premier Protein Clear ® High Protein|Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.
219577269|NCT06520579|BEHAVIORAL|Hydration Counseling|Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
219577270|NCT04816630|DEVICE|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
219577271|NCT03074396|DEVICE|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
219428633|NCT01237561|OTHER|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
219428634|NCT00095511|DRUG|aripiprazole|
219428635|NCT04178577|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
219428636|NCT04217083|DIAGNOSTIC_TEST|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
219428637|NCT02312583|BEHAVIORAL|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
219428638|NCT02312583|BEHAVIORAL|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
219428639|NCT02521623|DEVICE|SurgiMend® Acellular Dermal Matrix|See arm description.
219428640|NCT02521623|DEVICE|Strattice™ Acellular Dermal Matrix|See arm description.
219428641|NCT05314361|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
219428642|NCT02535078|DRUG|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
219577272|NCT03074396|DEVICE|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
219577273|NCT03340064|DRUG|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
219577274|NCT06133803|DRUG|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
219577275|NCT06133803|DRUG|Aspirin|Aspirin 81mg daily tablet.
219577276|NCT06133803|PROCEDURE|Embryo transfer|Embryo transfer
219577277|NCT02522403|PROCEDURE|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
219428643|NCT04201977|OTHER|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
219428644|NCT04201977|OTHER|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
219428645|NCT04201977|OTHER|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
219428646|NCT04201977|OTHER|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
219428647|NCT06005298|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~* It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~* The screening is universal.~* One or more specific behaviors related to risky alcohol and drug use are targeted.~* The services occur in a public health non-substance abuse treatment setting.~* It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~* Strong research or experiential evidence supports the model's effectiveness."
219428648|NCT05551091|DIETARY_SUPPLEMENT|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
219428649|NCT01861054|DRUG|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
219428650|NCT01841528|OTHER|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
219577278|NCT02522403|DEVICE|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
219577279|NCT05568979|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
219577280|NCT05568979|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
219577281|NCT02151812|DEVICE|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
219577282|NCT02151812|DEVICE|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
219006407|NCT01454622|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
219428651|NCT01841528|OTHER|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
219428652|NCT00599027|DRUG|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
219428653|NCT00599027|DRUG|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
219428654|NCT01928992|DEVICE|3D|subjects that underwent 3D mammography
219428655|NCT01928992|DEVICE|2D|those subjects that underwent 2D mammography
219428656|NCT04257227|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
219428657|NCT05344027|DRUG|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
219428658|NCT02477722|OTHER|EFP-NF|
219428659|NCT02477722|OTHER|Sham|
219428660|NCT05647629|PROCEDURE|Total hip arthroplasty|hip prosthesis surgery
219428661|NCT03879876|DRUG|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
219428662|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
219428663|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
219428664|NCT04176744|OTHER|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
219428665|NCT01152489|DEVICE|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
219428666|NCT01152489|DEVICE|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
219577283|NCT04325152|DEVICE|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
219006408|NCT05377385|BEHAVIORAL|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
219428667|NCT01434264|PROCEDURE|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
219428668|NCT05321940|BIOLOGICAL|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
219428669|NCT05321940|BIOLOGICAL|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
219428670|NCT03996434|DRUG|Gonadotropin|withholding gonadotropin administration for at least 24 hours
219428671|NCT03996434|DRUG|Antagonist|Cetrorelix acetate 0.25 mg
219428672|NCT05781763|BEHAVIORAL|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
219428673|NCT05781763|OTHER|Control group|Continuing with exercise as usual during 12 months
219428674|NCT01205958|PROCEDURE|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
219577284|NCT04325152|DEVICE|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
219577285|NCT01475006|DRUG|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
219577286|NCT04798365|BEHAVIORAL|Intervention group|medical education and distribution of educations materials
219006409|NCT00620867|DRUG|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
219006410|NCT00620867|DRUG|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
219006411|NCT00620867|OTHER|placebo|matched placebo orally for 6 weeks
219006412|NCT06141395|DIAGNOSTIC_TEST|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
219577287|NCT00997139|DRUG|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
219006413|NCT05713747|OTHER|Life Skills Boot Camp|"The boot camp is designed to be taken by undergraduate students across all disciplines with no pre-requisite coursework and students who participated in the Life skills 101 course and have selected to participate in a boot camp training as part of their Individual Self Development Plan. The boot camp will consist of 3 training programs with 4 sessions (1.5 hour per session) each, including an introductory and a closing part.~Content The boot camp was designed by a team of academics having several years of experience in clinical psychology, educational psychology, and health psychology. The focus of the bootcamp is to teach students practical skills in three different domains of soft skills: a) Interpersonal Skills, b) Resilience and Flexibility and c) Emotion Regulation."
219006414|NCT04159844|DEVICE|URGOBD001|Application with 50% overlapping
219577288|NCT01369017|DRUG|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
219577289|NCT01369017|DRUG|Placebo|Injection of NS
219577290|NCT00313443|PROCEDURE|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
219577291|NCT06224322|OTHER|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
219006415|NCT04159844|DEVICE|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
219006416|NCT00237198|DRUG|Letrozole|
219006417|NCT03037411|DEVICE|Peripheral stenting|stent implantation during the index procedure
219006418|NCT02643082|DRUG|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
219006419|NCT02643082|DRUG|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
219006420|NCT03283592|OTHER|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
219006421|NCT03283592|OTHER|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
219006422|NCT04341454|DRUG|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
219006423|NCT04341454|DRUG|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
219428675|NCT02797639|OTHER|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
219428676|NCT02797639|OTHER|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
219428677|NCT03860350|DIETARY_SUPPLEMENT|Aged Garlic Extract|
219006424|NCT04341454|DRUG|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
219006425|NCT04341454|DRUG|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
219428678|NCT03860350|DIETARY_SUPPLEMENT|Placebo|
219428679|NCT00002017|DRUG|Interleukin-2, Polyethylene Glycolated|
219006426|NCT01324999|DRUG|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
219006427|NCT03131765|BIOLOGICAL|YS-0N-001|Cancer vaccine
219006428|NCT00276744|BIOLOGICAL|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219428680|NCT04214730|COMBINATION_PRODUCT|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
219428681|NCT04214730|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
219428682|NCT01213368|DRUG|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
219428683|NCT01213368|DRUG|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
219428684|NCT04945824|DRUG|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
219428685|NCT04945824|DEVICE|Dilator|Intracanalicular Dilator Device
219428686|NCT05052541|DRUG|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
219428687|NCT05052541|DRUG|THC|Oral solution containing 5mg THC per 1 ml
219006429|NCT00276744|DRUG|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006430|NCT00276744|DRUG|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006431|NCT00276744|DRUG|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006432|NCT00276744|DRUG|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006433|NCT00276744|DRUG|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006434|NCT00276744|DRUG|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219428688|NCT05052541|DRUG|Placebo|Oral solution containing no active drug
219428689|NCT00405821|DRUG|Acyclovir|400mg twice daily for 24 months
219428690|NCT00405821|DRUG|Placebo|Placebo tablet twice daily for 24 months
219428691|NCT04376606|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
219577292|NCT00787579|DEVICE|Bifocal spectacles|+1.50D bifocal spectacles
219577293|NCT00787579|DEVICE|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
219006435|NCT00276744|DRUG|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219191501|NCT02296684|PROCEDURE|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
219577294|NCT03017118|DIETARY_SUPPLEMENT|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
219577295|NCT03017118|OTHER|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
219428692|NCT04376606|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
219428693|NCT04376606|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
219428694|NCT05687708|OTHER|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
219428695|NCT02320630|DRUG|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
219428696|NCT02320630|DRUG|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
219577296|NCT06360068|DRUG|Sulfasalazine Tablets|All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
219577297|NCT01651143|DRUG|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
219006436|NCT00276744|PROCEDURE|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
219006437|NCT00433121|DRUG|Risperidone|
219428697|NCT02320630|DRUG|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
219006438|NCT00433121|DRUG|Olanzapine|
219006439|NCT00433121|DRUG|Haloperidole|
219006440|NCT00433121|DRUG|Quetiapin|
219006441|NCT00433121|DRUG|Escitalopram|
219428698|NCT03277703|BIOLOGICAL|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
219577298|NCT01651143|DRUG|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
219577299|NCT04097171|OTHER|Diet|Participants will consume each diet for 14 days in a crossover design.
219577300|NCT00968760|PROCEDURE|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
219006442|NCT00433121|DRUG|Citalopram|
219577301|NCT00968760|PROCEDURE|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
219006443|NCT00433121|DRUG|Sertralin|
219006444|NCT01310101|DRUG|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
219577302|NCT00968760|PROCEDURE|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
219577303|NCT00968760|DRUG|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
219577304|NCT00968760|DRUG|Carmustine|300 mg/m\^2 IV over 1 hour on Day -6
219577305|NCT00968760|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
219577306|NCT00968760|DRUG|Cytarabine|200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
219577307|NCT00968760|DRUG|Melphalan|140 mg/m\^2 IV over 30 minutes on Day -1
219577308|NCT04386174|OTHER|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
219577309|NCT05253365|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
219577310|NCT03582761|BIOLOGICAL|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
219577311|NCT00856973|DRUG|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
219577312|NCT00856973|DRUG|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
219577313|NCT00856973|DRUG|Placebo|1 tablet per day for 12 weeks
219006445|NCT02423876|DRUG|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand."
219428699|NCT04819802|OTHER|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
219428700|NCT04819802|OTHER|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
219428701|NCT05474807|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
219428702|NCT05530278|DRUG|Galicaftor|Oral
219428703|NCT05530278|DRUG|ABBV-576|Oral
219428704|NCT05530278|DRUG|Navocaftor|Oral
219428705|NCT05530278|DRUG|Midazolam|Oral
219428706|NCT03721237|OTHER|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
219428707|NCT06252766|BEHAVIORAL|Experiment (Clown)|Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
219428708|NCT03153020|OTHER|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
219428709|NCT00476996|DRUG|Leflunomide|Oral repeating dose
219428710|NCT00476996|DRUG|Methotrexate|Oral or parenteral repeating dose
219428711|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (200mg)
219428712|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (500mg)
219428713|NCT00476996|DRUG|Placebo|Intravenous repeating dose
219428714|NCT00633308|DEVICE|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
219428715|NCT03241238|OTHER|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
219428716|NCT04791787|OTHER|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
219428717|NCT04791787|OTHER|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
219428718|NCT04791787|DIETARY_SUPPLEMENT|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
219428719|NCT04218799|DRUG|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
219428720|NCT00890071|OTHER|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
219428721|NCT03371342|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
219428722|NCT03371342|DRUG|Botox|Botox(Botulinum toxin type A)
219428723|NCT00852306|PROCEDURE|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
219428724|NCT05505097|DRUG|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
219577314|NCT03257033|DRUG|Gemcitabine|Chemotherapy
219006446|NCT02423876|OTHER|Intraoperative Complication Management and Prevention|Undergo ERP
219006447|NCT02423876|PROCEDURE|Pain Therapy|Undergo ERP
219577315|NCT03257033|DRUG|nab-paclitaxel|Chemotherapy
219006448|NCT01927172|DEVICE|AirSonea|
219006449|NCT02139631|OTHER|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
219006450|NCT00952575|DRUG|polyclonal anti-D immunoglobulin|single injection of 300 µg
219428725|NCT04955002|OTHER|No intervention|No intervention
219577316|NCT03257033|DEVICE|RenovoCath|Intra-arterial catheter
219428726|NCT04839991|DRUG|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
219428727|NCT01214317|PROCEDURE|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
219428728|NCT00505895|DRUG|Melphalan|Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
219428729|NCT00505895|DRUG|Fludarabine|30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
219428730|NCT00505895|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
219428731|NCT00505895|DRUG|Rituximab|375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
219428732|NCT05351710|BEHAVIORAL|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
219428733|NCT05351710|BEHAVIORAL|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
219428734|NCT01225978|DEVICE|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
219428735|NCT02586987|DRUG|Selumetinib|Selumetinib oral
219428736|NCT02586987|DRUG|MEDI4736|MEDI4736 IV
219428737|NCT02586987|DRUG|Tremelimumab|Tremelimumab, IV
219428738|NCT06396663|OTHER|Rapid Opioid de-escalation|"Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely"
219006451|NCT00952575|DRUG|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
219006452|NCT00970060|BEHAVIORAL|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
219006453|NCT03627247|BEHAVIORAL|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
219006454|NCT03178903|OTHER|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
219006455|NCT03178903|OTHER|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
219006456|NCT03178903|BEHAVIORAL|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
219006457|NCT03566147|BIOLOGICAL|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
219428739|NCT06396663|OTHER|Gradual Opioid de-escalation|Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
219428740|NCT06396663|OTHER|Continuation of opioids|Continue on opioids and review in 1 weeks time.
219428741|NCT02601066|DEVICE|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
219428742|NCT00780052|DRUG|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
219428743|NCT02746523|OTHER|Sensory Organization Test|Balance and proprioception test
219428744|NCT02746523|GENETIC|Biomarkers|Blood, urine, and saliva biomarkers
219428745|NCT02746523|OTHER|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
219428746|NCT02746523|OTHER|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
219428747|NCT02746523|OTHER|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
219428748|NCT07036653|DIAGNOSTIC_TEST|spinal ultrasound|Coronal, axial, sagittal scans of the spine using ultrasound
219428749|NCT01265420|BIOLOGICAL|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
219428750|NCT02667379|OTHER|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
219428751|NCT06884540|DRUG|Dexmedetomidine|"Intravenous bolus: between 0.2 and 0.5 mcg/kg.~followed by~Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
219428752|NCT06884540|DRUG|lidocaine|"Intravenous bolus: between 0.5 and 1.5 mg/kg.~followed by~Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
219428753|NCT06884540|OTHER|control group|Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.
219006458|NCT03630952|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
219006459|NCT03630952|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
219006460|NCT03630952|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
219006461|NCT00060008|RADIATION|fludeoxyglucose F 18|
219006462|NCT00060008|RADIATION|gadopentetate dimeglumine|
219006463|NCT04258397|DRUG|Pirfenidone|Pirfenidone vs. matching placebo
219006464|NCT04258397|DRUG|matching placebo|matching placebo
219006465|NCT00299910|DRUG|Montelukast|
219428754|NCT06190405|DIAGNOSTIC_TEST|Hemoglobin A1c|Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.
219428755|NCT06190405|DIAGNOSTIC_TEST|Risk-based screening by ACOG with two-step GTT|Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
219428756|NCT03589820|OTHER|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
219577317|NCT05079386|DEVICE|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
219577318|NCT02664363|BIOLOGICAL|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
219577319|NCT02813057|PROCEDURE|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
219577320|NCT02813057|PROCEDURE|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
219577321|NCT00865618|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
219577322|NCT00865618|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
219577323|NCT03075319|PROCEDURE|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
219006466|NCT05184218|DRUG|IGM-6268|Active Comparator
219006467|NCT05184218|DRUG|Placebo|Placebo Comparator
219006468|NCT03935204|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219006469|NCT03935204|BIOLOGICAL|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219006470|NCT02322398|DRUG|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
219006471|NCT02322398|DRUG|hMG|150-300 IU/d hMG
219006472|NCT04180228|OTHER|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
219006473|NCT00708968|BEHAVIORAL|FOCUS Program|Supportive, educative sessions with patients and spouses.
219006474|NCT02967835|BEHAVIORAL|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
219577324|NCT03075319|PROCEDURE|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
219577325|NCT00409318|DRUG|Etanercept|50 mg SC q week
219577326|NCT00409318|DRUG|Placebo|SC q week
219428757|NCT01349686|PROCEDURE|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
219577327|NCT02431819|DEVICE|contention socks|Patients wear contention socks during 15 days.
219006475|NCT06141109|DRUG|Sintilimab 200mg+MB07133 600mg|"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1."
219006476|NCT04548570|PROCEDURE|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
219006477|NCT04942691|OTHER|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
219006478|NCT06504602|DEVICE|Active Virtual Reality|Active virtual reality group will play a game through a virtual environment.
219006479|NCT06504602|DEVICE|Passive Virtual Reality|Passive virtual reality group will watch a movie through a virtual environment.
219006480|NCT01979887|PROCEDURE|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
219006481|NCT01714635|DEVICE|Tecnis Multifocal Intraocular Lens|
219006482|NCT01714635|DEVICE|Monofocal Intraocular Lens|
219006483|NCT05086991|OTHER|Follow up|like group descriptions
219006484|NCT04546945|DIAGNOSTIC_TEST|CD56|detection of CD56 by flow cytometry
219006485|NCT05322876|BEHAVIORAL|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
219006486|NCT04355845|DRUG|Sumatriptan|25 milligrams (mg) single dose tablet
219006487|NCT04355845|DRUG|PF-06651600|PF-06651600 400 mg single dose
219006488|NCT04804969|DEVICE|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
219006489|NCT02771054|DRUG|TAF/FTC|Change of nucleoside backbone
219006490|NCT01288105|DEVICE|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
219006491|NCT01927224|DRUG|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
219006492|NCT01927224|DRUG|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
219006493|NCT01927224|DRUG|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
219006494|NCT03103737|BEHAVIORAL|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
219428758|NCT01349686|PROCEDURE|Fasting|No intake of fluids during labour.
219428759|NCT05783453|OTHER|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~* Formula: 2039055 06~* Aspect: Emulsion~* Batch nº: RAUO0063~* Expiry date: 10/2022~* Application area: Face and Body~* Application mode: Apply to face and body twice a day.~* Quantity of product to be applied: About 1 flask (400g) per month"
219428760|NCT03805555|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
219428761|NCT03805555|PROCEDURE|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
219006495|NCT00230607|DRUG|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
219006496|NCT00095901|DRUG|Capecitabine|
219428762|NCT05632224|DRUG|Aprepitant|The drug is given 1 hour before the start of the surgery
219428763|NCT05632224|DRUG|Granisetron|The drug is given 10 minutes before the patients's extubation
219428764|NCT02915952|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
219428765|NCT02915952|OTHER|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
219428766|NCT01096043|DRUG|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
219577328|NCT03561441|DRUG|Tailored aggressive hydration|"1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
219760733|NCT06405126|DIAGNOSTIC_TEST|Optiek predictive model|Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.
219760734|NCT00742625|DRUG|daunorubicin hydrochloride|Given IV
219760735|NCT00742625|DRUG|cytarabine|Given IV
219760736|NCT00742625|DRUG|bortezomib|Given IV
219428767|NCT01096043|DRUG|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
219428768|NCT01096043|DRUG|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
219428769|NCT01096043|DRUG|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
219428770|NCT00700895|DRUG|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
219428771|NCT00907582|PROCEDURE|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
219428772|NCT02729077|DEVICE|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
219760737|NCT01291966|BEHAVIORAL|Motivational interview|
219760738|NCT05357833|DRUG|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
219006497|NCT00272467|DRUG|Rebamipide|"1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals"
219006498|NCT00272467|DRUG|Omeprazole|"1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea."
219428773|NCT06016790|GENETIC|cfDNA sequencing|Multi-omics sequencing of cfDNA in peripheral venous blood.
219428774|NCT06466928|PROCEDURE|Total pancreatectomy|Surgical removal of the entire pancreas
219428775|NCT06898099|OTHER|"Standard care control group (without hypnosis)"|"Randomization stratification on insomnia severity. In the Standard care group, the investigating physician will not change his or her current practice as part of the study. Treatment will be the same as usual, whether drug-based or not (psychotherapy, etc.), with the exception of hypnosis. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
219428776|NCT06898099|OTHER|"Experimental group: E2R hypnosis"|"Randomization stratification on insomnia severity. For the patients randomized to the Hypnosis E2R arm, patients summoned within 15 days to 3 weeks of inclusion for their first hypnotherapy session with the hypnotherapist. All patients will receive 4 hypnotherapy sessions over 6 weeks using the E2R method.~The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Practice of self-hypnosis requested of the patient (patient diary), Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
219577329|NCT03561441|DRUG|Tailored standard hydration|"1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
219577330|NCT05795179|BEHAVIORAL|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
219577331|NCT05795179|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
219577332|NCT05795179|BEHAVIORAL|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
219577333|NCT05795179|BEHAVIORAL|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
219577334|NCT05795179|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
219577335|NCT04125121|DRUG|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
219577336|NCT03667079|OTHER|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
219577337|NCT03667079|OTHER|Mass deworming only|Delivery of mass deworming to people only
219577338|NCT03667079|OTHER|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
219577339|NCT01432418|OTHER|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
219577340|NCT00033813|DRUG|Oxatomide (tinset)|
219577341|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
219577342|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
219577343|NCT02526511|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
219760739|NCT05357833|DRUG|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
219577344|NCT02526511|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
219577345|NCT02526511|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
219577346|NCT02526511|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
219577347|NCT03734211|DRUG|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
219577348|NCT03734211|DRUG|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
219760740|NCT05357833|DIAGNOSTIC_TEST|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
219760741|NCT02432430|BEHAVIORAL|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
219760742|NCT02432430|BEHAVIORAL|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
219428777|NCT05444348|BEHAVIORAL|Advance consultation concerning your life and treatment (ACT )|The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
219577349|NCT04802902|OTHER|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
219577350|NCT00054548|BIOLOGICAL|oblimersen sodium|Given IV
219577351|NCT00054548|DRUG|paclitaxel|Given IV
219577352|NCT00054548|OTHER|laboratory biomarker analysis|Correlative studies
219577353|NCT00054548|OTHER|pharmacological study|Correlative studies
219577354|NCT02016261|DRUG|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
219577355|NCT05001464|DEVICE|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
219577356|NCT05807516|OTHER|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
219577357|NCT00001045|DRUG|Nevirapine|
219006499|NCT02860169|BEHAVIORAL|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
219006500|NCT02601508|DRUG|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
219006501|NCT02601508|DRUG|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
219006502|NCT04743297|DRUG|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
219006503|NCT04743297|DRUG|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
219006504|NCT04031937|OTHER|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
219006505|NCT01917474|DIETARY_SUPPLEMENT|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
219006506|NCT01917474|DIETARY_SUPPLEMENT|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
219006507|NCT02258698|PROCEDURE|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
219006508|NCT02612974|BIOLOGICAL|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
219006509|NCT03793738|PROCEDURE|Anterior component separation|
219006510|NCT03793738|PROCEDURE|Posterior component separation|
219006511|NCT00738595|DRUG|EVT 302|EVT 302 5 mg once daily
219006512|NCT00738595|DRUG|Placebo|Placebo to match EVT 302, 5 mg
219006513|NCT00738595|DRUG|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
219006514|NCT00738595|DRUG|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
219006515|NCT03790488|DRUG|JTX-4014|Specified dose on specified days
219006516|NCT03566316|DRUG|Telmisartan/Amlodipine|
219006517|NCT03566316|DRUG|Rosuvastatin|
219006518|NCT03566316|DRUG|Telmisartan|
219006519|NCT04698460|PROCEDURE|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
219577358|NCT00001045|DRUG|Zidovudine|
219577359|NCT00001045|DRUG|Didanosine|
219577360|NCT00712426|DRUG|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
219428778|NCT07065305|DRUG|Curodont Repair Fluoride Plus (Self-assembling peptide remineralization agent)P11-4 peptide, fluoride, mild acidic buffer (pH ~4.5) , Credentis AG, Switzerland|Pretreatment with Curodont Repair Fluoride Plus (P11-4 + fluoride)
219428779|NCT07065305|DRUG|Beautifil II LS|Application of Giomer restorative material following standard adhesive procedures without pretreatment.
219428780|NCT07067346|DRUG|IR-101|IR-101 Dose Escalation
219428781|NCT07077317|OTHER|Airway Assessment Using Standard Clinical Tools|Preoperative airway evaluation using routine physical measurements (e.g., Mallampati score, neck circumference, STOP-Bang questionnaire), and intraoperative/postoperative observation of airway-related parameters.
219428782|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.03%|A topical drop of 0.03% BRM421 ophthalmic solution.
219428783|NCT07078955|DRUG|Vehicle Ophthalmic Solution|A topical drop of vehicle (minus active) ophthalmic solution.
219428784|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.06%|A topical drop of 0.06% BRM421 ophthalmic solution.
219428785|NCT06928753|BIOLOGICAL|IXCHIQ|Group of vaccinated arm will be with the IXCHIQ vaccine
219428786|NCT07086092|OTHER|Serum magnesium, uric acid, and vitamin D levels and motor recovery and ambulation stages|Serum magnesium, uric acid, and vitamin D levels, as well as motor recovery and ambulation levels, measured during the patients' rehabilitation stay will be obtained from past medical records.
219428787|NCT07084597|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D ,50000 IU/week will be given for 8 consecutive weeks
219428788|NCT07091708|OTHER|Acupuncture|Acupuncture
219428789|NCT07090096|OTHER|A whole food plant based diet|A whole food plant based (WFPB) diet
219428790|NCT07092020|DEVICE|EDF|Extended depth of focus
219577361|NCT00712426|DRUG|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
219577362|NCT03569150|OTHER|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
219577363|NCT00709839|DRUG|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
219577364|NCT00709839|DRUG|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
219577365|NCT02586142|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
219577366|NCT02586142|OTHER|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
219577367|NCT01825889|DRUG|Evacetrapib|
219577368|NCT01857960|BEHAVIORAL|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
219577369|NCT00793780|DRUG|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
219760743|NCT04256187|OTHER|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
219191502|NCT06051383|OTHER|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
219428791|NCT07092020|DEVICE|Monofocal IOL|Monofocal
219428792|NCT07091396|DEVICE|Soterix® tDCS - Home treatment|"Participants will receive transcranial direct current stimulation (tDCS) via the Soterix device at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current.~Each participant will be asked to perform tDCS on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions). The research team will decide on a number of therapy sessions depending on the patient's baseline condition and tolerance. Patients who receive 10 sessions of therapy over two weeks will have 4 weeks of washout. Patients who receive 12 sessions over four weeks will have 8 weeks of washout."
219577370|NCT00793780|OTHER|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
219577371|NCT05837572|OTHER|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
219760744|NCT05245539|DRUG|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
219428793|NCT07091396|BEHAVIORAL|Cognitive-linguistic therapy|Participants will be instructed to perform home activity based cognitive-linguistic task-based exercises. Each participant will be asked to perform tDCS concurrently with individualized activity based cognitive-linguistic therapy on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions)
219428794|NCT07091396|DEVICE|Soterix® tDCS - Lab treatment|Participants will receive transcranial direct current stimulation (tDCS) in person, via the same Soterix device the home based participants will use at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current. They will undergo 12 sessions over four weeks.
219428795|NCT07090486|DRUG|nirmatrelvir-ritonavir|Paxlovid standard of treatment care
219428796|NCT07090889|DRUG|KM-023|solution for oral administration
219428797|NCT07090889|DRUG|Placebo|solution for oral administration
219006520|NCT04698460|PROCEDURE|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
219006521|NCT04225611|DRUG|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
219006522|NCT04134013|DIETARY_SUPPLEMENT|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
219006523|NCT04134013|OTHER|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
219191503|NCT06390137|DEVICE|Frequency Specific Microcurrent|The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.
219428798|NCT07090837|OTHER|Caregiver Support Model|"1. CarePal: A one-stop resource library for caregivers of older adults~2. Nasogastric tube (NGT) webapp: An electronic training platform to learn NGT feeding and management~3. Carer OnBoard programme~4. Caregiver resources in NHG Health App (NHA): Relevant healthcare professionals or TTSH staff will introduce caregivers to the resources they may need in the NHA app.~5. Carer guide, a resource booklet providing information and community resources for caregivers.~6. Group Caregiver Training, for caregivers who are able to attend group caregiver training (instead of learning at the bedside);~7. NHG Care Telephonic team to provide telephonic support to caregivers post-discharge.~8. Nurses or other healthcare professionals providing relevant information on community programmes"
219428799|NCT07090837|OTHER|Standard caregiver support|Participants are provided standard bedside caregiver education as appropriate and information reinforcement through leaflets and booklets
219428800|NCT05090098|OTHER|None intervention|None intervention
219428801|NCT00977587|DRUG|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
219428802|NCT00977587|DRUG|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
219428803|NCT01770145|DRUG|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
219428804|NCT01770145|DRUG|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
219428805|NCT01770145|DRUG|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
219428806|NCT00595868|DRUG|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
219577372|NCT02737982|PROCEDURE|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
219006524|NCT05154006|BEHAVIORAL|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
219191504|NCT06390137|DEVICE|Sham microcurrent treatment|The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
219191505|NCT05603052|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
219428807|NCT00595868|DRUG|Placebo|same as Varenicline arm
219577373|NCT00044421|DRUG|Ruboxistaurin mesylate|
219577374|NCT00432302|DRUG|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
219577375|NCT00010192|BIOLOGICAL|rituximab|Given IV
219577376|NCT00010192|BIOLOGICAL|aldesleukin|Given SC
219191506|NCT05603052|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
219577377|NCT00010192|OTHER|laboratory biomarker analysis|Correlative studies
219577378|NCT00010192|OTHER|pharmacological study|Correlative studies
219428808|NCT03905824|BIOLOGICAL|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
219428809|NCT03905824|PROCEDURE|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
219428810|NCT03632668|DRUG|AD-2071 10/20mg|AD-2071 10/20 mg tablet
219428811|NCT03632668|DRUG|AD-2072 80/5mg|AD-2072 80/5mg tablet
219428812|NCT03632668|DRUG|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
219428813|NCT02402621|DRUG|fentanyl|fentanyl with antiemetic drug
219428814|NCT04478110|BEHAVIORAL|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
219428815|NCT04478110|BEHAVIORAL|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
219428816|NCT03380026|DRUG|Triamcinolone|Apply up to three times daily on select lesions.
219428817|NCT03380026|DRUG|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
219428818|NCT05373082|OTHER|questionnaire completion|Questionnaire to be completed by patients
219428819|NCT06508788|DEVICE|CO2 laser|Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
219428820|NCT01232192|BEHAVIORAL|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis"
219428821|NCT04268303|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Sublingual film containing dexmedetomidine (BXCL501)
219428822|NCT04268303|DRUG|Placebo Film|Placebo Film for BXCL501
219577379|NCT03838861|BEHAVIORAL|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
219577380|NCT03783273|DIETARY_SUPPLEMENT|Vitamin D3|Single dose vitamin D3
219577381|NCT03783273|COMBINATION_PRODUCT|Whey protein-complex|Whey protein complex-bound vitamin D3
219577382|NCT03783273|OTHER|Water|500 mL water
219428823|NCT03249753|DRUG|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
219428824|NCT03249753|DRUG|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
219428825|NCT05141357|DRUG|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
219428826|NCT01067313|DEVICE|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
219428827|NCT01067313|DEVICE|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
219577383|NCT03783273|OTHER|Milk|500 mL milk
219577384|NCT03783273|OTHER|Juice|500 mL juice
219577385|NCT05649241|DRUG|Nicotine patch|Nicotine replacement therapy patch
219577386|NCT05649241|DRUG|Nicotine gum|Nicotine replacement therapy gum
219577387|NCT05649241|BEHAVIORAL|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
219577388|NCT01097941|BIOLOGICAL|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
219577389|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
219577390|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
219577391|NCT02452541|OTHER|Prognostic tests|"* Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams"
219577392|NCT00937378|DRUG|SER120|Nasal Spray, once a day
219577393|NCT00937378|DRUG|Placebo|Nasal Spray
219577394|NCT06444945|DEVICE|Heating pad|Heating pad will be used for heating purpose.
219577395|NCT06444945|DEVICE|Transcutaneous electrical nerve stimulation(TENS)|TENS is used for symptomatic pain relief
219577396|NCT06444945|PROCEDURE|Mulligan mobilization with movement (MWM)|It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint
219577397|NCT06444945|PROCEDURE|Kaltenborn joint mobilization|The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.
219428828|NCT03185923|DRUG|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
219428829|NCT03185923|DRUG|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
219577398|NCT06444945|PROCEDURE|Resistance Training exercise|Resistance training increases muscle strength by making your muscles work against a weight or force.
219577399|NCT04795830|COMBINATION_PRODUCT|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
219577400|NCT04795830|COMBINATION_PRODUCT|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
219577401|NCT02704780|DRUG|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
219577402|NCT01066091|OTHER|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
219577403|NCT01066091|OTHER|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
219577404|NCT01066091|OTHER|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
219428830|NCT02245230|DRUG|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
219428831|NCT02245230|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
219577405|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~1. Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~3. ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
219577406|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~1. Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~3. ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
219577407|NCT03310411|DRUG|Lasmiditan|Administered orally
219577408|NCT03310411|DRUG|Sumatriptan|Administered orally
219006525|NCT05154006|BEHAVIORAL|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]"
219577409|NCT03310411|DRUG|Placebo for Lasmiditan|Administered orally
219006526|NCT05154006|BEHAVIORAL|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
219760745|NCT00891150|DRUG|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
219006527|NCT05154006|BEHAVIORAL|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
219006528|NCT05284214|BIOLOGICAL|Sargramostim|Sargramostim for injection
219006529|NCT05284214|BIOLOGICAL|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
219428832|NCT02245230|DRUG|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
219428833|NCT03424213|OTHER|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
219428834|NCT01830244|DRUG|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
219428835|NCT05685394|DRUG|Dapagliflozin|Dapagliflozin 10mg P.O. daily
219428836|NCT04481880|DIAGNOSTIC_TEST|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
219577410|NCT03310411|DRUG|Placebo for Sumatriptan|Administered orally
219577411|NCT00794755|DIETARY_SUPPLEMENT|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
219577412|NCT00794755|DIETARY_SUPPLEMENT|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
219760746|NCT01084889|DEVICE|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
219760747|NCT04429464|DEVICE|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
219428837|NCT06271239|OTHER|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
219428838|NCT06271239|OTHER|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
219428839|NCT03614819|PROCEDURE|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
219428840|NCT03614819|PROCEDURE|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
219428841|NCT00436020|DEVICE|TMS|Transcranial Magnetic Stimulation
219428842|NCT00436020|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
219428843|NCT04833920|DEVICE|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
219428844|NCT03197350|DIAGNOSTIC_TEST|cMR|cardiac MRI done to complete the diagnosis
219428845|NCT03197350|BIOLOGICAL|biomarker|Biomarker correlation with cMR parameters Prognostic information
219428846|NCT02733146|OTHER|cardiac arrest|
219428847|NCT06305091|DIAGNOSTIC_TEST|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
219428848|NCT02846051|PROCEDURE|venous mapping|clinical examination + doppler echo
219428849|NCT04848415|OTHER|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
219577413|NCT01300910|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
219577414|NCT01300910|PROCEDURE|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
219577415|NCT02968836|DIETARY_SUPPLEMENT|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
219577416|NCT02968836|DIETARY_SUPPLEMENT|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
219577417|NCT01440036|PROCEDURE|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
219191509|NCT04210947|OTHER|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
219191510|NCT04210947|OTHER|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
219191511|NCT04210947|OTHER|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
219428850|NCT05565157|PROCEDURE|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
219006530|NCT03705676|BEHAVIORAL|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
219006531|NCT03705676|DEVICE|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
219428851|NCT02581670|RADIATION|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
219428852|NCT04159818|DRUG|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
219428853|NCT04159818|DRUG|Cisplatin|40mg/m2, weekly for two weeks
219428854|NCT04159818|DRUG|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
219428855|NCT03277625|PROCEDURE|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
219428856|NCT06302998|DRUG|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
219428857|NCT06302998|DRUG|Standard of Care|This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
219428858|NCT03633591|DRUG|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
219428859|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
219428860|NCT03633591|DRUG|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
219428861|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
219428862|NCT04653389|DRUG|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
219428863|NCT04653389|DRUG|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
219428864|NCT04653389|RADIATION|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
219428865|NCT03958318|OTHER|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
219577418|NCT04006483|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
219577419|NCT04006483|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
219577420|NCT04006483|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
219006532|NCT03705676|DEVICE|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
219428866|NCT03958318|OTHER|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
219428867|NCT00519610|OTHER|Chart Review|Patients' charts will be reviewed for relevant medical information.
219428868|NCT01711541|DRUG|Carboplatin|Given IV
219577421|NCT04600778|OTHER|placebo|placebo
219191512|NCT03849651|DRUG|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
219428869|NCT01711541|DRUG|Cisplatin|Given IV
219428870|NCT01711541|DRUG|Fluorouracil|Given IV
219428871|NCT01711541|DRUG|Hydroxyurea|Given PO
219577422|NCT04600778|DRUG|Cavosonstat 5 mg|Cavosonstat (low dose)
219006533|NCT02619955|OTHER|samples with DNA|
219006534|NCT02516683|OTHER|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
219428872|NCT01711541|OTHER|Laboratory Biomarker Analysis|Correlative studies
219006535|NCT02749981|PROCEDURE|blood and tissue sampling|
219428873|NCT01711541|DRUG|Paclitaxel|Given IV
219428874|NCT01711541|OTHER|Placebo Administration|Given PO
219428875|NCT01711541|RADIATION|Radiation Therapy|Undergo radiation therapy
219428876|NCT01711541|DRUG|Veliparib|Given PO
219577423|NCT04600778|DRUG|Cavosonstat 10 mg|Cavosonstat (medium dose)
219577424|NCT04600778|DRUG|Cavosonstat 25 mg|Cavosonstat (high dose)
219577425|NCT03983083|BEHAVIORAL|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
219577426|NCT01860911|DRUG|Insulin|
219577427|NCT01860911|DRUG|NG-monomethyl-L-arginine|
219577428|NCT03802253|BEHAVIORAL|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
219577429|NCT03802253|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
219577430|NCT04029311|DEVICE|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
219577431|NCT04029311|DEVICE|autoPAP|autoPAP
219428877|NCT03161171|OTHER|This is an observational study|This is an observational study
219428878|NCT04301583|DIETARY_SUPPLEMENT|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
219428879|NCT00728936|DRUG|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
219428880|NCT00728936|DRUG|Saline placebo|saline placebo given subcutaneously
219428881|NCT03796234|OTHER|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
219006536|NCT03861351|DEVICE|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
219006537|NCT01923493|OTHER|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
219006538|NCT01923493|OTHER|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
219428882|NCT03796234|OTHER|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
219577432|NCT04029311|DEVICE|TAP PAP|TAP PAP
219577433|NCT04601298|OTHER||
219577434|NCT00452517|PROCEDURE|Percutaneous Coronary Intervention|
219577435|NCT03623386|OTHER|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
219577436|NCT03623386|OTHER|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
219577437|NCT05080426|BEHAVIORAL|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
219577438|NCT02903992|RADIATION|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
219428883|NCT00801346|OTHER|laboratory biomarker analysis|
219577439|NCT03282630|PROCEDURE|Sphenopalatine ganglion acupuncture|"* active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
219577440|NCT05502692|BEHAVIORAL|CHARACTERISE|Cohort 1 Cohort 2
219577441|NCT02636426|DRUG|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
219577442|NCT05483595|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 10ml
219428884|NCT00801346|OTHER|metabolic assessment|
219577443|NCT05347381|DRUG|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
219577444|NCT01996943|DRUG|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
219577445|NCT01996943|DRUG|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
219006539|NCT03785002|OTHER|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
219006540|NCT03785002|OTHER|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
219191513|NCT03849651|BIOLOGICAL|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
219191514|NCT03849651|DRUG|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
219191515|NCT03849651|DRUG|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
219428885|NCT00801346|OTHER|questionnaire administration|
219428886|NCT00801346|PROCEDURE|assessment of therapy complications|
219428887|NCT00801346|PROCEDURE|fatigue assessment and management|
219428888|NCT00801346|PROCEDURE|quality-of-life assessment|
219428889|NCT02911818|BEHAVIORAL|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
219428890|NCT02911818|DRUG|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
219428891|NCT02911818|OTHER|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
219428892|NCT02911818|DRUG|Placebo Oral Tablet|
219428893|NCT02911818|DRUG|Phentermine 15 MG|
219577446|NCT01468805|PROCEDURE|Cockroach mitigation/extermination|
219577447|NCT00863395|PROCEDURE|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
219577448|NCT05056883|DRUG|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
219428894|NCT02911818|BEHAVIORAL|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
219428895|NCT05474469|OTHER|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
219428896|NCT05474469|OTHER|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
219428897|NCT06196619|DIAGNOSTIC_TEST|SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level|Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
219428898|NCT05254652|DRUG|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
219428899|NCT05254652|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
219428900|NCT00973180|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
219428901|NCT01985165|DRUG|Imrecoxib|
219577449|NCT05056883|DRUG|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
219428902|NCT00457756|DIETARY_SUPPLEMENT|BiosLife Complete|
219428903|NCT00457756|DIETARY_SUPPLEMENT|Placebo|
219428904|NCT01175590|DRUG|Besivance|Ocular administration to affected eye for 7 days
219428905|NCT01175590|DRUG|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
219428906|NCT04775394|OTHER|Bronchoscopy|Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
219428907|NCT05851092|DRUG|HRS-2189 Tablets|HRS-2189 Tablets
219428908|NCT00223652|BEHAVIORAL|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
219428909|NCT00931294|BEHAVIORAL|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
219428910|NCT00931294|BEHAVIORAL|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
219577450|NCT05417035|DRUG|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
219577451|NCT04271735|DIETARY_SUPPLEMENT|Niagen|Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
219428911|NCT04754113|OTHER|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
219428912|NCT05536154|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
219428913|NCT05536154|DRUG|Cytarabine|Day 1\~Day 2: 200mg/m\^2, q12h
219428914|NCT05536154|DRUG|PEG-rhG-CSF|Day 6: 6mg
219577452|NCT04271735|OTHER|Placebo|Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
219577453|NCT00515541|DRUG|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
219577454|NCT05133791|DRUG|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
219577455|NCT04353765|DRUG|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
219428915|NCT00749268|DEVICE|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
219428916|NCT00749268|DEVICE|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
219428917|NCT05784870|DRUG|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
219428918|NCT05784870|DRUG|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
219428919|NCT00656578|DRUG|4975|Single dose, solution
219428920|NCT00656578|DRUG|Placebo|Single dose, solution
219428921|NCT00877006|DRUG|bendamustine|
219428922|NCT00877006|DRUG|rituximab|
219428923|NCT00877006|DRUG|vincristine|
219428924|NCT00877006|DRUG|prednisone|
219428925|NCT00877006|DRUG|cyclophosphamide|
219428926|NCT00877006|DRUG|doxorubicin|
219428927|NCT03948451|DRUG|[14C]AZD5718 Oral Suspension|200 mg dose of \[14C\]AZD5718 Oral Suspension
219577456|NCT04353765|DRUG|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
219577457|NCT01463735|DIETARY_SUPPLEMENT|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
219577458|NCT04964518|DRUG|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
219577459|NCT00746018|DEVICE|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
219577460|NCT03292536|DRUG|Merestinib|"\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
219428928|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
219428929|NCT00042562|DRUG|duloxetine|
219428930|NCT01089816|BIOLOGICAL|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
219428931|NCT02026518|DIETARY_SUPPLEMENT|Soy isoflavones|
219428932|NCT02026518|DIETARY_SUPPLEMENT|cholecalciferol|
219428933|NCT02026518|DIETARY_SUPPLEMENT|Placebo of soy isoflavones|
219428934|NCT02026518|DIETARY_SUPPLEMENT|placebo of cholecalciferol|
219428935|NCT02122926|OTHER|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
219577461|NCT05557032|PROCEDURE|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
219577462|NCT05530187|DEVICE|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
219577463|NCT00605761|DRUG|SB656933|50 mg treatment
219577464|NCT00605761|DRUG|SB656933|150 mg treatment
219577465|NCT06385561|DRUG|Tramadol|Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
219577466|NCT06385561|DRUG|Placebo|Placebo is administered orally twice daily.
219577467|NCT01030653|DRUG|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
219577468|NCT01030653|DRUG|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
219760748|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
219191516|NCT03849651|BIOLOGICAL|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
219191517|NCT03849651|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
219191518|NCT03849651|DEVICE|CliniMACS|Cells for infusion are prepared using the CliniMACS
219428936|NCT02053558|DRUG|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
219428937|NCT02053558|DRUG|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
219428938|NCT00209872|DRUG|Gabapentin|
219428939|NCT00209872|DRUG|Lidocaine|
219428940|NCT00209872|DRUG|S-ketamine|
219428941|NCT00209872|PROCEDURE|Epidural analgesia|
219428942|NCT03911869|DRUG|encorafenib|taken orally
219428943|NCT03911869|DRUG|binimetinib|taken orally
219428944|NCT03029676|DRUG|benzodiazepines|sedative
219428945|NCT03029676|DRUG|opioid|analgetic, sedative
219428946|NCT03029676|PROCEDURE|spinal anesthesia|
219428947|NCT01878097|BEHAVIORAL|Green Dot Bystander Intevention|Intervention allocated at the school level
219428948|NCT01878097|BEHAVIORAL|Control|Awareness Education
219428949|NCT04488081|DRUG|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
219760749|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
219760750|NCT00800800|DRUG|Rosuvastatin|40 mg, oral, single dose
219760751|NCT00800800|DRUG|Placebo|oral, single dose
219760752|NCT03984721|DIAGNOSTIC_TEST|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
219760753|NCT00363571|DRUG|GTN, Diamox|
219760754|NCT06345885|BIOLOGICAL|HPV vaccine|Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
219760755|NCT02227303|BEHAVIORAL|lifestyle modification instructional and motivational sessions|
219760756|NCT01012284|DRUG|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
219428950|NCT04488081|DRUG|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
219428951|NCT04488081|DRUG|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
219428952|NCT04488081|DRUG|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
219760757|NCT00093509|DRUG|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
219760758|NCT00093509|DRUG|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
219760759|NCT00093509|PROCEDURE|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
219760760|NCT00093509|RADIATION|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of \> 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
219760761|NCT03454789|DRUG|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
219760762|NCT03454789|DRUG|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
219760763|NCT03454789|DRUG|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
219428953|NCT04488081|DRUG|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
219428954|NCT04488081|DRUG|Apremilast|oral, 30 mg bid × 14 days.
219428955|NCT04488081|BIOLOGICAL|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
219428956|NCT04488081|DRUG|Celecoxib|Oral: 400 mg BID for 7 days.
219428957|NCT04488081|DRUG|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
219577469|NCT02564146|DRUG|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
219577470|NCT02564146|DRUG|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
219577471|NCT00922272|DRUG|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
219577472|NCT00922272|DRUG|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
219577473|NCT04910516|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
219760764|NCT03454789|DRUG|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
219428958|NCT04488081|BIOLOGICAL|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
219428959|NCT04488081|DRUG|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
219428960|NCT04488081|BIOLOGICAL|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
219428961|NCT04488081|DRUG|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
219428962|NCT04488081|DRUG|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
219577474|NCT03609723|PROCEDURE|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
219577475|NCT05672823|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
219577476|NCT02384135|OTHER|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
219577477|NCT02588950|DRUG|U-500R|
219760765|NCT04179110|DRUG|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
219760766|NCT02941614|BEHAVIORAL|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
219191519|NCT03849651|BIOLOGICAL|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
219191520|NCT03849651|DRUG|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
219191521|NCT03849651|BIOLOGICAL|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
219428963|NCT02040155|DEVICE|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
219428964|NCT05972395|OTHER|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
219428965|NCT04406012|PROCEDURE|paravertebral block|paravertebral block group
219428966|NCT05951543|OTHER|plyometric exercises|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
219428967|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
219428968|NCT03043846|OTHER|Follow-up every 3 months during 1 year (data collection in eCRF)|
219577478|NCT01830634|BEHAVIORAL|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
219577479|NCT01374139|DRUG|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
219577480|NCT01374139|DRUG|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
219577481|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
219760767|NCT02012803|PROCEDURE|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
219760768|NCT02012803|OTHER|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
219760769|NCT05009095|DEVICE|The Listening Program® with bone conduction headphones|The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
219191522|NCT03849651|BIOLOGICAL|CD19+|IV on day 0 and may receive an additional dose on day 1
219191523|NCT03849651|BIOLOGICAL|CD45RA-depleted DLI|infusion IV
219191524|NCT02405364|DRUG|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
219191525|NCT04846036|DRUG|Sonlicromanol|Oral administration of sonlicromanol twice daily
219191526|NCT04846036|DRUG|Placebo|Oral administration of matching placebo twice daily
219191527|NCT06273072|DRUG|Metformin hydrochloride extended-release tablets|titrated to 2000 mg once daily
219191528|NCT06273072|DRUG|Visually identical placebo Metformin hydrochloride extended-release tablets|placebo
219191529|NCT05361941|DEVICE|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a 2-stage or 1.5 stage revision of an infected total joint.
219191530|NCT05361941|DEVICE|empty voids|Voids are left empty
219006541|NCT06361030|DRUG|surufatinib combined with gemcitabine plus nab-paclitaxel|"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
219006542|NCT02374801|DEVICE|"SonR automatic optimization feature turned ON (AV+VV)."|
219006543|NCT01202474|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
219006544|NCT01202474|DRUG|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
219006545|NCT04575922|DRUG|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
219006546|NCT04575922|DRUG|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
219006547|NCT04575922|RADIATION|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
219006548|NCT01299792|OTHER|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
219006549|NCT06242951|DIAGNOSTIC_TEST|VO2 max assessment|Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
219006550|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
219006551|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
219006552|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
219006553|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
219006554|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
219006555|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
219006556|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given 2 doses intravenously
219191531|NCT05474027|OTHER|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
219428969|NCT03043846|OTHER|Follow-up every month to follow the pre-defined strategy|
219428970|NCT02566616|DEVICE|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
219428971|NCT06231914|DEVICE|StarWalker® PQX|Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
219428972|NCT03470311|BIOLOGICAL|Benralizumab|30mg in 1mL pre-filled syringe
219428973|NCT03470311|BIOLOGICAL|Placebo|Matched placebo (1mL) in pre-filled syringe
219428974|NCT05145803|DEVICE|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
219428975|NCT00224783|BIOLOGICAL|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
219577482|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
219577483|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
219577484|NCT04498741|DRUG|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
219006557|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
219006558|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
219006559|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
219006560|NCT04073589|BIOLOGICAL|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
219006561|NCT05471622|BEHAVIORAL|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
219006562|NCT05042167|OTHER|Resistance exercise|4 total resistance exercises that target all major muscle groups.
219006563|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
219006564|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
219006565|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
219428976|NCT00224783|BIOLOGICAL|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
219428977|NCT00367341|DRUG|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
219428978|NCT00367341|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
219428979|NCT03325556|DRUG|Placebo|Placebo, tablets, once daily by mouth
219428980|NCT03325556|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
219428981|NCT03325556|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
219577485|NCT04498741|DRUG|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
219577486|NCT04498741|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
219428982|NCT00595257|DEVICE|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
219428983|NCT02119026|DRUG|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
219428984|NCT02119026|DRUG|Capecitabine|1000mg/m2 bid d1-14,
219428985|NCT02119026|DRUG|Bevacizumab|7,5 mg/kg given on d1 q3w
219428986|NCT02119026|DRUG|Oxaliplatin|130mg/m2 iv. d 1 q3w
219577487|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
219577488|NCT04498741|DRUG|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
219428987|NCT02119026|DRUG|Irinotecan|200mg/m2 iv. d 1 q3w .
219428988|NCT00657722|OTHER|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
219428989|NCT03135288|DEVICE|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
219577489|NCT01417819|OTHER|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
219428990|NCT00340834|DRUG|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
219428991|NCT00340834|DRUG|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
219428992|NCT00340834|DRUG|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
219428993|NCT05868980|OTHER|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
219428994|NCT06293365|BIOLOGICAL|VAY736 1ml PFS|Solution for injection.
219428995|NCT06293365|BIOLOGICAL|VAY736 2 ml PFS|Solution for injection
219006566|NCT00531999|DRUG|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
219006567|NCT00531999|DRUG|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
219006568|NCT01366170|GENETIC|microarray analysis|
219428996|NCT06293365|BIOLOGICAL|VAY736 2ml AI|Solution for injection.
219577490|NCT04912115|DRUG|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
219006569|NCT01366170|GENETIC|protein expression analysis|
219428997|NCT05166395|DEVICE|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
219577491|NCT04912115|DRUG|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
219428998|NCT04516577|OTHER|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
219006570|NCT01366170|GENETIC|western blotting|
219428999|NCT05455736|OTHER|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
219429000|NCT03967509|BEHAVIORAL|Comet|
219429001|NCT02451488|DRUG|GM-CSF|14 days in a dose of 125 µg/m\^2
219006571|NCT01366170|OTHER|flow cytometry|
219006572|NCT01366170|OTHER|immunohistochemistry staining method|
219006573|NCT01366170|OTHER|laboratory biomarker analysis|
219006574|NCT01366170|OTHER|mass spectrometry|
219191532|NCT05474027|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
219429002|NCT02451488|OTHER|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
219429003|NCT02786836|DRUG|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
219429004|NCT03617913|DRUG|Avelumab|Given IV
219429005|NCT03617913|DRUG|Cisplatin|Given IV
219429006|NCT03617913|DRUG|Fluorouracil|Given IV
219429007|NCT03617913|DRUG|Mitomycin|Given IV
219429008|NCT03617913|OTHER|Quality-of-Life Assessment|Ancillary studies
219429009|NCT03617913|RADIATION|Radiation Therapy|Undergo RT
219006575|NCT04667650|OTHER|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
219429010|NCT01143714|DRUG|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
219429011|NCT01143714|OTHER|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
219577492|NCT05638841|OTHER|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
219577493|NCT03911921|DRUG|RSYRT decoction|Compound granules of traditional Chinese medicine
219577494|NCT03911921|DRUG|Astragalus membranaceus|One herb
219577495|NCT04233086|OTHER|No intervention, observational only|No intervention, observational only
219577496|NCT04252222|DEVICE|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
219577497|NCT02035839|DEVICE|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
219577498|NCT02035839|DEVICE|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
219577499|NCT02035839|DEVICE|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
219577500|NCT03678324|OTHER|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
219429012|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
219429013|NCT05063968|DRUG|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
219429014|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
219429015|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
219429016|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
219429017|NCT05063968|DRUG|Placebo|Tablet is administered orally once daily for 14 Days continuously
219429018|NCT02030249|BEHAVIORAL|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
219429019|NCT02030249|BEHAVIORAL|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
219429020|NCT02030249|BEHAVIORAL|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
219429021|NCT01387074|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
219429022|NCT06331312|BIOLOGICAL|Secukinumab|2 x 150mg/1mL PFS secukinumab
219429023|NCT05285267|BEHAVIORAL|Behavioral Parent Support|Parent training on effective child management strategies
219429024|NCT05285267|BEHAVIORAL|Shared Parent-Child Activities|Structured parent-child activities
219429025|NCT05285267|BEHAVIORAL|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
219429026|NCT02373163|DRUG|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
219429027|NCT02373163|DRUG|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
219429028|NCT02373163|DRUG|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
219429029|NCT00736788|DRUG|AZD1704|single dose oral suspension, 4 different dose levels
219429030|NCT00736788|DRUG|Placebo|single dose oral suspension
219429031|NCT05541523|BEHAVIORAL|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
219429032|NCT05541523|BEHAVIORAL|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
219429033|NCT01826526|DEVICE|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
218859454|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
219429600|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by mechanical articulator|"The therapeutic jaw position will be determined by the following steps:~1. Pre-treatment Jaw Position Recording Participants were seated upright with relaxed posture, eyes facing forward, and the Frankfort plane parallel to the floor. Intercuspal position (ICP) was recorded using silicone registration material. Edge-to-edge position of central incisors was recorded for protrusive position. Left/right lateral positions were recorded with opposing canines aligned.~2. Transfer of Jaw Positions Following the manufacturer's protocol for the Artex CR mechanical facebow (Amann Girrbach, Austria) to transfer Participants' jaw positions.~3. Determination of Therapeutic Position The Glenoid fossa was divided into 7 grids in the oblique-sagittal plane using Gelb's method, identifying grid 4 (Gelb 4/7) as the target condylar position.Condylar displacement knobs were set per VTO analysis.~Incisal pin height was increased to establish vertical dimension."
219429601|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual articulator|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Jaw Models CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The mandibular/maxillary bone models and dental arches were exported as .ply files. These .ply files were then imported into Exocad software.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The composite mandibular model was repositioned to the target occlusion using the Move Mesh function based on: Optimal mean joint space measurements and physiological condylar position."
219429602|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual patient|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Virtual Patients:~   CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The trajectory of mandibular movement was recorded by an electronic facebow.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The therapeutic position was determined based on: Optimal mean joint space measurements, physiological condylar position and optimal trajectory of mandibular movement."
219429603|NCT07092072|DEVICE|MYOFIX FULL FIELD PERIPHERAL DEFOCUS SPECTACLE|This is a plus peripheral add spectacle with the central part for the myopic correction.
219429604|NCT07090369|DRUG|Olaparib (300 mg BID)|oral tablet
219429605|NCT07090369|DRUG|Pembrolizumab|IV infusion
219429606|NCT07090369|RADIATION|177Lu-PSMA-I&T|PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen. PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen
219429607|NCT07089966|OTHER|HTS counselor-led PrEP care model|PrEP delivery ,including HIV testing, eligibility assessment, dispensing, adherence counseling, and provision of refills, provided by an HTS counselor
219429608|NCT07090694|PROCEDURE|Graftless Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention involves a minimally invasive internal (crestal) sinus lift performed without the use of any grafting material. The sinus membrane is elevated using sequential osteotomy drills, and a dental implant is immediately placed into the prepared site. The implant fixture acts as a tent pole, maintaining the lifted membrane and allowing for spontaneous bone regeneration through blood clot formation alone. This graftless method eliminates the need for additional biomaterials and is intended for patients with residual alveolar bone height of 5-7 mm
219429609|NCT07090694|BIOLOGICAL|Platelet-Rich Fibrin (PRF)-Assisted Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention utilizes autologous platelet-rich fibrin (PRF) as the sole grafting material during transcrestal sinus floor elevation. PRF is prepared from the patient's own venous blood using centrifugation and inserted into the osteotomy site after sinus membrane elevation. A dental implant is placed simultaneously to support the sinus membrane and stabilize the graft. The biologically active PRF matrix provides a scaffold rich in growth factors (e.g., TGF-β, PDGF, VEGF), promoting accelerated healing and enhanced bone formation beneath the elevated sinus floor. This technique is performed in a single-stage procedure, eliminating the need for synthetic or allogeneic grafts.
219429610|NCT07090967|OTHER|Project Planning Course|The Project Planning Course is conducted as a two-hour theoretical class per week. This course is being introduced for the first time in the nursing faculty curriculum. The course was conducted by two faculty members, both of whom have knowledge and experience in research and project writing. Since the goal at the end of the course was for students either to carry out a research project or to apply for a patent/utility model, it was planned for 20 students to enroll; however, 19 students chose the course. The course lasted 14 weeks in total. In the first week, topics such as what a project is, its characteristics, and its components were introduced to the students. As part of the course, students were asked to brainstorm solutions for problems they encountered in clinical settings. During the first seven weeks, theoretical lectures were delivered, and during the following five weeks, students worked with their academic advisors on research projects or patent/utility model topics.
219475178|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
218859455|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
219429611|NCT07091045|OTHER|Robot-Assisted Foot-Ankle Training|"Stage 1: Vibration Training Applied for Proper Stepping on the Sole of the Foot and Proper Pressure Distribution: The first step of the training will be constant vibration, and the second step will be sensory localization training with vibration.~Stage 2: Passive Joint Range of Motion Training with Virtual Reality: The platform will move the ankle passively (passive stretching).~Stage 3: Joint Position Sense Training: The platform will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the platform initially brought.~Stage 4: Active Joint Range of Motion Training with Virtual Reality: Along with active dorsiflexion, when necessary, assistance will be provided with the Assistance as Needed (AAN) control paradigm, a feature of the robotic device.~Stage 5: It is the same as Stage 1"
219429612|NCT07091045|OTHER|Conventional Foot-Ankle Training|Stage 1: Sensory Training to the Sole of the Foot: In the first step of the training, the physiotherapist will manually apply constant pressure with a blunt object, and in the second step, sensory localization training with a blunt object will be performed. Stage 2: Passive Joint Range of Motion Training: The ankle will be manually moved passively (passive stretching) by the physiotherapist. Stage 3: Joint Position Sense Training: The physiotherapist will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the physiotherapist initially brought. Stage 4: Active Joint Range of Motion Training: This stage will be performed with manual assistance provided by the physiotherapist when necessary, along with active dorsiflexion. Stage 5: It is the same as Stage 1
219429613|NCT07090798|DIAGNOSTIC_TEST|Static Head posture|After the participant sit down and put on the VR glasses, the VR will detect how many degrees the head position has displaced from the neutral position (X= 0, Y = 0, Z = 0). The x, y and z describe the head alignment, and in the table (3.3), they explain the 3D axis (X, Y, Z). Also in fig 3.3 the participant's head is in X=5.027058 Y=2.466827 Z=2.93206, which explains the degree of deviation from the neutral position.
219429614|NCT07090798|DIAGNOSTIC_TEST|"Angular distance ROM"|"Cervical range of motion assessment is achieved through virtual reality. After detecting the static head posture, Participants will be asked to flex their necks as far as possible toward their chins and anterior chests. Then elevate the head to the neutral and extend the neck to the most tolerable range. Following that, he/she performs maximal neck side-bending in both directions along the coronal plane. Lastly, each participant is required to return the neck to an upright position for the examination of the maximum angle of neck rotation by turning the chin toward the right and then left shoulders without shrugging the shoulders. All of the tests will be repeated three times, and the averaged values of neck movement in each direction will be taken for analysis"
219429615|NCT07092189|OTHER|Pre-colposcopy counseling by a clinical nurse|"In the intervention group, the clinical nurse conducted a structured pre-colposcopy counseling session covering the following topics: verification of the patient's understanding of the reason for the colposcopy referral, explanation of the cervical cytology result, the procedure of the colposcopy, expectations regarding pain, the role of HPV in the development of precancerous and cancerous cervical lesions, counseling on HPV vaccination, and smoking cessation."
219429616|NCT07092189|OTHER|Treatment as usual: regular call to schedule the appointment without pre-procedure conseilling|In the control group, patients simply received a phone call to notify them of their appointment and, upon arrival, were given an information sheet about colposcopy. No pre-colposcopy discussion was conducted.
219429617|NCT07089940|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219429618|NCT07089940|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219429619|NCT07089940|PROCEDURE|Computed Tomography|Undergo CT
219429620|NCT07089940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219429621|NCT07089940|DRUG|Myc Inhibitor OMO-103|Given IV
219429622|NCT06908694|DRUG|Semaglutide Pen Injector|The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.
219429623|NCT07090915|OTHER|nature sound|Modern audio technology is used to create a 3D natural atmosphere.
219429624|NCT07090538|DRUG|Eliglustat|Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor
219429625|NCT07090590|BEHAVIORAL|Thrive Digital Peer Platform (TDPP)|The Thrive Digital Peer Platform (TDPP) is a fully asynchronous, web-based training program designed to support the professional development of Peer Recovery Support Specialists (PRSS). The platform includes 11 interactive modules structured around the Connect, Grow, Apply (CGA) learning model. Content includes peer-led stories, behavioral simulations, scenario-based learning, and formative assessments. The intervention is intended to build competencies in professionalism, communication, and application of recovery-oriented peer support principles.
219429626|NCT07090603|OTHER|Knee extension exercise|Maximum repetitions of knee extension exercise at 20%, 30%, 40%, 50%, 60% and 70% of participants one rep max with and without blood flow occlusion
219429627|NCT07090421|DIETARY_SUPPLEMENT|Cellulose Powder|Participants consumed an inert cellulose powder dissolved in water, containing no active caffeine. The placebo was ingested orally 60 minutes prior to the rowing performance test. This condition served as the control and was administered once per session in a randomized, double-blind, crossover design.
219429628|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 3 mg/kg Oral Powder|Participants consumed caffeine in powder form at a dose of 3 milligrams per kilogram of body weight. The powder was dissolved in water and ingested orally approximately 60 minutes before the start of the 2000-meter rowing ergometer performance test. The intervention was administered once per session in a randomized, double-blind, crossover design.
219429629|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 6 mg/kg Oral Powder|Participants ingested caffeine in powder form, dissolved in water, at a dose of 6 milligrams per kilogram of body mass. The solution was consumed orally 60 minutes prior to the 2000-meter rowing performance test. This intervention was administered once per session as part of a randomized, double-blind, crossover design.
219429630|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 9 mg/kg Oral Powder|A powdered caffeine dose of 9 milligrams per kilogram was dissolved in water and consumed orally by participants 60 minutes before a 2000-meter rowing ergometer trial. The intervention was administered once per session under a randomized, double-blind, crossover design.
219429631|NCT07091487|BEHAVIORAL|Diabetes Homeless Medication Support|There will be 10 one-on-one sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors and psychologiccal wellness to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool matched to the patient's needs/goals and tailored diabetes education as needed.
219429632|NCT07091487|BEHAVIORAL|Enhanced Usual Care/ Education|Trained diabetes wellness coaches will provide approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will use the ask-offer-ask method to review these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
219429633|NCT07090473|DEVICE|transcutaneous spinal cord stimulation|Transcutaneous spinal stimulation will be delivered using the experimental ARC-EX device (ONWARD Medical), via skin surface electrodes placed over the spine (stimulating electrodes) and bilaterally on the iliac crests (reference electrodes) during the intervention.
219429634|NCT07090473|DEVICE|sham transcutaneous spinal cord stimulation|For sham transcutaneous spinal stimulation electrodes will be placed on the skin surface over the spine and bilaterally on the iliac crests and will be attached to the experimental ARCEX device (ONWARD Medical), however no electrical current will be delivered.
219429635|NCT07091331|PROCEDURE|Personalized 3D-printed pediatric ceromer crown|After primary molar crown preparation, digital impression using intraoral scanner (i700, Medit, Seoul, South Korea), crown will be designed with CAD software (CliniCAD, medit, South Korea) and fabricated using a 3D printer, (Sonic mini 4k, Phrozen, Taipei, Taiwan). Crown will be cemented by passive seating using a self-adhesive dual cure cement (Beauticem, shofu, San Marcos, CA, USA)
219429636|NCT07091331|DEVICE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparation of the tooth, the crown will be filled and cemented with type-1 glass ionomer cement (Ketac Cem easymix, 3M ESPE, Minnesota, USA)
219429637|NCT00257023|DRUG|paliperidone|
219429638|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium breve and Bifidobacterium longum
219429639|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium and Lactobacillus
219429640|NCT07091006|DRUG|VAH|For R/R AML patients, VAH bridging to conditioning regimen for allo-HCT.
219429641|NCT07092137|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
219429642|NCT07092137|OTHER|Nano-crystalline Megestrol Acetate Oral Suspension placebo|Nano-crystalline Megestrol Acetate placebo+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
219429643|NCT07092111|DEVICE|Auricular acupuncture treatment|Auricular acupuncture is an innovative intradermal acupuncture, which can directly use the meridian system of the ear skin to directly transmit the received stimulation to the lesion. Its stimulation time is long, and the amount of stimulation is strong. Studies have shown that needle pricking continuously delivers an adequate dose of acupuncture stimulation by continuously stimulating Aβ, Aδ, and/or C afferent fibers from the skin and transmitting them to the brain nucleus through the ventrolateral cord of the spinal cord. It is also believed that by stimulating the cranial nerves, especially the auricular branch of the vagus nerve, the effect of sensory afferent peripheral stimulation can be enhanced, and the analgesic effect of the auricular acupoints can be achieved.
219429644|NCT07092111|DEVICE|Sham acupuncture group|The treatment regimen is the same as that of the auricular acupuncture treatment group, but with a sham acupuncture (Seirin Pyonex Needles).
219429645|NCT07090356|OTHER|Instrument-Assisted Soft Tissue Mobilization|IASTM therapy will be provided to participants in whom a specialized instrument will be used to apply controlled pressure over the piriformis muscle as well as surrounding soft tissues.
219429646|NCT07090356|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|PNF stretching (contract relax; hold relax) will be implemented to stretch participants' muscles as flexibly and with as much control as possible.
219429647|NCT07091552|DEVICE|CAD/CAM monolithic denture|"Based on the workflow suggested by the Ivoclar digital denture, conventional complete dentures will be scanned by using desktop scanner (Medit T710). The cameo and intaglio surfaces of the complete dentures will be scanned, and the scanned data will be exported as Standard Tessellation Language (STL) file to start the milling process.~For the milling process, monolithic denture will be milled from a bicolored disk (Ivotion). One side is the denture base material made of high impact optimized polymethyl methacrylate (PMMA) while the other is the teeth material made of highly cross-linked PMMA with no filler. The bicolor disk is milled in a 5-axis milling machine in wet condition, through an uninterrupted milling process. Following the fast milling process the dentures will be finished and polished."
219429648|NCT07091552|DEVICE|Conventional denture|The conventional set will be fabricated with the 5-appointment process: preliminary impressions (first appointment); definitive impressions (second appointment); interocclusal records and tooth selection (third appointment), the size of the teeth will be selected according to the library provided by 3Shape Dental System software to match the disc size; wax trial placement (fourth appointment); and denture adjustment and placement (fifth appointment). Conventional CD will be fabricated with the conventional lost wax technique and heat-polymerizing acrylic resin. The heat-polymerized CDs will be finished, and polished before placement. Adjustments will be made for the polished surface, tissue surface, borders, and occlusion. Occlusal errors will be adjusted through clinical remount of the finished dentures.
219429649|NCT07092098|COMBINATION_PRODUCT|tDCS combined with resistance training|Transcranial direct current stimulation combined with resistance training
219429650|NCT07092098|BEHAVIORAL|Resistance training|low-limb resistance training
219429651|NCT07092098|DEVICE|tDCS|Transcranial direct current stimulation
219429652|NCT07092098|DEVICE|sham tDCS|Sham transcranial direct current stimulation
219429653|NCT07090161|DRUG|iloperidone|iloperidone
219429654|NCT07090161|DRUG|Placebo|placebo comparator
218859456|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
219429655|NCT07090200|COMBINATION_PRODUCT|Pulmonary Rehabilitation Care Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. The Pulmonary Rehabilitation Care Group received the Pulmonary rehabilitation exercise and usual care for three months. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function of the two groups of patients one year after the intervention.
219429656|NCT07090200|OTHER|The Routine Care (Non-Pharmacological and Pharmacological Treatments ) Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function one year after the intervention.
219429657|NCT07091643|BEHAVIORAL|Cognitive Behavioural Therapy|12 weeks of Cognitive Behavioural Therapy (CBT) will be administered. The first session will be accomplished in-person at Baycrest Hospital. After that, therapy will be conducted virtually, via video-conference. Individuals will undergo therapy once a week for approximately 1 hour, for 12-weeks. Following the 12-week period, individuals will receive three follow-up assessments with their therapist at 3, 6, and 9 months.
219429658|NCT07089979|DEVICE|Glunovo CGM device|Group 1 (Subjects that will use Glunovo CGM device) will be compared to Group 2 (subject that will use their glucometer)
219429659|NCT07089979|DEVICE|BG-meter|BG-meter
219429660|NCT07091786|DEVICE|Implant supported prosthesis|implant supported full arch prosthesis
219429661|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
219429662|NCT02992158|BEHAVIORAL|behavioral activation|
219429663|NCT02992158|BEHAVIORAL|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
219429664|NCT00225290|DRUG|Thalidomide(Thado)|
219429665|NCT02293902|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219429666|NCT02293902|OTHER|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219429667|NCT02293902|DRUG|Methotrexate|Dispensed according to local practice.
219429668|NCT02293902|DRUG|Folic acid|Dispensed according to local practice.
219429669|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
219429670|NCT05173961|OTHER|Survey Administration|Complete survey
219429671|NCT06934538|BIOLOGICAL|STC-1010 + IS regimen + SOC therapy|STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)
219761867|NCT06284837|OTHER|Access site|The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
219761868|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
219761869|NCT05974267|DRUG|M5717 60 mg|Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
219761870|NCT05974267|DRUG|Pyronaridine|Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
219429672|NCT03120637|DRUG|Methylene Blue|
219429673|NCT01929265|DRUG|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
219429674|NCT00369395|DRUG|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
219429675|NCT06300346|DRUG|Propofol|Ondansetron
219429676|NCT00954317|PROCEDURE|epidural placed low|epidural placed low
219429677|NCT00954317|PROCEDURE|high epidural|high epidural
219429678|NCT06935461|BEHAVIORAL|Families Moving Forward Bridges|Ten, 60-minute manualized FMF Bridges intervention sessions over 3-5 months (approximately every other week)
219761871|NCT05974267|DRUG|Atovaquone-Proguanil|Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
219761872|NCT05974267|DRUG|M5717 200 mg|Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
219761873|NCT05974267|DRUG|M5717 660mg|Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
219429679|NCT05562284|PROCEDURE|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
219429680|NCT05562284|OTHER|conservative treatments|conservative treatments
219429681|NCT03968341|OTHER|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
219429682|NCT00472355|DRUG|apomorphine|
219429683|NCT00330525|DRUG|sibutramine|
219429684|NCT02947022|DRUG|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
219429685|NCT02947022|DRUG|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
219429686|NCT06948760|DEVICE|Control-IQ insulin pump with Lyumjev insulin|Control-IQ insulin pump with insulin using settings determined by experimental conversion factor
219429687|NCT06948760|DEVICE|Control-IQ insulin pump with Humalog or Novolog|Control-IQ insulin pump with Humalog or Novolog using optimized insulin settings
219429688|NCT06388330|OTHER|low FODMAP diet|strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
219429689|NCT03129204|BEHAVIORAL|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
219429690|NCT03893773|DEVICE|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
219429691|NCT06954428|COMBINATION_PRODUCT|NT-301 1 mg|unidose of 1 mg apomorphine through nasal spray
219429692|NCT06954428|COMBINATION_PRODUCT|NT-301 2 mg|unidose of 2 mg apomorphine through nasal spray
219429693|NCT06954428|COMBINATION_PRODUCT|Placebo 1 mg|Matching Placebo to NT-301 1 mg
219429694|NCT06954428|COMBINATION_PRODUCT|Placebo 2 mg|Matching Placebo to NT-301 2 mg
219429695|NCT06954428|COMBINATION_PRODUCT|Placebo 3 mg|Matching Placebo to NT-301 3 mg
219429696|NCT06954428|COMBINATION_PRODUCT|NT-301 3 mg|unidose apomorphine nasal spray 3 mg
219429697|NCT06954428|COMBINATION_PRODUCT|NT-301 4 mg|unidose apomorphine nasal spray 4 mg
218859457|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
219429698|NCT06954428|COMBINATION_PRODUCT|Placebo 4 mg|Matching placebo to NT-301 4 mg
219429699|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
219596805|NCT01867463|BIOLOGICAL|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
219761874|NCT05205291|DRUG|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
219761875|NCT05205291|RADIATION|PET/MR with [11C]PBR28|A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
219761876|NCT06201676|DRUG|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
219761877|NCT06201676|OTHER|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
219761878|NCT02250937|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
219761879|NCT02250937|DRUG|Busulfan|Given IV
219761880|NCT02250937|DRUG|Cladribine|Given IV
219761881|NCT02250937|DRUG|Fludarabine Phosphate|Given IV
219761882|NCT02250937|OTHER|Laboratory Biomarker Analysis|Correlative studies
219761883|NCT02250937|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219761884|NCT02250937|OTHER|Pharmacological Study|Correlative studies
219761885|NCT02250937|DRUG|Venetoclax|Given PO
219761886|NCT03901469|DRUG|ZEN003694|PO QD
219761887|NCT03901469|DRUG|Talazoparib|PO QD
219429700|NCT02979444|BEHAVIORAL|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
219429701|NCT02740712|DRUG|Caffeine|200 mg (4 x 50mg) Tablet
219429702|NCT02740712|DRUG|Warfarin|10 mg (2 x 5mg) Tablet
219429703|NCT02740712|DRUG|Omeprazole|40 mg Tablet
219429704|NCT02740712|DRUG|Midazolam|5 mg/mL
219429705|NCT02740712|DRUG|digoxin|.25 mg Tablet
219429706|NCT02740712|DRUG|Vitamin K|10 mg Tablet
219429707|NCT02740712|DRUG|Rucaparib|200 \& 300 mg tablet
219429708|NCT04510402|DRUG|Povidine iodine nasal swabs|Daily versus twice daily nasal application
219429709|NCT05742841|DRUG|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
219429710|NCT06153069|DRUG|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
219429711|NCT06153069|DRUG|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
219429712|NCT01482572|PROCEDURE|biopsy|percutaneous lung biopsy and aspiration
218859458|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
218859459|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
219429713|NCT04983810|DRUG|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
219429714|NCT02558283|DEVICE|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
219429715|NCT02558283|DEVICE|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
218859460|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
219429716|NCT03148158|DEVICE|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
219429717|NCT06527261|OTHER|Real-time electronic data input into REDCap|"During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation."
219429718|NCT02833519|BEHAVIORAL|group exercise|"1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email."
219429719|NCT00198094|DRUG|Sertraline and Alprazolam XR|
219429720|NCT06121362|DIETARY_SUPPLEMENT|Protocatechuic Acid or PCA|PCA 1000 mg capsule
219429721|NCT06121362|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
219429722|NCT00362050|DRUG|Treatment with 3 dose groups of RBx11160 over 7 days|
219429723|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
219429724|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
219429725|NCT02565732|BIOLOGICAL|Placebo comparator|Placebo, Dose C, Topical
219761888|NCT06377384|OTHER|FLIGHT Intervention|Personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care.
219761889|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
219761890|NCT05534438|RADIATION|Stereotactic body radiotherapy|SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)
219761891|NCT02158858|DRUG|Pelabresib|CPI-0610 is administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
219761892|NCT02158858|DRUG|Ruxolitinib|Ruxolitinib is given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.
218859461|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
219429726|NCT05823610|DIAGNOSTIC_TEST|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
219429727|NCT03970018|OTHER|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
219429728|NCT03948113|OTHER|Dialysis|
219429729|NCT04985240|DIETARY_SUPPLEMENT|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
219429730|NCT04985240|DIETARY_SUPPLEMENT|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
219429731|NCT06104722|OTHER|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
219429732|NCT06104722|OTHER|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
219429733|NCT00809861|PROCEDURE|volar locking plating|open reduction and internal fixation
219429734|NCT00809861|PROCEDURE|external immobilisation|closed reduction and external fixation
219429735|NCT03245710|OTHER|Placebos|starch
219429736|NCT03245710|DIETARY_SUPPLEMENT|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
219429737|NCT05256316|OTHER|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
219429738|NCT01589263|DRUG|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
219429739|NCT01589263|DRUG|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
219429740|NCT02100202|OTHER|Placebo|
219429741|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
219429742|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
219429743|NCT02100202|DIETARY_SUPPLEMENT|MaQxan (Tagetes erecta flower extract)|
219429744|NCT03498092|DRUG|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
219429745|NCT03498092|DRUG|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
219429746|NCT03498092|DRUG|General anesthesia|Normal saline in a volume of 0.5 ml/kg
219429747|NCT02320240|DRUG|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429748|NCT02320240|DRUG|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429749|NCT02320240|DRUG|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429750|NCT02320240|DRUG|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429751|NCT02320240|DRUG|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
218859462|NCT02230683|DRUG|IDN-6556|25 mg BID
219429752|NCT02320240|DRUG|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429753|NCT02320240|DRUG|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429754|NCT02320240|DRUG|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429755|NCT02320240|DRUG|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
219429756|NCT01397045|OTHER|VATS|Video-assisted lung segmentectomy
219429757|NCT01397045|PROCEDURE|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
219429758|NCT03439111|DIETARY_SUPPLEMENT|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
219429759|NCT05128695|OTHER|there is no intervention; the study is observational|there is no intervention; the study is observational
219429760|NCT03384004|DEVICE|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
219429761|NCT03384004|DEVICE|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
219429762|NCT01107704|BEHAVIORAL|Family Support Intervention|Multifaceted family support intervention
219429763|NCT00800475|DRUG|Gemfibrozil Tablets|
219429764|NCT03105661|DRUG|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
219429765|NCT03105661|DRUG|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
219429766|NCT03105661|DRUG|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
219429767|NCT05137275|BIOLOGICAL|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
219429768|NCT06201169|PROCEDURE|implant placement|All patients received four implants in the lower arch
219429769|NCT05993572|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
219429770|NCT00081328|DRUG|Metformin|capsule, 1000 mg bid
219429771|NCT00081328|DRUG|Rosiglitazone|capsule, 4 mg bid
219429772|NCT00081328|BEHAVIORAL|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
219429773|NCT00568620|PROCEDURE|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
219429774|NCT00568620|PROCEDURE|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
219429775|NCT01223040|OTHER|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
219429776|NCT01639456|BIOLOGICAL|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
219429777|NCT01639456|BIOLOGICAL|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
219429778|NCT01639456|DEVICE|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
219429779|NCT01639456|DEVICE|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
219429780|NCT01639456|DRUG|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
219429781|NCT01639456|DRUG|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
219429782|NCT01639456|DRUG|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
219429783|NCT04671342|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
219429784|NCT05321966|OTHER|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
219429785|NCT05982145|OTHER|Individual interviews|Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
219429786|NCT05982145|OTHER|Focus groups|Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
219429787|NCT05982145|OTHER|Questionary and measures|To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
219429788|NCT06362447|DRUG|Gentamicin Injectable Solution|Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
219429789|NCT05132595|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
219429790|NCT05132595|DRUG|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
219429791|NCT05132595|DRUG|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
219429792|NCT05132595|DRUG|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
219429793|NCT05132595|DRUG|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
219476283|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
219429794|NCT03241667|DEVICE|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
219429795|NCT05304000|BEHAVIORAL|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
219429796|NCT05304000|BEHAVIORAL|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
219429797|NCT05304000|BEHAVIORAL|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
219429798|NCT05304000|BEHAVIORAL|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
219429799|NCT04137146|DEVICE|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
219429800|NCT03491930|DEVICE|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
219429801|NCT03491930|BEHAVIORAL|Telephone Coaching|Weekly Telephone Coaching
219429802|NCT03491930|BEHAVIORAL|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)"
219429803|NCT02273037|DEVICE|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
219429804|NCT02273037|PROCEDURE|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
219429805|NCT00901381|DRUG|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
219429806|NCT05628155|OTHER|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
219429807|NCT01371526|DRUG|depot tetracosactide|1mg, 3x weekly by sc injection
219429808|NCT00162526|DRUG|Tocopherol|
219429809|NCT02678637|OTHER|MRI and muscle dynamometer|
219429810|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
219429811|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
219429812|NCT01934933|DRUG|celebrex|
219429813|NCT01934933|DRUG|Enbrel|
219429814|NCT01934933|DRUG|Enbrel plus Celebrex|
219429815|NCT05690698|DRUG|Quatiapine|Atypical antipsychotic
219429816|NCT05690698|DRUG|Haloperidol|Antipsychotic
219429817|NCT04598711|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
219476284|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
219429818|NCT04598711|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
219429819|NCT04598711|BEHAVIORAL|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
219429820|NCT04598711|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
219429821|NCT04598711|BEHAVIORAL|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
219429822|NCT00270413|DRUG|SU11248|sutent 50 mg daily 4w on 2w off
219429823|NCT00028106|DRUG|[131]I-MIBG|
219429824|NCT00028106|DRUG|6-[18F]Fluorodopamine|
219429825|NCT00028106|DRUG|[123]I-MIBG|
219429826|NCT03351478|DRUG|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
219429827|NCT03351478|DRUG|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
219429828|NCT03351478|DRUG|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
219429829|NCT03351478|DRUG|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
219429830|NCT03518632|BEHAVIORAL|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
219429831|NCT03518632|OTHER|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
219429832|NCT04963881|DIAGNOSTIC_TEST|Antibody testing|Blood samples were taken and analyzed for APS antibodies
219429833|NCT02270801|DRUG|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
219429834|NCT00979719|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
219429835|NCT00979719|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
219429836|NCT02006498|DRUG|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
219429837|NCT02006498|DRUG|Placebo|Placebo capsule with same appearances as study drug
219429838|NCT04991272|OTHER|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
219429839|NCT03002285|BEHAVIORAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
219429840|NCT03002285|BEHAVIORAL|Control group|Group with typical development that performed the Fitts law in a computer task
219429841|NCT02583997|PROCEDURE|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
219429842|NCT02583997|PROCEDURE|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
219429843|NCT05027113|BEHAVIORAL|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
219429844|NCT01174836|OTHER|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
219429845|NCT03636113|DEVICE|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
219429846|NCT02425436|DRUG|Ginkgo Biloba Extract|
219429847|NCT02425436|OTHER|Placebo|
219761893|NCT05535361|DEVICE|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 chromic sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
219761894|NCT05482958|DEVICE|HOP watch|A multisensor smartwatch that includes neurophysiological sensors such as heart rate sensor to monitor the vitals of the participant.
219761895|NCT02072772|BEHAVIORAL|Positively Smoke Free group treatment|See Arm Description
219761896|NCT02072772|BEHAVIORAL|Standard Care|See Arm Description
219761897|NCT04485013|DRUG|TTX-080|Variable dose (Q3W)
219761898|NCT04485013|DRUG|TTX-080|Specified dose (Q3W)
219429848|NCT06047990|DEVICE|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
219429849|NCT00756678|DRUG|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
219761899|NCT04485013|DRUG|pembrolizumab|Specified dose (Q3W)
219761900|NCT04485013|DRUG|cetuximab|Specified dose on specified days
219761901|NCT04485013|DRUG|FOLFIRI|Specified dose (Q2W)
219761902|NCT04485013|DRUG|cetuximab|Specified dose (Q2W)
219761903|NCT04485013|DRUG|TTX-080|Specified dose (Q2W)
219429850|NCT00756678|DRUG|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
219429851|NCT06185478|DIAGNOSTIC_TEST|MRI scan|MRI scan
219429852|NCT00004467|DRUG|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
219577756|NCT00767065|RADIATION|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
219577757|NCT00767065|OTHER|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
219577758|NCT02635217|DEVICE|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
219577759|NCT02635217|DEVICE|room air insufflation|using standard care room air will be infused on demand
219577760|NCT02635217|PROCEDURE|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
219577761|NCT02635217|PROCEDURE|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
219577762|NCT04010019|BEHAVIORAL|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
219577763|NCT04010019|BEHAVIORAL|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
219577764|NCT00238849|DRUG|Oxaliplatin|
219577765|NCT05495113|DEVICE|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219577766|NCT05495113|DEVICE|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219429853|NCT00004467|DRUG|Placebo|Infusion of 5% dextrose
219429854|NCT02104323|DRUG|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
219429855|NCT03523949|BEHAVIORAL|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
219429856|NCT00017628|DRUG|cyclophosphamide|
219429857|NCT00017628|DRUG|filgrastim|
219429858|NCT00017628|DRUG|methylprednisolone|
219429859|NCT00017628|PROCEDURE|Autologous Stem Cell Transplantation|
219475179|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
219761904|NCT06838000|BIOLOGICAL|PCV21|Investigational pneumococcal conjugate vaccine
219761905|NCT06838000|BIOLOGICAL|20vPCV|20-valent pneumococcal conjugate vaccine
219761906|NCT06793215|DRUG|Divarasib|Divarasib will be administered orally QD
219761907|NCT06793215|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV infusion Q3W
219761908|NCT06793215|DRUG|Pemetrexed|Pemetrexed will be administered via IV infusion Q3W
219761909|NCT06793215|DRUG|Carboplatin|Carboplatin will be administered via IV infusion Q3W
219761910|NCT06793215|DRUG|Cisplatin|Cisplatin will be administered via IV infusion Q3W
219761911|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219761912|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219761913|NCT06453187|DEVICE|AmnioExcel Plus for Venous Leg Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219429860|NCT05531513|BEHAVIORAL|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
219429861|NCT05531513|BEHAVIORAL|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
219429862|NCT04399824|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
219429863|NCT04399824|OTHER|Quality-of-Life Assessment|Ancillary studies
219429864|NCT04399824|OTHER|Questionnaire Administration|Ancillary studies
219429865|NCT04399824|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219429866|NCT00116324|DRUG|Montelukast|
219429867|NCT04148768|DEVICE|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
219429868|NCT04148768|DEVICE|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
219429869|NCT02836483|DRUG|LCB01-0371 800mg, QD|Oral administration
219429870|NCT02836483|DRUG|LCB01-0371 400mg, BID|Oral administration
219429871|NCT02836483|DRUG|LCB01-0371 800mg, BID|Oral administration
219429872|NCT02836483|DRUG|Tubes 3~5Tablet, QD|Oral administration
219577767|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
219577768|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
219577769|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
219577770|NCT03902652|PROCEDURE|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
219577771|NCT03902652|PROCEDURE|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
219429873|NCT02836483|DRUG|Zyvox 600mg, BID|Oral administration
219429874|NCT02836483|DRUG|LCB01-0371 1200mg, QD|Oral administration
219429875|NCT05568927|OTHER|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
219429876|NCT05420415|OTHER|CSTME|Tumor microenvironment collagen signature
219429877|NCT00510484|DRUG|Pancrelipase Delayed Release|24000 unit Capsule
219577772|NCT02677649|OTHER|cranberry|the effect of cranberry on the gut microbiota
219429878|NCT00510484|DRUG|Placebo Comparator|Placebo
219429879|NCT05953207|OTHER|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
219429880|NCT05953207|OTHER|Standard Of Care|Sleep hygiene and safety education session
219429881|NCT00109005|DRUG|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
219429882|NCT05320328|DEVICE|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
219429883|NCT03858296|BEHAVIORAL|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
219429884|NCT03858296|BEHAVIORAL|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
219429885|NCT03858296|BEHAVIORAL|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
219429886|NCT00192595|DRUG|Tenofovir|
219429887|NCT00192595|DRUG|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
219429888|NCT00762268|DRUG|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
219429889|NCT00762268|DRUG|Placebo|
219429890|NCT00978224|DIETARY_SUPPLEMENT|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
219429891|NCT00978224|DIETARY_SUPPLEMENT|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
219429892|NCT00961441|DRUG|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
219429893|NCT02533401|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
219429894|NCT02533401|DRUG|Fludarabine|Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
219429895|NCT02533401|DRUG|Rituximab|Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
219429896|NCT00799760|DRUG|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
219429897|NCT00799760|DRUG|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
219429898|NCT00799760|DRUG|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
219429899|NCT04570514|PROCEDURE|PCI|percutaneous coronary intervention (PCI)
219429900|NCT00129740|DRUG|Nilotinib|400 mg orally twice daily
219429901|NCT01752725|DEVICE|BiCision®|
219429902|NCT01752725|DEVICE|Ultracision® Har-monic Scalpel(Ethicon)|
219429903|NCT00432913|DRUG|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
219429904|NCT00432913|PROCEDURE|Endoscopy|At baseline, month 3 and month 6.
219429905|NCT00432913|PROCEDURE|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
219429906|NCT00432913|PROCEDURE|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
219429907|NCT00432913|PROCEDURE|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
219429908|NCT00432913|PROCEDURE|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
219429909|NCT00432913|PROCEDURE|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
219429910|NCT00432913|PROCEDURE|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
219429911|NCT00432913|PROCEDURE|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
219429912|NCT02925559|DRUG|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
219429913|NCT02925559|DRUG|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
219429914|NCT00154193|DRUG|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
219429915|NCT01767181|OTHER|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
219429916|NCT01767181|OTHER|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
219429917|NCT01752075|DRUG|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
219429918|NCT00757640|PROCEDURE|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
219429919|NCT03791216|OTHER|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
219429920|NCT00703469|DRUG|MDX1106-02|Single dose
219429921|NCT00703469|DRUG|Placebo|Placebo single dose
219429922|NCT01324128|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
219429923|NCT01324128|DRUG|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
219429924|NCT01324128|DRUG|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
219429925|NCT02996955|BEHAVIORAL|social support|behaviour change intervention
219577773|NCT02677649|OTHER|placebo|the effect of placebo on the gut microbiota
219429926|NCT02996955|BEHAVIORAL|treatment of illness perceptions|educational interview
219429927|NCT02996955|DEVICE|Activ8|wearing a move monitor
219429928|NCT02996955|OTHER|activity advice|walking or cycling 5 days a week during at least half an hour
219429929|NCT01786863|PROCEDURE|Neuromuscular blockade|
219429930|NCT05018637|DRUG|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
219429931|NCT05018637|DRUG|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
219429932|NCT02988492|DEVICE|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
219429933|NCT02992873|DEVICE|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
219429934|NCT02992873|DEVICE|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
219429935|NCT02639923|PROCEDURE|Drawing of 7ml peripheral blood|puncture peripheral vein
219429936|NCT05200429|DRUG|Trikafta|Highly Effective CFTR Modulator Therapy
219577774|NCT04435106|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
219577775|NCT04435106|DRUG|Standard of Care|Study participants received Standard of Care
219577776|NCT04107142|BIOLOGICAL|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
219577777|NCT03097588|DRUG|Netupitant|300 mg, Given PO, QD
219577778|NCT03097588|DRUG|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
219577779|NCT03097588|OTHER|Questionnaire Administration|Ancillary studies
219429937|NCT04591145|OTHER|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
219429938|NCT03729661|BEHAVIORAL|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
219429939|NCT06481020|DIETARY_SUPPLEMENT|Plant sterols 2g/day|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
219429940|NCT06481020|DIETARY_SUPPLEMENT|Placebo|Sachet containing the powdered excipients of the dietary supplement during 8 weeks
219429941|NCT04687007|BEHAVIORAL|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
219429942|NCT04687007|BEHAVIORAL|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
219429943|NCT02456792|PROCEDURE|IVF|Women will undergo one IVF cycle
219429944|NCT02456792|PROCEDURE|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
219577780|NCT03021252|DEVICE|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
219577781|NCT03021252|DEVICE|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
219577782|NCT00838708|DRUG|SRD174 Cream|topical SRD174 Cream
219577783|NCT00838708|OTHER|vehicle cream|topical vehicle cream
219577784|NCT02687360|DEVICE|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
219429945|NCT05823870|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
219429946|NCT05267418|DEVICE|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
219429947|NCT01229891|DIETARY_SUPPLEMENT|plain yogurt drink|daily intake of two bottle of plain yogurt drink
219429948|NCT01229891|DIETARY_SUPPLEMENT|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
219429949|NCT01229891|DIETARY_SUPPLEMENT|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
219429950|NCT00003250|DRUG|fenretinide|
219429951|NCT04030949|OTHER|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
219429952|NCT03299036|DEVICE|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
219429953|NCT00028639|DRUG|bortezomib|
219429954|NCT03810378|BEHAVIORAL|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
219429955|NCT03810378|BEHAVIORAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
219429956|NCT05378048|DRUG|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
219429957|NCT05378048|DRUG|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
219429958|NCT03970707|OTHER|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
219429959|NCT03970707|OTHER|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
219429960|NCT02264171|DRUG|Tamsulosin HCl|
219429961|NCT02264171|DRUG|Ketoconazole|
219429962|NCT04767295|DRUG|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
219429963|NCT02189304|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
219429964|NCT02189304|DRUG|PT009|PT009 administered as 2 inhalations
219429965|NCT02189304|DRUG|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
219429966|NCT01171287|PROCEDURE|Driving with an Aircast Walker|
219429967|NCT01171287|PROCEDURE|Driving with a walking cast|
219429968|NCT01171287|PROCEDURE|Driving with a running shoe|
219429969|NCT04122586|DRUG|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
219429970|NCT02204033|DRUG|99mTc - labelled hMAb BIWA 4|
219429971|NCT02204033|DRUG|186 Re - labelled hMAb BIWA 4|
219429972|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - low dose|
219429973|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - medium dose|
219429974|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - high dose|
219429975|NCT01438307|DRUG|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
219429976|NCT01438307|DRUG|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
219429977|NCT03594864|PROCEDURE|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
219429978|NCT02307318|DEVICE|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
219429979|NCT02908633|PROCEDURE|canaloplasty and phacoemulsification|
219475180|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
219475181|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
219475182|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
219475183|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
219475184|NCT01829659|DRUG|Ticagrelor|
219475185|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
219475186|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
219199426|NCT06622031|PROCEDURE|Transjugular intrahepatic portosystemic shunt|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.
219429980|NCT05960513|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
219429981|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
219429982|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
219429983|NCT00973622|DEVICE|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
219429984|NCT04814407|DIAGNOSTIC_TEST|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
219429985|NCT04436588|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
219429986|NCT02525887|OTHER|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
219429987|NCT03948269|BEHAVIORAL|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
219429988|NCT03991182|OTHER|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
219429989|NCT03991182|OTHER|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
219429990|NCT03991182|BEHAVIORAL|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
219429991|NCT03991182|OTHER|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
219429992|NCT05718453|COMBINATION_PRODUCT|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
219429993|NCT05521971|OTHER|multifaceted pharmacist-led intervention|"* Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone."
219429994|NCT05521971|OTHER|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
219429995|NCT04517227|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
219429996|NCT04517227|PROCEDURE|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
219429997|NCT04517227|PROCEDURE|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
219429998|NCT02538939|DRUG|Sodium thiosulfate|
219429999|NCT04694625|OTHER|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
219199427|NCT06622031|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg
219199428|NCT06622031|DRUG|PD-1 inhibitor|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
219430000|NCT04694625|OTHER|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
219430001|NCT04649619|PROCEDURE|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
219430002|NCT00352066|DRUG|apricitabine|
219430003|NCT00707538|DRUG|BMS747158|2 IV injection of \~11 mCi (total) F-18 labeled compound
219430004|NCT05592041|DRUG|Banaba Leaf Extract|a herbal extract in the form of Bigel
219430005|NCT04090268|OTHER|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
219430006|NCT04860011|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
219430007|NCT04860011|DRUG|Metolazone Tablets|Metolazone 5MG or 10MG once daily
219430008|NCT04762953|DRUG|Paclitaxel|Intraperitoneal Paclitaxel
219430009|NCT04762953|DRUG|Paclitaxel|IV Paclitaxel
219430010|NCT04762953|DRUG|Leucovorin|IV Leucovorin
219430011|NCT04762953|DRUG|Fluorouracil|IV 5-FU
219430012|NCT04593875|DEVICE|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
219430013|NCT04593875|DEVICE|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
219430014|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
219430015|NCT03909672|OTHER|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
219430016|NCT01118715|DEVICE|Compression glove|A compression glove worn during recovery from distal radius fracture
219430017|NCT02241928|BIOLOGICAL|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
219430018|NCT00702247|PROCEDURE|Hematopoietic Stem Cell Transplantation|
219430019|NCT03123055|DRUG|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
219430020|NCT03123055|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
219430021|NCT02904187|OTHER|Positron Emission Tomography (PET)|
219430022|NCT02904187|OTHER|Electroencephalogram (EEG)|
219430023|NCT01566201|DRUG|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
219430024|NCT01566201|DRUG|placebo|water for injection
219430025|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
219430026|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
219430027|NCT05431569|DRUG|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
219430028|NCT03814005|DRUG|Azacitidine|Azacitidine subcutaneous or intravenous injection.
219430029|NCT03814005|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
219430030|NCT06218511|BIOLOGICAL|Peptide-based hepatocellular carcinoma vaccine IMA970A|IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
219430031|NCT06218511|COMBINATION_PRODUCT|Durvalumab|anti-PD-L1
219430032|NCT06218511|OTHER|Montanide (Adjuvant)|Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
219430033|NCT03395223|DRUG|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
219430034|NCT04026971|PROCEDURE|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
219430035|NCT05736978|DRUG|Azacitidine|75mg/m2 d1-7
219430036|NCT05736978|DRUG|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
219430037|NCT05736978|DRUG|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
219475187|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
219475188|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
219475189|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
219475190|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
219430038|NCT01236794|BEHAVIORAL|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
219430039|NCT04503863|DRUG|NPC-22|Single administration of middle dose NPC-22
219430040|NCT04503863|DRUG|NPC-22|Single administration of high dose NPC-22
219430041|NCT04503863|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
219430042|NCT00975026|PROCEDURE|Massages ± Stretches|Chair Massage
219430043|NCT02284230|DRUG|Liraglutide|
219430044|NCT02284230|DRUG|Placebo|
219430045|NCT01379170|DRUG|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
219430046|NCT03753815|DEVICE|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
219430047|NCT03753815|DEVICE|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
219430048|NCT05552807|DRUG|SCT-I10A|Administered intravenously
219430049|NCT05552807|DRUG|SCT200|Administered intravenously
219430050|NCT05552807|DRUG|paclitaxel|Administered intravenously
219430051|NCT05552807|DRUG|docetaxel|Administered intravenously
219430052|NCT01069367|BIOLOGICAL|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
219430053|NCT04446299|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
219430054|NCT00895778|OTHER|Neuromuscular blockade with rocuronium and reversal with sugammadex|
219430055|NCT01267344|DRUG|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
219430056|NCT01267344|DRUG|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
219430057|NCT01113190|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
219430058|NCT01113190|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
219430059|NCT01113190|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
219430060|NCT01113190|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
219430061|NCT00035152|DRUG|Paclitaxel and carboplatin|
219430062|NCT02275910|DRUG|E7090|
219430063|NCT06980350|DRUG|PD-1 Inhibitors|Patients received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.
219475191|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
219475192|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
219475193|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
219430064|NCT03819478|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
219430065|NCT03819478|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
219430066|NCT03819478|DIETARY_SUPPLEMENT|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
219430067|NCT03819478|DIETARY_SUPPLEMENT|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
219430068|NCT03819478|DIETARY_SUPPLEMENT|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
219430069|NCT05896046|DRUG|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
219430070|NCT05896046|DRUG|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
219430071|NCT00516412|DRUG|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219430072|NCT00516412|GENETIC|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
219430073|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
219430074|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
219430075|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
219430076|NCT01080612|DRUG|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
219430077|NCT00111111|DRUG|Etanercept|
219430078|NCT05876104|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
219430079|NCT03965793|DEVICE|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
219430080|NCT01855945|BIOLOGICAL|Swine Influenza|Comparison of different dosages of vaccines
219430081|NCT04095468|RADIATION|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
219430082|NCT06325306|BEHAVIORAL|Traditional APA|12 sessions of 1,5 hour are organized (once per week). The first session is primarily focused on the PL assessment, followed by a comprehensive introduction to physical conditioning exercises. Each of the subsequent sessions (n=10), participants will receive an intervention focused on the development of their physical fitness (endurance, strength, flexibility, balance). Each session will commence with a 15 minute warm-up comprising of a blend of cardiovascular and joint mobilization exercises. The core part of each session will be dedicated to session-specific exercises targeting key physical competencies such as endurance, strength, flexibility, and balance, along with other motor skills. . The size of the group will never exceed a number of 15 participants. At the conclusion of each session, participants will be guided through a return-to-calm sequence that included stretching and relaxation exercises.
219475194|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
219475195|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
219475196|NCT03583801|OTHER|without aromatherapy|no intervention
219475197|NCT02332044|DRUG|Erdos|capsule, 300mg
219475198|NCT02332044|DRUG|Talion|tablet, 10mg
219475199|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
219475200|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
219475201|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
219475202|NCT02378870|DRUG|Placebo|
219475203|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
219475204|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
219475205|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
219475206|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
219475207|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
219476285|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
219476286|NCT00423501|DRUG|Placebo|sc weekly
219430083|NCT06325306|BEHAVIORAL|APA+PL|The general content and duration of this intervention is the same as in the traditional APA intervention, but with an extra particular and explicit emphasis on PL dimensions (6) during the sessions. While the dimension of physical competence is consistently incorporated into the sessions, the remaining 5 dimensions of PL are addressed twicely over the course of the semester with the setting of specific goals and intervention content. This could involve quizzes or games integrated into circuits or exercise workshops, role-play exercises simulating real-life situations, or social interactions between participants with a particular focus on PL-related topics. In addition to the sessions, a follow-up telephone call is scheduled between the educator and each participant during the 2 weeks following the initial PL assessment to share individual PL assessment results and assist participants in setting person-centered goals using a motivational interviewing technique.
219430084|NCT02967094|DRUG|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
219430085|NCT02967094|DRUG|Administration of water before upper endoscopy|
219430086|NCT01824264|DRUG|LIK066|Experimental treatment doses
219430087|NCT01824264|DRUG|Sitagliptin|Active comparator treatment dose
219430088|NCT01824264|DRUG|Placebo|Placebo comparator dose
219430089|NCT00909519|DRUG|naproxcinod|naproxcinod 750 mg bid
219430090|NCT00909519|DRUG|Naproxen|Naproxen 500 mg bid
219430091|NCT00909519|DRUG|placebo|placebo
218859463|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
218859464|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
219430092|NCT00909519|DRUG|furosemide|furosemide
218859465|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
219577785|NCT02687360|DEVICE|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
219577786|NCT06682962|DEVICE|Transcorneal electrical stimulation (TES) with the OkuStim 2 System|Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
219430093|NCT04105647|BEHAVIORAL|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
219430094|NCT04105647|BEHAVIORAL|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
219430095|NCT01135017|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
219430096|NCT01135017|DRUG|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
219430097|NCT02136511|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
219430098|NCT02136511|DRUG|Rituximab|Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
219430099|NCT01148693|DRUG|gentamicin|10mg per 10ml of contrast media
219430100|NCT01148693|DRUG|Placebo|Distilled water
219430101|NCT00929045|DRUG|Growth Hormone Replacement|
219430102|NCT03313856|DRUG|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
219430103|NCT03313856|DRUG|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
219430104|NCT01695213|PROCEDURE|uncemented total hip arthroplasty|
219476287|NCT00423501|DRUG|taspoglutide|20mg sc weekly
219476288|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
219476289|NCT00423501|DRUG|taspoglutide|5mg sc weekly
219476290|NCT00423501|DRUG|taspoglutide|10mg sc weekly
219476291|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
219476292|NCT03621566|OTHER|No intervention|Routine care (registry)
219476293|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
219476294|NCT05935046|BEHAVIORAL|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
219476295|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
219476296|NCT06264830|DEVICE|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
219476297|NCT06264830|PROCEDURE|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
219476298|NCT06021431|DEVICE|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.~Combination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling."
219476299|NCT06021431|OTHER|Treatment as Usual|Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving
219476300|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
219476301|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
219476302|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
219476303|NCT04840979|DRUG|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
219476304|NCT04840979|DRUG|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
219476305|NCT06503224|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
219476306|NCT05151484|DRUG|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
218859466|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
219430105|NCT02410096|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
219430106|NCT02410096|OTHER|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
219430107|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
219430108|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
219430109|NCT04114344|PROCEDURE|TAPP|Trans Abdominal Pre Peritoneal approach
219430110|NCT04114344|PROCEDURE|TEP|Total Extra Peritoneal approach
219430111|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
219577787|NCT03493776|BIOLOGICAL|VZV subunit vaccine|VZV subunit vaccine
219577788|NCT05198882|PROCEDURE|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
219577789|NCT05483582|DEVICE|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219577790|NCT05483582|DEVICE|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219577791|NCT03885882|DRUG|E0302 SR1|E0302 SR1, oral tablet.
219577792|NCT03885882|DRUG|E0302 SR3|E0302 SR3, oral tablet.
219430112|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
219577793|NCT03885882|DRUG|E0302 SR2|E0302 SR2, oral tablet.
219577794|NCT03885882|DRUG|E0302 IR|E0302 IR, oral tablet.
219577795|NCT03184220|PROCEDURE|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid"
219577796|NCT03184220|PROCEDURE|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
219577797|NCT04668976|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
219577798|NCT04668976|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
219577799|NCT04668976|DRUG|Gemcitabine|Please see Detailed Description.
219577800|NCT04668976|DRUG|Oxaliplatin|Please see Detailed Description.
219577801|NCT04668976|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
219577802|NCT04668976|DRUG|Fluorouracil|Please see Detailed Description.
219577803|NCT04668976|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
218859467|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
219430113|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
219577804|NCT02782494|OTHER|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
219577805|NCT03456960|DRUG|TAK-438ASA|TAK-438ASA tablet.
219577806|NCT03456960|DRUG|TAK-438|TAK-438 tablet.
219199429|NCT06622135|DEVICE|Tasso Lancet Device|blood samples will be obtained from all participants using Tasso device
219430114|NCT03351439|DRUG|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
219430115|NCT03351439|DRUG|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
219430116|NCT03351439|DRUG|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
219430117|NCT03351439|DRUG|Percocet|Standard of Care
219430118|NCT03351439|DRUG|Naprosyn|Standard of Care
219430119|NCT03076125|BEHAVIORAL|SCORRE|3 components based on the Health Belief Model
219430120|NCT03076125|BEHAVIORAL|Attention-Control Activity|sexual health education
219577807|NCT03456960|DRUG|Aspirin|Aspirin enteric-coated tablet.
219577808|NCT04757701|OTHER|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
219577809|NCT05897268|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
219577810|NCT05897268|DRUG|Tislelizumab|a PD-1 immune check inhibitor
219577811|NCT05897268|DRUG|Lenvatinib|Lenvatinib capsules
219577812|NCT05739968|OTHER|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
219577813|NCT05739968|OTHER|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
219577814|NCT02989168|DRUG|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
219577815|NCT02099604|DRUG|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
219430121|NCT03178812|PROCEDURE|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
219430122|NCT03178812|DIAGNOSTIC_TEST|Laboratory Blood test|Laboratory Blood Test
219430123|NCT03688685|DRUG|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
219430124|NCT01074658|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
219430125|NCT04099849|DIETARY_SUPPLEMENT|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
219430126|NCT04099849|DIETARY_SUPPLEMENT|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
219430127|NCT04099849|DIETARY_SUPPLEMENT|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
219430128|NCT03048942|DRUG|Cabazitaxel|3 weekly cyctotoxic chemotherapy
219430129|NCT03048942|DRUG|Paclitaxel|Weekly cyctotoxic chemotherapy
219430130|NCT02219711|DRUG|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
219430131|NCT03748485|BEHAVIORAL|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
219430132|NCT03748485|DRUG|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
219430133|NCT02879916|DRUG|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
219430134|NCT02879916|DRUG|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
219430135|NCT02899741|DRUG|Omega-3|1000mg every day for 90 days
219430136|NCT00229229|OTHER|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
219430137|NCT00229229|OTHER|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
219430138|NCT00229229|OTHER|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
219430139|NCT00229229|OTHER|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
219430140|NCT01342952|DRUG|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
219430141|NCT02794090|BEHAVIORAL|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
219430142|NCT02794090|BEHAVIORAL|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
219430143|NCT02156804|DRUG|Nivolumab (BMS-936558)|
219430144|NCT03228394|DRUG|Ganaxolone|Ganaxolone IV
219430145|NCT03228394|DRUG|Placebo|Placebo IV
219430146|NCT01530555|DRUG|Rabbit ATG, Thymoglobuline (Genzyme)|"1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
219430147|NCT05767372|OTHER|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
219430148|NCT05767372|DEVICE|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks."
219430149|NCT01551472|DEVICE|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
219577816|NCT04300829|DRUG|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
219430150|NCT04581863|DEVICE|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
219430151|NCT04581863|OTHER|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
219430152|NCT04348994|DEVICE|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
219430153|NCT00650598|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
219430154|NCT00650598|DRUG|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
219430155|NCT02789826|PROCEDURE|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
219430156|NCT02789826|PROCEDURE|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
219430157|NCT03831737|BEHAVIORAL|stretching exercises|"Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch"
219430158|NCT03702426|DRUG|GMCSF|GMCSF 1.5mcg/Kg
219430159|NCT03702426|DRUG|Norfloxacin|Tablet Norfloxacin 400 mg
219430160|NCT02533219|DRUG|18 F-DOPA|Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
219430161|NCT04024072|DRUG|Brinzolamide 1% ophthalmic suspension|Test product
219430162|NCT04024072|DRUG|Azopt 1% Ophthalmic Suspension|Reference product
219577817|NCT04300829|OTHER|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
219577818|NCT06310265|OTHER|Retrospective observational study|Our study includes child earthquake victims, regardless of gender, between the ages of 0-18, who applied to our clinic within six months after the February 6, 2023 earthquake and underwent surgery.
219577819|NCT02337140|DEVICE|Pacemaker SORIN Group KORA DR|
219430163|NCT00436202|BEHAVIORAL|Iron supplement|
219430164|NCT00875303|BEHAVIORAL|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
219430165|NCT00875303|BEHAVIORAL|Control|Routine primary care.
219430166|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
219430167|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
219430168|NCT01803711|DRUG|Desvenlafaxine|
219430169|NCT01803711|DIETARY_SUPPLEMENT|Omega 3 Fatty acids|
219430170|NCT01803711|DRUG|Placebo (for Omega 3 fatty acid supplement)|
219430171|NCT04969211|DRUG|VHX-896 and iloperidone|oral tablet
219430172|NCT04969211|DRUG|Iloperidone and VHX-896|oral tablet
219430173|NCT03165864|DRUG|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
219430174|NCT03165864|OTHER|Placebo|Saline .9%
219430175|NCT00453232|BIOLOGICAL|bleomycin sulfate|
219430176|NCT00453232|BIOLOGICAL|pegfilgrastim|
219430177|NCT00453232|DRUG|cisplatin|
219577820|NCT02337140|PROCEDURE|transcatheter aortic valve implantation (TAVI)|
219577821|NCT06309446|DEVICE|Zoralan Wound|Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
219577822|NCT04887246|BIOLOGICAL|COVID-19 vaccines|COVID-19 vaccines available at Colombia
219430178|NCT00453232|DRUG|etoposide|
219430179|NCT04679558|DRUG|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
219577823|NCT00877357|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
219577824|NCT01565265|DRUG|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
219430180|NCT04679558|BEHAVIORAL|Preventive protocol|Preventive protocol
219430181|NCT05285033|DRUG|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
219430182|NCT02658981|BIOLOGICAL|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
219430183|NCT02658981|BIOLOGICAL|Anti-PD-1|Given IV
219430184|NCT02658981|OTHER|Pharmacological Study|Correlative Studies
219430185|NCT02658981|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219430186|NCT02658981|BIOLOGICAL|Anti-CD137|Given IV
219430187|NCT04823546|OTHER|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
219430188|NCT04823546|OTHER|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
219430189|NCT03584438|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
219430190|NCT03584438|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219430191|NCT02706119|DRUG|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
219430192|NCT02706119|DRUG|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
219430193|NCT02715050|DEVICE|Active or Placebo Phototherapy (MR4)|
219430194|NCT00167362|BEHAVIORAL|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
219430195|NCT00167362|BEHAVIORAL|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
219577825|NCT01565265|DRUG|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
219199430|NCT06618859|BEHAVIORAL|Time-restricted eating|Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
219430196|NCT02249026|DRUG|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
219430197|NCT02249026|DRUG|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
219430198|NCT01282567|OTHER|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
219430199|NCT02126813|PROCEDURE|increased interventional threshold for urinary bladder catheterization (800 ml)|
219430200|NCT02126813|PROCEDURE|Current used interventional threshold for urinary bladder catheterization (500 ml)|
219430201|NCT02126813|DEVICE|Intermittent bladder catheter|
219761914|NCT06453187|DEVICE|AmnioExcel Plus for Diabetic Foot Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219761915|NCT06453187|PROCEDURE|Standard of Care|Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219761916|NCT06794983|OTHER|In-person visit with study team member|Participants meet with a study team member before they are released from prison.
219761917|NCT06794983|OTHER|In-person visit with NCM|Participants meet with a NCM before they are released from prison.
219761918|NCT06794983|OTHER|Phone calls and texts|Study team member calls and texts participants after they are released from prison.
219761919|NCT06794983|OTHER|Phone calls and texts - NCM|Nurse case manager calls and texts participants after they are released from prison.
219761920|NCT06564896|DEVICE|CPAP Airsense 10 vs Air-Mini|Patients' satisfaction and CPAP efficacy
219761921|NCT06564636|DEVICE|CATALYSTEM|CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
219761922|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
219761923|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
219199431|NCT06618859|BEHAVIORAL|Active control|Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
219430202|NCT00091962|BEHAVIORAL|Psychoeducation; Treatment recommendations|Counseling program
219430203|NCT00091962|DRUG|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
219430204|NCT00091962|OTHER|Usual Care|Physicians' Usual care
219430205|NCT02284022|DEVICE|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
219430206|NCT01170221|DRUG|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
219430207|NCT01170221|DRUG|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
219430208|NCT04402619|BEHAVIORAL|Cognitive behavior therapy|"The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future"
219430209|NCT00432562|DRUG|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
219430210|NCT02693691|DEVICE|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
219430211|NCT05204758|DRUG|TCM Formula|three packages of TCM preparations with each meal three times a day
219430212|NCT05204758|DRUG|Placebo|three packages of placebo preparations with each meal three times a day
219430213|NCT00440336|DRUG|Cosopt|
219430214|NCT00440336|DRUG|Xalatan|
219430215|NCT04730310|PROCEDURE|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
219430216|NCT05800509|BEHAVIORAL|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
219430217|NCT05800509|DEVICE|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
219430218|NCT01488409|DRUG|Acipimox|250 mg by mouth (PO) three times daily
219430219|NCT01488409|DRUG|Placebo|0 mg by mouth (PO) three times daily
219430220|NCT05603494|DEVICE|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
219430221|NCT01020968|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
219577826|NCT03828448|DRUG|Ublituximab|\- anti-CD 20 monoclonal antibody administered via IV infusion
219577827|NCT03828448|DRUG|Umbralisib|\- PI3K Delta Inhibitor oral daily dose
219577828|NCT05506722|DEVICE|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
219577829|NCT01145131|OTHER|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
219577830|NCT02037165|DRUG|Placebo to BI 1026706|Placebo tablet
219577831|NCT02037165|DRUG|Pregabalin|Pregabalin hard capsule
219577832|NCT02037165|DRUG|BI 1026706|BI 1026706 oral solution
219577833|NCT02037165|DRUG|Celecoxib|Celecoxib hard capsule
219577834|NCT06453239|DIAGNOSTIC_TEST|Pro-Neurotensin level as a Serum Biomarker|Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
219577835|NCT03591939|DIAGNOSTIC_TEST|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
219577836|NCT01440439|DRUG|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
219577837|NCT01440439|DRUG|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
219577838|NCT04977063|DEVICE|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
219577839|NCT04977063|DEVICE|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
219577840|NCT05391334|DEVICE|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
219577841|NCT05980286|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
219577842|NCT05980286|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
219577843|NCT05290324|DRUG|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
219577844|NCT04750135|DRUG|metformin 500 mg TID Oral Tablet|biguanides derivatives
219577845|NCT04750135|DRUG|Placebo|Placebo
219577846|NCT06222541|BEHAVIORAL|"Nudges in Web-Based Supermarket"|"While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes."
219577847|NCT00926016|DRUG|Pioglitazone (Actos)|pioglitazone 45 mg a day
219577848|NCT06058221|DEVICE|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
219761924|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
219430222|NCT01020968|OTHER|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
219430223|NCT04394689|BIOLOGICAL|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
219430224|NCT04394689|BIOLOGICAL|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
219430225|NCT04394689|OTHER|PLA-MNP|One placebo dose of a dissolving microneedle patch
219430226|NCT04394689|OTHER|PLA-SC|Placebo saline as subcutaneous injection
219430227|NCT00790530|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
219430228|NCT00790530|OTHER|Usual Care|Usual Care
219430229|NCT04327050|PROCEDURE|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
219430230|NCT01250457|DRUG|topical Timolol|topical Timolol 0.5% solution applied twice daily
219430231|NCT01085604|OTHER|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
219430232|NCT05845489|DRUG|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
219577849|NCT06058221|DEVICE|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
219761925|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
219761926|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
219430233|NCT05845489|OTHER|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
219430234|NCT02820441|DRUG|Zopiclone|
219430235|NCT02820441|DRUG|Placebo|
219430236|NCT02951897|PROCEDURE|lobectomy|
219430237|NCT02951897|PROCEDURE|segmentecomy|
219430238|NCT02951897|DRUG|chemotherapy（pemetrexed+CISPLATIN）|
219430239|NCT02951897|PROCEDURE|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
219430240|NCT02951897|OTHER|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
219430241|NCT03288441|DRUG|Hold|Hold antithrombotic therapy
219430242|NCT03288441|DRUG|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
219430243|NCT03288441|DRUG|Change antithrombotic Drug|Change in type of antithrombotic therapy
219430244|NCT03288441|BIOLOGICAL|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
219430245|NCT03288441|DRUG|Full dose antithrombotics|Continue full dose antithrombotic therapy
219430246|NCT03288441|DEVICE|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
219430247|NCT03288441|DRUG|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
219430248|NCT00897936|GENETIC|DNA methylation analysis|
219430249|NCT00897936|GENETIC|comparative genomic hybridization|
219577850|NCT01235702|BEHAVIORAL|12-week lifestyle modification|
219577851|NCT06327802|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the Beck, Zarit, HAD, FAS CARERQOL-7D questionnaires
219577852|NCT01300923|DRUG|Acamprosate|
219430250|NCT00897936|GENETIC|fluorescence in situ hybridization|
219430251|NCT00897936|GENETIC|microarray analysis|
219430252|NCT00897936|GENETIC|polymerase chain reaction|
219430253|NCT00897936|OTHER|diagnostic laboratory biomarker analysis|
219430254|NCT00897936|OTHER|immunologic technique|
219430255|NCT00002268|DRUG|Sevirumab|
219430256|NCT05531968|BIOLOGICAL|BMI2006|IM
219430257|NCT05531968|BIOLOGICAL|BOTOX®|IM
219430258|NCT00953004|DIETARY_SUPPLEMENT|fiber drink and fiber bread|fiber drink or fiber bread three times daily
219430259|NCT00767845|OTHER|questionnaire/survey administration|
219577853|NCT01568866|DRUG|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
219430260|NCT01162304|DRUG|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
219761927|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
219430261|NCT01162304|DRUG|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
219430262|NCT04054102|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
219430263|NCT04054102|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
219430264|NCT05968625|DEVICE|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
219430265|NCT05968625|DEVICE|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
219430266|NCT02178306|DRUG|Telmisartan low dose|
219430267|NCT02178306|DRUG|Telmisartan high dose|patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment
219430268|NCT02178306|DRUG|Placebo|Run-in phase
219430269|NCT05883839|OTHER|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
219430270|NCT02798562|DEVICE|Native and dynamic contrast-enhanced CT|
219430271|NCT05488704|DIAGNOSTIC_TEST|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken"
219430272|NCT02629536|DRUG|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
219430273|NCT04324086|DEVICE|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
219430274|NCT04324086|DEVICE|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
219430275|NCT04324086|DEVICE|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
219430276|NCT02312115|DRUG|Furosemide|Diuretic
219430277|NCT02312115|DRUG|Placebo|Saline
219577854|NCT01568866|DRUG|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
219761928|NCT04609046|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
219430278|NCT04202549|DRUG|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
219430279|NCT05371067|OTHER|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
219430280|NCT07000864|OTHER|No intervention|Lab-based correlative study; no intervention
219430281|NCT00141700|DRUG|Rituximab|
219430282|NCT03553602|RADIATION|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])"
219430283|NCT00461578|DRUG|Chlorproguanil-dapsone + artesunate|
219430284|NCT02247401|DRUG|2 DAA|ABT-450/r/ABT-267 tablets
219430285|NCT02247401|DRUG|RBV|Ribavirin tablets
219430286|NCT00238225|DIETARY_SUPPLEMENT|calcitriol|
219430287|NCT00238225|DRUG|dexamethasone|
219430288|NCT00238225|DRUG|ketoconazole|
219430289|NCT01458314|OTHER|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
219430290|NCT01458314|OTHER|Rehabilitation without NIV|Training in patients without NIV adoption
219430291|NCT01142284|DRUG|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
219430292|NCT01064219|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
219577855|NCT01568866|DRUG|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
219577856|NCT03340870|DRUG|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
219577857|NCT03376542|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
219577858|NCT01698775|DRUG|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
219761929|NCT04609046|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
219761930|NCT04609046|PROCEDURE|Echocardiography Test|Undergo ECHO
219761931|NCT04609046|DRUG|Lenalidomide|Given PO
219761932|NCT04609046|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219761933|NCT04609046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219761934|NCT04609046|DRUG|Methotrexate|Given IV or PO
219761935|NCT04609046|BIOLOGICAL|Nivolumab|Given IV
219430293|NCT02683018|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
219430294|NCT02683018|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
219430295|NCT04082702|BEHAVIORAL|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
219430296|NCT04082702|BEHAVIORAL|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
219430297|NCT03210779|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
219430298|NCT03210779|DIETARY_SUPPLEMENT|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
219430299|NCT02061579|BEHAVIORAL|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
219430300|NCT03587870|OTHER|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
219430301|NCT04424199|BEHAVIORAL|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
219430302|NCT04424199|BEHAVIORAL|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
219430303|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
219430304|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
219430305|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
219430306|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
219430307|NCT00071851|BIOLOGICAL|VRC-HIVDNA009-00-VP|
219430308|NCT02340468|DEVICE|diffuse optical spectroscopy|diffuse optical spectroscopy
219430309|NCT05711680|DEVICE|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
219430310|NCT04377672|BIOLOGICAL|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
219430311|NCT05491044|DRUG|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
219577859|NCT01698775|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
219430312|NCT05995925|OTHER|Clinical Observation|Clinical Observation
219430313|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
219430314|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
219430315|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
219577860|NCT01698775|DRUG|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
219577861|NCT01698775|DRUG|Placebo to glipizide|Matching placebo to glipizide daily
219577862|NCT01698775|BIOLOGICAL|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
219577863|NCT01377675|OTHER|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
219761936|NCT04609046|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219430316|NCT01663844|BEHAVIORAL|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
219430317|NCT03954444|DRUG|Oxymetazoline Hydrochloride|Test Comparator
219430318|NCT03954444|DRUG|Rhofade Cream, 1%|Reference Comparator
219430319|NCT03954444|DRUG|Placebo|Placebo Comparator
219430320|NCT01300364|DRUG|Reboxetine|8mg/day.
219430321|NCT01300364|DRUG|citalopram (SSRI)|30mg/day
219430322|NCT00546286|DRUG|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
219430323|NCT00546286|DRUG|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
219430324|NCT02447458|DRUG|MLN3126|MLN3126 tablets
219430325|NCT02447458|DRUG|MLN3126 Placebo|MLN3126 placebo-matching tablets
219430326|NCT01492296|PROCEDURE|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
219430327|NCT01492296|PROCEDURE|conventional fasting|patients were evaluated after fasting for 8 hours
219430328|NCT02138396|DRUG|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
219430329|NCT02138396|DRUG|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
219430330|NCT02138396|DRUG|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
219430331|NCT02602717|OTHER|lymph nodes cyto-punction|
219430332|NCT02133742|DRUG|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
219430333|NCT02133742|DRUG|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
219430334|NCT02288611|DIETARY_SUPPLEMENT|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
219430335|NCT02288611|DIETARY_SUPPLEMENT|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
219430336|NCT03096444|DRUG|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
219761937|NCT04609046|BIOLOGICAL|Rituximab|Given IV
219430337|NCT03096444|DRUG|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
219430338|NCT03096444|DRUG|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
219430339|NCT03096444|COMBINATION_PRODUCT|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
219430340|NCT03096444|DRUG|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
219430341|NCT03505749|BEHAVIORAL|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
219430342|NCT03505749|BEHAVIORAL|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
219430343|NCT03448900|BEHAVIORAL|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
219430344|NCT03448900|BEHAVIORAL|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
219430345|NCT01688635|DRUG|LY2963016|Administered subcutaneously
219430346|NCT01688635|DRUG|US Approved Lantus|Administered subcutaneously
219430347|NCT05504577|DRUG|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
219761938|NCT04609046|PROCEDURE|Ultrasound Imaging|Undergo testicular ultrasound
219761939|NCT03610815|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
219761940|NCT06136559|DRUG|Nemtabrutinib|Administered orally
219430348|NCT05504577|DEVICE|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
219761941|NCT06136559|DRUG|Ibrutinib|Administered orally
219761942|NCT06136559|DRUG|Acalabrutinib|Administered orally
219430349|NCT05504577|DEVICE|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
219430350|NCT03351569|DRUG|Intravenous immunoglobulin|Intravenous drip.
219430351|NCT05380713|DRUG|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
219430352|NCT05380713|DRUG|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
219430353|NCT05380713|DRUG|Durvalumab|tremelimumab-durvalumab in adjuvant setting
219430354|NCT03742206|DEVICE|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
219430355|NCT03742206|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
219430356|NCT05073627|DRUG|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
219430357|NCT03752333|DRUG|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
219430358|NCT05386927|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
219430359|NCT05205278|OTHER|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
219430360|NCT01499901|PROCEDURE|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
219430361|NCT01499901|PROCEDURE|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
219430362|NCT04228562|OTHER|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
219430363|NCT04228562|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
219430364|NCT02016469|OTHER|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
219430365|NCT02016469|OTHER|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
219430366|NCT02016469|DIETARY_SUPPLEMENT|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
219430367|NCT03700268|OTHER|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
219430368|NCT05464472|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
219430369|NCT05720767|DRUG|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
219430370|NCT05720767|DRUG|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
219430371|NCT05720767|DRUG|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
219430372|NCT02111967|OTHER|Questionnaire administration|
219430373|NCT02111967|OTHER|Laboratory biomarker analysis|
219430374|NCT04491240|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
219430375|NCT04491240|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
219430376|NCT04491240|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
219430377|NCT00003735|DRUG|topotecan hydrochloride|given by mouth
219430378|NCT03549117|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
219577864|NCT01078337|PROCEDURE|bone marrow aspiration|
219577865|NCT01078337|PROCEDURE|peripheral blood sampling|
219577866|NCT03437915|RADIATION|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
219577867|NCT03437915|PROCEDURE|Partial mastectomy|4-12 weeks post NIBB
219577868|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3|600 IU Vitamin D3 capsule daily
219577869|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
219577870|NCT00571285|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given once a week
219577871|NCT01244061|DRUG|Varenicline|Varenicline 1mg twice daily
219577872|NCT01244061|DRUG|Placebo|Matched placebo twice daily
219430379|NCT03549117|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
219430380|NCT01249963|DIETARY_SUPPLEMENT|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
219430381|NCT01249963|DIETARY_SUPPLEMENT|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
219430382|NCT01312324|DRUG|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
219430383|NCT02205918|OTHER|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
219430384|NCT02205918|OTHER|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
219430385|NCT04086602|DRUG|IZD334|Active Drug
219430386|NCT04086602|DRUG|Placebos|Placebo to Match
219430387|NCT04679441|DEVICE|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
219430388|NCT04679441|DEVICE|Brain HQ Double Decision|Cognitive speed training program
219577873|NCT01706848|OTHER|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
219577874|NCT01706848|OTHER|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
219761943|NCT04344613|DEVICE|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
219761944|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
219577875|NCT02494102|DRUG|Modafinil|Atypical Psychomotor stimulant
219577876|NCT02494102|DRUG|Placebo|
219577877|NCT06690008|PROCEDURE|Experimental group|SDF application
219577878|NCT05777824|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
219577879|NCT05777824|RADIATION|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
219577880|NCT04365179|DRUG|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
219430389|NCT03764579|BEHAVIORAL|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
219430390|NCT01319019|DRUG|GSK961081|Comparison of different doses and dosing regimens of the drug
219430391|NCT01319019|DRUG|Salmeterol|Positive control
219577881|NCT03637335|COMBINATION_PRODUCT|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
219577882|NCT03637335|COMBINATION_PRODUCT|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
219577883|NCT04932941|DRUG|MP1032|Hard gelatin capsules for oral administration.
219577884|NCT04932941|DRUG|Placebo|Placebo capsules matched to MP1032 for oral administration.
219761945|NCT05611502|DEVICE|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
219761946|NCT05353439|PROCEDURE|Biopsy Procedure|Undergo biopsy
219761947|NCT05353439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219761948|NCT05353439|PROCEDURE|Computed Tomography|Undergo CT scan
219761949|NCT05353439|BIOLOGICAL|Pembrolizumab|Given IV
219761950|NCT05353439|DRUG|Tazemetostat Hydrobromide|Given PO
219761951|NCT05353439|DRUG|Topotecan Hydrochloride|Given IV
219761952|NCT02960893|DRUG|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
219761953|NCT02960893|DRUG|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
219761954|NCT02960893|DRUG|Troriluzole|OLE phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
219761955|NCT03692312|DRUG|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
219430392|NCT01319019|DRUG|Placebo|Placebo arm
219430393|NCT00939939|DRUG|sitagliptin|sitagliptin 100 mg/d for 10 weeks
219430394|NCT00939939|DRUG|glimepiride|glimepiride 1 mg/d for 10 weeks
219430395|NCT05142449|DRUG|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
219430396|NCT05142449|OTHER|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
219430397|NCT00471003|DRUG|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
219430398|NCT02847845|DIETARY_SUPPLEMENT|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
219761956|NCT03692312|DRUG|Placebo|Matching placebo formulation
219430399|NCT02847845|DIETARY_SUPPLEMENT|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
219430400|NCT04320290|DRUG|Direct Acting Antivirals|8 weeks of DAA treatment
219430401|NCT06195293|BIOLOGICAL|Neoantigen Polypeptide Vaccine|Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
219430402|NCT05836129|BEHAVIORAL|Transcendental Meditation (TM) practice|See previous description
219430403|NCT05836129|OTHER|Stress reduction class (online)|See previous description
219430404|NCT06193694|BEHAVIORAL|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
219430405|NCT05278676|DRUG|Dotinurad|Dotinurad oral tablet.
219430406|NCT01655238|OTHER|BMI|Screening guideline to assess body mass index.
219430407|NCT01078987|PROCEDURE|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
219430408|NCT04270487|OTHER|IBS Diet|Patients will be randomized to a diet or a mediation treatment
219430409|NCT04270487|DRUG|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
219430410|NCT03936270|DRUG|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
219577885|NCT00896324|BEHAVIORAL|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
219199553|NCT05934136|BEHAVIORAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
219430411|NCT03936270|DRUG|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
219430412|NCT05370742|PROCEDURE|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
219430413|NCT06006442|BEHAVIORAL|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
219430414|NCT02826993|DEVICE|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
219430415|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
219577886|NCT00896324|BEHAVIORAL|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
219430416|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
219430417|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
219430418|NCT02398084|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
219430419|NCT02518776|BEHAVIORAL|Neuropsychological tests|Neuropsychological tests
219430420|NCT00005092|DRUG|Cyclophosphamide|IV over 2 hours on days 2 and 3
219430421|NCT00005092|DRUG|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
219430422|NCT00005092|DRUG|Thiotepa|IV over 2 hours on day 1
219430423|NCT00005092|PROCEDURE|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
219430424|NCT00005092|PROCEDURE|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
219430425|NCT00005092|RADIATION|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
219430426|NCT04451291|BIOLOGICAL|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
219430427|NCT01305304|OTHER|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
219430428|NCT01305304|OTHER|Other|No history of endurance sports activity
219430429|NCT05064332|DRUG|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
219430430|NCT05064332|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
219430431|NCT02625987|PROCEDURE|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
219430432|NCT02625987|PROCEDURE|Separated stitches|Appendectomy wound closure with a separated stitches.
219430433|NCT00888615|DRUG|Elesclomol Sodium|Given IV
219430434|NCT00888615|DRUG|Paclitaxel|Given IV
219761957|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
219430435|NCT06197737|OTHER|Moderate Intensity Interval Training|Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.
219430436|NCT06197737|OTHER|Sprint Interval Training|sprint interval training in which they will do stair climbing 3 times a week with a fast pace.
219430437|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
219430438|NCT01672528|OTHER|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
219761958|NCT06356337|DEVICE|Light goggles plus text messages|Green light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks plus daily reminder text message
219761959|NCT06356337|DEVICE|Light Goggles|Green light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks
219761960|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
219761961|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
219761962|NCT06581211|PROCEDURE|Aromatherapy and Essential Oils|Inhale LA
219761963|NCT06581211|OTHER|Electronic Health Record Review|Ancillary studies
219761964|NCT06581211|OTHER|Jojoba Oil|Inhale jojoba oil aromatherapy
219761965|NCT06581211|OTHER|Lavender Oil|Inhale LAO
219761966|NCT06581211|OTHER|Questionnaire Administration|Ancillary studies
219761967|NCT06581328|DRUG|Vedolizumab IV|Vedolizumab IV infusion
219761968|NCT06581328|DRUG|Vedolizumab SC|Vedolizumab SC injection
219761969|NCT02153580|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
219761970|NCT02153580|DRUG|Bendamustine Hydrochloride|Given IV
219761971|NCT02153580|DRUG|Cyclophosphamide|Given IV
219761972|NCT02153580|DRUG|Etoposide|Given IV
219761973|NCT02153580|DRUG|Fludarabine Phosphate|Given IV
219761974|NCT05562258|BEHAVIORAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
219761975|NCT05562258|BEHAVIORAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
219761976|NCT06021132|DEVICE|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
219761977|NCT04095065|BEHAVIORAL|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
219761978|NCT04095065|BEHAVIORAL|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
219761979|NCT04095065|BEHAVIORAL|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
219761980|NCT04095065|BEHAVIORAL|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
219430439|NCT01672528|OTHER|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
219430440|NCT03714009|BEHAVIORAL|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
219430441|NCT03714009|BEHAVIORAL|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
219430442|NCT05428800|BEHAVIORAL|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
219430443|NCT00372034|DEVICE|Temporary Collagen Inserts|
219430444|NCT04073628|DEVICE|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
219430445|NCT05890313|DIAGNOSTIC_TEST|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
219430446|NCT05890313|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
219430447|NCT05890313|DEVICE|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
219430448|NCT03541655|DRUG|Bupivacaine HCl|0.25% Bupivacaine HCl
219430449|NCT03541655|DRUG|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
219430450|NCT03047850|DIAGNOSTIC_TEST|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
219430451|NCT01896908|OTHER|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY \_\_ / \_\_ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
219430452|NCT03657667|PROCEDURE|Ureteroscopy|Endoscopic removal of kidney stones
219430453|NCT03896113|DRUG|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
219430454|NCT05578235|PROCEDURE|stapled side-to-side anastomosis|Standard procedure for CD
219430455|NCT05578235|PROCEDURE|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
219430456|NCT06874556|BEHAVIORAL|CP-HF Management|Community Paramedics will visit patients up to twice daily. Visits will include patient care discussion with Heart Failure APP, IV placement, lab phlebotomy, heart failure education, and IV medication administration. Community Paramedics will administer up to 120 mg IV furosemide twice daily.
219430457|NCT06882460|OTHER|Low glycemic load|Low glycemic load diet
219430458|NCT06882460|OTHER|Electrical stimulation exercise|Lower-body electrical stimulation exercise for 1-h after eating
219430459|NCT06882460|OTHER|High glycemic load diet|High glycemic load diet
219430460|NCT06876636|DRUG|Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)|zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel Concurrent immunotherapy is permitted: pembrolizumab or toripalimab
219430461|NCT04567446|OTHER|Stool|collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
219430462|NCT04567446|OTHER|Blood sample|20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
219430463|NCT03032081|OTHER|High intensity exercise|High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
219577887|NCT00896324|BEHAVIORAL|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
219430464|NCT03032081|OTHER|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
219577888|NCT00892788|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
219577889|NCT00892788|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
219430465|NCT05442294|BEHAVIORAL|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
219430466|NCT05997017|DRUG|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
219430467|NCT02091921|DRUG|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
219430468|NCT05640856|PROCEDURE|intubation|Endotracheal tube placement
219430469|NCT01790009|DIETARY_SUPPLEMENT|Flavanol rich drink|
219430470|NCT01790009|DRUG|Acetaminophen|2x500 mg Acetaminophen
219430471|NCT06396572|PROCEDURE|IVR-Procedure|Using immersive virtual reality to learn urinary catheterisation procedure
219430472|NCT06396572|PROCEDURE|Nursing Clinical Laboratory practice|Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
219430473|NCT03601208|DIAGNOSTIC_TEST|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
219430474|NCT06373276|OTHER|multiplanar balance training exercise with education|7 minute daily balance training exercises
219430475|NCT06373276|BEHAVIORAL|education only|5 educational broshures
219430476|NCT04657653|PROCEDURE|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
219430477|NCT02447120|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
219430478|NCT06082869|DRUG|Protegera™ toothpaste (NaF)|Plaque Reduction
219430479|NCT06082869|DRUG|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
219430480|NCT05698043|DRUG|CKD-386(5)|Test
219430481|NCT05698043|DRUG|D013, D326, D337|Reference
219430482|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Mental health education|The intervention group will cover educational topics around mental health including: mental health literacy, individual coping skills, stigma reduction strategies, resources for mental health support, and mental health rights.
219430483|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Resources in the community|The control group will cover topics including: mental health resources in the community, violence (i.e. domestic violence), employment and education opportunities, housing and tenant rights, immigration and acculturation, and community team building and empowerment.
219430484|NCT01862432|OTHER|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
219430485|NCT02994381|DRUG|RPC1063|
219577890|NCT04177641|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
219430486|NCT07044310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219430487|NCT07044310|PROCEDURE|Bone Mineral Density Test|Undergo BMD
219430488|NCT07044310|OTHER|Questionnaire Administration|Ancillary studies
219577891|NCT04177641|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
219577892|NCT06483087|BEHAVIORAL|Animated Education Program|Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
219577893|NCT04254640|DRUG|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
219577894|NCT04254640|DRUG|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
219577895|NCT04254640|DRUG|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
219430489|NCT07044310|DRUG|WBF-038|Given WBF-038 PO
219191935|NCT05806645|OTHER|Risk-guided transition of care intervention delivered through an integrated digital health strategy|Patients will receive transition of care plans that are tailored to their medical profile and risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function, proteinuria and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral for high risk patients
219430490|NCT06723392|DRUG|Oral nitrofurantoin monohydrate/macrocrystals|7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)
219430491|NCT06723392|OTHER|Placebo|7-day course of oral placebo 100 mg twice daily (total of 14 doses)
219430494|NCT03307629|DRUG|NOX66|NOX66 delivered as rectal suppository.
219577896|NCT04254640|DRUG|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
219007239|NCT05508191|DEVICE|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
219007240|NCT00699621|BIOLOGICAL|platelets|Four units of fresh platelets will be infused immediately
219007241|NCT01285310|DRUG|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
219007242|NCT01285310|DRUG|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
219007243|NCT01285310|DRUG|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
219007244|NCT00208039|DRUG|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
219007245|NCT01330589|DRUG|Placebo|Non-active placebo for 7 days: PO/TID
219007246|NCT01330589|DRUG|St. Johns Wort|For 7 days: 300mg PO/TID
219007247|NCT02278250|DRUG|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007248|NCT02278250|DRUG|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007249|NCT02278250|DRUG|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007250|NCT02278250|DRUG|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007251|NCT02278250|DRUG|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007252|NCT02278250|DRUG|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007253|NCT02278250|DRUG|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219430495|NCT03307629|RADIATION|Irradiation Therapy|Radiation per selected tumour lesion.
219430496|NCT03296787|DRUG|TAK-954|TAK-954 intravenous infusion.
219577897|NCT04732988|DRUG|HSG4112|Once-daily oral administration
219577898|NCT04732988|DRUG|Placebo|Once-daily oral administration
219577899|NCT06289829|DRUG|remifentanil of the assigned dose|Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
219577900|NCT06289829|DEVICE|Ambu Auragain for airway management|Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
219577901|NCT04134026|DRUG|HIF-PHI|Drug will be dosed orally three times a week.
219577902|NCT04134026|DRUG|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
219577903|NCT00766155|DRUG|capecitabine|Given orally
219577904|NCT00766155|DRUG|oxaliplatin|Given IV
219577905|NCT00449319|PROCEDURE|Identification of appropriate therapies according to risks factors|
219577906|NCT00449319|DRUG|Daunorubicine|
219577907|NCT00449319|PROCEDURE|Transplant|
219430497|NCT04339270|DRUG|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
219430498|NCT04339270|DRUG|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
219430499|NCT04545099|DRUG|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
219430500|NCT04545099|DRUG|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
219430501|NCT02874183|BEHAVIORAL|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
219577908|NCT06451393|DRUG|Neoadjuvant chemotherapy with radical tumor resection surgery|All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
219577909|NCT03336957|PROCEDURE|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
219577910|NCT03421041|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
219577911|NCT03582280|DRUG|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
219577912|NCT03285789|OTHER|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
219577913|NCT03285789|OTHER|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
219577914|NCT02441244|DRUG|Visbiome|Visbiome probiotic
219577915|NCT02441244|OTHER|Placebo|Placebo
219430502|NCT01771211|DEVICE|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
219430503|NCT06890013|DIAGNOSTIC_TEST|Observation group|Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.
219430504|NCT03229681|BEHAVIORAL|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
219430505|NCT03229681|BEHAVIORAL|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
219430506|NCT02691221|BEHAVIORAL|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
219577916|NCT01286389|OTHER|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
219577917|NCT01286389|BEHAVIORAL|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
219577918|NCT00002006|DRUG|Zidovudine|
219577919|NCT00002006|DRUG|Sargramostim|
219007254|NCT02278250|DRUG|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007255|NCT02278250|DRUG|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007256|NCT02278250|DRUG|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007257|NCT02278250|DRUG|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007258|NCT02278250|DRUG|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007259|NCT02278250|DRUG|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007260|NCT02278250|DRUG|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007261|NCT02278250|DRUG|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007262|NCT02278250|DRUG|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219430507|NCT00325650|DRUG|Rimonabant|Tablet, oral administration
219430508|NCT00325650|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219577920|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
219577921|NCT01929031|DRUG|ibuprofen|tablet.
219577922|NCT01929031|DRUG|ibuprofen|tablet
219577923|NCT01929031|DRUG|caffeine|tablet
219577924|NCT01929031|DRUG|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
219577925|NCT01929031|DRUG|placebo|tablet
219577926|NCT01929031|DRUG|placebo|tablet
219577927|NCT01929031|DRUG|caffeine|tablet
219430509|NCT06745206|DRUG|Lyophilized Recombinant Human Brain Natriuretic Peptide|rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. Patients should receive at least the first 500μg dose infusion, with a recommended duration of 72 hours. The specific timing of discontinuation will be determined by the attending physician. Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
219430510|NCT00719953|DIETARY_SUPPLEMENT|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
219430511|NCT06728098|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
219430512|NCT06728098|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
219430513|NCT01626989|DEVICE|BiPAP auto Advanced|Auto Servo Ventilation Device
219430514|NCT01626989|DEVICE|BiPAP auto SV4|Auto Servo Ventilation Device
219430515|NCT07057466|OTHER|Traditional 12-lead Electrocardiogram|12-lead ECG investigation is a standard, non-invasive diagnostic procedure used as an intervention to assess participants' cardiac electrical activity. For the purposes of this study, 12-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
219430516|NCT07057466|OTHER|Apple Watch Series 4 Single-lead Electrocardiogram|Single-lead ECG taken using an Apple Watch Series 4 is a non-invasive, participant-initiated recording of cardiac electrical activity through a wearable device. While more limited than a 12-lead ECG, it can capture rhythm abnormalities-such as atrial fibrillation-and offers a convenient method for remote or continuous heart monitoring during the study. For the purposes of this study, single-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
219430517|NCT07057466|OTHER|Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram|Three-lead ECG recorded using the Eko CORE 500 digital stethoscope is a non-invasive, clinician-operated cardiac assessment tool that captures real-time electrical activity of the heart during auscultation. It provides enhanced diagnostic information compared to single-lead recordings, allowing detection of arrhythmias and signs of structural heart disease at the point of care, supporting integrated clinical and digital assessment. For the purposes of this study, 3-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
219430518|NCT07057466|OTHER|AliveCor KardiaMobile Single- and 6-lead Electrocardiogram|A single- or 6-lead ECG recorded using the AliveCor KardiaMobile 6L device which is a portable, non-invasive method for capturing cardiac electrical activity. Operated by the participant or clinician, the device enables rapid rhythm assessment and detection of abnormalities such as atrial fibrillation. The 6-lead configuration offers more comprehensive data than single-lead recordings, supporting enhanced arrhythmia and conduction analysis in both in-clinic and remote settings. For the purposes of this study, single- and 6-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
219430519|NCT07057466|OTHER|Phlebotomy for N-terminal pro-B-type natriuretic peptide|A minimally invasive biomarker assessment used to evaluate cardiac wall stress and function. Elevated levels can indicate the presence or severity of heart failure and other forms of structural heart disease, making it a valuable tool for diagnosis, risk stratification, and monitoring of cardiac status throughout the study period. For the purposes of this study, NT-proBNP will be collected to assess its accuracy at detecting HF, PH, and VHD with comparison with AI-ECG detections. The investigators will also evaluate the accuracy of AI-ECG detections combined with NT-pro-BNP, for detecting HF, VHD, and PH. The investigators will not be using NT-proBNP results to inform or alter patients' standard NHS care.
219430520|NCT07075484|DRUG|YTS109 cell|Subjects will receive YTS109 cell, and dose escalation will commence at 5E6 cells/kg or the starting dose may be adjusted based on accumulated data.
219577928|NCT01929031|DRUG|ibuprofen|tablet
219577929|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
219577930|NCT03352375|DEVICE|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
219577931|NCT03352375|DEVICE|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
219577932|NCT03944681|DRUG|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
219577933|NCT03721731|DEVICE|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
219577934|NCT02150759|DRUG|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
219577935|NCT02150759|DRUG|Fentanyl|add dexmedetomidine during position change
219577936|NCT02150759|DRUG|Ketamine|add dexmedetomidine during position change
219577937|NCT05684471|PROCEDURE|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
219577938|NCT05684471|PROCEDURE|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
219577939|NCT00321594|DRUG|belinostat|Given IV
219577940|NCT03478228|OTHER|Multi-Sensory Training|
219577941|NCT02394730|DRUG|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
219577942|NCT02394730|DRUG|Placebo|Sugar pill taken orally once daily for 12 weeks
219577943|NCT06225557|OTHER|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
219191936|NCT05802160|BEHAVIORAL|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
219191937|NCT06299124|DRUG|RGT-419B|RGT-419B will be administered orally
219430521|NCT07075991|DRUG|1 μm [14C]-labelled Polystyrene Microplastic|A single test day during which participants will orally ingest a single micro dose of 100 μg 1 µm \[14C\]-labelled PS-MP. Prior to and following ingestion of the labelled PS-MP, biological samples (i.e. blood, urine, faeces) will be collected at regular intervals, throughout the 5-day study period. Participants will spend the first 24h in the clinical laboratory, after which they are allowed to spend the remainder of the 5-day study period at home but with daily visits to the laboratory for blood sampling and home collection of urine and faeces.
219430524|NCT06783296|PROCEDURE|Renal Denervation|Renal denervation performed using the Symplicity Spyral™ multi-electrode renal denervation system, which is approved for interventional treatment of hypertension. This procedure involves catheter-based radiofrequency ablation of the renal nerves to reduce sympathetic activity and lower blood pressure.
219430525|NCT06783296|PROCEDURE|Renal Angiography|A sham procedure involving renal angiography without the application of radiofrequency energy. This control intervention is used to maintain blinding.
219430526|NCT06893081|DRUG|MK-8527|Oral Tablet
219430527|NCT06893081|DRUG|CBZ|Oral Extended-release Capsule
219430528|NCT07090512|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal ultrasound data collection will be conducted on all organ donors meeting the research criteria.
219430529|NCT07091110|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
219475208|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
219475209|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
219475210|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
219475211|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
219475212|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
219475213|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
219430530|NCT07091474|BEHAVIORAL|Educational Workshops for Parents and Early Educators|A structured series of age-specific educational workshops designed for parents, caregivers, and early childhood educators of children aged 0-36 months. The workshops are organized into three cohorts (0-12 months, 13-24 months, 25-36 months) and focus on typical motor milestones, active play, early stimulation strategies, and recognition of early warning signs of motor delays. Sessions include interactive activities, discussions, and distribution of educational resources. Pre- and post-workshop surveys and semi-structured interviews are conducted to evaluate changes in knowledge and attitudes.
219430531|NCT07091474|OTHER|Motor Development Assessment in Children 0-36 Months|Comprehensive motor development assessments performed on infants aged 0-36 months using validated tools (Standardized Infant Hand Assessment \[s-HAI\], Hammersmith Infant Neurological Examination \[HINE\], Infant Motor Profile \[IMP\], and Ages and Stages Questionnaire \[ASQ-3\]). These evaluations aim to collect normative data on typical early motor development and to identify early signs of motor delays or neurological conditions, enabling timely referral and intervention. Assessments are conducted annually for typically developing infants and monthly for those identified as at risk.
219430532|NCT07091656|OTHER|there is no intervention|NO INTERVENTION
219430533|NCT07090954|DRUG|GR1803 injection|Participants will receive GR1803 injection.
219430534|NCT07090954|DRUG|Anti-CD38 Monoclonal Antibody|Participants will receive anti-CD38 monoclonal antibody.
219430535|NCT07090187|DEVICE|LegoPress , Novel assistive device|novel assistive device for rehabilitation using functional electrical stimulation
219430536|NCT06890039|DRUG|Placebo|"Matching placebo for TAK-242: 5% dextrose solution and commercially available 20% intralipid (prepared by hospital pharmacy staff)~Matching placebo for G-CSF: identical to vehicle for filgrastim (prepared for injection by hospital pharmacy staff)"
219430537|NCT06890039|DRUG|TAK-242|"TAK-242 concentrate for solution for infusion (80 mg/ mL in 3 mL ethanol) ): 240 mg TAK-242 per vial. To be reconstituted with 5% dextrose (36 mL) and commercially available 20% intralipid (21 mL).~TAK-242) will be administered as a continuous IV infusion starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 10 days.~PLUS placebo for G- CSF"
219430538|NCT06890039|DRUG|G-CSF (Filgrastim)|"Commercially available vials for subcutaneous injection. Quantitative composition (per mL):~Filgrastim: 300 mcg Acetate: 0.59 mg Sorbitol: 50.0 mg Tween® 80: 0.04 mg Sodium: 0.035 mg Water for Injection USP q.s. ad 1.0 mL~G-CSF will be given subcutaneously once daily at a dose of 5 µg/kg for 5 days (Day 1-5) and at Day 8 (6 injections in total)"
219430539|NCT06805617|DRUG|Ivonescimab|An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial, via intravenous (into the vein) infusion per protocol.
219430540|NCT07091929|DRUG|SGC001|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
219430541|NCT07091929|DRUG|Placebo|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
219430542|NCT07090070|PROCEDURE|Cohort 1 Intervention group|Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins.
219430543|NCT07090070|PROCEDURE|Cohort 2 severe/CIS margins clear|Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear
219430544|NCT07090070|PROCEDURE|Cohort 2 p53 and severe/CIS margins clear|Excision of the lesion ensuring final negative p53 and severe/CIS margins
219430545|NCT07090070|PROCEDURE|Cohort 3 Excision and END|Excision of primary lesions with 5+mm margins and immediate elective neck dissection
219430546|NCT07090070|PROCEDURE|Cohort 3 Excision and Close follow up|Excision of primary lesion with 5+mm margins and close follow up with salvage elective neck dissection if development of nodal disease
219430547|NCT07090720|DRUG|Melatonin|Neonates were given Melatonin.
219430548|NCT07090720|OTHER|Placebo|Neonates received placebo.
219430549|NCT07091461|DEVICE|HOME Kit Tablet-based Telerehabilitation|Device-based behavioral intervention (motor, cognitive, and communication rehabilitation)
219430550|NCT07091461|OTHER|Conventional Home Physiotherapy|Participants in this arm will follow a conventional home rehabilitation protocol, focusing on upper limb function and postural control. The protocol includes traditional exercises prescribed and explained by a physiotherapist. Follow-up will be conducted through weekly phone calls to reinforce adherence and resolve concerns.
218859468|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
219430551|NCT01165697|OTHER|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
218859469|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
219430552|NCT07092306|DRUG|Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)|（NALIRI-VT，Nanoliposomal Irinotecan，Vincristine，Temozolomide）， Nanoliposomal Irinotecan：35 mg/m2/d，iv，D1，8，15， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
219475214|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
219475215|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
219475216|NCT01001091|DRUG|AL-38583 ophthalmic solution|
219475217|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
218859470|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
218859471|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
218859472|NCT04068519|DRUG|Tislelizumab|Administered intravenously
219430553|NCT07092306|DRUG|Irinotecan Combined with Temozolomide and Vincristine (VIT)|（VIT，Vincristine，Irinotecan，Temozolomide） Irinotecan：50 mg/m2/d，iv，D1-5， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
219430554|NCT07090824|DRUG|Diluted Humalog U-200 Insulin|Commercially available U-200 Humalog (insulin lispro) diluted 1:1 with a dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
219430555|NCT07090824|DRUG|Diluted U-500 Humulin Insulin|Commercially available U-500 Humulin (regular insulin) diluted 1:4 with dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
219430556|NCT07090824|DRUG|Lyumjev U-100 Insulin|Commercially available U-100 Lyumjev (insulin lispro-aabc) administered unmodified as comparator. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
219430557|NCT07090824|DIETARY_SUPPLEMENT|Boost Mixed Meal Test|Standardized mixed meal (Boost drink) administered at 8.0 mL/kg body weight (17.3 g carbohydrates per 100 mL) consumed immediately before insulin injection at each visit.
219430558|NCT06278155|OTHER|Social relation training with social robot|"The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response"
219430559|NCT06278155|OTHER|Traditional social relations training|Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
219430560|NCT01318668|BIOLOGICAL|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
219430561|NCT04366128|DRUG|CAPA indution immunotherapy|"1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1."
219430562|NCT05900466|DRUG|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
219430563|NCT05900466|DRUG|Placebo|Matching tablets once daily in the morning for 8 weeks
219430564|NCT05595135|OTHER|Text Message-Based Navigation Intervention|Receive interactive text messaging.
219430565|NCT05595135|OTHER|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
219430566|NCT05595135|OTHER|Survey Administration|Ancillary studies
219430567|NCT05595135|OTHER|Quality-of-Life Assessment|Ancillary studies
219430568|NCT03349580|BEHAVIORAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
219430569|NCT03393689|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
219430570|NCT03460470|DRUG|Sildenafil|PDE5 Inhibitor
219430571|NCT03460470|DRUG|Placebo oral capsule|Placebo for Sildenafil
219430572|NCT02944669|DEVICE|ReWalk Personal Device|
219430573|NCT00028418|DRUG|Clofarabine|
219430574|NCT02500277|DEVICE|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
219430575|NCT02500277|DEVICE|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
219430576|NCT02606396|PROCEDURE|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
219430577|NCT02606396|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
219430578|NCT02606396|PROCEDURE|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
219475218|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
219475219|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
219475220|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
219475221|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
219475222|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
219430579|NCT05571904|PROCEDURE|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
219430580|NCT01630941|DRUG|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
219430581|NCT01120821|DRUG|Gleevec|400 mg once daily for 12 months
219430582|NCT00124813|DRUG|thalidomide|
219430583|NCT00124813|DRUG|idarubicin|oral idarubicin
219430584|NCT04587921|DEVICE|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
219430585|NCT03459157|DRUG|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
219430586|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
218859473|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
219430587|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
219430588|NCT01432457|DRUG|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
219430589|NCT00132158|DRUG|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
219430590|NCT00621010|DRUG|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
219430591|NCT01843634|DRUG|ODSH|
219430592|NCT02574481|DEVICE|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
219430593|NCT02574481|DEVICE|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
219430594|NCT04134728|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
219430595|NCT04134728|BIOLOGICAL|Sarilumab|Sarilumab solution in PFS to be administered SC.
219430596|NCT04134728|DRUG|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
219430597|NCT04134728|DRUG|csDMARDs|Stable dose of csDMARD(s) as SoC.
219430598|NCT04059874|DRUG|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
219475223|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
219475224|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
219475225|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
219475226|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
219475227|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
218859474|NCT05438849|BEHAVIORAL|Mobile Health Application focused on behavioral treatments to treat urinary incontinence|Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans
219475228|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
219475229|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
219476307|NCT05151484|DRUG|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
219430599|NCT04131244|PROCEDURE|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
219430600|NCT04013165|BEHAVIORAL|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
219430601|NCT04013165|BEHAVIORAL|Village-based intervention|"1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
219007263|NCT02278250|DRUG|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
219007264|NCT02532790|DRUG|Prednisone|1.5mg/kg/d
219007265|NCT02532790|DRUG|ACEI|0.2-0.3mg/kg/d
219007266|NCT00192842|DRUG|curcumin (+ gemcitabine)|
219007267|NCT03775057|OTHER|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
219007268|NCT02848183|DRUG|Cytarabine|
219007269|NCT02848183|DRUG|Idarubicin|
219007270|NCT02848183|DRUG|Mitoxantrone|
219007271|NCT02848183|DRUG|Etoposide|
219007272|NCT02848183|PROCEDURE|Hematopoietic stem cell transplantation|
219007273|NCT04541576|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
219007274|NCT00237601|OTHER|obstetric care|
219007275|NCT06332651|OTHER|Black beans|Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
219007276|NCT06332651|OTHER|Milk|Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
219007277|NCT06332651|OTHER|Sorghum|Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
219007278|NCT03930576|OTHER|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
219007279|NCT04208620|DRUG|Placebo|Placebo administered subcutaneously
219007280|NCT04208620|DRUG|Cotadutide|Cotadutide administered subcutaneously
219007281|NCT04962633|OTHER|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
219007282|NCT04962633|OTHER|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
219007283|NCT03676933|DRUG|DS107E|
219007284|NCT03676933|DRUG|Vehicle|
219007285|NCT03676933|DRUG|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
219007286|NCT01373372|DRUG|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
219007287|NCT02792933|PROCEDURE|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
219007288|NCT02792933|PROCEDURE|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
219007289|NCT00290368|PROCEDURE|Skin Prick Test|
219007290|NCT00290368|PROCEDURE|Nasal allergen challenge|
219007291|NCT00290368|PROCEDURE|Nasal filter paper placement|
219007292|NCT00290368|PROCEDURE|Nasal lavage|
219007293|NCT00290368|PROCEDURE|Nasal scrape|
219007294|NCT00290368|PROCEDURE|Nasal symptoms score|
219191938|NCT03674619|PROCEDURE|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
219430602|NCT02483065|OTHER|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
219430603|NCT02880735|DEVICE|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
219430604|NCT03300258|DEVICE|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
219430605|NCT03300258|DEVICE|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
219430606|NCT03822702|OTHER|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
219430607|NCT03822702|OTHER|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
219430608|NCT05094076|RADIATION|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis \[ILO, 1980\]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
219430609|NCT05333003|DRUG|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
219430610|NCT05333003|OTHER|Placebo|Placebo will be provided to participants
219430611|NCT05325398|DIETARY_SUPPLEMENT|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
219430612|NCT05325398|DIETARY_SUPPLEMENT|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
219430613|NCT05970068|PROCEDURE|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
219430614|NCT05970068|DEVICE|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
219430615|NCT00716339|BEHAVIORAL|motivation|
219430616|NCT00640276|DRUG|pitavastatin|Pitavastatin 2mg daily once
219430617|NCT00640276|BEHAVIORAL|Lifestyle Modification|conducting mainly exercises and diet
219430618|NCT05309733|GENETIC|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
219430619|NCT01943188|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219430620|NCT01943188|DRUG|cyclophosphamide|Given PO
219430621|NCT01943188|BIOLOGICAL|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
219430622|NCT01943188|OTHER|laboratory biomarker analysis|Correlative studies
219430623|NCT00905268|DRUG|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
219430624|NCT00905268|DRUG|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
219191939|NCT03674619|BEHAVIORAL|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
219191940|NCT05781711|DRUG|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
219430625|NCT06241820|PROCEDURE|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
219430626|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
219430627|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
219430628|NCT03079557|DRUG|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
219430629|NCT02905825|DEVICE|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
219430630|NCT02905825|DRUG|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
219430631|NCT02905825|DIAGNOSTIC_TEST|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
219430632|NCT06166888|DRUG|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
219430633|NCT00013767|BEHAVIORAL|Individual and Community education|
219430634|NCT03714347|DEVICE|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
219430635|NCT03714347|DEVICE|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
219430636|NCT05710770|DEVICE|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
219430637|NCT03507192|DEVICE|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
219430638|NCT00045591|DRUG|celecoxib|100 mg PO bid
219430639|NCT00045591|DRUG|Celecoxib|400 mg PO bid
219430640|NCT00422123|DRUG|Quetiapine fumarate (Seroquel) SR|
219430641|NCT01281189|DRUG|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
219430642|NCT01281189|DRUG|Placebo|Oral tablet twice daily for up to 18 months.
219430643|NCT02356328|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
219577944|NCT06225557|OTHER|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
219430644|NCT05355818|DRUG|Delgocitinib|Cream for topical application
219430645|NCT05355818|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
219430646|NCT05848973|OTHER|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
219430647|NCT05848973|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
219430648|NCT01375738|PROCEDURE|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
219430649|NCT01375738|PROCEDURE|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
219430650|NCT02883920|OTHER|Allergy and respiratory functional tests|
219191941|NCT05781711|DRUG|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
219191942|NCT00302887|DEVICE|combined ultrasound therapy|
219430651|NCT03543527|OTHER|no intervention|no intervention
219191943|NCT00302887|PROCEDURE|connective tissue manipulation|
219191944|NCT00279162|DRUG|Calcipotriene/betamethasone gel and ointment|
219430652|NCT05215678|OTHER|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
219430653|NCT05215678|OTHER|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
219430654|NCT02228772|DRUG|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
219577945|NCT06490120|OTHER|sampling method|feasibility outcomes will be compared between the 3 groups
219430655|NCT02228772|DRUG|Vincristine|Standard chemotherapy dosage and duration
219430656|NCT02228772|DRUG|Cytarabine|Standard chemotherapy dosage and duration
219430657|NCT02228772|DRUG|Doxorubicin|Standard chemotherapy dosage and duration
219430658|NCT02228772|DRUG|Mercaptopurine|Standard chemotherapy dosage and duration
219430659|NCT02228772|DRUG|Cyclophosphamide|Standard chemotherapy dosage and duration
219430660|NCT02228772|DRUG|Methotrexate|Standard chemotherapy dosage and duration
219430661|NCT00274066|DRUG|Tiotropium + placebo|
219430662|NCT00274066|DRUG|Tiotropium + ipratropium|
219430663|NCT00274066|DRUG|Tiotropium + fenoterol|
219430664|NCT01135745|DEVICE|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
219430665|NCT04815538|BEHAVIORAL|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
219430666|NCT01234519|DRUG|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
219430667|NCT01234519|DRUG|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
219577946|NCT05512520|COMBINATION_PRODUCT|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
219430668|NCT06348758|OTHER|questionnaire|E-Questionnaire will be sent to the students
219577947|NCT01363804|DRUG|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
219577948|NCT03110601|DEVICE|Control - Conventional SCS|Conventional SCS Parameters
218859475|NCT05438849|COMBINATION_PRODUCT|Practice Facilitation|The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
218859476|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
219430669|NCT03955055|DEVICE|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
219430670|NCT01431651|DIETARY_SUPPLEMENT|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
219430671|NCT05757479|PROCEDURE|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
219430672|NCT05757479|DRUG|Steroid nasal spray|1 spray into each nostril once a day.
219430673|NCT05757479|PROCEDURE|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
219430674|NCT01136746|DRUG|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
219577949|NCT03110601|DEVICE|Test - Stimgenics SCS|Stimgenics SCS Parameters
219577950|NCT02384850|DRUG|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
219577951|NCT02384850|DRUG|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
219577952|NCT02384850|DRUG|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
219577953|NCT02384850|DRUG|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
219577954|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Amino Acid daily for 13 days|A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.
219577955|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Gluconate daily for 13 days|A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
219577956|NCT00804817|BEHAVIORAL|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
219596806|NCT01867463|BIOLOGICAL|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
219596807|NCT04107272|DEVICE|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
219596808|NCT04107272|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
219596809|NCT03013816|BEHAVIORAL|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
219596810|NCT03013816|BEHAVIORAL|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
219596811|NCT03013816|BEHAVIORAL|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
219191945|NCT03657342|DRUG|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
219430675|NCT01136746|DRUG|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
219430676|NCT01136746|DRUG|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
219430677|NCT03362203|OTHER|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
219430678|NCT03362203|OTHER|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
219430679|NCT00756093|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
219430680|NCT00756093|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
219430681|NCT00756093|OTHER|Blink Tears|Blink Tears one drop each eye one time
219430682|NCT00756093|OTHER|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
219430683|NCT01117025|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
219430684|NCT01117025|PROCEDURE|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
219430685|NCT03154294|DRUG|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
219430686|NCT03154294|DRUG|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
219430687|NCT03154294|DRUG|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
219430688|NCT02868255|PROCEDURE|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
219596812|NCT05469295|DEVICE|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
219430689|NCT00092677|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
219430690|NCT00092677|DRUG|Comparator: Placebo|matching Placebo
219596813|NCT05469295|DEVICE|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
219761981|NCT05051033|PROCEDURE|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
219761982|NCT05051033|DEVICE|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
219761983|NCT05898854|DRUG|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
219430691|NCT05459480|OTHER|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
219430692|NCT04251624|BEHAVIORAL|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
219430693|NCT04251624|BEHAVIORAL|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
219430694|NCT05116891|DRUG|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
219430695|NCT05116891|DRUG|mFOLFOX|mFOLFOX/CAN04
219430696|NCT05116891|DRUG|DTX|DTX/CAN04
219430697|NCT05116891|DRUG|G/C|G/C/CAN04
219430698|NCT05983016|DEVICE|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
219430699|NCT03444467|DRUG|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
219430700|NCT03444467|DRUG|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
219430701|NCT03444467|DRUG|Placebo|Participants will receive single dose of placebo (for double dummy injections).
219430702|NCT00617617|DIETARY_SUPPLEMENT|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
219430703|NCT00617617|OTHER|Placebo|Control Group - Control Group participants will receive an identical placebo.
219430704|NCT04903886|OTHER|observational|observational
219430705|NCT05849896|DEVICE|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
219430706|NCT04753749|DRUG|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
219430707|NCT04753749|DRUG|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
219430708|NCT05276765|PROCEDURE|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
219430709|NCT05276765|PROCEDURE|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
219430710|NCT03385694|DIAGNOSTIC_TEST|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
219430711|NCT01607294|DRUG|ETC-1002|ETC-1002 Daily for 4 weeks
219430712|NCT01607294|DRUG|Placebo|Placebo Daily for 4 weeks
219430713|NCT01601704|DRUG|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
219430714|NCT01601704|DRUG|PBO|Placebo. Administered in addition to the weight management program.
219430715|NCT01601704|BEHAVIORAL|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
219430716|NCT01090102|DRUG|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
219430717|NCT01090102|DRUG|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
219430718|NCT04391088|OTHER|vaccine coverage assessment|vaccine coverage assessment
219430719|NCT05211609|DIAGNOSTIC_TEST|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
219430720|NCT02283957|DRUG|CNTX-4975|
219430721|NCT02283957|OTHER|Placebo|
219430722|NCT03341234|DRUG|Bupivacaine|30 ml %0,25 bupivacaine
219430723|NCT03341234|DRUG|Saline|2 ml saline subcutaneously
219430724|NCT03341234|DEVICE|Ultrasound|Ultrasound guided block
219430725|NCT03518034|DRUG|AndroGel®|testosterone administered topically
219430726|NCT03518034|DRUG|Placebo|placebo administered topically
219430727|NCT02814448|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
219430728|NCT02814448|DEVICE|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
219430729|NCT02814448|DEVICE|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
219430730|NCT04655924|DEVICE|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
219430731|NCT03200093|DRUG|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
219430732|NCT03200093|DRUG|Placebo|Ora-Sweet 5mL taken by mouth once daily.
219430733|NCT00010803|DRUG|Ginkgo biloba|120mg twice a day
219430734|NCT00010803|DRUG|Placebo|One pill twice daily
219430735|NCT01283867|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
219430736|NCT00044525|DRUG|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
219430737|NCT00224692|DRUG|Low dose ketamine|
219430738|NCT04381533|BEHAVIORAL|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
219430739|NCT04381533|BEHAVIORAL|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
219430740|NCT01019252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
219430741|NCT03696940|DRUG|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
219430742|NCT03696940|DRUG|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
219430743|NCT02589743|DEVICE|Sealant|Application of preventive agent
219191946|NCT03657342|DRUG|standard of care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
219191947|NCT00449085|PROCEDURE|Electrophysiology|
219430744|NCT02589743|DEVICE|Adhesive and Sealant|Application of preventive agent and technique for control moisture
219430745|NCT06039150|PROCEDURE|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
219430746|NCT06039150|PROCEDURE|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
219430747|NCT02403141|OTHER|Questionnaire|
219430748|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
219430749|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
219430750|NCT00985738|DRUG|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
219430751|NCT00985738|OTHER|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
219430752|NCT02757404|DRUG|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
219430753|NCT02757404|DRUG|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
219430754|NCT02757404|DRUG|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
219577957|NCT00804817|BEHAVIORAL|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
219577958|NCT00646620|DRUG|budesonide/formoterol (Symbicort)|
219577959|NCT00646620|DRUG|fluticasone/salmeterol (Advair Diskus)|
219577960|NCT00646620|DRUG|albuterol (Ventolin)|
219577961|NCT00577902|OTHER|Observation|Head and neck cancer patients receiving chemoradiation
219577962|NCT02497118|DRUG|Endostatin|Endostatin,7.5mg/m\^2,intravenous, d1-14;
219577963|NCT02497118|DRUG|Vinorelbine|vinorelbine,25mg/m\^2,intravenous, d1, d8;
219430755|NCT01619488|DEVICE|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
219430756|NCT02653352|BEHAVIORAL|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
219430757|NCT03736551|BEHAVIORAL|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
219430758|NCT03736551|BEHAVIORAL|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
219430759|NCT02227849|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
219430760|NCT02227849|DRUG|GLP-1 analogue|
219577964|NCT02497118|DRUG|Cisplatin|Cisplatin，75mg/m\^2 intravenous,divide into d1-3
219430761|NCT03982238|DRUG|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
219430762|NCT03982238|DRUG|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
219430763|NCT03982238|DRUG|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
219430764|NCT00812604|DRUG|Ping On Ointment|Ping On Ointment
219430765|NCT00812604|DRUG|Vaseline|Placebo
219476308|NCT06120231|DIAGNOSTIC_TEST|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
219476309|NCT03198650|DRUG|Acalabrutinib|Acalabrutinib
219476310|NCT03198650|DRUG|Obinutuzumab|Obinutuzumab
219476311|NCT06472934|OTHER|Transcatheter aortic valve replacement in the absence of B-blocker treatment|Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.
219476312|NCT06472934|OTHER|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
219476313|NCT05182840|DRUG|BI 690517|Film-coated tablets
219476314|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
219476315|NCT05182840|DRUG|Empagliflozin|Empagliflozin
219476316|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
219476317|NCT04935164|OTHER|Psychiatric evaluations|At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
219476318|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
219476319|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
219476320|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
219476321|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
219476322|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
219476323|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
219476324|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
219476325|NCT00863265|OTHER|Placebo|
219476326|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
219476327|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
219476328|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
219476329|NCT04567849|BEHAVIORAL|message|patient portal message
219476330|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
219476331|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
219476332|NCT02268214|DRUG|Dapagliflozin|Tablets
219476333|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
219476334|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
219476335|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
219476336|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
219430766|NCT01590212|OTHER|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
219430767|NCT01590212|OTHER|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
219577965|NCT01851018|RADIATION|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
219430768|NCT06157372|DIAGNOSTIC_TEST|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
219430769|NCT00081939|DRUG|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
219430770|NCT00081939|DRUG|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
219430771|NCT01463124|BEHAVIORAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
219430772|NCT01463124|BEHAVIORAL|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
219430773|NCT00338260|DRUG|MK0954, /Duration of Treatment : 5 Years|
219430774|NCT00338260|DRUG|Comparator : atenolol /Duration of Treatment : 5 Years|
219430775|NCT05796349|DIAGNOSTIC_TEST|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
219430776|NCT04897594|DRUG|TERN-201|Investigational drug
219430777|NCT04897594|OTHER|Placebo|Matching placebo
219430778|NCT03387891|DEVICE|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
219430779|NCT04319640|BEHAVIORAL|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
219430780|NCT04319640|BEHAVIORAL|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
219430781|NCT03703960|OTHER|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
219430782|NCT03703960|OTHER|music|calm music conducive to relaxation
219577966|NCT01851018|RADIATION|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
219430783|NCT01721629|PROCEDURE|Sudden wean of nasal CPAP|
219430784|NCT01721629|PROCEDURE|Gradual wean of nasal CPAP|
219430785|NCT02849184|DRUG|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
219577967|NCT03784521|DEVICE|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
219577968|NCT03784521|DEVICE|Standard care|Patients are treated with standard intravenous solutions and vascular access management
219577969|NCT01099059|DRUG|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
219577970|NCT01099059|DRUG|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
219577971|NCT05060432|DRUG|EOS-448|Anti-TIGIT monoclonal antibody
219577972|NCT05060432|DRUG|pembrolizumab|Anti-PD-1 monoclonal antibody
219577973|NCT05060432|DRUG|inupadenant|A2A receptor antagonist
219577974|NCT05060432|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
219577975|NCT05060432|DRUG|SOC chemotherapies|SOC chemotherapies in 1L mNSCLC
219577976|NCT02384252|OTHER|functional tissu atrial analysis|
219577977|NCT06094452|OTHER|Computerized Cognitive Training|Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
219430786|NCT02849184|OTHER|Placebo|Placebo once daily before bedtime.
219430787|NCT00853190|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
219430788|NCT00853190|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
219430789|NCT01865838|DEVICE|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
219430790|NCT01242254|BIOLOGICAL|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
219430791|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, early treatment
219430792|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, deferred treatment
219430793|NCT03980626|BEHAVIORAL|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
219430794|NCT04526067|BEHAVIORAL|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
219430795|NCT04526067|BEHAVIORAL|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
219430796|NCT01661868|DRUG|Olaparib|Tablet formulation will be used.
219430797|NCT02835898|OTHER|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
219430798|NCT01457924|DRUG|Ofatumumab 3mg|3mg of investigational product
219430799|NCT01457924|DRUG|Ofatumumab 30mg|30mg of investigational product
219430800|NCT01457924|DRUG|Ofatumumab 60mg|60mg of investigational product
219430801|NCT01457924|DRUG|Placebo|Placebo
219430802|NCT01288586|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
219430803|NCT01002404|PROCEDURE|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
219430804|NCT05816291|DIETARY_SUPPLEMENT|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
219430805|NCT00636441|DRUG|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
219430806|NCT05228080|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
219430807|NCT04580823|DIETARY_SUPPLEMENT|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
219430808|NCT04580823|DIETARY_SUPPLEMENT|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
219476337|NCT04342390|OTHER|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
219476338|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
219476339|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
219761984|NCT06365892|OTHER|open-label placebo|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
218859477|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
219476340|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
219476341|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
219476342|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
219430809|NCT02042339|DRUG|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
219430810|NCT04350736|DRUG|TD-0903|Study drug to be administered by inhalation
219430811|NCT04350736|DRUG|Placebo|Placebo to be administered by inhalation
219430812|NCT00615251|DRUG|DR-2011|Progesterone vaginal ring for approximately 10 weeks
219430813|NCT00615251|DRUG|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
219430814|NCT06430710|DEVICE|Intrusion|2 different methods for incisor intrusion
219430815|NCT04419818|BEHAVIORAL|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
219430816|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
219430817|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
219430818|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
219430819|NCT01112423|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
219430820|NCT03495817|DRUG|ATI-50002|ATI-50002 Topical Solution
219430821|NCT03833375|OTHER|Decision Aid|Shared-decision making tool
219430822|NCT02303171|DRUG|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
219430823|NCT02303171|DRUG|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
219430824|NCT02293096|DRUG|metoprolol succinate|
219430825|NCT02293096|GENETIC|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
219577978|NCT06094452|OTHER|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
219430826|NCT02293096|PROCEDURE|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
219430827|NCT02616016|DEVICE|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
219430828|NCT03071003|DRUG|SENS-401|Oral Administration
219430829|NCT03071003|DRUG|Placebo|Oral Administration
219430830|NCT04169061|DRUG|Acthar|Acthar gel for subcutaneous injection
219430831|NCT02602171|OTHER|Oldenburger sentence test, localization test|
219430832|NCT02781454|DRUG|Mexiletine|
219430833|NCT02781454|DRUG|Placebo|
219430834|NCT04585451|DIAGNOSTIC_TEST|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
219430835|NCT04196205|BIOLOGICAL|Anti-CD19 CAR-T|1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
219577979|NCT06425770|PROCEDURE|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
219191948|NCT00449085|DEVICE|CARTO™ XP EP Navigation System V9|
219191949|NCT03565029|DRUG|XELOX|Capecitabine and Oxaliplatin (4x cycles)
219430836|NCT00593658|DRUG|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
219430837|NCT00326417|DRUG|Fludarabine|Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
219430838|NCT00326417|DRUG|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
219430839|NCT00326417|DRUG|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
219430840|NCT00326417|DRUG|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
219430841|NCT01867814|PROCEDURE|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
219577980|NCT06425770|PROCEDURE|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
219577981|NCT06425770|PROCEDURE|conventional impresion and cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
219761985|NCT06365892|OTHER|Treatment as usual|Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
219761986|NCT06352437|DRUG|BI 3034701|BI 3034701
219191950|NCT03565029|RADIATION|Radiotherapy|Pelvic radiotherapy
219191951|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
219191952|NCT05913817|BIOLOGICAL|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
219430842|NCT02441855|DEVICE|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
219430843|NCT00096590|OTHER|coagulation study|
219430844|NCT00096590|OTHER|immunoenzyme technique|
219430845|NCT00096590|OTHER|laboratory biomarker analysis|
219430846|NCT00096590|OTHER|physiologic testing|
219430847|NCT00096590|PROCEDURE|study of high risk factors|
219430848|NCT05510206|DEVICE|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
219430849|NCT00844285|DRUG|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
219430850|NCT04693689|OTHER|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
219430851|NCT04693689|OTHER|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
219430852|NCT04693689|OTHER|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
219430853|NCT04693689|OTHER|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
219430854|NCT04693689|OTHER|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
219430855|NCT04693689|OTHER|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
219430856|NCT04693689|OTHER|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
219430857|NCT04045626|PROCEDURE|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
219430858|NCT01352065|DRUG|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
219430859|NCT01352065|DRUG|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
219430860|NCT01352065|DRUG|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
219430861|NCT03485092|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
219430862|NCT03485092|DRUG|Placebo Oral Tablet|placebo tablets for oral self administration once a day
219430863|NCT01648829|DRUG|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
219430864|NCT01648829|DRUG|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
219430865|NCT01678716|BEHAVIORAL|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
219430866|NCT01678716|DIETARY_SUPPLEMENT|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
219430867|NCT01678716|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
219430868|NCT01682070|BIOLOGICAL|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
219430869|NCT01682070|BIOLOGICAL|Placebo|
219430870|NCT01995812|BEHAVIORAL|Hula and heart health education|
219430871|NCT01562704|DRUG|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
219430872|NCT01907841|OTHER|Ischemic Preconditioning|
219430873|NCT05937217|OTHER|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
219430874|NCT05937217|DEVICE|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
219430875|NCT00000196|DRUG|Naltrexone|
219430876|NCT02490917|DEVICE|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
219430877|NCT02490917|DEVICE|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
219430878|NCT00091923|DEVICE|Eye patch|
219430879|NCT00091923|DEVICE|Spectacles|
219430880|NCT00965406|DRUG|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
219761987|NCT06352437|DRUG|Placebo matching BI 3034701|Placebo matching BI 3034701
219761988|NCT03738228|DRUG|Atezolizumab|Given IV
219430881|NCT02140203|OTHER|Yoga Training|one-year experimental training (three times per week and one hour per session)
219430882|NCT02372097|DRUG|SYR-472|SYR-472 25mg, 50mg
219430883|NCT05366530|OTHER|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
219430884|NCT00321022|BEHAVIORAL|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
219430885|NCT01097148|DRUG|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
219430886|NCT03633994|DRUG|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
219430887|NCT03633994|DRUG|Normal saline|Normal saline bladder instillation
219430888|NCT01440907|OTHER|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
219430889|NCT01644981|OTHER|blood sampling|blood sampling
219430890|NCT00954837|PROCEDURE|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
219430891|NCT04163640|OTHER|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
219430892|NCT03198780|OTHER|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
219430893|NCT01273389|DRUG|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
219430894|NCT01273389|DRUG|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
219430895|NCT02608229|DRUG|BVD-523|
219430896|NCT02608229|DRUG|Nab-paclitaxel|
219430897|NCT02608229|DRUG|Gemcitabine|
219430898|NCT02608229|PROCEDURE|Tumor biopsy|
219430899|NCT04326023|DRUG|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
219430900|NCT02220946|DEVICE|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
219430901|NCT04997824|PROCEDURE|Artificial Intelligence-based atrial fibrillation catheter ablation|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above."
219430902|NCT04997824|PROCEDURE|Medical Therapy|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure"
219430903|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Plan + CHW|"* Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
219430904|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Management Plan|"* Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
219430905|NCT02190617|BEHAVIORAL|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
219430906|NCT02201355|RADIATION|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
219430907|NCT04009746|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
219430908|NCT04269655|DEVICE|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
219577982|NCT02860442|BEHAVIORAL|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
219577983|NCT02860442|OTHER|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
219577984|NCT05226559|PROCEDURE|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
219430909|NCT03718702|OTHER|ePain|Electronic pain management programme (ePain)
219430910|NCT02618343|DRUG|IPA|IPA Aromatherapy for the experimental arm
219430911|NCT02618343|DRUG|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
219430912|NCT00477555|DEVICE|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
219430913|NCT00467714|PROCEDURE|rhinoplasty|COLUMELLA STRUT PLACEMENT
219430914|NCT04526119|DRUG|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
219430915|NCT04526119|DRUG|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
219430916|NCT05389059|PROCEDURE|CAF+CM|Periodontal surgery including CAF+CM application
219430917|NCT05389059|PROCEDURE|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
219430918|NCT00001911|DRUG|Interleukin-12|
219430919|NCT01519401|DRUG|3 mg drospirenone and 20 µg ethinyl-estradiol|
219430920|NCT01519401|DRUG|3 mg drospirenone and 30 µg ethinyl-estradiol|
219430921|NCT06281405|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
219430922|NCT06281405|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
219430923|NCT06281405|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
219430924|NCT04019769|DRUG|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
219430925|NCT04631068|PROCEDURE|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
219430926|NCT03219567|DEVICE|Optical Coherence Tomography (OCT)|"Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye."
219430927|NCT03219567|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
219430928|NCT02714504|DRUG|Voriconazole or posaconazole|Azole with activity against molds
219430929|NCT05101395|OTHER|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
219430930|NCT03009812|PROCEDURE|Longitudinal uterine incision|
219430931|NCT03009812|PROCEDURE|Transverse uterine incision|
219430932|NCT03489681|DEVICE|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
219430933|NCT04070118|PROCEDURE|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
219430934|NCT02159261|DRUG|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
219430935|NCT05875376|BEHAVIORAL|Couple group therapy|"1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection"
219430936|NCT06437145|OTHER|Type of Exercise|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak. The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
219430937|NCT02849626|DRUG|Perampanel|E2007
219430938|NCT03941691|DEVICE|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
219430939|NCT03941691|DEVICE|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
219430940|NCT05589844|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
219430941|NCT05589844|PROCEDURE|Biospecimen Collection|Correlative studies
219430942|NCT05589844|BIOLOGICAL|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
219430943|NCT01654523|DEVICE|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
219430944|NCT01313208|DRUG|etanercept|Administered by subcutaneous injection once weekly.
219430945|NCT01313208|DRUG|Placebo|Placebo subcutaneous injection
219577985|NCT05226559|DRUG|Usual care|Standard pharmacological treatment alone.
219761989|NCT03738228|RADIATION|Brachytherapy|Undergo standard of care image guided brachytherapy
219430946|NCT01313208|DRUG|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
219430947|NCT01270100|BEHAVIORAL|Recovery management|
219430948|NCT06268587|COMBINATION_PRODUCT|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
219430949|NCT03258632|BEHAVIORAL|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
219430950|NCT01957787|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
219430951|NCT04176445|DEVICE|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
219430952|NCT04176445|OTHER|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
219430953|NCT02877849|DEVICE|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
219430954|NCT04393077|BEHAVIORAL|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
219430955|NCT01148316|DRUG|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
219430956|NCT01148316|BEHAVIORAL|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
219430957|NCT04571918|PROCEDURE|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
219430958|NCT04571918|PROCEDURE|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
219430959|NCT00538746|DEVICE|BIPAP|
219430960|NCT00538746|DEVICE|PSV|
219430961|NCT00538746|DEVICE|PSV + CPAP|
219430962|NCT04922034|DRUG|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
219430963|NCT05137886|DRUG|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
219430964|NCT04101435|BIOLOGICAL|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
219430965|NCT02496117|PROCEDURE|Electrical mapping, nerve stimulation checked renal denervation procedure|
219430966|NCT02496117|PROCEDURE|Electrial mapping, nerve stimulation guided renal denervation procedure|
219430967|NCT03076918|DEVICE|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
219430968|NCT03076918|DEVICE|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
219430969|NCT02581618|OTHER|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
219430970|NCT05113719|OTHER|Exercise|Both groups will perform bridge exercise
219430971|NCT01829217|DRUG|Sunitinib|
219577986|NCT02013375|PROCEDURE|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
219577987|NCT02013375|DRUG|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
219430972|NCT04046341|BEHAVIORAL|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
219430973|NCT00226395|DRUG|Oxymorphone immediate release|
219430974|NCT02679495|BEHAVIORAL|Active measures of lifestyle modification|
219430975|NCT03173612|DRUG|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
219430976|NCT01713855|BIOLOGICAL|Inactivated Trivalent Influenza vaccine|
219577988|NCT02013375|RADIATION|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
219577989|NCT02013375|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
219577990|NCT02013375|DRUG|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
219577991|NCT04810442|OTHER|Nap|45-minute nap between scanning procedures
219761990|NCT03738228|DRUG|Cisplatin|Given IV
219430977|NCT03486210|BEHAVIORAL|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
219761991|NCT03738228|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219761992|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
219761993|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
219761994|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
219761995|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
219761996|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
219430978|NCT03486210|OTHER|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
219430979|NCT01572818|PROCEDURE|phlebotomy|7 ml/kg without exceeding 500 mL
219007295|NCT06384716|OTHER|rehabilitation programme based on motor control of core muscles|The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
219430980|NCT01572818|BEHAVIORAL|dietary and lifestyle counseling|dietary and lifestyle counseling
219430981|NCT01536106|OTHER|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
219430982|NCT01536106|OTHER|Placebo control|Intracoronary infusion of autologous peripheral blood.
219430983|NCT05486936|RADIATION|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
219430984|NCT05163717|COMBINATION_PRODUCT|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
219430985|NCT05163717|COMBINATION_PRODUCT|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
219430986|NCT00440895|DRUG|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
219430987|NCT04077736|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
219430988|NCT04552717|OTHER|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
219430989|NCT01557764|DRUG|lapatinib ditosylate|Given PO
219430990|NCT01557764|BIOLOGICAL|trastuzumab|Given IV
219430991|NCT05575284|PROCEDURE|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
219430992|NCT05650515|OTHER|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
219430993|NCT06528015|DRUG|probiotics combined with enteric-coated budesonide capsule|"In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
219430994|NCT06528015|DRUG|probiotics placebo combined with enteric-coated budesonide capsules|"In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
219761997|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
219761998|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
219761999|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
219762000|NCT06170242|DRUG|EDP-323 Dose Regimen 1|EDP-323 capsule
219762001|NCT06170242|DRUG|EDP-323 Dose Regimen 2|EDP-323 capsule
219762002|NCT06170242|DRUG|Placebo|Placebo capsule
219762003|NCT04704024|DRUG|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
219577992|NCT02219971|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
219577993|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
219577994|NCT03090997|DIETARY_SUPPLEMENT|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
219577995|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
219430995|NCT04796428|DRUG|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
219430996|NCT04796428|DRUG|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
219430997|NCT04796428|DRUG|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
219430998|NCT00232440|DEVICE|BodyFIX|
219430999|NCT05893667|DIAGNOSTIC_TEST|Inflammatory markers|analysis of inflammatory scores
219431000|NCT04180501|COMBINATION_PRODUCT|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
219431001|NCT05181904|OTHER|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
219431002|NCT05165992|DRUG|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
219431003|NCT02486367|DRUG|Clopidogrel|Standard ADP receptor blockade
219431004|NCT02486367|DRUG|Ticagrelor|High potency ADP receptor blockade
219431005|NCT03859492|DEVICE|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
219577996|NCT01764282|BEHAVIORAL|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
219577997|NCT00463320|DRUG|Pazopanib eye drops and Allergen Refresh Plus eye drops|
219577998|NCT04407494|BIOLOGICAL|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
219577999|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
219578000|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
219578001|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
219431006|NCT02780596|OTHER|Item1|Does CHILD NAME often wake one or more times during the night?
219431007|NCT02780596|OTHER|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
219431008|NCT02780596|OTHER|Item3|Do you think CHILD'S SLEEP is a problem?
219431009|NCT02780596|OTHER|Item4|Do you think CHILD NAME has a sleep problem?
219431010|NCT02780596|OTHER|Item5|Do you have any concerns about CHILD NAME'S sleep?
219431011|NCT04377269|OTHER|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
219431012|NCT06044519|BIOLOGICAL|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
219578002|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
219578003|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
219578004|NCT00063414|DRUG|Alicaforsen|
219578005|NCT03898713|DIAGNOSTIC_TEST|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
219578006|NCT05662735|DEVICE|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
219578007|NCT05662735|PROCEDURE|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
219578008|NCT01378455|OTHER|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
219578009|NCT01378455|OTHER|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
219578010|NCT05935566|OTHER|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
219431013|NCT04715412|OTHER|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
219578011|NCT04014855|DRUG|Iron Supplement|in iron deficiency anemia
219578012|NCT05834166|OTHER|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
219578013|NCT02945605|OTHER|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
219578014|NCT02945605|OTHER|Standard of Care|Standard care as directed by a physician.
219578015|NCT04232813|DRUG|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
219578016|NCT04232813|DRUG|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
219578017|NCT00057213|DRUG|Radafaxine|
219578018|NCT02702713|DIETARY_SUPPLEMENT|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
219578019|NCT02702713|DIETARY_SUPPLEMENT|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
219578020|NCT02702713|DIETARY_SUPPLEMENT|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
219578021|NCT02702713|DIETARY_SUPPLEMENT|Bakery placebo|Bakery placebo: Biscuits without enrichment
219578022|NCT02702713|DIETARY_SUPPLEMENT|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
219578023|NCT02702713|DIETARY_SUPPLEMENT|Egg placebo|Egg placebo: Frozen pancakes without enrichment
219578024|NCT05882279|OTHER|No Intervention|This is a non-interventional study.
219578025|NCT02527018|DEVICE|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
219578026|NCT01475084|DEVICE|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
219578027|NCT01250483|OTHER|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
219578028|NCT03606876|DRUG|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
219578029|NCT03676699|DIAGNOSTIC_TEST|Ultrasound chest|Ultrasound detection of extravascular lung water
219578030|NCT00050232|DRUG|AVP-923|
219578031|NCT05533398|OTHER|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
219762004|NCT04704024|DRUG|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
219762005|NCT05267106|DRUG|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
219762006|NCT06004986|DRUG|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
219762007|NCT04635111|DRUG|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
219762008|NCT02329652|DEVICE|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
219762009|NCT01742299|DRUG|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
219762010|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
219762011|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
219762012|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
219431014|NCT04282681|OTHER|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
219431015|NCT04914117|DRUG|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
219431016|NCT02305875|OTHER|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
219431017|NCT00276770|OTHER|fluorine F 18 fluorothymidine|
219431018|NCT00276770|PROCEDURE|positron emission tomography|
219431019|NCT04376099|DIAGNOSTIC_TEST|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
219431020|NCT05808842|OTHER|CeraVe|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
219431021|NCT05808842|OTHER|CeraVe and Calecim|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
219431022|NCT01176370|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
219431023|NCT05200052|DRUG|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
219431024|NCT04014270|DEVICE|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
219431025|NCT04014270|OTHER|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
219431026|NCT00405652|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
219431027|NCT01637870|DEVICE|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
219431028|NCT01887106|DRUG|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
219431029|NCT01887106|DRUG|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
219431030|NCT01887106|DRUG|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
219431031|NCT01887106|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
219431032|NCT03823599|BEHAVIORAL|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
219431033|NCT03823599|BEHAVIORAL|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
219431034|NCT01090219|PROCEDURE|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
219431035|NCT00435994|DRUG|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
219431036|NCT00435994|OTHER|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
219431037|NCT05757089|DIETARY_SUPPLEMENT|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
219431038|NCT04649762|BEHAVIORAL|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
219431039|NCT04794946|BIOLOGICAL|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
219431040|NCT02941289|PROCEDURE|visual search performance of everyday objects in realistic scenes|
219431041|NCT02155348|PROCEDURE|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
219431042|NCT02155348|PROCEDURE|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
219431043|NCT02155348|DEVICE|Lentis LS-313|
219431044|NCT00772694|DRUG|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
219431045|NCT03288324|DRUG|Tofacitinib|Tofacitinib 5 mg twice daily
219431046|NCT00886717|DRUG|carboplatin|
219431047|NCT00886717|DRUG|paclitaxel-loaded polymeric micelle|
219762013|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
219762014|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
219762015|NCT06475781|DRUG|Mirivadelgat|Selective aldehyde dehydrogenase 2 (ALDH2) activator
219431048|NCT04078334|OTHER|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
219431049|NCT04078334|OTHER|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
219431050|NCT04078334|OTHER|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
219431051|NCT02790463|BEHAVIORAL|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
219762016|NCT06475781|DRUG|placebo|placebo
219431052|NCT00181935|DRUG|risperidone (Risperdal)|
219431053|NCT00181935|DRUG|olanzapine (Zyprexa)|
219431054|NCT03404635|DRUG|Apixaban|Apixaban as standard of care for VTE
219431055|NCT03404635|DRUG|Rivaroxaban|Rivaroxaban as standard of care for VTE
219431056|NCT02990455|DRUG|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
219431057|NCT03846219|DRUG|IMU-838 (30 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
219431058|NCT03846219|DRUG|IMU-838 (45 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
219431059|NCT03846219|DRUG|Placebo|"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
219431060|NCT03846219|DRUG|IMU-838 (10 mg/day)|"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
219431061|NCT04665414|DIAGNOSTIC_TEST|MRI|preoperative MRI
219431062|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound|preoperative transvaginal ultrasound
219431063|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
219431064|NCT04370912|DIAGNOSTIC_TEST|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
219431065|NCT00525408|BIOLOGICAL|Mycobacterium w.|Immunomodulator
219431066|NCT00525408|DRUG|Docetaxel|Chemotherapeutic agent
219431067|NCT01125618|OTHER|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
219431068|NCT01125618|OTHER|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
219431069|NCT02366390|BEHAVIORAL|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
219431070|NCT05109702|DRUG|0.25% Tanfanercept Ophthalmic Solution|Tanfanercept ophthalmic solution.
219431071|NCT05109702|DRUG|Placebo|Placebo vehicle solution.
219431072|NCT01396902|BEHAVIORAL|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
219431073|NCT01396902|BEHAVIORAL|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
219762017|NCT05832151|DRUG|CIN-102 Dose 15mg or 10mg|2 capsules twice daily for 12 weeks
219762018|NCT05832151|DRUG|Placebo|2 capsules twice daily for 12 weeks
218859478|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
219762019|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
219191953|NCT04175977|BEHAVIORAL|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
219191954|NCT04175977|BEHAVIORAL|Usual Care|Usual care as provided by the hospice agency
219431074|NCT06190743|OTHER|Prevention events organized by participating centers|Cardiovascular disease primary prevention events organized by centers participating in the study where capillary sampling will be performed on subjects to quantify plasma levels of cardiovascular risk factors and validated questionnaires will be administered
219431075|NCT05099237|DEVICE|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
219431076|NCT05099237|DEVICE|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
219431077|NCT05099237|DRUG|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
219431078|NCT05099237|OTHER|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
219431079|NCT05099237|DIAGNOSTIC_TEST|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~* Baseline blood sample during study enrolment~* Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~* Post CAR T-cell infusion:~  * Day 1~ * Day 3~ * Day 6~ * Day 9~ * Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
219431080|NCT05099237|OTHER|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
219431081|NCT06049615|DEVICE|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
219431082|NCT00475800|DRUG|Lumiracoxib|
219431083|NCT03812588|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
219431084|NCT03812588|DRUG|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
219431085|NCT01725256|DRUG|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
219431086|NCT04172337|BEHAVIORAL|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
219431087|NCT04172337|BEHAVIORAL|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
219431088|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431089|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219762020|NCT01900132|DEVICE|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
219762021|NCT01900132|DEVICE|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
219762022|NCT01900132|DEVICE|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
219762023|NCT01900132|DEVICE|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
219191955|NCT06150339|OTHER|OASIS Walking Intervention|Communication Care Plan, Sit to Stand Activity, Walking Program
219431090|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
219431091|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431092|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431093|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
219431094|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431095|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431096|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
219431097|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431098|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431099|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
219431100|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431101|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
219431102|NCT01025011|DEVICE|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
219431103|NCT02322411|DEVICE|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
219431104|NCT02322411|BEHAVIORAL|Compensatory approaches|
219431105|NCT02679807|BIOLOGICAL|Bifidobacterium animalis subsp. lactis Bl-04|
219431106|NCT02679807|OTHER|sucrose|
219431107|NCT02747771|BEHAVIORAL|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
219431108|NCT00180271|DEVICE|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
219431109|NCT00180271|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
219431110|NCT04350905|OTHER|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
219431111|NCT03780491|OTHER|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
219476343|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
219476344|NCT05339139|COMBINATION_PRODUCT|Dialysis|In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
219476345|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
219476346|NCT04563039|DEVICE|Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer|Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.
219476347|NCT04563039|DEVICE|Standard Ureteroscopic Laser Lithotripsy|Standard of care Ureteroscopic Laser Lithotripsy
219476348|NCT05035394|PROCEDURE|Cataract surgery|Cataract Surgery in a standardized fashion
219476349|NCT05035394|PROCEDURE|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
219476350|NCT05035394|PROCEDURE|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
219431112|NCT02610205|OTHER|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
219431113|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
219431114|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
219431115|NCT01473329|OTHER|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
219431116|NCT01977339|DRUG|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
219431117|NCT01977339|DRUG|Bupivacaine|20 cc of 0.25% bupivacaine
219431118|NCT04588831|DEVICE|Mouthguard|Protective device for orofacial complex for patients playing contact sports
219431119|NCT03655392|BEHAVIORAL|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
219431120|NCT03655392|DIAGNOSTIC_TEST|Induced sputum collection|All participants performed induced sputum collection
219431121|NCT03655392|DIAGNOSTIC_TEST|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
219431122|NCT03655392|DIAGNOSTIC_TEST|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
219431123|NCT03655392|OTHER|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
219431124|NCT03655392|OTHER|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
219431125|NCT03655392|DIAGNOSTIC_TEST|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
219431126|NCT03655392|DIAGNOSTIC_TEST|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
219762024|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219431127|NCT02266732|DEVICE|Stimuplex HNS 12|
219431128|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
219431129|NCT01892644|OTHER|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
219431130|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
219431131|NCT00048789|PROCEDURE|Extracorporeal Photopheresis|
219431132|NCT06206902|DRUG|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
218859479|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
219431133|NCT04564066|BIOLOGICAL|efgartigimod IV|intravenous infusions of efgartigimod
219431134|NCT04564066|BIOLOGICAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
219578032|NCT02757976|DEVICE|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
219431135|NCT03159806|DEVICE|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
219762025|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219431136|NCT04696237|OTHER|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
219431137|NCT05279716|DRUG|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
219431138|NCT03788863|DRUG|Diflucortolone valerate (BAY866146)|Follow clinical administration
219431139|NCT01338935|DRUG|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
219431140|NCT01338935|DRUG|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
219431141|NCT01338935|DRUG|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
219431142|NCT01052519|OTHER|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
219431143|NCT05247541|DRUG|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
219431144|NCT00532714|DRUG|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
219431145|NCT04097015|DEVICE|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
219431146|NCT04011800|PROCEDURE|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
219578033|NCT02757976|DEVICE|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
219431147|NCT04011800|COMBINATION_PRODUCT|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
219431148|NCT04286828|OTHER|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
219431149|NCT04286828|OTHER|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
219431150|NCT04286828|OTHER|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
219578034|NCT04078880|DIETARY_SUPPLEMENT|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
219578035|NCT04037930|BEHAVIORAL|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
219578036|NCT06357663|OTHER|Mindfulness practice with Calligraphy|The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
219578037|NCT02553278|DEVICE|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
219578038|NCT02553278|DEVICE|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
219578039|NCT01334710|DRUG|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
219578040|NCT05336110|OTHER|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
219578041|NCT03074747|DIAGNOSTIC_TEST|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
219578042|NCT01558297|BEHAVIORAL|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
219578043|NCT01558297|BEHAVIORAL|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
218859480|NCT00113750|BIOLOGICAL|TreeMATA MPL|
219431151|NCT05500183|BEHAVIORAL|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
219431152|NCT05500183|BEHAVIORAL|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
219431153|NCT02013128|DRUG|Ublituximab|Ublituximab (IV infusion)
219431154|NCT02013128|DRUG|Ibrutinib|Ibrutinib oral daily dose
219431155|NCT04457128|BEHAVIORAL|Just-in-Time Adaptive Intervention|Randomized factorial design
219431156|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
219431157|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
219431158|NCT03428451|DRUG|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
219431159|NCT02461394|DEVICE|Blood glucose monitoring systems for self-testing|
219431160|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
219431161|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
219431162|NCT01294982|DRUG|Placebo|Placebo Oral Capsules twice daily
219431163|NCT02713789|DRUG|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
219431164|NCT02713789|DRUG|Placebo (PBS-20% sucrose)|
219431165|NCT01564667|BEHAVIORAL|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
219431166|NCT05082506|BEHAVIORAL|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
219431167|NCT03674333|DIETARY_SUPPLEMENT|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
219431168|NCT03674333|OTHER|Placebo|Placebo - a sugar pill
219431169|NCT00897052|GENETIC|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
219431170|NCT00897052|OTHER|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
219431171|NCT03161782|OTHER|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
218859481|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
218859482|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
219431172|NCT03161782|OTHER|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
218859483|NCT02454062|DRUG|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
218859484|NCT02454062|DRUG|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
218859485|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
218859486|NCT01309776|DRUG|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
218859487|NCT01309776|DRUG|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
218859488|NCT00771290|PROCEDURE|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
219431173|NCT03161782|OTHER|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
218859489|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
218859490|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
218859491|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
219431174|NCT03161782|OTHER|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
219431175|NCT00960713|DRUG|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
219431176|NCT05569564|PROCEDURE|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
219431177|NCT05569564|PROCEDURE|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
219431178|NCT01683084|DRUG|Telmisartan|
219431179|NCT01683084|DRUG|Placebo|
219431180|NCT00061503|DRUG|Travoprost|
219431181|NCT00387270|DRUG|Dimebon|Dimebon 10 or 20 mg TID x 7 days
219431182|NCT00367432|DRUG|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
219431183|NCT00610285|OTHER|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
219431184|NCT00191737|DRUG|Atomoxetine|
219431185|NCT00903370|PROCEDURE|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
219431186|NCT00903370|DEVICE|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
219431187|NCT03950999|OTHER|Placebo|Sugar pill
219431188|NCT03683056|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
219431189|NCT00615797|BIOLOGICAL|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
219431190|NCT00615797|DRUG|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
219431191|NCT00014911|PROCEDURE|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
219431192|NCT00014911|DRUG|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
219431193|NCT00014911|DRUG|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
219431194|NCT00014911|DRUG|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
219431195|NCT00014911|DRUG|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
219431196|NCT00014911|DRUG|Ganciclovir|An antiviral used to kill viruses and stop viral replication
219431197|NCT00014911|DRUG|Trimethoprim|An antibacterial used to prevent opportunistic infections
219431198|NCT00014911|DRUG|Pentamidine|An antiprotozoal used to prevent disease
219431199|NCT04000347|DRUG|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
219431200|NCT04000347|DRUG|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
219431201|NCT02452177|DRUG|Vitamin D|
219578044|NCT01558297|BEHAVIORAL|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
219431202|NCT03256409|OTHER|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
219431203|NCT03256409|OTHER|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
219431204|NCT02165345|DRUG|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
219431205|NCT05599698|OTHER|Chemotherapy|Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
219431206|NCT05113498|DIETARY_SUPPLEMENT|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
219431207|NCT04391972|DEVICE|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
219431208|NCT06063239|OTHER|Test Group|Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days
219431209|NCT06063239|OTHER|Positive Control|Subjects will receive orally administred probiotics based on placebo 90 days
219431210|NCT06063239|OTHER|Negative Control|Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
219431211|NCT04711499|BEHAVIORAL|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
219431212|NCT01924299|DRUG|Baricitinib|Administered orally
219431213|NCT01924299|DRUG|Ketoconazole|Administered orally
219431214|NCT01924299|DRUG|Fluconazole|Administered orally
219578045|NCT00001253|BEHAVIORAL|cognitive tests and scales|
219578046|NCT03231319|PROCEDURE|Fascia iliaca compartment block with IV-PCA|1\. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
219431215|NCT00871091|PROCEDURE|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
219431216|NCT00871091|PROCEDURE|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
219431217|NCT00871091|PROCEDURE|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
219431218|NCT00568282|PROCEDURE|phlebotomy|Standard of care
219431219|NCT00605072|DRUG|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
219431220|NCT00605072|DRUG|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
219431221|NCT00605072|DRUG|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
219431222|NCT00605072|DRUG|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
219431223|NCT00605072|DRUG|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
219431224|NCT06383689|OTHER|Seizure placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
218859492|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
218859493|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
219431225|NCT06383689|OTHER|Well-being placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
219431226|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
219191956|NCT05334862|PROCEDURE|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and distal femur and fixation by using 8 plate and screws.
219431227|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
219431228|NCT05877703|OTHER|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
219431229|NCT05877703|OTHER|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
219431230|NCT05805670|OTHER|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
219431231|NCT04101734|DEVICE|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
219431232|NCT04101734|DEVICE|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
219431233|NCT04283357|OTHER|Exercise|Short Foot Exercises
219431234|NCT04283357|DEVICE|Virtual Reality|Exercise with virtual reality
219431235|NCT00005015|DRUG|Fluoxetine|
219431236|NCT03118011|OTHER|No smoking|No smoking
219431237|NCT03118011|OTHER|Smoking|Ability to go out to smoke
219431238|NCT05833971|DRUG|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
219431239|NCT01768234|OTHER|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
219431240|NCT03328585|BEHAVIORAL|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
219431241|NCT03328585|BEHAVIORAL|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
219431242|NCT03328585|OTHER|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
219431243|NCT06700148|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
219431244|NCT06700148|BIOLOGICAL|MPSV4|1 dose of MPSV4 on Day0
219191957|NCT06333639|OTHER|orthopaedic surgery|usual procedures for an orthopaedic surgery
219191958|NCT06333639|OTHER|orthopaedic surgery and fitted with a virtual reality headset|usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
219191959|NCT06420167|DRUG|Dapagliflozin|10mg orally once daily
219191960|NCT05164055|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
219431245|NCT01999946|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
219431246|NCT02595840|DRUG|Afatinib|
219431247|NCT02595840|DRUG|Pemetrexed|
219431248|NCT06876012|OTHER|Tai Chi Program|Twelve sessions (six weeks) of a Tai Chi Program to assist with balance and fall risk.
219431249|NCT04144855|DRUG|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
219431250|NCT02850952|OTHER|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
219431251|NCT04213508|DRUG|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
219431252|NCT04213508|DRUG|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
219431253|NCT05884359|DIAGNOSTIC_TEST|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
219431254|NCT06894862|DRUG|NYR-BI03|Participants receive NYR-BI03 nanosuspension formulated for continuous intravenous infusion to be given over 3 hours or 6 hours.
219431255|NCT06894862|DRUG|Matching placebo (all cohorts)|Administered as a continuous intravenous infusion over 3 hours or 6 hours
219431256|NCT03358654|DRUG|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
219431257|NCT02437487|DRUG|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
219431258|NCT02437487|DRUG|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
219431259|NCT07090850|BEHAVIORAL|Puzzle education group|It was evaluated the effect of using puzzles as a teaching technique in a nursing practice course.
219431260|NCT07091695|BIOLOGICAL|Nivolumab + relatlimab|As prescribed by the treating clinician
219431261|NCT07091695|BIOLOGICAL|Nivolumab + ipilimumab|As prescribed by the treating clinician
219431262|NCT07090980|OTHER|epilepsy education via podcast|Epilepsy education via podcast has never been provided in any clinical study in Turkey before. By providing education via podcast, we have made health education more accessible and repeatable.
219431263|NCT07090941|PROCEDURE|Endovascular Treatment|The vascular access route is selected based on the patient's anatomical characteristics and operator discretion. Endovascular treatment (EVT) procedures must adhere to each participating center's standardized operating protocols. Upon confirmation of vascular occlusion, EVT may be performed using devices approved by China's National Medical Products Administration (NMPA). Based on lesion-specific features and operator judgment, permissible techniques include stent retriever thrombectomy, aspiration thrombectomy, balloon angioplasty with or without stenting, or intra-arterial thrombolysis. Investigational devices are strictly prohibited.
219431264|NCT07092371|BEHAVIORAL|Digital Multimodal Intervention|Participants will undergo a 6-month multimodal intervention via a digital platform, which includes: (1) Personalized cognitive training; (2) Self-monitoring and management of stroke risk factors including hypertension, dyslipidemia, diabetes, smoking and obesity; (3) Smart wristband-based exercise monitoring and management; (4) Smart wristband-based sleep monitoring and management; (5) Health dietary recording and guidance
219431265|NCT07090707|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
219431266|NCT07090707|RADIATION|radiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
219431267|NCT07091773|DEVICE|OLIZ Photobiomodulation Device|OLIZ device utilizes dual-wavelength technology combining specific red (660nm) and near-infrared (850nm) light parameters optimized for post-surgical tissue healing. The device features controlled power density, precise treatment duration protocols, and targeted application to knee arthroplasty surgical sites. Treatment parameters include specific irradiance levels, treatment session duration of 15 minutes, and 3 times of daily application frequency designed.
219431268|NCT07091227|DRUG|AK112+oxaliplatin+capecitabine|participants will receive standard dose treatment of AK112 combined with oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery.
219431269|NCT07091227|DRUG|oxaliplatin+capecitabine|participants will receive standard dose treatment of oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery
219431270|NCT07091266|DEVICE|Sacral Neuromodulation (SNM)|A standardized two-stage implantation protocol was used. In Stage 1, a temporary lead (InterStim 3093, Medtronic) was implanted at the S3 sacral foramen under fluoroscopic guidance. Patients with ≥50% improvement in urinary symptoms over a 7-day test period proceeded to Stage 2, where a permanent neurostimulator (InterStim 3058, Medtronic) was implanted subcutaneously. Stimulation parameters were adjusted (amplitude: 0.5-10 V; frequency: 14 Hz; pulse width: 210 μs) to optimize symptom control.
219431271|NCT07091266|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|Patients received two 20-session courses (5 sessions/week) in a hyperbaric chamber at 2.0 atmospheres absolute (ATA). Each session consisted of 60 minutes of 100% oxygen inhalation, bracketed by compression and decompression periods.
219431272|NCT07092410|DRUG|Encorafenib & Binimetinib Treatment|The SuRage-EB post approval study will evaluate prospectively the potential impact of local treatment of melanoma metastases under encorafenib (E) + binimetinib (B) combination therapy while continuing EB therapy thereafter. It focusses on single melanoma metastases which develop resistance or show no response during EB treatment. These metastases will be treated locally before registration of the patients into the study. Directly after or during local treatment, EB combination therapy will be resumed. Locally treated EB-resistant melanoma cells cannot continue to grow during targeted therapy and the positive response may be prolonged.
219431273|NCT07090733|OTHER|Interscalene brachial plexus block|Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.
218859494|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
218859495|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
218859496|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
219431274|NCT07090733|OTHER|Suprascapular nerve block|Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.
219431275|NCT07090733|OTHER|Anterior glenoid block|Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.
218859497|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
219431276|NCT07090733|OTHER|Suprascapular nerve block + Anterior glenoid block|Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.
219431277|NCT07092124|DEVICE|test visionumVR|Two evaluation sessions with VisionumVR one month apart
219431278|NCT07090928|DRUG|5 ml of 0.5% bupivacaine infiltrated at each port site|5 ml of 0.5% bupivacaine infiltrated at each port site after the arthroscopic procedures
219431279|NCT07090928|DRUG|Placebo|5ml 0.9%normal saline infiltrated at port site
219431280|NCT07091383|OTHER|Exercise|Static stretching
218859498|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
218859499|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
219431281|NCT07091383|OTHER|Exercise|Soft Tissue Mobilization
219431282|NCT07091383|OTHER|Exercise|Functional soft tissue mobilization
219431283|NCT07091877|BEHAVIORAL|Cognitive Reappraisal|Cognitive Reappraisal (CR) is a cognitive-behavioral technique and will complete the Cognitive Reappraisal task.
219431284|NCT07091877|BEHAVIORAL|Control cue-reactivity task|Participants will complete a control cue-reactivity task.
219476351|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
219476352|NCT06103734|COMBINATION_PRODUCT|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
219476353|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
219476354|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
219476355|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
219476356|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
219476357|NCT05412225|DIAGNOSTIC_TEST|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
219476358|NCT05412225|RADIATION|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
219476359|NCT05412225|PROCEDURE|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
219476360|NCT06578624|DRUG|SA53-OS (phase 1)|Dose escalation phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years. Single participant cohorts will be enrolled until a Grade 2 or greater toxicity is observed and then 3+3 multi-participant cohorts will be enrolled until the MTD is identified.
219476361|NCT06578624|DRUG|SA53-OS (phase 2)|Dose expansion phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years at the MTD identified in phase 1.
219476362|NCT05836857|BEHAVIORAL|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
219476363|NCT05836857|BEHAVIORAL|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
219476364|NCT04950426|DRUG|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
219476365|NCT06192108|DRUG|Orforglipron|Administered orally
219476366|NCT06192108|DRUG|Dapagliflozin|Administered orally
219476367|NCT01891318|RADIATION|radiosurgery|Undergo radiosurgery
219476368|NCT01891318|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219476369|NCT01891318|PROCEDURE|quality-of-life assessment|Ancillary studies
219476370|NCT06523725|DRUG|PO BRC-003 (High Cannabidiol Cannabis Extract)|The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).
219476371|NCT06523725|DRUG|Placebo|Placebo
219476372|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
219476373|NCT06350630|DRUG|Hydroxychloroquine Oral Tablet|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
219476374|NCT06350630|DRUG|Placebo oral tablet|placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
219476375|NCT05685355|DIAGNOSTIC_TEST|Standardized intraoral photography|Mouth photos will be taken with a plastic retractor to retract the subject's cheek and lips. This is a standard clinical procedure that is non-invasive and does not cause any harm or adverse effect on subjects.
219476376|NCT00318357|DEVICE|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
219476377|NCT00318357|DEVICE|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
219476378|NCT02643992|OTHER|DOAC concentration measurement|
219762026|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219762027|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219762028|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219431285|NCT07090902|BEHAVIORAL|Progressive Relaxation-Based Childbirth Preparation Program|This intervention consists of a childbirth preparation program that integrates progressive muscle relaxation (PMR) exercises. Participants receive face-to-face education by trained health professionals, a printed booklet explaining both childbirth preparation and PMR techniques, and an audio CD with guided relaxation sessions produced by the Turkish Psychological Association. The participants are instructed to perform the relaxation exercises daily at home until delivery. The goal of this intervention is to reduce labour pain, support informed mode of delivery preference, and enhance breastfeeding comfort in the early postpartum period.
219476379|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
219476380|NCT03982381|DRUG|Metformin|Active comparator
218859500|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
219476381|NCT03982381|DRUG|Dapagliflozin 10 MG|Experimental treatment
219476382|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
219476383|NCT05124886|OTHER|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
219476384|NCT05266144|PROCEDURE|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
219476385|NCT05932875|OTHER|Exercise Training|4 day per week concurrent exercise training program
219476386|NCT02981979|DRUG|Leflunomide(LEF)|"Leflunomide:~For LEF arm, 20mg per day, p.o. through the whole study. For placebo group, 20mg per day, p.o. from week 25 to week 52."
219476387|NCT02981979|DRUG|Prednisone Acetate Tablets|Prednisone (5mg/tab): basic therapy, start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day.
219476388|NCT02981979|DRUG|Placebos|2 tabs/d used in placebo arm for the first 24 weeks.
219476389|NCT00696592|DRUG|Bevacizumab (Avastin), Verteporfin (Visudyne)|
219476390|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
219476391|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
219476392|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
219476393|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
219476394|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
219476395|NCT02259777|OTHER|high fat, high caloric meal|
219476396|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
219476397|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219476398|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219578047|NCT03231319|PROCEDURE|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
219578048|NCT03231319|PROCEDURE|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
218859501|NCT03654885|DEVICE|XEN-45 Gel Stent|XEN-45 gel stent device implant
219431286|NCT07091903|OTHER|Diaphragmatic breathing exercise|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. Diaphragmatic breathing exercise was performed with the participants in a supine position with bent knees, 10 repetitions and 3 sets.
219431287|NCT07091903|OTHER|Conventional physiotherapy and post-isometric relaxation technique|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included conventional physiotherapy and post-isometric relaxation technique. Conventional treatment included an exercise program consisting of Wand, Codman, and finger ladder exercise, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities. Each of the exercises was applied as 10 repetitions and 1 sets. Post-isometric relaxation technique was applied with 5 seconds of isometric contraction in the direction of flexion, abduction, internal and external rotation, 5 repetitions, 2 sets.
219431288|NCT06910202|BEHAVIORAL|Manipulation of nicotine/tobacco product price and availability|"This study does involve experimental manipulation of nicotine/tobacco product price and availability to understand consumers' behavior. Participants will be provided with a commercially available e-cigarette to use during the study, if they wish.~Every participant will purchase tobacco products in an online store under four different scenarios: a) cigarette flavor restricted and e-cigarette flavor restricted, b) cigarette flavor unrestricted and e-cigarette flavor restricted, c) cigarette flavor restricted and e-cigarette flavor unrestricted, d) cigarette flavor unrestricted and e-cigarette flavor unrestricted."
219431289|NCT07089953|OTHER|Questionnaire|Complete 3 questionnaires about your emotions and your trust in doctors.
219431290|NCT07089953|OTHER|Video|Four (4) videos, each 4 minutes long, have been made for use in this study.
219431291|NCT07092345|BEHAVIORAL|adaptive intervention|We will utilize an adaptive interventions via Sequential Multiple Assignment Randomized Trial (SMART) design provide a tailored, stepped-care approach for the type, intensity, and dose of treatment, thus, providing the most intensive care to only those who need it, particularly treatment non-response. First, youth and caregivers (dyads) will be randomized to receive 1st-stage interventions in the ED, either the digital psychosocial-only (PS) condition or the psychosocial with digital health communication (PS+text) condition. If identified as non-response at 2-weeks, then dyads will be re-randomized to 2nd-stage intervention(s). Specifically, the PS condition non-responders will be re-randomized to the PS+text condition or the PS+text+FN condition. The 1st-stage PS+text condition non-responders will receive the PS+text+FN condition only.
219431292|NCT07090551|DEVICE|occlusal splint therapy|Patients with myofascial pain will receive occlusal splint therapy, which is a clinically accepted treatment method.
219431293|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF neutral pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
219431294|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
219431295|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µM|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
219431296|NCT07092215|DRUG|LPS 5 ng / SIF neutral pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
219431297|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
219578049|NCT06881498|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
219578050|NCT05473819|DRUG|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
219578051|NCT05473819|DRUG|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
219578052|NCT05301530|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
219578053|NCT05301530|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
218859502|NCT03654885|PROCEDURE|Trabeculectomy|Trabeculectomy surgery
219191961|NCT03976544|DRUG|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
219431298|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH + BCTC 1 µM|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
219431299|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
219431300|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to 5.7)
219431301|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
219431302|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4 to pH 5.7)
219431303|NCT07092332|BEHAVIORAL|Multimodal treatment|"Vulvodynia Intervention adapted for late adolescents and young adults. A multimodal treatment for provoked vulvodynia~The treatment consists of 11 treatment sessions. Working with goal-directed behavior change that has both physiological and psychosocial components. The treatment sessions will be conducted with various professionals, bot simultaneously and separately.~The intervention is based on physiological and psychosocial components working with goal-directed behavioral change; both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are between 60 to 90 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions."
219431304|NCT06928155|DEVICE|Immersive Virtual Reality with Head Mounted Display|"The intervention will be carried out with an immersive virtual reality device, specifically, with a head mounted display. Specifically, it is the MetaQuest 3 model."
219431305|NCT06928155|OTHER|Aerobic exercise and strength training|The combination of aerobic and strength training is part of the conventional physiotherapy treatment carried out at the center.
219431306|NCT01091909|PROCEDURE|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
219431307|NCT06393894|DIAGNOSTIC_TEST|Near infrared spectroscopy|Near infrared spectroscopy (NIRS) is an intravascular imaging technique. Patients after coronary angiography with or without angioplasty will undergo NIRS if deemed suitable by the interventionalist. NIRS has a high sensitivity and specificity for lipid core plaque detection.
219431308|NCT06393894|GENETIC|Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.|Patients without explicit atherosclerosis risk factors and known genetic disorders will undergo genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 genes in order to evaluate the presence of gene variations as a cause for early atherosclerosis. MiRNA-126, -145 and -155 expression in patients serum samples will be evaluated and correlated with plaque lipid core in near infrared spectroscopy (NIRS) imaging.
219431309|NCT04690257|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
219431310|NCT01962285|DRUG|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
219431311|NCT06919614|DIAGNOSTIC_TEST|Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing|Xpert® CT/NG and TV testing
219431312|NCT06921473|DRUG|Norepinephrine|Intravenous bolus of norepinephrine (5-10 µg) to treat spinal anesthesia-induced hypotension during cesarean section.
219431313|NCT06921473|DRUG|Ephedrine|Intravenous bolus of 5-10 mg ephedrine administered as needed to treat maternal hypotension following spinal anesthesia during elective cesarean section. The drug is prepared in identical, unlabeled syringes to ensure blinding.
219431314|NCT02005224|OTHER|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
219578054|NCT05301530|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
219578055|NCT06716879|DRUG|Donzakimig|Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
219578056|NCT06716879|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Subcutaneous solution
219578057|NCT00375492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
219431315|NCT03258463|OTHER|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
219578058|NCT00375492|DRUG|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
219578059|NCT06181747|DEVICE|a serious mobile device-based game prototype (Save the Muse Home)|The cognitive impairment corresponding to the symptoms, which we are interested in, focuses on executive inhibition, motor inhibition, sustained attention, selective attention, working memory, and planning ability. The training content will be presented in different scenarios as effective training components. The story line of the warrior breakthrough runs through the whole game, each level is adapted according to the functional damage areas of different patients, and each level involves reward and punishment mechanisms to keep the interest of the players, the difficulty gradient of each level is kept moderate, and the game includes design elements such as space, time, object attributes, actions, rules, skills, and probabilities, etc., which ultimately completes Save the Muse Home, a serious game for the treatment of ADHD.
219578060|NCT01937247|PROCEDURE|Patients will be inducted in the induction room|The patients will be inducted in the induction room
219431316|NCT01379924|BEHAVIORAL|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
219431317|NCT01379924|OTHER|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
219431318|NCT03516734|DIETARY_SUPPLEMENT|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
219431319|NCT03516734|OTHER|Non Iron-fortified lentils|Non-fortified lentils will be provided
219431320|NCT03516734|OTHER|Usual Intake|No lentils will be provided.
219431321|NCT06924814|BEHAVIORAL|Standard of Care|Participant is allowed to use what they will use as a distraction tool while they are receiving treatment.
219431322|NCT06924814|BEHAVIORAL|Immersive technology|Participants will be randomly assigned to one of the following four groups; VR headsets, a bluetooth haptic device (Buddy Guard), a screen and projector (BERT), and a tablets with a game. Participant's anxiety will be assessed and pre- and post-intervention assessments will be completed.
219431323|NCT06829277|COMBINATION_PRODUCT|Sodium fluoride varnish|Sodium fluoride varnish
219431324|NCT06829277|OTHER|Curodont De Senz|Curodont De Senz
219431325|NCT06829277|COMBINATION_PRODUCT|Curodont De Senz plus laser irradiation|Curodont De Senz plus laser irradiation
219431326|NCT06829277|DEVICE|Laser irradiation|Laser irradiation
219578061|NCT01937247|PROCEDURE|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
219578062|NCT01937247|DRUG|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
219007296|NCT06185504|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows~1. The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~2. Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~3. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~4. Direct feeding training: with powdered milk, once a day, 5 days a week."
219191962|NCT03976544|DRUG|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
219431327|NCT02158702|DRUG|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
219431328|NCT00315978|DEVICE|Heart-to-Heart Decision Aid|
219431329|NCT01606293|BEHAVIORAL|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
219431330|NCT03801356|DRUG|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
219431331|NCT06937580|BEHAVIORAL|Peer Support and Baby Box|The intervention consists of five one-on-one peer support sessions and a Baby Box consisting of a woolen hat and socks for infant warmth, a cloth wrap to position the baby securely for skin-to-skin contact and improve comfort, a bar of soap for hygiene, and a real-time continuous temperature monitoring device for hypothermia detection
219431332|NCT01736631|BEHAVIORAL|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
219431333|NCT04552431|DRUG|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
219431334|NCT04552431|DRUG|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
219431335|NCT04552431|DRUG|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
219431336|NCT04552431|DRUG|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
219431337|NCT01230749|DRUG|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
219431338|NCT01230749|DRUG|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
219431339|NCT01230749|DRUG|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
219431340|NCT00002717|DRUG|cisplatin|
219191963|NCT05818553|DRUG|PRAX-562|Once daily oral or G-tube treatment.
219431341|NCT00002717|DRUG|paclitaxel|
219431342|NCT01017341|DEVICE|PSU hip protector|hip protetor
219431343|NCT04021706|DRUG|Anamorelin Hydrochloride|Ghrelin receptor agonist
219431344|NCT04021706|DRUG|Placebo|placebo is a inert substance
219431345|NCT04345302|BEHAVIORAL|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
219431346|NCT04345302|BEHAVIORAL|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
219431347|NCT02354092|PROCEDURE|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
219431348|NCT02354092|PROCEDURE|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
219431349|NCT02354092|PROCEDURE|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
219431350|NCT02354092|PROCEDURE|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
219431351|NCT02354092|BEHAVIORAL|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
219431352|NCT02354092|DRUG|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
219431353|NCT04008199|OTHER|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
219431354|NCT02999815|PROCEDURE|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
219431355|NCT02999815|PROCEDURE|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
219431356|NCT01923571|OTHER|intraoperative BGC measure|
219431357|NCT05031572|OTHER|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
219431358|NCT02870257|OTHER|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
219431359|NCT02870257|OTHER|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
219431360|NCT05728762|DEVICE|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
219431361|NCT01756638|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
219431362|NCT01756638|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
219431363|NCT01300585|OTHER|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
219431364|NCT00355134|DRUG|Fingolimod|Fingolimod capsules for oral administration
219431365|NCT00355134|DRUG|Placebo|Matching placebo capsules for oral administration.
219431366|NCT05912348|BEHAVIORAL|Low Physical Activity and Added Carbohydrate Group|Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
219578063|NCT01937247|PROCEDURE|STANDARD PROCESS|standard process
219578064|NCT04339751|DRUG|Vorinostat|Administration of Vorinostat
219431367|NCT05912348|BEHAVIORAL|Low physical Activity Control|Young men and women will transition into a low physically active lifestyle for 10 days.
219431368|NCT05912348|BEHAVIORAL|High Physical Activity and Added Carbohydrate Group|Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
219431369|NCT01257672|DRUG|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
219578065|NCT01513564|DRUG|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
219578066|NCT01513564|DRUG|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
219578067|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences. A patient navigator supports the patient/caregiver and social worker dynamic by helping patients access care and resources. The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
219578068|NCT01232491|DRUG|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
219578069|NCT01232491|DIETARY_SUPPLEMENT|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
219578070|NCT06928857|DEVICE|EMG-based FES rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises while using the FitFES device.
219578071|NCT06928857|OTHER|Traditional rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises.
219578072|NCT06927726|DRUG|4% Articaine HCL With 1:100,000 Epinephrine|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Septanest 4% Articaine HCL With 1:100,000 Epinephrine. The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
219578073|NCT06927726|DRUG|3% plain mepivacaine HCL|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Scandonest 3% plain mepivacaine HCL (Septodont, Manufactured By Novocol Pharmaceuticals of Canada). The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
219578074|NCT06927687|BIOLOGICAL|ZG005 for Injection|Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
219578075|NCT06928779|DRUG|Dazucorilant|Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration
219578076|NCT06926933|DRUG|Eligard® 45 mg|45 mg of leuprolide acetate
219578077|NCT01427166|OTHER|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
219578078|NCT01081314|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
219578079|NCT01081314|BEHAVIORAL|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
219578080|NCT06710457|OTHER|ESP|Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.
219578081|NCT06710457|OTHER|No ESP|Patients will receive standard medical treatment to prevent PONV and postoperative pain.
219578082|NCT03077529|DIETARY_SUPPLEMENT|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
219578083|NCT03077529|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
219578084|NCT06927518|OTHER|Receptive language intervention by using the total communication|Receptive language intervention using Total Communication (TC) for children with autism can be highly effective. Total Communication involves using a combination of communication methods to support language comprehension and expression. It recognizes that individuals with autism often benefit from multi-modal communication rather than relying solely on spoken language.
219578085|NCT06731374|BIOLOGICAL|PCV15|VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.
219578086|NCT06731374|BIOLOGICAL|Streptococcus pneumoniae serotype 3|Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.
219578087|NCT06731374|BIOLOGICAL|Placebo|The placebo consists of 0.9% sodium chloride for injection
219578088|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
219578089|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
219578090|NCT06702033|RADIATION|Radiation therapy|IMRT or IMPT
219578091|NCT06702033|DRUG|Cisplatin|Dose of 100 mg/m\^2 IVPB over 60 minutes
219578092|NCT06702033|PROCEDURE|Surgery|Standard of care
219578093|NCT03801421|PROCEDURE|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
219431370|NCT01257672|DRUG|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
219431371|NCT01257672|DRUG|placebo|placebo
219431372|NCT04928313|DRUG|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
219431373|NCT01412151|DRUG|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
219431374|NCT00533299|DRUG|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
219431375|NCT00533299|DRUG|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
219431376|NCT04898868|PROCEDURE|cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
219431377|NCT04898868|PROCEDURE|Umbilical cord miking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
219431378|NCT00049972|DRUG|paroxetine CR|
219431379|NCT04540783|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
219431380|NCT00520650|DRUG|Aripiprazole|
219431381|NCT02868164|DRUG|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
219578094|NCT03801421|PROCEDURE|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
219578095|NCT00885014|BEHAVIORAL|CBT|Telephone cognitive-behavioral therapy
219578096|NCT00885014|BEHAVIORAL|EAP|Employees Assistance Program
219578097|NCT02716350|DIETARY_SUPPLEMENT|B-GOS|comparison versus placebo
219578098|NCT02716350|DIETARY_SUPPLEMENT|Maltodextrin|placebo
219578099|NCT01706874|OTHER|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
219578100|NCT05565339|DEVICE|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
219431382|NCT02868164|DRUG|Standard Treatment|Standard Treatment
219431383|NCT02868164|OTHER|Weight Reduction|routine exercise for weight reduction
219431384|NCT02811172|OTHER|BEhavior of biomarkers during pregnanCy and lactatiOn|
219431385|NCT00713284|DRUG|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
219431386|NCT03127852|DEVICE|Medly|
219431387|NCT01451866|OTHER|resistance training|hypertrophic resistance training
219431388|NCT01451866|OTHER|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
219431389|NCT00741104|DRUG|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
219431390|NCT02813590|OTHER|Ascitic fluid puncture|
219431391|NCT02813590|OTHER|Skin swaps from puncture side|
219431392|NCT02813590|OTHER|Stool samples|
219431393|NCT01560104|DRUG|Veliparib|
219431394|NCT01560104|DRUG|Carboplatin|
219431395|NCT01560104|DRUG|paclitaxel|
219431396|NCT01560104|DRUG|placebo|
219431397|NCT00859573|DRUG|Modafinil|400 mg/day
219578101|NCT06912906|PROCEDURE|BIPAPasynchro: byphaisc positive pressure modality without any synchronisation|Patients will be switched to byphaisc positive pressure modality without any synchronisation (BIPAPasynchro) as soon as they are considered to be ready to initiate the weaning phase from mechanical ventilation. Lausanne adult intesive care physicians will be provided a protocol to help guide them with the setting of BIPAPasynchro, as this is different from standard clinical pratice.
219431398|NCT00859573|DRUG|Placebo|inactive substance
219431399|NCT00041704|DRUG|Anidulafungin, VER002|
219431400|NCT00250068|DRUG|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
219431401|NCT03383055|BIOLOGICAL|CMV-MVA Triplex Vaccine|"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"
219431402|NCT02123394|OTHER|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
219431403|NCT02123394|OTHER|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
219431404|NCT06206772|DIAGNOSTIC_TEST|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
219431405|NCT06111404|PROCEDURE|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
219431406|NCT06111404|PROCEDURE|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
219431407|NCT06111404|DEVICE|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
219431408|NCT06283134|BIOLOGICAL|BioTTT001 hepatic artery infusion|"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."
219431409|NCT06283134|DRUG|toripalimab|BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
219431410|NCT06283134|DRUG|regorafenib|BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
219431411|NCT00952601|DIETARY_SUPPLEMENT|Modified Atkins diet|Low carbohydrate diet
219431412|NCT02717676|PROCEDURE|Episiotomy|episiotomy will be done after crowning of the fetal head
219431413|NCT03192514|OTHER|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
219431414|NCT00952770|PROCEDURE|transradial coronary intervention|percutaneous coronary intervention with transradial approach
219431415|NCT05596474|DIETARY_SUPPLEMENT|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
219431416|NCT05596474|RADIATION|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
219476399|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219476400|NCT04792489|BIOLOGICAL|zamtocabtagene autoleucel (MB-CART2019.1)|Chimeric antigen receptor (CAR) T cell therapy
219476401|NCT04792489|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219476402|NCT04792489|DRUG|Fludarabine|Lymphodepleting chemotherapy
219476403|NCT04792489|DRUG|Bendamustine|Lymphodepleting chemotherapy
219476404|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
219191964|NCT04475640|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219191965|NCT04475640|OTHER|Genetic Testing|Undergo genetic testing
219191966|NCT00898235|GENETIC|clonality analysis|analyze clonality
219431417|NCT05596474|DIETARY_SUPPLEMENT|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
219431418|NCT05596474|RADIATION|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
219431419|NCT03850210|DEVICE|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
219431420|NCT03850210|DEVICE|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
219431421|NCT04446494|PROCEDURE|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
219431422|NCT02050828|DRUG|AKB-9778|
219431423|NCT02050828|DRUG|ranibizumab|
219431424|NCT02050828|DRUG|Placebo|
219431425|NCT02050828|DRUG|Sham|
219431426|NCT00574366|DRUG|erlotinib|"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"
219431427|NCT00574366|DRUG|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"
219431428|NCT04990531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
219578102|NCT06927323|OTHER|Otago exercise program|The Otago Exercise Program is composed of strength training and balance training. Strength training consisted of flexion and extension exercises of the knee, ankle, and toe joints, as well as hip opening exercises to strengthen the sides of the pelvis. Balance training consisted of walking backwards, walking in a figure of eight, heel-toe walking, standing on one leg, walking on the heels, walking on the toes, heel-toe walking backwards, standing up from a sitting position, and walking up stairs. Otago exercise program will be performed with action observation train will be instructed to watch a video on a 22-inch screen positioned 1 meter away from them, while comfortably seated in a chair with armrests. They are not allowed to follow along or engage in any movement while watching the video.
219578103|NCT06128720|DEVICE|Hyperbaric Oxygen|Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen
219578104|NCT06128720|DEVICE|Sham Hyperbaric Oxygen|Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
219578105|NCT06112184|OTHER|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
219578106|NCT06169657|DEVICE|Body-weight-supported treadmill training (BWSTT)|Walking on a treadmill in a harness with body weight support as needed
219578107|NCT06169657|DEVICE|EksoNR exoskeleton gait training|Walking in the EksoNR exoskeleton
219578108|NCT06169657|DEVICE|Overground gait training|Walking overground in a harness with body weight support as needed
219578109|NCT04520932|PROCEDURE|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
219191967|NCT00898235|GENETIC|polymerase chain reaction|analyze polymerase chain reaction
219191968|NCT00898235|GENETIC|protein analysis|analyze protein
219431429|NCT04990531|DIAGNOSTIC_TEST|Blood sample|Blood sample for diagnostic testing
219431430|NCT06380348|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
219431431|NCT06380348|DRUG|Osimertinib tablet|Osimertinib 160mg once po everyday
219578110|NCT06253052|BEHAVIORAL|Additional pre-OP-visit|OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.
219578111|NCT06253052|BEHAVIORAL|Liberal fasting regime|Patients may drink up to 200 ml clear fluids between 2 h prior to the surgery and the call to operation room.
219191969|NCT00898235|OTHER|biologic sample preservation procedure|preserve biologic samples
219431432|NCT06380348|DRUG|Cisplatin injection|Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
219431433|NCT06380348|DRUG|Pemetrexed injection|Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
219431434|NCT00769236|OTHER|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
219431435|NCT00769236|OTHER|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
219431436|NCT00769236|OTHER|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
219431437|NCT00529698|BIOLOGICAL|Biologically active recombinant Tat protein|
219431438|NCT01450475|PROCEDURE|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
219431439|NCT01746810|RADIATION|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
219431440|NCT00030030|DRUG|Silymarin (milk thistle)|
219431441|NCT04984564|OTHER|None. As this was an observational study.|Observational study.
219431442|NCT01256320|OTHER|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
219431443|NCT01256320|OTHER|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
219431444|NCT05586815|DRUG|Colistin|150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
219431445|NCT05586815|DRUG|Minocycline|200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
219431446|NCT05586815|DRUG|Placebo|Capsule without active compound
219431447|NCT04088565|OTHER|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
219431448|NCT04088565|OTHER|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
219431449|NCT04088565|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
219431450|NCT01072968|DRUG|BF2.649|1 capsule per day in the morning before the breakfast
219431451|NCT01072968|DRUG|Placebo|1 capsule per day in the morning before the breakfast
219431452|NCT01909609|OTHER|AAP Documents|
219431453|NCT01909609|OTHER|Parent Survival Guide|
219431454|NCT03221712|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
219431455|NCT03648463|PROCEDURE|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
219431456|NCT00653094|DEVICE|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
219431457|NCT00531908|DRUG|furosemide|furosemide
219431458|NCT01441518|OTHER|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
219431459|NCT01441518|OTHER|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
219431460|NCT04181957|DRUG|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
219431461|NCT04181957|DRUG|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
219431462|NCT03077243|RADIATION|Intensity Modulated Radiotherapy (IMRT)|60- 70 Gy at 2 Gy/fx
219431463|NCT03077243|DRUG|Cisplatin (or alternative)|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
219431464|NCT03077243|PROCEDURE|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
219431465|NCT02099760|DEVICE|STD testing (GC/Ct/trich)|
219431466|NCT00083304|DRUG|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
219191970|NCT00898235|OTHER|laboratory biomarker analysis|analyze laboratory biomarkers
219431467|NCT00083304|RADIATION|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
219431468|NCT00083304|OTHER|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
219431469|NCT01089166|DRUG|Metformin|
219431470|NCT02848313|DRUG|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
219431471|NCT04814511|DRUG|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
219431472|NCT04814511|DRUG|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
219431473|NCT04814511|DRUG|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
219431474|NCT04518722|RADIATION|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
219431475|NCT04518722|RADIATION|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
219431476|NCT04518722|OTHER|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
219431477|NCT01791790|DEVICE|Stimulation|
219431478|NCT01791790|DEVICE|SHAM|no stimulation
219431479|NCT02519062|OTHER|No intervention|This is a retrospective study
219431480|NCT02114489|DRUG|ibandronate|Unique perfusion of ibandronate 3 mg IV
219431481|NCT02114489|DRUG|Placebo|
219431482|NCT01596192|OTHER|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
219431483|NCT03382262|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
219431484|NCT03382262|DRUG|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
219431485|NCT05498025|OTHER|Deterra activated charcoal pouch|drug disposal pouch
219431486|NCT06067724|OTHER|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
219431487|NCT01736709|BIOLOGICAL|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
219431488|NCT01318421|DRUG|ELND002|
219431489|NCT02038790|DRUG|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
219431490|NCT02038790|DRUG|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
219431491|NCT06338813|DEVICE|Digital Manometry|"The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted."
219431492|NCT01089751|DRUG|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
219431493|NCT01089751|DRUG|placebo|Placebo once daily on an empty stomach for 14 weeks.
219431494|NCT02942706|DRUG|Cetuximab|anti-EGFR monoclonal antibody
219431495|NCT02942706|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
219431496|NCT02942706|DRUG|FOLFIRI|Irinotecan+LV5FU2
219431497|NCT01726816|DRUG|Probucol 250mg/day|Probucol 250mg + Placebo
219431498|NCT01726816|DRUG|Probucol 500mg/day|Probucol 500mg + Placebo
219431499|NCT01726816|DRUG|Placebo|Probucol matching placebo
219431500|NCT00438464|DRUG|Finasteride|Given PO
219431501|NCT00438464|OTHER|Placebo|Given PO
219431502|NCT00438464|PROCEDURE|Prostatectomy|Undergo prostatectomy
219431503|NCT00438464|OTHER|Laboratory biomarker analysis|Correlative studies
219431504|NCT03537092|DEVICE|Vaginal Film|"2 x 2 vaginal film with no active drug"
219431505|NCT03943446|DRUG|TAK-018|TAK-018 immediate-release tablets.
219431506|NCT03943446|DRUG|TAK-018 Placebo|TAK-018 placebo-matching tablets.
219431507|NCT03055572|OTHER|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
219431508|NCT03055572|OTHER|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
219431509|NCT01759160|PROCEDURE|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
219431510|NCT01759160|PROCEDURE|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
219431511|NCT00392119|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
219431512|NCT03214328|DIAGNOSTIC_TEST|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
219431513|NCT02394418|DRUG|Sevoflurane|Treatment of delirium by inhaled sevoflurane
219431514|NCT02394418|DRUG|Propofol|Treatment of delirium by propofol i.v. infusion
219191971|NCT00898235|PROCEDURE|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
219431515|NCT02394418|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
219431516|NCT06043401|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
219191972|NCT00898235|PROCEDURE|quality-of-life assessment|assess quality of life at each follow-up for life
219431517|NCT04368897|DIAGNOSTIC_TEST|CAG length <22|CAG repeat length in exon 1 of AR gene
219431518|NCT04368897|DIAGNOSTIC_TEST|CAG length >=22|CAG repeat length in exon 1 of AR gene
219431519|NCT04814524|DEVICE|Fitbit|Wear Fitbit
219431520|NCT04814524|OTHER|Questionnaire Administration|Ancillary studies
219431521|NCT04814524|DEVICE|Virtual Reality Device|Use VR
219431522|NCT00706394|DEVICE|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
219431523|NCT03030768|DRUG|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
219431524|NCT03030768|BEHAVIORAL|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
219431525|NCT04258293|DIAGNOSTIC_TEST|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
219431526|NCT03504462|PROCEDURE|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
219431527|NCT02708615|OTHER|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
219431528|NCT04675697|DRUG|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
219431529|NCT01529814|DEVICE|Implant with new abutment connection|New abutment connection implant system
219431530|NCT01529814|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
219431531|NCT01201707|PROCEDURE|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
219431532|NCT01201707|OTHER|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
219431533|NCT05267197|OTHER|3D Telemedicine|3D Telemedicine system
219431534|NCT05267197|OTHER|2D Telemedicine|2D Telemedicine system
219431535|NCT00574457|OTHER|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
219431536|NCT05815680|DRUG|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
219431537|NCT05815680|DRUG|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
219578112|NCT04082429|DRUG|Concizumab|When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
219431538|NCT05815680|DRUG|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
219431539|NCT05815680|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
219431540|NCT05815680|DRUG|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
219431541|NCT05855681|OTHER|therapeutic exercises|strengthening exercise and stretching exercise
219431542|NCT02302144|BEHAVIORAL|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
219431543|NCT01624688|PROCEDURE|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
219431544|NCT01084109|OTHER|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
219431545|NCT01084109|OTHER|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
219431546|NCT03290170|PROCEDURE|Measured Resection|Bony landmarks are used to set femoral component rotation.
219431547|NCT03290170|PROCEDURE|Gap Balancing|Relies on ligament releases prior to bone cuts.
219431548|NCT05096546|OTHER|No intervention|No intervention will be applied for the observational study.
219431549|NCT00472017|DRUG|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
219431550|NCT00979108|OTHER|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
219431551|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
219431552|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
219431553|NCT00971542|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
219431554|NCT03862495|DIAGNOSTIC_TEST|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
219431555|NCT03862495|DRUG|Azithromycin|Azithromycin 1g administered as a single oral dose
219431556|NCT03862495|OTHER|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
219431557|NCT02549248|OTHER|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
219431558|NCT02549248|OTHER|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
219431559|NCT02549248|OTHER|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
219431560|NCT02549248|OTHER|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
219431561|NCT02549248|OTHER|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
219431562|NCT04636320|DEVICE|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
219431563|NCT04636320|DIAGNOSTIC_TEST|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
219431564|NCT04636320|BIOLOGICAL|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
219431565|NCT04636320|DIAGNOSTIC_TEST|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
219431566|NCT04636320|DIAGNOSTIC_TEST|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
219431567|NCT02533778|DEVICE|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
219431568|NCT03673956|DRUG|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
219431569|NCT03673956|DRUG|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
219431570|NCT03673956|DRUG|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
219431571|NCT03673956|DRUG|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
219431572|NCT06342648|DRUG|Sterile Water Injection|Injection of intracutaneous sterile water
219431573|NCT06342648|DRUG|Diclofenac Sodium injection|Injection of intramuscular diclofenac sodium
219431574|NCT06366334|DRUG|Ketamine Hydrochloride|See arm description
219431575|NCT06366334|DRUG|Normal saline|See arm description
219431576|NCT05982834|DRUG|Disitamab Vedotin combined with fruquintinib and Tislelizumab|Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
219431577|NCT00270998|BEHAVIORAL|Behavioral Therapy|Pelvic muscle training and exercises
219431578|NCT00270998|DEVICE|Intravaginal Pessary|Intravaginal pessary
219431579|NCT00270998|DEVICE|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
219431580|NCT03242161|DIAGNOSTIC_TEST|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
219431581|NCT02366793|OTHER|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
219578113|NCT02664545|DEVICE|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
219578114|NCT02664545|PROCEDURE|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
219578115|NCT05395715|PROCEDURE|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
219578116|NCT06437600|PROCEDURE|Immediate angioplasty|See arm/group descriptions.
219578117|NCT06421701|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning. Anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
219431582|NCT02366793|OTHER|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
219431583|NCT02525952|PROCEDURE|Hepatectomy|Surgical removal of all lesions
219431584|NCT02525952|PROCEDURE|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
219431585|NCT04889612|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
219431586|NCT04889612|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
219431587|NCT00466024|BEHAVIORAL|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
219431588|NCT00466024|BEHAVIORAL|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
219431589|NCT00395837|BEHAVIORAL|Aerobic exercise|
219431590|NCT03963804|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
219431591|NCT00425113|DRUG|Metronidazole|
219431592|NCT00425113|PROCEDURE|Blood Draw|
219431593|NCT00425113|PROCEDURE|CT Scan|
219431594|NCT00425113|PROCEDURE|PET Scan|
219431595|NCT05019651|DEVICE|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
219431596|NCT04989088|DEVICE|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
219431597|NCT04989088|DEVICE|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
219431598|NCT06173609|PROCEDURE|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
219431599|NCT02253017|OTHER|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
219431600|NCT02842788|PROCEDURE|Prone positioning|Turning the patient face down for several consecutive hours
219431601|NCT05390307|DRUG|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
219431602|NCT05390307|DRUG|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
219431603|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
219431604|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
219431605|NCT05390307|OTHER|Usual care|Usual standard care
219762029|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
219431606|NCT02253472|DEVICE|Deep Brain Stimulation|
219431607|NCT01969513|PROCEDURE|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
219762030|NCT06566456|PROCEDURE|The puncture site is 1.5-2.5 cm proximal to the radial styloid process|The ultrasound-guided radial artery puncture site is1.5-2.5 cm proximal to the radial styloid process
219431608|NCT01969513|PROCEDURE|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
219431609|NCT00134017|DRUG|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
219431610|NCT00134017|DRUG|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
219431611|NCT06377072|DRUG|Shenqi Sherong Pill|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
219431612|NCT06377072|DRUG|Placebo|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
219431613|NCT04461028|DRUG|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
219431614|NCT04461028|DRUG|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
219431615|NCT00540306|DEVICE|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
219431616|NCT00388167|DRUG|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
219431617|NCT01463657|DEVICE|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
219431618|NCT01463657|DEVICE|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
219431619|NCT04795492|BEHAVIORAL|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
219431620|NCT04795492|BEHAVIORAL|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
219431621|NCT05462457|PROCEDURE|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
219431622|NCT04296916|DRUG|IOP lowering eye drops|"1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
219431623|NCT00446758|DIETARY_SUPPLEMENT|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
219431624|NCT05660889|OTHER|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
219431625|NCT00739960|DRUG|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
219431626|NCT00095719|DRUG|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
219431627|NCT00095719|DRUG|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
219431628|NCT00169039|DRUG|Clozapine|
219431629|NCT00169039|DRUG|Chlorpromazine|
219431630|NCT00763243|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
219431631|NCT02591043|PROCEDURE|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
219191973|NCT02262117|OTHER|standard care|No specific medical care
219431632|NCT00587834|DEVICE|Gintuit|Application of Gintuit at Day 0 to the gingival bed
219431633|NCT00587834|OTHER|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
219431634|NCT03251872|DRUG|Olaparib|Olaparib tablets
219431635|NCT02295800|OTHER|Standard of care|
219431636|NCT02295800|OTHER|Semi-structured interviews|
219431637|NCT05774613|DIETARY_SUPPLEMENT|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
219431638|NCT04717895|DIAGNOSTIC_TEST|Rocking environment forward (B) followed by a translation environment|Start by the virtual reality session by viewing a rocking environment followed by a translation environment
219431639|NCT04717895|DIAGNOSTIC_TEST|Translation environment followed by a rocking environment|Start by the virtual reality session by viewing a translation environment followed by a rocking environment
219431640|NCT02163772|PROCEDURE|Intracordal hyaluronate injection|
219431641|NCT03295604|PROCEDURE|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
219431642|NCT03295604|PROCEDURE|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
219431643|NCT01082588|DRUG|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
219431644|NCT01082588|DRUG|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
219431645|NCT00125372|DRUG|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
219431646|NCT01652937|DRUG|BIIB057|Oral
219431647|NCT01652937|DRUG|Placebo|Oral
219431648|NCT02656901|DEVICE|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
219431649|NCT02656901|DEVICE|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
219431650|NCT02656901|DEVICE|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
219431651|NCT02656901|DEVICE|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
219431652|NCT00439504|DRUG|Lobeline|
219431653|NCT01209806|DRUG|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
219431654|NCT05452824|OTHER|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
219431655|NCT05452824|OTHER|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
219431656|NCT04926844|DRUG|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
219431657|NCT04926844|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
219431658|NCT04926844|DRUG|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
219431659|NCT01679522|PROCEDURE|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
219431660|NCT01679522|PROCEDURE|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
219431661|NCT00807300|RADIATION|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
219431662|NCT00807300|PROCEDURE|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
219431663|NCT00716326|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
219431664|NCT00716326|DEVICE|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
219431665|NCT06609317|DEVICE|Digital therapeutic motion-based device|This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training
219431666|NCT06334172|DRUG|Oxytocin|Oxytocin
219431667|NCT06334172|OTHER|Placebo|Saline
219431668|NCT06065904|BEHAVIORAL|Nutrilect|This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
219431669|NCT03499340|BEHAVIORAL|text-only PWL|control condition (no image)
219431670|NCT03499340|BEHAVIORAL|low arousal graphic PWL|pictorial warning
219431671|NCT03499340|BEHAVIORAL|high arousal graphic PWL|pictorial warning
219431672|NCT03499340|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
219431673|NCT03499340|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
219431674|NCT00776321|DRUG|Eprotirome|
219431675|NCT00776321|DRUG|Placebo|
219431676|NCT05238987|DIETARY_SUPPLEMENT|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
219431677|NCT01224587|DRUG|D1000078|Oral, one single dose
219431678|NCT01224587|DRUG|D1000082|Oral, one single dose
219431679|NCT01224587|DRUG|D1000083|Oral, one single dose
219431680|NCT01224587|DRUG|D1000085|Oral, one single dose
219431681|NCT02157168|BEHAVIORAL|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
219431682|NCT00425100|DRUG|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
219431683|NCT03292341|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
219431684|NCT03292341|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
219431685|NCT03292341|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
219431686|NCT03292341|OTHER|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
219431687|NCT05452109|OTHER|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
219431688|NCT05452109|OTHER|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
219431689|NCT05705895|PROCEDURE|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process."
219431690|NCT02644148|PROCEDURE|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
219431691|NCT02644148|PROCEDURE|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
219431692|NCT01249534|OTHER|gastroesophageal cancer surgery|gastroesophageal cancer surgery
219431693|NCT03746067|DRUG|TS-134|5 mg, 10 mg, or 20 mg oral solution
219431694|NCT03746067|DRUG|Placebo|Matched Placebo oral solution
219431695|NCT01227304|DEVICE|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
219431696|NCT03249948|PROCEDURE|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
219431697|NCT03249948|PROCEDURE|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
219431698|NCT05161637|DRUG|TLC590|TLC590 490mg or 588mg
219431699|NCT05161637|DRUG|Bupivacain|Bupivacaine 75mg
219431700|NCT05161637|DRUG|Ropivacaine|Ropivacaine 150mg
219431701|NCT05161637|DRUG|Normal saline|Normal saline 20mL or 24mL
219431702|NCT03157440|DIAGNOSTIC_TEST|Ring oxymetry|a new type oxymetry wear on index finger like a ring
219431703|NCT04075773|BEHAVIORAL|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
219431704|NCT01884168|BIOLOGICAL|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
219431705|NCT03603834|DRUG|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
219431706|NCT04000087|OTHER|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
219431707|NCT00983359|RADIATION|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
219431708|NCT06092853|OTHER|Gingival crevicular fluid (GCF) and serum samples|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
219431709|NCT02680405|PROCEDURE|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
219431710|NCT02680405|PROCEDURE|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
219431711|NCT02680405|PROCEDURE|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
219431712|NCT04158986|BEHAVIORAL|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
219431713|NCT03335618|OTHER|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
219431714|NCT03335618|OTHER|Passive Activity Monitoring|Passive step tracking without check-ins
219431715|NCT04637971|OTHER|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
219431716|NCT04637971|OTHER|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
219578118|NCT04905290|DEVICE|Left ventricular coronary sinus (BiV) configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay. Patients with a defibrillator will receive two additional delays LV precedes default by 30ms and LV precedes default by 60ms.
219431717|NCT03357913|OTHER|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
219431718|NCT02855320|OTHER|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
219431719|NCT02011867|DEVICE|Cork Electrode|
219431720|NCT03332472|OTHER|Telemedicine group|
219431721|NCT03332472|OTHER|Conventional group|
219431722|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
219431723|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
219431724|NCT02183623|DRUG|Simvastatin|
219431725|NCT02183623|DRUG|10 mg BI 1356 BS|
219431726|NCT00931060|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
219431727|NCT00555906|DRUG|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
219431728|NCT00555906|DRUG|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
219431729|NCT00555906|DRUG|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
219431730|NCT05135351|DIETARY_SUPPLEMENT|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
219431731|NCT05135351|DIETARY_SUPPLEMENT|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
219762031|NCT06566456|PROCEDURE|traditional site|The ultrasound-guided radial artery puncture site is level with the radial styloid process and where the radial artery pulse is most prominent
219762032|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
219431732|NCT03400137|DIAGNOSTIC_TEST|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
219431733|NCT05693870|DEVICE|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
219431734|NCT05260892|DEVICE|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
219431735|NCT06155240|BEHAVIORAL|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
219431736|NCT01292044|OTHER|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
219431737|NCT00226967|DRUG|Sandostatin|Calculated per patient
219431738|NCT05912712|OTHER|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
219431739|NCT05912712|OTHER|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
219431740|NCT05912712|DRUG|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
219431741|NCT05912712|BIOLOGICAL|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
219431742|NCT06431178|OTHER|General Anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
219762033|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
219762034|NCT04487470|OTHER|Flavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
219762035|NCT04487470|OTHER|Unflavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
219431743|NCT06431178|OTHER|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
219431744|NCT05057143|DEVICE|Implants|3D printed implants
219431745|NCT05057143|DEVICE|Plates|Titanium plates
219431746|NCT00889681|DEVICE|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
219431747|NCT01383967|DRUG|LY2979165|Administered orally
219762036|NCT06039878|BEHAVIORAL|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
219762037|NCT06039878|BEHAVIORAL|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
219762038|NCT06039878|BEHAVIORAL|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
219762039|NCT06039878|BEHAVIORAL|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
219762040|NCT06039878|BEHAVIORAL|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
219762041|NCT06039878|BEHAVIORAL|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
219431748|NCT01383967|DRUG|placebo|Administered orally
219431749|NCT05079763|OTHER|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
219431750|NCT05079763|OTHER|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
219431751|NCT00159159|DRUG|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
219431752|NCT00159159|DRUG|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
219431753|NCT03865459|OTHER|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
219431754|NCT02790333|PROCEDURE|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
219431755|NCT02790333|PROCEDURE|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
219431756|NCT02855242|BEHAVIORAL|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
219431757|NCT02855242|OTHER|Controls Group|Subjects not participating in any lifestyle counseling
219431758|NCT03231215|DRUG|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
219431759|NCT01671956|BIOLOGICAL|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
219431760|NCT01671956|BIOLOGICAL|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
219431761|NCT00212485|PROCEDURE|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
219431762|NCT00212485|PROCEDURE|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
219431763|NCT03013829|BEHAVIORAL|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
219431764|NCT03082053|DRUG|varlitinib|IMP
219431765|NCT03082053|DRUG|capecitabine|Companion Medication
219431766|NCT05647018|PROCEDURE|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
219431767|NCT02195934|OTHER|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
219431768|NCT02195934|OTHER|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
219431769|NCT00013481|PROCEDURE|Stroke Rehabilitation|
219431770|NCT02993055|DRUG|Ulimorelin|
219431771|NCT02993055|OTHER|Placebo|
219431772|NCT00920478|OTHER|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
219431773|NCT00920478|OTHER|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
219431774|NCT03162458|DRUG|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
219431775|NCT03162458|DRUG|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
219431776|NCT04871581|DEVICE|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
219431777|NCT04871581|DEVICE|Placebo|Similar to Device, but having no influence on clenching intensity
219431778|NCT02741219|DRUG|Normal saline|Control Group receives normal saline bolus after delivery
219431779|NCT02741219|DRUG|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
219431780|NCT02741219|DRUG|Sufentanil|sufentanil PCA after surgery
219431781|NCT02741219|DRUG|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
219431782|NCT04183894|BEHAVIORAL|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
219431783|NCT04413721|PROCEDURE|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
219431784|NCT05121909|OTHER|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
219431785|NCT05121909|DEVICE|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
219431786|NCT05121909|OTHER|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
219431787|NCT05121909|OTHER|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
219431788|NCT05121909|OTHER|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
219431789|NCT05121909|OTHER|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
219431790|NCT05121909|OTHER|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
219431791|NCT00003893|DRUG|CMF regimen|
219431792|NCT00003893|DRUG|cyclophosphamide|
219431793|NCT00003893|DRUG|doxorubicin hydrochloride|
219431794|NCT00003893|DRUG|epirubicin hydrochloride|
219431795|NCT00003893|DRUG|fluorouracil|
219762042|NCT05220865|PROCEDURE|Hall Technique|"* Only food scraps or debris will be removed from the caries cavity.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
219431796|NCT00003893|DRUG|methotrexate|
219431797|NCT00003893|DRUG|mitomycin C|
219431798|NCT00003893|DRUG|mitoxantrone hydrochloride|
219431799|NCT00003893|PROCEDURE|adjuvant therapy|
219431800|NCT00003893|RADIATION|radiation therapy|
219431801|NCT04001309|OTHER|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
219431802|NCT00788697|DRUG|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
219431803|NCT00788697|OTHER|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
219431804|NCT03949140|PROCEDURE|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
219431805|NCT02248857|OTHER|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
219431806|NCT02248857|OTHER|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
219431807|NCT02745301|OTHER|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
219431808|NCT06524596|DRUG|tartaric acid butorphanol|The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
219431809|NCT06524596|DRUG|normal saline|The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
219431810|NCT06524596|DRUG|propofol and remifentanil|Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
219431811|NCT03384524|DRUG|Bromocriptine 2.5 MG|Administered daily
219431812|NCT03384524|DRUG|Metoprolol 25 MG|Administered daily
219431813|NCT03384524|DRUG|Tamsulosin 0.4 MG|Administered daily
219431814|NCT03384524|OTHER|Placebo|Three pills, matching active drugs to be administered daily
219476405|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
219476406|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
219476407|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
219476408|NCT01754610|BEHAVIORAL|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
219476409|NCT04564339|DRUG|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
219476410|NCT04564339|DRUG|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
219476411|NCT04564339|OTHER|Background Therapy|Participants will receive background therapy consistent with the standard of care.
219476412|NCT04100603|OTHER|No Intervention|There is no intervention for this study
219476413|NCT00003230|DRUG|paclitaxel|
219578119|NCT04905290|DEVICE|Conduction system pacing-only configuration|Conduction System Pacing (CSP) of the left bundle branch. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, and default - 60ms AV delay.
219007297|NCT06185504|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
219431815|NCT03453918|DIETARY_SUPPLEMENT|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
219431816|NCT03453918|OTHER|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
219431817|NCT05317013|DRUG|CBD|CBD
219431818|NCT05317013|OTHER|Placebo|Placebo
219431819|NCT04613999|DRUG|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
219578120|NCT04905290|DEVICE|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of Left Ventricle pacing and Conduction System Pacing of the left bundle branch. During the acute protocol, the eight delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay, CSP precedes default by 30ms, LV precedes default by 30ms and LV precedes default by 60ms.
219578121|NCT02673879|OTHER|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
219578122|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
219762043|NCT05220865|PROCEDURE|Modified Hall Technique|"* Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
219762044|NCT05946941|DRUG|Deucravacitinib|Specified dose on specified days
219762045|NCT05946941|OTHER|Placebo|Specified dose on specified days
219762046|NCT06265584|DRUG|ATG dosing platform when combined with standard tacrolimus and mini methotrexate|On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
219431820|NCT00517283|DRUG|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
219431821|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
219431822|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
219431823|NCT02261883|DRUG|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
219431824|NCT02261883|DRUG|Placebo|Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
219431825|NCT02562183|DRUG|kallikrein|Using kallikrein
219431826|NCT02671461|DRUG|BMS-986141|
219431827|NCT02671461|DRUG|Aspirin|
219431828|NCT02671461|OTHER|Placebo|
219431829|NCT03831893|OTHER|Nopal food product 1|Dried Nopal incorporated in a food product
219431830|NCT03831893|OTHER|Nopal food product 2|Dried Nopal incorporated in a food product
219431831|NCT03831893|OTHER|control|Food Product without nopal
219431832|NCT02037451|PROCEDURE|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
219431833|NCT05657951|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
219431834|NCT05606978|BEHAVIORAL|FASTb|FAST blended
219431835|NCT05606978|BEHAVIORAL|FASTr|FAST regular
219431836|NCT01412060|DRUG|Placebo|Placebo was supplied in capsules.
219191974|NCT02262117|DRUG|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
219431837|NCT01412060|DRUG|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
219431838|NCT04712266|DRUG|Glucagon|calculated IV insulin:Glucagon molar ratio
219431839|NCT04712266|DRUG|Insulin|calculated IV Insulin dose infused at a constant rate
219431840|NCT06187948|OTHER|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
219431841|NCT01752439|DEVICE|Anodal transcranial direct current stimulation|
219431842|NCT01752439|DEVICE|Sham transcranial direct current stimulation|
219431843|NCT00629525|DRUG|RAD001|RAD001 at a dose of 10 mg PO daily
219431844|NCT04643665|PROCEDURE|Double-lung transplantation|
219431845|NCT01043848|PROCEDURE|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
219431846|NCT01469572|DRUG|Pasireotide|Pasireotide is given as an injection.
219431847|NCT01469572|PROCEDURE|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
219431848|NCT01469572|DRUG|Everolimus|Given orally every day for the duration of the study
219431849|NCT04029324|PROCEDURE|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
219431850|NCT04029324|PROCEDURE|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
219431851|NCT04029324|PROCEDURE|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
219431852|NCT04029324|PROCEDURE|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
219431853|NCT04889963|BIOLOGICAL|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
219431854|NCT01343017|OTHER|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
219431855|NCT02219841|PROCEDURE|radiofrequency catheter ablation|
219431856|NCT00661102|DRUG|Corticosteroids|As prescribed
219431857|NCT00661102|DRUG|Placebo|As prescribed
219431858|NCT00661102|DRUG|capecitabine [Xeloda]|As prescribed
219431859|NCT00661102|DRUG|dexpantenol [Bepantol]|As prescribed
219431860|NCT00431821|BEHAVIORAL|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
219431861|NCT00431821|OTHER|Stroke education|Stroke education program with matched attention phone calls
219431862|NCT00505102|DRUG|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
219431863|NCT06281379|PROCEDURE|Total mesogastrectomy|More extended resection type with better oncological outcomes when compared to standard technique
219431864|NCT03303287|BEHAVIORAL|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
219431865|NCT00170742|DRUG|Octreotide, 30 mg i.m. LAR formulation|
219431866|NCT03441347|BEHAVIORAL|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
219431867|NCT03441347|OTHER|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
219431868|NCT03742115|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
219431869|NCT03742115|DRUG|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
219431870|NCT03742115|DRUG|Etoposide|150 mg/m2 weekly
219431871|NCT03742115|DRUG|IVIG|0.5 g/kg, once every 4 weeks
219431872|NCT00004732|PROCEDURE|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
219431873|NCT00004732|DEVICE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
219431874|NCT03574415|DRUG|DWP14012|DWP14012 tablets
219431875|NCT03574415|DRUG|Placebo|DWP14012 placebo-matching tablets
219431876|NCT03487393|DEVICE|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
219431877|NCT01183312|DRUG|Flumazenil|Sublingual flumazenil
219431878|NCT00442767|DRUG|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
219431879|NCT00442767|DRUG|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
219431880|NCT03159819|GENETIC|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
219431881|NCT00860119|DRUG|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
219191975|NCT03006432|DRUG|Oxaliplatin|
219431882|NCT00860119|DRUG|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
219431883|NCT05950971|DRUG|Amiodarone, diltiazem or esmolol|Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
219191976|NCT03006432|DRUG|5Fluorouracil bolus|
219191977|NCT03006432|DRUG|5Fluorouracil continu|
219191978|NCT03006432|DRUG|Docetaxel|
219431884|NCT05883007|RADIATION|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
219431885|NCT04373785|RADIATION|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
219431886|NCT04373785|DRUG|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
219431887|NCT04373785|DRUG|NG101m|Oral NG101m capsule continuously twice daily.
219431888|NCT01593228|DRUG|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431889|NCT01593228|DRUG|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431890|NCT01593228|DRUG|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431891|NCT01593228|DRUG|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431892|NCT01593228|DRUG|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431893|NCT01593228|DRUG|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431894|NCT01593228|DRUG|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
219431895|NCT05622357|RADIATION|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
219431896|NCT00815204|PROCEDURE|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
219431897|NCT00815204|PROCEDURE|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
219431898|NCT02915887|OTHER|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
219431899|NCT02289274|DRUG|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
219431900|NCT02289274|DRUG|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
219431901|NCT01530282|OTHER|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
219431902|NCT01530282|OTHER|Non invasive method|Non\_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
219431903|NCT02072382|DRUG|Metformin|metformin 850mg twice a day for eight weeks
219431904|NCT02072382|DRUG|Placebo|
219431905|NCT01441791|PROCEDURE|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
219431906|NCT01425229|DRUG|Bosentan|"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
219431907|NCT03059472|BEHAVIORAL|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
219431908|NCT03059472|BEHAVIORAL|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
219431909|NCT04777318|OTHER|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
219431910|NCT04777318|OTHER|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
219431911|NCT04777318|OTHER|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
219431912|NCT02333006|OTHER|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
219431913|NCT03855033|BEHAVIORAL|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
219431914|NCT02963415|BEHAVIORAL|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
219431915|NCT05594433|DRUG|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
219431916|NCT04477109|DEVICE|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
219431917|NCT04477109|OTHER|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
219431918|NCT00671983|PROCEDURE|Neurocognitive Testing|
219431919|NCT01634945|DRUG|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
219191979|NCT03006432|DRUG|Folinic Acid|
219431920|NCT01634945|DIETARY_SUPPLEMENT|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
219431921|NCT01634945|DRUG|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
219431922|NCT01634945|DIETARY_SUPPLEMENT|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
219431923|NCT01634945|OTHER|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
219431924|NCT01236859|DRUG|Gabapentin|Neurontin®, Pfizer
219431925|NCT00744848|DRUG|Bupivacaine HCl|100 mg Bupivacaine HCl
219431926|NCT00744848|DRUG|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
219431927|NCT00806689|PROCEDURE|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
219431928|NCT00806689|DEVICE|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
219431929|NCT00002544|DRUG|docetaxel|
219431930|NCT00002544|DRUG|mitoxantrone hydrochloride|
219431931|NCT00976248|DRUG|RAD001|Taken orally once a day
219431932|NCT04103775|BEHAVIORAL|Cognitive Remediation|See Cognitive Remediation Arm description.
219431933|NCT04103775|BEHAVIORAL|Active Control|See Active Control Arm description.
219431934|NCT03174613|DRUG|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
219431935|NCT03174613|DRUG|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
219431936|NCT05567393|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
219431937|NCT05567393|DRUG|TAK-951|TAK-951 SC injection
218859503|NCT05275582|BEHAVIORAL|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
219191980|NCT05608252|DRUG|VS-6766|Taken Orally
219191981|NCT05608252|DRUG|Abemaciclib|Taken Orally
219191982|NCT05608252|DRUG|Fulvestrant|Administered by intramuscular injection
219431938|NCT00884715|DRUG|Octreotide|short acting octreotide
218859504|NCT05723926|DEVICE|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
219431939|NCT03583788|BEHAVIORAL|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
219431940|NCT03583788|OTHER|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
219431941|NCT00113178|DEVICE|Catheter-based cardiac cryoablation|
218859505|NCT04763512|DIETARY_SUPPLEMENT|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
218859506|NCT04763512|DIETARY_SUPPLEMENT|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
219431942|NCT04101578|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
219431943|NCT01874873|DRUG|Anlotinib|
219431944|NCT03374644|DEVICE|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
219431945|NCT02278081|DRUG|lansoprazole|the lansoprazole will be taken orally.
219431946|NCT02278081|DRUG|placebo|the lansoprazole placebo will be taken orally.
219431947|NCT05803369|BEHAVIORAL|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
219431948|NCT05803369|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
219431949|NCT03615118|OTHER|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
219431950|NCT03615118|OTHER|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
219431951|NCT00765713|DEVICE|Nasal continuous positive airway pressure|Nocturnal
219431952|NCT00429390|BEHAVIORAL|Ramadan Fasting|
219431953|NCT03120364|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
219431954|NCT03120364|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
219431955|NCT05448599|DRUG|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
219431956|NCT04199793|DEVICE|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
219431957|NCT04199793|DEVICE|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
219431958|NCT01560611|DEVICE|Near infrared spectroscopy|
219431959|NCT02687932|DRUG|LCZ696|
219431960|NCT02687932|DRUG|Valsartan|
219431961|NCT05130372|OTHER|Static Stretching Method Group|Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.
219431962|NCT05130372|OTHER|PNF Stretching Method Group|The contract-relax technique was used in the PNF stretching method.
219431963|NCT05130372|OTHER|Myofascial Relaxation Method Group- Roller Massage|A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
219431964|NCT03292393|BEHAVIORAL|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
219431965|NCT03292393|BEHAVIORAL|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
219431966|NCT03292393|DEVICE|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
219578123|NCT03344978|OTHER|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
219007298|NCT06185504|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
219431967|NCT03292393|DEVICE|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
219431968|NCT05611515|PROCEDURE|TORS|"* Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)"
219431969|NCT03341611|BEHAVIORAL|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
219431970|NCT04179786|BIOLOGICAL|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
219578124|NCT03344978|OTHER|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
219578125|NCT04835649|OTHER|Exercise|Both groups will receive exercise-based training
219191983|NCT05953038|DRUG|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
219191984|NCT03245437|DRUG|Oxytocin nasal spray|nasal spray
219431971|NCT06106243|PROCEDURE|The conventional heat pressing temporary flexible maxillary removable partial denture|An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material
219431972|NCT06106243|PROCEDURE|3D-printed and digitally designed temporary flexible maxillary removable partial denture|3D-printed and digitally designed temporary flexible maxillary removable partial denture
219431973|NCT00393003|DEVICE|Closed-loop anesthesia system|
219431974|NCT05082064|DIAGNOSTIC_TEST|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
219431975|NCT04117399|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
219431976|NCT00001127|BIOLOGICAL|Influenza virus vaccine (CAIV-T)|
219431977|NCT01095068|BEHAVIORAL|Physical exercise|
219431978|NCT03638557|OTHER|Nutritious Lunch|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
219431979|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
219431980|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
219431981|NCT01548794|PROCEDURE|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
219431982|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
219431983|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
219431984|NCT03310580|DRUG|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
219431985|NCT02326389|BEHAVIORAL|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
219431986|NCT02326389|BEHAVIORAL|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
219431987|NCT03139929|DIAGNOSTIC_TEST|MSFP|MSFPhold and MSFParm
219431988|NCT03162029|OTHER|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
219431989|NCT06229067|DRUG|Adebrelimab|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219578126|NCT00821873|OTHER|CR Plug|CR Plug will be placed in the harvest site
219191985|NCT03245437|BEHAVIORAL|Social Cognition Skills Training|Group based training in social cognition skills
219578127|NCT06214169|DRUG|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
219578128|NCT06214169|DRUG|Lignocaine|Plain Lignocaine for IVRA
219578129|NCT06084962|BIOLOGICAL|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
219578130|NCT00754403|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
219578131|NCT00754403|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
219578132|NCT05842421|DEVICE|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
219431990|NCT06229067|DRUG|Vinorelbine|Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219431991|NCT06229067|DRUG|Cyclophosphamide (tablet)|Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219431992|NCT06229067|DRUG|Capecitabine|Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219431993|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
219007299|NCT06126133|DEVICE|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
219431994|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
219431995|NCT06530108|BEHAVIORAL|PLISSIT model based sexual health education|the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
219431996|NCT02584777|BIOLOGICAL|Pacritinib|QD (Once a day)
219431997|NCT00002577|RADIATION|radiation therapy|
219431998|NCT06151860|OTHER|Static stretching|Stretching exercises performed by maintaining the point of muscular discomfort without changing position for a certain period of time.
219431999|NCT06151860|OTHER|Pilates stretching|Stretching exercises performed dynamically, following the six basic principles of Pilates: concentration, control, center, precision, breathing and fluidity.
219432000|NCT01061320|DRUG|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
219432001|NCT01061320|DRUG|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
219432002|NCT02626364|DRUG|crenolanib|single-agent crenolanib at 100 mg PO TID
219432003|NCT04258007|DRUG|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
219432004|NCT04258007|DRUG|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
219432005|NCT04466072|DIAGNOSTIC_TEST|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
219432006|NCT01576120|OTHER|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
219432007|NCT01576120|OTHER|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
219432008|NCT06044129|DEVICE|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
219432009|NCT00271934|BIOLOGICAL|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
219432010|NCT05744323|OTHER|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
219432011|NCT06372808|OTHER|The Plyometric Exercise|The training group will perform plyometric exercises for eight weeks in addition to their regular training program.
219432012|NCT06372808|OTHER|The Regular Training|The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
219432013|NCT03108625|DRUG|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
219432014|NCT01003613|DRUG|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
219432015|NCT01003613|OTHER|Beriplast P|0.1 ml to attach graft
219432016|NCT04537754|DEVICE|bleaching device|activated bleaching
219432017|NCT06184542|BIOLOGICAL|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
219432018|NCT06184542|BIOLOGICAL|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
219007300|NCT04862845|DRUG|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
219432019|NCT06184542|BIOLOGICAL|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
219432020|NCT06184542|BIOLOGICAL|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
219432021|NCT06184542|BIOLOGICAL|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
219578133|NCT02161250|DIETARY_SUPPLEMENT|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
219432022|NCT06184542|BIOLOGICAL|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
219432023|NCT06184542|BIOLOGICAL|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
219432024|NCT00004999|DRUG|Lamivudine/Zidovudine|
219432025|NCT00004999|DRUG|Capravirine|
219432026|NCT00004999|DRUG|Nelfinavir mesylate|
219432027|NCT01258517|DEVICE|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
219432028|NCT03738189|OTHER|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
219432029|NCT03731546|PROCEDURE|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
219432030|NCT00002257|DRUG|Ganciclovir|
219432031|NCT05521646|OTHER|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
219432032|NCT06076772|DRUG|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
219432033|NCT04614350|BIOLOGICAL|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
219432034|NCT04614350|BIOLOGICAL|AlloDerm|AlloDerm tissue matrix
219432035|NCT02877667|DEVICE|planar acoustic wave device|accessory to laser treatment
219432036|NCT03010267|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
219432037|NCT03010267|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
219432038|NCT03010267|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
219432039|NCT01670812|DRUG|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
219432040|NCT01608607|OTHER|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
219432041|NCT03481569|OTHER|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
219432042|NCT02677623|DRUG|Pyridium|
219432043|NCT02677623|DRUG|Sodium Fluorescein|
219432044|NCT02677623|DRUG|Mannitol|
219432045|NCT02677623|OTHER|Normal Saline|
219432046|NCT00430547|DRUG|Carbimazole, radio-active iodine (I131)|
219007301|NCT04862845|DRUG|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
219007302|NCT04862845|DRUG|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
219432047|NCT00829127|DRUG|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
219432048|NCT00829127|DRUG|Placebo|Oral suspension
219432049|NCT00370890|DRUG|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
219432050|NCT01882244|BEHAVIORAL|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
219432051|NCT01882244|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
219432052|NCT02417896|DRUG|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
219432053|NCT06034015|DRUG|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
219432054|NCT06034015|DRUG|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
219432055|NCT04492878|DRUG|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
219432056|NCT04378699|OTHER|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
219432057|NCT04378699|OTHER|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
219191986|NCT03245437|BEHAVIORAL|Health Management|Group-based training in mental health management
219191987|NCT03245437|DRUG|Placebo nasal spray|placebo condition
219432058|NCT04124055|DIAGNOSTIC_TEST|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
219432059|NCT01005199|DRUG|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
219432060|NCT01005199|DRUG|sorafenib tosylate|Sorafenib 2 x 400 mg daily
219432061|NCT04397315|PROCEDURE|Pulpotomy to the level of canal orifices|Pulp tissue will be removed till the level of canal orifices.
219432062|NCT04397315|PROCEDURE|Pulpotomy up to superficial 2-3 mm of pulp chamber|Only superficial pulp from the chamber will be removed
219432063|NCT05799209|DEVICE|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
219432064|NCT05799209|DEVICE|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
219432065|NCT05564676|DIETARY_SUPPLEMENT|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
219432066|NCT05564676|DIETARY_SUPPLEMENT|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
219432067|NCT02583516|DRUG|vemurafenib and cobimetinib|Comparison between different treatment regimens
219191988|NCT03374657|BIOLOGICAL|CPK850|In one of 4 dose levels administered via subretinal injection under anesthesia
219432068|NCT01781663|DEVICE|KAM2904 Face Cream|
219432069|NCT01781663|DEVICE|KAM3008 Body Lotion|
219432070|NCT01781663|OTHER|petrolatum-based moisturizer|
219432071|NCT00618904|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
219432072|NCT00618904|DIETARY_SUPPLEMENT|Placebo|Placebo administered bid for 6 weeks.
219432073|NCT04959604|PROCEDURE|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
219432074|NCT03825510|RADIATION|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
219432075|NCT04186663|DRUG|Silver Diamine Fluoride|38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
219432076|NCT01569087|BIOLOGICAL|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
219432077|NCT01569087|BIOLOGICAL|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
219191989|NCT03813862|OTHER|Non-interventional (observational only)|
219432078|NCT02033655|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
219432079|NCT02033655|BEHAVIORAL|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
219432080|NCT03649334|DRUG|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
219432081|NCT03649334|DRUG|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
219432082|NCT04223063|BEHAVIORAL|Exercise program|As per the intervention arm
219432083|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
219432084|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
219432085|NCT02608034|DRUG|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
219432086|NCT02608034|DRUG|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
219432087|NCT02608034|DRUG|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
219432088|NCT04368468|OTHER|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
219432089|NCT04868747|DRUG|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
219432090|NCT04868747|DRUG|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
219432091|NCT03217201|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
219432092|NCT03217201|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
219191990|NCT06138197|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted hysterectomy following usual surgical technique
219191991|NCT04410731|DRUG|Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy|Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
219432093|NCT05976477|OTHER|educational intervention|"1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt."
219432094|NCT02130154|OTHER|18-FDG PET CT scan and 123I-MIBG SPECT scan|
219432095|NCT03291158|DRUG|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
219432096|NCT04586556|DIAGNOSTIC_TEST|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
219432097|NCT01781871|BIOLOGICAL|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
219432098|NCT01781871|BIOLOGICAL|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
219432099|NCT00897091|GENETIC|comparative genomic hybridization|
219432100|NCT00897091|GENETIC|microarray analysis|
219432101|NCT00897091|GENETIC|reverse transcriptase-polymerase chain reaction|
219432102|NCT00897091|OTHER|diagnostic laboratory biomarker analysis|
219432103|NCT00554138|DRUG|placebo|1 dd for 7-10 days
219432104|NCT00554138|DRUG|rosuvastatin|1 dd 20 mg for 7-10 days
219432105|NCT04261049|DRUG|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
219432106|NCT03052387|OTHER|assigned intervention|"\* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures."
219432107|NCT01894763|DEVICE|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
219432108|NCT05963295|DIAGNOSTIC_TEST|toxoplasma igG|Dignosis of toxoplasma
219432109|NCT05891691|BEHAVIORAL|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
219432110|NCT01549223|DRUG|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
219432111|NCT01549223|DRUG|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
219432112|NCT03944070|DRUG|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
219432113|NCT04409652|PROCEDURE|Head on bed|During emergence, head is kept on bed without pillow.
219432114|NCT04409652|PROCEDURE|Head on pillow|During emergence, head is kept on pillow.
219432115|NCT00889980|OTHER|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
219432116|NCT07091799|DIAGNOSTIC_TEST|P2X4 receptors in blood samples|This is an interventional study designed to assay P2X4 receptors in blood samples from ALS patients and healthy volunteers by comparing the mean levels of P2X4 expression.
219432117|NCT07090109|BEHAVIORAL|Genetic testing education video|patient education video about genetic testing for hereditary cancers
219432118|NCT07091019|OTHER|TKIs|There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.
219432119|NCT07092319|PROCEDURE|deferred cord clamping|DCC: deferred cord clamping successfully for 60 seconds;MISA: Surfactant administration by minimally invasive methods that allow for spontaneous breathing.
219432120|NCT07091760|OTHER|Su Jok Application|The patient's hands will be preferred for the application due to the comfort and convenience of the woman after cesarean section. Su Jok therapy, massage and seed will be applied to the reflection points on the hand based on the area to be treated.
219432121|NCT07091760|OTHER|Placebo Application|"Placebo Intervention:~The placebo group will be massaged and seed will be applied to an area where there is no reflection of the Su Jok organ."
219432122|NCT07091825|DEVICE|LACRIFRESH OCU-DRY 0.3% OSD|Use LACRIFRESH OCU-DRY 0.3% OSD as the daily contact lens lubricant product.
219432123|NCT07091825|DEVICE|Rigid contact lens lubricant|Use Rigid contact lens lubricant as the daily contact lens lubricant product.
219432124|NCT07091526|DIAGNOSTIC_TEST|serum uric acid test|Detect the serum uric acid in blood sample
219432125|NCT07092059|DEVICE|Smartphone digital therapeutic system|This intervention is composed of a smartphone app (Apple iOS or Android type) that prompts patients with Stimulant Use Disorder to (1) complete self-assessment questionnaires in the app about their health, health care needs and the services they receive and other health-related functions in life, (2) read educational modules about health and wellness and answer questions about these readings, (3) speak periodically with a Guide about their use of the app, and (4) take periodic saliva substance tests using video-selfies with their smartphone camera. The intervention includes testing and interviews with the study staff over a 12 month period. There is a follow-up period to measure the longer-term results at 15 months, as well.
219432126|NCT07092202|DRUG|Firmonertinib|Firmonertinib 160mg po qd
219432127|NCT07092202|DRUG|Intrathecal injection of pemetrexed|Intrathecal injection of pemetrexed. Weight above 50kg: Induction period: 40mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 40mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative); Weight below 50kg: Induction period: 30mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 30mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative)
219432128|NCT07090343|DRUG|Wegovy ®|Semaglutide 2.4 mg subcutaneous once-weekly starting 3 months prior TAVR and continued 24 months post-TAVR. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose as an add-on to standard-of-care. The treatment will continue until the 'end of treatment' visit followed by a 8 weeks follow-up period.
219432129|NCT07090343|DRUG|Placebo|Matching placebo subcutaneous once-weekly.
219432130|NCT04482244|DRUG|Cannabidiol|Liquid taken orally
219432131|NCT04482244|OTHER|Placebo|Liquid taken orally
219432132|NCT06928922|BIOLOGICAL|BMD006 monotreatment|After receiving the first dose of BMD006 treatment on Day 1, the patient will complete a single-treatment DLT observation (14 days). If the treatment is deemed safe and tolerable by the investigator, the patient will proceed to multiple-treatment DLT observation (14 days), with BMD006 treatment administered on Day 15 and Day 22. On Day 28, if the treatment is again assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level following a QW (once weekly) regimen for 6 doses. After that, starting from Week 11, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
219432133|NCT06928922|BIOLOGICAL|BMD006 in combination with PD-1 antibody|Once the dose escalation of BMD006 monotreatment is completed and the MTD (Maximum Tolerated Dose) is determined (i.e., the RP2D for this study), a dose escalation exploration of BMD006 in combination with PD-1 antibody will be conducted. On Day 1, patients will receive BMD006 in combination with PD-1 antibody treatment, followed by BMD006 treatment on Days 8 and 15. The DLT observation period will be 21 days. On Day 21, if the treatment is assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level according to the QW (once weekly) regimen for 6 doses. After Week 10, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
219432134|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
219578134|NCT02161250|DIETARY_SUPPLEMENT|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
219578135|NCT00256984|PROCEDURE|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
219578136|NCT02124941|DRUG|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
219432135|NCT04329494|DRUG|Cisplatin|Given via PIPAC
219578137|NCT02124941|DIAGNOSTIC_TEST|[18F]FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
219578138|NCT02124941|DIAGNOSTIC_TEST|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
219432136|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
219432137|NCT04329494|DRUG|Fluorouracil|Given IV
219432138|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
219432139|NCT04329494|DRUG|Irinotecan|Given IV
219432140|NCT04329494|DRUG|Leucovorin|Given IV
219578139|NCT02124941|DIAGNOSTIC_TEST|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
219578140|NCT01783249|OTHER|Stationary Exercise cycling|Stationary exercise cycling
219432141|NCT04329494|DRUG|Mitomycin|Given via PIPAC
219432142|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
219432143|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
219432144|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
219578141|NCT00300625|PROCEDURE|Application of the San Francisco Syncope Rule|
219432145|NCT05740579|PROCEDURE|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
219432146|NCT00642018|DRUG|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
219432147|NCT00642018|DRUG|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
219432148|NCT00642018|DRUG|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
219432149|NCT06935591|PROCEDURE|Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with Pulmonary Vein Isolation per standard of care.
219432150|NCT06935591|DEVICE|vMap® + Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with the use of the vMap® system and Pulmonary Vein Isolation.
219432151|NCT02504697|OTHER|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
219432152|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine QIV 0.5mL|
219432153|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine TIV 0.5mL|
219432154|NCT03040817|PROCEDURE|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
219432155|NCT03040817|DRUG|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
219432156|NCT03582267|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
219578142|NCT01374126|DRUG|Artesunate|Artesunate alone
219007303|NCT01370174|OTHER|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
219007304|NCT05545254|GENETIC|genetic testing|Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
219432157|NCT02816476|DRUG|Daratumumab|
219432158|NCT05610241|DEVICE|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
219432159|NCT05610241|DEVICE|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
219432160|NCT04746157|OTHER|Nurse intervention|Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
219432161|NCT03621189|DEVICE|intermittent theta burst stimulation|stimulatory protocol
219432162|NCT04412772|DRUG|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
219432163|NCT04412772|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
219432164|NCT03968081|BEHAVIORAL|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
219578143|NCT01374126|DRUG|Azithromycin + Artesunate|Combination of azithromycin + artesunate
219578144|NCT01995266|DRUG|Asunaprevir|
219578145|NCT01995266|DRUG|Daclatasvir|
219578146|NCT01673243|OTHER|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
219578147|NCT03596151|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
219578148|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given intravenously only once at dose of 10 mg
219432165|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
219578149|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
219578150|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
219432166|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
219578151|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
219578152|NCT05948514|OTHER|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
219578153|NCT02514850|DRUG|Biochaperone Combo|Injection of BioChaperone Combo
219432167|NCT03665493|BEHAVIORAL|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
219432168|NCT03665493|DRUG|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
219432169|NCT03665493|DRUG|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
219432170|NCT00247559|BIOLOGICAL|Botulinum toxin type A|
219432171|NCT00409916|DEVICE|BioZ Dx|
219432172|NCT05477446|BIOLOGICAL|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
219578154|NCT02514850|DRUG|Humalog Mix25|Injection of Humalog Mix25
219578155|NCT02514850|DRUG|Humalog|Injection of Humalog
219578156|NCT02514850|DRUG|Lantus|Injection of Lantus
219578157|NCT02514850|DRUG|Placebo|Injection of saline 0.9% solution
219578158|NCT01700036|DRUG|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
219432173|NCT02226419|DIETARY_SUPPLEMENT|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
219432174|NCT02508519|PROCEDURE|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
219432175|NCT04714944|DIETARY_SUPPLEMENT|Placebo|Supplementation period 12 weeks
219432176|NCT04714944|DIETARY_SUPPLEMENT|Whole fiber product|Supplementation period 12 weeks
219432177|NCT04569617|OTHER|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
219432178|NCT04569617|OTHER|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
219432179|NCT04569617|OTHER|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
219578159|NCT04190719|OTHER|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
219578160|NCT00062543|PROCEDURE|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
219578161|NCT00062543|DEVICE|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
219578162|NCT04414761|DRUG|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
219578163|NCT04414761|DRUG|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
219578164|NCT04390295|DRUG|Placebo|Once daily, 24 weeks
219578165|NCT04390295|DRUG|SHR3824|Once daily, 52 weeks
219578166|NCT04390295|DRUG|metformin|Three times daily, 52 weeks
219578167|NCT04166448|OTHER|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
219432180|NCT04569617|OTHER|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
219432181|NCT01544478|BIOLOGICAL|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
219432182|NCT03874416|OTHER|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
219432183|NCT03874416|OTHER|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
219432184|NCT00761358|DRUG|Z-338|Oral
219432185|NCT00761358|DRUG|Placebo|Oral
219432186|NCT04592848|OTHER|Questionnaires|"Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery"
219432187|NCT01461824|DRUG|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
219432188|NCT02168712|OTHER|Moderate continuous exercise training|
219432189|NCT02168712|OTHER|Interval exercise training|
219432190|NCT02310360|RADIATION|Fallypride|
219432191|NCT01802268|DRUG|Conversion from Tacrolimus to Sirolimus|
219432192|NCT01802268|DRUG|Maintenance on tacrolimus|
219432193|NCT00227968|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
219432194|NCT00227968|BEHAVIORAL|Clinical Status and Symptom Response Therapy (CSSRT)|
219432195|NCT03404219|BEHAVIORAL|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
219432196|NCT01072240|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
219432197|NCT01818986|DRUG|Sipuleucel-T|
219432198|NCT01818986|RADIATION|Stereotactic Ablative Body Radiation|
219432199|NCT03121066|DEVICE|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
219432200|NCT03121066|DEVICE|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
219432201|NCT03487887|DEVICE|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
219432202|NCT00250081|PROCEDURE|Upper Extremity Tendon transfer|
219432203|NCT00250081|PROCEDURE|Botulinum Toxin injections in Upper Extremity|
219432204|NCT00250081|PROCEDURE|Regularly ongoing therapy|
219432205|NCT01027104|OTHER|Education|Firearm injury prevention anticipatory guidance curriculum
219432206|NCT02031198|DRUG|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
219432207|NCT00690417|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
219432208|NCT03949543|OTHER|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
219432209|NCT03949543|OTHER|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
219432210|NCT03057912|BIOLOGICAL|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
219432211|NCT03057912|BIOLOGICAL|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
219475230|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
219432212|NCT05745025|DEVICE|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
219432213|NCT05745025|DEVICE|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
219432214|NCT05745025|OTHER|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
219432215|NCT04658810|OTHER|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
219432216|NCT05460390|OTHER|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
219432217|NCT02509611|OTHER|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
219432218|NCT03786406|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
219432219|NCT01309373|OTHER|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
219432220|NCT06849427|OTHER|multicomponent exercise intervention|"Multicomponent Exercise Program~A. Flexibility B. Targeted Strength Training C. Balance and Mobility~1. Center of Gravity Control Training~2. Multisensory Training~3. Postural Strategy Training~4. Gait Pattern Development Variation Training~5. Dual Task Exercises . D. Cardiovespiratory Fitness"
219578168|NCT03957330|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
219578169|NCT03074253|DIAGNOSTIC_TEST|Echocardiography|Patients are undergoing echocardiography
219578170|NCT03074253|DIAGNOSTIC_TEST|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
219578171|NCT03074253|DIAGNOSTIC_TEST|computed tomography|Patients are undergoing computed tomography
219578172|NCT03074253|DIAGNOSTIC_TEST|blood withdrawl|Peripheral blood samples are being collected from all patients
219578173|NCT01850186|DEVICE|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
219578174|NCT01850186|DRUG|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
219578175|NCT01103726|DRUG|PF-02545920|1 and 5 mg tablets, 6 mg single dose
219578176|NCT01103726|DRUG|placebo|matching placebo tablets, single dose
219578177|NCT01103726|DRUG|PF-02545920|1 mg tablets, 3 mg single dose
219578178|NCT01103726|DRUG|PF-02545920|5 mg tablets, 15 mg single dose
219578179|NCT01103726|DRUG|Placebo|matching placebo tablets, single dose
219578180|NCT00679926|DRUG|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
219578181|NCT03996148|DRUG|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
219578182|NCT03996148|DRUG|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
219578183|NCT03996148|DRUG|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
219578184|NCT00299026|DEVICE|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
219432221|NCT00821145|PROCEDURE|conventional surgery|AAA patients operated using a conventional incision
219432222|NCT00821145|PROCEDURE|laparoscopic AAA resection|laparoscopic AAA resection
219432223|NCT00821145|PROCEDURE|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
219432224|NCT00599170|DRUG|Rituximab|375 mg/m2 IV
219432225|NCT00356668|DEVICE|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
219432226|NCT04456595|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
219432227|NCT04456595|BIOLOGICAL|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
219432228|NCT01454479|DRUG|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
219432229|NCT04209530|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
219432230|NCT03588611|DRUG|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
219432231|NCT03588611|DRUG|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
219432232|NCT01192711|DEVICE|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
219432233|NCT00602381|DRUG|Lithium|
219432234|NCT02822651|BIOLOGICAL|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
219432235|NCT02822651|OTHER|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
219432236|NCT01192841|OTHER|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
219432237|NCT01395355|BEHAVIORAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
219432238|NCT01395355|BEHAVIORAL|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
219432239|NCT03625492|BEHAVIORAL|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
219432240|NCT03625492|BEHAVIORAL|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
219432241|NCT00586638|BEHAVIORAL|Video game based training|36 one-hour sessions over 12 weeks
219432242|NCT00607919|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
219432243|NCT00607919|DRUG|Placebo|oral, daily, for 16 weeks
219578185|NCT04342468|OTHER|non-interventional|No intervention
219578186|NCT03827746|OTHER|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
219578187|NCT00604123|DRUG|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
219578188|NCT00604123|DRUG|Placebo|Placebo nasal spray twice daily for 2 weeks.
219432244|NCT01660230|BIOLOGICAL|3K3A-APC, diluted in 0.9% sodium chloride in water|
219432245|NCT01660230|DRUG|0.9% NaCl in water|
219432246|NCT02053519|DRUG|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
219432247|NCT02053519|DRUG|Mygliol Oil|Matched placebo comparator
219432248|NCT02580240|DRUG|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
219432249|NCT02580240|DRUG|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
219432250|NCT03857607|GENETIC|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
219432251|NCT00760045|DRUG|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
219432252|NCT00760045|DRUG|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
219432253|NCT02005783|DRUG|DBD|DBD:one dose of medicine twice per day, orally
219432254|NCT02005783|DRUG|Epirubicin|Epirubicin:90mg/m2, d1, q3w\*4
219762047|NCT06446882|DEVICE|Personalized treatment according to molecular diagnosis with HER2DX|"Patients with HER2DX high-risk disease:~* Neoadjuvant treatment:~  * High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~ * Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.~ * Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.~* Adjuvant treatment:~  * pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).~ * No pCR at surgery: T-DM1 per 14 cycles.~Patients with HER2DX low-risk disease:~* Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~* Adjuvant treatment will be according to the pCR status at surgery:~  * pCR at surgery: trastuzumab or no adjuvant treatment.~ * No pCR at surgery: trastuzumab or T-DM1."
219762048|NCT06446882|OTHER|Treatment by physician´s choice, blinded to the diagnostic HER2DX test results|Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
219762049|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
219432255|NCT02005783|DRUG|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w\*4
219762050|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
219762051|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
219432256|NCT02005783|DRUG|Docetaxel|Docetaxel:75mg/m2, d1, q3w\*4
219475231|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
219475232|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
219475233|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
219475234|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
219475235|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
219475236|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
219475237|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
219475238|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
219475239|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
219475240|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
219475241|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
219475242|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
219475243|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
219475244|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
219475245|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
219475246|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
219475247|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
219475248|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
219475249|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
219475250|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1\) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
219475251|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219475252|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
219578189|NCT00258050|DRUG|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
219578190|NCT00258050|DRUG|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
219578191|NCT04602910|DEVICE|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
219578192|NCT02261350|DIETARY_SUPPLEMENT|Food fortification|
219191992|NCT05528939|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
219432257|NCT04466787|DIAGNOSTIC_TEST|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
219432258|NCT04466787|DIAGNOSTIC_TEST|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
219432259|NCT01709708|DRUG|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
219432260|NCT01709708|DRUG|Saline|Saline
219578193|NCT02261350|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|
219578194|NCT02603718|OTHER|Rehabilitation treatment|
219578195|NCT03917017|DEVICE|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
219578196|NCT01126411|PROCEDURE|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
219578197|NCT02796118|DRUG|ASP2151|Oral
219578198|NCT02796118|DRUG|Placebo|Oral
219578199|NCT03573505|DRUG|BG00011|Administered as specified in the treatment arm.
219432261|NCT00646581|DRUG|Placebo|Placebo
219432262|NCT00646581|DRUG|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
219578200|NCT03573505|DRUG|Placebo|Administered as specified in the treatment arm.
219762052|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
219762053|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
219762054|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
219762055|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
219762056|NCT06250985|OTHER|Timing of reimplantation|Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
219762057|NCT02586207|DRUG|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
219762058|NCT02586207|DRUG|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
219762059|NCT02586207|RADIATION|Radiation|70 Gy fractionated over 35 days
219762060|NCT03682068|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219762061|NCT03682068|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
219762062|NCT03682068|DRUG|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
219762063|NCT03682068|DRUG|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
219578201|NCT04280705|OTHER|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
219578202|NCT04280705|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
219578203|NCT03222583|DRUG|Placebo|Matching placebo tablet for oral administration
219578204|NCT03222583|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
219578205|NCT00316147|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
219578206|NCT05145179|DRUG|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
219578207|NCT01740635|DEVICE|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
219578208|NCT03145636|DEVICE|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
219578209|NCT03145636|OTHER|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
219578210|NCT03145636|OTHER|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
219762064|NCT06449313|DRUG|Cemiplimab-Rwlc|350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
219432263|NCT01527110|DRUG|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
219762065|NCT01362803|DRUG|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
219432264|NCT06516458|DIAGNOSTIC_TEST|Camera Based Kinematic Analysis|Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
219762066|NCT04701411|BIOLOGICAL|Darvadstrocel|Darvadstrocel perilesional injection.
219762067|NCT06260059|DRUG|Empagliflozin 10 MG|Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
219432265|NCT01714713|DRUG|EVP-6124|Arm 1, 2
219432266|NCT00527072|BIOLOGICAL|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
219432267|NCT05281068|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
219578211|NCT02802449|DRUG|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
219578212|NCT02802449|DRUG|Placebo|
219578213|NCT04268316|DEVICE|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
219578214|NCT04268316|BEHAVIORAL|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
219578215|NCT02216513|DRUG|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
219578216|NCT02216513|DRUG|placebo|normal saline IV for 4 hours for 5 consecutive days
219762068|NCT06260059|DRUG|Placebo|To patients randomized to the placebo group, a placebo pill will be given
219432268|NCT05281068|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
219432269|NCT05143918|OTHER|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
219432270|NCT02396693|DEVICE|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
219432271|NCT02396693|DEVICE|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
219432272|NCT02396693|DEVICE|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
219432273|NCT02007252|DRUG|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
219432274|NCT02007252|DRUG|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
219432275|NCT05551260|OTHER|Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition|"Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests"
219432276|NCT02080494|DRUG|Tranexamic Acid|
219432277|NCT03770676|DIETARY_SUPPLEMENT|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
219432278|NCT00003760|DRUG|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
219432279|NCT06133985|OTHER|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
219432280|NCT06133985|OTHER|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
219432281|NCT00257868|DRUG|Rivastigmine prevention of delirium|
219432282|NCT04441554|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI of cervical spine
219432283|NCT00805610|BIOLOGICAL|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
219432284|NCT02402712|DRUG|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
219432285|NCT02402712|DRUG|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
219432286|NCT02402712|DRUG|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
219432287|NCT03443895|DRUG|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
219432288|NCT03443895|DRUG|Placebo oral capsule|Matching placebo capsule
219432289|NCT05579119|DRUG|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
219432290|NCT05579119|DRUG|Glargine|Glargine once daily.
219432291|NCT05579119|DRUG|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
219578217|NCT06337253|DRUG|Sulfadoxine/pyrimethamine plus amodiaquine|Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
219578218|NCT01375153|DRUG|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
219432292|NCT03815123|DIAGNOSTIC_TEST|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
219432293|NCT05157776|DRUG|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
219578219|NCT01375153|DRUG|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
219578220|NCT03183648|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
219578221|NCT01405716|BEHAVIORAL|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
219432294|NCT01639391|PROCEDURE|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
219432295|NCT02394327|DEVICE|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
219432296|NCT02394327|DEVICE|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
219432297|NCT01785498|BEHAVIORAL|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
219432298|NCT01581996|DRUG|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
219432299|NCT04759222|DIAGNOSTIC_TEST|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
219432300|NCT00720824|BEHAVIORAL|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
219432301|NCT00720824|BEHAVIORAL|Office routine|Standard vaccine administration
219432302|NCT01216345|DRUG|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
219432303|NCT00469872|PROCEDURE|Context-focused compared to child-focused interventions|
219432304|NCT02001688|DRUG|Kamada-AAT for Inhalation, 80mg|
219432305|NCT02001688|DRUG|Placebo|
219578222|NCT01405716|BEHAVIORAL|Health Education|8-week health education program
219578223|NCT04141124|OTHER|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
219578224|NCT04141124|OTHER|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
219578225|NCT04141124|OTHER|Control|5 minutes of reading fictitious biological medical results
219191993|NCT05528939|OTHER|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
219191994|NCT04361487|DEVICE|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
219191995|NCT06414408|DRUG|Doxycycline Pill|200mg Dose
219578226|NCT02337023|RADIATION|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
219578227|NCT04619095|DIETARY_SUPPLEMENT|Psyllium|See the information already included in the arm descriptions.
219432306|NCT02001688|DRUG|Kamada-AAT for Inhalation, 160mg|
219432307|NCT04673812|DRUG|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
219432308|NCT06445569|DIETARY_SUPPLEMENT|KH-1|3 capsules and one stick packet consumed daily around the same time
219432309|NCT06445569|OTHER|Placebo|3 capsules and one stick packet consumed daily around the same time
219432310|NCT00052936|BIOLOGICAL|filgrastim|
219432311|NCT00052936|BIOLOGICAL|rituximab|
219432312|NCT00052936|DRUG|CHOP regimen|
219432313|NCT00052936|DRUG|cyclophosphamide|
219432314|NCT00052936|DRUG|doxorubicin hydrochloride|
219432315|NCT00052936|DRUG|prednisone|
219432316|NCT00052936|DRUG|vincristine sulfate|
219432317|NCT00052936|RADIATION|radiation therapy|36Gy on BULK and extranodal involvement
219432318|NCT04989881|DEVICE|da Vinci Simulator|Single training session
219432319|NCT04989881|DEVICE|Laparascopic training box|Single training session
219432320|NCT02527941|DRUG|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
219432321|NCT03611998|BEHAVIORAL|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
219432322|NCT01313832|OTHER|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
219432323|NCT04705987|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
219432324|NCT04705987|DRUG|Placebo|Placebo 1c/24h Treatment 8 weeks
219432325|NCT00858936|DRUG|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
219432326|NCT00858936|DRUG|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
219432327|NCT00813917|DRUG|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
219432328|NCT00813917|DRUG|placebo|12 weeks of placebo (double blinded) by mouth twice per day
219432329|NCT05441540|DEVICE|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
219578228|NCT04619095|DIETARY_SUPPLEMENT|Placebo|See the information already included in the arm descriptions.
219432330|NCT02595268|DRUG|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
219432331|NCT02595268|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
219432332|NCT01080456|DRUG|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
219432333|NCT02227056|DRUG|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
219432334|NCT01349972|DRUG|alvocidib|Given IV
219432335|NCT01349972|DRUG|daunorubicin hydrochloride|Given IV
219432336|NCT01349972|DRUG|mitoxantrone hydrochloride|Given IV
219432337|NCT01349972|DRUG|cytarabine|Given IV
219432338|NCT02137707|DRUG|Gilenya|All patients will receive Gilenya
219191996|NCT01726140|PROCEDURE|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.
219432339|NCT03043807|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
219432340|NCT03043807|DRUG|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
219432341|NCT03043807|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
219432342|NCT03043807|RADIATION|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
219432343|NCT03043807|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
219432344|NCT03670498|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219432345|NCT03670498|DEVICE|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219432346|NCT06277583|BEHAVIORAL|Urban care farming|An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
219432347|NCT00493441|DRUG|AVN944|150, 200, 250, 300, or 400 mg q12h
219432348|NCT02274415|BIOLOGICAL|Vaccination with the combined vaccine (Prevenar13 ®)|
219432349|NCT02274415|BIOLOGICAL|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
219578229|NCT03986138|DRUG|gadopiclenol|Single intravenous bolus injection
219578230|NCT03986138|DRUG|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
219578231|NCT06231264|DEVICE|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
219432350|NCT04390997|PROCEDURE|Non-surgical Periodontal Treatment|Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
219432351|NCT03157843|DRUG|low-molecular-weight heparin|
219432352|NCT05008133|BEHAVIORAL|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
219432353|NCT06374524|PROCEDURE|greater occipital nerve block|Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
219432354|NCT00430885|DRUG|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
219432355|NCT00666380|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
219432356|NCT05224817|OTHER|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
219432357|NCT04950842|BIOLOGICAL|JB-101|induced T cell with suppressive function
219432358|NCT04402346|PROCEDURE|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
219578232|NCT06231264|DEVICE|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
219432359|NCT04402346|PROCEDURE|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
219432360|NCT03027843|DRUG|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
219432361|NCT00792701|DRUG|cisplatin|Given IV
219432362|NCT00792701|DRUG|gemcitabine hydrochloride|Given IV
219432363|NCT01788150|DEVICE|Coronary Stenting|
219432364|NCT03943888|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
219432365|NCT03943888|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
219432366|NCT03943888|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
219432367|NCT03943888|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
219432368|NCT03040765|DRUG|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
219432369|NCT03040765|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
219432370|NCT05491447|DRUG|BMX-010|Ointment
219432371|NCT05491447|DRUG|Placebo|Ointment
219432372|NCT02923908|OTHER|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
219432373|NCT02923908|OTHER|Voice Recording|A voice recording will be made for the duration of the tasting period.
219432374|NCT02923908|OTHER|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
219432375|NCT02923908|OTHER|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
219432376|NCT02690324|BEHAVIORAL|cognitive stress (serial 7)|
219432377|NCT01535768|DRUG|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
219432378|NCT05251298|OTHER|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
219432379|NCT00456833|DRUG|RAD001|
219432380|NCT00456833|DRUG|erlotinib|
219432381|NCT01769495|OTHER|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
219432382|NCT01229514|OTHER|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
219432383|NCT01062919|PROCEDURE|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
219432384|NCT01062919|PROCEDURE|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
219432385|NCT02135900|DRUG|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
219432386|NCT01998438|DRUG|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
219432387|NCT06211127|DEVICE|Cold laser plaque ablation|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
219432388|NCT06211127|DEVICE|The excimer laser|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
219432389|NCT03568695|DIAGNOSTIC_TEST|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
219432390|NCT03257618|DRUG|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
219432391|NCT03257618|OTHER|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
219432392|NCT02143141|DRUG|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
219432393|NCT02143141|DRUG|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
219432394|NCT00064077|DRUG|Cisplatin|Given IV
219432395|NCT00064077|DRUG|Gemcitabine Hydrochloride|
219432396|NCT00064077|DRUG|Paclitaxel|Given IV
219432397|NCT00064077|OTHER|Quality-of-Life Assessment|Ancillary studies
219432398|NCT00064077|DRUG|Topotecan Hydrochloride|Given IV
219432399|NCT00064077|DRUG|Vinorelbine Tartrate|Given IV
219432400|NCT01179867|OTHER|Electronic Medication Reconciliation|"1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
219432401|NCT00182507|DRUG|Olanzapine|
219432402|NCT04328012|DRUG|Losartan|administered 14 days
219432403|NCT04328012|DRUG|Placebo|administered 14 days
219432404|NCT02048267|PROCEDURE|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
219432405|NCT01467661|DRUG|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
219432406|NCT04383613|OTHER|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
219432407|NCT02409147|PROCEDURE|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
219432408|NCT04955496|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
219432409|NCT03853304|OTHER|+ Folic acid|Salt fortified with folic acid
219578233|NCT03286010|BEHAVIORAL|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
219578234|NCT00228514|DRUG|Rosuvastatin|
219578235|NCT00228514|PROCEDURE|Positron emission tomography|
219578236|NCT03188718|DEVICE|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
219007305|NCT01908374|DIETARY_SUPPLEMENT|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
219432410|NCT03853304|OTHER|+ Vitamin B12|Salt fortified with vitamin B12
219432411|NCT03853304|OTHER|DFS|Salt fortified with iron and iodine
219432412|NCT04876586|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
219432413|NCT00563368|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
219432414|NCT00563368|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
219432415|NCT00563368|DRUG|topiramate|topiramate 46 mg, po once daily
219432416|NCT00563368|DRUG|topiramate|topiramate 92 mg, po once daily
219432417|NCT00563368|DRUG|phentermine|phentermine 7.5 mg, po once daily
219432418|NCT00563368|DRUG|phentermine|phentermine 15 mg, po once daily
219432419|NCT00563368|DRUG|VI-0521|placebo, po once daily
219432420|NCT02120144|OTHER|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
219432421|NCT02120144|OTHER|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
219432422|NCT00520637|DRUG|EZN-2208|
219432423|NCT00603850|DEVICE|ForeseeHome|human factor
219432424|NCT01204307|DRUG|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
219432425|NCT01204307|DRUG|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
219432426|NCT05318040|DRUG|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
219432427|NCT05318040|DRUG|Placebo|Placebo will be provided as visually matching placebo capsules.
219432428|NCT02135549|DIETARY_SUPPLEMENT|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
219432429|NCT02135549|DRUG|Placebo Oral Tablet|Placebo comparator
219432430|NCT05913518|DEVICE|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
219432431|NCT05913518|DEVICE|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
219432432|NCT03554304|DRUG|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
219432433|NCT03554304|DRUG|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
219432434|NCT03554304|DRUG|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
219432435|NCT01100294|BIOLOGICAL|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
219432436|NCT00453661|BEHAVIORAL|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
219432437|NCT00453661|BEHAVIORAL|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
219432438|NCT04414488|PROCEDURE|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
219432439|NCT02721654|DRUG|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
219432440|NCT02721654|DRUG|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
219432441|NCT03497611|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
219432442|NCT04323423|BEHAVIORAL|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
219432443|NCT04630964|DRUG|Psilocybin|psilocybin 25 mg Single Oral Dose
219432444|NCT04630964|DRUG|Niacin|niacin 100mg Single Oral Dose
219432445|NCT03459404|COMBINATION_PRODUCT|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
219007306|NCT00425360|BIOLOGICAL|sargramostim|
219432446|NCT00436293|DRUG|Docetaxel|75 mg/m²
219432447|NCT00436293|DRUG|Cisplatin|75 mg/m²
219432448|NCT01819506|BEHAVIORAL|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
219432449|NCT03838003|PROCEDURE|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
219432450|NCT05789849|DEVICE|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
219432451|NCT01395641|DRUG|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
219432452|NCT05544071|DEVICE|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
219432453|NCT04995614|DRUG|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
219432454|NCT00864344|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
219432455|NCT00864344|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
219432456|NCT01699295|BEHAVIORAL|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
219432457|NCT01699295|BEHAVIORAL|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
219007307|NCT00425360|BIOLOGICAL|telomerase peptide vaccine GV1001|
219007308|NCT00425360|DRUG|capecitabine|
219007309|NCT00425360|DRUG|gemcitabine hydrochloride|
219007310|NCT00005937|DRUG|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
219007311|NCT00005937|DRUG|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
219007312|NCT06507319|DEVICE|Direct bone anchored pull distal slider|distalization from the palatal side only.
219007313|NCT06507319|DEVICE|Indirect bone anchored dual force distalizer.|distalization from the palatal and buccal sides.
219432458|NCT04280406|DRUG|Azithromycin|azithromycin 500mg one hour before implant placement
219432459|NCT04280406|DRUG|Placebo oral tablet|identical placebo one hour before implant placement
219432460|NCT00879437|DRUG|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
219432461|NCT00879437|DRUG|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
219432462|NCT00879437|RADIATION|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
219432463|NCT01423955|DRUG|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
219432464|NCT01423955|DRUG|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
219432465|NCT02964988|DRUG|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
219432466|NCT02964988|DEVICE|PET/CT|Whole body PET/CT
219432467|NCT01039636|DRUG|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
219432468|NCT03000686|BIOLOGICAL|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
219432469|NCT03000686|OTHER|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
219432470|NCT00948038|DIETARY_SUPPLEMENT|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
219432471|NCT00948038|DIETARY_SUPPLEMENT|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
219432472|NCT00683007|OTHER|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
219432473|NCT00683007|OTHER|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
219432474|NCT05316480|DRUG|Nimotuzumab|nimotuzumab 200mg/week
219432475|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
219432476|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
219432477|NCT05097157|DEVICE|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
219432478|NCT00100646|BEHAVIORAL|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
219432479|NCT00100646|DRUG|Lamivudine|300 mg tablet taken orally daily
219432480|NCT00100646|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
219432481|NCT00100646|DRUG|Stavudine|Dosage dependent on weight
219432482|NCT00100646|BIOLOGICAL|Rabies de novo antigen|Vaccine injected intramuscularly
219432483|NCT02843750|BEHAVIORAL|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home"
219432484|NCT02843750|OTHER|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
219432485|NCT05806112|BEHAVIORAL|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
219432486|NCT05806112|BEHAVIORAL|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
219578237|NCT03213730|OTHER|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
219432487|NCT05806112|BEHAVIORAL|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
219432488|NCT03212807|DRUG|Durvalumab|Investigational Medicinal Product
219432489|NCT03212807|DRUG|Lenalidomide|Investigational Medicinal Product
219432490|NCT00228033|DRUG|Elemental calcium (as carbonate)|
219432491|NCT01647425|BEHAVIORAL|physician assessment|"* Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0"
219432492|NCT01604096|OTHER|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
219432493|NCT00054444|DRUG|Topotecan Hydrochloride Liposomes|Given IV
219432494|NCT00054444|RADIATION|3-Dimensional Conformal Radiation Therapy|
219432495|NCT00054444|DRUG|Cisplatin|Given IV
219432496|NCT05446922|OTHER|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
219432497|NCT00178698|OTHER|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
219432498|NCT00178698|DRUG|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
219432499|NCT00178698|OTHER|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
219432500|NCT06349850|DIAGNOSTIC_TEST|serum uric acid level to plasma HDL-c level ratio (UHR)|high UHR is considered to be a risk factor for development of DKI in type 2 DM
219432501|NCT01112982|OTHER|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
219432502|NCT01112982|DRUG|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
219432503|NCT01112982|DRUG|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
219432504|NCT06149754|DEVICE|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
219432505|NCT05512312|PROCEDURE|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
219432506|NCT05512312|PROCEDURE|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
219432507|NCT01244204|DIETARY_SUPPLEMENT|Vitamin D|Daily dose of 800IU of vitamin D
219578238|NCT03213730|OTHER|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
219578239|NCT01772264|DRUG|PF-05089771|titration from 150mg BID to 450mg BID
219578240|NCT01772264|DRUG|Placebo|matched placebo
219578241|NCT03214341|RADIATION|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
219432508|NCT01244204|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules
219432509|NCT06359704|BEHAVIORAL|Caregivers Of dementia Processing Emotions (COPE) program|a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
219432510|NCT04777604|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
219432511|NCT00361023|DRUG|losartan|
219432512|NCT02726334|DRUG|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
219432513|NCT02726334|DRUG|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
219432514|NCT05171881|OTHER|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
219432515|NCT06364384|COMBINATION_PRODUCT|PD-1 and CRT|Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
219432516|NCT01085019|DIETARY_SUPPLEMENT|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
219432517|NCT01085019|DIETARY_SUPPLEMENT|Oregano|2.8g/day of oregano in capsules during 4 weeks.
219432518|NCT01085019|DIETARY_SUPPLEMENT|Ginger|2.8g/day of ginger in capsules during 4 weeks.
219432519|NCT01085019|DIETARY_SUPPLEMENT|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
219432520|NCT01085019|DIETARY_SUPPLEMENT|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
219432521|NCT01085019|DIETARY_SUPPLEMENT|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
219432522|NCT02025049|DRUG|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
219007314|NCT03676595|OTHER|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
219007315|NCT03676595|OTHER|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
219432523|NCT02025049|DRUG|Placebo|mannitol-based DP-b99 look-alike
219432524|NCT00649168|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
219007316|NCT00505531|DRUG|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
219007317|NCT00505531|DRUG|Benadryl|Placebo group will take up to 25 mg of Benadryl
219007318|NCT00326989|PROCEDURE|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
219007319|NCT01516814|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
219007320|NCT01516814|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
219432525|NCT00649168|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
219432526|NCT00314041|BIOLOGICAL|Meningococcal C|
219432527|NCT00314041|BIOLOGICAL|DTP/Hib|
219432528|NCT00088114|DRUG|STA-4783/paclitaxel|
219432529|NCT02979028|DEVICE|TEAS|Transcutaneous electrical acupoint stimulation
219432530|NCT02357888|DRUG|V0018|Oromucosal - Single dose
219432531|NCT02357888|DRUG|Placebo|Oromucosal - Single dose
219432532|NCT02937688|DEVICE|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
219432533|NCT04430790|DRUG|Doxapram|Loading dose and continuous doxapram infusion.
219432534|NCT04430790|DRUG|Placebo|Loading dose and continuous placebo infusion.
219432535|NCT05263349|OTHER|Typical Dreams Questionnaire|"Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003)."
219432536|NCT05263349|OTHER|HAD Questionnaire|"The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21)."
219432537|NCT05263349|OTHER|Dream Booklet|The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
219432538|NCT05392166|DIAGNOSTIC_TEST|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
219432539|NCT00004234|PROCEDURE|management of therapy complications|
219432540|NCT00004234|RADIATION|radiation therapy|
219432541|NCT00300534|DEVICE|Abbott Laboratories Determine test for syphilis|
219432542|NCT00300534|DEVICE|Investigational syphilis immunochromatographic strip test|
219432543|NCT03504436|DEVICE|LEO +|LEO +: self-expanding intracranial stent
219432544|NCT05800834|DRUG|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
219432545|NCT05800834|DRUG|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
219432546|NCT04994704|DRUG|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
219432547|NCT04994704|DRUG|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
219432548|NCT02252757|DEVICE|CoVa|
219432549|NCT00049504|DRUG|cyclophosphamide|Given IV
219432550|NCT00049504|DRUG|fludarabine phosphate|Given IV
219432551|NCT00049504|DRUG|tacrolimus|Given IV or orally
219432552|NCT00049504|DRUG|mycophenolate mofetil|Given orally
219007321|NCT01516814|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
219007322|NCT01574612|DRUG|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
219007323|NCT00627003|DRUG|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
219432553|NCT00049504|GENETIC|polymerase chain reaction|Correlative studies
219432554|NCT00049504|GENETIC|fluorescence in situ hybridization|Correlative studies
219432555|NCT00049504|GENETIC|polymorphism analysis|Correlative studies
219432556|NCT00049504|GENETIC|gene expression analysis|Correlative studies
219432557|NCT00049504|RADIATION|total-body irradiation|Undergo total-body irradiation
219007324|NCT00627003|OTHER|Placebo|Placebo oral tablets administered daily for 5 weeks
219432558|NCT00049504|PROCEDURE|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
219432559|NCT00049504|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
219432560|NCT00702728|DRUG|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
219432561|NCT00702728|DRUG|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
219432562|NCT00736593|DRUG|Nexagon™ or Nexagon™ vehicle|
219432563|NCT00334204|DEVICE|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
219432564|NCT00045357|BIOLOGICAL|therapeutic autologous lymphocytes|
219432565|NCT04702204|DRUG|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
219007325|NCT04216017|DRUG|kenalog|Cortisone injection into shoulder
219432566|NCT02378493|BIOLOGICAL|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
219432567|NCT03781388|DRUG|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
219432568|NCT04432467|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
219432569|NCT04432467|OTHER|standard treatment|standard treatment according to clinical protocols
219432570|NCT05229991|DRUG|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
219432571|NCT05229991|DRUG|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
219432572|NCT00660075|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
219432573|NCT00660075|DRUG|Placebo|Placebo for 6 weeks
219432574|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
219432575|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
219432576|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
219432577|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
219432578|NCT05428449|DRUG|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
219432579|NCT05428449|DRUG|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
219432580|NCT00905372|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
219432581|NCT00905372|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
219432582|NCT01045434|DRUG|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
219432583|NCT03689868|BEHAVIORAL|Virtual Reality|Virtual Reality headset with calming scenery
219432584|NCT02842541|DRUG|EBI-031|
219432585|NCT00385034|DEVICE|Interactive computer based health-risk survey before doctor's visit|
219432586|NCT00000339|DRUG|Risperidone|
219432587|NCT00596804|DRUG|veltuzumab|once weekly intravenous dosing for 4 weeks
219007326|NCT04216017|DRUG|Lidocaine|Lidocaine injection into shoulder
219007327|NCT01957644|DRUG|Azacitidine|
219007328|NCT01957644|DRUG|Volasertib|
219432588|NCT00756704|BEHAVIORAL|Smoking cessation guideline implementation|"1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff"
219432589|NCT04489004|PROCEDURE|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
219432590|NCT04489004|PROCEDURE|Stepwise ablation|Patients receive stepwise ablation.
219432591|NCT03994276|DIETARY_SUPPLEMENT|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
219432592|NCT02657876|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
219432593|NCT05480839|PROCEDURE|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
219432594|NCT05480839|PROCEDURE|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
219432595|NCT05480839|PROCEDURE|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
219432596|NCT04463225|OTHER|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
219432597|NCT05168176|DRUG|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
219432598|NCT05168176|DRUG|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
219432599|NCT00993304|DRUG|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
219432600|NCT00993304|DRUG|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
219432601|NCT00424034|DRUG|GSK1325760A|
219432602|NCT06060704|DRUG|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
219432603|NCT06060704|DRUG|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
219432604|NCT06060704|DRUG|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
219432605|NCT03379376|OTHER|Questionnaire Administration|Receive questionnaire
219432606|NCT03379376|PROCEDURE|Supportive Care|Undergo eHealth mindful moving and breathing
219432607|NCT00778713|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
219432608|NCT03790072|BIOLOGICAL|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
219432609|NCT00735761|DRUG|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
219432610|NCT00735761|DRUG|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
219432611|NCT04300881|DRUG|Eplerenone|Following intravitreal ocriplasmin therapy
219007329|NCT02389010|BIOLOGICAL|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
219432612|NCT01611298|BIOLOGICAL|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
219432613|NCT02372110|DRUG|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
219432614|NCT02372110|DRUG|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
219432615|NCT01923649|DRUG|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
219432616|NCT01923649|DRUG|Placebo|Placebo for somatuline slow release 90 mg
219432617|NCT00753623|DRUG|Ramelteon|ramelteon (8 mg)
219432618|NCT00753623|DRUG|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
219432619|NCT03332303|DRUG|Estrace® Cream|Estrace® Cream
219432620|NCT03332303|DRUG|Estradiol Vaginal Cream|Estradiol Vaginal Cream
219432621|NCT03332303|DRUG|Vehicle Cream|Vehicle Cream
219432622|NCT05678478|OTHER|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
219432623|NCT05172531|DRUG|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
219432624|NCT05172531|DRUG|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
219432625|NCT00001890|DRUG|Estrogen therapy|
219432626|NCT00107822|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
219432627|NCT03365336|DRUG|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
219432628|NCT03365336|DRUG|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
219432629|NCT02872324|OTHER|Procurement questionnaires|
219432630|NCT00460629|PROCEDURE|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
219432631|NCT03504267|OTHER|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
219432632|NCT04974190|DEVICE|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
219432633|NCT05146934|RADIATION|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
219432634|NCT03549819|DRUG|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
219432635|NCT03549819|DRUG|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
219432636|NCT04322240|DRUG|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
219432637|NCT03639987|DRUG|Aducanumab|Administered as specified in the treatment arm.
219432638|NCT03639987|DRUG|Placebo|Administered as specified in the treatment arm.
219432639|NCT01816256|PROCEDURE|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
219432640|NCT04154371|DEVICE|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
219432641|NCT01011218|BEHAVIORAL|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
219432642|NCT01011218|BEHAVIORAL|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
219432643|NCT01011218|DRUG|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
219432644|NCT03820726|DRUG|Nintedanib|Bid
219432645|NCT05716594|COMBINATION_PRODUCT|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
219432646|NCT05716594|COMBINATION_PRODUCT|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
219432647|NCT03345992|DRUG|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
219432648|NCT03345992|DRUG|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
219432649|NCT00143962|BEHAVIORAL|Low Carbohydrate Diet|
219432650|NCT00206401|DRUG|Lantus and short acting analogs Vs NPH and short acting analogs|
219432651|NCT00345540|DRUG|NOV-002|60 mg / mL / day / 20-23 Days
219432652|NCT00345540|DRUG|Carboplatin|AUC 5 following IV bolus administration of NOV-002
219432653|NCT03164785|DRUG|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
219432654|NCT04384432|OTHER|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
219432655|NCT04384432|OTHER|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
219432656|NCT01406652|PROCEDURE|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
219432657|NCT03297333|OTHER|Resistance training|The resistance training group
219432658|NCT03297333|OTHER|Aerobic interval training|The aerobic interval training group
219432659|NCT01383187|PROCEDURE|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
219432660|NCT01383187|PROCEDURE|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
219432661|NCT00141037|DRUG|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
219432662|NCT00141037|DRUG|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m\^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m\^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
219432663|NCT00141037|DRUG|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40 kg and 1.5 mg/kg/day in subjects weighing \>40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
219432664|NCT00141037|DRUG|Tacrolimus|Taken orally from immediately preoperatively to those\>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects \<age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) \&5-7 ng/mL \>= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 \& 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
219432665|NCT00141037|DRUG|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
219432666|NCT00141037|DRUG|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
219432667|NCT00141037|DRUG|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
219432668|NCT05138237|PROCEDURE|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
219432669|NCT02535637|OTHER|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
219432670|NCT04186715|DEVICE|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
219432671|NCT03457311|DRUG|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
219432672|NCT03965871|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
219432673|NCT03965871|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
219432674|NCT03965871|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
219432675|NCT03965871|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
219432676|NCT02629328|DEVICE|CardioCel|Treatment with CardioCel implant
219432677|NCT03255811|DRUG|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
219432678|NCT00861380|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
219432679|NCT00861380|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."
219432680|NCT00861380|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.
219432681|NCT00260429|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
219432682|NCT00628758|DRUG|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
219432683|NCT00628758|DRUG|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
219007330|NCT02389010|OTHER|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
219007331|NCT05974033|COMBINATION_PRODUCT|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
219007332|NCT05974033|DRUG|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
219432684|NCT03379896|OTHER|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
219432685|NCT04404803|OTHER|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
219432686|NCT04041141|DIAGNOSTIC_TEST|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
219432687|NCT04041141|DEVICE|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
219432688|NCT04559087|PROCEDURE|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
219432689|NCT04504461|OTHER|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
219432690|NCT00637377|DRUG|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219432691|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219432692|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219432693|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219432694|NCT00378976|DRUG|valacyclovir|500 mg twice-daily oral
219432695|NCT00378976|DRUG|matching placebo|twice daily as per experimental drug
219432696|NCT05082402|DIAGNOSTIC_TEST|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
219432697|NCT02425280|BEHAVIORAL|Narrative Exposure Therapy|
219432698|NCT02425280|BEHAVIORAL|Treatment as Usual|
219432699|NCT03254862|PROCEDURE|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
219432700|NCT03254862|PROCEDURE|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
219432701|NCT04804280|GENETIC|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
219432702|NCT04804280|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
219432703|NCT02992301|DRUG|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
219007333|NCT01822340|DRUG|HM10560A|Once weekly HM10560A
219007334|NCT01822340|DRUG|Genotropin|Once daily Genotropin
219007335|NCT05457673|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
219432704|NCT00755872|DRUG|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
219578242|NCT03384017|OTHER|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
219578243|NCT01034787|DRUG|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
219432705|NCT00755872|DRUG|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
219432706|NCT00755872|DRUG|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
219432707|NCT00755872|DRUG|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
219432708|NCT01938001|DRUG|Rituximab|Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
219432709|NCT01938001|DRUG|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
219578244|NCT03262727|DRUG|BMS-986165|Oral administration of specified dose on specified days
219578245|NCT03262727|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
219578246|NCT04129320|BIOLOGICAL|enoblituzumab|anti-B7-H3 antibody
219578247|NCT04129320|BIOLOGICAL|MGA012|anti-PD-1 antibody
219432710|NCT01938001|DRUG|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
219432711|NCT04712799|DRUG|Otrivin|oxymetazoline nasal spray
219432712|NCT05320380|DRUG|Anti-CD123 ADC IMGN632|Given IV
219432713|NCT05320380|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
219432714|NCT05320380|DRUG|Cytarabine|Given IT and IV
219432715|NCT05320380|DRUG|Fludarabine Phosphate|Given IV
219432716|NCT05320380|DRUG|Hydrocortisone Sodium Succinate|Given IT
219432717|NCT05320380|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219578248|NCT04129320|BIOLOGICAL|MGD013|PD-1 X LAG-3 bispecific DART protein
219578249|NCT02072824|DRUG|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
219578250|NCT02072824|DRUG|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
219432718|NCT05320380|DRUG|Methotrexate|Given IT
219432719|NCT05320380|DRUG|Prednisolone|Given IT
219432720|NCT03056729|DRUG|BIIB076|Administered as single intravenous (IV) infusion
219432721|NCT03056729|DRUG|Placebo|Administered as single IV infusion
219432722|NCT00110474|DRUG|Glucosamine sulfate|
219432723|NCT00110474|DRUG|Acetaminophen|
219432724|NCT05715944|DRUG|AZD 1222|Vaccine
219432725|NCT02836132|BEHAVIORAL|Weight Watchers Online|
219432726|NCT02836132|BEHAVIORAL|Experience Success Virtual Reality Platform|
219578251|NCT02072824|DRUG|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
219578252|NCT03084367|DIAGNOSTIC_TEST|iFR pullback|iFR pullback assessment post angiographically successful PCI
219578253|NCT02893137|DEVICE|Optune|For further information see www.optune.com
219578254|NCT02893137|PROCEDURE|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
219578255|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
219578256|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Current Adhesive|single application
219578257|NCT02290275|DIETARY_SUPPLEMENT|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
219432727|NCT04559269|OTHER|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
219432728|NCT00828503|DRUG|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
219432729|NCT00828503|DRUG|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
219432730|NCT03707262|BIOLOGICAL|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
219432731|NCT03001323|DRUG|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
219432732|NCT03001323|DRUG|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
219432733|NCT02190630|DEVICE|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
219432734|NCT05754801|DRUG|Yunzhi Essence|Yunzhi Essence capsule
219432735|NCT05754801|OTHER|Placebo|Placebo capsules
219432736|NCT02539914|OTHER|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
219432737|NCT02539914|OTHER|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
219432738|NCT00527969|DRUG|HT1001 extract of Panax quinquefolius L|
219432739|NCT01620450|DRUG|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
219432740|NCT01495923|PROCEDURE|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
219432741|NCT01495923|PROCEDURE|Sham epidural steroid injection|Injection of saline into the back muscles
219432742|NCT01495923|DRUG|Gabapentin|Titration of gabapentin to effect
219432743|NCT01495923|DRUG|Placebo gabapentin|Titration of placebo gabapentin
219432744|NCT02762708|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
219432745|NCT02762708|BEHAVIORAL|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
219578258|NCT02290275|OTHER|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
219578259|NCT02290275|DIETARY_SUPPLEMENT|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
219578260|NCT00841906|DEVICE|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
219578261|NCT00841906|DEVICE|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
219578262|NCT06492200|OTHER|Psyllium husks|Patients in the intervention group will receive nutritional counseling and will be asked to take 10g (one tablespoon) of ground psyllium husks daily to significantly increase the fiber content of their diet.
219007336|NCT04941001|DEVICE|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
219578263|NCT03962582|DEVICE|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
219432746|NCT02762708|DRUG|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
219432747|NCT02762708|DRUG|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
219432748|NCT05216913|BEHAVIORAL|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
219432749|NCT05216913|DRUG|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
219432750|NCT05216913|OTHER|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
219432751|NCT01496170|DRUG|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
219432752|NCT01496170|DRUG|Placebo|Placebo capsules, orally, once per day for 7 days
219578264|NCT00903448|DRUG|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
219578265|NCT00903448|DRUG|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
219578266|NCT00453557|DRUG|rhGH|
219432753|NCT01115088|DIETARY_SUPPLEMENT|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
219432754|NCT01115088|DIETARY_SUPPLEMENT|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
219578267|NCT04340817|DIAGNOSTIC_TEST|Proteomics|Mass-spectometry proteomics
219578268|NCT04340817|DIAGNOSTIC_TEST|Transcriptomics|Next generation sequencing
219578269|NCT04340817|GENETIC|Genomics|Targeted genetics
219578270|NCT01739296|OTHER|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
219578271|NCT01739296|OTHER|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
219578272|NCT02212002|DRUG|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
219578273|NCT01816815|DRUG|BAY1002670|
219578274|NCT01816815|DRUG|Placebo|
219578275|NCT02957188|OTHER|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
219578276|NCT06219993|PROCEDURE|robot-assisted modified Kasai portoenterostomy|"1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
219578277|NCT06219993|PROCEDURE|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
219578278|NCT00912093|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
219578279|NCT00912093|DRUG|Placebo|Single subcutaneous injection of matching placebo
219578280|NCT04058574|DEVICE|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
219578281|NCT01672944|OTHER|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
219432755|NCT01115088|DIETARY_SUPPLEMENT|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
219432756|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
219432757|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
219432758|NCT05542693|BIOLOGICAL|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
219432759|NCT05542693|BIOLOGICAL|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
219432760|NCT01062009|DRUG|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
219432761|NCT03776097|OTHER|observational study|Observational study
219432762|NCT05199883|OTHER|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
219432763|NCT03145597|DEVICE|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
219432764|NCT03145597|DEVICE|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
219432765|NCT00217009|PROCEDURE|Narrowband Ultraviolet B (TL-01UVB) Therapy|
219432766|NCT00217009|PROCEDURE|Topical Psoralen plus ultraviolet A (PUVA)|
219432767|NCT00821860|OTHER|talc|Talc pleurodesis
219432768|NCT00821860|PROCEDURE|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
219432769|NCT00821860|PROCEDURE|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
219432770|NCT04100291|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
219432771|NCT04100291|OTHER|Placebo|Placebo by daily enema with placebo mixture
219432772|NCT04501757|BIOLOGICAL|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
219432773|NCT00419367|DRUG|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
219432774|NCT02577367|DRUG|Levothyroxine|Administer Levothyroxine
219432775|NCT00000440|DRUG|naltrexone (Revia)|
219432776|NCT00000440|DRUG|sertraline (Zoloft)|
219007337|NCT03077750|DRUG|VBP-245 Topical Gel|Topical application BID
219007338|NCT03077750|DRUG|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
219007339|NCT04245696|DEVICE|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
219432777|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
219432778|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
219432779|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
219432780|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
219432781|NCT02758119|OTHER|Serious Game|
219432782|NCT02758119|OTHER|Online course|
219432783|NCT04429412|BEHAVIORAL|MCT+|Metacognitive training
219475254|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
219475255|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
219475256|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
219475257|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
219475258|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
219475259|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
219475260|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
219475261|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
219475262|NCT03992456|BIOLOGICAL|Panitumumab|Given IV
219475263|NCT03992456|OTHER|Quality-of-Life Assessment|Ancillary studies
219475264|NCT03992456|OTHER|Questionnaire Administration|Ancillary studies
219475265|NCT03992456|DRUG|Regorafenib|Given PO
219475266|NCT03992456|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219475267|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
219432784|NCT01822223|DEVICE|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
219432785|NCT02439736|OTHER|Blood draw within 12 hours of head injury|
219432786|NCT06338007|DEVICE|Hand Dynamometer|Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.
219432787|NCT06338007|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.
219432788|NCT06338007|OTHER|Modified Frailty Index|The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
219432789|NCT01386892|OTHER|No intervention|There is no intervention for this study
219432790|NCT03519841|DEVICE|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
219432791|NCT06042192|DRUG|TK-254RX|Two TK-254RX per day to predetermined application site
219432792|NCT04366713|DRUG|Neratinib|Administered orally once daily as a single daily dose of 240 mg
219432793|NCT04366713|DRUG|Capecitabine|Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
219432794|NCT04366713|DRUG|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
219432795|NCT02733679|DRUG|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
219432796|NCT02733679|DRUG|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
219432797|NCT03717636|OTHER|medical evaluation|return of medical evaluation after discharge
219432798|NCT04888351|OTHER|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
219432799|NCT04888351|OTHER|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
219432800|NCT05387798|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
219432801|NCT05704439|DRUG|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
219432802|NCT05704439|OTHER|Placebo|Usual care
219432803|NCT04348539|OTHER|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
219432804|NCT00264446|DRUG|ADH300004|
219432805|NCT04213040|DIAGNOSTIC_TEST|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
219432806|NCT02715492|DRUG|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
219432807|NCT02715492|PROCEDURE|TACE|Trans arterial chemoembolization
219432808|NCT05418569|DEVICE|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
219432809|NCT05418569|OTHER|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
219432810|NCT00336778|DRUG|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
219578282|NCT01672944|OTHER|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
219432811|NCT04950140|PROCEDURE|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
219432812|NCT04950140|PROCEDURE|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
219432813|NCT02532387|OTHER|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
219432814|NCT01721512|OTHER|Breastfeeding|
219432815|NCT01721512|OTHER|Infant formula|
219432816|NCT00063310|DRUG|Leuprolide acetate|
219432817|NCT02318745|BEHAVIORAL|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
219432818|NCT02318745|BEHAVIORAL|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
219432819|NCT04458363|BIOLOGICAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
219432820|NCT04458363|DRUG|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
219432821|NCT06112912|OTHER|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
219432822|NCT01582958|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
219432823|NCT01582958|OTHER|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
219432824|NCT05865210|OTHER|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
219432825|NCT05865210|OTHER|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
219432826|NCT00500812|DRUG|Cethrin|
219432827|NCT02062476|DIETARY_SUPPLEMENT|Lactobacillus GG|
219432828|NCT05200455|DEVICE|Microelectrodes|Microelectrode implantation
219432829|NCT01153477|BEHAVIORAL|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
219432830|NCT00771173|DRUG|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
219432831|NCT00771173|OTHER|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
219432832|NCT01602549|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
219432833|NCT01602549|DRUG|Placebo|matching placebo tablet
219432834|NCT04026763|PROCEDURE|prostate biopsy|standard of care
219432835|NCT04026763|PROCEDURE|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
219432836|NCT04026763|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
219432837|NCT00719862|DRUG|Placebo nasal spray|Placebo
219432838|NCT00719862|DRUG|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
219432839|NCT03264833|OTHER|TempTraq|no intervention
219432840|NCT02669199|BIOLOGICAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
219432841|NCT04446871|DRUG|0.9% sodium chloride|Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
219432842|NCT04446871|DRUG|Methylene Blue|Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
219432843|NCT06098196|DRUG|Aminophyllin|Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
219432844|NCT05430672|DEVICE|The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. )|This is a objective performance criteria-controlled study, all subjects meet the criteria will receive the same treatment using the thoracic aortic stent graft system (Zylox-Tonbridge Medical Technology Co., Ltd. ).
219432845|NCT00293046|BIOLOGICAL|ALK Grass tablet - use of compliance device|
219432846|NCT03328624|DEVICE|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
219432847|NCT04019652|DRUG|CS-3150|Single, oral administration; 10-mg or 40-mg dose
219432848|NCT04019652|DRUG|Moxifloxacin|Single, oral administration; 400 mg-tablet
219432849|NCT04019652|DRUG|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
219432850|NCT04019652|DRUG|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
219432851|NCT00816855|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
219432852|NCT00892957|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
219432853|NCT00892957|OTHER|Surgical gauze pads|Manual compression with surgical gauze pads
219432854|NCT01184846|BIOLOGICAL|10% liquid formulation of human immunoglobulin|
219432855|NCT06079034|PROCEDURE|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
219432856|NCT06079034|PROCEDURE|Venoarterial ECMO|Initial support type of venoarterial ECMO
219432857|NCT06329999|DRUG|CMGV|"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
219432858|NCT01760187|DRUG|lomitapide|
219432859|NCT01794013|BEHAVIORAL|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
219432860|NCT01794013|BEHAVIORAL|Routine care|routine care
219432861|NCT05737407|OTHER|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
219432862|NCT05737407|OTHER|Standard choice of Peep|Choice of Peep according to standard practice
219432863|NCT01989182|DEVICE|Spiration Valve System|
219432864|NCT01989182|OTHER|Medical Management|
219432865|NCT05904353|PROCEDURE|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
219432866|NCT05904353|PROCEDURE|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
219432867|NCT02483078|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219432868|NCT02483078|DRUG|Placebo|
219432869|NCT02483078|DRUG|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
219432870|NCT02853955|DEVICE|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
219432871|NCT02853032|DEVICE|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
219432872|NCT02853032|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
219432873|NCT02853032|DEVICE|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
219475268|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
219475269|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
219475270|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
219475271|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
219475272|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
219475273|NCT00052507|DRUG|bortezomib|
219432874|NCT04591210|DRUG|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
219432875|NCT04591210|DRUG|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
219432876|NCT05942729|OTHER|Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone|The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
219432877|NCT01930240|DRUG|TRIA-662|1-MNA Chloride
219432878|NCT01930240|DRUG|Placebo|Double-blind placebo
219432879|NCT06202209|PROCEDURE|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
219432880|NCT06229587|PROCEDURE|furlow with buccinator flap|Assessment of speech and the middle ear function of patients between the age of 3 and 7 years surgically treated by ARC (Furlow z-palatoplasty with a buccinator myomucosal flap) was done
219432881|NCT04876599|BEHAVIORAL|IN FOCUS|Adapted Resiliency Group Intervention
219432882|NCT04876599|BEHAVIORAL|Usual Care|Referral to Virtual Group Support
219432883|NCT03175562|OTHER|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
219432884|NCT03175562|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
219432885|NCT04747522|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
219432886|NCT02146833|DRUG|Selinexor|Comparison of different dosages and dosing schedules of drug.
219432887|NCT07089927|PROCEDURE|Art Therapy|Complete virtual art therapy sessions. When complete the participant will receive a 3D printed replica of the avatar.
219578283|NCT04467268|BEHAVIORAL|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
219578284|NCT04831372|PROCEDURE|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
219578285|NCT04831372|PROCEDURE|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
219578286|NCT00127036|DRUG|XELOX|XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
219578287|NCT00127036|DRUG|XELIRI|XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
219578288|NCT00127036|DRUG|Bevacizumab|7.5 mg/kg intravenously (IV)
219578289|NCT00358293|DRUG|Tizanidine (sublingual or oral)|
219578290|NCT03921151|DRUG|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
219578291|NCT05717855|DIAGNOSTIC_TEST|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
219578292|NCT04273581|DRUG|placebo|100mg/d，qn，for 14 days.
219578293|NCT04273581|DRUG|Thalidomide|100mg/d，qn，for 14 days.
219007340|NCT04572932|DRUG|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
219578294|NCT00771381|DRUG|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
219432888|NCT07089927|OTHER|Interview|Ancillary studies
219432889|NCT07089927|OTHER|Survey Administration|Ancillary studies
219432890|NCT04984512|DRUG|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
219432891|NCT04984512|DRUG|Placebo-matching tablets|Placebo will be administered with food.
219432892|NCT01330563|DRUG|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
219432893|NCT03700736|BEHAVIORAL|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
219432894|NCT04532918|DRUG|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
219432895|NCT04532918|DRUG|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
219432896|NCT04532918|DRUG|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
219432897|NCT04532918|DRUG|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
219432898|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
219432899|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
219432900|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
219432901|NCT01336166|BIOLOGICAL|Placebo control|120 adults were assigned to receive 1 dose of placebo.
219432902|NCT04639908|OTHER|Interview|interview with patient
219578295|NCT00771381|DRUG|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
219578296|NCT04415736|OTHER|No intervention, observational study|
219432903|NCT03427138|BEHAVIORAL|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
219432904|NCT03427138|BEHAVIORAL|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
219432905|NCT01410799|DRUG|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
219432906|NCT05508399|OTHER|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~1. Blood cell samples;~2. Paraffin sample of residual tumor tissue of biopsy;~3. Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
219432907|NCT05435742|BIOLOGICAL|SON-080|Recombinant human interleukin-6 (rhIL-6)
219475274|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
219475275|NCT02974270|DRUG|Leuprolide|
219475276|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
219578297|NCT04413136|BEHAVIORAL|Web-ORLA|
219578298|NCT04413136|BEHAVIORAL|Control|
219578299|NCT03516396|BEHAVIORAL|Training Plus|Training plus enhanced community development activities
219578300|NCT03516396|BEHAVIORAL|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
219578301|NCT03516396|BEHAVIORAL|No Inputs then Community development and training|No inputs for 24 months then add community development and training
219578302|NCT04763018|DEVICE|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
219578303|NCT01431911|DRUG|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
219578304|NCT01431911|DRUG|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
219578305|NCT03219931|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
219578306|NCT03219931|DRUG|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
219578307|NCT03018210|PROCEDURE|Surgical repair of the rotator cuff|
219578308|NCT02799238|BIOLOGICAL|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
219578309|NCT02799238|RADIATION|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
219007341|NCT00954434|DIETARY_SUPPLEMENT|red wine|intake of red wine on a daily basis
219432908|NCT05243277|OTHER|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
219578310|NCT02799238|DRUG|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
219432909|NCT02564029|DRUG|PF-06372865|Single dose
219432910|NCT02564029|DRUG|Placebo|Placebo for PF-06372865 and placebo for lorazepam
219432911|NCT02564029|DRUG|Lorazepam|2 mg single oral dose
219432912|NCT01520584|DIETARY_SUPPLEMENT|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
219432913|NCT02235402|DRUG|Lacidipine|
219578311|NCT03869203|OTHER|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
219578312|NCT01403064|BIOLOGICAL|ALD518|IV
219432914|NCT02235402|DRUG|Bendrofluazide|
219578313|NCT01403064|DRUG|0.9% saline|IV Infusion
219578314|NCT02945670|BEHAVIORAL|Focus Group|We had recruited 64 women and completed 7 focus group sessions
219578315|NCT01718470|PROCEDURE|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
219578316|NCT01718470|PROCEDURE|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
219578317|NCT04250948|DRUG|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
219578318|NCT04250948|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
219578319|NCT04250948|DRUG|S1|S-1: 40\~60mg Bid，d1\~14, q3w
219578320|NCT04250948|DRUG|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
219578321|NCT02000401|DRUG|Ketorolac Tromethamine|
219578322|NCT06304025|BIOLOGICAL|Wharton's jelly mesenchymal stem cells (WJ-MSCs)|Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
219007342|NCT02193568|PROCEDURE|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
219007343|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
219007344|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Undergo craniotomy
219007345|NCT02193568|OTHER|Arm II (intubated general anesthesia)|Ancillary studies
219007346|NCT02193568|PROCEDURE|Arm I (light sedation)|Undergo craniotomy
219007347|NCT02193568|OTHER|Arm I (light sedation)|Ancillary studies
219432915|NCT02235402|DRUG|Placebo|
219432916|NCT03118076|DRUG|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
219432917|NCT03118076|DRUG|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
219432918|NCT04126031|DRUG|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
219432919|NCT04126031|DRUG|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
219432920|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
219432921|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
219432922|NCT01769144|DEVICE|Acticoat Absorbent|wound dressing
219432923|NCT01769144|DEVICE|BCT|wound dressing
219432924|NCT00002511|RADIATION|low-LET photon therapy|
219432925|NCT00326157|DRUG|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
219432926|NCT01344252|DRUG|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
219432927|NCT00176124|PROCEDURE|leukocyte depletion of whole blood|
219432928|NCT00176124|OTHER|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
219432929|NCT00617656|DRUG|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
219432930|NCT00617656|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
219432931|NCT00617656|DRUG|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
219432932|NCT00617656|DRUG|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
219432933|NCT00131664|DRUG|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
219432934|NCT00131664|DRUG|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
219432935|NCT00131664|DRUG|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
219432936|NCT03789890|DRUG|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
219432937|NCT03789890|DRUG|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
219432938|NCT05264558|DEVICE|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
219432939|NCT05264558|DRUG|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
219432940|NCT05264558|OTHER|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
219432941|NCT02952833|DRUG|Saline|Sodium chloride solution.
219432942|NCT02952833|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
219432943|NCT04030676|PROCEDURE|Biopsies|Two more biopsies in inflammatory zone will be collected.
219432944|NCT04030676|BIOLOGICAL|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
219432945|NCT06837792|DRUG|Experimental treatment arm|"Trastuzumab deruxtecan (T-DXd) 5.4mg/kg intravenous infusion every 3 weeks.~(1 cycle = 3 weeks)"
219432946|NCT06837792|DRUG|Control treatment arm|"1. Fulvestrant intramuscular injection of two 250mg injection every 4 weeks (every 2 weeks for the first cycle, 1 cycle = 4 weeks)~2. Fulvestrant (administered same as above) + alpelisib 300mg oral administration every day~   (1 cycle = 4 weeks)\*~3. Exemestane 25mg oral administration every day (1 cycle = 4 weeks)~4. Exemestane 25mg + everolimus 10mg oral administration every day (1 cycle = 4 weeks)~5. Tamoxifen 20mg oral administration every day (1 cycle = 4 weeks)~6. Fulvestrant (administered same as above) + Capivasertib 400mg oral administration twice a day(dosed on Days 1 to 4 in each week of a 28-day treatment cycle)~   * fulvestrant + alpelisib can be selected in PIK3CA activating mutation positive patients~  * Fulvestrant + Capivasertib can be selected in 1 or More mutation positive of PIK3CA/AKT1/PTEN"
219432947|NCT00556621|DRUG|cisplatin|
219432948|NCT00556621|DRUG|gemcitabine hydrochloride|
219432949|NCT00556621|PROCEDURE|biopsy|
219432950|NCT00556621|PROCEDURE|cystoscopy|
219432951|NCT00556621|PROCEDURE|therapeutic conventional surgery|
219432952|NCT00556621|RADIATION|radiation therapy|
219432953|NCT01060098|DRUG|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
219432954|NCT05440487|OTHER|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
219432955|NCT01499797|OTHER|The CareWell programme|"The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions"
219578323|NCT01939925|OTHER|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
219432956|NCT01819441|DRUG|Azelnidipine|8mg or 16mg
219432957|NCT01819441|DRUG|Perindopril|4mg or 8mg
219432958|NCT01819441|DRUG|hydrochlorothiazide|12.5mg or 25mg
219432959|NCT02979561|DRUG|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
219432960|NCT02979561|DRUG|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
219432961|NCT00005905|DRUG|hu Leptin (A-100)|
219432962|NCT06318260|DRUG|Dobutrex|Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
219432963|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
219432964|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
219432965|NCT02688153|DEVICE|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
219432966|NCT02688153|DEVICE|Stented aortic bioprostheses|In comparison to control valves available on the market.
219432967|NCT00107172|PROCEDURE|surgery|
219432968|NCT00107172|RADIATION|brachytherapy|
219432969|NCT01840436|DEVICE|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
219432970|NCT01840436|DEVICE|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
219578324|NCT01939925|OTHER|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
219432971|NCT01855841|DRUG|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
219432972|NCT01855841|DRUG|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
219432973|NCT02152150|OTHER|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
219432974|NCT02152150|OTHER|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
219432975|NCT01102140|DRUG|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
219432976|NCT01102140|DRUG|Sugar Pill|Matching sugar pill
219432977|NCT03199144|DRUG|Chemotherapy|3 cycles of Gemzar-Abraxane
219432978|NCT03199144|RADIATION|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
219432979|NCT03199144|PROCEDURE|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
219432980|NCT02540876|DRUG|Ilorasertib|Given PO
219432981|NCT02540876|OTHER|Laboratory Biomarker Analysis|Correlative studies
219432982|NCT03674307|OTHER|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
219432983|NCT03674307|OTHER|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
219432984|NCT01201304|BEHAVIORAL|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
219432985|NCT01201304|BEHAVIORAL|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
219432986|NCT01201304|BEHAVIORAL|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
219432987|NCT01201304|BEHAVIORAL|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
219432988|NCT03526341|DEVICE|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
219578325|NCT01787539|DRUG|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
219578326|NCT00686530|PROCEDURE|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
219432989|NCT00290303|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
219432990|NCT01069094|DRUG|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
219432991|NCT01069094|DRUG|Progenta|25 mg, administered as a once daily oral dose for 90 days.
219432992|NCT01069094|DRUG|Progenta|50 mg, administered as a once daily oral dose for 90 days.
219432993|NCT01069094|DRUG|Lucron Depot|3.75 mg IM monthly
219432994|NCT01069094|DRUG|Placebo|Administered as a once daily oral dose for 90 days.
219432995|NCT05278936|OTHER|The cataract surgery and the anterior vitrectomy|Surgical
219432996|NCT01614340|BEHAVIORAL|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
219432997|NCT02443051|BEHAVIORAL|Attention Bias Modification|Computer delivered modification in 80% of trials
219432998|NCT00125229|DRUG|Mannitol|
219432999|NCT00125229|DRUG|Hypertonic Saline|
219433000|NCT00733473|DRUG|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
219433001|NCT00733473|DRUG|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
219433002|NCT05395728|OTHER|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
219433003|NCT05395728|OTHER|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
219578327|NCT00686530|PROCEDURE|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
219578328|NCT01776463|DRUG|Z-360|
219578329|NCT01776463|DRUG|placebo|
219578330|NCT03479463|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
219433004|NCT05711862|DRUG|suvorexant (SUVO)|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
219433005|NCT05711862|DRUG|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
219433006|NCT02061748|DRUG|Observational|Retrospective Chart Review
219433007|NCT01742091|DRUG|LY2541546 - SC|Administered SC
219433008|NCT01742091|DRUG|LY2541546 - IV|Administered IV
219433009|NCT01742091|DRUG|Placebo - SC|Administered SC
219433010|NCT01742091|DRUG|Placebo - IV|Administered IV
219433011|NCT05227768|DRUG|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
219578331|NCT02271139|DRUG|Alectinib|Alectinib 600 mg administered orally with food.
219433012|NCT05227768|DRUG|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
219433013|NCT05227768|DRUG|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
219433014|NCT05227768|DRUG|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
219433015|NCT05227768|DRUG|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
219433016|NCT05286567|DRUG|RGRN-305|Heat shock protein 90 inhibitor
219433017|NCT05286567|DRUG|Placebo|Placebo (blinded)
219578332|NCT01521416|OTHER|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
219578333|NCT02603302|RADIATION|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
219578334|NCT02603302|PROCEDURE|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
219578335|NCT04688931|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
219578336|NCT04688931|PROCEDURE|TURBT|The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.
219578337|NCT06019520|DRUG|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
219578338|NCT06019520|DRUG|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
219578339|NCT03290365|DRUG|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
219578340|NCT03290365|DRUG|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
219578341|NCT04871763|OTHER|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
219578342|NCT04871763|OTHER|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
219578343|NCT04871763|OTHER|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
219433018|NCT02069249|BEHAVIORAL|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
219433019|NCT02069249|BEHAVIORAL|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
219433020|NCT05488418|OTHER|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
219433021|NCT03706040|BIOLOGICAL|Placebo|subcutaneous (SC) injection
219578344|NCT00450619|RADIATION|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
219578345|NCT00450619|BIOLOGICAL|Sargramostim|100 mcg/injection x 4 days given subcutaneously
219578346|NCT00450619|BIOLOGICAL|Recombinant vaccinia-TRICOM vaccine|2 x 10\^8 PFU given subcutaneously on day 1.
219578347|NCT00450619|BIOLOGICAL|Recombinant fowlpox-TRICOM vaccine|1 x 10\^9 PFU given subcutaneously on days 15 and 29
219578348|NCT05469217|OTHER|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
219578349|NCT04327713|DIETARY_SUPPLEMENT|fish oil supplement|daily fish oil supplement vs. placebo
219578350|NCT05222503|DEVICE|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
219578351|NCT05222503|DEVICE|Knee Brace|Knee Brace without OPUM Digital Knee
219433022|NCT03706040|BIOLOGICAL|Risankizumab|subcutaneous (SC) injection
219433023|NCT01340560|PROCEDURE|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
219433024|NCT04544124|BEHAVIORAL|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
219433025|NCT05243004|OTHER|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions."
219433026|NCT03658317|DIAGNOSTIC_TEST|renal arterial resistive index|done by dupplex on renal arteries
219433027|NCT03658317|DIAGNOSTIC_TEST|uric acid level|serum sample for doing the test
219433028|NCT03658317|DIAGNOSTIC_TEST|serum urea and creatinine|serum samples for doing the test
219433029|NCT03658317|DIAGNOSTIC_TEST|24 hours urinary proteins|urine collected over 24 hours for doing the test
219433030|NCT03658317|DIAGNOSTIC_TEST|lipogram|serum sample for doing the test
219433031|NCT03658317|DIAGNOSTIC_TEST|HbA1c level|serum sample for doing the test
219433032|NCT03658317|DIAGNOSTIC_TEST|urine analysis|urine sample for doing the test
219578352|NCT05232084|DRUG|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219578353|NCT04943978|OTHER||just observational blood and liver sampling
219578354|NCT00587015|DRUG|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
219578355|NCT05854888|PROCEDURE|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
219578356|NCT05854888|PROCEDURE|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
219578357|NCT00455611|DEVICE|CPAP (Continuous Positive Airway Pressure)|
219578358|NCT03106831|DRUG|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
219578359|NCT03106831|DRUG|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
219578360|NCT03752944|PROCEDURE|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
219578361|NCT05369286|DRUG|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
219578362|NCT04070586|DEVICE|4DCBCT images|Images are acquired and assessed offline
219578363|NCT01608386|PROCEDURE|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
219578364|NCT00425334|DRUG|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
219578365|NCT00425334|DRUG|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
219578366|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
219578367|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
219433033|NCT03658317|DIAGNOSTIC_TEST|abdominal ultrasonography|done by the ultrasonography device
219433034|NCT01475318|DRUG|mifepristone|200 mg mifepristone on day 1
219433035|NCT01475318|DRUG|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
219433036|NCT01475318|DRUG|Misoprostol|misoprostol 800mcg PV on day 3
219433037|NCT04260841|DEVICE|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
219433038|NCT04545034|OTHER|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
219578368|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
219433039|NCT01668134|RADIATION|Stereotactic radiation|
219433040|NCT03068936|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
219433041|NCT03068936|DRUG|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
219433042|NCT03010904|OTHER|Dietary intervention|
219433043|NCT03030183|DRUG|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
219433044|NCT04061941|BEHAVIORAL|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
219433045|NCT03788616|DRUG|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
219433046|NCT03788616|DRUG|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
219433047|NCT00212758|DRUG|Nutropin AQ|Nutropin AQ
219433048|NCT04936204|DEVICE|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
219433049|NCT04936204|DEVICE|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
219433050|NCT00141310|DRUG|Sildenafil citrate|
219433051|NCT03820908|DRUG|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
219433052|NCT02683707|OTHER|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
219433053|NCT02683707|DRUG|Fentanyl|IV peri-procedural analgesia
219433054|NCT02683707|DRUG|Lidocaine|Local Anesthetic
219433055|NCT02683707|DRUG|Midazolam|IV sedation
219433056|NCT03825445|DRUG|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
219433057|NCT03825445|DRUG|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
219433058|NCT00662389|DEVICE|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
219433059|NCT03562624|DRUG|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
219433060|NCT03562624|DRUG|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
219433061|NCT00095810|DRUG|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
219433062|NCT01783470|DRUG|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
219433063|NCT00247273|DRUG|risedronate|tablet, 5 mg risedronate, once a day for 2 years
219433064|NCT00247273|DRUG|risedronate|oral, 150 mg risedronate, once a month for 2 years
219433065|NCT01510834|BEHAVIORAL|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
219433066|NCT04238572|DEVICE|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
219578369|NCT05914935|DRUG|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
219433067|NCT04238572|DEVICE|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
219433068|NCT05059938|BEHAVIORAL|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
219433069|NCT04492787|DRUG|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
219433070|NCT04492787|DRUG|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
219433071|NCT02977533|DRUG|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219433072|NCT02977533|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219433073|NCT02977533|DRUG|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
219433074|NCT00001753|PROCEDURE|Magnetic resonance imaging|
219433075|NCT01419015|DEVICE|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
219433076|NCT04861519|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
219433077|NCT06552923|OTHER|ECHO Tele-Education|A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
219433078|NCT02972957|BIOLOGICAL|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
219433079|NCT02972957|DRUG|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
219433080|NCT01999907|DIETARY_SUPPLEMENT|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
219433081|NCT01999907|DIETARY_SUPPLEMENT|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
219433082|NCT01999907|OTHER|Placebo|placebo given in a 2ml dose by mouth at baseline.
219433083|NCT06347783|DEVICE|Insulin pump|Continuous subcutaneous insulin therapy.
219433084|NCT03276572|DRUG|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
219433085|NCT04491214|OTHER|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
219578370|NCT03438825|PROCEDURE|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
219578371|NCT01679106|OTHER|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
219578372|NCT01679106|OTHER|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
219578373|NCT05038579|PROCEDURE|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
219578374|NCT00000408|PROCEDURE|Patient education evaluation|
219762069|NCT06960187|BEHAVIORAL|Weyera Intervention|"Weyera intervention is an eight-week program featuring weekly, two-hour facilitated group sessions with 6-10 participants in each group, led by trained lay facilitators. Each session will address the weekly topic and introduce an evidence-based coping strategy (e.g., mindfulness, positive refocusing) that participants can practice over the following week. Within this outline, we will create intervention activities based on theory-based change methods and practical applications matched to objectives and determinants in the Logic Model of Change.~Outline of major modules for the eight weeks:~1. Introduction to mental health~2. Stress and family pressure~3. Self-exploration and critical reflection~4. Intersectional Identities~5. Family Relationships~6. Discussing mental health in the Ethiopian and Eritrean communities~7. Trauma and Abuse~8. Navigating mental health services"
219433086|NCT02784977|DEVICE|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
219433087|NCT02784977|DEVICE|Intraoral device (IOD)|Treatment of OSA with IOD
219433088|NCT02784977|PROCEDURE|Uvuloplasty|Uvuloplasty
219433089|NCT02784977|OTHER|Conservative treatment|No active intervention
219578375|NCT02773459|DRUG|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
219578376|NCT00755859|DRUG|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
219578377|NCT00755859|DRUG|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
219578378|NCT00173875|DRUG|Iressa|
219578379|NCT03045159|BEHAVIORAL|Strong Families Strong Forces|Parenting program
219578380|NCT03045159|BEHAVIORAL|Strong Parents|self-care program
219762070|NCT06960187|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (pre-intervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
219762071|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
219433090|NCT00048490|DEVICE|transcranial magnetic stimulation (TMS)|
219433091|NCT04933409|PROCEDURE|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
219433092|NCT04933409|PROCEDURE|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
219433093|NCT01444508|DRUG|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
219433094|NCT01444508|DRUG|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
219433095|NCT02657434|DRUG|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
219433096|NCT02657434|DRUG|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
219578381|NCT03311100|OTHER|immunohistochemistry assay|biomarkers expression
219578382|NCT02887300|BEHAVIORAL|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
219578383|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
219578384|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
219578385|NCT02044796|DRUG|Cladribine|Given IV
219762072|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
219762073|NCT06959524|DEVICE|Drug Eluting Balloon|AGENT DCB
219762074|NCT06959524|DEVICE|Drug eluting stent|Any commercially available DES used for standard of care.
219578386|NCT02044796|DRUG|Cytarabine|Given IV
219578387|NCT02044796|BIOLOGICAL|Filgrastim|Given SC
219578388|NCT02044796|OTHER|Laboratory Biomarker Analysis|Correlative studies
219578389|NCT02044796|DRUG|Mitoxantrone Hydrochloride|Given IV
219578390|NCT04102852|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
219578391|NCT00435396|BIOLOGICAL|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
219433097|NCT02657434|DRUG|Cisplatin|Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
219433098|NCT02657434|DRUG|Pemetrexed|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
219433099|NCT01576666|DRUG|LDE225|
219433100|NCT01576666|DRUG|BKM120|
219433101|NCT05247983|PROCEDURE|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
219433102|NCT04494529|DRUG|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
219433103|NCT04494529|DRUG|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
219433104|NCT04827940|OTHER|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
219578392|NCT02824718|DRUG|Teriparatide|human recombinant parathormone
219578393|NCT02824718|DRUG|Thiazide|Diuretic
219578394|NCT02824718|DRUG|Potassium sparing diuretic|Diuretic
219578395|NCT02824718|DRUG|Alfacalcidol|Belongs to the class of vitamin D and analogues
219578396|NCT04408599|DRUG|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
219578397|NCT05102136|DRUG|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
219578398|NCT05102136|DRUG|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
219578399|NCT00713999|DRUG|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
219433105|NCT03780985|PROCEDURE|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
219433106|NCT03780985|PROCEDURE|Cesarean section|to delivery of the fetus
219433107|NCT03780985|PROCEDURE|Suture|to fix the intrauterine device
219433108|NCT01155791|DRUG|Docetaxel|IV 75 mg/m2
219433109|NCT01155791|DRUG|Biosyn|IV dosage varies
219433110|NCT01155791|DRUG|Prednisone|5mg, orally
219433111|NCT02116738|PROCEDURE|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
219433112|NCT06507761|OTHER|Sham|An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.
219433113|NCT06507761|OTHER|Hot Pack|Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
219433114|NCT06507761|OTHER|Cold Pack|Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
219433115|NCT03808428|DEVICE|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
219433116|NCT05098418|DRUG|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
219433117|NCT01628393|DRUG|Ozanimod|Oral capsule taken once a day
219578400|NCT00714493|BIOLOGICAL|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
219578401|NCT02372071|DEVICE|BiliCare|Two measurements with the BiliCare device
219578402|NCT00132171|DRUG|Sequential therapy|
219578403|NCT05005871|OTHER|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
219578404|NCT01297387|OTHER|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
219578405|NCT04976998|DIAGNOSTIC_TEST|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
219578406|NCT02619877|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
219578407|NCT02619877|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
219578408|NCT00132093|DRUG|Eplerenone|
219578409|NCT05824247|DEVICE|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
219578410|NCT06156345|DEVICE|Conservative with Denneroll|Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.
219578411|NCT06156345|OTHER|Conservative|conservative management of stretching and relaxation with placebo traction.
219578412|NCT00506129|DRUG|Fludarabine|25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
219578413|NCT00506129|DRUG|Melphalan|70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
219433118|NCT01628393|DRUG|Placebo|Oral capsule taken once a day
219433119|NCT02273414|DRUG|BIIL 284 BS - rising dose|
219433120|NCT02273414|DRUG|Placebo|
219007348|NCT02845453|DRUG|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
219007349|NCT02845453|OTHER|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
219433121|NCT01089569|DRUG|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
219433122|NCT01089569|DRUG|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
219433123|NCT06402968|DRUG|Clevidipine Injection|Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
219433124|NCT06402968|DRUG|Alternate IV Antihypertensive Regimen|"The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour."
219433125|NCT00251017|PROCEDURE|Vancomycin|Two hour creatinine clearance before and after vancomycin
219433126|NCT00251017|PROCEDURE|DNA are extracted from the whole blood of subjects|
219433127|NCT01956266|BEHAVIORAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
219433128|NCT01220505|PROCEDURE|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
219433129|NCT02251678|DIETARY_SUPPLEMENT|Elimune Capsules|2 capsules BID for 28 days
219433130|NCT05838209|DRUG|test|Ozone oil used as an adjunctive of scaling and root planing and control,
219007350|NCT02101476|DRUG|Percocet|10mg/650mg
219007351|NCT02101476|DRUG|Xartemis|15mg/650mg
219433131|NCT05838209|DRUG|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
219433132|NCT01989754|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
219433133|NCT01989754|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
219433134|NCT01989754|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
219433135|NCT04391855|DRUG|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
219433136|NCT04391855|DRUG|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
219433137|NCT04391855|DRUG|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
219433138|NCT04391855|DRUG|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
219007352|NCT01116154|DRUG|lenalidomide|Given orally
219007353|NCT01116154|DRUG|vorinostat|Given orally
219007354|NCT01116154|OTHER|laboratory biomarker analysis|Correlative studies
219007355|NCT05914714|DRUG|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
219007356|NCT01107041|BEHAVIORAL|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
219475277|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
219476414|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
219578414|NCT00506129|PROCEDURE|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
219433139|NCT05856669|DEVICE|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
219433140|NCT00347477|DRUG|HyperHAES vs. RA-solution/NaCl|
219433141|NCT05572346|OTHER|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
219433142|NCT00003777|DRUG|amifostine trihydrate|
219433143|NCT00003777|DRUG|cisplatin|
219433144|NCT00003777|DRUG|fluorouracil|
219433145|NCT00003777|PROCEDURE|surgical procedure|
219433146|NCT00003777|RADIATION|radiation therapy|
219433147|NCT01994317|OTHER|Algorithm|IV sedation dosing calculated by algorithm
219433148|NCT01994317|OTHER|Standard care|IV sedation dosing calculated by standard care.
219433149|NCT01659268|OTHER|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
219433150|NCT01659268|OTHER|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
219578415|NCT00506129|DRUG|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
219433151|NCT01618526|DIETARY_SUPPLEMENT|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
219433152|NCT01618526|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
219433153|NCT01110226|DRUG|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
219578416|NCT05842096|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
219578417|NCT05842096|DIAGNOSTIC_TEST|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
219578418|NCT05842096|DIAGNOSTIC_TEST|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
219578419|NCT03979781|DRUG|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
219578420|NCT03979781|DRUG|standard of care|antiplatelet selection using standard of care
219578421|NCT00523224|PROCEDURE|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
219578422|NCT00523224|BIOLOGICAL|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
219433154|NCT01110226|DRUG|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
219433155|NCT02379312|DIETARY_SUPPLEMENT|Very low energy aerated beverage|
219433156|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 1|
219433157|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 2|
219433158|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 3|
219433159|NCT01286701|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
219433160|NCT03350841|PROCEDURE|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
219433161|NCT03350841|PROCEDURE|root canal treatment|conventional root canal treatment and obturation with guttapercha
219433162|NCT04857788|OTHER|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
219433163|NCT01498588|DRUG|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
219433164|NCT01498588|DRUG|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
219578423|NCT00354341|DRUG|Epoetin beta|
219762075|NCT06959524|PROCEDURE|Plain old balloon angioplasty|Bifurcation side branch - POBA
219191997|NCT01726140|PROCEDURE|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
219433165|NCT01498588|DRUG|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
219433166|NCT01498588|DRUG|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
219433167|NCT05388955|OTHER|None, transplantation recipients|None, observational
219433168|NCT05381207|DRUG|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
219433169|NCT00480207|DIETARY_SUPPLEMENT|folic acid|
219433170|NCT00480207|DIETARY_SUPPLEMENT|omega-3|
219433171|NCT00480207|DIETARY_SUPPLEMENT|vit B12|
219433172|NCT00480207|OTHER|folic acid placebo|
219433173|NCT00480207|OTHER|omega-3 placebo|
219433174|NCT06357884|PROCEDURE|Callus debridement|Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
219433175|NCT01369225|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
219433176|NCT01369225|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
219433177|NCT01369225|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
219433178|NCT01369225|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
219433179|NCT01369225|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
219433180|NCT01489267|OTHER|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
219433181|NCT00105183|BIOLOGICAL|Placebo|placebo infusion, single
219762076|NCT06819176|DRUG|Lenacapavir|Lenacapavir (Sunlenca) is a prescription drug approved by the Food and Drug Administration (FDA) for the treatment of people living with multidrug-resistant HIV. Lenacapavir is always used as part of a combination ART regimen. Participants will receive lenacapavir at 927 mg by subcutaneous injection (2x1.5 mL injections) on day 0 and 600 mg orally (2x300 mg tablets) on days 0 and 1, followed by 927 mg by subcutaneous injection (2x1.5 mL injections) at weeks 24 and 48.
219762077|NCT04896073|DRUG|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
219433182|NCT00105183|BIOLOGICAL|EZ-2053|single IV infusion, 9 mg/kg
219433183|NCT00105183|BIOLOGICAL|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
219433184|NCT04354441|DRUG|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
219433185|NCT04354441|DRUG|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
219433186|NCT01988597|OTHER|Dry eyes|
219433187|NCT01999023|DIETARY_SUPPLEMENT|Low protein formula group|Low protein formula formula (28.5 g) twice a day
219433188|NCT02108834|PROCEDURE|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
219433189|NCT02108834|PROCEDURE|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
219433190|NCT00695513|DIETARY_SUPPLEMENT|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
219433191|NCT04623463|BEHAVIORAL|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
219433192|NCT04724681|DEVICE|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
219433193|NCT01153906|OTHER|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
219433194|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
219762078|NCT04896073|DIAGNOSTIC_TEST|ECG|Screening and end of treatment visit.
219191998|NCT04507841|DRUG|Niraparib|Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
219433195|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
219433196|NCT00646568|DRUG|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
219433197|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
219433198|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
219433199|NCT05352867|OTHER|Placebo|0.5ml/person
219433200|NCT04198519|OTHER|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
219433201|NCT02980692|DRUG|SUNPG1623 I|injection
219433202|NCT02980692|DRUG|SUNPG1623 II|injection
219433203|NCT02980692|DRUG|SUNPG1623 III|injection
219433204|NCT02980692|DRUG|SUNPG1623 IV|injection
219433205|NCT02980692|DRUG|PLACEBO|injection
219433206|NCT01743885|DRUG|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
219433207|NCT01743885|DRUG|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
219433208|NCT05657509|OTHER|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.
219433209|NCT05657509|OTHER|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
219762079|NCT04896073|DIAGNOSTIC_TEST|CT/MRI|Screening. Subsequent cycles Day 1 (≤3days) and Day 15 (±2 days) (every other cycle). End of treatment visit.
219433210|NCT02972112|BEHAVIORAL|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
219433211|NCT02972112|OTHER|Sham|standard birth preparation sessions.
219433212|NCT03368326|DIAGNOSTIC_TEST|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
219433213|NCT01478295|BEHAVIORAL|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
219433214|NCT01478295|OTHER|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
219433215|NCT05561894|OTHER|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
219433216|NCT00000324|DRUG|Tryptophan|
219433217|NCT02641314|DRUG|metronomic therapy|"* Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
219433218|NCT03177785|BEHAVIORAL|EverydayMatters|
219433219|NCT03990090|DRUG|TG103|Administered SC
219433220|NCT03990090|DRUG|Placebo|Administered SC
219433221|NCT03607071|DRUG|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
219433222|NCT04701749|DEVICE|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
219433223|NCT04701749|OTHER|No Percutaneous left atrial closure|No Percutaneous left atrial closure
219476415|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
219476416|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
219762080|NCT04896073|PROCEDURE|Tumor Biopsy|Optional. Baseline Cycle 1, Day 1 and Cycle 1, Day 15. End of treatment visit or progressive disease.
219762081|NCT03866382|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219762082|NCT03866382|PROCEDURE|Bone Scan|Undergo bone scan
219762083|NCT03866382|DRUG|Cabozantinib S-malate|Given PO
219762084|NCT03866382|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
219762085|NCT03866382|PROCEDURE|Echocardiography Test|Undergo echocardiography
219762086|NCT03866382|BIOLOGICAL|Ipilimumab|Given IV
219762087|NCT03866382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762088|NCT03866382|BIOLOGICAL|Nivolumab|Given IV
219762089|NCT03866382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219433224|NCT03140124|BEHAVIORAL|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
219433225|NCT03140124|BEHAVIORAL|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
219433226|NCT04042012|OTHER|Eccentric exercise|soleus eccentric exercise
219433227|NCT04042012|OTHER|PNE|the application of galvanic current
219433228|NCT04042012|OTHER|Combined|soleus eccentric exercise and PNE
219433229|NCT03620253|DRUG|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
219433230|NCT03620253|DRUG|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
219433231|NCT03431909|DRUG|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
219433232|NCT03431909|DRUG|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
219433233|NCT00826488|DEVICE|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
219433234|NCT02716662|DIETARY_SUPPLEMENT|Axona|medical powder, supplement food
219433235|NCT02321072|DRUG|Oxygen|
219433236|NCT04840368|OTHER|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
219433237|NCT01616784|OTHER|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
219433238|NCT01616784|OTHER|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
219433239|NCT00129207|DRUG|bortezomib|
219433240|NCT02822157|DRUG|Olaparib|
219433241|NCT02822157|DRUG|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
219433242|NCT02867722|DRUG|aminolevulinic acid HCl|Drug will be administered to consented patients
219433243|NCT02695576|PROCEDURE|Lumbar Fusion Surgery|Interbody fusion with fixation
219433244|NCT02695576|OTHER|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
219433245|NCT02695576|OTHER|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
219433246|NCT02672618|OTHER||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
219433247|NCT02336048|DRUG|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
219433248|NCT02336048|DRUG|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
219433249|NCT02336048|DRUG|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
219433250|NCT02336048|OTHER|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
219433251|NCT02336048|DRUG|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
219596814|NCT02928055|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
219596815|NCT05349708|DEVICE|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
219433252|NCT04242459|RADIATION|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
219433253|NCT04140370|OTHER|There is no intervention|There is no intervention
219433254|NCT00294684|DRUG|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
219433255|NCT00294684|DRUG|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
219433256|NCT03528824|OTHER|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
219433257|NCT03528824|DRUG|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
219433258|NCT00389441|DRUG|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
219433259|NCT03429764|PROCEDURE|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
219433260|NCT03429764|PROCEDURE|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
219433261|NCT04373707|DRUG|Enoxaparin|"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"
219433262|NCT04373707|DRUG|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
219433263|NCT00422890|DRUG|5-Azacytidin|in case of decreasing CD34 chimerism
219433264|NCT04656288|DRUG|BI 764198 - Formula A|BI 764198
219433265|NCT04656288|DRUG|BI 764198 - Formula B|BI 764198
219433266|NCT04656288|DRUG|BI 764198 - Formula C|BI 764198
219433267|NCT04656288|DRUG|BI 764198 - Formula D|BI 764198
219433268|NCT01803113|DEVICE|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
219433269|NCT05134168|PROCEDURE|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
219433270|NCT05134168|PROCEDURE|LIFT|The fistula tract is ligated in the intersphincteric space
219433271|NCT02095990|DRUG|Hydroquinone|
219433272|NCT02095990|DRUG|Placebo|
219433273|NCT00971230|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
219433274|NCT00971230|DRUG|Placebo|Placebo
219433275|NCT04144049|DRUG|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
219433276|NCT04144049|DRUG|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
219191999|NCT06806410|DRUG|Liposomal bupivacaine (LB)|our study team wishes to determine effect of liposomal bupivacaine in regional nerve blocks for surgery of the upper extremity (finger, hand, wrist, elbow)
219433277|NCT03407170|BIOLOGICAL|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
219433278|NCT01998113|DRUG|Glyburide vs Insulin trials|Affecting groups 1 and 2
219433279|NCT01998113|DRUG|Metformin vs Insulin trials|Affecting groups 3 and 4
219192000|NCT06806410|DRUG|Dexamethasone|dexamethasone injected in perineural area can extend the regional nerve block
219192001|NCT06807450|PROCEDURE|closure of oro-nasal fistula in cleft palate patients|group I : Oro-nasal fistula will be closed in two layers, nasal layer by closing the fistula margin and turning over of flap and oral layer will be closed using two flap palatoplasty group II; the same procedure with insertion of free graft of buccal pad of fat between oral and nasal layers
219433280|NCT01998113|DRUG|Metformin vs Glyburide trials|Affecting groups 5 and 6
219433281|NCT04308954|DRUG|[18F]flumazenil|\[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
219433282|NCT00218361|DRUG|Hydromorphone|
219433283|NCT04530968|OTHER|No intervention|No intervention
219433284|NCT04913571|DRUG|Eribulin|Eribulin
219433285|NCT04913571|DRUG|Tislelizumab|Tislelizumab
219596816|NCT03815214|BEHAVIORAL|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
219192002|NCT03663218|RADIATION|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
219192003|NCT02988661|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
219433286|NCT06054438|OTHER|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
219192004|NCT06806384|OTHER|ExerGame-based Stroke Rehabilitation|The intervention involves training using the Dividat Senso platform (Dividat, Schindellegi, Switzerland), a pressure-sensitive platform (1.13 m × 1.13 m) equipped with 20 sensors. The training includes a series of ExerGames designed to challenge balance, coordination, and cognitive processing speed. These games focus on weight shifting, stepping accuracy, and reaction time, with difficulty levels progressively adjusted based on participant performance. To ensure safety, participants are allowed to use a waist-high parallel bar for support during the exercises. Additionally, participants receive conventional physical therapy methods that do not interfere with the study protocol. These include range-of-motion exercises, upper-limb training, and respiratory training, delivered in 30-minute sessions, five days per week, over a four-week period.
219433287|NCT03466671|DRUG|TTA-121|A nove intranasal spray of oxytocin and placebo
219433288|NCT05825313|BEHAVIORAL|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
219433289|NCT01591811|RADIATION|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
219433290|NCT01591811|RADIATION|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
219433291|NCT05678270|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 5mg, orally.
219433292|NCT00003408|BIOLOGICAL|aldesleukin|
219433293|NCT00003408|BIOLOGICAL|recombinant interferon alfa|
219433294|NCT00003408|BIOLOGICAL|sargramostim|
219433295|NCT03561168|DIAGNOSTIC_TEST|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
219433296|NCT01666860|PROCEDURE|Anterior Lumbar Interbody Fusion procedure|
219433297|NCT05210972|RADIATION|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
219433298|NCT04523467|DRUG|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
219433299|NCT04523467|DRUG|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
219433300|NCT04523467|PROCEDURE|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
219433301|NCT00126672|DRUG|Rapamycin|
219433302|NCT03373344|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
219578424|NCT06004219|BEHAVIORAL|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
219578425|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
219578426|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
219578427|NCT00251719|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
219578428|NCT05227300|DRUG|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
219578429|NCT05227300|DRUG|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
219433303|NCT03373344|BEHAVIORAL|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
219433304|NCT01522768|DRUG|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
219578430|NCT02047175|DRUG|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
219578431|NCT02047175|DRUG|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
219578432|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
219578433|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
219578434|NCT03324932|DRUG|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
219578435|NCT01799122|DEVICE|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
219578436|NCT01376193|DRUG|Naratriptan|Collection of safety data
219578437|NCT02494609|DRUG|sotagliflozin|400 mg sotagliflozin
219578438|NCT02494609|DRUG|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
219578439|NCT02494609|DRUG|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
219578440|NCT03947671|DEVICE|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
219578441|NCT03947671|DRUG|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
219433305|NCT01408134|OTHER|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
219433306|NCT00051090|DRUG|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
219433307|NCT00051090|DRUG|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
219433308|NCT00051090|DRUG|Efavirenz|Administered orally at a daily dose of 600 mg
219578442|NCT04392583|DEVICE|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
219578443|NCT01672112|DRUG|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
219578444|NCT01672112|DRUG|Codeine|Oral Codeine 60mg 6hrly/prn
219578445|NCT03239912|DEVICE|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
219578446|NCT03239912|OTHER|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
219578447|NCT03427502|DRUG|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
219578448|NCT03427502|DRUG|normal saline|normal saline
219578449|NCT03305406|OTHER|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
219578450|NCT03305406|OTHER|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
219433309|NCT00051090|DRUG|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
219433310|NCT00051090|DRUG|Abacavir|Administered orally twice daily in doses of 300 mg
219578451|NCT06095336|OTHER|telerehabilitation|The individuals included in the research will be divided into three groups. Group 1 (experiment): This is the exercise group followed by the telerehabilitation method. Group 2 (experiment): This is the group where traditional physical therapy methods will be applied. The 3rd group will be taken as the control group, there will be no intervention and they will be asked to continue their daily lives.
219578452|NCT02177656|BEHAVIORAL|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
219578453|NCT01725321|OTHER|Narrow band imaging|Colonoscopy with new narrow band imaging
219578454|NCT01527084|PROCEDURE|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
219578455|NCT03565393|COMBINATION_PRODUCT|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
219578456|NCT02408068|DRUG|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
219578457|NCT02408068|DRUG|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
219578458|NCT02408068|DRUG|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
219578459|NCT02408068|DRUG|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
219192005|NCT06806384|OTHER|General balance exercise for stroke rehabilitation|The intervention consists of a standardized program of balance exercises designed to improve postural control and stability. The program incorporates weight-shifting training performed once daily for 30 minutes, five days per week, over a four-week period. Weight-shifting activities include anterior-posterior and mediolateral movements, with a focus on loading the affected limb. Participants are instructed to adopt a lunge posture for forward-backward movements, maintain parallel foot positioning for lateral movements, and utilize a balance pad to enhance postural stability. A trained therapist adjusts the intensity and difficulty of the exercises to match the individual abilities of each participant, ensuring a personalized and progressive approach.
219433311|NCT01126502|DRUG|alvespimycin hydrochloride|Given IV
219433312|NCT01126502|OTHER|diagnostic laboratory biomarker analysis|
219433313|NCT01126502|OTHER|pharmacogenomic studies|
219433314|NCT01126502|OTHER|pharmacological study|
219433315|NCT01851863|DRUG|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
219433316|NCT01851863|DRUG|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
219192006|NCT06806384|OTHER|Conventional physical therapy for stroke rehabilitation|The intervention includes conventional physical therapy methods that are compatible with the study protocol. These methods consist of range-of-motion exercises, upper-limb training, and respiratory training. The sessions are delivered for 30 minutes per day, five days per week, over a four-week period.
219192007|NCT06541067|DRUG|Posaconazole|"Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose"
219192008|NCT05560165|PROCEDURE|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
219192009|NCT06374667|PROCEDURE|Y-3 ICO injection|Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
219433317|NCT01851863|DRUG|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
219433318|NCT01851863|DRUG|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
219433319|NCT02347852|DRUG|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
219433320|NCT03198104|DEVICE|MRI|
219433321|NCT01761994|DRUG|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
219433322|NCT02076334|OTHER|Far Infrared Fabric|
219433323|NCT02076334|OTHER|Spandex|
219433324|NCT04513405|DIAGNOSTIC_TEST|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
219433325|NCT04513405|PROCEDURE|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
219578460|NCT03041324|BIOLOGICAL|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
219578461|NCT02321735|BEHAVIORAL|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
219433326|NCT05059847|OTHER|Training|Training routine assigned by randomized chart
219433327|NCT00558740|OTHER|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
219578462|NCT04809935|DRUG|98% dehydrated alcohol|"* coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
219578463|NCT04809935|DEVICE|19G EUSRA needle, Taewoong Medical, Korea|"* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
219578464|NCT05778552|DEVICE|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
219192010|NCT06374667|DRUG|Y-3 intravenous injection|Patients included will be given Y-3 intravenous injection for 7 consecutive days.
219192011|NCT06374667|OTHER|Conventional treatment|standard treatment and management according to related guidelines during the entire treatment period
219192012|NCT05656092|DRUG|HIP0612|Test drug
219192013|NCT05656092|DRUG|HPP2202|Placebo drug
219192014|NCT05656092|DRUG|RLD2204|Reference drug
219433328|NCT02713945|DRUG|Simvastatin|Experimental drug administrated orally
219433329|NCT02713945|DRUG|Placebo|Treatment for the control group
219433330|NCT04546867|DIAGNOSTIC_TEST|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
219433331|NCT03183960|BEHAVIORAL|Mentor|Traditional rehabilitation.
219433332|NCT04992377|DRUG|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
219192015|NCT05656092|DRUG|HPP2201|Placebo drug
219192016|NCT06270134|OTHER|Bicarbonate|Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
219192017|NCT06805474|OTHER|Observational|Observational
219192018|NCT06185192|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
219007357|NCT04809207|OTHER|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
219007358|NCT01891695|RADIATION|39.6 Gy radiation|
219007359|NCT01800864|OTHER|obesity|
219192019|NCT06512337|DRUG|Deucravacitinib|As per product label
219192020|NCT03223155|DRUG|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
219192021|NCT03223155|DRUG|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
219192022|NCT03223155|RADIATION|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
219192023|NCT03571789|DEVICE|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
219192024|NCT06806735|OTHER|3D-Pictures|3D-Pictures will be taken of hypertrophic scars and keloids to document them.
219192025|NCT06807359|DEVICE|Photodynamic Therapy (PDT)|"The PDT treatment is provided with the SpectraCure P18 laser light delivery system.~PDT will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery. The photosensitizer is activated with light of a specific wavelength that is delivered to the tumor via optical fibers. The activated photosensitizer reacts with oxygen to form highly toxic radicals which induce cell death in the tumour.~* Phase 1: Light dose escalation. Three subjects will be treated per dose level (20 - 40 J/cm2). If no dose-limiting toxicities occur, dose will be escalated (20 - 40 J/cm2) until the Recommended Phase 2 Dose (RPD2) is established.~* Phase 2: Cohort expansion with the RPD2."
219192026|NCT06807359|DRUG|Verteporfin Injection|Verteporfin for Injection (VFI), photosensitizing drug, will be administered intravenously at a dose of 15 mg/m2 body surface area.
219578465|NCT05279365|BIOLOGICAL|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
219192027|NCT06805747|OTHER|Variable tidal volume ventilation (V-VCV)|Variable tidal volume ventilation (V-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
219433333|NCT04738604|OTHER|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
219433334|NCT04738604|OTHER|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
219433335|NCT04259060|DRUG|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
219433336|NCT04259060|DRUG|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
219433337|NCT05381675|OTHER|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
219433338|NCT05381675|OTHER|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
219433339|NCT02158455|PROCEDURE|NT SVG grafts|
219433340|NCT03121456|OTHER|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
219192028|NCT06805747|OTHER|Pressure-regulated volume-controlled ventilation (PRVC)|Pressure-regulated volume-controlled ventilation (PRVC) ：Initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), peak inspiratory pressure is capped at 30 cmH2O, maximum tidal volume (Vt\_max), and minimum tidal volume (Vt\_min) is set at 10-20% of basal tidal volume (Vt\_base). Respiratory Rate (RR) 12, Inspiratory Breathing Ratio (IBR) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
219192029|NCT06805747|OTHER|Conventional volume-controlled ventilation (C-VCV)|Conventional volume-controlled ventilation (C-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, FiO2 98%.
219192030|NCT06805747|OTHER|Pressure-controlled ventilation (PCV)|Pressure-controlled ventilation (PCV)：Set inspiratory pressure level, usually 20 cmH2O initial value, Respiratory Rate 12, Inspiratory to Expiratory Ratio 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, Inhaled Oxygen Concentration (FiO2) 98%.
219192031|NCT06805747|OTHER|Trendelenburg position|Trendelenburg position：Lower the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
219192032|NCT06805747|OTHER|Reverse Trendelenburg position|Reverse Trendelenburg position：Elevate the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
219192033|NCT06807554|DRUG|Ketamine|In Group K, ketamine 0.25mg/kg diluted in normal saline to a total volume of 40 ml was instilled by the surgeon, 20 ml before starting gall bladder dissection over the surgical site and liver while remaining 20 ml at the end of procedure after securing haemostasis over gall bladder bed and liver.
219192034|NCT06807554|DRUG|Bupivacaine|In Group B, bupivacaine at a dose of 2 mg/kg was diluted in normal saline to a total volume of 40 ml. The administration was performed by the surgeon in two stages: the first 20 ml was instilled before starting the gall bladder dissection, applied over the surgical site and liver, while the remaining 20 ml was instilled at the end of the procedure after achieving hemostasis, applied over the gall bladder bed and liver.
219192035|NCT03099057|OTHER|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
219192036|NCT04954885|PROCEDURE|Biospecimen Collection|Undergo stool sample
219192037|NCT04954885|OTHER|Physical Performance Testing|Undergo short physical performance battery
219433341|NCT03121456|OTHER|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
219433342|NCT03238352|DEVICE|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
219433343|NCT03238352|DRUG|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
219192038|NCT04954885|OTHER|Physical Performance Testing|Perform 6-minute walk test
219192039|NCT04954885|OTHER|Questionnaire Administration|Complete questionnaires
219192040|NCT05743426|OTHER|Survey|Patient Reported Outcome (PRO) questionnaire
219192041|NCT05743426|OTHER|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
219433344|NCT03238352|OTHER|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
219578466|NCT05279365|BIOLOGICAL|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
219578467|NCT05950230|DIAGNOSTIC_TEST|Assess Periodontal Health Status|"For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph."
219578468|NCT05950230|OTHER|Collecte GCF samples by paperstrip|GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
219578469|NCT04412265|OTHER|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
219192042|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
219578470|NCT00942435|DRUG|YM150|oral
219578471|NCT00942435|PROCEDURE|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
219578472|NCT01549106|DRUG|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
219578473|NCT01549106|DRUG|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
219192043|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
219192044|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
219433345|NCT02805062|PROCEDURE|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
219192045|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
219199554|NCT05934136|BEHAVIORAL|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
219433346|NCT02805062|PROCEDURE|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
219578474|NCT01983709|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
219433347|NCT01270724|DRUG|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
219578475|NCT05405972|BEHAVIORAL|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
219578476|NCT05437367|OTHER|Scapular Stabilization exercises|Therapeutic exercises
219578477|NCT05437367|OTHER|Postural correction exercises|Therapeutic exercises
219578478|NCT01053234|DIETARY_SUPPLEMENT|Standardised meals|
219433348|NCT05839639|DRUG|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
219578479|NCT02303041|DRUG|Buparlisib|Administered orally at starting dose of 80 mg/day
219578480|NCT02303041|DRUG|Sonidegib|Administered orally at starting dose of 200 mg/day
219578481|NCT02908035|DRUG|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
219578482|NCT02908035|DRUG|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
219578483|NCT00428636|PROCEDURE|ileostomy|
219578484|NCT05549518|OTHER|Core stabilization + Traditional Physical Therapy|"In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week."
219433349|NCT05839639|DRUG|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
219433350|NCT05839639|DRUG|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
219433351|NCT03713424|DRUG|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
219433352|NCT03713424|DRUG|Placebo oral capsule|placebo
219596817|NCT03815214|BEHAVIORAL|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
219596818|NCT03637010|OTHER|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
219762090|NCT06960291|BEHAVIORAL|Group Exercise Classes|Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.
219433353|NCT00928512|DRUG|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
219762091|NCT06960213|DRUG|ADX-324|siRNA duplex oligonucleotide
219762092|NCT06960213|DRUG|Placebo|saline
219762093|NCT06961006|BIOLOGICAL|V940|IM injection
219762094|NCT06961006|BIOLOGICAL|Pembrolizumab|IV infusion
219007360|NCT05874856|DIAGNOSTIC_TEST|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
219007361|NCT05874856|DIAGNOSTIC_TEST|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
219007362|NCT05874856|BEHAVIORAL|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
219007363|NCT05874856|BEHAVIORAL|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
219199555|NCT06874218|DEVICE|prefabricated CAD-CAM Zirconia crowns according to Egyptian sizes.|compare prefabricated zirconia crowns according to the Egyptian crown sizes with the international standard zirconia crowns sizes for primary upper central incisors
219433354|NCT00928512|DRUG|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
219199556|NCT06875817|OTHER|Feldenkrais exercises|Feldenkrais exercises focused on pain, improving mobility, and disability.
219433355|NCT04153929|DRUG|BI 456906|Solution for Injection
219433356|NCT04153929|DRUG|Placebo|Solution for Injection
219433357|NCT04153929|DRUG|Semaglutide|Solution for Injection
219433358|NCT01963780|DEVICE|OCS Lung Preservation|
219433359|NCT00086294|DRUG|Intravenous Levodopa|
219433360|NCT00086294|DRUG|ACP-103|
219433361|NCT00493480|DRUG|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
219433362|NCT00493480|DRUG|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
219433363|NCT02732223|DIETARY_SUPPLEMENT|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
219433364|NCT02732223|DIETARY_SUPPLEMENT|Control treatment|placebo supplements
219433365|NCT06238011|DRUG|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
219433366|NCT06238011|DRUG|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
219433367|NCT01060683|BIOLOGICAL|Hemoglobin determination + NaCl 0.9% bolus|
219433368|NCT01060683|BIOLOGICAL|hemoglobin determination + Venofundin bolus|
219433369|NCT04083794|OTHER|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
219433370|NCT04177875|DRUG|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
219433371|NCT01894867|DIETARY_SUPPLEMENT|magnesium|supply magnesium oxide for 6 weeks
219433372|NCT01894867|DIETARY_SUPPLEMENT|Placebo|
219433373|NCT03383614|DRUG|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
219433374|NCT01386567|DRUG|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
219433375|NCT01386567|DRUG|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
219433376|NCT01170949|DRUG|Miltefosine|50 or 100 or 150mg per day
219433377|NCT01170949|DRUG|Placebo|Placebo
219433378|NCT04673344|DEVICE|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
219433379|NCT05621018|DEVICE|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
219433380|NCT03907449|DIAGNOSTIC_TEST|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
219433381|NCT03623022|DRUG|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
219433382|NCT03623022|DRUG|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
219433383|NCT03395327|OTHER|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
219433384|NCT03477669|DIETARY_SUPPLEMENT|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
219433385|NCT03477669|DIETARY_SUPPLEMENT|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
219578485|NCT05549518|OTHER|Traditional Physical Therapy|"Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application"
219578486|NCT02140307|BEHAVIORAL|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
219192046|NCT05211596|BEHAVIORAL|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
219433386|NCT06071780|OTHER|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
219433387|NCT05609383|OTHER|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
219433388|NCT03250156|BEHAVIORAL|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
219762095|NCT06961006|OTHER|Placebo|IM injection
219762096|NCT05663320|OTHER|virtual educational based transition intervention self-paced|study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced
219762097|NCT03600701|DRUG|Atezolizumab|Given IV
219762098|NCT03600701|PROCEDURE|Biopsy Procedure|Undergo biopsy
219762099|NCT03600701|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219762100|NCT03600701|DRUG|Cobimetinib|Given PO
219762101|NCT03600701|PROCEDURE|Computed Tomography|Undergo CT scan
219762102|NCT03600701|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762103|NCT04267848|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762104|NCT04267848|DRUG|Carboplatin|Given IV
219762105|NCT04267848|DRUG|Cisplatin|Given IV
219007364|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
219007365|NCT04658095|DEVICE|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
219007366|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
219192047|NCT00780494|DRUG|bevacizumab|Intravenous 15 mg/kg
219192048|NCT00780494|DRUG|carboplatin|AUC 6, Intravenously Day 1 every 21 days
219192049|NCT00780494|DRUG|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
219192050|NCT05893940|PROCEDURE|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
219192051|NCT05893940|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
219762106|NCT04267848|PROCEDURE|Computed Tomography|Undergo CT
219762107|NCT04267848|PROCEDURE|Echocardiography Test|Undergo ECHO
219762108|NCT04267848|DRUG|Gemcitabine Hydrochloride|Given IV
219762109|NCT04267848|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219007367|NCT02601378|DRUG|LXS196|LXS196 as a single agent
219007368|NCT02601378|DRUG|LXS196 and HDM201|LXS196 in combination with HDM201
219192052|NCT05893940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219192053|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
219192054|NCT02154412|OTHER|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
219192055|NCT04781855|DRUG|Ibrutinib|Given PO
219762110|NCT04267848|OTHER|Observation Activity|Undergo observation
219007369|NCT03671460|BIOLOGICAL|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
219007370|NCT02475746|DRUG|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
219192056|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
219192057|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
219192058|NCT05701982|BEHAVIORAL|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
219192059|NCT05701982|OTHER|Usual Care|Usual Care
219192060|NCT06135545|COMBINATION_PRODUCT|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
219192061|NCT06135545|COMBINATION_PRODUCT|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
219192062|NCT03298945|DRUG|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
219433389|NCT03250156|BEHAVIORAL|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
219433390|NCT00640952|DRUG|acamprosate|333 mg 2 tabs tid
219433391|NCT05275452|OTHER|No intervention|No intervention
219433392|NCT01091051|DRUG|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
219433393|NCT01091051|DRUG|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
219433394|NCT04995900|OTHER|Community education|Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
219192063|NCT03298945|DRUG|Golytely|4-L split dose Golytely is the current standard prep at the VA
219192064|NCT06159842|COMBINATION_PRODUCT|Aminolevulinic Acid 20% Topical Solution with Blue Light|Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
219192065|NCT05384860|DEVICE|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
219192066|NCT05384860|OTHER|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
219192067|NCT06485310|OTHER|Teleconsultation for psychological support|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
219192068|NCT04128995|PROCEDURE|Advanced Medical Therapy and Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
219192069|NCT04128995|DRUG|Advanced Medical Therapy|Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
219433395|NCT01296698|DRUG|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
219433396|NCT01296698|DRUG|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
219433397|NCT05934721|OTHER|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
219578487|NCT00211965|BIOLOGICAL|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
219007371|NCT02475746|DRUG|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
219007372|NCT03586180|BEHAVIORAL|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
219192070|NCT04128995|PROCEDURE|Bariatric Surgery|Vertical Sleeve Gastrectomy for youth without type 2 diabetes
219192071|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
219192072|NCT06822192|DEVICE|temporally interfering electrical stimulation|temporally interfering electrical stimulation
219192073|NCT06342466|DRUG|Bortezomib|Bortezomib 1.3mg/m2 sc weekly
219192074|NCT06342466|DRUG|Pomalidomide|4mg per day taken orally on 1-21 of repeated 28-day cycles
219433398|NCT01605201|BIOLOGICAL|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
219433399|NCT05380908|OTHER|None of any intervention|The patients did not have any intervention.
219433400|NCT04150354|BEHAVIORAL|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
219433401|NCT01997697|OTHER|behavior change program|behavior change program among patients with obesity
219433402|NCT02077803|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
219433403|NCT02077803|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
219433404|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
219192075|NCT06342466|DRUG|Dexamethasone|Dexamethasone 20mg-40mg weekly
219192076|NCT06822647|PROCEDURE|Cervical Length Measurement at the Beginning of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the beginning of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
219192077|NCT06822647|PROCEDURE|Cervical Length Measurement at the End of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the end of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
219192078|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
219192079|NCT02413489|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
219192080|NCT05980533|DIAGNOSTIC_TEST|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
219192081|NCT06806631|OTHER|Video assisted discharge training|The researchers developed a training content by utilizing various sources and consulting expert opinions. DISCERN (quality criteria for consumer health information) tool was used to evaluate the information quality of the educational content and 5 expert opinions were obtained and the educational content was finalized in line with the suggestions. The training content included the problems that patients may experience in the postoperative period, postoperative interventions (movement, breathing and cough exercises), control times, nutrition, do's and don'ts and other nursing care issues. The content of the training video prepared according to the DISCERN scale was found to be sufficient. The training content was then converted into a video training given by the nurse researcher.
219192082|NCT05062200|DRUG|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
219192083|NCT05062200|DRUG|Placebo|Matching placebo will be administered as an oral tablet.
219192084|NCT06006247|DRUG|CVN424 150 mg|Participants will receive 1 CVN424 tablet (150 mg) per day.
219433405|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
219433406|NCT01012349|DRUG|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
219433407|NCT01012349|DRUG|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
219578488|NCT00211965|BIOLOGICAL|placebo|single dose IM
219192085|NCT06006247|DRUG|Placebo|Participants will receive 1 matching placebo tablet per day.
219192086|NCT00492817|PROCEDURE|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
219192087|NCT02812524|DRUG|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
219578489|NCT00144911|DRUG|Salmeterol|
219578490|NCT00144911|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
219596819|NCT04767438|OTHER|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
219596820|NCT03232671|DIAGNOSTIC_TEST|MIF ELISA|Blood sample
219762111|NCT04267848|DRUG|Paclitaxel|Given IV
219762112|NCT04267848|BIOLOGICAL|Pembrolizumab|Given IV
219762113|NCT04267848|DRUG|Pemetrexed Disodium|Given IV
219762114|NCT04267848|OTHER|Questionnaire Administration|Ancillary studies
219762115|NCT06507748|DEVICE|AlgometRx Nociometer|Novel objective pain measurement device
219762116|NCT05112601|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and/or blood samples
219762117|NCT05112601|PROCEDURE|Computed Tomography|Undergo CT
219762118|NCT05112601|BIOLOGICAL|Ipilimumab|Given IV
219192088|NCT06808282|OTHER|White chocolate|To determine the effects of white chocolate consumption on risk factors of cardiovascular diseases
219192089|NCT06808282|OTHER|Dark chocolate|To determine the effects of dark chocolate consumption on risk factors of cardiovascular diseases
219192090|NCT06809257|BEHAVIORAL|Exercise|12 week moderately aerobik exercise
219192091|NCT06569407|OTHER|Online Educational Intervention|An educational program for EBP based on the online learning model was planned to be developed based on the literature and expert opinions. In the program, in line with the literature, the introduction to the EBP, the importance of EBP, EBP steps, clinical research question design in line with PICO, and introduction of EBP databases. It is planned to include topics such as literature search strategies, types of research, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflection of EBP on patient care and clinical decision-making processes, and it is planned to determine the final version of the education content with expert opinions. The program will include recorded videos, slides and documents for each module. The content of the program will be integrated into the Koç University Online Programs Platform by the experts working at Koç University Educational Technologies Unit.
219192092|NCT06569407|OTHER|Educational Booklet|An educational booklet for EBP was planned to be developed based on the literature and expert opinions. The learning objectives and content of the educational booklet to be developed will be created by considering Bloom\&#39;s taxonomy. In line with the literature, it is planned to include topics such as introduction to EBP, importance of EBP, evidence-based practice steps, clinical research question design in line with PICO, introduction of evidence-based databases, literature search strategies, research types, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflections of EBP on patient care and clinical decision-making processes, and finalization of the booklet topics with expert opinions.
219192093|NCT06256939|OTHER|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
219192094|NCT06809465|DIETARY_SUPPLEMENT|Bactopral®|Oral Probiotic Bifidobacterium bifidum PRL2010 supplement
219192095|NCT06809465|OTHER|Plcebo|Oral placebo
219192096|NCT06808295|DRUG|Dexmedetomidine Hydrochloride|drug will be given before induction and anesthetic doses and hemodynamics will be assessed pre- intra and postoperative
219192097|NCT06809413|DRUG|Sitafloxacin|Study medication: Sitafloxacin 100mg QD for 14 days.
219192098|NCT04958486|DRUG|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
219433408|NCT03079245|OTHER|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
219433409|NCT03079245|OTHER|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
219192099|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
219192100|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
219192101|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
219192102|NCT05383274|COMBINATION_PRODUCT|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
219192103|NCT02575950|DRUG|LEO43204|
219192104|NCT02575950|DRUG|Placebo|
219596821|NCT00269425|BEHAVIORAL|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
219596822|NCT00269425|BEHAVIORAL|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
219192105|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
219192106|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
219192107|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
219192108|NCT06853535|DRUG|The ticagrelor|Ticagrelor 90mg should be taken as soon as possible. From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with ticagrelor 90mg twice a day (bid) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given ticagrelor 90mg bid for anti - platelet treatment.
219433410|NCT03079245|OTHER|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (\>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
219433411|NCT06526598|PROCEDURE|PMI-targeted pressure support setting and adjustment|During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.
219433412|NCT06526598|PROCEDURE|VT/RR-targeted pressure support setting and adjustment|During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
219433413|NCT01306851|DRUG|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
219433414|NCT00621088|PROCEDURE|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
219433415|NCT05190107|DIAGNOSTIC_TEST|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
219192109|NCT06853535|DRUG|The Clopidogrel|From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with clopidogrel 75mg once a day (qd) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given clopidogrel 75mg qd for anti - platelet treatment.
219433416|NCT01614912|DRUG|SM-13496|40 or 80 mg once daily orally
219433417|NCT06282536|DRUG|Iruplinalkib|60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.
219433418|NCT06282536|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
219433419|NCT05110599|DRUG|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
219433420|NCT05110599|OTHER|Placebo|Lactose with adaption in appearance and tast
219192110|NCT06853379|BEHAVIORAL|dietary recommendations|. receive dietary recommendations or nonspecific dietary advices such as reducing fluid intake after 6 p.m. The list of dietary advices have been made reviewing literature and consisted in a list of recommended food, not recommended food at evening and not recommended food
219192111|NCT06853379|OTHER|aroma therapy|the case receive aroma therapy
219192112|NCT06855446|BEHAVIORAL|Intervention with social robot NAO|12 session of 30 minutes, one sessione per week with social robot NAO and a therapist, working on social intransitive gestures
219192113|NCT06855446|BEHAVIORAL|Treatment as usual|Psychomotor/behavioral or speech therapy as usual
219192114|NCT06854003|DRUG|Bendamustine|An Alkylating agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
219192115|NCT06854003|DRUG|Rituximab|An Anti-CD20 antibody, single-use vials, via intravenous infusion per institutional standard of care.
219192116|NCT06854003|DRUG|Cytarabine|An Antineoplastic, single dose vial via intravenous infusion per institutional standard of care.
219192117|NCT06854003|DRUG|Zanubrutinib|A BTK inhibitor, capsule taken orally per protocol.
219433421|NCT04406389|DRUG|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
219192118|NCT06854003|DRUG|Sonrotoclax|A BCL 2 Protein Inhibitor, immediate release tablet, taken orally per protocol.
219192119|NCT06854510|DRUG|Gargle with 2.5% sodium bicarbonate solution during radiotherapy|"In addition to routine oral care, patients received sodium bicarbonate solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows:~For patients with oral mucositis of grade 0 - 1, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle."
219192120|NCT06854510|DRUG|Gargle with 0.9% sodium chloride solution during radiotherapy|In addition to routine oral care, patients received 0.9% sodium chloride solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows: For patients with oral mucositis of grade 0 - 1, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle.
219192121|NCT06223139|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
219192122|NCT06811428|DEVICE|A novel device for immobilization of babies undergoing upright LP, the present working name (non-proprietary) for the device is LP Comfort Seat (LPCS)|The participant will be placed in the LPCS for their lumbar puncture procedure
219192123|NCT06811428|OTHER|Standard of Care (SOC)|The patient will be held in the upright position by a human assistant
219192124|NCT06853691|OTHER|glasses-free 3D visual training|"Trail group Conduct 15 minutes of naked-eye 3D vision training. Twice a day, five days a week.~Control groups The subjects watched ordinary 2D videos for 15 minutes each time, all under the same lighting conditions. This was done twice a day, five days a week."
219192125|NCT06804915|BEHAVIORAL|simulation|"Each team of physician and nurses will participate in 4 scenarios: 2 adult, 2 pediatric. In each scenario, physician and nurses will have a clinical description of the scenario with the age and weight of each patient.~The simulations will be conducted at the clinical simulation laboratory at Jean-Marc Lepage Pavilion of the University of Sherbrooke using high-fidelity mannequins. SimMan 3GPus will be used for adult scenarios and SimJunior for pediatric scenarios, both from Laerdal company. Participants will receive a briefing containing key information about the scenario and the patient just before starting the simulation.~During the scenarios, the physician is expected to prescribe medications by mentioning the name, the dose and the route of administration of every medication. Moreover, if multiple dilution for a medication is possible, the physician is expected to mention the desired dilution."
219192126|NCT06810856|DEVICE|Abilar® Resin Salve|Abilar® Resin Salve is a medical-grade Norway spruce (Picea abies) resin-based topical medical device, classified as a Class IIb medical device in the EU. It is designed for wound care and skin protection, forming a moist healing barrier while exhibiting antimicrobial properties. It contains 10% of medical-grade Picea abies resin.
219192127|NCT06814964|DRUG|Low dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.009 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
219192128|NCT06814964|DRUG|Medium dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.018 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
219192129|NCT06814964|DRUG|High dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.027 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
219192130|NCT06598618|OTHER|Graston technique+ Conventional PT|IASTM technique (graston technique) on iliotibial band. Frequency 2 sessions of stroking with 20 seconds rest in between 3 times/week for 3 consecutive weeks Intensity as tolerated by patient. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps
219192131|NCT06598618|OTHER|Muscle energy technique + Conventional PT|Muscle energy technique (post facilitation stretch) on iliotibial band. Frequency 10 repetitions 3 times/week for 3 consecutive weeks Intensity starting from 50 percent resistance across barrier provided by physiotherapist.. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps.
219192132|NCT04527445|PROCEDURE|Reduced radiation fluoroscopy|See previous information about each arm
219192133|NCT04527445|PROCEDURE|Conventional fluoroscopy|See previous information about each arm
219192134|NCT06813859|OTHER|exercise testing|incremental cycling test on a bicycle ergometer
219192135|NCT06808386|OTHER|Strengthening 2 times per week|This group will consist of participants with patellofemoral pain and will receive treatment twice a week.
219433422|NCT04406389|DRUG|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
219433423|NCT04406389|DRUG|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily"
219433424|NCT04406389|DRUG|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
219192136|NCT06808386|OTHER|Strengthening 3 times per week|This group will consist of participants with patellofemoral pain and will receive treatment thrice a week.
219192137|NCT06807736|DRUG|Cabotegravir long-acting|3ml intramuscular injection containing 600mg of Cabotegravir
219192138|NCT06807736|DRUG|Tenofovir emtricitabine|Oral tablet taken daily to PrEP HIV infection.
219192139|NCT06807736|DRUG|Dapivirine containing vaginal ring|Intra-vaginal silicone ring containing slow-release Dapivirine, replaced every 28 days
219192140|NCT06814652|DRUG|Trodon® Hemofarm|Consent was taken from each patient prior to the enrollment into the study during the first interview and 2 ml of blood was withdrawal for the CYP2D6 genotyping. After the cesarean section surgery, each patient received one dose of 100mg/2ml Trodon® Hemofarm for treating the postpartum pain and the patients were monitored for 24 hours. Follow-up was performed for each enrolled patient in which the VAS score, blood pressure, heart rate, oxygen saturation and any new effects after 1 hour, 6 hours of tramadol administration were recorded. In addition, after 24 hours evaluations for nocturnal pain, dietary state and bowel movement were performed.
219192141|NCT06657079|DRUG|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
219433425|NCT04798313|DRUG|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
219433426|NCT04798313|DRUG|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
219433427|NCT02971293|DRUG|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
219433428|NCT02971293|DRUG|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
219433429|NCT02971293|DRUG|Placebo|The subject will receive Placebo single dose DPI.
219433430|NCT02451540|RADIATION|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
219578491|NCT06148064|OTHER|Collaplug with low level laser|Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.
219578492|NCT06148064|OTHER|Collaplug|Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
219578493|NCT04580121|DRUG|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
219007373|NCT03550456|OTHER|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
219192142|NCT06657079|DRUG|Placebo|Saline inhaler
219192143|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
219433431|NCT02451540|DRUG|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
219433432|NCT02451540|DRUG|Roflumilast|Roflumilast, once a day in the morning during 3 months
219433433|NCT00729326|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
219433434|NCT00729326|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
219192144|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
219192145|NCT05868733|DRUG|Placebo|Placebo
219192146|NCT04173949|DRUG|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
219192147|NCT02065765|BIOLOGICAL|Ramucirumab|Administered intravenously (IV)
219192148|NCT05645757|DRUG|Ertapenem|A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
219192149|NCT05645757|OTHER|Placebo|Placebo
219192150|NCT05645757|DRUG|WCK 6777|A combination of ertapenem (ERT) and zidebactam (ZID)
219192151|NCT05645757|DRUG|Zidebactam|A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
219192152|NCT06342986|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
219433435|NCT00729326|DRUG|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
219433436|NCT00729326|DRUG|placebo|oral administration (100mg), once a day in the morning
219192153|NCT06342986|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
219192154|NCT06342986|DRUG|CY|CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
219192155|NCT05238103|COMBINATION_PRODUCT|Corrie Hybrid Cardiac Rehabilitation Program|The Corrie Hybrid Cardiac Rehabilitation Program is a multi-component intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
219192156|NCT03924635|COMBINATION_PRODUCT|SYMBICORT and salbutamol|SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
219192157|NCT00539591|DRUG|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
219192158|NCT00539591|DRUG|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
219578494|NCT04580121|DRUG|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
219007374|NCT03550456|OTHER|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
219007375|NCT03550456|OTHER|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
219192159|NCT00539591|DRUG|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
219192160|NCT04972201|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
219192161|NCT06839066|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219192162|NCT06839066|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219192163|NCT06839066|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219192164|NCT05359328|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
219192165|NCT05919589|OTHER|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
219192166|NCT06834438|GENETIC|ST002|Single multi-point intra-tumoral injection of ST002, a lentiviral vector designed to drive expression of the NF2 protein product, Merlin.
219199557|NCT06875817|OTHER|Standard physical therapy interventions|"* Knee Isometrics: Isometric exercises targeting the quadriceps and hamstrings, performed for 10 minutes, twice a week.~* Knee Mobilization~* Transcutaneous Electric Nerve Stimulation (TENS).~* Heating Pad Duration: 30-minute sessions, conducted twice a week for 4 weeks."
219199558|NCT06118554|OTHER|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
219433437|NCT01235728|DRUG|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
219578495|NCT04580121|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
219578496|NCT04580121|DRUG|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
219578497|NCT04580121|DRUG|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
219192167|NCT06278558|OTHER|Interviews with a psychologist/psychiatrist|All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
219192168|NCT04118439|OTHER|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
219192169|NCT03811886|DRUG|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
219192170|NCT01960452|BEHAVIORAL|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
219192171|NCT06162390|DRUG|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
219192172|NCT06024564|DEVICE|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
219192173|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
219192174|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
219192175|NCT05705518|DRUG|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
219192176|NCT05705518|DRUG|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
219192177|NCT05705518|DRUG|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
219433438|NCT01235728|DRUG|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
219433439|NCT01235728|DRUG|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
219192178|NCT05705518|DRUG|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
219192179|NCT05603819|DEVICE|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
219192180|NCT03194971|OTHER|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
219192181|NCT03194971|DEVICE|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
219192182|NCT05682560|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
219578498|NCT04580121|DRUG|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
219192183|NCT05682560|BIOLOGICAL|Placebo|Normal Saline
219192184|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
219192185|NCT05926739|DEVICE|Electrical stimulation and biofeedback with Phenix Liberty medical device|"12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session"
219192186|NCT06569095|OTHER|Detection of MDS-SC using MFC|The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.
219578499|NCT04580121|DRUG|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
219578500|NCT00363753|DRUG|aspirin versus clopidogrel|
219578501|NCT02277678|DRUG|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
219578502|NCT02277678|DRUG|Opioid administration morphine|
219578503|NCT00975403|DEVICE|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
219578504|NCT00975403|DEVICE|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
219578505|NCT03994718|OTHER|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
219192187|NCT06384404|OTHER|Questionnaire|PROMIS questionnaire
219192188|NCT06168825|OTHER|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
219192189|NCT04824105|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
219192190|NCT06769984|DRUG|SCTT11|SCTT11 dose 1, dose 2, dose 3, dose 4
219192191|NCT06769984|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
219199559|NCT06873906|PROCEDURE|Deep Parasternal intercostal plane block|Patients will receive bilateral deep parasternal plane block using, 1mg/kg of 0.25% bupivacaine on each side under ultrasound guidance. The total dose of bupivacaine amounting to 2 mg/kg.
219578506|NCT03994718|OTHER|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
219578507|NCT03994718|OTHER|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
219578508|NCT06085118|OTHER|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
219578509|NCT05829213|PROCEDURE|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
219578510|NCT03358745|OTHER|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
219578511|NCT03358745|OTHER|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
219578512|NCT03358745|OTHER|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
219578513|NCT03358745|OTHER|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
219578514|NCT02571166|BIOLOGICAL|HSV529|Live, Replication-defective HSV-2 virus
219433440|NCT01808404|BEHAVIORAL|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
219192192|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
219192193|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
219192194|NCT05338268|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
219192195|NCT05338268|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
219433441|NCT01478893|BIOLOGICAL|SEL-068|Sub-cutaneous injection, multiple dose
219433442|NCT01478893|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
219433443|NCT03277768|DEVICE|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
219192196|NCT06143059|DRUG|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
219578515|NCT02571166|DRUG|Valacyclovir|500 mg orally, once daily for 4 weeks
219578516|NCT02623348|BEHAVIORAL|pedometer|pedometer-based physical activity recommendations
219192197|NCT06143059|DRUG|Saline|Saline is administered as the placebo
219192198|NCT04601064|BEHAVIORAL|Collaborative Care Model|Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
219192199|NCT05193409|DRUG|225 mg BNC210|225 mg BNC210
219192200|NCT05193409|DRUG|675 mg BNC210|675 mg BNC210
219192201|NCT05193409|DRUG|Placebo|Placebo
219433444|NCT04312438|DIAGNOSTIC_TEST|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
219433445|NCT04664140|OTHER|QFR-based virtual PCI|Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
219578517|NCT02870179|DEVICE|Pulse Oximeter|Measurement of physiological parameters
219578518|NCT05870137|DEVICE|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
219578519|NCT05870137|OTHER|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
219578520|NCT05537194|DRUG|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
219578521|NCT04289597|DIAGNOSTIC_TEST|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
219192202|NCT05916495|OTHER|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
219192203|NCT05916495|OTHER|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
219192204|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
219192205|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
219433446|NCT04664140|OTHER|angiography-based PCI|PCi according to international guidelines, local protocols and practice
219433447|NCT02793089|OTHER|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
219433448|NCT01876394|OTHER|Coconut Oil|Shake with 50 g Coconut oil
219433449|NCT01876394|OTHER|Canola Oil|Shake with 50 g Canola oil
219433450|NCT01876394|OTHER|Grapeseed Oil|Shake with 50 g Grapeseed oil
219433451|NCT01876394|OTHER|Chia Oil|Shake with 50 g Chia oil
219433452|NCT01876394|OTHER|Butter|Shake with 50 g Butter
219433453|NCT03686865|DEVICE|dental implants|extraction sockets regenerated with xenograft
219433454|NCT02559713|DRUG|Vedolizumab|Vedolizumab IV infusion
219433455|NCT05494749|OTHER|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
219433456|NCT05494749|OTHER|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
219433457|NCT05487313|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
219433458|NCT00219232|DRUG|Rivastigmine Transdermal Patch|
219433459|NCT04101760|DRUG|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
219433460|NCT04101760|DRUG|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
219433461|NCT03306485|OTHER|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
219433462|NCT03694041|DRUG|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
219433463|NCT03694041|DRUG|SAD: Placebo|Drug: Placebo Placebo for 1day
219433464|NCT03694041|DRUG|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
219433465|NCT03694041|DRUG|MAD: Placebo|Matching study drug will be repeatedly administered.
219433466|NCT03694041|OTHER|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
219433467|NCT03694041|OTHER|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
219433468|NCT03418051|OTHER|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
219433469|NCT03418051|OTHER|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
219433470|NCT05684653|DRUG|Orelabrutinib Tablets|50 mg, single oral dose
219433471|NCT00103597|DRUG|Fludrocortisone|
219433472|NCT00103597|DRUG|Domperidone|
219433473|NCT00103597|BEHAVIORAL|Conservative Measures for Orthostatic Hypotension|
219433474|NCT04587960|PROCEDURE|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
219192206|NCT04662619|OTHER|B. infantis|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."
219433475|NCT04587960|PROCEDURE|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
219433476|NCT06362460|DRUG|[14C] RAY1216|400 mg suspension containing 100μCi of \[14C\]RAY1216
219433477|NCT04227392|DEVICE|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
219192207|NCT04662619|OTHER|Lactose Placebo|Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
219192208|NCT05197465|OTHER|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
219192209|NCT06822309|PROCEDURE|External Oblique Intercostal Plane Block|The block is performed before skin incision by a specialized anesthetist. With the patient positioned in the supine position with their ipsilateral arm abducted, the skin was sterilized, using the high frequency linear probe (M-Turbo HF 38 transducer 13- 6 MHz) of Fujifilm Sonosite ultrasound is placed over the sixth rib medial to the anterior axillary line approximately in midclavicular line in a parasagittal orientation. A 20-guage needle is inserted in a cephalocaudal direction, and the external oblique intercostal plane was hydro dissected with saline. After hydro dissection, the needle is advanced 1 to 2 cm, and 20 mL of 0.25% bupivacaine (Sunny Pharmaceutical) with 4 mg dexamethasone as an additive was administered. The same procedure will be done at the other side (bilateral external oblique intercostal plane block).
219433478|NCT01928563|DRUG|Dapoxetine|
219433479|NCT01928563|DRUG|Udenafil|
219433480|NCT01928563|DRUG|Udenafil+Dapoxetine|
219192210|NCT06822309|DEVICE|Patient controlled analgesia|Patients in group will receive intravenous patient controlled analgesia device 100 ml (Accuafuser 100 mL, basal rate 4 mL/hr., bolus 0.5 mL/time, and lock time 15 minutes) for postoperative pain management that will contain 30 mg morphine (loading dose0.1mg/kg) will be given by infusion over 10 minutes then accuafuser will be connected),8 mg dexamethasone and 8 mg ondansetron diluted in 100 ml saline.
219192211|NCT06812897|OTHER|Sallie (TM) Life U|Testing of Sallie (TM) Life U platform
219192212|NCT06469177|DEVICE|Pain Coach App|Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
219192213|NCT03340051|BEHAVIORAL|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
219192214|NCT03340051|BEHAVIORAL|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
219192215|NCT05412082|RADIATION|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
219192216|NCT05412082|DRUG|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
219192217|NCT05412082|DRUG|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
219192218|NCT05412082|DRUG|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
219192219|NCT05412082|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
219433481|NCT05150834|OTHER|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
219433482|NCT03628950|PROCEDURE|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
219192220|NCT05412082|RADIATION|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions"
219192221|NCT05412082|DRUG|Irinotecan|Irinotecan dose of 180 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
219433483|NCT03628950|PROCEDURE|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
219578522|NCT04289597|DIAGNOSTIC_TEST|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
219762119|NCT05112601|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762120|NCT05112601|BIOLOGICAL|Nivolumab|Given IV
219192222|NCT04824885|DEVICE|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
219433484|NCT00002718|BIOLOGICAL|anti-thymocyte globulin|
219433485|NCT00002718|BIOLOGICAL|filgrastim|
219192223|NCT04882891|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219192224|NCT06646939|BEHAVIORAL|PT and OT with a simulated environment|Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
219192225|NCT06646042|DRUG|ibuzatrelvir|2x 300 mg tablet
219192226|NCT06646042|DRUG|carbamazepine ER|100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
219192227|NCT05520788|GENETIC|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
219199560|NCT06873906|PROCEDURE|Erector Spinae Plane Block|Patients will receive bilateral erector spinae plane block using, 1 mg/kg of 0.25% bupivacaine will be administered on each side under ultrasound guidance. The total dose of bupivacaine amounted to 2 mg/kg
219433486|NCT00002718|DRUG|cyclophosphamide|
219433487|NCT00002718|DRUG|cytarabine|
219433488|NCT00002718|DRUG|methylprednisolone|
219433489|NCT00002718|DRUG|thiotepa|
219433490|NCT00002718|PROCEDURE|in vitro-treated bone marrow transplantation|
219433491|NCT00002718|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219433492|NCT00002718|RADIATION|radiation therapy|
219433493|NCT01729650|BEHAVIORAL|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
219433494|NCT00234208|PROCEDURE|Medical thoracoscopy|
219433495|NCT00234208|PROCEDURE|Simple chest tube drainage|
219433496|NCT03046342|DIAGNOSTIC_TEST|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
219433497|NCT02193828|BIOLOGICAL|Collagenase clostridium histolyticum|Single injection into nodule
219433498|NCT02193828|BIOLOGICAL|Placebo|Single injection into nodule
219433499|NCT02487888|OTHER|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
219433500|NCT02487888|OTHER|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
219433501|NCT05568498|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
219433502|NCT05568498|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
219433503|NCT03587571|PROCEDURE|Surgical intervention|Open reduction and plate osteosynthesis.
219433504|NCT06460597|OTHER|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
219433505|NCT06460597|OTHER|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
219433506|NCT06386172|OTHER|Clinical decision support trigger|Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
219433507|NCT00717535|OTHER|cryopreservation|
219433508|NCT00717535|OTHER|questionnaire administration|
219433509|NCT00717535|OTHER|study of socioeconomic and demographic variables|
219192228|NCT06823739|OTHER|Exercise|This exercise program in PDE group was designed to be performed at home without re-quiring any specialized equipment. It aims to improve physical health, balance, and coor-dination while maintaining muscle strength and flexibility. Patients performed brist walking at least three times a week for a duration of 10 to 30 minutes per session. It also included balance practice and coordination exercises for 10 minutes. These include: Standing on tiptoes, balancing on one foot while holding onto a chair for support, walking in a straight line as if on a narrow beam. Finally, the exercise session ended with a 10-minute cool-down, focusing on relaxing muscles and performing gentle stretches to improve flexibility and reduce tension. All of the exercises were both explained and given in a figured chart, to the patients or the relatives
219192229|NCT06823310|DEVICE|Control (Standard treatment)|Directly printed orthodontic clear aligner without any additions
219192230|NCT06823310|DEVICE|Chitosan|Adding chitosan nanoparticles to directly printed orthodontic clear aligners in vivo to enhance anti- microbial activity against streptococcus mutans.
219192231|NCT05275998|DRUG|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
219192232|NCT06818383|DEVICE|Rezum therapy|minimal invasive technique for treating BPH
219192233|NCT04529070|BEHAVIORAL|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
219192234|NCT04529070|BEHAVIORAL|standard of care|standard of care
219192235|NCT05617040|BIOLOGICAL|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
219192236|NCT05617040|BIOLOGICAL|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
219192237|NCT01467180|DEVICE|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
219192238|NCT01467180|DEVICE|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
219192239|NCT06274723|OTHER|Expert|Participants will view a brief description of an expert source.
219192240|NCT06274723|OTHER|Peer|Participants will view a brief description of a peer source.
219192241|NCT06274723|OTHER|1 Sided|Participants will view e-cigarette education messages in one-sided.
219192242|NCT06274723|OTHER|2 Sided|Participants will view e-cigarette education messages in two-sided.
219192243|NCT04362085|DRUG|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
219192244|NCT06113965|DEVICE|Peripheral Nerve Stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
219192245|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
219192246|NCT05255393|OTHER|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
219192247|NCT06423820|DRUG|Ondansetron lozenge|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
219192248|NCT04660539|DRUG|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
219192249|NCT04660539|DRUG|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
219433510|NCT00549510|DRUG|COREG CR and lisinopril (FDC)|
219433511|NCT03106012|PROCEDURE|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
219433512|NCT03106012|PROCEDURE|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
219433513|NCT04250012|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
219433514|NCT04250012|BEHAVIORAL|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
219433515|NCT03043729|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
219192250|NCT04660539|DRUG|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
219433516|NCT03043729|DRUG|5-FU|5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
219433517|NCT03043729|DRUG|Leucovorin|Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
219192251|NCT04660539|DRUG|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
219192252|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
219192253|NCT04249362|DRUG|Durvalumab|All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
219192254|NCT06052839|DRUG|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
219192255|NCT06052839|DRUG|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
219433518|NCT03043729|BIOLOGICAL|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
219433519|NCT06067282|OTHER|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
219192256|NCT06052839|DRUG|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
219192257|NCT06202105|PROCEDURE|Laparoscopic gastrectomy|Gastrectomy with laparoscopic approach
219192258|NCT05938543|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
219192259|NCT03655028|BEHAVIORAL|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
219192260|NCT03655028|BEHAVIORAL|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
219192261|NCT03513302|DIETARY_SUPPLEMENT|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
219192262|NCT03513302|DIETARY_SUPPLEMENT|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
219433520|NCT02958904|OTHER|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
219192263|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
219578523|NCT04289597|DIAGNOSTIC_TEST|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
219192264|NCT05732779|OTHER|DOT intervention|A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
219192265|NCT05256654|DRUG|LY3561774|Administered SC
219192266|NCT05256654|DRUG|Placebo|Administered SC
219192267|NCT06285448|DRUG|Lecanemab|Bi-weekly infusions of lecanemab \[exposure\].
219192268|NCT04693533|DRUG|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
219192269|NCT01167309|DRUG|LEO 27847|First in patient
219192270|NCT04260854|DRUG|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
219192271|NCT04260854|DRUG|Saline|Normal saline injections.
219192272|NCT05167864|DRUG|Onabotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
219192273|NCT05167864|DRUG|Abobotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
219192274|NCT05167864|DRUG|IncobotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
219192275|NCT05167864|DRUG|PrabotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
219192276|NCT05786417|OTHER|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
219192277|NCT05786417|DRUG|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
219192278|NCT05786417|DRUG|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
219192279|NCT05897476|OTHER|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
219192280|NCT01976286|OTHER|Salicylic Acid Peels|
219192281|NCT01976286|OTHER|Glycolic Acid Peels|
219578524|NCT04289597|DIAGNOSTIC_TEST|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
219578525|NCT04289597|DIAGNOSTIC_TEST|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
219192282|NCT05207982|BEHAVIORAL|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
219433521|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)
219192283|NCT02807545|BEHAVIORAL|Scoliosis Specific Exercises|
219192284|NCT05469789|OTHER|No Intervention|As it is an observational study, no intervention is administered in this study.
219192285|NCT06254534|DIAGNOSTIC_TEST|optic nerve ultrasonography|The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
219192286|NCT05608109|BEHAVIORAL|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
219192287|NCT05608109|BEHAVIORAL|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
219192288|NCT03974893|OTHER|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
219192289|NCT04974151|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product.
219192290|NCT04974151|DRUG|Amlodipine besylate And Folic Acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
219192291|NCT04974151|DRUG|5-methyltetrahydrofolate (5-MTHF)|The 5-MTHF used in this study is a listed product.
219192292|NCT04974151|DRUG|Amlodipine placebo|Amlodipine placebos are dummy pills of amlodipine with identical appearance.
219192293|NCT04974151|DRUG|Amlodipine folic acid placebo|Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
219192294|NCT04974151|DRUG|5-MTHF Placebos|5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
219192295|NCT04868123|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
219192296|NCT04868123|BEHAVIORAL|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
219192297|NCT03608579|DRUG|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
219192298|NCT04149990|DRUG|Entresto Pill|NO other interventions
219192299|NCT04089059|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)"
219192300|NCT06551311|BEHAVIORAL|cycling training exercise|"Participants were randomly allocated to one of three groups: control (CTL), concentric cycling training (CON), or eccentric cycling training (ECC).~CTL: Received standard health education guidance.~CON and ECC: Participants in both the CON and ECC groups engaged in 24 exercise sessions, performed three times per week, lasting between 20 and 30 minutes. Both groups trained on a stationary bicycle, with the CON group performing concentric cycling and the ECC group performing eccentric cycling. The exercise intensity for both groups was set to a rating of perceived exertion (RPE) level of 13. Sessions began at 20 minutes and increased incrementally by 3-5 minutes each week until participants could sustain a 30-minute duration. The initial exercise intensity was set at 50% of the maximal output determined by a cardiopulmonary exercise test, and it was progressively increased by 5-10% of the estimated target power weekly, with adjustments made primarily to maintain an RPE of 13."
219192301|NCT06067945|OTHER|microleakage|prevention of microleakage and secondary carries
219433522|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)
219433523|NCT01185704|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
219433524|NCT01185704|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
219433525|NCT02993458|OTHER|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
219433526|NCT02993458|OTHER|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
219578526|NCT01877044|DIETARY_SUPPLEMENT|NAXUS|
219192302|NCT00186147|PROCEDURE|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
219192303|NCT04185246|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
219192304|NCT04185246|DIAGNOSTIC_TEST|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
219192305|NCT05165810|BEHAVIORAL|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
219192306|NCT05165810|BEHAVIORAL|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
219433527|NCT02993458|OTHER|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
219433528|NCT02993458|OTHER|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
219192307|NCT05165810|OTHER|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
219192308|NCT05165810|OTHER|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
219192309|NCT05165810|BEHAVIORAL|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
219007376|NCT06321315|BEHAVIORAL|Case-based instruction|"Case-based instruction will be applied to the students in the intervention group. Student Information Form, Critical Thinking Motivation Scale, Academic Motivation Scale and Knowledge Assessment Form will be . All students will receive classical in-class theoretical education about such as hemorrhages, hyperemesis gravidarum, oligohydramnios and urinary system diseases. In the intervention group, after the theoretical teaching of each subject within the scope of the Risky Pregnancy and Care course, cases prepared on the basis of the subject taught to the students will be applied. Student Information Form (13th and 14th questions), Critical Thinking Motivation Scale, Academic Motivation Scale, Knowledge Assessment Form and Visual Comparison Scale will be applied to all students as post-test data after case-based teaching of four topics."
219433529|NCT03788187|OTHER|Blood test sample|
219433530|NCT03788187|OTHER|Peritumoral adipose tissue sample|
219433531|NCT00830570|OTHER|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
219433532|NCT02026206|DEVICE|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
219192310|NCT05165810|BEHAVIORAL|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
219192311|NCT04032782|DRUG|HM15136|10 mg/mL as protein in prefilled syringes
219192312|NCT04032782|DRUG|Placebo of HM15136|Placebo in prefilled syringes
219192313|NCT03728608|DEVICE|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
219192314|NCT03728608|DEVICE|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
219192315|NCT04815239|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
219433533|NCT02026206|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
219433534|NCT00022152|DRUG|vinorelbine tartrate|
219433535|NCT03169049|DEVICE|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219433536|NCT03169049|DEVICE|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219578527|NCT01877044|DIETARY_SUPPLEMENT|Placebo|
219596823|NCT01403051|DRUG|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
219762121|NCT05041140|DEVICE|29-XeMRI imaging|129-XeMRI scan
219433537|NCT04783285|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
219192316|NCT04815239|BEHAVIORAL|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
219192317|NCT02329262|BEHAVIORAL|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
219192318|NCT02329262|BEHAVIORAL|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
219192319|NCT04579692|DEVICE|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
219192320|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
219192321|NCT05715814|DRUG|Empagliflozin 25 MG|PO once daily
219192322|NCT03529396|DRUG|Chloroquine|Standard chloroquine (three days)
219192323|NCT03529396|DRUG|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
219192324|NCT03529396|DRUG|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
219433538|NCT03864809|BEHAVIORAL|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
219433539|NCT03165942|OTHER|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
219578528|NCT06524856|DEVICE|Lung Master (Pulmonary Exerciser)|During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
219578529|NCT00857259|DRUG|Everolimus|5 mg oral tablet
219578530|NCT00857259|DRUG|Ranibizumab|0.5 mg administered by intravitreal injection
219578531|NCT01370213|DRUG|Preparative Regimen|"Preparative Regimen:~1\) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
219007377|NCT01533025|PROCEDURE|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
219007378|NCT04944953|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
219192325|NCT03529396|DRUG|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
219192326|NCT03529396|DRUG|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
219192327|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
219192328|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
219192329|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
219192330|NCT05207956|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
219433540|NCT03165942|OTHER|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
219007379|NCT04944953|DRUG|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
219007380|NCT00927784|BIOLOGICAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
219578532|NCT01370213|BIOLOGICAL|NK Cells|CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
219596824|NCT01403051|DRUG|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
219596825|NCT01403051|DRUG|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
219596826|NCT01403051|DRUG|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
219433541|NCT03165942|DRUG|Ethanol|
219433542|NCT00680160|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
219007381|NCT00927784|DRUG|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
219192331|NCT05207956|OTHER|Electronic platform|Electronic platform to collect data
219433543|NCT01686958|DEVICE|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
219433544|NCT01241019|DRUG|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
219192332|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
219192333|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
219192334|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
219192335|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
219192336|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
219192337|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
219192338|NCT06156670|DEVICE|PFO closure|"The operation of endovascular closure of PFO is performed on X-ray angiographic devices with digital processing of X-ray images. Endovascular closure of a PFO will be performed by femoral venous access using the following instruments: diagnostic catheter, diagnostic guidewire, high-stiffness guidewire for delivery system, interatrial septum occluders of PFO, UNI, ASD types.~Preoperative preparation and control of device implantation will be performed using modern echocardiographic equipment."
219192339|NCT05628584|COMBINATION_PRODUCT|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
219192340|NCT05628584|COMBINATION_PRODUCT|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
219433545|NCT05998655|OTHER|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
219433546|NCT02675738|OTHER|good clinical practice|
219433547|NCT02832596|DRUG|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
219433548|NCT02832596|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
219433549|NCT01151540|DRUG|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
219433550|NCT06327620|COMBINATION_PRODUCT|Daivobet ointment, topical steroids|"Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information."
219433551|NCT03094832|DRUG|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
219192341|NCT04979377|OTHER|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
219433552|NCT01213693|DRUG|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
219433553|NCT01213693|DRUG|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
219433554|NCT01998880|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
219433555|NCT01998880|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
219433556|NCT01998880|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
219433557|NCT04994080|DRUG|Paricalcitol|Paricalcitol QD Treatment
219433558|NCT04994080|DRUG|Placebo|Placebo QD or TIW
219433559|NCT02027922|OTHER|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
219433560|NCT05626244|BEHAVIORAL|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
219007382|NCT02170051|BEHAVIORAL|CBSST-CCT|
219007383|NCT02170051|BEHAVIORAL|Goal focused supportive contact|
219007384|NCT02353598|DRUG|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
219007385|NCT02353598|DRUG|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
219007386|NCT02353598|DRUG|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
219007387|NCT02353598|DRUG|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
219433561|NCT01104363|PROCEDURE|Snow white plaster 2|Test. Plaster impression not splinted.
219433562|NCT01104363|PROCEDURE|Primopattern LC gel + PVS|Control PVS impression
219192342|NCT04979377|DIAGNOSTIC_TEST|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
219192343|NCT04979377|DIAGNOSTIC_TEST|A1c (%)|High Performance Liquid Chromatography (HPLC)
219007388|NCT03580694|DRUG|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
219007389|NCT03580694|DRUG|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
219192344|NCT04979377|DIAGNOSTIC_TEST|Total cholesterol|Determined by enzymatic methods
219192345|NCT04979377|OTHER|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
219433563|NCT02584413|DEVICE|Magnetic resonance imaging|-Standard of care
219007390|NCT01867021|BIOLOGICAL|Fluvirin(TIVf)|
219192346|NCT04979377|DIAGNOSTIC_TEST|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
219192347|NCT04979377|DIAGNOSTIC_TEST|Polycystic ovary morphology|Sonographic assessment
219192348|NCT04979377|DIAGNOSTIC_TEST|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
219192349|NCT04979377|DIAGNOSTIC_TEST|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
219192350|NCT04979377|DIAGNOSTIC_TEST|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
219192351|NCT04979377|OTHER|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
219192352|NCT04979377|OTHER|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
219433564|NCT02584413|DRUG|Gadolinium contrast|-Standard of care
219192353|NCT04979377|OTHER|Body composition|Vital Scan HW7-HW6T
219192354|NCT04979377|DIAGNOSTIC_TEST|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
219433565|NCT03199638|DRUG|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
219433566|NCT03199638|BEHAVIORAL|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
219433567|NCT05002699|DIAGNOSTIC_TEST|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
219433568|NCT01575899|DRUG|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
219433569|NCT01575899|DRUG|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
219433570|NCT01237028|DRUG|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
219433571|NCT06187311|DRUG|Rivaroxaban 20 MG|Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
219433572|NCT06187311|DRUG|Rivaroxaban 15 MG|Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
219433573|NCT03226561|PROCEDURE|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
219433574|NCT06580860|DRUG|Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids|Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
219762122|NCT05256225|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219762123|NCT05256225|DRUG|Carboplatin|Given IV
219762124|NCT05256225|PROCEDURE|Computed Tomography|Undergo CT
219762125|NCT05256225|PROCEDURE|Echocardiography Test|Undergo ECHO
219762126|NCT05256225|RADIATION|High-Dose-Rate Vaginal Cuff Brachytherapy|Undergo vaginal brachytherapy
219762127|NCT05256225|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
219762128|NCT05256225|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762129|NCT05256225|DRUG|Paclitaxel|Given IV
219762130|NCT05256225|OTHER|Survey Administration|Ancillary studies
219762131|NCT05256225|DRUG|Trastuzumab/Hyaluronidase-oysk|Given SC
219762132|NCT03683251|DRUG|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
219762133|NCT05807399|DRUG|BTZ-043|BTZ-043 1000mg once daily in arms 4 and 6.
219762134|NCT05807399|DRUG|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3, 5 and 7.
219762135|NCT05807399|DRUG|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3 and 7.
219762136|NCT05807399|DRUG|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3, 5 and 7.
219762137|NCT05807399|DRUG|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2.
219762138|NCT05807399|DRUG|Alpibectir (GSK3729098)|Alpibectir 45 mg OD plus Ethionamide 500 mg OD combined with rifampicin pyrazinamide and ethambutol at standard weight-banded doses in arm 5.
219762139|NCT05807399|DRUG|Ganfeborole (GSK3036656)|Ganfeborole 20 mg OD in arm 6
219762140|NCT05807399|DRUG|Delpazolid (LCB01-0371)|Delpazolid 1200mg OD in arm 6
219762141|NCT05807399|DRUG|Pretomanid (Pa)|Pretomanid 20mg OD in arm 6.
219762142|NCT05807399|DRUG|Ethambutol (E)|Ethambutol 20mg/Kg OD in arm 3, 5 and 7
219762143|NCT05807399|DRUG|Ethionamide|Ethionamide 500mg OD in arm 5.
219762144|NCT01385176|DEVICE|Implant of investigational device system|Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
219762145|NCT01385176|PROCEDURE|Titration during the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
219433575|NCT04527276|OTHER|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
219192355|NCT04979377|DIAGNOSTIC_TEST|Time in target range (hours)|Continuous glucose monitoring (GCM) records
219192356|NCT04979377|DIAGNOSTIC_TEST|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
219192357|NCT04979377|OTHER|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
219192358|NCT04979377|OTHER|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
219192359|NCT04979377|DIAGNOSTIC_TEST|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
219192360|NCT04979377|DIAGNOSTIC_TEST|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
219433576|NCT02166229|DRUG|Divalproex sodium|
219433577|NCT02807844|DRUG|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
219433578|NCT02807844|DRUG|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
219433579|NCT04278482|DIETARY_SUPPLEMENT|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
219433580|NCT01390480|DRUG|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
219433581|NCT02238548|BIOLOGICAL|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
219433582|NCT02238548|OTHER|Raw milk|
219192361|NCT04979377|DIAGNOSTIC_TEST|Triglycerides (mg/dL)|Determined by enzymatic methods
219192362|NCT06153966|DRUG|ION717|ION717 will be administered by IT injection.
219192363|NCT06153966|DRUG|Placebo|Placebo-matching ION717 will be administered by IT injection.
219192364|NCT05772884|OTHER|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
219192365|NCT06503250|DRUG|Atezolizumab|Observational Study
219192366|NCT06503250|DRUG|Bevacizumab|Observational Study
219192367|NCT06503250|RADIATION|Transarterial Chemoembolization|Observational Study
219192368|NCT02275416|DRUG|Ipilimumab|
219192369|NCT02275416|BIOLOGICAL|UV1 vaccine|
219476417|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
219192370|NCT02275416|BIOLOGICAL|GM-CSF|
219192371|NCT06494774|DRUG|BI 1815368|BI 1815368
219192372|NCT06494774|DRUG|Placebo matching BI 1815368|Placebo matching BI 1815368
219192373|NCT05303584|BIOLOGICAL|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
219192374|NCT05303584|BIOLOGICAL|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
219007391|NCT01867021|BIOLOGICAL|Agriflu (TIV)|
219192375|NCT05303584|BIOLOGICAL|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
219192376|NCT05604274|OTHER|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
219192377|NCT06562257|OTHER|Honey|Honey has a long-standing reputation for promoting wound healing and offers a more economical treatment modality. Nusantara Honey, a GMP-certified product available on the market, met our criteria for quality and safety.
219192378|NCT06562257|OTHER|PHMB Solution|PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.
219192379|NCT03902912|DRUG|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
219192380|NCT04860830|DRUG|BI 425809|BI 425809
219192381|NCT04860830|DRUG|Placebo|Placebo
219596827|NCT01403051|DRUG|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
219578533|NCT01370213|DRUG|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
219192382|NCT06562933|DEVICE|Sham vacuum|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.
219433583|NCT05752786|BEHAVIORAL|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
219433584|NCT02576886|DEVICE|Gamma Camera|All images acquired with the General Electric Discovery 530c
219433585|NCT02576886|PROCEDURE|Prone Imaging|
219433586|NCT00353184|DRUG|Montelukast 5-mg orally added to standard therapy|
219433587|NCT02729805|DRUG|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
219433588|NCT02729805|DRUG|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
219433589|NCT02729805|DRUG|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
219433590|NCT03443609|DIAGNOSTIC_TEST|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
219433591|NCT04403854|DIAGNOSTIC_TEST|MRI|If possible with spectroscopy
219433592|NCT04403854|PROCEDURE|Spinal Tap|together with CSF pressure estimate
219578534|NCT01370213|BIOLOGICAL|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
219578535|NCT01370213|BIOLOGICAL|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
219578536|NCT02701413|DEVICE|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
219578537|NCT02701413|DEVICE|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
219578538|NCT00887328|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
219578539|NCT00887328|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
219578540|NCT04654897|DRUG|[14C]-NT-814|120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].
219578541|NCT03804398|DEVICE|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
219578542|NCT03804398|DEVICE|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
219578543|NCT04535752|DRUG|ANX009|Single or multiple ascending dose
219007392|NCT00881712|RADIATION|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
219433593|NCT05793216|BEHAVIORAL|VestibulOTherapy|"For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud."
219433594|NCT04294095|OTHER|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
219433595|NCT04294095|OTHER|Control|This is a 12-week basic prenatal education class.
219433596|NCT00034203|DRUG|efalizumab|
219433597|NCT00003203|BIOLOGICAL|filgrastim|Given IV
219433598|NCT00003203|DRUG|carboplatin|Given IV
219433599|NCT00003203|DRUG|cisplatin|Given IV
219433600|NCT00003203|DRUG|cyclophosphamide|Given IV
219433601|NCT00003203|DRUG|vincristine sulfate|Given IV
219433602|NCT00003203|PROCEDURE|adjuvant therapy|
219433603|NCT00003203|RADIATION|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
219192383|NCT06562933|DEVICE|Interferential Current Therapy Vacuum Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
219192384|NCT06562933|DEVICE|Interferential Current Therapy Carbon-silicon Pad Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
219192385|NCT06563388|PROCEDURE|Stereotactic Ablative Radiotherapy|Radiation therapy begins after 3 months of Standard of care
219192386|NCT06563388|OTHER|Best Practice|Receive standard of care therapy
219192387|NCT06556927|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
219192388|NCT05053854|DRUG|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
219578544|NCT04535752|DRUG|Placebo|Single or multiple ascending dose
218859507|NCT05400993|COMBINATION_PRODUCT|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
219007393|NCT00881712|RADIATION|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
219007394|NCT00881712|RADIATION|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
219192389|NCT05858346|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
219433604|NCT05075707|OTHER|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
219433605|NCT05075707|OTHER|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
219433606|NCT04863937|DEVICE|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
219433607|NCT02414971|OTHER|There is no intervention|There is no intervention
219433608|NCT02873364|DRUG|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
219433609|NCT02873364|DRUG|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
219433610|NCT00373100|DRUG|Zinc acetate|
219433611|NCT00373100|DRUG|Placebo|Placebo
219433612|NCT02920606|PROCEDURE|Pulpotomy|
219578545|NCT00472797|DRUG|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
219578546|NCT00472797|DRUG|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
219578547|NCT04647669|DRUG|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
219578548|NCT04647669|DRUG|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
219578549|NCT04647669|DRUG|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
219578550|NCT04647669|OTHER|Standard of Care|Treatment according to local hospital protocol
219578551|NCT03077906|OTHER|Medical Files data extraction|Medical Files data extraction
219578552|NCT00488670|DRUG|Escitalopram|See Detailed Description.
219578553|NCT03876977|PROCEDURE|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
219578554|NCT00148330|DRUG|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
219578555|NCT00988689|OTHER|Dietary Intervention|soup with or without starch
218859508|NCT05057507|DIAGNOSTIC_TEST|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
218859509|NCT05057507|DIAGNOSTIC_TEST|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
219192390|NCT05858346|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
219192391|NCT05326477|BEHAVIORAL|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
219433613|NCT02920606|PROCEDURE|Endodontic treatment|
219433614|NCT00036062|DRUG|Sivelestat|
219433615|NCT00265967|DRUG|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
218859510|NCT05057507|OTHER|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
218859511|NCT05057507|DIAGNOSTIC_TEST|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
219433616|NCT06202001|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
219192392|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
219192393|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219433617|NCT05652972|OTHER|Ketogenic diet|1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
219433618|NCT05652972|OTHER|Control diet|1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
219433619|NCT00546234|DRUG|tiotropium|18 mcg daily via Handihaler
219192394|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
219192395|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
219192396|NCT05835349|DEVICE|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
219192397|NCT02489604|DRUG|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
219578556|NCT04072016|DEVICE|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
219578557|NCT01621191|DRUG|Duloxetine|Administered Orally
218859512|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
218859513|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
219192398|NCT02489604|DRUG|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
219192399|NCT06454630|DRUG|REGN7508|Administered by single intravenous (IV) dose
219192400|NCT06454630|DRUG|Enoxaparin|Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
219192401|NCT05873517|BEHAVIORAL|Immediate Narrative Exposure Therapy (NET)+|The basis of this intervention is adapted Narrative Exposure Therapy (NET)+. All participants receive 4-8 active NET+ sessions, including a psychoeducational session.
219192402|NCT05873517|BEHAVIORAL|Waitlist + NET+|Waitlist control group participants receive 1 psychoeducational sessions and will be added to a waitlist; waitlist control group participants randomly selected from the waitlist be offered the opportunity to receive the active intervention (NET+).
219192403|NCT01254864|DRUG|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
219578558|NCT00568815|DRUG|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
219578559|NCT05757323|OTHER|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
218859514|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
219192404|NCT01254864|DRUG|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
219192405|NCT01254864|DRUG|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
219192406|NCT01254864|DRUG|Dasatinib|100 mg by mouth each day of a 28 day cycle.
219433620|NCT00546234|DRUG|long acting beta agonist|Turbohaler, 6 \& 12 mcg
218859515|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
219192407|NCT03895996|DRUG|AVT001|autologous dendritic cell therapy
219192408|NCT03895996|OTHER|Placebo|matched placebo
219433621|NCT01095341|OTHER|No intervention performed|
219433622|NCT05520918|DIAGNOSTIC_TEST|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
219433623|NCT02661464|BIOLOGICAL|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
219433624|NCT02661464|BIOLOGICAL|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
219433625|NCT02073903|BEHAVIORAL|Patient Survey|
219433626|NCT02073903|BEHAVIORAL|Provider Survey|
219433627|NCT05840978|DIETARY_SUPPLEMENT|Probiotics|Oral capsules
219433628|NCT05840978|DIETARY_SUPPLEMENT|Placebo|Oral capsules
219578560|NCT05757323|OTHER|infant formula based on intact protein|infant formula based on intact protein
219007395|NCT04770350|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
219433629|NCT00737685|DRUG|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
219433630|NCT03069898|BEHAVIORAL|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
219192409|NCT06278194|PROCEDURE|Gasserian Ganglion Radiofrequency Thermocoagulation|Gasserian ganglion radiofrequency thermocoagulation is performed in the operating room under fluoroscopy. In sterile condition, the foramen ovale is shown by the pain management specialist under fluoroscopy guidance. After this condition, the entry of the needle is marked and anaesthetised with local anaesthetic. After the entry of the gasserian ganglion with the radiofrequency needle, 10 cm long, the location is checked with sensory and motor stimulation. If the placement is correct, 70 degrees 70 seconds of radiofrequency thermocoagulation is applied.
219192410|NCT05260125|DRUG|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
219192411|NCT05260125|DRUG|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
219192412|NCT02693509|OTHER|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
219192413|NCT05312983|OTHER|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~* Session A : objective audiological tests~* Session B ; subjective audiological tests~* Session C : balance tests."
219192414|NCT05312983|OTHER|Blood sampling|A 10 mL blood sample will be collected during the study.
219192415|NCT05312983|OTHER|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
219192416|NCT06180980|DRUG|Pirtobrutinib|Administered orally.
219192417|NCT03730558|COMBINATION_PRODUCT|aflibercept + FOLFIRI|aflibercept + FOLFIRI
219192418|NCT04241276|DRUG|ATRA|45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
219192419|NCT04241276|DRUG|Gemcitabine|1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
219192420|NCT04241276|DRUG|nab-paclitaxel|125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
219192421|NCT05703360|DEVICE|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
219192422|NCT01828112|DRUG|Ceritinib|Ceritinib was the investigational treatment and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
219192423|NCT01828112|DRUG|Pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m\^2 every 21 days.
219192424|NCT01828112|DRUG|Docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m\^2 every 21 days.
219007396|NCT01397474|OTHER|PPTFM|Peripheral Perfusion Targeted Fluid Management
219192425|NCT04779827|BEHAVIORAL|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
219192426|NCT04779827|BEHAVIORAL|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
219192427|NCT06767696|OTHER|Cuff pressure measurement|"Intubation tube cuff pressure in cmH2O at 3 different time periods with a cuff manometer (VBM Medizintechnik, GmbH, Germany)~Time periods:~Cuff pressure value measured in neutral position after intubation (cmH2O) - T0 Cuff pressure measurement value after hyperextension (cmH2O) - T1 Cuff pressure measurement value in neutral position after surgical procedure (cmH2O) - T2"
219433631|NCT04780945|DIAGNOSTIC_TEST|Functional RAD51 assay|ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
219433632|NCT04780945|DRUG|Olaparib Oral Product|300 mg bid
219433633|NCT03947567|DRUG|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
219192428|NCT05326386|BEHAVIORAL|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
219192429|NCT01188928|DRUG|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
219192430|NCT01188928|DRUG|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
219192431|NCT01188928|DRUG|Calcipotriene|Topical suspension once daily for up to 8 weeks.
219192432|NCT01188928|DRUG|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
219192433|NCT02945176|DEVICE|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
219192434|NCT05244187|DEVICE|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
219192435|NCT05383196|DRUG|Onvansertib|oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
219192436|NCT05383196|DRUG|Paclitaxel|once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
219192437|NCT03403465|OTHER|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
219433634|NCT02213822|OTHER|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
219433635|NCT05456412|OTHER|JAK inhibitor treatment|Standard care
219433636|NCT00334152|DRUG|casopitant|
219433637|NCT00703859|DRUG|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
219762146|NCT01385176|PROCEDURE|Titration after the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
219762147|NCT01385176|DIAGNOSTIC_TEST|Blood Draw|Blood draw before implant and 6 months after implant at the end of the randomization phase.
218859516|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
219192438|NCT03891485|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
219762148|NCT06828055|DRUG|Placebo|Matching Placebo to VK2735
219762149|NCT06828055|DRUG|VK2735|Active Treatment
218859517|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
218859518|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
218859519|NCT06103487|GENETIC|No Intervention|Observational study
218859520|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
219192439|NCT04252989|OTHER|data collection|"* Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)"
219762150|NCT05675410|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762151|NCT05675410|BIOLOGICAL|Bleomycin Sulfate|Given IV
219762152|NCT05675410|DRUG|Brentuximab Vedotin|Given IV
219007397|NCT03519646|DRUG|Eliglustat|"1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
219192440|NCT06799689|BEHAVIORAL|esmadem education|"By providing information about Esma-i Husna, the journey of knowing oneself and character building with Esma-i Husna will be emphasized. It will be carried out with the aim of building on 99 names, namely Allah, Rahman and Rahim, and reducing depressive feelings by benefiting from the guidance of these names.In the second session, it will be explained through the names Esma-i Husna, Celal and Cemal in order to manage depressive feelings and contribute to positive coping. The togetherness of pain as well as happiness, ease along with difficulty, joy along with sadness in a balanced life will be discussed with the name Zü'l Celâl ve'l İkram and the study of Journey to perfection through the names Celal and Cemal. The meaning of existence and life in spirit will be discussed through the name Rab, the life cycle will be explained by establishing a relationship with the names Hafıd-Râfi, Kâbıd-Bâsıt, Muız-Müzil. In addition, it will be carried out within the framework of the name Hakim,"
219192441|NCT05184452|DRUG|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
219192442|NCT05184452|DRUG|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
219192443|NCT05184452|DRUG|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
219192444|NCT05184452|DRUG|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
219192445|NCT05184452|DRUG|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
219192446|NCT05184452|DRUG|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
219192447|NCT05184452|DRUG|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
219192448|NCT05184452|DRUG|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
219192449|NCT05184452|DRUG|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
219192450|NCT05184452|DRUG|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
219192451|NCT05184452|DRUG|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
219192452|NCT05184452|DRUG|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
219192453|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
219192454|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
219192455|NCT05184452|DRUG|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
219192456|NCT05184452|DRUG|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
219192457|NCT05184452|DRUG|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
219433638|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
218859521|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
218859522|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
219007398|NCT01966900|BIOLOGICAL|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
219192458|NCT04772196|DRUG|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
218859523|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
218859524|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
219192459|NCT03923374|DRUG|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
219433639|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
219433640|NCT01753388|DEVICE|Liberty Stent|
219433641|NCT03412500|DRUG|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
219433642|NCT03412500|DRUG|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
219192460|NCT03923374|DIAGNOSTIC_TEST|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
219433643|NCT02030470|OTHER|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
219192461|NCT03923374|DIAGNOSTIC_TEST|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
219192462|NCT05876533|DEVICE|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
219433644|NCT04864678|OTHER|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
219433645|NCT03148756|DRUG|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
219433646|NCT03148756|DRUG|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
219433647|NCT00358501|DRUG|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
219433648|NCT01867567|PROCEDURE|abdominal bandage|
219578561|NCT01884428|DRUG|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
219578562|NCT01884428|DRUG|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
219192463|NCT05654675|DIAGNOSTIC_TEST|FDG PET/CT|Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
219192464|NCT03187535|DEVICE|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
219433649|NCT05493540|DRUG|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
219433650|NCT05493540|DRUG|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
219433651|NCT02255643|DEVICE|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
219433652|NCT05386264|OTHER|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
219433653|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
219192465|NCT03187535|OTHER|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
219192466|NCT05586490|DEVICE|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
219192467|NCT05586490|DEVICE|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
219192468|NCT05247255|DRUG|Active Comparator|QL block with 0.25% ropivacaine
219192469|NCT05247255|DRUG|Placebo Comparator|QL block with saline
219192470|NCT05845502|BIOLOGICAL|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
219192471|NCT02935478|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
219192472|NCT06773754|OTHER|Five-days-On and Two-days-Off|Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)
219192473|NCT06048419|BEHAVIORAL|Home Program|Home program for 6 weeks (1 hr and 15 minutes per week)
219192474|NCT06263959|DRUG|GST-HG131|GST-HG131 will be administered.
219192475|NCT06263959|DRUG|Placebo to match GST-HG131|Placebo to match GST-HG131 will be administered.
219192476|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
219192477|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
219192478|NCT02584647|DRUG|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
219192479|NCT02584647|DRUG|sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
219192480|NCT03956784|DEVICE|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~* Normal situation~* Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~* Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
218859525|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
219192481|NCT03956784|OTHER|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~1. Immediate complications and warning signs:~   * Tachycardia\> 120 bpm~  * Dyspnea~  * Rectorragies and / or melena~  * Vomiting with or without presence of blood~  * Major abdominal pain (visual analogue scale\> 6/10)~  * Fever\> 38~2. Management to deal with complications: call the service and / or the surgeon~3. Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
219192482|NCT05650190|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
219192483|NCT05650190|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
219192484|NCT05839262|OTHER|Conventional physical rehabilitation plus Active video games (CPR+AVG)|"In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console."
219192485|NCT05839262|OTHER|Conventional physical rehabilitation alone (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
219192486|NCT06804694|BEHAVIORAL|TECC-T1D3 Program|The TECC-T1D3 program is a twelve-week virtual care intervention designed to support individuals with Type 1 Diabetes (T1D) and Diabetes Distress. The program includes a health coach (HC) and a virtual care team (VCT) of T1D, mental health experts and peer support, offering comprehensive care through various communication channels, including WebEx, phone calls, and text messaging. The program aims to: i. Provide T1D specific mental health and wellbeing support, ii. Provide guidance on how to communicate with others about T1D, manage stigma and ask for help with diabetes management and iii. Facilitate connections with T1D communities. Participants can choose topics of discussion based on their needs and will be directly supported by the HC and indirectly monitored by VCT.
219192487|NCT06804694|OTHER|Education Intervention|The Education Intervention is a low-intensity, education-focused intervention consisting of 10 automated emails over 12 weeks, providing generalized educational messages with links to resources for mental health support and well-being for individuals living with T1D.
219192488|NCT06804629|BEHAVIORAL|Moderate-to-High Intensity Resistance Exercise Training|Resistance exercise training was designed in accordance with World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed such that moderate-to-high intensity participants could achieve two sets of 8-12 repetitions of the eight exercises before volitional fatigue, a deterioration in lifting form, or failure to complete a repetition, using loads of approximately 70-80% of their estimated one-repetition maximum. Completed in the following order, the exercises were: barbell back squat, barbell bench press, hexagon bar deadlift, barbell bent over row, dumbbell lunges, seated dumbbell lateral raises, weighted or unweighted abdominal crunches, and seated dumbbell bicep curls. There was one minute of rest between each set, and two minutes of rest between each exercise. If participants could complete two sets of 12 repetitions, load was increased gradually by approximately 5% in the following session.
219192489|NCT06804629|BEHAVIORAL|Low Intensity SHAM Resistance Exercise Training Attention Control|The low intensity SHAM condition was matched all features of engagement with the moderate-to-high intensity intervention apart from load, and load progression. Low intensity SHAM participants completed the same program with loads of approximately 20% of their estimated one-repetition maximum. To maintain low intensity, repetitions completed on the main, heavier lifts (i.e., back squat, bench press, deadlift, bent over row) were increased from 10 in one session to 12 in the next; load was then increased by approximately 10% in the following session, and 10 reps were performed again. On the remaining lighter, assistance lifts, eight repetitions were performed per set, then one repetition was added to both sets in each session, and load was increased by the smallest increment possible when two sets of 12 repetitions were performed. Borg's 6-20 rating of perceived exertion scores were used to monitor intensity, such that if scores exceeded 11, load and reps were not progressed.
219192490|NCT06805682|OTHER|Usual Care|Children will be followed using each CPS participating center's usual practices
219578563|NCT01884428|DRUG|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
219578564|NCT01884428|DRUG|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
219578565|NCT01884428|DRUG|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
219578566|NCT01389583|DRUG|AUY922|70 mg/m2 60-min i.v. infusion weekly
219578567|NCT04145583|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
219578568|NCT04145583|DRUG|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
219578569|NCT00971958|PROCEDURE|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
219578570|NCT00971958|DEVICE|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
219578571|NCT00971958|DEVICE|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
219578572|NCT00971958|DEVICE|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
219578573|NCT00953641|DRUG|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
219578574|NCT00953641|DRUG|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
219578575|NCT04928274|OTHER|ball attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
219578576|NCT04928274|OTHER|locator attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
219578577|NCT04928274|OTHER|telescopic attachment to retain mandibular over denture|each patient in group receive 3 telescopic attachment for over denture retention
219192491|NCT01386138|BEHAVIORAL|Psycho-education|Receive RBT education and peer-support in a group format.
219192492|NCT01386138|BEHAVIORAL|Experimental|Receive RBT education and a pro-active counseling method
219192493|NCT06805812|DRUG|Palbociclib|Administered in combination with endocrine therapy
219192494|NCT06805812|DRUG|Ribociclib|Administered in combination with endocrine therapy
219192495|NCT06805812|DRUG|Abemaciclib|Administered in combination with endocrine therapy
219192496|NCT06805864|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab is administered at 200 mg every 3 weeks for the first 2 cycles during Chemo-CIRT, after completion of radiotherapy, the dose is increased to 400 mg and given every 6 weeks for a total of 17 cycles over 2 years.
219192497|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
219192498|NCT06578117|DEVICE|Vision Training and Learning Task|"Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard."
219192499|NCT06336902|BIOLOGICAL|Balstilimab|Given IV
219192500|NCT06336902|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219192501|NCT06336902|BIOLOGICAL|Botensilimab|Given IV
219192502|NCT06336902|PROCEDURE|Computed Tomography|Undergo CT scan
219192503|NCT06336902|OTHER|Dietary Intervention|Undergo FMD
219192504|NCT06336902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219192505|NCT06336902|DIETARY_SUPPLEMENT|Vitamin C|Given IV
219192506|NCT06804759|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
219192507|NCT06804759|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
219192508|NCT06804759|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
219192509|NCT04706832|DEVICE|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
219762153|NCT05675410|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
219192510|NCT03453567|PROCEDURE|Valve Replacement|Aortic valve replacement
219192511|NCT06802900|PROCEDURE|Clinical Outcomes and Surgical Insights from Nerve-Sparing Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis|In this retrospective study, the patents whom underwent nerve sparing modified radical hysterectomy for deeply infiltrating endometriosis with uterine skeletonization technique will be reviewed. The uterine skeletonization technique was developed by the princible investigator (BK) for DIE modified radical hsyterectomy and performed systematically in Basaksehir Cam ve Sakura City Hospital. The detailed surgical steps, surgical data such as operation duration, surgical type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections), and intraoperative complications (organ injuries, blood transfusions, conversion to open surgery) will be recorded. Early and late postoperative complications (fever, deep vein thrombosis, sepsis, pelvic abscess, genitourinary fistulas, anastomotic leaks, reoperation, vaginal cuff bleeding or abscess, and bladder dysfunction) will also be evaluated.
219192512|NCT06805227|OTHER|Kinesiology Tape Application|"Application Area: Applied specifically to the dominant leg, targeting the rectus femoris, vastus medialis, and vastus lateralis muscles.~Tension Level: Applied with a standardized 50% tension. Duration: The tape was kept in place continuously for 30 days. Color: A blue-colored kinesiology tape was used to standardize the intervention and eliminate potential psychological effects of tape color.~Technique: Applied by a licensed physical therapist with expertise in kinesiology taping techniques, certified by the Saudi Commission for Health Specialties."
219192513|NCT06804070|OTHER|Botanical Moisturizer + Unscented Soap|"The intervention includes the use of 2 products:~1. A botanical moisturizer~2. An unscented bar of soap"
219192514|NCT06558188|DRUG|Romosozumab|romosozumab 210 milligrams monthly
219192515|NCT06558188|DRUG|Teriparatide|teriparatide 20 micrograms daily
219192516|NCT06806072|OTHER|Balneotherapy|The intervention consists in 3 weekly sessions of balneotherapy during 4 weeks.
219192517|NCT06804330|PROCEDURE|root canal treatment and intracanal medicament|Root canal biomechanical preparation followed by intracanal placement of intracanal medicament according to the arm
219192518|NCT06246734|BEHAVIORAL|Hasbro Joy for All robot pet companion|The robot pets are stuffed animals (dogs and cats) that have features that make them seem lifelike. For example, the animal toys turn their heads when petted, purr or make puppy sounds, feel warm, have a heartbeat, and go to sleep when they are ignored. They respond to attention and petting like a real pet. The robot pets do not collect information and do not require any maintenance, except a battery. Engagement with the device is at the discretion of participants.
219192519|NCT02951091|OTHER|biomarker screening|immunohistochemistry and in situ hybridization
219433654|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
219433655|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
219433656|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
219433657|NCT04021459|PROCEDURE|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
219762154|NCT05675410|DRUG|Cyclophosphamide|Given IV
219762155|NCT05675410|DRUG|Dacarbazine|Given IV
219578578|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
219192520|NCT06617611|PROCEDURE|Surgical intervention and anesthesia|Any surgical procedure
219433658|NCT05832099|RADIATION|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
219433659|NCT06397742|OTHER|Physical activity|"Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches"
219578579|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
219578580|NCT04780841|DRUG|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
219192521|NCT05959616|BIOLOGICAL|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
219192522|NCT05959616|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
219192523|NCT06804577|OTHER|peanut ball|The experimental group will use peanut balls;
219192524|NCT06806007|DEVICE|Group A|"Each child in the group A will receive the incentive spirometer training , attending three sessions per week for three consecutive months. The duration of the session will be half an hour Set up~1. Begin bothering child sit on the mat or chair.~2. Hold the incentive spirometer in an upright position.~3. The child Breathe out normally.~4. Place the spirometer mouthpiece in child's mouth and ask him to close his / her lips tightly around it.~5. Ask the child to Breathe in through mouth as slowly and deeply as he can,~6. Hold breath for as long as possible, or at least five seconds. Exhale slowly~7. Rest for a few seconds, and then repeat the first five steps at least 10 times every hour you're awake.~8. After each set of 10 deep breaths, ask child cough deeply to clear lungs"
219578581|NCT04780841|DRUG|Placebo|Placebo treatment that looks identical to experimental treatment
219578582|NCT04463303|OTHER|lung ultrasound|patient with or without weaning induced pulmonary adema
219578583|NCT01077466|DRUG|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
219578584|NCT04514965|OTHER|Blood sampling|Blood sampling
219762156|NCT05675410|DRUG|Doxorubicin Hydrochloride|Given IV
219192525|NCT06806007|OTHER|Group B|"Each child in the group B will receive the oropharyngeal motor training programme , attending three sessions per week for three consecutive months. The duration of the session will be an hour The training programme consisted of 10 individual mobilization exercises involving orofacial and pharyngeal area that required 45 minutes Each exercise had to be repeated for 10 times.~The 10 exercises are:~* Exercise 1: Pushing Up The Tongue~* Exercise 2: Touching Nose~* Exercise 3: Touching Chin~* Exercise 4: Pushing Tongue Right and Left~* Exercise 5: Folding Tongue~* Exercise 6: Clicking the Tongue~* Exercise 7: Pushing Tongue Against Spoon~* Exercise 8: Holding A Spoon~* Exercise 9: Holding Button with Lips~* Exercise 10: Gargling"
219192526|NCT06806007|COMBINATION_PRODUCT|Group C|Each child in the group C will receive a combination program of the incentive spirometer training and oropharyngeal motor training programme attending three sessions per week for three consecutive months. The duration of the session will be one hour and half that Will be designed into half an hour for the incentive spirometer training and an hour for the oropharyngeal motor training programme
219762157|NCT05675410|DRUG|Etoposide|Given IV
219192527|NCT06804798|DEVICE|Latex metal alloy coated catheter|Metal alloy works as an antiseptic whereby preventing the attachment of biofilm to the catheter lining.
219192528|NCT06804798|DEVICE|conventional latex urinary catheter|Latex catheters prove to be soft, flexible, inexpensive and thermo-sensitive towards body temperature. However, there is a risk of developing CAUTI as bacteria are more susceptible to adhere to latex.
219192529|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
219192530|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
219192531|NCT05526196|DRUG|Cannabis|Dried flower cannabis cigarette with 22% THC
219192532|NCT05526196|DRUG|Tobacco|Dried flower cigarette with active nicotine
219192533|NCT05526196|DRUG|Cannabis tobacco|Dried flower cigarette with active nicotine and cannabis
219192534|NCT05526196|DRUG|Placebo|Dried flower cigarette with both placebo tobacco and cannabis
219192535|NCT04818671|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
219192536|NCT06457594|OTHER|Questionnaire|EORTC QLQ-INFO25 EORTC QLQ - H\&N43 and EORTC QLQ-C30
219192537|NCT05695222|OTHER|This is not an interventional study|This is not an interventional study
219762158|NCT05675410|DRUG|Etoposide Phosphate|Given IV
219762159|NCT05675410|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
219762160|NCT05675410|RADIATION|Involved-site Radiation Therapy|Undergo ISRT
219762161|NCT05675410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET-MRI
219762162|NCT05675410|BIOLOGICAL|Nivolumab|Given IV
219762163|NCT05675410|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
219762164|NCT05675410|DRUG|Prednisolone|Given PO
219762165|NCT05675410|DRUG|Prednisone|Given PO
219762166|NCT05675410|DRUG|Procarbazine Hydrochloride|Given PO
219762167|NCT05675410|OTHER|Questionnaire Administration|Ancillary studies
219762168|NCT05675410|DRUG|Vinblastine Sulfate|Given IV
219762169|NCT05675410|DRUG|Vincristine Sulfate|Given IV
219578585|NCT04514965|DEVICE|Fibroscan|Measurement of liver stiffness
219007399|NCT04510012|OTHER|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
219192538|NCT02567409|DRUG|Berzosertib|Given IV
219578586|NCT04514965|OTHER|Question|Question about pruritus
219192539|NCT02567409|DRUG|Cisplatin|Given IV
219192540|NCT02567409|DRUG|Gemcitabine Hydrochloride|Given IV
219578587|NCT00706381|DRUG|Sincalide|
219192541|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
219192542|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
219192543|NCT06787209|BEHAVIORAL|Program to improve lumbopelvic function.|"Each individual will receive a weekly session log at the start of the intervention, allowing them to record the total number of sessions performed between in-person visits and the perceived exertion.~In the strengthening phase, both compound and isolated exercises will be performed. These exercises will be of low intensity and maintained for prolonged periods until the patient reaches fatigue or can no longer perform the repetitions correctly. If the patient reaches 40 repetitions, the exercise will be progressed in difficulty. The patient will have one minute of rest after each set.~Each session will include a total of 4 sets focused on the gluteal muscles The speed of execution for each repetition will be between 4-6 seconds. After the strengthening phase, three unilateral static stretches targeting the hip flexors will be performed, each lasting one minute.~The entire program will be performed using bodyweight exercises and adapted exercises that can be done at home."
219192544|NCT06787209|BEHAVIORAL|generic health care|"The patients will receive 10 physiotherapy sessions at the health center throughout 4 weeks.They will be taught active exercises and undergo passive therapies to address their low back pain. Each session will last approximately 30 minutes.~The intervention will therefore be variable depending on the assigned physiotherapist, as there is no standardized protocol for action."
219192545|NCT05144555|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
219007400|NCT03138278|OTHER|Telephone support on demand|Dedicated phone number for help and advice for caregivers
219007401|NCT03823001|DIAGNOSTIC_TEST|virtual biopsy (VB) monitoring protocol|"1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
219007402|NCT00296881|DEVICE|PERIOWAVE|
219007403|NCT00824239|PROCEDURE|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
219192546|NCT05144555|OTHER|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
219192547|NCT06833619|DEVICE|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
219192548|NCT06156813|DIAGNOSTIC_TEST|Diagnostic test|Measurements for validity and reliability
219007404|NCT00824239|PROCEDURE|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
219007405|NCT03060629|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
219578588|NCT00706381|DRUG|Ursodiol|
219578589|NCT00706381|PROCEDURE|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
219578590|NCT00706381|PROCEDURE|Carb meal|600 calorie meal containing 100% carbohydrate
219578591|NCT00706381|DRUG|Placebo|IV and/or oral placebo
219578592|NCT00973401|OTHER|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
219192549|NCT06840418|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Injection is performed at the 3 o'clock and 9 o'clock positions of the cervix, with 1 ml on each side, for a total dose of 2 ml. Injection depth: The tracer is injected into the superficial (2 mm) and deep (1 cm) layers, with the superficial injection performed first, followed by the deep injection.
219192550|NCT05963646|DIAGNOSTIC_TEST|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
219192551|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
219192552|NCT04180202|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
219192553|NCT06533150|OTHER|multiomic profiling|2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.
219192554|NCT06031012|DRUG|CGECC combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
219192555|NCT06031012|DRUG|CGECC alone|Patients received CGECC alone from the beginning of radiotherapy to one week after radiotherapy.
219192556|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
219192557|NCT06194110|DIAGNOSTIC_TEST|Ergometric test|Ramp test followed by a step test, both with ergospirometry
219192558|NCT04428203|DRUG|Epidiolex Oral Liquid Product|600 mg Oral solution
219192559|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
219192560|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
219192561|NCT04134910|PROCEDURE|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
219192562|NCT05280574|DEVICE|Blinded GE Portrait Monitoring|Continuous vital signs will be monitored and recorded by GE Portrait but not available to clinicians.
219192563|NCT05280574|DEVICE|Unblinded GE Portrait Monitoring|Continuous vital signs will be monitored and evaluated by clinicians using GE Portrait.
219192564|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
219192565|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
219192566|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
219192567|NCT05068414|DIAGNOSTIC_TEST|Blood panel|"* Thrombin generation test~* Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~* International Normalized Ratio (if anti-vitamin K therapy is prescribed)~* Platelet aggregation test"
219192568|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
219433660|NCT06397742|OTHER|Physical therapy - myofascial techniques|"Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns."
219433661|NCT02177175|DRUG|Carvedilol|
219433662|NCT02177175|OTHER|placebo|
219578593|NCT02546336|DEVICE|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
219578594|NCT00276952|DRUG|Gonyautoxin|
219578595|NCT00954330|PROCEDURE|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
219433663|NCT03755999|OTHER|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
219433664|NCT04110860|DRUG|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
219433665|NCT04110860|DRUG|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
219433666|NCT04110860|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
219007406|NCT03060629|BIOLOGICAL|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
219433667|NCT02481063|OTHER|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
219433668|NCT02481063|OTHER|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
219578596|NCT00954330|DEVICE|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
219192569|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
219192570|NCT05025865|DRUG|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
219192571|NCT05025865|DRUG|Placebo|A placebo will be given in capsule form to study participants.
219192572|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
219192573|NCT05206565|PROCEDURE|Neurotization - Autologous Reconstruction with DIEP/TRAM|"* Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~* Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~* Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
219192574|NCT06521801|OTHER|Observation|Observation
219578597|NCT00054912|BIOLOGICAL|EP2101|
219578598|NCT02017548|BEHAVIORAL|Life-extension default advance directive|
219578599|NCT02017548|BEHAVIORAL|Comfort default advance directive|
219578600|NCT03664895|DRUG|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
219596828|NCT00862615|OTHER|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
219596829|NCT00547586|DRUG|N-methylnaltrexone bromide (MOA-728)|Oral
219596830|NCT00547586|OTHER|placebo|placebo
219007407|NCT03060629|BIOLOGICAL|Placebo|Participants will receive matching placebo.
219007408|NCT01987297|DRUG|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
219433669|NCT06391658|OTHER|Functional Training|Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
219433670|NCT02481596|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
219192575|NCT04902508|BEHAVIORAL|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
219192576|NCT04902508|BEHAVIORAL|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
219433671|NCT02481596|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
219433672|NCT02481596|BEHAVIORAL|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
219433673|NCT04447534|DRUG|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
219433674|NCT04447534|DRUG|zinc|Zinc tablets
219433675|NCT01619163|DRUG|Placebo|
219433676|NCT01619163|DRUG|Prednisolone|low dose, 7.5 mg/day
219433677|NCT01241955|BEHAVIORAL|video decision aid|video of CPR
219433678|NCT05315141|OTHER|No Intervention|No Intervention
219192577|NCT06852157|DIAGNOSTIC_TEST|Tissue, diagnostic and prognostic accuracy|"The clinical data and histological samples of patients with a diagnosis of CIN/SIL on cervical biopsies or conization (performed as required by the normal procedure) will be consecutively acquired from all those taken at the Operative Unit of Gynaecology and Physiopathology of Human Reproduction starting from January 2000 and stored at the Operative Unit of Pathological Anatomy and Histology.~Samples fixed in neutral buffered formalin and paraffin added at 50°C will be analysed by repeating histological examination and performing immunohistochemistry for BAG3. All analyses will be performed blinded to the clinical data of the patients and the results of the original examinations. No patients will be examined ex novo, as only paraffin-embedded tissue samples obtained at the time of the initial diagnosis will be analysed."
219433679|NCT02379611|PROCEDURE|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
219433680|NCT06040307|PROCEDURE|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
219433681|NCT05454397|OTHER|Observational study, no intervention|Observational study, no intervention
219433682|NCT01340391|DEVICE|Omnicast|dorsal splint 2-5 weeks
219433683|NCT04104373|OTHER|Observational Cohort|
219192578|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
219578601|NCT02477163|OTHER|Ayurveda treatment|"1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
219578602|NCT06074484|DRUG|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
219578603|NCT06074484|DRUG|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
219192579|NCT06851884|OTHER|Video capsules|3 video capsules of 3 minutes each
219192580|NCT06851884|OTHER|Cartoon|3 cartoons
219192581|NCT06851884|OTHER|Virtual reality|3 virtual reality programs
219433684|NCT02722629|PROCEDURE|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
219433685|NCT03998904|PROCEDURE|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
219433686|NCT03998904|PROCEDURE|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
219433687|NCT01676792|DRUG|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
219433688|NCT05953324|OTHER|Kiwifruit|2 kiwifruit for 6 weeks
219433689|NCT00089102|DRUG|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
219192582|NCT06851884|OTHER|"Set of end-of-life and grief informational and educational tools"|Including a video capsule, a cartoon, and a kit of two leaflets
219192583|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
219192584|NCT05603884|DRUG|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L"
219192585|NCT05466942|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
219192586|NCT06649539|DRUG|Collagenase Clostridium Histolyticum|"4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL"
219433690|NCT00089102|DRUG|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
219433691|NCT01990755|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
219433692|NCT01990755|OTHER|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
219578604|NCT00587600|PROCEDURE|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
219578605|NCT00587600|PROCEDURE|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
219578606|NCT01930955|DRUG|Amoxicillin|β-lactam antibiotics
219578607|NCT05243953|DRUG|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
219578608|NCT05243953|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
219578609|NCT00914914|DRUG|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
219433693|NCT01990755|DRUG|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
219192587|NCT06649539|DEVICE|RestoreX|Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.
219192588|NCT06649539|DRUG|Sildenafil|Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
219192589|NCT06848712|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
219192590|NCT06848504|BEHAVIORAL|MedSMA℞T Mobile|MedSMA℞T Mobile is an innovative mobile digital health intervention that integrates technology-based learning to facilitate family communication and creation of a personalized Family Medication Safety Plan. The Family Medication Safety Plan (FMSP) is a tool for families to record important information about their medications and create a plan for safe use, storage, and disposal. Participants will play MedSMA℞T Mobile for up to 30 minutes at the first study visit.
219192591|NCT06849804|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Group E (n=25): Erector spinae plain block group will receive 0.5 ml/kg of 0.25%bupivacaine.
219433694|NCT01990755|DIETARY_SUPPLEMENT|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
219433695|NCT01990755|DRUG|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
219578610|NCT05530148|BEHAVIORAL|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
219596831|NCT01092858|DRUG|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
219596832|NCT01092858|DRUG|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
219192592|NCT06849804|PROCEDURE|Caudal Block Anesthesia|Caudal block group will receive 1 ml/kg of 0.25% bupivacaine
219192593|NCT06849804|PROCEDURE|Local infiltration in the wound|Local Infiltration Group will receive 0.2 ml/kg 0.25% bupivacaine
219192594|NCT04197869|DRUG|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
219433696|NCT03644108|DRUG|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
219596833|NCT00674739|DRUG|Imiquimod|daily topical application for up to 8 weeks
219596834|NCT00674739|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
219596835|NCT00674739|DRUG|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
219192595|NCT05181462|DRUG|Carboplatin|Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
219192596|NCT05181462|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
219192597|NCT05181462|DRUG|Nadunolimab|Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
219433697|NCT04879784|OTHER|No intervention|No intervention
219433698|NCT02969538|OTHER|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
219433699|NCT02969538|OTHER|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
219433700|NCT06175442|DEVICE|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
219192598|NCT06264193|OTHER|hypoxia|The athletes were living in hypoxic rooms, and training was carried out on lowlands.
219192599|NCT04180462|OTHER|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
219192600|NCT04180462|OTHER|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
219578611|NCT05530148|BEHAVIORAL|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
219578612|NCT00160641|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
219578613|NCT03435718|DRUG|Oxfendazole|oral suspension
219578614|NCT03435718|DRUG|Albendazole|tablet
219192601|NCT04180462|OTHER|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
219433701|NCT00830154|DRUG|pagoclone|0.30 mg BID, 0.60 mg BID
219433702|NCT00830154|OTHER|placebo|placebo
219192602|NCT04180462|OTHER|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
219192603|NCT06068283|BEHAVIORAL|LOTUS mHealth Intervention Group|A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
219433703|NCT02766907|DEVICE|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
219578615|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with Listerine|
219578616|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with CHX|
219762170|NCT04781309|DRUG|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
219762171|NCT05564390|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
219762172|NCT05564390|DRUG|Azacitidine|Given IV or SC
219433704|NCT02681718|BEHAVIORAL|Community health worker education|Diabetes self-management education by community health workers
219192604|NCT06068283|BEHAVIORAL|LOTUS Control Group|Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
219192605|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
219192606|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
219762173|NCT05564390|OTHER|Best Practice|Receive SOC treatment
219192607|NCT05168722|OTHER|No interventions|No interventions
219192608|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
219192609|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
219192610|NCT04670874|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
219192611|NCT04670874|OTHER|Questionnaire Administration|Complete quality of life questionnaire
219762174|NCT05564390|PROCEDURE|Biopsy Procedure|Undergo biopsy
219762175|NCT05564390|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or buccal swab samples
219762176|NCT05564390|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219433705|NCT02681718|BEHAVIORAL|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
219433706|NCT00375960|DRUG|V3381|
219433707|NCT00375960|DRUG|Placebo|
219762177|NCT05564390|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219578617|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with serum|
219192612|NCT06641557|DRUG|200mg of Ikt-148009|4 50mg capsules
219192613|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
219192614|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
219192615|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
219192616|NCT06642168|GENETIC|Whole exome sequencing to detect myocardial genetic mutations (SCA group only)|Whole exome sequencing to detect myocardial genetic mutations
219578618|NCT05297695|DRUG|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
219578619|NCT00254228|DEVICE|Electrotactile sensory substitution|
219578620|NCT01283594|DRUG|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
219578621|NCT01283594|DRUG|Placebo|White-coated, modified-oval placebo tablets.
219578622|NCT01283594|DRUG|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
219578623|NCT01283594|DRUG|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
219578624|NCT01283594|DRUG|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
219578625|NCT01283594|DRUG|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
219762178|NCT05564390|DRUG|Busulfan|Given IV
219762179|NCT05564390|PROCEDURE|Chest Radiography|Undergo chest x-ray
219762180|NCT05564390|PROCEDURE|Computed Tomography|Undergo CT
219762181|NCT05564390|DRUG|Cytarabine|Given
219762182|NCT05564390|DRUG|Daunorubicin Hydrochloride|Given IV
219762183|NCT05564390|DRUG|Decitabine and Cedazuridine|Given PO
219762184|NCT05564390|PROCEDURE|Echocardiography Test|Undergo ECHO
219762185|NCT05564390|DRUG|Enasidenib|Given PO
219762186|NCT05564390|DRUG|Fludarabine|Given IV
219762187|NCT05564390|DRUG|Gemtuzumab Ozogamicin|Given IV
219762188|NCT05564390|DRUG|Gilteritinib|Given PO
219762189|NCT05564390|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219762190|NCT05564390|DRUG|Melphalan|Given IV
219762191|NCT05564390|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762192|NCT05564390|PROCEDURE|Mutation Carrier Screening|Undergo rapid genetic testing
219762193|NCT05564390|DRUG|Olutasidenib|Given PO
219762194|NCT05564390|DRUG|Placebo Administration|Given PO
219192617|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
219192618|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
219192619|NCT05237284|DRUG|SAR443820|Tablet oral
219192620|NCT05237284|DRUG|Placebo|Tablet
219192621|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
219192622|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
219433708|NCT01360229|PROCEDURE|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
219433709|NCT01360229|OTHER|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
219433710|NCT02140892|PROCEDURE|respiratory physical therapy manual technique- Autogenic Drainage|
219433711|NCT02140892|DEVICE|respiratory physical therapy technique- IPV|
219433712|NCT04454580|DRUG|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
219433713|NCT02017886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
219433714|NCT02017886|DIETARY_SUPPLEMENT|Placebo|Placebo tablet twice daily for three weeks
219433715|NCT05419414|DEVICE|Shear wave elastography|Both groups were examined with shear wave elastography.
219433716|NCT02829008|DRUG|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
219433717|NCT02829008|DRUG|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
219596836|NCT06509113|BEHAVIORAL|The online HIV-related stigma training|The intervention is an online HIV-related stigma training that takes 6 hours in 4 weeks to be completed.
219192623|NCT06241716|PROCEDURE|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
219192624|NCT06241716|PROCEDURE|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
219192625|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
219433718|NCT05334550|OTHER|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
219433719|NCT02640118|DRUG|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
219433720|NCT02640118|DRUG|Lixisenatide-Placebo|
219433721|NCT02640118|OTHER|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
219433722|NCT04085042|DEVICE|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
219192626|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
219192627|NCT05990426|BEHAVIORAL|FAST Intervention|"Participants will alternate fasting days (FAST) with unrestricted eating (OFF, or Feast) days, for one week surrounding the start of each chemotherapy cycle. The participants will fast for two consecutive days in the middle of the ADF week - the day prior to chemotherapy start date, and chemotherapy day 1 for each cycle. Participants will consume regular diet (OFF/Feast) during other days 5-18 of each cycle."
219192628|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
219192629|NCT05987072|DRUG|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
219433723|NCT01451151|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
219192630|NCT02371135|GENETIC|colonic biopsies|
219433724|NCT06216197|DRUG|FENT group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
219433725|NCT06216197|DRUG|DEX group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
219192631|NCT02371135|GENETIC|questionnaires|
219192632|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
219192633|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
219192634|NCT04056611|DRUG|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
219762195|NCT05564390|PROCEDURE|Positron Emission Tomography|Undergo PET
219433726|NCT03205982|BEHAVIORAL|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
219596837|NCT06509113|BEHAVIORAL|The online HIV epidemiology training with no specific content on stigma|Nursing students will be trained in an online HIV epidemiology training with no specific content on stigma. It will take 6 hours in 4 weeks to complete the training.
219596838|NCT00573378|DRUG|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
219596839|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Lenvatinib|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight \< 60kg, 8mg/qd; administered continuously from D5 of the first cycle
219762196|NCT05564390|RADIATION|Total-Body Irradiation|Undergo total body irradiation
219762197|NCT05564390|DRUG|Venetoclax|Given PO
219192635|NCT04056611|DRUG|Placebo|Matching placebo will be administered orally.
219192636|NCT04056611|DRUG|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
219596840|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Bevacizumab|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.
219433727|NCT03205982|BEHAVIORAL|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
219433728|NCT03355404|OTHER|standing patient|patient goes standing to the surgery room
219433729|NCT00994162|DEVICE|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
219192637|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.
219192638|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
219192639|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
219192640|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
219192641|NCT06806683|RADIATION|intensity modulated radiotherapy|intensity modulated radiotherapy
219192642|NCT05983445|DRUG|genakumab|200mg s.c.
219433730|NCT00185354|DRUG|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
219433731|NCT00185354|DRUG|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
219433732|NCT03253133|DRUG|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"
219433733|NCT03253133|DRUG|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
219433734|NCT03253133|DRUG|Oxycodone|Oxycodone
219433735|NCT06402786|DEVICE|Kitea ICP Sensor|Kitea ICP Sensor placed in brain during shunt surgery.
219192643|NCT05983445|DRUG|placebo for Diprospan|i.m.
219192644|NCT05983445|DRUG|placebo for genakumab|s.c.
219192645|NCT05983445|DRUG|Diprospan|7mg i.m.
219578626|NCT04271553|OTHER|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
219578627|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
219578628|NCT01704794|DRUG|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
219578629|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
219433736|NCT03001310|BIOLOGICAL|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
219433737|NCT00631540|DEVICE|Formula Balloon-Expandable Stent|renal artery stenting
219578630|NCT03418090|DRUG|129Xe MRI|Evaluation of pulmonary function
219578631|NCT03418090|DRUG|133XE scintigraphy|Evaluation of pulmonary function
219192646|NCT06651060|BEHAVIORAL|Menu label|Participants will view a sample of items from a restaurant menu, displayed with labels
219192647|NCT03733925|DRUG|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
219192648|NCT00005398|OTHER|There is no intervention|No applicable
219192649|NCT04724499|BEHAVIORAL|High-Intensity Intervals Training|16 week exercise program with stationary bike.
219192650|NCT04724499|OTHER|Attention Control|16 week stretching program.
219192651|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
219192652|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
219192653|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
219192654|NCT03774641|DRUG|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
219578632|NCT03529461|DEVICE|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
219596841|NCT04797026|OTHER|Letters to increase social connection with goal to alleviate loneliness|Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
219596842|NCT03032848|DRUG|Conjugated Estrogen|use of 1 gram per day
219596843|NCT03032848|DRUG|Promestriene|use of 1 gram per day
219007409|NCT01987297|DRUG|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
219007410|NCT05315128|DRUG|Methotrexate|A randomized comparative effectiveness clinical trial
219433738|NCT04759313|BEHAVIORAL|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
219433739|NCT04034043|DEVICE|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
218859526|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
219192655|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
219433740|NCT01963754|DEVICE|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
219433741|NCT01963754|DRUG|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
219433742|NCT01963754|DRUG|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
219433743|NCT01206790|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
219433744|NCT03157921|RADIATION|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
219192656|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
219433745|NCT03157921|DIAGNOSTIC_TEST|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
219433746|NCT00881790|OTHER|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
219433747|NCT01946412|DRUG|Ivacaftor|
219433748|NCT06063512|OTHER|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
219199561|NCT06873906|DRUG|conventional analgesic regimen|"Anesthesia will be induced with IV ketamine, 2 mg/kg, fentanyl, 2 µg/kg, and rocuronium 0.9 mg/kg, administered to facilitate endotracheal intubation.~Maintenance of anesthesia will be achieved by isoflurane at an end tidal concentration of 1-1.5% in FiO2 of 0.5, intravenous fentanyl at a dose of 1 µg/kg in incremental dosage, and intravenous rocuronium 0.15 mg/kg administration according to nerve stimulator."
219433749|NCT04640753|PROCEDURE|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
218859527|NCT01550393|GENETIC|proteomic profiling|
218859528|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
218859529|NCT01550393|OTHER|laboratory biomarker analysis|
218859530|NCT01550393|OTHER|medical chart review|
218859531|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
218859532|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
218859533|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
219433750|NCT03823898|BEHAVIORAL|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
219433751|NCT03823898|BEHAVIORAL|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
219433752|NCT03823898|BEHAVIORAL|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
219433753|NCT05124262|OTHER|Low- FODMAPdiet group intervention|Diet intervention
219433754|NCT01062828|DIAGNOSTIC_TEST|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
219433755|NCT00014170|DRUG|gefitinib|Given orally
219433756|NCT00014170|OTHER|pharmacological study|Correlative studies
219433757|NCT00014170|OTHER|laboratory biomarker analysis|Correlative studies
219433758|NCT00014170|OTHER|questionnaire administration|Ancillary studies
219433759|NCT00014170|PROCEDURE|quality-of-life assessment|Ancillary studies
219433760|NCT05182424|BEHAVIORAL|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
219578633|NCT03529461|DEVICE|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
219578634|NCT03529461|OTHER|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
219192657|NCT06649708|DRUG|HX044|Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
219433761|NCT01209975|PROCEDURE|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
219578635|NCT02281331|DIETARY_SUPPLEMENT|Supplement|supplement/placebo plus exercise training
219433762|NCT02542813|DRUG|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
219578636|NCT01071447|OTHER|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
219578637|NCT02003911|DRUG|Azithromycin|Azithromycin suspension (200mg/5mL)
219578638|NCT02003911|DRUG|Placebo|
219578639|NCT01782482|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
219578640|NCT01782482|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
219578641|NCT05507593|BIOLOGICAL|DLL3-CAR-NK cells|Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
219578642|NCT00511992|DRUG|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
219433763|NCT02542813|DRUG|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
219192658|NCT06650592|OTHER|All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR)
219433764|NCT02542813|DRUG|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
219578643|NCT00511992|DRUG|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
219433765|NCT02542813|DRUG|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
219578644|NCT00511992|DRUG|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
219578645|NCT05051501|DIETARY_SUPPLEMENT|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
219578646|NCT03895723|PROCEDURE|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
219578647|NCT03895723|PROCEDURE|open surgery|using open surgery procedure for liver resection
219762198|NCT06066138|DRUG|Atezolizumab|Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.
219762199|NCT06274749|DIETARY_SUPPLEMENT|Urolithin A|Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.
219762200|NCT06274749|DIETARY_SUPPLEMENT|Placebo|The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.
219762201|NCT06445959|DRUG|Olutasidenib|Given by PO
219762202|NCT06445959|DRUG|Venetoclax|Given by PO
219762203|NCT06445959|DRUG|Decitabine|Given by IV
219762204|NCT06445959|DRUG|Decitabine/cedazuridine|Given by PO
219762205|NCT06484088|OTHER|Frustration task|The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
219762206|NCT05652478|DRUG|Tenofovir alafenamide|25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.
219762207|NCT05652478|DRUG|Dolutegravir|50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
219192659|NCT06467448|DEVICE|EMG Assessement of Recovery of Neuromuscular Function|EMG Train of Four Assessment of Recovery of Neuromuscular Function
219192660|NCT06651411|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|"The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian."
219192661|NCT06651411|BEHAVIORAL|Basic psychoeducation|Basic psychoeducation includes basic information on stress management.
219433766|NCT02542813|DRUG|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
219433767|NCT02542813|DRUG|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
219433768|NCT01966653|DRUG|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
219433769|NCT01966653|DRUG|fosfomycin|fosfomycin 3g po single dose
219433770|NCT03596970|DRUG|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
219192662|NCT02631746|OTHER|Laboratory Biomarker Analysis|Correlative studies
219192663|NCT02631746|BIOLOGICAL|Nivolumab|Given IV
219192664|NCT02631746|OTHER|Pharmacogenomic Study|Correlative studies
219192665|NCT06581081|BIOLOGICAL|Senl_B19 autologous CAR-T (S1904) treatment|Subjects enrolled in this study will first receive Senl\_B19 autologous CAR-T (S1904) treatment.
219192666|NCT06380309|BIOLOGICAL|IDOV-SAFE|Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression
219192667|NCT05933499|DRUG|IV bimagrumab|IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
219192668|NCT05933499|DRUG|IV placebo|IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
219433771|NCT03596970|DRUG|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
219433772|NCT00111436|DRUG|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
219433773|NCT03682055|DRUG|VK-2019|EBNA1 inhibitor
219433774|NCT01352767|DEVICE|InsuPad|Heating pad
219433775|NCT04597515|PROCEDURE|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
219433776|NCT03596255|DIAGNOSTIC_TEST|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
219433777|NCT03596255|DIAGNOSTIC_TEST|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
219433778|NCT03556982|BIOLOGICAL|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
219433779|NCT04691557|OTHER|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
219433780|NCT04691557|OTHER|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
219433781|NCT06263725|OTHER|Restricted dietary protein|Participants will be allocated to 5 week isocaloric restricted protein intake
219192669|NCT05933499|DRUG|Semaglutide|Semaglutide 2.4mg SQ qweek
219192670|NCT05933499|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Elemental calcium 1200 mg + vitamin D3 800 IU PO daily
219192671|NCT05933499|BEHAVIORAL|Lifestyle and nutrition counseling|Lifestyle and nutrition counseling consistent with current guidelines for weight management
219192672|NCT05906069|BEHAVIORAL|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
219192673|NCT06105580|PROCEDURE|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
219192674|NCT06105580|PROCEDURE|Biventricular pacing|Biventricular pacing implant
219192675|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
219192676|NCT04571619|BEHAVIORAL|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
219192677|NCT04571619|DRUG|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
219192678|NCT05889247|OTHER|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
219192679|NCT05669391|DIAGNOSTIC_TEST|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
219192680|NCT05308238|BEHAVIORAL|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
219192681|NCT05308238|BEHAVIORAL|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
219192682|NCT05320718|DRUG|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
219578648|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
219578649|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
219578650|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
219578651|NCT03361852|DRUG|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
219578652|NCT03361852|BIOLOGICAL|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
219578653|NCT03361852|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
219578654|NCT00038649|DRUG|Gleevec|400 mg orally twice daily
219578655|NCT02974036|OTHER|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
219578656|NCT03831763|DEVICE|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
219578657|NCT03785535|DEVICE|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
219578658|NCT02701166|DRUG|Bezafibrate|bezafibrate 400mg per day
219578659|NCT02701166|DRUG|Placebo|placebo 400mg per day
219578660|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
219578661|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
219578662|NCT03519984|DRUG|Cytarabine|Given IV
219578663|NCT03519984|OTHER|Laboratory Biomarker Analysis|Correlative studies
219578664|NCT03519984|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219578665|NCT03519984|DRUG|Vincristine Liposomal|Given IV
219433782|NCT06263725|OTHER|Habitual diet|Participants will be follow their habitual, high protein intake
219433783|NCT04430868|BEHAVIORAL|lifestyle redesign program|In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
219433784|NCT04409496|BEHAVIORAL|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
219433785|NCT04409496|BEHAVIORAL|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
219433786|NCT04409496|BEHAVIORAL|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
219192683|NCT03536767|DRUG|AG10|AG10 800mg twice daily, oral administration
219192684|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
219192685|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
219578666|NCT05410054|OTHER|no intervention|observational research
219578667|NCT00995085|DRUG|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
219192686|NCT02224144|DRUG|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
219192687|NCT02224144|DRUG|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
219192688|NCT02224144|DRUG|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
219192689|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
219578668|NCT04593017|DIETARY_SUPPLEMENT|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
219578669|NCT04593017|OTHER|Placebo Probiotic|Placebo
219578670|NCT05946954|PROCEDURE|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
219578671|NCT05946954|PROCEDURE|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
219192690|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
219192691|NCT06118502|BEHAVIORAL|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
219192692|NCT06118502|BEHAVIORAL|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
219192693|NCT06118502|BEHAVIORAL|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
219433787|NCT05759390|DIAGNOSTIC_TEST|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
219192694|NCT03995550|DRUG|LEO 142397|A compound in development by LEO Pharma A/S
219578672|NCT04088266|COMBINATION_PRODUCT|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
219192695|NCT03995550|DRUG|Placebo|Placebo
219192696|NCT06371950|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis|5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
219192697|NCT06371950|OTHER|Placebo|Placebo
219192698|NCT04871568|PROCEDURE|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
219192699|NCT05520593|DIETARY_SUPPLEMENT|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
219596844|NCT03032848|DRUG|Estriol|use of 1 gram per day
219596845|NCT03032848|DRUG|Vaginal Moisturizer - Cream|use of 1 gram per day
219596846|NCT00825760|DRUG|Topical PPA904 gel and light|
219596847|NCT00825760|DRUG|Topical placebo gel plus light|
219596848|NCT02487914|DEVICE|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
219596849|NCT02487914|DRUG|Lidocaine 10% was sprayed at the identified region|
219596850|NCT02487914|DEVICE|interferential current|
219596851|NCT00307398|DRUG|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
219762208|NCT04266093|DRUG|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol.
219762209|NCT06064097|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219762210|NCT06064097|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219762211|NCT06064097|PROCEDURE|Chest Radiography|Undergo chest x-ray
219762212|NCT06064097|DRUG|Cisplatin|Given IV
219762213|NCT06064097|PROCEDURE|Computed Tomography|Undergo CT
219762214|NCT06064097|PROCEDURE|Echocardiography Test|Undergo ECHO
219762215|NCT06064097|OTHER|Electronic Health Record Review|Ancillary studies
219762216|NCT06064097|OTHER|Fluciclovine F18|Given IV
219192700|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group)|Different dose groups
219192701|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group)|Different dose groups
219192702|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）|Different dose groups
219192703|NCT05810987|OTHER|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]"
219762217|NCT06064097|DRUG|Gemcitabine|Given IV
219762218|NCT06064097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762219|NCT06064097|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219192704|NCT05810987|BEHAVIORAL|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
219192705|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
219762220|NCT06064097|BIOLOGICAL|Nivolumab|Given IV
219762221|NCT06064097|PROCEDURE|Positron Emission Tomography|Undergo PET
219762222|NCT06064097|OTHER|Quality-of-Life Assessment|Ancillary studies
219762223|NCT06064097|OTHER|Questionnaire Administration|Ancillary studies
219762224|NCT06064097|RADIATION|Radiation Therapy|Receive radiation therapy
219192706|NCT05516758|DRUG|Placebo|Administered SC
219192707|NCT03520790|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
219192708|NCT03520790|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
219192709|NCT03520790|DRUG|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
219192710|NCT03520790|OTHER|Placebo|Placebo
219433788|NCT01135394|DRUG|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
219433789|NCT02839811|PROCEDURE|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
219192711|NCT03619980|OTHER|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
219433790|NCT00191386|DRUG|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
219433791|NCT01191424|DRUG|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
219433792|NCT01191424|DRUG|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
219433793|NCT03552900|BEHAVIORAL|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
219433794|NCT03552900|BEHAVIORAL|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
219433795|NCT03422744|PROCEDURE|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
219433796|NCT03422744|PROCEDURE|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
219433797|NCT01970735|BIOLOGICAL|Blood test|
219433798|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
219433799|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
219433800|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
219433801|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
219433802|NCT02187133|DRUG|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"
219433803|NCT02187133|DRUG|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"
219433804|NCT02187133|DRUG|Rituximab|Given IV; 375 mg/m\^2
219433805|NCT00590941|PROCEDURE|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
219433806|NCT00134342|OTHER|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
219433807|NCT03592927|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
219578673|NCT05213143|DRUG|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
219578674|NCT02969993|OTHER|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
219578675|NCT02545647|DEVICE|BRYGB|65 patients undergo a banded RYGB
219192712|NCT05656105|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
219192713|NCT04181970|OTHER|Quality assessment|There is no intervention on study subjects. A tumor review will be performed by expert centers.
219192714|NCT04666636|DRUG|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
219192715|NCT04666636|DRUG|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
219192716|NCT05975580|DRUG|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
219433808|NCT03592927|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
219433809|NCT04116619|OTHER|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
219192717|NCT05975580|DRUG|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
219433810|NCT05616624|DRUG|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
219433811|NCT05616624|DRUG|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
219578676|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
219578677|NCT03736928|OTHER|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
219578678|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
219578679|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
219578680|NCT04206228|DRUG|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
219578681|NCT04206228|DRUG|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
219596852|NCT00307398|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
219596853|NCT00287586|DRUG|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
219596854|NCT00287586|DRUG|Placebo|Placebo-matching testosterone gel daily for 3 years
219192718|NCT05975580|DRUG|Placebo|Placebo is an inactive substance.
219596855|NCT01025414|DRUG|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
219596856|NCT01025414|DRUG|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
219596857|NCT03101605|OTHER|e-learning teaching module|As described
219596858|NCT03101605|OTHER|Standard teaching method|As described
219596859|NCT05238610|PROCEDURE|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
219596860|NCT02197819|DEVICE|Sling|
219596861|NCT02197819|DEVICE|External Rotation Brace|
219578682|NCT03662906|OTHER|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
219192719|NCT05088694|BEHAVIORAL|Peaceful Coexistence|"The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior."
219192720|NCT01761305|PROCEDURE|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
219192721|NCT01761305|BEHAVIORAL|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
219433812|NCT05616624|DRUG|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
219433813|NCT00184652|DRUG|somatropin|
219578683|NCT03662906|OTHER|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
219578684|NCT04080609|DRUG|Dorzagliatin|GKA currently under clinical development
219578685|NCT02662088|PROCEDURE|laparoscopic-lavage|
219433814|NCT04059991|BIOLOGICAL|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
219433815|NCT04681924|OTHER|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
218859534|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
219433816|NCT03750240|DIAGNOSTIC_TEST|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR"
219433817|NCT03750240|DIAGNOSTIC_TEST|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
219433818|NCT04764968|DRUG|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
219433819|NCT05316818|DRUG|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
219433820|NCT04011319|BEHAVIORAL|group culture|Four embryos were cultured in the same droplet by a special dish.
219578686|NCT06417333|DEVICE|xiaomi mi band 7 smart wristband|Patients with mild dementia have been distributed xiaomi mi band 7 smart wristbands for health data collection
219578687|NCT05338021|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
219578688|NCT03261882|OTHER|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
219578689|NCT00393120|DRUG|INCB009471|100mg SR (sustained release) orally once daily
219578690|NCT00393120|DRUG|INCB009471|300mg SR (sustained release) orally once daily
219578691|NCT00393120|DRUG|Placebo comparator|Orally once daily
219578692|NCT01084382|DIETARY_SUPPLEMENT|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
219578693|NCT05845294|PROCEDURE|Routine Care|Routine care for patients undergoing colorectal cancer stoma
219433821|NCT00927758|DRUG|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
219433822|NCT02401113|DIETARY_SUPPLEMENT|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
219433823|NCT02479295|DEVICE|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
219192722|NCT01761305|OTHER|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
219192723|NCT06378554|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
219192724|NCT05142384|BEHAVIORAL|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
219192725|NCT05142384|COMBINATION_PRODUCT|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
219192726|NCT05043051|DEVICE|Vagal stimulation|Vagal stimulation
219192727|NCT05043051|DEVICE|Sham stimulation|Sham vagal stimulation
219192728|NCT03835065|PROCEDURE|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
219192729|NCT03835065|OTHER|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
219192730|NCT03835065|OTHER|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
219433824|NCT03125018|DEVICE|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
219433825|NCT00439725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
219433826|NCT00439725|DRUG|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
219433827|NCT01444183|BEHAVIORAL|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
219433828|NCT01444183|BEHAVIORAL|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
219433829|NCT01755325|DRUG|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
219433830|NCT01755325|DRUG|placebo|
219433831|NCT03510910|DRUG|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
219578694|NCT05845294|PROCEDURE|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
219578695|NCT03096847|DRUG|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
219578696|NCT03096847|DRUG|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
219007411|NCT02505867|DEVICE|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
219192731|NCT04874688|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrient supplement|Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
219192732|NCT04874688|DIETARY_SUPPLEMENT|Provitamin A biofortified maize|Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
219192733|NCT04874688|DIETARY_SUPPLEMENT|NUA-45 biofortified sugar beans|NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
219192734|NCT04874688|DIETARY_SUPPLEMENT|Moringa oleifera|Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
219192735|NCT04874688|DIETARY_SUPPLEMENT|Whole egg powder|Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
219192736|NCT04874688|DIETARY_SUPPLEMENT|White maize meal|Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
219192737|NCT05230914|OTHER|Simplified imaging strategy|NCCT and CTA will be used to screen patients for endovascular treatment
219192738|NCT05230914|OTHER|Standard imaging strategy|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
219192739|NCT05255237|DRUG|Jaktinib|75mg BID
219192740|NCT06040476|BIOLOGICAL|hUCB|hUCB
219578697|NCT03096847|DRUG|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
219433832|NCT03510910|DRUG|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
219433833|NCT01105936|DRUG|Paracetamol|665 mg sustained release paracetamol caplets
219433834|NCT01105936|DRUG|Placebo|Placebo caplets
218859535|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
218859536|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
218859537|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
219433835|NCT04988321|PROCEDURE|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
219433836|NCT01673490|DRUG|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
219433837|NCT02338856|DRUG|MB12066 200mg|100mg bid (multiple dose, day 8)
219433838|NCT02338856|DRUG|Placebo|100mg bid (multiple dose, day 8)
219433839|NCT00439894|PROCEDURE|Blood draw|blood draw at baseline, week 12 and week 24
219433840|NCT00379236|DEVICE|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
219433841|NCT00379236|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
218859538|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
218859539|NCT02210832|BEHAVIORAL|Best practices|
218859540|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
218859541|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
219596862|NCT03831711|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
219596863|NCT03831711|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219007412|NCT00306618|DRUG|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
219007413|NCT01862874|BIOLOGICAL|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
219007414|NCT01862874|BIOLOGICAL|Placebo|Formulated with AAHS adjuvant
219192741|NCT05482360|OTHER|PrEP Optimization Interventions|There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders
219433842|NCT06119555|DIETARY_SUPPLEMENT|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
219192742|NCT06343610|DIETARY_SUPPLEMENT|Active product|Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
219192743|NCT06343610|DIETARY_SUPPLEMENT|Placebo|No active ingredients.
219192744|NCT02700009|BEHAVIORAL|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
219192745|NCT02700009|OTHER|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
219192746|NCT04417998|DRUG|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
219192747|NCT04417998|DRUG|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
219192748|NCT04417998|DEVICE|Siemens E7 Reconstruction Tool|Software to correct for motion
219192749|NCT06246409|BEHAVIORAL|Modernized patient instructions|Patients will be given modernized patient instructions prior to radiotherapy treatment.
219192750|NCT06246409|BEHAVIORAL|Existing patient instructions|Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
219192751|NCT06200779|DIAGNOSTIC_TEST|Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test|"Described in Arms section"
219433843|NCT02244229|DRUG|Tamsulosin|
219192752|NCT06200779|DRUG|Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)|"Described in Arms section"
219433844|NCT02244229|DRUG|Finasteride|
219433845|NCT02244229|DRUG|Placebo|
219192753|NCT06200779|DRUG|PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
219192754|NCT06200779|DRUG|PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
219192755|NCT06200779|DRUG|Bismuth quadruple therapy (Pylera®) for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
219192756|NCT06565546|OTHER|Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin|CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
219192757|NCT06565546|OTHER|Acetaminophen and Gabapentin: standard postoperative pain medications|Participants will receive standard postoperative pain medications
219192758|NCT05538286|DEVICE|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
219433846|NCT00110591|DRUG|PRO 140|Monoclonal antibody to CCR5
219596864|NCT03831711|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219596865|NCT03831711|DEVICE|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
219596866|NCT05244694|DRUG|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
219596867|NCT03743415|BEHAVIORAL|Handbook|see arm/group descriptions
219596868|NCT03743415|BEHAVIORAL|TIP-C plus Handbook|see arm/group descriptions
219596869|NCT03612921|DRUG|oral Amantadine sulfate|oral amantadine
219007415|NCT02097004|BIOLOGICAL|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
219007416|NCT02097004|BIOLOGICAL|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
219007417|NCT02097004|DRUG|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
219007418|NCT04847947|DRUG|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
219433847|NCT01877031|DEVICE|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
219433848|NCT01877031|DEVICE|Ultrasound|Standard of Care - Ultrasound guided intervention
219433849|NCT04573192|DRUG|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
219433850|NCT04573192|DRUG|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
219433851|NCT06198218|OTHER|Scapular mobilization|Group A: will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula.Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 min
219192759|NCT05538286|PROCEDURE|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
219192760|NCT04859608|DRUG|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is \> 150 mg/L). Spacing of infusion can be decided every 3 months.
219192761|NCT05278780|OTHER|Screening for eligibility|Asynchronous screening
219192762|NCT02780700|DRUG|Nintedanib|
219192763|NCT02780700|DRUG|Capecitabine|
219192764|NCT04824079|DRUG|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
219192765|NCT05925101|BEHAVIORAL|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
219192766|NCT05925101|BEHAVIORAL|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
219192767|NCT05925101|BEHAVIORAL|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
219192768|NCT05925101|BEHAVIORAL|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
219192769|NCT05925101|BEHAVIORAL|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
219433852|NCT06198218|OTHER|Conventional physical therapy program|Group B:will receive conventional physical therapy program including (heating to improve circulation and release muscle tension,EMS,stretching for stiff muscle,weight bearing, strengthening exercises \& graduated active exercises)for 20 min along with activity based scapular mobilization (Codman pendulum exercises,band wall apart,wall ball circles, scapular pushups and advance study wall pushups)for 20 min with 5 min resting interval.
219433853|NCT03700346|DEVICE|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
219433854|NCT03346291|BEHAVIORAL|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
219433855|NCT02451189|DIETARY_SUPPLEMENT|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
219433856|NCT02451189|DIETARY_SUPPLEMENT|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
219433857|NCT02451189|DIETARY_SUPPLEMENT|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
219433858|NCT02506491|OTHER|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
219433859|NCT02506491|OTHER|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
219433860|NCT02506491|OTHER|Control Group|No exercise
219433861|NCT03062267|OTHER|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
219433862|NCT01279967|DRUG|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
219433863|NCT01301404|DIETARY_SUPPLEMENT|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
219433864|NCT05637957|DEVICE|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
219433865|NCT05637957|DEVICE|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
219007419|NCT04847947|DRUG|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
219007420|NCT02873000|BEHAVIORAL|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
219007421|NCT02056314|OTHER|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
219578698|NCT01700426|DRUG|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
219578699|NCT01700426|OTHER|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
219433866|NCT02940860|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
219433867|NCT02940860|DRUG|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
219433868|NCT00866060|DRUG|Memantine|20mg memantine
219192770|NCT05925101|BEHAVIORAL|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
219192771|NCT05925101|BEHAVIORAL|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
219192772|NCT05925101|BEHAVIORAL|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
219433869|NCT00866060|DRUG|Donepezil|10mg donepezil
219433870|NCT00866060|DRUG|Placebo donepezil|Placebo donepezil
219433871|NCT00866060|DRUG|Placebo memantine|Placebo memantine
219578700|NCT04572282|DEVICE|Mentora app|Remote monitoring mobile app
219578701|NCT04178265|OTHER|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
219578702|NCT01345994|PROCEDURE|electro-acupuncture|acupuncture stimulation with electricity
219578703|NCT03663439|PROCEDURE|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
219007422|NCT02056314|OTHER|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
219433872|NCT02047968|BEHAVIORAL|wake therapy|
219433873|NCT06422572|OTHER|No Intervention|No Intervention
219433874|NCT04914819|BEHAVIORAL|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
219433875|NCT04914819|BEHAVIORAL|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
219433876|NCT01500863|DRUG|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
219433877|NCT01500863|DRUG|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
219433878|NCT01500863|DRUG|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
219433879|NCT01500863|DRUG|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
219578704|NCT02145312|DRUG|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
219596870|NCT03612921|DRUG|i.v Amantadine Sulfate|intra venous amantadine
219596871|NCT03612921|DRUG|placebo tablet|placebo tablet
219596872|NCT01701011|BEHAVIORAL|Coping intervention|Positive reappraisal coping intervention
219596873|NCT04598399|BEHAVIORAL|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
219596874|NCT04598399|BEHAVIORAL|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
219192773|NCT06406088|DEVICE|EarGenie MVP test|The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
219192774|NCT05210855|DIAGNOSTIC_TEST|CT scan|Scan with classic dose followed by ultra-low dose
219192775|NCT04795661|DRUG|Pembrolizumab|Administered intravenous (IV)
219192776|NCT03498638|BEHAVIORAL|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
219192777|NCT03498638|OTHER|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
219433880|NCT01500863|DRUG|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
219433881|NCT01500863|DRUG|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
219433882|NCT06450808|DIETARY_SUPPLEMENT|Dried Microalgae biomass|The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.
219192778|NCT05850351|OTHER|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
219192779|NCT05850351|OTHER|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
219192780|NCT06487559|DRUG|Livmoniplimab|Intravenous infusion
219192781|NCT06487559|DRUG|Budigalimab|Intravenous infusion
219192782|NCT03980925|DRUG|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin area under the curve (AUC5) Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
219192783|NCT03980925|DRUG|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
219192784|NCT03980925|DRUG|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
219192785|NCT06511245|OTHER|Randomisation|Technique assigned through randomization
219192786|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
219192787|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
219192788|NCT06222671|DRUG|Placebo|Placebo subcutaneous (SC) injection.
219192789|NCT06295237|DEVICE|Intellisync+|mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
219192790|NCT05965830|DEVICE|Diaphragm ultrasound|A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
219192791|NCT03149822|DRUG|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
219192792|NCT03149822|DRUG|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
219192793|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
219433883|NCT04410913|DRUG|Psilocybin plus Visual Healing Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
219596875|NCT02460367|DRUG|Docetaxel|
219596876|NCT02460367|BIOLOGICAL|Tergenpumatucel-L|
219596877|NCT02460367|DRUG|Indoximod|
219007423|NCT00335868|DRUG|danusertib|
219007424|NCT00335868|OTHER|laboratory biomarker analysis|
219007425|NCT00335868|OTHER|pharmacological study|
219433884|NCT04410913|DRUG|Psilocybin plus Standard Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
219192794|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
219433885|NCT00215813|DRUG|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
219433886|NCT02802956|OTHER|Daily Life Promotion Program|Daily Life Promotion Program
219433887|NCT02802956|OTHER|general rehabilitation treatment|general rehabilitation treatment
219433888|NCT00033059|DRUG|Tolcapone|
219192795|NCT02443961|BIOLOGICAL|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
219192796|NCT02770222|DRUG|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
219192797|NCT02770222|DRUG|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
219192798|NCT02770222|DRUG|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
219192799|NCT05789173|DRUG|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
219578705|NCT04203875|DRUG|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
219578706|NCT06031987|DEVICE|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
219578707|NCT06031987|DEVICE|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
219192800|NCT05789173|DRUG|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
219192801|NCT05776524|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
219433889|NCT01413828|DRUG|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
219578708|NCT01090999|OTHER|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
219578709|NCT02239198|OTHER|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
219192802|NCT05776524|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
219192803|NCT05776524|DEVICE|TheraBionic|This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
219192804|NCT04288128|PROCEDURE|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
219192805|NCT04288128|OTHER|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
219578710|NCT02014077|PROCEDURE|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
219192806|NCT03804905|OTHER|No-cost Medications|Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
219192807|NCT06202235|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both CKD Patients and Healthy Volunteers will undergo Magnetic Resonance Elastography (MRE) to evaluate liver and renal viscoelasticity. For CKD patients, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, CKD patients will undergo a renal biopsy to assess the extent of fibrosis
219192808|NCT05791864|GENETIC|TTX-381|One time subretinal dose in study eye
219192809|NCT04820322|OTHER|Fibersym|RS4-type resistant modified wheat starch
219192810|NCT04820322|OTHER|Control cookie|control cookie
219192811|NCT05677802|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219192812|NCT05677802|OTHER|Medical Chart Review|Undergo medical cart review
219192813|NCT05677802|PROCEDURE|Stress Management Therapy|Receive biobehavioral stress reduction intervention
219192814|NCT05677802|OTHER|Survey Administration|Ancillary studies
219192815|NCT04939649|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
219192816|NCT04939649|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
219192817|NCT05071287|OTHER|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
219192818|NCT05071287|OTHER|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
219192819|NCT06019637|OTHER|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
219192820|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
219192821|NCT04331509|OTHER|No Intervention|No Intervention
219192822|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see leucocyte telomere length
219192823|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see p16
219192824|NCT05795556|OTHER|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
219433890|NCT01413828|DRUG|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
219433891|NCT04090697|DRUG|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
219433892|NCT03587467|OTHER|collect fecal specimens|collect fresh fecal specimens of participants
219433893|NCT02164604|DRUG|intravitreal injection of 0.03ml ranibizumab|
219433894|NCT03665207|DRUG|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
219433895|NCT03582436|PROCEDURE|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
219578711|NCT02014077|PROCEDURE|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
219192825|NCT06054971|OTHER|Remote Administration of NSAA|Remote Administration of NSAA
219578712|NCT05748327|DEVICE|Alcasite restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
219192826|NCT04758390|BEHAVIORAL|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
219192827|NCT04758390|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
219192828|NCT05395871|BEHAVIORAL|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
219192829|NCT05395871|BEHAVIORAL|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
219192830|NCT05395871|OTHER|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
219578713|NCT05748327|DEVICE|Bulk fill glass hybrid restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
219578714|NCT02714231|DRUG|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
219192831|NCT03759522|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
219192832|NCT06032455|BEHAVIORAL|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
219007426|NCT02490228|PROCEDURE|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
219007427|NCT05541172|DRUG|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
219007428|NCT01877434|PROCEDURE|Reversed shoulder arthroplasty|
219192833|NCT06032455|BEHAVIORAL|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
219192834|NCT04116528|DRUG|Ketamine|0.5mg/kg
219192835|NCT04116528|DRUG|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
219433896|NCT05837507|OTHER|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
219192836|NCT04116528|DRUG|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
219192837|NCT06587737|DRUG|Colchicine 0.5 MG|colchicine 0.5mg once-daily
219192838|NCT06587737|DRUG|Placebo|matching placebo, lacking active ingredient, once-daily
219433897|NCT05837507|OTHER|Usual management including NIV.|Usual management including NIV.
219433898|NCT02715804|OTHER|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
219433899|NCT02715804|DRUG|Placebo|Matching placebo for PEGPH20
219192839|NCT02420977|DRUG|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
219192840|NCT06480734|OTHER|symptom-based scoring system (symptom-questionnaire, paper version)|The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
219192841|NCT05603650|OTHER|Lumineux Oral Essentials rinse|mouthrinse
219192842|NCT05603650|OTHER|Listerine rinse|mouthrinse
219192843|NCT05820490|OTHER|Whole Room Calorimeter|The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.
219192844|NCT05820490|OTHER|Mixed-Meal Tolerance Test (MMTT)|The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.
218859542|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
219192845|NCT05820490|OTHER|Core Body Temperature|Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.
218859543|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
219192846|NCT05820490|OTHER|Morningness-Eveningness Questionnaire|Participants will fill out a questionnaire that asks about your preference for morning or evening.
219192847|NCT05820490|PROCEDURE|Muscle Biopsy|Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.
219433900|NCT02715804|DRUG|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
219433901|NCT02715804|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
219192848|NCT05820490|OTHER|Serial Blood Sampling|Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
219433902|NCT04816786|OTHER|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
219433903|NCT04506281|DRUG|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
219433904|NCT05287724|DRUG|N-acetyl cysteine|1,500 mg twice daily for seven days
219433905|NCT05287724|DRUG|Placebo|Placebo taken twice daily for seven days
219433906|NCT04038385|BEHAVIORAL|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
219433907|NCT02550119|DRUG|Aprepitant|Given PO
219433908|NCT02550119|DRUG|Dexamethasone|Given PO or IV
219433909|NCT02550119|DRUG|Dolasetron Mesylate|Given PO or IV
219433910|NCT02550119|DRUG|Placebo|Given PO
219192849|NCT04538378|DRUG|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
219192850|NCT04538378|DRUG|Durvalumab|Durvalumab will be administered intravenous (IV) into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
219433911|NCT04431141|DRUG|Teneligliptin|Teneligliptin alone
219433912|NCT04431141|DRUG|Empagliflozin|Empagliflozin alone
219192851|NCT04538378|DIAGNOSTIC_TEST|EKG|Screening and all cycles Day 1 and Day 15 (+/- 3) days. One cycle is 28 days.
219192852|NCT04538378|PROCEDURE|Tumor biopsy|Baseline and all cycles Day 15 (+/- 3) days. One cycle is 28 days.
219192853|NCT04538378|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
219433913|NCT04431141|DRUG|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
219433914|NCT02435394|BEHAVIORAL|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
219433915|NCT02435394|BEHAVIORAL|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
219433916|NCT02435394|BEHAVIORAL|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
219433917|NCT02656862|OTHER|No intervention|
219192854|NCT04538378|DIAGNOSTIC_TEST|MRI chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
219192855|NCT04452851|DEVICE|BREATHE|The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
219192856|NCT04452851|DEVICE|BiPAP|BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
219192857|NCT04452851|DRUG|COPD Inhaler|Inhaler medication to support quick relief from COPD symptoms
219578715|NCT02714231|DRUG|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
219578716|NCT00671073|DRUG|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
219762225|NCT06064097|PROCEDURE|X-Ray Imaging|Undergo dental x-ray
219192858|NCT02834390|DRUG|Quizartinib|"\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19."
219192859|NCT02834390|DRUG|Cytarabine|"\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
219192860|NCT02834390|DRUG|Idarubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2."
219192861|NCT02834390|DRUG|Daunorubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2."
219433918|NCT03961295|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
219433919|NCT04524091|OTHER|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
219433920|NCT00005792|DRUG|etoposide phosphate|Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
219433921|NCT00005792|DRUG|melphalan|Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
219433922|NCT00005792|DRUG|topotecan|Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
219433923|NCT00005792|PROCEDURE|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
219578717|NCT00671073|DRUG|Placebo|Placebo, oral administration, once daily for 12 weeks
219578718|NCT00671073|DRUG|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
219578719|NCT00671073|DRUG|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
219192862|NCT06553157|DRUG|Statin|Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
219192863|NCT06553157|OTHER|placebo|placebo
219762226|NCT06833125|DRUG|Garlic powder standardized to allicin|The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial effect) for 6 days just after ICU admission
219762227|NCT05652465|DEVICE|Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)|Device described in protocol
219762228|NCT06760819|DRUG|BAY2927088|tablet, oral
219762229|NCT04181060|BIOLOGICAL|Bevacizumab|Given IV
219762230|NCT04181060|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219762231|NCT04181060|PROCEDURE|Computed Tomography|Undergo CT
219762232|NCT04181060|PROCEDURE|Echocardiography Test|Undergo ECHO
219762233|NCT04181060|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762234|NCT04181060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762235|NCT04181060|DRUG|Osimertinib|Given PO
219433924|NCT04942522|BIOLOGICAL|probiotics PS128|6×10\^10 CFU/capsule
219433925|NCT04942522|DRUG|placebo (Microcrystalline cellulose )|450 mg/capsule
219192864|NCT06246084|BEHAVIORAL|Endocrine Therapy Education Program|Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
219192865|NCT04538742|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
219192866|NCT04538742|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
219192867|NCT04538742|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
219192868|NCT04538742|DRUG|Pertuzumab|Pertuzumab: administered as an IV infusion
219192869|NCT04538742|DRUG|Tucatinib|Tucatinib administered orally (tablet) twice daily
219192870|NCT06578052|DRUG|Irinotecan liposome Capecitabine|"Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs."
219192871|NCT03694145|OTHER|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
219192872|NCT03604913|PROCEDURE|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
219192873|NCT03604913|PROCEDURE|Bentall operation|Aortic root replacement with replacement of aortic valve
219192874|NCT03647098|DRUG|Treatment|Treatment decisions guided by molecular profiling and clinical judgment of principal investigators
219192875|NCT02998528|BIOLOGICAL|Nivolumab|Specified dose on specified days
219192876|NCT02998528|DRUG|Cisplatin|Specified dose on specified days
219433926|NCT02866773|BEHAVIORAL|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
219433927|NCT02866773|BEHAVIORAL|PA2: Education sessions, Reminders|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
219192877|NCT02998528|DRUG|Vinorelbine|Specified dose on specified days
219192878|NCT02998528|DRUG|Gemcitabine|Specified dose on specified days
219192879|NCT02998528|DRUG|Docetaxel|Specified dose on specified days
219192880|NCT02998528|DRUG|Pemetrexed|Specified dose on specified days
219192881|NCT02998528|DRUG|Carboplatin|Specified dose on specified days
219192882|NCT02998528|DRUG|Paclitaxel|Specified dose on specified days
219192883|NCT02998528|BIOLOGICAL|Ipilimumab|This arm is closed and no longer enrolling patients.
219192884|NCT06478199|DIAGNOSTIC_TEST|semen analysis|lab invesigation
219192885|NCT06439407|DEVICE|SAT-014(Software as Medical Device)|SAT-014(Software as Medical Device) + maintain previous treatment
219192886|NCT04345874|BEHAVIORAL|Nutrition technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
219192887|NCT04345874|BEHAVIORAL|Children's environmental health technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
219578720|NCT01640873|DRUG|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
219578721|NCT01640873|DRUG|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
219433928|NCT02866773|BEHAVIORAL|PA3: Education sessions, Whataps group|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
219192888|NCT05829343|PROCEDURE|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
219192889|NCT05829343|PROCEDURE|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
219192890|NCT06029452|OTHER|Machine learning algorithm|Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
219192891|NCT05742932|DEVICE|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
219433929|NCT02866773|BEHAVIORAL|PA4: Education sessions|"The intervention includes one component only:~\- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
219433930|NCT02866773|BEHAVIORAL|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~\- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
219578722|NCT05574231|PROCEDURE|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
219578723|NCT02614313|PROCEDURE|Open breath test with fructose|Open randomised fructose 35g during breath test
219192892|NCT06807255|DIAGNOSTIC_TEST|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission; subsequent analysis was conducted using rapid processing (under 5 minutes from the pre-test) with the Rapidpoint 500 Systems-Siemens (Siemens, Milano) emogasanalyzer
219192893|NCT04098666|DRUG|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
219192894|NCT04098666|DRUG|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
219578724|NCT02614313|PROCEDURE|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
219578725|NCT02614313|PROCEDURE|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
219578726|NCT02614313|PROCEDURE|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
219578727|NCT01135628|OTHER|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
219578728|NCT01135628|DIETARY_SUPPLEMENT|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
219578729|NCT01135628|DRUG|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
219578730|NCT03941353|OTHER|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
219578731|NCT06167954|DEVICE|EXPLORER|8 sessions of use of the device in the home and the community of the participants
219433931|NCT02866773|BEHAVIORAL|HD2: Education sessions, Reminders|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
219578732|NCT01321008|RADIATION|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
219578733|NCT01321008|DRUG|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
219578734|NCT01321008|DRUG|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
219578735|NCT01321008|DRUG|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
219578736|NCT01321008|DRUG|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
219578737|NCT03688178|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
219192895|NCT05907252|BEHAVIORAL|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
219192896|NCT05907252|BEHAVIORAL|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
219192897|NCT05907252|BEHAVIORAL|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
219192898|NCT06410508|OTHER|Just Do You|"As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population."
219192899|NCT05924074|BIOLOGICAL|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
219192900|NCT06804993|DRUG|Transvaginal repair & botulinum toxin type A injection|100 units of lyophilized botulinum toxin type A were diluted in saline to 50 U/mL before the injections. A total of 30 units of type-A botulinum toxin was injected with a 22-G needle evenly divided in 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
219578738|NCT03688178|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
219578739|NCT03688178|BIOLOGICAL|Varlilumab|Varlilumab is an agonist anti-CD27 monoclonal antibody
219578740|NCT03688178|BIOLOGICAL|Td|A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
219578741|NCT03688178|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
219192901|NCT06804993|PROCEDURE|Transvaginal repair & distilled water injection|A total of 30 units of distilled water was injected with a 22-G needle evenly divided into 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
219192902|NCT04204083|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
219192903|NCT05533814|DRUG|Perampanel|Perampanel tablets.
219192904|NCT06548880|OTHER|Structured exercise program|The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
219762236|NCT03426891|DRUG|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
219578742|NCT02477774|DEVICE|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
219578743|NCT01381263|BEHAVIORAL|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
219578744|NCT01381263|OTHER|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
219578745|NCT03356886|PROCEDURE|Spinal Manipulative Technique|1\) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
219578746|NCT03356886|BEHAVIORAL|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
219578747|NCT03511274|BEHAVIORAL|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
219578748|NCT06213714|DEVICE|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
219192905|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
219192906|NCT06322212|DIETARY_SUPPLEMENT|Thiamine|Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
219192907|NCT06322212|OTHER|Placebo|Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
219192908|NCT06746350|DEVICE|Thermotherapy|Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
219192909|NCT03853031|PROCEDURE|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
219192910|NCT03853031|PROCEDURE|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
219192911|NCT05523869|DRUG|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
219192912|NCT05523869|PROCEDURE|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
219192913|NCT03473249|DRUG|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
219192914|NCT05660863|DRUG|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
219192915|NCT05660863|DRUG|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
219578749|NCT02030314|DRUG|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
219578750|NCT02519621|DEVICE|NPWT PRO without irrigation|NPWT PRO without irrigation.
219578751|NCT02519621|DEVICE|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
219578752|NCT02519621|DEVICE|KCI Ulta|KCI Ulta NPWT without irrigation
219192916|NCT05122416|DEVICE|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
219192917|NCT05122416|DEVICE|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
219192918|NCT05122416|DEVICE|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
219192919|NCT05122416|DEVICE|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
219192920|NCT06324344|DEVICE|High-Dose TENS|high-dose TENS device delivers 1 hour of TENS therapy per session.
219192921|NCT06324344|DEVICE|Low-Dose TENS|low-dose TENS device delivers 6 minutes of TENS therapy per session.
219192922|NCT04152096|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
219578753|NCT06102408|OTHER|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
219433932|NCT02866773|BEHAVIORAL|HD3:Education sessions, Whataps group|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
219433933|NCT02866773|BEHAVIORAL|HD4: Education sessions|"The intervention includes one component only:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
219433934|NCT04687436|DEVICE|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
219433935|NCT04376424|DIAGNOSTIC_TEST|Hand Held Ultrasound|Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
219433936|NCT01507623|DEVICE|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
219578754|NCT05302570|RADIATION|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
219578755|NCT04691310|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
219578756|NCT04309253|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
219578757|NCT04309253|DRUG|AV45|F-18 AV45 PET Imaging
219578758|NCT03692143|DRUG|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
219578759|NCT03692143|PROCEDURE|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
219578760|NCT03692143|DRUG|Alendronate|Alendronate Sodium, oral, 70mg, once a week
219192923|NCT04152096|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
219192924|NCT05284409|DRUG|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
219192925|NCT05284409|DRUG|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
219192926|NCT05284409|DRUG|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
219192927|NCT06205160|DEVICE|SOFT ECoG subdural grid electrode|"Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making."
219192928|NCT05000515|OTHER|High-resistance inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
219192929|NCT05000515|OTHER|Aerobic exercise|Participants will perform brisk walking.
219192930|NCT05389878|OTHER|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
219192931|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Carbohydrate Beverage|Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener
219192932|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Beverage|Beverage containing no carbohydrates or kilocalories and an artificial sweetener
219192933|NCT03624465|DEVICE|Levita Magnetic Surgical System|Device for use as a surgical tool.
219192934|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
219192935|NCT03213678|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219433937|NCT05726955|OTHER|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
219192936|NCT03213678|PROCEDURE|Computed Tomography|Undergo CT
219433938|NCT01124513|PROCEDURE|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
219433939|NCT00951119|DEVICE|Resperate|device-guided breathing exercises
219433940|NCT00951119|DEVICE|Resperate|breathing device without slowing of breathing frequency
219192937|NCT03213678|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
219192938|NCT03213678|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219433941|NCT01625611|DRUG|Naltrexone|Naltrexone 100 mg titrated over one week
219433942|NCT04053218|COMBINATION_PRODUCT|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
219433943|NCT04053218|DIETARY_SUPPLEMENT|Placebo|Olive oil placebo
219433944|NCT04671095|DEVICE|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
219192939|NCT03213678|DRUG|Samotolisib|Given PO
219192940|NCT03213678|PROCEDURE|X-Ray Imaging|Undergo x-ray
219192941|NCT04224064|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
219192942|NCT04218851|DRUG|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
219433945|NCT02455843|OTHER|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
219192943|NCT04218851|DRUG|Posaconazole PFS|Dosing based on weight-band taken orally
219192944|NCT04218851|DRUG|Posaconazole tablet|POS tablet 300 mg taken orally
219192945|NCT03742505|DRUG|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
219192946|NCT03742505|OTHER|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
219192947|NCT05109468|OTHER|Quality of life questionnaire|to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
219433946|NCT02941042|DRUG|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
219433947|NCT02941042|DRUG|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
219433948|NCT02479386|OTHER|No intervention|No intervention was administered in this study.
219433949|NCT00836524|PROCEDURE|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
219433950|NCT00948194|DRUG|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
219433951|NCT03875872|DRUG|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
219433952|NCT03875872|DRUG|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
219433953|NCT02431793|BEHAVIORAL|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
219433954|NCT02431793|BEHAVIORAL|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
219433955|NCT00233324|DRUG|Surfactant|Intubation and administration of surfactant by 1 hour of age.
219433956|NCT00233324|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
219433957|NCT00233324|DRUG|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
219433958|NCT00233324|DRUG|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
219192948|NCT04785092|PROCEDURE|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
219192949|NCT06478979|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
219192950|NCT05797428|OTHER|logotherapy|The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
219433959|NCT04838639|DRUG|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
219192951|NCT05851144|BEHAVIORAL|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
219192952|NCT04174495|DIAGNOSTIC_TEST|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
219192953|NCT02313194|DEVICE|Epidural Stimulation|Determine if epidural stimulation can improve motor function
219433960|NCT04838639|DRUG|Placebo|Two subjects per cohort will take a matched placebo.
219433961|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
219192954|NCT02313194|DRUG|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
219192955|NCT06151184|PROCEDURE|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
219192956|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219192957|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
219192958|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
219192959|NCT06249984|OTHER|Survey Administration|Ancillary studies
219433962|NCT02827370|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary counseling
219192960|NCT03174275|DRUG|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
219192961|NCT03174275|DRUG|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
219433963|NCT00829777|DRUG|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
219433964|NCT02929862|DRUG|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
219433965|NCT02286726|OTHER|Laboratory Biomarker Analysis|Correlative studies
219433966|NCT02286726|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219433967|NCT03267407|OTHER|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
219578761|NCT03748394|BEHAVIORAL|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
219433968|NCT04705610|OTHER|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"* Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment"
219433969|NCT05948319|DIAGNOSTIC_TEST|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
219433970|NCT04112771|DRUG|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
219192962|NCT03174275|DRUG|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
219192963|NCT03174275|DRUG|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
219192964|NCT03174275|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
219192965|NCT03174275|RADIATION|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
219433971|NCT04112771|OTHER|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
219433972|NCT03170258|DEVICE|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
219433973|NCT00753597|DRUG|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
219192966|NCT06821750|BIOLOGICAL|PF-07314470|subcutaneous injection
219192967|NCT06821750|BIOLOGICAL|Placebo for PF-07314470|subcutaneous injection
219762237|NCT03426891|DRUG|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy.
219007429|NCT02853110|RADIATION|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
219192968|NCT03040596|DRUG|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
219192969|NCT03040596|BEHAVIORAL|Standard voice therapy|Standard voice therapy sessions
219192970|NCT06823206|OTHER|Sensorimotor training with movement representation techniques|Sensorimotor training will be implemented with movement representation techniques using a standardized retraining sequence of a shoulder control exercise during arm elevation with 3 phases: Phase 1: Action Observation Training; Phase 2: Mirror therapy; and Phase 3: Sensorimotor training of the involved arm. Each session will last 60 minutes, with one supervised intervention session over the 12 weeks.
219192971|NCT06674954|PROCEDURE|Regional Anesthesia|"After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219007430|NCT06069284|OTHER|No intervention|No intervention
219007431|NCT04853511|DEVICE|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
219433974|NCT05633680|DIAGNOSTIC_TEST|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
219433975|NCT00779363|DEVICE|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
219762238|NCT03426891|DRUG|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
219007432|NCT02949102|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
219007433|NCT02949102|DIETARY_SUPPLEMENT|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
219192972|NCT06674954|PROCEDURE|General Anesthesia|"Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219192973|NCT04456296|DRUG|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
219433976|NCT01626534|DRUG|Clopidogrel|600mg loading dose then 75mg/day
219192974|NCT04456296|DRUG|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
219433977|NCT01626534|DRUG|trigagrelor|180 mg loading dose then 90 mg Twice a day
219762239|NCT03426891|RADIATION|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
219433978|NCT02556970|PROCEDURE|Single port VATS|Performing video-assisted thorascopic surgery through a single port
219433979|NCT02556970|DRUG|Paracetamol|1g intraoperatively
219433980|NCT02556970|DRUG|Diclofenac|75mg intraoperatively
219762240|NCT06529016|DEVICE|Luminopia, a virtual reality headset|Subjects will be provided with the equipment to use in their homes for six hours usage per week (1 hour 6 days a week), for 12 weeks.
219762241|NCT06529016|OTHER|Paper pre- survey|Pre-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
219762242|NCT06529016|OTHER|Paper Survey|Post-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
219762243|NCT05006716|DRUG|BGB-16673|Orally administered
219192975|NCT04456296|DRUG|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
218859544|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
218859545|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
219192976|NCT06808425|DEVICE|Intervention A|Weighted blanket
219192977|NCT06808425|DRUG|Intervention B|Standard treatment (melatonin)
219762244|NCT06229912|DRUG|Revumenib|Given by PO
219762245|NCT05620407|DRUG|Deucravacitinib|Specified dose on specified days
219762246|NCT05620407|OTHER|Placebo|Specified dose on specified days
219762247|NCT05947500|DRUG|Avelumab|Given IV
219192978|NCT05304819|DEVICE|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
219192979|NCT06374589|DEVICE|Closed-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
219433981|NCT02556970|DEVICE|Camera (5mm diameter 30 degree videothoracoscope)|
219433982|NCT02556970|DEVICE|Forceps grasper|
219433983|NCT02556970|DRUG|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
219433984|NCT03375970|OTHER|TCM|oral chinese herb, chinese topical ointment
219433985|NCT03375970|OTHER|Western medicine|oral steroid, oral antihistamine, topical steroid
219433986|NCT04447924|DIETARY_SUPPLEMENT|Bif195|Daily intake of Bif195 dietary supplement
219433987|NCT04447924|OTHER|Placebo|Daily intake of Placebo
219433988|NCT01883219|DRUG|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
219762248|NCT05947500|PROCEDURE|Biopsy Procedure|Undergo biopsy
219762249|NCT05947500|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
219762250|NCT05947500|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219762251|NCT05947500|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762252|NCT05947500|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219762253|NCT05947500|DRUG|Tuvusertib|Given PO
219762254|NCT02306161|DRUG|Cyclophosphamide|Given IV
219762255|NCT02306161|DRUG|Doxorubicin|Given IV
219762256|NCT02306161|DRUG|Doxorubicin Hydrochloride|Given IV
219762257|NCT02306161|DRUG|Etoposide|Given IV
219192980|NCT06374589|DEVICE|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
219192981|NCT04250051|DRUG|Cytarabine|Given IV
219192982|NCT04250051|BIOLOGICAL|Filgrastim|Given SC
219433989|NCT04834050|PROCEDURE|Quadriceps femoris isometric home-based exercise|All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
219433990|NCT01427114|DRUG|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
219433991|NCT01563107|RADIATION|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
219433992|NCT01563107|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
219192983|NCT04250051|DRUG|Fludarabine|Given IV
219578762|NCT03748394|BEHAVIORAL|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
219578763|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
219578764|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
219578765|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
219578766|NCT01550276|OTHER|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
219762258|NCT02306161|DRUG|Etoposide Phosphate|Given IV
219762259|NCT02306161|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219192984|NCT04250051|DRUG|Fludarabine Phosphate|Given IV
219192985|NCT04250051|DRUG|Ivosidenib|Given PO
219192986|NCT06810336|DRUG|Remifentanil|Intravenous Remifentanil
219192987|NCT06810336|DRUG|Methadone|Intravenous Methadone
219192988|NCT05589792|DRUG|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
219192989|NCT05589792|DRUG|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
219433993|NCT01563107|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
219762260|NCT02306161|BIOLOGICAL|Ganitumab|Given IV
219762261|NCT02306161|DRUG|Ifosfamide|Given IV
219762262|NCT02306161|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
219762263|NCT02306161|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
219762264|NCT02306161|DRUG|Vincristine|Given IV
219762265|NCT02306161|DRUG|Vincristine Sulfate|Given IV
219762266|NCT06287775|BIOLOGICAL|Atezolizumab|Given IV
219762267|NCT06287775|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
219007434|NCT04347044|OTHER|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
219007435|NCT04347044|OTHER|Standart care|Optimal medication and clinical follow-up
219007436|NCT01150864|DEVICE|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
219007437|NCT01244425|DRUG|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
219007438|NCT01244425|OTHER|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
219192990|NCT06810492|DRUG|Ribociclib; abemaciclib; palbociclib; Dalpiciclib|"Neoadjuvant therapy: CDK4/6 inhibitor combined with endocrine, a total of 6 cycles, 1 cycle every 28 days.~CDK4/6 inhibitors (choose one of the following four types):~* Dalpiciclib 125 mg orally once a day d1-21 every 28 days for a cycle (3 weeks/1 week off)~* Palbociclib 125 mg orally once a day, d1-21, every 28 days in cycles (3 weeks/1 week off)~* Abemaciclib 150 mg orally twice daily in 28-day cycles (may be reduced to 100 mg orally twice daily if not tolerated)~* Ribociclib 400 mg orally once a day in a 28-day cycle Endocrine therapy drugs: take according to the label. Premenopausal patients need to be treated for ovarian function suppression."
219192991|NCT06808568|COMBINATION_PRODUCT|STIMULAN VG|
219192992|NCT04745390|RADIATION|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
219192993|NCT02257060|PROCEDURE|Endocardial Ablation|
219578767|NCT02549794|PROCEDURE|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
219578768|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
219192994|NCT00223145|RADIATION|Radiotherapy 70 Gy|Radiotherapy to the prostate
219192995|NCT00223145|RADIATION|Radiotherapy 76 Gy|Radiotherapy to the prostate
219192996|NCT00223145|DRUG|Androgen blockade|Duration : 6 months
219192997|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
219192998|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
219762268|NCT06287775|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219762269|NCT06287775|PROCEDURE|Computed Tomography|Undergo CT scan
219762270|NCT06287775|BIOLOGICAL|Durvalumab|Given IV
219762271|NCT06287775|PROCEDURE|Echocardiography Test|Undergo ECHO
219762272|NCT06287775|DRUG|Iadademstat|Given PO
219762273|NCT06287775|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762274|NCT06287775|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762275|NCT04799275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762276|NCT04799275|DRUG|Cyclophosphamide|Given IV
219762277|NCT04799275|DRUG|Doxorubicin Hydrochloride|Given IV
219762278|NCT04799275|DRUG|Oral Azacitidine|Given PO
219762279|NCT04799275|DRUG|Prednisone|Given PO
219762280|NCT04799275|OTHER|Questionnaire Administration|Ancillary studies
219762281|NCT04799275|BIOLOGICAL|Rituximab|Given IV or SC
219762282|NCT04799275|DRUG|Vincristine Sulfate|Given IV
219762283|NCT05763537|BEHAVIORAL|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
219762284|NCT05763537|BEHAVIORAL|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
219762285|NCT06496178|DRUG|Petosemtamab|MCLA-158
219762286|NCT06496178|DRUG|Investigator's Choice|Cetuximab
219762287|NCT06496178|DRUG|Investigator's Choice|Methotrexate
219762288|NCT06496178|DRUG|Investigator's Choice|Docetaxel
219762289|NCT06303193|DRUG|pacritinib|Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
219762290|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
219762291|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
219762292|NCT05843253|DRUG|Temozolomide (TMZ)|Temozolomide PO qd on days 1-5 for the first 13 cycles
219762293|NCT06058377|PROCEDURE|Biospecimen Collection|Undergo optional collection of tissue and/or blood
219762294|NCT06058377|DRUG|Cyclophosphamide|Given IV
219762295|NCT06058377|DRUG|Doxorubicin|Given IV
219762296|NCT06058377|BIOLOGICAL|Durvalumab|Given IV
219762297|NCT06058377|OTHER|Genetic Testing|Undergo MammaPrint testing
219762298|NCT06058377|PROCEDURE|Mammography|Undergo mammography
219762299|NCT06058377|DRUG|Paclitaxel|Given IV
219762300|NCT06058377|OTHER|Quality-of-Life Assessment|Ancillary studies
219762301|NCT04530565|PROCEDURE|Biospecimen Collection|Correlative studies
219762302|NCT04530565|BIOLOGICAL|Blinatumomab|Given IV
219762303|NCT04530565|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219762304|NCT04530565|DRUG|Cyclophosphamide|Given IV
219762305|NCT04530565|DRUG|Cytarabine|Given IV or IT
219762306|NCT04530565|DRUG|Dasatinib|Given PO
219762307|NCT04530565|DRUG|Dexamethasone|Given PO or IV
219762308|NCT04530565|DRUG|Doxorubicin Hydrochloride|Given IV
219762309|NCT04530565|PROCEDURE|Echocardiography Test|Undergo ECHO
219762310|NCT04530565|PROCEDURE|Electrocardiography|Undergo ECG
219762311|NCT04530565|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219192999|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
219578769|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
219578770|NCT05636566|DRUG|Sevoflurane|inhalational anaesthesia for maintenance
219193000|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
219578771|NCT05636566|DRUG|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
219578772|NCT05636566|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
219578773|NCT02311920|BIOLOGICAL|Ipilimumab|Given IV
219578774|NCT02311920|OTHER|Laboratory Biomarker Analysis|Correlative studies
219578775|NCT02311920|BIOLOGICAL|Nivolumab|Given IV
219578776|NCT02311920|DRUG|Temozolomide|Given PO
219578777|NCT04764630|DRUG|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
219578778|NCT04764630|DRUG|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
219578779|NCT04764630|DRUG|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
219578780|NCT05485519|DRUG|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
219578781|NCT05485519|DRUG|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
219578782|NCT00970008|OTHER|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
219007439|NCT02502643|DRUG|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
219007440|NCT02502643|DRUG|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
219007441|NCT03957304|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
219578783|NCT00970008|OTHER|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
219578784|NCT00970008|OTHER|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
219578785|NCT00970008|OTHER|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
219578786|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
219578787|NCT00899470|DRUG|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
219762312|NCT04530565|DRUG|Mesna|Given IV
219578788|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
219578789|NCT00899470|DRUG|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
219578790|NCT05873361|OTHER|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
219762313|NCT04530565|DRUG|Methotrexate|Given IV or IT
219762314|NCT04530565|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762315|NCT04530565|DRUG|Ponatinib Hydrochloride|Given PO
219762316|NCT04530565|DRUG|Prednisone|Given PO
219762317|NCT04530565|DRUG|Vincristine Sulfate|Given IV
219762318|NCT02194738|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219762319|NCT02194738|DRUG|Carboplatin|Given IV
219762320|NCT02194738|DRUG|Cisplatin|Given IV
219762321|NCT02194738|OTHER|Clinical Observation|Undergo observation
219762322|NCT02194738|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219762323|NCT02194738|DRUG|Crizotinib|Given PO
219762324|NCT02194738|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
219762325|NCT02194738|PROCEDURE|Echocardiography Test|Undergo ECHO
219762326|NCT02194738|DRUG|Erlotinib|Given PO
219762327|NCT02194738|DRUG|Gemcitabine Hydrochloride|Given IV
219762328|NCT02194738|BIOLOGICAL|Nivolumab|Given IV
219762329|NCT02194738|DRUG|Paclitaxel|Given IV
219762330|NCT02194738|BIOLOGICAL|Pembrolizumab|Given IV
219762331|NCT02194738|DRUG|Pemetrexed|Given IV
219193001|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
219193002|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
219193003|NCT06853821|OTHER|Comfort Theory Based Care|In the research, this group includes care-based intervention
219193004|NCT06853821|OTHER|Virtual Reality Glasses|In the research, this group includes interventions with virtual reality glasses.
219193005|NCT06807840|OTHER|influenza virus infection|Participants with active influenza virus infection will be enrolled in this study.
219193006|NCT04271046|BEHAVIORAL|STAR-C-VTF|"1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
219193007|NCT04271046|BEHAVIORAL|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
219193008|NCT06807905|DRUG|Heparin anticoagulation|Hemodiafiltration will be performed with heparine anticoagulation
219193009|NCT06807905|DRUG|Citrate anticoagulation|Patient will perform dialysis with citrate anticoagulation
219193010|NCT06548958|PROCEDURE|Second Stem Cell Transplantation (SCT2)|"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
219193011|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
219193012|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
219193013|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
219193014|NCT06814106|DRUG|Enlicitide Chloride|Oral Capsule
219193015|NCT06814106|DRUG|Placebo|Placebo oral capsule matching enlicitide chloride
219578791|NCT03138447|DEVICE|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
219578792|NCT05480592|DRUG|HS-10380|Administered orally as a tablet
219578793|NCT05480592|DRUG|Placebo|Administered orally as a tablet
219578794|NCT03746548|DEVICE|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
219578795|NCT03746548|DEVICE|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
219578796|NCT02212912|BEHAVIORAL|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
219578797|NCT02212912|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
219762332|NCT02194738|DRUG|Pemetrexed Disodium|Given IV
219762333|NCT02194738|OTHER|Placebo Administration|Given PO
219762334|NCT02194738|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219762335|NCT00706420|PROCEDURE|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
219762336|NCT00706420|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
219762337|NCT06441578|DRUG|Recombinant ADAMTS13|Recombinant ADAMTS13, Intravenous injection
219762338|NCT06196684|PROCEDURE|Mitral allograft implantation|Tricuspid valve replacement with mitral valve allograft
219578798|NCT01303536|DRUG|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
219007442|NCT01490229|DRUG|Ezetimibe|os, 10 mg, once daily, 1 year
219007443|NCT01490229|DRUG|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
219193016|NCT06814366|OTHER|music and white noise intervention|The experimental groups were played a combination of music and white noise through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
219193017|NCT06814366|OTHER|music intervention|The experimental groups were played music a through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
219578799|NCT02192164|BEHAVIORAL|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
219578800|NCT03891017|OTHER|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
219578801|NCT03891017|OTHER|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
219578802|NCT04870723|BEHAVIORAL|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
219578803|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
219007444|NCT01259505|BIOLOGICAL|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219193018|NCT03899428|DRUG|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
219193019|NCT03899428|DRUG|Sorafenib|Prescribed by physician.
219193020|NCT03899428|DRUG|Lenvatinib|Prescribed by physician.
219578804|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
219578805|NCT02814435|OTHER|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
219007445|NCT05812612|DRUG|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
219007446|NCT00019578|PROCEDURE|Sterotactic radiosurgery|
219193021|NCT03899428|DRUG|Regorafenib|Prescribed by physician.
219007447|NCT04111484|OTHER|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
219007448|NCT04111484|OTHER|Saline|Placebo
219193022|NCT03899428|DRUG|Cabozantinib|Prescribed by physician.
219193023|NCT06817759|DEVICE|Virtual Reality Hypnosis|An intervention program (VRH) that combines VR and hypnosis; Can use it whenever and how much they want. It contains 200 landscapes in VR and 4 different VRH sessions
219193024|NCT06817759|DEVICE|VRH : Beach|Hypnosis session with a VR immersion at the beach; one accompanied session
219193025|NCT06817759|DEVICE|VRH : Forest|Hypnosis session with a VR immersion in forests; one accompanied session
219193026|NCT06817759|DEVICE|VRH : MagicHand|Hypnosis session with a VR immersion with techniques to reduce pain; one accompanied session
219193027|NCT06817759|DEVICE|VRH : SecurityProtection|Hypnosis session with a VR immersion with techniques to reduce anxiety; one accompanied session
219433994|NCT05211245|DEVICE|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
219193028|NCT06821295|OTHER|Smart-T Alcohol|The Smart-T Alcohol intervention offers on-demand content and automated contextually tailored messages to reduce alcohol consumption. The intervention period will span eight-weeks (i.e., weeks 2-9), with follow-up assessments occurring at weeks 9, 13, and 26. All participants will complete brief daily smartphone-based surveys for 13 weeks.
219193029|NCT06821295|OTHER|Usual Care|Participants will receive standard shelter-based treatment (Usual Care) along with completing surveys and assessments.
219193030|NCT06677918|DRUG|EP395|Capsule for oral use
219193031|NCT06677918|DRUG|Placebo|Capsule for oral use
219193032|NCT06839664|DRUG|HS-20094 injection|Administered SC
219193033|NCT06839664|DRUG|Placebo injection|Administered SC
219193034|NCT04826471|DEVICE|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
219578806|NCT02814435|OTHER|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
219578807|NCT03329079|BEHAVIORAL|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
219007449|NCT05173402|DEVICE|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
219193035|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
219193036|NCT06101511|PROCEDURE|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
219193037|NCT06789809|DIAGNOSTIC_TEST|Exercise MRI|Exercise stress MRI with ergometer
219193038|NCT04414722|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
219193039|NCT04414722|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
219193040|NCT04414722|OTHER|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
219193041|NCT06555081|DRUG|Ruxolitinib IR|Tablet
219193042|NCT06555081|DRUG|Ruxolitinib XR|Tablet
219433995|NCT02915289|PROCEDURE|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
219433996|NCT02915289|PROCEDURE|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
219433997|NCT01470365|PROCEDURE|quality-of-life assessment|Ancillary studies
219433998|NCT01470365|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219433999|NCT01470365|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
219434000|NCT03955497|OTHER|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
219434001|NCT03955497|DRUG|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
219578808|NCT03329079|BEHAVIORAL|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
219578809|NCT01844999|BEHAVIORAL|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
219193043|NCT05270876|DEVICE|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
219193044|NCT05764876|DRUG|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
219193045|NCT05764876|DRUG|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
219193046|NCT03956888|DRUG|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
219193047|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
219434002|NCT03955497|PROCEDURE|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
219434003|NCT03006900|OTHER|Pilates|Pilates
219434004|NCT03006900|OTHER|Massage|Massage
219434005|NCT05702372|OTHER|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219434006|NCT05702372|OTHER|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219434007|NCT05702372|OTHER|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219193048|NCT05437900|PROCEDURE|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
219193049|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
219193050|NCT05437900|PROCEDURE|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
219578810|NCT01844999|BEHAVIORAL|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
219578811|NCT00359788|DRUG|tiotropium|
219434008|NCT05702372|OTHER|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219193051|NCT06765564|DRUG|iPSC-MNP|Using iPSC-MNP Cells for the Treatment of ALS Patients
219578812|NCT00359788|DRUG|Combivent (Ipratropium/Albuterol)|
219578813|NCT03946254|OTHER|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
219193052|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
219193053|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
219193054|NCT05218096|DRUG|ALXN2050|Oral tablet.
219193055|NCT05218096|DRUG|Placebo|Oral tablet.
219193056|NCT05374018|DIAGNOSTIC_TEST|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
219193057|NCT00957684|DRUG|eslicarbazepine acetate|once-daily oral tablet
219193058|NCT00957684|DRUG|placebo|once daily placebo comparator
219193059|NCT04647630|DIAGNOSTIC_TEST|urine test|test for pneumococcal antigen in urine
219434009|NCT03696446|BEHAVIORAL|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
219434010|NCT03696446|BEHAVIORAL|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
219434011|NCT05526625|OTHER|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC \& IJV.
219434012|NCT01117805|BEHAVIORAL|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
219434013|NCT06020768|OTHER|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
219578814|NCT02463305|DRUG|Creatine monohydrate|21 grams creatine monohydrate total per day
219578815|NCT02463305|OTHER|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
219578816|NCT00940797|DRUG|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
219193060|NCT06390241|DRUG|Avidin-biotin-Dota-90Y|Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
219193061|NCT06823570|BEHAVIORAL|Individualized exercise therapy|Patients in the intervention group will receive an individualized exercise training program 3x/week.
219193062|NCT06823570|BEHAVIORAL|Lifestyle recommendations|The lifestyle recommendation group will receive general recommendations such as salt reduction, higher physical activity levels and stress reduction.
219007450|NCT05173402|DEVICE|face mask|orthopedic treatment was performed using a face mask.
219007451|NCT00751751|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
219007452|NCT00751751|DRUG|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
219193063|NCT06646484|DIAGNOSTIC_TEST|Impedancemetry evaluation|Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
219193064|NCT04222478|OTHER|Specific auriculotherapy|"3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
219193065|NCT04222478|OTHER|Non-specific auriculotherapy|3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
219193066|NCT06205602|DRUG|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
219193067|NCT06205602|DRUG|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
219007453|NCT04446546|PROCEDURE|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
219007454|NCT00070174|DRUG|asparaginase|
219007455|NCT00070174|DRUG|busulfan|
219007456|NCT00070174|DRUG|cyclophosphamide|
219007457|NCT00070174|DRUG|cyclosporine|
219007458|NCT00070174|DRUG|cytarabine|
219007459|NCT00070174|DRUG|daunorubicin hydrochloride|
219007460|NCT00070174|DRUG|etoposide|
219193068|NCT06205602|DRUG|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
219193069|NCT06205602|DRUG|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
219434014|NCT01333098|DRUG|Mifepristone|300mg per day, by mouth, for 21-28 days
219434015|NCT00398125|DRUG|GSK364735|
219434016|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
219007461|NCT00070174|DRUG|gemtuzumab ozogamicin|
219007462|NCT00070174|DRUG|methotrexate|
219007463|NCT00070174|DRUG|mitoxantrone hydrochloride|
219007464|NCT00070174|PROCEDURE|allogeneic bone marrow transplantation|
219007465|NCT01661439|DRUG|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
219007466|NCT05229237|DRUG|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
219193070|NCT06823791|DRUG|Furazolidone|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
219434017|NCT02218762|DRUG|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
219434018|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
219434019|NCT02218762|DRUG|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
219434020|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes"
219578817|NCT00940797|DRUG|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
219007467|NCT02973217|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|
219007468|NCT00488176|DRUG|montelukast|montelukast sodium
219007469|NCT00488176|DRUG|cetirizine|cetirizine
219007470|NCT00488176|DRUG|montelukast and cetirizine|montelukast and cetirizine
219007471|NCT00488176|DRUG|placebo|placebo
219193071|NCT06823791|DRUG|Clarithromycin|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + clarithromycin 500 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
219007472|NCT02325375|PROCEDURE|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
219007473|NCT04119492|BEHAVIORAL|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
219578818|NCT00673933|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
219578819|NCT05709483|DRUG|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
219578820|NCT03760614|DRUG|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
219578821|NCT03760614|DRUG|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
219578822|NCT04915014|PROCEDURE|sleeve gastrectomy with transit bipartition (SG +TB)|In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
219434021|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
219193072|NCT06730230|BEHAVIORAL|Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support|CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
219193073|NCT05269849|DRUG|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
219434022|NCT05480501|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
219007474|NCT03906838|DRUG|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
219007475|NCT02744391|DRUG|Levodopa|
219007476|NCT04041804|PROCEDURE|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
219007477|NCT01996709|DEVICE|Hydrogen peroxide-based contact lens solution|
219007478|NCT01996709|DEVICE|Habitual contact lens solution|Biguanide-preserved
219007479|NCT01996709|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
219007480|NCT04811625|DRUG|PL-ASA|Pharmacologic profile of different aspirin formulations
219007481|NCT02694510|OTHER|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
219007482|NCT02421315|BEHAVIORAL|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
219434023|NCT05559073|PROCEDURE|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
219193074|NCT04304144|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
219193075|NCT04304144|DRUG|SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|According to institutional standard of care.
219434024|NCT04914767|DRUG|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
219193076|NCT04304144|DRUG|Daratumumab|Treatment for AL amyloidosis
219193077|NCT05903820|DRUG|Estradiol patch|Transdermal patch of estradiol
219193078|NCT05903820|DRUG|Progesterone|Oral progesterone capsules 100mg/day
219193079|NCT06475950|OTHER|"Kid'EM app experimental group"|"In the Kid'EM app experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm.~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
219434025|NCT04914767|DRUG|Placebo|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
219434026|NCT05989295|DIETARY_SUPPLEMENT|probiotic LRa05|treatment about 12 weeks
219434027|NCT03111342|DRUG|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
219434028|NCT03111342|PROCEDURE|Dry-needling|A placement of thin needle into the cervix without substance injection
219434029|NCT04410081|DRUG|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
219434030|NCT04409990|DIAGNOSTIC_TEST|Shear Wave Elastography|SWE value of rectal lesions
219434031|NCT01225120|OTHER|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
219434032|NCT05884281|DRUG|Roflumilast|0.5 mg once daily for treatment period
219434033|NCT05884281|DRUG|Placebo|Placebo for treatment period
219434034|NCT00601146|PROCEDURE|chest computed tomography scan|Once a year for three years
219434035|NCT05200728|DRUG|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
219434036|NCT05200728|DRUG|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
219434037|NCT02268071|DRUG|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
219434038|NCT01174888|DRUG|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
219434039|NCT01174888|DRUG|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
218859546|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
218859547|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
218859548|NCT01722292|DRUG|LY2940680|Administered orally
218859549|NCT01722292|DRUG|Carboplatin|Administered IV
218859550|NCT01722292|DRUG|Etoposide|Administered IV
219434040|NCT01174888|DRUG|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
219193080|NCT06475950|OTHER|Kid'EM app control group|"Use of control application without guidance for goal setting~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
219434041|NCT01174888|DRUG|etoposide|Patients receive etoposide IV over 1 hour
219193081|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib~* Atezolizumab"
219193082|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib"
219193083|NCT05618587|DRUG|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
219193084|NCT05618587|DRUG|Placebo|Inactive pill
219193085|NCT03981263|DEVICE|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
219434042|NCT01174888|DRUG|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
219434043|NCT00054158|DRUG|dexamethasone|
219007483|NCT04500002|DRUG|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
219007484|NCT04500002|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
219007485|NCT03954756|DRUG|Apatinib and PD1|"1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
219007486|NCT01554384|PROCEDURE|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
219434044|NCT00054158|DRUG|doxorubicin hydrochloride|
219434045|NCT00054158|DRUG|thalidomide|
219434046|NCT00054158|DRUG|vincristine sulfate|
219434047|NCT05460572|DIETARY_SUPPLEMENT|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
219434048|NCT02923310|BIOLOGICAL|Platelets Rich Plasma|
219434049|NCT02923310|BIOLOGICAL|Leucocyte - Platelets Rich Plasma|
219434050|NCT02923310|DRUG|Hialuronic Acid|
219434051|NCT04238611|DEVICE|Microneedle|Lactate microneedle applied on the skin of participant
219434052|NCT04238611|DIAGNOSTIC_TEST|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
219434053|NCT04238611|OTHER|Exercise regimen|Standardised aerobic exercise regimen
219434054|NCT04483297|DRUG|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
219007487|NCT01554384|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
219007488|NCT05573607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
219434055|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
219434056|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219434057|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
219434058|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
219434059|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
219193086|NCT03981263|DEVICE|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
219434060|NCT03177746|DRUG|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
219434061|NCT05463172|OTHER|abdominal strengthening exercises|abdominal strengthening exercises
219193087|NCT06387147|DRUG|Gentamicin|Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
218859551|NCT01722292|DRUG|Placebo|Administered orally
218859552|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
218859553|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
218859554|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
218859555|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
219193088|NCT06387147|DRUG|Placebo|Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
219193089|NCT06387147|DRUG|Metronidazole|Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
219193090|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at Day 4|Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
219434062|NCT05463172|OTHER|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
219434063|NCT02480803|DRUG|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
219434064|NCT02480803|DEVICE|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
219434065|NCT02546310|DRUG|HTL0009936|
219193091|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at Day 4|Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
219193092|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at week 26|Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
219007489|NCT05573607|DIETARY_SUPPLEMENT|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
219007490|NCT01569711|PROCEDURE|Deep brain stimulation of nucleus accumbens|"* Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
219193093|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at week 26|Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
219193094|NCT04496154|DIETARY_SUPPLEMENT|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
219007491|NCT01073553|DRUG|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
219007492|NCT01073553|DRUG|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
219007493|NCT02538250|DIETARY_SUPPLEMENT|Nutricomp Drink Plus|Oral nutritional supplementation
218859556|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
218859557|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
218859558|NCT04345172|DEVICE|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
218859559|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
219007494|NCT00237094|BEHAVIORAL|Nurse Practitioner led multidisciplinary team approach|
219007495|NCT06434259|DEVICE|Digi-physical support system|A support system named Evira will be used to provide behavioral treatment.
219434066|NCT02546310|DRUG|HTL0009936 matching placebo|
219193095|NCT05842135|PROCEDURE|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
219193096|NCT06057324|DEVICE|AI-based Apps|Families which will use the digital interactive tools to empower parents in their daily dietary choices.
219193097|NCT06057324|BEHAVIORAL|Mediterranean-based diet toolkit and activities|Families which will receive educational materials and adolescents will perform educational activities.
219193098|NCT06057324|OTHER|Healthy plant-based snacks|Families in which children will include the snacks in their diet.
219193099|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities|Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.
219193100|NCT06057324|OTHER|AI-based Apps + Healthy plant-based snacks|Families which will use the digital interactive tools and children will include the snacks in their diet.
219193101|NCT06057324|OTHER|Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
219193102|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
219193103|NCT05815485|DRUG|Azeliragon|30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
219193104|NCT05815485|DRUG|Placebo|Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
218859560|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
219193105|NCT04470934|DEVICE|SeQuent® SCB drug-coated balloon catheter|"treatment of coronary artery disease with SeQuent® SCB of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
219193106|NCT05946850|PROCEDURE|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
219193107|NCT06285214|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
219434067|NCT04279652|OTHER|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
219434068|NCT03512119|DRUG|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
219193108|NCT06285214|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
219193109|NCT03268382|DRUG|APR-246|Intravenous infusion
219193110|NCT03268382|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
219193111|NCT06018064|DEVICE|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
219193112|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
219434069|NCT01823757|OTHER|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
219193113|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
219193114|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
219193115|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
219193116|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
219434070|NCT01858597|DIAGNOSTIC_TEST|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
219193117|NCT04576130|DEVICE|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
219193118|NCT06585358|OTHER|MIPD|This is a non-inverventional study
219193119|NCT06584656|BEHAVIORAL|Aerobic exercise condition|Aerobic session will last 30 min. The average intensity of the aerobic sessions will be 60-70% of the Maximal Heart Rate. Therefore, participant will perform a continuous moderate intensity aerobic bout of exercise on a cycle ergometer.
219193120|NCT06584656|BEHAVIORAL|Resistance exercise condition|Resistance exercise will last 30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion from 0-10). The bout of resistance exercise will include a combination of upper and lower body exercises using elastic bands and the participants' body weight as the primary resistance. Eight different exercises will be performed per set, with 40 seconds per exercise, for a total of 3 sets. The exercises are based on basic movement patterns and include: glute bridge, front plank, standing face pull, incline push-up, squat, pallof press, walking lunge and seated shoulder press.
219193121|NCT06252623|DRUG|Exenatide|Exenatide will be purchased commercially as Bydureon® for subcutaneous injection and administered at 2 mg once a week for 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
219193122|NCT06252623|DRUG|Placebo|Sterile saline will be used as the placebo and administered subcutaneously once a week for 6 weeks.
219193123|NCT06828523|BEHAVIORAL|Listener judgements of speech produced in different tasks|Listeners will hear recorded speech of PALS and age-matched speakers across interactive and non-interactive tasks and indicate what they heard by clicking one of four words displayed on the screen. Standard attention checks and minimum performance thresholds (Theodore, 2021) will be used to ensure that listeners are engaged and are able to provide meaningful perceptual judgments.
219434071|NCT05478057|DEVICE|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
219434072|NCT03218189|OTHER|Country characteristics|Observational study of country characteristics
219193124|NCT05786066|DRUG|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
219193125|NCT05786066|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
219193126|NCT05786066|DRUG|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
219193127|NCT06007781|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
219193128|NCT06007781|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
219193129|NCT05525702|DEVICE|VRFS|Participants wear VR headsets and experience immersive virtual environments, where their family members will be present and offer companionship and comfort.
219434073|NCT01998958|DRUG|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
219434074|NCT01998958|DRUG|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
219434075|NCT01998958|DRUG|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
219434076|NCT01998958|DRUG|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
219578823|NCT04915014|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
219578824|NCT01473550|BEHAVIORAL|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
219578825|NCT01678651|PROCEDURE|Stimulation with human FSH|Human FSH
219578826|NCT01678651|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
218859561|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
218859562|NCT01570049|DRUG|Bendamustine|for injection
219193130|NCT04403204|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
219193131|NCT04403204|OTHER|DCE-MRI|Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
219578827|NCT03442959|OTHER|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
219578828|NCT01366443|PROCEDURE|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
219578829|NCT01366443|PROCEDURE|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
219578830|NCT01366443|PROCEDURE|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
219578831|NCT05816200|DEVICE|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
219434077|NCT01998958|DRUG|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
219434078|NCT02281981|DIETARY_SUPPLEMENT|Curcumin|333mg CurcuWin OAHTCUR002-2014
219434079|NCT02281981|DIETARY_SUPPLEMENT|Placebo|OAHTCUR005-2014
219434080|NCT04045574|PROCEDURE|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
219434081|NCT00484276|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
219434082|NCT01473303|BIOLOGICAL|ganitumab|Given IV
219434083|NCT01473303|DRUG|fluorouracil|Given IV
219434084|NCT01473303|DRUG|irinotecan hydrochloride|Given IV
219434085|NCT01473303|DRUG|leucovorin calcium|Given IV
219434086|NCT01473303|DRUG|oxaliplatin|Given IV
219434087|NCT01473303|OTHER|placebo|Given IV
219434088|NCT01473303|OTHER|questionnaire administration|Completed on paper
219434089|NCT05474755|DRUG|GP681 40mg|2X20mg tablets taken orally
219434090|NCT05474755|DRUG|Placebo|Placebo tablets matching GP681 40mg
219434091|NCT01128881|BIOLOGICAL|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
219434092|NCT05428553|PROCEDURE|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
219434093|NCT05428553|PROCEDURE|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
219434094|NCT00724815|DRUG|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
219434095|NCT00724815|DRUG|Placebo|NP101 Placebo iontophoretic transdermal patch
219434096|NCT00810043|DEVICE|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
219434097|NCT05892263|OTHER|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
219434098|NCT03320889|OTHER|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
219434099|NCT03950960|DRUG|BMS-986256|Specified dose on specified days
219434100|NCT03950960|DRUG|Itraconazole|Specified dose on specified days
219007496|NCT01160978|DRUG|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
219434101|NCT02137304|DEVICE|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
219434102|NCT05330624|BIOLOGICAL|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
219434103|NCT04677023|OTHER|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
219434104|NCT04677023|OTHER|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
219434105|NCT04880772|OTHER|Prehabilitation|exercise \& multivitamin (nutritional/dietary advice)
219193132|NCT04862416|BIOLOGICAL|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
219434106|NCT02516150|DRUG|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
219434107|NCT02516150|DRUG|Glucagon|injection of 50 micrograms of glucagon
219434108|NCT00201981|DRUG|Rebamipide|"1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
219193133|NCT03442309|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
219193134|NCT03442309|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
219193135|NCT03442309|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
219434109|NCT03902041|DRUG|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
219434110|NCT01789658|OTHER|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
219434111|NCT05703139|PROCEDURE|TRIANGLE procedure|The Triangle procedure aims to develop a novel method for patients with locally advanced pancreatic cancer after neoadjuvant therapy and was described in 2017. The basis of this operation is the notice that after neoadjuvant therapy conventional imaging fails to differentiate between actual tumor encasement and only fibrotic residual tissue mainly to the arterial structures
219193136|NCT06580171|OTHER|Walking and Remembering Test|Only Walking and Remembering Test will be applied to the group.
219193137|NCT03495180|OTHER|Standard EEG or SSEP|The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
219193138|NCT06570863|OTHER|Antibiotics(doxycycline)|doxycycline 100 mg 2 stat the first day followed by od for 14 days
219193139|NCT06570863|OTHER|Probiotics|Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
219193140|NCT06570863|OTHER|Metronidazole gel 25%|After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
219193141|NCT03852550|OTHER|e-health application|In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
219434112|NCT02186457|DRUG|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
219434113|NCT02186457|OTHER|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
219434114|NCT03364491|DRUG|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
219434115|NCT03364491|DRUG|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
219434116|NCT05127291|OTHER|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
219434117|NCT03975712|OTHER|Not applicable, no intervention|Not applicable, no intervention
219578832|NCT05816200|DEVICE|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
219578833|NCT04352270|OTHER|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
219578834|NCT04352270|OTHER|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
219434118|NCT02198989|BEHAVIORAL|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
219578835|NCT00821002|DRUG|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
219193142|NCT05204654|OTHER|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
219193143|NCT05204654|DEVICE|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
219193144|NCT01836705|DRUG|SAR302503 (TG101348)|"Pharmaceutical form:capsule~Route of administration: oral"
219193145|NCT01836705|DRUG|Placebo SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219578836|NCT05115591|DIAGNOSTIC_TEST|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
219434119|NCT01661946|DRUG|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
219434120|NCT01661946|DRUG|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
219434121|NCT01977248|BEHAVIORAL|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
219434122|NCT01472991|DRUG|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
219434123|NCT01472991|DRUG|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
219434124|NCT01472991|DRUG|Placebo|Placebo capsules will be taken once daily for 4 weeks
219578837|NCT05115591|PROCEDURE|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
219007497|NCT01160978|DRUG|Control Rx|The transplant recipients who have received an organ from non-treated donors.
219007498|NCT01754623|DRUG|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
219193146|NCT01836705|DRUG|Panolosetron|"Pharmaceutical form:solution~Route of administration: intravenous"
219193147|NCT02745860|DRUG|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
219193148|NCT02745860|DRUG|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
219193149|NCT04779320|DRUG|Vedolizumab IV|Vedolizumab IV
219193150|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 1: low intensity clinician training|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
219434125|NCT05286996|DEVICE|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
219434126|NCT05286996|DRUG|Local anesthetic|Placebo - local anaesthesia
219434127|NCT01831804|DRUG|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
219434128|NCT01831804|DRUG|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
219434129|NCT04946162|DRUG|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
219578838|NCT00369382|DRUG|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
219578839|NCT00369382|DRUG|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
219007499|NCT01754623|DRUG|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
219007500|NCT01754623|DRUG|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
219007501|NCT01754623|RADIATION|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
219434130|NCT01902004|DRUG|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
219434131|NCT01902004|DRUG|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
219434132|NCT01902004|DRUG|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
219434133|NCT04019457|OTHER|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
219434134|NCT05214404|OTHER|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
219578840|NCT03554603|BEHAVIORAL|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
219578841|NCT00469768|DRUG|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
219193151|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 2: high intensity clinician training|"This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
219193152|NCT05001009|BEHAVIORAL|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
219193153|NCT05001009|BEHAVIORAL|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
219193154|NCT06198517|OTHER|Moxibustion|The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
219193155|NCT06198517|OTHER|Symptomatic treatment|The control group received conventional symptomatic treatment.
219193156|NCT04745520|DEVICE|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
219193157|NCT04745520|DRUG|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
219193158|NCT05342701|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
219193159|NCT01842477|PROCEDURE|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
219193160|NCT05496088|PROCEDURE|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
219193161|NCT05496088|PROCEDURE|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
219193162|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
219193163|NCT06038396|DRUG|RC118|Dose A or dose B, Q2W
219193164|NCT06038396|DRUG|Toripalimab|Fixed dose, Q3W
219578842|NCT00469768|DRUG|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
219578843|NCT00469768|OTHER|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
219578844|NCT00507546|DRUG|Ramelteon|8 mg nightly
219578845|NCT00507546|DRUG|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
219578846|NCT01673698|DEVICE|ReShape Duo balloon|
219578847|NCT01673698|OTHER|Diet counseling|
219578848|NCT01673698|OTHER|Exercise counseling|
219434135|NCT05752240|DEVICE|Transcranial direct current stimulation|Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
219434136|NCT04138212|DRUG|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
219193165|NCT06038396|DRUG|RC148|Fixed dose, Q3W Other Names: RC148 injection
219193166|NCT06214143|BIOLOGICAL|T3011 high dose|T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
219193167|NCT06214143|BIOLOGICAL|T3011 middle dose|T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
219193168|NCT06214143|BIOLOGICAL|T3011 low dose|T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
219193169|NCT06432699|OTHER|micro osteoperforation|one side used for mops while other side will be control in same patient
219193170|NCT02446236|DRUG|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
219434137|NCT04138212|RADIATION|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
219193171|NCT02446236|DRUG|Ibrutinib|560 mg PO daily
219193172|NCT02446236|DRUG|Rituximab|375 mg/m2 IV Day 1
219434138|NCT02062242|OTHER|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
219193173|NCT05010668|DRUG|cryoablation|Cryoablation treatment starts at day 0.
219193174|NCT05010668|DRUG|Sintilimab|Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219193175|NCT05010668|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219434139|NCT02062242|OTHER|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
219434140|NCT02062242|OTHER|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
219434141|NCT02062242|OTHER|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
219434142|NCT00055848|GENETIC|cytogenetic analysis|
219193176|NCT06526364|OTHER|All participants will be asked to provide data and samples for collection and analysis.|"During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC)."
219193177|NCT05231070|OTHER|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
219434143|NCT00055848|GENETIC|gene mapping|
219434144|NCT00055848|GENETIC|microarray analysis|
219193178|NCT02255799|DRUG|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
219193179|NCT02255799|DRUG|Placebo|Placebo capsule once daily for 70 days.
219193180|NCT04452721|OTHER|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
219193181|NCT06636370|DIAGNOSTIC_TEST|Contrast-enhanced mammography (CEM)|This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
219193182|NCT06636370|DIAGNOSTIC_TEST|Abbreviated MRI (AB-MRI)|This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
219193183|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
219193184|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
219193185|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
219193186|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
219434145|NCT02623491|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
219193187|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
219762339|NCT05321719|BEHAVIORAL|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
218859563|NCT03344627|DRUG|Meropenem standard dose|"* Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
218859564|NCT03344627|DRUG|Meropenem high dose|"* Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
219193188|NCT04160013|BEHAVIORAL|Discipline education|Discipline education using the Play Nicely program.
219193189|NCT04160013|BEHAVIORAL|Cavity Prevention|Cavity prevention using a 2 page handout.
219434146|NCT02623491|DRUG|Placebo|Participants will receive matching placebo.
219434147|NCT04344704|OTHER|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
219434148|NCT00834925|DRUG|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
219193190|NCT03500081|DEVICE|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
219193191|NCT03292484|BIOLOGICAL|AR101|AR101
219193192|NCT06142773|DEVICE|Tidal Volume set on ventilator|Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
219193193|NCT06485089|DRUG|tirzepatide|Women taking tirzepatide as part of standard care in the Weight Managment Clinic
219193194|NCT05438407|DRUG|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
219193195|NCT06180317|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
219193196|NCT06476392|DRUG|Melatonin 10 MG|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
219193197|NCT06476392|DRUG|Placebo|2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
219193198|NCT05290493|DRUG|NB-001|Non-stimulant modulator of metabotropic glutamate receptors (mGluRs)
219193199|NCT05290493|OTHER|Placebo|Matching, inactive placebo
219193200|NCT06071234|PROCEDURE|3D reconstruction technology|Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.
219193201|NCT03308578|DRUG|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
219193202|NCT03308578|DRUG|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
219193203|NCT06211933|PROCEDURE|HIFU intervention|HIFU intervention on non resectable pancreatic lesions at day 0 for each patient included
219434149|NCT00133185|DRUG|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
219193204|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
219193205|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
219434150|NCT00133185|DRUG|losartan 50 mg/hydrochlorothiazide 12.5 mg|
219193206|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
219193207|NCT04608318|BIOLOGICAL|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
219193208|NCT04608318|BIOLOGICAL|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
219193209|NCT04608318|BIOLOGICAL|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
219193210|NCT04400331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219193211|NCT05331729|RADIATION|FMISO-PET Protocol|"* injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT"
219193212|NCT06165172|DEVICE|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
219193213|NCT03804788|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
219193214|NCT03804788|BEHAVIORAL|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
219193215|NCT04615273|DRUG|Lonapegsomatropin|Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
219193216|NCT04615273|OTHER|Placebo|The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
219193217|NCT04615273|DRUG|Somatropin|Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
219193218|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures.
219193219|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files.
219193220|NCT05769283|OTHER|Platelet Rich Plasma|Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
219193221|NCT05769283|OTHER|Saline|Normal Saline to be injected into the anterior vaginal wall and periclitoral area
219434151|NCT03274245|BEHAVIORAL|Intervention Package|"* Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional."
219193222|NCT03677141|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
219434152|NCT03274245|OTHER|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
219434153|NCT03293186|COMBINATION_PRODUCT|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
219434154|NCT00117728|DRUG|nevirapine|
219193223|NCT03677141|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
219193224|NCT03677141|DRUG|Rituxumab|Participants will receive rituxumab via IV.
219193225|NCT03677141|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
219193226|NCT03677141|DRUG|Doxorubicin|Participants will receive doxorubicin via IV.
219434155|NCT06269588|DEVICE|Nexpowder|Endoscopic hemostasis
219434156|NCT01771367|BIOLOGICAL|Fluad|
219193227|NCT03677141|DRUG|Vincristine|Participants will receive vincristine via IV.
219193228|NCT03677141|DRUG|Prednisone|Participants will receive oral prednisone.
219193229|NCT03677141|DRUG|Tocilizumab|Participants will receive tocilizumab via IV.
219193230|NCT05498675|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
219193231|NCT05498675|DRUG|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
219193232|NCT05834777|DRUG|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
219193233|NCT05834777|DRUG|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
219193234|NCT05465239|DEVICE|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
219193235|NCT05094271|OTHER|Supplemental Oxygen|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
219434157|NCT01771367|BIOLOGICAL|Agrippal|
219434158|NCT01771367|BIOLOGICAL|Placebo|
219434159|NCT05897060|DEVICE|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
219434160|NCT02920450|DRUG|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
219193236|NCT05094271|DEVICE|Continuous Positive Airway Pressure Machine|Continuous positive airway pressure is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of a person.
219193237|NCT05094271|OTHER|Room Air|Subjects will be instrumented with a nasal cannula to receive 2L/min pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
219434161|NCT02920450|DRUG|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
219193238|NCT05918120|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
219434162|NCT02920450|DRUG|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
219434163|NCT05813613|OTHER|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
219434164|NCT01763983|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
219434165|NCT01763983|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
219434166|NCT03199742|BEHAVIORAL|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
219762340|NCT05321719|BEHAVIORAL|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
219434167|NCT03199742|BEHAVIORAL|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
219193239|NCT05918120|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
219193240|NCT05457478|OTHER|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
219193241|NCT05457478|OTHER|Questionnaire Administration|Ancillary studies
219193242|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
219193243|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
219007502|NCT01754623|OTHER|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
219007503|NCT01754623|PROCEDURE|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
219007504|NCT01754623|DRUG|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
219193244|NCT03947697|OTHER|Resistance Training|Group will receive exercise training.
219193245|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
219193246|NCT04743856|BEHAVIORAL|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
219193247|NCT04743856|BEHAVIORAL|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
219193248|NCT03344965|DRUG|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
219193249|NCT03018366|DRUG|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
219434168|NCT02532569|BIOLOGICAL|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
219434169|NCT05729269|DIAGNOSTIC_TEST|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
219434170|NCT00968708|DRUG|Alogliptin|Alogliptin tablets
219434171|NCT00968708|DRUG|Placebo|Alogliptin placebo matching tablets
219434172|NCT03632304|PROCEDURE|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
219434173|NCT00704431|DRUG|SB-480848 (darapladib)|160 mg darapladib
219434174|NCT01539213|DRUG|secukinumab (AIN457)|anti-IL-17 antibody
219434175|NCT00056836|DRUG|rhuFab V2 (ranibizumab)|
219434176|NCT01732107|DRUG|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
219434177|NCT03789968|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
219434178|NCT03891615|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
219434179|NCT03891615|DRUG|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
219007505|NCT05230290|BIOLOGICAL|KD6001 Injection|Solution for intravenous injection
219434180|NCT01627223|DRUG|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
219193250|NCT03018366|DRUG|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
219193251|NCT03018366|DRUG|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
219434181|NCT01627223|DRUG|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
219434182|NCT04746209|DEVICE|Alpha/Beta T-cell and B-cell depleted HCT|Device: Alpha/Beta T-cell and B-cell depletion
219434183|NCT04746209|DRUG|Blinatumomab|28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
219434184|NCT06452368|DEVICE|facemask|Fixation of miniplates by four screws in the maxilla and protraction by using facemask
219193252|NCT03018366|DRUG|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
219193253|NCT01853631|GENETIC|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2"
219578849|NCT04235452|DIAGNOSTIC_TEST|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
219578850|NCT00578981|BEHAVIORAL|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
219578851|NCT00448136|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
219578852|NCT00448136|DRUG|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
219578853|NCT00448136|DRUG|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
219007506|NCT03220360|PROCEDURE|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
219193254|NCT01853631|GENETIC|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
219193255|NCT04542616|DEVICE|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
219193256|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
219193257|NCT05739253|PROCEDURE|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
219434185|NCT00871936|DRUG|SLx-4090|SLx-4090
219434186|NCT00871936|OTHER|Placebo|matching tablets
219434187|NCT00871936|DRUG|Metformin|
219434188|NCT04466813|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
219434189|NCT04466813|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
219434190|NCT01153672|DRUG|vorinostat|Given PO
219434191|NCT01153672|OTHER|laboratory biomarker analysis|Correlative studies
219434192|NCT01153672|PROCEDURE|biopsy|Optional correlative studies
219434193|NCT01153672|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
219434194|NCT01153672|PROCEDURE|positron emission tomography|Correlative studies
219578854|NCT00448136|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
219578855|NCT00609466|DRUG|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
219578856|NCT00609466|DRUG|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
219578857|NCT00609466|DRUG|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
219578858|NCT04684303|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
219007507|NCT03220360|PROCEDURE|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
219007508|NCT03220360|PROCEDURE|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
219578859|NCT04684303|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
219007509|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
219007510|NCT01507597|DRUG|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
219193258|NCT04251481|RADIATION|PET/MRI with FDG|For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
219434195|NCT01153672|DRUG|anastrozole|Given PO
219434196|NCT01153672|DRUG|letrozole|Given PO
219434197|NCT01153672|DRUG|exemestane|Given PO
219434198|NCT01153672|GENETIC|gene expression analysis|Correlative studies
219434199|NCT00374270|BEHAVIORAL|Lifestyle Counselling; Opinion Leader Influence Statements|
219193259|NCT04251481|RADIATION|MRI scan without contrast|MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
219193260|NCT04251481|RADIATION|MRI with gadolinium|For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
219193261|NCT06805968|OTHER|High Intensity Exercise + Placebo|high intensity exercise
219193262|NCT06805968|OTHER|Low Intensity Exercise + Placebo|low intensity exercise
219193263|NCT06804382|BEHAVIORAL|Academic detailing|Academic detailing is an evidence-based, 1-on-1 outreach education technique intended to promote clinician behavior change. Information gained during earlier focus groups will be used to develop study-specific materials.
219193264|NCT05569772|DRUG|Semaglutide Pen Injector|maintenance dose of 1mg SC once weekly
219193265|NCT05569772|DRUG|Semaglutide placebo|maintenance dose of 1mg SC once weekly
219434200|NCT02899624|BIOLOGICAL|Extra blood draw samples|
219434201|NCT02899624|BIOLOGICAL|additional tissue samples|
219007511|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
219434202|NCT00615459|DRUG|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
219007512|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
219434203|NCT00615459|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
219434204|NCT00615459|DRUG|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
219007513|NCT04768595|DIETARY_SUPPLEMENT|Placebo|Two, 1g capsules taken daily with food
219193266|NCT06806124|DEVICE|Elevation Training Mask|The Elevation Training Mask (ETM) 2.0 was used in all 36 training sessions over the 12 weeks of the study with progressive increases in air restriction to simulate altitude training. This methodology of using ETM during exercise was chosen following the study by Porcari et al. The first week, the additional altitude simulation was 914 m and in the second, 1,829 m. These initial 2 weeks served to adjust the use of the ETM during training, as a process of acclimatization to the altitude simulation and airflow restriction. For the period between weeks 3 and 6 (both inclusive) the simulated altitude was 2,743 m, and for weeks 7-12 (both inclusive), the ETM was set to simulate 3658 m altitude.
219193267|NCT06806124|DEVICE|Sham Elevation Training Mask|For the Control Group, the Elevation Training Mask (ETM) 2.0 was used for 12 weeks with the largest openings available and without using the air restriction filters, so that there was little respiratory obstruction and the reduction in air flow was minimal, with the aim of having a simulated ETM treatment
219193268|NCT06805799|OTHER|Follow up to Mindfulness RCT using a Still Face Paradigm|Mothers who participated in an RCT of mindfulness to prevent hypertensive disorders of pregnancy and their infants at 6 months of age will attend one session in which they are consented and prepared for the Still Face Paradigm (SFP). The SFP consists of a sequence of three, 2-minute episodes in which the parent and the infant are seated about one meter away from each other. Across a pre-task baseline, task episodes (free play and still-face), and recovery periods, mothers and infants will wear wireless heart rate monitors to assess respiratory sinus arrhythmia and heart rate. At 12 months, mothers will complete lab work to assess cardiovascular risk and infants' growth velocity will be culled from pediatric medical records.
219434205|NCT02731976|OTHER|Dietary intervention|
219434206|NCT01150760|DRUG|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
219007514|NCT04768595|DIETARY_SUPPLEMENT|Ceto 10|Two, 1g capsules daily with food
219007515|NCT04768595|DIETARY_SUPPLEMENT|Fish oil|Two, 1g capsules daily with food
219007516|NCT02215187|BEHAVIORAL|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
219007517|NCT02215187|BEHAVIORAL|Attention Control|Social contact control (health education/no skill training)
219193269|NCT06804941|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
219434207|NCT03242304|OTHER|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
219434208|NCT04433156|DRUG|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219434209|NCT04433156|DRUG|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219434210|NCT04433156|DRUG|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219434211|NCT04433156|DRUG|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219434212|NCT04433156|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
219434213|NCT00490867|DRUG|Alpha lipoic acid|
219193270|NCT06804941|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
219193271|NCT06804460|BEHAVIORAL|Dietary intervention|The vegan mediterranean diet is mainly composed of whole plant-based foods, similar a una dieta mediterránea, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.
219434214|NCT01878240|PROCEDURE|EVAR without coils embolization/ Coils embolization during EVAR|
219434215|NCT04119401|PROCEDURE|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
219578860|NCT06456437|DEVICE|Post-conditioning Balloon dilation and contraction|The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
219578861|NCT02654171|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
219578862|NCT02654171|DRUG|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
219578863|NCT04216615|BEHAVIORAL|preoperative anxiety|patients who are anxious
219578864|NCT02287493|OTHER|Pharmacokinetic Analysis|
219578865|NCT01148641|DIETARY_SUPPLEMENT|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
219578866|NCT00453427|DRUG|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
219762341|NCT05321719|BEHAVIORAL|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
219193272|NCT06805981|OTHER|telerehabilitation group|Asynchronous exercise videos were sent for follow-up for 8 weeks.
219193273|NCT06805981|OTHER|conventional rehabilitation group|An exercise brochure with exercises to be followed for 8 weeks was given.
219434216|NCT04119401|PROCEDURE|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
219434217|NCT06122753|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
219193274|NCT06805916|BEHAVIORAL|NAO-Assisted Therapy|The intervention sessions included tasks designed to engage the child in verbal and social interactions, such as naming objects, responding to questions, and performing gestures. The NAO robot provided consistent and predictable feedback, while therapists supported and reinforced appropriate communicative behaviors.
219193275|NCT06805916|BEHAVIORAL|Standard therapeutic|Standard therapeutic approaches included exercises aimed at improving verbal communication and social engagement, such as naming objects, sentence construction, and comprehension tasks. Therapists adapted the intervention to the child's individual communication goals.
219193276|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
219193277|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
219434218|NCT06122753|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
219434219|NCT03358498|OTHER|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
219434220|NCT02987244|DRUG|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
219434221|NCT02987244|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
219193278|NCT04972942|DRUG|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)"
219193279|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
219193280|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
219193281|NCT04961593|DRUG|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
219193282|NCT06836921|OTHER|Standard of Care (Investigator Choice)|Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.
219199562|NCT06875336|DIAGNOSTIC_TEST|biomarker analysis|"PAXgene blood for RNA will be collected and stored. Results from these additional examinations are not included in the treatment monitoring of the patient concerned. If M. tuberculosis can be cultivated, strains will be stored for genotyping and whole genome sequencing. Serum biomarkers will be tested using commercially available kits.~In addition, TAM-TB assays will be performed from samples stored at each time-point. For this purpose, PBMCs will be collected and frozen using well-established protocols."
219434222|NCT02987244|DRUG|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
219434223|NCT02987244|DRUG|Vindesine|vindesine (4mg)was administered intravenously on d1;
219578867|NCT05203666|OTHER|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
219007518|NCT01343498|DRUG|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
219007519|NCT02952781|DEVICE|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
219007520|NCT00002581|DRUG|cyclophosphamide|
219193283|NCT06836921|OTHER|MDC visit|"The multidisciplinary clinic visit will use a shared appointment model and will include a specialized team comprising movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist (PT), an occupational therapist (OT), a speech-language pathologist, and a social worker. Care will be delivered in an outpatient setting at a University Hospital. Prior to the initial visit, patients with APS and their care partners will receive a pre-visit questionnaire to identify their top three care priorities.~During the visit, the multidisciplinary team will convene with the patient and their care partner in a single appointment room. The session will begin by addressing each of the priority issues identified by the patient and care partner. The team will collaboratively discuss management strategies, focusing on self-management, and will provide real-time guidance and recommendations. As indicated, hands-on PT and OT evaluatio"
219193284|NCT04508582|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
219434224|NCT02987244|DRUG|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
219578868|NCT04001920|OTHER|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
219007521|NCT00002581|DRUG|fluorouracil|
219434225|NCT02987244|DRUG|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
219578869|NCT02198326|DRUG|BIBN 4096 BS- in single rising doses|
219578870|NCT02198326|DRUG|Placebo|
219762342|NCT05321719|BEHAVIORAL|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
219762343|NCT06486441|DRUG|Sacituzumab govitecan-hziy|Administered intravenously
219007522|NCT00002581|DRUG|methotrexate|
219193285|NCT04508582|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart with ultrasound.
219434226|NCT02801006|DEVICE|stenfilcon A|contact lens
219434227|NCT02801006|DEVICE|etafilcon A|contact lens
219578871|NCT03407430|DRUG|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
219762344|NCT06486441|DRUG|Doxorubicin|Administered intravenously
219762345|NCT06486441|DRUG|Paclitaxel|Administered intravenously
219007523|NCT00002581|DRUG|tamoxifen citrate|
219007524|NCT00002581|PROCEDURE|conventional surgery|
219007525|NCT00002581|RADIATION|radiation therapy|
219007526|NCT01306591|DRUG|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
219007527|NCT01306591|DRUG|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
219007528|NCT04219943|PROCEDURE|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
219007529|NCT01302093|DRUG|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
219007530|NCT01302093|DRUG|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
219007531|NCT02299297|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
219007532|NCT03951844|DEVICE|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
219007533|NCT02480114|OTHER|Educational Intervention|Undergo oral care and pain management education session
219007534|NCT02480114|DRUG|Gabapentin|Given PO
219007535|NCT02480114|OTHER|Pain Therapy|Receive usual oral health care
219007536|NCT02480114|OTHER|Quality-of-Life Assessment|Ancillary studies
219007537|NCT02480114|OTHER|Questionnaire Administration|Ancillary studies
219007538|NCT02480114|DRUG|Oxycodone/Acetaminophen|Analgesia
219434228|NCT00251186|DRUG|Capecitabine and Cetuximab|
219434229|NCT01975675|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
219434230|NCT01975675|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
219434231|NCT00224003|DRUG|Sodium Ferric Gluconate Complex in Sucrose.|
219434232|NCT03225937|DRUG|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
219193286|NCT04508582|DIAGNOSTIC_TEST|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
219193287|NCT03866967|BIOLOGICAL|AK105|intravenous (IV) infusion
219193288|NCT04889521|OTHER|No intervention|No intervention. Study is cross-sectional observational.
219193289|NCT06434441|PROCEDURE|Autogenous bone augmentation|Maxillary alveolar bone reconstruction
219193290|NCT05165628|COMBINATION_PRODUCT|CYP-006TK|CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
219193291|NCT06649383|DEVICE|Virtual reality|Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
219193292|NCT06649201|OTHER|Vulvovaginal Symptom Questionnaire|Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.
219434233|NCT03225937|DRUG|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
219434234|NCT00567957|DRUG|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
219434235|NCT00567957|DRUG|Saline|same volume iv bolus before induction followed by same volume infusion
219434236|NCT03104985|DEVICE|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
219434237|NCT03104985|OTHER|Conventional therapy|"* An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment"
219434238|NCT05189704|DRUG|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
219434239|NCT05189704|DRUG|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
219434240|NCT03538275|OTHER|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
219434241|NCT05124340|BIOLOGICAL|BCG vial vaccine|Intradermal injection
219434242|NCT05124340|BIOLOGICAL|BCG ampoule vaccine|Intradermal injection
219434243|NCT03520725|OTHER|No Intervention|This gruop did not have an intervention
219434244|NCT03520725|DIETARY_SUPPLEMENT|Pineapple snack bar|30 g daily of pineapple snack bar
219193293|NCT06649201|DIAGNOSTIC_TEST|Vaginal Microbiome Evaluation|A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant.
219193294|NCT06647862|DRUG|IMM01|IV infusion
219193295|NCT06647862|DRUG|Azacitidine|subcutaneous injection
219193296|NCT06647862|DRUG|Placebo|IV infusion
219193297|NCT06852456|DRUG|Iparomlimab and Tuvonralimab (QL1706)Injection|PD-1/CTLA-4
219193298|NCT06852456|DRUG|Paclitaxel|Chemotherapy
219193299|NCT06852456|DRUG|Cisplatin|Chemotherapy
219193300|NCT01946386|DRUG|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
219193301|NCT01946386|DRUG|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
219193302|NCT01946386|DRUG|LEO 90100 Aerosol, foam, vehicle|
219193303|NCT01946386|DRUG|Daivobet® ointment|
219193304|NCT01946386|DRUG|Dermovate® cream|
219193305|NCT01946386|DRUG|Synalar® ointment|
219193306|NCT02398747|DRUG|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
219193307|NCT00875888|DEVICE|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
219193308|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
219193309|NCT06575738|DRUG|Injectable semaglutide|Subcutaneous weekly injectable semaglutide
219193310|NCT06575738|BEHAVIORAL|Standard postoperative care|Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
219193311|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
219193312|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
219193313|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
219193314|NCT06432309|DRUG|Opicapone 50 mg|Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
219193315|NCT06432309|DRUG|Duodopa|Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
219193316|NCT06299319|DRUG|Psilocybin|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
219434245|NCT03520725|DIETARY_SUPPLEMENT|Mango snack bar|30 g daily of mango snack bar
219578872|NCT03407430|DRUG|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
219434246|NCT03340311|DEVICE|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
219193317|NCT06573554|DEVICE|Total Contact Cast|Knee High Fiber Glass Total contact Cast
219193318|NCT06573554|DEVICE|Posterior Slab|Posterior Slab Knee high non walking
219193319|NCT06374147|DEVICE|SVS mattress|The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
219193320|NCT06416020|BEHAVIORAL|HC-MOUD Only|MOUD with buprenorphine provided in a hub buprenorphine clinic
219193321|NCT06416020|BEHAVIORAL|BT-MOUD with Buprenorphine|MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
219193322|NCT05032963|BEHAVIORAL|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
219193323|NCT01627301|DEVICE|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
219193324|NCT01627301|DEVICE|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
219193325|NCT01627301|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
219434247|NCT01202760|DRUG|LY2127399|
219193326|NCT01627301|DEVICE|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
219193327|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
219199563|NCT06874387|OTHER|Hypoxia, intermittent|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate) and Intermittent Hypoxia (maintained between 80-90% during hypoxic phases)
219434248|NCT01202760|DRUG|Placebo|
219434249|NCT03018457|DEVICE|ISQ|Measured by Osstell.
219434250|NCT02483689|DRUG|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
219434251|NCT02483689|OTHER|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
219578873|NCT06168435|OTHER|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
219578874|NCT04445779|DIETARY_SUPPLEMENT|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
218859565|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
219578875|NCT00192855|DRUG|Entacapone|Entacapone 600mg BID
218859566|NCT00592332|DRUG|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
218859567|NCT00592332|OTHER|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
219007539|NCT02480114|DRUG|Hydrocodone/Acetaminophen|Analgesia
219193328|NCT06642324|DIAGNOSTIC_TEST|Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing|Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
219193329|NCT05443906|BEHAVIORAL|Home exercise|Exercise to address limitations impacting walking
219193330|NCT04599634|DRUG|Obinutuzumab|Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
219193331|NCT04599634|DRUG|Venetoclax|For follicular lymphoma (FL) patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL (Marginal Zone Lymphoma), MCL (Mantle Cell Lymphoma) or CLL (Chronic Lymphocytic Leukemia) patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
219434252|NCT02483689|DRUG|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
219434253|NCT02483689|OTHER|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
219434254|NCT00871572|DRUG|LY2409021|4 capsules by mouth taken once daily for 12 weeks
219434255|NCT00871572|DRUG|Placebo|4 capsules by mouth once daily for 12 weeks
219434256|NCT01577199|DRUG|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
219434257|NCT01577199|DRUG|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
219434258|NCT00735670|DRUG|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
219193332|NCT04599634|DRUG|Magrolimab|Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
219193333|NCT04599634|DRUG|Acetaminophen|Premedication with 650mg acetaminophen 30-60 minutes prior to obinutuzumab doses.
219193334|NCT04599634|DRUG|Diphenhydramine|Premedication with 25-50mg diphenhydramine 30-60 minutes prior to obinutuzumab doses.
219193335|NCT04599634|DRUG|Prednisone/prednisolone|Premedication with 100mg intravenous prednisone/prednisolone 30-60 minutes before obinutuzumab infusion.
219193336|NCT04599634|DRUG|Methylprednisolone|Premedication with intravenous methylprednisolone 80mg 30-60 minutes before obinutuzumab infusion.
219193337|NCT04599634|DIAGNOSTIC_TEST|CT Scan chest/abdomen/pelvis|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
219193338|NCT04599634|DIAGNOSTIC_TEST|MRI|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
219193339|NCT04599634|DIAGNOSTIC_TEST|18-FDG-PET|Baseline, Cycle -1, Day 1, window Cycle -1/pre cycle 1, cycles 6-12, end of treatment and follow-up.
219762346|NCT06196853|DRUG|Aminophylline|Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
219007540|NCT02480114|DRUG|Fentanyl|Transdermal Analgesia
219007541|NCT02480114|DRUG|Ibuprofen|NSAID Analgesia
219007542|NCT02480114|DRUG|Magic Mouthwash|Oral Solution to treat mucositis
219193340|NCT04599634|PROCEDURE|Bone Marrow Biopsy|Screening, Cycle 7-12, Day 1 and end of treatment.
219193341|NCT04599634|PROCEDURE|Bone Marrow Aspiration|Screening, Cycle 7-12, Day 1 and end of treatment.
219193342|NCT03424850|RADIATION|HDR brachytherapy|"* Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%"
219434259|NCT00735670|OTHER|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
219434260|NCT02828007|DEVICE|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
219434261|NCT05713578|DRUG|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
219762347|NCT05571319|DRUG|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
219762348|NCT04716595|DRUG|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
219762349|NCT04716595|DRUG|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
219762350|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
219762351|NCT03290950|DRUG|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
219762352|NCT03290950|DRUG|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
219762353|NCT03290950|DRUG|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
219578876|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
219578877|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein)|Protein supplement as needed
219762354|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
219762355|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
219193343|NCT01878422|DRUG|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
219193344|NCT01878422|DRUG|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
219193345|NCT01878422|DRUG|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
219193346|NCT01878422|DRUG|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
219434262|NCT05713578|DRUG|apantamide+ADT treatment|apantamide+ADT treatment
219434263|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone
219193347|NCT03714815|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
219578878|NCT02794155|DRUG|HDV Insulin Lispro|HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
219578879|NCT02794155|DRUG|Insulin LISPRO|Insulin Lispro: no bound insulin
219007543|NCT00213798|PROCEDURE|Biopsy samples|
219007544|NCT00664391|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
219007545|NCT01535053|BIOLOGICAL|Dactinomycin|Given IV
219193348|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
219578880|NCT00770536|DRUG|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
219578881|NCT00770536|DRUG|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
219193349|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
219193350|NCT06532630|GENETIC|Anti-CD19-CAR-T cells|"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."
219578882|NCT00770536|DRUG|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
219762356|NCT06029270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762357|NCT06029270|PROCEDURE|Bone Scan|Undergo bone scan
219762358|NCT06029270|DRUG|Carboplatin|Given IV
219762359|NCT06029270|DRUG|Cisplatin|Given IV
219762360|NCT06029270|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219762361|NCT06029270|DRUG|Gemcitabine|Given IV
219762362|NCT06029270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762363|NCT06029270|BIOLOGICAL|Nivolumab|Given IV
219007546|NCT01535053|DRUG|Leucovorin Calcium|Given PO
219007547|NCT01535053|DRUG|Methotrexate|Given IV and IM
219007548|NCT01535053|OTHER|Quality-of-Life Assessment|Ancillary studies
219007549|NCT01627522|PROCEDURE|TURP|Transurthral resection of prostate
219007550|NCT00512707|DRUG|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
219007551|NCT00512707|DRUG|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
219007552|NCT00512707|OTHER|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
219007553|NCT02642328|OTHER|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
219434264|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
219434265|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with nivolumab combination
219434266|NCT03679429|DEVICE|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
219578883|NCT00770536|DRUG|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
219578884|NCT02775136|DEVICE|HS-1000 recording|
219578885|NCT03510182|DEVICE|transcranial direct current stimulation|
219578886|NCT02185313|OTHER|visual stimulus to follow|
219762364|NCT06029270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219762365|NCT06029270|BIOLOGICAL|Relatlimab|Given IV
219762366|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
219762367|NCT00581633|OTHER|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
219762368|NCT03306173|OTHER|Commercially available cigarette|Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.
219762369|NCT03422822|DRUG|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
219762370|NCT03422822|DRUG|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
219762371|NCT03422822|DRUG|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
219762372|NCT03422822|DRUG|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
219762373|NCT03422822|DRUG|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
219762374|NCT03422822|DRUG|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
219762375|NCT05600777|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
219762376|NCT05600777|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
219762377|NCT05018585|BIOLOGICAL|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
219762378|NCT05018585|DIETARY_SUPPLEMENT|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
219762379|NCT05018585|BIOLOGICAL|Placebo|Placebo for Diamyd, Alhydrogel® only
219434267|NCT04354155|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
219434268|NCT00187889|DRUG|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
219193351|NCT06532630|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
219193352|NCT06532630|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
219193353|NCT04409457|OTHER|fasting state|16 hours of fasting
219007554|NCT02642328|OTHER|Control|Continuous aerobic exercise at 65% of VO2Max
219007555|NCT01083368|DRUG|temsirolimus|Given IV
219007556|NCT01083368|BIOLOGICAL|bevacizumab|Given IV
219193354|NCT04409457|OTHER|fed state|fed a standardized meal
219007557|NCT01083368|GENETIC|polymorphism analysis|Correlative studies
219434269|NCT00187889|DRUG|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
219434270|NCT06299813|DRUG|Bentelan|The experimental treatment group will be administered betamethasone 0.1 mg per kg.
219434271|NCT06299813|DRUG|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
219434272|NCT00036543|DRUG|Atrasentan|
219434273|NCT04572581|OTHER|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
219434274|NCT04197986|DRUG|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
219434275|NCT04197986|DRUG|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
219434276|NCT05693038|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
219434277|NCT05693038|DIAGNOSTIC_TEST|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
219434278|NCT00979680|RADIATION|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
219434279|NCT00979680|RADIATION|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
219434280|NCT04248062|OTHER|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
219434281|NCT06303492|PROCEDURE|GUS|Aspiration risk assessment by GUS
219434282|NCT03380624|DRUG|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
219434283|NCT03380624|DRUG|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
219434284|NCT02576015|PROCEDURE|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
219193355|NCT04409457|OTHER|magnetic resonance imaging|neuroimaging with computational modeling
219193356|NCT05674851|OTHER|MRI|collection of MRI scans for mathematical model development
219193357|NCT05776875|DRUG|Atezolizumab Injection|Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).
219434285|NCT02576015|PROCEDURE|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
219434286|NCT02576015|DRUG|lidocaine|
219193358|NCT05776875|DRUG|Bevacizumab|Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
219193359|NCT05776875|COMBINATION_PRODUCT|Transarterial chemoembolization|Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
219193360|NCT06138977|DEVICE|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
219193361|NCT05354765|OTHER|blood sample|lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression
219193362|NCT05354765|OTHER|blood sample|lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment
219193363|NCT04280458|BEHAVIORAL|Intentive rehabilitation|"Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months."
219193364|NCT04280458|BEHAVIORAL|Routine care|"Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months."
219434287|NCT02576015|DEVICE|ultrasound|
219434288|NCT02576015|DEVICE|insulated needle (Contiplex B Braun, Melsungen, Germany)|
219434289|NCT02576015|DRUG|ropivacaine|
219434290|NCT02576015|DRUG|saline|
219434291|NCT02650297|OTHER|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
219193365|NCT06731621|DRUG|Psilocybin|"2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021)."
219193366|NCT06359002|DRUG|BYON4413|BYON4413 will be administered by IV infusion.
219193367|NCT03204916|BEHAVIORAL|Discussion|Participate in focus group
219193368|NCT03204916|OTHER|Medical Chart Review|Data abstraction and central review
219193369|NCT03204916|OTHER|Questionnaire Administration|Complete questionnaire
219193370|NCT05200923|DEVICE|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
219193371|NCT06088095|OTHER|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
219193372|NCT03505008|DRUG|Methotrexate|Route of Administration: Oral
219193373|NCT03505008|DRUG|Adalimumab|Route of Administration: Subcutaneous
219193374|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
219193375|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
219193376|NCT03671044|DRUG|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
219193377|NCT04014907|PROCEDURE|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
219007558|NCT01083368|OTHER|laboratory biomarker analysis|Correlative studies
219007559|NCT04449575|OTHER|eSwabs|from skin
219434292|NCT02650297|DEVICE|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
219434293|NCT02557854|DRUG|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
219434294|NCT02557854|DEVICE|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
219193378|NCT06015659|DRUG|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
219193379|NCT06015659|DRUG|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
219434295|NCT05750420|OTHER|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
219434296|NCT04953065|OTHER|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
219434297|NCT00108797|DRUG|eptacog alfa (activated)|
219434298|NCT00108797|DRUG|Feiba VH|
219434299|NCT03891394|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
219193380|NCT06350500|BEHAVIORAL|Patient Navigation|Receive patient navigation
219193381|NCT06350500|OTHER|Questionnaire|Ancillary studies
219193382|NCT06068413|DEVICE|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
219193383|NCT06452914|DEVICE|Semiconductor Embedded Therapeutic Socks|Semiconductor Embedded Therapeutic Socks
219193384|NCT06452914|DEVICE|Placebo Socks|Socks not containing the Semiconductor Embedded Therapeutic fabric
219193385|NCT03989778|DRUG|Vitamin D|Vitamin D supplementation
219578887|NCT03627741|DRUG|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
219578888|NCT05762484|PROCEDURE|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
219578889|NCT05762484|DRUG|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
219193386|NCT03911011|OTHER|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
219434300|NCT02389686|DEVICE|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
219434301|NCT05983835|PROCEDURE|Patients receive subsegmentectomy|Patients receive lobectomy
219434302|NCT01207817|OTHER|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
219434303|NCT03134924|BEHAVIORAL|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
219434304|NCT03134924|BEHAVIORAL|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
219434305|NCT02374034|OTHER|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
219434306|NCT02543502|PROCEDURE|periodontal treatment|treatment of periodontal cleaning
219434307|NCT06100549|OTHER|No intervention|No intervention will be provided.
219434308|NCT01042951|BIOLOGICAL|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
219193387|NCT05046639|DRUG|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine. Crossover treatment 5 days later using image guided sciatic nerve anesthetic block of the contralateral limb with 10 mL preservative-free saline.
219193388|NCT05046639|DRUG|10 mL preservative free saline|"Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.~Crossover treatment 5 days later using Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine."
219193389|NCT01401751|DEVICE|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
219193390|NCT06496581|DRUG|177Lu-PMSA-617|Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
219193391|NCT06496581|DRUG|Standard of Care|ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
219578890|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
219578891|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
219578892|NCT06928948|PROCEDURE|Femur replacement|Reconstruction using the Limb Preservation System™ for segmental resection of the distal femur.
219578893|NCT06877611|DRUG|S-4321|S-4321 via subcutaneous or intravenous administration
219578894|NCT06877611|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
219007560|NCT04675645|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
219193392|NCT06052514|DEVICE|Continuous positive airway pressure|Patients with moderate or severe OSA will be treated with CPAP
219193393|NCT06014749|PROCEDURE|undergo|regional anesthesia
219193394|NCT06014749|DEVICE|ultrasound|ultrasound guided
219193395|NCT06014749|DRUG|Local anesthetic|local anesthetic
219193396|NCT05175521|OTHER|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
219193397|NCT05175521|OTHER|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
219193398|NCT02962076|DRUG|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
219193399|NCT06024083|BEHAVIORAL|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
219193400|NCT03650712|DIAGNOSTIC_TEST|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
219193401|NCT03650712|DIAGNOSTIC_TEST|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
219193402|NCT03650712|DIAGNOSTIC_TEST|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
219193403|NCT06291350|OTHER|Plaque sampling and stool collection|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
219193404|NCT06291350|OTHER|periodontal examination|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
219193405|NCT06482359|BIOLOGICAL|coformulated CIC Vaccine|SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)
219193406|NCT06482359|BIOLOGICAL|Fluzone HD trivalent|60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
219193407|NCT05693701|BEHAVIORAL|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
219193408|NCT05693701|OTHER|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
219193409|NCT04741776|BEHAVIORAL|Resilience Enhancement Skills Training|Family therapy
219193410|NCT04741776|BEHAVIORAL|Problem-Solving Individual Therapy|Individual therapy
219193411|NCT04089865|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
219193412|NCT05660512|PROCEDURE|Intracept Procedure|Radiofrequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
219193413|NCT04093583|PROCEDURE|Exodontia|Atraumatic exodontia followed by simple suture
219193414|NCT04093583|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
219762380|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
219762381|NCT06094491|BEHAVIORAL|Virtual Group Visit|Group visits must have these core components: diabetes education, group social support and goal setting.
219193415|NCT04093583|DEVICE|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
219434309|NCT01042951|OTHER|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
219193416|NCT05623306|DEVICE|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
219193417|NCT05623306|DEVICE|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
219193418|NCT03868579|PROCEDURE|Biopsy|Undergo biopsy
219434310|NCT01597011|PROCEDURE|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
219434311|NCT01597011|PROCEDURE|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
219434312|NCT04480931|BEHAVIORAL|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
219434313|NCT04480931|BEHAVIORAL|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
219434314|NCT03097029|DRUG|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
219007561|NCT03482440|DRUG|Salsalate Oral Tablet|1500mg twice daily for 4 days prior to experimental testing
219007562|NCT03482440|DRUG|Placebo Oral Tablet|Placebo oral table twice daily for 4 days prior to experimental testing
219007563|NCT01954602|PROCEDURE|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
219578895|NCT06855030|OTHER|Scoliosis Specific Exercise|In the first session, the individual and their family will learn about AIS, the specific curvature, and the treatment process. They will also be taught correct posture and active self-correction, which means finding the best alignment in three planes. Once the individual becomes confident in their self-correction, they will start exercises. In the SEAS method, exercises begin in a sitting position, and as the individual improves, the exercises will be made more challenging and suited to their level. The rehabilitation protocol includes exercises in standing, squatting, single-leg stance, and on the floor. In each session, previous exercises will be reviewed, and new ones will be added. Individuals will be reminded to practice active self-correction during exercises and daily activities. In literature, there is no fixed protocol for exercise duration and frequency, but it is recommended to do exercises 2-3 times a week for 45 minutes or 20 minutes daily.
219762382|NCT04077723|DRUG|Englumafusp alfa|Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
219762383|NCT04077723|DRUG|Obinutuzumab|"A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III)."
218859568|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
219193419|NCT03868579|OTHER|Medical Chart Review|Review medical chart
219434315|NCT06236230|DRUG|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
219193420|NCT03868579|PROCEDURE|Thoracoscopy|Undergo pleuroscopy
219193421|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
219193422|NCT01569659|DRUG|Lurasidone|80 mg/day for up to 30 weeks
219193423|NCT01569659|DRUG|Lurasidone|Up to 240 mg/day for up to 30 weeks
219193424|NCT03687762|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
219193425|NCT03687762|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
219434316|NCT03323996|OTHER|Semi-Structured interviews|individual semi-structured interviews
219434317|NCT00411086|BIOLOGICAL|Rituximab|375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
219434318|NCT00411086|BIOLOGICAL|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
219762384|NCT04077723|DRUG|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
219007564|NCT01954602|PROCEDURE|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
219193426|NCT03687762|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
219193427|NCT05734222|PROCEDURE|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
219762385|NCT04077723|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
218859569|NCT03354624|DRUG|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
219007565|NCT05767645|DEVICE|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
218859570|NCT05934318|DIETARY_SUPPLEMENT|L-citrulline|Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring
219434319|NCT00709124|DEVICE|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
219434320|NCT00709124|DEVICE|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
219434321|NCT02758223|BIOLOGICAL|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
219434322|NCT00373490|DRUG|Vorinostat|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
219434323|NCT00373490|DRUG|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
219193428|NCT05471037|PROCEDURE|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
219434324|NCT03490435|DIAGNOSTIC_TEST|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
219434325|NCT02437552|DEVICE|ergometer cycle exercise|
219434326|NCT02437552|OTHER|routine physiotherapy|routine physiotherapy
219193429|NCT05471037|PROCEDURE|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
219193430|NCT06266299|DRUG|KK2269|KK2269 administered intravenously
219193431|NCT06266299|DRUG|Docetaxel|antineoplastic drug administered intravenously
219596878|NCT06521099|BEHAVIORAL|Evaluative Conditioning with positive stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with non-social positive stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
219193432|NCT03621254|OTHER|[LO-LONG]|Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
219193433|NCT03621254|OTHER|[HI-SHORT|One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
219193434|NCT03928002|OTHER|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
219193435|NCT03928002|PROCEDURE|Cardiac catheterization|pulmonary vascular resistance calculation ;
219193436|NCT05967390|DEVICE|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
219193437|NCT04980885|DRUG|AK117|Subjects receive AK117 intravenously.
219193438|NCT04980885|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
219193439|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
219193440|NCT03257969|BEHAVIORAL|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
219193441|NCT03257969|BEHAVIORAL|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
219762386|NCT06847542|DEVICE|Susvimo PDS Implant|Ranizumab will be administered via a PDS implant per the schedule described in the arm.
219193442|NCT05988931|BEHAVIORAL|Web Program + App|Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
219193443|NCT05988931|BEHAVIORAL|Web Program + App + Text Messages|Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
219193444|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout Each Hour|One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
219193445|NCT05316571|BEHAVIORAL|One 15-Minute Standing Bout Each Hour|One 15-minute standing break per hour throughout the 4-hour SB condition
219193446|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
219193447|NCT05316571|BEHAVIORAL|Uninterrupted Sitting|No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
219193448|NCT05526521|DRUG|Dupilumab|Injection solution Subcutaneous
219193449|NCT03824366|DEVICE|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
219193450|NCT03824366|RADIATION|Radiation therapy|-Standard of care
219193451|NCT06560502|OTHER|Standard of Care-DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219007566|NCT06897696|DRUG|Dexmedetomidine+propofol+remifentanyl group|The dexmedetomidine+TIVA group will receive a bolus of 0.8-1 µg/kg dexmedetomidine for 10 minutes followed by continuous dexmedetomidine infusion at a rate of 0.3-0.5 µg/kg/hour.
219193452|NCT06560502|OTHER|AmnioCore - DFU|Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219193453|NCT06560502|OTHER|Amnio Quad-Core - DFU|Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219434327|NCT01669642|DRUG|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
219434328|NCT00108953|DRUG|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
219596879|NCT06521099|BEHAVIORAL|Conditioning with neutral stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with with neutral non-social stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
219007567|NCT06897696|DRUG|propofol+remifentanyl group|propofol 5-8 mg/kg/h and remifentanil 5-10 µg/kg/h will be administered to all patients
219007568|NCT06848140|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
219007569|NCT06848140|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
219007570|NCT06770257|DRUG|daunorubicin, cytarabine liposomes|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
219007571|NCT06770257|DRUG|Azacitidine|Given SC on days 1-7
219007572|NCT06770257|DRUG|Venetoclax|Given PO on days 1-14 or 1-21 or 1-28
219007573|NCT05700045|DRUG|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
219007574|NCT06504901|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
219007575|NCT06504901|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
219193454|NCT06560502|OTHER|Standard of Care-VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219199564|NCT06874387|OTHER|physical exercise|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate)
219434329|NCT00108953|DRUG|Doxorubicin/Placebo|Chemotherapy plus Placebo
219434330|NCT05149612|OTHER|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
219434331|NCT05035095|DRUG|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
219434332|NCT05035095|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
219434333|NCT03934424|BEHAVIORAL|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
219434334|NCT03934424|BEHAVIORAL|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
219578896|NCT06855030|OTHER|Basic Body Awareness Therapy|"Body awareness movements will be performed in lying, sitting, and standing positions. Then, they will be varied by incorporating walking, running, and voice use. The patient will be asked to perform these movements with a specific rhythm and coordination. BBAT aims to enhance body awareness and create a more realistic body image by normalizing posture, balance, and muscle tension. The training process will involve gradually increasing awareness of the relationship with the floor, the vertical axis, centering, breathing, and flow. During this therapy process, the goal is to improve the individual's awareness of themselves and their surroundings, helping them adopt the here and now experience and later apply it in daily life. At the end of each session, time will be given for the patient to respond to their experience and express their thoughts. There is variability in the application duration in the literature."
219578897|NCT06929039|DRUG|Abatacept|Test Product (A) (Kashiv's Abatacept): KSHB002 (Abatacept) Injection, 125 mg/mL - Manufactured by: Kashiv Bioscience's LLC, USA.
219434335|NCT04503941|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
219434336|NCT04503941|DEVICE|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
219578898|NCT06929039|DRUG|Abatacept|Reference Product (B) (US-licensed ORENCIA): 'ORENCIA' (abatacept) injection 125 mg/mL - Manufactured for: Bristol-Myers Squibb Company Princeton, NJ 08543 USA.
219578899|NCT06929039|DRUG|Abatacept|Reference Product (C) (EU-authorized ORENCIA): 'ORENCIA' 125 mg solution for injection (abatacept) - Marketing Authorization Holder: Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland.
219578900|NCT01195272|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
219578901|NCT01893645|DEVICE|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
219007576|NCT06504901|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
219007577|NCT06504901|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
219007578|NCT06504901|DRUG|Neupogen|rhG-CSF 5mcg/kg HD, QD d1-d14
219007579|NCT05786885|PROCEDURE|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
219007580|NCT05786885|PROCEDURE|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
219434337|NCT01860963|PROCEDURE|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
219434338|NCT02986919|DRUG|CPI-0610|"* Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
219578902|NCT00018811|BEHAVIORAL|Relaxation training & thermal biofeedback|
219578903|NCT00018811|BEHAVIORAL|Surface EMG biofeedback|
219596880|NCT05242315|DRUG|Envarsus Oral Product|as described in arm/group description
219596881|NCT05242315|DRUG|Prograf (SOC)|Prograf (SOC)
219596882|NCT04610879|DRUG|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
219596883|NCT04610879|DRUG|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
219596884|NCT04610879|BEHAVIORAL|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
219596885|NCT00183560|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
219199565|NCT06874387|OTHER|Sham (No Treatment) hypoxia|Exposure to normoxic air (FiO₂ \~20.9%) instead of actual hypoxia.
219193455|NCT06560502|OTHER|Amnio Tri-Core - VLU|Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219193456|NCT06560502|OTHER|AmnioCore Pro|Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219596886|NCT00183560|DRUG|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
219596887|NCT00183560|DRUG|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
219193457|NCT06560502|OTHER|Amniocore Pro +|Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
219193458|NCT06017895|DRUG|doxepin solution|2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
219596888|NCT00071279|DRUG|SR34006 (idraparinux sodium) Injection|
219596889|NCT02816411|DIETARY_SUPPLEMENT|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
219596890|NCT02816411|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
219596891|NCT01577940|PROCEDURE|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
219596892|NCT01577940|PROCEDURE|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
219596893|NCT04353895|DEVICE|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
219434339|NCT03775590|PROCEDURE|Water|To evaluate using water in the treatment of atopic dermatitis
219434340|NCT03775590|PROCEDURE|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
219193459|NCT06017895|OTHER|Placebo|2.0 mL placebo sprayed to the posterior pharyngeal wall
219193460|NCT05561764|DRUG|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
219193461|NCT06560879|BIOLOGICAL|Lactobacillus casei|Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.
219193462|NCT06560879|BIOLOGICAL|Lactobacillus rhamnosus|A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.
219193463|NCT06560879|BIOLOGICAL|Bifidobacterium bifidum|B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
219434341|NCT03775590|PROCEDURE|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
219434342|NCT00702910|DRUG|Placebo|comparator
219434343|NCT00702910|DRUG|GW642444|investigational drug or placebo
219434344|NCT00702910|DRUG|Magnesium Stearate|Magnesium Stearate
219434345|NCT01154881|DRUG|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
219434346|NCT00516984|PROCEDURE|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
219434347|NCT00516984|PROCEDURE|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
219434348|NCT00516984|PROCEDURE|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
219434349|NCT04818541|DEVICE|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
219434350|NCT04818541|DEVICE|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
219434351|NCT00306241|BIOLOGICAL|HPV-16/18 L1 VLP AS04|
219434352|NCT01027013|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
219434353|NCT01027013|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
219434354|NCT00992602|DRUG|methotrexate|Given IV
219434355|NCT00992602|DRUG|liposomal cytarabine|Given IT or via LP
219434356|NCT00992602|OTHER|quality-of-life assessment|Ancillary studies
219434357|NCT00992602|OTHER|laboratory biomarker analysis|Correlative studies
219434358|NCT00210379|DRUG|rituximab|
219434359|NCT00210379|DRUG|CHOP|
219434360|NCT00210379|DRUG|intrathecal methotrexate|
219434361|NCT00210379|PROCEDURE|radiotherapy|
219434362|NCT01854593|DRUG|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
219434363|NCT01854593|PROCEDURE|Vitrectomy|vitrectomy of 25 gauge system.
219434364|NCT01854593|DEVICE|Sham injection|Sham injection one day before vitrectomy
219434365|NCT05400356|PROCEDURE|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
219434366|NCT00004685|DRUG|albuterol|
219434367|NCT00347893|PROCEDURE|Selective laser trabeculoplasty|
219434368|NCT03694054|OTHER|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
219434369|NCT00476177|BIOLOGICAL|Infusion of donor dendritic cells|Given in the outpatient setting
219434370|NCT00476177|BIOLOGICAL|Infusion of donor lymphocytes|Given in outpatient setting
219193464|NCT06560879|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
219434371|NCT03256071|DRUG|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
219193465|NCT06152614|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
219193466|NCT06152614|BEHAVIORAL|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes, and an additional 12 weeks of aerobic exercise.
219193467|NCT05372822|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
219193468|NCT05372822|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
219193469|NCT05372822|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead"
219193470|NCT05069896|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
219193471|NCT05069896|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
219193472|NCT06444698|DIETARY_SUPPLEMENT|cookies that contain 50 grams of quinoa|250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.
219193473|NCT06444698|DIETARY_SUPPLEMENT|cookies without quinoa|The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.
219193474|NCT04068831|DRUG|Talazoparib|1 mg talazoparib daily
219193475|NCT04068831|DRUG|Avelumab|800 mg avelumab every 2 weeks
219578904|NCT05250674|DEVICE|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
219578905|NCT03295318|BIOLOGICAL|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
219578906|NCT03295318|BIOLOGICAL|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
219578907|NCT03295318|BIOLOGICAL|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
219762387|NCT06847542|DRUG|Ranibizumab|"Participants will receive ranibizumab delivered through the PDS implant.~Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment."
219762388|NCT06072326|DRUG|Dapagliflozin (Forxiga®)|5 mg/day as a tablet
219762389|NCT06072326|DRUG|SC0062 strength 10mg|20 mg/day, twice daily, capsule
219762390|NCT06072326|DRUG|SC0062 and dapagliflozin|20 mg/day SC0062 10 mg twice daily as a capsule in combination with 5 mg/day dapagliflozin 5 mg as a tablet
219762391|NCT06848361|DEVICE|MPowerHub|The MPowerHub app allows participants to visualize combined trends from a continuous glucose monitor (CGM) and activity monitor as well as daily self-reports in a display that the participant can customize to overlay the behavioral data they would like to compare to intraday and daily glucose data. Summary data will be displayed over time to allow users to identify potential associations between activity, sleep, stress, diet, and medication adherence and time-in-range and blood glucose variability. Participants receive daily prompts to complete five brief questions about daily health behaviors and two weekly goals/action plans and reflections based on motivational interviewing principles.
219193476|NCT06274944|DEVICE|nasogastric tube placement pH confirmation device|Each participation will get the contents tested by the novel device and the standard of care procedure.
219193477|NCT02793999|DEVICE|Near-Infrared Spectroscopy (NIRS)|
219193478|NCT04999423|DEVICE|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
219193479|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
219193480|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
219434372|NCT03256071|DRUG|Modified BUCY|"1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
219434373|NCT02629614|DEVICE|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
219434374|NCT05445882|DRUG|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
219193481|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
219193482|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
219193483|NCT06779097|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab (IL-17A inhibitor)
219193484|NCT06777693|BEHAVIORAL|Unified Protocol|"The Unified Protocol group format involves 12 sessions focusing on goal setting and motivation, understanding emotions, mindful emotion awareness, cognitive flexibility, countering emotionat behaviours, understanding and confronting physical sensations, emotion exposure and relapse prevention.~The UP model directly approaches the patient\&#39;s emotion regulation by focusing on cognitive flexibility, exposure exercises, mindful awareness, acceptance, and other evidence-based therapeutic approaches known from cognitive-behavioural therapy (CBT), emotion-focused therapy (EFT) and mindfulness-based interventions."
219193485|NCT00323856|DRUG|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
219193486|NCT06100731|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
219578908|NCT06579261|OTHER|Core Shamanism|Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
219193487|NCT06071832|OTHER|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
219578909|NCT04319718|COMBINATION_PRODUCT|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
219578910|NCT04319718|COMBINATION_PRODUCT|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
219578911|NCT06483347|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
219578912|NCT02739945|PROCEDURE|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
219578913|NCT01288053|BIOLOGICAL|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
219578914|NCT04201886|OTHER|serum calprotectin|serum calcium binding leucocyte protein
219578915|NCT05920733|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
219434375|NCT05445882|DRUG|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
219434376|NCT05445882|BIOLOGICAL|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
219434377|NCT01331720|DRUG|hMG-HP|
219434378|NCT04132648|DRUG|Curcumin|Oral supplement one time at 2,000 mg
219434379|NCT04132648|OTHER|Placebo|Oral supplement one time at 2,000 mg
219578916|NCT06316648|DIETARY_SUPPLEMENT|whey intake group|It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
219578917|NCT06316648|PROCEDURE|control group|The patients were left fasting after 00:00.
219578918|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
219578919|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
219578920|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
219434380|NCT04695548|OTHER|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
219434381|NCT04695548|OTHER|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
219434382|NCT04695548|OTHER|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
219578921|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
219578922|NCT02068092|DRUG|Hydroxytyrosol|
219578923|NCT03684187|BEHAVIORAL|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
219578924|NCT04786548|DRUG|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
219578925|NCT06424067|DRUG|Fingolimod 0.5 milligram (mg) [Gilenya]|Oral fingolimod will be administered at a dose of 0.5 mg once a day.
219578926|NCT04196972|OTHER|Communication Intervention|Receive ECHO telementoring intervention
219578927|NCT04196972|OTHER|Questionnaire Administration|Ancillary studies
219578928|NCT04196972|OTHER|Waiting List|Placed on wait-list
219578929|NCT03607708|OTHER|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
219578930|NCT03607708|OTHER|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
219596894|NCT04353895|DEVICE|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
219596895|NCT04348695|DRUG|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
219596896|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
219596897|NCT06550544|PROCEDURE|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
219596898|NCT06550544|PROCEDURE|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
219596899|NCT01439256|BEHAVIORAL|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
219596900|NCT01439256|OTHER|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
219193489|NCT06634355|DRUG|Sugammadex|In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
219193490|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
219434383|NCT04695548|OTHER|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
219193491|NCT04691804|DRUG|Fuzuloparib , Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po"
219193492|NCT04691804|DRUG|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po"
219193493|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
219434384|NCT02522572|DRUG|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
219578931|NCT05948592|BIOLOGICAL|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
219578932|NCT05948592|OTHER|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
219434385|NCT02522572|DRUG|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
219434386|NCT02522572|OTHER|plasmapheresis|Plasmapheresis will be administered based on group assignment.
219007581|NCT04346537|DEVICE|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
219007582|NCT01134783|BEHAVIORAL|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
219007583|NCT02498860|DRUG|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
219007584|NCT02498860|DRUG|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
219007585|NCT04221009|BEHAVIORAL|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
219007586|NCT00133614|PROCEDURE|Prone Positioning|
219007587|NCT01080352|DRUG|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
219193494|NCT04116203|DRUG|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
219193495|NCT04116203|COMBINATION_PRODUCT|Fish Oil and Metformin|Combo of 2 other arms
219193496|NCT04116203|DIETARY_SUPPLEMENT|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
219434387|NCT01948869|DEVICE|Phoenix II (BAY81-2996)|
219434388|NCT01948869|DEVICE|Phoenix I (BAY81-2996)|
219434389|NCT00574444|PROCEDURE|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
219434390|NCT04237818|DIETARY_SUPPLEMENT|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
219434391|NCT04237818|DIETARY_SUPPLEMENT|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
219434392|NCT05706649|BEHAVIORAL|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
219434393|NCT02999100|DRUG|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
219434394|NCT02999100|DRUG|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
219434395|NCT02999100|DRUG|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
219434396|NCT02999100|DEVICE|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
219434397|NCT05955079|OTHER|Whole blood|3 samples (before, after surgery and before chemotherapy)
219434398|NCT00554476|DRUG|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
219434399|NCT05666882|OTHER|Non-interventional|Non-interventional
219434400|NCT02818127|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
219193497|NCT03420339|DRUG|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
219434401|NCT01385267|PROCEDURE|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
219434402|NCT03697486|BEHAVIORAL|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
219434403|NCT01664858|OTHER|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
219193498|NCT05423522|DRUG|NanoLithium® NP03|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
219193499|NCT05423522|DRUG|Placebo|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
219434404|NCT01664858|OTHER|SPECT|SPECT: Single Photon Emission Computed Tomography
219434405|NCT01664858|OTHER|CT calcium score|CT calcium score
219434406|NCT01664858|OTHER|CT coronary angiography|CT coronary angiography
219193500|NCT06543810|OTHER|Hula for Parkinson's|A feasibility study for a Hula program for Parkinson's Disease patients.
219193501|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
219434407|NCT01664858|OTHER|X-Ray coronary angiography|X-Ray coronary angiography
219434408|NCT04829266|BEHAVIORAL|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
219434409|NCT04709718|PROCEDURE|hepatectomy|liver resection taking over the liver hemangioma
219762392|NCT06848361|DEVICE|Continuous Glucose Monitor (CGM)|A CGM is a wearable device that collects frequent data on glucose levels. It includes an integrated sensor that is inserted under the skin and is connected to a small transmitter that automatically sends information to a smart device, allowing the user to track changes in glucose levels.
219193502|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
219193503|NCT04200313|OTHER|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
219193504|NCT04200313|OTHER|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
219762393|NCT06848361|DEVICE|Activity Monitor|A wearable activity monitor will be used to track activity (e.g., steps) and sleep levels. Data can be viewed on the activity monitor or a smart device.
219762394|NCT04896255|DRUG|peginterferon alpha based regimen|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
219762395|NCT04896255|DRUG|nucleos(t)ide|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
219193505|NCT06246188|DIAGNOSTIC_TEST|Cardiac MRI using Regadenoson and GE-267|Performing stress-cardiac MRI for clinical diagnostic in adult patients with suspected coronary artery disease
219193506|NCT05675865|DEVICE|cryoablation procedure|ablation procedure for VT using the investigational device
219193507|NCT06605157|BEHAVIORAL|AMUSED|Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.
219193508|NCT06605157|BEHAVIORAL|Reading Aloud|"Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study."
219193509|NCT05091112|PROCEDURE|Spinal surgery|In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
219007588|NCT04232124|BEHAVIORAL|Hypertension Management Model|"1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement"
219193510|NCT05091112|OTHER|Histology|The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
219193511|NCT04380337|DRUG|FOLFOXIRI|Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
219193512|NCT04380337|DRUG|FOLFOX regimen|Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
219193513|NCT04380337|DRUG|XELOX|Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
219193514|NCT04380337|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
219193515|NCT06368700|DEVICE|Hyalex Knee Cartilage System|Surgical implantation of the Hyalex Knee Cartilage System
219193516|NCT05759819|DEVICE|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
219193517|NCT06609148|DIETARY_SUPPLEMENT|De Simone formulation probiotic|Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
219193518|NCT06609148|DIETARY_SUPPLEMENT|Placebo|Subjects will be given a placebo for 21-24 days
219193519|NCT06489665|DIAGNOSTIC_TEST|Experimental Intervention|Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
219193520|NCT05516602|OTHER|Peer Support|"Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session."
219193521|NCT02676193|BEHAVIORAL|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
219193522|NCT04086121|DRUG|Spesolimab|Solution for SC injection
219434410|NCT03751423|DRUG|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
219434411|NCT03751423|DRUG|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
219434412|NCT03751423|DRUG|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
219007589|NCT00572702|PROCEDURE|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
219007590|NCT00572702|PROCEDURE|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
219007591|NCT04557397|DRUG|Fruquintinib|oral VEGFR inhibitor
219007592|NCT04557397|DRUG|Itraconazole|a synthetic triazole antifungal agent
219007593|NCT04557397|DRUG|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
219007594|NCT06245330|DRUG|AST-001|liquid formulation for Intravenous infusion
219434413|NCT03751423|DRUG|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
219434414|NCT03751423|DRUG|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
219434415|NCT06528808|OTHER|Simple reality simulator application|Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
219434416|NCT00860990|OTHER|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
219434417|NCT00457470|DRUG|AG-014699|
219193523|NCT03068689|PROCEDURE|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is \> 185mm HG the cuffs are inflated to 15 mmHG above that level.
219434418|NCT05883085|DRUG|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
219434419|NCT01585493|OTHER|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
219578933|NCT06499831|DIAGNOSTIC_TEST|0-(2-18F-Fluoroethyl)-L-Tyrosine|0-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (FET) is an amino acid agent derived from tyrosine that is able to cross the blood brain barrier. It has been studied primarily in diagnosis and detection of tumor recurrence in glioblastomas with emerging evidence for its use in brain metastases. Compared to conventional MRI, FET-PET has been shown to delineate geographically distinct tumor volume in newly diagnosed GBM suggesting the complementarity of the two modalities.
219434420|NCT01585493|BEHAVIORAL|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
219434421|NCT01585493|BEHAVIORAL|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
219434422|NCT01125293|DRUG|Everolimus|
219434423|NCT01125293|DRUG|Rituximab|
219434424|NCT01125293|DRUG|Bortezomib|
219434425|NCT04262622|DEVICE|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
219193524|NCT03068689|OTHER|Placebo|Placebo
219193525|NCT03193333|DRUG|PRO-122|Posology: 1 drop every 12 hours for 90 days
219193526|NCT03193333|DRUG|Timolol eye drops|1 drop every 12 hours for 90 days
219193527|NCT03193333|DRUG|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
219193528|NCT03193333|DRUG|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
219434426|NCT04262622|DEVICE|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
219434427|NCT00738829|DRUG|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
219193529|NCT03193333|OTHER|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
219193530|NCT03193333|OTHER|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
219434428|NCT00738829|DRUG|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
219193531|NCT03193333|DRUG|Krytantek|Posology: 1 drop every 12 hours for 90 days
219578934|NCT02842333|OTHER|Additional biological samples|Blood samples
219578935|NCT06084832|BIOLOGICAL|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
219578936|NCT06287801|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
219762396|NCT02969746|DRUG|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
219007595|NCT05253170|RADIATION|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
219007596|NCT05253170|RADIATION|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
219007597|NCT00677612|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
219434429|NCT00738829|BIOLOGICAL|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
219434430|NCT03411668|OTHER|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
219007598|NCT02213016|DEVICE|Transcranial Magnetic Stimulation|
219007599|NCT02213016|DEVICE|Sham Transcranial Magnetic Stimulation|
219434431|NCT03496727|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
219434432|NCT03496727|PROCEDURE|Patient controlled analgesia|Patient-controlled analgesia
219434433|NCT00357422|PROCEDURE|Operation|No drug needed
219434434|NCT00357422|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
219434435|NCT02407912|DRUG|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
219434436|NCT03279341|DRUG|polyethylene glycol|osmotic laxative
219193532|NCT05534321|RADIATION|Prophylactic Radiotherapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
219193533|NCT05534321|DRUG|Standard of care systemic therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
219193534|NCT06099093|DRUG|18F-DCFPyl|Fluorine-labeled small molecule, via intravenous infusion per protocol.
219193535|NCT06778967|DRUG|GZR18|Administered SC
219193536|NCT06778967|DRUG|semaglutide|Administered SC
219193537|NCT04444518|BEHAVIORAL|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
219193538|NCT04444518|BEHAVIORAL|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
219193539|NCT05699915|PROCEDURE|Cardiology consultation|"* Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio \> 15 and left atrial (LA) area \> 30 cm2."
219434437|NCT03279341|DRUG|Bisacodyl|stimulant laxative
219434438|NCT03279341|DRUG|Prucalopride|prokinetic
219434439|NCT06196918|DRUG|Rivaroxaban 10 MG|Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
219434440|NCT06196918|DRUG|Placebo|Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
219578937|NCT06287801|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
219007600|NCT04066673|DIAGNOSTIC_TEST|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
219007601|NCT06530225|OTHER|Education and Mentoring for Prescribing Pharmacists|Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
219434441|NCT02224638|DEVICE|TheraHoney HD|Honey
219434442|NCT02224638|DEVICE|SkinTegrity|Hydrogel
219007602|NCT00656344|OTHER|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
219007603|NCT00004482|DRUG|Cyclosporine|
219193540|NCT05699915|DIAGNOSTIC_TEST|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
219193541|NCT05699915|PROCEDURE|Non-invasive endothelial function tests|"* FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
219193542|NCT05699915|PROCEDURE|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
219578938|NCT04155034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219578939|NCT04155034|RADIATION|Prophylactic Cranial Irradiation|Undergo PCI
219193543|NCT05699915|DIAGNOSTIC_TEST|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
219578940|NCT06958926|PROCEDURE|Radical surgery for colon and rectum cancer|Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
219578941|NCT06958926|PROCEDURE|Radical surgery for colorectal cancer|Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
219193544|NCT04580914|DEVICE|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
219193545|NCT01540994|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy
219193546|NCT03580356|BIOLOGICAL|Ligelizumab|Liquid in vial
219434443|NCT02638870|DRUG|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
219434444|NCT01367860|PROCEDURE|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
219578942|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.3%|2 sprays in each nostril, twice daily for 14-day treatment period.
219578943|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.6%|2 sprays in each nostril, once daily for 14-day treatment period.
219193547|NCT03580356|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
219007604|NCT00004482|DRUG|methylprednisolone|
219007605|NCT00004482|DRUG|Muromonab-CD3|
219007606|NCT00004482|DRUG|prednisone|
219193548|NCT03580356|OTHER|Placebo|Liquid in vial
219193549|NCT03793023|DRUG|Teneligliptin 20mg|
219193550|NCT05709288|DRUG|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
219193551|NCT05359185|BEHAVIORAL|Family Wellness|https://familywellness.com/
219193552|NCT05359185|BEHAVIORAL|Career Coaching|Individualized career coaching and employment services.
219193553|NCT05359185|BEHAVIORAL|Financial Planning|Individualized financial planning services.
219578944|NCT06837233|DRUG|Placebo (twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
219578945|NCT06837233|DRUG|Pumecitinib nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
219578946|NCT06837233|DRUG|Placebo|2 sprays in each nostril, once daily for 14-day treatment period.
219578947|NCT01870882|BEHAVIORAL|Attentional retraining|
219007607|NCT03198949|DRUG|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
219007608|NCT03935009|BEHAVIORAL|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
219193554|NCT05715528|DRUG|Obeldesivir|Tablet administered orally without regard to food.
219193555|NCT05715528|DRUG|Obeldesivir Placebo|Tablet administered orally without regard to food.
219578948|NCT01870882|BEHAVIORAL|Control condition|
219578949|NCT05935436|DEVICE|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
219578950|NCT04055818|DRUG|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
219578951|NCT04476862|DRUG|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
219578952|NCT04476862|DEVICE|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
219193556|NCT04598932|DEVICE|Brillouin microscopy|The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
219193557|NCT06257901|OTHER|Interviews/Focus groups/Participatory workshops|Qualitative study (no intervention delivered)
219193558|NCT06091657|DRUG|Ketamine Hydrochloride|intravenous injection
219434445|NCT01367860|PROCEDURE|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
219578953|NCT04502758|DEVICE|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
219578954|NCT04502758|DEVICE|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
219578955|NCT06196021|OTHER|Intra-articular hyaluronic acid injection|"Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid."
219578956|NCT01045421|DRUG|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
219578957|NCT04922684|BEHAVIORAL|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
219578958|NCT00207779|DEVICE|heparin impregnated central venous catheters|
219578959|NCT06454942|DIETARY_SUPPLEMENT|Nutrient-fortified egg|Consumption of nutrient-fortified eggs with habitual diet
219434446|NCT03928860|OTHER|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
219193559|NCT04759456|OTHER|Remotely-supervised rehabilitation program|Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
219578960|NCT06454942|DIETARY_SUPPLEMENT|Regular egg with habitual diet|Consumption of regular egg with habitual diet
219578961|NCT03340753|DRUG|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
219762397|NCT05891613|DRUG|Bupivacaine Hydrochloride|20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
219762398|NCT05891613|DRUG|Liposomal Bupivacaine|20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
219762399|NCT06412029|OTHER|Non-Interventional|Non-interventional study
219762400|NCT00007150|PROCEDURE|Phlebotomy|Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
219762401|NCT06072664|BEHAVIORAL|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
219762402|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
219762403|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
219762404|NCT03228732|DRUG|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
219762405|NCT03228732|DRUG|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
219762406|NCT03228732|DRUG|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
219007609|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
219578962|NCT03340753|DRUG|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
219578963|NCT00146406|BEHAVIORAL|Project Connect|
219007610|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
219578964|NCT04551911|DRUG|Rayaldee|30 mcg calcifediol Extended-Release (ER) Capsule
219007611|NCT05654753|DRUG|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
219007612|NCT05654753|DRUG|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
219578965|NCT04551911|DRUG|Placebo|0 mcg calcifediol Extended-Release (ER) Capsule
219007613|NCT00878085|DEVICE|Robot Therapy Device|3x a week for 4 weeks
219007614|NCT00878085|BEHAVIORAL|Occupational Therapy|3x a week for 4 weeks
219007615|NCT04841902|OTHER|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
219007616|NCT04841902|OTHER|General Advice|General advice to stay healthy and active
219007617|NCT04841902|OTHER|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
219007618|NCT04597996|OTHER|web based education for students|"Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help"
219007619|NCT03556007|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
219007620|NCT03556007|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
219007621|NCT01404325|DRUG|standard therapy|centre specific CNI-based triple drug immunosuppression
219193560|NCT04689204|DRUG|CTA30X|CTA30X cell injection by intravenous infusion
219434447|NCT03734562|PROCEDURE|Ablation|Substrate-based radiofrequency catheter ablation
219434448|NCT03734562|DRUG|Antiarrhythmic drug|Amiodarone or sotalol therapy
219434449|NCT00314080|DRUG|Botulinum AntiToxin|
219434450|NCT00314080|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
219434451|NCT00314080|PROCEDURE|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
219434452|NCT02436044|PROCEDURE|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
219434453|NCT02436044|DRUG|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
219434454|NCT02436044|DRUG|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
219434455|NCT02436044|DRUG|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
219193561|NCT05285202|OTHER|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
219007622|NCT01404325|DRUG|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
219007623|NCT03025867|DRUG|Niraparib|
219578966|NCT03971149|BEHAVIORAL|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
219578967|NCT00354250|DRUG|ispinesib|Given IV
219578968|NCT00885521|OTHER|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
219578969|NCT03044041|DRUG|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
219007624|NCT03472027|BIOLOGICAL|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
219193562|NCT04116996|DEVICE|DEEP BRAIN STIMULATION|NEUROMODULATION
219193563|NCT06402383|BIOLOGICAL|Vaccination Provision|HPV vaccination #1 will be offered by provider at the first visit when the HPV self-sample is collected. HPV Vaccination #2 will be offered at 6 months for HPV negative women and at 12 months for HPV positive women.
219193564|NCT06402383|BIOLOGICAL|Vaccination Provision 2|"HPV vaccination #1 will be offered by the provider after an HPV negative result is received with vaccine #2 given at 3 months after negative test results obtained.~For HPV positive women - vaccination #1 will be offered at 12 months and vaccination #2 will be offered at the 15 month mark."
219193565|NCT03944772|DRUG|Osimertinib|Osimertinib given orally at 80 mg once daily
219193566|NCT03944772|DRUG|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
219193567|NCT03944772|DRUG|Gefitinib|Gefitinib given orally at 250 mg once daily
219193568|NCT03944772|DRUG|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
219193569|NCT03944772|DRUG|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
219193570|NCT03944772|DRUG|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
219193571|NCT03944772|DRUG|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
219193572|NCT03944772|DRUG|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
219193573|NCT03944772|DRUG|Selpercatinib|Selpercatinib given orally at 160mg twice daily
219578970|NCT02063243|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
219578971|NCT01030341|DEVICE|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
219193574|NCT03944772|DRUG|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
219193575|NCT03944772|DRUG|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
219193576|NCT03944772|DRUG|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
219193577|NCT03944772|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
219193578|NCT06574438|BEHAVIORAL|AIFIGA program|receives the Artificial Intelligence Family Involvement Generative Agent (AIFIGA) program and uses it for 3 months
219193579|NCT06461169|OTHER|stress ball|Patients squeeze the stress ball
219193580|NCT03118518|DEVICE|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
219193581|NCT03118518|DRUG|Antiarrhythmic drug|Antiarrhythmic drug initiation
219434456|NCT02540772|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
219578972|NCT03421158|BEHAVIORAL|breastfeeding|Newborns were breastfed during the procedure
219578973|NCT03421158|DIETARY_SUPPLEMENT|oral sucrose|Newborns were given oral sucrose during the procedure
219007625|NCT03451344|OTHER|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
219578974|NCT03421158|BEHAVIORAL|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
219578975|NCT03421158|BEHAVIORAL|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
219578976|NCT03880435|DEVICE|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
219578977|NCT00614809|DRUG|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
219578978|NCT04453098|BEHAVIORAL|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
219007626|NCT03451344|OTHER|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
219193582|NCT04393207|DRUG|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
219578979|NCT00507286|DRUG|combination of various doses of sildenefil and alprostadil|
219193583|NCT04393207|DRUG|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
219193584|NCT04393207|DRUG|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
219193585|NCT05412069|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
219578980|NCT03400072|OTHER|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
219762407|NCT05508867|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
219762408|NCT05508867|DRUG|bendamustine|IV infusion
219762409|NCT05508867|DRUG|gemcitabine|IV infusion
219762410|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive dose consistent injections (5x10\^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injection volume and dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1 and 57
219762411|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive a dose-consistent injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169.
219762412|NCT06205056|BIOLOGICAL|Placebo [Arm 1a]|Participants in Arm 1a will receive dose-consistent 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 1 and 57, followed by a 1.1 mL injection of Placebo on Study Day 169.
219434457|NCT01270958|DRUG|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
219578981|NCT03400072|OTHER|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
219434458|NCT02016222|PROCEDURE|tears sampling|
219434459|NCT01125540|DEVICE|Acuvue (Standard Daily Disposable Contact Lens)|
219434460|NCT01125540|DEVICE|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
219578982|NCT01752686|DRUG|carboplatin|carboplatin as adjuvant chemotherapy
219578983|NCT02731417|OTHER|acupuncture|Acupuncture for women with post partum urinary retention
219578984|NCT02731417|DEVICE|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
219578985|NCT05154630|DRUG|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
219578986|NCT04738474|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"Develops personal resilience resources through 1:1 sessions with a PRISM coach."
219193586|NCT05839587|PROCEDURE|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
219193587|NCT05839587|PROCEDURE|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
219434461|NCT01899586|OTHER|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
219434462|NCT01899586|OTHER|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
219434463|NCT02176304|DRUG|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
219434464|NCT02176304|DRUG|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
219434465|NCT00037544|DRUG|ReFacto AF|
219434466|NCT02467855|OTHER|No Intervention|No intervention was administered in this study.
219434467|NCT04688216|OTHER|risk factors of infection with multidrug-resistant organisms|"1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
219578987|NCT04738474|OTHER|Usual Care|No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
219434468|NCT03095404|DRUG|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
219578988|NCT05376709|DIETARY_SUPPLEMENT|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
219578989|NCT00687089|OTHER|Sexual, cognitive functional tests and measurement weight|
219578990|NCT02454660|BEHAVIORAL|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
219193588|NCT06197360|BEHAVIORAL|Based on BCW Theory of Health Education|Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.
219434469|NCT03095404|DRUG|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
219434470|NCT05608330|OTHER|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
219434471|NCT05608330|OTHER|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
219434472|NCT05129787|PROCEDURE|Surgical resection|Resection of metastasis
219193589|NCT06197360|BEHAVIORAL|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
219193590|NCT03536884|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219434473|NCT05129787|PROCEDURE|Thermal ablation|Ablation of metastasis
219434474|NCT02348424|DRUG|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
219193591|NCT03536884|DRUG|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
219193592|NCT03536884|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
219193593|NCT05364788|OTHER|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
219007627|NCT04951245|PROCEDURE|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
219193594|NCT04667468|BIOLOGICAL|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
219193595|NCT04667468|BIOLOGICAL|Standard Care|standard care including blood and blood component therapy
219193596|NCT05205486|DRUG|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg
219434475|NCT01477138|PROCEDURE|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
219193597|NCT06008353|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
219578991|NCT02453776|DRUG|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
219578992|NCT05340543|PROCEDURE|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
219193598|NCT05269706|DRUG|Cannabidiol 200mg|Cannabidiol 200mg (twice daily)
219193599|NCT05269706|DRUG|Epidiolex|Epidiolex 400mg (twice daily)
219193600|NCT05269706|DRUG|Cannabidiol 400mg|Cannabidiol 400mg (twice daily)
219193601|NCT05269706|DRUG|Placebo|Matching Placebo (Twice Daily)
219193602|NCT05210569|DEVICE|Vivity|Vivity intraocular lens (IOL)
219434476|NCT04142515|OTHER|no intervention|no intervention
219193603|NCT05583552|DRUG|Imetelstat sodium|Intravenous injection
219193604|NCT06263855|OTHER|CURE|A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
219193605|NCT05454852|OTHER|Survey|Interviewer-administered survey
219193606|NCT05454852|OTHER|Focus group|Focus group for selected participants
219193607|NCT04991857|OTHER|T-FAME-HF|16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
219193608|NCT04991857|OTHER|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
219193609|NCT05451108|DEVICE|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
219193610|NCT03485729|DRUG|Dordaviprone (ONC201)|625 mg dordaviprone (ONC201)
219193611|NCT05444699|DRUG|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
219193612|NCT05444699|DRUG|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
219193613|NCT05594368|DEVICE|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
219434477|NCT04800471|DEVICE|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
219434478|NCT04800471|OTHER|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
219434479|NCT01369407|OTHER|No Intervention|Not an interventional study
219434480|NCT03289871|DEVICE|Excilor|
219193614|NCT05912166|BEHAVIORAL|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content."
219193615|NCT00544414|DRUG|cisplatin|
219193616|NCT00544414|DRUG|docetaxel|
219578993|NCT02149290|DEVICE|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
219578994|NCT01164345|DRUG|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
219578995|NCT03548649|DEVICE|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
219578996|NCT01956695|DRUG|Lenalidomide|
219007628|NCT04951245|PROCEDURE|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
219007629|NCT01797003|OTHER|High tibial osteotomy|
219193617|NCT00544414|DRUG|fluorouracil|
219434481|NCT03289871|DRUG|Loceryl 5%|
219434482|NCT05419271|PROCEDURE|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
219434483|NCT06138028|DRUG|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
219434484|NCT03482128|DEVICE|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
219434485|NCT03482128|DEVICE|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
219007630|NCT03807869|PROCEDURE|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
219007631|NCT00823394|BEHAVIORAL|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
219434486|NCT01779596|DRUG|Bosentan|
219434487|NCT01779596|DRUG|Placebo|
219434488|NCT04774614|PROCEDURE|anterior laminate veneers|VITA ENAMIC multiColor
219434489|NCT05176860|DEVICE|CBCT Imaging|Two research CBCT images will be acquired per subject.
219434490|NCT06161857|OTHER|No intervention|There is no intervention this is an observational study to develop a diagnostic test
219578997|NCT01956695|DRUG|Rituximab|
219578998|NCT01301586|DRUG|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
219578999|NCT01301586|DRUG|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
219007632|NCT00823394|OTHER|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
219007633|NCT00823394|BEHAVIORAL|Self-help Materials|Information on how to lower risk for developing cancer.
219007634|NCT05885789|PROCEDURE|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
219007635|NCT01030939|DRUG|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
219434491|NCT00660777|BEHAVIORAL|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
219434492|NCT00660777|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
219434493|NCT00976729|DRUG|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
219434494|NCT00976729|DRUG|NOX-E36|single SC doses, at safe and tolerable dose level
219434495|NCT00976729|DRUG|Placebo|
219434496|NCT02824848|BEHAVIORAL|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
219434497|NCT02824848|BEHAVIORAL|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
219579000|NCT04996563|OTHER|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
219579001|NCT02835781|OTHER|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
219193618|NCT00544414|DRUG|gemcitabine hydrochloride|
219193619|NCT00544414|DRUG|leucovorin calcium|
219193620|NCT00544414|GENETIC|gene expression analysis|
219434498|NCT05713825|PROCEDURE|Endovascular embolization or surgery|"* Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~* Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
219579002|NCT00634881|BIOLOGICAL|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
219579003|NCT00634881|BIOLOGICAL|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
219579004|NCT00845819|DRUG|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
219579005|NCT00845819|DRUG|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
219579006|NCT00003224|BIOLOGICAL|QS21|vaccine adjuvant
219579007|NCT00003224|BIOLOGICAL|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
219434499|NCT00455936|DRUG|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
219579008|NCT00003224|BIOLOGICAL|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
219579009|NCT00003224|BIOLOGICAL|p946/tet-p|This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)
219434500|NCT00455936|PROCEDURE|chemotherapy|gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
219193621|NCT00544414|GENETIC|protein expression analysis|
219193622|NCT00544414|OTHER|laboratory biomarker analysis|
219579010|NCT00003224|BIOLOGICAL|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
219193623|NCT00544414|PROCEDURE|adjuvant therapy|
219193624|NCT00544414|PROCEDURE|biopsy|
219193625|NCT00544414|PROCEDURE|conventional surgery|
219193626|NCT00544414|PROCEDURE|neoadjuvant therapy|
219193627|NCT00544414|PROCEDURE|quality-of-life assessment|
219193628|NCT00544414|RADIATION|radiation therapy|
219193629|NCT05035654|DRUG|LYR-220 Design 1 (Part 1 only)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
219193630|NCT05035654|DRUG|LYR-220 Design 2 (Part 1 and Part 2)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
219434501|NCT02790294|DEVICE|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
219579011|NCT04156958|DRUG|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
219579012|NCT04059458|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
219579013|NCT04059458|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
219579014|NCT03370016|PROCEDURE|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
219193631|NCT05035654|DRUG|Bilateral sham procedure control (Part 2)|Bilateral sham procedure control
219193632|NCT05716373|BEHAVIORAL|pain|reiki
219193633|NCT06804291|OTHER|Running|Participants were expected to run 6.44 kilometers.
219193634|NCT06804291|OTHER|Cycling|Participants were expected to cycle 39 kilometers
219193635|NCT06804291|OTHER|Rugby|Participants were expected to play in one rugby match.
219193636|NCT06804291|OTHER|control group|Participants were asked to refrain from exercise for 24 hours.
219193637|NCT06804980|DRUG|Rosuvastatin (Crestor)|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
219193638|NCT06804980|DRUG|Placebo|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
219193639|NCT05848947|DRUG|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
219762413|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a lower dose of Ad26.Mos4.HIV (2.5x10\^10 vp/0.25 mL) in a 0.25 mL injection volume and a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS-21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2a will receive an injection Ad26.Mos4.HIV (5x10\^10 vp/0.5 mL) in a 0.5 mL injection volume and CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 57."
219762414|NCT06205056|BIOLOGICAL|CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2a will receive a injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169."
219762415|NCT06205056|BIOLOGICAL|Placebo [Arm 2a]|Participants in Arm 2a will receive a 0.25 mL injection and a 0.5 mL injection of Placebo on Study Day 1; followed by 0.5 mL, 0.5 mL, and 0.9 mL injections of Placebo on Study Days 4, 8, and 15, respectively; followed by a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Day 57; followed by a 1.1 mL injection of Placebo on Study Day 169.
219762416|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1b]|Participants in Arm 1b will receive dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1, 57, and 169.
219193640|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2"
219193641|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
219193642|NCT04710732|DRUG|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
219193643|NCT04710732|DEVICE|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
219193644|NCT04710732|DIAGNOSTIC_TEST|Thrombodynamic test (TD)|"Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
219193645|NCT05921162|BIOLOGICAL|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
219193646|NCT06145997|OTHER|Acupuncture therapy|Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
219193647|NCT06805240|DIAGNOSTIC_TEST|Air Charged Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with an air charged HRAM catheter will be collected in healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement.
219193648|NCT06805240|DIAGNOSTIC_TEST|Solid State Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with a solid state HRAM catheter will be collected in some healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement for comparison to the air charged catheter.
219193649|NCT06805110|BEHAVIORAL|Monthly RDT validation during DHIS2 data review meetings|The Nigeria national malaria program will lead monthly RDT validation at selected legal government areas (LGAs). Health facilities will be asked to retain all RDT cassettes performed for the prior month and bring them to a monthly validation meeting. During these meetings, RDT cassettes will be scanned using the HealthPulse application, which will automatically tally the number of RDTs by brand and result. The application will also allow for the entry of aggregated testing data, including the total number of tests conducted and the RDT results recorded in the health facility register. Discrepancies between the HealthPulse data and facility records will be calculated, with a focus on identifying and addressing discrepancies exceeding a designated threshold (e.g., 10%) that takes into account the proportion of cassettes that may have changed results over the past month. Facilities with significant discrepancies may undergo a detailed audit to align RDT cassettes with patient records.
219193650|NCT06805942|DEVICE|Lipiodol (ethiodized oil) injection|Lipiodol will be used as an embolic agent for arterial embolization targeting neovascularity in the plantar fascia to reduce inflammation and pain.
219193651|NCT05835297|OTHER|Physical exercise interventions|Participants will undergo a 12-week multicomponent exercise regimen, twice per week on non-consecutive days for 45-60 min each. The session will be divided into 4 min of warm-up; range of motion exercises of upper and lower extremities, followed by light walking, then 8 min balance exercises, followed by 15 min strength exercises; two sets of 13-15 repetitions maximum of chair rises with progression, two sets of 13-15 repetitions of modified squats (holding a chair backrest if needed) with progression, 2 sets of 20-30 repetitions of seated or 2 sets of 13-15 repetitions of standing calf raises, then 15 min aerobic exercises; five 3-min bouts of walking between two strengthening exercises and/or 2 balance exercises, finally 3 min cool down exercises of light walking and stretching exercises.
219434502|NCT06011980|DRUG|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
219434503|NCT01972594|PROCEDURE|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
219434504|NCT01972594|DEVICE|Accelerometer(ActivPAL)|
219434505|NCT05165550|DRUG|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
219762417|NCT06205056|BIOLOGICAL|Placebo [Arm 1b]|Participants in Arm 1b will receive a 1.1 mL injection of Placebo on Study Days 1, 57, and 169.
219434506|NCT02194517|DEVICE|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
219434507|NCT01349296|DRUG|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
219434508|NCT06388135|DRUG|Serplulimab Combined With Nab-paclitaxel and Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
219434509|NCT06388135|DRUG|nab-paclitaxel，Cisplatin|nab-paclitaxel，Cisplatin
219193652|NCT06804356|PROCEDURE|Tendon interposition arthroplasty|Trapeziometacarpal arthroplasty using autologous tendon interposition to fill the space left by resecting affected joint surfaces.
219434510|NCT01170312|BIOLOGICAL|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
219434511|NCT01170312|OTHER|Normal saline|Normal saline injection
219193653|NCT06804356|PROCEDURE|Poly-L-D-lactic acid implant (RegJoint) interposition arthroplasty|Trapeziometacarpal arthroplasty using poly-L-D-lactic acid implant (RegJoint) interposition to fill the space left by resecting affected joint surfaces.
219193654|NCT06807073|PROCEDURE|Prophylactic defect closure|Endoscopists will use at least one new generation closure device to approximate the healthy mucosal surrounding the submucosal defect to ensure complete defect closure. Adequate apposition of the mucosal defect margins will be achieved when no visible submucosal areas \>3 mm along the closure line are present.
219193655|NCT06807073|PROCEDURE|No prophylactic defect closure|After performing EMR with thermal ablation, prophylactic defect closure will not be performed.
219193656|NCT06314776|OTHER|Usual physiotherapy without Whole-Body Vibration|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
219434512|NCT01277913|DRUG|Vitamin D3|1000 IU once daily for 12 months
219434513|NCT01277913|DRUG|Vitamin D3|500 IU once daily for 12 months
219193657|NCT06314776|OTHER|Pre-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
219193658|NCT06314776|OTHER|Post-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
219193659|NCT06353061|DRUG|Metformin|Patients randomized to the metformin group will start taking metformin within 1 day after group allocation. They will take one tablet of metformin (850 mg) once daily for three consecutive days. Subsequently, they will take metformin orally twice daily throughout the entire external and internal irradiation period, with each administration consisting of one tablet.
219193660|NCT06353061|RADIATION|Radiotherapy|The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions \>4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
219193661|NCT06353061|DRUG|Chemotherapy|The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
219193662|NCT06353061|DIAGNOSTIC_TEST|PET/CT|Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
219193663|NCT04305444|DRUG|DTRM-555|Oral once-daily administration
219193664|NCT05331625|BEHAVIORAL|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
219579015|NCT04808310|DEVICE|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
219193665|NCT06443580|OTHER|interoceptive group based intervention|8 week online group intervention aiming to improve interoception.
219193666|NCT03314740|DRUG|Paclitaxel|Comparator active compound
219579016|NCT04808310|DIAGNOSTIC_TEST|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
219193667|NCT03314740|DRUG|Cediranib|Experimental compound
219193668|NCT03314740|DRUG|Olaparib|Experimental compound
219193669|NCT03426904|DRUG|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
219193670|NCT03426904|DRUG|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
219193671|NCT05877430|DRUG|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
219193672|NCT05877430|DRUG|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
219579017|NCT02767895|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
219579018|NCT02637661|OTHER|earlobe crease positive|
219579019|NCT02637661|OTHER|earlobe crease negative|
219193673|NCT02367040|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
219579020|NCT04032158|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
219579021|NCT04032158|DRUG|Avonex®|Participants received avonex® IM injection once a week.
219579022|NCT04032158|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
219579023|NCT04032158|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
219434514|NCT06117917|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
219193674|NCT02367040|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
219193675|NCT02367040|DRUG|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
219193676|NCT03785834|PROCEDURE|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
219193677|NCT04075318|BIOLOGICAL|UB-312|A synthetic peptide-based vaccine
219193678|NCT04075318|BIOLOGICAL|Placebo|Matching placebo
219193679|NCT04477291|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
219193680|NCT06269861|DEVICE|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
219193681|NCT06517719|OTHER|lutetium (177Lu) vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
219193682|NCT06550245|OTHER|Infants observing familiar and unfamiliar racial groups|All infants will see videos of people from familiar and unfamiliar racial backgrounds. Depending on the caregiver's race, infants will be assigned to see people who are from the same racial background as their caregiver (i.e., familiar) and people who are not.
219434515|NCT06117917|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
219193683|NCT05018377|PROCEDURE|Racz adhesolysis|adhesiolysis in failed back surgery
219434516|NCT00222248|BEHAVIORAL|Pelvic floor muscle training and bladder training|
219434517|NCT05353868|OTHER|No intervention|No intervention
219579024|NCT02479542|OTHER|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
219193684|NCT05018377|DEVICE|NAVI adhesolysis|adhesiolysis in failed back surgery
219193685|NCT05856435|BEHAVIORAL|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
219193686|NCT06756178|DRUG|Propofol Group 1|"Postoperative Use:~Bolus: 10-20 mg intravenously as needed for sedation initiation. Continuous infusion: 0.3-0.5 mg/kg/hour to maintain light sedation adjusted based on clinical response."
219193687|NCT06756178|DRUG|Remimazolam Intervention|"Postoperative Use:~Initial bolus: 5 mg intravenously upon ICU arrival. Continuous infusion: 0.2-0.3 mg/kg/hour to maintain light sedation with a maximum dose of 0.8 mg/kg/hour.~Rescue sedation with propofol or midazolam will be allowed if patients become agitated or if Remimazolam is ineffective in maintaining target sedation."
219193688|NCT06756178|DRUG|Dexmedetomidine Intervention|"Postoperative Use:~Loading dose: 0.5-1 μg/kg over 10-20 minutes after ICU arrival. Continuous infusion: 0.2-0.7 μg/kg/hour for sedation maintenance, adjusted as needed to maintain light sedation.~Rescue sedation with propofol or midazolam will be administered if Dexmedetomidine fails to maintain adequate sedation or if patients become agitated."
219193689|NCT02323880|OTHER|Pharmacological Study|Correlative studies
219579025|NCT02479542|DEVICE|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
219579026|NCT04375852|DIAGNOSTIC_TEST|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
219193690|NCT02323880|DRUG|Selinexor|Given PO
219193691|NCT01821612|DRUG|oxaliplatin|IV
219193692|NCT01821612|DRUG|irinotecan|IV
219193693|NCT01821612|DRUG|leucovorin|IV
219193694|NCT01821612|DRUG|5-fluorouracil|IV
219193695|NCT01821612|DRUG|capecitabine|PO
219193696|NCT01821612|RADIATION|radiation|
219193697|NCT01821612|PROCEDURE|surgery|
219193698|NCT01821612|DRUG|gemcitabine|IV
219193699|NCT03278379|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
219193700|NCT00360087|DRUG|Bosentan|
219193701|NCT03812289|OTHER|Quality-of-Life Assessment|Ancillary studies
219579027|NCT03413137|PROCEDURE|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
219193702|NCT03812289|OTHER|Questionnaire Administration|Ancillary studies
219193703|NCT03812289|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219193704|NCT04934072|DRUG|FKS518|subcutaneously by single-use prefilled syringe (PFS)
219434518|NCT03437213|DRUG|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
219579028|NCT03413137|PROCEDURE|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
219579029|NCT03863093|DEVICE|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
219193705|NCT04934072|DRUG|US-licensed Prolia (Amgen)|subcutaneously by single-use PFS
219434519|NCT03437213|DRUG|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
219434520|NCT03419910|DRUG|BMS-986165|Specified dose on specified days
219434521|NCT03419910|DRUG|Cyclosporine|Specified dose on specified days
219434522|NCT03984838|DRUG|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
219434523|NCT03136367|OTHER|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
219193706|NCT05023096|OTHER|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
219193707|NCT04523701|DRUG|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
219193708|NCT06361251|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
219579030|NCT03863093|DEVICE|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
219579031|NCT03251274|OTHER|machine bathing|machine bathing 20-min duration at evening
219579032|NCT03251274|OTHER|traditional bathing|traditional bathing
219579033|NCT05211999|BEHAVIORAL|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
219579034|NCT05211999|BEHAVIORAL|Control Group|No intervention in control group just theoretical education was done for them.
219579035|NCT02113553|DRUG|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
219579036|NCT00206765|DRUG|Risperidone|
219579037|NCT00206765|DRUG|Paroxetine|
219193709|NCT06361251|DEVICE|CRYONOVE (EC05osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
219193710|NCT05202951|OTHER|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
219193711|NCT02484430|OTHER|Laboratory Biomarker Analysis|Correlative studies
219193712|NCT02484430|OTHER|Pharmacological Study|Correlative studies
219193713|NCT02484430|DRUG|Sapanisertib|Given PO
219193714|NCT03932162|DRUG|Insulin-Like Growth Factor 1|Growth factor protein
219193715|NCT03932162|OTHER|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
219193716|NCT06162299|BIOLOGICAL|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
219193717|NCT05058040|DRUG|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
219579038|NCT03632317|DRUG|Panobinostat|30 mg/m\^2
219579039|NCT03632317|DRUG|Everolimus|3.0 mg/m\^2
219579040|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
219434524|NCT03136367|OTHER|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
219434525|NCT00034151|DRUG|S-8184 Paclitaxel Injectable Emulsion|
219434526|NCT05380960|DEVICE|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
219193718|NCT06026306|BEHAVIORAL|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
219193719|NCT05081934|BEHAVIORAL|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
219193720|NCT05081934|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
219193721|NCT06167239|OTHER|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
219434527|NCT03854812|DRUG|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
219434528|NCT03854812|DRUG|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
219434529|NCT03854812|DRUG|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
219193722|NCT06061159|DRUG|Remimazolam besylate|initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
219193723|NCT06061159|DRUG|Remimazolam besylate|initial dose is based on the findings from the school-age group；adjust dosage is 0.05mg/kg
219193724|NCT03394612|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
219193725|NCT03394612|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
219193726|NCT03964376|OTHER|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
219434530|NCT00935337|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
219434531|NCT00935337|BEHAVIORAL|Sleep Hygiene|treatment as usual
219434532|NCT02899806|OTHER|Written Information|A written information on peridural anesthesia is delivered
219434533|NCT02899806|OTHER|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
219434534|NCT04949555|OTHER|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
219193727|NCT03964376|OTHER|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
219193728|NCT03480776|DRUG|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
219193729|NCT03480776|OTHER|Placebo|One tablet PO daily
219193730|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
219434535|NCT00006372|DRUG|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
219434536|NCT00006372|DRUG|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
219434537|NCT00006372|DRUG|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
219434538|NCT00676208|BEHAVIORAL|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
219193731|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
219193732|NCT04935619|BEHAVIORAL|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
219434539|NCT00236522|DRUG|levofloxacin|
219193733|NCT04935619|BEHAVIORAL|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
219579041|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
219579042|NCT04111406|DRUG|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
219579043|NCT04111406|DRUG|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
219193734|NCT04548713|DEVICE|4% EDTA|Sterile Catheter Lock Solution
219193735|NCT04548713|DEVICE|Saline|Saline Lock Solution
219193736|NCT05282459|DRUG|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
219193737|NCT05660434|OTHER|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
219193738|NCT03421340|DEVICE|DSC|Stone removal without fluoroscopy using the SpyGlass device.
219193739|NCT03421340|DEVICE|ERC|Standard of care stone removal with fluoroscopy.
219193740|NCT05860413|BEHAVIORAL|Intermittent energy restriction (IER)|During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.
219193741|NCT05860413|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
219193742|NCT04732507|COMBINATION_PRODUCT|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
219193743|NCT06194188|DRUG|Subcutaneous injection of CU-20401|Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
219193744|NCT03978663|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
219434540|NCT04370730|OTHER|clinical, neuroimaging and DNA assessments|Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
219434541|NCT05867199|BEHAVIORAL|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
219193745|NCT04473378|DEVICE|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
219193746|NCT03533517|DEVICE|AccuCinch® Ventricular Restoration|AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
219193747|NCT06307886|PROCEDURE|Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator|patients who underwent laparoscopic hysterectomy with using uterine manipulator
219193748|NCT06307886|PROCEDURE|lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator|patients who underwent laparoscopic hysterectomy without using uterine manipulator
219434542|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg lorlatinib
219434543|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
219434544|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg QD lorlatinib
219434545|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
219434546|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
219579044|NCT00307606|DRUG|Solu-medrol 125 mg|
219579045|NCT01196078|DRUG|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
219579046|NCT01196078|DRUG|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
219193749|NCT05819476|PROCEDURE|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
219193750|NCT05819476|OTHER|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
219193751|NCT05819476|OTHER|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
219193752|NCT06371157|DRUG|AK104|intravenous
219193753|NCT06371157|DRUG|Lenvatinib|oral
219193754|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
219193755|NCT06371157|OTHER|Placebo for AK104|intravenous
219193756|NCT06371157|OTHER|Placebo for Lenvatinib|oral
219193757|NCT03636243|BIOLOGICAL|Vascularly biological assessment|22.5 ml of blood will be collected at day -15, month 3 and month 12.
219193758|NCT03636243|BIOLOGICAL|Analysis of vasomotor endothelial function|Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
219193759|NCT03636243|BIOLOGICAL|Analysis of arterial compliance|Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12
219434547|NCT03716453|PROCEDURE|Standard protocol|Give narcotic according to vital signs
219193760|NCT03636243|BIOLOGICAL|Exploration of microcirculation|The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
219193761|NCT03636243|BIOLOGICAL|Venous Doppler Ultrasound|aneurysm screening at day -15, month 3 and month 12
219193762|NCT03636243|BIOLOGICAL|Arterial pressure measurement|measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
219193763|NCT03636243|BIOLOGICAL|Intima-Media Thickness measurement|Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
219193764|NCT03636243|BIOLOGICAL|Exploration of neuropathy|non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
219434548|NCT03716453|PROCEDURE|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given."
219579047|NCT02667288|DRUG|A-101 Solution|
219579048|NCT00700609|BEHAVIORAL|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
219579049|NCT02182869|DRUG|Combivent® HFA inhalation aerosol|
219193765|NCT03636243|BEHAVIORAL|level of physical activity|pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
219193766|NCT03636243|OTHER|thoracic scanner|non-injected thoracic scanner visit at month 3
219434549|NCT00030095|DRUG|2-methoxyestradiol|
219193767|NCT04934462|PROCEDURE|physiotherapy|Six months physiotherapy aimed at hip stability.
219579050|NCT02182869|DRUG|Combivent® CFC inhalation aerosol|
219579051|NCT05029401|DRUG|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
219579052|NCT05029401|DRUG|Placebo|Matching placebo to the IMP (DMX-1002)
219193768|NCT04934462|PROCEDURE|arthroscopy|Arthroscopic plication of hip joint capsule.
219193769|NCT03647358|DEVICE|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
219434550|NCT00428376|DEVICE|Building Blocks|
219434551|NCT06150989|BEHAVIORAL|Observational Group|"All participants will go through a series of lab-based assessments to evaluate their vascular health. These assessments include: heart rhythm/rate, blood pressure, large blood vessel flow, central aortic blood pressure and pulse wave velocity, brain blood flow, carbon dioxide concentration, flow mediated dilation/blood vessel responsiveness, breathing rate, and cerebral vasomotor reactivity. In addition, venous blood sample will be taken to identify biomarkers that are associated with elevating blood pressure and decreasing blood flow.~The 10-day monitoring period includes a wrist-worn activity tracker and a blood pressure monitor bracelet; a smartphone app that will prompt surveys up to 6 times a day to assess behaviors, social/physical context, mood/stress, and experience of racial discrimination/microaggression. Participants will also collect saliva samples on three consecutive days during the 10-day monitoring period."
219434552|NCT06011603|DEVICE|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
219434553|NCT05300971|OTHER|Heat therapy|36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
219434554|NCT05300971|OTHER|Thermoneutral water immersion|36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature \>0.2°C, and 12 weeks of follow-up.
219434555|NCT01375647|BIOLOGICAL|IPV (inactivated polio vaccine)|Administered per protocol
219434556|NCT01375647|BIOLOGICAL|Rotarix|Administered per protocol
219579053|NCT02017730|DRUG|BMS-986020|
219579054|NCT02017730|DRUG|[11C]BMT-136088|
219579055|NCT05312242|DIETARY_SUPPLEMENT|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
219579056|NCT05312242|DIETARY_SUPPLEMENT|Iron Folic Acid Supplement|Standard of Care Intervention
219193770|NCT03647358|DRUG|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).
219579057|NCT03233425|BEHAVIORAL|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
219579058|NCT02133586|OTHER|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
219579059|NCT02133586|OTHER|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
219579060|NCT00700323|DIETARY_SUPPLEMENT|PS-Omega3 conjugate supplementation|
219579061|NCT00700323|DIETARY_SUPPLEMENT|placebo|
219579062|NCT02159781|PROCEDURE|periodontal treatment - scaling and root planning|
219579063|NCT02070302|DRUG|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
219579064|NCT02070302|DRUG|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
219579065|NCT02979236|DEVICE|STENTYS Xposition S|
219579066|NCT05389982|OTHER|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
219579067|NCT05389982|OTHER|Standard Care|Office based pathway
219762418|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 2b]|"Participants in Arm 2b will receive a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS 21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2b will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2b will receive a injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Days 57 and 169."
219007636|NCT02228551|OTHER|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
219007637|NCT00939328|BIOLOGICAL|rituximab|
219434557|NCT06195852|BEHAVIORAL|Usual Safe Touches|The in-person Safe Touches workshop is delivered in the classroom by 2 facilitators with live puppet skits, as designed.
219434558|NCT06195852|BEHAVIORAL|Modified Safe Touches|The modified Safe Touches workshop will be delivered by 1 facilitator in the classroom by utilizing prerecorded workshop skit videos.
219434559|NCT03366844|DRUG|Pembrolizumab|checkpoint inhibitor
219434560|NCT03366844|RADIATION|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
219193771|NCT04750538|DEVICE|BreEStim 120|120 BreEStim stimuli will applied for about 10-15 minutes.
219193772|NCT04750538|DEVICE|BreEStim 240|240 BreEStim stimuli will applied for about 20-30 minutes.
219193773|NCT05820516|DEVICE|TricValve implantation|TricValve implantation
219193774|NCT06783478|BIOLOGICAL|NK cell infusion|Six infusions of 1 x 10⁷/kg of haploidentical NK cells, in vitro expanded and activated.
219193775|NCT06783478|OTHER|Placebo|Six infusions of placebo
219193776|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
219434561|NCT03322397|BEHAVIORAL|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
219434562|NCT03322397|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
219193777|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
219579068|NCT03828266|OTHER|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
219579069|NCT04613674|DRUG|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
219007638|NCT00939328|DRUG|bendamustine hydrochloride|
219193778|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
219579070|NCT04613674|DRUG|placebo+chemotherapy|placebo+chemotherapy
219434563|NCT03322397|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
219434564|NCT06398951|DEVICE|Two nare high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
219434565|NCT02244658|DRUG|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
219579071|NCT00270257|DRUG|Buprenorphine/Naloxone|Oral tablet
219193779|NCT05935605|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
219579072|NCT01630681|BEHAVIORAL|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
219579073|NCT00393471|DRUG|Etanercept|
219579074|NCT04813315|OTHER|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
219579075|NCT04813315|OTHER|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
219579076|NCT02621034|PROCEDURE|Control|K-file hand instrumentation
219579077|NCT02621034|PROCEDURE|Reciproc|reciprocating rotary instrument
219579078|NCT02621034|PROCEDURE|One shape|full rotation protocol
219579079|NCT00929331|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
219579080|NCT01969448|PROCEDURE|Inframammary Fold Incision or Lateral Radial Incision|
219579081|NCT01969448|PROCEDURE|Lateral Radial Incision|
219579082|NCT01969448|PROCEDURE|Inframammary Fold Incision|
219579083|NCT01969448|DEVICE|Laser-assisted fluorescence angiography|
219579084|NCT01969448|DRUG|Indocyanine Green|
219579085|NCT05561530|DRUG|ALG-125755|single or multiple doses of ALG-125755
219762419|NCT06205056|BIOLOGICAL|Placebo [Arm 2b]|Participants in Arm 2b will receive a 0.5 mL injection of Placebo on Study Days 1, 4, and 8; followed by a 0.9 mL injection of Placebo on Study Day 15; followed by a 1.1 mL injection of Placebo on Study Days 57 and 169.
219762420|NCT04130854|DRUG|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
219762421|NCT04130854|DRUG|mFOLFOX and Radiation Therapy 5Gy x 5 days|"1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
219762422|NCT06529523|DRUG|Tislelizumab|Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
219762423|NCT04961567|DRUG|Litifilimab|Administered as specified in the treatment arm.
219762424|NCT04961567|DRUG|Placebo|Administered as specified in the treatment arm.
219762425|NCT03250975|DRUG|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
219434566|NCT00789724|DRUG|Anakinra|100 mg daily subcutaneous injection for 14 days
219579086|NCT05561530|DRUG|Placebo|single or multiple doses of placebo
219579087|NCT04941339|DRUG|MRG002|Administrated intravenously
219579088|NCT03970486|PROCEDURE|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
219579089|NCT00345735|DRUG|Fentanyl|
219579090|NCT02201238|DRUG|Diclofenac sodium|Diclofenac sodium
219579091|NCT02201238|DRUG|Menthol|Menthol
219579092|NCT02876783|OTHER|Observational - No intervention|
219579093|NCT01140490|PROCEDURE|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
219579094|NCT04724044|DRUG|Tablets|Oral tablets of similar appearance to active study drug
219579095|NCT04724044|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
219762426|NCT03250975|OTHER|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
219579096|NCT06124274|BEHAVIORAL|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.
219579097|NCT02926820|BEHAVIORAL|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
219579098|NCT00121316|DRUG|Pimecrolimus|Pimecrolimus Cream 1 %
219579099|NCT00121316|DRUG|Placebo|Vehicle cream (placebo cream)
219434567|NCT00789724|DRUG|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
219434568|NCT04624529|OTHER|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
219434569|NCT00554528|DEVICE|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
219434570|NCT00554528|PROCEDURE|arthrodesis - cervical disk surgery|discectomy and arthrodesis
219579100|NCT02018783|PROCEDURE|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
219579101|NCT02018783|PROCEDURE|Sensodyne|Digital application for 60 seconds.
219579102|NCT02018783|PROCEDURE|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
219579103|NCT02018783|PROCEDURE|Cocorico|Digital application for 60 seconds
219193780|NCT05935605|DIAGNOSTIC_TEST|Lung ultrasound|A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
219579104|NCT04597294|COMBINATION_PRODUCT|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
219579105|NCT04597294|COMBINATION_PRODUCT|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
219579106|NCT02788786|DRUG|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
219579107|NCT02788786|DRUG|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
219579108|NCT02788786|DRUG|Salt and Water|salt and water mix oral rinse
219579109|NCT03426566|OTHER|retrospective observational study with no intervention|no intervention
219193781|NCT05674981|DIETARY_SUPPLEMENT|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
219579110|NCT03054558|OTHER|Pelvic ultrasound both two dimensional and three dimentional|
219579111|NCT04641065|OTHER|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
219579112|NCT00467636|PROCEDURE|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
219762427|NCT02970617|OTHER|Memory Intervention|Ring bell after final radiation treatment
219762428|NCT02970617|OTHER|Questionnaire Administration|Ancillary studies
219193782|NCT05674981|OTHER|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
219193783|NCT05707598|PROCEDURE|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
219579113|NCT00467636|DRUG|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
219579114|NCT03377764|PROCEDURE|Landmark Technique Control group|Spinal Anesthetic
219579115|NCT03377764|PROCEDURE|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
219579116|NCT02933021|OTHER|Blood sample taken|
219579117|NCT02933021|OTHER|Answering a lifestyle questionnaire|
219579118|NCT02933021|OTHER|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
219579119|NCT02232490|BIOLOGICAL|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
219579120|NCT02232490|BIOLOGICAL|Placebo|
219579121|NCT02893202|OTHER|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
219579122|NCT01988506|DRUG|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
219579123|NCT00333879|DEVICE|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
219762429|NCT06534892|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
219762430|NCT02865408|DIETARY_SUPPLEMENT|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
219762431|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
219762432|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
219762433|NCT05579366|DRUG|Rina-S|Intravenous infusion of Rina-S
219762434|NCT05579366|DRUG|Carboplatin|Carboplatin intravenous infusion
219762435|NCT05579366|DRUG|Bevacizumab|Bevacizumab intravenous infusion
219762436|NCT05579366|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion
219762437|NCT04886804|DRUG|zongertinib|zongertinib
219193784|NCT05819268|BEHAVIORAL|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
219193785|NCT05819268|BEHAVIORAL|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
219193786|NCT04808323|DRUG|Capecitabine|825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
219193787|NCT04808323|DEVICE|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
219579124|NCT06258759|BIOLOGICAL|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
219193788|NCT04808323|DEVICE|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
219193789|NCT04808323|DEVICE|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
219193790|NCT04808323|DEVICE|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
219193791|NCT04808323|DRUG|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
219434571|NCT03914651|DRUG|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
219193792|NCT05783414|BEHAVIORAL|f2f CST|An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
219434572|NCT03914651|DRUG|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
219193793|NCT05783414|BEHAVIORAL|f2f carer support|Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
219193794|NCT05783414|BEHAVIORAL|vCST|A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
219434573|NCT04202796|PROCEDURE|Catheter ablation|Catheter ablation of arrhythmia
219434574|NCT04312789|DRUG|Avatrombopag|Given PO
219434575|NCT03397550|OTHER|salt restriction education|Salt intake target：\<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
219434576|NCT01788111|OTHER|Low back exercises 1|Excentric / concentric extension type exercises
219193795|NCT05783414|BEHAVIORAL|online carer support|A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
219193796|NCT05924113|BEHAVIORAL|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
219193797|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
219193798|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
219193799|NCT06492382|DIAGNOSTIC_TEST|Home Oxygen Monitors|Weaning of home oxygen using information gathered from home moniotr devise
219434577|NCT01788111|OTHER|Low back exercise 2|Traditional low back training
219434578|NCT00848445|DEVICE|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
219434579|NCT00848445|DEVICE|Atrial pacing preference turned on or off|programing changes in the device
219434580|NCT03636308|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
219193800|NCT04964310|GENETIC|genetic polymorphism|Observe the genetic polymorphism frequency difference between case and control groups
219193801|NCT04951076|DRUG|BNC210|BNC210 900 mg twice daily (b.i.d.) for 12 weeks
219434581|NCT03636308|DRUG|S1|S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
219434582|NCT03636308|DRUG|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
219434583|NCT02088541|DRUG|Selinexor|Selinexor oral tablet.
219434584|NCT02088541|DRUG|Hydroxyurea|
219434585|NCT02088541|DRUG|Ara-C|Ara-C Subcutaneous Injection.
219434586|NCT05685719|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
219434587|NCT05685719|DRUG|Itraconazole|A strong CYP3A4 inhibitor
219434588|NCT05685719|DRUG|Rifampin|A strong CYP3A4 inducer
219193802|NCT04951076|DRUG|Placebo|Placebo twice daily (b.i.d.) for 12 weeks
219193803|NCT05226871|DRUG|Palbociclib|oral
219193804|NCT05226871|DRUG|Cetuximab|Intravenous (IV) infusion
219193805|NCT05226871|DRUG|Fulvestrant|Intramuscular (IM)
219193806|NCT05226871|DRUG|Letrozole|oral
219193807|NCT03517007|OTHER|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
219193808|NCT02871167|PROCEDURE|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
219434589|NCT00612339|DRUG|Avastin and Temozolomide|This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
219434590|NCT01954810|BIOLOGICAL|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
219193809|NCT02871167|PROCEDURE|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
219193810|NCT05296889|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
219193811|NCT06823323|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|It is previously reported Lactobacillus johnsonii #CGMCC29884 in Cell. Animal studies showed it combined with Clostridium sporogenes to produce indolepropionic acid, modulating CD8+ T cell immune quiescence in the tumor microenvironment and sensitizing immunotherapy in CRC, breast cancer, and melanoma. Mager et al. found Lactobacillus johnsonii enhanced CTLA-4 mAb antitumor effects in CRC mouse models. Studies showed it's a typical probiotic widely distributed in various hosts' guts and has long been applied in food and feed industries. Preclinical studies indicated it improved memory through the gut-brain axis, had anti-inflammatory and antibacterial effects, and regulated metabolic diseases. Randomized trials found it effectively inhibited Helicobacter pylori colonization without obvious adverse reactions, suggesting it's a potentially safe and effective treatment.
219434591|NCT05833568|DEVICE|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
219434592|NCT05833568|DEVICE|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
219434593|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
219193812|NCT06823323|OTHER|Placebo|Placebo
219193813|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
219193814|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
219193815|NCT05631743|BEHAVIORAL|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
219193816|NCT05631743|BEHAVIORAL|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
219193817|NCT03995394|OTHER|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
219193818|NCT06822296|OTHER|Physical Therapy|Exercises to improve function of children with CP
219434594|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
219434595|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
219434596|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
219193819|NCT06822296|OTHER|Designed rehabilitation program|Program of exercises to enhance function
219193820|NCT04916626|BEHAVIORAL|OPUS YOUNG|OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
219434597|NCT03907969|DRUG|AZD7648|Core: AZD7648 will be administered orally
219434598|NCT03907969|DRUG|PLD|The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
219193821|NCT04916626|BEHAVIORAL|Treatment as Usual|The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
219193822|NCT05970640|DRUG|BI 3006337|BI 3006337
219193823|NCT05970640|DRUG|Placebo matching BI 3006337|Placebo matching BI 3006337
219193824|NCT05112302|OTHER|Virtual reality|Use of virtual reality goggles during procedure
219434599|NCT00666536|DRUG|valsartan and amlodipine|
219193825|NCT06274632|BEHAVIORAL|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
219434600|NCT00666536|DRUG|valsartan and amlodipine|
219434601|NCT02122055|DRUG|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
219193826|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
219193827|NCT05470218|OTHER|Meal|Liquid mixed meal with different amounts of protein and leucine
219193828|NCT04790058|OTHER|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements \[troponin and NT-proBNP\] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
219434602|NCT02122055|PROCEDURE|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
219434603|NCT02122055|PROCEDURE|Screen of weaning|1\. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
219434604|NCT02122055|DRUG|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
219434605|NCT02122055|DRUG|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
219579125|NCT06258759|BIOLOGICAL|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
219579126|NCT01016093|DRUG|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
219434606|NCT02122055|DRUG|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
219434607|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
219434608|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
219579127|NCT01016093|DRUG|Placebo|Placebo
219579128|NCT01968694|DRUG|IV Lidocaine|
219579129|NCT01968694|DRUG|IV diphenhydramine|
219579130|NCT03958123|DRUG|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
219434609|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
219434610|NCT01055470|DRUG|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
219434611|NCT01055470|DRUG|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
219434612|NCT01761136|BIOLOGICAL|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
219579131|NCT03958123|DRUG|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
219579132|NCT03958123|DRUG|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
219579133|NCT03958123|DRUG|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
219579134|NCT03958123|DRUG|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
219193829|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
219434613|NCT01761136|BIOLOGICAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
219434614|NCT01391468|DIETARY_SUPPLEMENT|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
219193830|NCT06000046|DEVICE|Automatic image analysis|After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).
219193831|NCT04271956|BIOLOGICAL|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
219193832|NCT04271956|DRUG|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
219193833|NCT04271956|DRUG|Sonrotoclax|"Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po"
219193834|NCT03977233|DRUG|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
219193835|NCT03977233|DRUG|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
219193836|NCT03977233|DRUG|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
219193837|NCT03977233|DRUG|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
219434615|NCT01391468|DIETARY_SUPPLEMENT|Cornstarch|placebo will be given in 6 months
219762438|NCT04057209|RADIATION|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
219434616|NCT00116194|BEHAVIORAL|Physical Activity|
219434617|NCT01674985|BIOLOGICAL|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
219434618|NCT02977039|OTHER|NDPR diet|nutrient rich plant based diert
219434619|NCT02977039|OTHER|USDA healthy eating diet|DASH diet
219434620|NCT03515239|PROCEDURE|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
219434621|NCT00608881|DRUG|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
219434622|NCT00608881|OTHER|placebo|an inactive substance
219434623|NCT00336661|DEVICE|PerioWave|
219193838|NCT05736458|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
219579135|NCT03958123|DRUG|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
219579136|NCT01400919|DEVICE|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
219579137|NCT01660399|DRUG|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
219579138|NCT01660399|DRUG|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
219193839|NCT05736458|PROCEDURE|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
219193840|NCT04833907|DRUG|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
219193841|NCT04833907|DRUG|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
219434624|NCT02125630|PROCEDURE|Surgery|Surgery to primary tumor
219434625|NCT02125630|DRUG|Systemic therapy|Systemic therapy based on tumor phenotype
219434626|NCT03638336|DEVICE|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
219434627|NCT04254445|OTHER|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
219434628|NCT00000768|DRUG|Glutamic acid hydrochloride|
219434629|NCT00000768|DRUG|Ganciclovir|
219434630|NCT03408288|OTHER|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
219434631|NCT03408288|OTHER|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
219434632|NCT03408288|OTHER|Color description|Describe color of reference sample
219434633|NCT02756741|DRUG|ALBUMIN|Albumin in two different doses
219434634|NCT06367335|DRUG|Ribociclib, palbociclib, abemaciclib|evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
219434635|NCT04618549|PROCEDURE|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
219579139|NCT03340142|DEVICE|VIVO™|Diagnose the area of a PVC or VT onset
219579140|NCT03940794|OTHER|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
219579141|NCT01732874|DRUG|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
219579142|NCT01732874|DRUG|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
219579143|NCT04539886|DEVICE|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
219579144|NCT04539886|DEVICE|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
219579145|NCT01261286|DRUG|verapamil|
219579146|NCT03097835|DRUG|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
219434636|NCT04618549|PROCEDURE|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
219579147|NCT03097835|DRUG|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
219579148|NCT03097835|OTHER|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
219579149|NCT05876455|PROCEDURE|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
219579150|NCT05876455|PROCEDURE|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
219579151|NCT03306524|DEVICE|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
219579152|NCT03306524|DEVICE|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
219434637|NCT04618549|PROCEDURE|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
219193842|NCT04833907|DRUG|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
219193843|NCT05541276|DRUG|Melatonin|Melatonin for injection 1 mg/mL
219193844|NCT05541276|DRUG|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
219193845|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming|Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.
219579153|NCT03306524|DEVICE|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
219579154|NCT03306524|DEVICE|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
219762439|NCT04057209|PROCEDURE|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
219434638|NCT01921699|PROCEDURE|taking blood samples from healthy people|
219434639|NCT00994760|DRUG|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
219434640|NCT06171815|BEHAVIORAL|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
219579155|NCT03306524|DEVICE|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
219579156|NCT03306524|DEVICE|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
219579157|NCT03306524|DEVICE|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
219579158|NCT03306524|DEVICE|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
219579159|NCT03306524|DEVICE|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
219579160|NCT03306524|DEVICE|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
219579161|NCT01620619|OTHER|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
219579162|NCT01620619|PROCEDURE|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
219193846|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback|Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.
219193847|NCT06513520|BIOLOGICAL|Blood sampling|Additional blood tube collection during routine blood sampling.
219193848|NCT02990338|DRUG|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
219193849|NCT02990338|DRUG|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
219193850|NCT02990338|DRUG|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
219762440|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
219193851|NCT02229968|DRUG|Amicar (ε-aminocaproic acid)|
219193852|NCT02229968|DRUG|normal saline|
219193853|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fasting condition, 1 tablet at a time, once a day.
219193854|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
219193855|NCT06569394|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
219193856|NCT06569394|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
219193857|NCT06808269|PROCEDURE|Vivalto Dom follow-up|"During the pre-operative consultation, the patient receives a prescription for medication (analgesics and anti-inflammatories) for immediate post-operative pain relief. They also receive a patient information booklet (see appendix 6). On discharge from surgery, the patient returns home with Vivalto Dom in charge of nursing care and follow-up medication.~Vivalto Dom is a homecare structure whose mission is to coordinate the discharge of patients back home, and to ensure continuity of overall care (care and social aspects) between the hospital and the city."
219193858|NCT06808269|PROCEDURE|Liberal follow-up|"The pre-operative and operative course (fasting rules, skin preparation, hospitalization, surgery) is the same as for all routine care patients. The patient is informed before surgery that he or she must make an appointment with a nurse for post-operative care at home; a prescription for medication (analgesics and anti-inflammatories) has been given by the anaesthetist for immediate analgesic treatment, and on discharge from hospital he or she receives another prescription from the surgeon for oral relay treatment.~Follow-up at home takes place over 3 days, with a private nurse visiting the patient's home every day.~During the follow-up, the nurse performs clinical monitoring of the following items: pulse, blood pressure, temperature, pain, bleeding, monitoring of the surgical wound, transit, nausea and vomiting. The patient is also guided through the medication protocol."
219434641|NCT01196312|BEHAVIORAL|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
219434642|NCT00716989|BIOLOGICAL|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
219434643|NCT05857007|DEVICE|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
219762441|NCT04613596|DRUG|Adagrasib|Adagrasib 600 mg BID monotherapy (Cohort 1b)
219762442|NCT04613596|DRUG|Adagrasib|adagrasib 400 mg BID in combination with pembrolizumab
219762443|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
219193859|NCT06808659|OTHER|Neural Mobilization|A total of 20 patients were selected in Group A received neural mobilization of sciatic nerves treatment for 3 days a week for 2 weeks
219193860|NCT06808659|OTHER|Stretching|A total of 20 patients were selected in Group B received stretching of piriformis muscle treatment for 3 days a week for 2 weeks
219193861|NCT06809959|DEVICE|In-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field, targeting the aIPS and PMv of the lesioned hemisphere. The stimulation is delivered at 24 Hz with the waveforms of both fields aligned in phase. A 10-second ramp-up at the beginning and a 10-second ramp-down at the end are included to ensure participant comfort. The protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
219762444|NCT04613596|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W
219762445|NCT05948943|DRUG|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 0-5 years of age will receive dose 3 of alpelisib"
219762446|NCT05948943|DRUG|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
219762447|NCT05479981|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
219762448|NCT05479981|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
219762449|NCT05357040|DRUG|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
219762450|NCT05357040|DRUG|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
219762451|NCT03373227|DRUG|Envarsus|Patients will take once daily Envarsus
219762452|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
219762453|NCT03610750|OTHER|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
219762454|NCT03792425|PROCEDURE|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
219762455|NCT00462696|DRUG|Neoadjuvant chemotherapy|"Neoadjuvant tehrapy as per standard practice :~Patients will be treated with six cycles of neoadjuvant chemotherapy combining epirubicin (75 mg/m² on day 1) and docetaxel (75 mg/m² on day 1), administered every 21 days (Delcambre, 2005; Wenzel, 1999). This treatment regimen is in line with the latest international recommendations (Kaufmann, 2003). The addition of a leukocyte growth factor in cases of grade IV leukopenia and/or treatment postponements due to grade 3-4 toxicity will be authorized with a maximum delay of 2 weeks per cycle. Dose reductions will be authorized in 25% increments for grade 3-4 toxicity~. Systematic surgical excision of the residual lesion (or the initial tumor site) will be performed between 22 and 35 days after the last chemotherapy treatment, in the form of a lumpectomy or mastectomy, depending on the residual tumor. Lymph node dissection will be systematically associated."
219762456|NCT04176718|DRUG|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
219762457|NCT04176718|DRUG|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
219762458|NCT04176718|DRUG|Pomalidomide|predetermined dose, orally, daily per cycle
219762459|NCT04176718|DRUG|Dexamethasone|predetermined dose, orally, given 8 times per cycle
219762460|NCT04544111|DRUG|Trametinib|"2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
219193862|NCT06809959|DEVICE|Out-of-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field over the aIPS and PMv of the lesioned hemisphere at 24 Hz. In this condition, the waveforms of the two fields are shifted by 180°, creating an out-of-phase stimulation pattern. A 10-second ramp-up and ramp-down are included, and the protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
219193863|NCT06809959|DEVICE|Sham -tACS|21 minutes and 30 seconds of stimulation mimicking the setup of active tACS, with an initial 10-second ramp-up followed by a 10-second ramp-down. The remainder of the session is stimulation-free. This protocol is administered using the Starstim® device and gel-based electrodes with a π cm² surface area, maintaining the same setup as the active conditions to ensure comparability.
219193864|NCT06808542|OTHER|No intervention|No intervention
219193865|NCT06809855|DRUG|Dexamethasone|single 8mg post-operative intramuscular injection
219434644|NCT04909294|RADIATION|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
219193866|NCT06809205|DRUG|Tamsulosin 0.4 mg|administered tamsulosin 0.4 mg
219193867|NCT06809205|DRUG|Tadalafil 5mg|administered tadalafil 5 mg
219434645|NCT06110104|OTHER|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
219434646|NCT06110104|OTHER|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
219193868|NCT06809205|DRUG|Tamsulosin and Tadalafil|administered tamsulosin 0.4 mg plus tadalafil 5 mg
219762461|NCT04544111|DRUG|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
219434647|NCT06110104|OTHER|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
219434648|NCT00074542|DRUG|Epanova™ (Omega-3 Free Fatty Acids)|
219434649|NCT03422016|DIAGNOSTIC_TEST|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
219762462|NCT04544111|DRUG|PDR001|400mg IV every 4 weeks
219762463|NCT03736707|DEVICE|HFOV|"HFOV + volume guarantee (VG) as the intervention group HFOV was provided only with piston or membrane oscillators capable of delivering true oscillatory pressure with an active expiratory phase (i.e., Acutronic FABIAN-III, SLE 5000, Löwenstein Med LEONI+, or Sensormedics 3100A). Other machines offering high frequency ventilation were excluded. The lung recruitment maneuver was performed as previously described, and lung volume was assessed by chest radiography or lung ultrasound, targeting the right diaphragm at the level of 8th-9th rib (or 7th-8th rib in case of air leak).~Crossover between HFOV and CMV This study allowed infants who failed to respond to their assigned ventilation mode to receive a trial of the alternate mode. Crossover criteria for HFOV-assigned neonates included failure for 3 hours to maintain SpO2 ≥ 50% despite FiO2 of 1.0, PaCO2 \> 60 mmHg for 3 hours, or signs of ventilator-induced cardiac output reduction. Non-responders to HFOV were switched to CMV."
219193869|NCT05215405|DRUG|Venetoclax|"Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast.~* Day 1 (200 mg equivalent):~  * Patients 20 \< 30 kg will take 70 mg~ * Patients 30 \< 35 kg will take120 mg~ * Patients 35 to 45 kg will take 200 mg~* Day 2 onwards (400 mg equivalent):~  * Patients 20 \< 30 kg will take 170 mg~ * Patients 30 \< 35 kg will take 250 mg~ * Patients 35 to 45 kg will take 400 mg"
219193870|NCT05215405|DRUG|Navitoclax|"Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations.~* Patients 20 \< 45 kg will take 25 mg~* Patients 45 kg or more will take 50 mg"
219193871|NCT06808698|OTHER|Determine the gut microbiome at baseline and 12 months.|There is no separate treatment, surgery, or other intervention.
219434650|NCT00005675|DRUG|Oral bovine type I collagen|500 mcg of CI daily for 15 months
219434651|NCT00005675|DRUG|Placebo|CI placebo daily for 15 months
219434652|NCT01600391|BEHAVIORAL|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
219434653|NCT01600391|BEHAVIORAL|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
219434654|NCT01600391|BEHAVIORAL|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
219434655|NCT00511108|DRUG|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
219434656|NCT00511108|DRUG|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
219434657|NCT00511108|DRUG|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
219434658|NCT00511108|DRUG|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
219434659|NCT01234311|DRUG|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
219434660|NCT01234311|DRUG|Placebo|
219434661|NCT03186040|DRUG|Lacosamide|Sodium channel blocker
219434662|NCT02698566|DRUG|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
219434663|NCT00163163|PROCEDURE|Echographic measurements|
219434664|NCT00163163|PROCEDURE|Blood samples|
219434665|NCT05560919|DRUG|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
219434666|NCT05560919|OTHER|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
219434667|NCT05560919|OTHER|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
219434668|NCT02528799|BIOLOGICAL|Nexvax2|Nexvax2 intra-dermal injections twice weekly
219434669|NCT02528799|BIOLOGICAL|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
219434670|NCT02404584|GENETIC|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
219579163|NCT04383236|OTHER|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
219579164|NCT04383236|DRUG|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
219579165|NCT06398821|DIETARY_SUPPLEMENT|G3P-01|Nutritional supplement to promote healthy aging
219193872|NCT06806189|DRUG|Lipiodal|Injection of lipiodal for delineation of interface between the removed mouth/throat cancer and the healthy tissue reconstructing the defect for radiation planning.
219579166|NCT06398821|DIETARY_SUPPLEMENT|Placebo|Placebo
219579167|NCT03544996|COMBINATION_PRODUCT|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
219193873|NCT06805344|PROCEDURE|Extracorporeal cardiopulmonary resuscitation based approach|ECPR-based approach is defined as ACLS per current guidelines with aim to proceed to in-hospital or out-of-hospital V-A ECMO if ROSC is not achieved before the cannulation.
219434671|NCT02404584|BIOLOGICAL|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
219579168|NCT00896909|GENETIC|gene expression analysis|
219579169|NCT00896909|GENETIC|mutation analysis|
219579170|NCT00896909|GENETIC|polymerase chain reaction|
219579171|NCT00896909|OTHER|diagnostic laboratory biomarker analysis|
219579172|NCT03326609|DRUG|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
219579173|NCT02736877|PROCEDURE|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
219579174|NCT02736877|PROCEDURE|Conventional Microscope|corneal transplantation guided by Conventional Microscope
219434672|NCT02579902|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
219193874|NCT06805344|PROCEDURE|Conventional cardiopulmonary resuscitation|CCPR is defined as conventional ACLS per current guidelines without MCS use until sustained ROSC is achieved or the patient pronounced dead.
219579175|NCT01340105|PROCEDURE|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
219579176|NCT01340105|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
219579177|NCT00666783|DRUG|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
219579178|NCT00666783|DRUG|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
219193875|NCT06804889|DEVICE|CANNEFF® VAG SUP vaginal suppositories|CANNEFF® VAG SUP vaginal suppositories containing 100 mg cannabidiol - CBD and 6.6 mg hyaluronic acid - HA.
219762464|NCT03736707|DEVICE|CMV|"CMV as the standard group CMV was delivered by time-cycled, pressure-limited ventilators. Only pressure regulated volume control (PRVC) will be provided by any type of neonatal ventilator.~Crossover criteria for CMV-assigned neonates included failure for 3 hours to maintain SpO2 ≥ 50% despite FiO2 of 1.0, PaCO2 \> 60 mmHg for 3 hours, or requiring \> 30 cm H2O PIP to sustain ventilation. Non-responders to CMV were switched to HFOV.~Ventilator settings were adjusted at the discretion of the attending clinician to maintain a SpO2 between 90%-94%, a PaO2 between 50 and 80 mm Hg and a PaCO2 between 35 and 60 mm Hg and a pH between 7.20 and 7.45. PO2 and PCO2 levels were monitored using arterial blood gas analysis and/or transcutaneous monitoring in both groups."
219193876|NCT06804889|DEVICE|Placebo Suppositories|Received placebo vaginal suppositories with identical composition as for Active Comparator, but without both active ingredients (CBD - cannabidiol and HA - hyaluronic acid).
219193877|NCT05887791|DIETARY_SUPPLEMENT|Collagen hydrolysate|Single dose
219193878|NCT05887791|OTHER|Placebo|Single dose
219434673|NCT02579902|DIETARY_SUPPLEMENT|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
219579179|NCT04068415|OTHER|Constipation risk assessment scale|questionnaires
219579180|NCT00325377|PROCEDURE|MME Procedure|
219579181|NCT00557076|BEHAVIORAL|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
219579182|NCT00557076|BEHAVIORAL|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
219579183|NCT00688376|DRUG|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
219579184|NCT00688376|DRUG|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
219434674|NCT02260674|DRUG|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
219434675|NCT02260674|DRUG|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
219434676|NCT02260674|DRUG|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
219434677|NCT06186492|DRUG|WVE-006|RNA editing oligonucleotide
219434678|NCT02954952|DEVICE|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
219193879|NCT03844061|DRUG|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
219193880|NCT03844061|DRUG|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
219193881|NCT03844061|OTHER|Placebo Subcutaneous Injection|Normal Saline
219193882|NCT03844061|OTHER|Placebo Infusion|Normal Saline
219193883|NCT03844061|DRUG|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
219193884|NCT06820606|DEVICE|Rezum|In the REZUM arm, water vapour treatment will be preformed.
219193885|NCT06820606|DEVICE|UroLift|In the UroLift arm, prostatic urethral lift treatment will be performed.
219193886|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
219193887|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
219434679|NCT02954952|DEVICE|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
219434680|NCT02382770|PROCEDURE|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
219434681|NCT04866823|BEHAVIORAL|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
219434682|NCT04179032|COMBINATION_PRODUCT|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
219434683|NCT06183242|DRUG|Remaxa, enteric-coated tablets|enteric-coated tablets
219434684|NCT06183242|DRUG|Remaxol|solution for infusions
219434685|NCT06183242|DRUG|Placebo|enteric-coated tablets
219434686|NCT06667674|BEHAVIORAL|iCBT for prolonged grief|Participants will undergo a 10-week internet-delivered, therapist-led cognitive behavioral therapy treatment (iCBT) for prolonged grief, which includes psychoeducation about grief and common grief reactions, exposure, cognitive restructuring and behavioral activation.
219762465|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
219762466|NCT05721222|BIOLOGICAL|GEN1160|IV infusion of GEN1160
219762467|NCT02015013|BIOLOGICAL|Filgrastim|10 microgram/kg daily for 5 days, Subcutaneous injection.
219762468|NCT02015013|DRUG|Plerixafor|IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
219762469|NCT05098158|OTHER|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
219434687|NCT06667674|BEHAVIORAL|Active control|Participants will undergo a 10-week internet-delivered, therapist-led treatment, which includes psychoeducation about grief and common grief reactions.
219762470|NCT04967274|PROCEDURE|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus (Transcranial magnetic stimulation).
219762471|NCT05509842|DEVICE|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
219762472|NCT04628026|DRUG|Venetoclax|Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
219762473|NCT04628026|DRUG|Placebo|Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
219434688|NCT04430946|DIAGNOSTIC_TEST|Standardized test meal|A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
219434689|NCT00297128|DRUG|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
219434690|NCT00297128|DRUG|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
219434691|NCT01901978|BEHAVIORAL|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
219434692|NCT04285710|DEVICE|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
219193888|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
219193889|NCT05900154|BIOLOGICAL|RSVpreF 120 µg|RSVpreF standard dose level
219579185|NCT05420974|PROCEDURE|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
219193890|NCT05900154|BIOLOGICAL|RSVpreF 60 µg|RSVpreF low dose level
219579186|NCT00573404|DRUG|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
219579187|NCT00573404|DRUG|sunitinib malate|
219579188|NCT00573404|OTHER|pharmacological study|
219762474|NCT04628026|COMBINATION_PRODUCT|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4 without daunorubicin.~Consolidation chemotherapy with intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
219007639|NCT01499667|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
219007640|NCT01499667|DRUG|Placebo|Matching placebo in capsules for oral administration once daily.
219007641|NCT03454581|PROCEDURE|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
219007642|NCT03454581|PROCEDURE|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
219007643|NCT02968745|OTHER|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
219007644|NCT02510859|OTHER|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
219007645|NCT00132145|BEHAVIORAL|Vascular Management Program|
219007646|NCT00132145|BEHAVIORAL|Clinical Care Coordinators|
219007647|NCT00132145|BEHAVIORAL|Web-based Vascular Tracker for Patient and Physician|
219007648|NCT00132145|BEHAVIORAL|Automated Telephone Reminder System|
219007649|NCT01601249|PROCEDURE|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
219007650|NCT01052051|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU/daily
219007651|NCT01052051|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 1500mg / daily
219579189|NCT06126068|DRUG|Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia|Loading dose magnesium sulfate versus the Pritchard regimen
219579190|NCT04570540|DIAGNOSTIC_TEST|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
219007652|NCT00384995|DRUG|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
219007653|NCT00384995|DRUG|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
219007654|NCT01550380|DRUG|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
219193891|NCT05904730|DRUG|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
219579191|NCT04570540|DIAGNOSTIC_TEST|Pulmonary Function Test|Bodyplethysmographic assessment
219579192|NCT04570540|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
219579193|NCT04570540|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
219579194|NCT02631967|PROCEDURE|Kono anastomosis|Kono anastomosis
219579195|NCT02631967|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
219579196|NCT00757757|DRUG|MCS110|Anti-M-CSF antibody
219579197|NCT04253496|OTHER|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
219579198|NCT04029441|OTHER|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
219193892|NCT06855238|DEVICE|THAITI software|"THAITI is an AI-based software which predicts on the fly personalised TI for late gadolinium enhancement imaging during cardiovascular magnetic resonance scans.~The clinical investigators will be provided by the computer scientists investigators with a software, based on the developed AI model. During the CMR in the experimental group, investigators will input patients' data on the software (e.g. age, sex, dose of contrast…). The software will provide a TI value to be input in the MRI scanner. TI will be set accordingly to the AI prediction. A LGE series of 3 long axis (4-, 2- and 3-chambers view) and a short-axis stack will be acquired.~For all the patients, a doctor expert in CMR will be at the scanner and quality check the images in real time. Every image where the myocardium is not optimally nulled will be repeated with a TI set by the CMR doctor."
219193893|NCT06811064|OTHER|Testimony video|A testimonial video on the experiences of parents of premature babies during the transfer of their newborn from the intensive care unit to the neonatal unit. This video will be performed with the collaboration of the carers and resource parents.
219434693|NCT04285710|PROCEDURE|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
219434694|NCT00533169|DRUG|ZD6474|Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
219434695|NCT00533169|DRUG|Retinoic Acid|Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
219434696|NCT06145217|DRUG|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
219434697|NCT02582931|DEVICE|MRI-guided SBRT|
219434698|NCT02582931|BEHAVIORAL|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
219434699|NCT02582931|BEHAVIORAL|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
219434700|NCT04913480|DRUG|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
219434701|NCT04913480|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
219193894|NCT06813313|DEVICE|repetitive transcranial magnetic stimulation|A burst of 3 pulses sent at a frequency of 50 Hz, repeated with a frequency of 5 Hz for 2 seconds, followed by an 8-second pause. This sequence is repeated for 59 cycles, totaling 9 minutes and 50 seconds, with a total of 1800 pulses.
219579199|NCT00759135|DRUG|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
219579200|NCT00759135|DRUG|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
219579201|NCT00759135|DRUG|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
219579202|NCT00846521|DRUG|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
219579203|NCT04481321|BIOLOGICAL|Biological/Vaccine|
219579204|NCT00153608|BIOLOGICAL|WT1 126-134 peptide|
219579205|NCT01792219|OTHER|Interprofessional collaboration in health care module|An educational module
219579206|NCT04213352|OTHER|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
219579207|NCT04213352|OTHER|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
219193895|NCT06807034|OTHER|buccal swabs|buccal swabs for microbiota analysis before and after radiotherapy
219193896|NCT06807528|BEHAVIORAL|Intermittent fasting|Participants will follow a 16:8 protocol whereby they will be asked to fast for 16 hours per day and allowed to eat ad-libitum for the remaining 8 hours. While (for feasibility purposes) it will be a requirement that the fasting period include time spent asleep, participants will be allowed some degree of flexibility in the start and end time of their fasting period. This will be performed in order to accommodate participant preferences (sleeping/eating/medication schedules) as best as possible and provide a sense of autonomy. During the non-fasting hours, participants will be permitted to eat ad libitum.
219193897|NCT06807528|BEHAVIORAL|Behavioral Support Strategies|Evidence-based self regulatory health behaviour support techniques including education, ongoing tailored feedback and encouragement, self monitoring tools, and goal setting will be used to help participants adhere to the fasting protocol. These techniques will be implemented via weekly phone calls to allow for coaching (e.g. barrier identification, strategies/action planning to overcome barriers, goal setting) as well as a smartphone app. The smartphone application will provide information pertaining to intermittent fasting including lay summaries of clinical trials as well as infographics related to healthy eating for the ad-libitum eating periods. Tips for healthy eating on a budget and adhering to an intermittent fasting protocol will also be provided. The smartphone app will also feature intermittent fasting start and stop time reminders, hydration reminders, and the ability to set one's individualized fasting schedule and record actual daily fasting windows.
219193898|NCT03309644|OTHER|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
219193899|NCT03309644|OTHER|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
219193900|NCT03434769|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
219193901|NCT03434769|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
219193902|NCT03434769|BIOLOGICAL|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
219579208|NCT00257218|BEHAVIORAL|Life style modification|
219579209|NCT04650152|DRUG|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
219579210|NCT04404452|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
219579211|NCT02551432|DRUG|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
219579212|NCT00593632|DIETARY_SUPPLEMENT|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
219579213|NCT00017537|BIOLOGICAL|MVF-HER-2(628-647)-CRL 1005 vaccine|
219579214|NCT02912585|BIOLOGICAL|Oropharyngeal administration of own mother's colostrum|
219579215|NCT02912585|OTHER|Oropharyngeal administration of sterile water (placebo)|
219579216|NCT02912585|BIOLOGICAL|Oropharyngeal administration of donor human milk|
219579217|NCT03816215|BEHAVIORAL|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
219579218|NCT05693207|DEVICE|EMG|wearables EMG
219579219|NCT01246011|DRUG|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
219579220|NCT00930371|OTHER|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
219579221|NCT00930371|OTHER|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
219579222|NCT02871271|DIETARY_SUPPLEMENT|IQP-AS-121|
219193903|NCT06397534|OTHER|Education|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
219434702|NCT05307341|DRUG|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
219434703|NCT03230721|PROCEDURE|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
219434704|NCT03230721|PROCEDURE|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
219434705|NCT03230721|PROCEDURE|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
219579223|NCT01988961|BIOLOGICAL|Golimumab|SC injections
219579224|NCT04406597|DEVICE|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
219579225|NCT02641197|DEVICE|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
219579226|NCT00902720|OTHER|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
219579227|NCT02468063|DRUG|Low dose terlipressin|Terlipressin-2mg (low dose )
219579228|NCT02468063|DRUG|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
219579229|NCT02468063|DRUG|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
219579230|NCT03795896|DIAGNOSTIC_TEST|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
219579231|NCT02599636|OTHER|None intervention|Investigators will study the usual medical assistance
219579232|NCT01663935|DRUG|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
219579233|NCT05089318|DIETARY_SUPPLEMENT|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
219579234|NCT02792959|DEVICE|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
219579235|NCT02792959|DEVICE|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
219579236|NCT05912907|OTHER|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
219579237|NCT00057083|OTHER|Telemedicine Care|
219579238|NCT00038987|BIOLOGICAL|Wetvax (APSV)|
219579239|NCT06168877|DIAGNOSTIC_TEST|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
219579240|NCT00040053|DRUG|Ondansetron|
219579241|NCT01524614|PROCEDURE|nasal mask|nasal mask use instead of face mask
219193904|NCT06671704|OTHER|Genetic counseling months 4-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.
219193905|NCT06671704|OTHER|Genetic counseling months 6-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.
219193906|NCT06671704|OTHER|Genetic counseling months 8-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.
219579242|NCT05206292|DIAGNOSTIC_TEST|Sulfitest|Urine strip to detect the presence of sulfites in urine. Immediate result.
219579243|NCT00119067|BIOLOGICAL|Anthrax Vaccine Adsorbed|
219579244|NCT00119067|BIOLOGICAL|Saline injection|
219579245|NCT03155386|OTHER|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
219579246|NCT03674086|DEVICE|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
219193907|NCT06671704|OTHER|Genetic counseling at months 10-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.
219193908|NCT06671704|OTHER|Genetic counseling at months 12-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.
219193909|NCT06671704|OTHER|Genetic counseling at months 14-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
219193910|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
219193911|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
219193912|NCT03668041|DRUG|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
219193913|NCT03668041|DRUG|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
219193914|NCT03668041|OTHER|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
219193915|NCT05039554|BEHAVIORAL|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
219434706|NCT04252248|DRUG|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
219193916|NCT05039554|OTHER|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
219434707|NCT03168841|DRUG|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
219434708|NCT05554718|BEHAVIORAL|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
219434709|NCT05554718|BEHAVIORAL|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
219434710|NCT06167772|DIETARY_SUPPLEMENT|BCAA|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days"
219434711|NCT06167772|OTHER|Standard nutrition|Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
219434712|NCT06167772|OTHER|Standard physiotherapy|A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
219434713|NCT01455506|DRUG|Decitabine plus Fludarabine and Busulfan|"* Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
219434714|NCT04539262|DRUG|Remdesivir (RDV)|Administered as an aerosolized solution
219434715|NCT04539262|DRUG|Placebo|Administered as an aerosolized solution
219434716|NCT05169736|BEHAVIORAL|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
219434717|NCT05590104|PROCEDURE|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
219434718|NCT04831268|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
219434719|NCT04831268|OTHER|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
219193917|NCT05039554|OTHER|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
219434720|NCT04831268|OTHER|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
219434721|NCT04831268|OTHER|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
219434722|NCT03157336|OTHER|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
219434723|NCT02270489|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
219434724|NCT02270489|BIOLOGICAL|AFFITOPE® PD03A + Adjuvant|s.c. injection
219579247|NCT04229524|PROCEDURE|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
219579248|NCT00242619|DRUG|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
219193918|NCT05961358|PROCEDURE|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
219193919|NCT05961358|PROCEDURE|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
219193920|NCT04528407|OTHER|Observation without intervention|This study is a follow-up study without intervention.
219579249|NCT04199013|DRUG|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
219193921|NCT04046094|DRUG|Ascorbic Acid|Ascorbic Acid Intravenous
219193922|NCT05975268|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
219193923|NCT02865538|DRUG|BAY3427080|
219193924|NCT02865538|DRUG|Placebo (for BAY3427080)|
219193925|NCT02622438|OTHER|Followed with an initial assessment, 12 months and followed annually corresponding to the usual follow-up of the patient.|
219193926|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
219579250|NCT04199013|DRUG|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
219193927|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
219579251|NCT02143635|DRUG|HDM201|
219579252|NCT02143635|DRUG|ancillary treatment|
219579253|NCT02517437|DRUG|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
219579254|NCT02517437|DRUG|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
219579255|NCT06088056|DRUG|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
219579256|NCT00327288|DRUG|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
219579257|NCT00327288|DRUG|docetaxel|IV once every 21 days for duration of study
219193928|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
219193929|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
219193930|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
219193931|NCT04112381|DEVICE|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
219193932|NCT05970809|DEVICE|SAGA-001 (A)|Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
219193933|NCT05970809|DEVICE|SAGA-001 (B)|Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
219434725|NCT02270489|BIOLOGICAL|Adjuvant without active component|s.c. injection
219434726|NCT04207008|OTHER|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
219434727|NCT03174561|DIETARY_SUPPLEMENT|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
219434728|NCT03174561|OTHER|diet restriction|diet restriction for 28 days
219434729|NCT02351739|DRUG|pembrolizumab|
219434730|NCT02351739|DRUG|ACP-196 in combination with pembrolizumab|
219007655|NCT05039242|OTHER|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
219007656|NCT05039242|OTHER|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
219007657|NCT05039242|OTHER|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
219007658|NCT01034462|DRUG|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
219007659|NCT01034462|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
219193934|NCT05532566|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
219193935|NCT02055833|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
219193936|NCT02055833|OTHER|Nutritional counseling|Nutritional counseling
219193937|NCT04565990|DRUG|Selexipag|Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
219434731|NCT04400227|OTHER|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
219434732|NCT02482740|DRUG|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
219434733|NCT02482740|DRUG|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
219434734|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
219193938|NCT05151302|DIAGNOSTIC_TEST|computer vision symptom scale (CVSS) questionnaire|Subjects working at VDT for \>20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
219193939|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
219434735|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
219434736|NCT02773056|DEVICE|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
219434737|NCT02773056|DEVICE|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
219193940|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
219193941|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
219193942|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
219193943|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
218859571|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
218859572|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
219193944|NCT06220721|DRUG|Nifedipine ER|Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.
219193945|NCT06860568|OTHER|Retrospective Study|Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.
219193946|NCT05612880|DRUG|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
219193947|NCT06717126|DRUG|roginolisib|rognolisib
219193948|NCT06717126|DRUG|Investigator choice of standard therapy|Investigator will choose the most appropriate treatment standardly given to patients
219193949|NCT06965049|OTHER|Probiotic|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
219193950|NCT06965049|OTHER|Placebo|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
219193951|NCT06965608|BEHAVIORAL|WhatsApp-Based Cancer Prevention Messaging|Participants in this group will receive a structured series of WhatsApp messages containing evidence-based cancer prevention recommendations from the Latin America and Caribbean Code Against Cancer (LAC Code). Messages will be delivered over four weeks, 3 times a week, covering key topics such as smoking cessation, healthy diet, physical activity, and regular screening. Engagement metrics will be tracked to assess feasibility and adherence.
219193952|NCT06965608|BEHAVIORAL|Online Cancer Prevention Workshop for Healthcare Professionals|Healthcare professionals assigned to this group will participate in an online workshop designed to improve their knowledge of the LAC Code and communication strategies for cancer prevention counseling. The workshop includes recorded lectures, interactive modules, and knowledge assessments. Completion rates and participant satisfaction will be measured.
219434738|NCT02773056|DEVICE|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
219434739|NCT02260895|DIETARY_SUPPLEMENT|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
219434740|NCT05471206|OTHER|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
219434741|NCT03184116|BEHAVIORAL|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
219434742|NCT03914534|DRUG|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
219434743|NCT03914534|DRUG|Valcote 500 mg|Administration of 500 mg of Valproic Acid
219434744|NCT02954302|PROCEDURE|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
219434745|NCT02954302|PROCEDURE|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
219434746|NCT05499598|PROCEDURE|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
218859573|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
219007660|NCT01252017|DRUG|nilotinib|nilotinib (200mg/tab) 1 tab everyday
219434747|NCT05499598|PROCEDURE|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
219007661|NCT05346159|DIAGNOSTIC_TEST|the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS|"Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior"
219007662|NCT01229059|DIETARY_SUPPLEMENT|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
219434748|NCT00292578|PROCEDURE|NAET Testing Modalities|
219434749|NCT00555282|DEVICE|central venous catheter|coated central venous catheter
219193953|NCT06965608|BEHAVIORAL|Combined WhatsApp Messaging and Online Workshop|Participants in this group will receive both interventions: WhatsApp messages with cancer prevention recommendations and access to the online workshop. The intervention aims to assess whether a combined approach enhances adherence and impact. Engagement with both interventions will be monitored.
219193954|NCT06965855|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
218859574|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
218859575|NCT06960031|OTHER|PET/CT technique|"Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner.~The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min."
219007663|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
219007664|NCT01594125|DRUG|Nintedanib low dose|twice daily oral dosing
219007665|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
219007666|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
219007667|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
219007668|NCT01404390|DRUG|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
219193955|NCT06965855|PROCEDURE|piezoelectric surgery|Description: This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
219193956|NCT05239000|OTHER|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
219193957|NCT05239000|OTHER|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
219193958|NCT04302051|DIAGNOSTIC_TEST|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
219193959|NCT04302051|DIAGNOSTIC_TEST|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
219193960|NCT04681690|OTHER|No intervention, observation only.|Observation only
219193961|NCT05789225|BEHAVIORAL|Fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program is group-based with 8 participants in each group, led by a facilitator, and performed online. It comprises seven two-hour sessions held once a week, and a booster session held four weeks after the seventh session. In addition participants will receive a brochure about falls and fall risk factors.
219193962|NCT05789225|OTHER|Brochure|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
219193963|NCT06559475|PROCEDURE|Super-Bore Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.
219193964|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
219434750|NCT00555282|DEVICE|central venous catheter|standard central venous catheter
219434751|NCT00511121|DRUG|STI571 and PEG INTRON|
219434752|NCT02665468|BEHAVIORAL|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
219193965|NCT05766670|DRUG|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
219193966|NCT05766670|DRUG|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
219193967|NCT05766670|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
219193968|NCT01961986|PROCEDURE|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
219193969|NCT01961986|PROCEDURE|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
219007669|NCT01404390|DRUG|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
219193970|NCT03850457|OTHER|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
219193971|NCT06514807|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
219193972|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
219193973|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
219193974|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
219193975|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
219193976|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
219193977|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
219193978|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
219193979|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
219193980|NCT03428828|DEVICE|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219193981|NCT03428828|DEVICE|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219193982|NCT05391737|DIAGNOSTIC_TEST|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
219434753|NCT02665468|BEHAVIORAL|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
219434754|NCT04045691|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
219434755|NCT04045691|DRUG|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
219434756|NCT03370198|BIOLOGICAL|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
219193983|NCT05391737|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
219193984|NCT05391737|DIAGNOSTIC_TEST|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
219193985|NCT05216653|DRUG|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
219193986|NCT05216653|DRUG|Oxaliplatin|130mg/m2，ivgtt，d1
219193987|NCT05216653|DRUG|Capecitabine|1000mg/m2，po，bid，d1-14
219193988|NCT05216653|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
219193989|NCT05216653|PROCEDURE|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
219193990|NCT01743950|DRUG|Bevacizumab|10mg/kg every 2weeks.
219007670|NCT02562430|DRUG|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
219007671|NCT02562430|DRUG|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
219007672|NCT02678845|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
219007673|NCT04688307|BEHAVIORAL|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
219762475|NCT04628026|OTHER|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
219762476|NCT03841617|DRUG|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
219762477|NCT03841617|RADIATION|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
219762478|NCT03841617|RADIATION|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
219762479|NCT03841617|OTHER|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
219007674|NCT03327298|PROCEDURE|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
219007675|NCT03206645|DRUG|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
219007676|NCT04914104|BEHAVIORAL|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
219007677|NCT06495164|DRUG|Palbociclib|CDK4/6 inhibitor
219193991|NCT01743950|RADIATION|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
219762480|NCT05756426|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
219762481|NCT06001268|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
219007678|NCT06495164|DRUG|Aromatase inhibitor|Aromatase inhibitor
219007679|NCT06495164|DRUG|Ribociclib|CDK4/6 inhibitor
219434757|NCT04612803|DRUG|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
219434758|NCT02021071|RADIATION|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
219434759|NCT02021071|RADIATION|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
219434760|NCT03487406|DRUG|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
219434761|NCT03487406|DRUG|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
219434762|NCT03487406|DRUG|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
219007680|NCT06495164|DRUG|Abemaciclib|CDK4/6 inhibitor
219007681|NCT03441854|DEVICE|HFNC group|Application of HFNC oxygen delivery after extubation.
219434763|NCT03487406|DRUG|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
219434764|NCT03720301|PROCEDURE|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression"
219434765|NCT03720301|PROCEDURE|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
219434766|NCT01442701|OTHER|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
219434767|NCT00398307|DRUG|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
219579258|NCT01390285|DEVICE|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
219579259|NCT01390285|DEVICE|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
219579260|NCT02693093|DRUG|NI-03|
219579261|NCT02693093|DRUG|Placebo|
219579262|NCT03580083|GENETIC|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
219579263|NCT01948713|OTHER|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
219007682|NCT01484873|DRUG|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
219007683|NCT04918550|OTHER|no drug and device|there is no intervention
219434768|NCT01494415|DRUG|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
219579264|NCT01948713|OTHER|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
219434769|NCT01494415|DRUG|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
219434770|NCT01494415|RADIATION|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
219434771|NCT01767012|DEVICE|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
219434772|NCT01767012|DEVICE|Polylens EC-Y10-PAL (uncoated)|
219434773|NCT04205695|PROCEDURE|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
219007684|NCT06131307|PROCEDURE|Education|Paternalistic leadership training will be given to clinical manager nurses.
219007685|NCT03416257|OTHER|No intervention|
219007686|NCT02461355|BEHAVIORAL|Aphasia therapy|Aphasia therapy using a computerized scripting program
219007687|NCT02461355|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
219007688|NCT02461355|DEVICE|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
219007689|NCT04751825|BEHAVIORAL|I-EAET|See information in arm description.
219007690|NCT01741922|DRUG|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
219007691|NCT01741922|DRUG|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
219007692|NCT01741922|DRUG|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
219193992|NCT03229057|DRUG|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
219579265|NCT00822341|DRUG|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
219579266|NCT05797818|DEVICE|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene Blue (0.01%) + 4 minutes of light treatment"
219762482|NCT06001268|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
219193993|NCT03229057|DRUG|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
219434774|NCT04205695|PROCEDURE|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
219434775|NCT04205695|PROCEDURE|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
219434776|NCT05872256|DRUG|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
219434777|NCT01600001|DRUG|KWA-0711|
219434778|NCT01600001|DRUG|Placebo|
219434779|NCT05289856|DRUG|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
219434780|NCT04898127|DIAGNOSTIC_TEST|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
219434781|NCT03496441|OTHER|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
219434782|NCT03954990|DRUG|Metronidazole Oral|4 tablets (2 g of metronidazole)
219434783|NCT03954990|DRUG|Placebo Oral Tablet|4 tablets
219434784|NCT03024385|BEHAVIORAL|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
219434785|NCT02608372|OTHER|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
219434786|NCT02608372|OTHER|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
219434787|NCT02608372|OTHER|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
219762483|NCT06001268|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
219762484|NCT05035212|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
219762485|NCT05035212|BIOLOGICAL|Placebo|Placebo
219762486|NCT05514444|BIOLOGICAL|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
219762487|NCT05514444|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
219762488|NCT05514444|DRUG|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
219762489|NCT06343298|DRUG|MANP|MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
219762490|NCT06343298|OTHER|Placebo Matched control|This is a placebo matched vehicle - Vehicle minus the active ingredient
219762491|NCT06476288|OTHER|Low-intensity resistance exercise training|The intervention protocol will consist of 60 minutes of low-intensity resistance exercise training 3x/week for 6 weeks.
219762492|NCT06476288|OTHER|High-Dose Remote ischemic conditioning (RIC)|Treatment dose of RIC- the RIC cuff will be inflated to 20 mmHg over the participant's systolic blood pressure. The treatment dose of RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
219762493|NCT06476288|OTHER|Low-Dose Remote ischemic conditioning (RIC)|This dose will be the control for the study. Low-dose RIC- the RIC cuff will be inflated to 10 mmHg below the participant's diastolic blood pressure. The low-dose RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
219762494|NCT03586609|DRUG|Azacitidine|Given SC or IV
219762495|NCT03586609|DRUG|Cladribine|Given IV
219762496|NCT03586609|DRUG|Cytarabine|Given SC
219762497|NCT03586609|DRUG|Venetoclax|Given PO
219762498|NCT06315751|DRUG|Gemlapodect|Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.
219762499|NCT06315751|DRUG|Placebo|Administered in the form of oral capsules with inert ingredients.
219762500|NCT06267248|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
219762501|NCT06065540|DRUG|Cagrilintide|Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
219434788|NCT06009068|OTHER|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
219762502|NCT06065540|DRUG|Semaglutide|Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
219762503|NCT06065540|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
219762504|NCT06065540|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
219762505|NCT00018044|DRUG|Clofazimine|
219762506|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
219762507|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
219762508|NCT05282485|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
219762509|NCT05282485|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
219762510|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
219762511|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
219762512|NCT05691530|DRUG|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
219762513|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
219762514|NCT05519449|DRUG|Darolutamide|Darolutamide is dosed via oral tablets
219762515|NCT06074861|PROCEDURE|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
219762516|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. \- Installation of a short stretch belt (urgo K2® kit)~2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. \- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
219762517|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
219762518|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
219762519|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219762520|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
219762521|NCT05941520|OTHER|Questionnaire Administration|Ancillary studies
219762522|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
219762523|NCT05941520|DRUG|Tamoxifen|Given PO
219762524|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
219762525|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
219762526|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
219762527|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
219193994|NCT03229057|DRUG|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
219193995|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
219193996|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
219579267|NCT05797818|DEVICE|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
219579268|NCT05797818|DEVICE|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
219579269|NCT05797818|DEVICE|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- 4 minutes of light treatment only"
219579270|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
219579271|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
219434789|NCT04399057|DIAGNOSTIC_TEST|shear Wave Elastosonography|both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
219434790|NCT01706991|DEVICE|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
219193997|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
219434791|NCT04655768|DEVICE|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
219434792|NCT03015623|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
219579272|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
219193998|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
219193999|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
219194000|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
219194001|NCT04842682|BIOLOGICAL|Late boost CD40 alone|CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
219194002|NCT04842682|BIOLOGICAL|Late boost CD40 adjuvanted|CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
219194003|NCT05423730|OTHER|White Wine|One serving (5 ounces) of white wine daily for 3 weeks
219194004|NCT05423730|OTHER|Grape Juice|One serving (6 ounces) of white grape juice daily for 3 weeks
219194005|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
219194006|NCT06578455|DRUG|Cannabidiol (CBD) Powder|66.68 mg CBD per capsule for a total of 400 mg CBD per serving
219194007|NCT06578455|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|100 mg CBD/mL for a total of 400 mg CBD per serving
219194008|NCT01989013|OTHER|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
219194009|NCT06561893|DIETARY_SUPPLEMENT|Broccoli sprouts extract supplementation|Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
219194010|NCT01130519|DRUG|Bevacizumab|Commercially available. Administered by intravenous infusion.
219194011|NCT01130519|DRUG|Erlotinib|Commercially available. Administered orally.
219434793|NCT03015623|DEVICE|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
219434794|NCT01744457|DEVICE|Measurement of tear film osmolarity with the TearLab® instrument|
219434795|NCT01744457|OTHER|Schirmer I test|
219762528|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
219762529|NCT03776812|DRUG|Relacorilant|Relacorilant is supplied as capsules for oral dosing.
219434796|NCT01744457|OTHER|Tear break up time|
219434797|NCT01744457|DEVICE|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
219194012|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
219194013|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
219194014|NCT05203445|DRUG|Olaparib|Olaparib 300 mg orally BID
219194015|NCT05203445|DRUG|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
219194016|NCT05363163|DEVICE|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
219194017|NCT03911739|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
219194018|NCT03911739|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
219434798|NCT01744457|OTHER|Ocular Surface Disease Index|
219434799|NCT02019017|DRUG|Botulinum Toxin Type A 25 IU|
219434800|NCT02019017|DRUG|Botulinum Toxin Type A 50 IU|
219434801|NCT00216268|DRUG|Ribavirin|
219434802|NCT00268463|DRUG|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
219434803|NCT00268463|DRUG|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
219434804|NCT00268463|DRUG|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
219434805|NCT02435862|DRUG|1.0mg Luminate®|
219434806|NCT02435862|DRUG|2.0mg Luminate®|
219434807|NCT02435862|DRUG|3.0mg Luminate®|
219434808|NCT02435862|OTHER|Balanced Salt Solution for intravitreal injection in 0.10cc|
219434809|NCT00228410|DRUG|Tigecycline|
219762530|NCT03776812|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
219762531|NCT06045247|DRUG|Prednisone|Given by IV (vein)
219762532|NCT06045247|DRUG|Rituximab|Given by IV (vein)
219762533|NCT06045247|DRUG|Cyclophosphamide|Given by IV (vein)
219762534|NCT06045247|DRUG|Vincristine|Given by IV (vein)
219762535|NCT06045247|DRUG|Epcoritamab|Given under the skin
219762536|NCT05145010|DRUG|Infigratinib|Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
219194019|NCT06466356|OTHER|Psychoeducational Course for Suicide Prevention|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
219194020|NCT06466356|OTHER|Individual therapy session|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
219194021|NCT06466356|OTHER|Treatment as usual|Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
219194022|NCT06574048|DRUG|saline placebo|IV saline bolus
219194023|NCT06574048|DRUG|Dexamethasone|10mg IV Dexamethasone
219434810|NCT00228410|DRUG|vancomycin with aztreonam|
219434811|NCT00047853|DEVICE|Shock device|A participant could receive a shock or not receive as shock
219434812|NCT00047853|DEVICE|Acoustic startle|Acoustic startle for MEG only
219434813|NCT00383877|DRUG|insulin detemir|
219434814|NCT00383877|DRUG|insulin NPH|
219434815|NCT04206670|DEVICE|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
219434816|NCT04206670|DEVICE|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
219434817|NCT02654470|DEVICE|Watchman FLX|Patients who are receiving the Watchman FLX device
219434818|NCT02443805|BIOLOGICAL|300 IR|300 IR tablet of HDM Allergen Extracts
219762537|NCT05145010|DRUG|Infigratinib|Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
219434819|NCT02443805|BIOLOGICAL|Placebo|Placebo tablet
219762538|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
219434820|NCT02090465|DRUG|Ingenol Mebutate|No intervention: observation of routine use of Picato®
219434821|NCT00400556|DRUG|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
219434822|NCT03656666|DRUG|Apremilast|Apremilast oral tablets
219434823|NCT03656666|DRUG|Placebo|Placebo oral tablets
219579273|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
219579274|NCT01008852|DRUG|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
219579275|NCT03282474|DRUG|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
219579276|NCT02257463|DRUG|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
219579277|NCT02257463|OTHER|peripheral muscles exercise training|
219579278|NCT02257463|DEVICE|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
219579279|NCT04236726|OTHER|Questionnaire|HRQoL questionnaires
219579280|NCT00006466|DRUG|beta alethine|
219579281|NCT02967796|DIETARY_SUPPLEMENT|Proteochoc|
219579282|NCT00003708|DRUG|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
219579283|NCT03591523|DIAGNOSTIC_TEST|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
219579284|NCT03591523|DIAGNOSTIC_TEST|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
219579285|NCT02263781|PROCEDURE|Blood draw|Blood draw
219579286|NCT02263781|PROCEDURE|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
219194024|NCT06575465|BEHAVIORAL|Healthy lifestyle nutrition, culture and physical activity workshops|The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
219194025|NCT06575465|OTHER|Usual care|Usual care patients receive in their primary health care
219194026|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
219194027|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
219434824|NCT04595409|DRUG|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
219194028|NCT01408225|PROCEDURE|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
219194029|NCT03673501|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
219194030|NCT03673501|DRUG|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
219194031|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
219762539|NCT06641050|DIAGNOSTIC_TEST|Triage+ Score|The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
219194032|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
219194033|NCT06790953|PROCEDURE|Group- A Conventional Sensed Mouth Wash|"In Group- A Conventional Sensed Mouth Wash will be used for treatment of Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
219194034|NCT06790953|PROCEDURE|Group-B Novel Titania nanoparticles enriched Mouth Wash|"In Group-B Novel Titania nanoparticles enriched Mouth wash will be used to treat the Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
219434825|NCT04595409|DRUG|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
219434826|NCT00419458|PROCEDURE|inspiratory muscle strength training|
219194035|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
219434827|NCT04362813|DRUG|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
219434828|NCT04362813|DRUG|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
219434829|NCT00961116|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
219434830|NCT00961116|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
219762540|NCT05673148|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
219762541|NCT05673148|PROCEDURE|Resection|undergo surgical resection
219762542|NCT05673148|PROCEDURE|Microwave Ablation|undergo microwave ablation
219762543|NCT05673148|DRUG|Chemotherapy|Receive SOC chemotherapy
219762544|NCT05673148|PROCEDURE|Computed Tomography|Undergo CT scan
219762545|NCT05673148|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762546|NCT05673148|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219762547|NCT04671667|DRUG|Carboplatin|Given IV
219762548|NCT04671667|DRUG|Cisplatin|Given IV
219762549|NCT04671667|PROCEDURE|Computed Tomography|Undergo CT
219762550|NCT04671667|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219762551|NCT04671667|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762552|NCT04671667|BIOLOGICAL|Pembrolizumab|Given IV
219762553|NCT04671667|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
219762554|NCT04496362|DRUG|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
219762555|NCT02917798|BEHAVIORAL|Assessments|
219762556|NCT06036875|OTHER|Non-Interventional Study|Non-interventional study
219762557|NCT06200207|DRUG|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
219762558|NCT06200207|DRUG|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
219762559|NCT04107077|DRUG|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
219762560|NCT04107077|DRUG|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
219762561|NCT06325683|PROCEDURE|Biopsy Procedure|Undergo biopsy
219762562|NCT06325683|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762563|NCT06325683|DRUG|Lomustine|Given PO
219762564|NCT06325683|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762565|NCT06325683|BIOLOGICAL|Nivolumab|Given IV
219762566|NCT06325683|BIOLOGICAL|Relatlimab|Given IV
219194036|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
219194037|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
219194038|NCT06529133|OTHER|Evaluation of postural control|Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
219194039|NCT05083806|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
219194040|NCT05684484|DRUG|Roflumilast 500 MCG Oral Tablet [DALIRESP]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
219434831|NCT04824222|DRUG|Human fecal microbiota, MBiotix HBI|The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
219194041|NCT05684484|DRUG|amino salicylic acid|conventional treatment
219194042|NCT02671448|BEHAVIORAL|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
219194043|NCT02671448|BEHAVIORAL|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
219762567|NCT06325683|PROCEDURE|Surgical Procedure|Undergo surgery
219762568|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
219194044|NCT02671448|BEHAVIORAL|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
219194045|NCT05969483|DEVICE|pEEG monitoring|pEEG monitoring during PICU admission
219194046|NCT06209684|PROCEDURE|Titanium|Spinal stabilization using titanium screws and rods
219194047|NCT06209684|PROCEDURE|Carbofix|Spinal stabilization using CarboFix screws and rods
219194048|NCT06579677|OTHER|Without any intervention|No interventions will be performed.
219194049|NCT03183895|DEVICE|Left ventricular restoration|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
219434832|NCT04824222|DRUG|Placebo|Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
219762569|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
219762570|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219762571|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
219762572|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
219762573|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219762574|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
219762575|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
219762576|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
219762577|NCT01154582|DIETARY_SUPPLEMENT|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
219007693|NCT01741922|DRUG|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
219007694|NCT03090854|DIAGNOSTIC_TEST|ADASCog|Neuropsychological test
219007695|NCT04922203|OTHER|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
219194050|NCT05611775|DEVICE|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
219194051|NCT05903274|DRUG|JSP191|Subjects will receive intravenous JSP191
219194052|NCT04191057|OTHER|Free light chains|Blood samples will be collected and analyzed
219194053|NCT04709419|DEVICE|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
219194054|NCT04709419|DEVICE|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
219434833|NCT04824222|DRUG|SOC|The standard COVID 19 pharmacological treatment
219434834|NCT01787955|PROCEDURE|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
219434835|NCT01787955|PROCEDURE|conventional PPPD|
219434836|NCT01543113|OTHER|sequencing|sequencing
219434837|NCT00354952|DRUG|Macrolides (azithromycin or clarithromycin)|
219434838|NCT01082003|DRUG|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
219007696|NCT05481645|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
219434839|NCT00007982|BIOLOGICAL|filgrastim|
219194055|NCT04225585|BEHAVIORAL|CST-PSP|skills training and experiential learning exercises
219194056|NCT04225585|BEHAVIORAL|General health education|general health education intervention that focuses on improving overall health
219194057|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
219194058|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
219194059|NCT05317234|GENETIC|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
219194060|NCT04540068|DRUG|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
219194061|NCT05653466|BEHAVIORAL|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
219194062|NCT05653466|BEHAVIORAL|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
219007697|NCT05481645|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219007698|NCT05481645|DRUG|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
219007699|NCT05481645|DRUG|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
219007700|NCT05481645|DRUG|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
219007701|NCT05481645|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
219579287|NCT06389643|PROCEDURE|Four-point scleral fixation of Akreos AO60 IOL|Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
219007702|NCT05481645|DRUG|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
219007703|NCT01053689|DRUG|Glimepiride tablets 1 mg|
219007704|NCT02618434|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
219007705|NCT02618434|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
219007706|NCT02618434|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
219007707|NCT02234375|DRUG|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
219007708|NCT03430596|DRUG|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
219007709|NCT03430596|DRUG|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
219007710|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
219007711|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
219434840|NCT00007982|DRUG|carmustine|
219007712|NCT01988103|DRUG|Placebo|Placebo tablet BID for 16 weeks
219194063|NCT05653466|BEHAVIORAL|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
219007713|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
219007714|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
219194064|NCT03931408|DRUG|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
219194065|NCT03931408|OTHER|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
219434841|NCT00007982|DRUG|cisplatin|
219434842|NCT00007982|DRUG|cyclophosphamide|
219434843|NCT00007982|DRUG|etoposide|
219434844|NCT00007982|DRUG|thiotepa|
219434845|NCT00007982|PROCEDURE|adjuvant therapy|
219434846|NCT00007982|PROCEDURE|autologous bone marrow transplantation|
219434847|NCT00007982|PROCEDURE|bone marrow ablation with stem cell support|
219434848|NCT00007982|PROCEDURE|peripheral blood stem cell transplantation|
219434849|NCT05191849|DIAGNOSTIC_TEST|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
219434850|NCT02763241|DRUG|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
219434851|NCT02763241|DRUG|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
219434852|NCT00753688|DRUG|PAZOPANIB|800 mg once daily orally
219434853|NCT00753688|DRUG|Placebo|matching placebo 800 mg once daily orally
219434854|NCT05738772|DIAGNOSTIC_TEST|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
219194066|NCT03931408|OTHER|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
219194067|NCT00319033|DRUG|bosentan|
219194068|NCT05422430|BEHAVIORAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
219194069|NCT05422430|BEHAVIORAL|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
219194070|NCT02829437|OTHER|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
219194071|NCT05759663|PROCEDURE|MIRRAD|Repair of the diastasis with MIRRAD technique
219194072|NCT05759663|PROCEDURE|Plication of the entire diastasis arm|Plication of the entire diastasis
219194073|NCT04340505|DRUG|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
219194074|NCT04086589|OTHER|Observational study without intervention|Observational study without intervention
219434855|NCT02043184|BEHAVIORAL|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
219434856|NCT00855387|OTHER|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
219434857|NCT04063072|PROCEDURE|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
219194075|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
219434858|NCT01893684|BEHAVIORAL|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
219762578|NCT01154582|DIETARY_SUPPLEMENT|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
219434859|NCT01893684|BEHAVIORAL|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
219434860|NCT01893684|BEHAVIORAL|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
219434861|NCT03595384|BEHAVIORAL|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
219434862|NCT03803202|BIOLOGICAL|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
219434863|NCT03803202|BIOLOGICAL|PCV13|Participants received a single dose of PCV13 intramuscularly.
219434864|NCT03803202|BIOLOGICAL|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
219194076|NCT01314105|DRUG|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
219194077|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
219434865|NCT00293241|DEVICE|Managed Ventricular Pacing programmed ON/OFF|Device programming
219434866|NCT02181985|DRUG|Full dose TNK-tPA|
219434867|NCT02181985|DRUG|Half dose TNK-tPA|
219434868|NCT02181985|DRUG|Heparin|
219434869|NCT02181985|DRUG|Enoxaparin|
219434870|NCT02181985|DRUG|Abciximab|
219434871|NCT03162393|PROCEDURE|nerve transfer|
219434872|NCT02715583|DRUG|11C-Acetate|
219434873|NCT03368040|DEVICE|Tcore|Monitoring system to measure body temperature based on heat-flux technology
219194078|NCT05342415|OTHER|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
219434874|NCT02080286|BEHAVIORAL|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
219762579|NCT05130866|DRUG|REC-2282|Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
219762580|NCT05130866|DRUG|Placebo|Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
219762581|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762582|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762583|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762584|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762585|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762586|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
219762587|NCT05812807|BIOLOGICAL|Pembrolizumab|Given IV
219762588|NCT05812807|OTHER|Patient Observation|Undergo observation
219762589|NCT05812807|PROCEDURE|Biopsy|Undergo biopsy
219762590|NCT05812807|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219194079|NCT05342415|OTHER|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
219194080|NCT03841253|PROCEDURE|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
219194081|NCT03841253|PROCEDURE|Trans-epithelial PTK (retrospective data collection)|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
219194082|NCT03841253|PROCEDURE|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
219194083|NCT06305078|OTHER|Personalized ADHD Medication Experiment|All parent/adolescent dyads will select and complete a medication experiment.
219194084|NCT03380962|DRUG|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
219194085|NCT06272734|DEVICE|Reprieve System|"The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features."
219579288|NCT06389643|PROCEDURE|Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique|The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
219579289|NCT01780987|DRUG|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
219579290|NCT01780987|DRUG|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
219194086|NCT02871726|DEVICE|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
219579291|NCT01780987|DRUG|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
219579292|NCT05765630|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
219579293|NCT03698448|DRUG|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
219579294|NCT02547155|PROCEDURE|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
219579295|NCT02547155|PROCEDURE|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
219194087|NCT02871726|OTHER|TRUS biopsy|Uronav for prostate biopsy.
219194088|NCT02056834|DEVICE|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
219434875|NCT02080286|DEVICE|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
219434876|NCT02080286|DEVICE|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
219434877|NCT02111512|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
219579296|NCT00920517|BIOLOGICAL|rDEN2/4delta30(ME) vaccine|10\^3 PFU dose
219579297|NCT00920517|BIOLOGICAL|Placebo|placebo for rDEN2/4delta30(ME) vaccine
219579298|NCT00296634|DRUG|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
219579299|NCT00296634|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
218859576|NCT06834984|DIETARY_SUPPLEMENT|Prebiotic, probiotic, postbiotic combination|The product consists of two probiotics, Lactobacillus rhamnosus LGG and Bifidibacterium animalis subsp. lactis BB-12, supplied at a total concentration of 11B CFU's, a prebiotic consisting of 1 × 106 Plaque Forming Units (PFU) LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae bacteriophages, marketed as PreforPro, and tributyrin- a stale form of butyrate
219579300|NCT06632522|DRUG|radiotherapy combined with Camrelizumab and Apatinib|Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
219579301|NCT06168786|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
219579302|NCT06168786|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
219579303|NCT06168786|RADIATION|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
219194089|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide with compression/ decompression technique|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Mulligan mobilisation consisted of Medial glide mobilisation with movement, Lateral glide mobilisation with movement, with active knee flexion (61) depending on the subjects condition. The gliding force was sustained while the patient performed 3 sets of 10 repetitions.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks."
219434878|NCT03073343|DIETARY_SUPPLEMENT|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
219434879|NCT00927264|BEHAVIORAL|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
219434880|NCT00927264|BEHAVIORAL|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
219434881|NCT03618602|DRUG|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
219434882|NCT01319279|DRUG|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
219434883|NCT01256203|DRUG|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
219434884|NCT01256203|PROCEDURE|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
219434885|NCT00936299|DRUG|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
219434886|NCT00936299|OTHER|Placebo|
219434887|NCT01730287|DRUG|Control|The teeth in this group restored only by filling material,without liner application.
219434888|NCT01730287|DRUG|Calcium Hydroxide|Calcium Hydroxide paste applied.
219434889|NCT01730287|DRUG|Mineral Trioxide Aggregate(MTA)|MTA applied .
219434890|NCT01730287|DRUG|CEM cement|CEM cement applied .
219434891|NCT04359342|DIETARY_SUPPLEMENT|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
219762591|NCT05812807|OTHER|Questionnaire Administration|Ancillary studies
219762592|NCT05812807|OTHER|Quality-of-Life Assessment|Ancillary studies
219762593|NCT05033288|OTHER|Electronic Health Record Review|Medical records are reviewed
219762594|NCT05033288|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
219762595|NCT03065335|DRUG|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
219762596|NCT03065335|OTHER|Placebo|Placebo comparator
219762597|NCT03065335|DEVICE|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
219762598|NCT03065335|DEVICE|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
219762599|NCT02489617|OTHER|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
219762600|NCT06560697|RADIATION|SABR VS Intracavitary 3D Brachytherapy|Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
219762601|NCT06556745|DRUG|BKR-017|BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
219762602|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
219762603|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
219762604|NCT06180460|BEHAVIORAL|CALM|The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.
219762605|NCT06180460|BEHAVIORAL|Treatment as usual|Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
219007715|NCT03590041|BEHAVIORAL|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
219434892|NCT04359342|DIETARY_SUPPLEMENT|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
219434893|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
219194090|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks. After completing the therapeutic session, post- intervention data of the outcome parameters were taken."
219194091|NCT05816655|DRUG|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
219194092|NCT05816655|DRUG|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
219194093|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
219762606|NCT01842386|DRUG|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
219762607|NCT03451799|OTHER|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
219762608|NCT03451799|RADIATION|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
219762609|NCT03451799|DRUG|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
219762610|NCT04138394|DRUG|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
219762611|NCT04138394|DRUG|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
219762612|NCT06316830|DRUG|Buprenorphine|Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
219762613|NCT06798909|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
219762614|NCT06798909|DRUG|Valganciclovir CMV Prophylaxis|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.
219762615|NCT06497413|DEVICE|Transcranial Photobiomodulation|The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
219762616|NCT06497413|DEVICE|Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered|In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
219762617|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
219762618|NCT05477576|DRUG|RYZ101|RP3D as determined in Phase 1b
219762619|NCT05477576|DRUG|Everolimus|Everolimus
219762620|NCT05477576|DRUG|Sunitinib|Sunitinib
219762621|NCT05477576|DRUG|Octreotide|High-dose octreotide
219762622|NCT05477576|DRUG|Lanreotide|Lanreotide
219762623|NCT06634849|DRUG|PTT-4256|Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohorts A1-A4 will receive 10mg, 20mg, 40mg \& 80mg. Following review by SRC, Cohort A5 participants will receive 160mg PTT-4256 daily
219762624|NCT04573023|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
219762625|NCT04573023|DRUG|Idursulfase|IV infusion
219762626|NCT04573023|DRUG|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
219762627|NCT05831176|DRUG|Dupilumab|Administered as described in the protocol
219762628|NCT02786277|OTHER|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
219762629|NCT01013649|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
219762630|NCT01013649|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219762631|NCT01013649|DRUG|Capecitabine|Given PO
219762632|NCT01013649|DRUG|Chemotherapy|Given combination chemotherapy
219762633|NCT01013649|PROCEDURE|Computed Tomography|Undergo CT
219762634|NCT01013649|DRUG|Erlotinib Hydrochloride|Given PO
219762635|NCT01013649|DRUG|Fluorouracil|Given IV
219762636|NCT01013649|DRUG|Gemcitabine Hydrochloride|Given IV
219762637|NCT01013649|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
219762638|NCT01013649|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219434894|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
219434895|NCT03260907|PROCEDURE|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
219434896|NCT03260907|PROCEDURE|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
219434897|NCT04896307|OTHER|Survey|Survey
219194094|NCT06046053|DRUG|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
219194095|NCT06046053|DRUG|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
219194096|NCT04378244|DRUG|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
219434898|NCT05797688|DEVICE|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
219434899|NCT04977973|BEHAVIORAL|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
219434900|NCT04977973|BEHAVIORAL|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
219434901|NCT04355494|BIOLOGICAL|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
219434902|NCT06278129|DIAGNOSTIC_TEST|Vestibular myogenic potentials|observational study
219579304|NCT00179816|DRUG|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
219579305|NCT03499210|DEVICE|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
219579306|NCT04168190|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219579307|NCT04168190|BIOLOGICAL|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219579308|NCT02637635|PROCEDURE|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
219579309|NCT02637635|PROCEDURE|Expander prosthesis|breast reconstruction with expander prosthesis.
219579310|NCT02841813|OTHER|No intervention|No intervention
219762639|NCT01013649|OTHER|Quality-of-Life Assessment|Ancillary studies
219762640|NCT01013649|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219762641|NCT04464707|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
219762642|NCT04464707|DRUG|Placebo|Matching placebo
219762643|NCT05646316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762644|NCT05646316|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
219762645|NCT05646316|PROCEDURE|Excisional Biopsy|Undergo sentinel lymph node excision
219762646|NCT05646316|DRUG|Indocyanine Green Solution|Given via injection
219762647|NCT05646316|PROCEDURE|Minimally Invasive Surgery|Undergo minimally invasive hysterectomy
219762648|NCT05646316|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymphadenectomy
219762649|NCT05646316|OTHER|Questionnaire Administration|Ancillary studies
219762650|NCT05646316|PROCEDURE|Sentinel Lymph Node Mapping|Undergo sentinel lymph node mapping
219475278|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
219762651|NCT05315492|BEHAVIORAL|Community Care Consortium (CCC)|The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
219762652|NCT04917601|BEHAVIORAL|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
219762653|NCT04917601|BEHAVIORAL|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
219762654|NCT06484062|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762655|NCT06484062|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219762656|NCT06484062|DRUG|Cirtuvivint|Given PO
219762657|NCT06484062|DRUG|Decitabine and Cedazuridine|Given PO
219579311|NCT06155318|DIAGNOSTIC_TEST|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
219579312|NCT01796613|DEVICE|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
219762658|NCT06484062|PROCEDURE|Echocardiography Test|Undergo ECHO
219762659|NCT06484062|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762660|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
219194097|NCT05701163|OTHER|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
219199566|NCT06870825|DEVICE|High-intensity Magnetic Field Muscle Stimulation|"1. The procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehabilitation duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation: muscle strengthening program~3. Stimulation site: quadriceps femoris muscle, applied above the motor point approximately 60% of the distance from the upper medial border of the patella to the anterior upper wing of the iliac bone.~4. device: BLT Super Inductive System~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
219762661|NCT04285567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
219762662|NCT04285567|DRUG|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
219762663|NCT04285567|DRUG|Fludarabine|Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
219762664|NCT04285567|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
219762665|NCT04285567|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
219762666|NCT04285567|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
219762667|NCT05826535|DRUG|LYL314|CAR T-cell therapy
219762668|NCT05826535|DRUG|Fludarabine|Conditioning chemotherapy
219762669|NCT05826535|DRUG|Cyclophosphamide|Conditioning chemotherapy
219762670|NCT05974722|DEVICE|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
219762671|NCT05974722|OTHER|Pledgeted sutures|Patient will receive pledgeted sutures
219762672|NCT05615844|DRUG|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
219194098|NCT05606900|BEHAVIORAL|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
219194099|NCT04432116|BEHAVIORAL|virtual reality 1|the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible
219194100|NCT04432116|BEHAVIORAL|virtual reality 2|Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
219194101|NCT06106022|DRUG|Vonoprazan|Administered orally
219194102|NCT03217110|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
219194103|NCT03217110|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
219194104|NCT05875519|DRUG|Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)|Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
219194105|NCT06193070|OTHER|Educational Intervention|Play virtual misinformation escape room game
219194106|NCT06193070|OTHER|Interview|Ancillary studies
219434903|NCT04496557|DEVICE|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
219194107|NCT06193070|OTHER|Survey Administration|Ancillary studies
219434904|NCT04505150|BEHAVIORAL|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
219194108|NCT06193070|OTHER|Telemedicine|Play virtual misinformation escape room game
219194109|NCT04426669|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
219434905|NCT04530396|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
219434906|NCT04530396|OTHER|placebo|placebo comparator
219475279|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
219475280|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
219475281|NCT05416567|PROCEDURE|Endovascular embolization|Therapeutic endovascular embolization in general anesthesia
219762673|NCT05615844|DEVICE|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
219762674|NCT06109779|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous) Q3W
219194110|NCT04426669|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
219762675|NCT06109779|DRUG|Placebo|Placebo IV (intravenous) Q3W
219762676|NCT06109779|DRUG|Capecitabine|Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
219762677|NCT06109779|DRUG|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
219762678|NCT06109779|DRUG|S-1 [Tegafur/Oteracil/gimeracil]|S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
219762679|NCT04888312|BIOLOGICAL|CD40 agonist mitazalimab in combination with chemotherapy|Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.
219434907|NCT05957588|OTHER|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
219434908|NCT05957588|OTHER|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
219194111|NCT04426669|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
219194112|NCT04426669|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
219434909|NCT03779061|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
219194113|NCT04520139|DRUG|N-Acetyl-Cysteine|Given PO
219194114|NCT04520139|OTHER|Placebo|Given PO
219194115|NCT03276676|DRUG|[18F]FLT|PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
219194116|NCT03276676|DRUG|[18F]Fluciclovine|PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
219194117|NCT03697577|DIAGNOSTIC_TEST|CT scans|Patients will undergo CT or PETCT as part of standard of care
219434910|NCT03779061|DRUG|Propofol|Initial dose plus supplemental doses as necessary
219434911|NCT05690971|BEHAVIORAL|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
219434912|NCT05690971|BEHAVIORAL|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
219434913|NCT03944083|OTHER|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
219434914|NCT02894528|DRUG|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
219434915|NCT02894528|DRUG|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
219434916|NCT05065307|DIAGNOSTIC_TEST|Venipuncture|Diagnostic venipuncture
219434917|NCT01100645|DRUG|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
219434918|NCT01100645|DRUG|Placebo|Excipient
219434919|NCT05859360|OTHER|Physical performance and cardiovascular health measures|"* Retinal vessel analysis~* Muscle ultrasound~* Knee extension~* Voluntary activation~* spiroergometry"
219434920|NCT00383227|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
219434921|NCT00659126|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
218859577|NCT06834984|DIETARY_SUPPLEMENT|Placebo|Placebo pill containing stomach acid-resistant outer vegan capsule (hypromellose, gellan gum), hi oleic safflower oil, inner vegan capsule (hypromellose, gellan gum) microcrystalline cellulose, ascorbyl palmitate, silica
219434922|NCT00659126|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
219434923|NCT00659126|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
219434924|NCT00659126|DRUG|Ferumoxytol|Given IV
219434925|NCT00659126|DRUG|Gadolinium|Given IV
219434926|NCT00659126|PROCEDURE|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
219434927|NCT00659126|PROCEDURE|Susceptibility Weighted Imaging|Undergo SWI
219434928|NCT03962712|OTHER|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
219194118|NCT03697577|DIAGNOSTIC_TEST|DEXA scan|Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)
219194119|NCT06799832|DEVICE|urethal perfusion index monitoring|The urethral perfusion index will be monitored using the IKORUS System (Vygon, Écouen, France)
219579313|NCT01796613|DEVICE|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
219579314|NCT03466437|DEVICE|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
219434929|NCT03962712|OTHER|No Increase in Minimum Wage|No increase in minimum wage
219434930|NCT06185894|PROCEDURE|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
219434931|NCT06185894|PROCEDURE|Conventional conservative surgery|Conventional conservative surgery
219579315|NCT03466437|DEVICE|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
219579316|NCT03466437|DEVICE|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
219762680|NCT06488430|BEHAVIORAL|Multidomain intervention package for preventing cognitive decline|Participants with mild cognitive impairment will be identified and they will participate in a pilot study for one-month duration. During pilot study they will be subjected to a multidomain intervention including nutritional advice, physical activity, cognitive stimulation training, social support and engagement and management of vascular risk factors.
219762681|NCT03485209|DRUG|tisotumab vedotin|Given into the vein (IV; intravenously)
219762682|NCT03485209|DRUG|pembrolizumab|200mg or 400mg given by IV
219579317|NCT00336245|DEVICE|Copper T Intrauterine Contraceptive Device|
219762683|NCT03485209|DRUG|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
218859578|NCT03460353|DRUG|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
219194120|NCT05576038|DRUG|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
219579318|NCT00336245|DRUG|Hormonal Contraception|
219579319|NCT05268068|DRUG|Risankizumab|Intravenous (IV) Infusion
219579320|NCT05268068|DRUG|Risankizumab|Subcutaneous (SC) Injection
219579321|NCT06072365|OTHER|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
219579322|NCT01094418|OTHER|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
219762684|NCT03485209|DRUG|cisplatin|100mg/m\^2 given by IV
219762685|NCT00001247|DRUG|Sirolimus|Drug not used in study.
219434932|NCT06422429|DRUG|Traditional deep-fried Youtiao|45g 4 times a week for 4 months
219434933|NCT06422429|DRUG|PI Youtiao|45g 4 times a week for 4 months
219434934|NCT01837017|BEHAVIORAL|Home-based Exercise|This is a control group with no intervention
219434935|NCT00222417|PROCEDURE|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
219434936|NCT00222417|PROCEDURE|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
219762686|NCT03713268|DEVICE|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
219194121|NCT05576038|DRUG|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
219194122|NCT04753788|DIAGNOSTIC_TEST|PCR|qPCR for T.pallidum
219194123|NCT04753788|DIAGNOSTIC_TEST|LAMP|LAMP assay for T.pallidum
219194124|NCT05015751|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
219194125|NCT03362177|BIOLOGICAL|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
219434937|NCT04961086|OTHER|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
219434938|NCT00870038|DEVICE|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
219434939|NCT00870038|DEVICE|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
219434940|NCT00870038|DEVICE|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
219434941|NCT01742533|BIOLOGICAL|human umbilical cord mesenchymal stem cells|
219434942|NCT01742533|BIOLOGICAL|hUCMSCs and hCBMNCs|
219434943|NCT01742533|BIOLOGICAL|human cord blood mononuclear cells|
219434944|NCT01742533|DRUG|Hormone Replacement Therapy|
219434945|NCT01265342|DRUG|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
219434946|NCT01265342|DRUG|Placebo|Placebo nebulised suspension twice a day for 10 days
219762687|NCT06508658|DRUG|Epcoritamab|Subcutaneous Injection
219762688|NCT06508658|DRUG|Rituximab|Intravenous (IV) Infusion
219434947|NCT01216397|DRUG|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
219194126|NCT03362177|OTHER|Placebo|Placebo Comparator
219194127|NCT06772584|DRUG|Desmopressin Acetate 0.2 mg Tablets|3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
219434948|NCT01216397|DRUG|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
219762689|NCT06508658|DRUG|Lenalidomide|Oral Capsule
219762690|NCT06508658|DRUG|Oxaliplatin|IV Infusion
219762691|NCT06508658|DRUG|Gemcitabine|IV Infusion
219762692|NCT06807281|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
219762693|NCT03917381|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
219762694|NCT03917381|BIOLOGICAL|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days.
219762695|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
219762696|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
219762697|NCT03555578|DRUG|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
219762698|NCT05640947|DEVICE|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
219762699|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
219762700|NCT06577363|DRUG|Maribavir|Maribavir tablets
219762701|NCT05132582|DRUG|Tucatinib|300mg given by mouth (orally) twice daily
219762702|NCT05132582|DRUG|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
219762703|NCT05132582|DRUG|Pertuzumab|420mg given by IV every 21 days
219762704|NCT05132582|DRUG|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
219762705|NCT05132582|DRUG|Placebo|Given orally twice daily
219762706|NCT06066515|DRUG|survodutide|once weekly subcutaneous injection
219762707|NCT06066515|DRUG|Placebo|once weekly subcutaneous injection
219762708|NCT04960241|PROCEDURE|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
219194128|NCT06772584|DRUG|Ginkgobiloba|Group s take it as treatment of deep sleep in nectornal enuresis
219434949|NCT05385627|PROCEDURE|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
219434950|NCT03514004|BEHAVIORAL|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
219194129|NCT05577234|OTHER|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
219194130|NCT05577234|BEHAVIORAL|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
219434951|NCT06059092|BEHAVIORAL|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
219434952|NCT06059092|BEHAVIORAL|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
219194131|NCT05499390|DRUG|AK112|Subjects receive AK112 intravenously.
219194132|NCT05499390|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
219475282|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
219475283|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
219475284|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
219475285|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
219194133|NCT03493230|BIOLOGICAL|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
219194134|NCT06391255|OTHER|scintigraphy|oesophageal and gastric emptying
219194135|NCT06461130|OTHER|Study Group|Group of people doing dual tasks during double-leg cycling training.
219194136|NCT06461130|OTHER|Control Group|The group that received only aerobic exercise.
219194137|NCT03583333|DRUG|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
219194138|NCT03583333|DRUG|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
219194139|NCT03583333|DRUG|Linezolid|Open-label 600 mg Linezolid
219194140|NCT03926130|DRUG|Mirikizumab|Administered IV
219194141|NCT03926130|DRUG|Mirikizumab|Administered SC
219194142|NCT03926130|DRUG|Ustekinumab|Administered IV
219762709|NCT04960241|PROCEDURE|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
219194143|NCT03926130|DRUG|Ustekinumab|Administered SC
219194144|NCT03926130|DRUG|Placebo|Administered IV
219194145|NCT03926130|DRUG|Placebo|Administered SC
219194146|NCT01730937|DRUG|Sorafenib|By mouth (PO)
219475286|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
219475287|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
219475288|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
219194147|NCT01730937|RADIATION|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
219194148|NCT05174611|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
219194149|NCT05174611|OTHER|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
219194150|NCT05687890|DRUG|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
219194151|NCT05687890|DRUG|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
219579323|NCT02502279|DEVICE|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
219579324|NCT02502279|DEVICE|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
219579325|NCT03587389|BIOLOGICAL|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
219579326|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
219579327|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
219762710|NCT04960241|PROCEDURE|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
219762711|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
219762712|NCT05518617|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,"
219762713|NCT06164678|BEHAVIORAL|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
219194152|NCT05687890|DRUG|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
219194153|NCT05687890|DRUG|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
219194154|NCT06423040|OTHER|Social Media Chatbot on Physical Activity Education|a social media chatbot was used to provide a continuous and real-time multimedia health education program on physical activity for the older adults, as well as supportive messages and feedbacks.
219199567|NCT06870825|DEVICE|Transcutaneous Neuromuscular Electrical Stimulation|"1. the procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehab. duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation (EMS, P3)~3. Stimulation site: quadriceps femoris muscle, applied above the motor point.~4. device: ITO ES-5200~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
219434953|NCT06059092|BEHAVIORAL|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
219434954|NCT06059092|BEHAVIORAL|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
219434955|NCT03182842|DEVICE|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
219434956|NCT03182842|DEVICE|SMBG - Blinded Sensor|Insulin dosing based on SMBG
219434957|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
219434958|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
219434959|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
219579328|NCT05875792|DEVICE|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
219579329|NCT02322463|DRUG|Arab children|Treatment with Oxycodone
219579330|NCT00202423|DRUG|Sativex|
219579331|NCT02393443|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
219579332|NCT02393443|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
219579333|NCT01070771|DEVICE|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
219579334|NCT04111393|PROCEDURE|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
219579335|NCT00870597|PROCEDURE|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
219579336|NCT00870597|PROCEDURE|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
219579337|NCT05750862|PROCEDURE|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
219579338|NCT05713968|OTHER|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
219579339|NCT05713968|OTHER|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
219579340|NCT05890495|DRUG|Lidocaine topical|4% aqueous solution
219579341|NCT05890495|DEVICE|Tampon|Tampon with plastic applicator provided
219762714|NCT05204719|PROCEDURE|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
219762715|NCT06807437|PROCEDURE|Biospecimen Collection|Undergo blood sample and pancreas fluid collection
219762716|NCT06807437|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
219762717|NCT06807437|DRUG|Lanreotide|Given SC
219762718|NCT06807437|OTHER|Questionnaire Administration|Ancillary studies
219579342|NCT02816099|BIOLOGICAL|Prise de sang|
219579343|NCT03525652|BIOLOGICAL|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
219579344|NCT03525652|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
219579345|NCT04605003|DEVICE|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
219579346|NCT04605003|DEVICE|Conventional Autoclave machine|The gold standard device to clean all medical instruments
219579347|NCT04536532|DRUG|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
219762719|NCT06807437|OTHER|Saline|Given SC
219434960|NCT03091699|DRUG|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
219579348|NCT04536532|DRUG|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
219579349|NCT04536532|DRUG|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
219434961|NCT03091699|BEHAVIORAL|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
219434962|NCT00648570|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
219434963|NCT00648570|DRUG|Lexapro® Tablets (20 mg|20mg, single dose fasting
219434964|NCT04219488|OTHER|Radial nerve mobilization|
219434965|NCT04219488|OTHER|Supervised home program|
219434966|NCT02633046|DRUG|Acthar Gel|Acthar Gel 80 U/mL solution for subcutaneous injection
219194155|NCT05865743|DRUG|SDD|"The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose."
219194156|NCT02818426|DRUG|UCPVax|
219194157|NCT04622774|DRUG|IMGC936|Antibody Drug Conjugate
219434967|NCT02339857|PROCEDURE|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
219434968|NCT02925312|OTHER|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
219434969|NCT04153643|PROCEDURE|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
219194158|NCT06298851|OTHER|Neural Mobilization Group (NMG)|"Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion."
219194159|NCT06298851|OTHER|Dynamic Stretching Group (DSG)|Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.
219199568|NCT06874634|DRUG|Human serum albumin injection|Infusion of human albumin injection into patients with abdominal sepsis admitted to the ICU
219434970|NCT03449121|BEHAVIORAL|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
219434971|NCT00869219|DRUG|Nevanac|1 drop of NEVANAC at random eye
219434972|NCT00869219|DRUG|Acular LS|One drop of Acular LS
219434973|NCT00927719|BIOLOGICAL|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
219434974|NCT00592670|DRUG|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
219194160|NCT06298851|OTHER|Static Stretching Group (SSG)|"Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally."
219434975|NCT00592670|DRUG|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
219434976|NCT02352103|PROCEDURE|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
219434977|NCT02352103|PROCEDURE|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
219194161|NCT06365697|DEVICE|Ton-bridge carotid stent|carotid artery stenting with Ton-bridge carotid stent
219434978|NCT02352103|DEVICE|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
219434979|NCT00482300|PROCEDURE|Systematic pelvic lymphadenectomy|
219194162|NCT06365697|DEVICE|WALLSTENT carotid stent|carotid artery stenting with WALLSTENT carotid stent
219194163|NCT04469270|BIOLOGICAL|Engensis|Intramuscular injections
219194164|NCT04469270|OTHER|Placebo|Intramuscular injections
219579350|NCT04536532|DRUG|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
219579351|NCT04300283|BEHAVIORAL|Hypnosis|See previous description
219579352|NCT03994497|OTHER|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
219762720|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
219762721|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
219579353|NCT02293291|DIETARY_SUPPLEMENT|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
219194165|NCT05233189|OTHER|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
219579354|NCT00143429|DRUG|Xalatan|
219579355|NCT01775969|OTHER|Text Message|A text message with instructions is sent to the patient
219194166|NCT05233189|OTHER|No intervention|Patients will be followed up until 18 months only
219194167|NCT05723575|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
219434980|NCT00463879|DRUG|Galantamine|
219579356|NCT01775969|OTHER|Voicemail|A voicemail with instructions is sent to the patient
219762722|NCT04628494|BIOLOGICAL|Epcoritamab|Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.
219762723|NCT04628494|DRUG|Investigator's Choice Chemotherapy|Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.
219762724|NCT05600426|DRUG|cyclosporine|cyclosporine
219762725|NCT05600426|PROCEDURE|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
219579357|NCT06205472|RADIATION|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
219579358|NCT00629265|DEVICE|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
219579359|NCT03651466|DRUG|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
219579360|NCT03651466|DRUG|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
219579361|NCT01917448|DRUG|Morphine|spinal morphine 0.15 mg
219579362|NCT01917448|OTHER|control|Patient receive only local infiltration without spinal analgesia
219579363|NCT01913925|OTHER|Tyrosine-Containing Food Bar|
219579364|NCT01913925|OTHER|Placebo Bar|
219762726|NCT05600426|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
219762727|NCT05600426|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
219762728|NCT05600426|DRUG|Methotrexate|methotrexate
219762729|NCT05600426|DRUG|Fludarabine|fludarabine
219762730|NCT05600426|DRUG|Cyclophosphamide|cyclophosphamide
219762731|NCT05600426|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
219194168|NCT05723575|BEHAVIORAL|somatosensory acuity measurement|Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
219434981|NCT00971633|DRUG|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
219434982|NCT00971633|DRUG|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
219434983|NCT00971633|DRUG|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
219762732|NCT05600426|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
219762733|NCT04265950|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219762734|NCT05359562|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
219434984|NCT04319406|PROCEDURE|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
219434985|NCT04319406|PROCEDURE|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
219434986|NCT03124901|DEVICE|DCI pulse oximeter sensor|
219434987|NCT02843919|OTHER|Electroencephalography and Electrocardiography|
219434988|NCT03094819|BEHAVIORAL|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
219762735|NCT06043323|DRUG|Axicabtagene Ciloleucel|Given by IV (vein)
219762736|NCT06043323|DRUG|Cyclophosphamide|Given by IV (vein)
219762737|NCT06043323|DRUG|Fludarabine phosphate|Given by IV (vein)
219762738|NCT06043323|DRUG|Prednisone|Given by IV (vein)
219762739|NCT06043323|DRUG|Diphenhydramine|Given by IV (vein)
219762740|NCT06043323|DRUG|Acetaminophen|Given by IV (vein)
219762741|NCT05862285|DRUG|Ipatasertib|Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762742|NCT05862285|DRUG|Tiragolumab|Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762743|NCT05862285|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
219762744|NCT05862285|DRUG|Tiragolumab and Atezolizumab|Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762745|NCT05862285|DRUG|Bevacizumab|Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762746|NCT05862285|DRUG|Entrectinib|Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762747|NCT05862285|DRUG|Inavolisib|Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
219762748|NCT06781385|DRUG|Intra-arterial Tenecteplase|One-time dose of intra-arterial tenecteplase post-thrombectomy
219762749|NCT06781385|DRUG|Intra-arterial Saline|One-time dose of intra-arterial saline post-thrombectomy
219762750|NCT06055036|BEHAVIORAL|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
219762751|NCT06469944|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion.
219762752|NCT06469944|BIOLOGICAL|Sacituzumab Tirumotecan (sac-TMT)|Administered via IV infusion.
219762753|NCT06469944|DRUG|Capecitabine|Administered via oral tablet.
219762754|NCT06469944|DRUG|Leucovorin|Administered via IV infusion.
219762755|NCT06469944|DRUG|Levoleucovorin|Administered via IV infusion.
219762756|NCT06469944|DRUG|5-FU|Administered via IV infusion
219762757|NCT06803056|DIAGNOSTIC_TEST|Clinical exam|An experienced physical therapist with expertise in dry needling will confirm study eligibility and complete a standard clinical exam for myofascial pain. Gold standard for diagnosing myofascial pain as defined by Travell and Simons will be used. The criteria for muscle trigger point (TrP) include: 1) a taut band of skeletal muscle that is tender to palpation, 2) sustained compression of the taut band reproduces or exacerbates the participant's symptoms. Healthy tissue is defined as no palpable taut band.
219762758|NCT06803056|DIAGNOSTIC_TEST|Ultrasound imaging|Shear wave elastography and b-mode ultrasound imaging techniques will capture the biomechanical and structural profile of foot and ankle muscle on the involved side.
219579365|NCT00999648|OTHER|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
219579366|NCT00999648|OTHER|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
219762759|NCT06803056|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|T1rho and IDEAL sequences will be used to capture the biochemical and structural profile of foot and ankle muscles on the involved side
219762760|NCT01812694|BEHAVIORAL|Enhanced standard care|Standard prenatal care plus education
219762761|NCT01812694|BEHAVIORAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
219762762|NCT05562947|DEVICE|PDS With Ranibizumab (100 mg/mL)|Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.
219762763|NCT05562947|DRUG|Ranibizumab (10 mg/mL)|Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
219762764|NCT03297723|OTHER|Therapeutic education Programm|"Intervention will include:~* an identification of educational needs and expectations,~* a bilateral agreement between patient and medical staff on the priority skills acquirement,~* a structured educational activities tailored to the patient's need.~* the making of an educational record."
219762765|NCT06803342|BIOLOGICAL|cAd3-Sudan Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
219762766|NCT06803342|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
219762767|NCT03304314|DIAGNOSTIC_TEST|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
219762768|NCT06379789|DRUG|REGV131|Single dose administered via intravenous (IV) infusion before LNP1265
219762769|NCT06379789|DRUG|LNP1265|Single dose administered via IV infusion following REGV131
219762770|NCT06465186|COMBINATION_PRODUCT|Efinopegdutide|Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks
219762771|NCT06465186|COMBINATION_PRODUCT|Placebo|Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.
219762772|NCT03737370|DRUG|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
219762773|NCT03737370|RADIATION|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
219762774|NCT04354012|COMBINATION_PRODUCT|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
219762775|NCT06353971|DRUG|Briquilimab|Subcutaneous Injection
219762776|NCT05832879|BEHAVIORAL|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
219762777|NCT05631301|OTHER|Exercise Circuits|Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination
219762778|NCT05631301|BEHAVIORAL|Goal Setting|Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities
219762779|NCT05631301|BEHAVIORAL|Psychoeducation-Youth|Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.
219762780|NCT05631301|BEHAVIORAL|Psychoeducation-Caregiver|Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms
219762781|NCT05631301|OTHER|Waitlist Control Surveys|Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
219762782|NCT04931017|PROCEDURE|Biopsy|Undergo biopsy
219762783|NCT04931017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219762784|NCT04931017|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
219762785|NCT04931017|DRUG|Extended Release Metformin Hydrochloride|Given PO
219762786|NCT04931017|OTHER|Questionnaire Administration|Ancillary studies
219762787|NCT04847063|DRUG|Mitomycin C|Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
219579367|NCT04465630|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
219579368|NCT04414462|OTHER|exergaming training|"* HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
219007716|NCT03590041|BEHAVIORAL|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
219007717|NCT05746754|RADIATION|CSI|30 Gy in 10 fractions to CNS
219007718|NCT04959344|BIOLOGICAL|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
219194169|NCT04948476|OTHER|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min"
219194170|NCT04948476|OTHER|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
219194171|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
219007719|NCT04959344|BIOLOGICAL|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
219194172|NCT03807401|BEHAVIORAL|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
219007720|NCT04959344|BIOLOGICAL|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
219194173|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
219194174|NCT05513261|DIAGNOSTIC_TEST|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
219194175|NCT05513261|DIAGNOSTIC_TEST|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
219194176|NCT06153602|DRUG|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.8 mg intrathecal
219194177|NCT06153602|DRUG|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
219194178|NCT06153602|DRUG|Bupivacaine Hydrochloride, Spinal|0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
219194179|NCT06153602|DRUG|Nalbuphine Hcl 10Mg/Ml Inj|4 mg IV prn for postoperative pain score\>=4 q 6 h
219194180|NCT06153602|DRUG|Acetaminophen 500Mg Tab|1 tab oral prn for postoperative pain score 1-3 q 6 h
219194181|NCT06153602|DRUG|Ondansetron 8mg|8 mg IV prn for nausea or vomiting q 8 h
219194182|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
219194183|NCT05127044|DEVICE|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
219194184|NCT05127044|DIAGNOSTIC_TEST|BiliChek|BiliChek will be used as a control for determining bilirubin content.
219194185|NCT05400122|DRUG|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 \[ALK5\]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
219434989|NCT03094819|BEHAVIORAL|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
219434990|NCT03366818|DEVICE|thrombectomy|mechanical thrombectomy
219434991|NCT00599235|DRUG|sildenafil|50mg 3 times daily for 7 days
219434992|NCT00599235|DRUG|hydralazine|25mg 3 times daily for 7 days
219434993|NCT00599235|DRUG|placebo|3 times daily for 7 days
219434994|NCT04420910|OTHER|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
219434995|NCT04420910|OTHER|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
218859579|NCT02483260|DRUG|Ribavirin|"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
219194186|NCT05400122|DRUG|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
219194187|NCT05400122|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
219194188|NCT05400122|DRUG|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
219194189|NCT05400122|DRUG|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer \[14, 19-23\]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (\~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
219194190|NCT04396145|DIAGNOSTIC_TEST|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
219194191|NCT04665648|DRUG|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
219194192|NCT04665648|DRUG|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
219194193|NCT01167725|BIOLOGICAL|bevacizumab|Given IV
219194194|NCT01167725|BIOLOGICAL|cetuximab|Given IV
219579369|NCT04414462|OTHER|training - Group II|"* Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
219579370|NCT04021849|OTHER|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
219194195|NCT01167725|DRUG|FOLFIRI regimen|Given IV
219194196|NCT01167725|DRUG|FOLFOX regimen|Given IV
219194197|NCT01167725|DRUG|capecitabine|Given IV
219194198|NCT01167725|DRUG|fluorouracil|Given IV
219194199|NCT01167725|DRUG|irinotecan hydrochloride|Given IV
219579371|NCT04021849|OTHER|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
219579372|NCT02666352|DRUG|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
219194200|NCT01167725|DRUG|leucovorin calcium|Given IV
219007721|NCT04959344|BIOLOGICAL|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
219434996|NCT04420910|OTHER|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
219475289|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
219007722|NCT04959344|BIOLOGICAL|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
219579373|NCT02666352|DRUG|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
219579374|NCT00250900|BEHAVIORAL|Prescription Fill Status|
219194201|NCT01167725|DRUG|mitomycin C|Given intraperitoneally
219194202|NCT01167725|DRUG|oxaliplatin|Given IV
219194203|NCT01167725|PROCEDURE|therapeutic conventional surgery|Patients undergo cytoreductive surgery
219007723|NCT02964962|DEVICE|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
219194204|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
219194205|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
219194206|NCT05723250|OTHER|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
219194207|NCT05473793|DIETARY_SUPPLEMENT|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).
219194208|NCT05473793|OTHER|Placebo|The control arm receives a placebo consisting of rice puff particles.
219194209|NCT05817812|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
219194210|NCT05509309|BEHAVIORAL|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
219194211|NCT01449513|DRUG|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
219194212|NCT01449513|DRUG|Placebo Gel|Gel vehicle of PEP005
219194213|NCT04587024|OTHER|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
219194214|NCT04587024|OTHER|standard of care|Subjects will receive standard of care observation for 12 weeks
219475290|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
219194215|NCT04947735|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
219475291|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
219579375|NCT04016961|OTHER|AAT - Dog|therapy dog added to inpatient PT and OT session
219579376|NCT04016961|OTHER|TAU - No Dog|PT and OT as usual without the addition of therapy dog
219475292|NCT01224769|DRUG|bendamustine +/- rituximab|
219194216|NCT04947735|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
219194217|NCT06340178|PROCEDURE|Fluid application during ct-guided lung biopsy|Injection of a small amount of fluid (max. 20 ml sodium chlorid) in the pleural cavity at the biopsy site
219194218|NCT04466098|BIOLOGICAL|Mesenchymal stromal cells|Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
219194219|NCT04466098|OTHER|Placebo|Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
219475293|NCT00910000|DRUG|Vorinostat|
219194220|NCT05637762|OTHER|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
219194221|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
219194222|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
219194223|NCT04209595|DRUG|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
219194224|NCT04209595|DRUG|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
219475294|NCT00910000|DRUG|Carboplatin|
219475295|NCT00910000|DRUG|Gemcitabine|
219475296|NCT05630989|OTHER|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
219475297|NCT05630989|DRUG|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
219475298|NCT05630989|DRUG|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
219475299|NCT05630989|DRUG|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
219475300|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
219475301|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
219475302|NCT06409325|DEVICE|MST|MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
219475303|NCT06409325|DEVICE|ECT|The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
219475304|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
219434997|NCT04420910|OTHER|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
219434998|NCT00686010|DRUG|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
219194225|NCT04209595|DRUG|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
219194226|NCT04667013|DRUG|Tetramethylpyrazine nitrone (TBN) tablet / Placebo|Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
219194227|NCT06125210|BEHAVIORAL|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
219194228|NCT06125210|DIETARY_SUPPLEMENT|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
219194229|NCT06125210|PROCEDURE|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
219194230|NCT03747419|DRUG|Avelumab|Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
219194231|NCT03747419|RADIATION|Radiation|Cancer treatment that uses ionizing radiation to kill cancer cells.
219194232|NCT05863052|BIOLOGICAL|Immunotherapy|immunotherapy
219194233|NCT05055804|DEVICE|ELG|"The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well."
219194234|NCT04925193|DRUG|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
219194235|NCT04925193|DRUG|Pomalidomide|Oral Table
219194236|NCT04925193|DRUG|Daratumumab|Injection
219434999|NCT00686010|DRUG|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
219435000|NCT00686010|DRUG|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
219435001|NCT00686010|DRUG|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
219435002|NCT02876679|DRUG|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
219435003|NCT02876679|DRUG|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
219435004|NCT02876679|DRUG|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
219435005|NCT03310736|DIAGNOSTIC_TEST|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
219194237|NCT04925193|DRUG|Carfilzomib|Injection
219194238|NCT04925193|DRUG|Dexamethasone|Oral tablet or injection
219194239|NCT05686525|PROCEDURE|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
219007724|NCT05870020|OTHER|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion"
219435006|NCT00003085|PROCEDURE|laparoscopy|
219435007|NCT00003085|PROCEDURE|ultrasound imaging|
219435008|NCT00987090|BIOLOGICAL|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
219579377|NCT05284461|DEVICE|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
219435009|NCT00987090|RADIATION|MRI|intervention at the inclusion and 18 months after
219194240|NCT05686525|PROCEDURE|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
219194241|NCT00254423|DRUG|Dasatinib|Given PO
219007725|NCT03252301|DEVICE|PMD 200|finger sensor which estimate objectively the pain level
219194242|NCT00254423|OTHER|Laboratory Biomarker Analysis|Correlative studies
219194243|NCT00254423|OTHER|Pharmacological Study|Correlative studies
219194244|NCT00254423|OTHER|Quality-of-Life Assessment|Ancillary studies
219194245|NCT00254423|OTHER|Questionnaire Administration|Ancillary studies
219435010|NCT00987090|PROCEDURE|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
219435011|NCT00987090|BIOLOGICAL|Apolipoprotein E genotyping|genotyping at the inclusion
219579378|NCT02078336|DRUG|Midazolam Mylan|
219194246|NCT05416424|OTHER|LIFE program|During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
219007726|NCT00298220|BEHAVIORAL|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
219007727|NCT00298220|BEHAVIORAL|Dissemination guideline and patient information letters|
219007728|NCT00298220|BEHAVIORAL|Tailored educational training|for GP(T)s
219194247|NCT03957902|DRUG|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
219194248|NCT02299999|DRUG|AZD2014|Target: m-TOR
219194249|NCT02299999|DRUG|AZD4547|Target: EGFR
219194250|NCT02299999|DRUG|AZD5363|Target: AKT
219194251|NCT02299999|DRUG|AZD8931|Target: HER2, EGFR
219194252|NCT02299999|DRUG|Selumetinib|Target: MEK
219194253|NCT02299999|DRUG|Vandetanib|Target: VEGF, EGFR
219194254|NCT02299999|DRUG|Bicalutamide|target: Androgen receptor
219194255|NCT02299999|DRUG|Olaparib|Target: PARP
219194256|NCT02299999|DRUG|Anthracyclines|DNA intercalation
219194257|NCT02299999|DRUG|Taxanes|Target: mitotic tubulin and microtubules
219194258|NCT02299999|DRUG|cyclophosphamide|Alkylating agents
219194259|NCT02299999|DRUG|DNA intercalators|DNA intercalators
219194260|NCT02299999|DRUG|Methotrexate|DNA intercalators
219194261|NCT02299999|DRUG|vinca alkaloids|Target: mitotic tubulin and microtubules
219194262|NCT02299999|DRUG|Platinum based chemotherapies|Platinum based chemotherapies
219194263|NCT02299999|DRUG|Bevacizumab|Target: VEGF
219194264|NCT02299999|DRUG|Mitomycin C|Alkylating agents
219194265|NCT02299999|DRUG|Eribulin|Microtubule modulator
219579379|NCT02078336|DRUG|Lorazepam Mylan|
219579380|NCT02078336|DRUG|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
219762788|NCT04847063|DRUG|Cisplatin|Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
219007729|NCT00298220|BEHAVIORAL|Tailored outreach based facilitator support|in the practices of the GPTs
219194266|NCT02299999|DRUG|MEDI4736|Target: PD-L1
219194267|NCT05092984|DRUG|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
219194268|NCT05092984|DRUG|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
219194269|NCT06002750|OTHER|disease|Do you have dermatomyositis
219435012|NCT00987090|BIOLOGICAL|Study of cerebrospinal fluid|intervention at the inclusion
219435013|NCT02281344|DRUG|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
219194270|NCT06676995|DEVICE|Transcranial Pulse Stimulation (TPS)|Transcranial Pulse Stimulation (TPS) is a non invasive brain stimulation technology that applies repetitive single high-pressure ultrashort shockwave pulses within the ultrasound frequency range to stimulate the brain. Subjects will receive 12 TPS sessions conducted three times weekly, for about 40 to 50 minutes/day, over four consecutive weeks.
219194271|NCT04153539|BEHAVIORAL|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
219194272|NCT04153539|BEHAVIORAL|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
219194273|NCT05023317|BEHAVIORAL|Strengths-based linkage to alcohol care|SLAC is a behavioral intervention designed to link persons with substance use/misuse to care
219194274|NCT05023317|BEHAVIORAL|Usual care|Usual care consists of brief screening and intervention and/or standard referral to alcohol care
219194275|NCT06225843|BIOLOGICAL|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
219194276|NCT06225843|COMBINATION_PRODUCT|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
219194277|NCT03983954|COMBINATION_PRODUCT|Obinutuzumab, naptumomab estafenatox and durvalumab|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion, as pre-treatment.~Dose escalation and MTD Expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses.~Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.~Esophageal cohort expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses on cycles 1-6 and one dose per cycle starting cycle 7. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle during cycles 1-6, and at a dose of 1500 mg delivered once every 28 days starting cycle 7."
219194278|NCT03983954|COMBINATION_PRODUCT|Naptumomab estafenatox and durvalumab|NAP was given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab was given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
219435014|NCT04006080|BIOLOGICAL|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
219435015|NCT01549457|OTHER|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
219435016|NCT02738762|OTHER|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
219007730|NCT00298220|BEHAVIORAL|Facilitation of co-operation with local addiction services|
219007731|NCT00298220|BEHAVIORAL|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
219007732|NCT00298220|BEHAVIORAL|Reminder-card for GP's desk|
219007733|NCT00298220|BEHAVIORAL|Personal feedback to patients|Patients receive advise based on their premeasurement answers
219435017|NCT04957680|BEHAVIORAL|CCBT|computer-based treatment program for depressed adolescents
219435018|NCT03222440|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
219435019|NCT00562016|DEVICE|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
219435020|NCT00562016|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
219194279|NCT03827382|BEHAVIORAL|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
219435021|NCT02024841|DRUG|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
219194280|NCT06111768|DRUG|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
219194281|NCT04742608|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219194282|NCT04742608|OTHER|Electronic Health Record Review|Medical charts are reviewed
219435022|NCT01462916|DIETARY_SUPPLEMENT|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
219435023|NCT00002908|DRUG|bryostatin 1|
219194283|NCT06593587|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine 120 mcg
219194284|NCT06593587|OTHER|Placebo|Placebo
219194285|NCT06103474|DIAGNOSTIC_TEST|Lumbar Magnetic Resonance Imaging (MRI)|Lumbar Magnetic Resonance Imaging (MRI)
219435024|NCT00002908|DRUG|vincristine sulfate|
219435025|NCT00259038|DRUG|Carperitide|
219194286|NCT05937308|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
219194287|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
219194288|NCT06826950|OTHER|comprehensive pharmaceutical care|The intervention group received comprehensive pharmaceutical care in addition to standard care. For first-cycle patients, oncology pharmacists conducted patient education, informing them about potential chemotherapy-induced adverse reactions and corresponding management strategies. Patients were instructed on the proper use of antiemetic medications, the recommended frequency of blood routine tests, and the appropriate timing, dosing, and administration of granulocyte colony-stimulating factor (G-CSF) and thrombopoietic agents. A QR code for oncology pharmacist consultation was provided to enable patients to seek advice on medication-related issues encountered outside the hospital.
219435026|NCT00259038|DRUG|Placebo|
219007734|NCT05908513|DRUG|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
219007735|NCT05908513|DRUG|Placebo|Similar chemical structure of NAC but without function
219007736|NCT00488436|DRUG|Antithymocyte globulin|
219007737|NCT00488436|DRUG|Cyclosporine|
219007738|NCT01828281|DEVICE|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
219007739|NCT05241106|DRUG|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
219007740|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
219007741|NCT05015127|DRUG|Placebo|Placebo
219007742|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
219007743|NCT05015127|DRUG|Placebo|Placebo qw by HBM9161 680mg qw from week 12
219007744|NCT02448420|DRUG|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
219007745|NCT02448420|DRUG|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
219007746|NCT02448420|DRUG|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
219007747|NCT02448420|DRUG|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
219007748|NCT02448420|DRUG|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
219007749|NCT00142584|DRUG|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
219007750|NCT00142584|DRUG|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
219194289|NCT06826950|OTHER|Routine pharmaceutical services|The control group received standard care: After the doctor issues the chemotherapy order, the oncology pharmacist only reviews the order to ensure that the chemotherapy regimen and pretreatment regimen during the study are consistent with those of the experimental group. No other interventions are performed.
219194290|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
219194291|NCT06630897|OTHER|Text Messages|small amounts of digital support will be in the form of text messages
219194292|NCT04204863|OTHER|collection of patient data|Extract data from the digital medical records, the electroencephalographic and microbiologic database.
219194293|NCT06827210|DEVICE|Optilume DCB|Optilume DCB is a drug-coated balloon catheter designed for the treatment of bulbar urethral strictures. It combines mechanical dilation with localized drug delivery to reduce stricture recurrence and promote urethral healing. The balloon is coated with paclitaxel, an antiproliferative agent, to minimize scar tissue formation and improve treatment outcomes.
219435027|NCT06183736|DRUG|CVL237 tablets|CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
219435028|NCT04254055|OTHER|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
219435029|NCT06165523|OTHER|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
219435030|NCT06165523|OTHER|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
219194294|NCT06827210|PROCEDURE|Standard Direct Visual Internal Urethrotomy (DVIU)|Standard Direct Visual Internal Urethrotomy (DVIU), also known as Sachse Internal Urethrotomy, is a minimally invasive endoscopic procedure for treating urethral strictures.
219435031|NCT06165523|OTHER|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
219579381|NCT03409393|OTHER|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
219194295|NCT03331835|BIOLOGICAL|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
219194296|NCT03331835|DRUG|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
219435032|NCT04271670|OTHER|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
219435033|NCT04271670|OTHER|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
219435034|NCT04271670|OTHER|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
219435035|NCT01856842|PROCEDURE|Angiography and embolotherapy|
219435036|NCT04228887|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
219435037|NCT04228887|DEVICE|Balance Training|Balance training will provide with Biodex® Balance Training System
219435038|NCT04228887|DEVICE|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
219007751|NCT03886233|DRUG|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
219007752|NCT00516438|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219007753|NCT00516438|DRUG|Topotecan|intravenous infusion
219007754|NCT01482754|DRUG|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
219007755|NCT05843981|DEVICE|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
219007756|NCT05843981|DEVICE|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
219007757|NCT01573572|DRUG|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
219007758|NCT03146715|OTHER|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
219007759|NCT03070782|DRUG|ISIS 681257|ISIS 681257 solution for SC injection.
219007760|NCT03070782|DRUG|Placebo|Sterile normal saline (0.9% NaCl)
219007761|NCT02338531|DRUG|PF-03084014|
219007762|NCT02338531|PROCEDURE|Breast cancer surgery|
219007763|NCT01083576|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
219007764|NCT01083576|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
219007765|NCT01970449|BIOLOGICAL|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007766|NCT01970449|BIOLOGICAL|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007767|NCT01970449|BIOLOGICAL|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007768|NCT01970449|BIOLOGICAL|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007769|NCT01970449|BIOLOGICAL|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007770|NCT01970449|BIOLOGICAL|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
219007771|NCT01970449|BIOLOGICAL|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
219007772|NCT01970449|DEVICE|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
219007773|NCT05109039|DIETARY_SUPPLEMENT|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
219007774|NCT05109039|DIETARY_SUPPLEMENT|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
219007775|NCT00337506|DRUG|Dexamethasone|
219007776|NCT00337506|DRUG|velcade|
219007777|NCT04333823|DRUG|Dapagliflozin 5mg|Dapagliflozin tablet
219435039|NCT01455415|DRUG|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
219435040|NCT01455415|DRUG|placebo|matching placebo 3 time a day
219007778|NCT04333823|DRUG|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
219007779|NCT04155112|BEHAVIORAL|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
219007780|NCT04155112|BEHAVIORAL|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
219007781|NCT03343808|PROCEDURE|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
219007782|NCT04237441|OTHER|number of participants with surgical complications|observation before and after multidisplinary team conference (MDT) was implemented
219007783|NCT03527966|BIOLOGICAL|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
219435041|NCT00891761|DRUG|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
219762789|NCT04847063|PROCEDURE|Heated Intraperitonial Chemotherapy|Heated Intraperitonial Chemotherapy (HIPEC) with with standardized doses of chemotherapeutic agents as indicated by the subject's Arm assignment
219007784|NCT03527966|BIOLOGICAL|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
219435042|NCT00891761|DRUG|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
219435043|NCT00891761|DRUG|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
219435044|NCT00891761|DRUG|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
219435045|NCT00891761|DRUG|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
219435046|NCT04374578|DRUG|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
219435047|NCT00818311|DEVICE|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
219435048|NCT02334553|DRUG|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
219435049|NCT02334553|DRUG|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
219199569|NCT05815667|BEHAVIORAL|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
219435050|NCT01601951|OTHER|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
219435051|NCT00014547|DRUG|BBR 3464|
219762790|NCT04847063|DRUG|Doxorubicin|Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
219762791|NCT04847063|DRUG|Oxaliplatin|Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
219007785|NCT05792371|PROCEDURE|induced membrane technique|Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
219007786|NCT05792371|PROCEDURE|Bone graft (Stage II of IMT)|Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
219007787|NCT02478801|DIETARY_SUPPLEMENT|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
219762792|NCT04847063|DRUG|5-Fluorouracil|Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
219007788|NCT02683889|DRUG|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
219007789|NCT01018368|DRUG|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
219007790|NCT01018368|DRUG|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
219199570|NCT03904576|DRUG|BI 1358894|Film-coated tablet
219199571|NCT03904576|DRUG|Placebo|Film-coated tablet
219762793|NCT04847063|DRUG|Sodium Thiosulfate|Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
219762794|NCT05361031|BIOLOGICAL|Engensis (VM202)|Intramuscular injections
219762795|NCT03479268|DRUG|Ibrutinib|Given PO
219762796|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
219762797|NCT03479268|DRUG|Pevonedistat|Given IV
219762798|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
219762799|NCT03479268|OTHER|Pharmacological Study|Correlative studies
219762800|NCT06406751|DEVICE|MI Paste|Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
219762801|NCT03414970|RADIATION|Radiation Therapy|Undergo RT
219762802|NCT03414970|OTHER|Questionnaire Administration|Ancillary studies
219762803|NCT03414970|OTHER|Quality-of-Life Assessment|Ancillary studies
219762804|NCT03414970|OTHER|Laboratory Biomarker Analysis|Correlative studies
219762805|NCT03414970|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
219762806|NCT06213311|DRUG|Glofitamab|Given by IV
219762807|NCT06213311|DRUG|Obinutuzumab|Given by IV
219762808|NCT06213311|DRUG|Axi-cel|Given by IV
219762809|NCT02879812|OTHER|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
219762810|NCT02879812|OTHER|Educational Video for Staff|Dialysis facility staff will watch a \~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
219762811|NCT02879812|OTHER|Educational Video for Patients|Dialysis facilities will receive a \~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
219762812|NCT02879812|OTHER|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and continuing medical education (CME) credits will be offered.
219762813|NCT02879812|OTHER|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
219762814|NCT02879812|OTHER|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
219762815|NCT02494544|DEVICE|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker
219762816|NCT02494544|DEVICE|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
219762817|NCT05672251|PROCEDURE|Biopsy|Undergo biopsy
219762818|NCT05672251|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219762819|NCT05672251|PROCEDURE|Computed Tomography|Undergo PET/CT
219762820|NCT05672251|BIOLOGICAL|Loncastuximab Tesirine|Given IV
219762821|NCT05672251|BIOLOGICAL|Mosunetuzumab|Given IV
219762822|NCT05672251|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219762823|NCT04995341|DEVICE|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
219762824|NCT04995341|DEVICE|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
219762825|NCT03116204|OTHER|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
219435052|NCT00587301|DEVICE|Lap-Band|Obesity and adolescents
219435053|NCT03670901|BIOLOGICAL|JHL1101|JHL1101, 100mg/10mL
219194297|NCT05781672|DIAGNOSTIC_TEST|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
219199572|NCT05516576|DEVICE|endomina®|Endoscopic gastroplasty
219762826|NCT05776004|DRUG|CAL02|CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
219762827|NCT05776004|DRUG|Placebo|Physiological 0.9% sodium chloride solution for iv administration
219762828|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
219435054|NCT03670901|BIOLOGICAL|MabThera|Rituximab, 100mg/10mL
219435055|NCT02758613|DRUG|Baricitinib|Administered orally.
219435056|NCT02758613|DRUG|Placebo|Administered orally.
219007791|NCT05820308|BEHAVIORAL|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
219007792|NCT05820308|BEHAVIORAL|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
219007793|NCT05516706|OTHER|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
219007794|NCT05516706|OTHER|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
219435057|NCT01496274|BIOLOGICAL|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
219435058|NCT04128527|DEVICE|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
219435059|NCT00351819|DRUG|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
219762829|NCT03600883|DRUG|sotorasib|Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
219762830|NCT03600883|DRUG|Anti PD-1/L1|Administered as an intravenous (IV) infusion
219762831|NCT03600883|DRUG|Midazolam|Administered as an oral hydrochloride (HCI) syrup
219762832|NCT05533697|BIOLOGICAL|mRNA-4359|Intramuscular Injection
219762833|NCT05533697|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219762834|NCT05533697|BIOLOGICAL|Ipilimumab|Intravenous infusion
219762835|NCT05533697|BIOLOGICAL|Nivolumab|Intravenous infusion
219762836|NCT05279729|OTHER|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
219762837|NCT06177977|DEVICE|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
219762838|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor restricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
219435060|NCT00351819|OTHER|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
219435061|NCT03364634|DIAGNOSTIC_TEST|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
219435062|NCT00002941|DRUG|carmustine|
219435063|NCT00002941|DRUG|cyclophosphamide|
219435064|NCT00002941|DRUG|etoposide|
219435065|NCT00002941|DRUG|mesna|
219435066|NCT00002941|PROCEDURE|peripheral blood stem cell transplantation|
219194298|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
219762839|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor unrestricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
219762840|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor restricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
219194299|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
219199573|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
219435067|NCT05153447|BEHAVIORAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
219435068|NCT05153447|OTHER|Usual Care|Participants randomized to the usual care arm will receive standard of care.
219194300|NCT03643510|DRUG|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
219435069|NCT01605383|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
219435070|NCT01605383|PROCEDURE|Standard treatment|Isolated core decompression
219435071|NCT00655161|BIOLOGICAL|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
219194301|NCT03643510|DRUG|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
219007795|NCT03884218|OTHER|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
219194302|NCT05316181|PROCEDURE|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
219199574|NCT06363591|PROCEDURE|Surgery|Wise or wide excision
219199575|NCT06363591|OTHER|No Surgery|No wide local excision
219435072|NCT05765292|DIETARY_SUPPLEMENT|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
219435073|NCT05765292|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
219435074|NCT03447119|BEHAVIORAL|Living Well with a Disability|Implementation of an adapted health promotion program.
219435075|NCT04490304|OTHER|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
219007796|NCT06103357|OTHER|blood sample collection|Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
219007797|NCT00558025|DRUG|Pramipexole Extended Release|
219194303|NCT06465121|PROCEDURE|peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse|Intravenous catheterization using ultrasound-guidance to allow real-time visualization of target veins in pediatric patients with difficult intravenous access
219007798|NCT00558025|DRUG|Pramipexole Immediate Release|
219007799|NCT04782089|DRUG|Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors|Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
219007800|NCT01057550|PROCEDURE|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
219007801|NCT01057550|PROCEDURE|TVT|Standard TVT as described by Ulmsten 1996
219007802|NCT01057550|PROCEDURE|Pelvicol|retropubic mid urethral sling made from Pelvicol
219007803|NCT00416559|OTHER|clinical observation|
219435076|NCT05211258|DEVICE|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
219762841|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
219199576|NCT05347771|DRUG|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
219762842|NCT05090566|DRUG|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
219762843|NCT05090566|DRUG|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
219007804|NCT04389567|DRUG|Famotidine|Use of oral Famotidine.
219762844|NCT05726032|DRUG|Empagliflozin 10 MG|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
219762845|NCT05726032|DRUG|Matching Placebo|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
219762846|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
219007805|NCT06215599|OTHER|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
219762847|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
219762848|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
219762849|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
219762850|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
219762851|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
219762852|NCT03118986|DRUG|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
219762853|NCT03118986|DRUG|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
219762854|NCT02168829|DRUG|Rivaroxaban|
219762855|NCT02168829|DRUG|Acetylsalicylic acid|
219762856|NCT05887271|DRUG|Low calorie meal replacement plan|Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
219762857|NCT05887271|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
219762858|NCT05887271|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
219762859|NCT05887271|DIAGNOSTIC_TEST|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
219762860|NCT05887271|DIAGNOSTIC_TEST|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
219762861|NCT05887271|DIAGNOSTIC_TEST|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
219762862|NCT05887271|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
219762863|NCT05887271|DIAGNOSTIC_TEST|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
219007806|NCT01942291|DRUG|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
219007807|NCT05353231|BEHAVIORAL|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
219007808|NCT05353231|BEHAVIORAL|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
219007809|NCT05353231|BEHAVIORAL|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
219007810|NCT01897740|DRUG|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
219007811|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
219007812|NCT00541073|DIETARY_SUPPLEMENT|vitamin B12|
219007813|NCT00541073|DRUG|cisplatin|
219007814|NCT00541073|DRUG|pemetrexed disodium|
219007815|NCT00541073|GENETIC|gene expression analysis|
219007816|NCT00541073|OTHER|laboratory biomarker analysis|
219007817|NCT00541073|OTHER|pharmacological study|
219007818|NCT02558257|BEHAVIORAL|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
219007819|NCT02299609|OTHER|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
219007820|NCT00596570|PROCEDURE|PCI|Percutaneous coronary interventiom
219007821|NCT01806831|DEVICE|"Biocellulose Mask, Farhorm®"|
219007822|NCT05519423|BEHAVIORAL|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
219007823|NCT00237874|DRUG|Aripiprazole|
219007824|NCT02135146|DRUG|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
219194304|NCT06414356|DRUG|Ketamine|Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
219007825|NCT02135146|DRUG|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
219007826|NCT02097810|DRUG|Entrectinib|
219007827|NCT03982823|PROCEDURE|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
219194305|NCT06414356|DRUG|Magnesium sulfate|Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
219194306|NCT06414356|DRUG|Ketamine + Magnesium sulfate|Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
219194307|NCT02418832|PROCEDURE|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
219579382|NCT03409393|OTHER|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
219579383|NCT01406392|DRUG|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
219579384|NCT01406392|DRUG|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
219007828|NCT03982823|PROCEDURE|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
219007829|NCT01482039|PROCEDURE|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
219007830|NCT01482039|PROCEDURE|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
219007831|NCT03231033|DRUG|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
219007832|NCT00170053|DRUG|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
219194308|NCT05405387|DRUG|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
219194309|NCT05405387|DRUG|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
219194310|NCT04250857|DEVICE|HeartStart FRX|Automated External Defibrillator
219194311|NCT00179842|PROCEDURE|Stem Cell Transplant|
219475305|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
219475306|NCT01977625|DRUG|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
219007833|NCT00569699|DRUG|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25 m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
219194312|NCT03634540|DRUG|Belzutifan|Belzutifan tablets administered orally.
219194313|NCT03634540|DRUG|Cabozantinib|Cabozantinib tablets administered orally.
219194314|NCT04838405|DRUG|CT-388|Synthetic Peptide
219194315|NCT04838405|DRUG|Placebo|Placebo
219194316|NCT05724745|DIAGNOSTIC_TEST|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
219194317|NCT05724745|DIAGNOSTIC_TEST|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
219194318|NCT05724745|DRUG|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
219194319|NCT05724745|DIAGNOSTIC_TEST|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
219007834|NCT06346990|OTHER|Holy Quran Recital|Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
219007835|NCT05016921|DEVICE|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
219007836|NCT04996888|DEVICE|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
219007837|NCT02424747|OTHER|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
219007838|NCT06013540|COMBINATION_PRODUCT|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
219007839|NCT06013540|COMBINATION_PRODUCT|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
219007840|NCT01863212|PROCEDURE|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
219007841|NCT01863212|BEHAVIORAL|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
219007842|NCT01863212|OTHER|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
219007843|NCT04123054|DEVICE|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
219194320|NCT05791435|DEVICE|PneuRIP|Measuring respiratory indices through Respiratory Inductance Plethysmography
219194321|NCT05791435|OTHER|biofeedback to assist with breathing|Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
219194322|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
219762864|NCT05887271|OTHER|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
219007844|NCT04123054|DEVICE|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
219007845|NCT02504008|DRUG|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
219007846|NCT02504008|DRUG|Placebo|Once weekly for 6 weeks
219007847|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219007848|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219007849|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219007850|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219007851|NCT03958799|BIOLOGICAL|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219007852|NCT03966001|OTHER|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
219007853|NCT03966001|OTHER|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
219007854|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
219194323|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
219762865|NCT05887271|OTHER|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
219007855|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
219007856|NCT04262505|BEHAVIORAL|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
219007857|NCT04262505|BEHAVIORAL|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
219199577|NCT05347771|DRUG|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
219762866|NCT05887271|OTHER|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
219762867|NCT05887271|OTHER|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
219762868|NCT05581303|DRUG|Placebo|Placebo given by subcutaneous injection once every 12 weeks (Q12W).
219762869|NCT05581303|DRUG|Olpasiran|Olpasiran given by subcutaneous injection Q12W.
219199578|NCT02905110|DRUG|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
219199579|NCT02905110|DRUG|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
219435077|NCT01955395|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
219435078|NCT04673955|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
219435079|NCT04673955|DRUG|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
219007858|NCT03315208|BEHAVIORAL|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
219007859|NCT03315208|OTHER|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
219007860|NCT03234751|DRUG|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
219007861|NCT03234751|DRUG|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
219475307|NCT01977625|OTHER|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
219475308|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
219475309|NCT04925622|DIAGNOSTIC_TEST|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
219007862|NCT03234751|DRUG|Placebo|48 hours of placebo.
219007863|NCT00449046|DRUG|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
219007864|NCT03973840|DRUG|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
219475310|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
219475311|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
219194324|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
219435080|NCT01425749|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
219435081|NCT00246064|DRUG|infliximab|
219435082|NCT04110184|OTHER|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
219435083|NCT03375138|DRUG|belatacept|Specified dose on specified days
219435084|NCT01293084|DRUG|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
219435085|NCT01293084|DRUG|7% saline|5mL 7% saline inhaled once over 20 minutes
219435086|NCT02855138|DRUG|oral isotretinoin|
219435087|NCT02096042|DRUG|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
219435088|NCT02096042|DRUG|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
219435089|NCT06154499|PROCEDURE|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
219435090|NCT00006299|DRUG|Celebrex|
219435091|NCT02983799|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily
219194325|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
219194326|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
219194327|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
219194328|NCT03886766|DRUG|Efavirenz solution|Efavirenz solution, 3 mg, oral administration (product 3)
219199580|NCT02905110|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
219199581|NCT05276219|DRUG|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
219199582|NCT05276219|DRUG|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
219199583|NCT05276219|DRUG|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
219435092|NCT00706615|BIOLOGICAL|Ad-sig-hMUC-1/ecdCD40L vaccine|
219435093|NCT03406715|DRUG|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
219435094|NCT03406715|DRUG|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
219475312|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
219475313|NCT02594384|DRUG|LAM-002A|25 mg capsules or 50 mg capsules
219475314|NCT02594384|DRUG|Rituximab|375 mg/m2 by vein
219475315|NCT02594384|DRUG|Atezolizumab|1200 mg by vein
219475316|NCT02427568|DRUG|Midomafetamine HCl|Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.
219007865|NCT06263751|OTHER|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
219475317|NCT02427568|DRUG|Placebo|Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.
219475318|NCT02427568|BEHAVIORAL|Therapy|Manualized therapy
219194329|NCT05834478|DEVICE|Transcutaneous Cervical Vagal Nerve Stimulation|Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
219435095|NCT03406715|BIOLOGICAL|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
219435096|NCT00845507|DRUG|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
219435097|NCT00845507|DRUG|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
219475319|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
219475320|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
219762870|NCT03832998|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
219475321|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
219475322|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
219475323|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
219762871|NCT03832998|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
219762872|NCT03832998|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
219762873|NCT03832998|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
219762874|NCT04362748|DRUG|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
219762875|NCT05280184|BEHAVIORAL|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
219762876|NCT01147445|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
219762877|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
219762878|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
219762879|NCT06129994|OTHER|Observational|Participants will complete an in-person baseline study visit with fasting blood draw, medical and health history, anthropometrics and vital signs, and surveys. If participants are not currently using a CGM, one will be placed. The LifeData study mobile app will be installed on the participant's smartphone. Over the two-week home monitoring period, participants will be asked to wear the CGM and respond to EMA questions three times daily. After the end of the home monitoring period, a remote visit will be performed in which the CGM will be removed by the study participant at home; the study team will obtain all data available from the CGM and insulin pump (if available); and surveys will be collected.
219762880|NCT06352918|OTHER|Palmar grasp reflex stimulation|This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
219762881|NCT06686615|DRUG|Bempedoic acid|No drug was administered in this observational study.
219762882|NCT06686615|DRUG|Ezetimibe|No drug was administered in this observational study.
219762883|NCT06686615|DRUG|Rosuvastatin|No drug was administered in this observational study.
219762884|NCT06686615|DRUG|Atorvastatin|No drug was administered in this observational study.
219762885|NCT04893291|DEVICE|Everolimus Eluting Stent|Patients assigned to this Arm will have an EES implanted after pre-dilatation, the angiography will be conducted as standard of care
219762886|NCT04893291|DEVICE|Sirolimus Coated Balloon|Patients assigned to this Arm will be treated with Magic Touch Drug Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care
219435098|NCT04820153|DEVICE|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
219194330|NCT05834478|DEVICE|Sham Stimulation|Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
219435099|NCT04820153|BEHAVIORAL|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
219435100|NCT03713606|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
219435101|NCT05881512|DEVICE|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
219435102|NCT02794623|DEVICE|Tinnitus masking|Tinnitus masking via CI system
219435103|NCT04009460|DRUG|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
219435104|NCT01105780|DRUG|Placebo|Matching placebo
219435105|NCT01105780|DRUG|JNJ-41443532|250mg tablet once daily for 1 day
219435106|NCT04486989|BEHAVIORAL|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
219435107|NCT04486989|OTHER|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
219435108|NCT06052189|PROCEDURE|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
219475324|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
219475325|NCT06568835|BEHAVIORAL|exercise|such as walking, jogging, swimming, Tai Chi, etc. It needs to be at a certain frequency and intensity
219475326|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219475327|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
219194331|NCT05834478|DRUG|[F-18]Fallypride|\[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
219194332|NCT06214936|OTHER|Benchtop Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the benchtop incubator for the remainder of embryo culture
219194333|NCT06214936|OTHER|Box Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the box incubator for the remainder of embryo culture
219475328|NCT02073591|OTHER|Ceradan Cream|
219475329|NCT02073591|OTHER|Ceradan Wash|
219475330|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
219475331|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
219194334|NCT02959502|OTHER|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
219194335|NCT02959502|OTHER|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
219194336|NCT04199871|OTHER|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
219194337|NCT04214860|DRUG|APR-246|APR-246 4.5 g/day
219435109|NCT06378060|DRUG|Modified transplantation system|Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
219435110|NCT03578380|PROCEDURE|Surgery|Lymphovenous anastomosis
219435111|NCT03578380|OTHER|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
219194338|NCT04214860|DRUG|Venetoclax|Venetoclax 400 mg once daily
219194339|NCT04214860|DRUG|Azacitidine|Subcutaneous injection, or intravenous infusion
219435112|NCT03450993|OTHER|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
219194340|NCT05626634|DRUG|LP352, bexicaserin|LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
219194341|NCT03972202|DIAGNOSTIC_TEST|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
219194342|NCT03972202|DEVICE|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
219194343|NCT03972202|BEHAVIORAL|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
219194344|NCT05988853|OTHER|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
219194345|NCT06419660|DRUG|BI 300202|BI 300202
219194346|NCT06419660|DRUG|esomeprazole|esomeprazole
219194347|NCT04078568|DRUG|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
219194348|NCT04078568|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
219194349|NCT04078568|DRUG|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
219194350|NCT06462729|DEVICE|LDGraft|LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
219194351|NCT06462729|DEVICE|LDGraft|LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
219194352|NCT06462729|OTHER|Allograft Bone|Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
219435113|NCT03271957|PROCEDURE|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
219435114|NCT02382757|DRUG|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
219435115|NCT06178757|DRUG|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
219435116|NCT06178757|DRUG|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
219194353|NCT05573243|OTHER|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
219194354|NCT04358315|BEHAVIORAL|Behavioral Intervention|Smell or puff e-liquids
219194355|NCT04358315|OTHER|Questionnaire Administration|Ancillary studies
219194356|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
219194357|NCT03083405|DRUG|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
219194358|NCT05346692|OTHER|Survey Administration|Complete Survey
219194359|NCT05346692|OTHER|Interview|Complete Interview
219194360|NCT05346692|OTHER|Text Message-Based Navigation Intervention|Complete mindfulness intervention
219194361|NCT05346692|OTHER|Interview|Complete interview
219194362|NCT03854500|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
219435117|NCT00607126|DEVICE|Lokomat|locomotor training using body weight support on a treadmill
219435118|NCT00607126|PROCEDURE|resistive training|resistive training using theraband and/or weights
219194363|NCT03854500|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
219194364|NCT06149702|OTHER|Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet|KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.
219194365|NCT04880733|PROCEDURE|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
219194366|NCT04880733|OTHER|Usual care for pain management|Patient will receive usual care for pain management.
219194367|NCT06166901|DEVICE|AcrySof IQ PanOptix IOL|Trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism, with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
219194368|NCT06166901|DEVICE|AcrySof IQ PanOptix Toric IOL|Toric trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
219435119|NCT05102331|OTHER|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
219194369|NCT06804707|BIOLOGICAL|blood sampling|"This procedure will take place once during the patient's CARPUS first visit (Croix Rousse hospital (Hospice civils de Lyon).~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse. A blood sample will be taken at the same time to check creatinine levels before the MRI scan and to record the patient's cholesterol levels for the eCRF."
219194370|NCT06804707|DEVICE|ultrasound imaging exam|"This procedure takes place once immediately after the intervention 1. The patient will first have an ultrasound acquisition with the clinical ultrasound scanner (\~5 minutes) in order to locate the plaque. An acquisition with the research ultrasound scanner and matrix probe will then be performed for measurement for ultrasound spectroscopy (\~5 minutes).~An injection of 2.4 ml Sonovue followed by 10 ml saline will be performed during acquisition with the research ultrasound scanner for ultrasound localization imaging measurement (\~10 minutes).~The patient must remain under observation (in the waiting room) for 30 minutes after the examination."
219194371|NCT06804707|DEVICE|High resolution MRI plaque exam|"This procedure will take place once during the patient's CARPUS second visit (Pierre Wertheimer hospital (Hospice civils de Lyon)).~The patient is greeted in radiology, and his/her identity and absence of contraindications are verified.~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse.~Injection of gadolinium and MRI examination of the plaque used in clinical routine."
219435120|NCT05102331|OTHER|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
219194372|NCT04750941|DRUG|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
219194373|NCT04750941|OTHER|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
219435121|NCT05102331|PROCEDURE|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
219007866|NCT06263751|OTHER|Product prescription program- NutriConnect Delivery|Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
219007867|NCT02746874|PROCEDURE|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
219007868|NCT02746874|PROCEDURE|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
219007869|NCT00499018|DRUG|Rituximab|375 mg/m2 day 1
219007870|NCT00499018|DRUG|Ciclofosfamide|1200 mg/m2 day 1
219007871|NCT00499018|DRUG|Doxorubicina|70 mg/m2 day 1
219435122|NCT03255304|BEHAVIORAL|health mindest|groups be confronted with health aspects of food items
219007872|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
219007873|NCT00499018|DRUG|Prednisone|100 mg day g 1-5
219007874|NCT00499018|DRUG|Pegfilgrastim|6 mg day +1
219007875|NCT00499018|DRUG|Mitoxantrone|8 mg/m2/days 1-3
219007876|NCT00499018|DRUG|ARA-C|2000 mg/m2/12h day 1 - 3
219007877|NCT00499018|DRUG|Lenograstim|5 μg/Kg/days +2
219007878|NCT00499018|DRUG|BCNU|300 mg/m2 day -7
219007879|NCT00499018|DRUG|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
219007880|NCT00499018|DRUG|VP-16|100 mg/m2/12h days -6,-5,-4,-3
219007881|NCT00499018|PROCEDURE|ASCT|PBSC Reinfusion
219194374|NCT06807645|DEVICE|Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stabilit|"Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stability post-alveolar cleft repair.~Primary Outcome: Premaxillary stability. Secondary Outcomes: Wound healing and complications. Intervention Details~1\. Common Procedures for Both Arms:~Surgical Procedure: All surgical procedures will be conducted under general anesthesia with nasotracheal intubation.~Antibiotic Prophylaxis: A first-generation cephalosporin will be administered prior to incision as per .~Bone Graft Harvesting: Autogenous bone grafts will be harvested from the anterior iliac crest using a pediatric minimally invasive technique with a 2 cm skin incision 1 cm lateral to the iliac crest.~Alveolar Cleft Repair:~Incision and Flap Design: A sulcular incision will be made to develop full thickness mucoperiosteal advancement flaps extending into the cleft with caref"
219435123|NCT03255304|BEHAVIORAL|palatability mindset|groups be confronted with palatability aspects of food items
219435124|NCT00578604|DEVICE|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
219007882|NCT00499018|DRUG|Ciclofosfamide|750 mg/m2 day 1
219007883|NCT00499018|DRUG|Doxorubicina|50 mg/m2 day 1
219007884|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
219007885|NCT03730493|BEHAVIORAL|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
219194375|NCT06033378|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
219194376|NCT06550401|OTHER|BREAST-Q Physical Well-Being|This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
219194377|NCT06550401|OTHER|QuickDASH|QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
219194378|NCT03979742|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
219194379|NCT03979742|OTHER|Locomotor Training|Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
219194380|NCT05403086|DRUG|Psilocybin|Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.
219435125|NCT02690168|BEHAVIORAL|Fasting|72 hour fasting
219435126|NCT04163055|DEVICE|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
219435127|NCT02219217|DRUG|Dolutegravir, Elvitegravir and Cobicistat|
219435128|NCT00005808|DRUG|motexafin lutetium|Given IV
219435129|NCT00005808|DRUG|photodynamic therapy|Undergo laser therapy
219435130|NCT00005808|PROCEDURE|loop electrosurgical excision procedure|Undergo LEEP
219435131|NCT00005808|OTHER|laboratory biomarker analysis|Correlative studies
219475332|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
219194381|NCT05403086|DRUG|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
219194382|NCT06752642|PROCEDURE|Implant overdenture|patients received implant overdenture
219435132|NCT02249208|DEVICE|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
219435133|NCT02249208|DEVICE|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
219435134|NCT02249208|DEVICE|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
219579385|NCT06654063|PROCEDURE|non-surgical periodontal therapy (SRP)|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage."
219762887|NCT06075953|DRUG|Tamoxifen|"For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).~For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen."
219194383|NCT05939518|OTHER|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
219762888|NCT06075953|DRUG|Exemestane|For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
219762889|NCT06075953|DRUG|Letrozole|For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
219762890|NCT06075953|DRUG|Anastrazole|For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
219435135|NCT00308321|DRUG|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
219435136|NCT00308321|DRUG|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
219435137|NCT03835013|DRUG|Saline 0.9%|Intravenous infusion of 0.9% saline
219435138|NCT03835013|DRUG|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
219194384|NCT05939518|OTHER|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
219194385|NCT05565989|BEHAVIORAL|MBM and II|An initiation to MBM practice (including 4 exercices) and 2 intention implementation exercices are proposed to participants
219194386|NCT05565989|BEHAVIORAL|MI|A motivational Interview will be conducted with participant.
219579386|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Omega-3|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure."
219435139|NCT03835013|DRUG|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
219435140|NCT03835013|DRUG|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
219435141|NCT03906175|DEVICE|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
219435142|NCT01998152|PROCEDURE|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
219435143|NCT00243685|OTHER|Laboratory Assay|Chemotherapy
219435144|NCT00243685|OTHER|Mick Assay|Chemotherapy doctor determined from results
219435145|NCT02783209|PROCEDURE|Cataract surgery|
219435146|NCT05750888|BEHAVIORAL|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
219762891|NCT06075953|DRUG|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
219762892|NCT06075953|DRUG|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
219762893|NCT06075953|DRUG|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
219762894|NCT05443568|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219762895|NCT03471364|DRUG|Ketoconazole|Applied topically
219762896|NCT03471364|OTHER|Laboratory Biomarker Analysis|Correlative studies
219762897|NCT03471364|OTHER|Placebo Administration|Applied topically
219762898|NCT03471364|OTHER|Quality-of-Life Assessment|Ancillary studies
219762899|NCT03471364|OTHER|Questionnaire Administration|Ancillary studies
219762900|NCT04128501|DRUG|Azacitidine|Given SC
219762901|NCT04128501|DRUG|Venetoclax|Given PO
219762902|NCT06473779|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
219762903|NCT06473779|COMBINATION_PRODUCT|Budesonide/formoterol|AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
219762904|NCT06473779|COMBINATION_PRODUCT|Albuterol/budesonide (AIRSUPRA®)|AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
219762905|NCT06473779|COMBINATION_PRODUCT|Mannitol|NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
219762906|NCT06473779|COMBINATION_PRODUCT|Salbutamol|AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
219762907|NCT04036045|OTHER|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
219762908|NCT04036045|OTHER|Echocardiogram|Patients will have an echocardiogram at four time points during the study
219762909|NCT04036045|OTHER|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
219762910|NCT05554406|DRUG|Azacitidine|Given SC or IV
219762911|NCT05554406|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219762912|NCT05554406|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219762913|NCT05554406|DRUG|Cytarabine|Given IV
219762914|NCT05554406|DRUG|Daunorubicin Hydrochloride|Given IV
219762915|NCT05554406|PROCEDURE|Echocardiography Test|Undergo ECHO
219762916|NCT05554406|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219762917|NCT05554406|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219762918|NCT05554406|DRUG|Venetoclax|Given PO
219762919|NCT05092152|DRUG|Esketamine|2 mg per kilogram of body weight
219762920|NCT05092152|DRUG|Propofol|1.5 mg per kilogram of body weight
219762921|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
219194387|NCT06266728|DEVICE|Total30 for Astigmatism Contact Lenses|Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
219194388|NCT06015672|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will have two accelerated transcranial magnetic stimulation (TMS) visits. Each TMS visit will be separated by 5 months. During each TMS visit, they will receive four TMS sessions, each separated by 60 minutes of rest.
219194389|NCT06080698|DRUG|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
219194390|NCT06080698|DRUG|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
219194391|NCT06645678|DRUG|Elranatamab|"Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 \> then 76mg bi-weekly from C7 for those achieving PR or better \> then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule."
219194392|NCT06645678|DRUG|Mezigdomide|"The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol."
219194393|NCT06645678|DRUG|Dexamethasone|"Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those \>=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -\> 5mg/day)"
219194394|NCT05695430|BEHAVIORAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
219194395|NCT05565326|DEVICE|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
219194396|NCT04203524|DIAGNOSTIC_TEST|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
219194397|NCT04203524|OTHER|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
219194398|NCT04080622|DRUG|Selenium|Selenium 300 µg/day (IV infusion)
219194399|NCT04080622|DRUG|Placebos|NaCl 0,9% (IV infusion)
219194400|NCT05656027|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
219435147|NCT05750888|BEHAVIORAL|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
219194401|NCT05656027|DRUG|Aceclidine|LNZ100 Aceclidine ophthalmic solution
219194402|NCT05656027|DRUG|Brimonidine|Brimonidine ophthalmic solution
219194403|NCT06514612|DRUG|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
219435148|NCT05235100|DRUG|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
219435149|NCT03380507|DRUG|Triple therapy group|Refer to arms description
219435150|NCT02195609|DIETARY_SUPPLEMENT|Omega-3|600 mg oral twice a day
219435151|NCT02195609|DIETARY_SUPPLEMENT|Soy Isoflavones|54.4 mg oral twice a day
219435152|NCT04516733|OTHER|supportive care|visit with supportiv unit and neuropsychologue every 3 months
219475333|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
219475334|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
219475335|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
219475336|NCT00000868|BIOLOGICAL|MF59|
219475337|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
219194404|NCT06514612|OTHER|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
219194405|NCT04347200|DRUG|Antiplatelet Drug|single or dual antiplatelets, triple antithrombotic therapy
219194406|NCT05424380|DRUG|GSK3745417|GSK3745417 will be administered
219194407|NCT05948995|DEVICE|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
219194408|NCT02879136|DRUG|Methylphenidate|Patient will be randomized to Methylphenidate
219194409|NCT02879136|OTHER|Physical Therapy|All Patients will have standard of care PT used for PD patients
219194410|NCT02879136|DRUG|Atomoxetine|Patient will be randomized to Atomoxetine
219194411|NCT05696119|BEHAVIORAL|I-PROTECT|I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.
219194412|NCT05696119|BEHAVIORAL|Control|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
219194413|NCT06135220|DIAGNOSTIC_TEST|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
219194414|NCT03998059|PROCEDURE|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
219194415|NCT06438029|OTHER|Education group|the students in the experimental group will be trained on disaster and disaster response
219194416|NCT06438029|OTHER|control group|the students in the experimental group will be trained on disaster and disaster response
219194417|NCT06391697|DEVICE|eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System|"The Magnetic Bead Tracking System is an investigational device that consists of pairs of magnetic beads, and a set of magnetic field sensors that measure and track the length of muscles and the speed at which they move in real-time. When the beads are implanted in muscle in the residual limb of an amputee, the muscle length signal is communicated to an investigational, robotic ankle-foot prosthesis.~The e-OPRA is an investigational implant system that lets a lower leg prosthesis attach securely to the remaining tibia bone. The e-OPRA device has been designed so that it can be implanted with an electrode set that consists of an electrical connector and electrodes to allow it to be used with both a neuro-mechanical (powered) prosthesis system, in addition to the standard prosthesis.~The operation to implant these devices will represent a modification of the surgical technique currently employed for standard below knee amputation."
219194418|NCT02909686|DIETARY_SUPPLEMENT|Boswellia Serrata|
219475338|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
219475339|NCT03125382|DEVICE|Carelink System|Patients start to perform device data transmission through Carelink system
219475340|NCT03125382|DEVICE|In office standard visit|Patients start or maintain in office standard visits
219194419|NCT02909686|DIETARY_SUPPLEMENT|Curcumin|
219194420|NCT02909686|DIETARY_SUPPLEMENT|Epimedium|
219194421|NCT02909686|DIETARY_SUPPLEMENT|Fisetin|
219194422|NCT02909686|DIETARY_SUPPLEMENT|Luteolin|
219194423|NCT02909686|DIETARY_SUPPLEMENT|Nettle|
219194424|NCT02909686|DIETARY_SUPPLEMENT|Pycnogenol|
219194425|NCT02909686|DIETARY_SUPPLEMENT|Reishi Mushroom|
219762922|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
219762923|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
219762924|NCT05316974|OTHER|Prevalence of lymphoedema|Measures of lymphoedema
219762925|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
219762926|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
219762927|NCT04203316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219762928|NCT04203316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219762929|NCT04203316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219762930|NCT04203316|DRUG|Enasidenib|Given PO
219762931|NCT04203316|DRUG|Enasidenib Mesylate|Given PO
219762932|NCT04932447|BEHAVIORAL|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
219762933|NCT06230718|OTHER|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
219762934|NCT06230718|OTHER|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
219762935|NCT06230718|OTHER|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
219435153|NCT02313415|PROCEDURE|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
219194426|NCT02909686|DIETARY_SUPPLEMENT|Resveratrol|
219194427|NCT02909686|DIETARY_SUPPLEMENT|Placebo|
219194428|NCT03113435|OTHER|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
219194429|NCT05943756|BEHAVIORAL|Signature Strengths|The treatment group will complete 6 web-based sessions of Signature Strengths(1 sessions per week for 6 weeks), designed to teach lessons focused on the Aware-Explore-Apply interventional framework. Sessions are approximately 60 minutes long.
219194430|NCT05943756|BEHAVIORAL|TBI Education Course|The control group will complete 6 web-based sessions of a TBI Education Course(1 sessions per week for 6 weeks), designed to teach lessons based on the TBI Model Systems Knowledge Translation Center's fact sheets. Sessions are approximately 60 minutes long.
219194431|NCT05291273|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
219194432|NCT05291273|DIAGNOSTIC_TEST|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
219194433|NCT05291273|DIAGNOSTIC_TEST|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
219194434|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
219194435|NCT03265808|DRUG|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
219194436|NCT03265808|DRUG|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
219194437|NCT06799208|PROCEDURE|Laparoscopy|Minimal invasive approach. Have peritoneal tissue sparing character . Minimal blood loss . Reduction of postoperative adhesions.
219194438|NCT04259281|DRUG|GTX-102|antisense oligonucleotide
219435154|NCT01313078|DRUG|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
219435155|NCT03558971|DRUG|Cortisol|Participants determine when to administer 5-day regimens of cortisol
219435156|NCT04628611|DEVICE|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
219435157|NCT04628611|DEVICE|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
219435158|NCT01757587|DRUG|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
219435159|NCT01757587|DRUG|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
219007886|NCT05421234|OTHER|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
219762936|NCT04692779|OTHER|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
219762937|NCT03972150|DRUG|BI 836880|Solution for infusion
219762938|NCT03972150|DRUG|BI 754091|Solution for infusion
219762939|NCT06143514|OTHER|No intervention|No intervention
219762940|NCT06411080|DIAGNOSTIC_TEST|Ultrasound evaluation of fluid tolerance|Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.
219194441|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) active|Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
219194442|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) non active|The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
219435160|NCT05666661|OTHER|Sound and light therapy (BBT and FL group)|During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).
219194443|NCT02507141|DEVICE|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
219194444|NCT06099379|DRUG|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
219194445|NCT06037668|DEVICE|BVR-100|Experimental self-guided VR intervention for the treatment of SAD
219194446|NCT06037668|DEVICE|BES-100|Active at-home VR intervention comparator
219194447|NCT04819737|PROCEDURE|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
219762941|NCT04365374|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
219762942|NCT04365374|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
219762943|NCT02233868|OTHER|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
219194448|NCT04819737|OTHER|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
219194449|NCT06035354|DRUG|AK120|subcutaneous injection once a week
219194450|NCT06035354|DRUG|AK120|subcutaneous injection once a week
219194451|NCT06035354|DRUG|Placebo|subcutaneous injection once a week.
219194452|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
219194453|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
219194454|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
219762944|NCT02233868|DRUG|neuroinflammation|The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
219762945|NCT02233868|OTHER|neurofunction|To assess regional brain glucose metabolism.
219762946|NCT05784402|DRUG|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
219762947|NCT05784402|DRUG|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
219762948|NCT05822687|BEHAVIORAL|Education|This is a constant component; all participants will get a psychoeducation digital module.
219762949|NCT05822687|BEHAVIORAL|Reappraisal Coping|This digital module will teach reappraisal coping skills.
219762950|NCT05822687|BEHAVIORAL|Distraction Coping|This digital module will teach distraction coping skills.
219762951|NCT05822687|BEHAVIORAL|Relaxation Coping|This digital module will teach relaxation coping skills.
219762952|NCT06134362|DRUG|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
219762953|NCT04437667|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application. Participants will be instructed to engage in a minimum of 10 hours of gameplay over the holiday period each year. The game will automatically collect for analysis data related to participants' in-game behavior, e.g. time spent playing, scores on knowledge-based mini-games, choices made in the narrative game, components to which the player was exposed. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma; and promote parent-child dialogue.
219762954|NCT04437667|BEHAVIORAL|Control Mobile Phone Game|Independent gameplay of control game. Total respondent burden: participants will be invited to engage in at least 10 hours of gameplay during each long school holiday (November-December).
219762955|NCT04183283|DRUG|LY3526318|Administered orally.
219762956|NCT04183283|DRUG|Placebo|Administered orally.
219762957|NCT04221893|RADIATION|Radiation Therapy (RT)|Undergo radiation therapy
219762958|NCT03418961|DRUG|Carvedilol|Given PO
219762959|NCT03418961|OTHER|Laboratory Biomarker Analysis|Correlative studies
219762960|NCT03418961|OTHER|Patient Observation|Undergo observation
219435161|NCT05666661|OTHER|Sound therapy group (BBT)|Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.
219194455|NCT06035354|DRUG|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
219194456|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks
219194457|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
219435162|NCT05666661|OTHER|Relaxing music group|Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
219194458|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
219194459|NCT06079255|DEVICE|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
219194460|NCT05180058|OTHER|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
219194461|NCT06614309|OTHER|Acute Placebo Visit|The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
219194462|NCT06614309|OTHER|Acute Progressive Carbon Dioxide|The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
219194463|NCT06614309|OTHER|Acute Intermittent Hypoxia|The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
219194464|NCT06614309|OTHER|Training: Progressive Carbon Dioxide Ramping|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
219435163|NCT01565811|PROCEDURE|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
219435164|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
219435165|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
219435166|NCT01227720|DRUG|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
219435167|NCT01227720|DRUG|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
219435168|NCT00501462|DRUG|GSK189075|single 250 mg dose of drug
219435169|NCT04745468|DEVICE|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
219435170|NCT04938089|OTHER|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
219435171|NCT01155960|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
219007887|NCT01693575|DEVICE|Pupil expansion with APX 100 device|Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
219194465|NCT06614309|OTHER|Training: Intermittent Hypoxic Exposure|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
219435172|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
218859580|NCT03858179|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
219435173|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
219435174|NCT00537680|DRUG|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
219435175|NCT01774292|PROCEDURE|Endotracheal intubation with injection of liquid in the cuff|
219435176|NCT05340491|DRUG|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
219435177|NCT05340491|DRUG|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
219435178|NCT05340491|RADIATION|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
219435179|NCT01961089|DEVICE|Galilei Lens Professional|Measurement device
219435180|NCT01961089|DEVICE|IOLMaster|Measurement device
219007888|NCT04139187|OTHER|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
219435181|NCT01961089|DEVICE|Lenstar|Measurement device
219435182|NCT05955430|OTHER|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
219435183|NCT05955430|OTHER|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
219435184|NCT05955430|OTHER|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
219435185|NCT05955430|OTHER|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
219435186|NCT05955430|OTHER|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
219435187|NCT01559701|DRUG|PF-00345439|5-80 mg twice-a-day for 12 months
219435188|NCT01268904|DRUG|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
219435189|NCT02476344|OTHER|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
219435190|NCT00014001|DRUG|perphenazine|
219435191|NCT00014001|DRUG|olanzapine|
219435192|NCT00014001|DRUG|quetiapine|
219435193|NCT00014001|DRUG|risperidone|
219435194|NCT00014001|DRUG|ziprasidone|
219435195|NCT00014001|DRUG|clozapine|
219435196|NCT00014001|DRUG|fluphenazine decanoate|
219435197|NCT01225172|DRUG|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
219194466|NCT06614309|OTHER|Training: Placebo Control|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
218859581|NCT03858179|DEVICE|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
219007889|NCT03140020|PROCEDURE|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
219007890|NCT03140020|PROCEDURE|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
219007891|NCT05049876|OTHER|urine sample taken during consultations|urine sample taken during consultations
219007892|NCT00022620|DRUG|paclitaxel|
219194467|NCT05899673|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
219435198|NCT01225172|DRUG|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
219435199|NCT03990701|COMBINATION_PRODUCT|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
219435200|NCT05739240|PROCEDURE|Osteosynthesis|Osteosynthesis of distal radius fractures
219435201|NCT01729104|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
219194468|NCT05241210|DEVICE|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
219435202|NCT01729104|DRUG|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
219435203|NCT01729104|DRUG|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
219007893|NCT03043027|DRUG|liposomal bupivicaine|local anesthetic
219007894|NCT03043027|DRUG|Bupivacaine|local anesthetic
219194469|NCT03919266|PROCEDURE|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
219194470|NCT03919266|PROCEDURE|Control: usual antibiotic treatment|usual antibiotic treatment
219194471|NCT05886933|DRUG|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
219435204|NCT03410134|DEVICE|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
219435205|NCT01414517|DIETARY_SUPPLEMENT|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
219435206|NCT01414517|DIETARY_SUPPLEMENT|Maltodextrin|a non-prebiotic carbohydrate
219435207|NCT05163834|BIOLOGICAL|Efgartigimod|intravenous infusion of efgartigimod
219435208|NCT05163834|OTHER|Placebo|intravenous infusion of placebo
219435209|NCT05163834|BIOLOGICAL|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
219007895|NCT03043027|DRUG|Saline Solution|saline injection
219007896|NCT05643768|BEHAVIORAL|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
219435210|NCT01692834|DRUG|Sandimmune® Injection|
219435211|NCT01692834|DRUG|NeuroSTAT®|
219007897|NCT03388060|PROCEDURE|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
219007898|NCT03388060|PROCEDURE|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
219007899|NCT03388060|PROCEDURE|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
219007900|NCT01881776|PROCEDURE|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
219007901|NCT05195827|DRUG|PRM-125|Antihypertensive
219435212|NCT02679781|DRUG|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
219007902|NCT03179995|DRUG|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
219007903|NCT03179995|OTHER|Placebo|Normal saline will be administered in the same fashion as Octreotide
219435213|NCT02679781|DRUG|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
219435214|NCT05581355|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
219435215|NCT03490019|DRUG|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
219435216|NCT04209400|BIOLOGICAL|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
219435217|NCT04209400|BIOLOGICAL|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
219435218|NCT03638115|DEVICE|VaSecure™|Drug Coated PTA Balloon Catheter
219435219|NCT02529670|PROCEDURE|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
219435220|NCT02529670|PROCEDURE|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
219007904|NCT01037647|OTHER|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
219194472|NCT01473784|PROCEDURE|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
219435221|NCT02529670|PROCEDURE|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
219007905|NCT02190084|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
219007906|NCT03198533|DEVICE|Triathlon PA|Implantation of Knee Prosthesis
219007907|NCT03198533|DEVICE|Triathlon Pressfit|Implantation of Knee Prosthesis
219007908|NCT01388764|DRUG|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
219007909|NCT00982592|DRUG|oxaliplatin|Given IV
219007910|NCT00982592|DRUG|leucovorin calcium|Given IV
219007911|NCT00982592|DRUG|fluorouracil|Given IV
219007912|NCT00982592|OTHER|placebo|Given PO
219007913|NCT00982592|DRUG|vismodegib|Given PO
219007914|NCT00982592|OTHER|laboratory biomarker analysis|Correlative studies
219007915|NCT02248610|OTHER|Non-interventional study|
219194473|NCT01473784|PROCEDURE|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
219194474|NCT05825508|DEVICE|ankle robot|home ankle robot and video game
219194475|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
219194476|NCT05137067|DIETARY_SUPPLEMENT|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
219435222|NCT05191732|COMBINATION_PRODUCT|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
219435223|NCT01754285|DRUG|LF-PB and Placebo|
219435224|NCT01754285|DRUG|Placebo|
219435225|NCT01754285|DRUG|LF-PB|
219435226|NCT04644484|BIOLOGICAL|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
219435227|NCT04644484|BIOLOGICAL|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
219435228|NCT04644484|BIOLOGICAL|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
219435229|NCT05225480|BEHAVIORAL|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
219194477|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|Placebo
219435230|NCT05225480|BEHAVIORAL|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
219435231|NCT02560480|DEVICE|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
219194478|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
219194479|NCT06698549|DRUG|ALG-097558|Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
219435232|NCT00317876|DRUG|cyclophosphamide|
219435233|NCT00317876|DRUG|cyclosporine|
219435234|NCT00317876|DRUG|methotrexate|
219194480|NCT06249295|OTHER|oral cryotherapy|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
219435235|NCT00317876|PROCEDURE|allogeneic bone marrow transplantation|
219435236|NCT00317876|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219194481|NCT06263257|BEHAVIORAL|Mandala Art Therapy|"In art therapy, visual arts (such as drawing, painting, and sculpting) can be used as a tool to facilitate the expression of emotions and enhance coping skills. Naisin and colleagues (2006) reported that a one-hour art therapy session significantly reduced anxiety levels in hospitalized adult oncology patients. The word mandala is now typically associated with circular, geometric designs and often appears in adult coloring books aimed at promoting mindfulness and stress reduction. However, the methodology and theory of Jung related to mandalas are based not only on coloring pre-drawn templates but also on the activity of creating mandalas. The act of creating a mandala is claimed to provide immediate benefits in improving mood. The mandala is expressed as an instantaneous outward expression of the inner world of the person drawing it."
219194482|NCT04012931|DRUG|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
219435237|NCT02152449|DIETARY_SUPPLEMENT|Oral nutritional supplementation|
219435238|NCT00156013|DRUG|CLOFARABINE|4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
219435239|NCT04128618|DEVICE|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
219007916|NCT03116607|OTHER|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
219435240|NCT03182153|DEVICE|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
219435241|NCT00209833|DRUG|Cytarabine|
219435242|NCT00209833|DRUG|Idarubicin|
219435243|NCT00209833|DRUG|Etoposide|
219435244|NCT00209833|DRUG|Fludarabine|
219435245|NCT00209833|DRUG|G-CSF|
219435246|NCT00209833|DRUG|Daunorubicine|
219435247|NCT03767998|OTHER|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
219435248|NCT03767998|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
219435249|NCT03767998|OTHER|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
219435250|NCT02191280|DRUG|Antistax®, low dose|
219435251|NCT02191280|DRUG|Antistax®, high dose|
219435252|NCT02191280|DRUG|Placebo|
219579387|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Vitamin D|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups."
219007917|NCT03128346|PROCEDURE|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
219007918|NCT03128346|DRUG|Hydromorphone Hydrochloride|IV, Hydromorphone
219007919|NCT03128346|DRUG|Aspirin|Oral Aspirin
219007920|NCT03128346|DRUG|Acetaminophen|Oral acetaminophen
219007921|NCT03128346|DRUG|Fentanyl|IV, fentanyl
219007922|NCT05373329|DEVICE|Sanvello (app)|Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
219194483|NCT04012931|DRUG|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
219194484|NCT05285137|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
219194485|NCT05285137|DRUG|Saline placebo|Sterile normal saline for injection
219007923|NCT02404376|DRUG|Exenatide|Intravenous administration of Exenatide
219194486|NCT06772103|PROCEDURE|self-locking biceps tenodesis|The LHB tendon is detached from its origin at the level of the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
219194487|NCT06772103|PROCEDURE|Biceps Tenodesis with 360 Suture anchor|The LHB tendon is detached from its origin and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-loop tenodesis technique with the Knotless FiberTak® biceps implant system. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
219194488|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
219194489|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
219435253|NCT03532984|DIAGNOSTIC_TEST|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
219007924|NCT02404376|OTHER|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
219007925|NCT02404376|DRUG|Placebo|Intrevenous administration of Placebo
219007926|NCT00487747|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
219194491|NCT01437787|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219435254|NCT01445964|DRUG|Atenolol|Atenolol oral administration
219435255|NCT01445964|DRUG|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
219435256|NCT01445964|DRUG|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
219435257|NCT03744130|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|"1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station"
219194492|NCT01437787|DRUG|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
219194493|NCT03717935|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) Supplement|Powder supplement
219194494|NCT03717935|OTHER|Placebo|Powder that will be similar to the essential amino acid supplement
219007927|NCT00276159|DRUG|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
219579388|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
219007928|NCT04059679|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
219007929|NCT04059679|DRUG|Aspirin 81 mg|EC aspirin 81 mg qd
219007930|NCT00333866|DRUG|pregabalin|600mg/day
219194495|NCT04601480|BEHAVIORAL|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
219007931|NCT00333866|DRUG|pregabalin|450mg/day
219007932|NCT00333866|DRUG|pregabalin|300mg/day
219007933|NCT00333866|DRUG|placebo|placebo
219007934|NCT02542878|DEVICE|Foam roller|A bout of 60 seconds of myofascial release with foam roller
219007935|NCT03508817|DRUG|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
219007936|NCT01710956|RADIATION|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
219435258|NCT04637191|DEVICE|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
219435259|NCT04066530|DRUG|AD-203|AD-203 administered two times daily for two weeks
219579389|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
219007937|NCT02533947|BEHAVIORAL|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
219007938|NCT02533947|BEHAVIORAL|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
219007939|NCT01586390|OTHER|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
219007940|NCT01586390|OTHER|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
219007941|NCT01454947|BEHAVIORAL|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
219579390|NCT02580084|PROCEDURE|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
219007942|NCT01454947|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
219007943|NCT01454947|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
219007944|NCT02370979|BIOLOGICAL|Blood samples|
219007945|NCT05492331|OTHER|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
219007946|NCT04247581|DEVICE|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
219007947|NCT05590754|DEVICE|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
219007948|NCT05590754|DEVICE|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
219435260|NCT04066530|DRUG|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
218859582|NCT04642157|OTHER|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
219194496|NCT04601480|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
219435261|NCT01752972|DIETARY_SUPPLEMENT|Spirulina|10 g/day orally for 12 weeks
219435262|NCT04409301|OTHER|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
219435263|NCT04409301|BEHAVIORAL|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
219435264|NCT05726448|BEHAVIORAL|Telehealth solution|Mobile-friendly nutrition education platform
219435265|NCT00795509|DRUG|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
219007949|NCT01517269|BEHAVIORAL|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
219007950|NCT01517269|BEHAVIORAL|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
219007951|NCT06064474|BEHAVIORAL|High ventilation breathwork with retention (HVBR)|Intervention
219007952|NCT06064474|BEHAVIORAL|Placebo HVBR|Placebo
219007953|NCT06408623|DRUG|chidamide combined with Sintilimab and bevacizumab|chidamide combined with Sintilimab and bevacizumab
219007954|NCT02969512|OTHER|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
219007955|NCT02969512|OTHER|OASIS Online Educational Webinars|2-hour online educational large group sessions
219435266|NCT00800930|BIOLOGICAL|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
219435267|NCT00800930|BIOLOGICAL|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
219435268|NCT02409758|BEHAVIORAL|Voice therapy|Voice therapy applied during 6 weeks.
219435269|NCT05474989|DRUG|LSD|Moderate to high dose LSD
219435270|NCT05474989|DRUG|Active placebo|Low dose LSD
219435271|NCT03305601|OTHER|application on smarthphone|application on smarthphone
219194497|NCT04872166|DRUG|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
219435272|NCT03967275|OTHER|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
219194498|NCT05882916|DEVICE|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
219194499|NCT05882916|BEHAVIORAL|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
219194500|NCT03560973|DRUG|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
219435273|NCT04249167|DRUG|Atezolizumab|Given IV
219435274|NCT04249167|PROCEDURE|Cryosurgery|Undergo cryoablation of the primary tumor
219435275|NCT04249167|DRUG|Nab-paclitaxel|Given IV
219435276|NCT01601470|DRUG|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
219435277|NCT01601470|DRUG|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
219435278|NCT01203787|DRUG|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
219007956|NCT01359449|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
219007957|NCT01359449|BIOLOGICAL|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
219007958|NCT00456547|PROCEDURE|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
219007959|NCT01804374|DRUG|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
219007960|NCT01804374|DRUG|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
219007961|NCT00330564|DRUG|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
219007962|NCT02716571|OTHER|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
219007963|NCT00529854|OTHER|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
219435279|NCT01203787|DRUG|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
219435280|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
219435281|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
219435282|NCT00909818|RADIATION|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
219007964|NCT04826705|DEVICE|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
219007965|NCT00256191|DRUG|TPI 287 Injection|
219007966|NCT04404296|DEVICE|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
219007967|NCT02393547|DRUG|Varenicline|All subjects receive Varenicline
219007968|NCT02393547|DRUG|Lorcaserin|All subjects receive Lorcaserin
219007969|NCT01967212|DEVICE|Game-based swallow biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
219007970|NCT01967212|BEHAVIORAL|Swallow training without biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
219435283|NCT00909818|RADIATION|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
219007971|NCT01271660|DRUG|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
219007972|NCT01271660|DRUG|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
219007973|NCT04343963|DRUG|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
219435284|NCT05759546|DRUG|Fluzoparib|Parp inhibitor
219435285|NCT05759546|DRUG|Dalpiciclib|CDK4/6 inhibitor
219435286|NCT05759546|DRUG|Fulvestrant/AI|Endocrine therapy
219435287|NCT04907318|DEVICE|Cataract surgery|
219435288|NCT01052181|DRUG|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
219435289|NCT01052181|DRUG|placebo|2 sachets monthly for an year
219435290|NCT06170281|BEHAVIORAL|Migraine Behavioral Treatment|Migraine Behavioral Treatment involving daily activities
219435291|NCT03404518|DRUG|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
219007974|NCT04343963|DRUG|Placebo|One tablet P.O. once per day for 14 days
219007975|NCT03296930|DRUG|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
219007976|NCT03296930|DRUG|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
219007977|NCT00068497|DRUG|gefitinib|Given orally
219007978|NCT00203125|DRUG|rasagiline mesylate|0.5 or 1 mg oral, once-daily
219435292|NCT03404518|DRUG|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
219007979|NCT00203125|OTHER|tyramine|50 mg once daily
219007980|NCT02927431|DRUG|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
219194501|NCT03560973|DRUG|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
219194502|NCT04666714|DRUG|Praga formulation|Praga formulation tablet
219194503|NCT04666714|OTHER|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
219194504|NCT04666714|OTHER|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
219762961|NCT06287255|BEHAVIORAL|EIM+|The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.
219762962|NCT01346124|RADIATION|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
218859583|NCT04642157|OTHER|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
218859584|NCT05587244|DEVICE|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
218859585|NCT04251052|PROCEDURE|Bilateral Salpingectomy|Undergo bilateral salpingectomy
218859586|NCT04251052|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
218859587|NCT04251052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218859588|NCT04251052|OTHER|Quality-of-Life Assessment|Ancillary studies
218859589|NCT04251052|OTHER|Questionnaire Administration|Ancillary studies
218859590|NCT04251052|PROCEDURE|Transvaginal Ultrasound|Undergo transvaginal ultrasound
219762963|NCT04438213|DRUG|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
219007981|NCT02927431|DRUG|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
219007982|NCT02927431|DRUG|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
219194505|NCT04666714|DRUG|Pregabalin 75mg|Pregabalin 75mg tablet
219762964|NCT04438213|DRUG|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
219762965|NCT04438213|DRUG|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
219762966|NCT05384769|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
219762967|NCT05384769|PROCEDURE|Low Dose Computed Tomography of the Chest|Undergo low dose CT
219762968|NCT05384769|OTHER|Survey Administration|Ancillary studies
219762969|NCT05219500|DRUG|FPI-2265|Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
219762970|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
219762971|NCT02796937|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
219762972|NCT05718817|DRUG|XEN1101|XEN1101 capsules
219762973|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
219762974|NCT01002235|BIOLOGICAL|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
219762975|NCT06249386|BEHAVIORAL|Behavioral Activation (BA)|BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.
219762976|NCT06249386|BEHAVIORAL|Relapse Prevention (RP)|RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
219762977|NCT05173064|DEVICE|The AI-powered Technological Surrogate Physiotherapist|"The AI-powered Technological Surrogate Physiotherapist will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records."
219762978|NCT05173064|BEHAVIORAL|Face-to-face physiotherapist-supervised exercise program|Physiotherapists will give usual face-to-face therapy. The assessment of participants' exercise movements will only be achieved in the traditional manner during face-to-face exercise sessions - by physiotherapists' visual inspection of and professional judgement on postural alignment and effectiveness, with verbal instructions for posture correction. The features of real-time movement feedback and tracking of exercise progress will not be provided.
219762979|NCT05173064|COMBINATION_PRODUCT|The AI-powered Technological Surrogate Physiotherapist Plus Face-to-face physiotherapist-supervised exercise program|This group will attend in-person group therapy sessions, while additionally completing weekly home exercise sessions using the TSP system.
219762980|NCT06479655|DRUG|Fentanyl|Intravenous fentanyl infusion with dilution of 10mcg/ml
219762981|NCT06479655|DRUG|Morphine|Intravenous morphine infusion with dilution 1mg/ml
219762982|NCT05761743|DIAGNOSTIC_TEST|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
219762983|NCT02615184|DRUG|Dexlansoprazole|Dexlansoprazole capsules
219762984|NCT06154252|BIOLOGICAL|CABA-201 following preconditioning with fludarabine and cyclophosphamide|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
219762985|NCT05111574|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219762986|NCT05111574|PROCEDURE|Bone Scan|Undergo bone scan
219762987|NCT05111574|DRUG|Cabozantinib S-malate|Given PO
219762988|NCT05111574|PROCEDURE|Computed Tomography|Undergo CT
219762989|NCT05111574|PROCEDURE|Echocardiography Test|Undergo ECHO
219762990|NCT05111574|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219762991|NCT05111574|BIOLOGICAL|Nivolumab|Given IV
219762992|NCT05111574|DRUG|Placebo Administration|Given PO
219762993|NCT05111574|PROCEDURE|Positron Emission Tomography|Undergo PET
219762994|NCT05461573|DRUG|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
219762995|NCT01154608|DRUG|Creon|
219762996|NCT01154608|OTHER|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
219762997|NCT06243744|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
219762998|NCT05393466|DRUG|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
219762999|NCT04145622|DRUG|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
219763000|NCT06352788|DEVICE|Modular Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a modular design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
219763001|NCT06352788|DEVICE|Mono Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a mono design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
219763002|NCT06005597|COMBINATION_PRODUCT|Combination Therapy|tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
219763003|NCT06005597|DRUG|Monotherapy obicetrapib|tablet; 10mg obicetrapib
219763004|NCT06005597|DRUG|Monotherapy ezetimibe|capsule; 10mg ezetimibe
219763005|NCT06005597|OTHER|Combination Therapy placebo|tablet; no active ingredient
219763006|NCT06005597|OTHER|Obicetrapib Placebo|tablet; no active ingredient
218859591|NCT04251052|PROCEDURE|Ultrasound Imaging|Undergo pelvic ultrasound
219763007|NCT06005597|OTHER|Ezetimibe Placebo|capsule; no active ingredient
219763008|NCT06251973|BIOLOGICAL|AgenT-797|AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
219763009|NCT06251973|BIOLOGICAL|Botensilimab|Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
219763010|NCT06251973|DRUG|Balstilimab|Botensilimab is supplied as a sterile, single-use solution for IV administration
219763011|NCT06251973|DRUG|Ramucirumab|Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
219763012|NCT06251973|DRUG|Paclitaxel|Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
219763013|NCT01424982|DRUG|Cyclophosphamide|Given IV
219763014|NCT01424982|DRUG|Cytarabine|Given IV
219763015|NCT01424982|DRUG|Dexamethasone|Given IV or PO
219763016|NCT01424982|DRUG|Doxorubicin|Given IV
219763017|NCT01424982|DRUG|Doxorubicin Hydrochloride|Given IV
219763018|NCT01424982|OTHER|Laboratory Biomarker Analysis|Correlative studies
219763019|NCT01424982|DRUG|Methotrexate|Given IV
219763020|NCT01424982|DRUG|Ponatinib|Given PO
219763021|NCT01424982|DRUG|Ponatinib Hydrochloride|Given PO
219763022|NCT01424982|DRUG|Prednisone|Given PO
219763023|NCT01424982|BIOLOGICAL|Rituximab|Given IV
219763024|NCT01424982|DRUG|Vincristine|Given IV
219763025|NCT01424982|DRUG|Vincristine Sulfate|Given IV
219763026|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 3T|Non-significant risk device used for brain imaging.
219763027|NCT02543983|DEVICE|NeurOptics PLRTM-3000 Pupillometer|The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
219763028|NCT02543983|DEVICE|Experimental Anxiety Devices|Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
219763029|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 7T|Non-significant risk device used for brain imaging.
219763030|NCT02543983|DRUG|Ketamine Hydrochloride|A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
219763031|NCT03247088|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
219763032|NCT03247088|DRUG|Busulfan|Given IV
219763033|NCT03247088|DRUG|Cyclophosphamide|Given IV
219763034|NCT03247088|BIOLOGICAL|Filgrastim|Given SC
219763035|NCT03247088|DRUG|Fludarabine|Given IV
219763036|NCT03247088|DRUG|Mycophenolate Mofetil|Given PO
219763037|NCT03247088|DRUG|Sorafenib|Given PO
219763038|NCT03247088|DRUG|Tacrolimus|Given PO
219763039|NCT03366116|DRUG|aza-TdC|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
219763040|NCT06035523|DEVICE|Endoform™ Antibacterial|Application of Endoform™ Antibacterial
219763041|NCT06035523|DEVICE|Endoform™ Natural|Application of Endoform™ Natural
219763042|NCT06035523|DEVICE|Symphony™|Application of Symphony™
219763043|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: IV solution
219763044|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV solution
219763045|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: SC solution
219763046|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC solution
219763047|NCT06290141|DRUG|IVIg|Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution
219763048|NCT06290141|DRUG|Placebo|Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
219763049|NCT04405167|DRUG|Tasquinimod|Tasquinimod will be supplied as oral capsules.
219763050|NCT04405167|DRUG|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
219763051|NCT00804154|DRUG|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
219763052|NCT06077383|DIETARY_SUPPLEMENT|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
219763053|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
219763054|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
219763055|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
219763056|NCT03375320|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219763057|NCT03375320|DRUG|Cabozantinib S-malate|Given PO
219763058|NCT03375320|PROCEDURE|Computed Tomography|Undergo CT
219763059|NCT03375320|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763060|NCT03375320|OTHER|Placebo Administration|Given PO
219763061|NCT03375320|OTHER|Quality-of-Life Assessment|Ancillary studies
219007983|NCT02927431|DRUG|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
219435293|NCT03907787|DIETARY_SUPPLEMENT|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
219007984|NCT06361485|BIOLOGICAL|Lumbar Injections with 10cc's of Wharton's Jelly Allograft|Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
219007985|NCT00005094|DRUG|celecoxib|Given orally
219435294|NCT05285436|DEVICE|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
219007986|NCT00005094|OTHER|placebo|Given orally
219194506|NCT04666714|DRUG|Pregabalin 150mg|Pregabalin 150mg tablet
219763062|NCT03375320|PROCEDURE|X-Ray Imaging|Undergo x-ray
219763063|NCT05300048|DRUG|Serabelisib|serabelisib administered orally
219763064|NCT05300048|OTHER|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
219763065|NCT05300048|DRUG|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
219763066|NCT06445907|DRUG|Azacitidine|Given by IV
219763067|NCT06445907|DRUG|Venetoclax|Given by PO
219763068|NCT06445907|DRUG|Q702|Given by PO
219763069|NCT05182164|DRUG|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
219763070|NCT06283979|COMBINATION_PRODUCT|STIMULAN VG|Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
219763071|NCT06283979|PROCEDURE|Standard of Care|Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
219763072|NCT00862433|DRUG|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
219763073|NCT00862433|OTHER|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
219763074|NCT00862433|OTHER|Vitamin C|Oral vitamin C, one gram daily.
219763075|NCT05552755|DRUG|REC-4881|REC-4881 4mg capsules
219763076|NCT05552755|DRUG|Placebo|Placebo capsules
219763077|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
219763078|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
219763079|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
219763080|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
219763081|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
219763082|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
219763083|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
219763084|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
219763085|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
219763086|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
219763087|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
219763088|NCT06624670|DRUG|Spesolimab|Solution for infusion
219763089|NCT06624670|DRUG|Placebo matching to spesolimab|Placebo matching to spesolimab
219763090|NCT06624670|DRUG|Prednisone|Prednisone
219763091|NCT06624670|DRUG|Prednisolone|Prednisolone
219763092|NCT05672381|PROCEDURE|Lower extremity and/or upper extremity surgery|Lower extremity and/or upper extremity surgery
219763093|NCT06489626|DRUG|Methylprednisolone 4 milligram Tab|6-day 4 milligram methylprednisolone oral taper
219763094|NCT06489626|DRUG|Dexamethasone injection|4 milligram intravenous dexamethasone will be administered intraoperatively
219763095|NCT03990610|PROCEDURE|Mammoplasty|Undergo standard of care breast reconstructive surgery
219763096|NCT03990610|PROCEDURE|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
219763097|NCT06208150|DRUG|Talquetamab|Talquetamab will be administered as a SC injection.
219763098|NCT06208150|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219763099|NCT06208150|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
219763100|NCT06208150|DRUG|Elotuzumab|Elotuzumab will be administered intravenously.
219763101|NCT06208150|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
219763102|NCT06208150|DRUG|Bortezomib|Bortezomib will be administered as a SC injection.
219763103|NCT05143229|DRUG|Alpelisib|PI3K inhibitor
219763104|NCT05143229|DRUG|Sacituzumab govitecan|Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
219763105|NCT05952518|DEVICE|Sprint PNS system|Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
219763106|NCT05952518|PROCEDURE|Radiofrequency Ablation|Thermal ablation of the medial nerve
219007987|NCT04287491|OTHER|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
219007988|NCT05244330|OTHER||
219007989|NCT04119882|DIAGNOSTIC_TEST|Blood collection|New biomarker test
219194507|NCT04666714|OTHER|Placebo Praga formulation|Placebo Praga formulation tablet
219194508|NCT03059264|OTHER|Natural history|Longitudinal disease progression
219194509|NCT06142292|BEHAVIORAL|Individual counseling|Individual counseling sessions with a licensed mental health counselor
218859592|NCT05020795|PROCEDURE|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
218859593|NCT06320509|BIOLOGICAL|Continuous measurement of uPO2 (both groups)|uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
218859594|NCT05775146|RADIATION|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
218859595|NCT05570435|BIOLOGICAL|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
218859596|NCT06456268|DEVICE|VibraCool mechanical stimulation and neuromodulatory therapeutic device|"Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression."
219007990|NCT01421108|BEHAVIORAL|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
219007991|NCT01421108|BEHAVIORAL|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
219007992|NCT01660698|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin powder
219007993|NCT01660698|DIETARY_SUPPLEMENT|Probiotic|probiotic blended in maltodextrin powder
219007994|NCT01053416|PROCEDURE|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
219007995|NCT01102504|DRUG|Placebo|Placebo
219007996|NCT01102504|DIETARY_SUPPLEMENT|Ateronon|Tomato extract containing 28 mg lycopene/ day
219007997|NCT03907358|PROCEDURE|phacoemulsification|
219763107|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
219007998|NCT02994212|DIETARY_SUPPLEMENT|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
219763108|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
219763109|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
219763110|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
219763111|NCT06666712|DRUG|Topotecan|Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)
219007999|NCT05717374|DRUG|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
219008000|NCT05717374|DRUG|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
219763112|NCT02523014|DRUG|Vismodegib|Given PO
219763113|NCT02523014|DRUG|FAK Inhibitor GSK2256098|Given PO
219763114|NCT02523014|DRUG|Capivasertib|Given PO
219763115|NCT02523014|DRUG|Abemaciclib|Given PO
219435295|NCT02288039|OTHER|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
219435296|NCT03765710|OTHER|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
219435297|NCT03765710|OTHER|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
219435298|NCT03006081|DRUG|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
219763116|NCT00692471|DEVICE|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
219763117|NCT05976763|DRUG|Zanubrutinib|Given PO
219763118|NCT05976763|BIOLOGICAL|Rituximab|Given IV
219008001|NCT00673465|DRUG|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
219008002|NCT00673465|DRUG|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
219008003|NCT00673465|DRUG|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
219008004|NCT05423028|PROCEDURE|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
219008005|NCT03578159|OTHER|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
219194510|NCT06142292|BEHAVIORAL|Group counseling|Group counseling sessions with a licensed mental health counselor
219435299|NCT03966495|OTHER|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
219435300|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
219435301|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
219435302|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
219435303|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
219435304|NCT04641910|OTHER|No intervention|No intervention
219763119|NCT05976763|OTHER|Patient Observation|Undergo observation
219763120|NCT05976763|PROCEDURE|Bone Marrow Biopsy|undergo bone marrow biopsy
219763121|NCT05976763|OTHER|Fludeoxyglucose F-18|Given IV
219763122|NCT05976763|PROCEDURE|Positron Emission Tomography|Undergo PET
219763123|NCT05976763|PROCEDURE|Computed Tomography|Undergo CT
219763124|NCT05976763|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763125|NCT05976763|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
219763126|NCT05976763|PROCEDURE|Colonoscopy|Undergo colonoscopy
219763127|NCT05976763|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763128|NCT05976763|OTHER|Questionnaire Administration|Ancillary studies
219763129|NCT05947058|PROCEDURE|Arthroplasty|The type of hip prothesis (hemi or total; cemented or uncemented) will be at the discretion of the treating surgeon.
219763130|NCT05947058|PROCEDURE|Internal Fixation|Both fixed angle devices and multiple screws will be permitted for the internal fixation group.
219763131|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
219763132|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
219763133|NCT06415344|DRUG|GTX-102|Antisense Oligonucleotide
219763134|NCT04940286|BIOLOGICAL|Durvalumab|Given IV
219763135|NCT04940286|DRUG|Gemcitabine|Given IV
219763136|NCT04940286|DRUG|Nab-paclitaxel|Given IV
219763137|NCT04940286|BIOLOGICAL|Oleclumab|Given IV
219763138|NCT03994796|DRUG|Abemaciclib|Given PO
219763139|NCT03994796|DRUG|PI3K Inhibitor paxalisib|Given PO
219763140|NCT03994796|DRUG|Entrectinib|Given PO
219763141|NCT03994796|DRUG|Adagrasib|Given PO
219763142|NCT06274515|PROCEDURE|Tumor Tissue and Blood Draw|Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
219763143|NCT06667726|PROCEDURE|Computed Tomography|Undergo PET/CT
219763144|NCT06667726|DRUG|Fluorodopa F 18|Given IV
219763145|NCT06667726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219763146|NCT04323098|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
219763147|NCT04136951|OTHER|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
219763148|NCT06422273|DRUG|Tranexamic Acid|Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
219763149|NCT06422273|OTHER|Saline (placebo)|Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
219008006|NCT04383405|OTHER|Aquatic Training|Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.
219008007|NCT04383405|OTHER|Conventional Training|Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
219435305|NCT03494023|DIAGNOSTIC_TEST|Endoscopic ultrasound|Measurement of the common bile duct diameter
219435306|NCT00053638|DRUG|efavirenz|
219435307|NCT00053638|DRUG|tenofovir|
219435308|NCT00053638|DRUG|abacavir/lamivudine|
219435309|NCT04905823|DIAGNOSTIC_TEST|blood test|assessment of humoral, immune cell response and glycemia
219435310|NCT05895695|PROCEDURE|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
219763150|NCT05857995|BEHAVIORAL|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program|KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
219763151|NCT05857995|BEHAVIORAL|Enhanced Usual Care|EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
219763152|NCT06706362|DRUG|Bactrim or Macrobid|Participants will be assigned to Bactrim or Macrobid depending on participants' allergies
219763153|NCT06706362|DRUG|Placebo|Participants will be assigned to identical appearing placebo
219435311|NCT05895695|PROCEDURE|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
219435312|NCT03822338|PROCEDURE|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
219008008|NCT05083962|BEHAVIORAL|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
219008009|NCT02649998|DRUG|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
219194511|NCT04866836|COMBINATION_PRODUCT|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
219435313|NCT03822338|PROCEDURE|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
219435314|NCT04213118|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
219435315|NCT04213118|PROCEDURE|TACE|TACE first, followed by anlotinib within day4（+/-1days）
219435316|NCT00825149|DRUG|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
219194512|NCT06178523|DRUG|Clomiphene Citrate.|Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
219194513|NCT06178523|DRUG|Sildenafil Citrate|Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
219194514|NCT06178523|PROCEDURE|Intrauterine Insemination|IUI (Group-B).
219194515|NCT03484819|DRUG|Copanlisib Hydrochloride|Given IV
219194516|NCT03484819|BIOLOGICAL|Nivolumab|Given IV
219435317|NCT00825149|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
219435318|NCT00825149|DRUG|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
219435319|NCT00825149|DRUG|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
219435320|NCT00825149|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
219435321|NCT00825149|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
219435322|NCT00825149|DRUG|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
219435323|NCT00301470|DEVICE|MR urography|undergoing both renal scintigraphy and MR within a month
219435324|NCT01871272|PROCEDURE|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
219435325|NCT05609851|OTHER|Short Physical Performance Batary|"The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function."
219435326|NCT05609851|OTHER|Occupational Balance Self-Assessment|"The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value."
219435327|NCT03066297|PROCEDURE|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
219008010|NCT02649998|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
219435328|NCT00644124|DRUG|aflibercept|in combination with standard treatment R-CHOP
219435329|NCT02468960|DEVICE|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
219435330|NCT02468960|DEVICE|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
219008011|NCT00429104|DRUG|Herceptin|4 mg/kg IV Over 90 Minutes
219008012|NCT00429104|DRUG|GM-CSF|250 mcg/m\^2 Subcutaneously
219008013|NCT01829191|DEVICE|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
219008014|NCT01829191|DEVICE|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
219008015|NCT01907815|DRUG|Akt Inhibitor GSK2141795|Given PO
219008016|NCT01907815|OTHER|Laboratory Biomarker Analysis|Correlative studies
219008017|NCT01907815|DRUG|Trametinib|Given PO
219008018|NCT00808977|DRUG|Dersalazine sodium|Dersalazine sodium 2400 mg daily
219008019|NCT00808977|DRUG|Mesalazine|Mesalazine 2400 mg daily
219008020|NCT00808977|DRUG|Placebo|Placebo matching active and experimental treatments
219435331|NCT02468960|DEVICE|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
219435332|NCT02468960|PROCEDURE|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
219435333|NCT02468960|OTHER|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
219008021|NCT03516591|DRUG|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
219008022|NCT05167214|DEVICE|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
219008023|NCT00937612|RADIATION|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
219435334|NCT02151968|PROCEDURE|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
219435335|NCT02151968|PROCEDURE|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
219435336|NCT01090869|BEHAVIORAL|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
219435337|NCT00083629|PROCEDURE|PET|
219008024|NCT05612984|COMBINATION_PRODUCT|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
219008025|NCT05612984|DIETARY_SUPPLEMENT|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
219008026|NCT01276353|DRUG|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
219008027|NCT01276353|DRUG|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
219008028|NCT05320120|DRUG|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
219008029|NCT05320120|DRUG|0.9% saline solution nasal spray|0.9% saline solution nasal spray
219435338|NCT02045056|DRUG|Gemfibrozil|
219435339|NCT02045056|DRUG|Placebo|
219435340|NCT00033982|DRUG|Posaconazole|
219435341|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
219435342|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
219435343|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
219008030|NCT05241496|DIAGNOSTIC_TEST|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
219008031|NCT01414283|DRUG|PSMA ADC|PSMA ADC administered IV
219008032|NCT04264637|DRUG|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
219008033|NCT04264637|DRUG|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
219008034|NCT04655274|DIAGNOSTIC_TEST|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
219008035|NCT00143403|DRUG|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
219008036|NCT00143403|DRUG|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
219008037|NCT00514540|DRUG|Docetaxel|75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
219008038|NCT00514540|DRUG|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
219008039|NCT00514540|DRUG|Etoposide|120 mg/m\^2 daily for 3 days of 21 day cycle.
219008040|NCT00514540|DRUG|Cisplatin|25 mg/m\^2 for 3 days of 21 day cycle.
219435344|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
219435345|NCT01626053|BEHAVIORAL|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
219435346|NCT01626053|OTHER|Control Group|no intervention
219435347|NCT02401243|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
219435348|NCT04193670|OTHER|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
219008041|NCT05426577|DIAGNOSTIC_TEST|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
219008042|NCT03030872|DEVICE|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
219008043|NCT03707327|OTHER|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
219008044|NCT03707327|OTHER|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
219008045|NCT03402386|DRUG|MT-6548|Oral tablet
219435349|NCT04193670|PROCEDURE|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
219435350|NCT04193670|OTHER|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
219435351|NCT02823080|DRUG|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
219435352|NCT00522574|DRUG|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
219435353|NCT06844396|OTHER|Music Therapy|"Music Therapy consisting of four types of protocol:~* Music combined with skin to skin~* Developmental multimodal technique~* Infant directed singing~* Parent/caregiver therapeutic support"
219435354|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
219435355|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
219435356|NCT00914719|BEHAVIORAL|Information only|
219435357|NCT00914719|BEHAVIORAL|Sexual risk reduction intervention|
219435358|NCT00914719|BEHAVIORAL|sexual risk reduction + alcohol risk reduction component|
219435359|NCT01786434|DRUG|Routine medication arm|50 micrograms of fentanyl given before the procedure
219579391|NCT02580084|PROCEDURE|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
219008046|NCT05505214|DRUG|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
219008047|NCT05505214|DRUG|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
219435360|NCT01786434|DRUG|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
219435361|NCT02481791|DRUG|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
219435362|NCT02481791|DRUG|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
219435363|NCT02481791|DRUG|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
219435364|NCT03505957|DEVICE|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
219435365|NCT03386006|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
219435366|NCT01979328|DEVICE|geko|
219435367|NCT01979328|DEVICE|Plaster cast|
219008048|NCT05505214|DRUG|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
219008049|NCT00587639|DEVICE|rTMS Treatment|Active rTMS treatment.
219008050|NCT02756689|OTHER|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
219435368|NCT02193854|DEVICE|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
219435369|NCT00150514|DRUG|Oralgen|
219435370|NCT00150514|PROCEDURE|Nasal biopsy|
219008051|NCT02756689|OTHER|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
219008052|NCT06190639|DRUG|sintilimab|200 mg once on day 1, every 21 days
219435371|NCT00150514|PROCEDURE|Nasal washing|
219435372|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
219435373|NCT03140722|DRUG|vadadustat|vadadustat
219435374|NCT03140722|DRUG|epoetin alfa|epoetin alfa
219435375|NCT04994275|OTHER|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or \<300 µg/L And TSAT\<20%) or no iron deficiency
219435376|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219435377|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219435378|NCT05988086|PROCEDURE|platelet rich fibrin|12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
219435379|NCT05988086|PROCEDURE|collagen membrane|12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
219435380|NCT03117699|DEVICE|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair"
219435381|NCT02564562|DRUG|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
219435382|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
219435383|NCT03185169|COMBINATION_PRODUCT|Replens and coconut oil|
219008053|NCT03656328|DIETARY_SUPPLEMENT|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
219435384|NCT01208389|BIOLOGICAL|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
219435385|NCT03190317|OTHER|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
219008054|NCT03656328|DIETARY_SUPPLEMENT|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
219008055|NCT00804830|DRUG|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
219008056|NCT00536406|BEHAVIORAL|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
219008057|NCT00536406|BEHAVIORAL|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
219008058|NCT02103764|DRUG|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
219008059|NCT02103764|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
219008060|NCT05546645|OTHER|Questionnaire|Hypersecretion questionnaire
219008061|NCT02060149|DRUG|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
219435386|NCT03190317|OTHER|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
219435387|NCT03190317|OTHER|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
219435388|NCT04233957|DIETARY_SUPPLEMENT|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
219435389|NCT04233957|OTHER|Placebo|10 days of enteric capsules filled with dextrose.
219579392|NCT04026685|DRUG|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
219579393|NCT04026685|DRUG|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
219008062|NCT02060149|DRUG|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
219008063|NCT02060149|DRUG|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
219008064|NCT02060149|DRUG|No nebulization|No nebulization will be given to the patients.
219008065|NCT02877420|OTHER|Non-Technical Skills Training Curriculum|
219008066|NCT02877420|OTHER|Conventional Simulation Training Group|
219008067|NCT01486251|DRUG|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
219008068|NCT02608710|DRUG|RDEA3170 4.5 mg|
219008069|NCT02608710|DRUG|RDEA3170 6 mg|
219008070|NCT02608710|DRUG|RDEA3170 12 mg|
219008071|NCT00433095|DRUG|Navelbine|
219008072|NCT00433095|DRUG|Herceptin|
219008073|NCT00433095|DRUG|Navelbine (oraly)|
219008074|NCT02237950|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
219008075|NCT02237950|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
219008076|NCT02237950|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
219008077|NCT04612556|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
219008078|NCT02818322|DEVICE|telemedical monitoring ( T)|
219008079|NCT02818322|DEVICE|classic monitoring|
219008080|NCT03530904|OTHER|mobilization|Early mobilization after CIED implantation
219008081|NCT01996982|DEVICE|CCS Device|Core Cooling System Device
219435390|NCT06410924|DRUG|DD01|Dual GLP-1 and glucagon receptor agonist
219435391|NCT06410924|DRUG|Placebo|Placebo matching DD01
219194517|NCT04576715|BEHAVIORAL|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up"
219194518|NCT04576715|BEHAVIORAL|Standard of Care|"Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
219194519|NCT04998162|PROCEDURE|SVF injection|Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
219194520|NCT04479761|BEHAVIORAL|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
219194521|NCT06186817|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
219194522|NCT06186817|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
219194523|NCT06186817|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
219008082|NCT05493527|DEVICE|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
219194524|NCT06186817|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
219008083|NCT05493527|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
219008084|NCT01294293|DRUG|TLR8 Agonist VTX-2337|Given SC
219008085|NCT01294293|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219194525|NCT04224558|DRUG|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
219194526|NCT04224558|DRUG|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
219194527|NCT04224558|DRUG|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL"
219194528|NCT04224558|PROCEDURE|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
219435392|NCT02559752|OTHER|NIH Toolbox Cognitive Battery|"* For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
219435393|NCT03705260|OTHER|Usual Care|Usual care from Primary Care Physician and dietitian.
219435394|NCT03705260|BEHAVIORAL|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
219435395|NCT03705260|OTHER|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
219435396|NCT03499613|OTHER|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
219435397|NCT00516958|DRUG|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
219435398|NCT00516958|DRUG|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
219435399|NCT00516958|DRUG|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
219194529|NCT04224558|PROCEDURE|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
219435400|NCT03892525|DRUG|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
219435401|NCT03892525|DRUG|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
219435402|NCT05523804|PROCEDURE|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
219435403|NCT05523804|PROCEDURE|delayed cytoreductive surgery|surgery after \>5 cycles of chemotherapy
219435404|NCT05523804|OTHER|no surgery|no cytoreductive surgery (\>5 cycles of chemotherapy alone)
219008086|NCT01294293|OTHER|Pharmacological Study|Correlative studies
219008087|NCT01294293|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219008088|NCT01294293|DRUG|Paclitaxel|Given IV
219008089|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
219008090|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
219008091|NCT02379806|DRUG|Enoxaparin|
219008092|NCT02379806|DRUG|Placebo|
219194530|NCT04224558|DRUG|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
219435405|NCT00323310|DRUG|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
219008093|NCT05276544|BEHAVIORAL|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
219008094|NCT00135720|DRUG|Enbrel (Etanercept)|
219194531|NCT04224558|DRUG|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
219194532|NCT04224558|DRUG|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
219194533|NCT04224558|DRUG|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
219008095|NCT03134027|PROCEDURE|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
219008096|NCT03134027|PROCEDURE|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
219008097|NCT02338284|OTHER|ultrasound of globe|"* A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~* A value \> 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
219008098|NCT00415103|DRUG|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
219008099|NCT00415103|DRUG|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
219008100|NCT00415103|DRUG|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
219194534|NCT04224558|DRUG|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
219579394|NCT03971487|BEHAVIORAL|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
219435406|NCT06257134|OTHER|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
219435407|NCT06257134|OTHER|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
219435408|NCT03984812|DRUG|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
219435409|NCT03984812|DRUG|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
219579395|NCT03971487|BEHAVIORAL|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
219579396|NCT03971487|DIAGNOSTIC_TEST|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
219194535|NCT04224558|DRUG|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
219194536|NCT04224558|BIOLOGICAL|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
219194537|NCT04224558|DRUG|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
219194538|NCT04357093|OTHER|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
219194539|NCT04357093|OTHER|Sodium fluoride mouthwash|Sodium fluoride mouthwash
219435410|NCT02707601|DRUG|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
219435411|NCT02707601|DRUG|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
219435412|NCT02707601|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219435413|NCT03551184|BIOLOGICAL|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
219435414|NCT03551184|BIOLOGICAL|Placebo|Saline administered intravenously
219435415|NCT00704392|DRUG|XL647|Tablets supplied at 50-mg strength administered orally daily
219435416|NCT00704392|DRUG|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
219435417|NCT01769612|OTHER|No Intervention|
219579397|NCT03971487|BIOLOGICAL|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
219579398|NCT04467359|OTHER|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
219435418|NCT01255189|DEVICE|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
219435419|NCT01255189|DEVICE|invos 5100|near infrared spectroscopy: invos 5100
219435420|NCT02779530|DRUG|Diclofenac|50 mg po, b.i.d for 6 days
219435421|NCT02779530|OTHER|Placebo|Placebo po, b.i.d. for 6 days
219435422|NCT02147691|DRUG|Azelaic acid 15%|Applied to the face each AM and PM
219435423|NCT02147691|DRUG|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
219579399|NCT04467359|OTHER|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
219435424|NCT02708472|DEVICE|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
219435425|NCT04971993|DEVICE|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
219435426|NCT04703244|PROCEDURE|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
219435427|NCT05767658|BEHAVIORAL|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents.
219008101|NCT01005420|DIETARY_SUPPLEMENT|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
219194540|NCT05728463|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
219435428|NCT05767658|BEHAVIORAL|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents.
219579400|NCT02138136|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration
219194541|NCT04291560|BEHAVIORAL|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
219194542|NCT05825170|DEVICE|FASY L|Subjects will receive FASY L in lips at level of their scar.
219008102|NCT01005420|DIETARY_SUPPLEMENT|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
219435429|NCT05767658|BEHAVIORAL|Early Brain Development and Parent-Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
219579401|NCT04192123|DEVICE|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
219435430|NCT02983279|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo caloric restriction diet
219435431|NCT02983279|OTHER|Counseling|Undergo counselor-led dietary counseling
219435432|NCT02983279|PROCEDURE|Therapeutic|Undergo standard of care surgery
219435433|NCT02432703|DRUG|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
219435434|NCT02432703|DRUG|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
219435435|NCT06307444|PROCEDURE|Ultrasound-Guided Stellate Ganglion Block|high frequency (6 to 13 MHz) linear transducer will be placed perpendicular to the tracheal axis at the cricoid cartilage and will be moved inferiorly until the superior aspect of the thyroid gland is visualized. Later, the transducer should be relocated laterally to visualize the anterior aspect of the Chassaignac's tubercle on \[\]the C6 transverse process. The carotid artery, internal jugular vein, thyroid gland, trachea, Longus colli, and Longus capitis muscle, prevertebral fascia, the root of C6 spinal nerve, and transverse process of C6 can be identified. Color Doppler will be used to detect the position of the vessels. With an in-plane approach, 22 to 25 gauge echo-enhanced needle is placed beside the trachea with a lateral to medial direction.
219435436|NCT06307444|PROCEDURE|T2 T3 (High Thorathic) ESP Block|We will count the laminae in the cephaled-to-caudal direction, starting from the C7 using the US to determine the exact vertebral level where the needle will be inserted. A linear high-frequency ultrasound probe will be used to perform the blocks. After the determination of the needle insertion site, the US probe was placed over the spinous processes of the vertebrae at the midline in the longitudinal plane. The US probe will then slid laterally from the spinous processes to visualize the transverse process. The needle will be advanced posterior-to-anteriorly, in the caudal to cephalic direction using the in-plane orientation within paraspinal muscles, targeting the transverse process. When the tip of the needle reaches and contact the transverse process, the local anesthetic drugs(0.2-0.3ml/kg(11) of bupivacaine 0.25% 8mg Dexamethazone) will be administered
219435437|NCT04929678|DEVICE|Braive™ Growth Modulation System (Braive™ GMS)|"The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw."
219435438|NCT02170350|PROCEDURE|Meditation therapy|Use brief mindful meditation practice
219435439|NCT02170350|OTHER|Quality-of-life assessment|Ancillary studies
219435440|NCT02170350|OTHER|Questionnaire administration|Ancillary studies
219435441|NCT03470857|DIAGNOSTIC_TEST|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
219435442|NCT03210220|PROCEDURE|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
219435443|NCT02268448|DRUG|Clonidine|
219435444|NCT02268448|DRUG|Naltrexone|
219435445|NCT00178061|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
219435446|NCT02911519|OTHER|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
219008103|NCT06362811|PROCEDURE|Sacral Erector Spinae Plane Block|Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
219008104|NCT01195415|DRUG|Gemcitabine Hydrochloride|Given IV
219008105|NCT01195415|OTHER|Laboratory Biomarker Analysis|Correlative studies
219008106|NCT01195415|DRUG|Vismodegib|Given PO
219008107|NCT05320523|DEVICE|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
219008108|NCT05320523|DEVICE|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
219008109|NCT05320523|DEVICE|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
219008110|NCT05320523|DEVICE|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
219008111|NCT02939898|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
219008112|NCT02939898|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
219435447|NCT02911519|OTHER|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
219435448|NCT00653328|DRUG|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
219008113|NCT00167882|DRUG|5-aminosalicylate (Pentasa, Ferring)|
219435449|NCT00653328|DRUG|doxil|50 mg/m2 intravenously every 28 days
219435450|NCT02667522|BEHAVIORAL|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
219435451|NCT06021847|OTHER|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
219435452|NCT06021847|OTHER|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
219008114|NCT02155842|BEHAVIORAL|High intensity endurance exercise|
219008115|NCT02155842|BEHAVIORAL|Moderate continuous endurance exercise|
219008116|NCT00533845|DRUG|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
219008117|NCT00728780|DRUG|ABT-143|once
219008118|NCT00728780|DRUG|ABT-335 and rosuvastatin|once
219008119|NCT03078647|DEVICE|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
219008120|NCT05447637|DIAGNOSTIC_TEST|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
219008121|NCT01860651|BEHAVIORAL|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
219579402|NCT03808662|RADIATION|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
219008122|NCT02151253|DRUG|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
219579403|NCT03808662|DRUG|Standard of care|Standard of care per physician discretion
219579404|NCT02593448|PROCEDURE|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB."
219194543|NCT05249114|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
219194544|NCT05249114|DRUG|Lu-177|Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
219199584|NCT06872255|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"All procedures will be performed by an experienced endoscopist, with a sufficient experience in third space endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center."
219763154|NCT01878617|RADIATION|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
219763155|NCT01878617|DRUG|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
219763156|NCT01878617|DRUG|Cisplatin|ROA: IV
219763157|NCT01878617|DRUG|Vincristine|ROA: IV
219763158|NCT01878617|DRUG|Vismodegib|ROA: Orally (PO)
219763159|NCT01878617|DRUG|Pemetrexed|ROA: IV
219763160|NCT01878617|DRUG|Gemcitabine|ROA: IV
219763161|NCT01878617|OTHER|Aerobic Training|
219763162|NCT01878617|OTHER|Neurocognitive Remediation|
219763163|NCT05796570|DRUG|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
219763164|NCT05796570|DRUG|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
219763165|NCT02589522|DRUG|Berzosertib|Given IV
219763166|NCT02589522|OTHER|Quality-of-Life Assessment|Ancillary studies
219763167|NCT02589522|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219763168|NCT02589522|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
219763169|NCT06620003|BIOLOGICAL|cAd3-Marburg Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg Vaccine) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
219763170|NCT06620003|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
219763171|NCT05415397|DRUG|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
219763172|NCT05415397|DRUG|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
219763173|NCT03587311|BIOLOGICAL|Anetumab Ravtansine|Given IV
219763174|NCT03587311|BIOLOGICAL|Bevacizumab|Given IV
219763175|NCT03587311|DRUG|Paclitaxel|Given IV
219763176|NCT01934660|DRUG|13N-amonia|PET/Scan
219763177|NCT01934660|DRUG|Fludeoxyglucose F18|PET/Scan
219763178|NCT06448806|OTHER|mobile health lifestyle intervention|You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
219763179|NCT06243952|DEVICE|ARC-BSI Lumbar system|Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
219763180|NCT06517888|COMBINATION_PRODUCT|AAVAnc80-antiVEGF via Akouos Delivery Device|AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
219194545|NCT06808165|DIAGNOSTIC_TEST|relaxin|The primary source of relaxin in pregnancy is the corpus luteum, but it is also produced in other tissues, such as the decidua and placenta. Importantly, relaxin's pleiotropic effects include endothelial-dependent vasodilation, extracellular matrix remodeling, and potential contributions to placental development. These properties make relaxin a molecule of interest in the context of PAS disorders, where abnormal placental invasion may reflect disruptions in vascular and extracellular matrix regulation. Additionally, recent findings have indicated altCirculating relaxin levels were assessed before routinely storing maternal venous blood and umbilical cord arterial blood samples are anelyzed. This study aimed to compare relaxin levels in umbilical cord and peripheral blood and estimated placental volumes (EPV) between PAS cases and controls. Additionally, subgroup analysis was conducted to evaluate relaxin levels and EPV among PAS subtypes (accreta, increta, and percreta).
219008123|NCT02151253|DRUG|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
219008124|NCT00002714|BIOLOGICAL|bleomycin sulfate|
219008125|NCT00002714|DRUG|Stanford V regimen|
219008126|NCT00002714|DRUG|doxorubicin hydrochloride|
219008127|NCT00002714|DRUG|etoposide|
219008128|NCT00002714|DRUG|mechlorethamine hydrochloride|
219008129|NCT00002714|DRUG|prednisone|
219008130|NCT00002714|DRUG|vinblastine sulfate|
219008131|NCT00002714|DRUG|vincristine sulfate|
219008132|NCT00002714|RADIATION|radiation therapy|
219194546|NCT06810557|BEHAVIORAL|Optimize Sleep Primary Care (OSPC)|In addition to standard care within Temple University Primary Care (TUPC), two face-to-face zoom sessions and four brief phone follow-ups (two during active treatment and two during maintenance) that focus on using effective behavioral strategies (e.g., goal setting, self-monitoring, positive reinforcement, stimulus control, problem-solving) to enhance children's sleep by approximately one hour/night.
219194547|NCT06810557|OTHER|Enhanced Usual Care|In addition to standard care within Temple University Primary Care (TUPC), the provision of six education contacts regarding children's sleep needs and the benefits of getting a good night's sleep.
218859597|NCT06456268|DEVICE|Cryocompression (Game Ready, Bregs) device|Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
219008133|NCT01288469|DRUG|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
219008134|NCT01288469|DRUG|Placebo (for alirocumab)|One SC injection in the abdomen only.
219008135|NCT01288469|DRUG|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
219008136|NCT01288469|DRUG|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
219008137|NCT01680523|PROCEDURE|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
219194548|NCT06810648|PROCEDURE|GDFT|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was provided with intravenous analgesics.
219194549|NCT06810648|PROCEDURE|GDFT/ED|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was administered via epidural analgesics.
219008138|NCT01680523|RADIATION|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
219008139|NCT01680523|RADIATION|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
219008140|NCT04537507|PROCEDURE|Coronary angiography|
219008141|NCT00255047|BIOLOGICAL|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
219008142|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
219008143|NCT00255047|BIOLOGICAL|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
219008144|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
219008145|NCT04358848|DEVICE|X-PLO2R|Portable Oxygen Concentrator (POC)
219008146|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin|Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique
219008147|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide|using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
219008148|NCT03417453|DEVICE|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
219194550|NCT06810648|PROCEDURE|CFT|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was provided with intravenous analgesics.
219008149|NCT03417453|DEVICE|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
219008150|NCT03092531|BEHAVIORAL|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
219008151|NCT04731168|DEVICE|Mandibular advancement device|Patients will have a mandibular advancement device during the first postoperative night
219008152|NCT02395900|DIETARY_SUPPLEMENT|Flaxseed|
219008153|NCT02395900|OTHER|control|
219008154|NCT06114355|PROCEDURE|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
219008155|NCT05982275|GENETIC|CARTemis-1|A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
219008156|NCT06250231|OTHER|No intervention|No intervention
219008157|NCT01894165|DRUG|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
219008158|NCT01894165|DRUG|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
219008159|NCT06229197|PROCEDURE|Billroth II reconstruction|Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant
219008160|NCT06229197|PROCEDURE|Braun Anastomosis|This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
219008161|NCT03987529|OTHER|sevoflurane|volatile anesthetic
219008162|NCT03987529|OTHER|propofol|intravenous anesthetic
219008163|NCT02523898|DRUG|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
219008164|NCT02523898|DRUG|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
219008165|NCT02523898|DRUG|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
219008166|NCT03970798|DRUG|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
219008167|NCT03970798|DRUG|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
219008168|NCT03970798|DRUG|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
219008169|NCT03970798|DRUG|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
219008170|NCT00376662|DRUG|Hormone Replacement Therapy and Etidronate|
219008171|NCT00230568|DRUG|Aricept|
219008172|NCT04376710|OTHER|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
219194551|NCT06810648|PROCEDURE|CFT/ED|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was administered via epidural analgesics.
219194552|NCT06808529|DEVICE|Pilates exercises and TENS Acupuncture|All performed Pilates exercises for 24 session, 3 sessions per week for (2 consecutive menstrual cycle), each session lasted for 30 minutes in addition to application of TENS acupuncture therapy for 30 minutes, 3 sessions in the first 3 days for (2 consecutive menstrual cycle).
219194553|NCT06808529|DRUG|ibuprofen 400 mg|All took capsules of ibuprofen(400-milligram) and instructed to take them once every eight hours for three days, one day before the start of their menstrual cycle and on the first two days of menstruation for (2 consecutive menstrual cycle).
219194554|NCT04011644|BEHAVIORAL|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
219008173|NCT04376710|OTHER|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
219008174|NCT04376710|OTHER|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
219008175|NCT06335914|DIAGNOSTIC_TEST|Ga 68 PSMA-11 PET|Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
219008176|NCT06335914|DIAGNOSTIC_TEST|18F-DCFPyL PET|Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
219194555|NCT04011644|BEHAVIORAL|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
219008177|NCT06335914|DIAGNOSTIC_TEST|FDG PET|Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
219008178|NCT00197964|BEHAVIORAL|Enhance asthma knowledge, self-efficacy, social support|
219008179|NCT03872167|DEVICE|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
219008180|NCT03872167|DEVICE|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
219008181|NCT05122273|DEVICE|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
219008182|NCT05316753|PROCEDURE|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
219008183|NCT05316753|PROCEDURE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
219008184|NCT05199298|OTHER|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
219579405|NCT02593448|PROCEDURE|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
219008185|NCT00569478|OTHER|rehabilitation|Nursing consultations and physical training
219008186|NCT00110149|BIOLOGICAL|rituximab|
219008187|NCT00110149|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219194556|NCT04011644|BEHAVIORAL|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
219194557|NCT06197503|PROCEDURE|Conduction system pacing|Left bundle branch pacing or His bundle branch pacing
219008188|NCT00563381|DRUG|Tiotropium bromide|18 mcg/daily
219008189|NCT00563381|DRUG|Salmeterol|100 mcg/daily
219008190|NCT00563381|DRUG|Placebo Salmeterol|Placebo identical to Salmeterol device
219194558|NCT06197503|PROCEDURE|Right ventricular pacing|Conventional pacing
219194559|NCT06809634|OTHER|Large Language Model|The intervention in the experimental group is distinguished by the integration of a Large Language Model (LLM)-based interactive platform (ChatGPT) into clinical reasoning training for physical therapy students. Unlike traditional educational approaches, this intervention provides real-time, AI-generated patient interactions, allowing students to actively engage in virtual clinical case simulations.
219194560|NCT06809634|OTHER|Conventional|The intervention in the control group follows a traditional case-based learning approach, which is commonly used in physical therapy education. Unlike the experimental group, this training method relies solely on human-led instruction and written case analysis, without the integration of artificial intelligence or interactive digital tools.
219194561|NCT06810102|OTHER|VIRTUAL REALITY GLASSES|There will be a video screening
219008191|NCT00563381|DRUG|Placebo Tiotropium|Placebo identical to Tiotropium device
219194562|NCT06167746|OTHER|Digital Health Information (DHI)|Digital health information websites.
219194563|NCT06167746|BEHAVIORAL|Virtual Health Coach for You|Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
219194564|NCT05757726|DEVICE|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
219194565|NCT04842877|DRUG|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
219194566|NCT06387342|DRUG|Namodenoson 25mg|oral capsule
219008192|NCT03477877|BEHAVIORAL|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
219194567|NCT06808880|DEVICE|Single-gene Noninvasive Prenatal Testing (sgNIPT)|Natera sgNIPT is intended for use in pregnant people whose 'fetus/ fetuses are identified as at increased risk for a single gene disorder when there is no reproductive partner (paternal) screening available or when there is positive reproductive partner screening, but prenatal diagnostic testing is not an option or when there is concern for a single-gene disorder in the fetus/ fetuses irrespective of carrier status (e.g., based on fetal ultrasound findings).
219194568|NCT06809816|DRUG|Sodium pentaborate pentahydrate|Sodium pentaborate pentahydrate will be administered orally in capsule form, following the standard protocol outlined in the study design.
219194569|NCT06564324|DRUG|Taletrectinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met."
219579406|NCT02593448|PROCEDURE|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
219579407|NCT00590278|DRUG|Tomudex|
219579408|NCT00590278|PROCEDURE|Radiotherapy|
219579409|NCT00590278|PROCEDURE|Haematology|
219579410|NCT00590278|PROCEDURE|Biochemistry|
219579411|NCT04940949|DRUG|Lu AF90103|Lu AF90103 - powder for solution for infusion
219579412|NCT04940949|DRUG|Placebo|Placebo - powder for solution for infusion
219194570|NCT06564324|DRUG|Crizotinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC."
219194571|NCT06810024|COMBINATION_PRODUCT|Home-based therapy|"The home-based intervention includes the following modules:~1. Management of Stroke Recurrence Risk Factors: Home-based monitoring and management of blood pressure, blood sugar, cholesterol, and medication adherence.~2. Functional Rehabilitation and Daily Living Skills: Home-based physical therapy, rehabilitation exercises, and recovery of daily living skills.~3. Psychological Health and Emotional Management: Home-based counseling and mental health support to address anxiety, depression, and stress.~4. Nutritional and Lifestyle Interventions: At-home guidance on healthy eating, lifestyle changes, and behavior modification to reduce stroke recurrence.~5. Risk and Complication Prevention: Home monitoring to prevent infections and other complications during recovery.~6. Caregiver Empowerment: Home-based caregiver training and support to improve caregiving skills and reduce caregiver stress."
219008193|NCT03477877|BEHAVIORAL|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
219194572|NCT06810024|OTHER|Standard Care (in control arm)|"The standard care intervention involves:~Outpatient Visits: Routine follow-up visits to healthcare providers for stroke recovery monitoring, medication management, and adjustments.~Inpatient Rehabilitation: Physical, occupational, and speech therapy delivered in hospital or rehabilitation centers, if required.~Follow-up Appointments: Regular visits with stroke specialists and rehabilitation professionals for ongoing care."
219194573|NCT06809244|OTHER|Exercise|"Strength training as described under arm"
219194574|NCT06808893|OTHER|Psychiatric interview and documentary|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes. Another component of the combination is the documentary Us, You, Them prepared by the Federation of Schizophrenia Associations of Turkey, which deals with the life stories of schizophrenia patients and lasts approximately 56 minutes."
219194575|NCT06808893|OTHER|Psychiatric interview|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes."
219194576|NCT02997202|DRUG|gilteritinib|oral
219008194|NCT03477877|BEHAVIORAL|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
219008195|NCT03477877|OTHER|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
219008196|NCT03477877|BEHAVIORAL|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
219008197|NCT04682015|OTHER|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
219008198|NCT02793141|OTHER|No intervention|No intervention will be administered
219008199|NCT03923855|DEVICE|BTL-899|BTL-899 therapy
219008200|NCT02452398|DEVICE|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
219008201|NCT02452398|OTHER|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
219008202|NCT00499876|DRUG|mefloquine|250mg weekly PO for 6 months
219194577|NCT02997202|DRUG|Placebo|oral
219194578|NCT05790655|OTHER|oPRP|Prepared sample from patient's own blood collected and processed. Either PRP or serum is injected into the patient's ovary. All other care is standard for the IVF process
219194579|NCT05790655|OTHER|Placebo- Serum|Patient's serum is injected into ovary instead of PRP as placebo
219194580|NCT05347563|PROCEDURE|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
219008203|NCT00499876|OTHER|placebo|1 tablet weekly PO for 6 months
219008204|NCT02301494|DRUG|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
219008205|NCT02301494|DRUG|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
219194581|NCT05634902|BEHAVIORAL|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
219194582|NCT05634902|BEHAVIORAL|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
219194583|NCT06056258|DIETARY_SUPPLEMENT|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
219194584|NCT06056258|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
219194585|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
219194586|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
219194587|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
219194588|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
219008206|NCT03970161|DEVICE|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
219008207|NCT00002245|DRUG|Abacavir sulfate|
219008208|NCT00002245|DRUG|Amprenavir|
219008209|NCT00002245|DRUG|Lamivudine|
219194589|NCT05726721|OTHER|Treatment as usual, Psychotherapy|The three treament sites will offer psychotherapy as usual. All including elements of cognitive behavioral therapy and some sites also additional elements from either narrative therapy or interpersonal therapy
219194590|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
219194591|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
219194592|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
219194593|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
219008210|NCT01435954|DRUG|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
219194594|NCT06651957|OTHER|Biospecimen Collection|Specimen swabs will be obtained.
219194595|NCT06651957|OTHER|Questionnaires|Given to participants
219194596|NCT06652932|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
219194597|NCT06652932|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
219194598|NCT03165786|BEHAVIORAL|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
219194599|NCT06652971|DRUG|CKD-379|QD, PO
219194600|NCT05818410|DEVICE|Prosthetic device (Lunaris)|Participants with an amputation will conduct experiments with the prosthetic device
219194601|NCT05818410|OTHER|No prosthetic device|Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation
219194602|NCT05818410|DEVICE|Prosthetic device (Sach foot)|Participants with an amputation will conduct experiments with the prosthetic device
219194603|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
219194604|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
219194605|NCT06651697|RADIATION|Radiation therapy|Radiation therapy with full bladder or empty bladder protocols
219194606|NCT06652347|OTHER|Cancer care delivery|Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
219194607|NCT05265065|BIOLOGICAL|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
219194608|NCT05265065|BIOLOGICAL|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
219008211|NCT01435954|DRUG|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
219008212|NCT03559465|PROCEDURE|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
219194609|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219194610|NCT06252038|BEHAVIORAL|Zoom Group Video (GV)|Zoom delivery of the DPP. Participants have access to Prevent T2 Curriculum and connected technology to track weight and physical activity.
219194611|NCT06252038|BEHAVIORAL|Self Directed (SD)|Self directed delivery of the DPP. Participants have access to online curriculum, lifestyle coach and connected technology to track weight and physical activity.
219008213|NCT03559465|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
219008214|NCT00168727|DRUG|ibritumomab tiuxetan (Zevalin®)|
219194612|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
219194613|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
219194614|NCT06641336|DEVICE|RehAtt|Each patient received the RehAtt intervention.
219194615|NCT04860635|DRUG|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
219194616|NCT06257290|BIOLOGICAL|blood sample|at Day 1 - date of patient inclusion at time of VTE diagnosis
219194617|NCT06257290|BIOLOGICAL|blood sample|at 6 months (in the patient follow-up)
219194618|NCT06024993|DEVICE|Flow-controlled ventilation (FCV)|20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
219194619|NCT06024993|DEVICE|Conventional volume-controlled ventilation (VCV)|20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
219194620|NCT06854302|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance imaging|Observational diagnostic tests will include adenosine-stress perfusion cardiovascular magnetic resonance imaging before undergoing percutaneous coronary intervention.
219194621|NCT06854302|DIAGNOSTIC_TEST|Coronary physiology|Invasive coronary function tests using a diagnostic guidewire (PressureWire-X, Abbott), thermodilution, intravenous or intracoronary infusion of adenosine and intracoronary infusions of acetylcholine.
219194622|NCT06853964|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
219008215|NCT03888547|OTHER|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
219008216|NCT05594914|DRUG|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
219194623|NCT06853769|DRUG|Anlotinib hydrochloride,Penpulimab|Penpulimab 200mg IV D1 Anlotinib 12mg P.O. QD D1-14
219008217|NCT05489809|PROCEDURE|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
219194624|NCT06855095|DRUG|Somatostatin analog|Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).
219194625|NCT06813040|DEVICE|Active rTMS|Repetitive TMS will be applied at 10Hz on the motor cortex. The protocol consists of 2000 pulses per session and an intensity of 90% of the resting motor threshold. There will be 10 sessions with a minimum interval of 24 hours and a maximum of 72 hours. A figure-8 coil will be used.
219008218|NCT05489809|PROCEDURE|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
219008219|NCT02046109|PROCEDURE|Repair|
219008220|NCT02046109|PROCEDURE|Replace|
219194626|NCT06813040|DEVICE|Sham rTMS|The sham TMS will have the same visual and sound characteristics, but without the passage of the magnetic field to the scalp.
219194627|NCT06853509|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219194628|NCT06852586|DEVICE|conventional nanohybrid composites|Incremental layering technique is used for restoration
219194629|NCT06852586|DEVICE|Bulk fill composites|Single increment in bulk form is applied for restoration
219194630|NCT06809556|OTHER|EEG (electroencephalogram) monitoring of Parkinson's patients undergoing deep brain stimulation|Parkinson's patients undergoing deep brain stimulation (DBS) will be monitored with EEG to detect burst suppression signals during surgery and will undergo postoperative cognitive testing for postoperative delirium.
219579413|NCT03792360|DRUG|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
219194631|NCT06804902|BEHAVIORAL|Monthly RDT Validation Meeting|Health facilities in intervention districts will bring all RDT cassettes performed in their facility and all outpatient registers to a monthly data validation meeting led by the surveillance, monitoring and evaluation officers (CSE). During these meetings, Audere's HealthPulse application will be used to take photos of each facility's RDT cassettes, tallying the total number of RDTs and total by result. The test positivity rates (TPRs) from the registers will be manually entered into the application and compared with the TPR from the RDT photos. Healthcare facilities with a discrepancy above a certain threshold between TPR derived from register data and the TPR derived from the RDT images may be asked to carry out a more detailed audit to better understand the source of discrepant results. If discrepancies are identified, the CSE will determine what corrections are required before entry into the DHIS2.
219194632|NCT06854770|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
219194633|NCT06855407|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
219579414|NCT06051565|DRUG|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
219579415|NCT04882566|OTHER|Paleolithic Diet|Advice to follow Paleolithic Diet for Inflammatory bowel disease Patients
219579416|NCT05614557|DEVICE|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
219579417|NCT05614557|DEVICE|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
219579418|NCT05520320|DEVICE|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
219194634|NCT06808906|OTHER|Hand Massage Application|Hand massage was applied for a total of 12 sessions in two weeks. Care was taken to perform the hand massage application outside the treatment and care hours, and it was performed in a quiet environment. The application was started from the same hand in the same patient in each session, and the same clinic nurse massaged all patients. Since the patients were in the intensive care unit, their vital signs were monitored 24. It was carefully monitored whether there was any change in vital signs during the massage. The patient's hand to be applied was placed on the pillow or bed. Clothes covering the upper extremity starting from the elbow area were removed. The patient was placed in a supine or semi-fowler position. The nurse practitioner took a standing position. She started the massage with effleurage, first on the back of the hand, then on the palm, from the fingertips towards the heart direction, placing the thumbs on the area to be treated and applying effleurage 5 times in a half-mo
219194635|NCT06809699|DRUG|Busulfan (Busulfex)|For myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d) For reduced intensity conditioning: (Bu，3.2 mg/kg/d IV -7d\~-5d)
219194636|NCT06809699|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide is only used in myeloablative conditioning (Cy，1.8g/m2, -5d, -4d)
219194637|NCT06809699|DRUG|Fludarabine (Fludara)|For myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d) For reduced intensity conditioning: Fludarabine（Flu，30mg/m2 /d IV -10d\~-5d）
219194638|NCT06809699|DRUG|Semustine (MeCCNU)|For both myeloablative and reduced intensity conditioning: Semustine (MECCNU，250 mg/m2 orally-3d).
219194639|NCT04984590|DEVICE|IOPCL AMD MAG|The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
219194640|NCT06793618|OTHER|Z-track technique|In this method, the neonates are in supine position, the skin is moved and held from the injection site 2 to 3 cm to the side or downward using the non- dominant hand, to ensure that blood vessel wasn't penetrated aspiration on the syringe must perceive the injection and then the medication is to be injected slowly. Researcher assistant that is unaware of the injection method performs the recording of the pain intensity and leakage diameter on the observation form.
219194641|NCT05274282|OTHER|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
219194642|NCT00303459|DRUG|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
219194643|NCT00303459|DRUG|placebo|Matching bosentan placebo/b.i.d.
219194644|NCT06878898|BEHAVIORAL|Education and mobile phone text-messaging|The investigators piloted a knowledge and mobile text-messaging intervention using a prospective group design, allocating 14 (asthma=8; COPD=6) and 15 (asthma=9; COPD=6) participants to control and intervention groups respectively, after stratifying by type of disease.
219194645|NCT06878898|OTHER|Education only|Participants in the control group only received the educational intervention.
219194646|NCT06879405|OTHER|The Labor Hopscotch|"Labor Hopscotch consists of 4 basic parameters including movement (mobilization), positioning (birth stool, sitting on the toilet, birth ball, birth mat), water therapy and non-pharmacological methods for reducing pain. There are sub-contents for each of these parameters and hopscotch consists of 7 steps in total. Labor Hopscotch Model Steps;~Step 1: Mobilization (squat, pelvic tilt, using stairs, movement) Step 2: Birth Stool (oral fluid support, massage, breathing techniques) Step 3: Sitting on the Toilet (urinating, dim lighting, music) Step 4: Water Therapy (Warm shower, breathing techniques, Squat, oral fluid support) Step 5: Birth Ball (drawing 8 with the birth ball, slow movement techniques) Step 6: Birth Mat (massage, exercise on the mat, quadruped position) Step 7: Alternative Methods (massage, aromatherapy)."
219579419|NCT05770921|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
219763181|NCT05958316|BEHAVIORAL|Computerized Symptom Capture Tool (C-SCAT) Intervention|"The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs)."
219579420|NCT03370874|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
219579421|NCT03370874|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
219579422|NCT04982874|DRUG|Furosemide 40 mg|Administered with 240 mL of water
219194647|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
219194648|NCT04129554|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
219194649|NCT04129554|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
219194650|NCT04129554|DRUG|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
219194651|NCT04129554|DRUG|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
219194652|NCT04129554|DRUG|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
219579423|NCT04982874|DRUG|Lasix® 40 mg Tablet|Administered with 240 mL of water
219579424|NCT05007314|BEHAVIORAL|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
219194653|NCT04129554|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
219008221|NCT03349749|DEVICE|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
219194654|NCT04129554|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
219194655|NCT01570361|DEVICE|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
219194656|NCT01570361|DRUG|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
219194657|NCT06815146|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
219194658|NCT06815146|DIAGNOSTIC_TEST|Quality of Results (QoR-40)|Several rating scales have been developed to measure quality of recovery after surgery and anaesthesia, but the most extensively used is the QoR-40, a 40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain.
219008222|NCT02548247|DIETARY_SUPPLEMENT|Orafti® Inulin|Dietary fiber
219008223|NCT02548247|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219008224|NCT02546557|PROCEDURE|Coronary Artery Bypass Graft surgery|
219008225|NCT02532933|DEVICE|DePuy Synthes Attune PS RP|
219008226|NCT01529879|DEVICE|New Abutment Connection implant|New abutment connection implant
219008227|NCT01529879|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
219194659|NCT06815146|OTHER|Opioid consuption|Opioid consuption will be recorded from PCA
219194660|NCT06812468|DEVICE|Bellus 3D smart application|Bellus3D is a modern multi-digital digicam, 3-D face scanning that captures in an expert grade, complete 3-D face scans with the pressing of an unmarried button in seconds. It takes 10 s to create an excessive decision 3-D face scan. Bellus3D's excessive precision scanning detects the soft tissue parameters and over a hundred facial andmarks. It uses two Infrared structured light VCSEL (vertical-cavity surface-emitting laser) projectors for high-resolution face scanning. The technique of facial scanning by (Bellus3D) and measuring facial index by (Medit) software was performed following manufacture instructions , The patient's head Stabilized and aligned with the center of the face scan software (Bellus 3D) to avoid scan distortion, The head was tilted towards right and then towards left along with the face analog in the scan software combined with upward and downward movement to ensure complete detection and record of facial landmarks. Then the obj 3D file exported to Medit Software.
219194661|NCT06812468|DEVICE|Medit i-700 intraoral scanner|Medit i-700 intra oral scanner was used to measure the teeth dimensions , it has several advantages including that it can capture up to 70 FPS (FRAMES PER SECOND), which is significantly faster than the previous model. It delivers high image resolution for better quality. The Medit i700 offers a remote control mode and a built-in UV-C disinfection function. In this study a zigzage movement was used which more accurate rout for recording all anterior teeth dimensions and surrounding tissue while scanning. In agreement with a previous study, we started from the posterior left area by scanning the occlusal side, then it proceeded toward the posterior right area by following a zigzag movement when the anterior teeth were scanned. After the occlusal area, the palatal/lingual side was scanned from the right to the left area, and then the buccal side was scanned from the posterior left area to the posterior right one,Then the obj 3D file exported to Medit Software.
219194662|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
219194663|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
219194664|NCT06431867|OTHER|Guidelines for primary care management of osteoporosis|All usual care of osteoporosis in primary care
219194665|NCT05163041|DRUG|BT7480|Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
219194666|NCT05163041|DRUG|Nivolumab|Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
219194667|NCT06496997|DRUG|Methylprednisolone|Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
219579425|NCT05120323|BEHAVIORAL|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
219579426|NCT00407693|DRUG|[C-11]PRB28|
219194668|NCT06496997|DRUG|Dexamethasone|Dexamethasone at an equivalent dose of 13 mg/day
219194669|NCT06496997|DRUG|Hydrocortisone|Hydrocortisone at an equivalent dose of 350 mg/day
219194670|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
219194671|NCT02846545|BIOLOGICAL|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
219194672|NCT02846545|BIOLOGICAL|Placebo|Matching Placebo to golimumab.
219579427|NCT04527653|DEVICE|Tixel|Non-invasive thermo-mechanical treatment
219579428|NCT03979820|DRUG|BI 1467335|Film-coated tablet
219008228|NCT01669733|OTHER|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
219008229|NCT01669733|OTHER|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
219008230|NCT04885686|DEVICE|Endomethasone N RCS|Root canal sealer
219194673|NCT06760351|DRUG|TCM Herbal Therapy|Administration of customized herbal formulations for the TCM group, targeting qi and blood regulation. Pulse diagnosis parameters were evaluated monthly to guide treatment adjustments.
219194674|NCT06760351|DRUG|Standard Western Medicine Treatment|Administration of standard Western medical care, including blood transfusions and erythropoiesis-stimulating agents, focusing on hemoglobin restoration and anemia management.
219194675|NCT04757337|DRUG|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
219194676|NCT04757337|DRUG|Cyclophosphamide|Until progression up to 24 months
219579429|NCT03979820|DRUG|Placebo|Film-coated tablet
219579430|NCT03979820|DRUG|Phenelzine sulfate|Film-coated tablet
219579431|NCT03979820|DRUG|Tyramine|Capsules
219579432|NCT04355663|BEHAVIORAL|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
219579433|NCT04355663|BEHAVIORAL|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
219579434|NCT04355663|BEHAVIORAL|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
219579435|NCT04390542|BEHAVIORAL|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
219579436|NCT05329298|DRUG|BPI-361175|Subjects will receive BPI-361175 until disease progression
219008231|NCT04885686|DEVICE|Endomethasone SP RCS|Root canal sealer
219008232|NCT00806754|DRUG|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
219008233|NCT00806754|DRUG|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
219008234|NCT01650233|BEHAVIORAL|Mindfulness-based stress reduction|
219008235|NCT01927510|BEHAVIORAL|Early mobilisation|
219008236|NCT00492037|DRUG|YM087 oral|
219194677|NCT04113382|DRUG|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
219194678|NCT04113382|DRUG|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
219194679|NCT06468982|DEVICE|Intra-aortic Balloon Pump|It will be applied to patients with acute myocardial infarction who have elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivascular disease, left main coronary artery disease, and patients with narrow and/or tortuous coronary artery anatomy in whom PCI has failed or is not applicable.
219194680|NCT05899387|PROCEDURE|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
219194681|NCT05899387|PROCEDURE|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
219194682|NCT05899387|PROCEDURE|Blood sampling|Blood sampling at defined time points according to protocol
219194683|NCT05899387|DIAGNOSTIC_TEST|Sonographic correlation Seroma|If a seroma occurs, a sonographic correlation is performed to determine the exact size of the seroma
219194684|NCT03509662|DRUG|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
219008237|NCT03100032|BIOLOGICAL|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
219194685|NCT03509662|DRUG|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
219194686|NCT03509662|DRUG|Placebos|One group receives a placebo.
219194687|NCT03691298|DEVICE|SUTUREFIX ULTRA Suture Anchor and SUTUREFIX CURVED Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone
219194688|NCT04072861|DRUG|RBT-9|intravenous administration
219194689|NCT02492711|BIOLOGICAL|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
219194690|NCT02492711|BIOLOGICAL|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
219579437|NCT02918747|DRUG|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
219579438|NCT02918747|DRUG|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
219579439|NCT02918747|DRUG|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
219579440|NCT02918747|DRUG|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
219579441|NCT02918747|DRUG|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
219579442|NCT02918747|DRUG|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
219579443|NCT02918747|DRUG|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
219194691|NCT02492711|DRUG|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
219194692|NCT05959889|OTHER|Placebo|Patients will receive placebo tablets for 4 cycles of AC.
219194693|NCT05959889|DRUG|Montelukast|Patients will receive motelukast 10 mg for 4 cycles of AC.
219194694|NCT06606119|OTHER|Data and tissue collection|Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
219194695|NCT05755087|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219194696|NCT05755087|PROCEDURE|Computed Tomography|Undergo CT
219194697|NCT05755087|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219194698|NCT05755087|DRUG|Tegavivint|Given IV
219579444|NCT02918747|DRUG|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
219194699|NCT06816641|PROCEDURE|Surgical Evacuation of Intracerebral Hemorrhage|Surgical Evacuation of Intracerebral Hemorrhage
219194700|NCT06817837|BEHAVIORAL|hypnosis|Eight hypnosis sessions will be offered to address various issues: sleep disorders, behavioral issues, anxiety, and pain.
219194701|NCT06820164|DRUG|Cooled Sodium Chloride Injection|Injection of a solution containing sterile, cooled 0.9% sodium chloride and 1% lidocaine with epinephrine (1:100,000).
219194702|NCT06820645|DRUG|calcium gluconate|3g IV or IO calcium gluconate.
219194703|NCT06820645|DRUG|Control: Placebo|3g of IV or IO saline placebo.
219194704|NCT06675227|DIETARY_SUPPLEMENT|electrolyte beverages|Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.
219008238|NCT03100032|PROCEDURE|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
219194705|NCT06817083|PROCEDURE|E-C Clamp Technique|"The E-C clamp technique involves forming a C with the thumb and index finger around the mask while the remaining fingers form an E to lift the mandible. This technique aims to provide a good seal while opening the airway."
219579445|NCT02918747|RADIATION|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
219435453|NCT00722098|BIOLOGICAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
219579446|NCT05622292|DEVICE|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
219579447|NCT01230892|DRUG|Nebivolol|10 mg PO qday
219579448|NCT01230892|DRUG|Atenolol|100 mg PO qday
219579449|NCT01687582|DRUG|GLP-1 analog|GLP-1 analog treatment
219579450|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
219579451|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
219579452|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
219579453|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
219579454|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp once daily for 24 weeks
219579455|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily for 24 weeks
219579456|NCT00679913|PROCEDURE|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
219579457|NCT00679913|PROCEDURE|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
219579458|NCT01006564|OTHER|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
219579459|NCT01006564|OTHER|Other|Insertion of gold seeds into prostate for image registration.
219579460|NCT00517959|RADIATION|Stereotactic Conformal radiotherapy|SCRT
219579461|NCT00517959|RADIATION|Conventional radiotherapy|
219579462|NCT00043537|BEHAVIORAL|Social Effectiveness Therapy for Children (SET-C)|
219579463|NCT00043537|DRUG|Fluoxetine|
219579464|NCT00043537|DRUG|Pill Placebo|
219579465|NCT03939988|RADIATION|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
219579466|NCT03939988|RADIATION|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
219579467|NCT01319786|OTHER|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
219579468|NCT01319786|OTHER|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
219579469|NCT02540317|BEHAVIORAL|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
219579470|NCT03323723|DEVICE|SUI Device|Pessary SUI device
219579471|NCT02963402|DRUG|Tocilizumab|
219579472|NCT02963402|DRUG|Adalimumab|
219579473|NCT04131049|OTHER|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
219579474|NCT04131049|OTHER|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
219579475|NCT04131049|OTHER|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
219579476|NCT04131049|OTHER|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
219579477|NCT04920903|DRUG|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
219579478|NCT04920903|DRUG|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
219579479|NCT03415984|DIAGNOSTIC_TEST|Color retinography|Color retinography
219579480|NCT03415984|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography
219579481|NCT03415984|DIAGNOSTIC_TEST|Fundus autofluorescence imaging|Fundus autofluorescence imaging
219579482|NCT04078438|DEVICE|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
219579483|NCT04078438|DRUG|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
219763182|NCT05958316|BEHAVIORAL|Usual Care Control|Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
219008239|NCT00352144|DRUG|Eszopiclone|Eszopiclone 3 mg
219579484|NCT04078438|OTHER|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
219579485|NCT03589521|BEHAVIORAL|ABCT_Military|15 Weekly Couple Therapy Sessions
219579486|NCT02307643|DRUG|MT-1303 Low dose|
219579487|NCT02307643|DRUG|MT-1303 High dose|
219579488|NCT02021370|DRUG|BAY85-3934|25mg Tablet
219579489|NCT02021370|DRUG|Placebo|Matching placebo tablet
219579490|NCT01606059|DRUG|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
219579491|NCT01606059|DRUG|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
219579492|NCT00109759|BIOLOGICAL|RagweedMATAMPL|
219579493|NCT00109759|DRUG|Placebo|
219579494|NCT03458637|BEHAVIORAL|LITE Program and Usual Care|Family based lifestyle Intervention
219579495|NCT03458637|BEHAVIORAL|Usual Care|Usual care consisting of 3 visits to weight management clinic
219579496|NCT05195749|DRUG|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
219579497|NCT05195749|DRUG|Placebo + SOC|Three consecutive days of placebo administration
219579498|NCT01092078|BEHAVIORAL|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
219579499|NCT01092078|BEHAVIORAL|Patient Navigation|Patient navigation for colonoscopy.
219579500|NCT04515537|DIETARY_SUPPLEMENT|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
219579501|NCT04515537|PROCEDURE|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
219579502|NCT00223353|OTHER|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
219579503|NCT01589861|DRUG|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
219579504|NCT02182128|DRUG|BIBF 1120|
219579505|NCT00963079|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
219579506|NCT00963079|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
219579507|NCT03345394|BEHAVIORAL|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
219579508|NCT03345394|BEHAVIORAL|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
219579509|NCT04013945|DIETARY_SUPPLEMENT|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
219579510|NCT04013945|DIETARY_SUPPLEMENT|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
219579511|NCT02593435|GENETIC|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
219579512|NCT04142008|DEVICE|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
219579513|NCT05084664|DEVICE|electrical stimulation|premodulated current+ exercises
219579514|NCT05084664|DEVICE|electrical stimulation|diadynamic current+ exercises
219579515|NCT01144364|DRUG|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
219579516|NCT04108247|DRUG|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
219579517|NCT06264791|OTHER|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (\~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (\~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
219763183|NCT04656535|DRUG|Zimberelimab|Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
219763184|NCT04656535|DRUG|Domvanalimab|Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
219008240|NCT00352144|DRUG|Placebo|Placebo tablet
219008241|NCT04912947|DIETARY_SUPPLEMENT|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
219008242|NCT04912947|OTHER|Placebo|Maltodextrin placebo capsule
219008243|NCT01032642|DEVICE|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
219763185|NCT04656535|DRUG|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
219008244|NCT02239757|PROCEDURE|Left radial approach|Primary PCI performed through left radial approach.
219763186|NCT05032820|DRUG|Lenalidomide|Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression
219763187|NCT05032820|BIOLOGICAL|bb2121|Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\^6 cells.
219763188|NCT05032820|DRUG|Cyclophosphamide|300 mg/m\^2/day for 3 consecutive days prior to the CAR T infusion
219763189|NCT05032820|DRUG|Fludarabine|30 mg/m\^2/day or 3 consecutive days prior to the CAR T infusion
219763190|NCT05032820|PROCEDURE|leukapheresis|Placement of central line catheter and leukapheresis
219008245|NCT02239757|PROCEDURE|Right radial approach|Primary PCI performed through right radial approach.
219008246|NCT03859349|DIAGNOSTIC_TEST|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
219763191|NCT01143558|DEVICE|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
219008247|NCT03859349|DIAGNOSTIC_TEST|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
219008248|NCT01307397|DRUG|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
219008249|NCT00302835|DRUG|non-phenacetin containing analgesics|
219008250|NCT05795075|PROCEDURE|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
219008251|NCT05795075|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
219008252|NCT01932112|DRUG|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
219008253|NCT04422470|OTHER|Non-interventional study|Non-interventional study
219579518|NCT06264791|OTHER|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
219579519|NCT02079168|DRUG|RXI-109|
219579520|NCT02079168|DRUG|Placebo|
219579521|NCT01635062|DRUG|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
219579522|NCT01635062|DRUG|Placebo|Subjects will receive placebo for 3 weeks.
219579523|NCT02880020|BIOLOGICAL|Ipilimumab|Given IV
219579524|NCT02880020|OTHER|Laboratory Biomarker Analysis|Correlative studies
219008254|NCT05475795|OTHER|Metapex|obturation of root canals of primary molars with Metapex
219008255|NCT05475795|OTHER|Endoflas|obturation of root canals of primary molars with Endoflas
219008256|NCT05628532|DEVICE|Use of the DBLG1 system|During the treatment period, the patient will use the DBLG1 system (consisting of a DBLG1 handset with an embedded software named loop mode, a TERUMO MEDISAFE WITH patch pump and a Dexcom continuous glucose monitoring (CGM) G6). The main function of DBLG1 System is to adjust the insulin delivery at the correct time in order to maintain the patient's blood glucose in the target range and thus minimize both hypoglycaemic events and long-term complications associated with elevated average glycemia.
219579525|NCT02880020|BIOLOGICAL|Nivolumab|Given IV
219579526|NCT05518266|PROCEDURE|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
219579527|NCT05518266|PROCEDURE|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
219763192|NCT06961591|BEHAVIORAL|Weight Loss Plus Cooking|"Participants in the eSLD+Chef-ID group will follow a healthy eating plan using the enhanced stoplight diet, meet with a health coach once a month on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~In addition, they will attend in-person cooking classes-twice a month during the first 6 months and once a month for the next 12 months. In these 60-minute classes, instructors will teach cooking skills, and participants will practice on their own or with a partner, depending on their comfort level. They will learn how to safely use kitchen tools and appliances (like ovens, blenders, knives, and measuring cups) and prepare simple meals or snacks."
219579528|NCT05199766|DRUG|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
219579529|NCT00040248|DRUG|Daclizumab|
219579530|NCT04698148|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
219579531|NCT04698148|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219579532|NCT04698148|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
219579533|NCT04757038|DEVICE|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
219579534|NCT02307214|OTHER|BaroReflex Sensitivity, endothelial function measurement|no other
219579535|NCT04734119|OTHER|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
219579536|NCT01631513|DRUG|Nucynta ER|100 to 250 mg every 12 hours
219579537|NCT01301508|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
219579538|NCT01301508|DRUG|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
219579539|NCT01301508|DRUG|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
219579540|NCT01301508|DRUG|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
219579541|NCT04048941|PROCEDURE|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
219579542|NCT04048941|PROCEDURE|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
219579543|NCT04048941|PROCEDURE|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
219579544|NCT00390702|DEVICE|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
219579545|NCT05173038|BEHAVIORAL|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
219579546|NCT02547402|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
219579547|NCT02547402|DRUG|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
219579548|NCT02547402|DRUG|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
219579549|NCT05260164|DEVICE|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
219579550|NCT01681966|DRUG|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
219579551|NCT00851643|BIOLOGICAL|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
219579552|NCT00851643|BIOLOGICAL|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
219579553|NCT00851643|BIOLOGICAL|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
219579554|NCT00851643|BIOLOGICAL|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
219579555|NCT00851643|BIOLOGICAL|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
219579556|NCT00157859|DRUG|Chloroquine and sulphadoxine-pyrimethamine|
219579557|NCT06088849|PROCEDURE|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
219579558|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
219579559|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
219008257|NCT01716767|OTHER|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
219194706|NCT06817083|PROCEDURE|T-E Technique|"The T-E technique is a variation where the thumb and index finger form a T over the mask while the other fingers provide chin lift and jaw thrust.~This method is designed to optimize airway patency and mask seal. While these techniques are widely taught and practiced, they often fall short in obese patients due to the difficulty in maintaining an adequate seal and achieving sufficient ventilation pressures. Complications such as hypoxemia and gastric insufflation are more common in this population."
219008258|NCT01716767|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
219008259|NCT02387060|DRUG|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
219008260|NCT02387060|DRUG|Fentanyl|Intrathecal administration of fentanyl 25 mcg
219008261|NCT00560859|PROCEDURE|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
219008262|NCT00560859|OTHER|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
219008263|NCT05419869|DRUG|ALTO-100 PO Tablet|Two tablets daily
219194707|NCT06817083|PROCEDURE|The Hook Technique|e is a novel method for single-hand ventilation that has shown promise in preliminary studies. This technique involves a unique hand positioning that aims to improve mask seal and ventilation efficacy, particularly in patients with challenging airway anatomy. In Hook Technique using the thumb and index finger to form a hook around the mask, creating a more secure and adjustable seal and utilizing the remaining fingers to apply consistent mandibular lift, enhancing airway patency.
219194708|NCT06819761|DIETARY_SUPPLEMENT|Salivarius SALI-10|Lozenge with 10B CFU (Colony Forming Units)
219435454|NCT00722098|BIOLOGICAL|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
219435455|NCT01707095|OTHER|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
219763193|NCT06961591|BEHAVIORAL|Traditional Weight Loss|"Participants in the eSLD group will follow a healthy eating plan using the enhanced stoplight diet, meet once a month with a health coach on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~They will also receive short (2-minute) video messages from their coach-twice a month during the first 6 months and once a month after that. These videos will include feedback on their progress, reminders about their goals, and tips to help them stay on track with healthy eating and exercise."
219763194|NCT05564052|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
219763195|NCT05564052|DRUG|Lenalidomide|Lenalidomide capsules will be administered orally.
219763196|NCT05564052|DRUG|Rituximab|Rituximab will be administered IV.
219763197|NCT05564052|DRUG|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
219763198|NCT05660967|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
219763199|NCT05660967|DRUG|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
219763200|NCT06456346|DRUG|Bomedemstat|Oral capsule
219763201|NCT06456346|DRUG|Hydroxyurea|Oral capsule
219763202|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
219763203|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
219763204|NCT03245541|DRUG|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
219763205|NCT03245541|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
219763206|NCT05869682|PROCEDURE|Bright White Light Therapy|Wear AYOpro BWL therapy
219763207|NCT05869682|DRUG|Combination Drug Therapy|Receive SOC ADT combination therapy
219763208|NCT05869682|OTHER|Electronic Health Record Review|Ancillary studies
219763209|NCT05869682|OTHER|Quality-of-Life Assessment|Ancillary studies
219763210|NCT05869682|OTHER|Questionnaire Administration|Ancillary studies
219763211|NCT06483334|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion at different dose levels
219763212|NCT06483334|BIOLOGICAL|Enfortumab Vedotin|IV infusion at different dose levels
219763213|NCT06483334|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
219763214|NCT03978624|DRUG|Pembrolizumab|200 mg IV on day 1 and day 22
219763215|NCT03978624|DRUG|Entinostat|5 mg given orally on day 1, day 8 and day 15
219763216|NCT03978624|PROCEDURE|Procedure/Surgery|A radical cystectomy is a surgical procedure to remove the entire urinary bladder and maximal transurethral resection of bladder tumor (TURBT) is a surgical procedure used to remove as much of the bladder tumor as possible.
219763217|NCT05574127|BEHAVIORAL|Behavioral Activation|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
218859598|NCT06456268|DEVICE|Standard ice packs|Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
218859599|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
218859600|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
218859601|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
218859602|NCT03918850|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
218859603|NCT03918850|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
218859604|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
218859605|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
218859606|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
219763218|NCT05574127|BEHAVIORAL|Supportive Psychotherapy|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
219435456|NCT01707095|OTHER|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
219008264|NCT01115725|DRUG|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
219435457|NCT04261283|OTHER|Experimental|"The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment"
219435458|NCT04261283|OTHER|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
219435459|NCT00839436|DRUG|CYT107|
219435460|NCT01578590|DIETARY_SUPPLEMENT|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
219435461|NCT05854797|OTHER|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
219435462|NCT05854797|OTHER|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
219435463|NCT00005061|BIOLOGICAL|bevacizumab|
219579560|NCT01832675|DRUG|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
219194709|NCT05666193|DEVICE|CBCT Imaging|Subjects are scheduled for two imaging sessions on the Ethos system with the HyperSight CBCT. One session is on the same day as the CT simulation scan for treatment planning. The second session is on the same day as the delivery of ther 21st treatment fraction. If the subject is sent for a mid-treatment FBCT for re-planning, a third HyperSight CBCT imaging session will be scheduled on the same day as the mid-treatment FBCT.
219194710|NCT06855602|DRUG|Chinese herbal medicine formula (S-2196)|During the 2-week intervention, all participants are required to take 150ml of S-2196 decoction (a Chinese herbal medicine formula containing four herbs) twice per day
219194711|NCT06857799|PROCEDURE|Light Power Density and Light Duration 40 mW/cm²*1000s|Use light power density and light duration 40 mW/cm²\*1000s treatment
219194712|NCT06857799|PROCEDURE|Light Power Density and Light Duration 80 mW/cm²*1000s|Use light power density and light duration 80 mW/cm²\*1000s treatment
219435464|NCT05466981|BEHAVIORAL|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
219579561|NCT01832675|DRUG|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
219008265|NCT04614064|OTHER|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
219008266|NCT04614064|OTHER|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
219008267|NCT01405742|DRUG|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
219008268|NCT05371691|DEVICE|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
218859607|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
218859608|NCT05740332|DRUG|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
219435465|NCT01521572|DRUG|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
218859609|NCT06367088|DRUG|Cadonilimab|Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
218859610|NCT05875883|PROCEDURE|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
218859611|NCT06980922|DRUG|Guilu Erxian Jiao|A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
218859612|NCT06979726|DRUG|Lasix ONYU|Providing subcutaneous furosemide to eligible patients
219435466|NCT02592668|DEVICE|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
219435467|NCT04969367|OTHER|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
219435468|NCT04969367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219435469|NCT04969367|OTHER|Questionnaire Administration|Complete questionnaires
219435470|NCT04969367|OTHER|Quality-of-Life Assessment|Complete questionnaires
219435471|NCT03402282|PROCEDURE|embolization|upper rectal artery embolization with coils
219435472|NCT03402282|PROCEDURE|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
219435473|NCT03460288|BEHAVIORAL|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
219435474|NCT04202978|DRUG|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
219435475|NCT04202978|DRUG|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
219763219|NCT05611996|BEHAVIORAL|Peers plus|Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texts to older adults with depression.
219763220|NCT06169280|BIOLOGICAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
218859613|NCT06981481|DEVICE|Breast tissue expander|Silimed brand breast tissue expander
218859614|NCT06985381|OTHER|Carotenoid-rich juice|The intervention is based on the additional consumption of 200 ml natural carotneoid-rich juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
219763221|NCT05524493|DIAGNOSTIC_TEST|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
219763222|NCT05524493|DIAGNOSTIC_TEST|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
218859615|NCT06985381|OTHER|Control|Participants assigned to the control group are asked to drink additional 200ml of water a day to control liquid intake.
219763223|NCT05524493|DIAGNOSTIC_TEST|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
219763224|NCT05524493|DIAGNOSTIC_TEST|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
219763225|NCT05524493|DIAGNOSTIC_TEST|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
219763226|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
219763227|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
219763228|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
218859616|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
219763229|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
219763230|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
219763231|NCT06548594|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
218859617|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
218859618|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
218859619|NCT06606067|DRUG|Placebo|Placebo tablet daily
218859620|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
218859621|NCT00304018|BIOLOGICAL|sargramostim|
218859622|NCT00304018|DRUG|busulfan|
218859623|NCT00304018|DRUG|etoposide|
219008269|NCT02503735|DRUG|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
219435476|NCT04202978|DRUG|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
218859624|NCT00304018|DRUG|fludarabine phosphate|
218859625|NCT00304018|DRUG|prednisone|
218859626|NCT00304018|DRUG|tacrolimus|
218859627|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218859628|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
218859629|NCT05193708|DEVICE|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
218859630|NCT05193708|DEVICE|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
218859631|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
218859632|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
218859633|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
219008270|NCT00996645|OTHER|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
219008271|NCT02160574|DRUG|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
218859634|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
219008272|NCT02160574|DRUG|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
219008273|NCT02160574|DRUG|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
219008274|NCT02160574|OTHER|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
219008275|NCT00118001|BEHAVIORAL|Worry exposure|
219008276|NCT00118001|BEHAVIORAL|Applied relaxation|
219008277|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
219008278|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
219435477|NCT04202978|DRUG|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
219435478|NCT04202978|RADIATION|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
219475341|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
218859635|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
218859636|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
218859637|NCT07006649|DIAGNOSTIC_TEST|Opthtalmologic diagnosis tests|Volunteer will be tested with : measurement of visual acuity, slit-lamp examination, fundus examination, optical coherence tomography
218859638|NCT06684977|BEHAVIORAL|360 Video|360° Video consists of video recordings, made with a camera to simultaneously capture and combine scenes in a 360 degrees perspective such as Instant Google Street View Instant Google Street View (instantstreetview.com). When uploaded to a VR headset, 360° videos may provide a more cost-effective method for rapidly creating virtual environments in which users can experience a sense of immersion and the viewer can control and change the viewing angle at any stage through head movement. While photorealism may be superior, this option is known to be less interactive as the viewer can't move or walk around within the virtual space. In addition, the landscape and imagery may have been changed or developed meaning the recordings captured do not match the traumatic memory. Despite these limitations, the use of 360° video has been trialled in clinical mental health settings showing positive outcomes for both user and clinician.
218859639|NCT06684977|BEHAVIORAL|VR Photoscan|VR Photoscan creates immersive virtual environments by transforming real-world imagery into detailed 3D models. Using high-resolution images captured from a smartphone, these images are processed in 3D graphics software to sculpt realistic virtual scenes. The resulting 3D models are imported into a game engine, adding VR functionality, allowing users to navigate freely with six degrees of freedom. Interactive content, such as animated cars and people, can be added in real-time, while menu systems guide users through the experience. Environmental factors like lighting, weather, and time of day can be adjusted to simulate real conditions. Spatial 360° audio enhances immersion, providing sounds from various directions. This VR environment creation process is efficient and cost-effective, requiring no specialised equipment, and ensuring high-quality immersive experiences at minimal production time and cost.
218859640|NCT06684977|BEHAVIORAL|Standard TF-CBT|Ehlers and Clark's model follows the general style of reliving (recommended by NICE) suggested by Foa and Rothbaum with some fluidity and in vivo exposure (i.e., trauma site visit). During the treatment process of reliving, clients are asked to close their eyes and intentionally recall the traumatic memories, i.e., relive the trauma in their mind in detail and narrate their experience in present tense, including recalling images, sensory experiences, thoughts, and feelings. VR-based PTSD treatments can promote emotional engagement and the process of trauma via providing visual, auditory, and haptic sensory cues.
218859641|NCT06689735|OTHER|schroth exercises|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
219008279|NCT00755092|BEHAVIORAL|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
219008280|NCT00755092|BEHAVIORAL|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
219008281|NCT02420392|DRUG|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
219008282|NCT06348602|DRUG|Cyclosporine ophthalmic solution 0.1%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
219475342|NCT06522360|DRUG|Brigatinib|Given by mouth
219475343|NCT06522360|DRUG|Carboplatin|Given by mouth
219475344|NCT06522360|DRUG|Pemetrexed|Given by vein
219475345|NCT05572814|BEHAVIORAL|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
219475346|NCT05572814|BEHAVIORAL|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
219475347|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
219475348|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
219475349|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
219475350|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
219475351|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
219008283|NCT06348602|DRUG|Tacrolimus ophthalmic ointment 0.03%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
219008284|NCT04236830|DRUG|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
219008285|NCT04236830|DRUG|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
219008286|NCT04236830|DRUG|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
219008287|NCT00922181|DEVICE|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
219008288|NCT00922181|DEVICE|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
219008289|NCT03478267|DIAGNOSTIC_TEST|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
219008290|NCT04973826|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
219008291|NCT00627120|DRUG|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
219008292|NCT04690491|OTHER|follicular cyclus|Days of cyclus 6-12
219008293|NCT04690491|OTHER|luteal cyclus|Days of cyclus 20-24
219008294|NCT00824512|DRUG|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
219008295|NCT00824512|DRUG|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
219008296|NCT03355040|OTHER|induction of labour|induction of labour
219008297|NCT06406985|BEHAVIORAL|Weight-loss through dietary and lifestyle changes|Weight-loss participants will complete one online, self-paced education session each week for 12 weeks. Education sessions focus on topics such as self-monitoring weight, meal routines, and dietary habits with an emphasis on protein and fiber intake. During these 12 weeks, participants will receive weekly messages from nutrition coaches as well as a monthly nutrition coaching call. After the first 12 weeks, participants will enter a follow-up period where nutrition coaching messaging will occur as needed and with the opportunity to still participate in a monthly nutrition coaching call. Participants are asked to weigh daily on a provided WiFi scale that automatically uploads their weight data to a website for researchers and coaches to monitor. Participants will also submit food records and self-reported weight and hip circumferences.
219008298|NCT02677467|BIOLOGICAL|Blood-pressure variability|Day to Night Blood pressure variability
219008299|NCT01412359|DRUG|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
219008300|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219008301|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
219008302|NCT01782495|DRUG|ribavirin|tablet
219008303|NCT00229060|DRUG|doripenem|
219579562|NCT01019707|DRUG|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
219579563|NCT01019707|DRUG|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
219008304|NCT01584102|BEHAVIORAL|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
219008305|NCT01584102|BEHAVIORAL|group fitness classes only|15 weeks biweekly group fitness
219008306|NCT01995032|DRUG|750 mg metformin and 7.5 g L-citrulline daily p.o.|
219008307|NCT01995032|DRUG|Placebo|
219008308|NCT00071513|BEHAVIORAL|CAST-T/HSTS|Skills training small group.
219008309|NCT00071513|BEHAVIORAL|Brief Intervention|Assessment of needs and referral to services as needed.
219579564|NCT03102593|DRUG|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
219008310|NCT04542772|OTHER|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
219008311|NCT04542772|OTHER|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
219008312|NCT03428360|DRUG|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
219008313|NCT05174260|DEVICE|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
219008314|NCT01904591|DIETARY_SUPPLEMENT|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
219008315|NCT01904591|DIETARY_SUPPLEMENT|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
219008316|NCT02260921|DEVICE|iovera°|
219008317|NCT02260921|DEVICE|Sham Comparator|
219008318|NCT02921854|OTHER|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
219579565|NCT03102593|OTHER|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
219194713|NCT06855472|OTHER|The MAR method|"The study was conducted in three isolated stations. Two faculty researchers designed the scenarios, while three others supervised training. Medical student investigators recorded blood loss estimates and estimation times.~Before the study, investigators received 20-minute training. Participants and investigators were blinded to actual blood volumes. Group 1 and Group 2 attended a 10-minute briefing, including consent and study introduction.~The study had two phases. In Phase 1, Group 1 used the Visual Estimation (VE) method, while Group 2 received a 2-minute MAR method training before making estimations. In Phase 2, Group 1 was trained in the MAR method and repeated estimations.A data form recorded demographics, blood loss estimates, and estimation times.~Group 1's VE data and Group 2's MAR data were compared between groups, while Group 1's VE and MAR data were analyzed within the group. Combined MAR data from both groups were used to assess the impact of gender, height, and weight."
219008319|NCT02863029|PROCEDURE|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
219194714|NCT06856083|BEHAVIORAL|Gamified Virtual Reality Sports Exercise Program|"Participants in the experimental group will participate in a variety of sports exercises designed in a virtual reality environment utilizing gamification elements to enhance engagement. The intervention will include:~* Structured virtual reality sports sessions guided by specially trained facilitators.~* Use of gamified features such as rewards, points, and friendly competition to stimulate motivation.~* Incorporation of social elements where participants can interact with each other during sessions to foster community and support."
219008320|NCT00707824|DRUG|nalbuphine|nalbuphine 5 mg epidural
219008321|NCT00707824|DRUG|nalbuphine|nalbuphine 10 mg epidural
219008322|NCT00707824|OTHER|NSS|NSS
219008323|NCT02319889|RADIATION|Stereotactic Body Radiotherapy|Undergo SBRT
219194715|NCT06856083|BEHAVIORAL|Traditional Sports Exercise Program for Elderly Individuals with Suicidal Thoughts|"participants will engage in a traditional sports exercise program aimed at elderly individuals experiencing suicidal thoughts. The intervention consists of structured physical activity sessions that include a variety of low-impact sports and exercises designed for older adults. These activities will be conducted in a supportive group setting to foster social interaction and community engagement.~The sessions will be led by experienced facilitators who specialize in elderly fitness and mental health. Each session will last approximately 60 minutes and will include a warm-up, the main exercise component, and a cooldown period to promote physical well-being and relaxation. Participants will be encouraged to engage at their own pace, ensuring that individual capabilities and comfort levels are respected."
219194716|NCT06857760|OTHER|Ice cube|ıce cube
219475352|NCT02686749|DEVICE|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
219008324|NCT02319889|DRUG|Carboplatin|Given IV
219008325|NCT02319889|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219008326|NCT00159471|DRUG|capecitabine, gemcitabine, docetaxel|
219008327|NCT01240447|BIOLOGICAL|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
219008328|NCT01240447|OTHER|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
219008329|NCT01650623|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
219008330|NCT01650623|BEHAVIORAL|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
219008331|NCT02281461|DEVICE|Male circumcision using a non-surgical device|Male Circumcision
219008332|NCT04061915|BEHAVIORAL|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
219435479|NCT00885885|DRUG|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
219475353|NCT02686749|DRUG|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
219475354|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
219194717|NCT06857760|OTHER|Mouth wash|Mouth wash
219194718|NCT06857760|OTHER|Menthol lozenge|menthol lozenge
219194719|NCT06857812|OTHER|there is no intervention|there is no intervention
219194720|NCT06857708|DEVICE|Cytal® Wound Matrix|This is the only study to use this intervention in necrotizing soft tissue wounds
219475355|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
219008333|NCT04061915|BEHAVIORAL|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
219475356|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
219008334|NCT06434844|PROCEDURE|Auricular acupunctures|After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
219008335|NCT06434844|PROCEDURE|Sham acupunctures|The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
219008336|NCT04855097|DIAGNOSTIC_TEST|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
219008337|NCT01267812|DRUG|bortezomib|Given SC or IV
219008338|NCT01267812|BIOLOGICAL|rituximab|Given IV
219194721|NCT06857708|DEVICE|MicroMatrix®|This is the only study to use this intervention in necrotizing soft tissue wounds
219194722|NCT06856200|DRUG|Sirolimus (albumin - bound)|Sirolimus (albumin - bound): Dose escalation, intravenous infusion
219194723|NCT06856200|DRUG|Palbociclib|Palbociclib: the dosage is 125 mg, orally once a day. taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
219194724|NCT06856200|DRUG|Fulvestrant|Fulvestrant: the dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
219194725|NCT05571267|DRUG|Avacincaptad Pegol|Zimura 2 mg, administered by intravitreal injection
219194726|NCT05571267|DRUG|Avastin|Avastin 1.25 mg, administered by intravitreal injection
219194727|NCT05571267|DRUG|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
219194728|NCT05571267|DRUG|Eylea|Eylea 2 mg, administered by intravitreal injection
219475357|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
219579566|NCT00552383|PROCEDURE|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff \[this includes 3 of the investigators\], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
219475358|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
219475359|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
219475360|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
219579567|NCT00974961|DRUG|bupivacaine, levobupivacaine|intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
219579568|NCT02707861|DRUG|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
219008339|NCT01267812|OTHER|laboratory biomarker analysis|Correlative studies
219194729|NCT06291896|DEVICE|MammoWave|"Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study.~A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts.~The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave.~When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm."
219475361|NCT06960460|OTHER|Dental implant surgery with ZygoFixU implants|Adult patients who have had dental implant surgery.
219008340|NCT01267812|OTHER|immunohistochemistry staining method|Correlative studies
219475362|NCT06959004|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (4.0 pmol/kg/min) over 20 minutes.
219008341|NCT01267812|GENETIC|RNA analysis|Correlative studies
219475363|NCT06959004|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
219475364|NCT05971329|DEVICE|Cervical Fusion (ZetaFuse™ Bone Graft)|Fusion of the C3-C7 cervical vertebral bodies
219475365|NCT06474325|BEHAVIORAL|Intervention via mobile application|Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
219475366|NCT05720039|DEVICE|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
219008342|NCT01267812|GENETIC|gene expression analysis|Correlative studies
219008343|NCT01267812|GENETIC|DNA analysis|Correlative studies
219008344|NCT01267812|OTHER|pharmacological study|Correlative studies
219008345|NCT01267812|OTHER|pharmacogenomic studies|Correlative studies
219008346|NCT01267812|OTHER|Questionnaire Administration|
219008347|NCT03241342|DRUG|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
219008348|NCT03241342|DRUG|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
219008349|NCT05833295|PROCEDURE|Downhill walking|Change in the H/M ratio after a downhill walk.
219475367|NCT05720039|PROCEDURE|Open NSM|open nipple-sparing mastectomy procedures
219475368|NCT04546126|DRUG|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
219194730|NCT06856928|OTHER|Meal Challenge|The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.
219475369|NCT04546126|DRUG|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
219008350|NCT05833295|PROCEDURE|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
219008351|NCT01719523|DRUG|EPI-743|
219008352|NCT00849810|DRUG|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
219579569|NCT02707861|DRUG|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
219435480|NCT00885885|DRUG|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
218859642|NCT06689735|OTHER|pilates exercises|The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively.
218859643|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
218859644|NCT00225589|DRUG|Rosuvastatin calcium|
218859645|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
218859646|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
218859647|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
218859648|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
218859649|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
218859650|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
218859651|NCT02516826|DRUG|Rosuvastatin|
218859652|NCT02516826|DRUG|Olmesartan|
218859653|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
219435481|NCT02521389|DRUG|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
219435482|NCT04874844|BIOLOGICAL|Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)|"The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials."
219435483|NCT00364819|DRUG|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
219579570|NCT01940497|DRUG|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
219579571|NCT01940497|DRUG|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
219579572|NCT01940497|DRUG|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
219579573|NCT01940497|DRUG|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
219579574|NCT00166153|DRUG|Mycophenolate Mofetil|
219579575|NCT01641133|BIOLOGICAL|Synflorix (3-Dose)|3 doses administered intramuscularly
219579576|NCT01641133|BIOLOGICAL|Synflorix (2-Dose)|2 doses administered intramuscularly
219579577|NCT01641133|BIOLOGICAL|Synflorix (Single Dose)|1 dose administered intramuscularly
219579578|NCT01641133|BIOLOGICAL|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
219579579|NCT01641133|BIOLOGICAL|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
219579580|NCT04554797|OTHER|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
219579581|NCT00034983|DRUG|aprepitant|
219579582|NCT00034983|DRUG|Comparator: paroxetine HCL|
219579583|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
219579584|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
219579585|NCT03123861|DRUG|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
219579586|NCT03123861|DRUG|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
219579587|NCT04622397|DRUG|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
218859654|NCT02516826|DRUG|Placebo of Rosuvastatin|
218859655|NCT02516826|DRUG|Placebo of Olmesartan|
218859656|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
218859657|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
218859658|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
218859659|NCT00810485|DRUG|ADX10059|oral administration
218859660|NCT00810485|DRUG|ADX10059|oral administration
218859661|NCT00810485|DRUG|ADX10059|oral administration
218859662|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
218859663|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
218859664|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
218859665|NCT01434329|GENETIC|DNA methylation analysis|
218859666|NCT01434329|GENETIC|gene expression analysis|
218859667|NCT01434329|GENETIC|microarray analysis|
218859668|NCT01434329|OTHER|laboratory biomarker analysis|
218859669|NCT01434329|OTHER|medical chart review|
218859670|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
218859671|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
218859672|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
219579588|NCT04622397|DRUG|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
219579589|NCT04186598|DEVICE|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
218859673|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
218859674|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
218859675|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
218859676|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
218859677|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
218859678|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
218859679|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
218859680|NCT02337530|DRUG|Selumetinib|
218859681|NCT02337530|DRUG|Pemetrexed|
218859682|NCT02337530|DRUG|Cisplatin|
218859683|NCT02337530|DRUG|Carboplatin|
219435484|NCT04227067|DEVICE|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
219435485|NCT04227067|DEVICE|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
219435486|NCT00086216|DRUG|Atiprimod|Oral, once a day, 14 days on 14 days off
219475370|NCT04546126|COMBINATION_PRODUCT|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
219475371|NCT06243731|OTHER|No Intervention|This is a non-interventional study.
219579590|NCT04186598|DRUG|Nifedipine 30 MG|All participants will receive this intervention
219008353|NCT00849810|DRUG|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
218859684|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
218859685|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
218859686|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
218859687|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
218859688|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
218859689|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
218859690|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
218859691|NCT00492479|DRUG|LubriDerm|
218859692|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
218859693|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
218859694|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
218859695|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
218859696|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
219008354|NCT03234764|OTHER|Immunotherapy|
219008355|NCT00864045|DRUG|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
219008356|NCT00864045|DRUG|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
219008357|NCT04333784|OTHER|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
219008358|NCT05487781|COMBINATION_PRODUCT|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
219194731|NCT06856447|DRUG|Coenzyme Q10|"100 mg once daily starting after the first chemotherapy cycle. Patients will receive 12 cycles of the modified FOLFOX-6 regimen with Coenzyme Q10 (100 mg once daily in the morning), starting after the first chemotherapy cycle and continuing until the end of the 12th cycle. Based on McRae (2023), 200 mg/day for 12 weeks reduced TNF-α and IL-6; thus, 100 mg/day for 6 months was selected (one cycle every 2 weeks = 24 weeks).~Supportive care: Includes a 5-HT3 antagonist for nausea prevention and pantoprazole to prevent gastric irritation.~Intervention Details:~Oxaliplatin: Part of the FOLFOX-6 regimen. 5-Fluorouracil (5-FU): Part of the FOLFOX-6 regimen. Leucovorin: Part of the FOLFOX-6 regimen. 5-HT3 Antagonist: Used for nausea prevention. Pantoprazole: Used to prevent gastric irritation."
219194732|NCT06856447|DRUG|Oxaliplatin|Part of the modified FOLFOX-6 chemotherapy regimen
219194733|NCT06856447|DRUG|5-Fluorouracil (5-FU)|Part of the modified FOLFOX-6 chemotherapy regimen.
219194734|NCT06856447|DRUG|5-HT3 Antagonist|Used for nausea prevention during chemotherapy.
219008359|NCT02519192|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
219008360|NCT02519192|PROCEDURE|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
219008361|NCT02519192|PROCEDURE|ostomy bag|Non Vac Arm will receive ostomy bag applications.
219008362|NCT02519192|PROCEDURE|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
219008363|NCT01846611|DRUG|Trabectedin|1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
219008364|NCT01846611|DRUG|DOXIL|30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
219008365|NCT01846611|DRUG|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
219194735|NCT06856447|DRUG|Pantoprazole|Used to prevent gastric irritation during chemotherapy
219194736|NCT06661304|OTHER|Benson Relaxation Exercise|Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
219194737|NCT06661304|OTHER|Ongoing treatment|In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
219008366|NCT01846611|DRUG|DOXIL|50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
219008367|NCT04021589|DRUG|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
219435487|NCT01444898|DRUG|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
219763232|NCT05699772|BEHAVIORAL|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
219008368|NCT04021589|DRUG|Chemotherapy|chemotherapy
219763233|NCT05699772|BEHAVIORAL|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
219008369|NCT06175260|DIAGNOSTIC_TEST|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
219194738|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
219475372|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
219763234|NCT04906460|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
219763235|NCT06736990|DRUG|CAL101|Intravenous infusions of CAL101 every 4 weeks over 24 weeks
219763236|NCT06736990|DRUG|Placebo|Intravenous infusions of placebo every 4 weeks over 24 weeks
219763237|NCT06347003|DRUG|Plozasiran Injection|ARO-APOC3 Injection
219763238|NCT06347003|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219763239|NCT05713799|DRUG|Placebo|Placebo
219763240|NCT05713799|DRUG|Mirabegron|selective beta3-AR agonist approved
219763241|NCT05713799|DRUG|Alpha-lipoic acid|ALA is an antioxidant that is available over the counter
219763242|NCT04863443|DEVICE|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
219763243|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
219763244|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
219763245|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
219763246|NCT05882357|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
219763247|NCT05882357|DRUG|IVA|Granules for oral administration
219763248|NCT06524128|DEVICE|Dreeft wheels (EPPUR company)|The braking system (Dreeft wheels) is installed directly on the participant's wheelchair, by a trained occupational therapist. The Dreeft wheels are supplied for a period of 1 month.
219763249|NCT00702533|DEVICE|Pentagastrin Injection BP|
219763250|NCT00702533|DRUG|Pentagastrin|
219763251|NCT02861573|BIOLOGICAL|Pembrolizumab 200 mg|IV Q3W
219763252|NCT02861573|DRUG|Olaparib 400 mg|Eight 50-mg capsules PO BID
219763253|NCT02861573|DRUG|Docetaxel 75 mg/m^2|IV Q3W
219763254|NCT02861573|DRUG|Prednisone 5 mg|One 5-mg tablet PO BID
219763255|NCT02861573|DRUG|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
219763256|NCT02861573|OTHER|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
219763257|NCT02861573|DRUG|Olaparib 300 mg|Two 150-mg tablets PO BID
219763258|NCT02861573|DRUG|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
219763259|NCT02861573|DRUG|Lenvatinib|20 mg PO QD
219763260|NCT02861573|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|IV Q3W
219763261|NCT02861573|DRUG|Carboplatin|IV Q3W
219763262|NCT02861573|DRUG|Etoposide|IV on Days 1, 2 and 3 of each cycle
219763263|NCT02861573|BIOLOGICAL|Belzutifan 120mg|PO QD
219763264|NCT03633708|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
219763265|NCT00353158|DRUG|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
219763266|NCT00353158|DRUG|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
219763267|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for major depressive disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
219763268|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for insomnia|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
219763269|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for social anxiety disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
219435488|NCT03273504|OTHER|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
219435489|NCT03273504|OTHER|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
219435490|NCT02928666|OTHER|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
219008370|NCT03922425|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
219435491|NCT02077842|DEVICE|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
219435492|NCT02077842|DEVICE|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
219435493|NCT02361619|DRUG|Caffeine|probe
219435494|NCT02361619|DRUG|Diclofenac|probe
219435495|NCT02361619|DRUG|Esomeprazole|probe
219435496|NCT02361619|DRUG|Metoprolol|probe
219435497|NCT02361619|DRUG|Midazolam|probe
219763270|NCT04954599|DRUG|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
219763271|NCT04954599|DRUG|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
219435498|NCT02361619|DRUG|Dabigatran|probe
219435499|NCT02361619|DRUG|Clarithromycin|perpetrator
218859697|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
218859698|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
218859699|NCT00450671|PROCEDURE|Collagen Plug Placement|
218859700|NCT00450671|PROCEDURE|Seton placement|
218859701|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
219435500|NCT02238782|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
219435501|NCT02238782|OTHER|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
219475373|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
219475374|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
219763272|NCT04954599|DRUG|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
219763273|NCT06457503|DRUG|Toripalimab|Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
219763274|NCT06457503|DRUG|Cisplatin|Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
219763275|NCT06457503|DRUG|Gemcitabine|Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
219763276|NCT06457503|DRUG|Carboplatin|In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
219763277|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
219763278|NCT01979367|DEVICE|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
219763279|NCT04499534|BIOLOGICAL|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
219763280|NCT05284747|DRUG|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
219763281|NCT05284747|DRUG|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
219763282|NCT05128032|DEVICE|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
219763283|NCT05128032|DEVICE|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
219763284|NCT01810913|DRUG|Atezolizumab|Given IV
219763285|NCT01810913|PROCEDURE|Biopsy Procedure|Undergo biopsy
219435502|NCT03498118|DRUG|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
219435503|NCT06370949|DRUG|Bupivacain|Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
219435504|NCT06370949|DRUG|bupivacain+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
219008371|NCT00901446|DEVICE|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
219435505|NCT00066508|DRUG|bortezomib|
219435506|NCT01567423|DRUG|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
219435507|NCT01567423|DRUG|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
219435508|NCT03029897|OTHER|My eReport France|"patients are educated to the use of My eReport France application"
219435509|NCT03261141|COMBINATION_PRODUCT|(PV-RQOL),(APA) ,Acoustic analysis|"1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
219435510|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
219435511|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
219435512|NCT01171014|DIETARY_SUPPLEMENT|Placebo|Placebo, once a day for 14 days
219435513|NCT02267369|BEHAVIORAL|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
219435514|NCT02267369|BEHAVIORAL|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
219435515|NCT02267369|BEHAVIORAL|Basic fitness program|Participants can register workshops online and track program participation.
219435516|NCT03336060|DIAGNOSTIC_TEST|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
219435517|NCT02580591|DRUG|Empagliflozin|
219435518|NCT02580591|DRUG|Placebo|For blinding purposes
219435519|NCT00696098|OTHER|sodium butyrate|1 enema (60 ml) once daily containing 100mM
219435520|NCT00696098|OTHER|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
219435521|NCT03304262|DEVICE|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
219435522|NCT03802240|DRUG|Sintilimab|200mg IV Q3W
219435523|NCT03802240|DRUG|IBI305|15mg/kg IV Q3W
219435524|NCT03802240|DRUG|Pemetrexed|500mg/m2 IV Q3W
219435525|NCT03802240|DRUG|Cisplatin|75mg/m2 IV Q3W
219435526|NCT03802240|DRUG|Placebo1|Placebo1 IV Q3W
219435527|NCT03802240|DRUG|Placebo2|Placebo2 IV Q3W
219435528|NCT03736668|DIAGNOSTIC_TEST|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
219435529|NCT04127461|DEVICE|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
219435530|NCT02152072|OTHER|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
219435531|NCT01937013|DRUG|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
219435532|NCT01937013|DRUG|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
219435533|NCT00493610|DRUG|N-acetylcysteine(Mucomyst)|
219435534|NCT03842501|DIETARY_SUPPLEMENT|Release Supplement|Calorie reduced diet plus Release supplement
219435535|NCT03842501|DIETARY_SUPPLEMENT|Placebo|Calorie reduced diet plus Placebo
219435536|NCT00655304|DEVICE|Prometheus (R) liver support dialysis|6-8 hours of dialysis
219435537|NCT00655304|DEVICE|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
219475375|NCT03778957|DRUG|Durvalumab|Durvalumab IV (intravenous)
219194739|NCT06218056|DRUG|Cannabidiol (CBD) 800 mg|CBD (400 mg) will be administered orally twice daily in the morning and again in the evening in 4 capsules each containing 100 mg of the active ingredient in the Ananda investigational new drug, ATL5. ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
219194740|NCT06218056|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
219435538|NCT01402024|DRUG|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
219475376|NCT03778957|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
219475377|NCT03778957|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
219475378|NCT03778957|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
219194741|NCT04710355|DEVICE|Spinal cord stimulation|Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
219579591|NCT04186598|DEVICE|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
219763286|NCT01810913|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219194742|NCT06825052|BEHAVIORAL|Resistance Training with Deloading Periods|Participants performed an 8-week unilateral resistance training program in which training volume and intensity were reduced during weeks 4 and 8 to facilitate recovery and adaptation.
219194743|NCT06825052|BEHAVIORAL|Continuous Resistance Training|Participants followed an 8-week unilateral resistance training program without any deloading periods. Training volume and intensity remained consistent throughout the study.
219194744|NCT06824142|OTHER|Evaluate in real-life conditions the effectiveness of an adapted external aid as a tool to support temporal orientation rehabilitation for individuals with Alzheimer's disease or related dementias in|Unlike other interventions, the E3D tool combines an intuitive, user-friendly interface with real-time temporal cues, offering a personalized experience designed to improve cognitive engagement. This external aid is aimed at fostering independence and improving daily functioning by providing clear and consistent information on time-related aspects, such as season, month, day of the week, and current date.
219194745|NCT06550726|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
219194746|NCT06825793|DRUG|Semaglutide Subcutaneous Injection|All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.
219194747|NCT04170855|DRUG|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
219194748|NCT05080283|DEVICE|CP1110 Sound Processor System with automated ForwardFocus On (SCAN 2 FF)|Sound Processor
219194749|NCT05080283|DEVICE|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
219008372|NCT03355651|DIETARY_SUPPLEMENT|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
219008373|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units of Vitamin D3 weekly
219194750|NCT05080283|DEVICE|CP1110 Sound Processor System with ForwardFocus Off (SCAN 2)|Sound Processor
219194751|NCT04334343|OTHER|Additional Muscle Biopsy Collection|Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
219194752|NCT04199689|BIOLOGICAL|9vHPV Vaccine|9vHPV is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
219194753|NCT04199689|OTHER|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
219194754|NCT03993392|DRUG|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
219194755|NCT03993392|DRUG|SUBLOCADE|300mg subcutaneous injection
219194756|NCT04094610|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
219194757|NCT04689360|DRUG|elamipretide|Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
219194758|NCT05385575|DRUG|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
219763287|NCT01810913|BIOLOGICAL|Cetuximab|Given IV
219194759|NCT05385575|DRUG|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
219763288|NCT01810913|DRUG|Cisplatin|Given IV
219194760|NCT05385575|DRUG|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
219194761|NCT05385575|DRUG|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
219194762|NCT05385575|DRUG|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
219194763|NCT05385575|DRUG|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
219194764|NCT05385575|DRUG|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
219194765|NCT06589362|DEVICE|Transcutaneous auricular vagus active nerve stimulation|In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve.
219194766|NCT06589362|DEVICE|Transcutaneous auricular vagus sham nerve stimulation|In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.
219194767|NCT06588920|BEHAVIORAL|Cognitive function, gait, and electroencephalogram|Measurement of cognitive function, gait performance, and electroencephalogram
219194768|NCT06600360|OTHER|Teledentistry|Measuring the accuracy of the mobile photographic method of teledentistry for diagnosis and treatment need in dental caries detection
219194769|NCT06604117|DRUG|Statin|Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.
219194770|NCT06604117|DRUG|Probucol|Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.
219194771|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
219194772|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
219194773|NCT01116895|DRUG|LEO 22811|Oral solution
219763289|NCT01810913|PROCEDURE|Computed Tomography|Undergo CT
219008374|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 units weekly
219008375|NCT04672928|DRUG|paclitaxel|80mg/m\^2,iv,Q4W
219194774|NCT01116895|DRUG|Placebo|Placebo
219194775|NCT06825325|OTHER|Music Listening|Selection of Sufi music will be played to the patients before the wound debridement.
219194776|NCT06825130|BEHAVIORAL|Exercise|Participants will attend 30-min training sessions 3 times a week for 12 weeks. The intensity of HIIT will be at 80% HR@VT2 measured in the first week and will increase to 90% in the second week. By week 3, the intensity will reach HR@VT2.
219194777|NCT04646395|DRUG|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
219194778|NCT04646395|DRUG|Acalabrutinib|100 mg hard gelatin capsules
219194779|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
219194780|NCT06825845|DRUG|Zevorcabtagene Autoleucel|Non-intervention
219194781|NCT04758533|BIOLOGICAL|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
219194782|NCT03794011|DEVICE|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
219194783|NCT05926258|DRUG|Chloroprocaine 3% eye gel|ocular surface anesthesia
219194784|NCT05926258|DRUG|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
219194785|NCT05748613|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
219194786|NCT05748613|BEHAVIORAL|Health Education Control|Brief computerized presentation on healthy behaviors
219194787|NCT05962814|DEVICE|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
219194788|NCT04221464|BIOLOGICAL|biological collection|Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
219763290|NCT01810913|DRUG|Docetaxel|Given IV
219763291|NCT01810913|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219763292|NCT01810913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763293|NCT01810913|OTHER|Survey Administration|Ancillary studies
219763294|NCT05879991|DRUG|zongertinib (C-14)|Oral solution
219763295|NCT05879991|DRUG|zongertinib|Film-coated tablet
219763296|NCT05879991|DRUG|zongertinib (C-14)|Solution for infusion
219194789|NCT04221464|OTHER|Tissues collections|Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
219194790|NCT04627922|DRUG|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
219194791|NCT04627922|OTHER|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
219194792|NCT04627922|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
219579592|NCT03504995|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
219194793|NCT06852300|DEVICE|Concussion Assessment Battery|"The conclusion test battery will comprise five assessment designed to evaluate sport-related concussion:~1. Health Questionnaire - Including as assessment of signs and symptoms.~2. Sport Concussion Assessment Tool (SCAT)~3. Vestibular Ocular Motor Screening (VOMS)~4. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)~5. Postural stability assessment (NeuroCom VSR Sport).~Functional Neuroimaging Functional Near-Infrared Spectroscopy (fNIRS) is a non-invasive neuroimaging technology that measures brain activity by detecting changes in blood oxygenation. The NIRSIT scanner will be employed at each testing session to assess cognitive function using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and postural stability using the NeuroCom VSR Sport system."
219194794|NCT06847750|DIAGNOSTIC_TEST|Elastography Ultrasound|The US imaging protocol will include three parts: (i) gray-scale; (ii) color Doppler, and (iii) Shear-wave elastography (SWE)
219579593|NCT01586403|BIOLOGICAL|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
219194795|NCT06847750|OTHER|The Localized Scleroderma Quality of Life Instrument (LoSQI )|The questionnaire is a validated disease-specific patient-reported outcome measure that covers different domains (skin sensations, physical functioning, body image and social support, designed for children and adolescents with localized scleroderma
219475379|NCT05979987|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
219579594|NCT01586403|BIOLOGICAL|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
219579595|NCT01586403|BIOLOGICAL|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
219194796|NCT06851923|OTHER|3Tesla magnetic resonance imaging of the healthy human visual system|The present project presents a series of monocentric MRI studies carried out on healthy adult human volunteers. All neuroimaging will be performed at the Cliniques Universitaires Saint-Luc (CUSL, IRM de recherche). Participants will not directly benefit from their participation. All studies will manipulate the visual properties of the experimental stimuli in a within-subject way, and therefore do not rely on any participation group assignation/randomization method. The duration of studies will vary between 3h to 6h, i.e., from 2 to 4x1h30 3Tesla magnetic resonance imaging sessions depending on the experimental design.
219194797|NCT06804473|PROCEDURE|Exercise|The exercise intensity will range from 60-75% of their maximum heart rate (HRmax), with each session lasting 28 minutes, three times per week. The exercise protocol will involve interval aerobic training consisting of four intervals
219194798|NCT05979337|BEHAVIORAL|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
219194799|NCT05979337|BEHAVIORAL|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
219475380|NCT05979987|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
219008376|NCT04672928|DRUG|IBI318|300mg,iv,Q4W
219008377|NCT01466855|DRUG|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
219194800|NCT05979337|BEHAVIORAL|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
219194801|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
219579596|NCT01586403|BIOLOGICAL|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
219579597|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
219579598|NCT01012557|BIOLOGICAL|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
219579599|NCT01012557|BIOLOGICAL|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
219579600|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
219579601|NCT02527928|OTHER|None intervention|
219579602|NCT05600881|DRUG|Methylphenidate|Participants will take their regular medication or a placebo (vitamin C)
219579603|NCT04681651|DRUG|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
219579604|NCT04681651|DRUG|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
219579605|NCT04681651|PROCEDURE|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
219579606|NCT00000824|DRUG|Lymphocytes, Activated|
219579607|NCT04310488|OTHER|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
219579608|NCT05134194|DRUG|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
219579609|NCT05134194|DRUG|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
219579610|NCT02206620|DRUG|Donepezil|
219579611|NCT04333381|OTHER|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions"
219579612|NCT04333381|OTHER|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
219579613|NCT02575274|PROCEDURE|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
219579614|NCT01551147|DRUG|ONO-6950|200 mg QD for 8 days
219579615|NCT01551147|DRUG|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
219579616|NCT01551147|DRUG|Montelukast|10 mg Montelukast QD for 8 days
219579617|NCT02040311|DRUG|Topiramate 96 mg daily|
219579618|NCT02040311|DRUG|Topiramate 192 mg daily|
219579619|NCT02040311|DRUG|Placebo|
219579620|NCT05960474|OTHER|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
219008378|NCT04405037|DRUG|Alvimopan|Alvimopan will be given to patients who are diagnosed with postoperative ileus after surgery
219008379|NCT07063576|DRUG|Baclofen 10mg|Tablet baclofen 10mg three times daily along with conventional treatment
219008380|NCT07063576|DRUG|Placebo|Tablet placebo three times daily along with conventional treatment
219008381|NCT01331447|DRUG|exemestane|25 mg tablet
219008382|NCT07133074|DIAGNOSTIC_TEST|RENEW-IN Algorithm for assessment of a beta-lactam intervention|The RENEW-IN intervention includes a detailed assessment of the participant's beta-lactam allergy history and determination of a risk-level for allergy-delabeling.
219008383|NCT07133074|OTHER|EMR Review|Electronic medical record review for comparative analysis
219008384|NCT02759471|DEVICE|comfilcon A sphere lens (control)|contact lens
219008385|NCT02759471|DEVICE|comfilcon A asphere lens (test)|contact lens
219008386|NCT00707707|DRUG|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
219194802|NCT02065726|DIETARY_SUPPLEMENT|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
219194803|NCT02065726|OTHER|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
219194804|NCT05726292|DRUG|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
219194805|NCT05726292|DRUG|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
219194806|NCT05726292|OTHER|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
219008387|NCT00707707|DRUG|Paclitaxel|Intravenous infusion over 1 hour
219008388|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
219008389|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
219194807|NCT05726292|OTHER|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
219579621|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
219579622|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
219579623|NCT02286219|DRUG|FS102|Experimental
219008390|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
219008391|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
219008392|NCT02879305|DRUG|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
219008393|NCT02879305|DRUG|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
219008394|NCT02879305|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
219008395|NCT02879305|DRUG|Iron therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
219008396|NCT00711854|DRUG|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
219475381|NCT05979987|BEHAVIORAL|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
219008397|NCT00711854|DRUG|Linezolid|Linezolid (600 mg IV or PO twice daily)
219008398|NCT00711854|DRUG|Rifampicin|Rifampicin (600 mg IV or PO once daily)
219194808|NCT05726292|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
219579624|NCT02923414|DEVICE|Standard escalating shocks|125 J, 150 J, 200 J
219008399|NCT04020198|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
219194809|NCT05762211|DRUG|Pooled allogeneic fecal microbiotherapy|Capsule for oral use
219194810|NCT05762211|DRUG|Placebo|Capsule for oral use
219194811|NCT06743152|BEHAVIORAL|Synchronous exercise program|The synchronous exercise group will be conducted online with synchronous supervision under the supervision of a physiotherapist. The exercise program will be performed for 8 weeks, 2 days a week. In the exercise program, 3 sets, 8 repetitions in 1 set will be progressed to 10-12-15-20-25 repetitions according to tolerance. There will be a 1-2 minute rest between sets.
219194812|NCT06743152|BEHAVIORAL|Asynchronous exercise group|The Asynchronous Exercise Group will be conducted with a video-based structured exercise program. For the asynchronous video-based group, a closed channel will be created on Youtube that only patients can access, and the exercises will be uploaded to the system asynchronously. In the asynchronous exercise group, how each exercise is performed will be shown in detail by the physiotherapist in the video content.
219194813|NCT06220851|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
219194814|NCT05460780|DEVICE|MATTISSE TEC|Tissue engineering chamber MATTISSE
219194815|NCT05101837|DEVICE|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
219008400|NCT01334268|DEVICE|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
219008401|NCT01334268|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
219008402|NCT00991666|PROCEDURE|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
219194816|NCT06805955|OTHER|NDT|"The neurodevelopmental therapy program aimed to reduce muscle tone, improve hand functions, enhance fine motor skills, and support daily living activities such as eating and personal care.~Specific exercises included:~Finger and wrist flexion/extension, Shoulder and elbow stretching and mobilization, PNF exercises, Functional tasks like screw and nut manipulation, Velcro tasks, door handle turning, button pressing, zipper pulling, and laundry peg placement/removal."
219194817|NCT06805955|OTHER|NDT+Hand Robot|"In this group, participants received 25 minutes of hand robot-assisted therapy following neurodevelopmental treatment. After the robot therapy, they performed fine motor skill exercises, including:~Picking up buttons from one container and placing them in another, Opening a loosely closed jar lid using the robot, Stacking checkers pieces on a table, Flipping over and placing cards back on the table, Transferring weighted cubes from one table to another at a different height. These activities aimed to improve fine motor coordination and hand functionality."
219194818|NCT06804343|BEHAVIORAL|first aid training|A pre-test will be applied to the participants in a single group before the training. After the training is applied, a post-test will be done and a follow-up will be done at the end of 6 months and a post-test will be applied.
219194819|NCT06805513|COMBINATION_PRODUCT|Tadalafil 5 mg tablets with a digital tool.|The combination product will be a Drug (Tadalafil 5 mg) and Health Survey Assessment (as a mandatory digital tool). Tadalafil 5 mg will be taken orally, 1 tablet daily to use for treatment of erectile dysfunction. This study will be conducted remotely, via video interaction.
219194820|NCT06804434|DRUG|Lidocaine Intravenous Infusion|intravenous lidocaine 10 mg/ml continuous infusion
219194821|NCT06804434|DEVICE|NOL|Intraoperative Nociception Level index monitoring and guided analgesia
219194822|NCT06804733|BEHAVIORAL|12-week individualized aerobic exercise training|After enrollment, subjects directly participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level measured by International Physical Activity Questionnaire (IPAQ), with the exercise intensity being increased every four weeks.
219194823|NCT06804733|BEHAVIORAL|12-week control intervention followed by 12-week aerobic exercise training|After enrollment, subjects first undergo a 12-week control intervention (i.e., routine treatment) and then participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level IPAQ, with the exercise intensity being increased every four weeks.
219579625|NCT02923414|DEVICE|High energy shock protocol|360 J, 360 J, 360 J.
219194824|NCT06804954|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
219435539|NCT01402024|DRUG|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
219194825|NCT06804954|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
219194826|NCT05818358|DIETARY_SUPPLEMENT|black beans|¾ cup of cooked black beans
219194827|NCT05818358|DIETARY_SUPPLEMENT|wheat berries|¾ cup of cooked whole wheat grain
219194828|NCT05818358|DIETARY_SUPPLEMENT|white rice|¾ cup of cooked white rice
219194829|NCT04484740|DRUG|Gepotidacin|Single oral dose of 1500 mg gepotidacin
219194830|NCT06572423|PROCEDURE|Personalized ultrafractionated stereotactic adaptive radiotherapy|PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
219194831|NCT06572423|RADIATION|Volume Modulated Arc Therapy|Use HyperArc technology
219194832|NCT06572423|PROCEDURE|Computed Tomography|Undergo CT simulation for radiation planning
219194833|NCT06572423|PROCEDURE|Positron Emission Tomography|Undergo PET
219194834|NCT06572423|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219194835|NCT06572423|OTHER|Best Practice|Undergo standard of care
219194836|NCT06572423|BEHAVIORAL|University of Washington Quality of Life Scale, Version 4|Complete questionnaire
219194837|NCT06572423|BEHAVIORAL|Functional Assessment of Cancer Therapy-Head & Neck|Complete questionnaire
219194838|NCT05075577|DRUG|Enzalutamide|Daily oral dose of enzalutamide
219194839|NCT05075577|DRUG|EPI-7386 with Enzalutamide|Daily oral dose of EPI-7386 in combination of enzalutamide
219194840|NCT06306638|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219008403|NCT02007876|BEHAVIORAL|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
219008404|NCT03712319|BEHAVIORAL|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
219008405|NCT03712319|BEHAVIORAL|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
219194841|NCT06306638|PROCEDURE|Computed Tomography|Undergo CT
219194842|NCT06306638|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
219194843|NCT06306638|PROCEDURE|Interstitial Photodynamic Therapy|Undergo I-PDT
219194844|NCT06306638|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
219194845|NCT06306638|OTHER|Physical Performance Testing|Ancillary studies
219194846|NCT06306638|OTHER|Questionnaire Administration|Ancillary studies
219435540|NCT04572698|DRUG|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
219435541|NCT04572698|DRUG|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
219435542|NCT00561340|DIETARY_SUPPLEMENT|Pediasure|50% will be randomized to pediasure with nutritional counseling
219435543|NCT00561340|BEHAVIORAL|Nutritional counseling|50% randomized to nutritional counseling only
219194847|NCT06306638|DRUG|Verteporfin|Given IV
219194848|NCT06306638|DEVICE|Laser: ML7710-PDT|Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
219194849|NCT05676905|DEVICE|Neocement|Bone graft substitutes
219194850|NCT05621187|DEVICE|Pamira ICD lead family|Implantation, measurements and follow-up schedule
219435544|NCT00445341|DRUG|Flavopiridol|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
219435545|NCT02733471|DRUG|Lidocaine|
219435546|NCT02733471|DRUG|Placebo|Placebo
219435547|NCT05326074|OTHER|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
219435548|NCT04567953|OTHER|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
219008406|NCT06173921|PROCEDURE|robotic system|Implant placement will be navigated by robotic system based on a digital plan
219435549|NCT03051217|OTHER|Placebo|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"
219008407|NCT06173921|PROCEDURE|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
219435550|NCT03051217|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
219435551|NCT00380406|DRUG|Leuprolide acetate|
219435552|NCT04880993|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
219435553|NCT04880993|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
219435554|NCT03879954|DEVICE|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
219435555|NCT04746989|DRUG|Probenecid|Probenecid claim is used as the exposure group.
219435556|NCT04746989|DRUG|Allopurinol|Allopurinol claim is used as the reference group.
219435557|NCT00591396|DRUG|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
219435558|NCT00109772|DRUG|lenalidomide|Two 5 mg capsules taken one time per day
219763297|NCT06407232|DRUG|Letermovir|480 mg taken orally once daily, for 84 days
219763298|NCT03594734|BEHAVIORAL|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
219763299|NCT03594734|OTHER|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
219763300|NCT06158022|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219763301|NCT06158022|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
219763302|NCT05564377|DRUG|Alpelisib|Given PO
219763303|NCT05564377|DRUG|Binimetinib|Given PO
219763304|NCT05564377|PROCEDURE|Biopsy Procedure|Undergo biopsy
219763305|NCT05564377|PROCEDURE|Biospecimen Collection|Undergo blood collection
219763306|NCT05564377|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219763307|NCT05564377|PROCEDURE|Bone Scan|Undergo bone scan
219763308|NCT05564377|PROCEDURE|Computed Tomography|Undergo CT
219763309|NCT05564377|PROCEDURE|Echocardiography Test|Undergo ECHO
219763310|NCT05564377|DRUG|Fluorouracil|Given IV
219763311|NCT05564377|DRUG|Fulvestrant|Given IM
219763312|NCT05564377|DRUG|Ipatasertib|Given PO
219763313|NCT05564377|DRUG|Leucovorin|Given IV
219763314|NCT05564377|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219435559|NCT00109772|DRUG|Placebo|Two placebo capsules taken one time per day
219763315|NCT05564377|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219763316|NCT05564377|PROCEDURE|Mutation Carrier Screening|Undergo tumor mutational screening
219763317|NCT05564377|DRUG|Neratinib Maleate|Given PO
219763318|NCT05564377|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
219763319|NCT05564377|DRUG|Olaparib|Given PO
219763320|NCT05564377|DRUG|Oxaliplatin|Given IV
219763321|NCT05564377|DRUG|Paclitaxel|Given PO or IV
219763322|NCT05564377|DRUG|Palbociclib|Given PO
219763323|NCT05564377|BIOLOGICAL|Panitumumab|Given IV
219763324|NCT05564377|PROCEDURE|Positron Emission Tomography|Undergo PET
219763325|NCT05564377|DRUG|Selumetinib Sulfate|Given PO
219763326|NCT05564377|DRUG|Sotorasib|Given PO
219435560|NCT01517828|DRUG|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
219435561|NCT01517828|DRUG|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
219763327|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
219763328|NCT05919264|DRUG|mFOLFOX-6|mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
219475382|NCT05979987|BEHAVIORAL|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
219763329|NCT05919264|DRUG|Nivolumab|Nivolumab will be administered per the prescribing information in combination with FOG-001
219763330|NCT05919264|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
219763331|NCT05919264|DRUG|Bevacizumab|Bevacizumab will be administered per the prescribing information in combination with FOG-001
219194851|NCT06575569|BEHAVIORAL|high-intensity interval training|Patients had no adverse events after 2 weeks of adaptive exercise training and voluntarily continued participants, intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times. Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and health education materials pushed by cardiovascular nurses.
219194852|NCT06575569|BEHAVIORAL|Moderate-intensity continuous training|Using routine postoperative care and follow-up, establish WeChat group as contact for postoperative follow-up, no adverse events after 2 weeks of adaptive exercise training and voluntary participants, patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve). Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and pushed health education materials by cardiovascular nurses.
219579626|NCT05388240|OTHER|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
219194853|NCT06385301|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
219194854|NCT06385301|OTHER|6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
219194855|NCT03154190|OTHER|Best Practice|Receive usual care
219194856|NCT03154190|OTHER|Laboratory Biomarker Analysis|Correlative studies
219194857|NCT03154190|PROCEDURE|Supportive Care|Undergo health care coach support
219194858|NCT03154190|OTHER|Survey Administration|Ancillary studies
219194859|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
219008408|NCT03323931|BEHAVIORAL|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
219194860|NCT06090279|DEVICE|OmniFlow Breathing Therapy BioFeeback System|FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
219194861|NCT01775085|BEHAVIORAL|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
219194862|NCT01775085|BEHAVIORAL|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
219194863|NCT04999111|BIOLOGICAL|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
219194864|NCT06806956|DRUG|Treatment of severe malaria with rectal artesunate + Artemisinin based Combination Therapy is not inferior to rectal artesunate + injectable artesunate + ACT in terms of effectiveness in remote areas|The Community Health Worker will give rectal artesunate (RAS) +artemisinin based combination Therapy (ACT) to children aged 6 months to less than or equal to 5 years who fail to make the referral trip. Those who make the referral trip will receive injectable artesunate and artemisinin based Combination Therapy for three days. Giving of RAS +ACT is unique to this study. Children with non malaria severe disease will also receive amoxicillin from the community health worker before they are referred to the next level of care
219194865|NCT04715685|BEHAVIORAL|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
219194866|NCT04715685|BEHAVIORAL|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
219435562|NCT04861311|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
219435563|NCT03437044|DRUG|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
219008409|NCT03323931|BEHAVIORAL|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
219008410|NCT01848587|OTHER|acupuncture|
219008411|NCT01848587|OTHER|usual care|
219008412|NCT04829903|DRUG|Dulaglutide|Dulaglutide injections
219008413|NCT04829903|DRUG|Liraglutide|Liraglutide injections
219435564|NCT03437044|DRUG|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
219008414|NCT05780333|PROCEDURE|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
219008415|NCT05780333|PROCEDURE|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
219008416|NCT05371028|OTHER|Non-interventional Study|This is non-interventional study.
219194867|NCT04715685|BEHAVIORAL|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
219194868|NCT04715685|BEHAVIORAL|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
219194869|NCT04715685|BEHAVIORAL|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
219194870|NCT00670241|DRUG|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
219194871|NCT00670241|DRUG|LEO 80185 vehicle|Once daily application
219194872|NCT00670241|DRUG|Tacalcitol ointment|Once daily application
219194873|NCT06346041|BIOLOGICAL|Oncolytic Virus injection(IDOV-SAFETM)|Administered by intravenous injection as single agent.
219194874|NCT05670236|DRUG|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
219763332|NCT06406114|DRUG|Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing|Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
219763333|NCT06406114|DRUG|Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge|After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
219194875|NCT02361554|DEVICE|Medtronic Percept with SensSight Deep Brain Stimulation System|Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
219008417|NCT06326567|OTHER|C4 Program|C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
219194876|NCT04806841|BEHAVIORAL|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
219194877|NCT04806841|OTHER|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
219435565|NCT00345501|DRUG|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
219435566|NCT00345501|DRUG|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
219435567|NCT05690672|DIAGNOSTIC_TEST|Delirium Screening|Either 3D-CAM or 4AT
219435568|NCT01359046|DEVICE|silver SPC|subject randomized to receive silver alloy impregnated catheter
219435569|NCT01359046|DEVICE|standard SPC|subject randomized to receive standard catheter
219194878|NCT05333068|PROCEDURE|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.
219194879|NCT05333068|PROCEDURE|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
219194880|NCT06651502|DEVICE|dental implant placement and immediate provisionalization|dental implant placement and immediate temporization
219194881|NCT06101277|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
219435570|NCT04397692|DEVICE|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
219435571|NCT02574819|DRUG|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
219435572|NCT02574819|DRUG|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
219194882|NCT04117100|PROCEDURE|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
219435573|NCT04018157|DRUG|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
219435574|NCT00035568|DRUG|Glucovance (metformin HCl/glyburide)|
219435575|NCT00035568|DRUG|or Metformin HCl alone|
219008418|NCT04048031|DIETARY_SUPPLEMENT|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
219435576|NCT00035568|DRUG|or Glyburide alone.|
219435577|NCT00134407|PROCEDURE|Normal diet|
219435578|NCT00134407|PROCEDURE|Nutrition via jejunal needle-catheter|
219435579|NCT06353360|DEVICE|Tumor Treating Fields|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
219435580|NCT06353360|DRUG|Tislelizumab|Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
219008419|NCT04048031|OTHER|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
219435581|NCT06353360|DRUG|Temozolomide (TMZ)|The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
219435582|NCT03286296|BIOLOGICAL|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
219435583|NCT00723268|DRUG|Prednisolone|5MG Prednisolone per day for 3 months
219435584|NCT00723268|DRUG|Colchicine|0.5 MG Colchicine per day for 3 months
219579627|NCT05388240|OTHER|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
219579628|NCT01839630|DRUG|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
219579629|NCT01957566|PROCEDURE|APS|
219579630|NCT06346002|BEHAVIORAL|Mindfulness-based intervention|The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
219579631|NCT03870113|BIOLOGICAL|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
219008420|NCT03381846|PROCEDURE|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
219008421|NCT03381846|PROCEDURE|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
219008422|NCT05000177|OTHER|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
219008423|NCT05000177|OTHER|30-minute rest|Rest for 30 minutes
219008424|NCT02906059|DRUG|AZD1775|
219008425|NCT02906059|DRUG|Irinotecan|
219435585|NCT04240912|DEVICE|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
219579632|NCT04083586|OTHER|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
219008426|NCT00327678|DRUG|Rituximab|
219008427|NCT00327678|DRUG|Imatinib Mesylate|
219008428|NCT03421119|DRUG|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
219008429|NCT03421119|DRUG|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
219435586|NCT01213290|DEVICE|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
219008430|NCT03421119|DRUG|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
219008431|NCT05595356|DEVICE|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
219008432|NCT05595356|DEVICE|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
219579633|NCT00732420|DRUG|topotecan|Topoisomerase I inhibition.
219435587|NCT01213290|DEVICE|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
219435588|NCT00703430|DRUG|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
219435589|NCT03800433|DRUG|Trental 400 MG Extended Release Oral Tablet|oral tablets
219579634|NCT00732420|DRUG|pazopanib|Tyrosine kinase inhibitor
219579635|NCT04683419|DEVICE|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
219008433|NCT05595356|DEVICE|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
219008434|NCT05595356|BEHAVIORAL|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
219008435|NCT05595356|BEHAVIORAL|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
219008436|NCT00543556|DRUG|MK0767|
219008437|NCT05667545|DRUG|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
219008438|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
219008439|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
219008440|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
219008441|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
219008442|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
219008443|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
219008444|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
219435590|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
219435591|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
219435592|NCT00332046|DRUG|GW679769|
219199432|NCT05211869|BEHAVIORAL|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
219435593|NCT00423241|DEVICE|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
219435594|NCT00423241|DEVICE|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
219435595|NCT01400074|DRUG|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
219435596|NCT03554785|BEHAVIORAL|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
219435597|NCT00789295|OTHER|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
219435598|NCT02465255|DRUG|Ketorolac|
219435599|NCT02465255|DRUG|Tramadol|
219435600|NCT02465255|DRUG|Acetaminophen|
219435601|NCT01181310|DRUG|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
219435602|NCT01181310|DRUG|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
219435603|NCT01181310|DRUG|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
219435604|NCT01181310|DRUG|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
219435605|NCT01181310|DRUG|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
219435606|NCT00179569|BEHAVIORAL|Relaxation response|8 weeks of relaxation response training
219435607|NCT00241449|DRUG|Fulvestrant|intramuscular injection 250 mg
219435608|NCT00241449|DRUG|Tamoxifen|20 mg oral tablet
219435609|NCT00791804|DRUG|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
219435610|NCT00914238|BEHAVIORAL|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
219435611|NCT00914238|BEHAVIORAL|OPUS 5 years|
219435612|NCT06097325|DIAGNOSTIC_TEST|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
219435613|NCT06097325|DIAGNOSTIC_TEST|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
219435614|NCT00137670|DEVICE|Video-based HIV/STD prevention intervention|
219435615|NCT05829395|OTHER|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test."
219435616|NCT00383006|BEHAVIORAL|Skills for affect regulation (behavior)|
219435617|NCT02705443|OTHER|No Intervention|Standard of Care Only
219435618|NCT02562976|OTHER|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
219435619|NCT00289393|BEHAVIORAL|Perceived outcome by both patient and physician|
219579636|NCT03594695|DIAGNOSTIC_TEST|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
219579637|NCT03764436|BEHAVIORAL|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
219579638|NCT04798118|PROCEDURE|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
219579639|NCT02268266|DEVICE|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
219579640|NCT03512262|DRUG|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
219579641|NCT03512262|DRUG|Placebo|Abaloparatide-matched placebo.
219435620|NCT04418219|DRUG|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
219008445|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
219435621|NCT04418219|BIOLOGICAL|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
219579642|NCT00324311|DRUG|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
219199433|NCT06870227|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency eclampsia in labour
219579643|NCT05289128|DEVICE|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
219579644|NCT05289128|DEVICE|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
219579645|NCT01953939|OTHER|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
219579646|NCT04901013|OTHER|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
219435622|NCT04418219|BIOLOGICAL|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
219435623|NCT04418219|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
219435624|NCT04418219|OTHER|Questionnaire Administration|Ancillary studies
219435625|NCT04418219|OTHER|Quality of Life Assessment|Ancillary studies
219435626|NCT06238115|DRUG|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
219579647|NCT05314894|BEHAVIORAL|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
219579648|NCT04216758|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219008446|NCT04563923|DRUG|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
219008447|NCT04563923|OTHER|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
219008448|NCT00435292|DRUG|Naproxen|nonsteroidal anti-inflammatory drug
219008449|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 250 mg|flavonoid mixture
219008450|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 500 mg|flavonoid mixture
219008451|NCT05989789|DEVICE|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
219008452|NCT02341053|OTHER|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
219435627|NCT06238115|DRUG|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
219435628|NCT00330239|DRUG|Paroxetine CR|
219199434|NCT06868680|BEHAVIORAL|Balance Program|A comprehensive program of tailored exercise therapy, educational content spanning a variety of topics related to balance improvement and fall prevention, a personalized clinical approach to improving balance, and access to a board-certified health coach and physical therapist.
219199435|NCT06868680|OTHER|Educational Reading Content|Informational articles on reducing risk for falls.
219435629|NCT01057862|DRUG|Naltrexone|Targeted dosage of 50mg PO daily
219435630|NCT01057862|OTHER|Placebo|Sugar pills daily PO
219008453|NCT02423577|DRUG|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
219008454|NCT02423577|DRUG|Placebo|Placebo dry powder administered by nasal inhalation
219435631|NCT00415584|DRUG|Cinacalcet HCl|
219435632|NCT05377827|BIOLOGICAL|WU-CART-007|Provided by Miltenyi Biotec
219435633|NCT01757977|DEVICE|double lumen endotracheal tube placement and use|
219435634|NCT00802867|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
219435635|NCT03067844|DRUG|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
219579649|NCT04216758|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219579650|NCT04216758|DRUG|tegafur|Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219579651|NCT05161650|DIETARY_SUPPLEMENT|Ketone monoester (3-OHB)|Commercially available ketone supplement
219579652|NCT05161650|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
219579653|NCT02622451|BEHAVIORAL|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
219008455|NCT04236011|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
219008456|NCT00000633|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219008457|NCT00000633|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
219008458|NCT06507449|DEVICE|Lithotripsy|Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
219008459|NCT06507449|DEVICE|Orbital atherectomy|Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
219008460|NCT06507449|DEVICE|High-pressure non-compliant balloon|Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
219008461|NCT06507449|DEVICE|Optical coherence tomography|Optical coherence tomography assessment of coronary arteries.
219008462|NCT06507449|DEVICE|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
219008463|NCT01396707|DRUG|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
219008464|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
219008465|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
219008466|NCT02853591|PROCEDURE|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
219008467|NCT04683536|PROCEDURE|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
219008468|NCT03114813|DRUG|Carvedilol|Non-selective beta-blocker as per routine clinical care
219008469|NCT03114813|OTHER|MRI scan|One hour non-invasive MRI scan
219008470|NCT03114813|PROCEDURE|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
219194883|NCT05320822|OTHER|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
219008471|NCT05295043|DRUG|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
219008472|NCT05158933|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219008473|NCT05016973|DRUG|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
219008474|NCT05016973|DRUG|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
219008475|NCT06221540|BEHAVIORAL|"Myth busting information leaflet"|A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
219008476|NCT06214104|BEHAVIORAL|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
219008477|NCT01051024|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
219008478|NCT01051024|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
219008479|NCT05715593|OTHER|health education intervention|health education intervention
219008480|NCT02577731|OTHER|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
219008481|NCT02577731|OTHER|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
219008482|NCT02577731|OTHER|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
219194884|NCT05320822|OTHER|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
218820246|NCT02455739|OTHER|chewing gum|postoperative gum chewing to improve gastrointestinal function
218820252|NCT06055751|DEVICE|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
219194885|NCT04134754|OTHER|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
219194886|NCT05057052|DRUG|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
219435636|NCT03434041|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
219435637|NCT03434041|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
219008483|NCT00505843|DRUG|MK0657|7mg MK0657 capsules
219008484|NCT00505843|DRUG|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
218820303|NCT04608019|OTHER|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
218820304|NCT04608019|OTHER|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
218820305|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
218820306|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
218820307|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
218820308|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
218820309|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
218820310|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
218820311|NCT00269113|DRUG|Standard chemotherapy|As prescribed
218820312|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
218820313|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
218820314|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
219008485|NCT00505843|DRUG|Comparator: levodopa|levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
219008486|NCT00505843|DRUG|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
219008487|NCT04056676|PROCEDURE|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
219008488|NCT04056676|PROCEDURE|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
219008489|NCT04056676|PROCEDURE|GA with ETT|General anesthesia with endotracheal intubation
219008490|NCT01770548|GENETIC|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
219008491|NCT01770548|GENETIC|DNA collection|DNA collection
219008492|NCT01770548|OTHER|Auditory evoked potentials|auditory evoked potentials
219008493|NCT05599568|OTHER|Exercise|Either concentric or excentric exercise
219008494|NCT01108705|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
218820315|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
219008495|NCT01108705|DRUG|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
219008496|NCT01080521|PROCEDURE|Cognitive Assessment|Ancillary studies
219008497|NCT01080521|OTHER|Quality-of-Life Assessment|Ancillary studies
219008498|NCT04774874|DRUG|Topical formulation|Topical administration on the scalp once daily for 16 weeks
219008499|NCT03821298|OTHER|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
219008500|NCT02862613|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
219008501|NCT02862613|BIOLOGICAL|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
219008502|NCT02723032|DEVICE|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
219008503|NCT04334291|COMBINATION_PRODUCT|Observational (registry)|Observational study.
219008504|NCT02392247|DEVICE|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
219008505|NCT04690543|PROCEDURE|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
219008506|NCT04690543|PROCEDURE|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
219008507|NCT01479153|PROCEDURE|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
219008508|NCT05558163|PROCEDURE|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
219008509|NCT05558163|PROCEDURE|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
219008510|NCT04085133|DIAGNOSTIC_TEST|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
219008511|NCT03010254|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
219008512|NCT03010254|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
219008513|NCT03010254|PROCEDURE|Cataract surgery|IOL bilateral implantation
219008514|NCT01947439|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
219194887|NCT05057052|DRUG|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219435638|NCT03434041|DRUG|Placebo|Participants will self-administer matching placebo as intranasal spray.
219008515|NCT06095427|BIOLOGICAL|LY06006 (Denosumab Biosimilar)|single dose of 60 mg LY006006 s.c.
219008516|NCT06095427|BIOLOGICAL|US-Prolia (Denosumab)|single dose of 60 mg US-Prolia s.c.
219008517|NCT06095427|BIOLOGICAL|EU-Prolia|single dose of 60 mg EU-Prolia s.c.
219008518|NCT02144233|PROCEDURE|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
219008519|NCT02144233|PROCEDURE|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
219008520|NCT02389088|DRUG|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
219008521|NCT03160534|OTHER|preoperative exercise|Each intervention session contains a stretching part and aerobic training
219008522|NCT03134989|DEVICE|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
219008523|NCT00569296|BIOLOGICAL|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
219008524|NCT00569296|BIOLOGICAL|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
219008525|NCT00569296|BIOLOGICAL|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
219008526|NCT05762003|DRUG|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
218820316|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
218820317|NCT04832347|OTHER|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
218820318|NCT04832347|OTHER|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
218820319|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
218820320|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
218820321|NCT01714323|BEHAVIORAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
218820322|NCT01714323|BEHAVIORAL|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
218820323|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
218820324|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
219008527|NCT00945139|DRUG|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
219008528|NCT00945139|DRUG|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
219435639|NCT03434041|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
218820325|NCT03704038|PROCEDURE|PEEP level|Patients will have variable PEEP levels and will be monitored
218820326|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
218820327|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
218820328|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
218820329|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
218820330|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
218820331|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
218820332|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
218820333|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
218820334|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
218820335|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music…).
218820336|NCT03875638|DRUG|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
219008529|NCT03370354|BEHAVIORAL|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
219008530|NCT02378701|BEHAVIORAL|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
219008531|NCT02378701|BEHAVIORAL|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
219008532|NCT03613935|OTHER|Product 1|Comparison with products 2, 3, and 4
219008533|NCT03613935|OTHER|Product 2|Comparison with products 1, 3, and 4
219008534|NCT03613935|OTHER|Product 3|Comparison with products 1, 2, and 4
218820337|NCT03875638|DRUG|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
218820338|NCT02495285|DRUG|Gelofusine 4%|
218820339|NCT02495285|DRUG|Gelaspan 4%|
218820340|NCT03957382|DEVICE|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
218820341|NCT04505761|DEVICE|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
218820342|NCT01783210|BEHAVIORAL|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
218820343|NCT01783210|BEHAVIORAL|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
218820344|NCT04937634|DRUG|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
218820345|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
218820346|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
218820347|NCT01231789|PROCEDURE|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
218820348|NCT01231789|PROCEDURE|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
218820349|NCT05367869|PROCEDURE|Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy|General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
218820350|NCT05111145|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
218820351|NCT05111145|DRUG|IVA|Tablets for oral administration.
218820352|NCT01836289|DRUG|High-dose Cyclophosphamide|
219008535|NCT03613935|OTHER|Product 4|Comparison with products 1, 2, and 3
219008536|NCT02068443|DRUG|Alogliptin|Alogliptin tablets
219008537|NCT02068443|DRUG|Metformin hydrochloride|Metformin hydrochloride tablets
219008538|NCT02068443|DRUG|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
219008539|NCT06186531|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
219008540|NCT06186531|DRUG|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
219008541|NCT03407378|DRUG|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
219008542|NCT03407378|GENETIC|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
219008543|NCT03407378|OTHER|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
219008544|NCT03407378|OTHER|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
219008545|NCT03407378|OTHER|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
219008546|NCT03407378|OTHER|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
219194888|NCT05057052|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
219435640|NCT03434041|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
218820353|NCT03201640|BEHAVIORAL|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
218820354|NCT03201640|BEHAVIORAL|virtual|Participants will be shown an immersive virtual reality preparation for surgery
219435641|NCT03434041|DRUG|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
219435642|NCT03434041|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
218820355|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
218820356|NCT02126046|GENETIC|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
218820357|NCT03549741|DRUG|Clomiphene Citrate 50mg|oral tablets
218820358|NCT03549741|DRUG|Cabergoline Oral Tablet|oral tablets
218820359|NCT03549741|DRUG|Placebo Oral Tablet|oral tablets
218820360|NCT00297869|PROCEDURE|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
218820361|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
218820362|NCT05135598|OTHER|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
219008547|NCT05178966|BEHAVIORAL|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
219435643|NCT04075396|DRUG|Lazertinib|Participants will receive Lazertinib tablets once daily.
219435644|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
219435645|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
219435646|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
219435647|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
219435648|NCT00654212|PROCEDURE|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
219435649|NCT00654212|PROCEDURE|open approach|emergency open surgery
219435650|NCT01362699|DRUG|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
219435651|NCT01362699|DRUG|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
219579654|NCT02622451|BEHAVIORAL|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
219579655|NCT01411865|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
219579656|NCT01411865|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
218820363|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
218820364|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
218820365|NCT00330369|DRUG|Darusentan|Darusentan administered orally once daily
218820366|NCT00330369|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
218820367|NCT00553566|PROCEDURE|medical chart review|
218820368|NCT00553566|PROCEDURE|questionnaire administration|
218820369|NCT00553566|PROCEDURE|study of socioeconomic and demographic variables|
219008548|NCT06161220|DRUG|Carbidopa capsule|Dose: 4x 100 mg
219008549|NCT06161220|DRUG|Moxifloxacin Tablets, USP|Dose: 400 mg
219008550|NCT06161220|DRUG|Placebo|Placebo capsules matching the carbidopa capsules
219579657|NCT01547949|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|
218820370|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
218820371|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
218820372|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
218820373|NCT03564574|COMBINATION_PRODUCT|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
218820374|NCT00952705|BIOLOGICAL|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
218820375|NCT00952705|BIOLOGICAL|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
218820376|NCT00952705|BIOLOGICAL|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
218820377|NCT05821452|DRUG|Camrelizumab|200mgQ3w
218820378|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
218820379|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
218820380|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
218820381|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
218820382|NCT01444820|RADIATION|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
218820383|NCT01444820|RADIATION|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
218820384|NCT04401774|DRUG|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
218820385|NCT06417671|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule per day.
218820386|NCT06417671|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule per day.
218820387|NCT02502552|OTHER|blood specimen|blood specimen
219579658|NCT01547949|DIETARY_SUPPLEMENT|placebo cherry fruit drink|
218820388|NCT05378802|OTHER|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
218820389|NCT06632782|BEHAVIORAL|Breath Awareness using pyramid|Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
218820390|NCT04615546|BEHAVIORAL|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
218820391|NCT04615546|OTHER|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
218820392|NCT04038879|DIAGNOSTIC_TEST|MRI|MRI of the heart
218820393|NCT06180603|PROCEDURE|Gravity fluid drainage in the radiology department|Patients will be referred to the radiology department. Thoracentesis will be performed according to local guidelines.
218820394|NCT06180603|PROCEDURE|Manual drainage in the emergency department|Thoracentesis will be performed according to current guidelines in the emergency department. Fluid will manually be drained using a syringe connected to a three-way stopcock. Thoracentesis will be stopped early if:
218820395|NCT01510574|DRUG|Misoprostol|3 x 200mcg tablets of oral misoprostol
218820396|NCT01510574|DRUG|placebo|3 x placebo tablets resembling misoprostol taken orally
218820397|NCT04445909|DEVICE|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
218820398|NCT03659578|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
218820399|NCT03659578|RADIATION|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
218820400|NCT03659578|DRUG|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
218820401|NCT02031614|PROCEDURE|Phlebotomy|Withdrawal of 500 mL of whole blood.
218820402|NCT04539171|OTHER|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
218820403|NCT04490798|PROCEDURE|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
219008551|NCT01986855|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
219008552|NCT01986855|DRUG|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
219008553|NCT01986855|DRUG|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
219008554|NCT01986855|DRUG|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
219008555|NCT00664742|DRUG|Fluvastatin XL®|Fluvastatin extended release 80 mg
219435652|NCT04189991|DEVICE|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
219579659|NCT05808673|BIOLOGICAL|Post-change CMAB807X|for subcutaneous injection only
219579660|NCT05808673|BIOLOGICAL|Pre-change CMAB807X|for subcutaneous injection only
219579661|NCT05808673|BIOLOGICAL|Xgeva®|for subcutaneous injection only
219579662|NCT05665920|RADIATION|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
219579663|NCT05665920|RADIATION|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
219579664|NCT06880783|OTHER|manual diaphragm release technique|The participant should be supine with relaxed limbs, and the therapist should position themselves at the head, making manual contact with the pisiform, hypothenar region, and fingers. The therapist should gently pull the contact towards the head, deepen it during exhalation, and gradually increase the depth.
219579665|NCT06880783|OTHER|deep breathing exercises|Participants in a crook laying position are instructed to inhale through the nose, lift the abdomen, and let out through the mouth, breathing six breaths per minute for 30 minutes.
219579666|NCT06723639|PROCEDURE|A new two-layer surgical technique|A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
219579667|NCT06723639|OTHER|Standard non-surgical treatment|Standard non-surgical treatment
219579668|NCT01469260|OTHER|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
219579669|NCT02156141|OTHER|Supervised high intensity training|8 weeks of supervised training
219579670|NCT02156141|OTHER|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
219579671|NCT02156141|OTHER|Control period|8 weeks with no training.
219579672|NCT02156141|OTHER|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
219579673|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo or 0.75 mg soluble Xanthohumol)
219008556|NCT01907503|PROCEDURE|Evaluation of the balance of force platform|
219008557|NCT03072628|OTHER|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
219008558|NCT03072628|OTHER|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
219008559|NCT03072628|OTHER|nicotine inhaler|use a nicotine inhaler for 30 minutes
219435653|NCT01765946|DRUG|Metformin|Metformin tablets 500 mg tris in die (tid)
219435654|NCT01765946|DRUG|placebo|
219579674|NCT06745102|DIETARY_SUPPLEMENT|Iso-alpha Acids|Participants receive a study drink supplemented with Iso-alpha Acids (0 mg = Placebo or 45 mg Iso-alpha Acids)
219579675|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha Acids|Participants receive a study drink supplemented with Xanthohumol and Iso-alpha Acids (0 mg = Placebo or 0.75 mg + 45 mg soluble Xanthohumol + Iso-alpha Acids)
219579676|NCT06281951|DRUG|Fentanyl - Inhalation by facial nebulization|3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
219579677|NCT06281951|DRUG|Fentanyl - Nebulisation|3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
219579678|NCT06927843|DEVICE|point of care test|DPP Syphilis Screen and Confirm antibody point-of-care-test (POCT)
219579679|NCT06846242|OTHER|Assessment|The group in which the assessments will be made.
219579680|NCT06319079|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
219579681|NCT06319079|OTHER|Powder milk|Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
219579682|NCT03596931|DRUG|Statins (Cardiovascular Agents)|Prescribed with statins
219579683|NCT06779292|DIAGNOSTIC_TEST|Large Language Model Diagnosis|Using the large language model for diagnosing emergency neurology conditions.
219579684|NCT06923332|OTHER|High Fiber bar with Inulin|Bar with inulin - high fiber
219579685|NCT06923332|OTHER|Low fiber bar - no inulin|Bar without inulin - low fiber
219579686|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
219008560|NCT03072628|OTHER|sham control|use an empty e-cigarette for 30 minutes
219008561|NCT02434731|DEVICE|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
219008562|NCT02152579|DRUG|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
219008563|NCT02930421|OTHER|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
219008564|NCT03670303|BEHAVIORAL|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures"
219008565|NCT06359470|OTHER|Positioning technique|"First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation."
218820404|NCT06358495|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.
218820405|NCT06358495|OTHER|Active Control|Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
218820406|NCT03399448|BIOLOGICAL|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
218820407|NCT03399448|DRUG|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
218820408|NCT03399448|DRUG|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
218820409|NCT03399448|DEVICE|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
218820410|NCT04781582|PROCEDURE|Lung volume reduction surgery|Surgical lung volume reduction
219194889|NCT06470217|DRUG|tirilizumab with albumin-bound paclitaxel and cisplatin|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
219579687|NCT06922383|DRUG|arfolitixorin (ARFOX + bevacizumab)|Every 14 days during treatment phase, Bevacizumab will be administered as an i.v. infusion of 5 mg/kg, Oxaliplatin will be administered as an 85 mg/m2 i.v. infusion, 5-FU will be administered as a 400 mg/m2 i.v. bolus + a 2,400 mg/m2 i.v. infusion and Arfolitixorin will be administred as an i.v. infusion.
219579688|NCT01489618|BIOLOGICAL|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
218820411|NCT04781582|PROCEDURE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
218820412|NCT05155982|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
218820413|NCT05155982|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
218820414|NCT05833217|PROCEDURE|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
219194890|NCT06470217|PROCEDURE|surgery|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
219008566|NCT04931862|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
219008567|NCT04931862|DRUG|Placebo|Artificial cerebrospinal fluid (aCSF)
219008568|NCT02635945|DRUG|PBF-680|
219008569|NCT02635945|DRUG|Placebo|
219008570|NCT04475653|BEHAVIORAL|Physical Activity using an Activity Tracker|
219008571|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
219579689|NCT01489618|BIOLOGICAL|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
219579690|NCT05397548|DIAGNOSTIC_TEST|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
218820415|NCT05833217|DIAGNOSTIC_TEST|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
218820416|NCT01381367|BIOLOGICAL|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
218820417|NCT01381367|DRUG|Normal Saline|normal saline, 0.5ml given subcutaneously
218820418|NCT05353686|DRUG|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
218820419|NCT05353686|DRUG|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
218820420|NCT06086743|OTHER|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
218820421|NCT06086743|OTHER|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
218820422|NCT03759600|DRUG|Niraparib|Niraparib capsule
218820423|NCT03317743|DRUG|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
218820424|NCT05173974|DEVICE|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
218820425|NCT05173974|DEVICE|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
219008572|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
219008573|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
219579691|NCT03502707|BIOLOGICAL|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
218820426|NCT05173974|DEVICE|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
218820427|NCT06319404|OTHER||
218820428|NCT06206863|OTHER|Exercise Intervention|Participate in virtual exercise classes
218820429|NCT06206863|OTHER|Questionnaire Administration|Ancillary studies
219008574|NCT03111901|DRUG|Pembrolizumab|Pembrolizumab solution
219008575|NCT03111901|DRUG|Interleukin-2|Interleukin-2 solution
219008576|NCT01711970|DRUG|Paclitaxel|
219008577|NCT05783778|DIAGNOSTIC_TEST|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
218820430|NCT01697085|DIETARY_SUPPLEMENT|Sea buckthorn oil|
218820431|NCT01697085|DIETARY_SUPPLEMENT|Placebo oil|
218820432|NCT00050583|BEHAVIORAL|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
218820433|NCT00050583|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
218820434|NCT02098304|DEVICE|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
218820435|NCT00733486|DEVICE|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
219008578|NCT02825992|DEVICE|AcQMap System|3D imaging and mapping system for cardiac chambers
219008579|NCT03903705|DRUG|Fruquintinib in Combination with Sintilimab|"Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
219008580|NCT02050776|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
219435655|NCT00444080|PROCEDURE|Trabeculectomy|"Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged."
219008581|NCT05451368|OTHER|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
219008582|NCT02279173|DRUG|Romiplostim|Romiplostim subcutaneous weekly injection
219008583|NCT01899690|DRUG|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
219008584|NCT06401395|DEVICE|DIGIPARK MONITOR|remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
219008585|NCT02090660|OTHER|ICG Localization with Spy thoracoscope localization|
219008586|NCT02240160|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
219008587|NCT00188149|DRUG|Combined chemotherapy (ABVD, BACOPP-D)|
219435656|NCT00444080|DEVICE|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged."
219435657|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
219435658|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
219435659|NCT03979872|DIAGNOSTIC_TEST|MC1R Genetic Testing|\[See arm/group descriptions\]
219194891|NCT02661932|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
219435660|NCT03979872|OTHER|Skin Cancer Education|\[See arm/group descriptions\]
219435661|NCT03979872|DEVICE|UV Photo|\[See arm/group descriptions\]
219435662|NCT03684070|BEHAVIORAL|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
219008588|NCT00188149|PROCEDURE|Radiation therapy|
219008589|NCT05001386|BIOLOGICAL|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
219008590|NCT05947370|DRUG|Berberine Chloride|Traditional Chinese medicine
219008591|NCT05947370|DRUG|Placebo|Placebo control
219435663|NCT03684070|BEHAVIORAL|Self-monitoring|Self-monitoring of data from wearable step count tracker
219008592|NCT06508073|OTHER|Neural Therapy|The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
219008593|NCT06391164|DRUG|XC243 25 mg|Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
219008594|NCT06391164|DRUG|XC243 50 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
219008595|NCT06391164|DRUG|XC243 75 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
219008596|NCT06391164|DRUG|Placebo|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
219008597|NCT00003204|DRUG|cyclophosphamide|Given IV
219008598|NCT00003204|DRUG|fludarabine phosphate|Given IV
219008599|NCT00003204|DRUG|vincristine sulfate|Given IV
219008600|NCT00003204|DRUG|prednisone|Given PO
219008601|NCT00003204|BIOLOGICAL|rituximab|Given IV
219008602|NCT00003204|OTHER|laboratory biomarker analysis|Correlative studies
219008603|NCT06363968|DEVICE|RETeval|as previous
219008604|NCT04416503|OTHER|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
219008605|NCT00002222|DRUG|Valganciclovir|
219008606|NCT00280462|DRUG|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
219008607|NCT00280462|DRUG|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
219763334|NCT06406114|DRUG|Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
218820436|NCT01891929|BEHAVIORAL|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
218820437|NCT01891929|BEHAVIORAL|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
218820438|NCT06487299|DRUG|Ferrous Lactate|The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
218820439|NCT06487299|DRUG|Iron sucrose|The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
218820440|NCT06487299|DRUG|0.9% NaCl solution|The same volume and color as Iron sucrose.
218820441|NCT04691921|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
218820442|NCT01774773|DRUG|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
218820443|NCT01774773|DRUG|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
218820444|NCT01774773|DRUG|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
219008608|NCT00280462|DRUG|Placebo|Placebo
219008609|NCT02545790|PROCEDURE|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
219008610|NCT02545790|BIOLOGICAL|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
219008611|NCT01477606|DRUG|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
219194892|NCT04104360|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
219194893|NCT04104360|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
219194894|NCT02437136|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACs)
219475383|NCT03241511|OTHER|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
219194895|NCT02437136|DRUG|pembrolizumab|A selective humanized monoclonal antibody (mAb)
219194896|NCT04117178|DRUG|Donepezil|Adjustment of treatment with donepezil according to serum level.
219008612|NCT01477606|DRUG|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
219008613|NCT01477606|DRUG|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
219008614|NCT00710710|DRUG|BI 2536|Intravenous Infusion
219008615|NCT01365325|OTHER|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
219008616|NCT01365325|OTHER|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
219008617|NCT02390401|DEVICE|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
219008618|NCT02390401|DEVICE|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
219008619|NCT04537767|DRUG|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
219008620|NCT04537767|DRUG|Placebo|Placebo
219008621|NCT04882267|BEHAVIORAL|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
218820445|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
218820446|NCT02547103|OTHER|Normal saline|
218820447|NCT02547103|OTHER|mupirocin ointment|
218820448|NCT03289143|DRUG|Semorinemab|Participants will receive Semorinemab intravenously (IV).
218820449|NCT03289143|DRUG|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
218820450|NCT03289143|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
219008622|NCT02034279|DRUG|Albumin|Intravenous infusion of 20% albumin
219008623|NCT05802667|DIAGNOSTIC_TEST|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
219008624|NCT04876625|DEVICE|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
218820451|NCT00328796|PROCEDURE|acupuncture in 6 specific points|
218820452|NCT00328796|DRUG|lidocaine 10mg/ml|
218820453|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
218820454|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
218820455|NCT05504759|OTHER|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
219008625|NCT04876625|DEVICE|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
219008626|NCT04682067|BEHAVIORAL|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
218820456|NCT05504759|OTHER|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
219008627|NCT04682067|BEHAVIORAL|Usual Care smoking cessation|Usual care smoking cessation support
219008628|NCT04762797|OTHER|Non|This is a retrospective study, without intervention.
219008629|NCT04234581|DIETARY_SUPPLEMENT|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
219008630|NCT00045500|DRUG|7-hydroxystaurosporine|
219008631|NCT00045500|DRUG|prednisone|
219008632|NCT00731289|DRUG|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
219008633|NCT00731289|DRUG|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
219008634|NCT03249766|OTHER|Observational|Observational study
219008635|NCT00715078|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
219194897|NCT04117178|DRUG|Memantine|Adjustment of treatment with memantine according to serum level.
219475384|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
219475385|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
219008636|NCT02990091|DRUG|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
219008637|NCT02990091|DIETARY_SUPPLEMENT|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
219008638|NCT00847054|DRUG|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
219008639|NCT03787251|DRUG|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
219008640|NCT03787251|DRUG|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
219008641|NCT02999945|DIETARY_SUPPLEMENT|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
219008642|NCT02999945|DIETARY_SUPPLEMENT|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
218820457|NCT05504759|OTHER|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
219008643|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
219008644|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
219008645|NCT03140644|OTHER|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
219008646|NCT04673331|OTHER|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
219435664|NCT03363165|DRUG|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
219194898|NCT04117178|DIAGNOSTIC_TEST|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
219194899|NCT04008563|PROCEDURE|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
219008647|NCT00005622|DRUG|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
219008648|NCT00005622|RADIATION|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
219194900|NCT04312841|DRUG|Letermovir|Given PO
219475386|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
219008649|NCT00402766|DRUG|Cisplatin|Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
219008650|NCT00402766|DRUG|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
219008651|NCT00402766|DRUG|Pemetrexed|Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
219475387|NCT06430268|PROCEDURE|implant decontamination with titanium curette|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.
219475388|NCT06430268|DEVICE|implant decontamination with Air-Flow device|Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
218820458|NCT00305877|BIOLOGICAL|cetuximab|Given IV
218820459|NCT00305877|DRUG|gemcitabine hydrochloride|Given IV
218820460|NCT00305877|DRUG|capecitabine|Given orally
218820461|NCT00305877|RADIATION|radiation therapy|Undergo radiation therapy
218820462|NCT00305877|BIOLOGICAL|bevacizumab|Given IV
218820463|NCT00305877|OTHER|laboratory biomarker analysis|Correlative studies
218820464|NCT05017870|DRUG|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
218820465|NCT05017870|DRUG|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
218820466|NCT05017870|DRUG|KSR-001-02|KSR-001-02
218820467|NCT05017870|DRUG|KSR-001-03|KSR-001-03
218820468|NCT04817202|DRUG|hzVSF-v13 (intravenous, single dose)|Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
218820469|NCT04817202|DRUG|hzVSF-v13 (subcutaneous, single dose)|Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
218820470|NCT04817202|DRUG|hzVSF-v13 (intravenous, multiple dose)|Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
218820471|NCT04817202|DRUG|Placebo (intravenous, single dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
218820472|NCT04817202|DRUG|Placebo (subcutaneous, single dose)|Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
219008652|NCT00402766|DRUG|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
219194901|NCT06029153|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
219579692|NCT03502707|BIOLOGICAL|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
218820473|NCT04817202|DRUG|Placebo (intravenous, multiple dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
218820474|NCT01152307|BEHAVIORAL|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
218820475|NCT01126190|BIOLOGICAL|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
218820476|NCT01126190|BIOLOGICAL|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
218820477|NCT01126190|DRUG|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
218820478|NCT04554303|DRUG|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
218820479|NCT04554303|DRUG|Amlodipine 5mg|Oral administration, 1 tablet per day
218820480|NCT00524121|DRUG|erlotinib hydrochloride|Oral
219008653|NCT03598192|PROCEDURE|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
219008654|NCT03598192|PROCEDURE|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
218820481|NCT00524121|OTHER|immunohistochemistry staining method|Correlative Study
218820482|NCT00524121|RADIATION|radiation therapy|Radiation Treatment
218820483|NCT03334838|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
218820484|NCT00572182|DRUG|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
219008655|NCT03598192|DRUG|Ropivacaine|Ropivacaine has been treated the both group
219008656|NCT03598192|DRUG|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
219008657|NCT00994292|DRUG|YM150|oral
219008658|NCT00994292|DRUG|Placebo|oral
219008659|NCT06503419|OTHER|non-intervention|non-intervention
219008660|NCT05029674|DEVICE|Whoop|Wear WHOOP Strap, complete surveys
219008661|NCT05725720|OTHER|Gut microbiome analysis|Characterization of the compositional and functional modifications of gut microbiome in patients affected by lymphoma undergoing therapy with CAR-T cells from baseline until the restaging after 18 months from the CAR-T cell infusion
219008662|NCT04137003|OTHER|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
219194902|NCT04134559|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
219363550|NCT03312569|PROCEDURE|Right Colectomy with Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
219579693|NCT03502707|BIOLOGICAL|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
219579694|NCT03502707|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
219579695|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
219579696|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
218820485|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
218820486|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
218820487|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
218820488|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
218820489|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
218820490|NCT00706147|DRUG|Arimoclomol|Drug: Arimoclomol capsules given three times per day
218820491|NCT00706147|DRUG|Placebo|Drug: Placebo capsules given three times per day
218820492|NCT01114737|DRUG|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
218820493|NCT01114737|DRUG|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
218820494|NCT04955067|DIAGNOSTIC_TEST|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
218820495|NCT03637283|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
218820496|NCT03637283|PROCEDURE|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
218820497|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
218820498|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
218820499|NCT04373304|OTHER|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
218820500|NCT00068289|DRUG|bortezomib|
218820501|NCT00983034|DRUG|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
218820502|NCT01446874|DRUG|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
218820503|NCT06395701|RADIATION|radioteraphy and chemotherapy after RTU --trimodality therapy--|TMT ( trimodality treatment) consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent.
218820504|NCT02554994|OTHER|Multifactorial intervention|"There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
218820505|NCT02554994|OTHER|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
218820506|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
218820507|NCT03925363|DEVICE|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
218820508|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
218820509|NCT00457392|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
219763335|NCT06406114|DRUG|Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
218820510|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
219475389|NCT04624204|BIOLOGICAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
218820511|NCT00457392|DRUG|placebo|Placebo daily by oral capsules in a continuous regimen
218820512|NCT05075889|DRUG|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
219475390|NCT04624204|BIOLOGICAL|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
219475391|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
219475392|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
219194903|NCT04722913|DIAGNOSTIC_TEST|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
219008663|NCT04137003|OTHER|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
219435665|NCT03363165|OTHER|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
219435666|NCT03855241|BEHAVIORAL|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
219435667|NCT03855241|BEHAVIORAL|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
219435668|NCT01287598|DRUG|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
219435669|NCT01287598|DRUG|Warfarin|CYP 2C9 (warfarin) at Cycle 1
219435670|NCT01287598|DRUG|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
219435671|NCT01287598|DRUG|Midazolam|CYP 3A4 (midazolam) at Cycle 1
219435672|NCT01287598|DRUG|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
219435673|NCT02255760|DRUG|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
219435674|NCT02255760|DRUG|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
219435675|NCT02255760|DRUG|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
219435676|NCT02255760|DRUG|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
219435677|NCT02255760|OTHER|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
219435678|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
219435679|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
219435680|NCT05636904|DRUG|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
219763336|NCT06406114|DRUG|Amoxicillin double-blind placebo-controlled drug challenge|Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well.
219763337|NCT04800484|DEVICE|Tall Soft|Tall heel wedge made of soft foam
219763338|NCT04800484|DEVICE|Tall Firm|Tall heel wedge made of firm foam
219763339|NCT04800484|DEVICE|Short Soft|Short heel wedge made of soft foam
219763340|NCT04800484|DEVICE|Short Firm|Short heel wedge made of firm foam
219763341|NCT03438747|DEVICE|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
219763342|NCT03438747|OTHER|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
219763343|NCT05084521|DRUG|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
219763344|NCT06400303|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
219763345|NCT06400303|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219763346|NCT05469737|DRUG|Oral Azacitidine|Specified dose on specified days
219763347|NCT05469737|DRUG|Placebo for Oral Azacitidine|Specified dose on specified days
219763348|NCT06077760|BIOLOGICAL|Intismeran autogene|IM injection
219763349|NCT06077760|BIOLOGICAL|Pembrolizumab|IV infusion
219763350|NCT06077760|OTHER|Placebo|IM injection
219763351|NCT05636176|DRUG|Ziltivekimab|Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
219763352|NCT05636176|DRUG|Placebo|Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
219763353|NCT06312137|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
219763354|NCT06312137|BIOLOGICAL|Pembrolizumab|Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
219763355|NCT06312137|DRUG|Cisplatin|Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
219763356|NCT06312137|DRUG|Pemetrexed|Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
219435681|NCT05636904|DRUG|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
219194904|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
219435682|NCT00003838|PROCEDURE|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
219435683|NCT00003838|DRUG|Methotrexate|IV MTX on days +1, +3, and +6 will be given
219435684|NCT00003838|DRUG|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.
219194905|NCT03735745|OTHER|Blood collection|30cc of blood will be collected.
219194906|NCT03735745|OTHER|Saliva collection|5cc of saliva will be collected.
219194907|NCT03735745|OTHER|Tissue collection|Up to 10mg of tissue will be collected.
219194908|NCT03735745|OTHER|Surveys|The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
219435685|NCT00003838|DRUG|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
219579697|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
219579698|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
219579699|NCT03502707|BIOLOGICAL|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
219579700|NCT03502525|BEHAVIORAL|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
219579701|NCT03502525|BEHAVIORAL|Bacterial Infection Prevention|Bacterial Infection Prevention is an attention control intervention. The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs. Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature. This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis.
219579702|NCT06158048|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219579703|NCT06158048|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
219579704|NCT04737421|DEVICE|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
219008664|NCT03527095|DRUG|FDL169|CFTR corrector
219194909|NCT05136755|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
219194910|NCT05136755|DRUG|Placebo Cap|Use of placebo as a comparator
219194911|NCT05850052|DEVICE|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
219194912|NCT05850052|DEVICE|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
219194913|NCT06678464|OTHER|Moiz MM|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
219435686|NCT00618813|OTHER|radiation therapy|Undergo radiation therapy
219435687|NCT00618813|OTHER|therapeutic conventional surgery|Undergo surgery
219435688|NCT00618813|DRUG|etoposide|Given IV
219435689|NCT00618813|DRUG|ifosfamide|Given IV
219435690|NCT00618813|DRUG|doxorubicin hydrochloride|Given IV
219435691|NCT00618813|DRUG|cyclophosphamide|Given IV
219435692|NCT00618813|DRUG|vincristine sulfate|Given IV
219435693|NCT00618813|DRUG|topotecan hydrochloride|Given IV
219435694|NCT00618813|BIOLOGICAL|filgrastim|Given SC
219435695|NCT01150604|BEHAVIORAL|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
219435696|NCT00022893|DRUG|Iodine-131 Anti-B1 Antibody|
218820513|NCT03991910|DRUG|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
218820514|NCT03991910|DRUG|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
218820515|NCT00776529|OTHER|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
219194914|NCT06678464|OTHER|Moiz XL|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
219194915|NCT06678464|OTHER|Moiz LMF 48|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical"
219194916|NCT03822494|RADIATION|CyberKnife SBRT|Radiation Therapy
219194917|NCT06235320|OTHER|routine clinical treatment of pain with paracetamol or ibuprofen|No intervention beside clinical routine management
219194918|NCT04209543|DRUG|Estetrol|Estetrol oral tablet: administered orally once daily
219763357|NCT06312137|DRUG|Gemcitabine|Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
219763358|NCT06312137|DRUG|Carboplatin|Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
219763359|NCT06312137|DRUG|Paclitaxel|Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
219763360|NCT06312137|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
219763361|NCT04402788|DRUG|Atezolizumab|Given IV
219763362|NCT04402788|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
219763363|NCT04402788|PROCEDURE|Computed Tomography|Undergo CT
219763364|NCT04402788|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763365|NCT04402788|PROCEDURE|Positron Emission Tomography|Undergo PET
218820516|NCT00776529|OTHER|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
218820517|NCT02878083|DRUG|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
218820518|NCT02878083|DRUG|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
218820519|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
219194919|NCT04209543|DRUG|Placebo|Placebo oral tablet: administered orally once daily
219194920|NCT04209543|DRUG|Progesterone|Progesterone oral tablet: administered orally once daily
219763366|NCT04402788|RADIATION|Radiation Therapy|Undergo radiation therapy
219763367|NCT05560763|DEVICE|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism via mechanical thrombectomy of thrombus in the pulmonary arteries.
219763368|NCT04781140|DRUG|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
219763369|NCT04781140|DRUG|Placebo|Placebo will be administered once daily
219194921|NCT05524116|BEHAVIORAL|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
219194922|NCT05524116|BEHAVIORAL|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
219435697|NCT04960462|PROCEDURE|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
219435698|NCT01336595|DEVICE|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
219435699|NCT01336595|DEVICE|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
219435700|NCT02208505|DRUG|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
219435701|NCT02208505|DRUG|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
219475393|NCT04624204|DRUG|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
219475394|NCT04624204|DRUG|Olaparib matching placebo|Olaparib matching placebo BID
219475395|NCT04624204|DRUG|Etoposide 100 mg/m^2|Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
219475396|NCT04624204|DRUG|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
219475397|NCT04624204|RADIATION|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
219475398|NCT04624204|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
219475399|NCT05791955|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
219008665|NCT00300586|DRUG|observation|observation, second line chemotherapy if progression
219008666|NCT00300586|DRUG|gemcitabine|1250 mg/m² D1, D8 q21 days
219008667|NCT00300586|DRUG|erlotinib|150 mg daily
219008668|NCT06369194|PROCEDURE|Colorectal Surgery|Postoperative Audit
219008669|NCT04090840|BEHAVIORAL|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
219435702|NCT03454724|DEVICE|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
218820520|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
218820521|NCT05886153|DEVICE|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
218820522|NCT00399074|DRUG|sulfadoxine pyrimethamine|Monthly SP
219579705|NCT04737421|DEVICE|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
218820523|NCT05504512|OTHER|No intervention|No intervention
218820524|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
219579706|NCT04737421|DEVICE|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
218820525|NCT04468373|DEVICE|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
218820526|NCT02448199|DRUG|Meloxicam and Glucosamine|Experimental
218820527|NCT02448199|DRUG|Meloxicam|Active Comparator
218820528|NCT02448199|DRUG|Glucosamine|Active Comparator
218820529|NCT02831660|DRUG|idarucizumab|
218820530|NCT05792748|PROCEDURE|Pulp hemostasis with a dry cotton pellet|Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
218820531|NCT05792748|PROCEDURE|Pulp hemostasis with a wet cotton pellet impregnated with FS|Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
218820532|NCT05792748|PROCEDURE|Stainless steel crown|Stainless steel crown placed as a final restoration
218820533|NCT03330444|PROCEDURE|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
218820534|NCT04470297|DRUG|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
219008670|NCT04464512|DRUG|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
219008671|NCT00840554|OTHER|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
219008672|NCT00840554|OTHER|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
219008673|NCT01503281|OTHER|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
219194923|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
219194924|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
219435703|NCT03454724|DEVICE|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
219435704|NCT00262327|DRUG|Antangiogenesis|
219435705|NCT00262327|GENETIC|endostatin gene|
219435706|NCT03115125|OTHER|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
219763370|NCT06568172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or plasma
219763371|NCT06568172|BIOLOGICAL|Cemiplimab|Given IV
218820535|NCT03767543|DRUG|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219435707|NCT03151538|BEHAVIORAL|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
219435708|NCT03151538|OTHER|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
219194925|NCT06778837|DEVICE|Wearable devices to detect lymphedema|All participants will undergo measurement of the upper extremities to test the validity and safety of wearable sensors to measure lymphedema.
219194926|NCT05345509|DRUG|Aricept Tablet|Donepezil Tablet once daily P.O
219435709|NCT06470620|DIAGNOSTIC_TEST|pelvic floor muscle assessment|no intervention will be performed - several diagnostic assessments tools
219435710|NCT06643260|DRUG|piclidenoson|Piclidenoson is a selective A3AR agonist, supplied as tablets.
219435711|NCT06643260|DRUG|Placebo|Inactive control
219435712|NCT01809197|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
219435713|NCT01809197|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
219435714|NCT01809197|DEVICE|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
219435715|NCT01809197|DEVICE|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
219435716|NCT06221436|BEHAVIORAL|Mental Imagery|"Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery."
219435718|NCT01016808|DRUG|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
219435719|NCT01016808|DRUG|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
219435720|NCT01016808|DRUG|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
219579707|NCT04737421|DEVICE|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
219435721|NCT04883697|OTHER|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
219435722|NCT00141206|DRUG|varenicline (CP-526,555)|
219435723|NCT01892241|DRUG|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
219435724|NCT01892241|DRUG|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
219435725|NCT04516941|DRUG|Edoxaban Tablets|Treatment
218820536|NCT02507154|DRUG|Cetuximab + NK cells|
219435726|NCT04516941|DRUG|Colchicine Tablets|Treatment
219435727|NCT02052141|BIOLOGICAL|CINRYZE 500|500 Units of CINRYZE administered by IV injection
219435728|NCT02052141|BIOLOGICAL|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
219435729|NCT05148169|DRUG|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
219435730|NCT05148169|DIETARY_SUPPLEMENT|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
219475400|NCT05791955|BEHAVIORAL|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
219475401|NCT05791955|BEHAVIORAL|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
219475402|NCT05978492|DRUG|TXN10128|TXN10128: Oral administration once daily everyday
219475403|NCT05978492|DRUG|Irinotecan|Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle
219475404|NCT05978492|DRUG|Paclitaxel|IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)
219475405|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
219475406|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
219435731|NCT01937481|BEHAVIORAL|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
219194927|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once S.C Injection
219194928|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once IM Injection
219579708|NCT05447923|OTHER|Educational Intervention|Undergo education for colorectal cancer screening
219579709|NCT05447923|OTHER|Fecal Immunochemical Test|Undergo FIT testing
219194929|NCT05974579|DRUG|89Zr-DFO-AP-101|"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."
219194930|NCT04911816|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
219194931|NCT06379607|DEVICE|"High Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.
219579710|NCT05447923|BEHAVIORAL|Patient Navigation|Undergo patient navigation for positive FIT results
219579711|NCT05447923|OTHER|Questionnaire Administration|Complete questionnaire about colorectal cancer screening and healthcare
219579712|NCT03994055|OTHER|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
219579713|NCT03994055|OTHER|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
219579714|NCT03994055|OTHER|Soluble fiber|Diet will include foods rich in soluble fiber.
219579715|NCT03994055|OTHER|Probiotics|Diet will include foods rich in probiotics.
219579716|NCT03994055|OTHER|Lactose restriction|Diet will be restricted to 5g lactose/day
218820537|NCT03313830|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
218820538|NCT03313830|DIETARY_SUPPLEMENT|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
218820539|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
218820540|NCT06512506|OTHER|non-intervention|non-intervention
219579717|NCT03994055|OTHER|Fiber restriction|Diet will be restricted to 20g fiber/day
219194932|NCT06379607|DEVICE|"Low Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
219194933|NCT03953144|DEVICE|Synapse 3D Lung Modelling|The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
219194934|NCT03953144|DRUG|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
219194935|NCT03065231|DEVICE|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
219194936|NCT03065231|DEVICE|Lumbar Drain|
219579718|NCT03994055|OTHER|Fat restriction|Diet will be restricted to 20% total energy intake
219579719|NCT05753306|DRUG|Cisplatin|Given via HIPEC
219579720|NCT05753306|PROCEDURE|Computed Tomography|Undergo CT scan or PET/CT
219579721|NCT05753306|PROCEDURE|Gastrectomy|Undergo robotic gastrectomy
219579722|NCT05753306|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219579723|NCT05753306|PROCEDURE|Positron Emission Tomography|Undergo PE/CT
219579724|NCT05753306|OTHER|Questionnaire Administration|Complete questionnaire
219579725|NCT05753306|DRUG|Paclitaxel|Given via HIPEC
219579726|NCT05753306|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
219579727|NCT05791682|DRUG|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
219579728|NCT06080841|DIETARY_SUPPLEMENT|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
219579729|NCT06080841|DIETARY_SUPPLEMENT|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
219579730|NCT05287347|DIAGNOSTIC_TEST|Blood Specimen|"Blood samples will be collected from study participants at one time-point in the study, for the following:~1. tumor markers CEA and CA 19-9: 2 ml blood will be collected.~2. glycomics: 0.5 cc blood will be collected~3. ctDNA: 20 cc blood will be collected"
219579731|NCT04637126|OTHER|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
219763372|NCT06568172|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
218820541|NCT00364247|DRUG|CG5503 IR;tapentadol|
218820542|NCT05029310|DRUG|Patiromer Oral Product|interaction study
218820543|NCT04698304|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
218820544|NCT05559099|DRUG|Tecovirimat Oral Capsule|"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
218820545|NCT05559099|DRUG|Placebo|Capsules to match tecovirimat
218820546|NCT00577200|DRUG|Midazolam|Midazolam
218820547|NCT00577200|DRUG|Sufentanil|Sufentanil
218820548|NCT00577200|DRUG|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
218820549|NCT03177538|DRUG|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
218820550|NCT03177538|DRUG|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
218820551|NCT05518461|DEVICE|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
218820552|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
218820553|NCT05185843|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
218820554|NCT06174740|BEHAVIORAL|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
219435732|NCT04903704|DIAGNOSTIC_TEST|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
219435733|NCT00396305|DRUG|Placebo|Sterile phosphate buffered saline solution.
219435734|NCT00396305|BIOLOGICAL|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
219579732|NCT02221037|DRUG|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
218820555|NCT06174740|BEHAVIORAL|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
218820556|NCT06121895|OTHER|Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
218820557|NCT06121895|OTHER|Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
218820558|NCT03179761|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
218820559|NCT03179761|OTHER|Laboratory Biomarker Analysis|Correlative studies
218820560|NCT03179761|BIOLOGICAL|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
218820561|NCT05289752|PROCEDURE|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
218820562|NCT05289752|DEVICE|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
218820563|NCT00584857|DRUG|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
219194937|NCT06018155|OTHER|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
219579733|NCT02221037|DRUG|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
219579734|NCT04669470|PROCEDURE|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
219579735|NCT05000970|DEVICE|blood pressure cuff PLUS tablet|all arms
219579736|NCT05000970|OTHER|Telehealth Consult|Telehealth consult with an RN
218820564|NCT03278522|DRUG|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
219579737|NCT04158960|BEHAVIORAL|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
218820565|NCT00448448|DEVICE|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
218820566|NCT00448448|OTHER|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
218820567|NCT04366856|BEHAVIORAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
218820568|NCT04366856|BEHAVIORAL|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
218820569|NCT02916316|DRUG|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
218820570|NCT03856866|DRUG|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
218820571|NCT03856866|DRUG|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
218820572|NCT04548206|OTHER|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
218820573|NCT04548206|OTHER|control|The program consisted of progressive relaxation exercises at home.
219579738|NCT04158960|BEHAVIORAL|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
219579739|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
219579740|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
219579741|NCT04511221|OTHER|Placebo|One 15mg capsule taken orally each day
219579742|NCT00031122|OTHER|No Intervention|There is no intervention in this study
219579743|NCT00306943|BIOLOGICAL|Influsplit SSW®|
219579744|NCT00640679|DRUG|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
219579745|NCT00640679|DRUG|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
219579746|NCT02872792|DEVICE|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
219579747|NCT02872792|OTHER|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
219579748|NCT05050890|OTHER|ctDNA level during neoadjuvant chemotherapy|ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
219579749|NCT05441995|OTHER|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
219579750|NCT03416803|RADIATION|Radiotherapy|Radiotherapy
219579751|NCT03362918|BEHAVIORAL|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
219579752|NCT03362918|BEHAVIORAL|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
219579753|NCT03805503|DRUG|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
219579754|NCT05692050|DRUG|Epcoritamab|Subcutaneous Injection
218820574|NCT01425476|DRUG|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
218820575|NCT01425476|DRUG|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
218820576|NCT01425476|DRUG|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
218820577|NCT01384318|OTHER|Manometer|Measuring cuff pressure
218820578|NCT01808469|BIOLOGICAL|Monoclonal antibody|
218820579|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
219579755|NCT01884311|BIOLOGICAL|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
219579756|NCT02637375|DRUG|Ganetespib|
219579757|NCT02637375|DRUG|Paclitaxel|
218820580|NCT06154590|DRUG|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
218820581|NCT06154590|DRUG|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
218820582|NCT02284191|RADIATION|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
218820583|NCT05678140|DEVICE|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
218820584|NCT05678140|OTHER|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
218820585|NCT01188967|DRUG|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
218820586|NCT01188967|DRUG|Placebo|Placebo
218820587|NCT01859013|DRUG|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
218820588|NCT01859013|OTHER|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
218820589|NCT04826380|PROCEDURE|Trapeziectomy|Simple trapeziectomy (without LRTI)
219008674|NCT04719507|PROCEDURE|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
219008675|NCT04719507|PROCEDURE|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
219008676|NCT04719507|DRUG|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
219008677|NCT06441344|DRUG|Toripalimab plus Anlotinib|For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
219008678|NCT06441344|DRUG|Toripalimab|For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
218820590|NCT01659060|OTHER|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
218820591|NCT01659060|OTHER|Placebo Chocolate|Placebo intervention
218820592|NCT02308514|DEVICE|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
218820593|NCT02308514|OTHER|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
218820594|NCT01363102|PROCEDURE|SOMS|Apply a number to mobilization goal for patient
218820595|NCT00784121|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
218820596|NCT02930148|OTHER|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
219008679|NCT01866501|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
219008680|NCT01866501|DEVICE|EZ-IO|
219008681|NCT00157950|BIOLOGICAL|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
219008682|NCT00157950|BIOLOGICAL|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
219579758|NCT02637375|DRUG|Doxorubicin|
219435735|NCT03945201|OTHER|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
219194938|NCT04341064|BEHAVIORAL|SHINE Intervention|\[see arm/group descriptions\]
219194939|NCT01726257|DEVICE|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
219763373|NCT06568172|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
219763374|NCT06568172|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219763375|NCT06568172|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219008683|NCT01516320|PROCEDURE|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
219008684|NCT01516320|PROCEDURE|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
219008685|NCT01516320|PROCEDURE|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
219008686|NCT00842686|DRUG|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
219008687|NCT03408756|DRUG|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
219194940|NCT06003608|DEVICE|Fluid biopsy capsule|Ingestion of two SIMBA capsules
219194941|NCT06003608|DRUG|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
219194942|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Auto-Injector (AI).
219194943|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
219194944|NCT04254107|DRUG|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
219194945|NCT04254107|DRUG|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
219194946|NCT04254107|DRUG|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
219579759|NCT02637375|DRUG|Cyclophosphamide|
219579760|NCT01764230|DRUG|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
219579761|NCT02307266|BEHAVIORAL|Standard of care + supplementary education|
219579762|NCT02307266|BEHAVIORAL|Standard of care + additional visits|
219579763|NCT02307266|BEHAVIORAL|Standard of care|
219579764|NCT05717504|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
219579765|NCT05717504|OTHER|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
219579766|NCT00423995|DRUG|Loratadine/montelukast combination|
219579767|NCT03098914|OTHER|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
219579768|NCT01864850|RADIATION|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
219579769|NCT01864850|RADIATION|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
219579770|NCT03034655|DEVICE|CDP|Vestibular rehabilitation using CDP
219579771|NCT03034655|DEVICE|Mobile posturography|Vestibular rehabilitation using mobile posturography
219579772|NCT03034655|OTHER|10 sessions|Vestibular rehabilitation, ten sessions
219579773|NCT03034655|OTHER|5 sessions|Vestibular rehabilitation, five sessions
219579774|NCT03867461|PROCEDURE|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
219579775|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
219579776|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
219763376|NCT06568172|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219763377|NCT06568172|OTHER|Questionnaire Administration|Ancillary studies
219763378|NCT06568172|PROCEDURE|Surgical Procedure|Undergo surgery per SOC
219763379|NCT06568172|PROCEDURE|Surgical Procedure|Undergo response-adaptive surgery
219763380|NCT03126916|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
219763381|NCT03126916|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763382|NCT03126916|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219763383|NCT03126916|DRUG|Busulfan|Given IV
219763384|NCT03126916|DRUG|Carboplatin|Given IV
219763385|NCT03126916|DRUG|Cisplatin|Given IV
219763386|NCT03126916|PROCEDURE|Computed Tomography|Undergo CT scan
219763387|NCT03126916|DRUG|Cyclophosphamide|Given IV
219763388|NCT03126916|DRUG|Dexrazoxane Hydrochloride|Given IV
219763389|NCT03126916|BIOLOGICAL|Dinutuximab|Given IV
219763390|NCT03126916|DRUG|Doxorubicin Hydrochloride|Given IV
219763391|NCT03126916|PROCEDURE|Echocardiography Test|Undergo echocardiography
218820597|NCT05358327|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
218820598|NCT01951053|DRUG|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
218820599|NCT01951053|DRUG|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
218820600|NCT01951053|DRUG|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
218820601|NCT01832727|DRUG|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
218820602|NCT01832727|DRUG|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
218820603|NCT05631444|BIOLOGICAL|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
218820604|NCT05430061|DIETARY_SUPPLEMENT|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
218820605|NCT02216526|OTHER|Cetaphil® Restoraderm|
218820606|NCT02216526|OTHER|Excipial|
218820607|NCT05918445|DRUG|PM8002|IV infusion
218820608|NCT00929266|BIOLOGICAL|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
218820609|NCT04350684|DRUG|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
218820610|NCT04350684|DRUG|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
218820611|NCT04350684|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
218820612|NCT04350684|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
218820613|NCT04350684|DRUG|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
218820614|NCT03083782|DRUG|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
218820615|NCT03083782|DRUG|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
218820616|NCT03083782|DRUG|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
218820617|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
218820618|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
218820619|NCT00749437|RADIATION|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
219008688|NCT03573895|OTHER|Foam-Roller|Application of foam roller in the posterior part of thigh.
219008689|NCT03573895|OTHER|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
219008690|NCT03573895|OTHER|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
219008691|NCT05390957|BEHAVIORAL|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
219763392|NCT03126916|DRUG|Etoposide Phosphate|Given IV
218820620|NCT03230188|OTHER|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
218820621|NCT03230188|OTHER|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
218820622|NCT03230188|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
218820623|NCT01326442|OTHER|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
218820624|NCT01326442|DIETARY_SUPPLEMENT|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
218820625|NCT04017130|DRUG|MT-0169|MT-0169 intravenous infusion.
218820626|NCT02478489|DRUG|Oral naltrexone (PO-NTX)|oral naltrexone
218820627|NCT02478489|DRUG|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
218820628|NCT04381247|DIAGNOSTIC_TEST|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
218820629|NCT02455167|DRUG|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
218820630|NCT02455167|DRUG|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
218820631|NCT02455167|DRUG|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
218820632|NCT04436744|DRUG|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
218820633|NCT04436744|DRUG|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
218820634|NCT04436744|DRUG|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
219435736|NCT03945201|OTHER|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
219435737|NCT02976545|DEVICE|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
219435738|NCT02976545|BEHAVIORAL|psychiatric evaluation|psychiatric evaluation
219435739|NCT03481504|BEHAVIORAL|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
219435740|NCT04931550|DEVICE|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
219435741|NCT00878891|DEVICE|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
219194947|NCT06804642|DEVICE|Spinal cord transcutaneous stimulation (scTS)|"scTS mapping: Each intervention session will be approximately 2 hours each which includes time to place the scTS stimulating pads and other sensors as needed. Participants will be asked to train 3 days per week during the intervention periods so that they achieve at least 12 sessions. In instances in which availability is limited or they must cancel a session, the intervention period will need to be extended slightly (up to a maximum of four weeks) so that they can achieve at least 12 sessions (1-month intervention period) or 24 sessions (2-month intervention periods) of training. The main study interventions are described below.~Step-scTS:~Step-scTS is spinal cord transcutaneous stimulation (scTS) targeted for stepping function. The scTS mapping assessment(s) will assist the study team in determining optimized stimulation parameters for each body and f"
219435742|NCT02262338|DRUG|AGT-182|Recombinant HIRMAb-IDS
219194948|NCT02839265|DRUG|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
219194949|NCT02839265|RADIATION|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
219194950|NCT04498026|DEVICE|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
219435743|NCT01599572|OTHER|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
219435744|NCT03275415|DRUG|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
219435745|NCT03275415|DRUG|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
219435746|NCT01233570|DRUG|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
219435747|NCT02668172|DRUG|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
219435748|NCT02668172|DRUG|Pegvisomant|only in combination with pasireotide LAR
219435749|NCT00290524|BEHAVIORAL|Oral alimentation started 12 hours after colorectal surgery|
219435750|NCT00291187|DRUG|20 mg VEC-162|20 mg VEC-162
219435751|NCT00291187|DRUG|50 mg VEC-162|50 mg VEC-162
219435752|NCT00291187|DRUG|100 mg VEC-162|100 mg VEC-162
219579777|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
219008692|NCT02892760|DEVICE|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
219008693|NCT00735592|OTHER|Observational|Retrospective data obtained from electronic files
219008694|NCT04867850|OTHER|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
219435753|NCT00291187|DRUG|Placebo|Placebo
219435754|NCT00114218|DRUG|Gemcitabine Hydrochloride|Given IV
219435755|NCT00114218|DRUG|Docetaxel|Given IV
219435756|NCT01927887|DRUG|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
219435757|NCT01927887|DEVICE|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
219435758|NCT00157170|BEHAVIORAL|supervised exercise|
219435759|NCT03168555|DRUG|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
219435760|NCT05666570|DEVICE|Avelle NPWT|wound management therapy
219435761|NCT02229253|DRUG|degarelix|
219435762|NCT02319408|RADIATION|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
219435763|NCT01020032|OTHER|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
219435764|NCT01782924|DRUG|KHK4827|
219435765|NCT04116216|COMBINATION_PRODUCT|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
219475407|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
219475408|NCT02844231|OTHER|Single-photon emission computed tomography|
218820635|NCT04436744|PROCEDURE|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
218820636|NCT05504499|DEVICE|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
218820637|NCT01133847|DRUG|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
218820638|NCT01133847|BEHAVIORAL|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
219435766|NCT04116216|COMBINATION_PRODUCT|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
219435767|NCT04116216|COMBINATION_PRODUCT|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
218820639|NCT01133847|BEHAVIORAL|Parent Training|Nine sessions on parenting a child with ADHD
218820640|NCT01133847|DRUG|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
218820641|NCT01133847|DRUG|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
219008695|NCT04867850|OTHER|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
219435768|NCT01040845|DRUG|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
219194951|NCT04498026|DEVICE|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
219008696|NCT04867850|OTHER|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
219008697|NCT00714454|OTHER|APS Topical Lotion|
219194952|NCT05145426|DEVICE|Low Intensity Focused Ultrasound|Application of LIFU
219194953|NCT05410587|DEVICE|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
219194954|NCT06412679|BEHAVIORAL|Life Skills Education|The RESETTLE-IDPs study compares two innovative delivery approaches for a culturally-adapted life skills education (LSE) intervention aimed at improving the mental health and well-being of internally displaced persons in Nigeria. The interventions are distinguished by their mode of delivery (in-person vs. WhatsApp-based), their focus on peer support and skill-building, and their tailoring to the specific needs and challenges of IDP populations.
219579778|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
219579779|NCT00915928|DRUG|Perindopril|2,5 mg daily for 3 months
218820642|NCT01133847|DRUG|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
218820643|NCT04430998|DRUG|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
218820644|NCT04430998|DRUG|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
218820645|NCT04430998|OTHER|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
218820646|NCT03430167|OTHER|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
218820647|NCT03430167|OTHER|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
218820648|NCT03586947|DRUG|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
218820649|NCT02539550|DRUG|Placebo|Placebo
218820650|NCT02539550|DRUG|PF-06266047|PF-06266047
218820651|NCT00335881|BIOLOGICAL|hepatitis B vaccine|
218820652|NCT01463033|DRUG|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
218820653|NCT00658268|DRUG|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
218820654|NCT00658268|DRUG|Placebo|10 ml, single dose mixed in bone graft at operation
219008698|NCT00714454|OTHER|Placebo|
219194955|NCT04465487|DRUG|REGN6569|Administered by intravenous (IV) infusion
219194956|NCT04465487|DRUG|Cemiplimab|Administered by IV infusion
218820655|NCT03950232|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
218820656|NCT04812925|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
219194957|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
219194958|NCT04560595|BEHAVIORAL|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
219435769|NCT01040845|DRUG|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
219579780|NCT00915928|DRUG|Placebo|Placebo dayli for 3 months
219579781|NCT04864405|OTHER|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
219435770|NCT01040845|DRUG|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
219435771|NCT02645461|DRUG|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
219435772|NCT02645461|DRUG|Riluzole|Riluzole 50 mg twice daily
219435773|NCT01852916|DEVICE|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
219435774|NCT01852916|DEVICE|NHFOV|Nasal High Frequency Oscillatory Ventilation
219435775|NCT02645071|BEHAVIORAL|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
219194959|NCT05533190|DEVICE|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
219194960|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
219194961|NCT05552508|COMBINATION_PRODUCT|Benralizumab|Participants will receive benralizumab subcutaneously.
219194962|NCT06077175|OTHER|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
219194963|NCT03261011|BIOLOGICAL|AK-104|Subjects will receive AK104 by intravenous administration.
218820657|NCT04222192|OTHER|Epidural block|Epidural catheter insertions
219194964|NCT05814211|DEVICE|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
219194965|NCT05814211|DEVICE|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
218820658|NCT03709901|OTHER|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
218820659|NCT03709901|OTHER|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
218820660|NCT04284709|OTHER|cognitive-physical training|combined physical and cognitive training
218820661|NCT03361488|OTHER|Trained anesthesiogist|
218820662|NCT01858727|OTHER|forced air warming group|30 minutes before the preoperative will use forced air warming
218820663|NCT01858727|OTHER|control group|do not heating group
218820664|NCT03573674|BEHAVIORAL|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
219008699|NCT00386776|OTHER|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
218820665|NCT03573674|BEHAVIORAL|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
218820666|NCT00967616|DRUG|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
219194966|NCT05814211|DEVICE|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
219435776|NCT00460681|DRUG|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
219579782|NCT04864405|OTHER|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
219579783|NCT01453894|BEHAVIORAL|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
219579784|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
219579785|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
219579786|NCT02475941|OTHER|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
219763393|NCT03126916|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219194967|NCT02772731|PROCEDURE|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
218820667|NCT00967616|DRUG|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
218820668|NCT05833711|DRUG|Froniglutide|SC Weekly Injection
218820669|NCT05833711|DRUG|Placebo|SC Weekly Injection
218820670|NCT05556889|PROCEDURE|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
218820671|NCT05556889|PROCEDURE|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
218820672|NCT04863794|DRUG|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
218820673|NCT05489471|OTHER|Artificial intelligence review|The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
218820674|NCT01368614|DEVICE|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
218820675|NCT01368614|DEVICE|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
218820676|NCT01368614|DEVICE|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
218820677|NCT02951780|DRUG|LY3185643|Administered SC
218820678|NCT02951780|DRUG|rGlucagon|Administered SC
218820679|NCT03522961|DRUG|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
218820680|NCT03522961|DRUG|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
218820681|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
218820682|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
218820683|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
219763394|NCT03126916|RADIATION|Iobenguane I-123|Given 123 I-MIBG
218820684|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
218820685|NCT01435161|DRUG|Nifedipine,|Nifedipine 30-60mg/day
219763395|NCT03126916|RADIATION|Iobenguane I-131|Given IV
219763396|NCT03126916|DRUG|Isotretinoin|Given PO
218820686|NCT01435161|DRUG|Telmisartan|Telmisartan 80-160mg/day
218820687|NCT01374425|DRUG|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
218820688|NCT01374425|DRUG|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
218820689|NCT01374425|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
218820690|NCT01374425|DRUG|Leucovorin|Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
218820691|NCT01374425|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
218820692|NCT01374425|DRUG|Capecitabine|Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
218820693|NCT04414293|RADIATION|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
218820694|NCT01245725|DRUG|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
218820695|NCT01245725|DRUG|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
218820696|NCT04804527|OTHER|Intensified physiotherapy|Physiotherapy x2
218820697|NCT04804527|OTHER|Usual care physiotherapy|Physiotherapy x1
218820698|NCT03279926|BEHAVIORAL|PLAY|Activity trackers + curriculum information
219194968|NCT02772731|PROCEDURE|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
219763397|NCT03126916|DRUG|Lorlatinib|Given PO
219763398|NCT03126916|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763399|NCT03126916|DRUG|Melphalan Hydrochloride|Given IV
218820699|NCT03279926|BEHAVIORAL|PLAY Parents|Enhanced parental engagement
218820700|NCT03279926|BEHAVIORAL|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
218820701|NCT01227057|BEHAVIORAL|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
218820702|NCT01227057|BEHAVIORAL|Case Management|Case management
218820703|NCT03152578|OTHER|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
218820704|NCT03152578|OTHER|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
218820705|NCT03152578|OTHER|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
218820706|NCT04549480|DRUG|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
218820707|NCT04549480|DRUG|Bosutinib tablet|100 mg dose of bosutinib tablet
218820708|NCT01840033|DEVICE|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
218820709|NCT01840033|DEVICE|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
218820710|NCT02752347|DEVICE|Surface EMG device|measuring the muscles activity using surface EMG device
218820711|NCT00300014|PROCEDURE|Intravitreal triamcinolone injection|
218820712|NCT00300014|PROCEDURE|Air-fluid exchange|
218820713|NCT01011114|DRUG|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
218820714|NCT01011114|DRUG|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
218820715|NCT02271529|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
218820716|NCT05986266|DRUG|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
218820717|NCT02953912|PROCEDURE|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
219763400|NCT03126916|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
218820718|NCT02953912|PROCEDURE|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
218820719|NCT03931226|DRUG|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
218820720|NCT04103021|DEVICE|Port-A-Cath|Totally implanted central venous access device
218820721|NCT01240863|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
218820722|NCT01240863|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
218820723|NCT05059886|OTHER|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
218820724|NCT03017443|BEHAVIORAL|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
218820725|NCT03017443|BEHAVIORAL|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
218820726|NCT03017443|BEHAVIORAL|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
219763401|NCT03126916|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219763402|NCT03126916|BIOLOGICAL|Sargramostim|Given SC
219194969|NCT06466980|OTHER|Ventilator associated event|Measure of incidence of Ventilator associated event
219435777|NCT05570799|OTHER|Augmented Reality and Kahoot game learning|"* An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
218820727|NCT03017443|BEHAVIORAL|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
218820728|NCT03224039|DRUG|Sufentanil|Intranasal for one dose (experimental)
218820729|NCT03224039|DRUG|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
218820730|NCT03224039|DRUG|Morphine|intravenous push for one dose (active comparator)
218820731|NCT01419119|DRUG|Cholecalciferol high dose at Vitamin D deficiency|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
218820732|NCT01419119|DRUG|Cholecalciferol median dose at Vitamin D insufficiency|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
218820733|NCT01419119|DRUG|Cholecalciferol low dose at Vitamin D deficiency|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
218820734|NCT01419119|DRUG|Cholecalciferol median dose at sufficient Vitamin D level|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
219435778|NCT04709913|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
219763403|NCT03126916|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219763404|NCT03126916|DRUG|Thiotepa|Given IV
219763405|NCT03126916|DRUG|Topotecan Hydrochloride|Given IV
219763406|NCT03126916|DRUG|Vincristine Sulfate|Given IV
218820735|NCT03783780|DEVICE|INVSENSOR00031|Noninvasive pulse oximeter sensor
218820736|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
218820737|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
218820738|NCT03768427|DRUG|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
218820739|NCT03768427|DRUG|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
218820740|NCT03768427|DRUG|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
218820741|NCT03358602|RADIATION|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
218820742|NCT03358602|PROCEDURE|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
218820743|NCT01440361|DRUG|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
218820744|NCT01440361|DRUG|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
219194970|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
219435779|NCT04965116|DRUG|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
219435780|NCT02708966|DRUG|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
219435781|NCT02708966|DRUG|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
219435782|NCT03377569|OTHER|Sleep, PD and DBS|Sleep, PD and DBS
218820745|NCT02031406|OTHER|Post-discharge counseling on medication adherence & literacy|
218820746|NCT00499668|DRUG|aprepitant|125 mg orally for 7 days
218820747|NCT00499668|DRUG|ondansetron hydrochloride|24 mg orally for 7 days
218820748|NCT03537443|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
219435783|NCT01515488|OTHER|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
219435784|NCT01515488|OTHER|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
219435785|NCT02714023|PROCEDURE|Normal Saline|Intra-operative irrigation with normal saline
219435786|NCT02714023|PROCEDURE|Sterile Water|Intra-operative irrigation with sterile water
219435787|NCT02687607|DEVICE|WEB Aneurysm Embolization System|
219763407|NCT05513378|DEVICE|Needle guide|Please see the arm/group description
219763408|NCT05645380|DRUG|Carboplatin|AUC=6, IV
219763409|NCT05645380|DRUG|Docetaxel|75 mg/m2, IV
219763410|NCT05645380|DRUG|Doxorubicin|60 mg/m2, IV
219763411|NCT05645380|DRUG|Cyclophosphamide|600 mg/m2, IV
219763412|NCT05645380|DRUG|Pembrolizumab|200 mg, IV
219763413|NCT06052826|OTHER|Best Practice|Undergo standard of care
219763414|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
219763415|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
219763416|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
218820749|NCT03037125|PROCEDURE|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
218820750|NCT03037125|PROCEDURE|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
218820751|NCT02710877|DEVICE|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
219008700|NCT02552563|BEHAVIORAL|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
219194971|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
218820752|NCT02710877|OTHER|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
218820753|NCT02710877|DRUG|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
218820754|NCT02710877|DRUG|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
218820755|NCT02710877|DRUG|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
218820756|NCT03160625|DEVICE|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
218820757|NCT03517670|OTHER|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
218820758|NCT03517670|OTHER|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
218820759|NCT03517670|OTHER|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
218820760|NCT03517670|OTHER|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
218820761|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
218820762|NCT01341743|DRUG|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
218820763|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
219194972|NCT05947331|PROCEDURE|Graded Anderson procedure|In graded Anderson proceduren only recession of yoke muscles is done.
219194973|NCT05947331|PROCEDURE|Kestenbaum procedure|In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
218820764|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
218820765|NCT02742129|DRUG|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
219008701|NCT01500629|DEVICE|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
219008702|NCT01500629|DEVICE|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
219008703|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
219435788|NCT04571476|PROCEDURE|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
219435789|NCT04571476|PROCEDURE|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
219435790|NCT04571476|PROCEDURE|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
219435791|NCT04571476|PROCEDURE|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
219435792|NCT04735809|DIETARY_SUPPLEMENT|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
219435793|NCT04735809|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
219435794|NCT02959190|DRUG|Galcanezumab|Administered SC
219435795|NCT02023268|DEVICE|T2762|1 drop in each eye 3 to 6 times daily during 84 days
218820766|NCT02742129|DRUG|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
218820767|NCT02448966|PROCEDURE|open esophagectomy|
218820768|NCT02448966|PROCEDURE|Minimally invasive esophagectomy|
218820769|NCT02747758|DEVICE|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
218820770|NCT02747758|DEVICE|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
218820771|NCT02747758|DEVICE|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
218820772|NCT02527395|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
218820773|NCT02527395|OTHER|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
218820774|NCT02527395|OTHER|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
218820775|NCT00518050|BEHAVIORAL|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
218820776|NCT00518050|BEHAVIORAL|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
218820777|NCT00002372|DRUG|Indinavir sulfate|
218820778|NCT00002372|DRUG|Amprenavir|
218820779|NCT00002372|DRUG|Nelfinavir mesylate|
218820780|NCT00002372|DRUG|Saquinavir|
218820781|NCT02959788|OTHER|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
218820782|NCT02775266|OTHER|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
218820783|NCT02775266|PROCEDURE|Scaling and Root planing|Scaling and root planing will be done at baseline.
218820784|NCT02008643|OTHER|filling questionnary to quality of life|filling questionnary to quality of life
218820785|NCT02873078|BEHAVIORAL|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
219008704|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
219008705|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
219008706|NCT02105792|DRUG|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
219008707|NCT05704608|OTHER|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
219435796|NCT02023268|DEVICE|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
219763417|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
219763418|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
218820786|NCT02803684|OTHER|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
218820787|NCT03225404|OTHER|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
218820788|NCT03225404|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
218820789|NCT02874092|DRUG|Ticagrelor|
218820790|NCT02874092|DRUG|MTX therapy|
218820791|NCT03582579|BEHAVIORAL|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
218820792|NCT03582579|BEHAVIORAL|Training on a computer screen|Action Video Game Based Training on a computer screen
218820793|NCT06187857|BEHAVIORAL|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
218820794|NCT02286063|DRUG|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
218820795|NCT03499756|BEHAVIORAL|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
218820796|NCT02693756|OTHER|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
218820797|NCT03810976|DRUG|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
218820798|NCT03780257|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
218820799|NCT03780257|OTHER|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
218820800|NCT05663060|DRUG|Probiotic Formula|Probiotic Formula
218820801|NCT01974284|DRUG|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
218820802|NCT02194413|PROCEDURE|therapeutic touch|receiving healing touch
218820803|NCT02194413|OTHER|quality-of-life assessment|Ancillary studies
219194974|NCT06058910|DIAGNOSTIC_TEST|Bilistick System 2.0 point-of-care testing device|The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
218820804|NCT02194413|OTHER|questionnaire administration|Ancillary studies
218820805|NCT00677794|DRUG|Clear fluids|Clear fluids only after lunch.
218820806|NCT00677794|DRUG|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
218820807|NCT00677794|DRUG|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
218820808|NCT03986957|OTHER|No interventions|No interventions - observational study
218820809|NCT01777867|PROCEDURE|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
218820810|NCT01777867|PROCEDURE|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
218820811|NCT02629861|DRUG|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
218820812|NCT02629861|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
218820813|NCT00685061|DRUG|Thymoglobulin|Induction
218820814|NCT00685061|DRUG|Campath-1H|Induction
218820815|NCT00685061|DRUG|Daclizumab|Induction
218820816|NCT03722979|PROCEDURE|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
218820817|NCT01090947|DEVICE|ProtoCAD|Aquiring acoustic signals from heart patients.
218820818|NCT05225909|DEVICE|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
219763419|NCT04735185|OTHER|Autologous stem cells|In this intervention participants will receive a 2 mL intradiscal injection into each affected disc of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium.
218820819|NCT01272427|DIETARY_SUPPLEMENT|water with glucose|0.75 g/kg body weight of glucose added to water
218820820|NCT01272427|DIETARY_SUPPLEMENT|water and whey protein|0.75 g/kg body weight of whey protein added to water
218820821|NCT01272427|DIETARY_SUPPLEMENT|water with noncaloric sweetener|0.15 g of sucralose added to water
218820822|NCT03627702|RADIATION|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
218820823|NCT01685684|DRUG|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
218820824|NCT01685684|DRUG|Placebo|Placebo, divided into 2 doses, q12h
218820825|NCT00907621|PROCEDURE|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
218820826|NCT00606489|DRUG|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
218820827|NCT00606489|DRUG|Placebo|Placebo
218820828|NCT06511583|PROCEDURE|Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
218820829|NCT06511583|PROCEDURE|Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department|"Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
218820830|NCT05815914|OTHER|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
219008708|NCT00588848|DEVICE|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
219194975|NCT01917084|OTHER|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
219194976|NCT04227288|DRUG|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
219194977|NCT03707808|DRUG|intratumoral injection of autologous CD1c (BDCA-1)+ myDC|intratumoral injections plus intravenous administration
219194978|NCT03707808|DRUG|Intratumoral injection of ipilimumab and AS01b|Intratumoral injection of ipilimumab and AS01b
219194979|NCT03707808|DRUG|IV nivolumab|Nivolumab administered intravenously
219194980|NCT03938246|DRUG|TVB-2640 25 mg (US)|Oral dose, tablet, daily dosing
219435797|NCT00299416|DRUG|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
219763420|NCT04735185|DRUG|Corticosteroid|In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
219008709|NCT00588848|DEVICE|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
219435798|NCT00299416|PROCEDURE|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
219194981|NCT03938246|DRUG|TVB-2640 50 mg (US)|Oral dose, tablet, daily dosing
218820831|NCT05815914|OTHER|control group|Routine nutritional and dietary recommendations will be given.
218820832|NCT00902330|PROCEDURE|energy-based therapy|Given once a day for 18 weeks
218820833|NCT00902330|PROCEDURE|sham intervention|Given once a day for 18 weeks
218820834|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
219008710|NCT02902965|DRUG|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
219008711|NCT02902965|DRUG|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
219194982|NCT03938246|DRUG|Placebo (US)|Oral dose, tablet, daily dosing
219194983|NCT03938246|DRUG|TVB-2640 50 mg (China)|Oral dose, tablet, daily dosing
219194984|NCT03938246|DRUG|Placebo (China)|Oral dose, tablet, daily dosing
219194985|NCT03938246|DRUG|TVB-2640 75 mg (US)|Oral dose, tablet, daily dosing
219194986|NCT05500690|DIETARY_SUPPLEMENT|Folic Acid Tablet|5 mg folic acid supplement
219194987|NCT06109805|OTHER|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
219194988|NCT05379348|OTHER|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
219194989|NCT04451772|DRUG|Elsubrutinib|Capsule; Oral
219194990|NCT04451772|DRUG|Placebo for Elsubrutinib|Capsule; Oral
219194991|NCT04451772|DRUG|Upadacitinib|Film-coated tablet; Oral
219194992|NCT04451772|DRUG|Placebo for Upadacitinib|Film-coated tablet; Oral
219194993|NCT06206486|OTHER|no intervention, observational|This study is observational. No intervention description available.
219194994|NCT00708448|RADIATION|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
219194995|NCT00708448|DRUG|Erlotinib|150 mg/day
219194996|NCT00708448|DRUG|Bevacizumab|15mg/kg q 21 days
219194997|NCT06377917|OTHER|Laser Assisted Hatching|Routine assisted hatching procedure will be performed on both groups at the different embryo developmental phases.
219194998|NCT06305013|OTHER|Pulseless electrical activity recognition|The ability of nurses to recognize the pulseless electrical activity in the questionnaire (electronic survey)
219194999|NCT01678872|DRUG|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
219195000|NCT04863261|OTHER|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
219195001|NCT03852758|BEHAVIORAL|Outdoor Exercise|2 outdoor exercise sessions per week
219195002|NCT03852758|BEHAVIORAL|Indoor Exercise|2 indoor exercise sessions per week
219763421|NCT04735185|DRUG|Local anesthetic|In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
219195003|NCT06350981|DRUG|Exparel|20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine
219008712|NCT02902965|DRUG|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
219008713|NCT02673489|DRUG|DCV|
218820835|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
219008714|NCT02673489|DRUG|SOF|
219195004|NCT06350981|DRUG|Bupivacain|Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
219008715|NCT02673489|DRUG|RBV|
218820836|NCT01911455|DRUG|acamprosate|
218820837|NCT01911455|DRUG|Placebo|
219008716|NCT00293254|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
219435799|NCT05812768|DEVICE|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
219435800|NCT03791268|PROCEDURE|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
219435801|NCT02331641|PROCEDURE|Hepatectomy|Removal of a part of the liver
219435802|NCT05768542|DRUG|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
218820838|NCT06543485|PROCEDURE|intramedullary screw fixation of metacarpal fractures|intramedullary screw fixation of metacarpal fractures through limited open approach
218820839|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
218820840|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
218820841|NCT03785184|DRUG|venetoclax|tablet; oral
218820842|NCT03785184|DRUG|lenalidomide|capsule; oral
218820843|NCT03785184|DRUG|dexamethasone|tablet; oral
218820844|NCT06328842|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218820845|NCT06328842|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
218820846|NCT00165789|DRUG|E2007|
219008717|NCT00293254|DRUG|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
219008718|NCT00066950|DRUG|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
219008719|NCT00066950|DEVICE|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
219008720|NCT02335489|DEVICE|Implantation with the commercially available Axium neurostimulator|
219008721|NCT02259582|DRUG|Pemetrexed|
219008722|NCT02259582|DRUG|Carboplatin|
219008723|NCT02259582|DRUG|demcizumab|
219008724|NCT04850131|PROCEDURE|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
219195005|NCT04832958|DRUG|99m-TC-PSMA-I&S|"* 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
219195006|NCT05730621|DRUG|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
219195007|NCT05730621|DRUG|Aspirin|Aspirin 100mg qd for 12 weeks
219195008|NCT05463913|DRUG|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
219195009|NCT05463913|RADIATION|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
219195010|NCT04789551|OTHER|Blood Sample|a blood sample will be collected
219195011|NCT06212791|BEHAVIORAL|Self- Report Evaluation-Duke Activity Status Index|Complete the Self- Report Evaluation-Duke Activity Status Index
219195012|NCT06212791|BEHAVIORAL|Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire|Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
219195013|NCT06212791|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise test (CPET)
219579787|NCT02475941|OTHER|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
218820847|NCT03544450|BEHAVIORAL|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
218820848|NCT03544450|OTHER|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
218820849|NCT00002414|DRUG|CPI-1189|
218820850|NCT03732989|DEVICE|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
218820851|NCT03732989|DEVICE|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
218820852|NCT03776084|DEVICE|Continuous Positive Airway Pressure|CPAP indication
218820853|NCT02001129|BEHAVIORAL|Automated Telephone System|Participants receive automated reminder phone calls.
218820854|NCT02001129|BEHAVIORAL|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
218820855|NCT02001129|BEHAVIORAL|Usual Care|Participants receive a standard reminder letter in the mail.
218820856|NCT05930080|DRUG|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
218820857|NCT05930080|DRUG|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
218820858|NCT01816048|DRUG|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
218820859|NCT01816048|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
218820860|NCT01816048|PROCEDURE|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
218820861|NCT01816048|PROCEDURE|Computed Tomography|Undergo 18F NaF PET/CT scan
218820862|NCT03625076|DRUG|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
218820863|NCT03625076|DRUG|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
218820864|NCT02663310|PROCEDURE|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
218820865|NCT02663310|PROCEDURE|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
218820866|NCT02692573|OTHER|positioning|prone positioning for the initial 5 minutes of life
218820867|NCT02692573|OTHER|positioning|supine positioning for the initial 5 minutes of life
219195014|NCT06212791|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
219195015|NCT06212791|DIAGNOSTIC_TEST|Ambulatory cardiac rhythm assessment|Ambulatory cardiac rhythm assessment
219195016|NCT06212791|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
219579788|NCT02279693|OTHER|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
219579789|NCT02279693|OTHER|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
219579790|NCT02279693|RADIATION|IGRT Associated With IMRT|
219195017|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
219195018|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
219195019|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
219195020|NCT06646055|DRUG|AK112, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
219195021|NCT06646055|DRUG|nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
219579791|NCT04299906|DEVICE|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
219579792|NCT05425693|OTHER|Hybrid Warm-up|Dynamic + stretching exercises
219579793|NCT05425693|OTHER|Dynamic Warm-up|Dynamic exercises
218820868|NCT03089814|PROCEDURE|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
218820869|NCT00197821|BIOLOGICAL|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
219579794|NCT05425693|OTHER|Stretching Warm-up|Stretching exercises
218820870|NCT02145936|OTHER|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
218820871|NCT02327767|DEVICE|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
218820872|NCT04620161|DRUG|Pradigastat Tablets 20mg|20mg, once daily, oral administration
218820873|NCT04620161|DRUG|Pradigastat Tablets 40mg|40mg, once daily, oral administration
219008725|NCT00243789|DRUG|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
219008726|NCT05070117|BEHAVIORAL|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
219008727|NCT04413409|PROCEDURE|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
219008728|NCT02680743|OTHER|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
219195022|NCT06308575|DRUG|Rivoceranib|Given by PO
219195023|NCT05910411|DEVICE|Inelastic compression|Inelastic compression used in the treatment of lymphedema
218820874|NCT04620161|DRUG|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
218820875|NCT04620161|DRUG|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
218820876|NCT03751397|OTHER|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
218820877|NCT03751397|OTHER|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
218820878|NCT04042805|BIOLOGICAL|Sintilimab|200mg intravenously every 3 weeks
218820879|NCT04042805|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
218820880|NCT00267930|DRUG|Vernakalant (oral)|
219195024|NCT06167213|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
218820881|NCT00267930|DRUG|Placebo comparator|
218820882|NCT04077177|BEHAVIORAL|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
219195025|NCT05717400|DRUG|Bevacizumab|Given by vein (IV)
219195026|NCT05717400|DRUG|Atezolizumab|Given by vein (IV)
219195027|NCT05717400|DRUG|Sofosbuvir|Given by PO
219195028|NCT05717400|DRUG|Velpatasvir|Given by PO
219195029|NCT05717400|DRUG|Voxilaprevir|Given by PO
219195030|NCT05717400|DRUG|Ribavirin|Given by PO
219195031|NCT05505825|DRUG|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
219195032|NCT06163274|DEVICE|Placebo Intravaginal Ring A|Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.
219435803|NCT05768542|DRUG|Saline|5 ml given IV
219435804|NCT05141734|DIAGNOSTIC_TEST|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
219435805|NCT01045928|DRUG|lenalidomide|Given orally
219435806|NCT01045928|BIOLOGICAL|rituximab|Given IV
219435807|NCT01045928|GENETIC|polymerase chain reaction|Correlative study
219435808|NCT01045928|GENETIC|nucleic acid sequencing|Correlative study
219435809|NCT01045928|GENETIC|polymorphism analysis|Correlative study
219435810|NCT01045928|OTHER|flow cytometry|Correlative study
219435811|NCT01045928|OTHER|laboratory biomarker analysis|Correlative study
219435812|NCT04732572|BEHAVIORAL|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
219195033|NCT06163274|DEVICE|Placebo Intravaginal Ring B|Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
219195034|NCT01895842|DRUG|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
219195035|NCT03631290|BEHAVIORAL|Deprescribing Intervention|"The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months."
219195036|NCT06342141|DRUG|Empagliflozin 25 milgrams (Mg)|Load dose
219435813|NCT04732572|OTHER|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
219195037|NCT06342141|DRUG|Empagliflozin 10 Mg|Maintenance dose
219195038|NCT06153212|PROCEDURE|Membrane placement with bone grafting|The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
219195039|NCT05101863|BEHAVIORAL|Motivational interviewing|MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.
219195040|NCT05920889|DRUG|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
219195041|NCT05268081|OTHER|Virtual specialist conferences|"The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min)."
219195042|NCT02828358|DRUG|Azacitidine|Given IV
218820883|NCT02018120|PROCEDURE|connective tissue graft|
218820884|NCT02018120|PROCEDURE|platelet rich fibrin|
218820885|NCT02598037|DIETARY_SUPPLEMENT|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
218820886|NCT05626491|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
218820887|NCT05626491|DEVICE|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
218820888|NCT04445662|BEHAVIORAL|Financial incentives|Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
218820889|NCT04445662|DRUG|Varenicline|"* Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement"
218820890|NCT04445662|BEHAVIORAL|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
219008729|NCT05618964|OTHER|Deep Neck Flexors & Extensors exercises|"Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
218820891|NCT05161871|DEVICE|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
218820892|NCT05161871|DEVICE|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
218820893|NCT02999009|DEVICE|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
218820894|NCT04832698|OTHER|Survey Administration|Complete survey
219195043|NCT02828358|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219195044|NCT02828358|PROCEDURE|Computed Tomography|Undergo CT scan
219195045|NCT02828358|DRUG|Cyclophosphamide|Given IV
219195046|NCT02828358|DRUG|Cytarabine|Given IV, SC, IT
219195047|NCT02828358|DRUG|Daunorubicin|Given IV
219195048|NCT02828358|DRUG|Daunorubicin Hydrochloride|Given IV
219195049|NCT02828358|DRUG|Dexamethasone|Given PO, NG, IV
219195050|NCT02828358|PROCEDURE|Echocardiography|Undergo ECHO
219195051|NCT02828358|DRUG|Hydrocortisone Sodium Succinate|Given IT
219195052|NCT02828358|DRUG|Leucovorin|Given PO, IV
218820895|NCT06560944|DRUG|Combined oral contraceptive pill|Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
218820896|NCT00425620|DRUG|SinuNase|Lavage
218820897|NCT02020161|DRUG|Atra|
219008730|NCT00531050|DRUG|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
219008731|NCT00531050|DRUG|Placebo|Single dose indacaterol matching placebo via Concept 1 device
219008732|NCT00531050|DRUG|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
219008733|NCT00369993|DRUG|fluticasone propionate/salmeterol|
219008734|NCT01067456|RADIATION|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
219008735|NCT02233309|OTHER|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
219008736|NCT01411696|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
219008737|NCT05651633|DRUG|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
219195053|NCT02828358|DRUG|Leucovorin Calcium|Given PO, IV
219195054|NCT02828358|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219195055|NCT02828358|DRUG|Mercaptopurine|Given PO, NG
219579795|NCT05579483|DIETARY_SUPPLEMENT|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
219008738|NCT04960150|DEVICE|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
219008739|NCT04960150|DEVICE|Plesterin|Plesterin
219008740|NCT01509833|DRUG|rFSH|Administration of rFSH for ovarian stimulation.
219008741|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
219008742|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
219008743|NCT04502953|PROCEDURE|Vertical plication|Vertical plication of the rectovaginal septum was done
219195056|NCT02828358|DRUG|Methotrexate|Given IT, IV, PO
219579796|NCT05579483|DIETARY_SUPPLEMENT|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
218820898|NCT02020161|DRUG|Idarubicin|
219008744|NCT04502953|PROCEDURE|Horizontal plication|Horizontal plication of the rectovaginal septum was done
219008745|NCT05738161|DRUG|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
219008746|NCT05738161|DRUG|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
219008747|NCT05738161|DRUG|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
219008748|NCT01151644|BIOLOGICAL|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
219579797|NCT00006438|DEVICE|Shoes with Rocker Soles|
218820899|NCT02020161|DRUG|methotrexate|
218820900|NCT05970328|DEVICE|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
218820901|NCT02998190|DRUG|Single Ascending Doses of EB8018|
218820902|NCT02998190|DRUG|Single Ascending Doses of placebo|
218820903|NCT02998190|DRUG|Multiple Ascending Doses of EB8018|
218820904|NCT02998190|DRUG|Multiple Ascending Doses of placebo|
218820905|NCT00601367|DRUG|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
219008749|NCT00232817|DRUG|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
219195057|NCT02828358|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219195058|NCT02828358|DRUG|Pegaspargase|Given IV
219195059|NCT02828358|DRUG|Prednisolone|Given PO, NG
219195060|NCT02828358|DRUG|Thioguanine|Given PO, NG
219195061|NCT02828358|DRUG|Vincristine|Given IV
219195062|NCT02828358|DRUG|Vincristine Sulfate|Given IV
219195063|NCT06407297|DRUG|UCMSCs|Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
219195064|NCT06407297|DRUG|Placebo|Peripheral intravenous infusion of Placebo
219195065|NCT05268276|OTHER|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
219195066|NCT05268276|OTHER|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
218820906|NCT04829513|PROCEDURE|Home Exercise|This is a home exercise programme that involves flexibility and strengthening of the waist, hip girdle and sacroiliac region. These exercises are first shown by the physiotherapist in hospital, and then they are asked to do the exercises at home using illustrated forms. Patients continue the exercises as a home programme once a day for 1 month.
218820907|NCT04829513|PROCEDURE|Ligament Correction Kinesiotaping|Ligament correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
218820908|NCT04829513|PROCEDURE|Lymphatic Correction Kinesiotaping|Lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
218820909|NCT00656370|DRUG|recombinant human hyaluronidase|150 Units in 1mL
218820910|NCT01445275|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
218820911|NCT01445275|OTHER|Medical Chart Review|Ancillary study
218820912|NCT01445275|OTHER|Study of Socioeconomic and Demographic Variables|Ancillary studies
218820913|NCT00646386|DRUG|adalimumab|40 mg eow Week 0 - Week 24
218820914|NCT00646386|DRUG|placebo for adalimumab|40 mg eow Week 0 - Week 24
218820915|NCT00285571|BEHAVIORAL|Controlled Feeding Intervention|
219195067|NCT05268276|OTHER|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
218820916|NCT03953807|DRUG|Dexamethasone Intravitreal Implant|Implant 700 μg
218820917|NCT01816984|DRUG|PI3K inhibitor BKM120|Given PO
218820918|NCT01816984|BIOLOGICAL|cetuximab|Given IV
218820919|NCT03833141|OTHER|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
218820920|NCT02266160|DRUG|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
218820921|NCT02266160|OTHER|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
218820922|NCT05688969|OTHER|early versus late biopsy|early (3-6 weeks) versus late (6-8 months) biopsy
219195068|NCT06520423|PROCEDURE|Urethral stent tube irrigation|During urethroplasty, a Fr3 ureteral catheter will be placed in the reconstructed urethra, with the proximal end extending approximately 2 cm beyond the urethral wound. The distal end will connect to an F6 single-lumen ureter and a urinary bag. On the second postoperative day, the urethra will be irrigated with 5 ml of saline twice daily. This irrigation routine will continue until the catheter is removed.
218820923|NCT00309218|DRUG|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
218820924|NCT01170351|DRUG|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
218820925|NCT01342094|DRUG|DE-111 ophthalmic solution|
218820926|NCT01342094|DRUG|Timolol ophthalmic solution 0.5%|
218820927|NCT01342094|DRUG|Placebo ophthalmic solution|
218820928|NCT01147302|BIOLOGICAL|Placebo|
218820929|NCT01147302|BIOLOGICAL|C1 Esterase Inhibitor (Human)|
218820930|NCT00281593|DRUG|Telmisartan|
218820931|NCT00281593|DRUG|Ramipril|
218820932|NCT03375099|BEHAVIORAL|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
218820933|NCT03375099|BEHAVIORAL|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
218820934|NCT04052009|OTHER|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
218820935|NCT04052009|OTHER|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
218820936|NCT04052009|OTHER|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
218820937|NCT01321814|BEHAVIORAL|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
218820938|NCT01061528|DRUG|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
218820939|NCT02070653|DRUG|Ticagrelor|
218820940|NCT02070653|DRUG|Placebo|
218820941|NCT02121509|DRUG|Linagliptin|1 x Linagliptin tablet
218820942|NCT02121509|DRUG|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
218820943|NCT02121509|DRUG|Metformin ER|3 x Metformin ER tablets
218820944|NCT04713189|DRUG|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
218820945|NCT04713189|DRUG|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
218820946|NCT04784156|PROCEDURE|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
219195069|NCT06520423|PROCEDURE|Urinary catheter drainage|During urethroplasty, intraurethral retention of urethral catheters is used to drain urine from the bladder.
218820947|NCT04784156|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
218820948|NCT01172028|DRUG|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
218820949|NCT01172028|DRUG|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
218820950|NCT01600287|OTHER|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
218820951|NCT01600287|OTHER|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
218820952|NCT03111030|BEHAVIORAL|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~1. An assessment of motivated the participant is to be physically active~2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~   B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~3. Progress and barriers will be reassessed and discussed."
219008750|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
219008751|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
219008752|NCT03864211|PROCEDURE|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
219008753|NCT03864211|DRUG|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
219008754|NCT05527145|PROCEDURE|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
219195070|NCT05958537|DEVICE|High flow nasal oxygen|Use of High-flow nasal oxygen at 60% 50 L/min.
219579798|NCT02470390|DRUG|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
219579799|NCT05157867|OTHER|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
219008755|NCT05527145|PROCEDURE|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
219008756|NCT03867929|OTHER|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
219008757|NCT04481750|DRUG|MT-1186|Solution or suspension
219008758|NCT04481750|DRUG|MT-1186-matching placebo|Solution or suspension
219008759|NCT02197507|DEVICE|Digitized sensor|Measure of grip strength of the dominant hand
219195071|NCT06359587|BEHAVIORAL|Laboratory test overuse (LTO) Bundle|"Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc."
219579800|NCT05157867|OTHER|Placebo|Intraduodenal administration of placebo (physiological saline).
219579801|NCT02766374|BEHAVIORAL|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
219195072|NCT05395299|PROCEDURE|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
219579802|NCT02766374|BEHAVIORAL|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
218820953|NCT02515318|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
218820954|NCT02515318|DRUG|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
219579803|NCT01006226|DRUG|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
219579804|NCT01338948|PROCEDURE|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
219579805|NCT03758404|BIOLOGICAL|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
218820955|NCT05556434|DIAGNOSTIC_TEST|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
218820956|NCT00619996|DRUG|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
218820957|NCT00619996|DRUG|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
219008760|NCT06147310|PROCEDURE|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
219008761|NCT06147310|PROCEDURE|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
219008762|NCT04316754|OTHER|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
219008763|NCT03263442|DRUG|Thiamine|200 mg IV three times daily for seven days
219008764|NCT03263442|DRUG|Normal saline|Normal saline IV three times daily for seven days
219008765|NCT02579850|DRUG|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
219008766|NCT02579850|DRUG|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
219008767|NCT02579850|PROCEDURE|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
219008768|NCT02579850|OTHER|COPD assessment test|COPD assessment test (CAT) at visit 1
219008769|NCT02579850|PROCEDURE|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
219008770|NCT02579850|OTHER|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
219008771|NCT02579850|OTHER|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
219008772|NCT02890706|DEVICE|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
219008773|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
219008774|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237 mL
219008775|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
219195073|NCT05766943|DEVICE|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
219579806|NCT02875158|PROCEDURE|Cyclophotocoagulation protocol|"* Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
218820958|NCT03703388|DIETARY_SUPPLEMENT|Arctigenin|Arctigenin capsule
218820959|NCT05311514|BIOLOGICAL|Allogeneic platelet lysate eye drops|Eye drops
219195074|NCT05766943|DEVICE|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
219195075|NCT05825742|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
219195076|NCT05825742|OTHER|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
219195077|NCT05099133|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
219195078|NCT05099133|DRUG|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
219579807|NCT02875158|PROCEDURE|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
219579808|NCT02875158|PROCEDURE|Modified cyclophotocoagulation|2000 mW for 2 seconds.
219579809|NCT00226421|DRUG|Oxymorphone Extended Release|
219579810|NCT04746911|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
219579811|NCT04551833|DRUG|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
219579812|NCT02648295|PROCEDURE|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
219579813|NCT00684489|DRUG|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
219579814|NCT00684489|DRUG|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
219579815|NCT05802251|DIAGNOSTIC_TEST|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
219008776|NCT04384666|DRUG|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
219008777|NCT04384666|OTHER|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
219579816|NCT00222989|DRUG|PPI|
219579817|NCT04094376|OTHER|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
219008778|NCT03917108|DEVICE|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
219008779|NCT03917108|DEVICE|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
219008780|NCT04445324|BEHAVIORAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
219008781|NCT04445324|OTHER|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
219579818|NCT03420664|DEVICE|Orthosis VACOped|Orthosis for lower limb immobilisation
219579819|NCT03420664|DEVICE|Below knee cast|Below knee cast for lower limb immobilisation
219579820|NCT00006239|DRUG|sodium phenylbutyrate|
219579821|NCT00006239|DRUG|tretinoin|
219579822|NCT02064114|PROCEDURE|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
219579823|NCT02064114|PROCEDURE|control group|Followed for a period of 3,6 and 12 months after the procedure.
219579824|NCT00060138|BIOLOGICAL|monoclonal antibody CAL|
219579825|NCT00060138|DRUG|zoledronic acid|
219579826|NCT06486961|DEVICE|BeatMove Application|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
219579827|NCT06486961|DEVICE|BeatMove Application without synchronized music|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
218820960|NCT02350218|DRUG|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
219195079|NCT04784494|DEVICE|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219195080|NCT04804540|DRUG|Vedolizumab IV|Vedolizumab IV infusion
218820961|NCT04021290|DRUG|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
218820962|NCT04021290|DRUG|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
218820963|NCT00636181|DEVICE|Auto AFlex|Positive pressure therapy treatment
218820964|NCT00636181|DEVICE|Auto CPAP|Positive pressure therapy treatment
218820965|NCT00636181|DEVICE|CPAP|Positive pressure therapy treatment
218820966|NCT04818905|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
218820967|NCT04818905|OTHER|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
218820968|NCT05477654|DIAGNOSTIC_TEST|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
218820969|NCT03820011|OTHER|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
218820970|NCT04188951|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
218820971|NCT05248490|OTHER|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
218820972|NCT02046018|OTHER|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
218820973|NCT02046018|OTHER|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
218820974|NCT02046018|OTHER|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
218820975|NCT06566014|OTHER|Evaluation of XAI-assisted spina bifida diagnosis|AI feedback
218820976|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
218820977|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
218820978|NCT04224701|BIOLOGICAL|Placebo|Tris NaCl Diluent
218820979|NCT04476576|BEHAVIORAL|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
218820980|NCT04476576|BEHAVIORAL|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
218820981|NCT05015504|BEHAVIORAL|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
218820982|NCT03069716|DEVICE|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
218820983|NCT03069716|DEVICE|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
219195081|NCT03340675|DRUG|Ifetroban|Weight based, once daily oral ifetroban
219195082|NCT03340675|DRUG|Placebo|Matching oral placebo
219195083|NCT05172232|DIAGNOSTIC_TEST|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
218820984|NCT06503185|BEHAVIORAL|Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
219008782|NCT03344432|DIAGNOSTIC_TEST|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
219008783|NCT03344432|DIAGNOSTIC_TEST|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
219008784|NCT02045706|OTHER|Community Health Worker Trainings|
219008785|NCT00475176|DRUG|Peginterferon alfa-2a|
219008786|NCT00475176|DRUG|Ribavirin|
219435814|NCT04732572|PROCEDURE|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
219195084|NCT05332613|BEHAVIORAL|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
219195085|NCT05332613|BEHAVIORAL|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
219195086|NCT05332613|BEHAVIORAL|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
218820985|NCT05437419|DRUG|TCK-276|Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
218820986|NCT05437419|DRUG|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
219195087|NCT06198725|DIETARY_SUPPLEMENT|Trimtab|High fiber group will take Trimtab (a kind of multi bran and high fiber grain compound powder) 60g per day to intake 28g dietary fiber for 12 weeks.
219195088|NCT03740282|DEVICE|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
219579828|NCT06486961|DEVICE|BeatMove Application without music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
219579829|NCT03047798|DRUG|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
219579830|NCT00147953|DRUG|Rituximab|
219579831|NCT00147953|PROCEDURE|Total nodal irradiation|
219579832|NCT00022542|DRUG|ixabepilone|Given IV
218820987|NCT05076045|DEVICE|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
218820988|NCT03014804|BIOLOGICAL|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
218820989|NCT03014804|OTHER|Laboratory Biomarker Analysis|Correlative studies
218820990|NCT03014804|BIOLOGICAL|Nivolumab|Given IV
218820991|NCT03014804|OTHER|Quality-of-Life Assessment|Ancillary studies
218820992|NCT03014804|OTHER|Questionnaire Administration|Ancillary studies
218820993|NCT03391882|DRUG|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
219008787|NCT00475176|DRUG|S-adenosyl methionine for Chronic Liver Disease|
219008788|NCT01725438|OTHER|sample blood|
219008789|NCT02178631|BEHAVIORAL|Deprexis|Online self-help
219008790|NCT02178631|OTHER|CAU|Care as usual
219008791|NCT03785665|DEVICE|MDI|Capsule MD1 (Motility dummy 1)
219008792|NCT03899142|BIOLOGICAL|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
219008793|NCT03520231|DRUG|Denosumab|RANK Ligand Inhibitor
219008794|NCT03520231|OTHER|Denosumab Placebo|Placebo
219008795|NCT03520231|DRUG|Gemcitabine|Antineoplastic Agent
219008796|NCT03520231|DRUG|Carboplatin|Antineoplastic Agent
219008797|NCT03520231|DRUG|Cisplatin|Antineoplastic Agent
219008798|NCT03520231|DIETARY_SUPPLEMENT|Calcium|Calcium Supplement
219008799|NCT03520231|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D Supplement
219008800|NCT00301574|DRUG|galantamine|
219008801|NCT01431833|DRUG|TR-701 FA|Oral single dose 200 mg
219008802|NCT01463878|DIETARY_SUPPLEMENT|Glycerna|Diabetes specific formula
219008803|NCT01463878|DIETARY_SUPPLEMENT|Jevity - Control Diet|Control Diet
219008804|NCT02461108|BEHAVIORAL|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
219008805|NCT02461108|BEHAVIORAL|Tax|Frame the price difference as a 10% tax on less nutritious food items.
219008806|NCT02461108|BEHAVIORAL|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
219579833|NCT02777814|DRUG|Entecavir|anti hepatitis B virus
219579834|NCT00005634|DRUG|vorinostat|
219435815|NCT03919006|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
219195089|NCT03632798|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
219195090|NCT03632798|DRUG|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel."
219195091|NCT01828021|BIOLOGICAL|Margetuximab|Anti-HER2 monoclonal antibody
219195092|NCT03964363|BEHAVIORAL|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
219195093|NCT03316053|OTHER|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
219195094|NCT04667455|DIAGNOSTIC_TEST|Biomarker analysis at enrolment|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
219195095|NCT04667455|DIAGNOSTIC_TEST|Biomarker analyses throughout the study|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
219195096|NCT03631173|PROCEDURE|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
219195097|NCT06481540|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
219435816|NCT03919006|OTHER|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
219579835|NCT02031458|DRUG|Atezolizumab|1200 mg IV every 3 weeks
219579836|NCT06632561|DRUG|Empagliflozin 10 mg|Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
219579837|NCT06632561|DRUG|Placebo|Sugar pills one tablet daily for 6 months
219579838|NCT05368311|OTHER|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
219579839|NCT05368311|OTHER|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
219579840|NCT02885597|DRUG|Juanbi pill|4g, twice a day, 3month, oral
219579841|NCT02885597|DRUG|Juanbi pill placebo|4g, twice a day, 3month, oral
219579842|NCT02885597|DRUG|Methotrexate|5mg, once a week, 3 month, oral
219579843|NCT01250197|DRUG|AR-12286|Ophthalmic Solution
219579844|NCT05910476|DRUG|a high dose of statin/ezetimib|"In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation."
219579845|NCT01510548|BIOLOGICAL|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
219579846|NCT06160700|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
219579847|NCT03487952|OTHER|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
219579848|NCT02180178|OTHER|observational only- no intervention|
219579849|NCT05855616|DEVICE|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
219579850|NCT05855616|OTHER|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
219579851|NCT02494934|BEHAVIORAL|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
218820994|NCT03391882|DRUG|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
218820995|NCT02786056|OTHER|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
218820996|NCT06080555|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
218820997|NCT06080555|DRUG|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
218820998|NCT02128022|DRUG|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
218820999|NCT02128022|DRUG|Glibenclamide|Oral Glibenclamide 5mg
218821000|NCT06322134|OTHER|Drowning incident|Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.
218821001|NCT05752656|OTHER|Clinical examinations|Clinical examinations and administration of clinical scales
218821002|NCT05230576|DIAGNOSTIC_TEST|Deep learning training cohort|train the deep learning model
218821003|NCT05230576|DIAGNOSTIC_TEST|Deep learning validation cohort|evaluate the model
218821004|NCT06519136|OTHER|Distance Reiki|"According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol."
218821005|NCT06519136|OTHER|Sham Reiki|It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
218821006|NCT02809885|BIOLOGICAL|Hepatitis E serology|
218821007|NCT04285697|OTHER|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
218821008|NCT01380665|DEVICE|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
218821009|NCT06126497|DRUG|Ropanicant|Tablet
218821010|NCT06573008|DRUG|GP681 40mg|2 x 20mg tablets taken orally
218821011|NCT06573008|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
218821012|NCT03913130|DRUG|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
218821013|NCT04194827|DIAGNOSTIC_TEST|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
218821014|NCT04194827|DIAGNOSTIC_TEST|Disease activity|Dose reduction based on adalimumab diseas activity
218821015|NCT04194827|DRUG|Adalimumab|Adalimumab
219195098|NCT06481540|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period).After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
219195099|NCT05196854|OTHER|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
218821016|NCT04979598|OTHER|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
218821017|NCT02558868|DRUG|Irinotecan|
219195100|NCT05196854|OTHER|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
218821018|NCT02558868|DRUG|Oxaliplatin|
218821019|NCT02878382|OTHER|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
218821020|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
218821021|NCT00267176|DRUG|lumiracoxib|
219195101|NCT01017055|OTHER|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
218821022|NCT03822026|OTHER|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
219195102|NCT04643041|BEHAVIORAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
219195103|NCT06264453|DRUG|KH001|topical applications of KH001
219195104|NCT06264453|DRUG|Placebo|topical applications of Water for Injection
219195105|NCT05862922|DEVICE|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
219195106|NCT06208085|DIETARY_SUPPLEMENT|Avocado|Intervention arm
219195107|NCT06225427|PROCEDURE|Biopsy|Undergo tissue biopsy
219195108|NCT06225427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219195109|NCT06225427|PROCEDURE|Computed Tomography|Undergo CT scan
219195110|NCT06225427|PROCEDURE|Echocardiography|Undergo echocardiography
219195111|NCT06225427|DRUG|Gilteritinib|Given PO
219195112|NCT06225427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219195113|NCT06225427|OTHER|Questionnaire Administration|Ancillary studies
218821023|NCT05709847|OTHER|Coffee|24 ounces of coffee will be consumed daily
218821024|NCT02948439|OTHER|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
218821025|NCT05646082|DRUG|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
218821026|NCT06126159|DIAGNOSTIC_TEST|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
218821027|NCT01015950|DIETARY_SUPPLEMENT|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
218821028|NCT01015950|DIETARY_SUPPLEMENT|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
219195114|NCT06244433|GENETIC|whole genome sequencing|Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
219195115|NCT00971087|DEVICE|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects undergoing a biopsy procedure will be imaged on the investigational device prior to their procedure.
218821029|NCT01015950|DIETARY_SUPPLEMENT|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
219195116|NCT06195553|BEHAVIORAL|STEPPS plus Family Connections|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
218821030|NCT01015950|DIETARY_SUPPLEMENT|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
218821031|NCT00365807|BEHAVIORAL|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
218821032|NCT00365807|OTHER|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
218821033|NCT05615064|OTHER|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
219195117|NCT06195553|BEHAVIORAL|STEPPS|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
219195118|NCT03552471|OTHER|Laboratory Biomarker Analysis|Correlative studies
219195119|NCT03552471|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
219195120|NCT03552471|OTHER|Pharmacokinetic Study|Correlative studies
219195121|NCT03552471|DRUG|Rucaparib Camsylate|Given PO
219195122|NCT04186819|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
219195123|NCT04186819|DIAGNOSTIC_TEST|Positron Emission Tomography scan|imaging test with radioligand
219195124|NCT06476483|BEHAVIORAL|DIALOG+|A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).
219195125|NCT06476483|BEHAVIORAL|DIALOG|An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
219195126|NCT06105203|PROCEDURE|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
219195127|NCT06105203|PROCEDURE|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
219195128|NCT06809426|DRUG|177Lu-LNC1011|75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.
219195129|NCT06809660|OTHER|Collection of biological samples and clinical data|"* Collection of a hair sample~* Collection of urine~* Collection of stool samples~* Collection of clinical, paraclinical data, and exposure questionnaire"
218821034|NCT04013178|BEHAVIORAL|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
218821035|NCT04013178|BEHAVIORAL|Conventional resistance training|A conventional approach to resistance training
218821036|NCT01085214|OTHER|Laboratory Biomarker Analysis|Correlative studies
218821037|NCT01085214|DRUG|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
218821038|NCT01482715|DRUG|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
218821039|NCT01634152|DRUG|Placebo|2 actuations once daily in the evening
218821040|NCT01634152|DRUG|Tiotropium low dose mcg|2 actuations once daily in the evening
218821041|NCT01634152|DRUG|Tiotropium high dose|2 actuations once daily in the evening
218821042|NCT04206761|DRUG|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
218821043|NCT04206761|DRUG|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
218821044|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
218821045|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
218821046|NCT03615885|DIETARY_SUPPLEMENT|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
218821047|NCT00251108|PROCEDURE|Cardiorespiratory fitness training|
218821048|NCT00094276|BEHAVIORAL|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
218821049|NCT00094276|BEHAVIORAL|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
218821050|NCT06039514|DEVICE|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
218821051|NCT06039514|DEVICE|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
218821052|NCT01349114|DRUG|aliskiren 300 mg once daily|aliskiren 300 mg daily
218821053|NCT01349114|DRUG|Placebo/sugar pill|Sugar pill/placebo
219195130|NCT06808360|BEHAVIORAL|Supportive and Dignified Maternity Care|SDMC is a theory-driven, inclusive service-delivery package which will be developed using the principles of the human-centred design approach. The model will include capacity-building of maternity teams, and the improvement of governance and accountability mechanisms within public health facilities to ensure that all women are treated with compassion and dignity, while also catering for their diverse needs, including disabilities and common mental health conditions. The integration of psychosocial support in routine maternity care will be a unique feature of the intervention package, a principal aim of which is to address the psychological needs of birthing women and their companions.
218821054|NCT00882089|DEVICE|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
218821055|NCT01233544|PROCEDURE|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
219195131|NCT06199505|DRUG|GZR101|Once daily
219195132|NCT06199505|DRUG|insulin degledec/insulin aspart|Once daily or twice daily
218821056|NCT04470765|DEVICE|Zida|Transcutaneous Tibial Nerve Stimulation
218821057|NCT00735657|DEVICE|needle|Peribulbar blockade with standard (25 mm) needle
218821058|NCT00735657|DEVICE|needle|Peribulbar blockade with short (12.5 mm) needle
218821059|NCT00735657|PROCEDURE|Pars Plana Vitrectomy|Peribulbar block
218821060|NCT01152437|DRUG|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
219195133|NCT06570720|BEHAVIORAL|Alcohol-focused Support of Survivors in Sororities Training (ASSIST)|A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
218821061|NCT01152437|DRUG|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
218821062|NCT05170685|BIOLOGICAL|Nivolumab plus Relatlimab FDC|
218821063|NCT01985022|BEHAVIORAL|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
219008807|NCT03804879|DRUG|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
219008808|NCT03804879|OTHER|Placebo|Placebo capsules for oral administration
219579852|NCT02494934|BEHAVIORAL|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
219579853|NCT04214717|COMBINATION_PRODUCT|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
219579854|NCT04214717|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
219579855|NCT05032521|BIOLOGICAL|collection of biological data|collection of biological data
219579856|NCT05032521|OTHER|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
219579857|NCT05032521|PROCEDURE|Standard treatment|usual management based on the use of drugs according to international recommendations
219579858|NCT05032521|PROCEDURE|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
219579859|NCT02276079|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
219579860|NCT02276079|BEHAVIORAL|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
219579861|NCT05222542|OTHER|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
219579862|NCT00059787|DRUG|paclitaxel|Given IV
219579863|NCT00059787|DRUG|carboplatin|Given IV
219579864|NCT00059787|DRUG|erlotinib|Given PO
219579865|NCT02253836|DRUG|Tipranavir|TPV
219579866|NCT02253836|DRUG|Ritonavir|RTV
219579867|NCT02253836|DRUG|Atazanavir|TAZ
219008809|NCT03804879|DRUG|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
219008810|NCT01262950|OTHER|portable motion detector|
219008811|NCT00052208|DRUG|gefitinib|Given PO
219008812|NCT00052208|RADIATION|radiation therapy|Undergo radiation therapy
219008813|NCT00052208|OTHER|laboratory biomarker analysis|Correlative studies
219008814|NCT02436889|DRUG|Mirabegron|
219008815|NCT02436889|DRUG|Tolterodine Tartrate|
219008816|NCT00221754|DRUG|Pravastatin (drug)|
219008817|NCT01738763|DIETARY_SUPPLEMENT|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
219008818|NCT01585428|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219579868|NCT00010608|BEHAVIORAL|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
219579869|NCT00010608|BEHAVIORAL|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
219579870|NCT03342599|DIETARY_SUPPLEMENT|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
219579871|NCT03342599|DIETARY_SUPPLEMENT|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
219579872|NCT02135653|RADIATION|Radiotherapy|
219579873|NCT02135653|OTHER|Eischens Yoga|
219579874|NCT02340845|BIOLOGICAL|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
219579875|NCT06190535|DRUG|Etamsylate|Enteral administration of Etamsylate as solution galenic form
219579876|NCT01796912|OTHER|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
219579877|NCT01796912|OTHER|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
219579878|NCT02726893|OTHER|no intervention|
219579879|NCT00725530|DEVICE|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
219579880|NCT00725530|DEVICE|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
219195134|NCT05493852|DEVICE|FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.
219195135|NCT06810232|PROCEDURE|Gastrointestinal endoscopy|Patients will be divided into groups according to general health risk factors detected during preoperative anesthesia evaluation (hypertension, diabetes, asthma, obesity, chronic disease, medication history, immobility, smoking, etc.) and will be evaluated in terms of age, gender, weight and height will be combined to report BMI in kg/m2, alcohol, allergy, ASA, endoscopy site, complications that may develop related to anesthesia and sedation (such as hemodynamic instability, hemoglobin desaturation, pulmonary aspiration and apnea), additional interventions, and hospital stay.
219579881|NCT03814525|RADIATION|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
219008819|NCT01585428|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
219008820|NCT01585428|BIOLOGICAL|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
219008821|NCT01585428|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219008822|NCT01655979|DIETARY_SUPPLEMENT|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
219008823|NCT01655979|OTHER|Control|Bed rest without dietary supplement
219008824|NCT01558830|DRUG|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
219008825|NCT01558830|DRUG|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
219008826|NCT00479661|DRUG|Dexmedetomidine|Continuous infusion
219008827|NCT00479661|DRUG|Propofol|Continuous infusion
219008828|NCT06413342|DRUG|Sintilimab|Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
219008829|NCT04913025|DRUG|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
219008830|NCT04913025|DRUG|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
219008831|NCT01879501|BEHAVIORAL|Low Vision Self-Management Program|The program has been describe above.
219008832|NCT02843932|OTHER|functional brain MRI|functional imagery during motor-perception tasks
219008833|NCT01806324|DRUG|HL040XC|single dose
219008834|NCT01806324|DRUG|Losartan + Atorvastatin|Single dose
219579882|NCT03814525|RADIATION|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
219195136|NCT06809088|BIOLOGICAL|Albumin|Albumin
219195137|NCT06809088|OTHER|Standard Medical Treatment|Standard Medical Treatment
219008835|NCT01084174|DRUG|Peanut powder|Delivered orally
219008836|NCT01084174|DRUG|Peanut extract|Delivered sublingually
219008837|NCT01084174|DRUG|Placebo extract|Delivered sublingually
219008838|NCT01084174|DRUG|Placebo powder|Delivered orally
219008839|NCT05066373|DRUG|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
219008840|NCT05066373|DRUG|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
219008841|NCT05066373|DRUG|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
219008842|NCT00273442|DRUG|timolol maleate|
219008843|NCT00273442|DRUG|dorzolamide/timolol maleate fixed combination|
219008844|NCT03582072|BEHAVIORAL|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
219008845|NCT06217289|OTHER|Observation|Observation and knowledgement on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
219195138|NCT05130268|DRUG|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
219195139|NCT06804161|DRUG|SGLT2|10 mg
219195140|NCT06804161|DRUG|Placebo|1 tablet
219195141|NCT06805604|PROCEDURE|Each group was received monolithic ceramic crowns fabricated using different technique|-Different digital techniques used for fabrication of the monolithic ceramic crowns were chosen for the current study, Clinical performance of all crowns regarding; marginal adaptation, fracture of restoration during service, color stability and wear behavior will be evaluated according to Modified United States Public Health Service (USPHS) Criteria at base line (1 week), 3 and 6 months after cementation of crowns.
219579883|NCT02882685|PROCEDURE|Roux-en-y gastric bypass|
219579884|NCT02882685|PROCEDURE|Single anastomosis gastric bypass|
219579885|NCT05018520|DRUG|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
219195142|NCT06805578|OTHER|Heritage art programme|The 6-week 'Refresh and Reconnect!' programme includes guided gallery tours led by the museum's Care Facilitator volunteers and artist-led hands-on activities based on various art forms (e.g. artist-led dance, art, or drama workshops).
219195143|NCT06081829|DRUG|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
219195144|NCT06808776|OTHER|Cancer survivor narrative|"The narrative video intervention has three parts: (1) Cancer experience - the cancer survivor narrates his/her experience with an HPV-related cancer, including diagnosis, treatment, and how cancer affected their personal life or family; (2) Vaccine recommendation - the cancer survivor provides brief information about the safety and effectiveness of the HPV vaccine and recommend that parents get the HPV vaccine for their child to prevent cancers; and (3) Closing message - The sentence HPV vaccine is cancer prevention. Talk to your child's healthcare provider about getting the HPV vaccine during the next clinic visit will appear on the screen."
219195145|NCT06808776|OTHER|Healthy eating tips|A publicly available video about healthy eating tips for families with children.
219195146|NCT06809946|DRUG|injection with 15 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
219195147|NCT06809946|DRUG|injection with 25 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
219195148|NCT06809335|OTHER|Personalized circadian mHealth|SHIFT is a mobile application designed to improve sleep in night shift workers. The SHIFT mobile application is used to collect data from an Apple Watch to assess an individual shift worker's body-clock timing and make personalized recommendations of light exposure schedules that are designed to align the body-clock with the night shift work schedule.
219195149|NCT06809504|BEHAVIORAL|Exercise based intervention|"12 sessions over 4 weeks, 45-minute sessions divided into:~o 15 minutes for physical exercises"
219195150|NCT06810596|PROCEDURE|Insulin infusion protocol|comparing the efficacy of 2 different protocols for glycemic control in diabetic critically ill patients.
219195151|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
219579886|NCT05018520|DRUG|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
218821064|NCT01985022|BEHAVIORAL|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
218821065|NCT01450345|DRUG|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
218821066|NCT00413114|DRUG|Obatoclax mesylate (GX15-070MS)|
218821067|NCT01507740|DRUG|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
218821068|NCT01507740|DRUG|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
218821069|NCT01507740|DRUG|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
218821070|NCT01623063|PROCEDURE|Hysteroscopy|hysteroscopy with guided biopsies
218821071|NCT02145884|DRUG|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
219195152|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
219195153|NCT06808087|PROCEDURE|Transversus abdominis plane blockage|"1. Patient monitoring~2. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~3. Placement of a high-frequency linear transducer transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles.~4. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer.~5. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed.~6. Visualization of the oval spread of bupivacaine in the TAP."
219195154|NCT06808087|PROCEDURE|Erector spinae plane blockage|"1. Patient monitoring~2. Positioning the patient in the prone position~3. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~4. Counting the transverse processes from the sacrum to find the L1 level~5. Placing a low-frequency curvilinear transducer (depth set to 3-5 cm) parasagittally, and identifying the tip of the right transverse process at this level~6. Visualizing the erector spinae muscle overlying the transverse process~7. Inserting a 22G, 80 mm needle between the transverse process and the fascia of the erector spinae muscle~8. Injecting 1 to 3 mL of saline to confirm the separation of the erector spinae muscle fascia from the transverse process after negative aspiration~9. Injecting 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, after another negative aspiration~10. Visualizing the oval spread of bupivacaine over the erector spinae muscle."
219579887|NCT02050425|DEVICE|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
219579888|NCT02050425|DEVICE|CPAP|Patients continue therapeutic CPAP therapy
219195155|NCT06808087|DRUG|Tramadol|50 mg of tramadol will be administered via IV infusion over 15 minutes in 100 cc of isotonic 0.9% NaCl (normal saline).
219195156|NCT06808347|DRUG|application of the vaginal estrogen cream|patients will apply the vaginal estrogen cream
219195157|NCT06173323|BEHAVIORAL|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
219195158|NCT05697250|OTHER|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
219195159|NCT01199133|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year.
219195160|NCT01199133|DRUG|Placebo tablet|One sublingual tablet daily for one year.
218821072|NCT04542122|BEHAVIORAL|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
218821073|NCT03374020|DEVICE|Notal OCT|Imaging using Notal OCT
218821074|NCT01624714|DRUG|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
218821075|NCT01624714|DRUG|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
219195161|NCT04200300|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
219195162|NCT04874948|DRUG|500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|Single oral administration of 14C-labeled radioactive 500mg BTZ-043
219195163|NCT05013385|DRUG|Spesolimab|Spesolimab
219195164|NCT05013385|DRUG|Placebo|Placebo
219195165|NCT06650514|DRUG|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
219195166|NCT06652503|BEHAVIORAL|online mental health coaching|SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
219195167|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
219195168|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
219195169|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
219579889|NCT06406517|DRUG|Gadopiclenol|Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
219579890|NCT06406517|DRUG|Gadobenate dimeglumine|Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
218821076|NCT03136120|DRUG|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
219195170|NCT06288659|DEVICE|Intraventricular intracranial pressure monitoring|The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
219195171|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
219195172|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
219195173|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
219195174|NCT05610319|DRUG|Faricimab|Faricimab will be administered via intravitreal injection.
219195175|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
219195176|NCT06044493|DRUG|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
219195177|NCT06044493|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
219195178|NCT06119503|BEHAVIORAL|Elongating Time HOrizons for Reentry (ETHoR)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in an incarceration free future.
219195179|NCT06119503|BEHAVIORAL|Standardized Episodic Thinking (SET)|In the standardized episodic thinking (SET) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
219195180|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
219195181|NCT01447719|DRUG|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
219435817|NCT02866929|PROCEDURE|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
218821077|NCT03136120|PROCEDURE|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
219195182|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
219195183|NCT06565611|DRUG|bremelanotide|bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
219195184|NCT06565611|DRUG|tirzepatide|tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
219195185|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
219195186|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
219195187|NCT06648629|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a trans-diagnostic treatment that targets experiential avoidance as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms via improved psychological acceptance.
218821078|NCT05173779|PROCEDURE|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
219195188|NCT06648629|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention (BI) is a standard intervention for reducing alcohol use in PWH. The BI includes the creation of a drinking agreement, self-monitoring via drinking diary cards, discussion of risky moods/situation, and strategies for managing these moods/situations.
219195189|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
219195190|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
219195191|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
219195192|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
219195193|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
219195194|NCT05606211|OTHER|No intervention|Observational, no intervention
219195195|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
219195196|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
219195197|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
219195198|NCT06568458|DRUG|Nintedanib|Specified Dose on specified days
219195199|NCT06568458|DRUG|BMS 986278|Specified dose on specified days
219195200|NCT05671666|DIAGNOSTIC_TEST|Urea cycle flux study|Quantification of ureagenesis
218821079|NCT01359124|BEHAVIORAL|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
218821080|NCT01359124|BEHAVIORAL|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
218821081|NCT01359124|BEHAVIORAL|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
219195201|NCT03347786|DRUG|10 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
219195202|NCT03347786|DRUG|20 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
219195203|NCT03717753|OTHER|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
219435818|NCT02866929|DEVICE|Orthodontics|Self-ligation brackets in upper and lower teeth
219435819|NCT02866929|DRUG|Mucograft|Porcine naturally cross-linked collagen matrix
219195204|NCT05102942|BEHAVIORAL|Attentional Control Training Program|The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).
219195205|NCT04791865|BEHAVIORAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
219195206|NCT04791865|BEHAVIORAL|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
219195207|NCT05637684|DEVICE|low intensity pulsed ultrasound|mechanical sound waves
219435820|NCT01066169|BIOLOGICAL|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
219435821|NCT05118568|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
219195208|NCT06124014|DEVICE|At-Home Stimulation|The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.
219195209|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
219435822|NCT01661504|BEHAVIORAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
219579891|NCT01660464|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
218821082|NCT04544306|OTHER|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
218821083|NCT01657357|OTHER|Routine followup|questionnaires
218821084|NCT00279214|DRUG|drotrecogin alfa (activated)|
218821085|NCT03445767|OTHER|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
218821086|NCT04662450|BEHAVIORAL|ABM affective pain stimuli|Patients undergo ABM training to shift attention away from affective pain stimuli
218821087|NCT04662450|BEHAVIORAL|ABM sensory pain stimuli|Patients undergo ABM training to shift attention away from sensory pain stimuli
219579892|NCT01646047|DIETARY_SUPPLEMENT|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
219579893|NCT01646047|DIETARY_SUPPLEMENT|multi-component dietary supplement|placebo capsules
219579894|NCT03535675|DRUG|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
219579895|NCT03535675|DRUG|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
219579896|NCT06063759|DEVICE|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
218821088|NCT04662450|BEHAVIORAL|Placebo|Patients undergo ABM training to receive affective/neutral and sensory/neutral word pairs
218821089|NCT01058850|BIOLOGICAL|Rindopepimut|250 or 500 mcg; intradermal injection
219579897|NCT00103311|DRUG|ispinesib|Given IV
219579898|NCT00103311|OTHER|laboratory biomarker analysis|Correlative studies
219579899|NCT05986331|DRUG|BCD-201|up to 8 treatment cycles
219579900|NCT05986331|DRUG|Keytruda|up to 8 treatment cycles
219579901|NCT00349557|DRUG|bevacizumab, bicalutamide and goserelin|
219579902|NCT00349557|PROCEDURE|intensity modulated radiation therapy (IMRT)|
219579903|NCT03928314|DRUG|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
219579904|NCT03928314|DRUG|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
219579905|NCT02681224|OTHER|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
219579906|NCT02681224|OTHER|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
219579907|NCT02681224|OTHER|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
219579908|NCT02681224|OTHER|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
219579909|NCT03063879|DRUG|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
219195210|NCT06738888|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
219195211|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
218821090|NCT03064308|OTHER|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
219008846|NCT03412487|PROCEDURE|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
219008847|NCT05609045|BIOLOGICAL|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
219195212|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
219195213|NCT06279533|DRUG|LV232/Placebo|"Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 60mg Group:~6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally."
219195214|NCT06279533|DRUG|LV232|"Drug: LV232 20mg Group:~12 subjects will receive LV232 20mg, orally~Drug: LV232 60mg Group:~12 subjects will receive LV232 60mg, orally"
219008848|NCT05609045|DRUG|Sodium chloride|0.9% sodium chloride
219195215|NCT04050410|DRUG|Moxonidine|active drug given as 1 dose
219195216|NCT04050410|DRUG|Placebo|placebo pill given as 1 dose
219195217|NCT05093933|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
219579910|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
219195218|NCT05093933|DRUG|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
219195219|NCT06070987|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
219195220|NCT06070987|OTHER|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
219195221|NCT06070987|OTHER|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
219195222|NCT04372433|BIOLOGICAL|IO-202|IO-202 as monotherapy
219195223|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
219195224|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine + Venetoclax|IO-202 and azacitidine + venetoclax combination therapy
219195225|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
219195226|NCT06038513|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours
219195227|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
218821091|NCT02642757|BEHAVIORAL|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
218821092|NCT02642757|OTHER|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
219008849|NCT02220582|OTHER|MRI|Magnetic Resonance Imaging
219579911|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
218821093|NCT04272164|OTHER|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
218821094|NCT04272164|OTHER|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
219195228|NCT06822153|DRUG|ET-26 0.8mg/kg(low-dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 0.8mg/kg for a duration of 60 ±5 seconds.
219195229|NCT06822153|DRUG|ET-26 2.8mg/kg(high dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 2.8mg/kg for a duration of 60 ±5 seconds.
218821095|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
219008850|NCT01830660|DRUG|Hetrombopag Olamine Tablets|
219008851|NCT01830660|DRUG|placebo|
219008852|NCT04497077|DIETARY_SUPPLEMENT|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
219008853|NCT04497077|DIETARY_SUPPLEMENT|placebo|either cornstarch capsule or kool-aid
219579912|NCT04029987|PROCEDURE|Control|Conventional analgesia
219579913|NCT00225537|DRUG|4-Methylumbelliferone (Heparvit®)|
219579914|NCT01264042|DIETARY_SUPPLEMENT|Ferrous Sulfate|60 mg with 200 mL water, single administration
218821096|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
218821097|NCT01214837|BIOLOGICAL|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
218821098|NCT05650866|DEVICE|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
218821099|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
218821100|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
219008854|NCT02310464|DRUG|OBI-833/OBI-821|
219008855|NCT04357392|DRUG|Prednisone|Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
219008856|NCT06151158|BEHAVIORAL|Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)|Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge
219008857|NCT06151158|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)|Five session crisis focused version of IPT for adolescents.
219195230|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
219195231|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
219195232|NCT04993170|DIAGNOSTIC_TEST|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
219195233|NCT06828770|DEVICE|Minima Stent System|Minima Stent System is indicated for use in the treatment of native or acquired pulmonary artery stenoses or coarctation of the aorta in neonates, infants, and children at least 1.5kg in weight.
219195234|NCT04350177|DRUG|IkT-148009|Oral administration gelatin capsule
219195235|NCT04350177|DRUG|Placebo|Oral administration gelatin capsule
219195236|NCT04936178|DRUG|NB003 tablets|NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
219195237|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
218821101|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
218821102|NCT06994130|DIAGNOSTIC_TEST|Seravue|. This study seeks to test the performance of the SeravueTM (LC-SPIK) device alone or in combination with ultrasound as a tool for HCC surveillance in diverse patient populations and clinical settings.
219195238|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
219195239|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
219579915|NCT03195153|DRUG|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
218821103|NCT06629389|DRUG|Cannabidiol 100 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
219195240|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
219195241|NCT05977556|BEHAVIORAL|Combined neuromuscular exercise training and 'sit less, move more' program|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
219195242|NCT06573619|OTHER|Validation of questionnaire|Validation of questionnaire
219195243|NCT03252288|BEHAVIORAL|Reminders|Text of phone-call based reminders to mobile phones
219195244|NCT03252288|BEHAVIORAL|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs \>1 week but within 4 weeks of the scheduled visit
219195245|NCT06638996|DIETARY_SUPPLEMENT|CBG Intervention|50 mg CBG Administered
219195246|NCT06638996|OTHER|Placebo Intervention|Participants will be administered a placebo
219195247|NCT05398770|DIETARY_SUPPLEMENT|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
219195248|NCT04574583|DRUG|SX-682|SX-682 will be given orally at designated dose twice a day every day
219195249|NCT04574583|DRUG|M7824|Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
218821104|NCT06629389|DRUG|cannabidiol 300 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
218821105|NCT06629389|DRUG|Cannabidiol 400 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
219008858|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
219008859|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
219008860|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphagia|Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
219008861|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphonia|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
219195250|NCT04574583|BIOLOGICAL|MVA-BN-CV301|MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
219195251|NCT04574583|BIOLOGICAL|recombinant fowlpox viral (FPV)-CV301|FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
219195252|NCT03309332|DEVICE|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
218821106|NCT06629389|DRUG|Placebo|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
218821107|NCT06694246|OTHER|Improving technique|"A checklist was developed to ensure the important steps were followed, with tips for obtaining a more adequate sample. This checklist was put in the outpatient procedures room, and each physician performing a biopsy was asked to fill it out.~Also, a diagram containing illustrative images with the basic steps was put in the procedures room.~The topic was covered in the biweekly scientific meeting, and all factors attributed to the inadequate sample were discussed.~The department lead mentioned the topic in the OBGYN department's private messaging group.~It was finally mentioned in the morning meeting."
218821108|NCT06694246|OTHER|Using hysteroscopy in candidate patients|"Patients with focal lesions on ultrasound will undergo hysteroscopy and biopsy instead of blind endometrial sampling.~Patient with stenosed cervix or failed previous sampling might also undergo hysteroscopic guided biopsy."
218821109|NCT06694246|OTHER|Analgesia|Analgesia in the form of paracetamol or NSAIDs might be given to some patients 30- 60 minutes before the procedure to reduce the procedure-associated pain and the resultant failure to complete it and obtain an adequate sample.
218821110|NCT01049087|RADIATION|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
218821111|NCT01049087|RADIATION|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
218821112|NCT06696261|DRUG|Lianxiaxiaopi Granules|The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
218821113|NCT06696261|DRUG|a simulated agent of Lianxiaxiaopi Granules|The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
218821114|NCT06716736|BIOLOGICAL|socket preservation using dentine graft mixed with i-PRF|surgical extraction of horizontally impacted third molar , placement of dentin graft mixed with i-PRF inside the socket , suturing
218821115|NCT06716736|BIOLOGICAL|socket preservation using bone allograft|surgical extraction of horizontally impacted third molar , placement of bone allograft inside the socket , suturing
218821116|NCT06716736|BIOLOGICAL|socket preservation using collagen cone|surgical extraction of horizontally impacted third molar , placement of collagen cone inside the socket , suturing
218821117|NCT01580228|DRUG|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
218821118|NCT01580228|DRUG|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
218821119|NCT03758183|PROCEDURE|total knee arthroplasty|
218821120|NCT02449187|DRUG|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
218821121|NCT02449187|DRUG|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
218821122|NCT03410160|DIAGNOSTIC_TEST|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
218821123|NCT00457626|DRUG|Valsartan|Extemporaneous suspension of valsartan, orally.
218821124|NCT04729790|DRUG|PRIM-DJ2727|oral FMT capsules
219195253|NCT06841107|OTHER|Training was provided on spinal health.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months.
218821125|NCT03730519|DEVICE|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
218821126|NCT02896309|DIETARY_SUPPLEMENT|Sodium bicarbonate|
218821127|NCT02896309|DIETARY_SUPPLEMENT|Sodium chloride|
218821128|NCT03279107|OTHER|Soluble corn fiber|soluble corn fiber
218821129|NCT03279107|OTHER|maltodextrin|maltodextrin
218821130|NCT01471613|PROCEDURE|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
218821131|NCT01471613|DRUG|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
218821132|NCT01471613|BIOLOGICAL|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
219195254|NCT06841107|OTHER|Training on spinal health was provided and lumbar region support was applied for 3 months.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months. In addition, lumbar region support was used every day during working hours for 3 months.
219195255|NCT05013411|OTHER|Qualitative study|Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
219579916|NCT03195153|DRUG|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
219579917|NCT03195153|DRUG|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
219008862|NCT01967121|DEVICE|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
218821133|NCT01471613|OTHER|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
218821134|NCT04587037|PROCEDURE|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
218821135|NCT04587037|PROCEDURE|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
218821136|NCT01761708|PROCEDURE|primary ventral hernia repair with mesh|
219195256|NCT03346343|DEVICE|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
219195257|NCT02630121|DRUG|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
219763422|NCT01203839|RADIATION|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
219763423|NCT04631601|DRUG|Acapatamab|Acapatamab will be administered as an intravenous (IV) infusion.
219763424|NCT04631601|DRUG|Enzalutamide|Enzalutamide will be administered orally.
219763425|NCT04631601|DRUG|Abiraterone|Abiraterone will be administered orally.
218821137|NCT00360958|PROCEDURE|ultrafiltration|
218821138|NCT02539186|BIOLOGICAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
218821139|NCT02539186|DEVICE|splint|
218821140|NCT00878267|BEHAVIORAL|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
218821141|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
218821142|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
219008863|NCT01967121|OTHER|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
219008864|NCT01538420|DRUG|GLPG0492|Oral solution
219008865|NCT01538420|DRUG|Placebo|Placebo oral solution
219008866|NCT02289898|DRUG|Demcizumab|administered intravenously
219195258|NCT02630121|DRUG|Placebo|Proportion of the subjects with 50% reduction in AHI.
219195259|NCT06853574|DRUG|Fluid therapy|Infusion of 8 ml/Kg/30' or 16 ml/kg/60' of fluids.
219195260|NCT06853574|DRUG|Noradrenaline infusion|dosage will be titrated in order to obtain mean arterial pressure target
219195261|NCT05626894|COMBINATION_PRODUCT|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
219763426|NCT04631601|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
219763427|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
219763428|NCT06237309|DRUG|Placebo|Single dose IV infusion
219763429|NCT06567041|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219763430|NCT06567041|DRUG|Placebo|Placebo will be administered subcutaneously.
219763431|NCT06221969|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
219763432|NCT06221969|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
219763433|NCT06221969|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
218821143|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
218821144|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
219008867|NCT02289898|DRUG|Abraxane®|administered intravenously
219008868|NCT02289898|DRUG|gemcitabine|administered intravenously
219008869|NCT02289898|DRUG|Placebo|
219008870|NCT03634449|DEVICE|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
219008871|NCT03634449|DEVICE|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
219195262|NCT05626894|OTHER|Usual Care|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
219195263|NCT06855381|PROCEDURE|the ISBC group, SonoPlex needle and E-catheter|in the ISBC group, a 22G 50 mm SonoPlex needle with an indwelling cannula will be used. The E-catheter will be inserted into the indwelling cannula.
219195264|NCT06855381|PROCEDURE|single bolus injection|An ultrasound-guided peripheral nerve block puncture will be performed from the lateral to the medial side of the neck. In this group a 22G 50 mm needle will be used
219195265|NCT06855121|DRUG|Teclistamab|Real-world use and dosing
219195266|NCT06855121|DRUG|Elranatamab|Real-world use and dosing
219195267|NCT06855121|BIOLOGICAL|Ciltacabtagene Autoleucel|Real-world use.
219195268|NCT06855121|DRUG|Talquetamab|Real-world use and dosing
219195269|NCT06855121|BIOLOGICAL|Idecabtagene vicleucel|Real-world use and dosing
219195270|NCT06854523|DRUG|PCSK9 inhibitor|The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months
219195271|NCT06854523|DRUG|Statin+ezetimibe|The patient used statins and ezetimibe within 24 hours before or after PCI, and then once a day for 12 months
219195272|NCT06854523|BEHAVIORAL|Blood lipid levels meet the recommended guidelines|Early use of intensified lipid-lowering therapy during hospitalization led to a rapid decrease in blood lipids and met the recommended guidelines.
218821145|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
218821146|NCT04337242|BEHAVIORAL|B-DIT|Blended Dynamic Interpersonal Therapy
218821147|NCT04337242|BEHAVIORAL|B-CBT|Blended Cognitive Behavioral Therapy
218821148|NCT04337242|BEHAVIORAL|DIT|Dynamic Interpersonal Therapy
218821149|NCT04337242|BEHAVIORAL|Cognitive Behavioral Therapy|CBT
219195273|NCT06854523|BEHAVIORAL|Blood lipid levels don't meet the recommended guidelines|The patient did not receive intensified lipid-lowering treatment during hospitalization or did not meet the recommended guidelines for blood lipids
219195274|NCT05974280|DRUG|Alofisel|Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
219195275|NCT05974280|DRUG|Fat stem cell|mesenchymal stem cells from adipose (fat) tissue injection
219195276|NCT06811402|OTHER|virtual reality|the patient will wear a VR mask during the session
219195277|NCT06853717|BEHAVIORAL|Therapy Together|CIMT consists of retraining the preferred hand by covering the hand with a soft mitt to promote the use of the assisting hand. With consistent practice, a toddler or infant builds the fine and gross motor skills of their assisting hand and bilateral coordination skills.
218821150|NCT03702179|DRUG|Durvalumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
218821151|NCT03702179|DRUG|Tremelimumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
218821152|NCT03702179|RADIATION|Radiotherapy|Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
219008872|NCT03353493|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
219195278|NCT06810284|DRUG|Sildenafil Citrate (IV)|Controlled hypothermia initiated before 6h after birth (servo-controlled 33.5°C during 72h followed by a 12-h rewarming period up to 36.5°C), open-label IV Sildenafil Citrate (Revatio®, 10 mg/12.5 mL, Pfizer) 0.4 mg/kg delivered over 3 hours, followed by a maintenance infusion at 1.6 mg/kg/day for 72h
219195279|NCT06813118|DRUG|Clomiphene Citrate and letrozole|clomiphene citrate 100mg once daily along with letrozole 5mg to one group and letrozole 5mg to second group
219195280|NCT06654739|DEVICE|Laser therapy + physiotherapy/exercise protocol|laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
219195281|NCT06654739|DEVICE|Sham Laser therapy + physiotherapy/exercise protocol|sham laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
219195282|NCT00783510|BIOLOGICAL|adalimumab|As prescribed by treating physician
219195283|NCT00783510|DRUG|Methotrexate|As prescribed by treating physician
218821153|NCT04633330|DRUG|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
218821154|NCT04633330|DRUG|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
218821155|NCT04287972|PROCEDURE|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
219008873|NCT03353493|OTHER|TAU|Treatment as usual (TAU)
219008874|NCT00002862|DRUG|perillyl alcohol|
219008875|NCT02118389|DIETARY_SUPPLEMENT|Glucerna|Glucerna 52g meal replacement
219195284|NCT05826600|DRUG|OMX-0407|Dose escalation, Dose expansion
219195285|NCT06602934|OTHER|Blood samples|Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
219195286|NCT06602934|OTHER|Oropharyngeal swabs|An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
219195287|NCT06602934|OTHER|Calcium score (CT scan)|A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
219195288|NCT06602934|OTHER|ECG|Performed at inclusion, M6, M18 and M30
219195289|NCT06602934|OTHER|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
219195290|NCT03904615|DIETARY_SUPPLEMENT|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
218821156|NCT04287972|PROCEDURE|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
218821157|NCT05522686|OTHER|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
218821158|NCT05522686|OTHER|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
218821159|NCT05522686|OTHER|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
218821160|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
218821161|NCT03085901|DEVICE|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
219195291|NCT03904615|DIETARY_SUPPLEMENT|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
218821162|NCT03085901|DEVICE|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
218821163|NCT04943237|DRUG|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
219008876|NCT04788888|DEVICE|Navitor Transcatheter Aortic Valve and FlexNav Delivery System|"For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system"
219008877|NCT02363517|DRUG|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
219008878|NCT02468323|DRUG|Placebo|Patients will receive regular spinal anesthesia
219008879|NCT02468323|DRUG|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
219008880|NCT02468323|DRUG|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
219008881|NCT00246727|DRUG|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
219008882|NCT00207207|PROCEDURE|Alternate site blood glucose testing|
219008883|NCT05833191|DEVICE|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
219195292|NCT03904615|DIETARY_SUPPLEMENT|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
219579918|NCT04973553|OTHER|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
219579919|NCT00635115|DEVICE|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
218821164|NCT04943237|DRUG|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
218821165|NCT02772029|DRUG|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
219579920|NCT00635115|DEVICE|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
219579921|NCT04324593|DEVICE|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
219579922|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).
218821166|NCT01944020|DEVICE|CPAP|use of CPAP each night for 2 months
218821167|NCT00602693|BIOLOGICAL|umbilical cord blood transplantation|Infusion of umbilical cord blood
218821168|NCT00602693|DRUG|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
218821169|NCT00602693|DRUG|fludarabine phosphate|40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
218821170|NCT00602693|DRUG|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
218821171|NCT00602693|RADIATION|Total body irradiation|200 cGy on Day -1
218821172|NCT00602693|BIOLOGICAL|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
219579923|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).
219579924|NCT02926430|DRUG|Placebo|Participants will receive placebo as formulation buffer.
218821173|NCT00602693|DRUG|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
218821174|NCT03793621|DRUG|BI 730357|single rising oral dose
218821175|NCT03793621|DRUG|Placebo|single rising oral dose
218821176|NCT02164526|OTHER|Routine therapy|Routine therapy
218821177|NCT04482725|OTHER|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
218821178|NCT04482725|OTHER|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
218821179|NCT04482725|OTHER|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
218821180|NCT04482725|OTHER|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
218821181|NCT04482725|OTHER|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
219008884|NCT05833191|DEVICE|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
219008885|NCT05533281|DRUG|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
219195293|NCT06815120|DEVICE|Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)|Kidney stone patients and Oncology patients admitted to either the University Hospital Southampton (UHS) or University College London Hospital (UCLH) for management of kidney stones or for the management of urine drainage in ureter will have a novel ureteric stent instead of their planned conventional stent. The novel stent will be removed after 4 weeks (kidney stone patients) or 25 weeks (oncology patients). Recruitment to the cohort of oncology patients will only commence once the results for kidney stones patients have been reviewed.
219579925|NCT05892146|DRUG|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
219579926|NCT05892146|DRUG|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
219579927|NCT02400424|RADIATION|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
219579928|NCT00003436|DRUG|amsacrine|
219579929|NCT00003436|DRUG|asparaginase|
219579930|NCT00003436|DRUG|cytarabine|
219579931|NCT00003436|DRUG|daunorubicin hydrochloride|
219579932|NCT00003436|DRUG|etoposide|
218821182|NCT04482725|OTHER|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
218821183|NCT04482725|OTHER|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
218821184|NCT04482725|OTHER|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
218821185|NCT04482725|OTHER|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
218821186|NCT04482725|OTHER|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
218821187|NCT04482725|OTHER|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
218821188|NCT04482725|OTHER|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
218821189|NCT04638751|DRUG|Immunotherapy|Checkpoint inhibitor
218821190|NCT04638751|DRUG|Chemotherapy|Any form of chemotherapy
218821191|NCT04638751|PROCEDURE|CRC surgical resection|Surgical resection to remove colorectal cancer
218821192|NCT04638751|PROCEDURE|Colonoscopy|Standard-of-care colonoscopy for CRC screening
218821193|NCT00815386|DEVICE|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
218821194|NCT02367963|BEHAVIORAL|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
219008886|NCT05533281|DRUG|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
219008887|NCT05533281|DRUG|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
219008888|NCT05533281|OTHER|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
219008889|NCT00805103|RADIATION|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
219195294|NCT06815120|OTHER|Qualitative interview|Kidney stone patients, Oncology patients and doctors will be interviewed about their experience of having a stent, or their experience in managing patients with a stent.
219579933|NCT00003436|DRUG|methotrexate|
219579934|NCT00003436|DRUG|mitoxantrone hydrochloride|
219579935|NCT00003436|DRUG|therapeutic hydrocortisone|
219579936|NCT00003436|PROCEDURE|allogeneic bone marrow transplantation|
218821195|NCT02367963|BEHAVIORAL|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
218821196|NCT02969642|DEVICE|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
218821197|NCT06110403|DRUG|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
218821198|NCT03257358|DRUG|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
218821199|NCT00251836|PROCEDURE|Laparoscopic hand-assisted donor nephrectomy|
218821200|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
218821201|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
218821202|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
218821203|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
218821204|NCT04843631|DRUG|BFI-751|Single use vial, solution
218821205|NCT04843631|DRUG|EU-STELARA®|Pre-filled syringe, solution
218821206|NCT04843631|DRUG|US-STELARA®|Pre-filled syringe, solution
218821207|NCT05747274|DEVICE|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
219008890|NCT01293721|DEVICE|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
219008891|NCT05322304|DIETARY_SUPPLEMENT|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
219008892|NCT00292695|OTHER|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
219579937|NCT04270136|PROCEDURE|total mastectomy|breast cancer non conserving surgery
219579938|NCT05017259|DIETARY_SUPPLEMENT|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
218821208|NCT03218774|BEHAVIORAL|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
218821209|NCT03218774|BEHAVIORAL|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
218821210|NCT02986633|OTHER|Echocardiography|
218821211|NCT05956847|PROCEDURE|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
218821212|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
218821213|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
218821214|NCT00000413|BEHAVIORAL|Psychoeducational program|
218821215|NCT06320704|DEVICE|Digital occlusal adjustment using Occulosense digital device|Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
218821216|NCT01997645|PROCEDURE|LIFT|
218821217|NCT01997645|PROCEDURE|RAF|
218821218|NCT05771714|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
218821219|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
218821220|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
218821221|NCT04441697|DIAGNOSTIC_TEST|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
218821222|NCT00046904|BIOLOGICAL|etanercept|
219579939|NCT00233506|DRUG|CpG 7909|
219579940|NCT00787397|BEHAVIORAL|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
219579941|NCT04530240|PROCEDURE|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
219195295|NCT04466683|RADIATION|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
219008893|NCT06119360|PROCEDURE|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
219008894|NCT06119360|PROCEDURE|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
219008895|NCT02986399|OTHER|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
219008896|NCT02405845|RADIATION|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
219008897|NCT01607086|DRUG|Cherry lamotrigine ODT|25mg, taken orally on one study visit
219008898|NCT01607086|DRUG|Cherry Placebo|Taken orally on one study visit
219008899|NCT03089450|DEVICE|CGBio stent|Percutaneous Coronary Intervention
219195296|NCT04466683|RADIATION|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
219195297|NCT06842329|BEHAVIORAL|Halfer Skin Tape Technique|Helfer Skin Tap Technique (HSTT) is a non-pharmacological pain management method that involves a series of gentle taps on the skin prior to an intramuscular injection. This technique is intended to distract the patient from the pain of the injection and reduce perceived pain intensity by stimulating different sensory pathways.
219195298|NCT06842329|BEHAVIORAL|ShotBlocker Technique|ShotBlocker is a non-pharmacological device that applies pressure to the skin at the injection site to disrupt pain signals and reduce the pain perception during intramuscular injections. The pressure stimulates the sensory nerve fibers, which helps block the sharp pain from the needle insertion.
219195299|NCT06842329|OTHER|Standard Intramusculer injection|The control group will receive a standard intramuscular injection without the use of any pain management techniques (such as HSTT or ShotBlocker). This group serves as a baseline to compare the effect
219195300|NCT06841276|DEVICE|QoLibri Digital Therapy|A personalized program intended for chronic pain patients. It includes digitalized physical and psychological complementary approaches dedicated to symptoms management and quality of life improvement.
219195301|NCT06814067|DRUG|Pembrolizumab|Two cycles of neoadjuvant pembrolizumab (200mg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of pembrolizumab (200mg q3w)maintenance therapy was given.
219195302|NCT06814067|DRUG|Ivonescimab|Two cycles of neoadjuvant Ivonescimab (10mg/kg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of Ivonescimab maintenance therapy (10mg/kg q3w) was given.
219579942|NCT02740829|DRUG|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
219579943|NCT02740829|DRUG|Intranasal placebo|Placebo
219008900|NCT03089450|DEVICE|Biomatrix flex|Percutaneous Coronary Intervention
219008901|NCT04337749|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
219008902|NCT04337749|DEVICE|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
219008903|NCT04337749|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
219195303|NCT06814067|PROCEDURE|Surgery|Radical surgery
219195304|NCT06814067|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy with/without concurrent cisplatin-based chemotherapy, based on pathologic risk factors.
219195305|NCT06814704|OTHER|Hypopressive exercises , hot packs, acetaminophen, progressive strengthening exercises|20 subjects combined HE with traditional treatments for low back pain (heat therapy, medication, and progressive strength training).
219195306|NCT06814704|OTHER|heat therapy, pharmacological therapy, progressive strengthening exercises|"Hypopressive exercises :The women were instructed to hold breath with chest extension for approximately 10 seconds before they began to breathe again. Then, using a series of upper and lower limb positions, the subjects were shown how to apply a series of hypopressive postures"
219579944|NCT03275766|OTHER|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
219579945|NCT03275766|OTHER|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
219579946|NCT03275766|OTHER|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
219008904|NCT04337749|DEVICE|Placebo socks|Placebo socks were given to patients for 2 weeks
219008905|NCT01761110|BEHAVIORAL|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
219008906|NCT05749445|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
219008907|NCT01901497|DEVICE|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
219579947|NCT03275766|OTHER|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
218821223|NCT04144777|DIETARY_SUPPLEMENT|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
219008908|NCT03295578|OTHER|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
219008909|NCT03295578|OTHER|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
219008910|NCT03295578|DEVICE|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
219008911|NCT01260285|DRUG|Vardenafil|10 mg PO once
219008912|NCT02821481|DIETARY_SUPPLEMENT|Beta-alanine|
219195307|NCT06814418|PROCEDURE|Non-surgical periodontal treatment|Step I and II of periodontal treatment.
219579948|NCT05320848|BEHAVIORAL|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
218821224|NCT01615783|OTHER|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
218821225|NCT01615783|OTHER|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
218821226|NCT02306811|DRUG|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
218821227|NCT03446898|OTHER|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
218821228|NCT06308224|OTHER|Modified-Otago Exercises|"Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking."
219008913|NCT02821481|DIETARY_SUPPLEMENT|Placebo|
219008914|NCT02821481|BEHAVIORAL|Muscular endurance exercise|
219195308|NCT06814418|PROCEDURE|Injectable Platelet Rich Fibrin (I-PRF)|Infusion of I-PRF in sited with PPD≥5mm.
219579949|NCT04460196|OTHER|survey|Each admitted patient will complete a questionnaire
218821229|NCT06308224|OTHER|Tai-Chi Exercises|"Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes."
218821230|NCT02184598|BEHAVIORAL|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
218821231|NCT02184598|BEHAVIORAL|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
218821232|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
219008915|NCT01848002|DRUG|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
219008916|NCT01848002|DRUG|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
219008917|NCT05248412|OTHER|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
219008918|NCT03886376|OTHER|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
219008919|NCT03886376|OTHER|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
219008920|NCT04905212|DRUG|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
219008921|NCT04905212|DRUG|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
219008922|NCT04905212|DRUG|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
219195309|NCT06812338|DEVICE|mechanical traction|Participants will receive traction therapy as follows: force will start at 25% of Body weight, gradually increasing until the tolerance for pulling is reached with maximum of 50% of body weight. The session will be 15 minutes long (1min for acceleration, 13 min application, 1min deceleration); it will be intermittent with ratio of 30 s on and 10s off
219195310|NCT06841796|DEVICE|Real time continuous glucose monitor (Stelo)|Real time CGM will be worn continuously for 24 weeks. Participants will be able to see the glucose data from the CGM facilitating changes in nutritional habits and physical activity
219195311|NCT06841159|RADIATION|Ultra-fractionated radiation therapy|Radiation therapy will be delivered every 3 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of sintilimab.
219579950|NCT03847103|OTHER|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
219195312|NCT06841159|DRUG|Sintilimab|Sintilimab will be given at 200 mg q3w every 3 weeks and schedule to the next day of every pulses of radiation.
219195313|NCT06841159|DRUG|Standard systemic therapy|"First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events."
219195314|NCT06842745|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
218821233|NCT04676100|OTHER|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
218821234|NCT06259318|BEHAVIORAL|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
218821235|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
219195315|NCT06842745|BEHAVIORAL|Speech-Language Therapy (SLT)|"Our SLT protocol draws from two theories and evidence-based cognitive-linguistic frameworks: (1) conversational alignment, which engages priming of lexical and syntactic structures through dialogue and conversation and (2) increased tolerance of memory load in the context of sentence repetition and dialogue tasks. Administration of these tasks will abide by principles of constraint-induced language therapy, i.e., intense treatment schedule and verbal responding only.~All participants will receive SLT."
219195316|NCT05550376|OTHER|Registry|Non-interventional registry
218821236|NCT01178840|DEVICE|WC then FC2|4 uses of WC followed by 4 uses of FC2
218821237|NCT01178840|DEVICE|FC2 then WC|4 uses of WC followed by 4 uses of FC2
218821238|NCT04515888|OTHER|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
218821239|NCT04844125|DRUG|SHR-1209|SHR-1209
219195317|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
218821240|NCT04844125|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
218821241|NCT04946630|DEVICE|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
219195318|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
219195319|NCT06752174|BIOLOGICAL|sIPV+bOPV|"2+1 sequential immunization program (sIPV-sIPV-bOPV)"
219579951|NCT03847103|OTHER|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
219579952|NCT03847103|OTHER|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
219579953|NCT04866849|OTHER|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
219195320|NCT06752174|BIOLOGICAL|wIPV+bOPV|"2+1 sequential immunization program (wIPV-wIPV-bOPV)"
219195321|NCT06599723|DRUG|Conventional lumbar steroid injections|Patients will receive conventional lumbar steroid injections.
219579954|NCT02592109|BEHAVIORAL|Enhanced Counseling using CFR based on Linear Programming|
219763434|NCT03981926|OTHER|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
219763435|NCT06052059|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
219195322|NCT06599723|PROCEDURE|Racz catheter|Patients will receive lumbar epidural steroid using Racz catheter.
218821242|NCT04946630|OTHER|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
218821243|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
218821244|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
218821245|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
218821246|NCT04458740|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
218821247|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
218821248|NCT01001351|DRUG|PRT-201|Applied topically during surgery.
218821249|NCT01001351|DRUG|Placebo|Applied topically during surgery
218821250|NCT01466491|DRUG|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
218821251|NCT00041340|DRUG|imatinib mesylate|Given orally
218821252|NCT00041340|OTHER|laboratory biomarker analysis|Correlative studies
218821253|NCT02727322|DRUG|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
218821254|NCT02727322|DRUG|Placebo|Placebo
219195323|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
219195324|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
218821255|NCT05595200|DIAGNOSTIC_TEST|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
218821256|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
218821257|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
218821258|NCT05745649|OTHER|Resistance exercises|Resistance exercises
218821259|NCT05745649|OTHER|Ankle weights|Ankle weights
218821260|NCT04110106|OTHER|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist.
218821261|NCT00772278|PROCEDURE|carotid artery stenting|carotid artery angiography, angioplasty and stenting
218821262|NCT00772278|PROCEDURE|carotid endarterectomy|open surgery including endarterectomy
218821263|NCT05510518|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
218821264|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
218821265|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
218821266|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
218821267|NCT04457986|DRUG|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
218821268|NCT04457986|DRUG|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
219195325|NCT04142632|PROCEDURE|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
219763436|NCT06052059|DRUG|IV Placebo|Placebo matching IV tulisokibart
218821269|NCT04457986|DRUG|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
218821270|NCT03795649|DRUG|Tranexamic Acid|Imunomodulatory effect
218821271|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
218821272|NCT00658489|BEHAVIORAL|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
218821273|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
219195326|NCT06591819|RADIATION|Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost|Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
219195327|NCT06603051|PROCEDURE|Cryoneurolysis|Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
219195328|NCT06590610|DEVICE|Radial pressure wave (RPW) - Intelect RPW2 Chattanooga|RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
219763437|NCT06052059|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
219763438|NCT06052059|DRUG|SC Placebo|Placebo matching SC tulisokibart
218821274|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
218821275|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
218821276|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
218821277|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
218821278|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
218821279|NCT05703217|PROCEDURE|classical physical therapy with physiotherapy.|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
218821280|NCT01123148|DEVICE|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
218821281|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
218821282|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
219008923|NCT03946033|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
219195329|NCT06593327|BEHAVIORAL|Intensive Prevention Strategy|Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
219195330|NCT06806891|BEHAVIORAL|Buddhist walking meditation|the participants will be on hemodialyis. they complain restless leg syndrome. the participants will receive Buddhist walking meditation. this program of meditation will be 30 minutes thrice weekly. before and after Buddhist walking meditation .. The number of patients in the group will be 20. the total duration of Buddhist walking meditation will be 12 weeks.
219195331|NCT06595212|OTHER|multiomic profile to assess genetic and environmental risk factiors|Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
219195332|NCT06597253|DEVICE|Lactate sensor|Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
218821283|NCT05367193|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
218821284|NCT05367193|DEVICE|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
218821285|NCT05143333|OTHER|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
218821286|NCT05124717|DRUG|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
219008924|NCT01362374|DRUG|5-FU|5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
219008925|NCT01362374|DRUG|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
219008926|NCT01362374|DRUG|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
219008927|NCT01362374|DRUG|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
219008928|NCT01362374|DRUG|Leucovorin|Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
219008929|NCT01362374|DRUG|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
219008930|NCT01362374|DRUG|Paclitaxel|Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
219008931|NCT01430156|DRUG|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
219008932|NCT01430156|DRUG|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
219008933|NCT00970333|DRUG|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
219195333|NCT02938923|DRUG|Testosterone|Topical testosterone gel 1%
219195334|NCT02938923|DRUG|Placebo gel|Inactive skin gel
219195335|NCT02938923|BEHAVIORAL|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
219195336|NCT02938923|BEHAVIORAL|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
219195337|NCT02938923|BEHAVIORAL|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
219195338|NCT04750564|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
219195339|NCT04750564|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
219195340|NCT06807684|DEVICE|transcranial magnetic stimulation|The investigators will deliver a type of high frequency rTMS known as intermittent theta burst stimulation (iTBS), 2400 stimulations per session, equally divided between the bilateral IPL and IFG.
219435823|NCT04615780|OTHER|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
219435824|NCT04615780|OTHER|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
219435825|NCT05915117|DIETARY_SUPPLEMENT|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
219579955|NCT02439671|BEHAVIORAL|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
219195341|NCT00721149|DEVICE|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
219195342|NCT04820036|DIAGNOSTIC_TEST|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
219195343|NCT04820036|BEHAVIORAL|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
219195344|NCT04820036|DIAGNOSTIC_TEST|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
219195345|NCT04820036|DIAGNOSTIC_TEST|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
218821287|NCT05124717|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
218821288|NCT00983866|BEHAVIORAL|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
218821289|NCT00987285|BEHAVIORAL|CASM +|Computer Assisted Self Management plus Social Support
218821290|NCT00987285|BEHAVIORAL|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
219008934|NCT00407823|PROCEDURE|Central venous oxygen saturation continuous monitoring|
219195346|NCT04820036|DIAGNOSTIC_TEST|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
219195347|NCT05428007|DRUG|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
219008935|NCT03296657|DRUG|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
219008936|NCT05245747|DEVICE|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
219008937|NCT05846906|DRUG|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
219008938|NCT05846906|DRUG|Clomiphene Citrate 50mg|used for ovionulation induct
219435826|NCT05915117|DRUG|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
219579956|NCT06111274|DRUG|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
218821291|NCT05446935|PROCEDURE|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
219763439|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.
219763440|NCT06305767|BIOLOGICAL|Intismeran autogene|Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
219763441|NCT06305767|OTHER|Placebo|Intismeran autogene diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
219763442|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.
218821292|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
218821293|NCT06495957|OTHER|Electroacupuncture group|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
218821294|NCT06495957|OTHER|Micro-acupuncture group|After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
218821295|NCT00593060|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
218821296|NCT00593060|DRUG|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
218821297|NCT01049373|DRUG|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
218821298|NCT01049373|DRUG|Placebo solution|10 drops, t.i.d, 15 weeks
218821299|NCT02061475|DRUG|Lidocaine Patches|
218821300|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
219435827|NCT02621645|PROCEDURE|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
219435828|NCT02621645|PROCEDURE|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
219579957|NCT03192865|PROCEDURE|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
218821301|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
218821302|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
219435829|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
219435830|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
219579958|NCT03754374|OTHER|access to healthcare|use or non-use of dedicated health facilities
219763443|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant intismeran autogene plus pembrolizumab plus EV treatment. Adjuvant intismeran autogene plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
219763444|NCT06966960|BEHAVIORAL|Online RPG adventure games and e-book learning.|Learning obstetric fetal heart rate monitoring technology through online RPG adventure games and e-book learning.
218821303|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
218821304|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
218821305|NCT02960633|DEVICE|Corail with collar.|
218821306|NCT02960633|DEVICE|Corail without collar.|
218821307|NCT00339040|BIOLOGICAL|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
218821308|NCT00339040|OTHER|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
218821309|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
218821310|NCT04602143|DRUG|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
218821311|NCT05399927|OTHER|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
218821312|NCT00003312|RADIATION|iodine I 125|
219435831|NCT02621645|DEVICE|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
219435832|NCT05226767|DIETARY_SUPPLEMENT|NLC-V|NLC-V
218821313|NCT03920501|BEHAVIORAL|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
218821314|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
218821315|NCT02135627|OTHER|Current standard therapy|
218821316|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
218821317|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
218821318|NCT06101004|DEVICE|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
218821319|NCT02961270|DRUG|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
218821320|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
218821321|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
218821322|NCT06338163|COMBINATION_PRODUCT|Polihexanide-based bundle|Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
218821323|NCT06338163|COMBINATION_PRODUCT|Standard bundle|Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
218821324|NCT02499887|DRUG|beclamethasone dipropionate|Inhaler
218821325|NCT02499887|DRUG|albuterol|Inhaler
219435833|NCT04500067|DRUG|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
218821326|NCT02499887|DRUG|Prednisone|Oral corticosteroid
218821327|NCT01805284|DRUG|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
218821328|NCT05254353|PROCEDURE|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
218821329|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
218821330|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
219008939|NCT03622307|DEVICE|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
219008940|NCT04124120|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
219008941|NCT04124120|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
219008942|NCT05913180|DRUG|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
219008943|NCT05913180|DRUG|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
219008944|NCT05520931|OTHER|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
219008945|NCT02848157|DRUG|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
219008946|NCT02848157|DRUG|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
219008947|NCT02848157|DRUG|Ropivacaine|
219435834|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
219435835|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
219008948|NCT03752359|DIETARY_SUPPLEMENT|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
219435836|NCT00427167|DRUG|AMA1-C1/Alhydrogel + CPG 7909|
219435837|NCT04761952|DRUG|azathioprine|daily orally
219435838|NCT04761952|DRUG|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
219435839|NCT04761952|DRUG|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
219435840|NCT01962389|DEVICE|Winsor Laser Catheter|
219435841|NCT01674738|DRUG|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
219435842|NCT01674738|DRUG|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
219435843|NCT01674738|DRUG|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
219435844|NCT02423460|OTHER|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
219435845|NCT05300893|OTHER|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
219435846|NCT04566757|BIOLOGICAL|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
219435847|NCT00466661|DRUG|Acamprosate|666 mg po TID
219435848|NCT00466661|DRUG|Placebo|2 tabs po TID
219435849|NCT06449846|DIAGNOSTIC_TEST|circulating tumor cell DNA detection|circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
219435850|NCT03701204|BEHAVIORAL|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule."
219435851|NCT05833555|BEHAVIORAL|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
219435852|NCT05833555|BEHAVIORAL|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
219435853|NCT05833555|BEHAVIORAL|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
219435854|NCT05833555|OTHER|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
219435855|NCT02494219|PROCEDURE|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
219435856|NCT00045812|DRUG|SCH-58235|
219435857|NCT02678728|DRUG|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
219435858|NCT02678728|DRUG|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
219435859|NCT00168909|DRUG|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
219435860|NCT00168909|DRUG|placebo|placebo once daily, oral, for 3 years
219435861|NCT02012881|BEHAVIORAL|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
219435862|NCT02012881|BEHAVIORAL|Usual practice|Normal curriculum
219435863|NCT02362542|DEVICE|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
219435864|NCT01125878|DIETARY_SUPPLEMENT|Placebo|placebo
219435865|NCT01125878|DIETARY_SUPPLEMENT|Starch composite B|fiber mixture
219435866|NCT01125878|DIETARY_SUPPLEMENT|Starch composite C|fiber mixture
219435867|NCT01125878|DIETARY_SUPPLEMENT|Starch composite D|fiber mixture
219435868|NCT02611700|DRUG|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
219435869|NCT02611700|DRUG|Paclitaxel|175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
219579959|NCT05887895|DRUG|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
219435870|NCT02611700|DRUG|Cisplatin|60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
219435871|NCT02611700|DRUG|Placebo|400mg,day1,weekly,until disease progression or toxicity
219435872|NCT02565615|OTHER|No intervention|Because this is a non-interventional study, there is no intervention here.
219579960|NCT00971841|DRUG|Paclitaxel|
218821331|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
218821332|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
218821333|NCT00104988|DRUG|temozolomide|75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
218821334|NCT00104988|DRUG|thalidomide|200 mg/day PO daily
218821335|NCT01720394|DEVICE|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
218821336|NCT01720394|DRUG|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
218821337|NCT00615576|DRUG|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
218821338|NCT00615576|DRUG|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
218821339|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
218821340|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
218821341|NCT00812955|DRUG|ABT-143|Once daily for 8 weeks
218821342|NCT00812955|DRUG|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
219008949|NCT03752359|DIETARY_SUPPLEMENT|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
218821343|NCT05499026|DRUG|Chenodeoxycholic Acid|Bile acid
218821344|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
218821345|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
218821346|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
218821347|NCT00775957|PROCEDURE|FLT-PET scan|imaging scan
218821348|NCT00775957|PROCEDURE|FDG-PET scan|imaging scan
218821349|NCT06061692|DRUG|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
219008950|NCT02950454|OTHER|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
219008951|NCT02950454|OTHER|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
219008952|NCT03766555|PROCEDURE|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
218821350|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
218821351|NCT05658718|PROCEDURE|refractive surgery|refractive surgery
218821352|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
218821353|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
218821354|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
218821355|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
219435873|NCT04655053|BEHAVIORAL|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
219435874|NCT04655053|BEHAVIORAL|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
219435875|NCT04655053|BEHAVIORAL|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
219435876|NCT03920865|DRUG|Risdiplam|5 milligram (mg) oral dose administered in fasted state
219435877|NCT01852929|OTHER|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
219435878|NCT01932658|BIOLOGICAL|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
219435879|NCT03686696|DRUG|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
219435880|NCT03686696|DRUG|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
219435881|NCT03686696|DRUG|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
219435882|NCT04197141|RADIATION|Conventionally-fractionated WPRT|Total dose: 45 Gy in 25 fractions WPRT
219435883|NCT04197141|RADIATION|Hypofractionated WPRT|Total dose: 25 Gy in 5 fractions WPRT
219435884|NCT03240718|PROCEDURE|Laser treatment|CORE fractional CO2 laser treatment
219435885|NCT00030355|DRUG|homoharringtonine|
219435886|NCT00030355|PROCEDURE|chemotherapy|
219435887|NCT00158223|DRUG|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
219435888|NCT00158223|DRUG|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
219435889|NCT03171311|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
219435890|NCT03171311|PROCEDURE|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
219435891|NCT00889395|BEHAVIORAL|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
219435892|NCT01787799|DEVICE|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
219435893|NCT03078959|OTHER|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
219579961|NCT03814616|DRUG|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
219435894|NCT03998761|DRUG|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
219435895|NCT03998761|DRUG|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
219435896|NCT01328197|DEVICE|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
219435897|NCT03846973|DRUG|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
219435898|NCT03846973|OTHER|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
219435899|NCT05276427|OTHER|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
219579962|NCT02920918|DRUG|Canagliflozin|
219579963|NCT02920918|DRUG|Sitagliptin|
219579964|NCT04572126|BEHAVIORAL|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
219579965|NCT04572126|BEHAVIORAL|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
218821356|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
218821357|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
218821358|NCT02649920|DEVICE|Cervical ripening balloon|
218821359|NCT02649920|DRUG|Dinoprostone|
218821360|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
218821361|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
218821362|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
218821363|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
218821364|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
218821365|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
218821366|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
219435900|NCT03620604|DEVICE|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
219435901|NCT05848076|OTHER|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
219435902|NCT05848076|OTHER|core stability|McGill exercises for the low back.
219435903|NCT01463020|BEHAVIORAL|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
219435904|NCT01463020|OTHER|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
218821367|NCT00820144|BIOLOGICAL|CTB by nasal way|
218821368|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
219008953|NCT03766555|PROCEDURE|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
219435905|NCT03483376|PROCEDURE|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
219435906|NCT03483376|DEVICE|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
219435907|NCT02445703|BIOLOGICAL|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
219435908|NCT02445703|BIOLOGICAL|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
219435909|NCT05941663|OTHER|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
218821369|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
218821370|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
218821371|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
218821372|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
218821373|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
219435910|NCT02867163|DRUG|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
219435911|NCT00721617|OTHER|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
218821374|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
218821375|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
218821376|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
218821377|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
218821378|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
218821379|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
218821380|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
218821381|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
218821382|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
218821383|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
219435912|NCT00721617|OTHER|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
219435913|NCT00721617|OTHER|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
219763445|NCT06966960|BEHAVIORAL|E-book|E-book learning mode for obstetric fetal heart rate monitoring technology.
219435914|NCT06204289|BEHAVIORAL|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
219435915|NCT01804114|PROCEDURE|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
219435916|NCT01804114|PROCEDURE|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
219435917|NCT01763112|DEVICE|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
218821384|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
218821385|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
218821386|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
218821387|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
218821388|NCT04244071|OTHER|routine hospital care|routine hospital care
218821389|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
218821390|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
218821391|NCT00257946|PROCEDURE|Repair of CDH w/SIS Gold|
218821392|NCT00257946|PROCEDURE|Repair of CDH w/Alloderm|
218821393|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
218821394|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
218821395|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
218821396|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
218821397|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
218821398|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
218821399|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
218821400|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
218821401|NCT06281743|OTHER|Survey|A web based survey is sent out to pediatric critical care physicians
218821402|NCT00925002|DRUG|Tafamidis|20 mg oral Fx-1006A daily
219435918|NCT01213914|DEVICE|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
218821403|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
218821404|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
218821405|NCT00613548|PROCEDURE|CABG alone|CABG alone
218821406|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
218821407|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
218821408|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
219435919|NCT01213914|OTHER|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
219435920|NCT05117749|DRUG|Saffron 100|to Mild and Moderate UC patients
219435921|NCT05117749|DRUG|Saffron 50|to Mild and Moderate UC patients
219435922|NCT05117749|DRUG|Placebo|to Mild and Moderate UC patients
219435923|NCT02285517|PROCEDURE|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
219435924|NCT02285517|PROCEDURE|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
219435925|NCT05369546|DIAGNOSTIC_TEST|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
219763446|NCT06966700|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
218821409|NCT05853354|BIOLOGICAL|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
219435926|NCT04714723|BEHAVIORAL|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
219579966|NCT03537274|BIOLOGICAL|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
219579967|NCT03537274|BIOLOGICAL|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
218821410|NCT03757429|OTHER|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
218821411|NCT00651222|OTHER|No intervention was required|Death records were reviewed, therefore, there was no intervention
218821412|NCT04038073|DIAGNOSTIC_TEST|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
218821413|NCT04038073|DIAGNOSTIC_TEST|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
218821414|NCT04038073|DIAGNOSTIC_TEST|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
218821415|NCT04038073|DIAGNOSTIC_TEST|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
218821416|NCT03200002|DRUG|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
218821417|NCT03200002|DRUG|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
218821418|NCT00293163|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
219435927|NCT04714723|BEHAVIORAL|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
219435928|NCT02294669|DEVICE|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
219579968|NCT00033124|BEHAVIORAL|Behavior Therapy|
219579969|NCT03952234|DRUG|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
219763447|NCT06966700|BIOLOGICAL|Pembrolizumab|IV infusion
218821419|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
218821420|NCT01017224|OTHER|18F-FAZA|PET scan
218821421|NCT00358319|DRUG|Karenitecin|
218821422|NCT00358319|DRUG|Valproic Acid|
218821423|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
218821424|NCT02259816|DRUG|Telmisartan|
219195348|NCT05428007|DRUG|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
219435929|NCT00561587|DRUG|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
219435930|NCT06345599|RADIATION|Radiotherapy|This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
218821425|NCT02259816|DRUG|Amlodipine|
219435931|NCT06345599|DRUG|Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab|GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
219435932|NCT06345599|DRUG|Chemotherapy:Albumin-bound paclitaxel、Gemcitabine|Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
219579970|NCT02409602|OTHER|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
219579971|NCT03743740|OTHER|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
219579972|NCT00974974|DRUG|IPX066|extended-release carbidopa-levodopa capsules
219435933|NCT01191632|RADIATION|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
218821426|NCT00346619|DRUG|Nelfinavir|
218821427|NCT04353687|DEVICE|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
218821428|NCT02834455|DEVICE|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
218821429|NCT02834455|DEVICE|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
218821430|NCT03667105|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
218821431|NCT03667105|OTHER|MC|Xenogenous graft placed in the surgical site.
218821432|NCT03667105|OTHER|XDM|Xenogenous dermal collagen graft placed in the surgical site.
218821433|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
218821434|NCT03064932|OTHER|Controlled feeding diet|Average American diet with different levels of spices
218821435|NCT04221633|BEHAVIORAL|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
218821436|NCT04221633|BEHAVIORAL|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
218821437|NCT02538120|OTHER|Microvascular assessment|Microvascular assessment
218821438|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
218821439|NCT05726149|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
218821440|NCT05726149|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
219435934|NCT01191632|RADIATION|No Radiation|Control group with 0Gy
219435935|NCT00719537|DRUG|Aspirin|Aspirin 81 mg once a day
219435936|NCT00719537|DRUG|Placebo Oral Tablet|Placebo 1 tab Daily
219435937|NCT00719537|DRUG|Progesterone|Oral Progesterone 200 mg Twice Daily
219435938|NCT00241878|BEHAVIORAL|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
219579973|NCT00974974|DRUG|IR CD-LD|immediate-release carbidopa-levodopa tablets
219579974|NCT04648566|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
218821441|NCT05726149|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
218821442|NCT00216281|DRUG|Clozapine augmented with atomoxetine up to 40 mg or placebo|
218821443|NCT00416741|BEHAVIORAL|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
218821444|NCT00473018|BEHAVIORAL|standard versus enhanced risk reduction counseling|
218821445|NCT01561911|DRUG|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
218821446|NCT04340518|DEVICE|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
218821447|NCT00305448|DRUG|Fulvestrant|250 intramuscular injection
218821448|NCT00305448|DRUG|Fulvestrant|500 mg intramuscular injection
218821449|NCT02918526|DEVICE|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
219579975|NCT04648566|PROCEDURE|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
219579976|NCT00422981|DRUG|AL-108|5 mg QD
219579977|NCT00422981|DRUG|AL-108|15 mg BID
219579978|NCT00422981|DRUG|Placebo|Placebo
219579979|NCT01898325|DEVICE|Fibroscan|Fibroscan
219579980|NCT01959035|DRUG|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
219579981|NCT03750435|PROCEDURE|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
219579982|NCT00531141|OTHER|examination only|OCT performed twice
219579983|NCT02317718|OTHER|monitor reproductive outcome|
218821450|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
218821451|NCT03401320|DRUG|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
218821452|NCT00429988|GENETIC|fluorescence in situ hybridization|
219435939|NCT00241878|BEHAVIORAL|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
218821453|NCT00429988|GENETIC|polymerase chain reaction|
218821454|NCT00429988|GENETIC|proteomic profiling|
218821455|NCT00429988|OTHER|cytology specimen collection procedure|
218821456|NCT00429988|OTHER|immunohistochemistry staining method|
218821457|NCT00429988|PROCEDURE|breast duct lavage|
218821458|NCT02803385|OTHER|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
218821459|NCT02803385|OTHER|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
218821460|NCT00066872|DRUG|imiquimod|
218821461|NCT00066872|PROCEDURE|conventional surgery|
218821462|NCT00328172|DRUG|Placebo|Placebo matching BI 1356
218821463|NCT00328172|DRUG|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
218821464|NCT00328172|DRUG|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
218821465|NCT00328172|DRUG|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
218821466|NCT00328172|DRUG|Metformin|Metformin
218821467|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at morning
218821468|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at night
218821469|NCT02782910|DEVICE|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
218821470|NCT03293121|BEHAVIORAL|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
218821471|NCT03293121|BEHAVIORAL|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
218821472|NCT00030147|DRUG|Raloxifene|60 mg a day orally administered
218821473|NCT00030147|DRUG|Rimostil|1000 mg twice a day administered orally
218821474|NCT00030147|DRUG|Transdermal Estradiol|100 microgram per day transdermal estradiol
218821475|NCT00030147|DRUG|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
218821476|NCT03750019|BEHAVIORAL|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
219008954|NCT02657382|BEHAVIORAL|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
219008955|NCT02657382|OTHER|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
219008956|NCT00132184|DRUG|Vitamin D|
218821477|NCT03750019|BEHAVIORAL|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
218821478|NCT03750019|BEHAVIORAL|Neutral rehearsal|Participants rehearsed their journey to campus that day.
218821479|NCT00875914|PROCEDURE|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
219435940|NCT01018693|DRUG|VAK694; Alutard Avanz SQ|
219763448|NCT06966700|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
218821480|NCT00558636|DRUG|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
218821481|NCT00558636|DRUG|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
218821482|NCT00374114|PROCEDURE|cervical conization|
218821483|NCT00374114|PROCEDURE|ultrasonic surgical aspiration of the cervix|
218821484|NCT01990742|BEHAVIORAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
218821485|NCT01868828|DRUG|PAD|Induction Therapy of PAD for 4 cycles.
218821486|NCT01868828|DRUG|VCD|Induction Therapy of VCD for 4 cycles.
218821487|NCT01868828|OTHER|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
219008957|NCT00805623|DIETARY_SUPPLEMENT|sucrose|1 cc of sucrose 33.5% with or without pacifier
219008958|NCT01926314|DEVICE|PHENIX Neuromuscular Stimulation Therapy System device|
218821488|NCT03443687|BEHAVIORAL|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
218821489|NCT03443687|DEVICE|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
218821490|NCT06314009|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
218821491|NCT02091076|DEVICE|Silk fibroin with bioactive coating layer dressing|
218821492|NCT02091076|DEVICE|Bactigras wound dressing|
218821493|NCT06337448|DEVICE|Blue LED|The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
218821494|NCT06563856|DRUG|TEPEZZA|Administered as a SubQ injection or IV injection.
218821495|NCT06563856|DRUG|EDP|Administered as a SubQ injection.
218821496|NCT04108273|BEHAVIORAL|Organizational Skills Training|OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
219008959|NCT01926314|OTHER|usual home care without device|
219008960|NCT02592785|DRUG|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
219008961|NCT02611778|BIOLOGICAL|ranibizumab|
219008962|NCT02526472|PROCEDURE|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
219435941|NCT01018693|DRUG|VAK694 placebo infusion; Alutard Avanz SQ|
219435942|NCT01018693|DRUG|VAK694 placebo infusion; Saline|
218821497|NCT05261659|BEHAVIORAL|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
219435943|NCT06508853|OTHER|Qualitative research (no intervention)|Interviews are being conducted with support workers and managers.
219435944|NCT05462405|PROCEDURE|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
219435945|NCT00158405|PROCEDURE|Structured Treatment Interruption|
219435946|NCT00158405|DRUG|Zidovudine (ZDV)|
219435947|NCT00158405|DRUG|Lamivudine (3TC)|
219435948|NCT00158405|DRUG|Efavirenz (EFV)|
219435949|NCT00158405|DRUG|Ritonavir (NRV)|
219435950|NCT00158405|DRUG|Indinavir (IDV)|
219435951|NCT01360853|DRUG|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
219435952|NCT01360853|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
219435953|NCT01360853|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
219435954|NCT01142193|DRUG|USL255|
219435955|NCT01142193|DRUG|Placebo|
219435956|NCT04397029|DEVICE|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
219435957|NCT02077504|OTHER|MEG and MRI|CONDUCTOME
218821498|NCT05261659|BEHAVIORAL|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
218821499|NCT04357899|DRUG|thrombolysis therapy|
218821500|NCT04357899|PROCEDURE|endovascular therapy|
218821501|NCT04357899|PROCEDURE|decompressive surgery|
218821502|NCT04357899|DIAGNOSTIC_TEST|multimodal imaging in acute ischemic stroke|
218821503|NCT04357899|PROCEDURE|transfer of acute stroke patients to tertiary stroke centers|
218821504|NCT04357899|DRUG|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
218821505|NCT03830879|OTHER|No intervention|This cohort study have any no intervention.
218821506|NCT03929692|BEHAVIORAL|Multi-layer health promotion program|
218821507|NCT03929692|OTHER|Standard health education|
218821508|NCT05173090|DRUG|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
218821509|NCT03715790|BEHAVIORAL|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
218821510|NCT03715790|BEHAVIORAL|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
218821511|NCT02007629|DRUG|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
218821512|NCT04933292|DRUG|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
218821513|NCT04933292|DRUG|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
218821514|NCT05639959|DRUG|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
218821515|NCT05639959|DEVICE|Nasal spray|device can work properly for actuation during trials
218821516|NCT04046393|DEVICE|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
219008963|NCT02526472|PROCEDURE|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
218821517|NCT04046393|DEVICE|Meridian Energy Analysis Device(MEAD)|measure meridian energy
218821518|NCT04046393|PROCEDURE|bacteria culture|use culture swab to culture nasal discharge
218821519|NCT04046393|PROCEDURE|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
218821520|NCT04046393|COMBINATION_PRODUCT|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
218821521|NCT05469919|DRUG|Ceralasertib|Ceralasertib taken orally
219008964|NCT02622542|DEVICE|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
219435958|NCT02381548|DRUG|Adavosertib|Given PO
218821522|NCT02953184|DRUG|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
218821523|NCT02953184|DRUG|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
218821524|NCT02953184|DRUG|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
218821525|NCT02953184|DRUG|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
218821526|NCT02953184|DRUG|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
218821527|NCT02953184|DRUG|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
218821528|NCT02953184|PROCEDURE|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
218821529|NCT02953184|PROCEDURE|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
218821530|NCT02953184|PROCEDURE|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
218821531|NCT02261961|BIOLOGICAL|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
218821532|NCT02261961|OTHER|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
218821533|NCT02261961|OTHER|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
218821534|NCT02261961|OTHER|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
218821535|NCT02261961|DIETARY_SUPPLEMENT|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
219435959|NCT02381548|DRUG|Belinostat|Given IV
219435960|NCT02381548|OTHER|Laboratory Biomarker Analysis|Correlative studies
219435961|NCT02381548|OTHER|Pharmacological Study|Correlative studies
219435962|NCT01459068|BEHAVIORAL|Common Elements Treatment Approach|"CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)"
218821536|NCT02261961|DIETARY_SUPPLEMENT|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
219435963|NCT00841269|DRUG|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
219435964|NCT00196196|DEVICE|Codman VPV System|Valve Positioning Verification (VPV) System
218821537|NCT04935255|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
218821538|NCT02097784|PROCEDURE|Echocardiography|
218821539|NCT04919720|BEHAVIORAL|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
219435965|NCT01154595|DIETARY_SUPPLEMENT|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
219435966|NCT01154595|BEHAVIORAL|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
219435967|NCT02910219|DRUG|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
219579984|NCT02613013|DEVICE|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
218821540|NCT03112876|OTHER|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
218821541|NCT02640027|PROCEDURE|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
218821542|NCT02908711|DRUG|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
218821543|NCT01198626|DRUG|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
218821544|NCT01198626|DRUG|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
218821545|NCT01198626|DRUG|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
218821546|NCT03817489|BEHAVIORAL|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
218821547|NCT03817489|BEHAVIORAL|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
218821548|NCT02563730|PROCEDURE|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
218821549|NCT05221008|DRUG|SHR6508；Placebo|Group A:SHR6508 low dose
218821550|NCT05221008|DRUG|SHR6508；Placebo|Group B:SHR6508 medium dose
218821551|NCT05221008|DRUG|SHR6508；Placebo|Group C:SHR6508 high dose
218821552|NCT05221008|DRUG|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
218821553|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
218821554|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
219435968|NCT05106218|DEVICE|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
219435969|NCT05106218|DEVICE|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
219435970|NCT01719679|BEHAVIORAL|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
219435971|NCT02659475|DRUG|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
219435972|NCT03810521|BIOLOGICAL|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
219579985|NCT02613013|DEVICE|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
219579986|NCT02613013|DRUG|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
219763449|NCT06966700|DRUG|Carboplatin|IV infusion
219763450|NCT06966700|DRUG|Paclitaxel|IV infusion
219763451|NCT06966700|DRUG|Doxorubicin|IV infusion
219763452|NCT06966700|DRUG|Epirubicin|IV infusion
219763453|NCT06966700|DRUG|Cyclophosphamide|IV infusion
219763454|NCT06966700|DRUG|Capecitabine|Oral tablet
218821555|NCT06467630|PROCEDURE|Preserving alveolar bone volume after tooth extraction|"* Visit 1: A periodontal or dental implant surgery is done aiming to preserve alveolar bone volume after extraction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* V2bis (1 month +/- 1 week) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
218821556|NCT06467630|PROCEDURE|Alveolar crest reconstruction|"* Visit 1: A periodontal or dental implant surgery is done aiming to alveolar crest reconstruction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
219008965|NCT02622542|OTHER|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
219008966|NCT04079829|OTHER|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
219008967|NCT01930747|DRUG|rocuronium|measure effect on laparoscopic workspace
219008968|NCT01930747|DRUG|Sevoflurane|1 MAC sevoflurane inhalation is given
219435973|NCT00708903|DRUG|neratinib|HKI-272
219435974|NCT00708903|OTHER|Placebo|Placebo
219435975|NCT00708903|DRUG|Moxifloxacin|
219435976|NCT02055170|DRUG|finasteride 5mg oral daily|
219435977|NCT01797315|DRUG|Sirolimus|
219435978|NCT02382653|DRUG|oral perixicam|Oral adminstration of buccal perixicam
219435979|NCT02840513|OTHER|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
219435980|NCT01513863|DRUG|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
219435981|NCT01513863|DRUG|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
218821557|NCT06467630|PROCEDURE|Covering bone defects during immediate implant placement.|"* Visit 1: A periodontal or dental implant surgery is done aiming to cover bone defects during immediate implant placement.~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (3 months ± 1 month) - Late post-surgery follow-up"
218821558|NCT00487981|DEVICE|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
218821559|NCT01345448|DRUG|Brimonidine|0.1% Brimonidine Lotion, dosed once.
218821560|NCT01345448|DRUG|Placebo Lotion|Placebo Lotion dosed once.
219435982|NCT01513863|DRUG|Placebo|Placebo applied to affected area once a day for 70 days
219435983|NCT01015820|PROCEDURE|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
219435984|NCT01015820|DEVICE|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
219435985|NCT01745913|DEVICE|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
219435986|NCT01745913|DRUG|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
219435987|NCT01745913|DRUG|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
218821561|NCT02869724|OTHER|Weekly divided delivery|
218821562|NCT02869724|OTHER|Monthly divided delivery|
219008969|NCT01930747|DRUG|remifentanyl|remifentanyl is given in infusion
219008970|NCT04653805|OTHER|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
218821563|NCT04145076|DRUG|Placebo|Two oral doses of placebo.
218821564|NCT04145076|DRUG|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
219008971|NCT02921698|DEVICE|FRED®|Flow Re-Direction Endoluminal Device
219008972|NCT02746016|OTHER|Infant Formula supplemented with Oligosaccharides|sole source nutrition
219008973|NCT01311570|DRUG|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
219008974|NCT00022633|DRUG|gemcitabine hydrochloride|
219008975|NCT00022633|DRUG|paclitaxel|
219008976|NCT04356690|DRUG|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
218821565|NCT04145076|DRUG|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
218821566|NCT00392093|DRUG|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
218821567|NCT03510130|OTHER|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
218821568|NCT01659450|OTHER|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
219435988|NCT01745913|DRUG|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
219435989|NCT01745913|PROCEDURE|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of \> 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
219763455|NCT06966700|DRUG|Olaparib|Oral tablet
219763456|NCT06967805|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
218821569|NCT01659450|OTHER|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
218821570|NCT01659450|OTHER|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
218821571|NCT05246969|OTHER|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
218821572|NCT01365793|DRUG|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
218821573|NCT01365793|DRUG|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
218821574|NCT01365793|DRUG|0.45% saline intravenous fluid|0.45% saline fluid
218821575|NCT01365793|DRUG|0.9% saline Intravenous fluid|0.9% saline fluid
218821576|NCT03764111|DEVICE|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
218821577|NCT03764111|DEVICE|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
218821578|NCT05468502|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
218821579|NCT02808429|DRUG|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
218821580|NCT02808429|DRUG|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
218821581|NCT02808429|DRUG|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
218821582|NCT01342731|DRUG|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
219008977|NCT04774198|DIAGNOSTIC_TEST|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
219435990|NCT01745913|PROCEDURE|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
219435991|NCT01909219|DRUG|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
219435992|NCT03682406|BEHAVIORAL|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
219435993|NCT02089503|OTHER|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
219435994|NCT04961879|PROCEDURE|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~\- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
219435995|NCT04961879|PROCEDURE|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~\- this flap is harvested from the same finger ."
219435996|NCT03127579|BEHAVIORAL|Longer meal duration|Participants have 50% more time to eat than usual
219763457|NCT06967805|OTHER|Placebo|Placebo
219763458|NCT06966453|DRUG|Disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
218821583|NCT01416961|RADIATION|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
218821584|NCT01416961|DRUG|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
218821585|NCT01416961|DRUG|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
218821586|NCT01794910|OTHER|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
219195349|NCT05428007|DRUG|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
219195350|NCT06806761|OTHER|Longitudinal prospective cohort study|Description: Patients after stroke who meet the in- and exclusion criteria will be examined up to 6 times during the first 6 months after their stroke.
219763459|NCT06107361|DEVICE|B. Braun 6.35cm 20 gauge ultralong intravenous catheter|B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter
219763460|NCT06107361|DEVICE|BD 5.71 cm 20 gauge Accucath|Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire
219195351|NCT05519683|DEVICE|TEA|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
219763461|NCT05689151|DRUG|Abrocitinib|Study Drug for Observational Data Collection
219195352|NCT05519683|DRUG|Lexapro|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
219195353|NCT05238311|DRUG|Elranatamab|
218821591|NCT01469039|DRUG|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
219435997|NCT02569021|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)"
219435998|NCT02569021|OTHER|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
218821592|NCT01469039|DRUG|Placebo|Placebo for IM injection, given monthly
218821593|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
219008978|NCT05127889|DRUG|curodont|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
219579987|NCT02613013|PROCEDURE|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
219763462|NCT03817502|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
219763463|NCT03817502|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
219763464|NCT06430801|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
218821594|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
218821595|NCT04037228|DEVICE|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
218821596|NCT03019887|DRUG|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
219435999|NCT02569021|OTHER|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
219436000|NCT02569021|DEVICE|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
219436001|NCT02569021|DEVICE|Trigno wireless system|The Trigno system measure muscle contractions.
219763465|NCT06430801|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
219763466|NCT06430801|OTHER|IV Placebo|Placebo matching IV tulisokibart
219763467|NCT06430801|OTHER|SC Placebo|Placebo matching SC tulisokibart
219763468|NCT06317649|DRUG|Azacitidine|Given IV or SC
219008979|NCT01876342|PROCEDURE|open repair|2-0 sutures
219008980|NCT01876342|PROCEDURE|endoscopic TEP repair|mesh
219436002|NCT02569021|OTHER|GaitRite walking assessment.|GaitRite records a patients gait pattern.
219436003|NCT02603406|DRUG|erythropoietin|
219436004|NCT04916756|DRUG|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
219763469|NCT06317649|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219436005|NCT01728727|OTHER|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
219436006|NCT01728727|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
219436007|NCT05830526|OTHER|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
219436008|NCT04454138|DEVICE|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
219763470|NCT06317649|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219763471|NCT06317649|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219763472|NCT06317649|DRUG|Gilteritinib|Given PO
219763473|NCT06317649|DRUG|Venetoclax|Given PO
219763474|NCT06265285|OTHER|Home Health Encounter|Receive in-home visits by a home health nurse
219763475|NCT06265285|BIOLOGICAL|Nivolumab|Given SC
219763476|NCT06265285|PROCEDURE|Patient Monitoring|Undergo remote patient monitoring
219763477|NCT06265285|OTHER|Questionnaire Administration|Ancillary studies
219763478|NCT03228537|DRUG|Atezolizumab|Given IV
219763479|NCT03228537|DRUG|Cisplatin|Given IV
219763480|NCT03228537|PROCEDURE|Extrapleural Pneumonectomy|Undergo EPP
219008981|NCT02877823|BEHAVIORAL|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
219008982|NCT02877823|BEHAVIORAL|Control|Healthy Lifestyle Education
219008983|NCT05747729|DRUG|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
219008984|NCT05037734|DEVICE|Persona Partial Knee System|Unicompartmental Knee Replacement
219008985|NCT03453710|PROCEDURE|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
219436009|NCT03693404|DRUG|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
219436010|NCT03693404|DRUG|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
219436011|NCT03693404|DRUG|General Anesthetics|Placebo group will only receive standard of care general anesthesia
219436012|NCT01700881|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
219436013|NCT01700881|OTHER|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
219436014|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
219436015|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
219436016|NCT00223912|DEVICE|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
219436017|NCT04848012|DEVICE|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
219436018|NCT05073913|DIAGNOSTIC_TEST|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
219763481|NCT03228537|DRUG|Pemetrexed Disodium|Given IV
219763482|NCT03228537|PROCEDURE|Pleurectomy|Undergo PD
219763483|NCT03228537|RADIATION|Radiation Therapy|Undergo RT
219763484|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219763485|NCT05101746|DRUG|Nitric Oxide (NO) 20 part per million (ppm)|Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
219763486|NCT05101746|OTHER|Standard of care cardiopulmonary bypass|Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
219763487|NCT06315309|DRUG|ATG Combined with Tacrolimus and Mini Methotrexate|On Day -7, subjects will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). Subjects will receive a steroid injection 3 hours before every ATG infusion. On day -6, subjects will receive a small dose of ATG as an IV infusion. ATG will be repeated on days -5,-4 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions. Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion. Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5, followed by total body radiation on days -3 to -1. Tacrolimus (standard immune suppression agent) starts on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate a standard immune suppression medication which is given IV on day +1,+3,+6, and +11 post-transplant. Blood draws on days -4,-1,+3,+7,+14 to measure ATG levels.
219763488|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
219763489|NCT06204809|DRUG|PGN-EDODM1 for infusion|Single dose of PGN-EDODM1 by intravenous (IV) infusion
219763490|NCT06204809|OTHER|Placebo|Administered by IV infusion
219763491|NCT04815278|BEHAVIORAL|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
219763492|NCT04815278|BEHAVIORAL|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
219763493|NCT04815278|BEHAVIORAL|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
219763494|NCT03652493|DRUG|Carboplatin|Tumoral evaluation every 3 cycles
218821597|NCT02983240|DEVICE|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
218821598|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
218821599|NCT02171026|DRUG|Dabigatran etexilate|
218821600|NCT02171026|DRUG|Amiodarone|
218821601|NCT01025557|OTHER|Dietary intervention|Dietary treatments with beverages
218821602|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
218821603|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
218821604|NCT00811954|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
218821605|NCT00811954|DRUG|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
218821606|NCT00811954|DRUG|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
218821607|NCT00811954|DRUG|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
218821608|NCT00811954|DRUG|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
219008986|NCT03453710|PROCEDURE|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
219008987|NCT01624389|DRUG|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
219436019|NCT02079519|DRUG|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
219436020|NCT01900756|BEHAVIORAL|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
218821609|NCT05680493|PROCEDURE|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
218821610|NCT05680493|PROCEDURE|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
218821611|NCT05680493|PROCEDURE|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
218821612|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
218821613|NCT06288425|OTHER|Non interventional|Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis
218821614|NCT01658553|DRUG|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
219008988|NCT00459784|PROCEDURE|Dementia Training Program|
219436021|NCT03769337|DIAGNOSTIC_TEST|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
219436022|NCT00127088|DRUG|docetaxel|
218821615|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
218821616|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
218821617|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
219008989|NCT06636045|OTHER|Not applicable- observational study|No intervention. Observational study.
219008990|NCT04034381|OTHER|No intervention (descriptive survey only)|No intervention
219008991|NCT03327649|DEVICE|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
219436023|NCT00127088|PROCEDURE|laparoscopic radical prostatectomy|
219436024|NCT02580838|DRUG|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
218821618|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
218821619|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
219436025|NCT00829660|DRUG|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
219579988|NCT02613013|DRUG|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
219436026|NCT00829660|DRUG|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
219436027|NCT02171949|BIOLOGICAL|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
219436028|NCT04541732|OTHER|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
219436029|NCT04541732|OTHER|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
219436030|NCT04541732|DRUG|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
219436031|NCT04541732|DRUG|Muscle Relaxant|Atracurium : 0.5mg/Kg.
219579989|NCT02613013|PROCEDURE|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
219579990|NCT01130636|DRUG|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
219579991|NCT05129436|DRUG|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
219579992|NCT01527136|DRUG|entolimod|Given IM or SC
219579993|NCT01527136|OTHER|pharmacological study|Correlative studies
219579994|NCT01527136|OTHER|laboratory biomarker analysis|Correlative studies
219579995|NCT05778136|OTHER|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
219579996|NCT02034058|DEVICE|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
219579997|NCT03254602|DEVICE|Intense Therapeutic Ultrasound Treatment|
219579998|NCT05367479|DRUG|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
219579999|NCT05937984|DEVICE|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
219580000|NCT05937984|DEVICE|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
219580001|NCT02369900|DRUG|Esmolol|
218821620|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
218821621|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Original doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
219436032|NCT04541732|DRUG|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
219436033|NCT04511936|DEVICE|i-Lumen AMD|Microcurrent stimulator
219436034|NCT04511936|DEVICE|i-Lumen AMD Sham|Sham microcurrent stimulator
219436035|NCT00509652|PROCEDURE|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
219436036|NCT00509652|PROCEDURE|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
219436037|NCT04821960|BEHAVIORAL|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
219436038|NCT04821960|BEHAVIORAL|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
219580002|NCT02369900|OTHER|Saline|
219580003|NCT03309007|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
219580004|NCT03309007|DRUG|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
219436039|NCT01522560|OTHER|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
218821622|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Monkey doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush monkey doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
219436040|NCT01522560|OTHER|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
219436041|NCT06022172|DIAGNOSTIC_TEST|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
219436042|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
219436043|NCT01225276|DRUG|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
219436044|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
219436045|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
219436046|NCT05160662|PROCEDURE|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
219436047|NCT00399867|DRUG|Simvastatin|
219436048|NCT01999348|DRUG|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
219436049|NCT04787926|DEVICE|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
219436050|NCT05820646|OTHER|Boswellia Sacra|"1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days"
219436051|NCT02720250|DIETARY_SUPPLEMENT|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
219436052|NCT02720250|DIETARY_SUPPLEMENT|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
218821623|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Dog without velcro doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush dog doll, without velcro in palms. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
218821624|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Bear doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush smiling bear doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
219008992|NCT02226055|DEVICE|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
219008993|NCT04468204|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
219436053|NCT00092404|BIOLOGICAL|measles, mumps, and rubella virus vaccine live|
218821625|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Rabbit doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush rabbit doll, with a neutral expression. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
218821626|NCT01421966|BIOLOGICAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
219008994|NCT04468204|DEVICE|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
219436054|NCT00092404|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
219008995|NCT01735513|DEVICE|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
219436055|NCT02524067|BEHAVIORAL|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
219436056|NCT00768768|OTHER|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
219436057|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
219436058|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
219436059|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
219436060|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
219436061|NCT01041404|DRUG|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
219580005|NCT03899311|OTHER|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
219580006|NCT02963311|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
219580007|NCT02963311|DRUG|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
219580008|NCT02982798|DRUG|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
219580009|NCT02982798|DRUG|JLP-1310|administration of JLP-1310
219580010|NCT06408883|DEVICE|Vibrabot capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
218821627|NCT01421966|BIOLOGICAL|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
218821628|NCT02057965|DRUG|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
219008996|NCT04937829|DRUG|BI 1569912|BI 1569912
219008997|NCT04937829|DRUG|Placebo|Placebo
219008998|NCT04803097|DIAGNOSTIC_TEST||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
218821629|NCT06016322|DIETARY_SUPPLEMENT|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
219436062|NCT01041404|DRUG|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
219436063|NCT01041404|DRUG|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
219763495|NCT06283550|DRUG|Abrocitinib 200 mg|Abrocitinib will be available in 100 mg strength tablet
219763496|NCT06283550|DRUG|Abrocitinib 100 mg|Abrocitinib will be available in 100 mg strength tablet
218821630|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
218821631|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
218821632|NCT02625350|OTHER|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
218821633|NCT02625350|OTHER|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
218821634|NCT02625350|OTHER|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
218821635|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
218821636|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
219436064|NCT01041404|DRUG|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
219436065|NCT01240304|DRUG|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
219763497|NCT06283550|DRUG|Placebo|Placebo tablet
218821637|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
218821638|NCT06391892|PROCEDURE|Neoadjuvant chemotherapy instead of upfront surgery|"All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.~If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.~* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.~* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.~FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin."
218821639|NCT06391892|PROCEDURE|Upfront surgery|Standard of care as recommended by tumor board (not affected by study conditions).
218821640|NCT01452477|DRUG|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
218821641|NCT01452477|DRUG|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
218821642|NCT06438991|OTHER|Adjustment of spinal cord stimulation parameters for voluntary motor control|All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
218821643|NCT03999580|DRUG|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
218821644|NCT03509818|OTHER|plyometric exercise|acute plyometric exercise
218821645|NCT03509818|OTHER|Aerobic exercise|acute aerobic exercise
218821646|NCT00205764|DRUG|Melphalan|
218821647|NCT03192098|DEVICE|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
218821648|NCT03421886|DEVICE|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
218821649|NCT03421886|DEVICE|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
218821650|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
218821651|NCT01138475|DRUG|Paricalcitol|1 microgram by mouth daily for 6 weeks
218821652|NCT01138475|DRUG|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
218821653|NCT01138475|DRUG|Placebo|Inactive substance, one capsule daily for 6 weeks
219763498|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 1|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
218821654|NCT02169011|PROCEDURE|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
219436066|NCT01240304|RADIATION|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
219436067|NCT01240304|PROCEDURE|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
219436068|NCT05308667|OTHER|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
219436069|NCT05308667|OTHER|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
219436070|NCT00195481|DRUG|Rapamune|
219436071|NCT01157455|PROCEDURE|Everolimus Drug Eluting Stent|Implantation
219436072|NCT01157455|DRUG|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
219436073|NCT01157455|DRUG|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
219436074|NCT01157455|DRUG|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
219436075|NCT01574937|DRUG|Cabozantinib|28 day cycle
219436076|NCT01574937|DRUG|Abiraterone|28 day cycle
219436077|NCT02795611|BEHAVIORAL|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
219436078|NCT02795611|BEHAVIORAL|regular occupational therapy|regular occupational therapy
219436079|NCT02795611|OTHER|intervention done outside our hospital|intervention done outside our hospital
219436080|NCT00005945|DRUG|cyclophosphamide|Given IV
219436081|NCT00005945|DRUG|cytarabine|Given IT
219580011|NCT06418685|DEVICE|Treatment with Vibrating Capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
219436082|NCT00005945|DRUG|daunorubicin hydrochloride|Given IV
219580012|NCT01211080|DRUG|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
218821655|NCT02169011|PROCEDURE|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
219436083|NCT00005945|DRUG|dexamethasone|Given PO
219436084|NCT00005945|DRUG|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
219436085|NCT00005945|DRUG|mercaptopurine|Given PO
218821656|NCT01941771|DRUG|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
218821657|NCT01941771|DRUG|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
218821658|NCT03413904|PROCEDURE|transanal TME|transanal approach to TME in rectal cancer
218821659|NCT03413904|PROCEDURE|laparoscopic TME|laparoscopic approach to TME in rectal cancer
219436086|NCT00005945|DRUG|methotrexate|Given PO and IT
218821660|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
218821661|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
219436087|NCT00005945|DRUG|pegaspargase|Given IM
219436088|NCT00005945|DRUG|thioguanine|Given PO
219436089|NCT00005945|DRUG|vincristine sulfate|Given IV
219436090|NCT00005945|RADIATION|radiation therapy|Undergo radiation therapy
219436091|NCT05060198|DRUG|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
219436092|NCT05060198|DRUG|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
219436093|NCT02143960|DEVICE|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
219436094|NCT02143960|DEVICE|CoolSculpt|Noninvasive Cryolipolysis
218821662|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
218821663|NCT00606645|BIOLOGICAL|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
218821664|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
218821665|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
218821666|NCT00893841|DRUG|placebo|placebo
218821667|NCT00893841|DRUG|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
219436095|NCT05239884|OTHER|ENDS Product A with 1.5% nicotine|P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436096|NCT05239884|OTHER|ENDS Product B with 1.5% nicotine|P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219580013|NCT05019820|OTHER|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
219580014|NCT05019820|OTHER|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
218821668|NCT00987714|PROCEDURE|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
218821669|NCT00605059|DRUG|[123I]AV94|Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
218821670|NCT01624935|BEHAVIORAL|interpersonal psychotherapy|interpersonal psychotherapy
218821671|NCT00459940|DRUG|Pioglitazone|
218821672|NCT05636202|OTHER|No intervention|There was no intervention in the retrospective study
218821673|NCT00883155|DRUG|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
218821674|NCT00883155|DRUG|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
218821675|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
219580015|NCT01234792|DRUG|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
219580016|NCT01234792|DRUG|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
218821676|NCT01871025|OTHER|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
218821677|NCT01871025|OTHER|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
218821678|NCT02373618|OTHER|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
218821679|NCT02373618|OTHER|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
218821680|NCT02125344|DRUG|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
218821681|NCT02125344|DRUG|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
218821682|NCT02125344|DRUG|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
218821683|NCT02125344|DRUG|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
218821684|NCT02125344|DRUG|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
218821685|NCT02125344|DRUG|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
218821686|NCT02125344|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
218821687|NCT02125344|DRUG|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
218821688|NCT04375527|DRUG|Binimetinib|Given PO
218821689|NCT04375527|BIOLOGICAL|Nivolumab|Given IV
218821690|NCT04375527|OTHER|Questionnaire Administration|Ancillary studies
218821691|NCT05120050|DEVICE|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
218821692|NCT03006588|PROCEDURE|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
219436097|NCT05239884|OTHER|ENDS Product C with 1.5% nicotine|P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436098|NCT05239884|OTHER|ENDS Product D with 1.5% nicotine|P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436099|NCT05239884|OTHER|ENDS Product E with 1.5% nicotine|P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219580017|NCT01234792|DRUG|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
219580018|NCT01295294|DRUG|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
219580019|NCT01295294|DRUG|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
218821693|NCT00547963|BEHAVIORAL|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
218821694|NCT02117778|PROCEDURE|Continuous Nerve Block|
218821695|NCT04344730|DRUG|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
218821696|NCT04344730|DRUG|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
218821697|NCT04344730|PROCEDURE|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
218821698|NCT04344730|PROCEDURE|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
219008999|NCT03054389|OTHER|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
219009000|NCT03054389|OTHER|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
219009001|NCT06399978|BEHAVIORAL|Brain Blossom - Gamified Differential Outcome Training|Digital cognitive training with a gamified DOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
219009002|NCT06399978|BEHAVIORAL|Gamified Non-Differential Outcome Training|Digital cognitive training with a gamified NDOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
219009003|NCT05003076|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
219009004|NCT05003076|DRUG|Placebo|Participants will be given a placebo capsule that will only contain lactose.
219009005|NCT03638024|DIAGNOSTIC_TEST|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
219009006|NCT00791167|DRUG|Paliperidone ER|
219009007|NCT00041327|BIOLOGICAL|filgrastim|5 ug/kg/d
219009008|NCT00041327|BIOLOGICAL|recombinant interferon alfa|9 mU subcutaneously per day for one year
219436100|NCT05239884|OTHER|ENDS Product F with 1.5% nicotine|P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436101|NCT05239884|OTHER|ENDS Product G with 1.5% nicotine|P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436102|NCT05239884|OTHER|ENDS Product H with 1.5% nicotine|P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
219436103|NCT01685203|DRUG|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
218821699|NCT04344730|PROCEDURE|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
218821700|NCT04344730|PROCEDURE|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
218821701|NCT05038696|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
218821702|NCT05394610|DEVICE|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
218821703|NCT05394610|DRUG|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
219436104|NCT01685203|DRUG|ABT-267|Tablet
219436105|NCT01685203|DRUG|Ribavirin (RBV)|Tablet
219436106|NCT03212599|DRUG|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
219436107|NCT04559412|DEVICE|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
219436108|NCT04559412|DRUG|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
219436109|NCT00383708|DRUG|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
219436110|NCT00383708|DRUG|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
219580020|NCT01295294|DRUG|Placebo|3 times daily per oral during bleeding/spotting episodes
218821704|NCT01534481|BIOLOGICAL|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
218821705|NCT01534481|DIETARY_SUPPLEMENT|Preterm Formula|Preterm Formula determined by center practice.
218821706|NCT01130337|DRUG|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
218821707|NCT01130337|DRUG|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
219009009|NCT00041327|DRUG|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
219009010|NCT00041327|DRUG|cyclophosphamide|750 mg/m2 IV on day 5
219009011|NCT00041327|DRUG|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
219009012|NCT00041327|DRUG|lamivudine|150 mg bid
219009013|NCT00041327|DRUG|prednisone|60 mg/m2 given orally days 1-5
219009014|NCT00041327|DRUG|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
219009015|NCT00041327|DRUG|zidovudine|300 mg bid
219009016|NCT02477254|BIOLOGICAL|Vaccination|A quadrivalent HPV vaccine
219009017|NCT06024421|DRUG|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
219009018|NCT06024421|DRUG|Placebo|Light yellow, film-coated tablet
219436111|NCT03191812|OTHER|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
219436112|NCT04555408|DEVICE|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
219436113|NCT04555408|DEVICE|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
219195354|NCT06660888|BEHAVIORAL|• Fatigue Severity Scale (FFS). • Hamilton Rating Scale for Depression (HRSD-17). • Hamilton Anxiety Rating Scale (HAM-A).|"1. Fatigue Severity Scale The FSS is one of the most commonly used fatigue questionnaires in chronic diseases. It measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, work, family, or social life.~2. Hamilton Depression Rating Scale The 17-item Hamilton Depression Rating Scale (HRSD-17) is the most popular depression measure in antidepressant clinical trials.~3. Hamilton Anxiety Rating Scale The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms."
219436114|NCT04555408|DEVICE|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
219436115|NCT02945306|PROCEDURE|Adenotonsillectomy|
219436116|NCT02945306|DRUG|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
219436117|NCT00318370|DRUG|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
218821708|NCT01130337|DRUG|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
218821709|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
219436118|NCT00318370|DRUG|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
219436119|NCT06266871|DRUG|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
219436120|NCT00054184|DRUG|docetaxel|
219436121|NCT00054184|DRUG|paclitaxel poliglumex|
219009019|NCT05805982|BEHAVIORAL|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
219436122|NCT05428540|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
219436123|NCT05428540|OTHER|Placebo|Placebo
219436124|NCT03908580|DRUG|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
219436125|NCT06156904|DEVICE|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
219436126|NCT01750840|DEVICE|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
219436127|NCT01750840|DEVICE|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
218821710|NCT01247623|BIOLOGICAL|GV1001|
218821711|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
218821712|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
218821713|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
218821714|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
219009020|NCT05805982|BEHAVIORAL|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
219009021|NCT03173599|DRUG|PNA 40mg|The beginning dose is 40mg.
219009022|NCT03173599|DRUG|PNA 80mg|The single dose is 80mg.
219009023|NCT03173599|DRUG|PNA 160mg|The single dose is 160mg.
219009024|NCT03173599|DRUG|PNA 240mg|The single dose is 240mg.
219436128|NCT01750840|DEVICE|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
219436129|NCT00121680|DRUG|E7080|Oral.
219436130|NCT02077491|OTHER|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
218821715|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
218821716|NCT03886493|DRUG|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
219009025|NCT03173599|DRUG|PNA 360mg|The single dose is 360mg.
219009026|NCT03173599|DRUG|PNA 480mg|The single dose is 480mg.
219009027|NCT03173599|DRUG|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
219009028|NCT04969549|OTHER|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
219009029|NCT01521455|DRUG|HCP0910|250/50, BID for 2 weeks
219580021|NCT01295294|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
219596901|NCT03936712|DIETARY_SUPPLEMENT|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
218821717|NCT00609752|DRUG|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
219009030|NCT01521455|DRUG|Seretide Diskus|250/50, BID for 2 weeks
219009031|NCT05534529|DRUG|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
219009032|NCT04427527|BEHAVIORAL|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
219009033|NCT01184625|OTHER|Physical Exercise|12 weeks of physical exercise.
219009034|NCT04282993|DEVICE|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
219009035|NCT04282993|OTHER|Standard of care monitoring|Periodical medical examinations
219009036|NCT06297733|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
219009037|NCT06297733|OTHER|Validity|The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.
219009038|NCT06297733|OTHER|Reliability|The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
219009039|NCT04224311|BIOLOGICAL|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
219009040|NCT06437860|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
219009041|NCT06437860|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
219009042|NCT03107325|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
219009043|NCT03107325|DRUG|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
219009044|NCT04052893|PROCEDURE|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
219009045|NCT04052893|PROCEDURE|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
219009046|NCT01878058|OTHER|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
219009047|NCT03238508|PROCEDURE|Deferred stenting|Previously described
219436131|NCT00530491|PROCEDURE|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
219436132|NCT01841294|DRUG|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
219436133|NCT01841294|DRUG|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
218821718|NCT00609752|DIETARY_SUPPLEMENT|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
218821719|NCT03901638|DRUG|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
218821720|NCT03901638|DRUG|Placebo|Placebo
218821721|NCT05016258|DEVICE|KONTACT MB|Dental implant surgery
218821722|NCT02669498|PROCEDURE|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
218821723|NCT05871619|PROCEDURE|Remin Pro|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
219436134|NCT05460689|OTHER|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
219436135|NCT05460689|OTHER|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
219436136|NCT03125993|BEHAVIORAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
219436137|NCT00936793|DRUG|Darunavir|
219436138|NCT00936793|DRUG|Ritonavir|
219580022|NCT02836626|PROCEDURE|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
219580023|NCT02836626|PROCEDURE|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
219580024|NCT03707665|DIAGNOSTIC_TEST|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
219580025|NCT06255301|DIAGNOSTIC_TEST|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
219580026|NCT02897986|DRUG|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
219580027|NCT03239886|OTHER|imatinib discontinuation|imatinib discontinuation
219580028|NCT02375139|DRUG|DA-1229_01|complex single administration
219580029|NCT02375139|DRUG|E+M|co-administration of 2 drugs
218821724|NCT05871619|PROCEDURE|X Pur Remin|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
218821725|NCT05871619|PROCEDURE|Fluoride varnish|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
218821726|NCT06146647|BEHAVIORAL|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
218821727|NCT06146647|BEHAVIORAL|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
218821728|NCT06146647|BEHAVIORAL|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
218821729|NCT06146647|BEHAVIORAL|Active control music video about brushing teeth|Music video of a tv character singing about brushing teeth
218821730|NCT04217109|DIAGNOSTIC_TEST|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
218821731|NCT01247064|DRUG|Nebulized 3% saline|4 mL of nebulized 3% saline once
218821732|NCT01247064|DRUG|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
219009048|NCT02312895|OTHER|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
219009049|NCT02312895|OTHER|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
219436139|NCT00936793|DRUG|Beclomethasone Dipropionate HFA|
219580030|NCT05162365|BIOLOGICAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
219580031|NCT05162365|OTHER|Placebo|Placebo, intravenously, once, on Day 1
219580032|NCT02195466|DRUG|Tipranavir (TPV)|500 mg bid on days 7-14
219580033|NCT02195466|DRUG|Ritonavir (RTV)|200 mg bid on days 7-14
219580034|NCT02195466|DRUG|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
219436140|NCT04535505|DIAGNOSTIC_TEST|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
219436141|NCT02880462|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
218821733|NCT04828707|DEVICE|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
218821734|NCT04828707|DEVICE|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
218821735|NCT04836442|OTHER|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
218821736|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
218821737|NCT04548973|DRUG|Esketamine|Esketamine
218821738|NCT04548973|DRUG|Normal saline|2ml normal saline
218821739|NCT04153487|DRUG|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
218821740|NCT04153487|DRUG|Placebo|Placebo saline / 6 hours for 96 hours
218821741|NCT00601744|BEHAVIORAL|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
218821742|NCT00601744|BEHAVIORAL|Questionnaire|5-10 minute questionnaire to be completed after the interview.
218821743|NCT01343472|BEHAVIORAL|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
218821744|NCT01343472|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
219009050|NCT02312895|OTHER|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
219436142|NCT02880462|OTHER|placebo|Placebo is made of starch
219436143|NCT03152396|OTHER|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
218821745|NCT04616898|DEVICE|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
218821746|NCT00916227|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
218821747|NCT03869112|BEHAVIORAL|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
218821748|NCT03869112|OTHER|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
219009051|NCT06249425|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219195355|NCT05602545|OTHER|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
219436144|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
219436145|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
219436146|NCT02320214|DEVICE|Miami w/ frag Personal lubricant|
219436147|NCT02398981|OTHER|Clinical decision support tool|
219436148|NCT06045143|DEVICE|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
219436149|NCT03550742|OTHER|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
219580035|NCT06625918|DEVICE|Ultraviolet B exposure to produce vitamin D synthesis|Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
218821749|NCT03139448|DEVICE|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
218821750|NCT03139448|DEVICE|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
218821751|NCT00713687|DRUG|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility"
218821752|NCT02250248|BIOLOGICAL|AttraX Putty|
218821753|NCT02250248|OTHER|Iliac Crest Bone Graft (ICBG)|
219009052|NCT06249425|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219009053|NCT06249425|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
219009054|NCT04987957|OTHER|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
219009055|NCT02029950|DRUG|Cytarabine|Given IV
219009056|NCT02029950|DRUG|Daunorubicin Hydrochloride|Given IV
219009057|NCT02029950|DRUG|Etoposide|Given IV
219009058|NCT02029950|DRUG|Idarubicin Hydrochloride|Given IV
219436150|NCT03717363|PROCEDURE|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
219436151|NCT03717363|BEHAVIORAL|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
219436152|NCT00663598|DRUG|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
218821754|NCT04269421|PROCEDURE|calcaneo-stop: arthrosis of the subtalar joint|arthrosis of the subtalar joint with a screw in the talus bone to stop pathological pronation of the heel
219436153|NCT00231855|DRUG|Topotecan and Taxotere|
219580036|NCT00212121|RADIATION|high dose boost|high dose boost
219580037|NCT00212121|PROCEDURE|boost|low dose versus high dose
219580038|NCT03728218|DEVICE|Contact lenses (Orthokeratology)|Contact lenses
219580039|NCT03728218|DEVICE|Contact lenses (Soft Multifocal)|Contact lenses
218821755|NCT02442050|OTHER|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
218821756|NCT02442050|OTHER|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
219009059|NCT02029950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219009060|NCT02029950|OTHER|Pharmacological Study|Correlative studies
219009061|NCT02029950|DRUG|Pomalidomide|Given PO
219009062|NCT00330616|DRUG|323U66 SR|
219580040|NCT05334264|PROCEDURE|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
219580041|NCT00874003|DRUG|mirtazapine|oral tablet, 30 mg daily
219580042|NCT00874003|DRUG|placebo|oral tablet, 1 daily
219580043|NCT04398264|OTHER|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
218821757|NCT04582214|DEVICE|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
219580044|NCT00845806|OTHER|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
219580045|NCT01031459|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
219580046|NCT01631175|BEHAVIORAL|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
219580047|NCT02721693|DEVICE|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
219580048|NCT00263991|DEVICE|EEC-techniques|
219436154|NCT01014949|OTHER|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia."
219436155|NCT01684891|DRUG|RG1662|multiple doses of RG1662
218821758|NCT04031729|DRUG|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
218821759|NCT04031729|DRUG|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
218821760|NCT00523978|DEVICE|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
218821761|NCT00523978|DRUG|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
218821762|NCT00637351|PROCEDURE|Blood sample|One blood sample will be collected at the time of screening for subjects
218821763|NCT00637351|PROCEDURE|Urine sample|One urine sample will be collected at the time of screening for subjects
218821764|NCT02490189|BEHAVIORAL|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
218821765|NCT02490189|BEHAVIORAL|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
218821766|NCT04145596|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
218821767|NCT04656405|OTHER|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
218821768|NCT04656405|OTHER|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
218821769|NCT04656405|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
218821770|NCT03899350|OTHER|No intervention|No intervention
219009063|NCT05091099|DRUG|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
219009064|NCT05332509|DEVICE|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
219009065|NCT05332509|DEVICE|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
219009066|NCT03893422|OTHER|WB-010|Medical food formulation
219436156|NCT01957852|OTHER|FloSeal|
219436157|NCT01810549|DRUG|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
219436158|NCT01810549|DRUG|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
219436159|NCT01094990|DRUG|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
219580049|NCT01101204|DRUG|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
219580050|NCT02163486|DEVICE|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
219580051|NCT02163486|DEVICE|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
219436160|NCT06528054|OTHER|Development of a model for predicting 90-day mortality and to compare various treatment strategies for anastomotic leakage|The prediction model and comparison of various treatment strategies will be studies when the data is available for analysis.
218821771|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
218821772|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
218821773|NCT00961038|DRUG|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
218821774|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
218821775|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
218821776|NCT03551782|DRUG|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
218821777|NCT03551782|DRUG|Apalutamide 240 mg|Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
218821778|NCT01554748|PROCEDURE|Total joint arthroplasty|
218821779|NCT00960089|DEVICE|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
218821780|NCT02348203|DRUG|Aspirin|Given PO
218821781|NCT02348203|OTHER|Laboratory Biomarker Analysis|Correlative studies
218821782|NCT02348203|OTHER|Placebo Administration|Given aspirin placebo PO
219436161|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
219436162|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
219436163|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
219580052|NCT06132217|DRUG|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
218821783|NCT02348203|OTHER|Placebo Administration|Given zileuton placebo PO
218821784|NCT02348203|DRUG|Zileuton|Given PO
218821785|NCT03025126|OTHER|Multimedial Rehabilitation|
218821786|NCT03025126|OTHER|Usual care program|Usual care at home program according to healthcare professional's advice
218821787|NCT05790291|OTHER|Checklist|the experimental group will practice using the checklist
218821788|NCT01523938|BEHAVIORAL|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
218821789|NCT00696878|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
218821790|NCT00696878|BIOLOGICAL|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
218821791|NCT00696878|BIOLOGICAL|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
218821792|NCT00696878|BIOLOGICAL|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
218821793|NCT00696878|DRUG|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
218821794|NCT02712788|DRUG|Milrinone|
218821795|NCT02712788|DRUG|Placebo|
218821796|NCT01901536|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
218821797|NCT04337047|OTHER|questionnaire assesment|questionnaire assesment
218821798|NCT00940602|DRUG|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
219009067|NCT03893422|OTHER|WB-011|WB-011 medical food product
219436164|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
219436165|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
219436166|NCT00141856|BEHAVIORAL|Telephone care|
219436167|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-NA)|Root canal treatment procedures explained in arm descriptions.
219436168|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-EA)|Root canal treatment procedures explained in arm descriptions.
219436169|NCT06403293|PROCEDURE|Root canal treatment (BC-NA)|Root canal treatment procedures explained in arm descriptions.
219436170|NCT06403293|PROCEDURE|Root canal treatment (BC-EA)|Root canal treatment procedures explained in arm descriptions.
219436171|NCT06068296|DIAGNOSTIC_TEST|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
219436172|NCT06068296|DIAGNOSTIC_TEST|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
219436173|NCT06068296|DIAGNOSTIC_TEST|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
219436174|NCT06068296|DIAGNOSTIC_TEST|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
219436175|NCT01109550|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
219580053|NCT06132217|DRUG|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
219580054|NCT02836496|DRUG|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
218821799|NCT00940602|DRUG|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
218821800|NCT01880957|DRUG|Lithium|
218821801|NCT01880957|DRUG|Lamotrigine|
218821802|NCT04994223|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
218821803|NCT04856878|DRUG|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
218821804|NCT02969135|BEHAVIORAL|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
218821805|NCT02969135|BEHAVIORAL|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
218821806|NCT01120405|DRUG|Xenon|
218821807|NCT01120405|DRUG|Sevoflurane|
218821808|NCT02107534|BEHAVIORAL|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
218821809|NCT02332473|DRUG|Ypeginterferon alfa-2b|
218821810|NCT02332473|DRUG|Granulocyte-macrophage colony stimulating factor|
219009068|NCT03893422|OTHER|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
219009069|NCT06522048|OTHER|Observational studies do not require intervention|This is an observational retrospective study and does not require any intervention.
219009070|NCT03993431|DRUG|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
219009071|NCT03993431|DRUG|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
219009072|NCT04831203|DIETARY_SUPPLEMENT|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
219436176|NCT04201938|COMBINATION_PRODUCT|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
219009073|NCT04831203|DIETARY_SUPPLEMENT|Placebo|As described in the Control arm
219009074|NCT05283668|BIOLOGICAL|i-PRF|"* Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
219195356|NCT04332211|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
218821811|NCT01459809|DRUG|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
218821812|NCT01459809|DRUG|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
219195357|NCT04332211|DRUG|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
219195358|NCT04332211|DRUG|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
219436177|NCT04201938|DIETARY_SUPPLEMENT|Placebo|Placebo
219436178|NCT03256838|DRUG|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
219436179|NCT05151367|BEHAVIORAL|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
218821813|NCT04902989|OTHER|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
218821814|NCT01418521|DRUG|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
218821815|NCT01418521|DRUG|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
218821816|NCT03053128|DEVICE|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
218821817|NCT03053128|OTHER|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
218821818|NCT03627052|DRUG|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
218821819|NCT03627052|DRUG|Placebo|Placebo administered orally twice daily in the double-blind period.
218821820|NCT04836533|OTHER|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
218821821|NCT04836533|DRUG|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
218821822|NCT04836533|OTHER|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
219580055|NCT02836496|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
219763499|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 2|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
218821823|NCT04836533|OTHER|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
218821824|NCT00575666|DRUG|Insulin or Placebo|intranasal, 40IU, 4 times daily
219436180|NCT01612442|BEHAVIORAL|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
219436181|NCT01612442|BEHAVIORAL|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
219436182|NCT06291467|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
219436183|NCT06291467|OTHER|questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)"
219436184|NCT00436267|DRUG|fluorouracil|
219436185|NCT00436267|RADIATION|selective external radiation therapy|
219436186|NCT00436267|RADIATION|tomotherapy|
219580056|NCT02836496|DRUG|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
219580057|NCT02836496|DRUG|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
219580058|NCT05737316|BEHAVIORAL|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
219580059|NCT05737316|BEHAVIORAL|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
219580060|NCT05549908|BIOLOGICAL|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
219763500|NCT05742802|COMBINATION_PRODUCT|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
219580061|NCT03438214|DRUG|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
219580062|NCT03438214|DRUG|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
219580063|NCT04483635|DIETARY_SUPPLEMENT|Placebo|Weekly oral dose of placebo
219580064|NCT04483635|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral dose of Vitamin D
219580065|NCT04236570|DEVICE|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
219580066|NCT04236570|DEVICE|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
219580067|NCT03822832|DRUG|BI 655130|Solution for infusion
219580068|NCT03822832|DRUG|Placebo|Solution for infusion
219580069|NCT00073242|DRUG|Leptin|leptin administration
219580070|NCT00073242|BEHAVIORAL|Dietary modification|Subjects lose 10% of body weight via dietary restriction
219580071|NCT00073242|DRUG|T3 repletion|administer T3
219580072|NCT06174870|OTHER|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
219580073|NCT05070871|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
219580074|NCT05070871|OTHER|Placebo|Pure maltodextrin.
219763501|NCT05317078|DRUG|AMG 794|Short-term intravenous (IV) infusion.
219763502|NCT04628767|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219763503|NCT04628767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763504|NCT04628767|DRUG|Cisplatin|Given IV
219436187|NCT00436267|RADIATION|yttrium Y 90 glass microspheres|
219436188|NCT00436267|RADIATION|yttrium Y 90 resin microspheres|
219436189|NCT02905903|DRUG|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
219436190|NCT00106821|DRUG|Tiotropium Bromide Inhalation Powder|
219436191|NCT03661372|OTHER|Robot|Use of a telesimulation robot using contextual interview format.
219763505|NCT04628767|PROCEDURE|Computed Tomography|Undergo CT
218821825|NCT04392973|COMBINATION_PRODUCT|Favipiravir and Hydroxychloroquine|"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."
219763506|NCT04628767|DRUG|Doxorubicin Hydrochloride|Given Iv
219763507|NCT04628767|BIOLOGICAL|Durvalumab|Given IV
219763508|NCT04628767|DRUG|Gemcitabine Hydrochloride|Given IV
219763509|NCT04628767|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763510|NCT04628767|DRUG|Methotrexate|Given IV
218821826|NCT00938301|DRUG|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
218821827|NCT00938301|DRUG|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
218821828|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
218821829|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
218821830|NCT00508482|OTHER|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
218821831|NCT00508482|DRUG|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
218821832|NCT00508482|OTHER|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
218821833|NCT02359903|DRUG|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
218821834|NCT02359903|DRUG|Infliximab (Remicade)|
218821835|NCT00327912|PROCEDURE|Laparoscopic Biliopancreatic diversion with Duodenal switch|
218821836|NCT00327912|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
218821837|NCT01402921|DEVICE|V0322 BC|"* Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment"
218821838|NCT06029205|BEHAVIORAL|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
219436192|NCT03661372|OTHER|Face-to-face|Use of face-to-face patient interview using contextual interview format.
219436193|NCT03655587|DEVICE|Solid ankle foot orthotic|
219436194|NCT03655587|DEVICE|Resting night splint|
219436195|NCT02937532|BEHAVIORAL|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
219436196|NCT02937532|BEHAVIORAL|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
219436197|NCT02881879|BIOLOGICAL|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
219436198|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
219436199|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
219436200|NCT06783244|OTHER|Low intraabdominal pressure (8 mmHg)|Only difference in treatment is the lower level of intraabdominal pressure by which the procedure is performed. The intervention does not change the treatment. The surgical procedure is performed due to Danish national guidelines and remains the same in the two arms.
219763511|NCT04628767|BIOLOGICAL|Pegfilgrastim|Given via injection
219763512|NCT04628767|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219763513|NCT04628767|DRUG|Vinblastine Sulfate|Given Iv
219763514|NCT06969573|DRUG|Placebo|Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
219763515|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 36 mcg|Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
219763516|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 78 mcg|Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
219763517|NCT06969898|OTHER|Single Ultramarathon runners|All participants underwent the same protocol: two laboratory assessments, a 106 km race, and post-race physiological parameter evaluations at 24 hours and 48 hours.
218821839|NCT06029205|BEHAVIORAL|Stress coping training|The effect of stress coping training on nurses
218821840|NCT02289469|OTHER|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
218821841|NCT03026244|DIETARY_SUPPLEMENT|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
218821842|NCT03026244|DIETARY_SUPPLEMENT|Placebo product|3 periods of 3 weeks placebo product
218821843|NCT03807388|DEVICE|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
219009075|NCT05283668|PROCEDURE|Diode Laser|"Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
219009076|NCT02403154|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
219009077|NCT02403154|PROCEDURE|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
219009078|NCT05545696|DEVICE|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
219009079|NCT05545696|DEVICE|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
219009080|NCT03764865|PROCEDURE|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
219009081|NCT03764865|PROCEDURE|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
219009082|NCT01250834|DRUG|Atorvastatin|Administered orally.
219009083|NCT01250834|BIOLOGICAL|LY2189265|Administered subcutaneously.
219009084|NCT01135199|DRUG|pomalidomide (CC-4047|
219009085|NCT03336853|DEVICE|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
219009086|NCT03336853|OTHER|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
219009087|NCT05125978|DRUG|Canadá|Canadá association 1 tablet twice a day
219009088|NCT05125978|OTHER|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
219580075|NCT05070871|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
218821844|NCT03807388|OTHER|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
218821845|NCT00546481|DRUG|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
218821846|NCT00546481|DRUG|Epoetin|As prescribed, iv, 3 times weekly
218821847|NCT05309044|BEHAVIORAL|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
218821848|NCT05309044|OTHER|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
218821849|NCT05309044|OTHER|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
218821850|NCT00157118|DRUG|Protein C Concentrate (Human) Vapor Heated|
218821851|NCT04996329|OTHER|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
219009089|NCT05125978|DRUG|Dipyrone|Dipyrone 1 tablet twice a day
219009090|NCT05125978|OTHER|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
219009091|NCT05125978|DRUG|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
219009092|NCT05125978|OTHER|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
218821852|NCT00587041|DIETARY_SUPPLEMENT|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
218821853|NCT00587041|DIETARY_SUPPLEMENT|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
218821854|NCT00587041|OTHER|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
219009093|NCT04326348|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
219009094|NCT01957553|DEVICE|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
219009095|NCT01957553|DEVICE|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
219009096|NCT04304391|PROCEDURE|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
218821855|NCT05016089|OTHER|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
218821856|NCT01769924|OTHER|Nephrectomy|Nephrectomy for the purposes of living kidney donation
218821857|NCT05268757|BEHAVIORAL|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
218821858|NCT02982330|BEHAVIORAL|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.
218821859|NCT02982330|BEHAVIORAL|Guidelines Breakfast|A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.
218821860|NCT05115435|BEHAVIORAL|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
218821861|NCT02375100|PROCEDURE|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
218821862|NCT02375100|PROCEDURE|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
218821863|NCT02375100|PROCEDURE|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
218821864|NCT02375100|DRUG|Bupivacaine %0.5 (hyperbaric)|
218821865|NCT02375100|DRUG|Bupivacaine %0.25 (isobaric)|
218821866|NCT02375100|DEVICE|25G Quincke needle|
218821867|NCT02375100|DEVICE|Echogenic Needle with 30° bevel|
218821868|NCT02375100|DRUG|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
218821869|NCT02375100|DRUG|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
218821870|NCT04298619|DIAGNOSTIC_TEST|Standard cohort: Clinical lab follow-up|
218821871|NCT04298619|DIAGNOSTIC_TEST|Imaging cohort: integrated imaging follow-up|
218821872|NCT02359656|PROCEDURE|surgical treatment|C1-C1 arthrodesis
218821873|NCT02359656|OTHER|non operative treatment for odontoid non unions|specific non operative treatment protocol
218821874|NCT05753462|DRUG|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
218821875|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
218821876|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
218821877|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
218821878|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
218821879|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
218821880|NCT00002143|DRUG|Acitretin|
218821881|NCT00770302|DRUG|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
218821882|NCT04418895|OTHER|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
218821883|NCT04418895|RADIATION|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
218821884|NCT04418895|DRUG|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
218821885|NCT04418895|DRUG|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
218821886|NCT04418895|DRUG|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
219763518|NCT06822049|DRUG|Combination Nicotine Replacement Therapy (patch and lozenge)|All participants receive 8 weeks of combination nicotine replacement therapy - long-acting transdermal patch and short-acting lozenge.
219763519|NCT06970665|DRUG|avacincaptad pegol|intravitreal injection
218821887|NCT02750930|DRUG|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
218821888|NCT02750930|DEVICE|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
218821889|NCT01585402|DRUG|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
218821890|NCT01585402|DEVICE|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
218821891|NCT00298636|DRUG|adenosine|
218821892|NCT00784862|DRUG|Anastrozole|1mg, orally, once daily
218821893|NCT00784862|DRUG|Tamoxifen|20mg, orally, once daily
218821894|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
218821895|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
218821896|NCT00776789|OTHER|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
218821897|NCT00776789|OTHER|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
218821898|NCT04607629|BIOLOGICAL|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
218821899|NCT04607629|BIOLOGICAL|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
218821900|NCT01951664|OTHER|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
218821901|NCT01951664|BEHAVIORAL|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
218821902|NCT01951664|BEHAVIORAL|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
218821903|NCT01951664|BEHAVIORAL|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
219580076|NCT05219461|DRUG|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
219580077|NCT05219461|DRUG|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
219580078|NCT05219461|DRUG|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
219580079|NCT05219461|DRUG|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
219580080|NCT05219461|DRUG|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
218821904|NCT01951664|OTHER|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
219009097|NCT05240456|DRUG|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
219009098|NCT05240456|DRUG|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
219580081|NCT05219461|DRUG|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
219580082|NCT00334061|DEVICE|Penumbra System|
219580083|NCT05340777|DEVICE|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
219580084|NCT01483053|DRUG|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
218821905|NCT06193564|OTHER|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
218821906|NCT06193564|OTHER|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
219580085|NCT01483053|DRUG|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
219580086|NCT01335373|DRUG|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
218821907|NCT06193564|OTHER|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
218821908|NCT03394989|DRUG|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
219580087|NCT02502773|DRUG|Hydroxethyl starch|
218821909|NCT03394989|OTHER|Placebo|Placebo
218821910|NCT03394989|DRUG|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
218821911|NCT04509258|DRUG|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
218821912|NCT04509258|DIETARY_SUPPLEMENT|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
218821913|NCT04509258|DRUG|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
218821914|NCT04509258|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
218821915|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
218821916|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
218821917|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
218821918|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
218821919|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
218821920|NCT01197547|DEVICE|Genesys HTA|Genesys HTA Endometrial Ablation
218821921|NCT01936883|RADIATION|HDR|High dose rate brachytherapy
218821922|NCT01936883|RADIATION|LDR|Low dose rate brachytherapy boost
218821923|NCT02669589|DRUG|Heparin|
218821924|NCT02669589|DRUG|Citrate|
219009099|NCT04544254|PROCEDURE|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
219580088|NCT03592576|DRUG|Navitoclax|Tablet, Oral
219580089|NCT03592576|DRUG|Venetoclax|Tablet, Oral
219580090|NCT03168594|DRUG|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
219580091|NCT03168594|DRUG|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
219580092|NCT03002662|OTHER|colonoscopy|
219580093|NCT00776165|BIOLOGICAL|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
218821925|NCT01778998|PROCEDURE|MICS-group|Micro incision cataract surgery is done
218821926|NCT01778998|PROCEDURE|SICS-group|small incision cataract surgery is done
218821927|NCT01778998|PROCEDURE|SICS pre-cut|Small incision cataract surgery with pre-cut is done
218821928|NCT01778998|PROCEDURE|SICS stab-incision|Small incision cataract surgery with stab-incision is done
218821929|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
219580094|NCT00776165|BIOLOGICAL|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
219580095|NCT02923674|BEHAVIORAL|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
219580096|NCT02923674|BEHAVIORAL|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
218821930|NCT05249686|OTHER|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
218821931|NCT05249686|OTHER|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
218821932|NCT03431597|DIETARY_SUPPLEMENT|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
218821933|NCT03431597|DIETARY_SUPPLEMENT|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
218821934|NCT03115372|OTHER|Educational Intervention|Attend CRC education session
218821935|NCT03115372|OTHER|Educational Intervention|Attend healthy nutrition session
219580097|NCT02923674|BEHAVIORAL|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
219580098|NCT04989712|OTHER|Exposure|Participants randomised to one of the three exposures
219580099|NCT01194336|DRUG|Huperzine A|dosage form: tablet dose frequency: once only
218821936|NCT03115372|OTHER|Informational Intervention|Receive CRC screening brochure
218821937|NCT03115372|OTHER|Survey Administration|Ancillary studies
218821938|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about CRC screening
218821939|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
218821940|NCT05670327|OTHER|Diaphragmatic ultrasound assessment|TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
218821941|NCT03129542|DRUG|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
218821942|NCT03129542|DRUG|Placebo capsule|Three doses taken every 8 hours.
218821943|NCT04898478|BEHAVIORAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
219009100|NCT04544254|PROCEDURE|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
219580100|NCT01194336|DRUG|Donepezil|dosage form: tablet dosage frequency: once only
219580101|NCT01194336|DRUG|Galantamine|dosage form: tablet dosage frequency: once only
218821944|NCT02374125|DEVICE|Diacutaneous Fibrolysis|Applied only around teres major muscle.
218821945|NCT02374125|OTHER|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
218821946|NCT02374125|OTHER|Protocolized physiotherapy|Exercises, TENS and cryotherapy
218821947|NCT04240691|BEHAVIORAL|60-Minutes-For-Health|Refer to description under Groups
218821948|NCT04240691|OTHER|Time-and-Attention Control Session|Refer to description under Groups
218821949|NCT01880190|OTHER|Ringer's Lactate|
218821950|NCT01880190|OTHER|HES 130/0.4 and Ringer's Lactate|
218821951|NCT03243227|OTHER|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
218821952|NCT03243227|OTHER|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
218821953|NCT04849273|DRUG|TPX-0131|Oral TPX-0131 tablets
218821954|NCT01604460|PROCEDURE|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
218821955|NCT01604460|PROCEDURE|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
218821956|NCT03304366|DIAGNOSTIC_TEST|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
219009101|NCT03009435|OTHER|prophylactic manual rotation|
219580102|NCT01194336|OTHER|Placebo|dosage form: tablet dosage frequency: once only
219436201|NCT05717166|RADIATION|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
218821957|NCT00930449|OTHER|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
218821958|NCT00930449|OTHER|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
218821959|NCT00930449|OTHER|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
218821960|NCT01645202|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
218821961|NCT00163098|DRUG|UK-369,003|
218821962|NCT01105663|OTHER|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
218821963|NCT02432573|BEHAVIORAL|Delayed rounds|
218821964|NCT04575519|DRUG|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
218821965|NCT04575519|DRUG|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
218821966|NCT04575519|DRUG|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
218821967|NCT04575519|DRUG|SoC TB|Standard of Care Tuberculosis treatment
218821968|NCT04290624|OTHER|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
218821969|NCT04290624|DEVICE|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
218821970|NCT04290624|OTHER|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
218821971|NCT02479191|DEVICE|Ovation Abdominal Stent Graft Platform|
218821972|NCT03041220|PROCEDURE|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
218821973|NCT03346993|DRUG|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
218821974|NCT02579811|DRUG|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
218821975|NCT04052373|PROCEDURE|Implantoplasty|Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
218821976|NCT04052373|PROCEDURE|Open flap debridement alone|Open flap debridement alone
219436202|NCT05717166|DRUG|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
219436203|NCT05717166|DRUG|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
219436204|NCT05717166|DRUG|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
219436205|NCT05717166|DRUG|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
219436206|NCT05717166|OTHER|Observation|Pre-specified based on the standard of care approach for that patient.
218821977|NCT05230498|DEVICE|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
218821978|NCT05230498|DEVICE|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
219436207|NCT05717166|RADIATION|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
219580103|NCT03150849|DIAGNOSTIC_TEST|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
219580104|NCT04476719|DRUG|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
218821979|NCT06268899|OTHER|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
218821980|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 6-10 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
218821981|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 12-15 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
219436208|NCT05717166|PROCEDURE|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
219436209|NCT05717166|OTHER|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
218821982|NCT00956384|PROCEDURE|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
219436210|NCT05717166|RADIATION|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
218821983|NCT00956384|PROCEDURE|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
219436211|NCT03906136|BIOLOGICAL|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab biosimilar 40 mg, s.c.
219436212|NCT03906136|OTHER|Standard-of-care|Treatment according to local practice standards by the rheumatologist following latest treatment recommendations with NSAIDs as the first-choice drug treatment and DMARDs for patients with active disease despite the use (or intolerance/contraindication) of NSAIDs.
219436213|NCT06088303|BEHAVIORAL|Adjunctive writing to amplify response and engagement (AWARE)|AWARE includes two components: 1) patients complete brief writing prompts asking about their experiences in treatment, and 2) therapists review patients' responses and facilitate guided discussion related to patients' experiences during check-ins at the beginning of each session.
219436214|NCT06088303|BEHAVIORAL|Cognitive processing therapy (CPT)|CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.
219580105|NCT04476719|DRUG|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
219580106|NCT03161964|DRUG|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
219580107|NCT03161964|DRUG|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
218821984|NCT01448642|DRUG|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
218821985|NCT01448642|DRUG|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
218821986|NCT02076945|PROCEDURE|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
218821987|NCT05320978|DEVICE|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
218821988|NCT02916485|DEVICE|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
218821989|NCT05471375|OTHER|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
218821990|NCT06104345|BIOLOGICAL|Oral typhoid fever vaccine|Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
218821991|NCT06104345|BIOLOGICAL|Oral cholera vaccine|Oral cholera vaccine (Dukoral®) on Days 0 and 7.
218821992|NCT02551588|PROCEDURE|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
219580108|NCT00004800|BIOLOGICAL|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
219580109|NCT00004800|BIOLOGICAL|diphtheria-tetanus vaccine|
218821993|NCT01331590|DRUG|G-CSF|
218821994|NCT01331590|DRUG|Ifosfamide|
218821995|NCT01331590|DRUG|Etoposide|
218821996|NCT01331590|DRUG|Dexamethasone|
218821997|NCT01331590|DRUG|Mesna|
218821998|NCT06032039|DRUG|Triamcinolone|Standard treatment for osteoarthritis knee pain
218821999|NCT06032039|OTHER|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
218822000|NCT02406417|DEVICE|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
218822001|NCT02406417|DEVICE|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
219580110|NCT00158600|BIOLOGICAL|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
219580111|NCT00158600|DRUG|Placebo|Placebo Comparator; qow for 78 weeks.
218822002|NCT05728554|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
218822003|NCT05728554|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
218822004|NCT05728554|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
218822005|NCT02494414|OTHER|Long-term follow-up|Vital and neurological follow-up
218822006|NCT04117633|DEVICE|Laparoscopy|Laparoscopic Procedures for Rectopexy
218822007|NCT03526211|DEVICE|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
218822008|NCT01088906|DRUG|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
218822009|NCT04705805|BEHAVIORAL|Self-assessment of olfactory disorders through two questionnaires.|"* Assessment of sense of smell or loss of smell using an Analogue Visual Scale~* Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~* Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
218822010|NCT05648812|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
218822011|NCT05648812|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
218822012|NCT05120492|PROCEDURE|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
218822013|NCT05017064|DEVICE|Cryotherapy group|The use of intraoral ice pack during root canal treatment
218822014|NCT05017064|OTHER|Control group|No cryotherapy will be used
218822015|NCT00538057|DRUG|GW685698X & GW642444M|study drug
218822016|NCT00102661|DRUG|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
218822017|NCT02133469|BIOLOGICAL|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
218822018|NCT02133469|BIOLOGICAL|Hib Vaccine|Single Dose
218822019|NCT04372303|BEHAVIORAL|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
218822020|NCT06448975|PROCEDURE|Deep cervical Lymphovenous Bypass|Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
218822021|NCT02782442|BEHAVIORAL|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
218822022|NCT02782442|BEHAVIORAL|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
218822023|NCT06101368|BEHAVIORAL|Phsical Activity|Combined Aerobic and Resistance Training
218822024|NCT06101368|DRUG|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
218822025|NCT02549079|OTHER|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
218822026|NCT04904172|DEVICE|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
218822027|NCT00761488|DEVICE|AcrySof® Toric IOL|Implanted into the study eye
218822028|NCT06226961|DEVICE|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
218822029|NCT02805790|DRUG|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
218822030|NCT02805790|DRUG|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
218822031|NCT00800735|DRUG|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
218822032|NCT00800735|DRUG|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
219436215|NCT06088303|BEHAVIORAL|Prolonged exposure (PE)|PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
219436216|NCT03374852|DRUG|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
219436217|NCT03374852|DRUG|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
219436218|NCT03162731|BIOLOGICAL|Nivolumab|Given IV
219436219|NCT03162731|BIOLOGICAL|Ipilimumab|Given IV
219436220|NCT03162731|RADIATION|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
219436221|NCT03162731|RADIATION|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
219436222|NCT04410835|DIAGNOSTIC_TEST|Online Survey|Psychological questionnaires
219436223|NCT06494501|DRUG|Inclisiran|Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
219436224|NCT04216706|DRUG|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
219436225|NCT00471783|PROCEDURE|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
219195359|NCT06746792|OTHER|Low-load resistance exercise with blood flow restriction|BFR-RE group performed bilateral leg extension exercises to volitional exhaustion (90 seconds rest between sets, 30% 1RM) with BFR cuffs applied at 60% of limb occlusion pressure.
219195360|NCT06746792|OTHER|High-load resistance exercise|The HL-RE group performed the same exercise to volitional exhaustion (90 seconds rest between sets, 70% 1RM) without BFR cuffs.
219195361|NCT03229083|OTHER|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
219195362|NCT06813612|BEHAVIORAL|cognitive behavioral play intervention|In the CBPI condition, children use dolls and miniature props to engage in play aimed at fostering positive thinking, a key element of quality of life. Each session includes stories on health, emotional well-being, social interactions, and school activities. The researcher demonstrates problem-solving steps, such as identifying and evaluating solutions, repeating this process three times. In each session, the researcher models problem-solving four times and provides at least five positive affirmations. Both the CBPI intervention and the free play control condition are similar, with the researcher using standardized prompts and providing equal time and positive attention. The key difference is that in the CBPI condition, the researcher models positive thinking and problem-solving, while in the free play condition, the researcher follows the child's lead without guiding play.
219436226|NCT06206707|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Capsule FMT
219436227|NCT06206707|PROCEDURE|Placebo|Placebo capsules
219436228|NCT02929628|DEVICE|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
219436229|NCT00405236|DRUG|tiotropium|
219436230|NCT02283346|RADIATION|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~\+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
219436231|NCT00446641|DRUG|Cilostazol|cilostazol 100mg twice a day for 4 weeks
219580112|NCT00107549|BIOLOGICAL|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
219580113|NCT00107549|BIOLOGICAL|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
219580114|NCT04583449|BEHAVIORAL|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
219580115|NCT04163978|DRUG|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
219580116|NCT04163978|DRUG|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
219195363|NCT06810258|OTHER|Blood sample during native kidney biopsy|blood sample during standard of care visit for a native kidney biopsy (17.5mL)
219195364|NCT06810258|OTHER|Blood sample during renal graft biopsy|blood sample during standard of care visit for a renal graft biopsy (17.5mL)
219195365|NCT06810258|OTHER|Urine sample during renal graft biopsy|Urine sample during standard of care visit for a renal graft biopsy (50mL)
219195366|NCT06810258|OTHER|Urine sample during native kidney biopsy|Urine sample during standard of care visit for a native kidney biopsy (50mL)
219436232|NCT00446641|DRUG|placebo|placebo 1 tablet twice a day matching for cilostazol
219436233|NCT04143425|DIAGNOSTIC_TEST|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
219436234|NCT04143425|DIAGNOSTIC_TEST|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
219436235|NCT04143425|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
219195367|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
219436236|NCT04236219|DRUG|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
219436237|NCT04236219|DRUG|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
219436238|NCT03368352|DIETARY_SUPPLEMENT|Melatonin|Dietary supplement melatonin
219436239|NCT03368352|OTHER|Hypoxia|Sleep in a hypoxic tent simulating high altitude
219436240|NCT00004300|DRUG|bromocriptine|
219436241|NCT00004300|DRUG|sertraline hydrochloride|
219436242|NCT01689324|BIOLOGICAL|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
219436243|NCT02736396|OTHER|fMRI|Functional MRI scan to be performed
219436244|NCT02736396|OTHER|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
219436245|NCT03565991|DRUG|Avelumab|IV treatment
219436246|NCT03565991|DRUG|Talazoparib|Oral treatment
219436247|NCT02049229|DEVICE|percutaneous coronary intervention|Optimax-stent implantation
219436248|NCT02049229|DEVICE|percutaneous coronary intervention|Synergy stent implantation
218822033|NCT01196195|DRUG|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
219195368|NCT06085820|BEHAVIORAL|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
219436249|NCT03073382|OTHER|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
219436250|NCT04127240|OTHER|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
219436251|NCT05914740|PROCEDURE|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
219436252|NCT02818270|DRUG|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
219436253|NCT02818270|DRUG|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
219436254|NCT04263493|OTHER|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
219580117|NCT06187493|DRUG|lisinopril, enalapril|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
219580118|NCT06187493|DRUG|dapagliflozin, empagliflozin|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
219580119|NCT02423356|PROCEDURE|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
219580120|NCT02737332|DRUG|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
219580121|NCT02737332|DRUG|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
219580122|NCT00858962|DRUG|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
219580123|NCT02775474|DRUG|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
219580124|NCT02775474|DRUG|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
219580125|NCT02181426|DRUG|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
219763520|NCT06972251|BEHAVIORAL|TARDIS Photo Elicitation|Using visual-based qualitative methods to help identify and more robustly describe DD in Veterans.
218822034|NCT01196195|DRUG|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
218822035|NCT04161209|DRUG|Citalopram|Single dose administration of citalopram (20mg)
218822036|NCT04161209|OTHER|Placebo|Lactose placebo tablet
218822037|NCT04275076|PROCEDURE|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
218822038|NCT01385150|GENETIC|mutation analysis|
218822039|NCT01385150|GENETIC|protein analysis|
218822040|NCT01385150|OTHER|laboratory biomarker analysis|
218822041|NCT01385150|OTHER|liquid chromatography|
218822042|NCT01385150|OTHER|mass spectrometry|
218822043|NCT00051714|BEHAVIORAL|Family-Based Preventive Intervention|
218822044|NCT04460183|DRUG|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
218822045|NCT04460183|OTHER|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
219436255|NCT05153863|DEVICE|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
219436256|NCT04251741|DIAGNOSTIC_TEST|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
219763521|NCT06972251|BEHAVIORAL|TARDIS Intervention|Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with type 2 diabetes (T2D), to promote engagement in self-management behaviors.
218822046|NCT03387215|DRUG|ITI-214|Oral
219436257|NCT04251741|OTHER|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
219763522|NCT06541704|DRUG|Pozelimab|Subcutaneous (SC) injection
219763523|NCT06541704|DRUG|Cemdisiran|SC injection
219763524|NCT06541704|DRUG|Placebo|SC injection
219763525|NCT05464069|DEVICE|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
219763526|NCT05464069|DRUG|Migraine Relief|Any drug for treatment of migraine relief
218822047|NCT03387215|OTHER|Placebo|Oral
218822048|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
218822049|NCT00702832|OTHER|standard treatment|treatment as usual
218822050|NCT03986125|BEHAVIORAL|Emotional Awareness & Expression Therapy|emotion-focused
218822051|NCT03986125|BEHAVIORAL|Mindfulness Meditation Training|meditation training and practice
218822052|NCT03307538|RADIATION|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
219436258|NCT04613271|DRUG|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
219436259|NCT04613271|DRUG|Azithromycin|Azithromycin 500 mg once a day for 5 days.
219436260|NCT05299645|BEHAVIORAL|Interview|Pilot study with digital browsers
219436261|NCT01245231|GENETIC|protein expression analysis|
219436262|NCT01245231|GENETIC|western blotting|
219436263|NCT01245231|OTHER|flow cytometry|
219436264|NCT01245231|OTHER|laboratory biomarker analysis|
219436265|NCT01245231|OTHER|medical chart review|
219436266|NCT06198894|PROCEDURE|steroid-eluting sinus stent implant|In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
219436267|NCT06198894|DRUG|Systemic glucocorticoids|Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
219436268|NCT06198894|DRUG|saline irrigations|Patients were routinely treated with saline irrigations (250ml) twice daily
219436269|NCT06198894|DRUG|Placebo|Groups were given systemic glucocorticoid placebo
219436270|NCT06198894|PROCEDURE|sham procedure|The sham procedure was performed in-office under local anesthesia
219436271|NCT05698004|OTHER|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
219436272|NCT04533516|OTHER|Manual therapy technics|Manual therapy technics
219436273|NCT04533516|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training
219436274|NCT03424044|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
219436275|NCT03424044|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
219436276|NCT03424044|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
219436277|NCT03424044|DRUG|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
219436278|NCT03498989|OTHER|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
219436279|NCT03498989|OTHER|exclusive breast milk|exclusive breast milk
219436280|NCT02971007|DRUG|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
219436281|NCT02971007|DRUG|Fluconazole|
219436282|NCT01720693|PROCEDURE|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
219436283|NCT00486512|DRUG|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
219436284|NCT00486512|DRUG|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
219436285|NCT00486512|DRUG|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
219436286|NCT00486512|DRUG|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
219436287|NCT00486512|PROCEDURE|Colonoscopy|
219436288|NCT02220530|DRUG|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
219436289|NCT01807611|RADIATION|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
219436290|NCT01807611|DRUG|Fludarabine|Given IV.
219436291|NCT01807611|DRUG|Cyclophosphamide|Given IV.
219436292|NCT01807611|DRUG|Thiotepa|Given IV.
219436293|NCT01807611|DRUG|Melphalan|Given IV.
219436294|NCT01807611|BIOLOGICAL|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
219436295|NCT01807611|BIOLOGICAL|TC-NK Infusion|Participants receive infusions of TC-NK.
219436296|NCT01807611|BIOLOGICAL|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
219436297|NCT01807611|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
218822053|NCT00369837|DRUG|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
218822054|NCT01884363|OTHER|Once ounce per day of walnuts|
218822055|NCT01716364|BIOLOGICAL|Anti-LeY- scFv-CD28-ζ vector,.|
219436298|NCT01807611|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219580126|NCT01021358|DRUG|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
219580127|NCT01021358|DRUG|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
219580128|NCT01423136|DEVICE|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
219436299|NCT01807611|DRUG|Mycophenolate mofetil|Given intravenously or orally.
219436300|NCT03174769|OTHER|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
219436301|NCT03174769|OTHER|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
219436302|NCT05265936|PROCEDURE|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
219436303|NCT05265936|PROCEDURE|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
219436304|NCT04450004|BIOLOGICAL|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
219436305|NCT04352881|OTHER|Questionary patient|Assessing pain reduction using a 4-step questionary
219436306|NCT03588104|DEVICE|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
219436307|NCT03588104|OTHER|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
219763527|NCT06582784|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219436308|NCT02935595|DRUG|Ketamine|Ketamine Hydrochloride Injection
219436309|NCT06380036|PROCEDURE|video assisted fistula tract surgery|in one group pt recieved VAAFTS
219436310|NCT00402285|DIETARY_SUPPLEMENT|lycopene supplement|
219436311|NCT00402285|DIETARY_SUPPLEMENT|fish oil supplement|
219436312|NCT00402285|OTHER|Placebo|placebos for lycopene and fish oil.
219436313|NCT01287988|DRUG|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
219436314|NCT01287988|DRUG|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
219436315|NCT04778644|DRUG|CBD|Oral gel capsule CBD
219436316|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
219436317|NCT03309241|DRUG|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
219436318|NCT03309241|OTHER|Placebo|Placebo Single Dose
218822056|NCT01267474|OTHER|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
218822057|NCT01267474|OTHER|Control|The control group received only three one-hour general sessions on health issues.
218822058|NCT02734329|PROCEDURE|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
218822059|NCT02734329|PROCEDURE|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
218822060|NCT00856323|DRUG|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
219436319|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
219436320|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
219436321|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
219436322|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
219436323|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
219436324|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
218822061|NCT00856323|BEHAVIORAL|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
218822062|NCT04941105|DRUG|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
218822063|NCT04941105|DRUG|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
218822064|NCT01087593|DRUG|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
218822065|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
218822066|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
218822067|NCT00134615|BEHAVIORAL|RQP patient health education module|
218822068|NCT04838184|DEVICE|Dental Implants (Straumann Roxolid® / SLActive®)|"In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation."
218822069|NCT01230320|PROCEDURE|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases."
218822070|NCT02972710|OTHER|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
218822071|NCT02972710|OTHER|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
219436325|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
219436326|NCT00784459|DRUG|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
219436327|NCT00784459|DRUG|Placebo|Treatment with Placebo, IV
219436328|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
219436329|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
219436330|NCT03464890|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
218822072|NCT05624983|DIAGNOSTIC_TEST|acoustic otoemisions|TOAE and DPOAE
218822073|NCT05624983|DIAGNOSTIC_TEST|Otoscopy|presence of earwax checked by video otoscop
218822074|NCT05624983|DIAGNOSTIC_TEST|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
218822075|NCT05624983|DIAGNOSTIC_TEST|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
218822076|NCT01847092|DRUG|AZD1722|
218822077|NCT01847092|DRUG|Placebo|Placebo for AZD1722
219436331|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
219436332|NCT03464890|OTHER|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
219436333|NCT01496989|BIOLOGICAL|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
219436334|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
219436335|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
219009102|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
219436336|NCT01496989|BIOLOGICAL|Ad35-GRIN/ENV|(2x10\^10vp) Delivered intramuscularly by standard needle injection
219436337|NCT04297345|DEVICE|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
219436338|NCT01498770|DRUG|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
219436339|NCT01498770|DRUG|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
219436340|NCT01498770|DRUG|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
219436341|NCT01498770|DRUG|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
219436342|NCT01498770|DRUG|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
219436343|NCT01498770|DRUG|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
219436344|NCT01498770|DRUG|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
219436345|NCT01498770|DRUG|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
219763528|NCT06582784|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
219763529|NCT06823713|DRUG|RTX001|RTX001 is an autologous engineered regenerative macrophage cell therapy
219763530|NCT06151574|DRUG|zongertinib|zongertinib
219763531|NCT06151574|DRUG|pembrolizumab|pembrolizumab
219763532|NCT06151574|DRUG|cisplatin|platinum-pemetrexed chemotherapy
219763533|NCT06151574|DRUG|carboplatin|platinum-pemetrexed chemotherapy
219763534|NCT06151574|DRUG|pemetrexed|platinum-pemetrexed chemotherapy
218822078|NCT03030898|DIAGNOSTIC_TEST|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
218822079|NCT03436901|DIAGNOSTIC_TEST|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
218822080|NCT00825994|DRUG|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
218822081|NCT03194399|BEHAVIORAL|Personalized health care service|Physical activity coaching, other functional outcome observation
218822082|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
219436346|NCT01498770|DRUG|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
219436347|NCT01498770|DRUG|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
219436348|NCT01498770|DRUG|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
219436349|NCT01498770|DRUG|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
219436350|NCT01498770|DRUG|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
219436351|NCT02398721|OTHER|Fine Needle Aspiration Cytology|
219436352|NCT04248686|BEHAVIORAL|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
219763535|NCT03223610|DRUG|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219763536|NCT03223610|DRUG|Ibrutinib|Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219763537|NCT03223610|DRUG|Prednisone|Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219763538|NCT03223610|BIOLOGICAL|Obinutuzumab|Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219763539|NCT03223610|DRUG|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219763540|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
219763541|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
219763542|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
219763543|NCT02056704|DEVICE|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
219763544|NCT02600949|DRUG|Imiquimod|Applied topically
219763545|NCT02600949|BIOLOGICAL|Pembrolizumab|Given IV
219763546|NCT02600949|BIOLOGICAL|Sotigalimab|Given IV
219763547|NCT02600949|BIOLOGICAL|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
219763548|NCT02600949|PROCEDURE|Computed Tomography|Undergo CT
219763549|NCT02600949|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219436353|NCT05421091|OTHER|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
219436354|NCT05905770|DRUG|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
219436355|NCT00877760|DRUG|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
219436356|NCT00877760|DRUG|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
218822083|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
218822084|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
218822085|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
218822086|NCT06078475|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
218822087|NCT01466283|GENETIC|DNA methylation analysis|
219009103|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
219436357|NCT04563572|DEVICE|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
219436358|NCT04846972|BEHAVIORAL|FASTRACS intervention|"Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
219580129|NCT02252718|OTHER|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
218822088|NCT01466283|GENETIC|fluorescence in situ hybridization|
218822089|NCT01466283|GENETIC|gene expression analysis|
218822090|NCT01466283|GENETIC|reverse transcriptase-polymerase chain reaction|
218822091|NCT01466283|OTHER|laboratory biomarker analysis|
218822092|NCT00535418|DRUG|Letrozole|
218822093|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
218822094|NCT00152204|DRUG|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
218822095|NCT00152204|DRUG|IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
218822096|NCT01776853|DIETARY_SUPPLEMENT|Glucose|
218822097|NCT01776853|DIETARY_SUPPLEMENT|Fructose|
218822098|NCT01776853|DIETARY_SUPPLEMENT|Fructans|
218822099|NCT06498115|DRUG|Norepinephrine|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
218822100|NCT03415503|DRUG|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
219009104|NCT00807157|DIETARY_SUPPLEMENT|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
218822101|NCT05087498|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
218822102|NCT05087498|BIOLOGICAL|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
218822103|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
218822104|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
218822105|NCT02047448|PROCEDURE|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
218822106|NCT01495325|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
218822107|NCT01495325|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
218822108|NCT05531500|DRUG|Injection|Injection of local anesthetic + steroids
218822109|NCT05531500|DEVICE|Radiofrequency|Application of radiofrequency on the diseased nerve
218822110|NCT04748692|PROCEDURE|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
218822111|NCT04748692|PROCEDURE|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
218822112|NCT03790644|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
218822113|NCT05175274|DRUG|Colchicine|Colchicine 0.5mg/tablet
218822114|NCT05175274|DRUG|Placebo|matching placebo
218822115|NCT02054975|DRUG|Vitamin D2 + vitamin D3|higher dose vitamin D
219436359|NCT02821988|DEVICE|External fetal monitor for Nonstress test|
218822116|NCT02054975|DRUG|Vitamin D3|lower dose vitamin D
219580130|NCT02618408|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
219580131|NCT02618408|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
218822117|NCT05680467|OTHER|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~* Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~* Bilateral medial lumbar soft tissue mobilization~* Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~* Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~* Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
219009105|NCT00807157|DIETARY_SUPPLEMENT|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
219009106|NCT02668133|DIETARY_SUPPLEMENT|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
219009107|NCT02668133|DIETARY_SUPPLEMENT|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
219009108|NCT02668133|DIETARY_SUPPLEMENT|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
219580132|NCT02618408|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
219580133|NCT02845765|DEVICE|Dynamic Vessel Analyzer (DVA)|
219009109|NCT02668133|DIETARY_SUPPLEMENT|1 mg isotopically enriched 68Zn|administered intravenously
219009110|NCT03030508|OTHER|No intervention|
219009111|NCT00718952|DRUG|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
219009112|NCT00718952|DRUG|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
219009113|NCT00718952|DRUG|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
219436360|NCT02821988|DEVICE|Ultrasonography for Biophysical profile|
219436361|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
219436362|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
219436363|NCT01332695|DRUG|ST101|tablets for oral administration
219436364|NCT01332695|DRUG|Placebo|placebo to match
219580134|NCT02845765|DRUG|Phosphodiesterase type 5 Inhibitor (PDE5I)|
219580135|NCT04492020|DRUG|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
219580136|NCT04492020|DRUG|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
218822118|NCT05680467|OTHER|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
219195369|NCT06085820|BEHAVIORAL|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
219436365|NCT05031806|DRUG|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
219436366|NCT05031806|DRUG|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
219436367|NCT05031806|DRUG|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
219436368|NCT05031806|DRUG|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
219436369|NCT03300427|DRUG|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
219436370|NCT03300427|DRUG|valsartan|Valsartan 80 or 160 mg BID
219436371|NCT03300427|DRUG|placebo to valsartan|placebo to valsartan 80 or 160 BID
219580137|NCT03858192|PROCEDURE|Colorectal surgery procedure|Elective admission for colorectal surgery
219580138|NCT03858192|PROCEDURE|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
219580139|NCT03858192|DRUG|Antibiotics|Treatment for infection and reason for admission
219580140|NCT06064292|DEVICE|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
219763550|NCT05832138|BEHAVIORAL|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
218822119|NCT05680467|OTHER|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
218822120|NCT05927987|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
219009114|NCT03491371|DRUG|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
219009115|NCT04372901|PROCEDURE|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
219009116|NCT04372901|PROCEDURE|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
219009117|NCT01003912|BIOLOGICAL|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
219195370|NCT06248086|DRUG|ASP2802|Intravenous (IV) infusion
219195371|NCT06248086|DRUG|MA-20|IV infusion
219436372|NCT03300427|DRUG|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
219436373|NCT04134377|OTHER|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
219436374|NCT01894555|DRUG|Aspirin|81 mg daily for 4 weeks
219436375|NCT00063986|PROCEDURE|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
219195372|NCT05992246|DIAGNOSTIC_TEST|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
219195373|NCT03441100|DRUG|IMA202 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
219436376|NCT01844791|DRUG|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
219436377|NCT01844791|DRUG|Platinum|Platinum is given as standard chemotherapy each cycle
219596902|NCT03936712|DIETARY_SUPPLEMENT|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
219009118|NCT02261155|PROCEDURE|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
219009119|NCT00314912|DRUG|Tramiprosate (3APS)|
219009120|NCT03672747|DEVICE|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
219009121|NCT06382792|PROCEDURE|proximal humeral resection for tumor and allograft prosthetic composite reconstruction|allograft prosthetic composite
219009122|NCT01335984|PROCEDURE|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
219009123|NCT01335984|PROCEDURE|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
219009124|NCT01335984|OTHER|control group|"\- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
219009125|NCT00718224|DRUG|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
219009126|NCT00718224|DRUG|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
219009127|NCT00718224|DRUG|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
219009128|NCT04631081|PROCEDURE|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
219195374|NCT03441100|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
219195375|NCT06653634|DRUG|Methotrexate|Gradual withdrawal of the medication
219195376|NCT06653634|DRUG|TNF Inhibitor|Gradual withdrawal of the medication
219195377|NCT06810362|BEHAVIORAL|Cognitive Remediation (CR)|The CR consists of three 1-hour sessions per week of domain-specific computerized exercises, for a period of 12 weeks, totaling 36 hours
219195378|NCT06810362|BEHAVIORAL|Aerobic Exercise|Aerobic exercise consists in two session per week of cycling. Each session lasts for 45 min, with 15 min of warm up pre and post session
219195379|NCT06810362|OTHER|Cognitve Remediation + Aerobic Exercise|Patients performed both CR exercises and cycling
219436378|NCT01844791|DRUG|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
219436379|NCT03669146|DEVICE|Glasses|Partial refractive correction in a pair of glasses.
219436380|NCT01114698|DRUG|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
219436381|NCT01114698|DRUG|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
219436382|NCT01114698|DRUG|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
219436383|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
219436384|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
219436385|NCT06103591|DEVICE|The EmStop Embolic Protection System (EmStop System)|The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
219436386|NCT02925208|OTHER|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
219436387|NCT00798473|DRUG|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
219436388|NCT00798473|OTHER|IV saline infusion|
219436389|NCT01591993|PROCEDURE|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
219436390|NCT01591993|PROCEDURE|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
219436391|NCT00221663|DEVICE|surgery techniques (sternotomy for aortic valve replacement)|
219436392|NCT00794859|DRUG|Sorafenib|400mg twice daily
219436393|NCT02172846|RADIATION|Proton beam radiation therapy (PBT)|
219580141|NCT02982031|PROCEDURE|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
219580142|NCT02982031|PROCEDURE|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
219009129|NCT04631081|OTHER|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
219009130|NCT04570150|DRUG|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
219009131|NCT04570150|DRUG|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
219009132|NCT04712305|OTHER|No intervention required|No intervention required
219009133|NCT00256893|DRUG|ropinirole|
219195380|NCT06811987|BEHAVIORAL|Instructor-led AI-Triage educational serious game|Participants will use the AI-triage serious game guided by the instructors.
219195381|NCT06811987|BEHAVIORAL|Self play AI-Triage educational serious game|Participants will self-play the AI-Triage serious game during the class.
219436394|NCT02172846|DRUG|Paclitaxel|
219436395|NCT02172846|DRUG|Carboplatin|
219436396|NCT02389530|DRUG|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
219436397|NCT02933372|DRUG|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
219436398|NCT03556332|DRUG|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
219436399|NCT03556332|DRUG|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
219436400|NCT03556332|DRUG|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
219580143|NCT02929446|PROCEDURE|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
219580144|NCT02929446|PROCEDURE|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
219580145|NCT03199430|DIETARY_SUPPLEMENT|Epigallocatechin gallate|
219580146|NCT03199430|DIETARY_SUPPLEMENT|Placebo|1450mg Corn Flour
219009134|NCT02931968|DEVICE|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
219009135|NCT05585697|OTHER|None - crossectional|None - crossectional
219195382|NCT06810635|DIETARY_SUPPLEMENT|Oral Polyphenol Challenge Test / PPPIL|Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)
219436401|NCT03556332|DRUG|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
219580147|NCT01305395|DRUG|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
219580148|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
219580149|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
219580150|NCT01305395|DRUG|Sirolimus|Will start sirolimus after they develop CAV by angiogram
219596903|NCT00142025|DRUG|Oxcarbazepine|
218822121|NCT06174675|PROCEDURE|combined bilateral infraorbital and infratrochlear nerve blocks|"Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma."
218822122|NCT03486353|DRUG|FF-10501-01|FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
218822123|NCT03486353|DRUG|Azacitidine|azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
218822124|NCT06521216|DRUG|Ferrous sulfate|all patients will receive 200 mg elemental iron (ferrous sulphate)
218822125|NCT02439905|DRUG|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
218822126|NCT02439905|DRUG|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
218822127|NCT06141551|PROCEDURE|total laminectomy decompression|Surgical decompression
218822128|NCT02132403|DRUG|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
218822129|NCT02132403|DRUG|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
218822130|NCT02132403|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
218822131|NCT02054065|OTHER|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
219009136|NCT00261664|DEVICE|telehomecare|
219195383|NCT06810635|DIAGNOSTIC_TEST|fasting blood sample|Fasting blood sample will be obtained for determination of markers of metabolic health.
219436402|NCT03556332|PROCEDURE|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
219436403|NCT01489228|DRUG|E1224|100 mg tablets
219436404|NCT01489228|DRUG|Benznidazole|100mg tablets
219436405|NCT01489228|DRUG|Placebo|tablets
218822132|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
218822133|NCT02679378|DEVICE|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
219580151|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
218822134|NCT06202469|DIETARY_SUPPLEMENT|Supplement 1|Creatine monohydrate (5 g/day)
218822135|NCT06202469|DIETARY_SUPPLEMENT|Supplement 2|Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)
218822136|NCT06202469|DIETARY_SUPPLEMENT|Placebo|Placebo (inulin)
218822137|NCT00390897|DRUG|Glivec|
219580152|NCT01691924|DRUG|PBF-509|
218822138|NCT00390897|DRUG|Interferon|
218822139|NCT05647499|BEHAVIORAL|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
218822140|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
218822141|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
219009137|NCT00725023|DEVICE|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
219009138|NCT00725023|DEVICE|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
219009139|NCT03590379|DRUG|CHF 5993 DPI|BDP/FF/GB DPI
219009140|NCT03590379|DRUG|CHF5993 pMDI|BDP/FF/GB pMDI
219009141|NCT03590379|DRUG|CHF 1535 pMDI|BDP/FF pMDI
219009142|NCT03590379|DRUG|Placebo DPI|CHF 5993 DPI matched placebo
219009143|NCT03590379|DRUG|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
219009144|NCT00137748|DRUG|CMV-Ig|Drug: CMV-Ig
219436406|NCT03820557|OTHER|Educational Intervention|Undergo Decision Counseling Program
219436407|NCT05092399|PROCEDURE|Bariatric Surgery|No study interventions
219580153|NCT01691924|DRUG|Placebo|
219596904|NCT00247494|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
219596905|NCT05153993|OTHER|Fascia stretch|"Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks"
219436408|NCT04839393|DRUG|PF-06882961 followed by PF-06882961/PF-06865571|Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
219436409|NCT04839393|DRUG|PF-06882961/PF-06865571 followed by PF-06882961|Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
219436410|NCT04839393|DRUG|PF-06882961 + PF-06865571|Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
219195384|NCT06810635|DIAGNOSTIC_TEST|Fasting urine collection|Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites
219195385|NCT06810635|DIAGNOSTIC_TEST|24 hours urine collection|Subjects collect urine over the entire 24h. for determination of polyphenol metabolites
219436411|NCT00715013|DRUG|Patupilone|Patupilone
219436412|NCT03613818|BEHAVIORAL|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
219436413|NCT04882358|DEVICE|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
219436414|NCT04882358|DRUG|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
219436415|NCT03379441|DRUG|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
219436416|NCT04039763|DEVICE|Dexcom G6|Realtime Continous Glucose Monitoring
219436417|NCT04039763|DEVICE|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
219436418|NCT04194515|DRUG|YH1|YH1 treatment for one month
219436419|NCT04194515|DRUG|metformin|metformin treatment for one month
219436420|NCT00956462|DRUG|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
219580154|NCT02774135|OTHER|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
219580155|NCT02263235|BIOLOGICAL|administration of stable isotope-labelled leucine-|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
219580156|NCT02263235|OTHER|collection of CSF, blood, urine, saliva|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
219580157|NCT02059018|DRUG|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
219580158|NCT02059018|DRUG|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
219580159|NCT02059018|DRUG|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
219436421|NCT01197092|DIETARY_SUPPLEMENT|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
219436422|NCT01197092|DIETARY_SUPPLEMENT|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
219580160|NCT05322499|DRUG|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
219580161|NCT05322499|DRUG|Irinotecan|100-125mg/m2，d1，d8；q21d
218822142|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
218822143|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
218822144|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
218822145|NCT04528238|OTHER|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
219436423|NCT01197092|DEVICE|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
219436424|NCT01197092|BEHAVIORAL|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
219436425|NCT00676156|DRUG|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
219580162|NCT05322499|DRUG|Paclitaxel|135-175mg/m2，d1，Q3W
219580163|NCT05322499|DRUG|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
219195386|NCT06810635|OTHER|Questionnaires|Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.
219436426|NCT00676156|DRUG|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
219436427|NCT00676156|DRUG|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
219580164|NCT05322499|DRUG|Docetaxel|60-75mg/m2，d1，Q3W
218822146|NCT03683810|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin in tablets 4g/daily
219580165|NCT05322499|DRUG|Anlotinib|12mg，qd，d1-d14，q3w
218822147|NCT03683810|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
218822148|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
218822149|NCT04709510|DIAGNOSTIC_TEST|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
218822150|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
218822151|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
219009145|NCT00378196|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
219009146|NCT00378196|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
219580166|NCT02075671|DRUG|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
218822152|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
218822153|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
218822154|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
218822155|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
218822156|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
218822157|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
218822158|NCT00373048|DRUG|mefloquine|tablet, once weekly
218822159|NCT00373048|DRUG|placebo|tablet, once weekly
218822160|NCT05911971|OTHER|Experimental|specific reeducation (not detailed to maintain blinding of participants)
218822161|NCT05911971|OTHER|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
219009147|NCT00931814|OTHER|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
219580167|NCT02075671|DEVICE|Blu-U Light Therapy|Intervention used in experimental and sham arms
219580168|NCT02075671|OTHER|Placebo vehicle only|Intervention only includes the placebo vehicle solution
219580169|NCT00376311|DRUG|oral salmon calcitonin|
219580170|NCT05941689|DEVICE|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
219580171|NCT04202809|DRUG|Durvalumab|Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
219580172|NCT03340363|BEHAVIORAL|environmental change|"1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store."
219009148|NCT04400240|BEHAVIORAL|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
219009149|NCT04411875|DRUG|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
219009150|NCT04411875|DRUG|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
219009151|NCT04620720|DRUG|capule gabapentin|neuropathic analgesic
219195387|NCT06810635|DIAGNOSTIC_TEST|Stool collection|Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.
219580173|NCT03340363|BEHAVIORAL|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
218822162|NCT04231071|DEVICE|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
218822163|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
218822164|NCT00255905|BEHAVIORAL|Clinician monitoring|
218822165|NCT05225883|GENETIC|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
218822166|NCT00413439|DRUG|Isavuconazole|Intravenous solution or oral capsules
218822167|NCT05225519|DEVICE|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
218822168|NCT05225519|DEVICE|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
218822169|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
218822170|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
218822171|NCT01967745|PROCEDURE|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
218822172|NCT01967745|PROCEDURE|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
218822173|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
219009152|NCT04772755|DEVICE|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
218822174|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
218822175|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
218822176|NCT06419452|OTHER|Unilateral resistance training programme|A method of training that increases muscle strength and endurance by using external resistance to a unilateral limb or movement.
218822177|NCT06419452|OTHER|Bilateral resistance training programme|A training method that increases muscle strength and endurance by using external resistance on both limbs or movements,
218822178|NCT06419452|OTHER|Combined（UL+BL） resistance training programme|A method of training that uses limbs or movements to increase muscle strength and endurance by external resistance using unilateral and bilateral combined forms,
218822179|NCT05309681|OTHER|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
218822180|NCT06124222|PROCEDURE|Prosthetic oral rehabilitation|Prosthetic rehabilitation with fixed and/or removable prosthesis.
218822181|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
218822182|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
218822183|NCT02457338|DIETARY_SUPPLEMENT|Bifidobacterium|
219009153|NCT03438175|BEHAVIORAL|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
219009154|NCT05071989|BEHAVIORAL|Sleep Education|A single-blind school- based randomized controlled design
219009155|NCT01905657|BIOLOGICAL|Pembrolizumab|IV infusion
219009156|NCT01905657|DRUG|Docetaxel|IV infusion
218822184|NCT06206850|DRUG|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
219009157|NCT01778881|OTHER|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
219009158|NCT01778881|OTHER|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
219009159|NCT01778881|OTHER|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
219009160|NCT01778881|OTHER|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
219436428|NCT04424004|OTHER|COVID-19 PCR and serology testing|"1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
219436429|NCT04890561|DRUG|Lemborexant|Lemborexant oral tablets.
219436430|NCT03381625|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
219580174|NCT05628519|BEHAVIORAL|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
219580175|NCT05628519|BEHAVIORAL|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
219580176|NCT02637921|OTHER|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
218822188|NCT04952571|DRUG|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
219009161|NCT02123745|DEVICE|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
219009162|NCT00432471|PROCEDURE|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
219009163|NCT03388879|DEVICE|Taylor Spatial Frame|Circular external fixator
219009164|NCT03388879|DEVICE|Intramedullary nail|Antegrade intramedullary nail
219009165|NCT04358133|DRUG|Chlorhydrate de morphine|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
219436431|NCT03381625|DRUG|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
219436432|NCT05272657|OTHER|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
218822189|NCT00730054|DRUG|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
218822190|NCT05122546|DRUG|Cabozantinib S-malate|Given PO
218822191|NCT05122546|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
219009166|NCT04358133|DRUG|NaCl 0,9%,|The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
219009167|NCT04953221|DRUG|YJ001|Skin spray
219009168|NCT00358124|DRUG|insulin glargine|
219009169|NCT00358124|DRUG|rosiglitazone|
219009170|NCT00358124|DRUG|metformin|
219009171|NCT01579175|OTHER|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
219436433|NCT05272657|OTHER|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
218822192|NCT05122546|BIOLOGICAL|Nivolumab|Given IV
218822193|NCT05387746|BEHAVIORAL|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
218822194|NCT01356394|OTHER|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
218822195|NCT02840279|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
218822196|NCT02840279|DRUG|Placebo|
219436434|NCT01063218|OTHER|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
219009172|NCT06284291|DIAGNOSTIC_TEST|transcranial magnetic stimulation (TMS)|The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
219009173|NCT05541952|BIOLOGICAL|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
219009174|NCT00179634|BEHAVIORAL|Visualization relaxation|
219009175|NCT00179634|BEHAVIORAL|Visual Milieu Enhancement (Fine art photograph)|
219009176|NCT01892228|BEHAVIORAL|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
219436435|NCT04105322|OTHER|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
218822197|NCT04663594|OTHER|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
219009177|NCT01386554|DRUG|Repository Corticotropin Injection|Acthar given SC for 6 months
219009178|NCT01386554|DRUG|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
219009179|NCT03164252|RADIATION|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
219009180|NCT03164252|RADIATION|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
219009181|NCT03164252|RADIATION|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
219009182|NCT04810845|DEVICE|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
219009183|NCT00355693|DEVICE|Pump for propofol delivery|
219436436|NCT00470678|DRUG|ranibizumab|
219436437|NCT05263726|BEHAVIORAL|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
218822198|NCT04663594|OTHER|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
218822199|NCT03840213|BEHAVIORAL|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
218822200|NCT04228458|DEVICE|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
218822201|NCT06301503|DRUG|USG Guided Combined LPB-SNB with Isobaric Bupivacaine|Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
218822202|NCT06301503|DRUG|Control|Local anesthetic infiltration of 2% lidocaine (3ml)
218822203|NCT02827721|DEVICE|impulse oscillometry|
219580177|NCT02637921|OTHER|Ambulatory|Participants hava a standardized activity level throughout the intervention
218822204|NCT02827721|DEVICE|multiple breath washout test|
218822205|NCT02827721|DEVICE|body plethysmography|
218822206|NCT06319781|OTHER|Observational|The study is a prospective non-interventional, observational study.
218822207|NCT01459094|DRUG|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
219009184|NCT05286281|DRUG|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
219009185|NCT00929799|DRUG|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
219009186|NCT00248014|DEVICE|Mandibular Advancement Via A Functional Appliance|Functional appliance
219009187|NCT01024452|DEVICE|DAWN AC|computerized dosing management system for anticoagulation clinics
219009188|NCT01024452|DEVICE|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
219009189|NCT03334903|DRUG|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
218822208|NCT01459094|DRUG|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
218822209|NCT04173182|DIAGNOSTIC_TEST|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
218822210|NCT06141512|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT)|Description same as Arm description.
218822211|NCT03795493|BEHAVIORAL|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
219436438|NCT06156449|OTHER|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
219436439|NCT00671970|DRUG|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
218822212|NCT04277312|BEHAVIORAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
219436440|NCT05528328|DEVICE|CACIPLIQ20®|CACIPLIQ20®
218822213|NCT04277312|BEHAVIORAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
218822214|NCT06565364|DIAGNOSTIC_TEST|"ZYMUTEST™ HIA immunoglobulin g ELISA (enzyme-linked immunosorbent assay )"|The enzyme-linked immunosorbent assay is an in vitro test done in the laboratory to detect specific antibodies against heparin/platelet factor-4 and protamine/heparin complexes.
218822215|NCT05111067|GENETIC|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
218822216|NCT03139058|OTHER|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
218822217|NCT02094391|DRUG|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
218822218|NCT00185341|DRUG|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
218822219|NCT00185341|DRUG|Placebo|Placebo
218822220|NCT01876381|DRUG|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
218822221|NCT00185094|DRUG|Olmesartan medoxomil|
218822222|NCT00185094|DRUG|Losartan potassium|
218822223|NCT00185094|DRUG|Atenolol|
218822224|NCT00006021|DIETARY_SUPPLEMENT|ascorbic acid|
218822225|NCT00006021|DRUG|arsenic trioxide|
218822226|NCT00943644|DEVICE|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
218822227|NCT00943644|DEVICE|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
219009190|NCT03254004|DRUG|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
219436441|NCT05528328|DRUG|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
218822228|NCT02657148|DRUG|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
218822229|NCT02657148|DRUG|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
218822230|NCT00114491|DRUG|Rosuvastatin|
219009191|NCT03949361|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
219009192|NCT03949361|DIAGNOSTIC_TEST|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
219009193|NCT03949361|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
219009194|NCT03949361|DIAGNOSTIC_TEST|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
219009195|NCT03949361|DIAGNOSTIC_TEST|FDG-PET|Dynamic PET scanning of the neck-region
219009196|NCT03949361|DIAGNOSTIC_TEST|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
219436442|NCT00633893|DRUG|Apixaban|Tablets, Oral, twice daily, 12 months
219436443|NCT00633893|DRUG|Placebo|Tablets, Oral, twice daily, 12 months
219436444|NCT00468611|DRUG|MBP8298|500mg MBP8298 IV every six months for a period of two years
219436445|NCT02741310|DRUG|Placebo|Administered by intravenous infusion
219436446|NCT02741310|DRUG|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
219436447|NCT02741310|DRUG|Erenumab|Administered by intravenous infusion
219436448|NCT00911222|OTHER|non-interventional|non-interventional
218822231|NCT03507582|OTHER|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
218822232|NCT03507582|OTHER|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
218822233|NCT04951531|PROCEDURE|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
218822234|NCT04951531|PROCEDURE|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
218822235|NCT04951531|PROCEDURE|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
218822236|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
219009197|NCT03949361|DIAGNOSTIC_TEST|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
219009198|NCT01823185|DRUG|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
219009199|NCT01823185|DRUG|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
219436449|NCT06393413|DRUG|Jiedu Yizhi Formula|Observation after 24 weeks of drug treatment
219436450|NCT06393413|DRUG|Donepezil Hydrochloride Tablets|Donepezil Hydrochloride Tablets
219436451|NCT00872781|DRUG|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
218822237|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
218822238|NCT00461708|DRUG|Erlotinib|100 mg, PO, once per day
218822239|NCT00461708|DRUG|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
219009200|NCT06076057|DIAGNOSTIC_TEST|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
219009201|NCT00349284|DRUG|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
219009202|NCT03018171|DRUG|Clonidine|Intrathecal clonidine addiction
219009203|NCT03018171|DRUG|Sufentanil|Intrathecal
219009204|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention using cookies containing milk or egg low dose.|Baked Group 1: consumed a daily fixed low dose of baked milk or egg (0.0375 g of milk protein or 0.11 g of egg protein) for 6 months, followed by an additional increase at that time (0.075 g or 0.22 g).
219009205|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention with cow's milk or egg baked cookies high dose|Baked Group 2: continued a daily high dose of baked milk (0.55 g of milk protein or 1.1g egg protein) for 6 months. An increase dose is given at that time (1.1g cow's milk or 2g egg protein).
219009206|NCT03032705|DEVICE|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
219009207|NCT03032705|DEVICE|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
219009208|NCT01000441|DRUG|infliximab, etanercept, adalimumab|
219009209|NCT01000441|DRUG|abatacept, rituximab or tocilizumab|
219009210|NCT05030974|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccination
219009211|NCT05030974|BIOLOGICAL|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
219195388|NCT06810635|DIAGNOSTIC_TEST|Transit time determination|Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.
219195389|NCT05459701|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
219195390|NCT05459701|OTHER|Placebo|Placebo
219436452|NCT05091918|DEVICE|MotionSense|MotionSense Wearable: Remote patient monitoring
219436453|NCT06169891|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
219436454|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
219436455|NCT06169891|DRUG|Compound Betamethasone Injection|1 mL i.m. once on Day 1
219436456|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
219436457|NCT02936336|OTHER|exercise|circuit exercise, aerobic dance and Tai Chi exercise
219436458|NCT00239356|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
219436459|NCT02312011|DRUG|IONIS-DMPKRx|Drug
219009212|NCT05644522|DEVICE|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
219009213|NCT03722537|PROCEDURE|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
219009214|NCT03722537|PROCEDURE|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
219009215|NCT04487639|DIAGNOSTIC_TEST|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
219009216|NCT02927080|DRUG|ACE-083|Recombinant fusion protein.
219009217|NCT02927080|DRUG|ACE-083 or placebo|Recombinant fusion protein or normal saline.
219009218|NCT04469114|DRUG|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
219009219|NCT04469114|DRUG|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
219009220|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
219009221|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
219009222|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
219009223|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
219009224|NCT04486781|DRUG|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
219009225|NCT05111158|DIAGNOSTIC_TEST|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
219009226|NCT00503308|PROCEDURE|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
219009227|NCT02031926|DEVICE|Positive expiratory pressure|
219009228|NCT02671591|BEHAVIORAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
219009229|NCT02671591|BEHAVIORAL|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
219009230|NCT04566081|OTHER|iTALKbetter: deterministic|A word retrieval therapy application
219195391|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly over six weeks.
219195392|NCT04986046|OTHER|Home Plate|Home Plate comprises six 1.5-hour weekly sessions where parents work together with a study staff member to discuss the learning objectives and prepare the components of a meal, including entrees, side dishes, and desserts.
219436460|NCT02312011|DRUG|Placebo|Placebo
219436461|NCT03309904|OTHER|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
219436462|NCT04616092|DRUG|FEFINJECT|FEFINJECT injection
219580178|NCT02637921|OTHER|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
219009231|NCT04566081|OTHER|iTALKbetter: reactive|A word retrieval therapy application
219009232|NCT06131242|OTHER|It is an observational study|It is an observational study
219009233|NCT00608231|DRUG|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
219009234|NCT00608231|DRUG|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
219009235|NCT03502226|BEHAVIORAL|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
219009236|NCT02564042|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
219009237|NCT02564042|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
219009238|NCT02564042|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
219009239|NCT04723550|DEVICE|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
219009240|NCT04723550|OTHER|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
219009241|NCT00213083|DRUG|Carraguard (PC-515)|
219009242|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
219009243|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
219580179|NCT02637921|OTHER|Bed Rest|Participants remain on supine bed rest throughout the intervention
218822240|NCT02462226|BEHAVIORAL|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
218822241|NCT02462226|BEHAVIORAL|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
218822242|NCT02394561|BIOLOGICAL|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
218822243|NCT00501644|DRUG|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
218822244|NCT00501644|DRUG|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
218822245|NCT00501644|DRUG|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
218822246|NCT02750514|BIOLOGICAL|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
218822247|NCT02750514|DRUG|Dasatinib|
218822248|NCT02750514|BIOLOGICAL|Relatlimab|
218822249|NCT02750514|BIOLOGICAL|Ipilimumab|
218822250|NCT02750514|DRUG|BMS-986205|Specified dose on specified days
218822251|NCT02553629|DRUG|Rocuronium|
218822252|NCT06350448|DRUG|Washed Microbiota Transplantation|Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
219009244|NCT06120556|DRUG|GLP-1 receptor agonist|Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
219436463|NCT02176980|BEHAVIORAL|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
219436464|NCT02176980|BEHAVIORAL|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
218822253|NCT02142088|DEVICE|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
218822254|NCT02801786|DRUG|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
218822255|NCT02801786|DRUG|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
218822256|NCT02801786|DRUG|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
218822257|NCT00239603|DEVICE|OV-Watch|
218822258|NCT05222685|BEHAVIORAL|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
218822259|NCT03140111|DEVICE|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
218822260|NCT03140111|DEVICE|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
218822261|NCT00872300|DRUG|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
218822262|NCT01932684|OTHER|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
218822263|NCT01932684|OTHER|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
218822264|NCT01932684|DEVICE|5000 Voldyne ® Sherwood Medical, USA|
218822265|NCT01932684|DEVICE|Silicone face mask|
219009245|NCT01356966|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
219009246|NCT01356966|DRUG|Placebo|2 placebo pills PO BID for12 weeks
219009247|NCT01356966|DIETARY_SUPPLEMENT|Folate|Folate 1 mg daily for 12 weeks
219009248|NCT01549392|DEVICE|DECT|DECT at tumor progression and 3 months later
219009249|NCT01549392|DEVICE|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
219009250|NCT04219332|DRUG|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
219009251|NCT04219332|DRUG|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
219009252|NCT01179945|OTHER|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
219436465|NCT05457400|DRUG|ENSO 16|30 g ENSO 16 dissolved in Water
219436466|NCT05457400|DRUG|Glucose Powder|30 g Glucose Powder dissolved in Water
219436467|NCT03998891|OTHER|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
219436468|NCT01378091|DRUG|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
219436469|NCT01378091|DRUG|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
219436470|NCT01378091|DRUG|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
219763551|NCT06089109|BEHAVIORAL|The Big 3|Our research team has developed an online, interactive learning management system (LMS) training. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide healthcare professionals with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
218822266|NCT03515161|DEVICE|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
218822267|NCT02040389|BEHAVIORAL|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
218822268|NCT02040389|BEHAVIORAL|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
218822269|NCT02022540|DRUG|PAN-90806 Ophthalmic Solution|
218822270|NCT02022540|DRUG|Lucentis|
218822271|NCT01812057|DRUG|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
218822272|NCT01812057|DRUG|Placebo|Sodium Chloride 0.9% -5 ml
218822273|NCT03819309|PROCEDURE|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
218822274|NCT03819309|PROCEDURE|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
218822275|NCT03166930|BEHAVIORAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
218822276|NCT03166930|BEHAVIORAL|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
219763552|NCT06089109|BEHAVIORAL|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
218822277|NCT05759780|DEVICE|Optical imaging of the tissues|OCT vibrography
218822278|NCT01882465|DEVICE|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
218822279|NCT01882465|DEVICE|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
219195393|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
219436471|NCT05843617|DIETARY_SUPPLEMENT|Liposomal Vitamin C|1000 mg of ascorbic acid in liposomal formulation
219436472|NCT05843617|DIETARY_SUPPLEMENT|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
218822280|NCT01882465|DEVICE|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
218822281|NCT00000276|DRUG|Bupropion|
218822282|NCT01814956|DRUG|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
219436473|NCT02596425|PROCEDURE|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
219436474|NCT02596425|PROCEDURE|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
219436475|NCT02596425|PROCEDURE|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
219436476|NCT04601181|BIOLOGICAL|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"
219436477|NCT02044822|DRUG|Idelalisib|150 mg tablets administered orally twice daily
219436478|NCT02044822|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly x 8 weeks
218822283|NCT01814956|DRUG|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
218822284|NCT01138410|BIOLOGICAL|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
218822285|NCT05021952|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
219436479|NCT04218513|DRUG|Compound Edaravone Injection|30 min intravenous infusion
219436480|NCT04218513|DRUG|Edaravone Injection|30 min intravenous infusion
219436481|NCT04218513|DRUG|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
219436482|NCT00164099|DRUG|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
219436483|NCT02967172|DRUG|Ropivacaine|
219436484|NCT02967172|DRUG|Epinephrine|
219436485|NCT02967172|DRUG|Morphine|
218822286|NCT05915611|OTHER|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
218822287|NCT05915611|OTHER|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
218822288|NCT02987582|BEHAVIORAL|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
218822289|NCT02148588|DRUG|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
218822290|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
218822291|NCT03763747|DEVICE|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
218822292|NCT02633735|OTHER|Appy CDS|See description under arm/group section
218822293|NCT00002219|DRUG|Nelfinavir mesylate|
218822294|NCT00002219|DRUG|Levocarnitine|
218822295|NCT00002219|DRUG|Adefovir dipivoxil|
218822296|NCT02563782|BIOLOGICAL|Sub-retinal transplantation of MA09-hRPE cells|transplantation
219009253|NCT01179945|OTHER|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
219009254|NCT01219920|DRUG|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
219009255|NCT01219920|DRUG|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
219009256|NCT02743806|DRUG|Vedolizumab|Vedolizumab IV infusion
219009257|NCT01550796|BEHAVIORAL|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
219009258|NCT03206853|PROCEDURE|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
219436486|NCT02967172|DRUG|0.9% sodium chloride solution|
218822297|NCT02563782|DRUG|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
218822298|NCT02563782|DRUG|Placebo tacrolimus and mycophenolate mofetil|placebo
218822299|NCT02563782|PROCEDURE|Sham Surgery|Sham surgery
218822300|NCT00617864|DRUG|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
218822301|NCT00617864|DRUG|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
218822302|NCT00029250|DRUG|Garlic powder standardized to allicin|
218822303|NCT00839969|PROCEDURE|Cystoscopy|Saline cystoscopy under general anaesthesia
218822304|NCT00839969|PROCEDURE|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
218822305|NCT05104827|OTHER|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
218822306|NCT02812914|OTHER|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
218822307|NCT02812914|BEHAVIORAL|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
219009259|NCT05383300|DRUG|Oxytocin nasal spray|Intranasal spray containing 40 IU of oxytocin
219009260|NCT05383300|OTHER|Placebo spray|Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
219436487|NCT05207709|DRUG|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
219436488|NCT05207709|DRUG|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
219436489|NCT05207709|DRUG|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
218822308|NCT02812914|BEHAVIORAL|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
218822309|NCT00834821|BEHAVIORAL|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
218822310|NCT00834821|BEHAVIORAL|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
219436490|NCT03417505|DEVICE|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
219436491|NCT03417505|DEVICE|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
219436492|NCT04437316|DEVICE|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
219436493|NCT05078307|PROCEDURE|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
219436494|NCT06950073|RADIATION|Radiotherapy|Radiotherapy is offered in the same dose to all patients eligible to reirradiation no matter if they are enrolled in the study or not. Meaning no intervention is done. This is a registration study.
219436495|NCT01650441|DRUG|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
218822311|NCT04270422|OTHER|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
218822312|NCT04270422|OTHER|Usual physiotherapy|Usual evidence based physiotherapy
218822313|NCT02259114|DRUG|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
218822314|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
218822315|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
218822316|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
218822317|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
218822318|NCT03937479|DRUG|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
218822319|NCT02578901|DRUG|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
219436496|NCT01650441|RADIATION|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
219436497|NCT06948331|DEVICE|PuraStat|Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.
219580180|NCT02637921|OTHER|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
219580181|NCT01333371|PROCEDURE|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
219580182|NCT00003875|DRUG|busulfan|Given PO or IV
219580183|NCT00003875|DRUG|etoposide|Given IV
219580184|NCT00003875|BIOLOGICAL|aldesleukin|Given SC
219580185|NCT00003875|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
219580186|NCT05668078|DIAGNOSTIC_TEST|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
219580187|NCT00188110|PROCEDURE|Water-Enema Computed Tomography|
219436498|NCT01877811|DRUG|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
218822320|NCT02578901|DRUG|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
218822321|NCT03048773|DEVICE|shockwave therapy|Intervention with shockwave therapy
218822322|NCT03048773|OTHER|PT|Physical therapy 3 times per week for 3 weeks
218822323|NCT03048773|OTHER|placebo|sham shockwave therapy
218822324|NCT05691387|BEHAVIORAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
218822325|NCT05691387|BEHAVIORAL|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
218822326|NCT00147329|DRUG|MM-093|
218822327|NCT04546100|OTHER|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
218822328|NCT00922961|BIOLOGICAL|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
218822329|NCT00922961|PROCEDURE|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
218822330|NCT04062058|RADIATION|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
218822331|NCT04062058|DRUG|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
219436499|NCT06109077|OTHER|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
219436500|NCT06109077|OTHER|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
219436501|NCT00220857|DRUG|Rabeprazole|
219436502|NCT06094114|DEVICE|pacemaker follow-up|Performance of an exercise test in patients previously implanted with Micra AV
219436503|NCT02100410|DEVICE|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
219436504|NCT02100410|DEVICE|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
218822332|NCT04062058|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
218822333|NCT04062058|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
218822334|NCT01378117|DRUG|Sitagliptin|Sitagliptin 50-100mg po once daily
218822335|NCT01378117|DRUG|glargine|glargine once daily
218822336|NCT01378117|DRUG|lispro|lispro before meals
218822337|NCT00740181|DRUG|chemotherapy|
218822338|NCT03305484|OTHER|No intervention|No intervention, observation only
218822339|NCT00233532|DRUG|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
218822340|NCT03322163|OTHER|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
219436505|NCT02100410|DEVICE|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
219436506|NCT02100410|DEVICE|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
219436507|NCT02100410|DEVICE|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
219436508|NCT02100410|DEVICE|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
219436509|NCT05423704|OTHER|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
219436510|NCT01237223|DRUG|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
219436511|NCT01237223|DRUG|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
219436512|NCT01237223|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
219436513|NCT01237223|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
218822341|NCT04464551|DRUG|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
218822342|NCT04044157|OTHER|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
218822343|NCT02150239|PROCEDURE|operation|
218822344|NCT03151031|PROCEDURE|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
219009261|NCT05692765|BEHAVIORAL|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
219009262|NCT03589443|DRUG|Multiplexed heptapeptides|Heptapeptides QRH and KSP
219195394|NCT03434548|RADIATION|PET imaging|"PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
219436514|NCT01237223|DRUG|Placebo of Aliskiren|Aliskiren placebo tablet
219436515|NCT01237223|DRUG|Placebo of Amlodipine|Amlodipine placebo capsule
219436516|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
219436517|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
219436518|NCT04570228|DEVICE|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
219436519|NCT04570228|DEVICE|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
218822345|NCT03988946|DEVICE|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
218822346|NCT01854528|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
218822347|NCT01854528|DRUG|Ribavirin|Tablet
218822348|NCT01854528|DRUG|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
219436520|NCT01222936|DRUG|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
219436521|NCT02488356|DIETARY_SUPPLEMENT|Litramine|
219580188|NCT00992524|DRUG|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
219763553|NCT05974488|DEVICE|McMurray Enhanced Airway|The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
219763554|NCT05974488|DEVICE|Nasal Cannula|Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
219009263|NCT02635555|DRUG|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
219009264|NCT01887574|OTHER|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
219009265|NCT03931421|BIOLOGICAL|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
219436522|NCT03288818|DRUG|Mechlorethamine Hydrochloride Gel|Given topically
219436523|NCT03288818|PROCEDURE|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
219436524|NCT05179343|DEVICE|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
219436525|NCT05179343|DEVICE|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
219580189|NCT00992524|DRUG|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
218822349|NCT01854528|DRUG|Telaprevir|Film-coated tablet
219436526|NCT05686044|DRUG|Buntanetap/Posiphen|HPMC (vegetarian source) capsule shells
219436527|NCT05686044|DRUG|Placebo|HPMC (vegetarian source) capsule shells
218822350|NCT02961244|OTHER|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
218822351|NCT02961244|DEVICE|Forced Air Warming blanket|
218822352|NCT03767049|OTHER|Colection of clinical data|Colection of clinical data
218822353|NCT02017184|BIOLOGICAL|Noninvasive core temperature thermistor|
218822354|NCT03525509|DRUG|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
218822355|NCT03525509|DRUG|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
218822356|NCT03789292|BIOLOGICAL|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
218822357|NCT03789292|BIOLOGICAL|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
218822358|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
218822359|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
218822360|NCT05597384|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
218822361|NCT02717325|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
218822362|NCT02832414|BEHAVIORAL|Intensive weight loss program|behavioral and dietary supplement
218822363|NCT03012750|DRUG|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
218822364|NCT02828384|OTHER|low fodmap diet|dietary teaching
219009266|NCT05687422|PROCEDURE|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
219009267|NCT05687422|PROCEDURE|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
219009268|NCT04750720|OTHER|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
219009269|NCT00660530|DRUG|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
219009270|NCT00660530|DRUG|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
219009271|NCT00849381|BIOLOGICAL|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
219009272|NCT04273217|DRUG|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
219009273|NCT04273217|DRUG|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
219009274|NCT05175690|DIAGNOSTIC_TEST|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
219009275|NCT02393833|PROCEDURE|Blood samples collection|"Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression"
219009276|NCT06208059|OTHER|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
219195395|NCT03434548|OTHER|Multi-modal MRI imaging|Multi-modal MRI imaging
219436528|NCT00407550|DRUG|gemcitabine HCL|1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
219436529|NCT00407550|DRUG|pemetrexed disodium|500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
218822365|NCT02828384|DIETARY_SUPPLEMENT|Psyllium|7.1g of psyllium daily
218822366|NCT00928967|DRUG|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
218822367|NCT06239558|OTHER|Qualitative exploration|Semi-structured Interviews and focus group
218822368|NCT00465673|DRUG|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
219436530|NCT00407550|DRUG|gemcitabine HCL|1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
219436531|NCT02183610|DRUG|[14C] BI 1356 as oral (p.o.) solution|
219436532|NCT02183610|DRUG|[14C] BI 1356 solution for i.v. infusion|
219436533|NCT03528590|DEVICE|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
219009277|NCT06208059|OTHER|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
219009278|NCT05502328|DIETARY_SUPPLEMENT|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
219009279|NCT02729974|PROCEDURE|ROTEM|rapid testing of blood clot formation
219009280|NCT02729974|PROCEDURE|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
219009281|NCT01548092|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
219009282|NCT00303498|DRUG|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
219009283|NCT00303498|DRUG|Placebo|placebo identical to the study drug in description, dose and duration
219009284|NCT03675490|BEHAVIORAL|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
219009285|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
219009286|NCT02776423|PROCEDURE|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
219009287|NCT01564121|DRUG|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
219436534|NCT03528590|DEVICE|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
219436535|NCT02403713|DRUG|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
219009288|NCT05554094|DRUG|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
219009289|NCT03071770|DRUG|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
219436536|NCT02403713|DRUG|Formoterol|Formoterol
219436537|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
219436538|NCT02403713|DRUG|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
219436539|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
219436540|NCT00443846|BIOLOGICAL|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
219436541|NCT00443846|BIOLOGICAL|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
219436542|NCT04280484|OTHER|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
219436543|NCT04280484|OTHER|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
219436544|NCT02477306|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
219436545|NCT02477306|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
219009290|NCT00430690|PROCEDURE|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
219009291|NCT03606733|PROCEDURE|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
219009292|NCT03369392|OTHER|Panda application|A smartphone-based postoperative pain management tool
219009293|NCT03303534|DIETARY_SUPPLEMENT|ScandiShake|weight gain supplement low in protein
219009294|NCT04920370|DRUG|ALXN1720 SC|ALXN1720 will be administered via SC route.
219009295|NCT04920370|DRUG|ALXN1720 IV|ALXN1720 will be administered via IV route.
219009296|NCT04920370|DRUG|rHuPH20|rHuPH20 will be administered via SC route.
219009297|NCT04920370|DRUG|Placebo SC|Placebo will be administered via SC route.
219009298|NCT04920370|DRUG|Placebo IV|Placebo will be administered via IV route.
219436546|NCT02812108|DEVICE|intracranial stent, flow diverter and coils|
219436547|NCT06272357|OTHER|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
219436548|NCT05539924|DRUG|Pregabalin 150mg gabapentin 400mg|oral administration
219436549|NCT00641706|DRUG|vorinostat|Given orally
219436550|NCT00641706|PROCEDURE|therapeutic conventional surgery|Patient undergoes surgery
218822369|NCT03920891|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
218822370|NCT03920891|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
218822371|NCT01497834|DRUG|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
218822372|NCT01497834|DRUG|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
218822373|NCT01709357|OTHER|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
218822374|NCT01709357|OTHER|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
219009299|NCT00004196|BIOLOGICAL|recombinant interferon alfa|
219009300|NCT00004196|PROCEDURE|lymphangiography|
219009301|NCT00004196|DRUG|Observation|
219436551|NCT00641706|DRUG|bortezomib|Given IV
219436552|NCT03612947|DRUG|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
219436553|NCT03612947|DRUG|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
219436554|NCT03436147|OTHER|POP-Q|Pelvic Organ Prolapse Quantification
219436555|NCT04642378|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
219436556|NCT04642378|DRUG|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
219580190|NCT05325307|OTHER|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
219763555|NCT06362824|BEHAVIORAL|De Pie Intervention|Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.
218822375|NCT01709357|OTHER|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
219009302|NCT02066870|DRUG|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
219009303|NCT02066870|DRUG|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
219009304|NCT01813578|OTHER|Exercise|Intensive aerobic and muscle endurance exercise
219009305|NCT05557604|DRUG|Decapeptyl|STAD androgen deprivation
219195396|NCT06409689|DRUG|Oliceridine fumarate low dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
219436557|NCT03395067|BEHAVIORAL|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
219436558|NCT04419662|DRUG|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
219009306|NCT05854732|OTHER|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
219009307|NCT05854732|OTHER|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
219009308|NCT04904887|PROCEDURE|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
219195397|NCT06409689|DRUG|Oliceridine fumarate high dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
219195398|NCT06409689|DRUG|Oliceridine fumarate moderate dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
219195399|NCT06409689|DRUG|morphine|The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg.
219436559|NCT04419662|OTHER|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
219436560|NCT00032006|RADIATION|brachytherapy|
218822376|NCT01709357|OTHER|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
218822377|NCT03789708|DIETARY_SUPPLEMENT|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
218822378|NCT03789708|OTHER|Placebo|Maltodextrin powder, easily soluble
218822379|NCT06304155|DIAGNOSTIC_TEST|Diagnostic efficacy,SUV|"The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.~Standardized uptake value (SUV) of 18F-FDG and 18F-FAPI for each target lesion of subject or suspected primary tumor or/and metastasis."
218822380|NCT05796687|BEHAVIORAL|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
218822381|NCT01909544|OTHER|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
218822382|NCT02435654|DRUG|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
218822383|NCT03260712|DRUG|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
218822384|NCT03260712|DRUG|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
219195400|NCT05026346|DIAGNOSTIC_TEST|Pathologic Exercise|"1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
219195401|NCT06759740|RADIATION|68Ga-DOTA-SEMA|68Ga-DOTA-SEMA is GLP1R imaging agent
219195402|NCT05301348|DEVICE|Photoacoustic Flow Cytometry|Detection of circulating blood clots
219436561|NCT00032006|RADIATION|radiation therapy|
219436562|NCT03006926|DRUG|lenvatinib|4 mg capsules
219436563|NCT03006926|DRUG|pembrolizumab (200 mg)|30-minute intravenous infusion
219436564|NCT03234972|DRUG|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
219436565|NCT03234972|DRUG|Velcade|Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
218822385|NCT03260712|DRUG|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
218822386|NCT03753022|OTHER|Group G5|Submitted to peep 5
219009309|NCT00064376|DRUG|paricalcitol|
218822387|NCT03753022|OTHER|Group G10|Submitted to peep 10
218822388|NCT03753022|OTHER|Group G15|Submitted to peep 15
218822389|NCT01855386|OTHER|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
218822390|NCT01855386|OTHER|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
218822391|NCT05362994|DEVICE|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is \>30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis \>30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
218822392|NCT05362994|DEVICE|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
218822393|NCT04123730|OTHER|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
219195403|NCT02893358|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
219195404|NCT02893358|DRUG|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
219195405|NCT06590623|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
219195406|NCT06759363|DRUG|Sodium-Butyrate|1000 mg/day of sodium-butyrate
219195407|NCT06759363|DRUG|Calcium Butyrate|1000 mg/day of calcium-butyrate
219436566|NCT03234972|DRUG|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
219436567|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg IV infusion.
218822394|NCT00001561|DRUG|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
218822395|NCT00001561|DRUG|GM-CSF|
218822396|NCT05100134|DRUG|ceritinib|Patients receive ceritinib
218822397|NCT02449941|DRUG|PPI (proton pump inhibitor)|"1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI."
218822398|NCT05236166|DRUG|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
218822399|NCT05236166|DRUG|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
218822400|NCT00956761|BIOLOGICAL|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
218822401|NCT01904721|DRUG|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
218822402|NCT01904721|DRUG|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
218822403|NCT01904721|DRUG|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
219195408|NCT06600997|DEVICE|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms
219436568|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
219436569|NCT05287204|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
219436570|NCT05287204|DIAGNOSTIC_TEST|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
219763556|NCT06362824|OTHER|Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)|Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
219763557|NCT05899608|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
219763558|NCT05899608|BIOLOGICAL|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
219763559|NCT06054893|DRUG|Omaveloxolone|Administered as specified in the treatment arm
219763560|NCT05673005|DEVICE|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
219763561|NCT02911103|PROCEDURE|DBS surgery|Unilateral thalamic DBS therapy
218822404|NCT01957865|DEVICE|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
218822405|NCT01957865|DEVICE|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
219009310|NCT03157258|BEHAVIORAL|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
219009311|NCT03157258|BEHAVIORAL|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
219009312|NCT01493570|DRUG|BI 409306|Film-coated tablet
219009313|NCT01493570|DRUG|Placebo|Film-coated tablet
219009314|NCT01149824|DRUG|Salvinorin A|
219009315|NCT01149824|DRUG|Placebo|
219009316|NCT05586529|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
219009317|NCT02809456|DRUG|Nicorandil|oral intake
219009318|NCT02899910|BEHAVIORAL|Health education|Education on lifestyle changes for treatment of metabolic syndrome
219009319|NCT02899910|BEHAVIORAL|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
219436571|NCT05287204|DIAGNOSTIC_TEST|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
219436572|NCT00611611|BIOLOGICAL|fluzone|once
219009320|NCT01503268|DEVICE|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
219009321|NCT01503268|PROCEDURE|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
219436573|NCT00611611|BIOLOGICAL|pneumovax|once
219009322|NCT01503268|PROCEDURE|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
219009323|NCT05120297|DRUG|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
219009324|NCT05120297|DRUG|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
219009325|NCT03815331|DRUG|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
219009326|NCT03815331|DRUG|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
219009327|NCT02279901|BEHAVIORAL|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
219009328|NCT02279901|BEHAVIORAL|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
219009329|NCT00295906|OTHER|educational intervention|
219009330|NCT00295906|OTHER|internet-based intervention|
219009331|NCT04484792|OTHER|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
219009332|NCT04484792|OTHER|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
219009333|NCT04484792|OTHER|placebo|Plain water
219009334|NCT03838640|DEVICE|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
219009335|NCT00103142|BIOLOGICAL|falimarev|Given subcutaneously and intradermally
219009336|NCT00103142|BIOLOGICAL|inalimarev|Given subcutaneously and intradermally
219009337|NCT00103142|BIOLOGICAL|sargramostim|Given subcutaneously
219580191|NCT05325307|OTHER|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
219580192|NCT00996138|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
219580193|NCT04276844|DIAGNOSTIC_TEST|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
219763562|NCT02911103|DEVICE|Medtronic Activa Rechargeable System|Used for diagnostic purposes.
218822406|NCT01465009|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
218822407|NCT01465009|DRUG|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
218822408|NCT01465009|DRUG|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
218822409|NCT04927221|DRUG|DC371739 Tablets|Participants received one of 5 dose levels of DC371739 administered as single oral doses.
218822410|NCT04927221|DRUG|Placebo|Placebo orally administered as comparison
218822411|NCT01082614|DEVICE|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
218822412|NCT01361984|DRUG|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
218822413|NCT01361984|DRUG|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
218822414|NCT02524561|DRUG|CEE pill|Conjugated equine estrogens 0.45 mg/day
218822415|NCT02524561|DRUG|Estradiol patch|Climara 50 mcg/day
218822416|NCT02524561|DRUG|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
218822417|NCT02524561|OTHER|Placebo tablet|Placebo tablet
218822418|NCT02524561|OTHER|Placebo patch|placebo patch
218822419|NCT02524561|OTHER|Placebo progesterone|placebo progesterone
219436574|NCT00432211|DRUG|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
219436575|NCT00175071|BEHAVIORAL|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
218822420|NCT02826616|DRUG|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
218822421|NCT03475602|DIAGNOSTIC_TEST|PLA2R|Determination of serum concentration of anti PLA2R antibody
218822422|NCT03475602|DIAGNOSTIC_TEST|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
218822423|NCT01246882|BEHAVIORAL|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
218822424|NCT01246882|BEHAVIORAL|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
218822425|NCT02616731|DRUG|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
218822426|NCT02616731|DRUG|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
218822427|NCT03979300|OTHER|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~* Quantitative features:~  * Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~ * Sociodemographical data and others questions~* Qualitative : Grounded Theory~  * Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~ * Semi-structured interview of learners and teachers"
218822428|NCT01357343|OTHER|Chiropractic|Spinal manipulation and active and passive therapy.
218822429|NCT01357343|OTHER|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
218822430|NCT00811720|DRUG|Placebo|as-needed use, tablets, orally, 6 months
218822431|NCT00811720|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
218822432|NCT01343212|OTHER|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
218822433|NCT03555058|OTHER|Treatment escalation|Treatment escalation per TDM and physician's decision.
218822434|NCT01077063|PROCEDURE|paracentesis|surgical drainage of malignant ascites
218822435|NCT01077063|DEVICE|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
218822436|NCT04127526|OTHER|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
218822437|NCT02066649|DRUG|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
219009338|NCT00103142|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
219009339|NCT04261751|OTHER|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
219436576|NCT03547349|DEVICE|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
219763563|NCT00581321|DIETARY_SUPPLEMENT|water|water 500 ml x 1
218822438|NCT02066649|PROCEDURE|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
218822439|NCT05874726|DIAGNOSTIC_TEST|Blood Collection|Blood collection via venipuncture
218822440|NCT05874726|DIAGNOSTIC_TEST|Urine Collection|Free catch urine sample collection
218822441|NCT05874726|DIAGNOSTIC_TEST|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
218822442|NCT05503329|DIAGNOSTIC_TEST|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
218822443|NCT00287924|DRUG|methotrexate|
218822444|NCT00287924|PROCEDURE|adjuvant therapy|
218822445|NCT05562115|OTHER|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
218822446|NCT05609357|DEVICE|Head-up Cardiopulmonary Resuscitation|Elevate patient's head to 30 degrees by EleGARD System during cardiopulmonary resuscitation
218822447|NCT02750969|DEVICE|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
218822448|NCT02750969|OTHER|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
218822449|NCT02750969|PROCEDURE|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
218822450|NCT02750969|OTHER|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
218822451|NCT01355614|DRUG|QAX576|
218822452|NCT01355614|DRUG|Infliximab|
218822453|NCT03894891|DRUG|Nivolumab|Nivolumab is a type of immunotherapy.
218822454|NCT03894891|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
218822455|NCT03894891|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
219436577|NCT03547349|DEVICE|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
219436578|NCT00096551|DRUG|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
218822456|NCT03894891|RADIATION|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
218822457|NCT00656682|BEHAVIORAL|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
218822458|NCT00656682|BEHAVIORAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
219009340|NCT00628992|OTHER|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
219009341|NCT00628992|OTHER|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
218822459|NCT03122938|DIETARY_SUPPLEMENT|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
219009342|NCT00628992|OTHER|Cycloergometer training|Muscular rehabilitation of the leg
219009343|NCT00628992|OTHER|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
219195409|NCT06600997|DEVICE|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms
219436579|NCT00096551|DRUG|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
219436580|NCT00096551|DRUG|Recombinant Fowlpox-GM-CSF|
219436581|NCT00324272|DRUG|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
219763564|NCT02312401|DEVICE|multi-parametric MRI(MP-MRI)|
218822460|NCT03122938|DIETARY_SUPPLEMENT|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
218822461|NCT03017105|OTHER|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
218822462|NCT03017105|OTHER|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
218822463|NCT02805543|DEVICE|Color doppler imaging|
218822464|NCT01287494|DRUG|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
218822465|NCT01730872|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
218822466|NCT01730872|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
218822467|NCT06011083|DRUG|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
218822468|NCT06011083|DEVICE|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
218822469|NCT03155763|PROCEDURE|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
218822470|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
218822471|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
218822472|NCT02761642|DRUG|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
218822473|NCT02453893|DRUG|Iloperidone|
218822474|NCT02453893|DRUG|Risperidone|
218822475|NCT00209937|DRUG|Gaboxadol|
218822476|NCT00820547|BIOLOGICAL|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
218822477|NCT00820547|DRUG|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
218822478|NCT00820547|DRUG|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
218822479|NCT00820547|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
218822480|NCT00820547|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
218822481|NCT05845112|DIAGNOSTIC_TEST|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
218822482|NCT05845112|DIAGNOSTIC_TEST|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
218822483|NCT05845112|DIAGNOSTIC_TEST|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
218822484|NCT05845112|DIAGNOSTIC_TEST|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
218822485|NCT05845112|DIAGNOSTIC_TEST|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
218822486|NCT00950651|DRUG|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
218822487|NCT00950651|DRUG|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
218822488|NCT00682149|DIETARY_SUPPLEMENT|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
218822489|NCT02184676|BIOLOGICAL|Analysis of early immune modifications|"* blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
219763565|NCT02312401|DEVICE|dynamic contrast-enhanced MRI (DCE)|
218822490|NCT02184676|OTHER|Collection of clinical and socio-demographic data|"1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
218822491|NCT01044030|DRUG|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
219436582|NCT01541501|DEVICE|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
219763566|NCT02312401|PROCEDURE|biopsy|
218822492|NCT01044030|DRUG|Placebo|7.5 mL by mouth three times daily
218822493|NCT05345548|DIAGNOSTIC_TEST|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
218822494|NCT03678545|DRUG|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
218822495|NCT03678545|DRUG|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
218822496|NCT03678545|DRUG|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
218822497|NCT03051958|BEHAVIORAL|Internet mindfulness&exposure treatment|"See description under Arm."
218822498|NCT03051958|OTHER|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
218822499|NCT00368030|DRUG|Eszopiclone|Eszopiclone 3 mg QD
218822500|NCT00368030|OTHER|Placebo|Placebo tablet
218822501|NCT00411424|DRUG|ASK8007|IV
218822502|NCT00411424|DRUG|Placebo|IV
219436583|NCT03498547|PROCEDURE|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
219763567|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
219763568|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
219763569|NCT06445972|BIOLOGICAL|Sacituzumab Tirumotecan|3 mg/kg or 4 mg/kg IV Infusion
218822503|NCT05486390|BEHAVIORAL|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
218822504|NCT01937520|DEVICE|acupuncture|One half of subjects will receive a standardized acupuncture regiment
218822505|NCT01937520|DEVICE|no acupuncture|placebo
218822506|NCT05922605|DRUG|S-ketamine & Ropivacaine|The experiment group (Group E) will receive a mixture of ropivacaine 0.2% 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
218822507|NCT05922605|DRUG|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 0.7 ml／kg plain and equial volume saline caudally for postoperative analgesia.
218822508|NCT06104137|OTHER|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
218822509|NCT06104137|OTHER|standard patient consent process|standard consenting and shared decision making in the clinic
218822510|NCT01111643|DEVICE|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
218822511|NCT04249401|DRUG|Rivaroxaban (Xarelto)|NOAC, reduced dose
218822512|NCT04249401|DRUG|Apixaban|NOAC, reduced dose
219009344|NCT05370222|BEHAVIORAL|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
219436584|NCT03498547|PROCEDURE|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
219436585|NCT00990249|DRUG|Busulfan|Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
219436586|NCT00990249|DRUG|Clofarabine|40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
218822513|NCT04249401|DRUG|Dabigatran|NOAC, reduced dose
218822514|NCT04249401|DRUG|Warfarin|VKA
218822515|NCT02756403|DRUG|Azithromycin|500 mg
218822516|NCT02756403|DRUG|Doxycycline|200 mg
218822517|NCT02756403|DRUG|Metronidazole|500 mg
218822518|NCT02756403|DRUG|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
219009345|NCT03267186|DRUG|Ibrutinib|Given PO
219009346|NCT03267186|OTHER|Laboratory Biomarker Analysis|Correlative studies
219009347|NCT05226325|DRUG|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
219436587|NCT00990249|DRUG|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
219436588|NCT00990249|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
219436589|NCT04624217|DRUG|SHR-1701|PDL1/TGFβ
218822519|NCT01060943|DEVICE|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
218822520|NCT01060943|DEVICE|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
218822521|NCT00276432|DEVICE|iSTAT point of care analyzer|
218822522|NCT01644643|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
218822523|NCT01644643|DRUG|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
219436590|NCT00371540|OTHER|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
219436591|NCT05200884|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
219436592|NCT05200884|DRUG|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
219436593|NCT06527859|DRUG|Levothyroxin|The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
219436594|NCT05452317|OTHER|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
218822524|NCT01644643|DRUG|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
218822525|NCT00159926|PROCEDURE|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
218822526|NCT00159926|PROCEDURE|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
218822527|NCT04645173|DEVICE|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
218822528|NCT06230484|DEVICE|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
218822529|NCT06230484|DEVICE|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
218822530|NCT02774434|DEVICE|JM-105|Measurement of TcB via the JM-105 device
218822531|NCT05173376|BEHAVIORAL|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
218822532|NCT01597726|DRUG|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
218822533|NCT01597726|DEVICE|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
218822534|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
218822535|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
218822536|NCT00235222|DRUG|stavudine|
218822537|NCT06185426|DRUG|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
218822538|NCT00997789|DRUG|Rebamide|Rebamipide 100 mg Tablet, three times a day
218822539|NCT01205503|DRUG|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
218822540|NCT01205503|DRUG|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
218822541|NCT01205503|DRUG|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
218822542|NCT01205503|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
218822543|NCT05850143|DRUG|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
218822544|NCT05850143|DRUG|Prednisolone|Oral Multidose Prednisolone
218822545|NCT05278026|OTHER|guideline recommended routine treatment|
218822546|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
218822547|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
218822548|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
219436595|NCT05452317|OTHER|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
218822549|NCT06160141|OTHER|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
218822550|NCT04305977|BEHAVIORAL|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
218822551|NCT06307847|DRUG|SP5M001 inj|pre-filled syringe
218822552|NCT06307847|DRUG|Synovian inj|pre-filled syringe
219009348|NCT01141907|BEHAVIORAL|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
219436596|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenate
219436597|NCT00212212|DIETARY_SUPPLEMENT|selenium|400 µg selenium as selenate
218822553|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
218822554|NCT02356536|DEVICE|Agilitas|WCD trial
218822555|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
218822556|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide placebo|collagen peptide placebo
218822557|NCT04379154|DEVICE|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
218822558|NCT04530201|DEVICE|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
218822559|NCT01344798|BIOLOGICAL|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
218822560|NCT00429754|DRUG|Aprepitant|
219009349|NCT01141907|OTHER|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
219009350|NCT04320446|BEHAVIORAL|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
218822561|NCT00921726|DRUG|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
218822562|NCT00921726|DRUG|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
218822563|NCT01999933|RADIATION|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
218822564|NCT01999933|DRUG|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
218822565|NCT01999933|DRUG|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
219009351|NCT04320446|BEHAVIORAL|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
219363551|NCT03312569|PROCEDURE|Right Colectomy with Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
219436598|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenomethionine
219436599|NCT00212212|DIETARY_SUPPLEMENT|placebo|placebo tablet
218822566|NCT01999933|DRUG|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
218822567|NCT06093464|OTHER|Natural Compound A (Hinoki essential oil)|"Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
218822568|NCT06093464|OTHER|Natural Compound B (Lemon essential oil)|"Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
218822569|NCT06093464|OTHER|Natural Compound C (Control/Water)|"Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
219009352|NCT00490854|DRUG|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
219009353|NCT00490854|DRUG|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
219009354|NCT04030754|COMBINATION_PRODUCT|amniotic membrane|amniotic membrane is a biological dressing
219436600|NCT03933124|DEVICE|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
219436601|NCT01548417|DRUG|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
219436602|NCT01548417|DRUG|Sugar Pill|600 mg/day, oral pill, 7 days
219436603|NCT00139841|DRUG|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
218822570|NCT03175107|DEVICE|Exergaming|
218822571|NCT03965182|DRUG|PEG|2 sachets of PEG will be used as the bowel prep regimen.
218822572|NCT03965182|DRUG|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
218822573|NCT03965182|DRUG|SPMC|2 sachets will be administered as the bowel prep regimen.
218822574|NCT02850978|DRUG|Spiolto|
218822575|NCT05754476|OTHER|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
218822576|NCT03775499|DIETARY_SUPPLEMENT|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
218822577|NCT03775499|OTHER|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
218822578|NCT03775499|DIETARY_SUPPLEMENT|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
218822579|NCT03775499|OTHER|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
218822580|NCT01123226|PROCEDURE|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
219009355|NCT04030754|COMBINATION_PRODUCT|duoderm dressing|duoderm dressing is a synthetic dressing
218822581|NCT01123226|PROCEDURE|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
218822582|NCT02616939|OTHER|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
218822583|NCT02404168|DRUG|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
218822584|NCT02404168|DRUG|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
219195410|NCT06815614|DEVICE|A Photoplethysmography-Based Continuous Automated Non-Invasive Sphygmomanometer|The investigation medical device under evaluation is oCareTM BP 100, a non-invasive continuous blood pressure monitoring system developed by Taiwan Biophotonic Co. (tBPC). The main function is to use a fingerclip sensor to receive PPG signals and collect continuous blood pressure values and uninterruptedly within the initialization time. In this study, according to the latest released ISO 81060-3:2022 standard requirements, non-invasive blood pressure measurement by cuff at the start and the end time points will be used as oCareTM BP 100 start-to-end blood pressure calibration. The A-line invasive arterial catheter blood pressure measurement will be used as a reference invasive BPM equipment. The purpose of the study is to confirm the stability of the investigational medical device under evaluation and its performance of blood pressure change tracking.
219363552|NCT01857609|DRUG|Metformin|
219363553|NCT01857609|DRUG|Metformin and Pantoprazole|
219363554|NCT01857609|DRUG|Metformin and Rabeprazole|
219363555|NCT01271621|DEVICE|Intubation|Endotracheal intubation
219363556|NCT06439849|DRUG|S-Gboxin|S-Gboxin (lyophilized form of S-Gboxin) for the treatment diffuse midline glioma with H3 K27M / H3 K28M mutation
218822585|NCT05233124|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15mg
218822586|NCT05233124|DRUG|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
218822587|NCT05233124|DRUG|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
218822588|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
219363557|NCT00820573|DRUG|Sitagliptin|tablet, 100 mg/day, 6 weeks
219363558|NCT00820573|DRUG|Metformin|tablet, 1000 mg/ bid, 6 weeks
219363559|NCT00820573|DRUG|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
219363560|NCT00820573|DRUG|Placebo|Placebo 6 weeks
219363561|NCT01756729|DEVICE|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
219363562|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Healthy Controls|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to healthy controls
219363563|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in NAFLD Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to NAFLD participants (defined as simple steatosis through NASH)
219363564|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Fibrosis Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to liver fibrosis stage (F0-F4)
219363565|NCT00211107|DRUG|Dapoxetine|
219363566|NCT00002520|DRUG|nicotine|
219363567|NCT00002520|BEHAVIORAL|Usual Care|
219363568|NCT06011720|OTHER|Improved transition of care.|Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
219363569|NCT04458844|OTHER|Exercise|Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
219363570|NCT04676048|BIOLOGICAL|ASC618|ASC618 will be given as a single IV infusion
219363571|NCT03728205|BEHAVIORAL|Yoga|Twice weekly yoga sessions for 12 weeks
219363572|NCT02456688|DRUG|Imrecoxib|
219363573|NCT00317213|DRUG|LIBERTAL- a phospholipid mixture|
219363574|NCT02544412|BEHAVIORAL|novel mindfulness-based well-being training|
219363575|NCT06314555|OTHER|Blood sample|Blood sample to analyse the values of sFlt-1 and PlGF
219363576|NCT06314555|OTHER|Vascular-renal sample|Usual vascular-renal sample to analyse the values of sFlt-1 and PlGF
219363577|NCT01358903|DRUG|RO5429083|Cohorts receiving multiple escalating doses iv
219363578|NCT01358903|DRUG|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
219363579|NCT05863117|DIAGNOSTIC_TEST|Reveal Rapid TP (from MedMira)|Point of care tests for HIV and Syphilis
219363580|NCT05087537|PROCEDURE|Valve ablation|Valve ablation
219363581|NCT05087537|PROCEDURE|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
219363582|NCT02868203|DEVICE|OCT|OCT after stent implantation
219363583|NCT02868203|DEVICE|eLuting stent|
219363584|NCT00681239|DIETARY_SUPPLEMENT|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
219363585|NCT02840851|DEVICE|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
219363586|NCT02840851|DEVICE|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
219363587|NCT03604445|DRUG|BI 905677|Solution for infusion
218822589|NCT00318669|DRUG|Paroxetine hydrochloride hydrate|
218822590|NCT04157881|DRUG|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
218822591|NCT04157881|DRUG|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
218822592|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
218822593|NCT03754322|DIAGNOSTIC_TEST|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
218822594|NCT03754322|DIAGNOSTIC_TEST|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
218822595|NCT03215498|DRUG|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
218822596|NCT03215498|DRUG|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
218822597|NCT06468787|DEVICE|Kosmos Anatomical Object Labeling and View Identification Algorithms|Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
218822598|NCT01953211|DRUG|combined oral contraceptives|
218822599|NCT05325762|DRUG|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
218822600|NCT05325762|DRUG|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
218822601|NCT05325762|DRUG|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
218822602|NCT04161690|DRUG|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
218822603|NCT04161690|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
218822604|NCT03938818|BEHAVIORAL|Tu'Washindi intervention|"The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
218822605|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
218822606|NCT02974829|OTHER|follow-up|
218822607|NCT02307448|PROCEDURE|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
218822608|NCT02307448|PROCEDURE|Standard of Care|Patients will receive weekly standard of care.
218822609|NCT01842373|DRUG|LMX4|
218822610|NCT01842373|DRUG|BLT|
218822611|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
218822612|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
218822613|NCT00407719|DRUG|Bevacizumab|
218822614|NCT01664754|DRUG|exemestane|Given PO
219009356|NCT02598076|BEHAVIORAL|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
218822615|NCT01664754|DRUG|pemetrexed disodium|Given IV
219009357|NCT02598076|BEHAVIORAL|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
219009358|NCT00198965|BEHAVIORAL|dietary education|
219009359|NCT00198965|BEHAVIORAL|dietary education and provided full fat snack foods|
219009360|NCT00198965|BEHAVIORAL|dietary education and provided fat free snack foods|
219009361|NCT04840290|DRUG|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
219009362|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
219009363|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
219363588|NCT00130286|DRUG|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
219363589|NCT00130286|DRUG|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
218822616|NCT01664754|DRUG|carboplatin|Given IV
218822617|NCT01664754|OTHER|laboratory biomarker analysis|Correlative studies
219436604|NCT05477017|DRUG|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
218822618|NCT01664754|OTHER|pharmacological study|Correlative studies
218822619|NCT01664754|OTHER|questionnaire administration|Ancillary studies
218822620|NCT01664754|PROCEDURE|quality-of-life assessment|Ancillary studies
218822621|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
218822622|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
218822623|NCT06312189|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
218822624|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
218822625|NCT00296218|DRUG|Irbesartan|
218822626|NCT00539240|DRUG|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
218822627|NCT00539240|DRUG|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
218822628|NCT00539240|DRUG|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
218822629|NCT05820048|DRUG|Lansoprazole 15 mg|"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"
218822630|NCT06167577|DIAGNOSTIC_TEST|Psychometric scales (BPRS, MRS, HAM-D, SES, and GAF) monthly|we will correlate the clinical/neuropsychological response to antipsychotics with the presence of the functional DysBray haplotype of the DTNBP1 gene
218822631|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
218822632|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
218822633|NCT04831905|DEVICE|Micro-wave ablation|Micro-wave ablation
218822634|NCT04539834|OTHER|electrolytes|measuring level of electrolytes
218822635|NCT01600404|DRUG|antimuscarinic treatment|
218822636|NCT01215656|DIETARY_SUPPLEMENT|Lactobacillus fermentum|
218822637|NCT01215656|DIETARY_SUPPLEMENT|Follow on formula without probiotics|
218822638|NCT02811822|DRUG|GMI-1271|
218822639|NCT01518387|DRUG|Lanthanum Carbonate (BAY77-1931)|
219009364|NCT01137045|BIOLOGICAL|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
219363590|NCT01360645|DRUG|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
219363591|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
219363592|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
219363593|NCT02981069|DRUG|Dapagliflozin|10mg
218822640|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
218822641|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
218822642|NCT01063790|BEHAVIORAL|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
218822643|NCT00285844|BEHAVIORAL|weight loss|
218822644|NCT00285844|DRUG|thiazolidinedione|
218822645|NCT06209294|DRUG|AK104|AK104(10 mg/kg) d1,22
218822646|NCT06209294|DRUG|Carboplatin|AUC=2 d1,8,15,22, 29, 36
218822647|NCT06209294|DRUG|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
218822648|NCT01055613|DEVICE|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
218822649|NCT01055613|DEVICE|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
218822650|NCT03707886|BEHAVIORAL|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
219363594|NCT02981069|DRUG|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
219363595|NCT02981069|DRUG|Placebo|Placebo for Dapagliflozin
219363596|NCT01267448|DRUG|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
219363597|NCT01267448|DRUG|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
219363598|NCT01267448|DRUG|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
219363599|NCT03198130|DRUG|REGN2810|Intravenous (IV) use
219436605|NCT03725293|DEVICE|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
219436606|NCT03725293|DEVICE|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
219436607|NCT00602771|DRUG|tipifarnib|Given orally
219436608|NCT00602771|DRUG|etoposide|Given orally
219436609|NCT04716478|OTHER|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
219436610|NCT02714608|DRUG|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
219436611|NCT02714608|DRUG|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
219436612|NCT02714608|DRUG|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
219436613|NCT04752917|DEVICE|Noise Cancelling headphones|Use of headphones playing patients choice of music
219436614|NCT00543868|DRUG|MK0782|
219436615|NCT04583969|BIOLOGICAL|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
219436616|NCT04583969|OTHER|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
219436617|NCT04583969|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
219436618|NCT06508970|BEHAVIORAL|Experimental RAM-based virtual reality glasses|"RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)"
219436619|NCT06508970|OTHER|pre-post test|Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
219436620|NCT02212080|DRUG|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
219436621|NCT02212080|DRUG|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
219436622|NCT05430204|DEVICE|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
219009365|NCT03109587|DIETARY_SUPPLEMENT|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
219436623|NCT05430204|DEVICE|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL"
219009366|NCT03109587|DIETARY_SUPPLEMENT|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
219009367|NCT05248945|DRUG|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
219009368|NCT05248945|DRUG|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
219009369|NCT03264495|OTHER|Weight the food served minus the left-overs|
219009370|NCT03003936|BEHAVIORAL|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
219009371|NCT04606173|OTHER|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
219436624|NCT03086148|DRUG|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
219436625|NCT03086148|DRUG|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
219436626|NCT05658419|PROCEDURE|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
219436627|NCT04485468|OTHER|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
219363600|NCT05618873|DEVICE|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
219363601|NCT05618873|DEVICE|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
219363602|NCT01014585|DRUG|Placebo|Placebo tablets administered orally twice daily
219363603|NCT01014585|DRUG|Milnacipran|Milnacipran tablets administered orally twice daily
219436628|NCT00718250|BIOLOGICAL|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
218822651|NCT03707886|OTHER|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
218822652|NCT02765399|DRUG|Liraglutide|
218822653|NCT02765399|DRUG|Placebo|
218822654|NCT02393339|DRUG|paracetamol|Pre-operative administration of Paracetamol syrup
218822655|NCT02393339|DRUG|placebo|Pre-operative administration of placebo syrup
219009372|NCT03630575|PROCEDURE|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
219009373|NCT00637507|OTHER|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
219009374|NCT01818908|DRUG|DA-EPOCH|DA-EPOCH regimen
219363604|NCT03459573|BEHAVIORAL|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
219363605|NCT03459573|BEHAVIORAL|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
219363606|NCT03459573|BEHAVIORAL|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
219363607|NCT03287180|BEHAVIORAL|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
219363608|NCT03287180|OTHER|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
219363609|NCT01324557|PROCEDURE|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
219363610|NCT02262169|DRUG|Omeprazole|2 Omeprazole capsules 20 mg, once daily
219363611|NCT02262169|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
219363612|NCT02262169|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
219363613|NCT02262169|DRUG|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
219363614|NCT04278911|DIAGNOSTIC_TEST|MMSE and MoCA|This is an observational study. All the patients evaluate with MMSE (Mini-mental State Examination) and MoCA (Montreal Cognitive Assessment), and investigate the incidence and characteristics of cognitive and MACE
219363615|NCT03418532|COMBINATION_PRODUCT|MP0250 DARPin® drug candidate, Osimertinib|Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
219363616|NCT02808390|DRUG|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
219363617|NCT02808390|DRUG|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
219363618|NCT02808390|DRUG|Placebo|Placebo BID for 8 Weeks
219363619|NCT04178772|DEVICE|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
219363620|NCT01154933|DRUG|exenatide 5 mcg|exenatide 5 mcg
219363621|NCT01154933|DRUG|exenatide 10 mcg|exenatide 10 mcg
219363622|NCT01154933|DRUG|placebo|saline sq
219363623|NCT00191516|DRUG|Atomoxetine|
219363624|NCT03867630|PROCEDURE|Transforaminal Block|Epidural block via neural foramen of lumbar spine
218822656|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
218822657|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
218822658|NCT04858373|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218822659|NCT04858373|OTHER|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218822660|NCT04858373|OTHER|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218822661|NCT04858373|OTHER|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219009375|NCT03485768|PROCEDURE|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
219195411|NCT06526221|DIAGNOSTIC_TEST|Urine isoniazid testing (IsoScreen test)|Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for \>48 hours (two or more missed doses).
219195412|NCT05932407|DRUG|Vortioxetine Tablet|Vortioxetine Tablet
219195413|NCT05932407|DRUG|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
219195414|NCT06797830|DEVICE|AllCore|"AllCore360° is a novel core-strengthening machine intervention designed to target trunk muscles through gravity by means of high-intensity constant velocity rotating exercise (allcore360.com).~AllCore360° is systematic, consistent and designed for use over time. The core is strengthened because a patient's core muscles are used in anterior, lateral, and posterior contractions sequentially during a single rotation (Palevo). The patient must resist gravity with the rotation as well as contract and fire isometrically to keep proper posture. Using proper posture, the patient must keep their back straight and neck neutral throughout the length of the intervention without relying on their lower body muscles at all (this is assisted by straps rendering the legs useless and by securing the pelvis in the chair)."
219195415|NCT06818474|BIOLOGICAL|Lanadelumab 300 mg|no other intervention
219436629|NCT00718250|BIOLOGICAL|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
219436630|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
218822662|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
218822663|NCT06495073|OTHER|PROMIS-10 and TOPICS-SF|"There will be no intervention. The participants will be asked to fill in questionnaires at two time points: the first time will be after informed consent when they are at the hospital for diagnostic evaluation of the TIA or ischemic stroke, and the second time will be 4 weeks later, with a window of 2 weeks (allowing a range of 2-6 weeks). The second time point is chosen because the investigators suspect that by then, around 50% will be in the improved group. At the first time point, the participants will be asked to fill in the PROMIS-10 and element D and E of the TOPICS-SF - which are the elements used to determine the functional limitations and the psychological wellbeing. At the second time point, the participants will be asked to answer the same questions, as well as three additional anchor questions."
218822664|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
218822665|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
218822666|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
218822667|NCT00989976|BEHAVIORAL|normal sleep times|8.5 h bedtimes
219436631|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
219436632|NCT02697058|BIOLOGICAL|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
219436633|NCT02697058|DRUG|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
219436634|NCT04249284|DRUG|BMS-986165|Specified dose on specified days
219436635|NCT04249284|DRUG|BMS-986165 prototype 1|Specified dose on specified days
219436636|NCT04249284|DRUG|BMS-986165 prototype 2|Specified dose on specified days
218822668|NCT00989976|BEHAVIORAL|bedtime restriction|4.5 h restricted bedtimes
218822669|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
218822670|NCT05267535|DRUG|Placebo|Tablets
218822671|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
218822672|NCT02636010|DRUG|Pembrolizumab|
218822673|NCT04915638|DIETARY_SUPPLEMENT|Experimental intervention group with enriched cookies|Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
218822674|NCT05023057|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
219009376|NCT03485768|PROCEDURE|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
219009377|NCT00826215|DEVICE|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
219009378|NCT00826215|DEVICE|Sham laser acupuncture|Sham laser acupuncture
219195416|NCT06816082|BEHAVIORAL|Internet delivered acceptance and commitment therapy|7 week long treatment with therapist asynchronous support in mainly text format. Treatment includes for example mindfulness, psychoeducation, values, and self-compassion
219195417|NCT06818565|DRUG|Meropenem Injection|Meropenem 2 gm iv TDS
219195418|NCT06818565|DRUG|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 gm iv TDS
219195419|NCT06818565|DRUG|Teicoplanin|Teicoplanin 400 mg iv BD 3 doses followed by 400mg iv OD
219363625|NCT02012530|PROCEDURE|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
219580194|NCT04276844|DIAGNOSTIC_TEST|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
219580195|NCT06332729|DEVICE|universal exercis unit|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
219580196|NCT06332729|DEVICE|functional electrical stimulation|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
219580197|NCT02363608|OTHER|standard post surgery care|
219580198|NCT02363608|BEHAVIORAL|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
218822675|NCT01080417|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
218822676|NCT04138511|DEVICE|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
218822677|NCT03484728|BEHAVIORAL|placebo manipulation|application of nonactive body cream on forearm
218822678|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
218822679|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
218822680|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
218822681|NCT05497375|DIAGNOSTIC_TEST|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
219009379|NCT04675840|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted surgery
219009380|NCT03905603|DRUG|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
219009381|NCT03905603|DRUG|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
219363626|NCT02012530|PROCEDURE|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
219363627|NCT01409460|PROCEDURE|Oburator Nerve block|Use of selective pain block.
219363628|NCT01409460|PROCEDURE|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
219363629|NCT00018902|DRUG|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
219363630|NCT00018902|DRUG|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
218822682|NCT05497375|DIAGNOSTIC_TEST|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
219436637|NCT05228756|OTHER|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
219436638|NCT01228188|PROCEDURE|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
219436639|NCT04397796|BIOLOGICAL|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
219436640|NCT04397796|BIOLOGICAL|Placebo|plasmalyte and human albumin
219436641|NCT04255966|DEVICE|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
219436642|NCT05582551|OTHER|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
219436643|NCT05885048|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in blood
219436644|NCT05885048|DIAGNOSTIC_TEST|Sperm samples for analysis|Spermiogram
219436645|NCT05885048|OTHER|Satisfaction evaluation|Participant satisfaction assessment
218822683|NCT05497375|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
218822684|NCT05497375|DIAGNOSTIC_TEST|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
218822685|NCT05497375|DIAGNOSTIC_TEST|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
218822686|NCT05497375|DIAGNOSTIC_TEST|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
218822687|NCT06361004|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
218822688|NCT05364398|PROCEDURE|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
218822689|NCT04155476|DRUG|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
218822690|NCT01832610|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
219009382|NCT02566655|BIOLOGICAL|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
219009383|NCT05757947|PROCEDURE|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
219009384|NCT05757947|PROCEDURE|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
219009385|NCT02095587|DRUG|IPI-145|25 mg single oral capsule
219009386|NCT00005970|DRUG|Aromatase Inhibition Therapy|Given orally
219009387|NCT00005970|DRUG|Cyclophosphamide|Given IV
219009388|NCT00005970|DRUG|Doxorubicin Hydrochloride|Given IV
219009389|NCT00005970|OTHER|Laboratory Biomarker Analysis|Correlative studies
219436646|NCT05885048|OTHER|Quality of Life questionnaire|The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
219436647|NCT03000634|DRUG|Elotuzumab|Administered through a small tube that goes directly into the vein
219436648|NCT03000634|DRUG|Bortezomib|Administered as a subcutaneous injection under the skin
219436649|NCT03000634|DRUG|Lenalidomide|Capsule taken by mouth
219436650|NCT03000634|DRUG|Dexamethasone|Taken by mouth
219436651|NCT02640755|DRUG|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
219436652|NCT02640755|DRUG|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
219436653|NCT02640755|DRUG|Fulvestrant|Hormonal Agent
219436654|NCT02640755|DRUG|Paclitaxel|Taxane
219436655|NCT00442182|DRUG|ITF2357|
219436656|NCT02808013|DRUG|NDS-446|
219436657|NCT02808013|DRUG|Placebo|
218822691|NCT02656667|DEVICE|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
219436658|NCT05851794|PROCEDURE|endomanometric guided LNF|use of endomanometry during LNF
219436659|NCT05851794|PROCEDURE|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
219580199|NCT02363608|BEHAVIORAL|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
219580200|NCT05476107|DRUG|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
219580201|NCT05476107|DRUG|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
219580202|NCT05476107|OTHER|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
218822692|NCT02656667|DEVICE|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
218822693|NCT02656667|OTHER|Conventional pulmonary rehabilitation|excercise training on treadmill
218822694|NCT03891888|PROCEDURE|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
218822695|NCT05253404|DEVICE|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
218822696|NCT02525679|DRUG|BI 655130 (spesolimab)|
219009390|NCT00005970|DRUG|Paclitaxel|Given IV
219009391|NCT00005970|DRUG|Tamoxifen Citrate|Given orally
219009392|NCT00005970|BIOLOGICAL|Trastuzumab|Given IV
219009393|NCT03715010|DIETARY_SUPPLEMENT|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
219195420|NCT06816966|RADIATION|split-course adaptive hypofractionated radiotherapy|Each treatment cycle comprises a solitary radiotherapy session, which allows for its integration with chemotherapy and immunotherapy. The radiotherapy sessions are scheduled at three-week intervals, thereby affording extended recovery periods for normal tissues. An adaptive radiotherapy plan is implemented for each cycle, enabling precise adjustments to the treatment target area in response to the reduction in tumor volume.
219363631|NCT00018902|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
218822697|NCT02525679|DRUG|Placebo|
218822698|NCT05691933|PROCEDURE|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
218822699|NCT05691933|PROCEDURE|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
218822700|NCT02940925|OTHER|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
218822701|NCT02940925|OTHER|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
218822702|NCT04540367|DEVICE|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
218822703|NCT05654584|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
218822704|NCT02001246|BEHAVIORAL|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
218822705|NCT02001246|BEHAVIORAL|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
218822706|NCT00406796|DRUG|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
219009394|NCT01125384|OTHER|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
219009395|NCT00367094|DRUG|Benazepril plus hydrochlorothiazide|
219009396|NCT03330808|OTHER|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
219363632|NCT00018902|DRUG|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
219363633|NCT05984563|DEVICE|Cardiopulmonary bypass|CPB will be ensured as usual care: priming volume will be set as 1200 to 1500 mL. Patient blood management and hemodynamic management will be left at the discretion of the anesthesiologist in charge of the patient. Anticoagulation during CPB will be handled through an initial heparin bolus of 300-400 UI/kg followed by additional boluses to maintain ACT above 400 s. Non-heparin-coated bypass circuits incorporating an integrated phosphorylcholine-coated oxygenation system will be used.
219363634|NCT00132067|DRUG|vorinostat|Given orally
219009397|NCT04492839|DEVICE|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
219009398|NCT03348033|BIOLOGICAL|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
219009399|NCT03879122|DRUG|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
219363635|NCT02557425|OTHER|No intervention in PROTECT|
219363636|NCT03163654|PROCEDURE|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
218822707|NCT05293340|DIETARY_SUPPLEMENT|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
219580203|NCT04972123|DRUG|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
218822708|NCT00897884|DRUG|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
218822709|NCT03200470|OTHER|No intervention: sample collection study|Sample collection and collection of laboratory values
219195421|NCT06818240|DEVICE|Active transcranial direct current stimulation|In the active tDCS session, real stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
219580204|NCT04972123|DIAGNOSTIC_TEST|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
219580205|NCT04972123|DRUG|Placebo|Placebo for CPC
219580206|NCT02032706|DEVICE|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
219580207|NCT03903809|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
219763570|NCT06445972|DRUG|Rescue Medications|Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent).
219763571|NCT05580458|BIOLOGICAL|Shingrix|Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
219763572|NCT06452277|DRUG|BAY2927088|Tablet, oral
219763573|NCT06452277|DRUG|Pembrolizumab|Intravenous (IV) infusion
219763574|NCT06452277|DRUG|Cisplatin|IV infusion
219763575|NCT06452277|DRUG|Carboplatin|IV infusion
219763576|NCT06452277|DRUG|Pemetrexed|IV infusion
219763577|NCT04572243|DRUG|Placebo|Placebo matching to lorcaserin oral tablet, administered as oral suspension.
219763578|NCT04572243|DRUG|Lorcaserin|Lorcaserin oral tablet, administered as oral suspension.
219763579|NCT04633252|DRUG|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
219763580|NCT04633252|DRUG|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
219763581|NCT04633252|DRUG|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
219763582|NCT04633252|DRUG|Docetaxel|Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
219763583|NCT04633252|DRUG|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
219763584|NCT04174105|GENETIC|zocaglusagene nuzaparvovec|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
219763585|NCT06159543|BEHAVIORAL|Mango|1.5 cups/day of mango for 12 weeks
219763586|NCT05232253|DEVICE|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
219763587|NCT05425641|BEHAVIORAL|Goal Setting|"Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?."
219763588|NCT05425641|BEHAVIORAL|Action Planning|"Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?"
219763589|NCT05425641|BEHAVIORAL|Self-Monitoring of Behavior|"Individuals will receive daily text messages that include the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Self-Monitoring BCT is Check your fitbit for yesterday. Type in the number of steps you did yesterday."
219763590|NCT05425641|BEHAVIORAL|Feedback on Behavior|"Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm. "
219763591|NCT05205512|OTHER|Exercise Intervention|Maintain current levels of physical activity
219763592|NCT05205512|OTHER|Questionnaire Administration|Ancillary studies
219763593|NCT05205512|OTHER|Telemedicine|Participate in telehealth exercise intervention
219763594|NCT06969287|DRUG|Fluvoxamine|"100mg Fluvoxamine Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
218822710|NCT06544070|DEVICE|Entia Liberty System|Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
218822711|NCT05204121|DRUG|Elpida|elsulfavirine, capsules
218822712|NCT03560492|OTHER|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
219009400|NCT03879122|DRUG|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
218822713|NCT03560492|DEVICE|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
218822714|NCT01931917|BEHAVIORAL|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
218822715|NCT01931917|BEHAVIORAL|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
218822716|NCT02234765|OTHER|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
219009401|NCT03879122|DRUG|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
219009402|NCT03879122|DRUG|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
219009403|NCT01923220|DRUG|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
219009404|NCT01923220|OTHER|Aloe Vera Jel|To be applied topically once daily
219009405|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
219009406|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
219009407|NCT02953054|DRUG|DMTS|DMTS applied before surgery and worn for 72 hours
219009408|NCT02953054|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
219009409|NCT01406431|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
219580208|NCT03903809|DRUG|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
218822717|NCT02234765|OTHER|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
218822718|NCT04039529|DEVICE|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
218822719|NCT05570032|DEVICE|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
219009410|NCT01406431|DRUG|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
219009411|NCT05854589|DRUG|Sodium Chloride Granules|Sodium Chloride crystals
218822720|NCT05448456|DRUG|Tranexamic acid|1 gram of tranexamic acid in 100 ml of 0.9% normal saline
218822721|NCT05448456|DRUG|Placebo|100 ml of 0.9% normal saline
218822722|NCT04047056|OTHER|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
219009412|NCT05854589|OTHER|Water|Plain distilled water
219009413|NCT05473338|DIAGNOSTIC_TEST|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
219009414|NCT05473338|OTHER|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
219009415|NCT05473338|OTHER|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
219009416|NCT04109755|DRUG|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
219009417|NCT02225990|OTHER|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
219009418|NCT02225990|OTHER|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
219009419|NCT02225990|OTHER|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
219580209|NCT00895947|DRUG|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
219580210|NCT00895947|OTHER|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
218822723|NCT05511779|DRUG|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
218822724|NCT00587119|DRUG|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
219009420|NCT02225990|OTHER|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
219009421|NCT03559153|OTHER|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
219436660|NCT03869671|BEHAVIORAL|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
219436661|NCT03869671|BEHAVIORAL|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
219436662|NCT03023241|PROCEDURE|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
219436663|NCT03819270|DRUG|LY3372689|Administered orally
219436664|NCT03819270|DRUG|Placebo|Administered orally
219436665|NCT01391455|PROCEDURE|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
219436666|NCT00001669|DRUG|rhIGF-1 (CEP-151)|
219436667|NCT02062372|DEVICE|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
219436668|NCT02062372|PROCEDURE|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
219436669|NCT00397553|DRUG|Insulin glulisine|
218822725|NCT05081921|DRUG|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
218822726|NCT05081921|DRUG|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
218822727|NCT00544856|BEHAVIORAL|complex cognitive training|
219009422|NCT03559153|OTHER|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
219436670|NCT03722992|OTHER|MBSR|Guided yoga and meditation practices
219436671|NCT05024890|OTHER|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide"
218822728|NCT04273360|OTHER|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
218822729|NCT04273360|OTHER|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
218822730|NCT02794571|DRUG|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
219009423|NCT02734238|DRUG|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
219009424|NCT02734238|DRUG|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
219009425|NCT02969304|DRUG|dimethyl fumarate|"Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
219009426|NCT02935088|DEVICE|Fractional Flow Reserve|Measurement of physiologic parameters
219436672|NCT01994278|DEVICE|Peri Clean|
219009427|NCT00965588|BIOLOGICAL|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
219009428|NCT01548482|OTHER|Laboratory Biomarker Analysis|Correlative studies
219009429|NCT01548482|OTHER|Pharmacological Study|Correlative studies
219009430|NCT01548482|DRUG|Temsirolimus|Given IV
219009431|NCT01548482|BIOLOGICAL|Trebananib|Given IV
219436673|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
219436674|NCT03509623|DIAGNOSTIC_TEST|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
219436675|NCT05438706|DRUG|chidamide|Chidamide, an HDAC inhibitor
219436676|NCT05438706|DRUG|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
219436677|NCT05438706|DRUG|carboplatin|Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
218822731|NCT02794571|DRUG|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
218822732|NCT02794571|DRUG|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
218822733|NCT02794571|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
218822734|NCT02794571|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
218822735|NCT02794571|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
218822736|NCT02794571|DRUG|Etoposide|Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
218822737|NCT02794571|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
218822738|NCT02794571|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
218822739|NCT02794571|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
219009432|NCT02838563|OTHER|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
219009433|NCT04994522|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
219009434|NCT01465087|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
219436678|NCT05438706|DRUG|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
219436679|NCT05952999|OTHER|Digital Care Solution as supportive personalized care|Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
219436680|NCT05952999|OTHER|Traditional Hospital Level Care|Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
219436681|NCT03540641|DEVICE|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
219436682|NCT02031510|DRUG|placebo|transversus abdominis plane block with saline 0.9%
219436683|NCT02031510|DRUG|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
219580211|NCT00192244|BIOLOGICAL|CAIV-T, Liquid|
218822740|NCT03120845|PROCEDURE|One visit RCT|Root canal treatment in one vist
218822741|NCT03120845|PROCEDURE|Post operative pain in two-visits RCT|Root canal treatment in Two visits
218822742|NCT04641091|DEVICE|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
218822743|NCT00012441|PROCEDURE|hemodialysis|
218822744|NCT03266029|DEVICE|Cordio App|
218822745|NCT06218979|DRUG|Risperidone oral solution|See arm/group descriptions
218822746|NCT04422431|DRUG|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
218822747|NCT06565468|DEVICE|Cold water immersion pool.|Participants will complete a session of cold-water immersion within one hour of finishing the last training session of the day. Cold water immersion will consist of ten minutes of submersion to the neck in a cold-water tub with a target temperature of 55 degrees Fahrenheit (daily temperatures will be recorded at the time of each session). The acceptable range for the cold water immersion protocol will be from 53-57 degrees Fahrenheit. The immersion process will not be completed if the temperature of the water is outside of this range. Participants will complete five sessions per week, with a total of 10 sessions to be completed over the 14-day intervention.
218822748|NCT06325215|OTHER|Hidrocolloid Bant|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied.
218822749|NCT02740270|DRUG|GWN323|
218822750|NCT02740270|DRUG|PDR001|
219009435|NCT05944341|DRUG|articaine hydrochloride 4% with epinephrine 1:100 000|Local anesthetic agent
219009436|NCT05944341|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Local anesthetic agent
219580212|NCT01531829|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
219580213|NCT01531829|DRUG|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
219763595|NCT06969287|DRUG|Placebo|"Placebo Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
218822751|NCT03168139|DRUG|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
218822752|NCT03168139|DRUG|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
218822753|NCT03447873|DRUG|Continue with triple therapy|To continue with triple therapy
218822754|NCT03447873|DRUG|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
218822755|NCT03447873|DRUG|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
219436684|NCT02031510|DRUG|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
218822756|NCT02152748|GENETIC|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
218822757|NCT00147576|DRUG|CP-866,087|
218822758|NCT04594746|DRUG|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
218822759|NCT04594746|DRUG|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
218822760|NCT00688714|DRUG|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
218822761|NCT00688714|DRUG|Placebo|
218822762|NCT01480167|DEVICE|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
219436685|NCT04602819|DEVICE|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
219436686|NCT04602819|DEVICE|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
219436687|NCT04602819|DEVICE|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
218822763|NCT01480167|OTHER|Non-operative Management|Conservative Care
218822764|NCT03210701|OTHER|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
219436688|NCT04602819|DEVICE|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
219436689|NCT01154907|DRUG|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
219436690|NCT00758407|DRUG|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
218822765|NCT01226108|DEVICE|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~\--------------------------------------------------------------------------------"
218822766|NCT02199041|DRUG|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
218822767|NCT02199041|DRUG|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
218822768|NCT02199041|DRUG|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
218822769|NCT02199041|DRUG|Melphalan|Given by intravenous infusion as part of the preparative regimen.
218822770|NCT02199041|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
218822771|NCT02199041|BIOLOGICAL|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.
218822772|NCT02199041|DRUG|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
218822773|NCT02199041|DRUG|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
218822774|NCT02199041|DRUG|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
218822775|NCT02199041|RADIATION|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
218822776|NCT02199041|BIOLOGICAL|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
218822777|NCT02199041|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
218822778|NCT02317627|DRUG|KD025|
218822779|NCT01903005|DRUG|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
218822780|NCT00191711|DRUG|Gemcitabine|
218822781|NCT06471543|DRUG|RN0361|Placebo
219009437|NCT02059460|DRUG|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
219009438|NCT02059460|DRUG|placebo|
219436691|NCT00758407|DRUG|Placebo|dosage according to an individual titration schedule
219436692|NCT02420990|BEHAVIORAL|Medication Integration Protocol (MIP)|
219436693|NCT02420990|BEHAVIORAL|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
219436694|NCT01402388|BEHAVIORAL|Group lifestyle programme|
218822782|NCT06818331|OTHER|SMES+PTX|This intervention involves the combined use of medication and device, where the specific mode electroacupuncture stimulation (SMES) intervention is administered simultaneously with the intravenous infusion of paclitaxel.
218822783|NCT06818331|DRUG|Paclitaxel|Paclitaxel is administered intravenously at a dose of 135-175mg/m², repeated every 3 weeks.
218822784|NCT06818331|DEVICE|Specific mode electroacupuncture stimulation|"Patients assume a supine position. After routine skin disinfection with 75% ethanol, a stainless steel needle (size 0.25mm×40mm) is inserted into GV20 (Baihui), and another stainless steel needle (size 0.25mm×25mm, as described above) is inserted into GV26 (Shuigou). The acupoints are manually stimulated until the patient experiences soreness, distension, or heaviness (the De Qi response). Subsequently, the needles are stimulated using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng Ltd., China) at a frequency of 2/100 Hz and an intensity of 3 mA for 40 minutes (a homemade relay cycled power supply to the electrode, with 6 seconds on and 6 seconds off). The intervention is administered every three weeks, concurrently with paclitaxel treatment"
218822785|NCT06996197|OTHER|Bioimpedance analysis|BIA parameters were measured within the first 24h of ICU admission, once the patient was receiving NIV support.
218822786|NCT06590038|BEHAVIORAL|Single Session Psychotherapy Intervention|This is a single session intervention which incorporates elements from second- and third wave psychotherapies (Acceptance and Commitment Therapy and Behavioral Activation), as well as basic psychoeducation. Session will take approximately three hours in total, with the option for breaks between blocks of session.
218822787|NCT06666231|PROCEDURE|QL (quadratus lumborum) block administration|"After endotracheal intubation, patients in the supine position will be given a lateral tilt and the areas to be treated will be cleaned with surgical antiseptic solution. The convex USG probe will be covered in a sterile manner. Then, the sterile probe will be placed transversely on the crista iliaca. The probe will be directed cranially until the external oblique muscle, internal oblique muscle and transverse abdominis muscle are clearly visualized. The psoas major muscle and the transverse process of the vertebra will be visualized. The QL muscle will be visualized between the aponeuros of the transverse abdominis muscle and the psoas major muscle. A 20 G 100 mm block needle will be advanced from posterolateral to anteromedial using the in-plane technique. The needle will be directed between the QL muscle and the psoas major muscles. 20 ml of 0.25% bupivacaine (Buvasin®, Vem İlaç, Turkey) will be injected on each side between the fasciae of these two muscles and the LA distribution"
218822788|NCT06666231|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 20-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
218822789|NCT03162432|DRUG|Vitamin D3|Oral Vitamin D3 therapy.
218822790|NCT06633393|OTHER|Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System|At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
218822791|NCT06633393|OTHER|Feedback on Ophthalmic Examinations|At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
218822792|NCT06715319|DRUG|OCA|OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
218822793|NCT06715319|DRUG|UDCA|13\~15 mg/kg/day
218822794|NCT06715319|DRUG|Placebo|Once a day (QD) by mouth (PO)
218822795|NCT06717711|DEVICE|Low-intensity Extracorporeal Shock Wave Therapy (LiESWT)|LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.
218822796|NCT06717711|DRUG|PDE5 inhibitor (tadalafil)|Phosphodiesterase-5 (PDE5) inhibitors
218822797|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone IV drip
218822798|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
218822799|NCT02784340|DRUG|Saline (IV fluids)|IV fluids 500 cc saline infusion
218822800|NCT02784340|DRUG|Bupivicaine and Fentany|
218822801|NCT02784340|DEVICE|25G spinal needles|
218822802|NCT05638828|DRUG|RD14-01 Cell injection|RD14-01 Cell injection
218822803|NCT00027560|BIOLOGICAL|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
218822804|NCT00027560|DRUG|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
218822805|NCT00027560|DRUG|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
219009439|NCT03593707|DRUG|Metformin|Metformin
219009440|NCT03593707|DRUG|PF-06865571|PF-06865571
219009441|NCT05766982|OTHER|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
219009442|NCT00000233|DRUG|Buprenorphine|
219009443|NCT00940394|BEHAVIORAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
219009444|NCT00940394|BEHAVIORAL|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
219009445|NCT00940394|OTHER|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
218822806|NCT00027560|DRUG|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
218822807|NCT00027560|PROCEDURE|allogeneic bone marrow transplantation|
219436695|NCT02788851|DRUG|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
218822808|NCT00027560|PROCEDURE|peripheral blood stem cell transplantation|
218822809|NCT04217434|PROCEDURE|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
218822810|NCT04217434|PROCEDURE|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
218822811|NCT04217434|PROCEDURE|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
219009446|NCT00229632|DRUG|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
219009447|NCT01727973|DRUG|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
219009448|NCT01035203|BEHAVIORAL|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
219009449|NCT01035203|BEHAVIORAL|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
219009450|NCT05938933|BEHAVIORAL|PHP|personalized health planning (PHP)
219009451|NCT05938933|BEHAVIORAL|SMA|shared medical appointments (SMAs)
219009452|NCT01676844|DRUG|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
219009453|NCT01676844|DRUG|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
219436696|NCT02788851|BEHAVIORAL|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
219436697|NCT04803890|PROCEDURE|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
219436698|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
219436699|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
219436700|NCT02955771|DEVICE|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
218822812|NCT04217434|PROCEDURE|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
218822813|NCT03703557|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
218822814|NCT03703557|DIAGNOSTIC_TEST|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
218822815|NCT01790607|DRUG|ONO-2745 /CNS 7056|
218822816|NCT06640179|OTHER|Standard medical care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
218822817|NCT06640179|BEHAVIORAL|Monitoring Contacts|Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
218822818|NCT06640179|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
218822819|NCT06640179|BEHAVIORAL|Diet|An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
218822820|NCT06640179|BEHAVIORAL|Physical Activity|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
218822821|NCT03906357|DRUG|Pemigatinib|
218822822|NCT05861141|OTHER|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights."
218822823|NCT05861141|DEVICE|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
218822824|NCT03384875|DEVICE|CytoSorb|To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
219436701|NCT02680392|PROCEDURE|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
218822825|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
219009454|NCT03394807|DRUG|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
219009455|NCT03394807|DRUG|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
219436702|NCT02680392|DRUG|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
219436703|NCT04159922|OTHER|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
219009456|NCT00455364|DRUG|Voriconazole|
219009457|NCT03682445|OTHER|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
219009458|NCT02536196|DEVICE|Embolic Protection Device|Embolic protection
218822826|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
218822827|NCT00896012|PROCEDURE|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
218822828|NCT00896012|DRUG|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
219009459|NCT02536196|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
219009460|NCT04857905|PROCEDURE|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
219009461|NCT04857905|PROCEDURE|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
219009462|NCT04199572|DRUG|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
219009463|NCT04790760|DIETARY_SUPPLEMENT|Supplement Consumption|Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
219009464|NCT04790760|DEVICE|Continuous Glucose Monitors|Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
219436704|NCT03792802|PROCEDURE|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
219436705|NCT04740333|OTHER|No intervention- observational study|No intervention- observational study
219436706|NCT01592006|DRUG|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
218822829|NCT00896012|DRUG|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
218822830|NCT03938831|DRUG|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
218822831|NCT03938831|DRUG|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
218822832|NCT00148863|DRUG|Peg-interferon alpha 2a (drug)|
218822833|NCT00148863|DRUG|Ribavirin (drug)|
218822834|NCT00148863|DRUG|Interferon gamma (drug)|
218822835|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
218822836|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
218822837|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
218822838|NCT01169480|BEHAVIORAL|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
218822839|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
218822840|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
218822841|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
219009465|NCT05130619|DIETARY_SUPPLEMENT|Ethanol|Crossover meal study
219009466|NCT01619683|DRUG|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
219009467|NCT01619683|DRUG|Placebo|1 placebo capsule per day, oral
219009468|NCT02145364|DEVICE|Ultherapy® treatment|Microfocused ultrasound treatment
219009469|NCT01455142|DRUG|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
219009470|NCT03753529|OTHER|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
219436707|NCT01592006|DRUG|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
218822842|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
218822843|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
218822844|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
218822845|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
218822846|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
218822847|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
218822848|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
218822849|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
218822850|NCT05182450|OTHER|Placebo capsule|Single dose
218822851|NCT02962245|DRUG|berberine|
219195422|NCT06818240|DEVICE|Sham transcranial direct current stimulation|In the Sham tDCS session, Sham stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
219436708|NCT01592006|DRUG|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
219436709|NCT00747539|DRUG|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
218822852|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
218822853|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
218822854|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
218822855|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
218822856|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
218822857|NCT03294005|DIAGNOSTIC_TEST|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
218822858|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
218822859|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
218822860|NCT06457477|DRUG|NAs|tablets
218822861|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
218822862|NCT00283946|DRUG|Zolpidem MR|Oral
218822863|NCT00283946|DRUG|Zolpidem|Oral
218822864|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
218822865|NCT02359032|DRUG|ASP6858|Oral tablets
218822866|NCT02359032|DRUG|Placebo|Oral tablets
218822867|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
218822868|NCT00939107|PROCEDURE|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
218822869|NCT00939107|PROCEDURE|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
218822870|NCT06392906|RADIATION|Short course radiation therapy|5 daily radiation treatments
218822871|NCT06392906|RADIATION|Standard course radiation therapy|10 daily radiation treatments
219195423|NCT06818617|PROCEDURE|Epidural steroid injection (ESI)|epidural nerve block procedures for patients with spinal conditions such as stenosis or disc herniation
218822872|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
218822873|NCT00628498|DRUG|Defibrotide|
218822874|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
218822875|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
218822876|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
218822877|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
218822878|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
218822879|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
218822880|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
218822881|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
218822882|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
219195424|NCT06819514|DRUG|EXG110 Injection|EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.
219195425|NCT06816381|DEVICE|Shear wave elastography measurements|Shear wave elastography measurements in kilopascals via ultrasound
219436710|NCT04282876|DRUG|Degarelix|Patients receiving Degarelix
219436711|NCT04355026|DRUG|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
219436712|NCT00344760|DRUG|Enfuvirtide|subcutaneously twice a day
219436713|NCT00344760|DRUG|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
218822883|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
218822884|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
218822885|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
218822886|NCT03247829|DEVICE|Hemodynamic management using CardioMEMS HF System|Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
218822887|NCT01783444|DRUG|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
219195426|NCT05623462|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
219436714|NCT01715272|DEVICE|TF037|
219436715|NCT01715272|DRUG|Fleet enema|
219436716|NCT03107598|DRUG|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
219436717|NCT01277471|BEHAVIORAL|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
219436718|NCT01277471|BEHAVIORAL|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
219436719|NCT02783417|OTHER|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
219436720|NCT03432117|OTHER|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
219436721|NCT03432117|OTHER|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
219436722|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - single-session
218822888|NCT01783444|DRUG|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
218822889|NCT01783444|DRUG|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
218822890|NCT04222530|DIAGNOSTIC_TEST|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
218822891|NCT04222530|DIAGNOSTIC_TEST|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
218822892|NCT01058239|DRUG|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
218822893|NCT01058239|DRUG|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
218822894|NCT02314676|BIOLOGICAL|PEG-somatropin|
218822895|NCT05346328|DRUG|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
218822896|NCT03557125|OTHER|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
218822897|NCT03557125|OTHER|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
218822898|NCT06022094|OTHER|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
218822899|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
218822900|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
218822901|NCT03733938|OTHER|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
219436723|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - multi-session
219436724|NCT00682240|PROCEDURE|laser treatment with PASCAL®|grid / focal laser treatment
218822902|NCT02868853|BEHAVIORAL|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
218822903|NCT02868853|BEHAVIORAL|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
218822904|NCT02868853|BEHAVIORAL|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
218822905|NCT02399787|OTHER|blastocyst biopsy|Performed on day 5
218822906|NCT04011592|DRUG|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
218822907|NCT04011592|DRUG|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
218822908|NCT02135744|BEHAVIORAL|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
219009471|NCT03753529|OTHER|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
219009472|NCT03753529|OTHER|control group|Stretching and transcutaneous electrical nerve stimulation
219009473|NCT06363006|DRUG|TKI+Cardunilimab|Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
219009474|NCT02986568|PROCEDURE|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
219009475|NCT02986568|PROCEDURE|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
219436725|NCT00682240|PROCEDURE|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
219436726|NCT02938221|DEVICE|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
218822909|NCT04587206|DRUG|CKD-348|QD, PO
218822910|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
218822911|NCT01302327|DRUG|Exenatide|Exenatide
218822912|NCT05373212|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
218822913|NCT05373212|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
218822914|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
218822915|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
218822916|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
218822917|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
218822918|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
218822919|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
218822920|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
218822921|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
218822922|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
219195427|NCT05623462|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~\- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
219195428|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI alone|patients use ventoline pMDI alone
219195429|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer
219195430|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
219195431|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber
218822923|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
219195432|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer
219195433|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer
218822924|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
218822925|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
218822926|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
219195434|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer|patient use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer
218822927|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
218822928|NCT01334554|DRUG|Sildenafil|20 mg three times a day.
218822929|NCT01334554|DRUG|Placebo|No active drug
218822930|NCT02393859|DRUG|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
218822931|NCT02393859|DRUG|Dexamethasone|10 mg/m\^2/day intravenous (IV) on Days 1-6
218822932|NCT02393859|DRUG|Vincrisitne|1.5 mg/m\^2/day IV on Days 1 and 6
218822933|NCT02393859|DRUG|Daunorubicin|30 mg/m\^2 IV over 24 hours on Day 5
218822934|NCT02393859|DRUG|Methotrexate|1 g/m\^2 IV over 36 hours on Day 1
218822935|NCT02393859|DRUG|Ifosfamide|800 mg/m\^2 IV for 1 hour on Days 2-4
218822936|NCT02393859|DRUG|PEG-asparaginase|1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
219195435|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer
219195436|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package
218822937|NCT02393859|DRUG|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
218822938|NCT00954447|DRUG|Placebo|Placebo, identical to Linagliptin tablet
218822939|NCT00954447|DRUG|Linagliptin|intended final marketed dose
218822940|NCT04120129|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
218822941|NCT04120129|DEVICE|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
218822942|NCT04592341|DRUG|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
218822943|NCT04812327|DIAGNOSTIC_TEST|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
218822944|NCT04812327|DIAGNOSTIC_TEST|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
218822945|NCT04812327|DIAGNOSTIC_TEST|viral culture|Nasopharyngeal Swab for the conduct of viral culture
218822946|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
218822947|NCT04818957|DIETARY_SUPPLEMENT|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
218822948|NCT04203589|BEHAVIORAL|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
218822949|NCT04203589|OTHER|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
218822950|NCT04772209|DRUG|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
218822951|NCT04772209|DRUG|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
218822952|NCT01405183|OTHER|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
219009476|NCT02986568|PROCEDURE|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
219009477|NCT02986568|PROCEDURE|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
219195437|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer
219436727|NCT04414527|BEHAVIORAL|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
219436728|NCT04414527|BEHAVIORAL|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
219436729|NCT02858284|DEVICE|TUG|Therapeutic Ultrasound for Glaucoma
219436730|NCT02858284|DEVICE|Sham|
219436731|NCT02157103|DRUG|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
219436732|NCT00405717|DRUG|atorvastatin,pravastatin|
219436733|NCT00228943|DIETARY_SUPPLEMENT|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
219436734|NCT00228943|DIETARY_SUPPLEMENT|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
219436735|NCT02648243|BEHAVIORAL|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
219436736|NCT03518489|DRUG|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
218822953|NCT04592406|OTHER|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR\<30mL/min/1.73m2 patients.
218822954|NCT03313414|DRUG|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
218822955|NCT00484796|PROCEDURE|MED-SEP|intraoperative neurophysiological monitoring
218822956|NCT00484796|PROCEDURE|TRI-SEP|intraoperative neurophysiologic monitoring
218822957|NCT00484796|PROCEDURE|neuropsychological tests|neurological short- and longterm outcome
218822958|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
218822959|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
218822960|NCT00003929|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
218822961|NCT00003929|DRUG|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
218822962|NCT00003929|DRUG|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
218822963|NCT00003929|RADIATION|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
218822964|NCT01014702|DEVICE|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
218822965|NCT01014702|DEVICE|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
218822966|NCT05399966|DIETARY_SUPPLEMENT|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
218822967|NCT05399966|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
218822968|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
218822969|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
218822970|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
219195438|NCT04315610|OTHER|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
219763596|NCT06320015|BEHAVIORAL|Substance Misuse Assistance Response Team (SMART)|The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.
218822971|NCT01041950|PROCEDURE|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
218822972|NCT00710983|BIOLOGICAL|Oral polio vaccine|
218822973|NCT02879513|DRUG|Paclitaxel|
219436737|NCT03518489|DRUG|standard care|Standard care will include mouth wash with antibiotics.
219763597|NCT06320015|OTHER|Usual Care Group|Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
218822974|NCT02879513|DRUG|Cisplatin|
218822975|NCT02879513|DRUG|Epirubicin|
219009478|NCT04197934|PROCEDURE|Biospecimen Collection - blood samples|Undergo collection of blood samples
219009479|NCT04197934|PROCEDURE|Biospecimen Collection - CSF samples|Undergo collection of CSF samples
219009480|NCT04197934|PROCEDURE|Computed Tomography|Undergo CT
218822976|NCT02879513|DRUG|Cyclophosphamide|
218822977|NCT02879513|DRUG|5-fluoruracil|
218822978|NCT04160104|OTHER|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
218822979|NCT04160104|OTHER|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
218822980|NCT00180037|DRUG|Coenzyme Q10 Nanodispersion (Nanoquinone)|
218822981|NCT00180037|DRUG|Placebo|
218822982|NCT02095756|OTHER|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
218822983|NCT02095756|OTHER|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
218822984|NCT06209489|OTHER|White cover|"* A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy."
218822985|NCT03861182|BIOLOGICAL|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
218822986|NCT00394576|BEHAVIORAL|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
218822987|NCT00394576|BEHAVIORAL|usual care|usual care
219009481|NCT04197934|DRUG|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
219009482|NCT04197934|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219009483|NCT04197934|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219009484|NCT03222050|OTHER|Distraction technique|
219009485|NCT02396901|OTHER|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
219195439|NCT04315610|OTHER|Treatment as usual|Active comparator group, based on traditional information and follow-up.
218822988|NCT00692003|DRUG|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
218822989|NCT00692003|DRUG|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
219009486|NCT01896531|DRUG|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
219436738|NCT03625089|DRUG|Atorvastatin|"Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
219436739|NCT00000608|BEHAVIORAL|diet, fat-restricted|
219436740|NCT00000608|BEHAVIORAL|diet, sodium-restricted|
219436741|NCT05704842|BEHAVIORAL|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
219436742|NCT02638272|PROCEDURE|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
219436743|NCT05480241|DRUG|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
219436744|NCT05480241|DRUG|Placebo|Placebo + Omeprazole 20mg once daily on fasting
219436745|NCT06037512|DIAGNOSTIC_TEST|subject|blood glucose measurement by subject
219436746|NCT06037512|DIAGNOSTIC_TEST|reference|blood glucose measurement with reference
219436747|NCT02019745|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
219436748|NCT01921452|DEVICE|Quantitative POC TSH Kit|A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
219436749|NCT01921452|DEVICE|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
219436750|NCT01921452|DEVICE|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
219436751|NCT02522078|DRUG|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
219009487|NCT01896531|DRUG|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
219009488|NCT01896531|DRUG|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
219436752|NCT02522078|DRUG|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
219009489|NCT01896531|DRUG|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
219009490|NCT01896531|DRUG|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
219436753|NCT05267483|OTHER|No intervention|No intervention
219436754|NCT00493155|DRUG|RG1530|Administered po at escalating doses (10 cohorts)
219436755|NCT06431412|OTHER|no intervention|no intervention
219436756|NCT05385926|RADIATION|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
219436757|NCT04815733|PROCEDURE|Mandatory ventilation|Use PCV-VG
219436758|NCT04815733|PROCEDURE|pressure support ventilation|Use PSVpro
219436759|NCT03809247|OTHER||have no any intervention
219436760|NCT03301233|DRUG|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
219436761|NCT04971369|DIAGNOSTIC_TEST|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
219436762|NCT03226548|OTHER|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
219436763|NCT00426933|DRUG|Daptomycin|
219436764|NCT00426933|DRUG|Vancomycin|
219436765|NCT01525667|BIOLOGICAL|150M PLX-PAD|Single course, multiple IM injections
219009491|NCT05354752|DRUG|VC005 tablets|VC005 groups repeat administration for 7 days
219436766|NCT01525667|BIOLOGICAL|300M PLX-PAD|Single course, multiple IM injections
219436767|NCT01525667|BIOLOGICAL|Placebo|Single course, multiple IM injections
219436768|NCT00116987|DEVICE|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
219436769|NCT00116987|DEVICE|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
218822990|NCT04152486|BIOLOGICAL|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
218822991|NCT01369043|DIETARY_SUPPLEMENT|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
218822992|NCT04677998|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
218822993|NCT02418520|DEVICE|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
218822994|NCT06239038|PROCEDURE|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
218822995|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
218822996|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP|1 x 10\^10 PU administered in deltoid
219436770|NCT00770224|BIOLOGICAL|rituximab|
219436771|NCT00770224|BIOLOGICAL|tositumomab|
219436772|NCT00770224|DRUG|cyclophosphamide|
219436773|NCT00770224|DRUG|doxorubicin|
219436774|NCT00770224|DRUG|prednisone|
218822997|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
218822998|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
218822999|NCT03895190|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
218823000|NCT04616937|DIETARY_SUPPLEMENT|GOS|Prebiotic
218823001|NCT04616937|DIETARY_SUPPLEMENT|Placebo|Placebo
218823002|NCT04016701|DEVICE|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
218823003|NCT04016701|BEHAVIORAL|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
218823004|NCT01248793|DRUG|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
218823005|NCT01248793|DRUG|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
218823006|NCT01248793|DRUG|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
218823007|NCT00140023|DRUG|Azithromycin microspheres 2.0 single dose|
218823008|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
218823009|NCT06112470|OTHER|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
218823010|NCT02905279|BEHAVIORAL|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
218823011|NCT02905279|BEHAVIORAL|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
218823012|NCT02905279|BEHAVIORAL|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
218823013|NCT02905279|BEHAVIORAL|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
218823014|NCT01506024|PROCEDURE|Total hip arthroplasty direct lateral approach|
219436775|NCT00770224|DRUG|vincristine|
219436776|NCT00770224|RADIATION|tositumomab|
219436777|NCT03954379|DRUG|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
219436778|NCT03954379|DRUG|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery"
219436779|NCT03954379|PROCEDURE|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
219436780|NCT03954379|DRUG|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
219436781|NCT02565277|BIOLOGICAL|Influenza Vaccine|
219763598|NCT04679012|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
219436782|NCT02565277|DRUG|Placebo|
219436783|NCT00152945|DRUG|Intravenous Intralipid|intravenous infusion
218823015|NCT01506024|PROCEDURE|Total hip arthroplasty posterior approach|
219009492|NCT05354752|DRUG|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
219009493|NCT03612297|DIAGNOSTIC_TEST|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
219009494|NCT00073554|DRUG|Alfimeprase|
219009495|NCT05810623|DRUG|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
219009496|NCT02697786|DEVICE|Transcranial doppler|Prolonged de airing to decrease the number of MES
219009497|NCT00632411|DRUG|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
219436784|NCT00152945|DRUG|Intravenous leucine, glycerol|intravenous infusion
219436785|NCT00517218|DRUG|Genasense® (, oblimersen sodium G3139)|
219436786|NCT02944734|DRUG|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
218823016|NCT01506024|PROCEDURE|Total hip arthroplasty, anterior approach|
218823017|NCT05067881|PROCEDURE|Pulmonary resection|Resection of pneumohematocele
218823018|NCT02250976|DRUG|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
219195440|NCT05158634|OTHER|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
219436787|NCT02944734|DRUG|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
219436788|NCT02944734|DRUG|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
219436789|NCT02944734|DRUG|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
219436790|NCT00395213|DRUG|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
219436791|NCT03854851|DRUG|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
219436792|NCT03854851|DRUG|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
219436793|NCT05929638|BEHAVIORAL|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
219436794|NCT01784614|DRUG|LY2624803 - Solution|Administered orally as reconstituted solution
219436795|NCT01784614|DRUG|LY2624803 - Capsule|Administered orally as a capsule
219436796|NCT01784614|DRUG|Placebo - Solution|Administered orally as solution
219436797|NCT01784614|DRUG|Placebo - Capsule|Administered orally as a capsule
219436798|NCT05569616|OTHER|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
219436799|NCT05569616|OTHER|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
219436800|NCT01712503|DEVICE|Phacoemulsfication cataract surgery and intra-ocular lens implant|
219436801|NCT01484561|DRUG|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
219436802|NCT01484561|DRUG|Placebo|Placebo BID orally, approximately 72 days
218823019|NCT02250976|DRUG|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
218823020|NCT02250976|DRUG|Livaro tab. 2mg|Pitavastatin Ca 2mg
218823021|NCT00161889|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
218823022|NCT01102595|DRUG|Temozolomide|"* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
218823023|NCT01102595|DRUG|Bevacizumab|"* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis."
218823024|NCT01102595|RADIATION|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
219436803|NCT00220454|DRUG|Climara|
219436804|NCT00220454|DRUG|Hydrocortone|
219436805|NCT00162513|BIOLOGICAL|Allogeneic tumor cell vaccine|
218823025|NCT01840943|DRUG|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
218823026|NCT01840943|DRUG|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
218823027|NCT02735018|DRUG|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
219195441|NCT06148012|OTHER|dental implant|"Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23)."
219436806|NCT03882853|OTHER|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
219436807|NCT03882853|OTHER|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
219436808|NCT05793424|OTHER|Cerebrospinal fluid (CSF) sample and additional blood samples|Lumbar puncture (Spinal Tap) and additional blood samples
219436809|NCT03371251|DRUG|BOS161721|SC administration
218823028|NCT02735018|DRUG|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
218823029|NCT00421512|DRUG|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
218823030|NCT03433547|PROCEDURE|Buckle|Surgical procedures of macular buckling
218823031|NCT03433547|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy
218823032|NCT03433547|OTHER|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
218823033|NCT03433547|OTHER|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
218823034|NCT03433547|OTHER|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
218823035|NCT03433547|OTHER|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
218823036|NCT04860115|PROCEDURE|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
218823037|NCT04606927|OTHER|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
218823038|NCT03426527|DRUG|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
218823039|NCT03426527|DRUG|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
218823040|NCT03426527|OTHER|General Anaesthesia|Using propofol, fentanyl and atracurium
218823041|NCT03100318|DRUG|FYU-981|Oral daily dosing for 14 weeks
218823042|NCT03100318|DRUG|Benzbromarone|Oral daily dosing for 14 weeks
218823043|NCT01078727|DEVICE|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
218823044|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
219009498|NCT00632411|BEHAVIORAL|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
219009499|NCT03233906|DIETARY_SUPPLEMENT|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
219009500|NCT03012425|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
219009501|NCT03012425|PROCEDURE|Acupuncture|
219009502|NCT03012425|BEHAVIORAL|questionnaires|
219009503|NCT03012425|OTHER|Diurnal Cortisol|saliva test
219436810|NCT03371251|DRUG|Placebo|SC administration
219436811|NCT00430391|OTHER|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
218823045|NCT02472912|BIOLOGICAL|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
218823046|NCT02472912|BIOLOGICAL|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
218823047|NCT02472912|BIOLOGICAL|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
218823048|NCT05617118|DRUG|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
219436812|NCT00430391|OTHER|Routine Control|Participants are assigned to the routine, standard consent.
218823049|NCT05617118|DRUG|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
218823050|NCT02580877|DRUG|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
218823051|NCT02580877|DRUG|500mg oral insulin crystals every other week|human insulin crystals in capsules
219009504|NCT00042172|DRUG|Donepezil|
219009505|NCT00042172|DRUG|Ginkgo Biloba Extract|
219009506|NCT03153254|DEVICE|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
219195442|NCT06816537|RADIATION|Low Level Laser Therapy|A low-level medical gallium-aluminum-arsenide (GaAlAs) diode laser device will be used on the 1st permanent molars in the test quadrants
219436813|NCT02915640|OTHER|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
219436814|NCT01476761|DEVICE|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
219436815|NCT04125875|DIAGNOSTIC_TEST|Electrogastrogram(EGG)|Heart Rate Variability
219436816|NCT04125875|DIAGNOSTIC_TEST|Heart Rate Variability(HRV)|Heart Rate Variability
219763599|NCT04679012|DRUG|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
219763600|NCT04679012|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218823052|NCT01674504|DRUG|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
218823053|NCT03186105|OTHER|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
218823054|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
218823055|NCT00098033|DRUG|clofarabine|
218823056|NCT02903823|DRUG|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
218823057|NCT01781377|DRUG|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
218823058|NCT01781377|DRUG|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
218823059|NCT01781377|DRUG|PLACEBO|SALINE INFUSION
218823060|NCT00356070|DRUG|Strattera|
218823061|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
219009507|NCT03153254|DEVICE|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
219009508|NCT06405061|DRUG|Adebrelimab|Adebrelimab: 1200 mg, IV, q3w
219009509|NCT00770289|OTHER|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
219009510|NCT01858090|DRUG|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
219009511|NCT01858090|DRUG|Group Fentanyl|
219009512|NCT01858090|DRUG|Group sufentanil|
219009513|NCT01858090|DRUG|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
219009514|NCT01858090|DRUG|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
219009515|NCT01858090|DRUG|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
219436817|NCT04672902|PROCEDURE|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
219436818|NCT01068613|DRUG|QAX028|QAX028 60 mcg via inhalation device
219436819|NCT01068613|DRUG|QAX028|QAX028 20 mcg via inhalation device
219436820|NCT01068613|DRUG|Tiotropium|Tiotropium via inhalation device
219436821|NCT01068613|DRUG|Placebo|Placebo to QAX028 via inhalation device
219763601|NCT04679012|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
219436822|NCT01505114|DRUG|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
219436823|NCT01505114|DRUG|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
218823062|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
218823063|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
218823064|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
218823065|NCT04165863|PROCEDURE|total knee replacement surgery|total knee replacement surgery
218823066|NCT00002286|DRUG|Zidovudine|
218823067|NCT06349824|DRUG|injection Dextrose water|dextrose will be injected around median nerve in wrist
219436824|NCT01505114|DRUG|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
219436825|NCT01505114|OTHER|Maraviroc placebo|Once daily from Week 0 through Week 48
219436826|NCT01505114|OTHER|Emtricitabine placebo|Once daily from Week 0 through Week 48
219436827|NCT01505114|OTHER|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
219436828|NCT04749160|DEVICE|Connected device|Connected device is a smart watch (with accelerometer without location data).
219436829|NCT02361489|DEVICE|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
219436830|NCT06423170|DRUG|Camrelizumab plus GEMOX|"1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses."
219436831|NCT02746770|OTHER|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
219436832|NCT06274268|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
218823068|NCT06349824|DEVICE|USG machine|usg guided nerve hydrdissection
218823069|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
218823070|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
218823071|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
218823072|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
218823073|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
218823074|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
218823075|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
219436833|NCT01053403|DRUG|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
219436834|NCT00454480|BIOLOGICAL|alemtuzumab|
218823076|NCT00222976|DRUG|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
219009516|NCT01858090|DRUG|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
219009517|NCT01858090|DRUG|Diphenhydramine|for severe pruritus
219009518|NCT01858090|DRUG|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
219009519|NCT01858090|DRUG|Diclofenac sodium|as additional analgesic among cases in which VAS\>3(Postoperatively)
219009520|NCT05733624|DRUG|SCAI-001 0.01% eyedrop|BID for 12weeks
219009521|NCT05733624|DRUG|SCAI-001 0.02% eyedrop|BID for 12weeks
219436835|NCT00454480|DRUG|arsenic trioxide|
219436836|NCT00454480|DRUG|azacitidine|
219436837|NCT00454480|DRUG|busulfan|
219009522|NCT05733624|DRUG|Restasis 0.05% eyedrop|BID for 12weeks
219436838|NCT00454480|DRUG|clofarabine|
219436839|NCT00454480|DRUG|cytarabine|
219436840|NCT00454480|DRUG|daunorubicin hydrochloride|
219436841|NCT00454480|DRUG|fludarabine phosphate|
219436842|NCT00454480|DRUG|gemtuzumab ozogamicin|
219436843|NCT00454480|DRUG|melphalan|
219436844|NCT00454480|DRUG|tipifarnib|
219436845|NCT00454480|GENETIC|DNA methylation analysis|
219436846|NCT00454480|GENETIC|cytogenetic analysis|
219436847|NCT00454480|GENETIC|gene expression analysis|
219436848|NCT00454480|GENETIC|mutation analysis|
219436849|NCT00454480|OTHER|diagnostic laboratory biomarker analysis|
219436850|NCT00454480|OTHER|immunologic technique|
219436851|NCT00454480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219436852|NCT00454480|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219436853|NCT00322751|DRUG|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
218823077|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
218823078|NCT05547412|DEVICE|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
218823079|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
219436854|NCT00288041|DRUG|carboplatin|Given IV
219436855|NCT00288041|DRUG|paclitaxel|Given IV
218823080|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
218823081|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
218823082|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
218823083|NCT00002493|DRUG|cisplatin|
218823084|NCT00002493|DRUG|doxorubicin hydrochloride|
218823085|NCT00002493|RADIATION|low-LET photon therapy|
218823086|NCT02598141|BIOLOGICAL|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
218823087|NCT02598141|BIOLOGICAL|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
219436856|NCT00288041|DRUG|bortezomib|Given IV
219436857|NCT05351190|DEVICE|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
219436858|NCT02441192|OTHER|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
219436859|NCT02441192|OTHER|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
219436860|NCT02441192|OTHER|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
219436861|NCT03645915|OTHER|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
219436862|NCT05810298|OTHER|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
219436863|NCT05810298|OTHER|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
218823088|NCT06118645|DRUG|cadonilimab combined +paclitaxel (albumin-bound)|"1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
218823089|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
219009523|NCT04447261|DRUG|BI 1356225|BI 1356225
219009524|NCT04447261|DRUG|Placebo|Placebo
219009525|NCT02956486|DRUG|Elenbecestat|Oral tablet.
219009526|NCT02956486|DRUG|Placebo|Oral tablet.
219009527|NCT00036504|DRUG|Insulin Lispro low mixture|
219009528|NCT03876431|DEVICE|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
219009529|NCT03876431|OTHER|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
219436864|NCT05810298|BEHAVIORAL|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
219763602|NCT04679012|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218823090|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
218823091|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
219195443|NCT06816537|OTHER|No Interventions|The handpiece was also held on the placebo treatment side without laser irradiation (fake irradiation) following the same application protocol as the LLLT treatment side.
218823092|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
218823093|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
218823094|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
218823095|NCT04878107|RADIATION|LDRT|low dose radation therapy
218823096|NCT01211561|DRUG|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
218823097|NCT01211561|DRUG|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
218823098|NCT02759445|OTHER|routine treatment|No intervention, only observation and describing
218823099|NCT01690754|OTHER|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
218823100|NCT03030456|DEVICE|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
218823101|NCT05208008|OTHER|With service dog|No intervention
218823102|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
218823103|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
218823104|NCT00940550|DRUG|Prolonged-release melatonin|2 mg tablet, once.
218823105|NCT00940550|DRUG|Temazepam|20 mg capsule, once
218823106|NCT00940550|DRUG|Zolpidem|10 mg capsule, once
219009530|NCT05202743|OTHER|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
219009531|NCT01905384|DEVICE|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
219580214|NCT02001220|PROCEDURE|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
218823107|NCT00940550|DRUG|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
218823108|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
219009532|NCT01905384|DEVICE|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
219195444|NCT04181736|DRUG|Guanfacine Tablets|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
219195445|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
219195446|NCT04372797|DEVICE|Diagnostic test|A battery of oculomotor tests
219195447|NCT06816654|OTHER|Data extraction from medical records|Data extraction from medical records
218823109|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
219009533|NCT00044356|GENETIC|Allovectin-7®|
219009534|NCT03325075|BIOLOGICAL|VAL-181388|Escalating dose levels
219009535|NCT03325075|OTHER|Placebo|Saline
218823110|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
218823111|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
218823112|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
218823113|NCT03299478|OTHER|Will look for immune infiltration|
218823114|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
218823115|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
218823116|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
218823117|NCT00887159|DRUG|Cisplatin|Given IV
218823118|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
218823119|NCT00887159|DRUG|Etoposide|Given IV
219009536|NCT06080607|BEHAVIORAL|Patient Reported Outcome (PRO)|Quality of Life evaluation
219009537|NCT00422591|DRUG|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
219009538|NCT00422591|DRUG|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
219009539|NCT00345254|PROCEDURE|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
219009540|NCT03579589|DRUG|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
218823120|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
218823121|NCT00887159|DRUG|Vismodegib|Given PO
218823122|NCT01007175|BIOLOGICAL|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
218823123|NCT01007175|BIOLOGICAL|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
218823124|NCT01007175|BIOLOGICAL|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
218823125|NCT01007175|BIOLOGICAL|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
218823126|NCT01007175|BIOLOGICAL|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
218823127|NCT00483678|OTHER|counseling intervention|
218823128|NCT00483678|OTHER|questionnaire administration|
218823129|NCT00483678|PROCEDURE|psychosocial assessment and care|
218823130|NCT02125955|DIETARY_SUPPLEMENT|Prebiotic fiber|Dissolved in water.
219436865|NCT05625815|DEVICE|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219436866|NCT05625815|DEVICE|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219763603|NCT04679012|DRUG|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
219763604|NCT05320406|RADIATION|Radiation therapy|Undergo radiation therapy
218823131|NCT02125955|DIETARY_SUPPLEMENT|Placebo|Dissolved in water
218823132|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
218823133|NCT02543853|OTHER|direct trocar entry|direct trocar entry to provide pneumoperitoneum
218823134|NCT02543853|OTHER|veres needle entry|veres needle entry to provide pneumoperitoneum
218823135|NCT03130829|DIETARY_SUPPLEMENT|Oligo Fucoidan|Oral, twice daily
218823136|NCT03130829|DIETARY_SUPPLEMENT|Placebo|Oral, twice daily
218823137|NCT04230967|BEHAVIORAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
218823138|NCT04230967|BEHAVIORAL|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
218823139|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
218823140|NCT01004536|OTHER|no treatment|left untreated during the study period
218823141|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
218823142|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
218823143|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
218823144|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
219763605|NCT05320406|DRUG|Leuprolide|Given IM or SC
219009541|NCT02985164|RADIATION|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
219009542|NCT02985164|RADIATION|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
219009543|NCT02769325|DRUG|Atropine|IV atropine 0.1%, 10 ml
219763606|NCT05320406|DRUG|Relugolix|Given PO
219763607|NCT04075916|DRUG|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
218823145|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
218823146|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
218823147|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
218823148|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
218823149|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
218823150|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
218823151|NCT00704067|BEHAVIORAL|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
218823152|NCT00704067|BEHAVIORAL|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
218823153|NCT00486356|DRUG|capecitabine|
218823154|NCT00486356|DRUG|carboplatin|
218823155|NCT00486356|DRUG|epirubicin hydrochloride|
218823156|NCT00486356|GENETIC|microarray analysis|
218823157|NCT00486356|GENETIC|polymorphism analysis|
218823158|NCT00486356|OTHER|pharmacological study|
218823159|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
218823160|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
218823161|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
218823162|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
219436867|NCT05625815|DEVICE|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
218823163|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
218823164|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
218823165|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
218823166|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
219763608|NCT04527926|BEHAVIORAL|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
218823167|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
218823168|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
218823169|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
218823170|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
218823171|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
218823172|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
218823173|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
218823174|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
218823175|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
218823176|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
218823177|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
218823178|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
218823179|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
219436868|NCT05625815|DEVICE|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219436869|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
218823180|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
219580215|NCT02001220|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
219580216|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+virtual reality+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.frequency:Stimulation perform for 30 minutes per day for 4 weeks .~duration 600 pulses (intratrain pulse) frequency =20 Hz ; Pulse duration =0.3ms ,lasting 30 seconds each time ,stimulating once every 5 minutes"
218823181|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
219763609|NCT04527926|BEHAVIORAL|Usual Care|Standard of Care
218823182|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
218823183|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
218823184|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
219009544|NCT02769325|DRUG|Placebo|IV saline, 10 ml
219009545|NCT02769325|DRUG|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
219009546|NCT02769325|DRUG|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
219009547|NCT02769325|DRUG|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
219009548|NCT02769325|DRUG|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
219009549|NCT02769325|DRUG|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
219009550|NCT02769325|DRUG|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
219009551|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv BID
219009552|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv TID
219009553|NCT05247268|DRUG|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
219009554|NCT05247268|DRUG|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
219009555|NCT05247268|DRUG|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
219009556|NCT05247268|DRUG|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
219009557|NCT01454869|DRUG|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
219009558|NCT01454869|DRUG|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
219009559|NCT04419454|DEVICE|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
219009560|NCT00676351|PROCEDURE|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
219009561|NCT02211001|OTHER|Pilates Group|The exercises were applied once a week during eight weeks.
219009562|NCT02211001|OTHER|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
219436870|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
219436871|NCT03739736|OTHER|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
219436872|NCT01046968|DIETARY_SUPPLEMENT|Lepticore|300 mg twice daily
219436873|NCT02548741|DRUG|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
219436874|NCT02548741|DRUG|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
218823185|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
218823186|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
218823187|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
218823188|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
218823189|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
218823190|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
218823191|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
218823192|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
218823193|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
218823194|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
218823195|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
219009563|NCT02211001|OTHER|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
219009564|NCT01485770|DRUG|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
219009565|NCT01485770|DRUG|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
219009566|NCT05201560|DRUG|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
219009567|NCT05201560|DRUG|Fentanyl|Patients of this group will receive Fentanyl
219009568|NCT02485574|PROCEDURE|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
219009569|NCT00264329|OTHER|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
219009570|NCT02308254|DRUG|Lixisenatide|Abdominal administration
219009571|NCT02308254|DRUG|Placebo|Abdominal administration
219009572|NCT04465539|DRUG|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
219009573|NCT04465539|DRUG|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
219009574|NCT04465539|DRUG|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
219009575|NCT05529043|BEHAVIORAL|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
219580217|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.Stimulation perform for 30 minutes per day for 4 weeks .~Routine physical therapy Stretching Areas :upper chest ,neck flexors ,shoulder flexor and adductors ,elbow and wrist flexors 10 minute per session,and stretches will held for 10s -30swith four repetition of each.30 minutes per day for 4 weeks Upper extremity Proprioception ,coordination,speed and agility increase such as followReach and grasp Handle turning simulated eating task Inserting object Opening bottle strenghtening exercise Muscles biceps brachii brachialis Coracobrachialis triceps brachii wrist extensors 10 minute per session for 4 weeks"
218823196|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
218823197|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
218823198|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
218823199|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
218823200|NCT00037440|GENETIC|Polymorphisms measured|
218823201|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
218823202|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
218823203|NCT01805687|DRUG|Zileuton extended release|
218823204|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
218823205|NCT00481455|DRUG|Temozolomide|Fixed dose
218823206|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
219436875|NCT02548741|OTHER|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
219436876|NCT02548741|OTHER|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
219436877|NCT04393909|BEHAVIORAL|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
219580218|NCT05637619|DEVICE|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
219580219|NCT05637619|DEVICE|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
219580220|NCT05637619|BEHAVIORAL|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
219009576|NCT05529043|BEHAVIORAL|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
219195448|NCT06818773|DRUG|Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor|A 21-day cycle is used, with the initial dose of inetuximab at 8 mg/kg (IV), followed by 6 mg/kg (IV) on Day 1 of each subsequent cycle. Gemcitabine (1000 mg/m²) + cisplatin (25 mg/m²) are administered in combination on Day 1 and Day 8 of each cycle. The appropriate PD-1/PD-L1 inhibitor will be selected by the investigator based on the patient's specific condition, and its administration will strictly follow the dosing instructions provided in the relevant drug's package insert.
219580221|NCT00173550|PROCEDURE|Hysterectomy and Bilateral salpingo-oophorectomy|
218823207|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
218823208|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
219009577|NCT01950845|DEVICE|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
219009578|NCT01950845|DEVICE|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
219580222|NCT01415765|DRUG|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
219580223|NCT01415765|DRUG|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
218823209|NCT02026947|DRUG|Placebo|
218823210|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
218823211|NCT02181946|DRUG|Fluconazole|
218823212|NCT02181946|DRUG|Nevirapine|
218823213|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
218823214|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
218823215|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
218823216|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
218823217|NCT04284137|BEHAVIORAL|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
218823218|NCT04284137|BEHAVIORAL|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
218823219|NCT04284137|BEHAVIORAL|Active Control|Participants will attend a 60-minute health education program once a week.
218823220|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
218823221|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
219009579|NCT01408914|DRUG|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
219436878|NCT04393909|BEHAVIORAL|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
219580224|NCT01415765|DRUG|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
219580225|NCT01415765|DRUG|Vincristine|CIV on days 1-4 of every 21 day cycle
218823222|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
218823223|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
218823224|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
218823225|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
219009580|NCT05526612|OTHER|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
219580226|NCT01415765|DRUG|Cyclophosphamide|IV on day 5 of each 21 day cycle
219580227|NCT01415765|DRUG|Doxorubicin|CIV on days 1-4 of each 21 day cycle
219580228|NCT01415765|DRUG|Rituximab|IV on day 1 of each 21 day cycle
219580229|NCT01415765|DRUG|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
219580230|NCT05934955|DRUG|BI 1839100|BI 1839100
219580231|NCT05934955|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
219580232|NCT05472662|DRUG|Placebo 152a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
219580233|NCT05472662|DRUG|Placebo 134a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
219580234|NCT03494335|OTHER|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
219436879|NCT04393909|BEHAVIORAL|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
218823226|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
218823227|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
218823228|NCT01187654|BIOLOGICAL|AC133|intra coronary injection of bone marrow derived AC133+ cells
218823229|NCT01187654|BIOLOGICAL|MNC|intra coronary injection of bone marrow derived MNC
218823230|NCT01187654|BIOLOGICAL|CONTROL|autologous serum injection
218823231|NCT05704153|DEVICE|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
218823232|NCT05704153|DEVICE|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
218823233|NCT05704153|DEVICE|Sham Intervention|Sham stimulation
218823234|NCT01544673|DRUG|linezolid|600 mg oral tablet twice daily for 4.5 days
218823235|NCT01544673|DRUG|Placebo|500 mg oral placebo twice daily for 4.5 days
218823236|NCT03855943|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
218823237|NCT03855943|BEHAVIORAL|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
218823238|NCT03940560|DEVICE|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
218823239|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
218823240|NCT01823107|DEVICE|Meso BioMatrix Device|
218823241|NCT04474639|DEVICE|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
218823242|NCT00819429|DIETARY_SUPPLEMENT|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
218823243|NCT00819429|BEHAVIORAL|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
219436880|NCT04393909|BEHAVIORAL|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
219436881|NCT01869803|DRUG|gemtuzumab ozogamicin|Given IV
219436882|NCT01869803|OTHER|laboratory biomarker analysis|Correlative studies
218823244|NCT00819429|OTHER|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
218823245|NCT00154349|DRUG|Imatinib Mesylate|
218823246|NCT06344637|DRUG|10 % lidocaine spray without adrenaline|Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
218823247|NCT06344637|OTHER|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
218823248|NCT05689879|DRUG|STOP arm|TNF-alpha antagonists withdrawal
219436883|NCT04445688|DRUG|AD036|Oral administration before bed
219436884|NCT04445688|DRUG|Atomoxetine|Oral administration before bed
219580235|NCT04620135|DRUG|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
218823249|NCT00659282|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
218823250|NCT02990650|BEHAVIORAL|Balance Task Training with therapist guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support"
218823251|NCT02990650|BEHAVIORAL|Balance task training with robotic guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
219436885|NCT04445688|DRUG|Placebo|Oral administration before bed
219436886|NCT01136213|RADIATION|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
218823252|NCT02990650|BEHAVIORAL|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
218823253|NCT01343888|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
218823254|NCT01343888|DRUG|BI 201335|BI 201335 once daily high dose
218823255|NCT01343888|DRUG|BI 201335|BI 201335 once daily low dose
218823256|NCT01343888|DRUG|Placebo|
218823257|NCT02217618|DRUG|LY2409021|
218823258|NCT01677260|DRUG|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
218823259|NCT01677260|DRUG|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
218823260|NCT03204760|DRUG|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
218823261|NCT03204760|DRUG|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
218823262|NCT03579758|DRUG|Capecitabine|Given PO
218823263|NCT03579758|DRUG|Cisplatin|Given IV
218823264|NCT03579758|DRUG|Gemcitabine|Given IV
218823265|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
219436887|NCT01136213|OTHER|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
219009581|NCT05526612|OTHER|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
219009582|NCT04060550|BIOLOGICAL|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
218823266|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
219009583|NCT05395468|OTHER|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
219009584|NCT00862745|DRUG|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
219436888|NCT01136213|DRUG|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
219436889|NCT03460613|OTHER|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
219436890|NCT05117593|DRUG|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
218823267|NCT03645538|OTHER|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
218823268|NCT03645538|OTHER|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
218823269|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
218823270|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
218823271|NCT00497900|DRUG|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
218823272|NCT04097652|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
218823273|NCT01056614|DRUG|fludarabine phosphate|Given IV
218823274|NCT01056614|DRUG|busulfan|Given IV
218823275|NCT01056614|BIOLOGICAL|anti-thymocyte globulin|Given IV
218823276|NCT01056614|DRUG|tacrolimus|Given IV and orally
218823277|NCT01056614|DRUG|methotrexate|Given IV
218823278|NCT01056614|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
218823279|NCT01056614|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
218823280|NCT01056614|OTHER|laboratory biomarker analysis|Correlative studies
218823281|NCT04411303|BEHAVIORAL|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
218823282|NCT04411303|BEHAVIORAL|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
218823283|NCT04411303|BEHAVIORAL|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
218823284|NCT04411303|BEHAVIORAL|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
218823285|NCT03563092|PROCEDURE|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
219436891|NCT05117593|DRUG|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
218823286|NCT04097990|OTHER|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
218823287|NCT05269186|DEVICE|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
218823288|NCT01132352|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
218823289|NCT02764996|DEVICE|Acupuncture|
218823290|NCT00506038|PROCEDURE|fine needle technique|
218823291|NCT04143230|OTHER|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
218823292|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
218823293|NCT00564109|PROCEDURE|retrospective Observation|retrospective Observation
218823294|NCT00981721|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
218823295|NCT06332976|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
218823296|NCT00263003|DRUG|Irbesartan/hydrochlorothiazide|
218823297|NCT00263003|DRUG|Irbesartan|
218823298|NCT00002139|DRUG|Azithromycin|
218823299|NCT02605356|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
218823300|NCT02605356|DRUG|Placebo|
218823301|NCT02605356|DRUG|Bortezomib|
218823302|NCT02605356|DRUG|Dexamethasone|
219009585|NCT00862745|DRUG|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
218823303|NCT03540420|DRUG|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
218823304|NCT02982811|DEVICE|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
218823305|NCT02818465|OTHER|Vascular calcifications by Xray|
218823306|NCT02818465|OTHER|Vascular calcifications by tomodentimetry|
219009586|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 30 ug/day|
219009587|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 10 ug/day|
219009588|NCT02689024|DRUG|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
219009589|NCT02689024|DRUG|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
219436892|NCT04758741|BEHAVIORAL|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
219436893|NCT04758741|OTHER|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
219436894|NCT01759355|PROCEDURE|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
219009590|NCT02689024|DRUG|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
219009591|NCT02689024|DRUG|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
219009592|NCT02689024|DRUG|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
219436895|NCT06082375|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 in the form of cholecalciferol.
218823307|NCT02818465|BIOLOGICAL|Blood sample withdrawn|
218823308|NCT00210847|DRUG|tramadol, acetaminophen|
218823309|NCT04414540|DRUG|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
218823310|NCT04414540|DRUG|Pembrolizumab|Pembrolizumab q 3 weeks
218823311|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
218823312|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
218823313|NCT01331681|PROCEDURE|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
218823314|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
218823315|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
219009593|NCT02689024|DRUG|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
219436896|NCT06082375|DIETARY_SUPPLEMENT|Placebo|Vegetable oil.
219436897|NCT02114398|OTHER|usual treatment|usual treatment
218823316|NCT03395028|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
218823317|NCT04188249|DRUG|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
218823318|NCT02804490|DIETARY_SUPPLEMENT|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
218823319|NCT02804490|DIETARY_SUPPLEMENT|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
218823320|NCT02804490|DIETARY_SUPPLEMENT|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
218823321|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
218823322|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
218823323|NCT01595087|DRUG|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
218823324|NCT01767896|BIOLOGICAL|ASP7374|subcutaneous (sc)
218823325|NCT01767896|BIOLOGICAL|approved egg-derived TIV|subcutaneous (sc)
218823326|NCT02325063|DRUG|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
218823327|NCT02325063|DRUG|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
218823328|NCT02325063|DRUG|Corticoid injection|Patients will be treated with an injection of Corticoids.
218823329|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
218823330|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
218823331|NCT05968846|DRUG|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
218823332|NCT05990244|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
218823333|NCT05990244|PROCEDURE|Assessment and Recording|Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
218823334|NCT03585387|PROCEDURE|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
218823335|NCT06145594|OTHER|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
218823336|NCT06145594|OTHER|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
219436898|NCT02114398|OTHER|usual treatment + sophrology|usual treatment + sophrology
218823337|NCT00011544|PROCEDURE|Performance Measure|
218823338|NCT06357104|DEVICE|electroencephalogram biofeedback|EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
218823339|NCT06357104|DEVICE|electrical brain stimulation|EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
218823340|NCT06357104|DEVICE|ultra-low frequency transcranial magnetic stimulation|ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
218823341|NCT06357104|DRUG|Sertraline Hydrochloride|Sertraline is taken in the morning for 150 mg per day.
219436899|NCT06227806|PROCEDURE|Tibial Tubercle Transfer|Patients will receive the TTT surgery followed by a home exercise program.
219436900|NCT06227806|PROCEDURE|Home Exercise Program|Patients will receive an extensive home exercise program.
219436901|NCT01023373|DRUG|Medical treatment|hypotensive drugs, statins and anti-platelets
218823342|NCT06357104|DRUG|Clonazepam|Clonazepam is taken in the morning for 1 mg per day.
218823343|NCT06357104|DRUG|Alprazolam|Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
218823344|NCT06357104|DRUG|Metoprolol|Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
218823345|NCT06357104|DRUG|Olanzapine|Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
219436902|NCT01023373|PROCEDURE|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
219436903|NCT01023373|DEVICE|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
219009594|NCT02689024|DRUG|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
218823346|NCT06357104|DRUG|Pravastatin Sodium 20 MG|Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
218823347|NCT06357104|DRUG|Sacubitril Valsartan Sodium Hydrate|Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
219436904|NCT01023373|DEVICE|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
218823348|NCT06297876|BEHAVIORAL|Storytelling|Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
218823349|NCT06297876|BEHAVIORAL|Learn More (Active Comparator)|Informational videos that are of similar length and on the same topic as the storytelling videos.
218823350|NCT06086964|OTHER|therapeutic diet.|gluten and casein free diet.
218823351|NCT06086964|OTHER|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
218823352|NCT05532969|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
218823353|NCT02803203|DRUG|osimertinib|
219009595|NCT02689024|DRUG|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
219009596|NCT02689024|DRUG|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
218823354|NCT02803203|DRUG|Bevacizumab|
219009597|NCT02689024|DRUG|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
219009598|NCT01831999|BEHAVIORAL|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
219009599|NCT05422599|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
218823355|NCT04577781|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
219009600|NCT05422599|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
219009601|NCT05822219|BEHAVIORAL|COVID-19 vaccine and booster training, and importance|COVID-19 vaccine and booster information training
219009602|NCT02730325|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
218823356|NCT04577781|DRUG|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
219009603|NCT02730325|OTHER|Placebo|
219009604|NCT03371992|DRUG|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
219009605|NCT03371992|DIAGNOSTIC_TEST|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
219009606|NCT03371992|OTHER|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
219009607|NCT04062721|DRUG|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
219009608|NCT04062721|PROCEDURE|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
219436905|NCT02032186|DRUG|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
218823357|NCT00811460|DRUG|Placebo|sc for 4 days
218823358|NCT00811460|DRUG|taspoglutide|300micrograms/day sc for 2 days
218823359|NCT00811460|DRUG|taspoglutide|800 micrograms/day sc for 2 days
218823360|NCT05713461|BEHAVIORAL|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
218823361|NCT05713461|BEHAVIORAL|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
218823362|NCT00120133|DRUG|Atorvastatin|
218823363|NCT02844985|OTHER|No Intervention|
218823364|NCT03159182|DEVICE|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
218823365|NCT03159182|DEVICE|Pressure garment|Custom made fabric pressure garment
218823366|NCT03489044|DRUG|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
218823367|NCT03489044|DRUG|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
218823368|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
219436906|NCT05362331|OTHER|Web Application|Internet based application
219436907|NCT02878629|DEVICE|Mandibular Advancement Devices|
219436908|NCT00592917|DIETARY_SUPPLEMENT|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
219436909|NCT01262599|DEVICE|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
218823369|NCT02172391|DRUG|Placebo inhalation powder capsules|
218823370|NCT05924139|DIETARY_SUPPLEMENT|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
218823371|NCT05924139|DIETARY_SUPPLEMENT|Placebo|4 capsules per day of coconut oil
218823372|NCT00985647|DRUG|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
218823373|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
218823374|NCT00529269|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
218823375|NCT05055076|DEVICE|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
218823376|NCT00270127|DRUG|Epoetin alfa|
218823377|NCT05361850|PROCEDURE|Extubation|Removal of the endotracheal tube
218823378|NCT04865666|DEVICE|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
218823379|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
218823380|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
218823381|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
218823382|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
218823383|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
218823384|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
218823385|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
218823386|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
218823387|NCT00881894|DRUG|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
218823388|NCT00421148|DRUG|Sugammadex 0.5 mg/kg|IV infusion
219009609|NCT04062721|DRUG|In situ immunotherapy|Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
219009610|NCT00811473|DRUG|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
218823389|NCT00421148|DRUG|Sugammadex 1 mg/kg|IV infusion
218823390|NCT00421148|DRUG|Sugammadex 2 mg/kg|IV infusion
218823391|NCT00421148|DRUG|Sugammadex 4 mg/kg|IV infusion
218823392|NCT00421148|DRUG|Placebo|IV infusion
218823393|NCT00421148|DRUG|Rocuronium bromide|IV infusion
218823394|NCT03576261|OTHER|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
218823395|NCT03576261|DIAGNOSTIC_TEST|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
218823396|NCT04991220|PROCEDURE|Preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
218823397|NCT01769053|OTHER|Variable Ventilation|
218823398|NCT03222674|BIOLOGICAL|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
218823399|NCT00844103|DRUG|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
218823400|NCT00844103|DRUG|Placebo|10ml oral solution administered once a day over 10 days.
218823401|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
219009611|NCT00811473|DRUG|Placebo|Oral treatment once daily in the evening
219009612|NCT01163487|DRUG|Dichloroacetate|25-50mg/kg per day; oral
219009613|NCT01163487|DEVICE|EF5|21 mg/kg; IV
219009614|NCT04801108|PROCEDURE|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
218823402|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
218823403|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
218823404|NCT00469833|DRUG|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
218823405|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
218823406|NCT04123301|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
218823407|NCT04123301|DEVICE|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
218823408|NCT04268069|DRUG|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
218823409|NCT04268069|DRUG|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
218823410|NCT02965638|OTHER|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
218823411|NCT04193735|DIAGNOSTIC_TEST|MRI scans after a liquid meal|Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
218823412|NCT04442568|OTHER|ERAS|early mobilisation, early oral intake, early discharge
218823413|NCT01908010|DRUG|ABT-354|ABT-354 Low Dose
218823414|NCT01908010|DRUG|ABT-354|ABT-354 High Dose
218823415|NCT01908010|DRUG|Placebo|Placebo
219436910|NCT01262599|DEVICE|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
219436911|NCT04562532|DEVICE|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
219436912|NCT04562532|DEVICE|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"* Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)"
219436913|NCT04294654|DRUG|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
219436914|NCT00588887|DEVICE|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
218823416|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
218823417|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
218823418|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
218823419|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
218823420|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
219436915|NCT00588887|DEVICE|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
218823421|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
218823422|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
218823423|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
218823424|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
218823425|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
218823426|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
218823427|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
218823428|NCT05784181|DEVICE|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
218823429|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
218823430|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
218823431|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
218823432|NCT05270993|BEHAVIORAL|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
218823433|NCT05270993|BEHAVIORAL|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
219436916|NCT03802656|DEVICE|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
218823434|NCT02093260|BIOLOGICAL|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
219580236|NCT04620135|DRUG|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
219580237|NCT02452983|DRUG|Sertraline|
219580238|NCT02452983|PROCEDURE|Bone Marrow Aspirate/Biopsy|
219436917|NCT03760276|DRUG|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
219436918|NCT05401591|DIETARY_SUPPLEMENT|Protein shake|Participant will drink a protein shake made using each of the four protein types.
218823435|NCT00624858|DRUG|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
218823436|NCT05318508|OTHER|Measurements of sagittal spinopelvic parameters|Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
218823437|NCT03396159|DIAGNOSTIC_TEST|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
218823438|NCT04908293|OTHER|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
218823439|NCT04908293|OTHER|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
218823440|NCT03391999|OTHER|A questionnaire; CHU9D|Measuring Health Related Quality of Life
218823441|NCT00447967|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
218823442|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
218823443|NCT00447967|DRUG|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
218823444|NCT00447967|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
219436919|NCT04975672|OTHER|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
219436920|NCT05291572|BEHAVIORAL|speech therapy only|fluency shaping technique
218823445|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
219436921|NCT05291572|DEVICE|hyperbaric oxygen therapy|chamber system using oxygen with pressure
219436922|NCT05291572|DRUG|medical treatment|brain stimulant
219436923|NCT00038272|DRUG|Mycophenolate mofetil|
219436924|NCT00038272|DRUG|Amdoxovir|
219436925|NCT01998399|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
218823446|NCT01822665|DRUG|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
218823447|NCT01822665|DRUG|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
218823448|NCT01822665|OTHER|Placebo|Placebo tablets
218823449|NCT03322982|BEHAVIORAL|Low-fat diet|less than 20% calories from fat daily
219436926|NCT01998399|DRUG|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
219436927|NCT01778270|DEVICE|Body Bioimpedance Sensor|
219436928|NCT03235375|DRUG|MEDI0382|MEDI0382 administered subcutaneously
219436929|NCT05218577|OTHER|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
219436930|NCT05218577|DIETARY_SUPPLEMENT|selenium supplement|20 microgram/day selenium suppplement powder.
219436931|NCT05218577|OTHER|Placebo|the placebo mocaf powder
219436932|NCT01269047|DRUG|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
219436933|NCT01269047|DRUG|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
218823450|NCT04781348|PROCEDURE|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
218823451|NCT01828840|DRUG|epidural morphine via PCEA|
218823452|NCT01828840|DRUG|epidural fentanyl via PCEA|
218823453|NCT01828840|DRUG|epidural methadone via PCEA|
218823454|NCT01828840|DRUG|intravenous morphine via PCA|
218823455|NCT04908150|OTHER|Core training|A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
218823456|NCT03257384|OTHER|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
218823457|NCT05572840|OTHER|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
219009615|NCT04801108|DEVICE|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
219009616|NCT04127331|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
219009617|NCT03038230|DRUG|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
219436934|NCT01269047|DRUG|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
219436935|NCT03126578|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
219436936|NCT03126578|DRUG|Midazolam|Benzodiazepine
219436937|NCT06192667|DEVICE|GC Geanial Injectable (Tokyo,Japan)|Highly filled composite resin
219436938|NCT06192667|DEVICE|3M Filtek Z250 Universal Restorative (Germany)|Conventional composite resin
219436939|NCT04114539|DRUG|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
219436940|NCT02918656|OTHER|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
218823458|NCT05423184|OTHER|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
219436941|NCT02918656|OTHER|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
219436942|NCT02918656|OTHER|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
219436943|NCT04671615|DRUG|palbociclib|As provided in real world practice
219436944|NCT00248105|BEHAVIORAL|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
219436945|NCT00003882|DRUG|anhydrovinblastine|
219436946|NCT01072448|DRUG|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219436947|NCT01072448|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
218823459|NCT05423184|OTHER|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
218823460|NCT00508092|PROCEDURE|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
218823461|NCT04089020|BEHAVIORAL|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
218823462|NCT00646126|DRUG|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
218823463|NCT00646126|DRUG|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
218823464|NCT01563055|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
219009618|NCT03103607|DIAGNOSTIC_TEST|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
219436948|NCT01699646|DEVICE|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
219009619|NCT03103607|DIAGNOSTIC_TEST|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
219009620|NCT00366288|DRUG|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
219009621|NCT01177917|OTHER|Infant Formula|
219009622|NCT00548925|DRUG|ABT-894|6 mg BID tablets, 8 weeks of treatment
219009623|NCT00548925|DRUG|placebo|BID tablets, 8 weeks of treatment
219436949|NCT01699646|PROCEDURE|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
219009624|NCT01680705|OTHER|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
219009625|NCT02188251|DIETARY_SUPPLEMENT|Activamp|
219009626|NCT02188251|OTHER|Placebo|
219009627|NCT00296478|DRUG|Endometrin|Endometrin 100mg BID x 10weeks
219009628|NCT00296478|DRUG|Endometrin|Endometrin 100mg TID x 10weeks
219009629|NCT00296478|DRUG|Crinone|Crinone QD x 10weeks
219436950|NCT05484427|OTHER|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
219436951|NCT02585076|OTHER|Standard of care|As prescribed by treated physician
219436952|NCT00877604|DRUG|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
219436953|NCT00877604|DRUG|Placebo|identical placebo by oral route at the same dosing schedule
219436954|NCT01799304|PROCEDURE|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
219436955|NCT01799304|PROCEDURE|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
219436956|NCT01799304|PROCEDURE|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
219580239|NCT00835965|DRUG|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
218823465|NCT01563055|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
218823466|NCT01601184|DRUG|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
218823467|NCT01601184|DRUG|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
218823468|NCT00420186|DRUG|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
218823469|NCT04672135|DRUG|REM0046127|Oral solution: 100 mg/mL REM0046127
218823470|NCT04672135|DRUG|Placebo|Oral solution with 0 mg/mL REM0046127
218823471|NCT06547762|OTHER|Hybrid approach (in-person and remote) to pediatric rehabilitation: A look beyond the COVID-19 crisis|Hybrid rehabilitation. Out patients will receive one day a week of remote therapy and the remaining (1-4 days) in person at rehabilitation hospital
218823472|NCT05074225|OTHER|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
218823473|NCT02116179|BEHAVIORAL|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
218823474|NCT01335126|OTHER|Emulsion type artificial tear|2 types of artificial tears
218823475|NCT00959907|DRUG|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
219009630|NCT04671225|BEHAVIORAL|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
219009631|NCT04671225|BEHAVIORAL|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
219436957|NCT01799304|PROCEDURE|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
219436958|NCT02358564|PROCEDURE|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
219436959|NCT02358564|PROCEDURE|Upper Endoscopy|
218823476|NCT04244266|OTHER|NO INTERVENTION, it is an observational study|No intervention
218823477|NCT01914250|DRUG|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
219009632|NCT00667368|DRUG|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
219009633|NCT01585194|BIOLOGICAL|Ipilimumab|Given IV
219009634|NCT01585194|OTHER|Laboratory Biomarker Analysis|Correlative studies
219009635|NCT01585194|BIOLOGICAL|Nivolumab|Given IV
218823478|NCT01678521|PROCEDURE|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
218823479|NCT00342134|PROCEDURE|Stem Cell Transplanataion|
218823480|NCT03958331|BEHAVIORAL|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
218823481|NCT03958331|BEHAVIORAL|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
218823482|NCT03958331|BEHAVIORAL|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
219009636|NCT01448811|DEVICE|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
219009637|NCT01448811|PROCEDURE|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
219009638|NCT05089760|OTHER|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
219009639|NCT05599607|DIETARY_SUPPLEMENT|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
219009640|NCT05599607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219009641|NCT00000854|DRUG|Nandrolone decanoate|
219009642|NCT02678260|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
219436960|NCT02358564|PROCEDURE|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
219436961|NCT01400139|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
219436962|NCT02251158|DRUG|Tipranavir oral solution|
219436963|NCT02251158|DRUG|Tipranavir capsules|
219436964|NCT02251158|DRUG|Ritonavir oral solution|
219436965|NCT02251158|DRUG|Ritonavir soft gel capsules|
219436966|NCT02251158|OTHER|High fat breakfast|
218823483|NCT04268914|DEVICE|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
218823484|NCT04268914|DEVICE|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
218823485|NCT04025892|BEHAVIORAL|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
218823486|NCT03765047|BEHAVIORAL|Intervention Arm|"The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
218823487|NCT04074564|COMBINATION_PRODUCT|MASCT-I, Camrelizumab,Apatinib|"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."
218823488|NCT02559973|DRUG|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
218823489|NCT02559973|DRUG|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
219009643|NCT03479606|BEHAVIORAL|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
219009644|NCT06494839|PROCEDURE|Bipolar electrocautery tonsillectomy technique|The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.
219199585|NCT06627075|PROCEDURE|Surface Guided RadioTherapy (SGRT) without mask|"Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan.~During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system.~Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm).~If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research.~Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist."
219436967|NCT00418717|DRUG|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
219436968|NCT04587596|OTHER|Pain education|70 minute lecture about chronic pain and one focus group afterwards
219436969|NCT03134612|DRUG|Ondansetron 8 mg|
219436970|NCT03134612|DRUG|Lidocain 40 mg|
219436971|NCT00249795|DRUG|Irbesartan|oral administration (tablets) once daily
219436972|NCT00249795|DRUG|placebo|oral administration (tablets) once daily
219436973|NCT01535612|DEVICE|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
219436974|NCT03179410|DRUG|Avelumab|10 mg/kg intravenously every 2 weeks
219436975|NCT05772442|DIAGNOSTIC_TEST|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
218823490|NCT05736393|DEVICE|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
218823491|NCT01003223|OTHER|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
218823492|NCT02025374|DRUG|Hyperbaric levobupivacaine|
218823493|NCT02025374|DRUG|Hyperbaric bupivacaine % 0.5|
218823494|NCT04456907|OTHER|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
218823495|NCT04456907|OTHER|saline injection|saline injection
218823496|NCT04256447|DIAGNOSTIC_TEST|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
218823498|NCT03940716|BEHAVIORAL|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
218823499|NCT02221973|DIETARY_SUPPLEMENT|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
218823500|NCT01722929|DEVICE|Skin sensor|
218823501|NCT01877174|DEVICE|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
218823502|NCT01877174|PROCEDURE|transcarotid stenting|
218823503|NCT01529229|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
218823504|NCT01529229|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
218823505|NCT01079364|DRUG|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
218823506|NCT01079364|DRUG|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
219436976|NCT02015806|BEHAVIORAL|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
218823507|NCT01079364|DRUG|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
218823508|NCT01171677|BEHAVIORAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
218823509|NCT04720378|BIOLOGICAL|ST266|1X ST266
218823510|NCT02308293|BEHAVIORAL|High intensity exercise|3x30 seconds 'all out' sprints
218823511|NCT02308293|BEHAVIORAL|Lay down comfortably|rest
218823512|NCT01143220|OTHER|No specific interventions|Observational investigation, only procedures according to local hospital standard.
218823513|NCT02194114|OTHER|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
218823514|NCT03534388|OTHER|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
218823515|NCT01847443|DRUG|Nicotine (2 mg)|2 mg nicotine gum in two formulations
218823516|NCT01847443|DRUG|Nicotine (4 mg)|4 mg nicotine gum in two formulations
218823517|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
218823518|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+5
219580240|NCT00835965|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
219580241|NCT00835965|DRUG|Placebo Dexamethasone|
219436977|NCT02015806|BEHAVIORAL|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
219436978|NCT02015806|BEHAVIORAL|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
218823519|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
218823520|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+1
218823521|NCT03381118|BIOLOGICAL|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
218823522|NCT05960487|OTHER|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
218823523|NCT03771339|PROCEDURE|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
218823524|NCT03771339|PROCEDURE|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
219436979|NCT04239170|DRUG|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
218823525|NCT03571971|OTHER|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
218823526|NCT03571971|OTHER|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
219436980|NCT05236959|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
219436981|NCT05236959|OTHER|Treatment as Usual|Following an initial interview session, patients continue with their usual care
218823527|NCT04264039|BIOLOGICAL|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
218823528|NCT04264039|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
218823529|NCT04264039|DRUG|Cytoxan|300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
218823530|NCT04264039|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
218823531|NCT06158867|DEVICE|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
218823532|NCT05425017|OTHER|Range of motion with spinal adjustment|With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion
218823533|NCT06341400|DRUG|DisitamabVedotinForIicction Toripalimab|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
218823534|NCT00578032|BEHAVIORAL|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
218823535|NCT05889091|OTHER|HRQOL instruments|These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
219436982|NCT04661852|DRUG|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
219436983|NCT04661852|DRUG|Topotecan|IV, over 30 minutes (schedule based upon dose level)
219436984|NCT04661852|DRUG|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
219436985|NCT04661852|DRUG|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
219436986|NCT02573337|DEVICE|Emervel Classic Lidocaine|Treatment of wrinkles and folds
219436987|NCT02573337|DEVICE|Emervel Deep Lidocaine|Treatment of wrinkles and folds
219436988|NCT00795171|DRUG|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
219436989|NCT00795171|DRUG|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
219436990|NCT00795171|DRUG|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
219436991|NCT02460978|DRUG|Dapagliflozin|Tablets
219436992|NCT02460978|OTHER|Placebo for dapagliflozin|Tablets
219436993|NCT04347278|DRUG|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
219436994|NCT01800851|OTHER|Energy expenditure evaluation in calorimetric chamber|
219195449|NCT06820619|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K1 and K2. Each lesson lasts for approximately 30-40 minutes.
219195450|NCT06817460|PROCEDURE|tran-sumbilical laparoendoscopic single-site surgery|Different types of surgery
219195451|NCT06817460|PROCEDURE|transvaginal natural orifice transluminal endoscopic surgery|Different types of surgery
219195452|NCT06817941|BEHAVIORAL|Speech only|Participants will be using a computer-based speech therapy games at home to train their speech clarity for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening.
218823536|NCT05889091|OTHER|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
218823537|NCT04826198|DRUG|AsiDNA|Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
218823538|NCT04826198|DRUG|Niraparib|"Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os"
218823539|NCT04826198|DRUG|Olaparib|Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.
218823540|NCT04826198|DRUG|Rucaparib|Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
218823541|NCT03747367|BEHAVIORAL|Insufficient Sleep|
218823542|NCT05326737|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
218823543|NCT05326737|OTHER|In hospital questionnaires|Patients are required to fill out the PCS questionnaire between on day -1 or +1.
218823544|NCT05326737|OTHER|Telephone contact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
218823545|NCT02279056|BEHAVIORAL|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
218823546|NCT02279056|BEHAVIORAL|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
218823547|NCT02421757|DEVICE|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
218823548|NCT02421757|DEVICE|Placebo|The placebo Transcutaneous device
218823549|NCT01752803|DIETARY_SUPPLEMENT|Probiotic|mix probiotic
218823550|NCT01752803|DIETARY_SUPPLEMENT|Placebo|placebo
218823551|NCT03846661|DEVICE|Physiomesh|difference in risk for recurrence and postoperative complication
218823552|NCT02382588|DRUG|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
218823553|NCT02382588|DRUG|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
218823554|NCT04940728|OTHER|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
219436995|NCT02301754|BIOLOGICAL|INVAC-1|intradermal injection combined with electroporation
219436996|NCT02091947|DEVICE|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
219436997|NCT03380000|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
219436998|NCT03380000|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
219436999|NCT04724512|DEVICE|suture|a type of suture used in entropion surgery
218823555|NCT02681393|BEHAVIORAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
218823556|NCT02681393|BEHAVIORAL|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
218823557|NCT03864068|OTHER|Placebo|Placebo
218823558|NCT03864068|DRUG|Inositol|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
218823559|NCT04035889|DIETARY_SUPPLEMENT|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
218823560|NCT04035889|DIETARY_SUPPLEMENT|Placebo|Placebo
218823561|NCT02701205|BIOLOGICAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
218823562|NCT02701205|BIOLOGICAL|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
218823563|NCT02701205|DRUG|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
218823564|NCT02685397|DRUG|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
218823565|NCT02685397|DRUG|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
219580242|NCT02343783|OTHER|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
218823566|NCT02685397|DRUG|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
218823567|NCT02685397|DRUG|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
218823568|NCT02685397|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
218823569|NCT05135728|BEHAVIORAL|Unstuck and On Target: Preschool|Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
218823570|NCT04722783|BEHAVIORAL|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, \& Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
218823571|NCT04722783|BEHAVIORAL|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
219195453|NCT06817941|BEHAVIORAL|Hand/Arm only|Participants will be using a computer-based therapy games at home to train their hand and arm movement for 8 weeks. While playing these games, a motion detector will be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
219195454|NCT06817941|BEHAVIORAL|Speech and arm combined|Participants will be using a computer-based therapy games at home to train their speech clarity and hand/arm movement together for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening. A motion detector will also be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
219195455|NCT06817070|DIAGNOSTIC_TEST|Food Consumption survey|A comprehensive survey was created using Google Forms® to collect sociodemographic, clinical, anthropometric, dietary data, and physical activity information from participants across most Mexican states. All self-administered surveys began with informed consent and were distributed via instant messaging (WhatsApp), social networks (Facebook, Twitter), and email using a snowball sampling method. Sociodemographic data included age, gender, and residence, while anthropometric data covered weight, height, and physical activity. Food intake was assessed using a 48-item semi-quantitative tool based on the National Health and Nutrition Survey 2021, with participants reporting the frequency and quantity of food consumed on a Likert scale. Responses were converted to daily consumption values and caloric intake using the Mexican System of Foods and Equivalents. Foods and beverages were categorized into twelve groups: six healthy (fruits, vegetables, legumes, natural dairy, white meat, nuts, and
218823572|NCT04722783|BEHAVIORAL|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
218823573|NCT04722783|BEHAVIORAL|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
218823574|NCT06482086|DRUG|Anlotinib|8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
219437000|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
219437001|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
219437002|NCT04263194|DEVICE|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
218823575|NCT06482086|DRUG|Lenvatinib|8/12 mg qd, po.
218823576|NCT06482086|DRUG|Sorafenib|0.4 g bid, po.
218823577|NCT06482086|DRUG|Donafenib|0.3 g bid, po.
218823578|NCT06482086|DRUG|Everolimus|10 mg qd, po.
219009645|NCT06494839|PROCEDURE|Cold steel dissection technique|The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
219437003|NCT04263194|DEVICE|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
219437004|NCT02021851|DRUG|Dexamethasone and aprepitant|
219437005|NCT02021851|DRUG|Dexamethasone and ondansetron|
219437006|NCT06174883|DIETARY_SUPPLEMENT|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
219763610|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
218823579|NCT06482086|DRUG|Apatinib|500 mg qd, po.
218823580|NCT06482086|DRUG|Dabrafenib + Trametinib|Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
218823581|NCT06482086|DRUG|Cabozantinib|Cabozantinib 60mg qd, po.
218823582|NCT06482086|DRUG|Vandetanib|Vandetanib 300mg qd, po.
218823583|NCT06482086|DRUG|Entrectinib|Entrectinib 600mg qd，po.
218823584|NCT06482086|DRUG|Pralsetinib|400mg qd, po.
218823585|NCT06482086|DRUG|Larotrectinib|100mg qd，po
218823586|NCT04351594|DRUG|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
218823587|NCT04351594|OTHER|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
218823588|NCT02177383|DIETARY_SUPPLEMENT|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
218823589|NCT02177383|DIETARY_SUPPLEMENT|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
218823590|NCT05910658|BEHAVIORAL|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
218823591|NCT01911351|DRUG|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
219009646|NCT00732615|DRUG|Placebo|Placebo for subcutaneous injection
219009647|NCT00732615|DRUG|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
219009648|NCT03600610|DEVICE|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
219763611|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
218823592|NCT04056247|OTHER|Plasma sample collection|Collect at least two plasma samples
218823593|NCT02530255|DIETARY_SUPPLEMENT|cycloastragenol|Oral telomerase activator - cycloastragenol.
218823594|NCT02530255|DIETARY_SUPPLEMENT|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
218823595|NCT05182918|OTHER|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
218823596|NCT05578014|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
218823597|NCT03848455|DIAGNOSTIC_TEST|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
218823598|NCT04821167|PROCEDURE|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
218823599|NCT02947191|BIOLOGICAL|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
218823600|NCT01329861|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
218823601|NCT05539326|OTHER|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
218823602|NCT02330614|OTHER|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
218823603|NCT02330614|OTHER|Nothing - control group|Only NEO-FFI test , data used as control
218823604|NCT03895073|OTHER|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
218823605|NCT04049773|PROCEDURE|haemodialysis|haemodialysis, thrice weekly in-center
218823606|NCT04046939|DRUG|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
218823607|NCT04046939|DRUG|Placebo|placebo twice daily oral dosing for up to 12 weeks
218823608|NCT00403130|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
218823609|NCT00403130|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
218823610|NCT00403130|DRUG|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
219009649|NCT05416320|DRUG|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
219009650|NCT05416320|DRUG|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
219009651|NCT02988505|OTHER|Standard care|
219009652|NCT01981291|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
219009653|NCT01981291|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
219763612|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
218823611|NCT06347913|RADIATION|ultrasound|Umbilical Artery Systolic/Diastolic Ratio and Amniotic Fluid Index in Prediction of Fetal Outcome in Term Pregnancies
218823612|NCT02622789|OTHER|Pilates Exercises|Pilates method based stability exercise intervention
218823613|NCT03704493|DIAGNOSTIC_TEST|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
218823614|NCT00806260|DRUG|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
218823615|NCT00806260|DRUG|Placebo|Placebo daily for 4 weeks
218823616|NCT00806260|OTHER|Alcohol|
218823617|NCT00806260|OTHER|alcohol placebo|fruit juice
218823618|NCT02162706|OTHER|Non intervention study|
218823619|NCT00767026|BEHAVIORAL|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
219009654|NCT01981291|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
219009655|NCT01981291|PROCEDURE|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
219009656|NCT01981291|DRUG|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
219009657|NCT01904682|DRUG|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
218823620|NCT00767026|BEHAVIORAL|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
218823621|NCT03250143|DRUG|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
219009658|NCT02829281|DRUG|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
219009659|NCT02829281|DRUG|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
219009660|NCT02829281|DRUG|Saline|Joint injection of Saline
219009661|NCT01333059|DRUG|Midazolam|
219009662|NCT01333059|DRUG|Normal saline|
219437007|NCT03549429|DEVICE|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
219437008|NCT05434104|OTHER|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
219437009|NCT05434104|DRUG|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
219437010|NCT02182297|DRUG|BI 201335 NA in single rising doses|
219437011|NCT02182297|DRUG|Placebo|
219437012|NCT05982639|PROCEDURE|two lung ventilation|The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
218823622|NCT01571622|DIETARY_SUPPLEMENT|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
219009663|NCT01333059|DRUG|Fentanyl|
219437013|NCT05982639|PROCEDURE|one lung ventilation|In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
218823623|NCT01571622|DIETARY_SUPPLEMENT|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
219009664|NCT05576493|PROCEDURE|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
219009665|NCT05576493|PROCEDURE|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
219009666|NCT05576493|PROCEDURE|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
219009667|NCT05576493|PROCEDURE|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
219009668|NCT02697175|DEVICE|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
219009669|NCT02697175|OTHER|No Live Video-Colposcopy|The TV will be shut off during colposcopy
219009670|NCT04990154|BEHAVIORAL|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
219437014|NCT05911412|BEHAVIORAL|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
219437015|NCT05674604|PROCEDURE|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
219437016|NCT00279032|DRUG|GW406381|
219009671|NCT06137716|DEVICE|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
219009672|NCT03566823|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
219009673|NCT03566823|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
219437017|NCT06239324|DRUG|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
219437018|NCT00201760|DRUG|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
218823624|NCT00002429|DRUG|Lamivudine/Zidovudine|
218823625|NCT00002429|DRUG|Nelfinavir mesylate|
218823626|NCT00002429|DRUG|Stavudine|
218823627|NCT00002429|DRUG|Didanosine|
218823628|NCT01470105|OTHER|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
218823629|NCT00708409|PROCEDURE|Cardiac valve surgery|Different autograft implantation techniques.
218823630|NCT01344343|OTHER|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
219437019|NCT00201760|DRUG|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
219437020|NCT00201760|DRUG|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
219437021|NCT04155125|DRUG|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
219437022|NCT04155125|DRUG|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
218823631|NCT02590289|DRUG|BBI-5000|BBI-5000 low dose, middle dose, or high doses
218823632|NCT06590181|OTHER|Yoga Nidra|This protocol is derived from The Origin and Clinical Relevance of Yoga Nidra (Pandi-Perumal, S. R. 2022)
218823633|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intention|Yoga Nidra with Pain Acceptance Intention
218823634|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery
218823635|NCT05814237|OTHER|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
218823636|NCT06608589|OTHER|CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers|COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
218823637|NCT02311725|BEHAVIORAL|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
218823638|NCT02311725|BEHAVIORAL|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
219009674|NCT03109574|DEVICE|BioFlo DuraMax Chronic Hemodialysis Catheter|
219009675|NCT03109574|DEVICE|Standard of Care Catheter|
219009676|NCT00528333|DRUG|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
218823639|NCT06715995|DEVICE|Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA)|Participants will receive light stimulation using the Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA) for 1 hour per day, 7 days a week, over 4 weeks, for a total of 28 hours.
218823640|NCT06715774|DEVICE|Impact of Twin Block and Motion above Hyoid bone|All patients were submitted to preoperative and postoperative lateral teleradiography (Vatech D052SB, Puteaux, France), with the following exposure parameters: 75KV, Intensity10mA, exposition times 11s28, 112,8 mAs, using the Frankfort plane as reference parallel to the floor; moreover, patients were required to avoid moving and swallowing. Afterwards, digital datasets were uploaded and aligned into a digital therapeutic planning software (Orthalis®, Orqualceph®,group orqual) to accurately record the position changes of the hyoid bone at horizontal, vertical, and angular level, according the gender, facial biotype and airway complex, by measuring the following anatomical references:
219009677|NCT00528333|DRUG|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
219009678|NCT00528333|DRUG|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
219009679|NCT02733367|DRUG|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
219009680|NCT01269060|PROCEDURE|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
219437023|NCT00273299|DRUG|valsartan plus hydrochlorothiazide|
219437024|NCT02655406|OTHER|Class 2 compression stockings|
219437025|NCT05663242|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
219437026|NCT05663242|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
219437027|NCT03990259|OTHER|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
219437028|NCT04939870|DIAGNOSTIC_TEST|Biochemical parameters evaluation|selected biochemical parameters
219763613|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
219763614|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
218823641|NCT05618444|BEHAVIORAL|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
218823642|NCT03303729|DIETARY_SUPPLEMENT|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
218823643|NCT03303729|DIETARY_SUPPLEMENT|Cluster Dextrin|75 grams of Cluster Dextrin
218823644|NCT03303729|DIETARY_SUPPLEMENT|Placebo|75 grams of Glucose
218823645|NCT03559270|DRUG|Baricitinib|Administered orally
219437029|NCT04212052|RADIATION|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
218823646|NCT01850953|DRUG|Varenicline|This is an approved smoking cessation medication.
218823647|NCT01850953|DRUG|Placebo|
218823648|NCT05187299|OTHER|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
218823649|NCT03836404|DEVICE|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
219009681|NCT04429737|DIETARY_SUPPLEMENT|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
219437030|NCT04212052|DRUG|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
219437031|NCT04212052|DRUG|consolidation immunotherapy|Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
219009682|NCT04429737|DIETARY_SUPPLEMENT|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
219195456|NCT06820775|COMBINATION_PRODUCT|A TRIPLE INTERVENTION NUTRITION AND PHYSICAL ACTIVITY|"Intervention group: Health advice and triple intervention: 15 ml apple cider vinegar diluted in a glass of water before meals, order in the sequence of meals (sequence of food intake: first vegetables, second proteins, third fats and finally carbohydrates) and physical activity immediately after meals.~Description of all interventions:~Patients in both groups: all patients will receive health advice on sports practice from the WHO, Osakidetza and the Basque Government."
219437032|NCT06365372|DIAGNOSTIC_TEST|Western blot|Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
218823650|NCT00548535|PROCEDURE|Reliability of complication assessment|
218823651|NCT04750083|DRUG|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
218823652|NCT04750083|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
218823653|NCT04750083|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
218823654|NCT04750083|DRUG|cisplatin/carboplatin|cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
218823655|NCT03910075|BEHAVIORAL|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
218823656|NCT03910075|BEHAVIORAL|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
218823657|NCT03910075|BEHAVIORAL|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
218823658|NCT03539679|OTHER|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
218823659|NCT03436342|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
218823660|NCT06278493|DRUG|AL2846 capsules|AL2846 is a multi -target receptor tyrosine kinase inhibitor.
218823661|NCT06278493|DRUG|Gemzar|It is a chemotherapeutic drug.
218823662|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
218823663|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
218823664|NCT05815888|DIAGNOSTIC_TEST|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
218823665|NCT06927661|BEHAVIORAL|Consumption of vegetables|ENSAND 2.0 is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. ENSAND aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables.
218823666|NCT06931106|BEHAVIORAL|HAPA and CEI behavioral intervention|The intervention group will receive a 3-month technology-facilitated PrEP intervention and tailored messages will be developed using BCTs based on theoretical guidance. PrEP teleconsultations will be delivered by certified healthcare professionals, including infectious disease specialists, CDC-affiliated prevention officers, and MSM community leaders. Participants will be stratified into peer cohorts through algorithm-driven grouping based on demographic characteristics. Six participants will form a peer group, and the economic incentive amount will be based on the group-level PrEP initiation rates (verified by physician prescriptions). The economic incentive will decrease progressively based on the average completion rate within the group and will be divided into three tiers: 22 USD (completion rate of 80-100%), 11 USD (completion rate of 50-79%), and 0 USD (completion rate \<50%).
218823667|NCT06931106|BEHAVIORAL|HAPA-based intervention|This group receives information pushes via a mini-program (3 messages per week) and two brief PrEP consultations; the first brief consultation is delivered jointly by community volunteers and a physician immediately after the baseline survey completion, based on a standardized consultation outline, and the second brief consultation is delivered jointly by community volunteers and a physician after the completion of the first monthly assessment (conducted within the mini-program), based on the standardized consultation outline and the results of that monthly assessment.
219009683|NCT04429737|DIETARY_SUPPLEMENT|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
219009684|NCT05298280|DEVICE|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
219437033|NCT05410899|OTHER|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
219437034|NCT00122304|DRUG|eculizumab|
219437035|NCT05243719|BIOLOGICAL|ADP101|Active dry powder formulation at various volumes.
219437036|NCT01962688|DEVICE|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
219437037|NCT01962688|DEVICE|Sham ultrasound|sham ultrasound to facilitate blinding
219437038|NCT02890732|DEVICE|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
219437039|NCT04437173|DEVICE|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
219580243|NCT05669183|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
219580244|NCT04934449|DEVICE|Occlusal splint|Using occlusal splints during sleep for 2 months
218823668|NCT06165055|DIAGNOSTIC_TEST|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
218823669|NCT06947811|DRUG|Almonertinib|Patients will be treated with Almonertinib, 110 mg p.o., daily
219009685|NCT05298280|DEVICE|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
219009686|NCT05395520|OTHER|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
219009687|NCT06489652|DRUG|89Zr-Oxine-RY_SW01 Cell Injection|Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY\_SW01 cells injection
219009688|NCT01839773|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
219009689|NCT01839773|DRUG|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
219009690|NCT02310945|OTHER|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
219195457|NCT04861740|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
219580245|NCT00390130|DRUG|Pentacel (DPTaP+Hib)|
219580246|NCT00390130|DRUG|Prevnar (conjugated pneumococcal vaccine)|
219580247|NCT03267875|PROCEDURE|Blood Test|draw out 2 blood tubes from a patient
218823670|NCT06947811|DRUG|Palbociclib|Patients will be treated with Palbociclib, 125 mg(dose determined from Part one of study) p.o., daily
218823671|NCT06951542|BEHAVIORAL|Stigma Reduction Counseling|The stigma reduction counseling sessions will include psychoeducation and activities to challenge myths and stereotypes, cope with experiences of discrimination, and overcome self-stigma.
218823672|NCT02982226|OTHER|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
219009691|NCT01341262|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
219009692|NCT01341262|DRUG|Dexamethasone|"* INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
219009693|NCT01341262|DRUG|Zoledronic acid|"* INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
219009694|NCT01341262|DRUG|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
219009695|NCT01341262|DRUG|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
219009696|NCT01348347|DRUG|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
218823673|NCT02982226|OTHER|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
218823674|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
218823675|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
219009697|NCT01348347|DRUG|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
219009698|NCT01348347|DRUG|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
219009699|NCT02507674|DEVICE|ultrasound|
219009700|NCT06313931|DEVICE|cognitive training via immersive virtual reality|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
219009701|NCT06313931|OTHER|cognitive training via paper and pencil|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
219009702|NCT06313931|OTHER|motor stimulation|motor stimulation for 12 sessions (20 minutes per session)
219195458|NCT04861740|OTHER|Screening Intervention|Autism screening intervention only.
219195459|NCT06657586|OTHER|neuromuscular exercises|The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
219580248|NCT01805830|DRUG|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
219580249|NCT01805830|DRUG|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
219580250|NCT02005887|DRUG|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
219437040|NCT03655574|BEHAVIORAL|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
218823676|NCT06132464|BEHAVIORAL|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
218823677|NCT02710188|DRUG|HTL0009936 modified release|HTL0009936 modified release
219009703|NCT02539277|DRUG|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
219009704|NCT02539277|DRUG|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
219009705|NCT02539277|DRUG|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
219009706|NCT02539277|DRUG|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
219009707|NCT03418298|BEHAVIORAL|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
219009708|NCT01683955|DRUG|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
219437041|NCT03655574|OTHER|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
219437042|NCT02186756|OTHER|EMG-Biofeedback and Usual care|Please refer to arm description
219580251|NCT02005887|DRUG|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
219580252|NCT02005887|DRUG|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
218823678|NCT02710188|DRUG|HTL0009936 immediate release|HTL0009936 immediate release
218823679|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
218823680|NCT06042426|DRUG|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
218823681|NCT06042426|DRUG|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
218823682|NCT06042426|DRUG|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
218823683|NCT02664480|OTHER|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
218823684|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
218823685|NCT02071901|DRUG|eltrombopag olamine|Given PO
218823686|NCT04754763|DRUG|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
218823687|NCT04754763|DRUG|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
218823688|NCT02835586|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
219009709|NCT01683955|DRUG|Placebo|100mL 0.9% sterile saline
219580253|NCT01550744|DRUG|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
219009710|NCT03402685|DEVICE|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
219009711|NCT00278083|DRUG|Study drug administration|
219009712|NCT00278083|PROCEDURE|Tuberculin intradermal skin test|
219009713|NCT00278083|PROCEDURE|Lung function test for FEV1|
219009714|NCT00278083|PROCEDURE|Asthma symptom scores diary|
219009715|NCT00278083|PROCEDURE|Quality of life diary|
219580254|NCT01550744|DRUG|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
219580255|NCT01550744|DRUG|Placebo|Form = Injection, route = subcutaneous
219580256|NCT01534923|BEHAVIORAL|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
219580257|NCT01457261|DRUG|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
219009716|NCT00278083|PROCEDURE|Breath nitric oxide|
219009717|NCT00278083|PROCEDURE|Breath condensate|
218823689|NCT02971709|BEHAVIORAL|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
219009718|NCT00278083|PROCEDURE|Sputum induction|
219009719|NCT00278083|PROCEDURE|Blood sampling|
218823690|NCT02890277|DEVICE|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
218823691|NCT02890277|DRUG|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
218823692|NCT03672149|DRUG|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
219009720|NCT00278083|PROCEDURE|Urinalysis|
219009721|NCT05034770|OTHER|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
219009722|NCT00539409|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
219009723|NCT01840709|BEHAVIORAL|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
219009724|NCT03580317|OTHER|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
219437043|NCT06403748|DIETARY_SUPPLEMENT|Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.|The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
219437044|NCT06403748|OTHER|Placebo|Placebo
219437045|NCT02292498|DEVICE|FLIR ONE|
219009725|NCT03580317|OTHER|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
219437046|NCT04871685|DIAGNOSTIC_TEST|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
219437047|NCT03148587|BEHAVIORAL|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
219437048|NCT03148587|BEHAVIORAL|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
218823693|NCT04630925|OTHER|isCGM|As previously described
219437049|NCT03404271|DIETARY_SUPPLEMENT|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
219437050|NCT03404271|OTHER|Resistance Training|Performing supervised resistance training three times per week.
219437051|NCT03404271|DIETARY_SUPPLEMENT|Protein Supplementation|Consuming a protein supplement daily.
219437052|NCT03404271|BEHAVIORAL|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
218823694|NCT00517699|DRUG|rituximab [MabThera/Rituxan]|750mg/m2 iv
218823695|NCT00517699|DRUG|Methotrexate|8g/m2 iv
218823696|NCT00517699|DRUG|Cytarabine|2g/m2 iv
218823697|NCT03951610|DEVICE|Test lens|contact lens
218823698|NCT03951610|DEVICE|Control lens|contact lens
219009726|NCT03580317|OTHER|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
219009727|NCT03580317|OTHER|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
219195460|NCT06657586|OTHER|conservative treatment|The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
219009728|NCT05657678|DRUG|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
219009729|NCT05657678|DRUG|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
219009730|NCT00293644|DRUG|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
218823699|NCT00540696|DRUG|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
218823700|NCT02332187|DEVICE|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
218823701|NCT02332187|DEVICE|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
218823702|NCT05141838|DRUG|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
218823703|NCT05141838|DIETARY_SUPPLEMENT|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
218823704|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
218823705|NCT00980148|DRUG|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
218823706|NCT00980148|DRUG|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
218823707|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
218823708|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
218823709|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
219437053|NCT03143868|BEHAVIORAL|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
219437054|NCT00439153|DEVICE|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
218823710|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
218823711|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
218823712|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
218823713|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
218823714|NCT03504228|DEVICE|Roadsaver|Dual layer micromesh Roadsaver carotid stent
218823715|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
219580258|NCT01660334|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
218823716|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
218823717|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
218823718|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
218823719|NCT00519727|DRUG|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
218823720|NCT01394380|OTHER|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
218823721|NCT02714660|OTHER|none, observational study|
218823722|NCT05083078|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
218823723|NCT05083078|DRUG|Risankizumab|Risankizumab will be administered subcutaneously.
218823724|NCT00644839|DRUG|CP-945,598|Administration of CP-945,598 alone in period 1
218823725|NCT00644839|DRUG|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
218823726|NCT04258852|DRUG|Low strength nicotine e-liquid|Low strength nicotine e-liquid
218823727|NCT04258852|DRUG|High strength nicotine e-liquid|High strength nicotine e-liquid
218823728|NCT02030132|BEHAVIORAL|Feedback compared to 75th percentile|
218823729|NCT02030132|BEHAVIORAL|Forgiveness|
218823730|NCT02030132|BEHAVIORAL|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
218823731|NCT02030132|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
219195461|NCT06657807|BEHAVIORAL|Online CBT|Online CBT targeting anxiety in pediatric asthma
219437055|NCT04239547|PROCEDURE|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
219437056|NCT04239547|PROCEDURE|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
218823732|NCT01643681|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
218823733|NCT04274595|DRUG|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
218823734|NCT04681989|BEHAVIORAL|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
218823735|NCT02361671|OTHER|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
219009731|NCT04337983|DEVICE|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
219009732|NCT04337983|DEVICE|Echocardiography|Daily echocardiography evaluation
219009733|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 1|Containing macro and micronutrients
219009734|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 2|Containing macro and micronutrients
219009735|NCT02051777|DIETARY_SUPPLEMENT|Dietary Advice|
219195462|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
219437057|NCT04416945|OTHER|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
219437058|NCT04416945|OTHER|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
219580259|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
219580260|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
218823736|NCT04635137|PROCEDURE|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
218823737|NCT00441766|DRUG|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
218823738|NCT00441766|DRUG|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
218823739|NCT00441766|DRUG|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
218823740|NCT00441766|DRUG|placebo|Part A: placebo capsule every 12 hours for 4 weeks
219009736|NCT06211348|DEVICE|Genomic Sequencing|Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
219009737|NCT03760783|OTHER|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
219009738|NCT00552916|DEVICE|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
219009739|NCT00552916|DEVICE|Compex Motion Stimulator|'False' FES
219009740|NCT02095574|DRUG|[14C]ABT-199 (GDC-0199)|\[14C\]ABT-199 will be administered as a single oral administration
219009741|NCT00748033|DEVICE|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
219009742|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
219009743|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
219195463|NCT05759039|PROCEDURE|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
219195464|NCT05759039|PROCEDURE|Tibial tubercle osteotomy|Tibial tubercle osteotomy
219195465|NCT05625204|BEHAVIORAL|Center based attention (stretching only) control|Center based attention (stretching only) control
219195466|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
218823741|NCT01732991|DEVICE|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
218823742|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
218823743|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
218823744|NCT04658927|DRUG|Dexamethasone, 0.4mg|iLUX + dextenza
218823745|NCT04658927|DRUG|Prednisone acetate|Prednisolone acetate 1% and iLux
218823746|NCT04658927|OTHER|Control|iLUX alone.
219195467|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
219437059|NCT04416945|OTHER|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
219437060|NCT05194787|DIAGNOSTIC_TEST|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
219437061|NCT03900741|PROCEDURE|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
219437062|NCT03900741|PROCEDURE|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
219437063|NCT00141557|DRUG|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
218823747|NCT03500211|DRUG|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
218823748|NCT03500211|OTHER|Sham Topical Patch|Sham patch after cesarean section delivery.
218823749|NCT05857566|DRUG|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
218823750|NCT04985084|BEHAVIORAL|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
218823751|NCT04985084|OTHER|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
218823752|NCT02250872|DRUG|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
218823753|NCT02250872|DRUG|Placebo|100mg in 2 divided doses plus cisplatin
218823754|NCT02250872|DRUG|Cisplatin|All patients will receive intravenous cisplatin
218823755|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
219195468|NCT06820086|DRUG|Rosuvastatin 20mg|Preventive statin treatment with rosuvastatin 20mg, 1 tablet per day, for healthy individuals with top 20% CAD PRS.
219195469|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
219195470|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
219437064|NCT00141557|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
219437065|NCT04006535|GENETIC|genetic analysis|Saliva sample collection for genetic analysis
219437066|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
219437067|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
218823756|NCT04614844|BEHAVIORAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
218823757|NCT04614844|BEHAVIORAL|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
218823758|NCT00225914|DRUG|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
218823759|NCT00225914|DRUG|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
218823760|NCT03420742|DRUG|Midazolam|Midazolam syrup.
218823761|NCT03420742|DRUG|Brigatinib|Brigatinib tablets.
219195471|NCT06820749|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 12-week treatment period in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
218823762|NCT01550601|PROCEDURE|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
218823763|NCT05192421|BEHAVIORAL|Wellness Education|Receive wellness education through a weekly email and web portal content.
218823764|NCT05192421|BEHAVIORAL|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
218823765|NCT05192421|BEHAVIORAL|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
218823766|NCT02799550|BIOLOGICAL|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
218823767|NCT04593121|DRUG|BIIB107|Administered as specified in the treatment arm.
218823768|NCT04593121|DRUG|Placebo|Administered as specified in the treatment arm.
218823769|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
218823770|NCT06251414|BEHAVIORAL|Exercise Intervention|Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.
218823771|NCT06251414|BEHAVIORAL|Instrument-Assisted Soft Tissue Mobilization|Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.
218823772|NCT06251414|BEHAVIORAL|Tuinal|Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
218823773|NCT04927676|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.
218823774|NCT04298489|DIAGNOSTIC_TEST|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
218823775|NCT00099021|DRUG|pioglitazone hydrochloride|Given PO
219009744|NCT02104713|BIOLOGICAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
219009745|NCT01474057|BEHAVIORAL|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
219437068|NCT00669032|DEVICE|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
219437069|NCT00669032|OTHER|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
219195472|NCT06820749|DRUG|Placebo|the placebo comparator of study
218823776|NCT02189889|DRUG|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
218823777|NCT02189889|DRUG|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
218823778|NCT06209944|PROCEDURE|Cardiopulmonary resuscitation|cardiac compression, endotracheal intubation, defibrillation, and use of cardiovascular medications, to restore circulation in patients with cardiac arrest
218823779|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
218823780|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
218823781|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
218823782|NCT00381654|DRUG|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
218823783|NCT00290810|BIOLOGICAL|bevacizumab|Given IV
218823784|NCT03224364|PROCEDURE|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
218823785|NCT03224364|PROCEDURE|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
219009746|NCT01474057|OTHER|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
219009747|NCT03038958|DRUG|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
219195473|NCT06648928|BEHAVIORAL|Clinician Supported PTSD Coach|Combines self-managed PTSD Coach application with four 20-30 minute sessions delivered by a clinician. The app includes modules on learning about PTSD, self-assessment, symptom management, and finding support.
219195474|NCT06648928|BEHAVIORAL|Self Managed PTSD Coach|A widely available mobile application designed to help individuals manage PTSD symptoms available in English and Spanish.
219580261|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
218823786|NCT03725956|PROCEDURE|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
219009748|NCT03038958|DRUG|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
219009749|NCT04433650|DEVICE|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
219009750|NCT04391127|DRUG|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
218823787|NCT04419545|DIAGNOSTIC_TEST|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
218823788|NCT06159257|DIAGNOSTIC_TEST|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
218823789|NCT00003365|DIETARY_SUPPLEMENT|curcumin|
218823790|NCT00003365|DIETARY_SUPPLEMENT|rutin|
218823791|NCT00003365|DRUG|quercetin|
218823792|NCT00003365|DRUG|sulindac|
218823793|NCT04608877|BEHAVIORAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
219009751|NCT04391127|DRUG|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
219009752|NCT04391127|DRUG|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
219009753|NCT01649661|BEHAVIORAL|questionnaire|
219009754|NCT03551054|BEHAVIORAL|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
219195475|NCT06856564|PROCEDURE|Frenectomy|The study involves using a diode laser and scalpel to treat ankyloglossia in cases that are unresponsive to tongue exercises or exhibit severe restrictions. The techniques employed range from simple frenotomy to complex frenuloplasty, depending on the severity of the condition. Electrocautery is frequently used to minimize bleeding, although it may result in scar formation.
218823794|NCT04608877|BEHAVIORAL|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
218823795|NCT03492047|DIETARY_SUPPLEMENT|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
218823796|NCT03492047|DIETARY_SUPPLEMENT|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
218823797|NCT03492047|DRUG|Paclitaxel|Paclitaxel 80mg /m2 IV
218823798|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
218823799|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
218823800|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
218823801|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
218823802|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
218823803|NCT01883700|OTHER|Boiled Pasta|
218823804|NCT01883700|OTHER|Boiled Chickpeas with Oil|
218823805|NCT01883700|OTHER|Instant Mashed Potatoes|
218823806|NCT01883700|OTHER|Instant Mashed Potatoes with Egg Whites|
218823807|NCT00477815|BIOLOGICAL|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
218823808|NCT00477815|DRUG|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
218823809|NCT00477815|BIOLOGICAL|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
218823810|NCT00477815|BIOLOGICAL|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
219763615|NCT05801939|DRUG|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
219763616|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
219763617|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
219763618|NCT00262470|DRUG|Acetazolamide|250 mg PO x 1
218823811|NCT00477815|RADIATION|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
218823812|NCT00477815|BIOLOGICAL|111In Zevalin|5.0 mCi by IV
218823813|NCT02070497|OTHER|case management|case management group will accept the case manager's service; the control group will just accept the routine care
218823814|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
218823815|NCT02078752|DRUG|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
218823816|NCT02078752|DRUG|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
218823817|NCT02398526|DRUG|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
218823818|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
218823819|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
219009755|NCT03551054|BEHAVIORAL|Health Education|
219009756|NCT02769455|OTHER|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
219195476|NCT06856785|OTHER|Resonance Tube Voice Therapy in Water|Resonance Tube of 28 cm in length and 9 mm diameter for adults will be submerged into a bowl of water .Both flexible soft walled tubes,glass tubes or straws can be used
219195477|NCT06855589|DRUG|6 months of Eligard|Total of two 3-month injections of a LHRH agonist for total duration of 6 months
218823820|NCT00775268|PROCEDURE|Biopsy|Biopsy taken
218823821|NCT00775268|DIAGNOSTIC_TEST|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
218823822|NCT00775268|OTHER|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
218823823|NCT00775268|PROCEDURE|computed tomography|Undergo scans
218823824|NCT00775268|PROCEDURE|fine-needle aspiration|sample collected
218823825|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
219195478|NCT06855589|DRUG|12 months of Eligard|Total of four 3-month injections of a LHRH agonist for total duration of 12 months
218823826|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
218823827|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
218823828|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
218823829|NCT02921295|DEVICE|Sidekick Stubbies|
218823830|NCT05937529|OTHER|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
218823831|NCT05937529|OTHER|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
218823832|NCT00895362|DRUG|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
218823833|NCT00895362|DRUG|Cetuximab|Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
218823834|NCT05921617|OTHER|No intervention|Routine care
218823835|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
218823836|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
218823837|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
218823838|NCT06170151|DIAGNOSTIC_TEST|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
218823839|NCT00196677|DRUG|Vitamins, minerals and medical herbs|
218823840|NCT05411107|PROCEDURE|Biospecimen Collection|Undergo collection of sputum sample
218823841|NCT05411107|PROCEDURE|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
218823842|NCT05411107|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
218823843|NCT05411107|DRUG|Iloprost|Given PO
218823844|NCT05411107|DRUG|Placebo Administration|Given PO
218823845|NCT05411107|OTHER|Questionnaire Administration|Ancillary studies
219009757|NCT02769455|OTHER|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
219009758|NCT01958320|OTHER|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
219009759|NCT01958320|OTHER|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
219195479|NCT06855589|RADIATION|prostate SBRT or prostate brachytherapy with radiation therapy|Patients may receive prostate stereotactic body radiation therapy or a combination of high-dose rate brachytherapy with radiation therapy; as per the treating physician's preference
219763619|NCT00262470|DRUG|Atomoxetine|10-40 mg PO x 1 dose
218823846|NCT00848419|DRUG|Epidural administration of bolus|
218823847|NCT03632096|RADIATION|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
218823848|NCT03632096|RADIATION|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
218823849|NCT00968773|DEVICE|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
218823850|NCT00968773|DEVICE|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
218823851|NCT00286897|DRUG|E2007|
218823852|NCT03420937|DRUG|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
218823853|NCT03420937|DRUG|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
218823854|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
219009760|NCT01958320|DRUG|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
219763620|NCT00262470|OTHER|NO Drug|No intervention - just monitoring
219763621|NCT00262470|DRUG|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
218823855|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
218823856|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
218823857|NCT02901691|OTHER|musical rhythmic stimulation|
218823858|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
218823859|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
218823860|NCT01642550|DRUG|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
218823861|NCT01642550|DRUG|Placebo|
218823862|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
218823863|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
218823864|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
218823865|NCT01194245|DRUG|Insulin lispro|
218823866|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
218823867|NCT01194245|DRUG|Insulin aspart|
218823868|NCT01194245|DRUG|Insulin glulisine|
218823869|NCT01194245|DRUG|Insulin glargine|
218823870|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"\- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
218823871|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"\- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
219009761|NCT00722033|DRUG|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
219009762|NCT01443988|DEVICE|iStent|Implantation of two iStent devices
219009763|NCT01443988|DRUG|Travoprost|Travoprost drops
218823872|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
218823873|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
218823874|NCT03381664|DRUG|AVP-923|capsule
219009764|NCT00241813|BEHAVIORAL|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
219009765|NCT00241813|BEHAVIORAL|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
219009766|NCT00241813|BEHAVIORAL|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
219009767|NCT01334814|DEVICE|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
219009768|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
219009769|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base|toothbrushing 2x a day for 2 minutes each time
219009770|NCT00267384|DRUG|Oral N-Acetylcysteine|
219009771|NCT00004860|DRUG|leucovorin calcium|
218823875|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
218823876|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
219009772|NCT00004860|DRUG|tegafur-uracil|
219009773|NCT05999136|OTHER|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
219009774|NCT05999136|OTHER|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
218823877|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
218823878|NCT01173510|DRUG|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
218823879|NCT01173510|DRUG|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
218823880|NCT03971929|DRUG|SHR0532|once daily(QD) for 4weeks
218823881|NCT03971929|DRUG|SHR placebo|once daily(QD) for 4weeks
218823882|NCT03971929|DRUG|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
218823883|NCT05069649|DRUG|Ergoferon|Tablet for oral use.
218823884|NCT05069649|DRUG|Placebo|Tablet for oral use.
218823885|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
218823886|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
218823887|NCT04555174|DEVICE|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
218823888|NCT05262413|DRUG|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
218823889|NCT02603276|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
218823890|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
218823891|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
218823892|NCT04749147|OTHER|Black and White Printed Survey|This survey will feature black and white text and graphics.
218823893|NCT04749147|OTHER|Red Printed Survey|This survey will feature red text and graphics.
218823894|NCT06450015|DEVICE|Vacuum Assisted Closure|VAC applied after debridement and saline packing
218823895|NCT06450015|OTHER|Saline Dressing|Wound was managed by saline dressing
219763622|NCT00262470|DRUG|Entacapone|Entacapone 200-400 mg PO x 1 dose
218823896|NCT05207111|DRUG|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
219580262|NCT00311311|DRUG|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
219580263|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
219763623|NCT00262470|DRUG|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
218823897|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
218823898|NCT02051478|OTHER|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
218823899|NCT02051478|OTHER|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
218823900|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
218823901|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
218823902|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
218823903|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
218823904|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
218823905|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218823906|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
218823907|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
218823908|NCT01662739|BEHAVIORAL|Questionnaire|
218823909|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
218823910|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
218823911|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
218823912|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
218823913|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
218823914|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
218823915|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
218823916|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
219763624|NCT00262470|DRUG|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
218823917|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
218823918|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
218823919|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
219009775|NCT05999136|OTHER|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
219009776|NCT00191789|DRUG|gemcitabine|1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
219009777|NCT00191789|DRUG|doxorubicin|60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
219009778|NCT00191789|DRUG|cisplatin|70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
219009779|NCT00191789|PROCEDURE|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
219009780|NCT00721552|DRUG|Sitagliptin 100 mg|28 days administration of 100 mg daily
219009781|NCT00721552|DRUG|Prednisolone 30 mg|14 days administration of 30 mg daily
219009782|NCT00721552|DRUG|Sitagliptin-placebo|28 days administration once daily
219437070|NCT03536650|DEVICE|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
218823920|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
218823921|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
218823922|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
218823923|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
218823924|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
218823925|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
218823926|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
218823927|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
218823928|NCT03044275|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
218823929|NCT03044275|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
218823930|NCT00044369|PROCEDURE|Varicocele repair|
218823931|NCT04963816|PROCEDURE|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5\_2 MHz with the patient in supine position and the block will be done by anterior approach
218823932|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
219009783|NCT00721552|DRUG|Prednisolone-placebo|14 days administration once daily
219437071|NCT03587818|OTHER|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
219437072|NCT00602511|DRUG|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
219763625|NCT00262470|DRUG|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
218823933|NCT04963816|DRUG|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
218823934|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
218823935|NCT06462313|DRUG|Dobutamine|Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
218823936|NCT06462313|DRUG|Norepinephrine|Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
218823937|NCT03573245|DRUG|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
218823938|NCT04187261|PROCEDURE|hip fracture surgeries|fixation or replacement
218823939|NCT06357845|OTHER|Survey|Participants will complete a brief web-based survey asking about their experiences related to the February 3, 2023 train derailment, health experiences and concerns following the derailment, and background information regarding their health history. The survey will last approximately 15 minutes.
219009784|NCT00759811|DRUG|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
219009785|NCT00759811|DRUG|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
219009786|NCT01922206|BEHAVIORAL|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
219763626|NCT00262470|DRUG|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
219763627|NCT00262470|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
218823940|NCT06357845|OTHER|Biological specimen collection|Participants may possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. Participants will be asked which samples they are interested in providing. Participants will receive a specific sample collection kit based on their selection. For blood samples, participants will receive a mailed collection kit at their mailing address. A member of the research team will reach out to schedule blood sample collection, which may take place at home with a trained phlebotomist or at a designated collection site. A total of 1-2 teaspoons of blood (5-10 milliliters) will be collected at a one-time blood draw. For either saliva, hair, and/or toenail clippings, participants will be sent a sample collection kit and receive instructions at their mailing address. This kit also includes a return mailing envelope. Participants will provide the selected samples in the collection kits, place them in the return mailing envelope, and send them back to the research team.
218823941|NCT06357845|OTHER|Communications about study updates and future research opportunities|By consenting to participate in this study, the research team will send updates about the research results and any additional study opportunities to participants.
218823942|NCT06357845|OTHER|Qualitative interview|A total of 40 study participants will be recruited to participate in a 90-minute interview with open-ended questions. The interviews will be video and audio-recorded.
218823943|NCT00977210|DRUG|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
218823944|NCT02614820|PROCEDURE|Remote Ischemic Preconditioning Training Apparatus|
218823945|NCT03051191|DIAGNOSTIC_TEST|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
218823946|NCT05722587|OTHER|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
218823947|NCT00000438|DRUG|naltrexone (Revia)|
218823948|NCT02590107|DIETARY_SUPPLEMENT|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
218823949|NCT02590107|DIETARY_SUPPLEMENT|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
219009787|NCT03577353|BEHAVIORAL|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
219437073|NCT00602511|DRUG|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
219437074|NCT06131229|BEHAVIORAL|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
219437075|NCT06131229|BEHAVIORAL|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
219437076|NCT05595603|PROCEDURE|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
219437077|NCT05595603|PROCEDURE|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
219437078|NCT01607073|DRUG|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
218823950|NCT02590107|DIETARY_SUPPLEMENT|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
218823951|NCT02590107|OTHER|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
218823952|NCT01896973|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
218823953|NCT00443742|PROCEDURE|Validation|
218823954|NCT06458556|DEVICE|Treatment with Morpheus|Radiofrequency device treatment
218823955|NCT03796910|DRUG|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
219009788|NCT03577353|BEHAVIORAL|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
219009789|NCT02236195|DRUG|Mocetinostat|
218823956|NCT03796910|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
218823957|NCT03796910|DRUG|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
218823958|NCT03796910|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
218823959|NCT04405531|OTHER|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
218823960|NCT04405531|OTHER|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
218823961|NCT04311450|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
218823962|NCT05072899|PROCEDURE|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
218823963|NCT05072899|PROCEDURE|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
218823964|NCT02373592|BEHAVIORAL|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
218823965|NCT02373592|DEVICE|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
218823966|NCT03978845|DRUG|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
218823967|NCT01240057|PROCEDURE|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
219009790|NCT00992576|DRUG|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
219009791|NCT00992576|DRUG|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
219009792|NCT02468544|OTHER|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
219009793|NCT00375076|DRUG|enoxaparin|
219437079|NCT05034458|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
219437080|NCT03468049|BIOLOGICAL|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
219437081|NCT03468049|BIOLOGICAL|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
219437082|NCT03468049|BIOLOGICAL|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
219437083|NCT03468049|OTHER|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
218823968|NCT01240057|OTHER|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
219437084|NCT00284349|DEVICE|Use of a rehabilitation brace instead of a plaster|
219437085|NCT03627494|DRUG|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
218823969|NCT01499537|DEVICE|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
218823970|NCT01499537|DEVICE|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
218823971|NCT01985230|DEVICE|ReActiv8 Implantable Stimulation System implanted and activated.|
218823972|NCT00332696|DRUG|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
218823973|NCT00332696|DRUG|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
218823974|NCT00332696|DRUG|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
218823975|NCT00332696|DRUG|Placebo|Physiologic saline solution
218823976|NCT00734448|DIETARY_SUPPLEMENT|myo-inositol|2 g twice a day until delivery
218823977|NCT03433976|DRUG|spinal anesthesia|spinal anesthesia for planned cesarean sections
218823978|NCT03091361|OTHER|imaging, no intervention|no intervention
218823979|NCT01470157|DRUG|Ketamine|5mg/kg as oral suspension
218823980|NCT01470157|DRUG|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
218823981|NCT04961905|DRUG|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
218823982|NCT04961905|DRUG|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002\_R2 NVP-2002, 1 tablet, once daily
219009794|NCT03151460|DRUG|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
219009795|NCT01822405|DRUG|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
219437086|NCT03627494|DRUG|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
219437087|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
219437088|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
218823983|NCT06118658|DRUG|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
219009796|NCT01822405|OTHER|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
219009797|NCT06145776|OTHER|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
219009798|NCT06145776|OTHER|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
219009799|NCT05532839|OTHER|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
219009800|NCT05532839|OTHER|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
219009801|NCT06001476|PROCEDURE|Cold snare polypectomy|For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
219009802|NCT02454881|DRUG|Dexmedetomidine|
219195480|NCT06857838|PROCEDURE|MBBG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
219195481|NCT06857838|PROCEDURE|MB CABG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
219195482|NCT06857838|PROCEDURE|MB unroof|"The patients with superficial type(depth\<2mm) and short-segement(length\<25mm) of myocardial bridge will be allocated to receive myocardialbridge unroof surgery，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The MB was superficial and short confirmed by coronory artery CT angiography."
219437089|NCT04057716|BEHAVIORAL|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
218823984|NCT05568329|DEVICE|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
218823985|NCT03512093|OTHER|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.
218823986|NCT03512093|OTHER|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
218823987|NCT03512093|OTHER|Interviews of mothers|Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
219437090|NCT04057716|BEHAVIORAL|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
219437091|NCT05443061|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
219437092|NCT05443061|DRUG|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
219009803|NCT02454881|DRUG|Oxycodone|
219009804|NCT05008250|DRUG|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
219009805|NCT05008250|DRUG|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
219009806|NCT05008250|DRUG|placebo|simulated pills
219009807|NCT06346496|OTHER|Douyin Xinqing AI dialog bot|"Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance."
218823988|NCT00602524|DRUG|Pilocarpine|
219009808|NCT06346496|OTHER|Douyin Xinqing AI dialog bot for delayed intervention|Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
219009809|NCT01124136|DEVICE|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
219009810|NCT01124136|DRUG|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
219009811|NCT02425657|BEHAVIORAL|Training of junior doctors|Training program
219009812|NCT00353912|DRUG|valsartan + amlodipine|
219009813|NCT01487226|DRUG|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
218823989|NCT01768949|DEVICE|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
219009814|NCT01487226|DRUG|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks \* 6 cycles"
219009815|NCT00940251|DRUG|Mersina|capsule, 3g/day, 3 months
219009816|NCT05855850|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
219195483|NCT06855797|OTHER|Observation|questionnaire
219195484|NCT03460769|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
219195485|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
219195486|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
219195487|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
219195488|NCT06657989|BEHAVIORAL|Walking|Overground walking
219437093|NCT06010472|DRUG|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
219437094|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
219763628|NCT00262470|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg PO x 1 dose
219009817|NCT05855850|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
219009818|NCT00081380|DRUG|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
219009819|NCT00081380|DRUG|lithium (mood stabilizer)|
219009820|NCT00081380|DRUG|divalproex (mood stabilizer)|
218823990|NCT04024826|BEHAVIORAL|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
218823991|NCT04024826|BEHAVIORAL|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
218823992|NCT04024826|BEHAVIORAL|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
218823993|NCT04024826|BEHAVIORAL|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
219009821|NCT02801240|OTHER|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
219009822|NCT04106921|OTHER|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
219009823|NCT00338702|PROCEDURE|Autologous Platelet Gel|
218823994|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
218823995|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
219009824|NCT00678054|DRUG|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
219009825|NCT01922089|DRUG|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
219009826|NCT03760120|DEVICE|PEP-MASK|
219009827|NCT05083104|DIAGNOSTIC_TEST|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
219009828|NCT04010682|OTHER|urine sample collection|no drug/devise intervention. sample collection study only
219009829|NCT05682781|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Oral Nutritional Supplement
219009830|NCT05682781|OTHER|Dietary Counseling|Dietary Counseling
219009831|NCT06228547|OTHER|Questionnaire|Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
219009832|NCT04458233|PROCEDURE|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
219009833|NCT02662946|PROCEDURE|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
219009834|NCT02662946|PROCEDURE|No angiography|Extension of resection based on subjective measures
219009835|NCT05200520|BEHAVIORAL|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
219009836|NCT04853979|OTHER|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
219437095|NCT01140464|OTHER|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
219437096|NCT01140464|OTHER|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
219437097|NCT00878644|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
219009837|NCT01590238|BIOLOGICAL|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
219009838|NCT03716882|DEVICE|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
219009839|NCT02904473|OTHER|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
219009840|NCT02619292|BEHAVIORAL|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
219009841|NCT03735433|DRUG|162mg aspirin dose|2 pills of 81mg aspirin
219437098|NCT00878644|OTHER|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
219437099|NCT00823186|DRUG|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
219009842|NCT03241251|OTHER|questionnaire|Questionnaire of psychosocial risk factors
219437100|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
219437101|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
219763629|NCT00262470|DRUG|Midodrine|midodrine 2.5-10 mg PO x 1 dose
219763630|NCT00262470|DRUG|Modafinil|modafinil 100-200 mg PO x 1 dose
218823996|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
218823997|NCT04383093|DRUG|Tadalafil 5mg|Combination therapy of daily tadalafil plus tamsulosin
218823998|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
218823999|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
218824000|NCT01467336|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
218824001|NCT00416117|PROCEDURE|Manual Physical Therapy and Exercise|
218824002|NCT00416117|PROCEDURE|Minimal Intervention|
218824003|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
218824004|NCT02299310|DRUG|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
218824005|NCT02299310|DRUG|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
218824006|NCT02003482|RADIATION|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
218824007|NCT02003482|DEVICE|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
218824008|NCT05987982|PROCEDURE|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
218824009|NCT05987982|PROCEDURE|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
218824010|NCT01074125|DRUG|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
218824011|NCT02118519|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
218824012|NCT02985411|BEHAVIORAL|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
218824013|NCT02985411|OTHER|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
218824014|NCT04451005|OTHER|0|Elderly patients with sarcopenia
218824015|NCT00871078|DEVICE|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
218824016|NCT00871078|DEVICE|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
218824017|NCT01555866|DRUG|isavuconazole|IV
218824018|NCT03506620|DRUG|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
218824019|NCT03506620|DRUG|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
218824020|NCT01193101|DRUG|LCZ696|LCZ696
219195489|NCT06354881|DEVICE|Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres|TCD will be used to measure the cerebral blood flow in the middle and posterior cerebral arteries. This will be done at rest and during two sit-stand manoeuvres, whereby the participant will be asked to stand (from a seated position) and stay standing for 1 minute. The participant will then be given time to recover before repeating the manoeuvre. This will occur at the first visit and the follow-up visit 4 weeks after.
218824021|NCT01193101|DRUG|Placebo|matching placebo to LCZ696
218824022|NCT00746187|DEVICE|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
218824023|NCT00746187|DEVICE|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
218824024|NCT02347085|DRUG|GFF MDI (PT003)|
218824025|NCT02347085|DRUG|Placebo MDI|
218824026|NCT05167812|OTHER|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
218824027|NCT00183014|BEHAVIORAL|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
218824028|NCT00183014|BEHAVIORAL|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
218824029|NCT01267786|PROCEDURE|Liver surgery|hepatectomy
219195490|NCT04472195|OTHER|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
219009843|NCT05624203|DEVICE|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
219009844|NCT02234453|DEVICE|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
219009845|NCT04903626|DRUG|Glecaprevir/Pibrentasvir (GLE/PIB)|Oral tablets
219009846|NCT05246761|DEVICE|Balloon catheter|In the two groups, if their bishop score \<6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
219009847|NCT01701557|OTHER|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
219009848|NCT01701557|OTHER|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
219009849|NCT04317131|DIAGNOSTIC_TEST|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
219009850|NCT04317131|DEVICE|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
219437102|NCT01549028|BEHAVIORAL|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
218824030|NCT00548834|DRUG|CDP870|
218824031|NCT04327440|BIOLOGICAL|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
218824032|NCT04327440|OTHER|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
218824033|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
219437103|NCT01389076|DRUG|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
219437104|NCT01389076|DRUG|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
219763631|NCT00262470|DRUG|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
218824034|NCT00754689|DRUG|Metformin|Tablet, oral administration
218824035|NCT00754689|DRUG|placebo|Tablet, oral administration
218824036|NCT00286377|DRUG|prosaptide|
218824037|NCT05431647|OTHER|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
219009851|NCT04317131|DEVICE|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
219009852|NCT04317131|DEVICE|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
219195491|NCT04784299|DEVICE|YVOIRE volume plus|Hyaluronic acid dermal filler
219763632|NCT00262470|RADIATION|Placebo|lactose tablet x 1 pill
219763633|NCT00262470|DRUG|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
219437105|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
218824038|NCT01313507|BIOLOGICAL|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
218824039|NCT04236089|DEVICE|robotic hand|mirror therapy with robotic hand
218824040|NCT03168802|PROCEDURE|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
218824041|NCT03168802|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
218824042|NCT04858399|DIAGNOSTIC_TEST|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
218824043|NCT01824290|DRUG|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
218824044|NCT01824290|DRUG|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
218824045|NCT01824290|DRUG|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
218824046|NCT06199024|DIETARY_SUPPLEMENT|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
218824047|NCT00800982|PROCEDURE|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
218824048|NCT00800982|DRUG|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
218824049|NCT02681081|OTHER|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
218824050|NCT02681081|OTHER|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
218824051|NCT02681081|OTHER|Control|Normal food intake
218824052|NCT03172273|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
218824053|NCT03172273|PROCEDURE|paracentesis|paracentasis plus albumine invision
218824054|NCT02343770|OTHER|blood sample for identifying biomarkers|
218824055|NCT00527618|DRUG|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
218824056|NCT00527618|DRUG|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
218824057|NCT02278315|DRUG|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
218824058|NCT02278315|DRUG|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
218824059|NCT02278315|DRUG|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
218824060|NCT02606318|OTHER|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
218824061|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
218824062|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
218824063|NCT04642521|DEVICE|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
219009853|NCT04317131|DEVICE|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
219009854|NCT03748758|COMBINATION_PRODUCT|Drug: OP0201|Drug OP0201
219009855|NCT03748758|COMBINATION_PRODUCT|Drug: Placebo|Placebo
219009856|NCT03971058|BIOLOGICAL|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
219009857|NCT04231357|DRUG|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
219195492|NCT04784299|DEVICE|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
219437106|NCT04089228|OTHER|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
219437107|NCT04089228|OTHER|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
219437108|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
219437109|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
219437110|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
219195493|NCT03615664|DRUG|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
218824064|NCT01198821|DRUG|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
219009858|NCT05613595|BEHAVIORAL|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
219009859|NCT05613595|BEHAVIORAL|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
219009860|NCT00280098|DRUG|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
219009861|NCT02206334|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
219009862|NCT00144092|PROCEDURE|stem cell source|
219009863|NCT03579160|DRUG|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
219195494|NCT03615664|DRUG|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
219009864|NCT03579160|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
219195495|NCT03615664|DRUG|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
219009865|NCT04342364|OTHER|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
219009866|NCT04342364|OTHER|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
219009867|NCT02317068|DEVICE|HBR|
219009868|NCT02317068|DEVICE|DD|
219009869|NCT00735956|BEHAVIORAL|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
219195496|NCT03615664|DIAGNOSTIC_TEST|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial"
219437111|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
218824065|NCT01198821|DRUG|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
219009870|NCT00774644|DRUG|Clarithromycin 500mg|
219437112|NCT05815004|DRUG|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
219437113|NCT05815004|DRUG|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
219437114|NCT01352312|DRUG|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
218824066|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
218824067|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
219009871|NCT01488682|PROCEDURE|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
219009872|NCT01488682|PROCEDURE|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
219009873|NCT05148754|DRUG|Elsulfavirine|Elsulfavirin 200 mg tablets.
219009874|NCT03358290|DRUG|JTE-051|Active drug tablets containing JTE-051
219009875|NCT03358290|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
219009876|NCT04867538|OTHER|no intervention|No intervention
219009877|NCT00194064|DRUG|Olanzapine|
219009878|NCT05552560|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
219195497|NCT03615664|PROCEDURE|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
219195498|NCT02636517|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
219437115|NCT01352312|DRUG|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
219437116|NCT01352312|DRUG|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
219437117|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
219009879|NCT01622153|PROCEDURE|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
218824068|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
218824069|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
218824070|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
219009880|NCT01622153|PROCEDURE|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
219009881|NCT01596608|DEVICE|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
219009882|NCT04899921|DRUG|Ipilimumab|Intravenous injection
219009883|NCT04899921|DRUG|Nivolumab|Intravenously (IV) into the vein
218824071|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
218824072|NCT00051207|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|
219009884|NCT04899921|DRUG|Troriluzole|Taken orally
219009885|NCT04899921|DRUG|Placebo|Taken orally
219009886|NCT03907553|DIAGNOSTIC_TEST|targeted genome sequencing|
219009887|NCT05466526|PROCEDURE|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
219009888|NCT00860964|DRUG|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
219009889|NCT00860964|DRUG|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
219195499|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease(PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.
218824073|NCT00051207|BEHAVIORAL|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
218824074|NCT05249205|BEHAVIORAL|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
218824075|NCT05249205|BEHAVIORAL|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
218824076|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
218824077|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
219009890|NCT06323278|BEHAVIORAL|Cognitive training|The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
219009891|NCT05810142|DRUG|furquimatinib and sintilimab|furquimatinib and sintilimab
219009892|NCT04856774|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
219009893|NCT02856230|DEVICE|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
218824078|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
218824079|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
218824080|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
218824081|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
218824082|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
218824083|NCT02537730|DEVICE|comfilcon A|contact lens
219009894|NCT01885143|RADIATION|Digital Breast Tomosynthesis|
219009895|NCT05678894|OTHER|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
219195500|NCT02245867|DRUG|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
219195501|NCT05338164|PROCEDURE|cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
219763634|NCT00262470|DRUG|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
219009896|NCT02563275|OTHER|motion analysis system|
219009897|NCT02563275|OTHER|parabolic flight|
219009898|NCT01403714|PROCEDURE|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
219009899|NCT01322360|DRUG|Morphine Sulfate|
218824084|NCT02235571|BEHAVIORAL|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
218824085|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
218824086|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
218824087|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
218824088|NCT02843412|PROCEDURE|choose two tumor tissue paraffin blocks|
218824089|NCT02793583|BIOLOGICAL|Ublituximab|
218824090|NCT02793583|DRUG|Umbralisib|
218824091|NCT02793583|BIOLOGICAL|Bendamustine|
218824092|NCT00648037|DRUG|Rituximab|Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
218824093|NCT04924621|DEVICE|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
218824094|NCT04924621|DEVICE|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
219009900|NCT00967525|PROCEDURE|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
219009901|NCT01706081|PROCEDURE|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
219009902|NCT01706081|PROCEDURE|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
219195502|NCT06825039|DEVICE|Shockwave therapy|Focused ESWT will be applied to the scarred area in the 3 intervention groups. Each group will receive 10 ESWT treatments with a frequency of 1x/week. Energy levels (EFD mJ/mm2) or bar in radial can range between 0.01-0.33 mJ/mm2 (33). Based upon experimental papers, the described energy flux density, frequency and number of shots should activate or modulate the signaling pathways of interest and are used in the treatment of scars.
219195503|NCT06825533|DIAGNOSTIC_TEST|Fasting blood sugar level|Assess the level of Blood sugar level in fasting conditions at inclusion
218824095|NCT04924621|DRUG|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
218824096|NCT04924621|DRUG|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
218824097|NCT04924621|DRUG|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
218824098|NCT04924621|DRUG|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
219009903|NCT02999854|BIOLOGICAL|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
219009904|NCT02999854|DRUG|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
219763635|NCT00262470|DRUG|Sertraline|sertraline 25-50 mg PO x 1 dose
218824099|NCT04924621|DRUG|Drug use target(T group)|Make BIS \< 60 .
218824100|NCT04924621|DRUG|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
218824101|NCT04924621|DRUG|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
218824102|NCT04924621|DRUG|Propofol|Propofol 1-2ug/ml, intravenous injection
218824103|NCT04924621|DRUG|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
218824104|NCT04924621|DRUG|Drug use target|Make the BIS between 70 and 80.
218824105|NCT02485587|BEHAVIORAL|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
218824106|NCT02485587|BEHAVIORAL|Treatment as usual|counseling, psychoeducation
218824107|NCT06017882|OTHER|Partial sleep deprivation|
218824108|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
218824109|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
218824110|NCT03457077|BEHAVIORAL|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
218824111|NCT01951898|DRUG|Montelukast|10mg/day, once a daily after dinner, for 28dyas
218824112|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
218824113|NCT01308359|DRUG|saline|saline
218824114|NCT02471313|DRUG|[18F] FMISO|\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
218824115|NCT02706925|DRUG|BI 443651|
218824116|NCT02706925|DRUG|Placebo|
218824117|NCT04877327|PROCEDURE|Ablation|Cryotherapy and radiofrequency
218824118|NCT01111162|BIOLOGICAL|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
219009905|NCT02999854|PROCEDURE|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
219009906|NCT02999854|PROCEDURE|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
219009907|NCT02136524|DRUG|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
219009908|NCT02136524|DRUG|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
219009909|NCT05470426|OTHER|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
219596906|NCT04420845|BEHAVIORAL|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
218824119|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
218824120|NCT04773548|OTHER|VR-JIT|Job interview with virtual interviewer
218824121|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
218824122|NCT00039169|DRUG|ortataxel|
218824123|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
218824124|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
218824125|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
218824126|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
218824127|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
218824128|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
219009910|NCT04140292|DRUG|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
219009911|NCT04140292|DRUG|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
219009912|NCT01013701|DRUG|fluticasone furoate|nasal steroid spray
218824129|NCT04005586|DEVICE|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
218824130|NCT00216918|DRUG|Atomoxetine Hydrochloride|
218824131|NCT00977639|PROCEDURE|Pathwork TOO test|
218824132|NCT01253369|DRUG|Pazopanib|
219009913|NCT01013701|OTHER|placebo|nasal steroid vehicle without drug
218824133|NCT03308682|DRUG|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
219009914|NCT04140851|DIETARY_SUPPLEMENT|Dietary fiber intervention|Dietary intervention
219009915|NCT04140851|DIETARY_SUPPLEMENT|Normal diet|Normal diet
219009916|NCT05759650|OTHER|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
219195504|NCT06825533|DIAGNOSTIC_TEST|Glycated hemoglobin|Assess the level of glycated hemoglobin at inclusion
219195505|NCT06822127|OTHER|CT scan|6 months postop CT scan
219195506|NCT06822127|OTHER|VLASTIC test|Measurement of the elasticity of the facial integument using the VLASTIC cutometer (Volume-based Light Aspiration device for in vivo Soft Tissue Characterization)
218824134|NCT03289533|DRUG|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
218824135|NCT03289533|DRUG|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
218824136|NCT05165095|DEVICE|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
218824137|NCT06450743|DIAGNOSTIC_TEST|Lymphocyte Immunophenotyping Test|Absolute enumeration of peripheral blood lymphocyte subpopulations
218824138|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
219437118|NCT04683133|DIAGNOSTIC_TEST|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
218824139|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
218824140|NCT00891696|DRUG|Rapamycin|Single 16-mg oral dose
218824141|NCT00891696|OTHER|Amino acid supplementation|Nutritional drink containing essential amino acids
218824142|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
218824143|NCT00891696|DRUG|Sodium nitroprusside|Variable rate for 3 hours
218824144|NCT00891696|DEVICE|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
218824145|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
218824146|NCT04912544|DEVICE|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
218824147|NCT02812745|DEVICE|recording of cardiac output|
218824148|NCT02812745|DEVICE|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
218824149|NCT06342765|DEVICE|Pedicle fixation surgery|Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.
218824150|NCT00561522|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
218824151|NCT00561522|OTHER|No other preventive treatment|No other preventive treatment
218824152|NCT01658085|DEVICE|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
218824153|NCT01658085|DEVICE|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
218824154|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
218824155|NCT06103344|BEHAVIORAL|4-7-8 Breathing Exercise Training|Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
218824156|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
218824157|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
219195507|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
218824158|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
218824159|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
218824160|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
218824161|NCT00363311|DRUG|Dutasteride|Dutasteride 0.5mg
219195508|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
218824162|NCT00363311|DRUG|Matching placebo|Matching placebo
218824163|NCT01816425|DEVICE|Thermoplastic partial denture|
218824164|NCT01816425|DEVICE|CoCr partial denture|
218824165|NCT03249194|DRUG|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
219437119|NCT03731975|PROCEDURE|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
219437120|NCT03731975|PROCEDURE|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
219437121|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
219596907|NCT03195335|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
219596908|NCT00834496|PROCEDURE|Liver biopsy|percutaneous liver biopsy
218824166|NCT05843461|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.
218824167|NCT05843461|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
218824168|NCT05843461|OTHER|Pulmonary artery OCT|OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
218824169|NCT01823380|PROCEDURE|Blood test|Blood test
219009917|NCT04608526|DIAGNOSTIC_TEST|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
219009918|NCT00556712|DRUG|erlotinib [Tarceva]|150mg po daily
219009919|NCT00556712|DRUG|Placebo|po daily
218824170|NCT04624308|DRUG|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
218824171|NCT00726128|DEVICE|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
218824172|NCT04882943|OTHER|questionnaires|Quality of life questionnaires
218824173|NCT03175731|DRUG|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
219009920|NCT03459248|OTHER|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
219009921|NCT03459248|OTHER|Monotherapy|10 mg metoclopramide
219009922|NCT03459248|OTHER|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
219009923|NCT00848367|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
219009924|NCT00380614|DRUG|Lamivudine|
219437122|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
219009925|NCT00850668|BIOLOGICAL|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
219009926|NCT01961388|DRUG|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
219009927|NCT01961388|DRUG|Metformin|Oral, dosage of Metformin as per the directions of treating physician
219437123|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
219437124|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
219437125|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
219437126|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
219437127|NCT03903536|PROCEDURE|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
219763636|NCT00262470|PROCEDURE|IV Saline|1 liter IV over 2 hours
218824174|NCT03175731|DRUG|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
218824175|NCT03313973|PROCEDURE|with self stretching same muscle|with self stretching
218824176|NCT03313973|PROCEDURE|with self stretching of forearm muscles|without self stretching
218824177|NCT01027858|BEHAVIORAL|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
218824178|NCT01027858|BEHAVIORAL|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
218824179|NCT04088799|OTHER|No intervention|No intervention
219009928|NCT05489055|DRUG|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
219009929|NCT04049123|DRUG|LY900014|Administered SC
219009930|NCT04049123|DRUG|Insulin Lispro|Administered SC
219009931|NCT00298051|PROCEDURE|Delayed umbilical cord clamping|
219009932|NCT01355341|DRUG|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
219009933|NCT03145350|OTHER|High-fat, low-carbohydrate|Dietary intervention: 4 week
219009934|NCT03145350|OTHER|Low-fat, high-carbohydrate|Dietary intervention: 4 week
219009935|NCT05459324|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
219009936|NCT04211051|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
219009937|NCT03668314|DRUG|RDN-929|Single dose from 2 mg to TBD
218824180|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
218824181|NCT03009461|PROCEDURE|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
218824182|NCT03009461|DRUG|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
218824183|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
218824184|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
218824185|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
218824186|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
218824187|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
218824188|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
218824189|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
218824190|NCT05634473|DRUG|Methacholine Chloride|Cholinergic agonists
219009938|NCT03668314|DRUG|Placebo oral capsule|Matching placebo Single dose
219009939|NCT03668314|DRUG|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
219437128|NCT03903536|PROCEDURE|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
218824191|NCT00442923|DRUG|Coreg|
218824192|NCT02377557|DRUG|Topical Steroids|
218824193|NCT01595529|DRUG|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
218824194|NCT01595529|DRUG|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
218824195|NCT01595529|OTHER|Placebo|Placebo to match the other four active treatments
219437129|NCT02094729|DRUG|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
219437130|NCT02094729|DRUG|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
219437131|NCT02094729|DRUG|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
219437132|NCT02094729|DRUG|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
219437133|NCT01364857|GENETIC|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
219763637|NCT00262470|OTHER|Drinking Water|16 fluid ounces
218824196|NCT01595529|DRUG|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
218824197|NCT01508910|BIOLOGICAL|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
218824198|NCT01508910|BIOLOGICAL|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
218824199|NCT01508910|OTHER|Standard of care|Standard of care for refractory angina
218824200|NCT04016714|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
218824201|NCT04016714|DRUG|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
218824202|NCT04016714|DRUG|Vaxelis™|Intramuscular 0.5 mL single dose
218824203|NCT04016714|DRUG|M-M-R®II|Subcutaneous 0.5 mL single dose
218824204|NCT04016714|DRUG|VARIVAX™|Subcutaneous 0.5 mL single dose
218824205|NCT04029207|PROCEDURE|Cesarean section|Abdominal, operative delivery of the fetus
218824206|NCT06373666|DEVICE|Spatz4 Adjustable Balloon System|Implantation of Spatz4 Adjustable Balloon system for weight loss treatment for Overweight and Obese patients and Adjustment of the balloon volume at week 16
219009940|NCT03668314|DRUG|RDN-929|Multiple dose based on results of previous cohorts
219009941|NCT03668314|DRUG|Placebo oral capsule|Matching placebo multiple dose
219009942|NCT01075945|DRUG|Dihydroartemisinin- piperaquine|three tablets per day
219009943|NCT01075945|DRUG|artemether- lumefantrine|twenty tablet in eight doses
219009944|NCT00258531|DEVICE|Olympus ScopeGuide®, 3-dimentional magnetic imager|
219009945|NCT05063747|OTHER|No intervention.|Observational study. No intervention.
219009946|NCT02589951|OTHER|admission to non-psychiatric service|
219009947|NCT00003623|DIETARY_SUPPLEMENT|multivitamin|
219437134|NCT01826448|DRUG|PLX3397|
219437135|NCT01826448|DRUG|vemurafenib|
219763638|NCT00262470|DEVICE|Breathing Device|Breathing through a dead space tube
219009948|NCT00003623|OTHER|Placebo|
219763639|NCT00262470|DRUG|memantine|memantine 5-20 mg PO x 1 dose
218824207|NCT05836272|DRUG|Norepinephrine Bitartrate|"The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion."
218824208|NCT05836272|OTHER|Placebo|For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
218824209|NCT04846335|DRUG|Doxycycline Hcl|tablets of DOXY hydrocloride (Bassado)
218824210|NCT04846335|DRUG|Placebo|tablets of placebo
218824211|NCT02073812|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
218824212|NCT02128737|BEHAVIORAL|Sleep|
218824213|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
218824214|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
218824215|NCT04963023|OTHER|Physical examinations|BPCO physical examinations
218824216|NCT04963023|DIAGNOSTIC_TEST|blood test|blood test in order to study immunologic markers
218824217|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
218824218|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
218824219|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
219009949|NCT01010516|DRUG|High-dose rosuvastatin|40 of rosuvastatin daily
219009950|NCT01010516|DRUG|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
219009951|NCT01010516|DRUG|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
219009952|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
219009953|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
218824220|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
218824221|NCT02246010|DIETARY_SUPPLEMENT|Lactose- free milk|Lactose- free milk
218824222|NCT04415554|DIAGNOSTIC_TEST|echocardiography|echocardiography exam of the infant
218824223|NCT01203709|DRUG|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
218824224|NCT02067507|BEHAVIORAL|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
218824225|NCT02067507|BEHAVIORAL|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
218824226|NCT02067507|BEHAVIORAL|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
218824227|NCT02273921|OTHER|EEG recording|EEG is recorded once for each participant
218824228|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
218824229|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
218824230|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
218824231|NCT00730886|DEVICE|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
218824232|NCT00730886|PROCEDURE|Myomectomy|Invasive surgical procedure for fibroid removal
218824233|NCT04707079|DRUG|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
218824234|NCT03992950|OTHER|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
218824235|NCT01991483|DRUG|LY2928057|Administered intravenously
218824236|NCT01991483|DRUG|Placebo|Administered intravenously
218824237|NCT04278248|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
218824238|NCT04344184|DRUG|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
218824239|NCT04344184|OTHER|Placebo|Dextrose 5% Water
218824240|NCT00390377|PROCEDURE|Cutting scalp hair|
218824241|NCT05115266|BEHAVIORAL|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
219009954|NCT01949350|DIETARY_SUPPLEMENT|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
219437136|NCT02833818|DIETARY_SUPPLEMENT|CAKE-intervention|Increased protein and energy supplementation and conversations
219437137|NCT02833818|DIETARY_SUPPLEMENT|CAKE-control|nutrition according to established procedures
218824242|NCT05115266|BEHAVIORAL|Usual treatment|receive usual treatment (group activities)
218824243|NCT02665260|DRUG|Cantharidin|cantharidin 0.7% topical liquid
218824244|NCT02665260|DRUG|Placebo|Placebo topical liquid
218824245|NCT02665260|DEVICE|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
218824246|NCT01252082|PROCEDURE|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
218824247|NCT05528575|DIETARY_SUPPLEMENT|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
218824248|NCT05528575|DIETARY_SUPPLEMENT|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
218824249|NCT05528575|DIETARY_SUPPLEMENT|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
218824250|NCT05528575|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin, 10g per day
218824251|NCT02305186|DRUG|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
218824252|NCT02305186|RADIATION|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
218824253|NCT01932788|DRUG|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
218824254|NCT01932788|DRUG|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
218824255|NCT05960838|DEVICE|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
218824256|NCT05960838|DEVICE|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
218824257|NCT01977378|DRUG|Sustained-Release Desvenlafaxine Hydrochloride|
218824258|NCT01977378|DRUG|Sustained-Release Venlafaxine Hydrochloride|
218824259|NCT03523689|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
219195509|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
219763640|NCT00262470|DEVICE|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
218824260|NCT03523689|PROCEDURE|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
218824261|NCT01637896|DEVICE|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
218824262|NCT01637896|DEVICE|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
218824263|NCT03643835|DEVICE|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
218824264|NCT03643835|OTHER|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
218824265|NCT01471964|DRUG|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
218824266|NCT04819113|BIOLOGICAL|Nimenrix|MenACWY-TT vaccine
218824267|NCT04141319|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
218824268|NCT04141319|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
218824269|NCT04141319|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
218824270|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
218824271|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
218824272|NCT04379674|OTHER|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
218824273|NCT04379674|OTHER|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
218824274|NCT04379674|OTHER|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
218824275|NCT04067492|DRUG|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
218824276|NCT04067492|DRUG|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
218824277|NCT04601116|DRUG|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
218824278|NCT04601116|DRUG|Placebo oral tablet|Placebo 1 tablet per day for 2 years
218824279|NCT02055950|PROCEDURE|Storage of kidney in refrigerated solution|
218824280|NCT02055950|PROCEDURE|Kidney perfused by pulsatile machine|
218824281|NCT04548427|DRUG|CKD-352|Eye Drop
218824282|NCT04548427|DRUG|Diquafosol Sodium 3%|Eye Drop
218824283|NCT03539757|DEVICE|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
219437138|NCT05769907|BEHAVIORAL|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
218824284|NCT05958589|DRUG|Caudal block with levobupivacaine|After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
218824285|NCT05958589|DRUG|General anesthesia|On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
218824286|NCT05958589|PROCEDURE|Inguinal hernioplasty|Elective inguinal hernioplasty
218824287|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
218824288|NCT00833027|DRUG|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
218824289|NCT04321005|PROCEDURE|arthroscopic rotator cuff reconstruction|arthroscopic rotator cuff reconstruction and assessment with evaluation and prediction of core outcomes
218824290|NCT02996812|DRUG|Exendin (9-39)|
218824291|NCT06252376|DIAGNOSTIC_TEST|Head-up tilt table|Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
218824292|NCT05555446|DIETARY_SUPPLEMENT|Bovine colostrum|Subject will receive bovine colostrum with gluten.
219437139|NCT00381589|DRUG|ipratropium bromide 0.03% spray|
219437140|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
219437141|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
219437142|NCT01038089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
219437143|NCT02690389|DRUG|Flumazenil|used alone or with acupuncture
219437144|NCT02690389|PROCEDURE|Acupuncture|used alone or with flumazenil
219437145|NCT04800094|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
219437146|NCT02490839|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
219437147|NCT02490839|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
219437148|NCT05339204|PROCEDURE|allo-HSCT|allo-HSCT from any type of donor
219437149|NCT05370846|OTHER|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
219437150|NCT00067626|DIETARY_SUPPLEMENT|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
219437151|NCT05402904|DIAGNOSTIC_TEST|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
219437152|NCT00059319|PROCEDURE|single aorta clamp with retrograde cardioplegia|
219437153|NCT00059319|PROCEDURE|multiple aorta clamps with antegrade cardioplegia|
219437154|NCT03869164|DEVICE|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
219437155|NCT02225925|RADIATION|Brachytherapy|
219437156|NCT00626834|DRUG|Vigabatrin|Dose 1 BID
219763641|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
218824293|NCT05555446|DIETARY_SUPPLEMENT|Placebo|Subject will receive a placebo with gluten.
218824294|NCT03092180|DRUG|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
219437157|NCT00626834|DRUG|Vigabatrin|Dose 2 BID
219437158|NCT00626834|DRUG|Vigabatrin|Dose 3 BID
219437159|NCT00626834|DRUG|Matching placebo|Matching placebo BID
219437160|NCT04336007|DEVICE|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
219437161|NCT04336007|DEVICE|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
218824295|NCT06433583|DEVICE|transcutaneous auricular vagal nerve stimulation|"The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks."
219437162|NCT04336007|OTHER|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
218824296|NCT01661543|DIETARY_SUPPLEMENT|Beans|120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
218824297|NCT01661543|DIETARY_SUPPLEMENT|Control (rice)|110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
218824298|NCT01661543|DIETARY_SUPPLEMENT|Peas|120 grams of peas will be consumed 5 out of 7 days per week
218824299|NCT06289400|DEVICE|Magnetic field application|The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
219437163|NCT05302804|DRUG|Menthol Gel|5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
219437164|NCT05302804|DRUG|Control Gel|Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
219437165|NCT00706758|BEHAVIORAL|IBS school|Structured patient group education
219437166|NCT00706758|BEHAVIORAL|IBS-guidebook|Written information - IBS-guidebook
218824300|NCT06289400|OTHER|Conventional treatment|Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
218824301|NCT05119582|DEVICE|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
218824302|NCT04857554|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
219437167|NCT01086904|BIOLOGICAL|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
218824303|NCT04857554|OTHER|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
218824304|NCT04857554|OTHER|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
218824305|NCT04857554|OTHER|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
219437168|NCT00797810|DRUG|Rituximab|
219437169|NCT04672317|DRUG|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
219437170|NCT06120192|BEHAVIORAL|Piano|Receives the piano training
219437171|NCT01680146|DIETARY_SUPPLEMENT|PRO+FAT|
219437172|NCT01680146|DIETARY_SUPPLEMENT|PRO|
219580264|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
219580265|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
219580266|NCT05376852|COMBINATION_PRODUCT|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
219580267|NCT01610453|PROCEDURE|ultrasound examination|transabdominal and transperineal ultrasound examinations
219580268|NCT00344851|DRUG|metformin, exenatide or combined (metformin & exenatide )|
219580269|NCT04184661|OTHER|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
219580270|NCT01957228|PROCEDURE|bone biopsies|
219580271|NCT04872972|OTHER|Simulation based learning|Faculty development courses on simulation based learning
218824306|NCT04857554|OTHER|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
218824307|NCT05019209|DRUG|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
218824308|NCT05019209|OTHER|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
218824309|NCT03564236|DEVICE|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
218824310|NCT03564236|OTHER|Standard care|Standard regular care of a COPD exacerbation
218824311|NCT03096886|BEHAVIORAL|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
218824312|NCT01939145|DRUG|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
219580272|NCT00264368|DRUG|intravenous (IV) ganciclovir|
219580273|NCT02440113|DEVICE|Nellix|Nellix Implantation
219009955|NCT03363204|DEVICE|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
219009956|NCT03130868|OTHER|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
219009957|NCT03705507|DRUG|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
219580274|NCT04153383|DRUG|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
219580275|NCT02660528|DRUG|Tocilizumab|Subcutaneous tocilizumab
219580276|NCT00080405|DRUG|Bortezomib|
219580277|NCT01521182|OTHER|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
219580278|NCT01521182|OTHER|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
219009958|NCT03705507|DRUG|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
219009959|NCT03493009|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
219009960|NCT02626520|DRUG|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
219009961|NCT02626520|DRUG|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
219009962|NCT02626520|RADIATION|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
219009963|NCT02626520|PROCEDURE|Definitive resection|Definitive surgical resection of primary tumor
219009964|NCT02568150|BIOLOGICAL|Single group, open-label|
219580279|NCT01475058|BIOLOGICAL|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
219763642|NCT04590235|DRUG|Selumetinib|"All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available."
219763643|NCT06469281|OTHER|27T51|Intravenous (IV) infusion
219763644|NCT06469281|DRUG|Cemiplimab|IV infusion
219009965|NCT01220882|RADIATION|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
219009966|NCT03300479|DRUG|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
219009967|NCT03300479|DRUG|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
219009968|NCT04702997|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
219009969|NCT04702997|DRUG|Placebo oral capsule|Capsule containing an inert placebo
219009970|NCT00011076|DRUG|Pirfenidone|
219009971|NCT02299700|OTHER|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
219009972|NCT05937204|OTHER|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
219009973|NCT01808989|OTHER|Exercise oxymetry|
219195510|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
218824313|NCT01939145|DEVICE|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
218824314|NCT03358082|DRUG|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
218824315|NCT03358082|DRUG|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
218824316|NCT02806414|DRUG|Ivermectin|
218824317|NCT06497309|DEVICE|Treadmill training|Therapy with treadmill-based advanced technology device.
218824318|NCT06497309|DEVICE|Overground training|Therapy using an advanced technological device enables exercise on the ground.
218824319|NCT06497309|DEVICE|DIERS|The examination starts and ends with the DIERS motion analysis system, a light-optical scanning method based on VRS (Video Raster Stereography) and a sensor-equipped treadmill that allows the measurement of several parameters of gait and balancing ability.
218824320|NCT06497309|OTHER|Traditional physiotherapy assessments|Traditional physiotherapy assessment methods (Timed Up and Go, Berg Balance Test, 6-minute gait test, 10-metre gait test, Functional Independence Measure, Barthel) are used to assess gait pattern and self-sufficiency.
218824321|NCT03974269|PROCEDURE|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
218824322|NCT00246363|DRUG|Silymarin|Silymarin (milk thistle)
218824323|NCT00246363|DRUG|Placebo|Placebo
219009974|NCT01305902|BEHAVIORAL|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
219195511|NCT04143295|DRUG|Diiodothyropropionic acid (DITPA)|Drug Administration
219195512|NCT06826001|DRUG|topical finasteride|Group A will receive topical finesteride spray 0.25% twice daily for 12 weeks
219195513|NCT06826001|DRUG|Topical minoxidil|Group B will receive topical 5% minoxidal twice daily for 12 weeks
219763645|NCT06469281|DRUG|Bevacizumab|IV Infusion
218824324|NCT03487094|OTHER|Infant formula|Multi-centered, prospective, randomized clinical trial
218824325|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
218824326|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
218824327|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
219009975|NCT01880840|DRUG|205.5 mcg of azelastine hydrochloride|nasal spray
219009976|NCT01880840|DRUG|137 mcg of azelastine hydrochloride|nasal spray
219009977|NCT03915496|DRUG|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
219009978|NCT03915496|DRUG|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
219009979|NCT03915496|DRUG|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
219009980|NCT02309502|DEVICE|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
219009981|NCT02309502|DEVICE|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
219009982|NCT00818818|DRUG|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
219195514|NCT06825650|OTHER|Questionnaire study|Questionnaire application
219195515|NCT06841705|DRUG|Vedolizumab 300 MG Injection [Entyvio]|This is a biologic medication to treat colitis
219195516|NCT06841705|DRUG|Prednisone (and methylprednisolone)|This is a steroid
219195517|NCT06841705|DRUG|Prednisone Taper|This is a tapering dose of prednisone
219195518|NCT06841705|OTHER|Placebo Prednisone Capsules|Placebo for Prednisone
218824328|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
218824329|NCT00067561|DRUG|Alosetron|
218824330|NCT02544854|DRUG|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended."
218824331|NCT04270344|DRUG|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
218824332|NCT06393842|DEVICE|Cardiopulmonary Management Wearable Device|Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
218824333|NCT03212976|PROCEDURE|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
218824334|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
218824335|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
218824336|NCT04289779|DRUG|Cabozantinib|Cabozantinib 40 mg orally daily for 3 cycles
218824337|NCT04289779|DRUG|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
219580280|NCT06303973|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218824338|NCT04289779|PROCEDURE|Cystectomy|Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
218824339|NCT06381336|DEVICE|TRAK-SILVER platform|"The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform."
218824340|NCT04287413|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
218824341|NCT04287413|BEHAVIORAL|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
219009983|NCT06036771|DEVICE|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
219009984|NCT01300598|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
219009985|NCT00833885|DEVICE|Masks|Wearing of surgical masks
219009986|NCT00833885|DEVICE|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
219009987|NCT00833885|OTHER|Control|General information about virus transmission in households and basic means to prevent it
219009988|NCT03276156|DRUG|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
219009989|NCT01065623|DRUG|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
219009990|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level|50g added sugar
219009991|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage|90 grams added sugar
219009992|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage|130 grams added sugar
219009993|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage|170 grams added sugar
219009994|NCT02200445|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
219009995|NCT04646889|DRUG|AR882 Single Dose|A single dose of AR882
219009996|NCT04646889|DRUG|AR882 Multiple Dose|AR882 taken once daily for 14 days
219009997|NCT04769544|DEVICE|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
219009998|NCT04802278|BIOLOGICAL|COVID-19 vaccine|Any COVID-19 vaccine
219009999|NCT00155350|DRUG|pioglitazone|
218824342|NCT06284759|OTHER|post-discharge telenursing intervention|Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
218824343|NCT06556485|PROCEDURE|Catheter ablation|Preventive ablation therapy
218824344|NCT06556485|DRUG|Medical therapy|Optimal medical therapy
218824345|NCT04516603|DRUG|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
218824346|NCT04516603|DRUG|Placebo|no active component
218824347|NCT03092479|BEHAVIORAL|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
218824348|NCT01337778|BEHAVIORAL|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
218824349|NCT01337778|BEHAVIORAL|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
218824350|NCT03404713|BEHAVIORAL|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
219010000|NCT02893878|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
219010001|NCT01906151|DEVICE|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
219010002|NCT04381598|DRUG|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
219010003|NCT04381598|OTHER|placebo|A placebo without the active drug will be placed in the control sites.
219010004|NCT01479699|DIETARY_SUPPLEMENT|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
219010005|NCT00700661|DRUG|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
219010006|NCT00700661|DRUG|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
219010007|NCT00353262|DRUG|Avastin|7.5mg/kg iv (cycle 3 only)
219010008|NCT00353262|DRUG|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
219010009|NCT00353262|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
219437173|NCT03582839|BEHAVIORAL|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
219437174|NCT01017666|DRUG|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
219437175|NCT01017666|DRUG|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
219010010|NCT01157936|DRUG|Allopurinol|daily dosage
219437176|NCT00442611|DRUG|Abatacept|
219437177|NCT00442611|DRUG|Placebo|
219763646|NCT05901233|DEVICE|Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)|tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
218824351|NCT03404713|BEHAVIORAL|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
218824352|NCT06255769|DEVICE|Magnetocardiography|Magnetocardiography
219010011|NCT01157936|OTHER|placebo|daily dosage
219010012|NCT05615779|OTHER|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
219010013|NCT05615779|OTHER|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
219010014|NCT05615779|OTHER|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
219010015|NCT05615779|OTHER|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
219010016|NCT00001596|DRUG|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
219010017|NCT00001596|DRUG|Placebo|Placebo (3 pills), three times daily.
219010018|NCT03867981|BEHAVIORAL|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
219010019|NCT03867981|BEHAVIORAL|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
219010020|NCT03867981|BEHAVIORAL|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
219010021|NCT05302154|BEHAVIORAL|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
219010022|NCT05302154|BEHAVIORAL|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
219010023|NCT05302154|BEHAVIORAL|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
219437178|NCT02726607|BEHAVIORAL|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
218824353|NCT06255769|DEVICE|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
219010024|NCT02936245|OTHER|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
219010025|NCT02033122|OTHER|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
219010026|NCT02033122|OTHER|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
219010027|NCT01909154|BIOLOGICAL|Mesenchymal stromal cell therapy|Stem cells administration locally
218824354|NCT04683913|BEHAVIORAL|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
219010028|NCT00463346|DRUG|Acamprosate|Acamprosate 1998 mg tid
219010029|NCT00463346|DRUG|Placebo|Placebo
219195519|NCT06841705|OTHER|Placebo Vedolizumab|Placebo for Vedolizumab
218824355|NCT04683913|OTHER|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
218824356|NCT06368401|DEVICE|Versa Implant|The Versa Vascular Implant and Delivery System consists of a percutaneously delivered, permanent right-atrial implant and the delivery catheter that is used to first position the implant over the native valve orifice and to then place the implant.
218824357|NCT06572293|BEHAVIORAL|Nurse-led intervention|Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
218824358|NCT05859178|OTHER|Exercise group|Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.
218824359|NCT00966459|PROCEDURE|Computed Tomography|1 low-dose CT is taken
218824360|NCT05067101|PROCEDURE|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
218824361|NCT05067101|PROCEDURE|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
218824362|NCT00543985|PROCEDURE|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
218824363|NCT03367884|PROCEDURE|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
218824364|NCT03367884|RADIATION|Definitive radiotherapy|Definitive radiotherapy (70Gy)
218824365|NCT03249818|DEVICE|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
218824366|NCT02568657|DEVICE|Celox group|
218824367|NCT02568657|DEVICE|Bakri Balloon|
218824368|NCT04848402|DEVICE|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
218824369|NCT04848402|DEVICE|Single Auto Injector|Used to administer placebo SC.
218824370|NCT04848402|DRUG|Placebo|Administered SC.
218824371|NCT06214403|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
219437179|NCT02726607|BEHAVIORAL|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
218824372|NCT06214403|DRUG|Placebo|Microcrystalline Cellulose
219195520|NCT06841705|OTHER|Sulfamethoxazole-Trimethoprim|Antibiotic if on \>21 days of steroids
219437180|NCT02431702|DRUG|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
219437181|NCT02431702|DRUG|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
219437182|NCT02431702|DRUG|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
219437183|NCT02431702|DRUG|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
219437184|NCT02431702|DRUG|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
219437185|NCT02431702|DRUG|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
219763647|NCT05901233|DEVICE|Remotely supervised sham tDCS (RS-sham-tDCS)|tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
218824373|NCT06088329|BEHAVIORAL|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
218824374|NCT05158413|DIETARY_SUPPLEMENT|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
218824375|NCT05158413|DIETARY_SUPPLEMENT|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
218824376|NCT00237042|BEHAVIORAL|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
219437186|NCT02431702|DRUG|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
219437187|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
218824377|NCT00237042|BEHAVIORAL|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
218824378|NCT00237042|DRUG|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
218824379|NCT00003525|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218824380|NCT05992129|OTHER|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
218824381|NCT05376722|DRUG|pamiparib|pamiparib 40 mg orally, twice a day
219010030|NCT05072561|DIAGNOSTIC_TEST|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
219010031|NCT01586169|DRUG|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
219010032|NCT05569187|DRUG|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
219010033|NCT04983576|PROCEDURE|spinal fusion|patients undergoing spinal fusion
219195521|NCT06841705|DRUG|Placebo for Sulfamethoxazole-Trimethoprim|Placebo for antibiotic (Sulfamethoxazole-Trimethoprim) Antibiotic. Only if on \>21 days of prednisone/placebo
219437188|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
219437189|NCT04479007|DEVICE|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
219437190|NCT00002146|DRUG|Magnesium sulfate|
219437191|NCT00002146|DRUG|Foscarnet sodium|
219437192|NCT02108223|DRUG|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
219437193|NCT02108223|DRUG|r-LH supplementation|recombinant luteinizing hormone
219437194|NCT02108223|DRUG|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
219437195|NCT00001036|DRUG|Thymalfasin|
218824382|NCT05376722|DRUG|abiraterone|biraterone acetate 1000 mg orally, once a day
218824383|NCT05376722|DRUG|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
218824384|NCT00210444|BIOLOGICAL|Botulinum toxin type A|
218824385|NCT01045369|DRUG|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
218824386|NCT03189732|DRUG|Metformin Oral|
218824387|NCT03189732|DRUG|Metformin local in AT|
218824388|NCT03189732|OTHER|Exercise|
218824389|NCT00295607|DRUG|Tacrolimus|immunosuppression
218824390|NCT00295607|DRUG|steroids, monoclonal anti-IL2R antibody|immunosuppression
218824391|NCT00411489|PROCEDURE|endolumenal surgery|
218824392|NCT01758094|DRUG|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
218824393|NCT01897532|DRUG|Placebo|placebo matching tablets
218824394|NCT01897532|DRUG|Linagliptin|
218824395|NCT01010607|DEVICE|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
219010034|NCT02602860|RADIATION|[11C]UCB-J|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv"
219010035|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv"
219010036|NCT02602860|DRUG|Levetiracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv"
219010037|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral"
219195522|NCT06826274|OTHER|tDCS|Transcranial direct current stimulation
219195523|NCT06818838|BIOLOGICAL|LY-M001 injection|LY-M001 injection is administered intravenously as a single dose
219437196|NCT00001036|DRUG|Interleukin-2, Polyethylene Glycolated|
219437197|NCT00001036|DRUG|Zidovudine|
219437198|NCT00763607|GENETIC|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
219437199|NCT05826041|BEHAVIORAL|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
218824396|NCT01010607|DEVICE|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
219195524|NCT06824272|OTHER|MOBIL AND ONLINE EDUCATION|The intervention group attended synchronous online sessions twice weekly (2 hours) for four weeks before IVF, with the mobile app available from the first session. During IVF cycles, the app provided scheduled educational content, reminders, creation of lifestyle maps, feedback,counseling scheduling, and daily motivational messages based on hypnofertility principles to enhance support.
218824397|NCT01010607|DEVICE|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
219195525|NCT06751680|DEVICE|Rhomboid Intercostal and Subserratus Plane Block|Upon entry, electrocardiogram (ECG), blood pressure, and oxygen saturation were monitored. The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.The RISS block is a composite nerve block technique that involves two injection sites, located in the inter-rhomboid plane and the sub-serratus plane, respectively. The choice of block plane depended on the patient's site of pain.
219195526|NCT06751680|DEVICE|PVB block|The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.After confirming needle tip placement, 10 mL of 0.5% ropivacaine with 10 mg of triamcinolone acetonide was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block. If multiple nerves were involved, the injection sites were spaced one thoracic vertebral segment apart.
219359849|NCT07178470|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) Dyspnea scale , , point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS) and physical examination|After obtaining informed consent, the Modified Medical Research Council (mMRC) Dyspnea scale will be administered to patients, and their responses will be recorded on a scale of 0 to +4. During the same clinical visit, a physical examination will be performed by the primary nephrologist, who will categorize the patient's volume status as hypovolemic, euvolemic, mild, moderate, or severe volume overloaded. Finally, point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), will be performed. Patients will be assigned a score based on the number of B-lines observed. We will measure discordance and concordance between the LUS and physical exam, the LUS and mMRC dyspnea scale, and between the physical exam and mMRc dyspnea scale.
218824398|NCT05772325|OTHER|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
218824399|NCT05772325|OTHER|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
218824400|NCT02217969|BEHAVIORAL|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
218824401|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
218824402|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
218824403|NCT05768594|OTHER|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
218824404|NCT05964894|OTHER|ergonomic training|ergonomic education \& exercise training
218824405|NCT06011265|DRUG|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
218824406|NCT06011265|DRUG|Placebo|Participants take empty capsule orally
218824407|NCT02928861|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
218824408|NCT01745653|DEVICE|Low level laser therapy|
218824409|NCT01745653|PROCEDURE|sham procedure|
218824410|NCT02392988|OTHER|acupuncture treatment|acupuncture treatment
218824411|NCT02392988|OTHER|Placebo Comparator|Placebo Comparator
218824412|NCT03132467|BIOLOGICAL|Durvalumab|Given IV
218824413|NCT03132467|BIOLOGICAL|Tremelimumab|Given IV
218824414|NCT04960670|OTHER|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
218824415|NCT03655847|DRUG|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
219763648|NCT05901233|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.
219763649|NCT05901233|BEHAVIORAL|Video Implemented Script Training in Aphasia (VISTA)|Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
218824416|NCT00038948|DRUG|Sirolimus|Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
218824417|NCT00038948|DRUG|tacrolimus|
218824418|NCT00038948|DRUG|Cyclosporine A|
218824419|NCT06656637|BEHAVIORAL|Memory Drilling|"The experimental group will receive the additional intervention during their seven sessions with their care providers. The intervention is computerized memory drills training. This training includes the completion of a list learning memory task (HVLT) and then a PM practice task conducted on the computer at each session."
218824420|NCT06656637|BEHAVIORAL|Compensatory Strategies|Participants learn compensatory strategies to assist with their memory performance. This involves both external strategies, such as calendering and setting alarms, and internal strategies, like imagery and mnemonics.
218824421|NCT06656637|BEHAVIORAL|Cognitive Processing Therapy|This is PTSD-targeted therapy.
218824422|NCT03682965|BIOLOGICAL|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
218824423|NCT03682965|BIOLOGICAL|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
218824424|NCT03271515|BIOLOGICAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
218824425|NCT05522738|DRUG|Combination: Fruquintinib + FOLFIRI|"Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w"
218824426|NCT00005935|DRUG|Mycophenolate mofetil|
218824427|NCT00005935|DRUG|Cyclosporine|
218824428|NCT06717607|DEVICE|low cylinder toric IOL|Clareon T2 toric IOL implantation
219010038|NCT01882621|DRUG|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
219010039|NCT01882621|DRUG|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
219010040|NCT03879655|DRUG|VTS-270|Administered IT via LP infusion of VTS-270
219010041|NCT02785107|BEHAVIORAL|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
219010042|NCT02659709|DEVICE|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
219010043|NCT02310685|OTHER|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
219359850|NCT07178587|DIAGNOSTIC_TEST|Single tracer PET/CT|Single tracer PET/CT for the HCC patients : one with \[18F\]FDG and one with \[18F\]F-choline Single tracer PET/CT for the GEP-NET patients : one with \[68Ga\]Ga-DOTATOC and one with \[18F\]FDG
218824429|NCT06717607|DEVICE|non-toric IOL implantation|Clareon non-toric IOL
218824430|NCT02425397|GENETIC|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
218824431|NCT02425397|GENETIC|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
218824432|NCT02805452|DRUG|Succinate of Solifenacin|
218824433|NCT02805452|DRUG|Placebo of Succinate of Solifenacin|
219010044|NCT01326416|DIETARY_SUPPLEMENT|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
219010045|NCT01326416|OTHER|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
219010046|NCT02123498|DRUG|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
219010047|NCT02123498|DRUG|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
218824434|NCT05678946|OTHER|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
218824435|NCT05678946|OTHER|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
218824436|NCT05678946|OTHER|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
218824437|NCT06663449|PROCEDURE|subcostal transversus abdominis plane block|subcostal transversus abdominis plane block will be performed using 20 mL of 0.25 bupivacaine
218824438|NCT06663449|PROCEDURE|erector spinae plane block|erector spinae plane block will be performed using 20 mL of 0.25 bupivacaine
218824439|NCT06604429|OTHER|Aerobic exercise|aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
218824440|NCT06604429|OTHER|Diet Advice|Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)
218824441|NCT06604429|OTHER|Virtual reality exercise|Virtual reality game exercise involves 25 min of exercise where adolescent girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 30 min of Virtual reality exercises.
218824442|NCT03276442|OTHER|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
218824443|NCT03276442|OTHER|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
218824444|NCT04971577|DRUG|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
218824445|NCT05212792|BIOLOGICAL|COVID-19 vaccines|Any licensing COVID-19 vaccine platform
218824446|NCT00172809|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
218824447|NCT00172809|DRUG|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
219010048|NCT02123498|DRUG|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
219010049|NCT02123498|PROCEDURE|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
218824448|NCT01627184|DEVICE|Dexcom G4 CGM System|
218824449|NCT06333548|DIAGNOSTIC_TEST|Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM|No intervention
219010050|NCT02123498|PROCEDURE|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
219010051|NCT05563233|OTHER|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
219010052|NCT05563233|DEVICE|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
219580281|NCT06303973|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219359851|NCT07178587|DIAGNOSTIC_TEST|Multiplexed PET-CT|Multiplexed PET-CT for HCC patients : \[18F\]FDG + \[18F\]F-choline. Multiplexed PET-CT for GEP-NET patients : \[18F\]FDG + \[68Ga\]Ga-DOTATOC. The PET scans must be performed in any order and at least 24 hours apart.
219359852|NCT07177456|BIOLOGICAL|UCB-MNCs|UCB-MNCs were administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
219580282|NCT03214874|DRUG|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
219580283|NCT03214874|DRUG|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
219580284|NCT02996760|DRUG|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
218824450|NCT05710952|DEVICE|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
218824451|NCT03972527|DEVICE|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
218824452|NCT03972527|OTHER|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
218824453|NCT05223673|BIOLOGICAL|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
218824454|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
218824455|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
218824456|NCT00497003|DRUG|Treatment with either metoprolol or carvedilol|
218824457|NCT01786590|PROCEDURE|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
218824458|NCT01286597|DIETARY_SUPPLEMENT|dietary restriction|restrict intake of lactose
218824459|NCT02665091|BEHAVIORAL|Peer Education Program|
218824460|NCT06248151|BEHAVIORAL|Exercise session|Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
218824461|NCT06248151|BEHAVIORAL|Control session|Remain seated for 60 min
218824462|NCT06715722|DEVICE|hexed non hexed|A 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using one hexed and one non-hexed abutment.
218824463|NCT06715722|DEVICE|non-hexed non-hexed|a 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using two non-hexed abutments
218824464|NCT06715800|DIETARY_SUPPLEMENT|Honey|Functional content analyses were performed to identify the specific properties of the different types of honey used.
218824465|NCT06716294|DEVICE|Radiofrequency Ablation and Bone Augmentation|Percutaneous Tumor Ablation of Spine Lesions followed by Polymer Augmentation
219580285|NCT00988065|DRUG|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
218824466|NCT06715865|PROCEDURE|Thymus Transplantation|Thymus Transplantation
218824467|NCT06712342|OTHER|Neuromuscular Exercise Training|"This group will receive neuromuscular exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.~Warm-up Program - 5 minutes Postural Control-Weight Transfer - 10-15 minutes Strength Training - 30-35 minutes Proprioception - Coordination - Reaction Speed 10-15 minutes Cool-down Program - 5 minutes"
218824468|NCT06712342|OTHER|Conventional Exercise Training|"This group will be given traditional strength exercise training consisting of 60-75 minute sessions per day, 2 days per week for 8 weeks.~Warm-up Program - 5 minutes Strength Training - 30-35 minutes Manuel Dexterity - 15-20 minutes Cool-down Program - 5 minutes"
218824469|NCT06715631|DEVICE|Hands-free exoskeleton|Before the simulated-use test, the SCI user and his/her companion must attend five training sessions provided by a Wandercraft certified trainer. Training will be composed by a theoretical part including presentation and description of the personal exoskeleton and its use modes and a hands-on practice. Each session lasts between 1 to 2 hours, varying according to the user's learning pace and tolerance. The training program is representative of the intended training for the end product.
218824470|NCT06902376|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.
218824471|NCT06902376|DRUG|XL092|XL092 will be administered at a dose of 100mg PO daily for 8 weeks (weeks 1-8)
218824472|NCT04743011|DRUG|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
218824473|NCT04743011|DRUG|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
219359853|NCT07179432|PROCEDURE|V-E facial mask ventilation maneuver|"The V-E maneuver is achieved by placing the thumbs and thenar eminence of each hand on the sides of the mask, creating a V shape, while the rest of the fingers perform a jaw thrust described as an E shape. This will be performed after anesthetic induction when the patient is unconscious and apneic. The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
219580286|NCT00988065|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
219580287|NCT00988065|DRUG|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
219580288|NCT00988065|DRUG|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
219580289|NCT05142098|DRUG|Dexamethasone|Intramuscular
219580290|NCT05142098|DRUG|Etoricoxib 60 mg|Orally
218824474|NCT05750407|BEHAVIORAL|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
218824475|NCT03423433|BEHAVIORAL|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
219580291|NCT04890951|PROCEDURE|Hysteropexy|Uterine preservation through suspension
219580292|NCT04890951|PROCEDURE|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
218824476|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
218824477|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
218824478|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
218824479|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
218824480|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
218824481|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
218824482|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
218824483|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
218824484|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
218824485|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
218824486|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
219437200|NCT05826041|BEHAVIORAL|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
219437201|NCT04269941|OTHER|total or subtotal gastrectomy|resection of the gastric tumor
219437202|NCT02947490|OTHER|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
218824487|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
218824488|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
219437203|NCT02947490|OTHER|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
219437204|NCT02947490|OTHER|Standard BP management|GP to measure BP and manage BP control
219437205|NCT02947490|OTHER|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
219437206|NCT01063504|DRUG|teriparatide|
218824489|NCT01861665|DRUG|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
218824490|NCT01861665|DRUG|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
218824491|NCT01033929|BIOLOGICAL|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
219437207|NCT02561676|OTHER|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
219437208|NCT02561676|OTHER|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
219437209|NCT02959970|DRUG|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
219437210|NCT04695418|DIETARY_SUPPLEMENT|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
219437211|NCT04695418|COMBINATION_PRODUCT|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
218824492|NCT03401203|PROCEDURE|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
218824493|NCT03401203|PROCEDURE|Balloon angioplasty|Percutaneous coronary intervention
218824494|NCT05152511|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
218824495|NCT00495703|BEHAVIORAL|Exercise|6-months of regular aerobic exercise
218824496|NCT00495703|BEHAVIORAL|Usual Care|6-months of behavioral strategies to aid memory/cognition
218824497|NCT02722408|DRUG|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
219010053|NCT05063669|BEHAVIORAL|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
219195527|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
219195528|NCT06767540|DRUG|Placebo|placebo subcutaneous injection Q2W until week 46.
219195529|NCT06767540|DRUG|placebo|placebo subcutaneous injection Q3W until week 45.
219195530|NCT05619432|DEVICE|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
219437212|NCT03486561|DRUG|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
219437213|NCT02667028|PROCEDURE|PCI|percutaneous coronary intervention
219580293|NCT05438498|DRUG|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
219437214|NCT00092391|BIOLOGICAL|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
219437215|NCT00092391|BIOLOGICAL|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
219437216|NCT01060722|DRUG|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
219437217|NCT01060722|DRUG|Placebo|Single subcutaneous dose of placebo material
219580294|NCT01229735|DRUG|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
218824498|NCT05035043|OTHER|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
218824499|NCT01900067|DEVICE|BARRIER® EasyWarm Active Self-Warming Blanket|
218824500|NCT03121144|DEVICE|Masimo Centroid System|Noninvasive positional monitoring device
218824501|NCT00937495|DRUG|vorinostat|400 mg given PO
218824502|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
218824503|NCT05526053|OTHER|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
218824504|NCT00143000|DRUG|Peginterferon alfa-2a 40KD and Ribavirin|
219437218|NCT00693420|DRUG|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
219437219|NCT00693420|DRUG|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
219580295|NCT01229735|DRUG|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
219580296|NCT05286723|OTHER|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
219580297|NCT03241381|DIAGNOSTIC_TEST|vitamin D serum assay study and control groups|Serum- vitamin D assay
219580298|NCT03241381|DIAGNOSTIC_TEST|Photometry|Serum- Hemoglobin assay
219580299|NCT03241381|OTHER|Russels periodontal index|Clinical examination for periodontitis
219437220|NCT02252068|BEHAVIORAL|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
219437221|NCT02252068|BEHAVIORAL|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
219437222|NCT04944927|OTHER|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
219437223|NCT02352649|DRUG|Neovasculgen|
219437224|NCT04246268|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
219580300|NCT02685202|DEVICE|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
219580301|NCT02747862|OTHER|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
219580302|NCT03726281|DRUG|Nivolumab|Nivolumab 240 mg, IV
219580303|NCT03956836|DIAGNOSTIC_TEST|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
219580304|NCT00968292|DEVICE|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
219580305|NCT06469489|OTHER|Liver Disease of all etiologies|No intervention
219580306|NCT03880916|DRUG|Duloxetine|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
219580307|NCT03880916|DRUG|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
219580308|NCT05711836|GENETIC|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
219580309|NCT04412148|DRUG|Triamcinolone Acetonide|intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
219580310|NCT04412148|OTHER|saline|intralesional injection of saline
219580311|NCT03203486|OTHER|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
219580312|NCT00128414|DRUG|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
219580313|NCT00128414|DRUG|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
219010054|NCT00850824|BEHAVIORAL|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
219437225|NCT02568852|PROCEDURE|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
219437226|NCT02568852|PROCEDURE|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
219580314|NCT03080415|DRUG|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
219580315|NCT03164421|DRUG|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
219580316|NCT03164421|DRUG|L-carnitine|L-carnitine in clomiphene resistant pcos women
219010055|NCT02045368|DRUG|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
219010056|NCT00489398|DRUG|epinastine HCL and olopatadine HCL|
219580317|NCT00005595|DRUG|arsenic trioxide|
219580318|NCT02041910|BIOLOGICAL|Stem Cells|MSCs injection intratesticular
219580319|NCT02041910|BIOLOGICAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
219580320|NCT02400242|DRUG|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
219580321|NCT02400242|DRUG|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
219580322|NCT02400242|DRUG|Dexamethasone|40 mg qd on days 1, 8, 15, 22
218824505|NCT02159625|DEVICE|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
218824506|NCT01964183|DRUG|tolterodine|Oral
218824507|NCT01964183|DRUG|mirabegron|Oral
218824508|NCT04118829|DRUG|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
218824509|NCT01889394|PROCEDURE|secondary wound healing|secondary wound healing
218824510|NCT01889394|PROCEDURE|primary wound closure using a limberg flap|primary wound closure using a limberg flap
218824511|NCT03412825|DIETARY_SUPPLEMENT|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
218824512|NCT06136143|PROCEDURE|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
218824513|NCT06136143|PROCEDURE|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
219437227|NCT03250624|DRUG|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
219437228|NCT03250624|DRUG|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
219437229|NCT03756870|PROCEDURE|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
219437230|NCT03972605|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
219437231|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
219437232|NCT00926991|OTHER|No intervention|No intervention; observation only
219437233|NCT01235338|DRUG|LDX + Venlafaxine XR|"* Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily."
219580323|NCT05296538|OTHER|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
218824514|NCT06136143|PROCEDURE|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
218824515|NCT06136143|PROCEDURE|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
218824516|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
218824517|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
218824518|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
218824519|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
218824520|NCT00441272|DRUG|Pioglitazone|
218824521|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
218824522|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
218824523|NCT03644719|BEHAVIORAL|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
218824524|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
218824525|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
218824526|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
218824527|NCT02954224|OTHER|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
218824528|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
218824529|NCT01856322|DRUG|Sulindac|one tablet 150mg twice daily
218824530|NCT01856322|DRUG|Placebo|One tablet twice daily
218824531|NCT01856322|OTHER|Validate assays and shipping methods|
218824532|NCT00427011|DRUG|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
218824533|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
218824534|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
218824535|NCT04738994|OTHER|Control group|Standard hospital diet
218824536|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
219010057|NCT00672789|BEHAVIORAL|Blood smear education|education at baseline and three month follow-up
219437234|NCT01235338|DRUG|Venlafaxine XR + LDX|"* Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg."
219195531|NCT05362721|DIAGNOSTIC_TEST|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
219195532|NCT06610994|DEVICE|local vibration apply|Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
219437235|NCT02359136|PROCEDURE|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
219437236|NCT02359136|PROCEDURE|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
219437237|NCT02359136|PROCEDURE|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
219437238|NCT01597440|DRUG|N-carbamylglutamate|"Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
218824537|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
218824538|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
218824539|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
218824540|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
218824541|NCT02886650|PROCEDURE|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
218824542|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
218824543|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
218824544|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
219010058|NCT00672789|OTHER|standard education|standard education
219010059|NCT01941901|DRUG|Calcium electroporation|Intratumoral injection, once only treatment.
219010060|NCT01941901|DRUG|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
219195533|NCT06612125|OTHER|volume controlled ventilation|Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
218824545|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
219195534|NCT06612125|OTHER|pressure controlled ventilation|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
219195535|NCT06612125|OTHER|pressure controlled volume grantanteed ventilation|Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
219437239|NCT01597440|OTHER|Standard of Care|Standard of Care
219437240|NCT02809118|DRUG|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
219580324|NCT05296538|OTHER|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
219580325|NCT04422353|OTHER|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
219580326|NCT04422353|OTHER|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
219580327|NCT02189980|OTHER|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
219580328|NCT02189980|OTHER|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
219580329|NCT02189980|OTHER|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
219580330|NCT02450955|OTHER|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
218824546|NCT01333722|DRUG|Placebo|Placebo tablet
219580331|NCT02450955|OTHER|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
219580332|NCT02748811|OTHER|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
218824547|NCT00443703|DRUG|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
219195536|NCT06612112|OTHER|No Interventions|No Interventions
219195537|NCT06210009|OTHER|DASH-Style Diet|Participants will be randomized to a DASH-style diet
219195538|NCT06210009|OTHER|Western-Style Diet|Participants will be randomized to a Western-style diet
218824548|NCT00443703|DRUG|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
218824549|NCT00443703|DRUG|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
218824550|NCT00443703|DRUG|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
219195539|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
219195540|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
219195541|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
219437241|NCT02809118|DRUG|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
219437242|NCT02809118|OTHER|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
219437243|NCT01951911|DRUG|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
219437244|NCT01951911|DRUG|Placebo|
219437245|NCT04472819|DRUG|SHR2285 tablet|single dose or multi-dose
219437246|NCT04472819|DRUG|Placebo|single dose or multi-dose
219437247|NCT02027064|DRUG|Interferon-alpha|
219437248|NCT01801774|DRUG|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
219437249|NCT01801774|DRUG|Placebo|
218824551|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
218824552|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
218824553|NCT00066339|DRUG|gefitinib|
218824554|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
218824555|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
219580333|NCT02787408|DEVICE|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
219580334|NCT04293978|BEHAVIORAL|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
219580335|NCT01889212|OTHER|11C-erlotinib PET/CT|
218824556|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
218824557|NCT03620032|DRUG|Vinorelbine|Chemotherapy
218824558|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
219195542|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
219195543|NCT06566716|DIAGNOSTIC_TEST|CleoDX ovarian cancer test|A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
219195544|NCT04817176|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
219437250|NCT04185740|DEVICE|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
219437251|NCT05505539|DRUG|5-fluorouracil|Given intralesionally by injection
219437252|NCT00509028|DRUG|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
219437253|NCT00509028|DRUG|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
219437254|NCT00948428|DRUG|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
219437255|NCT00948428|DRUG|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
219437256|NCT00948428|DRUG|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
219437257|NCT00004695|DRUG|PEG-interleukin-2|
219437258|NCT00904111|DRUG|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
219437259|NCT00904111|DRUG|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
219437260|NCT00132522|DRUG|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
219437261|NCT06139939|PROCEDURE|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
219580336|NCT04819399|DRUG|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"
219580337|NCT00985712|DRUG|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
219580338|NCT00985712|DRUG|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
219580339|NCT00985712|DEVICE|HumaPen Memoir|subcutaneously, daily for 24 weeks
219580340|NCT00985712|DEVICE|HumaPen Luxura|subcutaneously, daily for 24 weeks
219580341|NCT04056975|BIOLOGICAL|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
219580342|NCT04978064|BEHAVIORAL|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
218824559|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
218824560|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
218824561|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
218824562|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
218824563|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
218824564|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
218824565|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
218824566|NCT05653245|DRUG|RGD Peptide|adhesion molecules
219195545|NCT04817176|OTHER|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
219580343|NCT06502197|PROCEDURE|Silastic Stenting|Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
219580344|NCT05162651|BEHAVIORAL|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
219580345|NCT05162651|OTHER|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
218824567|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
218824568|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
218824569|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
218824570|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
218824571|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
218824572|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
218824573|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
219195546|NCT06657248|DEVICE|univation® XF Pro|Primary medial unicompartmental knee arthroplasty
219195547|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
219195548|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
219359854|NCT07179432|PROCEDURE|C-E facial mask ventilation maneuver|"The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
219580346|NCT02931045|DRUG|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
219580347|NCT02931045|DRUG|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
218824574|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
218824575|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
218824576|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
218824577|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
218824578|NCT03203811|DRUG|HTI-2088|3 dose levels
218824579|NCT03203811|DRUG|Placebo|placebo oral tablet
218824580|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
218824581|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
218824582|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
218824583|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
218824584|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
218824585|NCT04552041|DRUG|Prospekta|Oral administration.
219195549|NCT06586320|DRUG|150% of their routine home dopaminergic medications dose right in the clinic|IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
219437262|NCT05563259|RADIATION|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
219437263|NCT02186535|DIETARY_SUPPLEMENT|Vitamin D and Calcium|
219437264|NCT02918721|DEVICE|Restylane Lidocaine|Intradermal injection
219437265|NCT02918721|DEVICE|Restylane|Intradermal injection
219437266|NCT04371185|DRUG|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
219437267|NCT04371185|DRUG|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
218824586|NCT04552041|DRUG|Placebo|Oral administration.
218824587|NCT03955783|DRUG|Venetoclax|Given by mouth
218824588|NCT03955783|DRUG|Selinexor|Given by mouth
219195550|NCT06586320|DEVICE|Evaluation of mathematical models|Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
219195551|NCT06606262|PROCEDURE|Tonsillotomy|Bilateral partial removal of the palatine tonsils to a level between the pharyngeal pillars and the tonsillar capsule. Surgery will be performed under general anesthesia using monopolar electrocautery.
219437268|NCT04371185|DRUG|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
219437269|NCT02936362|OTHER|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
219437270|NCT02936362|OTHER|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
219437271|NCT03667794|DIAGNOSTIC_TEST|body plethysmography|measurement of conventional lung function parameters
219437272|NCT03667794|DIAGNOSTIC_TEST|impulse oscillometry|measurement of central and peripheral airway resistance
219437273|NCT03667794|DIAGNOSTIC_TEST|multiple breath washout|measurement of ventilation heterogeneity
219580348|NCT00466973|DEVICE|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
219580349|NCT00466973|DEVICE|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
219580350|NCT00466973|DEVICE|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
219437274|NCT01656018|DRUG|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
218824589|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
218824590|NCT00960544|DRUG|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
218824591|NCT01106989|DRUG|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
218824592|NCT05520684|DIAGNOSTIC_TEST|urine culture and urinalysis|urine culture and urinalysis
218824593|NCT05013814|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
218824594|NCT05013814|DIAGNOSTIC_TEST|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
219010061|NCT04067544|DEVICE|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
219010062|NCT02655562|DRUG|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
219010063|NCT04615923|DRUG|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
219010064|NCT04615923|DRUG|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
219437275|NCT01069809|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
219437276|NCT01069809|BIOLOGICAL|Placebo|Inactive Placebo Injection
219437277|NCT04395989|DRUG|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219437278|NCT04395989|DRUG|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219437279|NCT04395989|DRUG|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219437280|NCT04395989|DRUG|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
218824595|NCT05013814|DIAGNOSTIC_TEST|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
219010065|NCT02597348|PROCEDURE|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
219010066|NCT00933309|DRUG|Exemestane|25 mg tablets orally once a day
219437281|NCT04395989|DRUG|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
219437282|NCT04395989|DRUG|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219437283|NCT04395989|DRUG|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
219437284|NCT04395989|DRUG|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
219437285|NCT04395989|DRUG|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219010067|NCT00933309|DRUG|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
219195552|NCT06606262|PROCEDURE|Tonsillectomy|"Bilateral extracapsular removal of palatine tonsils. Surgery will be performed under general anesthesia using cold knife dissection."
219437286|NCT04395989|DRUG|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
219437287|NCT02408484|BIOLOGICAL|Octafibrin|Plasma-derived Fibrinogen concentrate
219437288|NCT03671642|DEVICE|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
219437289|NCT03671642|PROCEDURE|White light perfusion assessment|Traditional visual perfusion assessment in white light
219437290|NCT03671642|PROCEDURE|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
219580351|NCT00466973|DEVICE|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
218824596|NCT05013814|DIAGNOSTIC_TEST|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
218824597|NCT05013814|DIAGNOSTIC_TEST|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
218824598|NCT05013814|DIAGNOSTIC_TEST|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
218824599|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
218824600|NCT04951102|BEHAVIORAL|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
218824601|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
218824602|NCT04951102|BEHAVIORAL|Standard Care|Standard Care for asthma.
218824603|NCT02603679|DRUG|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
218824604|NCT02603679|DRUG|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
218824605|NCT02603679|DRUG|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
218824606|NCT02603679|DRUG|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
218824607|NCT02100293|DRUG|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
218824608|NCT02100293|DRUG|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
218824609|NCT06218810|DRUG|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
218824610|NCT02492243|DEVICE|PCI|
218824611|NCT02492243|DEVICE|ILR implantation|
218824612|NCT05759208|DRUG|OK-101|Ophthalmic Solution
218824613|NCT05759208|DRUG|Placebo|Placebo
218824614|NCT04764721|DEVICE|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
218824615|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
218824616|NCT00661830|DRUG|Placebo|Placebo
218824617|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
218824618|NCT00203385|DRUG|Divalproex|Depakote up to 2000mg/d
218824619|NCT02869321|DRUG|Fentanyl|
219010068|NCT03618992|OTHER|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
219010069|NCT04142853|OTHER|Training intervention + Dance intervention|Training intervention + Dance intervention
219010070|NCT05872672|BEHAVIORAL|Sleep Program|Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).
219010071|NCT05872672|OTHER|Waitlist|Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
219195553|NCT06296810|DEVICE|aDBS|adaptive deep brain stimulation
219359855|NCT07178808|PROCEDURE|Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy|CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use of heated and high dose chemotherapy to address microscopic residual disease.
218824620|NCT02869321|DRUG|Morphine Sulfate|
218824621|NCT02869321|DRUG|Fentanyl placebo|
218824622|NCT02869321|DRUG|Morphine Sulfate placebo|
218824623|NCT02869321|PROCEDURE|Gastrostomy|
218824624|NCT00488514|DRUG|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
218824625|NCT04256525|DRUG|Rivaroxaban 10mg|10mg orally per day
218824626|NCT04256525|DRUG|Aspirin 100mg|100mg orally per day
218824627|NCT04256525|DRUG|low molecule heparin|0.4ml per day subcutaneous injection
218824628|NCT04346511|OTHER|Acupuncture|Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
218824629|NCT02527473|OTHER|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
219359856|NCT07178951|DEVICE|Neurotomy|Use of high intensity focused ultrasound to ablate the genicular nerve.
218824630|NCT01535287|DRUG|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
218824631|NCT01047189|DRUG|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
218824632|NCT01047189|DRUG|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
218824633|NCT01047189|DRUG|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
218824634|NCT01641107|DRUG|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
218824635|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
218824636|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
218824637|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
218824638|NCT01370187|DRUG|Montelukast|Montelukast 4mg daily for 2 months
218824639|NCT02890459|OTHER|Prize incentive - Low|Low expected prize value.
218824640|NCT02890459|OTHER|Prize incentive - High|High expected prize value.
218824641|NCT02890459|OTHER|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
218824642|NCT02890459|OTHER|Travel Voucher|Travel voucher to assist with linkage to care.
218824643|NCT02890459|OTHER|Standard care|Includes HIV viral load and treatment adherence counseling.
218824644|NCT02890459|BEHAVIORAL|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
218824645|NCT02890459|BEHAVIORAL|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
218824646|NCT02890459|BEHAVIORAL|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
218824647|NCT02890459|BEHAVIORAL|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
218824648|NCT02890459|BEHAVIORAL|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
218824649|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
218824650|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
219195554|NCT06862076|PROCEDURE|Lung Function Prehabilitation|Participants assigned to the prehabilitation group received personalized exercise prescriptions, including aerobic training, muscle strengthening, and inspiratory muscle training with a threshold device. The prehabilitation program was conducted at the participants' homes for a minimum duration of two weeks. Adherence was monitored through logbook entries and video call evaluations to ensure correct implementation of the prescribed exercises.
219580352|NCT00466973|DEVICE|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
218824651|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
218824652|NCT01129492|DEVICE|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
219580353|NCT00466973|DEVICE|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
218824653|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
218824654|NCT02907658|BEHAVIORAL|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
218824655|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
218824656|NCT01030120|DRUG|placebo|placebo
218824657|NCT00052910|DRUG|cisplatin|Given IV
218824658|NCT00052910|DRUG|epirubicin hydrochloride|Given IV
218824659|NCT00052910|DRUG|fluorouracil|Given IV
218824660|NCT00052910|DRUG|leucovorin calcium|Given IV
218824661|NCT00052910|RADIATION|radiation therapy|Given 5 days a week for 5 weeks
218824662|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
218824663|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
218824664|NCT05964491|OTHER|No intervention|No intervention studied
219010072|NCT05877794|DEVICE|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
219195555|NCT02396823|BEHAVIORAL|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
219195556|NCT05249543|BEHAVIORAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy
219195557|NCT05249543|BEHAVIORAL|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
219195558|NCT05221619|DRUG|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
219195559|NCT06668636|BEHAVIORAL|ED-PATCH|Participants will access ED-PATCH using their personal mobile device and use it to track important information throughout their visit. The summary will be checked by a healthcare provider and corrected, if necessary, before being locked and sent to the patient or caregiver to keep for their own records.
218824665|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
219195560|NCT02518048|DRUG|LEO 90100 Aerosol foam|
219195561|NCT02518048|DRUG|Betesil® 2.25 mg|
219437291|NCT05794880|DEVICE|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
219437292|NCT04889690|DRUG|Danicopan|
219437293|NCT04889690|DRUG|Placebo|
219437294|NCT01787045|OTHER|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
218824666|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
218824667|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
218824668|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
219195562|NCT05220631|BEHAVIORAL|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
219195563|NCT05220631|BEHAVIORAL|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
219437295|NCT01787045|OTHER|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
219580354|NCT00876018|OTHER|Nutritional supplement|Fortified nutritional powder
219580355|NCT00876018|OTHER|Placebo|Un-fortified nutritional powder
218824669|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
218824670|NCT01187095|BEHAVIORAL|Expressive writing|3 consecutive days of writing
218824671|NCT01187095|BEHAVIORAL|Active ctrl|Control
218824672|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
218824673|NCT01559415|OTHER|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
218824674|NCT01559415|OTHER|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
218824675|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
219010073|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
219010074|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
219010075|NCT05415085|PROCEDURE|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
219437296|NCT05055037|OTHER|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
219437297|NCT05679440|BEHAVIORAL|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
219437298|NCT04230590|OTHER|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
219010076|NCT03867604|PROCEDURE|Sham injection|Injection to the subcutaneous layer at upper trapezium level
219437299|NCT02668952|DRUG|0.9% Normal Saline (0.9% Sodium Chloride) injection|
218824676|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
218824677|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
218824678|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
218824679|NCT05595850|BEHAVIORAL|Mindfulness|Online non-meditation mindfulness program
218824680|NCT05595850|BEHAVIORAL|Mindful Learning|Online learning program
218824681|NCT03663855|DRUG|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
218824682|NCT01475721|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
219010077|NCT03867604|PROCEDURE|Fascia injection|Injection to the fascia below upper trapezium muscle
219010078|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
219010079|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
219010080|NCT00308503|DRUG|eplivanserin (SR46349)|oral administration
219010081|NCT00308503|DRUG|placebo|oral administration
218824683|NCT01475721|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
218824684|NCT01475721|DRUG|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
218824685|NCT01475721|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
218824686|NCT01475721|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
218824687|NCT01475721|DRUG|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
218824688|NCT04343092|DRUG|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
219010082|NCT01304901|DRUG|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
219010083|NCT01304901|DRUG|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
219195564|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
219195565|NCT06745960|DEVICE|electrical muscle stimulation device (EMS gymna)|muscle stimulant device
219195566|NCT06745960|OTHER|physical therapy program|neck exercises
218824689|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
218824690|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
218824691|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
218824692|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
218824693|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
218824694|NCT02377024|DIETARY_SUPPLEMENT|placebo|
218824695|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
218824696|NCT04861779|DRUG|HSK29116|Oral HSK29116
218824697|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
218824698|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
218824699|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
218824700|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
219437300|NCT02668952|DRUG|Isolyte S injection|
219437301|NCT02970396|BEHAVIORAL|self-management|
219437302|NCT06104891|DIETARY_SUPPLEMENT|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
219437303|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
218824701|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
218824702|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
218824703|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
218824704|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
218824705|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
218824706|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
218824707|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
218824708|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
218824709|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
218824710|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
218824711|NCT00619944|DRUG|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
218824712|NCT00619944|DRUG|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
218824713|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
218824714|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
219195567|NCT06767761|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
219195568|NCT06767761|DRUG|Insulin Glargine U100 group|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
219195569|NCT06677541|OTHER|Instructional handout|A handout on how to improve sexual dysfunction/function will be provided
219437304|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
219437305|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
219437306|NCT01958554|BEHAVIORAL|Intervention Group|
219437307|NCT02474914|DRUG|Octreotide|Octreotide will be given after PD
219437308|NCT02474914|DRUG|Placebo|Octreotide will NOT be given after PD
219437309|NCT03358004|DRUG|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
219437310|NCT03358004|DRUG|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
219437311|NCT03809156|DRUG|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
219437312|NCT02231489|DRUG|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
219437313|NCT02231489|DRUG|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
218824715|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
218824716|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
218824717|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
219437314|NCT02231489|DRUG|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
219437315|NCT00441727|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
219437316|NCT00441727|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
219437317|NCT00441727|DRUG|Placebo|Placebo once daily
219437318|NCT06392178|DEVICE|SugarVita|Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
219437319|NCT01829867|DRUG|sNN0031|
219437320|NCT03042195|OTHER|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
219437321|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
219437322|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
219437323|NCT04578119|PROCEDURE|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
219437324|NCT03058848|DIETARY_SUPPLEMENT|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
219437325|NCT00161811|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
219437326|NCT00161811|BIOLOGICAL|Egg cell-derived Influenza Vaccine|
219437327|NCT02315105|PROCEDURE|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
219437328|NCT04770298|OTHER|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
219437329|NCT04751058|GENETIC|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~1. Automatic DNA extraction (ChemagicTM 360)~2. Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~3. Bioinformatic analysis:.~   * Identification of point mutations and small deletions or insertions~  * Analysis of CNVs using the BEDtools program package~  * Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF\> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
219437330|NCT05661175|PROCEDURE|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
219596909|NCT04800549|OTHER|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
219437331|NCT02949687|PROCEDURE|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
218824718|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
218824719|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
218824720|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
219195570|NCT06677541|DEVICE|Vibrator|An FDA approved vibrator device to improve sexual function will be provided
219437332|NCT00549354|DEVICE|Endoluminal Graft|
219437333|NCT04112745|OTHER|Static magnet|Static magnet with 2,000 Gauss
218824721|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
219437334|NCT04112745|OTHER|Placebo|Polyvinyl chloride resin material black jewelry
219437335|NCT04067115|DRUG|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
218824722|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
218824723|NCT00111072|DRUG|dexamethasone 0.01% solution|
218824724|NCT04941690|OTHER|A questionnaire method was used.|The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
218824725|NCT01142440|BEHAVIORAL|behavioral intervention|"* Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups"
218824726|NCT01820806|DRUG|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
218824727|NCT04849637|DRUG|Virgin Coconut Oil|Oral supplementation of virgin coconut oil to COVID-19 patients
219437336|NCT04067115|DRUG|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
219437337|NCT04067115|DIAGNOSTIC_TEST|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
219437338|NCT04067115|OTHER|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
219437339|NCT06105853|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors, representing the judging panel, and a faked exam situation (15 minutes duration).
219437340|NCT06105853|BEHAVIORAL|Barlab Cue-Exposure|Participants are exposed to a bar situation with their individual favorite alcohol presented. They handle their favorite alcoholic drink and water (9 minutes duration).
219437341|NCT06105853|BEHAVIORAL|Functional magnetic resonance imaging|Participants undergo a fMRI screening including three different behavioral tasks assessing alcohol cue reactivity, response inhibition, and emotion processing
219437342|NCT01290055|BIOLOGICAL|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
219437343|NCT01290055|OTHER|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
219437344|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^9 vp
219437345|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^10 vp
219437346|NCT04586673|BIOLOGICAL|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10\^8 pfu
219437347|NCT04586673|BIOLOGICAL|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10\^8 pfu
218824728|NCT04180111|DEVICE|CATS Tonometer|CATS Tonometer Prism
218824729|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
218824730|NCT02053844|OTHER|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
218824731|NCT02053844|OTHER|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
218824732|NCT03238989|OTHER|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
218824733|NCT02611102|DIETARY_SUPPLEMENT|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
218824734|NCT02830243|DRUG|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
218824735|NCT02830243|DRUG|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
219195571|NCT06677398|OTHER|Debriefing Method 1|The researchers used a debriefing method that they chose after a virtual simulation
219195572|NCT06677398|OTHER|Debriefing Method VP|The researchers used the debriefing method that virtual patient simulator presents
219437348|NCT04675788|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
219437349|NCT04675788|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
219437350|NCT04675788|DRUG|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
219437351|NCT04675788|DRUG|Placebo|Lactose capsules
219437352|NCT01349075|RADIATION|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
219437353|NCT06225284|DRUG|Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg|After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.
218824736|NCT03505333|PROCEDURE|conventional suture|we use Liga-sure device for hysterectomy
218824737|NCT04567524|DRUG|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
219195573|NCT06677398|OTHER|Debriefing Method 2|The researchers used a debriefing method that they chose after a virtual simulation
219195574|NCT01258036|RADIATION|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
219437354|NCT06851910|DRUG|Lacosamide|Patients will be included if they are prescribed intravenous lacosamide for their trigeminal neuralgia exacerbation
219437355|NCT01700647|OTHER|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
219437356|NCT01700647|OTHER|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
219437357|NCT01709214|DRUG|Cebranopadol (GRT6005) Low-Dose Range|Capsules
219437358|NCT01709214|DRUG|Cebranopadol (GRT6005) High-Dose Range|Capsules
219437359|NCT01709214|DRUG|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
219437360|NCT01709214|DRUG|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
219596910|NCT04808336|OTHER|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
218824738|NCT00901303|DRUG|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
218824739|NCT01739894|DRUG|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
218824740|NCT02452073|OTHER|Thyroid function tests|
218824741|NCT04923243|PROCEDURE|hip/knee replacement|hip/knee replacement
218824742|NCT03092310|DEVICE|Artificial Pancreas Device|Artificial Pancreas Device
219010084|NCT05335564|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
219010085|NCT04843423|DRUG|Cariprazine|"At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit."
219010086|NCT02282020|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
219010087|NCT02282020|DRUG|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
219010088|NCT05990101|BEHAVIORAL|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
219010089|NCT05620004|DRUG|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
219010090|NCT02244489|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
219010091|NCT02244489|DRUG|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
219010092|NCT02244489|DRUG|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
219010093|NCT02305108|OTHER|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
219010094|NCT02305108|OTHER|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
219010095|NCT04941235|DEVICE|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
219010096|NCT02747706|BEHAVIORAL|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
219010097|NCT06221904|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
219195575|NCT01258036|BIOLOGICAL|Sampling|Urine and blood samples
219195576|NCT01258036|RADIATION|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
218824743|NCT06388252|PROCEDURE|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
218824744|NCT06388252|PROCEDURE|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
219437361|NCT03235726|DRUG|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
219437362|NCT03235726|DRUG|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
219596911|NCT04808336|PROCEDURE|fixation surgical procedure|Group 2: thirty patients underwent surgery
219596912|NCT04651413|DIAGNOSTIC_TEST|PCR Value|Data collection and interpretation
218824745|NCT00173017|DEVICE|wearing N95 masks|
219596913|NCT06632808|OTHER|Exercise|Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
218824746|NCT01789242|DRUG|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
218824747|NCT01789242|DRUG|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
218824748|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
218824749|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
218824750|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
218824751|NCT05404971|OTHER|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
219010098|NCT00082355|DRUG|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
219010099|NCT01051050|BEHAVIORAL|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
219010100|NCT01051050|BEHAVIORAL|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
219010101|NCT06443840|DEVICE|AutonHome® device|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
219010102|NCT01207765|DRUG|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
218824752|NCT05404971|OTHER|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
218824753|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
218824754|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
218824755|NCT00439335|DRUG|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
218824756|NCT00439335|DRUG|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
218824757|NCT01615744|PROCEDURE|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
218824758|NCT01615744|PROCEDURE|Non-surgical management|Early active exercises and elevation to decrease swelling
218824759|NCT00753948|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
218824760|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
218824761|NCT01981798|BEHAVIORAL|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
219437363|NCT04813302|PROCEDURE|Coronally advanced flap and connective tissue graft|CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
219437364|NCT00305734|DRUG|bortezomib|Given IV
219437365|NCT00305734|DRUG|gemcitabine hydrochloride|Given IV
219437366|NCT00305734|OTHER|laboratory biomarker analysis|Correlative studies
219437367|NCT04436783|DEVICE|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
219437368|NCT04436783|OTHER|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
219580356|NCT05195866|DIAGNOSTIC_TEST|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
219596914|NCT02242045|DRUG|Idelalisib|150 mg tablet(s) administered orally twice daily
219596915|NCT03039270|OTHER|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
219010103|NCT01207765|DRUG|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
219010104|NCT00759863|BEHAVIORAL|Lifezig|Personalized Reminiscence Video
219010105|NCT04213365|OTHER|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
218824762|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
218824763|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
218824764|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
218824765|NCT03314610|OTHER|Gait speed|No intervention, only propose water and wait for need to void
218824766|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
218824767|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
218824768|NCT00060710|DRUG|CP-461|
218824769|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
218824770|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
218824771|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
219195577|NCT05027529|DEVICE|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
219195578|NCT05027529|OTHER|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
218824772|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
218824773|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
218824774|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
218824775|NCT02994745|DRUG|Fimasartan, Atorvastatin|
219010106|NCT02653391|DRUG|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
219010107|NCT02653391|DRUG|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
219195579|NCT05312645|DRUG|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
219195580|NCT05312645|OTHER|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
219195581|NCT04505410|OTHER|"A plant based high fiber diet that mimics fasting (FMD) plus advanced therapy"|Patients will do two 5-day cycles of a fasting mimicking diet. They will start the first diet cycle 1 week after initiating a new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
218824776|NCT02065492|DRUG|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
218824777|NCT02065492|DRUG|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
218824778|NCT00827177|DRUG|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
219010108|NCT02653391|DRUG|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
219010109|NCT02653391|DRUG|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
219010110|NCT01973647|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
219010111|NCT01973647|BEHAVIORAL|COPD Education|Six weekly sessions of COPD education
219010112|NCT01973647|BEHAVIORAL|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
219010113|NCT02845245|OTHER|3D printed plastic model prototype|
219010114|NCT02845245|OTHER|3D CT scan|
219010115|NCT02845245|OTHER|Plain film radiographs|
219010116|NCT02040454|DRUG|Paclitaxel|
219010117|NCT02040454|PROCEDURE|Standard Therapy|
219010118|NCT04791566|DRUG|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
219010119|NCT04791566|DRUG|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
219010120|NCT02014896|OTHER|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
219195582|NCT04505410|DRUG|Advanced therapy only without dietary intervention|Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
219195583|NCT06862531|BIOLOGICAL|blood sample|A sample of blood (1mL) was taken
219195584|NCT06592599|DRUG|Toripalimab|Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.
218824779|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
219437369|NCT03590093|PROCEDURE|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
219437370|NCT03590093|PROCEDURE|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
218824780|NCT03842267|DRUG|Gemigliptin 50mg|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
218824781|NCT03842267|DRUG|Gemigliptin Placebo|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* \- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
218824782|NCT03068897|DRUG|Metaxalone|Metaxalone 400-800mg
218824783|NCT03068897|DRUG|Tizanidine|Tizanidine 2-4mg
218824784|NCT03068897|DRUG|Baclofen|Baclofen 10-20mg
218824785|NCT03068897|DRUG|Ibuprofen 600 mg|Ibuprofen
219437371|NCT00854438|OTHER|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
219437372|NCT02003118|DRUG|AKR 202|
219437373|NCT02003118|DRUG|Placebo|
219580357|NCT01516866|PROCEDURE|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
218824786|NCT03068897|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
218824787|NCT04280575|PROCEDURE|Percutaneous coronary intervention|Coronary artery stenting for stable angina
218824788|NCT02996422|BEHAVIORAL|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
219437374|NCT05975372|DEVICE|Blossom tissue expander|Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
218824789|NCT02996422|BEHAVIORAL|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
218824790|NCT01051037|RADIATION|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
218824791|NCT01051037|RADIATION|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
219437375|NCT05975372|DEVICE|Standard tissue expansion|Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
219437376|NCT03531606|DRUG|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
219437377|NCT03531606|DRUG|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
219437378|NCT02864706|DRUG|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
219437379|NCT02864706|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
219437380|NCT02864706|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
219437381|NCT02864706|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
219437382|NCT04415190|OTHER|early palliative care|early palliative care
218824792|NCT01688297|BIOLOGICAL|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
218824793|NCT01688297|BIOLOGICAL|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
218824794|NCT02910141|DEVICE|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
218824795|NCT06487234|DEVICE|Functional band|Participants will wear the functional band for 1-hour electroacupuncture stimulation
218824796|NCT06487234|DEVICE|Placebo band|Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
219010121|NCT00953446|PROCEDURE|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
219010122|NCT05620550|PROCEDURE|ozonated oil|Post operative scar treatment with ozonated oil
219010123|NCT05620550|PROCEDURE|non ozonated oil|Post operative scar treatment with non ozonated oil
219010124|NCT00834860|DRUG|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
219010125|NCT02328755|DRUG|peg-IFN-α|
219010126|NCT02328755|PROCEDURE|Hematopoietic Cell Transplant (HCT)|
219010127|NCT02328755|DRUG|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
219010128|NCT02328755|DRUG|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
219359857|NCT07178665|RADIATION|Radiation: Accelerated Partial Breast Irradiation (APBI)|"Radiation: Accelerated Partial Breast Irradiation (APBI) - 5 fractions delivered every other day before surgery.~Procedure: Surgery - lumpectomy or mastectomy scheduled 1-3 weeks after RT; additional whole-breast/lymph node RT if indicated."
219359858|NCT07178730|DRUG|Sacituzumab govitecan|"SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle.~The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines.~SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC."
219580358|NCT05009966|DRUG|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
219580359|NCT00387920|DRUG|sunitinib malate|Given orally
219580360|NCT00387920|OTHER|pharmacological study|Correlative studies
219580361|NCT00387920|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219580362|NCT00387920|OTHER|laboratory biomarker analysis|Correlative studies
219580363|NCT01774825|DIETARY_SUPPLEMENT|IQP-CL-101|2 softgels twice a day
219580364|NCT01774825|OTHER|Placebo|2 softgels twice a day
218824797|NCT03657836|DIETARY_SUPPLEMENT|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
218824798|NCT03657836|DRUG|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
218824799|NCT02566811|PROCEDURE|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
218824800|NCT02566811|PROCEDURE|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
219010129|NCT03253887|DRUG|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
219010130|NCT03877289|DRUG|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
219010131|NCT03877289|OTHER|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
219010132|NCT03877289|DRUG|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
219010133|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
219359859|NCT07178730|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.
219359860|NCT07178730|DRUG|SoC Chemotherapy|Standard of care chemotherapy as per common treatment guidelines and recommendations
219437383|NCT03135262|DRUG|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
219437384|NCT03135262|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
218824801|NCT05975346|DRUG|Ketamine|description
218824802|NCT05975346|OTHER|saline nebulization|description
218824803|NCT00616642|DRUG|rosiglitazone maleate|Given orally
218824804|NCT00886418|DRUG|muscle relaxant|muscle relaxant administration throughout anesthesia
218824805|NCT00886418|DRUG|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
218824806|NCT03856359|DRUG|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
218824807|NCT04340492|OTHER|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
218824808|NCT04340492|OTHER|Standard care|Standard care concerning Parkinson's disease and physical activity
218824809|NCT04686344|DRUG|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
218824810|NCT04686344|DRUG|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
218824811|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
219010134|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
219010135|NCT03838133|DRUG|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
219010136|NCT03838133|DRUG|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
219010137|NCT03838133|DRUG|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
218824812|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
218824813|NCT04284501|BEHAVIORAL|Non|questionnaire
218824814|NCT04845594|BEHAVIORAL|MySmileBuddy (MSB)|The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
218824815|NCT06257225|PROCEDURE|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
218824816|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
218824817|NCT00001964|DRUG|ATG|ATG
218824818|NCT00001964|DRUG|MMF|MMF
218824819|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
218824820|NCT00915889|OTHER|counseling intervention|counseling and communications studies
218824821|NCT00915889|OTHER|questionnaire administration|Ancillary studies
218824822|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
218824823|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
218824824|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
218824825|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
219010138|NCT03838133|DRUG|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
219010139|NCT00060112|BIOLOGICAL|oblimersen sodium|Given IV
219010140|NCT00060112|DRUG|gemcitabine hydrochloride|Given IV
219010141|NCT00060112|OTHER|pharmacological study|Correlative studies
219010142|NCT00060112|OTHER|laboratory biomarker analysis|Correlative studies
219010143|NCT02046356|PROCEDURE|MESS-RFA|
219010144|NCT05087784|COMBINATION_PRODUCT|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
219010145|NCT05060159|OTHER|Hemofiltration|Postdilutional Hemofiltration
219010146|NCT00003514|DRUG|antineoplaston A10|
219010147|NCT00003514|DRUG|antineoplaston AS2-1|
219010148|NCT00003514|PROCEDURE|alternative product therapy|
218824826|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
219437385|NCT03135262|DRUG|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
218824827|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
218824828|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
218824829|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
218824830|NCT01722344|BEHAVIORAL|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
218824831|NCT01722344|BEHAVIORAL|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
218824832|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
218824833|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
218824834|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
218824835|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
218824836|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
218824837|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
218824838|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
218824839|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
218824840|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
218824841|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
218824842|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
218824843|NCT02141672|DRUG|Voclosporin High Dose|
218824844|NCT02141672|DRUG|Voclosporin Low Dose|
218824845|NCT02141672|DRUG|Placebo|
219010149|NCT00003514|PROCEDURE|biological therapy|
219010150|NCT00003514|PROCEDURE|biologically based therapies|
219010151|NCT00003514|PROCEDURE|cancer prevention intervention|
219010152|NCT00003514|PROCEDURE|complementary and alternative therapy|
219010153|NCT00003514|PROCEDURE|differentiation therapy|
219437386|NCT03135262|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
219437387|NCT05442125|OTHER|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
219437388|NCT05442125|OTHER|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
219580365|NCT04919941|OTHER|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
219580366|NCT01983319|DEVICE|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
218824846|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
218824847|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
218824848|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
218824849|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
218824850|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
218824851|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
218824852|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
218824853|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
218824854|NCT04992026|PROCEDURE|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
218824855|NCT04992026|DRUG|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
218824856|NCT04992026|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
218824857|NCT04992026|DRUG|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
218824858|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
218824859|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
218824860|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
219010154|NCT02295150|DRUG|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
219010155|NCT05022784|DRUG|Nintedanib|Nintedanib
219010156|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
219010157|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
219010158|NCT05549206|DRUG|Placebo|Saline solution
219359861|NCT07178639|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
219359862|NCT07178639|DRUG|Nepafenac 0.3% Oph Susp|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
219359863|NCT07178639|DRUG|diclofenac 0.1% ophthalmic susp.|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
219010159|NCT01711177|DRUG|placebo|Placebo
219010160|NCT01711177|DRUG|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
219010161|NCT05195112|DRUG|MT921|Active ingredient
219010162|NCT05195112|DRUG|Placebo|Normal Saline
219010163|NCT05715008|OTHER|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
219010164|NCT05715008|OTHER|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
219010165|NCT03835585|DEVICE|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
219359864|NCT07177833|DEVICE|Fractional CO2 laser|Fractional CO2 Laser Therapy is an extra-dermal (applied to the surface of the skin) and non-invasive treatment that involves the use of lasers to destroy and reduce abnormal collagen in scarred tissue.
219359865|NCT07177833|OTHER|Sham (No Treatment)|Patients will undergo a treatment with a vibratory device capable of mimicking fractional CO2 laser therapy
219359866|NCT07177417|BIOLOGICAL|FluMist|intranasal administered live attenuated influenza vaccine
219359867|NCT07177417|BIOLOGICAL|inactivated influenza vaccine|intramuscular administered inactivated influenza vaccine
219359868|NCT07177417|PROCEDURE|bronchoscopy|bronchoscopy with bronchoalveolar lavage and endobronchial biopsy sampling
219359869|NCT07177352|OTHER|No Intervention|Participants will have their blood drawn and cognitive score measured by the ISLT.
219359870|NCT07177391|OTHER|Discontinuous subcostal echocardiographic cardiac output assessment|Right Ventricular Outflow Chamber Diameter (RVOD) and Left Ventricular Outflow Chamber Diameter (LVOD) assessments via subcostal approach
219195585|NCT06592599|RADIATION|Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation|"Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation."
219580367|NCT01983319|DEVICE|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
219580368|NCT01983319|BEHAVIORAL|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
218824861|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
218824862|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
219580369|NCT01519102|DEVICE|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
218824863|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
218824864|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
218824865|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
218824866|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
218824867|NCT05554302|DRUG|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
218824868|NCT04333615|BEHAVIORAL|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
218824869|NCT05045716|DRUG|Lecanemab|Lecanemab IV infusion.
218824870|NCT05045716|DRUG|Lecanemab|Lecanemab SC injection.
218824871|NCT02864264|DRUG|BMS-986184|
218824872|NCT02864264|DRUG|Placebo matching BMS-986184|
218824873|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
218824874|NCT01184976|BIOLOGICAL|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
218824875|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
218824876|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
218824877|NCT04992468|DRUG|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
218824878|NCT04992468|DRUG|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
218824879|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
218824880|NCT03952403|DRUG|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
218824881|NCT03952403|DRUG|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
219596916|NCT03039270|OTHER|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
218824882|NCT03952403|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
218824883|NCT03952403|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
218824884|NCT02457247|DRUG|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
219195586|NCT06681441|DRUG|QRL-101 Dose A|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
218824885|NCT02457247|DRUG|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
218824886|NCT02457247|DRUG|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
218824887|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
218824888|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
218824889|NCT00724100|DRUG|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
218824890|NCT04582006|PROCEDURE|Bariatric surgery|Surgical treatment of morbid obesity.
218824891|NCT01061385|DEVICE|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
218824892|NCT01061385|OTHER|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
218824893|NCT04850326|DIETARY_SUPPLEMENT|AP green tea extract|single intake of AP green tea extract
218824894|NCT04427293|DRUG|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
218824895|NCT04427293|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
218824896|NCT00533429|DRUG|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
218824897|NCT00533429|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
218824898|NCT00533429|DRUG|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
219010166|NCT03835585|OTHER|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
219580370|NCT03986450|OTHER|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
218824899|NCT00533429|DRUG|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
218824900|NCT00533429|DRUG|Placebo|oral, daily
218824901|NCT01464879|DRUG|Testosterone Gel (FE 999303)|
218824902|NCT02271893|DRUG|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
218824903|NCT03115918|DEVICE|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
218824904|NCT03115918|OTHER|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
218824905|NCT03800030|DEVICE|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
218824906|NCT03800030|DEVICE|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
218824907|NCT03800030|DEVICE|Sham tACS|NeuroConn technologies, direct current-stimulator plus
218824908|NCT03965845|DRUG|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
218824909|NCT03965845|DRUG|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
218824910|NCT05232656|BEHAVIORAL|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
218824911|NCT02230189|BIOLOGICAL|Segmental airway allergen challenge|
218824912|NCT02230189|PROCEDURE|Bronchoscopy|
218824913|NCT02230189|DIAGNOSTIC_TEST|Methacholine challenge test|
218824914|NCT02230189|DIAGNOSTIC_TEST|Spirometry|
218824915|NCT02230189|DIAGNOSTIC_TEST|Allergen skin prick test|
218824916|NCT02363530|DEVICE|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
219010167|NCT03835585|BEHAVIORAL|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
219359871|NCT07177534|OTHER|No intervention|This study is a retrospective observational study without intervention.
219359872|NCT05513027|DEVICE|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.
219359873|NCT05513027|DEVICE|PET/CT|-Standard of care
219359874|NCT05634408|DEVICE|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
219359875|NCT06452797|BEHAVIORAL|ProVent-14 score|A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
219359876|NCT02192931|DRUG|Creatine monohydrate|
219010168|NCT03835585|BEHAVIORAL|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
219010169|NCT05951010|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
219010170|NCT05221814|DIAGNOSTIC_TEST|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
219195587|NCT06681441|DRUG|QRL-101 Dose B|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
219195588|NCT06681441|DRUG|Placebo|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
219195589|NCT04554940|BIOLOGICAL|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
219437389|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
219580371|NCT06437106|BEHAVIORAL|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
218824917|NCT02363530|DEVICE|BSS|Balanced Salt Solution including normal saline and glucose
218824918|NCT00432393|DRUG|levodopa-carbidopa|
218824919|NCT04712747|PROCEDURE|Ophthalmological examinations|"* OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~* Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~* Color retinophotography~* Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
218824920|NCT04712747|PROCEDURE|Blood pressure measurement at rest|At the inclusion visit
218824921|NCT05749640|OTHER|Precontoured sectional matrix EZ COAT|All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)
218824922|NCT05749640|OTHER|PerForm™|Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
218824923|NCT05749640|OTHER|AdDent Trimax™|Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
218824924|NCT05749640|OTHER|Contact Pro™|Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
218824925|NCT03110705|BEHAVIORAL|sport|recreaational sport : diving or multisport
218824926|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
218824927|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
219010171|NCT00607529|OTHER|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
218824928|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
219010172|NCT04375189|OTHER|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
219195590|NCT06838221|OTHER|A Before and After study|interactive oral health educational program for children with intellectual disability and their care givers
219195591|NCT06838221|OTHER|before and after study|To evaluate the oral health of a group of children with disability and determine the effectiveness of the interactive oral health education program on oral health of children and care givers' oral health knowledge.
218824929|NCT04067232|DIAGNOSTIC_TEST|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
218824930|NCT01979679|DRUG|Lurasidone 80 mg|
218824931|NCT01979679|DRUG|Lurasidone 120 mg|
218824932|NCT01979679|DRUG|Lurasidone 160 mg|
218824933|NCT06246747|OTHER|In clinic physical therapy|Patients visit the clinic to receive traditional physical therapy treatment
218824934|NCT06246747|OTHER|Telerehabilitation only|Patients receive remote treatment using the Wizecare platform
218824935|NCT02960425|DIETARY_SUPPLEMENT|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
218824936|NCT02960425|DIETARY_SUPPLEMENT|Placebo|Topical placebo
218824937|NCT04266522|OTHER|Informational Intervention|Receive printed materials
218824938|NCT04266522|OTHER|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
218824939|NCT04266522|OTHER|Questionnaire Administration|Ancillary studies
219195592|NCT05769608|DRUG|Placebo|Placebo once daily for 12 weeks
219195593|NCT05769608|DRUG|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
219437390|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
219437391|NCT01675141|DRUG|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
219437392|NCT04002258|DRUG|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
219437393|NCT02057276|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
219437394|NCT02057276|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|
219437395|NCT02057276|OTHER|Occupational Therapy|
219437396|NCT00810095|DEVICE|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
219437397|NCT02030665|BEHAVIORAL|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
219437398|NCT02030665|BEHAVIORAL|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
219437399|NCT02030665|BEHAVIORAL|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
219437400|NCT01949298|PROCEDURE|dental implant placement|
219437401|NCT04535206|DIAGNOSTIC_TEST|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
219580372|NCT06437106|BEHAVIORAL|blanket without mother's smell|Intervention group two consists of preterm infants who receive blanket without mother's odor.
218824940|NCT03053778|OTHER|Early follow-up|Early follow-up until 4 weeks after discharge
218824941|NCT00328029|DRUG|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
218824942|NCT00328029|PROCEDURE|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
218824943|NCT00328029|PROCEDURE|pharmacokinetics, done during the treatment|"12 blood collections :~* after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~* 3 hours after 2nd taken of Busulfan~* 3 hours after 3rd taken of Busulfan~* 3 hours after 4th taken of Busulfan~* 3 hours after 5th taken of Busulfan~* 3 hours after 6th taken of Busulfan."
218824944|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
218824945|NCT01220492|DRUG|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
218824946|NCT01220492|DRUG|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
219195594|NCT05769608|DRUG|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
219437402|NCT03046160|OTHER|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
219437403|NCT03046160|OTHER|neck and scapular exercises.|A program of 12 neck and scapular exercises.
219580373|NCT06437106|BEHAVIORAL|control group|The control group includes premature babies who are not subjected to any intervention and receive the usual care.
219580374|NCT01597219|PROCEDURE|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
218824947|NCT00818493|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
218824948|NCT00818493|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
218824949|NCT00818493|DRUG|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
218824950|NCT02170844|DRUG|BIBR 1048 MS|
218824951|NCT02170844|DRUG|Placebo of BIBR 1048 MS|
218824952|NCT01459692|OTHER|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
219195595|NCT04440592|DRUG|MT-7117|MT-7117
219195596|NCT04440592|DRUG|Placebo|Placebo
219195597|NCT02818829|OTHER|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
219195598|NCT05193019|OTHER|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
219195599|NCT06465108|DRUG|MBX 2109|Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
218824953|NCT01480102|DRUG|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
219010173|NCT06085079|DRUG|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
219010174|NCT00708162|DRUG|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
219580375|NCT01597219|PROCEDURE|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
218824954|NCT01480102|OTHER|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
219010175|NCT00708162|DRUG|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
219010176|NCT00708162|DRUG|EVG placebo|Placebo to match elvitegravir administered orally once daily
219010177|NCT00708162|DRUG|RAL placebo|RAL placebo administered orally twice daily.
219010178|NCT00708162|DRUG|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
219010179|NCT05590065|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
219195600|NCT06465108|OTHER|Placebo|Supplied in 1.4 mL water for injection
219195601|NCT06348316|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
219195602|NCT06348316|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
219195603|NCT06804746|PROCEDURE|DHOPE-COR-NMP|Resuscitation and viability assessment through the previously published protocol of sequential hypo- and normothermic liver machine perfusion with controlled oxygenated rewarming (DHOPE-COR-NMP) based on a blood-based perfusate.
219437404|NCT03046160|OTHER|corrective tape|elastic tape used to correct the anterior tilt of the scapula
219437405|NCT01770093|OTHER|Questionnaire|
219437406|NCT05301803|DEVICE|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
219437407|NCT01599806|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
219437408|NCT01599806|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
219580376|NCT00287313|DRUG|Vitamin K|
219580377|NCT05086718|OTHER|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
218824955|NCT05545748|BEHAVIORAL|Zero (0) Tolerance Program (SToP)|"1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative telephone text messages: Reminder phone messages related to SHS and THS"
219010180|NCT02425150|PROCEDURE|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
219010181|NCT02425150|PROCEDURE|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
219010182|NCT03858088|PROCEDURE|Liver transplantation|Liver transplantation from deceased donors
219580378|NCT02658513|OTHER|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
219010183|NCT00818233|DEVICE|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
219195604|NCT06560216|DIETARY_SUPPLEMENT|Apigenin|0.2 mM in freezing medium
219010184|NCT00830843|DRUG|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
219010185|NCT00830843|DRUG|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
219010186|NCT04320381|BEHAVIORAL|Qualitative Interview|2 Semi-Structured Qualitative Interviews
218824956|NCT05545748|BEHAVIORAL|Exposure Feedback Group|1\. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
219010187|NCT04212247|BEHAVIORAL|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
219010188|NCT04212247|BEHAVIORAL|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
219010189|NCT00708643|DEVICE|Habitual Silicone Hydrogel Contact Lens|contact lens
219010190|NCT00708643|DEVICE|narafilcon A|contact lens
219010191|NCT02063490|BEHAVIORAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~\+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
219010192|NCT04345263|PROCEDURE|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
219010193|NCT02105428|BEHAVIORAL|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
219010194|NCT00128570|BEHAVIORAL|behavioral dietary intervention|
219195605|NCT01586910|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
219437409|NCT01599806|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
219437410|NCT01599806|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
219437411|NCT05599854|PROCEDURE|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
219437412|NCT05325944|BEHAVIORAL|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
219437413|NCT05325944|BEHAVIORAL|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
219437414|NCT05325944|BEHAVIORAL|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
219437415|NCT01407848|DRUG|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
219437416|NCT01407848|DRUG|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
219437417|NCT02023918|DRUG|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
219437418|NCT02779881|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus LGG|
219580379|NCT02658513|OTHER|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
219580380|NCT00000813|BIOLOGICAL|ALVAC-HIV gp160MN (vCP125)|
219580381|NCT00000813|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219580382|NCT00000813|BIOLOGICAL|rgp120/HIV-1 SF-2|
219580383|NCT03560921|DIAGNOSTIC_TEST|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
218824957|NCT01192880|DRUG|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
218824958|NCT01192880|DRUG|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
218824959|NCT01192880|DRUG|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
218824960|NCT02340884|BEHAVIORAL|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
219010195|NCT00128570|OTHER|educational intervention|
219010196|NCT00128570|OTHER|internet-based intervention|
219010197|NCT00128570|OTHER|preventative dietary intervention|
219010198|NCT00128570|PROCEDURE|evaluation of cancer risk factors|
219195606|NCT01586910|PROCEDURE|Surgical Aortic Valve Replacement (SAVR)|
219195607|NCT01586910|DEVICE|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
219195608|NCT06280495|DRUG|Oxaliplatin|5 mg/m2 IV on day 1
218824961|NCT02834819|DRUG|3% Nebulized Hypertonic Saline|
218824962|NCT04479592|OTHER|Particle counter|Particle counter to measure the aerosol generated
218824963|NCT05604443|OTHER|retrospective analyze|retrospective analyze of MS39 and Pentacam images
218824964|NCT06007417|DRUG|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
218824965|NCT06007417|DRUG|Genotropin|Genotropin
218824966|NCT01663792|OTHER|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
218824967|NCT01663792|OTHER|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
219010199|NCT01244906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
219010200|NCT04379089|OTHER|Observational study only|No Intervention
219437419|NCT00489034|BEHAVIORAL|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
219437420|NCT00489034|BEHAVIORAL|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
219437421|NCT00489034|BEHAVIORAL|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
219437422|NCT03149926|OTHER|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
218824968|NCT01663792|OTHER|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
218824969|NCT00006356|DRUG|carboplatin|
219437423|NCT03423563|DEVICE|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
218824970|NCT00006356|DRUG|cisplatin|
219010201|NCT06031454|DRUG|Midazolam|oral
219010202|NCT06031454|DRUG|Omeprazole|oral
219010203|NCT06031454|DRUG|Rosuvastatin|oral
219010204|NCT06031454|DRUG|Verapamil|oral
219010205|NCT06031454|DRUG|Rifampin|oral
219010206|NCT06031454|DRUG|Leritrelvir|oral
219010207|NCT00388635|DRUG|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
219195609|NCT06280495|DRUG|Fluorouracil|400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
219437424|NCT03423563|DEVICE|Fexible intubation video endoscopy|Fexible intubation video endoscopy
219437425|NCT00391807|DRUG|Norethindrone acetate/ethinyl estradiol|one tablet per day
219580384|NCT00725621|BIOLOGICAL|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
218824971|NCT00006356|PROCEDURE|conventional surgery|
218824972|NCT01251302|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
218824973|NCT02255669|DEVICE|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
218824974|NCT02255669|DEVICE|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
218824975|NCT06054399|OTHER|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
218824976|NCT04280003|OTHER|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
218824977|NCT04280003|DRUG|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
218824978|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
219010208|NCT00388635|DRUG|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
219010209|NCT00388635|DRUG|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
219010210|NCT00584142|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
218824979|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
219010211|NCT01702701|DRUG|Montelukast|montelukast 10mg po pill q day for 12 weeks
219195610|NCT06280495|DRUG|Serplulimab|200 mg IV infusion on day 1
219010212|NCT01702701|DRUG|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
219010213|NCT02959047|DRUG|Alirocumab|150mg SQ every 2 weeks
218824980|NCT04547465|DIAGNOSTIC_TEST|Echocardiography|2D Speckle-tracking echocardiography
218824981|NCT00853892|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
218824982|NCT00853892|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
218824983|NCT02621437|OTHER|Osteopathy sessions|\- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
218824984|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
218824985|NCT01100281|BEHAVIORAL|Neuropsychological examination|Examination including especially concept formation
219195611|NCT06280495|DRUG|Bevacizumab|5 mg/kg IV infusion on day 1
219437426|NCT04521920|DRUG|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
219437427|NCT04521920|DRUG|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
219010214|NCT02959047|DRUG|Matching placebo|SQ every 2 weeks
219437428|NCT04843969|BEHAVIORAL|Stress induction|Exposure to a psychosocial stressor
219437429|NCT04843969|BEHAVIORAL|Control stress exposure|Exposure to a control task (no stress)
219437430|NCT04843969|BEHAVIORAL|Cue induction|Exposure to a smoking-related task
219437431|NCT04843969|BEHAVIORAL|Neutral cue exposure|Exposure to neutral cues
219580385|NCT00428779|PROCEDURE|running during 24 hours without sleep|patients running during 24 hours without sleep
218824986|NCT01100281|OTHER|MRI|MRI performed in T1-weighted three dimensional sequence
218824987|NCT00598819|DEVICE|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
218824988|NCT04389866|DEVICE|JUVÉDERM VOLUMA™ XC|Injectable gel
218824989|NCT04408677|DEVICE|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
218824990|NCT05745766|OTHER|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
218824991|NCT05745766|OTHER|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
218824992|NCT05745766|OTHER|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
218824993|NCT01339936|DEVICE|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
218824994|NCT05200312|DRUG|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
218824995|NCT05200312|DRUG|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
218824996|NCT05200312|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
218824997|NCT05200312|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
219010215|NCT03694860|OTHER|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
219010216|NCT04804943|DEVICE|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
219010217|NCT02408939|DRUG|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
219195612|NCT06952608|DRUG|Ciprofol group|General anesthesia induction and maintenance were performed using ciprofol.
219195613|NCT06952608|DRUG|Propofol group|General anesthesia induction and maintenance were performed using propofol.
219195614|NCT06488859|BEHAVIORAL|Positive Affect Treatment|Sessions 1-8: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects
219195615|NCT06488859|BEHAVIORAL|Positive Affect Treatment and Negative Affect Treatment|Sessions 1-4: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects Sessions 5-8: Exposure therapy to feared or avoided situations, sensations, or memories
219195616|NCT06154382|DRUG|Eltroxin administration|eltroxin administration
219437432|NCT00310349|BIOLOGICAL|23 valent pneumococcal polysaccharide vaccine|
219580386|NCT00428779|OTHER|no sleeping|patients without sleep during 24 hours
219580387|NCT05702879|DRUG|Ozanimod|Start of standard therapy
218824998|NCT05200312|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
218824999|NCT05200312|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
218825000|NCT05200312|DRUG|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
218825001|NCT02901600|OTHER|Detection of the expression of DMTB1 by immunohistochemistry|
218825002|NCT01680926|DIETARY_SUPPLEMENT|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
218825003|NCT03661177|OTHER|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
219010218|NCT01782807|PROCEDURE|Salpingectomy or Fimbriectomy|
219010219|NCT01971450|DRUG|Iloprost (Ventavis, BAYQ6256)|
219010220|NCT00891722|OTHER|biologic sample preservation procedure|
219580388|NCT05702879|DRUG|TNF Inhibitor|Start of standard therapy
219580389|NCT05702879|DRUG|Steroids|Start of standard therapy
219580390|NCT05702879|DRUG|Vedolizumab|Start of standard therapy
219580391|NCT05702879|DRUG|Ustekinumab|Start of standard therapy
219580392|NCT01189500|DRUG|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
218825004|NCT04197284|DEVICE|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
218825005|NCT04197284|DEVICE|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
218825006|NCT04197284|OTHER|kinesitherapy|isometric exercise of the quadriceps muscle
218825007|NCT01122979|DRUG|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
218825008|NCT01122979|DRUG|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
218825009|NCT01122979|DRUG|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
219010221|NCT00891722|OTHER|laboratory biomarker analysis|
219010222|NCT00891722|OTHER|questionnaire administration|
219010223|NCT03629821|OTHER|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
219010224|NCT05027412|DEVICE|En bloc TURBT Collins Loop|En bloc TURBT Collins Loop
219010225|NCT05027412|DEVICE|Conventional TURBT|Conventional TURBT
219010226|NCT01526265|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
219010227|NCT01526265|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
219010228|NCT01526265|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
219010229|NCT01526265|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
219010230|NCT01526265|BEHAVIORAL|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
219010231|NCT04532099|DEVICE|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
219010232|NCT04532099|DEVICE|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
219010233|NCT04532099|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
219010234|NCT04532099|DEVICE|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
218825010|NCT01122979|DRUG|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
218825011|NCT05187260|DRUG|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
218825012|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
219010235|NCT04002531|OTHER|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
219010236|NCT04002531|OTHER|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
219010237|NCT04002531|PROCEDURE|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
219010238|NCT04002531|PROCEDURE|Echocardiogram|A non-invasive sonogram of the heart
219010239|NCT04002531|PROCEDURE|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
219010240|NCT04002531|PROCEDURE|Urine collection|Urine will be collection to evaluate renal function (kidney health)
219010241|NCT04002531|PROCEDURE|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
219010242|NCT04002531|OTHER|Brief Pain Inventory questionnaire|A questionnaire about daily pain
219010243|NCT04002531|OTHER|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
219195617|NCT05502315|DRUG|Cabozantinib|40 mg taken orally
219195618|NCT05502315|DRUG|Nivolumab|480 mg by infusion
218825013|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
218825014|NCT00467376|DRUG|Insulin Glulisine|3 times a day before each meal
218825015|NCT00467376|DRUG|Lispro|3 times a day before each meal
218825016|NCT00467376|DRUG|Insulin Glargine|once daily
218825017|NCT04800393|DRUG|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
218825018|NCT04800393|DRUG|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
218825019|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
218825020|NCT02590536|DRUG|placebo|
218825021|NCT02525640|DEVICE|Hearing Aid|Hearing aid comparison
218825022|NCT05818826|DRUG|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
218825023|NCT05818826|DRUG|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
218825024|NCT04412681|DIAGNOSTIC_TEST|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
218825025|NCT02694601|DIETARY_SUPPLEMENT|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
218825026|NCT02694601|DIETARY_SUPPLEMENT|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
219010244|NCT02086864|DRUG|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
219010245|NCT02086864|DRUG|Placebo lactose/sucrose pill|
219010246|NCT02086864|BEHAVIORAL|Homeopathic consultation|
219010247|NCT00326443|BIOLOGICAL|CVD 909|5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
218825027|NCT02694601|DIETARY_SUPPLEMENT|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
218825028|NCT03793686|DRUG|PBCLN-003|Investigational drug
219580393|NCT01189500|DRUG|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
219580394|NCT04792359|DEVICE|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
218825029|NCT03793686|DRUG|Placebo|Placebo
219010248|NCT00326443|DRUG|Placebo|Buffer placebo administered on Day 0.
219010249|NCT00326443|BIOLOGICAL|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
219010250|NCT03454919|DRUG|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
219010251|NCT04644627|DRUG|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
219010252|NCT01847222|BIOLOGICAL|SANGUINATE™|PEG-bHb-CO
219010253|NCT01847222|DRUG|Normal Saline Solution|Placebo
219010254|NCT04779840|OTHER|anemia assessment|evaluation of anemia status
219010255|NCT02023398|DEVICE|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
219010256|NCT02023398|DEVICE|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
219010257|NCT05780112|OTHER|breathing exercise|"* Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand."
219010258|NCT04446910|BEHAVIORAL|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to promote attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
218825030|NCT00395109|DEVICE|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
218825031|NCT04256239|BEHAVIORAL|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
218825032|NCT01022970|DRUG|QAX576 placebo|
218825033|NCT01022970|DRUG|QAX576|
219437433|NCT02712281|BEHAVIORAL|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
219010259|NCT04446910|BEHAVIORAL|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
219010260|NCT00644995|BEHAVIORAL|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
218825034|NCT02264743|DRUG|Femoston Conti|Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
219010261|NCT00644995|BEHAVIORAL|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
219437434|NCT02712281|BEHAVIORAL|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
219437435|NCT02919410|DEVICE|iodophor-impregnated adhesive drapes|
219437436|NCT02919410|OTHER|No adhesive drapes|
219437437|NCT04694716|OTHER|No intervention|No intervention will be applied.
219437438|NCT01307553|DEVICE|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
219580395|NCT05672693|OTHER|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
219437439|NCT03895918|OTHER|Educational Activity|Undergo parenting skills intervention
219437440|NCT03895918|PROCEDURE|Patient Monitoring|Undergo medication adherence monitoring
219437441|NCT03895918|OTHER|Questionnaire Administration|Ancillary studies
219437442|NCT04897646|OTHER|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. \[Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal\]. Rev. Mal. Respir., 2020, 37: 550-560."
219580396|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
218825035|NCT02264743|DRUG|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
218825036|NCT02967679|DRUG|MD1003|
218825037|NCT00133341|DRUG|Goldnatriomthiosulphate, MDBGN, parthenolide|
219580397|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
219580398|NCT00062751|DRUG|Letrozole|Letrozole 2.5 mg daily
219580399|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
218825038|NCT03351946|PROCEDURE|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
218825039|NCT03351946|PROCEDURE|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
218825040|NCT01545765|DRUG|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
218825041|NCT01654874|DRUG|99mTc-MIP-1404|
218825042|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
218825043|NCT04319250|OTHER|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
218825044|NCT04319250|OTHER|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
218825045|NCT04319250|OTHER|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
218825046|NCT00020150|DRUG|O6-benzylguanine|
218825047|NCT00020150|DRUG|temozolomide|
218825048|NCT02379195|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
218825049|NCT02379195|DRUG|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
218825050|NCT02379195|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
218825051|NCT02379195|DRUG|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
219195619|NCT06962995|PROCEDURE|Blood Draw|Up to 60 mL (about 4-5 Tbsp) of blood will be collected for an initial blood draw and up to 30 mL (about 2-3 Tbsp) may be collected for a second blood draw, 25-45 days after first blood draw. The research blood will be collected at the time of a clinical blood draw, if possible.
219195620|NCT06962995|OTHER|Surveys|Participants will complete surveys related to attitudes and beliefs around Multi-Cancer Detection testing.
219195621|NCT06953440|DRUG|Dexamethasone Sodium Phosphate Injection|Patients will receive 4 milligrams of dexamethasone submucosal injection next to the extraction site.
218825052|NCT02379195|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
218825053|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
219010262|NCT04517474|BEHAVIORAL|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
219010263|NCT04517474|BEHAVIORAL|psychological support|psychological support
219195622|NCT06953440|OTHER|Normal Saline (Placebo)|Patients will receive 4 milligrams of normal saline solution next to the extraction site.
219195623|NCT06141252|DEVICE|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
219195624|NCT06888765|OTHER|Optical Coherence Tomography (OCT) and Body Composition Analysis|"This observational study included non-invasive diagnostic assessments to evaluate retinal, choroidal, ocular, and body composition parameters. Optical Coherence Tomography (OCT) measured macular and peripapillary retinal parameters, including retinal volume and cup/disc ratio. Enhanced Depth Imaging OCT (EDI-OCT) assessed choroidal thickness and vascularity, while Optical Coherence Tomography Angiography (OCTA) analyzed vessel density and foveal avascular zone (FAZ) metrics.~Optical biometry measured axial length, anterior chamber depth, lens thickness, K1, K2, and central corneal thickness. Autorefractometry and tonometry were part of the routine ophthalmologic examination, including slit-lamp biomicroscopy. Bioelectrical impedance analysis (BIA) assessed body composition, including BMI, fat percentage, muscle mass, and metabolic age. These assessments were for research purposes only, without therapeutic intervention."
219195625|NCT05278234|BEHAVIORAL|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
219195626|NCT03475212|BIOLOGICAL|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (\>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
219195627|NCT06201299|OTHER|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
219437443|NCT02556411|DRUG|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
219437444|NCT02556411|DRUG|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
219437445|NCT05062551|PROCEDURE|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
219010264|NCT02226406|OTHER|A: Chair - Leg Cycle ergometer|
219010265|NCT02226406|OTHER|B: Chair - Arm Cycle ergometer|
219010266|NCT02226406|OTHER|C: Walk in place|
219010267|NCT06215040|PROCEDURE|Endoscopic retrograde cholangiopancratography|common bile duct stone removal
219010268|NCT00399776|RADIATION|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
219010269|NCT04233645|OTHER|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
219010270|NCT04233645|OTHER|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
219437446|NCT03628495|DEVICE|compression|compression will be delivered using compression garment
219437447|NCT03628495|DEVICE|occlusion|occlusion will be delivered using silicone gel sheeting
219437448|NCT02680119|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
219437449|NCT02680119|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
219437450|NCT01721148|DRUG|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
219437451|NCT05539872|DRUG|I004|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
219437452|NCT05539872|DRUG|NovoLog|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
218825054|NCT05695170|BEHAVIORAL|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years."
218825055|NCT05695170|BEHAVIORAL|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
218825056|NCT04495686|BEHAVIORAL|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
219010271|NCT06157723|OTHER|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
219010272|NCT02482987|DEVICE|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
219010273|NCT02482987|DEVICE|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
219010274|NCT02482987|PROCEDURE|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
219010275|NCT02482987|PROCEDURE|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
219010276|NCT02891083|DRUG|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
219010277|NCT02891083|RADIATION|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
219010278|NCT02891083|OTHER|Control group (Surgery alone)|
219437453|NCT03432767|DEVICE|Non-invasive hemoglobin monitor|
219437454|NCT01952093|BEHAVIORAL|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
219437455|NCT01952093|BEHAVIORAL|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
219010279|NCT05376969|DRUG|DWP16001|DWP16001 Tablets
219010280|NCT02066233|DEVICE|EG Scan II (transnasal endoscopy)|
219010281|NCT02066233|PROCEDURE|Standard Endoscopy|
219010282|NCT02772081|COMBINATION_PRODUCT|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
219010283|NCT02772081|DRUG|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
219437456|NCT02877316|OTHER|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
219437457|NCT02877316|OTHER|safety plan on paper|Standard treatment with safety plan on paper
219437458|NCT00510107|DRUG|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
219437459|NCT00510107|DRUG|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
219437460|NCT01544686|DEVICE|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
219437461|NCT02856906|OTHER|occlusal adjustment|
219437462|NCT05968872|BEHAVIORAL|no intervation|it is observational, no intervention was taken
219437463|NCT04746560|DEVICE|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
219437464|NCT04430686|OTHER|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
219437465|NCT03683043|DRUG|Long GnRH agonist protocol|"8\. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9\. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
218825057|NCT04375956|DRUG|Pembrolizumab|Experimental
218825058|NCT02372695|DRUG|Paricalcitol|
218825059|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
218825060|NCT00769795|DRUG|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
219010284|NCT00314015|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
219010285|NCT00314015|PROCEDURE|Questionnaires|Questionnaires will be used
219010286|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care group|Self-hypnosis/self-care
219195628|NCT06201299|OTHER|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
219195629|NCT06562790|BIOLOGICAL|Gamma PN3|500, 1000 or 1500 µg by IM injection on Days 1 and 29
219437466|NCT03683043|PROCEDURE|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
219437467|NCT04673188|PROCEDURE|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
219437468|NCT02314871|OTHER|Epidural analgesia|see Arm/group description
219010287|NCT04218227|BEHAVIORAL|Music/self-care|Music-therapy/self-care
219195630|NCT06562790|BIOLOGICAL|Prevnar|1 dose on Day 1 and saline placebo on Day 29
219195631|NCT06839859|BEHAVIORAL|Family Acceptance Project - Online|a 9-week long online group program for LGBTQ+ youth of color and their parents / caregivers
218825061|NCT00769795|DRUG|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
218825062|NCT00769795|DRUG|Goserelin|10.8 mg subcutaneous once
219195632|NCT06966089|DEVICE|Urinary ExoDx test|A urine sample for ExoDx Study Kit will be collected onsite and shipped to Exosome Diagnostic's laboratory.
219195633|NCT06966089|DIAGNOSTIC_TEST|Transrectal ultrasound-guided prostate biopsy|Participants will be scheduled for transrectal ultrasound-guided prostate biopsy as per the standard diagnostic practice after urinary test.
218825063|NCT04725019|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
218825064|NCT04725019|BEHAVIORAL|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
218825065|NCT03483454|OTHER|Exercise class|Same as above.
219195634|NCT06966089|DIAGNOSTIC_TEST|Transperineal 12-core prostate biopsy|Participants will be scheduled for transperineal 12-core prostate biopsy as per the standard diagnostic practice after urinary test.
219437469|NCT02314871|DRUG|Piritramide|see Arm/group description
218825066|NCT03483454|OTHER|Home exercise|Same as above.
218825067|NCT03138785|DRUG|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
218825068|NCT03138785|RADIATION|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
219437470|NCT02314871|DRUG|Morphine|see Arm/group description
219437471|NCT01263314|DRUG|MK-8266|Oral capsules, 0.1 mg potency
219437472|NCT01263314|DRUG|Placebo|Oral placebo capsules to match MK-8266 capsules
218825069|NCT00600067|DRUG|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
218825070|NCT00600067|DRUG|Placebo|Oral placebo capsules, once daily, 28 weeks
218825071|NCT00003631|BIOLOGICAL|filgrastim|
218825072|NCT00003631|DRUG|carboplatin|
218825073|NCT00003631|DRUG|carmustine|
218825074|NCT00003631|DRUG|cyclophosphamide|
218825075|NCT00003631|DRUG|cytarabine|
218825076|NCT00003631|DRUG|etoposide|
218825077|NCT00003631|DRUG|ifosfamide|
218825078|NCT00003631|DRUG|melphalan|
219010288|NCT04218227|BEHAVIORAL|Self-care|Self-care
219010289|NCT04218227|BEHAVIORAL|Psycho-education|Psycho-education
219010290|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
219010291|NCT04924647|DRUG|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
219010292|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
219010293|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
219010294|NCT00191555|DRUG|olanzapine|
218825079|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
218825080|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
218825081|NCT00003631|RADIATION|radiation therapy|
219010295|NCT00191555|DRUG|haloperidol|
219010296|NCT00770796|DRUG|Atorvastatin|80 mg die
219010297|NCT00770796|DRUG|Placebo|
219010298|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC or intravenous injection.
219010299|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC injection.
219010300|NCT03876912|DRUG|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
219010301|NCT05704504|BEHAVIORAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
219010302|NCT05704504|BEHAVIORAL|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
219010303|NCT02248389|DEVICE|Sonatherm 600i ablation system|HIFU ablation of tumor.
219010304|NCT00094627|DRUG|gaboxadol|Duration of Treatment - 6 weeks
219010305|NCT00094627|DRUG|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
219010306|NCT06267950|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219010307|NCT06267950|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218825082|NCT05847647|OTHER|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
219010308|NCT06267950|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
218825083|NCT05847647|OTHER|Retrograde Filling+L-PRF Group|2\. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
218825084|NCT05847647|OTHER|(Orthograde Filling Group / OG Group).|3\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
218825085|NCT05847647|OTHER|(Orthograde Filling+L-PRF Group|4\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
219010309|NCT02256228|DRUG|Ropivacaine|Active Group
218825086|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
218825087|NCT04339413|DRUG|Gantenerumab|Gantenerumab was administered as SC injection Q4W.
218825088|NCT00869167|DRUG|Ramelteon|melatonin agonist
218825089|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
218825090|NCT02132897|DRUG|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
218825091|NCT02132897|DRUG|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
218825092|NCT02043990|DEVICE|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
219010310|NCT02256228|DRUG|Saline|Placebo Comparator
219010311|NCT01982747|DRUG|MGN-Placebo|
219010312|NCT01982747|DRUG|Placebo-MGN|
219437473|NCT04071171|DRUG|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
219437474|NCT04071171|DRUG|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
219437475|NCT04071171|DRUG|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
219437476|NCT04071171|DRUG|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
219437477|NCT00816283|DRUG|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
219437478|NCT00816283|DRUG|vorinostat|100 mg orally 2 times per day
219437479|NCT00816283|GENETIC|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
219437480|NCT00816283|GENETIC|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
219437481|NCT00816283|GENETIC|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
219437482|NCT00816283|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
219580400|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
219580401|NCT04560465|DRUG|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
219580402|NCT05028231|PROCEDURE|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
219580403|NCT04999930|DEVICE|Aerochamber|efficacy and patients satisfaction
219580404|NCT00530686|DRUG|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
218825093|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
218825094|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
218825095|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
218825096|NCT05073939|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
218825097|NCT05073939|DRUG|Oral Placebo|Administration of placebo orally
218825098|NCT00107731|DRUG|quetiapine fumarate|
218825099|NCT00107731|DRUG|lithium|
218825100|NCT00107731|DRUG|divalproex|
218825101|NCT01224236|DRUG|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
218825102|NCT01224236|DRUG|control|multivitamin solution without iron
218825103|NCT03606148|DIAGNOSTIC_TEST|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
218825104|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
218825105|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
219010313|NCT06065033|BEHAVIORAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
219010314|NCT00001482|DRUG|Lamotrigine (Lamictal® (Registered Trademark)|
218825106|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
218825107|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
218825108|NCT03924544|DRUG|Decorin|Antifibrotic agent
218825109|NCT03924544|DRUG|Mitomycin c|Antifibrotic agent
219010315|NCT00001482|DRUG|Gabapentin (Neurontin® (Registered Trademark))|
219010316|NCT05104034|BEHAVIORAL|Osteoporosis screening and treatment as needed|All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
219437483|NCT00816283|OTHER|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
219437484|NCT00816283|OTHER|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
219437485|NCT05911737|BEHAVIORAL|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
219437486|NCT03957746|OTHER|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
219437487|NCT04331925|BEHAVIORAL|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
219437488|NCT04331925|BEHAVIORAL|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
219437489|NCT00995267|BEHAVIORAL|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
219437490|NCT02068950|BEHAVIORAL|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
219437491|NCT00623285|DRUG|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
218825110|NCT03291106|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
218825111|NCT03291106|DIAGNOSTIC_TEST|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
218825112|NCT03291106|DIAGNOSTIC_TEST|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
219010317|NCT05104034|BEHAVIORAL|Sarcopenia|Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
219010318|NCT05104034|BEHAVIORAL|Exercise|TheraBand (resistance band) was utilized as the exercise tool within the community. T
219010319|NCT05104034|DIETARY_SUPPLEMENT|Nutrition|Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
219010320|NCT05104034|BEHAVIORAL|Pharmaceutical care|We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
218825113|NCT03291106|DIAGNOSTIC_TEST|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
218825114|NCT04304079|DEVICE|ARssist system|As stated in ARssist system arm description
218825115|NCT01111227|DRUG|Propofol and isoflurane|Comparison of two anesthetic drugs
218825116|NCT05085483|DIETARY_SUPPLEMENT|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
218825117|NCT05085483|DIETARY_SUPPLEMENT|Isocaloric placebo supplement|Isocaloric placebo supplement
218825118|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
218825119|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
218825120|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
218825121|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
218825122|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
218825123|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
218825124|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
218825125|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
218825126|NCT02103062|DRUG|ABI-007|
218825127|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
218825128|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
218825129|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
218825130|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
218825131|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
218825132|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
218825133|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
218825134|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
219437492|NCT00623285|DRUG|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
218825135|NCT02422979|COMBINATION_PRODUCT|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
218825136|NCT02422979|COMBINATION_PRODUCT|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
218825137|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
218825138|NCT03844308|BEHAVIORAL|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
219437493|NCT02551913|BEHAVIORAL|Control|the adolescents will not receive any specific intervention
219437494|NCT02551913|BEHAVIORAL|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
219437495|NCT04250025|PROCEDURE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
219580405|NCT04800341|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
219580406|NCT00653484|BEHAVIORAL|Physical Activity|
218825139|NCT00761345|DRUG|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
218825140|NCT00761345|DRUG|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
219580407|NCT00653484|BEHAVIORAL|Energy Restriction|
218825141|NCT00761345|RADIATION|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
219580408|NCT00653484|BEHAVIORAL|Physical Activity and Energy Restriction|
218825142|NCT00948077|DRUG|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)"
218825143|NCT04255771|DRUG|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
218825144|NCT04255771|DRUG|Placebos|Use a placebo as a comparison
218825145|NCT05775302|OTHER|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
218825146|NCT05775302|OTHER|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
218825147|NCT06017492|BEHAVIORAL|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
218825148|NCT03435068|DEVICE|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
218825149|NCT03435068|DEVICE|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
218825150|NCT03435068|DEVICE|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
219010321|NCT04251598|BEHAVIORAL|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
219010322|NCT04251598|BEHAVIORAL|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
219363637|NCT03163654|PROCEDURE|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
219437496|NCT04460040|BEHAVIORAL|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
219437497|NCT00366418|DRUG|Rituximab|
218825151|NCT02030821|DRUG|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
218825152|NCT02030821|DRUG|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
219010323|NCT05188690|OTHER|Data collection from medical records|Data collection from medical records
219010324|NCT03743389|DEVICE|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
219437498|NCT01142544|OTHER|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
219437499|NCT01590667|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
219437500|NCT01590667|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
219437501|NCT00519883|OTHER|Exercise|
218825153|NCT02913963|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
219010325|NCT03743389|DEVICE|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
219010326|NCT03086889|OTHER|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
219437502|NCT00519883|OTHER|Supportive Care|
218825154|NCT02913963|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
218825155|NCT00484263|DRUG|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
219010327|NCT03086889|OTHER|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
218825156|NCT04092114|OTHER|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
218825157|NCT04092114|BEHAVIORAL|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
218825158|NCT04314817|DRUG|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
218825159|NCT03192137|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
218825160|NCT03192137|OTHER|Vehicle|Vehicle twice daily for 16 days
218825161|NCT02799589|DRUG|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
218825162|NCT02799589|DRUG|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
218825163|NCT02799589|DRUG|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
218825164|NCT03218969|DRUG|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
218825165|NCT03218969|DRUG|Placebo|matching placebo
218825166|NCT02153489|DRUG|Aclidinium bromide|
219010328|NCT04397653|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
219010329|NCT04397653|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
219010330|NCT04397653|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
219363638|NCT03221894|DIETARY_SUPPLEMENT|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
219437503|NCT04645004|DRUG|Aspirin 81Mg Non-enteric coated Tab|one tab daily
219437504|NCT04260529|DRUG|CyPep-1|Intratumoral injection
219437505|NCT04260529|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
218825167|NCT02153489|DRUG|Placebo|
219010331|NCT00311623|DRUG|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
219437506|NCT01464814|DIETARY_SUPPLEMENT|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
219437507|NCT01464814|DIETARY_SUPPLEMENT|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
219437508|NCT02201667|DRUG|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
219437509|NCT02201667|DRUG|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
218825168|NCT04793516|OTHER|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
218825169|NCT05784818|BEHAVIORAL|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
218825170|NCT05784818|BEHAVIORAL|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
219437510|NCT02201667|DRUG|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
219437511|NCT02201667|PROCEDURE|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
218825171|NCT04302116|DRUG|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
218825172|NCT04302116|DRUG|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
218825173|NCT01591629|DRUG|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
218825174|NCT01591629|DRUG|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
218825175|NCT01591629|DRUG|Placebo|Placebo
218825176|NCT00657267|DRUG|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
219010332|NCT00311623|DRUG|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
219010333|NCT00311623|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed on Day 15
219010334|NCT02389348|DRUG|DSM265|Single oral doses of DSM265
219010335|NCT02389348|DRUG|OZ439|Single oral doses of OZ439
219010336|NCT03998189|OTHER|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
219010337|NCT03998189|OTHER|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
218825177|NCT04373421|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
218825178|NCT04373421|PROCEDURE|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
218825179|NCT04373421|PROCEDURE|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
218825180|NCT04794348|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
218825181|NCT04794348|BIOLOGICAL|Freeze Dried Plasma (FDP)|Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
218825182|NCT03622047|DRUG|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
218825183|NCT03622047|DRUG|No analgesia labor|No analgesia labor control group
218825184|NCT02737501|DRUG|Brigatinib|Brigatinib tablets
218825185|NCT02737501|DRUG|Crizotinib|Crizotinib tablets
218825186|NCT00437749|DRUG|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
218825187|NCT00437749|OTHER|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
219010338|NCT03998189|OTHER|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
219010339|NCT03998189|OTHER|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
219363639|NCT02744157|BEHAVIORAL|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
219580409|NCT03325400|OTHER|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
218825188|NCT04044014|DEVICE|Gellan sheet|Gellan sheet.
219580410|NCT04887233|OTHER|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
219580411|NCT04887233|OTHER|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
219580412|NCT02992626|OTHER|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
218825189|NCT04044014|DEVICE|Gellan fluid gel|Gellan fluid gel.
218825190|NCT04044014|DEVICE|Mepitel One|Control dressing-- Mepitel One.
218825191|NCT01261975|PROCEDURE|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
218825192|NCT01261975|PROCEDURE|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
218825193|NCT02785692|RADIATION|Radiation|preoperative Radiotherapy/ IMRT
218825194|NCT02152189|OTHER|Screening for Fabry disease|
218825195|NCT00716274|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
218825196|NCT00716274|DRUG|Placebo|oral, daily, for 16 weeks
218825197|NCT00551889|DRUG|celecoxib|
219010340|NCT03998189|OTHER|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
219010341|NCT03998189|OTHER|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
219010342|NCT03140384|BIOLOGICAL|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
218825198|NCT00551889|DRUG|cyclophosphamide|
218825199|NCT00551889|OTHER|laboratory biomarker analysis|
218825200|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (1RDA+CoQ10)|
218825201|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (3RDA)|
218825202|NCT02381964|DIETARY_SUPPLEMENT|Placebo|
218825203|NCT02582827|DRUG|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
218825204|NCT00405288|DRUG|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
218825205|NCT01642303|OTHER|vodcasting|listening to downloaded vodcasting files
218825206|NCT01642303|OTHER|no intervension|Listen to student book listening files
218825207|NCT05527600|DIAGNOSTIC_TEST|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
218825208|NCT00994864|DRUG|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
218825209|NCT00440817|OTHER|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
218825210|NCT03593148|OTHER|Lifestyle|Lifestyle treatment
218825211|NCT02447185|DRUG|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
219580413|NCT02992626|OTHER|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
218825212|NCT02447185|DRUG|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
218825213|NCT05545943|OTHER|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
218825214|NCT05545943|OTHER|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
218825215|NCT05545943|OTHER|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
218825216|NCT05545943|OTHER|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
218825217|NCT01406132|DRUG|ASP015K|oral
218825218|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
218825219|NCT01153035|DEVICE|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
218825220|NCT05324579|BEHAVIORAL|Behavioral testing during neuronal recordings|Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
218825221|NCT01461525|PROCEDURE|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
218825222|NCT01461525|PROCEDURE|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
219010343|NCT02992106|OTHER|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~* Children aged 0-6 years old:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Ages and Stages Questionnaire~ 5. Strengths and Difficulties Questionnaire~ 6. Questionnaire on developmental milestones~ 7. Questionnaire on behaviour~* Children older than 6 years:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Pediatric Quality of Life Questionnaire~ 5. Children's Behaviour Questionnaire in Dutch~ 6. Questionnaire on developmental milestones~ 7. Developmental Coordination Disorder Questionnaire~ 8. Strengths and Difficulties Questionnaire"
219363640|NCT05857176|OTHER|COVID-19 Vaccine questionnaire|An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).
219580414|NCT01346774|DRUG|Cranberry powder capsules|2 cranberry powder capsules twice a day
218825223|NCT05488054|PROCEDURE|Physical Therapy|Patients will undergo physical therapy following surgical intervention
218825224|NCT05488054|PROCEDURE|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
218825225|NCT05488054|DEVICE|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
218825226|NCT04406987|PROCEDURE|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
218825227|NCT04406987|PROCEDURE|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
218825228|NCT01302184|DEVICE|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
219580415|NCT01346774|DRUG|Placebo powder capsules|2 placebo capsules twice a day
218825229|NCT01302184|DEVICE|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
218825230|NCT02394158|DRUG|Metformin|
218825231|NCT02394158|DRUG|placebo|
218825232|NCT00786422|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
218825233|NCT06414044|DRUG|Atogepant 60 mg|Patients using atogepant 60 mg tablet daily as migraine prevention
218825234|NCT01646814|DRUG|PL2200|PL2200, containing 325 mg aspirin active ingredient
218825235|NCT01646814|DRUG|Aspirin tablets|325 mg aspirin tablets (USP)
218825236|NCT03941847|OTHER|music|listening music
218825237|NCT05658328|BEHAVIORAL|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
218825238|NCT05942716|DRUG|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
218825239|NCT01011608|OTHER|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
219010344|NCT02992106|OTHER|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
219010345|NCT02992106|OTHER|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
219580416|NCT05031247|OTHER|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
218825240|NCT01011608|OTHER|standard hospital food|standard hospital diet ad. lib.
218825241|NCT02470702|DRUG|Oritavancin|
218825242|NCT02470702|DRUG|Placebo (D5W)|
218825243|NCT03051802|DEVICE|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
218825244|NCT06482567|BEHAVIORAL|iCOVER|"The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior."
219010346|NCT02992106|OTHER|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
219010347|NCT02992106|OTHER|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
219010348|NCT02992106|OTHER|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
219010349|NCT02992106|OTHER|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
219010350|NCT03227029|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L|10\^6 plaque-forming units (PFU); administered as nose drops
218825245|NCT06482567|BEHAVIORAL|Physical Presence with Reassurance|The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
218825246|NCT03648710|OTHER|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
218825247|NCT03648710|OTHER|Mobile Health|A mobile health application created as a resource for young adults transitioning.
218825248|NCT06060210|DRUG|normal Saline|50-ml Saline
218825249|NCT06060210|DRUG|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
218825250|NCT00156325|DRUG|Escitalopram (Lexapro)|
218825251|NCT02015039|DRUG|BoNT Injections|
218825252|NCT02015039|PROCEDURE|Occupational Therapy|
219010351|NCT03227029|BIOLOGICAL|RSV 276|10\^5 PFU; administered as nose drops
219010352|NCT03227029|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
219010353|NCT01083394|DEVICE|PTA|PTA using a conventional balloon
219010354|NCT01083394|DEVICE|PTA with PEB|PTA using a paclitaxel eluting balloon
219010355|NCT01083394|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
219010356|NCT05683379|DIAGNOSTIC_TEST|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
219580417|NCT05445726|DEVICE|CPM Device|CPM device used in tangent with reference ECG for validation
219580418|NCT03580122|DRUG|Arginine Aspartate|Asparten
219580419|NCT05266820|DRUG|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
219763650|NCT06059690|DIAGNOSTIC_TEST|pH Measurement of in vivo tissue|The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
219763651|NCT06616051|OTHER|Multicomponent SMS reminder|"SMS reminder will be delivered every Sunday, Tuesday and Thursday for a duration of eight weeks, or until the child attends the hospital. Research team has already developed an automated text message reminder system for this study, taking into account the local context. The messages was designed with input from a panel of public health consultants and research supervisors, drawing on resources from the WHO Health Promotion and Disease Prevention Messages Library \[21\].~It will comprise two main components: a) web-based application for children registration and automated reminder scheduling, and b) an SMS application for text messaging that is sent automatically. Messages will be sent in Urdu, the native language, and will not require a reply. Each message will include four elements: Health promotion message, visual depiction of a child's vision, a customized action plan detailing how to get to the hospital including the location, how much money is needed and what to carry with them."
219763652|NCT04889898|DEVICE|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|\[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
219763653|NCT04889898|RADIATION|Modified Barium Swallow Study (MBSS)|\[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
219437512|NCT05154357|OTHER|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
219437513|NCT05154357|OTHER|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
219437514|NCT05723874|DRUG|BI 425809|BI 425809
218825253|NCT04570384|DRUG|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
219437515|NCT05723874|DRUG|bosentan|bosentan
219437516|NCT00130468|DRUG|Hyalgan (sodium hyaluronate)|
219437517|NCT02945839|DRUG|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
219437518|NCT02945839|BEHAVIORAL|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
219437519|NCT02945839|BEHAVIORAL|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
219437520|NCT01083225|BEHAVIORAL|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
219437521|NCT01083225|BEHAVIORAL|Treatment as usual|Treatment as usual, consultations
219437522|NCT03224104|DRUG|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
219437523|NCT03224104|RADIATION|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
219437524|NCT03224104|DRUG|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
219437525|NCT04211844|DRUG|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
219437526|NCT04211844|DRUG|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
219437527|NCT06212388|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
219437528|NCT06212388|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
219437529|NCT06212388|DRUG|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
219437530|NCT01365013|BEHAVIORAL|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
218825254|NCT04570384|DRUG|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
218825255|NCT01935453|BIOLOGICAL|Recombinant hGM-CSF Herpes Simplex Virus Injection|
219437531|NCT01365013|BEHAVIORAL|Control group|Standard advice for lifestyle change
219437532|NCT04314609|DEVICE|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
219437533|NCT02169960|BEHAVIORAL|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
219437534|NCT02169960|BEHAVIORAL|Breaking Free|Online based intervention for Drug and Alcohol Use
219437535|NCT02169960|BEHAVIORAL|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
219437536|NCT02169960|BEHAVIORAL|Resiliency Training|Op Volle Kracht (OVK)
219437537|NCT00678236|OTHER|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
219437538|NCT00678236|OTHER|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
219437539|NCT02011672|OTHER|nutrient-enriched milk|
219437540|NCT02011672|OTHER|regular milk|
219437541|NCT00282568|DRUG|Tacrolimus Modified Release (MR)|Oral
219437542|NCT00282568|DRUG|tacrolimus|Oral
219437543|NCT00534924|DRUG|Vit C|
219437544|NCT00534924|PROCEDURE|Postconditioning|
219437545|NCT00534924|OTHER|no intervention|
219437546|NCT02645136|OTHER|Pilates|Pilates exercises
219437547|NCT02645136|OTHER|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
219437548|NCT02645136|OTHER|Control|
219437549|NCT01266070|DRUG|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
219437550|NCT03782844|DEVICE|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
219437551|NCT03782844|DEVICE|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
219437552|NCT05375786|BIOLOGICAL|Vaccination completion status|the relation between vaccination completion status and the target population
219437553|NCT02131389|DEVICE|Iconacy Hip System|
219437554|NCT02721446|BEHAVIORAL|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
219580420|NCT05266820|DRUG|TAS-102|TAS-102
219437555|NCT02721446|BEHAVIORAL|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
219437556|NCT02721446|BEHAVIORAL|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
219437557|NCT02721446|BEHAVIORAL|Incentive + Salience|Combined message of incentive plus salience.
219437558|NCT04231513|DRUG|E2814|E2814, intravenous infusion.
219437559|NCT04231513|DRUG|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
219580421|NCT03282149|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
218825256|NCT01673126|DEVICE|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
219437560|NCT05137210|OTHER|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
219437561|NCT05137210|OTHER|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
219437562|NCT05137210|OTHER|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
219437563|NCT02417064|DRUG|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
219437564|NCT02417064|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
219580422|NCT05365841|DRUG|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
219580423|NCT00116519|DRUG|PPAR alpha|
219195635|NCT06533423|BEHAVIORAL|Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention (NISMA)|The NISMA intervention is a flexible intervention and comprises three mandatory individual sessions with a nurse, supplemented by two optional group sessions over a period of 12 months, to provide comprehensive support tailored to each participant's needs. The intervention is grounded in the theoretical framework Social Cognitive Theory and inspired by the questioning techniques in Acceptance and Commitment Therapy (ACT). These methods play a crucial role in helping participants enhance their self-efficacy. The key components of our approach include: a person-centered approach by addressing challenges identified by each participant to foster self-efficacy through targeted problem-solving and goal-setting. This is utilized by interviewing techniques derived from ACT to assist participants in accepting and committing to self-management. The program is designed to last between 6-12 months, allowing for gradual skill development and adaptation.
219195636|NCT03989141|PROCEDURE|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
219195637|NCT03989141|PROCEDURE|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
219195638|NCT00085930|BIOLOGICAL|EBV specific CTLs|CTLs: 2x10e7 cells/m2
219195639|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
218825257|NCT01673126|DEVICE|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
219195640|NCT06805760|OTHER|variable tidal volume ventilation (V-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
219195641|NCT06805760|OTHER|pressure-regulated volume-controlled ventilation (PRVC)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), the upper limit of peak inspiratory pressure was 30 cmH2O, the maximum tidal volume (Vt\_max) and the minimum tidal volume (Vt\_min) was set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate is 12, Inspiration to Expiration Ratio is 1:2, Positive End-Expiratory Pressure (PEEP) is 5cmH2O, and Inhaled Oxygen Concentration (FiO2) is 98%.
219195642|NCT06805760|OTHER|conventional volume-controlled ventilation (C-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
219195643|NCT06805760|OTHER|pressure-controlled ventilation (PCV)|The inspiratory pressure level is set, usually with an initial value of 20 cmH2O, a respiratory rate of 12, an inspiratory/expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 5 cm water column, and an inspired oxygen concentration (FiO2) of 98%.
219195644|NCT06804525|DIAGNOSTIC_TEST|CIDI-5|The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
219437565|NCT02417064|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
219437566|NCT02417064|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
219437567|NCT02417064|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
218825258|NCT03836443|OTHER|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
218825259|NCT04462601|OTHER|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
218825260|NCT02347384|DEVICE|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
219437568|NCT02417064|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
219437569|NCT02628951|DRUG|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
219437570|NCT02628951|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
218825261|NCT02347384|DEVICE|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
218825262|NCT01876212|BIOLOGICAL|DC vaccine|
218825263|NCT01876212|DRUG|Dasatinib|
218825264|NCT02167321|DRUG|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
218825265|NCT02167321|DRUG|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
218825266|NCT03322904|DIAGNOSTIC_TEST|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula \[IEC-PC¬\] - \[CC-PC\] / \[CC-PC\]."
218825267|NCT03111316|DRUG|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
218825268|NCT03111316|DEVICE|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
218825269|NCT04630821|OTHER|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
218825270|NCT01468480|DRUG|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
218825271|NCT01468480|DRUG|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
218825272|NCT01468480|DRUG|MultiCal|application of Multical in forth group as a pulp dressing agent
219010357|NCT04822064|DRUG|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
219010358|NCT04822064|DRUG|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
219763654|NCT04889898|BEHAVIORAL|Speech Intelligibility Test (SIT)|\[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
219010359|NCT03686371|PROCEDURE|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
219010360|NCT01250262|OTHER|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
219010361|NCT01250262|OTHER|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
219010362|NCT01250262|OTHER|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
219010363|NCT03280420|PROCEDURE|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
219010364|NCT03280420|PROCEDURE|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
219363641|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
219363642|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
219363643|NCT03215784|DIETARY_SUPPLEMENT|Fish Oil|
219363644|NCT03215784|DIETARY_SUPPLEMENT|Probiotic|
219363645|NCT03215784|DIETARY_SUPPLEMENT|Placebo|
219363646|NCT05797272|PROCEDURE|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
219363647|NCT06370416|DRUG|Trilaciclib|After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
218825273|NCT01468480|DRUG|Dycal|application of Dycal in first group as a pulp dressing agent
218825274|NCT06277440|OTHER|cognitive training|cognitive training, 15 min, three times per week, for 12 weeks
218825275|NCT06277440|OTHER|active control|Traditional rehabilitation programs
219010365|NCT00390858|DRUG|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
219010366|NCT05629624|DIETARY_SUPPLEMENT|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
219010367|NCT05629624|DIETARY_SUPPLEMENT|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
219010368|NCT05629624|DIETARY_SUPPLEMENT|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case \& control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
219010369|NCT03414424|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
219010370|NCT03414424|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
219763655|NCT04889898|BEHAVIORAL|SIT Scoring|\[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
218825276|NCT05739292|BIOLOGICAL|EuNmCV-5|0.5mL single intramuscular dose on Day 0
218825277|NCT05739292|BIOLOGICAL|Menveo|0.5mL single intramuscular dose on Day 0
218825278|NCT05932173|BIOLOGICAL|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
218825279|NCT03402100|DRUG|eye drops|children who received daily eye drops for myopia
219010371|NCT00877877|PROCEDURE|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
219010372|NCT02610179|DIETARY_SUPPLEMENT|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
219010373|NCT02610179|DIETARY_SUPPLEMENT|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
219010374|NCT03080311|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
219010375|NCT00403663|DRUG|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
219010376|NCT02159690|DRUG|Enzalutamide|160mg
219010377|NCT02159690|DRUG|Abiraterone acetate|1000mg
218825280|NCT05999331|OTHER|initial aspartate aminotransferase (AST) to platelet (PLT) ratio index|All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
218825281|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
218825282|NCT05002725|DRUG|Lidocain|300mg (20ml) will be injected
218825283|NCT02670473|DEVICE|fanfilcon A (test)|contact lens
219010378|NCT02159690|DRUG|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
219437571|NCT03942146|BEHAVIORAL|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
219437572|NCT01585168|DRUG|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
219763656|NCT03519451|OTHER|Internet-Based Intervention|Given KickAsh smartphone mobile application
219763657|NCT03519451|OTHER|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
219763658|NCT03519451|OTHER|Questionnaire Administration|Ancillary studies
218825284|NCT06053528|DRUG|Antibiotic|Effect if treatment
218825285|NCT01404234|DRUG|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
218859702|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
219010379|NCT02159690|DRUG|Dutasteride|0.5mg
219010380|NCT02159690|DRUG|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
219010381|NCT05313074|BIOLOGICAL|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
219010382|NCT00795522|DRUG|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
218825286|NCT02248896|DRUG|Telmisartan|
218825287|NCT02248896|DRUG|Other angiotensin-receptor blockers (ARBs)|
218825288|NCT02248896|DRUG|Angiotensin-converting enzyme inhibitors (ACEIs)|
218825289|NCT02248896|DRUG|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
219010383|NCT04931108|DRUG|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
219010384|NCT04931108|DRUG|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
219010385|NCT04931108|DRUG|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
219010386|NCT04899414|DRUG|Dexamethasone, azacytidine, Pegaspargase, Tislelizumab|Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
219010387|NCT02308852|DEVICE|tDCS|
219010388|NCT02677142|BEHAVIORAL|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
219010389|NCT02677142|BEHAVIORAL|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
219010390|NCT01639651|OTHER|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
219010391|NCT01639651|OTHER|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
219010392|NCT01949051|DRUG|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
219010393|NCT01949051|DRUG|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
218825290|NCT00387088|DEVICE|Respimat|
219010394|NCT00492661|DRUG|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
219010395|NCT03978429|OTHER|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
219010396|NCT03978429|OTHER|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
219010397|NCT01782859|DRUG|Prednisone|
219010398|NCT01782859|DRUG|Hydrocortisone|
219010399|NCT01782859|DRUG|Placebo (for Prednisone)|
219010400|NCT04905173|OTHER|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
219437573|NCT01585168|DRUG|Placebo|Identically appearing sugar pill, given orally
218825291|NCT00387088|DRUG|Tiotropium|
218825292|NCT02280993|DRUG|DHAP|DHAP
218825293|NCT02280993|DRUG|Brentuximab Vedotin|Brentuximab Vedotin
218825294|NCT02280993|OTHER|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
219437574|NCT01194414|DRUG|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
218825295|NCT05363488|DRUG|Bosutinib|Patients receiving bosutinib treatment
218825296|NCT00551096|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
218825297|NCT00551096|DRUG|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
218825298|NCT00551096|DRUG|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
218825299|NCT04794738|DRUG|SHR8554|SHR8554 Injection; high dose
218825300|NCT04794738|DRUG|SHR8554|SHR8554 Injection; low dose
218825301|NCT04794738|DRUG|Saline Solution|Saline Solution
218825302|NCT04794738|DRUG|Morphine|Morphine
218825303|NCT02663154|DRUG|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
218825304|NCT02663154|DRUG|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
219010401|NCT04905173|DRUG|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
219010402|NCT04905173|OTHER|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
219195645|NCT06804525|DIAGNOSTIC_TEST|LHC-CIDI-5|The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
219195646|NCT05624489|BEHAVIORAL|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
219195647|NCT06852950|DEVICE|Libre 3 Plus Continuous Glucose Monitor|Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
219195648|NCT06852950|DEVICE|Dexcom G7 Continuous Glucose Monitor|Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
219437575|NCT01194414|DRUG|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
219437576|NCT01194414|DRUG|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
219437577|NCT01194414|DRUG|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
219437578|NCT01194414|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
219437579|NCT02256345|DRUG|KNO3|Active Comparator
219010403|NCT03294733|PROCEDURE|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
219010404|NCT02475577|DEVICE|Peripherals with HealthInterlink technology|home remote monitoring
219437580|NCT02256345|DRUG|KCl|Placebo Comparator
218825305|NCT02015403|DRUG|Standard Care + NAC (N -ACETYLCYSTEINE)|
219010405|NCT00279890|DRUG|Topical SR-01|
219010406|NCT02659631|DRUG|PF-06671008|Dose Escalation Phase - Part 1
219010407|NCT02659631|DRUG|PF-06671008|Dose Expansion Phase - Part 2
219010408|NCT02377466|DRUG|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
219010409|NCT02377466|DRUG|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
219010410|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
219010411|NCT04465851|DIETARY_SUPPLEMENT|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
219010412|NCT04465851|OTHER|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
219010413|NCT04465851|OTHER|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
219437581|NCT02552667|DRUG|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
219010414|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
219010415|NCT00495170|DRUG|Carboplatin|2 area under curve (AUC) by vein Weekly
219010416|NCT00495170|RADIATION|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
219010417|NCT00495170|DRUG|Paclitaxel|50 mg/m\^2 by vein Weekly
219437582|NCT02552667|DRUG|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
219195649|NCT06574802|PROCEDURE|ERL + air polishing|Er:YAG laser (ERL) plus sub-gingival air polishing treatment
219195650|NCT06574802|PROCEDURE|ERL|ERL treatment
219195651|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
219437583|NCT03385408|DEVICE|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
219580424|NCT00116519|DRUG|placebo|
218825306|NCT02015403|DRUG|Standard Care (in control arm)|
219010418|NCT00103181|RADIATION|3-dimensional conformal accelerated partial breast irradiation|
219010419|NCT00103181|RADIATION|brachytherapy|
219010420|NCT00103181|RADIATION|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
219010421|NCT00103181|RADIATION|MammoSite or other single-entry intracavitary device|
219010422|NCT05845684|OTHER|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
219437584|NCT03385408|DEVICE|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
218825307|NCT03401437|BEHAVIORAL|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
219437585|NCT01495364|BIOLOGICAL|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
219437586|NCT01495364|OTHER|placebo|matching placebo
219437587|NCT01913197|OTHER|An MRI-based technique to identify prostate cancer|
219437588|NCT00633048|DRUG|NSA-789|
219437589|NCT00633048|DRUG|placebo|
219437590|NCT04420208|PROCEDURE|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
219437591|NCT02260388|DRUG|Nortriptyline|
219437592|NCT02260388|DRUG|Duloxetine|
219437593|NCT02260388|DRUG|Pregabalin|
219437594|NCT02260388|DRUG|Mexiletine|
219437595|NCT03556865|OTHER|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
219437596|NCT00005883|DRUG|phenethyl isothiocyanate|
219437597|NCT02792283|BIOLOGICAL|whole blood collection|
219580425|NCT01955213|DRUG|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
218825308|NCT03401437|BEHAVIORAL|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
218825309|NCT03401437|OTHER|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
218825310|NCT04882865|DEVICE|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
219010423|NCT05845684|OTHER|Control Group|standard daily applications will be performed on patients
219010424|NCT06504758|OTHER|Breathing Retraining Program|"* 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks."
219010425|NCT06504758|OTHER|Postural Exerises Program (Stretching and Strengthening Exercises)|"* TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks"
219010426|NCT00697203|DRUG|Placebo|po daily for 12 weeks
219010427|NCT00697203|DRUG|Pravastatin|40mg po daily for 12 weeks
219437598|NCT01496404|PROCEDURE|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
219437599|NCT01496404|PROCEDURE|Scalpel|Incising skin (epidermis and dermis) with scalpel.
219437600|NCT05615155|OTHER|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
219437601|NCT03152188|DRUG|FMT|Fifteen FMT Openbiome capsules administered at the same time
219437602|NCT03152188|OTHER|Placebo|Fifteen placebo capsules administered at the same time
219437603|NCT01235507|DRUG|methotrexate|stable dose as prescribed
219437604|NCT01235507|DRUG|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
219437605|NCT00856817|DRUG|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
219580426|NCT02213913|DRUG|lenalidomide|Given PO
219010428|NCT00697203|DRUG|Dalcetrapib|300mg po daily for 12 weeks
219010429|NCT00697203|DRUG|Dalcetrapib|600mg po daily for 12 weeks
219010430|NCT00697203|DRUG|Dalcetrapib|900mg po daily for 12 weeks
219010431|NCT06471894|RADIATION|Magnetic resonance imaging scanning|Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
219010432|NCT06471894|DRUG|FMT Protocol|Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
219437606|NCT00856817|DRUG|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
219580427|NCT02213913|DRUG|etoposide|Given IV
219580428|NCT02213913|DRUG|prednisone|Given PO
219580429|NCT02213913|DRUG|vincristine sulfate|Given IV
219580430|NCT02213913|DRUG|doxorubicin hydrochloride|Given IV
219580431|NCT02213913|DRUG|cyclophosphamide|Given IV
219580432|NCT02213913|BIOLOGICAL|rituximab|Given IV
219580433|NCT02213913|OTHER|quality-of-life assessment|Ancillary studies
218825311|NCT06563947|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
218825312|NCT03679390|DRUG|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
218825313|NCT02665533|DRUG|Dexamethasone|Dexamethasone 8 mg
218825314|NCT02665533|DRUG|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
218825315|NCT05587660|PROCEDURE|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
218825316|NCT02178800|DRUG|GSK1265744 Tablets|30-mg tablets, taken orally
218825317|NCT02178800|DRUG|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
218825318|NCT02178800|DRUG|Placebo for GSK1265744 Tablets|Taken orally
218825319|NCT02178800|DRUG|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
218825320|NCT05120700|BIOLOGICAL|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
218825321|NCT05988736|DEVICE|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
218825322|NCT05988736|DEVICE|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
218825323|NCT05511012|OTHER|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
219010433|NCT01765205|DEVICE|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
219010434|NCT00363922|BEHAVIORAL|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
219010435|NCT00363922|BEHAVIORAL|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
218825324|NCT05994768|OTHER|18F-FDG PET/CT|Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
218825325|NCT04741932|OTHER|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
218825326|NCT05233514|OTHER|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
218825327|NCT05771532|BEHAVIORAL|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
218825328|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
218825329|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
219010436|NCT00363922|BEHAVIORAL|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
219437607|NCT02397967|OTHER|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
219437608|NCT00137293|DRUG|GAP-486 (ZP-123)|
219437609|NCT00137293|DRUG|0.9% Sodium Chloride, USP|
219437610|NCT00202345|DRUG|Iron sucrose|
219437611|NCT00442260|DRUG|DOXIL|
219437612|NCT00442260|DRUG|Abraxane|
218825330|NCT01343745|DRUG|Placebo|pressurised metered dose inhaler
218825331|NCT00259844|BIOLOGICAL|TroVax|
218825332|NCT01176760|DRUG|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
218825333|NCT01176760|OTHER|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
218825334|NCT00059631|DRUG|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
218825335|NCT00059631|DRUG|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
218825336|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
218825337|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
218825338|NCT03534050|RADIATION|postoperative adjuvant RT|
218825339|NCT02837718|PROCEDURE|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
218825340|NCT03631264|DEVICE|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
218825341|NCT02817178|OTHER|Additional biological samples|blood and tumor tissue samples
218825342|NCT04199585|DRUG|Lu AF95245|solution, single dose, orally
218825343|NCT04199585|DRUG|Lu AF95245 14C radiolabelled spiked dosage|solution, single dose, orally
218825344|NCT04199585|DRUG|Placebo|solution, single dose, orally
218825345|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
218825346|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
218825347|NCT02848092|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
218825348|NCT02848092|OTHER|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
218825349|NCT00607802|BIOLOGICAL|leukocyte therapy|
218825350|NCT00607802|GENETIC|polymerase chain reaction|
218825351|NCT06131905|DRUG|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
218825352|NCT06131905|DRUG|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
218825353|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
218825354|NCT00287950|DRUG|carboplatin|
218825355|NCT00287950|DRUG|cisplatin|
218825356|NCT00287950|DRUG|cyclophosphamide|
218825357|NCT00287950|DRUG|etoposide|
218825358|NCT00287950|DRUG|vincristine sulfate|
218825359|NCT00287950|PROCEDURE|adjuvant therapy|
218825360|NCT00287950|PROCEDURE|conventional surgery|
218825361|NCT00287950|PROCEDURE|neoadjuvant therapy|
218825362|NCT00287950|RADIATION|radiation therapy|
219437613|NCT04725201|DRUG|Intravenous unfractionated heparin|See experimental arm description for intervention description.
219437614|NCT04725201|DRUG|Sham|See sham comparator arm description for intervention description.
219437615|NCT06212206|DEVICE|PillBot|The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
219437616|NCT00004852|DRUG|Efavirenz|
218825363|NCT03186430|BEHAVIORAL|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
218825364|NCT02768285|PROCEDURE|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
218825365|NCT01244711|DRUG|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
218825366|NCT04656587|DEVICE|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
219437617|NCT00004852|DRUG|Lamivudine|
219437618|NCT00004852|DRUG|Zidovudine|
219580434|NCT02213913|OTHER|laboratory biomarker analysis|Correlative studies
219437619|NCT05003141|DRUG|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
219437620|NCT03828500|BEHAVIORAL|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
218825367|NCT04656587|OTHER|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
218825368|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
218825369|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
218825370|NCT01861847|DRUG|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
218825371|NCT01861847|DRUG|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
218825372|NCT01798381|DIETARY_SUPPLEMENT|Essential fatty acids|
218825373|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
219010437|NCT02604108|BEHAVIORAL|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
219437621|NCT04182906|BEHAVIORAL|Care Coordination|Screening and referral for basic needs and adult mental health
219437622|NCT04182906|BEHAVIORAL|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
219437623|NCT04182906|BEHAVIORAL|Usual Care|Usual Primary Pediatric Care
219437624|NCT04163913|OTHER|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
219437625|NCT04163913|OTHER|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
219437626|NCT00959881|DRUG|Donepezil plus placebo|5- and 10-mg tablets, single dose
219437627|NCT00959881|DRUG|Donepezil|5- and 10-mg tablets, single dose
219437628|NCT00959881|DRUG|Begacestat|6 x 50-mg capsules, single dose
219580435|NCT03736213|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
219437629|NCT00617838|OTHER|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
218825374|NCT01639469|BEHAVIORAL|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
218825375|NCT01639469|BEHAVIORAL|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
218825376|NCT02833883|DRUG|Enzalutamide|
218825377|NCT02833883|DRUG|CC-115|
218825378|NCT03888014|DEVICE|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
218825379|NCT03888014|DRUG|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
218825380|NCT03155139|DIAGNOSTIC_TEST|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
218825381|NCT03155139|DIAGNOSTIC_TEST|Confirmatory tests|Captopril challenge test, Saline infusion test
218825382|NCT02156193|PROCEDURE|Prophylactic clip|Prophylactic clipping
218825383|NCT02156193|PROCEDURE|No prophylactic management|No prophylaxis
218825384|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
218825385|NCT01201551|DRUG|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
218825386|NCT01201551|DRUG|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
218825387|NCT01201551|DRUG|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
218825388|NCT05542459|DRUG|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
218825389|NCT02329743|DRUG|RX-10045|topical therapy
218825390|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
218825391|NCT03024424|BEHAVIORAL|Early disclosure|
218825392|NCT03024424|BEHAVIORAL|Late disclosure|
218825393|NCT03087175|DEVICE|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
219437630|NCT01896661|DRUG|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
219437631|NCT01896661|DRUG|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
219437632|NCT02074904|DRUG|Topiramate|
219437633|NCT02074904|DRUG|Placebo|
219437634|NCT03591913|DRUG|Misoprostol|Oral tablets
218825394|NCT03087175|DEVICE|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
218825395|NCT05298943|OTHER|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
218825396|NCT04954534|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
218825397|NCT02431546|BEHAVIORAL|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
218825398|NCT00641732|DRUG|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
218825399|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
218825400|NCT00641732|DRUG|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
219010438|NCT02604108|BEHAVIORAL|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
219010439|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
219010440|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
219437635|NCT02533076|OTHER|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
219437636|NCT02533076|OTHER|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
218825401|NCT00641732|DRUG|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
219010441|NCT02398851|BEHAVIORAL|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
218825402|NCT00641732|DRUG|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
219195652|NCT06572566|OTHER|Non-invasive examination and assessment.|1\) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
219437637|NCT02533076|DEVICE|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
219437638|NCT02533076|DEVICE|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
219437639|NCT01980225|PROCEDURE|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
218825403|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
218825404|NCT00641732|DRUG|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
219010442|NCT02398851|BEHAVIORAL|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
219010443|NCT00132587|DEVICE|cement Palacos R40 and LV40|
219195653|NCT06207513|PROCEDURE|Suction Circuit Flushing with Chlorhexidine|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
218825405|NCT06320600|OTHER|no intervention|It's an observational study, no intervention included
218825406|NCT00512278|DRUG|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
218825407|NCT00512278|DRUG|Placebo|Placebo
218825408|NCT03584347|BEHAVIORAL|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
218825409|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
218825410|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
219195654|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
219195655|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
219580436|NCT03736213|BEHAVIORAL|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
219580437|NCT05077436|DRUG|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
219580438|NCT05077436|DRUG|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
219580439|NCT03083236|OTHER|Standard PBI|Standard Parent Based Intervention (PBI)
219580440|NCT03083236|OTHER|Enhanced|Enhanced Parent Based Intervention (EPBI)
218825411|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
218825412|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
218825413|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
218825414|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
218825415|NCT03745768|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
218825416|NCT03745768|DEVICE|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
219195656|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
219195657|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
219363677|NCT02041962|BEHAVIORAL|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
219363678|NCT02041962|OTHER|Educational Control|
219363679|NCT00189644|PROCEDURE|6 FEC 100|
219363680|NCT00189644|PROCEDURE|4 FEC 100 followed by 4 Taxol|
218825417|NCT01100112|DRUG|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
218825418|NCT01864083|PROCEDURE|Positron Emission Tomography (PET)|
218825419|NCT01864083|DRUG|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
218825420|NCT01864083|PROCEDURE|Positron emission mammography (PEM) When available|
219363681|NCT01812967|DIETARY_SUPPLEMENT|Milk Fat|
219363682|NCT01812967|DIETARY_SUPPLEMENT|Milk Protein|
219363683|NCT01812967|DIETARY_SUPPLEMENT|Lactose|
219363684|NCT01812967|OTHER|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
219363685|NCT01812967|DIETARY_SUPPLEMENT|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
219363686|NCT00000815|BIOLOGICAL|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
219363687|NCT00000815|BIOLOGICAL|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
219363688|NCT01799057|DRUG|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
219363689|NCT01799057|DRUG|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
219437640|NCT05221255|OTHER|spinal magnetic stimulation|"* Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
218825421|NCT01864083|PROCEDURE|MR|
218825422|NCT05879952|BEHAVIORAL|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
218825423|NCT05879952|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
219437641|NCT05106439|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
219437642|NCT05106439|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
219195658|NCT06008860|DRUG|Experimental: Primary Cohort|Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
219195659|NCT06008860|OTHER|Placebo Comparator: Primary Cohort - Placebo|A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
219437643|NCT05106439|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
219437644|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
219437645|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
219437646|NCT05218304|BIOLOGICAL|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
219010444|NCT05911776|DRUG|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
219010445|NCT05911776|DRUG|Intravenous Dexmedetomidine|patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
219010446|NCT02703389|BEHAVIORAL|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
219010447|NCT02703389|BEHAVIORAL|Pamphlet|Contains same information as video.
219195660|NCT02539290|BEHAVIORAL|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
219195661|NCT02539290|PROCEDURE|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
219010448|NCT03254927|DRUG|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
219437647|NCT00663104|BEHAVIORAL|exercise|exercise: 3 joint sessions/week for 12 months
219437648|NCT00663104|BEHAVIORAL|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
219437649|NCT00663104|BEHAVIORAL|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
219437650|NCT05031104|OTHER|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
219437651|NCT05031104|OTHER|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
219437652|NCT02907281|OTHER|Observational|Observational
219437653|NCT01363258|BEHAVIORAL|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
219010449|NCT01031732|PROCEDURE|MIS-2 THA|MIS two-incision THA
219010450|NCT01031732|PROCEDURE|MIS-WJ|MIS-Watson Jones THA
219437654|NCT01363258|PROCEDURE|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
219437655|NCT05170672|BIOLOGICAL|Abatacept|
219437656|NCT04582604|DRUG|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
219437657|NCT02428673|OTHER|Assisted Standing Treatment Program|
219437658|NCT02819349|BEHAVIORAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
219437659|NCT01914783|OTHER|ultrafine particles|exposure to ultrafine particles
219437660|NCT01914783|OTHER|ultrafine particles and ozone|exposure to ultrafine particles and ozone
219437661|NCT01914783|OTHER|clean air|Exposure to clean air.
219437662|NCT02017704|RADIATION|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
218825424|NCT04461353|DRUG|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
218825425|NCT04461353|OTHER|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
218825426|NCT01773954|DRUG|Intravitreal Aflibercept Injection|Increased or decreased time between visits
218825427|NCT03911856|OTHER|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
218825428|NCT03911856|OTHER|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
218825429|NCT00225862|DRUG|ropinirole|
218825430|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
218825431|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
218825432|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
218825433|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
218825434|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
218825435|NCT01023217|DRUG|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
218825436|NCT01023217|DRUG|Entecavir|Entecavir 1 mg/day orally
218825437|NCT01023217|DRUG|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
218825438|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
218825439|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
218825440|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
218825441|NCT00028158|DRUG|G207, an oncolytic virus|
218825442|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
218825443|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
218825444|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
219010451|NCT01031732|PROCEDURE|MIS-AL THA|Transgluteal approach
219010452|NCT01031732|PROCEDURE|MIS-PL THA|Posterolateral approach
219010453|NCT00187811|PROCEDURE|Delta amino leavulinic acid photodynamic therapy|
219010454|NCT00993291|PROCEDURE|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
219010455|NCT00993291|PROCEDURE|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
219010456|NCT00446290|DRUG|Docetaxel, Capecitabine and Oxaliplatin|
219010457|NCT01490957|OTHER|Database|Database
219010458|NCT03740958|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
219010459|NCT03740958|DRUG|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
219010460|NCT00670865|OTHER|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
219010461|NCT04152603|BEHAVIORAL|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
219010462|NCT03181854|BEHAVIORAL|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
219010463|NCT03181854|BEHAVIORAL|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
219010464|NCT01214018|OTHER|Questionnaires and interview|Questionnaires and interview
219010465|NCT02763189|OTHER|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
218825445|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
219437663|NCT02017704|DRUG|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
219437664|NCT02017704|RADIATION|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
218825446|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
218825447|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
218825448|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
218825449|NCT06512610|OTHER|Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
218825450|NCT02281656|PROCEDURE|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
218825451|NCT02281656|PROCEDURE|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
218825452|NCT01913847|DRUG|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
219437665|NCT02017704|DRUG|FOLFOX6|"* Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
218825453|NCT01913847|DRUG|Placebo|Oral placebo TID for 12 weeks
218825454|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
218825455|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
219010466|NCT02763189|OTHER|Self-study|All subjects will receive self-study
219010467|NCT05284149|DIETARY_SUPPLEMENT|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
219010468|NCT05284149|DIETARY_SUPPLEMENT|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
219010469|NCT02049957|DRUG|Sapanisertib|Sapnisertib capsules
219010470|NCT02049957|DRUG|Fulvestrant|Fulvestrant IM injection.
219010471|NCT02049957|DRUG|Exemestane|Exemestane tablets.
219010472|NCT00573534|DRUG|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
219010473|NCT02966990|DEVICE|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
219010474|NCT02650362|OTHER|fMRI|
219010475|NCT04358380|OTHER|Liver injury|LFTs elevation or liver decompensation
218825456|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
218825457|NCT04867083|DRUG|ARV bitherapie|"1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
218825458|NCT01106157|DRUG|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
218825459|NCT01106157|DRUG|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
218825460|NCT01106157|DRUG|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
218825461|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
218825462|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
218825463|NCT03084705|DEVICE|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
219195662|NCT02539290|PROCEDURE|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
218825464|NCT01673646|DRUG|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
218825465|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
218825466|NCT06049550|OTHER|no intervention|no intervention
218825467|NCT01899781|DRUG|Antibiotic-Cefamezin|
218825468|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
218825469|NCT03064074|DRUG|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
218825470|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
218825471|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
218825472|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
218825473|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
218825474|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
218825475|NCT04590599|DRUG|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
218825476|NCT04590599|DRUG|Placebo|Placebo Q3W, for a total of 4 cycles
218825477|NCT04590599|DRUG|Sintilimab|Sintilimab 200mg,Q3W
218825478|NCT04312503|DRUG|Lurasidone|Patients are treated with dosages according clinical practice
218825479|NCT04312503|DRUG|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
218825480|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
218825481|NCT01580410|DRUG|mitomycin C|Given by HIPEC
218825482|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
219195663|NCT02539290|BEHAVIORAL|Sexual intercourse|Sexual intercourse on the day of the intervention and the following day
218825483|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218825484|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
219195664|NCT06462482|DRUG|Nandrolone Decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
219195665|NCT06462482|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
219195666|NCT06644300|DRUG|BM230|SC injection
218825485|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
218825486|NCT03417466|DEVICE|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
218825487|NCT01397227|BIOLOGICAL|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
218825488|NCT01397227|BIOLOGICAL|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
218825489|NCT01397227|BIOLOGICAL|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
218825490|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
218825491|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
218825492|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
218825493|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
218825494|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
218825495|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
218825496|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
218825497|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
218825498|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
218825499|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
218825500|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
218825501|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
218825502|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
218825503|NCT01725802|DRUG|Placebo|
218825504|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
218825505|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
218825506|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
219195667|NCT06644300|DRUG|BM230|SC injection
219195668|NCT06369142|DEVICE|Intravascular lithotripsy (IVL)|Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
219195669|NCT06369142|DEVICE|Standard non-IVL methods|Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
218825507|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
218825508|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
218825509|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
218825510|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
218825511|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
218825512|NCT00272831|DRUG|Placebo|1 tablet twice daily
218825513|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
218825514|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
218825515|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
218825516|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
218825517|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
218825518|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
218825519|NCT03162133|OTHER|Baduanjin exercise|
218825520|NCT00407615|DEVICE|Flex Pad/Static Magnet|
218825521|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
218825522|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
218825523|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
218825524|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
218825525|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
218825526|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
218825527|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
218825528|NCT03541278|PROCEDURE|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
218825529|NCT03541278|PROCEDURE|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
218825530|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
219010476|NCT05747781|BEHAVIORAL|Pilot Phase: standardized behavioral task|"Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests)."
219010477|NCT05747781|BEHAVIORAL|Validation Phase: standardized behavioral task|"Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test)."
219010478|NCT01572220|OTHER|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
219363690|NCT05644171|DEVICE|RESToration Of Rehabilitative function with Epidural spinal Stimulation|Three patients with chronic motor SCI will be recruited in total for this study. The recruited patients will not be randomized nor blinded due to the nature of this study. Pre-op rehabilitation session will take place over 4 weeks. 1 month post-surgical implants, patients will undergo 24 weeks of rehabilitation. The training sessions may continue to take place after the stipulated 24 weeks as long the electrode remains implanted, and the patient is available.
218825531|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
218825532|NCT00003262|BIOLOGICAL|bleomycin sulfate|
218825533|NCT00003262|BIOLOGICAL|filgrastim|
218825534|NCT00003262|DRUG|Stanford V regimen|
218825535|NCT00003262|DRUG|doxorubicin hydrochloride|
218825536|NCT00003262|DRUG|epirubicin hydrochloride|
218825537|NCT00003262|DRUG|etoposide|
218825538|NCT00003262|DRUG|mechlorethamine hydrochloride|
218825539|NCT00003262|DRUG|prednisone|
218825540|NCT00003262|DRUG|vinblastine sulfate|
218825541|NCT00003262|DRUG|vincristine sulfate|
218825542|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
218825543|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
219010479|NCT04565860|OTHER|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
219010480|NCT02642952|OTHER|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
219010481|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 11
219010482|NCT05497674|DRUG|Rifampin|QD for 10 days
219010483|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 6
219010484|NCT05497674|DRUG|Probenecid|twice a day, for 5 days
219437666|NCT02017704|PROCEDURE|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
219010485|NCT02908503|OTHER|Placebo Film|placebo vaginal films
219010486|NCT00310791|DRUG|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
218825544|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
218825545|NCT03186092|OTHER|sham muscle training|sham comparator
218825546|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
218825547|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
218825548|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
218825549|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
218825550|NCT05796258|DIAGNOSTIC_TEST|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
218825551|NCT06199232|DRUG|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
218825552|NCT00002811|DRUG|liposomal T4N5 lotion|
218825553|NCT06026280|BEHAVIORAL|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
218825554|NCT06026280|OTHER|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
218825555|NCT05018689|OTHER|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
218825556|NCT05018689|OTHER|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
219010487|NCT00310791|OTHER|Placebo (Sugar Pill)|Placebo (sugar pill)
219010488|NCT00310791|DRUG|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
219437667|NCT04176536|DRUG|BI 764198|Capsules
219010489|NCT03180151|PROCEDURE|piezotome assisted orthodontic tooth movement|"Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover."
218825557|NCT05282667|PROCEDURE|Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)|"A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure"
219010490|NCT05281185|DRUG|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
219010491|NCT05281185|DRUG|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
219010492|NCT06379178|PROCEDURE|Oral colostrum application 2 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
219010493|NCT06379178|PROCEDURE|Oral colostrum application 4 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
218825558|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
218825559|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
218825560|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
218825561|NCT02557451|OTHER|Surgery|
218825562|NCT02557451|OTHER|Intravitreal injections of gas|
218825563|NCT02557451|PROCEDURE|injections of an antiangiogenic|
218825564|NCT05207098|OTHER|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
219010494|NCT03528993|OTHER|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
219010495|NCT03528993|OTHER|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
219010496|NCT03528993|OTHER|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
219010497|NCT00923598|DRUG|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
219010498|NCT00959621|DRUG|Aspirin|ASA 100 mg once daily per os
219010499|NCT00959621|DRUG|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
219010500|NCT00959621|DRUG|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
219363691|NCT03488160|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
219363692|NCT02765451|BEHAVIORAL|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
219363693|NCT05443204|OTHER|Fortimel energy|Standard nutritional oral supplement
219363694|NCT05443204|OTHER|Nutrision Advanced Diason Energy HP|Specifc nutritional oral supplement in diabetics patients
219363695|NCT04669990|DRUG|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
219363696|NCT01670266|DRUG|ONO-9054|
219363697|NCT01670266|DRUG|Placebo|
219363698|NCT01549548|DRUG|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
219363699|NCT00874302|DRUG|Proellex|One 25mg capsule taken orally once every day.
219010501|NCT06034236|OTHER|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles"
219195670|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
219195671|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
218825565|NCT05207098|OTHER|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
219195672|NCT03169972|BIOLOGICAL|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
218825566|NCT03962855|DRUG|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
218825567|NCT03962855|DRUG|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
219010502|NCT06034236|OTHER|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1\. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2\. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
219010503|NCT02697032|DRUG|Bicalutamide|150mg
219195673|NCT00950638|DRUG|Avacincaptad Pegol|intravitreal injection
219195674|NCT04600544|OTHER|Non-interventional|Translational, observational study
219195675|NCT05476900|DRUG|HR19042 Capsules|HR19042 Capsules
219195676|NCT04030533|DRUG|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
219195677|NCT04030533|DRUG|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
219195678|NCT04030533|DRUG|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
219195679|NCT04030533|DRUG|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
219195680|NCT04030533|DRUG|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
219195681|NCT01862315|DRUG|Floxuridine (FUDR)|
219195682|NCT01862315|DRUG|dexamethasone|
219010504|NCT02697032|PROCEDURE|FDHT PET|PET scan
219195683|NCT01862315|DRUG|Gemcitabine|
219195684|NCT01862315|DRUG|Oxaliplatin|
219195685|NCT01862315|OTHER|MRI|
219195686|NCT01862315|OTHER|Research blood draws|These are optional
219195687|NCT06280378|DRUG|KL003 Cell Injection Drug Product|Administered by intravenous infusion after myeloablative conditioning with busulfan.
219195688|NCT03974022|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
219195689|NCT06772129|OTHER|Aromatherapy|Studies have been reviewed and no lavender aromatherapy has been found to be used for delirium.
219195690|NCT06179524|BIOLOGICAL|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
219195691|NCT02827838|BIOLOGICAL|Durvalumab|Given IV
219437668|NCT01864317|DEVICE|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
219195692|NCT02827838|OTHER|Laboratory Biomarker Analysis|Correlative studies
219195693|NCT02827838|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219195694|NCT03654131|DEVICE|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
219195695|NCT03654131|RADIATION|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
219363700|NCT00874302|DRUG|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
219363701|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~* The American Cancer Society~* The American Academy of Dermatology~* The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~* Sun protection practices~* Risk factors for melanoma~* Information about what melanoma looks like~* How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
219437669|NCT01864317|OTHER|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
218825568|NCT06049173|DEVICE|Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.
218825569|NCT06049173|OTHER|stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
218825570|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
218825571|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
218825572|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
218825573|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
218825574|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
218825575|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
219010505|NCT03383198|DRUG|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
219010506|NCT03383198|DRUG|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
219010507|NCT04939402|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
219010508|NCT04940351|PROCEDURE|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
219010509|NCT04940351|PROCEDURE|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
219437670|NCT01864317|OTHER|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
219437671|NCT01864317|OTHER|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
219437672|NCT01864317|OTHER|Humphrey Perimetry|Visual Field Testing
219580441|NCT03077321|BEHAVIORAL|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
219437673|NCT01864317|OTHER|Applanation Tonometry|Measurement of Intraocular Pressure
219437674|NCT01635036|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
218825576|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
219010510|NCT01935271|DIETARY_SUPPLEMENT|Muscle Armor Supplement|
219010511|NCT01935271|DIETARY_SUPPLEMENT|Placebo|
219010512|NCT00976092|DRUG|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
219010513|NCT00976092|DRUG|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
219010514|NCT00976092|DRUG|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
219010515|NCT00976092|DRUG|Heparin|i.v. bolus of 70-100 IU/kg body weight
218825577|NCT03157050|OTHER|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
218825578|NCT06135948|DRUG|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
218825579|NCT02651116|DRUG|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
219010516|NCT02759679|OTHER|Human breath samples|
219195696|NCT05627726|DEVICE|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
219195697|NCT05627726|OTHER|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
219195698|NCT05709145|OTHER|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
219195699|NCT06404905|DRUG|BT02 monoclonal antibody injection|It is expected to include 10-30 patients assigned to dose escalation cohorts.
219437675|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
219437676|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
219437677|NCT05260606|DIAGNOSTIC_TEST|F-18 FDG PET/CT|"1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan."
218825580|NCT02651116|DRUG|Placebo|10 mL Placebo
219437678|NCT04584931|PROCEDURE|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
219010517|NCT05037591|DRUG|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
218825581|NCT02651116|DEVICE|Cough recording device|FDA approved device validated for use in adults and children
218825582|NCT04336657|OTHER|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
218825583|NCT04336657|DIAGNOSTIC_TEST|IgG|Measure the past immunity of the disease (if possible)
218825584|NCT04064476|DRUG|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
218825585|NCT00269607|DRUG|Implantation of naltrexone implants|
218825586|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
219010518|NCT05037591|DRUG|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
219010519|NCT03123653|DRUG|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
219010520|NCT02814851|DEVICE|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
219010521|NCT02814851|DEVICE|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
218825587|NCT03384186|DRUG|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams \[mg\]) oral tablet.
218825588|NCT03384186|DRUG|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
218825589|NCT03384186|DRUG|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
218825590|NCT01893710|PROCEDURE|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
218825591|NCT06101134|DRUG|relatlimab+nivolumab|Specified dose on specified days
218825592|NCT06101134|DRUG|relatlimab+nivolumab+rHuPH20|Specified dose on specified days
218825593|NCT06101134|DRUG|nivolumab|Specified dose on specified days
218825594|NCT06101134|DRUG|nivolumab+rHuPH20|Specified dose on specified days
218825595|NCT00419055|PROCEDURE|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
218825596|NCT03893981|OTHER|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
218825597|NCT03893981|OTHER|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
218825598|NCT04660734|PROCEDURE|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
218825599|NCT04662164|DRUG|hepalatide|3 different dosage will be given sequentially to T2D patients
218825600|NCT01492088|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
218825601|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Eurofarma)|
218825602|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Zodic)|
218825603|NCT01406600|DRUG|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
218825604|NCT02184065|DRUG|Meloxicam|
219010522|NCT02814851|DEVICE|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
219010523|NCT02814851|DEVICE|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
219010524|NCT00102882|DRUG|fluticasone propionate/salmeterol|
219010525|NCT00102882|DRUG|salmeterol xinafoate|
219010526|NCT00258245|DIETARY_SUPPLEMENT|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11
219010527|NCT00258245|DRUG|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
218825605|NCT05180513|BEHAVIORAL|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
218825606|NCT05180513|BEHAVIORAL|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
218825607|NCT04791293|OTHER|MELD-Na score|MELD-Na scores will be compared between the groups
218825608|NCT02636296|OTHER|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
218825609|NCT02636296|OTHER|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
218825610|NCT02132286|DRUG|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
218825611|NCT00066326|DRUG|imatinib mesylate|
218825612|NCT00066326|DRUG|tanespimycin|
218825613|NCT03053934|BEHAVIORAL|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
218825614|NCT03053934|BEHAVIORAL|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
218825615|NCT02379052|DRUG|Dupilumab|
218825616|NCT02379052|DRUG|Placebo|
218825617|NCT05363592|DRUG|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
219010528|NCT00258245|DRUG|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
218825618|NCT05363592|DRUG|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
218825619|NCT05363592|DRUG|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
218825620|NCT04324892|DRUG|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
218825621|NCT03824392|BIOLOGICAL|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
218825622|NCT03824392|BIOLOGICAL|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
218825623|NCT03824392|BIOLOGICAL|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
218825624|NCT00127855|BIOLOGICAL|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
218825625|NCT00127855|BIOLOGICAL|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
218825626|NCT00127855|BIOLOGICAL|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
218825627|NCT00127855|BIOLOGICAL|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
218825628|NCT00127855|BIOLOGICAL|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
218825629|NCT00127855|BIOLOGICAL|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
218825630|NCT00127855|BIOLOGICAL|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
218825631|NCT01686113|OTHER|NEFA|
218825632|NCT01686113|OTHER|Sucrose|
218825633|NCT02007304|BEHAVIORAL|Eccentric exercise training|12 weeks of lower leg eccentric training
218825634|NCT02343302|DEVICE|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
218825635|NCT02343302|DEVICE|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
218825636|NCT01527630|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
218825637|NCT04660760|DRUG|Paclitaxel|Given IV
218825638|NCT04660760|OTHER|Quality-of-Life Assessment|Complete questionnaires
218825639|NCT04660760|BIOLOGICAL|Ramucirumab|Given IV
218825640|NCT04660760|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
218825641|NCT04559061|DEVICE|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
218825642|NCT03201120|BEHAVIORAL|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
218825643|NCT03201120|BEHAVIORAL|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
218825644|NCT01887717|DEVICE|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
219010529|NCT00258245|DRUG|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
219010530|NCT00258245|DRUG|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
219010531|NCT00258245|DRUG|Aspirin|Aspirin - 325 mg by mouth (PO) every day
219010532|NCT01516346|DRUG|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
219010533|NCT01516346|DRUG|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
219010534|NCT01516346|DRUG|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
219010535|NCT04541862|OTHER|Intensive care|intensive care for critically ill patients in the intensive care units
218825645|NCT01887717|DRUG|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
218825646|NCT03984773|BEHAVIORAL|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
218825647|NCT01564342|PROCEDURE|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
218825648|NCT02448147|BEHAVIORAL|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
218825649|NCT02448147|BEHAVIORAL|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
218825650|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
218825651|NCT04163939|OTHER|Vista Therapy Collar|The patient will wear the cervical collar
218825652|NCT04163939|OTHER|Placebo|The patient will not wear the cervical collar
218825653|NCT01258673|DRUG|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
218825654|NCT01258673|DRUG|Fimasartan|Fimasartan 60mg, 120mg
218825655|NCT00308334|DRUG|Domperidone|10 mg po TID X 14 days
218825656|NCT00308334|DRUG|Placebo- Sugar pill|placebo po TID x 14 days
218825657|NCT06135584|DRUG|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
218825658|NCT06135584|DRUG|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
218825659|NCT06135584|OTHER|Drug-free|Drug-free
218825660|NCT05518006|DIETARY_SUPPLEMENT|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
218825661|NCT05518006|DIETARY_SUPPLEMENT|Placebo Drink|Blended Placebo drink
218825662|NCT02655887|DEVICE|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
219437679|NCT04584931|PROCEDURE|restorative intervention|colored composite restoration to camouflage the gingival recession defect
218825663|NCT01306695|BEHAVIORAL|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
218825664|NCT01306695|OTHER|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
218825665|NCT03119168|DRUG|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
218825666|NCT03119168|OTHER|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
218825667|NCT03332121|BIOLOGICAL|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
218825668|NCT03565172|DIAGNOSTIC_TEST|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
219010536|NCT01915082|DRUG|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
219437680|NCT03381911|OTHER|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
219437681|NCT02858102|BEHAVIORAL|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
218825669|NCT03565172|OTHER|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
218825670|NCT03565172|DIAGNOSTIC_TEST|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
218825671|NCT05011149|DRUG|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
218825672|NCT02757807|BEHAVIORAL|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
218825673|NCT05547113|DIAGNOSTIC_TEST|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
218825674|NCT03988426|BIOLOGICAL|Octanorm|Octanorm
218825675|NCT01734824|DRUG|Denosumab|sc RANKL-inhibitor
218825676|NCT01734824|DRUG|Teriparatide|daily subcutaneous injection of teriparatide
219010537|NCT01915082|DRUG|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
219010538|NCT05988099|DIETARY_SUPPLEMENT|Complex product|400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
219010539|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in liposomal formulation|400 mg of chokeberry extract in liposomal formulation
219195700|NCT05885256|DIAGNOSTIC_TEST|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
219437682|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
218825677|NCT01734824|DRUG|Placebo Denosumab|one subcutaneous injection denosumab placebo
219010540|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in traditional formulation|400 mg of chokeberry extract in traditional formulation
219010541|NCT05988099|OTHER|Placebo|Placebo
218825678|NCT01734824|DRUG|Placebo Teriparatide|daily subcutaneous placebo injection
218825679|NCT03637491|DRUG|Avelumab|IV treatment
219010542|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
219010543|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
219010544|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
219010545|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
219010546|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
219010547|NCT05449652|OTHER|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
219010548|NCT02703662|DEVICE|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
218825680|NCT03637491|DRUG|Binimetinib|Oral treatment
218825681|NCT03637491|DRUG|Talazoparib|Oral treatment
218825682|NCT00532844|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
219437683|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
219437684|NCT01587274|DRUG|Naproxen|Naproxen 500mg twice/ day x 10 days
219437685|NCT01587274|DRUG|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
219437686|NCT01587274|DRUG|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
218825683|NCT00532844|DRUG|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
218825684|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
218825685|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
219010549|NCT02703662|DEVICE|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
219010550|NCT00002014|DRUG|Zidovudine|
219010551|NCT00002014|DRUG|Didanosine|
219010552|NCT00828347|DRUG|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
218825686|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
219195701|NCT01545999|OTHER|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
219195702|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219195703|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219195704|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219195705|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
219195706|NCT05492422|DEVICE|Central Executive Training (CET)|Central Executive Training (CET)
219437687|NCT00083876|DRUG|Thalidomide|
218825687|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
219437688|NCT04055025|OTHER|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
219437689|NCT04055025|OTHER|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
219437690|NCT00821899|BIOLOGICAL|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
219437691|NCT01121952|OTHER|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
219437692|NCT00232414|DRUG|Quetiapine|
218825688|NCT00405249|DRUG|elvucitabine|
218825689|NCT02077231|DRUG|Vitamin A|use one drop in the eye
218825690|NCT02077231|DRUG|carbomer eye gel|use one drop in the eye
218825691|NCT03335202|DIAGNOSTIC_TEST|analysis of microbiome|microbial profiling by next generation sequencing
218825692|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
218825693|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
218825694|NCT01428310|DIETARY_SUPPLEMENT|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
218825695|NCT01428310|DIETARY_SUPPLEMENT|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
219010553|NCT00828347|DRUG|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
219010554|NCT01411904|DEVICE|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
219010555|NCT02012075|DRUG|Extended-Release Carvedilol Sulfate|
219010556|NCT02012075|DRUG|Sustained-release Metoprolol Succinate|
219010557|NCT03471130|DRUG|MT-8554 Low dose|Oral, 7 days
219010558|NCT03471130|DRUG|MT-8554 High dose|Oral, 7 days
219010559|NCT03471130|DRUG|Placebo|Oral, 7 days
219195707|NCT05492422|BEHAVIORAL|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
219437693|NCT01553760|PROCEDURE|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
219437694|NCT01553760|PROCEDURE|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
219437695|NCT04289194|DRUG|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
219437696|NCT04289194|DRUG|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
219437697|NCT04289194|DRUG|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
218825696|NCT02581436|OTHER|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
218825697|NCT02581436|OTHER|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
218825698|NCT02861287|OTHER|Economic evaluation|
218825699|NCT06546475|DRUG|N-Acetylcysteine|regular dose or high dose add-on
218825700|NCT04300387|BEHAVIORAL|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
218825701|NCT01750125|DEVICE|measure ascending aortic blood flow with pulse wave Doppler|
218825702|NCT01107067|DRUG|Sustanon|250 mg/21 days
218825703|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
218825704|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
219437698|NCT01301417|DEVICE|ColonRing™|Creation of a circular Compression Anastomosis
219010560|NCT05862415|OTHER|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
219195708|NCT03640286|DEVICE|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
219195709|NCT05823948|DRUG|Insulin Icodec|Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
219437699|NCT03896906|DEVICE|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
219437700|NCT03896906|DEVICE|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
219437701|NCT05369780|DIETARY_SUPPLEMENT|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
218825705|NCT02020590|DRUG|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
218825706|NCT03069508|DRUG|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
218825707|NCT02308761|DRUG|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
218825708|NCT01709526|BEHAVIORAL|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
218825709|NCT05979961|RADIATION|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
218825710|NCT05979961|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
218825711|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
218825712|NCT01186250|DRUG|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
218825713|NCT01186250|DRUG|Placebo|placebo taken daily for one year
218825714|NCT01234493|PROCEDURE|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
218825715|NCT01234493|PROCEDURE|no fixation|No syndesmosis fixation.
218825716|NCT02273102|DRUG|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
218825717|NCT02273102|DRUG|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
218825718|NCT05490758|OTHER|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
219010561|NCT03068481|DRUG|KDT-3594|Oral administration
219010562|NCT03068481|DRUG|Placebo|Oral administration
219010563|NCT00304993|DRUG|fenofibrate|
218825719|NCT05490758|OTHER|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
218825720|NCT05295264|OTHER|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
218825721|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
218825722|NCT00002170|DRUG|Nelfinavir mesylate|
218825723|NCT03465722|DRUG|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
218825724|NCT03465722|DRUG|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
218825725|NCT03457714|BEHAVIORAL|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
218825726|NCT03457714|OTHER|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
218825727|NCT05497661|OTHER|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
219010564|NCT00304993|DRUG|niacin|
219010565|NCT00304993|DRUG|rosiglitazone|
219010566|NCT00002416|DRUG|Emtricitabine|
219010567|NCT00002416|DRUG|Lamivudine|
218825728|NCT05497661|OTHER|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
218825729|NCT05887037|DIAGNOSTIC_TEST|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
218825730|NCT05887037|DIAGNOSTIC_TEST|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
218825731|NCT02965066|DEVICE|Coloplast Test Catheter|Newly developed intermittent catheter
218825732|NCT02965066|DEVICE|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
218825733|NCT04144114|DIETARY_SUPPLEMENT|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
218825734|NCT04144114|DIETARY_SUPPLEMENT|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
218825735|NCT04144114|DIETARY_SUPPLEMENT|Placebo|Placebo
218825736|NCT00131521|DRUG|mucomyst|
218825737|NCT00131521|DRUG|sodium chloride (saline)|
218825738|NCT00499200|DRUG|SRA-444|
218825739|NCT02745873|DRUG|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
218825740|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
218825741|NCT03046836|DRUG|Oxytocin|40 IU oxytocin nasal spray
218825742|NCT03046836|DRUG|Placebo|Saline
218825743|NCT01490918|DRUG|Acarbose|Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
218825744|NCT01490918|DRUG|Placebo acarbose|acarbose placebo
218825745|NCT01490918|DRUG|placebo metformin|metformin placebo
218825746|NCT03154671|OTHER|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
218825747|NCT01476410|DRUG|brentuximab vedotin|Given IV
218825748|NCT01476410|DRUG|doxorubicin hydrochloride|Given IV
218825749|NCT01476410|DRUG|vinblastine|Given IV
218825750|NCT01476410|DRUG|dacarbazine|Given IV
218825751|NCT01476410|PROCEDURE|quality-of-life assessment|Ancillary studies
218825752|NCT01476410|GENETIC|DNA analysis|Optional correlative studies
218825753|NCT01476410|GENETIC|RNA analysis|Optional correlative studies
218825754|NCT01476410|RADIATION|fludeoxyglucose F 18|Correlative studies
218825755|NCT01476410|PROCEDURE|positron emission tomography|Correlative studies
218825756|NCT01476410|OTHER|laboratory biomarker analysis|Optional correlative studies
218825757|NCT01476410|OTHER|immunohistochemistry staining method|Optional correlative studies
219010568|NCT05655962|OTHER|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
219010569|NCT01129960|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
219010570|NCT01129960|DRUG|Placebo|Tablets will be used.
219010571|NCT00050518|BIOLOGICAL|Aventis Pasteur Smallpox Vaccine|
219010572|NCT03259776|OTHER|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
219010573|NCT00892762|DRUG|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
219010574|NCT00892762|DRUG|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
219010575|NCT02974517|DEVICE|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
219010576|NCT02790203|DRUG|Celecoxib|NSAIDS
219010577|NCT02790203|DRUG|Placebo|Placebo
219437702|NCT00918346|DRUG|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
219437703|NCT04753723|COMBINATION_PRODUCT|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
218825758|NCT01476410|GENETIC|polymorphism analysis|Optional correlative studies
218825759|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
218825760|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
218825761|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
218825762|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
218825763|NCT06270238|DEVICE|High-Frequency1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825764|NCT06270238|DEVICE|cTBS1|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825765|NCT06270238|DEVICE|High-Frequency2|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825766|NCT06270238|DEVICE|cTBS2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825767|NCT06270238|DEVICE|High-Frequency3|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825768|NCT06270238|DEVICE|cTBS3|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
218825769|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
218825770|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
218825771|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
218825772|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
218825773|NCT01293136|PROCEDURE|Femoral nerve block|Ropivacaine
218825774|NCT01293136|DRUG|Intravenous opioids|Whatever opioids prescribed
218825775|NCT03962959|DEVICE|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
218825776|NCT03141255|DEVICE|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
218825777|NCT03141255|DEVICE|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
219476418|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
219010578|NCT04450368|DEVICE|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
218825778|NCT04940130|BIOLOGICAL|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
218825779|NCT04940130|OTHER|Normal Saline|placebo control- saline
218825780|NCT00532701|DRUG|Peg-IFN + WB RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16"
218825781|NCT00532701|DRUG|Peg-IFN + LD RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
218825782|NCT00532701|DRUG|Peg-IFN + WB RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
218825783|NCT00532701|DRUG|Peg-IFN + WB RBV for 48 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
218825784|NCT00532701|DRUG|Peg-IFN + LD RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
218825785|NCT02240121|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
218825786|NCT02240121|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
218825787|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
218825788|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
218825789|NCT02329093|PROCEDURE|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
218825790|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
218825791|NCT02274961|DRUG|S-pantoprazole 10mg|
218825792|NCT02274961|DRUG|Placebo|
218825793|NCT03152123|DRUG|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
218825794|NCT03152123|DRUG|Placebos|tablets over-capsuled
218825795|NCT03152123|DRUG|Phentermine|Phentermine 60 mg (capsule over-capsuled)
218825796|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
218825797|NCT04581785|BIOLOGICAL|hLB-001|hLB-001 via IV infusion
218825798|NCT03117959|DEVICE|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
218825799|NCT03117959|DEVICE|Stryker Triathlon Custom Fit Knee|
219437704|NCT00646438|DRUG|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
219437705|NCT01089218|DRUG|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
218825800|NCT03278548|DRUG|Volulyte 6%|Solution for infusion
218825801|NCT03278548|DRUG|Ionolyte|Solution for infusion
219010579|NCT04429139|DRUG|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
218825802|NCT02156024|DRUG|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
218825803|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
218825804|NCT00334568|DRUG|Placebo|Placebo
218825805|NCT02228161|BEHAVIORAL|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
218825806|NCT04419467|BIOLOGICAL|CSL346|VEGF-B antagonist monoclonal antibody
218825807|NCT04419467|DRUG|Placebo|Normal saline
218825808|NCT02989181|DEVICE|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
218825809|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
218825810|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
218825811|NCT05724082|OTHER|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
218825812|NCT00981903|DRUG|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
218825813|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
218825814|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
218825815|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
218825816|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
218825817|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
218825818|NCT03511001|OTHER|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
218825819|NCT06525038|OTHER|All groups were observed for clinical end-points described in the study protocol|All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
218825820|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
218825821|NCT05490316|DRUG|placebo|placebo
218825822|NCT01730612|DRUG|TF2 - 68 Ga-IMP-288:|ImmunoTEP
218825823|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
218825824|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
218825825|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
218825826|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
218825827|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
219010580|NCT04011761|OTHER|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
218825828|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
218825829|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
218825830|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
218825831|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
218825832|NCT02214069|DEVICE|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
218825833|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
218825834|NCT00446329|DRUG|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
218825835|NCT00366210|BEHAVIORAL|Constraint-Induced Movement (CI) Therapy|
218825836|NCT00366210|BEHAVIORAL|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
218825837|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
218825838|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
219010581|NCT01895569|DRUG|Metformin|Metformin will be added to therapy for the first threre months.
218825839|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
218825840|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
219010582|NCT01895569|DRUG|Pioglitazone|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
219010583|NCT01895569|DRUG|Sitagliptin|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
219437706|NCT01089218|DRUG|control|no intervention with the same procedure of FB
219763659|NCT05558059|DEVICE|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
219763660|NCT06418204|OTHER|Non-interventional Study|Non-interventional study
219763661|NCT05421858|DRUG|Fosmanogepix|IV infusion
219763662|NCT05421858|DRUG|Fosmanogepix|Oral tablet
219763663|NCT05421858|DRUG|Caspofungin|IV infusion
219195710|NCT06779266|PROCEDURE|Suturing|Endoscopic Suturing is a technique of the wound closure after advanced endoscopic third-space resections in the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
219195711|NCT06779266|PROCEDURE|Clipping|Clipping is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the through-the-scope clips are delivered to the site through the working canal. The arms of the clip are properly put on the both sides of the defect and the clip is closed to seal the margins. The procedure may be repeated along the resection site for complete closure.
219763664|NCT05421858|DRUG|Fluconazole|Fluconazole oral capsule
219763665|NCT05421858|DRUG|Placebo|Matching placebo for caspofungin (IV infusion)
219763666|NCT05421858|DRUG|Placebo|Matching placebo for fluconazole (oral capsule)
219763667|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (IV infusion)
219763668|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (oral tablet)
218825841|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
218825842|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
218825843|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
218825844|NCT05501639|DRUG|tiotropium|tiotropium
219195712|NCT06779266|PROCEDURE|No closure|The resection site after endoscopic submucosal dissection was left open, without additional closure.
219437707|NCT03907813|DRUG|Exparel|liposomal bupivacaine wound infiltration
219437708|NCT03907813|OTHER|Saline infiltration|saline wound infiltration
219437709|NCT02475629|BIOLOGICAL|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
219437710|NCT02475629|DRUG|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
219763669|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
219763670|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
219763671|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
219763672|NCT05176093|OTHER|Placebo|Injectable Liquid
219763673|NCT06672510|DEVICE|ATC|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P
219763674|NCT05677490|DRUG|Fluorouracil|Given IV
219437711|NCT04257604|DRUG|Perampanel|Perampanel tablets.
219437712|NCT01964729|DEVICE|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
219763675|NCT05677490|DRUG|Leucovorin Calcium|Given IV
219763676|NCT05677490|DRUG|Oxaliplatin|Given IV
219763677|NCT05677490|DRUG|Irinotecan|Given IV
219763678|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
219763679|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763680|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
219763681|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763682|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
219763683|NCT05312229|BEHAVIORAL|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
219763684|NCT05312229|OTHER|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
219763685|NCT05312229|OTHER|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
219763686|NCT05853458|DRUG|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
219763687|NCT05268562|DRUG|Ketamine|1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions
219763688|NCT05268562|DRUG|Propofol|0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
219763689|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
219763690|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
218825845|NCT05501639|DRUG|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
218825846|NCT05501639|DRUG|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
218825847|NCT02069977|DRUG|Aripiprazole|
218825848|NCT04240106|DRUG|Niraparib|Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
218825849|NCT04240106|DRUG|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
218825850|NCT02881736|OTHER|electroencephalographic,magnetic resonance imaging|
218825851|NCT00004927|DRUG|ixabepilone|
219010584|NCT01074112|DEVICE|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
219010585|NCT01074112|DEVICE|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
219437713|NCT01964729|DEVICE|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
219437714|NCT03520205|PROCEDURE|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
219010586|NCT01074112|PROCEDURE|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
219010587|NCT01074112|DEVICE|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
219010588|NCT01074112|DEVICE|Cardiac Ultrasound|Ultrasound views of the heart
219010589|NCT02870296|BEHAVIORAL|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
219437715|NCT03520205|PROCEDURE|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
218825852|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
218825853|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
218825854|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
218825855|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
218825856|NCT00104390|BIOLOGICAL|Grass MATA MPL|
218825857|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
219010590|NCT06501768|DRUG|Genistein|Escalation genistein dosing, followed by wash-out period
219010591|NCT00165776|DRUG|BOTULINUM TOXIN TYPE B|
219010592|NCT00492583|DRUG|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
219010593|NCT00492583|DRUG|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
219010594|NCT00442078|DEVICE|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
219010595|NCT00767637|DRUG|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
219010596|NCT01681225|OTHER|Esophageal-pressure guided mechanical ventilation|
219010597|NCT01681225|OTHER|High PEEP mechanical ventilation|
219010598|NCT04673864|DRUG|CKD-386|QD, PO
218825858|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
218825859|NCT02779777|DRUG|Tipifarnib|Oral tablet
218825860|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
218825861|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
218825862|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
218825863|NCT01280786|DRUG|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
218825864|NCT04944147|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
218825865|NCT04944147|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
218825866|NCT04944147|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
218825867|NCT04944147|BEHAVIORAL|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
218825868|NCT00224081|DRUG|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
219010599|NCT04673864|DRUG|D012, D326, D337|QD, PO
219010600|NCT06431490|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
219010601|NCT03330769|DRUG|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
219010602|NCT00251550|DRUG|Pemetrexed|
219010603|NCT00251550|DRUG|Cisplatin|
219010604|NCT00479076|DRUG|aflibercept (AVE0005)|intravenous infusion
218825869|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
218825870|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
219437716|NCT02257125|BEHAVIORAL|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
218825871|NCT01117194|DEVICE|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
218825872|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
218825873|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
218825874|NCT04571060|DRUG|Placebo|One dose of matching placebo
218825875|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
218825876|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
219010605|NCT00479076|DRUG|S-1|oral administration
219010606|NCT05677724|DIAGNOSTIC_TEST|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
219010607|NCT03053804|RADIATION|MR/PET|MR/PET with contrast media and FDG-18
219010608|NCT00349804|OTHER|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
219010609|NCT04464369|DRUG|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
219437717|NCT02257125|BEHAVIORAL|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
219437718|NCT02403960|DIETARY_SUPPLEMENT|probiotic|the patients used probiotic tablets in addition to scaling and root planning
219437719|NCT02403960|DIETARY_SUPPLEMENT|placebo|the patients used placebo tablets in addition to scaling and root planning
219437720|NCT01813968|PROCEDURE|Ischemic postconditioning|
219437721|NCT04115345|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
219437722|NCT06291545|DEVICE|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
219437723|NCT06291545|DEVICE|ScoreFlex NC Coronary Dilatation Catheter|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
219437724|NCT03676205|BIOLOGICAL|PRP|Platelet-Rich Plasma
218825877|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
218825878|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
218825879|NCT05834985|PROCEDURE|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
218825880|NCT06364397|PROCEDURE|ERCP|Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
218825881|NCT06364397|COMBINATION_PRODUCT|Health education and conservative management of clinical routines|Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
218825882|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
218825883|NCT00932074|DRUG|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
218825884|NCT02393820|DRUG|pazopanib|treatment will be given until progression or unacceptable toxicity .
218825885|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
219010610|NCT04464369|DRUG|Placebo|placebo pills matching the look and weight of the itopride tablets
219437725|NCT03676205|OTHER|Traumeel|Homeophatic Treatment
219437726|NCT02593461|DEVICE|Daifert|
219437727|NCT02593461|OTHER|Control Group|
219437728|NCT03616847|OTHER|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
219437729|NCT03616847|OTHER|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
219437730|NCT02242760|DRUG|SB204 2%|Applied topically twice daily
219437731|NCT02242760|DRUG|SB204 4%|Applied topically daily
218825886|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
218825887|NCT02342353|DRUG|Pacritinib|
218825888|NCT02342353|DRUG|Erlotinib|
218825889|NCT00974155|DRUG|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
218825890|NCT00974155|DRUG|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
218825891|NCT05657535|DEVICE|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
218825892|NCT00525434|DEVICE|Seraffix LTB|wounds closure by using laser and albumin
218825893|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
218825894|NCT04410159|DRUG|Povidone-Iodine|Gargle
218825895|NCT04410159|DRUG|Essential oils|Gargle
218825896|NCT04410159|OTHER|Tap water|Gargle
218825897|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
218825898|NCT01361217|DRUG|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
218825899|NCT01705340|DRUG|Akt inhibitor MK2206|Given PO
218825900|NCT01705340|BIOLOGICAL|trastuzumab|Given IV
218825901|NCT01705340|DRUG|lapatinib ditosylate|Given PO
218825902|NCT01705340|OTHER|laboratory biomarker analysis|Optional correlative studies
218825903|NCT05110573|PROCEDURE|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
218825904|NCT00087698|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
218825905|NCT00087698|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
218825906|NCT05753514|OTHER|ESWT|ESWT
218825907|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
218825908|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
218825909|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
218825910|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
218825911|NCT03411018|OTHER|Mechanical ventilation exposure|
218825912|NCT03810846|BEHAVIORAL|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
218825913|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
218825914|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
218825915|NCT02073162|PROCEDURE|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
219437732|NCT02242760|DRUG|Vehicle Gel|Applied topically twice and once daily
218825916|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
218825917|NCT01233024|DIETARY_SUPPLEMENT|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
218825918|NCT01233024|DIETARY_SUPPLEMENT|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
218825919|NCT01233024|DIETARY_SUPPLEMENT|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
219437733|NCT00643097|BIOLOGICAL|PEP-3 vaccine|Given intradermally
219437734|NCT00643097|BIOLOGICAL|sargramostim|Given intradermally
219437735|NCT00643097|DRUG|Temozolomide|Standard of care chemotherapy
219437736|NCT05778929|DIAGNOSTIC_TEST|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
219437737|NCT05210621|DRUG|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
218825920|NCT01233024|DIETARY_SUPPLEMENT|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
218825921|NCT01233024|DIETARY_SUPPLEMENT|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
218825922|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
218825923|NCT03491033|DRUG|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
218825924|NCT04970069|OTHER|Video on analgesic education|A four minute video informing the patient about opioids.
218825925|NCT04970069|OTHER|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
218825926|NCT01484457|DEVICE|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
218825927|NCT04750863|OTHER|diagnosis criteria performance|
218825928|NCT01992224|OTHER|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation"
218825929|NCT01992224|OTHER|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
219010611|NCT02622321|DRUG|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
219010612|NCT02622321|DRUG|rFVIIa|Participants will continue to receive rFVIIa.
219010613|NCT02622321|DRUG|aPCC|Participants will continue to receive aPCC.
219010614|NCT05070299|BEHAVIORAL|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
219010615|NCT00886899|DEVICE|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
219010616|NCT02835404|DRUG|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
219010617|NCT02835404|RADIATION|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
219437738|NCT05720962|PROCEDURE|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
219437739|NCT02754661|DEVICE|COLON Capsule endoscopy|
219010618|NCT02835404|RADIATION|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
219010619|NCT01958008|DRUG|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
219010620|NCT01958008|DRUG|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
219010621|NCT01958008|DRUG|BI 113608 high dose b.i.d.|Film-coated tablet
219010622|NCT01958008|DRUG|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
219010623|NCT01958008|DRUG|BI 113608 low dose b.i.d.|Film-coated tablet
219010624|NCT01958008|DRUG|BI 113608 medium dose b.i.d.|Film-coated tablet
219010625|NCT00241280|DEVICE|etafilcon A|
219437740|NCT02754661|DEVICE|Computed Tomographic Colonography|
219437741|NCT00002204|BIOLOGICAL|HIV p24/MF59 Vaccine|
219010626|NCT00241280|DEVICE|galyfilcon A|
219010627|NCT00138203|DRUG|vorinostat|Given PO
219010628|NCT00138203|OTHER|laboratory biomarker analysis|Correlative studies
219010629|NCT02148198|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
219010630|NCT02148198|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
219010631|NCT00965718|BIOLOGICAL|Activated T lymphocyte|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
219010632|NCT01092611|PROCEDURE|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
219437742|NCT02969967|DEVICE|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
219437743|NCT04423757|DRUG|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
219437744|NCT04423757|DRUG|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
219437745|NCT02709109|DRUG|VX-371 + HS|
218825930|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
218825931|NCT04550897|DRUG|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
218825932|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
218825933|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
218825934|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
218825935|NCT02099825|DRUG|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
218825936|NCT00400855|DRUG|Fluticasone propionate|Study drug
219010633|NCT01092611|BIOLOGICAL|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
219437746|NCT02709109|DRUG|Hypertonic saline|
219437747|NCT02709109|DRUG|Placebo|
219437748|NCT02709109|DRUG|Orkambi|
219437749|NCT02709109|DRUG|VX-371|
219437750|NCT00708747|DRUG|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
219580442|NCT03077321|BEHAVIORAL|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
218825937|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
218825938|NCT05851885|DIAGNOSTIC_TEST|AI-based reporting system|AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
218825939|NCT03154021|COMBINATION_PRODUCT|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
218825940|NCT03154021|COMBINATION_PRODUCT|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
218825941|NCT04096105|DRUG|CC-93538|a single dose CC-93538 SC
218825942|NCT01862081|DRUG|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
218825943|NCT01862081|DRUG|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
218825944|NCT01862081|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
218825945|NCT04618588|PROCEDURE|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
218825946|NCT00185887|DRUG|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
218825947|NCT02271061|DEVICE|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
218825948|NCT02271061|DEVICE|Control tape|Apply tape in same technique without tension.
218825949|NCT02405988|DRUG|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
219010634|NCT05712616|DRUG|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
219010635|NCT05712616|DRUG|Lacto-N-Hexaose|Placebo look alike drug
219010636|NCT02820272|PROCEDURE|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
219010637|NCT02820272|PROCEDURE|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
219010638|NCT02820272|PROCEDURE|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
219010639|NCT06121687|PROCEDURE|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
219010640|NCT06121687|PROCEDURE|PPI|Penile prosthesis implantation (PPI) will be performed
219437751|NCT00708747|DRUG|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
219437752|NCT03044080|DRUG|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
218825950|NCT02405988|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
218825951|NCT00142792|DEVICE|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
218825952|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
219010641|NCT01634360|DRUG|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
219010642|NCT02385552|BEHAVIORAL|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
219010643|NCT02563353|OTHER|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
218825953|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
218825954|NCT02874443|OTHER|Knowledge Translation of labor management guidelines|
219010644|NCT02563353|DRUG|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
219010645|NCT02028065|DRUG|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
218825955|NCT04796038|DEVICE|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
218825956|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
218825957|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
218825958|NCT00003109|DRUG|irinotecan hydrochloride|
218825959|NCT00003109|DRUG|raltitrexed|
218825960|NCT01409408|DRUG|Aliskiren|300 mg of aliskiren daily for 8 weeks.
218825961|NCT01409408|DRUG|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
218825962|NCT02771405|DRUG|Sofosbuvir|Sofosbuvir 400 mg orally once daily
219010646|NCT02028065|DRUG|Placebo|Placebo administered as a single IV bolus over 10 seconds
219010647|NCT03498300|BIOLOGICAL|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
219010648|NCT01441505|DRUG|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
219010649|NCT01441505|DRUG|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
219010650|NCT01414855|DRUG|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
219010651|NCT01414855|DRUG|cyclophosphamide|750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
219476419|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
218825963|NCT02771405|DRUG|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218825964|NCT02771405|DRUG|Simeprevir|Simeprevir 150 mg orally once daily
218825965|NCT02771405|DRUG|daclatasvir|Daclatasvir 60 mg orally once daily
218825966|NCT02771405|DRUG|Ledipasvir|Ledipasvir 90 mg orally once daily
218825967|NCT04330209|OTHER|weight loss diets|The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
218825968|NCT00893854|DRUG|Diclophenac|
218825969|NCT00893854|DRUG|Triamcinolone|
218825970|NCT03783598|BEHAVIORAL|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
219010652|NCT01414855|DRUG|doxorubicin|50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
219010653|NCT01414855|DRUG|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
219010654|NCT01414855|DRUG|vincristine|1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
219010655|NCT00830596|OTHER|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
219010656|NCT00830596|OTHER|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
219010657|NCT00830596|OTHER|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
219010658|NCT05877781|DIETARY_SUPPLEMENT|Palmitoylethanolamide|8-week treatment 3x400 mg per day
219010659|NCT03912116|OTHER|CLARIX FLO|100mg CLARIX FLO
219010660|NCT03912116|OTHER|Saline|Saline
219010661|NCT03236974|DRUG|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
219010662|NCT03236974|DRUG|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
219010663|NCT04255524|DEVICE|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
219476420|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
218825971|NCT06112301|DIAGNOSTIC_TEST|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
218825972|NCT01846702|DRUG|Placebo|Given as a SC injection.
218825973|NCT01846702|DRUG|LY3084077|Given as a SC injection.
218825974|NCT01328743|BEHAVIORAL|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
218825975|NCT06646952|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
218825976|NCT03787329|OTHER|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
218825977|NCT03787329|OTHER|Core decompression surgery|Core decompression surgery only
218825978|NCT01218269|DEVICE|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
218825979|NCT05105321|DRUG|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
218825980|NCT05105321|BEHAVIORAL|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
218825981|NCT00011583|DEVICE|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
219010664|NCT03027778|OTHER|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
219010665|NCT04851314|DEVICE|ICU certified ventilator|Examine anesthetic consumption rates
219010666|NCT04851314|DEVICE|Non-ICU certified ventilator|Examine anesthetic consumption rates
219010667|NCT00877383|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219010668|NCT00877383|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
219010669|NCT00877383|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219010670|NCT03669172|BIOLOGICAL|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
219010671|NCT03012256|OTHER|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
219010672|NCT03544502|DEVICE|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
219010673|NCT03544502|DEVICE|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
219010674|NCT03544502|DEVICE|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
219010675|NCT03544502|PROCEDURE|Ambient operating room noise|patients were exposed to the ambient operating room noise.
219010676|NCT03735225|DRUG|Dasiglucagon|Dasiglucagon injection
219010677|NCT03735225|DRUG|Placebo|Placebo for Dasiglucagon injection
219010678|NCT02107482|DEVICE|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
219010679|NCT02107482|DEVICE|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
218825982|NCT00011583|DEVICE|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
218825983|NCT00299364|DRUG|Black Cohosh (iCR) or tibolone|
218825984|NCT01478022|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
218825985|NCT01478022|DRUG|Ibuprofen|Ibuprofen 200 mg daily, capsules
218825986|NCT01478022|OTHER|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
218825987|NCT02481258|DRUG|Ataciguat (HMR1766)|
219010680|NCT02402127|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
219010681|NCT02402127|DEVICE|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
219010682|NCT02402127|DEVICE|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
219010683|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010684|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010685|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
218825988|NCT02481258|OTHER|Placebo Comparator: Matching Placebo|
218825989|NCT03518021|DRUG|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
218825990|NCT03518021|DRUG|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
219437753|NCT03044080|DRUG|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
219437754|NCT00996593|BIOLOGICAL|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
219437755|NCT02491827|OTHER|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
219437756|NCT04657354|PROCEDURE|Assessment|Early surgical assessment
219437757|NCT02666690|DEVICE|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
219437758|NCT05533073|DRUG|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
219437759|NCT05533073|DRUG|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
219437760|NCT05533073|DRUG|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
219437761|NCT04907162|DIAGNOSTIC_TEST|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
219437762|NCT04907162|DIAGNOSTIC_TEST|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
219437763|NCT04907162|DIAGNOSTIC_TEST|Brief Pain Inventory|Validated questionnaire for pain.
219437764|NCT04907162|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
219437765|NCT04907162|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
219437766|NCT04907162|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
219437767|NCT04907162|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
219437768|NCT04907162|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
219437769|NCT04907162|DIAGNOSTIC_TEST|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
219437770|NCT04907162|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
219437771|NCT04907162|DIAGNOSTIC_TEST|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
219437772|NCT02995473|DRUG|NP000888|270 µg/g topical (BID) for 24 weeks
219437773|NCT02995473|DRUG|Vehicle|Topical (BID) for 24 weeks
219437774|NCT03483831|BEHAVIORAL|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
218825991|NCT03518021|DRUG|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
218825992|NCT03518021|DRUG|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
218825993|NCT01900665|DRUG|Solanezumab|Administered Intravenously (IV)
218825994|NCT01900665|DRUG|Placebo|Administered IV
218825995|NCT05106348|DIAGNOSTIC_TEST|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
218825996|NCT03076606|DIAGNOSTIC_TEST|ophthalmologist examination|ophthalmologist examination after geriatric consultation
218825997|NCT04282850|PROCEDURE|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
218825998|NCT02606630|DRUG|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
218825999|NCT01039389|DRUG|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
218826000|NCT01039389|DRUG|Placebo|bid placebo
218826001|NCT04617080|PROCEDURE|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
218826002|NCT04617080|PROCEDURE|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
218826003|NCT03132285|DEVICE|PrePex|Prepex is a non surgical male circumcision device
219010686|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010687|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010688|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010689|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010690|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010691|NCT01678677|DRUG|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219010692|NCT06201702|DIETARY_SUPPLEMENT|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
219010693|NCT04740502|PROCEDURE|Parahtyroidectomy|Parathyroidectomy
219437775|NCT00000240|DRUG|Buprenorphine|
219437776|NCT03195504|DEVICE|HFNC|High flow nasal oxygen (60 l) under GA
219437777|NCT03195504|DEVICE|CON (control)|Standard oxygen (10-15 l) under GA
219010694|NCT04868890|BIOLOGICAL|Ampion|Inhaled Ampion
219010695|NCT04868890|OTHER|Placebo|Inhaled Placebo
219010696|NCT01008007|DIETARY_SUPPLEMENT|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
219010697|NCT01008007|DRUG|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
219437778|NCT03039933|BEHAVIORAL|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
219437779|NCT03039933|OTHER|Treatment As Usual|Treatment As Usual
219437780|NCT02950012|DIETARY_SUPPLEMENT|OPTI-BIOME™ Bacillus subtilis MB40|
219437781|NCT02950012|OTHER|Placebo|
219580443|NCT03499002|OTHER|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
218826004|NCT02908581|DRUG|Placebo|Administered orally once daily
219010698|NCT00228059|DRUG|Licarbazepine|
219010699|NCT00867009|DRUG|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
219010700|NCT00867009|DRUG|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
219010701|NCT00867009|DRUG|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
219010702|NCT00140595|DRUG|rituximab|
219010703|NCT00140595|DRUG|doxorubicin|
219010704|NCT00140595|DRUG|cyclophosphamide|
219437782|NCT02810951|GENETIC|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
219437783|NCT05550896|DIAGNOSTIC_TEST|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
219437784|NCT05438810|DRUG|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
219580444|NCT04516512|BIOLOGICAL|Blood draw|For each participants to the research a peripherical blood draw will be performed
218826005|NCT02908581|DRUG|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
218826006|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
218826007|NCT03668964|DIETARY_SUPPLEMENT|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
218826008|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
218826009|NCT03668964|DIETARY_SUPPLEMENT|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
218826010|NCT03668964|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
218826011|NCT03668964|DIETARY_SUPPLEMENT|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
218826012|NCT03668964|DIETARY_SUPPLEMENT|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
219010705|NCT05117320|DEVICE|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
219010706|NCT00438113|DRUG|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
219010707|NCT01194180|BIOLOGICAL|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
219010708|NCT01194180|BIOLOGICAL|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
219010709|NCT02715674|DEVICE|Plasti-med TRIFLO|
219010710|NCT02715674|DEVICE|BIPAP VISION|
218826013|NCT02795494|BEHAVIORAL|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
219010711|NCT02715674|DEVICE|Plasti-med oxygen therapy mask|
219010712|NCT03383172|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
219010713|NCT02418026|OTHER|hypnosis|Conversational hypnotic induction and therapeutic suggestions
219010714|NCT00470639|DEVICE|Transcranial Magnetic Stimulation|
219010715|NCT01782144|OTHER|NutriSystem portion-controlled pre-packaged meals|
218826014|NCT02795494|BEHAVIORAL|ASK-P questionnaire at baseline|Patient-reported activity level score
218826015|NCT02795494|BEHAVIORAL|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
219010716|NCT00147199|DRUG|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
218826016|NCT01070342|DEVICE|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
218826017|NCT05691920|PROCEDURE|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
218826018|NCT05691920|PROCEDURE|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
219010717|NCT00147199|DRUG|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
219010718|NCT02381249|DRUG|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
219010719|NCT02381249|DRUG|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
219010720|NCT03066271|OTHER|Exercise +|Usual care
219010721|NCT03066271|OTHER|Control +|Usual care
219010722|NCT01850524|DRUG|Ixazomib|IXAZOMIB capsules.
219010723|NCT01850524|DRUG|Placebo|IXAZOMIB matching-placebo capsules.
219010724|NCT01850524|DRUG|Dexamethasone|Dexamethasone tablets.
219010725|NCT01850524|DRUG|Lenalidomide|Lenalidomide capsules.
219010726|NCT00210002|DRUG|Darbepoetin alfa (Aranesp®)|
219010727|NCT00210002|DRUG|Ferric saccharose(Venofer®)|
219010728|NCT05604690|BIOLOGICAL|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
219010729|NCT05604690|COMBINATION_PRODUCT|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
219010730|NCT05604690|OTHER|Placebo|Placebo will be administered via intranasal route.
219010731|NCT02727751|DRUG|Tenapanor|
219010732|NCT03992742|BEHAVIORAL|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
219195713|NCT03695016|BEHAVIORAL|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
219195714|NCT06778356|OTHER|Built environment|Participants will complete the study session at a University student center.
219195715|NCT06778356|OTHER|Natural environment|Participants will complete the study session in a nature trail.
219195716|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
218826019|NCT01298843|DRUG|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
218826020|NCT00994903|DRUG|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
218826021|NCT00994903|DRUG|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
218826022|NCT01527994|DRUG|Aprepitant|Aprepitant 125 mg oral tablets
218826023|NCT01527994|DRUG|Placebo pill|Placebo oral pill- inactive compound
218826024|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive sulfentanil for PCIA.
218826025|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive oxycodone for PCIA.
218826026|NCT02305121|DEVICE|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
218826027|NCT06715813|PROCEDURE|pelvic floor strengthening|"pelvic floor strengthening exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises"
218826028|NCT06715813|PROCEDURE|Transversus abdominal strengthening|core stabilization exercises for 2 weeks like stomach hallowing , dead bugs and pelvic tilt exercises and after 2 weeks dead bug progression, planks
218826029|NCT06717061|PROCEDURE|Harvesting of biological material|During the sampling of biological material, the test subjects will be under general anesthesia, which is why the sampling will not mean increased pain or discomfort other than what is standard after a gallbladder operation with the peephole technique. . The sampling is not planned to be repeated, but is performed at the time when the patients perform their biliary surgery. During the sampling, centimeter-sized pieces of skin, fatty tissue, connective tissue and muscle are taken. Furthermore, serum and plasma will be collected. Two tubes of blood samples (10 ml total) are taken, centrifuged and pipetted before being frozen for later analysis. Pieces of tissue are placed in formalin before transport to the laboratory. The study form regarding the patient\&#39;s basic state of health will be filled in by the operator on the day of surgery.
218826030|NCT06714305|DEVICE|Group B will be assigned to rotary instrumentation.|group B, NiTi rotary protaper system will be used for canal preparation by crown down technique.
218826031|NCT06714305|DEVICE|will be assigned to rotary instrumentation.|the canal will be prepared by conventional hedstorm files manually by step back technique.
218826032|NCT06716125|BEHAVIORAL|aerobic treadmill walking plus low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking treadmill aerobic training for 45 minutes 3 times per week for 12 weeks).
218826033|NCT06716125|BEHAVIORAL|low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks
218826034|NCT06719271|DEVICE|Participants this group will receive gait training in robotic assisted gait training (RAGT) three times per week for eight weeks|Robotic Assited Gait Training is a device used to train children with CP how to walk in effective manner by connecting their body to the harness, robotic devices that attached to the electronic treadmill
218826035|NCT06719271|DEVICE|Body Weight Supported Treadmill Training|Participants in this group will receive gait training on conventional treadmill three times per week for eight weeks
218826036|NCT06717386|PROCEDURE|diagonal pelvic osteotomy|supraacetabular pelvic osteotomy in oblique shape
218826037|NCT05900076|DIAGNOSTIC_TEST|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
218826038|NCT00226356|DRUG|Supplements of L-methionine, betaine and folate|
218826039|NCT00003156|DRUG|topotecan hydrochloride|
218826040|NCT04254406|OTHER|Descriptive study|Evaluation of routine treatment
218826041|NCT04494685|DEVICE|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
218826042|NCT04494685|OTHER|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
218826043|NCT03829592|DRUG|misoprostol in a neutral media|giving misoprostol in a neutral media
218826044|NCT03829592|DRUG|misoprostol in an acidic media|giving misoprostol in an acidic media
218826045|NCT03829592|DRUG|misoprostol in an alkaline media|giving misoprostol in an alkaline media
218826046|NCT01186276|DIETARY_SUPPLEMENT|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
218826047|NCT01186276|DIETARY_SUPPLEMENT|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
218826048|NCT01336816|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
219437785|NCT05438810|DRUG|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
218826049|NCT01336816|OTHER|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
219437786|NCT01688440|OTHER|#1 Respiratory Care Solution|Respiratory care solution.
218826050|NCT05528406|DRUG|HLX208|900mg bid po
218826051|NCT03816176|DRUG|Isavuconazonium sulfate|Intravenous (IV) infusion
218826052|NCT03816176|DRUG|Isavuconazonium sulfate|Oral capsule
219195717|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
219195718|NCT05107219|PROCEDURE|Biopsy|Undergo biopsy
219195719|NCT05107219|PROCEDURE|Biospecimen Collection|Undergo collection of luminal fluid
219437787|NCT02229110|OTHER|Signal|Automatic signal in the electronic medical record
219437788|NCT05576610|PROCEDURE|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
219580445|NCT05480826|GENETIC|study of the transmission of genetic variants|the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
219437789|NCT05576610|PROCEDURE|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
218826053|NCT05178784|DEVICE|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
218826054|NCT02530177|OTHER|Clinical Assessments|
218826055|NCT02530177|BEHAVIORAL|Questionnaires|
218826056|NCT02530177|OTHER|Saliva sample|(only once, preferably at baseline)
218826057|NCT00408980|BEHAVIORAL|Fat and calorie controlled diet|
218826058|NCT02267889|PROCEDURE|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
218826059|NCT02267889|DEVICE|D-SPECT dedicated cardiac nuclear camera|
218826060|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
218826061|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
218826062|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
218826063|NCT05741476|OTHER|Placebo|DBV712 matching placebo epicutaneous system.
218826064|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
218826065|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
218826066|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
218826067|NCT04600726|OTHER|no intervention|no interventioni
218826068|NCT00003421|BIOLOGICAL|bleomycin sulfate|
218826069|NCT00003421|DRUG|ABVD regimen|
219437790|NCT04146337|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
218826070|NCT00003421|DRUG|chlorambucil|
218826071|NCT00003421|DRUG|dacarbazine|
218826072|NCT00003421|DRUG|doxorubicin hydrochloride|
218826073|NCT00003421|DRUG|etoposide|
218826074|NCT00003421|DRUG|prednisolone|
218826075|NCT00003421|DRUG|procarbazine hydrochloride|
219195720|NCT05107219|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
218826076|NCT00003421|DRUG|vinblastine sulfate|
218826077|NCT00003421|DRUG|vincristine sulfate|
218826078|NCT00003421|RADIATION|radiation therapy|
218826079|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
218826080|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
218826081|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
218826082|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
218826083|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
218826084|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
218826085|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
218826086|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
218826087|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
218826088|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
218826089|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
218826090|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
218826091|NCT01506635|DRUG|Timolol|
218826092|NCT01506635|DRUG|Placebo|artificial tear twice a day
218826093|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
218826094|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
218826095|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
218826096|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
218826097|NCT04799002|DRUG|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
219195721|NCT05107219|DRUG|Linaclotide|Given PO
219195722|NCT05107219|DRUG|Plecanatide|Given PO
219437791|NCT02205398|DRUG|INC280|
218826098|NCT04799002|DRUG|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
218826099|NCT00552071|DRUG|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
218826100|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
218826101|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
218826102|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
218826103|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
218826104|NCT03076281|DRUG|Metformin Hydrochloride|Given orally
218826105|NCT03076281|DRUG|Doxycycline|Given orally
218826106|NCT03076281|DRUG|Metformin +Doxycycline|Given orally
218826107|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
218826108|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
218826109|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
218826110|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
218826111|NCT00102986|DRUG|Lopinavir/ritonavir|
218826112|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
218826113|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
218826114|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
218826115|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
218826116|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
218826117|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
218826118|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
218826119|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
218826120|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
218826121|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
218826122|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
218826123|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
218826124|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
218826125|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
219437792|NCT02205398|DRUG|cetuximab|
218826126|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
218826127|NCT01206829|BEHAVIORAL|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
218826128|NCT01206829|BEHAVIORAL|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
218826129|NCT01979614|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
218826130|NCT01979614|OTHER|Placebo|5% v/v glucose solution
218826131|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
218826132|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
218826133|NCT03320187|DRUG|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
218826134|NCT03320187|DRUG|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
218826135|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
218826136|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
218826137|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
218826138|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
218826139|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
218826140|NCT00666081|DRUG|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
218826141|NCT02497222|DRUG|RNS60|
218826142|NCT02497222|DRUG|Normal Saline|
218826143|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
218826144|NCT00756275|DRUG|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
218826145|NCT00756275|DRUG|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
218826146|NCT00756275|BEHAVIORAL|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
218826147|NCT01466465|DRUG|Cholecalciferol|given orally, once daily, before grass pollen season
218826148|NCT01466465|OTHER|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
218826149|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
218826150|NCT02268110|OTHER|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
218826151|NCT02268110|OTHER|Abdominal binding|Wearing an abdominal binder for 12 weeks
218826152|NCT04380623|BEHAVIORAL|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
218826153|NCT05940506|DRUG|KX-826-2.5 mg (0.25%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
218826154|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL QD|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
219195723|NCT03947112|BEHAVIORAL|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
219195724|NCT05927688|BEHAVIORAL|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
219195725|NCT06806423|PROCEDURE|Immediate Dental Implant Placement without Adjunctive Treatments|Atraumatic extractions using periotomes and anterior forceps. Osteotomy was prepared with a standardized drilling sequence under copious irrigation. ROOTT R-line implants were selected based on socket dimensions. No topical vitamin D3 was applied. Implants were placed into fresh extraction sockets.
218826155|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
218826156|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
218826157|NCT00376636|DRUG|SPP635 (drug)|
218826158|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
218826159|NCT02849002|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
218826160|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
218826161|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
218826162|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
218826163|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
218826164|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
218826165|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
218826166|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
218826167|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
218826168|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
218826169|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
218826170|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
218826171|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
218826172|NCT02827812|OTHER|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
218826173|NCT02827812|OTHER|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
219195726|NCT06806423|PROCEDURE|Immediate Dental Implant Placement with Topical Vitamin D Gel Application|The same procedure as the control group, with the addition of sterile topical vitamin D3 (calcitriol) gel applied to both the implant surface and osteotomy site immediately before implant placement.
219437793|NCT03511820|DRUG|Lipo-AB® (amphotericin B) liposome|"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
219195727|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
219437794|NCT01928082|DRUG|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
219195728|NCT06804447|RADIATION|Proton Beam Therapy|Proton Beam Therapy
219195729|NCT06479096|OTHER|Brush / Espresso Mild Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
219195730|NCT06479096|OTHER|Brush / Espresso Intense Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
219195731|NCT06479096|OTHER|Brush / Fresh Breath Oral Rinse|Subjects will brush and rinse with their assigned mouthwash twice daily.
218826174|NCT02827812|OTHER|Home-Based telemedicine program|"1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
218826175|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
218826176|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
218826177|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
218826178|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
218826179|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
218826180|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
218826181|NCT01594840|DEVICE|Changing chat|Diapers with tips
219437795|NCT05568056|BEHAVIORAL|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
219437796|NCT00006063|DRUG|pancrelipase with bicarbonate|
218826182|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
218826183|NCT03533699|DRUG|Propranolol|
218826184|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
218826185|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
218826186|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
218826187|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
218826188|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
218826189|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
218826190|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
218826191|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
218826192|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
218826193|NCT03561155|DEVICE|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
218826194|NCT03561155|OTHER|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
218826195|NCT01684670|BEHAVIORAL|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
219437797|NCT03890393|DEVICE|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
218826196|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
218826197|NCT02044679|OTHER|Water|
218826198|NCT02044679|OTHER|No intervention|
219580446|NCT04226573|OTHER|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
219580447|NCT02033330|DIETARY_SUPPLEMENT|phenolics form orange peel|
219580448|NCT00004734|DRUG|pyridoxine|
218826199|NCT05361265|OTHER|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
218826200|NCT00959426|DRUG|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
219437798|NCT00583661|DEVICE|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
218826201|NCT00959426|DRUG|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
218826202|NCT04967066|DIAGNOSTIC_TEST|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
218826203|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 1|\[¹⁴C\] BI 685509 formulation 1
218826204|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 2|\[¹⁴C\] BI 685509 formulation 2
218826205|NCT05515328|DRUG|BI 685509 formulation 3|BI 685509 formulation 3
218826206|NCT03613155|OTHER|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
218826207|NCT03815747|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
218826208|NCT00913510|DEVICE|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
218826209|NCT00913510|DRUG|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
219195732|NCT06479096|OTHER|Brush / Hydroalcohol|Subjects will brush and rinse with their assigned mouthwash twice daily.
219437799|NCT01679561|DRUG|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
218826210|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
218826211|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
219010733|NCT03992742|BEHAVIORAL|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
219010734|NCT03992742|BEHAVIORAL|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
219195733|NCT04787848|DRUG|Relistor Injectable Product|Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
219437800|NCT03129633|OTHER|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
218826212|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
219195734|NCT02161783|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
218826213|NCT01123343|DEVICE|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
218826214|NCT06187324|DIAGNOSTIC_TEST|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
218826215|NCT02791347|OTHER|Nutrition Intervention|
218826216|NCT00705705|BEHAVIORAL|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
218826217|NCT00705705|BEHAVIORAL|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
218826218|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
218826219|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
219195735|NCT02161783|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
219195736|NCT02161783|RADIATION|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
219195737|NCT02161783|BIOLOGICAL|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
219580449|NCT00004734|DRUG|cyanocobalamin|
219580450|NCT00004734|DRUG|folic acid multivitamin|
219580451|NCT01876550|DRUG|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
219437801|NCT04893928|OTHER|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
218826220|NCT05160363|DRUG|Pyronaridine Tetraphosphate|A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
218826221|NCT05160363|DRUG|Piperaquine tetraphosphate|A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
218826222|NCT05160363|DRUG|Placebo|Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
219437802|NCT04893928|OTHER|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
219010735|NCT03992742|BEHAVIORAL|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
219010736|NCT03992742|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
219010737|NCT03992742|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
219010738|NCT03992742|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
219010739|NCT03992742|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
219010740|NCT06089928|PROCEDURE|vertical augmentation|sandwich osteotomy with an Interpositional inlay graft
219010741|NCT03218007|BIOLOGICAL|blood samples|to evaluate expression and functionnaly activity of A2AR
219010742|NCT00368355|DRUG|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
219437803|NCT04893928|OTHER|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~* Frequency of use of ten different ICTs for personal purposes;~* Frequency of use of ten different ICTs for IBD-related purposes;~* A free question about others ICTs that the patient uses for IBD-related purposes;~* Eight specific IBD-related purposes ICTs are used to;~* Assessment of ICTs for eight IBD-related purposes;~* Eight Features an IBD-related App must comprehend."
219580452|NCT01876550|DRUG|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
219580453|NCT01876550|DRUG|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
219010743|NCT00368355|DRUG|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
219010744|NCT00368355|BIOLOGICAL|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
219010745|NCT00368355|RADIATION|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
219010746|NCT00368355|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
219010747|NCT02235012|DRUG|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
219195738|NCT06066567|DEVICE|Interferential current stimulation|IF Current parameters will be applied as follow: Amplitude modulated frequency (AMF) 30Hz, Autosweep-5 sec, Dose-15 minutes, type of current dynamic vector field (Mitra, 2006), three days per week over four weeks (Corrêa et al., 2016) and current intensity will be increased gradually, according to the subject's condition
218826223|NCT02126319|BEHAVIORAL|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
219010748|NCT02235012|DRUG|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
219010749|NCT01847417|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
219010750|NCT01847417|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
219010751|NCT01847417|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
218826224|NCT02126319|BEHAVIORAL|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
218826225|NCT01399112|BEHAVIORAL|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
219195739|NCT06066567|OTHER|Draw- In exercises,,|From prone position, participants will lay face down on the bed and flexed their hips and knees at 0°. A PBU will be positioned below the pubis symphysis with the decreasing edge consistent with the ASIS and will be overstated to 70 mmHg. The participants will be trained to gently draw in the lower part of the abdomen under the navel. In addition, while maintaining the neutral pelvic position, the movement of the upper part of the abdomen will be restricted so that the pressure will be decreased by approximately 10 mmHg. The participants will maintain this position for 10 s
219195740|NCT03037242|PROCEDURE|Transtibial pullout technique|Evaluating radographs
219437804|NCT04893928|OTHER|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
219437805|NCT04077411|OTHER|Observational|This is an observational study with no interventions.
219437806|NCT04208646|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
219437807|NCT04208646|BIOLOGICAL|No mesenchymal progenitor cells|No mesenchymal progenitor cells for intra- articular use
219195741|NCT06370585|DRUG|PRO-229|\- Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.
219195742|NCT06370585|DRUG|Lagricel® Ofteno PF|\- Sodium hyaluronate 0.4%. Ophthalmic solution.
219437808|NCT00339118|DRUG|doxorubicin, cytoxan|
219437809|NCT03557515|BEHAVIORAL|Stress Management and CBT|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention"
219437810|NCT03557515|BEHAVIORAL|Stress Management and Metta-Meditation|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future"
219437811|NCT02882737|DRUG|Glucagon before exercise|
219437812|NCT02882737|DRUG|Glucagon after exercise|
219580454|NCT05620602|OTHER|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
219580455|NCT05620602|OTHER|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
219580456|NCT05620602|OTHER|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
218826226|NCT02609425|DEVICE|Stratafix PGA Suture|Subject leak Stricture rates post procedure
218826227|NCT00917319|OTHER|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
218826228|NCT05480176|OTHER|Comprehensive intervention and management Ⅰ|Mainly health advisory.
218826229|NCT05480176|OTHER|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
218826230|NCT05480176|OTHER|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
218826231|NCT03816787|PROCEDURE|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
218826232|NCT04157699|DRUG|TDF tablet|TDF tablet 300mg QD
218826233|NCT04157699|DRUG|QL-007|QL-007 tablet
218826234|NCT02540590|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
218826235|NCT02540590|DEVICE|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
218826236|NCT02011269|BIOLOGICAL|Trichuris Suis Ova|
218826237|NCT02656836|OTHER|Home tonometry, diagnostic study|Evaluating intraocular pressure
218826238|NCT00728156|DRUG|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
218826239|NCT00728156|DRUG|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
218826240|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
218826241|NCT02462187|DRUG|NVN1000 16%|once daily
218826242|NCT02462187|DRUG|Vehicle|placebo comparator
218826243|NCT02462187|DRUG|NVN1000 24%|once daily
218826244|NCT01428219|DRUG|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
218826245|NCT05927116|OTHER|Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)|TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
218826246|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
218826247|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
218826248|NCT04624516|OTHER|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
218826249|NCT04144283|BEHAVIORAL|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep."
218826250|NCT04144283|BEHAVIORAL|WAKE|For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
219195743|NCT06753578|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.
219195744|NCT06753578|BEHAVIORAL|standard care|standard care
219437813|NCT02882737|DRUG|Glucagon after resting|
219763691|NCT05856539|PROCEDURE|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
218826251|NCT01333410|DRUG|tacrolimus ointment|2 applications per days for 6 months
218826252|NCT01333410|DRUG|Mometasone furoate|2 applications per day for 6 months
218826253|NCT02458872|BEHAVIORAL|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
218826254|NCT05894057|OTHER|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
218826255|NCT00835458|PROCEDURE|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
218826256|NCT02102958|BEHAVIORAL|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
218826257|NCT02102958|BEHAVIORAL|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
218826258|NCT01882335|BEHAVIORAL|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
218826259|NCT00114725|PROCEDURE|Laser-assisted intracytoplasmic sperm injection|
218826260|NCT00083980|DRUG|Venlafaxine ER|75 to 225 mg daily
218826261|NCT00083980|DRUG|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
218826262|NCT00083980|DRUG|Kava|140 to 280 mg per day
218826263|NCT04884503|DRUG|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
218826264|NCT04884503|DEVICE|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
218826265|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
218826266|NCT01760577|DRUG|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
219010752|NCT01847417|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
219010753|NCT01641770|OTHER|Nutritional beverage 10003RF|2 sachets per day
219010754|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
219010755|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
219010756|NCT03585608|PROCEDURE|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
219010757|NCT01563003|OTHER|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
219010758|NCT01563003|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
218826267|NCT01760577|DRUG|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
219010759|NCT04874727|PROCEDURE|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
219010760|NCT05178524|DRUG|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
219010761|NCT03731988|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
219010762|NCT03731988|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
219010763|NCT03731988|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
219010764|NCT03731988|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
219010765|NCT03731988|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
219195745|NCT05895929|DRUG|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
219195746|NCT06053190|BEHAVIORAL|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
218826268|NCT05302310|OTHER|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
218826269|NCT00912626|BEHAVIORAL|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
218826270|NCT02443701|OTHER|Exercise|Warmup program, maximum isometric strengthening, and jump training
218826271|NCT02443701|OTHER|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
218826272|NCT02443701|OTHER|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
218826273|NCT04014426|OTHER|Blood sample|"Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~\- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
218826274|NCT04014426|OTHER|Urinary sample|"Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~\- During the morning (8 to 10 a.m) (T0)"
218826275|NCT02213614|DIETARY_SUPPLEMENT|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
218826276|NCT02213614|DIETARY_SUPPLEMENT|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
218826277|NCT02213614|OTHER|natural spring water|A group will drink natural spring water for 4 months
218826278|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
218826279|NCT05608954|OTHER|Pediasuit|Pediasuit
218826280|NCT05608954|OTHER|Locomotor training|Locomotor training
219010766|NCT06395454|DIAGNOSTIC_TEST|Shorten antibiotics duration based on procalcitonin test levels|procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
219437814|NCT05563714|BEHAVIORAL|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
219437815|NCT05563714|BEHAVIORAL|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
219437816|NCT05750316|OTHER|Cowpea leaves mixed with Jam|6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
219010767|NCT00029614|DRUG|Atomoxetine|
219010768|NCT01973166|DEVICE|Picosecond Q-switched Laser Treatment|
219010769|NCT01973166|DEVICE|Nanosecond Q-switched Laser Treatment|
219010770|NCT05397756|OTHER|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
219010771|NCT02388945|OTHER|APD|PDGO APD machines used in the PD patients for 8 weeks
219010772|NCT02388945|OTHER|CAPD|CAPD used in the PD Patients for 8 weeks
219010773|NCT03156673|BIOLOGICAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
218826281|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
218826282|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
218826283|NCT05608954|OTHER|Virtual reality|Virtual reality
218826284|NCT02654496|OTHER|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
218826285|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
218826286|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
218826287|NCT02652910|DRUG|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
218826288|NCT02433912|PROCEDURE|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
218826289|NCT02433912|PROCEDURE|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
219010774|NCT01952431|DEVICE|Total Lung Capacity (TLC) testing|Comparison of TLC results
219437817|NCT05750316|OTHER|Jam mixed with green food colour|Jam with green food colouring spread on bread
219437818|NCT02473835|OTHER|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
218826290|NCT02433912|DRUG|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
219437819|NCT02473835|OTHER|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
218826291|NCT02433912|DRUG|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
218826292|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
218826293|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
218826294|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
218826295|NCT01797757|DRUG|Orlistat|
218826296|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
218826297|NCT00592631|DEVICE|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
218826298|NCT00592631|DEVICE|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
219437820|NCT02473835|OTHER|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
218826299|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
218826300|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
218826301|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
218826302|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
218826303|NCT00437398|BIOLOGICAL|Islet Transplant|Purified pancreatic islets
218826304|NCT03102983|OTHER|MRI functional|vowels records and MRI session
218826305|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
218826306|NCT02432937|DRUG|Corever|Corever
219437821|NCT04087603|BEHAVIORAL|Weekend Morning Bright Light & Early Bedtime|
219437822|NCT01815580|DRUG|Atripla or Stribild|Antiretroviral therapy
219437823|NCT02016729|DRUG|AMG 232|Given an an oral tablet in escalating doses.
219437824|NCT02016729|DRUG|Trametinib|Trametinib is an oral tablet given in a fixed dose.
218826307|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
218826308|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
218826309|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
218826310|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
218826311|NCT00878592|BEHAVIORAL|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
219437825|NCT05610722|DEVICE|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
218826312|NCT03811522|OTHER|carbon dioxide insufflation|Receives CO2 insufflation
218826313|NCT03811522|OTHER|Air insufflation|Receives air insufflation
218826314|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
218826315|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
218826316|NCT01162551|DRUG|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
218826317|NCT06284239|OTHER|Tell me about the game.|It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
219437826|NCT00295737|PROCEDURE|bronchoscopy, allergen/endotoxin instillation|
218826318|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
218826319|NCT03292003|DEVICE|Journey II BCS Total Knee System|
218826320|NCT03440073|OTHER|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
218826321|NCT03440073|OTHER|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
218826322|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
218826323|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
219010775|NCT03993340|DEVICE|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
219010776|NCT06340815|DEVICE|Radiation: Proton Therapy System (ProBeam)|"All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA."
219010777|NCT01339429|DEVICE|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
219437827|NCT05584904|OTHER|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
219437828|NCT00184158|PROCEDURE|decompression|Conservative, simple decompression and nerve transfer
219437829|NCT03867110|DRUG|Placebo|
219437830|NCT03867110|DRUG|Ezetimibe 10 mg|
218826324|NCT02383862|OTHER|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
219010778|NCT01849380|DRUG|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
219010779|NCT01849380|DRUG|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
219010780|NCT02088255|PROCEDURE|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
219010781|NCT02088255|PROCEDURE|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
219010782|NCT01103791|DRUG|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
219010783|NCT01497132|DRUG|Vitamin D3|Oral drops 30000 IU weekly
219010784|NCT01497132|DRUG|Placebo|Matching placebo
219010785|NCT03102021|DRUG|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
219010786|NCT03102021|DRUG|saline|saline 10 ml for 3 days
219010787|NCT01085591|DRUG|CB-183,315|
219010788|NCT01085591|DRUG|Placebo|
219010789|NCT01085591|DRUG|Vancomycin|
219010790|NCT01744054|DEVICE|PET/MR|
219437831|NCT03867110|DRUG|Atorvastatin 10 mg|
219437832|NCT03867110|DRUG|Atorvastatin 20 mg|
219437833|NCT03867110|DRUG|Atorvastatin 40 mg|
218826325|NCT02631291|BEHAVIORAL|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
219010791|NCT01744054|DEVICE|PET/CT|
219010792|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
219437834|NCT03867110|DRUG|Atorvastatin 80 mg|
219437835|NCT04480541|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
219437836|NCT04480541|OTHER|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
219437837|NCT04480541|OTHER|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
219437838|NCT02228564|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
219437839|NCT02228564|DEVICE|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
218826326|NCT02631291|BEHAVIORAL|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
218826327|NCT01154491|DRUG|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
219010793|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
219010794|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
219010795|NCT05652946|DEVICE|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
219010796|NCT05652946|OTHER|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
219437840|NCT03481387|DEVICE|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
219476421|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
219476422|NCT02730832|OTHER|Questionnaires completed at D0|
219476423|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
218826328|NCT01154491|DRUG|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
218826329|NCT01154491|DRUG|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
218826330|NCT05866692|DRUG|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
218826331|NCT01833494|DRUG|PA21|
218826332|NCT04357561|BEHAVIORAL|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
218826333|NCT06167226|DRUG|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
218826334|NCT02135068|DEVICE|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
218826335|NCT02135068|OTHER|Snacking|Up to 45 g of oral glucose via Gatorade
218826336|NCT04708262|OTHER|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
218826337|NCT04403308|BIOLOGICAL|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
218826338|NCT04726891|BEHAVIORAL|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
218826339|NCT01694433|DRUG|Calcipotriene|1g daily BID
218826340|NCT01694433|DRUG|Placebo|1g daily BID
218826341|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
218826342|NCT03071861|DRUG|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
219476424|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
218826343|NCT03071861|DRUG|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
219476425|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
219476426|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
219476427|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
219476428|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
218826344|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
218826345|NCT01109186|OTHER|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
218826346|NCT03729986|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
218826347|NCT04862559|DEVICE|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
218826348|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
218826349|NCT03925272|GENETIC|Genetic determinants analysis|
218826350|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
218826351|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
218826352|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
219437841|NCT02879370|PROCEDURE|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
219437842|NCT05706961|OTHER|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
219437843|NCT05706961|OTHER|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
219437844|NCT02620709|BEHAVIORAL|Hula intervention|Hula and heart health education
219437845|NCT00907972|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3
219437846|NCT00907972|OTHER|Placebo|Placebo
219437847|NCT02894489|DEVICE|corneal lenses|wear corneal lenses on daily basis
218826353|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
218826354|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
219437848|NCT02894489|DEVICE|large diameter lenses|
219437849|NCT00018629|OTHER||
219437850|NCT03141892|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
219437851|NCT04432740|PROCEDURE|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
219437852|NCT05163067|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
219437853|NCT00617591|DRUG|Lenalidomide|25 mg orally on days 1-21
218826355|NCT00443118|DEVICE|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
218826356|NCT00443118|DEVICE|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
218826357|NCT00443118|DEVICE|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
218826358|NCT03673540|BEHAVIORAL|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
218826359|NCT00476320|PROCEDURE|Magnetic Resonance Imaging|
218826360|NCT00476320|PROCEDURE|Revascularization|
218826361|NCT00476320|PROCEDURE|Echocardiography with myocardial deformation imaging|
219010797|NCT02241174|DRUG|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
218826362|NCT04361292|PROCEDURE|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
218826363|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
218826364|NCT06455722|DRUG|[68Ga]Ga-P15-041|Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
218826365|NCT01673659|DRUG|Mometasone furoate|
218826366|NCT01673659|DRUG|Nasonex Nasal Spray|
218826367|NCT01673659|DRUG|Placebo nasal spray|
218826368|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
218826369|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
218826370|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
218826371|NCT06151470|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
218826372|NCT06151470|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
218826373|NCT06178367|DRUG|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
218826374|NCT06178367|DRUG|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
218826375|NCT06178367|DRUG|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
218826376|NCT04021446|OTHER|Exercise|personalized exercise prescription
219010798|NCT06304753|DEVICE|Telebot|"This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
218826377|NCT01718522|DEVICE|sensor augmented pump (SAP)|
219010799|NCT05945914|PROCEDURE|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
219010800|NCT05548829|BIOLOGICAL|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
219010801|NCT03314402|DRUG|Jaktinib Dihydrochloride Monohydrate|Active Substance
219010802|NCT03314402|DRUG|placebo|Placebo
218826378|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
219010803|NCT04065906|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
219010804|NCT04065906|DRUG|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
219010805|NCT02045134|DIETARY_SUPPLEMENT|Placebo|Soluble corn flour not rich in anthocyanins
219010806|NCT02045134|DIETARY_SUPPLEMENT|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
219010807|NCT00396591|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
219596917|NCT02473523|OTHER|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
218826379|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
218826380|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
219010808|NCT03393741|DRUG|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
219010809|NCT03393741|DRUG|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
219010810|NCT03393741|DRUG|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
219010811|NCT03393741|DRUG|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
219437854|NCT00617591|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
219010812|NCT03393741|DRUG|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
219010813|NCT01494194|OTHER|Air Structuring Protein|A novel food protein preparation
219010814|NCT01494194|OTHER|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
219010815|NCT05070533|BEHAVIORAL|Individual treatment|Participants will receive 7 home visits to implement the program.
219010816|NCT05070533|BEHAVIORAL|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
219437855|NCT00617591|DRUG|Dexamethasone|40 mg orally on days on 1-4
219437856|NCT00376246|DRUG|Ezetimibe|
219437857|NCT04948814|BIOLOGICAL|Fecal microbiota transplantation|FMT utilizing stool from healthy children
219437858|NCT04948814|DRUG|Vancomycin|40mg/kg/day
219437859|NCT01875510|DIETARY_SUPPLEMENT|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
219437860|NCT01875510|DIETARY_SUPPLEMENT|soybean-oil emulsion|soybean-oil emulsion
219580457|NCT05620602|OTHER|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
219580458|NCT00982449|OTHER|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
219580459|NCT00982449|OTHER|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
218826381|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
218826382|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
218826383|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
218826384|NCT00560092|DRUG|intrathecal magnesium sulfate|intrathecal magnesium sulfate
219010817|NCT00525707|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
219010818|NCT05018299|BIOLOGICAL|FB704A placebo|Placebo
219010819|NCT05018299|BIOLOGICAL|FB704A|Anti-IL-6 antibody
219010820|NCT02724306|BEHAVIORAL|Active Lifestyle Programme|
219010821|NCT05545215|DEVICE|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
219010822|NCT01659463|OTHER|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
219010823|NCT01659463|BEHAVIORAL|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
219010824|NCT04744142|DRUG|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
219010825|NCT04744142|DIETARY_SUPPLEMENT|Increased protein intake|Subjects receive either normal or increased protein intake
219010826|NCT04358653|OTHER|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
219010827|NCT02006745|DRUG|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
219010828|NCT02006745|DRUG|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
219010829|NCT04307693|DRUG|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
219010830|NCT04307693|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
219010831|NCT04766801|PROCEDURE|Laparoscopic adjustable gastric banding|Weight-loss surgery, with the use of gastric banding
219437861|NCT03224910|OTHER|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
219437862|NCT04841694|DIETARY_SUPPLEMENT|Probiotic|Bacillus indicus
219437863|NCT04911829|BEHAVIORAL|Psychotherapy|
219437864|NCT03391076|DIAGNOSTIC_TEST|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
219580460|NCT02216318|OTHER|blue light|
218826385|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
218826386|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
219437865|NCT05630560|OTHER|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
219437866|NCT01711658|RADIATION|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
218826387|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
218826388|NCT06302465|DRUG|narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide|Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
219010832|NCT05525143|PROCEDURE|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
219010833|NCT05744453|DIETARY_SUPPLEMENT|Olive Leaf Extract|experimental arm
219010834|NCT05744453|DIETARY_SUPPLEMENT|Cellulose|placebo comparator arm
219010835|NCT04604821|BEHAVIORAL|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
219010836|NCT04604821|BEHAVIORAL|Parent Education|Parents receive information on child developmental milestones.
219010837|NCT04395469|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
219010838|NCT03032094|PROCEDURE|connective tissue graft|palatal connective tissue graft to attain root coverage
219010839|NCT02888522|BIOLOGICAL|immunomodulation|Immunomodulation depending on chimerism
219010840|NCT02031731|DRUG|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
219010841|NCT02031731|DRUG|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
219010842|NCT02031731|DRUG|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
219010843|NCT03251066|OTHER|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
219010844|NCT05351762|DRUG|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
219010845|NCT04097808|DIETARY_SUPPLEMENT|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
219010846|NCT05745779|DIAGNOSTIC_TEST|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
219010847|NCT02855333|OTHER|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
219437867|NCT01711658|DRUG|Cisplatin|100 mg/m\^2 administered intravenously on days 8 and 29
218826389|NCT06302465|DRUG|doxorubicin、cisplatin、methotrexate、ifosfamide|doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
219010848|NCT01502189|OTHER|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
219010849|NCT03684954|OTHER|Prf|Take 10 cc blood from patient and gain prf
219010850|NCT01214954|OTHER|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
219010851|NCT01214954|OTHER|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
219010852|NCT02915276|PROCEDURE|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
219010853|NCT02915276|PROCEDURE|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
219010854|NCT04080297|DRUG|oral capsule of Q-122|
219010855|NCT05486858|OTHER|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
219010856|NCT05486858|OTHER|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
219010857|NCT01953133|BEHAVIORAL|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
219437868|NCT01711658|DRUG|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
219437869|NCT01711658|DRUG|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
219437870|NCT04155658|OTHER|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
219437871|NCT04155658|OTHER|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
219437872|NCT04155658|OTHER|Toothpaste with no fluoride|Toothpaste with no fluoride
219437873|NCT00044642|DRUG|Lorazepam|
219010858|NCT05928897|DRUG|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
218826390|NCT05064046|BEHAVIORAL|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
219010859|NCT00165243|PROCEDURE|Tangential radiation|Radiation given over 6 1/2 weeks
218826391|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
218826392|NCT02232971|OTHER|Isotonic saline solution|Placebo
218826393|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
219010860|NCT01409655|BEHAVIORAL|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
219010861|NCT00989339|DRUG|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
219010862|NCT00875251|DEVICE|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
219010863|NCT01259323|BIOLOGICAL|REGN668|Dose 1: REGN668 or placebo
219010864|NCT01259323|BIOLOGICAL|REGN668|Dose 2: REGN668 or placebo
219010865|NCT01259323|BIOLOGICAL|REGN668|Dose 3: REGN668 or placebo
219437874|NCT04737980|DRUG|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
219437875|NCT04737980|DRUG|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
219437876|NCT04737980|DRUG|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
219437877|NCT04737980|DRUG|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
219437878|NCT00498225|DRUG|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
218826394|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
218826395|NCT04738175|DRUG|Placebo|Diluent solution
218826396|NCT04790747|DRUG|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
218826397|NCT03982277|DRUG|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
218826398|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
219010866|NCT02397759|OTHER|Blood draw and cerebrospinal fluid draw|
219010867|NCT02978261|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
219010868|NCT02018328|DIETARY_SUPPLEMENT|Curcumin|
219010869|NCT01572545|DRUG|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
219010870|NCT01572545|DRUG|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
219437879|NCT00498225|DRUG|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
219580461|NCT03828136|DEVICE|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
218826399|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
219010871|NCT04711408|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
219010872|NCT03799770|DIAGNOSTIC_TEST|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
219010873|NCT05782608|DRUG|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
218826400|NCT02615977|BEHAVIORAL|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
219437880|NCT00498225|DRUG|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
219437881|NCT02562989|DRUG|[18F]MK-6240, ~185 MBq|IV dose of \~185 MBq \[18F\]MK-6240
219580462|NCT03828136|DEVICE|Allograft Ring or Block|Standard of Care
219580463|NCT00602277|OTHER|Laboratory Biomarker Analysis|Correlative studies
218826401|NCT02615977|BEHAVIORAL|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
219437882|NCT02562989|DRUG|[18F]MK-6240, ~160 MBq|IV dose of \~160 MBq \[18F\]MK-6240
219437883|NCT00531492|BEHAVIORAL|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
219437884|NCT00531492|OTHER|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
219437885|NCT03420313|DRUG|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
219437886|NCT00518843|BEHAVIORAL|FBT-BN|Mobilizing parents to curtail binge eating and purging
219437887|NCT00518843|BEHAVIORAL|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
219437888|NCT01641718|DRUG|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
219437889|NCT01641718|DEVICE|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
219437890|NCT00588523|DRUG|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
219437891|NCT02711605|DEVICE|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
219437892|NCT03879993|OTHER|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
219580464|NCT00602277|BIOLOGICAL|Wild-type Reovirus|
219580465|NCT04120584|DEVICE|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
219010874|NCT05782608|DRUG|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
219010875|NCT04649125|RADIATION|dose escalation|single fraction dose escalation to the tumour
219437893|NCT01233180|OTHER|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
219437894|NCT01233180|DEVICE|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
219437895|NCT02020291|DRUG|Foxy-5|
219580466|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
219580467|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
219580468|NCT00697684|DRUG|Antithymocyte Globulin|
219580469|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
219596918|NCT02473523|OTHER|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
219596919|NCT02473523|DEVICE|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
219596920|NCT02473523|DEVICE|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
219596921|NCT02473523|OTHER|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
219596922|NCT02473523|OTHER|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
219596923|NCT02473523|OTHER|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
219437896|NCT01709968|DRUG|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
218826402|NCT01128725|OTHER|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
218826403|NCT01739608|OTHER|Invitation to screening|Invitation to screening
218826404|NCT02789462|PROCEDURE|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
218826405|NCT04176107|BEHAVIORAL|Informative video|Exposure to informative video before cesarean delivery
218826406|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
218826407|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
218826408|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
218826409|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
218826410|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
218826411|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
218826412|NCT06512688|OTHER||This is a cross-sectional study without intervention.
218826413|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
218826414|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
219437897|NCT01709968|DRUG|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
219437898|NCT03958994|OTHER|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
219437899|NCT04742972|RADIATION|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
219437900|NCT04742972|OTHER|SOC|"Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment"
219437901|NCT00126854|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|
218826415|NCT03957863|BIOLOGICAL|Plasma collection for EPO assay|Plasma collection for EPO assay
218826416|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
219010876|NCT03517761|BIOLOGICAL|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
219437902|NCT00313755|PROCEDURE|Narrow Band Imaging|
219437903|NCT02226978|DRUG|Tipranavir|
219437904|NCT02226978|DRUG|Ritonavir|
219437905|NCT02226978|DRUG|Valaciclovir|
219437906|NCT03347812|PROCEDURE|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
219437907|NCT03347812|PROCEDURE|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
218826417|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
218826418|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
218826419|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
219437908|NCT03032510|DRUG|Eravacycline|
219437909|NCT03032510|DRUG|Ertapenem|
219437910|NCT03032510|DRUG|Placebo|
219437911|NCT03032510|DRUG|Levofloxacin|
219437912|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
219437913|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
219437914|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
219437915|NCT03061812|DRUG|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
219437916|NCT03061812|DRUG|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
219437917|NCT03061812|DRUG|Dexamethasone|Oral tablet.
218826420|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
218826421|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
218826422|NCT01885650|OTHER|Airway Clearance Techniques|
218826423|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
218826424|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
218826425|NCT03516578|OTHER|Cardiac magnetic resonance imaging|
218826426|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
218826427|NCT03770858|DRUG|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
218826428|NCT03770858|DEVICE|Scratch sensor|advanced, flexible and wearable skin sensor
218826429|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
219010877|NCT03517761|OTHER|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
219010878|NCT04767204|BEHAVIORAL|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
219010879|NCT03572140|DIAGNOSTIC_TEST|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
219010880|NCT00121550|DRUG|clarithromycin|
219010881|NCT02549183|DEVICE|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
219437918|NCT01291849|DRUG|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
219437919|NCT00259467|BEHAVIORAL|Home-Based Behavorial Intervention|
219437920|NCT01821404|DRUG|Atorvastatin|Capsules including 80 mg of atorvastatin
219010882|NCT04138420|DRUG|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
219195747|NCT06053190|BEHAVIORAL|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
219437921|NCT01821404|DRUG|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
219437922|NCT05506696|DIETARY_SUPPLEMENT|Fultium|3200IU Fultium
219437923|NCT01753700|DIETARY_SUPPLEMENT|UHT treated milk|
219476429|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
219476430|NCT00854776|DRUG|lansoprazole|30 mg once daily
219476431|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
219580470|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
218826430|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
218826431|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
218826432|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
218826433|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
218826434|NCT03368196|DRUG|DS-8201a|An antibody drug conjugate
218826435|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
218826436|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
218826437|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
218826438|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
218826439|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
218826440|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
218826441|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
218826442|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
218826443|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
218826444|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
218826445|NCT03734822|OTHER|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
218826446|NCT03734822|DEVICE|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
218826447|NCT03734822|DIAGNOSTIC_TEST|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
218826448|NCT03734822|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
218826449|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
218826450|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
218826451|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
218826452|NCT00846846|DEVICE|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
218826453|NCT02002988|PROCEDURE|endomyocardial BT injection|
218826454|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
218826455|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
218826456|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
219437924|NCT05067712|PROCEDURE|Open Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
219476432|NCT05933278|BIOLOGICAL|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
218826457|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
218826458|NCT06416228|DIETARY_SUPPLEMENT|Beetroot juice|Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
218826459|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
218826460|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
218826461|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
218826462|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
218826463|NCT02852798|DRUG|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
218826464|NCT04292197|DRUG|18-MC Compound|18-MC
218826465|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
218826466|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
218826467|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
218826468|NCT04256473|DRUG|mutant pro-urokinase|Intravenous administration
218826469|NCT04256473|DRUG|Alteplase|Intravenous administration
218826470|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
219476433|NCT00045136|DRUG|melphalan|
219476434|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
219476435|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
219580471|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
218826471|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
218826472|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
218826473|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
218826474|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
218826475|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
218826476|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
218826477|NCT01669746|BIOLOGICAL|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
218826478|NCT05137691|OTHER|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
218826479|NCT05137691|OTHER|NHS 1:1 weight management programme|NHS 1:1 weight management programme
218826480|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
218826481|NCT06406244|DEVICE|TEAS group|Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
218826482|NCT06406244|DEVICE|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
218826483|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
218826484|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
218826485|NCT01284959|DRUG|placebo|lactose PO, 3times
219010883|NCT04365920|COMBINATION_PRODUCT|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
219437925|NCT05067712|PROCEDURE|Closed Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
219437926|NCT01613508|PROCEDURE|Direct Anterior Approach|
219580472|NCT00712205|DRUG|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
219580473|NCT00712205|DRUG|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
219580474|NCT01662349|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
219437927|NCT01613508|PROCEDURE|Mini-Posterior Approach|
219580475|NCT05485220|OTHER|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
218826486|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
218826487|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
218826488|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
219010884|NCT04365920|COMBINATION_PRODUCT|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
219010885|NCT04959279|OTHER|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
219010886|NCT04267926|DRUG|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
219010887|NCT04267926|DRUG|Placebo|Subject will receive Placebo
219010888|NCT04267926|DRUG|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
219010889|NCT01988259|PROCEDURE|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
219010890|NCT01988259|PROCEDURE|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
219437928|NCT05376956|DIAGNOSTIC_TEST|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
219437929|NCT05376956|DIAGNOSTIC_TEST|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
219580476|NCT05485220|OTHER|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
219010891|NCT01988259|PROCEDURE|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
219010892|NCT01988259|PROCEDURE|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
219010893|NCT03420118|PROCEDURE|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
219010894|NCT03420118|PROCEDURE|Blood draws|"Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
219010895|NCT00473460|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
219010896|NCT00473460|DRUG|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
219010897|NCT06288464|DIETARY_SUPPLEMENT|Soluble Fibre|Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
219010898|NCT04465331|OTHER|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
219010899|NCT03502044|DEVICE|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
219010900|NCT03502044|DEVICE|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
219437930|NCT04742036|DRUG|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
219580477|NCT01690221|DRUG|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
219580478|NCT01690221|DRUG|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
219195748|NCT06280781|DIAGNOSTIC_TEST|MRI Scans|"The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."
219195749|NCT04724460|DRUG|Long DOAC|Administration of Rivaroxaban for 18 months
219010901|NCT00511615|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
219010902|NCT04372680|DIAGNOSTIC_TEST|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
219010903|NCT03026010|PROCEDURE|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
219010904|NCT01694641|OTHER|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
219010905|NCT04279951|OTHER|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
219010906|NCT04279951|DIETARY_SUPPLEMENT|Omega-3|1 gram of omega-3 per day for 20 weeks
219010907|NCT04279951|DIETARY_SUPPLEMENT|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
219195750|NCT04724460|DRUG|Short DOAC|Administration of Rivaroxaban for 6 months
219010908|NCT00237757|BEHAVIORAL|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
219010909|NCT00237757|BEHAVIORAL|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
219010910|NCT00180414|DEVICE|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
219010911|NCT03095391|DEVICE|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
219010912|NCT03095391|DEVICE|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
219010913|NCT00306761|DEVICE|Dynamic Wheelchair Seating System|
219010914|NCT05485298|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
219010915|NCT06678113|DRUG|BSG005|Single arm dose escalation in patients with invasive fungal infection
219010916|NCT04704167|OTHER|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
219010917|NCT02161627|DEVICE|Saluda Medical External Trial System|
219010918|NCT02161627|DEVICE|Saluda Medical External Trial System|
219010919|NCT02180633|OTHER|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
219010920|NCT02792556|DEVICE|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
219010921|NCT01199289|DRUG|AMG 827|SC injection.
219010922|NCT01199289|DRUG|Placebo|SC injection.
219010923|NCT03980457|DEVICE|Indego Exoskeleton|Powered generated orthosis
219010924|NCT03980457|OTHER|Standard Rehabilitation|Standard Rehabilitation
219010925|NCT02074787|DEVICE|Thermography|Standard thermographic images
219010926|NCT02074787|DEVICE|Laser Doppler|standard laser doppler analysis
219010927|NCT02074787|DEVICE|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
219010928|NCT01657279|OTHER|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
219195751|NCT04167553|DRUG|HM15136|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
219195752|NCT04167553|DRUG|Placebo|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
218826489|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
218826490|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
218826491|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
218826492|NCT04646577|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
218826493|NCT04646577|DEVICE|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
218826494|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
218826495|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
218826496|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
218826497|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
218826498|NCT01840488|DRUG|Irosustat (BN83495)|"Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
218826499|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
219010929|NCT02290509|BIOLOGICAL|Flublok Quadrivalent|Intramuscular injection of study vaccine
219010930|NCT02290509|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
219010931|NCT02533037|OTHER|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
219010932|NCT02533037|OTHER|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
219580479|NCT06729138|OTHER|Resisted Sprint Training|In this intervention, participants will perform 16 sessions of resisted sprint training with external loads using a sled over eight weeks. In these 16 sessions the intensity will vary in both the distance to be covered and the load to be moved.
219010933|NCT01950923|DRUG|sildenafil citrate|Given PO
219010934|NCT01950923|OTHER|placebo|Given PO
219010935|NCT01950923|PROCEDURE|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
219010936|NCT04972084|DEVICE|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
219010937|NCT00501293|DRUG|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
219195753|NCT05668351|RADIATION|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV\_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV\_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
218826500|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
218826501|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
218826502|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
219010938|NCT04012385|BEHAVIORAL|lifestyle counseling|Nutritional plan and Physical activity goals
219195754|NCT04565834|GENETIC|SNP (single nucleotide polymorphism) genotyping|"We use TaqMan technique to perform SNP genotyping. The PCR reactions are carried out using the Roche Light Cycler 480 thermal cycler following the protocol recommended by Thermo Fisher Scientific. Then, replication of 10% of the samples is carried out."
219195755|NCT06514482|DIAGNOSTIC_TEST|Diagnosis|Diagnosis
219580480|NCT06729138|OTHER|Sprint Training|In this intervention, participants will perform 16 sessions of sprint training over eight weeks. In these 16 sessions the intensity will vary in the distance.
218826503|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
218826504|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
218826505|NCT00736112|OTHER|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
218826506|NCT00736112|PROCEDURE|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
219437931|NCT04742036|DRUG|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
218826507|NCT00736112|PROCEDURE|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
218826508|NCT00599352|DIETARY_SUPPLEMENT|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
218826509|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
218826510|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
218826511|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
219195756|NCT06763224|OTHER|Questionnaire and Physical Exam|The neuropathic pain measured with the Neuropathic pain DN4 Questionnaire (Echelle de la Douleur Neuropathique en 4 questions - Neuropathic Pain Scale in 4 questions) The global pain measured with Visual Analogue Scale (VAS) The patient's permanent functional disability measured with the Oswestry disability index (ODI) The quality of life measured with the questionnaire EuroQol-5 Dimension (EQ-5D-5L)
219437932|NCT00846469|PROCEDURE|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
218826512|NCT04364555|DRUG|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
218826513|NCT04364555|DRUG|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
218826514|NCT04364555|DRUG|Placebo|Placebo/placebo
218826515|NCT00003869|DRUG|carboxyamidotriazole|Given PO
218826516|NCT00003869|OTHER|placebo|Given PO
218826517|NCT00003869|PROCEDURE|quality-of-life assessment|Ancillary studies
218826518|NCT00003869|OTHER|laboratory biomarker analysis|Correlative studies
218826519|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
218826520|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
218826521|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
218826522|NCT01619761|DRUG|Cyclophosphamide|Given IV
218826523|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
218826524|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
218826525|NCT01619761|DRUG|Lenalidomide|Given PO
218826526|NCT01619761|DRUG|Melphalan|Given IV
218826527|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
218826528|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
218826529|NCT01619761|BIOLOGICAL|Rituximab|Given IV
218826530|NCT01619761|DRUG|Tacrolimus|Given IV or PO
218826531|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
218826532|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
218826533|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
218826534|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
218826535|NCT03364231|DRUG|Umbralisib|Oral Daily Dose
218826536|NCT04068922|BEHAVIORAL|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
218826537|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
218826538|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
218826539|NCT02272946|DRUG|Canakinumab|150mg Canakinumab received subcutaneously
218826540|NCT02272946|DRUG|Placebo|150mg Placebo received subcutaneously
218826541|NCT00720577|DRUG|Simvastatin|40 Mg. tablet, 1 tablet daily
218826542|NCT00720577|DRUG|Losartan|50 mg., tablets, 1 tablet once daily
218826543|NCT00720577|DRUG|Pioglitazone|30 mg, tablet, 1 tablet once daily
218826544|NCT04273165|DRUG|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
218826545|NCT05164315|PROCEDURE|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
218826546|NCT05164315|PROCEDURE|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
218826547|NCT04780529|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
218826548|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
218826549|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
218826550|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
218826551|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
218826552|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
218826553|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
218826554|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
218826555|NCT00382317|DRUG|Iobitridol|
219010939|NCT06371053|BEHAVIORAL|Community Intervention|"The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression."
219010940|NCT01453257|DRUG|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
219010941|NCT03362398|DRUG|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
219437933|NCT00846469|OTHER|Control section|Normal emergency room treatment for symptoms of chest pain.
219437934|NCT00671619|DRUG|ESBA105|eye drops
219437935|NCT03032250|OTHER|Communication Intervention|Attend interventionist sessions
219437936|NCT03032250|OTHER|Watch video|Watch video on a DVD
219437937|NCT03032250|OTHER|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
219437938|NCT03032250|OTHER|Quality-of-Life Assessment|Ancillary studies
219437939|NCT03032250|OTHER|Survey Administration|Ancillary studies
219437940|NCT03032250|OTHER|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
219437941|NCT00026195|DRUG|irinotecan hydrochloride|
219437942|NCT05225740|BEHAVIORAL|Standard Exposure|The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
218826556|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
218826557|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
218826558|NCT03040089|DEVICE|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
218826559|NCT03040089|DRUG|Neoquine Cream 2%|2% hydroquinone cream
218826560|NCT04170920|DEVICE|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
218826561|NCT04892030|BEHAVIORAL|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
218826562|NCT01070979|DRUG|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
219437943|NCT05225740|BEHAVIORAL|Stress Management Training|Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
218826563|NCT01070979|DRUG|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
218826564|NCT01070979|DRUG|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
218826565|NCT01371058|DRUG|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
218826566|NCT01371058|DRUG|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
218826567|NCT01371058|DRUG|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
218826568|NCT02691026|DRUG|Pembrolizumab|
218826569|NCT01900886|OTHER|Peginterferon alfa-2a|Treatment as usual clinical practice
218826570|NCT01900886|DRUG|Ribavirin|Treatment as usual clinical practice
218826571|NCT01474304|DRUG|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
218826572|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
218826573|NCT03376464|DEVICE|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
218826574|NCT01952938|PROCEDURE|LINK SL versus EnduRo|
218826575|NCT01881815|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
218826576|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
218826577|NCT02269696|DRUG|Metoprolol|Intraoperative metoprolol infusion.
218826578|NCT02269696|DRUG|Normal saline|Equal of volume compared to metoprolol.
218826579|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
218826580|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
218826581|NCT05670912|DRUG|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
218826582|NCT05670912|DRUG|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
218826583|NCT05231876|OTHER|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
218826584|NCT05160701|OTHER|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
219195757|NCT03928236|OTHER|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
219580481|NCT06727877|DIAGNOSTIC_TEST|Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.|"The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.~The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns."
219580482|NCT06925204|OTHER|Observation|Based on the patient's specific clinical condition, the appropriate examination and treatment in accordance with the conventional diagnosis and treatment standards of CP will be performed, including but not limited to: CT, MRI, endoscopic ultrasound (EUS) with or without biopsy, endocrine hormone testing (such as oral glucose tolerance test or mixed meal tolerance testing), pancreatic exocrine function tests (such as fecal elastase-1 test), extracorporeal shock wave lithotripsy (ESWL), endoscopic retrograde cholangiopancreatography (ERCP), and pancreatic enzyme replacement therapy. Patients were followed up regularly.
218826585|NCT05858177|DRUG|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
218826586|NCT03870048|DEVICE|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
218826587|NCT05462899|OTHER|Purpose in life, goals, and expectations|There is no intervention. This is a cross-sectional study.
218826588|NCT05914194|DRUG|NLS-2|Participants will receive NLS-2 tablets orally.
218826589|NCT05914194|DRUG|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
218826590|NCT03484429|DEVICE|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
218826591|NCT03484429|OTHER|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
218826592|NCT06176248|DRUG|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
219010942|NCT03362398|DRUG|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
219010943|NCT04500834|BIOLOGICAL|Metal Panel T.R.U.E. Test|Diagnostic patch test
219195758|NCT03928236|OTHER|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
219195759|NCT05083754|DRUG|Retifanlimab|Anti-PD-1 Therapy
219195760|NCT05083754|DRUG|Temozolomide|Anti-PD-1 Therapy
219195761|NCT05083754|RADIATION|Radiation Therapy|Standard of Care
219010944|NCT03281954|DRUG|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
219010945|NCT03281954|DRUG|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
219010946|NCT00127712|DRUG|Amiodarone|
219010947|NCT02526407|BEHAVIORAL|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
219010948|NCT02526407|BEHAVIORAL|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
218826593|NCT06176248|DRUG|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
218826594|NCT03447392|BEHAVIORAL|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
219010949|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219010950|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
219010951|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
219010952|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
219010953|NCT03197506|DRUG|Temozolomide|Given PO
219010954|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219010955|NCT05140031|OTHER|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
219010956|NCT05686447|OTHER|Observational studies, no intervention|Observational studies, no intervention
219437944|NCT05225740|BEHAVIORAL|Enhanced Exposure|The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.
219437945|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
219437946|NCT05144542|PROCEDURE|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
219580483|NCT05524961|DEVICE|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
219580484|NCT05524961|DEVICE|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
218826595|NCT06506110|OTHER|Retrieving of retrospective data from Epic|Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
218826596|NCT03533010|DIETARY_SUPPLEMENT|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
218826597|NCT03533010|DIETARY_SUPPLEMENT|VitD800IU|subjects receive a daily dose of 800IU VitD3
218826598|NCT03533010|OTHER|Placebo|subjects receive placebo tablet
218826599|NCT04276025|OTHER|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
219010957|NCT05497713|OTHER|Mindsets|The primary objective of this trial is to determine whether mindsets sustain the feasibility of taking cold showers over a 3-month period.
219010958|NCT03433768|GENETIC|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
219195762|NCT04561492|DRUG|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor
219195763|NCT06106204|OTHER|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will undergo (1) a baseline needs assessment to create a customized suite of stewardship strategies, (2) supported decision-making in selecting ROAD Home strategies to implement, and (3) external facilitation following an implementation blueprint.
218826600|NCT05595928|OTHER|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
218826601|NCT04933500|DEVICE|Whitacre spinal needle|25G Whitacre spinal needle
218826602|NCT05910047|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
218826603|NCT05910047|DIETARY_SUPPLEMENT|Placebo|Inert substance
219437947|NCT05144542|PROCEDURE|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
219437948|NCT05144542|DRUG|Nicotine Replacement|Smoke usual brand of cigarettes
219437949|NCT05144542|DRUG|Nicotine Replacement|Vape e-cigarettes
219580485|NCT05524961|DEVICE|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
219580486|NCT03531398|OTHER|Metabolic test meal challenge|Metabolic test meal challenge
219195764|NCT06197997|BEHAVIORAL|Chicago Parent Program (CPP)|The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.
218826604|NCT06138171|OTHER|Psychological self-reported measures assesment (questionnaire)|The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
218826605|NCT02525926|PROCEDURE|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
218826606|NCT02525926|PROCEDURE|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
219437950|NCT05144542|OTHER|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
219437951|NCT01731990|DRUG|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
219437952|NCT01731990|DRUG|Placebo|Matching placebo of Canakinumab
219580487|NCT06456879|OTHER|extra-coronal restoration type|primary molar crown type
218826607|NCT06391268|BEHAVIORAL|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
218826608|NCT03669887|BEHAVIORAL|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
218826609|NCT04326790|DRUG|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
218826610|NCT04326790|DRUG|Standard treatment|Standard treatment
218826611|NCT01333436|OTHER|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
218826612|NCT00444106|DRUG|Artesunate-mefloquine|
219580488|NCT04441645|OTHER|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
219580489|NCT06785480|DEVICE|Computer Controlled Local Anesthetic Delivery (CCLAD)|Administering local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline) with CCLAD. The CCLAD device is set to 60sec/ml in continuous mode.
218826613|NCT00444106|DRUG|Atovaquone-proguanil|
218826614|NCT00444106|DRUG|Artemether-lumefantrine|
218826615|NCT02192957|DEVICE|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
218826616|NCT04749914|DRUG|Lasmiditan|Administered orally.
218826617|NCT04749914|DRUG|Dabigatran Etexilate|Administered orally.
218826618|NCT04749914|DRUG|Rosuvastatin|Administered orally.
219010959|NCT06346964|OTHER|Health education|Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
219010960|NCT02642614|DRUG|BI 1026706|
219010961|NCT02642614|DRUG|Placebo|
219010962|NCT02642614|DRUG|Placebo|For blinding purposes
219010963|NCT02450903|DRUG|LDK378|Oral LDK378 750mg once daily
219010964|NCT00604539|DRUG|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
219010965|NCT00604539|DRUG|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
219437953|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
219437954|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
219437955|NCT01280812|BEHAVIORAL|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
219437956|NCT04032197|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
219437957|NCT04032197|DRUG|Placebo (semaglutide)|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
219580490|NCT06785480|DEVICE|Conventional metallic syringe|A conventional metallic syringe is used to administers local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline).
219580491|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
219580492|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
219580493|NCT00321737|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
219437958|NCT04483544|DRUG|pembrolizumab|PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
219580494|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using mechanical bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~GIA Device will be used to perform bowel anastomosis"
218826619|NCT01402960|DEVICE|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
218826620|NCT01079312|DEVICE|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
218826621|NCT01079312|DEVICE|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
218826622|NCT01079312|DRUG|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
218826623|NCT01079312|DRUG|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
218826624|NCT01079312|DRUG|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
218826625|NCT01079312|DRUG|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
218826626|NCT06047743|OTHER|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
218826627|NCT06047743|OTHER|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
218826628|NCT05573139|DIAGNOSTIC_TEST|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
218826629|NCT02550015|BEHAVIORAL|High intensity interval training|Uphill treadmill walking
218826630|NCT02550015|BEHAVIORAL|General information|Standard care
219010966|NCT04412720|OTHER|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
219010967|NCT04412720|OTHER|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
219010968|NCT00421538|DRUG|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
219010969|NCT00421538|DRUG|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
219010970|NCT03967964|DRUG|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
219010971|NCT03967964|DRUG|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
219010972|NCT03967964|DRUG|Testosterone|Vaginal ring with 35 mg testosterone.
219010973|NCT03967964|DRUG|Testosterone Topical Gel|Gel containing 1% testosterone.
219010974|NCT03967964|DRUG|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
219437959|NCT04483544|DRUG|olaparib|PARP inhibitor olaparib 300 mg orally, twice daily (BID)
219437960|NCT04291079|BIOLOGICAL|SRK-181|anti-latent TGFβ1 monoclonal antibody
219437961|NCT04291079|BIOLOGICAL|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
219437962|NCT05569850|OTHER|Brushing|Brushing the teeth 2x a day for 4 weeks.
219437963|NCT06846528|DRUG|AZD2389|AZD2389 is administered orally
219437964|NCT06846528|DRUG|Itraconazole|Itraconazole is administered orally
219437965|NCT06843863|OTHER|No intervention.|Participants allocated to the groups were assessed only once. No intervention was applied, and they were not followed up.
219437966|NCT03147573|DIAGNOSTIC_TEST|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
219437967|NCT03147573|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
219437968|NCT03147573|DIAGNOSTIC_TEST|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
219437969|NCT03147573|DIAGNOSTIC_TEST|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
219437970|NCT01871415|DRUG|aleglitazar|150 mcg orally daily
219437971|NCT01871415|DRUG|metformin|pre-existing background regimen and dose
219437972|NCT01871415|DRUG|placebo|matching aleglitazar placebo orally daily
219437973|NCT05305053|OTHER|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
219437974|NCT03197948|OTHER|Internet-Based Intervention|Complete questionnaire via a smartphone application
219437975|NCT03140488|DRUG|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
218826631|NCT04795401|DEVICE|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
219437976|NCT01131078|DRUG|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
219437977|NCT01131078|DRUG|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
219580495|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using manual bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~Vycryl suture will be used to perform manual bowel anastomosis"
218826632|NCT06168240|OTHER|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
218826633|NCT04326062|OTHER|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
218826634|NCT04326062|OTHER|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
218826635|NCT06274983|DEVICE|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
218826636|NCT04303975|OTHER|clinical measurements|Only clinical parameters were recorded, no intervention was made.
218826637|NCT01650454|OTHER|2 night polysomnography|Polysomnography
218826638|NCT01650454|OTHER|battery of neuropsychological tests|
218826639|NCT01650454|OTHER|virtual reality test|
218826640|NCT01650454|OTHER|subjective evaluation of sleep and somnolence|
218826641|NCT03041935|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
219010975|NCT03767530|DEVICE|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
219010976|NCT03767530|OTHER|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
219010977|NCT03951740|DEVICE|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
219437978|NCT01131078|DRUG|Irinotecan|Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
218826642|NCT03041935|PROCEDURE|Caudal-epidural nerve block|See arm description
218826643|NCT03041935|DRUG|Acetaminophen|See arm description
219437979|NCT03675594|DEVICE|CAD/CAM titanium denture base|metallic denture base made of titanium
219437980|NCT03675594|DEVICE|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
219437981|NCT01636453|DEVICE|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
219596924|NCT02473523|OTHER|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
218826644|NCT03041935|DRUG|Sevoflurane|See arm description
218826645|NCT03041935|DRUG|Remifentanil|See arm description
218826646|NCT03041935|DRUG|Propofol|See arm description
219437982|NCT03612544|OTHER|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218826647|NCT03041935|DRUG|Morphine|See arm description
219437983|NCT03612544|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218826648|NCT03041935|DRUG|Ondansetron|See arm description
219763692|NCT05244928|OTHER|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A quasi-experimental, pre- post design, provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
218826649|NCT03041935|DRUG|Dexamethasone|See arm description
218826650|NCT03041935|DRUG|Ketorolac|See arm description
218826651|NCT03041935|DRUG|Ropivacaine|See arm description
218826652|NCT01127620|DRUG|Bilastine|20 mg encapsulated tablets
218826653|NCT01127620|DRUG|Cetirizine|10 mg encapsulated tablets
218826654|NCT01127620|DRUG|Placebo|encapsulated tablets
218826655|NCT00882024|DRUG|Tranilast|150 mg tranilast tablets, bid, 12 weeks
218826656|NCT00882024|DRUG|Tranilast|75 mg tablets, bid, 12 weeks
218826657|NCT00882024|DRUG|Placebo|Placebo tablets, bid, 12 weeks
218826658|NCT02804061|BEHAVIORAL|NELIP|
218826659|NCT02965989|PROCEDURE|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
218826660|NCT02619747|DRUG|Compound Sodium Alginate Oral Suspension sachet|
218826661|NCT02619747|DRUG|Matched placebo|
218826662|NCT02057926|DRUG|The effect of tetracycline in degradation and permeability of collagen membranes.|
218826663|NCT01381770|BIOLOGICAL|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
218826664|NCT00672230|DIETARY_SUPPLEMENT|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
218826665|NCT04892186|DRUG|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
218826666|NCT04892186|DRUG|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
218826667|NCT05659849|OTHER|Manual therapy techniques|Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
218826668|NCT05659849|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
218826669|NCT04593550|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219010978|NCT03951740|DEVICE|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
218826670|NCT04593550|BEHAVIORAL|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
218826671|NCT04593550|PROCEDURE|Cognitive Assessment|Undergo 3D-Confusion assessment
218826672|NCT04593550|PROCEDURE|Electroencephalography|Undergo EEG
218826673|NCT00004227|BIOLOGICAL|cetuximab|
218826674|NCT00004227|PROCEDURE|conventional surgery|
218826675|NCT00004227|RADIATION|radiation therapy|
218826676|NCT03069066|DEVICE|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
218826677|NCT02243683|DRUG|AX-024.HCl|
218826678|NCT02243683|OTHER|Placebo|
218826679|NCT03302143|PROCEDURE|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
219580496|NCT06928077|BEHAVIORAL|ROC-Stand training with specific environmental features|A licensed, independent therapist along with caregivers will conduct the training program in a public space at the university. The initial phase of the training will concentrate on developing the participants' understanding of cause-and-effect in relation to the control system and the movement of the car, focusing on specific public spaces such as hallways, convenience stores, gardens, and museums. Following this, the therapist will collaborate with caregivers to direct the participants' gaze towards specific physical structures and objects. Furthermore, the therapist will guide and coach caregivers on how to lead the participants in engaging with these environmental features through various exploratory actions, as supported by previous evidence. These actions include touching, hitting, squeezing, pointing, holding objects with one or two hands, object touching own body, fingering, banging, manipulating, and transferring objects.
218826680|NCT03302143|PROCEDURE|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
218826681|NCT02558101|BEHAVIORAL|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling"
218826682|NCT02558101|BEHAVIORAL|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
218826683|NCT01079325|DRUG|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
218826684|NCT01079325|OTHER|Saline|
218826685|NCT02459561|DEVICE|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
218826686|NCT02459561|OTHER|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
218826687|NCT05272189|BEHAVIORAL|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
218826688|NCT05272189|BEHAVIORAL|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
218826689|NCT00207220|PROCEDURE|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
218826690|NCT00207220|PROCEDURE|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
218826691|NCT06184191|OTHER|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
218826692|NCT01465035|BIOLOGICAL|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
218826693|NCT01465035|BIOLOGICAL|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
219010979|NCT03951740|DEVICE|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
219010980|NCT01164956|DRUG|methylphenidate|
219010981|NCT01164956|OTHER|Placebo|
219010982|NCT04693325|PROCEDURE|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
218826694|NCT03037762|PROCEDURE|Flexible Endoscopic Evaluation of Swallowing|
218826695|NCT04546919|OTHER|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
218826696|NCT02264613|DRUG|ALRN-6924|ALRN-6924 will be administered as an IV infusion
218826697|NCT05476081|DRUG|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
218826698|NCT05476081|DRUG|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
218826699|NCT05476081|DRUG|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
218826700|NCT03081104|DEVICE|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
219010983|NCT05796765|BIOLOGICAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
219010984|NCT05796765|BIOLOGICAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
219010985|NCT05796765|DRUG|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
219010986|NCT00967798|DRUG|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
219010987|NCT06208891|PROCEDURE|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
219195765|NCT04842513|DRUG|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
219195766|NCT06305117|OTHER|Distraction strategy|Distraction strategy combining the use of virtual reality and music
219195767|NCT03477435|BEHAVIORAL|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
219437984|NCT03869216|BEHAVIORAL|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
219437985|NCT02300506|OTHER|No intervention|
218826701|NCT03081104|DEVICE|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
218826702|NCT03081104|PROCEDURE|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
219195768|NCT02787031|PROCEDURE|Neuraxial anesthesia|
218826703|NCT01074931|DRUG|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
219195769|NCT02787031|PROCEDURE|General anesthesia|
218826704|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
219010988|NCT02941965|PROCEDURE|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
219010989|NCT02941965|PROCEDURE|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
219195770|NCT05248802|DRUG|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
219010990|NCT03218553|DRUG|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
219010991|NCT03218553|DRUG|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
219010992|NCT05100524|OTHER|Motivational interview|The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
219010993|NCT05100524|OTHER|Ongoing treatment|Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
219195771|NCT05248802|DRUG|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
219195772|NCT06402864|RADIATION|contact X-ray brachytherapy (CXB)|3 fractions of contact X-ray brachytherapy (CXB) every two weeks before neoadjuvant chemo radiotherapy (nCRT).
219437986|NCT05223686|DRUG|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
219010994|NCT03626922|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
219010995|NCT03626922|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
219010996|NCT03626922|DRUG|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
219010997|NCT03626922|DRUG|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
219437987|NCT02616328|OTHER|No intervention|No intervention administered in this study
219437988|NCT02613338|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
219437989|NCT01018251|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Given IV
219437990|NCT01018251|PROCEDURE|Positron Emission Tomography/computed tomography|
219437991|NCT01018251|RADIATION|FLT-PET/CT|
219437992|NCT05077280|RADIATION|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
219010998|NCT03626922|DIETARY_SUPPLEMENT|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
219010999|NCT03626922|DIETARY_SUPPLEMENT|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
218826705|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
218826706|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
218826707|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
218826708|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
218826709|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
218826710|NCT02862886|OTHER|myometrium biopsy|
218826711|NCT03888248|DEVICE|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
218826712|NCT03888248|OTHER|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
218826713|NCT05158920|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
218826714|NCT00953706|DRUG|Ivacaftor|Tablet
218826715|NCT00953706|DRUG|Placebo|Tablet
218826716|NCT05238415|DIAGNOSTIC_TEST|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
218826717|NCT00001937|DRUG|FK463|
218826718|NCT00001937|DRUG|Fluconazole|
219011000|NCT01320085|DRUG|MEK162|
219011001|NCT06293170|OTHER|DETECT|DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
219011002|NCT06293170|OTHER|Conventional care|Conventional care
219011003|NCT03807466|BEHAVIORAL|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
219437993|NCT05077280|DRUG|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
219437994|NCT05841069|PROCEDURE|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
219011004|NCT03807466|BEHAVIORAL|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
218826719|NCT04859192|OTHER|gamified flipped classroom|moodle will be gamified
218826720|NCT05548764|PROCEDURE|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
218826721|NCT00921050|DRUG|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
218826722|NCT00921050|DRUG|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
218826723|NCT05007327|OTHER|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
219011005|NCT03187093|DRUG|Vortioxetine|10-20 mg once daily for 8 weeks
219011006|NCT03187093|DRUG|Escitalopram|10-20 mg once daily for 8 weeks
219195773|NCT04278339|OTHER|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
219437995|NCT05841069|RADIATION|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
219437996|NCT05841069|PROCEDURE|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
219437997|NCT03600220|OTHER|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
219437998|NCT05659004|BEHAVIORAL|Qualitative interview|No intervention
218826724|NCT05414175|DRUG|Mavacamten|Specified dose on specified days
219011007|NCT03060239|OTHER|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
219011008|NCT03966378|OTHER|Grape seeds extract|Grape seeds extract powder
219011009|NCT03966378|OTHER|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
219011010|NCT04949126|BEHAVIORAL|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
219195774|NCT02785029|DEVICE|OCT|
219195775|NCT06083766|BEHAVIORAL|hormone therapy|Determine how gender affirming hormone therapy affects muscle physiology
219437999|NCT02579551|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical excision
219438000|NCT03687931|DRUG|Dexamethasone|Drop
219438001|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
218826725|NCT04183712|DRUG|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
218826726|NCT04183712|DRUG|Afatinib|Target therapy Drug: afatinib
218826727|NCT03490929|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
218826728|NCT03490929|DEVICE|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
218826729|NCT04895371|OTHER|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
218826730|NCT04895371|OTHER|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
218826731|NCT06669455|BEHAVIORAL|Personalized and combined lifestyle approach|In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.
218826732|NCT05599100|BEHAVIORAL|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
218826733|NCT03081689|DRUG|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
218826734|NCT03081689|DRUG|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
218826735|NCT03081689|DRUG|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
218826736|NCT05969275|BIOLOGICAL|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
219011011|NCT05956860|PROCEDURE|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
219011012|NCT03785431|DEVICE|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
219011013|NCT04235049|DRUG|Glecaprevir/pibrentasvir|Treatment for HCV Infection
219011014|NCT03316131|DRUG|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
219438002|NCT00698139|DEVICE|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
219438003|NCT02937090|OTHER|Blood Draw|Blood sample will be drawn from participants at study entry.
218826737|NCT05969275|OTHER|Placebo|Intravenous infusion of placebo, with excipients
218826738|NCT06333496|DIETARY_SUPPLEMENT|GLP-1 Booster (GB)|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
218826739|NCT06537791|BEHAVIORAL|Home-Based Rehabilitation Program|Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
218826740|NCT05762432|DEVICE|Wound Dressing|RTD Wound Dressing that is being investigated
218826741|NCT05762432|DEVICE|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
218826742|NCT03549780|DEVICE|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
218826743|NCT03899415|BIOLOGICAL|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
218826744|NCT05124353|DRUG|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
218826745|NCT00361465|OTHER|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
218826746|NCT06073678|OTHER|Photobiomodulation|Irradiation with red laser on palate wound each 48h for 4 sessions.
218826747|NCT06073678|OTHER|Protection with surgical dressing|Protection of the palatal wound with surgical dressing for 7 days
219596925|NCT00866879|DRUG|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
218826748|NCT06292819|DEVICE|Bright light|Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.
218826749|NCT06292819|DEVICE|Near-infrared light|Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.
218826750|NCT06292819|DEVICE|Bright light+ near-infrared light|After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
218826751|NCT02112656|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
218826752|NCT02112656|DRUG|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
218826753|NCT06675461|BEHAVIORAL|Gold Card Intervention|A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
218826754|NCT06675461|BEHAVIORAL|Treatment as usual|Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
218826755|NCT06681649|BEHAVIORAL|Intervention|"The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge"
218826756|NCT05852327|OTHER|Observation only|Observation only
218826757|NCT04486040|PROCEDURE|Drainage|Use of the suction drainage after hip revision arthroplasty
218826758|NCT04486040|PROCEDURE|No-drainage|Patients without drainage after surgery
218826759|NCT06324656|PROCEDURE|crystallized phenol + platelet rich plasma application|"At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy."
218826760|NCT06324656|PROCEDURE|crystallized phenol|At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
218826761|NCT05342298|OTHER|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
218826762|NCT04576494|OTHER|Monthly assessments of functional motor abilities by a trained therapist|Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist
218826763|NCT04576494|DRUG|Nusinersen|nusinersen
218826764|NCT06159907|DIAGNOSTIC_TEST|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
218826765|NCT01938261|DRUG|paracetamol|
218826766|NCT01938261|DRUG|0.45 % saline solution|Placebo
219011015|NCT03316131|DRUG|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
219195776|NCT05663801|DRUG|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
218826767|NCT06037564|DRUG|DOR/DTG/3TC|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
219011016|NCT03316131|DRUG|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
219195777|NCT05663801|DRUG|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
219195778|NCT05663801|DRUG|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
219596926|NCT00866879|OTHER|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
218826768|NCT03761056|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
218826769|NCT03761056|DRUG|Fludarabine|Administered according to package insert
218826770|NCT03761056|DRUG|Cyclophosphamide|Administered according to package insert
218826771|NCT03493139|BEHAVIORAL|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
218826772|NCT06629688|DRUG|semaglutide|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
218826773|NCT06691126|OTHER|Terpinolene in olive oil|Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
219011017|NCT03316131|OTHER|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
219011018|NCT02352714|DRUG|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
219011019|NCT02352714|DRUG|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
219011020|NCT00618059|DRUG|Pilocarpine|
219195779|NCT06515691|PROCEDURE|M-TAPA block|After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
218826774|NCT06710080|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
218826775|NCT06710080|DRUG|Placebo|Placebo twice daily
218826776|NCT06717022|BIOLOGICAL|CHT102 allogeneic CAR T cells|CHT102 allogeneic CAR T cells
218826777|NCT06717035|DEVICE|EYE001|Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic
218826778|NCT06712095|DEVICE|Video capsule investigation|Participants will undergo both a video capsule examination and a colonoscopy on the same day.
218826779|NCT06706167|DEVICE|stainless steel crown|Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
218826780|NCT06706167|DEVICE|Zirconia crown|Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.
218826781|NCT06706167|DEVICE|Bioflx crown|Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
218826782|NCT06714721|DEVICE|Repetitive peripheral magnetic stimulation|"Repetitive peripheral magnetic stimulation treatment will be performed with the BTL-6000 Super Inductive System Elite available in our clinic. rPMS treatment will be adjusted to use the stimulus intensity above the motor threshold determined specifically for each patient by selecting the respiratory muscle strengthening protocol set in the device menu. The patient will be given a side-lying position, with the arms in front of the body and the elbows flexed, and the hips and knees in semiflexion. The applicator will be aligned to the diaphragm placement determined by ultrasonography (ninth intercostal space) and placed as close as possible to the skin, and rPMS will be applied for a total of 16 minutes, 8 minutes to the right diaphragm muscle and 8 minutes to the left diaphragm muscle. The treatment period is a total of 16 sessions according to the respiratory muscle strengthening protocol created by the company that developed the device."
218826783|NCT06714721|OTHER|Sham (No Treatment)|rPMS will be applied to the sham group as sham and the device will not be operated, the applicator of the device will be positioned on the right and left diaphragm muscle for a total of 16 minutes in the same way as the patients in the treatment group, and the sounds recorded during the operation of the device will be played to the patients as if the device was operating in the background. The patients will not know which group they are in.
218826784|NCT06719479|BIOLOGICAL|IAE0972+ Methotrexate|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Methotrexate is used according to the instructions.
218826785|NCT06719479|BIOLOGICAL|IAE0972+Docetaxel|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Docetaxel is used according to the instructions.
219011021|NCT01409564|DRUG|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
219011022|NCT01409564|DRUG|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
219011023|NCT02329561|DRUG|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
219011024|NCT02329561|BEHAVIORAL|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
219011025|NCT02329561|DRUG|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
219363702|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~* Melanoma and skin cancer protection guidelines~* The benefits of skin screening practices~* Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
219596927|NCT00866879|PROCEDURE|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
219596928|NCT00866879|PROCEDURE|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
219363703|NCT00816374|OTHER|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment"
219363704|NCT02838173|PROCEDURE|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
219363705|NCT02838173|PROCEDURE|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
219363706|NCT02838173|PROCEDURE|serratus plane bloc : placebo|
219363707|NCT02838173|PROCEDURE|tissue infiltration : placebo|
218826786|NCT06719479|BIOLOGICAL|IAE0972+Gemcitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Gemcitabine is used according to the instructions.
218826787|NCT06719479|BIOLOGICAL|IAE0972+Taxanes|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Taxanes is used according to the instructions.
218826788|NCT06719479|BIOLOGICAL|IAE0972+Capecitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Capecitabine is used according to the instructions.
218826789|NCT06717490|DRUG|Magnesium sulphate|"In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.~Thromboelastometry will be performed pre and post magnesium administration."
218826790|NCT06717490|OTHER|Placebo Drug|"In patients allocated to the NS group, a fixed dose of natural saline will be administered intravenously, through a fixed volume of solution.~Thromboelastometry will be performed pre and post magnesium administration."
218826791|NCT06710210|DEVICE|PCI with a bioresorbable scaffold and drug-coated balloon(s)|Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)
218826792|NCT06710210|DEVICE|PCI with drug-eluting stent(s)|PCI with \>1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)
218826793|NCT06719024|DRUG|Ruxolitinib Cream 1.5%|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
218826794|NCT06719024|DRUG|Aqueous cream|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
218826795|NCT06716788|DRUG|68Ga-HSA|68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
218826796|NCT06718205|DRUG|Nimotuzumab|Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
218826797|NCT06718205|DRUG|Sintilimab|Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD
218826798|NCT06718205|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle
218826799|NCT06718205|DRUG|Cisplatin|Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
218826800|NCT06718608|DIAGNOSTIC_TEST|imaging|Magnetic resonance imaging (MRI) Shear wave elastography (SWE) Electronic oscillatory device (EOD)
219438004|NCT02937090|OTHER|Stool collection|Stool will be collected from participants at study entry.
219438005|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
218826801|NCT03584906|PROCEDURE|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
218826802|NCT03584906|PROCEDURE|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
218826803|NCT03584906|PROCEDURE|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
219011026|NCT06036459|OTHER|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
219011027|NCT00478569|DRUG|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
219011028|NCT02566226|DRUG|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
219011029|NCT02566226|DRUG|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
219011030|NCT01486914|DRUG|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
219011031|NCT03021421|PROCEDURE|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
219011032|NCT03021421|PROCEDURE|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
219011033|NCT00454610|BEHAVIORAL|FLOW|
219011034|NCT00454610|BEHAVIORAL|SelfHelp|
219363708|NCT01196559|DRUG|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
219363709|NCT03308864|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
218826804|NCT03584906|PROCEDURE|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
218826805|NCT03584906|PROCEDURE|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
218826806|NCT06717997|OTHER|ultrasound|The placenta thickness will be performed on transabdominal images obtained in a longitudinal plane. Three measurements will be performed at the thickest portion of the placenta. The average of these three measurements was used for statistical analysis. The cohorts will be classified into 1) thick placenta (\>4 cm) and average placenta (2-4 cm).
218826807|NCT06718725|DIAGNOSTIC_TEST|ROSE-AI system|The cytopathological slide images of the patients' ROSE samples will be identified by the ROSE-AI system.
218826808|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
218826809|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
219011035|NCT05947812|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
219011036|NCT05947812|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
219011037|NCT01317082|DEVICE|Acupressure|P 6 Pressure Point
219011038|NCT02070692|DRUG|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
219011039|NCT02070692|DRUG|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
219011040|NCT05411679|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
219438006|NCT00547989|DRUG|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
219438007|NCT00547989|DRUG|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
219438008|NCT00547989|DRUG|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
219580497|NCT06928077|BEHAVIORAL|ROC-Stand training without specific environmental features|The initial phase of training will also focus on teaching participants about cause-and-effect as it pertains to the control system and movement of the car. This phase will include goal-oriented driving activities, such as traveling 200 meters to reach a preferred toy or to interact with someone, and engaging in games like hide-and-seek in various public spaces including hallways, convenience stores, gardens, and museums. The training, without a specific emphasis on environmental features, will highlight the use of upper limbs in functional tasks during driving sessions, and incorporate a range of motor skills to enhance mobility and socialization during natural play sessions. The details of the program will also be established through collaborative discussions between the family and the treating therapist. These discussions will take into account clinical observations of the participant's performance in previous sessions.
219580498|NCT06928077|BEHAVIORAL|Conventional therapy|The overarching goal of this training is to support developmental progress and improve mobility, socialization, and upper limb functionality in everyday tasks. Participants in this group will have the opportunity to walk in the same public space used by the ROC training groups, allowing interaction with both the therapist and caregivers based on their individual motor capabilities.
219580499|NCT06928311|OTHER|Exercise Environment|This intervention focused around the environmental design of the exercise room.
219011041|NCT05411679|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
219011042|NCT04733092|DRUG|Lipiodol|Lipiodol in emulsion with contrast agent
219011043|NCT01549093|DRUG|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
219011044|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
219011045|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
219011046|NCT02029625|DRUG|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
219011047|NCT02029625|DRUG|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
219011048|NCT01223989|OTHER|hypocaloric diet balanced + nutrition education + ruled physical activity|
219011049|NCT03733691|DRUG|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
219438009|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
219438010|NCT04006704|DRUG|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
219438011|NCT03132441|OTHER|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
219438012|NCT03597503|DRUG|SPN-810|Flexible dose
219438013|NCT03597503|DRUG|Placebo|Placebo
218826810|NCT04610983|DIETARY_SUPPLEMENT|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
218826811|NCT04749745|DRUG|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
219580500|NCT04772391|OTHER|Exercise Sessions|Participant will complete up to 8 exercise sessions
219011050|NCT03733691|DRUG|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
219011051|NCT00277888|PROCEDURE|Femoral route for hemodialysis|
219011052|NCT00277888|PROCEDURE|Jugular route for hemodialysis|
219011053|NCT04669483|OTHER|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
219011054|NCT00258882|BIOLOGICAL|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
219011055|NCT04154020|PROCEDURE|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
219011056|NCT04906044|DRUG|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
219011057|NCT00507754|OTHER|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
219011058|NCT03398395|PROCEDURE|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
219596929|NCT00866879|PROCEDURE|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
219011059|NCT03398395|PROCEDURE|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
219011060|NCT02184182|PROCEDURE|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~\- laparoscopic/laparotomic right trisectionectomy"
219011061|NCT00108667|DRUG|IV Levodopa|
219011062|NCT00108667|DRUG|Talampanel|
219011063|NCT03857191|DIETARY_SUPPLEMENT|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
219011064|NCT03645980|DRUG|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
219011065|NCT03645980|DRUG|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
219011066|NCT03645980|DRUG|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
219011067|NCT04900194|BEHAVIORAL|mindfulness-based sexual counseling|Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
219011068|NCT00726076|BEHAVIORAL|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
219011069|NCT00726076|BEHAVIORAL|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
219011070|NCT01842256|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
219011071|NCT01842256|DRUG|atorvastatin 40mg|"* 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
219011072|NCT05744947|OTHER|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
219011073|NCT03707314|PROCEDURE|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
219011074|NCT01120912|DRUG|Oshadi Oral Insulin|Oral insulin single administration
219011075|NCT05931679|DEVICE|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
219011076|NCT05931679|OTHER|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
219011077|NCT04488289|OTHER|Lifestyle|Cardiovascular risk and lifestyle
219011078|NCT03020407|PROCEDURE|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
219596930|NCT00866879|OTHER|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
218826812|NCT04749745|DRUG|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
218826813|NCT02478541|OTHER|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
218826814|NCT01679483|DRUG|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
218826815|NCT02551185|DRUG|ACY-241|
218826816|NCT04541667|OTHER|Air|Air will be used for luminal inflation.
219011079|NCT03020407|DRUG|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
219011080|NCT03020407|DRUG|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
219011081|NCT05870709|OTHER|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
219011082|NCT02699554|PROCEDURE|Single-event multilevel surgery|
219011083|NCT02989675|DRUG|10% dextrose|Bolus of 10% dextrose 5mls/kg
219195780|NCT06515691|PROCEDURE|Postoperative pain management|ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
219195781|NCT06228248|OTHER|metagenomics|Feces used for metagenomic testing
219011084|NCT00492687|DRUG|carboplatin|
219011085|NCT00492687|DRUG|tamoxifen citrate|
219011086|NCT00492687|DRUG|temozolomide|
219011087|NCT00492687|PROCEDURE|adjuvant therapy|
219011088|NCT00492687|RADIATION|radiation therapy|
219011089|NCT03506607|OTHER|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
219195782|NCT03401840|RADIATION|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
219438014|NCT04023136|PROCEDURE|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
218826817|NCT04541667|OTHER|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
218826818|NCT04167254|BEHAVIORAL|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
218826819|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
218826820|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
218826821|NCT00914576|DRUG|Placebo|2 capsules/day for 14 days
218826822|NCT00914576|DRUG|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
219011090|NCT03506607|OTHER|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
219195783|NCT03718637|BIOLOGICAL|Smith & Nephew Bioinductive Implant|A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
219195784|NCT03718637|PROCEDURE|Lateral Epicondylectomy|This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
219438015|NCT05932381|OTHER|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
219438016|NCT05932381|OTHER|Medical treatment|the patients will receive routine medical treatment
219438017|NCT01399255|BIOLOGICAL|Insulin lispro|Dosage form- Subcutaneous Injection
219438018|NCT01318525|DRUG|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
218826823|NCT00914576|DRUG|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
218826824|NCT01987076|DRUG|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
218826825|NCT01987076|DRUG|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
218826826|NCT04050384|DEVICE|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
218826827|NCT04676906|DRUG|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
218826828|NCT04676906|DRUG|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
218826829|NCT04676906|DRUG|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
218826830|NCT03719014|DEVICE|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
218826831|NCT05281913|OTHER|Psychoeducational Game|Psychoeducational Game
218826832|NCT03554655|DEVICE|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
218826833|NCT01594242|DRUG|Bortezomib|
218826834|NCT03653182|DIAGNOSTIC_TEST|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
218826835|NCT03827239|OTHER|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
218826836|NCT02096978|PROCEDURE|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
219011091|NCT03506607|OTHER|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
219011092|NCT00788151|BIOLOGICAL|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
219438019|NCT01318525|DRUG|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
219438020|NCT01506219|PROCEDURE|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
219438021|NCT01337518|DRUG|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
218826837|NCT00577278|BIOLOGICAL|rituximab|Given IV
218826838|NCT00577278|DRUG|fludarabine phosphate|Given IV
218826839|NCT00577278|DRUG|melphalan|Given IV
218826840|NCT00577278|DRUG|sirolimus|Given PO
218826841|NCT00577278|DRUG|tacrolimus|Given PO or IV
218826842|NCT00577278|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
218826843|NCT00577278|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
218826844|NCT00577278|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
218826845|NCT00577278|OTHER|laboratory biomarker analysis|Correlative Studies
218826846|NCT02428829|PROCEDURE|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
218826847|NCT02428829|PROCEDURE|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
218826848|NCT03965403|DEVICE|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
218826849|NCT05193006|OTHER|No intervention|No intervention
219438022|NCT05058118|DRUG|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
218826850|NCT02622269|DEVICE|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
218826851|NCT02622269|DEVICE|Standard compression device|Compression of the abdomen with the standard compression device
218826852|NCT01926743|PROCEDURE|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
218826853|NCT02292537|DRUG|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
218826854|NCT02292537|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
218826855|NCT01474967|DRUG|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
218826856|NCT01474967|DRUG|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
218826857|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218826858|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
218826859|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
218826860|NCT05121025|DIAGNOSTIC_TEST|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
218826861|NCT03672630|DRUG|Azithromycin|Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
219011093|NCT00788151|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL, SC
218826862|NCT03672630|DRUG|Ethambutol|Ethambutol 25 mg/kg \[MYAMBUTOL\]
218826863|NCT03672630|DRUG|Rifampin|Rifampin 600 MG \[RIFADIN\]
218826864|NCT06518304|OTHER|GentleWave|GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
218826865|NCT06518304|OTHER|Conventional Protocol|Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
218826866|NCT06184178|OTHER|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
218826867|NCT06114719|DRUG|Silymarin|Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
218826868|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
218826869|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
218826870|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
218826871|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
219011094|NCT03324854|PROCEDURE|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
219438023|NCT05058118|DRUG|Placebo|empty bottle
219438024|NCT01847690|DRUG|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
219438025|NCT05666908|DEVICE|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
219438026|NCT01013090|DRUG|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
219438027|NCT01013090|DRUG|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
219438028|NCT04695236|DEVICE|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
219438029|NCT04695236|OTHER|Standard Treatment|Standard Treatment for Ischemic Strokre
219438030|NCT00033592|OTHER|placebo|
218826872|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
218826873|NCT02259725|DRUG|regorafenib|Given PO
218826874|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
218826875|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
218826876|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
219011095|NCT03324854|PROCEDURE|Drainage|Placement of active-close drainage in surgical site.
219011096|NCT03324854|DRUG|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
219011097|NCT02600377|OTHER|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
219011098|NCT00503009|DRUG|fluticasone propionate/salmeterol|comparator
219011099|NCT00503009|DRUG|fluticasone propionate|Comparator
219011100|NCT00503009|DRUG|placebo|Placebo
219195785|NCT03718637|RADIATION|Ultrasound Imaging|An ultrasound will be performed on each patient both preoperatively and at 6 months.
219438031|NCT00033592|DRUG|bupropion hydrochloride|
219438032|NCT00033592|DRUG|nicotine|
219438033|NCT04921657|DRUG|Rosuvastatin 10mg|
219438034|NCT01841489|DRUG|Treatment A|1600 mg GS-9973 (Formulation 1)
219438035|NCT01841489|DRUG|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
219438036|NCT01841489|DRUG|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
219438037|NCT01841489|DRUG|Treatment D|1600 mg GS-9973 (Formulation 2)
219438038|NCT01841489|DRUG|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
219438039|NCT01841489|DRUG|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
219438040|NCT01841489|DRUG|Treatment G|1600 mg GS-9973 (Reference formulation)
219438041|NCT01841489|DRUG|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
219438042|NCT01841489|DRUG|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
219438043|NCT01841489|DRUG|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
218826877|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
219195786|NCT05575882|OTHER|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
219438044|NCT05478538|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
219438045|NCT00040950|BIOLOGICAL|rituximab|
219438046|NCT00040950|DRUG|agatolimod sodium|
219438047|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
219438048|NCT03320486|DRUG|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
219438049|NCT03320486|DRUG|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
219438050|NCT04894357|OTHER|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02\_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
219438051|NCT03981185|DEVICE|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
219438052|NCT03641794|DRUG|DN1406131|IDO1 and TDO2 inhibitor
219438053|NCT03641794|DRUG|Placebo|Placebo
219438054|NCT00790218|DRUG|CF102|CF102 capsules twice daily by mouth
219438055|NCT03016039|DIETARY_SUPPLEMENT|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
219438056|NCT01921283|DEVICE|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
219438057|NCT01921283|DRUG|no- BIS sensor attachment|
219438058|NCT02764086|RADIATION|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
219438059|NCT02279160|DRUG|APD811|
219438060|NCT02279160|DRUG|Placebo|Placebo
219438061|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
219438062|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
219596931|NCT00866879|PROCEDURE|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
218826878|NCT00034021|DRUG|Ginkgo Biloba|
218826879|NCT00034021|BEHAVIORAL|Sex Therapy (genital focus)|
218826880|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
218826881|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
219438063|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
218826882|NCT00672594|DRUG|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
218826883|NCT03039387|DEVICE|anodal transcranial direct current stimulation|
218826884|NCT03039387|DEVICE|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
219011101|NCT00534989|PROCEDURE|FDG PET|FDG PET
219011102|NCT01356745|DRUG|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
219011103|NCT01356745|DRUG|medical air|inhalation gas for inhalation use
219011104|NCT01558388|DRUG|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
219438064|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
219438065|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
219011105|NCT01558388|DRUG|Placebo|One vaginal tablet daily for 10 days.
219438066|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
218826885|NCT03037866|BEHAVIORAL|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
218826886|NCT03757507|DEVICE|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
219011106|NCT03914781|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
218826887|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
219011107|NCT03413566|OTHER|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
219011108|NCT03724539|DEVICE|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
219011109|NCT03724539|OTHER|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
218826888|NCT05010083|BEHAVIORAL|diet and lifestyle program|See description of main arm.
219011110|NCT02935322|DRUG|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
219011111|NCT02935322|DRUG|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
219011112|NCT02935322|DRUG|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
219195787|NCT05575882|OTHER|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
219011113|NCT02935322|OTHER|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
219195788|NCT05575882|OTHER|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
219195789|NCT05575882|OTHER|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
219438067|NCT02468804|DEVICE|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
219438068|NCT02468804|DEVICE|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
219438069|NCT02628704|DRUG|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
219438070|NCT02628704|DRUG|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
219438071|NCT02628704|DRUG|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
219438072|NCT02628704|DRUG|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
218826889|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
218826890|NCT05575700|DRUG|Placebo|tablet three times daily
219438073|NCT03932890|DEVICE|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
218826891|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
218826892|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
218826893|NCT00618007|DRUG|Placebo|Placebo
218826894|NCT05065593|OTHER|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
218826895|NCT05065593|OTHER|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
218826896|NCT02479880|DRUG|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
218826897|NCT02479880|RADIATION|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
218826898|NCT01424943|BEHAVIORAL|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
219011114|NCT00141076|BEHAVIORAL|low vs high glycemic index diet|
219011115|NCT04275440|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
219011116|NCT04275440|BEHAVIORAL|Caloric restriction|"1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
219011117|NCT03367481|DEVICE|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
219195790|NCT05575882|OTHER|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
219195791|NCT05575882|OTHER|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
219195792|NCT05575882|OTHER|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
219438074|NCT03932890|DEVICE|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
219438075|NCT02054663|DRUG|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
219438076|NCT00776191|DRUG|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
219438077|NCT00776191|DRUG|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
218826899|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
218826900|NCT01291108|DRUG|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
218826901|NCT01291108|DRUG|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
218826902|NCT01291108|DRUG|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
218826903|NCT05592821|PROCEDURE|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
218826904|NCT01144143|DRUG|Infliximab|the study drug will be injected into the joint through a needle
218826905|NCT01144143|DRUG|Placebo|the placebo will be injected into the joint through a needle
218826906|NCT01144143|DRUG|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
218826907|NCT05910515|OTHER|Debriefing|Structured debriefing in non-technical skills. (This is an educational study)
218826908|NCT06110559|DEVICE|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes."
218826909|NCT06110559|DEVICE|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
219438078|NCT03832816|DRUG|Placebo|Placebo vapor (distilled water)
219438079|NCT03832816|DRUG|Vaporized THC alone|Acute exposure to vaporized THC
219195793|NCT05955846|PROCEDURE|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
219195794|NCT05955846|DEVICE|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
218826910|NCT01762683|OTHER|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
219011118|NCT03351179|COMBINATION_PRODUCT|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
219438080|NCT03832816|DRUG|Vaporized CBD alone|Acute exposure to vaporized CBD
219011119|NCT04461171|PROCEDURE|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
219011120|NCT03619187|DRUG|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
219011121|NCT05949242|DEVICE|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
219011122|NCT05949242|DEVICE|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
219195795|NCT03068390|BEHAVIORAL|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
219195796|NCT03068390|BEHAVIORAL|Usual care|Referral to primary care provider
219195797|NCT05224544|DEVICE|Investigational device|The test product is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
219195798|NCT05224544|DEVICE|Comparator|The comparator is a urinary catheter for bladder drainage through the urethra.
219438081|NCT03832816|DRUG|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
219438082|NCT01644019|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
219438083|NCT04672031|OTHER|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
219476436|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
219476437|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
218826913|NCT00848458|OTHER|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
218826914|NCT00848458|OTHER|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
218826915|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
218826916|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
218826917|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
218826918|NCT03824951|BIOLOGICAL|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
218826919|NCT01482195|BIOLOGICAL|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
219011123|NCT01349803|DRUG|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
219011124|NCT01349803|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
219011125|NCT01349803|DRUG|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
219011126|NCT01349803|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
219195799|NCT05837169|OTHER|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
219195800|NCT00844415|DRUG|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
219195801|NCT04943445|DRUG|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
219195802|NCT04943445|RADIATION|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
218826920|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
218826921|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
218826922|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
218826923|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
218826924|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
218826925|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
218826926|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
219763693|NCT04136912|DRUG|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
218826927|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
218826928|NCT01323985|DRUG|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
219011127|NCT01545284|DRUG|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
219011128|NCT05916391|GENETIC|FT-003|Administration via intraocular injection
219011129|NCT03959020|PROCEDURE|Anti-reflux surgery|Anti-reflux surgery for verified GERD
219763694|NCT04136912|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
219011130|NCT05829889|PROCEDURE|FFR-Guided PCI|Fractional Flow Reserve-Guided PCI
219011131|NCT05829889|PROCEDURE|Angiography-Guided PCI|Angiography-Guided PCI
219011132|NCT01565785|BEHAVIORAL|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
219011133|NCT04378140|OTHER|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
219476438|NCT02463500|OTHER|DFU|Standard care.
219476439|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
219763695|NCT04692675|DIAGNOSTIC_TEST|mpMRI|3T endorectal coil MR imaging of the prostate gland
219195803|NCT04943445|DRUG|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
219763696|NCT05853367|DRUG|MK-0472|Oral Administration
219763697|NCT05853367|BIOLOGICAL|Pembrolizumab|IV infusion
219763698|NCT05853367|DRUG|MK-1084|Oral Administration
219763699|NCT02621151|BIOLOGICAL|Pembrolizumab|
219763700|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
219763701|NCT02621151|DRUG|Gemcitabine|
219763702|NCT02621151|RADIATION|External Beam Radiation Therapy|
218826929|NCT01323985|DRUG|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
219011134|NCT05570565|PROCEDURE|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
219011135|NCT05570565|PROCEDURE|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
219011136|NCT02260050|DRUG|WAL 801 CL dry syrup new formulation|
219011137|NCT02260050|DRUG|WAL 801 CL dry syrup conventional formulation|
219011138|NCT00100815|BIOLOGICAL|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
219438084|NCT05668806|DEVICE|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
218826930|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
219438085|NCT00949949|DRUG|everolimus|Given PO
219438086|NCT00949949|DRUG|gemcitabine hydrochloride|Given IV
219438087|NCT00949949|DRUG|cisplatin|Given IV
219438088|NCT03965806|BEHAVIORAL|SURVEY|SURVEY
218826931|NCT04884607|OTHER|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"* Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
218826932|NCT00005844|DRUG|oxaliplatin|
218826933|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
219011139|NCT00100815|DRUG|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
219011140|NCT00100815|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
219011141|NCT01710033|DRUG|Placebo|Placebo tables twice daily (BID) for 28 days
219011142|NCT01710033|DRUG|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
219011143|NCT01710033|DRUG|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
219011144|NCT01710033|DRUG|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
219011145|NCT00815945|DRUG|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
219011146|NCT00815945|DRUG|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
219011147|NCT01305850|DRUG|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
219011148|NCT01305850|DRUG|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
219011149|NCT01305850|DRUG|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
219011150|NCT01305850|DRUG|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
219011151|NCT05933512|BIOLOGICAL|SCTV01E-2|intramuscular injection
219011152|NCT05933512|BIOLOGICAL|SCTV01E|intramuscular injection
219011153|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
219011154|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
219011155|NCT01141439|DRUG|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
219011156|NCT01141439|DRUG|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
219011157|NCT01141439|DRUG|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
219011158|NCT01141439|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
219011159|NCT00996047|GENETIC|cytogenetic analysis|
219011160|NCT00996047|GENETIC|fluorescence in situ hybridization|
218826934|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
218826935|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
218826936|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
218826937|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
218826938|NCT04469205|OTHER|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
218826939|NCT02666313|BEHAVIORAL|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
218826940|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
218826941|NCT02533310|OTHER|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
218826942|NCT02533310|OTHER|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
218826943|NCT01899430|DRUG|liraglutide|
218826944|NCT01899430|DRUG|metformin|
218826945|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
219580501|NCT06928428|BEHAVIORAL|Metacognitive therapy, blended format|Blended metacognitive therapy (bMCT): New about this treatment is that it is given both via the internet and through meetings with a therapist. Participants work with the treatment independently via an internet platform and meets their therapist for therapy sessions up to 6 times during the course of the treatment. Key components of the original manual are retained, but adapted to better fit the digital format. A handbook for therapists is developed to facilitate the implementation of the blended format and optimize execution. The digital parts of the treatment for depression and GAD consist of 10 interactive modules located in the Support and Treatment (SoB) platform. The sessions are divided in a flexible way between physical and digital sessions that therapist and patient agree on. The patient has access to all modules but receive instructions from their therapist which module is relevant for each week. During the treatment, the patient can write text messages to his/her therapist.
219580502|NCT06928701|DIETARY_SUPPLEMENT|omega-3 (n-3 Lc-PUFA), EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) plus a source of palmitoleic acid (hexadecenoic acid)|Nutritional supplements
218826946|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
218826947|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
218826948|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
219011161|NCT05615571|GENETIC|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
219195804|NCT06822023|DEVICE|virtual reality mask|Patients will be prepared as per the standard routine clinical care; they will then be wearing the VR mask for 10 minutes. No other study have looked into VR mask prior to cataract surgery
219195805|NCT03555422|DRUG|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
219596932|NCT04278716|OTHER|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
218826949|NCT02735057|DRUG|Carboplatin|
218826950|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
218826951|NCT00185237|DRUG|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
218826952|NCT00185237|DRUG|Placebo|Placebo patch
218826953|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
218826954|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
219011162|NCT05615571|GENETIC|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
218826955|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
218826956|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
218826957|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
218826958|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
218826959|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
218826960|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
218826961|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
218826962|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
218826963|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
219011163|NCT02880189|DEVICE|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
219011164|NCT02880189|PROCEDURE|Endoscopic Ultrasound Guided Core Liver Biopsy|
219011165|NCT01647282|DRUG|locally-applied minocycline HCl (1 mg)|
219011166|NCT01647282|PROCEDURE|scaling and root planing (Sc/RP)|
219011167|NCT04976166|BEHAVIORAL|Education|More informed and detailed education
219011168|NCT04976166|BEHAVIORAL|Education|Shared decision making
219011169|NCT04976166|BEHAVIORAL|Education|education as usual
219011170|NCT02956265|DEVICE|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
219438089|NCT02617706|DEVICE|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
219438090|NCT04241120|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
219438091|NCT04241120|BEHAVIORAL|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
219011171|NCT00394628|DRUG|AQ4N|
219011172|NCT00394628|DRUG|Temozolomide|
219011173|NCT00394628|PROCEDURE|Radiotherapy|
219011174|NCT00826020|DRUG|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
219011175|NCT00678119|BIOLOGICAL|AGS-003|Dendritic cell Immunotherapeutic
219011176|NCT00678119|DRUG|Sunitinib|An approved drug for the treatment of RCC
219195806|NCT03555422|DRUG|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
219438092|NCT01557127|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
219438093|NCT05509491|BEHAVIORAL|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
219438094|NCT00649610|DRUG|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
218826964|NCT02733744|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
218826965|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
218826966|NCT00856635|DRUG|placebo|injected daily subcutaneously
218826967|NCT04478903|OTHER|Questionnaire|Zarit Burden Inventory French version and SF12
218826968|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
218826969|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
218826970|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
218826971|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
218826972|NCT02229981|DRUG|ABC294640|
218826973|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
218826974|NCT02971319|DEVICE|F-18 FDG PET|
219011177|NCT05554757|DEVICE|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
219011178|NCT05554757|DEVICE|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
219011179|NCT06120816|DRUG|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
219011180|NCT06066645|DRUG|Travoprost Intraocular Implant|anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite
219011181|NCT06066645|OTHER|Sham procedure|Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite
219011182|NCT06066645|DEVICE|iStent infinite|Successful iStent infinite surgery
219011183|NCT05931250|DEVICE|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
219011184|NCT05931250|DEVICE|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
218826975|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
219011185|NCT00111592|PROCEDURE|current usual care|current usual care
218826976|NCT04660175|OTHER|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
218826977|NCT04660175|OTHER|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
218826978|NCT04660175|OTHER|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
218826979|NCT04660175|OTHER|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
218826980|NCT04660175|DRUG|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
218826981|NCT02796833|DRUG|SMOFlipid20%|
218826982|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
218826983|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
218826984|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
218826985|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
218826986|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
218826987|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
218826988|NCT05407805|OTHER|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
218826989|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
218826990|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
218826991|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
218826992|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
219011186|NCT00111592|PROCEDURE|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
218826993|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
219011187|NCT06398054|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg tablet
219011188|NCT06398054|DRUG|Hyoscine N-Butil Bromide|Hyoscine N-Butil Bromide 10 mg two tablets
219011189|NCT06398054|DRUG|placebo|Two tablets
218826994|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
219011190|NCT01525550|DRUG|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
219011191|NCT03366376|RADIATION|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
219011192|NCT05474742|OTHER|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
219011193|NCT04902716|BEHAVIORAL|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
219011194|NCT06430138|DIETARY_SUPPLEMENT|300ml Orange Juice|Acute intervention in populations with and without colon
219011195|NCT00111618|DRUG|AS1404 (DMXAA)|
219011196|NCT03889158|BIOLOGICAL|Typhoid Vaccine|All participants will receive the typhoid vaccine.
219011197|NCT03889158|DIETARY_SUPPLEMENT|Ascorbic Acid|All participants will receive ascorbic acid.
219011198|NCT03878914|DRUG|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
218826995|NCT00088491|DRUG|Oral Olanzapine|
219011199|NCT01843751|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
218826996|NCT00641108|DRUG|ADAM SPECT plus Cognitive Therapy|
219195807|NCT05966181|BEHAVIORAL|experimental group|"Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
219195808|NCT06166498|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
219195809|NCT06166498|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
219438095|NCT00649610|DRUG|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
219438096|NCT06118944|DEVICE|ICB00 IOL|Bilateral implantation of ICB00 IOL
218826997|NCT00641108|DRUG|ADAM SPECT plus No Therapy|
219438097|NCT06118944|DEVICE|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
219438098|NCT06118944|DEVICE|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
219438099|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
219438100|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
219438101|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
219438102|NCT06139094|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
219438103|NCT03793894|BEHAVIORAL|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
219438104|NCT03793894|BEHAVIORAL|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
218826998|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
218826999|NCT05926063|OTHER|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
218827000|NCT04527055|DRUG|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218827001|NCT04527055|DIETARY_SUPPLEMENT|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
218827002|NCT04527055|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218827003|NCT04527055|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218827004|NCT04527055|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218827005|NCT02234440|DRUG|Metformin|
218827006|NCT02234440|DRUG|Insulin|
218827007|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
218827008|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
218827009|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
219438105|NCT03793894|BEHAVIORAL|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
219438106|NCT03793894|BEHAVIORAL|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
218827010|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
218827011|NCT01370304|OTHER|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
218827012|NCT01370304|OTHER|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
218827013|NCT01370304|OTHER|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
218827014|NCT02797756|PROCEDURE|Esophago-gastro-duodenoscopy (EGD) with biopsy|
218827015|NCT02797756|PROCEDURE|Esophageal Impedance Monitoring (EIM)|
218827016|NCT03723980|DRUG|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
218827017|NCT03723980|DRUG|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
218827018|NCT04218812|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
218827019|NCT04218812|DIAGNOSTIC_TEST|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch."
219011200|NCT05352009|OTHER|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
219011201|NCT05352009|OTHER|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
219011202|NCT03794414|PROCEDURE|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
219011203|NCT03040466|DEVICE|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
219011204|NCT03040466|DEVICE|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
218827020|NCT05544435|BEHAVIORAL|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
218827021|NCT02745496|PROCEDURE|TRUS Biopsy|Standard of Care Treatment
218827022|NCT02745496|PROCEDURE|TRUS/FUSION Biopsy|Interventional Treatment
218827023|NCT00237237|DRUG|vildagliptin|
218827024|NCT00389753|DRUG|Application of Aruba Aloë formula F-BC-096 or control|
219011205|NCT00810290|BEHAVIORAL|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
219011206|NCT05551494|DIAGNOSTIC_TEST|Urinary sample|"At study entry, we will collect urinary samples from women. Participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).~In addition, women will be asked to report about their habits about consumption of plastic"
219011207|NCT04237090|DRUG|Diphenhydramine|Drug identification number : 02369567
219438107|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
219438108|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
219438109|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
219438110|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
219438111|NCT06441227|DRUG|HRS-5346 tablets|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
219438112|NCT06441227|DRUG|placebo|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
219438113|NCT05201404|DRUG|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
219438114|NCT05201404|DRUG|Placebo|Control arm
219438115|NCT04349800|DRUG|KVD900|Active
219580503|NCT06928181|OTHER|Blood Flow Restriction Training|BFR training involves the application of blood flow restriction during passive or active movement interventions to elicit an additional metabolic stimulus. The cuffs are applied as proximally as possible on the thigh, and a pressure is exerted during the movement that partially restricts venous return from the limb, resulting in venous pooling. Venous occlusion is achieved using a cuff system commonly employed in resistance training (Delfi Medical Innovations Inc., Vancouver, Canada; CE-certified). The pressure applied is individually determined at the start of each training session based on the participant's arterial occlusion pressure, measured via duplex ultrasonography. For this measurement, the participant rests in a supine position while the cuff is gradually inflated until no blood flow is detectable in the limb (i.e., occlusion pressure). For the BFR intervention, 60-80% of this occlusion pressure is subsequently applied. The exercise protocol consists of daily
218827025|NCT03228862|DRUG|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
218827026|NCT02491177|BEHAVIORAL|cMM|Home visits from community mentor mothers
218827027|NCT02491177|BEHAVIORAL|Text Messaging|Text messages received on mobile phone
218827028|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
218827029|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
218827030|NCT00521677|PROCEDURE|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
218827031|NCT00521677|PROCEDURE|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
218827032|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
219011208|NCT04237090|DRUG|Cetirizine|Drug identification number : 02231603
219011209|NCT04237090|DRUG|Lactose pill|Natural product number : 00501190
219011210|NCT04237090|DRUG|Sodium chloride 0.9%|Drug identification number : 00037796
219011211|NCT00517621|DRUG|Paclitaxel|
219011212|NCT00517621|DRUG|EPO|
219438116|NCT04349800|DRUG|Placebo to KVD900|Placebo
219438117|NCT02708992|DRUG|Azithromycin|
219438118|NCT02708992|DRUG|Cefixime|
219438119|NCT06092086|DRUG|Loratinib|Continuous daily PO dosing of lorlatinib 100mg QD.
219011213|NCT04983992|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
219011214|NCT00204347|DRUG|risperidone|
219011215|NCT02505620|PROCEDURE|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
219011216|NCT02505620|PROCEDURE|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
219011217|NCT02947529|DRUG|Tranexamic Acid|intravenous dose
219011218|NCT02947529|OTHER|Placebo|intravenous dose
219011219|NCT02492620|DRUG|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
219011220|NCT00294073|PROCEDURE|Fascia Iliaca Block|
219011221|NCT00294073|PROCEDURE|Femoral Block (with stimulating catheter)|
219011222|NCT00294073|PROCEDURE|Femoral Block (without stimulating catheter)|
219011223|NCT04309656|DRUG|Pretomanid|"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."
219011224|NCT01678092|BIOLOGICAL|omalizumab|
219011225|NCT02164747|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
219011226|NCT05559255|OTHER|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~1. Find the tender point.~2. Assess the tenderness using a pain scale.~3. Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~4. Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~5. Passively return the patient to a neutral position.~6. Re-test for tenderness at the tender point."
219011227|NCT03772847|DRUG|ginkgolide|ginkgolide plus alteplase
219011228|NCT04659889|DIAGNOSTIC_TEST|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
219011229|NCT03720470|DRUG|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
219011230|NCT03720470|DRUG|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
219011231|NCT03720470|DRUG|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
219011232|NCT03720470|DRUG|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
219011233|NCT03720470|DRUG|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
219011234|NCT01003509|PROCEDURE|modified shouldice and double|one arm modified shouldice, other one is double repair
219580504|NCT06928181|OTHER|Sham-BFR|Patients in the control group (CG) follow the same exercise protocol as those in the BFR intervention group; however, the cuff is only inflated to a minimal pressure of 20 mmHg. This pressure does not induce any relevant venous stasis, nor can any local or systemic metabolic effects be expected.
219580505|NCT06927271|OTHER|phone call based intervention|The phone call based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
219011235|NCT02395718|OTHER|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
219011236|NCT02395718|OTHER|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
219011237|NCT01226446|DRUG|vitamin D|Vitamin D on top of the standard treatment
219011238|NCT04464343|OTHER|no intervention|This is an observation study, with no intervention
219011239|NCT05394987|DEVICE|Spectacles|"Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study."
219011240|NCT04028596|DRUG|Paracetamol|once, 1000mg, 2 h before ECT session
219011241|NCT04028596|DRUG|Nimotop|once, 60mg, 2 h before ECT session
218827033|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
219011242|NCT06291051|DEVICE|Electrical spinal cord stimulation|electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia
219011243|NCT00453921|DRUG|Methylphenidate|Dosage dependent on weight
219011244|NCT00453921|BEHAVIORAL|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
218827034|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
218827035|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
218827036|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
218827037|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
218827038|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
218827039|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
218827040|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
219011245|NCT00453921|OTHER|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
219011246|NCT01076881|BEHAVIORAL|exercise training|
219011247|NCT00460031|DRUG|ketoconazole|400 tid
219011248|NCT00460031|DRUG|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
219580506|NCT06927271|OTHER|Video based intervention|The video based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
219011249|NCT00460031|DRUG|therapeutic hydrocortisone|20mg qam 10mg qhs
219011250|NCT00660582|DRUG|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
218827041|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
219011251|NCT00660582|DRUG|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
219011252|NCT04852458|DRUG|Intravenous (IV) hydrocortisone|"Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg."
219011253|NCT01194479|DRUG|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
219011254|NCT01194479|OTHER|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
219011255|NCT05683288|OTHER|IASTM|IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
219011256|NCT05683288|OTHER|Myofascial Release|Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
218827042|NCT05236322|DEVICE|soft tissue laser|Surgical laser used in excision purpose
218827043|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
218827044|NCT01431898|DRUG|GS-9669 tablets|
218827045|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
219011257|NCT05683288|OTHER|250W infrared application|For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
219011258|NCT05683288|DEVICE|TENS|TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
219011259|NCT05683288|OTHER|Home exercise|Cervical strengthening and stretching exercises five days a week will given
219011260|NCT05547074|PROCEDURE|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
219011261|NCT02450032|BIOLOGICAL|G17DT|
219011262|NCT04588402|BIOLOGICAL|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
219011263|NCT03860428|DRUG|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
219011264|NCT03860428|DRUG|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
219011265|NCT03860428|OTHER|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
219011266|NCT03893136|BIOLOGICAL|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
219580507|NCT06927271|OTHER|Usual Care|The usual care concerns the care the participants receive from the health facility. Participants in this group would neither receive the phonecall or video based interventions.
218827046|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
218827047|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
218827048|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
218827049|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
218827050|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
218827051|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
219763703|NCT04073225|DEVICE|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
219763704|NCT04073225|BEHAVIORAL|10 Keys to Healthy Aging|"The 10 Keys™ to Healthy Aging Program in an evidence-based program that originated from the University of Pittsburgh Center for Aging and Population Health. This educates and empowers older adults to reach personal goals and help others to so in the community as well. It is designed to teach older adults how to reduce the risk of disease over the aging process by promoting healthy lifestyle changes with the most recent established scientific guidelines. The 10 Keys program also aims to empower individuals to be health ambassadors in the individual's own families and communities, teaching individuals to 'Share the Wealth on Health'. Participants will work towards personal health goal(s) adapted to the participant's lifestyle and abilities."
219763705|NCT05827081|DRUG|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
219763706|NCT05827081|DRUG|Letrozole|Letrozole 2.5 mg orally once daily continuously
219763707|NCT05827081|DRUG|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
218827052|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
218827053|NCT01261364|BEHAVIORAL|GeneSightRx|Multi-genetic pharmacogenomic panel
218827054|NCT01261364|BEHAVIORAL|Treatment as usual|Treatment as usual
218827055|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
218827056|NCT01065025|DRUG|4SC-205|Repeated ascending oral doses of 4SC-205.
218827057|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
218827058|NCT02385006|BIOLOGICAL|Blood sample|
218827059|NCT00412581|DRUG|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
218827060|NCT00412581|DRUG|Dacarbazine|600 mg/m\^2 intravenously on Day 1 of every study cycle.
218827061|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
219011267|NCT03893136|DRUG|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
219011268|NCT02604524|DEVICE|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
219011269|NCT02604524|OTHER|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
218827062|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
218827063|NCT05040646|OTHER|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
218827064|NCT03110484|DRUG|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
218827065|NCT03110484|DRUG|Erlotinib|Erlotinib 100mg once daily
218827066|NCT03389308|DRUG|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
218827067|NCT03100448|DEVICE|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
219011270|NCT03034421|BEHAVIORAL|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
219438120|NCT05229640|DEVICE|Fibroscan|Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
218827068|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
218827069|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
218827070|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
218827071|NCT01059006|PROCEDURE|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
218827072|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
218827073|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
218827074|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
218827075|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
218827076|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
218827077|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
218827078|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
218827079|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
218827080|NCT01952743|PROCEDURE|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
218827081|NCT01952743|PROCEDURE|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
218827082|NCT00570323|DRUG|Arimidex|Aromatase inhibitors
218827083|NCT00570323|DRUG|Faslodex|Hormone Receptor
218827084|NCT04636567|DRUG|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
218827085|NCT03067792|DRUG|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
218827086|NCT03067792|DRUG|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
218827087|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
218827088|NCT05734664|DEVICE|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
218827089|NCT05734664|DEVICE|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
218827090|NCT05502003|OTHER|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
219011271|NCT03380585|PROCEDURE|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
218827091|NCT05502003|OTHER|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
218827092|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
218827093|NCT04702386|BEHAVIORAL|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
218827094|NCT04702386|BEHAVIORAL|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
219011272|NCT03380585|PROCEDURE|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
219763708|NCT05827081|DRUG|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
219011273|NCT02607436|DRUG|Sarpogrelate|Sarpogrelate
219011274|NCT02607436|DRUG|Aspirin|Aspirin
219763709|NCT05827081|DRUG|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
219763710|NCT05827081|DRUG|Exemestane|Exemestane 25 mg once daily continuously
218827095|NCT01379807|DRUG|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
218827096|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
219011275|NCT05217407|OTHER|Genomic sequence|Genomic sequence
219763711|NCT04811560|DRUG|Bleximenib|Bleximenib is administered orally.
219763712|NCT05240898|DRUG|RO7623066|Administered orally in capsule
218827097|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
218827098|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
218827099|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
218827100|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
218827101|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
218827102|NCT05976659|DEVICE|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
218827103|NCT00435630|OTHER|LapSim training|complete curriculum training on LapSim surgical simulator
218827104|NCT03101319|DRUG|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
218827105|NCT03101319|DRUG|B Complex Oral Tablet|As mentioned in the description of the study arm
218827106|NCT00484341|DRUG|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
218827107|NCT00484341|DRUG|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
218827108|NCT00484341|DRUG|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
218827109|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
218827110|NCT02575443|DRUG|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
218827111|NCT02575443|DRUG|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
219011276|NCT05667922|DRUG|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
219763713|NCT05240898|DRUG|Olaparib|"Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts."
219763714|NCT05240898|DRUG|Carboplatin|Administered intravenously.
219763715|NCT04442451|OTHER|Control Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
218827112|NCT00000226|DRUG|Buprenorphine|
218827113|NCT04164810|OTHER|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
218827114|NCT04164810|OTHER|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
218827115|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
218827116|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
218827117|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
218827118|NCT00484783|PROCEDURE|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
218827119|NCT00484783|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
218827120|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
219011277|NCT02106728|BEHAVIORAL|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
219011278|NCT02106728|BEHAVIORAL|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
219438121|NCT04484506|DRUG|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
219195810|NCT06756243|OTHER|Hydrogen Ion Water（Shan Shang Water）|Hydrogen Ion Water (also known as Hydrogen-Rich Water or Hydrogen Water) refers to water that contains dissolved hydrogen gas (H₂). Hydrogen gas is a powerful antioxidant that is believed to neutralize free radicals in the body, which may help reduce oxidative stress and improve overall health.
218827121|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
219763716|NCT04442451|OTHER|Blood Flow Restriction Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
219763717|NCT06976372|DRUG|AMG 133|AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.
218827122|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
218827123|NCT02448134|BEHAVIORAL|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
218827124|NCT06260605|OTHER|Education|Nursing students learning about diabetes complications
218827125|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
218827126|NCT01623505|DRUG|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
218827127|NCT01623505|DRUG|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter."
218827128|NCT01623505|DRUG|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
218827129|NCT00267306|DRUG|Visilizumab|
218827130|NCT00871663|DRUG|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
219011279|NCT06609902|BEHAVIORAL|Future Self-BD|The Future Self group will attend 6 virtual sessions during which they will be encouraged to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. All participants will complete the adjusting amount discounting task. All participants will also receive brief, CBT-based smoking cessation counseling. This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
219011280|NCT06609902|BEHAVIORAL|Daily Check-Ins|The Daily Check-Ins (DCI) group will attend 6 virtual sessions during which they will complete the adjusting amount discounting task and receive brief, CBT-based smoking cessation counseling (consistent with counseling received by Future Self-BD). This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
219195811|NCT06756243|DRUG|Budesonide Nasal Spray therapy|Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).
219195812|NCT06821659|BIOLOGICAL|anti-CD19 CAR-T cells|UWD-CD19
219195813|NCT04844294|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
219763718|NCT06975371|OTHER|No drug|No study drug was administered in this non-interventional study.
219763719|NCT06971744|DRUG|Hydroxychloroquine|3 x 200 milligram tablets twice daily
219763720|NCT06971744|DRUG|Nelfinavir|2x 625 milligram tablets twice daily
219763721|NCT06971744|DRUG|Bevacizumab|IV 15 milligram/kilogram every 3 weeks
219763722|NCT06972407|BIOLOGICAL|Exendin 9-39|A competitive antagonist of the GLP-1 receptor
219438122|NCT02969694|OTHER|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
219438123|NCT01116310|DRUG|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
219438124|NCT01116310|DRUG|Placebo|Bottles containing 60 capsules.
219438125|NCT02744560|DIETARY_SUPPLEMENT|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
219438126|NCT00185536|BEHAVIORAL|Packaging and identification of source|
219580508|NCT06928636|BEHAVIORAL|Supper Heroes online environmentally friendly eating intervention for families|Families randomized to the intervention group will complete a 7-week Supper Heroes program that includes activities focused on making more meals at home, reducing food waste, and eating more plant-based foods.
219580509|NCT06928636|BEHAVIORAL|Monthly emails about environmentally friendly habits|Families randomized to the control group will receive monthly emails for 6 months about environmentally friendly habits.
219580510|NCT06929013|BIOLOGICAL|Blood sampling|Inclusion (baseline): 28 mL Incision (surgery): 18 mL End surgery: 18 mL H+12 after end surgery: 18 mL H+4 after end surgery: 18 mL H+48 after end surgery: 18 mL H+72 after end surgery: 18 mL D+7 after end surgery: 18 mL D+14 after surgery: 18 mL 4 to 6 weeks after surgery:28 mL
219763723|NCT06972407|OTHER|Saline|Saline infusion will serve as an inactive comparator
219763724|NCT06460506|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
219763725|NCT06460506|DRUG|IVA|Granules for oral administration
218827131|NCT02930707|DRUG|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
218827132|NCT02930707|DRUG|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
218827133|NCT03001661|DEVICE|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
218827134|NCT03001661|DRUG|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
218827135|NCT00017069|DRUG|arsenic trioxide|
218827136|NCT00017069|DRUG|dexamethasone|
218827137|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
218827138|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
218827139|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
218827140|NCT06426446|DEVICE|Withings Body Comp Pro|Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
219011281|NCT05488431|DRUG|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in \>4300 individuals and is currently being studied in \>14,000 individuals in CLEAR Outcomes (NCT02993406).
219011282|NCT05488431|OTHER|Placebo|Placebo
219011283|NCT00176826|PROCEDURE|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
219011284|NCT00176826|DRUG|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
219011285|NCT03731884|OTHER|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
219011286|NCT01012856|BEHAVIORAL|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
219438127|NCT06148649|DRUG|HEC88473, Placebo, Dulaglutide|T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
219438128|NCT01461798|DIETARY_SUPPLEMENT|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
219438129|NCT01461798|DIETARY_SUPPLEMENT|Placebo Yogurt|Yogurt without the active principle
219438130|NCT01461798|DIETARY_SUPPLEMENT|yogurt|yogurt without plant stanols
219580511|NCT02287129|DRUG|Oxaliplatin|130 mg/m2
219580512|NCT02287129|DRUG|Epirubicin|50 mg/m2
219580513|NCT02287129|DRUG|Capecitabine|625 mg/m2
219580514|NCT02287129|DRUG|5-FU|200 mg/m2
219580515|NCT02287129|DRUG|Carboplatin|2 mg/ml min
219580516|NCT02287129|DRUG|Paclitaxel|50 mg/m2
219580517|NCT02287129|RADIATION|radiation|total dosage 41,4 Gy
219580518|NCT02287129|PROCEDURE|Biopsy|translational analysis
219438131|NCT05145673|OTHER|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
218827141|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
218827142|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
218827143|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
218827144|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
218827145|NCT02229786|DRUG|Buscopan® plus|
218827146|NCT02229786|DRUG|Buscopan®|
218827147|NCT02229786|DRUG|Paracetamol|
218827148|NCT02229786|DRUG|Placebo|
218827149|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
218827150|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
218827151|NCT02607124|DRUG|Ribociclib|
218827152|NCT03974074|DRUG|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
218827153|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
218827154|NCT01616277|BIOLOGICAL|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
218827155|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
218827156|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
218827157|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
218827158|NCT01616277|BIOLOGICAL|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
218827159|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
218827160|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
218827161|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
218827162|NCT01616277|BIOLOGICAL|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
218827163|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
218827164|NCT01616277|BIOLOGICAL|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
218827165|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
218827166|NCT01616277|BIOLOGICAL|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
218827167|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
218827168|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
219011287|NCT01012856|BEHAVIORAL|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
219011288|NCT05243225|PROCEDURE|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
219011289|NCT06131008|DIAGNOSTIC_TEST|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
219011290|NCT06131008|BEHAVIORAL|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
219011291|NCT06131008|BEHAVIORAL|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
218827169|NCT03842046|PROCEDURE|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
218827170|NCT03842046|PROCEDURE|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
218827171|NCT01791517|OTHER|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
218827172|NCT01791517|OTHER|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
218827173|NCT01791517|OTHER|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
218827174|NCT01791517|OTHER|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
219011292|NCT02428946|DRUG|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
219011293|NCT00471744|DRUG|Treatment with levetiracetam or sulthiame over a six-month period.|
219011294|NCT03664557|DEVICE|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
219011295|NCT06220422|PROCEDURE|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
218827175|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
218827176|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
218827177|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
218827178|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
218827179|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
218827180|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
218827181|NCT02298868|DRUG|Baclofen|
218827182|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
218827183|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
219011296|NCT06220422|PROCEDURE|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
219011297|NCT05953246|BEHAVIORAL|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
219011298|NCT05953246|BEHAVIORAL|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
219011299|NCT05953246|BEHAVIORAL|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
219011300|NCT05953246|BEHAVIORAL|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
219195814|NCT04844294|BEHAVIORAL|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
218827184|NCT01000506|BIOLOGICAL|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
218827185|NCT01000506|BIOLOGICAL|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
218827186|NCT01000506|BIOLOGICAL|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
218827187|NCT01000506|DRUG|Placebo saline|Placebo saline every four weeks by i.v.
218827188|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
219011301|NCT05953246|BEHAVIORAL|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
219011302|NCT03941431|DRUG|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
219011303|NCT03941431|DEVICE|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
219011304|NCT03941431|DEVICE|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
219011305|NCT03941431|DRUG|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
219011306|NCT03941431|DEVICE|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
219011307|NCT03941431|DEVICE|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
218827189|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
218827190|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
218827191|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
219011308|NCT03742154|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
219011309|NCT03779464|DRUG|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
219011310|NCT02354989|DEVICE|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
218827192|NCT00463086|DRUG|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
218827193|NCT00463086|DRUG|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
218827194|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
218827195|NCT02255929|RADIATION|Gamma Knife Radiosurgery|
218827196|NCT00905190|DRUG|Ondansetron|24 mg one time
218827197|NCT02994966|DEVICE|Surrosense|
218827198|NCT02994966|OTHER|Standard care|
218827199|NCT03116425|DEVICE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
218827200|NCT03116425|DEVICE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
218827201|NCT03116425|DEVICE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
218827202|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
218827203|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
219011311|NCT02354989|DEVICE|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
219011312|NCT00231595|DRUG|topiramate|
219011313|NCT03491241|DIETARY_SUPPLEMENT|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
218827204|NCT03116425|PROCEDURE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
219011314|NCT04688710|BEHAVIORAL|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed …) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
219195815|NCT06245135|BEHAVIORAL|TIME at Home|"Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators."
219011315|NCT04688710|BEHAVIORAL|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
219011316|NCT04766125|BEHAVIORAL|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
219011317|NCT02011737|DRUG|naftopidil 75mg|
219011318|NCT05670990|OTHER|Equine assisted therapy|"A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group."
219011319|NCT05309564|DRUG|Botulinum toxin type A|Single intervention
219195816|NCT03406351|OTHER|Observational|Observational deep phenotyping physiological readouts
218827205|NCT03149146|OTHER|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
218827206|NCT03149146|OTHER|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
218827207|NCT03577262|OTHER|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
218827208|NCT01336244|DRUG|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
218827209|NCT01336244|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
218827210|NCT00568594|DRUG|APL180|
218827211|NCT00568594|DRUG|Placebo|
218827212|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
218827213|NCT00451399|DRUG|metformin|
218827214|NCT00451399|BEHAVIORAL|lifestyle intervention|
218827215|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
218827216|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
218827217|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
218827218|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
218827219|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
218827220|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
218827221|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
219011320|NCT04210310|DRUG|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
219011321|NCT04210310|OTHER|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
219011322|NCT03894579|BIOLOGICAL|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
219438132|NCT05145673|OTHER|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
218827222|NCT01419496|GENETIC|protein expression analysis|
218827223|NCT01419496|OTHER|flow cytometry|
219011323|NCT00063973|DRUG|cilengitide|Given IV
219011324|NCT00063973|OTHER|laboratory biomarker analysis|Correlative studies
218827224|NCT01419496|OTHER|laboratory biomarker analysis|
218827225|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
218827226|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
218827227|NCT02622477|DRUG|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
218827228|NCT06311591|DEVICE|Jaspr App|Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
218827229|NCT01071954|BIOLOGICAL|Romiplostim|Administered by subcutaneous injection once a week.
218827230|NCT05070130|DEVICE|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
218827231|NCT03156218|DRUG|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
218827232|NCT02814188|OTHER|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
218827233|NCT02814188|OTHER|Placebo Beverage|750 ml of an artificially-sweetened beverage
218827234|NCT00590967|RADIATION|IMRT extended field external beam radiation therapy|
218827235|NCT00590967|RADIATION|Brachytherapy|
218827236|NCT00590967|DRUG|Cisplatin|
218827237|NCT00664482|BIOLOGICAL|AGS-006|Autologous Therapy for Pancreatic Cancer
219763726|NCT06649084|BEHAVIORAL|Multicomponent Lexical Retrieval Training (Multi-LRT)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing names of personally relevant target in multiple communication modalities. Treatment focuses on the use of strategies which capitalize on residual linguistic ability and autobiographical memory to support word retrieval. The participant completes two one-hour-long sessions per week plus daily homework. The participant also meets 4 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
219763727|NCT06649084|BEHAVIORAL|Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing personally relevant scripts of 3-5 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician are held which target clear and accurate script production, script memorization, and conversational usage of the script and multimodal communication. The participant also meets 6 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
219763728|NCT06649084|BEHAVIORAL|Multicomponent Communication Partner Training (Multi-CPT)|In person or via teletherapy: A multi-component treatment incorporating elements of compensatory and care-partner focused interventions. Biweekly (one hour each) sessions with a clinician are held which target use of communication strategies including multimodal communication for the participant and study partner (e.g., spouse). The participant also completes regular assignments meant to increase generalization of communication strategies and progress on personal goals.
219763729|NCT06730009|BIOLOGICAL|SLOG + Allogeneic NK cell|"Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD."
219763730|NCT06730009|DRUG|SLOG chemotherapy|Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
219763731|NCT06575075|DRUG|RR-HNK/Hydroxynorketamine|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.
219763732|NCT06575075|DRUG|Placebo|Sterile Saline
219763733|NCT01858896|DRUG|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
219763734|NCT01858896|OTHER|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
219763735|NCT06337318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763736|NCT06337318|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
219763737|NCT06337318|BIOLOGICAL|Mosunetuzumab|Given SC
219763738|NCT06337318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219763739|NCT06337318|BIOLOGICAL|Rituximab|Given IV
219763740|NCT06337318|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219763741|NCT05638295|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218827238|NCT05228405|OTHER|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
218827239|NCT02045784|DIETARY_SUPPLEMENT|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
218827240|NCT02045784|OTHER|Breast milk|Unlimited breast feeding
218827241|NCT06181981|DIAGNOSTIC_TEST|MRI fingerprinting|This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition
218827242|NCT00265915|BIOLOGICAL|rituximab|
218827243|NCT00265915|BIOLOGICAL|sargramostim|
218827244|NCT01685814|DRUG|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
218827245|NCT01685814|BIOLOGICAL|autologous stem cell transplant|
219363710|NCT03308864|BEHAVIORAL|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
219763742|NCT05638295|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219763743|NCT05638295|PROCEDURE|Computed Tomography|Undergo CT scan
219763744|NCT05638295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763745|NCT05638295|BIOLOGICAL|Panitumumab|Given IV
219763746|NCT05638295|DRUG|Sotorasib|Given PO
219763747|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
218827246|NCT01685814|BIOLOGICAL|allogeneic stem cell transplant|
219363711|NCT00055952|DRUG|exatecan mesylate|
219763748|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
218827247|NCT03538093|OTHER|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
218827248|NCT03538093|OTHER|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
218827249|NCT03538093|OTHER|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
218827250|NCT03847831|BEHAVIORAL|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
218827251|NCT01847755|DRUG|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
218827252|NCT03479489|OTHER|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
218827253|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
218827254|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
218827255|NCT02565992|BIOLOGICAL|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
218827256|NCT02565992|DRUG|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
218827257|NCT00509327|DRUG|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
218827258|NCT00509327|DRUG|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
218827259|NCT02961036|OTHER|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
218827260|NCT02961036|OTHER|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
219011325|NCT06193369|BEHAVIORAL|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
219363712|NCT03653598|OTHER|Atrial Fibrillation|Data collection on Atrial Fibrillation
219438133|NCT03008187|DRUG|MEN1703|MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
219438134|NCT00500838|DEVICE|Transthoracic Impedance|Impedance measures will be automatically collected via the device
219363713|NCT04000802|BEHAVIORAL|response to questionnary|No intervention. Observational study
219363714|NCT00617877|DRUG|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
219363715|NCT00617877|DRUG|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
219363716|NCT04301141|OTHER|Virtual Reality Assisted Cognitive Behavioural Therapy|The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
218827261|NCT02961036|OTHER|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
218827262|NCT02961036|OTHER|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
218827263|NCT02961036|OTHER|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
218827264|NCT02961036|OTHER|Group A Reminder|One survey reminder at 14 days
218827265|NCT02961036|OTHER|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
218827266|NCT00920556|DRUG|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
218827267|NCT00920556|DRUG|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
218827268|NCT04038294|DIETARY_SUPPLEMENT|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
218827269|NCT04038294|DIETARY_SUPPLEMENT|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
218827270|NCT01746290|OTHER|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
218827271|NCT04138095|DEVICE|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
218827272|NCT00403143|PROCEDURE|cataract surgery|
218827273|NCT05908838|DRUG|Modified Banxia Xiexin Decoction|The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
218827274|NCT05908838|DRUG|combination chemotherapy with Placebo granules|combination chemotherapy with Placebo granules
219011326|NCT01450839|DRUG|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
219580519|NCT06296654|BEHAVIORAL|Empowerment-Based Interventions|The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
218827275|NCT02516501|DIETARY_SUPPLEMENT|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
218827276|NCT02516501|DIETARY_SUPPLEMENT|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
218827277|NCT02516501|RADIATION|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
218827278|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
219011327|NCT01450839|DRUG|Placebo|Matching Placebo tablets and tape
219011328|NCT01065233|GENETIC|DNA extraction|DNA extraction of blood sample for DNAship analysis
219011329|NCT03438812|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
219011330|NCT00164190|PROCEDURE|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
219011331|NCT05544240|DRUG|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
219011332|NCT03447132|DRUG|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
219011333|NCT03447132|DRUG|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
219011334|NCT03447132|DRUG|Goserelin 3.6 MG|Only for pre or peri menopausal patient
219011335|NCT03447132|DRUG|Placebos|Placebo
219580520|NCT06296654|BEHAVIORAL|Standard Health Education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
219580521|NCT01769339|DRUG|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
218827279|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
219438135|NCT03805971|DEVICE|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
219438136|NCT04128605|PROCEDURE|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
219438137|NCT04128605|PROCEDURE|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
218827280|NCT00889707|DRUG|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
218827281|NCT00889707|DRUG|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
218827282|NCT03729843|RADIATION|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
218827283|NCT02185534|DRUG|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
218827284|NCT05330871|BIOLOGICAL|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827285|NCT05330871|BIOLOGICAL|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827286|NCT05330871|BIOLOGICAL|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827287|NCT05330871|BIOLOGICAL|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827288|NCT05330871|BIOLOGICAL|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827289|NCT05330871|BIOLOGICAL|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827290|NCT05330871|BIOLOGICAL|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827291|NCT05330871|BIOLOGICAL|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
218827292|NCT05330871|BIOLOGICAL|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
218827293|NCT05330871|BIOLOGICAL|10 Intramuscular injection for booster groups|1 dose 0.5ml
218827294|NCT05330871|BIOLOGICAL|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827295|NCT05330871|BIOLOGICAL|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827296|NCT05330871|BIOLOGICAL|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827297|NCT05330871|BIOLOGICAL|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
218827298|NCT05330871|BIOLOGICAL|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827299|NCT05330871|BIOLOGICAL|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827300|NCT05330871|BIOLOGICAL|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
218827301|NCT05330871|BIOLOGICAL|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
218827302|NCT05330871|BIOLOGICAL|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
218827303|NCT05330871|BIOLOGICAL|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
218827304|NCT05330871|BIOLOGICAL|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
218827305|NCT05330871|BIOLOGICAL|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
218827306|NCT05330871|BIOLOGICAL|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
218827307|NCT05330871|BIOLOGICAL|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
219011336|NCT04006197|OTHER|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
219011337|NCT01554150|BEHAVIORAL|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
219011338|NCT03950648|BEHAVIORAL|Spatial Cognitive Training|map reading and route-learning skills
219011339|NCT00530764|DRUG|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
218827308|NCT04236271|DEVICE|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
218827309|NCT00175929|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
218827310|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
218827311|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
219438138|NCT05543824|DRUG|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
219011340|NCT00530764|DRUG|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
219011341|NCT00530764|DRUG|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
219011342|NCT00007657|PROCEDURE|Intensive medical therapy|
219011343|NCT00007657|PROCEDURE|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
219011344|NCT03929575|DIETARY_SUPPLEMENT|Placebo of calcium|Ingestion of 250 mg of calcium
219011345|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola|Ingestion of 250 mg of Rhodiola
219011346|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
219011347|NCT01180491|DEVICE|K101 nail solution|
219011348|NCT02408458|DEVICE|MIROMESH®|
219011349|NCT05255406|DRUG|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
219011350|NCT04205071|DRUG|Lorcaserin|Given PO
219011351|NCT04205071|DRUG|Lorcaserin Hydrochloride|Given PO
219011352|NCT04205071|OTHER|Questionnaire Administration|Ancillary studies
219011353|NCT04053205|DRUG|Gentuximab|Administered intravenously (IV)
219011354|NCT04053205|DRUG|Paclitaxel|Administered intravenously (IV)
219011355|NCT01020851|BEHAVIORAL|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
219011356|NCT01020851|BEHAVIORAL|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
219011357|NCT03578601|OTHER|Thyroid surgery|Patient undergoing thyroid surgery
218827312|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
218827313|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
219011358|NCT02630498|PROCEDURE|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
219011359|NCT05392998|DEVICE|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
219011360|NCT00149084|DRUG|Lansoprazole, clarithromycin, amoxicillin|
219011361|NCT05909098|COMBINATION_PRODUCT|autologous NK cell|autologous NK cell
219011362|NCT00875225|BEHAVIORAL|DVD|Control group will receive usual care DVD from health professionals
219011363|NCT00875225|BEHAVIORAL|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
219011364|NCT05633121|PROCEDURE|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
219011365|NCT04925128|OTHER|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
219011366|NCT04925128|OTHER|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
219011367|NCT00467259|DRUG|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
219438139|NCT03507881|DEVICE|fusion|Internal fixation
219011368|NCT00467259|DRUG|Placebo patch|placebo patch, changed twice a week for 52 weeks
218827314|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
218827315|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
218827316|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
218827317|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
218827318|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
218827319|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
218827320|NCT00198328|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
218827321|NCT00198328|PROCEDURE|Surgical Excision|Patients have their tumor surgically removed.
219011369|NCT04694144|DEVICE|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
219011370|NCT03655197|DRUG|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
219011371|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
219011372|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
219011373|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
219011374|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
219438140|NCT03012594|DRUG|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
219438141|NCT03962634|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
218827322|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
218827323|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
218827324|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
218827325|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
218827326|NCT03762161|DRUG|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
218827327|NCT02213068|DRUG|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
218827328|NCT02213068|DRUG|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
218827329|NCT02213068|DRUG|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
218827330|NCT02067143|DRUG|Prephase PDN + CY|
218827331|NCT02067143|DRUG|Cycle 1 Induction|
218827332|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
218827333|NCT02067143|DRUG|Cycle 3 Early consolidation|
218827334|NCT02067143|DRUG|Cycle 4 Consolidation|
218827335|NCT02067143|DRUG|Cycle 5 Consolidation|
218827336|NCT02067143|DRUG|Cycle 6 Consolidation|
218827337|NCT02067143|DRUG|Cycle 7 Consolidation|
218827338|NCT02067143|DRUG|Cycle 8 Reinduction|
218827339|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
218827340|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
219011375|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
219011376|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
219438142|NCT03962634|DRUG|Articaine Injection|Local anesthetic
219438143|NCT02542670|GENETIC|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
219438144|NCT02264015|DRUG|Cilobradine, low, film-coated tablets|
218827341|NCT02797912|OTHER|No intervention|
218827342|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
218827343|NCT02041299|DRUG|Deferiprone|
218827344|NCT02041299|DRUG|Deferoxamine|
218827345|NCT02034643|PROCEDURE|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
218827346|NCT05159258|OTHER||
218827347|NCT03123770|DRUG|Pegylated liposomal doxorubicin|a new kind of doxorubicin
218827348|NCT03123770|DRUG|Cyclophosphamide|traditional chemotherapy drug
218827349|NCT03123770|DRUG|Epirubicin|traditional chemotherapy drug used in breast cancer
218827350|NCT03123770|DRUG|Docetaxel|traditional chemotherapy drug used in breast cancer
218827351|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
219438145|NCT02264015|DRUG|Cilobradine, high, film-coated tablets|
219438146|NCT02264015|DRUG|Placebo, film-coated tablets|
219438147|NCT02264015|DRUG|Moxifloxacin, film-coated tablets|
219438148|NCT00517413|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
219438149|NCT00442949|PROCEDURE|Catheterization immediate PCI|Catheterization immediate PCI
219438150|NCT00442949|PROCEDURE|delayed PCI|delayed PCI
219438151|NCT02866461|OTHER|No treatment|Observation
219438152|NCT06180733|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
218827352|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
218827353|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
218827354|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
218827355|NCT06073197|PROCEDURE|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
218827356|NCT06073197|PROCEDURE|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
218827357|NCT06287372|OTHER|Cardioplegic solution|Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
218827358|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
218827359|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
218827360|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
218827361|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
218827362|NCT03667989|DIAGNOSTIC_TEST|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
218827363|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
218827364|NCT02076854|BEHAVIORAL|Text-Message Intervention|
218827365|NCT00457678|DRUG|Visudyne|
218827366|NCT00457678|DRUG|Lucentis|
218827367|NCT00457678|DRUG|Dexamethasone|
218827368|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
218827369|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
218827370|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
218827371|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
218827372|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
218827373|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
218827374|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
218827375|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
218827376|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
218827377|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
218827378|NCT03800277|DIETARY_SUPPLEMENT|Cranberry|Supplementation of polyphenols from cranberry extract
219580522|NCT03801538|DRUG|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
218827379|NCT03800277|DIETARY_SUPPLEMENT|Agaves|Supplementation of inulin from Agaves powder
218827380|NCT03800277|DIETARY_SUPPLEMENT|Placebo|Supplementation with placebo
218827381|NCT00530634|DRUG|cisplatin|
218827382|NCT00530634|DRUG|gemcitabine hydrochloride|
218827383|NCT00530634|GENETIC|gene expression analysis|
218827384|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
218827385|NCT00530634|OTHER|immunohistochemistry staining method|
218827386|NCT00530634|PROCEDURE|adjuvant therapy|
218827387|NCT00530634|PROCEDURE|conventional surgery|
218827388|NCT00530634|RADIATION|radiation therapy|
218827389|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
218827390|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
218827391|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
219011377|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
218827392|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
218827393|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
218827394|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
218827395|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
218827396|NCT00872274|DRUG|sumatriptan 100mg|
218827397|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
218827398|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
218827399|NCT02822742|DRUG|DE-117 ophthalmic solution|
218827400|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
218827401|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
218827402|NCT02945163|DRUG|Lamivudine|Lamivudine
218827403|NCT02945163|DRUG|Efavirenz|Efavirenz
218827404|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
219011378|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
219580523|NCT03801538|DRUG|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
218827405|NCT01366573|DRUG|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
219011379|NCT04885972|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
219580524|NCT06919796|BIOLOGICAL|COMIRNATY®|COVID-19 Vaccine, mRNA suspension
218827406|NCT01366573|OTHER|Placebo|Placebo
218827407|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
218827408|NCT00757952|OTHER|chromatography|
218827409|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
218827410|NCT00757952|OTHER|questionnaire administration|
218827411|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
218827412|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
218827413|NCT06292377|DIAGNOSTIC_TEST|ECG|An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
218827414|NCT06292377|DIAGNOSTIC_TEST|Transthoracic echography (TTE)|A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
218827415|NCT06292377|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
218827416|NCT02824523|DRUG|aspirin|
218827417|NCT01715363|DRUG|Oxaliplatin|
218827418|NCT01715363|DRUG|Folinic Acid|
218827419|NCT01715363|DRUG|Fluorouracile|
218827420|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
218827421|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
218827422|NCT06172816|OTHER|SARS-CoV-2|a virus infection
219011380|NCT04885972|DRUG|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
219011381|NCT04885972|DRUG|Placebo|Vehicle solution
218827423|NCT04718740|DRUG|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
218827424|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
218827425|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
218827426|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
218827427|NCT04179305|BEHAVIORAL|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
218827428|NCT04179305|BEHAVIORAL|Usual Care Arm|Oncologists will provide care in non-specific manner.
218827429|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
218827430|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
218827431|NCT02501681|OTHER|priming solution during cardiovascular surgery|
218827432|NCT04680624|PROCEDURE|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
218827433|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
219580525|NCT06926725|DEVICE|Cavitation : Study group A only will receive one session per week for three months (total 12 sessions ). Ultrasound treatments are performed using an applicator head with diameter 7 cm . Intensity :|"Cavitation :~Study group A only will receive one session per week for three months (total 12 sessions ).~Ultrasound treatments are performed using an applicator head with diameter 7 cm .~Intensity : 0.1-0.5 w/cm2 (low) Frequency : 30-40 KHZ (low) Duration : 30 minutes"
218827434|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
218827435|NCT00004744|DRUG|immune globulin|
218827436|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
218827437|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
218827438|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
218827439|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
218827440|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
218827441|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
218827442|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
218827443|NCT05424965|OTHER|no intervention|no intervention
218827444|NCT02122497|PROCEDURE|abdominal aortic surgery|
218827445|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
218827446|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
218827447|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
218827448|NCT02705612|DRUG|Cisplatin|
218827449|NCT02705612|RADIATION|External Beam Radiation Therapy|
218827450|NCT02705612|RADIATION|Internal Radiation Therapy|
218827451|NCT02705612|DRUG|nimotuzumab|
218827452|NCT01214473|DIETARY_SUPPLEMENT|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
218827453|NCT01214473|DIETARY_SUPPLEMENT|Maltodextrin|Only maltodextrin as placebo
218827454|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
219011382|NCT04600674|PROCEDURE|Delayed cord clamping|DCC performed at 60 sec after birth
219011383|NCT04600674|PROCEDURE|Early cord clamping|ECC performed at 15 sec after birth
219011384|NCT04357678|OTHER|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
219438153|NCT05194605|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
218827455|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
219438154|NCT02939313|DEVICE|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
219438155|NCT02939313|DEVICE|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
219438156|NCT02939313|DEVICE|sham|sham stimulation
219438157|NCT02768389|DRUG|Bevacizumab|Subjects receive Bevacizumab as standard of care
219580526|NCT06926725|OTHER|high intenisty exercise|"type: alternate high intensity exercise (aerobic or strength training) with recovery stages Intensity: high intensity (75%-95% HRmax) or RPE(14-16 hard to very hard ) ( according to patient tolerance), followed by active or passive recovery stage (30%-60% HRmax) or RPE(7-11 extremely light to light) .~frequency : 3 days per week for three months (with no more than 2 consecutive days between sessions) Duration: 10 seconds to 4 minutes high intensity ,12 seconds to 5 minutes active or passive recovery .(according to patient tolerance) 5 minutes warm up pre exercise . 5 minutes cool down post exercise . Progress gradually. total duration :20-40 minutes (according to patient tolerance and progression)"
219011385|NCT04357678|OTHER|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
219011386|NCT01150981|DRUG|Rosiglitazone|One 8mg capsule daily for 6 weeks.
219011387|NCT01150981|DRUG|Placebo|One capsule daily for 6 weeks.
219580527|NCT06926725|DIETARY_SUPPLEMENT|Diet|In all groups (both study groups A\&B and control group).
219011388|NCT03019133|DEVICE|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
218827456|NCT05246878|DRUG|EDP-235|Oral administration
218827457|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
218827458|NCT00326599|DRUG|carboplatin|Given IV
219011389|NCT03019133|DEVICE|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
219011390|NCT00563979|DIETARY_SUPPLEMENT|VitaluxPlus®|1 tablet daily
219011391|NCT00563979|DIETARY_SUPPLEMENT|Omega 3|1 tablet daily
219011392|NCT02010554|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
219011393|NCT02010554|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
219438158|NCT02768389|BEHAVIORAL|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
219438159|NCT05573568|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
219438160|NCT00784706|OTHER|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
219438161|NCT00784706|OTHER|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
219438162|NCT00784706|OTHER|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
219438163|NCT01510028|BIOLOGICAL|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
219438164|NCT00837239|DRUG|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
219438165|NCT00837239|DRUG|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
219438166|NCT00837239|DRUG|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
219438167|NCT01355497|DRUG|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
219580528|NCT06927414|DEVICE|Functional lens|Diffractive Optical Element, D.O.E, technology for controlling myopia progression in children and adolescents. and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
219438168|NCT01355497|DRUG|placebo|subject will receive matching placebo for the duration of the trial
219438169|NCT02321397|DRUG|Oxycodone|
219438170|NCT02321397|DRUG|Naloxone|Prolonged Release Tablets
219438171|NCT01502761|DRUG|Magnesium Sulfate|Intra-arterial
219011394|NCT04285879|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
219438172|NCT01384188|DRUG|ONO-5334|150 mg for 5 days administered in the morning or in the evening
218827459|NCT00326599|DRUG|cediranib maleate|Given orally
218827460|NCT00326599|DRUG|gemcitabine hydrochloride|Given IV
218827461|NCT02370472|OTHER|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
218827462|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
218827463|NCT05508646|BEHAVIORAL|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
218827464|NCT05508646|BEHAVIORAL|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
218827465|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
218827466|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
218827467|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
218827468|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
218827469|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
218827470|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
218827471|NCT00135616|DEVICE|surgical placement of a suburethral sling tvt or tvt-o|
218827472|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
218827473|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
218827474|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
218827475|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
218827476|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
218827477|NCT05214430|OTHER|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
218827478|NCT01983007|PROCEDURE|High-intensity exercise|Performance of high-intensity exercise
218827479|NCT01983007|PROCEDURE|Low-intensity exercise|Performance of low-intensity exercise
219011395|NCT02056340|DRUG|Atorvastatin|
219011396|NCT02056340|DRUG|Placebo|
219011397|NCT05740644|DEVICE|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
219438173|NCT01384188|DRUG|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
219438174|NCT00650364|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
219438175|NCT00650364|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fasting
219438176|NCT01224106|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
219438177|NCT01224106|DRUG|Placebo|Participants received Placebo SC injection Q4W.
218827480|NCT01059747|OTHER|no intervention applied|no intervention applied
219438178|NCT00446797|DRUG|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
219438179|NCT00446797|DRUG|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
219438180|NCT03138291|DEVICE|Somnodent|Each pregnant women will be treat with a Somnodent
218827481|NCT00640003|DRUG|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
219011398|NCT06163313|OTHER|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
219011399|NCT01817621|BEHAVIORAL|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
219011400|NCT01817621|BEHAVIORAL|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
219011401|NCT03009578|DRUG|Iron Sucrose Injection|iron Intramuscular injections
219011402|NCT03009578|DRUG|Ferrous Bisglycinate|oral iron tablets
219011403|NCT05838105|DRUG|GnRH agonist|125 mcg once at the day mentioned
219011404|NCT05838105|DRUG|hCG|dose as mentioned
219011405|NCT05838105|DRUG|Progesterone 100Mg Vag Tab|dose as mentioned
219011406|NCT05606497|DRUG|Corticosteroid|Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
219011407|NCT05289180|OTHER|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
219011408|NCT02852785|BEHAVIORAL|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
219011409|NCT02852785|BEHAVIORAL|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
219011410|NCT02852785|BEHAVIORAL|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
219011411|NCT02852785|BEHAVIORAL|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
219011412|NCT05696678|DRUG|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
219011413|NCT05696678|DRUG|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
219011414|NCT01185132|RADIATION|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
219011415|NCT01185132|RADIATION|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
219011416|NCT04455802|DRUG|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
219011417|NCT04455802|DRUG|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
219011418|NCT04900220|DRUG|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
219011419|NCT04900220|DRUG|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
219011420|NCT02196558|DRUG|E6011|
219438181|NCT02314169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219438182|NCT02314169|PROCEDURE|Computed Tomography|Undergo CT scan
219438183|NCT02314169|BIOLOGICAL|Ipilimumab|Given IV
218827482|NCT00640003|DRUG|Placebo|placebo drug
218827483|NCT01653444|DRUG|GC1119|biweekly, IV infusion
218827484|NCT03288844|PROCEDURE|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
218827485|NCT03288844|OTHER|Digital pictures|Digital pictures 2D to be taken at each visit
218827486|NCT03288844|OTHER|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
218827487|NCT02789085|DEVICE|ULF TENS stimulation|
218827488|NCT00374517|DRUG|Pimonidazole hydrochloride|
218827489|NCT00741169|DRUG|TMC435350|200 mg taken by mouth once daily for 7 days
218827490|NCT00741169|DRUG|Rifampin|600 mg taken by mouth once daily for 7 days
218827491|NCT00741169|DRUG|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
218827492|NCT05853588|OTHER|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
218827493|NCT04487197|PROCEDURE|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
218827494|NCT01177124|BEHAVIORAL|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
218827495|NCT01514721|DRUG|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
218827496|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
218827497|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
218827498|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
218827499|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
218827500|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
218827501|NCT03654144|DRUG|Dienogest|oral tablets
218827502|NCT03654144|DRUG|Combined Oral Contraceptive|oral tablets
218827503|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
218827504|NCT00123825|DRUG|Gemcitabine|
219438184|NCT02314169|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218827505|NCT00123825|DRUG|Cisplatin|
218827506|NCT02636387|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
218827507|NCT05634330|OTHER|exercise treatment|core stabilization exercise
219011421|NCT02291198|DEVICE|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
219011422|NCT04432896|OTHER|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
219011423|NCT00089765|DRUG|Ranibizumab|
219011424|NCT02645110|DEVICE|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
219011425|NCT02645110|DEVICE|Tap water|Washing hand with water alone in comparison to hand washing with soap
219011426|NCT01447602|BEHAVIORAL|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
219011427|NCT02742324|DRUG|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
219438185|NCT02314169|BIOLOGICAL|Nivolumab|Given IV
219438186|NCT05935982|BEHAVIORAL|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
219438187|NCT03238365|BIOLOGICAL|Nivolumab|Given IV
218827508|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
218827509|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
218827510|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
218827511|NCT06068374|OTHER|Break of sedentary behavior with dual task|Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously
218827512|NCT06068374|OTHER|Break of sedentary behavior with walking|Patients will interrupt sedentary behavior performing walking
218827513|NCT04538157|OTHER|Comprehensive Geriatric Assessment|A CGA is a diagnostic and therapeutic intervention which initially identifies an older person's medical, functional, psychosocial problems and then tailors coordinated management plans to address them.
218827514|NCT00057057|BEHAVIORAL|Telephone Care|
218827515|NCT05905237|PROCEDURE|Cataract surgery, Femtosecond-LASIK, SMILE|Cataract surgery includes both conventional and femtosecond laser assisted. Femtosecond-LASIK and SMILE are options for patients to correct myopia.
218827516|NCT06350422|OTHER|Head-Down tilt Bed Rest test|All of the volunteers underwent 60 days of the Head-Down tilt Bed Rest test.
218827517|NCT00444925|DRUG|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
219011428|NCT02742324|DRUG|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
219011429|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
219011430|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
219011431|NCT00150982|DRUG|Mechanism of action of alefacept|
219011432|NCT04258722|OTHER|Resuscitation Personnel|Type of resuscitation team
219011433|NCT06347614|PROCEDURE|Two-step Radical Prostatectomy|The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
219438188|NCT03238365|DRUG|Tadalafil|Given orally
219438189|NCT03238365|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219438190|NCT03967847|DRUG|Ketorolac|Oral Ketorolac
219438191|NCT04647695|DRUG|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
219438192|NCT04647695|DRUG|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
219438193|NCT03382197|DEVICE|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
218827518|NCT00444925|DRUG|placebo|once daily (OD)for 12 weeks
218827519|NCT00444925|DRUG|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
218827520|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
218827521|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
218827522|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
219363717|NCT04434352|DEVICE|Storz Duolith Low-Intensity Shockwave Therapy|"A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete."
219438194|NCT03382197|DEVICE|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
219438195|NCT03382197|DEVICE|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
219438196|NCT02498392|DRUG|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
219438197|NCT02498392|OTHER|Placebo|Matching Placebo will be administered orally.
219438198|NCT05256992|OTHER|Standard Servies + Ray of Hope Curriculum|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.
219438199|NCT05256992|OTHER|Standard Services|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.
218827523|NCT00227084|DRUG|Arista AH hemostasis powder|
218827524|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
218827525|NCT01991379|DRUG|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
218827526|NCT01991379|DRUG|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
218827527|NCT01991379|OTHER|Blood draws|
219011434|NCT00503802|PROCEDURE|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
219011435|NCT00503802|PROCEDURE|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
219011436|NCT00136617|DRUG|chlordiazepoxide|
219011437|NCT06170723|DRUG|BMS-986368|Specified dose on specified days
219011438|NCT06170723|DRUG|Itraconazole|Specified dose on specified days
219580529|NCT06927986|DRUG|SYS6010|SYS6010,Q3W
219580530|NCT06927986|DRUG|Pemetrexed|Pemetrexed injection 500 mg/m\^2 administered via intravenous infusion，Q3W
219580531|NCT06927986|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via intravenous infusion，Q3W
219580532|NCT06927986|DRUG|Carboplatin|Carboplatin (AUC=5, Calvert formula) administered via intravenous infusion，Q3W
218827528|NCT01991379|PROCEDURE|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
219011439|NCT06170723|DRUG|Famotidine|Specified dose on specified days
219011440|NCT00408356|DRUG|Zinc|
219011441|NCT01877499|OTHER|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
219011442|NCT05532007|DIETARY_SUPPLEMENT|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
219011443|NCT05532007|OTHER|Habitual Diet|continue with habitual diet and abstain from eating peanuts
218827529|NCT05828186|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
218827530|NCT05973201|DEVICE|Virtual reality headset|"A HEALTHY MIND® brand VR headset is dedicated to the study. The kit includes a noise-reducing audio headset, a face mask diffusing the visual part, a touchscreen tablet connected to the two VR headset systems, and a microphone connected to the tablet.~The available software allows patients to choose between 5 natural environments in which a hypnotic speech is broadcast, available in several languages (French, English, Spanish, Russian, Arabic)."
218827531|NCT03129464|DEVICE|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
218827532|NCT05008705|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
218827533|NCT05008705|DEVICE|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
218827534|NCT05008705|DIETARY_SUPPLEMENT|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
218827535|NCT05008705|DEVICE|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
218827536|NCT04023942|BEHAVIORAL|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
218827537|NCT05525741|OTHER|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
218827538|NCT05525741|OTHER|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
218827539|NCT06313203|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy
219580533|NCT00221962|DRUG|Aripiprazole|Open label
218827540|NCT06313203|PROCEDURE|Selective Internal Radiation Therapy (SIRT)|Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
218827541|NCT03333356|RADIATION|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
218827542|NCT01293812|DRUG|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
218827543|NCT01293812|DRUG|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
219580534|NCT06927232|DRUG|Azacitidine (AZA)|Azacitidine 75mg/m/ day \*5 days, 28 days for 1 course
219580535|NCT06927232|DRUG|Luspatercept|Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin ≥120g/L, luspatercept can be discontinued.
219580536|NCT00290251|DRUG|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
218827544|NCT03495934|DRUG|pracinostat|\[14C\]-pracinostat
219580537|NCT00290251|DRUG|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
218827545|NCT04700150|OTHER|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
219363718|NCT01225562|DRUG|Ticagrelor 90 mg|Oral dose twice a day
219363719|NCT01225562|DRUG|Ticagrelor 60 mg|Oral dose twice a day
219363720|NCT01225562|DRUG|Ticagrelor Placebo|Oral dose twice a day
219363721|NCT00838019|PROCEDURE|Intrabone administration of umbilical cord blood|Single administration
219363722|NCT03183544|COMBINATION_PRODUCT|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
219438200|NCT05071443|OTHER|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
218827546|NCT04700150|OTHER|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
218827547|NCT05829837|OTHER|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
218827548|NCT02136784|DRUG|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827549|NCT02136784|DRUG|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827550|NCT02136784|DRUG|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827551|NCT02136784|DRUG|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827552|NCT02136784|DRUG|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827553|NCT02136784|DRUG|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
219011444|NCT02638727|DRUG|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
219011445|NCT02638727|DRUG|placebo|This group treat with placebo dayley
219011446|NCT03725280|PROCEDURE|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
219011447|NCT05803005|OTHER|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers \[IL-6, IL-8, TNF\_alpha\] in children with autism spectrum disorder
219438201|NCT05071443|OTHER|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
219580538|NCT00290251|DRUG|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
218827554|NCT02136784|DRUG|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
218827555|NCT03198156|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
218827556|NCT03198156|DEVICE|Sham stimulation|Sham stimulation
219011448|NCT04120545|DEVICE|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
219011449|NCT04120545|DEVICE|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
219011450|NCT01090960|DRUG|GDC-0068|Oral repeating dose
219011451|NCT02947997|DEVICE|OFDI capsule|Imaging of esophagus using OFDI capsule and system
219011452|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
219011453|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
219580539|NCT05788575|PROCEDURE|surgery|any surgery that an inpatient has undergone
219580540|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
219580541|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
219580542|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
219580543|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
219195817|NCT06429956|BEHAVIORAL|Mindful emotion awareness|"The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With mindful mood induction, the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With anchoring in the present, the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file."
219438202|NCT04223206|DIETARY_SUPPLEMENT|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
218827557|NCT02025790|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"* Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
218827558|NCT02025790|PROCEDURE|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
218827559|NCT05424601|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
218827560|NCT05424601|BEHAVIORAL|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
218827561|NCT04743713|OTHER|UWRI-Tr|Questionnaire
218827562|NCT05111288|DEVICE|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
218827563|NCT05111288|DEVICE|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
218827564|NCT02520778|DRUG|Navitoclax|Given PO
218827565|NCT02520778|DRUG|Osimertinib|Given PO
218827566|NCT06315192|DEVICE|Stroke Alarm|Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
219011454|NCT00969202|RADIATION|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
219011455|NCT03728660|DEVICE|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
219011456|NCT03728660|DEVICE|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
219011457|NCT03553667|DEVICE|Standard group|Use radial arterial line to monitor mean arterial pressure
219363723|NCT03633188|BIOLOGICAL|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~* Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~* Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~* Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
219438203|NCT04771546|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
218827567|NCT03841942|OTHER|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
218827568|NCT03841942|OTHER|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
219011458|NCT03553667|DEVICE|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
219011459|NCT03552263|DRUG|T89 capsule|T89 capsules (75mg), orally, twice daily.
219011460|NCT03552263|DRUG|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
219011461|NCT00905398|DRUG|Nilotinib|400mg, Oral, Bid, Daily for three years
219363724|NCT03856151|DEVICE|"HEALTHY BOX Powered heating pad (electronic moxibustion)"|Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
219363725|NCT01692808|DRUG|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
219363726|NCT01692808|DRUG|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
219580544|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
219580545|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
219438204|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
219011462|NCT00039364|DRUG|imatinib mesylate|
219438205|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
219438206|NCT01425320|DRUG|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
219438207|NCT01425320|DRUG|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
219438208|NCT00922519|OTHER|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
219438209|NCT02324868|DEVICE|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
219438210|NCT02324868|DEVICE|Conventional IV catheter protection|No Shower patch will be provided during study period
219011463|NCT03487029|OTHER|Short duration|exercise Short duration high intensity training
219011464|NCT03487029|OTHER|Long duration|exercise Long duration high intensity training
219011465|NCT02118051|DRUG|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
219011466|NCT02118051|DRUG|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed
219011467|NCT02118051|DRUG|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
219011468|NCT03697629|DRUG|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
219011469|NCT04698902|DEVICE|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
219011470|NCT05040997|DIAGNOSTIC_TEST|Small airways assessment|Small airways assessment
219011471|NCT01026467|DRUG|cisplatin|Given IV
219011472|NCT01026467|DRUG|carboplatin|Given IV
219011473|NCT01026467|OTHER|questionnaire administration|
219011474|NCT04474704|DEVICE|Cheetah® non-invasive cardiac monitoring system|Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
219011475|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate
219011476|NCT02669433|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
219011477|NCT02669433|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
219011478|NCT02669433|DRUG|Placebo|once daily, oral, matching tablets
219011479|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
219011480|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
219438211|NCT05967208|BEHAVIORAL|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
219438212|NCT05967208|BEHAVIORAL|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
219438213|NCT00026585|DRUG|Tamoxifen|
219438214|NCT02868099|DRUG|Romiplostim|
219438215|NCT02868099|DRUG|Placebo|
219438216|NCT05703113|BEHAVIORAL|Web 2.0 tools|Education with Web 2.0 tools
219438217|NCT05987475|PROCEDURE|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
219438218|NCT04776915|DIAGNOSTIC_TEST|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
219438219|NCT03097133|DRUG|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
219011481|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011482|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
219011483|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011484|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
219011485|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
219011486|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
219011487|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
219011488|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
219011489|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011490|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011491|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011492|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
219011493|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
219011494|NCT02229747|DRUG|Meloxicam|
219011495|NCT02229747|DRUG|Diclofenac|
219011496|NCT02229747|DRUG|Nimesulide|
219011497|NCT00576927|DRUG|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
219011498|NCT00576927|DRUG|Placebo|
219011499|NCT04684355|OTHER|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
219438220|NCT03097133|DRUG|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
218827569|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
219011500|NCT02707510|OTHER|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
218827570|NCT00708357|DRUG|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
218827571|NCT02793661|DEVICE|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
219011501|NCT02429895|DRUG|ABT-122|Injection
219011502|NCT00379574|DRUG|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
219011503|NCT00379574|DRUG|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
219011504|NCT00379574|DRUG|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
219011505|NCT00379574|DRUG|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
219195818|NCT06429956|BEHAVIORAL|Cognitive flexibility|The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
219438221|NCT03097133|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
219438222|NCT06585202|DRUG|ATI-2138|ATI-2138 Oral Tablets BID
219438223|NCT02068586|DRUG|Sunitinib|Given PO
219438224|NCT02068586|DRUG|Valproic Acid|Given PO
219580546|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
219580547|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
219580548|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
219580549|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
219580550|NCT01512706|BIOLOGICAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
218827572|NCT02793661|OTHER|Control|Hydration protocol following ESC Guidelines 2014
218827573|NCT04461496|PROCEDURE|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
219011506|NCT00379574|DRUG|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
219011507|NCT00379574|DRUG|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
219438225|NCT02068586|DRUG|Sunitinib Malate|Given PO
219438226|NCT02068586|DRUG|Sunitinib Malate + Valproic Acid|Given PO
219438227|NCT05249712|DRUG|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
219438228|NCT05249712|OTHER|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
219438229|NCT05444985|OTHER|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
219438230|NCT04309838|COMBINATION_PRODUCT|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
219580551|NCT01512706|BIOLOGICAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
219011508|NCT05999045|OTHER|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
219011509|NCT02250365|OTHER|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
219011510|NCT02250365|OTHER|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
219011511|NCT02850029|OTHER|Observational study, no intervention|
219011512|NCT00459108|DRUG|dasatinib|Given orally
219011513|NCT04887051|OTHER|pulmonory based home exercises|web based telerehablitation
219011514|NCT00788476|OTHER|Survey|"Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
219011515|NCT00097110|DRUG|Vitamin C and E|
219195819|NCT02473445|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
218827574|NCT04461496|PROCEDURE|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
218827575|NCT04581811|OTHER|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
218827576|NCT04581811|OTHER|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
219011516|NCT03265275|OTHER|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
219011517|NCT00268957|DRUG|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
219011518|NCT00268957|DRUG|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
219011519|NCT02654522|DRUG|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
219011520|NCT03910608|DEVICE|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
219011521|NCT06474585|DEVICE|Plantar orthosis|Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
219011522|NCT00426491|DRUG|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
219011523|NCT01239654|DEVICE|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
219011524|NCT03680573|DRUG|Control: Lacated Ringers|This site will serve as the control site
219011525|NCT03680573|DRUG|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
219011526|NCT03680573|DRUG|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
219011527|NCT03680573|DRUG|BH4|This site will be use to locally supplement BH4.
219011528|NCT03680573|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
219011529|NCT03680573|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
219011530|NCT03680573|DRUG|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
219011531|NCT06231615|OTHER|Fascia exercises|Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.
219011532|NCT06231615|OTHER|Conventional physiotherapy and breathing exercises|Head and neck exercises and breathing exercises
219011533|NCT03473808|BEHAVIORAL|task-practice therapy|Standardized hand therapy program
219011534|NCT03473808|OTHER|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
219011535|NCT01880385|BIOLOGICAL|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
219011536|NCT01880385|DRUG|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
219011537|NCT01880385|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
219011538|NCT01880385|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
219011539|NCT01880385|DRUG|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
219011540|NCT01880385|BIOLOGICAL|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
219011541|NCT02853578|DRUG|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
219011542|NCT00128778|DRUG|Pegylated liposomal doxorubicin|
219011543|NCT01009125|OTHER|$2 cash|$2 cash incentive will be included in the mailed survey
219011544|NCT01009125|OTHER|$5 cash|$5 cash incentive will be included in the mailed survey
219011545|NCT02315378|BEHAVIORAL|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
219438231|NCT01691053|DRUG|Spironolactone|50mg once daily
218827577|NCT00714948|DRUG|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
218827578|NCT03537638|BEHAVIORAL|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
218827579|NCT00693888|BEHAVIORAL|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
218827580|NCT05110326|OTHER|ERGON Technique|"* Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets."
218827581|NCT05110326|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"* The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group"
218827582|NCT00002593|DRUG|fluorouracil|Given IV as described in Arm Description
218827583|NCT00002593|DRUG|leucovorin calcium|Given IV as described in Arm description.
218827584|NCT00002593|DRUG|levamisole hydrochloride|Given as described in arm description
218827585|NCT03310944|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
218827586|NCT03382912|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Nivolumab
218827587|NCT03382912|DRUG|Nivolumab|Nivolumab Alone
219011546|NCT02315378|BEHAVIORAL|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
219011547|NCT04576832|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
219011548|NCT02723669|DRUG|AR10|effervescent tablet
219011549|NCT02723669|DRUG|acetylcysteine|oral solution
219011550|NCT02384889|DRUG|Difluoromethylornithine|Active Therapy with DFMO
219011551|NCT02384889|DRUG|Placebo|Placebo Comparitor
218827588|NCT01086696|DRUG|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
218827589|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
218827590|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
219195820|NCT06250374|PROCEDURE|Bilateral trans-cranial Doppler ultrasound|Velocity measurements in the middle cerebral artery are made using an ultrasound probe applied to the patient's temple during surgery.
219195821|NCT03015532|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
219195822|NCT03015532|DRUG|Saline Placebo|Saline placebo via injection
219438232|NCT01691053|DRUG|Placebo|Placebo
219438233|NCT02575677|OTHER|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
219438234|NCT04451317|OTHER|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
219438235|NCT01637818|PROCEDURE|Lichtenstein's operation|
219438236|NCT01637818|PROCEDURE|Mesh Plug Repair|
219438237|NCT01637818|DRUG|Opiate|Postoperative pain therapy
219438238|NCT01637818|DRUG|Paracetamol|Postoperative pain therapy
219438239|NCT01637818|DRUG|non-steroidal anti-inflammatory drug|Postoperative pain therapy
219438240|NCT04727645|OTHER|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
219438241|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
219438242|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
219438243|NCT05263687|DIAGNOSTIC_TEST|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
218827591|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
218827592|NCT05588440|BIOLOGICAL|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
218827593|NCT05588440|DRUG|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
218827594|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
219438244|NCT04411706|DRUG|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
219438245|NCT02873208|DRUG|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
219438246|NCT04401410|BIOLOGICAL|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
219438247|NCT04401410|BIOLOGICAL|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
219438248|NCT04401410|OTHER|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
219438249|NCT05126134|DIAGNOSTIC_TEST|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
219438250|NCT01240967|DRUG|TC-5214|Oral tablets, single dose
218827595|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
218827596|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
218827597|NCT05000372|DRUG|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
218827598|NCT05508126|DIAGNOSTIC_TEST|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
218827599|NCT05508126|DIAGNOSTIC_TEST|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
218827600|NCT01405430|BIOLOGICAL|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
218827601|NCT04519931|OTHER|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
218827602|NCT03934866|RADIATION|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
219011552|NCT00491998|DRUG|V1512|6 doses of IMP at 2-hourly intervals
219438251|NCT04080752|DRUG|JNJ-61393215|JNJ-61393215 will be administrated orally.
219438252|NCT04080752|DRUG|Placebo|Matching placebo will be administered orally.
219438253|NCT06265467|PROCEDURE|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
219438254|NCT06265467|PROCEDURE|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
219438255|NCT00379886|DRUG|Propofol Thiopental|
219438256|NCT01192100|BEHAVIORAL|Breakfast Skipping|Participants will continue to skip breakfast each morning.
219438257|NCT01192100|BEHAVIORAL|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
219438258|NCT01192100|BEHAVIORAL|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
219580552|NCT01512706|BIOLOGICAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
219580553|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
219580554|NCT01512706|BIOLOGICAL|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
219011553|NCT00491998|DRUG|V1512|3-hourly dosing
219580555|NCT00468429|DRUG|Subconjunctival Bevacizumab|
219580556|NCT01745211|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser with array handpiece
219580557|NCT01295866|DEVICE|nasal nitric oxide|
219580558|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
218827603|NCT01643460|PROCEDURE|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
218827604|NCT06073704|PROCEDURE|antimicrobial photodynamic therapy (aPDT)|Scaling and root planing followed by antimicrobial photodynamic therapy
218827605|NCT06073704|PROCEDURE|Control|Treatment of scaling and root planing
219011554|NCT00491998|DRUG|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
219011555|NCT01397032|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
218827606|NCT05195203|DRUG|HS-10353|Single or multiple dose(s) of HS-10353
218827607|NCT05195203|DRUG|Placebo|Single or multiple dose(s) of placebo
218827608|NCT02991339|DRUG|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
218827609|NCT05653700|DEVICE|Arena Strive|This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience. The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
218827610|NCT05653700|OTHER|Control Cohort|Participants randomized into the control cohort - survey at baseline and end of the study
218827611|NCT06128057|OTHER|Blood products|Massive blood transfusion
218827612|NCT02317692|BEHAVIORAL|Parent training|
218827613|NCT03424395|OTHER|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
218827614|NCT05180968|DRUG|Nabilone 0.5 MG Oral Capsule|This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
219011556|NCT01397032|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
219011557|NCT04867603|DRUG|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
219763749|NCT00018057|BEHAVIORAL|Attention Bias Modification Training|The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
219763750|NCT00018057|DRUG|Fluoxetine|Randomized assignment.
218827615|NCT05180968|DRUG|Placebo Nabilone|This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
218827616|NCT02148848|DRUG|Risedronate|Take risedronate 35 mg orally every week
218827617|NCT02573948|OTHER|no intervention is assessed|
218827618|NCT05962255|DRUG|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
218827619|NCT05962255|DRUG|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
218827620|NCT05962255|DRUG|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
218827621|NCT02366325|DRUG|EPO-018B|
218827622|NCT04663074|DIAGNOSTIC_TEST|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
218827623|NCT04421404|BIOLOGICAL|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
218827624|NCT04421404|BIOLOGICAL|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
218827625|NCT06058962|DRUG|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
218827626|NCT00707993|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
219011558|NCT04867603|DEVICE|PET/CT imaging|PET/CT imaging procedure
219011559|NCT03763123|DRUG|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
219011560|NCT03763123|DRUG|Paclitaxel|paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
219011561|NCT03763123|DRUG|Topotecan|topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
219011562|NCT03176251|OTHER|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
219011563|NCT03876197|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
219011564|NCT03876197|OTHER|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
218827627|NCT00707993|DRUG|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
219011565|NCT04339127|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
218827628|NCT00076440|DRUG|Leuprolide acetate|
218827629|NCT00204529|DRUG|pegylated interferon-alpha-2a|
218827630|NCT00204529|DRUG|interferon-alpha-2a|
219011566|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D and calcium|
219011567|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D|
219011568|NCT02662491|DIETARY_SUPPLEMENT|Calcium|
219011569|NCT02662491|DIETARY_SUPPLEMENT|Placebo|
219011570|NCT01554553|PROCEDURE|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
219011571|NCT06357598|DRUG|Tislelizumab|Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
219195823|NCT03015532|DRUG|Bupivicaine HCl|Bupivacaine HCl without epinephrine
219195824|NCT03015532|DRUG|Ropivacaine|Ropivacaine, via injection
219580559|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
219763751|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
218827631|NCT05907811|PROCEDURE|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
218827632|NCT05948189|OTHER|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
218827633|NCT02224534|DRUG|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
218827634|NCT02224534|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
218827635|NCT00038844|DRUG|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
219011572|NCT06357598|DRUG|Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
219011573|NCT06357598|DRUG|Carboplatin or Cisplatin|"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
219011574|NCT06357598|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
219011575|NCT00177398|DRUG|Glargine insulin vs regular insulin|
219011576|NCT03715764|OTHER|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
219195825|NCT02600208|DEVICE|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
219195826|NCT05970861|DIETARY_SUPPLEMENT|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
219195827|NCT05549479|BEHAVIORAL|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
219195828|NCT05549479|BEHAVIORAL|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
219195829|NCT04710030|DRUG|Valacyclovir hydrochloride 500mg caplet|Active Comparator
219580560|NCT05925777|DEVICE|THEAL (Mectronic, Bergamo)|laser therapy high intensity
219195830|NCT04710030|DRUG|Placebo sugar pill caplet|Placebo Comparator
218827636|NCT00038844|DRUG|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
219011577|NCT03715764|OTHER|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
219011578|NCT00667004|DRUG|ecabet ophthalmic solution|sterile ophthalmic solution
219011579|NCT00667004|DRUG|placebo|sterile ophthalmic solution
219011580|NCT03445650|DRUG|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
219011581|NCT03445650|DRUG|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
219011582|NCT00512993|DRUG|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
219011583|NCT01654731|DRUG|Bezafibrate|
219011584|NCT01654731|DRUG|placebo|
219011585|NCT03969394|DIAGNOSTIC_TEST|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
219011586|NCT02543008|PROCEDURE|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
218827637|NCT00038844|DRUG|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
218827638|NCT00038844|DRUG|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
218827639|NCT00490581|OTHER|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
218827640|NCT00947128|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
218827641|NCT00947128|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
219011587|NCT02543008|PROCEDURE|Physical activity|Information already included in arm/group descriptions.
219011588|NCT02543008|PROCEDURE|Placebo|Information already included in arm/group descriptions.
219011589|NCT04212104|OTHER|watch a mukbang|watch the dim sum mukbang
219011590|NCT04212104|OTHER|watch a non-food video|watch the Big Bang Theory video
219011591|NCT00162201|DRUG|Abatacept|Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
219011592|NCT03835494|OTHER|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
219011593|NCT01320761|DRUG|ATX-101-BA-free|ATX-101-BA-free
219011594|NCT01320761|DRUG|ATX-101-BA|ATX-101-BA
219011595|NCT01045512|DRUG|fluvastatin|40-80mg once daily
219011596|NCT01537029|DRUG|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
219011597|NCT01537029|DRUG|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
218827642|NCT03061292|PROCEDURE|Pectoral Nerve Block|
219438259|NCT04409730|OTHER|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
219438260|NCT00921427|BEHAVIORAL|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
219438261|NCT00921427|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
218827643|NCT03061292|PROCEDURE|Without Pectoral Nerve Block|
218827644|NCT03730610|BEHAVIORAL|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
218827645|NCT05317598|OTHER|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
218827646|NCT01913327|DRUG|Aripiprazole|
218827647|NCT01913327|DRUG|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
218827648|NCT01913327|DRUG|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
218827649|NCT02605408|DEVICE|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
218827650|NCT02605408|PROCEDURE|Phacoemulsification|Removal of the cataractous lens
219011598|NCT02204163|DRUG|Eutropin|
219011599|NCT02204163|DRUG|Genotropin|
219011600|NCT04637789|BEHAVIORAL|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
219011601|NCT04637789|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
219011602|NCT02245490|DRUG|Tamsulosin HCl controlled release capsules|
219011603|NCT02245490|DRUG|Matching placebo capsule|
219011604|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
219011605|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
219011606|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
219011607|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
219011608|NCT04299412|DEVICE|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
219011609|NCT01879150|DEVICE|Cyclaplex bone anchor|Device implantation
219011610|NCT01472081|BIOLOGICAL|Nivolumab|
219011611|NCT01472081|BIOLOGICAL|Pazopanib|
219011612|NCT01472081|DRUG|Sunitinib|
219011613|NCT01472081|BIOLOGICAL|Ipilimumab|
219195831|NCT06041334|BIOLOGICAL|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
219438262|NCT04493593|BEHAVIORAL|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
218827651|NCT01352286|GENETIC|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
218827652|NCT04500457|BEHAVIORAL|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
218827653|NCT00000134|DRUG|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
218827654|NCT00000134|DRUG|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
218827655|NCT02137070|PROCEDURE|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
218827656|NCT02137070|OTHER|Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
218827657|NCT06022926|PROCEDURE|warmed with electric blankets|warmed with electric blankets
218827658|NCT06022926|OTHER|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
218827659|NCT06663501|DEVICE|Assisted Motion with Enhanced Sensation training|During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
218827660|NCT05961371|OTHER|Resistance Training|Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
218827661|NCT04543851|DEVICE|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
218827662|NCT02664519|BEHAVIORAL|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
218827663|NCT06622044|OTHER|Vision therapy group|accommodation and vergence exercise
219011614|NCT01040897|BEHAVIORAL|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
219011615|NCT01040897|BEHAVIORAL|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
219011616|NCT00003903|PROCEDURE|management of therapy complications|
219438263|NCT04337723|BEHAVIORAL|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
219438264|NCT01784003|DEVICE|Powered ankle-foot prosthesis|
218827664|NCT06622044|OTHER|Prism|wearing prism glasses
218827665|NCT06625528|BIOLOGICAL|open flap debridement|does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
218827666|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 1 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 1, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
218827667|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 2 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 2, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
219011617|NCT04832685|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
219195832|NCT06041334|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
219195833|NCT06366724|DRUG|Pyridostigmine|"Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)"
219195834|NCT06366724|DRUG|Low-Dose Naltrexone|"LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)"
219438265|NCT04611061|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
219438266|NCT04611061|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
219438267|NCT01009736|DIETARY_SUPPLEMENT|tomato-soy juice|
219438268|NCT01009736|OTHER|laboratory biomarker analysis|
219438269|NCT01009736|OTHER|pharmacological study|
219438270|NCT01009736|PROCEDURE|therapeutic conventional surgery|
218827668|NCT06685198|PROCEDURE|Titrated administration of propofol to a BIS value ≤ 60 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve a BIS value ≤ 60, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
218827669|NCT06715345|DEVICE|Bone graft materials and rhBMP-2|NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
218827670|NCT06714981|DRUG|Opioid Free Anaesthesia|patients received opioid free anesthesia
218827671|NCT06714981|DRUG|Opioid based Anesthesia|patients received opioid based anesthesia
218827672|NCT06718231|BEHAVIORAL|Transcutaneous electrical acupoint stimulation|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints, and sham acupoints. The target treatment acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery.
218827673|NCT06718231|BEHAVIORAL|Sham-TAES|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral sham acupoints. The Sham acupoints is 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints. The sham acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery
218827674|NCT06716684|BEHAVIORAL|Cognitive-Behavioral Approach Based Psychoeducation Program|A 6 session cognitive-behavioral approach based psychoeducation program developed in line with the literature review is applied in the research. Group training sessions have been held once a week with each session 90 minutes on average. The techniques such as automatic thought recording, finding cognitive errors, thought-stopping, forming alternative thoughts, daydreaming, countdown, problem solving, role playing, modeling, deep breathing, relaxation exercises, summarizing, explaining, informing, homework were used in the sessions.
218827675|NCT06718504|DEVICE|Virtual Reality Glasses|Virtual reality is a method that can be used to distract and prepare patients for medical procedures. Virtual reality is a computer-generated environment where three-dimensional interaction is possible. It is an advanced technology that allows an individual to move into a virtual environment and focus their attention on other thoughts, allowing them to pay less attention to pain and anxiety. In this study, the virtual reality glasses were put on for the intervention group five minutes before the procedure began and were kept on until the procedure was completed. The virtual reality glasses showed the patient-selected images of a relaxing nature setting or images without any violent content.
218827676|NCT06717984|DIAGNOSTIC_TEST|Biopsy, Mastectomy, Histopathology|"Biopsy:~This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes.~Mastectomy:~This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer.~Histopathology:~This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions."
218827677|NCT06715137|BEHAVIORAL|Exercise training|Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight.
218827678|NCT06718556|BEHAVIORAL|Virtual reality|"The virtual reality intervention program was carried out in a 30-meter2 area covered with soft ground to prevent injuries. The Microsoft Kinect for Xbox 360 was used for the virtual reality intervention. For the current study, a team of experts was formed to select the games to be used within the virtual reality intervention program. This team determined which skills were required for the games to be run successfully, which skills could be developed, which games were purposeful, and independently observed each game. As a result, 9 different games were chosen. Since all games involve similarly intense visual, cognitive and motor skill requirements, game selection was left to the participants' preference during the intervention process to encourage motivation and participation. The virtual reality intervention procedure was created by utilizing the literature"
218827679|NCT06718556|BEHAVIORAL|Client-centered|"The client-centered (CC) intervention procedure for individuals with schizophrenia was created using literature and the intervention procedure is presented below:~1. Active Communication and Evaluation~2. Daily Routine, Roles, and Occupational Performance~3. Strengths and Barriers~4. Intervention Program Development~5. Implementation of the intervention program~6. Feedback and Revision:"
218827680|NCT06710925|BIOLOGICAL|TNM001|single dose intramuscular injection
218827681|NCT06710925|BIOLOGICAL|placebo|single dose intramuscular injection
218827682|NCT06715059|OTHER|Tele-rehabilitation exercise program|A progressive core stability exercise program will be performed based on motor control principles via an online platform.
218827683|NCT06715059|OTHER|Home-based exercise program|A core stability exercise program will be performed at home.
218827684|NCT06712680|DRUG|Test Product HYP-6589|HYP-6589 should be administered orally at the recommended dosage
218827685|NCT06715046|DIAGNOSTIC_TEST|Sample collation for cfDNA methylation analysis|Sample collation for cfDNA methylation analysis
219438271|NCT03326583|DRUG|Patiromer|Patiromer will be orally self-administered by participants.
218827686|NCT06715046|DIAGNOSTIC_TEST|Sample collection for EV phenotype analysis|Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.
218827687|NCT06716827|PROCEDURE|In-office bleaching system|As the whitening agent, an in-office bleaching system containing 35% hydrogen peroxide (Whiteness HP, FGM) was chosen. The gingiva was isolated using an isolation material (Opaldam, Ultradent Products Inc.), which was light-cured with a standard curing light. The whitening gel was applied to the labial surfaces of the maxillary incisors and canines with a 1mm thickness and left for 20 minutes. After cleaning the teeth with an aspiration tip, the whitening procedure was repeated.
218827688|NCT06716827|PROCEDURE|Laser-assisted bleaching|Whitening was performed 10 days prior to treatment, with laser treatment applied without removing brackets in the fixed appliance group and without cleaning attachments in the aligner group. The laser was applied to the buccal surface of the teeth with a 1mm distance for 30 seconds in three applications. After a 10-minute rest, the laser procedure was repeated.
218827689|NCT06716827|PROCEDURE|Home-bleaching|The whitening trays were custom-made for the fixed appliance patients, and they used them for 2-4 hours each evening after brushing their teeth. In the transparent aligner group, whitening was done using the aligners worn for treatment.
218827690|NCT06716827|OTHER|Control|This group of patients did not undergo any whitening procedures.
219011618|NCT04406961|PROCEDURE|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
219011619|NCT04406961|DEVICE|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
219195835|NCT06366724|OTHER|Placebo|"Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)"
219195836|NCT06435624|DEVICE|intelligent robotic-assisted training|"Using an intelligent robotic-assisted training (IRAT) system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd."
219438272|NCT01317693|DEVICE|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
219438273|NCT04368689|OTHER|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
219438274|NCT04685538|DRUG|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
219438275|NCT04685538|DRUG|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
219438276|NCT03121482|DEVICE|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
219763752|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
219438277|NCT03121482|DEVICE|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
218827691|NCT06717542|DIAGNOSTIC_TEST|histochemical and immunohistochemical analysis|2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1
218827692|NCT06717542|DIAGNOSTIC_TEST|RT-PCR|Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
218827693|NCT06714838|DRUG|Rituximab (Mabthera)|Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.
218827694|NCT06717009|DIAGNOSTIC_TEST|Preoperative three-dimensional reconstruction|On the basis of conventional CT/MRI, the patient will undergo 3D reconstruction within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the 3D reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
218827695|NCT03670160|DRUG|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
218827696|NCT03670160|DRUG|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
218827697|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
218827698|NCT04357184|OTHER|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
218827699|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
218827700|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
218827701|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
218827702|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
218827703|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
218827704|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
218827705|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
218827706|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
218827707|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
218827708|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
218827709|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
218827710|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
218827711|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
218827712|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
218827713|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
218827714|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
218827715|NCT03427814|DRUG|Placebo|60 mg orally twice daily
218827716|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
218827717|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
219438278|NCT01655745|PROCEDURE|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
219763753|NCT06620523|DRUG|CoQ10 1200 mg orally with Glutathione 1000 mg orally|This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
219195837|NCT06435624|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
219195838|NCT06435624|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
219438279|NCT04737759|BEHAVIORAL|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
219438280|NCT04737759|OTHER|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
219763754|NCT06620523|DRUG|Group B: Placebo CoQ10 orally and Placebo Glutathione orally|A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
219763755|NCT01291576|PROCEDURE|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
219763756|NCT01291576|PROCEDURE|Rectal nodule excision|Either full thickness excision or rectal shaving
219763757|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
219763758|NCT06572852|OTHER|No intervention|No intervention
219763759|NCT05931276|DRUG|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
219438281|NCT03882723|DEVICE|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
218827718|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
218827719|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
218827720|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
218827721|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
218827722|NCT06375525|DEVICE|Janssen's icon Application (App)|
218827723|NCT01761513|DRUG|YH4808|"Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks"
218827724|NCT01761513|DRUG|YH4808|"Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks"
218827725|NCT01761513|DRUG|YH4808|"Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks"
218827726|NCT01761513|DRUG|YH4808|"Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks"
219011620|NCT04406961|PROCEDURE|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
219011621|NCT04406961|DEVICE|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
219011622|NCT02248194|DEVICE|Tactile electrosurgical ablation probe|
219011623|NCT02248194|DEVICE|Hysteroscopic endometrial ablation|
219011624|NCT03229161|BEHAVIORAL|IWT-group|
219011625|NCT00811551|DEVICE|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
219011626|NCT01777256|DRUG|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
219763760|NCT05931276|DRUG|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
218827727|NCT06003439|BEHAVIORAL|Virtual Reality Program|Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
218827728|NCT06003439|BEHAVIORAL|VR Program|VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
218827729|NCT04450030|DRUG|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
218827730|NCT04450030|PROCEDURE|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
218827731|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
218827732|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
218827733|NCT04764240|PROCEDURE|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
218827734|NCT03048435|OTHER|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
218827735|NCT03048435|OTHER|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
218827736|NCT06243614|DRUG|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
218827737|NCT06243614|DRUG|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
219011627|NCT01777256|DRUG|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
219011628|NCT01777256|DRUG|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
218827738|NCT06243614|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
218827739|NCT06243614|DRUG|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
218827740|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
218827741|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
219011629|NCT01777256|DRUG|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
219011630|NCT01777256|DRUG|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
219011631|NCT00425451|DRUG|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
219011632|NCT01972503|DRUG|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
219011633|NCT01972503|PROCEDURE|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
219011634|NCT00847704|DEVICE|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
219011635|NCT01962207|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
219011636|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
219011637|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
218827742|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
218827743|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
218827744|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
219011638|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
219011639|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
219195839|NCT02832505|OTHER|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
219195840|NCT06809127|OTHER|Behavioral tasks with MEG recording|The patients will undergo two visits, during which MEG will be recorded in two types of behavioral tasks: motor task and emotion recognition task. One visit will take place before surgery. The second visit will take place after the surgical intervention and the face motor rehabilitation, 3 to 18 months after the 1st visit.
219438282|NCT01007513|PROCEDURE|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
219438283|NCT01007513|PROCEDURE|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
219438284|NCT06405685|DRUG|Nimotuzumab|Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
219438285|NCT06405685|DRUG|AG|Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
219011640|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
219011641|NCT05127473|DRUG|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
219011642|NCT05127473|DRUG|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
219195841|NCT06809829|PROCEDURE|Immediate Implant Placement|Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline loaded gelatin nanoparticles along with gelatin sponge (group A) Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline along with gelatin sponge (group B)
219011643|NCT05127473|DRUG|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
219011644|NCT03852940|OTHER|Parenteral nutrition|
218827745|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
218827746|NCT01470222|OTHER|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
218827747|NCT02948764|DEVICE|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
218827748|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
218827749|NCT02655718|DEVICE|MRI|
218827750|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
218827751|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
218827752|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
218827753|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
218827754|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
219438286|NCT02225236|BEHAVIORAL|Classroom Intervention|
219438287|NCT01428440|RADIATION|18FML10|apoptosis imaging radio ligand
219438288|NCT06004193|BEHAVIORAL|Exercise|At least 150 minutes of exercise in a week
218827755|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
218827756|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
219011645|NCT03852940|OTHER|Enteral Nutrition|
219011646|NCT00820131|PROCEDURE|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
219011647|NCT00820131|PROCEDURE|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
219011648|NCT00863603|OTHER|oxygen|5 Liter/minute by nasal cannula for 6 wks
219011649|NCT00541489|DRUG|Naproxcinod|750 mg, bid
219011650|NCT00541489|DRUG|Naproxen|500 mg, bid
219438289|NCT01421069|DRUG|etanercept|"Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW."
219438290|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
219438291|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
218827757|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
218827758|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
219011651|NCT00541489|DRUG|Placebo|bid
219011652|NCT00616954|DRUG|ATG-F|ATG-f
219011653|NCT03293810|OTHER|Observational study|Post-Authorization Safety Study
219011654|NCT01518166|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
219438292|NCT01641081|DRUG|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
218827759|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
218827760|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
218827761|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
218827762|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
218827763|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
218827764|NCT03323138|PROCEDURE|Ex-PRESS and phacoemulsification|
219011655|NCT01518166|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
219011656|NCT01518166|DRUG|atorvastatin|One single dose of 40 mg. Tablet
219011657|NCT01518166|DRUG|lisinopril|One single dose of 20 mg. Tablet
219011658|NCT01518166|DRUG|griseofulvin|One single dose of 500 mg. Tablet
219011659|NCT01518166|DRUG|digoxin|One single dose of 1 mg. Tablet
219011660|NCT00001576|DRUG|Melphalan|
219438293|NCT01641081|DRUG|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
219438294|NCT01641081|DRUG|Placebo|Placebo in the Pressair for 14 days
219011661|NCT00001576|DRUG|Floxuridine|
219011662|NCT00001576|DRUG|Leucovorin|
219011664|NCT02584114|BEHAVIORAL|Peak app for memory training|
219011665|NCT02584114|BEHAVIORAL|Non-memory training group|
219011666|NCT04980859|DRUG|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
219011667|NCT00704158|DRUG|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
218827765|NCT03126643|BIOLOGICAL|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
218827766|NCT04485845|DRUG|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
218827767|NCT04485845|DRUG|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
218827768|NCT04485845|DRUG|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
218827769|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
218827770|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
218827771|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
218827772|NCT06252844|BEHAVIORAL|Resistance exercise training|Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
218827773|NCT06252844|BEHAVIORAL|Active control|Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
218827774|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
218827775|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
218827776|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
218827777|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
218827778|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
218827779|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
219763761|NCT05591924|PROCEDURE|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
218827780|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
218827781|NCT01597648|DRUG|Maraviroc|300 mg
218827782|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
218827783|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
218827784|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
218827785|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
219011668|NCT03605303|DEVICE|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
219011669|NCT03605303|DEVICE|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
219011670|NCT05368857|DRUG|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
219438295|NCT02491216|OTHER|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
218827786|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
218827787|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
218827788|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
218827789|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
218827790|NCT02955888|DRUG|Placebo|Comparator
218827791|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
218827792|NCT04532125|OTHER|Placebo|Subjects treated with placebo
218827793|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
218827794|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
218827795|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
218827796|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
218827797|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
218827798|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
218827799|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
218827800|NCT02353858|OTHER|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
218827801|NCT02353858|RADIATION|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
218827802|NCT02353858|DRUG|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
218827803|NCT01078792|OTHER|CT pulmonary angio, blood tests|
218827804|NCT00720694|DEVICE|Duolith SD1|
218827805|NCT00720694|DEVICE|Sham Duolith SD1|
218827806|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
218827807|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
218827808|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
218827809|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
218827810|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
218827811|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
218827812|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
218827813|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
218827814|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
218827815|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
218827816|NCT00535769|DEVICE|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
219195842|NCT06810037|BEHAVIORAL|Mindfulness Practice Based on the Solution-Focused Approach|the experimental group received 90 minutes of solution-oriented based mindfulness practices one day a week for eight weeks
219195843|NCT06805669|OTHER|Early referral to palliative care|Participant will be referred to palliative care at start of systemic treatment
219195844|NCT06805669|OTHER|Standard Treatment|Participants will be referred to palliative care upon appearance of uncontrollable symptoms.
219438296|NCT00781404|DRUG|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
219438297|NCT06224868|OTHER|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
219438298|NCT06224868|OTHER|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
219438299|NCT00565006|DRUG|MK0859|
219438300|NCT03850171|OTHER|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
219580561|NCT06267547|OTHER|HAIL Online Platform|The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F\&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F\&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F\&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F\&S! program, which yielded positive results.
219580562|NCT06267547|BEHAVIORAL|Fit and Strong! Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
219580563|NCT06964750|BEHAVIORAL|Exercise|Groups will practice the exercises by different method for 6 week
219580564|NCT06964750|BEHAVIORAL|home based exercise|Participant were practice for 6 weeks home based exercises.
218827817|NCT00535769|DEVICE|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
218827818|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
218827819|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
218827820|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
218827821|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
218827822|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
218827823|NCT04311112|DRUG|Placebos|Placebo
218827824|NCT04311112|DRUG|ZA Low dose|ZA low dose
219011671|NCT03027726|BEHAVIORAL|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
219011672|NCT03027726|OTHER|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
219011673|NCT01606345|DRUG|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
219011674|NCT01913912|DRUG|LDX.|"In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
219011675|NCT01913912|DRUG|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
219011676|NCT01913912|DEVICE|computer task (Go/No-Go task)|
219011677|NCT01913912|DEVICE|EEG|event-related potentials (ERP) and heart rate measurements
219011678|NCT01913912|DEVICE|pupil size measurements (by using eye tracking)|
219011679|NCT05156489|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
219011680|NCT04161560|DRUG|Cetuximab-IRDye800|does of Cetuximab-IRDye800
219011681|NCT05266742|OTHER|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
219011682|NCT00743314|OTHER|screening questionnaire administration|
219011683|NCT00743314|PROCEDURE|computed tomography|
218827825|NCT04311112|DRUG|ZA high dose|ZA high dose
219011684|NCT00743314|PROCEDURE|lymphoscintigraphy|
219011685|NCT00743314|PROCEDURE|single photon emission computed tomography|
219011686|NCT00743314|RADIATION|intensity-modulated radiation therapy|
219011687|NCT00743314|RADIATION|technetium Tc 99m sulfur colloid|
219011688|NCT01491503|DRUG|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
219195845|NCT06805201|DIETARY_SUPPLEMENT|Gyngerlean|Alpinia galangal (Red Ginger), Kaempferia parviflora (Black Ginger), and Zingiber officinale (Yellow Ginger).
219580565|NCT03673332|DRUG|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
218827826|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
218827827|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
218827828|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
218827829|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
218827830|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
218827831|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
218827832|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
218827833|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
218827834|NCT06164522|OTHER|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
218827835|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
218827836|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
218827837|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
218827838|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
218827839|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
219011689|NCT01491503|DRUG|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
219011690|NCT01491503|DRUG|Montelukast & levocetirizine|Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
219011691|NCT00815009|BEHAVIORAL|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
218827840|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
219195846|NCT06368206|DEVICE|Investigational device Aktiia G2C|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
219195847|NCT06368206|DEVICE|Marketed device used as reference for blood pressure monitoring: double auscultation cuff|Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
218827841|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
219011692|NCT00815009|BEHAVIORAL|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
219011693|NCT00815009|BEHAVIORAL|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
219011694|NCT03059654|PROCEDURE|tracheostomy|
219011695|NCT03414723|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
219011696|NCT03414723|DRUG|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
219011697|NCT04961554|OTHER|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
219195848|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
219580566|NCT04011215|OTHER|wool clothing|superfine merino wool ensembles for baby/child wear
219580567|NCT04011215|OTHER|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
219580568|NCT04209686|DRUG|Paclitaxel|"1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV"
218827842|NCT01232439|DRUG|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
218827843|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
218827844|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
218827845|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
218827846|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
218827847|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
218827848|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
218827849|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
218827850|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
218827851|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
218827852|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
219011698|NCT00763308|BEHAVIORAL|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
219011699|NCT05526495|BEHAVIORAL|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
219195849|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
219195850|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
219580569|NCT04209686|DRUG|Olaparib|"1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg"
219580570|NCT04209686|DRUG|Pembrolizumab|"1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV"
218827853|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
218827854|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
219011700|NCT01031069|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
219011701|NCT01031069|BIOLOGICAL|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
219011702|NCT01659515|DRUG|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
219011703|NCT03755492|OTHER|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
218827855|NCT00066612|DRUG|irinotecan hydrochloride|Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
218827856|NCT01462929|DRUG|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
218827857|NCT01462929|DRUG|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
218827858|NCT01462929|DRUG|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
218827859|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
218827860|NCT02453698|OTHER|Placebo|Lactose Placebo
218827861|NCT03240562|PROCEDURE|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
219011704|NCT05286307|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
219011705|NCT06508216|DRUG|Dato-DXd|Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
219580571|NCT05759806|DEVICE|Nephronyx system (Perfuser)|Temporary deployment of the Nephronyx system (Perfuser)
219580572|NCT03649685|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
219580573|NCT03649685|DEVICE|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
219580574|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
218827862|NCT03240562|DRUG|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
218827863|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
218827864|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
218827865|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
218827866|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
218827867|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
218827868|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
219011706|NCT06508216|DRUG|Durvalumab|Patients in module 2 only will receive Durvalumab 1120mg every 21 days
219011707|NCT01103284|DRUG|DiaPep277|1.0 mg dose in 0.5 mL of solution
219011708|NCT01103284|DRUG|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
219438301|NCT01283893|PROCEDURE|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
219438302|NCT05181241|DRUG|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
219438303|NCT00112567|DRUG|fludarabine phosphate|
219438304|NCT00112567|DRUG|thiotepa|
219438305|NCT00112567|PROCEDURE|peripheral blood stem cell transplantation|
219580575|NCT03188666|DRUG|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
218827869|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
218827870|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
218827871|NCT00670566|DRUG|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
218827872|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
218827873|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
219011709|NCT03723928|OTHER|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
219011710|NCT03723928|OTHER|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
219011711|NCT03723928|OTHER|Quality-of-Life Assessment|Ancillary studies
219011712|NCT03723928|OTHER|Anxiety Questionnaire Administration|Ancillary studies
219011715|NCT05177419|DRUG|Lysergic Acid Diethylamide|100 micrograms LSD base
219195851|NCT06368206|DEVICE|Marketed device used as reference for pulse rate monitoring: pulse finger oximeter|Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
219438306|NCT00112567|RADIATION|radiation therapy|
219438307|NCT01335594|PROCEDURE|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
219438308|NCT00853619|OTHER|Service based decision support intervention|Delivering CDS via services
218827874|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
218827875|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
218827876|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
218827877|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
218827878|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
218827879|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
218827880|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
219011716|NCT05177419|DRUG|Lysergic Acid Diethylamide|Low dose of LSD base
219011717|NCT00459173|DRUG|rimonabant (SR141716)|
219011718|NCT00001339|DRUG|doxorubicin, vincristine, and etoposide with mitotane|
219438309|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
219438310|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
219438311|NCT01095666|DRUG|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
219438312|NCT01095666|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
219438313|NCT01095666|DRUG|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
219438314|NCT04677049|DRUG|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
219438315|NCT05152667|DEVICE|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
219438316|NCT01042054|OTHER|Standard optimised recovery protocol.|"* Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
219580576|NCT03188666|DRUG|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
218827881|NCT04781556|OTHER|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
218827882|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
218827883|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
218827884|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
218827885|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
218827886|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
218827887|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
218827888|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
218827889|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
218827890|NCT02786212|DRUG|Dexmedetomidine|
219438317|NCT01042054|OTHER|Wound catheter plus patient-controlled analgesia.|"* Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
219438318|NCT00674375|OTHER|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
218827891|NCT02786212|DRUG|Normal Saline|
218827892|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
219438319|NCT03011775|DRUG|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
219580577|NCT03516253|DIETARY_SUPPLEMENT|Fish oil + EPO|Supplementation with both fish oil and EPO
219580578|NCT01400802|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
219580579|NCT03696953|BIOLOGICAL|Florajen3|Probiotic combination product One capsule daily by mouth.
218827893|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
218827894|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
218827895|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
218827896|NCT04856605|PROCEDURE|surgery|regular surgery
218827897|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
218827898|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
218827899|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
218827900|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
219195852|NCT03245593|OTHER|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
219195853|NCT03245593|OTHER|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
219438320|NCT03011775|DRUG|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
219438321|NCT03011775|DRUG|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
219438322|NCT03011775|DRUG|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
219438323|NCT03011775|DRUG|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
219438324|NCT03011775|DRUG|Ramipril 5 MG|1 tablet per a day
219438325|NCT04556448|OTHER|Aligners|Clear aligners
219438326|NCT04556448|OTHER|Clear braces|Clear braces
219438327|NCT00588380|DRUG|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
219438328|NCT01505244|BEHAVIORAL|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
218827901|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
218827902|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
219011719|NCT02932033|PROCEDURE|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
219011720|NCT02932033|PROCEDURE|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
219011721|NCT01346839|BEHAVIORAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
219195854|NCT05667480|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
219438329|NCT00369044|DRUG|prednisone|
219438330|NCT01502670|DRUG|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
219438331|NCT00742040|DRUG|Captopril|A rapid 3-day up-titration protocol
219580580|NCT05892289|PROCEDURE|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
219011722|NCT01968590|DRUG|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
219011723|NCT00893087|DEVICE|Triggering mode of the ventilator|10 min of each triggering mode
219011724|NCT00893087|DEVICE|Triggering method of the ventilator|Flow triggering
219011725|NCT00893087|DEVICE|Triggering method of the ventilator|Pressure triggering
219011726|NCT00893087|DEVICE|Triggering method of the ventilator|NAVA triggering
219011727|NCT00320099|DRUG|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
219011728|NCT00320099|DRUG|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
219011729|NCT00320099|DRUG|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
219011730|NCT00320099|DRUG|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
219011731|NCT04345796|DRUG|Carvedilol+Empagliflozin|Group A
219011732|NCT04345796|DRUG|Carvedilol|Group B
219195855|NCT05667480|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
219438332|NCT00742040|DRUG|Captopril|A slower 9-day up-titration protocol
219438333|NCT01781624|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
219011733|NCT04345796|DRUG|Empagliflozin|Group C
219011734|NCT04345796|DRUG|Placebo|Group D
219011735|NCT05439408|DRUG|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
219011736|NCT05439408|DRUG|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
219438334|NCT00353990|DRUG|Insulin Aspart|
219438335|NCT04000022|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
219438336|NCT05355181|OTHER|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
219438337|NCT05355181|OTHER|Core stabilization exercises|Core stabilization exercises
219580581|NCT06274164|DIAGNOSTIC_TEST|Electroencephalography/Polysomnography (EEG/PSG)|Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.
218827903|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
218827904|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
219011737|NCT04348734|DIAGNOSTIC_TEST|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
219011738|NCT04785014|PROCEDURE|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
219011739|NCT02744235|DEVICE|Polysomnography Data|
219011740|NCT02744235|DEVICE|Jawbone UP®|
219011741|NCT02744235|DEVICE|Fitbit Charge ®|
219011742|NCT05325151|OTHER|Educational Intervention|Receive GCPP intervention videos
219011743|NCT05325151|OTHER|Genetic Counseling|Receive genetic counseling
219011744|NCT05325151|OTHER|Survey Administration|Ancillary studies
219438338|NCT03555071|BIOLOGICAL|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
219438339|NCT03555071|BIOLOGICAL|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
219011745|NCT00496093|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
219580582|NCT06274164|PROCEDURE|Skin Biopsy|A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.
218827905|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
219011746|NCT00289315|BEHAVIORAL|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
219011747|NCT00289315|BEHAVIORAL|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
219011748|NCT00289315|BEHAVIORAL|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
219011749|NCT03599024|PROCEDURE|PCEA|The patients were able to control the administration of analgesics by themselves.
219011750|NCT03599024|PROCEDURE|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
219011751|NCT03599024|PROCEDURE|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
219011752|NCT03590236|OTHER|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
219195856|NCT06806111|PROCEDURE|Suture|Hemostatic sutures at the palatal donor site; 5-0 non-resorbable suspensory mattress sutures will be anchored to the soft tissues apical to the palatal wound area (5-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA).
219438340|NCT02447640|DRUG|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
219580583|NCT06274164|DIAGNOSTIC_TEST|Blood draw|A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
219580584|NCT06491511|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
219580585|NCT06432660|OTHER|Data collection|Information about radiation therapy via eye plaque brachytherapy and follow up
219011753|NCT03590236|OTHER|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
219011754|NCT04383808|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
219011755|NCT04383808|DIAGNOSTIC_TEST|Pre-injected group with PET insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
218827906|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
218827907|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
219011756|NCT00812370|DRUG|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
219438341|NCT02447640|RADIATION|[18F]FPEB|radiotracer used for PET scanning
219438342|NCT01749800|DEVICE|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
219438343|NCT01749800|DEVICE|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
219438344|NCT01749800|DEVICE|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
219438345|NCT02180490|DRUG|UHAC 62 XX tablet|
219438346|NCT02180490|DRUG|UHAC 62 XX capsule|
218827908|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
219438347|NCT04214041|OTHER|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
219438348|NCT04214041|OTHER|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
219438349|NCT04046276|BEHAVIORAL|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
219438350|NCT04046276|OTHER|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
219438351|NCT04046276|BEHAVIORAL|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
219438352|NCT01339208|OTHER|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
218827909|NCT00003923|DRUG|porfimer sodium|
218827910|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
218827911|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
218827912|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
218827913|NCT03470350|DRUG|Galunisertib|treatment with capecitabine and galunisertib
218827914|NCT06154616|DIETARY_SUPPLEMENT|Control Product|Lactose-free skimmed milk
218827915|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250|Lactose-free skimmed milk enriched with 250 mg aswaghanda
218827916|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250 + TRP|Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
218827917|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 600|Lactose-free skimmed milk enriched with 600 mg aswaghanda
218827918|NCT02402595|DRUG|AVP-923|
218827919|NCT02402595|DRUG|AVP-786|
218827920|NCT02402595|DRUG|Itraconazole|
218827921|NCT04982991|DRUG|RIPK1 inhibitor|Capsule Oral
218827922|NCT04317235|DRUG|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
218827923|NCT01306643|DRUG|Idelalisib|Tablet(s) administered orally twice daily
218827924|NCT05385211|OTHER|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
218827925|NCT02981056|OTHER|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
218827926|NCT02981056|OTHER|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
218827927|NCT02981056|OTHER|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
218827928|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
219195857|NCT06806111|PROCEDURE|Cyanoacrylate bioadhesive|Several drops of a high-viscosity cyanoacrylate bioadhesive will be applied (Cuantum Oral Adhesive, Cuantum Medical Cosmetics S.L., Spain) to create a uniform adhesive layer.
219438353|NCT03111589|BIOLOGICAL|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
218827929|NCT02071771|DEVICE|Nelfilcon A toric contact lenses|
218827930|NCT02071771|DEVICE|Etafilcon A toric contact lenses|
218827931|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
218827932|NCT04523584|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
218827933|NCT04523584|DEVICE|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
219438354|NCT03111589|DIAGNOSTIC_TEST|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
218827934|NCT04868383|BEHAVIORAL|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
218827935|NCT02746406|DEVICE|Peritron+|Peritron+ device to measure intravesical pressure
218827936|NCT01450644|OTHER|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
218827937|NCT06133881|DRUG|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
218827938|NCT06133881|DRUG|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
218827939|NCT01516632|BEHAVIORAL|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
218827940|NCT00700648|DRUG|insulin aspart|Intravenous NovoRapid dose \& frequency as decided by treating physician
218827941|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
218827942|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
218827943|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
218827944|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
218827945|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
218827946|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
218827947|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
218827948|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
218827949|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
218827950|NCT04778748|DIAGNOSTIC_TEST|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
218827951|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
218827952|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
218827953|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
218827954|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
218827955|NCT02345616|DRUG|Nitric oxide|
218827956|NCT02471053|OTHER|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
218827957|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
219438355|NCT03758872|DIAGNOSTIC_TEST|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
218827958|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
218827959|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
218827960|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
218827961|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
219438356|NCT01040754|OTHER|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
219438357|NCT04733872|DIETARY_SUPPLEMENT|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
219438358|NCT04733872|DIETARY_SUPPLEMENT|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
219438359|NCT03077789|PROCEDURE|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
218827962|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
218827963|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
218827964|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
218827965|NCT02257749|OTHER|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
218827966|NCT02257749|OTHER|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
218827967|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
218827968|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
218827969|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
218827970|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
218827971|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
218827972|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
218827973|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
218827974|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
218827975|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
218827976|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
218827977|NCT01411423|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
218827978|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
218827979|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
218827980|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
218827981|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
218827982|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
218827983|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
218827984|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
218827985|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
219011757|NCT06216145|OTHER|formative evaluation|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method"
219011758|NCT01798199|OTHER|The training by Verve System|
219438360|NCT01511640|DRUG|Pregabalin|pregabalin 2x daily for duration of study
219438361|NCT01511640|DRUG|Placebo|placebo 2x daily for duration of study
219438362|NCT00000281|BEHAVIORAL|Amantadine|
219011759|NCT02949492|DRUG|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
218827986|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
218827987|NCT03234647|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
218827988|NCT00094562|DRUG|Fish oil supplement|
218827989|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
218827990|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
218827991|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
218827992|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
218827993|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
219011760|NCT01399138|DIETARY_SUPPLEMENT|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
219011761|NCT01572909|DRUG|Bendavia (MTP-131)|0.05 mg/kg/hr
219011762|NCT01572909|DRUG|Placebo|Identically appearing placebo
219011763|NCT03641651|OTHER|Rehabilitation technology|"* Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session"
219011764|NCT02734381|OTHER|Elderly patients|Elderly patients who visited the Emergency Department
219011765|NCT02984189|OTHER|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
219011766|NCT04779489|RADIATION|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
219011767|NCT00623727|BIOLOGICAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
219580586|NCT05557357|PROCEDURE|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
219011768|NCT00623727|BIOLOGICAL|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
218827994|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
218827995|NCT01810900|DEVICE|Protescal|
218827996|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
218827997|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
218827998|NCT00002186|DRUG|Crofelemer|
218827999|NCT00002186|DRUG|Acyclovir|
218828000|NCT00447798|BEHAVIORAL|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
218828001|NCT00511758|PROCEDURE|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
218828002|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
218828003|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
218828004|NCT01590368|DEVICE|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
218828005|NCT01590368|DEVICE|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
218828006|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
218828007|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
218828008|NCT06301646|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218828009|NCT06301646|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
218828010|NCT06301646|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
218828011|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
218828012|NCT00348946|OTHER|placebo|an inactive substance
218828013|NCT00268281|DEVICE|Left Ventricular Capture Management Software|
218828014|NCT03688919|BEHAVIORAL|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
218828015|NCT01533441|DIETARY_SUPPLEMENT|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
219011769|NCT01575665|DEVICE|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
218828016|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
218828017|NCT02776683|DRUG|BI 695502|
218828018|NCT02776683|DRUG|Avastin|
218828019|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
218828020|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
218828021|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
218828022|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
218828023|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
218828024|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
218828025|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
218828026|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
218828027|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
218828028|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
219011770|NCT00951665|DRUG|paclitaxel|Intravenous repeating dose
219011771|NCT00951665|DRUG|pertuzumab [Perjeta]|Intravenous repeating dose
219011772|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
218828029|NCT03700164|OTHER|Temperature|Water-perfused suit.
219011773|NCT00951665|DRUG|paclitaxel|Intravenous escalating dose
219011774|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
218828030|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
218828031|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
218828032|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
218828033|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
219438363|NCT02489851|PROCEDURE|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
218828034|NCT00143559|DRUG|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
218828035|NCT00143559|PROCEDURE|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
218828036|NCT00143559|DEVICE|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
219011775|NCT04813094|OTHER|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
219011776|NCT04813094|OTHER|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
219438364|NCT02489851|PROCEDURE|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
219011777|NCT06299774|OTHER|Emergency care at home|A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.
219011778|NCT06299774|OTHER|Emergency care at a brick-and-mortar emergency department|Standard emergency care delivered in a brick-and-mortar emergency department.
218828037|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
218828038|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
218828039|NCT03975153|BIOLOGICAL|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
218828040|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
218828041|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
219011779|NCT01978587|DRUG|JTZ-951|
219011780|NCT04711473|BEHAVIORAL|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
219011781|NCT04711473|BEHAVIORAL|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
219011782|NCT04711473|BEHAVIORAL|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
219011783|NCT06376747|PROCEDURE|In line sampling|closed technique of sample collection
219011784|NCT06376747|PROCEDURE|Standard blood sampling technique|Blood draws using standard steps: blood withdrawal for catheter, decontamination (disposed),blood draw for laboratory analysis,catheter flush
219438365|NCT02997774|OTHER|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
218828042|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
219011785|NCT06368960|RADIATION|Radiotherapy|Radiation： Hypofractionated radiotherapy
219438366|NCT02997774|OTHER|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
218828043|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
218828044|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
218828045|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
219438367|NCT04418739|DRUG|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
219438368|NCT01459887|DRUG|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
219438369|NCT01459887|DRUG|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
219438370|NCT03297944|DRUG|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
219438371|NCT03297944|DRUG|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
219438372|NCT03297944|DRUG|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
218828046|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
218828047|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
218828048|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
218828049|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
218828050|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
218828051|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
219011786|NCT06368960|DRUG|BM201 injection|BM201 injection：Dose escalation：24mg to 240mg
219011787|NCT05581537|OTHER|Systematic Desensitization|"Systematic desensitization: 2 techniques~1. Jacobson's technique (progressive muscle relaxation):~   It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~2. Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
219011788|NCT02723084|DRUG|ABT-493/ABT-530|Co-formulated tablet
219011789|NCT02723084|DRUG|sofosbuvir (SOF)|Tablet
219011790|NCT02723084|DRUG|ribavirin (RBV)|Capsule
219011791|NCT05029986|BEHAVIORAL|Socialization phase|Control condition: does not involve speech-related exercises
219011792|NCT05029986|BEHAVIORAL|Speech breathing intervention|Experimental condition: involves speech-related exercises
219011793|NCT04748315|OTHER|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
219011794|NCT04748315|OTHER|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
219011795|NCT01718847|DRUG|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
219011796|NCT04900688|DEVICE|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
219011797|NCT04430933|DRUG|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
218828052|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
219011798|NCT04430933|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
219438373|NCT03297944|DRUG|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
219438374|NCT03297944|DRUG|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
219438375|NCT03297944|DRUG|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
218828053|NCT06004297|PROCEDURE|ACL reconstruction|performed arthroscopically
218828054|NCT03417583|OTHER|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
218828055|NCT03771040|DRUG|Masitinib|
218828056|NCT03771040|DRUG|Placebo|
218828057|NCT01786681|PROCEDURE|Positive pressure|
218828058|NCT05575544|PROCEDURE|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
218828059|NCT05529251|RADIATION|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm"
218828060|NCT05529251|DRUG|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
218828061|NCT05529251|DRUG|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
218828062|NCT02869542|OTHER|Data collection|
218828063|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
218828064|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
218828065|NCT02153437|DRUG|BMS-919373|
218828066|NCT02153437|DRUG|Sotalol|
218828067|NCT02153437|DRUG|Placebo for BMS-919373|
219011799|NCT04430933|DRUG|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
219011800|NCT04430933|DRUG|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
219011801|NCT05024058|DRUG|Ligelizumab|Ligelizumab treated groups and arms
219011802|NCT05024058|OTHER|Placebo|Placebo treated groups and arms
219011803|NCT02428881|DRUG|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
219011804|NCT04821206|DRUG|DMARDs|New Initiation of a DMARDs
219011805|NCT04821206|DRUG|biologic DMARDs|New Initiation of a biologic DMARDs
219011806|NCT04821206|DRUG|JAK Inhibitor|New Initiation of a JAK Inhibitor
219011807|NCT00002670|DRUG|chemotherapy|
219011808|NCT00002670|DRUG|cisplatin|
219011809|NCT00002670|RADIATION|low-LET cobalt-60 gamma ray therapy|
219011810|NCT00002670|RADIATION|low-LET electron therapy|
219438376|NCT04063644|DEVICE|Vis Glyc Neo|1 drop in each eye, three times a day.
219438377|NCT04063644|DEVICE|Physiological saline solution|1 drop in each eye, three times a day.
218828068|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
218828069|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
218828070|NCT04149496|COMBINATION_PRODUCT|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
218828071|NCT05313763|OTHER|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of \<150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
218828072|NCT05313763|OTHER|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
218828073|NCT05313763|OTHER|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
218828074|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
218828075|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
218828076|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
219011811|NCT00002670|RADIATION|low-LET photon therapy|
219011812|NCT01758783|DRUG|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
219011813|NCT00925418|PROCEDURE|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
219011814|NCT04571775|DEVICE|Qi-Shield user group|real device Qi-Shield (treatment)
219011815|NCT04571775|DEVICE|Sham Qi-Shield user group|sham device (placebo)
219011816|NCT05577676|DRUG|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament \& MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
219011817|NCT06074913|OTHER|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
219011818|NCT06074913|PROCEDURE|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
219011819|NCT06074913|OTHER|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
219438378|NCT02293590|DRUG|Certolizumab Pegol|
218828077|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
218828078|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
219011820|NCT00139399|PROCEDURE|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
219011821|NCT02680028|DEVICE|targon pft nail|220 mm vs 175mm nail
219011822|NCT00876954|PROCEDURE|Normothermia|Warming without increase in core temperature
219011823|NCT00876954|PROCEDURE|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
219011824|NCT06245590|DRUG|Albumin|20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
219011825|NCT06245590|DRUG|Midodrine|Midodrine
219011826|NCT06245590|OTHER|Standard of Care|Standard of Care
219011827|NCT04096625|DEVICE|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
219438379|NCT03049085|DRUG|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
219438380|NCT03049085|DRUG|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
219438381|NCT00357786|DRUG|Replagal agalsidase alfa|
219438382|NCT00357786|DRUG|Replagal|
219438383|NCT00616291|BIOLOGICAL|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
219438384|NCT02703142|PROCEDURE|Patients after esophagectomy|postoperative endoscopic evaluation
219438385|NCT04390789|PROCEDURE|Non surgical Single visit Retreatment|Non-surgical endodontic retreatment will be carried out in single visit.
219438386|NCT04390789|PROCEDURE|Multi visit Retreatment with calcium hydroxide dressing|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
218828079|NCT03678051|BEHAVIORAL|Treatment as Usual (TAU)|Standard of care residential treatment
219438387|NCT05983042|GENETIC|Ibuprofen|Ibuprofen 400mg three times a day for three days
218828080|NCT03678051|BEHAVIORAL|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
218828081|NCT02261207|DRUG|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
218828082|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
218828083|NCT02639247|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
218828084|NCT02639247|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
218828085|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
218828086|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
218828087|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
218828088|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
218828089|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
219011828|NCT04096625|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
219011829|NCT04096625|DEVICE|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
219011830|NCT01459965|PROCEDURE|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
219011831|NCT01459965|PROCEDURE|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
219011832|NCT02013648|DRUG|Dasatinib|
219011833|NCT02013648|DRUG|Cytarabine|
219011834|NCT02013648|DRUG|Daunorubicin|
218828090|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
219011835|NCT02013648|DRUG|Idarubicin|
219011836|NCT04901494|DRUG|SSRI|Selective serotonin reuptake inhibitor
219011837|NCT05098145|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
219011838|NCT02801942|PROCEDURE|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
219011839|NCT02801942|PROCEDURE|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
219011840|NCT02801942|PROCEDURE|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
219438388|NCT02854670|DRUG|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
219438389|NCT01564602|DEVICE|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
218828091|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
218828092|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
218828093|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
218828094|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
218828095|NCT03553537|DRUG|Decitabine|10mg/m² iv on day 1-5
218828096|NCT03553537|DRUG|Cyclophosphamide|750mg/m² iv on day 6
218828097|NCT03553537|DRUG|Doxorubicin|DOX
218828098|NCT03553537|DRUG|Vincristine|1.4mg/m² iv on day 6
218828099|NCT03553537|DRUG|Prednisone|100mg/m² po on day6-10
218828100|NCT02982655|PROCEDURE|Individualized BP lowering|
218828101|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
218828102|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
218828103|NCT02964806|DIETARY_SUPPLEMENT|Ordinary Diet|
219011841|NCT02801942|OTHER|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
219011842|NCT02260284|OTHER|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
219011843|NCT02260284|OTHER|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
219011844|NCT02260284|OTHER|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
219011845|NCT02187588|DRUG|Eschscholtzia Californica - low dose|
219011846|NCT02187588|DRUG|Eschscholtzia Californica - high dose|
219438390|NCT01451398|DRUG|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
218828104|NCT02964806|DIETARY_SUPPLEMENT|Modified Atkin's Diet|
218828105|NCT02964806|DIETARY_SUPPLEMENT|Ketogenic Diet|
218828106|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
218828107|NCT06090058|DIAGNOSTIC_TEST|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
218828108|NCT03462758|DEVICE|IUD|Postpartum IUD placement
218828109|NCT05985707|DRUG|KN026|KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
218828110|NCT05985707|DRUG|KN046|KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
218828111|NCT05985707|DRUG|XELOX|XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
218828112|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
218828113|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
218828114|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
218828115|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
218828116|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
218828117|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
218828118|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
218828119|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
219011847|NCT02187588|DRUG|Ibuprofen|
219011848|NCT02187588|DRUG|Eschscholtzia Californica - low dose Placebo|
219011849|NCT02187588|DRUG|Eschscholtzia Californica - high dose Placebo|
219011850|NCT02187588|DRUG|Ibuprofen Placebo|
219011851|NCT04538066|DRUG|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
219011852|NCT04538066|OTHER|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
219011853|NCT02331225|OTHER|No intervention given|There is no intervention for this study
219011854|NCT00696696|DRUG|Gemcitabine|1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
219011855|NCT00696696|DRUG|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
219438391|NCT01451398|DRUG|Technosphere Powder|Placebo Comparator
219438392|NCT04016987|BEHAVIORAL|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
218828120|NCT04231097|OTHER|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
218828121|NCT02266147|DRUG|SD-101|
218828122|NCT02266147|RADIATION|Radiation therapy|
218828123|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
218828124|NCT02177630|OTHER|Endomyocardial Biopsy|
218828125|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
218828126|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
218828127|NCT01916486|BEHAVIORAL|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
218828128|NCT01916486|BEHAVIORAL|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
218828129|NCT01916486|BEHAVIORAL|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
218828130|NCT00507585|DRUG|Fluorouracil|300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
218828131|NCT00507585|DRUG|Avastin|10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
218828132|NCT00507585|DRUG|Leucovorin|200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
218828133|NCT00507585|DRUG|Oxaliplatin|60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
218828134|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
218828135|NCT01896687|DEVICE|Scrambler|Electrotherapy
218828136|NCT04377503|DRUG|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
218828137|NCT04377503|DRUG|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
218828138|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
218828139|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
218828140|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
218828141|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
218828142|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
218828143|NCT00413660|DRUG|CP-690,550|Oral tablets
218828144|NCT00413660|OTHER|placebo|Placebo
218828145|NCT05292690|DEVICE|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
218828146|NCT05439551|DIAGNOSTIC_TEST|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
218828147|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
218828148|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
218828149|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
218828150|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
218828151|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
218828152|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
218828153|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
218828154|NCT02785783|DEVICE|Standard colonoscopy|
218828155|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
218828156|NCT05794737|BIOLOGICAL|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
218828157|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
219438393|NCT04107428|DRUG|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
218828158|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
218828159|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
218828160|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
219011856|NCT00696696|DRUG|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
218828161|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
218828162|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
218828163|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
218828164|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
218828165|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
218828166|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
218828167|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
218828168|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
218828169|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
218828170|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
219011857|NCT00791245|BIOLOGICAL|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
219011858|NCT04061200|DRUG|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
219011859|NCT04061200|OTHER|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
219011860|NCT04061200|DRUG|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
219011861|NCT02507505|PROCEDURE|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
219011862|NCT02507505|PROCEDURE|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
219011863|NCT00002054|DRUG|Pentamidine isethionate|
219011864|NCT05407467|DIETARY_SUPPLEMENT|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
219011865|NCT03182829|DIAGNOSTIC_TEST|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
218828171|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
218828172|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
218828173|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
219011866|NCT03026608|BEHAVIORAL|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
219011867|NCT00254540|DRUG|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
218828174|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
219011868|NCT00225251|DRUG|bupropion XL|Antidepressant medication
219011869|NCT00225251|OTHER|Placebo|Placebo
219011870|NCT04778579|DRUG|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
219011871|NCT06825806|DEVICE|Femoral artery Doppler|Right common femoral artery will be examined before and after spinal anesthesia to evaluate pulsatility index, resisitive index, and waveform morphology
219011872|NCT04850690|DIAGNOSTIC_TEST|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
218828175|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
218828176|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
218828177|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
218828178|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
218828179|NCT05421676|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
218828180|NCT00541112|BIOLOGICAL|cetuximab|
218828181|NCT00541112|DRUG|capecitabine|
218828182|NCT00541112|DRUG|fluorouracil|
218828183|NCT00541112|DRUG|leucovorin calcium|
218828184|NCT00541112|DRUG|oxaliplatin|
218828185|NCT00541112|PROCEDURE|adjuvant therapy|
218828186|NCT00541112|PROCEDURE|conventional surgery|
218828187|NCT00541112|PROCEDURE|neoadjuvant therapy|
218828188|NCT00541112|RADIATION|radiation therapy|
219438394|NCT04107428|DRUG|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
218828189|NCT00001034|DRUG|Ganciclovir|
218828190|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
218828191|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
218828192|NCT01942824|BEHAVIORAL|Text Messages|
218828193|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
218828194|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
218828195|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
218828196|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
218828197|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
218828198|NCT04476667|BEHAVIORAL|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
218828199|NCT04541485|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
218828200|NCT04541485|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
218828201|NCT02388880|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
218828202|NCT01404650|DRUG|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
218828203|NCT03940079|DEVICE|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
218828204|NCT02957513|BEHAVIORAL|Text Messaging (TM)|As specified in the arm description above
218828205|NCT02957513|BEHAVIORAL|Health Coaching (HC)|As specified in the arm description above
218828206|NCT02957513|BEHAVIORAL|Enhanced Usual Care (EC)|As specified in the arm description above
218828207|NCT03586271|PROCEDURE|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
218828208|NCT03586271|PROCEDURE|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
218828209|NCT03586271|PROCEDURE|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
218828210|NCT03586271|PROCEDURE|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
218828211|NCT02112305|DRUG|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
218828212|NCT02112305|DRUG|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
218828213|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
218828214|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
218828215|NCT00042237|BEHAVIORAL|Schema Therapy|
218828216|NCT04229888|DEVICE|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
218828217|NCT04229888|DEVICE|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
218828218|NCT05156411|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
218828219|NCT02592421|DRUG|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
218828220|NCT02592421|DRUG|Placebo|Placebo Comparator
218828221|NCT03925987|BEHAVIORAL|Exposure therapy|10 weekly sessions of group-based exposure therapy
218828222|NCT00005989|DRUG|tipifarnib|
218828223|NCT04240431|DIAGNOSTIC_TEST|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
218828224|NCT01305187|DEVICE|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
218828225|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
218828226|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
218828227|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
219011873|NCT05752201|BIOLOGICAL|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
219011874|NCT05752201|BIOLOGICAL|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
219011875|NCT05752201|BIOLOGICAL|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
219011876|NCT05752201|OTHER|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
219011877|NCT05631886|BIOLOGICAL|TP53-EphA-2-CAR-DC|5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
218828228|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
218828229|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
218828230|NCT02560727|DEVICE|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
218828231|NCT02560727|DEVICE|colonoscope|FMT via colonoscope is the most common approach.
218828232|NCT03533088|OTHER|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
218828233|NCT03533088|OTHER|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
218828234|NCT00314821|DRUG|ropinirole|
218828235|NCT01299389|DRUG|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
218828236|NCT01299389|DRUG|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
218828237|NCT03882281|DRUG|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
219011878|NCT05631886|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
219011879|NCT05631886|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
219011880|NCT05631886|DRUG|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
219011881|NCT05631886|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
219011882|NCT06401616|DRUG|OAC will be discontinued for the duration of the trial|Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
218828238|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
218828239|NCT01749527|BEHAVIORAL|minimal activity|Pad test with minimal activity
218828240|NCT01382771|DRUG|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
218828241|NCT01382771|DRUG|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
218828242|NCT02950103|DRUG|Phosphoethanolamine|Phosphoethanolamine PO daily
218828243|NCT03363178|BIOLOGICAL|GC3107|BCG Vaccine, 0.1mL
218828244|NCT01060787|PROCEDURE|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
219438395|NCT03419845|DEVICE|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
218828245|NCT01060787|PROCEDURE|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
218828246|NCT04904107|DIAGNOSTIC_TEST|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
218828247|NCT04904107|OTHER|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
218828248|NCT00006132|DRUG|acyclovir|
218828249|NCT02784392|DRUG|Ulimorelin|Active
218828250|NCT02784392|DRUG|Metoclopramide|Comparator
218828251|NCT00817934|DRUG|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
218828252|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
218828253|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
218828254|NCT04596683|PROCEDURE|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
218828255|NCT01667341|BIOLOGICAL|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
218828256|NCT01667341|BIOLOGICAL|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
218828257|NCT01667341|BIOLOGICAL|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
218828258|NCT04118725|DIAGNOSTIC_TEST|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
218828259|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
218828260|NCT01023152|PROCEDURE|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
218828261|NCT01263457|DEVICE|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
218828262|NCT01151020|DEVICE|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
218828263|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
218828264|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
218828265|NCT01778959|DEVICE|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
218828266|NCT01778959|DEVICE|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
218828267|NCT01778959|DEVICE|standard OVD|use of a standard cohesive OVD during cataract surgery
218828268|NCT01778959|DEVICE|OVD|use of a highly cohesive OVD during cataract surgery
218828269|NCT02008994|OTHER|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
218828270|NCT01738633|BEHAVIORAL|nutritional counseling|
218828271|NCT01738633|BEHAVIORAL|respirology counseling|
218828272|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
219011883|NCT04533308|BEHAVIORAL|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
219011884|NCT05633524|OTHER|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
218828273|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
218828274|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
218828275|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
218828276|NCT02563145|BEHAVIORAL|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
218828277|NCT02563145|BEHAVIORAL|Treatment as usual|Psychoeducation, general counselling
218828278|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
218828279|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
218828280|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
218828281|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
218828282|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
218828283|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
218828284|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
218828285|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
218828286|NCT05723744|DEVICE|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
218828287|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
218828288|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
218828289|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
219438396|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"* 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
218828290|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
218828291|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
218828292|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
218828293|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
218828294|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
218828295|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
218828296|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
218828297|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
219011885|NCT01577823|DEVICE|Foley Catheter|
219011886|NCT00005892|DRUG|cyclophosphamide|
219011887|NCT00005892|PROCEDURE|Allogeneic Bone Marrow Transplantation|
219438397|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"* 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
219438398|NCT02562027|BEHAVIORAL|Modified Medical Research Council|"* Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
219363727|NCT00786045|OTHER|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
218828298|NCT04767672|DIETARY_SUPPLEMENT|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
218828299|NCT04767672|DIETARY_SUPPLEMENT|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
218828300|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
218828301|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
218828302|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
218828303|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
219580587|NCT05557357|PROCEDURE|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
219580588|NCT05557357|OTHER|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
218828304|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
218828305|NCT05789459|DEVICE|Stapler|Stapler
218828306|NCT05789459|OTHER|Suture|Suture
218828307|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
218828308|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
218828309|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
218828310|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
218828311|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
218828312|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
218828313|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
218828314|NCT00452075|DRUG|erlotinib|150mg daily
219011888|NCT04358666|PROCEDURE|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
219011889|NCT01138631|DEVICE|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
219580589|NCT04908683|BIOLOGICAL|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
219011890|NCT02529514|DRUG|Baclofen|25 mg for 7 days at 10 pm every day
219011891|NCT02529514|DRUG|Placebo|Placebo for 7 days at 10 pm every day
219011892|NCT00536601|DRUG|etoposide|Given IV
219011893|NCT00536601|DRUG|cyclophosphamide|Given IV
219011894|NCT00536601|DRUG|carmustine|Given IV
219011895|NCT00536601|DRUG|melphalan|Given IV
219011896|NCT00536601|DRUG|busulfan|Given IV
219011897|NCT00536601|DRUG|carboplatin|Given IV
219580590|NCT04908683|BIOLOGICAL|Placebo|Participants will receive a single IM injection of matching placebo.
219580591|NCT05748483|DRUG|Atogepant|Oral Tablet
219580592|NCT05748483|DRUG|Placebo for Atogepant|Oral Tablet
219580593|NCT05748483|DRUG|Topiramate|Oral Capsule
219580594|NCT05748483|DRUG|Placebo for Topiramate|Oral Capsule
219011898|NCT00536601|DRUG|thiotepa|Given IV
219011899|NCT00536601|RADIATION|total-body irradiation|Undergo TBI
219011900|NCT00536601|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo ASCT
219011901|NCT00536601|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
219011902|NCT03045328|DRUG|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
219011903|NCT03045328|DRUG|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
219438399|NCT02562027|BEHAVIORAL|EQ-5D|"* 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
219580595|NCT06639854|PROCEDURE|Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study."
219580596|NCT06639854|DRUG|Letermovir|Given by PO
219580597|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
219580598|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
219580599|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
219011904|NCT04090645|DEVICE|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
219011905|NCT01313767|DRUG|Botulinum toxin type A|Botulinum toxin type A
219011906|NCT01313767|DRUG|Botulinum Toxin type A|Botulinum Toxin type A
219011907|NCT01389544|DRUG|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
219011908|NCT01389544|DRUG|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
219011909|NCT01389544|DRUG|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
219011910|NCT00320983|DRUG|Topotecan|Topotecan
219580600|NCT04848038|BEHAVIORAL|Exercise|Standard public health exercise recommendations
219011911|NCT00320983|DRUG|Cisplatin|Cisplatin
219011912|NCT06280573|COMBINATION_PRODUCT|Wim Hoff method|breathing exercises, cold exposure, and meditation
219011913|NCT01648907|OTHER|Imaging exams|"Radiological examinations:~* Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~* MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~* Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~* Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~* Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
219011914|NCT01453634|DRUG|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
219011915|NCT01453634|DRUG|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
219011916|NCT04466254|DRUG|CPGJ602|Q2W/QW iv
219011917|NCT04466254|DRUG|cetuximab|QW iv
219011918|NCT01287897|DRUG|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
219011919|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
219011920|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
219011921|NCT01819077|PROCEDURE|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
219011922|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
219011923|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
219011924|NCT00468572|BEHAVIORAL|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
219438400|NCT02562027|BEHAVIORAL|Center for Epidemiological Studies Depression Scale|"* 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
218828315|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
218828316|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
219363765|NCT06446557|DRUG|treatment adaptation guided by ctDNA variation|"after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA."
218828317|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
218828318|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
218828319|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
218828320|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
218828321|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
218828322|NCT01162473|OTHER|Food Challenge|
218828323|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
218828324|NCT06120686|OTHER|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
218828325|NCT06120686|OTHER|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
218828326|NCT05329337|DIAGNOSTIC_TEST|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
218828327|NCT00440492|DRUG|PLA-695|
218828328|NCT01478932|BEHAVIORAL|diaphragmatic breathing retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
218828329|NCT01478932|BEHAVIORAL|Health Promotion|n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
218828330|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
218828331|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
218828332|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
219363766|NCT06446557|DRUG|standard management|At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
218828333|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
219363767|NCT01162421|BIOLOGICAL|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
218828334|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
218828335|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
219011925|NCT00468572|BEHAVIORAL|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
219363768|NCT01162421|DRUG|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
219363769|NCT03336502|DRUG|Posaconazole|Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
219363770|NCT04326634|OTHER|controlled exercises|controlled exercises
219363771|NCT04326634|OTHER|non controlled exercises group|non controlled exercises
219363772|NCT03798288|BEHAVIORAL|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
219363773|NCT03798288|OTHER|Usual care|Participants will receive usual care
219363774|NCT02249702|DRUG|gemcitabine + docetaxel|
219363775|NCT02249702|DRUG|trabectedin|
219363776|NCT04673097|OTHER|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
219363777|NCT04673097|OTHER|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
219438401|NCT02562027|BEHAVIORAL|Medical Outcomes Study Social Support Survey|"* 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
218828336|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
218828337|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
219011926|NCT04028076|BEHAVIORAL|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
219011927|NCT01436981|PROCEDURE|CABG|Preparation of artery mammaria interna
219011928|NCT03916757|BIOLOGICAL|V-Boost|Open label setting
219011929|NCT00484211|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
219011930|NCT05217433|OTHER|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
219011931|NCT05217433|OTHER|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
219011932|NCT04332354|OTHER|routine care. No intervention|no intervention
219011933|NCT05882240|OTHER|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
219011934|NCT00065507|DRUG|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
219011935|NCT00065507|DRUG|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
219011936|NCT05726812|BEHAVIORAL|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
219011937|NCT03255486|BIOLOGICAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
218828338|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
219011938|NCT02169739|DEVICE|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
219011939|NCT06495346|OTHER|self-questionnaires exploring|At each stage, subjects are asked to fill in self-questionnaires exploring the quality of their sleep, their potential distressing symptoms, their psychological state and the quality of their life at that moment. They complete the self-questionnaires at t
219011940|NCT05846061|OTHER|Prevalence study population|No intervention
219011941|NCT03635957|BIOLOGICAL|Pegloticase|pegloticase administered intravenously (IV)
219438402|NCT00784082|DRUG|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
219438403|NCT00661570|DEVICE|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
218828339|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
218828340|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
219011942|NCT03635957|DRUG|Methotrexate (MTX)|oral MTX
219438404|NCT04049812|DEVICE|PEMF|
219438405|NCT04049812|DEVICE|Hot pack|
219438406|NCT04049812|DEVICE|TENS|
219438407|NCT04049812|DEVICE|Sham PEMF|
219011943|NCT03635957|DRUG|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
219011944|NCT03635957|DRUG|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
219438408|NCT02134041|OTHER|traumatic brain injury|mild TBI, GCS \>/=13 after traumatic brain injury
219438409|NCT05011331|DEVICE|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
218828341|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
218828342|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
218828343|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
219011945|NCT03635957|DIETARY_SUPPLEMENT|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
219011946|NCT02537054|DRUG|Aflibercept|Intravitreal injection
219363778|NCT03594968|DIAGNOSTIC_TEST|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
219363779|NCT04959357|DIAGNOSTIC_TEST|Two dimensional speckle tracking imaging|lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
219580609|NCT06235307|OTHER|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
219580610|NCT06204887|PROCEDURE|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
218828344|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
218828345|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
218828346|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
218828347|NCT05568563|OTHER|Honey|Honey is a natural dietary product
218828348|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
218828349|NCT03555877|DRUG|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
218828350|NCT03555877|DRUG|Anastrozole|1mg once daily as indicated in the SmPC
218828351|NCT03555877|DRUG|Letrozole|2,5mg once daily as indicated in the SmPC
218828352|NCT03555877|DRUG|Exemestane|25mg once daily as indicated in the SmPC
218828353|NCT03555877|DRUG|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
218828354|NCT02797314|OTHER|Bone biopsies|Bone biopsies
218828355|NCT03503396|BEHAVIORAL|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
218828356|NCT03503396|BEHAVIORAL|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
218828357|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
218828358|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
218828359|NCT01930604|DRUG|NaCl (placebo)|
218828360|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
218828361|NCT03662282|DRUG|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
218828362|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
218828363|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
218828364|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
219363780|NCT02431416|DRUG|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
219363781|NCT02431416|DRUG|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
219363782|NCT04497519|DRUG|inhaled hydroxychloroquine|ascending dose of iHCQ
219363783|NCT03409874|OTHER|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
219363784|NCT03409874|OTHER|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
219363785|NCT03409874|OTHER|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
219363786|NCT03409874|DRUG|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
219363787|NCT03409874|OTHER|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
219363788|NCT00216970|DIETARY_SUPPLEMENT|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
218828365|NCT05419752|DRUG|bioceramic sealer|bioceramic based obturating sealer
218828366|NCT05419752|DRUG|MTA|MTA based obturating sealer
218828367|NCT05419752|DRUG|resin sealer|resin based obturating sealer
218828368|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
218828369|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
219011947|NCT05047679|BEHAVIORAL|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
219011948|NCT05047679|BEHAVIORAL|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
219011949|NCT03012412|BEHAVIORAL|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
219011950|NCT00350636|DRUG|Oxybutynin topical gel|1 application daily to skin for 12 weeks
219011951|NCT00350636|OTHER|Placebo topical gel|1 application daily to skin for 12 weeks
219011952|NCT05939375|BEHAVIORAL|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
219011953|NCT06320795|DEVICE|SOUNDI|Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
219195858|NCT06810674|BEHAVIORAL|Get out of your head campaign and website 2.0|"The Get out of your head campaign and website were launched in 2022 to improve men's mental health and reduce stigma (Stas et al., 2024). Developed with experts, a communication agency, and the target audience, the campaign included videos, testimonies, and a website with tailored information on mental health, suicide prevention, and help-seeking (www.komuitjekop.be).~The new campaign and updated website will focus specifically on facilitating help-seeking behaviour among men experiencing suicidal thoughts by increasing their perceived need for support. More specifically, the new campaign will aim to enhance the recognition of their suffering, the relevance of seeking and receiving help and changing the perception of suicidal thoughts, namely that these are not fixed or part of life, but instead are changeable and can improve with the correct help."
219580611|NCT06204887|PROCEDURE|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
219580612|NCT06204887|PROCEDURE|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
218828370|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
218828371|NCT05554276|COMBINATION_PRODUCT|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
218828372|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
218828373|NCT04966234|DRUG|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
218828374|NCT04966234|DRUG|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
218828375|NCT02977338|OTHER|Retrospective review|
218828376|NCT05985837|DEVICE|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
218828377|NCT05985837|DEVICE|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
218828378|NCT05985837|DEVICE|KalobaGOLA tablets|1 tablets, 6 times per day
218828379|NCT01547156|DEVICE|Intervention group|
218828380|NCT05221645|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
218828381|NCT05221645|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
218828382|NCT05221645|DRUG|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
218828383|NCT05221645|DRUG|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
218828384|NCT05221645|DRUG|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
218828385|NCT04881682|DEVICE|Immunoadsorption|see arm/group description
218828386|NCT04881682|BIOLOGICAL|Immunoglobulins|see arm/group description
218828387|NCT06567002|DRUG|MK-6552|Oral Administration
218828388|NCT02157909|DEVICE|Lotrafilcon B sphere modified design contact lenses|
218828389|NCT02157909|DEVICE|Lotrafilcon B sphere contact lenses|
219011954|NCT03164343|DEVICE|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
219011955|NCT01214161|DRUG|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
219011956|NCT01214161|OTHER|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
219011957|NCT05852743|DEVICE|shear wave and strain elastography|shear wave elastography is a quantitative technique , while strain elastography is qualitative technique
219011958|NCT03356951|PROCEDURE|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
219011959|NCT03356951|PROCEDURE|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
219011960|NCT04396990|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
219580613|NCT05422703|DEVICE|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
219011961|NCT04396990|DRUG|Topical Prednisolone|Standard of care topical drop treatment
219011962|NCT04890639|PROCEDURE|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
219011963|NCT03009565|OTHER|coronary artery disease|
219011964|NCT01042236|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
218828390|NCT00287781|DRUG|Lidocaine|
218828391|NCT00943761|DRUG|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
218828392|NCT00943761|DRUG|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
218828393|NCT00943761|DRUG|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
218828394|NCT00943761|DRUG|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
218828395|NCT02268383|DRUG|Luspatercept|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
218828396|NCT01911468|DRUG|metformin|
218828397|NCT01911468|DRUG|liraglutide|
218828398|NCT01911468|DRUG|metformin and liraglutide|
219011965|NCT04138329|PROCEDURE|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
219580614|NCT05422703|OTHER|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
219580615|NCT05422703|DEVICE|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
219580616|NCT05422703|PROCEDURE|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
218828399|NCT03099473|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
218828400|NCT03099473|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
218828401|NCT03099473|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
218828402|NCT02576873|OTHER|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
218828403|NCT02338388|PROCEDURE|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
218828404|NCT03246607|DEVICE|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
218828405|NCT04355650|OTHER|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
218828406|NCT02708680|DRUG|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
218828407|NCT02708680|DRUG|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
218828408|NCT02708680|DRUG|Placebo|A pill containing no active drug ingredient
218828409|NCT05894603|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
218828410|NCT05894603|DRUG|Molnupiravir|Molnupiravir
218828411|NCT01342926|DRUG|GSK933776|GSK933776
218828412|NCT01342926|DRUG|Placebo|Placebo
219011966|NCT04138329|PROCEDURE|Onstep Technique|In this group was used the Onstep technique for inguinal repair
219011967|NCT02133027|PROCEDURE|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
218828413|NCT04162470|DRUG|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
218828414|NCT00394264|PROCEDURE|Soft Tissue|
218828415|NCT00394264|PROCEDURE|Myofascial release|
218828416|NCT00394264|PROCEDURE|Counterstrain|
218828417|NCT00394264|PROCEDURE|Muscle energy|
218828418|NCT00394264|PROCEDURE|Sacro-iliac articulation|
218828419|NCT00394264|PROCEDURE|High-velocity, low amplitude|
218828420|NCT02568722|OTHER|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization."
218828421|NCT02568722|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
218828422|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
218828423|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
218828424|NCT01818843|OTHER|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
218828425|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
218828426|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
218828427|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
218828428|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
218828429|NCT04475107|DRUG|Placebo|Placebo
218828430|NCT01102920|BEHAVIORAL|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
218828431|NCT01102920|DEVICE|CPAP|CPAP-treatment as usual (during nights)
219011968|NCT02133027|DEVICE|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
219011969|NCT00227903|BEHAVIORAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
219011970|NCT00227903|BEHAVIORAL|Brief Advice|Advice and education
219011971|NCT02445482|PROCEDURE|Biopsy|archival tissue or fresh biospsy
219011972|NCT05767892|DRUG|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
219580617|NCT05422703|DRUG|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
218828432|NCT06173505|COMBINATION_PRODUCT|Vudalimab + Carboplatin + Pemetrexed|Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
218828433|NCT06173505|COMBINATION_PRODUCT|Pembrolizumab + Carboplatin + Pemetrexed|Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
218828434|NCT03552016|DRUG|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
218828435|NCT00066053|PROCEDURE|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
218828436|NCT00066053|PROCEDURE|Referral|
218828437|NCT06473051|OTHER|Original set|The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
218828438|NCT06473051|OTHER|Adapted set|The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
218828439|NCT05575466|DIAGNOSTIC_TEST|Blood samples|Hemostatic biomarkers
218828440|NCT05575466|DIAGNOSTIC_TEST|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
218828441|NCT06293937|BEHAVIORAL|Numerical label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
218828442|NCT06293937|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
219011973|NCT05767892|DRUG|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
219011974|NCT05959330|OTHER|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
219011975|NCT05959330|OTHER|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
219011976|NCT05959330|OTHER|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
219011977|NCT01475331|DRUG|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
219438410|NCT04083118|DIAGNOSTIC_TEST|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
218828443|NCT06293937|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
218828444|NCT06293937|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
218828445|NCT06358521|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral.~4. Additional PT care: Patients who require community PT but do not have the appropriate coverage for community-based services will be managed by the PT who provided the assessment in the primary care setting."
218828446|NCT06358521|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
219011978|NCT01475331|DRUG|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
219011979|NCT01475331|DRUG|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
219438411|NCT04083118|DIAGNOSTIC_TEST|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
219580618|NCT05422703|DRUG|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
219580619|NCT05422703|DRUG|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
219580620|NCT05422703|DIETARY_SUPPLEMENT|Soft cold diet|For the day of surgery
219580621|NCT05034120|DRUG|XZP-3621|Administer a single dose of XZP-3621 tablet after a low-fat meal.
219580622|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
219580623|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
219438412|NCT06283225|DEVICE|Pia-App|The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
219438413|NCT01000025|DRUG|PF-00299804|PF-804 45 mg PO, daily
218828447|NCT05580614|DEVICE|Sham|MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
218828448|NCT05580614|DEVICE|tVNS|MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
218828449|NCT04372875|BEHAVIORAL|SHS-derived CDS|This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
218828450|NCT05196308|DRUG|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
218828451|NCT05196308|DRUG|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
218828452|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
218828453|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
218828454|NCT00788814|BEHAVIORAL|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
218828455|NCT03338985|GENETIC|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
218828456|NCT04185350|DRUG|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
218828457|NCT00962871|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
218828458|NCT00962871|DRUG|tenofovir|300mg po daily for 2 weeks
218828459|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
218828460|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
218828461|NCT02270281|DRUG|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
218828462|NCT04196725|OTHER|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
218828463|NCT04196725|BEHAVIORAL|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
218828464|NCT01544348|OTHER|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
218828465|NCT01544348|BIOLOGICAL|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
219011980|NCT01197053|BIOLOGICAL|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
219011981|NCT01197053|BIOLOGICAL|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
219011982|NCT02334007|DRUG|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
219438414|NCT01000025|DRUG|Placebo|Placebo 45 mg PO, daily
219438415|NCT00810589|DRUG|Levemir|0,4 IE per kg bodyweight
218828466|NCT01544348|BIOLOGICAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
218828467|NCT01544348|BIOLOGICAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
218828468|NCT01544348|BIOLOGICAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
218828469|NCT01544348|BIOLOGICAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
218828470|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
218828471|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
218828472|NCT02705092|OTHER|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
218828473|NCT02705092|OTHER|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
218828474|NCT05871580|RADIATION|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
218828475|NCT05871580|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
218828476|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
218828477|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
218828478|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
218828479|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
218828480|NCT00752414|DRUG|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
219438416|NCT00810589|DRUG|Humalog NPL Insulin|0,4 IE per kg bodyweight
219438417|NCT04307173|DRUG|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
219438418|NCT04307173|DRUG|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
219438419|NCT05681897|PROCEDURE|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
219438420|NCT01632072|DIETARY_SUPPLEMENT|Nutritional support|Nutritional support and counseling
219438421|NCT04123171|DIAGNOSTIC_TEST|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
219438422|NCT00422669|DEVICE|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
219438423|NCT00422669|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
219438424|NCT04360772|DIAGNOSTIC_TEST|mHLA-DR|"* Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~* At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~* At Month 24 : Collection from medical report of~* any infectious events that would have occured during the follow-up~* course of the disease with corticosteroids~* survival or death at 24 months of follow-up."
219438425|NCT02791360|OTHER|Brain MRI|
219438426|NCT05663476|OTHER|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
218828481|NCT00752414|DRUG|Placebo|same frequency as MP-376
218828482|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
218828483|NCT03911297|OTHER|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
219438427|NCT03736811|DEVICE|Polyglactin 910 or polydioxanone|Vicryl or PDS II
219438428|NCT03736811|DEVICE|Polyester or polypropylene|Ethibond Excel or prolene
219438429|NCT02738580|DRUG|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
219438430|NCT02738580|DRUG|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
219438431|NCT03295591|DIAGNOSTIC_TEST|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
219580624|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
219580625|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
219580626|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
218828484|NCT03695887|DRUG|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
218828485|NCT03695887|DRUG|Placebo|Inactive comparator
219011983|NCT02334007|OTHER|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
218828486|NCT05200559|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
218828487|NCT05200559|DRUG|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
218828488|NCT05006066|OTHER|Temporal Summation|4 type of stimulations applied on the right arm
218828489|NCT01204957|DIETARY_SUPPLEMENT|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
218828490|NCT01204957|DIETARY_SUPPLEMENT|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
218828491|NCT03695445|DRUG|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
218828492|NCT01710566|DRUG|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
218828493|NCT01710566|DRUG|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
219011984|NCT06176573|PROCEDURE|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
219011985|NCT04853927|DRUG|Proxalutamide|Proxalutamide 300mg q.d suspension
219011986|NCT04853927|DRUG|Placebo|Proxalutamide 300mg q.d placebo
219011987|NCT05356455|BEHAVIORAL|motivational interview technique|Difference between pre-test and post-test
219011988|NCT03593265|OTHER|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
219438432|NCT03175874|PROCEDURE|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
219438433|NCT01250756|BIOLOGICAL|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
219438434|NCT01250756|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
219438435|NCT01250756|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
218828494|NCT02257320|DEVICE|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
218828495|NCT01647854|PROCEDURE|Teleconsultation|Teleconsultation in prehospital emergencies
218828496|NCT04079660|DIAGNOSTIC_TEST|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
218828497|NCT03649802|DIETARY_SUPPLEMENT|Low dose vitamin D3|Low dose arm-800 IU given daily
218828498|NCT03649802|DIETARY_SUPPLEMENT|High dose vitamin D3|High dose arm-5000 IU given daily
218828499|NCT03790748|PROCEDURE|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
219438436|NCT05560178|OTHER|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
219580627|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
219580628|NCT03947736|DIAGNOSTIC_TEST|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
218828500|NCT03790748|PROCEDURE|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
218828501|NCT03790748|PROCEDURE|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
218828502|NCT02314442|DRUG|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
218828503|NCT02314442|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
218828504|NCT03834896|OTHER|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
218828505|NCT00626041|OTHER|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
218828506|NCT03768323|OTHER|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
218828507|NCT03768323|OTHER|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
218828508|NCT00251992|DRUG|Esomeprazole|
218828509|NCT03332147|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
218828510|NCT03332147|DEVICE|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
218828511|NCT01445847|DRUG|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
218828512|NCT01445847|OTHER|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
218828513|NCT02004301|DRUG|Radiolabelled T4 Tablet|
218828514|NCT02004301|DRUG|Radiolabelled T6 Tablet|
219011989|NCT00562939|BIOLOGICAL|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
219011990|NCT00562939|BIOLOGICAL|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
219011991|NCT01533233|PROCEDURE|thoracoscopic lobectomy and mediastinal lymph node dissection|
219195859|NCT06808620|OTHER|The group where the peanut ball is used|Before the application, the appropriate ball size for the physical characteristics and comfort of the pregnant women will be determined. Pregnant women will be given 4 different sizes of peanut balls with a diameter of 40, 55, 65 and 75 cm. In order for the pregnant woman to continue her in-bed balance exercises and position changes, she will be allowed to sit on the peanut ball with her knees and hips at an angle of approximately 90° and her spine upright. A 40-55 cm birthing ball will be used for women between 150-160 cm tall, a 65 cm birthing ball for women between 160-170 cm tall, and a 75 cm birthing ball for women between 170-185 cm tall. Position changes with the peanut ball will be carried out in accordance with a position/exercise guide prepared by researchers in line with literature information. The peanut ball will be applied in 6 different positions. These positions to be applied will consist of side-lying positions, semi-sitting pose, forward bending pose and squatting pos
219195860|NCT06808373|BEHAVIORAL|hypnosis|Hypnosis will be applied to periodontitis patients
219438437|NCT00460837|DRUG|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
219438438|NCT00248378|DRUG|Smoked Cannabis|
219438439|NCT00106288|DRUG|Micafungin|IV
219580629|NCT00229736|GENETIC|AAV-hAADC-2|9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
219580630|NCT00229736|GENETIC|AAV-hAADC-2|3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
219438440|NCT00106288|DRUG|Liposomal Amphotericin B|IV
219580631|NCT03249974|DEVICE|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
219438441|NCT02533193|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem"
218828515|NCT01166035|DRUG|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
219195861|NCT05031832|DIAGNOSTIC_TEST|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
219438442|NCT02533193|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed"
219438443|NCT05226897|DRUG|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
218828516|NCT01166035|DRUG|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
218828517|NCT02962921|DRUG|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
218828518|NCT04052165|PROCEDURE|Glaucoma Implant|
218828519|NCT00222820|DRUG|escitalopram|
218828520|NCT00222820|BEHAVIORAL|Interpersonal Psychotherapy|
218828521|NCT04527835|DIAGNOSTIC_TEST|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
218828522|NCT00125788|DRUG|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
218828523|NCT00125788|DRUG|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
218828524|NCT04443114|OTHER|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
218828525|NCT04443114|OTHER|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
218828526|NCT02060981|BEHAVIORAL|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
218828527|NCT02060981|BEHAVIORAL|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
218828528|NCT02060981|BEHAVIORAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
218828529|NCT00128999|PROCEDURE|Intensity-Modulated Radiation Therapy|
218828530|NCT01987466|BIOLOGICAL|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
218828531|NCT05805163|BEHAVIORAL|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
218828532|NCT05805163|BEHAVIORAL|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
218828533|NCT05843331|PROCEDURE|implants|Four implants in the maxilla with locator attachments
218828534|NCT01677871|DRUG|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
218828535|NCT01677871|DRUG|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
219195862|NCT06196710|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
219438444|NCT05226897|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
219438445|NCT05226897|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
219438446|NCT05226897|DRUG|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
218828536|NCT01677871|DRUG|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
218828537|NCT01677871|DRUG|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
218828538|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
218828539|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
218828540|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
218828541|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
218828542|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
218828543|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
218828544|NCT06607263|DEVICE|Dental floss|Dental floss
218828545|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
218828546|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
218828547|NCT06716164|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
218828548|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
218828549|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
219011992|NCT02261714|BIOLOGICAL|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
219011993|NCT02261714|BIOLOGICAL|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
219011994|NCT03113019|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
219011995|NCT00361855|DRUG|NX-CP105|
219195863|NCT06196710|DEVICE|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
219438447|NCT02219997|DEVICE|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
218828550|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
218828551|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
218828552|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
218828553|NCT00211796|DRUG|Divalproex Sodium ER|
218828554|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
218828555|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
218828556|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
218828557|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
218828558|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
218828559|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
219011996|NCT02411292|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
218828560|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
219195864|NCT05392283|DEVICE|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
219195865|NCT05970016|DRUG|TCC1727 tablet（1）|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
219195866|NCT05970016|DRUG|TCC1727 tablet（2）|Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.
219438448|NCT02219997|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
219438449|NCT02219997|DEVICE|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
219438450|NCT02219997|DEVICE|Clear IOL|Clear IOL, previously implanted
219580632|NCT03572166|DIAGNOSTIC_TEST|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
218828561|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
218828562|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
218828563|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
218828564|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
218828565|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
218828566|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
219011997|NCT03304574|BEHAVIORAL|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
219011998|NCT00966173|DEVICE|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
219011999|NCT03816085|OTHER|Shoes|Shoes with different heel heights
219012000|NCT02149927|DRUG|Sevoflurane|
219012001|NCT00048295|DRUG|Alicaforsen|
219012002|NCT02657707|DEVICE|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
219012003|NCT02657707|DEVICE|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
219012004|NCT00882193|DRUG|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
219012005|NCT00882193|DRUG|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
219012006|NCT00882193|DRUG|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
219012007|NCT04352855|DRUG|Ceftolozane/tazobactam|Administration
219012008|NCT00293696|DRUG|bicalutamide (Casodex), goserelin (Zoladex)|
219195867|NCT06808191|DEVICE|pulsed electromagnetic currant machine|Pulsed electromagnetic therapy will be delivered at the frequency of 12Hz, with magnetic flux density of 12G. Each treatment session will last for 1 hour, which will be repeated for 14 sessions within 4weeks.
219438451|NCT04751968|OTHER|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
219438452|NCT04751968|BEHAVIORAL|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
219438453|NCT01037972|BEHAVIORAL|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
219012009|NCT01908257|DRUG|lesinurad 400 mg|
219012010|NCT01908257|DRUG|ranitidine 150 mg|
219012011|NCT01908257|DRUG|lesinurad 400 mg + ranitidine 150 mg|
219012012|NCT05749302|DRUG|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
219012013|NCT02015780|DRUG|Fasiglifam|Fasiglifam tablets
219012014|NCT02015780|DRUG|Placebo|Fasiglifam placebo-matching tablets
219012015|NCT02015780|DRUG|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
219012016|NCT02784990|BIOLOGICAL|Lipase, amylase and CRP (C-reactive protein) dosages|
219012017|NCT00279734|DRUG|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
218828567|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
218828568|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
218828569|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
218828570|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
218828571|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
218828572|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
218828573|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
218828574|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
219012018|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
219012019|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
219012020|NCT00279734|DRUG|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
219012021|NCT01938911|DRUG|Syntocinon-Spray|Intranasal oxytocin (24 IU)
219012022|NCT01938911|DRUG|Placebo of syntocinon|Intranasal administration
219012023|NCT01938911|BEHAVIORAL|Social support|Social support from the best friend
219012024|NCT06279689|OTHER|Ultrasound scans|Ultrasound scans connected with an application enabling the measurement of the force applied.
219012025|NCT04103632|DIAGNOSTIC_TEST|EVH test|"* Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement"
218828575|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
218828576|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
218828577|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
218828578|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
218828579|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
218828580|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
218828581|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
218828582|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
219012026|NCT01011660|DRUG|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
219012027|NCT00638313|BIOLOGICAL|Placebo|Subjects will be given either Placebo or PF-04603629.
219012028|NCT00638313|BIOLOGICAL|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
219012029|NCT02208947|BEHAVIORAL|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
218828583|NCT06306911|DIETARY_SUPPLEMENT|Aronia Melanocarpa extract|Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
218828584|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
218828585|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
219012030|NCT02208947|BEHAVIORAL|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
219012031|NCT02852408|PROCEDURE|Laparoscopic cholecystectomy|
219012032|NCT05313594|DIAGNOSTIC_TEST|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
219012033|NCT05313594|DIAGNOSTIC_TEST|MRI|MRI imaging
219012034|NCT05313594|DIAGNOSTIC_TEST|DEXA|DEXA scan
219012035|NCT05313594|DEVICE|Freestyle Libre|Continuous blood glucose measurement
218828586|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
219012036|NCT05313594|DEVICE|ActivPAL3|Continuous physical activity measurement
219012037|NCT04417881|OTHER|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
219012038|NCT01988831|DRUG|Propranolol hydrochloride|This intervention apply to Propranolol group
218828587|NCT02899455|DRUG|HGP0904|
218828588|NCT02899455|DRUG|HGP0608|
218828589|NCT02899455|DRUG|HGP0816|
218828590|NCT02899455|DRUG|HGP0904 Placebo|
218828591|NCT02899455|DRUG|HGP0816 Placebo|
218828592|NCT00318318|DRUG|Premarin|
218828593|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
219012039|NCT01988831|DRUG|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
219012040|NCT03644199|OTHER|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
219012041|NCT03644199|OTHER|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
219012042|NCT05305950|OTHER|Patient population|Questionnaire, standard of care
219012043|NCT04003922|OTHER|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
219195868|NCT06808191|OTHER|Placebo|control group will receive intervention by using the same PEMF unit, but the output will be shut off.
218828594|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
219438454|NCT01037972|BEHAVIORAL|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
219438455|NCT01324687|OTHER|Telemedicine care|Availability of telemedicine
218828595|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
218828596|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
218828597|NCT06405438|OTHER|No intervention|No intervention.
218828598|NCT00005903|DRUG|GDNF & Synchro Med Infusion System|
218828599|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
219012044|NCT01569178|PROCEDURE|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
219012045|NCT04276597|DRUG|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
219012046|NCT05512611|DIAGNOSTIC_TEST|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
219012047|NCT00398060|BEHAVIORAL|Cognitive-behavioral life-style counseling|
219012048|NCT03476694|PROCEDURE|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
219012049|NCT03512509|OTHER|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
219012050|NCT03512509|OTHER|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
219195869|NCT04667572|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
219195870|NCT06808711|OTHER|Buccocéan mouthwash|Normal conditions of use
219195871|NCT06808711|OTHER|Marketed mouthwash|Normal conditions of use
219195872|NCT06810271|BEHAVIORAL|Eccentric resistance exercise|150 maximal, unilateral eccentric contractions of the quadriceps muscles on a computerized dynamometer.
219195873|NCT06810245|DRUG|PIPE-791|PIPE-791 tablet, taken once daily for 4 weeks
219195874|NCT06810245|DRUG|Placebo|Placebo tablet, taken once daily for 4 weeks
219438456|NCT02657187|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
219438457|NCT02657187|DRUG|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
219438458|NCT04969432|OTHER|Client-centered|Rehabilitation
218828600|NCT04289558|DRUG|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
218828601|NCT01433406|DRUG|TAK-875|
218828602|NCT01433406|DRUG|TAK-875|
219012051|NCT04462549|BEHAVIORAL|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
219012052|NCT02234089|DRUG|Degarelix|According to medical practice
219012053|NCT02234089|DRUG|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
219012054|NCT00814528|DRUG|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
219012055|NCT00814528|DRUG|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
219012056|NCT01654094|DEVICE|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
219012057|NCT01654094|OTHER|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
219012058|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
219012059|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
219012060|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
219012061|NCT01291173|DRUG|Placebo|Placebo capsule taken once daily for up to 11 weeks
219012062|NCT03913793|OTHER|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
219012063|NCT02349581|PROCEDURE|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
219012064|NCT02349581|DRUG|Bupivacaine|
219012065|NCT03468257|BEHAVIORAL|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
218828603|NCT03402932|OTHER|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
218828604|NCT03402932|OTHER|Visual|The cognitive test will be administered visually by using timed computer slides.
218828605|NCT03402932|OTHER|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
219012066|NCT00504933|DRUG|bilastine|20 mg (encapsulated) tablets QD/14days
219012067|NCT00504933|DRUG|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
219012068|NCT00504933|DRUG|Placebo|(encapsulated) Tablets QD/14 days
219012069|NCT01883843|DEVICE|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
219012070|NCT01883843|DEVICE|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
219012071|NCT01113801|DRUG|LY2382770|Subcutaneous injection given monthly for 12 months
218828606|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
218828607|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
219012072|NCT01113801|DRUG|Placebo|Subcutaneous injection given monthly for 12 months
218828608|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
219012073|NCT06112444|OTHER|scale|The scale of Short Western Ontario Rotator Cuff İndex
219580633|NCT03572166|DIAGNOSTIC_TEST|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
219580634|NCT01935466|DRUG|Pioglitazone|Ever users of Pioglitazone
218828609|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
218828610|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
218828611|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
218828612|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
218828613|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
218828614|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
218828615|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
218828616|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
218828617|NCT02533544|DRUG|tenofovir disoproxil fumarate|
218828618|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
218828619|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
218828620|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
218828621|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
218828622|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
218828623|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
218828624|NCT02478112|DEVICE|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
218828625|NCT06295380|BEHAVIORAL|Virtual environment practiced on the Caren|The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.
218828626|NCT06295380|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy
218828627|NCT00288548|DRUG|Metoprolol|
218828628|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
218828629|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
218828630|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
218828631|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
218828632|NCT02904369|DRUG|Emtricitabine|
218828633|NCT02904369|DRUG|Tenofovir alafenamide|
218828634|NCT02904369|DRUG|Tenofovir disoproxil|
218828635|NCT03856736|OTHER|MIAT|Moderated aerobic exercise
218828636|NCT03856736|OTHER|Control|Weekly body relaxation and sham group
218828637|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
218828638|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
219012074|NCT03833973|BEHAVIORAL|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
219012075|NCT02728895|DRUG|Vedolizumab|Vedolizumab Injection.
218828639|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
218828640|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
218828641|NCT05460897|BEHAVIORAL|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
218828642|NCT05687981|DRUG|Bupivacaine|the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
218828643|NCT05687981|DRUG|Dexamethasone|2 mg dexamethasone
218828644|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
218828645|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
218828646|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
218828647|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
218828648|NCT00002798|DRUG|asparaginase|
218828649|NCT00002798|DRUG|daunorubicin hydrochloride|
218828650|NCT00002798|DRUG|fludarabine phosphate|
218828651|NCT00002798|DRUG|therapeutic hydrocortisone|
218828652|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
218828653|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
218828654|NCT00002798|BIOLOGICAL|filgrastim|Given SC
218828655|NCT00002798|DRUG|cytarabine|Given IV or IT
218828656|NCT00002798|DRUG|idarubicin|Given IV
218828657|NCT00002798|DRUG|dexamethasone|Given PO
218828658|NCT00002798|DRUG|thioguanine|Given PO
218828659|NCT00002798|DRUG|etoposide|Given IV
218828660|NCT00002798|DRUG|methotrexate|Given IT
218828661|NCT00002798|DRUG|cyclophosphamide|Given IV
218828662|NCT00002798|BIOLOGICAL|aldesleukin|
218828663|NCT00002798|DRUG|busulfan|
218828664|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
218828665|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
218828666|NCT00174850|DRUG|Gaitril|
218828667|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
218828668|NCT02386462|DRUG|Propofol|
218828669|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
218828670|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
218828671|NCT05071612|DRUG|AD109|Oral administration at bedtime
218828672|NCT05071612|DRUG|AD504|Oral administration at bedtime
218828673|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
218828674|NCT05071612|DRUG|Placebo|Oral administration at bedtime
218828675|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
218828676|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218828677|NCT00003846|BIOLOGICAL|filgrastim|
218828678|NCT00003846|DRUG|carboplatin|
218828679|NCT00003846|DRUG|cyclophosphamide|
218828680|NCT00003846|DRUG|thiotepa|
218828681|NCT00003846|DRUG|vincristine sulfate|
218828682|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
218828683|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
218828684|NCT00003846|RADIATION|radiation therapy|
218828685|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
218828686|NCT00784368|DRUG|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
218828687|NCT00784368|DRUG|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
218828688|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
218828689|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
218828690|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
218828691|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
218828692|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
218828693|NCT01596855|DRUG|Epoetin Alfa|TIW
218828694|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
218828695|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
219012076|NCT01862198|DEVICE|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
219438459|NCT01195194|DRUG|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
219438460|NCT03509844|BEHAVIORAL|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
219438461|NCT03383627|DEVICE|Continuous Glucose Monitoring|"* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
219012077|NCT06495047|DRUG|Long-acting bronchodilator therapy (LABD)|Long-acting inhaler therapy
219012078|NCT06495047|DRUG|Short-acting bronchodilator therapy (SABD)|Short-acting inhaler therapy
219438462|NCT02600494|DRUG|ITI-007 (Lumateperone)|
219438463|NCT02600494|DRUG|Placebo|
219438464|NCT03402269|OTHER|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
219438465|NCT04853589|DEVICE|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
219438466|NCT04853589|DEVICE|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
219438467|NCT03032289|BEHAVIORAL|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
219438468|NCT02673723|DRUG|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
219438469|NCT02673723|DRUG|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
219438470|NCT00346138|PROCEDURE|Corneal transplantation|
219438471|NCT00351091|DRUG|RISEDRONATE|
219438472|NCT04003181|DRUG|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
219438473|NCT04003181|DRUG|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
219438474|NCT01433120|DIETARY_SUPPLEMENT|Lactobacillus paracasei ssp paracasei F19|10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
219438475|NCT01433120|DIETARY_SUPPLEMENT|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
219438476|NCT01433120|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
219438477|NCT05793957|OTHER|Questionnaire Administration|Ancillary studies
219438478|NCT05793957|BEHAVIORAL|Telephone-Based Intervention|Use smartphone
219438479|NCT05793957|OTHER|Virtual Technology Intervention|Use VR headset
219438480|NCT03525626|BEHAVIORAL|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
219438481|NCT03972826|OTHER|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
219438482|NCT02532426|PROCEDURE|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
219438483|NCT06202339|DEVICE|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
219438484|NCT03446989|BEHAVIORAL|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
219438485|NCT05114148|DEVICE|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
218828696|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
218828697|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
218828698|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
219012079|NCT01506479|BEHAVIORAL|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
219012080|NCT01506479|BEHAVIORAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
218828699|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
218828700|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
219012081|NCT01506479|BEHAVIORAL|No Intervention|No-exercise control (i.e., usual care);
219012082|NCT04053959|DRUG|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
219012083|NCT04053959|DRUG|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
219012084|NCT01811173|OTHER|Nurse-physician comprehensive care|"Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan."
219012085|NCT03711045|BEHAVIORAL|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
219438486|NCT04768530|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
219012086|NCT00938379|DRUG|20% deet insect repellent|skin-applied repellent lotion
219012087|NCT00938379|DRUG|placebo control|Identical base formulation of lotion but without any deet active
219012088|NCT04375137|DIAGNOSTIC_TEST|Oxidative Stress ELISA Kit|Checking oxidative stress markers and redox system status
219438487|NCT04768530|DRUG|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
219438488|NCT04539925|OTHER|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
218828701|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
218828702|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
219012089|NCT00427258|DRUG|MOA-728|
219012090|NCT03318315|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
219012091|NCT03318315|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
219012092|NCT03318315|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
219012093|NCT03318315|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
219012094|NCT00687765|DRUG|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
219012095|NCT03327311|DEVICE|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
219012096|NCT02064647|OTHER|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
219012097|NCT02064647|OTHER|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
219012098|NCT02436356|DEVICE|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
219012099|NCT02436356|RADIATION|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
219012100|NCT02436356|RADIATION|MRI|Determines bound water and pore water of bone.
219012101|NCT04577118|DEVICE|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
218828703|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
218828704|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
219012102|NCT03410940|DEVICE|CLS Brevius stem with Kinectiv technology|
219012103|NCT04695925|DRUG|Osimertinib 80 MG [Tagrisso]|osimertinib 80 mg po qd until disease progression
219438489|NCT06090448|DEVICE|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
219438490|NCT00819104|DRUG|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
219438491|NCT00819104|DRUG|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
218828705|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
218828706|NCT02079909|DRUG|Placebo|Placebo
218828707|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
218828708|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
218828709|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
219438492|NCT00819104|DRUG|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
218828710|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
219438493|NCT00819104|DRUG|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
218828711|NCT00470002|DRUG|Somatropin|
219438494|NCT00819104|DRUG|Amlodipine 5mg|tablet,oral,OD,8 weeks
219438495|NCT01939964|OTHER|Activation Mist|Activation Mist topical spray
218828712|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
218828713|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
218828714|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
218828715|NCT00727545|OTHER|iron bisglycine chelate|
219012104|NCT04695925|DRUG|Pemetrexed 500 MG Injection|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
219012105|NCT04695925|DRUG|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
219012106|NCT00810407|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
218828716|NCT00727545|OTHER|placebo|
218828717|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
219012107|NCT05625009|PROCEDURE|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
219438496|NCT02142504|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
219438497|NCT02142504|DRUG|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
218828718|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
218828719|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
218828720|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
219012108|NCT05625009|PROCEDURE|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
219012109|NCT04742933|OTHER|There is no intervention in this observational trial|There is no intervention in this observational trial
219012110|NCT01337947|DRUG|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
219012111|NCT06456060|DRUG|Alvogyl|Alvogyl soaked in a sterile gauze will be applied to cover the socket.
219012112|NCT06456060|DRUG|Honey|Honey soaked in a sterile gauze will be applied to cover the socket.
219438498|NCT05007223|DRUG|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
219438499|NCT02483455|DRUG|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
218828721|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
218828722|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
218828723|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
218828724|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
218828725|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
218828726|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
218828727|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
218828728|NCT00290992|DRUG|rasburicase (SR29142)|
218828729|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
218828730|NCT03045614|OTHER|No intervention|No intervention
218828731|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
218828732|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
218828733|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
219012113|NCT04995133|DRUG|Colistin|intravenous administration
219012114|NCT06061653|COMBINATION_PRODUCT|IPT plus HD-tDCS|psychotherapy plus device
219012115|NCT06061653|COMBINATION_PRODUCT|IPT plus sham HD-tDCS|psychotherapy plus sham device
219438500|NCT02483455|DRUG|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
219438501|NCT01629979|PROCEDURE|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
219438502|NCT01629979|RADIATION|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
219438503|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
219438504|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
219438505|NCT01351064|OTHER|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
218828734|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
218828735|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
218828736|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
218828737|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
219012116|NCT04208399|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
219012117|NCT05703256|DEVICE|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219012118|NCT05703256|DEVICE|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
219580635|NCT01957072|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
219580636|NCT04243434|DRUG|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
219580637|NCT04243434|COMBINATION_PRODUCT|CHOP|CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
219580638|NCT04243434|COMBINATION_PRODUCT|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
219580639|NCT06151496|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
219580640|NCT06151496|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
219580641|NCT03275636|BIOLOGICAL|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
219580642|NCT03621059|BEHAVIORAL|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
219596933|NCT03563911|BEHAVIORAL|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
219012119|NCT04843774|DRUG|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
219012120|NCT05890937|DIAGNOSTIC_TEST|Oral and practical exam|Oral and practical exam that performed at the end of the semester
219012121|NCT02826031|DRUG|Sodium Hyaluronate Injection|
219012122|NCT02826031|DRUG|DICL-SR|
218828738|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
218828739|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
218828740|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
218828741|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
218828742|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
218828743|NCT01887730|BEHAVIORAL|Control|
218828744|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
219012123|NCT00439426|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
219012124|NCT00439426|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
219012125|NCT01080690|PROCEDURE|EGD|In this arm EGD will be performed before EUS.
218828745|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
218828746|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
218828747|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
218828748|NCT00062855|PROCEDURE|Skin Biopsy|
218828749|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
219012126|NCT01080690|PROCEDURE|EUS|In this arm EUS will be performed before EGD.
219012127|NCT03784404|PROCEDURE|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
219763762|NCT05591924|PROCEDURE|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
218828750|NCT00025571|DRUG|HPPH|
218828751|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
218828752|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
218828753|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
218828754|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
218828755|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
218828756|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
218828757|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
218828758|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
218828759|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
218828760|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
218828761|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
218828762|NCT02112643|DRUG|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
219012128|NCT03784404|PROCEDURE|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
219438506|NCT01670136|DRUG|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
219438507|NCT00055575|DRUG|Scopolamine Nasal Spray|
219438508|NCT03895970|DRUG|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
219438509|NCT01610206|DRUG|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
219438510|NCT01610206|DRUG|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
219012129|NCT03784404|DRUG|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
218828763|NCT02112643|DIETARY_SUPPLEMENT|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
218828764|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
219438511|NCT05186987|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219438512|NCT05186987|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219580643|NCT04267107|OTHER|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
219580644|NCT02422771|OTHER|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
219580645|NCT04069871|DEVICE|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
218828765|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
218828766|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
218828767|NCT01741493|DRUG|Tofacitinib|Oral administration
218828768|NCT02155101|DRUG|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
218828769|NCT02155101|DRUG|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
218828770|NCT04649216|DRUG|PCO371|PCO371 Capsule
218828771|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
218828772|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
218828773|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
218828774|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
218828775|NCT01647698|BEHAVIORAL|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
218828776|NCT01647698|BEHAVIORAL|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
218828777|NCT01647698|BEHAVIORAL|No training|No training during the experiment.
219012130|NCT00988455|RADIATION|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
218828778|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
218828779|NCT04564235|GENETIC|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
218828780|NCT04564235|GENETIC|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
218828781|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
218828782|NCT03310359|OTHER|Placebo|Matching placebo pill
218828783|NCT01405404|BEHAVIORAL|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
218828784|NCT01405404|OTHER|Parent Training|12-session group on parenting skills and child behavior management
219438513|NCT00216515|DRUG|galantamine hydrobromide|
219438514|NCT01046656|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
219438515|NCT03274180|OTHER|Nursing consultation|travel preventive consultation was performed by nurse
218828785|NCT06167967|DIAGNOSTIC_TEST|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
219012131|NCT01132157|DRUG|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
219012132|NCT01132157|DRUG|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
219012133|NCT05681455|DEVICE|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
219012134|NCT04528979|OTHER|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
219195875|NCT04890067|OTHER|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
219195876|NCT06350877|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
219195877|NCT05637541|DRUG|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
218828786|NCT06167967|DIAGNOSTIC_TEST|standard treatment|This group was treated according to standard procedure
218828787|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
218828788|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
218828789|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
218828790|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
218828791|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
218828792|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
218828793|NCT03245346|DRUG|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
218828794|NCT03245346|DRUG|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
218828795|NCT03245346|DRUG|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
218828796|NCT03245346|DRUG|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
218828797|NCT04968392|DRUG|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
218828798|NCT04968392|DRUG|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
218828799|NCT00014274|DRUG|carboplatin|
219012135|NCT04528979|OTHER|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
219012136|NCT00385879|BEHAVIORAL|Case management|
219580646|NCT04069871|DEVICE|Sham TENS|Patients in the control group will receive sham TENS.
219580647|NCT00266071|BEHAVIORAL|Cutaneous response|
218828800|NCT00014274|DRUG|gemcitabine hydrochloride|
218828801|NCT00014274|DRUG|methotrexate|
218828802|NCT00014274|DRUG|vinblastine sulfate|
218828803|NCT03225391|BEHAVIORAL|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
218828804|NCT03225391|BEHAVIORAL|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
218828805|NCT00153413|BEHAVIORAL|Cookin' Up Health|A brief nutrition intervention designed to improve dietary habits
219580648|NCT05874583|DRUG|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
219580649|NCT05874583|DRUG|Intravenous route Tranexamic acid injection|Intra venous route administration
219580650|NCT04848311|PROCEDURE|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
219580651|NCT04022928|OTHER|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
219012137|NCT03208842|RADIATION|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
218828806|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
219012138|NCT00878527|DEVICE|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
219012139|NCT00674661|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
219012140|NCT00674661|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
219012141|NCT01028365|OTHER|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
219012142|NCT06175403|DRUG|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
218828807|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
218828808|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
218828809|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
218828810|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
218828811|NCT03495726|BEHAVIORAL|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
218828812|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
219012143|NCT01968668|DRUG|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
219195878|NCT04631445|OTHER|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
219195879|NCT03427996|PROCEDURE|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
219195880|NCT06175754|PROCEDURE|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
219195881|NCT06175754|PROCEDURE|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
219012144|NCT01968668|DRUG|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
219012145|NCT01968668|DRUG|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
219012146|NCT01968668|DRUG|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
218828813|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
218828814|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
218828815|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
218828816|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
218828817|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
218828818|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
218828819|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
218828820|NCT00196690|DRUG|Donepezil|
218828821|NCT03460652|DRUG|KP415 oral capsule|Once-daily oral dose
218828822|NCT00548197|DRUG|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
219012147|NCT01968668|DRUG|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
219012148|NCT01968668|DRUG|Placebo|Placebo tablet once daily in the morning
219012149|NCT01968668|DRUG|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
219012150|NCT01968668|DRUG|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
219012151|NCT00614315|DEVICE|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
219763763|NCT05591924|PROCEDURE|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
219195882|NCT06175754|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
219012152|NCT03108027|DRUG|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
219012153|NCT03108027|DRUG|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
219012154|NCT03108027|DRUG|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
219195883|NCT06645132|BEHAVIORAL|exercise intervention|Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.
219195884|NCT05415709|DRUG|Carboplatin|Given IV
219195885|NCT05415709|DRUG|Cisplatin|Given IV
219195886|NCT05415709|PROCEDURE|Cytoreductive Surgery|Undergo CRS
219195887|NCT05415709|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
219195888|NCT05415709|DRUG|Paclitaxel|Given IV
219195889|NCT05415709|OTHER|Quality-of-Life Assessment|Ancillary studies
219195890|NCT05415709|OTHER|Questionnaire Administration|Ancillary studies
219195891|NCT05415709|PROCEDURE|Biospecimen Collection|Undergo stool sample collection
219195892|NCT05415709|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
219195893|NCT06827522|PROCEDURE|Birth Under General Anesthesia|Before anaesthesia, GSR electrodes will be connected and signal recording will be started. After caesarean section, the newborn will be evaluated and GSR signals will be recorded again after the mother wakes up by providing skin-to-skin contact.
219438516|NCT01324427|BEHAVIORAL|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
218828823|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
218828824|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
218828825|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
218828826|NCT00245388|DRUG|Muraglitazar|
218828827|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
218828828|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
218828829|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
218828830|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
218828831|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
218828832|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
218828833|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
218828834|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
218828835|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
218828836|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
218828837|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
218828838|NCT01876303|OTHER|questionnaire administration|Ancillary studies
218828839|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
218828840|NCT03377595|DRUG|Exparel|Wound infiltration
218828841|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
219195894|NCT06827522|PROCEDURE|Birth Under Spinal Anesthesia|GSR electrodes will be connected before anaesthesia, and since the mother will be conscious during caesarean section, the newborn will have skin-to-skin contact with the mother immediately after birth. During this process, GSR signals of the mother and the baby will be recorded.
219195895|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
219195896|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
219438517|NCT04108819|DIETARY_SUPPLEMENT|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
219438518|NCT02581124|DRUG|JTZ-951|
219763764|NCT05591924|PROCEDURE|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
219763765|NCT03937154|DRUG|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
219012155|NCT04777695|OTHER|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
219012156|NCT02536352|DRUG|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
219012157|NCT02536352|DIETARY_SUPPLEMENT|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
219012158|NCT02426892|BIOLOGICAL|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
219012159|NCT02426892|DRUG|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
219012160|NCT04967157|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
219012161|NCT04967157|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin ®
219195897|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
219195898|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
219195899|NCT05977907|DRUG|Pembrolizumab|Pembrolizumab is an investigational drug in this study
219438519|NCT02581124|DRUG|Lapatinib|
219438520|NCT02549963|DEVICE|WATCHMAN Left Atrial Appendage Occlusion Device|
219438521|NCT02549963|DRUG|Rivaroxaban|
219438522|NCT01454024|DEVICE|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
219438523|NCT01454024|DEVICE|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
219438524|NCT06530121|BEHAVIORAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
219438525|NCT00004910|PROCEDURE|bowel obstruction management|
219438526|NCT00004910|PROCEDURE|quality-of-life assessment|
219438527|NCT02796612|OTHER|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
219438528|NCT02796612|BEHAVIORAL|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
219438529|NCT02796612|BEHAVIORAL|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
219438530|NCT04550936|DRUG|Isavuconazole|antifungal agent
219438531|NCT05843591|BEHAVIORAL|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
219438532|NCT04976296|DIAGNOSTIC_TEST|MRD detection|The Geneplus OncoMRD lung assay is used to detect the MRD status.
219438533|NCT00991224|BIOLOGICAL|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
219438534|NCT00991224|BIOLOGICAL|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
219438535|NCT00991224|OTHER|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
219763766|NCT03937154|DRUG|Placebo|Placebo comparator
219438536|NCT00897741|GENETIC|microarray analysis|
219438537|NCT00897741|OTHER|laboratory biomarker analysis|
219438538|NCT03527316|DRUG|MDMA|125 mg MDMA per os, single dose
219438539|NCT03527316|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
219438540|NCT00868335|DEVICE|Activ C disc prosthesis|cervical disc prosthesis
219438541|NCT00868335|PROCEDURE|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
219438542|NCT03014921|OTHER|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
219438543|NCT03014921|OTHER|saline solution injection|Injection of a 250mL saline solution
219438544|NCT01578538|PROCEDURE|inguinal hernia repair|strangulated hernias will be repaired surgically
219438545|NCT03091595|DRUG|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
219438546|NCT03091595|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
219438547|NCT03082417|OTHER|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture"
219438548|NCT02209038|BEHAVIORAL|Expanded AD Choice|
219438549|NCT02209038|BEHAVIORAL|Expanded Life-sustaining Therapy Choice|
219438550|NCT00166517|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
219438551|NCT00166517|BIOLOGICAL|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
218828842|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
218828843|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
218828844|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
218828845|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
218828846|NCT03774771|DRUG|Placebo|Capsules for oral administration
218828847|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
218828848|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
218828849|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
218828850|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
218828851|NCT03449849|OTHER|Base Diet|Base Diet
218828852|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
218828853|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
219012162|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
219012163|NCT04447079|BEHAVIORAL|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
219012164|NCT05922787|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
219012165|NCT00702819|DRUG|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
219012166|NCT03124433|DRUG|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
219012167|NCT04382573|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
219012168|NCT02382679|DIETARY_SUPPLEMENT|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
219012169|NCT02382679|DIETARY_SUPPLEMENT|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
219012170|NCT02574247|PROCEDURE|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
219012171|NCT04758754|OTHER|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
219012172|NCT00252954|DRUG|Levetiracetam|Tablets 2000-3000 mg per day
219195900|NCT05977907|DRUG|IO102-103|IO102-103 is an investigational drug in this study.
219195901|NCT05868421|BEHAVIORAL|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
219438552|NCT04783870|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO QD
219438553|NCT04783870|DRUG|Placebo|Placebo
219763767|NCT05629585|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
218828854|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
218828855|NCT02515344|OTHER|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
219580652|NCT05803928|DRUG|lenvatinib + anti-PD-1 antibodies|A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group
219580653|NCT05803928|PROCEDURE|ablation|radiofrequency ablation or microwave ablation
219580654|NCT03970928|DEVICE|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
219580655|NCT04132583|DRUG|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
219580656|NCT04132583|DRUG|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
219580657|NCT00292487|DRUG|Iopamidol 370 mgI/mL|
219580658|NCT05464043|DIAGNOSTIC_TEST|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
219580659|NCT04162054|OTHER|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
219580660|NCT05533762|DEVICE|arch insole and sham insole|children wear insoles on feet
219012173|NCT06542120|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
219012174|NCT06542120|DIAGNOSTIC_TEST|Chest Auscultation and Chest imaging examinations|Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
219763768|NCT05629585|DRUG|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
219012175|NCT06542120|DIAGNOSTIC_TEST|Abdominal Auscultation and Abdominal imaging examinations|Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
219012176|NCT05405205|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
219012177|NCT05405205|DIETARY_SUPPLEMENT|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
219012178|NCT05405205|DIETARY_SUPPLEMENT|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
219012179|NCT02608749|BEHAVIORAL|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
219012180|NCT02608749|BEHAVIORAL|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
219012181|NCT02608749|BEHAVIORAL|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
219012182|NCT05548842|DIETARY_SUPPLEMENT|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
219012183|NCT05548842|DIETARY_SUPPLEMENT|Placebo group|Placebo 1,000 mg/day for 4 weeks
219012184|NCT01248377|PROCEDURE|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
219012185|NCT04923204|DIAGNOSTIC_TEST|Pharmacogenomic-testing with NEUROPHARMAGEN|"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."
219012186|NCT05389345|BEHAVIORAL|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
219195902|NCT05868421|BEHAVIORAL|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
219195903|NCT05868421|BEHAVIORAL|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
219580661|NCT02433262|OTHER|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
219580662|NCT02433262|OTHER|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
219580663|NCT04054960|DEVICE|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
219763769|NCT05629585|DRUG|Capecitabine|Active Comparator. Tablet. Oral route of administration
218828856|NCT02515344|OTHER|Providing general information about CRC sreening|
218828857|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
218828858|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
218828859|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
218828860|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
218828861|NCT03475069|OTHER|Custom Designed Exercises|
218828862|NCT03475069|OTHER|Plates Exercises|
219438554|NCT01854671|OTHER|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
219763770|NCT05629585|DRUG|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
218828863|NCT03475069|OTHER|Calisthenics Exercises|
218828864|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
218828865|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
219012187|NCT05389345|BEHAVIORAL|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
218828866|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
218828867|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
218828868|NCT00074139|DRUG|cyclophosphamide|
218828869|NCT00074139|DRUG|docetaxel|
218828870|NCT00074139|DRUG|doxorubicin hydrochloride|
218828871|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
218828872|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
218828873|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
219012188|NCT04084301|PROCEDURE|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
219012189|NCT00098085|BIOLOGICAL|HSPPC-96|
219012190|NCT01705821|DEVICE|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
219012191|NCT01705821|PROCEDURE|Removal of pituitary tumor using modified curette|
219012192|NCT05991076|OTHER|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
219438555|NCT04310878|OTHER|Survey among perioperative nurses and surgeons|Online survey
219438556|NCT04835571|OTHER|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
219438557|NCT06527209|OTHER|Coffee and agave inulin-based beverage (A)|"Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g"
219438558|NCT06527209|OTHER|Control beverage (B)|"Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g."
218828874|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
218828875|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
218828876|NCT02089932|DRUG|Placebo|
218828877|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
218828878|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
218828879|NCT02559635|PROCEDURE|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
218828880|NCT02559635|DRUG|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
218828881|NCT00002081|DRUG|Zidovudine|
218828882|NCT00002081|DRUG|Zalcitabine|
219438559|NCT00149383|DRUG|Rosiglitazone|
219438560|NCT00149383|DRUG|Placebo|
219438561|NCT02186561|DEVICE|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
219438562|NCT00934011|OTHER|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
219438563|NCT00934011|OTHER|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
219438564|NCT03275428|DEVICE|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
219438565|NCT01758211|PROCEDURE|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
219438566|NCT01758211|PROCEDURE|conventional resection|conventional resection in AVM patients
219438567|NCT02197598|DRUG|nalmefene|
219438568|NCT01821547|DRUG|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
219438569|NCT04285853|DRUG|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
219438570|NCT04285853|DRUG|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
219438571|NCT03704805|BEHAVIORAL|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
219438572|NCT03704805|OTHER|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
219438573|NCT04030897|BEHAVIORAL|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
219438574|NCT04030897|BEHAVIORAL|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
219438575|NCT04030897|BEHAVIORAL|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
219580664|NCT04054960|DEVICE|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
219580665|NCT04054960|DRUG|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
218828883|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
218828884|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
218828885|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
219438576|NCT00790127|DRUG|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
219438577|NCT00790127|DRUG|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
219438578|NCT00002004|DRUG|CD4 Antigens|
219438579|NCT01718964|DRUG|Cortisol 20 mg|
219438580|NCT01718964|DRUG|Mannitol|Mannitol used as placebo
218828886|NCT01034501|DEVICE|sham procedure|non activated laser tip
218828887|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
219012193|NCT02786251|OTHER|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
219438581|NCT00119236|DRUG|tanespimycin|
219438582|NCT00119236|DRUG|irinotecan hydrochloride|
219438583|NCT01009021|DRUG|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
219438584|NCT00294827|PROCEDURE|Liver transplantation and colo-rectal cancer|Liver transplantation
219438585|NCT04606641|OTHER|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
219438586|NCT04606641|OTHER|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
219438587|NCT05565014|DRUG|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
219438588|NCT05565014|DRUG|Saline|The use of saline was the same as VAK group.
219438589|NCT02895412|BIOLOGICAL|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
219580666|NCT03589586|OTHER|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
219580667|NCT00662948|DRUG|Rituximab|375 mg/m2 every 8 weeks during 24 months
219438590|NCT03543670|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
218828888|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
218828889|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
218828890|NCT01999244|BEHAVIORAL|Self-monitoring skills|
218828891|NCT01999244|BEHAVIORAL|Technology|
218828892|NCT01999244|BEHAVIORAL|Interventionist Contact|
218828893|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
219438591|NCT02455778|DIETARY_SUPPLEMENT|Cinnamon|
219438592|NCT02455778|DIETARY_SUPPLEMENT|Placebo|
219438593|NCT04714489|OTHER|NO.|NO.
219438594|NCT05245994|DRUG|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
219580668|NCT00662948|DRUG|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
219580669|NCT02427035|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
219580670|NCT02427035|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
219580671|NCT03139786|OTHER|Study the natural history of bicuspid|Study the natural history of bicuspid
219580672|NCT04190810|BEHAVIORAL|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219580673|NCT04190810|BEHAVIORAL|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219580674|NCT04190810|BEHAVIORAL|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
219580675|NCT04645810|PROCEDURE|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
219580676|NCT02203214|DEVICE|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
219580677|NCT06060808|GENETIC|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
219580678|NCT00807248|DRUG|Escitalopram placebo|Once daily before bedtime for 8 weeks
218828894|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
218828895|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
218828896|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
218828897|NCT01048242|DRUG|Placebo|placebo
218828898|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
218828899|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
219580679|NCT00807248|DRUG|Gaboxadol placebo|Once daily before bedtime for 8 weeks
219580680|NCT00807248|DRUG|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
219580681|NCT00807248|DRUG|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
219580682|NCT00807248|DRUG|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
219580683|NCT04901598|OTHER|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
219580684|NCT06442423|DRUG|Psilocybin|Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
219580685|NCT00813566|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
219580686|NCT00813566|DRUG|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
219580687|NCT00813566|DRUG|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
219580688|NCT00813566|DRUG|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
219580689|NCT02390349|OTHER|Placebo|
219580690|NCT02390349|DIETARY_SUPPLEMENT|Curamin|
219580691|NCT02390349|DIETARY_SUPPLEMENT|CuraMed|
219580692|NCT02242916|RADIATION|Photon therapy versus proton therapy|
218828900|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
218828901|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
218828902|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
219438595|NCT06413368|DRUG|Maralixibat 9.5 MG/ML [Livmarli]|Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
219580693|NCT02242916|RADIATION|Photon therapy versus C-ion therapy|
219580694|NCT04959591|DRUG|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
218828903|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
218828904|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
218828905|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
218828906|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
219012194|NCT02786251|OTHER|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
219012195|NCT03499223|DRUG|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
219438596|NCT01210755|DRUG|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
219438597|NCT01210755|DRUG|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
219438598|NCT00631618|DRUG|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
219438599|NCT02685787|BEHAVIORAL|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
219438600|NCT02685787|BEHAVIORAL|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
219438601|NCT03180242|BIOLOGICAL|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
219438602|NCT03180242|BIOLOGICAL|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
219438603|NCT03180242|BIOLOGICAL|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
219438604|NCT01716026|DRUG|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
219438605|NCT01814826|DRUG|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
219438606|NCT01814826|DRUG|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~\- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
219438607|NCT02917629|OTHER|Laboratory Biomarker Analysis|Correlative studies
219438608|NCT02917629|DRUG|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
219438609|NCT02917629|OTHER|Pharmacological Study|Correlative studies
219438610|NCT02917629|OTHER|Placebo|Given PO
219438611|NCT00718523|DRUG|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
219438612|NCT00718523|DRUG|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
219438613|NCT03154177|BEHAVIORAL|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
219438614|NCT03154177|PROCEDURE|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
219438615|NCT03636880|BEHAVIORAL|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
219438616|NCT03636880|BEHAVIORAL|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
219580695|NCT04959591|DRUG|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
219763771|NCT04161885|DRUG|Venetoclax|Tablet; Oral
219438617|NCT05070325|OTHER|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
219438618|NCT05070325|OTHER|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
219012196|NCT03499223|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
218828907|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
218828908|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
218828909|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
219012197|NCT03499223|DRUG|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
219012198|NCT04498611|DIAGNOSTIC_TEST|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
219012199|NCT05945693|DIETARY_SUPPLEMENT|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
219012200|NCT05945693|DIETARY_SUPPLEMENT|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
219012201|NCT05945693|DIETARY_SUPPLEMENT|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
219012202|NCT00268996|DRUG|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
219012203|NCT00268996|DRUG|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
218828910|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
218828911|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
218828912|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
218828913|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
219438619|NCT05070325|OTHER|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
219438620|NCT01042938|DRUG|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
218828914|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
218828915|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
218828916|NCT00559104|DRUG|etoposide|Used in Both Arms
219012204|NCT01588808|BEHAVIORAL|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
219012205|NCT03692364|DEVICE|Ceramic-on-ceramic uncemented hip arthroplasty|
219012206|NCT03692364|DEVICE|Metal-on-polyethylene uncemented total hip arthroplasty|
219012207|NCT03448822|PROCEDURE|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
219012208|NCT00679146|DRUG|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
219012209|NCT00679146|DRUG|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
219012210|NCT05230810|DRUG|Alpelisib|Orally twice a day
219438621|NCT01042938|DRUG|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
219012211|NCT05230810|DRUG|Tucatinib|Orally once a day
219438622|NCT05400538|OTHER|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
219438623|NCT05400538|OTHER|Biorepair Toothpaste|Domiciliary application of the product twice a day.
218828917|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
219012212|NCT05230810|DRUG|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
219012213|NCT00357487|DEVICE|peroperative scintillating probe|
219012214|NCT00357487|DEVICE|operative gamma camera|
219195904|NCT03890614|OTHER|Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
219195905|NCT03988621|BEHAVIORAL|ViCCY|Virtual Caregiver Coach for You
218828918|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
218828919|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
218828920|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
218828921|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
218828922|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
218828923|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
218828924|NCT05294497|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
218828925|NCT05294497|OTHER|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
219012215|NCT05356247|BEHAVIORAL|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
219012216|NCT01096225|BIOLOGICAL|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
219012217|NCT00913003|DRUG|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
219012218|NCT00913003|DRUG|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
219438624|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
218828926|NCT05294497|OTHER|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
218828927|NCT05294497|OTHER|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
218828928|NCT05294497|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
218828929|NCT05294497|OTHER|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
218828930|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
219012219|NCT05301426|OTHER|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
219012220|NCT05301426|OTHER|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
219012221|NCT05301426|OTHER|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
219012222|NCT04902456|PROCEDURE|Power chain and Crimpable hook fro En-masse Retraction|"Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew"
219580696|NCT04959591|DRUG|Placebo|placebo comparator: administration of normal saline
219580697|NCT06227013|BEHAVIORAL|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
219580698|NCT02518919|OTHER|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
219580699|NCT02518919|OTHER|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
218828931|NCT01957293|DRUG|Placebo|single oral administration
218828932|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
218828933|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
219012223|NCT04902456|PROCEDURE|T-loop|closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
219195906|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
218828934|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
218828935|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
218828936|NCT00512850|OTHER|Placebo|One placebo pill per day
218828937|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
218828938|NCT00111449|DRUG|Etanercept|
218828939|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
218828940|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
218828941|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
218828942|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
218828943|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
219012224|NCT05982509|DEVICE|EasyDew Regen MD Cream|For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.
219012225|NCT01859754|BIOLOGICAL|Octagam 5%|Intravenous immunoglobulin 5%
219012226|NCT01859754|BIOLOGICAL|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
219012227|NCT01986660|DRUG|Ibuprofen Cream (SST-0225)|
219012228|NCT04735380|DEVICE|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
219012229|NCT05581849|BEHAVIORAL|Prolonged Nightly Fasting|"Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks. Participants will be allotted one cheat day per week, during which they will not need to fast (or track their times)- the day may change weekly and will be based on participant preference. Study staff and study participants will engage in a weekly coaching call (via phone; 5-10 minutes). Weekly coaching calls will last through the duration of the 8-week intervention."
219438625|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
219438626|NCT04867200|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
219438627|NCT04867200|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
218828944|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
218828945|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
218828946|NCT02944721|GENETIC|Genetical analyses|
218828947|NCT02944721|OTHER|Chronic pain identification questionnaires|
218828948|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
218828949|NCT02944721|OTHER|Quality of life questionnaires|
218828950|NCT04463563|OTHER|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
218828951|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
218828952|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
218828953|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
218828954|NCT06547697|OTHER|Dialysate sodium concentration|
218828955|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
219438628|NCT03465384|BEHAVIORAL|Comet|The intervention is a behaviorally based and manualized parent training program.
218828956|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
218828957|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
218828958|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
218828959|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
218828960|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
218828961|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
218828962|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
218828963|NCT02469701|DRUG|nivolumab and ablation|
218828964|NCT00001901|DRUG|Etanercept|
218828965|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
218828966|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
218828967|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
218828968|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
218828969|NCT04300504|OTHER|observational study|observational study
218828970|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
218828971|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
218828972|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
218828973|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
218828974|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
218828975|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
218828976|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
218828977|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
218828978|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
218828979|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
218828980|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
219438629|NCT03136484|DRUG|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
219012230|NCT05581849|BEHAVIORAL|Health Education Control|Participants in this group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks. Participants will be asked to review the video at their convenience, prior to their weekly coaching call (5-10 minutes) with the study staff. Weekly topics will be as follows: Week 1: Sleep hygiene, Week 2: Sun safety, Week 3: Home safety, Week 4: Driving safety, Week 5: Hydration, Week 6: Dental health, Week 7: Working environment, Week 8: Communication.
218828981|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
218828982|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
218828983|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
218828984|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
219012231|NCT00483808|DEVICE|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
219438630|NCT03136484|DRUG|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
219438631|NCT03136484|DRUG|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
219012232|NCT02913391|OTHER|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
219012233|NCT02913391|OTHER|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
219012234|NCT00784992|PROCEDURE|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
219012235|NCT00764153|PROCEDURE|Bipolar hemiarthroplasty|Lateral approach. FWB.
219012236|NCT00764153|PROCEDURE|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
219012237|NCT06166849|DEVICE|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
219012238|NCT02140229|DEVICE|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
219012239|NCT02140229|OTHER|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
219012240|NCT02140229|OTHER|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
219438632|NCT03136484|DRUG|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
219438633|NCT03083275|OTHER|Resistance Training|
219438634|NCT02352532|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
219763772|NCT04161885|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
218828985|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
218828986|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
218828987|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
218828988|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
219012241|NCT03035708|DRUG|Varenicline|1 mg BID
219012242|NCT03035708|DRUG|Placebo oral capsule|1 mg BID
219438635|NCT02352532|OTHER|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
219438636|NCT00360685|DRUG|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
218828989|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
218828990|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
218828991|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
218828992|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
218828993|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
218828994|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
218828995|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
218828996|NCT02319460|BIOLOGICAL|Plasma|
218828997|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
218828998|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
219580700|NCT03237949|BEHAVIORAL|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
219580701|NCT03237949|BEHAVIORAL|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
218828999|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
218829000|NCT02225704|DRUG|Radium-223 and enzalutamide|
218829001|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
218829002|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
218829003|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
218829004|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
218829005|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
219438637|NCT00360685|DRUG|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
219438638|NCT04629638|OTHER|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
219438639|NCT05307627|DRUG|low-dose naltrexone|LDN doses \<20 mg/day
219438640|NCT02239367|BEHAVIORAL|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
218829006|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
218829007|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
218829008|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
218829009|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
218829010|NCT00000870|DRUG|Indinavir sulfate|
219580702|NCT00197288|BIOLOGICAL|Influenza|
218829011|NCT00000870|DRUG|Lamivudine|
219596934|NCT03563911|BEHAVIORAL|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
218829012|NCT00000870|DRUG|Stavudine|
218829013|NCT00000870|DRUG|Zidovudine|
218829014|NCT00000870|DRUG|Didanosine|
218829015|NCT00000870|DRUG|Aldesleukin|
218829016|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
218829017|NCT00159679|DRUG|Pregabalin|
218829018|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
218829019|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
219012243|NCT03779789|DRUG|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
219012244|NCT03779789|DRUG|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
219012245|NCT03779789|DRUG|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
219012246|NCT03779789|DRUG|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
219012247|NCT03779789|DRUG|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
219012248|NCT03779789|DRUG|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
219012249|NCT03779789|DRUG|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
219012250|NCT00869531|OTHER|wholegrain|wholegrain wheat vs. refined wheat products
219012251|NCT00869531|OTHER|refined wheat|refined wheat products
219012252|NCT06478160|DEVICE|Closed-Blood Sampling Devices|blood collection with Closed-Blood Sampling System (CBSD)
219476440|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
218829020|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
218829021|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
218829022|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
218829023|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
218829024|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
218829025|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
218829026|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
218829027|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
218829028|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
218829029|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
219012253|NCT06478160|OTHER|Waste discard volume|Blood collection without CBSD, usual practice, need to waste discard volume
219012254|NCT01637467|OTHER|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
218829030|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
218829031|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
218829032|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
219438641|NCT04253808|BEHAVIORAL|Carbohydrate-restricted, high-fat diet|"Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
219438642|NCT04253808|BEHAVIORAL|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
219596935|NCT03443271|PROCEDURE|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
218829033|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
218829034|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
218829035|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
218829036|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
218829037|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
218829038|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
218829039|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
219596936|NCT03443271|PROCEDURE|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
218829040|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
218829041|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
218829042|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
218829043|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
218829044|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
219012255|NCT01637467|OTHER|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
219012256|NCT00568750|DRUG|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
219012257|NCT05404919|DRUG|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
218829045|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
218829046|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
218829047|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
218829048|NCT02695017|DEVICE|Iso inertial|
218829049|NCT02695017|DEVICE|Conventional machine|
218829050|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
218829051|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
219438643|NCT05131529|OTHER|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
219596937|NCT00976911|DRUG|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
219596938|NCT00976911|DRUG|liposomal doxorubicin|40mg/m2 iv every 4 weeks
219596939|NCT00976911|DRUG|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
218829052|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
218829053|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
218829054|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
218829055|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
218829056|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
218829057|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
218829058|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
219012258|NCT02597322|DRUG|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
219438644|NCT05131529|OTHER|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
219438645|NCT05131529|OTHER|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
218829059|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
218829060|NCT03346421|BEHAVIORAL|diet and physical activity|
218829061|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
218829062|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
218829063|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
218829064|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
218829065|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
218829066|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
219012259|NCT03342287|OTHER|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
219438646|NCT04399980|DRUG|Mavrilimumab|Treatment infusion
219438647|NCT04399980|DRUG|Placebos|Placebo infusion
219438648|NCT02463760|OTHER|Medical imaging|
218829067|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
218829068|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
218829069|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
218829070|NCT00601692|DRUG|cisplatin|Given IV
218829071|NCT00601692|DRUG|docetaxel|Given IV
218829072|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
218829073|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
218829074|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
219012260|NCT03342287|OTHER|cognitive evaluation|Administration of online cognitive battery
219012261|NCT03342287|OTHER|Blood|Measurement of cytokines/inflammatory biomarkers
219012262|NCT03342287|OTHER|Fecal sample|Measurement of the gut microbiome
219438649|NCT06350149|OTHER|Sugar Sweetened Beverages (SSB)|The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
219438650|NCT06350149|OTHER|Hi GI|The Glycemic Index of the high-GI meals will be at least 75
219438651|NCT06350149|OTHER|Lo GI|The Glycemic Index of the low- -GI meals will not be higher than 55.
219438652|NCT04334512|DRUG|Hydroxychloroquine|Treatment with hydroxychloroquine
218829075|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
218829076|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
218829077|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
218829078|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
218829079|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
218829080|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
218829081|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
218829082|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
218829083|NCT06407453|OTHER|control|There will be no interference ergonomics training
218829084|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
219012263|NCT01435109|BEHAVIORAL|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
219012264|NCT01435109|BEHAVIORAL|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
219012265|NCT01435109|BEHAVIORAL|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
219012266|NCT00451321|DRUG|Otelixizumab|Infusion
219012267|NCT00114465|DRUG|VSL#3|VSL#3 1 sachet twice a day
219012268|NCT00114465|OTHER|Placebo|Placebo 1 sachel twice a day
218829085|NCT03073525|BIOLOGICAL|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
218829086|NCT03073525|DRUG|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
219012269|NCT05173740|OTHER|Individually tailored rehabilitation intervention|Individually tailored rehabilitation intervention
219012270|NCT05173740|OTHER|Usual care|Usual care
219012271|NCT00641862|DIETARY_SUPPLEMENT|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
219012272|NCT00641862|OTHER|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
219012273|NCT06377956|OTHER|Observation without intervention|Observation of gut length, food intake, fecal and urine calories, body composition, microbiota, metabolic rate, metabolomics.
219012274|NCT04797793|DRUG|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219012275|NCT04797793|DRUG|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219012276|NCT04797793|DRUG|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219012277|NCT05479955|OTHER|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
219012278|NCT05479955|OTHER|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
218829087|NCT03569124|OTHER|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
218829088|NCT03263403|BIOLOGICAL|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
218829089|NCT03263403|BIOLOGICAL|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
218829090|NCT04140617|BEHAVIORAL|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
218829091|NCT06100757|DEVICE|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
218829092|NCT06100757|DEVICE|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
218829093|NCT06097403|DIAGNOSTIC_TEST|Covid 19 swap|diagnostic tool
218829094|NCT01273038|DEVICE|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
218829095|NCT01273038|DEVICE|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
218829096|NCT03248388|DEVICE|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
218829097|NCT03248388|DEVICE|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
218829098|NCT02682459|DRUG|Lisinopril|
218829099|NCT04116593|BEHAVIORAL|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
218829100|NCT01976299|DEVICE|AVERT|
218829101|NCT05865951|OTHER|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
219012279|NCT05451147|DRUG|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
219012280|NCT05451147|DRUG|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
219012281|NCT01661192|DRUG|AAT( Alpha 1 Antitrypsin)|
219012282|NCT03540966|COMBINATION_PRODUCT|CapulinTM|a kind of camouflage agent
218829102|NCT05865951|OTHER|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
218829103|NCT00977483|DRUG|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
218829104|NCT00977483|DRUG|Placebo|1 tablet once daily 4 years double-blind treatment period
218829105|NCT03692403|DRUG|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
218829106|NCT03692403|DRUG|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
218829107|NCT03692403|DRUG|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
218829108|NCT03692403|DRUG|Placebo|Matching placebo
218829109|NCT00649350|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
218829110|NCT00649350|DRUG|Glucophage XR 750 mg|750mg, single dose fed
218829111|NCT02722213|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
218829112|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
218829113|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
218829114|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
219438653|NCT04334512|DRUG|Azithromycin|Treatment with azithromycin
219438654|NCT04334512|DIETARY_SUPPLEMENT|Vitamin C|Treatment with vitamin C
218829115|NCT05783895|DIAGNOSTIC_TEST|Post screening diagnostic test|1\) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
218829116|NCT01057537|DRUG|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
218829117|NCT01057537|DRUG|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
218829118|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
219012283|NCT03540966|OTHER|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
219012284|NCT01528254|DRUG|Placebo of vildagliptin|
219012285|NCT01528254|DRUG|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
219012286|NCT01528254|DRUG|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
219438655|NCT04334512|DIETARY_SUPPLEMENT|Vitamin D|Treatment with vitamin D
219438656|NCT04334512|DIETARY_SUPPLEMENT|Zinc|Treatment with Zinc
219012287|NCT01166763|DRUG|vitamin D3|oral capsules, 10,000 IU per week for 6 months
219012288|NCT04339296|DEVICE|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
219012289|NCT01909479|DRUG|MOD-4023|Individualized once weekly dose of MOD-4023
219012290|NCT01909479|OTHER|Placebo|Once weekly administration of placebo
219012291|NCT02232542|DRUG|Duloxetine - low dose|
219012292|NCT02232542|DRUG|Duloxetine - high dose|
218829119|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
218829120|NCT05922995|DRUG|Tasimelteon|20 mg capsules taken on a nightly basis
219012293|NCT02232542|DRUG|Placebo|
219438657|NCT01525303|BEHAVIORAL|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
219438658|NCT03983213|PROCEDURE|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
218829121|NCT03895294|OTHER|Health care under the strategic purchase-Clinical pathway|1\) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
218829122|NCT03895294|OTHER|Usual care process prior strategic purchase-clinical pathway|1\) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
218829123|NCT03852784|OTHER|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
219438659|NCT03284021|DEVICE|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
219438660|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.
219476441|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
218829124|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
218829125|NCT03985280|DEVICE|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
218829126|NCT03985280|DRUG|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
218829127|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
219012294|NCT04320485|DIAGNOSTIC_TEST|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
219012295|NCT02502539|PROCEDURE|Controlled physical activity|
219012296|NCT04571580|DRUG|Normal Saline|intracoronary infusion with normal saline
219012297|NCT04571580|DRUG|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
218829128|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
219012298|NCT04571580|DRUG|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
219012299|NCT01032876|PROCEDURE|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
219012300|NCT01032876|PROCEDURE|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
219012301|NCT00212030|DRUG|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
219012302|NCT00212030|DRUG|placebo|Control
218829129|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
218829130|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
218829131|NCT00034671|DRUG|Posaconazole oral suspension|
218829132|NCT02056444|DRUG|Tranexamic Acid|
218829133|NCT01864265|DRUG|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
218829134|NCT01864265|DRUG|Placebo|Placebo will be administered according to the label of the biological
218829135|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
218829136|NCT01349673|DRUG|Budesonide Foam|Topical
218829137|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
218829138|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
218829139|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
218829140|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
218829141|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
219012303|NCT04446377|DRUG|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
219763773|NCT04161885|OTHER|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
218829142|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
218829143|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
218829144|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
218829145|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
218829146|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
219012304|NCT04446377|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
219012305|NCT01733407|DRUG|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
219012306|NCT01733407|DRUG|placebo|400mg/kg/d divided TID for year 1 only.
219012307|NCT04810676|DRUG|CKD-501, D745, D150|QD, PO
219012308|NCT04810676|DRUG|CKD-383|QD, PO
219012309|NCT05483855|OTHER|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
219763774|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
219763775|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
219763776|NCT06517758|DRUG|Iptacopan|Hard gelatin capsule
218829147|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
219012310|NCT05483855|OTHER|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
219012311|NCT01328821|DRUG|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
219012312|NCT01328821|DRUG|CTP-499|400 mg immediate release capsule
218829148|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
218829149|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
218829150|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
218829151|NCT05214937|BEHAVIORAL|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
219012313|NCT01936103|DRUG|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
219012314|NCT01936103|DRUG|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
219012315|NCT01060930|DRUG|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
219012316|NCT00006080|DRUG|fenretinide|
219012317|NCT04804410|DEVICE|LCR Meter (Brand: Keysight, Serial Number:E498AL)|The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
219012318|NCT00235898|DRUG|CoFactor|
219012319|NCT00235898|DRUG|5-FU|
219012320|NCT00235898|DRUG|Leucovorin|
219012321|NCT03557151|OTHER|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
219012322|NCT03557151|BEHAVIORAL|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
219012323|NCT03283228|DIAGNOSTIC_TEST|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
219012324|NCT01414075|DRUG|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
219012325|NCT01414075|DRUG|Oral Iron|Administered per oral dose and schedule specified in the arm.
219438661|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
219438662|NCT02452749|DIETARY_SUPPLEMENT|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
219438663|NCT03747536|DRUG|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
219012326|NCT01414075|DRUG|IV Iron|Administered per IV dose and schedule specified in the arm.
219438664|NCT03747536|OTHER|Placebo|normal saline delivered via metered dose spray
219438665|NCT05444413|BIOLOGICAL|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
219438666|NCT03949998|DEVICE|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
219438667|NCT03949998|OTHER|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
219438668|NCT03997760|DRUG|TAK-755|Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
219438669|NCT03997760|OTHER|Placebo|Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
219438670|NCT03499769|PROCEDURE|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
219438671|NCT01854489|DRUG|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
219763777|NCT06517758|OTHER|Matching Placebo|Hard gelatin capsule
219763778|NCT03869190|DRUG|Atezolizumab|"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
219763779|NCT03869190|DRUG|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
219763780|NCT03869190|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
219763781|NCT03869190|DRUG|Magrolimab (Hu5F9-G4)|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
219763782|NCT03869190|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
219763783|NCT03869190|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
219763784|NCT03869190|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
219763785|NCT03869190|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
219763786|NCT03869190|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
219763787|NCT05294367|DRUG|Magnesium Chloride-based Lotion|Given topically
219763788|NCT05294367|OTHER|Quality-of-Life Assessment|Ancillary studies
219763789|NCT05294367|BEHAVIORAL|Special Diet Therapy|Consume magnesium rich foods
219763790|NCT06284811|BEHAVIORAL|HIIT Exercise program focusing on quadriceps|Participants will be asked to perform the exercise program that focusing on quadriceps muscle.the participants started to 20-minute HIIT for the lower extremity. The HIIT protocol included static lunch, squats, squat walk, sumo squat, lateral squat walk, front and back lunge, kneel to squat, squat pulses and side lunge exercises. Exercises were performed as 40 seconds exercise and 10 seconds rest. During training, heart rate (HR) was monitored using an activity monitor. All participants completed HIIT Training, after received either percussion therapy or massage therapy according to their randomizations.
219763791|NCT05039619|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
219763792|NCT05039619|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
219763793|NCT05039619|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
219763794|NCT05039619|DRUG|Acetaminophen/paracetamol|Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
219763795|NCT05039619|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
219763796|NCT05039619|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
219763797|NCT05039619|DRUG|Prednisone|Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
219438672|NCT01854489|DRUG|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
219438673|NCT01854489|DRUG|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
219438674|NCT00856986|DRUG|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
219438675|NCT00856986|DRUG|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
219438676|NCT00856986|DRUG|metformin|Metformin tablets, at least 1500 mg/day
219763798|NCT04118998|BEHAVIORAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
219763799|NCT04118998|BEHAVIORAL|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
219763800|NCT04526886|OTHER|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
219763801|NCT02393794|DRUG|Romidepsin|Histone deacetylase inhibitor
219763802|NCT02393794|DRUG|Cisplatin|Platinum compound
219763803|NCT02393794|DRUG|Nivolumab|Monoclonal antibody, checkpoint inhibitor
219763804|NCT05382312|DRUG|GSK3036656|GSK3036656 will be administered.
219763805|NCT05382312|DRUG|Bedaquiline|Bedaquiline will be administered.
219763806|NCT05382312|DRUG|Delamanid|Delamanid will be administered.
219763807|NCT05382312|DRUG|RIFAFOUR e-275|RIFAFOUR e-275 will be administered.
219763808|NCT05382312|DRUG|BTZ-043|BTZ-043 will be administered.
219763809|NCT06976801|DEVICE|Intramedullary tibial Nail|Subjects will receive the micromotion MicroMotion Intramedullary tibial Nail
219763810|NCT06976801|DEVICE|Intermedullary nail|The non-micromotion intermedullary nail
219763811|NCT03886246|DRUG|Spesolimab|Solution for infusion
219763812|NCT03886246|DRUG|Spesolimab|Solution for injection
219763813|NCT04058756|DRUG|PDR001|PDR001
219763814|NCT02285439|DRUG|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
219763815|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
219763816|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
219012327|NCT03847233|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
218829152|NCT05214937|BEHAVIORAL|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
218829153|NCT00506779|DRUG|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
218829154|NCT00506779|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 Hours every 21 Days
218829155|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
218829156|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
218829157|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
218829158|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
218829159|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
218829160|NCT02737319|DRUG|Rosuvastatin|40 mg of rosuvastatin before angioplasty
218829161|NCT04676893|DRUG|D418 Tab.|1T
218829162|NCT04676893|DRUG|CKD-388 Tab.|1T
218829163|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
218829164|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
218829165|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
218829166|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
218829167|NCT01456130|DRUG|Alogliptin|Alogliptin tablets
219195907|NCT06650098|OTHER|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
219195908|NCT06650098|OTHER|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
218829168|NCT01456130|DRUG|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
218829169|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
218829170|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
218829171|NCT02748252|OTHER|stroke center referral|
218829172|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
218829173|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
218829174|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
218829175|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
218829176|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
218829177|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
218829178|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
218829179|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
218829180|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
218829181|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
218829182|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
218829183|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
218829184|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
218829185|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
218829186|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
218829187|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
218829188|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
218829189|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
218829190|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
219012328|NCT01133301|DRUG|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
219438677|NCT04580212|BEHAVIORAL|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
219438678|NCT01077869|PROCEDURE|endoscopic examination|on a weekly basis during 7 weeks
219438679|NCT01077869|PROCEDURE|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
219476442|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
218829191|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
218829192|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
218829193|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
218829194|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
218829195|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
218829196|NCT00104338|DRUG|FK778|
218829197|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
218829198|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
218829199|NCT02692963|BIOLOGICAL|BCG vaccination|BCG vaccine InterVax
218829200|NCT04475159|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
218829201|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
218829202|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
218829203|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
218829204|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
218829205|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
219012329|NCT01133301|DRUG|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
219012330|NCT02645214|OTHER|Non-antiseptic scrubs|
219012331|NCT02645214|OTHER|Antiseptic scrubs|
219012332|NCT04715763|DRUG|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
219012333|NCT04715763|DRUG|Placebo|Gelatin capsules filled with an inactive ingredient
219012334|NCT00645073|DRUG|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
219012335|NCT00645073|DRUG|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
219012336|NCT02394847|DRUG|propofol|
219012337|NCT01763216|OTHER|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
219012338|NCT01763216|OTHER|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
219012339|NCT04425174|PROCEDURE|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
218829206|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
218829207|NCT00353080|DRUG|risedronate (HMR4003)|
218829208|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
218829209|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
218829210|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
218829211|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
218829212|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
218829213|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
218829214|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
218829215|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
218829216|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
218829217|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
218829218|NCT00681395|DRUG|ABT-143|once daily for 6 days
218829219|NCT00681395|DRUG|ABT-335|once daily for six days
218829220|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
218829221|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
218829222|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
218829223|NCT02326727|DRUG|Ropivacaine|Epidural analgesia
218829224|NCT02326727|DRUG|Fentanyl|General Anesthesia
218829225|NCT02326727|DRUG|Propofol|General Anesthesia
219012340|NCT04425174|PROCEDURE|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
219012341|NCT03022565|DRUG|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
219012342|NCT01187043|DRUG|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
219012343|NCT04087876|DRUG|derazantinib|derazantinib will be administered orally
218829226|NCT02326727|DRUG|Isoflurane|General Anesthesia
218829227|NCT02326727|DRUG|Nitrous Oxide|General Anesthesia
219596940|NCT00976911|DRUG|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
218829228|NCT03396887|OTHER|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
218829229|NCT03396887|OTHER|Control group|The control group will receive treatment as usual.
218829230|NCT01459666|DRUG|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
218829231|NCT01459666|DRUG|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
218829232|NCT01152788|DRUG|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
218829233|NCT01152788|DRUG|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
218829234|NCT01984047|DRUG|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
218829235|NCT01984047|DRUG|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
218829236|NCT01881789|DRUG|Oprozomib|Extended release (ER) tablets administered orally
218829237|NCT01881789|DRUG|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
218829238|NCT01881789|DRUG|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
218829239|NCT01881789|DRUG|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
218829240|NCT02512380|DRUG|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
218829241|NCT02512380|DRUG|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
218829242|NCT00473109|PROCEDURE|Dialysis without systemic heparinization|Dialysis without systemic heparinization
218829243|NCT02972229|RADIATION|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
218829244|NCT02972229|RADIATION|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
218829245|NCT05089292|BEHAVIORAL|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
218829246|NCT06121648|OTHER|hydrotherapy|30 degrees temperature pool balance and breathing therapy
218829247|NCT06121648|OTHER|neurological physiotherapy|Balance and neurological physiotherapy on land
218829248|NCT04651205|DIETARY_SUPPLEMENT|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
218829249|NCT01282866|DEVICE|LightSheer Duet|LightSheer Duet HS handpiece
219012344|NCT02151760|DRUG|18F-DCFPyL|
218829250|NCT06113757|DEVICE|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
218829251|NCT06113757|OTHER|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
218829252|NCT05285228|BEHAVIORAL|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
218829253|NCT05285228|BEHAVIORAL|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
219012345|NCT00086320|DRUG|Paliperidone ER|
219012346|NCT04226378|DEVICE|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
219012347|NCT04226378|OTHER|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
219012348|NCT03796429|DRUG|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
218829254|NCT02143349|DIETARY_SUPPLEMENT|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
219012349|NCT02573298|DEVICE|ice|local ice application for 30 minutes
219195909|NCT05283265|BEHAVIORAL|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
219438680|NCT04368104|DIAGNOSTIC_TEST|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
219438681|NCT04990375|DEVICE|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
219438682|NCT03345368|DEVICE|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
219012350|NCT02573298|DEVICE|cold gas|local cold gas application for 2 minutes
219012351|NCT01092559|DRUG|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
219012352|NCT00851383|BIOLOGICAL|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
219012353|NCT00851383|BIOLOGICAL|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
219195910|NCT05283265|OTHER|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
219195911|NCT03887780|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
219195912|NCT06649994|DEVICE|Active iTBS of the DLPFC|Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
219195913|NCT06649994|DEVICE|Active iTBS of the vmPFC|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
219438683|NCT03345368|DEVICE|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
219438684|NCT03345368|OTHER|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
219476443|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
219596941|NCT02101580|DRUG|ADI-PEG 20|
218829255|NCT02143349|OTHER|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
218829256|NCT02573571|OTHER|Development of biomarkers|Blood sampling
218829257|NCT00005579|DRUG|dolastatin 10|
218829258|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
218829259|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
218829260|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
218829261|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
218829262|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
219012354|NCT03744923|PROCEDURE|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
219012355|NCT03744923|PROCEDURE|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
218829263|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
218829264|NCT04224922|DRUG|Paclitaxel|
218829265|NCT04224922|DRUG|Carboplatinum|
218829266|NCT04224922|DRUG|Epirubicin|
218829267|NCT04224922|DRUG|Cyclophosphamide|
218829268|NCT00362882|DRUG|docetaxel|Given IV
219012356|NCT00403793|DRUG|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
218829269|NCT00362882|DRUG|bortezomib|Given IV
219012357|NCT00403793|DRUG|Placebo|42 or 44 weeks with placebo implant and placebo injections
219438685|NCT00642967|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
219438686|NCT03689881|DEVICE|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
219438687|NCT04883567|DIAGNOSTIC_TEST|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
218829270|NCT00362882|OTHER|laboratory biomarker analysis|correlative study
218829271|NCT00362882|OTHER|immunoenzyme technique|correlative study
218829272|NCT00362882|OTHER|immunohistochemistry staining method|correlative study
218829273|NCT00362882|OTHER|pharmacological study|correlative study
218829274|NCT03073863|DRUG|Atorvastatin|Analysis
218829275|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
218829276|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
218829277|NCT00093262|DRUG|clevidipine|
218829278|NCT00093262|DRUG|placebo|
219012358|NCT00478985|BEHAVIORAL|Imatinib ending|Interruption of the treatment by Imatinib
219012359|NCT01257997|BIOLOGICAL|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
219012360|NCT03748147|DRUG|Misoprostol|prostaglandin e1
219195914|NCT06649994|DEVICE|iTBS of the vertex (sham)|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
219438688|NCT03774368|OTHER|Emergency contraception website|Existing website with factual information about emergency contraception
219438689|NCT03774368|OTHER|Emergency contraception video|Existing video with factual information about emergency contraception
219438690|NCT00259350|DRUG|Skin disinfection|
219438691|NCT05041062|DRUG|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
218829279|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
218829280|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
218829281|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
218829282|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
218829283|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
218829284|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
218829285|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
218829286|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
218829287|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
218829288|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
218829289|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
218829290|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
218829291|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
218829292|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
218829293|NCT01738685|OTHER|Nutritional Education.|
218829294|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
218829295|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
218829296|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
218829297|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
219012361|NCT05723237|OTHER|Breast Cancer Education|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
219438692|NCT05041062|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
219012362|NCT00533195|DRUG|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
219012363|NCT00533195|DEVICE|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
219012364|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
219438693|NCT02206321|PROCEDURE|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
219438694|NCT02206321|PROCEDURE|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
219438695|NCT00235664|PROCEDURE|Collection of stool and endotracheal aspirate samples|collection of samples
219438696|NCT02945995|PROCEDURE|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
219438697|NCT03418064|DEVICE|Fanfilcon A toric lens|Contact lens
219438698|NCT03418064|DEVICE|Lotrafilcon B toric lens|Contact lens
219438699|NCT00594087|DRUG|eszopiclone|eszopiclone 2mg or 3mg at bedtime
219438700|NCT00594087|OTHER|placebo|2 mg or 3 mg at bedtime
219438701|NCT00136838|BEHAVIORAL|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
219438702|NCT03865238|BIOLOGICAL|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
218829298|NCT03532022|DRUG|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
218829299|NCT03532022|DRUG|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
218829300|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
218829301|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
218829302|NCT03093714|DRUG|FDL169|CFTR corrector
218829303|NCT03093714|DRUG|Placebo|Placebo for FDL169
218829304|NCT03098095|BEHAVIORAL|Physical Activity|Moderate physical activity
218829305|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
218829306|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
218829307|NCT05353413|DEVICE|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
218829308|NCT05353413|DIAGNOSTIC_TEST|VEP - visual evoked potential|Electrophysiology of the visual pathway.
218829309|NCT05353413|DIAGNOSTIC_TEST|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
218829310|NCT01392573|DRUG|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
218829311|NCT01392573|DRUG|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
218829312|NCT02374229|PROCEDURE|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
218829313|NCT02374229|PROCEDURE|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
218829314|NCT05807126|PROCEDURE|Biopsy|Undergo biopsies
219012365|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
219012366|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
219012367|NCT03973385|DEVICE|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
219438703|NCT03865238|BIOLOGICAL|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
219438704|NCT02279979|DEVICE|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
219438705|NCT01347632|DRUG|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
219438706|NCT04864600|OTHER|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
219438707|NCT04864600|OTHER|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
219438708|NCT02865265|PROCEDURE|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
219438709|NCT00689169|DRUG|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
219438710|NCT00689169|PROCEDURE|ASCT|ASCT : D0
219763817|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
218829315|NCT05807126|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218829316|NCT05807126|PROCEDURE|Computed Tomography|Undergo CT
218829317|NCT05807126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218829318|NCT05807126|BIOLOGICAL|Magrolimab|Given IV
218829319|NCT05807126|DRUG|Olaparib|Given PO
218829320|NCT01027429|DRUG|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
218829321|NCT01027429|DRUG|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
218829322|NCT01027429|DRUG|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
218829323|NCT02789852|DEVICE|Orthosis|use orthosis
218829324|NCT02636647|BIOLOGICAL|Fecal transplant|
218829325|NCT00100737|DRUG|interleukin-2|
218829326|NCT00100737|DRUG|rituximab|
218829327|NCT01545596|BEHAVIORAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
218829328|NCT05006105|DEVICE|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
219438711|NCT00689169|DRUG|Rituximab|Rituximab 250 mg/m² :D-21 D-14
219012368|NCT01119885|DRUG|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
219012369|NCT01119885|DRUG|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
218829329|NCT05006105|DEVICE|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
219012370|NCT03198234|BIOLOGICAL|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
219012371|NCT01340898|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
219012372|NCT01340898|BIOLOGICAL|SynflorixTM|Intramuscular injection
219012373|NCT01340898|BIOLOGICAL|Infanrix-IPV/HiberixTM|Intramuscular injection
219438712|NCT04447118|DRUG|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
218829330|NCT05006105|OTHER|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
218829331|NCT05006105|OTHER|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
218829332|NCT05006105|DEVICE|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
218829333|NCT03670849|DEVICE|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
218829334|NCT03008070|DRUG|IVA337|1200mg
218829335|NCT03008070|DRUG|IVA337|800mg
218829336|NCT03008070|DRUG|Placebo|Placebo to match
218829337|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
218829338|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
218829339|NCT04631809|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
218829340|NCT04631809|PROCEDURE|CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
218829341|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
218829342|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
218829343|NCT04409834|DRUG|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
218829344|NCT04409834|DRUG|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
218829345|NCT04409834|DRUG|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
218829346|NCT04409834|DRUG|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
218829347|NCT04409834|DRUG|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
219012374|NCT01573975|DRUG|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
219012375|NCT01573975|DRUG|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
219012376|NCT01573975|DRUG|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
219012377|NCT02417701|OTHER|Laboratory Biomarker Analysis|Correlative studies
219012378|NCT02417701|OTHER|Pharmacological Study|Correlative studies
219012379|NCT02417701|DRUG|Sapanisertib|Given PO
219012380|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
219012381|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
219012382|NCT01214629|DRUG|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
219012383|NCT00303277|DRUG|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
219012384|NCT00303277|DRUG|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
219012385|NCT04352504|OTHER|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
219012386|NCT04352504|OTHER|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
219012387|NCT01636804|DEVICE|Quicksite|St. Jude Medical produced lead called Quicksite
219012388|NCT01636804|DEVICE|Quickflex|St. Jude Medical produced lead called Quickflex
219012389|NCT05135897|DEVICE|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
219012390|NCT05135897|DEVICE|rTMS|repetitive Transcranial Magnetic Stimulation
219012391|NCT05573789|GENETIC|Tumor molecular profiling|Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
219195915|NCT06649994|BEHAVIORAL|Computerized inhibitory control training|"Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal"
219195916|NCT06203834|DIETARY_SUPPLEMENT|I-Fiber Pearl|Eat 200g for once, and once a day.
218829348|NCT00668759|DRUG|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
219195917|NCT06203834|DIETARY_SUPPLEMENT|placebo|Eat 200g for once, and once a day.
219195918|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
219438713|NCT04447118|DRUG|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
219438714|NCT04957303|DEVICE|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
219438715|NCT01577355|RADIATION|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
219438716|NCT00492414|DRUG|Paroxetine CR|
219438717|NCT01802515|DRUG|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
218829349|NCT00668759|DRUG|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
218829350|NCT05419245|OTHER|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
218829351|NCT05419245|OTHER|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
218829352|NCT05419245|OTHER|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
219195919|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
219195920|NCT01585623|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219195921|NCT01585623|DRUG|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
219195922|NCT01585623|DRUG|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
219438718|NCT01802515|DRUG|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
219438719|NCT01802515|DRUG|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
219438720|NCT04287439|BEHAVIORAL|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
219438721|NCT04287439|BEHAVIORAL|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
219438722|NCT04287439|OTHER|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
219438723|NCT00568204|DEVICE|Mexyn-A|Atomised topical self-chilled pressurised spray
219438724|NCT04307901|DEVICE|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
219438725|NCT06221072|DRUG|JMT103|120 mg by subcutaneous injection every 4 weeks
219438726|NCT06221072|DRUG|zoledronic acid|4 mg by intravenous drip (100mL:4mg) every 4 weeks
219438727|NCT01917240|OTHER|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
219438728|NCT00615212|DRUG|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
219012392|NCT06507592|DIAGNOSTIC_TEST|Saliva samples collection|The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
219012393|NCT01594879|DEVICE|MIrena(LNG-IUS), oral MPA|"1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
218829353|NCT05419245|OTHER|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
218829354|NCT05419245|OTHER|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
218829355|NCT05419245|OTHER|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
218829356|NCT05419245|OTHER|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
218829357|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
219012394|NCT03041545|DEVICE|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
219012395|NCT03935906|OTHER|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
219012396|NCT03935906|OTHER|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
219012397|NCT01803919|DEVICE|Silver Alloy-Coated Urinary Catheters|
219012398|NCT01803919|DEVICE|Conventional Urinary Catheter|
219012399|NCT01988805|OTHER|Blood Draw|
219012400|NCT06498947|OTHER|This study was observational with no intervention.|This study was observational with no intervention.
219012401|NCT02886520|DEVICE|PVDF transobturator tape|
219012402|NCT02886520|DEVICE|Polypropylene transobturator tape|
218829358|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
218829359|NCT05419245|OTHER|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
219012403|NCT03266094|DEVICE|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
219012404|NCT05071456|OTHER|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
219012405|NCT01622972|DRUG|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
219012406|NCT03128892|DEVICE|Oxygen Reserve Index - RD Lite Sensors|
219012407|NCT04661657|OTHER|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
219012408|NCT04661657|OTHER|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
219012409|NCT03774511|OTHER|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
219012410|NCT02980445|BEHAVIORAL|Outdoor activity 1|40-minute outdoor activity
219012411|NCT02980445|BEHAVIORAL|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
219012412|NCT04757064|OTHER|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
219012413|NCT05248022|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
219195923|NCT01585623|DRUG|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
219438729|NCT00615212|DRUG|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
218829360|NCT06712017|DEVICE|Yttrium-90 (Y-90) resin microspheres|selective internal radiation therapy
218829361|NCT06716073|PROCEDURE|Surgery|comparison of 2 surgical procedures
218829362|NCT06715657|DRUG|Morphine intrathecal|patients intrathecal anaesthesia with morphine
218829363|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection 15 min before the end of surgery
218829364|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection just before intrathecal anaesthesia
218829365|NCT06718023|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
218829366|NCT06718023|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
218829367|NCT06718023|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, , a total of 12 weeks. Participants used professional Bungy Pump Pole.
218829368|NCT06719401|OTHER|Foot Chest Compression|Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.
218829369|NCT06719401|OTHER|Hand Chest Compression|Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.
219012414|NCT05248022|DRUG|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
219012415|NCT01457521|DRUG|Ibuprofen|Ibuprofen
219438730|NCT00615212|DRUG|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
219438731|NCT00615212|DRUG|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
219012416|NCT02042885|DRUG|OPB-111001|
219012417|NCT02075450|DEVICE|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
219012418|NCT02075450|OTHER|Just in Time Video|CPR Just in Time training video administered before the simulation case
219438732|NCT01176240|DRUG|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
218829370|NCT06717568|DIAGNOSTIC_TEST|no intervention|This is a diagnostic test with no intervention.
218829371|NCT06715956|OTHER|Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis|This observational study classifies patients with non-cystic fibrosis bronchiectasis into inflammatory subtypes based on sputum analysis. No active treatment or intervention is administered during this observational phase. Participants will later be considered for treatment with HSK31858 as part of an independent clinical trial.
218829372|NCT03070990|DRUG|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
219012419|NCT05325450|PROCEDURE|Program A|Presentation of the sentence to the implant alone
219012420|NCT05325450|PROCEDURE|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
219012421|NCT05325450|PROCEDURE|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
219012422|NCT05908370|PROCEDURE|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
219012423|NCT02269345|OTHER|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
219012424|NCT02269345|OTHER|Standard Treatment|Standard Treatment alone.
219012425|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
219438733|NCT01176240|OTHER|Placebo|Placebo
219438734|NCT01115517|DRUG|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
219438735|NCT01115517|DRUG|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
219438736|NCT01053572|PROCEDURE|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
219438737|NCT02480504|OTHER|dietary intervention intermittent energy restriction|Randomized clinical trial
219438738|NCT02480504|OTHER|continuous energy restriction|
219438739|NCT04016103|DEVICE|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
219012426|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
219438740|NCT03038672|BIOLOGICAL|Nivolumab|Given IV
219438741|NCT03038672|DRUG|Varlilumab|Given IV
219438742|NCT04694911|BEHAVIORAL|Focus Group|Participate in focus group
219438743|NCT04694911|OTHER|Interview|Complete cognitive interview
219438744|NCT04694911|OTHER|Research or Clinical Assessment Tool|Receive OOCAT
219438745|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
219438746|NCT04122118|OTHER|Medical Chart Review|Review of medical chart
219438747|NCT04122118|OTHER|Educational Intervention|Receive pharmacist-led education
219438748|NCT04122118|OTHER|Survey Administration|Ancillary studies
219438749|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
219438750|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
219438751|NCT01640080|DRUG|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
219438752|NCT00628316|DIETARY_SUPPLEMENT|caffeine|caffeine daily intake will be reduced form 150 ml per day
219438753|NCT01751204|DIETARY_SUPPLEMENT|Calcium tablet|
219438754|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (250mg)|
219438755|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (125mg)|
219438756|NCT04576260|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
219438757|NCT01174940|DRUG|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
219438758|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
219438759|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
219438760|NCT00959894|DRUG|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
219438761|NCT00959894|DRUG|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
219438762|NCT02744053|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
219438763|NCT02744053|OTHER|Laboratory Biomarker Analysis|Correlative studies
219438764|NCT02744053|RADIATION|Scintimammography|Undergo MBI
219438765|NCT02744053|DRUG|Technetium Tc-99m Sestamibi|Given via injection
219438766|NCT05406245|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
219438767|NCT01654393|OTHER|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
219438768|NCT05935813|OTHER|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
219438769|NCT00653068|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219438770|NCT00653068|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
219438771|NCT00653068|DRUG|Carboplatin|Given IV
219012427|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
219438772|NCT00653068|DRUG|Cisplatin|Given IV
219438773|NCT00653068|DRUG|Cyclophosphamide|Given IV
219438774|NCT00653068|DRUG|Etoposide|Given IV
219438775|NCT00653068|BIOLOGICAL|Filgrastim|Given IV or SC
219438776|NCT00653068|OTHER|Laboratory Biomarker Analysis|Correlative studies
219438777|NCT00653068|DRUG|Leucovorin Calcium|Given IV or PO
219438778|NCT00653068|DRUG|Methotrexate|Given IV
219438779|NCT00653068|DRUG|Thiotepa|Given IV
219438780|NCT00653068|DRUG|Vincristine Sulfate|Given IV
219438781|NCT06287658|BEHAVIORAL|Training on Kegel exercise and Ba Duan Jin applications online|Kegel exercises and Ba Duan Jin applications online
219438782|NCT06287658|BEHAVIORAL|training on Kegel exercises and Ba Duan Jin applications after the research is completed|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
219438783|NCT01017692|PROCEDURE|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
219438784|NCT03275519|OTHER|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
219438785|NCT03275519|OTHER|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
219438786|NCT03908086|OTHER|Risk factors in RA cohort|
219438787|NCT03908086|OTHER|Risk factors in general population|
219438788|NCT01305941|DRUG|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
219438789|NCT01305941|DRUG|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
219438790|NCT01305941|DRUG|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
219476444|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
218829373|NCT02856022|DEVICE|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
218829374|NCT02856022|PROCEDURE|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
218829375|NCT01365455|DRUG|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
218829376|NCT01365455|DRUG|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
218829377|NCT04632017|DIAGNOSTIC_TEST|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
218829378|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
218829379|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
218829380|NCT00928187|DRUG|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
218829381|NCT00928187|DRUG|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
218829382|NCT00928187|DRUG|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
218829383|NCT05729906|OTHER|psychological and physical tests|"Once included (T0), participants will be reviewed at 6 (T1), and 12 (T2) months. At the three measurement times, research professionals (belonging to the PAVeA laboratory) will carry out, within the nursing home the physical and psychological measurements (classic standardized tests for the population). These measurements will be carried out in parallel with the routine biological explorations performed in the institution.~At each visit, the remaining blood sampled in routine will be frozen in 2 aliquots for metabolomic and spectrometric analyses at the end of the study by the iBrain and Research Center for Respiratory Diseases laboratories."
218829384|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
218829385|NCT01682356|DIETARY_SUPPLEMENT|Beetroot juice|double-blind placebo-controlled cross-over study
218829386|NCT05393245|DRUG|Tiotropium+Olodaterol|Tiotropium+Olodaterol
218829387|NCT05393245|DEVICE|Spiolto Respimat|Spiolto Respimat Inhaler device
218829388|NCT05393245|DRUG|Long-acting muscarinic antagonists (LAMAs)|Long-acting muscarinic antagonists (LAMAs)
218829389|NCT05393245|DRUG|Long-acting β2-agonists (LABAs)|Long-acting β2-agonists (LABAs)
218829390|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
218829391|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
219012428|NCT00775645|DIETARY_SUPPLEMENT|acetyl-L-carnitine hydrochloride|Given orally
219012429|NCT00775645|OTHER|placebo|Given orally
219012430|NCT03036072|OTHER|Strict normothermia|
219012431|NCT03036072|DEVICE|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
219012432|NCT04926350|BEHAVIORAL|Resistance Exercise|8 total resistance exercises that target all major muscle groups
219012433|NCT04193657|OTHER|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
219012434|NCT04768231|DRUG|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
219012435|NCT00924456|BEHAVIORAL|Transcendental Meditation program|a natural effortless mental technique
219012436|NCT02484729|DRUG|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
219012437|NCT02484729|DRUG|Placebo, oral suspension|Matching placebo
219012438|NCT02484729|DRUG|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
219012439|NCT03715166|DRUG|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
219012440|NCT03715166|DRUG|Placebo|Oral Solution Taken twice daily
219012441|NCT04532957|DRUG|KBP-7072|QD oral capsules
219012442|NCT04532957|DRUG|Placebo|matching placebo capsules
219012443|NCT03444519|DRUG|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
219476445|NCT01054443|DRUG|Placebo|Tablet
219012444|NCT06187727|DRUG|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
219476446|NCT01054443|DRUG|Lusutrombopag|Tablet
219438791|NCT01326676|DRUG|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
218829392|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
218829393|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
218829394|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
218829395|NCT05840835|DRUG|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
218829396|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
218829397|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
218829398|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
218829399|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
218829400|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
218829401|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
218829402|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
218829403|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
218829404|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
218829405|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
219012445|NCT02760667|DRUG|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
219438792|NCT01326676|DRUG|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
219438793|NCT04979962|DEVICE|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
219476447|NCT06991387|OTHER|Myofascial Release|A single session of myofascial release techniques including Single Arm Pull, Lateral Neck Shoulder Release, Thoracic Transverse Release, and Anterior Cervical Release applied by a physiotherapist trained in manual therapy.
219476448|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
219476449|NCT06992596|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
219012446|NCT02760667|DRUG|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
219012447|NCT02760667|DRUG|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
219012448|NCT02760667|PROCEDURE|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
219012449|NCT02111850|BIOLOGICAL|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
219012450|NCT02111850|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
219012451|NCT02111850|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
219438794|NCT01207674|OTHER|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
218829406|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
218829407|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
218829408|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
218829409|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
218829410|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
218829411|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
218829412|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
218829413|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
218829414|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
218829415|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
218829416|NCT02963363|OTHER|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
218829417|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
218829418|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
218829419|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
218829420|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
218829421|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
218829422|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
218829423|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
218829424|NCT05536882|DRUG|Benzoyl peroxide|See arm description
218829425|NCT05536882|DRUG|Adapalene Gel|See arm description
218829426|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
218829427|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
218829428|NCT00725946|DRUG|Iodine-124|
218829429|NCT00725946|RADIATION|PET/CT with Iodine-124|
218829430|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
218829431|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
218829432|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
219438795|NCT04949425|DRUG|Adavosertib|Patients will receive Adavosertib orally.
218829433|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
218829434|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
218829435|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
219438796|NCT05212402|DIETARY_SUPPLEMENT|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
218829436|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
218829437|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
218829438|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
218829439|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
218829440|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
218829441|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
218829442|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
218829443|NCT05386342|DEVICE|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
219438797|NCT05212402|OTHER|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
219438798|NCT01319513|OTHER|whey protein bolus|single dose of 25 g whey protein
219438799|NCT01319513|OTHER|whey protein pulses|10 2.5 g pulses of whey protein
219438800|NCT00619606|DEVICE|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
219438801|NCT00619606|DEVICE|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
219438802|NCT00619606|DEVICE|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
219438803|NCT00619606|DEVICE|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
219438804|NCT04203108|DRUG|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
219438805|NCT04203108|DRUG|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
219438806|NCT04203108|DRUG|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
219438807|NCT04203108|DRUG|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
219438808|NCT05537506|DEVICE|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
219438809|NCT05537506|DEVICE|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
219438810|NCT02944513|DEVICE|Quell|
219438811|NCT03921606|BEHAVIORAL|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
219438812|NCT03921606|BEHAVIORAL|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
219438813|NCT04263415|DRUG|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
219438814|NCT04263415|OTHER|Placebo|once-weekly injection with placebo pen for 16 weeks
219438815|NCT02619006|OTHER|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
219438816|NCT02130752|DEVICE|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
219438817|NCT02130752|DEVICE|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
219438818|NCT02314598|OTHER|No treatment|
219438819|NCT05135429|OTHER|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
218829444|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
218829445|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
218829446|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
218829447|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
219438820|NCT03690674|BEHAVIORAL|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
219438821|NCT04409626|OTHER|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
218829448|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
218829449|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
218829450|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
218829451|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
218829452|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
218829453|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
218829454|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
218829455|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
218829456|NCT00002124|DRUG|Delavirdine mesylate|
218829457|NCT00002124|DRUG|Lamivudine|
218829458|NCT00002124|DRUG|Zidovudine|
218829459|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
218829460|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
218829461|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
218829462|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
219438822|NCT03205189|OTHER|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
219438823|NCT00937326|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
219438824|NCT00937326|DRUG|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
219438825|NCT03225560|OTHER|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
219438826|NCT02578992|PROCEDURE|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
219438827|NCT02578992|DEVICE|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
219438828|NCT01782404|DEVICE|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
219438829|NCT00681291|DEVICE|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
219438830|NCT00681291|DEVICE|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
219438831|NCT02002065|BIOLOGICAL|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
219438832|NCT02002065|BIOLOGICAL|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
219438833|NCT05258526|OTHER|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
219438834|NCT04151446|DEVICE|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
219438835|NCT06117904|DRUG|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
219438836|NCT06117904|DRUG|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
219438837|NCT00040469|DRUG|Campath -1H|
219438838|NCT00040469|DRUG|Dilantin|
219438839|NCT00040469|DRUG|Busulfan|
219438840|NCT00040469|DRUG|Cyclophosphamide|
219438841|NCT05193604|DRUG|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
219438842|NCT05193604|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219012452|NCT02111850|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
219012453|NCT03194698|DEVICE|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
219012454|NCT03194698|PROCEDURE|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
218829463|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
218829464|NCT02374281|DRUG|Glucose sucking|
218829465|NCT02374281|DRUG|Water sucking|
218829466|NCT02374281|OTHER|No sucking|
218829467|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
218829468|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
218829469|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
218829470|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
218829471|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
218829472|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
218829473|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
218829474|NCT03271164|DEVICE|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
218829475|NCT03271164|OTHER|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
218829476|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
219012455|NCT05899309|DIAGNOSTIC_TEST|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
219012456|NCT02389933|DRUG|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
219438843|NCT05193604|DRUG|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
218829477|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
218829478|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
218829479|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
218829480|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
218829481|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
218829482|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
218829483|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
218829484|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
218829485|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
218829486|NCT00700908|BEHAVIORAL|automated telephone intervention vs. usual care|
219012457|NCT06138106|DIETARY_SUPPLEMENT|Natural Product Supplement|Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
219438844|NCT05193604|DRUG|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
219438845|NCT02001922|OTHER|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
219438846|NCT03491904|DRUG|Fasinumab AI|Self-administered with auto injector
219438847|NCT03491904|DRUG|Fasinumab PFS|Prefilled syringe administered by study staff
219438848|NCT02758925|DRUG|Rituximab|375mg/m2 IV day 1
219438849|NCT02758925|DRUG|Bendamustine|90mg/m2 IV day 1-2
219438850|NCT02758925|DRUG|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
219438851|NCT04442386|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
219438852|NCT06437639|DRUG|Mexidol|Neurocytoprotector
219476450|NCT06992596|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
219763818|NCT05189366|BEHAVIORAL|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
219763819|NCT05189366|BEHAVIORAL|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
219763820|NCT06609226|DRUG|Etavopivat A|Participants will receive an oral dose of Etavopivat A.
219763821|NCT06609226|DRUG|Etavopivat B|Participants will receive an oral dose of Etavopivat B.
218829487|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
218829488|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
219763822|NCT06609226|DRUG|Etavopivat C|Participants will receive an oral dose of Etavopivat C.
219763823|NCT05799625|BEHAVIORAL|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
219763824|NCT06436742|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
219763825|NCT06436742|OTHER|Placebo|Intravenous infusion of placebo
219763826|NCT05432791|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219763827|NCT05432791|PROCEDURE|Bone Scan|Undergo bone scan
219763828|NCT05432791|PROCEDURE|Computed Tomography|Undergo CT scan
219763829|NCT05432791|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763830|NCT05432791|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219763831|NCT05432791|DRUG|Olaparib|Given PO
219763832|NCT05432791|DRUG|Pazopanib|Given PO
218829489|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
218829490|NCT06075875|DIETARY_SUPPLEMENT|mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
219763833|NCT05432791|DRUG|Temozolomide|Given PO
219763834|NCT05432791|DRUG|Trabectedin|Given IV
219763835|NCT05432791|PROCEDURE|Transthoracic Echocardiography Test|Undergo TTE
219763836|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
218829491|NCT06075875|DIETARY_SUPPLEMENT|pure vegetable proteins|pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
218829492|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
218829493|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
218829494|NCT02985177|DRUG|INF2.0 + IBU|Analgesics
218829495|NCT02985177|DRUG|INF1.0 + IBU|Analgesics
218829496|NCT03606486|OTHER|Biospecimen Collection|Undergo collection of tumor sample and blood draw
218829497|NCT03606486|OTHER|Laboratory Biomarker Analysis|Correlative studies
218829498|NCT03606486|DEVICE|Lavage|Undergo uterine lavage
218829499|NCT03606486|OTHER|Pap Smear|Undergo pap smear
218829500|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
218829501|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
219763837|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
219763838|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
219763839|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
219763840|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
219763841|NCT05802186|PROCEDURE|Computed Tomography|Undergo CT
219763842|NCT05802186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219763843|NCT05802186|PROCEDURE|Positron Emission Tomography|Undergo PET
218829502|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
219476451|NCT06140407|DRUG|Cisplatin|Receive Cisplatin
219763844|NCT05802186|OTHER|Quality-of-Life Assessment|Ancillary studies
219763845|NCT05802186|OTHER|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
219763846|NCT05802186|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219763847|NCT05802186|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
218829503|NCT04536051|BIOLOGICAL|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
218829504|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
218829505|NCT04536051|BIOLOGICAL|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
218829506|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
218829507|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
218829508|NCT03765580|DIETARY_SUPPLEMENT|Fish|Lunch containing fish
218829509|NCT03765580|OTHER|Control|Lunch containing no fish
218829510|NCT01918865|DRUG|ISIS-PTP1BRx|
218829511|NCT01918865|DRUG|Placebo|
218829512|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
218829513|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
218829514|NCT01934907|OTHER|Washing of packed RBC by normal saline|
218829515|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
218829516|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
219012458|NCT06138106|DIETARY_SUPPLEMENT|Placebo control|Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
219012459|NCT04890223|BEHAVIORAL|Brief MI intervention|Brief MI intervention
219012460|NCT04890223|BEHAVIORAL|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
219012461|NCT00665847|DRUG|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
219012462|NCT00665847|DRUG|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
219012463|NCT04845789|OTHER|Non-interventional|Non-interventional. Interview would be conducted for data collection.
219012464|NCT04802460|DEVICE|Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)|Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
219438853|NCT05047016|OTHER|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
219012465|NCT02867787|DRUG|Botox arm|
219012466|NCT05814939|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
218829517|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
218829518|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
219012467|NCT05814939|DRUG|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
219438854|NCT00086385|DRUG|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
218829519|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
218829520|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
218829521|NCT04003844|DRUG|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
218829522|NCT04003844|DRUG|Acetylsalicylic acid|Coadministration
218829523|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
218829524|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
218829525|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
218829526|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
219012468|NCT05814939|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
219012469|NCT01364207|OTHER|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
219012470|NCT01364207|OTHER|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
219012471|NCT05557461|DEVICE|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
219012472|NCT05168410|OTHER|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
219012473|NCT02286505|DEVICE|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
219012474|NCT02286505|OTHER|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
219012475|NCT04434794|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
219012476|NCT04434794|OTHER|standard treatment|standard treatment according to clinical protocols
219012477|NCT04481633|DIAGNOSTIC_TEST|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
219012478|NCT04481633|OTHER|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
219012479|NCT03388294|BEHAVIORAL|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
219012480|NCT00492115|DEVICE|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
219012481|NCT00492115|DEVICE|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
218829527|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
218829528|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
218829529|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
218829530|NCT02638467|DRUG|Bone Marrow cells|
219012482|NCT04521075|BIOLOGICAL|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
219012483|NCT03564145|DRUG|S5G4T-1|Once a day topical cream
219012484|NCT03143569|DEVICE|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
219012485|NCT03143569|DEVICE|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
219012486|NCT05780567|DRUG|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
219012487|NCT05780567|DRUG|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
219012488|NCT04982198|PROCEDURE|ROSA assisted TKA|Robotic assisted total knee arthroplasty
219012489|NCT00099346|DRUG|MK0457, VX-680 (Aurora Kinase Inhibitor)|
219012490|NCT00602706|BIOLOGICAL|sargramostim|
219012491|NCT00602706|DRUG|melphalan|
219012492|NCT00602706|PROCEDURE|autologous hematopoietic stem cell transplantation|
219012493|NCT00602706|PROCEDURE|peripheral blood stem cell transplantation|
219012494|NCT00602706|RADIATION|samarium Sm 153 lexidronam pentasodium|
219012495|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
219012496|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
219012497|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
219012498|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
219476452|NCT06140407|DRUG|Carboplatin|Receive Carboplatin
219476453|NCT06140407|DRUG|Etoposide|Receive Etoposide
219476454|NCT06140407|BIOLOGICAL|Pembrolizumab|Receive Pembrolizumab by IV
219476455|NCT06140407|PROCEDURE|Computed Tomography|Undergo Computed Tomography
219476456|NCT06140407|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
219476457|NCT06140407|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
219476458|NCT06140407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218829531|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
218829532|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
219438855|NCT00899600|DRUG|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
219438856|NCT00899600|OTHER|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
219438857|NCT02428075|BEHAVIORAL|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
219438858|NCT00767793|DRUG|Placebo|One drop in each eye every 12 hours for seven days
219438859|NCT00767793|DRUG|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
219438860|NCT00767793|DRUG|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
218829533|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
218829534|NCT04615624|OTHER|Placebo|Normal saline
218829535|NCT00002343|DRUG|Ethambutol hydrochloride|
218829536|NCT00002343|DRUG|Rifabutin|
218829537|NCT05247684|DRUG|AK112|IV infusion
218829538|NCT05247684|DRUG|Carboplatin|IV infusion
218829539|NCT05247684|DRUG|Cisplatin|IV infusion
218829540|NCT05247684|DRUG|Paclitaxel|IV infusion
218829541|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
218829542|NCT03920241|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
218829543|NCT03920241|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
218829544|NCT03920241|OTHER|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
218829545|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
218829546|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
218829547|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
218829548|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
218829549|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
218829550|NCT00755963|DRUG|placebo|maltodextrin
218829551|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
218829552|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
218829553|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
218829554|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
218829555|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
218829556|NCT01153204|BEHAVIORAL|Group Psychotherapy|
218829557|NCT01153204|OTHER|Group Psychotherapy plus Sildenafil citrate|
218829558|NCT01153204|DRUG|Sildenafil citrate|
218829559|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
218829560|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
218829561|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
218829562|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
218829563|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
218829564|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
218829565|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
218829566|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
219438861|NCT00767793|DRUG|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
219438862|NCT03372447|DRUG|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
219476459|NCT06140407|RADIATION|Radiation Therapy|Undergo Radiation Therapy
219476460|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
219476461|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
219012499|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
219012500|NCT02835274|DEVICE|BSC Deep Brain Stimulation System with Directional Lead|
219012501|NCT01182493|DEVICE|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
218829567|NCT04887194|DRUG|Digoxin|P-gp probe substrate
218829568|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
219012502|NCT01853826|DRUG|Afatinib|Patients received a daily dose of 40 milligrams (mg) of afatinib (Giotrif®), in the form of film-coated tablet over a 28 day cycle. Afatinib was taken orally with 250 milliliters (mL) of water at the same time of the day and without eating anything for at least 3 hours. Patients continued on treatment for as long as there was no disease progression or no other trial withdrawal criteria. The dose was reduced to 30 mg or 20 mg once daily when the initial dose was not tolerated by the patient.
219012503|NCT06099327|DEVICE|Image-based vital sign monitoring|Unobtrusive, vital signs measurements with remote photoplethysmography
219012504|NCT04338295|DEVICE|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
219012505|NCT00360828|DRUG|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
219012506|NCT00360828|DRUG|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
219012507|NCT01133054|PROCEDURE|revascularization|surgery or stenting
219012508|NCT06406673|DRUG|Cadonilimab+EC/ET+RT|Cohort\_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
219012509|NCT06406673|DRUG|Cadonilimab+vorolanib|Cohort\_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
219012510|NCT05828199|DRUG|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
219012511|NCT05828199|DRUG|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
219012512|NCT05373420|OTHER|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
219012513|NCT05373420|OTHER|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
219012514|NCT05373420|OTHER|Gender|Male or female. This variable is obtained from the Belgian national registry.
219012515|NCT05373420|OTHER|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
219012516|NCT05373420|OTHER|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
219012517|NCT05373420|OTHER|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
219012518|NCT00982488|DRUG|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
219012519|NCT00982488|DRUG|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
219438863|NCT04154397|DEVICE|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
219438864|NCT00880100|DRUG|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
219438865|NCT00505518|DRUG|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
218829569|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
218829570|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
218829571|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
218829572|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
219438866|NCT00505518|BEHAVIORAL|Collaborative psychiatric and primary medical care|Regular care visits from health workers
218829573|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
218829574|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
218829575|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
218829576|NCT04005495|BEHAVIORAL|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
218829577|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
218829578|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
218829579|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
218829580|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
218829581|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
218829582|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
219012520|NCT04208906|DEVICE|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
219012521|NCT03342976|OTHER|My-AHA platform|ICT strategy for early detection of frailties
219012522|NCT00165893|DEVICE|Accu-Spina Device/IDD therapy|
219012523|NCT00165893|PROCEDURE|Physical Therapy|
219012524|NCT00084981|DRUG|decitabine|Given IV
219012525|NCT00084981|DRUG|valproic acid|Given PO
219012526|NCT00084981|OTHER|pharmacological study|Correlative studies
219195924|NCT06651866|DRUG|D-CMG|"Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study."
218829583|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
218829584|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
218829585|NCT03204877|DRUG|Melatonin|Oral capsules
218829586|NCT03204877|OTHER|Placebo|Oral capsules
218829587|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
219012527|NCT00084981|OTHER|laboratory biomarker analysis|Correlative studies
219195925|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
219195926|NCT03973827|OTHER|Control|No intervention. Control subjects.
218829588|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
218829589|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
219012528|NCT05482633|OTHER|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
219438867|NCT02972736|RADIATION|Radiation dose expressed as DAP|
219438868|NCT02668055|BIOLOGICAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
219438869|NCT03472768|DIAGNOSTIC_TEST|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
219438870|NCT04100044|OTHER|Exercise Counseling|Meet with physical therapist
219438871|NCT04100044|BEHAVIORAL|Exercise Intervention|Receive personalized home exercise intervention
219438872|NCT04100044|OTHER|Questionnaire administration|Ancillary studies
219438873|NCT04100044|OTHER|Quality-of-Life Assessment|Ancillary studies
218829590|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
219476462|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
219438874|NCT03130504|DRUG|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
219763848|NCT05835986|DRUG|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment part (arm).
218829591|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
218829592|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
218829593|NCT02148263|DEVICE|senofilcon A|
218829594|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
218829595|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
218829596|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
218829597|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
218829598|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
218829599|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
218829600|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
218829601|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
218829602|NCT06493175|DIAGNOSTIC_TEST|Application of large language model in emergency chest pain triage.|The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.
219438875|NCT05098808|OTHER|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
219476463|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
219763849|NCT05835986|DRUG|Tocilizumab|When applicable, tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
218829603|NCT06493175|DIAGNOSTIC_TEST|According to the normal procedures to receive medical treatment|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
218829604|NCT03386435|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
218829605|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
218829606|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
218829607|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
218829608|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
218829609|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
218829610|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
218829611|NCT02663427|DEVICE|serological examination and gastroscope|
219012529|NCT00733044|BEHAVIORAL|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
218829612|NCT00751712|DEVICE|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
218829613|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
218829614|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
218829615|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
218829616|NCT06235918|DRUG|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
218829617|NCT06235918|DRUG|Nab-paclitaxel|260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
218829618|NCT06235918|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
219012530|NCT00733044|OTHER|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
219012531|NCT05113186|DRUG|Lenvatinib Pill|"The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
218829619|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
218829620|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
218829621|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
218829622|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
219012532|NCT01269697|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules 2 times per day during 6 month
219012533|NCT01269697|DIETARY_SUPPLEMENT|Placebo Nutrof total|2 capsules 2 times per day during 6 month
219012534|NCT04244786|DEVICE|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
219012535|NCT04244786|OTHER|No intervention|No intervention for participants who discontinued prior to randomization
219012536|NCT05584696|OTHER|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
219012537|NCT05584696|OTHER|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
219012538|NCT01101347|DEVICE|Aneurysm-Embolization System|
219012539|NCT02659527|DRUG|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
219012540|NCT02659527|DEVICE|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
219012541|NCT05693714|DIAGNOSTIC_TEST|Pcr|Polymerase chain reaction
219438876|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
218829623|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
219012542|NCT01424254|DEVICE|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
219012543|NCT01424254|PROCEDURE|Push-Enteroscopy|currently recommended standard
219195927|NCT06653036|PROCEDURE|Dural puncture epidural|The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.
218829624|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
218829625|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
218829626|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
218829627|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
218829628|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
218829629|NCT01971671|OTHER|no intervention.|
218829630|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
219012544|NCT00264641|DRUG|Human insulin|Hyperinsulinaemic induced hypoglycaemia
219195928|NCT06653036|PROCEDURE|Standard Epidural Technique|The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
219438877|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
219438878|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
219438879|NCT02884193|PROCEDURE|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
218829631|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
218829632|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
219012545|NCT02107027|DEVICE|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
219012546|NCT02107027|DEVICE|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
219012547|NCT03376854|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
219012548|NCT03376854|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
219012549|NCT03376854|DEVICE|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
219012550|NCT00074087|DRUG|pegylated liposomal doxorubicin hydrochloride|
219012551|NCT03032367|DRUG|bedaquiline|
219012552|NCT01238679|DRUG|PF-04958242|Administered as specified in the treatment arm
219012553|NCT01238679|DRUG|Placebo|Administered as specified in the treatment arm
219012554|NCT02703909|DRUG|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
219438880|NCT02884193|PROCEDURE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
219438881|NCT02884193|PROCEDURE|Sham Ice Bag|"Placebo application through an ice bag empty."
219438882|NCT04012333|DRUG|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
219438883|NCT02853123|DRUG|Tiotropium|fixed dose combination once daily
219438884|NCT02853123|DRUG|Olodaterol|fixed dose combination once daily
218829633|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
219012555|NCT02703909|DEVICE|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
219012556|NCT01830582|PROCEDURE|Advanced MR Imaging|
219012557|NCT00613938|DRUG|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
219012558|NCT00613938|DRUG|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
219012559|NCT00613938|DRUG|oxycodone|10mg capsule q4-6 hrs for 3 days
219438885|NCT02853123|DRUG|Tiotropium|
218829634|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
218829635|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
218829636|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
218829637|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
218829638|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
218829639|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
219012560|NCT00613938|DRUG|placebo|1 capsule q4-6 hrs for 3 days
219012561|NCT00480272|DRUG|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
219012562|NCT00480272|DRUG|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
219012563|NCT02939235|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
219438886|NCT00564603|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
219438887|NCT00564603|OTHER|0.9% Saline|Saline, in same volume of 2mL
219438888|NCT01116349|PROCEDURE|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
219476464|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
219476465|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
218829640|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
218829641|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
218829642|NCT03118336|DRUG|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
218829643|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
218829644|NCT02869672|BIOLOGICAL|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
218829645|NCT02869672|BIOLOGICAL|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
218829646|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
218829647|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
218829648|NCT00092820|DRUG|MK0653, ezetimibe|
218829649|NCT00092820|DRUG|Comparator: placebo|
219580703|NCT01615237|BEHAVIORAL|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
218829650|NCT03040128|DRUG|Minocycline|high-dose, intravenous minocycline
218829651|NCT03040128|OTHER|normal saline infusion|
218829652|NCT01736033|DRUG|Tamsulosin|1 tablet(0.2mg) orally q.d.
218829653|NCT01736033|DRUG|Finasteride|1 tablet(5mg) orally q.d.
218829654|NCT01736033|DRUG|Placebo|1 tablet(0.2mg) orally q.d.
218829655|NCT02534883|DRUG|Misoprostol|To be place vaginally
218829656|NCT02534883|DRUG|Placebo|To be placed vaginally
218829657|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
218829658|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
219012564|NCT02939235|DRUG|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
219012565|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
219580704|NCT01615237|BEHAVIORAL|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
218829659|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
218829660|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
218829661|NCT00198679|DRUG|Chlorhexidine|
218829662|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
218829663|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
218829664|NCT03980392|OTHER|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
218829665|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
218829666|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
218829667|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
219012566|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
219012567|NCT02636868|DRUG|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
219012568|NCT02636868|DRUG|nCPAP|Nasal CPAP
218829668|NCT05231759|DEVICE|L'DISQ|
218829669|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
218829670|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
218829671|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
218829672|NCT03816722|DEVICE|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
218829673|NCT03816722|OTHER|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
218829674|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
218829675|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
218829676|NCT06555341|BEHAVIORAL|Experimental: Six Thinking Hats Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4\. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5\. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins."
218829677|NCT06555341|BEHAVIORAL|Other: Video Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4\. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5\. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy."
219012569|NCT00590109|OTHER|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
219012570|NCT00590109|OTHER|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
219012571|NCT02443012|DRUG|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
219012572|NCT02443012|PROCEDURE|Laser|Grid/Focal Laser Photocoagulation
219012573|NCT05124951|RADIATION|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
219012574|NCT05124951|DRUG|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
219012575|NCT05124951|DRUG|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
219012576|NCT05124951|PROCEDURE|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
219012577|NCT01288950|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
219012578|NCT03220217|DRUG|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
219012579|NCT03220217|DRUG|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
219012580|NCT01755923|DRUG|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
219012581|NCT01755923|DRUG|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
219012582|NCT00376909|OTHER|educational intervention|
219012583|NCT00376909|OTHER|study of socioeconomic and demographic variables|
219012584|NCT04759872|OTHER|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
219012585|NCT03854656|OTHER|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
219195929|NCT06652100|DIAGNOSTIC_TEST|ProNephro AKI (NGAL)|ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
219012586|NCT06308120|DEVICE|Ion Endoluminal System|Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.
219012587|NCT06308120|DEVICE|superDimension Navigation System and Accessories|Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
219012588|NCT01384396|DRUG|KW-3357|Intravenous infusion once a day
219012589|NCT03025542|DRUG|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
219012590|NCT03025542|OTHER|Placebo|Subjects will receive injections of Placebo.
219012591|NCT03745937|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
219012592|NCT03745937|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
219012593|NCT02635828|DRUG|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
219012594|NCT02635828|DRUG|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
219012595|NCT02635828|DRUG|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
219012596|NCT06036576|DRUG|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
219012597|NCT00616460|DRUG|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
218829678|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
218829679|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
218829680|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
218829681|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
219012598|NCT06051188|DEVICE|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
219012599|NCT00239707|DRUG|GIP|One-time 20 ng/kg/min infusion over 3 hours
219012600|NCT00239707|DRUG|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
219012601|NCT00239707|DRUG|Normal Saline|one-time infusion over 3 hours
219012602|NCT05240404|DRUG|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
219012603|NCT05240404|PROCEDURE|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
219012604|NCT03880656|BIOLOGICAL|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
219012605|NCT05456243|BIOLOGICAL|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10\^5 cells/kg
218829682|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
219012606|NCT05456243|BIOLOGICAL|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
219012607|NCT03790527|PROCEDURE|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
219012608|NCT03790527|PROCEDURE|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
219012609|NCT05138679|PROCEDURE|Revascularization|Endovascular or surgical restoration of arterial blood flow.
218829683|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
218829684|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
218829685|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
218829686|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
218829687|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
218829688|NCT01587248|DEVICE|Harmonic|Dissection with harmonic scalpel
219012610|NCT05138679|PROCEDURE|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
219012611|NCT05138679|OTHER|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
219012612|NCT04471753|BEHAVIORAL|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
219012613|NCT04592965|BEHAVIORAL|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
219012614|NCT04592965|BEHAVIORAL|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
219012615|NCT04592965|OTHER|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
219195930|NCT04629339|DRUG|INCB086550|INCB086550 will be administered orally twice a day.
218829689|NCT01587248|PROCEDURE|electrocautery|Dissection in modified radical mastectomy
218829690|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
218829691|NCT03242226|DEVICE|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
218829692|NCT03242226|DEVICE|single vision spectacles|Wear single vision spectacle only
218829693|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
218829694|NCT00166127|DRUG|Levosimendan|
218829695|NCT05687227|BEHAVIORAL|Online education and counseling|Online education and counseling regarding gynecological examination
218829696|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
218829697|NCT03159910|BEHAVIORAL|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
218829698|NCT03159910|BEHAVIORAL|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
218829699|NCT00375466|DRUG|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
218829700|NCT00375466|DRUG|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
218829701|NCT00439101|DRUG|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
218829702|NCT00439101|OTHER|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
218829703|NCT03271216|DEVICE|No intervention|no intervention
219012616|NCT04592965|OTHER|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
218829704|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
218829705|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
218829706|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
219012617|NCT04800003|DIAGNOSTIC_TEST|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
219012618|NCT05424042|BEHAVIORAL|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
219012619|NCT05424042|BEHAVIORAL|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
219012620|NCT05424042|BEHAVIORAL|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
219012621|NCT03595033|DEVICE|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
219012622|NCT00539448|DRUG|insulin glargine|in combination with insulin Glulisine as bolus regimen
219438889|NCT01116349|DEVICE|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
219438890|NCT03207724|DRUG|Xilonix plus Onivyde and 5FU|Xilonix by IV
219438891|NCT00050336|DRUG|Lonafarnib (SARASAR)|
219438892|NCT02074397|PROCEDURE|Distant extrafascial injection|
219438893|NCT02074397|PROCEDURE|Subfascial injection|
219195931|NCT05844150|DRUG|PM8002|IV infusion
219438894|NCT01314144|DRUG|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
219438895|NCT00443625|DRUG|SK3530|
218829707|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
218829708|NCT00224965|BEHAVIORAL|Behavior Therapy|
218829709|NCT04877678|DRUG|Bepotastine|10 mg Bepotastine, twice a day
218829710|NCT04877678|DRUG|Placebo|Identical looking placebo, twice a day
218829711|NCT05002348|DEVICE|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
218829712|NCT01060254|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
218829713|NCT01060254|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
218829714|NCT02358408|DEVICE|Blood glucose monitoring systems for self-testing|
218829715|NCT04113889|DRUG|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
219012623|NCT00539448|DRUG|insulin glulisine|in combination with insulin Glargine as bolus regimen
219012624|NCT03558399|OTHER|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
219012625|NCT03558399|OTHER|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
219012626|NCT06110988|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
219012627|NCT01942187|DRUG|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
219012628|NCT01942187|DRUG|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
219012629|NCT01942187|BEHAVIORAL|Problem Solving Therapy|Weekly specialized psychotherapy
219012630|NCT01437215|DEVICE|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
219195932|NCT05844150|DRUG|Platinum|IV infusion
219195933|NCT05844150|DRUG|Etoposide|IV infusion
219438896|NCT06258265|DRUG|TAK-279|TAK-279 capsule.
219438897|NCT06258265|DRUG|TAK-279 Placebo|TAK-279 matching placebo capsule.
219438898|NCT06258265|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
219438899|NCT06258265|DRUG|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
219476466|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
219476467|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
219012631|NCT00429507|DRUG|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
219195934|NCT06616467|BEHAVIORAL|Tummy Time for the prevention of childhood obesity|"A cognitive-behavioral intervention aimed at mothers of infants is presented that aims to increase the practice of TT and maintain a healthy weight in the infant, called \&#34;Tummy Time for the prevention of childhood obesity\&#34;, within the intervention modifiable variables are involved that directly impact the expected results such as: the knowledge and beliefs of the mothers, infant temperament, parental self-efficacy and self-efficacy for the practice of TT.~The intervention lasts 12 weeks from the first contact with the participants and consists of eight sessions broken down as follows: the first session is presented in a face-to-face format with expository, audiovisual and demonstrative means; sessions two, four, five and seven are provided through a text message with use WhatsApp® and the use of visual media. Sessions three, six and eight are delivered via telephone call with the aim of offering feedback on the doubts generated up to that point."
219012632|NCT00429507|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
219195935|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
219195936|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
219438900|NCT05166486|OTHER|Calisthenic exercise|"Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks."
219438901|NCT03477344|DRUG|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
219438902|NCT03477344|DRUG|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
219438903|NCT03945656|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
218829716|NCT04113889|DRUG|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
218829717|NCT01830348|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
219438904|NCT03945656|DRUG|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
219438905|NCT05283499|DRUG|OPIOID|Analgesic assignment
219438906|NCT05283499|DRUG|NON-OPIOID|Analgesic assignment
219438907|NCT01711476|BEHAVIORAL|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
219763850|NCT05420012|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
218829718|NCT01830348|DRUG|placebo vehicle gel|
218829719|NCT02321605|BEHAVIORAL|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
218829720|NCT02321605|BEHAVIORAL|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
219012633|NCT00429507|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
219438908|NCT01711476|OTHER|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
219012634|NCT05164042|BIOLOGICAL|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
219012635|NCT00528398|DRUG|cytarabine|
219012636|NCT00528398|DRUG|idarubicin|
219012637|NCT02480543|DRUG|Misoprostol (cytotec)|
219012638|NCT00353405|BEHAVIORAL|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
219012639|NCT00353405|BEHAVIORAL|Mass media|Mass media provides messages that support sexual health skills.
219012640|NCT00353405|BEHAVIORAL|Control|Control group received no social skills training and no media mass media messages.
219476468|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
218829721|NCT05655975|PROCEDURE|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
218829722|NCT06014307|BEHAVIORAL|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
218829723|NCT06014307|BEHAVIORAL|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
218829724|NCT00622921|BEHAVIORAL|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
218829725|NCT01630317|PROCEDURE|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
218829726|NCT01630317|PROCEDURE|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
218829727|NCT01949129|DRUG|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
218829728|NCT01949129|RADIATION|TBI|2 x 2Gy/day , 3 days (total 12Gy)
218829729|NCT01949129|DRUG|Thiotepa|2x5 mg/kg BW, 1 day
218829730|NCT01949129|DRUG|Treosulfan|14g/m² BS, 3 days
218829731|NCT01949129|DRUG|Fludarabine|30 mg/m² BS, 5 days
218829732|NCT01949129|DRUG|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
218829733|NCT01949129|DRUG|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
218829734|NCT01949129|DRUG|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
218829735|NCT01949129|DRUG|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
218829736|NCT04480229|BEHAVIORAL|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
218829737|NCT03388541|DRUG|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
218829738|NCT03388541|DRUG|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
219012641|NCT03042247|DIAGNOSTIC_TEST|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
219012642|NCT02734810|DRUG|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
218829739|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
218829740|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
218829741|NCT04512118|DIAGNOSTIC_TEST|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
218829742|NCT05710250|BEHAVIORAL|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
219012643|NCT06268093|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
219012644|NCT05330338|BIOLOGICAL|Genetic analyses: whole genome sequencing|Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
219012645|NCT02101645|PROCEDURE|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
219012646|NCT02101645|PROCEDURE|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
219012647|NCT00488345|DRUG|Tygacil|
219012648|NCT03781609|BEHAVIORAL|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
219195937|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
219476469|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
218829743|NCT05710250|BEHAVIORAL|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
219438909|NCT04387591|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
219438910|NCT04387591|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
219438911|NCT01464398|BEHAVIORAL|Stress reduction|8 weekly sessions
219438912|NCT01464398|BEHAVIORAL|Stress reduction with Health education|8 weekly sessions
219438913|NCT03021044|OTHER|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
219438914|NCT03021044|OTHER|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
219438915|NCT06257615|BEHAVIORAL|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
219438916|NCT03247218|DRUG|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
219438917|NCT03036930|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219438918|NCT03036930|PROCEDURE|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
219438919|NCT03036930|OTHER|Questionnaire Administration|Ancillary studies
219438920|NCT03036930|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219438921|NCT02515188|DRUG|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
219438922|NCT02515188|DRUG|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
219438923|NCT01978392|BEHAVIORAL|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
219476470|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
219476471|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg twice daily (BID)
219476472|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg once daily (OD)
219476473|NCT02977052|DRUG|Ipilimumab|
219476474|NCT02977052|DRUG|Nivolumab|
219476475|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
219476476|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
219476477|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
219763851|NCT05420012|DRUG|Placebo|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
218829744|NCT06170567|OTHER|The effect of puzzles on students' course success|The effect of puzzles on students' course success
218829745|NCT02012218|DRUG|ADT|
218829746|NCT02012218|DRUG|Brexpiprazole|
218829747|NCT02253043|DEVICE|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
218829748|NCT04590053|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
218829749|NCT01796288|RADIATION|simultaneous radiotherapy|
219438924|NCT05737667|BEHAVIORAL|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
219438925|NCT05194397|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
218829750|NCT01796288|DRUG|Erlotinib|
218829751|NCT02765048|BEHAVIORAL|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
219195938|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
219438926|NCT05194397|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
219438927|NCT05194397|OTHER|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
219438928|NCT01823016|DRUG|Placebo|Placebo tablet, taken once daily
219438929|NCT01823016|DRUG|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
219580705|NCT01615237|BEHAVIORAL|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
219580706|NCT02755077|PROCEDURE|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
219580707|NCT03279497|BEHAVIORAL|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
219580708|NCT03279497|BEHAVIORAL|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
219195939|NCT04705519|DRUG|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
219195940|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
219195941|NCT00302744|OTHER|Niacin|Active Placebo
219195942|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
219580709|NCT00002353|BIOLOGICAL|P3C541b Lipopeptide|
219580710|NCT00811356|DRUG|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
219580711|NCT00004151|DRUG|acridine carboxamide|
219580712|NCT04227353|BEHAVIORAL|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
219580713|NCT02948153|OTHER|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
219763852|NCT02684201|DEVICE|Boston Scientific Stimulator Lead|A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
218829752|NCT01830985|DRUG|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
219012649|NCT03781609|BEHAVIORAL|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
219012650|NCT03781609|BEHAVIORAL|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
219012651|NCT03541018|PROCEDURE|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
219438930|NCT05516134|BEHAVIORAL|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
218829753|NCT02880228|DRUG|Dexamethasone|Given PO
218829754|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
219438931|NCT03354572|DRUG|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
219438932|NCT03354572|DRUG|Placebos|saline 0.9% prior to surgery
219438933|NCT05392049|OTHER|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
219438934|NCT05392049|OTHER|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
219438935|NCT06086236|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
219438936|NCT03622541|DRUG|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
219438937|NCT00254163|DRUG|Fludarabine|
219438938|NCT00254163|DRUG|Cyclophosphamide|
219438939|NCT00254163|DRUG|Rituximab|
219438940|NCT00254163|DRUG|Pentostatin|
219438941|NCT02557334|DIETARY_SUPPLEMENT|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
219438942|NCT02557334|DIETARY_SUPPLEMENT|High Dose Strawberry Powder|40 g freeze dried strawberry powder
219438943|NCT02557334|DIETARY_SUPPLEMENT|Placebo Powder|40 g color and taste matched placebo powder
219438944|NCT05068388|DRUG|Z-Endoxifen|Z-Endoxifen
219438945|NCT05068388|DRUG|Placebo|Placebo
219438946|NCT00519168|PROCEDURE|Urine sample|Standard of care
219438947|NCT00519168|DEVICE|Electrode sleep recorder|Standard of care
219438948|NCT00519168|PROCEDURE|phlebotomy|Standard of care
219438949|NCT01952288|DRUG|simvastatin|simvastatin 40 mg/day for 12 months
219438950|NCT01952288|DRUG|Placebo Oral Tablet|placebo comparator
219438951|NCT06005038|BEHAVIORAL|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
219438952|NCT06005038|BEHAVIORAL|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
219580714|NCT05382169|OTHER|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~* At least two clinical signs compatible with MAS before the first consultation (V1)~* Improvement of symptoms on antihistamines within 2 months of initiation of treatment~* Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~* At least two clinical signs consistent with MAS before the first consultation (V1)~* Improvement of symptoms with antihistamines within 2 months of initiation of treatment~* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
219580715|NCT02390687|DRUG|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
219580716|NCT02390687|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
219580717|NCT03990597|OTHER|Placebo Administration|Applied topically
219580718|NCT03990597|OTHER|Questionnaire Administration|Ancillary studies
218829755|NCT02880228|DRUG|Lenalidomide|Given PO
218829756|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
219012652|NCT04851886|DEVICE|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
219580719|NCT03990597|DRUG|Wound Dressing Material|Applied StrataXRT topically
219012653|NCT04851886|DEVICE|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
219012654|NCT02138903|OTHER|trans thoracic echocardiography|
219012655|NCT05541549|BIOLOGICAL|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
219012656|NCT02143908|DIETARY_SUPPLEMENT|lysine supplementation|
219012657|NCT02143908|DIETARY_SUPPLEMENT|Placebo|
219012658|NCT03626714|DRUG|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
218829757|NCT03406403|DEVICE|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
218829758|NCT03406403|DRUG|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
218829759|NCT03406403|OTHER|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
218829760|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
218829761|NCT02593058|BEHAVIORAL|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
218829762|NCT02593058|BEHAVIORAL|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
219012659|NCT00860912|PROCEDURE|Collagen Matrix|surgical/reinforcing material
219012660|NCT02211573|OTHER|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
219012661|NCT02626637|OTHER|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
219012662|NCT03070379|PROCEDURE|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
219012663|NCT05734079|OTHER|Standard of care|A written hand out containing all information required for bowel preparation
218829763|NCT01642446|PROCEDURE|Precise hepatectomy|Precise hepatectomy
218829764|NCT01642446|OTHER|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
218829765|NCT03475342|DRUG|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
219438953|NCT04965285|BEHAVIORAL|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
219438954|NCT04262908|OTHER|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
219438955|NCT01230918|RADIATION|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
219438956|NCT03193450|BEHAVIORAL|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
219012664|NCT05734079|OTHER|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
219012665|NCT05734079|OTHER|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
219012666|NCT05919303|RADIATION|CT Scan|CT scan study of abdomen
219012667|NCT00654173|DRUG|Rosuvastatin|
219012668|NCT00654173|DRUG|Simvastatin|
219012669|NCT00654173|DRUG|Atorvastatin|
219438957|NCT03193450|BEHAVIORAL|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
219438958|NCT00632996|OTHER|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
219438959|NCT02792660|DEVICE|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
219438960|NCT02478918|OTHER|Phone call|Automated phone call reminder
219438961|NCT01917552|DRUG|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
219195943|NCT03998527|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
219195944|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
218829766|NCT03475342|OTHER|Placebo|Ampoules and packaging for both arms will be identical in appearance.
218829767|NCT00746525|OTHER|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
218829768|NCT00746525|OTHER|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
218829769|NCT00746525|OTHER|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
218829770|NCT05035459|DIAGNOSTIC_TEST|lung ultrasound|drug adjustment based on lung ultrasound results
219012670|NCT02127567|OTHER|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
218829771|NCT05035459|DIAGNOSTIC_TEST|Lung ultrasound|drug adjustment independent on lung ultrasound results
218829772|NCT02102243|DRUG|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
218829773|NCT02102243|DRUG|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
218829774|NCT02102243|DRUG|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
218829775|NCT02102243|PROCEDURE|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
219012671|NCT02127567|OTHER|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
219012672|NCT05578287|DRUG|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
219012673|NCT02065232|DRUG|Tilmanocept|
219012674|NCT02065232|DRUG|Sulfur Colloid|
219012675|NCT02751515|OTHER|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
219012676|NCT02751515|OTHER|Untreated skin|One site is patched without treatment as control
219012677|NCT06294418|DEVICE|Field Cycling Imaging (FCI)|FCI scan
219012678|NCT04250571|OTHER|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
219012679|NCT04250571|OTHER|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
219195945|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
219195946|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
219195947|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
219195948|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
219438962|NCT01519349|BIOLOGICAL|rAAV1.CMV.huFollistatin344|"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
219438963|NCT02463318|DRUG|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
219438964|NCT02463318|OTHER|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
219580720|NCT02960061|DRUG|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
218829776|NCT02102243|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
218829777|NCT02102243|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
218829778|NCT02102243|PROCEDURE|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
219012680|NCT04250571|OTHER|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
219012681|NCT01161914|DRUG|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
219012682|NCT01161914|DRUG|ISU302|administered by IV infusion for a dose of 60 U/kg
219438965|NCT01122888|DRUG|Cilengitide|Given IV
219580721|NCT02960061|PROCEDURE|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
218829779|NCT02579434|DRUG|Midazolam I.V.|Midazolam I.V. 1mg/ml
219012683|NCT03754712|DIETARY_SUPPLEMENT|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
219438966|NCT01122888|OTHER|Clinical Observation|Patients undergo a 2-week rest period
219438967|NCT01122888|OTHER|Laboratory Biomarker Analysis|Correlative studies
218829780|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
219438968|NCT01152411|OTHER|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
219438969|NCT01838655|DRUG|Nitisinone|Oral dose of 2mg daily for 12 months.
219438970|NCT02916199|DEVICE|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
218829781|NCT04831437|RADIATION|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
218829782|NCT04831437|RADIATION|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
218829783|NCT04987827|OTHER|No intervention|No intervention
218829784|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
218829785|NCT04872569|BEHAVIORAL|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
219012684|NCT00258453|OTHER|metabolic assessment|
219012685|NCT00258453|OTHER|physiologic testing|
219012686|NCT00258453|PROCEDURE|biopsy|
219012687|NCT00258453|PROCEDURE|computed tomography|
219012688|NCT00258453|PROCEDURE|conventional surgery|
219012689|NCT00258453|PROCEDURE|magnetic resonance imaging|
219438971|NCT05915104|DRUG|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
219438972|NCT05915104|DRUG|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
219438973|NCT01495260|DRUG|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
219438974|NCT01495260|DRUG|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
219438975|NCT01495260|DRUG|vitamin E|vitamin E, 150-300 mg daily for 2 months
219438976|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
219580722|NCT02960061|DRUG|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
219580723|NCT02960061|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
219580724|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
219580725|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
219012690|NCT00258453|PROCEDURE|management of therapy complications|
219438977|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
219438978|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
219438979|NCT02935907|DRUG|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
219438980|NCT01784211|DRUG|LY2605541|
219580726|NCT04343326|PROCEDURE|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
218829786|NCT05211089|OTHER|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
218829787|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
218829788|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
218829789|NCT00945373|DRUG|calcium dobesilate|2.5% gel
218829790|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
218829791|NCT00432068|DRUG|Octreotide pamoate|
218829792|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
219012691|NCT00258453|PROCEDURE|psychosocial assessment and care|
219012692|NCT00258453|PROCEDURE|quality-of-life assessment|
219012693|NCT00258453|RADIATION|radiation therapy|
219012694|NCT01188694|DRUG|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
219012695|NCT01188694|BEHAVIORAL|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
219012696|NCT01188694|BEHAVIORAL|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
219012697|NCT06429501|DRUG|Bupivacaine/Epinephrine|injection
219012698|NCT06429501|DRUG|Saline|injection
219012699|NCT00772356|DEVICE|Accu-Chek Spirit Insulin Pump|
219012700|NCT00772356|DEVICE|Comparator insulin pump|
219012701|NCT01577667|DEVICE|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
219012702|NCT03197233|OTHER|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
219012703|NCT01200628|BEHAVIORAL|DEPITAC|heteroevaluation scale by a nurse during hospitalization
219438981|NCT01784211|DRUG|Insulin Glargine|
219438982|NCT03022604|DIETARY_SUPPLEMENT|C4/Generation 4|12 grams of C4/Generation 4
219438983|NCT03022604|DIETARY_SUPPLEMENT|C450X|12 grams of C450X
219438984|NCT03022604|DIETARY_SUPPLEMENT|Placebo|12 grams of flavored dextrose
219580727|NCT04304365|OTHER|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
219580728|NCT04304365|OTHER|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
219012704|NCT00730782|BIOLOGICAL|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
219012705|NCT00545857|DRUG|pioglitazone|Pioglitazone daily; dose varies with size
219012706|NCT00545857|DRUG|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
219012707|NCT06460896|OTHER|pharmacokinetic study|Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
219012708|NCT06061393|DRUG|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
219012709|NCT06061393|DRUG|Ferinject|ferinject 500 mg, once a week for 2 weeks
219438985|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
219580729|NCT04304365|OTHER|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
218829793|NCT04896801|RADIATION|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
218829794|NCT05788601|DRUG|Dapiglutide|GLP-1/GLP-2 receptor agonism
218829795|NCT05788601|DRUG|Placebo|Placebo
218829796|NCT04095052|DIETARY_SUPPLEMENT|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
218829797|NCT04095052|DIETARY_SUPPLEMENT|Placebo|Microcrystalline Cellulose capsule
218829798|NCT04635202|BEHAVIORAL|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
218829799|NCT04635202|BEHAVIORAL|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
218829800|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
218829801|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
218829802|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
218829803|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
218829804|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
218829805|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
218829806|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
218829807|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
218829808|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
218829809|NCT00876252|BIOLOGICAL|IC43|
218829810|NCT00876252|DRUG|Placebo|NaCl
218829811|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
218829812|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
218829813|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
218829814|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
218829815|NCT00451061|DRUG|Alfuzosin|
218829816|NCT00451061|DRUG|Tamsulosin|
219012710|NCT01104636|DRUG|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
219195949|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
218829817|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
218829818|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
218829819|NCT00560300|DRUG|1 alpha D2|Vitamin D sterol
218829820|NCT00560300|DRUG|1,25 dihydroxy vitamin D3|Active vitamin D sterol
218829821|NCT00560300|DRUG|Sevelamer HCl|Phosphate binder
218829822|NCT00560300|DRUG|Calcium Carbonate|Phosphate binder
218829823|NCT01166347|DEVICE|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
218829824|NCT01166347|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
218829825|NCT02469220|DIETARY_SUPPLEMENT|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
218829826|NCT02469220|DIETARY_SUPPLEMENT|Standardized FODMAP|Blinded food supplements containing FODMAPs
218829827|NCT05364710|DIETARY_SUPPLEMENT|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
218829828|NCT05325203|BIOLOGICAL|Ongericimab|Administered by subcutaneous injection
218829829|NCT05325203|DRUG|Placebo|Administered by subcutaneous injection
218829830|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
218829831|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
219195950|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
218829832|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
218829833|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
218829834|NCT05807373|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
218829835|NCT02822053|PROCEDURE|US-guided laser ablation for refractory neoplasms|
218829836|NCT05000307|DIAGNOSTIC_TEST|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
218829837|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
218829838|NCT02351011|BIOLOGICAL|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
218829839|NCT02351011|BIOLOGICAL|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
219580730|NCT00307034|BIOLOGICAL|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
219580731|NCT00307034|BIOLOGICAL|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
218829840|NCT02351011|BIOLOGICAL|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
218829841|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
218829842|NCT01718899|BIOLOGICAL|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
218829843|NCT05468645|DRUG|[14C]Hemay005|Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
218829844|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
218829845|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
218829846|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
218829847|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp)
218829848|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
218829849|NCT00900497|BIOLOGICAL|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
218829850|NCT05362292|DRUG|Tolterodine Tartrate ER|Anticholinergic
218829851|NCT05362292|DRUG|Mirabegron|Beta-3-adrenergic agonist
218829852|NCT05362292|DRUG|Placebo|matching placebo pill
218829853|NCT04010097|OTHER|chewing gum|The test involves chewing a chewing gum for 4 minutes
218829854|NCT05918978|DRUG|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
219195951|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
218829855|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
219580732|NCT00307034|BIOLOGICAL|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
219580733|NCT00322504|PROCEDURE|Accupuncture|
219580734|NCT02917330|OTHER|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
218829856|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
218829857|NCT06340230|DRUG|SHR-A1811 Injection|Drug: SHR-A1811 Injection
218829858|NCT05223998|PROCEDURE|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
218829859|NCT05171166|PROCEDURE|HAIC|Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
218829860|NCT05171166|PROCEDURE|TACE|A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.
218829861|NCT05171166|DRUG|FOLFOX|oxaliplatin,leucovorin, and 5-FU
218829862|NCT05171166|DRUG|cTACE or DEB-TACE|lipiodol or microspheres that mixed with EPI
218829863|NCT05171166|DRUG|Donafenib|200 mg of donafenib (consisting of two 100-mg tablets) twice daily.
218829864|NCT06016075|DEVICE|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
218829865|NCT06016075|DEVICE|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
218829866|NCT06016075|DEVICE|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
219012711|NCT04472936|PROCEDURE|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
219012712|NCT04472936|PROCEDURE|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
218829867|NCT04792190|DRUG|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
219012713|NCT05947136|BEHAVIORAL|Interpretation of the results from the detection visit|"\- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
219012714|NCT05947136|BEHAVIORAL|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
219012715|NCT05947136|BEHAVIORAL|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
219012716|NCT05947136|BEHAVIORAL|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
219012717|NCT01508975|OTHER|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
219012718|NCT00407563|DRUG|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
219012719|NCT00407563|DRUG|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
219012720|NCT02920268|OTHER|Dance and yoga intervention|
219012721|NCT05268159|OTHER|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
219012722|NCT02855749|PROCEDURE|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
219012723|NCT03786016|BEHAVIORAL|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
219012724|NCT05192746|OTHER|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
219438986|NCT06171711|BEHAVIORAL|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
219438987|NCT04313101|OTHER|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
218829868|NCT04792190|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
218829869|NCT04740151|PROCEDURE|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
218829870|NCT04740151|PROCEDURE|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
219012725|NCT05192746|DEVICE|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
218829871|NCT06551350|OTHER|Data Collection|Collection of medical data from MICU intervention file and the medical records of patients at the destination hospital
219012726|NCT05192746|DEVICE|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
219012727|NCT04814134|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
218829872|NCT02894398|DRUG|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
218829873|NCT02894398|DRUG|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
218829874|NCT02894398|DRUG|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
218829875|NCT02894398|DRUG|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
218829876|NCT02894398|DRUG|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
219438988|NCT06070636|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
219438989|NCT06070636|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219438990|NCT06070636|DRUG|Sintilimab|200mg intravenously every 32 weeks
219438991|NCT03713827|DEVICE|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
219438992|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
219438993|NCT04694820|OTHER|Survey Administration|Ancillary studies
219012728|NCT04814134|OTHER|Standard of care|Available standard treatment
219012729|NCT05438056|OTHER|education with mobile application|providing training to mothers of premature babies with a mobile application
219012730|NCT03055260|DEVICE|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
219012731|NCT03055260|DEVICE|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
219438994|NCT01001572|DRUG|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
218829877|NCT06351826|OTHER|ELLASI|A structured intervention for polytrauma patients
218829878|NCT06351826|OTHER|Standard|Unstructured interventions that are given in everyday practice (standard intervention)
218829879|NCT04841993|DRUG|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
219012732|NCT06184815|BEHAVIORAL|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
219438995|NCT01001572|DRUG|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
219438996|NCT01001572|DRUG|Placebo|1 capsule or tablet taken orally once daily
219580735|NCT03829696|DRUG|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
218829880|NCT04841993|DRUG|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
218829881|NCT04841993|DRUG|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
218829882|NCT01881282|DRUG|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
218829883|NCT01881282|DRUG|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
218859703|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
219012733|NCT06184815|BEHAVIORAL|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
218829884|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
218829885|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
218829886|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
218829887|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
218829888|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
218829889|NCT00659841|DRUG|Placebo|placebo
219012734|NCT04900831|DIAGNOSTIC_TEST|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
219012735|NCT04246060|DRUG|Cysteamine Bitartrate|ERT
219012736|NCT00592839|DRUG|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
219012737|NCT00592839|DRUG|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
219012738|NCT00851812|BEHAVIORAL|Exercise|Standard care monitoring
219012739|NCT00851812|BEHAVIORAL|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
219012740|NCT00319917|DRUG|tacrolimus|oral
219012741|NCT00319917|DRUG|placebo|oral
219438997|NCT05265793|DRUG|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
219438998|NCT02772224|DEVICE|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
219012742|NCT02366845|BIOLOGICAL|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
219012743|NCT02366845|DIAGNOSTIC_TEST|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
219195952|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
218829890|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
219012744|NCT02366845|DIAGNOSTIC_TEST|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
219012745|NCT03861715|DIAGNOSTIC_TEST|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
219012746|NCT01531374|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
219012747|NCT00223951|DRUG|R89674 (generic name not yet established)|
219012748|NCT05369455|PROCEDURE|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
219012749|NCT05369455|PROCEDURE|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
219012750|NCT00934154|DRUG|Thalidomide|100 mg/day continuously for 12 months
219012751|NCT00934154|DRUG|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
219195953|NCT03270059|DRUG|Ferumoxytol|Given IV
219195954|NCT03270059|DRUG|Gadolinium|Given IV
219195955|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219195956|NCT05303129|BIOLOGICAL|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
218829891|NCT05237583|BEHAVIORAL|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
218829892|NCT04990583|BEHAVIORAL|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
218829893|NCT04990583|BEHAVIORAL|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
218829894|NCT05121961|PROCEDURE|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
218829895|NCT05004415|DRUG|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
218829896|NCT02891226|DRUG|Mirikizumab|
218829897|NCT02891226|DRUG|Placebo|
218829898|NCT02977078|BEHAVIORAL|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
219012752|NCT02622516|OTHER|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
219012753|NCT02622516|OTHER|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
219195957|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
219438999|NCT02772224|DEVICE|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
219439000|NCT03652545|BIOLOGICAL|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
218829899|NCT02977078|DEVICE|Inhaler casing|Monitors inhaler use
218829900|NCT02977078|DEVICE|Mobile application|Mobile application software linked to inhaler casing
218829901|NCT01928433|DRUG|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
218829902|NCT01928433|DRUG|Finafloxacin placebo i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
218829903|NCT01928433|DRUG|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
218829904|NCT01928433|DRUG|Finafloxacin placebo tablets once daily|Administered as four tablets
218829905|NCT01928433|DRUG|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
218829906|NCT01928433|DRUG|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
218829907|NCT01928433|DRUG|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
218829908|NCT01928433|DRUG|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
219012754|NCT01714154|DRUG|danoprevir|100 mg orally every 12 hours
219012755|NCT01714154|DRUG|ritonavir|100 mg orally every 12 hours
219012756|NCT01714154|DRUG|setrobuvir|200 mg orally every 12 hours
218829909|NCT05271942|PROCEDURE|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
218829910|NCT05271942|PROCEDURE|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
218829911|NCT00145626|DRUG|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
218829912|NCT00145626|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
218829913|NCT00145626|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
218829914|NCT05535114|OTHER|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
218829915|NCT00220506|DRUG|Provigil|
218829916|NCT05592301|DIAGNOSTIC_TEST|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
218829917|NCT05592301|DIAGNOSTIC_TEST|Transcranial Doppler (TCD)|Used to diagnose PFO
218829918|NCT05592301|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
218829919|NCT04883255|DRUG|10 mg Δ9-tetrahydrocannabinol (THC)|5-day course of orally-administered THC (dronabinol), 10 mg
219195958|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
219439001|NCT02597192|OTHER|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
219439002|NCT02597192|OTHER|oral hygiene products without Bacillus|products without Bacillus
218829920|NCT04883255|DRUG|600 mg cannabidiol (CBD)|5-day course of orally-administered CBD, 600 mg
218829921|NCT04883255|DRUG|Placebo|5-day course of orally-administered placebo
218829922|NCT01058252|COMBINATION_PRODUCT|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst \> 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
218829923|NCT01058252|PROCEDURE|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
218829924|NCT01058252|PROCEDURE|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (\> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive"
218829925|NCT01058252|PROCEDURE|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level \> 2,500 pg/ml"
218829926|NCT01058252|PROCEDURE|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
218829927|NCT05254756|DEVICE|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
218829928|NCT05254756|DEVICE|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
218829929|NCT00436436|DRUG|O6-benzylguanine|
218829930|NCT00436436|DRUG|temozolomide|
218829931|NCT04803474|DIAGNOSTIC_TEST|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
218829932|NCT01326299|OTHER|Carbohydrate placebo|dissolve in water and consume with meal
218829933|NCT01326299|OTHER|Nutritional ingredient|Dissolve in water and consume with meals
218829934|NCT01326299|OTHER|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
218829935|NCT01326299|OTHER|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
218829936|NCT01326299|OTHER|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
218829937|NCT01983592|OTHER|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
218829938|NCT01983592|OTHER|Unmedicated lactose/sucrose globule|
219195959|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
219195960|NCT04864353|BEHAVIORAL|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
219195961|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
219439003|NCT00643799|DRUG|Celecoxib|200 mg oral capsule once daily for 6 months
219439004|NCT00643799|DRUG|Naproxen|500 mg oral capsule twice daily for 6 months
219439005|NCT00643799|DRUG|Placebo|Matched oral placebo for 6 months
219439006|NCT00964600|PROCEDURE|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
219439007|NCT01094808|DRUG|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
219439008|NCT01094808|DRUG|Placebo|Placebo capsules
219439009|NCT01094808|OTHER|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
219439010|NCT03127436|DRUG|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
219439011|NCT01481506|PROCEDURE|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
219439012|NCT00646750|DRUG|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
219580736|NCT03829696|DRUG|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
218859704|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
219195962|NCT04158739|DRUG|Cytarabine|Given IT
219439013|NCT02020928|DEVICE|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
219439014|NCT05104788|DRUG|Icotinib|Oral
219439015|NCT05104788|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
219580737|NCT03829696|DRUG|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
219580738|NCT03829696|DIAGNOSTIC_TEST|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
219580739|NCT01874795|DEVICE|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
219580740|NCT01874795|DEVICE|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
219580741|NCT02733315|BEHAVIORAL|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
218859705|NCT00055354|PROCEDURE|Acupuncture|
218859706|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
218859707|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
218859708|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
218859709|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
218859710|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
219195963|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
218859711|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
218859712|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
218859713|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
218859714|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
218859715|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
218859716|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
218859717|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
218859718|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
218859719|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
218859720|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
218859721|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
219195964|NCT04354129|DRUG|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
218829939|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC \< 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
218829940|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC \< 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC \> or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC \> or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
218829941|NCT04698070|OTHER|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~1. SAM: Children with MUAC\<115 or WHZ\<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~2. MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ\>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
218829942|NCT00006261|BIOLOGICAL|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
218829943|NCT00006261|DRUG|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
218829944|NCT00006261|DRUG|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
218829945|NCT00006261|DRUG|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
218829946|NCT00006261|DRUG|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
218829947|NCT00006261|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
218829948|NCT00947219|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
218829949|NCT00947219|DEVICE|Control device|Device is used 3 times a week on non-consecutive days
218829950|NCT01906268|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
218829951|NCT01906268|OTHER|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
218829952|NCT00766116|DRUG|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
218829953|NCT00766116|DRUG|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
218829954|NCT06332586|BEHAVIORAL|Diversified teaching|Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
218859722|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
218859723|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
218859724|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
218859725|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
218859726|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
218859727|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
218859728|NCT01371643|DRUG|Octreotide LAR|
218859729|NCT01371643|PROCEDURE|transsphenoidal surgery|
218859730|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
219195965|NCT04539392|OTHER|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
219195966|NCT06585696|DRUG|CU-20101 treatment for Moderate to Severe Glabellar Striae|"Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36)."
219195967|NCT05981573|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
219012757|NCT01969240|OTHER|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
219012758|NCT04489667|OTHER|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
219195968|NCT05981573|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
219195969|NCT05981573|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
219195970|NCT06567730|OTHER|Ni-ti Closed-coil Spring|Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.
219439016|NCT05104788|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
219439017|NCT05104788|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
219439018|NCT00565357|DEVICE|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
219439019|NCT00565357|OTHER|Control|Standard care in the neonatal intensive care unit
219439020|NCT03534791|OTHER|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
219439021|NCT06263790|DEVICE|Intubating laryngeal mask|Intubation through a laryngeal mask
219439022|NCT06263790|DEVICE|Direct laryngoscopy|Intubation by using a direct laryngoscope
219439023|NCT05778357|OTHER|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
219580742|NCT02667171|BEHAVIORAL|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
219012759|NCT00745147|DRUG|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
219012760|NCT00745147|DRUG|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
219012761|NCT05109507|BEHAVIORAL|Visitor Mindset|Single-session, self-guided intervention
219439024|NCT00369278|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
219439025|NCT00943410|RADIATION|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
219439026|NCT00943410|DRUG|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
219439027|NCT02019758|DRUG|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
219439028|NCT02019758|DRUG|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
219439029|NCT02019758|DRUG|Placebo slurry|Slurry of sucralose - 4 mL twice daily
219439030|NCT02019758|DRUG|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
219012762|NCT05109507|BEHAVIORAL|Relaxing with Nature|Single-session, self-guided intervention
219012763|NCT02452346|DRUG|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
219012764|NCT02986789|DEVICE|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
218829955|NCT03309982|DIETARY_SUPPLEMENT|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
218829956|NCT03309982|OTHER|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
218829957|NCT03261921|DRUG|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
218829958|NCT03261921|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
218829959|NCT03261921|DRUG|Bupivacaine|local anesthetic agent
219012765|NCT02461901|OTHER|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
219012766|NCT02461901|OTHER|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
219012767|NCT02461901|OTHER|Fecal sampling|Collection of fecal samples for C. difficile spores
219012768|NCT05003154|OTHER|Digitalized management|"In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision."
219012769|NCT04128384|DIAGNOSTIC_TEST|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
219012770|NCT03439020|PROCEDURE|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
219439031|NCT05994495|DIAGNOSTIC_TEST|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
219439032|NCT05994495|OTHER|Clinical Syndromic Approach|Physical examination
219439033|NCT04171167|DRUG|Fluticasone Propionate|three visits: 0, after washout, after FP usage
219439034|NCT02703649|DRUG|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
219439035|NCT05865756|OTHER|Acoustic cough features analysis|Acoustic cough features analysis
219439036|NCT05983679|DIAGNOSTIC_TEST|Blood sample|Blood sample
219439037|NCT03948594|DIETARY_SUPPLEMENT|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
219439038|NCT03948594|OTHER|plain water|250ml plain water
219439039|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners are blinded to each other and to the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
219439040|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners is now being informed of the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
219012771|NCT03439020|PROCEDURE|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
219012772|NCT03518073|DRUG|Zagotenemab|Administered IV
218829960|NCT00466180|BEHAVIORAL|Nevirapine from twice-a-day to once-a-day|
218829961|NCT06460870|OTHER|Mojzisova method|The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.
219012773|NCT03518073|DRUG|Placebo|Administered IV
219195971|NCT06567730|OTHER|Elastomeric Power chain|Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
219195972|NCT05405556|DIAGNOSTIC_TEST|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"
219195973|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
219439041|NCT01548209|DRUG|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
219439042|NCT01548209|DRUG|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
219439043|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
218829962|NCT06460870|OTHER|Stretching exercises|Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
218829963|NCT05809427|DEVICE|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
218829964|NCT04063917|DEVICE|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
219439044|NCT03455634|DEVICE|Twin Block|functional appliances for the stimulation of the mandibular growth
218829965|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
218829966|NCT03654274|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
218829967|NCT03654274|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
218829968|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
218829969|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
219195974|NCT03914469|BEHAVIORAL|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
219195975|NCT04778410|DRUG|Magrolimab|Administered intravenously
219439045|NCT03455634|DEVICE|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
219439046|NCT04464798|DRUG|CC-220|Oral
219439047|NCT04464798|DRUG|Rituximab|SC and IV infusion
219439048|NCT04464798|DRUG|Obinutuzumab|IV Infusion
219439049|NCT05746533|PROCEDURE|Hip Arthroscopy|Hip Preservation surgeries
219439050|NCT05364437|DIETARY_SUPPLEMENT|Dietary Fibres Supplement|The dietary fibres supplement, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
219439051|NCT05364437|DIETARY_SUPPLEMENT|Cellulose Control|The control, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
219439052|NCT05947318|DEVICE|transcranial alternating current stimulation 70 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 70 Hz"
219439053|NCT05947318|BEHAVIORAL|Training|Training of the upper limb with specific kinematic and kinetic tasks plus functional training
219439054|NCT05947318|DEVICE|transcranial alternating current stimulation 7 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 7 Hz"
219439055|NCT05947318|DEVICE|transcranial alternating current stimulation Sham|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The stimulation will be turn on for 30 seconds (at 70 Hz)"
219439056|NCT04236479|BIOLOGICAL|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
219439057|NCT02133001|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
219195976|NCT04778410|DRUG|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
219439058|NCT02133001|DRUG|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
219439059|NCT05038553|OTHER|No intervention|No intervention
219439060|NCT05509933|DRUG|Budesonide|budesonide starting day 5 after transplant
219439061|NCT05168566|DRUG|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
218829970|NCT01152801|DRUG|Everolimus (RAD001)|
218829971|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
218829972|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
218829973|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
219012774|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
219012775|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
219012776|NCT01378351|OTHER|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
219012777|NCT05881603|OTHER|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
219012778|NCT01853046|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
219012779|NCT05992610|OTHER|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
219439062|NCT01349985|OTHER|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
219439063|NCT01349985|OTHER|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
219439064|NCT02061904|RADIATION|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
218829974|NCT01771874|DRUG|MDMA|125 mg per os, single dose
219439065|NCT02061904|OTHER|Short Form Health Survey 12|questionnaire for general health monitoring
218829975|NCT01771874|DRUG|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
218829976|NCT01771874|DRUG|Placebo|per os
218829977|NCT00539123|BEHAVIORAL|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
218829978|NCT00539123|BEHAVIORAL|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
219012780|NCT00002418|DRUG|Emivirine|
219439066|NCT02061904|OTHER|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
219439067|NCT02061904|OTHER|VAS-pain|questionnaire for pain monitoring
219439068|NCT02061904|OTHER|Harris Hip Score|questionnaire for hip function monitoring
219439069|NCT04307953|DRUG|AZD0530 Difumarate|AZD0530 for the duration of the trial
219439070|NCT04307953|DRUG|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
219439071|NCT01301755|PROCEDURE|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
219439072|NCT05932394|BEHAVIORAL|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
219439073|NCT05932394|BEHAVIORAL|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
218829979|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
218829980|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
218829981|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
219439074|NCT01456728|DIETARY_SUPPLEMENT|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
219439075|NCT01456728|DIETARY_SUPPLEMENT|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
219439076|NCT01156363|PROCEDURE|Dialysis|regular haemodialysis or peritoneal dialysis
219580743|NCT02667171|BEHAVIORAL|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
218829982|NCT05005273|OTHER|Placebo|Specified dose on specified days
218829983|NCT06199765|OTHER|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
219439077|NCT01156363|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
219439078|NCT03484689|BEHAVIORAL|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
218829984|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
218829985|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
218829986|NCT06598072|DEVICE|Dental floss|Dental Floss
219012781|NCT00002418|DRUG|Hydroxyurea|
219012782|NCT00002418|DRUG|Nevirapine|
219439079|NCT03363568|BEHAVIORAL|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
219439080|NCT03363568|BEHAVIORAL|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
219580744|NCT00653965|DRUG|Rosuvastatin|
219580745|NCT00653965|DRUG|Atorvastatin|
219580746|NCT01867944|BEHAVIORAL|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
219580747|NCT01867944|BEHAVIORAL|Educational Control|Education on conventional treatment options for chronic constipation.
219580748|NCT00580216|DRUG|Idrabiotaparinux sodium|"Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
219580749|NCT00580216|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
219012783|NCT00002418|DRUG|Stavudine|
219012784|NCT00002418|DRUG|Didanosine|
219012785|NCT01397123|OTHER|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
219012786|NCT01485640|DRUG|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
219012787|NCT01802723|DRUG|Drug: salmeterol xinafoate|
219012788|NCT01802723|DRUG|Drug: Placebo|
219195977|NCT04778410|DRUG|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
219580750|NCT00580216|DRUG|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
218829987|NCT00002348|DRUG|Mitoguazone|
218829988|NCT05951647|DRUG|Chamomile extract mouthwash|5% chamomile extract mouthwash in a dose of 15 ml twice daily.
218829989|NCT05951647|DRUG|Pomegranate peel extract mouth wash|5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
218829990|NCT05951647|DRUG|Combination of 5% chamomile extract and pomegranate peel extract mouthwash|Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
218829991|NCT05951647|PROCEDURE|Scaling|Patients will be managed by scaling
218829992|NCT05951647|DRUG|Scaling and Chlorohexidine mouthwash|scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
218829993|NCT05125146|BEHAVIORAL|e-CBTi|See arm/group description
218829994|NCT05125146|DRUG|Trazodone|See arm/group edescription
219195978|NCT04778410|DRUG|Mitoxantrone|Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
219195979|NCT04778410|DRUG|Etoposide|Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
219195980|NCT04778410|DRUG|Cytarabine|Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
219195981|NCT04778410|DRUG|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
219439081|NCT04769336|DEVICE|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
219439082|NCT04769336|DEVICE|Point of Care CBC|lab samples will be analyzed at point of care
219580751|NCT00580216|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
219439083|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
219580752|NCT00580216|DRUG|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
219580753|NCT00580216|DRUG|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
219580754|NCT01983917|BEHAVIORAL|Diabetes Mobile Application|
219580755|NCT03792724|DRUG|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
219580756|NCT05389683|BEHAVIORAL|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
219580757|NCT00470457|BIOLOGICAL|Allergen specific immunotherapy|
218829995|NCT03289754|DEVICE|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
218829996|NCT06613880|DRUG|standard IST combined with Romiplostim N01|Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
218829997|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
218829998|NCT04814953|OTHER|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
218829999|NCT03533660|BEHAVIORAL|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
218830000|NCT03533660|BEHAVIORAL|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
218830001|NCT02909088|DRUG|Ecopipam 50mg|
219580758|NCT01076686|DRUG|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
219580759|NCT01527617|OTHER|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
219580760|NCT01527617|OTHER|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
218830002|NCT02909088|DRUG|Ecopipam 100mg|
218830003|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
218830004|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
218830005|NCT04544735|BEHAVIORAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
218830006|NCT06183489|DRUG|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
218830007|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
218830008|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
219195982|NCT04060108|DRUG|MDMA|80mg, 120mg, Placebo
219439084|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
219439085|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
219439086|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
219439087|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
219439088|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
219580761|NCT00186758|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
219580762|NCT04442490|DRUG|SAGE-217|SAGE-217 oral capsules.
219580763|NCT04442490|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
219580764|NCT02227147|DRUG|rhNGF 20µg/ml|
219580765|NCT02227147|OTHER|Placebo|Formulation containing antioxidant
219580766|NCT03514641|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
219580767|NCT03514641|DRUG|Placebo|Placebo (inactive) tablet to match the active drug
219580768|NCT01216696|DRUG|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
219439089|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
218830009|NCT06630533|OTHER|Baduanjin Exercise Group|Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
218830010|NCT05570708|DRUG|MDMA, LSD, psilocybin|"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
218830011|NCT03586375|OTHER|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
218830012|NCT04666974|BEHAVIORAL|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
218830013|NCT04666974|BEHAVIORAL|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
218830014|NCT06692894|OTHER|Observational|Blood will be collected from one cohort to identify potential blood biomarkers.
218830015|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
218830016|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
218830017|NCT06719466|OTHER|low linoleic acid (LA)|diet guidance with low linoleic acid (LA) diet
218830018|NCT06717100|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
218830019|NCT06716853|GENETIC|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
218830020|NCT06716853|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks commencing at D+30
218830021|NCT06716853|DRUG|Cabozantinib|40mg QD once PD occurs as assessed at D+30 or at subsequent visits
219439090|NCT05630898|DIAGNOSTIC_TEST|CMV PCR|Saliva CMV PCR
219439091|NCT03634878|OTHER|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
218830022|NCT06715930|PROCEDURE|Interventional treatment|The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.
218830023|NCT06716944|DEVICE|Acupuncture|self-acupuncture
218830024|NCT06716762|PROCEDURE|Open Surgery|Open cyst excision and Roux-en-Y hepaticojejunostomy performed through a 10 cm incision
218830025|NCT06716762|PROCEDURE|Laparoscopic Surgery|Laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy performed through small incisions with a laparoscope
218830026|NCT06717620|BEHAVIORAL|Body composition before and after exams|Measurement of body composition, eating habits, physical exercise in the same group of students before and after the exams
218830027|NCT06718829|OTHER|Core Stability Exercises|Patients will perform core stability exercises three times weekly for eight weeks. The exercises include abdominal hollowing, bridge, right-angle leg lifts with thigh press, seated twist, knee-to-chest with elbow flexion, prone abdominal hollowing, prone arm and leg lift, quadruped abdominal hollowing, quadruped arm or arm-leg lifts, and various plank positions: forearm plank, side plank, forearm plank with hip raise, and forearm plank with straight legs.
219439092|NCT00559416|DRUG|Cell Transfer|
219439093|NCT04018586|DEVICE|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
219439094|NCT04018586|DEVICE|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
219439095|NCT04018586|DEVICE|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
219439096|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
219439097|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
219476478|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
219012789|NCT05359666|DEVICE|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
219012790|NCT05359666|DEVICE|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline \& Irrisept and Irrisept); Chloraprep; Gentamicin \& saline; unknown; and none."
219012791|NCT03823352|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
219012792|NCT03586388|OTHER|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
219439098|NCT05735613|PROCEDURE|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
218830028|NCT06718829|OTHER|Sensorimotor Training Exercises|Patients will perform sensorimotor training exercises three times weekly for eight weeks, progressing through three phases: static (weeks 1-2), dynamic (weeks 3-4), and functional (weeks 5-8). Exercises, repeated 3-5 times per session with rest intervals, advance from simple to complex as patients master each level. Static exercises include standing on firm/soft surfaces and single-leg balances. Dynamic exercises add forward lunges and T-band kicks. Functional training incorporates walking on various surfaces, toe and heel skipping, squats, balance drills on wobble boards, and multidirectional rolling movements with visual and single-leg variations. This progression enhances coordination, balance, and functional stability.
218830029|NCT06718829|OTHER|Traditional physical therapy program|All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.
218830030|NCT06717529|OTHER|Sodium hyaluronate (hyaluronic acid)|The patient will receive one 3mL Sodium Hyaluronate injection containing 75 mg of active substance in one knee joint.
218830031|NCT06717529|DRUG|Methylprednisolone Acetate Injection|The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
218830032|NCT06719323|BEHAVIORAL|Family Walking Instruction with Support by Heart (Family WISH) program|Researchers will compare the 12-week Family WISH program, based on self-efficacy theory, to a comparison group receiving a family walking health education sheet to evaluate the long-term effectiveness of the Family WISH program.
218830033|NCT06719323|BEHAVIORAL|Comparison group|a family walking health education sheet received
219476479|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
219476480|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
219476481|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
218830034|NCT06719388|BEHAVIORAL|combination of exercise therapy and a jaw-mobilizing device|Participants in the experimental group will receive a combination of exercise therapy and a jaw-mobilizing device. The intervention includes structured exercise therapy sessions and the use of the jaw-mobilizing device for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
219012793|NCT00911495|DRUG|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
218830035|NCT06719388|BEHAVIORAL|exercise therapy only|Participants in the control group will receive exercise therapy only. This intervention involves the same structured exercise therapy sessions as the experimental group for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
218830036|NCT06719310|DRUG|ACC017+FTC/TAF|ACC017+FTC/TAF
218830037|NCT06719310|DRUG|Placebo|Placebo
219195983|NCT05695820|OTHER|Blood Flow Restriction training|It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
219195984|NCT06082050|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1， Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.
219476482|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
219476483|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
218830038|NCT06719193|COMBINATION_PRODUCT|Enhanced community-wide TB intervention|"Interventions in the intervention arms consist of the following key components:~1. an optimized national recommended set of interventions; such as the implementation of all types of contact investigation, targeted TB screening and diagnosis at key affected population, and optimized HIV screening and TPT for PLHIV;~2. intensive, active, and community-based HH screening and diagnosis of TB using combined TB screening (clinical and X-ray) and X-pert MTB/RIF, as indicated;~3. community-based enhanced TPT; and~4. community-based awareness creation and health education using the community social associations."
218830039|NCT06719193|COMBINATION_PRODUCT|Routine TB program activities|In the control arm, the standard of care will continue per the national guideline.
219012794|NCT04528654|OTHER|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
219012795|NCT03459742|BEHAVIORAL|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
219012796|NCT04634747|DRUG|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
219012797|NCT00149487|BEHAVIORAL|Tailored Problem Solving Intervention|
219012798|NCT00149487|BEHAVIORAL|Family Education Intervention|
219012799|NCT05584176|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
219012800|NCT05584176|DEVICE|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
219012801|NCT01772303|DRUG|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
219012802|NCT04388267|DRUG|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
219012803|NCT05283798|DEVICE|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
219012804|NCT02057198|DRUG|Fidaxomicin|
219012805|NCT02057198|DRUG|Metronidazole|
219195985|NCT05209984|DRUG|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
219012806|NCT02057198|DRUG|Vancomycin|
219012807|NCT01985581|DRUG|Guanfacine extended release|
219012808|NCT01985581|DRUG|Placebo|
219012809|NCT01985581|DRUG|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
219012810|NCT00022451|DRUG|tipifarnib|
219012811|NCT01264146|PROCEDURE|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
219476484|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
218830040|NCT06718842|BEHAVIORAL|walking free online supervised program|this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
219012812|NCT01264146|PROCEDURE|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
219012813|NCT03878745|DEVICE|Terumo Nanopass® 34G pen needle|Insulin pen needle
219012814|NCT03878745|DEVICE|BD Nano™ PRO 32G pen needle|Insulin pen needle
219012815|NCT04309643|DRUG|CTP-543|Investigational Drug
219012816|NCT04309643|DRUG|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
219012817|NCT00001929|DRUG|Eliprodil|
219012818|NCT03540147|DEVICE|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
219012819|NCT03540147|DEVICE|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
219012820|NCT05275764|PROCEDURE|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
219012821|NCT05555212|DRUG|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
219012822|NCT04474067|OTHER|No intervention|This is an observational study, with no intervention.
219012823|NCT04146025|BEHAVIORAL|Nature Coach Intervention|"1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
219012824|NCT01813539|DRUG|ARGX-110|ARGX-110 will be administered as an IV infusion.
219012825|NCT03191760|BEHAVIORAL|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
219012826|NCT03054545|DRUG|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
219012827|NCT05372848|DIAGNOSTIC_TEST|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
219012828|NCT05372848|DIAGNOSTIC_TEST|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
219012829|NCT06244225|DRUG|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
219012830|NCT03633487|DRUG|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
219012831|NCT04833621|DEVICE|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
219012832|NCT04743427|OTHER|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
219012833|NCT04743427|DEVICE|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
219012834|NCT06246318|OTHER|virtual reality|The virtual reality protocol here is based on perceptual-motor activities, supported by Nintendo Wii resources. The user will be able to control a game character in a virtual environment using a remote control with a motion sensor. Wii Fit Plus requires the use of the Wii Balance Board that the player stands on during gameplay. The Wii Balance Board is not a wobbly balance board, but is able to detect and track the user's center of balance, a feature used extensively in the game. Wii Fit Plus includes more than 40 activities including yoga, strength training, aerobics and balance games. During the virtual reality application, different games will be preferred in each session depending on the duration of the games. Virtual reality application will be carried out in a corner prepared for virtual reality application in the room where the conventional occupational therapy session is held. Families have the right to observe and attend all sessions whenever they wish.
219012835|NCT06246318|OTHER|conventional occupational therapy|"Sensory integration and gross motor training approaches will be used in the conventional occupational therapy program. A manualized protocol based on Ayres sensory integration principles will be followed (Schaaf et al., 2012). The intervention will be carried out by a licensed occupational therapist trained in sensory integration.~This approach suggests that if a child engages in individually adapted sensorimotor activities, the nervous system is better able to modulate, organize, and integrate sensory information and is also more likely to use sensory information in adaptive ways (Ayres, 1972). Components of the intervention include a sensory-rich, playful, child-centered approach, providing a decision challenge, and facilitating increasingly complex adaptive behaviors by engaging the child in individually tailored, developmentally appropriate play interactions"
219012836|NCT02054416|DEVICE|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
219012837|NCT06154954|DIAGNOSTIC_TEST|Semen analysis|Semen analysis for extracellular matrix proteins analysis
219012838|NCT03686163|DRUG|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
219012839|NCT03686163|DRUG|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
219012840|NCT00383279|OTHER|counseling intervention|
219012841|NCT00383279|OTHER|study of socioeconomic and demographic variables|
219476485|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
219012842|NCT03474120|PROCEDURE|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
219439099|NCT05735613|PROCEDURE|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
219476486|NCT06854952|DRUG|TERN-601|Investigational drug
219012843|NCT05322642|BEHAVIORAL|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
219580769|NCT01449279|DRUG|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
218830041|NCT06719206|BEHAVIORAL|Digital self-management program|The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
218830042|NCT06714903|OTHER|treatment option-sintilimab plus fruquintinib|sintilimab plus fruquintinib
219012844|NCT05322642|BEHAVIORAL|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
219012845|NCT03683758|OTHER|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
219476487|NCT06854952|OTHER|Matching Placebo|Matching placebo
219476488|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
219476489|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
218830043|NCT06714903|OTHER|treatment option-fruquintinib alone|fruquintinib alone
219476490|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
219476491|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
219476492|NCT00100282|DRUG|PPI-1019 (APAN)|
218830044|NCT06719297|OTHER|Personalized cognitive-sensorimotor VR/MR training|Thinking task integrated walking and balance training program
218830045|NCT06719297|OTHER|Standard of Care|Standard walking and balance training
218830046|NCT06714994|DEVICE|free spectacles|Children will receive free spectacles
219012846|NCT03683758|OTHER|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
219012847|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 10 mg, once daily
219012848|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 30 mg, once daily
219012849|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 100 mg, once daily
218830047|NCT06715176|OTHER|Clinical periodontal measurements at baseline (T0)|Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.
218830048|NCT06715176|OTHER|Saliva collection at baseline (T0)|Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
219012850|NCT01142700|DRUG|Placebo|Capsule, Oral, 0 mg, once daily
219012851|NCT01142700|DRUG|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
219012852|NCT01142700|DRUG|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
219580770|NCT01449279|RADIATION|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
218830049|NCT06715176|OTHER|Scaling and root planing|Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.
218830050|NCT06715176|OTHER|Clinical periodontal measurements at T1, T3, and T6.|Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
218830051|NCT06715176|OTHER|Saliva collection at T1, T3, and T6.|Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
219012853|NCT02594839|DRUG|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
219012854|NCT02594839|DRUG|Placebo|intravenous infusion of 400 mL saline
219012855|NCT00723892|BIOLOGICAL|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
219012856|NCT00723892|DRUG|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
219012857|NCT00723892|BEHAVIORAL|Psychotherapy support program|Each site has implemented a psychotherapy support program.
219012858|NCT04609787|DEVICE|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
219012859|NCT03809442|DRUG|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
219012860|NCT03809442|DRUG|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
219012861|NCT03809442|DRUG|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
219012862|NCT03809442|DRUG|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
219012863|NCT03809442|DRUG|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
219012864|NCT03809442|DRUG|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
219012865|NCT01622699|DEVICE|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
219012866|NCT01622699|OTHER|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
219012867|NCT00001960|DEVICE|Pacemaker therapy|
219012868|NCT02901535|OTHER|Spirometry|Spirometry in baseline
219012869|NCT02901535|OTHER|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
219012870|NCT02901535|OTHER|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
219012871|NCT02901535|OTHER|Spirometry - 20 weeks|Spirometry (20 weeks)
218830052|NCT06714695|DRUG|Chitosan|chitosan mouthwash
219476493|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
219012872|NCT01172847|DRUG|oseltamivir [Tamiflu]|multiple oral doses
219012873|NCT01172847|DRUG|rimantadine|multiple oral doses
219012874|NCT00785109|DIETARY_SUPPLEMENT|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
219012875|NCT04975360|DIETARY_SUPPLEMENT|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
219012876|NCT04975360|OTHER|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
219012877|NCT05248841|DRUG|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
219012878|NCT05248841|DRUG|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
219012879|NCT01163279|BEHAVIORAL|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
218830053|NCT06715202|PROCEDURE|Patient Education Booklet|Before the surgery, a personal information form and the SF-36 Quality of Life Scale will be filled out. The educational content regarding the problems that these patients may encounter with the DJ stent after the surgery until they are discharged will be explained in sections and the patients' questions will be answered. When the patient comes to the hospital for DJ stent removal 4 weeks after discharge, the Ureteral Stent Symptom 1st Questionnaire and the SF-36 Quality of Life Scale will be filled out while the DJ stent is in place. The Ureteral Stent Symptom 2nd Questionnaire and the SF-36 Quality of Life Scale will be applied 4 weeks after the stent is removed. The education booklet will be prepared by the researchers in accordance with the recommendations of the European Association of Urology and the relevant literature.
219012880|NCT01163279|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
219476494|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
219012881|NCT00119392|BIOLOGICAL|rituximab|Given IV
219012882|NCT00119392|DRUG|cyclosporine|Given orally
218830054|NCT06716476|DRUG|Vitamin D|Supplemental with Vitamin D 4000 IU
218830055|NCT06717204|DRUG|Vericiguat Oral Tablet [Verquvo]|Vericiguat in addition to conventional treatment
219012883|NCT00119392|DRUG|fludarabine phosphate|Given IV
219012884|NCT00119392|DRUG|mycophenolate mofetil|Given orally
219012885|NCT00119392|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219012886|NCT00119392|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
219012887|NCT00119392|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
219012888|NCT00119392|RADIATION|total-body irradiation|Undergo TBI
219012889|NCT02526888|DRUG|ACT-541468|Oral capsule (25 mg) as single dose
219012890|NCT02526888|DRUG|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
219012891|NCT01237873|DRUG|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
219012892|NCT03030573|PROCEDURE|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
219012893|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
219012894|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
219012895|NCT02816840|RADIATION|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
219012896|NCT02816840|RADIATION|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
219012897|NCT02034955|RADIATION|Post-operative Adaptive Radiation Therapy|
219012898|NCT01912417|OTHER|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
219012899|NCT04145999|PROCEDURE|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
219476495|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
219476496|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
218830056|NCT06717204|DRUG|Prescription Drugs|Conventional treatment only
218830057|NCT06716554|DIETARY_SUPPLEMENT|Shatavari extract|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
219476497|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
219476498|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
218830058|NCT06716554|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
218830059|NCT06716554|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
218830060|NCT06715189|DIAGNOSTIC_TEST|serum Adiponectine and Resistin|corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
218830061|NCT06715189|DIAGNOSTIC_TEST|fibroscan|hepatic fibrosis detection in type 2 diabetes mellutis
219439100|NCT05735613|PROCEDURE|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
219439101|NCT03555968|DRUG|THC 0|THC dose = 0mg
219439102|NCT03555968|DRUG|THC 5|THC dose = 5mg
218830062|NCT06717724|DRUG|Periarticular Procaine Injection (PAPI)|Participants will receive periarticular 5 ml procaine injections targeting painful joints for 10 consecutive days alternating between knee- and/or hip joints
219439103|NCT03555968|DRUG|THC 10|THC dose = 10mg
219439104|NCT03555968|OTHER|BAC 0|Blood alcohol concentration = .000%
219439105|NCT03555968|OTHER|BAC .025|Blood alcohol concentration = .025%
219439106|NCT03555968|OTHER|BAC .049|Blood alcohol concentration = .049%
219439107|NCT03827980|OTHER|no intervention, only clinical examination|standardised interview and clinical examination
219439108|NCT06812637|DRUG|WJ-MSC- Exosomes|warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC
219439109|NCT06812637|COMBINATION_PRODUCT|SOC (Standard of care)|Wound depridement for necrotic parts , local antibiotic , dressing , unloading
219580771|NCT05579275|BIOLOGICAL|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
219580772|NCT03934320|OTHER|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
219580773|NCT05991830|PROCEDURE|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
219580774|NCT02717858|DRUG|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
219439110|NCT06812637|OTHER|Vehicle (placebo)|Vehicle for the MSC-EXO
219439111|NCT00954824|BIOLOGICAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
219439112|NCT04334772|DEVICE|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
219439113|NCT04334772|DEVICE|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
219580775|NCT02717858|DRUG|placebo|Injected s.c./subcutaneously (under the skin) once daily.
219580776|NCT00283790|DRUG|zolpidem tartrate|
219580777|NCT01055132|DEVICE|Etafilcon A toric contact lens|contact lens to correct astigmatism
219580778|NCT01055132|DEVICE|Nelfilcon A toric contact lens|contact lens to correct astigmatism
219580779|NCT01466452|DRUG|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
218830063|NCT06717724|OTHER|Kinesiotherapy|Kinesiotherapy
218830064|NCT06717737|BEHAVIORAL|Control group： Maintaining old exercise habits|The control group will maintain their original daily habits without any intervention behaviors for them
218830065|NCT06717737|BEHAVIORAL|Intervention group：Conducted a 6-month team training intervention|"Spanning six months, the program incorporated aerobic training, resistance training, and functional exercises essential for rescue operations. Each training session was led by certified professionals who emphasized adherence to safety protocols and provided real-time feedback.~Central to the training process was the significance of teamwork and mutual support, with sessions conducted in small groups focused on shared objectives. This framework fostered a collaborative environment that promoted peer support and motivated participants to actively engage in their fitness regimen. The group setting enabled firefighters to encourage one another and share individual progress, thereby enhancing their sense of responsibility and belonging."
218830066|NCT06719154|DEVICE|Profhilo Structura|2 injections (30 days apart) of investigated medical device into superficial fat compartments of zygomatic arch and preauricular area
218830067|NCT06719154|OTHER|Sham (No Treatment)|Sham (No Treatment)
218830068|NCT06717633|DEVICE|extracorporeal shock wave therapy|The ESWT will be administered using an ESWT device (Modus ESWT Compact Model-Portable) once weekly over three consecutive weeks, resulting in a total of three sessions. A radial shockwave mode was chosen for the therapy. During each session, participants will receive 3000 pulses at an 12-Hz frequency and pneumatic pressure of 2.5 bars
218830069|NCT06717633|DEVICE|low-level laser therapy|The MLS (Multiwave Locked System) laser is a specific type of low-level laser therapy (LLLT) that combines two different wavelengths of light-typically 808 nm (near-infrared) and 905 nm (mid-infrared)-to produce therapeutic effects. These wavelengths are delivered simultaneously in a synchronized manner, which is intended to enhance the overall effectiveness of the treatment. LLLT will be conducted with the laser device (MLS Laser M6 Robotic Multiwave Lock System, Asalaser, Italy) with the use of protective goggles, and the treatment parameters were set as follows: 100% power, 3 Joules per treatment spot with 904 nm wavelength, and a treatment area of 20 cm². The LLLT will be applied to five points on the anterior part of the joint space, with each point treated for 3 minutes, totaling 15 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
218830070|NCT06717633|DEVICE|pulsed electromagnetic field therapy|For PEMF, the applicator of the device (Easy QS Magnetotherapy Portable Magnetotherapy Medical Device, Asalaser, Italy) will be positioned to target the medial and lateral aspects of the knee. The treatment parameters were defined as follows: rectangular field shape, 30 Hz frequency, 10 mT intensity, and a duration of 20 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
219012900|NCT04145999|OTHER|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
219012901|NCT04145999|RADIATION|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
219012902|NCT04145999|OTHER|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
219012903|NCT02820896|DRUG|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
219012904|NCT02820896|DRUG|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
219012905|NCT03864471|OTHER|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
219012906|NCT03864471|OTHER|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
219012907|NCT01367574|DRUG|SC MNTX|Dose 1
219012908|NCT01367574|DRUG|SC MNTX|Dose 2
219012909|NCT01367574|DRUG|SC MNTX|Dose 3
219012910|NCT03413813|DEVICE|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
219012911|NCT02232425|DRUG|IX-01|
219012912|NCT02232425|DRUG|Placebo|
219012913|NCT05766774|OTHER|Low-added sugar, high-fat diet|Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
219012914|NCT05766774|OTHER|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be \>60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
219012915|NCT01042730|DRUG|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
219012916|NCT04946357|RADIATION|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
219012917|NCT04946357|RADIATION|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
219012918|NCT01108133|DRUG|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
219439114|NCT04334772|OTHER|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
219439115|NCT02017457|BIOLOGICAL|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6"
219476499|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
219476500|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
219476501|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
219476502|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
219012919|NCT01108133|DRUG|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
219012920|NCT01108133|DRUG|Placebo|Placebo
219012921|NCT00665353|DRUG|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
219012922|NCT00665353|DRUG|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
219012923|NCT00665353|DRUG|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
219012924|NCT00000999|DRUG|Zidovudine|
219012925|NCT00257647|OTHER|SV40 vectors carrying siRNA|in vitro only use of gene therapy
219012926|NCT01953341|DRUG|AMG 333|Oral administration available in varying dose strength.
219012927|NCT01953341|DRUG|Placebo|Placebo containing no active drug
219012928|NCT03678532|DRUG|Midazolam|
219012929|NCT05636930|OTHER|Test the accuracy of the wearable device|No intervention was done for the subjects
219012930|NCT05245708|DRUG|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
219012931|NCT05245708|DRUG|intranasal placebo|Each subject will be assigned to intranasal placebo.
219012932|NCT03200496|DRUG|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
219012933|NCT03200496|DRUG|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
219012934|NCT03200496|DRUG|TALION®|Reference drug : Talion®
219012935|NCT04983056|PROCEDURE|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
219012936|NCT00368056|DRUG|Eszopiclone|eszopiclone 3 mg
219012937|NCT00368056|DRUG|Placebo|Placebo tablet
219012938|NCT01978665|DRUG|prednisone|similar size tablets
219012939|NCT01981447|DRUG|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
219012940|NCT01988792|DIETARY_SUPPLEMENT|Human milk fortifiers|
219012941|NCT01601626|DRUG|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
219012942|NCT01601626|DRUG|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
219012943|NCT01601626|DRUG|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
219012944|NCT01601626|DRUG|Isoniazid|300 mg orally once daily from entry through Week 24.
219012945|NCT01601626|DRUG|Pyridoxine|25 mg orally once daily from entry to Week 24.
219012946|NCT01601626|DRUG|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
219012947|NCT01601626|DRUG|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
219012948|NCT01601626|DRUG|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
219012949|NCT01601626|DRUG|Rifampin|Weight-based dose; for weight \< 45 kg: 450 mg orally once daily; for weight \> 45 kg: 600 mg orally once daily, from entry to week 24.
219012950|NCT06053073|DEVICE|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
219012951|NCT06053073|DEVICE|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
219012952|NCT04897360|BEHAVIORAL|Increased breathing|hyperventilation to lower ETCO2
219012953|NCT04897360|OTHER|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
219012954|NCT04290884|DRUG|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
219012955|NCT01058889|DEVICE|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
219012956|NCT00189657|PROCEDURE|5FU/LV Mayo Clinic or LV5FU2|
219199436|NCT06870162|BEHAVIORAL|Pain Disengagement Training|The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.
219476503|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
219012957|NCT00189657|PROCEDURE|LV5FU2 + irinotecan|
219012958|NCT00498602|BIOLOGICAL|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
219012959|NCT00498602|BIOLOGICAL|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
219012960|NCT00498602|OTHER|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
219012961|NCT00498602|BIOLOGICAL|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
219012962|NCT04432662|DRUG|Darbepoetin Alfa|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
219012963|NCT02456142|DRUG|caudal bupivacaine|
219012964|NCT02456142|DRUG|intravenous morphine|
219012965|NCT01382017|DRUG|Lacosamide|Lacosamide 200 or 400 mg
219012966|NCT01382017|DRUG|Placebo|Placebo
219012967|NCT01382017|DRUG|Carbamazepine|Carbamazepine 600 mg
219012968|NCT04411589|DEVICE|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
219012969|NCT04411589|DEVICE|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
219012970|NCT05874661|OTHER|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
219012971|NCT05874661|OTHER|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
219012972|NCT01623323|DRUG|Fluticasone Propionate|Fluticasone Propionate 400 μg
219012973|NCT01879241|DRUG|Rasagiline|
219012974|NCT01879241|DRUG|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
219012975|NCT01364662|DRUG|SPN-810|administered orally
219476504|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
219476505|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
219476506|NCT02409017|PROCEDURE|Insulin drip|
219476507|NCT00516217|BIOLOGICAL|galiximab|
218830071|NCT06718660|BEHAVIORAL|Tailored Educational Nursing program|The intervention is a structured educational program designed to enhance nursing competence in biomedical waste management at El-Minia University Hospital. It was developed based on evidence-based guidelines, national and international standards, and a detailed assessment of baseline knowledge and practices among the participating nurses.
218830072|NCT06719115|DIETARY_SUPPLEMENT|UClear|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
218830073|NCT06719115|OTHER|Placebo|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
219012976|NCT01364662|DRUG|Placebo|administered orally
219012977|NCT04585022|DEVICE|Magnum, Zimmer Biomet, Warsaw, IN|
219012978|NCT04585022|DEVICE|Recap, Zimmer Biomet, Warsaw, IN|
219012979|NCT01369576|DRUG|Placebo|3.75-7.5mg 14 doses 4 weeks
219012980|NCT01369576|DRUG|Zopiclone|3.75-7.5mg 14 doses 4 weeks
219012981|NCT02615054|DEVICE|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
219012982|NCT02615054|DEVICE|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
219012983|NCT04937621|DIAGNOSTIC_TEST|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
219012984|NCT04937621|DRUG|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
219012985|NCT04937621|BIOLOGICAL|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
219012986|NCT04937621|OTHER|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
219012987|NCT00866411|PROCEDURE|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
219439116|NCT02017457|DRUG|Azacytidine|"* Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
219476508|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
219476509|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
218830074|NCT06715826|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
218830075|NCT06715826|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
218830076|NCT06715826|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
218830077|NCT06715826|DRUG|[18F]F-RESCA-RB14|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
218830078|NCT06715449|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.
219012988|NCT00866411|PROCEDURE|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
219012989|NCT02632552|BEHAVIORAL|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
219012990|NCT02632552|BEHAVIORAL|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
219012991|NCT02601742|OTHER|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
219012992|NCT02601742|OTHER|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
219012993|NCT06397898|OTHER|Educational video|Viewing an educational video before Novasure treatment
219012994|NCT05503147|DRUG|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
219012995|NCT01800240|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
218830079|NCT06715215|DIAGNOSTIC_TEST|Acute phase proteins|Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
218830080|NCT06718153|DIAGNOSTIC_TEST|Immunohistochemistry and in situ hybridisation analysis|immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.
219012996|NCT00585819|PROCEDURE|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
219012997|NCT00585819|PROCEDURE|Freebreathing in Body fix mold|Freebreathing in Body fix mold
219012998|NCT01721616|DRUG|Azithromycin|
219012999|NCT01721616|DRUG|Cefazolin|
219013000|NCT02375568|OTHER|103024-F|mesenchymal stem cell isolation
219013001|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
219439117|NCT03109444|DIAGNOSTIC_TEST|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
219439118|NCT05591651|DRUG|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
219439119|NCT05591651|DRUG|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
219439120|NCT05960136|PROCEDURE|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
219439121|NCT05960136|PROCEDURE|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
219439122|NCT05825586|DEVICE|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
219439123|NCT00744692|BIOLOGICAL|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
219439124|NCT00744692|DRUG|Reduced Intensity Conditioning|
219439125|NCT01870791|DRUG|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
219439126|NCT03170908|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
218830081|NCT06718985|OTHER|No intervention|No intervention
218830082|NCT06715293|DEVICE|Hemopill|Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract
218830083|NCT06715293|PROCEDURE|OGD|OGD will be performed to compare the results of the hemopill
218830084|NCT06718400|PROCEDURE|Sentinel Skin Flap|Willing participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor
218830085|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
218830086|NCT06716398|OTHER|Test product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
218830087|NCT06716398|OTHER|Comparator product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
219013002|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
219013003|NCT04864379|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
219439127|NCT02253628|OTHER|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
219439128|NCT02253628|OTHER|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
219439129|NCT02253628|OTHER|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
219580780|NCT01466452|DRUG|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
218830088|NCT00790049|DRUG|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
218830089|NCT00790049|DRUG|Placebo; oral|matching placebo
218830090|NCT06715969|OTHER|Myofascial Release Techniques|Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.
218830091|NCT06715969|OTHER|Myofascial Induction Techniques|"MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)"
218830092|NCT06715969|OTHER|classıcal phsyotherapy|15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
219013004|NCT04864379|OTHER|GM-CSF|GM-CSF: 40 mcg
219013005|NCT04864379|DRUG|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
219013006|NCT04864379|PROCEDURE|RFA|Radiofrequency ablation surgery
219363789|NCT04568564|OTHER|Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.
218830093|NCT06715332|DEVICE|Colorectal ESD with SpydrBlade Flex|"The allocated intervention would be performed under sedation or monitored anaesthesia by experienced endoscopists with at least 50 case experience of colon ESD.~Colon ESD procedure would be performed as per described in the literature. After submucosal injection of solution to create a cushion, mucosal incision and submucosal dissection would be performed with the SydrBlade Flex. Submucosal plane dissection will be performed using the SpydrBlade Flex (BRF, cutting frequency 400kHz, power setting 35W). The exact resection strategy would be according to the endoscopists' preference, including different adjunctive techniques such as countertraction, tunnelling or pocket creation method. Upon completion of ESD, the resultant mucosal defect would be examined for any perforation or bleeding."
218830094|NCT06718777|OTHER|0.1% polyhexanide Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.1% polyhexanide solution. Then, 2 treatments were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care and four follow-ups were performed.
218830095|NCT06718777|OTHER|0.9 % NaCl Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.9% sodium chloride. Then, 2 care sessions were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care sessions and four follow-ups were performed.
218830096|NCT06714877|OTHER|prism treatment group|wearing prism glasses
218830097|NCT06714877|PROCEDURE|botulinum toxin group|botulinum toxin injection
218830098|NCT06716268|OTHER|phonation and respiratory tasks|"Participants performed various tasks to evaluate pelvic floor muscle activity and displacement. These included a maximum voluntary contraction (cutting off the flow of urine mid-stream), a pelvic floor strain (bearing down for a bowel movement), and the Valsalva maneuver to clear the Eustachian tubes. Additionally, phonation and respiratory exercises were conducted, such as producing the ah sound at different pitches, open-mouth exhalation, coughing, and semi-occluded vocal tract (SOVT) exercises using a small coffee straw, commonly used in singing warm-ups to enhance vocal efficiency. Each task lasted 3 seconds, with 1-minute rest intervals to assess their impact on pelvic floor displacement"
219439130|NCT02253628|OTHER|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
219439131|NCT04894227|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219439132|NCT03480646|DRUG|CPI-1205|Administered orally
219439133|NCT03480646|DRUG|Enzalutamide|Administered orally
219439134|NCT03480646|DRUG|Abiraterone/Prednisone|Administered orally
219439135|NCT05495191|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
219439136|NCT03592394|DEVICE|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
219439137|NCT01787851|DRUG|Triheptanoin oil|
219439138|NCT01577628|DRUG|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
219439139|NCT03250130|BEHAVIORAL|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
219439140|NCT00215228|DRUG|duloxetine vs. escitalopram|
219439141|NCT01058057|DRUG|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
219439142|NCT05078671|DRUG|Olaparib|olaparib treatment
219439143|NCT05078671|DRUG|Cobicistat|Pharmacokinetic booster
219439144|NCT05226572|DIAGNOSTIC_TEST|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
219439145|NCT06093945|DRUG|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
219439146|NCT06093945|DRUG|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
219439147|NCT00841672|DRUG|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
219439148|NCT00841672|DRUG|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
219439149|NCT02932319|DEVICE|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
219439150|NCT02932319|OTHER|expectative|expectative until the next day befor starting the induction
219439151|NCT01180764|DRUG|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
219439152|NCT01180764|DRUG|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
219439153|NCT02755610|OTHER|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
219439154|NCT00356057|DEVICE|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
219439155|NCT00750178|DRUG|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
219439156|NCT00127699|PROCEDURE|Alcohol swab of umbilical cord|
219439157|NCT06276842|DRUG|Inferior Alveolar Nerve Block|Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
218830099|NCT06716892|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle and subcutaneos regions.
218830100|NCT06717945|DRUG|remimazolam besylate|Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
219013007|NCT03034720|BEHAVIORAL|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
219013008|NCT04954963|DIAGNOSTIC_TEST|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
219013009|NCT03103919|DEVICE|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
219013010|NCT03103919|DEVICE|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
219013011|NCT03103919|DRUG|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
219013012|NCT04220008|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
219013013|NCT04220008|DRUG|Busulfan|Given IV
219013014|NCT04220008|DRUG|Clofarabine|Given IV
219013015|NCT04220008|DRUG|Cyclophosphamide|Given IV
219013016|NCT04220008|DRUG|Gemcitabine|Given IV
219013017|NCT04220008|DRUG|Mycophenolate Mofetil|Given IV
219013018|NCT04220008|BIOLOGICAL|Rituximab|Given IV
219013019|NCT04220008|DRUG|Tacrolimus|Given IV
219013020|NCT04220008|DRUG|Vorinostat|Given PO
219013021|NCT05325528|DRUG|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
219013022|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
219013023|NCT04444596|DIAGNOSTIC_TEST|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
219013024|NCT03821792|DRUG|Abiraterone Acetate|Given PO
219013025|NCT03821792|DRUG|Apalutamide|Given PO
218830101|NCT06717945|DRUG|propofol|Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
218830102|NCT06718478|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
218830103|NCT06716775|DEVICE|Tumor treating felds (TTF)|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.
219013026|NCT03821792|DRUG|Prednisone|Given PO
219013027|NCT06196333|DEVICE|Non-contact specular microscopy|using specular microscope to do morphological examination of corneal endothelial cells
219013028|NCT06678529|DEVICE|active tDCS|The active-tDCS group will receive a 15-second ramp up phase at the start, 2 mA of tDCS for 20 minutes and a 15-second ramp down phase at the end.
219013029|NCT06678529|DEVICE|sham tDCS|The sham-tDCS group will only receive the 15-second ramp up phase at the beginning and the 15-second ramp down phase at the end of each session, without the continuous 2 mA current for 20 minutes
219013030|NCT01324336|DRUG|6-Mercaptopurine|75 mg/m2/dose/day
219013031|NCT04057391|DIAGNOSTIC_TEST|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
219013032|NCT01426880|DRUG|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
219439158|NCT06276842|DRUG|Buccal Infiltration|Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
219013033|NCT01426880|DRUG|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
219439159|NCT06276842|COMBINATION_PRODUCT|Inferior Alveolar Nerve Block and Buccal Infiltration|Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
219439160|NCT00002968|BIOLOGICAL|edrecolomab|Given IV
219439161|NCT00002968|OTHER|laboratory biomarker analysis|Correlative studies
219439162|NCT00274040|DRUG|Tiotropium|
219439163|NCT00274040|DRUG|Ipratropium|
219013034|NCT06319508|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
218830104|NCT06716775|OTHER|Best Standard of Care|Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
218830105|NCT06719518|DEVICE|ViTrack device|In the operating room the ViTrack™ device will be applied the wrist. Monitoring will start in the operating room and will continue throughout the surgery. The device can be worn on either wrist. It will be connected to a power unit that will capture blood pressure data and stream the data to a secure laptop
218830106|NCT06716515|DEVICE|digital inclinometer|Digital inclinometer to assess gender difference in knee repositioning error
218830107|NCT06719336|RADIATION|High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy|Twice-daily thoracic radiotherapy at a dose of 54 Gy in 30 fractions with IMRT and VMAT
219013035|NCT06319508|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219013036|NCT06319508|DRUG|Lidocaine hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
219013037|NCT06319508|PROCEDURE|Placebo injection|The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
219013038|NCT04199611|PROCEDURE|Liposuction|This is a type of fat removal procedure used in plastic surgery.
219013039|NCT04199611|BEHAVIORAL|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
219013040|NCT01773382|BEHAVIORAL|weight reduction|"1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary"
219013041|NCT03145285|DRUG|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
219013042|NCT03846011|OTHER|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
219013043|NCT03383679|DRUG|Darolutamide|treatment with darolutamide
219013044|NCT03383679|DRUG|Capecitabine|treatment with capecitabine
219013045|NCT00480597|DRUG|gemcitabine|
219013046|NCT00480597|DRUG|cisplatin|
219013047|NCT00480597|DRUG|vinorelbine|
219013048|NCT00480597|DRUG|capecitabine|
219013049|NCT01453712|RADIATION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
219013050|NCT01453712|RADIATION|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
219439164|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
218830108|NCT06719336|DRUG|atezolizumab or durvalumab|atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
218830109|NCT06717048|DEVICE|Repeated Low-level Red-light|In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.
218830110|NCT06717048|DEVICE|Red LED|In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
218830111|NCT04685213|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
219013051|NCT04665284|DRUG|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
218830112|NCT04685213|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
219013052|NCT04665284|DRUG|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
219439165|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
219439166|NCT02233907|DRUG|Ventilat® - metered dose inhaler|
219439167|NCT05940441|DRUG|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
218830113|NCT06717087|OTHER|Acupuncture+lifestyle intervention|8 weeks Acupuncture treatment for 2-3 times/week, 30min each time and lifestyle intervention((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
219013053|NCT05522101|DEVICE|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
219439168|NCT00415545|BEHAVIORAL|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
219439169|NCT00415545|BEHAVIORAL|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
219439170|NCT03924648|OTHER|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
219439171|NCT05158530|OTHER|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
219439172|NCT05158530|OTHER|Pulmonary Exercises|"4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)"
218830114|NCT06717087|OTHER|Metformin+lifestyle intervention|8 weeks Metformin 500 mg three times a day with meals and lifestyle intervention ((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
218830115|NCT06716697|BEHAVIORAL|physical and mental fatigue|physical and mental fatigue as a result of exposed to exams
218830116|NCT06716411|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
218830117|NCT06716047|OTHER|Oral administration|Take it directly
218830118|NCT06714890|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation Combined with Accommodation-related Visual Training
218830119|NCT06714890|OTHER|Visual Training|Accommodation-related Visual Training
218830120|NCT02161536|DEVICE|Motus Cleansing System|
218830121|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
218830122|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
218830123|NCT00752921|DRUG|etoricoxib|120 mg
218830124|NCT00752921|DRUG|placebo|placebo
218830125|NCT03898284|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
218830126|NCT04999735|BEHAVIORAL|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
218830127|NCT04999735|BEHAVIORAL|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
218830128|NCT04999735|BEHAVIORAL|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
218830129|NCT04999735|BEHAVIORAL|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
218830130|NCT00971282|DRUG|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
218830131|NCT00971282|OTHER|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
218830132|NCT05246202|BEHAVIORAL|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
218830133|NCT05246202|BEHAVIORAL|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
218830134|NCT04486690|DRUG|Ketofol (propofol to ketamine ratio 1:1)|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
218830135|NCT04486690|DRUG|propofol|"Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min."
218830136|NCT01101529|DRUG|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
218830137|NCT01101529|DRUG|Placebo|Placebo will be administered instead of Emend
218830138|NCT03440866|DRUG|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
218830139|NCT01085526|BIOLOGICAL|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
218830140|NCT01085526|DRUG|Alutard phl prat|
218830141|NCT03005340|DRUG|Treatment B|Bazedoxifene 20 mg
218830142|NCT03005340|DRUG|Treatment C|Cholecalciferol granule 10 mg
218830143|NCT03005340|DRUG|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
218830144|NCT00769054|DRUG|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
218830145|NCT00769054|DRUG|Isotonic NaCl|Local Infiltration with NaCl
218830146|NCT01207206|DRUG|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
218830147|NCT04446312|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
218830148|NCT02175186|DRUG|ALBIS|
218830149|NCT02175186|DRUG|Placebo|
219195986|NCT05209984|DRUG|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
219763853|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
218830150|NCT05379699|OTHER|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
218830151|NCT05379699|OTHER|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
218830152|NCT00655837|DRUG|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
218830153|NCT00655837|DRUG|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
218830154|NCT00655837|DRUG|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
218830155|NCT02224170|DRUG|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
218830156|NCT02224170|DRUG|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
218830157|NCT00192543|BEHAVIORAL|diet of fish and fruit|fish and fruit in specified quantities
218830158|NCT00192543|BEHAVIORAL|fruit and fish|no drugs
218830159|NCT00192543|BEHAVIORAL|diet only|Fish and fruit
218830160|NCT00192543|BEHAVIORAL|regular diet|no change in regular diet
218830161|NCT03931187|BEHAVIORAL|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
218830162|NCT04734158|OTHER|corneal imaging|corneal imaging using AS-OCT
218830163|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
218830164|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
218830165|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
218830166|NCT03154476|DRUG|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
218830167|NCT03154476|DRUG|Placebo|Placebo capsules matching study drug
218830168|NCT06091358|DEVICE|PrO2|"The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week."
218830169|NCT00200967|DRUG|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
218830170|NCT00200967|DRUG|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
218830171|NCT02751944|DIETARY_SUPPLEMENT|NEM|Dietary supplement for the support of joint health.
218830172|NCT02751944|DIETARY_SUPPLEMENT|Placebo|Placebo
219763854|NCT06179303|DRUG|Abemaciclib|Given PO
218830173|NCT01950728|DEVICE|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
219013054|NCT05522101|DEVICE|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
219013055|NCT02527460|DRUG|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
218830174|NCT01950728|DEVICE|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
218830175|NCT01950728|DEVICE|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
219013056|NCT04698720|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
218830176|NCT04892706|DRUG|IDP-126 Gel|Gel applied to face once daily in the evening.
218830177|NCT04892706|DRUG|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
218830178|NCT04892706|DRUG|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
218830179|NCT00936663|DRUG|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
218830180|NCT00936663|DRUG|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
218830181|NCT01444430|DRUG|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
218830182|NCT01444430|DRUG|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
219363790|NCT04568564|OTHER|Exercise booklet|Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.
219363791|NCT03611699|DRUG|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
219439173|NCT03886922|DRUG|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
219439174|NCT03886922|DRUG|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
218830183|NCT03273686|PROCEDURE|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
218830184|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
218830185|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
218830186|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
218830187|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
218830188|NCT04991493|DRUG|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
218830189|NCT04991493|OTHER|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
219363792|NCT03611699|DRUG|Placebo|Placebo inhaler
218830190|NCT05989568|BEHAVIORAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
219363793|NCT05495295|DRUG|PhOx430|"A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
218830191|NCT05989568|BEHAVIORAL|Attention Control (ACC)|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
219013057|NCT04698720|BEHAVIORAL|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
219013058|NCT04698720|BEHAVIORAL|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
219013059|NCT04025307|DRUG|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
219013060|NCT01846507|DRUG|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
219013061|NCT00350714|OTHER|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
219013062|NCT00989794|DEVICE|GelrinC|Applied once during surgery
219013063|NCT01428089|DRUG|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
219013064|NCT01428089|DRUG|Placebo|Placebo
219013065|NCT00450450|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
219013066|NCT00450450|OTHER|laboratory biomarker analysis|Correlative studies
219013067|NCT00450450|BIOLOGICAL|filgrastim|Given IV
219013068|NCT03643276|DRUG|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
219013069|NCT03643276|DRUG|Bortezomib|Experimental therapy in randomization R-eHR
219013070|NCT03643276|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
219013071|NCT03643276|DRUG|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
219439175|NCT05869786|DEVICE|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
218830192|NCT03994016|BEHAVIORAL|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
219013072|NCT03643276|DRUG|Daunorubicin|Part of standard chemotherapy
219013073|NCT03643276|DRUG|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
219013074|NCT03643276|DRUG|Dexamethasone|Part of standard chemotherapy
219013075|NCT03643276|DRUG|Doxorubicin|Part of standard chemotherapy
219013076|NCT03643276|DRUG|Etoposide|Part of standard chemotherapy
219013077|NCT03643276|DRUG|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
219013078|NCT03643276|DRUG|Ifosfamide|Part of standard chemotherapy
219013079|NCT03643276|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
219013080|NCT03643276|DRUG|Methotrexate|Part of standard chemotherapy
219013081|NCT03643276|DRUG|Pegaspargase|Part of standard chemotherapy
219013082|NCT03643276|DRUG|Prednisolone|Part of standard chemotherapy
219013083|NCT03643276|DRUG|Tioguanin|Part of standard chemotherapy
219013084|NCT03643276|DRUG|Vincristine|Part of standard chemotherapy
219013085|NCT03643276|DRUG|Vindesine|Part of standard chemotherapy
219013086|NCT03643276|DRUG|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
219013087|NCT00963287|DRUG|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
219013088|NCT03826979|OTHER|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
219439176|NCT05869786|OTHER|conventional rehabilitation program|conventional rehabilitation program
219439177|NCT05869786|BEHAVIORAL|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
219439178|NCT06197022|DEVICE|Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
219580781|NCT01466452|DRUG|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
218830193|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
219439179|NCT01000818|DRUG|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
219439180|NCT01000818|DRUG|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
219439181|NCT01000818|DRUG|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
219439182|NCT04115527|PROCEDURE|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
219439183|NCT04115527|PROCEDURE|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
218830194|NCT05910567|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
218830195|NCT05910567|OTHER|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
218830196|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
218830197|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
218830198|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
218830199|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
218830200|NCT00643942|OTHER|No intervention required|
218830201|NCT05812339|DEVICE|Gastric Alimetry System|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
218830202|NCT04405440|BEHAVIORAL|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
218830203|NCT03300206|DEVICE|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
218830204|NCT06525480|PROCEDURE|Percutaneous pulmonary thrombectomy|Pulmonary thrombus extraction
218830205|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
218830206|NCT01239277|OTHER|protein|20g protein
218830207|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
218830208|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
218830209|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
218830210|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
218830211|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
218830212|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
218830213|NCT03572231|DRUG|mirabegron|oral
218830214|NCT03572231|DEVICE|solifenacin|oral
218830215|NCT03572231|DRUG|darifenacin|oral
218830216|NCT03572231|DRUG|imidafenacin|oral
218830217|NCT03572231|DRUG|tolterodine|oral
218830218|NCT03572231|DRUG|oxybutynin|oral
218830219|NCT03572231|DRUG|trospium|oral
218830220|NCT03572231|DRUG|fesoterodine|oral
218830221|NCT03572231|DEVICE|propiverine|oral
218830222|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
218830223|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
218830224|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
218830225|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
218830226|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
218830227|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
218830228|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
218830229|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
218830230|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
218830231|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
218830232|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
218830233|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
218830234|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
218830235|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
218830236|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
218830237|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
218830238|NCT03033680|DRUG|[F-18]PBR06|PET radiopharmaceutical
219013089|NCT05647473|BEHAVIORAL|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
218830239|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
219013090|NCT05647473|DRUG|add-on low dose Astragalus|Participants received an additional 10g of astragalus per day.
219013091|NCT05647473|DRUG|add-on high dose Astragalus|Participants received an additional 20g of astragalus per day.
219013092|NCT00001054|DRUG|Valacyclovir hydrochloride|
219013093|NCT04142021|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
219013094|NCT01730209|DRUG|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
219013095|NCT01730209|DRUG|Placebo|
219013096|NCT05395806|OTHER|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
219013097|NCT05395806|OTHER|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
219013098|NCT04844632|BIOLOGICAL|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
219013099|NCT02707991|BEHAVIORAL|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
219013100|NCT01737788|PROCEDURE|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
219013101|NCT01727453|DRUG|warfarin|Warfarin in anticoagulant dose
219013102|NCT01727453|DRUG|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
219013103|NCT01396720|DRUG|fluvoxamine|Fluvoxamine 100mg daily, 7 days
219013104|NCT01396720|DRUG|citalopharm|Citalopharm 20mg daily, 7 days
219013105|NCT03542344|DRUG|BI 1015550|Single rising oral dose
219013106|NCT03542344|DRUG|Placebo|Single rising oral dose
219013107|NCT05115734|DIAGNOSTIC_TEST|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
219439184|NCT00741260|DRUG|Neratinib|Neratinib orally once daily continually
219013108|NCT05787691|OTHER|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
219439185|NCT00741260|DRUG|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
219439186|NCT02606344|OTHER|Mico-finance based intervention|
219439187|NCT03026049|DEVICE|deep venous stenting|Deep venous stent
219580782|NCT02038907|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
218830240|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
218830241|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
218830242|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
218830243|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
218830244|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
218830245|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
218830246|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
218830247|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
218830248|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
218830249|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
219013109|NCT04035681|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
219013110|NCT04035681|OTHER|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
219013111|NCT00075049|BIOLOGICAL|RTS,S with AS02A/AS01B adjuvant|
219013112|NCT04270123|OTHER|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
219013113|NCT02911181|OTHER|BIVA measurement|
219013114|NCT00859768|OTHER|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
219195987|NCT05209984|DRUG|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
219439188|NCT02675179|DEVICE|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
219580783|NCT02038907|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
218830250|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
218830251|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
219013115|NCT05901779|DRUG|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
219013116|NCT00845169|PROCEDURE|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
219013117|NCT03681392|DIETARY_SUPPLEMENT|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
219013118|NCT03903731|DEVICE|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
219013119|NCT05073991|PROCEDURE|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
218830252|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
219013120|NCT05073991|PROCEDURE|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
219013121|NCT05073991|PROCEDURE|TEVAR|Patients underwent TEVAR.
219439189|NCT02675179|DEVICE|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
219439190|NCT05518799|DRUG|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
219439191|NCT00503737|BEHAVIORAL|National Colorectal Cancer Roundtable Toolbox|
219439192|NCT01664819|DIETARY_SUPPLEMENT|Antioxidant|
219439193|NCT01664819|DIETARY_SUPPLEMENT|Placebo|
219580784|NCT00805753|DRUG|ACTH|comparison of different dosages of drug
218830253|NCT01470131|DRUG|Placebo|Matching placebo
218830254|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
218830255|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
218830256|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
218830257|NCT05274412|OTHER|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
218830258|NCT05274412|OTHER|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
218830259|NCT02449811|DRUG|Perindopril|
219580785|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
219763855|NCT06179303|DRUG|Anastrozole|Given PO
218830260|NCT02449811|DRUG|Olmesartan|
218830261|NCT02449811|DRUG|Amlodipine|
218830262|NCT02449811|DRUG|Hydrochlorothiazide|
218830263|NCT01819207|OTHER|blood test by thromboelastography|
218830264|NCT00192920|BEHAVIORAL|Transfusion practice|
218830265|NCT00115271|DRUG|Nutritional supplements|
218830266|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
218830267|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
218830268|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
218830269|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
218830270|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
218830271|NCT01798901|DRUG|decitabine|Given IV
218830272|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
218830273|NCT01798901|OTHER|pharmacological study|Correlative studies
218830274|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
218830275|NCT06345261|DRUG|Saline|injection of saline
218830276|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
218830277|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
218830278|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
218830279|NCT00154817|PROCEDURE|radiotherapy|
218830280|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
219013122|NCT05073991|PROCEDURE|EVAR|Patients underwent EVAR.
219013123|NCT01182545|PROCEDURE|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
219013124|NCT00765375|DRUG|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
219013125|NCT00765375|DRUG|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
219013126|NCT01486628|DRUG|ND0612|levodopa and carbidopa solution for subcutaneous administration
218830281|NCT01903772|OTHER|Inspiratory Muscle Training|
218830282|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
218830283|NCT00125814|DRUG|Interferon alfa-2b|
218830284|NCT00125814|PROCEDURE|Structured treatment interruptions|
218830285|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
218830286|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
218830287|NCT00003420|PROCEDURE|computed tomography|
218830288|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
218830289|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
218830290|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
218830291|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
218830292|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
218830293|NCT00164840|DRUG|Esomeprazole|
218830294|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
218830295|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
218830296|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
218830297|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
218830298|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
218830299|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
219013127|NCT01486628|DRUG|Placebo|Saline solution for SC continuous administration
219013128|NCT06135987|DEVICE|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
219013129|NCT01037608|DRUG|Sativex(Registered Trademark)|
219013130|NCT01037608|DRUG|THC|
218830300|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
218830301|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
218830302|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
218830303|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
218830304|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
218830305|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
219013131|NCT02308410|PROCEDURE|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
219013132|NCT00101114|DRUG|sorafenib tosylate|Given PO
219013133|NCT00101114|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
219013134|NCT00101114|OTHER|laboratory biomarker analysis|Optional correlative studies
219013135|NCT04426682|DIAGNOSTIC_TEST|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
219013136|NCT04226274|DRUG|REN001|Once daily for 12 weeks
219013137|NCT01288794|DRUG|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
219439194|NCT04335708|DIETARY_SUPPLEMENT|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
219439195|NCT04335708|DIETARY_SUPPLEMENT|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
219439196|NCT02170038|DRUG|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
219013138|NCT01288794|DRUG|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
219013139|NCT01202305|PROCEDURE|Lymph node biopsy|Inguinal lymph node biopsy
219013140|NCT03933202|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
219013141|NCT05287867|BIOLOGICAL|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
219013142|NCT05287867|OTHER|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
219013143|NCT03442907|PROCEDURE|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
219013144|NCT03442907|PROCEDURE|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
219013145|NCT06342531|BEHAVIORAL|eDASA+APP FI|A CDSS for nurses to assist in their daily short-term violence risk assessment and management, is integrated into an EPIC-based EHR system.
219439197|NCT02170038|DRUG|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
219439198|NCT02120352|DRUG|CAB Oral Tablets|White to almost white oval shaped film coated 30 mg tablets for oral administration.
219439199|NCT02120352|DRUG|CAB LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
219439200|NCT02120352|DRUG|ABC/3TC Oral tablets|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
219763856|NCT06179303|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219439201|NCT02120352|DRUG|RPV Oral Tablets|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
219013146|NCT02058576|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
219013147|NCT02058576|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
219439202|NCT02120352|OTHER|HAART|Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
219439203|NCT02120352|DRUG|RPV|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
219439204|NCT01273987|PROCEDURE|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
219439205|NCT02427100|BEHAVIORAL|Diet/Physical Activity|Diet/Physical Activity Intervention
219013148|NCT04883190|OTHER|Fulfilling Questionaires|Fulfilling Questionaires PHQ-D (brief) and FSMC
219439206|NCT06124885|DIAGNOSTIC_TEST|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
219439207|NCT02322099|DRUG|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
219439208|NCT02322099|DRUG|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
219439209|NCT02322099|DIETARY_SUPPLEMENT|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
219013149|NCT00811538|PROCEDURE|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
219013150|NCT00811538|PROCEDURE|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
219763857|NCT06179303|PROCEDURE|Computed Tomography|Undergo PET/CT
219013151|NCT04443504|BEHAVIORAL|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
219013152|NCT03533179|DRUG|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
219013153|NCT03533179|DRUG|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
219013154|NCT03533179|DRUG|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
219013155|NCT03533179|DRUG|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
219013156|NCT04157608|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
219013157|NCT04157608|DEVICE|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
219013158|NCT05951868|BEHAVIORAL|Continuum of support on breastfeeding.|A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
219013159|NCT04319120|OTHER|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
219013160|NCT03577704|DRUG|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
219013161|NCT03577704|DRUG|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
219013162|NCT03577704|DRUG|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
219439210|NCT02322099|DRUG|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
219439211|NCT06145087|DIETARY_SUPPLEMENT|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
219763858|NCT06179303|PROCEDURE|Diagnostic Imaging Testing|Undergo clinical imaging for tumor assessment
219763859|NCT06179303|DRUG|Exemestane|Given PO
219763860|NCT06179303|OTHER|Fludeoxyglucose F-18|Given IV
219763861|NCT06179303|DRUG|Fluorine F 18 Fluoro Furanyl Norprogesterone|Given IV
219763862|NCT06179303|DRUG|Fulvestrant|Given IM injection
219763863|NCT06179303|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given GnRH analog
219763864|NCT06179303|DRUG|Letrozole|Given PO
219439212|NCT06145087|DIETARY_SUPPLEMENT|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
219439213|NCT05684588|DIAGNOSTIC_TEST|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
219439214|NCT05993000|OTHER|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
219439215|NCT05993000|OTHER|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
219439216|NCT05993000|OTHER|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
219439217|NCT05993000|OTHER|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
219439218|NCT05993000|OTHER|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
219439219|NCT01241656|BEHAVIORAL|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
219439220|NCT01241656|BEHAVIORAL|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
219580786|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
218830306|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
218830307|NCT00395473|DRUG|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
218830308|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate venous blood sampling
218830309|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
218830310|NCT00057564|DRUG|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
218830311|NCT00057564|DRUG|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
218830312|NCT01537315|DRUG|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
218830313|NCT01537315|OTHER|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
218830314|NCT03323853|BEHAVIORAL|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
218830315|NCT03323853|BEHAVIORAL|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
218830316|NCT02197572|DRUG|Sapanisertib|Sapanisertib capsules.
218830317|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
218830318|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
218830319|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
218830320|NCT01971684|DRUG|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
218830321|NCT03938051|OTHER|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
218830322|NCT03938051|OTHER|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
218830323|NCT04310696|OTHER|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
218830324|NCT04310696|OTHER|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
219439221|NCT01241656|BEHAVIORAL|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
219439222|NCT04766983|DIAGNOSTIC_TEST|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
219763865|NCT06179303|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218830325|NCT01147393|DRUG|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
218830326|NCT01147393|BIOLOGICAL|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
218830327|NCT02529111|DEVICE|"Echonavigator software"|
218830328|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
218830329|NCT00852579|DRUG|Placebo|Placebo
218830330|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
218830331|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
218830332|NCT00752492|OTHER|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
218830333|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
218830334|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
218830335|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
218830336|NCT02769429|DEVICE|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
218830337|NCT02769429|DEVICE|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
218830338|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
219013163|NCT05725850|OTHER|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
219013164|NCT05725850|OTHER|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
219013165|NCT05453344|DEVICE|DexCom one|Provision of DexCom One for glucose monitoring
219013166|NCT01129648|DRUG|Placebo|Administered daily for 21 days
219439223|NCT00943254|OTHER|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
218830339|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
218830340|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
218830341|NCT03457610|BEHAVIORAL|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
218830342|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
218830343|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
218830344|NCT01563900|DEVICE|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
218830345|NCT01563900|DEVICE|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
218830346|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
218830347|NCT02859831|OTHER|water samples|
218830348|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
218830349|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
218830350|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
219013167|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219580787|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
219580788|NCT02067429|PROCEDURE|Limbal Relaxing Incisions|
219580789|NCT02067429|DEVICE|Toric Intraocular Lens|
219580790|NCT04670666|DRUG|MADALENA ASSOCIATION|Madalena association coated tablet.
219013168|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013169|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013170|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
219013171|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013172|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013173|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013174|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
219013175|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013176|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013177|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013178|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
219013179|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013180|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219439224|NCT00943254|OTHER|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
219013181|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
219013182|NCT01129648|DRUG|BCX4208|Adminstered daily for 21 days
219013183|NCT00737282|DRUG|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
219013184|NCT00737282|DRUG|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
219013185|NCT00477282|DRUG|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
219013186|NCT00477282|DRUG|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
219013187|NCT00528658|DRUG|Paracetamol|1g qid
219013188|NCT00528658|DRUG|Ibuprofen|400mg tid
219013189|NCT00528658|DRUG|Paracetamol Placebo|equivalent to 1g qid
219013190|NCT00528658|DRUG|Ibuprofen placebo|Equivalent to 400mg tid
219013191|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
219013192|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
219013193|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
219013194|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
219013195|NCT04576429|PROCEDURE|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months)."
219013196|NCT04576429|PROCEDURE|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
219013197|NCT04658277|DRUG|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
219013198|NCT04658277|OTHER|Usual care|Patients will receive usual medical care
219013199|NCT00220402|DRUG|SPM 907|
219013200|NCT06437899|DRUG|intravesical botulinum toxin A injection unter local anaesthesia|"Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor."
219013201|NCT00755287|DRUG|insulin glargine|starting dose 10 IU daily
219013202|NCT00755287|DRUG|metformin|As prescribed
219013203|NCT00755287|DRUG|taspoglutide|10 mg once weekly
219580791|NCT04670666|DRUG|METFORMIN|Metformin 1000 mg extended-release tablet.
219013204|NCT00755287|DRUG|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
219013205|NCT02716064|BEHAVIORAL|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
219013206|NCT01634971|PROCEDURE|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
219013207|NCT00945048|DEVICE|electrical velocimetry|determination of cardiac output by electrical velocimetry
219013208|NCT00945048|DEVICE|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
219013209|NCT00945048|DEVICE|spirometry|spirometry for testing the ventilatory function
219013210|NCT00945048|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
219013211|NCT03626623|DEVICE|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
219763866|NCT06179303|DRUG|Tamoxifen|Given PO
219013212|NCT03626623|OTHER|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
218830351|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
219013213|NCT02157298|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
219013214|NCT02157298|DRUG|Placebo tablet|Placebo tablet. Oral dose
219013215|NCT06469866|DEVICE|low-pressure pneumoperitoneum|low-pressure pneumoperitoneum (LPP) with deep NMB.
219013216|NCT06469866|DEVICE|standard-pressure pneumoperitoneum|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
219013217|NCT02739204|DRUG|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
219195988|NCT05209984|DRUG|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
219195989|NCT06541041|DEVICE|Brief intraoperative electrical stimulation|Intraoperative brief electrical stimulation (BES) will be performed using a handheld nerve stimulator (Checkpoint Guardian) to stimulate the donor nerves at 2 mA with a 200 µs pulse duration for 10 minutes per nerve.
219439225|NCT05468762|PROCEDURE|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
219439226|NCT02376491|DEVICE|Transcranial magnetic stimulation|
219439227|NCT04749563|DRUG|IGC AD1|IGC AD1 oral Solution
219439228|NCT04749563|DRUG|Placebo|Placebo of IGC AD1 oral Solution
219439229|NCT01078519|DRUG|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
219439230|NCT00373412|BIOLOGICAL|VCL CT02 pDNA vaccine|
219439231|NCT00373412|BIOLOGICAL|Towne CMV vaccine|
219439232|NCT02077946|DRUG|liraglutide|No treatment given.
219439233|NCT02077946|DRUG|sitagliptin|No treatment given.
219439234|NCT00444964|DRUG|Nutropin AQ|0.0125 mg/kg/day
218830352|NCT03263065|DIETARY_SUPPLEMENT|Bran|220g rice pudding meal with raspberry jam with added bran flakes
218830353|NCT03263065|DIETARY_SUPPLEMENT|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
219013218|NCT03171415|DRUG|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
219013219|NCT03171415|DRUG|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
219013220|NCT04128176|DRUG|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
219013221|NCT03677505|DEVICE|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
219013222|NCT03677505|DEVICE|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
219013223|NCT05146401|OTHER|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
219439235|NCT04429321|DRUG|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
219439236|NCT04429321|DRUG|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
218830354|NCT03263065|DIETARY_SUPPLEMENT|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
219013224|NCT04059094|DRUG|BI 1265162|Inhalation solution
219013225|NCT04059094|DRUG|Placebo|Inhalation solution
219013226|NCT02994979|OTHER|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
219439237|NCT04429321|DEVICE|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
219439238|NCT02596685|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
219439239|NCT02596685|OTHER|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
219439240|NCT02596685|OTHER|Laboratory Biomarker Analysis|Correlative studies
219439241|NCT02596685|OTHER|Questionnaire Administration|Ancillary studies
219439242|NCT05201482|DEVICE|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
219580792|NCT04670666|DRUG|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
219195990|NCT06541041|DEVICE|Temporary Postoperative Peripheral Nerve Stimulation|An implantable temporary peripheral nerve stimulator (SPRINT PNS System) will be placed during the surgery with one lead for each donor nerve. The implantable peripheral nerve stimulator will be programmed to optimize postoperative pain control on an individualized basis. The peripheral nerve stimulator will be explanted after 60 days, as is intended for this device.
219013227|NCT02994979|OTHER|Sham comparator|Usual care plus sham visits by CNA
219013228|NCT00901160|PROCEDURE|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
219013229|NCT06232811|BEHAVIORAL|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
219013230|NCT01038050|DRUG|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
219013231|NCT01574040|BEHAVIORAL|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
219013232|NCT01574040|BEHAVIORAL|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
219013233|NCT01574040|BEHAVIORAL|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
219013234|NCT01574040|BEHAVIORAL|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
219013235|NCT06220682|DIAGNOSTIC_TEST|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
219195991|NCT05683132|BEHAVIORAL|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
218830355|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
218830356|NCT05495880|PROCEDURE|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
219013236|NCT05029440|OTHER|Pulsed Electromagnetic Field|PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
219013237|NCT05029440|OTHER|Exercise Program|The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.
219439243|NCT05322915|OTHER|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
219439244|NCT01966861|OTHER|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
218830357|NCT05495880|PROCEDURE|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
219013238|NCT05029440|OTHER|Pulsed High Laser Therapy|High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
219013239|NCT04013724|BEHAVIORAL|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
219013240|NCT03305822|DRUG|LY900014|Administered SC
219195992|NCT05683132|BEHAVIORAL|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
219195993|NCT06828484|DRUG|Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)|Cat-allergic and non-allergic participants will be exposed to AP Cat in the NAC.
219195994|NCT05308979|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
219439245|NCT03094611|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219013241|NCT03305822|DRUG|Insulin Lispro|Administered SC
218830358|NCT00901225|DRUG|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
219013242|NCT02593474|DRUG|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
219013243|NCT02856503|DRUG|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
218830359|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
218830360|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
219013244|NCT01463553|PROCEDURE|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
219013245|NCT02234960|DRUG|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
219013246|NCT04337125|OTHER|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
219013247|NCT05778123|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
219013248|NCT05047510|DRUG|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
219013249|NCT00671502|DRUG|Carisoprodol SR|700 mg twice daily
219013250|NCT00671502|DRUG|Carisoprodol SR|500 mg twice daily
219013251|NCT00671502|DRUG|Placebo|Placebo tablet
218830361|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
218830362|NCT01408277|PROCEDURE|Control|Standard Care
219013252|NCT02651727|DRUG|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
219013253|NCT02651727|DRUG|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
219013254|NCT02651727|DRUG|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
219013255|NCT04855825|DEVICE|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
219013256|NCT04855825|OTHER|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
219439246|NCT01432093|OTHER|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
219439247|NCT01432093|OTHER|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
219439248|NCT00842361|DRUG|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
219763867|NCT06179303|DRUG|Therapeutic Estradiol|Given PO
218830363|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
218830364|NCT00000792|DRUG|Hypericin|
218830365|NCT05802277|DIAGNOSTIC_TEST|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
218830366|NCT02039011|DRUG|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
218830367|NCT02039011|DRUG|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
218830368|NCT02620475|DEVICE|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
219013257|NCT03249298|DRUG|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
219013258|NCT03249298|DRUG|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
219013259|NCT01000389|DEVICE|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
219013260|NCT01898728|DRUG|topical povidone-iodine after premedication with topical liquid eye drops|
219439249|NCT00842361|DRUG|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
218830369|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
218830370|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
218830371|NCT05285579|BIOLOGICAL|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
218830372|NCT05285579|OTHER|Tumour samples|reuse of tumour tissue collect in usual patient care
218830373|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
218830374|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
218830375|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
218830376|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
218830377|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
218830378|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
218830379|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
218830380|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
218830381|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
218830382|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
218830383|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
218830384|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
218830385|NCT03011749|OTHER|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
218830386|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830387|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830388|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830389|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830390|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830391|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830392|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
218830393|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
219439250|NCT02573233|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
219439251|NCT02573233|DRUG|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
219439252|NCT02573233|DRUG|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
218830394|NCT00465608|DRUG|propranolol|propranolol by mouth (per os)
218830395|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
218830396|NCT05116397|OTHER|Inspired gas|Inspired gas content
218830397|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
218830398|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
218830399|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
219439253|NCT02573233|DRUG|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
219439254|NCT02573233|DRUG|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
219439255|NCT06178094|BEHAVIORAL|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
219439256|NCT05073172|DRUG|Calendula Ointment|Applied topically
219195995|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
218830400|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
218830401|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
218830402|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
219013261|NCT01898728|DRUG|topical povidone-iodine after premedication with topical gel|
219013262|NCT01338493|PROCEDURE|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
219013263|NCT05712928|BEHAVIORAL|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
219013264|NCT04348929|OTHER|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
219013265|NCT00630279|DRUG|Placebo|Placebo
219013266|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
219013267|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
219013268|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
219013269|NCT05339594|DEVICE|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
219013270|NCT05339594|DEVICE|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
219013271|NCT01705652|DRUG|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
219013272|NCT01183897|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
219195996|NCT06818409|DIAGNOSTIC_TEST|The Diagnostic and Statistical Manual of Mental Disorders (DSM) - 5 criteria for delirium diagnosis|Delirium presence will be assessed using DSM-5 criteria twice daily (morning and evening) for three days, after surgery.
219439257|NCT05073172|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied topically
219439258|NCT05073172|OTHER|Polyethylene Glycol Hydrogel|Applied topically
219439259|NCT05073172|DRUG|Silicone-based Film Forming Topical Gel|Applied topically
219439260|NCT05073172|DRUG|Silver Sulfadiazine|Applied topically
219439261|NCT05073172|DRUG|Topical Hydrocortisone|Applied topically
219439262|NCT02119468|DRUG|ixazomib citrate|Given orally
219439263|NCT02119468|DRUG|dexamethasone|Given orally
218830403|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
218830404|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
218830405|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
219013273|NCT02671994|OTHER|G8 screening|
219013274|NCT02671994|OTHER|Geriatric assessment|
219013275|NCT03463343|OTHER|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
219013276|NCT03463343|OTHER|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
219013277|NCT03463343|OTHER|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
219013278|NCT02269020|PROCEDURE|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
219013279|NCT00541034|BIOLOGICAL|rituximab|
219013280|NCT00541034|DRUG|cyclophosphamide|
219439264|NCT02119468|DRUG|pomalidomide|Given orally
219476510|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
218830406|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
218830407|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
218830408|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
218830409|NCT04420832|PROCEDURE|Surgical treatment|Se above
218830410|NCT04420832|OTHER|Non-surgical treatment|See above
218830411|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
218830412|NCT04036201|DRUG|Bupivacaine|peribulbar block
218830413|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
218830414|NCT00864175|DRUG|INCB007839|100 mg BID
218830415|NCT00864175|DRUG|INCB007839|200 mg BID
218830416|NCT00864175|DRUG|INCB007839|300 mg BID
218830417|NCT00864175|DRUG|INCB007839|300 mg BID
218830418|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
218830419|NCT00864175|DRUG|Docetaxel|
218830420|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
219013281|NCT00541034|DRUG|pentostatin|
219013282|NCT00656474|DRUG|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
219439265|NCT01303458|BEHAVIORAL|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
219439266|NCT03371927|OTHER|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
219439267|NCT01570608|DRUG|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
218830421|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
218830422|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
218830423|NCT02590276|BEHAVIORAL|characterization|
218830424|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
218830425|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
218830426|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
218830427|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
218830428|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
218830429|NCT01360814|OTHER|questionnaire administration|Ancillary studies
218830430|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
218830431|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
218830432|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
218830433|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
218830434|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
218830435|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
218830436|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
218830437|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
219013283|NCT00656474|DRUG|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
219013284|NCT03163550|DRUG|ACHN-383|Oral dose
219013285|NCT03163550|DRUG|ACHN-789|Oral dose
219013286|NCT03163550|DRUG|Placebo|Oral dose
219013287|NCT01894451|DRUG|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
219439268|NCT01570608|DRUG|Verteporfin|Verteporfin photodynamic therapy standard fluence
219013288|NCT01894451|PROCEDURE|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
219013289|NCT01894451|PROCEDURE|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
219013290|NCT01894451|PROCEDURE|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
219013291|NCT02922608|OTHER|simulation practice|simulation session
219013292|NCT03382392|OTHER|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
219013293|NCT04108533|BEHAVIORAL|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
219013294|NCT03855098|OTHER|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
219013295|NCT03128333|OTHER|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
219013296|NCT03128333|OTHER|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
219013297|NCT06128395|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
219013298|NCT02447549|RADIATION|WBRT|One RT plan with whole bladder treated to standard dose.
219013299|NCT02447549|RADIATION|SART|Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
219013300|NCT02447549|RADIATION|DART|Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
219013301|NCT02484742|BEHAVIORAL|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
219013302|NCT00696176|DRUG|STAT 3 DECOY|single administration to a head and neck tumor
219013303|NCT01980875|DRUG|Idelalisib|150 mg tablet administered orally twice daily
219013304|NCT01980875|DRUG|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
219013305|NCT01980875|DRUG|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
219013306|NCT02966587|BIOLOGICAL|Durvalumab|Given IV
219763868|NCT04079530|DRUG|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
219013307|NCT02966587|OTHER|Laboratory Biomarker Analysis|Correlative studies
219013308|NCT02625259|DRUG|TAK-117|TAK-117 capsules
219013309|NCT02625259|DRUG|Lansoprazole|Lansoprazole capsules
219013310|NCT02625259|DRUG|TAK-117|TAK-117 tablets
219013311|NCT05941923|OTHER|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
219013312|NCT00513474|DRUG|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
219013313|NCT00513474|DRUG|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
219013314|NCT00513474|DRUG|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
219013315|NCT00513474|DRUG|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
219439269|NCT04369768|PROCEDURE|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
219439270|NCT01877941|DEVICE|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
219439271|NCT01877941|DEVICE|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
219476511|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
219476512|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
219476513|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
219476514|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
219476515|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
219013316|NCT00513474|DRUG|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
219013317|NCT00513474|DRUG|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
219195997|NCT06815809|BEHAVIORAL|Floor-HI (intervention combines floor exposure with floor rise strategies)|"Floor HI training consists of the following three systematic steps~1. Positioning on the floor: Participants are first taught the backward chaining method. This technique involves using nearby furniture as support to move from an upright position to a kneeling position, through prone and side lying positions, and finally to a supine position.~2. Ground hugging: In this phase, participants will assume a position on the floor. They are encouraged to simulate a fall scenario by observing their surroundings while using relaxation techniques. This includes deep breathing exercises.~3. Getting up from the floor: The final phase focuses on teaching participants techniques to recover from a fall, tailored to their individual balance abilities.~The intervention is carried out on printed surfaces that mimic high fall risk surfaces such as icy, cluttered, wet surfaces."
218830438|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
219013318|NCT00513474|DRUG|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
219013319|NCT00513474|DRUG|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
219013320|NCT00513474|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219013321|NCT00513474|PROCEDURE|peripheral blood stem cell transplantation|
219013322|NCT00513474|RADIATION|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
219013323|NCT00513474|DRUG|fludarabine|Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
219013324|NCT00513474|DRUG|allopurinol|Allopurinol per institutional guidelines
219013325|NCT04573907|DRUG|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
219013326|NCT04573907|DRUG|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
219013327|NCT01325389|DIETARY_SUPPLEMENT|Myo-Mel|
219013328|NCT01325389|DIETARY_SUPPLEMENT|Placebo|
219013329|NCT00935844|DRUG|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
219195998|NCT06036147|BEHAVIORAL|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
219439272|NCT01877941|DEVICE|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
219439273|NCT02568163|OTHER|Non surgical periodontal treatment|
219439274|NCT04443296|DRUG|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
219580793|NCT04670666|OTHER|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
219013330|NCT03404557|OTHER|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
219013331|NCT02530554|DRUG|CHG|Single application
219013332|NCT04432857|DRUG|AN0025|oral administration
219439275|NCT01205919|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
219439276|NCT01205919|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
219439277|NCT04233710|COMBINATION_PRODUCT|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
219439278|NCT04233710|BEHAVIORAL|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
219013333|NCT04432857|DRUG|Pembrolizumab|Infusion
219013334|NCT01441310|PROCEDURE|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
219013335|NCT04878588|OTHER|patients received high resolution impedance manometry|patients received the above two examination at the same time
219013336|NCT02987920|DRUG|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
219013337|NCT02987920|DRUG|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
219013338|NCT02987920|DRUG|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
219013339|NCT02987920|DRUG|Oxycodone|Multimodal analgesic regimen to Group A and Group B
219580794|NCT04670666|OTHER|METFORMIN PLACEBO|Metformin placebo tablet.
219580795|NCT04670666|OTHER|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
219763869|NCT04079530|DRUG|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
219013340|NCT02987920|DRUG|Celecoxib|Multimodal analgesic regimen to Group A and Group B
219013341|NCT02987920|DRUG|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
218830439|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
219013342|NCT02987920|DRUG|Ketorolac|Multimodal analgesic regimen to Group A and Group B
218830440|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
218830441|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
219013343|NCT02987920|DRUG|Gabapentin|Multimodal analgesic regimen to Group A and Group B
219013344|NCT02987920|DRUG|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
219013345|NCT02707250|DRUG|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
219013346|NCT02707250|DRUG|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
219013347|NCT02707250|DRUG|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
219013348|NCT02707250|DRUG|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
219013349|NCT03359447|DRUG|Weekly Ferrous Sulfate|Drops
219013350|NCT03359447|DRUG|Daily Ferrous Sulfate|Drops
219013351|NCT03287505|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
219013352|NCT05886608|DEVICE|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
219013353|NCT00051402|DRUG|Isoflavones|
219013354|NCT01671189|OTHER|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
219013355|NCT01506427|RADIATION|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
219013356|NCT02331836|DEVICE|Arc Endocuff (AEC 110, 120, 130, 140)|
219013357|NCT02331836|DEVICE|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
219476516|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
218830442|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
219013358|NCT02331836|DEVICE|Standard colonoscope|
219013359|NCT02463474|BEHAVIORAL|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
219013360|NCT02970409|DEVICE|saline|catheter lock using saline
219013361|NCT02970409|DEVICE|Heparin|catheter lock using Heparin
219013362|NCT03212612|DIAGNOSTIC_TEST|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
219013363|NCT03474354|DEVICE|chemoembolization|correlation of necrosis with the deposition of beads
219013364|NCT00805311|PROCEDURE|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
219013365|NCT00805311|DRUG|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
219013366|NCT01710254|DRUG|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
219013367|NCT01710254|DRUG|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
219013368|NCT03164200|OTHER|High fat breakfast|High fat breakfast
219013369|NCT03164200|OTHER|Higher carbohydrate breakfast|Higher carbohydrate breakfast
219013370|NCT02663674|DRUG|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
219013371|NCT02663674|OTHER|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
219020717|NCT07206303|BIOLOGICAL|Bifidobacterium probiotics supplementation|"The 10-week research period consists of one prescreening and baseline visit (week -1) and two follow-up visits (week 5 (±7days) and week 10 (±7days)). The participants will be instructed to fast overnight before their visits in the mornings of week -1 and week 10.~The measurements will include documentation of personal and demographic information; three consecutive clinic BP readings; 24-hour ambulatory BP monitoring; a 3-day diet diary to monitor consistency of dietary intake; collection of fecal samples and blood samples for analysis of GM composition and biomarkers, respectively at baseline, and week 5 and 10.~Only participants who are able to provide all the required data and samples within 7 days after the prescreening and baseline visit (week -1) will be eligible to receive the Bifidobacterium supplementation with 20 billion cfu once a day for 10 weeks. They will be instructed to mix the probiotics with water and consume with their dinner."
219580796|NCT03294486|DRUG|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
219580797|NCT01219413|DRUG|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
219580798|NCT00749736|DIETARY_SUPPLEMENT|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
218830443|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
218830444|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
218830445|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
218830446|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
218830447|NCT03371199|DRUG|Sodium chloride|Sodium chloride tablets, 250 mg
218830448|NCT03371199|DRUG|Placebo Oral Tablet|Starch tablets
218830449|NCT00573391|DRUG|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
218830450|NCT00573391|DRUG|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
218830451|NCT03961243|BIOLOGICAL|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
218830452|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
218830453|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
218830454|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
218830455|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
218830456|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
218830457|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
218830458|NCT01179308|OTHER|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
218830459|NCT01179308|OTHER|Balanced general anesthesia and postoperative opioids|General anesthesia alone
218830460|NCT03369665|DRUG|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
218830461|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
218830462|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
218830463|NCT02553928|DRUG|Memantine (once daily)|
218830464|NCT02553928|DRUG|Memantine (twice daily)|
218830465|NCT03366363|OTHER|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
219013372|NCT02081690|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
219580799|NCT00749736|DIETARY_SUPPLEMENT|doxercalciferol|1 mcg of doxercalciferol per day
219580800|NCT00749736|DIETARY_SUPPLEMENT|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
219763870|NCT04079530|DRUG|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
218830466|NCT01316458|DRUG|STI571 (Glivec®)|
218830467|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
218830468|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
218830469|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
219013373|NCT04057404|DEVICE|Alivecor Heart Monitor|
219013374|NCT00959842|DRUG|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
219013375|NCT01566955|PROCEDURE|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
219013376|NCT05305872|DRUG|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
219013377|NCT00084565|DRUG|estramustine phosphate sodium|
218830470|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
218830471|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
218830472|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
218830473|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
218830474|NCT04858542|BEHAVIORAL|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
218830475|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
218830476|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
218830477|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
218830478|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
218830479|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
218830480|NCT01053533|DRUG|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
218830481|NCT01053533|DRUG|western therapy|supportive therapy and antivirus therapy when necessary
219013378|NCT00084565|DRUG|paclitaxel|
219439279|NCT04690712|BEHAVIORAL|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
218830482|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
218830483|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
218830484|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
218830485|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
219013379|NCT00084565|DRUG|topotecan hydrochloride|
219013380|NCT03204981|DEVICE|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
219013381|NCT03204981|PROCEDURE|Ablation|standard ablation
219013382|NCT01662908|DRUG|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
219439280|NCT01436695|DEVICE|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
219439281|NCT04117412|OTHER|Exercise|Same participants will undergo different one bout of exercise protocols
219439282|NCT00832481|DRUG|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
219439283|NCT00832481|DRUG|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
219439284|NCT03608046|DRUG|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
218830486|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
218830487|NCT00209144|DRUG|Intensive insulin therapy|
218830488|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
218830489|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
218830490|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
218830491|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
218830492|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
218830493|NCT04065698|DRUG|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
218830494|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
218830495|NCT00004049|DRUG|apomine|
218830496|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
218830497|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
218830498|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
218830499|NCT01352208|DRUG|ASP9521|oral
218830500|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
218830501|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
218830502|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
218830503|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
218830504|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
218830505|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
218830506|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
218830507|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
218830508|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
219013383|NCT01662908|DRUG|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
218830509|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
218830510|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
218830511|NCT03409081|DRUG|gilteritinib|oral
218830512|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
218830513|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
218830514|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
218830515|NCT02688192|BEHAVIORAL|Exercise Intervention|Participate in fitness program
218830516|NCT02688192|BEHAVIORAL|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
218830517|NCT02688192|DEVICE|Monitoring Device|Wear an electronic accelerometer
218830518|NCT02688192|OTHER|Quality-of-Life Assessment|Ancillary studies
218830519|NCT04965298|DRUG|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
218830520|NCT04965298|OTHER|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
218830521|NCT00075764|DRUG|anastrozole|Given orally
218830522|NCT00075764|DRUG|fulvestrant|Given intramuscularly
218830523|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
218830524|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
219439285|NCT03608046|DRUG|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
218830525|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
218830526|NCT00088270|DRUG|OSI-7904L|
219439286|NCT03608046|DRUG|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
219439287|NCT00204412|DIETARY_SUPPLEMENT|Flax lignan|543 mg SDG per day
219439288|NCT00204412|BEHAVIORAL|Exercise (walking)|walking 45 minutes per day 5 days per week
219439289|NCT00004210|OTHER|loss of heterozygosity analysis|
219439290|NCT00004210|OTHER|microsatellite instability analysis|
219439291|NCT00004210|OTHER|mutation analysis|
219439292|NCT00004210|OTHER|counseling intervention|
219439293|NCT00789646|PROCEDURE|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
219439294|NCT00789646|PROCEDURE|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
219439295|NCT05534152|OTHER|sumac|1% iranian brown sumac
219439296|NCT03986242|DEVICE|rolling|use non- vibration rolling and the total time is 20 minutes.
219763871|NCT06547489|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
218830527|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
218830528|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
218830529|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
218830530|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
218830531|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
219013384|NCT01662908|DRUG|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
219013385|NCT06458608|DEVICE|virtual reality glasses|virtual reality glasses
219013386|NCT01832025|PROCEDURE|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
219013387|NCT01832025|PROCEDURE|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
219013388|NCT01148745|DRUG|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
219195999|NCT06036147|BEHAVIORAL|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
219439297|NCT03986242|DEVICE|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
219439298|NCT03986242|OTHER|static stretching|static stretching and the total time is 20 minutes.
219439299|NCT01536652|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
219439300|NCT05103475|BEHAVIORAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
219439301|NCT05103475|BEHAVIORAL|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
219439302|NCT06508528|BEHAVIORAL|a 12-week growth mindset intervention|This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
219763872|NCT04242095|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
218830532|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
218830533|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
218830534|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
218830535|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
218830536|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
218830537|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
218830538|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
218830539|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
218830540|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
218830541|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
219013389|NCT03510286|DIAGNOSTIC_TEST|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
219013390|NCT02756884|BIOLOGICAL|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
219013391|NCT02756884|BIOLOGICAL|adipose derived stem cells|control arm will only received the adipose derived stem cells.
219013392|NCT00397982|BIOLOGICAL|Bevacizumab|Given IV
219013393|NCT00397982|OTHER|Laboratory Biomarker Analysis|Correlative studies
219013394|NCT00397982|DRUG|Temsirolimus|Given IV
219013395|NCT00397982|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
219013396|NCT04895215|DRUG|AB-2004|Taken 3 times daily with food
219013397|NCT04895215|DRUG|Placebo|Take 3 times daily with food
219013398|NCT05789979|DEVICE|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
219013399|NCT03331679|BEHAVIORAL|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
219013400|NCT00229099|DRUG|GerEPO|
219013401|NCT06380088|OTHER|Isometric Task|The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
219013402|NCT04202991|OTHER|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
219013403|NCT00786487|DRUG|20% lipid infusion|1.5 ml/min for 6 hours
219013404|NCT00786487|DRUG|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
219013405|NCT06309212|OTHER|Observation|Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
219013406|NCT00785395|DRUG|Oxytocin infusion|Up-down dosing determination
219013407|NCT05800795|DEVICE|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
219439303|NCT06508528|OTHER|Hospital mentoring|The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
218830542|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
218830543|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
219013408|NCT05800795|DEVICE|plasma spray|surface treatment with plasma spray for heating abutments
219013409|NCT03940664|OTHER|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
219439304|NCT03471104|OTHER|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
218830544|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
218830545|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
218830546|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
218830547|NCT02226588|DRUG|Misoprostol|
218830548|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
218830549|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
219013410|NCT00249444|DRUG|Mirtazapine|Mirtazapine
219013411|NCT00249444|DRUG|Placebo|placebo
219013412|NCT03081507|BEHAVIORAL|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
219013413|NCT03081507|BEHAVIORAL|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
218830550|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
218830551|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
218830552|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
219013414|NCT05398601|OTHER|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide"
219013415|NCT05398601|OTHER|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
219013416|NCT00936910|DRUG|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
219013417|NCT01938599|DRUG|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
219013418|NCT01938599|DRUG|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
219013419|NCT04843644|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
219013420|NCT04843644|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
219013421|NCT04843644|BEHAVIORAL|Control|usual care
219013422|NCT04436185|BEHAVIORAL|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
219013423|NCT00412854|BIOLOGICAL|Infanrix™/Hib|
219013424|NCT00412854|BIOLOGICAL|Infanrix|
219013425|NCT00412854|BIOLOGICAL|Hiberix|
219013426|NCT03483883|DRUG|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
219013427|NCT03483883|DRUG|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
219013428|NCT02561650|DRUG|COV155|COV155 tablets
219013429|NCT04898257|DIETARY_SUPPLEMENT|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
219439305|NCT01469091|BEHAVIORAL|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
219013430|NCT03529240|DEVICE|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
219013431|NCT05967611|DIAGNOSTIC_TEST|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
219013432|NCT04225351|PROCEDURE|MCAF+CM|CAF procedure + collagen matrix
219013433|NCT04225351|PROCEDURE|MCAT+CM|Tunnel procedure + collagen matrix
219013434|NCT04483011|DIETARY_SUPPLEMENT|RiaGev|Dietary supplementation
219013435|NCT05187793|DRUG|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
219013436|NCT05187793|DRUG|Standard therapy|"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
219439306|NCT02902822|PROCEDURE|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
219763873|NCT04242095|OTHER|Medical Chart Review|Review of medical records
218830553|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
218830554|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
218830555|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
218830556|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
219580801|NCT00523536|BEHAVIORAL|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
218830557|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
218830558|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
219013437|NCT04425265|PROCEDURE|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
219439307|NCT02902822|DEVICE|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
219439308|NCT00924729|DRUG|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
219580802|NCT00002679|BIOLOGICAL|filgrastim|
218830559|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
219013438|NCT04425265|PROCEDURE|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
219580803|NCT00002679|DRUG|cyclophosphamide|
218830560|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
219013439|NCT01857466|PROCEDURE|Floseal|
218830561|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
218830562|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
218830563|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
218830564|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
219013440|NCT01857466|PROCEDURE|Bipolar coagulation|
219013441|NCT03657758|DRUG|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
219013442|NCT03657758|DRUG|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
219013443|NCT03637972|OTHER|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
219013444|NCT03637972|OTHER|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
219013445|NCT03637972|OTHER|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
219013446|NCT03637972|OTHER|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
219013447|NCT00658593|DRUG|capecitabine|
219013448|NCT00658593|DRUG|gemcitabine hydrochloride|
219013449|NCT00658593|PROCEDURE|quality-of-life assessment|
219013450|NCT03045081|BEHAVIORAL|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
219439309|NCT00924729|DRUG|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
219580804|NCT00002679|DRUG|doxorubicin hydrochloride|
219580805|NCT00002679|DRUG|paclitaxel|
219580806|NCT00002679|DRUG|tamoxifen citrate|
219580807|NCT00002679|RADIATION|radiation therapy|
219580808|NCT05237518|DEVICE|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
219580809|NCT03477552|DEVICE|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
219439310|NCT05850013|DEVICE|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
219439311|NCT05222295|OTHER|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
219439312|NCT05222295|OTHER|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
219580810|NCT03477552|OTHER|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
219580811|NCT02513511|PROCEDURE|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
219580812|NCT01653561|DRUG|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
219580813|NCT00129051|PROCEDURE|Tomotherapy|
219580814|NCT04215848|DRUG|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
219580815|NCT04215848|DRUG|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
219580816|NCT02253030|DEVICE|Optical Coherence Tomography|
219580817|NCT04814030|DRUG|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
218830565|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
218830566|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
218830567|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
218830568|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
218830569|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
218830570|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
218830571|NCT01194219|DRUG|Apremilast|
218830572|NCT01194219|DRUG|Placebo|Identical matching placebo
218830573|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
218830574|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
219580818|NCT03317886|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
219580819|NCT03474250|DIAGNOSTIC_TEST|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
219580820|NCT04790838|DRUG|Test|2 inhalations of Test and Reference product in each study period
218830575|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
218830576|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
218830577|NCT01039324|OTHER|Usual care|This is the study's control group
218830578|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
218830579|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
218830580|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
218830581|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
218830582|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
219013451|NCT03531307|OTHER|Data correlation|Correlation between lactate levels and Ki-67 index
219580821|NCT04790838|DRUG|Reference|2 inhalations of Test and Reference product in each study period
219580822|NCT04690517|PROCEDURE|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
219580823|NCT00063635|DRUG|Metformin|500 mg, twice daily
219580824|NCT00063635|DIETARY_SUPPLEMENT|Vitamin E|400 IU, twice daily
219580825|NCT00063635|DRUG|Matching placebo|Twice daily
219580826|NCT05050006|BIOLOGICAL|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
219580827|NCT00562575|DRUG|SLx-4090|
219580828|NCT00562575|DRUG|Placebo|
219580829|NCT06360315|OTHER|Incentive letter for pneumococcal vaccination to the patient and to the GP|Incentive letter for pneumococcal vaccination to the patient and to the GP
218830583|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
218830584|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
218830585|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
218830586|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
218830587|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
218830588|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
218830589|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
218830590|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
218830591|NCT04295837|OTHER|Usual Care|Standard occupational therapy
218830592|NCT04474197|DRUG|VX-864|Tablets for oral administration.
218830593|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
218830594|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
218830595|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
218830596|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
218830597|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
218830598|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
218830599|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
218830600|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
219013452|NCT01108601|DRUG|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
219013453|NCT03959293|DRUG|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
219013454|NCT03959293|DRUG|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
219439313|NCT02685111|DRUG|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
219439314|NCT02685111|DRUG|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
219013455|NCT03959293|DRUG|FOLFIRI Protocol|"* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
219439315|NCT03027193|BIOLOGICAL|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
219439316|NCT03027193|BIOLOGICAL|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
219013456|NCT05400954|PROCEDURE|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
218830601|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
218830602|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
218830603|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
218830604|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
219013457|NCT05400954|PROCEDURE|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
219013458|NCT05400954|PROCEDURE|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
219013459|NCT03186833|OTHER|no intervention|no intervention
219013460|NCT05660564|PROCEDURE|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
219196000|NCT06036147|BEHAVIORAL|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
219196001|NCT02815150|DIETARY_SUPPLEMENT|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
219196002|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
219439317|NCT04902768|OTHER|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
218830605|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
218830606|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
218830607|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
219013461|NCT02977689|DRUG|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
219013462|NCT04934345|DIAGNOSTIC_TEST|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
219013463|NCT03885141|DRUG|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
219013464|NCT03585179|DRUG|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
219013465|NCT03585179|DRUG|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
219439318|NCT04401904|DRUG|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
219013466|NCT03585179|DRUG|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
219013467|NCT03575312|DRUG|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
219013468|NCT03462550|DEVICE|Laryngeal mask|LMA insertion
219013469|NCT06197815|BEHAVIORAL|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
219439319|NCT04401904|BEHAVIORAL|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
219013470|NCT04645641|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
219013471|NCT03800927|DEVICE|Long duration ultrasound|Low-intensity long duration ultrasound treatment
219013472|NCT02937779|DRUG|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
219013473|NCT02937779|DEVICE|Rapid tests HBe Ag|For all HBs Ag positive women
219439320|NCT04381572|BEHAVIORAL|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
219439321|NCT02841592|OTHER|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
218830608|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
218830609|NCT00521209|OTHER|Stand procedures, no intervention|
218830610|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
218830611|NCT00162591|DRUG|remifentanyl|
218830612|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
218830613|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
218830614|NCT01476540|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
218830615|NCT00888914|DRUG|RT001|RT001
218830616|NCT00888914|DRUG|RT001|RT001
218830617|NCT00888914|DRUG|RT001|RT001
218830618|NCT00888914|DRUG|RT001|RT001
218830619|NCT00888914|OTHER|Vehicle Comparator|Vehicle Comparator
218830620|NCT06307249|GENETIC|SNP|Diagnostics of patients' carriers or not of the risk allele(s)
218830621|NCT06307249|DRUG|Palbociclib 125mg|Palbociclib 125mg/day/os over 21 days every 28 days
219439322|NCT02841592|OTHER|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
219439323|NCT02668744|BEHAVIORAL|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
219580830|NCT00554307|DEVICE|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
218830622|NCT06307249|DRUG|Bevacizumab|10mg/kg every 21 days
218830623|NCT04388007|OTHER|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
218830624|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
218830625|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
218830626|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
218830627|NCT02490397|OTHER|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
218830628|NCT02490397|OTHER|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
218830629|NCT02370992|RADIATION|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
218830630|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
218830631|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
218830632|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
218830633|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
218830634|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
218830635|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
218830636|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
219196003|NCT03318159|DRUG|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
218830637|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
218830638|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
219013474|NCT04063956|BEHAVIORAL|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
219013475|NCT04063956|BEHAVIORAL|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
219013476|NCT02338960|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
219013477|NCT02338960|DRUG|Placebo|Placebo
219013478|NCT03037255|OTHER|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
219196004|NCT06212193|DEVICE|Trillium™|Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
219196005|NCT05217589|OTHER|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
219476517|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
218830639|NCT00056173|DRUG|GTI-2040|
218830640|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
218830641|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
218830642|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
218830643|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
219013479|NCT03721315|BEHAVIORAL|Intervention|"The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities"
219013480|NCT02307955|DEVICE|firefly|
219196006|NCT05217589|OTHER|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
219196007|NCT05217589|OTHER|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
219196008|NCT00677365|DRUG|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
219196009|NCT00677365|DRUG|Placebo|same frequency as study drug using the same nebulizer
219196010|NCT06854172|BEHAVIORAL|Mindfulness based self-compassion training|Self-compassion training is a program that aims to help individuals develop a kind, understanding and tolerant approach towards themselves. In this training, individuals learn to be more compassionate towards themselves and to share. This training can help manage negative emotional states such as stress, anxiety and stress and can lead to a healthier internal balance. When combined with mindfulness techniques, self-compassion training allows individuals to accept the moment and develop a more compassionate approach towards themselves. It is thought that this training will be applied to the experimental group to develop parents' feelings of self-compassion and positively affect the parameters of caregiver burden, self-efficacy and emotion regulation designed in the study.
219196011|NCT06854276|DRUG|SSS06|SSS06 is a highly glycosylated, long-acting recombinant protein product produced through recombinant gene technology by introducing site-specific mutations into the rHuEPO gene.
219196012|NCT06854276|DRUG|rhEPO|a recombinant human erythropoietin injection.
219196013|NCT04924868|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
219196014|NCT04924868|DRUG|Placebo|Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
219476518|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
219476519|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
219013481|NCT02307955|OTHER|Standard of care|
219439324|NCT04322162|OTHER|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
218830644|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
218830645|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
218830646|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
218830647|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
218830648|NCT00060671|DRUG|rituximab|
218830649|NCT00060671|DRUG|Pixantrone (BBR 2778)|
219439325|NCT00088972|DRUG|celecoxib|Given orally
219439326|NCT00088972|OTHER|placebo|Given orally
219439327|NCT02811796|OTHER|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
218830650|NCT00202696|DRUG|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
218830651|NCT00202696|OTHER|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
218830652|NCT03930589|PROCEDURE|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
218830653|NCT03930589|OTHER|Standard of care|Standard of care
218830654|NCT04532515|DEVICE|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
219013482|NCT02345811|DEVICE|Sapphire|silicone-hydrogel contact lens
218830655|NCT04532515|DEVICE|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
218830656|NCT01567033|BEHAVIORAL|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
218830657|NCT04828135|DRUG|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
218830658|NCT02058979|DRUG|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
218830659|NCT02058979|DRUG|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
218830660|NCT03694951|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
219013483|NCT02345811|DEVICE|senofilcon A|contact lens
219013484|NCT02877082|BIOLOGICAL|Thymoglobulin|Given IV
219439328|NCT02023112|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
218830661|NCT02118948|BEHAVIORAL|Abuse-focused intervention|
218830662|NCT02118948|BEHAVIORAL|Sexual behavior-focused intervention|
218830663|NCT02553187|DRUG|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
219013485|NCT02877082|DRUG|Bortezomib|Given IV
219013486|NCT02877082|DRUG|Tacrolimus|Given IV and PO
219013487|NCT02489344|DRUG|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
219013488|NCT03480750|DRUG|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
219013489|NCT03480750|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
219013490|NCT03480750|DRUG|carboplatin|carboplatin AUC 4 IV D1
219013491|NCT03896555|DEVICE|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
219013492|NCT00798044|BEHAVIORAL|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
219013493|NCT00798044|BEHAVIORAL|Patient Feedback|Weekly feedback reports provided to counselors
219013494|NCT05308745|DIETARY_SUPPLEMENT|Yakult®|Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
219013495|NCT05308745|DIETARY_SUPPLEMENT|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
219013496|NCT01857349|OTHER|Chlora Prep|Surgical Scrub skin preparation
219439329|NCT02023112|DRUG|Ribavirin|Capsule
219439330|NCT02452710|OTHER|Placebo|Open-label placebo
219439331|NCT01989819|OTHER|skin biopsy|
219439332|NCT00193349|DRUG|Imatinib|
219439333|NCT00193349|DRUG|Irinotecan|
219439334|NCT00193349|DRUG|Carboplatin|
219439335|NCT05371938|PROCEDURE|Volar locking plate|Volar locking plate is the intervention
219439336|NCT05371938|PROCEDURE|external fixation|surgery with external fixation
219439337|NCT00214487|DEVICE|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
219763874|NCT05571696|BEHAVIORAL|Immune Strength|Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
219763875|NCT05027789|BEHAVIORAL|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
219439338|NCT00214487|DEVICE|Placebo Control|Single vision soft contact lenses
219439339|NCT00050479|DRUG|Celecoxib (Celebrex)|
219439340|NCT02639403|RADIATION|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
219439341|NCT03148964|BIOLOGICAL|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
219439342|NCT05188599|DIAGNOSTIC_TEST|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
218830664|NCT00598507|DRUG|ZK-EPO|Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
219439343|NCT03147599|DRUG|Coloverin|Mebeverine hydrochloride 135 mg
219439344|NCT03147599|DRUG|Placebo|Placebo
218830665|NCT00300378|DRUG|desvenlafaxine 50 mg|
218830666|NCT00300378|DRUG|desvenlafaxine 100 mg|
218830667|NCT00934583|BEHAVIORAL|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
218830668|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
218830669|NCT04834726|BEHAVIORAL|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
218830670|NCT04834726|BEHAVIORAL|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
218830671|NCT04834726|BEHAVIORAL|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
218830672|NCT04834726|BEHAVIORAL|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
218830673|NCT04834726|BEHAVIORAL|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
218830674|NCT04834726|BEHAVIORAL|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
218830675|NCT04834726|BEHAVIORAL|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
219013497|NCT01857349|OTHER|Dura Prep|Surgical Scrub skin preparation
219013498|NCT00735774|DRUG|11C-ORM-13070|Single dose of i.v. solution
219013499|NCT04022447|DRUG|Dupilumab|retrospective data collection
219013500|NCT00575913|DRUG|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
219439345|NCT02898142|OTHER|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
219439346|NCT01646853|RADIATION|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
219439347|NCT01646853|DRUG|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
219439348|NCT00649051|DRUG|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
219439349|NCT00649051|DRUG|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
219439350|NCT00101153|DRUG|cytarabine|
219439351|NCT00101153|DRUG|daunorubicin hydrochloride|
219439352|NCT00101153|DRUG|tipifarnib|
219439353|NCT00773851|PROCEDURE|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
219439354|NCT00773851|PROCEDURE|mesh fixation by staples|mesh fixation by staples
219439355|NCT03536923|DEVICE|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
219763876|NCT05027789|BEHAVIORAL|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
219763877|NCT05287854|DEVICE|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
219763878|NCT05755620|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
219763879|NCT05755620|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
219763880|NCT05755620|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
219763881|NCT04222413|DRUG|Metarrestin|Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
219763882|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).
219763883|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.
219763884|NCT04623541|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.
219763885|NCT04623541|DRUG|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.
219763886|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
219763887|NCT04623541|DRUG|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.
219763888|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
219763889|NCT04623541|DRUG|Pirtobrutinib|Pirtobrutinib tablets will be administered in cycles of 28 days.
219763890|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
219763891|NCT00004847|DRUG|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
219763892|NCT00004847|DRUG|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
219763893|NCT06285890|DRUG|HC-7366|Given by PO
219763894|NCT04723836|DIETARY_SUPPLEMENT|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
218830676|NCT02647476|DIETARY_SUPPLEMENT|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
218830677|NCT02647476|DIETARY_SUPPLEMENT|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
218830678|NCT00833443|DRUG|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
218830679|NCT03111212|DRUG|Iloprost|Iloprost nebulized
219439356|NCT00981747|DRUG|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
219763895|NCT04723836|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
219763896|NCT04723836|DIETARY_SUPPLEMENT|Placebo|From 16th week gestation until end of pregnancy
219763897|NCT06477120|BEHAVIORAL|Time Restricted Eating|The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
219763898|NCT03019471|GENETIC|Isolation of tumor DNA|
219763899|NCT06424288|DRUG|vicadrostat|vicadrostat
219763900|NCT06424288|DRUG|empagliflozin|empagliflozin
219763901|NCT06424288|DRUG|Placebo|Placebo matching vicadrostat
219763902|NCT05051397|BIOLOGICAL|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
219763903|NCT05051397|BIOLOGICAL|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
219763904|NCT05313308|DRUG|Midazolam|Midazolam oromucosal solution
219763905|NCT05308966|OTHER|Data collection|Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
218830680|NCT03111212|DRUG|control|sodium chloride 0,9% nebulized
218830681|NCT02739958|DRUG|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
218830682|NCT02739958|DRUG|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
218830683|NCT00426803|DRUG|activated recombinant human factor VII|
218830684|NCT04061109|DRUG|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
218830685|NCT02328521|DRUG|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
218830686|NCT02328521|DRUG|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
218830687|NCT02176629|OTHER|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
218830688|NCT02176629|OTHER|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
218830689|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
218830690|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
218830691|NCT00283543|DRUG|Gliadel Wafer|
218830692|NCT00283543|DRUG|Temozolomide|
218830693|NCT00283543|PROCEDURE|Limited field radiation|
218830694|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
218830695|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
218830696|NCT00514930|DEVICE|Hexablate|
218830697|NCT04734262|DRUG|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
219013501|NCT04020679|BEHAVIORAL|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
219013502|NCT06113432|DIAGNOSTIC_TEST|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
219013503|NCT06113432|DIAGNOSTIC_TEST|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
218830698|NCT04734262|DRUG|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
219013504|NCT06113432|DIAGNOSTIC_TEST|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
219439357|NCT00981747|DRUG|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
219476520|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
218830699|NCT04734262|DRUG|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
218830700|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
218830701|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
218830702|NCT03161210|OTHER|Saline|Saline is a control group
218830703|NCT00208065|DRUG|almotriptan or pseudoephedrine|
218830704|NCT02137447|DEVICE|Negative Pressure treatment|
218830705|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
218830706|NCT03467256|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
218830707|NCT03467256|DRUG|Fludarabine|given IV
218830708|NCT03467256|DRUG|Cyclophosphamide|given IV
218830709|NCT03467256|DRUG|Tocilizumab|given IV
218830710|NCT03467256|DRUG|Cytarabine|given IV
218830711|NCT03467256|DRUG|Etoposide|given IV
218830712|NCT03467256|DRUG|Dexamethasone|given IV
218830713|NCT03806530|DRUG|Gabapentin|100 mg capsule
218830714|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
218830715|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
218830716|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
218830717|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
218830718|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
218830719|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
218830720|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
218830721|NCT06283277|DEVICE|Obstetric Ultrasound|Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
218830722|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
218830723|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
218830724|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
218830725|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
219013505|NCT06113432|DIAGNOSTIC_TEST|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
219763906|NCT06072638|BEHAVIORAL|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
219763907|NCT02133196|DRUG|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
219763908|NCT02133196|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
218830726|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
218830727|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
218830728|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
218830729|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
219439358|NCT00981747|DRUG|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
219439359|NCT00981747|DRUG|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
219439360|NCT03114098|OTHER|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
219439361|NCT01606397|DRUG|Placebo|Administered orally (capsule)
219439362|NCT01606397|DRUG|LY2409021|Administered orally (capsule)
219439363|NCT02228824|DRUG|Very low nicotine content cigarettes|0.07 mg nicotine delivery
219439364|NCT02228824|DRUG|Normal nicotine content cigarettes|0.8 mg nicotine delivery
219439365|NCT05317260|DRUG|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
219439366|NCT00647946|DRUG|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
219439367|NCT00647946|DRUG|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
219439368|NCT02521857|DRUG|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
219439369|NCT00309257|DRUG|ACE I, ATA II and Statins|
219763909|NCT02133196|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
219763910|NCT02133196|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
219763911|NCT06498635|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763912|NCT06498635|PROCEDURE|Computed Tomography|Undergo CT
219763913|NCT06498635|BIOLOGICAL|Durvalumab|Given IV
219763914|NCT06498635|OTHER|Patient Observation|Undergo active surveillance
219763915|NCT06498635|OTHER|Questionnaire Administration|Ancillary studies
219763916|NCT05401227|DRUG|Ketamine|Ketamine during an MRI
219013506|NCT06113432|DIAGNOSTIC_TEST|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
219013507|NCT06113432|DIAGNOSTIC_TEST|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
219439370|NCT00309257|DRUG|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
219439371|NCT01960829|DRUG|Everolimus|
219439372|NCT03962946|OTHER|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
219439373|NCT03962946|OTHER|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
219439374|NCT00377104|DRUG|alvocidib|Given IV
219439375|NCT00377104|OTHER|pharmacological study|Correlative studies
219439376|NCT00377104|OTHER|laboratory biomarker analysis|Correlative studies
219439377|NCT01320969|BEHAVIORAL|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
219476521|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
219476522|NCT02839213|DRUG|Hyoscine Butyl bromide|
219476523|NCT02839213|DRUG|Saline|
219763917|NCT05401227|DRUG|Ts-134|4 days of TS-134 20 mg
219763918|NCT05401227|DRUG|Placebo|4 days of placebo TS-134
219439378|NCT04218604|PROCEDURE|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
219439379|NCT03339401|OTHER|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
219439380|NCT03339401|DRUG|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
219580831|NCT03914950|DIAGNOSTIC_TEST|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
219580832|NCT04101500|DRUG|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
218830730|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
218830731|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
218830732|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
218830733|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
218830734|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
218830735|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
219013508|NCT06113432|DIAGNOSTIC_TEST|Noninvasive blood pressure|Noninvasive blood pressure
219013509|NCT06113432|DIAGNOSTIC_TEST|Heart rate|Heart rate calculation using electrocardiogram monitoring
219439381|NCT03271307|BEHAVIORAL|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
219439382|NCT03271307|DIAGNOSTIC_TEST|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
219439383|NCT03271307|DIAGNOSTIC_TEST|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
219580833|NCT04101500|DRUG|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
219580834|NCT04101500|DRUG|Placebo Tablets|Applied only to the control group.
219763919|NCT03836495|DIETARY_SUPPLEMENT|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
219763920|NCT05526443|DRUG|all approved chemotherapeutic agents from second line|all approved chemotherapeutic agents from second line
219580835|NCT03365752|DRUG|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
219580836|NCT03365752|DRUG|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
218830736|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
219013510|NCT00524550|DIETARY_SUPPLEMENT|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
219013511|NCT00082654|PROCEDURE|psychosocial assessment and care|
219013512|NCT00527007|OTHER|External cooling|External cooling
219580837|NCT03365752|DRUG|General Anesthetics|General anesthetics will be administered intravenously
219763921|NCT04632225|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
219763922|NCT04632225|OTHER|Placebo|Injectable liquid
219763923|NCT02592317|DRUG|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
219763924|NCT02592317|DRUG|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
219013513|NCT02647086|DRUG|Dupilumab|
219013514|NCT02647086|DRUG|Midazolam|Cytochrome P450 substrate
218830737|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
219439384|NCT02816437|BIOLOGICAL|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
219439385|NCT01043783|OTHER|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
219439386|NCT03365947|DRUG|ARO-HBV|sc injection
219439387|NCT03365947|OTHER|Sterile Normal Saline (0.9% NaCl)|sc injection
219439388|NCT03365947|DRUG|JNJ-56136379|oral tablets
219439389|NCT00190645|DRUG|Duloxetine|
219439390|NCT04459494|PROCEDURE|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
219439391|NCT04459494|PROCEDURE|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
219439392|NCT02932644|OTHER|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
219439393|NCT02932644|OTHER|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
219580838|NCT04866732|BEHAVIORAL|Physical Activity Cardiac Health Program|The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
219580839|NCT02655744|RADIATION|Standard treatment protocol with combined chemoradiation|
219763925|NCT02592317|DRUG|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
219580840|NCT03063840|DEVICE|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
219580841|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
218830738|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
218830739|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
218830740|NCT02676947|DRUG|Tocilizumab|
218830741|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
218830742|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
218830743|NCT02472587|OTHER|Questionnaire|
218830744|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
218830745|NCT00161915|DRUG|Fibrin Sealant|
218830746|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
218830747|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
218830748|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
218830749|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
218830750|NCT06125184|DRUG|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
218830751|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
218830752|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
218830753|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
218830754|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
218830755|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
218830756|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
219013515|NCT02647086|DRUG|Omeprazole|Cytochrome P450 substrate
219013516|NCT02647086|DRUG|Warfarin|Cytochrome P450 substrate
219013517|NCT02647086|DRUG|Caffeine|Cytochrome P450 substrate
219013518|NCT02647086|DRUG|Metoprolol|Cytochrome P450 substrate
218830757|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
219439394|NCT03698422|DIAGNOSTIC_TEST|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
219439395|NCT04506944|OTHER|No intervention|No specific exposure is explored.
219439396|NCT05477225|DEVICE|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
219580842|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
219580843|NCT01335386|DRUG|KLYX|
219580844|NCT01335386|DRUG|Glycerine|
219580845|NCT05344430|PROCEDURE|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
219580846|NCT04727814|OTHER|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
218830758|NCT01737762|BIOLOGICAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
218830759|NCT01737762|BIOLOGICAL|Vehicle|
218830760|NCT01525823|DRUG|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
218830761|NCT01525823|DRUG|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
218830762|NCT03301337|DIETARY_SUPPLEMENT|Meat protein absorption|Meat protein absorption when digested together with a full meal.
218830763|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
218830764|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
218830765|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
219013519|NCT01132482|DRUG|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
219013520|NCT01132482|DRUG|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
219439397|NCT05477225|DEVICE|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
219439398|NCT01482468|DRUG|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
219580847|NCT00398996|DRUG|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
219580848|NCT06478264|DRUG|Etoposide|100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
219580849|NCT06478264|DRUG|Cisplatin|25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
219763926|NCT02592317|DRUG|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
218830766|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
218830767|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
218830768|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
218830769|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
219013521|NCT04025658|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
219013522|NCT01837979|PROCEDURE|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
219013523|NCT04623918|OTHER|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
219013524|NCT04623918|OTHER|Control rice|Control rice (C4), identical in appearance
219196015|NCT06855108|DRUG|Caffeine citrate oral solution|Caffeine citrate oral solution will be used and administered by enteral route (oral or by gavage tube). The loading dose (20 mg/kg) will be administered once followed by daily doses of 10 mg per kg body weight every 24 hours for two doses. The study Standard Operating Procedures (SOPs) includes details regarding caffeine preparation based on the participant's body weight.
219196016|NCT06855108|DRUG|Oral placebo solution|Identical placebo oral solution
219580850|NCT06478264|DRUG|Carboplatin|Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
219013525|NCT04278547|DIAGNOSTIC_TEST|ELISPOT IFN-γ assay|"ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available."
219013526|NCT03348020|PROCEDURE|Blood Donation|Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
219013527|NCT01578395|RADIATION|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
219013528|NCT01578395|RADIATION|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
219013529|NCT01578395|OTHER|No radiation exposure|Subjects not undergoing any radiation exposure
219013530|NCT04102215|DEVICE|HEARO|Robotic system for otological procedures
219196017|NCT06853743|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Nicotinamide riboside, 2 capsules of 500mg taken twice daily for 2 years
219439399|NCT01482468|DRUG|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
218830770|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
218830771|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
219013531|NCT04102215|DEVICE|OTOPLAN|Otological surgical planning software
219013532|NCT03130166|PROCEDURE|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
219013533|NCT03130166|PROCEDURE|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
219013534|NCT05584644|DRUG|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
219013535|NCT05584644|DRUG|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
219196018|NCT06853743|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 capsules twice daily for 2 years
219196019|NCT06854146|DIAGNOSTIC_TEST|gastric cancer|patients diagnosed with gastric cancer
219439400|NCT02620735|DEVICE|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
219439401|NCT02620735|BEHAVIORAL|Exercise Only|12 week exercise program
219439402|NCT02620735|BEHAVIORAL|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
219013536|NCT06219057|BEHAVIORAL|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
219013537|NCT03853447|DIAGNOSTIC_TEST|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
219013538|NCT02493608|DEVICE|scalpel|used to cut the abdominal wall.
219013539|NCT02493608|DEVICE|Diathermy|Diathermy used to cut , coagulate the tissue
219013540|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system
219013541|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
219013542|NCT01517009|DRUG|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
219013543|NCT01517009|DRUG|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
219196020|NCT06854146|DIAGNOSTIC_TEST|healthy|healthy participants
219196021|NCT06854250|PROCEDURE|Prostate cryoablation|Enrolled patients will receive prostate cryoablation within 6 months of starting androgen deprivation therapy.
219196022|NCT06854250|DRUG|Cyclophosphamide (CTX)|Enrolled patients will receive cyclophosphamide (50mg daily) one day after prostate cryoablation and continue for a total of six months.
219439403|NCT02620735|BEHAVIORAL|Health Coaching|10 over the phone health coaching sessions.
219439404|NCT04140539|BIOLOGICAL|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
219476524|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
219476525|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
218830772|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
218830773|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
218830774|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
218830775|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
219013544|NCT01517009|DRUG|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
219439405|NCT02853149|BEHAVIORAL|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
219439406|NCT02853149|BEHAVIORAL|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
219439407|NCT02853149|BEHAVIORAL|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
219439408|NCT01191281|BEHAVIORAL|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
219439409|NCT01191281|OTHER|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
219439410|NCT04042038|BEHAVIORAL|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
219439411|NCT06114030|PROCEDURE|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
219439412|NCT01674946|OTHER|saline|intraduodenal perfusion
219439413|NCT01674946|OTHER|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
219439414|NCT01674946|OTHER|oleanolic acid|intraduodenal perfusion
219439415|NCT01674946|DIETARY_SUPPLEMENT|oleic acid|intraduodenal perfusion
219439416|NCT01674192|DRUG|prucalopride|single dose of 2 mg prucalopride
219439417|NCT01676441|DRUG|cellgram-spine|Mesenchymal stem cells transplantation
219439418|NCT03626480|OTHER|No treatment|No treatment
219439419|NCT00004041|BIOLOGICAL|Ad5CMV-p53 gene|
219439420|NCT00004041|PROCEDURE|conventional surgery|
219439421|NCT04165005|BEHAVIORAL|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
219439422|NCT04165005|BEHAVIORAL|guided imagery|relaxing guided imagery including breathing exercises.
219439423|NCT03815812|DRUG|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
219439424|NCT03815812|DRUG|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
219013545|NCT01517009|PROCEDURE|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
219013546|NCT00854074|DEVICE|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
219013547|NCT04079153|DEVICE|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
219013548|NCT00049101|DRUG|erlotinib hydrochloride|
219013549|NCT00049101|DRUG|fluorouracil|
219013550|NCT00049101|DRUG|leucovorin calcium|
219013551|NCT00049101|DRUG|oxaliplatin|
219439425|NCT02899260|DEVICE|Peanut Exercise Ball|A Peanut shaped exercise ball.
218830776|NCT04062084|DEVICE|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
218830777|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
219439426|NCT04018612|DRUG|Acetaminophen|Acetaminophen is an analgesic and antipyretic
219439427|NCT04018612|OTHER|Placebo|Saline
219439428|NCT01651312|DRUG|14C-labeled YM178|oral solution (1.85 MBq)
219439429|NCT01915095|DEVICE|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
218830778|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
218830779|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
218830780|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
218830781|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
218830782|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
218830783|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
218830784|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
218830785|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
218830786|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
218830787|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
218830788|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
218830789|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
218830790|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
218830791|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
218830792|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
218830793|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
218830794|NCT03328832|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
218830795|NCT03328832|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
218830796|NCT03328832|DRUG|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
218830797|NCT03480984|OTHER|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
218830798|NCT03480984|OTHER|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
218830799|NCT00132301|DRUG|Docetaxel|Chemotherapy agent
218830800|NCT00132301|DRUG|Prednisone|steroid in combination with chemotherapy agent
219013552|NCT01462721|DEVICE|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
219439430|NCT01915095|DEVICE|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
219439431|NCT01915095|OTHER|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
219763927|NCT03253744|DRUG|18F-DCFPyL|Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
218830801|NCT01288157|DRUG|Golimumab|Single dose of 100 mg subcutaneously
219763928|NCT03253744|RADIATION|Tumor Irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.
218830802|NCT01288157|DRUG|Golimumab|Single dose of 50 mg subcutaneously
218830803|NCT01043718|BEHAVIORAL|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
218830804|NCT01043718|BEHAVIORAL|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
218830805|NCT03186625|DRUG|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
218830806|NCT03186625|DRUG|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
218830807|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
218830808|NCT02903693|OTHER|cross sectional|
218830809|NCT02193997|OTHER|Fiber|
218830810|NCT02193997|OTHER|Fiber|
218830811|NCT02193997|OTHER|Placebo|
218830812|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
218830813|NCT01265017|DRUG|Estradiol, medroxyprogesterone, hydrocortisone, GH|"* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,"
218830814|NCT01265017|DRUG|Matching placebo|matching placebo
218830815|NCT00836771|DIETARY_SUPPLEMENT|Infant Formula|
218830816|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
218830817|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
219013553|NCT02695745|DRUG|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
218830818|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
218830819|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
218830820|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
218830821|NCT02746328|DRUG|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
219013554|NCT02695745|DRUG|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
219763929|NCT03253744|RADIATION|Prostate + tumor irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.
218830822|NCT04042454|OTHER|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
218830823|NCT04042454|OTHER|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
218830824|NCT04118543|OTHER|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
218830825|NCT04118543|OTHER|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
219013555|NCT02695745|DRUG|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
219013556|NCT02695745|DRUG|Capsaicin|1% administered topically
219013557|NCT04086290|PROCEDURE|RARP|Radical prostatectomy + extended pelvic lymph node dissection
219013558|NCT04086290|RADIATION|SBRT|Stereotactic body radiotherapy to osseous lesions
219013559|NCT04086290|DRUG|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
219013560|NCT04358887|PROCEDURE|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
219013561|NCT04358887|PROCEDURE|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
219013562|NCT03287167|DRUG|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
219013563|NCT03287167|DRUG|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
218830826|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
218830827|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
218830828|NCT02720523|DRUG|Placebo|Tablet; Oral
218830829|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
218830830|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
218830831|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
218830832|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
218830833|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
218830834|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
218830835|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
218830836|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
218830837|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
219013564|NCT02190227|DEVICE|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
219439432|NCT01915095|OTHER|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
219439433|NCT01911208|BEHAVIORAL|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
219439434|NCT01911208|BEHAVIORAL|Control|Non-intervention control.
218830838|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
218830839|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
219013565|NCT05128877|OTHER|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
219013566|NCT05757921|DEVICE|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
218830840|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
218830841|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
218830842|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218830843|NCT05778994|DEVICE|INTORUS|Exercise protocol with intorus
218830844|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
218830845|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
218830846|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
218830847|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
218830848|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
219013567|NCT05757921|OTHER|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
219013568|NCT00010465|PROCEDURE|Craniosacral Osteopathic Manipulative Treatment|
219013569|NCT00010465|DRUG|Botanicals|
219439435|NCT02537223|DRUG|BYL719|
219439436|NCT02537223|DRUG|Cisplatin|
219439437|NCT02537223|RADIATION|Intensity modulated radiation therapy (IMRT)|
219439438|NCT06396455|PROCEDURE|interscalene block group|The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
219476526|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
219476527|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
219580851|NCT06478264|DRUG|Adebrelimab|1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
219476528|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
219763930|NCT03253744|RADIATION|Tumor Irradiation|External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
219763931|NCT06522893|OTHER|Electrical Dry Needling and Therapeutic exercise|The group receiving dry needling combined with therapeutic exercise (n=35) will receive up to 6 sessions of stimulation at the active trigger points in the cervical region, according to Travell and Simons: occipitofrontalis, sternocleidomastoid, splenius capitis, anterior, middle, and posterior scalene muscles, upper, middle, and lower trapezius, and multifidus at the C6 level, bilaterally, once a week for 3 weeks. Using ultrasound guidance, 0.25 mm x 25 mm needles will be inserted into the active trigger points. The needles will be connected to a TENS (transcutaneous electrical nerve stimulation) device (TensMed S82-Enraf Nonius), applying an asymmetric biphasic square wave current, low frequency (2 Hz), pulse duration of 250 μs, for 30 minutes. In addition, this group will perform a protocol of specific therapeutic exercises for the cervical spine during the same electropuncture session and immediately afterward.
218830849|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
219013570|NCT00000278|DRUG|Disulfiram|
219476529|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
219580852|NCT06478264|RADIATION|radiotherapy|Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.
219580853|NCT01965470|OTHER|Combination Prevention|
219013571|NCT02976623|OTHER|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
219013572|NCT00312091|DRUG|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
219013573|NCT00312091|DRUG|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
219013574|NCT00312091|DRUG|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
219580854|NCT01965470|OTHER|Enhanced Care|
219580855|NCT02953470|BEHAVIORAL|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
219580856|NCT02953470|BEHAVIORAL|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
219580857|NCT02865252|OTHER|MWM Treatment|
219580858|NCT02865252|OTHER|MWM Sham|
219580859|NCT02575911|DEVICE|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
219580860|NCT02575911|PROCEDURE|LASIK surgery|
219580861|NCT01330771|DRUG|hMG-HP/r-FSH|
219580862|NCT02589483|PROCEDURE|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
219580863|NCT02589483|DEVICE|Hemopatch|The rectal anastomosis reinforced with Hemopatch
219580864|NCT05418166|DRUG|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
219580865|NCT01249365|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
219580866|NCT03069950|DRUG|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
219580867|NCT03069950|DRUG|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
219580868|NCT03069950|DRUG|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
219580869|NCT03069950|DRUG|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
219580870|NCT03069950|DRUG|DEXAMETHASONE|flat dose of 25 mg on Day 1
219580871|NCT03069950|DRUG|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
219580872|NCT00003851|BIOLOGICAL|proteolytic enzymes|
219580873|NCT00003851|DRUG|gemcitabine hydrochloride|
219580874|NCT00003851|PROCEDURE|Gonzalez regimen|
219580875|NCT04402775|OTHER|Tourniquet|A tourniquet will be used during surgery
219580876|NCT03074773|DRUG|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
219580877|NCT03074773|DEVICE|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
219580878|NCT03074773|PROCEDURE|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
219580879|NCT03074773|DRUG|Bupivacaine|it is an amino amide local anesthetic drug
219013575|NCT00312091|DRUG|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
219013576|NCT04178746|DEVICE|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
219013577|NCT03345667|DRUG|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
219013578|NCT03025061|OTHER|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
219013579|NCT06847698|DRUG|AVR-48|Investigational drug reconstituted in normal saline will be administered via IV
219439439|NCT06396455|PROCEDURE|Suprascapular nerve block group|After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
218830850|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
218830851|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
218830852|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
219013580|NCT06847698|DRUG|Placebo|Normal saline will be administered via IV
219013581|NCT01109225|BIOLOGICAL|blood sample|
219013582|NCT01109225|PROCEDURE|MRI|
219013583|NCT01109225|PROCEDURE|echocardiography|
219013584|NCT01109225|BIOLOGICAL|urine sample|
219013585|NCT01109225|PROCEDURE|pulmonary echography|
219013586|NCT01109225|PROCEDURE|vascular check|
219013587|NCT01109225|PROCEDURE|renal echography|
219763932|NCT06522893|OTHER|Therapeutic exercise|The therapeutic exercise group (n=35) will perform progressive exercises for the cervical flexor and extensor muscles, once a week for 6 weeks (12 sessions in total). The protocol includes activation and recruitment of the deep cervical flexor muscles, isometric co-contraction exercises for both deep and superficial flexors, and eccentric and isokinetic exercises for both flexors and extensors. Each week's session will include the exercises for that week, along with the exercises from previous weeks, as detailed in the specific cervical spine exercise table, which indicates sets, repetitions, contraction time, and rest periods.
218830853|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
218830854|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
218830855|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
218830856|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
219013588|NCT04159233|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
219013589|NCT04328324|PROCEDURE|Endoscopy|Diagnostic upper Git endoscopy
219013590|NCT02681120|PROCEDURE|Biopsy|
219013591|NCT02681120|PROCEDURE|Blood draw|
219013592|NCT02681120|PROCEDURE|Mammogram|
219013593|NCT02681120|PROCEDURE|MRI|
219013594|NCT01995084|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
219013595|NCT03733288|BEHAVIORAL|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
219013596|NCT03733288|BEHAVIORAL|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
219439440|NCT00044655|DRUG|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
219439441|NCT00044655|DRUG|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
219439442|NCT00044655|DRUG|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
219439443|NCT00044655|DRUG|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
219439444|NCT00044655|DRUG|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
219439445|NCT04593836|DRUG|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
219439446|NCT04593836|DRUG|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
219439447|NCT02067533|PROCEDURE|soft tissue repair in flexion position|
219439448|NCT02067533|PROCEDURE|soft tissue repair in extension position|
219439449|NCT05560152|DRUG|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
219439450|NCT03489070|COMBINATION_PRODUCT|Traumastem®|Intraoperative application as secondary hemostatic treatment
219439451|NCT03489070|COMBINATION_PRODUCT|Surgicel®|Intraoperative application as secondary hemostatic treatment
219439452|NCT02213549|DIETARY_SUPPLEMENT|Placebo|
219439453|NCT02213549|DIETARY_SUPPLEMENT|Ume paste and ginger powder|
219439454|NCT01983878|DRUG|Ramucirumab|Administered IV
219439455|NCT02087293|BEHAVIORAL|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
219439456|NCT01873807|DRUG|IDA|Idarubicin: 15mg/m2/d: -8-\>-6d
219439457|NCT01873807|RADIATION|TBI|TBI: 4.5 Gy/d, -5d, -4d
218830857|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
218830858|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
218830859|NCT04940468|OTHER|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
218830860|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
218830861|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
218830862|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
218830863|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
218830864|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
218830865|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
218830866|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
218830867|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
218830868|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
218830869|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
218830870|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
218830871|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
218830872|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
218830873|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
218830874|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
218830875|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
218830876|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
218830877|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
219439458|NCT01873807|DRUG|CTX|CY:60mg/kg/d, -3d, -2d
219439459|NCT01873807|DRUG|VP-16|VP-16: 15mg/kg, -2d, -1d
219439460|NCT04854577|PROCEDURE|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
219439461|NCT04854577|PROCEDURE|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
219439462|NCT01693497|BEHAVIORAL|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
219439463|NCT01693497|BEHAVIORAL|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
219439464|NCT00639496|DRUG|n-acetylcysteine|600 mg x 3, for 12 months
219439465|NCT00639496|DRUG|placebo|Placebo
219439466|NCT02024945|DRUG|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
219439467|NCT03063398|DIAGNOSTIC_TEST|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
219439468|NCT05702398|DRUG|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
219439469|NCT05702398|DRUG|Nicotinamide|500 mg NAM twice a day for 6 months
219439470|NCT05702398|OTHER|Other: Placebo|Identical placebo pills twice a day
219439471|NCT03454945|DRUG|Vibramycin|Antibiotic
219439472|NCT03454945|DEVICE|Phototherapy|UVA+Psoralen
219439473|NCT06134869|PROCEDURE|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
219439474|NCT00004898|BIOLOGICAL|filgrastim|
219439475|NCT00004898|DRUG|cyclophosphamide|
219439476|NCT00004898|DRUG|etoposide|
219439477|NCT00004898|PROCEDURE|peripheral blood stem cell transplantation|
219580880|NCT03074773|OTHER|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
218830878|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
218830879|NCT02725905|BEHAVIORAL|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
218830880|NCT02725905|BEHAVIORAL|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
218830881|NCT04821934|OTHER|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
218830882|NCT04821934|OTHER|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
218830883|NCT00648258|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
218830884|NCT00648258|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
218830885|NCT00003935|DRUG|etoposide|
218830886|NCT00003935|DRUG|vincristine sulfate|
218830887|NCT00003935|RADIATION|radiation therapy|
218830888|NCT00137059|DRUG|acetaminophen sustained-release|
218830889|NCT00572598|DRUG|4- [F-18] fluoropaclitaxel|4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
218830890|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
218830891|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
218830892|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
218830893|NCT02881775|DEVICE|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
218830894|NCT02881775|DEVICE|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
219439478|NCT00004898|RADIATION|radiation therapy|
219439479|NCT01907776|DRUG|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
219439480|NCT01907776|DRUG|ME1100 placebo inhalation solution|Vehicle placebo
219439481|NCT01670682|PROCEDURE|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
219439482|NCT01670682|PROCEDURE|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
219439483|NCT01670682|DEVICE|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
219439484|NCT04657445|DIAGNOSTIC_TEST|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
219439485|NCT05954260|DIAGNOSTIC_TEST|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
219580881|NCT03900065|PROCEDURE|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
219013597|NCT03733288|BEHAVIORAL|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
219013598|NCT03733288|DEVICE|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
219013599|NCT05778396|PROCEDURE|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
219196023|NCT06854796|DEVICE|Recombinant collagen gel|The test device uses a recombinant collagen gel developed by Shaanxi Juzi Biotechnology Co., Ltd., which is different from other designs. The main components of recombinant collagen gel are recombinant collagen, disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, water for injection, after the injection, collagen can occupy a place at the injection site to improve the visual aging caused by soft tissue loss, wrinkles and depressions, and the special manufacturing process can ensure that the gel has smoothness and ductility, which helps to achieve a smooth and natural appearance, effectively and gradually improve wrinkles and plump cheeks.
219439486|NCT03343782|COMBINATION_PRODUCT|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
219439487|NCT05522296|DRUG|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
219763933|NCT06127316|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthoses (CDOs) used in this study will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee. The CDO will be modular in design which will allow three carbon fiber struts of the same stiffness and differing lengths to be used to implement 0cm, 1cm, and 2cm levels of heel distraction height. A longer posterior strut will move the carbon fiber footplate away from the participants foot to create the heel distraction height.
218830895|NCT05925348|DIAGNOSTIC_TEST|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
218830896|NCT01654939|DRUG|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
218830897|NCT01634217|BIOLOGICAL|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
218830898|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
218830899|NCT05088044|OTHER|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
218830900|NCT01224886|BEHAVIORAL|Physical activity|Supervised exercise intervention
218830901|NCT06324474|DRUG|Hyaluronic acid|Gengigel syringe containing 1ml of 0.8% HA
218830902|NCT06324474|BEHAVIORAL|scaling and root planning|scaling and root planning using ultrasonic scaler
219439488|NCT02081560|DRUG|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
219439489|NCT01577004|DIETARY_SUPPLEMENT|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
219476530|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging|Participants in the harm messaging arm will receive messages about the 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking.
218830903|NCT06290388|DRUG|23ME-01473|23Me-01473 given by intravenous infusion
218830904|NCT03929913|DEVICE|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
218830905|NCT02294032|DRUG|Immunosuppressive Agents|standard of care for patients post-transplant
219476531|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging Contextualized to Outcome Expectancies|Participants in the harm messaging contextualized to outcome expectancies arm will receive messages about the health harm and nicotine addiction risks of cigarillo smoking (i.e., 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking) contextualized to one of the following themes: 1) smoking sensory experience, 2) anticipated pleasure, relaxation, and satisfaction from smoking, 3) social persona/admiration related to smoking, and 4) that smoking does not align with personal values and authenticity.
219763934|NCT03204825|DEVICE|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
218830906|NCT03961802|OTHER|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
218830907|NCT01154452|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
218830908|NCT01154452|OTHER|Laboratory Biomarker Analysis|Correlative studies
218830909|NCT01154452|OTHER|Pharmacological Study|Correlative studies
219013600|NCT05778396|PROCEDURE|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
219013601|NCT02007018|DEVICE|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
219013602|NCT02007018|OTHER|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
219013603|NCT06506227|BEHAVIORAL|Low risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine
219013604|NCT06506227|BEHAVIORAL|Medium risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
219013605|NCT06506227|GENETIC|High risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
219013606|NCT06506227|BEHAVIORAL|Control group COBB 10-20°|Specific Exercise Therapy
219013607|NCT06506227|BEHAVIORAL|Control group COBB 20-45°|Orthopedic Braces + Specific Exercise Therapy
219013608|NCT06506227|BEHAVIORAL|Control group COBB >45°|Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
219013609|NCT06506227|OTHER|Experimental group (AIS group)|Molecular marker exploration and validation
219013610|NCT06506227|OTHER|Control group (healthy control)|Molecular marker exploration and validation
219013611|NCT06506227|OTHER|Controlled follow-up before and after AIS|Construction and validation of AIS risk prediction model completed
219013612|NCT04954274|DRUG|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
219013613|NCT00705081|DRUG|ezetimibe|10 mg once daily
219013614|NCT00705081|DRUG|statin|
219013615|NCT02988921|DEVICE|MRI and CT|
219013616|NCT02988921|RADIATION|Ratiotherapy|
219013617|NCT02988921|DRUG|Paclitaxel, platinum-based drug|
219013618|NCT01290640|DEVICE|DePuy fixed-bearing Total Condylar III (TC3) TKA|
219013619|NCT01290640|DEVICE|DePuy PFC Rotating Platform TC3 TKA|
219013620|NCT01170507|DRUG|vitamin D3 1000 IU orally daily for 5 months|
219013621|NCT01170507|DRUG|vitamin D3 3000 IU orally daily for 5 months|
219013622|NCT01170507|DRUG|vitamin D3 5000 IU orally daily for 5 months|
219013623|NCT01170507|DRUG|Placebo orally daily for 5 months|
219013624|NCT06107712|OTHER|Online yoga exercise|"The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week."
218830910|NCT01154452|DRUG|Vismodegib|Given PO
218830911|NCT05949918|BEHAVIORAL|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
219476532|NCT06861673|DEVICE|Pulmonary vein isolation|concomitant PVI and LAAC
218830912|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
218830913|NCT04073901|OTHER|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
219763935|NCT03204825|BEHAVIORAL|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
219763936|NCT03204825|DEVICE|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
219763937|NCT06975787|DRUG|Vonsetamig|Administered as per the protocol
219763938|NCT06975787|DRUG|Odronextamab|Administered as per the protocol
219763939|NCT05072691|DIAGNOSTIC_TEST|CSF immunoglobulin (Ig) free light chains (FLC) dosage|CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
218830914|NCT02932826|BIOLOGICAL|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
218830915|NCT02932826|DRUG|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
218830916|NCT03381287|DRUG|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
218830917|NCT03381287|DRUG|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
218830918|NCT03381287|DRUG|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
218830919|NCT03381287|DRUG|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
218830920|NCT03381287|DRUG|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
219013625|NCT06107712|OTHER|Face-to-face yoga exercise|"The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath."
219476533|NCT07000526|DRUG|Isoflurane|Inhaled sedation with isoflurane via Sedaconda ACD-S
219476534|NCT07000526|DRUG|Propofol|Intravenous sedation with Propofol 20 mg/ml
219763940|NCT06312176|DRUG|Sacituzumab tirumotecan|IV infusion
218830921|NCT03381287|DRUG|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
218830922|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
218830923|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
218830924|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
218830925|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
218830926|NCT02847169|DEVICE|filcon IV1 toric lens|toric contact lens
218830927|NCT02847169|DEVICE|ocufilcon D toric lens|toric contact lens
218830928|NCT03359369|DIAGNOSTIC_TEST|level of serum cholesterol and triglyceride|other
218830929|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
218830930|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
218830931|NCT05086965|OTHER|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
218830932|NCT01837680|DRUG|Insulin|
218830933|NCT02544347|OTHER|gingival crevicular fluid|gingival crevicular fluid was collected
218830934|NCT02544347|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
218830935|NCT00788060|DRUG|Everolimus (RAD001)|5mg per day, continuously
218830936|NCT00788060|DRUG|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
218830937|NCT02276742|BEHAVIORAL|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
219763941|NCT06312176|BIOLOGICAL|Pembrolizumab|IV infusion
219763942|NCT06312176|DRUG|Paclitaxel|IV infusion
219763943|NCT06312176|DRUG|Nab-paclitaxel|IV infusion
219763944|NCT06312176|DRUG|Capecitabine|oral tablet
219763945|NCT06312176|DRUG|Liposomal doxorubicin|IV infusion
219763946|NCT05832281|DRUG|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
219763947|NCT05832281|DRUG|Placebo|Placebo for Purysis
218830938|NCT02276742|OTHER|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
218830939|NCT02612493|OTHER|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
218830940|NCT03128983|DEVICE|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
218830941|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
218830942|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
218830943|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
218830944|NCT04972266|DEVICE|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
219013626|NCT03117712|DIAGNOSTIC_TEST|Delirium Scores|"* Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5"
219439490|NCT05018169|BEHAVIORAL|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
219439491|NCT02333669|OTHER|no intervention|no intervention
219439492|NCT02671760|DRUG|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
218830945|NCT01471821|DRUG|antiretroviral treatment|antiretroviral treatment
219013627|NCT03117712|DIAGNOSTIC_TEST|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB"
219013628|NCT03117712|DIAGNOSTIC_TEST|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation"
219439493|NCT02671760|DRUG|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
219439494|NCT02671760|DRUG|Placebo|Placebo
219439495|NCT00138229|BIOLOGICAL|aldesleukin|
219439496|NCT00138229|BIOLOGICAL|filgrastim|
219763948|NCT06208605|BEHAVIORAL|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
219439497|NCT00138229|BIOLOGICAL|therapeutic autologous lymphocytes|
219439498|NCT00138229|DRUG|cyclophosphamide|
219439499|NCT00138229|DRUG|fludarabine phosphate|
219439500|NCT03966729|OTHER|Time (outcome)|
219763949|NCT06208605|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
219763950|NCT05245201|OTHER|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
218830946|NCT05409703|BEHAVIORAL|reiki therapy|reiki therapy for nurses
218830947|NCT06376864|BEHAVIORAL|Activity Breaks|The Activity Breaks intervention is a 5-minute Activity Breaks programme that allows classroom teachers of all ages and ability levels to lead simple movement activities within their classrooms, negating the need for additional personnel or space.
218830948|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
218830949|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
218830950|NCT06007027|DEVICE|SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy|The laser probe is gently inserted up to the top of the vagina, and subsequently withdrawn and rotated in order to deliver a complete treatment of the vaginal wall.
218830951|NCT00297739|DRUG|Risperidone|
219439501|NCT01611480|DRUG|Imiquimod (topical use)|
219439502|NCT02999191|DRUG|BI 1467335 (Treatment A)|
219439503|NCT02999191|DRUG|BI 1467335 (Treatment B)|
219439504|NCT02999191|DRUG|BI 1467335 (Treatment C)|
219439505|NCT00200512|DRUG|apomorphine HCl injection|
219439506|NCT01280019|PROCEDURE|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
219439507|NCT03777085|DRUG|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
219439508|NCT03777085|DRUG|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
218830952|NCT06619899|OTHER|PAP exercise with 0% body mass|The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.
218830953|NCT06619899|OTHER|PAP exercise with 20% body mass|Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass
218830954|NCT06619899|OTHER|No PAP exercise|No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.
218830955|NCT05750108|DEVICE|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
218830956|NCT05750108|DEVICE|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
218830957|NCT06709079|DRUG|Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)|Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
218830958|NCT06116981|OTHER|High Induction Magnetic Field Therapy|High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.
219439509|NCT06047106|RADIATION|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
219439510|NCT06047106|PROCEDURE|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
219439511|NCT06047106|BIOLOGICAL|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
219439512|NCT06047106|BIOLOGICAL|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
219439513|NCT05467488|PROCEDURE|photofunctionalization|UVA and UVC photofunctionalization of dental implants
219439514|NCT04269837|OTHER|Counseling|Receive sexual health counseling
219439515|NCT04269837|OTHER|Quality-of-Life Assessment|Ancillary studies
219763951|NCT05245201|OTHER|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
219763952|NCT04624659|DRUG|Etavopivat Tablets Low dose|200 mg once daily
218830959|NCT06116981|OTHER|Conservative Treatment|Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
218830960|NCT06718764|DEVICE|Neurosteer's single-channel EEG monitoring device|"Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters."
218830961|NCT06714942|DIETARY_SUPPLEMENT|Proprietary Blend of Ashwagandha|One capsule (300mg) is taken twice daily with water
218830962|NCT06714942|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha root extract|One capsule (300mg) is taken twice daily with water
218830963|NCT06714942|DIETARY_SUPPLEMENT|Placebo|One capsule (300mg) is taken twice daily with water
218830964|NCT06716489|BEHAVIORAL|Aerobic exercise|Participants will undergo an aerobic exercise training program on a motorized treadmill at an intensity corresponding to 60-70% of their heart rate reserve (calculated by adding baseline heart rate to 60-70% of reserve heart rate). The program will last 16 weeks and will consist of three 1-hour, 10-minute sessions per week, divided into four phases: a 5-minute warm-up at an intensity below the target exercise heart rate (baseline + 30-40% of the reserve heart rate); a 50-minute main exercise session at the target exercise heart rate intensity; a 5-minute cool-down at an intensity below the target exercise heart rate; and a 10-minute relaxation and general stretching phase. This structured exercise protocol was designed to evaluate the effects of aerobic exercise on sensory perception, musculoskeletal alterations, and psychosocial factors in patients with migraine.
218830965|NCT06713031|PROCEDURE|cannulated compression screws + iliac bone graft|"Using cannulated compression screws + iliac bone graft technique to treat old femoral neck fractures"
219013629|NCT02054221|PROCEDURE|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
219013630|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
219439516|NCT04269837|OTHER|Questionnaire Administration|Ancillary studies
219439517|NCT03189407|DIETARY_SUPPLEMENT|Moringa oleifera tea|
219439518|NCT03358615|PROCEDURE|cesarean section|assessment of the indications of cesarean section according to Robson criteria
219439519|NCT05525832|OTHER|Normal saline|Nasopharyngeal washes with NaCl 0.9%
219439520|NCT02408185|DRUG|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
218830966|NCT06713031|PROCEDURE|DCS + medial support plate + iliac bone graft|"Using DCS + medial support plate + iliac bone graft technique to treat old femoral neck fractures"
219439521|NCT02408185|DRUG|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
219439522|NCT01090674|OTHER|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
218830967|NCT00775255|DRUG|clarithromycin 250 mg/5 mL powder for oral suspension|
218830968|NCT03672214|PROCEDURE|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
218830969|NCT03672214|PROCEDURE|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
218830970|NCT01852643|PROCEDURE|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
218830971|NCT01852643|PROCEDURE|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
218830972|NCT02348190|OTHER|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
219013631|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
219013632|NCT04518150|DEVICE|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
219013633|NCT04518150|PROCEDURE|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
219013634|NCT00873756|DRUG|FOLFOX regimen|Intravenous repeating dose
219013635|NCT00873756|DRUG|bevacizumab|Intravenous repeating dose
219013636|NCT00873756|DRUG|dulanermin|Intravenous repeating dose
219013637|NCT00546637|DRUG|Fesoterodine|Fesoterodine 4mg or 8mg
219013638|NCT00546637|DRUG|Placebo|Placebo
219013639|NCT01635972|DRUG|Isavuconazole|oral
219013640|NCT01635972|DRUG|bupropion hydrochloride|oral
219013641|NCT01606930|BEHAVIORAL|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
219439523|NCT05054231|OTHER|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
219196024|NCT06854796|DEVICE|collagen implant agent|1\. After the product is injected into the skin, the collagen implant forms a soft mesh structure through condensation, which can make up for skin defects. 2. After implantation of this product, the connective tissue cells around the implantation site will grow into the collagen network structure and gradually form a bionic structure similar to normal tissue. 3. This product is absorbable and degradable. The collagen implant will be gradually decomposed by protease in the body, and the pressure, elongation and hierarchy of the implant site tissue will affect the final degradation and duration.
219196025|NCT06855316|DEVICE|electromagnetic stimulation|After performing a high-intensity eccentric exercise session, participants will undergo a daily session of transcranial and/or peripheral magnetic stimulation for three days. The objective is to enhance nerve conduction, which, according to the latest theories on DOMS, may be the cause of decreased athletic performance
219196026|NCT06855017|OTHER|create a pillbox day|create a pillbox day based on two separate fictitious prescriptions
219763953|NCT04624659|DRUG|Etavopivat Tablets High dose|400 mg once daily
219763954|NCT04624659|DRUG|Placebo Tablets|Placebo once daily
219013642|NCT00300937|DIETARY_SUPPLEMENT|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
218859731|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
219013643|NCT02228785|BIOLOGICAL|G17DT|
219013644|NCT05853198|OTHER|ctDNA analysis|ctDNA amount and mutations analysis
219013645|NCT00703079|DRUG|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
219439524|NCT01883804|DRUG|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
219439525|NCT01297946|DEVICE|Conventional continuous subcutaneous insulin infusion therapy|
219439526|NCT01297946|DEVICE|Dual-hormone closed-loop|
219013646|NCT00703079|PROCEDURE|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
219439527|NCT00805012|DRUG|docetaxel+CDDP|docetaxel+CDDP
219439528|NCT00805012|DRUG|docetaxel+S-1|docetaxel+S-1
219763955|NCT04624659|DRUG|Etavopivat Tablets|Selected dose once daily
219763956|NCT06191744|DRUG|Epcoritamab|Subcutaneous (SC) Injection
219580882|NCT04905030|BEHAVIORAL|Information T1|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
219763957|NCT06191744|DRUG|Prednisone|Oral Tablet
219763958|NCT06191744|DRUG|Rituximab|Intravenous (IV) Infusion
219763959|NCT06191744|DRUG|Lenalidomide|Oral Capsule
219763960|NCT06191744|DRUG|Doxorubicin|IV Injection
218830973|NCT03874767|BEHAVIORAL|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
218830974|NCT03199833|DEVICE|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
218830975|NCT03199833|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
218830976|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
218830977|NCT05095298|DRUG|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
218859732|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
218859733|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
218859734|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
218859735|NCT04920721|OTHER|no intervention|no intervention descriptiv study
218859736|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
218859737|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
218859738|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
218859739|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
218859740|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
218859741|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
218859742|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
218859743|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
218859744|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
218859745|NCT02727556|BEHAVIORAL|visual images|
218859746|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
218859747|NCT01229943|DRUG|Everolimus|Given PO
218859748|NCT01229943|DRUG|Octreotide Acetate|Given IM
218859749|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
218830978|NCT04317144|BEHAVIORAL|Web-based follow-up programme.|Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
218830979|NCT04317144|BEHAVIORAL|No follow-up|"Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity."
218830980|NCT03919565|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
218830981|NCT03919565|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
218830982|NCT03919565|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
219013647|NCT04415255|OTHER|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
219013648|NCT04415255|OTHER|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
219013649|NCT03274440|DRUG|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
219013650|NCT03274440|OTHER|Placebo|Placebo control group, not receiving THC or CBD.
219013651|NCT03874897|DRUG|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
219013652|NCT03874897|DRUG|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
219013653|NCT03874897|DRUG|Chemotherapy|First-line systemic therapy according to physician's choice
219013654|NCT03817177|PROCEDURE|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
219439529|NCT05793684|DRUG|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
218830983|NCT02108886|DRUG|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
218830984|NCT02108886|DRUG|Placebo|empty capsule filled with sugar
218830985|NCT02108886|OTHER|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
218830986|NCT00894777|OTHER|Clinical record review|
219013655|NCT03817177|PROCEDURE|nasal prong|conventional nasal prong application in PACU
219013656|NCT04192877|DIAGNOSTIC_TEST|Vagus Nerve Neurodynamic test|The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
219013657|NCT00622960|OTHER|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
219013658|NCT00622960|OTHER|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
219439530|NCT05793684|DRUG|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
219439531|NCT05793684|DRUG|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
218830987|NCT06012630|DIAGNOSTIC_TEST|Ultarsound|Median nerve evaluation of participants with ultrasound
218830988|NCT02560220|BIOLOGICAL|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
219439532|NCT05826990|DRUG|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
219763961|NCT06191744|DRUG|Vincristine|IV Injection
218830989|NCT03280368|OTHER|Bloodtest|
219013659|NCT03165279|PROCEDURE|Zenith Alpha Abdominal stentgraft|
219196027|NCT06854211|DRUG|Morphine p.o.|Morphine 50mg PO will be given on sleep study night.
219196028|NCT06854211|DRUG|Placebo|Placebo will be given on the sleep study night.
219439533|NCT00220259|DRUG|Fluticasone or placebo|
219439534|NCT02597491|BEHAVIORAL|TLC monthly|Tobacco longitudinal care monthly
219439535|NCT02597491|BEHAVIORAL|TLC quarterly|Tobacco longitudinal care quarterly
219439536|NCT02597491|BEHAVIORAL|MTM|Medication management therapy
219439537|NCT02597491|BEHAVIORAL|4 week assessment|4 week assessment
219439538|NCT02597491|BEHAVIORAL|8 week assessment|8 week assessment
219763962|NCT06191744|DRUG|Cyclophosphamide|IV Injection
219763963|NCT06191744|DRUG|Obinutuzumab|IV Infusion
219196029|NCT06812676|DEVICE|Virtual Reality Goggles|The VR group will be given a VR headset to wear during the nasal endoscopic procedure at the clinic.
219439539|NCT03561246|OTHER|Incline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
219013660|NCT01433601|BEHAVIORAL|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
219439540|NCT03561246|OTHER|Decline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
219013661|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
218830990|NCT03280368|OTHER|Questionnaires|
219013662|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
219013663|NCT05540301|OTHER|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
219013664|NCT05540301|OTHER|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
219196030|NCT06811662|PROCEDURE|mitral valve replacement|complete versus partial preservation of subvavular apparatus during mitral valve replacement
219196031|NCT06813144|OTHER|inspiratory muscle exercise|Inspiratory muscle training will be given with or without smart adaptor.
219439541|NCT03561246|OTHER|Level Treadmill (Control)|Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
219439542|NCT03945448|DRUG|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
219439543|NCT03945448|DRUG|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
219580883|NCT04905030|BEHAVIORAL|Information T2|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
218830991|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
219013665|NCT06230068|OTHER|Expressive writing|See description under arm/group description.
219196032|NCT06420687|DEVICE|Clinically prescribed prosthesis|Clinically prescribed prosthesis:
219196033|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + 1-DOF|1-DOF wrist rotation and1-DOF hand
219580884|NCT04905030|BEHAVIORAL|Information C|A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
219763964|NCT06191744|DRUG|Bendamustine|IV Infusion
218830992|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
218830993|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
219196034|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF|2-DOF wrist (rotation and flexion) and 1-DOF hand
219196035|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Multi DOF hand|1-DOF wrist rotation and multi-DOF hand
219439544|NCT00292812|DRUG|Nutritional supplementation (nucleotides)|
219439545|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
219439546|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
219439547|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
219439548|NCT05537493|OTHER|Telerehabilitation|It will be followed by exercising on whatsapp
219439549|NCT05537493|OTHER|Face to face|It will be followed by face to face
219439550|NCT00410904|DRUG|cediranib maleate|
218830994|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
219013666|NCT04938557|DEVICE|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
219013667|NCT04938557|DEVICE|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
219196036|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand|2-DOF wrist (rotation and flexion) and multi-DOF hand
219196037|NCT06811792|PROCEDURE|Intrathecal Therapy|Patients who underwent at least one lumbar puncture and spinal canal administration of glucocorticoids during hospitalisation were classified as receiving intrathecal (IT) therapy. Dexamethasone was the glucocorticoid administered intrathecally at a dose of 5 mg per administration. All patients also received oral or intravenous anti-TB regimens, which included at least isoniazid and rifampicin for drug-sensitive TBM cases. Patients diagnosed with or suspected of having drug-resistant TBM who required second-line anti-TB drugs were excluded from the study.
219196038|NCT06812767|DIAGNOSTIC_TEST|electrocardiography|12 standard leads
218830995|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
218830996|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
218830997|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
218830998|NCT01780844|DRUG|ASKP1240|intravenous infusion
218830999|NCT01780844|DRUG|Tacrolimus|intravenous or oral
218831000|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
218831001|NCT01780844|DRUG|Basiliximab|intravenous
218831002|NCT01780844|DRUG|Methylprednisone|Intravenous
219013668|NCT04880512|DRUG|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
219013669|NCT04880512|DRUG|Placebo|Matching placebo, oral tablets, in fasted state
219013670|NCT02646280|OTHER|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
219013671|NCT02646280|OTHER|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
219013672|NCT03909412|DRUG|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
219013673|NCT03909412|DRUG|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
219439551|NCT00410904|DRUG|pemetrexed disodium|
219439552|NCT00544804|DRUG|lapatinib ditosylate|
219013674|NCT03909412|DRUG|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
219013675|NCT03909412|DRUG|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
219439553|NCT00544804|GENETIC|gene expression analysis|
219439554|NCT00544804|OTHER|diagnostic laboratory biomarker analysis|
219439555|NCT04703062|BEHAVIORAL|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
219580885|NCT04974866|DRUG|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
218831003|NCT01780844|DRUG|Prednisone|Oral
218831004|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
218831005|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
218831006|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
218831007|NCT00600275|DRUG|BGT226|
218831008|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
218831009|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
218831010|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
218831011|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
218831012|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
218831013|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
218831014|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
218831015|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
218831016|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
218831017|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
218831018|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
219013676|NCT05735392|OTHER|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
219013677|NCT00649701|BEHAVIORAL|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
219013678|NCT00649701|BEHAVIORAL|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
219013679|NCT00649701|BEHAVIORAL|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
219580886|NCT00517179|DRUG|Vardenafil 10mg|
219580887|NCT05291039|DRUG|Infliximab|group 1 (n=20): patients will receive IFX
219580888|NCT05291039|DRUG|Adalimumab|group 2 (n=20): patients will receive ADA
219580889|NCT04569396|DIAGNOSTIC_TEST|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
219580890|NCT04569396|DIAGNOSTIC_TEST|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
219580891|NCT04569396|OTHER|BMI measurement|BMI was measured among the study subjects before and after the surgery.
218831019|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
218831020|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
218831021|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
218831022|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
218831023|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
218831024|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
218831025|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
218831026|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
218831027|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
218831028|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
218831029|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
219013680|NCT00649701|BEHAVIORAL|Both Videos|Morning After and Talking About HIV videos
219013681|NCT04984993|DEVICE|MED3000 (Male)|Gel formulation
219013682|NCT04984993|DRUG|Tadalafil 5mg (Male)|Tablets
219196039|NCT06812767|DIAGNOSTIC_TEST|analysis for glucose and cholesterol in the capillary blood|express test
218831030|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
219196040|NCT06812767|DIAGNOSTIC_TEST|detection of microalbumuria|express test
218831031|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
218831032|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
218831033|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
218831034|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
218831035|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
219013683|NCT04984993|DEVICE|MED3000 (Female)|Gel formulation
219013684|NCT04984993|DRUG|Tadalafil 5mg (Female)|Tablets
219013685|NCT02402309|DRUG|Active topical NS2 1% dermatologic cream|
219013686|NCT02402309|DRUG|Vehicle placebo 0.0% NS2 dermatologic cream|
219013687|NCT02360956|DRUG|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
219196041|NCT06812767|DIAGNOSTIC_TEST|heart ultrasound examination|Ultrasound examination with Lumify Handheld S4-1 Phased Array Ultrasound (Philips)
219196042|NCT06812767|DIAGNOSTIC_TEST|carotid artery ultrasound examination|Ultrasound examination with Lumify Handheld L12-4 Linear Array Ultrasound (Philips)
219196043|NCT05236764|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
219196044|NCT06854978|OTHER|RETHA|The study will enroll up to 10 participants with stroke who will be paired with trained therapists to receive R3THA telerehabilitation. The participants with stroke will participate in 7 training sessions. The training includes hand and arm exercises.
218831036|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
218831037|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
218831038|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
218831039|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
219196045|NCT06806202|DRUG|conventional 2% lignocaine at room temperature|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
219439556|NCT04703062|BEHAVIORAL|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
219439557|NCT00535444|OTHER|Parish nurse visit|One visit with the parish nurse in 2 weeks
219439558|NCT04570969|PROCEDURE|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
219439559|NCT05878691|DRUG|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
219439560|NCT05878691|DRUG|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
219439561|NCT05878691|DRUG|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
219439562|NCT01769482|DRUG|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
219439563|NCT01769482|DRUG|placebo|
219439564|NCT00807014|DRUG|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
218831040|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
218831041|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
218831042|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
218831043|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
218831044|NCT00703742|DRUG|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
218831045|NCT00370266|DRUG|Triamcinolone|
218831046|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
218831047|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
218831048|NCT01087983|DRUG|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
218831049|NCT01087983|DRUG|Sirolimus|Starting oral dose 1 mg daily.
218831050|NCT01087983|DRUG|Metformin|Starting oral dose 1000 mg daily.
218831051|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
218831052|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
218831053|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
218831054|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
218831055|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
218831056|NCT02840253|DEVICE|NIRS|
218831057|NCT00473889|DRUG|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
218831058|NCT00473889|DRUG|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
218831059|NCT00473889|DRUG|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
218831060|NCT00473889|DRUG|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
218831061|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
218859750|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
218859751|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
218859752|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
218831062|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
218831063|NCT03153501|DIAGNOSTIC_TEST|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
218831064|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
218831065|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
218831066|NCT05433701|PROCEDURE|Radiofrequency Ablation|\- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
219013688|NCT02360956|DRUG|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
219013689|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
219013690|NCT06228378|OTHER|Raman microspectroscopy|Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
219013691|NCT02865187|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 600IU/day
219013692|NCT02865187|DRUG|Hormonal contraception|Hormonal contraceptives
219013693|NCT04751344|DRUG|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
219013694|NCT04751344|DRUG|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
219013695|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
219013696|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
218831067|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
218831068|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
219013697|NCT00067366|BEHAVIORAL|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
219013698|NCT00067366|BEHAVIORAL|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
218831069|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
219013699|NCT03311958|DRUG|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
219013700|NCT00144976|DRUG|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
219013701|NCT00256373|PROCEDURE|Mod. functional restoration-Individ. dynamic back-muscle|
219013702|NCT05041504|BEHAVIORAL|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
219013703|NCT05041504|OTHER|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
219013704|NCT01412346|OTHER|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
219013705|NCT04542655|OTHER|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
219013706|NCT04542655|OTHER|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
219013707|NCT04542655|OTHER|Rest|The participants undergo ergometer cycling, treadmill running and rest.
219196046|NCT06806202|DRUG|pre-warmed 2% lignocaine at 42°C|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
218831070|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
219013708|NCT01110707|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
218831071|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
218831072|NCT04199065|OTHER|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
218831073|NCT00337831|PROCEDURE|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
218831074|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
218831075|NCT05370274|PROCEDURE|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
219013709|NCT01110707|DRUG|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
219013710|NCT03264209|BEHAVIORAL|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
219013711|NCT05069454|BIOLOGICAL|COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine|To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
219013712|NCT04265274|DRUG|Disulfiram|dosing 400mg daily
219013713|NCT04265274|DRUG|Vinorelbin|25mg/m2 day 1 and 8,
219013714|NCT04265274|DRUG|Cisplatin|75mg/m2 day 1
219013715|NCT04265274|DRUG|Copper|2 mg of elementary Copper daily
219013716|NCT00000954|DRUG|Bleomycin sulfate|
219013717|NCT00000954|DRUG|Vincristine sulfate|
219013718|NCT00000954|DRUG|Doxorubicin hydrochloride|
219013719|NCT00000954|DRUG|Zalcitabine|
219439565|NCT00807014|DRUG|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
219439566|NCT01792297|DIETARY_SUPPLEMENT|Bovine colostrum|
219439567|NCT01792297|DIETARY_SUPPLEMENT|Whey protein|
219439568|NCT00651313|DRUG|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
219013720|NCT00000954|DRUG|Didanosine|
219013721|NCT03020680|DIETARY_SUPPLEMENT|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
219439569|NCT00651313|DRUG|Placebo|Placebo vaginal gel administered once daily for 4 days
219439570|NCT02650895|BIOLOGICAL|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
218831076|NCT05370274|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
218831077|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
218831078|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
218831079|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
219013722|NCT00549523|DRUG|Placebo|Capsules containing 0 mg bid (placebo)
219013723|NCT00549523|DRUG|Low Dose|Capsules containing 400 mg bid of L. frutescens.
219013724|NCT00549523|DRUG|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
219013725|NCT00549523|DRUG|High Dose|Capsules containing 1200 mg bid of L. frutescens.
219013726|NCT02051829|OTHER|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
219013727|NCT03032666|DRUG|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
219439571|NCT02650895|DRUG|Saline|0.9% sodium chloride
219439572|NCT01628042|DRUG|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
219439573|NCT00316654|BIOLOGICAL|Meningococcal C conjugate vaccine|
219439574|NCT05974007|DRUG|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
219439575|NCT05974007|DRUG|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
219439576|NCT01511991|DRUG|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
218831080|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
218831081|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
218831082|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
218831083|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
218831084|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
218831085|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
218831086|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
218831087|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
219763965|NCT06823518|BEHAVIORAL|Thrive Initiative Parent-Education Programming|The Thrive Initiative Parent-Education programs are universal prevention programs designed to support parents as they raise their children. There are four programs that correspond to specific child developmental periods. The programs include: Take Root for parents/caregivers of 0-3-year-old children; Sprout for parents/caregivers of 3-5-year-old children; Grow for parents/caregivers of 5-10-year-old children; and Branch Out for parents/caregivers of 10-18-year-old children. Each program focuses, in developmentally appropriate ways, on three primary dimensions: positive parenting, stress management, and healthy lifestyles. Each program is available in either an online-only format or a hybrid format, which includes group meetings in addition to the online program components.
218831088|NCT02039765|DRUG|Brimonidine tartrate|
218831089|NCT03663309|DIAGNOSTIC_TEST|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~* Bring 4-day food diary (attached)~* Fill symptoms and complaints questionnaire (attached)~* Provide 24 h diet recall in case a food diary absents~* Fill Biagi score questionnaire (attached)~* Perform blood test of TTG~* Provide stool and urine samples"
218831090|NCT00820989|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
218831091|NCT01634230|DRUG|OCR-002|daily dose: 10 g infused over 24 hours
218831092|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
218831093|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
218831094|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
218831095|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
218831096|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
218831097|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
219763966|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
218831098|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
218831099|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
218831100|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
218831101|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
218831102|NCT00454740|DRUG|solifenacin succinate|Oral
218831103|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
218831104|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
218831105|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
218831106|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
218831107|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
218831108|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
218831109|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
219763967|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
219763968|NCT06022965|OTHER|Best Practice|Receive SOC
219763969|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
218831110|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
218831111|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
218831112|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
218831113|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
218831114|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
218831115|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
219013728|NCT01042704|DRUG|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
219013729|NCT01042704|DRUG|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
219013730|NCT01042704|DRUG|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
219013731|NCT01042704|DRUG|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
219013732|NCT01042704|DRUG|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
219013733|NCT01042704|DRUG|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
219013734|NCT01042704|OTHER|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
219013735|NCT01042704|OTHER|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
219013736|NCT01042704|OTHER|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
219013737|NCT01042704|OTHER|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~* Physical exam~* Performance status (check of ability to perform daily functions)~* Recording of any new symptoms and any new medications being taken~* Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~* Urine test (24hr urine)~* Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~* A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
218831116|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
219013738|NCT02982967|OTHER|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
219013739|NCT01444326|OTHER|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
218831117|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
218831118|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
218831119|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
218831120|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
218831121|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
219013740|NCT01243970|DRUG|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
219196047|NCT06808503|BEHAVIORAL|NIMH Clinical Pathway|Complete the implemented workflow and tools for suicide risk screening, assessment, safety planning and follow-up.
219439577|NCT04472637|DRUG|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
219580892|NCT04569396|DIAGNOSTIC_TEST|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
218831122|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
218831123|NCT02869165|DRUG|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
218831124|NCT02869165|DRUG|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
218831125|NCT04406103|BEHAVIORAL|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
218831126|NCT04406103|BEHAVIORAL|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
218831127|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
218831128|NCT03618667|DRUG|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
218831129|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
218831130|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
218831131|NCT02228044|BEHAVIORAL|Prevention program|
218831132|NCT03801928|DRUG|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
218831133|NCT04847440|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
219013741|NCT01243970|DRUG|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
219013742|NCT03120819|BEHAVIORAL|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
218831134|NCT04847440|DRUG|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
218831135|NCT04847440|DRUG|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
218831136|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
218831137|NCT02520492|DEVICE|noninvasive method of ICP measurements (Elios)|
219013743|NCT03120819|BEHAVIORAL|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
219013744|NCT02140788|DRUG|Metformin|
218831138|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
218831139|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
218831140|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
219013745|NCT02140788|DRUG|Fish Oil|
219013746|NCT01093807|DRUG|Placebo|once daily for 10 weeks
219013747|NCT01093807|DRUG|Lercanidipine|10 mg once daily for 10 weeks
219013748|NCT01093807|DRUG|Lercanidipine|20 mg once daily for 10 weeks
219013749|NCT01093807|DRUG|Enalapril|10 mg once daily for 10 weeks
219013750|NCT01093807|DRUG|Enalapril|20 mg once daily for 10 weeks
219013751|NCT01093807|DRUG|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
219013752|NCT01093807|DRUG|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
219013753|NCT01093807|DRUG|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
219013754|NCT01093807|DRUG|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
219013755|NCT02968563|DRUG|Tirabrutinib|Tablets administered orally
218831141|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
218831142|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
219013756|NCT02968563|DRUG|Idelalisib|Tablets administered orally
219013757|NCT02968563|DRUG|Obinutuzumab|Administered intravenously
219439578|NCT04472637|DRUG|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
218831143|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
218831144|NCT00118274|BIOLOGICAL|incomplete Freund's adjuvant|Given intradermally and subcutaneously
218831145|NCT00118274|BIOLOGICAL|melanoma helper peptide vaccine|Given intradermally and subcutaneously
218831146|NCT00118274|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
219013758|NCT03654950|OTHER|No intervention|Interviews and questionnaires
219013759|NCT05548231|DRUG|LY3437943|Administered SC
219013760|NCT05548231|DRUG|Placebo|Administered SC
219013761|NCT02766062|OTHER|metabolic syndrome|metabolic syndrome
219013762|NCT04787029|DEVICE|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
219439579|NCT05386849|DEVICE|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
219763970|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
219763971|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
218831147|NCT00118274|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally and subcutaneously
218831148|NCT00118274|DRUG|cyclophosphamide|Given IV
218831149|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
218831150|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
218831151|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
218831152|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
218831153|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
218831154|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
218831155|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
218831156|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
218831157|NCT01724216|DEVICE|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
218831158|NCT02770066|DEVICE|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~* Antiplatelet therapy (usually standard)~* Cholesterol-lowering drugs (usually standard)~* Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~* Smoking cessation, diet and physical activity (usually standard)"
218831159|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
218831160|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
219439580|NCT00981682|DRUG|SER120|once a day treatment of nocturia
219580893|NCT04569396|DIAGNOSTIC_TEST|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
218831161|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
218831162|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
218859753|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
218859754|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
218859755|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
218859756|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
218859757|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
218859758|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
219580894|NCT04514536|DEVICE|Health monitors|"* The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
219763972|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
219763973|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
218831163|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
219013763|NCT04990414|OTHER|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
218831164|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
218831165|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
218831166|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
218831167|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
218831168|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
218831169|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
218831170|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
218831171|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
218831172|NCT02821065|DEVICE|Remote Patient Monitoring|
218831173|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
218831174|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
218831175|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
219013764|NCT03585439|PROCEDURE|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
219013765|NCT02369341|BIOLOGICAL|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
219013766|NCT00295347|DRUG|Spironolactone|
219013767|NCT00295347|DRUG|fludrocortisone|
219013768|NCT00295347|DRUG|escitalopram|
219013769|NCT03287804|BIOLOGICAL|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
219013770|NCT02044744|BEHAVIORAL|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
219439581|NCT04465461|PROCEDURE|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
219439582|NCT04465461|DEVICE|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
219763974|NCT03930251|BEHAVIORAL|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
218831176|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
218831177|NCT01005641|DRUG|exemestane|25 mg daily
218831178|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
218831179|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
218831180|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
218831181|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
219013771|NCT00385996|DRUG|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
219013772|NCT05270655|OTHER|Cognitive-behavioural intervention|Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
219013773|NCT03913650|PROCEDURE|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
219013774|NCT04921254|DRUG|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
219013775|NCT03832621|DRUG|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
219013776|NCT03832621|DRUG|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
219013777|NCT03832621|DRUG|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
219013778|NCT03028831|DIETARY_SUPPLEMENT|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
219013779|NCT03028831|DIETARY_SUPPLEMENT|Resistant starch|70g high-amylose maize starch
219013780|NCT01273402|DRUG|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
219763975|NCT03930251|BEHAVIORAL|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
219763976|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
219763977|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
218831182|NCT00564733|DRUG|carboplatin|Given IV
218831183|NCT00564733|DRUG|docetaxel|Given IV
218831184|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
218831185|NCT00564733|DRUG|paclitaxel|Given IV
218831186|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
219013781|NCT05826899|OTHER|54Fe SO4|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe
219763978|NCT02253316|BIOLOGICAL|Ixazomib|
219763979|NCT02253316|DRUG|Lenalidomide|
219763980|NCT02253316|DRUG|Dexamethasone|
219763981|NCT00001595|PROCEDURE|MRI|
219763982|NCT00001595|PROCEDURE|Tissue specimen collection|
219763983|NCT06034925|DRUG|Maribavir|maribavir 400mg twice daily
218831187|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
218831188|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
218831189|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
218831190|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
219013782|NCT05826899|OTHER|57Fe Oat-1|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
219013783|NCT05826899|OTHER|58Fe Oat-2|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
219013784|NCT05826899|OTHER|54 FeSO4 + Acai puree with honey|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
219013785|NCT05826899|OTHER|57Fe Oat-1 + Acai puree with honey|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
219013786|NCT05826899|OTHER|58Fe Oat-2 + Acai puree with honey|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
219013787|NCT03163615|DRUG|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
219013788|NCT03163615|DRUG|Placebo oral capsule|4 capsules, po, from admission up to 84 days
219013789|NCT05158114|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219763984|NCT06034925|DRUG|Valganciclovir|valganciclovir 900mg once daily
218831191|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
218831192|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
218831193|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
218831194|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
218831195|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
218831196|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
219013790|NCT01109199|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
218831197|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
219013791|NCT01109199|DIETARY_SUPPLEMENT|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
219013792|NCT04093219|DRUG|IV acetaminophen|use of IV tylenol for pain
219013793|NCT04093219|OTHER|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
219439585|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
219439586|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
219013794|NCT06003348|DIETARY_SUPPLEMENT|OHCit- standard dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
219013795|NCT06003348|DRUG|Potassium Citrate|10 mEq Extended-release tablets for oral use
219013796|NCT06003348|DRUG|Placebo|Placebo
219439587|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
219439588|NCT04586166|DEVICE|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
219763985|NCT06809595|OTHER|Placebo|A substance that is designed to have no therapeutic value
219763986|NCT06809595|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
218831198|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
218831199|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
218831200|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
218831201|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
218831202|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
218831203|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
218831204|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
218831205|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
218831206|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
218831207|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
219013797|NCT06003348|DIETARY_SUPPLEMENT|OHCit- low dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
219013798|NCT01662518|DEVICE|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
219013799|NCT00981955|DIETARY_SUPPLEMENT|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
219013800|NCT02758015|OTHER|Standardized Meal|
219013801|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
219013802|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
219013803|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
219439589|NCT04586166|DEVICE|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
219763987|NCT06806033|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab 7 days prior to the first dose of glofitamab.
219763988|NCT06806033|DRUG|Glofitamab|Participants will receive IV glofitamab, both in combination with gemcitabine and oxaliplatin and as monotherapy, for up to 12 cycles (cycle length = 21 days).
219763989|NCT06806033|DRUG|Gemcitabine|Participants will receive IV gemcitabine in combination with glofitamab and oxaliplatin for up to 8 cycles (cycles length = 21 days).
219439590|NCT06096259|DRUG|Metformin|Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
218831208|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
218831209|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
218831210|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
218831211|NCT01489709|DRUG|Vesicare|oral
218831212|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
218831213|NCT01579058|DRUG|placebo|placebo for 4 years
218831214|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
218831215|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
218831216|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
218831217|NCT00000763|DRUG|TNP-470|
218831218|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
218831219|NCT01963182|DRUG|Irinotecan|
219763990|NCT06806033|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin in combination with glofitamab and gemcitabine for up to 8 cycles (cycle length = 21 days).
219763991|NCT05102019|DEVICE|Arm 1: treatment with Shockwave Reducer|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
219763992|NCT05102019|OTHER|Arm 2 (control): Implantation procedure with no device implanted|No device is implanted
218831220|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
218831221|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
218831222|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
218831223|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
218831224|NCT02802293|DEVICE|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
218831225|NCT02802293|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
218859759|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
218859760|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
218859761|NCT02261129|DRUG|Telmisartan film-coated tablet|
218859762|NCT02261129|DRUG|Telmisartan uncoated tablet|
218859763|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
218859764|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
218859765|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
218859766|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
218859767|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
218859768|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
218859769|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
218859770|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
218859771|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
218859772|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
218859773|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
218859774|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
218859775|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
218831226|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
218831227|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
218831228|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
218831229|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
218831230|NCT02406521|DRUG|Pazopanib|
218831231|NCT02406521|DRUG|Sorafenib|
218831232|NCT02406521|DRUG|Radium-223|
219013804|NCT05626595|BEHAVIORAL|Project Group - PRO-ECO Project|The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.
219013805|NCT05626595|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
219013806|NCT00939081|BEHAVIORAL|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
219013807|NCT00939081|BEHAVIORAL|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
219439591|NCT06096259|DRUG|Placebo|The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
218831233|NCT02621476|BEHAVIORAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
218831234|NCT02621476|BEHAVIORAL|Usual care|Usual care
219439592|NCT04772469|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
218831235|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
218831236|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
219013808|NCT02977988|BEHAVIORAL|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
219439593|NCT04772469|OTHER|Small monetary incentives|Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
219439594|NCT04772469|BEHAVIORAL|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
219439595|NCT06382207|DEVICE|Eko Duo electronic stethoscope|A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.
218831237|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
218831238|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
218831239|NCT01484496|BIOLOGICAL|Placebo|Placebo
218831240|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
218831241|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
218831242|NCT01890096|RADIATION|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
218831243|NCT01890096|RADIATION|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
218831244|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
218831245|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
219439596|NCT06382207|DEVICE|CORE 500 electronic stethoscope|The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
219439597|NCT06136494|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
218831246|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
218831247|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
218831248|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
218831249|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
218831250|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
218831251|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
218831252|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
218831253|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
218831254|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
219013809|NCT02977988|BEHAVIORAL|Brain and Recovery (B&R)|B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
219013810|NCT05028439|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
219013811|NCT05028439|DRUG|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
219439598|NCT06136494|BEHAVIORAL|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
219439599|NCT03443180|OTHER|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
219439600|NCT02518568|DRUG|V0355|Oral administration (2 tablets)
219439601|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
219439602|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
219439603|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
219439604|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
219439605|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
219439606|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
219013812|NCT02015650|DRUG|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
219013813|NCT02015650|DRUG|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
219013814|NCT03872219|COMBINATION_PRODUCT|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
219013815|NCT03016286|OTHER|vibration|Whole body vibration at 25Hz frequency
219013816|NCT00003644|DRUG|carboplatin|
219013817|NCT00003644|DRUG|paclitaxel|
219013818|NCT04249310|DRUG|Tiotropium/Olodaterol|Soft Mist Inhaler product
219013819|NCT04249310|DRUG|Tiotropium|Soft Mist Inhaler product
219013820|NCT01797692|OTHER|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
219013821|NCT00590447|DRUG|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
219013822|NCT00590447|DRUG|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
219013823|NCT04877470|OTHER|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
219013824|NCT06505577|OTHER|No additional intervention|All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
219013825|NCT05587400|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
219013826|NCT05587400|DRUG|dobutamine test|infusion dobutamine
219439607|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
219439608|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
219763993|NCT05102019|DEVICE|Arm 3 (unblinded, non-randomized): Single arm registry|Shockwave Reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
218831255|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
219013827|NCT05587400|DRUG|inhaled nitric oxide|nitric oxide inhalation
219013828|NCT06560970|BEHAVIORAL|COPPEhR Intervention|Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
219013829|NCT06560970|BEHAVIORAL|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
219013830|NCT02316067|OTHER|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
219439609|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
219439610|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
219013831|NCT06163846|DIAGNOSTIC_TEST|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
219013832|NCT01477840|DRUG|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
219013833|NCT03904433|OTHER|Coconut oil|Coconut oil given in coffee with cream
219013834|NCT03904433|DIETARY_SUPPLEMENT|Caprylic acid|Caprylic acid given in coffee with cream
219013835|NCT03904433|OTHER|Sunflower oil|Sunflower oil given in coffee with cream
219013836|NCT03904433|OTHER|Glucose|Glucose dissolved in water
219013837|NCT05092685|GENETIC|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
219013838|NCT00750711|PROCEDURE|Radiofrequency ablation for atrial flutter by catheters|
219013839|NCT03456674|DEVICE|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
219763994|NCT00006421|DRUG|2-Fluorodeoxyglucose|
219763995|NCT04840602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219763996|NCT04840602|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
218831256|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
218831257|NCT00344175|DRUG|pitavastatin|
218831258|NCT00344175|DRUG|simvastatin|
218831259|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
218831260|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
219439611|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
218831261|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
218831262|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
218831263|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
218831264|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
218831265|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
218831266|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
218831267|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
218831268|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
218831269|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
218831270|NCT00122876|PROCEDURE|Photodynamic therapy|
219439612|NCT02992912|DRUG|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
218831271|NCT00122876|DRUG|Talaporfin Sodium|
218831272|NCT06312163|DEVICE|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.|The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
218831273|NCT02678754|OTHER|No intervention required, purely observational|
219013840|NCT02710045|BIOLOGICAL|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
219013841|NCT02710045|BIOLOGICAL|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
219013842|NCT02710045|BIOLOGICAL|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
219013843|NCT00158509|DRUG|Valacyclovir|
219013844|NCT02987400|DRUG|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
219013845|NCT02987400|DRUG|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
218831274|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
218831275|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
218831276|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
218831277|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
218831278|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
218831279|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
218831280|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
218831281|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
218831282|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
218831283|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
219013846|NCT01054781|DRUG|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
219439613|NCT02992912|PROCEDURE|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
219763997|NCT04840602|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219763998|NCT04840602|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219763999|NCT04840602|DRUG|Ibrutinib|Given PO
219764000|NCT04840602|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219764001|NCT04840602|BIOLOGICAL|Rituximab|Given IV
218831284|NCT01719848|OTHER|Measurements of parameters related with physical examinations for difficult airway prediction|
218831285|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
218831286|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
218831287|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
218831288|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
219013847|NCT02128633|DRUG|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
219013848|NCT02128633|DRUG|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
219013849|NCT02128633|DRUG|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
219013850|NCT02808026|DRUG|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
219013851|NCT01411709|DRUG|Vitano|two 200mg tablets per day for 14 days
219013852|NCT00304564|BEHAVIORAL|Music Listening|subjects listen to music
219013853|NCT01002469|OTHER|sodium [1-13C] acetate|
219013854|NCT03307720|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
219013855|NCT03307720|DRUG|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
219013856|NCT05133947|OTHER|Non interventional|Non interventional
219013857|NCT00879281|BEHAVIORAL|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
219013858|NCT01747941|DRUG|PF-06305591|single dose, solution
218831289|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
219013859|NCT01747941|DRUG|Placebo|matching placebo
219013860|NCT01747941|DRUG|PF-06305591|single dose, solution
219439614|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
219439615|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
218831290|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
218831291|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
219013861|NCT01747941|DRUG|Placebo|matching placebo
218831292|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
219013862|NCT01747941|DRUG|PF-06305591|single dose, solution
219439616|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
218831293|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
218831294|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
218831295|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
219013863|NCT01747941|DRUG|Placebo|matching placebo
219013864|NCT04244279|OTHER|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
219013865|NCT04244279|OTHER|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
219013866|NCT04244279|OTHER|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
219013867|NCT03178773|BEHAVIORAL|TExT-MED|messages designed to inspire motivation and behavior change
219013868|NCT03178773|BEHAVIORAL|FANS|SMS delivered messages to family members to improve social support
219013869|NCT04495842|OTHER|Essential Oil Blend|5 drops of on a tester strip
219013870|NCT04495842|OTHER|Control Blend|5 drops on a tester strip
219013871|NCT05688046|DRUG|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
219013872|NCT05688046|DRUG|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
219013873|NCT00321282|PROCEDURE|Atrial Fibrillation|
219013874|NCT01382446|DRUG|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
219013875|NCT01382446|OTHER|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
219013876|NCT05199467|BEHAVIORAL|Health Coaching|Health coaches help people focus on goals, identify strengths and values, and work towards building the kind of life they wish to live.
219013877|NCT05199467|BEHAVIORAL|VA Benefits Information|Printed materials with information on VA benefits.
219013878|NCT05549934|DRUG|PF-06651600|tablets containing active drug (a combined JAK3/TEC inhibitor)
219439617|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
219439618|NCT00394277|DRUG|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
219439619|NCT00394277|DRUG|Ribavirin|1200 mg po daily for 48 weeks
219439620|NCT00394277|DRUG|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
219439621|NCT00394277|DRUG|Ribavirin|1400-1600 mg po daily for 48 weeks
218831296|NCT01387750|OTHER|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
218831297|NCT01387750|OTHER|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
218831298|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
218831299|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
218831300|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
218831301|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
218831302|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
218831303|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
218831304|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
218831305|NCT03117114|DEVICE|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
218831306|NCT03117114|OTHER|Standard polypectomy|Absence of an EVD, standard polypectomy
218831307|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
218831308|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
218831309|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
218831310|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
218831311|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
218831312|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
218831313|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
218831314|NCT00807183|OTHER|Active air filter|air filter units correctly operating
218831315|NCT02209935|OTHER|Early Rehabilitation Protocol|
218831316|NCT02209935|OTHER|Usual care|
219013879|NCT04861155|DEVICE|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
219013880|NCT04890327|OTHER|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
219013881|NCT02116244|DRUG|Civamide Nasal Spray|
219196048|NCT06812364|PROCEDURE|one level ESPB|Ultrasound will be sagittal placed against the target vertebral level T7 vertebrae in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process. The Erector Spinae muscle and transverse process will be then identified, and a blunted tip ,100mm, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in caudal -to- cephalad direction, through the inter fascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 3 ml normal saline to confirm the correct needle tip position. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the T7 vertebrae
218831317|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
218831318|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
218831319|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
218831320|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
218831321|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
218831322|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
219764002|NCT04840602|DRUG|Venetoclax|Given PO
218831323|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
218831324|NCT04679961|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
219439622|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
219439623|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
219764003|NCT07113743|DRUG|Busulfan|Conditioning drug
219764004|NCT07113743|DRUG|Tocilizumab|Monoclonal Antibody
219764005|NCT07113743|DRUG|Eltrombopag|Thrombopoietin Receptor Agonist
219196049|NCT06812364|PROCEDURE|two level ESPB|"The target vertebral levels are T5 transverse process (at the level of Sternal Angle, above T7 by tow vertebra)(19) and T10 transverse process (at the level of Xiphisternal Junction, below T7 by 3 vertebrae).~The block will be performed bilaterally by injecting 60mL of 0.25% bupivacaine (15mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) in the same technique."
219439624|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
219439625|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
219439626|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
219764006|NCT07113743|DRUG|Sirolimus|Post transplant immunosuppressant drug
218831336|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
218831337|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
218831338|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
218831339|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
218831340|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
218831341|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
218831342|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
218831343|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
218831344|NCT05461599|DEVICE|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
218831345|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
218831346|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
218831347|NCT01802099|OTHER|Enteral nutrition|
218831348|NCT01802099|OTHER|Parenteral nutrition|
218831349|NCT04762082|DRUG|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
218831350|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
218831351|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
218831352|NCT02872870|BEHAVIORAL|auditory lexical decision task|
218831353|NCT02872870|DEVICE|electroencephalogram|
218831354|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
218831355|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
218831356|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
218831357|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
218831358|NCT02933879|DRUG|NVXT topical|topical treatment
218831359|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
218831360|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
218831361|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
218831362|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
218831363|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
218831364|NCT01530529|DRUG|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
218831365|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
218831366|NCT00220155|DRUG|Gemcitabine|
218831367|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
218831368|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
218831369|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
218831370|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
218831371|NCT01206140|DRUG|Selumetinib|Given PO
218831372|NCT01206140|DRUG|Temsirolimus|Given IV
219439627|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
218831373|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
219439628|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
219439629|NCT03719430|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
219439630|NCT03719430|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
219439631|NCT03076242|OTHER|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
219439632|NCT05732493|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
219439633|NCT05732493|RADIATION|short-term radiotherapy|radiation: 25Gy/5Fx
219439634|NCT05732493|DRUG|Oxaliplatin|130mg/m2 d1 q3w
219439635|NCT05732493|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
219439636|NCT05010863|OTHER|Blood collection|The subject will be drawn a 5ml blood sample
219439637|NCT02591251|DRUG|Povidone-iodine solution|
218831374|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
218831375|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
218831376|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
219580895|NCT05041621|DEVICE|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
219013882|NCT02519530|BEHAVIORAL|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
219013883|NCT02850393|OTHER|Functional magnetic resonance imaging|
219439638|NCT02591251|DRUG|Normal saline solution|
219439639|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
219439640|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
219439641|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
219439642|NCT01976585|DRUG|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
219439643|NCT01976585|DRUG|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
219580896|NCT01022944|PROCEDURE|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
219580897|NCT01022944|PROCEDURE|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
219439644|NCT01729676|DRUG|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
219580898|NCT03141866|OTHER|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
219580899|NCT03141866|OTHER|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
218831377|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
218831378|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
219013884|NCT02850393|BEHAVIORAL|behavioral measures|
219013885|NCT02850393|OTHER|physiological measurements|
219013886|NCT05106374|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
219439645|NCT01507441|GENETIC|gene mapping|
219439646|NCT01507441|GENETIC|microarray analysis|
219439647|NCT01507441|GENETIC|mutation analysis|
219439648|NCT01507441|GENETIC|nucleic acid sequencing|
219439649|NCT01507441|OTHER|laboratory biomarker analysis|
219580900|NCT00283023|PROCEDURE|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
219580901|NCT03638778|DRUG|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
218831379|NCT05504187|DRUG|KP104|KP104 will be administered.
218831380|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
219439650|NCT04901390|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
219013887|NCT05106374|PROCEDURE|Cognitive Assessment|Complete thinking test
219013888|NCT05106374|OTHER|Physical Performance Testing|Complete walking test
218831381|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
218831382|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
218831383|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
218831384|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
219013889|NCT05106374|OTHER|Quality-of-Life Assessment|Ancillary studies
219013890|NCT05106374|OTHER|Questionnaire Administration|Complete questionnaire
219013891|NCT06336460|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn."
218831385|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
218831386|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
218831387|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
218831388|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
219013892|NCT06336460|PROCEDURE|Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures|"Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn."
219013893|NCT04994990|DRUG|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
219013894|NCT04994990|DRUG|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
219013895|NCT05190380|OTHER|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
219013896|NCT05190380|OTHER|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
219013897|NCT04349488|DEVICE|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
219439651|NCT04945304|PROCEDURE|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
219013898|NCT04352114|DRUG|LY3461767 - SC|Administered SC.
219013899|NCT04352114|DRUG|LY3461767 - IV|Administered IV.
219013900|NCT04352114|DRUG|Placebo - SC|Administered SC.
219439652|NCT04945304|PROCEDURE|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
219439653|NCT02892734|BIOLOGICAL|Ipilimumab|Given IV
219439654|NCT02892734|OTHER|Laboratory Biomarker Analysis|Correlative studies
219439655|NCT02892734|BIOLOGICAL|Nivolumab|Given IV
219439656|NCT02043509|BEHAVIORAL|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
219013901|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), within 28 days (+/- 28 days) of their CABG surgery and again at 12 month follow-up.
219013902|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), prior to their clinical invasive coronary angiography.
219013903|NCT02335164|BIOLOGICAL|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
218831389|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
218831390|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
218831391|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
219013904|NCT02335164|BIOLOGICAL|Advax1|Delta inulin adjuvant formulation 1
219013905|NCT02335164|BIOLOGICAL|Advax2|Delta inulin adjuvant formulation 2
219013906|NCT02715323|OTHER|Cross-sectional study|
219013907|NCT05894733|OTHER|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
219013908|NCT05894733|OTHER|control group|first and sixth month face to face interwiew
219013909|NCT04941248|DEVICE|total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)|This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
219580902|NCT03638778|DRUG|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
219013910|NCT01679379|PROCEDURE|Absorbable suture group|Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
219013911|NCT01679379|PROCEDURE|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
218831392|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
218831393|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
218831394|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
218831395|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
219013912|NCT04336982|DRUG|CC-90009|Injection
219013913|NCT04336982|DRUG|Venetoclax|Tablet
219013914|NCT04336982|DRUG|Azacitidine|Injection
219013915|NCT04336982|DRUG|Gilteritinib|Tablet
219013916|NCT03720496|BIOLOGICAL|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
219580903|NCT03638778|DRUG|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
218831396|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
218831397|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
219013917|NCT05319795|BEHAVIORAL|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
219013918|NCT02741882|OTHER|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
219013919|NCT05756946|PROCEDURE|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
219013920|NCT05756946|PROCEDURE|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
219013921|NCT00442975|BIOLOGICAL|Fluarix|
219013922|NCT02733991|DEVICE|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
219013923|NCT02733991|DEVICE|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
219013924|NCT01862562|PROCEDURE|Open surgery|Conventional technique
219013925|NCT01862562|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
218831398|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
218831399|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
218831400|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
218831401|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
218831402|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
218831403|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
218831404|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
218831405|NCT00022295|DRUG|idronoxil|
218831406|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
218831407|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
218831408|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
218831409|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
218831410|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
218831411|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
219764007|NCT07113743|OTHER|pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene|Intervention Infusion on Day 0
218831412|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
218831413|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
218831414|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
218831415|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
218831416|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
218831417|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
218831418|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
219580904|NCT03638778|DRUG|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
219580905|NCT03638778|DRUG|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
219580906|NCT03638778|DRUG|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
219580907|NCT03638778|DRUG|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
219580908|NCT03638778|DRUG|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
219764008|NCT03551951|DIAGNOSTIC_TEST|Test for circulating tumor cells, DNA alterations|
218831419|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
218831420|NCT00770562|DRUG|rituximab|
218831421|NCT00770562|DRUG|Dexamethasone|
218831422|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
218831423|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
218831424|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
218831425|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
218831426|NCT01696799|DRUG|Econazole Nitrate|
218831427|NCT01696799|DRUG|placebo|
218831428|NCT05523830|OTHER|No Intervention|No intervention
218831429|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
218831430|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research\_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
218831431|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
218831432|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
218831433|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
218831434|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
218831435|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
218831436|NCT02147210|OTHER|biological analysis|
218831437|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
218831438|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
218831439|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
218831440|NCT02289196|DRUG|Vx-006: 0,5mg|
218831441|NCT02289196|DRUG|Vx-006: 1mg|
218831442|NCT02289196|DRUG|Vx-006: 5mg|
218831443|NCT02289196|DRUG|Vx-006: 10mg|
218831444|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
218831445|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
218831446|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
218831447|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
218831448|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
218831449|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
218831450|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
218831451|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
218831452|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
218831453|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
218831454|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
218831455|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
218831456|NCT00001040|DRUG|Saquinavir|
218831457|NCT00001040|DRUG|Zidovudine|
218831458|NCT00001040|DRUG|Zalcitabine|
218831459|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
218831460|NCT01288625|DRUG|Amifostine|500 mg sc, qod, 3 times per week
219013926|NCT05533450|DEVICE|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
218831461|NCT01288625|RADIATION|Amifostine|500mg rinsing wash, qod, 3 times per week
218831462|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
218831463|NCT03487016|DRUG|Gemcitabine|Arm A
218831464|NCT03487016|DRUG|Nab-paclitaxel|Arm A
218831465|NCT03487016|DRUG|5-FU|Arm B Arm C
218831466|NCT03487016|DRUG|Irinotecan Liposomal Injection|Arm B Arm C
218831467|NCT03487016|DRUG|Oxaliplatin|Arm C
218831468|NCT03819257|DIAGNOSTIC_TEST|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
219580909|NCT05068089|PROCEDURE|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
218831469|NCT03819257|DIAGNOSTIC_TEST|High-resolution anorectal manometry|"1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension."
218831470|NCT03819257|DIAGNOSTIC_TEST|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
218831471|NCT05842525|DRUG|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
218831472|NCT05842525|DRUG|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
218831473|NCT02613195|DRUG|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
218831474|NCT05350540|OTHER|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
218831475|NCT00363142|DRUG|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
218831476|NCT00363142|DRUG|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
218831477|NCT02701309|DEVICE|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
218831478|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
218831479|NCT01541865|DEVICE|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
218831480|NCT05715658|DRUG|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
218831481|NCT04254146|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
218831482|NCT06393777|DIETARY_SUPPLEMENT|honey|analgesic effect of honey
218831483|NCT03775317|PROCEDURE|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
218831484|NCT03775317|PROCEDURE|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
218831485|NCT00004891|DRUG|chemotherapy|
218831486|NCT00004891|PROCEDURE|computed tomography|
218831487|NCT00004891|PROCEDURE|conventional surgery|
218831488|NCT00004891|PROCEDURE|neoadjuvant therapy|
218831489|NCT00004891|PROCEDURE|positron emission tomography|
218831490|NCT00004891|PROCEDURE|radionuclide imaging|
218831491|NCT00004891|RADIATION|fludeoxyglucose F 18|
218831492|NCT00004891|RADIATION|radiation therapy|
218831493|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
218831494|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
218831495|NCT03888378|DRUG|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
218831496|NCT03888378|DRUG|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
218831497|NCT03888378|OTHER|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
218831498|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
218831499|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
218831500|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
218831501|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
218831502|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
218831503|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
218831504|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
218831505|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
218831506|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
218831507|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
218831508|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
218831509|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
218831510|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
219013927|NCT05533450|DEVICE|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
219013928|NCT03189758|OTHER|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
218831511|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
218831512|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
218831513|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
218831514|NCT02186483|DRUG|Metformin|Metformin,1000mg, once daily
218831515|NCT02186483|DRUG|Rosuvastatin|Rosuvastatin, 20 mg, once daily
218831516|NCT02186483|DRUG|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
218831517|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
218831518|NCT00048945|DRUG|PEGASYS|
218831519|NCT04013776|DIETARY_SUPPLEMENT|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
218831520|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
218831521|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
218831522|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
218831523|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
218831524|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
219013929|NCT03189758|OTHER|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
218831525|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
218831526|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
218831527|NCT00295646|DRUG|tamoxifen|20 mg/d
218831528|NCT00295646|DRUG|anastrozole|1 mg/d
218831529|NCT00295646|DRUG|zoledronic acid|4 mg q6m
218831530|NCT00295646|OTHER|goserelin|3.6 mg goserelin subcutaneously every 28 days
218831531|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
218831532|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
218831533|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
218831534|NCT04972188|DRUG|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
218831535|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
218831536|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
218831537|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
218831538|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
218831539|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
218831540|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
218831541|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
218831542|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
218831543|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
218831544|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
219013930|NCT05273138|OTHER|Blood sampling and skin biopsy|Blood sampling and skin biopsy
219013931|NCT00775151|DRUG|amlodipine 10 mg tablet|
219013932|NCT01523574|DRUG|Vitamin E|Vitamin E 400mg PO orally
218831545|NCT00955474|DRUG|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
218831546|NCT00955474|DRUG|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
218831547|NCT00955474|DRUG|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
218831548|NCT00955474|DRUG|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
218831549|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
219013933|NCT01523574|DRUG|Placebo|Placebo, given orally
219013934|NCT04231539|DRUG|Nicotine|Vape different flavor nicotine products
219013935|NCT04231539|DEVICE|Vaporizer Device|Take puffs from vaporizer filled with different flavors
219013936|NCT03627689|OTHER|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
219013937|NCT03627689|OTHER|Sham air purifier|control arm
219013938|NCT03680950|DEVICE|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
218831550|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
219013939|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
219013940|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
219013941|NCT04501367|DRUG|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
219013942|NCT02646176|BEHAVIORAL|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
219013943|NCT05665062|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
219013944|NCT05665062|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
219013945|NCT05665062|DRUG|Cyclophosphamide|lymphodepletion
219013946|NCT05665062|DRUG|Fludarabine|lymphodepletion
219013947|NCT04822207|PROCEDURE|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
219439657|NCT03672552|OTHER|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
219580910|NCT05068089|BIOLOGICAL|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
219580911|NCT05702671|DIAGNOSTIC_TEST|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
219580912|NCT01328665|OTHER|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
219580913|NCT02594085|OTHER|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
219580914|NCT02594085|OTHER|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
219580915|NCT02594085|OTHER|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
219580916|NCT02594085|OTHER|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
219580917|NCT02594085|OTHER|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
218831551|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
218831552|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
218831553|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
218831554|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
218831555|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
218831556|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
218831557|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
218831558|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
218831559|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
218831560|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
218831561|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
219013948|NCT06259240|OTHER|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
219013949|NCT06259240|DEVICE|Electrical Stimulation|Electrical Stimulation
219013950|NCT03574740|OTHER|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
219013951|NCT05167734|DRUG|Iron Dextran|1000 mg IV
219013952|NCT05167734|DRUG|Erythropoietin (EPO)|40,000 units subcutaneous
219439658|NCT06398665|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
219439659|NCT01940549|DEVICE|Trauma Focused Therapy + tDCS|
219439660|NCT06280391|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
219439661|NCT06280391|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
219439662|NCT02659137|OTHER|HV measurement|Electrophysiology (EP) study during the TAVI procedure
219439663|NCT03930277|DIAGNOSTIC_TEST|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
218831562|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
218831563|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
218831564|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
218831565|NCT01999686|DRUG|DLBS3233|
219439664|NCT04724291|DEVICE|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
219439665|NCT04093206|DIETARY_SUPPLEMENT|EpiCor and Vitamin C|One daily dose
219439666|NCT04093206|DIETARY_SUPPLEMENT|Vitamin C|One daily dose
219439667|NCT03185091|OTHER|rapid ventricular pacing|
219439668|NCT03185091|PROCEDURE|Surgery|
219580918|NCT02594085|OTHER|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
219764009|NCT02219659|DRUG|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
218831566|NCT01999686|DRUG|Metformin XR|
218831567|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
218831568|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
218831569|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
218831570|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
218831571|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
218831572|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
218831573|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
218831574|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
218831575|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
218831576|NCT00881530|DRUG|Metformin|open label comparator
218831577|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
218831578|NCT00881530|DRUG|Sitagliptin|open label comparator
218831579|NCT06041022|OTHER|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
218831580|NCT02843438|OTHER|Fluorescein angiography|
218831581|NCT02843438|OTHER|Dilated fundus examination|
218831582|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
218831583|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
218831584|NCT02843438|DRUG|Anti-inflammatory treatments|
218831585|NCT02843438|OTHER|Puncture in anterior chamber|
218831586|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
218831587|NCT05429580|OTHER|5% Dextrose|given placebo.
218831588|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
218831589|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
218831590|NCT06438198|OTHER|Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg|A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
218831591|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
218831592|NCT03541499|BIOLOGICAL|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
218831593|NCT03541499|OTHER|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
218831594|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
218831595|NCT02131662|DRUG|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
218831596|NCT02131662|DRUG|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
218831597|NCT02131662|DRUG|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
218831598|NCT02131662|DRUG|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
218831599|NCT02131662|DRUG|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
218831600|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
218831601|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
218831602|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
218831603|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
218831604|NCT02360852|DRUG|A4250|A4250 once daily
218831605|NCT04103476|COMBINATION_PRODUCT|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
218831606|NCT04103476|OTHER|Placebo|Placebo
218831607|NCT05920174|DEVICE|NEO|Subjects will be implanted with the NEO device.
218831608|NCT05698303|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
218831609|NCT05112614|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
218831610|NCT05112614|OTHER|Electronic Health Record Review|Review of medical records
218831611|NCT01708044|DRUG|Pramlintide acetate|
218831612|NCT01708044|OTHER|Placebo|Placebo Comparator
218831613|NCT01402869|DRUG|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
218831614|NCT01402869|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
218831615|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
218831616|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
218831617|NCT01740687|DEVICE|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
218831618|NCT01740687|PROCEDURE|NovaSure|Nova Sure Endometrial Ablation
218831619|NCT03139461|OTHER|PT-REFER Capacity-building Toolkit|"1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls"
219013953|NCT01198054|DRUG|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
218831620|NCT05452252|DIAGNOSTIC_TEST|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
218831621|NCT04217018|DIAGNOSTIC_TEST|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
218831622|NCT02588157|DEVICE|Macintosh|Direct laryngoscopy
218831623|NCT02588157|DEVICE|Glidescope|Glidescope videolaryngoscope
218831624|NCT02588157|DEVICE|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
219013954|NCT05025488|DRUG|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
219439669|NCT01200563|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
218831625|NCT05125744|DIAGNOSTIC_TEST|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
218831626|NCT05004844|DIAGNOSTIC_TEST|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
218831627|NCT00827814|DRUG|Dutasteride|Dutasteride 0.5 mg od.
218831628|NCT04294355|DEVICE|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
218831629|NCT04294355|PROCEDURE|Conventional colonoscopy|Conventional colonoscopy
218831630|NCT00611390|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
218831631|NCT00611390|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
218831632|NCT01226303|DRUG|ATRA|see the protocol
218831633|NCT01226303|DRUG|ATRA + IDA|see the protocol
218831634|NCT02171689|DRUG|[14C]- BIBW 2992 MA2|
218831635|NCT03914989|OTHER|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
218831636|NCT02529683|DRUG|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
218831637|NCT02006186|BEHAVIORAL|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
218831638|NCT00196209|PROCEDURE|catheter ablation|catheter ablation to treat persistent atrial fibrillation
218831639|NCT00196209|PROCEDURE|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
218831640|NCT01562886|DRUG|Rilpivirine|Rilpivirine 26mg
218831641|NCT06160323|PROCEDURE|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
218831642|NCT02151656|DRUG|F17464|
219439670|NCT01200563|DEVICE|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
219439671|NCT01200563|DEVICE|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
219439672|NCT03189563|DRUG|DA-9805 45mg|DA-9805 15mg tid
218831643|NCT02151656|DRUG|Placebo|
218831644|NCT03390725|BEHAVIORAL|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
218831645|NCT00741065|PROCEDURE|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
218831646|NCT05964179|BEHAVIORAL|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
218831647|NCT05964179|BEHAVIORAL|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
219013955|NCT05025488|DRUG|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
219013956|NCT01163708|DEVICE|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
219013957|NCT01163708|DEVICE|Navigation System|
219013958|NCT04882527|DEVICE|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
219013959|NCT04882527|DEVICE|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
219013960|NCT02604212|DRUG|ARC-520|
219013961|NCT02604212|OTHER|Placebo|
219013962|NCT02604212|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
219013963|NCT02604212|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
219013964|NCT02604212|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
219013965|NCT03559946|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
219196050|NCT06851169|DRUG|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
219196051|NCT06851169|DRUG|Cohort 2: Neoadjuvant therapy (benmelstobart only)|Cohort 2: Neoadjuvant therapy (benmelstobart only, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
219439673|NCT03189563|DRUG|DA-9805 90mg|DA-9805 30mg tid
219439674|NCT03189563|OTHER|Placebo|Placebo, tid
219439675|NCT02392676|DRUG|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
219439676|NCT02392676|DRUG|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
218831648|NCT03420144|DRUG|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
218831649|NCT03420144|DRUG|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
218831650|NCT06286332|OTHER|Music Therapy|30 minutes of self-selected music playback every day.
218831651|NCT03333694|DRUG|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
218831652|NCT03333694|DRUG|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
218831653|NCT03100266|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamonosus GG
218831654|NCT03100266|OTHER|Inactive capsules|Placebo
218831655|NCT01103856|BEHAVIORAL|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
218831656|NCT01103856|BEHAVIORAL|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
218831657|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
218831658|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
218831659|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
218831660|NCT05340530|DRUG|Placebo|It is a placebo.
218831661|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
218831662|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
218831663|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
218831664|NCT04679038|BIOLOGICAL|SHR-1701|Intravenous (IV) on Day 1 of each cycle
218831665|NCT04679038|DRUG|Famitinib|Famitinib, po, qd
218831666|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
218831667|NCT04871828|OTHER|Placebo|Placebo
218831668|NCT02062515|DRUG|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
218831669|NCT02060786|DRUG|generic clopidogrel (Plavitor® )|
218831670|NCT02060786|DRUG|original clopidogrel (Plavix® )|
218831671|NCT01310010|DRUG|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
218831672|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
218831673|NCT03780751|BEHAVIORAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
219439677|NCT04535258|DEVICE|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
218831674|NCT03780751|BEHAVIORAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
218831675|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
218831676|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
218831677|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
218831678|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
218831679|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
218831680|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
219439678|NCT00505544|BEHAVIORAL|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
219439679|NCT00505544|DEVICE|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
219439680|NCT00093158|DRUG|Angiomax (bivalirudin) anticoagulant|
219439681|NCT03254849|DRUG|Empagliflozin|1 tablet
219439682|NCT03254849|DRUG|Hydrochlorothiazide 25 mg|1 tablet
219439683|NCT00307944|DRUG|Pantoprazole|
219439684|NCT00608244|DRUG|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
219439685|NCT00608244|DRUG|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
218831681|NCT05112848|BIOLOGICAL|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
218831682|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
218831683|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
218831684|NCT02656394|DRUG|GL101|Topical Gel
218831685|NCT02656394|DRUG|Placebo|Placebo topical gel
218831686|NCT06511687|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
218831687|NCT00104728|DRUG|ZD1839|
218831688|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
218831689|NCT00126152|BEHAVIORAL|Exercise, education and medical management|
219439686|NCT00492895|DRUG|Discontinuation of Azathioprin|Discontinuation of Azathioprin
219439687|NCT04350918|DEVICE|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
219580919|NCT03595085|PROCEDURE|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
219580920|NCT03595085|DRUG|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
219580921|NCT02045082|PROCEDURE|Corneal sampling|Slit lamp corneal sampling with a Swab
219580922|NCT01460901|BIOLOGICAL|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
218831690|NCT03520309|PROCEDURE|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
218831691|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
218831692|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
218831693|NCT00190333|DRUG|escitalopram|escitalopram
218831694|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
218831695|NCT01723969|GENETIC|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
218831696|NCT06006871|BEHAVIORAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
218831697|NCT06006871|DRUG|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
218831698|NCT04277624|DRUG|fezolinetant - test formulation|Administered orally
219013966|NCT03559946|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
219439688|NCT04350918|DEVICE|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
219439689|NCT00251849|DRUG|Rifalazil|
219439690|NCT03474237|OTHER|Hormone study and Imaging study|"1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging"
219439691|NCT02572089|DRUG|Naloxone|
219439692|NCT02748785|DRUG|Methotrexate|Methotrexate will be continued
219439693|NCT02748785|BIOLOGICAL|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
219439694|NCT02410746|OTHER|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
219439695|NCT02410746|OTHER|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
219439696|NCT02410746|OTHER|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
218831699|NCT04277624|DRUG|fezolinetant - reference formulation|Administered orally
218831700|NCT03960684|DEVICE|Levita Magnetic Surgical System|Levita Magnetic Surgical System
218831701|NCT06452732|OTHER|MFC for the determination of leukemia stem cell|MFC for the determination of leukemia stem cell
218831702|NCT06617286|BIOLOGICAL|CD30 CAR T-cell|After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
218831703|NCT02524249|DRUG|Caffeine|
218831704|NCT02524249|DRUG|Placebo (dextrose)|
218831705|NCT02043145|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
218831706|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
218831707|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
218831708|NCT03015285|BEHAVIORAL|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
218831709|NCT06619821|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
218831710|NCT06619821|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
219013967|NCT01669447|BIOLOGICAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
219013968|NCT05580341|BIOLOGICAL|Zerun HPV-9|Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
219013969|NCT05580341|BIOLOGICAL|GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
219013970|NCT03927183|OTHER|person-centred practice|The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
219013971|NCT03353831|DRUG|Bevacizumab|Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
219013972|NCT03353831|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
219013973|NCT03353831|DRUG|Chemotherapy|Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
219013974|NCT03353831|DRUG|Placebos|Placebo will be administered by intravenous route q14 during the treatment period
219013975|NCT01636401|DRUG|aclidinium bromide 400 μg|
219013976|NCT01636401|DRUG|aclidinium bromide placebo|
219013977|NCT05891314|PROCEDURE|Botox Injectable Product|one group will have botox injection in the internal sphincter
219013978|NCT05891314|PROCEDURE|Internal sphincterotomy|this group will have internal sphincterotomy
219013979|NCT00514033|BIOLOGICAL|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
219013980|NCT05651451|DEVICE|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
219013981|NCT05651451|DIETARY_SUPPLEMENT|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
219013982|NCT06208228|DEVICE|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
219439697|NCT00726492|OTHER|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
219439698|NCT00726492|OTHER|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
219439699|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of multiple IVT injection
219439700|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of single IVT injection
219439701|NCT05489718|BIOLOGICAL|IBI324|Dose 1 IBI324 of single IVT injection
219013983|NCT01119131|DRUG|Vitamin D3|Vitamin D3 at 10,000 IU a day
218831711|NCT06619821|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
218831712|NCT06709287|OTHER|clear aligners|The investigators measured pain and chewing performance at 8 time points during the first 6 months.
218831713|NCT06709287|OTHER|orthodontic metal bracket|Conventional metal bracket.
218831714|NCT00954161|OTHER|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
218831715|NCT00954161|OTHER|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
218831716|NCT06718582|DEVICE|Delfi Training Device|Delfi (Vancouver, Canada) training devices will be used for exercise and testing sessions. Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) following manufacturer specifications. In the supine LOP session, the BFR cuffs will be pressurized to 60% of the supine LOP. In the seated LOP session, the BFR cuffs will be pressurized to 60% of the seated LOP. And, in the standing LOP session, the BFR cuffs will be pressurized to 60% of the standing LOP. The cuffs will maintain pressure during training and rest periods. The LOP will be reduced to 0% immediately after completing the last set.
218831717|NCT06716723|PROCEDURE|Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
218831718|NCT06715566|BEHAVIORAL|ActForStroke|ActForStroke is a combination of 10 sessions high-intensity gait training and subsequent with up 7 coaching sessions until 1 year after stroke.
219439702|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of single IVT injection
218831719|NCT06715566|BEHAVIORAL|Standard care|Usual rehabilitation services
218831720|NCT06718894|OTHER|Biologic fluid sampling|The only interventions in addition to standard clinical practice will be blood sampling, the collection of morning spot urine and the collection of the discarded effluent of the plasmapheresis procedure (when performed according to clinical indication).
218831721|NCT06718881|OTHER|simulation application in a virtual reality environment|In the project, theoretical lessons were given on preeclampsia, postpartum care, and condom counseling, each in a separate week. After each theoretical lesson, an application was made in the laboratory on the subject explained in the same week. The applications were made in the form of a simulation application in a virtual reality environment for the students in the experimental group.
218831722|NCT06718114|PROCEDURE|immediate urinary catheter removal|Immediate urinary catheter removal indicates that the urinary catheter will be removed immediately after surgery.
219013984|NCT01119131|DIETARY_SUPPLEMENT|calcium|1000mg calcium daily
219439703|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of multiple IVT injection
219439704|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - weekly
219439705|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - fortnightly
218831723|NCT06718114|PROCEDURE|early removal of urinary catheter|The urinary catheter will be kept after surgery and be removed within 48 hours after surgery.
218831724|NCT06714760|PROCEDURE|Reconstruction following parcellar resections of the mandibular gingival region|"In our surgical approach, we have used periosteum, galea, or pericranium flaps for reconstruction of bone and tissue defects in the cervicofacial region, with excellent results. To treat mandibular osteoradionecrosis, we harvested periosteum flaps from the radius, demonstrating efficacy in bone regeneration. For minor defects, such as those of the nose, we used flaps from the medial femoral condyle, despite the complexity of harvesting.~The cranial region, particularly the temporo-parietal area, offered excellent vascularization, allowing the use of revascularized flaps for reconstruction of the oral mucosa after removal of carcinomas. These flaps have also been effective in the treatment of pharyngeal fistulas, proving to be a functionally reliable solution for oral cavity and cervicofacial defects."
218831725|NCT06718062|DRUG|Aliskiren|Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20138002. The primary objective is to evaluate the non-inferiority of Aliskiren in lowering serum uric acid levels, and its effects on blood pressure and kidney function.
218831726|NCT06718062|DRUG|Losartan|Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20143030. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
219013985|NCT01119131|OTHER|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
219439706|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - weekly
219439707|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - fortnightly
219439708|NCT00854685|DRUG|Placebo|Placebo s.c. - weekly
219439709|NCT00854685|DRUG|Placebo|Placebo s.c. - fortnightly
219439710|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
219439711|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
219439712|NCT02089178|DRUG|propofol-remifentanil|
219439713|NCT02089178|DRUG|sevoflurane-remifentanil|
219439714|NCT01670825|PROCEDURE|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
219439715|NCT01670825|DRUG|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
219439716|NCT01670825|DRUG|Local anethestic injection|
219439717|NCT04287205|DRUG|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
219439718|NCT00003282|DRUG|EF5|Given IV
218831727|NCT05913544|OTHER|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
219439719|NCT00003282|PROCEDURE|therapeutic conventional surgery|Undergo resection
219439720|NCT00003282|PROCEDURE|biopsy|Undergo biopsy
218831728|NCT06716996|DEVICE|repeated transcranial magnetic stimulation|20 sessions of repeated transcranial magnetic stimulation
218831729|NCT06716996|DEVICE|sham treatment|20 sessions of sham treatment
218831730|NCT06716918|DRUG|Corticosteroid Injection|Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care.
219013986|NCT04170257|DIAGNOSTIC_TEST|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
219013987|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
219013988|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
219013989|NCT01614054|OTHER|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
219013990|NCT05283057|DRUG|Empagliflozin 25 MG|single dose of the SGLT inhibitor Empagliflozin was given
219439721|NCT00003282|OTHER|pharmacological study|Correlative studies
219439722|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
219439723|NCT04513106|BEHAVIORAL|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
219439724|NCT04513106|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
219439725|NCT04493489|DRUG|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
218831731|NCT06717464|DRUG|Capecitabine|1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)
218831732|NCT06717464|DRUG|Toripalimab|240mg intravenous injection, q3w, for 54 weeks (18 cycles)
218831733|NCT06714825|BIOLOGICAL|HS235|Up to 4 Single and 3 Multiple Ascending Doses
218831734|NCT06714825|DRUG|Placebo|Subcutaneous Injection
218831735|NCT06719167|BEHAVIORAL|Psychoterapy|During 11 weeks admission the programme will include group sessions using different modalities (psychoeducation videos, live psychoeducation groups, expressive arts therapy, equine facilitated therapy, mindfulness and discussion groups) all using TIST methodology. Parallell individual therapy with therapist (psychologist or psychiatrist) and milieu therapist. All therapists will be trained minimum in TIST level 1 and recieve supervision from an expert TIST therapist.
218831736|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
218831737|NCT06713278|OTHER|masseter muscle thickness measurement|masseter muscle thickness measurement with ultrasonography
218831738|NCT06713278|OTHER|scales|headache impact scale (HIT-6) Short SF-36 fibromyalgia total score widespread pain index symptom severity scale fibromyalgia impact questionnaire (FIQ)
218831739|NCT03941483|DRUG|ASP1128|Intravenous Infusion
218831740|NCT03941483|DRUG|Placebo|Intravenous Infusion
218831741|NCT01211392|OTHER|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
218831742|NCT01586689|BEHAVIORAL|Oxford House|community-based recovery home for participants recovering from substance dependency
218831743|NCT01586689|BEHAVIORAL|Safe Haven|professionally-staffed treatment facility
219439726|NCT04493489|DRUG|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
219013991|NCT05283057|DRUG|placebo|single dose of placebo that is similar to Empagliflozin in physical appearance
219439727|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
219439728|NCT02054936|DRUG|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
219013992|NCT03586856|DEVICE|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
219439729|NCT02054936|DRUG|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
219439730|NCT02330445|DRUG|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
218831744|NCT01586689|BEHAVIORAL|Usual aftercare|control group - participants may or may not seek treatment on their own
218831745|NCT01252589|OTHER|HRQOL questionnaire|
218831746|NCT02835144|OTHER|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
218831747|NCT02835144|OTHER|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
218831748|NCT04283188|BEHAVIORAL|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
218831749|NCT00529672|PROCEDURE|crossectomy and short stripping|under spinal or complete anaesthesia
219013993|NCT03586856|DEVICE|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
219013994|NCT01341964|DRUG|Clopidogrel|600mg (2 pills)
219013995|NCT01341964|DRUG|Aspirin|325mg (1 pill)
219013996|NCT01341964|DRUG|Aspirin|81mg (1 pill)
219013997|NCT02168179|PROCEDURE|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
219013998|NCT02168179|OTHER|questionnaire administration|Ancillary studies
219013999|NCT03505944|DRUG|Venetoclax|venetoclax + lenalidomide + rituximab
218831750|NCT00529672|PROCEDURE|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
218831751|NCT00529672|PROCEDURE|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
218831752|NCT04624100|PROCEDURE|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
218831753|NCT04416243|BEHAVIORAL|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
219014000|NCT04264598|BIOLOGICAL|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
219014001|NCT04264598|BIOLOGICAL|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
219363860|NCT02342132|DEVICE|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
219439731|NCT01149772|BEHAVIORAL|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
219439732|NCT02599857|DEVICE|CONCOR smartphone application|
218831754|NCT00570843|DRUG|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
218831755|NCT00570843|DRUG|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
218831756|NCT02668341|OTHER|non-interventional|non-interventional survey study
218831757|NCT02345733|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
218831758|NCT02345733|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
219014002|NCT04264598|BIOLOGICAL|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
218831759|NCT01082081|DRUG|Paracetamol 1000 mg|Paracetamol 1000 mg
218831760|NCT01082081|DRUG|Paracetamol 500 mg|Paracetamol 500 mg
219014003|NCT00278655|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
219014004|NCT05065177|BIOLOGICAL|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
219439733|NCT05195424|DIAGNOSTIC_TEST|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
219439734|NCT02443155|DRUG|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
219439735|NCT02443155|DRUG|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
219439736|NCT02443155|DRUG|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
219439737|NCT03527186|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
219439738|NCT00650897|DRUG|Escitalopram|10-20 mg once daily
219439739|NCT05298228|DRUG|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
219439740|NCT01759693|PROCEDURE|Blood sampling|Blood sampling
219764010|NCT02219659|DRUG|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
219439741|NCT02389218|DEVICE|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
219439742|NCT02389218|DRUG|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
219439743|NCT00992914|PROCEDURE|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
218831761|NCT01082081|DRUG|Placebo|Placebo
218831762|NCT04698239|DEVICE|LASER MILESMAN 445 NM|Laser application
218831763|NCT00928343|DRUG|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
218831764|NCT00928343|DRUG|Placebo|Matching subcutaneous or oral placebo
218831765|NCT00054743|PROCEDURE|Blood draw|
218831766|NCT03714438|DRUG|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
218831767|NCT03714438|DIETARY_SUPPLEMENT|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
218831768|NCT00537537|DRUG|Telbivudine|
218831769|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
218831770|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
218831771|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
218831772|NCT00932035|DRUG|isosulfan blue based lymphatic mapping|
218831773|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo standard axillary lymph node dissection
218831774|NCT00932035|PROCEDURE|quality-of-life assessment|Ancillary studies
218831775|NCT00932035|OTHER|Questionnaire administration|Ancillary studies
218831776|NCT00670930|DRUG|omalizumab at a dose of 0.016mg/kg/IU/mL|
218831777|NCT00670930|DRUG|Placebo|
218831778|NCT01464749|BEHAVIORAL|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
219014005|NCT05065177|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
219014006|NCT05850572|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
219439744|NCT00992914|PROCEDURE|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
218831779|NCT01464749|BEHAVIORAL|usual care|no specific rehabilitation
218831780|NCT04949945|BEHAVIORAL|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
218831781|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
218831782|NCT04584047|PROCEDURE|Cell-based non-invasive prenatal testing|Blood sampling.
219439745|NCT01670708|BEHAVIORAL|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
218831783|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
218831784|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
218831785|NCT01539447|DRUG|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
218831786|NCT01539447|DRUG|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
218831787|NCT01235663|BEHAVIORAL|advisory support|regular advisory support to the prolong breast-feeding period
218831788|NCT00187304|DEVICE|Aortic valve replacement|
218831789|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
218831790|NCT02587832|DEVICE|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
218831791|NCT02587832|DEVICE|NCPAP|Bubble CPAP System.
219014007|NCT05850572|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
219439746|NCT01670708|BEHAVIORAL|Probation as Usual|Probation officer supervises following standard protocols.
219439747|NCT02000219|BIOLOGICAL|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
219439748|NCT01442519|BIOLOGICAL|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0\_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
219580923|NCT02766426|BEHAVIORAL|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
219580924|NCT01322126|DEVICE|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
219014008|NCT04101825|DEVICE|Auralya|Hyaluronic Acid-Dermal Filler
219014009|NCT04399577|BIOLOGICAL|Candida antigen|Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
219014010|NCT05993260|BEHAVIORAL|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
219014011|NCT05993260|BEHAVIORAL|Control|Control vaccination eligibility reminder text message
219014012|NCT04827927|PROCEDURE|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
219014013|NCT04827927|PROCEDURE|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
218831792|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
218831793|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
218831794|NCT03368781|DEVICE|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
218831795|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
218831796|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
219439749|NCT01442519|DRUG|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
218831797|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
218831798|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
218831799|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
218831800|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
218831801|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
219014014|NCT03719976|OTHER|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
219014015|NCT02810392|DRUG|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
219014016|NCT02810392|DRUG|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
219014017|NCT01914744|DRUG|Entecavir|entecavir 0.5 mg/day PO
219014018|NCT01914744|DRUG|Lamivudine|lamivudine 100 mg/day PO
219014019|NCT05752903|DRUG|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
219439750|NCT02936115|OTHER|TruSkin®|
219439751|NCT02936115|OTHER|Wound Cover|
218831802|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
218831803|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
218831804|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
218831805|NCT05962281|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
218831806|NCT01107639|BIOLOGICAL|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
218831807|NCT01107639|DRUG|cisplatin|"* Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5"
218831808|NCT01107639|DRUG|docetaxel|"* Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5"
218831809|NCT01107639|PROCEDURE|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
218831810|NCT01107639|PROCEDURE|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
218831811|NCT05923697|BEHAVIORAL|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
218831812|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
218831813|NCT05304442|DRUG|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
218831814|NCT05304442|DRUG|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
218831815|NCT03431454|PROCEDURE|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
218831816|NCT03431454|PROCEDURE|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
218831817|NCT03431454|PROCEDURE|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
219014020|NCT05752903|DRUG|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
219014021|NCT00240253|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC injection
219014022|NCT00840294|DRUG|Ciprofloxacin|
219014023|NCT06014489|DRUG|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
219014024|NCT06014489|DRUG|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
219439752|NCT02866318|DEVICE|Echocardiography|
218831818|NCT01949766|DRUG|Glycerol phenylbutyrate|
218831819|NCT03493451|DRUG|Tislelizumab|Administered intravenously
218831820|NCT05262777|DEVICE|GP0112|Injectable gel
218831821|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
218831822|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
218831823|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
219014025|NCT06014489|DRUG|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
219014026|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
218831824|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
218831825|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
219014027|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
219014028|NCT05980650|OTHER|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
219014029|NCT05117398|DRUG|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
219014030|NCT05117398|DRUG|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
219014031|NCT04057014|DRUG|Amoxicillin|Antibiotic given at different dosages and durations.
219014032|NCT04057014|PROCEDURE|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
219014033|NCT00713154|DRUG|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
219580925|NCT01857765|BEHAVIORAL|Rehabilitation|Range of motion stretching exercises
219014034|NCT00713154|DRUG|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
219014035|NCT05569200|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
219014036|NCT05612178|BIOLOGICAL|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
219014037|NCT05612178|BIOLOGICAL|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
219014038|NCT05612178|OTHER|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
219014039|NCT04195685|PROCEDURE|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
219580926|NCT01857765|BEHAVIORAL|Follow-up|Follow-up with surgeon's clinic
219580927|NCT04775186|PROCEDURE|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
218831826|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
218831827|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
218831828|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
218831829|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
218831830|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
218831831|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
218831832|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
218831833|NCT03370419|BEHAVIORAL|Usual care|Usual care
218831834|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
218831835|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
218831836|NCT01297608|DRUG|coated suppository|coated suppository with placebo
218831837|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
218831838|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
218831839|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
219014040|NCT02278198|DRUG|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
218831840|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
218831841|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
218831842|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
219014041|NCT05443932|DRUG|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
218831843|NCT03272386|OTHER|Observational study|Completing a questionnaire
219014042|NCT05443932|DRUG|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
219014043|NCT03129243|DIAGNOSTIC_TEST|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
219439753|NCT04347902|DRUG|Intravenous Lipid Emulsion|Various types of intravenous lipids
219439754|NCT02117791|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
219439755|NCT00302055|BEHAVIORAL|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
218831844|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
218831845|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
219439756|NCT00302055|BEHAVIORAL|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
219580928|NCT05263622|OTHER|Split-mouth administration for group B|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
219580929|NCT05263622|OTHER|Split-mouth administration for group A|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
219580930|NCT02566993|DRUG|Lurbinectedin (PM01183)|
218831846|NCT05915195|OTHER|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
218831847|NCT05915195|OTHER|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
218831848|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
218831849|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
219014044|NCT04463095|PROCEDURE|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
219014045|NCT04490538|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
219580931|NCT02566993|DRUG|Doxorubicin (DOX)|
219580932|NCT02566993|DRUG|Cyclophosphamide (CTX)|
219580933|NCT02566993|DRUG|Vincristine (VCR)|
219580934|NCT02566993|DRUG|Topotecan|
219580935|NCT04488835|OTHER|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
219580936|NCT01834430|DIETARY_SUPPLEMENT|enteral nutrition|
218831850|NCT05236179|OTHER|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
218831851|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
218831852|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
219580937|NCT05337774|DRUG|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
218831853|NCT00145210|DRUG|Nebivolol and Atenolol|
218831854|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
218831855|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
218831856|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
218831857|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
219014046|NCT04825418|DEVICE|Artic Sun|"1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
218831858|NCT00711048|DRUG|AZD1386|oral, single dose
218831859|NCT00711048|DRUG|Placebo|Oral solution, single dose
218831860|NCT00349011|PROCEDURE|Personalized risk assessment|
218831861|NCT00349011|PROCEDURE|genetic counseling intervention|
219014047|NCT02406482|BEHAVIORAL|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
219363861|NCT02342132|DEVICE|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
219363862|NCT02342132|DEVICE|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
219363863|NCT01446419|DEVICE|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
219363864|NCT01446419|DEVICE|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
219363865|NCT02161159|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
219363866|NCT03311048|OTHER|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
219363867|NCT03311048|OTHER|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
219363868|NCT01228903|DRUG|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
219363869|NCT01228903|OTHER|Placebo|Placebo tablets with no active ingredient
219363870|NCT02867761|DRUG|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
219363871|NCT02867761|DRUG|Placebo|27.5/15.6 mcg placebo
219363872|NCT06405464|DRUG|VOCABRIA 30Mg Tablet|CAB 30 mg Film-coated tablets
219363873|NCT06405464|DRUG|EDURANT 25Mg Tablet|RPV 25 mg film-coated tablets
218831862|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
218831863|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
218831864|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
219014048|NCT02406482|BEHAVIORAL|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
219014049|NCT05781607|COMBINATION_PRODUCT|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
219439757|NCT04958525|PROCEDURE|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
219439758|NCT04958525|PROCEDURE|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
219439759|NCT05537272|DRUG|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
218831865|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
219014050|NCT05781607|COMBINATION_PRODUCT|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
219014051|NCT00461682|DRUG|SB-705498|
219014052|NCT03457129|DRUG|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
219014053|NCT00102102|DRUG|[18F]SPA-RQ|
219439760|NCT05537272|DRUG|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
219439761|NCT05537272|OTHER|Placebo|Administration of placebo ( Vitamin C \[ascorbic acid\] 500mg tablet) once daily seven days before and seven days after prostate biopsy
219439762|NCT01300000|OTHER|Human Milk|ad lib
219439763|NCT01300000|OTHER|Investigational infant formula|ad lib
219439764|NCT01300000|OTHER|Milk based standard infant formula|ad lib
219439765|NCT00923624|OTHER|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
219580938|NCT02356003|DEVICE|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
219580939|NCT06206200|OTHER|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
218831866|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
218831867|NCT01530178|DRUG|Placebo Oral Tablet|
218831868|NCT06846086|DRUG|Melatonin 10 MG|Melatonin
218831869|NCT06846086|DRUG|Placebo|placebo
218831870|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
218831871|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
218831872|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
218831873|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
219439766|NCT00923624|BEHAVIORAL|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
219439767|NCT05295836|OTHER|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
219439768|NCT05295836|DIETARY_SUPPLEMENT|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
218831874|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
218831875|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
218831876|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
218831877|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
218831878|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
218831879|NCT06284460|DRUG|ASTX029|Given by PO
218831880|NCT06284460|DRUG|ASTX727|Given by PO
218831881|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
218831882|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
219439769|NCT03973749|OTHER|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
219439770|NCT02525809|DEVICE|Novae E®|
219439771|NCT02525809|DEVICE|Sunfit®|
218831883|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
218831884|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
218831885|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
218831886|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
218831887|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
218831888|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
218831889|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
218831890|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
218831891|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
219014054|NCT04081311|DEVICE|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
219014055|NCT00883116|DRUG|Ixabepilone|
219014056|NCT00883116|DRUG|Doxorubicin|
219014057|NCT00883116|DRUG|Paclitaxel|
219014058|NCT05562076|DEVICE|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
219014059|NCT05562076|DEVICE|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
219014060|NCT03352622|OTHER|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
219014061|NCT03352622|OTHER|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
219014062|NCT00432107|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
219439772|NCT02525809|DEVICE|Quartz®|
218831892|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
218831893|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
218831894|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
218831895|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
218831896|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
218831897|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
218831898|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
219439773|NCT05991895|DRUG|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
219439774|NCT02434913|DEVICE|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
219014063|NCT02859675|OTHER|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
218831899|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
219014064|NCT02859675|BIOLOGICAL|blood sampling|sampling of 2 mL
219014065|NCT02859675|OTHER|Questionnaires|Stunkard, PrefQuest
219439775|NCT01934868|DRUG|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
219439776|NCT01934868|DRUG|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
219580940|NCT06206200|OTHER|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
218831900|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
218831901|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
218831902|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
218831903|NCT05327660|COMBINATION_PRODUCT|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
218831904|NCT05327660|COMBINATION_PRODUCT|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
218831905|NCT05327660|COMBINATION_PRODUCT|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
218831906|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
218831907|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
218831908|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
218831909|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
218831910|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
218831911|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
218831912|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
218831913|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
218831914|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
218831915|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
219014066|NCT06023420|DRUG|4 Herbs Formula|4 herbs formula dose: 5g/day
219363874|NCT06405464|DRUG|Cabotegravir Injectable Suspension|CAB LA 600 mg prolonged release suspension for injection (3 mL)
219363875|NCT06405464|DRUG|Rilpivirine Injectable Suspension|RPV LA 900 mg prolonged release suspension for injection (3 mL)
219363876|NCT06405464|BIOLOGICAL|Intact proviral DNA assay|HIV-1 latent reservoir size
219363877|NCT06405464|BIOLOGICAL|Full-length sequencing|Proviral DNA
219363878|NCT03885271|OTHER|Hall Technique|The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
218831916|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
218831917|NCT00600106|DRUG|Placebo|1 mg placebo
218831918|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
218831919|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
218831920|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
218831921|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
218831922|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
219439777|NCT00982748|BEHAVIORAL|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
219439778|NCT05587608|PROCEDURE|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
219439779|NCT03067480|DEVICE|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
219439780|NCT05117268|PROCEDURE|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
219439781|NCT05117268|PROCEDURE|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
219439782|NCT05117268|PROCEDURE|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
218831923|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
218831924|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
219580941|NCT03086837|BEHAVIORAL|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
219580942|NCT02820649|OTHER|Sleep deprivation|40 hours of continuous wakefullness
219580943|NCT00298779|DRUG|omeprazole and bortezomib|
219580944|NCT04002336|BEHAVIORAL|Traditional Voice therapy|Traditional method of voice therapy
219580945|NCT04002336|BEHAVIORAL|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
219580946|NCT06428318|DIAGNOSTIC_TEST|Conventional Sputum culture|Sputum culture was done to patients and they received Antibiotics According to its results
219580947|NCT06428318|DIAGNOSTIC_TEST|BioFire Pneumonia Panel (BFPP)|BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
219580948|NCT00649818|DRUG|Lorazepam Tablets 2 mg|2mg, single dose fasting
218831925|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV\_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV\_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV\_2000 and PTV\_6670, respectively).
218831926|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
218831927|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
218831928|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
218831929|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
218831930|NCT02322580|DRUG|etanercept|
218831931|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
218831932|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
218831933|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
218831934|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
219580949|NCT00649818|DRUG|Ativan Tablets 2 mg|2mg, single dose fasting
218831935|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
218831936|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
218831937|NCT01734798|RADIATION|Radiation|
218831938|NCT01734798|DRUG|gemcitabine and cisplatin|
218831939|NCT01734798|OTHER|Radiotherapy and Drug|
218831940|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
218831941|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
218831942|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
218831943|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
218831944|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
218831945|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
218831946|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
218831947|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
218831948|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
218831949|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
218831950|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
218831951|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
218831952|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
218831953|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
218831954|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
219014067|NCT03149185|BEHAVIORAL|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
219363879|NCT03885271|OTHER|Formecresol Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
219363880|NCT04506294|BEHAVIORAL|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
219363881|NCT02990260|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
219363882|NCT02990260|DIETARY_SUPPLEMENT|Lynside Wall Basic|yeast cell walls
219363883|NCT02990260|DIETARY_SUPPLEMENT|Placebo|Maize starch and magnesium stearate
219363884|NCT01928160|DRUG|pemetrexed disodium|Given IV
219363885|NCT01928160|DRUG|carboplatin|Given IV
219363886|NCT01928160|DRUG|cisplatin|Given IV
219363887|NCT01928160|DRUG|erlotinib hydrochloride|Given PO
219363888|NCT01928160|OTHER|laboratory biomarker analysis|Correlative studies
219363889|NCT01465659|DRUG|temozolomide|Given PO
219363890|NCT01465659|DRUG|pazopanib hydrochloride|Given PO
219363891|NCT02989792|GENETIC|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
218831955|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
218831956|NCT00284414|PROCEDURE|Ultrasonography or MRI|
218831957|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
218831958|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
218831959|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
218831960|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
218831961|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
218831962|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
218831963|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
218831964|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
218831965|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
218831966|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
218831967|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
218831968|NCT01897727|DRUG|Spironolactone|
219014068|NCT03149185|BEHAVIORAL|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
219014069|NCT01326689|DRUG|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
219014070|NCT01326689|DRUG|Placebo|
219014071|NCT01772706|PROCEDURE|low level laser therapy|
219014072|NCT01772706|PROCEDURE|placebo (laser low level energy nonfunctional)|
219014073|NCT02707874|DRUG|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
219014074|NCT02707874|DRUG|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
219014075|NCT01852578|DRUG|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
219014076|NCT06136754|DRUG|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
219014077|NCT06204718|OTHER|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
219014078|NCT06204718|OTHER|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
218831969|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
219014079|NCT03750812|BEHAVIORAL|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
219014080|NCT03750812|BEHAVIORAL|Watching television|Sitting and watching television for 30 minutes
219439783|NCT00106249|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
219580950|NCT06127368|DRUG|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
219580951|NCT06127368|DRUG|GB-5001D|Depending on the cohort, volume will be varied to administer.
218831970|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
218831971|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
218831972|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
218831973|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
218831974|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
218831975|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
218831976|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
218831977|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
218831978|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
218831979|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
218831980|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
218831981|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
218831982|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
218831983|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
218831984|NCT00212875|DRUG|epoetin alfa|
218831985|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
218831986|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
218831987|NCT01734785|DRUG|Linagliptin|tablet
218831988|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
218831989|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
218831990|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
218831991|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
218831992|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
219439784|NCT00106249|DEVICE|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
219439785|NCT01432704|DRUG|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
219439786|NCT05841641|DEVICE|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
219439787|NCT05841641|PROCEDURE|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
218831993|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
218831994|NCT01212887|BIOLOGICAL|aldesleukin|
218831995|NCT01212887|DRUG|cyclophosphamide|
218831996|NCT01212887|DRUG|fludarabine phosphate|
218831997|NCT01212887|OTHER|laboratory biomarker analysis|
218831998|NCT01212887|OTHER|pharmacological study|
218831999|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
218832000|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
219014081|NCT03387839|OTHER|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
219014082|NCT03939884|DRUG|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
218832001|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
218832002|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
218832003|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
218832004|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
218832005|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
218832006|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
218832007|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
218832008|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
218832009|NCT02468531|OTHER|oxygen|50% oxygen inhalation
218832010|NCT02468531|DRUG|Xenon|50% Xenon inhalation
219014083|NCT03939884|DRUG|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
219014084|NCT03939884|DRUG|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
219014085|NCT04472624|OTHER|Fasting|Acute fasting for 72 hours
219014086|NCT04472624|OTHER|Ketogenic diet|Intake of a ketogenic diet for 14 days
219439788|NCT03855761|BEHAVIORAL|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
219439789|NCT03855761|BEHAVIORAL|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
218832011|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
218832012|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
218832013|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
218832014|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
218832015|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
218832016|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
218832017|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
218832018|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
218832019|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
218832020|NCT02013778|DRUG|HCQ|
218832021|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
218832022|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
218832023|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
218832024|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
218832025|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
219439790|NCT00910936|BEHAVIORAL|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
219439791|NCT00240929|DRUG|MEDI-493|Active Comparator
219439792|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
219439793|NCT05257629|COMBINATION_PRODUCT|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
219439794|NCT05257629|OTHER|Varenicline Plus Counseling|Varenicline plus counseling
219439795|NCT01851525|DEVICE|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
219439796|NCT03487315|DIAGNOSTIC_TEST|immunoblot|immunoblot
219439797|NCT03908268|BEHAVIORAL|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
219439798|NCT03908268|BEHAVIORAL|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
219580952|NCT06127368|DRUG|Oral cohort|Single dose of Aricept tablet.
218832026|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
218832027|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
218832028|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
218832029|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
218832030|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
218859776|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
218832031|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
218832032|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
219014087|NCT03566251|OTHER|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
219439799|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
219439800|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
219439801|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
219439802|NCT00250367|DRUG|risperidone|
219439803|NCT04628338|DRUG|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
219439804|NCT04379609|OTHER|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
219439805|NCT00112684|DRUG|alvocidib|Given IV
219439806|NCT00112684|OTHER|pharmacological study|Correlative studies
219439807|NCT00112684|OTHER|laboratory biomarker analysis|Correlative studies
219439808|NCT00488059|DRUG|enfuvirtide [Fuzeon]|90 mg SC twice daily
219439809|NCT00488059|DRUG|Optimized background ARV|As prescribed
219439810|NCT00488059|DRUG|Integrase inhibitor|As prescribed
219439811|NCT00488059|DRUG|enfuvirtide [Fuzeon]|180 mg SC once daily
219439812|NCT02289716|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
219439813|NCT02289716|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
219439814|NCT02289716|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
219439815|NCT00179998|DRUG|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
219439816|NCT00179998|DRUG|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
219439817|NCT03338881|DRUG|[14C]-TAK-659|\[14C\]-TAK-659 solution.
219439818|NCT03338881|DRUG|TAK-659|TAK-659 tablets.
219439819|NCT03912324|PROCEDURE|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
219580953|NCT03024736|OTHER|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
219439820|NCT03912324|PROCEDURE|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
218832033|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
218832034|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
218832035|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
218832036|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
219014088|NCT03566251|OTHER|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
219014089|NCT03566251|OTHER|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
219014090|NCT03566251|OTHER|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
219014091|NCT02667574|DRUG|ERIVEDGE|
219580954|NCT03776721|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs.
219014092|NCT06320028|DEVICE|Non-Invasive Transcranial Focused Ultrasound|The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.
219014093|NCT04617444|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218832037|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
218832038|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
218832039|NCT01087658|DRUG|Glutamine|Per os
218832040|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
218832041|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
219014094|NCT04617444|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218832042|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
218832043|NCT02853396|OTHER|Cognitive Behaviour Therapy|
218832044|NCT02853396|OTHER|Psychoeducation|
219014095|NCT01361464|DRUG|Tipifarnib|Given PO
219580955|NCT03776721|PROCEDURE|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
219580956|NCT03776721|PROCEDURE|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
219580957|NCT03776721|BIOLOGICAL|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
218832045|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
218832046|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
218832047|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
218832048|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
218832049|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
218832050|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
218832051|NCT01285570|DRUG|5% dextrose in water|Placebo
218832052|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
218832053|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
218832054|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
218832055|NCT00788931|DRUG|IV LBH589|
218832056|NCT00788931|DRUG|Oral LBH589|
218832057|NCT00788931|DRUG|trastuzumab|
218832058|NCT00788931|DRUG|paclitaxel|
218832059|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
218832060|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
218832061|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
218832062|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
218832063|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
218832064|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
218832065|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
218832066|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
218832067|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
218832068|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
219439821|NCT03912324|PROCEDURE|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
218832069|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
218832070|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
218832071|NCT02706418|PROCEDURE|Clinical Massage Therapy|
218832072|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
218832073|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
218832074|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
218832075|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
218832076|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
218832077|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
218832078|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
218832079|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
218832080|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
218832081|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
218832082|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
218832083|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
218832084|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
218832085|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
218832086|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
218832087|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
218832088|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
218832089|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
218832090|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
218832091|NCT02144402|OTHER|infant formula with DHASCO|
218832092|NCT02144402|OTHER|infant formula with DHASCO-B|
218832093|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
218832094|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
218832095|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
218832096|NCT01692288|BEHAVIORAL|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
218832097|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
218832098|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
218832099|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
218832100|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
219014096|NCT01361464|OTHER|Laboratory Biomarker Analysis|Correlative studies
219014097|NCT04489212|OTHER|Medical Chart Review|Review of medical chart
219014098|NCT04489212|OTHER|Patient Observation|Undergo observation
219014099|NCT04489212|OTHER|Quality-of-Life Assessment|Ancillary studies
219014100|NCT04489212|OTHER|Questionnaire Administration|Ancillary studies
219014101|NCT04588792|DRUG|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
218832101|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
218832102|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
218832103|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
218832104|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
219014102|NCT04588792|DRUG|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
219014103|NCT04666584|DEVICE|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
219014104|NCT04666584|DEVICE|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
219014105|NCT03087760|DRUG|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
219580958|NCT03776721|PROCEDURE|Saline injection|4mL saline injected at the affected axillary site.
218832105|NCT02985918|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
218832106|NCT02985918|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
219014106|NCT04520737|BEHAVIORAL|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
219014107|NCT00894049|DRUG|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
219014108|NCT04501666|DRUG|Nemolizumab 30 mg|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
219014109|NCT04501666|DRUG|Placebo|Participants received matching placebo as SC injection.
219014110|NCT01537744|DRUG|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
219014111|NCT05020990|DEVICE|Lens A (delefilcon A)|Daily disposable for one week
219014112|NCT05020990|DEVICE|Lens B (stenfilcon A)|Daily disposable for one week
219014113|NCT05821114|OTHER|Head elevation_H|High flow\_Head-elevation
219014114|NCT05821114|OTHER|Supine_H|High flow\_Supine
219014115|NCT05821114|OTHER|Head elevation_L|Low flow\_head elevation
219014116|NCT05821114|OTHER|Supine_L|Low flow\_supine
219014117|NCT02747901|OTHER|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
219014118|NCT02747901|OTHER|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
219014119|NCT03007381|DRUG|Ketorolac Tromethamine|Intravenous analgesic
219014120|NCT03007381|DRUG|Normal Saline|Sham comparator
219014121|NCT01106898|DRUG|cyclophosphamide|Given IV
219014122|NCT01106898|DRUG|paclitaxel|Given IV
219014123|NCT01106898|BIOLOGICAL|trastuzumab|Given IV
219014124|NCT01106898|OTHER|laboratory biomarker analysis|Correlative studies
219014125|NCT01722071|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
219014126|NCT01722071|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
219014127|NCT03736291|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
219014128|NCT03021265|DRUG|T80/A5/H12.5 FDC|Drug
219014129|NCT03834701|DEVICE|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
219014130|NCT05072574|OTHER|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
219014131|NCT00642941|DRUG|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
219014132|NCT01266512|DRUG|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
219014133|NCT01266512|RADIATION|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
219014134|NCT01266512|DRUG|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
219014135|NCT00941473|DRUG|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
219014136|NCT03689803|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy.
219014137|NCT03689803|PROCEDURE|gastric bypass|gastric bypass
219014138|NCT04881708|DEVICE|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
219014139|NCT02632539|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
219014140|NCT02632539|PROCEDURE|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
219014141|NCT01692327|DIETARY_SUPPLEMENT|High fat meal|
219439822|NCT02305550|DEVICE|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
218832107|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
218832108|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
218832109|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
218832110|NCT03197610|PROCEDURE|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
218832111|NCT02318017|DRUG|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
218832112|NCT02318017|DRUG|Placebo|
219014142|NCT02188212|DEVICE|NobelProcera Crown Shaded Zirconia|
219014143|NCT02062879|DRUG|Ketamine|Ketamine administered as patient-controlled analgesia.
218832113|NCT04719221|DRUG|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol \<70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
218832114|NCT04719221|DEVICE|NIRS IVUS|near-infrared spectroscopy
218832115|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
218832116|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
218832117|NCT06000592|DEVICE|Digitimer|transcutaneous spinal cord stimulation for blood pressure control following spinal cord injury.
218832118|NCT02414516|DRUG|OBP-801|OBP-801 will be administered IV
218832119|NCT01465386|DRUG|bortezomib|Given SC
218832120|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 15 opioid tablets for post-operative pain
218832121|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 25 opioid tablets for post-operative pain
219014144|NCT02062879|DRUG|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
219014145|NCT02289079|DRUG|Bupivacaine|
219014146|NCT02289079|DRUG|liposomal bupivacaine|
219014147|NCT00110825|BEHAVIORAL|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
219014148|NCT05001074|DRUG|Extended release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
218832122|NCT04278703|DRUG|oxycodone|Patients will be given a prescription for 35 opioid tablets for post-operative pain
218832123|NCT05741892|DEVICE|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
218832124|NCT02945124|OTHER|K tape|Applying K tape to children to the lower limb muscles during motor activities.
218832125|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
218832126|NCT03284983|OTHER|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
219014149|NCT05001074|DRUG|Immediate release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
219014150|NCT04741061|BIOLOGICAL|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
219014151|NCT04741061|OTHER|Placebo|Placebo
219014152|NCT01105195|OTHER|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
219014153|NCT01105195|OTHER|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
219014154|NCT01114321|BEHAVIORAL|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
219439823|NCT02676453|OTHER|Intervention|Dental hygienist support
219439824|NCT02221960|BIOLOGICAL|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
219439825|NCT02221960|BIOLOGICAL|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
219439826|NCT00169013|DRUG|Gabapentin|
219439827|NCT01945788|DRUG|Teriparatide (rDNA origin)|
219439828|NCT04531397|DRUG|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
219439829|NCT04531397|DRUG|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
219439830|NCT04942769|DRUG|Selenium|selenium 100ug ，take it orally twice daily
219439831|NCT05800613|OTHER|Survey|Questionnaire
219439832|NCT02429349|PROCEDURE|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
219580959|NCT00952549|PROCEDURE|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
219580960|NCT03748849|PROCEDURE|Physiotherapy|
218832127|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
218832128|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
218832129|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
218832130|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
218832131|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
218832132|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
218832133|NCT00460655|DRUG|Placebo|Placebo
218832134|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
218832135|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
218832136|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
218832137|NCT03056235|DEVICE|Saline|Saline control
218832138|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
218832139|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor|Arm A
218832140|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
218832141|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
218832142|NCT04463940|OTHER|No intervention|No intervention
219014155|NCT03263494|DEVICE|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
219014156|NCT01757054|DIETARY_SUPPLEMENT|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
219014157|NCT03402789|DRUG|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
219014158|NCT03402789|DRUG|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
218832143|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
218832144|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~\- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
218832145|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
218832146|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
218832147|NCT03238703|DRUG|Anastrozole|Given PO
218832148|NCT03238703|DRUG|Exemestane|Given PO
218832149|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
219014159|NCT00553150|DRUG|everolimus|
219014160|NCT00553150|DRUG|temozolomide|
219014161|NCT00553150|RADIATION|radiation|
219014162|NCT05491954|DEVICE|Dexcom G6|Continuous glucose monitoring
219580961|NCT04050150|BEHAVIORAL|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
219014163|NCT03061331|DRUG|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
219014164|NCT03061331|DRUG|Placebo|No Active Drug
219014165|NCT02998840|BIOLOGICAL|B244|odorless suspension
219580962|NCT01622374|BEHAVIORAL|Music|Ten minutes of music or silence were applied prior to dental procedures
219580963|NCT01775865|DRUG|Salsalate|4 weeks of daily salsalate
219439833|NCT04694157|DEVICE|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
218832150|NCT03238703|DRUG|Letrozole|Given PO
219439834|NCT05791006|BEHAVIORAL|Neuropsychological tests|"Neuropsychological assessment with:~* NADL-F~* Frontal Assessment Battery (FAB)~* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
219580964|NCT01775865|DRUG|Placebo (for salsalate)|4 week of daily placebo
218832151|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
218832152|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
218832153|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
218832154|NCT03238703|DRUG|Toremifene Citrate|Given PO
218832155|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
218832156|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
218832157|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
218832158|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
218832159|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
218832160|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
218832161|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
218832162|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
218832163|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
218832164|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
218832165|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
218832166|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
218832167|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
218832168|NCT02443337|DRUG|LY3023414|Administered orally
219580965|NCT01169532|DRUG|ridaforolimus|Given PO
218832169|NCT02443337|DRUG|Necitumumab|Administered IV
218832170|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
219014166|NCT02998840|BIOLOGICAL|Vehicle|odorless suspension
219439835|NCT04829461|DEVICE|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
219439836|NCT04829461|DEVICE|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
219580966|NCT01169532|DRUG|vorinostat|Given PO
219580967|NCT01169532|PROCEDURE|biopsy|Optional correlative studies
219580968|NCT01169532|OTHER|pharmacological study|Correlative studies
218832171|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
218832172|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
218832173|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
218832174|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
218832175|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
218832176|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
218832177|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
218832178|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
218832179|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
218832180|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
219014167|NCT02143869|DEVICE|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
219014168|NCT05181423|OTHER|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
219014169|NCT03195088|DRUG|BI 473494|Solution for injection
219439837|NCT05829564|OTHER|virtual reality|The individuals participating in the study will experience virtual reality.
219580969|NCT01169532|OTHER|laboratory biomarker analysis|Correlative studies
218832181|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
219014170|NCT03195088|DRUG|Placebo|Solution for injection
218832182|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
218832183|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
218832184|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
218832185|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
218832186|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
218832187|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
218832188|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
218832189|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
218832190|NCT00305903|DRUG|Rivastigmine, memantine|
218832191|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
218832192|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
218832193|NCT01059045|OTHER|Control|No intervention
218832194|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
218832195|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
218832196|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
218832197|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
218832198|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
218832199|NCT02838043|DIETARY_SUPPLEMENT|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
218832200|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
218832201|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
218832202|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
218832203|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
219014171|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
219014172|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
219014173|NCT01686633|DRUG|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
219014174|NCT04771507|DRUG|Ibrutinib|Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
219014175|NCT00437554|DRUG|Glimepiride|
219014176|NCT03228589|DIETARY_SUPPLEMENT|probiotic strain|8 weeks of treatment with probiotic strain
219014177|NCT03228589|DIETARY_SUPPLEMENT|Placebo|8 weeks of treatment
218832204|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
218832205|NCT04169464|DRUG|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
218832206|NCT04198883|COMBINATION_PRODUCT|Protheracytes|Intramyocardiac (LV) injection of stem cells with a dedicated catheter
219014178|NCT05328791|BEHAVIORAL|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
219014179|NCT00703989|DIETARY_SUPPLEMENT|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
219014180|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics|pharmacogenomics
219014181|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics \& therapeutic drug monitoring
219014182|NCT04207385|DRUG|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
219014183|NCT05200533|OTHER|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
219014184|NCT05200533|OTHER|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
219014185|NCT05054959|OTHER|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
219014186|NCT05054959|OTHER|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
219014187|NCT00717340|DRUG|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
219014188|NCT05969873|OTHER|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
219014189|NCT05969873|OTHER|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
219014190|NCT00535223|BEHAVIORAL|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
219014191|NCT00535223|BEHAVIORAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
219014192|NCT02953314|DRUG|TEZ|
219439838|NCT05829564|OTHER|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
218832207|NCT00318929|DRUG|Divalproex Sodium Extended-Release Tablets|Once a day dosing
218832208|NCT00127881|DRUG|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
218832209|NCT00352859|DRUG|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
218832210|NCT00352859|DRUG|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
219014193|NCT02953314|DRUG|TEZ/IVA|
219014194|NCT02953314|DRUG|IVA|
219014195|NCT04269980|OTHER|MAP|MAP
219014196|NCT01455337|DRUG|pentoxifylline|400mg tid
219014197|NCT01455337|DRUG|Prednisolone|40mg qd
219014198|NCT02024620|BEHAVIORAL|Behavioral activation plus mobile app|
219014199|NCT02024620|BEHAVIORAL|Standard behavioral activation|
219014200|NCT02032966|PROCEDURE|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
219439839|NCT05829564|OTHER|exercise|The individuals participating in the study will performed neck-specific exercises.
219439840|NCT02037204|OTHER|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
219439841|NCT02660060|DRUG|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
219439842|NCT02660060|DRUG|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
219439843|NCT06219876|DEVICE|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
218832211|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
218832212|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
218832213|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
218832214|NCT06341361|DIAGNOSTIC_TEST|OCT-based machine learning FFR|OCT-based machine learning FFR and wire-based FFR
218832215|NCT01313910|DIETARY_SUPPLEMENT|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
218832216|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
218832217|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
218832218|NCT00903422|DRUG|eltrombopag olamine|thrombopoietin receptor agonist
218832219|NCT00903422|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
218832220|NCT05663008|PROCEDURE|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
218832221|NCT02552095|DEVICE|Triathlon PKR|
219014201|NCT02032966|PROCEDURE|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
219014202|NCT01421758|BEHAVIORAL|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
219014203|NCT01421758|BEHAVIORAL|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
219439844|NCT06219876|DEVICE|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
219439845|NCT06219876|OTHER|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
219439846|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
219439847|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
219439848|NCT03329664|BIOLOGICAL|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
219439849|NCT03329664|OTHER|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
219439850|NCT00564200|DRUG|Bortezomib|"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~\- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"
219439851|NCT00564200|DRUG|dexamethasone|"PREACONDICIONAMIENTO:~\- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
219439852|NCT00564200|DRUG|Fludarabine|"ACONDICIONAMIENTO:~\- Days -9 al -5: Fludarabine"
218832222|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
218832223|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
218832224|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
218832225|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
218832226|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
218832227|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
218832228|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
218832229|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
218832230|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
218832231|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
218832232|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
218832233|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
218832234|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
218832235|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
218832236|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
218832237|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
218832238|NCT00415870|BEHAVIORAL|Printed Material|Printed Material
218832239|NCT00415870|BEHAVIORAL|Weekly Weighing|Weekly Weighing
218832240|NCT00415870|BEHAVIORAL|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
218832241|NCT00415870|DEVICE|Text Message|Text Message
218832242|NCT00415870|BEHAVIORAL|Diet Goals via Cell Phone|Diet Goals via Cell Phone
218832243|NCT00415870|BEHAVIORAL|Food Monitoring|Food Monitoring
218832244|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
218832245|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
218832246|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
218832247|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
218832248|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832249|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
219363892|NCT02989792|OTHER|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
219439853|NCT00564200|DRUG|Melphalan|"ACONDICIONAMIENTO:~\- Days -4 and -3: Melphalan."
219764011|NCT02219659|DRUG|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
218832250|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832251|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832252|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
219363893|NCT00620243|PROCEDURE|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
218832253|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832254|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832255|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832256|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
218832257|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
218832258|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
218832259|NCT02977364|DRUG|HS-10241|
218832260|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
218832261|NCT01119144|DEVICE|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
218832262|NCT01119144|DEVICE|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
219363894|NCT03083028|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
219363895|NCT03083028|PROCEDURE|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
218832263|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
218832264|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
218832265|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
218832266|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
218832267|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
218832268|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
218832269|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
218832270|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
218832271|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
218832272|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
218832273|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
218832274|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
218832275|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
218832276|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
219439854|NCT05743517|BEHAVIORAL|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
218832277|NCT01509846|BIOLOGICAL|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
218832278|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
218832279|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
218832280|NCT05833412|DIAGNOSTIC_TEST|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
218832281|NCT05833412|DIAGNOSTIC_TEST|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
218832282|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
218832283|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
218832284|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
218832285|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
219439855|NCT02977442|BEHAVIORAL|exercise|
219439856|NCT03798678|DRUG|Carfilzomib|Given IV
219439857|NCT03798678|DRUG|Dexamethasone|Given PO
218832286|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
218832287|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
218832288|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
218832289|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
218832290|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
219764012|NCT06979375|DRUG|CDR132L|Administered intravenous infusion of CDR132L once every 4 weeks for 48 weeks.
219764013|NCT06979375|DRUG|Placebo|Administered intravenous infusion of placebo once every 4 weeks for 48 weeks.
219764014|NCT06114628|DRUG|Ganfeborole|Oral daily dosage of 20mg.
219764015|NCT06114628|DRUG|BTZ-043|Oral daily dosage of 1000mg.
219014204|NCT04974710|DIAGNOSTIC_TEST|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
219014205|NCT05192551|OTHER|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
219014206|NCT05067582|DRUG|L1-79|tyrosine hydroxylase inhibitor
219014207|NCT01765153|BEHAVIORAL|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
219439858|NCT03798678|DRUG|Telaglenastat Hydrochloride|Given PO
219764016|NCT06114628|DRUG|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
218832291|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
218832292|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
218832293|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
218832294|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
219014208|NCT01765153|BEHAVIORAL|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
219014209|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
219014210|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
219439859|NCT03765476|BEHAVIORAL|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
219439860|NCT03765476|BEHAVIORAL|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
219439861|NCT06185868|OTHER|No intervention measures|No intervention measures
219439862|NCT03648606|OTHER|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
219439863|NCT01480232|DRUG|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
219439864|NCT01480232|DRUG|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
219439865|NCT01480232|DRUG|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
219439866|NCT01480232|DRUG|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
219764017|NCT06114628|DRUG|Delamanid (D)|Oral daily dosage of 300mg.
219764018|NCT06114628|DRUG|Pretomanid (Pa)|Oral daily dosage of 200mg.
219764019|NCT06114628|DRUG|Moxifloxacin (M)|Oral daily dosage of 400mg.
219764020|NCT06114628|DRUG|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
218832295|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
218832296|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
218832297|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
218832298|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
219014211|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
219014212|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
219014213|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
219014214|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
219764021|NCT06114628|DRUG|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
219764022|NCT06114628|DRUG|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
218832299|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
218832300|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
218832301|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
218832302|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
218832303|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
219014215|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
219014216|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
219014217|NCT00319644|DEVICE|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
219014218|NCT05646797|DRUG|ASP2074|intravenous (IV) infusion
219014219|NCT06032000|BIOLOGICAL|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
219014220|NCT06032000|BIOLOGICAL|Placebo|0.9% Sodium Chloride Solution
219014221|NCT05257681|PROCEDURE|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
219014222|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
219439867|NCT01480232|BEHAVIORAL|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
219580970|NCT02664233|BEHAVIORAL|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
219014223|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
218832304|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
218832305|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
219014224|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
219014225|NCT01152086|OTHER|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)"
219014226|NCT04700618|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
219014227|NCT02894931|DIETARY_SUPPLEMENT|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
219014228|NCT02894931|DIETARY_SUPPLEMENT|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
219014229|NCT02894931|DIETARY_SUPPLEMENT|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
219014230|NCT02894931|DIETARY_SUPPLEMENT|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
219014231|NCT02894931|OTHER|Control- water|Chilled water flavored with lemon juice as control
219014232|NCT05563896|OTHER|No intervention|No intervention
219014233|NCT02554812|DRUG|Avelumab|Anti-PD-L1 antibody
219439868|NCT00524043|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
219439869|NCT00524043|DRUG|Placebo|Once daily for 6 weeks
219439870|NCT00524043|DRUG|Paliperidone ER|6 mg tablet once daily for 6 weeks
219439871|NCT01512472|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
219439872|NCT00391248|DRUG|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
219580971|NCT01716689|DRUG|oral cyclophosphamide|50mg daily
219580972|NCT01708590|DRUG|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
219580973|NCT01708590|DRUG|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
219580974|NCT01708590|DRUG|placebo|Placebo administered subcutaneous (SC)
219580975|NCT03731871|DIAGNOSTIC_TEST|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
219580976|NCT00297856|BIOLOGICAL|Boostrix®|Single dose
219580977|NCT00297856|BIOLOGICAL|Td (Tetanus diphtheria) vaccine|Single dose
219580978|NCT00760565|DRUG|RO4905417|3mg/kg iv every 28 days for 3 infusions
219580979|NCT00760565|DRUG|RO4905417|20mg/kg iv every 28 days for 3 infusions
219580980|NCT00760565|DRUG|RO4905417|7mg/kg iv every 28 days for 3 infusions
219580981|NCT00760565|DRUG|placebo|3mg/kg iv every 28 days for 3 infusions
219580982|NCT00760565|DRUG|placebo|7mg/kg iv every 28 days for 3 infusions
219014234|NCT02554812|DRUG|Utomilumab|Anti-4-1BB antibody
219014235|NCT02554812|DRUG|PF-04518600|OX40 Agonist
218832306|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
218832307|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
218832308|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
218832309|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
219014236|NCT02554812|DRUG|PD 0360324|Anti-M-CSF
219014237|NCT02554812|DRUG|CMP-001|TLR9 agonist
219014238|NCT03229668|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
219014239|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
219014240|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
219014241|NCT01448278|PROCEDURE|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
219014242|NCT01448278|PROCEDURE|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
219014243|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
219014244|NCT05767632|DRUG|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
219014245|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
219014246|NCT05885074|DRUG|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
219014247|NCT05885074|OTHER|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
219014248|NCT05885074|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
219014249|NCT05885074|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
219014250|NCT02071355|DRUG|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
219014251|NCT02071355|DRUG|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
219014252|NCT00415909|DRUG|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
219439873|NCT06245824|DRUG|Trastuzumab deruxtecan (T-DXd) with pyrotinib|T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
219764023|NCT06114628|DRUG|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
218832310|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
218832311|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
218832312|NCT02967419|OTHER|No Intervention|
218832313|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
218832314|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
219014253|NCT00415909|DRUG|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
219014254|NCT03226431|DRUG|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
219014255|NCT00312494|DRUG|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
219014256|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
219014257|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
219014258|NCT03981081|DRUG|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
219014259|NCT05657665|OTHER|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
219014260|NCT01862887|DRUG|PH-797804|Tablet, 24 mg, single dose
219764024|NCT06114628|DRUG|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
219764025|NCT06114628|DRUG|Delpazolid (DZD)|Oral daily dosage of 1200mg
218832315|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
218832316|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
219439874|NCT01843205|DRUG|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
218832317|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
218832318|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
218832319|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
219014261|NCT01862887|DRUG|Moxifloxacin|Tablet, 400 mg, single dose
219014262|NCT01862887|DRUG|Placebo|Tablet, PH-797804 matched placebo, single dose
219014263|NCT04526483|DEVICE|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
219014264|NCT04792632|DEVICE|Veye Lung nodules|Veye Lung Nodules
219439875|NCT01843205|DRUG|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
219439876|NCT00836303|BEHAVIORAL|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
219439877|NCT04876963|DEVICE|Holter-monitor|7-day holtermonitoring of each patient
219439878|NCT00606177|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
218832320|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
218832321|NCT00890435|OTHER|questionnaire administration|
218832322|NCT00890435|PROCEDURE|psychosocial assessment and care|
218832323|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
218832324|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
218832325|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
218832326|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
219014265|NCT01871610|DRUG|[18F]AV-45 PET amyloid binding imaging|
219014266|NCT00903617|DRUG|GSK256073|5 mg for 8 weeks
219014267|NCT00903617|DRUG|GSK256073|50 mg for 8 weeks
219014268|NCT00903617|DRUG|GSK256073|150 mg for 8 weeks
219014269|NCT00903617|DRUG|Placebo|placebo for 8 weeks
219014270|NCT00903617|DRUG|Niaspan|1500 mg for 8 weeks
219014271|NCT00903617|DRUG|GSK256073|x mg for 8 weeks based from data from Part A
219014272|NCT00903617|DRUG|GSK256073|optional dose based on data from Part A
219014273|NCT02512237|DRUG|ARX788|ARX788, an antibody drug conjugate
219439879|NCT00606177|DRUG|placebo|oral, 0mg(4tablets)/day
219439880|NCT05722977|DRUG|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
219014274|NCT00366145|BIOLOGICAL|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
219014275|NCT00366145|DRUG|Placebo|2 infusions per week for 4 weeks
219014276|NCT00366145|DRUG|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
219439881|NCT03571113|OTHER|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
219439882|NCT05872698|DRUG|Carvedilol|Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
219439883|NCT05872698|DRUG|Placebo|Placebo
219580983|NCT00760565|DRUG|placebo|20mg/kg iv every 28 days for 3 infusions
219764026|NCT06114628|DRUG|Quabodepistat (Q)|Oral daily dosage of 30mg
218832327|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
218832328|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
218832329|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
218832330|NCT04532840|DEVICE|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
218832331|NCT04532840|OTHER|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
218832332|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
219014277|NCT06092489|OTHER|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
219196052|NCT06852716|OTHER|Health education based on BCW theory|The intervention stage lasted for 3 months. The intervention measures in the intervention stage were as follows: stimulate the motivation to change (M), guide and motivate MCI patients to establish the health belief of insisting on long-term home oxygen therapy, and strengthen the importance and necessity of self-management; Training in behavioural change (C) Dissemination and presentation of knowledge manuals; Guide patients to correctly understand the definition, causes, clinical manifestations and hazards of COPD and MCI related diseases to improve their cognition and prevention awareness of the disease; Create a behavior change environment (O), provide a platform for patient communication, share and demonstrate home oxygen therapy skills, and improve long-term home oxygen therapy compliance. Along with the Visit stage: Collect relevant data during the patient's outpatient visit or home visit to understand the patient's long-term home oxygen therapy situation.
219439884|NCT06396988|OTHER|Novamin application|Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
219439885|NCT06396988|OTHER|Parodontax application|Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
219439886|NCT00136357|BEHAVIORAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
219439887|NCT04878289|BEHAVIORAL|TOTAL with Motivational Telemedicine Sessions|Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
219439888|NCT03405974|DRUG|Aspirin|Aspirin (acetylsalicylic acid)
219439889|NCT03405974|DRUG|Placebo|Placebo
219439890|NCT00763178|DRUG|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
219439891|NCT01799161|BIOLOGICAL|gp96-Ig Vaccine|
219439892|NCT01799161|DRUG|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
219439893|NCT01799161|OTHER|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
219439894|NCT01799161|PROCEDURE|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response \[frequency of CD4+, FoxP3 (Treg), et al\] in treated patients.
218832333|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
218832334|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
218832335|NCT02484443|OTHER|Pharmacological Study|Correlative studies
218832336|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
219439895|NCT00415753|BEHAVIORAL|No antibiotics if se-procalcitonin is below stated limit|
219439896|NCT04545411|DRUG|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
219439897|NCT04545411|DRUG|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
219439898|NCT04545411|DRUG|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
219580984|NCT06110728|BEHAVIORAL|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
218832337|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
219439899|NCT02124928|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
219439900|NCT00675688|DRUG|Bazedoxifene/Conjugate Estrogens (CE)|
218832338|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
218832339|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
218832340|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
218832341|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
218832342|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
218832343|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
218832344|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
218832345|NCT00178971|DRUG|adjunctive treatment with buspirone|buspirone 15-30 mg qd
218832346|NCT00178971|DRUG|placebo|placebo
218832347|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
218832348|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
218832349|NCT04149171|DRUG|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
218832350|NCT04149171|DRUG|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
218832351|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
218832352|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
219439901|NCT00675688|DRUG|Raloxifene|
219439902|NCT00675688|DRUG|Placebo|
218832353|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
218832354|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
218832355|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
218832356|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
218832357|NCT00429871|DRUG|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
218832358|NCT00429871|DRUG|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
219439903|NCT04884997|DRUG|toripalimab|toripalimab 3mg/kg, Q2w;
219439904|NCT04884997|DRUG|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
219439905|NCT01735097|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (200 mg, soft capsule)
219439906|NCT01735097|DIETARY_SUPPLEMENT|Nigella sativa|Nigella sativa (200 mg, soft capsule)
219439907|NCT01735097|DIETARY_SUPPLEMENT|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
219439908|NCT00003761|BIOLOGICAL|rV-DF3/MUC1|"\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
219764027|NCT06976697|DEVICE|Transcranial direct current stimulation|In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
218832359|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
218832360|NCT02969915|BEHAVIORAL|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
218832361|NCT02969915|BEHAVIORAL|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
218832362|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
218832363|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
218832364|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
218832365|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
218832366|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
218832367|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
219014278|NCT06092489|OTHER|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
219439909|NCT05567224|OTHER|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
219439910|NCT04316286|PROCEDURE|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
218832368|NCT00124969|DRUG|Amlodipine|10mg
218832369|NCT00124969|DRUG|Placebo|10mg
218832370|NCT03353662|OTHER|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
218832371|NCT03353662|OTHER|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
218832372|NCT03353662|OTHER|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
219439911|NCT04316286|OTHER|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
219439912|NCT05387135|DEVICE|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
219439913|NCT01085773|BEHAVIORAL|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
219439914|NCT01085773|BEHAVIORAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
219439915|NCT01011595|PROCEDURE|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
219439916|NCT01011595|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
219439917|NCT01011595|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
219439918|NCT01285414|DRUG|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
219439919|NCT01285414|DRUG|Temozolomide & Radiation Therapy|Temozolomide \& Radiation Therapy
219764028|NCT06976697|DEVICE|Sham transcranial direct current stimulation|Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
219439920|NCT00289614|DRUG|Iopamidol 370 mgI/dL|
218832373|NCT03353662|OTHER|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
218832374|NCT03353662|OTHER|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
219014279|NCT03596528|PROCEDURE|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
218832375|NCT03353662|OTHER|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
219014280|NCT00426192|DRUG|i.v. mannitol|
219580985|NCT04787393|DEVICE|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
219580986|NCT04787393|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
219580987|NCT01182558|OTHER|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
219580988|NCT01182558|OTHER|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
219580989|NCT01182558|OTHER|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
219580990|NCT01182558|OTHER|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
219580991|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
219580992|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
219580993|NCT03127644|DRUG|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
219580994|NCT01599065|OTHER|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
219014281|NCT00426192|PROCEDURE|hemofiltration|
219014282|NCT04893603|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
219580995|NCT01795274|RADIATION|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
219580996|NCT04738682|OTHER|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
218832376|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
219014283|NCT05152901|DRUG|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
219014284|NCT05152901|DRUG|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
219014285|NCT05152901|DRUG|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
219014286|NCT05152901|DRUG|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
219014287|NCT05047328|BIOLOGICAL|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
218832377|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
219014288|NCT03577743|DRUG|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
219014289|NCT03279328|DRUG|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
218832378|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
219580997|NCT04738682|OTHER|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
219580998|NCT02536326|DEVICE|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
218832379|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
219196053|NCT06852716|OTHER|Routine health education|(1) Give disease-related knowledge guidance according to nursing routine; (2) Guide patients and their families to standardize oxygen inhalation and ensure that patients correctly master oxygen inhalation operation methods; (3) Patiently answer patients' doubts about the disease, encourage patients to treat the disease with a positive attitude, and establish a good relationship of trust with patients and their families.
219439921|NCT00440141|DRUG|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
219439922|NCT00440141|DRUG|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
219580999|NCT01617694|DRUG|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
219581000|NCT01617694|DRUG|Normal Saline|
219581001|NCT04587063|BEHAVIORAL|Fear Appeals|Email
219581002|NCT04587063|BEHAVIORAL|Message about Future Healthcare Costs|Email
219581003|NCT04587063|BEHAVIORAL|Endorsement from a Doctor|Email
219581004|NCT04587063|BEHAVIORAL|Comparison Table|Email
219581005|NCT04587063|BEHAVIORAL|Highlighting Cost Savings and Convenience|Email
218832380|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
218832381|NCT01393899|DRUG|Placebo|oral tablets twice daily
218832382|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
218832383|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
218832384|NCT02503085|DRUG|Nurofen for Children®|
218832385|NCT02503085|DRUG|Algifor Dolo Junior®|
218832386|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
218832387|NCT03017339|OTHER|Functional Exercise|
218832388|NCT03017339|RADIATION|Low Level Laser Therapy|
218832389|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
218832390|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
218832391|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
218832392|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
218832393|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
218832394|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
218832395|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
218832396|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
218832397|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
218832398|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
218832399|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
218832400|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
218832401|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
218859777|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
219764029|NCT06086496|DEVICE|GENOSS® DES Sirolimus Eluting Coronary Stent System|The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
218832402|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
218832403|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
218832404|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
218832405|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
218832406|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
218832407|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
218832408|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
218832409|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
219014290|NCT03279328|OTHER|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
219439923|NCT02948504|PROCEDURE|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
219439924|NCT00296166|PROCEDURE|Catheter ablation|
219764030|NCT06977880|DRUG|LY4292009|Administered orally
219764031|NCT06977880|DRUG|Placebo|Administered orally.
219764032|NCT06979336|DRUG|RO7837195|RO7837195 will be administered as per the schedule specified in the protocol.
219764033|NCT06979336|DRUG|RO7837195 Matched Placebo|RO7837195 matched placebo will be administered as per the schedule specified in the protocol.
218832410|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
218832411|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
218859778|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
218859779|NCT00004729|BEHAVIORAL|Ketogenic diet|
218859780|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
218859781|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
218859782|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
218859783|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
218859784|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
218859785|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
218859786|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
218859787|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
218859788|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
218859789|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
218832412|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
219439925|NCT00296166|PROCEDURE|Thoracoscopic epicardial ablation|
219439926|NCT02524535|OTHER|Therapeutic alliance|
219439927|NCT03463213|BEHAVIORAL|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
219439928|NCT05505149|OTHER|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
219439929|NCT01492738|PROCEDURE|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
219439930|NCT06213415|DRUG|Corticosteroid|Oral steroids plus intratympanic injection
219439931|NCT03038516|DRUG|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
219439932|NCT03038516|DEVICE|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
219439933|NCT04371549|PROCEDURE|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
219439934|NCT04371549|PROCEDURE|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
219439935|NCT03642275|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
219439936|NCT03820206|DRUG|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
219439937|NCT03820206|PROCEDURE|Cesarean section|Lower segement transverse cesarean section
219439938|NCT05468580|PROCEDURE|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
219439939|NCT05468580|PROCEDURE|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
219439940|NCT04480749|DIAGNOSTIC_TEST|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
219439941|NCT04480749|DIAGNOSTIC_TEST|Syphilis Self-Test|Rapid Treponemal Test kit
219439942|NCT00927576|BEHAVIORAL|Digit span testing|Testing of short-term verbal memory with digit span
219764034|NCT05677100|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
219764035|NCT07124598|DEVICE|VR Headset Device - Meta Quest 3|The VR sessions will be conducted using hardware and software developed by AugMend Health Company. The AI-guided sessions will be administered using the commercially available Meta Quest 3 headset, which delivers high-resolution VR images and spatial audio through a standalone, wireless system.
219764036|NCT03609216|DRUG|Gemcitabine Hydrochloride|Given IV
218832413|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
218832414|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
218832415|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
218832416|NCT01294137|DEVICE|ventilatory polygraphy|
218832417|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
219439943|NCT00927576|BEHAVIORAL|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
218832418|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
219439944|NCT00927576|BEHAVIORAL|Finger tapping|Testing motor speed with a finger tapping test.
219439945|NCT00927576|BEHAVIORAL|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
219439946|NCT00927576|BEHAVIORAL|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
219439947|NCT00927576|BEHAVIORAL|Verbal fluency|Evaluating how many words are produced in 90s.
219764037|NCT03609216|DRUG|Cisplatin|Given IV
219764038|NCT03609216|BIOLOGICAL|Pegfilgrastim|Given SC
219764039|NCT03609216|PROCEDURE|Conventional Surgery|Undergo bladder sparing
219764040|NCT03609216|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
219764041|NCT03609216|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
219439948|NCT00927576|BEHAVIORAL|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
219439949|NCT00927576|BEHAVIORAL|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
219439950|NCT00927576|BEHAVIORAL|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
219439951|NCT00927576|BEHAVIORAL|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
219581006|NCT03908762|DEVICE|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
219581007|NCT03908762|BEHAVIORAL|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
219581008|NCT04710966|PROCEDURE|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
219581009|NCT04710966|PROCEDURE|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
219581010|NCT05912283|DEVICE|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
219581011|NCT05912283|DEVICE|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
219581012|NCT05912283|DEVICE|Control Latex Condom|Commercial natural rubber latex condom
219581013|NCT03762486|OTHER|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
219581014|NCT03762486|OTHER|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
219581015|NCT01186601|DRUG|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
219581016|NCT05102214|DRUG|HLX301|A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
219581017|NCT06262802|DEVICE|Active decompression|Intracystic active negative pressure
219581018|NCT05493137|OTHER|No intervention will be provided|No intervention will be provided, this is an observational study
219581019|NCT03343652|DRUG|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
219581020|NCT03343652|DRUG|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
219764042|NCT00124306|DRUG|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
219764043|NCT00124306|OTHER|Placebo|Placebo will be dosed exactly as active arm.
218832419|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
218832420|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
218832421|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218832422|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
218832423|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
219439952|NCT03846622|OTHER|Calculation of scoring systems for bleeding|
219581021|NCT02115932|OTHER|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
219581022|NCT02451332|BIOLOGICAL|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
219581023|NCT01156142|DRUG|doxepin hydrochloride|Oral rinse
219581024|NCT01156142|OTHER|placebo|Oral rinse
218832424|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218832425|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
218832426|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
218832427|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
218832428|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
218832429|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
218832430|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
218832431|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
219014291|NCT03279328|DRUG|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
219439953|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
219439954|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
219439955|NCT00216086|PROCEDURE|EUS|biopsy per EUS
219764044|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
218832432|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
218832433|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
218832434|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
218832435|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
218832436|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
218832437|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
218832438|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
219764045|NCT00068003|DRUG|Anti-CD19 CAR PBL|
219764046|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
218832439|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
218832440|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
218832441|NCT06482775|DRUG|dexmedetomidine|The dosing and administration will be implemented according to an algorithm based on pain scoring results
218832442|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
218832443|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
218832444|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
218832445|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
218832446|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
218832447|NCT02520388|DRUG|Placebo|
219439956|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
219439957|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
219439958|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
219439959|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
219439960|NCT00269685|DRUG|vasopressin|
219439961|NCT01446991|DRUG|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
219439962|NCT01446991|DRUG|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
219439963|NCT05210413|DRUG|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
219764047|NCT06828159|DIETARY_SUPPLEMENT|Wild blueberry|Freeze-dried wild blueberry powder 25g/day
219764048|NCT06828159|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for calories and no polyphenols
219764049|NCT05537025|DRUG|ARO-MMP7 Inhalation Solution|ARO-MMP7 by inhalation of nebulized solution
219764050|NCT05537025|DRUG|Placebo|Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
219764051|NCT06855498|DRUG|povorcitinib|Study drug will be taken orally as defined by the protocol.
218832448|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
218832449|NCT02860234|DRUG|Oxaliplatin|
219439964|NCT05210413|DRUG|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
219439965|NCT05210413|DRUG|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
219439966|NCT05210413|DRUG|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
219439967|NCT02025530|OTHER|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
219439968|NCT00728728|DRUG|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
219439969|NCT00728728|DIETARY_SUPPLEMENT|Placebo|Placebo
219439970|NCT03551626|DRUG|Dabrafenib|Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration
219764052|NCT06812494|BIOLOGICAL|VRC07-523LS 400mg|Intravenous infusion (IV)
219764053|NCT06812494|BIOLOGICAL|PGT121.414.LS 400mg|IV infusion
219764054|NCT06812494|BIOLOGICAL|PGDM1400LS 400mg|IV infusion
219764055|NCT06812494|BIOLOGICAL|VRC07-523LS 3200mg|IV infusion
219764056|NCT06812494|BIOLOGICAL|PGT121.414.LS 1600mg|IV infusion
219764057|NCT06812494|BIOLOGICAL|PGDM1400LS 1600mg|IV infusion
219764058|NCT03872401|DRUG|Evolocumab|Administered subcutaneously using an autoinjector pen.
219764059|NCT03872401|DRUG|Placebo|Administered subcutaneously using an autoinjector pen.
219764060|NCT06902714|DRUG|oral tranexamic acid|one group of subjects will receive oral tranexamic acid and the other will receive oral placebo
218832450|NCT02860234|DRUG|Capecitabine|
218832451|NCT02860234|RADIATION|intensity modulated radiotherapy|
218832452|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
218832453|NCT02860234|PROCEDURE|Nonoperative Management|
218832454|NCT02860234|PROCEDURE|Local Excision|
218832455|NCT02860234|PROCEDURE|Total Mesorectal Excision|
218832456|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
218832457|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
219439971|NCT03551626|DRUG|Trametinib|Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
219581025|NCT00893737|DRUG|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
219439972|NCT04211961|OTHER|Placebo / Saline|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
219439973|NCT04211961|DRUG|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
219764061|NCT06902714|DRUG|Placebo|one group of randomized subjects will receive placebo and the other will receive oral tranexamic acid
219764062|NCT05554172|DEVICE|taVNS|Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
218832458|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
218832459|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
218832460|NCT02919891|OTHER|Questionnaire|Questionnaires
218832461|NCT02592278|DRUG|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
219439974|NCT04906863|GENETIC|Blood draw|Blood draw for identification of genetic variants associated with the development of memory problems
219764063|NCT05554172|DEVICE|Sham|Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
219764064|NCT06979596|DRUG|MK-5684|Tablet for oral administration.
219764065|NCT06979596|DRUG|Fludrocortisone/ Fludrocortisone acetate|Tablet for oral administration.
219764066|NCT06979596|DRUG|Dexamethasone/Dexamethasone acetate|Tablet for oral administration.
218832462|NCT02592278|DRUG|Control Group|Twice a day brush with fluoride toothpaste.
218832463|NCT04326218|OTHER|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing"
218832464|NCT01480726|PROCEDURE|Surgery|
218832465|NCT03345303|DRUG|Bortezomib|Bortezomib Injectable Solution
218832466|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
218832467|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
218832468|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
219439975|NCT04906863|OTHER|Neurocognitive testing|Brief memory test
219439976|NCT04906863|OTHER|Medical questionnaire|Collection of medical history
219439977|NCT05250518|PROCEDURE|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
219439978|NCT05250518|PROCEDURE|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
219439979|NCT05616845|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
219439980|NCT02649829|BIOLOGICAL|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
219439981|NCT02940028|BEHAVIORAL|Expressive writing|Brief expressive writing intervention
219439982|NCT02940028|BEHAVIORAL|Control writing|Brief fact-based writing exercise.
219764067|NCT06979596|DRUG|Rescue Medications|Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.
218832469|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
218832470|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
218832471|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
218832472|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
218832473|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
218832474|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
218832475|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
218832476|NCT02339805|OTHER|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
218832477|NCT02339805|DEVICE|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
219439983|NCT04741295|DRUG|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
219439984|NCT05685186|DIAGNOSTIC_TEST|Spirometry|To assess lung function
219439985|NCT05685186|DIAGNOSTIC_TEST|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
219439986|NCT05685186|DIAGNOSTIC_TEST|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
219439987|NCT05685186|DIAGNOSTIC_TEST|CT of the chest|Low radiation to assess structural lung disease
219439988|NCT05685186|DIAGNOSTIC_TEST|MRI of the chest|To assess lung function and structural lung disease
219581026|NCT05173675|BEHAVIORAL|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~1. Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~2. Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~3. Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
219439989|NCT06400992|DEVICE|Cochlear implant processor Sky CITM M90 (CI-5295)|"The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
219581027|NCT05173675|BEHAVIORAL|Control Phase 2 Materials Only|"1. Material Incentives:~   a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~   i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~2. Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
219581028|NCT00566007|PROCEDURE|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
219581029|NCT00566007|DRUG|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
219581030|NCT00566007|DRUG|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
219581031|NCT02140411|DRUG|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
219581032|NCT00002444|DRUG|Nitazoxanide|
219581033|NCT02369991|PROCEDURE|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
219581034|NCT03749486|PROCEDURE|Cataract surgery|Cataract surgery will be done following ArcScan measurement
219581035|NCT04709367|OTHER|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
219581036|NCT01016886|DRUG|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
219581037|NCT03584724|DRUG|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
218832478|NCT05196750|OTHER|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
218832479|NCT03563482|DIAGNOSTIC_TEST|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
219581038|NCT03584724|DRUG|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
218832480|NCT02171143|DRUG|ASP2409|intravenous (IV)
218832481|NCT02171143|DRUG|Placebo|intravenous (IV)
218832482|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
218832483|NCT06220877|PROCEDURE|Buccal Pad of Fat|surgical procedure
218832484|NCT06220877|PROCEDURE|A-PRF|blood sample
218832485|NCT06220877|PROCEDURE|fibrin glue|procedure
218832486|NCT06220877|PROCEDURE|oxidized cellulose|procedure
218832487|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
218832488|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
218832489|NCT01176617|DEVICE|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
218832490|NCT03305952|BEHAVIORAL|CBCT|
218832491|NCT03305952|OTHER|TAU|
218832492|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
218832493|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
218832494|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
218832495|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
218832496|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
219363896|NCT04492280|DRUG|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
219363897|NCT00502190|DEVICE|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
219439990|NCT06400992|DEVICE|Hearing Aid, including sound processor Phonak: Sky Link M90|"The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
219439991|NCT06400992|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
219439992|NCT06400992|BEHAVIORAL|Audiologist Fitting Questionnaire|After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
219439993|NCT06400992|BEHAVIORAL|Patient Satisfaction Questionnaire|The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
219363898|NCT03390738|DRUG|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
219363899|NCT00282841|OTHER|ultrasound|single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
218832497|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Index|Nutritional Risk Index
218832498|NCT05417672|DIAGNOSTIC_TEST|Mini Nutritional Assessment|Mini Nutritional Assessment
219581039|NCT06284603|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session includes exposure of 60 minutes to 100% oxygen at 2.5 atmosphere absolute (ATA), with 5-minute air breaks every 20 minutes
219581040|NCT03981419|BIOLOGICAL|GRF6021|for IV infusion
219439994|NCT06400992|BEHAVIORAL|AutoSens Feedback Discussion Form|6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
219439995|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
219439996|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
219439997|NCT00230295|PROCEDURE|IMR LAG|
219581041|NCT03981419|OTHER|Placebo|for IV infusion
219581042|NCT00985179|BEHAVIORAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
219764068|NCT06979596|DRUG|Fulvestrant|Administered via intramuscular injection.
219764069|NCT06979596|DRUG|Exemestane|Tablet for oral administration.
219764070|NCT06979596|DRUG|Megestrol acetate/Medroxyprogesterone acetate|Tablet for oral administration.
218832499|NCT05417672|DIAGNOSTIC_TEST|Glasgow Prognostic Score|Glasgow Prognostic Score
218832500|NCT05417672|DIAGNOSTIC_TEST|Prognostic Nutritional Index|Prognostic Nutritional Index
218832501|NCT05417672|DIAGNOSTIC_TEST|Anthropometric measurements|middle arm circumference
218832502|NCT05417672|DEVICE|Handgrip strength test|Handgrip strength test
218832503|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
218832504|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
218832505|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
218832506|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
218859790|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
218859791|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
218859792|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
218859793|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
218859794|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
218859795|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
218859796|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
218859797|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
218859798|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
218832507|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
218832508|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
219014292|NCT02097407|DRUG|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
219014293|NCT02097407|DRUG|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
219439998|NCT05856149|BEHAVIORAL|Mobile Diabetes Prevention Program|The intervention is a mobile, web-based diabetes prevention program that participants will have access to for a total of 12 weeks. The intervention is a behavioral intervention aimed at increasing the knowledge and skills of participants to reduce type 2 diabetes risk behaviors.
219439999|NCT06851871|DRUG|Deucravacitinib|Specified dose on specified days
219440000|NCT06851871|DRUG|Famotidine|Specified dose on specified days
219440001|NCT06280053|DEVICE|HealiAid Collagen Wound Dressing|HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
219440002|NCT00049140|DRUG|EF5|
219440003|NCT00049140|OTHER|bioluminescence|
219440004|NCT00049140|OTHER|flow cytometry|
219440005|NCT00049140|OTHER|immunohistochemistry staining method|
219440006|NCT00049140|PROCEDURE|biopsy|
219440007|NCT02637648|DRUG|Sodium Oxybate|parallel Group administration
219440008|NCT02637648|DRUG|Placebo|parallel Group administration
219440009|NCT03793634|DRUG|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
219440010|NCT01686347|DRUG|ropivacaine|
219440011|NCT04368000|BEHAVIORAL|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
219440012|NCT04368000|BEHAVIORAL|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
219440013|NCT04293042|BIOLOGICAL|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
219764071|NCT06979596|DRUG|Tamoxifen|Tablet for oral administration.
218832509|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
219440014|NCT05212376|OTHER|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
219440015|NCT03684525|PROCEDURE|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
219440016|NCT00135525|DRUG|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
219440017|NCT00135525|DRUG|Placebo|Placebo
219764072|NCT06979596|DRUG|Letrozole|Tablet for oral administration.
219764073|NCT06604468|DIAGNOSTIC_TEST|Thoracic bioimpedance tomography|Data collection using a thoracic bioimpedance tomography device
219764074|NCT06780098|BIOLOGICAL|R-DXD|IV Infusion
219764075|NCT06780098|BIOLOGICAL|I-DXD|IV Infusion
219014294|NCT05502393|DRUG|JS107|JS107, i.v., q3w
219014295|NCT05502393|DRUG|Toripalimab|Toripalimab i.v., q3w
219014296|NCT00026351|BIOLOGICAL|rituximab|
219014297|NCT00026351|DRUG|pentostatin|
219014298|NCT06125015|DIAGNOSTIC_TEST|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
219014299|NCT04886050|DRUG|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
219440018|NCT02103595|DEVICE|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
219014300|NCT04886050|DRUG|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
219014301|NCT04563689|OTHER|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
218832510|NCT02947633|DRUG|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
218832511|NCT02947633|DRUG|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
218832512|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
219014302|NCT04563689|OTHER|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
219014303|NCT05851950|OTHER|group rumination focused cognitive behavioural therapy|Psychotherapy
219014304|NCT05851950|OTHER|Treatment as usual|opus treatment
219440019|NCT02103595|DEVICE|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
218832513|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
218832514|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
218832515|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
219014305|NCT03077802|OTHER|Modified Seldinger technique, Experienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
219014306|NCT03077802|OTHER|Seldinger technique, Experienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
219014307|NCT03077802|OTHER|Modified Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
219440020|NCT02989480|RADIATION|PET CT|PET CT scans
219440021|NCT02989480|OTHER|Cardiac MRI|Cardiac MRI
219440022|NCT03321890|DRUG|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
219440023|NCT03321890|DRUG|prednisone|oral, 20mg / day,after breakfast
218832516|NCT01890265|DRUG|Placebo|Solution for infusion
218832517|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
218832518|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
219440024|NCT03321890|DRUG|Cyclophosphamide|oral, 50mg / day,after lunch
219440025|NCT03321890|DRUG|etoposide|oral, 50mg / day,after dinner
219440026|NCT03321890|DRUG|Methotrexate|oral, 10mg / times, once a week,after breakfast
219440027|NCT01801124|DRUG|EXPAREL|single dose 266 mg of undiluted EXPAREL
219440028|NCT00004690|DRUG|monolaurin cream|
219440029|NCT00877734|DRUG|baclofen|10 mg Baclofen administered tid for 11 weeks
219440030|NCT00877734|DRUG|placebo|Placebo administered tid for 11 weeks
218832519|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
219440031|NCT00877734|BEHAVIORAL|BRENDA counseling|
219440032|NCT04383964|DEVICE|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
219014308|NCT03077802|OTHER|Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
218832520|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
218832521|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
218832522|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
218832523|NCT04373148|OTHER|There is no intervention|There is no intervention
218832524|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
218832525|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
218832526|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
219014309|NCT03077802|OTHER|Long-axis technique|Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
219014310|NCT03077802|OTHER|Short-axis technique|Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
218832527|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
218832528|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
218832529|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
218832530|NCT02321228|PROCEDURE|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
219014311|NCT00704925|DRUG|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
218832531|NCT02321228|PROCEDURE|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
218832532|NCT03034707|DIETARY_SUPPLEMENT|biotin|
218832533|NCT04650295|OTHER|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
218832534|NCT04650295|OTHER|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
219440033|NCT04383106|OTHER|no intervention|no intervention
218832535|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
218832536|NCT04335071|DRUG|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
218832537|NCT04335071|DRUG|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
218832538|NCT03343561|BEHAVIORAL|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
218832539|NCT04787003|DRUG|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
218832540|NCT06159283|DRUG|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
219014312|NCT05793320|PROCEDURE|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
219014313|NCT05548166|OTHER|Interview and scale development|Interview and scale development
219014314|NCT00016146|BIOLOGICAL|GPI-0100|
219014315|NCT00016146|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
219014316|NCT01647412|DRUG|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
219014317|NCT01647412|DIETARY_SUPPLEMENT|Nutraceutical Combination|
219014318|NCT01647412|OTHER|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
219014319|NCT01647412|OTHER|Placebo Growth Hormone|
219440034|NCT02394262|RADIATION|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
219764076|NCT06780098|DRUG|Docetaxel|IV Infusion
218832541|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
218832542|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
218832543|NCT01849315|BEHAVIORAL|AKIDS II|Physically active intervention
218832544|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
218832545|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
218832546|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
218832547|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
218832548|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
218832549|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
218832550|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
218832551|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
218832552|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
218832553|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
218832554|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
218832555|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
218832556|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
218832557|NCT00642707|DRUG|Placebo Comparator|
218832558|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
218832559|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
218832560|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
218832561|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
218832562|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
218832563|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
218832564|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
218832565|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
218832566|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
218832567|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
218832568|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
218832569|NCT00286650|PROCEDURE|3rd molar teeth extraction|
218832570|NCT03586960|DEVICE|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
218832571|NCT05881707|DRUG|CKD-828, D064, D702|QD, PO
218832572|NCT03321071|BEHAVIORAL|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
218832573|NCT03321071|BEHAVIORAL|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
219014320|NCT03017950|DRUG|CKD-330|
219014321|NCT03017950|DRUG|D086|
219440035|NCT02394262|OTHER|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
218832574|NCT05007548|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
218832575|NCT06237634|OTHER|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
218832576|NCT06237634|OTHER|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
218832577|NCT06237634|OTHER|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
218832578|NCT05715060|PROCEDURE|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
218832579|NCT01296503|DRUG|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
218832580|NCT01296503|DRUG|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
218832581|NCT06093399|DEVICE|System ON|The DBS system will be turned on, and the individual's stutter will be assessed.
218832582|NCT06093399|DEVICE|System OFF|The DBS system will be turned off, and the individual's stutter will be assessed.
218832583|NCT01541488|DRUG|BI 1021958|tablet
218832584|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
218832585|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
218832586|NCT00100802|OTHER|Laboratory Biomarker Analysis|Correlative studies
218832587|NCT00100802|DRUG|Lomustine|Given PO
218832588|NCT00100802|RADIATION|Radiation Therapy|Undergo radiation therapy
218832589|NCT00100802|DRUG|Temozolomide|Given PO
219440036|NCT02569333|OTHER|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
219440037|NCT02728206|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
218832590|NCT04454060|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
218832591|NCT01521598|DRUG|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
218832592|NCT01521598|DRUG|Placebo|This is the placebo. Patients will be randomized the placebo.
218832593|NCT02607410|DRUG|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
218832594|NCT02607410|DRUG|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
218832595|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
218832596|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
219440038|NCT02373306|PROCEDURE|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
219440039|NCT04989504|OTHER|Best Practice|Receive standard of care
219440040|NCT04989504|DEVICE|Wound Dressing Material|Apply Mepitel Film
219440041|NCT04989504|OTHER|Quality-of-Life Assessment|Ancillary studies
219440042|NCT04989504|OTHER|Questionnaire Administration|Ancillary studies
218832597|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
218832598|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
218832599|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
218832600|NCT03478670|GENETIC|Strimvelis|"Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273."
218832601|NCT03744338|OTHER|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
218832602|NCT02132572|DEVICE|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
218832603|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
218832604|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
218832605|NCT01484145|DRUG|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
218832606|NCT02462031|DRUG|KD101|200mg, 400mg, 800mg, 1400mg
218832607|NCT02462031|DRUG|placebo|200mg, 400mg, 800mg
218832608|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
218832609|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
219014322|NCT03017950|DRUG|CKD-330 + D086|
219014323|NCT03658850|DRUG|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
219014324|NCT03658850|DRUG|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
219014325|NCT04299204|PROCEDURE|Percutaneous nephrolitotomy|Pediatric PCNL
218832610|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
219440043|NCT01070706|DRUG|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
219440044|NCT06343454|OTHER|Digital Interocclusal Record In Different Head Positions|Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
219440045|NCT04176562|DEVICE|RTI Spine products|"* Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~* Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~* Bone graft substitute - is intended to aid in fusion."
219440046|NCT03167827|OTHER|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
219440047|NCT03167827|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
218832611|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
218832612|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
218832613|NCT00711152|OTHER|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
218832614|NCT00711152|OTHER|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
219014326|NCT05783115|PROCEDURE|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
219014327|NCT05783115|PROCEDURE|Tibial Transportation|transverse bone transport
219014328|NCT05652998|BIOLOGICAL|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
219014329|NCT05652998|OTHER|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
219440048|NCT03167827|OTHER|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
219440049|NCT01880879|DEVICE|helios stent|the group with helios stent implanted
219764077|NCT03076554|DRUG|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
219764078|NCT06812988|DRUG|SAR442970|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
219764079|NCT06812988|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
218832615|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
219014330|NCT05652998|OTHER|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
219014331|NCT02355691|DEVICE|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
219014332|NCT05685082|BEHAVIORAL|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
219014333|NCT05685082|BEHAVIORAL|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
219014334|NCT06146933|DIAGNOSTIC_TEST|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
219014335|NCT06146933|DIAGNOSTIC_TEST|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
219764080|NCT06841354|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
219764081|NCT06841354|BIOLOGICAL|Pembrolizumab|IV Infusion
219014336|NCT00462761|DRUG|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
219014337|NCT05383560|BIOLOGICAL|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
219014338|NCT05383560|BIOLOGICAL|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
219014339|NCT05383560|BIOLOGICAL|Placebo|Normal Saline for injection
219014340|NCT05383560|BIOLOGICAL|MRNA-1273.222 Vaccine|Moderna's commercial COVID-19 Vaccine
219014341|NCT02522286|BEHAVIORAL|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
218832616|NCT06400628|BEHAVIORAL|Self-management education|The base line data will be taken and used as control, while the final result will be utilized as the case
218832617|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
218832618|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
218832619|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
218832620|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
218832621|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
218832622|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
218832623|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
218832624|NCT00965289|DRUG|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
218832625|NCT00550186|OTHER|placebo|
218832626|NCT00550186|DRUG|Ringers Lactate|
218832627|NCT00550186|DRUG|HaemoHES 6%|
219440050|NCT04307589|OTHER|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
219581043|NCT03562559|OTHER|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
219581044|NCT01330459|DRUG|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
219581045|NCT01330459|DRUG|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
219581046|NCT01330459|DRUG|Ibuprofen|800 mg oral ibuprofen
218832628|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
218832629|NCT01840813|DRUG|Normal saline|It is a placebo group
218832630|NCT02489149|OTHER|Multi-sector interventions|"* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
218832631|NCT02489149|OTHER|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
218832632|NCT05047133|DRUG|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
218832633|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
218832634|NCT03814135|DRUG|Hipnos 3|1 tablet, oral, once a day.
218832635|NCT03814135|DRUG|Hipnos 5|1 tablet, oral, once a day.
219014342|NCT02522286|BEHAVIORAL|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2\) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3\) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
219014343|NCT04952142|OTHER|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
219014344|NCT02848014|BEHAVIORAL|Writing task|
219440051|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
219581047|NCT01330459|DRUG|Lorazepam|2 mg oral lorazepam
219581048|NCT01330459|DRUG|Lidocaine|20 ml 1% buffered lidocaine, injected
219581049|NCT02337959|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
219581050|NCT01231399|DRUG|fluorouracil|Given IV
218832636|NCT03814135|OTHER|Hipnos 5 Placebo|1 tablet, oral, once a day.
218832637|NCT03814135|OTHER|Hipnos 3 Placebo|1 tablet, oral, once a day.
218832638|NCT01038505|DRUG|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
218859799|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
218832639|NCT03751826|OTHER|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
219014345|NCT01175733|DRUG|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
219014346|NCT00774228|DEVICE|I-ZIP Ocular Bandage|
219014347|NCT00774228|DEVICE|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
219014348|NCT04922983|DRUG|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
219014349|NCT04922983|BEHAVIORAL|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
219440052|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
219440053|NCT05035823|DEVICE|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
219440054|NCT00821054|DRUG|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
219440055|NCT06305923|OTHER|colostrum cream|the intervention in our study is everyday using a cream with active ingridient
219440056|NCT06305923|OTHER|placebo cream|using a placebo cream
219581051|NCT01231399|DRUG|leucovorin calcium|Given IV
219581052|NCT01231399|DRUG|oxaliplatin|Given IV
219581053|NCT01231399|DRUG|everolimus|Given orally
219581054|NCT01231399|OTHER|laboratory biomarker analysis|Correlative studies
219581055|NCT01231399|OTHER|immunohistochemistry staining method|Correlative studies
219581056|NCT01231399|GENETIC|microarray analysis|Correlative studies
219014350|NCT04922983|BEHAVIORAL|Placebo|Used as placebo
219581057|NCT00760851|OTHER|probiotic strain Bb-12|10\^9 CFU Bb-12 per 4 oz yogurt
219014351|NCT04057079|COMBINATION_PRODUCT|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
219014352|NCT04057079|COMBINATION_PRODUCT|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
219014353|NCT00366158|DEVICE|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
219014354|NCT00366158|DEVICE|Ventricular Intrinsic Preference|Programming of pacemaker
219440057|NCT01633528|DRUG|Asprin|100 mg
219440058|NCT01633528|DRUG|placebo|100mg
219440059|NCT05529134|DRUG|PTW-002 10 mg/g gel|poloxamer hydrogel for topical administration
219440060|NCT05529134|DRUG|Placebo|placebo poloxamer hydrogel for topical administration
219440061|NCT01620658|DEVICE|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
219440062|NCT01620658|DEVICE|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
219440063|NCT01620658|DEVICE|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
219581058|NCT00760851|OTHER|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
219581059|NCT01843036|OTHER|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
219581060|NCT04146506|OTHER|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
219581061|NCT04746300|PROCEDURE|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
219581062|NCT04746300|PROCEDURE|Blood sample|Blood samples will be taken for additional translational research
219581063|NCT04988152|BIOLOGICAL|sotrovimab|sotrovimab IV infusion, single dose
219581064|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
219581065|NCT04988152|BIOLOGICAL|sotrovimab|Sotrovimab IM injection, single dose
219581066|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
219581067|NCT06458842|DRUG|Ketamine|
219581068|NCT06458842|OTHER|Placebo|
219581069|NCT02705404|GENETIC|Multifocal Tissue Banking|
219581070|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire at inclusion in registry
219581071|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
219581072|NCT01941355|BEHAVIORAL|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
218832640|NCT03751826|OTHER|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
218832641|NCT03751826|OTHER|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
218832642|NCT03739151|BEHAVIORAL|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
218832643|NCT02971371|DEVICE|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
218832644|NCT05859139|OTHER|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
218832645|NCT06715410|DEVICE|CO2|To collect CO2 data
218832646|NCT00014729|DRUG|isotretinoin|
218832647|NCT04824014|DIAGNOSTIC_TEST|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
218832648|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
218832649|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
218832650|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
219014355|NCT00605813|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
219014356|NCT04599920|DIETARY_SUPPLEMENT|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
219014357|NCT04930354|DRUG|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
219440064|NCT03607292|PROCEDURE|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
219440065|NCT03607292|PROCEDURE|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
219440066|NCT04481724|DIETARY_SUPPLEMENT|gamma-linolenic acid|3 capsules per day of GLA for 24 months
218832651|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
219440067|NCT04481724|DIETARY_SUPPLEMENT|placebo|3 capsules per day of placebo for 24 months
219440068|NCT03908931|RADIATION|MRI|Follow up of osteochondral surgery by MRI and clinical examination
219440069|NCT04154761|PROCEDURE|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
219440070|NCT00000368|BEHAVIORAL|Cognitive behavior therapy|
218832652|NCT00100256|DRUG|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
218832653|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
218832654|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
218832655|NCT00040781|DRUG|gefitinib|Given orally
218832656|NCT00040781|OTHER|pharmacological study|Correlative studies
218832657|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
218832658|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
218832659|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
218832660|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
218832661|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
218832662|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
218832663|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
218832664|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
218832665|NCT00219596|DRUG|Xalacom|
218832666|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
218832667|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
218832668|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
218832669|NCT02018029|OTHER|cardiac resynchronisation therapy|
218832670|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
218832671|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
219014358|NCT05771142|DEVICE|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
219440071|NCT00000368|DRUG|Paroxetine or other medication - algorithm used|
219440072|NCT02773368|DRUG|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
218832672|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
218832673|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
218832674|NCT01582009|DRUG|panobinostat|Given orally
218832675|NCT01582009|DRUG|everolimus|Given orally
218832676|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
218832677|NCT01582009|OTHER|pharmacological study|Correlative studies
218832678|NCT01582009|OTHER|liquid chromatography|Correlative studies
218832679|NCT01582009|OTHER|mass spectrometry|Correlative studies
218832680|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
218832681|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
218832682|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
218832683|NCT04739111|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
218832684|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
218832685|NCT01558284|DRUG|Placebo|Placebo
218832686|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
219014359|NCT05771142|DEVICE|ECG Holter|24h ECG Monitoring with ECG Holter
219014360|NCT05771142|DEVICE|Smartwatch|24h ECG Monitoring with a smartwatch
219440073|NCT02773368|DRUG|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
219440074|NCT01929018|BEHAVIORAL|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
218832687|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
218832688|NCT00358033|BEHAVIORAL|Counseling|
218832689|NCT00358033|BEHAVIORAL|Interactive Education|
218832690|NCT00358033|BEHAVIORAL|Group Support|
218832691|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
219014361|NCT01763437|DRUG|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
219014362|NCT00573755|DRUG|anastrozole|given orally
219014363|NCT00573755|DRUG|exemestane|given orally
219014364|NCT00573755|DRUG|letrozole|given orally
219014365|NCT00573755|DRUG|sorafenib tosylate|given orally
219014366|NCT00573755|OTHER|placebo|given orally
219014367|NCT01020279|DRUG|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
219014368|NCT01020279|DRUG|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
219014369|NCT03674918|DIAGNOSTIC_TEST|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
219440075|NCT01929018|BEHAVIORAL|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
219440076|NCT01929018|BEHAVIORAL|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
219440077|NCT02776852|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
219581073|NCT01941355|BEHAVIORAL|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
219581074|NCT00000476|DRUG|digitalis|
218832692|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
218832693|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
218832694|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
219014370|NCT04384510|PROCEDURE|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
219014371|NCT04384510|PROCEDURE|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
219014372|NCT06012045|BEHAVIORAL|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. Session #1 will be used to introduce to the participant the rationale and procedures of E-CET to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. Sessions #2 to #5 will be in vivo exposures. The interventionist will prompt the participant to evaluate the CS-US expectancy to facilitate the violation of the CS-US expectancy maintaining NEE. Between-session homework exposures will be planned and conducted by the participant in their naturalistic environment. They will also be reviewed at the beginning of the following session to consolidate learning. The final session will consist of consolidation of treatment gains and relapse prevention.
219014373|NCT06012045|BEHAVIORAL|Behavioral Lifestyle Intervention|The BLI will consist of six weekly sessions of behavioral counselling integrating behavioral strategies for participants to make dietary changes. These behavioral strategies will include education about healthy and balanced diets, goal-setting, problem-solving, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
219014374|NCT02684760|DRUG|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
219014375|NCT06366321|OTHER|relining technique|construction of complete denture by flasking and casting the relining impression
219014376|NCT06366321|OTHER|CAD/CAM milling technique|construction of complete denture by milling of the scanned relining impression
218832695|NCT03320837|OTHER|Breast milk|Breast milk
218832696|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
218832697|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
219440078|NCT03349593|DIAGNOSTIC_TEST|Echocardiography|Preoperative transthoracic echocardiography
219581075|NCT01359644|DRUG|PSI-7977|Tablets, oral, 400 mg, once daily
219581076|NCT01359644|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily
219581077|NCT01359644|DRUG|Ribavirin|Tablets, oral, 200 mg
219581078|NCT01763814|PROCEDURE|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
219581079|NCT01763814|PROCEDURE|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
218832698|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
218832699|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
218832700|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
218832701|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
218832702|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
218832703|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
218832704|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
218832705|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
218832706|NCT03851627|DRUG|Placebo|Placebo Arm
218832707|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
218832708|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
218832709|NCT00000407|BEHAVIORAL|Reading materials for control participants|
218832710|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
218832711|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
219014377|NCT01812824|BEHAVIORAL|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
219014378|NCT05284669|OTHER|Experimental e-learning|Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance
219014379|NCT05284669|OTHER|Traditional e-learning|Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
219014380|NCT04049968|DEVICE|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
218832712|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
218832713|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
218832714|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
218832715|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
218832716|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
218832717|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
218832718|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
218832719|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
219014381|NCT04049968|OTHER|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
219581080|NCT01763814|PROCEDURE|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
219581081|NCT02130882|DRUG|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
218832720|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
218832721|NCT01825330|DEVICE|sham|
218832722|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
218832723|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
218832724|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
218832725|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
218832726|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
218832727|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
218832728|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
219581082|NCT02130882|OTHER|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
219581083|NCT05816369|OTHER|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
218832729|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
218832730|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
218832731|NCT03369366|DEVICE|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
218832732|NCT03369366|DEVICE|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
218832733|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
218832734|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
218832735|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
218832736|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
218832737|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
218832738|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
219440079|NCT03616262|DRUG|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
219440080|NCT03616262|DRUG|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
219440081|NCT01935570|DRUG|Magnesium chloride (ChronoMag Smart Tablet®)|
219440082|NCT01935570|DRUG|Magnesium carbonate (Mag2® Tablet)|
219581084|NCT00520286|DRUG|Modafinil|200 mg or 400 mg /daily
219581085|NCT00520286|DRUG|Placebo|Placebo / daily
219581086|NCT06484634|DRUG|Low molecular weight heparin|A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
219581087|NCT03752463|DRUG|DAOI-A group|DAOI with A dose
219581088|NCT03752463|DRUG|DAOI-B group|DAOI with B dose
219581089|NCT03752463|DRUG|DAOI-C group|DAOI with C dose
219581090|NCT03752463|DRUG|Placebo oral capsule|Placebo
219581091|NCT04997941|DRUG|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
218832739|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
218832740|NCT03918382|OTHER|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
218832741|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
218832742|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
218832743|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
218832744|NCT04186325|PROCEDURE|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
219440083|NCT04767776|DRUG|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
219440084|NCT04767776|DRUG|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
219581092|NCT04997941|DIAGNOSTIC_TEST|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
219581093|NCT04997941|PROCEDURE|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
219581094|NCT01878162|OTHER|Exercise|
219581095|NCT00227786|BEHAVIORAL|smoking cessation intervention|
219581096|NCT00227786|OTHER|counseling intervention|
219581097|NCT02109510|DRUG|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
219581098|NCT02109510|DRUG|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
219581099|NCT02109510|PROCEDURE|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
219014382|NCT03155074|BEHAVIORAL|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
219196054|NCT06813183|OTHER|The palmar grasping reflex|"In the experimental group, the baby is monitored under a radiant heater before the procedure. After the infant's initial physiologic parameters and NIPS are recorded, the palmar grasp reflex is stimulated just before the procedure begins. The palmar grasp reflex can be stimulated by moving an object distally across the palm of the hand. In newborns, the right hand is more dominant than the left hand in the palmar grasp reflex ( Fagard et al., 2017). The researcher will stimulate the palmar grasp reflex by moving the index finger distally along the palm of the infant's right hand. The reflex stimulation will be continued until the end of the 5th minute.~Physiologic parameters will be scored by the investigator and a second nurse with at least 5 years of experience in neonatal intensive care and recorded on the follow-up form by scoring the pain levels 1 minute before (0 min), during, 2 and 5 min after the heel pricking procedure in the neonates in the NIPS intervention groups via the be"
219440085|NCT05784103|DEVICE|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
219440086|NCT05784103|DEVICE|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
219440087|NCT05784103|DEVICE|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
219440088|NCT05784103|DEVICE|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
219440089|NCT01789255|DRUG|vorinostat|Given PO
219764082|NCT06841354|DRUG|Rescue Medication|Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
218832745|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
218832746|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
219014383|NCT06094673|OTHER|No intervention|No intervention
219014384|NCT05798429|OTHER|compassion education|6 weeks of compassion training
219440090|NCT01789255|DRUG|tacrolimus|Given IV or PO
219440091|NCT01789255|DRUG|cyclosporine|Given IV or PO
219440092|NCT01789255|DRUG|methotrexate|Given IV
219440093|NCT01789255|OTHER|laboratory biomarker analysis|Correlative studies
219440094|NCT01789255|OTHER|pharmacological study|Correlative studies
219440095|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
219014385|NCT00918658|OTHER|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
219440096|NCT02635867|PROCEDURE|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
219440097|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
219440098|NCT02635867|PROCEDURE|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
219764083|NCT06841354|DRUG|Paclitaxel|IV Infusion
219440099|NCT02635867|PROCEDURE|Direct Pulp capping-Calcium hydroxide - Dycal|\\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
218832747|NCT00119197|BIOLOGICAL|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
219440100|NCT01866813|BEHAVIORAL|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
219440101|NCT04693312|DRUG|Depo medrol|local injection
219440102|NCT06950034|BIOLOGICAL|STX-0712|STX-0712 is IV administered every 21 days until the patient discontinues treatment.
219440103|NCT00553761|DEVICE|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
219440104|NCT05068999|DEVICE|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
219581100|NCT01484613|DEVICE|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
219581101|NCT01715064|BEHAVIORAL|Exercise|1 hour of moderate-intensity exercise
219764084|NCT06841354|DRUG|Nab-paclitaxel|IV Infusion
219764085|NCT06841354|DRUG|Gemcitabine|IV Infusion
219764086|NCT06841354|DRUG|Carboplatin|IV Infusion
218832748|NCT00119197|BIOLOGICAL|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
218832749|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
218832750|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
218832751|NCT00833469|DRUG|Escitalopram|Once daily by mouth
218832752|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
218832753|NCT05042401|DRUG|placebo|placebo low dose
218832754|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
218832755|NCT05042401|DRUG|placebo|placebo high dose
219014386|NCT00918658|OTHER|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
219014387|NCT00918658|OTHER|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
219014388|NCT01431560|DEVICE|fixation of the ankle fracture (Solco )|fixation with metallic implant
219014389|NCT01431560|DEVICE|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
219014390|NCT02132767|DRUG|Amiodarone|"Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
219014391|NCT02132767|PROCEDURE|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
219014392|NCT02132767|DRUG|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
219014393|NCT02074631|DRUG|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
219014394|NCT02074631|DRUG|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
219014395|NCT03193931|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
219014396|NCT03193931|DRUG|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
219014397|NCT03573947|DRUG|Nivolumab|360 mg intravenously every 3 weeks
219014398|NCT03573947|DRUG|Ipilimumab|1 mg/kg intravenously over 30 minutes
219014399|NCT03573947|DRUG|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
219581102|NCT03275818|DRUG|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
218832756|NCT02438033|DEVICE|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
218832757|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
218832758|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
218832759|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
218832760|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
218832761|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
218832762|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
218832763|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
218832764|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
218832765|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
218832766|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
218832767|NCT02671006|OTHER|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
219014400|NCT02588170|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
218832768|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
219014401|NCT02588170|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
219014402|NCT00842283|OTHER|skin tissue sample|skin tissue sample
219014403|NCT03806959|OTHER|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
219014404|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
219014405|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
219764087|NCT05283720|DRUG|Epcoritamab|Subcutaneous Injection (SC)
218832769|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
218832770|NCT03275090|DRUG|Smoflipid ®|
219014406|NCT01838993|DRUG|Lidocaine inhalation|Lidocaine inhalation before intubation
219014407|NCT01838993|DRUG|Placebo|
219014408|NCT00010075|DRUG|fluorouracil|
219014409|NCT00010075|DRUG|leucovorin calcium|
219014410|NCT00010075|DRUG|mitoxantrone hydrochloride|
219581103|NCT00856219|DIETARY_SUPPLEMENT|Enteral Continuous|Continuous Tube Feeding for 72 hours
219581104|NCT00856219|DIETARY_SUPPLEMENT|Enteral Intermittent|Intermittent Tube Feedings
219581105|NCT00856219|DIETARY_SUPPLEMENT|Parenteral Continuous|Parenteral Continuously for 72 hours
219764088|NCT05283720|DRUG|Lenalidomide|Oral; Capsule
219764089|NCT05283720|DRUG|Ibrutinib|Oral; Capsule
218832771|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
218832772|NCT06096090|DRUG|Placebo|Placebo administration
218832773|NCT02872597|DRUG|Ipratropium|
218832774|NCT02872597|DRUG|0.9% Sodium Chloride|
219014411|NCT04215380|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
219764090|NCT05283720|DRUG|Rituximab|Intravenous (IV); Injection
219764091|NCT05283720|DRUG|Cyclophosphamide|IV; Injection
219764092|NCT05283720|DRUG|Doxorubicin Hydrochloride [HCl]|IV; Injection
219764093|NCT05283720|DRUG|Prednisone|Oral; Tablet
219764094|NCT05283720|DRUG|Polatuzumab Vedotin|IV; Injection
219764095|NCT05283720|DRUG|Venetoclax|Oral; Tablet
218832775|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
218832776|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
219014412|NCT04215380|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
219014413|NCT05217329|OTHER|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
218832777|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
218832778|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
218832779|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
218832780|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
218832781|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
218832782|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
218832783|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
218832784|NCT00090961|OTHER|educational intervention|
218832785|NCT00090961|OTHER|supervised exercise program|
219014414|NCT05217329|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
219014415|NCT04778189|DRUG|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
219014416|NCT04778189|DRUG|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
219014417|NCT00017992|DRUG|Lopinavir/Ritonavir|
219014418|NCT00017992|DRUG|Emtricitabine|
219014419|NCT00017992|DRUG|Stavudine|
219014420|NCT05426226|DEVICE|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
219014421|NCT05426226|DEVICE|sham device|using sham device on sleep acupoints during sleep
219014422|NCT04923087|DEVICE|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
219014423|NCT01275833|DEVICE|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
219014424|NCT05098860|OTHER|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
218832786|NCT01173107|DRUG|colchicine|colchicine 1T tid
218832787|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
218832788|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
218832789|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
218832790|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
218832791|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
218832792|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
218832793|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
218832794|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
218832795|NCT05617989|OTHER|lung ultrasound|non-invasive ventilation and diuretic
219014425|NCT05098860|OTHER|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
219014426|NCT05098860|OTHER|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
219014427|NCT02870660|OTHER|Registry|
219014428|NCT06399588|BEHAVIORAL|Intervention for Adolescent Tobacco Initiation Prevention (IATIP)|The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
219014429|NCT00374725|BEHAVIORAL|Administration of probiotic (L. rhamnosus and L. acidophilus)|
219196055|NCT06853106|OTHER|Waitlist control group|The participants in the waitlist control group will be informed that they are on a waiting list during the intervention period, serving as a no-treatment control. They will receive the sleep intervention (i.e., the digital-based sleep management program) four weeks after the intervention period is completed.
218832796|NCT02056028|PROCEDURE|Hepatic resection|
218832797|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
219764096|NCT05283720|DRUG|CC-99282|Oral; Capsule
218832798|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
218832799|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
218832800|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
218832801|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
218832802|NCT03101189|DRUG|ACT-541468|Capsule
219014430|NCT04400786|PROCEDURE|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
219014431|NCT04400786|PROCEDURE|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
219014432|NCT02087475|DRUG|Irinotecan|
219014433|NCT02087475|DRUG|5-fluorouracil|
219581106|NCT03108092|OTHER|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
219581107|NCT03108092|OTHER|Control|Standard care in the department where the trial is conducted
219581108|NCT00725751|BIOLOGICAL|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
219581109|NCT00725751|DRUG|Ribavirin|Ribavirin administered according to European labeling.
219581110|NCT02570516|PROCEDURE|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
219581111|NCT01167959|PROCEDURE|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
219581112|NCT01167959|BEHAVIORAL|Prodimed dietary intervention|3 months of using the prodimed diet
219581113|NCT02365870|DRUG|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
219764097|NCT05283720|DRUG|Pirtobrutinib|Oral; Tablet
219581114|NCT02365870|DRUG|placebo|Participants will receive a placebo transdermal patch to be worn daily
219581115|NCT00195234|BIOLOGICAL|HIV CTL MEP 1000 micrograms, 19 months per subject|
219581116|NCT00069836|DRUG|Rosiglitazone/metformin|
219764098|NCT06159673|DRUG|ACP-204|ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
219764099|NCT06159673|DRUG|Placebo|ACP-204 matching placebo
219764100|NCT06598423|DEVICE|Specialized soft contact lens 1|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.
219764101|NCT06598423|DEVICE|Specialized soft contact lens 2|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
218832803|NCT03101189|DRUG|placebo|Matching placebo capsule
218832804|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
219014434|NCT02087475|RADIATION|Local radiotherapy|
219014435|NCT02087475|PROCEDURE|R0 resection|
219014436|NCT03830060|DIAGNOSTIC_TEST|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
219014437|NCT03008083|DRUG|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
219014438|NCT03008083|DRUG|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
219014439|NCT05303207|DIETARY_SUPPLEMENT|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
219014440|NCT05393141|BEHAVIORAL|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
219014441|NCT00000381|DRUG|Fluoxetine|
219581117|NCT01379001|DRUG|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
219581118|NCT01379001|DRUG|Placebo|IM or PO placebo
219581119|NCT01379001|DRUG|Donepezil|donepezil 5mg PO x 1
219764102|NCT06600425|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
219764103|NCT06358040|DEVICE|Opioid-Dispensing Device|Addinex Opioid-Dispensing Device
219764104|NCT06358040|OTHER|App|Addinex App
219764105|NCT06358040|OTHER|Standard Opioid Pill Bottle|Standard Opioid Pill Bottle
219764106|NCT04477603|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
219764107|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Adductor Canal Block|0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block
218832805|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
218832806|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
218832807|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
218832808|NCT05128864|PROCEDURE|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
218832809|NCT02227030|DRUG|BIIB 722 CL solution|
218832810|NCT02227030|DRUG|BIIB 722 CL tablet|
218832811|NCT02227030|DRUG|Placebo solution|
219014442|NCT01304966|PROCEDURE|biopsy|excisional biopsy
219014443|NCT00870896|DRUG|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
218832812|NCT02227030|DRUG|Placebo tablet|
218832813|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
219014444|NCT05891483|DRUG|SHR-1905 Injection|SHR-1905 Injection
219014445|NCT05891483|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
219014446|NCT04467879|DEVICE|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
219764108|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block|10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
219764109|NCT06982131|DRUG|RO7795081|RO7795081 will be administered orally during Periods 3, 4, and 5, according to the protocol.
218832814|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
218832815|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
218832816|NCT03644498|OTHER|Non-Interventional|Non-Interventional
218832817|NCT02419378|DRUG|Alemtuzumab|
218832818|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
218832819|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
219014447|NCT04467879|DEVICE|Control Device|Zona Plus control sham device, with a nominal weaker grip
219014448|NCT04164615|DRUG|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
219196056|NCT06853106|BEHAVIORAL|digital-based multimodal sleep management program|The digital-based multimodal sleep management program consists of (1) sleep hygiene education, (2) sleep restriction, and (3) mindfulness breathing exercises. The program is internet-integrated and delivered via Google Meet, with 45-minute weekly sessions over four weeks. To increase participants' adherence to the sleep management program , the course instructor will request the participants to record their daily sleep diaries (time to bed, time to sleep, wake time during sleep and wake time) and sleep journals(practices of sleep hygiene, sleep restriction and mindfulness breathing exercise) in the mobile app for at least five consecutive days each week.
219440105|NCT02782104|DRUG|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
218832820|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
219440106|NCT02058641|DRUG|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
219440107|NCT00120510|DRUG|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
219764110|NCT06982131|DRUG|Placebo|Placebo will be administered orally during Periods 3, 4, and 5, according to the protocol.
218832821|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
218832822|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
218832823|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
218832824|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
219440108|NCT00120510|DRUG|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
218832825|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
219014449|NCT04164615|DRUG|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
219014450|NCT00003901|OTHER|immunohistochemistry staining method|
219014451|NCT00003901|PROCEDURE|biopsy|
219014452|NCT00003901|PROCEDURE|surgery|
219014453|NCT03134482|PROCEDURE|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
219014454|NCT03134482|PROCEDURE|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
219014455|NCT00144209|DRUG|pramipexole|
219014456|NCT00144209|DRUG|levodopa in combination with benserazide|
219014457|NCT03486795|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
219014458|NCT03486795|DEVICE|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
219440109|NCT03288727|OTHER|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
219440110|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
219440111|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
218832826|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
218832827|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
218832828|NCT02212366|DEVICE|Active TDCS|Active Stimulation
218832829|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
218832830|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
218832831|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
219014459|NCT03486795|DEVICE|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
219014460|NCT02813564|BEHAVIORAL|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
219014461|NCT00262808|BIOLOGICAL|sargramostim|
219014462|NCT00262808|DRUG|fluorouracil|
219014463|NCT00262808|DRUG|leucovorin calcium|
219014464|NCT00262808|DRUG|oxaliplatin|
219014465|NCT00262808|PROCEDURE|adjuvant therapy|
219014466|NCT00262808|PROCEDURE|conventional surgery|
219440112|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219440113|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219440114|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219440115|NCT02114060|BIOLOGICAL|Placebo|0.9% Normal Saline (NaCl)
219440116|NCT02762136|DRUG|placebo|
219440117|NCT02762136|DRUG|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
219440118|NCT03900663|DEVICE|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
219440119|NCT03447821|DRUG|400 mg Rifamycin SV dosage|
219014467|NCT00262808|PROCEDURE|neoadjuvant therapy|
219014468|NCT02637752|BEHAVIORAL|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
219014469|NCT03119194|DRUG|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
219440120|NCT03447821|DRUG|800 mg Rifamycin SV dosage|
219440121|NCT03447821|DRUG|1200 mg Rifamycin SV dosage|
218832832|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
218832833|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
218832834|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
218832835|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
218832836|NCT03741907|PROCEDURE|MLC|Gold standard
218832837|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
219196057|NCT06854666|OTHER|effectiveness of platelet-rich plasma (PRP) in treating lateral epicondylar tendinopathy (LET)|"The intervention involves the administration of PRP (platelet-rich plasma), L-PRP (leukocyte-rich platelet-rich plasma), and saline according to a protocol developed for patients with lateral epicondylitis (EPi lat). The intervention includes specific parameters such as centrifugation speed and dual injection to the painful site, which is repeated after one week.~Following the procedure, treatment continues with a rehabilitation program, including the use of an orthosis. The orthosis serves as support during the recovery process after the injection. The rehabilitation program and the use of the orthosis aim to improve joint function and reduce pain, supporting tissue healing and regeneration."
218832838|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
219196058|NCT06854848|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219196059|NCT06854848|BIOLOGICAL|urine sample|10 ml
219196060|NCT06855420|DEVICE|Vibration on|Sole vibration will be applied by a vibrating insole system for 10 days. Participants will wear the device for at least 4 hours per day.
219196061|NCT06855420|DEVICE|Vibration off|Participants will wear the device with vibration turned off for at least 4 hours per day during 10 days of intervention.
219196062|NCT06808815|DRUG|DC-806|administered orally.
219196063|NCT06808815|OTHER|Placebo|administered orally.
219363900|NCT05688787|PROCEDURE|Perineural Injection|".injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1\_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest\&amp; T10 cross over iliac crest at a distance 8-10cm"
219440122|NCT04152746|OTHER|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
219440123|NCT04632745|OTHER|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
218832839|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
218832840|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
218832841|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
218832842|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
218832843|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
218832844|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
218832845|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
218832846|NCT00618735|DRUG|BIIB021|Twice daily dosing
218832847|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
218832848|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
218832849|NCT01842672|DRUG|Clofarabine|Dose Escalation of Clofarabine
218832850|NCT01842672|DRUG|Mitoxantrone|
218832851|NCT01775553|DRUG|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
218832852|NCT03240861|OTHER|18F-FHBG|Given IV
219440124|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
219440125|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
219440126|NCT04073641|OTHER|No intervention|No intervention
219440127|NCT02575989|OTHER|1: control group|Classic - current management of trauma patients by French medical teams
219581120|NCT02987101|PROCEDURE|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
218832853|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
218832854|NCT03240861|DRUG|Busulfan|Given IV
218832855|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
218832856|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
218832857|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
218832858|NCT03240861|DRUG|Fludarabine|Given IV
218832859|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
219014470|NCT00774618|DEVICE|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
218832860|NCT03240861|DRUG|Plerixafor|Given SC
218832861|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218832862|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
218832863|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
218832864|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
219014471|NCT05615012|DRUG|BMS-986322|Specified dose on specified days
219014472|NCT05615012|DRUG|Rosuvastatin|Specified dose on specified days
219014473|NCT05615012|DRUG|Metformin|Specified dose on specified days
219014474|NCT05615012|DIETARY_SUPPLEMENT|Glucose|Specified dose on specified days
219014475|NCT05615012|DRUG|Methotrexate|Specified dose on specified days
219196064|NCT06808737|PROCEDURE|Transversus Abdominis Plane Blockage|Patient monitoring will be conducted, followed by the preparation of the skin with 10% povidone-iodine and ensuring appropriate draping. A high-frequency linear transducer will be placed transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed, followed by the visualization of the oval spread of bupivacaine in the TAP.
219196065|NCT06853834|DEVICE|Cryobiopsy with liquid nitrogen|Forceps vs Cryo Endobronchial Biopsy
219196066|NCT06853834|DEVICE|Endobronchial Forceps Biopsy|Comparision of forceps and cryo endobronchial biopsy
218832865|NCT00164008|DRUG|zoledronic acid vs pamidronate|
218832866|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
218832867|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
218832868|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
218832869|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
218832870|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
218832871|NCT00002322|DRUG|Atevirdine mesylate|
218832872|NCT00002322|DRUG|Zidovudine|
219014476|NCT05615012|DRUG|Leucovorin|Specified dose on specified days
219014477|NCT01078012|BEHAVIORAL|Trained counselling|
219014478|NCT02417688|DEVICE|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
219014479|NCT04197089|DRUG|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
219014480|NCT06377228|BIOLOGICAL|TAK-007|TAK-007 IV infusion.
219014481|NCT06377228|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide IV infusion.
219014482|NCT00329654|PROCEDURE|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
219014483|NCT03190161|BEHAVIORAL|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
219014484|NCT02464345|BEHAVIORAL|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
219440128|NCT02575989|OTHER|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
219440129|NCT00329784|BIOLOGICAL|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
219440130|NCT04741087|DRUG|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
219440131|NCT04741087|DRUG|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
219014485|NCT02464345|BEHAVIORAL|CBT-E|CBT-E therapy
219440132|NCT04255992|DIETARY_SUPPLEMENT|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
219440133|NCT04255992|DIETARY_SUPPLEMENT|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
219440134|NCT03858569|PROCEDURE|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
219440135|NCT01525420|BEHAVIORAL|Acceptance Therapy (ACT)|ACT
219440136|NCT01525420|OTHER|Cognitive Behavioral Therapy (CBT)|CBT
219440137|NCT04179604|DRUG|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
219440138|NCT04179604|DRUG|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
218832873|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
218832874|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
218832875|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
219014486|NCT06378541|BEHAVIORAL|Virtual Hope Box Enhanced Facilitation|The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will receive a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
219014487|NCT06378541|BEHAVIORAL|Enhanced Usual Care|The EUC condition will involve a one-on-one, 30-minute session delivered prior to hospital discharge, during which the study interventionist will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).
219014488|NCT06108791|DRUG|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
219014489|NCT06108791|DRUG|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
219014490|NCT04240925|DEVICE|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
219014491|NCT04240925|DEVICE|Standard NIMV|Will be treated by standard NIMV with no sigh
219014492|NCT02902640|DRUG|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
219440139|NCT06047860|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
219014493|NCT02902640|DRUG|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
219014494|NCT02902640|DRUG|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
219440140|NCT06047860|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
219440141|NCT06047860|DRUG|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
219014495|NCT04404075|OTHER|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
219014496|NCT03737747|PROCEDURE|induced hypothermia|
219440142|NCT06047860|DRUG|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
219440143|NCT06047860|DRUG|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
219440144|NCT00838383|DRUG|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
219440145|NCT00838383|DRUG|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
219440146|NCT00838383|DRUG|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
219440147|NCT04137562|BIOLOGICAL|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
219440148|NCT04137562|OTHER|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
219440149|NCT03293628|PROCEDURE|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
218832876|NCT04907630|BEHAVIORAL|Antenatal Education|educational intervention
218832877|NCT06393803|DRUG|2mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
218832878|NCT06393803|DRUG|5mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
218832879|NCT06393803|DRUG|10mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
219014497|NCT03366402|DIAGNOSTIC_TEST|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
219014498|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the upper arm
219014499|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the lower abdomen
219440150|NCT00003340|DRUG|cyclophosphamide|
219440151|NCT00003340|DRUG|topotecan hydrochloride|
219440152|NCT02216890|DRUG|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
219440153|NCT00263835|BEHAVIORAL|Empowerment|
219440154|NCT00003852|BIOLOGICAL|filgrastim|
219440155|NCT00003852|DRUG|carboplatin|
219440156|NCT00003852|DRUG|cyclophosphamide|
218832880|NCT06393803|DRUG|20mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
219440157|NCT00003852|DRUG|epirubicin hydrochloride|
219440158|NCT00003852|DRUG|etoposide|
219440159|NCT00003852|DRUG|ifosfamide|
218832881|NCT06393803|DRUG|30mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
219440160|NCT00003852|DRUG|paclitaxel|
218832882|NCT06393803|DRUG|40mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
218832883|NCT06393803|DRUG|50mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
218832884|NCT06393803|DRUG|60mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
218832885|NCT02494154|DEVICE|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
219440161|NCT00003852|DRUG|thiotepa|
219581121|NCT02987101|OTHER|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
219764111|NCT06982131|DRUG|Rosuvastatin|A single 10 mg dose of rosuvastatin (ROS) will be taken on Day 1 of Period 1 and on Day 1 of Period 4.
218832886|NCT02494154|DEVICE|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
219014500|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the thigh
219014501|NCT02049307|DRUG|Losartan 100mg daily|
219014502|NCT02049307|DRUG|Matching placebo|
219440162|NCT00003852|PROCEDURE|bone marrow ablation with stem cell support|
219440163|NCT00003852|PROCEDURE|peripheral blood stem cell transplantation|
219440164|NCT00045630|DRUG|carboplatin|
219440165|NCT00045630|DRUG|gemcitabine|
219581122|NCT02987101|DRUG|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
219581123|NCT03544619|OTHER|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
219581124|NCT06052930|DEVICE|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
219764112|NCT06982131|DRUG|Pitavastatin|A single 1 mg dose of pitavastatin (PIT) will be taken on Day 1 of Period 2 and on Day 1 of Period 5.
218832887|NCT00222144|DRUG|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
218832888|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
219014503|NCT03063658|DRUG|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
219014504|NCT03063658|DRUG|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
219014505|NCT02550366|DRUG|MRI Contrast|MRI Contrast
219014506|NCT05357274|DIAGNOSTIC_TEST|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
219440166|NCT00045630|DRUG|paclitaxel|
218832889|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
219440167|NCT00045630|PROCEDURE|surgery|
219440168|NCT02855112|BIOLOGICAL|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
219440169|NCT03355768|DRUG|Romidepsin|Intravenous administration on a 28 day cycle
219440170|NCT03355768|DRUG|Pralatrexate|Intravenous administration on a 28 day cycle
219440171|NCT00346255|DRUG|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
219440172|NCT01566591|DEVICE|Deep TMS Treatment|24 TMS treatments over 6 weeks .
219440173|NCT01566591|DEVICE|Sham Treatment|24 TMS treatments over 6 weeks
219440174|NCT03034057|DRUG|Sayana Press|Sayana Press in the Uniject injection system
219440175|NCT03350867|OTHER|Personalized Insole Group|Personalized Insole Group
219440176|NCT03350867|OTHER|Placebo Group|Placebo Group
219440177|NCT05426018|DRUG|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
219440178|NCT01929707|DRUG|LY3050258|
219440179|NCT01929707|DRUG|Placebo|
219764113|NCT04062266|DRUG|Azacitidine|Given SC or IV
218832890|NCT02597530|DEVICE|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
218832891|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
218832892|NCT03589287|BIOLOGICAL|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
218832893|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
218832894|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
218832895|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
219014507|NCT02289976|PROCEDURE|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
219440180|NCT00143988|BEHAVIORAL|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
219440181|NCT00143988|BEHAVIORAL|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
219440182|NCT00263315|DRUG|nebulised liposomal amphotericin B|
219440183|NCT03432611|OTHER|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
219440184|NCT03432611|OTHER|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
219440185|NCT00437203|DRUG|PF-00477736|"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
219440186|NCT00437203|DRUG|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
219440187|NCT01485432|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
219764114|NCT04062266|DRUG|Venetoclax|Given PO
218832896|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
219014508|NCT05276245|BEHAVIORAL|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
219440188|NCT00084604|DRUG|irinotecan hydrochloride|Given IV
219440189|NCT00084604|BIOLOGICAL|bevacizumab|Given IV
219440190|NCT00084604|DRUG|cisplatin|Given IV
219440191|NCT00084604|PROCEDURE|computed tomography|Correlative studies
219440192|NCT00084604|OTHER|laboratory biomarker analysis|Correlative studies
219440193|NCT05771506|OTHER|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
219440194|NCT05771506|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
219581125|NCT01642459|OTHER|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
219581126|NCT01642459|OTHER|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
219581127|NCT02029586|DRUG|MB12066 200mg|oral administration, 100mg bid
219581128|NCT02029586|DRUG|Placebo|oral administration, 100mg bid
219581129|NCT00001586|BIOLOGICAL|Rituximab|Rituxan
219581130|NCT00001586|DRUG|Fludarabine phosphate|Fludara
219196067|NCT06809452|BEHAVIORAL|Transdiagnostic Oncologic Program|"The Transdiagnostic Oncology Program (TOP) is a 12-month interdisciplinary aftercare program aimed at improving cancer survivors' quality of life by addressing common clinical issues.~In the first three months, participants attended two weekly 1-hour exercise sessions led by physiotherapists. Once a week, this was followed by 1-hour mind-body therapy for stress reduction. A dietitian provided an initial group session on nutrition and advised at least two personal consultations.~Between months 3-6, exercise was reduced to once weekly, with encouragement to continue independent exercise and relaxation. A second informational session on stress and sleep hygiene was given.~After six months, participants continued independently, meeting the family doctor quarterly to evaluate progress.~For the participants who experienced some psychological problems, sessions with a psychologist at an institute specialized for psycho-oncology, were available."
219440195|NCT05771506|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
219440196|NCT05771506|OTHER|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
218832897|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
218832898|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
218832899|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
218832900|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
218832901|NCT00243139|DEVICE|Mandibular advancement device (activator)|
218832902|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
218832903|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
218832904|NCT00645840|DRUG|Anakinra|Patients will receive daily anakinra therapy for 28 days
219196068|NCT00758862|DRUG|2% TD1414 Cream|Application 3 times daily for 7 days
219440197|NCT05771506|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
219440198|NCT05771506|OTHER|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
219581131|NCT00001586|OTHER|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
219581132|NCT03358784|PROCEDURE|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
219581133|NCT03358784|PROCEDURE|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
219581134|NCT01201941|OTHER|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
219581135|NCT00364806|DRUG|Prochlorperazine|
218832905|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
218832906|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
218832907|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
218832908|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
218832909|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
218832910|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
219196069|NCT06853899|DIETARY_SUPPLEMENT|Truology A2|Truology A2 (0.2% Retinaldehyde Serum) - Applied once daily at night after cleansing.
218832911|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
218832912|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
218832913|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
218832914|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
218832915|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
218832916|NCT02625220|DEVICE|Prototype toric lens senofilcon A|Investigational prototype
218832917|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
218832918|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
218832919|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
218832920|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
218832921|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
218832922|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
218832923|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
218832924|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
219014509|NCT04184531|OTHER|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
219014510|NCT01524848|DRUG|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
219014511|NCT00073359|BEHAVIORAL|Cognitive Behavioral Therapy|
219014512|NCT00204854|BEHAVIORAL|telephone counseling|
219014513|NCT03888872|DEVICE|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
219014514|NCT03888872|OTHER|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:"
219440199|NCT01449955|DRUG|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
219440200|NCT01449955|DRUG|Placebo|Inactive
218832925|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
218832926|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
218832927|NCT04023760|DRUG|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
219440201|NCT02661945|DEVICE|Near focus with narrow band imaging|
219581136|NCT00364806|DRUG|Metoclopramide|
219581137|NCT02289235|DRUG|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
218832928|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
219581138|NCT02289235|DRUG|Placebo|Placebo powder 2 capsules twice daily for 3 months
218832929|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
218832930|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
218832931|NCT03235921|OTHER|placebo|no drug given to the control group
218832932|NCT02805959|DEVICE|MTS2|
218832933|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
218832934|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
218832935|NCT05011253|OTHER|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
219014515|NCT03096327|DRUG|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
219014516|NCT03096327|DRUG|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
219014517|NCT00035464|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
219014518|NCT00035464|DRUG|Placebo|placebo tablets, twice a day for 6 months
219014519|NCT00177528|DRUG|venlafaxine-XR|
219014520|NCT02794662|PROCEDURE|Oxygen Environment|FiO2 delivered by servo-controlled incubator
219014521|NCT02794662|PROCEDURE|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
219014522|NCT01869296|PROCEDURE|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
219440202|NCT00822562|OTHER|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
218832936|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
219440203|NCT00822562|PROCEDURE|surgery|only surgery
219440204|NCT00964262|DRUG|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
219014523|NCT01869296|PROCEDURE|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
219014524|NCT00441311|BEHAVIORAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
219014525|NCT00579956|DRUG|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
219014526|NCT00579956|DRUG|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
219014527|NCT02612935|DEVICE|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
219014528|NCT00680745|DRUG|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
219014529|NCT00680745|DRUG|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
219196070|NCT06853899|DIETARY_SUPPLEMENT|Truology C-Boost|Truology C-Boost - Applied twice daily (morning \& night).
219196071|NCT06853899|DIETARY_SUPPLEMENT|Truology Barrier Restore|Applied twice daily (morning \& night) as the final skincare step.
219440205|NCT00964262|DRUG|Placebo|Plcacebo of each doasage, single subcutanoeus injection
219440206|NCT00004125|DRUG|cyclophosphamide|
219440207|NCT00004125|DRUG|docetaxel|
219581139|NCT00663767|DRUG|Placebo; oral|dose 1, dose 2
219581140|NCT00663767|DRUG|Placebo; oral|dose 1
218832937|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
218832938|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
218832939|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
219014530|NCT00680745|DRUG|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
219014531|NCT00680745|DRUG|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
219014532|NCT00680745|DRUG|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
219014533|NCT05874076|BEHAVIORAL|Physiotherapy|Physiotherapy
219014534|NCT03704961|BEHAVIORAL|music and audiobook listening|
219196072|NCT06810479|DIAGNOSTIC_TEST|Polygraphy|Polygraphy will be caried out at the patients home to evaluate each MRA after 3 monhts
219196073|NCT06810479|OTHER|Questionaire|"Epworth Sleepiness Scale~o Johns, Murray W. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep, vol. 14, no. 6, 1991, pp. 540-545."
219196074|NCT06810479|OTHER|Questionaire|"Patient experience questionnaire~o Ng, E.T., Perez-Garcia, A., en Lagravère-Vich, M.O. Development and Initial Validation of a Questionnaire to Measure Patient Experience with Oral Appliance Therapy. Journal of Clinical Sleep Medicine, vol. 19, nr. 8, 1 aug. 2023, pp. 1437-1445. doi: 10.5664/jcsm.10562. PMID: 37082817; PMCID: PMC10394373"
219196075|NCT06810479|OTHER|Question|Patient final choice of preferred MRA
219440208|NCT00004125|DRUG|doxorubicin hydrochloride|
219440209|NCT00004125|DRUG|paclitaxel|
219440210|NCT00004125|DRUG|tamoxifen citrate|
219440211|NCT00004125|RADIATION|radiation therapy|
219440212|NCT00308243|DRUG|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
219440213|NCT02048358|DRUG|2B3-201|
219440214|NCT02048358|DRUG|Placebo|
219440215|NCT02048358|DRUG|Methylprednisolone hemisuccinate|
219014535|NCT00352521|DRUG|bevacizumab|
219014536|NCT00352521|DRUG|irinotecan|
219014537|NCT00352521|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219014538|NCT02612428|BIOLOGICAL|ELAD System|An extracorporeal human hepatic cell-based liver treatment
219014539|NCT02612428|OTHER|Standard of Care (Control)|Standard medical treatment as defined by the protocol
219581141|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
219581142|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
219581143|NCT00663767|DRUG|Celecoxib, COX-2 inhibitor; oral|dose 1
219581144|NCT00663767|DRUG|Placebo; oral|dose 2
219581145|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
219581146|NCT01194973|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
219581147|NCT01131962|PROCEDURE|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
219581148|NCT02031952|PROCEDURE|hepatectomy combined with lymphadenectomy|
219581149|NCT02031952|PROCEDURE|hepatectomy alone|
219581150|NCT00074737|DRUG|cenersen|cenersen with standard of care
219581151|NCT00074737|DRUG|Idarubicin|standard of care for AML
219581152|NCT00074737|DRUG|Cytarabine|standard of care Ara-C and High dose Ara-C
219581153|NCT01831453|DRUG|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
218832940|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
218832941|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
218832942|NCT01858441|DRUG|Abiraterone Acetate|
218832943|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
218832944|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
218832945|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
219014540|NCT04846621|DRUG|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
218832946|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
218832947|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
219196076|NCT06854887|DEVICE|digital breast tomosynthesis and mammography|tomosynthesis is 3D image for the breast mammography is 2D image for the breast
218832948|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
218832949|NCT03584815|PROCEDURE|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
218832950|NCT03584815|OTHER|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
218832951|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
218832952|NCT02508545|OTHER|Parabolic flight|
218832953|NCT01736267|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
218832954|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
218832955|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
218832956|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
218832957|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
218832958|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
219014541|NCT04846621|DRUG|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
219014542|NCT02211521|BIOLOGICAL|PRP|3ml of PRP
219014543|NCT02211521|DRUG|Hyaluronic acid|3ml hyaluronic acid
219014544|NCT00829881|DRUG|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
219581154|NCT01831453|DRUG|placebo|soft gelatinous capsules filled with isopropylmyristate oil
219581155|NCT04477772|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
218832959|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
218832960|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
218832961|NCT05270018|OTHER|normal saline|14.0ml once a day
218832962|NCT00149539|DRUG|Buprenorphine/naloxone|
218832963|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
218832964|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
218832965|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
218832966|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
219014545|NCT00829881|DRUG|Placebo Capsule|A single placebo capsule
219014546|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
219014547|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
219014548|NCT04573816|OTHER|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
219014549|NCT00795756|DRUG|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
219196077|NCT06654960|DRUG|HRS9531 injection|HRS9531 injection single dose.
219440216|NCT05834101|OTHER|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
218832967|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
218832968|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
218832969|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
218832970|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
218832971|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
218832972|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
218832973|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
218832974|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
218832975|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
218832976|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
219581156|NCT04477772|BIOLOGICAL|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
219581157|NCT00015028|DRUG|Buprenorphine/naloxone|
218832977|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
218832978|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
218832979|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
218832980|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
218832981|NCT04677543|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
218832982|NCT04677543|DRUG|Azithromycin|Oral tablet
219014550|NCT00795756|DRUG|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
219014551|NCT00137423|DRUG|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
219014552|NCT01928329|DRUG|Exenatide (Bydureon®)|
219014553|NCT01928329|DRUG|Placebo|
219014554|NCT03219489|OTHER|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
219581158|NCT02114476|DEVICE|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
218832983|NCT04677543|DRUG|Ethambutol|Oral tablet
218832984|NCT04677543|DRUG|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
218832985|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
218832986|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
218832987|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
218832988|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
218832989|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
219196078|NCT06654960|DRUG|Metformin Hydrochloride tablets|Metformin Hydrochloride tablets 500mg.
219196079|NCT06654089|DIETARY_SUPPLEMENT|Emergen-C Core Super Orange Powder|A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.
218832990|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
218832991|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
218832992|NCT01759342|BEHAVIORAL|Aerobic exercise|
218832993|NCT01759342|BEHAVIORAL|Resistance exercise|
218832994|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
218832995|NCT01759342|BEHAVIORAL|Balance exercise|
219196080|NCT06654089|DIETARY_SUPPLEMENT|Placebo|A study product identical to the test product without active ingredients.
219014555|NCT04512209|PROCEDURE|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
218832996|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
218832997|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
219014556|NCT03611790|DEVICE|NeVa VS|mechanical dilatation
219014557|NCT03187262|DRUG|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
219014558|NCT05811390|DEVICE|erythritol jet|Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole
218832998|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
218832999|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
218833000|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
218833001|NCT00181818|DRUG|bupropion SR (sustained-release)|
219014559|NCT05811390|DEVICE|Manual instrumentation|Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
219196081|NCT06654557|OTHER|Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
219196082|NCT06654557|OTHER|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219440217|NCT05834101|OTHER|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
219440218|NCT05300646|BEHAVIORAL|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
219440219|NCT00431496|DRUG|Cinacalcet|Cinacalcet tablets
219440220|NCT00493194|DRUG|sirolimus|
219440221|NCT00493194|DRUG|cyclosporine|
219440222|NCT00493194|DRUG|daclizumab|
219440223|NCT04734769|OTHER|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
219440224|NCT04516031|PROCEDURE|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
219440225|NCT04516031|PROCEDURE|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
219440226|NCT00876486|DRUG|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
219440227|NCT00876486|DRUG|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
219440228|NCT06034912|DEVICE|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
218833002|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
218833003|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
218833004|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
218833005|NCT00100958|DRUG|indole-3-carbinol|
218833006|NCT05767788|OTHER|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
218833007|NCT05767788|OTHER|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
218833008|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
219014560|NCT00528099|DRUG|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
219440229|NCT01983618|PROCEDURE|Interscalene nerve block and catheter|
219440230|NCT01983618|PROCEDURE|Interscalene catheter|
219440231|NCT03678818|OTHER|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
219581159|NCT02114476|DEVICE|Placebo|
218833009|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
219014561|NCT03863990|DRUG|PAH medication|Any PAH-targeted medication
218833010|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
219014562|NCT02617511|DIETARY_SUPPLEMENT|Omega-3 Supplementation|
219014563|NCT02617511|DIETARY_SUPPLEMENT|Placebo|
219014564|NCT01893073|BEHAVIORAL|Mindful walking program|
219014565|NCT01613625|PROCEDURE|Elastography|
219014566|NCT00034333|DRUG|MTC-DOX for Injection|
219196083|NCT06654557|OTHER|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
218833011|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
218833012|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
219014567|NCT06200077|PROCEDURE|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
219014568|NCT01602250|DRUG|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
219014569|NCT01602250|DRUG|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
219014570|NCT02141997|BIOLOGICAL|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
219014571|NCT02141997|BIOLOGICAL|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
219014572|NCT02158338|OTHER|Asthma|mothers who have children that have been diagnosed with respiratory issues
219014573|NCT02158338|OTHER|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
219014574|NCT02630355|OTHER|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
219440232|NCT05911113|OTHER|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
219440233|NCT05911113|OTHER|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
219440234|NCT00568607|DRUG|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
219440235|NCT02938507|DRUG|Formulation 1 solabegron|
219440236|NCT02938507|DRUG|Formulation 2 solabegron|
219440237|NCT00475371|DRUG|MKC253 Inhalation Powder|Inhalation powder
219014575|NCT01180673|BEHAVIORAL|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
219014576|NCT01180673|BEHAVIORAL|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
219014577|NCT02981719|PROCEDURE|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
219014578|NCT02981719|PROCEDURE|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
219014579|NCT02336022|DEVICE|Respiratory Motion Inc|
219014580|NCT01782261|DRUG|Liraglutide|once daily subcutaneous injection
219014581|NCT01782261|DRUG|Saxagliptin|once daily tablet
219196084|NCT06654557|OTHER|1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219014582|NCT03688477|DEVICE|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
219014583|NCT04061096|DIAGNOSTIC_TEST|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
219014584|NCT04061096|DIAGNOSTIC_TEST|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
219014585|NCT04061096|DIAGNOSTIC_TEST|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
219764115|NCT06807918|DIETARY_SUPPLEMENT|Kenetik|Drink a single dose of ketone supplement 25g, three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits.
219764116|NCT06807918|OTHER|magnetic resonance imaging scan|Each subject will undergo 2 research MRI scan evaluations of the brain (up to 90 min.). The MRI is FDA-approved 7.0T Magentom Prisma scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) with an approved radiofrequency head coil.
218833013|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
219764117|NCT06807918|OTHER|fludeoxyglucose-18 positron emission tomography scan|Each subject will undergo 2 FDG PET/CT scans. FDG is a positron emitting radiopharmaceutical. In addition to the radioactive FDG tracer, a low-dose CT of the chest is typically performed with the FDG PET/CT for the purpose of anatomical registration and attenuation correction of PET images. There are no separate diagnostic CT scans performed as part of this study.
218833014|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
218833015|NCT02001324|OTHER|Web-based data collection|
218833016|NCT02001324|OTHER|Paper-based data collection|
218833017|NCT04432922|OTHER|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
218833018|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
218833019|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
218833020|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
218833021|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
219440238|NCT02566109|DIAGNOSTIC_TEST|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
218833022|NCT01145963|OTHER|Control pasta|control pasta
218833023|NCT01145963|OTHER|Experimental pasta B|experimental pasta
218833024|NCT01145963|OTHER|Experimental pasta C|experimental pasta
218833025|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
218859800|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
219014586|NCT04105998|DRUG|Oxytocin|Oxytocin 10 IU
219014587|NCT04105998|DRUG|Placebo|Placebo
219014588|NCT05128851|PROCEDURE|HTO|Hight Tibial Osteotomy
219014589|NCT05128851|PROCEDURE|Arthroscopy treatment|Arthroscopy treatment
219440239|NCT04203940|PROCEDURE|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
219440240|NCT04203940|PROCEDURE|Suture|mesh fixation was done with polypropylene 2/0 sutures
219440241|NCT05944159|BEHAVIORAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
219440242|NCT05944159|OTHER|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
219440243|NCT02167724|OTHER|Bucco-dental examination|
219014590|NCT05128851|PROCEDURE|Micro fractures|Micro fractures
219014591|NCT03432546|OTHER|Non-interventional|Non-interventional
219014592|NCT02621411|DRUG|Substance use|Patients are found use of substances by preoperative screen
219014593|NCT03536403|RADIATION|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
219440244|NCT02167724|OTHER|Blood sample|
219440245|NCT02167724|OTHER|Clinical and social questionnaire|
219440246|NCT05670249|PROCEDURE|suboccipital decompressive craniectomy|extensive bilateral suboccipital decompressive craniectomy with duraplasty
219440247|NCT01906476|BEHAVIORAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
219764118|NCT06807918|OTHER|Alcohol bar lab|Each subject will undergo 2 alcohol bar labs. Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%.
218833026|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
218833027|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
218833028|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
218833029|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
218833030|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
218833031|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
218833032|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
218833033|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
218833034|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
218833035|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
219014594|NCT03536403|OTHER|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
219196085|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219440248|NCT01906476|BEHAVIORAL|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
219440249|NCT05483660|OTHER|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
218833036|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
218833037|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
218833038|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
218833039|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
218833040|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
219440250|NCT05483660|OTHER|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
219440251|NCT05483660|OTHER|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
219764119|NCT06807918|OTHER|Placebo beverage|Drink a single dose of placebo beverage, that will look and taste the same as the ketone supplement. Subjects will recieve the beverage three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits, opisite of the Kenetik beverage.
218833041|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
218833042|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
218833043|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
218833044|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
218833045|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
218833046|NCT00000553|DRUG|simvastatin|
219440252|NCT05483660|OTHER|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
219440253|NCT05057325|OTHER|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
218833047|NCT00000553|DRUG|niacin|
218833048|NCT00000553|DRUG|antioxidants|
219440254|NCT05057325|OTHER|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
219440255|NCT03037567|BEHAVIORAL|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
218833049|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
218833050|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
218833051|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
219014595|NCT06493266|BEHAVIORAL|neurolinguistic programmino|In this randomized controlled study, the group of patients with an indication for colposcopy in the Gynecological Oncology Department of Şanlıurfa Training and Research Hospital, Department of Gynecology and Obstetrics, will be divided into two groups and NLP training will be given before colposcopy in a double-blind manner, and after colposcopy, VAS (visual pain scale), fear of pain scale will be given. 3, evaluation will be made using the pain catastrophizing scale. NLP training will be given for approximately 20 minutes, and the group that will not receive NLP training will remain silent for 20 minutes. The results will be compared.
219440256|NCT01807767|DRUG|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
219440257|NCT01807767|DRUG|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
219440258|NCT01993667|DRUG|Low Dose Acetazolamide|Administration of low dose acetazolamide
219440259|NCT01993667|DRUG|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
219440260|NCT03119441|DEVICE|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
219764120|NCT05458908|DIAGNOSTIC_TEST|Non-contrast cranial MDCT head scan|Non-contrast cranial MDCT imaging for visualization of the brain parenchyma (the choice of the device is up to the investigator)
219014596|NCT00598663|DEVICE|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
219014597|NCT00598663|DEVICE|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
219014598|NCT04800692|DRUG|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
219014599|NCT04800692|DRUG|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
219014600|NCT04800692|DRUG|L-Ascorbate|3300 mg of l-ascorbate once daily
219014601|NCT04800692|DRUG|L-Arginine|3400mg of l-arginine once daily
219014602|NCT01621620|DRUG|Yohimbine|
219014603|NCT00563251|DRUG|Azithromycin|
219014604|NCT00563251|DRUG|Placebo tablet|
219014605|NCT00510133|BIOLOGICAL|GRNVAC1|Autologous dendritic cell vaccine
219014606|NCT05142865|DRUG|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
219196086|NCT06654557|OTHER|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219440261|NCT03119441|DEVICE|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
219440262|NCT04220710|DIAGNOSTIC_TEST|DNA extraction and methylation detection|DNA extraction and methylation detection
219440263|NCT01482455|OTHER|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
218833052|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
218833053|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
218833054|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
218833055|NCT03544593|DEVICE|Revolve System|Fat grafting system
218833056|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
218833057|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
218833058|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
218833059|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
219014607|NCT05142865|DRUG|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
219014608|NCT05142865|DRUG|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
219014609|NCT05142865|DRUG|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
219014610|NCT05142865|DRUG|Apatinib|250 mg given orally, once daily in 21-day cycle
219014611|NCT00204607|BIOLOGICAL|mRNA|
219014612|NCT00204607|DRUG|GM-CSF s.c.|
219440264|NCT01482455|OTHER|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
219440265|NCT04777123|OTHER|sitting position|patients will be left seated for 2 minutes after subarachnoid injection
219440266|NCT05024617|OTHER|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
219440267|NCT03889964|OTHER|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
218833060|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
218833061|NCT00293930|DRUG|Tacrolimus|
218833062|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
219014613|NCT03954951|OTHER|Multimodality behavioral strategy|"* On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
219440268|NCT01931150|DRUG|Topical Dapsone 5% Gel|
218833063|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
218833064|NCT01740258|RADIATION|Radiation Therapy|
218833065|NCT01740258|DRUG|Temozolomide|
218833066|NCT01740258|DRUG|Bevacizumab|
218833067|NCT05116956|OTHER|non interventional|Multinational prospective, standard care data collection, non-interventional, study not involving human subjects
219014614|NCT02184689|DRUG|fexinidazole|
219014615|NCT00909389|DRUG|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
219014616|NCT02630433|PROCEDURE|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
219440269|NCT01931150|OTHER|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
219764121|NCT05458908|DIAGNOSTIC_TEST|Non-contrast syngo DynaCT Sine Spin head scan and application software|Non-contrast syngo DynaCT Sine Spin imaging for visualization of the brain parenchyma with ARTIS icono biplane angiography system and syngo application software with syngo DynaCT Sine Spin 3-D head imaging protocol.
219764122|NCT02669251|DRUG|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
219764123|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
219764124|NCT05629871|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
219764125|NCT05629871|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
218833068|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
219014617|NCT02630433|PROCEDURE|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
219014618|NCT02859207|DRUG|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
219014619|NCT04471012|OTHER|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
219014620|NCT04565301|DRUG|Dexamethasone|adductor canal block
219014621|NCT04565301|DRUG|neostigmine|adductor canal block
219014622|NCT04565301|OTHER|NaCl solutions|adductor canal block
219014623|NCT00003492|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219014624|NCT03350633|DRUG|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
219014625|NCT03350633|DRUG|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
219014626|NCT04993989|DRUG|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
219440270|NCT01931150|DRUG|oral antibiotics|
219475409|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
218833069|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
218833070|NCT01091038|OTHER|Routine Care|Routine Care
218833071|NCT05358743|OTHER|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
218833072|NCT05358743|OTHER|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
218833073|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
218833074|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
218833075|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
218833076|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
218833077|NCT02112539|OTHER|platelet aggregation measurement|
218833078|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
218833079|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
219014627|NCT01516424|DRUG|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
219014628|NCT01516424|DRUG|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
219014629|NCT01045642|DRUG|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
218833080|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
218833081|NCT02596139|OTHER|No Interventions|
218833082|NCT04230616|PROCEDURE|total knee arthroplasty|total knee arthroplasty
218833083|NCT04230616|RADIATION|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
218833084|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
219014630|NCT01314833|DRUG|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6"
219014631|NCT01314833|DRUG|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3"
219014632|NCT01314833|DRUG|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4"
219196087|NCT06654557|OTHER|2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
218833085|NCT00310336|DRUG|S-adenosyl-L-methionine|
218833086|NCT00310336|DRUG|betaine|
218833087|NCT00310336|DRUG|pegylated interferon alpha2b|
218833088|NCT00310336|DRUG|ribavirin|
218833089|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
218833090|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
218833091|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
219475410|NCT06509880|BIOLOGICAL|Placebo|Placebo
219475411|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
219475412|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219475413|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
218833092|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
218833093|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
219475414|NCT02504099|DRUG|ribavirin|Tablet
219475415|NCT01917149|DRUG|Benazepril|
219475416|NCT01917149|DRUG|Valsartan|
219475417|NCT01917149|DRUG|Metoprolol|
218833094|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
218833095|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
218833096|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
218833097|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
218833098|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
218833099|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
218833100|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
218833101|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
218833102|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
218833103|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
218833104|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
218833105|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
218833106|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
218833107|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
218833108|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
218833109|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
218833110|NCT00343499|DRUG|valsartan|
218833111|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
219764126|NCT05629871|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
219014633|NCT05347550|OTHER|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
219014634|NCT02100059|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
219764127|NCT05629871|PROCEDURE|Actimetry|Measurement of actimetrics for 14 days at inclusion and at 24 months
219764128|NCT05629871|DIAGNOSTIC_TEST|Fractional diuresis|Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
218833112|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
218833113|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
218833114|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
218833115|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
218833116|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
218833117|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
219014635|NCT06296108|OTHER|acute kidney injury|The incidence of acute kidney injury was determined in patients included to the study
219014636|NCT00778089|DEVICE|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
219014637|NCT00597766|DRUG|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
218833118|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
218833119|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
218833120|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
218833121|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
219014638|NCT00597766|DRUG|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
219014639|NCT00597766|DRUG|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
219014640|NCT00597766|DRUG|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
219014641|NCT04680442|DRUG|Trastuzumab|Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
219014642|NCT04680442|DRUG|Pertuzumab|Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
219014643|NCT04680442|DRUG|Trastuzumab emtansine|Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
219014644|NCT03505983|DEVICE|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
219014645|NCT03505983|DEVICE|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
219014646|NCT03505983|DEVICE|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
219014647|NCT02908048|OTHER|Blood samples|Blood samples collected at varying intervals over a two to three year period.
219014648|NCT05528796|DIAGNOSTIC_TEST|Whole genome sequencing|"The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family."
219014649|NCT06407518|DRUG|Midazolam oral solution|Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
219014650|NCT06407518|OTHER|Placebo|Each individual administers placebo solution nightly from enrollment to the surgry.
219764129|NCT05629871|PROCEDURE|Internal temperature measurement|eCelsius capsule to measure internal temperature at inclusion and 24 months
219764130|NCT05629871|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
218833122|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
219014651|NCT05340374|DRUG|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
219014652|NCT05340374|DRUG|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
219475418|NCT06125847|GENETIC|NGGT006|Single intravenous infusion of NGGT006 at dose 1 (7.5e12vg/kg), dose 2 (1.5e13vg/kg) , dose 3 (3e13vg/kg) and dose 4 (4e13vg/kg).
219764131|NCT02112916|DRUG|Bortezomib|Given IV
219764132|NCT02112916|DRUG|Cyclophosphamide|Given IV
219764133|NCT02112916|DRUG|Cytarabine|Given IT, IV, or SC
219764134|NCT02112916|DRUG|Daunorubicin|Given IV
219764135|NCT02112916|DRUG|Daunorubicin Hydrochloride|Given IV
219764136|NCT02112916|DRUG|Dexamethasone|Given PO or IV
218833123|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
218833124|NCT02277574|OTHER|Placebo|Placebo
218833125|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
218833126|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
218833127|NCT00033423|BIOLOGICAL|rituximab|
218833128|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
218833129|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
218833130|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
218833131|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
218833132|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
218833133|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
218833134|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
218833135|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
218833136|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
218833137|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
218833138|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
218833139|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
218833140|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
218833141|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
218833142|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
218833143|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
218833144|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
219014653|NCT05414279|DIAGNOSTIC_TEST|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
219014654|NCT01463319|OTHER|air insufflation|air insufflation during insertion phase colonoscopy
219014655|NCT01463319|OTHER|warm water irrigation|warm water irrigation during insertion phase colonoscopy
219014656|NCT02771158|DRUG|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
219014657|NCT02771158|DRUG|placebo|placebo will be administered to double blind the study
219014658|NCT02671279|DIETARY_SUPPLEMENT|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
219014659|NCT04124289|OTHER|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
219014660|NCT00991055|DRUG|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
219014661|NCT02250755|OTHER|MRI T1 T2 sequences|MRI
219014662|NCT00134160|DRUG|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
219014663|NCT00134160|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
219014664|NCT03030690|OTHER|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
219014665|NCT03030690|OTHER|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
219014666|NCT03030690|OTHER|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
219014667|NCT03822247|PROCEDURE|Multidisciplinary Recovery Program|"Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings"
219014668|NCT01608659|DRUG|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
219014669|NCT04958005|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
219014670|NCT01275391|BEHAVIORAL|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
219014671|NCT04566224|DEVICE|Macintosh size 2 blade|intubate with Macintosh size 2 blade
218833145|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
218833146|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
218833147|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
218833148|NCT00577707|PROCEDURE|Resection|
218833149|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
218833150|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
218833151|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
218833152|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
218833153|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
218833154|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
218833155|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
219014672|NCT04566224|DEVICE|Macintosh size 3 blade|intubate with Macintosh size 3 blade
219014673|NCT03398291|PROCEDURE|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
219014674|NCT03398291|DRUG|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
219196088|NCT06853405|BEHAVIORAL|Nutrition-related lifestyle group sessions|"In person lifestyle group sessions of 180-minutes per week, directed by a nutritionist, and comprising:~1. 120-minute nutrition education session for preparing healthy meals, followed by a period of social interaction while consuming the meals prepared. Participants will be encouraged to apply the healthy cooking techniques covered in each session in their home context.~2. 60-minute sessions of daily activities to reduce physical inactivity (e.g., walking to the supermarket to buy ingredients, playing traditional games, caring for community gardening, among others)."
219196089|NCT06853405|BEHAVIORAL|Nutrition-related cognitive training|Individualized nutrition-based cognitive training performed remotely, at home on their own. The participants will be invited to perform cognitive training exercises including novel nutrition-related exercises, and watch educational videos promoting nutrition literacy at least twice a week using COGWEB®, an online platform for cognitive training. For those unable to use computer devices, similar exercises will be available in paper-and-pencil format.
219440271|NCT01786850|PROCEDURE|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
219440272|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
219440273|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
219440274|NCT00820807|OTHER|Placebo|oral consumption in beverage
219440275|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
219440276|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
219440277|NCT04816045|PROCEDURE|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
219440278|NCT04816045|PROCEDURE|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
219764137|NCT02112916|DRUG|Doxorubicin|Given IV
219014675|NCT03067649|BEHAVIORAL|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
219014676|NCT03067649|BEHAVIORAL|Information only control|Participants are provided with a pamphlet containing referral information
219014677|NCT03407105|BIOLOGICAL|MDX-010|Specified dose on specified days
219014678|NCT00719121|DRUG|Talarozole|Topical Application (20 mg)
219014679|NCT00719121|DRUG|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
219196090|NCT06853405|BEHAVIORAL|Clinical nutrition consultations|A registered nutritionist will conduct individualized clinical nutrition consultations to each participant three times over the course of the study period.
219764138|NCT02112916|DRUG|Doxorubicin Hydrochloride|Given IV
219764139|NCT02112916|DRUG|Etoposide|Given IV
219764140|NCT02112916|DRUG|Hydrocortisone Sodium Succinate|Given IT
219440279|NCT06275997|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
218833156|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
218833157|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
218833158|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
218833159|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
218833160|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
218833161|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
219764141|NCT02112916|DRUG|Ifosfamide|Given IV
219764142|NCT02112916|DRUG|Leucovorin Calcium|Given PO or IV
219764143|NCT02112916|DRUG|Mercaptopurine|Give PO
219764144|NCT02112916|DRUG|Methotrexate|Given IT, IV, or PO
219764145|NCT02112916|DRUG|Pegaspargase|Given IV
219764146|NCT02112916|RADIATION|Radiation Therapy|Undergo radiation therapy
219440280|NCT05933798|OTHER|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
219440281|NCT05933798|OTHER|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
219440282|NCT01022645|DEVICE|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
219440283|NCT01022645|DEVICE|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
219440284|NCT03647176|OTHER|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
218833162|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
218833163|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
218833164|NCT01777464|BIOLOGICAL|sham|sham solution
218833165|NCT00431444|DRUG|Raloxifene|
218833166|NCT00431444|DRUG|Zoledronic acid|
218833167|NCT00431444|DRUG|Placebo oral pills|
218833168|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
218833169|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
218833170|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
218833171|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
218833172|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
218833173|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
218833174|NCT03679949|DRUG|Oxycodone|Oxycodone, 2.5 mg
218833175|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:0)|Cannabis with high THC concentration and negligible CBD concentrations
218833176|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 0:1)|Cannabis with high CBD concentration and negligible THC concentrations
218833177|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:1)|Cannabis with equivalent CBD and THC concentrations
218833178|NCT03679949|DRUG|Placebo|Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
218833179|NCT01603043|DRUG|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
218833180|NCT01603043|DRUG|Sham injection|Mock injection administered as an empty hub without needle
218833181|NCT00000333|DRUG|Benztropine|
218833182|NCT05561647|OTHER|No Intervention|This is non-interventional study.
218833183|NCT02747147|DEVICE|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
218833184|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
218833185|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
218833186|NCT01628068|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
218833187|NCT05945498|BIOLOGICAL|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
218833188|NCT05945498|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of placebo buffer solution
218833189|NCT03160456|DEVICE|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
218833190|NCT03160456|DEVICE|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
218833191|NCT00392977|DIETARY_SUPPLEMENT|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
218833192|NCT05827289|DEVICE|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
219440285|NCT01500941|DIETARY_SUPPLEMENT|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
219440286|NCT01500941|OTHER|maltodextrin|sachets
219440287|NCT04121689|DIETARY_SUPPLEMENT|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
219475419|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
219475420|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
219475421|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
219475422|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
218833193|NCT03265444|BIOLOGICAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
218833194|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
218833195|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
218833196|NCT00360178|DRUG|Amlodipine|
219014680|NCT05893433|DEVICE|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
219014681|NCT05893433|OTHER|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
219764147|NCT02112916|DRUG|Thioguanine|Given PO
219764148|NCT02112916|DRUG|Vincristine|Given IV
219764149|NCT02112916|DRUG|Vincristine Sulfate|Given IV
219014682|NCT02814513|DEVICE|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
219196091|NCT06812234|OTHER|DAX Copilot|"* Enrolled in DAX Copilot program.~* Epic Haiku verified and adapted to record visits for DAX.~* Virtual training to add Patient List column to schedule for DAX Note Status, add appropriate smartlinks to note templates (AI-generated history of present illness, physical exam, and assessment and plan).~* In person at-the-elbow support from Children's Epic Support on Site team at initiation and up to 2 additional sessions."
219196092|NCT06853951|DRUG|ACE Inhibitors|0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
219196093|NCT06853951|DRUG|β -Blockers|0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
219440288|NCT05721196|BEHAVIORAL|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
219581160|NCT05315635|OTHER|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
219764150|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
219764151|NCT06984328|BIOLOGICAL|Acasunlimab|Intravenous (IV) infusion
219764152|NCT06984328|BIOLOGICAL|Pembrolizumab|IV infusion
218833197|NCT01763333|DRUG|BI 1026706 Placebo|Placebo to BI 1026706
218833198|NCT01763333|DRUG|BI 1026706|different dose formulations
218833199|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
218833200|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
218833201|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
218833202|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
218833203|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
219196094|NCT06812923|DEVICE|transcranial Alternating Current Stimulation (tACS)|tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
219440289|NCT05721196|DRUG|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
219440290|NCT01847079|OTHER|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
219764153|NCT04542824|BIOLOGICAL|Epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
219764154|NCT04542824|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
219764155|NCT04542824|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
219764156|NCT04542824|DRUG|Gemcitabine and oxaliplatin|28-day cycles
219764157|NCT04542824|BIOLOGICAL|Epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
219764158|NCT04542824|DRUG|Rituximab and lenalidomide|28-day cycles.
219764159|NCT06589245|DRUG|Alvesco Inhalant Product|Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
219440291|NCT05410808|OTHER|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
219440292|NCT05410808|OTHER|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
219581161|NCT06233357|DRUG|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
219581162|NCT03844789|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
219581163|NCT03844789|DEVICE|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
219581164|NCT00359632|DRUG|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
219581165|NCT00359632|DRUG|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
218833204|NCT01663311|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
218833205|NCT01663311|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
219764160|NCT06815965|DRUG|neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.
218833206|NCT06269510|BEHAVIORAL|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
219014683|NCT02814513|DEVICE|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
219014684|NCT02814513|DEVICE|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
219014685|NCT02814513|DEVICE|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
219014686|NCT02814513|DEVICE|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
219014687|NCT01490476|DRUG|RAD001|10 mg per os / day or 05mg per os / day with 12 month
219014688|NCT00001889|PROCEDURE|Myocardial contrast echocardiography|
219014689|NCT00001889|PROCEDURE|Stress echocardiography with dobutamine|
219014690|NCT00376350|PROCEDURE|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
219014691|NCT00376350|PROCEDURE|Light Massage|light pressure massage of the low back.
219014692|NCT00376350|PROCEDURE|Pulsed Ultrasound|5 minutes pulsed ultrasound
219014693|NCT00447642|DRUG|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
219014694|NCT00447642|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
219014695|NCT01570374|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
219014696|NCT01526616|DRUG|Metformin|Metformin 850 mg twice a day for six months
219014697|NCT01526616|DRUG|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
219014698|NCT04225728|DRUG|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
219440293|NCT03930303|BEHAVIORAL|Multimedia- based patient education|Patients will receive a 5 minutes video education before D\&C
219440294|NCT02896192|DRUG|Setmelanotide|Once daily SC injection
219440295|NCT02896192|DRUG|Placebo|Once daily SC injection
219440296|NCT00215592|DRUG|Zonegran|
219440297|NCT02533856|OTHER|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
218833207|NCT06269510|BEHAVIORAL|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
218833208|NCT06269510|BEHAVIORAL|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
218833209|NCT05895097|DEVICE|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
219440298|NCT00464711|DRUG|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
219440299|NCT01308294|BIOLOGICAL|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
219440300|NCT01308294|BIOLOGICAL|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
219440301|NCT01308294|BIOLOGICAL|"2 vaccine injections in distinct limbs"|
219440302|NCT03615989|BEHAVIORAL|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
219440303|NCT03615989|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
219440304|NCT03615989|DIETARY_SUPPLEMENT|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
219440305|NCT03064269|BIOLOGICAL|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
219440306|NCT04488757|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
219440307|NCT04488757|OTHER|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
219440308|NCT00479167|DRUG|Bortezomib and Tositumomab I-131|
219440309|NCT01264068|DRUG|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
218833210|NCT05895097|DEVICE|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
219196095|NCT06812923|DEVICE|Sham stimulation|Sham stimulation, matched with real tACS, except for providing electrical stimulation
219440310|NCT03702140|DRUG|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
219440311|NCT04919772|OTHER|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
219440312|NCT02650440|PROCEDURE|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
219440313|NCT02650440|PROCEDURE|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
219581166|NCT02448849|BIOLOGICAL|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
219581167|NCT02448849|OTHER|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
219581168|NCT04328571|DIETARY_SUPPLEMENT|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
219581169|NCT04328571|DIETARY_SUPPLEMENT|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
219581170|NCT04328571|DIETARY_SUPPLEMENT|OLE|OLE (Olive leaf extract) + maltodextrin
219581171|NCT02615171|BEHAVIORAL|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
219014699|NCT04225728|DRUG|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
218833211|NCT05312840|DRUG|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1\. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
218833212|NCT01605357|DRUG|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
218833213|NCT01605357|DRUG|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
218833214|NCT01202240|DRUG|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
218833215|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
219014700|NCT04225728|OTHER|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
219014701|NCT05390879|OTHER|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
219014702|NCT05390879|OTHER|Control|After the circuit, a 6 minutes long emotionally neutral video.
219014703|NCT06146426|DIETARY_SUPPLEMENT|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
219014704|NCT06242587|DEVICE|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
219196096|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy with omentopexy|Laparoscopic Sleeve Gastrectomy with omental fixation to the gastric tube
219196097|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy without omentopexy|Laparoscopic Sleeve Gastrectomy without omental fixation to the gastric tube
219196098|NCT06655727|DIAGNOSTIC_TEST|Ultrasound evaluation|No intervention
219196099|NCT01121588|DRUG|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
219196100|NCT06498128|DRUG|Daridorexant|Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
219440314|NCT04125992|PROCEDURE|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
219440315|NCT04125992|PROCEDURE|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
219440316|NCT02448914|DRUG|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
219440317|NCT02448914|DRUG|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
219440318|NCT06089655|DEVICE|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
219440319|NCT06089655|BEHAVIORAL|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
219440320|NCT01624610|OTHER|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
219764161|NCT05123612|BEHAVIORAL|Fiber|Additional 20 grams of fiber/day.
219196101|NCT06498128|DRUG|Non-orexin receptor antagonist medications for insomnia|Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
219440321|NCT02175303|BIOLOGICAL|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
219440322|NCT01997281|DIETARY_SUPPLEMENT|dietary fiber-enriched cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast"
219440323|NCT01997281|OTHER|conventional cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
219440324|NCT02143323|DRUG|Augmentin tablet|
219440325|NCT06450223|DRUG|Perampanel 12 MG|1 tablet of Perampanel Tablets 12 mg
219440326|NCT06450223|DRUG|Fycompa 12 mg film-coated tablets|1 tablet of Perampanel Tablets 12 mg
219581172|NCT02615171|BEHAVIORAL|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
219581173|NCT04376528|DRUG|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
219581174|NCT04376528|DRUG|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
219581175|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
219581176|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
219581177|NCT02617524|DEVICE|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
219581178|NCT04338217|DEVICE|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
219440327|NCT05725200|DRUG|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
219440328|NCT05725200|DRUG|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219764162|NCT05123612|BEHAVIORAL|Fermented Foods|6 servings of fermented foods/day
219581179|NCT04338217|DEVICE|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
219581180|NCT04375865|DRUG|AD-2111|celecoxib 200mg
219581181|NCT04375865|DRUG|AD-2112|Tramadol 150mg
219764163|NCT03693014|RADIATION|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
219581182|NCT04243408|OTHER|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
219764164|NCT03693014|BIOLOGICAL|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
219581183|NCT04243408|OTHER|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
219581184|NCT03816813|OTHER|blood and saliva sampling|blood and saliva sampling
219764165|NCT04875429|DEVICE|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2|Endovascular aneurysm repair
218833216|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
218833217|NCT00087087|DRUG|pemetrexed disodium|
219196102|NCT06498128|OTHER|No insomnia medication|No insomnia medication was administered.
219196103|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
219196104|NCT05923970|DIAGNOSTIC_TEST|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
219440329|NCT05725200|DRUG|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
218833218|NCT02274220|DIETARY_SUPPLEMENT|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
219440330|NCT05725200|DRUG|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440331|NCT05725200|DRUG|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
219196105|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
219440332|NCT05725200|DRUG|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440333|NCT05725200|DRUG|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
219440334|NCT05725200|DRUG|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440335|NCT05725200|DRUG|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440336|NCT05725200|DRUG|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440337|NCT05725200|DRUG|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440338|NCT05725200|DRUG|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440339|NCT05725200|DRUG|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440340|NCT05725200|DRUG|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440341|NCT05725200|DRUG|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440342|NCT05725200|DRUG|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440343|NCT05725200|DRUG|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
219440344|NCT03012542|DIETARY_SUPPLEMENT|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
219440345|NCT03012542|DIETARY_SUPPLEMENT|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
219440346|NCT02066545|DRUG|CLS001 Topical Gel|
219440347|NCT02066545|DRUG|CLS001 Topical Gel Vehicle|
219440348|NCT00759083|DRUG|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
219440349|NCT03326661|PROCEDURE|Aspiration|Needle aspiration of pus from the peritonsilar abscess
219440350|NCT03326661|PROCEDURE|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
219440351|NCT03326661|DRUG|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
219440352|NCT00145197|BEHAVIORAL|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
219440353|NCT01569997|OTHER|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
219440354|NCT00513994|DRUG|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
219440355|NCT00560794|BIOLOGICAL|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
219440356|NCT01024062|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
219440357|NCT04857892|DRUG|GSK3640254|GSK3640254 will be administered via oral route.
219440358|NCT04857892|DRUG|DTG|DTG will be administered via oral route.
219440359|NCT04857892|DRUG|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
219440360|NCT04853199|DRUG|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
219440361|NCT04853199|DRUG|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
219440362|NCT01279980|OTHER|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
219581185|NCT00621049|DRUG|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
219581186|NCT00621049|DRUG|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
219581187|NCT04712149|DEVICE|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
219581188|NCT00016718|DRUG|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
219581189|NCT00016718|DRUG|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
219581190|NCT00016718|DRUG|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
219581191|NCT04960306|BIOLOGICAL|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
219581192|NCT04960306|BIOLOGICAL|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
219581193|NCT01593033|DIETARY_SUPPLEMENT|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
219581194|NCT01593033|DIETARY_SUPPLEMENT|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
219581195|NCT01593033|DRUG|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
219581196|NCT00888459|DRUG|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
218833219|NCT02274220|DIETARY_SUPPLEMENT|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
218833220|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
218833221|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
219440363|NCT01279980|OTHER|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
219440364|NCT03230357|DEVICE|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
219581197|NCT00888459|DRUG|placebo NRT|Placebo nicotine lozenges
218833222|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
218833223|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
218833224|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
218833225|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
219581198|NCT05622136|DRUG|Regorafenib Oral Product|Dose escalation strategy
219581199|NCT05897918|DRUG|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
219581200|NCT05736536|BEHAVIORAL|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
218833226|NCT06495892|DRUG|Diuretic therapy|Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
218833227|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
219014705|NCT06242587|PROCEDURE|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
219440365|NCT00701246|DRUG|ferrous sulfate|
219440366|NCT00701246|DRUG|folic acid|
219440367|NCT00701246|DRUG|placebo (folic acid)|
219440368|NCT02813863|DRUG|SP2086|
219440369|NCT02813863|DRUG|Metformin|
219440370|NCT04379323|DIAGNOSTIC_TEST|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
219440371|NCT04631614|OTHER|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
219581201|NCT05811702|OTHER|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
219581202|NCT06237387|OTHER|Periodontal examination|Determining the patient's oral hygiene status and the severity of gingivitis. For this purpose, the non-invasive Löe-Silness plaque and gingival index system will be used.
218833228|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
218833229|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
219196106|NCT05923970|DIAGNOSTIC_TEST|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
219581203|NCT01000493|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
219581204|NCT01000493|OTHER|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
219581205|NCT04277871|BEHAVIORAL|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
219581206|NCT01045915|BIOLOGICAL|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
219581207|NCT06041841|DRUG|LB54640|LB54640 QD Oral
219581208|NCT04102631|DIAGNOSTIC_TEST|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
219581209|NCT04102631|DIAGNOSTIC_TEST|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
219581210|NCT02701231|DEVICE|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
219581211|NCT02701231|DRUG|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
219581212|NCT02701231|DEVICE|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
219581213|NCT03223948|DEVICE|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
219581214|NCT03977831|PROCEDURE|Radical Cystectomy|Participants are randomly and blinded assigned
219581215|NCT00429520|DRUG|Hyaluronic acid filler/IMD1 basic|
219581216|NCT01713231|DIETARY_SUPPLEMENT|standard-dose vitamin D (400IU per day)|
219581217|NCT01713231|DIETARY_SUPPLEMENT|high-dose vitamin D (2000 IU per day)|
219581218|NCT05282979|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
219581219|NCT05487365|DEVICE|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
218833230|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
219196107|NCT04257461|DRUG|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
219196108|NCT04257461|DRUG|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
219196109|NCT06108479|DRUG|DF6215|Immunotherapy (cytokine) targeting effector cells.
219581220|NCT05487365|OTHER|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
219764166|NCT06817161|DEVICE|transcutaneous auricular vagus nerve stimulation|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
219764167|NCT06817161|DEVICE|Placebo device|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
218833231|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
218833232|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
218833233|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
218833234|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
218833235|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
218833236|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
218833237|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
218833238|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
219440372|NCT04631614|OTHER|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
219440373|NCT04631614|OTHER|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
219440374|NCT04631614|OTHER|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
219440375|NCT04631614|OTHER|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
219440376|NCT04631614|OTHER|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
219764168|NCT06170788|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
219764169|NCT06170788|BIOLOGICAL|Pembrolizumab|IV infusion
219440377|NCT04631614|OTHER|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
219581221|NCT04161183|DEVICE|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
219581222|NCT04161183|DEVICE|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
219014706|NCT04048824|BEHAVIORAL|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
219440378|NCT04631614|OTHER|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
219581223|NCT05571072|OTHER|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
219581224|NCT05571072|OTHER|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
219581225|NCT01197430|OTHER|exercise training|
219581226|NCT02170948|DRUG|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
219581227|NCT01949948|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
219581228|NCT01949948|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
219581229|NCT01435226|DRUG|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
219581230|NCT01435226|DRUG|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
219581231|NCT01435226|DRUG|tegobuvir|tegobuvir 30 mg BID
219581232|NCT01435226|DRUG|placebo to match tegobuvir|tegobuvir placebo BID
219581233|NCT01435226|DRUG|placebo to match RBV|Ribovirin placebo BID
219581234|NCT01435226|DRUG|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
219581235|NCT00502801|DRUG|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
219581236|NCT03095573|DEVICE|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
219581237|NCT03095573|DEVICE|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
219581238|NCT01506544|DRUG|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
219581239|NCT01565616|DRUG|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
219581240|NCT05886439|DRUG|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
219581241|NCT05886439|DRUG|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
219014707|NCT04048824|BEHAVIORAL|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
219014708|NCT02348541|DEVICE|CollaGUARD|
219196110|NCT06108479|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
219196111|NCT06108479|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
219196112|NCT06508567|RADIATION|High Dose Rate Brachytherapy|2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
219581242|NCT05886439|DRUG|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
219196113|NCT02215265|DRUG|Cisplatin|Chemotherapy
218833239|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
218833240|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
219440379|NCT05549414|DEVICE|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
219440380|NCT04541095|OTHER|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
219440381|NCT04541095|OTHER|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
219440382|NCT01311895|DRUG|H2O|2 mg IV hydromorphone
219440383|NCT01311895|DRUG|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
219440384|NCT00187850|PROCEDURE|PP|Partial pulpotomy
219440385|NCT00187850|PROCEDURE|DPC|Direct pulp capping
219440386|NCT03571503|PROCEDURE|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
219440387|NCT03571503|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
219440388|NCT03571503|PROCEDURE|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
219440389|NCT03571503|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219440390|NCT03571503|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219440391|NCT03571503|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219440392|NCT03571503|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219440393|NCT03571503|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219440394|NCT03571503|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
219440395|NCT06058884|DRUG|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
219440396|NCT03049943|DEVICE|low level laser|
219440397|NCT04773847|PROCEDURE|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
219440398|NCT01269177|DEVICE|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability"
219581243|NCT00145639|DRUG|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
219581244|NCT00145639|PROCEDURE|Limb Sparing|See Detailed Description for treatment plan.
219581245|NCT04691050|PROCEDURE|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
219581246|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
219196114|NCT02215265|RADIATION|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
219196115|NCT05335122|DRUG|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
219581247|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
219581248|NCT00759720|DRUG|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
218833241|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
218833242|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
218833243|NCT00295789|DRUG|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
218833244|NCT00295789|DRUG|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
219581249|NCT02243839|DRUG|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
219581250|NCT02243839|PROCEDURE|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
219581251|NCT06415617|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving . The participants will be engaged in psychoeducation through group discussion, individualised goal setting and reflective exercises."
219581252|NCT06415617|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
219581253|NCT05246033|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
219581254|NCT05246033|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
219581255|NCT04705870|DEVICE|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~* SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~* SWI non EPI QSM 6 echo (10 minutes)~* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~* SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
219581256|NCT03149458|OTHER|dance|dance program
218833245|NCT02712996|DRUG|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
218833246|NCT02712996|DRUG|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
218833247|NCT04815200|DEVICE|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
218833248|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
219581257|NCT03149458|OTHER|control|upper limb rehabilitation
219581258|NCT02116699|OTHER|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
219581259|NCT02116699|OTHER|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
219581260|NCT02523196|DRUG|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
219581261|NCT02523196|DEVICE|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
219581262|NCT02031016|DRUG|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
219581263|NCT02031016|DRUG|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
219581264|NCT02031016|DRUG|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
219581265|NCT05241717|BEHAVIORAL|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
219581266|NCT03903458|DRUG|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
219581267|NCT02452996|DRUG|GNbAC1|Single dose of IMP, IV infusion
219581268|NCT01154959|DRUG|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
218833249|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
218833250|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
218833251|NCT02778984|DEVICE|QuadraLite masks|The intervention is identical in the two group
218833252|NCT02778984|OTHER|standard mask|
219196116|NCT05335122|DRUG|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
219196117|NCT05335122|DRUG|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
218833253|NCT00644826|BEHAVIORAL|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
218833254|NCT03623438|BEHAVIORAL|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
218833255|NCT03623438|BEHAVIORAL|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
218833256|NCT02434211|OTHER|Questionnaire and focus group|
218833257|NCT02065349|DRUG|ASP8477|oral
218833258|NCT02065349|DRUG|Placebo|oral
218833259|NCT01016132|DEVICE|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
219581269|NCT00161798|BIOLOGICAL|Tick-borne encephalitis vaccine|
219581270|NCT05042934|PROCEDURE|Fine-Needle Aspiration|Undergo fine-needle aspiration
219581271|NCT05042934|DRUG|Irinotecan|Given IV
219581272|NCT05042934|DRUG|Irinotecan Hydrochloride|Given IV
219581273|NCT05042934|DRUG|Lurbinectedin|Given IV
218833260|NCT04160312|DIETARY_SUPPLEMENT|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
218833261|NCT04160312|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
218833262|NCT06213207|OTHER|Simulator based training to manage asphyxia and essential newborn care using neonatalie|The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
218833263|NCT05795270|OTHER|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
219440399|NCT05156333|DIETARY_SUPPLEMENT|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
219440400|NCT03634176|DIAGNOSTIC_TEST|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
219581274|NCT03813693|OTHER|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2\) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3\) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
219581275|NCT03813693|OTHER|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
219581276|NCT01733147|DRUG|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
219581277|NCT01733147|DRUG|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
219581278|NCT02055443|OTHER|12-lead holter monitor application|"\-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
218833264|NCT02227810|OTHER|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
219014709|NCT02614430|OTHER|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
219014710|NCT05982626|RADIATION|68Ga/131I-SGMIB-ZT-199|68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
219014711|NCT01979484|DRUG|PPI-668 capsule|
219014712|NCT01979484|DRUG|PPI-668 tablet|
218833265|NCT02227810|OTHER|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
219440401|NCT02050451|DIETARY_SUPPLEMENT|Ensure Plus®|
219581279|NCT04149886|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
219581280|NCT04149886|DEVICE|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
219440402|NCT02050451|DIETARY_SUPPLEMENT|Multivitamin|
219440403|NCT04713111|BEHAVIORAL|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
219581281|NCT03412786|BIOLOGICAL|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl\_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
219581282|NCT03359824|OTHER|Exercise|
219581283|NCT04899817|DRUG|Granisetron|The drug is given after induction of general anesthesia
219581284|NCT03639519|DRUG|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
219581285|NCT03639519|OTHER|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
219581286|NCT01372241|BEHAVIORAL|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
218833266|NCT02227810|OTHER|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
218833267|NCT00718536|DRUG|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
219440404|NCT04713111|BEHAVIORAL|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
219440405|NCT02565953|DEVICE|Paclitaxel-releasing PTA balloon catheter|
219440406|NCT02565953|DEVICE|PTA balloon catheter|
219440407|NCT00194727|DRUG|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
219440408|NCT00194727|DRUG|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
219581287|NCT04586153|DRUG|Meplazumab for Injection|humanized antibody target CD147
218833268|NCT01451749|DRUG|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
218833269|NCT01451749|DRUG|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
218833270|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
218833271|NCT04093960|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
218833272|NCT03905915|DEVICE|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
219440409|NCT01350011|BEHAVIORAL|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
219581288|NCT04586153|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
219581289|NCT05814003|DRUG|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
219581290|NCT05814003|OTHER|Placebo|Dough inert material without any therapeutic action
219581291|NCT03322384|DRUG|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
219581292|NCT03322384|DRUG|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
219581293|NCT03322384|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
219581294|NCT04323241|OTHER|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
219581295|NCT04832321|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
219581296|NCT04320550|DIAGNOSTIC_TEST|abdominal ultra sound|non invasive tests to exclude pathological causes
219440410|NCT01350011|BEHAVIORAL|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
219475423|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
219475424|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
219475425|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
219581297|NCT01193738|PROCEDURE|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
219581298|NCT04704141|DRUG|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
219581299|NCT01484418|BEHAVIORAL|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
219014713|NCT00453544|OTHER|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
219014714|NCT00453544|OTHER|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
219014715|NCT05683054|BIOLOGICAL|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
219014716|NCT05683054|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
219014717|NCT05683054|OTHER|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
219014718|NCT05683054|OTHER|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
219014719|NCT05683054|PROCEDURE|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
219014720|NCT03434054|DRUG|Losartan|blood pressure medication
219014721|NCT03434054|OTHER|Placebo|non-active sham intervention
219014722|NCT06477458|OTHER|Single inspiratory phase computed tomography.|Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
219014723|NCT06477458|OTHER|Respiratory dual-phase computed tomography.|Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
219014724|NCT03721276|BEHAVIORAL|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
219440411|NCT01361880|BEHAVIORAL|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
219440412|NCT04437680|DEVICE|Votiva device|A retrospective chart review of the medical records
219440413|NCT04486612|OTHER|spinal anesthesia|prospective observational study
219440414|NCT01877824|OTHER|Fast-track training|
219440415|NCT00655811|DRUG|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
219440416|NCT00655811|DRUG|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
219440417|NCT05818072|PROCEDURE|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
219440418|NCT05818072|PROCEDURE|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
219440419|NCT05818072|PROCEDURE|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
219440420|NCT05818072|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
219440421|NCT01237301|DEVICE|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
219440422|NCT01237301|DEVICE|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
219440423|NCT00300716|DRUG|Memantine|
219440424|NCT04888728|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
219440425|NCT04888728|DRUG|Nebivolol|Nebivolol
219440426|NCT04888728|DRUG|Paroxetine|Paroxetine
219440427|NCT03304912|BEHAVIORAL|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
219440428|NCT05305001|GENETIC|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
219581300|NCT01484418|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
219581301|NCT00444457|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
219581302|NCT00444457|BIOLOGICAL|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
219581303|NCT00041249|DRUG|brostallicin|
219014725|NCT03234192|PROCEDURE|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
219014726|NCT03234192|PROCEDURE|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
219014727|NCT03234192|PROCEDURE|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
219014728|NCT00874965|DEVICE|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
219014729|NCT00874965|DEVICE|Sham stimulation|30 min; 5 times / week
219014730|NCT02297074|OTHER|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
219014731|NCT02297074|OTHER|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
219014732|NCT02297074|OTHER|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
219196118|NCT06220162|DRUG|chidamide in combination with venetoclax and azacitidine (VAC)|Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
219196119|NCT03655080|RADIATION|Radiation therapy|Using the View Ray System
219196120|NCT03655080|DRUG|nab-Paclitaxel|"* Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes"
219196121|NCT05655520|DRUG|SAGE-718|Oral softgel lipid capsules
219440429|NCT05458362|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
219440430|NCT05458362|BEHAVIORAL|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
219440431|NCT02984891|PROCEDURE|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
219440432|NCT02984891|PROCEDURE|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of \< 40 microns and tissue penetration of 10 mm.
219440433|NCT01024660|DRUG|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
219440434|NCT01024660|DRUG|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
219440435|NCT01024660|DRUG|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
219440436|NCT01570062|DEVICE|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
219440437|NCT01570062|DEVICE|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
219440438|NCT00728663|BIOLOGICAL|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
219440439|NCT00728663|DRUG|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
219440440|NCT01675206|DIETARY_SUPPLEMENT|Vitamin K2 supplementation|
219764170|NCT06170788|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
219764171|NCT06656351|DRUG|Tafenoquine 100mg|Tafenoquine
219764172|NCT06649812|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
219764173|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218833273|NCT02308267|OTHER|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
218833274|NCT02308267|OTHER|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
218833275|NCT02308267|PROCEDURE|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
219014733|NCT02297074|OTHER|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
219014734|NCT02297074|OTHER|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
219014735|NCT02297074|OTHER|Glucose|50 g of glucose were administered as a reference
219014736|NCT00165347|DRUG|PTK787/ZK222584|
219014737|NCT02083952|OTHER|Swaddle Blanket|Two arms involve varying time spent in blanket
219196122|NCT05732272|DRUG|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
219196123|NCT04663204|DRUG|Sparsentan|Target dose of 400 mg daily
219440441|NCT02384993|BEHAVIORAL|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
219440442|NCT01570205|DRUG|XG-102|single intravenous infusion
219440443|NCT00349037|BIOLOGICAL|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
219440444|NCT00118404|BEHAVIORAL|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
219440445|NCT00118404|DRUG|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
219440446|NCT00118404|OTHER|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
219440447|NCT00118404|BEHAVIORAL|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
219440448|NCT01406158|DRUG|Solifenacin Succinate Formulation A|oral suspension
219440449|NCT01406158|DRUG|Solifenacin Succinate Formulation B|oral suspension
219440450|NCT01406158|DRUG|Solifenacin Succinate|oral tablet
219440451|NCT02313922|DRUG|etanercept combined with methotrexate or etanercept combined with placebo|
219764174|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219196124|NCT03686748|BEHAVIORAL|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
219196125|NCT03686748|BEHAVIORAL|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
219196126|NCT02944968|DEVICE|THERMOCOOL SMARTTOUCH® SF-5D catheter|
219196127|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
219196128|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
219440452|NCT03222622|DRUG|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
219440453|NCT03222622|DRUG|Placebo cream|Apply topically twice daily for 12 consecutive weeks
219440454|NCT05679609|DEVICE|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
219440455|NCT01223768|DRUG|Acetyl-l-Carnitine|2g per day
219440456|NCT01223768|DRUG|placebo|twice per day
219440457|NCT02747446|DIETARY_SUPPLEMENT|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
219440458|NCT03182127|RADIATION|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
219581304|NCT05306171|BEHAVIORAL|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
219581305|NCT01401049|DRUG|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
219581306|NCT01401049|DRUG|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
219581307|NCT03660436|DRUG|BMS-986165|Specified dose on specified days
219581308|NCT03660436|DRUG|MMF|Specified dose on specified days
219581309|NCT01121666|DRUG|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
219581310|NCT03546803|OTHER|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
219581311|NCT02881164|OTHER|Low glycemic index|Subjects intake a low glycemic index breakfast
219581312|NCT02881164|OTHER|High glycemic index|Subjects intake a high glycemic index breakfast
219581313|NCT03082664|DEVICE|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
219581314|NCT01112943|OTHER|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
219581315|NCT01112943|OTHER|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
219581316|NCT01112943|OTHER|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
219581317|NCT03054259|DRUG|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
219581318|NCT03054259|DRUG|Methylprednisolone|100mg infusion on days 1 and 15
218833276|NCT04522934|BEHAVIORAL|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
219581319|NCT03054259|DRUG|Normal Saline|250ml infusion on days 1 and 15
219581320|NCT00554775|DRUG|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
219581321|NCT00554775|DRUG|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
219581322|NCT03176459|DRUG|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
218833277|NCT04522934|BEHAVIORAL|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
218833278|NCT02824692|DEVICE|heart lungs and abdomen ultrasound|
218833279|NCT04704713|DRUG|Afamelanotide|
218833280|NCT04704713|DRUG|Placebo|
218833281|NCT03063606|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
218833282|NCT03063606|DRUG|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
218833283|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
218833284|NCT04691037|DIAGNOSTIC_TEST|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
218833285|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
219581323|NCT03176459|DRUG|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
219581324|NCT00222352|DIAGNOSTIC_TEST|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
219581325|NCT01668693|OTHER|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
219581326|NCT01668693|OTHER|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
219581327|NCT01668693|OTHER|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
219581328|NCT03235661|DEVICE|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
219581329|NCT03235661|DEVICE|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
218833286|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
218833287|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
218833288|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
218833289|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
219196129|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
219440459|NCT03182127|DEVICE|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
219440460|NCT01708538|DRUG|CXL|corneal crosslinking
219440461|NCT02988401|DRUG|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
219440462|NCT02988401|DRUG|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
219440463|NCT04139629|DIAGNOSTIC_TEST|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
219440464|NCT04139629|DRUG|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
219440465|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
219440466|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
219440467|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
219440468|NCT06275698|DIETARY_SUPPLEMENT|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
219440469|NCT06275698|DIETARY_SUPPLEMENT|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
219440470|NCT00858676|DRUG|acarbose|50mg acarbose 3 times a day PO. duration: one year
219440471|NCT04260672|BEHAVIORAL|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
219440472|NCT05841953|DEVICE|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
219440473|NCT01955785|DEVICE|pressure controlled ventilator|
219440474|NCT01955785|DEVICE|Pressure Regulated Volume Controlled Ventilator|
219440475|NCT01161927|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
219440476|NCT01161927|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
219440477|NCT02335034|BEHAVIORAL|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
219440478|NCT02335034|BEHAVIORAL|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
219440479|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
219440480|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
219440481|NCT04790734|DRUG|Sedation drugs|Different sedation drugs
219440482|NCT04576416|OTHER|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group."
219440483|NCT02310724|OTHER|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
219014738|NCT05430737|RADIATION|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
219014739|NCT01857232|DRUG|Ondansetron|5HT3-antagonist
219014740|NCT01857232|DRUG|Placebo|Comparator
219014741|NCT01857232|DRUG|Dexamethasone|Corticosteroid
218833290|NCT04944615|PROCEDURE|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
219014742|NCT01857232|DRUG|Fosaprepitant|NK1 antagonist
219014743|NCT01857232|DRUG|APD403 IV|Amisulpride IV 20 mg
219581330|NCT00906984|DEVICE|TheraSphere|Given IV
219581331|NCT03597360|RADIATION|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
219581332|NCT04294420|BEHAVIORAL|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
219581333|NCT05862194|DRUG|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
218833291|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
218833292|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
219014744|NCT01857232|DRUG|APD403 oral|Amisulpride oral 10, 20 or 40 mg
219014745|NCT01784640|DRUG|Hsp90 inhibitor AUY922|Given IV
219014746|NCT01784640|DRUG|pemetrexed disodium|Given IV
219014747|NCT01784640|OTHER|pharmacological study|Correlative studies
219014748|NCT01784640|OTHER|laboratory biomarker analysis|Correlative studies
219014749|NCT00277290|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
219014750|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
219014751|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
219014752|NCT04334720|OTHER|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
219014753|NCT04489329|DEVICE|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
219014754|NCT04489329|DIETARY_SUPPLEMENT|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
219440484|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
219581334|NCT05862194|DRUG|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
219014755|NCT02323477|BIOLOGICAL|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
219014756|NCT01286181|BEHAVIORAL|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
219014757|NCT00895323|OTHER|enzyme-linked immunosorbent assay|
219014758|NCT00895323|OTHER|pharmacological study|
219440485|NCT01199198|DRUG|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
219440486|NCT01199198|DRUG|Placebo|Placebo by mouth once a day for 14 days.
219440487|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
219440488|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
219440489|NCT05906368|DIAGNOSTIC_TEST|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
219764175|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219764176|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
219764177|NCT06649812|DRUG|Ibrutinib|Given PO
219764178|NCT06649812|DRUG|Lenalidomide|Given PO
219764179|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764180|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
218833293|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
218833294|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
219764181|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
219764182|NCT06649812|DRUG|Prednisone|Given PO
219196130|NCT06588946|DIETARY_SUPPLEMENT|Ketone monoester (KME) supplement|15g of a KME supplement orally consumed 3x daily for 14 days. This dosing protocol raises plasma β-OHB consistently during the waking hours. Oral KME will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a drink providing 15g of a KME supplement: \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK).
219440490|NCT05906368|DIAGNOSTIC_TEST|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
219440491|NCT00922974|RADIATION|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
219764183|NCT06649812|DRUG|Venetoclax|Given PO
219764184|NCT05125731|BEHAVIORAL|Parental absence|Parent does not accompany the child during dental treatment
219764185|NCT05125731|BEHAVIORAL|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
219764186|NCT05125731|BEHAVIORAL|Parental presence|Parent accompanies the child during dental treatment
219764187|NCT06820281|DRUG|Tirzepatide 2.5mg weekly|"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."
219764188|NCT06820281|DRUG|Placebo injection (normal saline)|Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.
219764189|NCT05552976|DRUG|Mezigdomide|Specified dose on specified days
219764190|NCT05552976|DRUG|Carfilzomib|Specified dose on specified days
219764191|NCT05552976|DRUG|Dexamethasone|Specified dose on specified days
218833295|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
218833296|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
218833297|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
218833298|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
218833299|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
218833300|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
218833301|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
219440492|NCT00922974|RADIATION|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
219440493|NCT06573814|DIETARY_SUPPLEMENT|Bio Gelee Royale Forte|Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
219440494|NCT06573814|OTHER|Placebo|Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
219440495|NCT04335656|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
218833302|NCT02953561|DRUG|Avelumab|Given IV
218833303|NCT02953561|DRUG|Azacitidine|Given SC or IV
219196131|NCT06588946|DIETARY_SUPPLEMENT|Placebo supplement|50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding.
219440496|NCT04335656|OTHER|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
219440497|NCT04062799|OTHER|no intervention|It is an observationa study. There is no intervention.
219764192|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
219764193|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
219764194|NCT06658002|DRUG|Cyclosporine A|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
219764195|NCT06658002|OTHER|Placebo Comparator: Placebo|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
219764196|NCT06855771|DRUG|BMS-986504|Specified dose on specified days
219764197|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
219764198|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
219581335|NCT01179126|PROCEDURE|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
219581336|NCT01179126|PROCEDURE|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
218833304|NCT02953561|OTHER|Laboratory Biomarker Analysis|Correlative studies
219581337|NCT06440187|DRUG|Gemcitabine+ nivolumab|Gemcitabine+ nivolumab q 2wks
219581338|NCT05985733|OTHER|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
219581339|NCT01349582|PROCEDURE|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
219581340|NCT01349582|OTHER|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
218833305|NCT00899418|GENETIC|gene expression analysis|
218833306|NCT00899418|GENETIC|polymerase chain reaction|
218833307|NCT00899418|GENETIC|polymorphism analysis|
218833308|NCT00899418|OTHER|immunohistochemistry staining method|
219196132|NCT06430918|OTHER|physical examination, questionnaires and inventories|Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
219196133|NCT05651503|DIETARY_SUPPLEMENT|Probiotics|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
219440498|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
219440499|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
219440500|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
219440501|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose\_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 Group in Stage 2 (Africa).
219581341|NCT01349582|PROCEDURE|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
219581342|NCT01349582|PROCEDURE|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
219581343|NCT01349582|PROCEDURE|surgical clipping|clipping of the aneurysm following invasive brain surgery
219581344|NCT00777127|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
219581345|NCT00777127|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
219581346|NCT03772431|OTHER|Female Voice|The survey was narrated by a female voice
219581347|NCT03772431|OTHER|Motivational Introduction|The survey introduction was worded to include motivational content
219581348|NCT03772431|OTHER|Male Voice|The survey was narrated by a male voice
219581349|NCT03772431|OTHER|Informational Introduction|The survey introduction was worded to include informational content
219581350|NCT02441582|OTHER|Telemetry|
219581351|NCT02441582|OTHER|Non-telemetry|
219581352|NCT05370755|DRUG|ICP-189|Administered orally
219581353|NCT03356574|PROCEDURE|Single-ventricle palliation surgery|Single-ventricle palliation surgery
219581354|NCT03274674|OTHER|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
219581355|NCT00191633|DRUG|Atomoxetine|
219581356|NCT01669473|OTHER|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
218833309|NCT00781638|DEVICE|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
219014759|NCT00895323|PROCEDURE|whole-body scintigraphy|
219014760|NCT00895323|RADIATION|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
219581357|NCT01602965|PROCEDURE|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
219581358|NCT01602965|PROCEDURE|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
219581359|NCT04476966|DRUG|Bladogra|1 tablet contains 25 mg Mirabegron
219581360|NCT04476966|DRUG|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
218833310|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
218833311|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
218833312|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
218833313|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
218833314|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
218833315|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
218833316|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
218833317|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
218833318|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
219196134|NCT05651503|DIETARY_SUPPLEMENT|Placebo tablet|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
219196135|NCT05265299|DRUG|Aspirin 81mg|Aspirin 81mg once daily
219196136|NCT05265299|DRUG|Aspirin 162 mg|Aspirin 162 mg once daily
219440502|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
219440503|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
219440504|NCT05480800|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
219581361|NCT04476966|DRUG|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
219581362|NCT01272726|BEHAVIORAL|Education|Education on the genetics of ADHD and treatment options for ADHD
219581363|NCT06426173|OTHER|Resistance Training Program|The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
219581364|NCT06426173|OTHER|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
219581365|NCT06927765|OTHER|No abdominal drain is placed|No abdominal drain is placed
219581366|NCT06928688|DIETARY_SUPPLEMENT|Saskatoon berry powder|After oral intake of SB powder, dried whole SB fruit or glucose drink, finger tip blood glucose will be measured 15, 30, 45, 60, 90 and 120 minutes after the consumption.
219581367|NCT06927895|BEHAVIORAL|Educational Intervention|"The research-specific educational intervention is the enhancement of communications and SDM in AE management.~To this end, interventions will include pre-recorded videos that address:~1. SDM methodologies (\~30 minutes)~2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes)~3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes)~Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives."
219581368|NCT06928623|OTHER|Surveys|In the present study, no intervention will be carried out, with the recruited subjects only completing the questionnaires set out in the study variables.
219581369|NCT06927479|OTHER|Training about Electronic Decision Support System|"1. System Registration and Usage~2. Pressure Ulcer Prevention~3. Urinary Infection Prevention~4. Nutrition and Hydration Management~5. Physical Activity and In-Bed Mobilization~6. Emergency Management and Reporting~7. Continuous Monitoring and Feedback"
219196137|NCT05265299|DRUG|Aspirin 325mg|Aspirin 325mg once daily
219196138|NCT05875506|DRUG|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
219196139|NCT05875506|DRUG|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
219196140|NCT06100315|DRUG|Nalbuphine|bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
219440505|NCT05480800|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
219440506|NCT05480800|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
219440507|NCT05480800|DRUG|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo\_Step 1 and Placebo\_Step 2 in Stage 1 (Europe).
218833319|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
219440508|NCT05480800|OTHER|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo\_Step 1, iNTS-TCV full dose\_1, Placebo\_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 and Control\_Stage 2 groups in Stage 2 (Africa).
219440509|NCT03649139|DRUG|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
219440510|NCT03649139|DRUG|Placebo drops|sublingual placebo drops
219440511|NCT02798640|DEVICE|Celliant|100% Celliant garment
219440512|NCT02798640|DEVICE|Control|Control Garment
219440513|NCT00948714|BEHAVIORAL|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
219440514|NCT00948714|BEHAVIORAL|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
219440515|NCT00948714|OTHER|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
219440516|NCT03723408|DEVICE|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
219440517|NCT03458988|DEVICE|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
219581370|NCT06928103|OTHER|Dynamic stretching|dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues.
219581371|NCT06928103|OTHER|Static stretching and dynamic stretching|Static stretching: help patients do the movement that they\&amp;amp;#39;re limited to stretch their soft tissue; Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues
219581372|NCT06928103|OTHER|Dynamic stretching and foam rolling|Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues; Foam rolling: Teach the participants how to use a massage ball so that they can perform movements to warm up their soft tissues
219581373|NCT06928883|DEVICE|Sirolimus drug eluting ballooon therapy|Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.
219581374|NCT06928883|DRUG|Optimal guidelines-directed medical therapies (GDMT)|Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques
219581375|NCT06927011|BEHAVIORAL|Capscan|"Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life.~Participants in this study will be over after all study procedures are completed."
219581376|NCT02283294|DRUG|Apixaban|
219581377|NCT02283294|DRUG|Warfarin|
219581378|NCT02123212|OTHER|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
218833320|NCT02100423|DRUG|curcumin|Given PO
218833321|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
218833322|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
218833323|NCT02100423|OTHER|pharmacological study|Correlative studies
218833324|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
218833325|NCT00496977|PROCEDURE|annual CT screening|
218833326|NCT00315510|DRUG|Rosuvastatin|
218833327|NCT02298309|OTHER|Test-and-Treat TB|
218833328|NCT06059807|DEVICE|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
218833329|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
218833330|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
218833331|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
218833332|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
218833333|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
218833334|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
219440518|NCT04476615|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
219440519|NCT04476615|DIETARY_SUPPLEMENT|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
218833335|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
218833336|NCT04369456|OTHER|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
218833337|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
218833338|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
218833339|NCT01704508|DRUG|Artemether-lumefantrine|
219475426|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
218833340|NCT01704508|DRUG|Dihydroartemisinin-piperaquine|
218833341|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
218833342|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
218833343|NCT04690218|DIAGNOSTIC_TEST|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
219475427|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
219475428|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
219475429|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
219475430|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
219475431|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
219475432|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
219475433|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
219475434|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
219475435|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
219475436|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
219475437|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
219475438|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
219475439|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
219475440|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
219475441|NCT05240313|BEHAVIORAL|kiR venezolano|A multi-week intervention focused on drug refusal skills and self-regulation.
219475442|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
219475443|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
219475444|NCT00516698|GENETIC|polymorphism analysis|
219475445|NCT00516698|OTHER|high performance liquid chromatography|
219475446|NCT00516698|OTHER|laboratory biomarker analysis|
219475447|NCT00516698|PROCEDURE|radiomammography|
219475448|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
219475449|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
219475450|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
219440520|NCT03025516|DEVICE|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
219440521|NCT03025516|DEVICE|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
219440522|NCT00075660|DRUG|triapine|
219014761|NCT02670564|GENETIC|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
219014762|NCT02670564|OTHER|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
219014763|NCT02055690|DRUG|Pazopanib|Tyrosine Kinase Inhibitor
219014764|NCT02055690|DRUG|Fosbretabulin|Vascular Disrupting Agent
219014765|NCT00416078|BEHAVIORAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
219014766|NCT00416078|BEHAVIORAL|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
219014767|NCT06073353|BEHAVIORAL|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
219196141|NCT03307915|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
219196142|NCT03307915|BIOLOGICAL|MVA-Mosaic|Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.
219440523|NCT02180568|PROCEDURE|Lipiodol|Lipiodol-guided lung localization technique
219440524|NCT02180568|PROCEDURE|Hookwire|Hookwire-guided lung localization technique
219440525|NCT02180568|DRUG|Lipiodol|
219440526|NCT05601050|OTHER|There is no intervention|There is no intervention
219440527|NCT02798445|OTHER|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
219440528|NCT02798445|OTHER|CONTROL|Multilayer bandages and wound care
219440529|NCT02706795|BIOLOGICAL|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
219440530|NCT05753202|DEVICE|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
219440531|NCT00026039|DRUG|estrogen|
219440532|NCT02306941|BEHAVIORAL|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
219440533|NCT04625088|OTHER|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
219440534|NCT04625088|DRUG|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
219440535|NCT00030160|BEHAVIORAL|Strength Training|
219581379|NCT02123212|OTHER|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
219440536|NCT01614275|BEHAVIORAL|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
219475451|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
218833344|NCT04690218|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
218833345|NCT04690218|BEHAVIORAL|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
218833346|NCT00055926|DRUG|CP-724,714|
218833347|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
218833348|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
218833349|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
219196143|NCT03307915|BIOLOGICAL|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
219475452|NCT04651569|OTHER|Observational study|none, Observational study
219475453|NCT06240468|OTHER|not have|not have
219475454|NCT04864704|OTHER|dry needling|Physical therapy
219475455|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
219475456|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
219475457|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
219475458|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
219475459|NCT05056909|OTHER|Standard of care|Standard of care
219475460|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
219475461|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
219475462|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
219475463|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
219475464|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
219475465|NCT00390338|BIOLOGICAL|polarized dendritic cells|
219475466|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
219475467|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
219475468|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
219475469|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
219475470|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
219475471|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
219475472|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
219475473|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
219475474|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
219475475|NCT03522506|DRUG|Modafinil|Modafinil tablets.
219475476|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
219196144|NCT03307915|DRUG|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
219440537|NCT01614275|BEHAVIORAL|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
219440538|NCT01614275|BEHAVIORAL|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
219440539|NCT01614275|BEHAVIORAL|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
219440540|NCT03059511|DRUG|Nalbuphine|Opioid Pain Medicine
219440541|NCT00004833|DRUG|Immune globulin|
219440542|NCT00430027|DRUG|Capecitabine|Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
219440543|NCT00430027|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
219440544|NCT00430027|DRUG|Cetuximab|Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
219440545|NCT00269295|BIOLOGICAL|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
219440546|NCT00269295|DRUG|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
219440547|NCT01957215|DRUG|Indomethacin|Topical indomethacin
219440548|NCT01957215|DRUG|Placebo|Placebo patch
219440549|NCT04376736|OTHER|Home visit|Home visit by medical provider
219440550|NCT01221662|DRUG|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
219440551|NCT02668328|BEHAVIORAL|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
219440552|NCT02451865|DRUG|Binimetinib|Given PO
219440553|NCT02451865|DRUG|Docetaxel|Given IV
219440554|NCT02451865|OTHER|Laboratory Biomarker Analysis|Correlative studies
219440555|NCT04532281|DRUG|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
219440556|NCT04609215|OTHER|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
219440557|NCT04908969|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
219440558|NCT03419507|DEVICE|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
218833350|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
218833351|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
218833352|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
218833353|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
218833354|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
218833355|NCT02454530|BIOLOGICAL|Nivestim®|
218833356|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
219014768|NCT05699798|OTHER|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
219014769|NCT05699798|OTHER|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
219196145|NCT06595719|DIETARY_SUPPLEMENT|Multi-Strain Probiotics|Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120
219440559|NCT03419507|DEVICE|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
219440560|NCT01407406|DRUG|BIIB023 - low dose IV Dose|
219440561|NCT01407406|DRUG|BIIB023 - high dose IV Dose|
219440562|NCT02978170|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
219440563|NCT00174928|DRUG|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
219440564|NCT00174928|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
219440565|NCT06507228|DIAGNOSTIC_TEST|NWL PEBBLE STT|At home testing for OSA with AcuPebble.
219440566|NCT02348294|OTHER|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
219440567|NCT04673240|DRUG|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
219440568|NCT04480515|OTHER|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
219440569|NCT05455307|DEVICE|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
219440570|NCT04986111|PROCEDURE|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
219440571|NCT04986111|PROCEDURE|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
219440572|NCT02030093|BEHAVIORAL|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
219440573|NCT00012207|BIOLOGICAL|aldesleukin|
219440574|NCT00012207|BIOLOGICAL|therapeutic autologous lymphocytes|
219440575|NCT00012207|DRUG|cyclophosphamide|
219440576|NCT00012207|DRUG|prednisone|
219440577|NCT00012207|DRUG|vincristine sulfate|
219440578|NCT00012207|PROCEDURE|adjuvant therapy|
219440579|NCT00003110|BIOLOGICAL|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
219440580|NCT01605890|DRUG|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
219440581|NCT04063228|OTHER|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
219440582|NCT04063228|OTHER|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
219440583|NCT05335252|DRUG|Dronabinol|5mg 2x daily for 7 days
219440584|NCT05335252|DRUG|Placebo|1 caplet 2x daily for 7 days
219440585|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
219440586|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
219440587|NCT02249351|DRUG|Talsaclidine|
219440588|NCT02249351|DRUG|Placebo|
219440589|NCT05431036|DEVICE|transthoracic ultrasonography|"1. The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~2. The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
219440590|NCT05538585|DRUG|Galicaftor|Oral
219440591|NCT05538585|DRUG|Navocaftor|Oral
219440592|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
219440593|NCT02490241|DRUG|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
219014770|NCT05699798|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
219440594|NCT05389306|DIAGNOSTIC_TEST|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
219014771|NCT06340828|OTHER|Washing Microbiota Transplantation|Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
219014772|NCT00243581|BEHAVIORAL|Dean Ornish Heart Disease Reversing Program|
219440595|NCT05389306|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
219475477|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
219475478|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
219475479|NCT06565845|PROCEDURE|Surgery|patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
219475480|NCT06565845|DRUG|triple anti-tuberculosis drug|Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
219475481|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
219475482|NCT02152930|DRUG|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
219475483|NCT06312917|BEHAVIORAL|Physical activity|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
219475484|NCT05990725|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
219475485|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
219475486|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
219014773|NCT05977582|BEHAVIORAL|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
219196146|NCT06595719|DIETARY_SUPPLEMENT|Placebo|Replicate for multi-strain probiotics without any active ingredients
219196147|NCT05111834|BEHAVIORAL|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
219196148|NCT05111834|BEHAVIORAL|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
219475487|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
219475488|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
219475489|NCT00761085|DRUG|Morphine|Standard of care for pain management of acute episode of pain
219475490|NCT00761085|DRUG|Methadone|Compare to standard of care for pain management of acute episode of pain
219475491|NCT00083356|PROCEDURE|Wisdom tooth extraction|
219475492|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
219475493|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
219475494|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
219581380|NCT02123212|OTHER|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
219581381|NCT05476614|OTHER|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
219581382|NCT05476614|OTHER|Yoga (Human-instructed)|Yoga that is instructed by a human
219581383|NCT05344248|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
219581384|NCT05344248|BIOLOGICAL|JS005 placebo|Subcutaneous injection
219581385|NCT06926998|DRUG|9MW2821+other anticancer therapy|Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol
219581386|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe was moved 3 cm laterally from the midline. The erector spinae musclewill be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution will be injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered
219581387|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probewill be moved laterally to identify the longissimus and iliocostalis muscles . The needlewill be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered
219581388|NCT06926816|GENETIC|Natera® Empower™ hereditary cancer panel test|The test will be the Natera® Empower™ hereditary cancer panel test and will be collected by saliva.
219581389|NCT06926816|OTHER|Specialist Referral|Participants with actionable pathogenic variants will be referred to the appropriate specialists (e.g., medical oncologist, gynecologic oncologist, breast surgeon) to discuss risk-reduction strategies and offered genetic counseling
219014774|NCT05977582|BEHAVIORAL|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
219014775|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed QD
219014776|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed BID
219581390|NCT06927258|DRUG|changyanning granules|From one day before the procedure to five days postoperatively, patients in the experimental group will be administered Chanyanning granules.
219581391|NCT06927258|DRUG|Placebo|control
219581392|NCT04062448|DRUG|Ibrutinib|Ibrutinib 420 mg will be administered orally.
219581393|NCT04062448|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered intravenously.
219581394|NCT05731713|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
219581395|NCT05178017|DIAGNOSTIC_TEST|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
219581396|NCT04008368|DEVICE|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
219581397|NCT02477930|OTHER|No interventions are done|No intervention is done. This is a registry study.
219581398|NCT04450147|BEHAVIORAL|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
219581399|NCT04990609|DEVICE|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
219581400|NCT04990609|DRUG|Neoadjuvant Chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician \[possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)\].
219014777|NCT01190878|DRUG|DuraSite Vehicle|Vehicle dosed BID
219014778|NCT01190878|DRUG|Xibrom™|0.09% bromfenac dosed BID
219014779|NCT02060604|DRUG|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
219440596|NCT05389306|DIAGNOSTIC_TEST|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
219440597|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min."
219440598|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
219440599|NCT05728424|DRUG|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
219581401|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
219440600|NCT03092622|OTHER|Exercise|Exercise training intervention as described earlier.
219440601|NCT02259764|DRUG|KUC 7483 CL - single rising dose|
219440602|NCT02259764|DRUG|Placebo|
219014780|NCT02060604|DRUG|Ranibizumab|3 monthly ranibizumab, then as needed
219581402|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
219581403|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
219581404|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
219014781|NCT02520401|OTHER|Probiotic - BioGaia|Use of a probiotic tablet
219440603|NCT02259764|OTHER|standardized high fat meal|
219581405|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
219581406|NCT02543567|BIOLOGICAL|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
219581407|NCT02543567|BIOLOGICAL|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
219581408|NCT02543567|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
219581409|NCT05101486|BIOLOGICAL|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
219581410|NCT02788045|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
219014782|NCT02520401|OTHER|Placebo|Use of a placebo tablet
219014783|NCT02733588|DRUG|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
219014784|NCT00233103|DRUG|Sertraline|Sertraline arm
219014785|NCT00233103|DRUG|Placebo|Placebo
219440604|NCT05208346|DIETARY_SUPPLEMENT|Mixed meals|Mixed meals enriched with either 25 or 50 g of canola or coconut oil
219440605|NCT01172561|BEHAVIORAL|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
219440606|NCT01172561|BEHAVIORAL|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
219440607|NCT03712670|DRUG|Aflibercept|monthly intravitreal injections
219440608|NCT03712670|DRUG|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
219014786|NCT01829230|DEVICE|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
219014787|NCT00045123|DRUG|tarenflurbil|
219014788|NCT00045123|PROCEDURE|adjuvant therapy|
219014789|NCT01272414|DRUG|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
219014790|NCT01272414|DRUG|Saline injection|Injection of 0.4cc 0.9% normal saline
219014791|NCT04969120|DRUG|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
219014792|NCT04969120|DRUG|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
219014793|NCT03807063|BIOLOGICAL|Rivogenlecleucel|Given IV
219014794|NCT03807063|DRUG|Rimiducid|Given IV
219014795|NCT01907204|DRUG|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
219014796|NCT01907204|DRUG|Budesonide|Budesonide by metered dose inhaler
219014797|NCT01907204|DRUG|Budesonide|Budesonide by nebulization
219440609|NCT03712670|DIETARY_SUPPLEMENT|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
219440610|NCT02554201|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
219440611|NCT02554201|DEVICE|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
219440612|NCT00088595|DRUG|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
219440613|NCT03089008|OTHER|Eccentric exercises|
219440614|NCT03089008|OTHER|Stretching exercises|
219440615|NCT03180294|DRUG|Bupropion 150 mg XL|By mouth
219440616|NCT03180294|DRUG|Placebo|By mouth
219440617|NCT00608894|DRUG|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
219475495|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
219014798|NCT04387435|OTHER|A change or titration in the current or frequency settings of the VNS therapy system.|The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
219014799|NCT03144362|PROCEDURE|Bilateral Sliding Techniques|Bilateral Sliding Techniques
219014800|NCT03144362|PROCEDURE|Unilateral Sliding Techniques|Unilateral Sliding Techniques
219014801|NCT00757744|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
219014802|NCT00757744|BEHAVIORAL|Drug counseling|individual drug counseling
219014803|NCT03855280|DRUG|APVO101|Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
219014804|NCT04993456|PROCEDURE|Caridac surgery|Cardiac surgery
219014805|NCT05205733|OTHER|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
219014806|NCT01508858|DRUG|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
219014807|NCT01508858|DRUG|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
219014808|NCT01508858|DRUG|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
219014809|NCT00783250|DRUG|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
219014810|NCT00783250|DRUG|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
219014811|NCT00004182|DRUG|irinotecan hydrochloride|
219014812|NCT01014650|DRUG|GLYX-13|single IV or SC dose
219014813|NCT01014650|DRUG|IV normal saline|Single IV dose of normal saline
219014814|NCT01243879|OTHER|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
219014815|NCT01243879|OTHER|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
219440618|NCT00608894|DRUG|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
219440619|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
219581411|NCT02788045|BIOLOGICAL|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.
219581412|NCT02788045|BIOLOGICAL|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
219581413|NCT02788045|DRUG|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
219581414|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
219581415|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
219581416|NCT06189118|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
219581417|NCT06570928|OTHER|Cannabis|0,2 ml of CBD:THC (50 mg:5 mg)
219581418|NCT06570928|OTHER|Placebo|Product vehicle, medium chain triglycerides (MCT)
219581419|NCT05870800|DRUG|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
219581420|NCT05870800|DRUG|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
219581421|NCT05870800|DRUG|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
219581422|NCT05312398|DRUG|Cetuximab|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
219581423|NCT05312398|DRUG|FOLFIRI|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
219581424|NCT05312398|DRUG|FOLFOX regimen|"II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
219581425|NCT05312398|DRUG|Irinotecan|"III LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
219014816|NCT03818828|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
219440620|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
219440621|NCT03105869|DIAGNOSTIC_TEST|fluorocholine PET/CT|standard diagnostic PET/CT procedure
219440622|NCT00562536|PROCEDURE|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
219440623|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
219440624|NCT03870893|BEHAVIORAL|hippotherapy|16weeks hippotherapy program
219440625|NCT03149497|PROCEDURE|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
219440626|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
219440627|NCT00653406|DRUG|Risperidone long acting injectable|
218833357|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
218833358|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
219014817|NCT03818828|OTHER|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
219014818|NCT03818828|OTHER|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
219014819|NCT06327451|DRUG|Atorvastatin 20mg|Liptor is a capsule in the form of 20 mg, once daily.
218833359|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
218833360|NCT03826459|PROCEDURE|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
219014820|NCT04404751|COMBINATION_PRODUCT|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
219014821|NCT03594292|DEVICE|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
219014822|NCT03594292|PROCEDURE|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
219014823|NCT04156425|DRUG|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
219440628|NCT01314456|DEVICE|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
219440629|NCT02900599|OTHER|Observationnal (no intervention)|
219440630|NCT05789706|BEHAVIORAL|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
219440631|NCT04468464|OTHER|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
219440632|NCT04468464|OTHER|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
219440633|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
219440634|NCT00792857|DRUG|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
219440635|NCT00792857|DRUG|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
219440636|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
218833361|NCT03826459|PROCEDURE|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
218833362|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
218833363|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
218833364|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
218833365|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
219014824|NCT04156425|DIETARY_SUPPLEMENT|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
219014825|NCT04156425|DRUG|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
219014826|NCT01122836|OTHER|Massage|Therapeutic Massage
219014827|NCT03352206|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
219014828|NCT03352206|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
219014829|NCT05918692|DRUG|BMF-500|Investigational Product
219014830|NCT00989014|DRUG|CD07805/47|0.5% Topical Gel
219014831|NCT00989014|DRUG|CD07805/47|0.18% Topical Gel
219014832|NCT00989014|DRUG|CD07805/47|0.07% Topical Gel
219440637|NCT04503473|BEHAVIORAL|High Intensity Stepping Training|"The goals will be to maximize stepping activity at high intensities for 40 minutes per 1 hour session, with rest breaks as needed~Conventional Therapy: : Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions"
219440638|NCT04503473|BEHAVIORAL|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions
219440639|NCT02411877|PROCEDURE|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
219440640|NCT02411877|PROCEDURE|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
219440641|NCT02411877|DEVICE|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
218833366|NCT04202666|DEVICE|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
218833367|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
219014833|NCT00989014|DRUG|CD07805/47 placebo|Vehicle Topical Gel
219014834|NCT00120770|DRUG|Cellulose Sulfate Vaginal Gel (Microbicide)|
219014835|NCT00643032|PROCEDURE|Transcutaneous iliohypogastric|
219196149|NCT06814873|BEHAVIORAL|Neurofeedback|The participants received visual feedback of the processed result of neural signals acquired online.
219440642|NCT02411877|DEVICE|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
219440643|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
219440644|NCT03245294|PROCEDURE|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
219440645|NCT05609305|OTHER|Discharge|observational study, not intervention
219440646|NCT03689699|DRUG|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
219440647|NCT03689699|DRUG|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
219440648|NCT03689699|DRUG|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
219440649|NCT04359121|OTHER|Questionnaires for specific phobia|Questionnaires will be used.
219440650|NCT05787366|OTHER|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
219440651|NCT05787366|OTHER|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
219440652|NCT06828302|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy|Parent management training delivered online where Internet-modules are combined with video sessions for live coaching.
219440653|NCT03412162|BEHAVIORAL|Ethnic and Racial Identity Promotion|See arm description
219440654|NCT03412162|BEHAVIORAL|Academic Skills Promotion|See arm description
219440655|NCT05920200|PROCEDURE|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
219440656|NCT05920200|PROCEDURE|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
219440657|NCT05920200|PROCEDURE|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
219440658|NCT03743298|DRUG|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
219440659|NCT05264636|OTHER|Sucrose|Sucrose Beverage
219440660|NCT05264636|OTHER|Steviol Glycosides|Steviol Glycoside Beverage
219440661|NCT01376388|DRUG|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
219440662|NCT03643016|OTHER|Surgical strategy based on a software|Surgical strategy décision based on a software
219475496|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
218833368|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
218833369|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
218833370|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
218833371|NCT04824664|OTHER|survey|survey among surgeon
218833372|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
218833373|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
219014836|NCT00643032|PROCEDURE|Perioperative administration near the nerve|
219014837|NCT01949168|DRUG|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
219014838|NCT01949168|DRUG|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
219014839|NCT01949168|DRUG|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
219014840|NCT02525341|OTHER|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
219014841|NCT02525341|OTHER|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
219196150|NCT06814873|BEHAVIORAL|Sham-feedback|Previously recorded neural signals are processed and presented to participants as if the signals from them are processed online.
219440663|NCT05589012|BIOLOGICAL|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
218833374|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
218833375|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
218833376|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
219440664|NCT05589012|BIOLOGICAL|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
219475497|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
219475498|NCT06115707|OTHER|The lying flat (0°-10°) head position for 72 hours|The lying flat (0°-10°) head position for 72 hours after endovascular therapy.
219475499|NCT06115707|OTHER|The The head elevation (30°-40°) position for 72 hours|The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
218833377|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
218833378|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
218833379|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
218833380|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
218833381|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
218833382|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
218833383|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
218833384|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
218833385|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
218833386|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
218833387|NCT02070328|OTHER|Registry|
218833388|NCT00328718|DRUG|montelukast (5mg QD)|
218833389|NCT00328718|DRUG|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
218833390|NCT05863403|DIAGNOSTIC_TEST|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
218833391|NCT05863403|DIAGNOSTIC_TEST|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
218833392|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
218833393|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
218833394|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
218833395|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
218833396|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
219196151|NCT06815094|PROCEDURE|Regional analgesia either CEA or ESP|Ultrasound guided local anesthetic injection in the course of the conducting nerve to decrease pain transmission.
218833397|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
219475500|NCT05021315|DRUG|10% povidone iodine|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
219475501|NCT05016219|DEVICE|Circadian-Effective Light|Narrowband blue light
219475502|NCT05016219|DEVICE|Rhythmic Light|40 hertz (Hz) flicker
219475503|NCT05016219|DEVICE|Placebo Light|Narrowband red light
219475504|NCT05016219|DEVICE|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
219475505|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
219581426|NCT05703347|BEHAVIORAL|Fixed sleep goal|Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
218833398|NCT05698394|DRUG|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
218833399|NCT05698394|DRUG|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
218833400|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
218833401|NCT01633255|DRUG|18F-Fluciclatide|
218833402|NCT06614036|DRUG|Remimazolam|Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
218833403|NCT06614036|DRUG|Midazolam|Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
218833404|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
218833405|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
218833406|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
218833407|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
218833408|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
218833409|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
218833410|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
219014842|NCT02525341|OTHER|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
219014843|NCT01879332|DRUG|Placebo|Matching placebo tablets for oral administration
219014844|NCT01879332|DRUG|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
219014845|NCT01879332|DRUG|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
218833411|NCT05593315|OTHER|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
218833412|NCT05883202|DEVICE|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
218833413|NCT05883202|DEVICE|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
219475506|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
219475507|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
219475508|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
219475509|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
219475510|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
219475511|NCT04366518|DRUG|Rivastigmine Transdermal System|Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
219475512|NCT04366518|DRUG|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
219475513|NCT04366518|DRUG|Placebo Patch|Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
219475514|NCT04366518|DRUG|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
219475515|NCT01522755|DEVICE|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
219475516|NCT03414658|DRUG|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
219581427|NCT05703347|BEHAVIORAL|Personalized sleep goal|Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
218833414|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
218833415|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
218833416|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
219581428|NCT05703347|BEHAVIORAL|Digital sleep health messaging without virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
219581429|NCT05703347|BEHAVIORAL|Digital sleep health messaging with virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
219440665|NCT05589012|BIOLOGICAL|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
219440666|NCT03542149|DRUG|480 mg Piperaquine phosphate|480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
219440667|NCT03542149|DRUG|640 mg Piperaquine phosphate|640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
219440668|NCT03542149|DRUG|200 mg OZ 439|200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
219440669|NCT03542149|DRUG|400 mg OZ 439|400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
219440670|NCT03542149|DRUG|800 mg OZ 439|800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
219440671|NCT03542149|DRUG|960 mg PQP|960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
219440672|NCT03542149|DRUG|320 mg PQP|320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
219440673|NCT01789892|DRUG|methylprednisolone|Given IV
219440674|NCT01789892|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT scan
219440675|NCT01789892|PROCEDURE|positron emission tomography|Undergo FDG PET/CT scan
219440676|NCT01789892|PROCEDURE|computed tomography|Undergo FDG PET/CT scan
219440677|NCT04518020|PROCEDURE|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
219440678|NCT02953067|PROCEDURE|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
219440679|NCT02953067|PROCEDURE|Primary arthrodesis|Primary arthrodesis versus ORIF
219440680|NCT02953067|PROCEDURE|Conservative treatment|Conservative treatment versus open reduction and internal fixation
219440681|NCT04720690|DEVICE|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
219440682|NCT04720690|DEVICE|NICaS|Measurement of cardiac output
219440683|NCT04720690|DEVICE|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
219440684|NCT00054418|DIETARY_SUPPLEMENT|calcium carbonate|calcium 600 mg daily administered orally for one year
219440685|NCT00054418|DIETARY_SUPPLEMENT|vitamin D|vitamin D 400 U daily administered orally for one year
219581430|NCT05703347|BEHAVIORAL|Inactive Parent-Directed Loss-Framed Incentive|No parental incentive
219440686|NCT00054418|DRUG|risedronate sodium|risedronate 35 mg weekly administered orally
219440687|NCT00054418|OTHER|placebo|placebo tablet weekly administered orally for one year
219440688|NCT01845519|BEHAVIORAL|Tailored Email|Participants will receive tailored emails.
219440689|NCT01845519|BEHAVIORAL|Targeted Email|Participants will receive targeted emails.
219440690|NCT02027974|DEVICE|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
219440691|NCT02027974|DEVICE|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
219014846|NCT01847157|DEVICE|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
219014847|NCT01847157|DRUG|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
219014848|NCT01847157|DRUG|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
218833417|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
219014849|NCT01847157|OTHER|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
219014850|NCT01847157|DEVICE|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
219014851|NCT00969150|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
219014852|NCT00969150|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
219014853|NCT03059498|PROCEDURE|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
219014854|NCT03059498|PROCEDURE|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
219440692|NCT00644241|BIOLOGICAL|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
219440693|NCT00644241|PROCEDURE|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
219440694|NCT02928081|PROCEDURE|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
219440695|NCT02928081|PROCEDURE|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
219440696|NCT02325804|BEHAVIORAL|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
219440697|NCT02942693|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
219440698|NCT02942693|RADIATION|Particle Therapy|Same total dose and fractionation will be used in both arms.
218833418|NCT02521974|BIOLOGICAL|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
218833419|NCT05250921|PROCEDURE|Corticision|Corticision will be performed to enhance teeth alignment.
219014855|NCT03059498|DRUG|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
219440699|NCT03535090|DRUG|Methylprednisolone|
219440700|NCT02126527|DRUG|auranofin|Given PO
219440701|NCT02126527|DRUG|sirolimus|Given PO
219440702|NCT02126527|OTHER|laboratory biomarker analysis|Correlative studies
219440703|NCT02126527|OTHER|pharmacological study|Correlative studies
219440704|NCT01784250|DRUG|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
219440705|NCT01784250|DRUG|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
219440706|NCT01784250|DRUG|Placebo|Sugar pill manufactured to mimic a drug
219440707|NCT04146402|DRUG|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
219440708|NCT04146402|DRUG|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
219440709|NCT06011785|DRUG|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
219440710|NCT01779895|DIETARY_SUPPLEMENT|Lactobacillus paracasei probiotic strain|
219440711|NCT01779895|DIETARY_SUPPLEMENT|Placebo|maltodextrin
219440712|NCT06063837|BEHAVIORAL|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
219440713|NCT04268706|DRUG|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
218833420|NCT05250921|DEVICE|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
218833421|NCT06716541|PROCEDURE|ERCP implantation of a biodegradable stent|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a biodegradable stent to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
218833422|NCT06716541|PROCEDURE|ERCP implantation of plastic stents|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a plastic stent or multiple stents to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
219014856|NCT02872467|DRUG|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
219014857|NCT02872467|OTHER|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
219440714|NCT04268706|DRUG|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
218833423|NCT06714968|OTHER|Digital|After the pre-test application is completed, the students in the experimental group will be allowed to install the designed game application on their phones. After the installation process, students will be allowed to play the game for 2 weeks. After 2 weeks from the date of downloading the game, access to the game will be automatically blocked. After completing the application steps, when the student thinks that he/she is ready to apply the post-test, he/she will be able to perform the post-test application. In the post-test application, there will be no repeated return of the student to the questions or multiple answer submission. Two weeks after the application is completed, the knowledge test will be applied to the students again in order to objectively evaluate the learning. In this process, students will be prevented from accessing the application.
218833424|NCT06715839|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
219014858|NCT00006344|RADIATION|radiation therapy|
219014859|NCT05815472|DEVICE|Fitbit charge|Internet of Things Technologies Device
219014860|NCT05625672|OTHER|Training|Hemovigilance module training
219014861|NCT02703584|DRUG|Buseralin|
219014862|NCT02703584|OTHER|Placebo|
219014863|NCT02703584|DRUG|pregnyl|
219014864|NCT03138395|DIAGNOSTIC_TEST|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
219440715|NCT04268706|DRUG|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
219440716|NCT02255955|DRUG|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
219440717|NCT02255955|DRUG|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
219440718|NCT02255955|DRUG|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
219440719|NCT06158854|DRUG|ABBV-383 (Etentamig)|Intravenous Infusion
219440720|NCT02673528|PROCEDURE|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
219440721|NCT05305625|PROCEDURE|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
219440722|NCT05305625|DRUG|standard therapy|received standardized treatment
219440723|NCT02298075|DRUG|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
219440724|NCT02298075|DRUG|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
219440725|NCT03991624|DIAGNOSTIC_TEST|cognitive assessment|"* MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease"
219440726|NCT03991624|OTHER|Inhibition evaluation|"* Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
219475517|NCT03414658|DRUG|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
219475518|NCT03414658|DRUG|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
219475519|NCT03414658|DRUG|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
219475520|NCT03532399|DRUG|Bivalirudin|"CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos\_f/6317841), but will ultimately be determined by patient's primary provider."
219014865|NCT02066974|GENETIC|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
218833425|NCT06715839|DRUG|[18F]F-RESCA-RB14|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
218833426|NCT06715839|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
218833427|NCT06715839|DRUG|[18F]F-RESCA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
218833428|NCT06715839|DRUG|[68Ga]Ga-NOTA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
218833429|NCT06715839|DRUG|[18F]F-RESCA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
218833430|NCT06715839|DRUG|[68Ga]Ga-NOTA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
219014866|NCT01901198|BIOLOGICAL|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
219014867|NCT01901198|BIOLOGICAL|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
219440727|NCT03991624|OTHER|Assessment of mental flexibility|"* a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
219440728|NCT03991624|OTHER|Evaluation of the update|"* an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
219440729|NCT03991624|OTHER|working memory|"* the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
219440730|NCT03991624|OTHER|episodic memory|\- A recognition task with a Remember/Know paradigm
219440731|NCT04068038|OTHER|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
219440732|NCT05732597|PROCEDURE|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
219440733|NCT00062595|DRUG|phylloquinone (K1)|
219440734|NCT00062595|DRUG|menatetranone (MK4)|
219440735|NCT04186546|DEVICE|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
219440736|NCT04796948|DRUG|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
219440737|NCT00969488|OTHER|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
219440738|NCT04880681|DEVICE|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
218833431|NCT06715839|DRUG|[18F]F-RESCA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
218833432|NCT06715839|DRUG|[68Ga]Ga-NOTA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
219440739|NCT04880681|DEVICE|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
219440740|NCT03938636|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219440741|NCT04914195|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
219440742|NCT00492518|DRUG|Acetylcysteine|
219440743|NCT00492518|DRUG|Theophylline|
219581431|NCT05703347|BEHAVIORAL|Active Parent-Directed Loss-Framed Incentive|Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
219581432|NCT05703347|BEHAVIORAL|Inactive Supportive Feedback|No supportive feedback
219440744|NCT00492518|DRUG|Placebo|
218833433|NCT06715839|DRUG|[18F]F-RESCA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
218833434|NCT06717828|BEHAVIORAL|Tai Chi Exercise|Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.
219581433|NCT05703347|BEHAVIORAL|Active Supportive Feedback|Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
219581434|NCT04901429|PROCEDURE|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
219764199|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
219764200|NCT05647265|BIOLOGICAL|Nivolumab|Given IV
219764201|NCT05647265|BIOLOGICAL|Ipilimumab|Given IV
219440745|NCT03175952|DIAGNOSTIC_TEST|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
219581435|NCT06135064|DEVICE|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
219581436|NCT02111941|OTHER|Laboratory Biomarker Analysis|Correlative studies
219581437|NCT02111941|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
219764202|NCT05647265|PROCEDURE|Surgical Procedure|Undergo surgery
219764203|NCT05647265|PROCEDURE|Computed Tomography|undergo CT
219764204|NCT05647265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219014868|NCT03352830|BEHAVIORAL|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
219014869|NCT03352830|OTHER|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
219014870|NCT02548494|DRUG|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
219440746|NCT03415672|BIOLOGICAL|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
219440747|NCT03415672|BIOLOGICAL|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
219440748|NCT03520894|RADIATION|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
219440749|NCT00130494|DRUG|Zoledronic acid|
219581438|NCT02912845|DRUG|KamRAB - HRIG|wound infiltration or IM injection
219581439|NCT01463215|DRUG|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
219581440|NCT01910012|DRUG|ADI-PEG 20|
219581441|NCT01195792|DRUG|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
219581442|NCT01195792|DRUG|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
219014871|NCT02548494|DRUG|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
218833435|NCT06717828|BEHAVIORAL|Regular Exercise|The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.
218833436|NCT06717828|BEHAVIORAL|Control|All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
219014872|NCT02548494|OTHER|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
219014873|NCT02548494|OTHER|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
219014874|NCT00000210|DRUG|Buprenorphine|
219014875|NCT03732001|DRUG|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
219014876|NCT03732001|DRUG|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
219014877|NCT01269424|BIOLOGICAL|MGMTP140K-encoding retroviral vector|
219014878|NCT01269424|DRUG|O6-benzylguanine|
219014879|NCT01269424|DRUG|temozolomide|
219014880|NCT01269424|OTHER|laboratory biomarker analysis|
219014881|NCT01269424|PROCEDURE|autologous hematopoietic stem cell transplantation|
219014882|NCT01269424|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219014883|NCT01269424|RADIATION|radiation therapy|
219014884|NCT05336955|OTHER|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
219014885|NCT05336955|OTHER|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
219014886|NCT05336955|OTHER|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
219014887|NCT05336955|OTHER|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
219440750|NCT01964027|DRUG|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
219764205|NCT05647265|PROCEDURE|Positron Emission Tomography|Undergo PET
219014888|NCT03867305|DEVICE|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
219014889|NCT01131923|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
219014890|NCT02573857|DRUG|DSM265|Oral suspension from bulk powder
219014891|NCT02573857|DRUG|OZ439|Oral suspension from powder in a bottle
219014892|NCT02511366|OTHER|Ileal infusion of casein|Intraileal infusion of casein
219440751|NCT01660646|BEHAVIORAL|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
219440752|NCT03928340|DRUG|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
219581443|NCT04034537|DIAGNOSTIC_TEST|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
219014893|NCT02511366|OTHER|Ileal infusion of tap water|Intraileal infusion of tap water
219014894|NCT04128267|DEVICE|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
218833437|NCT06718959|DEVICE|the test product (Jet Floss EX)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day. Subjects used the test product (standard sprinkler, water twice) to flush all gingival margins and adjacent spaces with 440ml of water, start with water pressure gear 1 for the first time and continued with this gear after reaching the highest level that can be asapted. If felt uncomfortable, eligible subjects can adjust it to a suitable gear. The specific installation and usage of the teeth punch refer to the product instruction.
218833438|NCT06718959|OTHER|the control product (interdental brush)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add auxiliary product (interdental brush) twice a day.
218833439|NCT01643057|DEVICE|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
218833440|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
219014895|NCT04128267|DEVICE|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
219014896|NCT04128267|OTHER|Correlative Studies|Administration of questionnaires via computer
219014897|NCT05062681|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
219014898|NCT05062681|DRUG|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
219014899|NCT06391723|DEVICE|Active rTMS|rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
219014900|NCT06391723|DEVICE|Sham rTMS|Sham rTMS will be administered over the left dorsolateral prefrontal cortex
219014901|NCT00999791|DRUG|Bevacizumab|
219014902|NCT00999791|DRUG|Diclofenac|
219014903|NCT00090311|DRUG|quetiapine fumarate|
218833441|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
218833442|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
218833443|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
218833444|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
218833445|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
219014904|NCT04728061|DRUG|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
219581444|NCT00388401|DRUG|Alvimopan|
219581445|NCT02208986|DRUG|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
218833446|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
219014905|NCT04728061|DRUG|Placebo|Intravenously-infused vehicle.
219014906|NCT01698047|BEHAVIORAL|Resiliency Class|See Arm Description
219014907|NCT01698047|OTHER|Case Management|See Case Management description
219014908|NCT02416440|OTHER|blood sample|blood sample
219581446|NCT03288181|DEVICE|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
219014909|NCT02649907|DIETARY_SUPPLEMENT|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
219014910|NCT02649907|OTHER|Nutritional counseling|nutritional counseling for healthy eating behaviour
219014911|NCT02649907|DIETARY_SUPPLEMENT|formula diet|formula diet to help weight loss
219014912|NCT01698801|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
219014913|NCT01698801|DRUG|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
219014914|NCT04080817|DEVICE|Neolexon|Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
219014915|NCT04080817|OTHER|Speech therapy|standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
219014916|NCT04080817|OTHER|Self training|Same frequency \& intensity as in the other interventions
219014917|NCT01255657|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
219014918|NCT00815581|DEVICE|photorefraction,cycloautorefraction,cycloretinoscopy|
219014919|NCT04343599|OTHER|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
219014920|NCT01778829|PROCEDURE|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
219014921|NCT01778829|PROCEDURE|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
219014922|NCT01988857|BIOLOGICAL|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
219014923|NCT00447161|DRUG|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
219014924|NCT00447161|DRUG|Placebo|Matched placebo
219764206|NCT04637984|BEHAVIORAL|PREP2 algorithm|A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
218833447|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
218833448|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
218833449|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
218833450|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
218833451|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
218833452|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
218833453|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
219014925|NCT02567942|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation
219014926|NCT02567942|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
219014927|NCT01614067|DRUG|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
219014928|NCT04506489|OTHER|Psychological investigation|Psychological tests, psychological interviews.
219014929|NCT02152839|BEHAVIORAL|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
219014930|NCT06376799|OTHER|Self-questionnaire|Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
219014931|NCT03838822|DIETARY_SUPPLEMENT|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
219440753|NCT03928340|DRUG|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
219440754|NCT01876472|BEHAVIORAL|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
219440755|NCT01100658|DRUG|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
219440756|NCT01100658|DRUG|Placebo|1 capsule per day for 1 week.
219440757|NCT01238705|DRUG|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
219440758|NCT01238705|DRUG|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
219440759|NCT03058302|BEHAVIORAL|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
219440760|NCT05472376|OTHER|Retrospective study|Retrospective study
219440761|NCT00711412|DRUG|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
219440762|NCT00711412|DRUG|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
219014932|NCT00751244|BEHAVIORAL|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
219440763|NCT00711412|DRUG|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
219764207|NCT04238819|DRUG|Abemaciclib|Administered orally
219764208|NCT04238819|DRUG|Irinotecan|Administered IV
218833454|NCT03159468|BEHAVIORAL|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
219440764|NCT00711412|DRUG|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
219440765|NCT00711412|RADIATION|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
219440766|NCT00711412|PROCEDURE|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
219440767|NCT06633198|PROCEDURE|Passive Heating|The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
219440768|NCT06633198|DRUG|L-NAME|L-NAME will be used during measurement of cutaneous microvascular function to test the dependency upon NO to elicit vasodilation.
219440769|NCT00288522|DRUG|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
219440770|NCT02790684|DRUG|DS-8500a|
219440771|NCT02527564|DRUG|Suvorexant|
219440772|NCT02527564|DRUG|Placebo|
219440773|NCT01902693|OTHER|No intervention for this study|No intervention
219440774|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
219440775|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
219440776|NCT00420342|DRUG|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
219440777|NCT01017549|RADIATION|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
219440778|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
219440779|NCT02901340|DIETARY_SUPPLEMENT|one to two liters of water daily|
219440780|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
219440781|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
219440782|NCT00429572|DRUG|Fludarabine|30 mg/m\^2 intravenously Daily for 5 Days
219440783|NCT00429572|DRUG|Melphalan|70 mg/m\^2 intravenously Daily for 2 Days
219440784|NCT00429572|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
219440785|NCT01665872|BEHAVIORAL|Cognitive-Behavioral Group Therapy|CBT Group
219440786|NCT05821036|BEHAVIORAL|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
219440787|NCT04030468|OTHER|Educational intervention addressed to general practitioners|"* feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course"
219440788|NCT04030468|OTHER|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
219440789|NCT01366534|BIOLOGICAL|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
219440790|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
219440791|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
218833455|NCT03159468|BEHAVIORAL|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
218833456|NCT03159468|OTHER|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
218833457|NCT02377414|DRUG|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
218833458|NCT02377414|DRUG|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
218833459|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
218833460|NCT01327235|DRUG|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
218833461|NCT01327235|DRUG|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
218833462|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
218833463|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
219440792|NCT01366534|OTHER|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
219764209|NCT04238819|DRUG|Temozolomide|Administered orally
219764210|NCT04238819|DRUG|Dinutuximab|Administered IV
219764211|NCT04238819|DRUG|GM-CSF|Administered SC
219764212|NCT06824467|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
219764213|NCT06824467|BIOLOGICAL|Bevacizumab|IV Infusion
219581447|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
219014933|NCT00751244|BEHAVIORAL|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
219581448|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
219581449|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
219581450|NCT04649073|BIOLOGICAL|OPC-415|OPC-415 (up to 1×10\^7cells/kg) On 2 days
219581451|NCT05102981|PROCEDURE|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
219581452|NCT02205762|DRUG|Prednisone|Stratum I
219581453|NCT02205762|DRUG|Vinblastine|Stratum I
219581454|NCT02205762|DRUG|mercaptopurine|Stratum I
219581455|NCT02205762|DRUG|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
219581456|NCT02205762|DRUG|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
219581457|NCT02205762|DRUG|Cytosine Arabinoside|
219581458|NCT02205762|DRUG|2-chlorodeoxyadenosine|
219581459|NCT02205762|PROCEDURE|hematopoietic stem cell transplantation (RIC-HSCT)|
219764214|NCT06824467|DRUG|H1 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
219764215|NCT06824467|DRUG|H2 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
219014934|NCT00751244|OTHER|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
219581460|NCT02205762|BIOLOGICAL|Intravenous immunoglobulin|
219581461|NCT06210399|PROCEDURE|Extracorporeal Shockwave Therapy|3 to 6 shock wave treatment sessions will be performed (PiezoWave 2 Control Unit Generator, classification 93/42/EEC class IIb), with a frequency of two sessions per week.
219581462|NCT05801965|DEVICE|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
219581463|NCT05801965|OTHER|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
219581464|NCT03928158|DRUG|LCZ 696|50-100-200 mg tablet
219581465|NCT03928158|DRUG|Valsartan|40-80-160 mg tablet
219581466|NCT03047473|BIOLOGICAL|avelumab|add on of avelumab 10mg/kg IV to standard therapy
219581467|NCT05468359|DRUG|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
219581468|NCT05468359|DRUG|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
219581469|NCT05468359|DRUG|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
219764216|NCT06824467|DRUG|Acetaminophen (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
219764217|NCT06824467|DRUG|Dexamethasone (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
219764218|NCT06824467|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Rescue medication taken orally 4 times daily
219764219|NCT06665594|PROCEDURE|Hyaluronic Acid (HA)|Injectable gel
219764220|NCT06665594|DRUG|Tranexamic Acid (TXA)|Injection of TXA
219581470|NCT05468359|DRUG|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
219581471|NCT05464667|RADIATION|Radiation Therapy (RT)|"Dose Escalation: 4 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 50 Gy in 5 fractions (Par 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)"
219581472|NCT04523610|BEHAVIORAL|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
219581473|NCT04523610|OTHER|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
219581474|NCT04523610|OTHER|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
219581475|NCT02935686|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
219581476|NCT02935686|BIOLOGICAL|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
219764221|NCT06665594|DRUG|Saline (placebo)|Injection of saline
219581477|NCT02935686|BIOLOGICAL|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
219581478|NCT02935686|OTHER|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
219014935|NCT05695690|DEVICE|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
219014936|NCT02415751|BEHAVIORAL|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
219014937|NCT00002667|OTHER|cytology specimen collection procedure|
219014938|NCT00002667|OTHER|immunoenzyme technique|
219014939|NCT00002667|PROCEDURE|study of high risk factors|
219440793|NCT03710694|DEVICE|DAV132|"DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
219440794|NCT02565576|DRUG|Placebo|
219440795|NCT02565576|DRUG|CFZ533|
219440796|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
219440797|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
219014940|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
219014941|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
219014942|NCT02392741|OTHER|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
219440798|NCT01500265|BIOLOGICAL|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
219440799|NCT05067114|DEVICE|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
219581479|NCT02935686|BIOLOGICAL|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
219581480|NCT06228794|OTHER|Peripheral blood test|We will draw 2-5 mL of peripheral blood and utilize multiparameter flow cytometry to measure the level of circulating plasma cells.
219581481|NCT06330194|DEVICE|2nd Generation Automated Insulin Delivery (AID) system|The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
219581482|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
219581483|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
219440800|NCT00045045|PROCEDURE|positron emission tomography|
219440801|NCT00045045|RADIATION|fludeoxyglucose F 18|
219440802|NCT03345342|DRUG|PP6M|Participants will receive intramuscular injection of PP6M.
219440803|NCT03345342|DRUG|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
219440804|NCT03345342|DRUG|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
219440805|NCT03345342|DRUG|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
219581484|NCT06383052|DRUG|177Lu-NYM032 injection|Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.
219581485|NCT02556372|DRUG|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
219014943|NCT01505868|DRUG|Cabazitaxel|Given IV
219014944|NCT01505868|DRUG|Carboplatin|Given IV
219014945|NCT01505868|OTHER|Laboratory Biomarker Analysis|Correlative studies
219440806|NCT03345342|OTHER|Placebo|Participants will receive matching placebo.
219440807|NCT01268943|DRUG|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
219440808|NCT01268943|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
219440809|NCT01268943|DRUG|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
219440810|NCT01268943|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
219440811|NCT00414505|DEVICE|Intradermal Acupuncture Treatment|
219440812|NCT03185819|DRUG|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
219440813|NCT03185819|DRUG|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
219440814|NCT03185819|DRUG|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
219440815|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
219440816|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
219440817|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
219440818|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
218833464|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
218833465|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
218833466|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
218833467|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
219014946|NCT01929850|PROCEDURE|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
219014947|NCT01929850|BEHAVIORAL|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
219014948|NCT03627754|DRUG|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
219014949|NCT01410045|PROCEDURE|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
219014950|NCT01382979|BEHAVIORAL|AlcoholEdu for College|Online course for college freshmen.
219014951|NCT04892888|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
219440819|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
219014952|NCT03935191|DEVICE|Dexcom CGM System|Dexcom CGM System
219014953|NCT00563511|PROCEDURE|adherence intervention|
219196152|NCT06813560|DIAGNOSTIC_TEST|hair cortisol|To extract cortisol from the hair, the sample is carefully sectioned into segment lengths that will approximate the time period of interest (from the outermost part, if the hair is 3 cm long, the cortisol secreted proportionally by the individual in the last 3 months of life will be extracted). Then, an approximate average weight per sample of 150 mg will be selected. The samples will be individualised and placed in eppendorfs (one for each patient) and sprayed with scissors. After incubation in methanol for 36 hours, the supernatant portion is extracted, which already contains dissolved cortisol. This solution shall be evaporated to dryness, and then the pellet shall be reconstituted with phosphate (PBS). A commercial kit for the quantification of cortisol by immunoassay (ELISA Victor X5) shall be used. The ELISA kit for the detection of cortisol in saliva (ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen).
219440820|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
219440821|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
219440822|NCT03375203|DRUG|Placebo|Matching placebo will be administered once daily based upon dosing group.
219440823|NCT03375203|DRUG|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
219440824|NCT03375203|DRUG|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
219014954|NCT00563511|PROCEDURE|intervention without adherence advice|
219014955|NCT00563511|PROCEDURE|control|
219440825|NCT03375203|DRUG|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
219440826|NCT03375203|DRUG|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
219440827|NCT03321526|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
219440828|NCT03321526|DRUG|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
219440829|NCT03321526|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
219440830|NCT03321526|DRUG|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
219440831|NCT03321526|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
219440832|NCT03321526|DRUG|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
219440833|NCT02907086|OTHER|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
219440834|NCT00220584|DRUG|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
219440835|NCT00064636|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
218833468|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
218833469|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
219581486|NCT02934763|DRUG|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
219764222|NCT06824649|BIOLOGICAL|Biologic Agents|Evidence by way of phase III clinical trials has shown efficacy of dupilumab, omalizumab, and mepolizumab to placebo, leading to regulatory approval and widespread clinical use. However, data from these clinical trials does not show universal improvement and ideal control of disease across all patients with Chronic Sinusitis with Nasal Polyps (CRSwNP). Successful completion of this trial will help answer some of the most pressing clinical questions related to biologics and CRSwNP. Specifically, findings will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.
219764223|NCT06117501|DEVICE|Axoguard HA+ Nerve Protector™|Axoguard HA+ Nerve Protector™ is a surgical implant that provides non-constricting protection for non-transected peripheral nerve injuries where there is no gap. Axoguard HA+ Nerve Protector™ is designed to be an interface between the nerve and the surrounding tissue.
219014956|NCT02867033|PROCEDURE|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
219014957|NCT02867033|OTHER|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
219196153|NCT06813560|DIAGNOSTIC_TEST|salivary cortisol|Three saliva samples will be collected from each subject, at 8:00, 15:00 and 23:00 hours. Before collecting the saliva they will be instructed to rinse their mouth with cold water, without brushing their teeth. They should also not eat or drink in the hour before the sample is taken. Approximately 1 ml of saliva, collected by direct expectoration into an ependymal tube, shall be obtained and the samples shall be stored for 24 hours at 4°C . Subsequently, samples shall be centrifuged at 2 500 rpm/10 min and the supernatant shall be stored at -20 °C until processing by ELISA kit as per the above protocol.
219440836|NCT00479349|DRUG|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
219440837|NCT00732641|DRUG|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
219440838|NCT00467012|DRUG|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
219440839|NCT00467012|DRUG|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
219440840|NCT04883918|BIOLOGICAL|ASC930|4 intravenous doses of ASC930
219440841|NCT03246711|BEHAVIORAL|Fasting|Totally or partially fasting the holy month of ramadan for muslims
219440842|NCT02777164|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
219581487|NCT02934763|DRUG|Saline|Saline as placebo
219764224|NCT03014414|BEHAVIORAL|Fun First|Learn key enjoyable maintenance skills before losing weight
219764225|NCT03014414|BEHAVIORAL|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
219764226|NCT05887089|OTHER|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
219764227|NCT05589155|OTHER|Mobile health application|Intervention will be with mobile health application
218833470|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
218833471|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
218833472|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
219014958|NCT02867033|PROCEDURE|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
219014959|NCT02867033|PROCEDURE|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
219014960|NCT02867033|OTHER|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
219014961|NCT02867033|PROCEDURE|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
219440843|NCT04449718|DIETARY_SUPPLEMENT|Vitamin D|200,000 IU on admission
219440844|NCT04449718|DIETARY_SUPPLEMENT|Placebo|200,000 IU on admission
219440845|NCT01386190|OTHER|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
219440846|NCT03718468|BIOLOGICAL|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
219440847|NCT03718468|BIOLOGICAL|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
219440848|NCT02174809|BEHAVIORAL|Use of 5As to discuss gestational weight gain|
219440849|NCT02174809|BEHAVIORAL|Usual care|
219440850|NCT01880203|PROCEDURE|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
219440851|NCT04427410|DIAGNOSTIC_TEST|Salivary test|Salivary test for measured of oxytocin levels
219440852|NCT01129414|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
219440853|NCT01129414|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
219440854|NCT01129414|DRUG|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
219581488|NCT02884349|PROCEDURE|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
219581489|NCT03592342|DRUG|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
219764228|NCT04880707|DRUG|Twin block local anesthetic nerve block using standard dental anesthetic|2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use. This drug will be administered as the Twin block local anesthetic nerve block targeting the branches of the mandibular nerve supplying the temporalis and masseter muscles.
218833473|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
219014962|NCT04203953|OTHER|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
219014963|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
219581490|NCT06433635|DRUG|Cariprazine|"1. Cariprazine monotherapy outperformed placebo in improving depressive symptoms in most large randomized control trials (RCT). Pooled data showed higher remission rates (30.2%) with cariprazine (1.5 mg and 3 mg/day) compared to placebo (20.9%). Its efficacy extends to bipolar I depression, including mixed features and anxiety.~2. Common adverse effects include nausea (8%) and akathisia (7%). Somnolence and sedation were slightly more common with cariprazine than placebo.~3. Results from a large RCT evaluating cariprazine for bipolar disorder maintenance treatment (NCT03573297) are awaited. An open-label trial reported reduced manic symptoms over 16 weeks.~4. Cariprazine is a D3-preferring partial agonist for D3 and D2 receptors. It antagonizes 5-HT2A and 5-HT2B receptors and partially agonizes 5-HT1A receptors. Affinity for 5-HT1C and histamine 1 receptors is low to moderate."
219581491|NCT06433635|DRUG|Aripiprazole/Escitalopram combination|"1. 40-70% of bipolar patients use antidepressants, often with antipsychotics or mood stabilizers. Aripiprazole lacks efficacy in bipolar depression but is used for mania. Escitalopram, studied alongside mood stabilizers, showed some efficacy.~2. Aripiprazole in bipolar depression trials led to higher rates of akathisia, insomnia, nausea, fatigue, and impulse control disorders. Escitalopram's is generally safe but adverse effects include nausea, diarrhea, insomnia, dry mouth, ejaculatory dysfunction and dizziness.~3. Aripiprazole monotherapy in bipolar I patients reduced relapse rates and delayed relapse time, but not for depressive episodes.~4. Aripiprazole acts as a partial agonist at D2, D3, 5-HT1A, and 5-HT2C receptors, with antagonistic effects on α1 and possibly H1 receptors. Escitalopram is highly selective for the serotonin transporter, with no significant activity at other receptors."
219764229|NCT04880707|OTHER|Twin block with placebo|Instead of the standard dental anesthetic, sterile normal saline will be delivered using the Twin block injection
219581492|NCT06433635|DRUG|Quetiapine|"1. Both immediate and extended-release quetiapine monotherapies showed superiority over placebo in acute BD depression across three 8-week randomized trials, confirmed by meta-analysis. Quetiapine exhibited significantly higher remission rates (52.8%) compared to placebo (34.7%) and improved various aspects of life, including quality of life, clinical global impression, sleep, functioning, and anxiety.~2. Common adverse events of quetiapine include sedation, hypotension, increased appetite, weight gain, dyslipidemia, and elevated glucose levels, particularly in a population already at risk.~3. Four studies examined quetiapine's maintenance effects in patients with manic, mixed, or depressive episodes. Overall, quetiapine prolonged the time to recurrence for both depressive and manic episodes."
219764230|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
219764231|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
219764232|NCT06260033|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764233|NCT06260033|PROCEDURE|Bone Scan|Undergo bone scan
219764234|NCT06260033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219764235|NCT06260033|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
219764236|NCT06260033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219764237|NCT06260033|OTHER|Questionnaire Administration|Ancillary studies
219764238|NCT06260033|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219764239|NCT03383419|DRUG|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
218833474|NCT05340868|DRUG|Semaglutide Pill|Oral semaglutide treatment
219764240|NCT06979700|DIAGNOSTIC_TEST|Automated Pupillometry|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment for both pupils and include: Neurological pupil index, pupillary size, pupillary minimum diameter, pupillary constriction amplitude, pupillary constriction velocity, pupillary maximum constriction velocity, pupillary latency and pupillary dilation velocity.
218833475|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
218833476|NCT00084708|DRUG|dexamethasone|
218833477|NCT00084708|DRUG|gefitinib|
218833478|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
218833479|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
219014964|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219014965|NCT00680043|DRUG|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219014966|NCT04108520|OTHER|Exercise|Exercise with respiratory training
219581493|NCT06433635|DRUG|Lurasidone|"1. Lurasidone, either alone or with lithium/valproate, proved more effective than placebo for acute BD depression in two 6-week randomized trials. Remission rates were significantly higher with lurasidone monotherapy (40.9%) and in combination (50.3%) compared to placebo (24.7% and 35.4% respectively). Lurasidone also improved anxiety, quality of life, and disability.~2. Common mild adverse events included nausea, headache, akathisia, somnolence, sedation, dry mouth, and vomiting. Weight gain, dyslipidemia, and increased glucose levels were not observed.~3. In a 6-month double-blind discontinuation study post-acute treatment response, lurasidone combined with lithium/valproate prolonged time to depressive episode recurrence compared to placebo (hazard ratio: 0.68). Although not statistically significant due to low placebo recurrence and shorter follow-up, it hints at maintenance efficacy."
219014967|NCT00023543|BEHAVIORAL|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
219014968|NCT00023543|BEHAVIORAL|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
219440855|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
219581494|NCT01917864|BEHAVIORAL|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
219581495|NCT06489457|DRUG|Semaglutide|Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
219581496|NCT06489457|DRUG|Testosterone Undecanoate|Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
219440856|NCT04946760|OTHER|Sham Manipulation|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
219440857|NCT05737485|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
219440858|NCT06297798|OTHER|Telerehabilitation|"The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
219581497|NCT01264731|BIOLOGICAL|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
219581498|NCT01264731|DRUG|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
219581499|NCT04957836|OTHER|reversal with sugammadex|reversal with sugammadex for immediate extubation in the operating room
218833480|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
219014969|NCT06136923|DEVICE|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
219014970|NCT06136923|DEVICE|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
219014971|NCT05107687|BEHAVIORAL|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
218833481|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
218833482|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
218833483|NCT00802997|DEVICE|Placebo sham|sham procedure
218833484|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
218833485|NCT02315807|DEVICE|transcranial direct current stimulation|
219014972|NCT02344160|OTHER|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
219581500|NCT02579161|DRUG|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
219764241|NCT06979700|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both middle cerebral arteries and include the following: Peak systolic velocity, end diastolic velocity, mean velocity, pulsatility index and resistance index.
218833486|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
219014973|NCT05114785|DIAGNOSTIC_TEST|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
219196154|NCT06813560|DIAGNOSTIC_TEST|salivary Oxytocin|The treatment and collection of saliva as a biological sample shall be identical to the protocol described for the determination of cortisol. The determination of oxytocin shall be carried out by the use of ELISA kit for immunoassay (Oxytocin ELISA Kit (ab133050 ABCAM)
219440859|NCT04084080|BIOLOGICAL|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.
219440860|NCT04084080|OTHER|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
219440861|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
219440862|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
219440863|NCT01148576|DRUG|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
219440864|NCT01148576|DRUG|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
219440865|NCT00821782|DRUG|Levofloxacin; Azithromycin|
219440866|NCT04066010|OTHER|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
219440867|NCT02939976|DEVICE|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
219440868|NCT02939976|PROCEDURE|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
219440869|NCT02939976|PROCEDURE|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
219440870|NCT02939976|DEVICE|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
219440871|NCT02939976|DEVICE|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
219440872|NCT02939976|DEVICE|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
219440873|NCT02939976|DEVICE|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
219440874|NCT02613091|DRUG|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
219440875|NCT01872897|DRUG|Sodium Alginate Double Action Chewable Tablets|4 tablets as a single dose
219581501|NCT02579161|DRUG|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
219764242|NCT06979700|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both eyes using ultrasound and include the following: optic nerve sheath diameter of right and left side and mean optic nerve sheath diameter.
218833487|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
218833488|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
218833489|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
218833490|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
218833491|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
218833492|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
218833493|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
218833494|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
218833495|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
218833496|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
218833497|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
218833498|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
218833499|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
218833500|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
218833501|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
218833502|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
219196155|NCT06813560|DIAGNOSTIC_TEST|Bayley-III Child Development Assessment Scales|They are a set of three standardised assessment scales, which assess the cognitive, motor and language development of children aged 1 and 42 months. For our study, we will use only the motor scale, which is composed of two subscales, the gross motor scale and the fine motor scale. This motor scale is composed of 138 items (the gross motor scale is composed of 72 items and the fine motor scale of 66 items) which assess the degree of control of the body, the coordination of large muscle masses and the manipulative ability of hands and fingers. The total administration time of the motor area for 12-month-old children, as in the case of the sample, is between 15 and 20 minutes.
219196156|NCT06813560|DIAGNOSTIC_TEST|Strange Situation|The Strange Situation is a standardised observational procedure in which the child is exposed to two moments of separation from his/her attachment figure, two moments of reunion with the attachment figure and moments in which he/she interacts with an unknown person, specifically 8 episodes (lasting 3 minutes) in which the level of stress provoked in the child increases in intensity as the situation progresses. It is estimated to last around 20 minutes. It is assessed on a 7-point Likert-type scale, so that low scores indicate low frequency and intensity of the behaviour. These responses allow us to identify three types of attachment: secure attachment, insecure-avoidant attachment and insecure-ambivalent attachment. The strange situation only allows us to assess attachment in children between 1 and 2 years of age.
219764243|NCT06979700|DIAGNOSTIC_TEST|Continuous EEG and EEG Reactivity|"Continuous 4-channel EEG will be established on participants as soon as possible within 0-6 hours. EEG will be stopped at successful extubation or when 72 hours has passed since study inclusion.~EEG Reactivity will be performed on comatose participants at the following times: 0-6, 20-28, 44-52 and 66-72 hours after study inclusion. Reactivity includes 7 standardized stimuli, including 1 visual, 3 auditive and 3 pain stimuli.~EEG data will be reviewed in Stratus EEG Analysis (Kvikna Mediacal ehf. version 5.1). Timestamps for EEG-reactivity will be manually inserted in the file. EEG Reactivity will be analysed quantitatively by power spectrum analyses performed in LabVIEW 2016 (National Instruments) according to the principles of a previous method (PMID: 36041343). Background activity within 5 minutes following reactivity stimuli, prioritizing time periods without artifacts, will be analysed by power spectrum analyses, Mindray quantitative analysis and manually analyzed by experts."
219764244|NCT06608927|DRUG|Quemliclustat|Administered as specified in the treatment arm
219764245|NCT06608927|DRUG|Placebo|Administered as specified in the treatment arm
218833503|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
219764246|NCT06608927|DRUG|Nab-paclitaxel|Administered as specified in the treatment arm
218833504|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
218833505|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
218833506|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
218833507|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
218833508|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
218833509|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
218833510|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
218833511|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
218833512|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
218833513|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
218833514|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
219581502|NCT02579161|DRUG|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
218833515|NCT00282633|DEVICE|Dermabond|
218833516|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
218833517|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
218833518|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
219014974|NCT05756374|BEHAVIORAL|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
219196157|NCT06813560|DIAGNOSTIC_TEST|Parenting Stress Index (PSI)|It assesses the stress experienced in parenting through several subscales such as parental distress, dysfunctional parent-child interaction and whether the child is a difficult child based on how parents perceive their children's behaviour.
219440876|NCT01872897|DRUG|Placebo|4 tablets as a single dose
219440877|NCT06296472|OTHER|Rehabilitation|-the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.
219440878|NCT06296472|OTHER|Standard|-the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
219440879|NCT04254796|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
219764247|NCT06608927|DRUG|Gemcitabine|Administered as specified in the treatment arm
219764248|NCT06981923|DEVICE|CMAC D-Blade|Intubation will be performed using the CMAC D-Blade
219581503|NCT02579161|DRUG|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
219581504|NCT00134043|DRUG|vorinostat|Given orally
219581505|NCT04882423|OTHER|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
219764249|NCT06981923|DEVICE|CMAC Video Stylet|Intubation will be performed using the CMAC Video stylet
219764250|NCT00001465|DEVICE|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
218833519|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
218833520|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
218833521|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
218833522|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
218833523|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
218833524|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
218833525|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
218833526|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
218833527|NCT02234713|BEHAVIORAL|Motivational Interview|
218833528|NCT02234713|OTHER|Video Attention Control|
218833529|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
218833530|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
218833531|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
218833532|NCT00479505|DRUG|Placebo|Placebo
218833533|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
218833534|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
218833535|NCT03601442|BIOLOGICAL|CTL019|CTL019
218833536|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
218833537|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
218833538|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
218833539|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
218833540|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
218833541|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
219440880|NCT05303025|OTHER|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
219440881|NCT05303025|OTHER|Semi-structured group discussion|Semi-structured group discussion.
219440882|NCT03953040|DIAGNOSTIC_TEST|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
219440883|NCT01830322|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
218833542|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
218833543|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
218833544|NCT02565693|DRUG|Apixaban|
218833545|NCT02565693|DRUG|Aspirin|
218833546|NCT02565693|DRUG|Carbasalate calcium|
218833547|NCT02565693|DRUG|Clopidogrel|
218833548|NCT02565693|DRUG|Dipyridamole|
218833549|NCT02565693|OTHER|No antithrombotic treatment|
218833550|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
218833551|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
219014975|NCT02192814|DRUG|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
218833552|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
218833553|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
218833554|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
218833555|NCT00069875|DRUG|Gemcitabine|
218833556|NCT00069875|DRUG|LY293111|
218833557|NCT00069875|DRUG|cisplatin|
218833558|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
218833559|NCT06010784|BEHAVIORAL|Family support|"* Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~* Weeks 1-4 (4 weeks):~  i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~* Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~  i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
219014976|NCT01082406|DRUG|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
219440884|NCT01830322|DRUG|Gemcitabine|
219440885|NCT01830322|DRUG|Any non-gemcitabine chemotherapies or best supportive care|
219440886|NCT05845411|BEHAVIORAL|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
219440887|NCT05845411|OTHER|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
219440888|NCT02418585|DRUG|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
219440889|NCT02418585|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
219440890|NCT02418585|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
219440891|NCT02418585|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
219440892|NCT02418585|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
219440893|NCT02418585|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
219440894|NCT02040857|DRUG|Palbociclib|CDK 4/6 inhibitor
219440895|NCT02040857|DRUG|Aromatase Inhibitor|Endocrine Therapy
219440896|NCT00671398|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
218833560|NCT06010784|BEHAVIORAL|BGCAA's after-school program with CATCH curriculum|"1. The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~2. In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~3. Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
219440897|NCT00671398|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
219440898|NCT00671398|DRUG|Placebo|Ramelteon placebo-matching tablets, orally for one night only
219440899|NCT02957474|DRUG|GED-0301|
219440900|NCT02957474|DRUG|Omeprazole|
219440901|NCT04159701|DRUG|LY3454738|Administered IV
219440902|NCT04159701|DRUG|Placebo|Administered IV
219440903|NCT05342142|BEHAVIORAL|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
219440904|NCT02682576|PROCEDURE|Brachial artery ultrasound imaging|
219440905|NCT00517725|DRUG|carvedilol|
219440906|NCT00517725|DRUG|bisoprolol|
219440907|NCT00517725|DRUG|Nebivolol|
219440908|NCT03180021|PROCEDURE|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
219440909|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
219440910|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
219440911|NCT03316742|COMBINATION_PRODUCT|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
219440912|NCT03316742|COMBINATION_PRODUCT|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
219440913|NCT06261411|DIAGNOSTIC_TEST|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
219440914|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
218833561|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
218833562|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
218833563|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
218833564|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
218833565|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
218833566|NCT03941873|DRUG|Tislelizumab|Administered intravenously
218833567|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
218833568|NCT05832606|OTHER|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
218833569|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
218833570|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
219014977|NCT01082406|DRUG|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
219440915|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
219475521|NCT01162993|PROCEDURE|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
219475522|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
218833571|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
219475523|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
218833572|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
218833573|NCT05168371|BEHAVIORAL|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
218833574|NCT05168371|BEHAVIORAL|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
219475524|NCT05312658|PROCEDURE|External aortic compression|External aortic compression by assistant in cesarean section.
219475525|NCT02388906|DRUG|Ipilimumab|Specified dose on specified days
218833575|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
218833576|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
219475526|NCT02388906|DRUG|Nivolumab|Specified dose on specified days
219475527|NCT02388906|OTHER|Placebo matching Ipilimumab|Specified dose on specified days
219475528|NCT02388906|OTHER|Placebo matching Nivolumab|Specified dose on specified days
219475529|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
219475530|NCT04008121|COMBINATION_PRODUCT|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
219475531|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
219475532|NCT04008121|COMBINATION_PRODUCT|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
219475533|NCT05363878|BEHAVIORAL|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
219475534|NCT02510417|BIOLOGICAL|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
219475535|NCT06636526|GENETIC|The i4i PRODICT™ test.|The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
219475536|NCT06636526|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all participants identified as high risk from the i4i PRODICT™ test for three years in order to track development of cancer in the future.
219475537|NCT06636526|PROCEDURE|MRI Scan|MRI scan will be offered to participants identified in the high-risk category of the i4i PRODICT™ test depending on their PSA test results. Where PSA is above age-specific threshold (\&gt;2.5ug/L for people with prostates (PwPs) aged 40-50 years and \&gt;3.5ug/L for PwPs aged 50-55 years), those with raised PSA levels will be referred for multiparametric MRI at The Royal Marsden Hospital.
219475538|NCT06636526|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to to participants identified in the high-risk category of the i4i PRODICT™ test depending on their MRI results. Where a lesion is visible on MRI (defined as a PIRAD score ≥3) onward referral will be made for a transperineal targeted prostate biopsy (or current gold standard NHS practice).
219475539|NCT06636136|DEVICE|OPRA|Surgery
219764251|NCT06604715|DRUG|JNJ-87562761|JNJ-87562761 will be administered.
219764252|NCT06479434|DRUG|Metformin|Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)
219764253|NCT01209572|DEVICE|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
219764254|NCT01209572|DEVICE|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
219764255|NCT06360094|DRUG|BI 1839100|BI 1839100
219764256|NCT06360094|DRUG|Placebo|Placebo
219764257|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 1|Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
219764258|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 1.1 Usage|Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
219764259|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 2|Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
219014978|NCT06459908|OTHER|Robot Glove Hand Training|Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.
219014979|NCT06459908|OTHER|Conventional Hand Rehabilitation Exercises|Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
219014980|NCT00005972|DRUG|gemcitabine hydrochloride|
219014981|NCT00005972|DRUG|irinotecan hydrochloride|
219014982|NCT02890446|BEHAVIORAL|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
219014983|NCT04646798|OTHER|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
219014984|NCT04646798|OTHER|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
219014985|NCT02138760|PROCEDURE|MRI UroNav fusion biopsy|
219196158|NCT06813560|DIAGNOSTIC_TEST|Perinatal Risk Inventory|"\- The Perinatal Risk Inventory is a measuring instrument that provides information on the neonatal situation prior to discharge and facilitates an estimate of the biological risk that the child may present from a very early age. The factors that are analysed in this inventory are evaluated with a score from 0 to 3 for each of the factors mentioned above, ranging from a minimum of 0 points to a maximum of 51. The levels of risk were determined as follows:~1. Low Neonatal Risk: 0 to 6 points.~2. Moderate Neonatal Risk: 7 to 9 points.~3. High Neonatal Risk: 10 or more points."
219475540|NCT04365387|DRUG|Nemolizumab|Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
219475541|NCT04365387|DRUG|Placebo|Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
219475542|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
219475543|NCT05770401|BEHAVIORAL|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
219475544|NCT05770401|BEHAVIORAL|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
219475545|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
219475546|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
219475547|NCT05440942|DRUG|Trametinib|Trametinib will be administered orally once daily via tablet.
219475548|NCT05440942|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily (BID) via tablet.
219475549|NCT05440942|DRUG|Retifanlimab|Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
219475550|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
219475551|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
219475552|NCT06798389|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post-appointment follow-up call.
219475553|NCT04884256|DRUG|CBT-004|Dose response study
219475554|NCT03804853|OTHER|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
219475555|NCT00402298|DRUG|Full Dose Midomafetamine HCl|Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2.5 hours later by 62.5 mg midomafetamine HCl orally during the course of a day-long therapy session.
219014986|NCT04915833|DIAGNOSTIC_TEST|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
218833577|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
219363901|NCT04812626|DRUG|5-Fluorouracil|Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
219440916|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
219440917|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
218833578|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
218833579|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
218833580|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
218833581|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
218833582|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
218833583|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
218833584|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
218833585|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
218833586|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
218833587|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
218833588|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
218833589|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
218833590|NCT02866162|GENETIC|High-throughput exome sequencing|
218833591|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
218833592|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
218833593|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
218833594|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
218833595|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
218833596|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
218833597|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
218833598|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
218833599|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
218833600|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
218833601|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
218833602|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
218833603|NCT00371202|PROCEDURE|keratoplasty|
218833604|NCT01435473|PROCEDURE|Cardiac Surgery|
218833605|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
218833606|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
218833607|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
218833608|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
218833609|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
218833610|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
218833611|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
218833612|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
218833613|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
218833614|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
218833615|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
218833616|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
218833617|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
218833618|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
218833619|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
218833620|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
218833621|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
219363902|NCT05844215|DIAGNOSTIC_TEST|MMP-9 and TIMP-1|Examine level of serum MMP-9 and TIMP-1
219363903|NCT02445586|DRUG|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
219363904|NCT02445586|DRUG|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
219440918|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
219440919|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
219440920|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
219475556|NCT00402298|DRUG|Low Dose Midomafetamine HCl|Participants will receive an initial dose of 25 mg midomafetamine HCl orally followed 2.5 hours later by a supplemental dose of 12.5 mg midomafetamine HCl orally during the course of each of two day-long therapy sessions.
219581506|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
219440921|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
219440922|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
218833622|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
219440923|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
218833623|NCT02183493|DRUG|BI 1356|
218833624|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
218833625|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
218833626|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
218833627|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
218833628|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
219440924|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
219440925|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
219440926|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
219440927|NCT02918422|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
219581507|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
218833629|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
219581508|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
219581509|NCT00541970|BIOLOGICAL|Cervarix|Intramuscular injection, different dosing /schedule
219581510|NCT00541970|DRUG|Placebo|Intramuscular injection, different dosing /schedule
219581511|NCT00321828|BIOLOGICAL|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
218833630|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
218833631|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
218833632|NCT00042952|DRUG|imatinib mesylate|Given orally
218833633|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
218833634|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
218833635|NCT02222688|DRUG|cirmtuzumab|
218833636|NCT00001033|DRUG|Ethambutol hydrochloride|
218833637|NCT00001033|DRUG|Isoniazid|
218833638|NCT00001033|DRUG|Pyrazinamide|
218833639|NCT00001033|DRUG|Pyridoxine hydrochloride|
218833640|NCT00001033|DRUG|Levofloxacin|
218833641|NCT00001033|DRUG|Rifampin|
218833642|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
218833643|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
218833644|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
218833645|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
218833646|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
219764260|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 2.1 Usage|Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
219764261|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control 4.1.0|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
219764262|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 4.1.1 Usage|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
218833647|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
218833648|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
218833649|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
218833650|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
218833651|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
218833652|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
218833653|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
218833654|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
218833655|NCT04248712|DRUG|Placebo|Contains no active ingredient
218833656|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
218833657|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
218833658|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
218833659|NCT02580032|OTHER|No treatment given|No treatment given.
218833660|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
218833661|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
218833662|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
218833663|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
219014987|NCT04915833|DIAGNOSTIC_TEST|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
219014988|NCT01792674|OTHER|In situ simulation|
219014989|NCT01792674|OTHER|Off site simulation|
219014990|NCT00195676|DRUG|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
219014991|NCT06395974|OTHER|fetal ultrasound|2D, 3D , Doppler ultrasound
219014992|NCT01189812|DRUG|Lithium Carbonate|300 mg one time per day for 4 weeks
219014993|NCT01189812|DRUG|Placebo|Take one time daily for 4 weeks
219014994|NCT01189812|DRUG|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
219014995|NCT01031940|DEVICE|macintosh laryngoscope|intubate with the macintosh laryngoscope
219014996|NCT01031940|DEVICE|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
219014997|NCT01031940|DEVICE|Airtraq device|intubate with the Airtraq device
219014998|NCT01806753|PROCEDURE|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
219014999|NCT01806753|PROCEDURE|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
219015000|NCT02891460|DEVICE|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
219015001|NCT02891460|DEVICE|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
219015002|NCT02022098|DRUG|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
219015003|NCT02022098|RADIATION|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
219015004|NCT02022098|DRUG|Debio 1143|Debio 1143 solution
219764263|NCT05926596|DEVICE|Wearable Robotic Exoskeleton|"* Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)"
219764264|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: IV Infusion
218833664|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
218833665|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
218833666|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
218833667|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
218833668|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
218833669|NCT00439595|DEVICE|Copack HBCS|
218833670|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
218833671|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
218833672|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
218833673|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
218833674|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
218833675|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
219015005|NCT02022098|DRUG|Placebo|Matching placebo solution
219015006|NCT03447756|DRUG|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
219015007|NCT03447756|DRUG|Placebo oral capsule|placebo to match
219015008|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
219015009|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
219015010|NCT00616655|DRUG|Placebo|Placebo total daily dose 0.9 mg
219015011|NCT03552146|DRUG|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
219015012|NCT03552146|DRUG|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
219015013|NCT02181439|DEVICE|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
219440928|NCT00175838|DRUG|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
219440929|NCT00175838|DRUG|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
219440930|NCT01944254|PROCEDURE|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
219440931|NCT01944254|PROCEDURE|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
219440932|NCT01944254|PROCEDURE|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
219440933|NCT05166551|PROCEDURE|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
219440934|NCT05166551|PROCEDURE|Placebo Acupressure|Placebo Acupressure
219440935|NCT03210064|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
219764265|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV Infusion
219015014|NCT00003150|BIOLOGICAL|rituximab|
219015015|NCT00003150|DRUG|CHOP regimen|
219015016|NCT00003150|DRUG|cyclophosphamide|
219015017|NCT00003150|DRUG|doxorubicin hydrochloride|
219015018|NCT00003150|DRUG|prednisone|
219015019|NCT00003150|DRUG|vincristine sulfate|
219440936|NCT03210064|DRUG|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
219440937|NCT04192318|BEHAVIORAL|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
219581512|NCT00321828|DRUG|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
219581513|NCT00321828|DRUG|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
218833676|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
218833677|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
219581514|NCT00321828|DRUG|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
219581515|NCT01461226|BEHAVIORAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
218833678|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
218833679|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
218833680|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
218833681|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
218833682|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
218833683|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
219015020|NCT00867425|BEHAVIORAL|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
219015021|NCT01863225|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
219015022|NCT01863225|DRUG|Rosuvastatin|20 mg daily, 28-42 days
219015023|NCT01863225|DRUG|Atorvastatin|40 mg daily, 28-42 days
219440938|NCT04192318|OTHER|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
219440939|NCT04192318|OTHER|Treatment as usual|Treat and release
219440940|NCT00476398|PROCEDURE|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
219440941|NCT02366247|DRUG|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
219440942|NCT02366247|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
219440943|NCT02366247|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
219440944|NCT04146038|DRUG|Azacitidine|Given IV
219440945|NCT04146038|DRUG|Decitabine|Given IV
219440946|NCT04146038|DRUG|Salsalate|Given PO
219440947|NCT04146038|DRUG|Venetoclax|Given PO
219440948|NCT04605185|DRUG|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
219440949|NCT04605185|BIOLOGICAL|Toripalimab Injection|240 mg, iv drip,q3w
219581516|NCT01461226|BEHAVIORAL|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
219581517|NCT00218166|DRUG|GABA Agonists|GABA drugs administered acutely by mouth
219581518|NCT04006314|OTHER|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
219581519|NCT04265339|OTHER|Smoking cessation|Participants are required to quit smoking
219581520|NCT04141358|DIAGNOSTIC_TEST|Advanced ultrasound measurements|"Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks"
219764266|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: SC Injection
219440950|NCT00881140|DRUG|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
219440951|NCT04587895|BEHAVIORAL|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
219440952|NCT04587895|BEHAVIORAL|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
219440953|NCT04587895|BEHAVIORAL|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
219581521|NCT04336514|DEVICE|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
219581522|NCT01816919|OTHER|collecting breath samples|
219015024|NCT01863225|DRUG|Rosuvastatin|40 mg daily, 28-42 days
219015025|NCT01863225|DRUG|Atorvastatin|80 mg daily, 28-42 days
219015026|NCT03761147|OTHER|Paula exercises|structured exercises aimed to stimulate ring muscles
219015027|NCT06387745|DEVICE|Hepatoscope|The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body. In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
219015028|NCT03038633|OTHER|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
219015029|NCT01679977|DEVICE|Vibrational-proprioceptive Resistance Exercise Training|
219015030|NCT01679977|DEVICE|Neuromuscular Electrical Stimulation Training|
219015031|NCT05184920|OTHER|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
219015032|NCT05184920|OTHER|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
219015033|NCT05184920|OTHER|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
219015034|NCT05184920|OTHER|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
219015035|NCT05184920|OTHER|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
219015036|NCT05184920|OTHER|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
219015037|NCT05184920|OTHER|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
219015038|NCT05184920|OTHER|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
219015039|NCT05184920|OTHER|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
219015040|NCT05184920|OTHER|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
219015041|NCT05184920|OTHER|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
219015042|NCT05184920|OTHER|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
219015043|NCT05598775|OTHER|Non Interventional long term safety follow up|Non Interventional long term safety follow up
219015044|NCT06242314|PROCEDURE|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
219015045|NCT06242314|PROCEDURE|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
219015046|NCT06242314|PROCEDURE|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
219015047|NCT06502626|OTHER|Regular training|performed their routine programs
219015048|NCT06502626|OTHER|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
219015049|NCT00099385|BEHAVIORAL|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg \& Kusche) curriculum.
219015050|NCT03670550|DEVICE|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
219015051|NCT01460420|DRUG|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
219015052|NCT01460420|DRUG|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
219015053|NCT05482763|DRUG|Terbinafine Topical Gel|Topical application of terbinafine
219015054|NCT05482763|DRUG|Itraconazole 200 mg|systemic itraconazole pulse therapy
219015055|NCT05482763|DRUG|Terbinafine 250 mg|systemic terbinafine
219581523|NCT00062010|BIOLOGICAL|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
219581524|NCT00062010|DRUG|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
219581525|NCT00062010|DRUG|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
219581526|NCT02715934|OTHER|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
219015056|NCT05482763|DRUG|Ciclopirox Topical Gel|Topical application of ciclopirox
219015057|NCT05482763|DRUG|Amorolfine 50 MG/ML|Topical application of amorolfine
219015058|NCT03437525|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
219015059|NCT02689401|DRUG|Ferumoxytol|
219015060|NCT02689401|DEVICE|MRI 3T scanner|
219015061|NCT02059057|DEVICE|LVRC System|
219015062|NCT05931939|PROCEDURE|Ileal Interposition|Bariatric surgery by laparoscopic Ileal Interposition
219015063|NCT05931939|PROCEDURE|Traditional surgical technique|Bariatric surgery by laparoscopic traditional technique
219581527|NCT02715934|OTHER|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
219015064|NCT05278247|DIAGNOSTIC_TEST|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
219015065|NCT02675413|DRUG|Dimethyl Fumarate|Open-label
219581528|NCT02856880|OTHER|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
219581529|NCT02856880|OTHER|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
219581530|NCT02856880|OTHER|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
219015066|NCT03443284|BEHAVIORAL|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
219015067|NCT03443284|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
219015068|NCT05153512|PROCEDURE|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
219015069|NCT04212260|BEHAVIORAL|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
219015070|NCT04212260|BEHAVIORAL|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
219015071|NCT03984604|DRUG|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
219764267|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC Injection
219015072|NCT03984604|DRUG|Placebo|Placebo is a vehicle oil will match CHI-921
219015073|NCT00902369|DRUG|AK106-001616|Part1: Dose escalation Part2: Dose expansion
219015074|NCT00902369|DRUG|Placebo|
219015075|NCT00902369|DRUG|Active comparator|
219015076|NCT00309842|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
219015077|NCT00309842|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
219015078|NCT00309842|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
219015079|NCT00309842|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
219015080|NCT00309842|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
219015081|NCT00309842|PROCEDURE|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
219015082|NCT00309842|RADIATION|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
219015083|NCT01297140|BEHAVIORAL|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
219196159|NCT06813560|DIAGNOSTIC_TEST|Neonatal Behavioural Assessment (NBAS)|is an assessment technique that provides a profile of scores that allows us to detect a possible alteration or pathology, but at the same time, within normal parameters, to detect both the potential or 'strong points' and the problems or 'weak points' of the newborn, as well as their peculiar ways of acting and reacting to environmental variables. Therefore, a profile of the child's behavioural characteristics is obtained, which can be considered as a first outline of the child's temperamental traits. It evaluates the behavioural repertoire of the newborn in 28 behavioural items that are assessed according to a 9-point scale. The scale also includes an assessment of neurological status in 18 reflex items, each with a 4-point rating. In the second edition of the NBAS a series of 7 supplementary items were added with the intention of better capturing the degree of fragility and the quality of behaviour of high-risk children.
219196160|NCT06813560|DIAGNOSTIC_TEST|Galvanic Response|Galvanic Response: has the function of measuring the galvanic response of the skin, also known as electrodermal activity (EDA). It is used to record the electrical behaviour of the skin, which varies according to the activity of the sweat glands. This measurement of electrodermal activity is essential for studying the activity of the autonomic nervous system, which controls involuntary body functions such as sweating and heart rate. It will be measured with the BIOPAC MP36R device.
219196161|NCT06813560|DIAGNOSTIC_TEST|electrocardiography (ECG)|"ECG is used as a monitoring target for various cardiovascular conditions. It will be measured with the BIOPAC MP36R device.~P, Q, R, S, T, U waves; QRS complex, PR interval and QT interval and PR segment and ST segment."
219196162|NCT06813560|DIAGNOSTIC_TEST|Breathing respiratory rate|The transducer is attached to a strap that is placed around the subject's chest, allowing chest movements to be detected during breathing. The strap ensures a secure and comfortable fit for the subject during the measurement process. This transducer is used in conjunction with other BIOPAC components to assess physiological responses. The data obtained from the transducer provides information on respiratory patterns and their relationship to other physiological measures. It will be measured with the BIOPAC MP36R device.
219440954|NCT03996889|DEVICE|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink"
219440955|NCT01782885|PROCEDURE|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
219440956|NCT01782885|DRUG|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
219440957|NCT02839044|DIETARY_SUPPLEMENT|Menaquinone-7|
219440958|NCT02839044|DIETARY_SUPPLEMENT|Placebo|
219440959|NCT02680561|DRUG|Fluticasone Propionate MDPI|
219440960|NCT02680561|DRUG|Fluticasone Propionate/Salmeterol MDPI|
219581531|NCT02856880|OTHER|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
219581532|NCT02856880|OTHER|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
219581533|NCT05741515|OTHER|Vestibular Balance Therapy|see intervention arm description
219581534|NCT05741515|OTHER|Sham Intervention|see sham intervention arm description
219581535|NCT01452711|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
219581536|NCT01452711|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
219581537|NCT01452711|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
219581538|NCT01452711|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
219581539|NCT05354830|OTHER|Foot Massage|Foot Massage
219581540|NCT01289444|BEHAVIORAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
219764268|NCT01808911|DRUG|Steroid + cyclophosphamide|
219764269|NCT01808911|DRUG|Steroid + rituximab|
219015084|NCT00502177|BEHAVIORAL|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
219015085|NCT03249233|DEVICE|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
219764270|NCT06610474|BEHAVIORAL|"Use of the online Talk to Nathan about Prostate Cancer decision aid"|This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html
219764271|NCT06610474|BEHAVIORAL|Use of a standard prostate cancer screening decision aid|The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html
219015086|NCT03249233|DEVICE|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
219015087|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
219015088|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
219440961|NCT02680561|DRUG|Fluticasone propionate/salmeterol|
218833684|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
218833685|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
218833686|NCT00230776|DRUG|pregabalin|
218833687|NCT00230776|DRUG|placebo|
219015089|NCT02045797|DRUG|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
219440962|NCT05451602|DRUG|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
219440963|NCT03030391|OTHER|PET|
219440964|NCT03030391|OTHER|MRI|
219440965|NCT06009198|DRUG|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
219440966|NCT01964287|DRUG|GEMBRAX|
219440967|NCT01964287|DRUG|FOLFIRINOX|
219440968|NCT05118750|DRUG|ALTO-300 oral (PO) tablet|One tablet daily
219440969|NCT06617949|DRUG|Regional Anesthesia|Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.
219440970|NCT06617949|DRUG|Hydromorphone Patient Controlled Analgelsic|This group will be administered epidural PCA as a modality for pain control post cesarian section
219440971|NCT06617949|PROCEDURE|Epidural local anesthetic infusion|Epidural group will receive pain control via a local anesthetic intermediate bolus infusion
219440972|NCT02200068|OTHER|SANOIA Website|
219440973|NCT05437913|OTHER|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
219440974|NCT00809510|DRUG|ABT-089|20 mg ABT-089 taken once-daily for 6 months
219440975|NCT06298760|COMBINATION_PRODUCT|Knee Massage With Black Cumin Oil Group:|The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
219440976|NCT06298760|COMBINATION_PRODUCT|Foot Reflexology Group With Black Cumin Oil|The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
219440977|NCT06298760|COMBINATION_PRODUCT|placebo group|Applications were made with vaseline
219440978|NCT03158090|PROCEDURE|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
219440979|NCT03158090|DRUG|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
219440980|NCT03158090|RADIATION|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
219440981|NCT02884128|DRUG|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
219440982|NCT02884128|DRUG|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
219440983|NCT02884128|DRUG|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
218833688|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
218833689|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
218833690|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
218833691|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
218833692|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
219440984|NCT04663542|PROCEDURE|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
218833693|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
219440985|NCT02353403|OTHER|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
219440986|NCT02353403|OTHER|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
219440987|NCT00481988|DEVICE|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
219440988|NCT00481988|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
219440989|NCT00481988|DEVICE|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
219440990|NCT00481988|DEVICE|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
219440991|NCT04373213|DIAGNOSTIC_TEST|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
219440992|NCT03101449|OTHER|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
219440993|NCT03101449|OTHER|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
219581541|NCT01289444|BEHAVIORAL|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3\. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
219015090|NCT02045797|DRUG|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
219581542|NCT03416244|DRUG|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
219015091|NCT00221598|PROCEDURE|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
219015092|NCT05343975|PROCEDURE|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
219440994|NCT04655690|DRUG|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
219440995|NCT04655690|DRUG|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
219440996|NCT01052636|OTHER|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
219581543|NCT03416244|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
219581544|NCT00573157|DRUG|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
219581545|NCT00573157|DRUG|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
219764272|NCT06610474|BEHAVIORAL|Use of standard prostate cancer education materials|The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
218833694|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
218833695|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
219015093|NCT03202797|OTHER|audiometric tests|tone and speech audiometry
219015094|NCT03202797|OTHER|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
219015095|NCT03202797|OTHER|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
219015096|NCT03635710|DEVICE|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
219015097|NCT03849859|DEVICE|Single plastic stent|Deployment of single plastic stent
219015098|NCT03849859|DEVICE|Multiple plastic stents|Deployment of multiple plastic stents
219015099|NCT01725334|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
219015100|NCT01058109|OTHER|calcium-rich diet|dietary calcium intake of 1500 mg/d
219015101|NCT01058109|OTHER|Calcium rich diet|dietary intake of 1500 mg/d from food
219015102|NCT04233554|BEHAVIORAL|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
219015103|NCT01239706|DRUG|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
219015104|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
219015105|NCT02872636|DEVICE|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
219015106|NCT01064791|DRUG|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
219015107|NCT01064791|DRUG|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
219015108|NCT01064791|DRUG|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
219015109|NCT01064791|DRUG|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
219440997|NCT02781415|PROCEDURE|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
218833696|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
218833697|NCT00479570|DRUG|PF-00446687|Single 200mg dose
218833698|NCT00479570|DRUG|Placebo|
218833699|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
219581546|NCT00573157|DRUG|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
219581547|NCT00573157|DRUG|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
219764273|NCT06610461|DEVICE|HFNO-Treatment|The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
218833700|NCT00003730|DRUG|fluorouracil|
218833701|NCT00003730|DRUG|vinorelbine tartrate|
218833702|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
218833703|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
218833704|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
218833705|NCT03136224|DEVICE|Thermocautery|
218833706|NCT03136224|DEVICE|Plastic Clamping|
218833707|NCT03136224|DEVICE|Surgical Circumcision|
218833708|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
218833709|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
218833710|NCT06547333|DRUG|Placebo|Placebo
219581548|NCT05567484|DRUG|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
219581549|NCT04317183|DRUG|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
219581550|NCT04317183|DRUG|Miconazole Topical Gel|topical anti fungal agent
219581551|NCT04317183|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
219581552|NCT04317183|DRUG|Oracure gel|Topical analgesic gel
219581553|NCT01632111|OTHER|Lung function measurement|Spirometry
219764274|NCT06859710|DRUG|Placebo|Vaporized Placebo
218833711|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
218833712|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
218833713|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
218833714|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
218833715|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
218833716|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
218833717|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
219764275|NCT06859710|DRUG|THC|Vaporized THC (20 mg)
219764276|NCT06859710|DRUG|CBD 20 mg|Vaporized CBD (20 mg)
219764277|NCT06859710|DRUG|CBD 40 mg|Vaporized CBD (40 mg)
219764278|NCT06859710|DRUG|CBD 80 mg|Vaporized CBD (80 mg)
219764279|NCT06859723|DRUG|Placebo Comparator: Placebo|Placebo
219440998|NCT02781415|DRUG|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
219440999|NCT03080051|DRUG|[18F]MNI-952|Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
218833718|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
218833719|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
219441000|NCT03080051|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
219441001|NCT00654420|DRUG|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
219441002|NCT00654420|DRUG|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
219441003|NCT01673425|DRUG|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
219441004|NCT02613988|DEVICE|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
219441005|NCT02613988|DEVICE|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
218833720|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
218833721|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
218833722|NCT00239993|DRUG|glatiramer acetate|
219441006|NCT02613988|DEVICE|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
218833723|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
219441007|NCT02613988|DEVICE|Dynamic susceptibility contrast MRI|dual echo EPI sequence
218833724|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
218833725|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
219441008|NCT03383068|DRUG|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
219441009|NCT03383068|DRUG|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
218833726|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
218833727|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
218833728|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
218833729|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
218833730|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
218833731|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
218833732|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
218833733|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
218833734|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
218833735|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
219015110|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
218833736|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
218833737|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
218833738|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
219441010|NCT03383068|DRUG|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
219441011|NCT03383068|DRUG|Metformin|metformin effective subjects,act as control group
219441012|NCT00882830|PROCEDURE|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
219441013|NCT01816373|DEVICE|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
219441014|NCT00334698|DRUG|Cetirizine|
219441015|NCT00334698|DRUG|Pseudoephedrine|
219441016|NCT00334698|DRUG|Cetirizine with Pseudoephedrine|
219581554|NCT03557528|PROCEDURE|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
219015111|NCT06175793|BEHAVIORAL|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
219015112|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
219015113|NCT01119014|DRUG|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
218833739|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
219015114|NCT01119014|DRUG|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
219015115|NCT05919329|DRUG|Piflufolastat|Given IV
219015116|NCT05919329|PROCEDURE|PSMA PET/CT Scan|Undergo PSMA PET/CT
219441017|NCT04477525|PROCEDURE|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
219441018|NCT04477525|DRUG|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
219441019|NCT06507332|DRUG|Letrozole 2.5mg|to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
219441020|NCT00264095|PROCEDURE|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
219441021|NCT03476434|DEVICE|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
219441022|NCT00374036|DRUG|ECC|capecitabine
219441023|NCT00374036|DRUG|FOLFIRI|Irinotecan
219441024|NCT00159380|DRUG|Aminoguanidine|500mg
219441025|NCT00159380|DRUG|Placebos|2ml
219015117|NCT05919329|PROCEDURE|PSMA PET/MRI scan|Undergo PET/MRI
219015118|NCT05919329|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219015119|NCT05919329|OTHER|Electronic Health Record Review|Ancillary studies
219196163|NCT06813820|DEVICE|Revivent System|BioVentrix has developed the Revivent System to mirror SVR. The Revivent System is used to place permanent cardiac implants to the epicardial surface for the purpose of reconfiguring abnormal cardiac geometry that is contributing to the dysfunction.
219441026|NCT01942304|PROCEDURE|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
219441027|NCT01942304|PROCEDURE|Anorganic bovine bone mineral in direct sinus augmentation|
219581555|NCT02944383|DRUG|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
219015120|NCT04114851|DEVICE|NoL|NoL active
219015121|NCT06426108|DRUG|Fluoride Varnishes|the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
219015122|NCT06426108|DRUG|Varnishes placebo|the investigators will apply a placebo varnish without the active ingredient (fluoride), ensuring that it is packaged identically to the fluoride varnish and has the same taste and texture, thus maintaining consistency in application. The varnish will be applied using a microbrush, spreading it evenly over the entire length of the lesion for a duration of 30 seconds. Following the interventions, patients will receive instructions to avoid consuming hard foods and to delay tooth brushing for at least four hours after applying the varnish.
219441028|NCT02287805|OTHER|qualitative survey|
219441029|NCT02287805|OTHER|quantitative survey|
219441030|NCT00471276|DRUG|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
219441031|NCT02174328|DRUG|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
219441032|NCT02174328|DRUG|Placebo|Placebo once a day until 36 week
219441033|NCT05923151|PROCEDURE|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
219441034|NCT00650182|DRUG|fentanyl; naltrexone|
219441035|NCT03466112|OTHER|endurance training|endurance training with stationary bicycles
219441036|NCT03466112|OTHER|balance and tone program|flexibility, core strength, balance, relaxation
219441037|NCT04035538|DRUG|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
219581556|NCT02944383|DRUG|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
219764280|NCT06859723|DRUG|Low dose THC|Smoked low dose THC
219764281|NCT06859723|DRUG|High dose THC|Smoked high dose THC
219764282|NCT06858306|DEVICE|Sphere-9™ Catheter and Affera™ Ablation System|De novo pulmonary vein isolation procedure using commercially available Sphere-9™ Catheter and Affera™ Ablation System
219764283|NCT06859788|DRUG|Ebselen|Glutathione peroxidase mimetic
219015123|NCT06426108|RADIATION|Low-Intensity Laser 1J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
219015124|NCT06426108|RADIATION|Low-Intensity Laser 2J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
219015125|NCT06114992|DEVICE|Servo-n HFOV modes|Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
219015126|NCT02960776|BEHAVIORAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
219015127|NCT04365855|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
219015128|NCT04365855|OTHER|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
219015129|NCT04365855|PROCEDURE|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
219015130|NCT04365855|PROCEDURE|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
219015131|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
219015132|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
219441038|NCT03838380|OTHER|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
219441039|NCT01316029|PROCEDURE|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
219441040|NCT00701103|DRUG|Dalotuzumab|IV infusion
219441041|NCT03368599|PROCEDURE|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
219441042|NCT03368599|PROCEDURE|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
219441043|NCT05185817|BIOLOGICAL|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
219441044|NCT02458677|DRUG|PRX003|
219441045|NCT02458677|OTHER|Placebo|
219441046|NCT01804491|OTHER|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
219441047|NCT01976169|DRUG|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
219764284|NCT06669208|BIOLOGICAL|HydroVax-005 CHIKV|HydroVax-005 CHIKV vaccine
219764285|NCT06669208|OTHER|Placebo|NaCl 0.9%, Normal Saline
219764286|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.1.0|Participants will use their placebo control 7.1.0 as directed for a period of 6 weeks.
219764287|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.1 usage|Participants will use their Radicle Health Active Study Product 7.1.1 as directed for a period of 6 weeks.
219764288|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.2 usage|Participants will use their Radicle Health Active Study Product 7.1.2 as directed for a period of 6 weeks.
219764289|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.2.0|Participants will use their placebo control 7.2.0 as directed for a period of 6 weeks.
219764290|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.2.1 usage|Participants will use their Radicle Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
219764291|NCT06990581|OTHER|regular core exercises|regular core exercises on trunk stability and balance
219764292|NCT06990581|OTHER|specific type of core exercises|specific type of core exercises on trunk stability and balance
219764293|NCT06990269|DRUG|ADX-038|siRNA duplex oligonucleotide
219764294|NCT06990269|DRUG|Placebo|Saline
219764295|NCT05909904|DRUG|Tislelizumab|Administered intravenously
219764296|NCT05909904|DRUG|BGB-A425|Administered intravenously
219764297|NCT05909904|DRUG|LBL-007|Administered intravenously
219764298|NCT05446272|DEVICE|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
219764299|NCT05446272|DEVICE|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
219764300|NCT03892967|OTHER|Interview|Participate in interview
219764301|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
219764302|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
219764303|NCT06992427|DRUG|Gabapentin|Given PO
219764304|NCT06992427|DRUG|Placebo|Given PO
219764305|NCT06992427|DRUG|Chemotheraphy|Receive standard of care chemotherapy
219764306|NCT06992427|RADIATION|Radiation Therapy|Undergo standard of care radiation
219764307|NCT06992427|DRUG|Analgesic Agent|Receive standard of care pain medication
219764308|NCT06992427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764309|NCT06992427|OTHER|Survey Administration|Ancillary studies
219441048|NCT00179517|DRUG|Anastrozole 1mg|
219441049|NCT00179517|DRUG|Placebo Oral Tablet|
219441050|NCT06211452|DRUG|ARM A: Active Comparator Drug|Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
219441051|NCT06211452|DRUG|ARM B: Blocks Therapy Drug|"Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15."
219441052|NCT01920438|PROCEDURE|Percutaneous Endoscopic Gastrostomy|PEG
219441053|NCT01920438|PROCEDURE|Radiologically-guided insertion of Gastrostomy|RIG
219441054|NCT05048199|DEVICE|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
219441055|NCT05048199|DEVICE|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
219441056|NCT00003413|BIOLOGICAL|filgrastim|
219441057|NCT00003413|DRUG|carmustine|
219441058|NCT00003413|DRUG|cisplatin|
219441059|NCT00003413|DRUG|melphalan|
219441060|NCT00003413|DRUG|paclitaxel|
219441061|NCT00003413|PROCEDURE|peripheral blood stem cell transplantation|
219441062|NCT00003413|PROCEDURE|surgical procedure|
219441063|NCT05849636|BEHAVIORAL|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
219441064|NCT03037606|DRUG|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
219441065|NCT03037606|DRUG|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
219441066|NCT03611049|DIETARY_SUPPLEMENT|High dose Vitamin D3|High dose arm- 5000IU given daily
219441067|NCT03611049|DIETARY_SUPPLEMENT|Low dose Vitamin D3|Low dose arm-800 IU given daily
219441068|NCT00292955|DRUG|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
219441069|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
219441070|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
219441071|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
219581557|NCT05960318|DEVICE|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
219441072|NCT05387213|BEHAVIORAL|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
218833740|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
219581558|NCT05960318|DEVICE|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
219581559|NCT04987242|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
219581560|NCT04987242|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
219581561|NCT02646930|PROCEDURE|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
219581562|NCT02823860|OTHER|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
218833741|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
218833742|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
218833743|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
218833744|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
219441073|NCT00003551|DRUG|aminocamptothecin colloidal dispersion|
219581563|NCT00494039|PROCEDURE|Radioactive seed implant to prostate|
218833745|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
218833746|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
218833747|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
219441074|NCT04734977|DEVICE|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
219441075|NCT04734977|DEVICE|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
219581564|NCT02058212|DRUG|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
218833748|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
218833749|NCT02661555|OTHER|Aerobic exercise|
218833750|NCT01932229|DRUG|Afatinib treatment|
218833751|NCT00446823|DEVICE|XCell cellulose wound dressing|
218833752|NCT00446823|DEVICE|Impregnated gauze dressing|
218833753|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
218833754|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
218833755|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
218833756|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
218833757|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
218833758|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
218833759|NCT03792438|DIAGNOSTIC_TEST|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
219581565|NCT00055614|DRUG|topotecan hydrochloride|
219581566|NCT00055614|PROCEDURE|adjuvant therapy|
219581567|NCT01183221|DRUG|Syntocinon|One dose of 24 IU (3 sprays/nostril)
219581568|NCT01183221|DRUG|Placebo|Intranasal Placebo
219581569|NCT02674321|DRUG|SD-809|
219581570|NCT05367336|DRUG|Morphine|second group will be receiving morphine
219581571|NCT05367336|DRUG|Fentanyl|third group receiving fentanyl
219581572|NCT04763564|DRUG|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
218833760|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
218833761|NCT00752739|OTHER|placebo|Given orally
218833762|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
218833763|NCT00263042|DRUG|Rimonabant|Tablet, oral administration
219441076|NCT04734977|OTHER|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
219441077|NCT01332097|DRUG|BCT197|
218833764|NCT00263042|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219441078|NCT01332097|DRUG|Prednisone placebo|capsules
219441079|NCT01332097|DRUG|BCT197 placebo|capsules
218833765|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
218833766|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
218833767|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
218833768|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
218833769|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
218833770|NCT02414607|BIOLOGICAL|Elderberry Juice|
218833771|NCT02414607|OTHER|Placebo|
218833772|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
218833773|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
218833774|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
218833775|NCT04709003|DIAGNOSTIC_TEST|Serologic test|A blood test to check antibodies type and amount
219441080|NCT01332097|DRUG|Prednisone|capsules
219441081|NCT05037916|OTHER|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
219441082|NCT05795868|DEVICE|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
219441083|NCT05795868|OTHER|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
219441084|NCT00361218|DRUG|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
219441085|NCT03581682|OTHER|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
219441086|NCT01703104|DRUG|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
219441087|NCT01703104|DIETARY_SUPPLEMENT|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
219441088|NCT01505972|OTHER|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
218833776|NCT04709003|DIAGNOSTIC_TEST|Respiratory swabs|PCR test to Covid-19
218833777|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
218833778|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
218833779|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
218833780|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
218833781|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
218833782|NCT02140970|DRUG|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
218833783|NCT02140970|DRUG|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
218833784|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
218833785|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
219015133|NCT05698446|PROCEDURE|Modified Broström + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
219015134|NCT05698446|PROCEDURE|Anatomic reconstruction operation|Anatomic reconstruction operation
219015135|NCT05698446|PROCEDURE|Open Modified Broström procedure|Open Modified Broström-Gould surgery
219015136|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
219581573|NCT04763564|DRUG|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
219581574|NCT00003538|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
218833786|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
218833787|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
219581575|NCT00003538|PROCEDURE|allogeneic bone marrow transplantation|
218833788|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
219581576|NCT03912441|BIOLOGICAL|BCD-147|Bispecific anti-HER2 monoclonal antibody
219581577|NCT02086630|BEHAVIORAL|Heart to Heart|
219581578|NCT00343343|DEVICE|NovoFine® needle 6 mm|
219581579|NCT00343343|DEVICE|NovoFine® needle 4 mm|
219581580|NCT00858143|OTHER|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
219581581|NCT01551641|OTHER|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
219581582|NCT01551641|DRUG|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
218833789|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
218833790|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
218833791|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
219015137|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
219441089|NCT01505972|OTHER|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
219441090|NCT05527106|DIETARY_SUPPLEMENT|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
219441091|NCT05527106|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
219441092|NCT05527106|DIETARY_SUPPLEMENT|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
219441093|NCT05527106|DIETARY_SUPPLEMENT|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
219441094|NCT06382961|DRUG|Dexmedetomidine injection|Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
219441095|NCT06382961|DRUG|Sufentanil injection|3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
219441096|NCT01248585|DRUG|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
219764310|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for breast cancer per local standard.
219441097|NCT01248585|DRUG|Placebo|2 placebo tablets taken once daily for 5 days
219581583|NCT01551641|OTHER|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
219581584|NCT05726175|DRUG|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
219581585|NCT05726175|DRUG|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
219581586|NCT06406270|OTHER|Fava|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
219764311|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
219764312|NCT06992999|DRUG|Low Dose Psilocybin|10mg dose of psilocybin
219764313|NCT06992999|DRUG|High Dose Psilocybin|30mg dose of psilocybin
219764314|NCT06608901|DRUG|REGN7544|Administered per the protocol
219764315|NCT06608901|DRUG|PB|Administered per the protocol
219764316|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
219764317|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
219581587|NCT06406270|OTHER|Buckwheat|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
219196164|NCT06813729|BIOLOGICAL|Shotblocker|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Before the injection, while one nurse held the infants' leg for the injection, Shotblocker® was applied to the skin by the experienced nurse ensuring that the points were in direct contact. Then, the nurse administered the pneumococcal conjugate vaccine (0.5 ml, IM, Vastus Lateralis Site) through the central hole. After each use, the Shotblocker® was disinfected with 70% alcohol before being used on another infant.
219196165|NCT06813729|BIOLOGICAL|Manuel Pressure|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Next, while one nurse held the infants' leg for the injection, 10-second manual pressure was applied on the vaccine injection site by the experienced nurse. Then pneumococcal conjugate vaccine was administered in accordance with the standard injection technique (0.5 ml, IM, Vastus Lateralis Site).
219363905|NCT02445586|DRUG|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
218833792|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
218833793|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
218833794|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
218833795|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
218833796|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
218833797|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
218833798|NCT05447520|DRUG|Placebo|Oral tablet once daily
218833799|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
218833800|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
218833801|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
218833802|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
219363906|NCT00685594|DRUG|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
219363907|NCT00685594|DRUG|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
219363908|NCT01931059|DRUG|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
218833803|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
218833804|NCT00219193|DRUG|aliskiren|
219363909|NCT01931059|OTHER|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
219363910|NCT01213212|OTHER|Caloric restriction|Caloric restriction.
219363911|NCT01213212|OTHER|No intervention|"Diet ad libitum"
219363912|NCT01833884|OTHER|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
219363913|NCT06103903|BEHAVIORAL|Questionnaire|Questionnaire according to age (6-13;14-17); the parents for minors and adults
219363914|NCT03657719|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
219363915|NCT03657719|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
219363916|NCT05797077|PROCEDURE|Colorectal resection surgery.|Colorectal cancer radical resection combined with liver metastasis resection or ablation.
219363917|NCT05797077|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
219363918|NCT05797077|DRUG|Capecitabine|Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
218833805|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
218833806|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
218833807|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
218833808|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
218833809|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
218833810|NCT01709110|DRUG|Teriparatide|Administered SC
218833811|NCT01709110|DRUG|Risedronate|Administered orally
218833812|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
218833813|NCT01709110|DRUG|Calcium|Administered orally
218833814|NCT01709110|DRUG|Vitamin D|Administered orally
218833815|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
218833816|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
218833817|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
219441098|NCT04822311|BEHAVIORAL|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
219441099|NCT02954445|BIOLOGICAL|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
219441100|NCT03718676|PROCEDURE|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
219441101|NCT03718676|PROCEDURE|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
219441102|NCT03718676|PROCEDURE|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
219441103|NCT01369446|DEVICE|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
219441104|NCT05664555|DRUG|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
219441105|NCT03825497|OTHER|Promotion of activity during and after hospitalization|1\) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
219441106|NCT01570309|DRUG|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
219441107|NCT01570309|OTHER|Sugar pill|Oral capsule, once a week, 12 weeks
219441108|NCT01399840|DRUG|BMN 673|Oral capsule with multiple dosage forms given once daily
219441109|NCT01010269|DEVICE|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
219441110|NCT01010269|DEVICE|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
219441111|NCT06391567|OTHER|There was no intervention in this study.|There was no intervention in this study.
219441112|NCT01024101|DRUG|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
219441113|NCT04165304|DIETARY_SUPPLEMENT|sugar reduction|sugar reduction in the offered drinks
219441114|NCT02949713|BEHAVIORAL|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
219441115|NCT00741806|BIOLOGICAL|GHB04L1|single dose intranasal administration of GHB04L1
219764318|NCT03564691|DRUG|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
219441116|NCT00741806|OTHER|Placebo|SPGN buffer
219441117|NCT02820688|DRUG|Bupivacaine 0.25%|
218833818|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
218833819|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
218833820|NCT02076529|DRUG|Ramosetron 0.3mg|
218833821|NCT02076529|DRUG|Ramosetron 0.45mg|
218833822|NCT02076529|DRUG|Ramosetron 0.6mg|
218833823|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
218833824|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
218833825|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
218833826|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
219015138|NCT03645655|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
219015139|NCT00087581|DRUG|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
219441118|NCT02820688|DRUG|Prilocaine 1%|
219441119|NCT02820688|PROCEDURE|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
219764319|NCT03564691|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
219764320|NCT03564691|DRUG|Carboplatin|Carboplatin will be administered IV Q3W.
219764321|NCT03564691|DRUG|Pemetrexed|Pemetrexed will be administered IV Q3W.
219764322|NCT03564691|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily.
218833827|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
218833828|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
218833829|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
218833830|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
219363919|NCT00428597|DRUG|sunitinib malate|"* sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
218833831|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
219363920|NCT00428597|DRUG|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
219363921|NCT01425112|PROCEDURE|Phacoemulsification|Surgery for complications of trabeculectomy
219363922|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Clinician-Guided version|Internet delivered Cognitive Behavioral Therapy- Guided version
219441120|NCT02820688|DRUG|Bupivacaine 0.167%|
219441121|NCT02820688|DRUG|Bupivacaine 0.125%|
219441122|NCT02820688|DRUG|Prilocaine 0.66%|
219441123|NCT02820688|DRUG|Prilocaine 0.5%|
219441124|NCT02820688|DEVICE|Ultrasound|All nerve blocks will be performed with ultrasound guidance
219363923|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Self-Guided version|Internet delivered Cognitive Behavioral Therapy- Self-Guided version
219363924|NCT01465308|DIETARY_SUPPLEMENT|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
219441125|NCT00081744|DRUG|Tigecycline|
219441126|NCT01313468|BEHAVIORAL|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
219441127|NCT01313468|BEHAVIORAL|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
219441128|NCT01313468|BEHAVIORAL|Moderate continuous Training|47 minutes of Moderate continuous Training
219441129|NCT01766544|OTHER|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
219441130|NCT01766544|OTHER|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
219441131|NCT01394367|OTHER|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
219441132|NCT00272480|DRUG|Zidovudine/lamivudine|
219441133|NCT00272480|DRUG|Placebos|
218833832|NCT00292526|DRUG|Enalapril|enalapril orally administered
218833833|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
218833834|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
218833835|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
218833836|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
218833837|NCT02456207|DRUG|SCT400|
218833838|NCT02456207|DRUG|Rituximab|
218833839|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
218833840|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
218833841|NCT00033566|DRUG|S-3304|
219363925|NCT01465308|OTHER|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
219363926|NCT05589285|BIOLOGICAL|Injection of autologous whole blood to the plantar fascia|Patients assigned in this group will have 2 ml of blood withdrawn from a peripheral vein, then mixed with 1 mL Lidocaine 2% for a total of 3mL volume in one syringe. The patient will be asked to lie down in the clinic bed, and the injection will be administered to the plantar fascia by the principal investigator using a sterile technique.
219363927|NCT05589285|DEVICE|Injection of normal saline to the plantar fascia|This will be the control group receiving sham injection. Patients will have 2 ml of blood withdrawn from a peripheral vein for blinding proposes. They will be asked to lie down on the clinic bed, 1 ml of normal saline will be administered under sterile technique by the principal investigator. The blood that was withdrawn initially will be discarded.
219441134|NCT05906667|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
219441135|NCT02788591|DRUG|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
219441136|NCT02788591|DRUG|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
219441137|NCT02390960|DRUG|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
218833842|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
218833843|NCT00408265|BEHAVIORAL|Contingency Management|
218833844|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
218833845|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
218833846|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
218833847|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
218833848|NCT00742521|PROCEDURE|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
219441138|NCT02390960|DRUG|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
219441139|NCT02390960|DEVICE|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
219441140|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
219441141|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
219581588|NCT03591393|DIAGNOSTIC_TEST|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
218833849|NCT00742521|PROCEDURE|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
218833850|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
218833851|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
219015140|NCT00087581|DRUG|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
219581589|NCT03529578|PROCEDURE|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
219581590|NCT03668561|DEVICE|Caligaloc|15 days of wearing of the Caligaloc orthosis
219581591|NCT00299845|DRUG|Lansoprazole|
219581592|NCT01706237|DEVICE|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
219581593|NCT04785859|DIAGNOSTIC_TEST|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
218833852|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
218833853|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
218833854|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
218833855|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
218833856|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
218833857|NCT01435694|BEHAVIORAL|Conventional Therapy|
218833858|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
218833859|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
219015141|NCT00087581|DRUG|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
219581594|NCT04461561|GENETIC|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
219581595|NCT06432049|OTHER|restoration for endodontically treated molar|prefabricated stainless steel crown or endocrown
218833860|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
219581596|NCT01495156|DRUG|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
219581597|NCT01495156|DRUG|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
219581598|NCT00167687|DRUG|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
219581599|NCT03853148|BEHAVIORAL|Otago|Exercise program for strength and balance
219581600|NCT03853148|BEHAVIORAL|Gentle yogic breathing|yogic breathing
218833861|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
218833862|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
219581601|NCT03853148|BEHAVIORAL|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
219581602|NCT03853148|BEHAVIORAL|Caregiver Gentle yogic breathing|yogic breathing
219764323|NCT03564691|DRUG|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
218833863|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
218833864|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
218833865|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
219015142|NCT01357265|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
219015143|NCT02809690|DEVICE|CAT|Undergo 18F-FMAU PET/CT
219015144|NCT02809690|DRUG|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
219581603|NCT00852969|DRUG|Niacin|1000 mg tablets once per day
219764324|NCT03564691|DRUG|Cisplatin|Cisplatin will be administered IV Q3W.
219764325|NCT03564691|BIOLOGICAL|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
218859801|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
219015145|NCT02809690|OTHER|Laboratory Biomarker Analysis|Correlative studies
219015146|NCT02809690|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
219015147|NCT02809690|DEVICE|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
219015148|NCT02809690|DEVICE|Ultrasound|Undergo TRUS-guided biopsy
219581604|NCT00852969|DRUG|Active Placebo|100 mg Niacin tablets once per day
219581605|NCT02537366|DRUG|Dexmedetomidine|
219764326|NCT06596902|BEHAVIORAL|Physical Activity|The 12-month intervention will progressively increase in intensity and complexity to teach parents/children more complex sports skills and behavioral techniques, to prepare them to become future team leaders for nutrition education and sports sessions. In addition, the family Olympics events will take place after every 3-month to reinforce progression, social support; progressive improvements: Phase 1: Beginner (months 0-3) will focus on introductory concepts and basic sports skills and will focus on establishing consistent behavioral patterns and social support. Phase 2: Intermediate (months 4-6) will begin to introduce slightly more complex nutrition behavioral concepts and increase difficulty of sport skills, and reinforce behavioral patterns from phase 1. Phase 4: Advanced (months 10-12) will teach parents and children advanced sports skills ; nutrition knowledge so that they may become team leaders to help implement future activity sessions and nutrition education sessions.
219764327|NCT06862375|BEHAVIORAL|Mayo Clinic Diet|"Subjects will utilize their choice of the following resources for 12 weeks:~* Mayo Clinic Diet book, 3rd Edition~* Digital Wellness app subscription~* Both the Mayo Clinic Diet book and Digital Wellness app"
218833866|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
218833867|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
218833868|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
218833869|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
218833870|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
218833871|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
218833872|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
219015149|NCT00813085|OTHER|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
219015150|NCT03341832|DRUG|NVP-1203|oral dose for 7 days
219015151|NCT03341832|DRUG|NVP-1203-R|oral dose for 7 days
219015152|NCT03341832|DRUG|NVP-1203 placebo|oral dose for 7 days
219015153|NCT03341832|DRUG|NVP-1203-R placebo|oral dose for 7 days
219015154|NCT01930851|PROCEDURE|Gastric bypass operation|
219015155|NCT03674242|DRUG|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
219015156|NCT03674242|DRUG|Gemcitabine|IV infusion 1000 mg/m2
219015157|NCT03674242|DRUG|Carboplatin|IV infusion AUC2
219015158|NCT03554226|BEHAVIORAL|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
219015159|NCT03415750|DRUG|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
219015160|NCT03415750|DRUG|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
219015161|NCT03415750|DRUG|Tacrolimus|
219015162|NCT03232281|DRUG|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
219581606|NCT02537366|DRUG|Placebo|
219581607|NCT03865186|BEHAVIORAL|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
219581608|NCT03865186|BEHAVIORAL|no intervention|
219581609|NCT04335526|DRUG|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
219581610|NCT00658658|BIOLOGICAL|Panitumumab|Panitumumab administered by intravenous infusion
219581611|NCT02440022|COMBINATION_PRODUCT|Lutonix DCB|
219581612|NCT02440022|DEVICE|Standard Balloon Angioplasty Catheter|
219363928|NCT05345925|DEVICE|Moderato|Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.
219363929|NCT00578643|DRUG|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
219581613|NCT02440022|PROCEDURE|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
218833873|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
219015163|NCT03232281|DRUG|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
219015164|NCT03210870|BEHAVIORAL|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
219015165|NCT01403246|DRUG|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
219581614|NCT04644835|DEVICE|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
219581615|NCT04644835|DEVICE|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
219015166|NCT01472250|DRUG|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
219581616|NCT05495958|DRUG|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
218833874|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
218833875|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
218833876|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
218833877|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
219015167|NCT01700855|PROCEDURE|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
219015168|NCT01700855|PROCEDURE|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
219015169|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
219015170|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
219581617|NCT05495958|DRUG|Topical placebo eye drop|The same-shape packed drop without vitamin D
219764328|NCT06862375|BEHAVIORAL|Usual Care|Subjects will be given the 'Eat Well Use the Plate' informational hand-out, as well as a list of food, physical activity and weight tracking apps to be utilized as resources for self-monitoring .
219764329|NCT06613477|DRUG|PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease|Table 3: Digoxin dosing regimen based on optimized Cmin,ss Dose to be given twice daily (mcg/kg/dose) PNA\<30 days 30 days \< PNA \< 180 days eGFR≤40 1.4 1.4 40\<eGFR≤60 1.6 1.6 eGFR\>60 1.9 2.8
218833878|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
218833879|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
218833880|NCT03024112|OTHER|Standard oxygen therapy|
218833881|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
219015171|NCT01329640|DEVICE|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
219363024|NCT05501119|BEHAVIORAL|A Program of SUPPORT-D (dementia)|The SUPPORT-D intervention consists educational materials will be presented in a format with enhanced content (face-to-face virtually delivered by nurse interventionist via telehealth (e.g., MS Teams), with printed booklet, and identical digital content (electronic pdf and recorded videos of printed content). The SUPPORT-D intervention will be addressed in four sequential sections including: 1) understanding the disease 2) caring for myself; 3) information for the caregiver; and 4) planning for the future. Within the four sections of the intervention seven topics are addressed included symptom management, understanding your disease, putting safety first, ongoing conversations, respite care, palliative care, and alternative treatments. Participants will attend a total of 4 study visits across 8 weeks (approximately every 2 weeks).
219441142|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
218833882|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
218833883|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
218833884|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
219015172|NCT01924312|BEHAVIORAL|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
219441143|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
219441144|NCT01084330|DRUG|AUY922|70mg/m2
219015173|NCT02825927|OTHER|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
219015174|NCT03195114|DIAGNOSTIC_TEST|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
219441145|NCT01084330|DRUG|Docetaxel|Docetaxel 75mg/m2
219441146|NCT01084330|DRUG|Irinotecan|Iriniotecan 350mg/m2
219441147|NCT05154565|BEHAVIORAL|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
219441148|NCT04006067|OTHER|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
219441149|NCT00757367|DRUG|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
219441150|NCT05817981|OTHER|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
219441151|NCT05817981|OTHER|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
219441152|NCT00113412|DRUG|SP01A|
219441153|NCT01603212|DRUG|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
219441154|NCT01603212|DRUG|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
219441155|NCT01603212|DRUG|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
219441156|NCT00750217|DRUG|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
219441157|NCT01390038|DEVICE|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
219441158|NCT01856803|DRUG|anti thymoglobulin|
219441159|NCT04125303|BEHAVIORAL|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
219441160|NCT05198427|OTHER|review of medical patient file|"The outcome measure is the evolution of HPV related lesions between :~* favourable evolution including partial or total regression~* unfavourable evolution including non-evolution or aggravation or recurrence."
219441161|NCT02468141|DRUG|SJDBT|Sipjeondaebo-tang
219441162|NCT02468141|DRUG|Placebo|Placebo
219441163|NCT01545414|BEHAVIORAL|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
219441164|NCT01545414|BEHAVIORAL|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
218833885|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
218833886|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
219441165|NCT03367611|DIAGNOSTIC_TEST|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
218833887|NCT04226625|DRUG|Propofol|Intravenous administration
218833888|NCT04226625|DRUG|Desflurane|Volatile administration
218833889|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
218833890|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
218833891|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
218833892|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
218833893|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
218833894|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
218833895|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
218833896|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
218833897|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
218833898|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
218833899|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
218833900|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
219363025|NCT00955994|DRUG|asimadoline|
218833901|NCT03133494|OTHER|ABG analysis|ABG analysis was performed and compared between two groups
218833902|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
218833903|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
218833904|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
219363026|NCT04983160|DRUG|Allopurinol|Allopurinol
219363027|NCT04983160|DRUG|Placebo|Placebo
219363028|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
219363029|NCT05536349|DRUG|Pirtobrutinib|Given by PO
219363030|NCT05536349|DRUG|Obinutuzumab|Given by (IV) vein
219363031|NCT05536349|DRUG|Venetoclax|Given by PO
219363032|NCT05536349|DRUG|Valacyclovir|Given by PO
219363033|NCT05536349|DRUG|Allopurinol|Given by PO
219363034|NCT05243628|BIOLOGICAL|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
219363035|NCT05243628|BIOLOGICAL|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219363036|NCT05243628|DEVICE|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
219363037|NCT05948956|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-ketone Powder ™ and electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
219363038|NCT05948956|DIETARY_SUPPLEMENT|Electrolyte Beverage|Participants will consume an electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
219363039|NCT05948956|BEHAVIORAL|Cycling Intervention|"Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down."
219363040|NCT02353533|DEVICE|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
219363041|NCT02353533|DEVICE|EMR|Standard endoscopic mucosal resection using a resection snare
219363930|NCT00578643|BIOLOGICAL|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
219363931|NCT00578643|DRUG|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
219363932|NCT00578643|DRUG|Fludarabine|"Day -5 through Day -2~30 mg/m\^2"
219363933|NCT00578643|DRUG|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
219363934|NCT00578643|PROCEDURE|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.
219363935|NCT04241965|DRUG|OPC-214870|Tablet(s)
219363936|NCT04241965|OTHER|Placebo|Tablet(s)
219363937|NCT00375102|PROCEDURE|Acupuncture|
219363938|NCT00375102|BEHAVIORAL|Relaxation Response|
218833905|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
219581618|NCT02878941|PROCEDURE|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
219581619|NCT05326321|OTHER|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
219581620|NCT02567643|RADIATION|Stereotactic Radiosurgery|
219581621|NCT02254213|OTHER|EEG recording|A short EEG recording is performed 10 times over the span of three months.
219363939|NCT03042936|BEHAVIORAL|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
218833906|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
218833907|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
218833908|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
218833909|NCT02859285|OTHER|Placebo vulvar cream|
219363940|NCT01990261|DRUG|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
219363941|NCT05152290|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219441166|NCT00772811|DRUG|Flu-Mel|"* Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2."
219441167|NCT04078529|OTHER|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
219441168|NCT04078529|OTHER|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
219441169|NCT04078529|OTHER|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
219363942|NCT04251377|DEVICE|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
219363943|NCT05016804|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219363944|NCT05618366|DRUG|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
219441170|NCT00185172|OTHER|placebo|Placebo oral tablets for 2 weeks
219441171|NCT00185172|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
219441172|NCT00185172|DRUG|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
219441173|NCT00368472|DRUG|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
219441174|NCT04261881|DIETARY_SUPPLEMENT|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
219441175|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast
219441176|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
219441177|NCT01579149|DRUG|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
219441178|NCT01579149|DRUG|Placebo|Single subcutaneous (SC) dose of placebo
219441179|NCT01044056|DRUG|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
219441180|NCT01044056|DRUG|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
219363945|NCT05618366|DRUG|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
219363946|NCT01509352|PROCEDURE|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
219363947|NCT01509352|PROCEDURE|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
219363948|NCT00324285|DRUG|Amylase resistant starch added ORS|
219363949|NCT00804388|PROCEDURE|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
219015175|NCT03900000|OTHER|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
219581622|NCT02689050|DEVICE|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
219581623|NCT02504671|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
218833910|NCT02859285|OTHER|Estradiol vulvar cream|
218833911|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
218833912|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
219015176|NCT05243368|DIETARY_SUPPLEMENT|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
219015177|NCT00261677|DRUG|epoetin alfa|
219015178|NCT00488163|DRUG|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
219015179|NCT06021015|DEVICE|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
219581624|NCT02504671|DRUG|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
219581625|NCT02504671|DRUG|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
219015180|NCT06021015|DEVICE|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
219015181|NCT03445819|PROCEDURE|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
219441181|NCT01044056|DRUG|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
219441182|NCT05481970|DRUG|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
219581626|NCT02504671|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
219015182|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
219015183|NCT00174915|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
219015184|NCT00174915|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
219015185|NCT00174915|DRUG|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
219015186|NCT00174915|DRUG|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
219015187|NCT00174915|DRUG|Placebo|Placebo, orally, once daily for up to 28 weeks.
219015188|NCT03632278|BEHAVIORAL|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
219441183|NCT05481970|DRUG|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
219581627|NCT05526261|PROCEDURE|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
219581628|NCT03220061|BEHAVIORAL|music therapy|
219581629|NCT02562105|PROCEDURE|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
219581630|NCT06633718|DRUG|Meropenem and Pralurbactam|3g，q8h，120min infusion
219581631|NCT06633718|DRUG|Saline|100mL，q8h，60min infusion
219581632|NCT06633718|DRUG|Ceftazidime-avibactam|2.5g，q8h，120min infusion
219581633|NCT06633718|DRUG|Metronidazole|0.915g，q8h，60min infusion
219581634|NCT06016036|DRUG|SAL-0951|"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
219581635|NCT06016036|DRUG|Placebo|"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
219764330|NCT06231940|OTHER|Complex Decongestive Therapy (CDT) in venous insufficiency,|Complex Decongestive Therapy (CDT) is a comprehensive treatment approach primarily used for lymphedema and related conditions, but it's also beneficial for chronic venous insufficiency and other edematous conditions. CDT aims to reduce swelling and maintain the reduction, improve skin condition, and alleviate symptoms. It typically involves two phases: an intensive phase to reduce swelling as much as possible and a maintenance phase to sustain the achieved results. The main components of CDT include: Manual Lymph Drainage (MLD),Compression Therapy, Exercise, Skin Care, Education and Self-Care:
219581636|NCT04842565|DRUG|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
219581637|NCT04842565|DEVICE|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
219581638|NCT04498403|DRUG|Crisaborole 2%|Crisaborole 2% ointment
219581639|NCT03554213|BIOLOGICAL|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
218833913|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
218833914|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
218833915|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
218833916|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
219015189|NCT03889821|BEHAVIORAL|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
219015190|NCT03889821|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
219015191|NCT01837992|DRUG|Primaquine|
219581640|NCT03760003|DRUG|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
219581641|NCT03760003|DRUG|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
219015192|NCT01837992|DRUG|delayed primaquine|
219581642|NCT03760003|DRUG|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
218833917|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
219015193|NCT00183092|DRUG|Quinacrine|100mg by mouth three times a day
218833918|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
218833919|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
218833920|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
219015194|NCT00183092|DRUG|Placebo|100mg by mouth three times a day
218833921|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
218833922|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
219015195|NCT03459378|OTHER|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
219015196|NCT05791045|PROCEDURE|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
219363950|NCT02534636|DRUG|BMS-986165|
219363951|NCT02534636|DRUG|Interferon alpha-2a recombinant|
219581643|NCT03760003|DRUG|Placebo|Two capsules of placebo once daily for 16 weeks
219581644|NCT00599521|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
219581645|NCT00599521|DRUG|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
219581646|NCT00237913|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
219764331|NCT06997081|DRUG|Lenalidomide|Participants will receive 25mg of Lenalidomide orally on Days 2-21 of Cycle 1, then 25 mg by mouth on Days 1-21 of the remaining cycles.
219581647|NCT00237913|DRUG|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
219764332|NCT06997081|DRUG|Dexamethasone|Participants will receive 20mg of Dexamethasone orally on Days 1, 3, 8, and 15 of Cycle 1, then 4mg orally on Days 1 and 15 of Cycles 4-6.
219581648|NCT04602715|DRUG|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
219581649|NCT04602715|DRUG|Placebo|Placebo Control
219581650|NCT05211661|DIAGNOSTIC_TEST|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
219581651|NCT05903456|PROCEDURE|TACE（transcatheter arterial chemoembolization）|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
219581652|NCT05903456|DRUG|lenvatinib|Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
219581653|NCT05903456|DRUG|Icaritin soft capsules|Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
219581654|NCT03882528|BIOLOGICAL|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
219581655|NCT02385253|BEHAVIORAL|Educational training program|"The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency"
219581656|NCT02789397|DRUG|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
219581657|NCT02789397|DRUG|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
219581658|NCT04731337|DEVICE|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
219581659|NCT04830059|BEHAVIORAL|Exercise|Two types of exercise intervention and control group
219581660|NCT04830059|BEHAVIORAL|Air purification|Air purification in order to reduce the PM2.5 and PM10
219581661|NCT01674153|PROCEDURE|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
219581662|NCT04131777|DEVICE|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
218833923|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
218833924|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
219581663|NCT01951885|DRUG|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
219581664|NCT01951885|DRUG|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
218833925|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
218859802|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
219764333|NCT06997081|DRUG|Elranatamab|Participants will receive 12mg Elranatamab subcutaneous (SC) on Cycle 1; 32mg subcutaneous (SC) on Cycle 1 Day 3; 76mg subcutaneous (SC) on Cycle 1 Day 8 and Day 15. Then, participants will receive 76mg subcutaneous (SC) on Days 1 and 15 of Cycles 2-6. Lastly, participants will receive Elranatamab subcutaneous (SC) on Day 1 of the remaining cycles.
219764334|NCT06996639|BEHAVIORAL|Non-Fasting|No pre-procedural fasting required; participants may eat and drink as usual.
219764335|NCT06996639|BEHAVIORAL|Fasting|"Standard pre-procedural fasting (≥6 hours for solids, ≥2 hours for clear liquids) or NPO at Midnight."
218859803|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
219363952|NCT02534636|DRUG|Famotidine|
218859804|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
219764336|NCT06995872|DRUG|rhIL-15|rhIL-15 will be given at a dose of 0.13-2 mcg/kg/day (based on dose level) as a continuous IV infusion for 5 days each cycle.
219764337|NCT06995872|DRUG|Dinituximab|Dinituximab will be given at a dose of 17.5 mg/m\^2/dose by IV on days 2-5 of each cycle.
218833926|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
218833927|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
218833928|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
218833929|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
218833930|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
219015197|NCT02451410|OTHER|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
219015198|NCT01127308|DRUG|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
219015199|NCT04375488|OTHER|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
219015200|NCT04375488|OTHER|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
219015201|NCT03060447|DRUG|Vesatolimod|Tablets Administered orally
219015202|NCT03060447|DRUG|Placebo|Tablets Administered orally
219015203|NCT03060447|DRUG|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
219363953|NCT02534636|OTHER|Placebo|
219441184|NCT04095793|DRUG|ampreloxetine|Oral tablet, QD
219441185|NCT02224937|DRUG|Melatonin|
219441186|NCT02224937|DRUG|Placebo|
219441187|NCT04434105|DRUG|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
219441188|NCT04434105|DRUG|Triamcinolone Acetonide|40 mg triamcinolone acetonide
219441189|NCT04434105|DRUG|Saline|Saline
219441190|NCT05580185|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
219441191|NCT03619837|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
219441192|NCT03619837|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
219441193|NCT03366597|DRUG|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
219441194|NCT05065268|DEVICE|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
219441195|NCT00044213|DRUG|EDTA|Participants will receive 40 infusions of standard chelation solution.
219441196|NCT00044213|DRUG|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
219441197|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin|
219441198|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin Placebo|
219441199|NCT01372813|DRUG|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
219441200|NCT03785470|OTHER|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
219441201|NCT05097170|PROCEDURE|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
219441202|NCT01680939|DRUG|Morphine|0.2-0.5 mg/kg PO q4h
219441203|NCT01680939|DRUG|Ibuprofen|10mg/kg PO q6hrs
219441204|NCT01960504|DEVICE|Percutaneous Coronary Intervention (DREAMS) stenting|
219441205|NCT01927068|DEVICE|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
219441206|NCT05240612|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
219441207|NCT05240612|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
219441208|NCT01529619|DRUG|Rivastigmine transdermal patch|
219441209|NCT02121314|DRUG|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
219441210|NCT02814136|PROCEDURE|Ablation|
219441211|NCT00880607|DRUG|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
218833931|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
218833932|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
218833933|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
218833934|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
218833935|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
218833936|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
218833937|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
218833938|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
219363042|NCT01032551|BEHAVIORAL|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
219441212|NCT00880607|DRUG|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
219441213|NCT00735527|DRUG|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
219764338|NCT06995872|DRUG|Temozolomide|Temozolomide will be given orally (PO) at a dose based on weight on days 1-5 of each cycle beginning with cycle 2.
219764339|NCT06995872|DRUG|Irinotecan Hydrochloride|Irinotecan will be given at a dose of 50 mg/m\^2/dose by IV on days 1-5 of each cycle beginning with cycle 2.
219764340|NCT06433752|OTHER|No Intervention|No Intervention
219764341|NCT06997016|DIETARY_SUPPLEMENT|pre-operative carbohydrate drink|50 g of carbohydrate drink 2 hours before surgery
219764342|NCT06997016|DRUG|Acetaminophen|650mg acetaminophen 30 minutes prior to surgery
219764343|NCT06997016|DRUG|Gabapentin|300 mg gabapentin 30 minutes prior to surgery
219441214|NCT00735527|DRUG|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
219441215|NCT01507571|OTHER|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
219441216|NCT00128752|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
219441217|NCT05846269|OTHER|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
219441218|NCT03933072|PROCEDURE|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
219475557|NCT05043857|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
219764344|NCT06997016|DRUG|Bupivacaine|intraoperative local anesthetic
219764345|NCT06997016|OTHER|Ambulation|Assisted ambulation 12 hours after surgery
219764346|NCT06590428|OTHER|Therapeutic Drug Monitoring for Linezolid|TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
219764347|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
219764348|NCT06865027|OTHER|Ventilation strategy|"The selected PaCO2 targets are:~Normocapnia: PaCO2: 5.0-5.5 kPa Hypercapnia: PaCO2: 6.4-7.0 kPa~The adjustments on the ventilator needed to achieve these targets will be administered by the anesthetic nurse and attending anesthesiologist and held within the following limitations:~Tidal volume: 4 - 8ml ml/kg IBW Inspiratory pressure 5-30 cm H2O Respiration rate 10-18 per minute PEEP 5-10 mmHg~\*IBW: 50 + 0.91 (height in centimeters - 152.4) Peep, I:E ratio, and FiO2 will be administered at the anesthetic nurse's and the anesthesiologist's discretion."
219764349|NCT05913908|DEVICE|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
218833939|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
218833940|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
218859805|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
218859806|NCT06361602|OTHER|inapplicable|inapplicable
219441219|NCT03933072|BIOLOGICAL|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
219441220|NCT03933072|PROCEDURE|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
218833941|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
219441221|NCT02104141|DEVICE|ROIA Interbody Cage with VerteBRIDGE plating|
218833942|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
218833943|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
218833944|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
218833945|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
218833946|NCT00002509|BIOLOGICAL|filgrastim|
218833947|NCT00002509|DRUG|carboplatin|
218833948|NCT00002509|DRUG|cyclophosphamide|
218833949|NCT00002509|DRUG|etoposide|
218833950|NCT00002509|DRUG|mesna|
218833951|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
218833952|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
218833953|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
218833954|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
218833955|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
218833956|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
218833957|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
218833958|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
219441222|NCT02654041|DRUG|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
219441223|NCT00331084|DRUG|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
218833959|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
218833960|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
218833961|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
218833962|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
218833963|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
218833964|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
218833965|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
218833966|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
218833967|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
218833968|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
218833969|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
219441224|NCT00331084|DRUG|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
219441225|NCT00433667|DRUG|RWJ-333369|
219764350|NCT06863402|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764351|NCT06863402|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219764352|NCT06863402|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219764353|NCT06863402|PROCEDURE|Echocardiography|Undergo ECHO
219581665|NCT01951885|DRUG|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
219581666|NCT01951885|DRUG|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
219581667|NCT01546376|RADIATION|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
219581668|NCT01546376|OTHER|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
219581669|NCT05192694|PROCEDURE|Computed tomography|Positron Emission Tomography
219581670|NCT05250648|DRUG|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
218833970|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
218833971|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
218833972|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
218833973|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
219764354|NCT06863402|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219015204|NCT04442204|OTHER|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
219764355|NCT06863402|DRUG|Nemtabrutinib|Given PO
218833974|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
219015205|NCT03634787|DIAGNOSTIC_TEST|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
219015206|NCT01988142|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
219441226|NCT04616794|BEHAVIORAL|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
219581671|NCT05250648|PROCEDURE|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
219581672|NCT02933268|DIETARY_SUPPLEMENT|High water intake|High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
219581673|NCT02933268|OTHER|Ad libitum water intake|Water intake guided by thirst
218833975|NCT05033886|DRUG|fezolinetant|oral
218833976|NCT05033886|DRUG|placebo|oral
218833977|NCT02569476|DRUG|Zanubrutinib|
218833978|NCT02569476|DRUG|Obinutuzumab|
218833979|NCT01929200|DRUG|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
218833980|NCT01929200|DRUG|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
219015207|NCT06340438|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
219015208|NCT06340438|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
219441227|NCT04616794|BEHAVIORAL|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
219581674|NCT01167322|DRUG|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
219581675|NCT04706286|DRUG|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
219581676|NCT04706286|DRUG|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
219581677|NCT06400134|OTHER|Cognitive Function|The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
219764356|NCT06863402|BIOLOGICAL|Pembrolizumab|Given IV
219764357|NCT06863402|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219764358|NCT06863402|OTHER|Questionnaire Administration|Ancillary studies
219764359|NCT06863961|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
219764360|NCT06863961|DRUG|Placebo|Placebo will be administered as SC injection.
219764361|NCT06863272|DRUG|Docetaxel|Administered via Intravenous (IV) infusion at a specified dose on specified days
219764362|NCT06863272|DRUG|Ifinatamab Deruxtecan|Administered via IV infusion at a specified dose on specified days
219764363|NCT06863272|DRUG|MK-5684|Administered orally at a specified dose on specified days
219764364|NCT06863272|DRUG|Abiraterone|Administered orally at a specified dose on specified days
219581678|NCT06400134|OTHER|Physical Performance|The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).
219581679|NCT06400134|OTHER|Grip Strength|Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.
219581680|NCT06400134|OTHER|Walking speed|Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
219581681|NCT06400134|OTHER|Mobility|The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
219581682|NCT06400134|OTHER|Fraility|Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
219581683|NCT00555386|DIETARY_SUPPLEMENT|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
219581684|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
219581685|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
219581686|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
219764365|NCT06863272|DRUG|Enzalutamide|Administered orally at a specified dose on specified days
218833981|NCT02569346|DRUG|Triumeq|Single-dose Triumeq as a whole tablet
218833982|NCT02569346|DRUG|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
218833983|NCT02569346|DRUG|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
218833984|NCT04301323|DRUG|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
218833985|NCT04301323|DRUG|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
218833986|NCT04301323|DRUG|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
218833987|NCT02042287|DEVICE|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
218833988|NCT02042287|DRUG|Metronidazole|Oral antibiotic
219581687|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
219581688|NCT01160172|DRUG|Saline placebo|intramuscular vaccination according to protocol schedule
218833989|NCT01382914|OTHER|chlorhexidine 0.12%|twice daily, 10 ml, topical
218833990|NCT01410929|PROCEDURE|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
218833991|NCT06059677|DRUG|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
218833992|NCT06059677|DRUG|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
218833993|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
218833994|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
218833995|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
219581689|NCT01293539|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
219581690|NCT03465124|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
219581691|NCT03465124|OTHER|Manual Cataract Surgery|conventional cataract surgery as control
219581692|NCT06318286|DRUG|Lenvatinib|Induction treatment: lenvatinib, 8 mg QD on Day 1 of a 21-day cycle for 4-6 cycles. Maintenance treatment: Lenvatinib, 20 mg QD may be given for up to a total of 35 cycles.
219581693|NCT06318286|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 will be given by intravenous (IV) infusion on Day 1 of a 21-day cycle for 4-6 cycles.
219581694|NCT06318286|DRUG|Cisplatin/Carboplatin|Carboplatin (AUC 5 mg/mL/min) or Cisplatin (75 mg/m2) will be given by IV infusion on Day 1 of a 21-day cycle for 4-6 cycles.
219581695|NCT06318286|DRUG|Pembrolizumab|Pembrolizumab, 200 mg will be given by IV infusion on Day 1 of a 21-day cycle for up to a total of 35 cycles.
219581696|NCT05903014|DRUG|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
219764366|NCT06671054|DRUG|AP1189, 40 mg|AP1189 tablets for oral use
219015209|NCT05648370|GENETIC|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
219363043|NCT06508580|BEHAVIORAL|Component 1: Calorie Goal Attainment|On weeks that participants are randomized to receive this component, they will be provided with feedback on the number of days that they met their calorie goal.
219764367|NCT06671054|DRUG|AP1189, 70 mg|AP1189 tablets for oral use
219764368|NCT06671054|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
219764369|NCT06671054|DRUG|AP1189 matching placebo|AP1189 tablets for oral use
218833996|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
219581697|NCT05903014|BEHAVIORAL|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
219764370|NCT06991556|DRUG|JSB462|JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
218833997|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
218833998|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
218833999|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
218834000|NCT01288170|DRUG|Nebcinal Tobi|
218834001|NCT01288170|DRUG|Tobi Nebcinal|
218834002|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
218834003|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
218834004|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
218834005|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
218834006|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
218834007|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
218834008|NCT02198859|DRUG|Lithium Carbonate|
218834009|NCT00997984|DRUG|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
218834010|NCT00997984|DRUG|placebo|dosed in the AM or PM
218834011|NCT00997984|DRUG|extended-release guanfacine hydrochloride|Dosed in the PM
218834012|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
218834013|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
218834014|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
219015210|NCT04674046|DEVICE|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
218834015|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
218834016|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
218834017|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
218834018|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
218834019|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
219015211|NCT04674046|PROCEDURE|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
219015212|NCT04674046|BEHAVIORAL|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
219581698|NCT00887055|DEVICE|CRT device|
219581699|NCT04441710|OTHER|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
219581700|NCT03074123|DIAGNOSTIC_TEST|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
219764371|NCT06991556|DRUG|Abiraterone|Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
218834020|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
218834021|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
218834022|NCT02261064|OTHER|Japanese meal|
218834023|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
218834024|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
218834025|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
219581701|NCT03429517|DIAGNOSTIC_TEST|Lipogram|liporgram samples
219581702|NCT00866658|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219581703|NCT00866658|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219581704|NCT00866658|DEVICE|Pen auto-injector|
219581705|NCT00866658|DRUG|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
219581706|NCT00866658|DRUG|Basal Insulin|To be continued at a stable dose.
218834026|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
218834027|NCT03132558|DRUG|Radiopaque Media|
218834028|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
219581707|NCT00267449|DEVICE|SoftScan Optical Breast Imaging System|
219581708|NCT06104995|OTHER|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
219581709|NCT06104995|OTHER|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
219581710|NCT04106167|GENETIC|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
219581711|NCT04493866|OTHER|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
219581712|NCT03617757|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
218834029|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
218834030|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
218834031|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
218834032|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
218834033|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
219581713|NCT03617757|DIAGNOSTIC_TEST|HbA1c|2mL blood will be taken for analysis of HbA1c.
219581714|NCT04478630|OTHER|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
219581715|NCT03482700|BEHAVIORAL|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
219581716|NCT03482700|BEHAVIORAL|Control Arm|Usual standard of care
219581717|NCT03547700|DRUG|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
219581718|NCT03547700|DRUG|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
219581719|NCT04540354|DRUG|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
219581720|NCT04540354|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
219764372|NCT06991556|DRUG|Enzalutamide|Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
218834034|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
218834035|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
218834036|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
218834037|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
218834038|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
218834039|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
218834040|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
218834041|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
218834042|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
219581721|NCT00609518|DRUG|pemetrexed|500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
219581722|NCT00609518|DIETARY_SUPPLEMENT|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
219581723|NCT00609518|DIETARY_SUPPLEMENT|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
219581724|NCT00609518|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
219581725|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
219581726|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
219581727|NCT01687478|DRUG|Olanzapine|Administered Orally
218834043|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
218834044|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
218834045|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
219015213|NCT05348382|PROCEDURE|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
219015214|NCT05348382|PROCEDURE|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
219015215|NCT05048121|OTHER|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
219015216|NCT05048121|OTHER|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
219015217|NCT02629341|DIETARY_SUPPLEMENT|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
219015218|NCT02629341|DIETARY_SUPPLEMENT|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
219015219|NCT02990208|BEHAVIORAL|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
219363044|NCT06508580|BEHAVIORAL|Component 2: Diet Quality|On weeks that participants are randomized to receive this component, they will receive three comments regarding specific dietary choices that may impact weight loss success, including reinforcing comments for behaviors consistent with weight loss and potential areas for change.
219363045|NCT06508580|BEHAVIORAL|Component 3: Physical Activity Goal Attainment|On weeks that participants are randomized to receive this component, they will receive feedback related to attainment of that week's physical activity goal.
219581728|NCT01687478|DRUG|Fluoxetine|Administered Orally
218834046|NCT00821158|OTHER|Placebo|Placebo tablet and iv
219581729|NCT01687478|DRUG|Placebo|Administered Orally
219581730|NCT00006267|DRUG|rubitecan|
219581731|NCT05479916|DIETARY_SUPPLEMENT|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
219581732|NCT05479916|DIETARY_SUPPLEMENT|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
219581733|NCT01546935|DRUG|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
219581734|NCT00742066|DRUG|Irbesartan|Single dose 600mg orally
219581735|NCT00742066|DRUG|Felodipine|single dose 10mg Felodipine ER
219581736|NCT00742066|DRUG|Placebo|Single dose tablet orally
219581737|NCT06055530|DIAGNOSTIC_TEST|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
218834047|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
218834048|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
218834049|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
219581738|NCT04120038|DEVICE|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
219015220|NCT02990208|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
219015221|NCT04830527|BEHAVIORAL|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
219015222|NCT04830527|BEHAVIORAL|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
219015223|NCT06353880|OTHER|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
219581739|NCT02382055|BEHAVIORAL|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
219581740|NCT02382055|BEHAVIORAL|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
219581741|NCT02382055|BEHAVIORAL|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
219581742|NCT03544710|OTHER|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
219581743|NCT04641078|DRUG|Darolutamide|600 mg BID
219581744|NCT04641078|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
219764373|NCT06991738|DIAGNOSTIC_TEST|68Ga-DOTA-TATE PET Scan|68Ga-DOTATATE is administered via intravenous injection of 5 1 mCi in a volume of 3 - 5 ml containing up to 50 micrograms \[68Ga\] DOTATATE.
219764374|NCT06991738|OTHER|Amino acid infusions|Appropriate amino acid solutions infused for this purpose should have a total lysine and arginine content between 18g and 25g and have an osmolality of \<= 1050 mOsmol. Concomitant administration of an amino acid infusion with the study drug 177Lu-DOTA-EB-TATE is for renal protection.
219764375|NCT06991738|DRUG|177Lu-DOTA-EB-TATE|Each single-dose vial contains sodium acetate (24.6 mg/mL), gentisic acid (3.7 mg/mL), L-ascorbate (0.445 mg/mL), DTPA (0.051 mg/mL). 177Lu-DOTA-EB-TATE, is a long-acting radiopharmaceutical for PRRT. It consists of a somatostatin analog peptide (TATE) conjugated with a truncated Evans blue (EB) molecule and the metal chelator 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) with the radioisotope 177Lu stably complexed.
219764376|NCT06807593|DRUG|Ustekinumab|Given by infusion
218834050|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
218834051|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
218834052|NCT01236261|OTHER|Non intervention|Non interventional study
218834053|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
218834054|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
219363046|NCT06508580|BEHAVIORAL|Component 4: Goal Setting|On weeks that participants are randomized to receive the goal setting component, they will be asked to complete an open-text prompt encouraging them to set a specific weight-related behavior change goal for the next week.
219581745|NCT02381626|DEVICE|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
219581746|NCT02381626|BEHAVIORAL|questionnaires|
219581747|NCT02381626|OTHER|Log-book|PM and biological measurements
219764377|NCT06997146|BIOLOGICAL|Blood and Urine Sampling|Collection of 10 mL of blood (separated into aliquots for RNA-seq and metabolomic analysis) and 5 mL of urine from participants at various timepoints during sleep and wakefulness. These samples will be used to analyze biomarkers and dysregulated biological pathways related to CCHS.
219441228|NCT04616794|BEHAVIORAL|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
219441229|NCT04616794|BEHAVIORAL|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
219441230|NCT00444418|DRUG|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
219441231|NCT00444418|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
219441232|NCT00444418|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
219441233|NCT02963766|DRUG|Dulaglutide|Administered SC
219441234|NCT02963766|DRUG|Placebo|Administered SC
219441235|NCT05270083|DIAGNOSTIC_TEST|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
219441236|NCT06135454|PROCEDURE|Open Wedge High Tibial Osteotomy|For OWHTO,The osteotomy plane, directed from 30 to 35 mm distal to the medial tibial plateau to 10-15 mm distal to the lateral tibial plateau in the coronal plane, was marked by two Kirschner wires with threaded tips. A transverse osteotomy was performed, leaving the lateral cortex intact as a hinge. After the ascending osteotomy and opening. The medial opening gap was filled with two β-TCP wedges and fixed with a TomoFix anatomical plate and locking screws .
219441237|NCT06135454|PROCEDURE|Double Level Osteotomy|The DLO was started from a lateral DFO. A 5-6-cm incision was made proximally at the distal femur from the lateral femoral epicondyle.Two Kirschner wires with threaded tips were inserted to make a length between the wires that was preoperatively planned as the lateral closed osteotomy. Transverse and ascending osteotomies were performed using a Precision Oscillating Tip Saw. The gap was closed and fixed using a TomoFix medial distal femur anatomical plate , which was bent for the lateral distal femur. The subsequent OWHTO was performed as described above.
219441238|NCT05695404|PROCEDURE|Segmentectomy|Lung resection
219441239|NCT00499460|DIETARY_SUPPLEMENT|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
219441240|NCT00499460|DRUG|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
219441241|NCT00662727|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
219441242|NCT00662727|DEVICE|Placebo|Placebo
219441243|NCT06025084|DRUG|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
219441244|NCT05899894|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
219441245|NCT05268705|OTHER|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
219441246|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
219441247|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
219441248|NCT06507085|RADIATION|Radio-guided interventions to correct heart rhythm disorders|"All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate"
219441249|NCT03082807|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
219441250|NCT03082807|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
219441251|NCT03432572|DRUG|Pyridium|a urine discoloration agent
219581748|NCT02381626|OTHER|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
219441252|NCT03432572|DRUG|Riboflavin|a urine discoloration agent
219441253|NCT03432572|DRUG|Thiamine|active placebo not known to cause urine discoloration
219441254|NCT04339322|OTHER|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
219581749|NCT03126357|OTHER|Product A|Usual Brand Cigarette
219581750|NCT03126357|OTHER|Product B|FT21039 an electronic tobacco vapor product
219581751|NCT03126357|OTHER|Product C|FT21092 an electronic tobacco vapor product
219441255|NCT00546507|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
219441256|NCT00546507|DRUG|celecoxib|
219441257|NCT00546507|OTHER|placebo|
219441258|NCT00814307|DRUG|CP-690,550|5mg CP-690,550 BID PO for 6 months
219581752|NCT03126357|OTHER|Product D|FT21018 an electronic tobacco vapor product
219581753|NCT03126357|OTHER|Product E|4mg nicotine gum
219581754|NCT03324321|OTHER|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
218834055|NCT02092727|BEHAVIORAL|Behavioral Interventions for Dialysis Facilities|"1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video"
218834056|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
218834057|NCT04875494|BEHAVIORAL|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
218834058|NCT04875494|BEHAVIORAL|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
218834059|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
219363954|NCT05869825|PROCEDURE|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
219363955|NCT05869825|PROCEDURE|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
219441259|NCT00814307|DRUG|CP-690,550|10 mg CP-690,550 BID PO for 6 months
219363956|NCT04263831|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
219363957|NCT01251328|PROCEDURE|General anaesthesia|general anaesthesia is performed according to the hospitals standard
219363958|NCT01251328|PROCEDURE|Sedation|Sedation is performed according to the hospitals standard
219363959|NCT00744900|DRUG|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
219363960|NCT00624390|DEVICE|Sepraspray|
219363961|NCT06485219|DRUG|11.2 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
219363962|NCT06485219|DRUG|15 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
219363963|NCT01314950|BEHAVIORAL|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
219363964|NCT01314950|BEHAVIORAL|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
219363965|NCT00954109|BEHAVIORAL|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
219363966|NCT03929887|OTHER|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
219363967|NCT01893398|OTHER|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
219363968|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
219363969|NCT00573001|DRUG|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
219764378|NCT06997146|DEVICE|Polysomnography|Participants will undergo polysomnography to assess sleep patterns and respiratory function during sleep. This will help evaluate any sleep-related breathing abnormalities in patients with CCHS and compare them with healthy controls.
218834060|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
218834061|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
218834062|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
218834063|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
218834064|NCT05600829|BEHAVIORAL|BWLT+CR|Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.
218834065|NCT05600829|BEHAVIORAL|CR-Only|The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
219363970|NCT00573001|DRUG|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
219363971|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
219363972|NCT02532270|DRUG|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
219363973|NCT02153099|DRUG|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
219363974|NCT02153099|DRUG|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
219363975|NCT06127524|DEVICE|SEM Scanner|Implementation of the SEM Scanner as part of weekly standard skin assessments of sacrum and heels
219363976|NCT06264700|BEHAVIORAL|Video Directly Observed Therapy (VDOT)|VDOT is an adherence-promoting intervention that involves partnering with an adolescent with SCD (or caregiver of a young patient with SCD) and observing the patient administer their hydroxyurea. In this study, VDOT will be delivered by a small business partner, Scene Health, via a smart phone app.
219363977|NCT06264700|BEHAVIORAL|Health Reminder Tip Alerts|"Participants randomized to this arm will receive an automated, daily, short health or safety tip alert (e.g. Time to get moving! You should be active for at least 30 minutes each day) to receive during the 180-day intervention period on their smartphone. The daily tip will be unrelated to hydroxyurea adherence. After the 180-day intervention period, participants complete a 180-day ongoing monitoring period where they will no longer receive these messages, but they will be reminded to continue to use their electronic adherence monitoring device. All participants will be offered a smart phone with a data plan at enrollment to ensure equal opportunity for participation."
219363978|NCT02305862|DRUG|Rosuvastatin 5mg|drug intervention
219363979|NCT02305862|DRUG|Rosuvastatin 20mg|drug intervention
219363980|NCT00004001|DRUG|docetaxel|
219363981|NCT00004001|DRUG|estramustine|
219363982|NCT00004001|DRUG|mitoxantrone|
219363983|NCT00004001|DRUG|prednisone|
219363984|NCT01677715|DIETARY_SUPPLEMENT|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
219363985|NCT01677715|DIETARY_SUPPLEMENT|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
219363986|NCT01910714|BEHAVIORAL|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
219363987|NCT01910714|BEHAVIORAL|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
219363988|NCT01445678|DRUG|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
219764379|NCT06997146|OTHER|lung function tests|spirometry, ventilatory response to CO2
218834066|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
219441260|NCT00814307|DRUG|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
219015224|NCT05681585|OTHER|Implementation support program|"The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels"
219441261|NCT00814307|DRUG|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
219441262|NCT06067932|RADIATION|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
219441263|NCT06067932|DIAGNOSTIC_TEST|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
218834067|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
218834068|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
218834069|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
218834070|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
218834071|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
218834072|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
218834073|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
218834074|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
218834075|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
218834076|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
218834077|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
218834078|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
218834079|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
218834080|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
218834081|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
218834082|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
218834083|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
218834084|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
218834085|NCT04762836|DRUG|Placebo|Placebo control in oral form
219441264|NCT04628273|PROCEDURE|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
219441265|NCT01525524|DEVICE|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
219441266|NCT02210455|BEHAVIORAL|Strongest Families FASD intervention|
219441267|NCT02210455|OTHER|Psychoeducation|
219441268|NCT04459923|PROCEDURE|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
219441269|NCT04459923|PROCEDURE|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
219441270|NCT03871465|DRUG|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
219441271|NCT03871465|PROCEDURE|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
219475558|NCT04594772|DRUG|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
218859807|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
219015225|NCT01730157|BIOLOGICAL|ipilimumab|Given IV
219015226|NCT01730157|RADIATION|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
219015227|NCT01730157|OTHER|laboratory biomarker analysis|Correlative studies
219015228|NCT00075140|GENETIC|Mutation in the gene|
219015229|NCT00009854|DRUG|carmustine in ethanol|
219015230|NCT00009854|PROCEDURE|conventional surgery|
219015231|NCT01375907|DRUG|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
219015232|NCT00778700|OTHER|Placebo Cream|Cream with no active drug
219015233|NCT00778700|DRUG|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
219441272|NCT03871465|DRUG|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
219441273|NCT04509362|DEVICE|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
219441274|NCT05448508|DEVICE|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
219441275|NCT04313088|DRUG|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
219441276|NCT05625633|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
219441277|NCT05625633|OTHER|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
219441278|NCT02740218|OTHER|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
219441279|NCT05337150|BEHAVIORAL|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
219441280|NCT05337150|BEHAVIORAL|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
219441281|NCT05337150|BEHAVIORAL|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
219441282|NCT00002657|BIOLOGICAL|bleomycin sulfate|5 mg/m\^2
219441283|NCT00002657|BIOLOGICAL|recombinant interferon alfa|3.0 x 10\^6 IU/m\^2
219441284|NCT00002657|DRUG|cyclophosphamide|650 mg/m\^2
219441285|NCT00002657|DRUG|cytarabine|300 mg/m\^2
219441286|NCT00002657|DRUG|doxorubicin hydrochloride|25 mg/m\^2
219441287|NCT00002657|DRUG|etoposide|120 mg/m\^2
219441288|NCT00002657|DRUG|methotrexate|120 mg/m\^2
219441289|NCT00002657|DRUG|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
218859808|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
218859809|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
218859810|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
219015234|NCT03895281|DIAGNOSTIC_TEST|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
219015235|NCT00816075|DRUG|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
219015236|NCT04152720|DEVICE|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
219581755|NCT05052242|DIAGNOSTIC_TEST|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
218859811|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
219015237|NCT03716921|OTHER|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
219015238|NCT04933942|DRUG|Lomustine|Oral administration of Lomustine
219015239|NCT04933942|DRUG|Romiplostim|Subcutaneous administration of Romiplostim
219441290|NCT00002657|DRUG|vincristine sulfate|1.4 mg/m\^2
219581756|NCT00292188|DRUG|pregabalin|pregabalin
218859812|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
218859813|NCT02403895|DRUG|paclitaxel|Taxane
218859814|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
218859815|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
219441291|NCT00002657|PROCEDURE|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
219441292|NCT00002657|RADIATION|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
219441293|NCT02290340|DRUG|Placebo|Participants will receive placebo intramuscularly.
219441294|NCT02290340|DRUG|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
219441295|NCT02290340|DRUG|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
219441296|NCT02290340|DRUG|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
219441297|NCT06099353|BEHAVIORAL|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
219441298|NCT06099353|BEHAVIORAL|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
219441299|NCT06099353|BEHAVIORAL|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
219441300|NCT00118469|BEHAVIORAL|Psychoeducation|
219441301|NCT00118469|BEHAVIORAL|Cognitive behavior therapy|
219441302|NCT05463159|OTHER|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
219441303|NCT05797363|OTHER|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
219441304|NCT00264667|DRUG|GW677954|
219441305|NCT06326671|DRUG|Tiotropium Bromide Inhalation Powder|It's a generic product of Spiriva HandiHaler.
219441306|NCT06326671|DRUG|Spiriva HandiHaler|Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
219441307|NCT03046043|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
219441308|NCT03046043|PROCEDURE|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
219581757|NCT00292188|DRUG|Placebo|placebo
219581758|NCT00824616|DRUG|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
218859816|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
218859817|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
218859818|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
218859819|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
218859820|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
218859821|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
218859822|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
218859823|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
218859824|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
218859825|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
218859826|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
218834086|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
218859827|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
218859828|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
219196166|NCT06813482|BEHAVIORAL|Digitally enabled cardiac rehabilitation|"The intervention consists of an 8-week remotely delivered cardiac rehabilitation program. It includes an initial assessment during week 1, six weeks of participation in a digitally enabled cardiac rehabilitation (DeCR) program (weeks 2-7), and a final assessment in week 8. Participants will utilize a digital mobile application and receive weekly telehealth consultations with a cardiac nurse. The program is designed to facilitate behavior change and improve outcomes through the following modalities:~1. Telehealth - individualized coaching delivered via telephone by a cardiac nurse, to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~2. Mobile application (called SmartCR) and nurse web portal - for remote monitoring and personalized care planning. The app monitors health and physical activity, has prompted tasks and delivers education via video, audio and written articles."
219196167|NCT06813482|BEHAVIORAL|F2F-CR|Traditional Face-to-face cardiac rehabilitation
219581759|NCT00824616|DRUG|Placebo|Placebo tablets, taken 3 times daily.
219581760|NCT00824616|DRUG|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
219764380|NCT06999642|DIETARY_SUPPLEMENT|GI Health Placebo Control|Participants will use their GI Health Placebo Control as directed for a period of 6 weeks.
218859829|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
218859830|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
218859831|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
218859832|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
218859833|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
218859834|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
218859835|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
218859836|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
218859837|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
218859838|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
218859839|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
218859840|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
218859841|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
218859842|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
218859843|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
218859844|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
218859845|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
218859846|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
218859847|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
218859848|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
218859849|NCT00000224|DRUG|Buprenorphine|
218859850|NCT00236496|DRUG|topiramate|
218859851|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
218859852|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
219441309|NCT02693236|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
219441310|NCT05366257|OTHER|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
219441311|NCT05366257|OTHER|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
218834087|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
218834088|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
218834089|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
218834090|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
218834091|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
218834092|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
218834093|NCT04861272|BEHAVIORAL|Survey|Online survey
218834094|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
218834095|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
218834096|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
218834097|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
218834098|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
218834099|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
218834100|NCT03448016|RADIATION|[C-11]|Radiolabel
218834101|NCT03448016|DRUG|NOP-1A|Tracer
219441312|NCT03942237|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
219441313|NCT03942237|PROCEDURE|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
219441314|NCT02509676|OTHER|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
219441315|NCT04213183|DIAGNOSTIC_TEST|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
219441316|NCT02861053|OTHER|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
219441317|NCT02861053|OTHER|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
219441318|NCT03307018|PROCEDURE|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
219441319|NCT01594749|DRUG|Fosaprepitant dimeglumine|
219441320|NCT01594749|DRUG|Fosaprepitant Placebo|
219441321|NCT01594749|DRUG|Dexamethasone|
219441322|NCT01594749|DRUG|Ondansetron|
219441323|NCT01594749|DRUG|Dexamethasone Placebo|
219441324|NCT01594749|DRUG|Ondansetron Placebo|
219441325|NCT01594749|DRUG|Rescue Therapy|
219441326|NCT04602013|DRUG|Sintilimab|Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
218834102|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
218834103|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
218834104|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
218834105|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
219015240|NCT05153044|OTHER|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
219015241|NCT02573727|DRUG|Nor adrenaline + albumin|
218834106|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
219015242|NCT02573727|DRUG|Terlipressin + albumin|
219015243|NCT03863223|DRUG|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
219015244|NCT03863223|DRUG|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
219015245|NCT01230801|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
219015246|NCT00789451|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
219015247|NCT01494480|PROCEDURE|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
219015248|NCT03375801|OTHER|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
219015249|NCT05826886|BEHAVIORAL|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
219015250|NCT03241355|DIETARY_SUPPLEMENT|prebiotic inulin-type fructan|
219015251|NCT03241355|DIETARY_SUPPLEMENT|Placebo maltodextrin|
219015252|NCT05317533|PROCEDURE|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
219441327|NCT04602013|DRUG|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
219015253|NCT02962804|DRUG|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
219015254|NCT02962804|RADIATION|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
219015255|NCT05969288|OTHER|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
219581761|NCT00665938|OTHER|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
218834107|NCT00187538|BEHAVIORAL|Dietary|dietary
218834108|NCT01979718|DEVICE|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
218834109|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
218834110|NCT04032925|DEVICE|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
219015256|NCT05342259|PROCEDURE|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
219196168|NCT06813482|BEHAVIORAL|Usual Care Group|Usual Care - eligible for cardiac rehabilitation and who unlikely participated in any formal cardiac rehabilitation program
219441328|NCT04602013|RADIATION|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
219441329|NCT01508793|BEHAVIORAL|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
219581762|NCT00206492|DRUG|Iressa|Iressa
219015257|NCT05342259|PROCEDURE|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
219015258|NCT05342259|PROCEDURE|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
219015259|NCT05070065|DEVICE|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
219015260|NCT00003010|DRUG|marimastat|
219015261|NCT04267133|DIAGNOSTIC_TEST|Facial video of detection of cardiac disease|This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
219015262|NCT02282670|DRUG|DA-5204|
219015263|NCT02282670|DRUG|Stillen tab.|
219015264|NCT04067557|DIAGNOSTIC_TEST|molecuar test of BV|diagnosis of BV
219196169|NCT06815380|OTHER|No Intervention|This is non-interventional study.
219196170|NCT06814457|PROCEDURE|a nursing care bundle on oral intake|a nursing care bundle on oral intake will be started the day after their successful extubation and extend for 14th days. Additionally, the participants will be provided with a brief education on safe swallowing.
219764381|NCT06999642|DIETARY_SUPPLEMENT|GI Health Active Product|Participants will use their GI Health Active Product as directed for a period of 6 weeks.
219015265|NCT05700981|DIAGNOSTIC_TEST|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
219015266|NCT06413797|BEHAVIORAL|FDA warnings + Image|For six days (days 2-7) participants will be contacted and asked to complete a daily survey. As part of the survey, participants will view FDA-proposed LCC warnings with images at 30% size on a cigarillo package. Participants will be contacted each day to be invited to complete the survey for that day of the study protocol.
219015267|NCT06413797|BEHAVIORAL|FDA Warnings Text-Only|Participants will receive messages including images in 30% size.
219196171|NCT06842394|OTHER|Adaptive E-learning|An adaptive e-learning program comprising 13 modules each unfolding and testing the learners knowledge and ability to assess own competence regarding specific acute and time critical medical patient conditions.
219196172|NCT06841848|DIAGNOSTIC_TEST|Fundoscopic Exam|visualization of the retina using an ophthalmoscope
219363989|NCT01445678|DRUG|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
219363990|NCT04934787|DEVICE|ENMS-BSF assisted gait training|"1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
219363991|NCT02721537|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Three capsules, twice per day for 84 days
219363992|NCT02721537|OTHER|Matching placebo|Three matching capsules, twice per day for 84 days
219363993|NCT01318330|DRUG|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
219363994|NCT04299295|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
219363995|NCT04299295|DEVICE|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
219363996|NCT01393197|OTHER|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
219363997|NCT00317525|DEVICE|Spectacle Lenses|
219363998|NCT01845038|DRUG|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
219363999|NCT01845038|DRUG|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
219364000|NCT01845038|DRUG|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
219364001|NCT04003688|DRUG|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
219364002|NCT04003688|DRUG|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
219364003|NCT04003688|DRUG|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
219364004|NCT02307370|DEVICE|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
219364005|NCT01744132|BEHAVIORAL|Aim 3: Contract|
219364006|NCT06176157|DIETARY_SUPPLEMENT|vitamin D2, vitamin D3|comparing parentral D2, D3, to oral D2, D3
219364007|NCT05821140|PROCEDURE|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
219364008|NCT05821140|OTHER|oral health check up|regular preventive follow-up visit (every 6 months)
219364009|NCT02482584|DEVICE|CPAP|CPAP intervention
219364010|NCT02482584|OTHER|Control|Control
219364011|NCT02667080|OTHER|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
218834111|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
218834112|NCT05144672|OTHER|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
219441330|NCT03401216|DEVICE|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
219764382|NCT07000149|DRUG|Volrustomig|Volrustomig will be administered as an intravenous (IV) infusion.
218834113|NCT05144672|PROCEDURE|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
218834114|NCT05144672|OTHER|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
218834115|NCT05144672|OTHER|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
218834116|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
218834117|NCT05144672|RADIATION|Abdominal ultrasound.|It will be performed for patients only.
218834118|NCT05707338|PROCEDURE|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
218834119|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
218834120|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
218834121|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
218834122|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
218834123|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
218834124|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
218834125|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
218834126|NCT00183144|BEHAVIORAL|Contingency management|
218834127|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
218834128|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
218834129|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
218834130|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
218834131|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
219364012|NCT02667080|OTHER|2 hours of sexual abstinence|2 hours of sexual abstinence
219764383|NCT07000149|DRUG|Casdatifan|Casdatifan will be administered orally.
219764384|NCT07000149|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion.
218834132|NCT01689987|DRUG|Cyclophosphamide|Given IV
218834133|NCT01689987|DRUG|Dexamethasone|Given PO
218834134|NCT01689987|DRUG|Hydroxychloroquine|Given PO
218834135|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
219364013|NCT00004156|BIOLOGICAL|MUC1-KLH vaccine/QS21|
219364014|NCT02878980|BEHAVIORAL|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
219364015|NCT02878980|OTHER|Laboratory Biomarker Analysis|Correlative studies
219364016|NCT02878980|OTHER|Quality-of-Life Assessment|Ancillary studies
219364017|NCT02878980|OTHER|Questionnaire Administration|Ancillary studies
219364018|NCT00054977|DRUG|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
219364019|NCT00054977|DRUG|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
219364020|NCT00004260|BIOLOGICAL|recombinant interleukin-12|
219364021|NCT00004260|BIOLOGICAL|rituximab|
219364022|NCT06917170|BEHAVIORAL|Structured Music Therapy Program|"Description:~Content: Participants engage in passive music therapy sessions where they listen to pre-selected music with smooth rhythms and harmonies (e.g., classical, ambient, or instrumental tracks). The music is chosen to align with evidence-based criteria for promoting relaxation and emotional regulation.~Frequency: Daily (1 session/day).~Duration: 1 hour per session, for a total of 14 sessions over 2 weeks.~Setting: Conducted in a quiet, controlled environment to minimize external distractions.~Goal: To reduce symptoms of psychological distress (depression, anxiety, stress) and enhance self-efficacy through auditory stimulation and emotional engagement."
219364023|NCT06915532|BEHAVIORAL|Pain Neurophysiology Education|"The program used for PNE was based on a brochure written in the Tunisian dialect with simple, patient-accessible language. The brochure includes different sections: definition of pain, origin of pain, types of pain, components of pain, role of nervous system in pain modulation and pain management. Thus, all main concepts of the neurophysiology of pain were explained and discussed using visual presentation.~At the end of the sessions, a test was provided to the patient to assess their understanding of the brochure's content.~At the follow-up session a month later, the main ideas taught were reinforced and any questions were answered."
219581763|NCT00206492|DRUG|Tamoxifen|Tamoxifen
219581764|NCT04449757|DRUG|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
219015268|NCT06413797|BEHAVIORAL|Surgeon General Text-Only Warnings|Participants will receive messages including Surgeon General Text-only Warnings.
219015269|NCT03348345|BEHAVIORAL|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
219015270|NCT02913547|DEVICE|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
219015271|NCT03914040|OTHER|IPSE program|"1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
219015272|NCT02773927|DRUG|Metformin|Metformin in tablet presentation of 500 mg
219015273|NCT02773927|DIETARY_SUPPLEMENT|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
219196173|NCT06812962|OTHER|Online quiz competition|The intervention and control students participated in an online quiz game on tobacco and healthy eating topics, respectively. Each day, students could answer a maximum of 5 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 4 weeks (i.e. total of 20 days).
219196174|NCT06811025|DRUG|Contezolid|Contezolid 800mg once daily (QD) for 7 days;
219196175|NCT06811025|DRUG|Linezolid (LZD)|Linezolid 600mg once daily (QD) for 7 days.
219196176|NCT06813768|DEVICE|Microfractured adipose tissue injection and plug placement|surgery + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice and placement of a biological prosthesis
219196177|NCT06814808|OTHER|Conventional Therapy|All three groups will receive a conventional physiotherapy program (TENS, therapeutic ultrasound, hot pack) 5 times a week for 4 weeks and the same exercise program 3 days a week for 4 weeks.
219196178|NCT06814808|OTHER|Ischemic Compression Group|The ischemic compression group will receive ischemic compression therapy for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
219441331|NCT03401216|PROCEDURE|PCI|Standard PCI procedure
219581765|NCT04449757|DRUG|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
219581766|NCT01714375|DEVICE|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
219581767|NCT03762499|DIAGNOSTIC_TEST|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
219764385|NCT07000149|DRUG|Ipilimumab|Ipilimumab will be administered as an IV infusion.
219196179|NCT06814808|OTHER|Strain-Counter Strain|The strain counterstrain technique will be applied to the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
219441332|NCT03401216|PROCEDURE|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
219441333|NCT03401216|PROCEDURE|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
219441334|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
219441335|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
219764386|NCT06998134|DEVICE|Extension assist knee ankle foot orthosis (EA-KAFO)|A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion).
219764387|NCT06999655|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
219764388|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
219764389|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
219196180|NCT06814808|OTHER|Integrated Neuromuscular Inhibition Technique (INIT)|This group will be subjected to INIT for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles, 3 sessions per week for 4 weeks (12 sessions in total).
219196181|NCT06842810|DIAGNOSTIC_TEST|Serum FGF21 measurement by Enzyme- linked immunosorbent assay (ELISA)|Venous 5 ml blood will be collected, then centrifugation at the speed of 2000-3000 rpm for 20-min., supernatant will be collected and stored at -20°C for later analysis then tha sample will be tested for fibroblast growth factor 21
219196182|NCT06106529|DRUG|Oxybutynin|Oxybutynin 5 mg twice per day for 6 weeks
218834136|NCT01689987|OTHER|Pharmacological Study|Correlative studies
218834137|NCT01689987|DRUG|Sirolimus|Given PO
218834138|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
218834139|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
218859853|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
218859854|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
218859855|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
218859856|NCT02088502|DRUG|N-acetylcysteine|
218859857|NCT02088502|DRUG|Theophylline|
218859858|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
219015274|NCT02773927|OTHER|Placebo of agave inulin|Calcinated magnesia powder
219441336|NCT02177786|DRUG|Selonsertib|Tablets administered orally once daily
219441337|NCT02177786|DRUG|Placebo to match selonsertib|Tablets administered orally once daily
219441338|NCT02055729|BIOLOGICAL|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
219441339|NCT02055729|BIOLOGICAL|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
218859859|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
218859860|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
219441340|NCT02055729|BIOLOGICAL|Stool sample|Stool samples will be collected on days 0 and 28.
219441341|NCT02055729|BIOLOGICAL|Urine sample|Urine samples will be collected on days 0 and 28.
219441342|NCT01074840|OTHER|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
219441343|NCT01402323|OTHER|time point of tooth extraction|
219441344|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
219441345|NCT00439309|DEVICE|VascuSeal|VascuSeal
219441346|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
219441347|NCT02453139|BEHAVIORAL|Exercise|6 month supervised and home based aerobic exercise intervention
219441348|NCT02233491|BEHAVIORAL|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
219441349|NCT02233491|OTHER|Control|No additional support other than lifestyle advice by clinician
219441350|NCT03857477|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
219441351|NCT03857477|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
219441352|NCT03857477|PROCEDURE|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
219441353|NCT03857477|PROCEDURE|Prostate biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
219441354|NCT04594668|DRUG|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
219441355|NCT00148525|BEHAVIORAL|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
219441356|NCT00148525|BEHAVIORAL|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
219441357|NCT03167125|OTHER|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
219441358|NCT03167125|OTHER|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
219441359|NCT05045105|OTHER|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
219015275|NCT02773927|OTHER|Metformin placebo|Calcinated magnesia tablet
219015276|NCT06245291|DRUG|Imdusiran|subcutaneous injection
219015277|NCT06245291|DRUG|Durvalumab|intravenous injection
219015278|NCT05435079|DEVICE|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
219196183|NCT06106529|DRUG|Venlafaxine|Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
219196184|NCT02542631|DEVICE|Bolus Insulin Patch (Calibra Finesse)|
218834140|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
218834141|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
218834142|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
218834143|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
218834144|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
218834145|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
218834146|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
218834147|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
218834148|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
218834149|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
218834150|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
218834151|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
219196185|NCT02542631|DEVICE|Insulin Pen (Novo-Nordisk FlexPen®)|
219441360|NCT04116190|BEHAVIORAL|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
219441361|NCT04116190|BEHAVIORAL|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
219441362|NCT00205946|DRUG|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
218834156|NCT05104866|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
218834157|NCT05104866|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
218834158|NCT05104866|DRUG|Gemcitabine|IV Infusion. Active comparator
218834159|NCT05104866|DRUG|Eribulin|IV Infusion. Active comparator
219441363|NCT00205946|DRUG|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
219441364|NCT05524558|DEVICE|Pulmonary artery catheter|PAC already in place
218834160|NCT05104866|DRUG|Vinorelbine|IV Infusion. Active comparator
218834161|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
218834162|NCT01010672|DRUG|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
218834163|NCT04201639|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
218834164|NCT01718158|BIOLOGICAL|Peginterferon Lambda-1a|
218834165|NCT01718158|BIOLOGICAL|Peginterferon Alfa-2a|
218834166|NCT01718158|DRUG|Ribavirin|
218834167|NCT01718158|DRUG|Daclatasvir|
218834168|NCT01718158|DRUG|Telaprevir|
219441365|NCT05524558|DEVICE|Esophagal pressure|Esophagal pressure already in place
219441366|NCT01604434|PROCEDURE|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
219441367|NCT01604434|PROCEDURE|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
219441368|NCT02111629|DRUG|Fluconazole and Secnidazole|
219441369|NCT02652546|DRUG|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
218834169|NCT04335448|OTHER|No intervention is planed|No intervention is planed
219441370|NCT02652546|DRUG|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
219441371|NCT02652546|DRUG|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
218834170|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
218834171|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
218834172|NCT03228784|PROCEDURE|LASIK|
218834173|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
218834174|NCT02214901|DRUG|BIBW 2948 BS for oral inhalation|
218834175|NCT02214901|DRUG|Placebo|
218834176|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
219441372|NCT02652546|DRUG|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
219441373|NCT03634293|DRUG|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
219441374|NCT03634293|DRUG|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
219441375|NCT04835688|PROCEDURE|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
218834177|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
218834178|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
218834179|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
218859861|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
218859862|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
218859863|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
218859864|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
218859865|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
218859866|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
218859867|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
218859868|NCT02961790|OTHER|Placebo|Given PO
219441376|NCT04835688|PROCEDURE|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
219441377|NCT02027272|DRUG|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
219441378|NCT04987424|DIAGNOSTIC_TEST|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
219441379|NCT00064623|DRUG|Capsaicin Dermal Patch|
219441380|NCT06356415|DRUG|Bupivacaine injection|Group one will receive infraclavicular block using bupivacaine
219441381|NCT06356415|DRUG|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
219441382|NCT01643304|BEHAVIORAL|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
219441383|NCT01936597|OTHER|Therapeutic and preventive strategies|Single set (control Arm)
219441384|NCT01936597|OTHER|Therapeutic and preventive strategies|Controller
219441385|NCT01936597|OTHER|Therapeutic and preventive strategies|Audio
219441386|NCT00096824|BEHAVIORAL|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
219441387|NCT04036513|PROCEDURE|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
219441388|NCT04036513|PROCEDURE|Conventional SRP|Scaling and root planing with conventional instruments.
219581768|NCT05476653|OTHER|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
218834180|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
218834181|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
218834182|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
218834183|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
218834184|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
218834185|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
218834186|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
219015279|NCT06508593|DIAGNOSTIC_TEST|Serum metabolic profile|Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques
219015280|NCT05171283|OTHER|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
219441389|NCT01780324|DRUG|Lidocaine|Intervention - intraurethral lidocaine
218834187|NCT02013349|DEVICE|coronary intervention|
218834188|NCT00981162|DRUG|sorafenib tosylate|Given PO
218834189|NCT00981162|DRUG|everolimus|Given PO
219015281|NCT00939276|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
219441390|NCT04574674|BEHAVIORAL|Flexibility exercise programme|Static passive flexibility exercises.
219441391|NCT04574674|BEHAVIORAL|Resistance exercise programme|Body weight and resistance bands exercises.
219441392|NCT04026646|PROCEDURE|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
219441393|NCT04026646|PROCEDURE|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
219581769|NCT04322149|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
219581770|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
218834190|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
218834191|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
218834192|NCT00981162|OTHER|pharmacological study|Correlative study
218834193|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
218834194|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
218834195|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
218834196|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
218834197|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
218834198|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
218834199|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
219015282|NCT00939276|DRUG|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
219015283|NCT00372931|DRUG|AL-37807|
219581771|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
219581772|NCT00676325|PROCEDURE|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
219581773|NCT00676325|DEVICE|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
219581774|NCT00676325|PROCEDURE|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
219581775|NCT03040557|DEVICE|Flexible footwear|\- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
219581776|NCT03040557|DEVICE|Orthopedic insole|\- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
219581777|NCT06221267|DRUG|Rimegepant|No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.
219581778|NCT04283201|OTHER|Physical activity|Moderate activity 150 min per week
219581779|NCT04283201|OTHER|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
219581780|NCT06209411|BEHAVIORAL|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
219581781|NCT06209411|BEHAVIORAL|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
219581782|NCT01276301|DRUG|Verapamil|single dose verapamil
219581783|NCT01276301|DRUG|BI 10773|single dose BI 10773
219581784|NCT01276301|DRUG|BI 10773|single dose BI 10773
219581785|NCT03550001|PROCEDURE|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
218834200|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
218834201|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
218834202|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
218859869|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
219581786|NCT00798148|DRUG|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
219581787|NCT01700049|DRUG|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
219581788|NCT03659526|DIAGNOSTIC_TEST|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
219581789|NCT05909930|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 6 months at home, with a frequency of 1-3 sessions per week at the hospital.
219581790|NCT05909930|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
219581791|NCT00850434|DEVICE|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
219581792|NCT00850434|DEVICE|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
219581793|NCT03534843|PROCEDURE|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
218859870|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
218859871|NCT02387125|BIOLOGICAL|CMB305|
218859872|NCT02387125|BIOLOGICAL|G100|
218859873|NCT02387125|DRUG|Metronomic CPA|
218859874|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
218859875|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
218859876|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
218859877|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
218859878|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
218834203|NCT04554732|DRUG|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
218834204|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
219581794|NCT03534843|OTHER|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
219581795|NCT05394311|OTHER|sports based mental health promotion program|sports related programs
219581796|NCT05189886|PROCEDURE|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
219581797|NCT06251492|RADIATION|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
219581798|NCT06251492|DRUG|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
219015284|NCT01354847|DEVICE|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
219015285|NCT00343200|DRUG|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
219441394|NCT04447625|DRUG|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
219581799|NCT00871273|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
219581800|NCT01206101|DRUG|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
219581801|NCT01206101|DRUG|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
219581802|NCT01906892|OTHER|Group drumming (participatory)|Active participation in group drumming workshops
219581803|NCT01906892|OTHER|Group drumming (live)|Listening to live performances of group drumming
219581804|NCT01906892|OTHER|Group drumming (recorded)|Listening to recorded performances of group drumming
219581805|NCT01906892|OTHER|Comparative activity|Taking part in a literary-based activity
219581806|NCT06633068|DRUG|Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block|Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
219015286|NCT00343200|DRUG|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
219015287|NCT03667560|PROCEDURE|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
219015288|NCT03667560|PROCEDURE|FlexHD|Patient will be implanted with FlexHD.
219441395|NCT04447625|DRUG|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
219441396|NCT04037462|DRUG|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
219441397|NCT05519124|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
219581807|NCT01258712|DRUG|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
219581808|NCT01258712|DRUG|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
219581809|NCT00037024|PROCEDURE|fatigue assessment and management|
219581810|NCT00037024|PROCEDURE|nutritional support|
219581811|NCT00037024|PROCEDURE|physical therapy|
219581812|NCT00037024|PROCEDURE|psychosocial assessment and care|
219581813|NCT00037024|PROCEDURE|quality-of-life assessment|
218834205|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
218834206|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
218834207|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
219581814|NCT01248013|BEHAVIORAL|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
219581815|NCT04653272|OTHER|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
219581816|NCT03328195|DEVICE|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
219581817|NCT03328195|DEVICE|Sham|Twenty minutes, six days per week for 12 weeks with sham device
219581818|NCT03328195|DEVICE|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
219581819|NCT06102681|OTHER|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
219581820|NCT02154295|DEVICE|Infraredx Test Catheter|
219581821|NCT05834530|OTHER|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer\* that relies on SLA technology and post cured by post curing unit.
219581822|NCT01859130|DEVICE|Zimmer Persona Total Knee System|
219581823|NCT02468622|OTHER|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
219581824|NCT06632249|OTHER|Practice with the virtual reality game|4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
219581825|NCT05530343|DIAGNOSTIC_TEST|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
219581826|NCT05530343|DIAGNOSTIC_TEST|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
219581827|NCT03426137|DRUG|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
219581828|NCT03426137|DRUG|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
219581829|NCT03426137|OTHER|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
218834208|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
219015289|NCT05009940|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
219015290|NCT02350881|DEVICE|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
219581830|NCT04604743|BEHAVIORAL|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
219581831|NCT00709436|DRUG|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
219581832|NCT00709436|DRUG|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
219581833|NCT02631018|BEHAVIORAL|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
219581834|NCT02631018|BEHAVIORAL|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
219581835|NCT03976583|DRUG|Cpp-Acp|Remineralising agent
219581836|NCT03976583|OTHER|Pearl powder|Natural product
219581837|NCT02746471|DEVICE|Reveal LINQ|
219581838|NCT03868462|DEVICE|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
219581839|NCT03868462|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
219581840|NCT00784186|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
219581841|NCT00784186|DRUG|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
219581842|NCT00784186|DRUG|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
219581843|NCT04701515|OTHER|Chart review|Chart review
218834209|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
218834210|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
218834211|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
218834212|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
219581844|NCT04596228|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
219581845|NCT04781101|OTHER|conventional therapy|Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
219581846|NCT04781101|OTHER|RoboGait®|The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
218834213|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
219581847|NCT02218125|BIOLOGICAL|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
219581848|NCT02218125|BIOLOGICAL|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
219581849|NCT00244530|DRUG|Nifedipine|
219581850|NCT00595686|DRUG|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
219581851|NCT04870138|DRUG|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
218834214|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
218834215|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
219581852|NCT04870138|DRUG|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
219581853|NCT04870138|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
219581854|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
219581855|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
219581856|NCT06445634|OTHER|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
219581857|NCT02564419|DEVICE|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
219581858|NCT03559621|BEHAVIORAL|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
219581859|NCT00208806|OTHER|congestive heart failure patients|observational echo data on congestive heart failure patients
218834216|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
218834217|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
218834218|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
218834219|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
218834220|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
218834221|NCT01130909|DRUG|AZD6765|75 mg
218834222|NCT01130909|DRUG|AZD6765|150 mg
218834223|NCT01130909|DRUG|Ketamine|0.5 mg/kg
218834224|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
219581860|NCT00798187|BEHAVIORAL|Group Meetings|10 weekly group meetings lasting 2 hours.
219581861|NCT00798187|BEHAVIORAL|Questionnaire|Surveys
219015291|NCT04516590|OTHER||There was no intervention in this observational study
219015292|NCT05350033|DEVICE|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
219015293|NCT05350033|DEVICE|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
219015294|NCT05350033|DEVICE|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
219015295|NCT05350033|DEVICE|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
219015296|NCT06058767|DIAGNOSTIC_TEST|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
219015297|NCT06058767|DIAGNOSTIC_TEST|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
219015298|NCT05338892|OTHER|Non-Interventional|No study treatment will be administered on this study.
219441398|NCT02945943|OTHER|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
219441399|NCT02945943|OTHER|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
219015299|NCT01631877|DRUG|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
219441400|NCT00634751|DRUG|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
219015300|NCT01631877|OTHER|placebo|injection placebo will be given for 5 days along with placebo tablets
219015301|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
219015302|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
219441401|NCT00634751|DRUG|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
219475559|NCT04594772|DRUG|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
219475560|NCT04594772|RADIATION|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
219475561|NCT04594772|PROCEDURE|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
219475563|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
219475564|NCT04785287|BIOLOGICAL|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
219015303|NCT01900327|RADIATION|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
219015304|NCT01900327|DRUG|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
219015305|NCT01900327|PROCEDURE|Surgery|Upfront pancreato-duodenectomy
219015306|NCT01900327|DRUG|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
219015307|NCT00775970|BEHAVIORAL|walking activity|
219015308|NCT04730830|OTHER|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
219015309|NCT00006337|DRUG|KW-6002|
219015310|NCT00006337|DRUG|IV Levodopa|
219475565|NCT04785287|BIOLOGICAL|Nivolumab|Given IV
219441402|NCT00634751|DRUG|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
219441403|NCT01962116|DRUG|Citrate 4%|
219441404|NCT01962116|DRUG|unfractionated heparin|
219441405|NCT00189436|DRUG|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
219441406|NCT00189436|DRUG|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
219441407|NCT04469556|DRUG|Folfirinox|Chemotherapy
218834225|NCT01941654|RADIATION|preemptive local ablative therapy|
219441408|NCT04469556|DRUG|Gemcitabine/nab-paclitaxel|Chemotherapy
218834226|NCT01941654|DRUG|Oral TKI|
218834227|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
219441409|NCT04017624|OTHER|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
219441410|NCT04017624|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
219475566|NCT04785287|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218834228|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
218834229|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
219475567|NCT04214548|OTHER|No Intervention|There is no intervention for this study
219475568|NCT06770049|BEHAVIORAL|Standard Lifestyle Intervention (SLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts in a 12-month structured follow up. Participants will meet with a registered dietician as well as member of the study team to learn more about their intervention. Diets will be prescribed for each participant with a 30% calorie deficit calculated from measured REE. Macronutrient composition will be guided based on the patient preference. Participants will be prescribed 150 minutes of physical activity per week (spread across 4-5 days) and recommendations to reach 10,000 steps daily. During the first 12 weeks, participants will be scheduled a 12-week behavioral program focusing on self-monitoring and stimulus control using cognitive-behavioral approaches to promote adherence to diet and exercise prescriptions.
219475569|NCT06770049|BEHAVIORAL|Phenotype-tailored Lifestyle Intervention (PLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts. The recommendations will be determined a priori to tailor for each obesity phenotype
219475570|NCT04810377|PROCEDURE|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
219475571|NCT05637879|DRUG|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
219475572|NCT05637879|OTHER|Placebo|Compounded, inactive pill equal in appearance to active study drug
219475573|NCT06806865|PROCEDURE|Periarticular nerve group block (PENG)|The pericapsular nerve group (PENG) block targets the nerves that supply the hip capsule. The continuous PENG block will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used.
219475574|NCT06806865|PROCEDURE|Continuous supra-inguinal fascia iliaca compartment block (SIFICB)|The supra-inguinal fascia iliaca compartment block (SIFICB) targets the femoral, lateral femoral cutaneous, and obturator nerves. Under ultrasound guidance, 30 mL of 0.25% bupivacaine is administered, followed by catheter placement for continuous infusion at 5 mL/h.
219475575|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
219475576|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
219475577|NCT04119440|OTHER|Placebo|Administrations of placebo via the intramuscular route
219581862|NCT04594707|DRUG|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
219581863|NCT02691793|DRUG|Sunitinib|sunitinib 37.5mg QD
219441411|NCT00655122|DRUG|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
218834230|NCT02931838|DRUG|BMS-986165|
218834231|NCT02931838|DRUG|Placebo for BMS-986165|
219441412|NCT00655122|DRUG|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
218834232|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
218834233|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
218834234|NCT04893512|DRUG|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
219441413|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
219441414|NCT03731169|GENETIC|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
219441415|NCT03731169|DRUG|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
218834235|NCT02701764|DRUG|Pregabalin|
218834236|NCT02701764|DRUG|Placebo|
218834237|NCT06715020|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET scan.
218834238|NCT06718309|DRUG|Chemotherapy|Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
218834239|NCT06718309|DRUG|Immunotherapy|Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
218834240|NCT06718309|PROCEDURE|Radical resection of lung cancer|Radical resection of lung cancer with lymph node dissection
218834241|NCT06718309|RADIATION|SBRT|SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy
218834242|NCT02317198|DRUG|Clopidogrel|
218834243|NCT02317198|DRUG|Ticagrelor or Prasugrel|
218834244|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
219581864|NCT03080753|DEVICE|Sphinkeeper|Intersphincteric implants in the anal sphincter
219581865|NCT02403453|DEVICE|Rhine Cervical Disc|RHINE Cervical Disc
218834245|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
218834246|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
218859879|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
218859880|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
218859881|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
218834247|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
218834248|NCT02779868|DIETARY_SUPPLEMENT|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
218834249|NCT02779868|DIETARY_SUPPLEMENT|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
218834250|NCT01027650|DRUG|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
218834251|NCT01027650|DRUG|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
219441416|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
219441417|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
219441418|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
219441419|NCT02136316|DRUG|ASP7962|Oral
219441420|NCT02136316|DRUG|Placebo|Oral
219441421|NCT02058706|DRUG|enzalutamide|Given PO
219441422|NCT02058706|DRUG|bicalutamide|Given PO
219441423|NCT02058706|PROCEDURE|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
219441424|NCT02058706|DRUG|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
219441425|NCT02058706|DRUG|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
219441426|NCT02058706|OTHER|laboratory biomarker analysis|Correlative studies
219441427|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
218834252|NCT02136225|BEHAVIORAL|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
218834253|NCT05807412|DRUG|PrabotulinumtoxinA-Xvfs|"All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
218834254|NCT05807412|DRUG|OnabotulinumtoxinA|"All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
218834255|NCT03110029|DRUG|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
218834256|NCT03110029|OTHER|Application of Nail Polish|Application of Nail Polish
218834257|NCT05031143|DRUG|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
218834258|NCT01866748|DRUG|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
218834259|NCT01866748|DRUG|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
218834260|NCT01866748|DRUG|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
218834261|NCT01866748|DRUG|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
218834262|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
218834263|NCT00994825|DRUG|Levosimendan|
218834264|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
218859882|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
218859883|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
218859884|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
218859885|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
218859886|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
219441428|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
219441429|NCT03643198|DRUG|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
219441430|NCT03643198|OTHER|CONTROL|NO treatment
219441431|NCT04325919|OTHER|No intervention|No intervention
219581866|NCT00755404|DRUG|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
219581867|NCT00755404|DRUG|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
219581868|NCT05665114|DRUG|QN-030a|NK cell therapy
219581869|NCT05665114|DRUG|Cyclophosphamid|Lympho-conditioning Agent
219015311|NCT00197730|DRUG|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
219015312|NCT00197730|DRUG|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
219015313|NCT03731520|DIAGNOSTIC_TEST|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
219015314|NCT04729569|PROCEDURE|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
219015315|NCT04729569|PROCEDURE|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
219015316|NCT00336713|DRUG|Saredutant (SR48968C)|oral administration (capsules)
219015317|NCT00336713|DRUG|Placebo|oral administration (capsules)
219441432|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
219475578|NCT04741256|BEHAVIORAL|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
219475579|NCT00393783|BIOLOGICAL|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
219581870|NCT05665114|DRUG|Fludarabine|Lympho-conditioning Agent
219581871|NCT05665114|DRUG|Cytarabine|Lympho-conditioning Agent
219581872|NCT05665114|DRUG|VP-16|Lympho-conditioning Agent
219581873|NCT04439695|BIOLOGICAL|Low dose|Low dose of KBP-V001
219581874|NCT04439695|BIOLOGICAL|Intermediate dose|Intermediate dose of KBP-V001
219015318|NCT02937519|DEVICE|Chrono-chemotherapy pump:Melodie|
219015319|NCT02937519|DEVICE|Routine intravenous drip|
219015320|NCT02937519|DRUG|induction Chrono-chemotherapy|
219015321|NCT02937519|DRUG|induction Routine-chemotherapy|
219015322|NCT02937519|DRUG|cisplatin chrono-chemotherapy|
219015323|NCT02937519|DRUG|cisplatin routine-chemotherapy|
219015324|NCT02937519|RADIATION|intensity-modulated radiation therapy|
219015325|NCT00527943|DRUG|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
219475580|NCT03328078|DRUG|Emavusertib|Emavusertib will be provided as a tablet dosage form to be taken BID.
219475581|NCT03328078|DRUG|Ibrutinib|Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
219475582|NCT05658432|OTHER|Exercise via telehealth|Same as arm/group description
219581875|NCT04439695|BIOLOGICAL|High dose|High dose of KBP-V001
219581876|NCT04439695|BIOLOGICAL|Placebo|Buffered Saline Solution
219581877|NCT03311035|PROCEDURE|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
219015326|NCT00527943|DRUG|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
219015327|NCT01447810|OTHER|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
219015328|NCT05954624|DRUG|Digoxin|oral
219015329|NCT05954624|DRUG|Rosuvastatin|oral
219015330|NCT05954624|DRUG|ZSP1273|oral
219015331|NCT05954624|DRUG|Itraconazole|oral
219015332|NCT05954624|DRUG|Probenecid|oral
219015333|NCT02345967|DEVICE|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
219015334|NCT04245384|OTHER|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
219015335|NCT04245384|OTHER|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
219015336|NCT04523233|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
218834265|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
218834266|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
218834267|NCT04212130|OTHER|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
218834268|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
218834269|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
218834270|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
218834271|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
218834272|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
218834273|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
218834274|NCT02400970|OTHER|malignant cells|
219015337|NCT01908361|BEHAVIORAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
219015338|NCT01908361|BEHAVIORAL|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
219441433|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
219441434|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
219441435|NCT04285177|PROCEDURE|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
219441436|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
219441437|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
219441438|NCT05746000|BEHAVIORAL|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
219441439|NCT05746000|BEHAVIORAL|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
219441440|NCT00320632|DRUG|Desipramine|
219441441|NCT03887975|PROCEDURE|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
219441442|NCT03887975|PROCEDURE|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
219441443|NCT06378606|BEHAVIORAL|cognitive therapy|"intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement .~group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only."
219475583|NCT05658432|OTHER|Exercise unsupervised|Same as arm/group description
218834275|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
218834276|NCT00076089|DRUG|Roflumilast|
218834277|NCT00095472|DRUG|L-NMMA|
218834278|NCT00095472|DRUG|Sodium Nitrite|
218834279|NCT05174338|OTHER|Registry|Observational, data collection
218834280|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
218834281|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
218834282|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
219441444|NCT05863806|OTHER|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
219441445|NCT05863806|OTHER|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
219764390|NCT06596044|BEHAVIORAL|VA BIC|VA BIC is a suicide prevention strategy that is designed to meet the needs of Veterans who receive acute psychiatric treatment. VA BIC can be delivered by a trained mental health provider (e.g., mental health nurse, social worker, psychologist, psychiatrist). VA BIC includes two synergistic elements to support the patient after a mental health discharge. The elements include a brief educational session, where the patient receives a one-on-one, one-hour, personalized educational session on suicide prevention. The session incorporates aspects of motivational interviewing. The patient then receives 7 regular follow-up contacts that are conducted by the interventionist. Here the interventionist monitors symptoms, assesses treatment adherence, reviews the safety plan, and assists the patient with engaging in steps to promote their well-being. The sessions incorporate aspects of motivational interviewing. Of note patients in this arm will also receive standard care.
218834283|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
218834284|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
218834285|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
218834286|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
218834287|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
219441446|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
219441447|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
219441448|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
219441449|NCT00000995|DRUG|Zidovudine|
219441450|NCT00000995|DRUG|Ganciclovir|
219441451|NCT00935467|DRUG|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
219441452|NCT03375762|OTHER|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
219441453|NCT03375762|OTHER|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
219441454|NCT05315024|DRUG|Fluarix Tetra|Fluarix Tetra
219441455|NCT05315024|DRUG|Imiquimod cream|Imiquimod cream
219441456|NCT00053014|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219441457|NCT00053014|DRUG|cyclosporine|
219441458|NCT00053014|DRUG|fludarabine|
218834288|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
218834289|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
218859887|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
218859888|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
218859889|NCT00933920|DRUG|Aliskiren|
218859890|NCT00933920|DRUG|Aliskiren|
218859891|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
218859892|NCT04546295|OTHER|Water-flosser|Water-flosser
218859893|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
218859894|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
218859895|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
218859896|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
218859897|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
218859898|NCT00387179|DRUG|Melatonin|5mg, pill, once
218859899|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
218859900|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
218859901|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
218859902|NCT05084560|DRUG|Placebo|Placebo
218859903|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
218859904|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
219441459|NCT00053014|DRUG|mycophenolate mofetil|
219441460|NCT00053014|PROCEDURE|peripheral blood stem cell transplantation|
219441461|NCT00053014|RADIATION|radiation therapy|
219015339|NCT01908361|BEHAVIORAL|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
219015340|NCT04702477|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
219015341|NCT03016962|DEVICE|cap-assisted colonoscopy|cap-assisted colonoscopy
219015342|NCT03016962|DEVICE|Standard colonoscopy|Standard colonoscopy
219015343|NCT03246113|DRUG|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
219441462|NCT01979380|DRUG|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
219441463|NCT01979380|DRUG|placebo|PO, once in the morning
219441464|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
219441465|NCT01126281|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
219441466|NCT01822015|DRUG|Sirolimus|Given PO
219441467|NCT01822015|DRUG|Idarubicin|Given IV
219441468|NCT01822015|DRUG|Cytarabine|Given IV
219441469|NCT06310785|DRUG|Esketamine|The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
219441470|NCT06310785|DRUG|Sufentanil|In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
219441471|NCT00602069|BEHAVIORAL|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
219441472|NCT00602069|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
219441473|NCT05373316|RADIATION|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
219441474|NCT01119963|DRUG|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
219441475|NCT01119963|DRUG|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
219441476|NCT02278224|BEHAVIORAL|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
219441477|NCT02278224|BEHAVIORAL|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
219441478|NCT05515445|DRUG|Chiglitazar|Oral single dose 48 mg
219441479|NCT04737161|BIOLOGICAL|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
219441480|NCT03835988|DEVICE|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
219441481|NCT03272971|DEVICE|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
219441482|NCT03304652|DRUG|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
219441483|NCT03304652|OTHER|Natural Sleep|Natural Sleep without medication
219015344|NCT03246113|DRUG|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
219015345|NCT03246113|RADIATION|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
219015346|NCT05048446|OTHER|observational|Non intervention
219015347|NCT00330941|DRUG|lidocaine|
219015348|NCT02465801|DRUG|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
219015349|NCT02465801|DRUG|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
219015350|NCT02465801|DRUG|GCSF|GCSF 5 mcg/kg/day
219015351|NCT04532866|BEHAVIORAL|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
219015352|NCT00742001|BIOLOGICAL|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
219015353|NCT03388333|PROCEDURE|Catheter Ablation|
219015354|NCT00819351|DRUG|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
219015355|NCT00819351|DRUG|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
219441484|NCT02532413|DRUG|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
219764391|NCT06596044|OTHER|Standard Care|Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.
218834290|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
218834291|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
218834292|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
218834293|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
219015356|NCT00807807|DIETARY_SUPPLEMENT|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
219015357|NCT00807807|DRUG|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
219015358|NCT02423538|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
219015359|NCT02423538|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
219015360|NCT02373020|OTHER|colonoscopic biopsies|
219441485|NCT02532413|DRUG|Entecavir|Entecavir can inhibit the replication of HBV.
219441486|NCT05194215|DEVICE|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
219441487|NCT00236613|DRUG|topiramate|
219441488|NCT06329713|PROCEDURE|Group I: 30 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every 30 minutes, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minuts may be administered
218834294|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
218834295|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
218834296|NCT06788197|DRUG|SHR-A1811+ Fulvestrant|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular
218834297|NCT06788197|DRUG|SHR-A1811+ Fulvestrant+HS-10352|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally
218834298|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
219015361|NCT03124914|OTHER|Neuromuscular tests|Neuromuscular tests
219441489|NCT06329713|PROCEDURE|Group II: 60 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programme
219441490|NCT05038787|DRUG|LY3473329|Administered orally.
219441491|NCT05038787|DRUG|Placebo|Administered orally.
219441492|NCT00131170|PROCEDURE|paravertebral block|
219441493|NCT06086782|OTHER|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
219441494|NCT06086782|OTHER|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
219441495|NCT04645576|DEVICE|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
219441496|NCT03537183|OTHER|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
219441497|NCT04113278|GENETIC|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
219441498|NCT00252317|DRUG|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
219441499|NCT00252317|DRUG|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
219441500|NCT04557007|DRUG|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
219441501|NCT01231828|DRUG|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
219441502|NCT01231828|DRUG|Lactulose|Lactulose (30-60 ml per day)
219441503|NCT02897154|DIAGNOSTIC_TEST|In-vitro|
219441504|NCT04391153|PROCEDURE|ERCP with tissue sampling|Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
219441505|NCT04629586|OTHER|No intervention|Observational research study
219441506|NCT04513041|PROCEDURE|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
218834299|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
218834300|NCT00346281|DEVICE|32P BioSilicon|
219441507|NCT03201484|OTHER|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
219441508|NCT04507490|DEVICE|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
218834301|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
218834302|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
218834303|NCT02220855|DRUG|BKM120|
218834304|NCT03280303|OTHER|non-interventional|
218834305|NCT06492902|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in four weeks using patches (four sessions), each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. The patch with the needle will remain in place for one week.
218834306|NCT06492902|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for four weeks using patches (four sessions), each with a square shape and a side length of 10 mm. The patches will not contain any needles and will remain in place for one week.
218834307|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
219441509|NCT03510403|DEVICE|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
219441510|NCT00351390|OTHER|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
219441511|NCT00351390|OTHER|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
219441512|NCT06015841|BIOLOGICAL|Placebo|The placebo is a solution matching the study vaccine formulation.
219441513|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
219441514|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
219441515|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
219441516|NCT01736163|DRUG|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
219441517|NCT01736163|DRUG|131I|28 mCi or ≥ 1.036 GBq.
219441518|NCT01736163|OTHER|Thyroid Hormone Withdrawal|Stop taking hormone therapy
219441519|NCT02269904|DRUG|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
219441520|NCT02269904|DRUG|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
219441521|NCT02603172|DRUG|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
219441522|NCT06409104|DRUG|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
219441523|NCT06409104|DRUG|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
219441524|NCT03076203|DRUG|Niraparib|Given orally
219441525|NCT03076203|RADIATION|Radium Ra 223 Dichloride|Given intravenously
219441526|NCT04062526|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
219441527|NCT05665738|RADIATION|High Dose Rate Monotherapy|High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
219441528|NCT03550092|BEHAVIORAL|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
218834308|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
218834309|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
218834310|NCT03419897|DRUG|Tislelizumab|Administered intravenously
219015362|NCT00631527|DRUG|Leuprolide|Injections given through a needle in the muscle every 3 months.
219015363|NCT00631527|DRUG|Goserelin|Subcutaneous injections given once every 3 months.
219015364|NCT00631527|DRUG|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
219015365|NCT00631527|DRUG|Casodex|Once a day by mouth for 2 weeks.
219015366|NCT00631527|RADIATION|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
219441529|NCT06061315|DIETARY_SUPPLEMENT|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
219441530|NCT06061315|DIETARY_SUPPLEMENT|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
219475584|NCT04469790|BEHAVIORAL|SIT+WALK|Participants will interrupt their sitting for one week
219581878|NCT03311035|PROCEDURE|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
219581879|NCT02521935|DEVICE|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
219581880|NCT02521935|DEVICE|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
219581881|NCT03009916|DRUG|"cholestagel® (Colesevelam)"|3750mg
219581882|NCT03009916|DRUG|Placebos|3750mg
219581883|NCT01593696|BIOLOGICAL|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
219581884|NCT00002785|BIOLOGICAL|filgrastim|
218834311|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
218834312|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
218834313|NCT04769323|DEVICE|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
219441531|NCT06403475|DEVICE|Transcutaneous Vagus Nerve Stimulation|"Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device."
219441532|NCT06403475|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.
219581885|NCT00002785|DRUG|asparaginase|
219581886|NCT00002785|DRUG|cyclophosphamide|
218834314|NCT04769323|OTHER|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
218834315|NCT06315413|PROCEDURE|Socket preservation using xenograft and composite plug|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
218834316|NCT06315413|PROCEDURE|Socket preservation using xenograft and intentionally exposed d-PTFE|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
218834317|NCT06532071|DRUG|[68Ga]CBP8|Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
218834318|NCT06532071|DRUG|Gadoterate Meglumine|Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
218834319|NCT04986566|OTHER|Best Practice|Use standard reporting procedures
218834320|NCT04986566|BEHAVIORAL|Health Education|Use Aetonixx app
218834321|NCT04986566|OTHER|Medical Device Usage and Evaluation|Wear Vivofit 4
218834322|NCT04986566|OTHER|Quality-of-Life Assessment|Complete questionnaires
218834323|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
218834324|NCT04941183|DRUG|NTR-441|NTR-441
218834325|NCT04941183|DRUG|Placebo|Placebo
219581887|NCT00002785|DRUG|cyclosporine|
219581888|NCT00002785|DRUG|cytarabine|
219581889|NCT00002785|DRUG|daunorubicin hydrochloride|
219581890|NCT00002785|DRUG|dexamethasone|
219581891|NCT00002785|DRUG|etoposide|
219581892|NCT00002785|DRUG|leucovorin calcium|
218834326|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
218834327|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
219015367|NCT03063476|DRUG|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
219015368|NCT03063476|DRUG|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
219015369|NCT05776654|DEVICE|Biometric wearable devices|Passive data collection using biometric wearable devices.
219015370|NCT01510379|DEVICE|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
219015371|NCT01510379|DRUG|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
219015372|NCT01510379|DRUG|IV promethazine 25 mg q 6 hours prn|
219015373|NCT01510379|DRUG|Elixir promethazine 25 mg q 6 hours prn after discharge|
219015374|NCT03024723|DEVICE|nasal mask CPAP|CPAP and ventilation administered via nasal mask
219015375|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
219015376|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
219015377|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
219015378|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
219015379|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
219015380|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
219441533|NCT06403475|BEHAVIORAL|Computer Based Speech and Language Therapy (Step by Step)|Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
219441536|NCT04072575|DRUG|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
219441537|NCT04072575|DRUG|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
219441538|NCT02473289|DRUG|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
219441539|NCT02473289|DRUG|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
219441540|NCT04377126|DRUG|Ghrelin|Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.
219441541|NCT04377126|DRUG|Placebo|Placebo will consist of saline- no active ingredient.
219441542|NCT04290260|OTHER|Use of breast bra|Patients will use a breast from admission to hospital discharge
219441543|NCT04290260|OTHER|Usual care (not use of bra)|
219015381|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
219015382|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
219015383|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
219441544|NCT04575844|DRUG|Liraglutide|24 weeks of Liraglutide
219441545|NCT04575844|OTHER|Exercise training|24 weeks of Exercise training
219441546|NCT04575844|DRUG|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
219441547|NCT02912949|DRUG|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
219441548|NCT06061094|DRUG|Imatinib|Imatinib 600mg QD plus Chemotherapy
219441549|NCT06061094|DRUG|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
219441550|NCT06061094|DRUG|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
219441551|NCT06061094|OTHER|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
218834328|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
218834329|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
218834330|NCT00005077|DRUG|oxaliplatin|
219015384|NCT00242957|BEHAVIORAL|Intervention with Microfinance for AIDS and Gender Equity|
219015385|NCT01540656|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
219015386|NCT03994692|DEVICE|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
219015387|NCT03994692|PROCEDURE|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
219015388|NCT01050257|DRUG|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
219015389|NCT01050257|DRUG|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
219015390|NCT00002130|DRUG|Vesnarinone|
219015391|NCT01618552|BEHAVIORAL|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
219015392|NCT01618552|OTHER|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
219015393|NCT00584558|PROCEDURE|Catheter Ablation|Catheter Ablation of arrhythmias
219015394|NCT01236937|DEVICE|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
219441552|NCT04788758|OTHER|Educational Intervention|Receive G8 screening tool administration training
219581893|NCT00002785|DRUG|mercaptopurine|
219581894|NCT00002785|DRUG|mesna|
219581895|NCT00002785|DRUG|methotrexate|
218834331|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
218834332|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
218834333|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
218834334|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
219015395|NCT00116051|DEVICE|Acetabular implant, Monoblock cup|
218834335|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
219441553|NCT04788758|OTHER|Screening Questionnaire Administration|Complete G8 screening tool
219441554|NCT04788758|OTHER|Referral|Receive referral
219441555|NCT04788758|OTHER|Questionnaire Administration|Ancillary studies
219441556|NCT05031520|PROCEDURE|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
218834336|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
218834337|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
218834338|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
218834339|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
219441557|NCT05031520|DRUG|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
219441558|NCT05031520|DRUG|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
219581896|NCT00002785|DRUG|methylprednisolone|
219581897|NCT00002785|DRUG|pegaspargase|
219581898|NCT00002785|DRUG|prednisone|
219581899|NCT00002785|DRUG|therapeutic hydrocortisone|
219581900|NCT00002785|DRUG|vincristine sulfate|
219581901|NCT00002785|PROCEDURE|allogeneic bone marrow transplantation|
219581902|NCT00002785|RADIATION|low-LET cobalt-60 gamma ray therapy|
219581903|NCT00002785|RADIATION|low-LET photon therapy|
219581904|NCT03178565|OTHER|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
219581905|NCT03178565|OTHER|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
219581906|NCT04921020|OTHER|Photography|Facial photographs and blinking videos are taken
218834340|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
219581907|NCT01936623|BEHAVIORAL|Computerized Brief Intervention|No additional information needed.
219581908|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
219581909|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
219581910|NCT01374295|OTHER|video|watch a 3 minute video
219581911|NCT01374295|OTHER|standard education|Receives standard verbal education from healthcare provider
219581912|NCT03167723|DEVICE|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
219764392|NCT06676319|DRUG|Lunsekimig|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
218834341|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
218834342|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
218834343|NCT06000462|DRUG|Metformin 1000 mg (ttd)|A dose of 1000 mg, PO, once daily, given over 8 months period
219015396|NCT04849806|DIAGNOSTIC_TEST|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
218834344|NCT06000462|OTHER|Placebo|a non-medicated pill will be used as a placebol
219015397|NCT04849806|DIAGNOSTIC_TEST|OSA severity|OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
219015398|NCT04849806|DIAGNOSTIC_TEST|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
219015399|NCT04849806|DIAGNOSTIC_TEST|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
219441559|NCT05031520|DRUG|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
219441560|NCT01478061|DEVICE|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
219441561|NCT04836091|BEHAVIORAL|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
219581913|NCT04873765|BIOLOGICAL|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
219581914|NCT04873765|BIOLOGICAL|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
218834345|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
218834346|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
218834347|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
219015400|NCT04849806|DIAGNOSTIC_TEST|Assessment of systemic inflammation|Based on blood samples taken.
219015401|NCT00278109|DRUG|cyclophosphamide|chemotherapy
219015402|NCT00278109|DRUG|Doxorubicin|doxorubicin
219015403|NCT00278109|RADIATION|radiation|radiation
219581915|NCT03816566|DEVICE|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
219581916|NCT00997568|DEVICE|PET-511BTM|Transesophageal Transducer
219581917|NCT02620150|DRUG|Escitalopram|10 week trial
219581918|NCT02620150|OTHER|Placebo|10 week trial
219581919|NCT02203422|DRUG|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
219764393|NCT06676319|DRUG|Short-Acting Beta Agonists (SABA)|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
218834348|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
218834349|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
219015404|NCT02090517|DEVICE|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
219015405|NCT02090517|DEVICE|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
219015406|NCT02090517|DEVICE|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
219441562|NCT04836091|BEHAVIORAL|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
219441563|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
219441564|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
219441565|NCT02244619|DRUG|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
219441566|NCT02244619|DRUG|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
219441567|NCT02283541|BEHAVIORAL|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
219441568|NCT06397391|DEVICE|TREM-AB|Wearing medical device on site during 1 hour
219441569|NCT03134469|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
219441570|NCT03134469|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement
219441571|NCT02382289|PROCEDURE|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
219441572|NCT02282891|DRUG|Propofol|Induction of general anesthesia using propofol 2mg/kg
219441573|NCT02282891|DRUG|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
219441574|NCT05320536|DRUG|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
219441575|NCT05320536|DRUG|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
219441576|NCT04617106|PROCEDURE|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
219441577|NCT05837000|DRUG|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
219441578|NCT05837000|DRUG|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
219441579|NCT05837000|DRUG|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
219441580|NCT06034041|DRUG|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
219441581|NCT06034041|DRUG|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
218834350|NCT06378632|DEVICE|Hearo App|No intervention - only data collection
218834351|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
218834352|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
218834353|NCT04473950|DRUG|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
218834354|NCT04473950|DRUG|Placebo|An IM injection of 0.9% normal saline will be given.
218834355|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
218834356|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
218834357|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
218834358|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
218834359|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
218834360|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
218834361|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
218834362|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
218834363|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
218834364|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
218834365|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
218834366|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
218834367|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
218834368|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
218834369|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
218834370|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
218834371|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
219441582|NCT05240963|PROCEDURE|Temporal PEEK implant|Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
219441583|NCT00610077|DRUG|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
219441584|NCT00610077|DRUG|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
219441585|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
219441586|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
219441587|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
219441588|NCT06840743|OTHER|Emotional intervention|The participant will wait for 2.20 minutes while simultaneously experience experimentally induced pain.
219441589|NCT03215745|BEHAVIORAL|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
219441590|NCT00383266|DRUG|Pemetrexed|
219441591|NCT00383266|DRUG|Carboplatin|
219441592|NCT05298163|DRUG|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
219441593|NCT05298163|DRUG|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
219441594|NCT03285490|DRUG|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
219441595|NCT03285490|DRUG|Placebo|Dosage form: Ointment; Route of administration: Topical
219441596|NCT03052465|OTHER|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
219441597|NCT03745989|DRUG|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
219441598|NCT03745989|DRUG|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
219475585|NCT04469790|BEHAVIORAL|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
219764394|NCT06676319|DRUG|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
218834372|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
218834373|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
218834374|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
218834375|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
218834376|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
218834377|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
218834378|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
218834379|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
218834380|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
218834381|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
219441599|NCT03486184|DIAGNOSTIC_TEST|Cystatin-C|"* Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~* Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
219441600|NCT02425969|PROCEDURE|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
219441601|NCT02425969|DRUG|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
219441602|NCT05364112|DEVICE|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
219441603|NCT05386875|DIAGNOSTIC_TEST|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
219441604|NCT01687049|DRUG|Red yeast rice|
219581920|NCT02203422|DRUG|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
219581921|NCT02878486|DEVICE|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
219581922|NCT02878486|BEHAVIORAL|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
219581923|NCT02878486|DEVICE|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
219581924|NCT01713049|DRUG|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
219764395|NCT06676319|DRUG|Fluticasone/salmeterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
219764396|NCT06676319|DRUG|Budesonide/formoterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
219441605|NCT02444806|OTHER|Full polysomnography|Full sleep and respiratory monitoring with EEG
219581925|NCT02815449|OTHER|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
219581926|NCT02815449|OTHER|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
219581927|NCT02815449|OTHER|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
219581928|NCT05385159|DRUG|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
219581929|NCT05385159|DRUG|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
219581930|NCT00145275|DRUG|zoledronic acid|
219581931|NCT01584206|DRUG|Ezetimibe|10mg ezetimibe/day, at least 4 months
219581932|NCT01194518|BEHAVIORAL|Lifestyle Intervention Program|
219581933|NCT01239875|BIOLOGICAL|dendritic cell vaccine therapy|Given intratumorally
219581934|NCT01239875|PROCEDURE|cryotherapy|Undergo cryoablation
219764397|NCT07001423|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy within 2 weeks after endoscopic removal of common bile duct stone
219764398|NCT06999837|RADIATION|[68Ga]Ga-PSMA-11|Dynamic whole-body \[68Ga\]Ga-PSMA acquisition to HCC patients
219764399|NCT05832086|BEHAVIORAL|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
219764400|NCT05832086|BEHAVIORAL|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
219764401|NCT00608725|RADIATION|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
219764402|NCT00608725|PROCEDURE|QSweat|Quantitative Sweat Testing
219764403|NCT00608725|DRUG|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
219764404|NCT06746506|BEHAVIORAL|Amigurumi toy|A toy prepared using anti-allergic yarn to suit children's developmental stages.
219764405|NCT07003919|COMBINATION_PRODUCT|DBV712 250 mcg|DBV712 250 mcg epicutaneous system.
218834382|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
218834383|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
218834384|NCT00425022|PROCEDURE|thoracoscopy|
219441606|NCT02444806|OTHER|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
218834385|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
219441607|NCT03178175|PROCEDURE|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
218834386|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
219441608|NCT03178175|PROCEDURE|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
219441609|NCT03381703|DRUG|YH12852|YH12852 administration
219441610|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
219441611|NCT00287755|DRUG|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
219441612|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
219441613|NCT01250301|OTHER|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
219441614|NCT01250301|OTHER|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
219441615|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
219441616|NCT05192044|OTHER|Conventional Care|Conventional Care
219441617|NCT01291511|DRUG|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
219441618|NCT01291511|DRUG|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
219441619|NCT04367649|OTHER|Hall technique|"* Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement"
218834387|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
219441620|NCT04367649|OTHER|Atraumatic restorative treatment|Caries removal using excavators, then restoration using glass ionomer (GIC)
219441621|NCT04367649|OTHER|Conventional restorative treatment|Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
219441622|NCT02367859|DRUG|Dabrafenib|Given PO
219441623|NCT02367859|DRUG|Trametinib|Given PO
219441624|NCT01528995|DEVICE|Medtronic Interstim II-3058|impulse generator
218834388|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
218834389|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
218834390|NCT02159898|DEVICE|EndoMAXX|
219441625|NCT01528995|PROCEDURE|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
218834391|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
218834392|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
218834393|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
218834394|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
218834395|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
218834396|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
218834397|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
218834398|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
218834399|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
218834400|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
218834401|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
218834402|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
218834403|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
218834404|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
219581935|NCT01239875|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
219581936|NCT01239875|OTHER|laboratory biomarker analysis|Correlative studies
219581937|NCT01239875|OTHER|immunoenzyme technique|Correlative studies
219441626|NCT00047008|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22
219441627|NCT00047008|RADIATION|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
219441628|NCT00047008|RADIATION|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
219441629|NCT00047008|PROCEDURE|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
219581938|NCT01239875|OTHER|immunohistochemistry staining method|Correlative studies
219581939|NCT01239875|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given intradermally
218834405|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
219581940|NCT02377518|RADIATION|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
219581941|NCT00185666|PROCEDURE|Stereotactic radiosurgery|
219764406|NCT07003919|COMBINATION_PRODUCT|Placebo|DBV712 matching placebo epicutaneous system.
219764407|NCT04073706|PROCEDURE|TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|"Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread."
219764408|NCT04073706|PROCEDURE|TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|Removal of uterus, tubes and ovaries without retroperitoneal node dissection
219581942|NCT04296058|OTHER|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
219581943|NCT05806619|OTHER|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
219764409|NCT02956291|DEVICE|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
219764410|NCT06671912|DRUG|Anastrozole|Given PO
219764411|NCT06671912|DRUG|Letrozole|Given PO
219764412|NCT06671912|DRUG|Exemestane|Given PO
218834406|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
218834407|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
218834408|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
218834409|NCT05223179|OTHER|Saline|Saline
218834410|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
218834411|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
218834412|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
218834413|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
218834414|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
218834415|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
219764413|NCT06671912|DRUG|Tamoxifen|Given PO
219764414|NCT06671912|PROCEDURE|Mammogram|Undergo mammogram
219764415|NCT06671912|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764416|NCT06671912|BIOLOGICAL|Dual X-ray Absorptiometry|Undergo DEXA
219764417|NCT06671912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218834416|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
219015407|NCT02090517|PROCEDURE|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
219581944|NCT06295848|BEHAVIORAL|Exercise|An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
219015408|NCT00149123|DRUG|hydrocortisone 200 mg/day|
219015409|NCT02580357|PROCEDURE|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
219015410|NCT02580357|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
219015411|NCT04563741|BEHAVIORAL|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
219441630|NCT01769625|DRUG|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
219581945|NCT02894281|DEVICE|pupillary light reflex|measure with infra-red cameras
219581946|NCT00628537|DEVICE|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
219581947|NCT00807677|DRUG|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
219764418|NCT06671912|OTHER|Questionnaire Administration|Ancillary studies
219015412|NCT04563741|BEHAVIORAL|MOVE!|standard VA weight management intervention
219764419|NCT06672107|BEHAVIORAL|Active Driver Training Intervention|simulated driver training focusing on practice of 4 specific driving skills including lane positioning, speed management, collision avoidance, and dashboard attention
219764420|NCT06672107|BEHAVIORAL|Control Intervention|pre-scripted familiarization with driving simulator controls in the absence of any complex driving scenarios, decision making requirements, or feedback pertaining to driving skills
219764421|NCT04804553|DRUG|Apremilast|Participants will receive apremilast orally.
219764422|NCT04804553|DRUG|Placebo|Participants will receive the matching placebo orally.
219441631|NCT03529929|DRUG|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
219441632|NCT03599544|BEHAVIORAL|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
219764423|NCT06588634|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
219764424|NCT06588634|PROCEDURE|Standard of Care|Standard of care treatment for pulmonary embolism
219015413|NCT04238351|DEVICE|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
219015414|NCT04238351|DEVICE|Conventional face mask|applying oxygen using usual face mask
219015415|NCT03770650|PROCEDURE|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
219015416|NCT02064166|DRUG|Intranasal Insulin|"1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks."
219441633|NCT03599544|BEHAVIORAL|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
219441634|NCT02971527|DEVICE|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
219015417|NCT05173649|OTHER|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1\. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
219015418|NCT05173649|OTHER|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1\. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
219015419|NCT01909037|DIETARY_SUPPLEMENT|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
218834417|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
218834418|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
219015420|NCT05093296|DRUG|Oxytocin nasal spray|24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
219015421|NCT05093296|DRUG|Naltrexone Pill|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
219015422|NCT05093296|DRUG|Placebo|Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
219015423|NCT03171987|DRUG|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
219015424|NCT03171987|DRUG|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
219015425|NCT03362281|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
219441635|NCT02971527|DEVICE|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
219015426|NCT03362281|DRUG|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
219015427|NCT03362281|DRUG|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
219015428|NCT03362281|DRUG|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
219015429|NCT05356494|OTHER|Postural drainage|(Group A will be treated with postural drainage)
219015430|NCT05356494|OTHER|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
218834419|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
218834420|NCT05769855|DRUG|HR18034|HR18034 380mg
218834421|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
218834422|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
218834423|NCT06221761|DRUG|not using antibiotic|no antibiotic application
218834424|NCT06221761|DRUG|using antibiotic|antibiotic application
218834425|NCT05961241|OTHER|runnin training program|gradual training program
219015431|NCT00315198|DEVICE|Eye Patch|2 hours daily patching
219015432|NCT00315198|PROCEDURE|Near activities|near visual activities while patching
219015433|NCT00315198|PROCEDURE|Distance activities|distance visual activities while patching
219015434|NCT03053076|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
219015435|NCT03053076|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
219015436|NCT01569490|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
219015437|NCT01569490|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
219015438|NCT02577211|DIETARY_SUPPLEMENT|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
219015439|NCT02577211|DIETARY_SUPPLEMENT|Normocaloric enteral nutrition|25 kcal/kg of body weight
219015440|NCT02202642|PROCEDURE|collagenase|Cultured limbal stem cells transplantation
219015441|NCT05081401|COMBINATION_PRODUCT|Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z|A-SOC: 4Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z/5Lfx(Mfx)+Cfz(Cs)+E+Z During the intensive phase: Bedaquiline(Linezolid);Levofloxacin(Moxifloxacin) All treatment is taken orally
219441636|NCT01762527|RADIATION|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
218834426|NCT00678769|DRUG|Cixutumumab|Given IV
218834427|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
218834428|NCT00678769|OTHER|Pharmacological Study|Correlative studies
219441637|NCT00550992|BIOLOGICAL|anti-thymocyte globulin|
219441638|NCT00550992|DRUG|asparaginase|
219441639|NCT00550992|DRUG|busulfan|
219441640|NCT00550992|DRUG|cyclophosphamide|
219441641|NCT00550992|DRUG|cyclosporine|
219441642|NCT00550992|DRUG|cytarabine|
219441643|NCT00550992|DRUG|daunorubicin hydrochloride|
219441644|NCT00550992|DRUG|etoposide|
219441645|NCT00550992|DRUG|leucovorin calcium|
219441646|NCT00550992|DRUG|melphalan|
219441647|NCT00550992|DRUG|mercaptopurine|
219441648|NCT00550992|DRUG|methotrexate|
219441649|NCT00550992|DRUG|mitoxantrone hydrochloride|
219441650|NCT00550992|DRUG|pegaspargase|
219441651|NCT00550992|DRUG|prednisolone|
219441652|NCT00550992|DRUG|prednisone|
219441653|NCT00550992|DRUG|therapeutic hydrocortisone|
219441654|NCT00550992|DRUG|thioguanine|
219441655|NCT00550992|DRUG|vincristine sulfate|
218834429|NCT00678769|DRUG|Temsirolimus|Given IV
219441656|NCT00550992|PROCEDURE|allogeneic bone marrow transplantation|
219441657|NCT00550992|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219441658|NCT00550992|PROCEDURE|umbilical cord blood transplantation|
219441659|NCT03959956|DIAGNOSTIC_TEST|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
219441660|NCT03960658|DRUG|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
219441661|NCT03753386|OTHER|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test."
219441662|NCT02387450|DRUG|Sildenafil|100 mg per day
219441663|NCT02387450|DRUG|Placebo|Placebo with same presentation as the active drug
219441664|NCT02748525|OTHER|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
219441665|NCT02748525|BIOLOGICAL|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
219441666|NCT01047436|DRUG|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
218834430|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
218834431|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
218834432|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
218834433|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
219015442|NCT05081401|COMBINATION_PRODUCT|A1|9Bdq(6m)+Fq+Lzd+Cs+Cfz
219441667|NCT01047436|DRUG|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
219441668|NCT05462691|PROCEDURE|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
219441669|NCT02837861|DRUG|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
218834434|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
218834435|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
218834436|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
218834437|NCT00455819|PROCEDURE|home treatment|
219015443|NCT05081401|COMBINATION_PRODUCT|A2a|9Bdq(6m)+Fq+Lzd(600mg)+Cs+Z
219015444|NCT05081401|COMBINATION_PRODUCT|A2b|9Bdq(6m)+Fq+Lzd(2m)+Cs+Z
219015445|NCT05081401|COMBINATION_PRODUCT|A2c|9Bdq(6m)+Fq+Lzd(600mg-300mg)+Cs+Z
219015446|NCT05081401|COMBINATION_PRODUCT|A3|9Bdq(6m)+Fq+Lzd+Cfz+Z
219015447|NCT05081401|COMBINATION_PRODUCT|A4|9Bdq(6m)+Fq+Cfz+Cs+Z
219015448|NCT05081401|COMBINATION_PRODUCT|A5|9Fq+Lzd+Cfz+Cs+Z
219441670|NCT02837861|OTHER|Routine Nutritional Support|Enteral nutrition as tolerated.
219441671|NCT05969262|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
219441672|NCT02769013|OTHER|Pre-treatment follow up|No active intervention; medical support provided if needed
219441673|NCT02769013|OTHER|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
219441674|NCT02769013|OTHER|Post treatment follow up|No active intervention; medical support provided if needed.
219015449|NCT05081401|COMBINATION_PRODUCT|B-SOC|6Bdq+Lzd+Cs+Cfz/14Lzd+Cfz+Cs
219015450|NCT05081401|COMBINATION_PRODUCT|B1|9Bdq(6m)+Lzd+Cs+Cfz+Z
219441675|NCT02769013|OTHER|Olfactometer experiment|No active intervention; medical support provided if needed.
219475586|NCT04708717|BEHAVIORAL|Stimulation Rate|Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
219475587|NCT04708717|BEHAVIORAL|Electrode Location|Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
218834438|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
218834439|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
218834440|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
218834441|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
218834442|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
218834443|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
218834444|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
218834445|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
218834446|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
218834447|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
218834448|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
218834449|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
219441676|NCT06340776|OTHER|Acupressure|For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
218834450|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
218834451|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
218834452|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
218834453|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
218834454|NCT02681653|DRUG|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
218834455|NCT02681653|DRUG|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
218834456|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
218834457|NCT00000277|DRUG|Mazindol|
219441677|NCT01900405|DRUG|Dexmedetomidine|
218834458|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
219441678|NCT05440344|DRUG|Imlunestrant|Administered orally.
219441679|NCT01496144|PROCEDURE|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
219441680|NCT01496144|PROCEDURE|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
219441681|NCT00902512|DRUG|Treatment A|Viagra® 100 mg tablet, administered with water single dose
219441682|NCT00902512|DRUG|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
219441683|NCT00902512|DRUG|Treatment B|Sildenafil 100 mg CT administered with water single dose
219441684|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
219441685|NCT00902512|DRUG|Treatment C|Sildenafil 100 mg CT administered without water single dose
219441686|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
219441687|NCT04172376|PROCEDURE|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
219441688|NCT04172376|DRUG|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
219441689|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
219441690|NCT01890733|DEVICE|InSpace™ system|
219441691|NCT00312741|PROCEDURE|empirical versus microbiological guided treatment|
219441692|NCT04299256|BEHAVIORAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
219015451|NCT03918590|DRUG|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
219441693|NCT01834638|DRUG|ABT-126|capsule(s)
219441694|NCT05939700|DRUG|Mavacamten|Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
219441695|NCT02747329|DEVICE|BuMA Supreme™ stent|
219441696|NCT02747329|DEVICE|Xience V/Prime stent|
219441697|NCT01408732|DRUG|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
219581948|NCT05803174|DIAGNOSTIC_TEST|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
219581949|NCT01141244|DRUG|temsirolimus|Given IV
219581950|NCT01141244|DRUG|temozolomide|Given orally
218834459|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
218834460|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
218834461|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
219581951|NCT01141244|DRUG|irinotecan hydrochloride|Given IV
218834462|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
218834463|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
218834464|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
218834465|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
218834466|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
218834467|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
219441698|NCT01408732|OTHER|Standard Treatment|Normal standard of care followed by Drug interevention
219581952|NCT01141244|OTHER|laboratory biomarker analysis|Correlative studies
219581953|NCT06024889|DRUG|Furosemide Injection|Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
219581954|NCT02008786|DRUG|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
219581955|NCT02008786|DRUG|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
218834468|NCT03080571|OTHER|standard care|
218834469|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
219015452|NCT03918590|DRUG|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
219015453|NCT03918590|OTHER|patching|no drug/ patching
219015454|NCT05769543|PROCEDURE|WATSU application|20-minute application of WATSU
219015455|NCT05769543|OTHER|Lecture|20-minute lecture on WATSU technique
219015456|NCT00508625|DRUG|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
219015457|NCT00508625|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
219015458|NCT00508625|DRUG|Carboplatin|Standard platinum based chemotherapy
219015459|NCT00508625|DRUG|Paclitaxel|Standard taxane chemotherapy
219441699|NCT00424099|DRUG|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
219441700|NCT00424099|BEHAVIORAL|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
219441701|NCT00424099|DRUG|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
219441702|NCT00424099|BEHAVIORAL|Non NTI|Non NTI are calls from research staff 3 times weekly.
219441703|NCT06391970|DEVICE|Cognitive screening|The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
219441704|NCT01524809|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
219441705|NCT01524809|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
219581956|NCT02008786|DRUG|placebo|Placebo
219581957|NCT03906396|DEVICE|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
219581958|NCT03791723|DRUG|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
219581959|NCT03791723|DRUG|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
219581960|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
219581961|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate|28 mg iron
219581962|NCT04469010|DIETARY_SUPPLEMENT|Placebo|Matched placebo
218834470|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
218834471|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
218834472|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
218834473|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
218834474|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
218834475|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
218834476|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
218834477|NCT05202899|DRUG|sugammadex|The use of sugammadex
219015460|NCT06234007|DRUG|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
219015461|NCT01744990|OTHER|Oral food challenges to multiple nuts|
219015462|NCT03121547|DRUG|Tapentadol 50 mg Oral Tablet|1 tablet administered
219015463|NCT03121547|DRUG|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
219581963|NCT02444923|DEVICE|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
219581964|NCT02444923|DEVICE|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
219581965|NCT02053935|DRUG|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
219581966|NCT04425135|DRUG|Camrelizumab|200mg,D1,ivgtt, Q3w.
219581967|NCT04425135|DRUG|Apatinib|250mg,Qd,Q3W.
219581968|NCT04425135|DRUG|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
219581969|NCT04425135|DRUG|Carboplatin|AUC=5\~6,D1,ivgtt, Q3w.
219581970|NCT06138236|DRUG|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
219581971|NCT00003960|DRUG|busulfan|
219581972|NCT00003960|DRUG|cyclophosphamide|
219581973|NCT00003960|DRUG|methylprednisolone|
219581974|NCT00003960|PROCEDURE|allogeneic bone marrow transplantation|
219581975|NCT00003960|PROCEDURE|in vitro-treated bone marrow transplantation|
219581976|NCT05759936|DIETARY_SUPPLEMENT|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
219581977|NCT05759936|OTHER|Placebo|4 week placebo supplement of 1 capsule per day
219581978|NCT01912274|DRUG|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
219581979|NCT01912274|DRUG|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
219581980|NCT05006768|DRUG|Barcimiant|1 tablet contains 4 mg Barcitinib
219581981|NCT05006768|DRUG|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
219581982|NCT05006768|DRUG|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
219581983|NCT02890836|DRUG|Antihypertensiva, mainly Metyldopa|
219581984|NCT02808949|DRUG|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
219441706|NCT00796003|DRUG|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
219581985|NCT00737763|DRUG|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
219441707|NCT00796003|DRUG|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
219441708|NCT03880006|BEHAVIORAL|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
219441709|NCT04123444|DRUG|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
219441710|NCT04123444|DRUG|Isotonic saline|Continuously infusion for 72 hours.
219441711|NCT02727504|DEVICE|Electrocardiogram|ECG at inclusion and M12
219441712|NCT02727504|DEVICE|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
219441713|NCT02727504|DEVICE|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
219581986|NCT00737763|DRUG|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
219581987|NCT04804865|OTHER|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
219581988|NCT05941455|DEVICE|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
218834478|NCT05484466|DRUG|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
218834479|NCT05484466|OTHER|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
218834480|NCT05484466|COMBINATION_PRODUCT|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
218834481|NCT03346187|DRUG|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
218834482|NCT03346187|DRUG|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
218834483|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
219015464|NCT03121547|DRUG|Placebo Oral Tablet|calcium tablet
219015465|NCT05589233|BIOLOGICAL|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
219441714|NCT02727504|BIOLOGICAL|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
219581989|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
219581990|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
219581991|NCT00132028|DRUG|vorinostat|Given orally
219581992|NCT00132028|OTHER|laboratory biomarker analysis|Correlative studies
219581993|NCT02041156|OTHER|aerobic and resistance training|
219581994|NCT02041156|OTHER|aerobic combined with balance training|
219581995|NCT04467801|DRUG|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
218834484|NCT03782259|OTHER|Placebo|Placebo
218834485|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
218834486|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
218834487|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
218834488|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
218834489|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
218834490|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
219015466|NCT00383149|DRUG|Ixabepilone|Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
219015467|NCT00383149|DRUG|Cetuximab|Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
219015468|NCT01166724|DRUG|Sirolimus|Tacrolimus to Sirolimus
219015469|NCT01166724|DRUG|Tacrolimus|dosage per trough level
219015470|NCT01270711|DRUG|Study Drug|non interventional study - usage as per usual care
219015471|NCT00604331|DRUG|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
219441715|NCT02727504|DEVICE|Cardiac MRI|Cardiac MRI at inclusion
219441716|NCT02727504|DEVICE|Cardiac scanner|Cardiac scanner at inclusion
219441717|NCT02727504|OTHER|6-minutes walking test|6-minutes walking test at inclusion and M12
219441718|NCT02727504|OTHER|Duke Activity Score|Duke Activity Score at inclusion and M12
219581996|NCT00889369|DRUG|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
219581997|NCT02909946|BEHAVIORAL|Multi-modal Infection Control Program|"1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
219581998|NCT00437840|DRUG|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
219581999|NCT00437840|DRUG|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
219441719|NCT00776373|DRUG|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
219441720|NCT00657930|DRUG|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
219441721|NCT02155504|DRUG|ASP3700|oral
219441722|NCT02155504|DRUG|itraconazole|oral
219441723|NCT02155504|DRUG|Placebo|oral
219441724|NCT01929512|DRUG|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
219441725|NCT01929512|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
219441726|NCT01929512|DRUG|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
219441727|NCT04409691|DRUG|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
218834491|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
218834492|NCT00828958|DRUG|Risperidone long-acting injectable|
218834493|NCT00128024|DRUG|lipid-lowering treatment|
218834494|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
218834495|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
218834496|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
218834497|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
218834500|NCT05069597|DRUG|CREON|Capsule; Oral
218834501|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
218834502|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
218834503|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
218834504|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
218834505|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
218834506|NCT04789629|DEVICE|low level laser therapy|3 session per week laser with exercises
218834507|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
218834508|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
219441728|NCT04409691|DRUG|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
219441729|NCT00529646|DRUG|APD791|
219441730|NCT03376776|PROCEDURE|Vitrectomy|
219441731|NCT03356795|BIOLOGICAL|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
219441732|NCT06002997|OTHER|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
219441733|NCT06002997|OTHER|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
219441734|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
219441735|NCT04420065|DEVICE|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
219441736|NCT04420065|DEVICE|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
219582000|NCT01517230|BEHAVIORAL|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
219582001|NCT04259983|OTHER|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
219582002|NCT04259983|OTHER|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
219582003|NCT04259983|OTHER|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
219582004|NCT01921530|PROCEDURE|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
219582005|NCT01921530|PROCEDURE|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
219582006|NCT02166814|DRUG|Fimasartan and Rosuvastatin|
218834509|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
218834510|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
219582007|NCT02166814|DRUG|Fimasartan|
219582008|NCT02166814|DRUG|Rosuvastatin|
219582009|NCT03473626|DRUG|Alicaforsen|Alicaforsen tablet
218834511|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
218834512|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
218834513|NCT00037518|DRUG|AMG 073|
218834514|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
218834515|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
218834516|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
218834517|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
218834518|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
218834519|NCT02243319|DRUG|HGP1201|
219582010|NCT03670290|PROCEDURE|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
219582011|NCT03670290|PROCEDURE|epidural catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
218834520|NCT02243319|DRUG|HGP0904|
218834521|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
219582012|NCT03670290|PROCEDURE|patient controlled analgesia|Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
219582013|NCT00150943|DEVICE|Renal artery stent|
219582014|NCT02344719|DRUG|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
219582015|NCT02344719|PROCEDURE|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
219015472|NCT04294511|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
219015473|NCT06020365|OTHER|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
219015474|NCT04997785|PROCEDURE|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
219015475|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
219015476|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
219015477|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
219015478|NCT03272490|PROCEDURE|Medartis|Surgery using the medartis implant
219015479|NCT03272490|PROCEDURE|Synthes|Surgery using the Synthes implant
219015480|NCT04453033|DEVICE|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
219015481|NCT02457910|OTHER|Biomarker Analysis|Correlative studies
219015482|NCT02457910|DRUG|Enzalutamide|Given PO
219015483|NCT02457910|OTHER|Pharmacological Study|Correlative studies
219015484|NCT02457910|DRUG|Taselisib|Given PO
219015485|NCT01331954|DEVICE|Ultrasonic ablation device|One or two HIFU procedures
219015486|NCT05076474|DRUG|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
219015487|NCT02223273|BEHAVIORAL|Multifaceted Strategy|"1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices"
219015488|NCT03630003|DEVICE|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
219015489|NCT03630003|OTHER|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
219441737|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
219441738|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
219441739|NCT00644813|OTHER|Scapular with glenoid neck fractures|
219441740|NCT05092347|DRUG|Vonsetamig|Administered by intravenous (IV) infusion
219441741|NCT02437162|DRUG|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
219441742|NCT02437162|DRUG|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
219441743|NCT02437162|DRUG|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
219015490|NCT04304807|DRUG|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
219015491|NCT04304807|DRUG|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
219015492|NCT00438087|DRUG|methylprednisolone|methylprednisolone administrated intra and post operatively
219015493|NCT01096264|OTHER|SSI and SphygmoCor® evaluations|"* SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
219441744|NCT02437162|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
219015494|NCT02315170|DEVICE|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
219015495|NCT02315170|DEVICE|standard lid speculum|standard wire lid speculum
219441745|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
219441746|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
219015496|NCT00619801|DRUG|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
219015497|NCT00619801|DRUG|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
219582016|NCT02344719|PROCEDURE|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
219582017|NCT02344719|DRUG|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
219441747|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
219582018|NCT06022900|BEHAVIORAL|Online training group|online health education with video call
219582019|NCT06022900|BEHAVIORAL|Face-to-face training group|Face-to-face health education with home visit
219582020|NCT06010537|DRUG|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
219582021|NCT05310162|BEHAVIORAL|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
219582022|NCT05310162|BEHAVIORAL|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
219582023|NCT04732910|DRUG|Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor|observational
219582024|NCT04647721|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
219441748|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
219582025|NCT04647721|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection.
219582026|NCT05070546|BIOLOGICAL|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
218834522|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
219582027|NCT05070546|OTHER|Placebo|Participants will receive a single IM injection of matching placebo.
219582028|NCT03262506|OTHER|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
219441749|NCT04338321|DRUG|Esketamine 28 mg|Esketamine will be self-administered at a dose of 28 mg as nasal spray.
219441750|NCT04338321|DRUG|Esketamine 56 mg|Esketamine will be self-administered at a dose of 56 mg as nasal spray.
219441751|NCT04338321|DRUG|Esketamine 84 mg|Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
219582029|NCT00853086|DRUG|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
219582030|NCT06249776|DEVICE|Supernova revascularization device|Mechanical Thrombectomy
219582031|NCT05841732|OTHER|Usual Care|Education; Pain Medication, imaging, referrals to other health services, other health care appointments
218834523|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
218834524|NCT04353375|DRUG|HMPL-453|Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
219441752|NCT04338321|DRUG|Quetiapine XR 50 mg|Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
219582032|NCT05841732|OTHER|MyBack Program|A tailored exercise and behavioural change program
218834525|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
219441753|NCT04338321|DRUG|Quetiapine XR 100 mg|Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
219441754|NCT04338321|DRUG|Quetiapine XR 150 mg|Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
219441755|NCT04338321|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
219582033|NCT04180176|OTHER|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
219582034|NCT01956019|DEVICE|MRI scanning|
219582035|NCT00535587|BEHAVIORAL|Exercise|
219582036|NCT00535587|DRUG|pyridostigmine|
219582037|NCT00535587|DRUG|Placibo|
219582038|NCT00535587|BEHAVIORAL|Attention Control|
219582039|NCT04944719|DIAGNOSTIC_TEST|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
219582040|NCT02689245|DRUG|Tenofovir|
219582041|NCT02689245|DRUG|Fecal Microbiota Transplantation (FMT)|
219582042|NCT00183885|DRUG|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
219582043|NCT01567748|PROCEDURE|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
219582044|NCT01078129|BEHAVIORAL|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
219582045|NCT01078129|BEHAVIORAL|non-CRT|waiting list
218834526|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
218834527|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
218834528|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
218834529|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
218834530|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
218834531|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
218834532|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
218834533|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
218834534|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
218834535|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
219441756|NCT03107793|DRUG|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
218834536|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
218834537|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
218834538|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
218834539|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
218834540|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
218834541|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
218834542|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
218834543|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
218834544|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
218834545|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
218834546|NCT01882712|DRUG|CD07805/47 Gel Placebo|
218834547|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
219441757|NCT06122909|DRUG|Group VTI|Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
219441758|NCT06122909|DRUG|Group IVC|Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
219441759|NCT06685484|BEHAVIORAL|Modified Mindfulness Training Program (MMTP)|"The intervention, designed as a Modified Mindfulness Training Program (MMTP), aims to reduce antenatal depression and perceived stress among pregnant women, especially those with a preference for a male child. This program is adapted to address culturally specific stressors relevant to these women, promoting mental health and resilience during pregnancy.~The intervention is based on Nola Pender's Health Promotion Model and structured using the ADAPT-ITT framework, which includes Assessment, Decision, Adaptation, Production, Topical Experts, Integration, Training, and Testing phases. This phased approach ensures cultural relevance and feasibility within the target population of pregnant women in Pakistan.~Duration and Frequency: The intervention consists of six weekly sessions, each lasting two hours, held in a serene, controlled environment within a seminar room at Sindh Govt. Qatar Hospital, Karachi."
219582046|NCT01168765|BEHAVIORAL|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
219582047|NCT05314114|PROCEDURE|No axillary surgery|No axillary surgery
219441760|NCT02808507|OTHER|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
219441761|NCT06667401|DEVICE|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia.We also aim to see of how it enhances teaching and training of residents by experienced regional anesthesia providers. We intend to use surveys/questionnaires of both resident and regional anesthesia provider as they utilize the device in real time.
219582048|NCT05249530|OTHER|Chiropractic spinal adjustment|Chiropractic spinal adjustment
218834548|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
219582049|NCT05249530|OTHER|Non-force simulation|Non-force simulation
219582050|NCT00816361|DRUG|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
219582051|NCT03306953|PROCEDURE|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
218834549|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
219441762|NCT03198286|OTHER|Informational Intervention|Receive treatment summary and survivor care plan
219582052|NCT05028049|DRUG|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
219582053|NCT05028049|DRUG|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
219582054|NCT05028049|OTHER|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
219582055|NCT05028049|OTHER|plateau areas|Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
219582056|NCT00436904|DRUG|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
219582057|NCT00436904|DRUG|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
219582058|NCT00546572|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
219582059|NCT00546572|BIOLOGICAL|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
219582060|NCT01472328|PROCEDURE|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
219582061|NCT01472328|PROCEDURE|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
219582062|NCT04629261|BEHAVIORAL|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
219582063|NCT02902783|OTHER|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
219582064|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
219582065|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
218834550|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
218834551|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
219015498|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
219015499|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
219015500|NCT00450333|DRUG|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
219015501|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
219582066|NCT02546401|DRUG|Insulin Aspart|Injection of Insulin Aspart before or after meals
219582067|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
219582068|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
219441763|NCT04248192|BIOLOGICAL|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
219441764|NCT06527196|BEHAVIORAL|Team Communication Training|Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
219441765|NCT06527196|BEHAVIORAL|Early Identification Universal Depression Screening|Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
219441766|NCT01989572|OTHER|Laboratory Biomarker Analysis|Correlative studies
219582069|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
218834552|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
218834553|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
218834554|NCT00290719|DRUG|cisplatin|
218834555|NCT00290719|DRUG|gefitinib|
218834556|NCT00290719|DRUG|irinotecan hydrochloride|
218834557|NCT00290719|PROCEDURE|conventional surgery|
218834558|NCT00290719|PROCEDURE|neoadjuvant therapy|
219015502|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
219441767|NCT01989572|OTHER|Placebo|Given GM-CSF placebo SC
219441768|NCT01989572|OTHER|Placebo|Given peptide placebo SC
219441769|NCT01989572|BIOLOGICAL|Sargramostim|Given SC
219441770|NCT01989572|BIOLOGICAL|Tyrosinase Peptide|Given SC
219441771|NCT06322017|PROCEDURE|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|"The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner."
219441772|NCT06322017|DRUG|Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)|"Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations."
219441773|NCT03009149|OTHER|Aerobic exercise|Aerobic exercise will perform 3 days per week
219441774|NCT01665976|DRUG|RO4917838|film coated tablet, single dose
219441775|NCT01665976|DRUG|RO4917838|oral suspension, single dose
219441776|NCT01665976|DRUG|RO4927838|hard gelatin capsule, single dose
219441777|NCT02910089|BEHAVIORAL|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
219582070|NCT01120041|BEHAVIORAL|health education|Traditional health education given during the prenatal phase and the postpartum phase
219582071|NCT01690741|DRUG|Nerofe|Nerofe administered intravenously 3x/week
219764425|NCT07005674|BEHAVIORAL|Cycle Nation|Participants will be asked to attend nine weekly 90-minute face-to-face sessions, delivered by trained facilitators at community cycling organisations. Sessions include off road cycling skills and on-road group rides, behaviour change techniques (e.g. goal setting), and bicycle maintenance training. Two extra group rides will be offered during the programme for additional practice, along with two catch-up sessions at the end for those who missed any content. Participants will be added to a WhatsApp group to encourage peer communication. Bicycles, helmets, and locks will be loaned to participants for 10-12 weeks to support participation.
219015503|NCT00450333|DRUG|Dynepo|subcutaneous, Q2W for 24 weeks
219015504|NCT00616681|DRUG|Oxcarbazepine|
219015505|NCT05931354|OTHER|HPV test and Pap Smear|HPV test and Pap Smear
219015506|NCT00230230|DRUG|SCH 486757|
219015507|NCT04100304|DIAGNOSTIC_TEST|resection|CT volumetry,liver function,biopsy before resection
219015508|NCT03659305|BIOLOGICAL|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
219015509|NCT03659305|BIOLOGICAL|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
218834559|NCT00290719|RADIATION|radiation therapy|
218834560|NCT02869581|OTHER|Data collection|
218834561|NCT01485796|BIOLOGICAL|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
218834562|NCT01485796|BIOLOGICAL|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
218834563|NCT04089527|DRUG|CC-95775|CC-95775
218834564|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
218834565|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
219015510|NCT02469454|DRUG|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
219015511|NCT02469454|DRUG|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
219015512|NCT06296758|PROCEDURE|Regional anesthesia|ultrasound-guided suprainguinal fascia iliaca block with 40ml of ropivacaine local or ultrasound-guided femoral nerve block with 20ml of ropivacaine local anesthetic
219015513|NCT05429762|DRUG|Tusamitamab ravtansine|Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion
218834566|NCT04444271|DRUG|Mesenchymal stem cells|1\. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
219015514|NCT02941445|DRUG|sitagliptin and metformin|
219015515|NCT02941445|DRUG|Metformin|
219015516|NCT01689701|DIETARY_SUPPLEMENT|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
219441778|NCT03644381|OTHER|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
219441779|NCT00732238|OTHER|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
218834567|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
219441780|NCT00732238|OTHER|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
219441781|NCT04689217|DRUG|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
219441782|NCT04212403|DRUG|Levofloxacin|The control group receives AMP.
219441783|NCT00826384|PROCEDURE|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
219441784|NCT06009575|DIETARY_SUPPLEMENT|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
218834568|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
219441785|NCT00632515|BEHAVIORAL|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
219015517|NCT01689701|DIETARY_SUPPLEMENT|Placebo|Placebo(1.3g/d)
219441786|NCT01455155|OTHER|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
219015518|NCT05360576|DRUG|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
219015519|NCT05360576|DRUG|NuvaRing Vaginal Ring|To prevent pregnancy
218834569|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
219015520|NCT06560762|DRUG|STM01|Neonatal mesenchymal stem cells (nMSCs),
218834570|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
218834571|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
218834572|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
218834573|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
219015521|NCT04925037|BEHAVIORAL|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
219015522|NCT04235231|DEVICE|Bed tilting|15° lateral tilt, original product brand name LINET Eleganza 5
219015523|NCT04235231|OTHER|Body positioning|Manual positioning of body by nurse: left side, back, right side, using positioning pillows
219015524|NCT05116930|DRUG|Neostigmine|IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
219015525|NCT05116930|DRUG|Glycopyrrolate|IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
219015526|NCT03253250|DRUG|ETV；TDF；ADV|NAs
219015527|NCT03253250|DRUG|Peginterferon Alfa-2a|peginterferon
219015528|NCT02375113|DIETARY_SUPPLEMENT|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
219015529|NCT01948453|DIETARY_SUPPLEMENT|Garlic|Garlic tablet in adjunct to medical treatment
218834574|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
219015530|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
219015531|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
219015532|NCT00388271|DRUG|Alfuzosin (Xatral)|standard treatment plus alfuzosin
219015533|NCT00388271|DRUG|standard treatment|standard treatment
219015534|NCT03107754|DRUG|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
219015535|NCT03107754|DRUG|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
218834575|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
218834576|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
219015536|NCT04756791|PROCEDURE|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
219015537|NCT04756791|PROCEDURE|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
219015538|NCT04918264|DRUG|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
219015539|NCT04918264|OTHER|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
219015540|NCT04918264|BEHAVIORAL|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
219015541|NCT02766725|DRUG|preparation F12 sildenafil in situ gel|in situ vaginal gel
219015542|NCT02766725|DRUG|preparation F2 sildenafil in situ gel|in situ vaginal gel
219015543|NCT02766725|DRUG|placebo gel|vaginal gel
219015544|NCT01721382|DRUG|Sitagliptin|
219015545|NCT00734903|BEHAVIORAL|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
219015546|NCT00734903|BEHAVIORAL|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
219015547|NCT06391151|OTHER|exposure: OSA resulting from chronic tonsillitis|exposure: OSA resulting from chronic tonsillitis
219015548|NCT03259204|DEVICE|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
219015549|NCT01953120|DRUG|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
219441787|NCT01455155|OTHER|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
219441788|NCT00736606|DRUG|simvastatin|One single dose of 40mg
219441789|NCT00736606|DRUG|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
219441790|NCT05537961|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
219441791|NCT02280096|DRUG|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
219441792|NCT02280096|DRUG|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
219441793|NCT02047708|DRUG|Zibotentan|Selective endothelin-A antagonist
219441794|NCT00521118|OTHER|Laboratory Biomarker Analysis|Correlative studies
218834577|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
218834578|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
218834579|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
218834580|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
218834581|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
218834582|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
218834583|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
218834584|NCT01485276|PROCEDURE|DBS Surgery|
219015550|NCT02516215|OTHER|No intervention|
219015551|NCT04300114|DRUG|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
219015552|NCT04300114|DRUG|Placebo|Placebo capsules po. twice daily
219015553|NCT05729659|DIETARY_SUPPLEMENT|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
219015554|NCT05729659|DIETARY_SUPPLEMENT|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
219015555|NCT03760211|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
219441795|NCT00521118|PROCEDURE|Therapeutic Conventional Surgery|Undergo second curettage
219475588|NCT05085236|PROCEDURE|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
219015556|NCT03760211|BEHAVIORAL|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
219582072|NCT05237336|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
219582073|NCT05237336|BEHAVIORAL|Counselling as usual|Control group, Counselling as usual
219582074|NCT02310711|OTHER|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
219582075|NCT04373044|DRUG|Baricitinib|Given PO
219582076|NCT04373044|DRUG|Hydroxychloroquine|Given PO
218834585|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
219582077|NCT04373044|DRUG|Placebo Administration|Given Po
219582078|NCT06179927|OTHER|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
219582079|NCT06179927|OTHER|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
219582080|NCT00044967|GENETIC|microsatellite instability analysis|
219582081|NCT00543608|DRUG|iclaprim|
219582082|NCT00543608|DRUG|vancomycin|
219582083|NCT05033912|DRUG|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
219582084|NCT01355159|DRUG|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
219582085|NCT01355159|DRUG|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
219582086|NCT01634282|DRUG|OPC-262|Orally administered once daily
219582087|NCT05143151|BIOLOGICAL|CD276 CAR-T cells|CD276 CAR-T cells infusion
219582088|NCT00937651|DRUG|Placebo|Placebo
219582089|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
219582090|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
219582091|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
219582092|NCT00004153|GENETIC|reverse transcriptase-polymerase chain reaction|
219582093|NCT00004153|PROCEDURE|sentinel lymph node biopsy|
219582094|NCT05801653|DIETARY_SUPPLEMENT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
219582095|NCT01254682|DEVICE|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
219582096|NCT01254682|PROCEDURE|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
218834586|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
218834587|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
218834588|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
218834589|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
218834590|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
218834591|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
218834592|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
218834593|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
218834594|NCT04954300|OTHER|no intervention|No intervention
219582097|NCT02056470|DEVICE|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
218834595|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
218834596|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
218834597|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
218834598|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
218834599|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
218834600|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
219015557|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
219015558|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class I|New york Heart Association Class I
219015559|NCT06095453|OTHER|Pain control regimens|Narcotics in cholecystectomy and hernia repairs
219015560|NCT03196934|DRUG|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
219441796|NCT05756205|DEVICE|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
219441797|NCT02296905|DRUG|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
219441798|NCT02296905|DRUG|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
219441799|NCT00410345|DRUG|Mifepristone|
218834601|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
218834602|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
218834603|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
218834604|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
218834605|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
218834606|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
218834607|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
218834608|NCT02793973|DEVICE|shoe lifts|
218834609|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
218834610|NCT01736423|DRUG|YM060|oral
218834611|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
218834612|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
218834613|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
218834614|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
218834615|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
219015561|NCT04253145|DRUG|PM 01183|Lyophilisate for solution for infusion
219015562|NCT04253145|DRUG|Atezolizumab|Concentrate for solution for infusion
219015563|NCT01868685|DRUG|BYM338|BYM338
219015564|NCT01868685|DRUG|Placebo|Placebo
219015565|NCT05609240|DRUG|Cefuroxime|See arm/group description
219015566|NCT01347008|DRUG|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
219015567|NCT01347008|DRUG|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
219015568|NCT03403595|DRUG|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
219015569|NCT00776958|OTHER|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
219015570|NCT05102799|OTHER|No intervention|No intervention
219475589|NCT05085236|PROCEDURE|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
219475590|NCT06160414|DRUG|Metformin|Participants will receive Metformin orally, after fasting.
219475591|NCT06160414|DRUG|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
219475592|NCT06160414|DRUG|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
219582098|NCT02056470|DEVICE|Total Knee Replacement|total Knee replacement implant
218834616|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
218834617|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
218834618|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
219015571|NCT05901168|OTHER|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
219015572|NCT05901168|OTHER|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
219015573|NCT06179797|DEVICE|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
219015574|NCT02968927|DRUG|Everolimus 0.5 MG|
219441800|NCT05934890|BIOLOGICAL|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
219441801|NCT05934890|BIOLOGICAL|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
219441802|NCT04308109|BEHAVIORAL|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
219441803|NCT06181708|OTHER|N/A - Questionnaire based study|Questionnaire based study
219441804|NCT04517916|DEVICE|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
219582099|NCT02056470|DEVICE|Freedom Total Knee System|Total Knee replacement implant
219582100|NCT05116488|DIAGNOSTIC_TEST|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
219015575|NCT02968927|DRUG|Auranofin 6 MG|
219015576|NCT02968927|DRUG|Vitamin D3|
219015577|NCT02968927|DRUG|CC-11050|
219764426|NCT07005674|BEHAVIORAL|Cycling Scotland standard cycling session|Participants will be asked to participate in Cycling Scotland's 'Introduction to On-Road Cycling' a single 2-2.5-hour session that is offered as standard. The session covers key cycling skills such as hazard awareness, road positioning, and communicating with other road users. Activities are tailored to participants' needs and may include navigating junctions, using shared infrastructure, and performing U-turns. Bicycles and helmets will be provided for the session.
219764427|NCT06868264|DRUG|Bemnifosbuvir-Ruzasvir (BEM/RZR)|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
219015578|NCT02968927|DRUG|2HRbZE/4HRb|
219015579|NCT03176329|OTHER|Nursing 1 : INTELLIVENT-ASV|
219015580|NCT03176329|OTHER|Nursing 2 : INTELLIVENT-ASV|
219015581|NCT03176329|OTHER|Nursing 1 : Conventional mode|
219015582|NCT03176329|OTHER|Nursing 2 : Conventional mode|
219015583|NCT00622479|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
219582101|NCT04594174|PROCEDURE|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
219582102|NCT03982576|OTHER|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
219582103|NCT03982576|BEHAVIORAL|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
219582104|NCT03982576|BEHAVIORAL|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
219582105|NCT03982576|BEHAVIORAL|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
219582106|NCT03982576|BEHAVIORAL|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
218834619|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
218834620|NCT01390298|OTHER|Observational|Observational study only
218834621|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
218834622|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
218834623|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
218834624|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
218834625|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
218834626|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
218834627|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
218834628|NCT00040742|OTHER|placebo|Given orally
218834629|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
218834630|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
218834631|NCT00392834|BIOLOGICAL|rituximab|given IV
218834632|NCT00392834|DRUG|cyclophosphamide|given IV
218834633|NCT00392834|DRUG|cytarabine|given intrathecally
218834634|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
218834635|NCT00392834|DRUG|etoposide|given IV
218834636|NCT00392834|DRUG|ifosfamide|given IV
218834637|NCT00392834|DRUG|leucovorin calcium|given IV
219015584|NCT03642236|DRUG|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
219015585|NCT03946384|OTHER|data collection|data collection on the history of the disease, hemophilia
219015586|NCT03643640|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
219582107|NCT04700280|DRUG|GLPG3970|GLPG3970 film-coated tablet.
219582108|NCT04700280|DRUG|Placebo|Placebo film-coated tablet.
219582109|NCT01742780|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
218834638|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
218834639|NCT00392834|DRUG|methotrexate|given intrathecally
218834640|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
218834641|NCT00392834|DRUG|vincristine sulfate|given IV
218834642|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
218834643|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
218834644|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
218834645|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
218834646|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
218834647|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
218834648|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
218834649|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
218834650|NCT03999099|DRUG|Placebo oral tablet|Placebo
218834651|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
218834652|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
218834653|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
218834654|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
219015587|NCT03643640|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
219764428|NCT06868264|DRUG|Sofosbuvir-Velpatasvir (SOF/VEL)|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
219015588|NCT00647790|PROCEDURE|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
219015589|NCT00531817|DRUG|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
219015590|NCT00531817|DRUG|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
219441805|NCT06154993|OTHER|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
219441806|NCT06154993|OTHER|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
219441807|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol|Patients would begin taking myoinositol upon recruitment
219441808|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol placebo|Patients would begin taking placebo upon recruitment
219441809|NCT06642311|PROCEDURE|Empty bladder group|Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty. All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
219441810|NCT06642311|PROCEDURE|Bladder distension group|Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended . All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
219441811|NCT03892434|DRUG|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
219441812|NCT03892434|DEVICE|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
219441813|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
219441814|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
219441815|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
219441816|NCT04826120|PROCEDURE|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
219441817|NCT04826120|PROCEDURE|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
219441818|NCT00979472|DRUG|Solifenacin|oral
219441819|NCT05074394|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
219441820|NCT05074394|DRUG|Placebo|Diluent solution
219441821|NCT03525873|OTHER|Laboratory Biomarker Analysis|Correlative studies
219764429|NCT06617858|DRUG|AMB-05X|Given by IV
218834655|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
218834656|NCT00405392|DRUG|Ibandronate (SB743830HD)|
218834657|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
218834658|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
218834659|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
218834660|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
218834661|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
218834662|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
218834663|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
218834664|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
218834665|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
218834666|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
218834667|NCT00955643|OTHER|oxygen|
218834668|NCT00955643|OTHER|other|
218834669|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
219015591|NCT00531817|DRUG|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
219015592|NCT03181204|PROCEDURE|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
219015593|NCT03181204|PROCEDURE|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
219015594|NCT03181204|PROCEDURE|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
219015595|NCT03338855|DRUG|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
219441822|NCT03525873|DRUG|Methylphenidate|Given PO
219441823|NCT03525873|OTHER|Physical Activity|Participate in physical activity
219582110|NCT03358160|BEHAVIORAL|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
219582111|NCT04627480|DEVICE|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
219015596|NCT04857515|DEVICE|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
219015597|NCT00511667|DRUG|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
219015598|NCT00511667|DRUG|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
219015599|NCT04053192|PROCEDURE|BAV|BAV
219015600|NCT04053192|PROCEDURE|BAV + TAVR|BAV + TAVR
219015601|NCT04053192|PROCEDURE|SAVR|Surgical aortic valve replacement (SAVR)
219015602|NCT00056407|DRUG|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
219015603|NCT00056407|DRUG|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
219015604|NCT04394104|OTHER|Survey|No intervention is being administered.
219015605|NCT03487757|OTHER|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
219015606|NCT03487757|OTHER|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
219015607|NCT05230225|BEHAVIORAL|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
219015608|NCT02543645|DRUG|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
219015609|NCT01230268|OTHER|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
219015610|NCT02042248|BIOLOGICAL|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
219015611|NCT01073982|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
219441824|NCT03525873|OTHER|Placebo|Given PO
219441825|NCT03525873|OTHER|Quality-of-Life Assessment|Ancillary studies
219441826|NCT03525873|OTHER|Questionnaire Administration|Ancillary studies
219441827|NCT03438513|BEHAVIORAL|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
219441828|NCT03438513|BEHAVIORAL|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
219441829|NCT03438513|BEHAVIORAL|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
219441830|NCT03438513|BEHAVIORAL|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
219441831|NCT01733524|BEHAVIORAL|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
219764430|NCT06865079|DRUG|TPX-100 200mg, Once weekly for 4 weeks|"TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 \& 4) to a single target knee of the subject for 4 injections.~TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection."
219015612|NCT05748977|DRUG|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
219015613|NCT00324324|DRUG|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
219015614|NCT00324324|DRUG|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
219015615|NCT05372328|OTHER|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
219015616|NCT00816231|BEHAVIORAL|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
219015617|NCT00816231|OTHER|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
219015618|NCT00816231|OTHER|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
219015619|NCT03666845|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
219015620|NCT02158104|PROCEDURE|Deep dry needling|
219441832|NCT01733524|BEHAVIORAL|Picture of a fish|Participants will receive a picture of a betta fish.
219441833|NCT00246376|BEHAVIORAL|Diet|ATP-III diet
219441834|NCT00246376|BEHAVIORAL|Exercise|Supervised exercise in study gym
219441835|NCT00246376|DRUG|Niacin|Niaspan, titrated up to 2 grams per day
219441836|NCT00246376|DRUG|Fenofibrate|Tricor, 120 mg per day
219441837|NCT00246376|OTHER|Placebos|Placebos for Niaspan and Tricor
219441838|NCT03998241|OTHER|No intervention was provided|No intervention given
219441839|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
219441840|NCT05310669|DEVICE|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose).
219441841|NCT06183554|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary aldosteronism will receive a CXCR4 PET imaging.
219582112|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
219582113|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
219015621|NCT00129493|BEHAVIORAL|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
219015622|NCT06046456|OTHER|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
219015623|NCT06018259|PROCEDURE|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
219015624|NCT05821868|DEVICE|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
219015625|NCT05821868|DEVICE|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
219015626|NCT05517889|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
219015627|NCT01665066|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
219015628|NCT01665066|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
219015629|NCT01665066|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
219441842|NCT00047593|DRUG|IOP Lowering Medications|
219441843|NCT00558233|BEHAVIORAL|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
219441844|NCT00558233|BEHAVIORAL|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
219441845|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
219441846|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
219441847|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
219582114|NCT02555020|DIETARY_SUPPLEMENT|Allocated to MN NPO group,|Patients received NPO from MN.
219764431|NCT06865079|OTHER|PBS|PBS / placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections
219441848|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
219582115|NCT04555304|DRUG|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
219441849|NCT03371212|DEVICE|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
219441850|NCT03371212|DEVICE|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
219015630|NCT01665066|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
219582116|NCT04555304|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
219582117|NCT00352235|DRUG|KRN7000|
219582118|NCT03509714|DIETARY_SUPPLEMENT|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
219582119|NCT03509714|DIETARY_SUPPLEMENT|rice flour (Placebo)|250 mg rice flour (Placebo)
219582120|NCT01908790|DEVICE|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
219015631|NCT01665066|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
219015632|NCT02967497|DRUG|YQ1|Oral administered powder
219582121|NCT01908790|DEVICE|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
219441851|NCT02621255|DRUG|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
219441852|NCT02621255|DRUG|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
219441853|NCT04964804|PROCEDURE|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
219441854|NCT04964804|PROCEDURE|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
219582122|NCT01393184|DRUG|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
219582123|NCT02743143|BEHAVIORAL|Exercise therapy|
219582124|NCT02743143|OTHER|Follow-up care as usual|
219582125|NCT03380533|DRUG|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
219582126|NCT03380533|DRUG|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
219582127|NCT03380533|DRUG|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
219582128|NCT03380533|DRUG|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
219441855|NCT01137448|BEHAVIORAL|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
219441856|NCT05682768|PROCEDURE|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
219441857|NCT00024674|DRUG|SS1(dsFv)-PE38|
219582129|NCT03380533|DRUG|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
219582130|NCT06273787|OTHER|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
219582131|NCT00305552|DRUG|THALIDOMIDE|THALIDOMIDE
219582132|NCT05617937|OTHER|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
219582133|NCT06202924|BEHAVIORAL|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
219582134|NCT06202924|BEHAVIORAL|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
219764432|NCT06619509|DRUG|Brigimadlin|Brigimadlin
219015633|NCT01338831|DRUG|LFA102|
219015634|NCT01857388|BEHAVIORAL|ParentCorps|
219015635|NCT02793102|OTHER|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
219015636|NCT02793102|OTHER|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
219015637|NCT02793102|OTHER|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
219015638|NCT05814887|DEVICE|ReLink|Medical device
219015639|NCT03256539|BEHAVIORAL|Sleep intervention|Behavioral sleep intervention program
219015640|NCT03256539|BEHAVIORAL|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
219764433|NCT02266615|GENETIC|Biobanking of biomaterial for future genetic research.|
219764434|NCT03141684|DRUG|Atezolizumab|Given IV
219764435|NCT03141684|BIOLOGICAL|Bevacizumab|Given IV
219764436|NCT03141684|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine
219764437|NCT03141684|PROCEDURE|Computed Tomography|Undergo CT
219582135|NCT06202924|BEHAVIORAL|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
219582136|NCT06446141|OTHER|Osteopathic technique|Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
218834670|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
219441858|NCT00780104|DRUG|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
219441859|NCT00780104|DRUG|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
219441860|NCT01655641|DRUG|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
219441861|NCT01655641|OTHER|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
219441862|NCT02795065|DRUG|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
219582137|NCT02907541|OTHER|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
219582138|NCT02907541|OTHER|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
219582139|NCT02907541|OTHER|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
219582140|NCT04158336|DRUG|ZN-c3|ZN-c3 is a study drug
218834671|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
218834672|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
219441863|NCT02795065|DRUG|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
219441864|NCT06380972|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
219582141|NCT02448121|PROCEDURE|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
219582142|NCT04799678|OTHER|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
219582143|NCT03827928|BEHAVIORAL|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
219582144|NCT02581007|DRUG|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
219582145|NCT02581007|DRUG|Melphalan|
219582146|NCT02581007|DRUG|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
219582147|NCT02581007|PROCEDURE|peripheral blood stem cell transplant|
219764438|NCT04070183|BEHAVIORAL|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
219764439|NCT04070183|BEHAVIORAL|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
218834673|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
218834674|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
218834675|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
218834676|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
219582148|NCT00630890|RADIATION|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
218834677|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
219015641|NCT04891783|DEVICE|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
219015642|NCT06209645|DEVICE|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
219015643|NCT06209645|DEVICE|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
219015644|NCT03556189|DEVICE|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
219441865|NCT05538429|PROCEDURE|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
219441866|NCT04563104|DIAGNOSTIC_TEST|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
219764440|NCT07000084|BIOLOGICAL|BCG Solution|Given intravesically
218834678|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
218834679|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
218834680|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
218834681|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
218834682|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
218834683|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
218834684|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
218834685|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
219015645|NCT01375985|DRUG|AVI-7100|Single intravenous administration
219015646|NCT01375985|DRUG|Placebo|Single intravenous administration
219015647|NCT02242409|DRUG|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
219015648|NCT01026792|DRUG|Temsirolimus|Given IV
219015649|NCT01026792|OTHER|Laboratory Biomarker Analysis|Correlative studies
219015650|NCT04859881|OTHER|No intervention|No intervention
219015651|NCT03968302|DRUG|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
219015652|NCT03968302|DRUG|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
219015653|NCT00423150|DRUG|Temozolomide|Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
219441867|NCT04685369|OTHER|Medical Data extraction|Medical Data extraction
219582149|NCT00932139|PROCEDURE|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
219764441|NCT07000084|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
219764442|NCT07000084|PROCEDURE|Cystoscopy|Undergo cystoscopy
219764443|NCT07000084|PROCEDURE|Computed Tomography|Undergo CT Scan
219764444|NCT07000084|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219015654|NCT04018950|DRUG|ETX2514|intravenous infusion
219015655|NCT04018950|DRUG|14C-ETX2514|intravenous infusion
219196186|NCT05378620|BEHAVIORAL|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
219196187|NCT06803732|OTHER|Observations on postoperative pain intensity|pain intensity was assessed using a standard visual analogue score, with a score of 0 to 10 corresponding to no pain to the most severe pain on operation day, postoperative day 1, postoperative month 1, postoperative month 3
219196188|NCT01850888|DRUG|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
219441868|NCT04018105|OTHER|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
219441869|NCT06186024|DEVICE|Bridge|Stent implantation
219441870|NCT00005065|DRUG|paclitaxel|Given IV
219441871|NCT00005065|DRUG|carboplatin|Given IV
219441872|NCT00005065|DRUG|motexafin gadolinium|Given IV
219441873|NCT00005065|PROCEDURE|conventional surgery|Undergo complete surgical resection
219441874|NCT00005065|RADIATION|radiation therapy|Undergo radiation therapy
219441875|NCT03605836|DRUG|Centanafadine SR|100 mg, BID, oral tablets
219441876|NCT03605836|OTHER|Placebo|BID, oral tablet
219441877|NCT03605836|DRUG|Centanafadine SR|200 mg, BID, oral tablets
219441878|NCT02474628|DIETARY_SUPPLEMENT|sodium bicarbonate|
219441879|NCT02474628|DIETARY_SUPPLEMENT|calcium carbonate|
219441880|NCT00194415|BEHAVIORAL|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
219441881|NCT00194415|PROCEDURE|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
219441882|NCT00964639|DRUG|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
219441883|NCT00964639|DRUG|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
219441884|NCT06315686|DRUG|pemetrexed|The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
219441885|NCT00260091|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
219441886|NCT00260091|PROCEDURE|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
219441887|NCT03968211|BIOLOGICAL|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
219441888|NCT02463227|BIOLOGICAL|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
219441889|NCT04696328|BIOLOGICAL|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
219764445|NCT07000084|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219015656|NCT04082325|DRUG|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
219015657|NCT04082325|DRUG|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
219015658|NCT04082325|DRUG|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
219015659|NCT04082325|DRUG|Placebo|Placebo to Lu AF88434 oral solution, single dose
219015660|NCT02051946|DEVICE|Retroject Device|
219441890|NCT03746340|DRUG|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
219441891|NCT03746340|DRUG|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
219441892|NCT02845440|OTHER|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
219764446|NCT07000084|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
219015661|NCT02051946|DRUG|ethacrynic acid injection|
219015662|NCT02051946|DRUG|balanced salt solution|
219441893|NCT02845440|OTHER|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
219764447|NCT07000084|DRUG|Gemcitabine|Given intravesically
219015663|NCT02316041|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
219015664|NCT02316041|DEVICE|ReLEx® (SMILE)|
219015665|NCT03510520|DEVICE|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
219015666|NCT03510520|DEVICE|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
219015667|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
219015668|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
219015669|NCT05398562|DIAGNOSTIC_TEST|Placebo|solution for intradermal injection
219015670|NCT04963933|DEVICE|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
219015671|NCT00743327|DRUG|Pioglitazone|45mg capsule, once daily for 1 year
219441894|NCT02845440|OTHER|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
219441895|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
219441896|NCT02894892|DRUG|(A)Bismuth|
219441897|NCT02894892|DRUG|(B)Bismuth|
219441898|NCT02894892|DRUG|(C)Bismuth|
219441899|NCT02894892|DRUG|(D)Esomeprazole and Bismuth|
219441900|NCT02894892|DRUG|(E)Esomeprazole and Bismuth|
219441901|NCT02894892|DRUG|(F)Esomeprazole and Bismuth|
219441902|NCT02894892|OTHER|(G)Control|
219441903|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
219441904|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
219441905|NCT04428762|DEVICE|I-Port Advance use|participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
219441906|NCT02057068|BEHAVIORAL|SLEEP-E Dyads Intervention|Described in arm/group description
219441907|NCT03127462|BEHAVIORAL|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
219441908|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
219441909|NCT04802928|DRUG|Placebo|Placebo
219441910|NCT00865046|OTHER|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
219764448|NCT06149481|DRUG|Retifanlimab|500 mg infused via IV over 30 minutes every 28 days
219015672|NCT02919501|DRUG|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
219015673|NCT02919501|OTHER|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
219015674|NCT02919501|DRUG|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
219441911|NCT00865046|OTHER|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
219015675|NCT03204305|DRUG|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
219015676|NCT03204305|DRUG|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
219015677|NCT05105061|DRUG|Ketamine (Ketalar)|0.5 mg/kg of body weight
219015678|NCT05105061|DRUG|Placebo|IM injection of matching placebo
219441912|NCT00235053|DRUG|fluticasone/salmeterol DISKUS 250/50|
219441913|NCT01222897|DRUG|Valacyclovir hydrochloride|
219441914|NCT05326568|OTHER|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
219441915|NCT06387277|OTHER|RV1551P GB3224|"RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9)."
219441916|NCT03431506|BEHAVIORAL|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
219582150|NCT00932139|PROCEDURE|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. At end of 8-week treatment, 24 hours blood pressure and heart rate will be measured.
219582151|NCT00342836|PROCEDURE|Akt levels|
219582152|NCT04781036|DRUG|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 2 weeks
219441917|NCT03929783|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEM
219441918|NCT02217683|DRUG|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
219015679|NCT02025244|PROCEDURE|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
219015680|NCT02025244|PROCEDURE|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
219015681|NCT03793582|DIAGNOSTIC_TEST|ApneaLink Type III portable sleep study|Type III portable sleep study
219196189|NCT01850888|DRUG|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
219582153|NCT06922409|DEVICE|Naturalistic Light Intervention|Naturalistic light as an Intervention A 24-hour naturalistic lighting scheme is implemented in all areas and rooms in the unit at Rigshospitalet Glostrup with a computer-controlled lighting scheme (ChromaViso, Denmark). The naturalistic lighting scheme is constantly running. The lighting imitate the sunlight rhythm following the principles of Lucas et al.
219764449|NCT06149481|BIOLOGICAL|Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that
218834686|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
219196190|NCT01850888|DRUG|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
219764450|NCT06149481|DRUG|N-803|15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
218834687|NCT00899821|BIOLOGICAL|aldesleukin|
218834688|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
218834689|NCT00899821|BIOLOGICAL|sargramostim|
218834690|NCT00899821|OTHER|immunologic technique|
219196191|NCT01850888|PROCEDURE|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
219196192|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
219475593|NCT05842122|BEHAVIORAL|Client-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 250 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 0 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
219582154|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
219582155|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
219582156|NCT00686582|PROCEDURE|Blood Draw Only|
219582157|NCT03480126|OTHER|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
219582158|NCT02009748|DIETARY_SUPPLEMENT|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
219582159|NCT02009748|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo (vehicle) once daily
219764451|NCT06149481|DRUG|SX-682|100 mg administered orally twice per day on days 6-26 of every cycle
218834691|NCT00899821|PROCEDURE|biopsy|
218834692|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
218834693|NCT04904744|OTHER|No message|No reminders are sent
218834694|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
218834695|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
218834696|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
218834697|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
218834698|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
218834699|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
218834700|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
218834701|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
218834702|NCT01794312|DEVICE|T4020|
219015682|NCT01979809|BEHAVIORAL|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
219015683|NCT01571414|DRUG|PA-824|200-mg tablets once a day
219015684|NCT01571414|DRUG|Efavirenz (EFV)|600-mg tablets once a day
219441919|NCT03662555|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
219441920|NCT00176878|PROCEDURE|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
219441921|NCT00176878|DRUG|Fludarabine monophosphate|fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
219015685|NCT01571414|DRUG|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
219441922|NCT00176878|PROCEDURE|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
219441923|NCT00176878|DRUG|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
219441924|NCT00176878|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
219441925|NCT01024920|DRUG|BIBF 1120|VEGF inhibitor
219441926|NCT01024920|DRUG|sunitinib|VEGF inhibitor
219441927|NCT06168890|DIAGNOSTIC_TEST|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
219441928|NCT06705842|DRUG|PVI|After removal of the appendix from the patient's abdomen and attainment of hemostasis, 10 mL/kg of 1% PVI (up to a maximum of 1,000 mL) will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned out
219441929|NCT06705842|DRUG|Usual Care|Surgeons may utilize local irrigation with saline if deemed necessary, defined as instillation of a small volume (\<100 mL) of liquid followed by aspiration, for the purpose of confirming hemostasis or suctioning thick fluid. Some surgeons may utilize large volume irrigation with saline solution, if that is consistent with their usual practice. Patients in the usual care arm will not receive PVI irrigation.
219441930|NCT06424392|OTHER|General Health Questionnaire (GHQ-12)|Anxiety and depression self-reported scales for both parents
219441931|NCT06424392|OTHER|State-Trait Anxiety Inventory (STAI-Y)|Anxiety and depression self-reported scales for both parents
219441932|NCT06424392|OTHER|Revised Children's Manifest Anxiety Scale (RCMAS)|Anxiety and depression self-reported scales for children
219441933|NCT06424392|OTHER|World Health Organization Quality of Life (WHOQOL-BREF)|Quality of life self-reported scales for parents
219441934|NCT06424392|OTHER|"Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)"|Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
219441935|NCT06424392|OTHER|Parental interview|The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
219441936|NCT06410469|PROCEDURE|rug weaving-like plication technique|anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
219441937|NCT06039969|OTHER||This is an obvertional study and there is no intervention
219441938|NCT01131845|DRUG|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
219441939|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
219441940|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
219441941|NCT05015322|DRUG|bupivacaine and methylprednisolone|suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
218834703|NCT01794312|DEVICE|Vehicle|
218834704|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
218834705|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
218834706|NCT02180685|OTHER|Anchor fixation|
218834707|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
219015686|NCT01571414|DRUG|Rifampin (RIF)|300-mg capsules once a day
219582160|NCT05566548|DIAGNOSTIC_TEST|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
218834708|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
218834709|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
218834710|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
218834711|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
219582161|NCT03335579|COMBINATION_PRODUCT|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
219764452|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
218834712|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
218834713|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
218834714|NCT01989429|DRUG|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
218834715|NCT04595643|OTHER|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
218834716|NCT03010943|DEVICE|Virtual reality headset|Feasibility and tolerance
218834717|NCT03731403|OTHER|MI varnish|CPP- ACP with 5 % sodium fluoride GC
218834718|NCT03210857|OTHER|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
218834719|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
218834720|NCT06012539|OTHER|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
218834721|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube plus bougie|"Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted."
219015687|NCT01402674|DRUG|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
219441942|NCT02977507|OTHER|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
219441943|NCT02977507|DRUG|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
219441944|NCT02977507|OTHER|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
219582162|NCT05192759|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
219441945|NCT02977507|OTHER|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
219441946|NCT02977507|OTHER|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
218834722|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube alone|"During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted."
218834723|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
218834724|NCT00146861|DEVICE|sensor programming|
219441947|NCT02785666|DRUG|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
219441948|NCT02785666|BEHAVIORAL|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
219441949|NCT06236763|DEVICE|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
219441950|NCT00171002|DRUG|valsartan/amlodipine|
219441951|NCT06201923|DRUG|Honey Mouthwash|0.2% thyme honey mouth rinse
219441952|NCT06201923|DRUG|Normal saline|0.9% sodium chloride
219441953|NCT04252261|DRUG|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
219441954|NCT04252261|DRUG|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
219441955|NCT00949845|DRUG|Endotoxin|
219441956|NCT06180876|DRUG|remimazolam|continuous infusion
219441957|NCT06180876|DRUG|propofol|continuous infusion
219441958|NCT01956058|RADIATION|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
219441959|NCT00004141|DRUG|Cisplatin|
219441960|NCT00004141|DRUG|dacarbazine|
219441961|NCT00004141|DRUG|Granulocyte-macrophage colony-stimulating factor|
219441962|NCT04630210|DRUG|Letrozole|Letrozole 2.5 mg/day oral until surgery
219441963|NCT04630210|DRUG|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
219441964|NCT01188460|BEHAVIORAL|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
219441965|NCT01188460|BEHAVIORAL|Sleep diary|
219441966|NCT00633360|DRUG|Drospirenone and ethinyl estradiol|Once daily by mouth
219441967|NCT00633360|DRUG|Placebo|Once daily by mouth
219441968|NCT06087731|DRUG|Tocilizumab|Tocilizumab (8mg/kg) every 4 wekks
219441969|NCT02036268|BEHAVIORAL|Standard|Standard ostomy education
219441970|NCT02036268|BEHAVIORAL|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
219441971|NCT02036268|BEHAVIORAL|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
219441972|NCT03749213|DRUG|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
219441973|NCT05467605|DIETARY_SUPPLEMENT|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
219441974|NCT05467605|OTHER|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
219441975|NCT01098032|DEVICE|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
218834725|NCT04824703|DRUG|Oxygen|"* Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
218834726|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
218834727|NCT03446963|BEHAVIORAL|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
219441976|NCT01098032|DRUG|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
219441977|NCT01229956|GENETIC|DNA methylation analysis|
219441978|NCT01229956|GENETIC|gene expression analysis|
219441979|NCT01229956|GENETIC|microarray analysis|
219441980|NCT01229956|GENETIC|reverse transcriptase-polymerase chain reaction|
219441981|NCT01229956|OTHER|laboratory biomarker analysis|
218834728|NCT02253095|DRUG|Albendazole|
219582163|NCT02167542|DEVICE|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
219582164|NCT02167542|DEVICE|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%."
218834729|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
218834730|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
219015688|NCT04178499|DIAGNOSTIC_TEST|cytokine analysis|analysis of intraocular cytokines
219015689|NCT01947920|DRUG|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
219441982|NCT04649190|DEVICE|TAVI|Coronary access for PCI after TAVI
219441983|NCT05427175|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
219441984|NCT05427175|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
219441985|NCT05821192|DRUG|Rituximab|375mg/m2 by IV infusion once every 3 weeks
218834731|NCT02253095|DRUG|Placebo|
218834732|NCT05970926|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
219015690|NCT01947920|DRUG|Placebo|Size-matching capsules containing an appropriate inactive excipient
219015691|NCT03282942|OTHER|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal"
219441986|NCT05821192|DRUG|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
219441987|NCT05821192|DRUG|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
219441988|NCT05821192|DRUG|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
219441989|NCT05821192|DRUG|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
219441990|NCT05122013|BEHAVIORAL|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
218834733|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
218834734|NCT03202212|PROCEDURE|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
218834735|NCT03202212|PROCEDURE|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
218834736|NCT02564588|DRUG|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
218834737|NCT02564588|DRUG|Placebo|Placebo once daily
218834738|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
219015692|NCT03282942|OTHER|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
219015693|NCT01392976|DRUG|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
219441991|NCT05122013|BEHAVIORAL|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
219441992|NCT04682249|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
219441993|NCT04682249|DRUG|Sintilimab|Sintilimab
219441994|NCT04682249|DRUG|Apatinib|Apatinib
219441995|NCT06268509|DIAGNOSTIC_TEST|Nutritional panel laboratory examination|As stated in group description
219441996|NCT06268509|DIETARY_SUPPLEMENT|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
219441997|NCT06268509|DIAGNOSTIC_TEST|Fetomaternal ultrasound|As stated in group description
219441998|NCT02052323|DRUG|Artesunate/mefloquine (AS/MQ)|"* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
219582165|NCT01427842|DRUG|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
218834739|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
219582166|NCT00741936|DRUG|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
219582167|NCT00741936|DRUG|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
219015694|NCT01392976|DRUG|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
219015695|NCT05196009|BEHAVIORAL|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
219196193|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
219196194|NCT01240122|DEVICE|Biotrue MPS|Multi-purpose contact lens care solution
219441999|NCT05001568|DEVICE|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
219442000|NCT05001568|DEVICE|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
219582168|NCT03347136|DEVICE|CPAP|
219582169|NCT03347136|DEVICE|NIPPV|
219582170|NCT03045237|OTHER|physical exercises classes|3 physical exercises classes, one of them in the pool.
219582171|NCT01408628|BEHAVIORAL|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm."
219582172|NCT04160845|PROCEDURE|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
219582173|NCT02015689|BEHAVIORAL|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
218834740|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
219196195|NCT01240122|DEVICE|Investigational MPS|Multi-purpose contact lens care solution
219582174|NCT02015689|BEHAVIORAL|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
219582175|NCT02015689|BEHAVIORAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
219582176|NCT02015689|BEHAVIORAL|CDC VIS|CDC Vaccine Information Statement (VIS)
219582177|NCT05768126|DRUG|Rivastigmine Transdermal Product|The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
219582178|NCT05768126|OTHER|Sham|The sham patches will be administered during the same period of time as the rivastigmine.
219582179|NCT01941940|DRUG|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
219582180|NCT01941940|DRUG|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
219582181|NCT01846117|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
219582182|NCT00750308|DRUG|Ramipril|Ramipril 10 mg per day for three weeks
218834741|NCT01103440|DRUG|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
218834742|NCT01103440|DRUG|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
218834743|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
218834744|NCT00110045|DRUG|caspofungin acetate|
218834745|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
218834746|NCT00729443|DRUG|AZD3241|single oral dose
218834747|NCT00729443|DRUG|Placebo|
218834748|NCT00161044|DRUG|Galantamine|
219015696|NCT05589207|DIAGNOSTIC_TEST|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
219015697|NCT04183920|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
219196196|NCT06809023|BEHAVIORAL|Sleep restriction|Participants will be asked to sleep 4h/night
219196197|NCT06812585|DRUG|Metformin (Cidophage®)|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
218834749|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
218834750|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
219582183|NCT00750308|DRUG|Tadalafil|tadalafil 10 mg every other day for three weeks
219582184|NCT00750308|DRUG|placebo|placebo matching ramipril
219582185|NCT00750308|DRUG|placebo|placebo matching tadalafil
218834751|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
218834752|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
219582186|NCT05120102|DEVICE|Diode laser|K2 diode laser of 980nm wavelength
219582187|NCT03035552|BEHAVIORAL|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
219582188|NCT01679587|DRUG|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
218834753|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
218834754|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
218834755|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
219015698|NCT04183920|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
219442001|NCT05001568|DEVICE|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
219582189|NCT01679587|DRUG|Placebo|Single oral dose of matching placebo will be given in each treatment arm
218834756|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
219582190|NCT02169349|OTHER|laboratory biomarker analysis|
219582191|NCT02169349|OTHER|Next Generation Sequencing|
219582192|NCT02169349|GENETIC|DNA Analysis|
219582193|NCT03143478|DEVICE|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
219582194|NCT02274207|DEVICE|NPWT application|NPWT mode is cyclic mode : -125\~-50 mmHg
219582195|NCT03875937|DRUG|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
219582196|NCT00399971|PROCEDURE|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
219582197|NCT00399971|DRUG|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
219582198|NCT02218112|PROCEDURE|bariatric surgery (gastric bypass)|
218834757|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
219015699|NCT02716103|OTHER|blood collection|
219015700|NCT02716103|OTHER|bone marrow collection|
219015701|NCT04888156|OTHER|Unchanged treatment|Treatment is the same pre- and post self-tonometry
219015702|NCT04888156|OTHER|Changed treatment|Treatment is changed post self-tonometry
219015703|NCT02335099|DRUG|ticagrelor|ticagrelor 90 mg twice a day for 6 months
219015704|NCT02335099|DRUG|Placebo|1 pill twice a day for 6 months
219015705|NCT01312688|OTHER|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
219015706|NCT05523661|DRUG|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
219015707|NCT02278588|DRUG|Rasagiline|
219015708|NCT00762242|PROCEDURE|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
219015709|NCT01264978|DEVICE|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
219582199|NCT04882319|DRUG|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
219582200|NCT04882319|DRUG|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
219015710|NCT01134978|BEHAVIORAL|Practice Order|"Blocked order - predictable~Random order - unpredictable"
219196198|NCT06812585|OTHER|Usual Care|Active Comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
219196199|NCT04583280|DRUG|Rilematovir|Participants of age group greater than or equal to (\>=) 28 days to less than (\<) 3 months (age group 1) or \>= 3 months to \< 6 months (age group 2) or \>= 6 months to less than or equal to (\<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.
219582201|NCT04882319|DRUG|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
219582202|NCT00281476|DRUG|Simvastatine|
219582203|NCT01921491|PROCEDURE|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
219442002|NCT05001568|DEVICE|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
219442003|NCT03352869|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
219582204|NCT01921491|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
219582205|NCT02196740|DRUG|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
219582206|NCT02196740|DRUG|creosote|Pulp removal,Root canal irrigation and disinfection
219442004|NCT03352869|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
219582207|NCT00513682|DRUG|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
219582208|NCT03797820|OTHER|Our study type is observational|Our study type is observational
219582209|NCT02941276|DEVICE|Active Electrostimulator device|Patients who will receive a fully functioning device
219582210|NCT02941276|DEVICE|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
219582211|NCT03316326|DRUG|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
219582212|NCT03316326|DRUG|Oxaliplatin|85 mg/m2, D1
219582213|NCT03316326|DRUG|Irinotecan|150 mg/m2, D8
219442005|NCT02531503|OTHER|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
219442006|NCT06087094|DRUG|HRS-7450 ；Placebo|HRS-7450 or Placebo
219442007|NCT00776490|DRUG|Glimepiride 1mg Tablets|
219442008|NCT04825249|PROCEDURE|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
219582214|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
219582215|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
219442009|NCT04825249|PROCEDURE|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
219582216|NCT02450526|DRUG|Placebo|50 Units
219582217|NCT02450526|DRUG|Placebo|20 Units
219582218|NCT01468376|DIETARY_SUPPLEMENT|GLU-01|14 day dosing
219582219|NCT01468376|DIETARY_SUPPLEMENT|GLU-02|14 day dosing
219582220|NCT01468376|DIETARY_SUPPLEMENT|GLU-03|14 day dosing
219582221|NCT01468376|DIETARY_SUPPLEMENT|GLU-04|14 day dosing
219582222|NCT01468376|DIETARY_SUPPLEMENT|GLU-05|14 day dosing
219582223|NCT01468376|DIETARY_SUPPLEMENT|GLU-06|14 day dosing
219582224|NCT03992794|DIAGNOSTIC_TEST|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
219015711|NCT02461225|DEVICE|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
219015712|NCT02461225|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
219015713|NCT00484939|DRUG|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
219015714|NCT00484939|DRUG|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
219015715|NCT00735787|BIOLOGICAL|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
219015716|NCT00735787|BIOLOGICAL|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
219015717|NCT00776347|DRUG|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
219015718|NCT00776347|DRUG|Donepezil|
219196200|NCT04583280|DRUG|Rilematovir X mg/kg|Participants of age group birth at term (after at least 37 weeks of gestation) to \< 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.
219196201|NCT04583280|DRUG|Placebo|Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
219442010|NCT06347692|OTHER|antigravity treadmill|An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
219442011|NCT06347692|OTHER|physical therapy exercise program|Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
219442012|NCT05110404|OTHER|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
219442013|NCT05110404|OTHER|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
219442014|NCT02955368|DRUG|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
219442015|NCT02955368|DRUG|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
219442016|NCT02955368|DRUG|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
219442017|NCT02001506|DRUG|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
219442018|NCT01960192|DRUG|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
219442019|NCT01960192|DRUG|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
219442020|NCT01986517|BEHAVIORAL|No feedback|Therapists will receive no feedback.
219442021|NCT01986517|BEHAVIORAL|Feedback after every fourth session|
219442022|NCT02826876|DRUG|Topical use|Topical use of Ropivacaine in laparoscopic surgery
219442023|NCT02826876|OTHER|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
219764453|NCT06869954|DEVICE|Internal HAART 200 annuloplasty device|For the INTERNAL group, the HAART 200 internal annuloplasty ring (CorCym, London, UK), specifically designed for BAV morphology, will be used for all patients. Intraoperative sizing for the internal ring is based on the geometric orientation and size of the non-fused cusp. A standard ball sizer is used for the measurement of the non-fused cusp to assess commissural orientation and surface area of the non-fused cusp. Sizing typically results in values of 23mm or 25mm, with other sizes being very rare. Both commissural posts of the internal annuloplasty ring are fixed using two subcommissural sutures \[10\]. A modified technique for placement of transannular looping sutures will be used to secure the internal ring in the subannular position, as recently published \[21\]. Cusp maneuvers (i.e., shaving, thinning of the raphe, central plication sutures) will be performed to achieve an effective height of 8-10 mm. When indicated (i.e., for ascending aortic diameter \> 45mm or aiming to achieve th
219442024|NCT02826876|OTHER|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
219015719|NCT02493673|DEVICE|Continuous positive airway pressure device|(ResMed Spirit S8)
219015720|NCT03251508|DRUG|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
219015721|NCT00101907|DRUG|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
219015722|NCT00101907|BIOLOGICAL|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
219015723|NCT00101907|DRUG|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
219015724|NCT00101907|DRUG|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
219015725|NCT04062838|DRUG|Dextrose 50|As above
219442025|NCT00610207|DEVICE|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
219442026|NCT00838370|DRUG|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
219442027|NCT00481741|DEVICE|SafeSeal(TM) Hemostasis Patch|
219442028|NCT02558985|PROCEDURE|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
219442029|NCT02117804|OTHER|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
219442030|NCT02621372|OTHER|platelet count|Correlation of esophageal varices with platelet count
219442031|NCT06231030|OTHER|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
219442032|NCT02299804|DRUG|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
219442033|NCT02299804|DRUG|Placebo|No active ingredient
219442034|NCT02465489|DRUG|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
219442035|NCT02465489|DRUG|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
219442036|NCT02171039|DRUG|Dabigatran|
219442037|NCT02171039|DRUG|Atorvastatin|
219442038|NCT02950441|DIETARY_SUPPLEMENT|Nicotinamide Riboside|
219442039|NCT02950441|OTHER|Placebo|
219442040|NCT02972593|BIOLOGICAL|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
219442041|NCT03241589|OTHER|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
219442042|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
219442043|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
219442044|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
219442045|NCT04776889|DRUG|Rosuvastatin 20mg|Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
219442046|NCT04776889|PROCEDURE|surgical castration|bilateral subcapsular orchiectomy
219442047|NCT04319770|DEVICE|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
219442048|NCT04319770|DEVICE|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
219582225|NCT05010044|BEHAVIORAL|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
219582226|NCT05010044|OTHER|Antipsoriatic treatment|The routine drug therapy for psoriasis.
219582227|NCT00093002|DRUG|Fulvestrant|250 mg \& 500 mg intramuscular injection
219582228|NCT00561314|OTHER|questionnaire administration|
219582229|NCT00561314|PROCEDURE|biopsy|
219582230|NCT00561314|PROCEDURE|high-intensity focused ultrasound ablation|
219582231|NCT00561314|PROCEDURE|magnetic resonance imaging|
219582232|NCT00561314|PROCEDURE|quality-of-life assessment|
219582233|NCT04921124|DRUG|Teriparatide|PTH(1-34) cartridge and pen device
219582234|NCT02505490|OTHER|Television|The purpose is to determine whether television impacts liking of food.
219582235|NCT02505490|OTHER|No Television|The purpose is to determine whether the lack of television impacts liking of food.
219582236|NCT03212521|DRUG|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
219582237|NCT05790421|OTHER|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
218834758|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
218834759|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
218834760|NCT03012828|OTHER|Placebo|
218834761|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
218834762|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
218834763|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
218834764|NCT00480831|DRUG|placebo|Intravenous repeating dose
219582238|NCT05790421|OTHER|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
219582239|NCT04320979|RADIATION|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
219582240|NCT04320979|RADIATION|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
219582241|NCT03022058|DEVICE|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
219582242|NCT05496335|DRUG|AGN-151586|Intramuscular Injection
219582243|NCT05496335|DRUG|BOTOX|Intramuscular Injection
219582244|NCT05496335|DRUG|Placebo|Intramuscular Injection
219582245|NCT05372133|DRUG|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
219582246|NCT00000651|DRUG|Zidovudine|
219582247|NCT00000651|DRUG|Zalcitabine|
219582248|NCT01970865|DRUG|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
219582249|NCT01970865|DRUG|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
219582250|NCT03642782|DEVICE|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
219582251|NCT01576874|DRUG|Oxytocin|40 IUs of oxytocin administered intranasally one time
219582252|NCT01576874|DRUG|placebo|placebo administered intranasally one time
219582253|NCT06485960|OTHER|ESDAM validation|"* 3\* 24-Hour Dietary Recalls~* Experience Sampling Dietary Assessment Method (mobile application)~* Continuous Blood Glucose Monitoring~* Doubly-labeled water administration~* Blood drawings (Erythrocyte Membrane Fatty Acid composition, Carotenoids)~* Urine sampling (Doubly-labeled water, urinary nitrogen)"
219582254|NCT05102292|DRUG|HLX208|HLX208 450mg bid po
219582255|NCT06356363|OTHER|Data collection|data collection
219582256|NCT01721811|OTHER|Hyperoxia|
219582257|NCT01721811|OTHER|Glucose|
218834765|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
218834766|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
218834767|NCT00003776|BIOLOGICAL|filgrastim|
218834768|NCT00003776|DRUG|cisplatin|
218834769|NCT00003776|DRUG|doxorubicin hydrochloride|
218834770|NCT00003776|DRUG|ifosfamide|
218834771|NCT00003776|DRUG|leucovorin calcium|
218834772|NCT00003776|DRUG|methotrexate|
218834773|NCT00003776|DRUG|trimetrexate glucuronate|
218834774|NCT00003776|PROCEDURE|surgical procedure|
218834775|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
218834776|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
218834777|NCT02100930|DRUG|oral isotretinoin|
219582258|NCT00912483|BIOLOGICAL|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
219582259|NCT00912483|BIOLOGICAL|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
219582260|NCT05643248|DRUG|NEX-20A|Subcutaneous prolonged-release injection
218834778|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
218834779|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
219442049|NCT02572804|DEVICE|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
219442050|NCT02572804|DEVICE|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
219442051|NCT00408291|PROCEDURE|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
219442052|NCT04599972|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
219442053|NCT04599972|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
219442054|NCT01951872|BEHAVIORAL|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
219442055|NCT04306757|DEVICE|Evone|Airway ventilation device
219442056|NCT04306757|DEVICE|Primus|Airway ventilation device
219442057|NCT01977157|DEVICE|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
219442058|NCT00783549|DRUG|an undetermined dose of GSK1292263|GSK investigational product or placebo
219442059|NCT00783549|DRUG|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
219442060|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
219442061|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposures.
219442062|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
219442063|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
219442064|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
219442065|NCT02597985|OTHER|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
219442066|NCT02597985|OTHER|Usual Care|
219442067|NCT00028795|DRUG|temozolomide|
219442068|NCT00028795|PROCEDURE|adjuvant therapy|
219442069|NCT00028795|RADIATION|radiation therapy|
219442070|NCT06434025|DRUG|Iron Carboxymaltose|Iron Carboxymaltose 500 mg. 2 vials administered IV.
219442071|NCT06434025|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab, PO, onde a day.
219442072|NCT06434025|DRUG|Placebo of Iron Carboxymaltose|Solution Sodium Chloride 0,9% 100 ml, IV, once.
219442073|NCT06434025|DRUG|Placebo of Dapagliflozin|Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
219442074|NCT05831514|OTHER|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
219442075|NCT01407289|DRUG|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
219442076|NCT03394118|DRUG|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
219442077|NCT03923504|OTHER|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
219582261|NCT02756026|DIETARY_SUPPLEMENT|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
219582262|NCT01002014|PROCEDURE|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
219582263|NCT00678041|DRUG|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
218834780|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
219582264|NCT00678041|DRUG|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
219582265|NCT05968443|DEVICE|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
219582266|NCT03861403|DRUG|TRX518|Administered by IV infusion
219582267|NCT03861403|DRUG|Cyclophosphamide|Administered by IV infusion
218834781|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
218834782|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
219442078|NCT03923504|OTHER|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
219442079|NCT01259921|BEHAVIORAL|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
218834783|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
218834784|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
218834785|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
218834786|NCT03751371|DEVICE|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
219442080|NCT00937508|BEHAVIORAL|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
219015726|NCT05883930|OTHER|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change \[not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)\] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
219015727|NCT05883930|OTHER|no intervention|No intervention will be applied to the control group.
219582268|NCT03861403|DRUG|Avelumab|Administered by IV infusion
219015728|NCT02500784|DRUG|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
219015729|NCT02500784|OTHER|Formoterol B (placebo)|2mL, BID inhaler for 12 months
219015730|NCT00230464|DRUG|LAF 237|
219015731|NCT04111679|OTHER|Music|Participant selected music, applied using noise cancelling headphones
219015732|NCT01566461|DEVICE|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
219015733|NCT01566461|DEVICE|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
219015734|NCT05270954|BIOLOGICAL|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
219015735|NCT05270954|DRUG|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
219015736|NCT01997515|DRUG|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
219015737|NCT01997515|DRUG|placebo|Group P (placebo) will receive the same amount of saline.
218834787|NCT03751371|OTHER|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
218834788|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
218834789|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
218834790|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
218834791|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
219015738|NCT04882228|DRUG|Entelon Tab.150mg|twice daily for 8 weeks
219442081|NCT00937508|DRUG|varenicline|varenicline (an approved medication for smoking cessation)
219442082|NCT00937508|DRUG|placebo|sugar pill without any active medication
219442083|NCT00252876|DRUG|tesaglitazar|
219442084|NCT01987752|DRUG|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
219442085|NCT05655728|DRUG|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
219442086|NCT05655728|OTHER|Placebo|The participants will receive treatment of placebo.
219442087|NCT03188302|OTHER|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
218834792|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
218834793|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
218834794|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
218834795|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
218834796|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
218834797|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
218834798|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
218834799|NCT01098331|PROCEDURE|Radical Prostatectomy|
218834800|NCT01098331|PROCEDURE|Brachytherapy|
218834801|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
218834802|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
218834803|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
218834804|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
218834805|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
218834806|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
218834807|NCT03127696|PROCEDURE|Sham|Sham
218834808|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
218834809|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
219015739|NCT04882228|DRUG|Venitol Tab.|twice daily for 8 weeks
219015740|NCT04882228|DRUG|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
219015741|NCT04882228|DRUG|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
219015742|NCT04521465|DEVICE|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
219196202|NCT06675344|DEVICE|Apollo Neuro Device|The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
219442088|NCT04078074|DEVICE|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
219442089|NCT04078074|DEVICE|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
219442090|NCT04078074|DEVICE|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
219442091|NCT05847556|OTHER|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
219442092|NCT05847556|OTHER|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
219582269|NCT02358343|BEHAVIORAL|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
219764454|NCT06869954|DEVICE|double external ring annuloplasty|For the EXTERNAL group, all study patients will undergo double external Dacron ring annuloplasty by simultaneous stabilization of the basal virtual ring and the STJ \[22\]. The surgical technique of double external annuloplasty, detailed by the Lansac group \[22\], involves aortic annulus sizing with a Hegar dilator to select the sizes of the external subannular annuloplasty ring and STJ ring (same size). After deep dissection of the aortic root, 6-7 2-0 pledgeted U sutures are placed circumferentially at the level of the virtual basal ring for external subannular ring implantation. Cusp maneuvers are performed similar to those in the INTERNAL group. STJ stabilization is achieved using an external STJ ring or ascending aortic replacement with a vascular tube graft (e.g., in cases with a high offspring of the right coronary artery). Treatment of the tubular ascending aorta is identical to the INTERNAL group.
219764455|NCT05514509|DRUG|APRETUDE|Available as intramuscular injection.
219442093|NCT03718273|DRUG|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
218834810|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
218834811|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
218834812|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
218834813|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
218834814|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
218834815|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
218834816|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
218834817|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
218834818|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
218834819|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
218834820|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
218834821|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
218834822|NCT01501890|DRUG|Placebo|0.9% NaCl
218834823|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
218834824|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
218834825|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
218834826|NCT00705770|DRUG|Anecortave Acetate|"Low dose~Sustained release depot suspension"
218834827|NCT00705770|DRUG|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
218834828|NCT00705770|DRUG|Anecortave Acetate|"High dose~Sustained release depot suspension"
218834829|NCT00705770|DRUG|Placebo|Placebo treatment with vehicle
218834830|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
218834831|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
219196203|NCT06675344|DEVICE|Sham device|The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
219442094|NCT03718273|DRUG|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
218834832|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
218834833|NCT04855240|DRUG|Placebo|Oral dose of placebo
218834834|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
218834835|NCT02385903|OTHER|Flammacerium|
219442095|NCT00389129|DRUG|acetylsalicylic acid|
219442096|NCT05116111|DRUG|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
219442097|NCT05116111|DRUG|Placebo|Placebo, oral, twice daily
219442098|NCT05027776|BIOLOGICAL|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
219442099|NCT05027776|BIOLOGICAL|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
219442100|NCT05027776|BIOLOGICAL|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
218834836|NCT02385903|OTHER|Standard dressing procedure|
218834837|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
218834838|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
218834839|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
219196204|NCT05559866|DEVICE|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
219196205|NCT05559866|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label.
219196206|NCT00631475|DRUG|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"
219442101|NCT03542292|DIAGNOSTIC_TEST|placental drainage|
219442102|NCT03803449|DRUG|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
219442103|NCT03803449|DRUG|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
219442104|NCT03803449|DRUG|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
219442105|NCT01594411|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
219442106|NCT06505681|PROCEDURE|Pharmacopuncture|"The selection of acupoints, depth of insertion, and other parameters will be determined based on the clinical judgment of the Korean medicine practitioner, considering the patient's symptoms, imaging results, and degree of improvement. All acupoints where pharmacopuncture is administered will be recorded at the time of treatment.~The type and dosage of pharmacopuncture solution to be used during treatment will be determined entirely based on the clinical judgment of the Korean medicine practitioner performing the pharmacopuncture. Retrospective chart reviews will be conducted to record the type of pharmacopuncture solution used and the total amount administered (in ml).~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
219442107|NCT06505681|PROCEDURE|Physical therapy|"The selection of physical therapy methods, treatment areas, and treatment duration will be determined based on the clinical judgment of the physician, considering the patient's symptoms, imaging results, and degree of improvement. The type, frequency, and areas of prescribed and administered physical therapy will be recorded.~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
219442108|NCT01698073|BEHAVIORAL|mCOL|
219442109|NCT01698073|OTHER|AS+|
219442110|NCT02144376|DIETARY_SUPPLEMENT|Ispaghula|
219442111|NCT02144376|DIETARY_SUPPLEMENT|Maltodextrin|
219442112|NCT01620593|DRUG|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
219442113|NCT01620593|DRUG|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
219442114|NCT04238689|BIOLOGICAL|TB31F|Monoclonal antibody
219442115|NCT00079820|BIOLOGICAL|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
219442116|NCT04449276|BIOLOGICAL|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
219442117|NCT04449276|DRUG|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
219442118|NCT01614795|BIOLOGICAL|Cixutumumab|Given IV
219442119|NCT01614795|OTHER|Laboratory Biomarker Analysis|Correlative studies
219442120|NCT01614795|DRUG|Temsirolimus|Given IV
219442121|NCT04586296|OTHER|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
219442122|NCT02970539|DRUG|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
219442123|NCT02970539|DRUG|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
219015743|NCT05879406|DIETARY_SUPPLEMENT|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
219015744|NCT05879406|OTHER|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
219015745|NCT03583138|DRUG|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
219015746|NCT00847457|BEHAVIORAL|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
219015747|NCT00847457|BEHAVIORAL|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
219015748|NCT00437593|PROCEDURE|ppVE, MP, ICG|surgery with ILM staining
219015749|NCT00437593|PROCEDURE|ppVE, MP, MB|Surgery with ERM staining
219015750|NCT05289011|OTHER|Interviews and questionnaires|"* Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment"
219015751|NCT01523886|DRUG|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
219442124|NCT01633229|PROCEDURE|Bone Marrow Stromal Cell Infusion|
219015752|NCT01523886|DRUG|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
219015753|NCT04733365|OTHER|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
219015754|NCT02221375|DRUG|BHT low|
219442125|NCT02449772|OTHER|No intervention|No intervention
219442126|NCT00655057|DRUG|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
219442127|NCT00655057|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
219442128|NCT00655057|PROCEDURE|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
219442129|NCT00910728|DRUG|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
219442130|NCT02384304|BEHAVIORAL|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
219442131|NCT02384304|BEHAVIORAL|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
219442132|NCT02384304|BEHAVIORAL|Self help|A self help program consisting of 8 modules
219442133|NCT00023712|DRUG|bortezomib|Given IV
219442134|NCT00023712|OTHER|laboratory biomarker analysis|Correlative studies
219442135|NCT00023712|OTHER|pharmacological study|Correlative studies
219442136|NCT05074862|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
219015755|NCT02221375|DRUG|BHT medium|
219015756|NCT02221375|DRUG|BHT high|
219015757|NCT02221375|DRUG|BI 54903 XX low|
219015758|NCT02221375|DRUG|BI 54903 XX medium 1|
219015759|NCT02221375|DRUG|BI 54903 XX medium 2|
219015760|NCT02221375|DRUG|BI 54903 XX high|
219015761|NCT02221375|DRUG|Ciclesonide|
219196207|NCT06815666|PROCEDURE|Bronchoscopy & Metastasectomy|Routine bronchoscopy and standard of care metastasectomy
219196208|NCT05153317|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
219196209|NCT05153317|DRUG|IVA|Granules or tablets for oral administration.
219442137|NCT05074862|DIETARY_SUPPLEMENT|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
219442138|NCT02866604|PROCEDURE|Sterofundin|
219442139|NCT02866604|PROCEDURE|0.9% saline|
219442140|NCT05834699|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
219442141|NCT03823430|DIAGNOSTIC_TEST|Pupillometry|Pupillar diameter variation measurement
219442142|NCT01985386|DIETARY_SUPPLEMENT|GDS capsule with meal|GDS capsule with meal
219442143|NCT01985386|DIETARY_SUPPLEMENT|Ferrous sulfate with meal|Ferrous sulfate with meal
219442144|NCT04907812|DRUG|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
219442145|NCT04907812|PROCEDURE|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
219764456|NCT05514509|DRUG|Cabotegravir tablet|Available as marketed orally administered tablets.
219582270|NCT02358343|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
219582271|NCT02358343|DRUG|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
219582272|NCT02931903|OTHER|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
219582273|NCT02931903|OTHER|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
219582274|NCT02861079|DEVICE|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
219582275|NCT02861079|DRUG|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
219015762|NCT01481142|DEVICE|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
219442146|NCT01054612|OTHER|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
219442147|NCT00323427|BEHAVIORAL|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
219442148|NCT00323427|DEVICE|hearing aid services|Standard VA audiological hearing aid dispensing services
219582276|NCT02015559|DRUG|mucoadhesive oral wound rinse|Given PO
218834840|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
218834841|NCT01537471|DRUG|Placebo|Placebo
218834842|NCT01537471|DRUG|Meclizine|Meclizine 12.5 mg
218834843|NCT01537471|DRUG|Meclizine|Meclizine 25 mg
218834844|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
218834845|NCT00244725|DRUG|Odiparcil|
218834846|NCT00244725|DRUG|Warfarin|
218834847|NCT00244725|DRUG|Coumadin|
218834848|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
218834849|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
218834850|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
218834851|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
219442149|NCT04829942|BEHAVIORAL|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
219582277|NCT02015559|OTHER|laboratory biomarker analysis|Correlative studies
219582278|NCT05447000|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
219582279|NCT05447000|BEHAVIORAL|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
219582280|NCT05447000|OTHER|No Intervention|No Intervention
219582281|NCT05404607|OTHER|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
218834852|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
218834853|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
218834854|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
218834855|NCT02655952|DRUG|Foxy-5|
219015763|NCT05266092|OTHER|Observational study|Observational study
219015764|NCT01976234|OTHER|Fresh RBC|Patients will receive fresh blood only
219015765|NCT01976234|OTHER|Old RBC|
219582282|NCT05404607|OTHER|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
219582283|NCT04317209|DRUG|SHR0410|administered intravenously
219582284|NCT04317209|DRUG|Placebo|administered intravenously
219582285|NCT05332028|DRUG|bupivacaine|Block applications
219582286|NCT05332028|DEVICE|22 gauge 100 mm needle|Block applications
219582287|NCT05332028|DRUG|Propofol|Routine general anesthesia protocol
219582288|NCT05332028|DRUG|fentanyl|patient-controlled analgesia
219582289|NCT00281671|DRUG|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
219582290|NCT00281671|DRUG|Placebo|0.9% sodium chloride infusion
219582291|NCT06037837|PROCEDURE|Robotic Surgery|Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
218834856|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
218834857|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
219582292|NCT03410251|PROCEDURE|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
218834858|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
219015766|NCT01038024|DIETARY_SUPPLEMENT|1 tablet composed of antioxidants and minerals|1 tablet daily
219582293|NCT03166423|DRUG|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
219582294|NCT03166423|DEVICE|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
219582295|NCT04920643|PROCEDURE|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
219582296|NCT00090610|DRUG|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
219582297|NCT00090610|DRUG|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
219582298|NCT00788749|DRUG|Prednisolone|tablets 25 mg/day
219582299|NCT00788749|DRUG|Placebo|tablets once daily
218834859|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
218834860|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
219015767|NCT03616899|DRUG|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
219015768|NCT03616899|DRUG|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
219582300|NCT00788749|OTHER|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
219582301|NCT00788749|OTHER|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
219582302|NCT02444793|DRUG|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
219582303|NCT02444793|DRUG|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
219582304|NCT01685411|DRUG|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
219582305|NCT01685411|DRUG|Keppra|Day -8 (prior to transplant): Per institutional guidelines
219582306|NCT01685411|DRUG|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
219582307|NCT01685411|DRUG|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
219582308|NCT01685411|DRUG|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
219582309|NCT01685411|DRUG|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
219582310|NCT01685411|BIOLOGICAL|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
219582311|NCT01685411|BIOLOGICAL|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
219582312|NCT01685411|BIOLOGICAL|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
218834861|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
219582313|NCT03686449|PROCEDURE|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
219442150|NCT06794697|OTHER|Questionnaire including APAIS scale|Patients will complete a questionnaire in two stages : upon admission and just before leaving for the operating room
219582314|NCT03686449|PROCEDURE|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
218834862|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
218834863|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
218834864|NCT02840305|OTHER|Evaluation of visual function|
218834865|NCT02840305|OTHER|Magnetic Resonance Imaging|
218834866|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
218834867|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
218834868|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
218834869|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
218834870|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
218834871|NCT00117780|DRUG|insulin detemir|
218834872|NCT00117780|DRUG|insulin aspart|
218834873|NCT00232323|BEHAVIORAL|simulation training|
218834874|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
218834875|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
218834876|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
218834877|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
218834878|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
218834879|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
218834880|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
218834881|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
218834882|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
218834883|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
218834884|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
219015769|NCT05339503|OTHER|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
219015770|NCT02863133|DEVICE|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
219015771|NCT03448185|BEHAVIORAL|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
219442151|NCT02707679|OTHER|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
219442152|NCT02707679|OTHER|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
219582315|NCT03686449|PROCEDURE|Split skin graft|Traditional method for treatment of post-burn raw area
219582316|NCT02711683|DRUG|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
219015772|NCT03448185|DIETARY_SUPPLEMENT|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
219015773|NCT03448185|BEHAVIORAL|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
219015774|NCT03448185|DIETARY_SUPPLEMENT|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
219015775|NCT00177892|PROCEDURE|sleep disruption|experimentally-induced Sleep Fragmentation
219582317|NCT02711683|DRUG|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
219582318|NCT00069511|DRUG|UT-231B|
219582319|NCT03576183|BIOLOGICAL|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
219582320|NCT03576183|BIOLOGICAL|Placebo|buffer component of VLA1701
219582321|NCT03576183|OTHER|Challenge Strain|LSN03-016011/A
219764457|NCT06866743|OTHER|There will be no intervention.|This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.
218834885|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
218834886|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
218834887|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
218834888|NCT04074083|BEHAVIORAL|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
218834889|NCT04074083|BEHAVIORAL|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
218834890|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
218834891|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
218834892|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
218834893|NCT00287001|DEVICE|Cold air cooling|
218834894|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
218834895|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
218834896|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
218834897|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
218834898|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
219015776|NCT00177892|PROCEDURE|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
219015777|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 400|dose 400 UNT/day for 12 months
219015778|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 800|dose 800 UNT/day for 12 months
219582322|NCT00042458|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
219582323|NCT00042458|DRUG|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
219582324|NCT02860221|DRUG|Tranexamic acid (TXA)|IV and topical administration
219582325|NCT02860221|DRUG|Epinephrine|
219582326|NCT05191017|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
219582327|NCT05191017|DRUG|Enzalutamide|Enzalutamide
219582328|NCT01685450|DEVICE|Echodia® hand-held equipment|
219582329|NCT05362734|BEHAVIORAL|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
219582330|NCT00081536|DRUG|Aroplatin (Liposomal NDDP) in combination with capecitabine|
219582331|NCT06273839|DRUG|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
219582332|NCT06273839|DRUG|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
219582333|NCT06273839|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
219582334|NCT06020287|PROCEDURE|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
219582335|NCT01878461|DRUG|Vehicle|
219582336|NCT01878461|DRUG|M518101|
218834899|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
219582337|NCT05900128|BEHAVIORAL|workshop|Patients will receive workshops and they will encourage to practice physical activity
218834900|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
218834901|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
219582338|NCT05900128|OTHER|no workshop|patients won't receive educative workshops
219582339|NCT00418301|OTHER|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
219582340|NCT00142233|DIETARY_SUPPLEMENT|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
219582341|NCT00142233|DRUG|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
219582342|NCT00142233|OTHER|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
219582343|NCT00142233|OTHER|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
219582344|NCT00004553|PROCEDURE|Electromyography|
219582345|NCT03748030|RADIATION|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
219582346|NCT04819048|DEVICE|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
219582347|NCT04819048|DEVICE|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
219582348|NCT04105426|DIETARY_SUPPLEMENT|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
219582349|NCT04105426|DIETARY_SUPPLEMENT|Placebo|one placebo tablet three times per day for 3 months.
219582350|NCT01948466|BEHAVIORAL|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
219582351|NCT05445661|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
219582352|NCT05445661|OTHER|Normal Saline|Sham Comparator
219582353|NCT03929276|DEVICE|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
219582354|NCT03929276|DEVICE|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
219764458|NCT06679400|BEHAVIORAL|Massage|"Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage."
219764459|NCT04192591|DEVICE|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
218834902|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
218834903|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
218834904|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
218834905|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
218834906|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
219015779|NCT03691896|DRUG|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
219015780|NCT01799616|DRUG|Pamidronate|
219015781|NCT01799616|OTHER|Placebo|
219015782|NCT00982475|PROCEDURE|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
218834907|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
219015783|NCT00862446|DRUG|Omegaven|1 gram/kg/day daily until on feeds
219015784|NCT04640519|OTHER|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
219015785|NCT04640519|OTHER|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
219015786|NCT03022760|BEHAVIORAL|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
219015787|NCT00668486|DRUG|Lactic acid (Dermacid)|
219442153|NCT02707679|OTHER|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
219764460|NCT06664879|DRUG|MBG-453 + Azacitidine|Given intravenously (by vein)
219764461|NCT07005154|DRUG|ASP5541|Intramuscular Injection
218834908|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
219015788|NCT05459103|OTHER|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
219015789|NCT05459103|OTHER|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
219015790|NCT01173718|DEVICE|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
219015791|NCT03384979|DRUG|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
219015792|NCT01525043|DRUG|Naproxen|Naproxen 500mg BID for the first 2 weeks
219015793|NCT01525043|DRUG|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
219015794|NCT01525043|DRUG|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
219015795|NCT01525043|DRUG|Naproxen|500mg bid
219015796|NCT01525043|DRUG|Synera|Topical appication of single patch to elbow for 12hrs/day
219015797|NCT01525043|DRUG|Synera|Single patch applied to elbow for 4hrs/twice daily
219015798|NCT01279551|DRUG|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
219015799|NCT01279551|DRUG|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
219442154|NCT02707679|OTHER|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
219475594|NCT05842122|BEHAVIORAL|Implementor-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 250 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
219764462|NCT07005154|DRUG|Prednisone|Oral
219764463|NCT07005154|DRUG|Prednisolone|Oral
219764464|NCT07005154|DRUG|abiraterone acetate|Oral
218834909|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
218834910|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
218834911|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
219015800|NCT01367158|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
219015801|NCT01367158|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
219015802|NCT01367158|BIOLOGICAL|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
219015803|NCT02850315|DEVICE|optimal coherence tomography|
219015804|NCT01764009|BIOLOGICAL|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
219015805|NCT04854811|DRUG|Roflumilast Oral Tablet|Once daily for 12 weeks
219015806|NCT03613051|BEHAVIORAL|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
219015807|NCT01749579|DRUG|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
218834912|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
218834913|NCT01023685|BIOLOGICAL|CAD106|
219442155|NCT04493463|DRUG|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
218834914|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
218834915|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
218834916|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
218834917|NCT02515968|DRUG|Propofol|
218834918|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
218834919|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
218834920|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
219442156|NCT04493463|DRUG|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
218834921|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
218834922|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
218834923|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
218834924|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
218834925|NCT02998671|BIOLOGICAL|CJM112|
218834926|NCT02998671|OTHER|Placebo|
218834927|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
218834928|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218834929|NCT02038946|DRUG|Nivolumab|
218834930|NCT01211977|DRUG|XOMA 052|
218834931|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
218834932|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
218834933|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
218834934|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
218834935|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
218834936|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
218834937|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
218834938|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
219015808|NCT01749579|DRUG|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
219442157|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
219442158|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
219442159|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
218834939|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
218834940|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
218834941|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
219442160|NCT06020833|DRUG|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
219015809|NCT01749579|DRUG|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
218834942|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
218834943|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
219442161|NCT03137017|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
219442162|NCT03137017|DRUG|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
219442163|NCT01924741|PROCEDURE|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
219442164|NCT04843943|DRUG|Sintilimab|Sintilimab: 200mg IV Q3W D1
219442165|NCT04843943|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
219442166|NCT02571972|DRUG|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
219442167|NCT02451033|DRUG|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
219442168|NCT02451033|DRUG|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
219442169|NCT02451033|DRUG|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
219442170|NCT01070238|DIETARY_SUPPLEMENT|Isomaltulose|
219442171|NCT01391338|DRUG|ASP3652|Oral
218834944|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
218834945|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
218834946|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
218834947|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
218834948|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
218834949|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
218834950|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
218834951|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
218834952|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
218834953|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
218834954|NCT02131311|DEVICE|disposable, single-use pessary|
218834955|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
219015810|NCT00161993|DRUG|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
219015811|NCT00161993|DRUG|Gammagard S/D (Solvent/Detergent)|
219015812|NCT05921019|DEVICE|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
219442172|NCT01391338|DRUG|Placebo|Oral
219442173|NCT01359852|DRUG|[11C] JNJ-42491293|Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
219442174|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
219442175|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|"Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
219442176|NCT01359852|DRUG|[11C] JNJ-42491293|Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
219442177|NCT01146548|DRUG|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
219442178|NCT03519399|DEVICE|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
219442179|NCT03529370|RADIATION|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
219442180|NCT03039192|DRUG|Esketamine|Intranasal esketamine solution 84 milligram (mg)
219442181|NCT03039192|OTHER|Placebo|Intranasal Placebo solution
219442182|NCT03039192|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
219442183|NCT02493868|DRUG|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
219015813|NCT05921019|DEVICE|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
219442184|NCT02493868|DRUG|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
219015814|NCT00275951|DRUG|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
219015815|NCT02226003|DRUG|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
219015816|NCT02226003|DRUG|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
219582355|NCT03929276|OTHER|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
219582356|NCT02910674|DEVICE|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
219582357|NCT05748106|DEVICE|Ultrasound-based imaging|Ultrasound-based imaging
219582358|NCT01879930|DRUG|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
219582359|NCT01879930|DRUG|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
219582360|NCT03361930|DEVICE|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
219582361|NCT01216618|DEVICE|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
219582362|NCT00244478|DIETARY_SUPPLEMENT|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
219442185|NCT02493868|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
219582363|NCT00244478|DIETARY_SUPPLEMENT|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
219582364|NCT04885153|DRUG|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
219582365|NCT04885153|DRUG|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
219582366|NCT04029753|BEHAVIORAL|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
219582367|NCT01034254|BIOLOGICAL|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
219582368|NCT01034254|BIOLOGICAL|saline placebo|Vaccination of pregnant women with saline placebo.
219582369|NCT01242995|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
219582370|NCT00914953|DRUG|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
219582371|NCT03828916|OTHER|NuShield|SOC surgery with the addition of NuShield
219015817|NCT02226003|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
219015818|NCT02226003|DRUG|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
219015819|NCT02226003|DRUG|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
219015820|NCT05751239|OTHER|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
219015821|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
219015822|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
219015823|NCT05308641|PROCEDURE|standard multimodal pain therapy|standard multimodal pain therapy
219015824|NCT02467465|OTHER|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
219015825|NCT02467465|DEVICE|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
219015826|NCT03578081|DRUG|Palonosetron Hydrochloride|Given IV
219015827|NCT03578081|DRUG|Ondansetron Hydrochloride|Given IV or PO
219015828|NCT03578081|DRUG|Dexamethasone|Given PO
219015829|NCT03578081|DRUG|Fosaprepitant Dimeglumine|Given IV
219015830|NCT03578081|DRUG|Olanzapine|Given PO
219015831|NCT03578081|OTHER|Placebo|Given IV
219015832|NCT05936996|DEVICE|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
219015833|NCT05139563|OTHER|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
219015834|NCT05139563|OTHER|Placebo implant|placebo subdermal implant rod
219015835|NCT03242174|OTHER|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
219015836|NCT03293381|DEVICE|additional biopsies|additional biopsies
219015837|NCT02795442|OTHER|Even protein|5 day intake of even protein 3 day rotating menu.
219015838|NCT02795442|OTHER|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
219015839|NCT01572194|BIOLOGICAL|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
219015840|NCT01689584|GENETIC|salivary kit|The saliva samples will be made of selected related (DNA).
219015841|NCT04167683|OTHER|No intervention|No intervention
219015842|NCT06596148|OTHER|Access to Shingrix dashboard|The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.
219442186|NCT02493868|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
219442187|NCT02493868|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
219015843|NCT05986019|DEVICE|transcranial focused ultrasound (tFUS)|Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.
219015844|NCT06007560|OTHER|Exercise|Aerobe cycling training consisting of 12-weeks of HR-controlled training at 50-60% of VO2max (maximal oxygen uptake) for 1 hour, for 2 times (week: 1-6) to 3 times (week: 7-12) per week
219442188|NCT02493868|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
219442189|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
219442190|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
219442191|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
219442192|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
219442193|NCT02324738|DRUG|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
219442194|NCT02324738|OTHER|Wash-out period|
219442195|NCT02324738|DRUG|Mefloquine|2 tablets of Mefloquine single dose
219442196|NCT02299271|DRUG|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
219442197|NCT02299271|DRUG|Saline|Saline as a one-time, 60 milliliter injection.
219442198|NCT03725449|OTHER|Best Practice|Receive standard of care
219442199|NCT03725449|BEHAVIORAL|mySmartCheck|Receive access to mySmartcheck program
219442200|NCT03725449|OTHER|Survey Administration|Ancillary studies
219442201|NCT03461185|DRUG|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
219442202|NCT03461185|DRUG|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
219442203|NCT04819724|DIAGNOSTIC_TEST|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
218834956|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
219015845|NCT05448066|DIAGNOSTIC_TEST|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
218834957|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
218834958|NCT00414323|DRUG|Duloxetine|
218834959|NCT00414323|DRUG|Escitalopram|
218834960|NCT00414323|DRUG|Placebo|
218834961|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
218834962|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
218834963|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
218834964|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
219015846|NCT05448066|DIAGNOSTIC_TEST|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
219015847|NCT05776667|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
219015848|NCT05436951|BEHAVIORAL|Brief on-shift nap|The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
219015849|NCT05459116|DEVICE|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients \>40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
219015850|NCT05785000|OTHER|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
219015851|NCT05785000|OTHER|Control patients receiving usual care|No exercise intervention
219015852|NCT01896440|DRUG|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
219015853|NCT05151146|DRUG|ANJ900|Metformin hydrochloride delayed-release tablets
219196210|NCT06815159|BIOLOGICAL|Identification any tissue markers predictive or favoring early stenosis in AVF for haemodialysis.|"Primary objective~1. Identify any predictive or favoring tissue markers of early stenosis in AVF for hemodialysis.~   Secondary objectives~2. Compare the results on the possible different expression of tissue markers before and during dialysis.~3. Compare the results on the possible different expression of tissue markers between AVFs made with portions of cephalic vein and AVFs made with portions of basilic vein, in order to evaluate whether the different topographic origin of the AVF can influence its duration."
219442204|NCT04819724|DIAGNOSTIC_TEST|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
218834965|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
218834966|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
218834967|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
219015854|NCT05151146|DRUG|Metformin IR|metformin hydrochloride
219015855|NCT02176330|OTHER|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
219196211|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
219442205|NCT04819724|DIAGNOSTIC_TEST|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
219442206|NCT04819724|DIAGNOSTIC_TEST|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
219442207|NCT04819724|OTHER|data collection by health questionnaires|data collection by health questionnaires
218834968|NCT00190736|DRUG|Atomoxetine Hydrochloride|
218834969|NCT00190736|DRUG|placebo|
219015856|NCT02176330|OTHER|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
219015857|NCT06112782|DEVICE|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
219015858|NCT00437099|DRUG|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
219015859|NCT00437099|DRUG|Placebo|Placebo
219015860|NCT06151795|DIAGNOSTIC_TEST|XTR006|Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
219015861|NCT01384968|DIETARY_SUPPLEMENT|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
219015862|NCT02104700|DRUG|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
219015863|NCT03847454|COMBINATION_PRODUCT|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
219015864|NCT03847454|OTHER|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
219442208|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
219442209|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
219442210|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
219442211|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
219442212|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
219442213|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
219442214|NCT00054860|BIOLOGICAL|EP HIV-1090|
219442215|NCT00544505|DRUG|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
219442216|NCT04246346|OTHER|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
218834970|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
218834971|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
219015865|NCT01017614|DRUG|Monofer|"* administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
219015866|NCT01017614|DRUG|Iron Sulphate|200 mg daily
219015867|NCT00000901|DRUG|Indinavir sulfate|
219442217|NCT04246346|OTHER|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
219442218|NCT00464620|DRUG|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
219442219|NCT04347252|DRUG|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
219442220|NCT04402385|DRUG|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
219442221|NCT04402385|DRUG|Placebo|Participants randomized to placebo daily
219442222|NCT02465762|DEVICE|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
219582372|NCT03996629|OTHER|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
219582373|NCT00933348|DRUG|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
219582374|NCT00933348|DRUG|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
219015868|NCT00000901|DRUG|Lamivudine|
219015869|NCT00000901|DRUG|Stavudine|
219582375|NCT00000326|DRUG|Heroin Dependence|
219582376|NCT05373121|BEHAVIORAL|Online Peer Support|Signposting to online peer support groups and forums
219015870|NCT01851564|DEVICE|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
219015871|NCT01851564|OTHER|Standard Therapy|Standard Medical and Endoscopic Therapy
219015872|NCT03284164|DRUG|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
219015873|NCT01401868|DRUG|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
219442223|NCT01879475|DEVICE|032-11|Topical haemostat
219582377|NCT03745157|DRUG|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
219582378|NCT01959854|DEVICE|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
219764465|NCT07003308|PROCEDURE|Anterior White Line Advancement Surgery|This technique involves a skin incision at the eyelid crease, dissection through the orbicularis muscle to expose the tarsus, and proximal dissection in the pre-Müller-conjunctival plane to visualize the white line. A double-armed 5-0 absorbable suture is used to advance the white line to the anterior tarsal surface. Eyelid height and contour are assessed before final fixation. Skin closure is completed with a non-absorbable suture.
219764466|NCT07003308|PROCEDURE|Posterior White Line Advancement Surgery|This conjunctival technique uses a traction suture and eyelid eversion to access the posterior surface of the eyelid. A conjunctival incision is made above the superior tarsal border, followed by dissection to expose the white line. A double-armed 5-0 absorbable suture is passed through the anterior tarsus and the white line, and tied after confirming adequate eyelid position. The conjunctiva is not sutured.
219015874|NCT06860477|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
219015875|NCT06860477|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily
219196212|NCT04225572|BEHAVIORAL|Physical Therapy: Dependent on Patient's Needs|"Therapeutic exercise:~* ROM: Begin with passive upper extremity ROM and progress to active ROM.~* Strengthening: Progressive upper extremity resistive exercises starting with light weights.~* Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~* Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~* Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~* Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema."
219442224|NCT01879475|DEVICE|Floseal (R)|Topical haemostat
219442225|NCT00854984|BEHAVIORAL|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
219442226|NCT02796079|BIOLOGICAL|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
219442227|NCT02796079|BIOLOGICAL|saline|saline injections
219442228|NCT05490381|OTHER|Iodixanol|Given via injection
219582379|NCT01959854|DEVICE|xanthan gum|0.2% xanthan gum preservative free
219582380|NCT02033057|PROCEDURE|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
219582381|NCT03019159|DEVICE|Teleconsulting|
219764467|NCT06624631|OTHER|Adherence support strategy a|Monthly SMS reminders
219764468|NCT06624631|OTHER|Adherence support strategy b|Community Health Promoters' (CHPs) monthly reminder home visits
219015876|NCT06860477|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus Tislelizumab will be administered 1-3 days after cryoablation.
219015877|NCT06860477|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
219015878|NCT06740526|DRUG|Sibeprenlimab|"Sibeprelimab SC (Period 1)~Sibeprelimab SC (Period 2)"
219442229|NCT05490381|PROCEDURE|Angiogram|Undergo diagnostic cerebral angiogram
219442230|NCT05490381|PROCEDURE|Arterial Embolization|Undergo tumor vessel embolization
219442231|NCT05490381|DRUG|Polyvinyl Alcohol|Given via catheter
219442232|NCT05490381|DRUG|Ethiodized Oil|Given via catheter
219015879|NCT04366453|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
219015880|NCT04087798|BEHAVIORAL|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
219015881|NCT04087798|BEHAVIORAL|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
219582382|NCT06633107|BEHAVIORAL|Cardiac、rehabilitation、exercise|"Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week"
219582383|NCT03507647|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
219582384|NCT03507647|OTHER|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
219582385|NCT02677181|DRUG|ATG|rabbit ATG（Sanofi）
219582386|NCT02677181|DRUG|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
219582387|NCT02677181|DRUG|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
219582388|NCT02677181|DRUG|Methotrexate|short-term methotrexate
219582389|NCT00209105|DRUG|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
219582390|NCT00209105|BEHAVIORAL|Psychosocial stress induction|Laboratory stress induction, no drug administration
219582391|NCT00209105|PROCEDURE|Brain imaging of sad mood , self-reference, reward|Brain imaging
219196213|NCT03606512|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
219442233|NCT05490381|PROCEDURE|Computed Tomography|Undergo head and neck CT scans
219442234|NCT05490381|OTHER|Chart Abstraction|Ancillary studies
219442235|NCT04262557|DIAGNOSTIC_TEST|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
219442236|NCT04262557|DIAGNOSTIC_TEST|Polysomnography|Gold standard method to diagnose SAS used as comparator
219582392|NCT00209105|BEHAVIORAL|Acoustic startle|No drugs involved
219582393|NCT01914055|DEVICE|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
219196214|NCT03606512|BIOLOGICAL|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
219196215|NCT03606512|BIOLOGICAL|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
219442237|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|\- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
219442238|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
219442239|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
219442240|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
219582394|NCT01914055|DEVICE|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
219582395|NCT03954314|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
219582396|NCT00166036|DRUG|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
219015882|NCT05689320|OTHER|Behavioral: EMA-based intervention|This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
218834972|NCT01726543|PROCEDURE|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
219015883|NCT06648382|BEHAVIORAL|Self-directed psychotherapy program for premenstrual disorders|The intervention consists of receiving 11 videos that are 10-15 minutes in length along with a workbook containing homework exercises. Participants are instructed to watch the videos over the course of two menstrual cycles: the first 6 during the first cycle and the last 5 during the second cycle. Each module focuses on a different skill inspired by cognitive behavioral therapy and dialectical behavior therapy.
219015884|NCT04735666|DEVICE|TauroPace™|TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.
219015885|NCT04219891|DEVICE|WaveLight EX500 excimer laser system with InnovEyes sightmap|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the WaveLight EX500 software will be upgraded to include the InnovEyes treatment.
219015886|NCT04219891|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system and data obtained from the InnovEyes sightmap.
219015887|NCT04219891|DEVICE|InnovEyes sightmap|Non-contact ophthalmic diagnostic device that captures images of the eye and collects ocular data preoperatively to generate a patient-specific ablation profile for refractive correction surgery
219015888|NCT06910046|DIAGNOSTIC_TEST|CLE and ssRAB-guided cryobiopsy|All procedures are performed under general anesthesia with endotracheal intubation and mechanical ventilation. A conventional flexible bronchoscope is used to examine the subject's airway and clear the secretion. After the registration procedure is completed, the catheter of the ssRAB system is navigated to the target lesion. Cone beam computed tomography (CBCT) is used to confirm whether the target lesion has been reached. After that, an appropriate CLE probe is inserted. Right before CLE imaging, 2.5 ml of 10% fluorescein sodium is administered intravenously. CLE is then used to examine the target lesion. Based on real-time CLE imaging, the optimal biopsy location is identified and localized on the fluoroscopy. After CLE imaging, the CLE probe is retracted, followed by cryobiopsy at the same location under fluoroscopy guidance. Rapid on-site evaluation is available during the procedure to assess sample adequacy.
219015889|NCT04889352|OTHER|Access to colonoscopy web app|There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.
219015890|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
219015891|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
219015892|NCT00436254|OTHER|flow cytometry|Correlative studies
219015893|NCT00436254|OTHER|immunologic technique|Correlative studies
219015894|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
219015895|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
219015896|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
219015897|NCT05636098|DEVICE|Masimo Rainbow Sensors|Noninvasive pulse oximeter sensor
219442241|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
219015898|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
219015899|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
219015900|NCT06913023|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3mg for 4 weeks.
219015901|NCT06913023|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7mg for 4 weeks.
219015902|NCT06913023|DRUG|Semaglutide 14 MG [Rybelsus]|Semaglutide 14mg for 16 weeks.
219442242|NCT00469976|DRUG|bevacizumab|
219442243|NCT00469976|DRUG|carboplatin|
219442244|NCT00469976|DRUG|enzastaurin hydrochloride|
219015903|NCT06913023|DRUG|Placebo Oral Tablet|Placebo tablet
219015904|NCT06914323|PROCEDURE|Acupressure|improvements in pain, limb swelling, and comfort
219442245|NCT00469976|DRUG|gemcitabine hydrochloride|
219442246|NCT04653727|OTHER|Cross-sectional survey|No intervention.
219442247|NCT01125904|DRUG|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
219442248|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
219442249|NCT00146224|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
219015905|NCT06914739|BEHAVIORAL|The Health Empowerment Theory (HET) program|The intervention group received the HET-based intervention program for 12 weeks. From the first week to the fourth week, community nurses interacted with the participants face-to-face to analyze and establish their problems and needs in health management (usual community health services utilization, such as medicine purchases and vaccinations) and helped clarify the importance of health management and their strengths (such as existing health knowledge). From the fifth to twelfth weeks, participants attended health knowledge lectures led by community nurses, covering topics such as: a) healthy lifestyle, primarily diet, exercise, and disease prevention and management for older adults; and b) community health services, which included recent or long-term community health services (such as health examinations for older adults and family doctor contracts). WeChat groups and offline gatherings at community health centers (with groups of eight to ten peers) were organized to interact and comm
219015906|NCT06914739|BEHAVIORAL|routine community care|The control group received routine community care, including notifications of community- related activities and lectures through WeChat group chats or telephone calls, and had questions answered by researchers and community nurses.
219015907|NCT06914232|COMBINATION_PRODUCT|Warm Compress|The intervention involves perioperative Warm compress therapy administered to the participants in the intervention group before and after cataract surgery for 3 seesions per week for 6 weeks. The therapy aims to enhance tear film stability and alleviate symptoms of dry eye by delivering warm compress to the meibomian glands to restore their function. Participants will undergo a session of warm compress therapy prior to surgery and another one following the surgery.
219015908|NCT06914232|DIAGNOSTIC_TEST|Standard Care|The control group will receive standard care, which includes artificial tears or other conventional methods for dry eye management for 3 sessions per week for 6 weeks. , but they will not receive Warm Compress therapy.
219196216|NCT06554379|OTHER|Periodontal health and gingivitis|The presence or absence of periodontal disease in the gingiva was determined.
219196217|NCT04646187|BIOLOGICAL|Infliximab|Dosing interval lengthening from 8 to 12 weeks
219196218|NCT04646187|BIOLOGICAL|Adalimumab|Dosing interval lengthening from 2 to 3 weeks
219196219|NCT05513937|DRUG|Nebivolol|Tablets administered orally once daily according instructions provided by Principal Investigator.
219442250|NCT00146224|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
219442251|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
219442252|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
219442253|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
219442254|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
219442255|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
219442256|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablet
219442257|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablets
219442258|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
219442259|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
219442260|NCT06118190|DRUG|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
219442261|NCT03013426|DRUG|NVX-508|Administration of NVX-508 emulsion intravenously
219442262|NCT02899104|DRUG|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
219442263|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
219442264|NCT02894294|OTHER|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
219442265|NCT02550860|DRUG|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
219582397|NCT00166036|DRUG|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
219442266|NCT02550860|DRUG|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
219442267|NCT03990922|PROCEDURE|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
219442268|NCT03990922|PROCEDURE|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
219442269|NCT03990922|DRUG|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
219442270|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
219442271|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219442272|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
219442273|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
219442274|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
219442275|NCT02204410|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|
219442276|NCT02204410|DRUG|ADHD Medication|
219442277|NCT00852423|DRUG|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
219582398|NCT01462318|DRUG|Midazolam|5 mg
219582399|NCT01462318|OTHER|Caffeine|200 mg
219582400|NCT01462318|DRUG|S-warfarin|10 mg
219442278|NCT00852423|DRUG|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
218834973|NCT01726543|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
218834974|NCT03082677|DRUG|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
218834975|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
218834976|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
218834977|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
219015909|NCT06914531|OTHER|Questionnaire comprehension test|Participants will complete a standardized questionnaire assessing social cognition, adapted for cochlear-implanted children aged 3 to 6 years. The assessment includes the Item Scale and the Test of Emotions Comprehension adapted and mixed together. The questionnaire evaluates children's ability to understand emotions, social interactions, and cognitive perspective-taking. Each child will complete the test in a single session lasting approximately 20 minutes, under the supervision of a trained investigator, with an orthophonist and a parent present
219015910|NCT06913413|COMBINATION_PRODUCT|core stabilization exercise|Will receive 8 week core stabilization exercise 3 session per week which include 10 min warm up and 10 min cool down (walking ) 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug ,plank with 50,000 IU of vitamin D weekly
219196220|NCT05513937|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
219442279|NCT00852423|DRUG|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
219442280|NCT00852423|DRUG|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
219442281|NCT06100107|OTHER|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
219442282|NCT03654560|DEVICE|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
219442283|NCT03654560|DEVICE|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
219582401|NCT01462318|OTHER|Vitamin K|10 mg
219582402|NCT01462318|DRUG|Omeprazole|40 mg
219582403|NCT01462318|DRUG|Dextromethorphan|30 mg
219582404|NCT01462318|BIOLOGICAL|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
219582405|NCT03827564|DEVICE|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
219582406|NCT00326287|DRUG|Ceftobiprole medocaril|
218834978|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
219582407|NCT00326287|DRUG|Ceftriaxone with or without Linezolid|
219582408|NCT02799030|DRUG|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
219582409|NCT02799030|DRUG|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
218834979|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
218834980|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
219015911|NCT06913413|DIAGNOSTIC_TEST|stabilization exercise|stabilization exercise 3 session per week which include 10 min warm and 10 min cool down (walking ) sham medicine, 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug and plank
219015912|NCT06913179|BIOLOGICAL|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission following CAR-T infusion will subsequently undergo allo-HSCT|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission (CR) following CAR-T infusion will subsequently undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on clinical assessment. The entire treatment process will be standardized and closely monitored, with follow-up evaluations focusing on adverse events, engraftment success, relapse risk, and overall survival.
219015913|NCT06912620|DIETARY_SUPPLEMENT|Soy-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
219015914|NCT06912620|DIETARY_SUPPLEMENT|Soy-maize-sorghum-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
219015915|NCT06912620|DIETARY_SUPPLEMENT|Standard RUTF|This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
219015916|NCT06914583|DEVICE|Sodium Hyaluronate|Sodium Hyaluronate 32 mg/ml
219015917|NCT06913634|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
219015918|NCT06914804|DEVICE|Stomasense|A smart device worn alongside stoma pouch systems which detects onset of a leak.
219442284|NCT02126241|OTHER|NICaS guided CRT optimization|"1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay"
219442285|NCT01473355|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
219442286|NCT05648123|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
219442287|NCT02792036|DRUG|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
219442288|NCT02792036|DRUG|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
219582410|NCT02799030|DRUG|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
218834981|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
218834982|NCT03163134|DEVICE|Lumbar Drain|
218834983|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
218834984|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
218834985|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
218834986|NCT01626573|DRUG|Itacitinib|
218834987|NCT01626573|DRUG|Itacitinib Placebo|
218834988|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
218834989|NCT00109252|DRUG|Raptiva (efalizumab)|
218834990|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
218834991|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
218834992|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
218834993|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
218834994|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
218834995|NCT02209792|DRUG|Placebo|
218834996|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
218834997|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
218834998|NCT00876707|DEVICE|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
218834999|NCT00876707|DEVICE|ReSTOR implant|Implant of multifocal IOL ReSTOR
218835000|NCT00876707|DEVICE|ReZoom implant|Implant of multifocal IOL ReZoom
218835001|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
219015919|NCT02697695|OTHER|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
218835002|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
219015920|NCT00433849|DRUG|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
219015921|NCT00433849|DRUG|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
219015922|NCT00290914|DRUG|Vilazodone|
219015923|NCT02914808|OTHER|Patients will undergo a lower limb MRI and blood tests|
219015926|NCT04958785|DRUG|Magrolimab|Administered intravenously
219015927|NCT04958785|DRUG|Nab-Paclitaxel|Administered intravenously
219015928|NCT04958785|DRUG|Paclitaxel|Administered intravenously
219015929|NCT04958785|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219442289|NCT02792036|PROCEDURE|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
219442290|NCT02792036|PROCEDURE|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
219442291|NCT00744731|DRUG|placebo|placebo for 1 week
219442292|NCT00744731|DRUG|carisbamate|400 mg/day to 1,200 mg per day
219442293|NCT04065815|OTHER|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
219442294|NCT04065815|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
219442295|NCT04065815|OTHER|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week"
219764469|NCT06624631|OTHER|Adherence support strategy c|No monthly reminders
218835003|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
218835004|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
218835005|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
219015934|NCT06419985|DRUG|80mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 40mg BID
219015935|NCT06419985|DRUG|160mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 80mg BID
219015936|NCT05621668|DRUG|Cyclophosphamide|Given by IV (vein)
219015937|NCT05621668|DRUG|attIL2-T cells|Given by IV (vein)
219015939|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
219015940|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
219015941|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
219015944|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
219015945|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
219015946|NCT04800159|DRUG|Placebo|Vaporization of placebo
219015949|NCT06207591|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
219582411|NCT05562908|PROCEDURE|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
219764470|NCT06624514|BEHAVIORAL|Training Group|Implicit approach bias is the behavioral action tendency to be faster to approach rather than avoid cues for a stimulus category. The Approach-Avoidance Task (AAT)is a computerized program in which participants make approach or avoidance movements in response to an irrelevant feature of an image presented on a computer screen (e.g., push when in portrait, pull when in landscape). The intervention in this study is a treatment version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).
219764471|NCT06624514|BEHAVIORAL|Sham Training Group|A sham-training control condition
219764472|NCT06676111|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
219764473|NCT06676111|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
219764474|NCT06676826|DEVICE|Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)|Infrabony defects will be filled with a volume-stable collagen matrix
219764475|NCT06676826|DEVICE|Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen|Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
219764476|NCT06615050|DRUG|Tacrolimus (Tac)|Tablet or intravenously (IV)
219764477|NCT06615050|DRUG|Methotrexate (MTX)|Intravenously (IV)
219764478|NCT06615050|DRUG|Ruxolitinib (Rux)|Tablet
219582412|NCT05562908|PROCEDURE|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
219582413|NCT05562908|PROCEDURE|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
219582414|NCT01841775|DRUG|interferon α 2b + ribavirin|"1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
219582415|NCT00891371|DRUG|lanreotide (Autogel formulation)|Autogel 120mg
219582416|NCT02238626|DRUG|Placebo (for MN-166)|
219582417|NCT02238626|DRUG|MN-166|
219582418|NCT02238626|DRUG|riluzole|Patient is given 50 mg riluzole twice daily.
219764479|NCT06615050|DRUG|Cyclophosphamide|Intravenously (IV)
219764480|NCT06615050|DRUG|Mycophenolate mofetil (MMF)|Tablet or intravenously (IV)
219764481|NCT07012395|DRUG|SPY001|Experimental
219764482|NCT07012395|DRUG|SPY002|Experimental
218835006|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
218835007|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
218835008|NCT01958580|DRUG|Docetaxel|Given IV
219442296|NCT04065815|OTHER|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week"
219582419|NCT00197392|DEVICE|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
218835009|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
218835010|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218835011|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219582420|NCT00197392|DEVICE|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
218835012|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
218835013|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
218835014|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
218835015|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
218835016|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
218835017|NCT01018173|DRUG|placebo|sc weekly
218835018|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
218835019|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
218835020|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
218835021|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
218835022|NCT02094378|DRUG|Placebo|Placebo administered intranasally
218835023|NCT01095991|DRUG|AZD1656|Oral tablet bd,
218835024|NCT01095991|DRUG|Sitagliptin|Oral tablet od
219764483|NCT07012395|DRUG|SPY003|Experimental
219764484|NCT07012395|OTHER|Placebo|Placebo
219764485|NCT05563051|DEVICE|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
219764486|NCT07011745|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
219764487|NCT07011745|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
219764488|NCT07011745|DRUG|Placebo|Specified dose on specified days
219764489|NCT07011732|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
219764490|NCT07011732|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
219764491|NCT07011732|DRUG|Placebo|Specified dose on specified days
219764492|NCT06685757|DRUG|Felzartamab|Participants will receive felzartamab by intravenous infusion.
219764493|NCT06685757|DRUG|Placebo|Participants will receive 0.9% saline solution by intravenous infusion.
219764494|NCT07014722|DEVICE|MERITMEDICAL Careflow™ Two-Lumen Central Venous Catheter|7 Fr, 150 mm, radio-opaque polyurethane catheter (OD 2.4 mm)
218835025|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
218835026|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
218835027|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
218835028|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
218835029|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
218835030|NCT00771212|OTHER|Observational pain control study|Observational pain control study
218835031|NCT01276548|DRUG|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
218835032|NCT01276548|DRUG|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
218835033|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
219442297|NCT05081089|DRUG|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
218835034|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
219442298|NCT05081089|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
219442299|NCT05081089|DRUG|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
219442300|NCT05081089|DRUG|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
218835035|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
218835036|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
218835037|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
218835038|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
219442301|NCT04838795|BIOLOGICAL|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
219442302|NCT04459078|DRUG|Camrelizumab|Intravenous administration of (200mg/3weeks)
219442303|NCT04459078|DRUG|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
219442304|NCT04459078|DRUG|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
219442305|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
219442306|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
219442307|NCT00249912|DRUG|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
219442308|NCT04457661|DIETARY_SUPPLEMENT|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
219442309|NCT05933993|OTHER|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
218835039|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
218835040|NCT02320864|PROCEDURE|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
219442310|NCT01467089|OTHER|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
219442311|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
219442312|NCT01984359|OTHER|Obtaining Human tissue|
219442313|NCT00912496|BIOLOGICAL|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
219442314|NCT00912496|BIOLOGICAL|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
219442315|NCT00912496|DRUG|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
219015966|NCT06828588|DRUG|ABY-025 Loading Dose|Subjects will receive a loading dose (400 micrograms) of ABY-025 prior to the \[68Ga\]Ga-ABY-025 infusion.
219015967|NCT06828588|DRUG|[68Ga]Ga-ABY-025|Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.
219764495|NCT07014722|DEVICE|ARROW Two-Lumen Central Venous Catheter|7 Fr, 160 mm, radio-opaque polyurethane catheter (OD 2.5 mm)
219764496|NCT07014722|DEVICE|ARROWg+ard Blue Plus® Two-Lumen Central Venous Catheter|8 Fr, 160 mm, radio-opaque polyurethane catheter with antimicrobial coating
219015989|NCT05232916|BIOLOGICAL|Placebo|0.9% Normal Saline
219015990|NCT05232916|BIOLOGICAL|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
219015991|NCT06217094|DRUG|NP-101 (3 g)|Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
219015992|NCT06217094|DRUG|NP-101 (4.8 g)|Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
219015993|NCT06217094|DRUG|NP-101 (6 g)|Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
219015994|NCT04202354|DRUG|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
219015995|NCT04202354|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
219016002|NCT01880567|DRUG|Ibrutinib|Given PO
219016003|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
219016004|NCT01880567|BIOLOGICAL|Rituximab|Given IV
219016009|NCT04983823|OTHER|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
219016010|NCT04983823|OTHER|Usual care|This will be provided by participants' usual healthcare professional(s).
219764497|NCT07014722|DEVICE|Multicath 2 Expert UP Two-Lumen Central Venous Catheter|7.5 Fr, 160 mm, central venous catheter (OD 2.5 mm). Polyurethane shaft embedded with silver ions.
219764498|NCT02999477|DRUG|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
219764499|NCT02999477|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
219764500|NCT02999477|PROCEDURE|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
219764501|NCT07015983|DRUG|CC-97540|Specified dose on specified days
218835041|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
218835042|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
218835043|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
218835044|NCT00087984|BIOLOGICAL|MB-002|Dendritic Cell Immunotherapy
218835045|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
218835046|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
218835047|NCT00967681|DIETARY_SUPPLEMENT|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
218835048|NCT00967681|DIETARY_SUPPLEMENT|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
218835049|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
218835050|NCT04187248|DRUG|Asparaginase|
218835051|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
218835052|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
218835053|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
218835054|NCT04535089|DRUG|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
218835055|NCT04535089|DRUG|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
218835056|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
218835057|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
218835058|NCT05312606|OTHER|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
218835059|NCT05312606|OTHER|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
218835060|NCT00976157|PROCEDURE|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
218835061|NCT02250469|DEVICE|Treatment with the Axium SCS system|
218835062|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
218835063|NCT05523557|BEHAVIORAL|Urban Training|1\) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
219764502|NCT07015983|DRUG|Fludarabine|Specified dose on specified days
219764503|NCT07015983|DRUG|Cyclophosphamide|Specified dose on specified days
219764504|NCT07015905|DRUG|REGN7508|Administered per the protocol
219764505|NCT07015905|DRUG|Apixaban|Administered per the protocol
219764506|NCT07015905|DRUG|Enoxaparin|Administered per the protocol
219764507|NCT07015905|DRUG|Placebo|Administered per the protocol
219764508|NCT07013487|BIOLOGICAL|V181|Participants will receive a single 0.5 mL SC dose of V181 on Day 1.
219582421|NCT05969379|GENETIC|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
219582422|NCT02622113|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
219582423|NCT02622113|DRUG|Insulin|
219582424|NCT02239341|OTHER|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
218835064|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
218835065|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
218835066|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
219582425|NCT02239341|OTHER|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
219582426|NCT05623072|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
219582427|NCT05623072|DEVICE|Sham tDCS|20 min, vmPFC Sham tDCS
219764509|NCT07013487|BIOLOGICAL|Placebo|Participants will receive a single 0.5 mL SC dose of placebo on Day 1.
218835067|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
218835068|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
218835069|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
218835070|NCT03436498|DRUG|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
218835071|NCT03436498|DRUG|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
218835072|NCT02088125|OTHER|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
218835073|NCT02088125|OTHER|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
218835074|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
218835075|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
218835076|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
218835077|NCT05978336|BEHAVIORAL|Health Coaching Program|"The HC program will be delivered over 26-weeks. Participants will have an initial hour-long HC session where the BAP coach will conduct a brief physical assessment and work with the participant to establish their physical activity goals and develop a plan. After the initial consult, coaches will conduct 8 x 20-minute phone calls with participants over the 26-week trial decreasing from bi-weekly phone calls in weeks 1-12 to monthly phone calls in weeks 13-26.~Participants in the HC group will have an overall goal of increasing their weekly participation in moderate to vigorous physical activity by 50 minutes, via 5-, 7-, or 10-minute bouts of progressive exercises, at a rate of perceived exertion range of 13-14 (somewhat hard) by week 16. Participants will have access to specific exercise sessions made available by YouTube and/or hardcopy manuals created by the research team."
218835078|NCT05978336|BEHAVIORAL|Health Education Program|Participants will begin with a one-hour, group-based, interactive education session on falls prevention delivered either in-person or by Zoom. Following the initial education session, ED participants will receive additional group education sessions (in-person or by Zoom) with the same duration and schedule as the HC program covering a variety of healthy aging topics.
218835079|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
218835080|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
218835081|NCT05823974|BIOLOGICAL|F2C22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835082|NCT05823974|BIOLOGICAL|F2B22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835083|NCT05823974|BIOLOGICAL|F2B22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835084|NCT05823974|BIOLOGICAL|F2B22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835085|NCT05823974|BIOLOGICAL|F2B22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
219582428|NCT03525158|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
219582429|NCT02969941|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
219582430|NCT00221611|DRUG|Administration of intrathecal baclofen|
219582431|NCT01562340|OTHER|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
218835086|NCT05823974|BIOLOGICAL|F2B22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
219582432|NCT01562340|OTHER|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
219582433|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
218835087|NCT05823974|BIOLOGICAL|F2F22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835088|NCT05823974|BIOLOGICAL|F2F22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835089|NCT05823974|BIOLOGICAL|F2F22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835090|NCT05823974|BIOLOGICAL|F2F22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835091|NCT05823974|BIOLOGICAL|F2F22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835092|NCT05823974|COMBINATION_PRODUCT|Control 1|Control vaccine was administered intramuscularly in Phase 1, at Day 1.
218835093|NCT05823974|BIOLOGICAL|F2F23D/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
218835094|NCT05823974|BIOLOGICAL|F2F23A/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
218835095|NCT05823974|BIOLOGICAL|F2F23B/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
218835096|NCT05823974|COMBINATION_PRODUCT|Control 2|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
218835097|NCT05823974|BIOLOGICAL|F2F23C/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
218835098|NCT05823974|COMBINATION_PRODUCT|Control 3|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
218835099|NCT05823974|BIOLOGICAL|F2F22F/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
218835100|NCT05835505|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
218835101|NCT05835505|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
218835102|NCT05364775|OTHER|Focus group|Focus group
218835103|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
218835104|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
218835105|NCT04109807|OTHER|Ozone|ozone exposure
218835106|NCT04109807|OTHER|FA|Filtered air exposure
218835107|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
218835108|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
218835109|NCT01186042|OTHER|Observational|No intervention
218835110|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
218835111|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
218835112|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
219582434|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
219582435|NCT00672165|BIOLOGICAL|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
219582436|NCT00774696|DRUG|clarithromycin 500mg tablets|
219582437|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
219582438|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
219582439|NCT00667810|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
219582440|NCT05619055|OTHER|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
219582441|NCT05034341|OTHER|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
219582442|NCT05034341|OTHER|Standard Pre-Surgical Clinical Care|"* Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
219582443|NCT03265613|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
219582444|NCT05921513|PROCEDURE|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
219582445|NCT01946360|DEVICE|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
219582446|NCT02244918|DRUG|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
219582447|NCT02244918|BEHAVIORAL|Smoking Cessation Counseling|
219582448|NCT04650503|OTHER|No intervention|No intervention
219582449|NCT03142906|DIAGNOSTIC_TEST|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
219582450|NCT05154435|DRUG|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
219582451|NCT00505375|DRUG|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
219582452|NCT00505375|OTHER|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
219582453|NCT02000661|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
219582454|NCT05631353|DEVICE|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
218835113|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
218835114|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
218835115|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
218835116|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
218835117|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
218835118|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
218835119|NCT05562518|DRUG|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
218835120|NCT05562518|DRUG|dehydroepiandrosterone|1 vaginal ovule daily
218835121|NCT05562518|DRUG|Estrogen + probiotics|1 vaginal ovule daily for 12 consecutive days, followed by 1 vaginal ovule 2 times per week
218835122|NCT05562518|DRUG|Moisturizer|1 vaginal ovule daily for 14 consecutive days, followed by 1 vaginal ovule every three days
218835123|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
218835124|NCT03980743|BEHAVIORAL|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
219582455|NCT04821531|OTHER|PT Pal|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength balance and mobility
219582456|NCT04821531|OTHER|Exercise Manual|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength, balance and mobility
219764510|NCT07014462|DRUG|Dexamethasone plus Venetoclax-based Low-Intensity Therapy|Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or low-dose cytarabine, per treating physician's discretion. In addition, participants will receive dexamethasone administered orally at 10 mg twice daily on days 1-3 of cycles 1 and 2, and 20 mg orally on day 1 of cycles 3 through 6. This intervention is being studied to evaluate whether the addition of dexamethasone improves tolerability and clinical outcomes in patients unfit for intensive chemotherapy.
219582457|NCT00324766|DRUG|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
219582458|NCT00324766|DRUG|placebo,|24 h, infusion
219582459|NCT00070057|DRUG|celecoxib|Given orally
219582460|NCT00070057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219582461|NCT00070057|OTHER|pharmacological study|Correlative studies
219582462|NCT00070057|OTHER|laboratory biomarker analysis|Correlative studies
219582463|NCT03709823|DRUG|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
219582464|NCT03709823|DRUG|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
219582465|NCT03709823|BEHAVIORAL|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
219764511|NCT06685835|DRUG|Brensocatib|Film-coated Oral tablet
218835125|NCT03980743|BEHAVIORAL|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
218835126|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
218835127|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
218835128|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
218835129|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
218835130|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
219582466|NCT05998941|DRUG|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
219582467|NCT05998941|DRUG|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
219764512|NCT06685835|DRUG|Placebo|Film-coated Oral tablet
219764513|NCT06619860|DRUG|VX-993|Tablets for oral administration.
219582468|NCT05998941|DRUG|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
219582469|NCT05998941|DRUG|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
219582470|NCT05998941|DRUG|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
219582471|NCT02716935|DIETARY_SUPPLEMENT|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
219582472|NCT02716935|DIETARY_SUPPLEMENT|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
219582473|NCT02960919|DRUG|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
219582474|NCT02960919|DRUG|parenteral ampicillin/ penicillin|
219582475|NCT02960919|DRUG|gentamicin|
219582476|NCT00094003|DRUG|NS-9 [Poly I: Poly C]|
219582477|NCT00334100|BEHAVIORAL|Exercise|Treadmill exercise
219582478|NCT06410170|DEVICE|MIRA Device|At home diagnostic testing
219582479|NCT03201250|DRUG|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
219582480|NCT01439750|DRUG|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
219582481|NCT01439750|DRUG|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
219582482|NCT01439750|DRUG|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
219764514|NCT06619860|DRUG|Pregabalin|Capsules for oral administration.
219764515|NCT06619860|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
219764516|NCT06619860|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
219764517|NCT06623422|BIOLOGICAL|Pembrolizumab|IV Infusion
219582483|NCT04859621|DRUG|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
219582484|NCT04859621|DRUG|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
219582485|NCT04859621|DRUG|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
219582486|NCT04859621|OTHER|standard antibiotic therapy|standard antibiotic therapy
219582487|NCT06157203|DEVICE|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
219764518|NCT06623422|DRUG|Cisplatin|IV infusion
219764519|NCT06623422|DRUG|Carboplatin|IV infusion
219764520|NCT06623422|DRUG|Pemetrexed|IV infusion
219764521|NCT06623422|DRUG|Gemcitabine|IV infusion
219764522|NCT06623422|DRUG|Paclitaxel|IV infusion
219764523|NCT06623422|BIOLOGICAL|Intismeran autogene|IM injection
219764524|NCT06623422|OTHER|Placebo|IM injection
219764525|NCT07012057|DRUG|Deucravacitinb|Participants will receive a 6mg pill taken 2 times per day over 24 weeks and an optional extension period
219764526|NCT07011771|DRUG|gene therapy|IV gene therapy
219764527|NCT07011771|DRUG|gene therapy|IV gene therapy
219764528|NCT06874491|BEHAVIORAL|Moving and 3D Book|After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a moving and 3D book that will be specially designed for inhalation treatment. After the treatment is completed, the child's reactions will be evaluated and the scales will be filled out again. Filling out the forms will take an average of 5-10 minutes.
219764529|NCT06874491|BEHAVIORAL|Hand Puppet|After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a hand puppet that will be specially designed for inhalation treatment by the researcher. After the treatment is completed.
219764530|NCT07015957|BEHAVIORAL|In-person training|An in-person educational session.
219764531|NCT07015957|BEHAVIORAL|Virtual training|A virtual educational session.
219764532|NCT07015957|BEHAVIORAL|Coaching|Short video vignettes plus reinforcing messages
219764533|NCT07015957|BEHAVIORAL|Prompts|Visual aide to remind providers to discuss cervical cancer prevention methods.
219764534|NCT06626438|OTHER|Treatable traits model of care|Embedded multidisciplinary clinic with treatable traits model of care.
219016029|NCT03500445|DRUG|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1"
219016030|NCT03500445|DRUG|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
219016031|NCT03500445|DRUG|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
219016032|NCT03500445|DRUG|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
219582488|NCT01175811|DRUG|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
219582489|NCT01175811|DRUG|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
219582490|NCT01175811|DRUG|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
219582491|NCT03579966|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
219582492|NCT01340768|DRUG|Sitagliptin|One 100 mg tablet taken orally once daily
219582493|NCT01340768|DRUG|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
219764535|NCT07011706|DRUG|ATI-045|ATI-045 group
219764536|NCT07011706|DRUG|Placebo|Placebo group
219764537|NCT07017673|DRUG|Ivonescimab|Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
219764538|NCT07017673|DRUG|Carboplatin|Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
219764539|NCT07017673|DRUG|Docetaxel|Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
219764540|NCT05183646|DRUG|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
219764541|NCT05183646|DRUG|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
219764542|NCT03704389|BEHAVIORAL|Clinical decision support|Clinical decision support nudges within the electronic health record
219442316|NCT01726504|DEVICE|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
219582494|NCT01340768|DRUG|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
218835131|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
218835132|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
218835133|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
218835134|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
218835135|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
218835136|NCT00463138|BEHAVIORAL|Crisis intervention|
218835137|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
218835138|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
218835139|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
218835140|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
218835141|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
218835142|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
218835143|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
218835144|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
219582495|NCT03052959|BEHAVIORAL|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
219016046|NCT06320366|DEVICE|Sham TMS|The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.
219016047|NCT06320366|DEVICE|Active TMS|The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.
219582496|NCT03052959|OTHER|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
218835145|NCT03005561|BEHAVIORAL|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
218835146|NCT03107052|DRUG|Fremanezumab|Fremanezumab
218835147|NCT00321243|BEHAVIORAL|Visual clues|
219016058|NCT06262113|OTHER|Letters about NF1 Care (Content Type 1)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
219016059|NCT06262113|OTHER|Letters about NF1 Care (Content Type 2)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
219016063|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
219196221|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
219196222|NCT00517153|DRUG|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
219196223|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
219582497|NCT01166906|DEVICE|pain blocking|pain blocking
218835148|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
219582498|NCT04183075|DIETARY_SUPPLEMENT|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
219582499|NCT04183075|DIETARY_SUPPLEMENT|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
219582500|NCT03886987|DEVICE|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
218835149|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
218835150|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
218835151|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
219442317|NCT01726504|DEVICE|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
219016064|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
219016065|NCT06380517|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
219016066|NCT06380517|OTHER|Eye Patch|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
219764543|NCT07020741|PROCEDURE|Indispensable Amino Acid Oxidation|Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.
219196224|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
219764544|NCT07020741|PROCEDURE|Stable Isotope Oral Glucose Tolerance Test|Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.
219764545|NCT04266795|DRUG|Pevonedistat|Pevonedistat IV infusion.
219196225|NCT06309784|PROCEDURE|Drill Guidance System (DGS)|During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
219442318|NCT03054025|DEVICE|Smart Phone Monitoring Device|Use activity tracker application
219442319|NCT04078269|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
219442320|NCT04078269|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
219442321|NCT04078269|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
219442322|NCT00149110|PROCEDURE|Sleep deprivation|3 days with a normal night between
219442323|NCT00149110|PROCEDURE|Light therapy|Daily light therapy for 29 weeks
219442324|NCT00149110|PROCEDURE|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
219442325|NCT00149110|BEHAVIORAL|Exercise|Moderate intensity daily exercise for 30 minutes at least
219442326|NCT00149110|DRUG|duloxetine|60 mg daily
219764546|NCT04266795|DRUG|Venetoclax|Venetoclax tablets.
219442327|NCT00149110|DRUG|duloxetine|60 mg daily
219442328|NCT00432263|DRUG|Genotropin (PN-180,307) Somatropin|
219442329|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
219442330|NCT03249701|DEVICE|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
219442331|NCT03249701|DEVICE|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
219442332|NCT03249701|DEVICE|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
219764547|NCT04266795|DRUG|Azacitidine|Azacitidine IV or SC injection.
219442333|NCT04264494|PROCEDURE|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
219764548|NCT07015242|DRUG|Rituximab|Specified dose on specified days
219764549|NCT07015242|DRUG|Methotrexate|Specified dose on specified days
219764550|NCT07015242|DRUG|Procarbazine|Specified dose on specified days
219764551|NCT07015242|DRUG|Temozolomide|Specified dose on specified days
219764552|NCT07015242|BIOLOGICAL|Liso-cel|Specified dose on specified days
219764553|NCT07015242|DRUG|Fludarabine|Specified dose on specified days
219764554|NCT07015242|DRUG|Cyclophosphamide|Specified dose on specified days
219764555|NCT07015242|DRUG|Calcium folinate|Specified dose on specified days
219764556|NCT07018102|OTHER|Trunk Control Care Program|"1. The intervention group underwent a 4-week bedside trunk control care module intervention based on routine care in a rehabilitation ward.~2. trunk control care module: combine the care strategies of arm training, butterfly technique, shoulder control, diaphragmatic breathing and body awareness, practice twice a day, each time for 20-30 minutes, and can be adjusted according to the patient's condition."
219764557|NCT02940613|BEHAVIORAL|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
219764558|NCT05338944|BEHAVIORAL|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
219764559|NCT05338944|BEHAVIORAL|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
219764560|NCT05990166|OTHER|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
219764561|NCT05990166|OTHER|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
219764562|NCT06868914|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|"TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.~Each subject will receive 3 active TBS (3-,4-, and 5-pulse TBS) and 1 sham TBS on 4 visits separated by at least 48 hours."
219764563|NCT06626633|DRUG|CRD3874|CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
219764564|NCT06693674|DRUG|Entresto Pill|Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
219764565|NCT06693674|OTHER|Placebo|Patients taking placebo tablets will take 1 tablet orally, twice daily
219764566|NCT05120349|DRUG|Osimertinib|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
219764567|NCT05120349|DRUG|Placebo|Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
219442334|NCT04264494|PROCEDURE|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
219442335|NCT01440504|OTHER|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
219442336|NCT02276794|OTHER|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
219764568|NCT01475786|BIOLOGICAL|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
219764569|NCT01475786|BIOLOGICAL|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
219764570|NCT01475786|OTHER|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
219764571|NCT06685068|DRUG|GEN1286|Specified dose on specified days
219016077|NCT03694171|OTHER|Any cancer treatment|
219442337|NCT02276794|OTHER|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
219442338|NCT00883649|DIETARY_SUPPLEMENT|Hydroeye|2 Capsules BID
219442339|NCT00883649|OTHER|Inactive Capsule|2 Capsules BID
219442340|NCT02277236|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
219442341|NCT02277236|RADIATION|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
219442342|NCT00878813|PROCEDURE|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
219442343|NCT00878813|PROCEDURE|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
219442344|NCT00863317|DRUG|montelukast sodium|4mg granules daily for 14 days
219442345|NCT00863317|OTHER|sucrose|table sugar as placebo daily for 14 days
219442346|NCT02253394|DRUG|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
219442347|NCT02253394|DRUG|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
219442348|NCT02485067|DRUG|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
219442349|NCT02485067|DRUG|Placebo(For THVD-201)|
219442350|NCT02485067|DRUG|Detrusitol 2mg tablet|Tolterodine 2mg
219442351|NCT02485067|DRUG|Placebo(For Detrusitol 2mg tablet)|
219442352|NCT05363618|DIETARY_SUPPLEMENT|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
219442353|NCT05363618|OTHER|Placebo 1.4 ml|Placebo
219442354|NCT01737138|PROCEDURE|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
219442355|NCT01737138|DRUG|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
219442356|NCT00038142|DRUG|Vincristine|2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
219442357|NCT00038142|DRUG|Doxorubicin|90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
219442358|NCT00038142|DRUG|Cyclophosphamide|2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
219442359|NCT00038142|DRUG|Dexrazoxane|900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
219442360|NCT00038142|BIOLOGICAL|ImmTher|900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
219442361|NCT06407336|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
219442362|NCT06407336|OTHER|Refraction|Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
219442363|NCT03531762|DRUG|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
219442364|NCT03531762|DRUG|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
219442365|NCT05345704|OTHER|cardiopulmonary resuscitation (CPR)|Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
219442366|NCT01486940|DRUG|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
219442367|NCT01486940|DRUG|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
219442368|NCT01486940|DRUG|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
219442369|NCT01486940|DRUG|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
219442370|NCT03128255|OTHER|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
219442371|NCT01231672|BIOLOGICAL|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
219442372|NCT05759104|DRUG|Infliximab|Drug
219442373|NCT05759104|PROCEDURE|Stomy|Surgery
219442374|NCT00809614|BIOLOGICAL|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
219442375|NCT00809614|BIOLOGICAL|Placebo|Matching placebo to AIN457
219442376|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
219442377|NCT00779818|DEVICE|Laser|Treatment by laser
219442378|NCT04514406|DEVICE|APERTO OTW DCB|Drug Coated Balloon Angioplasty
219442379|NCT03185325|OTHER|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
219442380|NCT03185325|OTHER|venous blood samples|venous blood samples are collected in healthy voulnteers
219442381|NCT03482336|OTHER|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
219016083|NCT06785675|OTHER|Secukinumab|This is an observational study. There is no treatment allocation.
219442382|NCT01080625|DRUG|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
218835152|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
218835153|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
218835154|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
219016086|NCT05296265|BEHAVIORAL|VR treatment for phantom limb pain|8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention
219196226|NCT06819618|OTHER|Monitoring with Apple Watch|Patients will receive Apple Watch for Monitoring of Biosignals throughout the hospital stay
219442383|NCT01080625|DRUG|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
219442384|NCT01080625|DRUG|placebo control|10ml of normal saline is administered at the time of reperfusion
219442385|NCT03563586|OTHER|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
219442386|NCT03563586|OTHER|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
219442387|NCT00740428|PROCEDURE|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
219442388|NCT05499689|DRUG|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
219442389|NCT05499689|OTHER|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
219442390|NCT04324268|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
219442391|NCT04324268|OTHER|Placebo|Placebo
219442392|NCT04225312|DRUG|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
219442393|NCT04225312|DRUG|Standard interval dosing|Standard interval dosing in control group and historic group
219582501|NCT05016193|DEVICE|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
219582502|NCT05016193|BEHAVIORAL|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
219764572|NCT06628401|BEHAVIORAL|Educational information (Control)|Information packs will be developed for participants outlining the importance of a control group in research studies to maximise compliance. Participants will receive a £10 gift voucher weekly that they can spend at selected retailers of their choosing.
219196227|NCT06817785|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
219442394|NCT01092364|BEHAVIORAL|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
219442395|NCT02412527|OTHER|Patch III heart rate sensor|
219442396|NCT03946644|DEVICE|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
219442397|NCT03946644|DEVICE|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
219442398|NCT03696849|OTHER|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
219442399|NCT00364832|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
219442400|NCT04024735|DIAGNOSTIC_TEST|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
219442401|NCT03885076|PROCEDURE|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
219442402|NCT05601765|OTHER|Standard communication pathways after discharge|Standard communication pathways after discharge
219442403|NCT05601765|OTHER|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
219442404|NCT02148601|OTHER|Fecal Microbiota Transplantation|
219442405|NCT02148601|DRUG|Standard Antibiotic Therapy|
219442406|NCT02148601|DRUG|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
219582503|NCT02431182|BEHAVIORAL|Memory Training Workshop|"1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop"
218835155|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
218835156|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
218835157|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
218835158|NCT00234663|DRUG|PTC124|
219442407|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
219442408|NCT05032287|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily
219442409|NCT05032287|DRUG|Placebo|Placebo once daily
219442410|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
219442411|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1\. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
219442412|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2\. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
219442413|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3\. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
219582504|NCT01874067|DEVICE|Arthritis glove|Isotoner three-quarter finger arthritis glove
219582505|NCT03205891|DRUG|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
219582506|NCT03205891|DRUG|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
219764573|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, excluding fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
218835159|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
218835160|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
219196228|NCT06817785|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
219442414|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
219442415|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
219442416|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
219442417|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
219442418|NCT05010395|BEHAVIORAL|Letter intervention|Letter intervention
219442419|NCT00954473|OTHER|laboratory biomarker analysis|Correlative studies
219442420|NCT02766049|BIOLOGICAL|DC|Autologous dendritic cells (3x10e7)
219442421|NCT02766049|BIOLOGICAL|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
219442422|NCT02766049|BIOLOGICAL|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
219442423|NCT00068822|DEVICE|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
219442424|NCT00068822|PROCEDURE|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
219442425|NCT04944758|DEVICE|Light therapy|Light therapy
219442426|NCT03881644|DRUG|Imigran|All patients will undergo this intervention on one of two study days
219442427|NCT03881644|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
219442428|NCT03881644|OTHER|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
219442429|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|DBS Active Treatment Group - implanted with investigational device and activated for stimulation
219442430|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
219582507|NCT03205891|DEVICE|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
219582508|NCT04351048|PROCEDURE|Stepwise Excavation|"* stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
219582509|NCT04351048|PROCEDURE|One Step Excavation|\*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
219582510|NCT01476592|DIETARY_SUPPLEMENT|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
219582511|NCT03669939|OTHER|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
219582512|NCT03669939|OTHER|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
219582513|NCT02743234|OTHER|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
219582514|NCT02743234|DRUG|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
219582515|NCT02743234|DRUG|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
219582516|NCT03956810|OTHER|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
219582517|NCT03956810|OTHER|Usual transportation|Usual transportation scheduling via call-center.
219582518|NCT03967535|DEVICE|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
219582519|NCT03967535|BEHAVIORAL|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
219582520|NCT05298319|DEVICE|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
219582521|NCT02903719|DRUG|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
219764574|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake + Juice)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, including fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
218835161|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
218835162|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
218835163|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
218835164|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
218835165|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
218835166|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
219442431|NCT00489502|BEHAVIORAL|Brief Counseling|
219442432|NCT00489502|DEVICE|REE Assessment|
219582522|NCT02430779|PROCEDURE|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
219582523|NCT02430779|DEVICE|NanoKnife|
219764575|NCT06629584|DRUG|Asciminib|Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
219442433|NCT02837055|DEVICE|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
219442434|NCT02837055|DEVICE|conventional intubation|patients are intubated with a conventional endotracheal tube
219442435|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
219582524|NCT03895671|DRUG|Ponatinib|"Induction phase (first three cycles)~\- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
219442436|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
219442437|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
219442438|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
219442439|NCT01960179|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
219442440|NCT03227094|DIAGNOSTIC_TEST|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage
219442441|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
219442442|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
219442443|NCT03638362|DIETARY_SUPPLEMENT|Placebo|Participants consumed placebo beverage for 4 weeks.
219442444|NCT03638362|DIETARY_SUPPLEMENT|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
219442445|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
219442446|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
219442447|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
219442448|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
219442449|NCT03312361|DRUG|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
219442450|NCT02837809|RADIATION|Low dose CT|annual CT vs biennial CT
219442451|NCT00748865|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
219442452|NCT00748865|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
219442453|NCT05588713|PROCEDURE|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
219442454|NCT05588713|PROCEDURE|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
219442455|NCT00987727|DRUG|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
219442456|NCT00987727|DRUG|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
219442457|NCT03938025|PROCEDURE|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
219442458|NCT06149741|PROCEDURE|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
219442459|NCT05939076|DEVICE|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
219442460|NCT05939076|DRUG|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
219442461|NCT00591162|DRUG|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
219764576|NCT06688916|BEHAVIORAL|Behavioral assessment|A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.
219442462|NCT00591162|RADIATION|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
219442463|NCT00591162|PROCEDURE|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
219442464|NCT03885609|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
219442465|NCT03885609|DEVICE|powered toothbrush|regular powered toothbrush with no RF
219442466|NCT00608803|DRUG|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
219442467|NCT00786461|PROCEDURE|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
219442468|NCT00786461|PROCEDURE|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
218835167|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
218835168|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
218835169|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
218835170|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
218835171|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
219442469|NCT04366739|DRUG|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
218835172|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
218835173|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
218835174|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
218835175|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
218835176|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
218835177|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
219196229|NCT06818864|DEVICE|Deep Brain Stimulation|Patients will arrive on the morning of surgery to the medical imaging department of the Sunnybrook Hospital. They will have a stereotactic frame attached directly to their skull, after infiltration with local anesthesia. The frame allows precise coordinates to be acquired so that deep brain structures can be targeted with implanted electrodes. The patient will then undergo a CT scan with the frame in place, followed by transport directly to the operating room. The anesthesia team will insert an intravenous line and may use gentle sedation to relax the patient prior to and during the operation, as they will remain awake during the first stage of the operation. In the operating room the patient's head, via the frame, will be attached to the operating room table, and their scalp infiltrated with additional local anesthetic. A skin incision will be made and two burr holeswith approximately 1.4cm in diameter drilled through the skull. A small electrode will identify the optimal spot for ele
219196230|NCT06820398|OTHER|Functional exercise with progressive strength and resistance load|This group will perform functional exercises with progressive strength and resistance load, adjusted based on heart rate.
219196231|NCT06820398|OTHER|Functional exercises without any load|This group will perform functional exercises, without strength or resistance load
219442470|NCT04366739|COMBINATION_PRODUCT|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
219442471|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
219442472|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
219442473|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
219442474|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
219442475|NCT04564690|DIETARY_SUPPLEMENT|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
219442476|NCT04564690|DIETARY_SUPPLEMENT|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
219442477|NCT05379764|OTHER|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
219442478|NCT05379764|OTHER|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
219442479|NCT00914095|DRUG|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
219442480|NCT00914095|DRUG|placebo|tablets of placebo 3 times a day
219442481|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
219764577|NCT06688916|BEHAVIORAL|Functional Magnetic Resonance Imaging (fMRI)|"Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment."
219764578|NCT06872892|DRUG|BI 1291583|BI 1291583
219764579|NCT06872892|DRUG|Placebo matching BI 1291583|Placebo matching BI 1291583
219764580|NCT07023627|DRUG|INCB123667|Administered orally twice daily (BID).
219764581|NCT05484635|PROCEDURE|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
219764582|NCT05484635|PROCEDURE|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
219764583|NCT07024316|DRUG|ATL-001 (Ciclopirox oral solution)|Daily administration of oral ATL-001
219582525|NCT03895671|DRUG|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~\- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;"
219582526|NCT02789553|OTHER|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
219582527|NCT02789553|OTHER|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
219764584|NCT07025447|BEHAVIORAL|Familia Bora|"Familia Bora is a couples-based group parenting program that takes place in a preferred location within the community among participants. Twelve couples will be enrolled in each village and form one parenting group. CHWs will be trained to deliver the intervention.~The program will involve 17 group sessions. Each session is expected to last 1.5 hours and will be delivered weekly for approximately 5 months. Each session will focus on various topics, including responsive caregiving, positive discipline, managing emotions and stress management, child nutrition, couples' communication, non-violent conflict resolution strategies in relationships, gender equity, and early child care and education. In addition to the weekly group parenting sessions, CHWs will be encouraged to conduct home visits to engage couples who miss sessions, reinforce key messages, and provide extra support for caregivers and children as needed."
219764585|NCT06697353|DRUG|vericiguat (BAY 1021189)|2.5 mg initiating dose
219764586|NCT07026448|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
219764587|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
219764588|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
218835178|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
218835179|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
218835180|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
218835181|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
218835182|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
219582528|NCT05492253|OTHER|Infant fruit|Infants will be fed prune puree
219582529|NCT05492253|OTHER|Infant vegetable|Infants will be fed carrot puree
219764589|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 3|Participants will use their Energy Active Product 3 as directed for a period of 6 weeks.
219764590|NCT07024823|DRUG|AZD4248|AZD4248 will be administered orally.
219764591|NCT07024823|DRUG|Placebo|Placebo will be administered orally.
219764592|NCT07024823|DRUG|AZD4248|AZD4248 will be administered via IV infusion.
219764593|NCT07024823|DRUG|Placebo|Placebo will be administered via IV infusion.
219582530|NCT05492253|OTHER|Infant meat|Infants will be fed beef puree
219764594|NCT06632327|PROCEDURE|Surgical Procedure|undergo surgery
219764595|NCT06632327|DRUG|Cisplatin|Give cisplatin
219764596|NCT06632327|DRUG|Carboplatin|Give Carboplatin
219764597|NCT06632327|DRUG|Pemetrexed|Give Pemetrexed
219764598|NCT06632327|DRUG|Gemcitabine|Give Gemcitabine
219764599|NCT06632327|DRUG|Docetaxel|Give Docetaxel
219764600|NCT06632327|DRUG|Vinorelbine|Give Vinorelbine
219764601|NCT06632327|DRUG|Nivolumab|Give Nivolumab
219764602|NCT06632327|DRUG|Pembrolizumab|Give Pembrolizumab
219764603|NCT06632327|DRUG|Atezolizumab|Give Atezolizumab
219582531|NCT05492253|OTHER|Infant grain|Infants will be fed oatmeal cereal
218835183|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
218835184|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
219016092|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
219582532|NCT03850951|DEVICE|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
219582533|NCT03850951|DEVICE|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
219582534|NCT05497193|DRUG|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
219582535|NCT00140426|DRUG|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
219582536|NCT00140426|DRUG|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
219016093|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
219016094|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
219196232|NCT06815796|PROCEDURE|Arthroscopic Loop tenodesis of long head of biceps.|Loop tenodesis of the long head of biceps tendon.
219442482|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
219442483|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
219442484|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
219442485|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
219442486|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
219582537|NCT04603235|BEHAVIORAL|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
218835185|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
218835186|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
218835187|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
219196233|NCT06815796|PROCEDURE|Anchor Tenodesis of Long head of biceps tendon|Anchor Tenodesis of Long head of biceps tendon
219442487|NCT04741204|DRUG|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
219582538|NCT02651779|PROCEDURE|Open reduction and internal plate fixation|
219582539|NCT02651779|OTHER|Closed reduction and plasterimmobilisation|
219582540|NCT02149108|DRUG|Nintedanib (BIBF 1120)|
219582541|NCT02149108|DRUG|Placebo|
219582542|NCT02149108|DRUG|BSC|
219582543|NCT02149108|DRUG|BSC|
219582544|NCT04419792|OTHER|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
219582545|NCT00950963|BEHAVIORAL|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
219582546|NCT00950963|OTHER|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
219582547|NCT02175316|DEVICE|Enhanced External Counterpulsation|Enhanced External Counterpulsation
219764604|NCT06632327|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219764605|NCT06632327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764606|NCT06632327|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219764607|NCT06632977|OTHER|Genetic testing|undergo genetic testing
219764608|NCT06632977|DRUG|Valemetostat Tosylate|Given PO
219764609|NCT06632977|PROCEDURE|Magnetic Resonance Imaging|undergo Magnetic Resonance Imaging
219764610|NCT06632977|PROCEDURE|Computed Tomography|undergo Computed Tomography
219764611|NCT06632977|PROCEDURE|Bone scan|undergo Bone scan
219764612|NCT06632977|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
219764613|NCT06632977|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
219764614|NCT06632977|PROCEDURE|Biospecimen Collection|undergo blood collection
219582548|NCT02447796|DRUG|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
219582549|NCT02447796|DRUG|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
219582550|NCT04047914|DEVICE|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
219582551|NCT04047914|DRUG|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
219582552|NCT03716414|PROCEDURE|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
218835188|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
218835189|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
218835190|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
218835191|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
219442488|NCT04904640|DEVICE|Hip stem|In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
219442489|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
219764615|NCT06632977|DRUG|Carboplatin|Given IV
219442490|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
219442491|NCT05904938|DEVICE|Lenodiar Pediatric|Medical Device made of natural substance
219442492|NCT05904938|OTHER|Placebo|Product appearance similar to verum without clinical efficacy
219442493|NCT03687476|DRUG|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
219442494|NCT04569760|DRUG|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
219442495|NCT04569760|DRUG|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
219764616|NCT06632977|DRUG|Cabazitaxel|Given IV
219764617|NCT06632977|DRUG|Abiraterone Acetate|Given PO
219764618|NCT06632977|DRUG|Enzalutamide|Given PO
219016113|NCT03471260|DRUG|Azacitidine|Given IV or SC
219016114|NCT03471260|DRUG|Ivosidenib|Given PO
219442496|NCT05844774|DEVICE|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
219442497|NCT05844774|DEVICE|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
219442498|NCT06250504|DRUG|APRETUDE (cabotegravir) 600 mg\3 mL|choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
219764619|NCT06632977|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
219764620|NCT05668013|DRUG|TEV-48574 Dose Regimen A|Subcutaneous (sc) administration using a commercial sc infusion system
219764621|NCT05668013|DRUG|TEV-48574 Dose Regiment B|Subcutaneous (sc) administration using a commercial sc infusion system
219016115|NCT03471260|DRUG|Venetoclax|Given PO
219582553|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219582554|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219442499|NCT06250504|DRUG|DAPIRING (Dapivirine) 25mg Vaginal Ring|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
219442500|NCT06250504|DRUG|tenofovir disoproxil and emtricitabine|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
219582555|NCT02775708|DEVICE|Pillcam endoscopy system|
219582556|NCT00627315|PROCEDURE|Gastric bypass|NOTE: Surgery will not be paid by the study
218835192|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
218835193|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
218835194|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
218835195|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
218835196|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
218835197|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
218835198|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
218835199|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
218835200|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
218835201|NCT03391830|DRUG|Placebo|Placebo
219582557|NCT00627315|PROCEDURE|Gastric banding|NOTE: Surgery will not be paid by the study
219582558|NCT02895607|PROCEDURE|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
218835202|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
218835203|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
218835204|NCT00146926|DRUG|kétamine 20mg|
218835205|NCT00146926|DRUG|ephedrine 3mg|
218835206|NCT00146926|DRUG|lidocaine 40mg|
218835207|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
218835208|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
218835209|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
219196234|NCT06816745|PROCEDURE|Modified high flow tracheal oxygen|Modified high-flow tracheal oxygen with flow rates of 40L/min and 60L/min will be performed.
219442501|NCT06250504|DRUG|Tenofovir Disoproxil, Lamuvidine and Dolutegravir|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
219196235|NCT06816745|PROCEDURE|Standard high flow tracheal oxygen|Standard high-flow tracheal oxygen with flow rates of 40 L/min and 60 L/min will be performed.
219442502|NCT03745404|DRUG|Lidocaine 5% medicated Plaster|
219442503|NCT03745404|DRUG|Placebo Plaster|
219442504|NCT03163940|BEHAVIORAL|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
219764622|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
219582559|NCT01776697|DRUG|pelubiprofen (30mg) tablet IR|
219582560|NCT01776697|DRUG|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
219764623|NCT07028125|DRUG|cabozantinib and nivolumab|"cabozantinib and nivolumab according to the labelling indication, namely:~* CABOZANTINIB 40 mg per oral route once daily~* NIVOLUMAB 240 mg per intravenous route every 2 weeks~During this combined treatment, the digital monitoring system is used to collect weekly data on treatment tolerance by patient self-report."
219764624|NCT07029568|DRUG|NNC0705-0001|NNC0705-0001 will be administered orally.
218835210|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
218835211|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
218835212|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
219442505|NCT05179057|DRUG|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
219442506|NCT05179057|DRUG|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
219442507|NCT03749668|OTHER|non applicable|no intervention in this observational study
219442508|NCT02374359|OTHER|follow-up|
219442509|NCT01897259|DRUG|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
219442510|NCT01897259|BEHAVIORAL|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
219442511|NCT01897259|DRUG|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
219442512|NCT01897259|DRUG|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
219442513|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
219582561|NCT03508505|DEVICE|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
219764625|NCT07029568|DRUG|Placebo|Placebo matching NNC0705-0001 will be administered orally.
219764626|NCT07029737|DRUG|Acalabrutinib + R-CHOP standard of care|Acalabrutinib will be administered 100 mg twice per day (BID) orally (PO) until disease progression if medically appropriate, along with R-CHOP standard of care up to six 21-day cycles of the induction phase.
219582562|NCT02941757|BEHAVIORAL|Mediterranean diet Intervention|"1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention."
219582563|NCT02161822|DRUG|simvastatin|simvastatin 80mg qd for 5weeks
219582564|NCT02435095|DRUG|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
219764627|NCT07029737|DRUG|Acalabrutinib combination with Rituximab|If the subject achieves response during the induction phase, acalabrutinib will be administered 100 mg BID PO until disease progression and rituximab 375 mg/m2 on Day 1 of every other 28-day cycle for a maximum of 12 additional doses.
219764628|NCT07029737|DRUG|Acalabrutinib monotherapy|If the subject does not achive response during the induction phase, monotherapy acalabrutinib will be administered 100 mg BID PO until disease progression.
219764629|NCT07028749|DRUG|MAR001|Subcutaneous Injection
219764630|NCT07028749|DRUG|Placebo|Subcutaneous injection
219764631|NCT07028853|DRUG|Mevrometostat|Oral continuous
218835213|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
218835214|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
218835215|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
218835216|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
218835217|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
218835218|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
218835219|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
218835220|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
218835221|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
218835222|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
218835223|NCT00001106|DRUG|Zidovudine|
218835224|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
219016127|NCT05606809|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
219764632|NCT07028853|DRUG|Placebo|Oral continuous
219764633|NCT07028853|DRUG|Enzalutamide|Oral continuous
219764634|NCT06693531|DRUG|dupilumab|No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
219764635|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
219764636|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
219764637|NCT07027839|DRUG|Intravenous Ethanol|Intravenous ethanol infusion before PET Scan
219764638|NCT07027839|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
219764639|NCT07029282|DIETARY_SUPPLEMENT|MMS|Pregnant women in this arm will receive 6gms of MMS (UNIMAPP MMS) in a ready to use sachet form which includes 15 nutrients.
219764640|NCT07029282|DRUG|MMS Plus|Pregnant women in this arm will receive 6gms of MMS Plus in a ready to use sachet form which includes 18 nutrients.
219764641|NCT07029282|DIETARY_SUPPLEMENT|IFA|Pregnant women in this arm will receive 6gms of IFA (Iron/Folic Acid) in a ready to use sachet form which includes 2 nutrients.
219764642|NCT06185205|DRUG|Accelerated partial breast irradiation|High Dose Rate treatment delivery
219582565|NCT02435095|DRUG|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
219582566|NCT02728570|OTHER|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
219582567|NCT02728570|OTHER|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
219582568|NCT00848107|DRUG|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
219582569|NCT05965115|DIAGNOSTIC_TEST|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
219582570|NCT00237783|DRUG|dialysate sodium (140 mmol/L)|
219764643|NCT07025811|DRUG|Vevye®|Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.
219764644|NCT07025811|DRUG|Xiidra®|Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.
219764645|NCT06868368|OTHER|Biospecimen Collection|Undergo blood sample collection
218835225|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
218835226|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
218835227|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
218835228|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
218835229|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
218835230|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
218835231|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
218835232|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
218835233|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
218835234|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
219582571|NCT00237783|DRUG|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
219582572|NCT02335983|DRUG|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
219582573|NCT02335983|DRUG|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
219582574|NCT02335983|DRUG|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
219582575|NCT01041183|DRUG|intravenous ramosetron|0.3 mg IV ramosetron (group I)
219582576|NCT01041183|DRUG|oral ramosetron|0.1 mg oral ramosetron (group II)
219582577|NCT01041183|DRUG|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
218835235|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
218835236|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
218835237|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
218835238|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
218835239|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
219016132|NCT06284473|DRUG|Ketamine|Ketamine is an N-methyl-D aspartate receptor agonist
219016133|NCT06284473|OTHER|Saline|Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
219582578|NCT05134753|BIOLOGICAL|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
219582579|NCT05134753|BIOLOGICAL|Control|PRF will be placed for patients undergoing sinus augmentation
219764646|NCT06868368|OTHER|Survey Administration|Complete Surveys
219764647|NCT06868368|BEHAVIORAL|Vaping Topography|Use e-cigarette connected to a topography device
219764648|NCT06868368|OTHER|Participant's Own Preferred E-cigarette|Participant vapes their own preferred e-cigarette for 30 minutes
219764649|NCT06868368|OTHER|Nicotine E-cigarette|Participant vapes a commercially available nicotine e-cigarette for 30 minutes
219764650|NCT06868368|OTHER|6-methyl-nicotine (metatine) e-cigarette|Participant vapes a commercially available metatine e-cigarette for 30 minutes
219442514|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
219442515|NCT02611934|PROCEDURE|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
219582580|NCT01819974|OTHER|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
219582581|NCT00987389|PROCEDURE|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
219442516|NCT01345825|OTHER|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
219442517|NCT01085162|DRUG|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
219582582|NCT00987389|OTHER|No Plasma Exchange|No plasma exchange.
219582583|NCT00987389|DRUG|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
219582584|NCT00987389|DRUG|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
219582585|NCT02437240|BEHAVIORAL|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
219764651|NCT07027826|DEVICE|Esophageal string test|The esophageal string test consists of a gelatin or cellulose capsule containing a nylon string. The capsule dissolves allowing the nylon string to absorb esophageal secretions which can be analyzed for various inflammatory mediators.
219442518|NCT01653756|DRUG|IPI-145, a PI3K Inhibitor|Active drug
219442519|NCT01653756|DRUG|Placebo to match IPI-145|Comparator
219442520|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
219442521|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
219582586|NCT02437240|BEHAVIORAL|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
219582587|NCT02195089|DRUG|BLS_ILS_E710c 500mg|\- 2 capsules per day for 20 days (week 1,2,4 \& 8)
219582588|NCT02195089|DRUG|BLS_ILB_710c 1000mg|\- 4 capsules per day for 20 days (week 1,2,4 \& 8)
219582589|NCT02195089|DRUG|BLS_ILS_E710c 1500mg|\- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
219582590|NCT04048044|DEVICE|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
219582591|NCT06436040|OTHER|Pathological response assessment|The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
219582592|NCT02928367|OTHER|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
219582593|NCT02928367|OTHER|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
219764652|NCT07031817|DIAGNOSTIC_TEST|Venous blood sample for measuring blood biomarkers related to bipolar disorder|Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.
219442522|NCT05574712|DRUG|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
219442523|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
219442524|NCT01863706|DRUG|Misoprostol|400µg oral misoprostol
219442525|NCT01863706|DRUG|Oxytocin|20 IU Oxytocin
219442526|NCT00645515|DRUG|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
219442527|NCT00645515|DRUG|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
219442528|NCT03577522|DEVICE|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
219442529|NCT03577522|DEVICE|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
219442530|NCT00003304|DRUG|temozolomide|
219582594|NCT02928367|OTHER|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
219582595|NCT00655876|DRUG|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
219582596|NCT00655876|DRUG|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
219582597|NCT00655876|DRUG|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
219582598|NCT00655876|RADIATION|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
219582599|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
218835240|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
219442531|NCT06248944|OTHER|observational-retrospective and prospective|observational-retrospective and prospective
219442532|NCT00060151|DRUG|pazopanib hydrochloride|
219442533|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
219442534|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
219442535|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
219442536|NCT01886404|DRUG|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
219442537|NCT04955509|OTHER|MRI|conventional MRI and diffusion MRI
219442538|NCT02329145|PROCEDURE|renal denervation|
219442539|NCT01581905|PROCEDURE|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
219442540|NCT01581905|PROCEDURE|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
219442541|NCT00978133|PROCEDURE|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
219582600|NCT01831765|DRUG|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
219582601|NCT01831765|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
219582602|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
219582603|NCT00767169|DEVICE|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
219582604|NCT00326963|DRUG|Background ARVs|As prescribed
219442542|NCT00978133|PROCEDURE|Skin closure with skin staples|Skin closure with skin staples
219582605|NCT00326963|DRUG|PI|As prescribed
219582606|NCT00326963|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
219582607|NCT04514068|PROCEDURE|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
219582608|NCT04514068|PROCEDURE|Sham acupuncture|Sham acupuncture
219442543|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
219442544|NCT03146403|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
219582609|NCT04877886|DIAGNOSTIC_TEST|Ultrasound with IV contrast|To compare the efficiency over the ultrasound scan within contrast
219582610|NCT04877886|DIAGNOSTIC_TEST|CT with IV contrast|CT with IV contrast
219764653|NCT07031817|OTHER|Standardized psychiatric assessment tools|Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.
219764654|NCT06703333|COMBINATION_PRODUCT|Extracorporeal photopheresis (ECP)|"* Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures).~* Total: 18 procedures (within 6 months \~24 weeks)."
219582611|NCT04877886|DIAGNOSTIC_TEST|Ultrasound without IV contrast|Ultrasound without IV contrast
219442545|NCT03146403|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219442546|NCT03146403|OTHER|0.9% normal saline|Placebo
219442547|NCT00077922|DRUG|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
219442548|NCT04917250|DRUG|Gemcitabine|1000mg/㎡，d1,4 ivdrip
219442549|NCT04917250|DRUG|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
219442550|NCT04917250|DRUG|Etoposide|100mg/㎡，d1-3 ivdrip
219442551|NCT04917250|DRUG|Dexamethasone|20mg/d d1-4 ivdrip
219442552|NCT01983449|DRUG|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
219442553|NCT01608529|DEVICE|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
219582612|NCT04877886|DIAGNOSTIC_TEST|CT without IV contrast|CT without IV contrast
219582613|NCT00507130|BIOLOGICAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
219582614|NCT00507130|BIOLOGICAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
219582615|NCT00507130|BIOLOGICAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
219582616|NCT00507130|OTHER|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
219764655|NCT06876363|GENETIC|EN-374|Single dose of EN-374 administered by intravenous infusion after mobilization and followed by enrichment
219764656|NCT06879652|OTHER|Increasing Dairy intake|The prediabetic and overweight participants aged 14-17 and 60-75 years consuming ≤1 serving of dairy per day who are assigned to the intervention group will consume 3 servings of dairy (milk, yogurt, cheese) before each meal throughout a day for 24 weeks.
219764657|NCT00862017|DIETARY_SUPPLEMENT|MSg supplementation|
219442554|NCT06055049|OTHER|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
219442555|NCT00127816|PROCEDURE|Permanent prostate implant|
219582617|NCT00859586|DEVICE|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
219582618|NCT00374426|DRUG|sertraline|
219582619|NCT01597466|DEVICE|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
219582620|NCT01597466|PROCEDURE|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
219582621|NCT00006055|DRUG|anti-thymocyte globulin|
219442556|NCT04606407|DEVICE|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
219582622|NCT00006055|DRUG|cyclophosphamide|
219582623|NCT00006055|DRUG|cyclosporine|
219582624|NCT00006055|DRUG|filgrastim|
219582625|NCT00006055|DRUG|methylprednisolone|
219582626|NCT00006055|DRUG|prednisone|
219582627|NCT00006055|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplantation|
219582628|NCT02140723|RADIATION|preoperative short course radiation|
219582629|NCT05040438|BIOLOGICAL|Vax-NK/HCC|autologous NK cells expanded ex vivo.
219582630|NCT03024658|OTHER|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
219582631|NCT01772758|DRUG|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
219582632|NCT01772758|DRUG|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
219764658|NCT00862017|DIETARY_SUPPLEMENT|NaCl supplementation|
219442557|NCT02804373|DRUG|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
219442558|NCT02804373|DRUG|Placebo|Placebo daily during 28 days
219442559|NCT02804373|DRUG|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
219442560|NCT02804373|DRUG|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
219442561|NCT00626769|DIETARY_SUPPLEMENT|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
219442562|NCT00626769|DIETARY_SUPPLEMENT|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
219442563|NCT04517110|DRUG|Pregabalin 300 mg|Pregabalin 300 mg, capsule
219442564|NCT04517110|DRUG|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
219442565|NCT04517110|DRUG|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
219442566|NCT04517110|DRUG|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
219582633|NCT01772758|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
219582634|NCT04099550|DEVICE|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
219582635|NCT04099550|OTHER|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
219582636|NCT04525235|COMBINATION_PRODUCT|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
219764659|NCT07034261|DEVICE|Blinded Continuous Glucose Monitoring Device|Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.
219764660|NCT07137455|DEVICE|EDEN Intracardiac Electrogram Recording and Classifying System|EDEN will be used to record and classify intracardiac electrograms obtained in the practice of medicine.
218835241|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
218835242|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
218835243|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
218835244|NCT00700622|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
218835245|NCT00700622|DRUG|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
218835246|NCT00700622|DRUG|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
218835247|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
218835248|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
218835249|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
218835250|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
218835251|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
218835252|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
218835253|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
218835254|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
218835255|NCT02777411|BIOLOGICAL|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
218835256|NCT02777411|BIOLOGICAL|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
218835257|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
218835258|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
218835259|NCT02777411|BIOLOGICAL|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
218835260|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
219442567|NCT04517110|OTHER|Usual Care|Usual Care
219442568|NCT01547962|DEVICE|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
219442569|NCT01547962|OTHER|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
219442570|NCT00422357|DRUG|Urtica Dioica (Tea bag)|
219442571|NCT01789710|DRUG|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
219442572|NCT01789710|DRUG|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
218835261|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
218835262|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
219442573|NCT01789710|BEHAVIORAL|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
219442574|NCT05007262|DRUG|Tangningtongluo tablets|Four pills each time and three times a day after meals.
219442575|NCT05007262|DRUG|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
219442576|NCT01158638|BEHAVIORAL|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
219442577|NCT02236650|BEHAVIORAL|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
218835263|NCT02890745|DRUG|Empagliflozin|
218835264|NCT02890745|DRUG|Placebo|
218835265|NCT00385385|DRUG|Rifalazil|
218835266|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
218835267|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
218835268|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
218835269|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
218835270|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
218835271|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
218835272|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
218835273|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
218835274|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
218835275|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
218835276|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
218835277|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
218835278|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
218835279|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
218835280|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
218835281|NCT01598714|DEVICE|Darco shoe|Darco shoe
218835282|NCT01598714|DEVICE|Podalux shoe|Podalux shoe
218835283|NCT01598714|DEVICE|Standard dressing shoe|Standard dressing shoe
218835284|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
218835285|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
218835286|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
218835287|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
218835288|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
218835289|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
218835290|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
218835291|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
218835292|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
219442578|NCT02236650|OTHER|Treatment as Usual|Treatment as Usual for 4 weeks
219442579|NCT02098148|DRUG|Xenon|
219442580|NCT02098148|DRUG|Placebo|
219442581|NCT04246424|BEHAVIORAL|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
219764661|NCT07035132|DIETARY_SUPPLEMENT|Oral supplementation with nutritional oligomeric formula|Patients will be supplemented with the specific oligomeric formula (1 or 2 bottles/day, as per investigator's decision) during, at least, the 12 weeks of the study follow-up.
219764662|NCT06704269|GENETIC|YTB323|CAR-T cell suspension for intravenous infusion
218835293|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
218835294|NCT00068263|RADIATION|radiation therapy|
218835295|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
219442582|NCT04246424|BEHAVIORAL|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
219442583|NCT04246424|BEHAVIORAL|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
219442584|NCT05526092|OTHER|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
219442585|NCT05344612|RADIATION|CT Coronary Angiography|Upfront ct-coronary angiography
219442586|NCT04346277|BIOLOGICAL|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
218835296|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
218835297|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
218835298|NCT02583633|DRUG|Transdermal nitroglycerin|
218835299|NCT02583633|DRUG|nifedipine|
218835300|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
218835301|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
219442587|NCT00531895|DRUG|duloxetine|duloxetine 60 mg/d
219442588|NCT03849014|PROCEDURE|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
219442589|NCT03849014|PROCEDURE|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
218835302|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
218835303|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
218835304|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
218835305|NCT05034042|DRUG|Fezolinetant|oral
218835306|NCT05034042|DRUG|Placebo|oral
218835307|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
218835308|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
218835309|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
218835310|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
218835311|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
218835312|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
218835313|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
218835314|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
219016141|NCT05123053|DRUG|Amifampridine|10mg tablet
219442590|NCT00760890|DIETARY_SUPPLEMENT|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
219442591|NCT00760890|DIETARY_SUPPLEMENT|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
219442592|NCT05241288|COMBINATION_PRODUCT|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
219442593|NCT02616536|OTHER|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
219442594|NCT04246489|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
219442595|NCT04027036|BIOLOGICAL|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
219442596|NCT03428295|DEVICE|Dose Safety AP system|Device will be used to automatically dose insulin
219442597|NCT00529412|OTHER|Seprafilm|two sheets per body
219442598|NCT02219672|DRUG|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
219582637|NCT04525235|DRUG|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
218835315|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
218835316|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
218835317|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
218835318|NCT05614258|DRUG|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
218835319|NCT01703091|DRUG|Ramucirumab|Administered IV
218835320|NCT01703091|DRUG|Placebo|Administered IV
218835321|NCT01703091|DRUG|Docetaxel|Administered IV
218835322|NCT01809509|PROCEDURE|Endometrial biopsy|
218835323|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
218835324|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
218835325|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
219442599|NCT02219672|DRUG|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
219442600|NCT04783714|DIETARY_SUPPLEMENT|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
218835326|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
218835327|NCT04813614|DEVICE|Active control group|Injection in the lips
218835328|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
218835329|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
218835330|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
219442601|NCT04783714|DIETARY_SUPPLEMENT|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
219442602|NCT05374291|DRUG|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
218835331|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
218835332|NCT01937663|DRUG|KWA-0711|
218835333|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
218835334|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
218835335|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
218835336|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
219442603|NCT05374291|DRUG|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
219442604|NCT03723785|DRUG|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
219442605|NCT04336111|PROCEDURE|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
219442606|NCT00964249|DRUG|GW642444|Long acting Beta 2 agonist
219442607|NCT00964249|DRUG|Placebo|Matching placebo
219442608|NCT05782348|BEHAVIORAL|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
219442609|NCT05782348|OTHER|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
219442610|NCT01619813|DRUG|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
219442611|NCT01619813|DRUG|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
218835337|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
218835338|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
218835339|NCT00803361|DRUG|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
218835340|NCT00803361|DRUG|Placebo|placebo capsules, oral, once a day for 15 weeks
218835341|NCT01220102|DRUG|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
218835342|NCT02984670|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
218835343|NCT02984670|BEHAVIORAL|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
218835344|NCT02984670|BEHAVIORAL|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
218835345|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
218835346|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
219442612|NCT04328441|DRUG|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
218835347|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
218835348|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
218835349|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
218835350|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
218835351|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
218835352|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
218835353|NCT01309789|DRUG|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
218835354|NCT00989508|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
218835355|NCT00989508|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
219016147|NCT04945460|DRUG|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
219016148|NCT04945460|DRUG|Placebo|Administered by subcutaneous injection
219016149|NCT04945460|DRUG|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
219442613|NCT04328441|DRUG|Placebo|Intracutaneously 0.1ml NaCl 0,9%
219442614|NCT01498536|BEHAVIORAL|aerobic exercise|3 times per week for 12-weeks
219442615|NCT05642065|OTHER|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
219442616|NCT02909582|PROCEDURE|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
219442617|NCT04246541|DRUG|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
219442618|NCT04246541|DRUG|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
219442619|NCT03034109|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
218835356|NCT02065934|OTHER|cardio-pulmonary resuscitation|
218835357|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
218835358|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
218835359|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
218835360|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
218835361|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
218835362|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
218835363|NCT00003322|DRUG|cisplatin|
218835364|NCT00003322|DRUG|paclitaxel|
218835365|NCT00003322|PROCEDURE|quality-of-life assessment|
218835366|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
218835367|NCT03121300|OTHER|Lung CT|CT lung ventilation
219442620|NCT00026975|PROCEDURE|Hyperbaric Oxygen|
219442621|NCT04847739|PROCEDURE|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
219442622|NCT04847739|DRUG|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
219442623|NCT04346004|DRUG|Normal saline|"Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery."
219442624|NCT04346004|DRUG|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery."
219442625|NCT03099798|OTHER|Questionnaires|"All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment"
219442626|NCT03099798|DIAGNOSTIC_TEST|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
219442627|NCT00873704|OTHER|supplemental postoperative oxygen|
219442628|NCT01681290|DRUG|CBX129801|
219442629|NCT04253470|OTHER|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
219442630|NCT04125381|OTHER|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
219442631|NCT00926185|DRUG|Lifitegrast|Ophthalmic Solution
219442632|NCT00926185|DRUG|Placebo|Ophthalmic Solution
219442633|NCT00823160|PROCEDURE|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
219442634|NCT00823160|PROCEDURE|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
219442635|NCT06031376|DRUG|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
219442636|NCT06031376|DRUG|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
219442637|NCT06031376|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
219442638|NCT06031376|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
219442639|NCT02885272|PROCEDURE|Computed Tomography|Undergo PET/CT scans
219442640|NCT02885272|RADIATION|Fludeoxyglucose F-18|Given IV
219442641|NCT02885272|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
218835368|NCT03121300|OTHER|MRI|DCE MRI
218835369|NCT03121300|OTHER|Walk Test|6 minute hall walk test
219016152|NCT04842266|DEVICE|IlluminOss pelvic implant for oncologic indication|Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
219582638|NCT00080938|DRUG|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
219582639|NCT00080938|RADIATION|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
219582640|NCT06279559|BEHAVIORAL|Music-therapy|10 sessions of online music therapy held by expert music therapists
219582641|NCT01987037|BEHAVIORAL|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
219582642|NCT00077545|DRUG|triapine|Given IV
219582643|NCT00077545|DRUG|cisplatin|Given IV
219016153|NCT04842266|DEVICE|IlluminOss pelvic implant for geriatric trauma indication|Pelvic fragility fracture in a geriatric patients (age 65 or older)
219582644|NCT04509882|DRUG|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
219582645|NCT04509882|DRUG|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
218835370|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
218835371|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
219016159|NCT06095063|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
219016160|NCT06095063|DEVICE|Sham Brainsway H7-Coil Deep TMS System|In addition to the active H-coil, a sham coil is included in the system. The active and sham coils are connected to a control switch, which alternates between real and sham operation modes. The sham treatment will be administered daily for 4 consecutive weeks.
219016161|NCT06095063|OTHER|Cognitive Training|Cognitive training will be conducted using the BrainHQ software program.
218835372|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
218835373|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
218835374|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
218835375|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
218835376|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
218835377|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
218835378|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
218835379|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
218835380|NCT06128850|OTHER|disease|compare to diseases
218835381|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
219582646|NCT00440960|DRUG|propofol|
219582647|NCT00440960|DRUG|midazolam|
219582648|NCT00440960|DRUG|alfentanil|
219582649|NCT00440960|DRUG|lidocaine|
219582650|NCT00121472|DEVICE|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
219582651|NCT02711735|BIOLOGICAL|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
219582652|NCT02711735|BIOLOGICAL|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
219582653|NCT02080013|OTHER|radiofrequency|ClosureFAST
219442642|NCT02885272|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
219442643|NCT02500472|DIETARY_SUPPLEMENT|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
219442644|NCT02069704|DRUG|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
219442645|NCT02069704|DRUG|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
219442646|NCT03949621|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
219442647|NCT01236768|DRUG|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
219442648|NCT01236768|DRUG|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
219442649|NCT05955872|DRUG|VX-147|Tablets for oral administration.
219582654|NCT01342107|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
219582655|NCT01342107|DEVICE|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
219582656|NCT01342107|DEVICE|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
219582657|NCT06504420|DRUG|Sirolimus|Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
219582658|NCT06504420|DRUG|Placebo|Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
219582659|NCT04849962|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
219582660|NCT04849962|OTHER|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
219582661|NCT02538848|DRUG|HTD4010|injectable solution
219582662|NCT03651258|BEHAVIORAL|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
219582663|NCT02992418|BIOLOGICAL|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
218835382|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
218835383|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
218835384|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
219016169|NCT05226455|DRUG|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
219016170|NCT03274687|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219016171|NCT03274687|OTHER|Laboratory Biomarker Analysis|Correlative studies
219442650|NCT05146037|OTHER|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
219442651|NCT05146037|OTHER|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
219582664|NCT02992418|BIOLOGICAL|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
219582665|NCT02992418|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
219582666|NCT05979649|BEHAVIORAL|behavioral corrective tasks|"After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence."
219582667|NCT05979649|OTHER|Counselling on psychological knowledge|Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.
218835385|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
219016172|NCT03274687|OTHER|Quality-of-Life Assessment|Ancillary studies
219016173|NCT03274687|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
219442652|NCT05305976|OTHER|Telerehabilitation|The 8 week exercise program with telerehabilitation
219442653|NCT00813267|BIOLOGICAL|mesenchymal stem cell infusion|
219442654|NCT00813267|BIOLOGICAL|bone marrow mononuclear cell infusion|
219582668|NCT05979649|OTHER|placebo-controlled study|"feel-good articles without professional psychological knowledge will be sent to the control group participants weekly."
219582669|NCT05979649|OTHER|Peer Interventionist Training|The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
218835386|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
219016178|NCT06957535|BEHAVIORAL|Navigation|Navigation is provision of 1:1 support from a Diné peer-navigator
219442655|NCT04189640|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
219442656|NCT06252740|OTHER|No intervention|Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
219442657|NCT04443894|OTHER|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
219442658|NCT04443894|OTHER|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
219442659|NCT01517906|BEHAVIORAL|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
219442660|NCT01517906|BEHAVIORAL|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
219442661|NCT04313504|DRUG|Niraparib|Niraparib \& Dostarlimab combination
219442662|NCT04313504|DRUG|Dostarlimab|Niraparib \& Dostarlimab combination
219442663|NCT01909986|DRUG|[14C]ONO-4053|Single dose \[14C\]ONO-4053
219442664|NCT00638690|DRUG|Placebo|Four tablets once daily until disease progression
219442665|NCT00638690|DRUG|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
219442666|NCT00638690|DRUG|Prednisone/prednisolone|5 mg twice daily until disease progression
219442667|NCT00111891|DRUG|niacin (+) laropiprant|
219442668|NCT00111891|DRUG|Comparator: placebo (unspecified)|
219442669|NCT00605358|BEHAVIORAL|Open Door intervention|"Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
219442670|NCT01181297|OTHER|Extensively Hydrolyzed Formula with a Probiotic|
219442671|NCT01181297|OTHER|Extensively Hydrolyzed Formula without a Probiotic|
219582670|NCT01454908|DEVICE|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
219582671|NCT03915353|OTHER|No Intervention|No Intervention
219582672|NCT01830205|DRUG|Daclatasvir|
219582673|NCT03246126|DEVICE|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
219582674|NCT01996618|DRUG|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
219582675|NCT06189547|OTHER|different prior cancer history type|different types of prior cancer history
218835387|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
218835388|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
218835389|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
219016179|NCT06957535|BEHAVIORAL|TEAM|TEAM encompasses culturally tailored mammography education modules
218835390|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
218835391|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
219016185|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
219016186|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
219016187|NCT03554083|DRUG|Atezolizumab|Given IV
219016188|NCT03554083|DRUG|Cobimetinib|Given PO
219442672|NCT03859804|PROCEDURE|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
219442673|NCT03859804|PROCEDURE|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
218835392|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
218835393|NCT00413673|PROCEDURE|PRK|PRK
219016189|NCT03554083|BIOLOGICAL|Tiragolumab|Given IV
219016190|NCT03554083|DRUG|Vemurafenib|Given PO
219016191|NCT02894710|DRUG|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
219016192|NCT02894710|DRUG|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
219442674|NCT00115544|DRUG|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
219442675|NCT00725829|DRUG|simvastatin|Simvastatin 40mg/d
219442676|NCT00725829|DRUG|ezetimibe|ezetimibe 10mg/d
219442677|NCT00725829|DRUG|placebo|placebo
219442678|NCT02861118|OTHER|No Intervention|
219442679|NCT04949828|DRUG|CREON|Oral Capsules
219442680|NCT06353867|OTHER|Group Exercise|The children with special needs included in the study were included in group exercises for 45 minutes 2 days a week in groups of 10 children each. Group exercises were planned as balance and coordination exercises including warm-up and cool-down periods. In the warm-up and cool-down periods, counting in place and balance exercises were performed. The exercises included tasks such as side walking, tandem walking, walking on a balance board, walking in a figure 8, walking over obstacles, throwing a ball to the person next to him/her while passing through cones, and throwing a ball by jumping while passing through cones.The exercises were made more difficult by following a progressive method every 2 weeks. The exercises were performed in 3 sets of 5 repetitions under the supervision of a physiotherapist.
219442681|NCT02607462|BIOLOGICAL|PRP|
219442682|NCT02607462|OTHER|Placebo|
219442683|NCT02454894|DRUG|lidocaine|surface anesthesia with lidocaine
219582676|NCT05943808|OTHER|Book reading|subjects are given an acupuncture textbook to read for 30 minutes
219582677|NCT05943808|OTHER|VR pre-recorded video watching|subjects are given an pre-recorded VR video to watch for 30 minutes
219016197|NCT04734652|COMBINATION_PRODUCT|Biktarvy®|"Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose."
219016198|NCT04734652|COMBINATION_PRODUCT|TLD- fixed-drug combination single tablet|Standard of care Dolutegravir-based regimen
219442684|NCT02454894|PROCEDURE|postoperative management|lying without the pillow for half an hour after lumbar puncture
219442685|NCT01147367|BEHAVIORAL|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
219442686|NCT00625014|DRUG|Haloperidol|Haloperidol 3 mg/day for 8 days
219442687|NCT05589740|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
219582678|NCT00005399|OTHER|No interventions|No interventions
219582679|NCT05644015|OTHER|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
219582680|NCT00045188|DRUG|imatinib mesylate|Given PO
219582681|NCT00045188|OTHER|laboratory biomarker analysis|Optional correlative studies
218835394|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
218835395|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
218835396|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
218835397|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
218835398|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
218835399|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
218835400|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
219442688|NCT05589740|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
219016206|NCT05619211|BEHAVIORAL|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
219442689|NCT03674294|DRUG|Aprepitant|Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
219442690|NCT03674294|DRUG|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
219582682|NCT01059266|DRUG|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
219582683|NCT01992523|DRUG|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
218835401|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
218835402|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
218835403|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
218835404|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
218835405|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
218835406|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
219016211|NCT02592291|DEVICE|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
219016212|NCT04296903|DEVICE|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
218835407|NCT01670279|DRUG|Placebo|
218835408|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
219016238|NCT06329401|DRUG|AP01|Oral inhalation solution
219016239|NCT06329401|OTHER|Placebo|Placebo oral inhalation solution
218835409|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
219442691|NCT03674294|DRUG|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
219442692|NCT03674294|DRUG|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
219442693|NCT01679340|DRUG|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
219442694|NCT01679340|DRUG|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
219442695|NCT01679340|DRUG|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
219442696|NCT02635685|OTHER|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
219442697|NCT05287269|DIAGNOSTIC_TEST|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
219442698|NCT01359527|DEVICE|Hip Resurfacing|
219442699|NCT01359527|DEVICE|Total Hip Arthroplasty|
219442700|NCT00621244|DRUG|LBH589|
219442701|NCT06323499|PROCEDURE|Induction of atypical atrial flutter|Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
219442702|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
218835410|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
218835411|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
218835412|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
218835413|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
218835414|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
218835415|NCT01901614|DRUG|Topical Anesthesia|
218835416|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
218835417|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
219016246|NCT06783660|DEVICE|Peptide-loaded collagen sponge and collagen gel complex|A piece of peptide-loaded collagen sponge (Regenomer®) and collagen gel complex
218835418|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
219016247|NCT06783660|DEVICE|Collagen sponge|Type 1 Collagen sponge (Regenomer)
219442703|NCT00175318|BEHAVIORAL|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
219442704|NCT04422197|BIOLOGICAL|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
219442705|NCT04422197|PROCEDURE|surgery without botox injection|surgery without botox injection
219442706|NCT03052699|PROCEDURE|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
219442707|NCT00717951|DRUG|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
219442708|NCT00659906|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
219442709|NCT00659906|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
219582684|NCT01992523|DRUG|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
219582685|NCT00730223|DRUG|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
219764663|NCT06710548|BEHAVIORAL|REVITALIZE Intervention|A remotely delivered tele-health intervention to address cancer fatigue that is based on an acceptance-based approach. The intervention includes 8 one-on-one weekly sessions and 2 booster sessions with trained psychology doctoral students based at University of Colorado. Sessions will focus on fatigue education, Acceptance and Commitment Therapy (ACT) skills, and behavior changes. Wi-Fi enabled tablets and keyboards will be provided to participants if needed. All sessions will be conducted via the Zoom platform and will either be videotaped or audiotaped.
219764664|NCT06710548|BEHAVIORAL|Educational Materials|The educational materials arm will receive specialized cancer survivorship educational materials created by the National Cancer Institute
218835419|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
218835420|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
219442710|NCT04716049|OTHER|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
219582686|NCT06289803|DEVICE|probe confocal laser endomicroscopy|probe confocal laser endomicroscopy will be used to identify the tumor behavior
219582687|NCT03425695|DEVICE|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
219582688|NCT03425695|OTHER|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
219582689|NCT05626439|DRUG|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
219582690|NCT05626439|DRUG|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
218835421|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
218835422|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
218835423|NCT02506855|DRUG|Ropivacaine|
218835424|NCT02506855|OTHER|Placebo|
218835425|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
218835426|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
218835427|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
218835428|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
218835429|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
218835430|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
218835431|NCT00110435|DRUG|Comparator: atorvastatin|
218835432|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
219764665|NCT06710119|OTHER|Visual Feedback|Visual feedback of foot loading during gait.
219764666|NCT06707688|DEVICE|Amulet™ 2 Left Atrial Appendage (LAA) Occluder|Patient will undergo the implantation of the Amulet™ 2 Left Atrial Appendage (LAA) Occluder
219764667|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples for ctDNA testing
219764668|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo possible collection of tissue
219764669|NCT07136493|OTHER|Electronic Health Record Review|Ancillary studies
219764670|NCT07136493|OTHER|Survey Administration|Ancillary studies
218835433|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
218835434|NCT05937386|DRUG|AGMB-129|Oral capsule
218835435|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
218835436|NCT03138525|OTHER|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
218835437|NCT03138525|OTHER|Blood sampling (controls)|Blood samples will be collected once at enrollment.
218835438|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
218835439|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
218835440|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
218835441|NCT04916392|DRUG|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
218835442|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
219582691|NCT03274882|DRUG|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
219442711|NCT04716049|OTHER|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
219582692|NCT01320748|BEHAVIORAL|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
219582693|NCT01320748|BEHAVIORAL|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
219582694|NCT03641521|BEHAVIORAL|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
219582695|NCT01051219|DRUG|Losartan|50 milligrams to be taken orally, daily
219582696|NCT00144664|DRUG|MRA(Tocilizumab)|
219582697|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
219442712|NCT05238558|BIOLOGICAL|FMPV-1|Intradermal administration
219442713|NCT05238558|BIOLOGICAL|GM-CSF (as adjuvant)|Intradermal administration
219582698|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
219582699|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
219582700|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
219582701|NCT00030979|DRUG|Donepezil|
219582702|NCT00423475|DRUG|goserelin acetate|
219582703|NCT00423475|PROCEDURE|adjuvant therapy|
218835443|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
218835444|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
218835445|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
218835446|NCT01823198|DRUG|Busulfan|Given IV
218835447|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
218835448|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
218835449|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
218835450|NCT01823198|OTHER|Pharmacological Study|Correlative studies
218835451|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
218835452|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
218835453|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
219442714|NCT00911066|DRUG|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
219442715|NCT00911066|DRUG|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
219442716|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
219442717|NCT01857024|DRUG|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
218835454|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
218835455|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
218835456|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
218835457|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
218835458|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
219364051|NCT06083220|BEHAVIORAL|Smart Start - School Readiness Program|Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
219442718|NCT02918955|PROCEDURE|up-front neck dissection|
219442719|NCT02918955|RADIATION|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
219442720|NCT02918955|DRUG|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
219442721|NCT02918955|PROCEDURE|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
219442722|NCT02727517|PROCEDURE|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
219442723|NCT02727517|PROCEDURE|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
219442724|NCT03020264|DEVICE|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
219442725|NCT06268483|DIETARY_SUPPLEMENT|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
219442726|NCT06268483|DIETARY_SUPPLEMENT|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
219442727|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
219442728|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
219442729|NCT06430645|DRUG|Saline|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
219442730|NCT02046382|DRUG|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
219442731|NCT02046382|DRUG|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
219442732|NCT00565812|DRUG|SD-6010|200 mg tablets once a day for 2 years
219582704|NCT00423475|RADIATION|radiation therapy|
219442733|NCT00565812|DRUG|SD-6010|50 mg tablets once a day for 2 years
219442734|NCT00565812|DRUG|Placebo|Placebo tablets once a day for 2 years
219582705|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
219442735|NCT05246475|DIAGNOSTIC_TEST|PET-MRI|Simultaneous PET-MRI measurement
219582706|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
219582707|NCT06128070|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218835459|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
218835460|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
219442736|NCT01887756|DEVICE|Tele Rehabilitation|
219582708|NCT06128070|PROCEDURE|Chest Computed Tomography|Undergo chest CT
219582709|NCT06128070|PROCEDURE|Echocardiography|Undergo ECHO
218835461|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
218835462|NCT04079231|DRUG|Aflibercept|Intravitreal injection
218835463|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
218835464|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
219582710|NCT06128070|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219582711|NCT06128070|DRUG|Methotrexate|Given IV
219582712|NCT06128070|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219582713|NCT06128070|DRUG|Ruxolitinib Phosphate|Given PO
219582714|NCT06128070|DRUG|Tacrolimus|Given IV
219582715|NCT02758522|DRUG|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
218835465|NCT00894699|DRUG|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
218835466|NCT00894699|DRUG|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
218835467|NCT01122446|OTHER|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
218835468|NCT01122446|DRUG|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
218835469|NCT00814021|DRUG|sunitinib malate|
218835470|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
218835471|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
218835472|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
218835473|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
219196236|NCT06813586|OTHER|hospital-based registry|"The clinical data collected for each patient will reflect comprehensive multiprofessional clinical insights necessary for diagnostic definition and typically obtained during diagnostic evaluation and/or monitoring visits. In addition to these, instrumental data commonly acquired in clinical practice, such as neuroradiological and electrophysiological information, will also be collected.~For each enrolled subject, a checklist (CRF) will be completed to gather study-related data. These data will be entered into a specific database constructed on the REDCap platform and managed in an anonymized form. Subject enrollment will be conducted progressively.~This data collection will enable monitoring of study progress, including the number of enrolled subjects, completed assessments, and study adherence. Every three months, monitoring will be performed to assess study progress and the achievement of enrollment targets."
219196237|NCT06819553|DRUG|Oral Potassium Citrate|Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones
219442737|NCT04425460|DRUG|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
219442738|NCT04425460|OTHER|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
219442739|NCT03926260|OTHER|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
219442740|NCT00317057|PROCEDURE|Patient education and disease management|
219442741|NCT03790540|DEVICE|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
219442742|NCT03790540|DRUG|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
219442743|NCT03403855|DEVICE|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
219442744|NCT03403855|DEVICE|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
219442745|NCT01128166|DEVICE|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
219442746|NCT05693103|DEVICE|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
219442747|NCT01733836|DRUG|Metformin|
219442748|NCT01733836|DRUG|placebo|
219442749|NCT06071390|BEHAVIORAL|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
219442750|NCT02536157|DEVICE|Thermoplastic splinting|
219442751|NCT00006030|DRUG|tamoxifen citrate|
219442752|NCT00006030|PROCEDURE|conventional surgery|
219442753|NCT00006030|RADIATION|radiation therapy|
218835474|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
218835475|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
218835476|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
219196238|NCT06816576|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels. Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with Subjective Units of Disturbance again"
219442754|NCT02121444|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|
219442755|NCT02121444|DEVICE|BETACONNECT auto-injector.|
219764671|NCT07034924|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
219764672|NCT07037459|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
219196239|NCT06808581|DIAGNOSTIC_TEST|blood test for pro-inflammatory cytokines and ultrasound of the median nerves|Blood test and ultrasound
219764673|NCT07037459|DRUG|Placebo|Placebo will be administered SC.
218835477|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
218835478|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
218835479|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
218835480|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
219442756|NCT06103019|OTHER|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
219442757|NCT06103019|OTHER|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
219442758|NCT04743271|OTHER|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
219442759|NCT04743271|OTHER|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
219442760|NCT01398228|BEHAVIORAL|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
219442761|NCT04968353|DEVICE|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
219442762|NCT04968353|DEVICE|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
219442763|NCT04968353|DEVICE|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
219442764|NCT04968353|DEVICE|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
219442765|NCT01425645|OTHER|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
219442766|NCT03455062|OTHER|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
219442767|NCT03472963|DRUG|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
219442768|NCT02635529|PROCEDURE|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
219442769|NCT02635529|PROCEDURE|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
219442770|NCT05229419|OTHER|complete blood count|complete blood count will be done for corrosive cases
219764674|NCT06880991|OTHER|Arm 1|Participant completion of questionnaires and participation in focus group(s) and/or interview sessions.
219764675|NCT06704100|DRUG|Fosamprenavir Calcium & Sodium Alginate|1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
219764676|NCT06704100|OTHER|Placebo|15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate
219764677|NCT06880692|OTHER|Educational Materials delivered via the Tick App|Education about tick bite prevention
219764678|NCT06487481|PROCEDURE|Surgical resection|Planned surgical resection (all participants) 4 weeks after completion of the preoperative RT
218835481|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
218835482|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
218835483|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
218835484|NCT01369199|DRUG|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
218835485|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
218835486|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
219442771|NCT04212936|PROCEDURE|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
218835487|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
218835488|NCT01071252|DRUG|AIN457|
218835489|NCT01071252|DRUG|Placebo|
218835490|NCT04169516|DIAGNOSTIC_TEST|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
218835491|NCT00303654|PROCEDURE|biopsy|
219442772|NCT04266158|DEVICE|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
219442773|NCT02169713|DRUG|Mirabegron|Oral
219442774|NCT02169713|DRUG|Solifenacin succinate|Oral
219442775|NCT02169713|DRUG|Tamsulosin HCl|Oral
219442776|NCT02169713|DRUG|Placebo|Oral
219442777|NCT03595449|DRUG|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
219442778|NCT03595449|DRUG|Surgilube|surgilube (placebo) applied during Mohs surgery
219442779|NCT00663338|DRUG|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
219442780|NCT03999385|BEHAVIORAL|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
219442781|NCT03126279|PROCEDURE|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
219442782|NCT02667392|PROCEDURE|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
219582716|NCT02758522|DRUG|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
219582717|NCT02758522|DRUG|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
219582718|NCT00067899|DRUG|Vitamin E with and without Vitamin C|
219582719|NCT01684436|DEVICE|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
218835492|NCT00303654|PROCEDURE|therapeutic conventional surgery|
219016250|NCT06786819|OTHER|ERACS with Digital Platform|The assistance provided to patients in the intervention group will be sequential and prospective. The project will utilize an app based on protocols that prepare patients for rapid recovery (ERAS), starting before surgery and extending up to 30 days post-discharge. This includes pre-operative evaluations (dental, psychological, nutritional, and others), scheduling and confirming hospital admission, and following specific protocols during surgery and intensive care. The app aims to enhance communication and teamwork, improving patient-centered care. It will feature modules for patient and family education, team communication, and activity management through a dashboard. Additionally, it will facilitate interaction with patients through messages and surveys, monitor multidisciplinary team communication, and collect patient-reported outcomes 30 days after the surgical procedure.
219442783|NCT02667392|PROCEDURE|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
219764679|NCT06487481|RADIATION|Preoperative RT|Preoperative RT at escalating doses in daily fractions over approximately 2-3 weeks; 2 weeks (DL1), or 3 weeks (DL2 or DL3) based on assigned Cohort and Dose Level (DL). Cohorts are by mitotane status at enrollment: Cohort 1 (with detectable mitotane levels), Cohort 2 (never had or without detectable mitotane levels), Cohort 3 (either).
219764680|NCT07033494|BIOLOGICAL|MK-2214|IV infusion
219764681|NCT07033494|DRUG|Placebo|IV infusion
219764682|NCT06688058|BIOLOGICAL|V540D|Experimental vaccine and adjuvant administered via intramuscular (IM) injection
219764683|NCT06688058|BIOLOGICAL|GARDASIL®9|Suspension administered via IM injection
219764684|NCT07040566|DRUG|Varenicline 1mg BID|12 weeks following the standard titration of 1 mg, twice daily
219764685|NCT07040566|DRUG|Placebo|Matching placebo twice daily
218835493|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
218835494|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
218835495|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
219016255|NCT06427824|OTHER|Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)|An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
219016256|NCT06427824|OTHER|Geriatric Service/ Discharge Planning|A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.
219016257|NCT06427824|OTHER|Questionnaires|These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
219016268|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
219582720|NCT00172536|BEHAVIORAL|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
219582721|NCT00172536|OTHER|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
219582722|NCT01732484|PROCEDURE|intraocular lens implantation|
219582723|NCT00476983|DRUG|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
219582724|NCT04040023|DRUG|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
219764686|NCT07042217|DEVICE|transcranial direct current stimulation (tDCS) and mindfulness instruction|tDCS together with audio providing mindfulness instruction and music
219764687|NCT07042217|DEVICE|Sham tDCS and Mindfulness|Placebo electrical sitmulation and audio-guided mindfulness instruction
219764688|NCT07041541|PROCEDURE|Esthetic Crown Lengthening|Conventional Esthetic Crown Lengthening
219764689|NCT07041541|PROCEDURE|Esthetic Crown Lengthening using GingivalStat approach|Esthetic Crown Lengthening using GingivalStat approach (composite stops)
219016269|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
219442784|NCT03412123|BEHAVIORAL|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
219442785|NCT02033850|BEHAVIORAL|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
219016270|NCT04562389|OTHER|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
219442786|NCT03215667|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
219442787|NCT02998255|DRUG|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
219442788|NCT02998255|DRUG|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
219442789|NCT00260195|BEHAVIORAL|School-based cognitive behavioral support group|
219582725|NCT04040023|OTHER|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
219442790|NCT03352128|DIETARY_SUPPLEMENT|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
219016271|NCT04562389|DRUG|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
219442791|NCT03352128|DIETARY_SUPPLEMENT|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
219582726|NCT02266134|BEHAVIORAL|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
219582727|NCT02266134|BEHAVIORAL|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
218835496|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
218835497|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
219442792|NCT03374761|OTHER|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
219442793|NCT04208880|BEHAVIORAL|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
219442794|NCT04208880|BEHAVIORAL|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
219442795|NCT04208880|BEHAVIORAL|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
219442796|NCT04208880|BEHAVIORAL|TBH Memory 1.0|TBH Memory program with easy challenge activities.
219442797|NCT04208880|BEHAVIORAL|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
219764690|NCT06883240|DRUG|Von Willebrand Factor Concentrates|Used according to local labeling or local treatment guidelines.
219764691|NCT06883240|DRUG|Von Willebrand Factor Concentrates and Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
219764692|NCT06883240|DRUG|Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
219764693|NCT06883240|DRUG|Recombinant Activated Factor VII|Used according to local labeling or local treatment guidelines.
219764694|NCT06883240|DRUG|Activated Prothrombin Complex Concentrate|Used according to local labeling or local treatment guidelines.
219764695|NCT06718998|DRUG|NNC0519-0130|Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
219764696|NCT07032727|DRUG|Olutasidenib|Given by po
219764697|NCT07032727|DRUG|Cladribine (CLAD)|Given by IV
219764698|NCT07032727|DRUG|Venetoclax|Given by po
219764699|NCT07032727|DRUG|Gilteritinib|Given by po
219764700|NCT07032727|DRUG|Ruxolitinib|Given by po
219764701|NCT07032727|DRUG|Cytarabine|Given SQ
218835498|NCT00315952|DRUG|Exubera|
218835499|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
218835500|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
219582728|NCT02951468|PROCEDURE|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
219582729|NCT04260438|DRUG|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
219582730|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
219582731|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
218835501|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
218835502|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
219582732|NCT04035915|PROCEDURE|Limited driving pressure|Keep driving pressure \<15 cmH2O
219582733|NCT04035915|PROCEDURE|Conventional mechanical ventilation strategies|Keep tidalvolume \</= 8
219582734|NCT01715792|OTHER|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
219582735|NCT00328016|BEHAVIORAL|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
219582736|NCT00328016|DEVICE|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
219582737|NCT04607330|OTHER|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
218835503|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
218835504|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
218835505|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
218835506|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
218835507|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
218835508|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
218835509|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
218835510|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
219196240|NCT06817148|PROCEDURE|transcatheter aortic valve replacement (TAVR)|percutaneous transcatheter aortic valve replacement
219442798|NCT06118762|DRUG|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
219442799|NCT01810380|DRUG|Placebo|Once daily as tablets and capsules, orally
219442800|NCT01810380|DRUG|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
219442801|NCT01810380|DRUG|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
219016286|NCT04975334|DRUG|Naloxone|One bolus of naloxone
219442802|NCT02408926|BIOLOGICAL|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
219442803|NCT02408926|BIOLOGICAL|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
219442804|NCT02408926|BIOLOGICAL|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
219442805|NCT02408926|BIOLOGICAL|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
219442806|NCT00614991|DRUG|Raltegravir|400mg BID
219442807|NCT00614991|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
219442808|NCT00614991|DRUG|Ritonavir|100 mg BID or QD
219442809|NCT00578422|OTHER|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
219442810|NCT00578422|PROCEDURE|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
219582738|NCT03893435|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
218835511|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
218835512|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
218835513|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
218835514|NCT03082443|OTHER|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
218835515|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
218835516|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
219196241|NCT06817148|PROCEDURE|surgical aortic valve replacement (SAVR)|surgical aortic valve replacement
219442811|NCT01311739|DRUG|Cyanocobalamin|
218835517|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
218835518|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
218835519|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
219016295|NCT06202196|PROCEDURE|Risk prevention session|"The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS)."
219016296|NCT06202196|PROCEDURE|Usual Therapeutic Patient Education (TPE) management|The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
219442812|NCT06216106|PROCEDURE|Prepectoral breast reconstruction with polyurethane implants|Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
219442813|NCT04202276|OTHER|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
219442814|NCT03975530|BEHAVIORAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
219442815|NCT03975530|BEHAVIORAL|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
219442816|NCT05651984|DEVICE|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
219442817|NCT03148795|DRUG|Talazoparib|1 mg daily
219442818|NCT06166290|PROCEDURE|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
219442819|NCT06166290|PROCEDURE|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
219442820|NCT01638169|DEVICE|adding a heel|walking with and without heels on the gaitrite system
219442821|NCT01238952|DRUG|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
218835520|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
218835521|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
218835522|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
218835523|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
218835524|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
218835525|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
218835526|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
218835527|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
218835528|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
218835529|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
218835530|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
218835531|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
219764702|NCT07041385|DRUG|Aspirin 75 mg|"This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition.~Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized:~Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly."
219764703|NCT07041385|DRUG|Aspirin 150 mg|"This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition.~Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized:~Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly."
219764704|NCT07037758|DRUG|Tarlatamab|Administered as an IV infusion.
219764705|NCT07037758|DRUG|AB248|Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.
219016305|NCT06690775|DRUG|TORL-1-23|2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
219016306|NCT06690775|DRUG|TORL-1-23|3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
219764706|NCT03520660|DRUG|Epclusa|sofosbuvir/velapatasvir combination (Epclusa)
219764707|NCT06723015|DRUG|18F-AV-1451|"Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment.."
219764708|NCT05562830|BIOLOGICAL|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
219764709|NCT05562830|BIOLOGICAL|Pembrolizumab|Administered via IV infusion on Day 1 of each 6 week cycle.
218835532|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
218835533|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
218835534|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
218835535|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
219016307|NCT06690775|DRUG|TORL-1-23|3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
219016308|NCT06690775|DRUG|Pegfilgrastim (drug)|6.0 mg subcutaneous injection on Day 4 of each cycle.
219016309|NCT03882034|DRUG|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
219196242|NCT06817291|PROCEDURE|Laparoscopic endobiliary stent|During laparoscopic gallblader surgery, a quidewire is inserted in the cystic duct, via the common bile duct and advanced into the duodenum. The plastic stent is threaded over the wire and pushed in position, with a catheter. When the stent is crossing the papilla, the wire is first removed, and then the catheter. The procedure is done under x-ray guidance.
218835536|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
218835537|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
218835538|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
218835539|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
218835540|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
218835541|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
218835542|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
218835543|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
218835544|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
218835545|NCT00000673|DRUG|Ganciclovir|
218835546|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
218835547|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
218835548|NCT00039039|DRUG|carboplatin|
218835549|NCT00039039|DRUG|chemotherapy|
218835550|NCT00039039|DRUG|cisplatin|
218835551|NCT00039039|DRUG|paclitaxel|
218835552|NCT00039039|RADIATION|radiation therapy|
218835553|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
218835554|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
219442822|NCT02590640|DEVICE|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
219442823|NCT02590640|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
219442824|NCT04297410|RADIATION|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
219442825|NCT02840526|PROCEDURE|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
219442826|NCT02840526|DRUG|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
219442827|NCT02840526|DRUG|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
219442828|NCT02840526|DRUG|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
219442829|NCT02840526|DRUG|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
219442830|NCT02840526|DRUG|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
219442831|NCT02840526|DEVICE|Intubation|Intratracheal intubation with a single lumen endotracheal tube
219442832|NCT02840526|DRUG|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
219442833|NCT02840526|DRUG|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
218835555|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
218835556|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
218835557|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
219442834|NCT02840526|DRUG|Ketonal|100 mg ketoprofen intravenously every 12 hours
219442835|NCT02840526|DRUG|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
219442836|NCT04203017|BIOLOGICAL|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
219582739|NCT01921621|BEHAVIORAL|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
219764710|NCT05562830|BIOLOGICAL|MK-3120|Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.
218835558|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
218835559|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
218835560|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
218835561|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
218835562|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
218835563|NCT02110186|DEVICE|Dynamic Stabilization|
218835564|NCT02110186|PROCEDURE|Discectomy|
218835565|NCT02110186|DEVICE|Instrumentation and fusion|
218835566|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
218835567|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
218835568|NCT01994746|DRUG|Nasal Glucagon|
218835569|NCT01994746|DRUG|Intramuscular Glucagon|
218835570|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
218835571|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
218835572|NCT03248167|DRUG|Cannabidiol|600 mg daily
219442837|NCT03375723|OTHER|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
219442838|NCT03375723|OTHER|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
219442839|NCT04129086|DRUG|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
219442840|NCT04129086|DRUG|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
219442841|NCT05008458|DIAGNOSTIC_TEST|von willebrand factor and copeptin|biomarkers increase in children with febrile seizures
219442842|NCT03783338|COMBINATION_PRODUCT|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
219442843|NCT00045487|DRUG|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
219442844|NCT04752943|OTHER|Tips By Text Messages|Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
219442845|NCT03527771|DEVICE|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
219442846|NCT03527771|DRUG|telephone-assisted CPR|Emergency call with telephone assistance in CPR
219442847|NCT00001827|BIOLOGICAL|aldesleukin|
219442848|NCT00001827|BIOLOGICAL|incomplete Freund's adjuvant|
219442849|NCT00001827|BIOLOGICAL|p53 peptide vaccine|
219442850|NCT00001827|BIOLOGICAL|sargramostim|
219442851|NCT00001827|BIOLOGICAL|therapeutic autologous dendritic cells|
219442852|NCT00001827|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219442853|NCT03209362|COMBINATION_PRODUCT|SI-613|SI-613 will be repeated intra-articularly administered.
219442854|NCT03209362|COMBINATION_PRODUCT|Placebo|Placebo will be repeated intra-articularly administered.
219442855|NCT01176188|OTHER|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
219582740|NCT01921621|BEHAVIORAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
219582741|NCT06593639|OTHER|Prehabilitation before surgery|Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
219582742|NCT06593639|OTHER|Prehabilitation before and during CRT|Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
219582743|NCT00019786|DRUG|isolated perfusion|
219582744|NCT00019786|DRUG|melphalan|
219582745|NCT00019786|PROCEDURE|conventional surgery|
219764711|NCT06876142|DRUG|Mirdametinib|Capsules taken by mouth twice a day (2-12mg) for days 1-21 days of each 28 day cycle
219764712|NCT06876142|DRUG|Sirolimus|Tablets taken by mouth once a day for days 1-28 days of each 28 day cycle. Loading dose of 12 mg on Day 1 Cycle 1 with 4 mg being taken for the remaining doses.
219764713|NCT07032545|OTHER|Broccoli microgreen (BMG)|All participants will consume one serving size (one cup, \~57 gram) of raw BMG daily for 2-week period of time.
219764714|NCT06709014|DRUG|buntanetap/posiphen|30mg capsule by mouth once daily for 18 months
219764715|NCT06709014|DRUG|Placebo|Placebo capsule by mouth once daily for 18 months
219764716|NCT07038798|DEVICE|Brainsway H1-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H1-coil.
218835573|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
218835574|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
218835575|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
218835576|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
218835577|NCT00000788|DRUG|Methadone hydrochloride|
218835578|NCT00000788|DRUG|Fluconazole|
218835579|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
218835580|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
218835581|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
218835582|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
218835583|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
218835584|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
218835585|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
219442856|NCT01176188|OTHER|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
219442857|NCT02511275|PROCEDURE|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
219442858|NCT03048357|DEVICE|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
219442859|NCT03048357|OTHER|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
219442860|NCT03982745|DEVICE|bonfils|bonfils intubation
219442861|NCT00740363|DRUG|sitagliptin|Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
219442862|NCT00740363|DRUG|placebo|No active sitagliptin treatment for 4 weeks
219442863|NCT00225888|BEHAVIORAL|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
219442864|NCT02844673|DRUG|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
219442865|NCT02844673|DEVICE|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
219442866|NCT04262791|DEVICE|Wrist Actigraphy Device|Wrist Actigraphy Device
219442867|NCT04262791|DEVICE|Sleep Headband|Sleep Headband
219442868|NCT03878225|DIETARY_SUPPLEMENT|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
219442869|NCT03878225|OTHER|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
219442870|NCT06425263|BIOLOGICAL|adipose tissue fragmented|harvested from the case form buccal pad of fat
219442871|NCT05597241|DRUG|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
219442872|NCT05597241|DRUG|Placebo|Placebo
219442873|NCT06725264|DRUG|Deucravacitinib|6 mg twice daily
219442874|NCT04184505|DRUG|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
219582746|NCT02731326|DEVICE|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
219582747|NCT02731326|BEHAVIORAL|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
219582748|NCT02272634|DRUG|YPL-001 80 mg|twice daily \[BID\]
219582749|NCT02272634|DRUG|YPL-001 160 mg|twice daily \[BID\]
219582750|NCT02272634|DRUG|Placebo|twice daily \[BID\]
219582751|NCT01716624|DRUG|Oxybutynin|standard oral therapy
219582752|NCT01716624|DRUG|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
219582753|NCT01920607|DEVICE|magnetic anal sphincter|
219582754|NCT01920607|DEVICE|sacral nerve stimulation|
219582755|NCT00751907|DRUG|atorvastatin|40mg daily for 4 months
219582756|NCT00751907|DRUG|Placebo|Matching placebo daily for 4 months
219764717|NCT07038798|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H4-coil.
219764718|NCT07038798|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H7-coil.
219196243|NCT04555278|DEVICE|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
219196244|NCT04555278|DEVICE|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
219582757|NCT05924854|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
219582758|NCT00006243|BIOLOGICAL|tyrosinase peptide|Given SC
219582759|NCT00006243|BIOLOGICAL|MART-1:27-35 peptide vaccine|Given SC
219764719|NCT06728553|DRUG|MTX101|One 2 mg sublingual tablet of MTX101
219196245|NCT04555278|OTHER|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
219196246|NCT05735964|DRUG|Indocyanine green|Intravenous and endoluminal dosing
219764720|NCT06728553|DRUG|Placebo|One sublingual tablet of placebo
219764721|NCT07042347|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
219764722|NCT07042347|DEVICE|Electronic platform|Electronic platform to collect data
219764723|NCT07043426|OTHER|THRIVE-DM|Low-SS and High-SS will be referred by the CHW to appropriate community-based organizations through the THRIVE Directory. High-SS participants will also receive additional support from a patient navigator (PN), who will follow up to facilitate service connection and address barriers to engagement. CHWs and PNs will coordinate care to ensure services are aligned with the patient's assessed needs.
219764724|NCT07043426|OTHER|Standard of care|Standard of care may include support from the primary care team, health related social needs (HRSN) screening via the THRIVE screener, printed resource guides, and referrals to community-based organizations initiated at the discretion of clinic staff using the THRIVE Directory.
219764725|NCT07043647|OTHER|Shamba Maisha|"The Shamba Maisha Intervention has three key parts: A. Agricultural Commodities: KickStart Starter Pump (\~$60 USD, 2.5 Kg), hosing, fertilizer, and seeds. B. Training: We developed model farms near each health facility where didactic and hands on training will be conducted. Our weekly didactic and practical skills training will rotate topics to ensure all participants receive full coverage. Women will be encouraged to invite a key farming support person to trainings. C. Model farm harvest: Participants will harvest vegetables at the model farms for their own consumption until their individual farms start producing in 6-8 weeks to ensure access to a nutritious diet from the time of enrollment."
218835586|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
218835587|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
218835588|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
218835589|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
218835590|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
219196247|NCT05489120|OTHER|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
219196248|NCT05685225|DRUG|Stage 1: Naltrexone/Acetaminophen|Combination
219196249|NCT05685225|DRUG|Stage 1: Naltrexone|Naltrexone alone
219196250|NCT05685225|DRUG|Stage 1: Acetaminophen|Acetaminophen alone
219196251|NCT05685225|DRUG|Stage1: Placebo|Matching placebo
219582760|NCT00006243|BIOLOGICAL|gp100 antigen|Given SC
219582761|NCT00006243|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
219582762|NCT00006243|BIOLOGICAL|sargramostim|Given SC
219582763|NCT00006243|OTHER|laboratory biomarker analysis|Correlative studies
219582764|NCT00460538|DIETARY_SUPPLEMENT|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
219582765|NCT00460538|DIETARY_SUPPLEMENT|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
219582766|NCT01437943|DRUG|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
219764726|NCT07044297|DRUG|MK-8527|Oral tablet
219764727|NCT07044297|DRUG|FTC/TDF|Oral tablet
219764728|NCT07044297|DRUG|Placebo to MK-8527|Placebo tablet matched to MK-8527
219764729|NCT07044297|DRUG|Placebo to FTC/TDF|Placebo tablet matched to FTC/TDF
219764730|NCT06888154|OTHER|compress application with heated saline|Covering intestines with sterile gauze soaked in 36°C heated saline during surgery to prevent drying and reduce infection risk
219582767|NCT01437943|DRUG|Placebo|Take 1 tablet (0 mg) daily for 180 days.
219582768|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
219582769|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
218835591|NCT02473471|DEVICE|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
219764731|NCT07047118|DRUG|JSB462|Administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
219582770|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
219582771|NCT01471119|BIOLOGICAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
219582772|NCT03821870|DIAGNOSTIC_TEST|Inditreat|Tumoroid formation and drug sensitivity analysis
219582773|NCT03821870|DRUG|Experimental drug|Second line treatment based on drug sensitivity analysis
219582774|NCT03667209|OTHER|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
219582775|NCT03667209|OTHER|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
219582776|NCT06160297|PROCEDURE|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking"
219582777|NCT06160297|PROCEDURE|Neuromuscular Exercise|"* Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair"
218835592|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
218835593|NCT01928290|DRUG|Irinotecan|
218835594|NCT01928290|DRUG|Trastuzumab|
218835595|NCT01928290|DRUG|Oxaliplatin|
218835596|NCT01928290|DRUG|Leucovorin|
218835597|NCT01928290|DRUG|Fluorouracil|
218835598|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
219196252|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen high dose|Combination high dose
219196253|NCT05685225|DRUG|Stage 2: Naltrexone/Acetaminophen medium dose|Combination medium dose
219196254|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen low dose|Combination low dose
218835599|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
218835600|NCT01331746|DRUG|Placebo|qds for 7 days
218835601|NCT00006695|DRUG|carmustine|300 mg/m2 IV on Day -6
218835602|NCT00006695|DRUG|cytarabine|100 mg/m2 BID on Days -5 through -2
218835603|NCT00006695|DRUG|etoposide|100 mg/m2 BID on Days -5 through -2
218835604|NCT00006695|DRUG|melphalan|140 mg/m2 IV on Day -1
218835605|NCT00006695|PROCEDURE|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
219196255|NCT05685225|DRUG|Stage 2: Placebo|Matching Placebo
219196256|NCT06819709|OTHER|Botanical Moisturizer + Oral Supplement + Unscented Soap|"The intervention includes 3 products:~1. A botanical moisturizer~2. An oral supplement containing l-histidine (an amino acid) and antioxidants~3. An unscented bar of soap"
219196257|NCT06476704|DRUG|Administration of L-TC|Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
219582778|NCT03112785|DEVICE|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
219582779|NCT04116762|DEVICE|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
219582780|NCT04116762|DEVICE|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
219582781|NCT05669963|DRUG|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
219582782|NCT05828576|DIAGNOSTIC_TEST|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
219582783|NCT02395952|DRUG|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
219582784|NCT02395952|DEVICE|Acuvue Oasys Bandage Contact Lens|
219582785|NCT02395952|DEVICE|Ambiodisk|
219582786|NCT02395952|DEVICE|Prokera|
219764732|NCT07047118|DRUG|AAA617|administered at 7.4 GBq intravenously every 6 weeks for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
218835606|NCT00006695|RADIATION|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
218835607|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
219442875|NCT04184505|DRUG|Standard Chemotherapy|"1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
219442876|NCT04184505|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
219764733|NCT07046819|DRUG|Tirzepatide|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
219764734|NCT07046819|OTHER|Placebo|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
218835608|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
218835609|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
218835610|NCT00003566|PROCEDURE|videothoracoscopy|
218835611|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
218835612|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
219442877|NCT06436820|PROCEDURE|Lumbar puncture|Lumbar puncture procedure performed within a clinical setting
219442878|NCT01531361|DRUG|Crizotinib|Given PO
219442879|NCT01531361|OTHER|Laboratory Biomarker Analysis|Correlative studies
219442880|NCT01531361|OTHER|Pharmacological Study|Correlative studies
219582787|NCT00291980|BIOLOGICAL|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
219582788|NCT00291980|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
219582789|NCT05097313|DIETARY_SUPPLEMENT|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
219764735|NCT01374984|BIOLOGICAL|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
219442881|NCT01531361|DRUG|Sorafenib Tosylate|Given PO
219442882|NCT01531361|DRUG|Vemurafenib|Given PO
219442883|NCT02663180|BEHAVIORAL|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
219442884|NCT02663180|BEHAVIORAL|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
219442885|NCT03043261|BEHAVIORAL|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
219582790|NCT05097313|OTHER|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
219582791|NCT02802774|OTHER|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
219582792|NCT02802774|OTHER|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
219582793|NCT02802774|OTHER|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
219582794|NCT06406218|BEHAVIORAL|Phase I Cardiac Rehabilitation Exercise Training|"A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day.~Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level."
219764736|NCT06733922|DEVICE|ETNATM-ProgMS|To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
219764737|NCT07050264|OTHER|Simulated burn injury via application of absorbent and impermeable material over 60% of the body|Simulated burn injury via application of absorbent and impermeable material over 60% of the body
219442886|NCT06189248|BEHAVIORAL|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
219442887|NCT03385525|DRUG|BIIB074|Administered as specified in the treatment arm
219442888|NCT03385525|DRUG|Valproic Acid|Administered as specified in the treatment arm
219196258|NCT06476704|RADIATION|HFRT alone|"HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week."
219442889|NCT06925802|OTHER|visceral manipulation|The procedure begins with the patient lying in a comfortable supine position to ensure relaxation and access to the abdominal region. Gentle palpation is used to assess tissue mobility and identify any restrictions or tension points. The practitioner applies light, rhythmic pressure to the gastroduodenal junction to stimulate movement and improve coordination between the stomach and duodenum. Attention is then given to the sphincter of Oddi, where soft, sustained pressure is employed to facilitate the release of bile and pancreatic juices, aiding digestive processes. Moving to the duodenojejunal flexure, the therapist uses gentle stretching and mobilization techniques to alleviate any obstructions, promoting smoother passage of intestinal contents. Finally, the sigmoid colon is manipulated with circular and oscillatory pressures to enhance peristalsis and relieve constipation.
219442890|NCT06728800|BEHAVIORAL|FBT 2.0|FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traﬃc Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The ﬁnal product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.
219442891|NCT06728800|BEHAVIORAL|Information-and-referral|Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
219442892|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
219582795|NCT01265810|OTHER|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
219582796|NCT01265810|OTHER|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
219764738|NCT06778382|COMBINATION_PRODUCT|Oligometastasis Treatment|"Oligometastatic Radiotherapy Group: Patients will receive radiotherapy to lung lesions, with the lung metastases outlined as the Gross Tumor Volume (GTV). The prescribed dose will be based on a BED (Biologically Effective Dose) of 72-100 Gy, using either conventional split, macrodissected, or SBRT (Stereotactic Body Radiation Therapy) at the investigator's discretion. No systemic therapy will be administered.~Oligometastatic Radiofrequency Ablation Group: For lesions suitable for radiofrequency ablation, this will be performed in consultation with the Department of Interventional Medicine, considering patient and family preferences. Systemic therapy will not be given.~Oligometastatic Surgery Group: For lesions suitable for surgical resection, patients will undergo surgery after consultation with the Department of Surgery. No systemic therapy will be performed."
219764739|NCT07050017|BEHAVIORAL|The study will investigate how different amounts of protein (0 g, 15 g, and 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.|The study will investigate how different amounts of protein (carbohydrate control drink : 0 g, reguler milk : 15 g, and high-protein milk : 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.
218835613|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
218835614|NCT02059564|DRUG|Placebo|Normal saline solution
218835615|NCT02059564|DRUG|Victoza|doses of 1.8 mg
218835616|NCT01650948|DEVICE|RetnaGene AMD LDT|
218835617|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
218835618|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
219582797|NCT03759119|BEHAVIORAL|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
218835619|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
218835620|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
218835621|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
219442893|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
219442894|NCT01186003|DRUG|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
219442895|NCT04344262|DRUG|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
219582798|NCT03759119|BEHAVIORAL|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
219442896|NCT04344262|DRUG|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
219582799|NCT02664714|OTHER|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
219582800|NCT06532604|DEVICE|Electroretinography (ERG)|ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
219582801|NCT04824248|BEHAVIORAL|Pain Neuroscience Education|Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.
219582802|NCT04824248|BEHAVIORAL|Cognition-targeted exercise therapy|Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.
219582803|NCT04824248|BEHAVIORAL|Behavioral weight reduction program|Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.
219582804|NCT04117360|OTHER|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
219582805|NCT06260332|BEHAVIORAL|Supportive Care (Fitbit)|Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
219582806|NCT05987917|DEVICE|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
219582807|NCT05987917|OTHER|No Treatment|The subject who will serve as control will not be treated with the study device.
219582808|NCT05855486|DEVICE|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
219582809|NCT00043758|DRUG|Tolvaptan|
219582810|NCT06483542|OTHER|bioenergetic balance|Bioenergetic balance is calculated for all patients who had a resting energy expenditure measurement with indirect calorimetry.
219582811|NCT02068521|DRUG|somavaratan|Subcutaneous injection
219582812|NCT06036888|OTHER|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
219582813|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
219764740|NCT05418244|OTHER|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
219764741|NCT05418244|DRUG|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
219764742|NCT05418244|OTHER|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
219764743|NCT03568461|BIOLOGICAL|tisagenlecleucel|Tisagenlecleucel is single infusion.
219764744|NCT06664775|BIOLOGICAL|TachoSil|Adjunct to hemostasis
219442897|NCT03625804|GENETIC|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
219442898|NCT03625804|GENETIC|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
219442899|NCT03625804|GENETIC|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
219764745|NCT06664775|BIOLOGICAL|Surgicel Original|Adjunct to hemostasis
219764746|NCT06852053|DEVICE|Closed-loop Vibro-Tactile Stimulator|Vibro-Tactile stimulation when bradycardia is predicted or predicted.
219442900|NCT00550290|DRUG|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
219442901|NCT00550290|DRUG|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
219764747|NCT06852053|DEVICE|Control|Sham closed-loop vibrotactile stimulator
218835622|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
219442902|NCT01802541|DIETARY_SUPPLEMENT|diacylglycerol oil|
219442903|NCT01802541|DIETARY_SUPPLEMENT|triacylglycerol oil|
219442904|NCT03044470|OTHER|cryotherapy|Role of cryotherapy in reduction of post operative pain
219442905|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
219442906|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
219442907|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
219442908|NCT02293941|DRUG|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
219442909|NCT02293941|DRUG|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
218835623|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
219442910|NCT02293941|DRUG|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
219442911|NCT02293941|DRUG|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
219442912|NCT02109068|BEHAVIORAL|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
219475595|NCT05842122|BEHAVIORAL|Counselor-supported delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
219764748|NCT06760546|DRUG|Setmelanotide|Solution for daily subcutaneous injection
219764749|NCT06760546|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
219764750|NCT06829914|DEVICE|Shockwave Catheter|Shockwave™ IVL + DCB procedure
219764751|NCT06829914|PROCEDURE|CFA Endarterectomy|Standard CFA endarterectomy
219764752|NCT04143243|BEHAVIORAL|ACT on Life|1 day group workshop of ACT plus ERS
219764753|NCT04143243|BEHAVIORAL|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
219764754|NCT07047404|DRUG|BP1.4979|selective dopamine D3 partial agonist
219764755|NCT07047404|DRUG|Placebo|matching placebo of BP1.4979 30mg tablet
219764756|NCT03812653|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
218835624|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
218835625|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
218835626|NCT00255723|DRUG|carboplatin|Given IV
218835627|NCT00255723|DRUG|etoposide|Given IV
218835628|NCT00255723|DRUG|ifosfamide|Given IV
218835629|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
218835630|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
218835631|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
219442913|NCT02109068|BEHAVIORAL|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
219442914|NCT01082341|BIOLOGICAL|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
219442915|NCT00251589|DRUG|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
219442916|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
219442917|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
219442918|NCT00251589|DRUG|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
219442919|NCT00251589|DRUG|erlotinib|erlotinib 150 mg once a day.
219442920|NCT02450500|BEHAVIORAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
219764757|NCT07046845|DIETARY_SUPPLEMENT|Perelel Prenatal Vitamin|Daily Perelel prenatal vitamin supplement throughout pregnancy
219442921|NCT03723499|OTHER|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
219764758|NCT07046845|DIETARY_SUPPLEMENT|Generic Prenatal Vitamin|Daily generic prenatal vitamin supplement throughout pregnancy.
219764759|NCT06891755|DEVICE|Apreo BREATHE Airway Scaffold|The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM).
219764760|NCT06891755|OTHER|Optimal Medical Management (OMM)|Subjects will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.
219764761|NCT06738420|DIETARY_SUPPLEMENT|ABB S3|Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
219764762|NCT06738420|DIETARY_SUPPLEMENT|ABB C22|Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
219764763|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
219764764|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
219764765|NCT06736795|OTHER|Exercise|All participants will be instructed in a progressive Achilles tendon loading exercise program.
218835632|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
219582814|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
219582815|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
218835633|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
218835634|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
218835635|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
218835636|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
218835637|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
218835638|NCT05576324|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
219442922|NCT04963634|OTHER|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
219442923|NCT05289154|OTHER|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
219442924|NCT05289154|BEHAVIORAL|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
219582816|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
219764766|NCT06736795|OTHER|Education|All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.
219442925|NCT02376478|DRUG|TNF-alpha inhibitors|therapy for at least 6 months
219582817|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
219582818|NCT00045175|DRUG|7-hydroxystaurosporine|
219582819|NCT00045175|DRUG|topotecan hydrochloride|
218835639|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
218835640|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
218835641|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
219442926|NCT02376478|DRUG|Alternative/no medication|therapy for at least 6 months or no therapy
219442927|NCT02376478|OTHER|Alternative/no medication|phototherapy for at least 6 months
219442928|NCT02376478|DRUG|Purine/folic acid analogues|therapy for at least 6 months
219582820|NCT06276036|OTHER|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
219764767|NCT06743373|BEHAVIORAL|Cannabis Discontinuation|Cannabis-using participants will participate in an orientation session with a clinician and asked to abstain from cannabis use for four weeks, using established procedures for abstinence monitoring and reinforcement.
218835642|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
218835643|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
218835644|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
218835645|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
218835646|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
218835647|NCT01326806|BEHAVIORAL|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
218835648|NCT01326806|BEHAVIORAL|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
218835649|NCT00536718|GENETIC|gene expression analysis|
218835650|NCT00536718|GENETIC|molecular diagnostic method|
218835651|NCT00536718|GENETIC|polymorphism analysis|
219442929|NCT03954977|DIAGNOSTIC_TEST|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
219442930|NCT01915017|BEHAVIORAL|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
219442931|NCT01915017|BEHAVIORAL|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
219442932|NCT01915017|BEHAVIORAL|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
219442933|NCT01915017|OTHER|Treatment as Usual|Standard medication follow up and limited case management
219442934|NCT00695500|DRUG|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
219442935|NCT00695500|DRUG|Placebo|Placebo tablets, 0 mg per day for 3 weeks
219442936|NCT01085656|DRUG|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
219442937|NCT02078661|DRUG|PG101|A topical gel containing either 1% or 0.25% PG101 active.
219442938|NCT04298931|OTHER|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
219442939|NCT01770756|BEHAVIORAL|Self-Care Training|
219442940|NCT06460831|DEVICE|Microcatheter|The microcatheter group undergoes alcohol ablation using a microcatheter.
219442941|NCT06460831|DEVICE|OTW|The OTW group undergoes alcohol ablation using an OTW balloon.
219442942|NCT03771989|BIOLOGICAL|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
219442943|NCT03771989|OTHER|Saline|The placebo is an injection with saline
219442944|NCT00355329|PROCEDURE|Tongue Acupuncture (Procedure)|
219442945|NCT00868361|DRUG|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
219582821|NCT05789693|BEHAVIORAL|Physical activity changes|Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
219582822|NCT00763438|DRUG|Sertindole|Flexible dose
219582823|NCT04771403|DEVICE|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
219582824|NCT04771403|DEVICE|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
219582825|NCT04771403|DEVICE|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
219582826|NCT00045539|DRUG|leucovorin calcium|
218835652|NCT00536718|GENETIC|protein expression analysis|
218835653|NCT00536718|OTHER|medical chart review|
219442946|NCT06429397|DRUG|Anlotinib and Benmelstobart|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
219442947|NCT06905483|DRUG|Budesonide/Glycopyrronium/Formoterol (BGF)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
219442948|NCT06905483|DRUG|Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
219442949|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE+HAIC."
219582827|NCT00045539|DRUG|methotrexate|
219582828|NCT00045539|DRUG|thiotepa|
219582829|NCT02125253|DRUG|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
219582830|NCT02125253|DRUG|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
219582831|NCT02125253|DRUG|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
219582833|NCT06006897|OTHER|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
219582834|NCT06006897|OTHER|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
218835654|NCT00536718|OTHER|questionnaire administration|
218835655|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
218835656|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
219016351|NCT06709521|DRUG|Iohexol|Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)
219016352|NCT02940301|DRUG|Ibrutinib|Given PO
219016353|NCT02940301|OTHER|Laboratory Biomarker Analysis|Correlative studies
219582835|NCT06973512|DEVICE|deep brain stimulation and stereoelectroencephalography|Deep brain stimulation guided by stereoelectroencephalography
219016354|NCT02940301|BIOLOGICAL|Nivolumab|Given IV
219764768|NCT06743126|BIOLOGICAL|IMA203|one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
218835657|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
219442950|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE."
219442951|NCT03976518|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
219442952|NCT00108836|DRUG|XBD173|
219442953|NCT02345044|DRUG|CS-3150|
219442954|NCT02345044|DRUG|placebo|
219442955|NCT02345044|DRUG|eplerenone|
219442956|NCT04010162|OTHER|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
219442957|NCT06926647|DRUG|Nucleos(t)ide Analogues|Administer NAs \[LAM, ETV, TDF, TAF (TAF preferred for those aged 6 years and older)\] continuously for 48 weeks based on age.
219442958|NCT06926647|DRUG|Interferon alfa|IFNα monotherapy for 48 weeks (select conventional IFNα for ages ≥1 and \<3 years, select PEG-IFNα-2b for ages ≥3 years)
219442959|NCT06926647|DRUG|NAs combined with IFNα|Receive NAs combined with IFNα treatment for 48 weeks.
219442960|NCT06926647|OTHER|comparative observation|Blank control observation for 48 weeks.
219442961|NCT06926647|OTHER|drug withdrawal observation|This group is the drug withdrawal observation group, which will strictly monitor virological indicators and biochemical results, and will reinitiate antiviral treatment if necessary based on antiviral treatment standards and the willingness of the child (or family members)
219442962|NCT03074318|DRUG|Avelumab|Given IV
219442963|NCT03074318|DRUG|Trabectedin|Given IV
219442964|NCT02275520|DEVICE|NIO Adult device|IO access-1
219442965|NCT02275520|DEVICE|Bone Iniection Gun|IO access-2
219442966|NCT02275520|DEVICE|EZ-IO|IO access-3
219442967|NCT02275520|DEVICE|Jamshidi Intraosseous Needle|IO access-4
219442968|NCT02275520|DEVICE|Cook Intraosseous Needle|IO access-5
219442969|NCT00093756|RADIATION|3-dimensional conformal radiation therapy|
219442970|NCT00093756|DRUG|bortezomib|Given IV
219442971|NCT00093756|DRUG|paclitaxel|Given IV
219764769|NCT06743126|BIOLOGICAL|nivolumab plus relatlimab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219442972|NCT00093756|DRUG|carboplatin|Given IV
219442973|NCT00006968|BIOLOGICAL|filgrastim|
219442974|NCT00006968|DRUG|cyclosporine|
219442975|NCT00006968|DRUG|pentostatin|
219442976|NCT00006968|PROCEDURE|allogeneic bone marrow transplantation|
219442977|NCT00006968|PROCEDURE|peripheral blood stem cell transplantation|
219442978|NCT00890669|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
219442979|NCT01627782|DRUG|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
219442980|NCT01627782|DRUG|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
219442981|NCT03573401|COMBINATION_PRODUCT|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
219475596|NCT05842122|BEHAVIORAL|Referral to clinic-based PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) referral to clinic-based PrEP/PEP services~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP referral~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP referral \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
219475597|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
219475598|NCT04784455|DRUG|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
219764770|NCT06743126|BIOLOGICAL|lifileucel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
218835658|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
218835659|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
218835660|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
218835661|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
219582836|NCT06969313|OTHER|Structured Questionnaire on Telemedicine Needs|Participants will complete a structured questionnaire designed to assess their telemedicine needs, expectations, and current knowledge. The questionnaire includes items on demographics, osteoporosis management, and telemedicine service expectations. No clinical or pharmacological intervention will be applied.
219582837|NCT06973083|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
219582838|NCT06973083|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
218835662|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
218835663|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
219442982|NCT03573401|COMBINATION_PRODUCT|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
219442983|NCT04813978|OTHER|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
219442984|NCT05218538|DIAGNOSTIC_TEST|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
219442985|NCT02881671|GENETIC|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
219442986|NCT00360672|DRUG|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
219442987|NCT04359225|OTHER|3D Telemedicine|Telemedicine using 3D broadcast to clinician
219442988|NCT04359225|OTHER|2D Telemedicine|Standard care with 2D telemedicine
219442989|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
219442990|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
219442991|NCT00643448|DRUG|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
219442992|NCT06148350|OTHER|Stroke Rehabilitation|Both the groups received interventions three days/week for 30-60 minutes for four weeks
219582839|NCT05957809|OTHER|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes"
219582840|NCT06968182|DIETARY_SUPPLEMENT|Sodium Chloride|During the examination day after a baseline period, from 11.00 AM to 11.30 AM, a sustained infusion of 1 L isotonic NaCl, was administered.
219582841|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
219582842|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
219582843|NCT05442866|DEVICE|Virtual reality experience for 10 minutes|Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
219582844|NCT06014073|BIOLOGICAL|TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (1 × 10\^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10\^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
219582845|NCT06014073|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
219582846|NCT06014073|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
219582847|NCT04838522|OTHER|No Intervention|This is a non-interventional study.
218835664|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
219442993|NCT01969305|BEHAVIORAL|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
219442994|NCT01969305|BEHAVIORAL|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
219442995|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
219582848|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
219582849|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
219582850|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
219764771|NCT06743126|BIOLOGICAL|nivolumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219764772|NCT06743126|BIOLOGICAL|pembrolizumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
218835665|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
218835666|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
218835667|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
218835668|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
218835669|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
218835670|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
218835671|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
218835672|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
218835673|NCT02901249|DRUG|sertraline|
218835674|NCT02901249|DRUG|Nortriptyline|
219442996|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
219442997|NCT04709874|OTHER|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
219582851|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
219764773|NCT06743126|BIOLOGICAL|ipilimumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219764774|NCT06743126|DRUG|Dacarbazine|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219764775|NCT06743126|DRUG|temozolomide|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219764776|NCT06743126|DRUG|paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
218835675|NCT02901249|DRUG|Lithium|
218835676|NCT04739319|OTHER|N/A Observational study|N/A Observational study
218835677|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
218835678|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
218835679|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
218835680|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
218835681|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
218835682|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
218835683|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
219764777|NCT06743126|DRUG|paclitaxel plus carboplatin|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
218835684|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
219196259|NCT02266719|DEVICE|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
219196260|NCT02266719|DEVICE|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
219442998|NCT04709874|OTHER|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
219442999|NCT00888680|DRUG|BGC20-1531|BGC20-1531 administered orally
219443000|NCT00888680|DRUG|Lactose|Placebo administered orally
219443001|NCT03529890|DRUG|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
219443002|NCT03529890|RADIATION|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
219443003|NCT03529890|PROCEDURE|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
219443004|NCT03396640|PROCEDURE|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
219443005|NCT03396640|PROCEDURE|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
219443006|NCT05166603|OTHER|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
219443007|NCT00435357|DEVICE|mobile-bearing TKA|
219443008|NCT00435357|DEVICE|fixed- bearing TKA|
219443009|NCT00024128|BIOLOGICAL|anti-thymocyte globulin|
219443010|NCT00024128|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219443011|NCT00024128|DRUG|cyclophosphamide|
219443012|NCT00024128|DRUG|cyclosporine|
219443013|NCT00024128|PROCEDURE|peripheral blood stem cell transplantation|
219443014|NCT00024128|RADIATION|radiation therapy|
219443015|NCT02778373|DIETARY_SUPPLEMENT|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
219443016|NCT02778373|DIETARY_SUPPLEMENT|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
219443017|NCT02778373|OTHER|Placebo: Water|
219443018|NCT04505878|DRUG|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
219443019|NCT01562145|PROCEDURE|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
219443020|NCT01111721|BEHAVIORAL|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
219443021|NCT01111721|BEHAVIORAL|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
219443022|NCT06434090|DRUG|Liposomal irinotecan|Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
219443023|NCT06434090|DRUG|Bevacizumab|bevacizumab will be given biweekly at a dose of 5mg/m2
219443024|NCT03048409|OTHER|Enteral Formula|Enteral feeding with a peptide-based formula.
219443025|NCT01734278|OTHER|No intervention|This is a non-interventional study.
219443026|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
219764778|NCT06743126|DRUG|Albumin-Bound Paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
219443027|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
219443028|NCT03157999|BEHAVIORAL|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy."
219443029|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
219443030|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
219582852|NCT01912638|DEVICE|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
219582853|NCT01912638|DRUG|Provisc|Provisc is an cohesive viscoelastic.
219582854|NCT02859948|DRUG|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
219582855|NCT05294419|DEVICE|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
219582856|NCT01986010|BIOLOGICAL|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
218835685|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
219582857|NCT01986010|BIOLOGICAL|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
219582858|NCT01986010|BIOLOGICAL|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
219582859|NCT01986010|BIOLOGICAL|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
219582860|NCT01986010|BIOLOGICAL|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
218835686|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
218835687|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
218835688|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
219582861|NCT01986010|BIOLOGICAL|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
219582862|NCT01986010|OTHER|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
219582863|NCT01986010|BIOLOGICAL|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
219582864|NCT01986010|OTHER|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
219582865|NCT00093600|DRUG|cytarabine|
219582866|NCT00093600|DRUG|daunorubicin hydrochloride|
219764779|NCT06894043|OTHER|Adapted Physical Activity (APA)|The APA intervention will consist of a 2-week running-in period, followed by a period of adapted physical activity (APA) for 8 weeks.
218835689|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
218835690|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
218835691|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
219443031|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
219443032|NCT06819189|DRUG|Ethanol|IV Ethanol
219443033|NCT04623931|OTHER|Quality-of-Life Assessment|Ancillary studies
219443034|NCT04623931|OTHER|Questionnaire Administration|Ancillary studies
219443035|NCT04623931|RADIATION|Radiation Therapy|Undergo radiation therapy
219443036|NCT04623931|DRUG|Temozolomide|Given PO
219443037|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
219443038|NCT00854867|DRUG|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
219582867|NCT00093600|DRUG|midostaurin|
219582868|NCT05832528|OTHER|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
219582869|NCT05456711|DIAGNOSTIC_TEST|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
219582870|NCT02838511|OTHER|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
219764780|NCT06894043|BEHAVIORAL|Compensatory Nutrition (NC)|The Compensatory Nutrition (NC) intervention will consist of a 2-week running-in period, followed by a period of compensated nutrition (NC) for 8 weeks.
219443039|NCT00854867|DRUG|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
219443040|NCT00777257|BIOLOGICAL|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
219443041|NCT00777257|BIOLOGICAL|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
219582871|NCT02838511|OTHER|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
219582872|NCT01335997|DRUG|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
219582873|NCT01335997|DRUG|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
219582874|NCT01335997|DRUG|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
219582875|NCT01335997|DRUG|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
219582876|NCT01335997|DRUG|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
219582877|NCT05666219|DRUG|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
219582878|NCT04368611|PROCEDURE|start with fundus|fundus first dissection then complete cholecystectomy as usual
219582879|NCT04368611|PROCEDURE|calot first dissection|start dissection by calot approach
219582880|NCT03297528|DRUG|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
219582881|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
219582882|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
219582883|NCT03003273|OTHER|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
219582884|NCT03003273|OTHER|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
219582885|NCT03003273|OTHER|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
219582886|NCT03535779|BIOLOGICAL|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
219582887|NCT03535779|BIOLOGICAL|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
219582888|NCT00516009|DRUG|DEXAMETHASONE|
219582889|NCT00516009|OTHER|PLACEBO|
219582890|NCT01066689|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
219582891|NCT01066689|DRUG|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
219582892|NCT06227156|DRUG|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
219764781|NCT07051304|OTHER|numerical rating scale|"The Numerical Rating Scale (NRS) is a standardized, self-reported pain assessment tool in which patients are asked to rate their pain intensity on a scale from 0 to 10.~0 represents no pain~10 represents the worst pain imaginable"
219582893|NCT04315870|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
219582894|NCT01923623|DRUG|Ropivacaine block|
219582895|NCT05863143|BEHAVIORAL|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
219582896|NCT06007131|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
219582897|NCT03206580|OTHER|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
219582898|NCT03206580|OTHER|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
219582899|NCT03386565|DRUG|sodium chloride solution|intraoperative IV infusion
219582900|NCT03386565|DRUG|Lidocaine|intraoperative IV infusion
219582901|NCT02043665|BIOLOGICAL|CVA21/pembrolizumab|
219582902|NCT06077331|DRUG|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
219582903|NCT06077331|DRUG|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
219582904|NCT06077331|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
219582905|NCT04761874|OTHER|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
219582906|NCT00512382|DEVICE|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
219582907|NCT04740814|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
219582908|NCT05435716|DEVICE|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
219582909|NCT05435716|DEVICE|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
219582910|NCT02187510|PROCEDURE|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
219582911|NCT02187510|PROCEDURE|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
219582912|NCT02309775|OTHER|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
219582913|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
219582914|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
219582915|NCT00952536|DIETARY_SUPPLEMENT|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
219582916|NCT03933436|OTHER|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
218835692|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
218835693|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
218835694|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
219582917|NCT03933436|OTHER|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
219582918|NCT00188487|DEVICE|magnetic resonance imaging (MRI) of the thorax|
219582919|NCT05367726|OTHER|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
219582920|NCT05466006|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
219764782|NCT07051304|OTHER|Video-Based Pain Expression Scenarios|"This novel pain assessment method involves showing postoperative patients a set of pre-recorded video scenarios that visually represent different levels of pain intensity. The videos are 8 seconds long and were created using AI-generated scripts and VEO-3 software. Each scenario corresponds to a specific Numerical Rating Scale (NRS) range (1-2, 3-4, 5-6, 7-8, 9-10) and is portrayed by actors matched to the patient's age group and gender (18-44, 45-65, \>65 years; male and female versions available).~Participants are asked to watch the full video set and select the one that best represents their current postoperative pain experience. This intervention is designed to offer a visual and contextual method of pain expression, particularly beneficial for patients who have difficulty understanding or using abstract numerical scales."
219582921|NCT05466006|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
219582922|NCT00545207|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
219582923|NCT00545207|DRUG|Placebo|po monthly for 2 years
219764783|NCT07052630|OTHER|Internet-Based Intervention|Interact with PACT website
219764784|NCT07052630|BEHAVIORAL|Patient Navigation|Receive a patient navigation session
219764785|NCT07052630|OTHER|Best Practice|Receive standard/usual care
219764786|NCT07052630|OTHER|Survey Administration|Ancillary studies
219764787|NCT07052929|GENETIC|ASP2957|Intravenous infusion
219582924|NCT05238818|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
219582925|NCT05167604|DRUG|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
219764788|NCT07052929|DRUG|Methylprednisolone|Intravenous infusion
219764789|NCT07052929|DRUG|Prednisolone|Route of administration based on locally sourced product
219764790|NCT07052929|DRUG|Sirolimus|Route of administration based on locally sourced product
219764791|NCT07054515|DRUG|AZ-3102|Oral dispersible tablets
218835695|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
218835696|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
218835697|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
218835698|NCT01595971|OTHER|usual care|Received the usual care provided
219582926|NCT03982472|OTHER|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
219582927|NCT01844739|DRUG|NVN1000 4% Gel|Applied topically twice daily
219443042|NCT00777257|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
219443043|NCT03023319|DRUG|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
219582928|NCT01844739|DRUG|Vehicle Gel|Applied topically twice daily
219443044|NCT03023319|DRUG|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
219443045|NCT02267902|DRUG|DA-1229|
219582929|NCT03891186|BEHAVIORAL|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
219582930|NCT03891186|OTHER|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
219582931|NCT04489758|DIAGNOSTIC_TEST|X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis|Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
219764792|NCT07054515|DRUG|Placebo|A matching placebo will be administered in the same regimen as the intervention
219582932|NCT04093635|DEVICE|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
219582933|NCT01222286|DRUG|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
219582934|NCT02500641|DRUG|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
219582935|NCT02500641|DRUG|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
219582936|NCT02500641|DRUG|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
219582937|NCT02500641|DRUG|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
219764793|NCT06784336|DRUG|Iron chelation|Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100
219764794|NCT06784336|DRUG|Potato Resistant Starch|Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily
219764795|NCT06788912|BIOLOGICAL|Pembrolizumab (neoadjuvant)|Before surgery neoadjuvant Pembrolizumab 200 mg by intravenous (IV) infusion on day 1 of each 21-day cycle for 4 cycles
219764796|NCT06788912|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
219764797|NCT06788912|DRUG|Gemcitabine|In squamous tumors Gemcitabine 1000 mg/m\^2 by IV infusion on day 1 and day 8 of each 21-day cycle for 4 cycles.
219764798|NCT06788912|DRUG|Pemetrexed|In nonsquamous tumors Pemetrexed 500 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
219764799|NCT06788912|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg by IV infusion on day 1 of each 14-day cycle for up to 6 cycles
219443046|NCT04841681|BEHAVIORAL|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
219764800|NCT06788912|DRUG|H1 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
219764801|NCT06788912|DRUG|H2 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
219764802|NCT06788912|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
219764803|NCT06788912|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication 8 -10 mg before Sacituzumab tirumotecan infusion per approved product label
219764804|NCT06788912|DRUG|Carboplatin|AUC 5 mg/mL min or AUC 6 mg/mL min by IV infusion on day 1 of each 21-day cycle for 4 cycles
219764805|NCT06788912|BIOLOGICAL|Pembrolizumab (adjuvant)|After surgery adjuvant Pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for 13 cycles
219764806|NCT06788912|DRUG|Paclitaxel|Paclitaxel 175 or 200 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles.
219443047|NCT04315298|DRUG|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
219443048|NCT04315298|DRUG|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
219443049|NCT00364468|DRUG|pegfilgrastim|
219764807|NCT06788912|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Administered orally as rescue medication 2-5 mL 4 times daily
219764808|NCT06797635|BIOLOGICAL|Patritumab deruxtecan|Administered via IV infusion as neoadjuvant treatment
219764809|NCT06797635|BIOLOGICAL|Pembrolizumab|Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
219764810|NCT06797635|DRUG|Paclitaxel|Administered via IV infusion as neoadjuvant treatment
218835699|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
218835700|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
219443050|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
219443051|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
219443052|NCT02150785|DRUG|Streptokinase|
218835701|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
218835702|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
218835703|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
219443053|NCT02411994|DRUG|Pyronaridine-artesunate|
219443054|NCT02411994|DRUG|Artemether-lumefantrine combination|
219443055|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
219443056|NCT00131131|BEHAVIORAL|Exercise|
219443057|NCT02113644|OTHER|Lifestyle intervention|
219443058|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
219475599|NCT03572283|DRUG|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
219475600|NCT04631510|DRUG|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
219475601|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
219475602|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
219475603|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
219475604|NCT04150809|OTHER|No intervention|There is no intervention for this study
219475605|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
219475606|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
219475607|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
219475608|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
219475609|NCT06433557|DRUG|Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections|For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
219475610|NCT06545552|DIETARY_SUPPLEMENT|An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast|Hard shell capsule containing 280mg of the oral formulation
219475611|NCT06545552|DIETARY_SUPPLEMENT|Placebo|Hard shell capsule containing maltodextrine
219475612|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
219475613|NCT05479708|DEVICE|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
219475614|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide (NAM)|500 mg a day
219475615|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|1000 mg a day
219475616|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
219475617|NCT05517122|DIETARY_SUPPLEMENT|Microcrystalline cellulose|500 mg a day
219475618|NCT00147290|DEVICE|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
219475619|NCT05792852|BEHAVIORAL|ENGAGE|ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
219475620|NCT05733520|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
219475621|NCT05733520|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
219582938|NCT02500641|DRUG|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
219582939|NCT04694183|DRUG|Camrelizumab|200mg, intravenous drip administration, d1, every 3 weeks.
219582940|NCT04694183|DRUG|S-1|Oral, d1-14, every 3 weeks.
219582941|NCT04694183|DRUG|Oxaliplatin|130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
219443059|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
219582942|NCT04694183|DRUG|Paclitaxel|Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
219582943|NCT03424512|BEHAVIORAL|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
219582944|NCT03989622|OTHER|evaluation of the visual field on the ground|evaluation of the visual field on the ground
219582945|NCT00543946|DRUG|GAP-134|24-Hour IV infusion, SAD
219582946|NCT05066763|OTHER|Non-interventional|non-interventional
219582947|NCT03508414|BEHAVIORAL|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
219582948|NCT03508414|BEHAVIORAL|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
219582949|NCT03508414|BEHAVIORAL|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
218835704|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
219475622|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
219475623|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
219475624|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
219475625|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
219582950|NCT01604590|RADIATION|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
219582951|NCT05555563|OTHER|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
219582952|NCT01031953|DRUG|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
219582953|NCT01031953|DRUG|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
219582954|NCT01031953|OTHER|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
219582955|NCT01031953|PROCEDURE|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
218835705|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
218835706|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
219582956|NCT03744702|DRUG|Ascorbic Acid|Patients will receive IV ascorbic acid.
219582957|NCT01763684|DEVICE|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
219582958|NCT01763684|PROCEDURE|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
219582959|NCT03113513|PROCEDURE|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
219582960|NCT04340609|BIOLOGICAL|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
219582961|NCT03453671|BEHAVIORAL|Mindfulness|Participants will use mindfulness techniques while exercising
219582962|NCT03453671|BEHAVIORAL|Distraction|Participants will distract themselves while exercising
218835707|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
219582963|NCT03453671|BEHAVIORAL|Self-monitoring|Participants will use associative attentional focus while exercising
219582964|NCT04312529|OTHER|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
219443060|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
219582965|NCT00000723|DRUG|Methotrexate|
218835708|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
218835709|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
218835710|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
219016359|NCT03028246|DEVICE|ExAblate 4000 System|Focused ultrasound
219443061|NCT00098865|DRUG|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
219443062|NCT00098865|DRUG|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
219443063|NCT00010244|RADIATION|radiation therapy|
219443064|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
219443065|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
219443066|NCT01183104|DRUG|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
219582966|NCT00000723|DRUG|Leucovorin calcium|
219582967|NCT00000723|DRUG|Zidovudine|
219582968|NCT00000723|DRUG|Dexamethasone|
219582969|NCT01339481|DRUG|abatacept|Intravenous Infusion
219582970|NCT00090181|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
219582971|NCT00090181|DRUG|Comparator: diclofenac / Duration of Treatment: 4 weeks|
219582972|NCT03341819|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
219582973|NCT03341819|PROCEDURE|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
219582974|NCT03043859|BEHAVIORAL|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
219582975|NCT04906083|DRUG|Avatrombopag|"Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d."
219582976|NCT04906083|DRUG|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
219582977|NCT04582461|DEVICE|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
219582978|NCT05739344|BEHAVIORAL|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
219582979|NCT00643565|DRUG|Standard chemotherapy|As prescribed
219764811|NCT06797635|DRUG|Carboplatin|Administered via IV infusion as neoadjuvant treatment
219764812|NCT06797635|DRUG|Doxorubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
219764813|NCT06797635|DRUG|Epirubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
219764814|NCT06797635|DRUG|Cyclophosphamide|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
219764815|NCT06797635|DRUG|Capecitabine|Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
219764816|NCT06797635|DRUG|Olaparib|Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
218835711|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
218835712|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
219443067|NCT01183104|DRUG|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
219443068|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
219443069|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
219443070|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
219443071|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
219443072|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
218835713|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
218835714|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
218835715|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
218835716|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
218835717|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
218835718|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
218835719|NCT05084248|DRUG|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
218835720|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
218835721|NCT02474303|DRUG|Truvada|Demonstration Study
218835722|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
218835723|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
218835724|NCT01728142|DEVICE|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
218835725|NCT01728142|OTHER|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
219016368|NCT05704205|DEVICE|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
219475626|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
219475627|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
218835726|NCT04362306|BEHAVIORAL|Planned Intervention|Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.
218835727|NCT04362306|BEHAVIORAL|No planned intervention|Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
218835728|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
218835729|NCT03089047|BIOLOGICAL|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
218835730|NCT03089047|BIOLOGICAL|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
218835731|NCT03599518|DRUG|DS-1205c|DS-1205c 200 mg capsule for oral administration
218835732|NCT03599518|DRUG|Gefitinib|Gefitinib 250 mg tablet for oral administration
218835733|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
218835734|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
219443073|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
219443074|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
219443075|NCT00297284|DRUG|Modafinil|
219443076|NCT02292615|OTHER|Medical Imaging|
219443077|NCT00364351|DRUG|Vandetanib|once daily oral tablet
219443078|NCT00364351|DRUG|Erlotinib|oral dose
219443079|NCT03812198|DRUG|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
219443080|NCT03812198|DRUG|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
219443081|NCT03812198|DRUG|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
219443082|NCT03812198|DRUG|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
219443083|NCT03812198|DRUG|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
219443084|NCT03812198|DRUG|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
219443085|NCT03812198|OTHER|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
219443086|NCT06424041|OTHER|Fecal Microbiome Transplantation|Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
219443087|NCT06424041|OTHER|Sham Fecal Microbiome Transplantation|Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
219443088|NCT05375656|OTHER|Cross-over study|Traditional Inuit Diet and Western Diet.
219443089|NCT04008667|OTHER|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
219443090|NCT04008667|OTHER|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
219443091|NCT04872504|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
219443092|NCT05977374|OTHER|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
219443093|NCT04120350|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
219443094|NCT04120350|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
219764817|NCT06566742|DRUG|Olutasidenib|Given by PO
219764818|NCT05155332|DRUG|BI 1831169|BI 1831169
219764819|NCT05155332|DRUG|anti-PD-1 antibody|anti-PD-1 antibody
219764820|NCT05334069|OTHER|Questionnaire Administration|Complete questionnaire
219764821|NCT05334069|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
219764822|NCT04111627|BEHAVIORAL|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
218835735|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
218835736|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
219764823|NCT04111627|DRUG|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
218835737|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
219764824|NCT06567743|DRUG|Cretostimogene Grenadenorepvec|Respective Cohort
219764825|NCT06860607|BEHAVIORAL|Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption|This study investigates how different environments and activities affect alcohol consumption and related outcomes.
219764826|NCT06868316|OTHER|Walking|"Weeks 1-2, Sessions 1-4: The first condition will be walking with the speed self-selected based on a comfortable pace to walk for exercise as determined during the Baseline testing session. This speed will be held constant for the 10-minute walking portion prior to each condition but will be progressed for the remaining walking condition sessions (Sessions 2-4). The minimum speed will be limited to 1 mph."
219016369|NCT05704205|COMBINATION_PRODUCT|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
218835738|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
218835739|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
218835740|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
218835741|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
219443095|NCT04120350|DRUG|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
219443096|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
219443097|NCT03613168|DRUG|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
218835742|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
219443098|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
219443099|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
219443100|NCT00858975|PROCEDURE|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
219443101|NCT02145754|OTHER|MKP media|one half of skin specimen was put in MKP media
219443102|NCT02145754|OTHER|BSK-H media|one half of skin specimen was put in BSK-H media
218835743|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
218835744|NCT01927523|OTHER|Match|An intensive math tutoring program.
219443103|NCT05799911|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
219443104|NCT05799911|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
219443105|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
219475628|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
219475629|NCT06071767|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
219475630|NCT06071767|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
219475631|NCT06071767|BIOLOGICAL|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
219475632|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
219475633|NCT06071767|DRUG|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
219475634|NCT06071767|DRUG|GS-5423|Administered via intravenous (IV) infusion at week 7
219475635|NCT06071767|DRUG|GS-2872|Administered via IV infusion at week 7
219475636|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
219475637|NCT06071767|BIOLOGICAL|Placebo|Placebos for vaccines, VES, and bnAbs
219582980|NCT00643565|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
219443106|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
219443107|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
219443108|NCT02282774|DRUG|Sham subtenon block|
219582981|NCT02317614|BEHAVIORAL|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
219582982|NCT06162130|DIAGNOSTIC_TEST|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
219582983|NCT06405217|DRUG|Recombinant Human Thyroid Stimulating Hormone|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
218835745|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
218835746|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
219443109|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
219443110|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
219582984|NCT04763694|DEVICE|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
219443111|NCT03020797|DRUG|Perampanel|
219443112|NCT03020797|DRUG|Placebo Oral Tablet|
219443113|NCT05424744|BEHAVIORAL|Telemedicine Management of Hypertension|Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
219443114|NCT05992935|BIOLOGICAL|mRNA-1403|Sterile liquid for injection
219443115|NCT05992935|BIOLOGICAL|mRNA-1405|Sterile liquid for injection
219582985|NCT00673244|DRUG|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
219582986|NCT01011179|BEHAVIORAL|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
219582987|NCT01011179|BEHAVIORAL|Self-Management|"Adolescents' own best efforts at managing their JIA"
219582988|NCT02667015|BEHAVIORAL|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
218835747|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
218835748|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
218835749|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
218835750|NCT01393795|DRUG|Qutenza|8% patch
218835751|NCT01393795|DRUG|Tegaderm|No active drug
218835752|NCT00511628|DRUG|Risperidone|As prescribed
219443116|NCT05992935|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219443117|NCT01594086|DIETARY_SUPPLEMENT|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
219582989|NCT00669071|DRUG|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
219582990|NCT00669071|DRUG|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
219582991|NCT00556023|DRUG|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
219443118|NCT02958085|DRUG|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
219582992|NCT00360737|BIOLOGICAL|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
219582993|NCT04178161|DEVICE|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
219764827|NCT06868316|OTHER|Rucking|"Weeks 3-4, Session 5-8: The second condition will require participants to wear a standard rucksack equal to 20% of their body weight (minimum ruck weight: 15 pounds, maximum ruck weight: 45 pounds). The initial speed used during this condition will be self-selected based on a comfortable pace to walk for exercise carrying this weight as determined during the Baseline testing session."
218835753|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
218835754|NCT02561481|DRUG|Sulforaphane|See under active arm description
219443119|NCT02958085|DRUG|Placebo|Dosed either once daily or once weekly
219443120|NCT00688623|DRUG|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
219443121|NCT02667236|DRUG|A-101 Solution|Active Drug
219443122|NCT02667236|OTHER|Vehicle Solution|Placebo
219443123|NCT03286634|DRUG|Daunorubicin|Given IV
219443124|NCT03286634|DRUG|Prednisolone|Given PO or IV
219443125|NCT03286634|DRUG|Vincristine|Given IV
219443126|NCT03286634|DRUG|Epirubicin|Given IV
219582994|NCT02593513|DEVICE|Daifert|
219582995|NCT02593513|PROCEDURE|Control Group|Control - Morphological Assessment
219582996|NCT03528473|OTHER|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
219443127|NCT03286634|DRUG|E-coli L-asparaginase|Given IM or IV
219443128|NCT03286634|DRUG|6-Mercaptopurine|Given PO
219443129|NCT03286634|DRUG|Methotrexate|Given IV, PO or IT
219443130|NCT03286634|DRUG|Hydrocortisone|Given IT
219582997|NCT00433316|DRUG|ropivacaine|1% ropivacaine
219582998|NCT00433316|DEVICE|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
219582999|NCT00598624|DRUG|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
219764828|NCT06868316|OTHER|Running|"Weeks 5-6, Sessions 9-12: The final condition is running. The self-selected running pace will be chosen as a pace that the participant can sustain for a leisure run for 20 minutes, as determined at the Baseline testing session. Participants will only run for the 15-minute condition period."
218835755|NCT02561481|DRUG|Placebo|See under placebo arm description
218835756|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
218835757|NCT00148486|DRUG|NS 2330|
218835758|NCT02398136|DRUG|Ketamine|
218835759|NCT02398136|DRUG|Midazolam|
218835760|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
218835761|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
219443131|NCT03286634|DRUG|Cytarabine|Given IV, IT or SC
219443132|NCT03286634|DRUG|Cyclophosphamide|Given IV
219443133|NCT05326906|DRUG|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
219443134|NCT00032305|DRUG|Visilizumab|
219443135|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
219443136|NCT04453618|DRUG|FE-SYHA1402 100mg|in either a fasted state or with a meal
219443137|NCT04453618|DRUG|SYHA1402-25mg|SYHA1402 25mg, oral tablets
219443138|NCT04453618|DRUG|Placebo-25mg|Matching placebo tablets
219443139|NCT04453618|DRUG|SYHA1402-50mg|SYHA1402 50mg, oral tablets
219443140|NCT04453618|DRUG|Placebo-50mg|Matching placebo tablets
219443141|NCT04453618|DRUG|SYHA1402-150mg|SYHA1402 150mg, oral tablets
219443142|NCT04453618|DRUG|Placebo-150mg|Matching placebo tablets
219443143|NCT01945190|DEVICE|Electroacupuncture|
219583000|NCT00110162|DRUG|antiandrogen therapy|
219583001|NCT00110162|DRUG|releasing hormone agonist therapy|
219583002|NCT00110162|PROCEDURE|orchiectomy|
219583003|NCT04962984|PROCEDURE|blood sampling|additional blood sampling for coagulation tests
219583004|NCT01625130|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
219583005|NCT01625130|DIETARY_SUPPLEMENT|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
219443144|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
219443145|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
219583006|NCT02980874|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
219583007|NCT02980874|DRUG|suprachoroidal sham|suprachoroidal sham procedure
219583008|NCT02980874|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
219583009|NCT02251691|DRUG|Advagraf|Compare the drug compliance between once daily or twice daily regimen
219583010|NCT02251691|DRUG|Prograf|Compare the drug compliance between once daily or twice daily regimen
219583011|NCT05303376|BIOLOGICAL|IBIO123|5 or 10 mg
219583012|NCT05303376|OTHER|Placebo|matching placebo
219583013|NCT04298060|DRUG|DAS181|SD (4.5mg/day), HD (9mg/day)
219583014|NCT04298060|DRUG|Placebo|Placebo 0mg/day
219583015|NCT02024373|DRUG|Atorvastatin|20 mg (every evening orally) for 8 weeks
219583016|NCT02024373|DRUG|placebo|20 mg (every evening orally) for 8 weeks
219583017|NCT00539357|DEVICE|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
219583018|NCT02516904|DRUG|CD101 IV|antifungal
219583019|NCT02516904|DRUG|Placebo|normal saline
219583020|NCT05221424|OTHER|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
219583021|NCT00210236|PROCEDURE|Conventional surgery|
219583022|NCT02435836|DRUG|Aripiprazole|
219583023|NCT00002321|DRUG|Aldesleukin|
219583024|NCT02963870|OTHER|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
219583025|NCT05372874|DRUG|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
219583026|NCT02520752|DRUG|INC280|
219443146|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
219443147|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
219583027|NCT02520752|DRUG|Midazolam|
219583028|NCT02520752|DRUG|Caffeine|
219583029|NCT02041091|DRUG|Tabalumab Auto-Injector|Administered SC
219583030|NCT02041091|DRUG|Tabalumab Prefilled Syringe|Administered SC
219583031|NCT01855074|DRUG|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
219583032|NCT00601666|DRUG|Zolpidem|
219583033|NCT01747720|DIETARY_SUPPLEMENT|Vitamin D3|Given orally
219583034|NCT01747720|DIETARY_SUPPLEMENT|Placebo|
219583035|NCT05258331|GENETIC|CT303|"1. Cohort 1 : Single-dose administration, intravenous injection~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg"
219583036|NCT03880773|DEVICE|Stapler|for transection of the pancreas and pancreatic stump treatment
219583037|NCT03880773|DEVICE|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
219583038|NCT02349620|BIOLOGICAL|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
219583039|NCT05697926|OTHER|No intervention|This is a preclinical study. No intervention will be performed.
219583040|NCT05560789|BEHAVIORAL|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
219583041|NCT02724865|DEVICE|Somnodent® (Oral appliance therapy)|
219583042|NCT02724865|DEVICE|Herbst® (Oral appliance therapy)|
219583043|NCT00002040|DRUG|Fluconazole|
219443148|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
219443149|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
219443150|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
219443151|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
219443152|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
219443153|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
219443154|NCT04984876|DRUG|ligelizumab|Subcutaneous injection once every 4 weeks
219443155|NCT04984876|DRUG|Placebo|Subcutaneous injection once every 4 weeks
219443156|NCT05109078|DRUG|[14C]- Rongliflozin|Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
219443157|NCT02444936|DRUG|ZOSTAVAX|Shingles vaccine
219443158|NCT01048255|DRUG|VX-765|300mg Oral Tablet, 900mg TID
219443159|NCT03793283|DEVICE|CSII|Currently receiving CSII therapy during 6 or more months.
219443160|NCT03793283|DRUG|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
219443161|NCT00003613|DRUG|O6-benzylguanine|Given IV
219443162|NCT00003613|DRUG|carmustine|Given topically
219443163|NCT00003613|OTHER|laboratory biomarker analysis|Correlative studies
219443164|NCT00395616|DRUG|Botox (drug)|
219443165|NCT04713670|DRUG|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
219443166|NCT04713670|DRUG|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
219443167|NCT04713670|DRUG|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
219443168|NCT04713670|DRUG|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
219443169|NCT04713670|DRUG|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
219443170|NCT04713670|DRUG|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
219443171|NCT04713670|DRUG|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
219443172|NCT04713670|DRUG|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
219443173|NCT00995813|BIOLOGICAL|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
219443174|NCT00209092|DRUG|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1."
219443175|NCT00209092|DRUG|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
219443176|NCT06177015|DRUG|Darolutamide continuous|standard of care
219443177|NCT06177015|DRUG|Darolutamide intermittent|experimental group
219443178|NCT05399160|BEHAVIORAL|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
219443179|NCT02929368|DEVICE|PICC implantation under fluoroscopy|PICC Catheter implantation
219443180|NCT02929368|DEVICE|PICC Implantation under Sherlock System|PICC Catheter implantation
219443181|NCT00584779|DRUG|Gabapentin|CLcr:14-5 mL/min
219443182|NCT00584779|DRUG|Gabapentin|CLcr: 29-15 mL/min
219443183|NCT00584779|DRUG|Gabapentin|Hemodialysis
219443184|NCT00584779|DRUG|Gabapentin|CLcr: 29-30 mL/min
219443185|NCT03726541|OTHER|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
219443186|NCT01462045|BEHAVIORAL|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
219443187|NCT01193049|DRUG|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
219443188|NCT01193049|DRUG|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
219443189|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
219443190|NCT05187494|DRUG|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
219443191|NCT05187494|DRUG|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
219443192|NCT05187494|DRUG|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
218835762|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
218835763|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
218835764|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
218835765|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
219443193|NCT05187494|DRUG|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
218835766|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
219443194|NCT00076856|DRUG|Temozolomide|
219443195|NCT04737954|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
219443196|NCT04737954|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
219443197|NCT00053105|DRUG|cisplatin|
219443198|NCT00053105|DRUG|cytarabine|
219443199|NCT00053105|DRUG|methylprednisolone|
219443200|NCT00053105|DRUG|pixantrone dimaleate|
219443201|NCT03425851|OTHER|Diapers|Receive 600 diapers.
219443202|NCT03425851|OTHER|Resources of diaper banks|Caregivers will receive resources of diaper banks.
219443203|NCT04506385|DIETARY_SUPPLEMENT|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
219443204|NCT01711437|DEVICE|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
219443205|NCT01711437|DEVICE|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
219443206|NCT01711437|DEVICE|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
219443207|NCT01711437|DEVICE|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
219443208|NCT03581565|OTHER|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
219443209|NCT04761575|OTHER|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
219443210|NCT03793270|DIAGNOSTIC_TEST|for patients and healthy donors|"1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate"
219443211|NCT02462122|DRUG|IDP-118 Lotion|Lotion
219443212|NCT02462122|DRUG|IDP-118 Vehicle Lotion|Lotion
219443213|NCT00741741|DRUG|TMC278|
219583044|NCT04610463|DIAGNOSTIC_TEST|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
219583045|NCT01298401|BIOLOGICAL|ganitumab|
219583046|NCT01298401|DRUG|capecitabine|
219443214|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
219443215|NCT01253967|PROCEDURE|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
219443216|NCT01253967|OTHER|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
219443217|NCT05894486|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
219443218|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
219583047|NCT01298401|DRUG|gemcitabine hydrochloride|
219583048|NCT01298401|RADIATION|3-dimensional conformal radiation therapy|
219583049|NCT05134896|DEVICE|Spatial light modulator|This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
219583050|NCT00026286|DRUG|conjugated estrogens|
219583051|NCT00026286|DRUG|medroxyprogesterone|
219583052|NCT02299817|DRUG|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
219583053|NCT02299817|DRUG|Placebo|Placebo
219583054|NCT02643017|DRUG|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
219583055|NCT02643017|DRUG|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
219764829|NCT06700356|DEVICE|Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring|Epilepsy monitoring unit evaluation will follow standard of care practices for seizure characterization, and antiseizure medications may be reduced to facilitate the recording of seizures. Patient clinical management, and video-EEG interpretation will be completed by the clinical epilepsy monitoring unit team which consists of physicians, nurse practitioners, registered nurses, and in-house 24-hour 7-days-per-week EEG technicians. Continuous full-bandwidth thalamus recordings (250 Hz) will be acquired by the research study team using a standard clinician programmer and telemetry module. Hospital monitoring will last up to 4 days.
219764830|NCT06700356|DEVICE|Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient|Patients will then transition to the ambulatory phase. In the outpatient setting, patients will have constrained ambulatory thalamus recordings using recording parameters determined by Phase 1. DBS treatment stimulation will be programmed in the clinical epilepsy neuromodulation lab using typical high frequency (\>50 Hz) stimulation. High frequency stimulation is the conventional approach to DBS for epilepsy, as was used in the pivotal study leading to premarket approval (SANTE study)2 of anterior nucleus of the thalamus (ANT) DBS for focal epilepsy, which is typical for epilepsy DBS practice3, and several studies of DBS for generalized epilepsy4-6, in a sensing friendly electrode configuration. Patients will keep a detailed seizure diary. Ambulatory thalamus recordings by the DBS system and patient reported seizure diaries will be collected during routine clinical DBS programming visits (q3-9 months).
219764831|NCT06732401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764832|NCT06732401|DRUG|Ceralasertib|Given PO
219764833|NCT06732401|PROCEDURE|Computed Tomography|Undergo CT scan
219764834|NCT06732401|BIOLOGICAL|Durvalumab|Given IV
219443219|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
219764835|NCT06732401|PROCEDURE|Echocardiography Test|Undergo echocardiography
219764836|NCT06741228|OTHER|Placebo|A substance that is designed to have no therapeutic value
219443220|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
219443221|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
219443222|NCT04722289|BEHAVIORAL|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
219443223|NCT03928509|OTHER|No intervention|No intervention
219443224|NCT02828644|DEVICE|EVO|videogame-like digital therapy
219583056|NCT01150890|BIOLOGICAL|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
219583057|NCT01150890|DRUG|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
219583058|NCT02715206|BEHAVIORAL|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
219583059|NCT02715206|BEHAVIORAL|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
219583060|NCT02715206|BEHAVIORAL|control|control group continues to teach whatever prevention curriculum they were using prior to study
219583061|NCT01859806|PROCEDURE|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
219583062|NCT01859806|PROCEDURE|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
219583063|NCT02647736|OTHER|Hypertonic saline infusion|
219443225|NCT01446549|OTHER|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
219443226|NCT01446549|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation implantation
219443227|NCT00611416|DIETARY_SUPPLEMENT|green tea|different catechin combinations
219443228|NCT00611416|DIETARY_SUPPLEMENT|Mix of catechins and caffeine|3 tablet a day
219443229|NCT00611416|DIETARY_SUPPLEMENT|EGCG|3 tablets a day
219583064|NCT00922987|DRUG|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
219764837|NCT06741228|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
219583065|NCT06213870|DIAGNOSTIC_TEST|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
219764838|NCT06887647|OTHER|Physical Therapy Using Hippotherapy and the Equine Environment|"Subjects will be mounted on a horse for 15-30 minutes. Therapeutic activities will include movements like reaching, throwing, and bilateral coordination tasks in addition to assuming various positions on the horse during equine movement, per the tolerance of individual participants. Remaining treatment time will involve participation-based functional motor activities in the equine environment, such as feeding and grooming horses.~Treatment will include the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities with equines to guide practice of functional motor skills.~3. Design therapeutic activities with the equines to practice participation (ie. activities involved in life situations).~4. Utilize the presence of the equines to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use the equines as positive reinforcement)"
219764839|NCT06887647|OTHER|Standard Play-Based Physical Therapy|"The treatment will focus on encouragement of functional play activities, such as reaching, throwing, and catching games. Treatment will incorporate the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities using play and games to guide practice of functional motor skills.~3. Design therapeutic activities with play and games to practice participation (ie. activities involved in life situations).~4. Utilize play and games to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use play and games as positive reinforcement)"
219443230|NCT00611416|DIETARY_SUPPLEMENT|EGC|3 tablets a day
219583066|NCT01547364|DRUG|Saline|Injection of 10 ml of normal saline into the caudal epidural space
219583067|NCT01547364|DRUG|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
219583068|NCT05163197|PROCEDURE|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
219764840|NCT05592938|RADIATION|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
219764841|NCT06752928|DEVICE|Dexcom G7 rtCGM|The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 CGM System or G7) is a glucose monitoring system that continuously measures glucose in the interstitial fluid. It aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments
218835767|NCT06305780|DRUG|IVIG + Coordinated Care|Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
218835768|NCT06305780|DRUG|IVIG Placebo + Coordinated Care|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.~Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator."
218835769|NCT06305780|DRUG|Ivabradine + Coordinated Care|Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
218835770|NCT06305780|DRUG|Ivabradine Placebo + Coordinated Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator."
218835771|NCT06305780|DRUG|IVIG + Usual Care|Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
218835772|NCT06305780|DRUG|IVIG Placebo + Usual Care|"Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.~Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration."
219443231|NCT00611416|DIETARY_SUPPLEMENT|Caffeine|3 tablets a day
219443232|NCT00611416|DIETARY_SUPPLEMENT|Placebo|3 tablets a day
219475638|NCT06467981|OTHER|Retrospective study|The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.
219475639|NCT05329961|DRUG|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
219475640|NCT05355545|BEHAVIORAL|Virtually supervised exercise|Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
219583069|NCT00446199|DRUG|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
219583070|NCT00446199|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
219583071|NCT00446199|DRUG|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
219583072|NCT00446199|DRUG|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
219583073|NCT02289859|PROCEDURE|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
219583074|NCT02289859|PROCEDURE|Wound Closure without Undermining|One side of the wound will remain un-undermined.
219764842|NCT06752928|DIAGNOSTIC_TEST|Capillary Blood glucose Testing (POC)|POC glucose meters measure whole blood and convert the results to plasma glucose concentrations, which is the standardized form used in clinical practice.
219764843|NCT04569591|DRUG|Acthrel|Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
219443233|NCT05974891|OTHER|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
219443234|NCT02461849|DRUG|Imatinib|Imatinib 400mg qd daily
219443235|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
219443236|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
218835773|NCT06305780|DRUG|Ivabradine + Usual Care|Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
219443237|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
218835774|NCT06305780|DRUG|Ivabradine Placebo + Usual Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration."
218835775|NCT00402129|PROCEDURE|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
219443238|NCT03517735|DEVICE|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
219443239|NCT03517735|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
219443240|NCT03517735|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
219443241|NCT02493335|DRUG|Budesonide 0.5mg orodispersible tablet twice daily|
219443242|NCT02493335|DRUG|Budesonide 1mg orodispersible tablet twice daily|
219764844|NCT06124157|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
218835776|NCT05287243|OTHER|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
219443243|NCT02493335|DRUG|Placebo orodispersible tablet twice daily|
219443244|NCT03042585|RADIATION|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
219443245|NCT01392014|DRUG|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
219583075|NCT03120533|DRUG|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
219583076|NCT03120533|DRUG|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
219583077|NCT02381951|DEVICE|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
219764845|NCT06124157|BIOLOGICAL|Blinatumomab|Receive IV
219764846|NCT06124157|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219764847|NCT06124157|DRUG|Calaspargase Pegol|Receive IV
219764848|NCT06124157|DRUG|Cyclophosphamide|Receive IV
219764849|NCT06124157|DRUG|Cytarabine|Receive IV or subcutaneously
219764850|NCT06124157|DRUG|Dasatinib|Receive PO
219764851|NCT06124157|DRUG|Daunorubicin|Receive IV
219764852|NCT06124157|DRUG|Doxorubicin|Receive IV
218835777|NCT00577694|DRUG|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
218835778|NCT00577694|DRUG|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
219764853|NCT06124157|PROCEDURE|Echocardiography Test|Undergo ECHO
219764854|NCT06124157|DRUG|Imatinib|Given PO
219764855|NCT06124157|DRUG|Leucovorin|Receive PO or IV
219764856|NCT06124157|DRUG|Mercaptopurine|Receive PO
219764857|NCT06124157|DRUG|Methotrexate|Receive IT or IV or PO
219764858|NCT06124157|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219583078|NCT01822574|PROCEDURE|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
219583079|NCT01822574|PROCEDURE|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
219583080|NCT01822574|PROCEDURE|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
219583081|NCT03071094|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
219764859|NCT06124157|DRUG|Pegaspargase|Receive IV or intramuscularly
219443246|NCT01392014|DRUG|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
219443247|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
219583082|NCT03071094|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
219583083|NCT02074592|BEHAVIORAL|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
219764860|NCT06124157|DRUG|Prednisolone|Receive PO
219764861|NCT06124157|DRUG|Prednisone|Receive PO
219583084|NCT02074592|BEHAVIORAL|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
219583085|NCT02312063|DRUG|Sitagliptin|
219764862|NCT06124157|RADIATION|Radiation Therapy|Undergo radiation therapy
219443248|NCT00071604|BEHAVIORAL|Friendly Support Group|
219443249|NCT02436915|OTHER|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
219764863|NCT06124157|DRUG|Thioguanine|Receive PO
219764864|NCT06124157|DRUG|Vincristine|Receive IV
219764865|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
219764866|NCT06752096|PROCEDURE|cerebral angiography, arterial embolization, thrombectomy|This intervention will be conducted using robotic navigation.
219764867|NCT06752096|DEVICE|Cerebral angiogram using robotic device|Diagnostic cerebral angiogram will be performed using a robot to navigate guidewires and catheters to target vessels.
219764868|NCT06752096|DEVICE|Meningioma embolization using robotic device.|Meningioma tumors will be embolized using a robot to navigate catheters and wires to the target vessels to the tumor.
219764869|NCT06752096|DEVICE|Mechanical thrombectomy for stroke using a robotic device.|Mechanical thrombectomy procedure will use a robot to navigate catheters, guidewires, and thrombectomy devices to the target vessel.
219764870|NCT07060807|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
219764871|NCT07060807|DRUG|Paclitaxel|Administered via IV infusion
219764872|NCT07060807|DRUG|Nab-paclitaxel|Administered via IV infusion
219764873|NCT07060807|DRUG|Capecitabine|Administered via oral tablets
219764874|NCT07060807|DRUG|Liposomal doxorubicin|Administered via IV infusion
219764875|NCT07060807|BIOLOGICAL|Trastuzumab deruxtecan|Administered via IV infusion
219764876|NCT06898606|DRUG|Psilocybin and Psilocyn|Oral dose administered via Psilocybe mushrooms material batch-assayed by LC-MS to standardize psilocybin and psilocyn content.
219764877|NCT06898606|DRUG|Placebo|Matching capsules, once daily for 4 weeks (-14 to +14 days).
219764878|NCT06898606|BEHAVIORAL|Psychotherapy-assisted session|Same manualized procedures as Arm 1.
219764879|NCT06898606|DRUG|Fluoxetine|20 mg/day for 4 weeks (-14 to +14 days relative to dosing day).
219764880|NCT06899061|DRUG|Saruparib|"Module 1:~Period 2: participants will receive saruparib orally once daily from Day 1 to Day 9. On Day 5 saruparib will be administered orally in combination with the cocktail of substrates.~Period 3: participants will receive saruparib orally once daily for up to 3 cycles of 28 days each.~Module 2:~Period 1 and Period 2: participants will receive a single oral dose of DC or RC saruparib.~Period 3: participants will receive an oral dose of rabeprazole twice daily from Day 1 to 3, and a single oral dose of rabeprazole prior to DC saruparib on Day 4.~Period 4: participants will receive an oral dose of RC saruparib daily for 3 cycles."
219443250|NCT02436915|OTHER|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
219443251|NCT05120375|DRUG|BAT6021|Ⅳ infusions
219443252|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
219583086|NCT02312063|DRUG|Glimepiride|
219443253|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
218835779|NCT05043948|DIAGNOSTIC_TEST|Blood samples|for evaluation of the genome-wide association study
219443254|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
219583087|NCT00239655|DRUG|MK0812|
219583088|NCT05137470|OTHER|This is an observational study|This is an observational study
219583089|NCT01079832|RADIATION|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
219583090|NCT01079832|PROCEDURE|quality-of-life assessment|Ancillary studies
219583091|NCT02053675|DRUG|Vasopressin infusion|
219583092|NCT06077487|DRUG|Ketamine|Given orally (PO)
219443255|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
219443256|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
219583093|NCT06077487|DRUG|Ketamine Injectable Product|Given intramuscularly (IM)
219583094|NCT06077487|BEHAVIORAL|Meaning and Purpose therapy|In-person sessions
219583095|NCT06077487|OTHER|Placebo|Given PO or IM
219583096|NCT06077487|OTHER|Questionnaires|Questionnaires will be given over the course of the study
219583097|NCT06214988|PROCEDURE|selective approach defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
219583098|NCT05382221|OTHER|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
219443257|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
219443258|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
219443259|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
219443260|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
219583099|NCT05382221|OTHER|Standard Care|one offer of cessation treatment annually
219583100|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
219583101|NCT06299956|OTHER|Supervised exercise therapy|Walking on a treadmill at increasing elevation and pace.
219583102|NCT04267302|OTHER|Baby Bouncer|Fischer Price baby bouncer.
219583103|NCT04267302|OTHER|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
219583104|NCT04267302|OTHER|Baby Carrier|Ergobaby Baby carrier.
219583105|NCT00759902|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
219583106|NCT00759902|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
219583107|NCT02609412|OTHER|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
219583108|NCT02609412|OTHER|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
218835780|NCT03091088|OTHER|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
218835781|NCT03091088|OTHER|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
218835782|NCT00429182|DRUG|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
219583109|NCT02609412|DEVICE|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
219583110|NCT03722095|DEVICE|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
219583111|NCT03722095|DEVICE|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
219583112|NCT03722095|DEVICE|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
219583113|NCT05989724|DRUG|SON-DP|Solution for IV administration
219583114|NCT01754116|DRUG|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
219583115|NCT01754116|DRUG|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
219583116|NCT01754116|DRUG|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
219583117|NCT01754116|DRUG|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
219583118|NCT01754116|DRUG|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
219583119|NCT02128217|DRUG|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
219583120|NCT02128217|DRUG|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
219443261|NCT05595213|DEVICE|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
219764881|NCT06899061|DRUG|Digoxin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
219443262|NCT05595213|DEVICE|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
219443263|NCT05595213|OTHER|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
219583121|NCT02128217|DRUG|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
219583122|NCT02327117|DRUG|Tranexamic Acid|
219583123|NCT02327117|DRUG|Normal saline|
219583124|NCT05071313|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as single IM injection.
219764882|NCT06899061|DRUG|Furosemide|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
219764883|NCT06899061|DRUG|Metformin Hydrochloride|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
219764884|NCT06899061|DRUG|Rosuvastatin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
219764885|NCT06899061|DRUG|Rabeprazole|Period 3: Participants will receive two doses of rabeprazole per day from Day 1 to 3. On Day 4, participants will receive a dose of rabeprazole followed by DC saruparib.
219764886|NCT05109234|DRUG|Brivaracetam Film-coated tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses."
219764887|NCT05109234|DRUG|Brivaracetam oral solution|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses."
219764888|NCT06721156|DRUG|MK-1167|MK-1167 oral capsule
219443264|NCT02437968|BEHAVIORAL|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
219443265|NCT03889522|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition \[47, 49\]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
219443266|NCT03889522|DIAGNOSTIC_TEST|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
219443267|NCT03889522|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
219443268|NCT03856086|BEHAVIORAL|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
219764889|NCT06721156|DRUG|Placebo|Placebo oral capsule
219764890|NCT06841055|DRUG|Pumitamig|Intravenous infusion
219764891|NCT06841055|DRUG|Docetaxel|Intravenous infusion
219764892|NCT06841614|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
219764893|NCT06841614|BIOLOGICAL|Inmazeb|Inmazeb (REGN-EB3), developed by Regeneron, is a cocktail of 3 neutralising humanised mAbs directed against 3 epitopes of the EBOV GP (atoltivimab, maftivimab and odesivimab). It is indicated for the treatment of EVD in adult patients (including pregnant women) and in children, including neonates born to mothers with confirmed EVD.
218835783|NCT00429182|DRUG|Cyclophosphamide|1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
218835784|NCT00429182|DRUG|Thiotepa|120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
219443269|NCT03856086|BEHAVIORAL|NCCN Problem List|NCCN Distress Thermometer
219443270|NCT03856086|BEHAVIORAL|FACT-GP|Greater overall quality of life
219443271|NCT03856086|BEHAVIORAL|HADS|Lower anxiety and depression
219443272|NCT03856086|BEHAVIORAL|CSS-CG|web-based CSS-CG
219583125|NCT05071313|BIOLOGICAL|Quadrivalent High-dose Influenza Vaccine|Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.
219583126|NCT05071313|BIOLOGICAL|Placebo|Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
219583127|NCT03911050|DIETARY_SUPPLEMENT|Apple consumption|Apple blends (600 g) One single dose
219583128|NCT03911050|DIETARY_SUPPLEMENT|Control group|Breakfast without any apple-related products
219583129|NCT02733081|PROCEDURE|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
219583130|NCT06074081|OTHER|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
219583131|NCT06074081|OTHER|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
219764894|NCT06814145|BIOLOGICAL|Sotatercept|subcutaneous injection
219764895|NCT06872645|DRUG|5% Dextrose/Water|Patients will be randomized to undergo up to two-hour dwell with 5% dextrose in sterile water for 5 days
219443273|NCT05572541|DIAGNOSTIC_TEST|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
218835785|NCT00429182|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0.
218835786|NCT04348071|DRUG|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
218835787|NCT01667250|DEVICE|GammaCore Active Device|
218835788|NCT01667250|DEVICE|GammaCore Sham Device|
218835789|NCT03902795|DIAGNOSTIC_TEST|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
218835790|NCT03902795|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
218835791|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
219016378|NCT00854698|OTHER|exercise training|subjects are asked to exercise 20 or 30 minutes.
219443274|NCT01117181|DRUG|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
219443275|NCT01117181|DRUG|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
219443276|NCT01117181|OTHER|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
219443277|NCT04976309|DRUG|Lu AG09222|Single dose
219443278|NCT04976309|DRUG|Placebo|Single dose
219443279|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~\- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
219443280|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
219443281|NCT05270967|DIAGNOSTIC_TEST|F-18 FDG PET/CT imaging|Oncological imaging
219443282|NCT05270967|BIOLOGICAL|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
219443283|NCT01518309|DRUG|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
219443284|NCT02647892|DRUG|lidocaine|local anesthesia
219443285|NCT02647892|DRUG|sodium bicarbonate|additional drug added to lidocaine
219443286|NCT05431738|DEVICE|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
219443287|NCT04548479|DEVICE|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
219443288|NCT02855086|BIOLOGICAL|Cetuximab|Administered intravenously (IV)
219443289|NCT02855086|DRUG|Cetuximab-IRDye 800CW|Administered intravenously (IV)
219443290|NCT02855086|PROCEDURE|Tumor resection|Standard of care treatment
219443291|NCT02283372|DRUG|nab-Paclitaxel|
219443292|NCT02283372|DRUG|Gemcitabine|
219443293|NCT02283372|RADIATION|Intensity modulated radiation|
219443294|NCT02579863|BIOLOGICAL|Pembrolizumab|IV infusion
219443295|NCT02579863|DRUG|Lenalidomide|oral capsules
219443296|NCT02579863|DRUG|Dexamethasone|oral tablets
219443297|NCT06188728|DIETARY_SUPPLEMENT|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
219443298|NCT06188728|BEHAVIORAL|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
219443299|NCT06188728|COMBINATION_PRODUCT|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
219443300|NCT06188728|OTHER|Control|No intervention
219443301|NCT04344015|OTHER|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
219443302|NCT05608200|DRUG|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
219443303|NCT05608200|DRUG|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
219443304|NCT02209259|OTHER|PROMIS Upper Extremity Function|
219443305|NCT02209259|OTHER|Pain intensity|
219443306|NCT02209259|OTHER|PROMIS depression|
219443307|NCT02209259|OTHER|Positive affect negative affect scale (PANAS)|
219443308|NCT02209259|OTHER|standard PCS|
219196261|NCT02266719|DEVICE|Arch cohort|Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
219764896|NCT06872645|DRUG|1.5% standard PD fluid|Patients will be randomized to undergo up to two-hour dwell with 1.5% standard PD fluid for 5 days
219443309|NCT02209259|OTHER|positively-adjusted version of the PCS|
219764897|NCT06795048|DRUG|Faricimab|Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
219764898|NCT06126276|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219764899|NCT06126276|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219764900|NCT06126276|PROCEDURE|Computed Tomography|Undergo CT scan
219443310|NCT06379880|DEVICE|CONTINUUM+ CONNECT remote monitoring|"CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group."
219764901|NCT06126276|PROCEDURE|Echocardiography Test|Undergo ECHO
219764902|NCT06126276|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764903|NCT06126276|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219764904|NCT06126276|DRUG|Neratinib Maleate|Given PO
219764905|NCT06126276|DRUG|Palbociclib|Given PO
219764906|NCT04958239|DRUG|BI 765179|BI 765179
218835792|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
219443311|NCT03878160|OTHER|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
219443312|NCT04461613|OTHER|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
219443313|NCT04461613|OTHER|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
219443314|NCT00032110|DRUG|erlotinib hydrochloride|Given orally
219443315|NCT00032110|OTHER|pharmacological study|Correlative studies
219443316|NCT00032110|OTHER|laboratory biomarker analysis|Correlative studies
218835793|NCT04530305|DRUG|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
218835794|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
218835795|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
219443317|NCT01679704|DIETARY_SUPPLEMENT|Food products|
219196262|NCT06818253|DIETARY_SUPPLEMENT|The Effect of Glycerol Supplements|The main factor that distinguishes this intervention is first of all the dosage of the dietary supplement and the effects on the variables to be analyzed related to physical performance.
219443318|NCT06099028|OTHER|no intervention|no intervention
219443319|NCT01571167|DRUG|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
219764907|NCT04958239|DRUG|Ezabenlimab|Ezabenlimab
219764908|NCT04958239|DRUG|Pembrolizumab|Pembrolizumab
219764909|NCT04548752|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219764910|NCT04548752|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764911|NCT04548752|PROCEDURE|Computed Tomography|Undergo CT scan
219764912|NCT04548752|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764913|NCT04548752|DRUG|Olaparib|Given PO
219764914|NCT04548752|BIOLOGICAL|Pembrolizumab|Given IV
219764915|NCT06347133|DRUG|Plozasiran Injection|ARO-APOC3 Injection
218835796|NCT00389376|DRUG|Placebo|Placebo
218835797|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
218835798|NCT00389376|DRUG|Silymarin|280 mg single dose
218835799|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
219764916|NCT06347133|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219764917|NCT06241573|DRUG|Spesolimab|Spesolimab
219764918|NCT04370795|DRUG|Sirolimus|Post transplant immunosuppressant drug
219764919|NCT04370795|DRUG|Busulfan|Conditioning drug
219764920|NCT04370795|DRUG|Horse -Anti-thymocyte|Immune suppression conditioning drug
219764921|NCT04370795|DRUG|G-CSF|Used to prevent infection and neutropenic fevers caused by chemotherapy
219764922|NCT04370795|RADIATION|Total Body Irradiation (TBI)|Conditioning (only patients in Group 1 will receive TBI)
219764923|NCT06423430|DEVICE|Sham-stimulation|Sham-stimulation
219764924|NCT06423430|DEVICE|Active-stimulation|Active DBS
219764925|NCT06810310|DRUG|Psilocybin (high dose)|PEX010 is the psilocybin produced by Filament
219764926|NCT06810310|DRUG|psilocybin (low dose)|1mg psilocybin, produced by Filament
218835800|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
218835801|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
219196263|NCT06816849|OTHER|Recommended water intake|All participants received personalized consultation from a dietitian on adequate fluid intake and the selection of drinks based on dietary guidelines. They were required to follow the intervention for four months.
219196264|NCT06817343|BIOLOGICAL|Aflibercept (2.0 mg)|PRN IVT Aflibercept
219443320|NCT01571167|DRUG|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
219443321|NCT01571167|DRUG|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
219443322|NCT02000544|DEVICE|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
219443323|NCT00171613|DRUG|Octreotide|
219443324|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
219443325|NCT02368730|DRUG|desmopressin|
219443326|NCT02672150|BEHAVIORAL|Core|
219443327|NCT02672150|BEHAVIORAL|Enhanced|
219443328|NCT04179760|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
219443329|NCT04179760|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
219443330|NCT01942408|PROCEDURE|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
219443331|NCT05386004|OTHER|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
219443332|NCT06317441|DIETARY_SUPPLEMENT|Probiotic|The intervention consists of a probiotic either with a low or high dosage
219443333|NCT00054756|DRUG|TRH (Thyrotropin Releasing Hormone)|
219443334|NCT00589602|PROCEDURE|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
219443335|NCT00589602|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
219443336|NCT00589602|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
219443337|NCT00589602|RADIATION|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
219443338|NCT05525065|DRUG|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
219443339|NCT00762528|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
219443340|NCT00762528|DRUG|Sodium monofluorophosphate toothpaste|Twice daily usage
219443341|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
219443342|NCT04634318|OTHER|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
219443343|NCT04634318|OTHER|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
219443344|NCT03432208|PROCEDURE|GI consult|
219443345|NCT04781725|DRUG|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
219443346|NCT04781725|OTHER|Saline injection|Standard 0.9 % NaCl Normal Saline
219443347|NCT01174589|OTHER|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
219443348|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
219443349|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
219443350|NCT04974944|DRUG|Camrelizumab|IV injection
219443351|NCT04974944|DRUG|Apatinib|Oral
218835802|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
218835803|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
218835804|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
218835805|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
218835806|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
219443352|NCT04974944|DRUG|Paclitaxel|IV injection
218835807|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
218835808|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
218835809|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
219443353|NCT04974944|DRUG|Cisplatin|IV infusion
219443354|NCT04974944|DRUG|Carboplatin|IV infusion
219443355|NCT04974944|DRUG|Bevacizumab|IV infusion
218835810|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
219443356|NCT05393544|BEHAVIORAL|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
219443357|NCT04210232|DEVICE|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
219443358|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
219443359|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
219443360|NCT03986476|DIETARY_SUPPLEMENT|Probiotics|5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
219443361|NCT03986476|OTHER|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
219443362|NCT02658149|DRUG|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
219443363|NCT02658149|DRUG|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
219443364|NCT02658149|DRUG|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
219443365|NCT02658149|DRUG|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
219443366|NCT02658149|DRUG|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
218835811|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
218835812|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
219016379|NCT00854698|OTHER|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
219443367|NCT00438724|BEHAVIORAL|Information, counseling and support|
219443368|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
219443369|NCT00478595|DRUG|Rimonabant|Tablet, oral administration
219443370|NCT00478595|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219443371|NCT00478595|DRUG|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
219443372|NCT01525745|RADIATION|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
219443373|NCT01525745|RADIATION|External Beam Radiation Therapy|10 consecutive days of standard radiation
219443374|NCT01037751|BEHAVIORAL|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
219443375|NCT01037751|BEHAVIORAL|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
219443376|NCT04709250|PROCEDURE|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
219443377|NCT04709250|PROCEDURE|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
219443378|NCT04709250|DRUG|bupivacaine|bupivacaine
219443379|NCT02869685|RADIATION|radiotherapy|radiotherapy
219443380|NCT03456414|OTHER|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
219443381|NCT04358991|DRUG|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
219443382|NCT01329068|BEHAVIORAL|individual consult|regular individual consultations
219443383|NCT01329068|BEHAVIORAL|group medical consult|group medical consult
219443384|NCT00794469|OTHER|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
219443385|NCT04481945|DRUG|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
219443386|NCT02163668|OTHER|Yoga Group|8 months of Yoga training
219443387|NCT01397513|DRUG|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
219443388|NCT02458352|DEVICE|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
219443389|NCT02458352|DEVICE|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
219443390|NCT04331210|DRUG|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
219583132|NCT01211418|BEHAVIORAL|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
219016381|NCT06155500|BIOLOGICAL|OTQ923|There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
219016382|NCT06102304|DEVICE|Focused Extracorpeal Shock wave|Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.
219016383|NCT06102304|DEVICE|Sham Extracorpeal shock wave|(EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
219583133|NCT01211418|BEHAVIORAL|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
219583134|NCT00057993|BIOLOGICAL|trastuzumab|
219583135|NCT00057993|DRUG|exemestane|
219583136|NCT00304226|DRUG|valsartan|
219764927|NCT06753123|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
219583137|NCT00304226|DRUG|amlodipine|
219583138|NCT04438226|PROCEDURE|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
219583139|NCT03107026|DRUG|dasotraline 4mg|dasotraline 4mg tablet once daily
219583140|NCT03107026|DRUG|dasotraline 6mg|dasotraline 6mg tablet once daily
219583141|NCT03107026|DRUG|Placebo|Placebo tablet once daily
219583142|NCT02267668|BEHAVIORAL|STEP|Physical therapists guide participants through novel set of assigned exercises
219764928|NCT06872125|DRUG|zorevunersen|Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg on Day 169 and Day 281.
219764929|NCT06872125|OTHER|Sham Comparator|Sham group will not have drug administered. Sham group will have a lumbar puncture with CSF withdrawal.
219764930|NCT06172296|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219016397|NCT05249998|OTHER|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
219443391|NCT05181215|DRUG|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
219443392|NCT05181215|DRUG|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
219443393|NCT06179108|DRUG|LB-102|LB-102 is a dopamine D2/3 and 5HT7 antagonist.
219443394|NCT04228107|DEVICE|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
219443395|NCT03209011|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
219583143|NCT02267668|BEHAVIORAL|Control|Participants self-guide through standard exercises
219583144|NCT04365218|DRUG|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
219583145|NCT04365218|DRUG|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
219443396|NCT00668850|DRUG|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
219583146|NCT05522985|DRUG|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
219583147|NCT02049450|DRUG|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
219583148|NCT04331938|DRUG|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
219583149|NCT03771248|DEVICE|peek telescopic partial denture|removable partial denture
219583150|NCT00002865|BIOLOGICAL|filgrastim|
219443397|NCT00668850|DRUG|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
219443398|NCT03053401|PROCEDURE|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
219443399|NCT03053401|PROCEDURE|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
219443400|NCT03053401|DEVICE|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
219583151|NCT00002865|DRUG|cyclophosphamide|
219583152|NCT00002865|DRUG|cytarabine|
219583153|NCT00002865|DRUG|dexamethasone|
219583154|NCT00002865|DRUG|doxorubicin hydrochloride|
219583155|NCT00002865|DRUG|etoposide|
219583156|NCT00002865|DRUG|ifosfamide|
219583157|NCT00002865|DRUG|leucovorin calcium|
219583158|NCT00002865|DRUG|mesna|
219764931|NCT06172296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219443401|NCT03053401|DEVICE|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
219443402|NCT03053401|DRUG|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
219443403|NCT03053401|DRUG|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
219443404|NCT01973972|BEHAVIORAL|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
219443405|NCT01973972|BEHAVIORAL|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
219443406|NCT00257322|DRUG|GM-CSF|250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
219443407|NCT00862498|OTHER|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
219443408|NCT00921570|DRUG|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
219583159|NCT00002865|DRUG|methotrexate|
219583160|NCT00002865|DRUG|therapeutic hydrocortisone|
219583161|NCT00002865|DRUG|vincristine sulfate|
219583162|NCT00002865|RADIATION|low-LET cobalt-60 gamma ray therapy|
219583163|NCT00002865|RADIATION|low-LET photon therapy|
219583164|NCT00471289|DEVICE|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
219583165|NCT00471289|DEVICE|PTA|PTA
219583166|NCT00411957|DRUG|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
219583167|NCT04736043|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
219583168|NCT06186934|DRUG|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
219583169|NCT00577395|DRUG|placebo|oral tablet once a month for 12 months
219583170|NCT00577395|DRUG|risedronate|tablet, 150 mg once a month for 12 months
219583171|NCT03888781|DEVICE|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
219583172|NCT05202730|PROCEDURE|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
219764932|NCT06172296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219764933|NCT06172296|DRUG|Carboplatin|Given IV
219764934|NCT06172296|DRUG|Cisplatin|Given IV
219764935|NCT06172296|PROCEDURE|Computed Tomography|Undergo CT scan
219764936|NCT06172296|DRUG|Cyclophosphamide|Given IV
219583173|NCT03363399|DIAGNOSTIC_TEST|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
219583174|NCT03364166|PROCEDURE|surgical excision|"* Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
219764937|NCT06172296|BIOLOGICAL|Dinutuximab|Given IV
219583175|NCT06632392|OTHER|Simulation training|Theory and simulation training
219583176|NCT06632392|OTHER|Theory training|Theory training
219764938|NCT06172296|DRUG|Doxorubicin|Given IV
219764939|NCT06172296|PROCEDURE|Echocardiography Test|Undergo ECHO
219764940|NCT06172296|DRUG|Etoposide|Given IV
219764941|NCT06172296|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG PET
219764942|NCT06172296|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell infusion
219016398|NCT05561881|OTHER|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
219016399|NCT05561881|OTHER|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
219443409|NCT00921570|DRUG|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
219443410|NCT01519336|DRUG|danoprevir|100 mg q12h
219443411|NCT01519336|DRUG|darunavir|600 mg q12h
219764943|NCT06172296|DRUG|Irinotecan|Given IV
219196267|NCT06820437|OTHER|Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training|Intervention group 1: Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training will be conducted on active external bleeding control management skills of caregivers of elderly individuals. In this intervention poster and cards will be used.
219443412|NCT01519336|DRUG|ritonavir|100 mg q12h
219764944|NCT06172296|DRUG|Isotretinoin|Given PO
219764945|NCT06172296|PROCEDURE|Leukapheresis|Undergo apheresis
219764946|NCT06172296|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764947|NCT06172296|DRUG|Melphalan|Given IV
219764948|NCT06172296|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219443413|NCT01804842|DRUG|Met DR|metformin delayed-release tablets
219443414|NCT03224156|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
219443415|NCT03887052|DEVICE|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
219443416|NCT06234085|OTHER|VCA feedback report available|Access to feedback report described in the intervention
219443417|NCT04248556|OTHER|Health care product|Health care product (gel) - to be applied on the participant's skin
219764949|NCT06172296|RADIATION|Radiation Therapy|Undergo radiation therapy
219764950|NCT06172296|PROCEDURE|Radionuclide Imaging|Undergo I-MIBG scan
219764951|NCT06172296|OTHER|Survey Administration|Ancillary studies
219764952|NCT06172296|DRUG|Temozolomide|Given PO or via NG or G tube
219764953|NCT06172296|DRUG|Thiotepa|Given IV
219764954|NCT06172296|DRUG|Topotecan|Given IV
219764955|NCT06172296|PROCEDURE|Tumor Resection|Undergo tumor resection surgery
219764956|NCT06172296|DRUG|Vincristine|Given IV
219764957|NCT06897930|BIOLOGICAL|AZD0120|Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
219764958|NCT06897930|DRUG|Cyclophosphamide|Lymphodepletion - specified dose prior to receiving AZD0120
219764959|NCT06897930|DRUG|Fludarabine|Lymphodepletion - specified dose prior to receiving AZD0120
219764960|NCT05621291|DIAGNOSTIC_TEST|NGS testing|antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
219016403|NCT05276492|DRUG|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
219016404|NCT05276492|DRUG|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
219443418|NCT03797885|OTHER|No treatment given|No treatment is administered to the participants for this study
219443419|NCT03734770|DRUG|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
219443420|NCT03734770|DRUG|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
219443421|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
219443422|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
219443423|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
219443424|NCT00728195|DRUG|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
219443425|NCT00728195|DRUG|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
219443426|NCT01738074|BIOLOGICAL|trivalent rotavirus genetic reassortment vaccine|
219443427|NCT01738074|BIOLOGICAL|Placebo|
219443428|NCT05591430|PROCEDURE|Ganglion Impar Neurolysis|block of Ganglion Impar by neurolytic drug
219443429|NCT05591430|PROCEDURE|Bilateral S2, S3 and S4 Pulsed radiofrequency|Bilateral S2, S3 and S4 Pulsed radiofrequency
219443430|NCT01440972|OTHER|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
219443431|NCT01440972|OTHER|low intensity resistance training|low intensity resistance training without partial blood flow restriction
219443432|NCT04258904|COMBINATION_PRODUCT|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
219443433|NCT03237390|DRUG|Gemcitabine Hydrochloride|Given IV
219443434|NCT03237390|OTHER|Laboratory Biomarker Analysis|Correlative studies
219583177|NCT02562339|BEHAVIORAL|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
219583178|NCT00273039|DRUG|paroxetine|
219583179|NCT04242914|DRUG|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
219583180|NCT04242914|DRUG|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
219583181|NCT00429195|BEHAVIORAL|Dietary Fatty Acid Modification|
219443435|NCT03237390|OTHER|Pharmacological Study|Correlative studies
219583182|NCT06082895|BEHAVIORAL|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
219583183|NCT02527538|DEVICE|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
219583184|NCT05078164|BEHAVIORAL|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
219583185|NCT01404078|DRUG|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
219583186|NCT01404078|DRUG|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
219583187|NCT04775849|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed uni- or bilateral
219583188|NCT05282225|BEHAVIORAL|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
219583189|NCT05282225|BEHAVIORAL|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
219583190|NCT05282225|BEHAVIORAL|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
219764961|NCT00001230|DRUG|Diethylcarbamazine|Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
219764962|NCT04929041|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219764963|NCT04929041|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219764964|NCT04929041|PROCEDURE|Computed Tomography|Undergo CT
219764965|NCT04929041|PROCEDURE|Echocardiography Test|Undergo ECHO
219764966|NCT04929041|BIOLOGICAL|Ipilimumab|Given IV
219764967|NCT04929041|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219764968|NCT04929041|BIOLOGICAL|Nivolumab|Given IV
219764969|NCT04929041|PROCEDURE|Positron Emission Tomography|Undergo PET
219764970|NCT04929041|OTHER|Quality-of-Life Assessment|Ancillary studies
219764971|NCT04929041|RADIATION|Radiation Therapy|Undergo radiation therapy
219764972|NCT04826341|DRUG|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
219764973|NCT04826341|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
219764974|NCT01306019|BIOLOGICAL|Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector|Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
219764975|NCT01306019|DRUG|Busulfan|3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day
219764976|NCT01306019|DRUG|Palifermin|Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
219764977|NCT07069361|BEHAVIORAL|Mindfulness-Based Cognitive Therapy - Life Course Adaptation (MBCT-L)|MBCT-L (Mindfulness-Based Cognitive Therapy for Life) Is a structered, group-based intervention developed for use with healthy adults. The programs runs for 8 consecutive weeks, with sessions lasting 2 hours and 15 minutes. It includes formal and informal mindfulness practices, exercises to develop cognitive and emotion awareness, with elements adapted from cognitive therapy. The course was designed to support participants in cultivating habits that increase emotion regulation and psychological well-being. Home practice is assigned daily using audio-guided meditations. The intervention is standardized and delivered by a instructor trained under Oxford Mindfulness Centre (OMC) protocols. MBCT-L is distinct from the clinical MBCT model used for relapse prevention. And it is also disting from other Mindfulness-Based interventions as it uses different exercises than, for example, Mindfulness-Based Stress Reduction which emphasis stress theories in the intervention.
219764978|NCT06855524|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219583191|NCT05282225|BEHAVIORAL|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
219583192|NCT05282225|BEHAVIORAL|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
219583193|NCT05479656|OTHER|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
219764979|NCT06855524|DIETARY_SUPPLEMENT|Oligo-fucoidan|Given PO
219764980|NCT06855524|DRUG|Placebo Administration|Given PO
219764981|NCT06855524|OTHER|Questionnaire Administration|Ancillary studies
219764982|NCT04083599|BIOLOGICAL|GEN1042|Intravenous
219764983|NCT04083599|DRUG|Pembrolizumab|Intravenous
219764984|NCT04083599|DRUG|Cisplatin|Intravenous
219764985|NCT04083599|DRUG|Carboplatin|Intravenous
219764986|NCT04083599|DRUG|5-FU|Intravenous
219764987|NCT04083599|DRUG|Gemcitabine|Intravenous
219764988|NCT04083599|DRUG|Nab paclitaxel|Intravenous
219764989|NCT04083599|DRUG|Pemetrexed|Intravenous
219764990|NCT04083599|DRUG|Paclitaxel|Intravenous
219764991|NCT06779617|DEVICE|SEPSys|The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
219764992|NCT06779617|DEVICE|RESCUE|The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
219764993|NCT06693908|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified.
219764994|NCT07071285|BEHAVIORAL|E-Book|Breastfeeding eBook learning mode.
219764995|NCT07071285|BEHAVIORAL|face-to-face teaching|face-to-face teaching of breastfeeding
219016405|NCT05276492|OTHER|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
219016406|NCT05276492|DRUG|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
219764996|NCT03891251|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
219764997|NCT05723380|PROCEDURE|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
219583194|NCT03781401|DEVICE|Ambulatory blood pressure monitoring|
218835813|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
219443436|NCT03237390|DRUG|Ribociclib|Given PO
219443437|NCT02811081|PROCEDURE|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
219443438|NCT02811081|PROCEDURE|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
219443439|NCT02811081|PROCEDURE|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
219764998|NCT07066254|DEVICE|Mepilex Ag Dressing|A silver-impregnated antimicrobial foam dressing (Mepilex Ag) will be placed over the cesarean incision immediately following skin closure in the operating room. Participants assigned to this intervention will be instructed to leave the dressing in place for 7 days, in accordance with manufacturer guidelines, unless earlier removal is necessary due to dressing saturation, displacement, or clinical concern. Mepilex Ag is FDA-cleared for use as a wound dressing and is designed to maintain a moist wound environment while providing sustained antimicrobial protection to help reduce the risk of surgical site infection.
219764999|NCT07066254|DEVICE|Standard Surgical Dressing (Telfa non-adhesive dressing, gauze, and Primapore adhesive bandage)|A standard postoperative dressing consisting of a sterile Telfa non-adhesive pad placed over the cesarean incision, covered with gauze, and secured with a Primapore adhesive bandage. The dressing is applied immediately following skin closure in the operating room as part of routine institutional care. It is typically removed within 24 to 48 hours postoperatively, depending on wound condition and provider discretion.
219765000|NCT06770101|BEHAVIORAL|Behavioral: Enhanced Friendship Bench + Safety Planning|The protocol will include six sessions, starting with the development of the SP during the first session. Each of the following sessions will include SIBs and suicide risk assessments, SP check-ins and revisions, as well as FB problem-solving to address SIBs and suicide risk. SP+FB will be delivered by selection of young counselors (mixed genders, aged 20-35) who are motivated to work with young people. Counseling sessions will take place in a discrete location within the HIV clinic and be available on weekends. Each structured session lasts 30-45 minutes and conducted in the participant's local language (Chichewa). After 4 sessions of individual therapy, the counselor can refer participants not improving or with suicidal ideation to a supervisor trained in mental health to reassess and manage the case. Case management may include additional counseling or pharmacotherapy, at the discretion of the managing clinician. Participants may also receive text message support and peer-support.
219443440|NCT03933215|DRUG|Cladribine|Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
219443441|NCT02964182|DRUG|Cigarette|Smoke usual brand of cigarettes
219583195|NCT03788304|DEVICE|non-invasive ventilation|conventional NIV
219583196|NCT03788304|DEVICE|high flow nasal cannula|HFNC ventilation
219583197|NCT00853463|BEHAVIORAL|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
219583198|NCT00569530|DRUG|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
219443442|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
219583199|NCT00569530|DRUG|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
218835814|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
218835815|NCT05402254|OTHER|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
219443443|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
219583200|NCT04709835|DRUG|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
219583201|NCT04709835|DRUG|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
219583202|NCT06634017|BIOLOGICAL|Platelet rich fibrin|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
219583203|NCT00169481|BIOLOGICAL|Pneumococcal (vaccine)|
219583204|NCT01832207|DEVICE|Transcutaneous electrical nerve stimulation|
219583205|NCT01832207|DEVICE|Placebo transcutaneous electrical nerve stimulation|
219583206|NCT03545230|PROCEDURE|":Four Not Techniques"|":Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft."
219583207|NCT01630577|OTHER|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
219583208|NCT06336395|DRUG|Prednisolone|Oral
219583209|NCT06336395|DRUG|Dexamethasone|Oral
219583210|NCT06336395|DRUG|Vincristine|Intravenous
218835816|NCT03365063|OTHER|Active Knowledge Translation|"1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
219443444|NCT02964182|OTHER|Questionnaire Administration|Ancillary studies
219443445|NCT02964182|OTHER|Survey Administration|Ancillary studies
219443446|NCT02964182|DRUG|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
219443447|NCT02964182|DEVICE|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
219443448|NCT02964182|DEVICE|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
219443449|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
219443450|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
219443451|NCT04222673|BEHAVIORAL|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
219583211|NCT06336395|DRUG|Methotrexate|Oral/ intrathecal/intravenous/subcutaneous
218835817|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
218835818|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
218835819|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
218835820|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
218835821|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
219583212|NCT06336395|DRUG|L-Asparaginase|Intramuscular
219583213|NCT06336395|DRUG|Pegylated asparaginase|Intravenous
219443452|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
219443453|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
219443455|NCT02352090|DRUG|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
219443456|NCT02352090|DRUG|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
219443457|NCT02352090|DRUG|Dienogest|One tablet orally for 9 weeks, continuous use
219583214|NCT06336395|DRUG|Erwinase|Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
219443458|NCT01199497|DRUG|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
219443459|NCT01199497|DRUG|Group 2|placebo
219443460|NCT02622048|BEHAVIORAL|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
219443461|NCT00029341|BEHAVIORAL|Treatment Interruption|
219583215|NCT06336395|DRUG|Dasatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
219583216|NCT06336395|DRUG|Imatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
219583217|NCT06336395|DRUG|Cyclophosphamide|Intravenous
219583218|NCT06336395|DRUG|Cytarabine|Subcutaneous/ Intravenous
219583219|NCT06336395|DRUG|Mercaptopurine|Oral
219583220|NCT06336395|DRUG|Thioguanine|Oral
219583221|NCT06336395|DRUG|Rituximab|Intravenous
219583222|NCT06336395|DRUG|Doxorubicin|Intravenous
219583223|NCT06336395|DRUG|Fludarabine|Intravenous
219196268|NCT06820437|OTHER|High-fidelity (simulated patient/standard patient) simulation training|Intervention group 2: High-fidelity (simulated patient/standard patient) simulation training will be conducted for caregivers of elderly individuals in active external bleeding control management skills. Standardized patient who will act as elderly will be used in this intervention.
219196269|NCT04622644|DEVICE|Device: clinical investigation microwave device class IIa not marked CE for stroke detection|Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
219196270|NCT06856538|DRUG|Bupivacain|After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
219196271|NCT06856538|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
219196272|NCT06664021|DRUG|Tislelizumab combined with S-1|Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
219443462|NCT00996541|BEHAVIORAL|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
219196273|NCT06857578|PROCEDURE|Total revision of Roux-en-Y gastric bypass|"1. The entire previous gastric bypass construction is released from any adhesions and all parts of the small intestine are measured and assessed.~2. All or parts of the first part of the intestine that food reaches after the gastric pouch (so-called Roux) is resected. The reason is that parts of the intestine that are considered to be of poor quality (for example, affected by a lot of adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine.~   The gastric pouch will be small (\<30 ml).~3. A new gastric bypass construction is constructed where the intestine receiving food from the esophagus (Roux) will be 1 meter, and the small intestine part from the closed stomach at least 1.5 meters.~The remaining length of the small intestine below the jejuno-jejunal anastomosis should be minimum 3 meters."
219196274|NCT06661681|BEHAVIORAL|Cognitive Functional Therapy (CFT)|"Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains:~i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability.~ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain.~iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement."
219196275|NCT06661681|OTHER|Therapeutic exercises group|Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.
218835822|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
219196276|NCT04408430|DEVICE|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
219196277|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
219196278|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
219196279|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
219196280|NCT06164444|OTHER|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
219196281|NCT06164444|OTHER|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
219443463|NCT03633513|DIAGNOSTIC_TEST|LBT-3627|Immunomodulatory agent
219443464|NCT03633513|DIAGNOSTIC_TEST|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
219443465|NCT02295436|DRUG|minodronic acid|comparison of different doses, ages and medication conditions
219443466|NCT01766245|DRUG|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
218835823|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
218835824|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
219443467|NCT01849562|DRUG|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
219443468|NCT01849562|DRUG|ACH-3102|Nonstructural protein 5A inhibitor.
219443469|NCT01849562|DRUG|Ribavirin|
219443470|NCT01849562|DRUG|Placebo|
219443471|NCT04085692|BEHAVIORAL|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
219443472|NCT05394207|DIETARY_SUPPLEMENT|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
219443473|NCT05394207|OTHER|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
219443474|NCT04403841|OTHER|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
219443475|NCT04403841|OTHER|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
219443476|NCT04031157|DEVICE|Predictix Antidepressant|Predictix Antidepressant guided treatment
219443477|NCT02480062|OTHER|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
219443478|NCT02480062|OTHER|Usual Care|Usual care at the community health centers
219443479|NCT00113711|BEHAVIORAL|smoking cessation|
219443480|NCT00113711|BEHAVIORAL|reducing diet|
219443481|NCT01554189|DRUG|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
219443482|NCT01554189|DRUG|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
219443483|NCT04306666|OTHER|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
219443484|NCT04114045|DIETARY_SUPPLEMENT|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
219443485|NCT04114045|DIETARY_SUPPLEMENT|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
219443486|NCT04114045|OTHER|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
219443487|NCT02456454|DRUG|Risperidone|Liquid risperidone
219443488|NCT02456454|DRUG|Valproic Acid|Liquid valproic acid
219443489|NCT02456454|DRUG|Placebo|
219443490|NCT01916187|DRUG|Imetelstat|
219443491|NCT03121807|OTHER|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
219443492|NCT03121807|DRUG|Oxaliplatin|
219443493|NCT03121807|DRUG|5Fluorouracil|
219443494|NCT03121807|DRUG|Leucovorin|
219443495|NCT05551910|DRUG|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
219443496|NCT05551910|DRUG|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
219443497|NCT05551910|DRUG|propofol|propofol
219443498|NCT00504192|DRUG|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
219443499|NCT00365742|DRUG|simvastatin|
219443500|NCT00365742|DRUG|red yeast rice|
219443501|NCT00365742|DRUG|pharmaceutical grade fish oil|
219443502|NCT00365742|BEHAVIORAL|therapeutic lifestyle changes|
219443503|NCT03954249|PROCEDURE|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
218835825|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
219765001|NCT06770101|BEHAVIORAL|Augmented usual care|Care for suicidality in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic's psychiatric nurse, or, for acute cases or crises, referral to the psychiatric units at tertiary care hospitals (Bwaila Hospital in Lilongwe District). Nurses and clinicians at the study sites have been specifically trained to use the Tool for Assessment of Suicide Risk for Adolescents (TASR-A) to assess ALWH considered at elevated risk for suicide. For this study, usual care will be augmented by a trained study nurse who will provide mental health evaluation, brief supportive counseling, information, education and support on SIBs, and (if indicated) facilitation of referral to the clinic's psychiatric nurse or to Bwaila Hospital.
219765002|NCT07067138|DEVICE|Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT)|This is a computational algorithm that takes RNA-seq data from tumor FFPE blocks and, given a list of pre-specified treatments, generates as output the predicted responses to those treatments.
219765003|NCT07067138|DEVICE|TruSight(R) Oncology 500|TSO500 uses formalin-fixed, paraffin-embedded (FFPE) tumor blocks to generate a 523-gene DNA panel (with tumor mutational burden and microsatellite instability) to assess for biomarkers linked to FDA-approved, on-label therapies as well as whole-exome RNA-seq that can be used with the ENLIGHT algorithm.
219765004|NCT07067138|DEVICE|TruSeq Matched Tumor Normal Whole Exome Sequencing Assay|The TruSeq Matched Tumor-Normal Whole Exome Sequencing assay is a next-generation sequencing assay that uses tumor DNA from formalin-fixed, paraffin-embedded (FFPE) tumor blocks and germline DNA drawn from blood to provide extended sequencing information on the tumor as well as any pathogenic variants, likely pathogenic variants, and variants of uncertain significance in 156 genes from the normal blood sample.
219765005|NCT07073547|BIOLOGICAL|AZD0120|AZD0120 is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma
219765006|NCT06899594|DRUG|Psilocybin 25 mg|25 mg administered orally (capsules)
219765007|NCT05642195|BIOLOGICAL|Montanide (Registered Trademark) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
219443504|NCT03954249|PROCEDURE|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
219443505|NCT00333424|BIOLOGICAL|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
219443506|NCT01091142|DRUG|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
219443507|NCT01091142|DRUG|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
219443508|NCT03356808|BIOLOGICAL|Lung cancer-specific T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
219443509|NCT00549653|DRUG|GW856553|
219443510|NCT02262013|BEHAVIORAL|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
218835826|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
218835827|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
219196282|NCT05246319|DIAGNOSTIC_TEST|preoperative imaging|evaluation of preoperative imaging (versus nodes observed on pathology)
219443511|NCT02262013|BEHAVIORAL|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
219443512|NCT03003013|PROCEDURE|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
219443513|NCT03136913|DEVICE|Cytoplast® TXT-200|Non-resorbable membrane
219443514|NCT03136913|DEVICE|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
219443515|NCT03136913|PROCEDURE|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
219443516|NCT03136913|PROCEDURE|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
219443517|NCT00250497|BEHAVIORAL|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
218835828|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
218835829|NCT06004154|DIAGNOSTIC_TEST|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
218835830|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
218835831|NCT02811120|OTHER|venepuncture only|single venepuncture
218835832|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
218835833|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
219583224|NCT04325204|BEHAVIORAL|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
219583225|NCT03557879|GENETIC|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
219583226|NCT00820443|DEVICE|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
219583227|NCT06355102|OTHER|Conventional treatment and care|Conventional treatment and care
219583228|NCT04711902|DRUG|AIN457|Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
218835834|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
219443518|NCT03562520|BEHAVIORAL|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
219583229|NCT04711902|OTHER|Secukinumab Placebo|Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
219583230|NCT04556851|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
219765008|NCT05642195|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
218835835|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
219443519|NCT01197781|DRUG|FOSTAMATIN|Oral tablets - single dose
219443520|NCT01197781|DRUG|Verapamil|Oral tablets - administered 3 times daily over 4 days
219443521|NCT02182999|DEVICE|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
219583231|NCT04556851|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
219583232|NCT04556851|DRUG|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
219583233|NCT05643053|OTHER|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
219583234|NCT05643053|OTHER|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
219583235|NCT05643053|OTHER|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
218835836|NCT01899638|DRUG|VI 25 mcg|LABA mono
218835837|NCT00331916|DRUG|quinolone|
218835838|NCT02870985|DEVICE|Coronary Stent|
218835839|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
219583236|NCT05643053|OTHER|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
219583237|NCT00138554|DRUG|vildagliptin|
219583238|NCT00138554|DRUG|pioglitazone|pioglitazone 45 mg qd
219765009|NCT05642195|DRUG|N-803|N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.
219765010|NCT05642195|DEVICE|Ventana PD-L1 (SP263 or SP142) assay|FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.
219443522|NCT02182999|DRUG|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
219443523|NCT02182999|DRUG|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
219443524|NCT05566327|BEHAVIORAL|De-implementation Bundle|"A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests."
219443525|NCT02762123|DRUG|BMS-986142 200mg|
219443526|NCT02762123|DRUG|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
219583239|NCT05063435|DIAGNOSTIC_TEST|Carotid ultrasonography|"1. Study takes 10 - 15 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~4. Blood pressure and heart rate will be obtained during the study~5. Results will be anonymized, digitized and stored on CD with unique identifier"
219443527|NCT02762123|DRUG|BMS-986142 350mg|
219583240|NCT05063435|DIAGNOSTIC_TEST|Echocardiography, transthoracic|"1. Study takes 15 - 20 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~4. Results will be digitized and stored on CD"
219583241|NCT05063435|PROCEDURE|Venipuncture|"1. 10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~2. Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
219583242|NCT02077218|PROCEDURE|computed tomography|Undergo cardiac CT
219583243|NCT02077218|OTHER|cytology specimen collection procedure|Undergo collection of blood samples
219583244|NCT02077218|OTHER|laboratory biomarker analysis|Correlative studies
219583245|NCT02077218|OTHER|questionnaire administration|Ancillary studies
219583246|NCT05501990|BEHAVIORAL|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
219583247|NCT05177302|OTHER|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
219583248|NCT05177302|OTHER|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
218835840|NCT03675113|OTHER|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
218835841|NCT03675113|OTHER|Control Group|Deep breathing exercises combinated with arm movements
218835842|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
218835843|NCT01552837|DRUG|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
218835844|NCT03693144|OTHER|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
219443528|NCT01427127|DRUG|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
219443529|NCT03216395|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
219443530|NCT03216395|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
219583249|NCT04710979|BEHAVIORAL|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
219583250|NCT05349643|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
219583251|NCT04637932|PROCEDURE|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
219765011|NCT06782373|DRUG|Pacritinib|Supplied in hard capsules.
218835845|NCT03693144|OTHER|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
218835846|NCT03693144|OTHER|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
218835847|NCT05572879|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
219443531|NCT03216395|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 8 pulses
219583252|NCT00501098|DRUG|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
219583253|NCT01446328|DRUG|Amisulpride|Tablets, dose range 50-1200 mg/ day
219583254|NCT01446328|DRUG|Aripiprazole|Tablets, dose range 5-30 mg/ day
219583255|NCT01446328|DRUG|Olanzapine|Tablets, dose range 2.5-20 mg/ day
219583256|NCT01775449|BEHAVIORAL|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
219583257|NCT01966588|OTHER|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
219583258|NCT01966588|OTHER|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
219583259|NCT00521417|BEHAVIORAL|short-term dynamic therapy|
219583260|NCT00521417|BEHAVIORAL|long-term dynamic therapy|
219583261|NCT00026221|BIOLOGICAL|Recombinant Interferon Alfa|Given SC
219583262|NCT00026221|BIOLOGICAL|Bevacizumab|Given IV
219443532|NCT03216395|DRUG|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
219443533|NCT06138392|DEVICE|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
219443534|NCT03228992|DRUG|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
219583263|NCT03178526|DRUG|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
219583264|NCT03178526|DRUG|Placebo|placebo gel
219583265|NCT02459496|BEHAVIORAL|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
219583266|NCT04766190|BEHAVIORAL|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
219583267|NCT04766190|BEHAVIORAL|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
218835848|NCT05572879|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
218835849|NCT02861339|DEVICE|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
218835850|NCT01603225|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
218835851|NCT02311881|DRUG|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
218835852|NCT02311881|DRUG|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
218835853|NCT02311881|DRUG|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
219443535|NCT03228992|OTHER|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
219443536|NCT02252588|DRUG|Chlorhexidine|Oral Rinse
219443537|NCT02252588|OTHER|Placebo|Oral Rinse
219443538|NCT04993755|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219583268|NCT04766190|BEHAVIORAL|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
219583269|NCT02075827|BEHAVIORAL|Competitive video game|1 hour playing video game
219583270|NCT02075827|BEHAVIORAL|Little Big Planet|1 hour playing video game
219583271|NCT03265366|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
219583272|NCT03265366|DEVICE|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
219583273|NCT05296486|PROCEDURE|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
219583274|NCT05296486|PROCEDURE|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
219583275|NCT05296486|PROCEDURE|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
219583276|NCT05296486|PROCEDURE|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
219583277|NCT01339663|DRUG|cyclophosphamide|Given IV
219583278|NCT01339663|BIOLOGICAL|aldesleukin|Given SC
219583279|NCT01339663|BIOLOGICAL|autologous tumor cell vaccine|Receive T-APC via IV
219583280|NCT01339663|OTHER|laboratory biomarker analysis|Correlative studies
219583281|NCT01339663|OTHER|immunologic technique|Correlative studies
219583282|NCT01339663|OTHER|immunohistochemistry staining method|Correlative studies
219583283|NCT01339663|GENETIC|polymerase chain reaction|Correlative studies
219583284|NCT01339663|BIOLOGICAL|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
219583285|NCT06394349|COMBINATION_PRODUCT|PRP+308nm|PRP+308nm
219583286|NCT06394349|COMBINATION_PRODUCT|NS+308nm|NS+308nm
219765012|NCT06782373|DRUG|Placebo|Supplied in hard capsules.
219765013|NCT06780085|BIOLOGICAL|Raludotatug Deruxtecan|IV Infusion
218835854|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
218835855|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
219443539|NCT04993755|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219443540|NCT03039790|BIOLOGICAL|NoV Vaccine|NoV vaccine injection administered.
219765014|NCT06780085|BIOLOGICAL|Ifinatamab Deruxtecan|IV Infusion
218835856|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
219443541|NCT04912661|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
219443542|NCT00058188|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
219443543|NCT00058188|DRUG|calcium gluconate|Given orally
219443544|NCT00058188|DRUG|zoledronic acid|Given IV
219443545|NCT01520688|DRUG|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
219443546|NCT01520688|DRUG|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
218835857|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
219443547|NCT01520688|DRUG|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
218835858|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
218835859|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
219443548|NCT01520688|DRUG|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
219443549|NCT01520688|DRUG|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
219443550|NCT01520688|DRUG|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
219443551|NCT00498368|DRUG|Intravenous Rituximab|"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
219443552|NCT00498368|DRUG|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
219443553|NCT00498368|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
219443554|NCT00964769|BIOLOGICAL|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
219443555|NCT02266004|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
219443556|NCT02266004|OTHER|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
219443557|NCT01791465|DRUG|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
219443558|NCT03289052|DEVICE|Restylane Volyme|Subcutis injection
219765015|NCT06780085|DRUG|Docetetaxel|IV Infusion
219765016|NCT06780137|BIOLOGICAL|Gocatamig|IV infusion
219765017|NCT06780137|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
219765018|NCT06780137|BIOLOGICAL|Durvalumab|IV infusion
219765019|NCT00001168|BEHAVIORAL|Balanced diet|Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
219765020|NCT06919081|DRUG|Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome|Eye Drops
219765021|NCT06919081|OTHER|Vehicle Control|Eye Drops
219765022|NCT06105541|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
219765023|NCT06597734|DRUG|Olutasidenib|Given by PO
219765024|NCT06561828|DEVICE|continuous Theta Burst Stimulation (cTBS)|Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).
219765025|NCT06561828|DEVICE|intermittent Theta Burst Stimulation (iTBS)|Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).
219765026|NCT06561828|DEVICE|sham Theta Burst Stimulation (sham TBS)|iTBS or cTBS delivered with placebo side of A/P coil.
218835860|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
218835861|NCT01266330|DIETARY_SUPPLEMENT|Low Dairy|Less than 0.5 standard servings of dairy products per day
218835862|NCT01266330|DIETARY_SUPPLEMENT|Adequate Dairy|3.5 standard servings of dairy foods per day
218835863|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
218835864|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
219016418|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
219443559|NCT03174808|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
219443560|NCT01720472|GENETIC|Biomarker studies|
219443561|NCT01452191|BEHAVIORAL|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
219016421|NCT00314405|DRUG|Methylene blue (1%)|
219016422|NCT00314405|DRUG|Rhenium sulfure|
219016423|NCT00314405|PROCEDURE|Surgical procedure|
219016424|NCT00314405|PROCEDURE|Anatomo-pathologic procedure|
219016426|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each retainer, completing a total of 4 weeks of whitening procedure.
219443562|NCT01452191|BEHAVIORAL|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
219443563|NCT03486249|OTHER|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
219443564|NCT05743725|DRUG|Dexmedetomidine|dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
219443565|NCT05743725|DRUG|Magnesium sulfate|2 gm magnesium infusion for 30 minutes
219443566|NCT04703049|OTHER|Blood Viscosity Testing|we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
219443567|NCT04064944|DEVICE|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
219443568|NCT02625467|PROCEDURE|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
219443569|NCT02625467|PROCEDURE|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
219443570|NCT02625467|DRUG|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
219443571|NCT03378973|DRUG|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
219443572|NCT04226144|DEVICE|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
219443573|NCT04226144|DEVICE|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
219443574|NCT00702936|DRUG|TELMISARTAN|80 mg daily
219443575|NCT00702936|DRUG|RAMIPRIL|5 mg daily
219443576|NCT01347073|DRUG|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
219443577|NCT02204059|DRUG|hMAb BIWA 4|
219443578|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
219443579|NCT01478581|DRUG|PCI-32765|
219443580|NCT01478581|DRUG|Dexamethasone|
219765027|NCT06391775|BIOLOGICAL|GEN1055|Intravenous (IV) administration.
219765028|NCT06391775|BIOLOGICAL|Pembrolizumab|IV administration
219765029|NCT06391775|DRUG|Standard Chemotherapy|IV administration
219765030|NCT06856226|OTHER|Arm 1|Short tandem repeat (STR) analysis from genomic DNA extracted from biospecimens.
219765031|NCT06828939|DEVICE|pulsed field ablation|Pulsed field ablation using a ultra-compliant endoscopic PFA balloon.
219765032|NCT06356129|DRUG|Golcadomide|Specified dose on specified days
219765033|NCT06356129|DRUG|Placebo|Specified dose on specified days
219765034|NCT06356129|DRUG|Rituximab|Specified dose on specified days
219765035|NCT06356129|DRUG|Cyclophosphamide|Specified dose on specified days
219765036|NCT06356129|DRUG|Doxorubicin|Specified dose on specified days
219765037|NCT06356129|DRUG|Vincristine|Specified dose on specified days
219765038|NCT06356129|DRUG|Prednisone|Specified dose on specified days
219765039|NCT00001452|DRUG|oCRH|
219443581|NCT06446895|DIAGNOSTIC_TEST|Coronariography|Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
219443582|NCT05941910|DRUG|Q10|240mg of Q10 orally, every day
219443583|NCT00338429|BEHAVIORAL|FHP Sleep Program|Cognitive-Behavioral Intervention
219443584|NCT02705352|DRUG|5-Fluorouracil|Treatment medication
219443585|NCT02705352|OTHER|Normal saline|Placebo
219443586|NCT00372489|DRUG|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
219443587|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
219443588|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
219443589|NCT05148429|OTHER|Ultrasound exam|Ultrasound exam
219583287|NCT03296436|BIOLOGICAL|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
219583288|NCT02998970|DRUG|Empagliflozin|single oral tablet once daily.
219583289|NCT02998970|DRUG|Placebo|single oral tablet once daily.
219583290|NCT06032962|PROCEDURE|salpingectomy|surgical removal of the fallopian tubes
219583291|NCT01289665|PROCEDURE|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
219583292|NCT01289665|PROCEDURE|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
219583293|NCT05430126|DRUG|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
219583294|NCT01561430|DRUG|LY2886721|
219583295|NCT01561430|DRUG|Placebo|
219583296|NCT00879892|DRUG|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
219583297|NCT00879892|OTHER|Hypothermia|24 hour, target core temperature 33
219583298|NCT03972267|PROCEDURE|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
219583299|NCT03972267|DEVICE|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
219765040|NCT05554328|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219765041|NCT05554328|PROCEDURE|Biospecimen Collection|Undergo blood collection
219765042|NCT05554328|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
219765043|NCT05554328|PROCEDURE|Computed Tomography|Undergo CT scan
219765044|NCT05554328|PROCEDURE|Echocardiography Test|Undergo ECHO
218835865|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
218835866|NCT02494635|OTHER|Laboratory Biomarker Analysis|Biomarker analysis
218835867|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
218835868|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
219443590|NCT05148429|OTHER|Fetal MRI|Fetal MRI
219443591|NCT05148429|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
219443592|NCT05148429|OTHER|Pediatric Follow up|Pediatric Follow up
219443593|NCT04494477|BEHAVIORAL|The IN•clued program|The INclued program as previously described.
219443594|NCT03634228|DRUG|Cytarabine|Given SC
219443595|NCT03634228|DRUG|Milademetan Tosylate|Given PO
219443596|NCT03634228|DRUG|Venetoclax|Given PO
219583300|NCT01145430|OTHER|Laboratory Biomarker Analysis|Correlative studies
219583301|NCT01145430|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219583302|NCT01145430|OTHER|Pharmacological Study|Correlative studies
219583303|NCT01145430|DRUG|Veliparib|Given PO
219583304|NCT03347422|DRUG|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
219583305|NCT03347422|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
219583306|NCT02255825|GENETIC|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
219583307|NCT02255825|PROCEDURE|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
219583308|NCT02255825|OTHER|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
219583309|NCT05268263|DEVICE|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
219765045|NCT05554328|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219765046|NCT05554328|DRUG|Olaparib|Given PO
219765047|NCT05554328|DRUG|Selumetinib Sulfate|Given PO
219583310|NCT02905214|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
219583311|NCT00111423|DRUG|Pegsunercept (PEG sTNF-RI)|
219583312|NCT06073210|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
219583313|NCT06073210|BEHAVIORAL|Action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).
219765048|NCT06217666|DRUG|PCX-12|treatment combining radiation therapy with PCX12
219765049|NCT02759744|DEVICE|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
219765050|NCT04960709|DRUG|Durvalumab|Anti- PD-L1 Antibody
219765051|NCT04960709|DRUG|Tremelimumab|Human IgG2 mAb
219765052|NCT04960709|DRUG|Enfortumab Vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate
219765053|NCT04960709|PROCEDURE|Radical Cystectomy|For cisplatin-ineligible or cisplatin-refusal patients
219765054|NCT06656936|BEHAVIORAL|PharmFIT|The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
218835869|NCT04980469|OTHER|Vitex negundo + Zingiber officinale|200 mg/ Capsule
218835870|NCT04980469|OTHER|Placebo (MCC)|200 mg/ Capsule
219765055|NCT06537999|DRUG|DNTH103|"* Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks"
218835871|NCT04350801|DIAGNOSTIC_TEST|home-based cognitive monitoring|a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
218835872|NCT00270751|PROCEDURE|1 apical pleurectomy|
218835873|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
218835874|NCT05214066|DRUG|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
218835875|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
218835876|NCT02990975|DRUG|ketamine|
218835877|NCT02032576|DEVICE|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
218835878|NCT02816268|OTHER|Pulmonary vein isolation|
219016428|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
218835879|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
218835880|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
219016429|NCT06525766|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218835881|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
218835882|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
218835883|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
218835884|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
218835885|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
218835886|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
218835887|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
219016430|NCT06525766|PROCEDURE|Bone Scan|Undergo bone scan
219016431|NCT06525766|DRUG|Capecitabine|Given PO
219016432|NCT06525766|PROCEDURE|Computed Tomography|Undergo CT
219016433|NCT06525766|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219016434|NCT06525766|OTHER|Questionnaire Administration|Ancillary studies
219016435|NCT06524882|DEVICE|Vivid Vision|dichoptic video games played through a virtual reality headset
219016436|NCT06524882|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
219583314|NCT06073210|BEHAVIORAL|Sham action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
219583315|NCT03683524|DRUG|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
219583316|NCT03683524|DRUG|Current ART|To continue with their current ART
219765056|NCT06537999|DRUG|Placebo|"* Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks"
219443597|NCT04281823|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
218835888|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
218835889|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
219016437|NCT06524882|DEVICE|Optical Correction|Glasses prescribed at investigator discretion
219443598|NCT01084473|DRUG|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
219443599|NCT01084473|DRUG|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
219443600|NCT01084473|DRUG|Placebo|0.9 % NaCl will be infused.
219443601|NCT01901367|DIETARY_SUPPLEMENT|nutritional intervention|Receive nutritional intervention
219443602|NCT01901367|BEHAVIORAL|exercise intervention|Receive exercise intervention
219443603|NCT01901367|OTHER|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
219443604|NCT01901367|BEHAVIORAL|counseling intervention|Receive phone counseling with a trained health coach
219443605|NCT01901367|OTHER|quality-of-life assessment|Ancillary studies
219443606|NCT01901367|OTHER|laboratory biomarker analysis|Correlative studies
219443607|NCT01901367|OTHER|questionnaire administration|Ancillary studies
219443608|NCT02927535|DRUG|TNF blockers monotherapy|
219443609|NCT03978286|DRUG|Vortioxetine|10 mg per day
219443610|NCT03978286|DRUG|Sertraline|75 mg per day
219443611|NCT00552344|BIOLOGICAL|Cimzia|"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
219443612|NCT03914872|BIOLOGICAL|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
219443613|NCT03914872|DEVICE|Integrated electroporation device|"* Ichor Medical Systems~* All study injections will be given intramuscularly using an integrated electroporation device"
219475641|NCT05355545|BEHAVIORAL|Health education|Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
219475642|NCT05048875|DRUG|Cohort 1 - Group 1 JNJ High Dose|High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days
219475643|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Medium Dose|Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days
219475644|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Low Dose|Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days
219475645|NCT05048875|DRUG|Cohort 1 - Group 1/2 Placebo|Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.
219475646|NCT06798922|RADIATION|Standard post-operative radiotherapy without flap sparing (current practice)|Standard post-operative radiotherapy without flap sparing (current practice)
219475647|NCT06798922|RADIATION|Post-operative radiotherapy with flap sparing|Post-operative radiotherapy with flap sparing
219475648|NCT04957979|OTHER|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues"
219475649|NCT04957979|OTHER|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
219475650|NCT01550237|RADIATION|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
219475651|NCT01550237|RADIATION|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
219475652|NCT06066424|DRUG|Rimiducid|Given by (IV) vein
219583317|NCT06155058|PROCEDURE|SYREBO|Serial ADL training of upper extremities with robotic aid
219583318|NCT06155058|PROCEDURE|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
219583319|NCT03269331|BEHAVIORAL|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
219583320|NCT06197958|OTHER|eccentric exercises|eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.
219583321|NCT06197958|OTHER|concentric exercises|concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
219443614|NCT02407665|BEHAVIORAL|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
219443615|NCT00997828|DEVICE|everolimus-eluting stent|Xience V stent
219443616|NCT00997828|PROCEDURE|coronary artery bypass graft surgery|coronary artery bypass graft surgery
219443617|NCT01662986|DRUG|tiotropium bromide|18 mcg once a day (QD)
219583322|NCT03327636|DEVICE|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
219583323|NCT02633488|DRUG|Placebos|A 12 week single blind placebos
219583324|NCT02633488|DRUG|metformin|A 12 week single blind metformin
219765057|NCT06129916|DRUG|long-acting depot buprenorphine (LADB)|The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
219765058|NCT06585787|DRUG|KarXT|Specified dose on specified days
219765059|NCT06585787|DRUG|Placebo|Specified dose on specified days
219016439|NCT06441552|OTHER|non-interventional|non-interventional
219016440|NCT05864534|DRUG|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
219443618|NCT01662986|DRUG|Placebo|Once a day (QD)
219583325|NCT05535985|DEVICE|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
219583326|NCT05535985|DEVICE|placebo acupuncture|placebo acupuncture
219583327|NCT02866045|PROCEDURE|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
219583328|NCT02866045|PROCEDURE|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
219583329|NCT03335293|DRUG|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
219583330|NCT03335293|OTHER|normal saline|placebo comparator
219765060|NCT06516952|DRUG|Povorcitinib|Oral Tablet
219765061|NCT06516952|DRUG|Placebo|Oral Tablet
219765062|NCT06780111|BIOLOGICAL|Pembrolizumab|IV infusion
219765063|NCT06780111|BIOLOGICAL|I-DXd|IV infusion
219765064|NCT06780111|DRUG|Leucovorin|IV infusion
219765065|NCT06780111|DRUG|Levoleucovorin|IV infusion
219765066|NCT06780111|DRUG|5-Fluorouracil (5-FU)|IV Infusion
219443619|NCT02252328|DRUG|Simvastatin|Simvastatin 80mg once daily
219443620|NCT02252328|DRUG|Placebo|Placebo tablets once daily
219443621|NCT00482365|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
219443622|NCT00482365|OTHER|medical chart review|review of patients' medical records at study entry and every 6 months
219443623|NCT00482365|OTHER|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
219443624|NCT03774706|DRUG|Misoprostol|two tablets misoprostol 400 μg sublingual
219765067|NCT06780111|DRUG|Oxaliplatin|IV infusion
219765068|NCT06115499|DRUG|Nab paclitaxel|Given IV
219765069|NCT06115499|DRUG|Gemcitabine|Given IV
219765070|NCT06115499|DRUG|Cisplatin|Given IV
219765071|NCT06115499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219443625|NCT03774706|DRUG|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
219765072|NCT06115499|PROCEDURE|Computed Tomography|Undergo CT
219765073|NCT06115499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218835890|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
218835891|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
219196283|NCT06825299|DIAGNOSTIC_TEST|Chest-Tube Insertion|The technique was performed according to a combination of the Chest-Tube Insertion (BTS) guidelines for chest tube insertion and ultrasound (US)-guided technique for chest tube insertion and US-guided pigtail insertion.
219443626|NCT03774706|DRUG|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
219443627|NCT00553618|DRUG|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
219443628|NCT04023344|DRUG|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
219443629|NCT04023344|DRUG|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
219443630|NCT03007628|DEVICE|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219475653|NCT06066424|DRUG|TROP2-CAR-NK Cells|Given by (IV) vein
219475654|NCT06066424|DRUG|Fludarabine phosphate|Given by (IV) vein
219475655|NCT06066424|DRUG|Cyclophosphamide|Given by (IV) vein
219475656|NCT02392312|DRUG|ATF-Fresenius S|intravenous
218835892|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
218835893|NCT04446221|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
218859905|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
219475657|NCT04213651|OTHER|No intervention|There is no intervention for this study
219475658|NCT06626737|DRUG|Dapagliflozin (DAPA)|Participants will take Dapagliflozin 10mg every day in -1 to 14 days
219475659|NCT06374381|BEHAVIORAL|PEACE Online Resources|The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.
219475660|NCT06374381|BEHAVIORAL|PEACE Weekly Group Facilitation|Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.
219475661|NCT06374381|BEHAVIORAL|PEACE Weekly Individual Facilitation|Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
219475662|NCT04211402|OTHER|No Intervention|There is no intervention for this study
219475663|NCT04591093|DEVICE|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
219475664|NCT05740956|DRUG|HS-10502|HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
219475665|NCT06535347|BEHAVIORAL|Information about scheduling a follow-up appointment|Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
219475666|NCT01860937|PROCEDURE|leukapheresis or collection of PBMCs|
219475667|NCT01860937|DRUG|cyclophosphamide based chemotherapy regimens|
219475668|NCT01860937|BIOLOGICAL|modified T cells|
219475669|NCT02780310|DRUG|Lenvatinib|
219475670|NCT05690282|DRUG|Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|Multimodal Pain Management to minimize patients' reliance on opioids.
219475671|NCT06647849|PROCEDURE|centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases|"The simulation training sessions for the announcement consultation are set up directly in the centers participating in the with training arm of the study, after the first phase of patient inclusion. These sessions will take place in situ in the center's maternity ward, and will be run by a single team trained in simulation and announcement.~This team of trainers is identical for all centers randomized in the with training arm, and is made up of two trainers: an obstetrician-gynecologist and a psychologist."
219765074|NCT06827860|DRUG|Talquetamab|SC monotherapy starting with three step-up doses followed by the standard 800 μg/kg dose every other week. Cycles will be 28 days long.
219765075|NCT06827860|DRUG|Daratumumab|SC at the standard dose (weekly for 2 cycles, every other week for 4 cycles, monthly thereafter)
219765076|NCT00646022|DRUG|[18F]-DOPA|18F-DOPA PET/CT Scan.
219765077|NCT06801041|DRUG|Psilocybin|Participants will recive treatment by mouth on an outpatient basis.
219765078|NCT02039401|BIOLOGICAL|VM202|
219443631|NCT03007628|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219765079|NCT06895174|DEVICE|Titanium miniplates|Titanium miniplates are used for open reduction and internal fixation in mandible fractures according to Champy's principle of osteosynthesis
219765080|NCT06895174|OTHER|Arch Bar|Arch bars are used for intermaxillary fixation in facial fractures as a mean of closed reduction.In this study arch bars placed in tension zone will be combined with single miniplate placed at inferior border of mandible and this modality efficacy will be compared with two miniplate group.
219765081|NCT04858334|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219765082|NCT04858334|PROCEDURE|Computed Tomography|Undergo CT or CT/MRI
219765083|NCT04858334|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
219765084|NCT04858334|DRUG|Olaparib|Given PO
219765085|NCT04858334|DRUG|Placebo Administration|Given PO
219765086|NCT01747213|DRUG|BNC|
219765087|NCT01747213|OTHER|Placebo|Microcrystalline cellulose fiber
219765088|NCT06435429|DRUG|Zanidatamab|Administered by intravenous infusion
219765089|NCT06435429|DRUG|Trastuzumab|Administered by intravenous infusion
218859906|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
218859907|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
218859908|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
219443632|NCT03007628|OTHER|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
219443633|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
219443634|NCT00314054|DRUG|HCV-796|HCV-796 1000mg single dose
219443635|NCT01531686|PROCEDURE|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
219443636|NCT03700086|DEVICE|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
219443637|NCT03700086|DEVICE|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
219443638|NCT02809846|DEVICE|Quell|
219443639|NCT02809846|DEVICE|Sham Quell|
219443640|NCT05875012|OTHER|action observation physical training|Action observation training 3 sessions per week for 3 successive months
219443641|NCT05875012|OTHER|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
219443642|NCT05221489|OTHER|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
219443643|NCT03637894|DIETARY_SUPPLEMENT|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
219443644|NCT03637894|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
219443645|NCT03637894|OTHER|Breastfeeding infants|Reference group
219443646|NCT03317366|DRUG|ARQ 092|Open-label expanded access for ARQ 092 capsules
219443647|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
219443648|NCT04453605|OTHER|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
219443649|NCT04827173|PROCEDURE|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
219443650|NCT02940197|BEHAVIORAL|MediterrAsian diet|no other description
219443651|NCT01751789|BEHAVIORAL|Linkage|
219443652|NCT01751789|OTHER|Treatment as Usual|
219765090|NCT06435429|DRUG|Eribulin|Administered by intravenous infusion
219765091|NCT06435429|DRUG|Vinorelbine|Administered by intravenous infusion
219765092|NCT06435429|DRUG|Gemcitabine|Administered by intravenous infusion
219765093|NCT06435429|DRUG|Capecitabine|Given orally
219765094|NCT06529614|OTHER|In-situ detection for Micro-RNA|a new in-situ detection methods for Micro-RNA
219765095|NCT06121297|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
219765096|NCT04086485|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
219765097|NCT04086485|DRUG|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
219765098|NCT04086485|DIAGNOSTIC_TEST|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
219765099|NCT04086485|DIAGNOSTIC_TEST|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
219443653|NCT05321589|OTHER|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
219583331|NCT03335293|DRUG|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
218835894|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
219443654|NCT05076552|DRUG|TACH101|Orally via capsules
219583332|NCT00365131|DRUG|Cerezyme (imiglucerase for injection)|
219583333|NCT04053686|BEHAVIORAL|Breaks|3-min breaks every half hour at work
219583334|NCT04644822|DIAGNOSTIC_TEST|[18F] PSMA-1007 Injection|a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
218835895|NCT05356273|PROCEDURE|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
218835896|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
219583335|NCT03816514|PROCEDURE|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
219583336|NCT03816514|PROCEDURE|Conventional management|Conventional management without SpHb monitoring
219583337|NCT03355014|DRUG|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
218835897|NCT00257569|DRUG|Cetirizine Dry Syrup|
218835898|NCT06715098|DEVICE|RoboGait|RoboGait: robotic-assisted gait training
218835899|NCT06715098|DEVICE|RehaWalk|RehaWalk: body weight-supported treadmill training
218835900|NCT06715098|OTHER|Conventional|Conventional: conventional walking training
219443655|NCT05013099|BIOLOGICAL|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
219443656|NCT01512693|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
219443657|NCT04326881|DRUG|SHR-1314|single dosing
219583338|NCT03355014|DRUG|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
219583339|NCT00986713|DRUG|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
218835901|NCT06844604|PROCEDURE|robotic colorectal procedures|any colorectal procedure planed robot-assisted
219583340|NCT05134506|BEHAVIORAL|Dance for PD® classes|The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
219583341|NCT02122406|OTHER|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
219583342|NCT00250796|DRUG|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
219583343|NCT00250796|DRUG|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
219583344|NCT05291065|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
219583345|NCT05291065|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
219583346|NCT05291065|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
219583347|NCT05691686|OTHER|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
219583348|NCT05691686|OTHER|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
219583349|NCT05691686|OTHER|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
219583350|NCT05691686|OTHER|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
219583351|NCT03778658|BEHAVIORAL|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
219583352|NCT01150318|DRUG|Administration of 131 iodine|100 mCi 131 iodine irradiation
219583353|NCT00476554|DRUG|Sapacitabine|Sapacitabine
219583354|NCT04258475|DRUG|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
218835902|NCT06844604|PROCEDURE|laparoscopic colorectal procedures|any colorectal procedure planed laparoscopically
218835903|NCT06844604|PROCEDURE|open colorectal procedures|any colorectal procedure planed open
219443658|NCT05859581|PROCEDURE|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
219443659|NCT01442090|DRUG|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
219443660|NCT01442090|DRUG|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
219443661|NCT00596895|DIETARY_SUPPLEMENT|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
219443662|NCT00000199|DRUG|Piracetam|
219443663|NCT04731922|DRUG|TAK-510|TAK-510 solution.
219443664|NCT04731922|DRUG|TAK-510 Placebo|TAK-510 placebo-matching solution.
219443665|NCT03225651|BIOLOGICAL|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
219443666|NCT03225651|BEHAVIORAL|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
219443667|NCT05345938|DRUG|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
219443668|NCT05018468|DEVICE|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
219443669|NCT03696628|OTHER|Electrocardiogram|heart testing
219443670|NCT03696628|OTHER|physical examination|done by the investigator
219443671|NCT03696628|OTHER|echocardiography|heart testing
219443672|NCT03696628|BIOLOGICAL|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
219443673|NCT00666055|DRUG|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
219443674|NCT04866095|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
219443675|NCT04866095|DEVICE|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
219443676|NCT05920070|PROCEDURE|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
219443677|NCT05193877|PROCEDURE|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
219443678|NCT00845845|DRUG|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
219443679|NCT00845845|DRUG|Placebo|Daily placebo with dietary counseling for 24 weeks.
219443680|NCT04853277|BEHAVIORAL|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
219443681|NCT05013294|OTHER|Intervention|Text messages through a basic phone or smart phone
218835904|NCT01059357|DEVICE|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
218835905|NCT04068454|DEVICE|Virtual reality device|Functional exercises will be done by virtual reality group
218835906|NCT04068454|OTHER|EBM rehabilitation exercises|scapular exercises will be done
218835907|NCT03464526|DRUG|Orvepitant|Tablet, once daily, oral
218835908|NCT03464526|DRUG|Placebo|Tablet, once daily, oral
219443682|NCT05606380|DRUG|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
219443683|NCT04841213|PROCEDURE|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
219443684|NCT03242590|DRUG|LPCN 1021|Oral testosterone undecanoate
219443685|NCT05845008|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
219443686|NCT06512831|DRUG|Isoniazid|Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
219443687|NCT01999712|PROCEDURE|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
219443688|NCT06179706|DIAGNOSTIC_TEST|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
219583355|NCT04258475|DRUG|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
219583356|NCT05410132|OTHER|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
219765100|NCT04086485|DRUG|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
219765101|NCT07076212|DRUG|Liposomal Irinotecan|50 mg/m2 will be administered on Day 1 of a 2-week cycle
219765102|NCT07076212|DRUG|Oxaliplatin|60 mg/m2 will be administered on Day 1 of a 2-week cycle
219196284|NCT06824090|OTHER|Smartphone Addiction Scale-Short Form|Smartphone Addiction Scale-Short Form: In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The scale is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60 and an increase in the score indicates an increased risk for smartphone addiction. The cut-off score of the scale was determined as 31 for men and 33 for women. In the Turkish validity and reliability study, Cronbach's alpha coefficient was found to be 0.86.
219443689|NCT01250743|DIETARY_SUPPLEMENT|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
219443690|NCT01920971|RADIATION|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
219443691|NCT01255293|PROCEDURE|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
219443692|NCT01255293|PROCEDURE|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
219443693|NCT04951180|OTHER|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
219443694|NCT02820038|BEHAVIORAL|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
219583357|NCT01884818|OTHER|Manipulation vs. TNS thoracic pain|
219583358|NCT01904617|OTHER|Dextrose|
219765103|NCT07076212|DRUG|5-Fluorouracil|5-fluorouracil (2400 mg/m2 over 46 hours) will begin administration on Day 1 of a 2-week cycle
219765104|NCT07076212|DRUG|Leucovorin|400 mg/m2 will be administered on Day 1 of a 2-week cycle
219765105|NCT07076212|DRUG|Gemcitabine (mg/m²)|1000 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
219765106|NCT07076212|DRUG|Nab-paclitaxel|125 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
219765107|NCT07076212|DRUG|Cisplatin|25 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
219765108|NCT03383094|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
219765109|NCT03383094|RADIATION|Radiation therapy|70 Gy in 33-35 fractions
219765110|NCT03383094|DRUG|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
219765111|NCT06769126|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
219765112|NCT06769126|DRUG|Ceralasertib|Given PO
218835909|NCT03469167|DEVICE|CEGP003|Application of CEGP003 to peptic ulcer bleeding
219443695|NCT02820038|BEHAVIORAL|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
219443696|NCT02820038|BEHAVIORAL|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
219443697|NCT03702855|DRUG|Tetrabenazine Tablets 25 mg|
219583359|NCT01904617|OTHER|Normal Saline|
219583360|NCT05001932|PROCEDURE|Cataract surgery|Randomized Clinical Trial
219583361|NCT00437632|DRUG|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
219583362|NCT00437632|DRUG|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
219765113|NCT06769126|PROCEDURE|Computed Tomography|Undergo CT scan
219765114|NCT06769126|BIOLOGICAL|Durvalumab|Given IV
219765115|NCT06769126|DRUG|Etoposide|Given etoposide
219765116|NCT06769126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219765117|NCT06769126|BIOLOGICAL|Monalizumab|Given IV
219765118|NCT06769126|DRUG|Platinum Compound|Given platinum compound
219765119|NCT06769126|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219765120|NCT06769126|DRUG|Saruparib|Given PO
219765121|NCT06769126|RADIATION|Thoracic Radiation Therapy|Undergo thoracic radiation
219765122|NCT07079995|BEHAVIORAL|Mentoring program|Schools in this group will participate in meetings and receive newsletters to help with program implementation.
219765123|NCT07079995|BEHAVIORAL|Waitlist|Schools in this group will wait 1 year to receive HSRC. Schools will not add or remove any current physical activity and/or healthy eating programs.
218835910|NCT03469167|DEVICE|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
218835911|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
218835912|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
218835913|NCT02743767|PROCEDURE|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
219443698|NCT01886755|DIETARY_SUPPLEMENT|ORS rehydration solution|
219443699|NCT01886755|DIETARY_SUPPLEMENT|placebo|
219443700|NCT02918539|DRUG|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
219443701|NCT02253940|DRUG|BILR 355 - Treatment A (current tablet formulation)|
218835914|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
219443702|NCT02253940|DRUG|BILR 355 - Treatment B (new tablet formulation)|
219443703|NCT02253940|DRUG|BILR 355 - Treatment C (new capsule formulation)|
219443704|NCT02253940|DRUG|BILR 355 - Treatment D (current tablet formulation)|
219443705|NCT02253940|DRUG|BILR 355 - Treatment E (new capsule formulation)|
219443706|NCT02253940|DRUG|Ritonavir|
219443707|NCT03029767|OTHER|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
219443708|NCT03029767|OTHER|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
219443709|NCT03029767|OTHER|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
219443710|NCT02067572|OTHER|Saline mouthwash|
219443711|NCT02067572|OTHER|Salvia mouthwash|
219443712|NCT03476967|PROCEDURE|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
219443713|NCT02235168|PROCEDURE|six minute walking test|
219443714|NCT04585672|OTHER|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
219443715|NCT03771781|DRUG|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
219443716|NCT03771781|DRUG|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
219443717|NCT02732249|DRUG|Esomeprazole|Given 30 min before morning and evening meals
219443718|NCT02732249|DRUG|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
219443719|NCT02732249|DRUG|Clarithromycin|Given 30 min after morning and evening meals
219583363|NCT00437632|DRUG|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
219583364|NCT03121287|OTHER|Imaging Biomarkers|Whole lung volumetric CT scans
219583365|NCT03121287|OTHER|Pulmonary|Pulmonary Function Tests \& 6 minute hall walk
219583366|NCT03121287|OTHER|Imaging|Cardiac MRI
219583367|NCT03121287|OTHER|Specimen Collection|Blood draw
219583368|NCT06300671|OTHER|Foot Posture Index-6|Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
219583369|NCT04842773|DIAGNOSTIC_TEST|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
218835915|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
218835916|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
218835917|NCT04436445|OTHER|Life style modification|Life style modification
218835918|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
218835919|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
219443720|NCT02732249|DRUG|Metronidazole|Given 30 min after meals or at bedtime
219443721|NCT02530099|PROCEDURE|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
219443722|NCT02530099|PROCEDURE|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
219443723|NCT06306352|OTHER|Vibrotactile feedback|The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
219443724|NCT02623699|DRUG|Tofersen|Administered as specified in the treatment arm.
219443725|NCT02623699|DRUG|Placebo|Administered as specified in the treatment arm.
219443726|NCT02699671|DEVICE|Bioresorbable Vascular Scaffold|
219443727|NCT02726048|DEVICE|Simplus/Eson|Released product Simplus and Eson masks
219443728|NCT01026350|DIETARY_SUPPLEMENT|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
219443729|NCT02302755|DRUG|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
219443730|NCT02949557|PROCEDURE|Decortication + bone grafts|
219443731|NCT05106335|DRUG|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
219443732|NCT05106335|DRUG|famitinib|famitinib malate capsules for oral administration
219443733|NCT05106335|DRUG|docetaxel|docetaxel for intravenous injection
219443734|NCT00278551|BIOLOGICAL|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
219443735|NCT00125437|DRUG|spironolactone|
219443736|NCT06451276|DEVICE|Nasoalveolar molding in unilateral cleft lip and palate|compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
219443737|NCT03177967|BEHAVIORAL|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
219443738|NCT03177967|OTHER|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
219443739|NCT03177967|OTHER|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
219443740|NCT04340960|OTHER|Home Monitoring|Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
219443741|NCT05656391|DIETARY_SUPPLEMENT|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
219443742|NCT06916338|RADIATION|18F-FAPI-04 PET scan|FAPI-04, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-FAPI-04 PET scan.
219443743|NCT02177812|DRUG|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
218835920|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
218835921|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
218835922|NCT01527045|DRUG|Cyclosporine|Given PO
218835923|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
218835924|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
218835925|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
218835926|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
218835927|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
218835928|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
219443744|NCT02177812|DRUG|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
219443745|NCT06032572|PROCEDURE|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
219443746|NCT06032572|PROCEDURE|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
219443747|NCT00089999|DRUG|Lapatinib|
219583370|NCT02070874|BEHAVIORAL|telehealth enhanced pain management|
219583371|NCT03357965|OTHER|Questionnaire|Women who had gave birth in 6 weeks
219583372|NCT03590392|BIOLOGICAL|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
219583373|NCT00415194|DRUG|pemetrexed|500 mg/m\^2, IV, every 21 days, six 21 day cycles
219583374|NCT00415194|DRUG|cisplatin|75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
219583375|NCT00415194|DRUG|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
219583376|NCT01297465|DRUG|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
219583377|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
219765124|NCT07081568|DEVICE|transcutaneous auriculai vagus nerve stimulation|During bi-ear synchronous vagus nerve stimulation, the patient was positioned in a supine position. Two stimulating electrodes were placed bilaterally in the concha cymba and concha cavum of the ears. The patient received treatment for 30 minutes per session, once daily, 5 days per week, for a total of 4 weeks. Following each treatment session, the device was disinfected with 75% alcohol.
219765125|NCT06297226|BIOLOGICAL|Arlocabtagene Autoleucel|Specified dose on specified days
219196285|NCT06824090|OTHER|Hand Grip Strength Assessment|Hand grip strength was measured with 'Saehan Hydraulic Hand Dynamometer'. Participants were informed about the correct holding position and use of the instrument. In the measured arm, the position of 90̊ flexion from the elbow joint and completely adjacent to the body was used. The participant's hand was placed in the second grip position of the dynamometer and asked to make the strongest grip he/she could make, right and left measurements were taken.
219443748|NCT05979155|BIOLOGICAL|NWY001|Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
219765126|NCT05851443|DRUG|povorcitinib|povorcitinib
219765127|NCT05851443|OTHER|placebo|placebo
219765128|NCT05851443|DRUG|ICS-LABA|Background Therapy
219765129|NCT06282159|DRUG|DNTH103|Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks
219765130|NCT06282159|DRUG|Placebo|Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
219765131|NCT06212999|DRUG|Povorcitinib|Oral; Tablet
219765132|NCT06834373|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219765133|NCT06834373|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219765134|NCT06834373|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219443749|NCT05979155|BIOLOGICAL|NWY001|Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
219443750|NCT00453323|DRUG|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
219443751|NCT00453323|DRUG|Capecitabine|capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
219443752|NCT02370550|DRUG|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
219443753|NCT02370550|DRUG|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
219443754|NCT02370550|DRUG|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
219443755|NCT02370550|DRUG|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
219443756|NCT00616772|DRUG|ABT-335|Capsule
219443757|NCT00616772|DRUG|Placebo|Capsule
219443758|NCT00616772|OTHER|Atorvastatin|Capsule
219443759|NCT03389269|OTHER|Meal test|240 min mixed meal test with aspiration using AspireAssist.
219443760|NCT00588757|DEVICE|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
219583378|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
219765135|NCT06834373|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo standard of care CAR-T therapy
219765136|NCT06834373|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219765137|NCT06834373|DRUG|Golcadomide|Given PO
219765138|NCT06834373|PROCEDURE|Leukapheresis|Undergo leukapheresis
218835929|NCT00649285|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
218835930|NCT00649285|DRUG|Macrobid® Capsules 100 mg|100mg, single dose fed
218859909|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
219583379|NCT01297465|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
219583380|NCT05067530|DRUG|Palbociclib|CDK4/6 inhibitor
219583381|NCT05067530|DRUG|Paclitaxel|Chemotherapy
219583382|NCT05067530|DRUG|Carboplatin|Chemotherapy
219583383|NCT00969540|DEVICE|Active Mattress Cover|Active Mattress Cover
219583384|NCT00969540|DEVICE|Placebo Mattress Cover|Placebo Mattress Cover
219583385|NCT06162104|OTHER|No intervention|No intervention
219765139|NCT06834373|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219765140|NCT06834373|BIOLOGICAL|Rituximab|Given IV
219765141|NCT06858787|DEVICE|Continuous glucose monitor|Device is a remote sensor applied to the upper extremity that continuously samples glucose of interstitial fluid and uploading results to a mobile application.
219765142|NCT06846723|OTHER|Stress ball|In addition to the routine treatment and care practices of the outpatient clinic, the patients included in the study group will be applied stress ball during ESWL. The researcher (CK) will explain and show the patients how to apply the stress ball 10 minutes before the procedure. The stress ball will be applied during the ESWL session and a round, medium-hard, high-quality silicone ball with an average diameter of 6 cm will be used. Patients will be asked to take the ball in the palm of their hand and squeeze and release the ball once after counting to three. Patients will be instructed to continue this practice until the end of the ESWL procedure and to pay attention to the stress ball during the procedure. The ball will be washed and cleaned after each use and wiped with disposable asepsis wipes before being given to the patient.
219443761|NCT00588757|DEVICE|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
219765143|NCT04645160|DRUG|Tivozanib|Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
219583386|NCT04616339|DRUG|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
219583387|NCT00270348|DRUG|ciclesonide|
219583388|NCT05304286|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
219583389|NCT05816057|BIOLOGICAL|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
218835931|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
218835932|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
219443762|NCT03091426|DRUG|Omiganan|Omiganan 1%
219443763|NCT03091426|DRUG|Omiganan|Omiganan 1.75%
219443764|NCT03091426|DRUG|Omiganan|Omiganan 2.5%
219443765|NCT03091426|DRUG|Placebo|Vehicle
219583390|NCT00986063|GENETIC|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
219583391|NCT00986063|OTHER|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
219765144|NCT02355184|DRUG|PRO 140 350mg weekly subcutaneous (SC) injection.|CCR5 Antagonist
219765145|NCT06668584|DRUG|Olutasidenib|Given by mouth
219765146|NCT07082543|DRUG|AZ-3102|Nizubaglustat
219765147|NCT07082543|DRUG|Placebo|Placebo
219765148|NCT07083596|OTHER|Experimental: Probiotic with LcS|Probiotic drink with LcS will be consumed once per day for four weeks
219765149|NCT07083596|OTHER|Control|Brochure containing recommendations to improve constipation will be provided at end of study.
219765150|NCT07122193|DRUG|NT 201|Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
219765151|NCT07122193|DRUG|NT 201 Placebo|NT 201 matching-placebo
219765152|NCT07079865|DEVICE|SPRINT PNS modulation system|Participants will receive treatment using the commercially available SPRINT PNS system. Their pain levels will be assessed using qualified scales including NRS and BPI and their quality of life using the PROMIS scale.
219765153|NCT07077005|OTHER|Exercise training|Supervised, combined endurance and resistance training
219765154|NCT06903065|DRUG|RO7790121|Participants will be administered RO7790121 via IV infusion on Day 1, and Weeks 2, 6 and 10. Participants will then be administered RO7790121 SC injections every four weeks (Q4W) from week 14 up to and including Week 50.
219765155|NCT05607004|DRUG|(Z)-endoxifen|(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
219765156|NCT05607004|DRUG|goserelin|goserelin 3.6 mg subcutaneous implant
219765157|NCT02655016|DRUG|Niraparib|Niraparib will be administered.
219765158|NCT02655016|DRUG|Placebo|Placebo will be administered.
219765159|NCT07081932|DRUG|Nerandomilast|Nerandomilast
219765160|NCT07081932|DRUG|Bosentan|Bosentan
219765161|NCT07086079|DRUG|DOR/ISL|Oral tablet
218835933|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
219443766|NCT02846857|OTHER|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
219765162|NCT06664814|DRUG|ManNAc|2 grams twice daily by mouth
219765163|NCT06929273|DRUG|KarXT|Specified dose on specified days
218835934|NCT04301661|OTHER|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
218835935|NCT04301661|DRUG|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
218835936|NCT04301661|DRUG|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
218835937|NCT04301661|DRUG|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
219016441|NCT05864534|DRUG|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
219016442|NCT05864534|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
219443767|NCT02846857|OTHER|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
219443768|NCT02846857|OTHER|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
219443769|NCT02846857|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
219443770|NCT02846857|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
219443771|NCT02846857|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
219443772|NCT02846857|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
219443773|NCT06932133|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound will be performed on symptomatic breast patients. The images will be analysed by AI
219443774|NCT06286267|DIAGNOSTIC_TEST|imaging|Patient medical imaging materials including ultrasound, mammography, CT, MRI
219443775|NCT01186094|DEVICE|Cypher|Sirolimus-eluting stent
219443776|NCT01186094|DEVICE|Endeavor Resolute|Zotarolimus-eluting Stent
219443777|NCT06234072|DRUG|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
219443778|NCT06234072|DRUG|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
219443779|NCT01655940|DEVICE|Somanetics cerebral oximeter|Somanetics cerebral oximeter
219443780|NCT01655940|DEVICE|CASMED cerebral oximeter|CASMED cerebral oximeter
219443781|NCT05316519|OTHER|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
219443782|NCT06939465|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The participants will undergo a 6-week cognitive behavioral therapy (CBT) guided by a psychologist, with one session per week, each lasting 1 hour.
219443783|NCT06939465|BEHAVIORAL|Lifestyle management (sham control)|The participants will undergo a 6-week lifestyle management (sham control) guided by a psychologist, with one session per week, each lasting 1 hour.
219475672|NCT06647849|OTHER|centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department|"In the participating centers included in the no training arm, interns will have no specific training in announcement. Patients will receive information concerning the diagnosis of a terminated pregnancy or miscarriage from interns not trained in simulation.~During the course of the study, training in the announcement of a miscarriage will be offered to interns from centers in the no training group."
219475673|NCT02318342|DRUG|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
219765164|NCT03057054|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
219765165|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299|Given PO or via NJ, NG or G tube
219765166|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299v|Given PO or via NJ, NG or G tube
219016443|NCT05864534|DEVICE|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
219016444|NCT05488457|DRUG|deuterated oxytocin (d5OT)|Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
219016445|NCT02343042|DRUG|Selinexor|Oral tablets
219016446|NCT02343042|DRUG|Dexamethasone|Oral tablets
219016447|NCT02343042|DRUG|Lenalidomide|Oral capsule
219016448|NCT02343042|DRUG|Pomalidomide|Oral tablets
219016449|NCT02343042|DRUG|Bortezomib|Subcutaneous Injection (single use vial)
219016450|NCT02343042|DRUG|Daratumumab|Intravenous Infusion
219016451|NCT02343042|DRUG|Carfilzomib|Intravenous infusion
219016452|NCT02343042|DRUG|Ixazomib|Oral capsule
218835938|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
219583392|NCT01593514|BIOLOGICAL|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
218835939|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
218835940|NCT06472037|DRUG|Cadonilimab|10mg/kg，IV，D1，Q3W
219443784|NCT05286268|DIAGNOSTIC_TEST|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
219443785|NCT00354939|DRUG|Insulin glargine|
219583393|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
219583394|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
219583395|NCT01593514|BIOLOGICAL|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
219583396|NCT01593514|BIOLOGICAL|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
219583397|NCT02714517|OTHER|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
219583398|NCT02714517|OTHER|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
219583399|NCT00378612|DEVICE|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
219765167|NCT03057054|OTHER|Placebo Administration|Given PO or via NJ, NG or G tube
219765168|NCT05675527|BIOLOGICAL|Low-dose PRP|Injection
218835941|NCT06472037|DRUG|Gemcitabine|1000mg/m2，IV，D1、D8、D15，Q4W
218835942|NCT06472037|DRUG|Nab-Paclitaxel|125mg/m2，IV，D1、D8、D15，Q4W
218835943|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
218835944|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
218835945|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
219765169|NCT05675527|BIOLOGICAL|High-dose PRP|Injection
219765170|NCT05675527|OTHER|Saline|Injection
219765171|NCT06895070|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
219765172|NCT06561360|DRUG|Vemurafenib|Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.
219443786|NCT06506851|OTHER|AR-based Training with Microsoft HoloLens 2®|Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
219443787|NCT06506851|OTHER|Traditional Guideline-based Self-Learning|Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
219443788|NCT03688893|DEVICE|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
219443789|NCT06944444|DRUG|SSS59|A humanized antibody targeting MUC17
219443790|NCT02794025|DRUG|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
219443791|NCT02794025|DRUG|natural saline|Control group also received natural saline via a micro pump,
219443792|NCT06350357|OTHER|punching closure|The hole clamping and the grooves hold the metal clips better
219443793|NCT06350357|OTHER|Conventional clipping|Metal lip closure is one of the most commonly used closure methods
219443794|NCT03872557|DIETARY_SUPPLEMENT|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
219443795|NCT02072746|DIETARY_SUPPLEMENT|Zinc|
219443796|NCT02072746|DIETARY_SUPPLEMENT|Placebo|
219443797|NCT06948552|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Participants will receive a single oral dose of 5-aminolevulinic acid (20 mg/kg) approximately 2 to 4 hours prior to surgery. The goal is to evaluate the feasibility of using fluorescence cystoscopy with blue light to improve tumor detection and visualization during ureteroscopic resection of upper tract urothelial carcinoma.
219443798|NCT06949930|OTHER|Optimized package of child essential health and nutrition services|Optimized package of child essential health and nutrition services
219443799|NCT06949930|OTHER|Standard package of essential child and nutrition services|Standard package of essential child and nutrition services
219443800|NCT06949358|DRUG|Olipudase alfa|Pharmaceutical form:Powder for concentrate for solution for infusion-Route of administration:intravenous infusion
219443801|NCT06948188|DIAGNOSTIC_TEST|Infrared exposure test|"Patients will undergo a standardized infrared exposure test (this test is specifically for research purposes) to evaluate the occurrence of cholinergic urticaria reaction.~IR exposure test with non-invasive core body temperature measurements, evaluate the occurrence of cholinergic urticaria up to 10 minutes after the end of the test, stop the test at the first clinical signs of urticaria.~Desk lamp with infrared bulb, switched on 20cm vertically from the forearm posteriorly for 3 minutes. Reading up to 10 minutes after end of exposure test: diagnosis of cholinergic urticaria flare-up if presence of pruritic micropapules on erythematous background of trunk +/- limbs. Stop the test as soon as urticarial lesions appear."
219443802|NCT06949293|OTHER|Hand massage with lavender oil|Each hand of the patient will be massaged with lavender oil for 5 minutes before and during cystoscopy. Before the application, 5% lavender oil will be applied to a small part of the hand and this area will be monitored for signs of allergic reaction such as swelling and redness. If no allergic reaction is observed, the study will continue.
219443803|NCT06949293|OTHER|Classic hand massage|Each hand of the patient will be massaged with baby oil for 5 minutes before and during the cystoscopy procedure.
219443804|NCT06949293|OTHER|Lavender inhalation|Before and during the cystoscopy procedure, 2-3 drops of 5% lavender oil will be poured onto a 5x5 cm sterile gauze. It will be placed 10 cm away from the patient's nose and sniffed for 10 minutes.
219443805|NCT06949891|DIETARY_SUPPLEMENT|Ketogenic diet|A eucaloric ketogenic diet (30-40 g carbohydrate per day) for 3 months, followed by a less strict ketogenic diet (50-60 g carbohydrate per day) for another 3 months.
219583400|NCT02397408|DRUG|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
219583401|NCT02397408|DRUG|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
219583402|NCT02397408|PROCEDURE|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
219765173|NCT06561360|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.
219443806|NCT06949891|DIETARY_SUPPLEMENT|Mediterranean diet|The control group will receive a eucaloric diet according to the national healthy food guidelines/Mediterranean diet.
219443807|NCT01570452|PROCEDURE|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
219443808|NCT06948734|DIAGNOSTIC_TEST|Clinical and radiographic examination|In order to evaluate the pulpal and periapical health of natural teeth adjacent to dental implants at specific time intervals, percussion, palpation, and pulpal diagnostic tests were performed, and the presence of any pathological changes was monitored using radiographic examinations.
219443809|NCT06949059|DRUG|Hydromorphone|Hydromorphone 1mg was given intravenously and conventional treatment was performed at the same time.
219583403|NCT01560481|DRUG|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
219583404|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
219583405|NCT01560481|DRUG|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
219583406|NCT01560481|DRUG|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
219583407|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
219583408|NCT01560481|DRUG|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
219583409|NCT01560481|DRUG|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
219583410|NCT05621408|BEHAVIORAL|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
219583411|NCT00369655|BIOLOGICAL|ziv-aflibercept|
219765174|NCT06561360|DRUG|Cladribine|Cladribine IV on days 1-5 concurrently with rituximab.
219583412|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
219583413|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
219583414|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
219583415|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
219583416|NCT00573781|DIETARY_SUPPLEMENT|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
219583417|NCT00573781|DIETARY_SUPPLEMENT|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
219583418|NCT00573781|DIETARY_SUPPLEMENT|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
219583419|NCT05886010|DEVICE|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219583420|NCT05886010|DEVICE|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219583421|NCT05886010|DEVICE|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219765175|NCT06561360|DRUG|Rituximab|Rituximab on days 1-5 concurrently with rituximab.
219765176|NCT06904261|DRUG|Migalastat HCl 20 mg|Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.
218835946|NCT03611816|GENETIC|Blood taken|Collection of DNA
219443810|NCT06949761|DRUG|QLC1101+QL1203|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1203, developed by Qilu Pharmaceutical Co., Ltd., is a recombinant anti-EGFR fully human monoclonal antibody injection and a biosimilar to Vectibix®
219443811|NCT06949761|DRUG|QLC1101+QL2107|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL2107 developed by Qilu Pharmaceutical Co., Ltd. is a potential biosimilar to Pembrolizumab (Keytruda®)
219583422|NCT05886010|DEVICE|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219583423|NCT05886010|DEVICE|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219583424|NCT05029830|COMBINATION_PRODUCT|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
219583425|NCT05634850|DEVICE|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
219765177|NCT06878859|BEHAVIORAL|Amplification of Positivity - Cannabis Use (AMP-C)|AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
218835947|NCT03611816|GENETIC|Blood taken|Collection of plasma
219765178|NCT06735534|DEVICE|FARAPULSE™ Pulsed Field Ablation System|"The FARAPULSE™ Pulsed Field Ablation System is indicated for the treatment of symptomatic atrial fibrillation.~The FARAWAVE Catheter is indicated for the isolation of pulmonary veins and posterior wall in the treatment of drug-refractory, recurrent, symptomatic paroxysmal and persistent atrial fibrillation. The FARAWAVE Catheter is also indicated for the for the isolation of pulmonary veins and posterior wall in the treatment of persistent atrial fibrillation as an alternative to anti-arrhythmic drug (AAD) therapy as an initial rhythm control strategy.~The FARAPOINT™ PFA Catheter is indicated for use as an adjunctive device for 1) the creation of an ablation line between the inferior vena cava and the tricuspid valve and/or 2) Mitral Isthmus, when the FARAWAVE Catheter is used in the endocardial treatment of persistent atrial fibrillation (episode duration no greater than 12 months)."
219765179|NCT00001529|DRUG|G-CSF|After medical clearance, volunteers will undergo outpatient mobilization with daily subcutaneous injections of filgrastim (G-CSF). The first dose will be administered at the NIH Clinical Center, with one-hour monitoring for immediate reactions. Volunteers may either return to NIH for daily injections or self-administer at home after training.
219583426|NCT02881138|DRUG|RC48-ADC|
219443812|NCT06949761|DRUG|QLC1101+QL1706|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1706 Injection (QL1706) is a combination antibody developed by Qilu Pharmaceutical Co., Ltd. It consists of two full-length immunoglobulin G (IgG) antibodies: anti-PD-1 monoclonal antibody (hereafter referred to as anti-PD-1) and anti-CTLA-4 monoclonal antibody (hereafter referred to as anti-CTLA-4)
219443813|NCT06949761|DRUG|QLC1101+docetaxel|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；Docetaxel is a tubulin binding agent that prevents cell division by stabilizing microtubule structure and leads to apoptosis
219583427|NCT01683838|DRUG|Fampridine-SR|25mg bid (twice daily)
219765180|NCT05180474|BIOLOGICAL|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
219765181|NCT06817226|BEHAVIORAL|Assess decision making context.|Semistructured interviews will be conducted to understand the situations and settings in which breast reconstruction decisions occur for this population, including the role of digital tools and social media.
219765182|NCT06817226|BEHAVIORAL|Solicit input from the target population|Solicit input from the target population about the tool such as translation, website programming, and community feedback.
219765183|NCT06817226|BEHAVIORAL|Integration and refinemen of the decision aid|A final round of cognitive interviews with breast cancer survivors while they use the revised tool and a final round of website programming.
219765184|NCT06828835|OTHER|Reach for Equity in Pediatric Obstructive Sleep Evaluation (REPOSE)|The REPOSE intervention consists of a centralized patient navigator who (1) identifies and addresses dynamic individual barriers, (2) provides support for parent-child dyads, and (3) facilitates bidirectional SDB care coordination between clinical teams and parents to achieve evidence-based care. The goals of the REPOSE intervention are to systematically address barriers to care, develop parental self-efficacy to enhance healthcare utilization (e.g., receipt of recommended care and adherence to evidence-based care), and to improve symptom severity and quality of life.
219765185|NCT06828835|OTHER|Usual Care|Usual care is defined by standard clinical care delivered without a protocolized intervention (e.g., the ordinary course of care).
219765186|NCT05973630|BIOLOGICAL|ATA-200|single intravenous infusion
219443814|NCT06174961|DRUG|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
219443815|NCT06174961|BEHAVIORAL|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
219583428|NCT01683838|DRUG|Placebo|Placebo
219583429|NCT04662138|DRUG|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
219583430|NCT01646138|BIOLOGICAL|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
219583431|NCT00256438|DEVICE|Transcranial Direct Current Stimulation|
219583432|NCT05638958|DEVICE|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
219583433|NCT04049617|DRUG|Evixapodlin|Tablets administered orally.
218835948|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
219583434|NCT04657796|DEVICE|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
219583435|NCT05157958|BIOLOGICAL|ALLO-ASC-SHEET|Weekly administration
219583436|NCT05157958|OTHER|Vehicle Control|Weekly administration
219583437|NCT05721118|DIAGNOSTIC_TEST|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
219583438|NCT03551496|COMBINATION_PRODUCT|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
219583439|NCT03551496|DEVICE|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
219016453|NCT02343042|DRUG|Elotuzumab|Intravenous infusion
219016454|NCT02343042|DRUG|Clarithromycin|Tablets
219016455|NCT02343042|DRUG|Belantamab Mafodotin|Intravenous infusion
219765187|NCT06746402|DRUG|BMS-986278|Specified dose on specified days
219583440|NCT02413216|BEHAVIORAL|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
219583441|NCT02413216|OTHER|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
219443816|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
218835949|NCT06835322|DRUG|Finerenone|50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
218835950|NCT06835322|DRUG|Placebo|50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
219443817|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
219443818|NCT06174961|BEHAVIORAL|No exercise|No exercise
219443819|NCT01167153|DRUG|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
219443820|NCT01167153|DRUG|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
219443821|NCT06240793|PROCEDURE|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
219443822|NCT06240793|PROCEDURE|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
219583442|NCT00986518|BIOLOGICAL|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
219583443|NCT02882243|DEVICE|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
219583444|NCT04340921|BIOLOGICAL|COVID-19 exposure|Observation only
219765188|NCT06746402|DRUG|Placebo|Specified dose on specified days
219765189|NCT06746402|DRUG|Moxifloxacin|Specified dose on specified days
219765190|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
219765191|NCT05411081|BIOLOGICAL|Atezolizumab|Given IV
219765192|NCT05411081|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219765193|NCT05411081|PROCEDURE|Bone Scan|Undergo bone scans
218835951|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
218835952|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
218835953|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
218835954|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
218835955|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
219016456|NCT02343042|DRUG|Mezigdomide|Oral Capsules
219443823|NCT06066853|DRUG|MDMA|MDMA-assisted psychotherapy
219443824|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
219443825|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
219443826|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
219443827|NCT06949020|DRUG|JMKX003142 placebo|JMKX003142 placebo for placebo groups once daily for five days.
219583445|NCT01524679|DRUG|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
219765194|NCT05411081|DRUG|Cabozantinib S-malate|Given PO
219765195|NCT05411081|PROCEDURE|Computed Tomography|Undergo CT scans
219765196|NCT05411081|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218835956|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
219765197|NCT01087294|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant
219765198|NCT01087294|BIOLOGICAL|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
219583446|NCT03835143|PROCEDURE|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
219583447|NCT04631952|BEHAVIORAL|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
219583448|NCT04631952|BEHAVIORAL|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
219443828|NCT06949046|OTHER|nursing-led communication support|nursing-led communication support program using mobile health information
219443829|NCT06949046|OTHER|Nursing routine treatment|Nursing routine treatment
219443830|NCT06949540|DIETARY_SUPPLEMENT|Blue Burn Tincture|Participants will complete self-assessments and provide weight and blood measurements during the study.
219443831|NCT06948305|BEHAVIORAL|instant messaging software|instant messaging software
219443832|NCT03186261|DRUG|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
219443833|NCT03186261|DRUG|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
219443834|NCT00633802|DRUG|Risperidone|1 mg/d risperidone for 10 weeks or placebo
219583449|NCT06348706|DRUG|Dipeptidyl peptidase 4 (DPP-4) inhibitor|Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
219583450|NCT00801099|DRUG|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
219583451|NCT01551888|DRUG|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
219443835|NCT01039311|DEVICE|Optical Coherence Tomography|Obtain OCT images.
219765199|NCT01087294|PROCEDURE|Leukapheresis|Donors will undergo leukapheresis
218835957|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
219583452|NCT01551888|DRUG|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
219583453|NCT06130098|OTHER|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
219583454|NCT06130098|OTHER|experimental group|"Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge."
219583455|NCT06314789|DIAGNOSTIC_TEST|doing lung ultrasonography|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
218835958|NCT00332579|DRUG|Naltrexone|daily
219443836|NCT00517205|PROCEDURE|Non-contrast helical computerized tomogram (NCHCT)|
218835959|NCT00332579|DRUG|Placebo|daily
218835960|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
218835961|NCT05856929|OTHER|no Intervention|no intervention
218835962|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
218835963|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
219443837|NCT04628598|BEHAVIORAL|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
219443838|NCT05628402|OTHER|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
219443839|NCT01203124|DRUG|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
219443840|NCT01203124|DRUG|Placebo|Placebo
219443841|NCT00797706|DRUG|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
219443842|NCT00048009|DRUG|Dual Integrin Antagonist|
218835964|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
219443843|NCT06948877|BEHAVIORAL|ARMOR Online|"The online version of ARMOR comprised three core components. The first was an MI-based relationship check-up with a brief relationship assessment. In the second component, SMs chose relationship improvement domains from a list of 10 topic areas or modules and watched a short (5-7 minute) video on their chosen area providing (a) evidence-based or evidence-informed psychoeducation, (b) modeling of skills, and (c) practice of the skills. For the third component, SMs were asked MI's key question (i.e., What's the next step? Miller \& Rollnick, 2023) and, if desired, completed a planning module where they were given the opportunity to create a personalized action plan (specifying how they might test any planned changes to see if they had the desired impact)."
219443844|NCT06569160|DEVICE|Upper-room UVGI (Ultra-Violet Germicidal Irradiation)|"Nursing homes are equipped with UVGI devices in all common living places. UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team. The centers included will be randomized into two arms. In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2. In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.~The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI equipments will be switched off in both arms."
219765200|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
219765201|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
219765202|NCT06906562|DRUG|Pemigatinib|Pemigatinib will be taken orally with a targeted starting does of 13.5 mg
219765203|NCT06906562|PROCEDURE|Computed Tomography (CT)|Undergo CT scan
219443845|NCT05444829|DEVICE|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
219765204|NCT06906562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219443846|NCT05444829|DEVICE|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
219443847|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
219443848|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
219765205|NCT06906562|PROCEDURE|Optical Coherence Tomography|Undergo OCT
219765206|NCT06906562|PROCEDURE|Bone Scan|Undergo whole body bone scan
219765207|NCT06906562|PROCEDURE|Ophthalmoscopy|Undergo dilated ophthalmoscopy
219765208|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
219765209|NCT07091630|BIOLOGICAL|Empasiprubart IV|Intravenous infusion of empasiprubart
219016476|NCT05707871|DRUG|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
219443849|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
219765210|NCT07091630|OTHER|Placebo IV|Intravenous infusion of placebo
219765211|NCT01000350|DRUG|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
219765212|NCT01000350|OTHER|Placebo|Placebo x1 lactose tablet
219765213|NCT07082725|DRUG|Nizubaglustat|AZ-3102
219765214|NCT07082725|DRUG|Placebo|Matching placebo
219443850|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
219583456|NCT06169189|BEHAVIORAL|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
219583457|NCT02331329|DEVICE|NICOM cardiac output measurement|
219583458|NCT02331329|DEVICE|Cardiac MRT cardiac output measurement|
219583459|NCT03422367|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
219583460|NCT03281863|DIAGNOSTIC_TEST|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
219583461|NCT06483139|PROCEDURE|Plasma exchange|Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
219443851|NCT03024151|DRUG|Synthroid|T4 mono replacement
219443852|NCT00912639|DRUG|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
219443853|NCT03380169|OTHER|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
219443854|NCT03380169|OTHER|Prophylactic conventional wound dressing|Conventional gauze dressing
219443855|NCT00645190|DRUG|Galantamine HBr|
219443856|NCT02308553|DRUG|Nintedanib|Nintedanib (150 mg or 200 mg BID)
219583462|NCT06483139|DRUG|Daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
219583463|NCT02455050|DRUG|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
219583464|NCT02455050|DRUG|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
219765215|NCT06792695|DRUG|Volrustomig|Volrustomig will be administered as intravenous (IV) infusion.
219765216|NCT06792695|DRUG|FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|FOLFIRI will be administered as IV infusion.
219765217|NCT06792695|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion.
219765218|NCT07094269|OTHER|Occupational Therapy Intervention|"Participants in the intervention group will take part in the structured, manualized Packer Managing Fatigue Group Program (Packer et al.), delivered in groups of 8-10 by a licensed occupational therapist. The intervention will consist of six weekly sessions, each lasting 120 minutes, held in a dedicated outpatient room equipped with a whiteboard, group seating, and educational materials.~Each session will address a specific theme: (1) The importance of Rest, (2) Communication and Body Mechanics, (3) Tools, Technology, and ergonomics, (4) Priorities and Standard (5) Putting it all Together, (6) Some Closing Thoughts. Materials will include a participant workbook2, printed handouts, pens, markers, and name tags. All materials will be provided in Italian."
219765219|NCT07094269|BEHAVIORAL|Fact-sheets|Participants in the control group will receive six weekly fact sheets containing general information about Parkinson's disease. These fact sheets serve as a placebo intervention to control for attention and information exposure, without providing any structured fatigue management strategies. This approach helps isolate the specific effects of the active intervention compared to usual care.
219443857|NCT02308553|DRUG|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
219443858|NCT02308553|DRUG|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
219443859|NCT04830657|OTHER|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
219443860|NCT05091073|DRUG|NNC0385-0434|All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
219443861|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
219443862|NCT05191381|BIOLOGICAL|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
219583465|NCT02455050|DRUG|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
219583466|NCT06299917|OTHER|WORK-ON|The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
219583467|NCT03545035|DRUG|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
219583468|NCT02981303|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
219583469|NCT02981303|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
219583470|NCT02325518|DRUG|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
219583471|NCT02325518|DRUG|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
219583472|NCT02325518|DRUG|Subject's habitual PGA monotherapy|
219583473|NCT05578196|DRUG|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
219583474|NCT05578196|DRUG|physiological saline solution|physiological saline solution 20ml
219583475|NCT00103818|DRUG|gaboxadol|Duration of Treatment: 3 months
219583476|NCT00103818|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
219583477|NCT00631449|DRUG|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
219016477|NCT05707871|OTHER|usual brand of Cigarettes|Usual Brand of Cigarettes
219443863|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
219583478|NCT00631449|DRUG|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
219443864|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
219016483|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
219016484|NCT04746235|DRUG|Venetoclax|Given PO
219443865|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
219443866|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
219443867|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
219443868|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
219443869|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
219443870|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
219443871|NCT05450445|DEVICE|myHealthHub|myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
219443872|NCT05450445|DEVICE|TV-only|myHealthHub device equipped with the TV-only entertainment option.
219443873|NCT00225667|DRUG|Irbesartan|
219443874|NCT02763267|OTHER|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
219443875|NCT04193605|BEHAVIORAL|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
219443876|NCT02144090|DEVICE|Fractional flow reserve measurement|Fractional flow reserve measurement
219443877|NCT02870244|BIOLOGICAL|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells."
219765220|NCT07091968|BEHAVIORAL|Technology-Enabled Tailored Referral|Participants in the intervention arm will receive a technology-enabled, text-based referral platform designed to improve depression referral uptake. The platform includes an initial text with a brief video explaining common barriers, tailored text messages based on participant-identified barriers, and an automated referral link. Messages are mapped to stages of readiness using the Transtheoretical Model and sent every two days over a two-week period to non-responders or decliners. This approach aims to engage survivors with depression through personalized, accessible, and stage-matched communication.
219765221|NCT06901531|DRUG|zolbetuximab|Participants will receive an IV infusion of zolbetuximab on Cycle 1 Day 1 (C1D1) followed by subsequent IV infusion every 2 weeks or every 3 weeks.
219765222|NCT06901531|DRUG|Pembrolizumab|Participants will receive an IV infusion of pembrolizumab every 3 weeks or every 6 weeks.
219765223|NCT06901531|DRUG|Capecitabine|Participants receiving CAPOX regimen of chemotherapy will receive capecitabine Tablet twice daily orally on days 1 through 14 and days 22 through 35 of each cycle.
219765224|NCT06901531|DRUG|Oxaliplatin|Participants receiving CAPOX or mFOLFOX6 regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
219765225|NCT06901531|DRUG|Folinic acid (leucovorin or local equivalent)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.
219196286|NCT06824090|OTHER|Finger Lateral Grip Strength Assessment|Finger lateral grip strength was measured with 'Saehan Hydraulic pinch gauge'. Participants were informed about the correct holding position and use of the instrument. While the participant was sitting on a chair with arms supported, the shoulder was adjacent to the trunk and neutral, the elbow joint was in 90 ̊ flexion, the forearm was neutral, the wrist was in 0-30 ̊ extension and 0-15 ̊ ulnar deviation. Right and left finger lateral grip measurements were taken.
219443878|NCT04765657|DRUG|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
219765226|NCT06901531|DRUG|5-fluorouracil (5-FU)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion, or IV bolus of 5-FU once every 2 weeks.
218835965|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
219443879|NCT04765657|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
219765227|NCT06901531|DRUG|Placebo|Participants will receive an IV infusion of placebo (0.9% of sodium chloride) on C1D1 followed by subsequent IV infusion every 2 weeks or every 3 weeks.
219765228|NCT07085572|DRUG|Cemiplimab|350 mg IV Q3W
219765229|NCT07094906|DEVICE|Isometric handgrip exercise training|Maximum voluntary contraction (MVC) will be assessed first in both hands using a hand dynamometer with a digital display (Handexer HFEH20); the participant squeezes the hand dynamometer as hard as they can for 3 to 5 attempts to obtain the MVC. The intervention is an 8- week training protocol that consists of handgrip exercises performed by the participant at home. Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 30% of MVC for 2 minutes (i.e. isometric) followed by 1 minute of rest.
219765230|NCT07094906|DEVICE|Sham Training|Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 3 - 5% of MVC rather than 30%.
219443880|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~\+ 3 extra exercise sessions led by a caregiver (+Care)"
219443881|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
219443882|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
219443883|NCT02734849|DRUG|AK001 low dose|25 mg AK001 will be administered as multiple doses
219443884|NCT02734849|DRUG|AK001 high dose|250 mg AK001 will be administered as multiple doses
219443885|NCT02734849|DRUG|Placebo|Placebo will be administered as multiple doses
219443886|NCT05129124|DEVICE|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
218835966|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
218835967|NCT02515799|OTHER|Placebo|Inhaled Placebo
218835968|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
218835969|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
218835970|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
218835971|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
218835972|NCT01282242|DRUG|IV rt-PA|open-label
219016492|NCT00594997|BEHAVIORAL|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
219443887|NCT05129124|DEVICE|Commercially available Ultra for Astigmatism Contact Lenses|Commercially available Ultra for Astigmatism Contact Lenses at different fittings
219583479|NCT00586352|OTHER|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
218835973|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
219016493|NCT00594997|BEHAVIORAL|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
219583480|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
219583481|NCT04505137|OTHER|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
219443888|NCT04744883|OTHER|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
219583482|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
219583483|NCT04847349|DIETARY_SUPPLEMENT|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
219583484|NCT04847349|DIETARY_SUPPLEMENT|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
219583485|NCT04847349|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
219765231|NCT05618782|DRUG|LEVI-04|LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR), for the treatment of chronic pain.
219765232|NCT05618782|OTHER|Placebo|Saline vehicle
219765233|NCT06730100|PROCEDURE|Biopsy Procedure|Undergo biopsy
219583486|NCT04193306|DRUG|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
219583487|NCT04193306|OTHER|Placebo|Placebo s.c. every 2 weeks
219765234|NCT06730100|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219583488|NCT03393806|DRUG|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
219765235|NCT06730100|PROCEDURE|Computed Tomography|Undergo CT scan
219765236|NCT06730100|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219765237|NCT06730100|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
219583489|NCT03393806|DRUG|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
219765238|NCT06730100|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
218835974|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
218835975|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
218835976|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
218835977|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
218835978|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
219583490|NCT04086836|DEVICE|TAVR|Patient recieving a TAVR
219583491|NCT00152178|DRUG|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
219583492|NCT00152178|DRUG|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
219583493|NCT02552056|OTHER|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
219765239|NCT06904391|OTHER|Educational Intervention|Receive access to SWOG APP Clinical Research workshop. Receive The Advanced Practice Provider Clinical Trials Research Manual
219765240|NCT06904391|OTHER|Behavioral Intervention|Complete mentorship intervention
219765241|NCT06904391|OTHER|Survey Administration|Ancillary studies
219765242|NCT06904391|OTHER|Interview|Ancillary studies
219765243|NCT06911944|DRUG|Donanemab|Donanemab will be administered as an IV infusion every 4 weeks using an up-titration regimen that will allow participants to reach a target dose of 1400 mg within 24 weeks.
219765244|NCT06911944|DRUG|Placebo|The control product (placebo) will be supplied in vials containing 350 mg/20 mL of donanemab Placebo for donanemab is supplied to the clinical site to match the active study intervention and contains only inactive ingredients. Normal sterile saline solution (0.9% sodium chloride) will be used for dilution.
219765245|NCT07089784|DRUG|MK-2828|Oral capsule of MK-2828 taken once per day for 28 days.
219765246|NCT07089784|DRUG|Placebo|Placebo to match MK-2828 oral capsule, taken once per day for 28 days.
219765247|NCT07092501|BEHAVIORAL|Mentholated cigarette sampling|Participants will participate in five sampling trials (menthol cigarette, non-menthol cigarette, non-menthol cigarette mentholated with accessory 1, with accessory 2, and with accessory 3). They will be exposed to these trials in a randomized order. In each trial, participants will take four guided puffs from one cigarette. They will have a 20-minute washout period between trials. They will first complete subjective ratings for the product they just sampled. Then, during the washout period, participants will be instructed to rinse their mouth thoroughly with room-temperature water three times. Each rinse will last approximately 10 seconds, and participants will be guided to swish the water around all areas of the mouth before expectorating. A one-minute rest will follow each rinse to allow residual taste to dissipate. No food or drink will be allowed during this period.
218835979|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
218835980|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
219443889|NCT04744883|DRUG|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
219443890|NCT04744883|DRUG|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
219443891|NCT04744883|BEHAVIORAL|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
219443892|NCT03482362|DRUG|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
219443893|NCT03541590|PROCEDURE|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
219443894|NCT01271595|OTHER|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
219443895|NCT00865995|PROCEDURE|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
219443896|NCT04216511|DIAGNOSTIC_TEST|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
219443897|NCT04821297|OTHER|Health Promotion and Education|Receive messages
219443898|NCT04821297|OTHER|Survey Administration|Complete survey
219443899|NCT04821297|OTHER|Interview|Participate in an interview
219443900|NCT00732706|PROCEDURE|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
219443901|NCT00732706|PROCEDURE|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
219443902|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219016495|NCT04718441|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
219016496|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
218835981|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
219016501|NCT00583804|DEVICE|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
219443903|NCT04097028|DRUG|Oxaliplatin|Given IV
219443904|NCT01006694|OTHER|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
219443905|NCT01006694|DRUG|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
219443906|NCT06071923|DEVICE|Fibroscan|Scan the liver for metabolic fatty changes
219583494|NCT01259115|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
219583495|NCT01259115|DRUG|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
219583496|NCT01259115|DRUG|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
219583497|NCT06387485|DEVICE|3D Printed Anatomic Model|Patient-specific 3D printed anatomic model for pre-surgical planning
219583498|NCT06387485|DIAGNOSTIC_TEST|CT/MRI|Standard imaging type for bony tumors
219765248|NCT07092501|BEHAVIORAL|Hypothetical Policy Scenarios|Participants will complete the real Experimental Tobacco Marketplace consisting of one control trial and two menthol flavor restrictions (menthol cigarettes unavailable and both menthol cigarettes and menthol-flavored accessories unavailable). Participants will complete a total of 3 purchasing trials each for 7 days worth of products. In each trial, participants will buy tobacco products to use throughout the next 7 days. At the end of the session, the participant will randomly draw an individual purchasing trial and will receive all the products purchased at that trial to use over the next week. During the following 7 days, the participant is asked to use only the tobacco/nicotine products received during the study.
219765249|NCT07092501|BEHAVIORAL|Subjective value assessment|Participants will complete a hypothetical purchase task where the price of a variety of products will increase progressively during the task.
219765250|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
219765251|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
219443907|NCT04520308|DRUG|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
219443908|NCT00279266|DRUG|Thiamine|
219443909|NCT03073369|DRUG|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
219443910|NCT03073369|DRUG|Placebo|Oral Placebo - one capsule once daily for 6 weeks
219443911|NCT05270265|BIOLOGICAL|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
219443912|NCT06205680|DEVICE|NAA for topical anaesthesia of the nasal cavity|NAA for topical anaesthesia of the nasal cavity
219443913|NCT00269958|DRUG|epoetin alfa|
219765252|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
219765253|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
219765254|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
219765255|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB|Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).
219016511|NCT04967170|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
219443914|NCT01191957|DRUG|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
219443915|NCT01191957|DRUG|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
219583499|NCT00040183|DRUG|Tarceva (erlotinib HCl, OSI-774)|
219583500|NCT01675661|DRUG|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
219583501|NCT01675661|DRUG|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
219583502|NCT00006083|DRUG|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
219583503|NCT00006083|OTHER|placebo|placebo injected subcutaneously daily
219583504|NCT04809883|DIAGNOSTIC_TEST|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
219583505|NCT01151228|OTHER|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
219765256|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4|Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).
219765257|NCT06747585|DRUG|ALE.P02|ALE.P02, will be administered by IV infusion according to the assigned arms.
219443916|NCT00498641|PROCEDURE|computer program and patching|
219443917|NCT02111707|DRUG|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
219443918|NCT04525560|OTHER|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
219443919|NCT04525560|OTHER|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
219443920|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
219443921|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
219443922|NCT01678313|DRUG|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
219443923|NCT01678313|DRUG|Doxazosin 4 mg every day (QD)|Control group
219443924|NCT00164788|DRUG|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
219443925|NCT00164788|DRUG|Oral esomeprazole|40mg every 12 hours for 24 hours
219443926|NCT02128958|DRUG|CF102|orally q12h
219443927|NCT02128958|DRUG|Placebo|orally q12 hours
219443928|NCT06242106|DEVICE|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
219443929|NCT00981292|DIETARY_SUPPLEMENT|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
219443930|NCT00981292|DIETARY_SUPPLEMENT|Placebo|Pharmaceutical grade silica was utilized as placebo
219443931|NCT04694794|OTHER|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
219443932|NCT05565066|DEVICE|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
219443933|NCT05565066|DEVICE|FNA group|Fine-needle-aspiration (Echotip Needle)
219443934|NCT04691349|DRUG|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
219583506|NCT02620644|DEVICE|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
219583507|NCT03485183|DEVICE|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
219583508|NCT03485183|OTHER|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
219583509|NCT04428515|DEVICE|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
219583510|NCT00567047|DRUG|vildagliptin|
219583511|NCT03512860|DRUG|E4/DRSP|Administered as specified in the treatment arm.
219016512|NCT04967170|OTHER|Sham Procedure|Intralesional needle insertion without any injectate.
219016515|NCT04651452|BEHAVIORAL|Value Affirmation|Participants will complete writing tasks regarding their personal values.
219016516|NCT04651452|BEHAVIORAL|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
219583512|NCT03512860|DRUG|VAL|Administered as specified in the treatment arm.
219583513|NCT02393248|DRUG|Pemigatinib|
219583514|NCT02393248|DRUG|Gemcitabine|
219583515|NCT02393248|DRUG|Pembrolizumab|
219583516|NCT02393248|DRUG|Docetaxel|
219583517|NCT02393248|DRUG|Trastuzumab|
219583518|NCT02393248|DRUG|Retifanlimab|
219583519|NCT02393248|DRUG|Cisplatin|
219583520|NCT02555748|DRUG|Pazopanib|
219583521|NCT02555748|DRUG|Sunitinib|
219583522|NCT01096030|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
219583523|NCT02890030|BEHAVIORAL|Questionnaire|"* Neurotoxicity~* Medications of interest~* General health~* Family history"
219583524|NCT04765384|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
219583525|NCT03202524|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
219765258|NCT06058455|BEHAVIORAL|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
219443935|NCT02314286|DRUG|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
219765259|NCT06058455|BEHAVIORAL|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
219765260|NCT06542874|DRUG|NNC0487-0111 subcutanous|NNC0487-0111 administered subcutanously (under the skin)
219765261|NCT06542874|DRUG|Placebo (NNC0487-0111 subcutanous)|NNC0487-0111 placebo administered subcutanously (under the skin)
219765262|NCT06542874|DRUG|NNC0487-0111 oral|NNC0487-0111 administered orally (in the mouth)
219765263|NCT06542874|DRUG|Placebo (NNC0487-0111 oral)|NNC0487-0111 placebo administered orally (in the mouth)
219443936|NCT02314286|DRUG|Placebo|
219765264|NCT06904066|DRUG|aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
219016518|NCT05139056|BIOLOGICAL|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
219443937|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
219016519|NCT05139056|PROCEDURE|Resection|Undergo surgical resection
219443938|NCT01131130|DEVICE|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
219443939|NCT01131130|DEVICE|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
219443940|NCT01131130|DEVICE|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
219443941|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
219443942|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
219443943|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
219443944|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
219443945|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
219443946|NCT05267145|COMBINATION_PRODUCT|blood preservation solution III|Blood bag added blood preservation solution III
219443947|NCT03464136|BIOLOGICAL|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
219443948|NCT03464136|BIOLOGICAL|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
219765265|NCT06904066|DRUG|cyclophosphamide|300 mg/m\^2 IV infusion over 30 minutes. Daily x 3 doses on days -5, -4, -3.
219583526|NCT03202524|BIOLOGICAL|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
219765266|NCT06904066|DRUG|fludarabine phosphate|30 mg/m\^2 IV infusion over 30 minutes administered immediately following cyclophosphamide on day -5, -4, -3. Participants with renal dysfunction receive a lower dose of fludarabine.
219583527|NCT02554136|DRUG|HGP0918|
219583528|NCT02554136|DRUG|HGP0816|
219583529|NCT02554136|DRUG|HGP0918 + HGP0816|
219583530|NCT01971970|BIOLOGICAL|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
219016523|NCT05703399|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219443949|NCT03464136|BIOLOGICAL|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
219443950|NCT03464136|BIOLOGICAL|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
219443951|NCT03464136|BIOLOGICAL|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
219583531|NCT01971970|BIOLOGICAL|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
219016524|NCT05703399|OTHER|Questionnaire Administration|Complete questionnaire
219583532|NCT06351475|OTHER|Intra-operative albumin administration|Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
219583533|NCT06351475|OTHER|Control|Ringer lactate
219583534|NCT05107388|DEVICE|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
219016532|NCT06466278|DRUG|Icosapent ethyl|2dd2
219016533|NCT06466278|DRUG|Placebo|2dd2
219443952|NCT03412565|DRUG|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
219765267|NCT06904066|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Up to 1.5x10\^11 total cells for non-transplant subjects. 1x10\^10 total cells for post-alloHSCT subjects.
219765268|NCT06904066|DEVICE|TruSight Oncology (TSO) 500|TSO500 sequencing panel performed in the NCI Laboratory of Pathology to detect TP53 or RAS mutations
219765269|NCT07094932|DRUG|TBD09|TBD09 will be administered orally
219443953|NCT03412565|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
219443954|NCT03412565|DRUG|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
219443955|NCT03412565|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
219765270|NCT07094932|DRUG|Placebo|Placebo will be administered orally
219765271|NCT07100080|DRUG|Iza-bren|Specified dose on specified days
219765272|NCT07100080|DRUG|Carboplatin|Specified dose on specified days
218835982|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
219583535|NCT06437483|PROCEDURE|Sustained Natural Apophyseal Glides|"SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions."
219196287|NCT06824090|OTHER|Myoton Assessment|Myoton PRO device was used to objectively evaluate the biomechanical properties of the hand and wrist muscles such as tone, stiffness and elasticity. Tenar region, flexor carpi radialis, flexor carpi ulnaris, extensor digitorum, extensor carpi radialis and extensor carpi ulnaris muscles were evaluated bilaterally. Three measurements were recorded at one second intervals and the mean value was used for analysis.
218835983|NCT01680354|PROCEDURE|ReLEx|
219583536|NCT06437483|PROCEDURE|Kinesiotaping|"Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension."
218835984|NCT01680354|PROCEDURE|LASIK|
218835985|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
219196288|NCT06346873|DEVICE|JOGO|AI driven mobile app and wearable sensors to provide virtual treatments
219443956|NCT03412565|DRUG|Melphalan|Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
219443957|NCT03412565|DRUG|Prednisone|Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
219443958|NCT03412565|DRUG|Carfilzomib|Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
219443959|NCT03277105|DRUG|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
219443960|NCT03277105|DRUG|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
219443961|NCT06243315|DEVICE|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
219443962|NCT05566574|DRUG|RP-3500|RP-3500 on Days 1-5.
219443963|NCT05566574|RADIATION|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
219443964|NCT01769638|DRUG|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
219583537|NCT06437483|PROCEDURE|Conventional Treatment|Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
219443965|NCT01769638|DRUG|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
219583538|NCT03528083|OTHER|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
219765273|NCT07100080|DRUG|Cisplatin|Specified dose on specified days
219765274|NCT07100080|DRUG|Pemetrexed|Specified dose on specified days
218835986|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
218835987|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
218835988|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
218835989|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
218835990|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
218835991|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
218835992|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
218835993|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
218835994|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
218835995|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
219583539|NCT02190474|BEHAVIORAL|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
219765275|NCT06830720|DRUG|ribociclib + AI ± LHRH|ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
219443966|NCT00262639|DRUG|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
219583540|NCT03806374|DRUG|Ketamine|ketamine
219583541|NCT03806374|DRUG|Propofol|propofol
219443967|NCT00262639|DRUG|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
219443968|NCT03066310|DIAGNOSTIC_TEST|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
219443969|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
219583542|NCT03806374|DRUG|Fentanyl|fentanyl
219583543|NCT03806374|DRUG|Cisatracurium|cisatracurium
219583544|NCT03806374|DRUG|Lidocaine|lidocaine
219583545|NCT02757365|DRUG|aspirin|
219583546|NCT02757365|DRUG|Levofloxacin|
219583547|NCT03043976|DEVICE|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
219765276|NCT06830720|DRUG|abemaciclib + ET ± LHRH|abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
218835996|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
219196289|NCT06608316|DEVICE|Intermittent Theta Burst Stimulation|A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.
219196290|NCT06597604|DEVICE|Intraoperative use of TenaTac in lung surgery|Use of innovative medical device : TenaTac
219443970|NCT06478550|DRUG|Semaglutide|Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
219443971|NCT00449995|PROCEDURE|confocal laser microscopy|
219443972|NCT04026945|DRUG|Lidocaine|Sustained-release lidocaine injection
219443973|NCT02656524|DRUG|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
219443974|NCT03846089|PROCEDURE|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
219443975|NCT01530373|DRUG|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
219443976|NCT01530373|DRUG|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
219443977|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
219443978|NCT06587802|DRUG|Triprolizumab|At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
219443979|NCT06587802|DEVICE|rodiotherapy|SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)
219443980|NCT04031924|OTHER|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
219443981|NCT03489538|PROCEDURE|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
219443982|NCT02304419|DRUG|Galunisertib|Administered orally.
219443983|NCT02219737|DRUG|Carboplatin|Given IVPB
219583548|NCT02524730|DEVICE|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
219583549|NCT03967496|PROCEDURE|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
219583550|NCT03967496|PROCEDURE|Access of Surgery|Type of surgical access
219583551|NCT03967496|OTHER|Comorbidities|A patient may have more than one comorbidity
219583552|NCT03967496|DRUG|Preoperative Medication|Preoperative medications
219765277|NCT06830720|DRUG|ET mono ± LHRH|endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
219765278|NCT06892548|BIOLOGICAL|BNT324|Intravenous infusion
219765279|NCT06892548|BIOLOGICAL|BNT327|Intravenous infusion
218835997|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
218835998|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
218835999|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
218836000|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
218836001|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
218836002|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
218836003|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
218836004|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
218836005|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
218836006|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
218836007|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
218836008|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
218836009|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
218836010|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
218836011|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
218836012|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
218836013|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
218836014|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
218836015|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
218836016|NCT04060069|OTHER|Ringer Lactate|Fluids
218836017|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
218836018|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
218836019|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
219443984|NCT02219737|DRUG|Etoposide|Given IVPB
219443985|NCT02219737|DRUG|Ibrutinib|Given PO
219443986|NCT02219737|DRUG|Ifosfamide|Given IV
219443987|NCT02219737|OTHER|Laboratory Biomarker Analysis|Correlative studies
219443988|NCT02219737|OTHER|Pharmacological Study|Correlative studies
219443989|NCT02219737|BIOLOGICAL|Rituximab|Given IV
219443990|NCT01465451|PROCEDURE|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
219443991|NCT01465451|DRUG|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
219443992|NCT04816370|DIAGNOSTIC_TEST|FSFI|2 group and 2 subgroup
219443993|NCT01364142|PROCEDURE|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
219583553|NCT03967496|DIAGNOSTIC_TEST|Routine blood test|Preoperative and Intraoperative Investigations
218836020|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
218836021|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
218836022|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
218836023|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
218836024|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
218836025|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
218836026|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
218859910|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
218859911|NCT00215566|DRUG|DDP733|
218859912|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
218859913|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
218859914|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
219583554|NCT01570803|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
219583555|NCT01570803|DEVICE|Complete SE Stent|same to SMART CONTROL Stent
219583556|NCT04120090|DRUG|low dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
219583557|NCT04120090|DRUG|high dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
219583558|NCT00977379|RADIATION|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
219443994|NCT06386536|DEVICE|Intelligent stationary bike|A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
219443995|NCT06386536|DEVICE|Conventional stationary bilke|A conventional stationary bike that can be found in gyms or rehab centers.
219583559|NCT00977379|DRUG|Capecitabine|825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
219583560|NCT00977379|DRUG|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
219583561|NCT00787059|DRUG|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
219583562|NCT00787059|DRUG|Sucrose (3%)|
219583563|NCT00556400|DRUG|Lo-Ovral Oral Contraceptive Pills|
219583564|NCT00556400|DRUG|Placebo - sugar pill|
219765280|NCT07102160|DEVICE|Aspiration thrombectomy system|The Cleaner Vac® Thrombectomy System is a percutaneous mechanical aspiration thrombectomy device designed for the removal of fresh, soft thrombi and emboli from the peripheral venous vasculature. The system includes an aspiration canister with integrated pump, an 18F aspiration catheter, a handpiece with aspiration control lever, a dilator, and an optional flushing adapter. The device operates via controlled suction to extract thrombus and restore venous patency.
219765281|NCT07087600|OTHER|Automatic lateralization therapy|Program the bed to vary angle and time continuously during the intervention
219765282|NCT07087600|OTHER|Supine Positioning|In this intervention, participants will be positioned in the supine position with the head of the bed elevated at 30°
219765283|NCT05777941|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
219443996|NCT02521168|DRUG|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
219443997|NCT02521168|DRUG|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
219443998|NCT02396004|DEVICE|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
219443999|NCT05367713|OTHER|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
219444000|NCT01716949|RADIATION|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
219444001|NCT01716949|PROCEDURE|Hyperthermia|10 sessions, therapeutic time 60 min
219765284|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
219444002|NCT01716949|DRUG|5-Fluorouracil|250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
219444003|NCT01716949|DRUG|Capecitabine|1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
219444004|NCT01716949|DRUG|Oxaliplatin|50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
219583565|NCT06452875|PROCEDURE|Primary Needle Knike Fistulotomy|"After verifying the eligibility of the papillary morphology (excluding flat or diverticular papillae according to Viana's classification), access to the bile duct will be initiated using the primary needle knife fistulotomy technique. After the first contact of the needle knife with the papilla, the endoscopist will have a total of 8 minutes, after which he can change to other cannulation techniques (eg standard cannulation methods through the papillary orifice) or even stop the procedure.~During ERCP all patients will be submitted to PEP prophylaxis with indomethacin. Also as a prophylactic PEP measure a pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct. For the purpose of this study, a dedicated form (attached) will be created with the various variables to be analyzed."
219583566|NCT04561375|DRUG|Sufentanil|30 µg tablet of sublingual sufentanil
219583567|NCT04561375|DRUG|Fentanyl|50 µg fentanyl
218859915|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
218859916|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
219583568|NCT03216018|BEHAVIORAL|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
219765285|NCT07104474|OTHER|RESTORE|RESTORE is a process intervention that combines systems analysis and human-centered design (HCD) approaches to directly engage hospital nursing staff in ongoing organizational redesign to address burnout. Specifically, RESTORE is comprised of multiple in-person sessions with hospital unit design teams. In these sessions, hospital nurses are guided through using a well-known systems analysis model to understand their unit, including what factors act as drivers of burnout, what can be modified, and/or what constraints might be in place regarding system changes. Then, using HCD, nursing staff design, develop, and implement a system redesign solution to address the unique drivers of burnout in their unit that works within their constraints.
219765286|NCT07096193|DRUG|GS-4321|Administered subcutaneous (SC) or intravenously IV
219016537|NCT05023889|DRUG|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
219444005|NCT03935490|PROCEDURE|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
219444006|NCT02373566|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
219444007|NCT00802724|BEHAVIORAL|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
219444008|NCT00802724|BEHAVIORAL|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
219444009|NCT00934713|DRUG|montelukast|montelukast 4mg once per day for 8 weeks period
219444010|NCT00537771|DRUG|Anastrozole|1 mg once daily oral dose
219444011|NCT00537771|DRUG|Tamoxifen|20 mg once daily oral dose
219444012|NCT03423615|BEHAVIORAL|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
219765287|NCT07096193|DRUG|GS-4321 Placebo|Administered SC
219444013|NCT05312268|DRUG|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
219444014|NCT02323308|OTHER|blood sampling|
219444015|NCT02575300|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
219444016|NCT00063388|BIOLOGICAL|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
219444017|NCT02078089|DRUG|Morphine|Morphine will be given to patients as part of their standard care
219444018|NCT02078089|DRUG|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
219444019|NCT05190757|OTHER|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
219444020|NCT03144830|DEVICE|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
219444021|NCT03431792|DEVICE|Long Tail Balloon|s. description of experimental Arm
219444022|NCT02736929|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
219583569|NCT04173832|DRUG|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
219583570|NCT04173832|DRUG|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
219583571|NCT05036356|OTHER|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
219583572|NCT02861742|OTHER|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
219583573|NCT02861742|BEHAVIORAL|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
219444023|NCT03068052|BEHAVIORAL|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
219444024|NCT03068052|BEHAVIORAL|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
219444025|NCT04130880|DIAGNOSTIC_TEST|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
219765288|NCT07096193|DRUG|GS-4321|Administered SC
219765289|NCT07072234|DRUG|Lymphodepleting chemotherapy|Given by IV
218836027|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
218836028|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
218836029|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
219583574|NCT02861742|BEHAVIORAL|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
219583575|NCT02861742|BEHAVIORAL|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
219765290|NCT07072234|DRUG|Dexamethasone|Given PO
219444026|NCT06417398|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
219444027|NCT03521401|BEHAVIORAL|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
219444028|NCT01351857|OTHER|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
219444029|NCT01744041|BEHAVIORAL|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
219444030|NCT01744041|OTHER|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
219444031|NCT01438775|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
219583576|NCT02861742|BEHAVIORAL|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
219765291|NCT07072234|DRUG|Fludarabine|Given by IV
219765292|NCT07072234|DRUG|Cyclophosphamate|Given by IV
219765293|NCT07072234|DRUG|TGFBR-2 KO CD70 CAR NK|Given by IV
219765294|NCT07105722|BIOLOGICAL|Pn-MAPS30plus|The Pn-MAPS30plus vaccine will be administered intramuscularly.
219016538|NCT05717127|BEHAVIORAL|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
219016539|NCT05717127|BEHAVIORAL|Standard lifestyle|Standard lifestyle recommendations
219016540|NCT05353569|DIAGNOSTIC_TEST|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
219016542|NCT05641831|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
219016543|NCT05641831|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
219016544|NCT05641831|DRUG|Canakinumab|Given SC
219583577|NCT02861742|BEHAVIORAL|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
219583578|NCT00706511|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
219583579|NCT01025271|DRUG|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
219583580|NCT01312571|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
219583581|NCT01312571|BEHAVIORAL|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
219765295|NCT07105722|COMBINATION_PRODUCT|PCV20|The PCV20 vaccine will be administered intramuscularly.
219765296|NCT00065676|OTHER|Quercetin|1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
219765297|NCT00065676|OTHER|Placebo|
219765298|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
219583582|NCT06035471|DIAGNOSTIC_TEST|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).
219583583|NCT05872893|DRUG|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
219583584|NCT05872893|DRUG|Dexamethasone|Patients will receive dexamethasone 4mg/m2
219583585|NCT00231647|DRUG|topiramate|
218836030|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
219583586|NCT01386151|DRUG|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
219583587|NCT01386151|DRUG|Saline placebo|Normal (0.9%) saline will be used as a placebo.
219583588|NCT01041066|DRUG|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
219583589|NCT01041066|DRUG|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
219444032|NCT01614041|DRUG|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
219765299|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
219765300|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
218836031|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
219444033|NCT01614041|DRUG|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
219444034|NCT00432185|DRUG|PEP005|0.25% PEP005 Gel
219444035|NCT05221593|DRUG|Lithium Carbonate|400 mg tablet in controlled released formula
219444036|NCT01936272|DEVICE|Chhabra Shunt Placement|
219444037|NCT01936272|PROCEDURE|ETV/CPC|
219583590|NCT00654966|DRUG|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
219583591|NCT00654966|DRUG|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
219583592|NCT00654758|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
219583593|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
219583594|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
219583595|NCT02117700|OTHER|Placebo twice/day|Placebo capsules twice/day for 16 weeks
219765301|NCT06179160|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
219444038|NCT00285649|OTHER|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
219444039|NCT00285649|OTHER|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
219444040|NCT00285649|OTHER|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
219444041|NCT04364906|OTHER|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
219583596|NCT02934659|DEVICE|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
219583597|NCT01334983|BEHAVIORAL|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
219583598|NCT01398215|PROCEDURE|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
219583599|NCT05515692|PROCEDURE|Biospecimen Collection|Correlative studies
219583600|NCT05515692|PROCEDURE|Computed Tomography|Undergo radiotherapy simulation using CT
219583601|NCT05515692|COMBINATION_PRODUCT|Electron Beam Therapy|Undergo electron beam radiotherapy
219765302|NCT06179160|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
219765303|NCT06548360|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219765304|NCT06548360|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
219765305|NCT03899155|DRUG|Nivolumab|Specified dose on specified days
219765306|NCT03899155|DRUG|Ipilimumab|Specified dose on specified days
219765307|NCT03899155|DRUG|Cabozantinib|Specified dose on specified days
219765308|NCT03899155|DRUG|Trametinib|Specified dose on specified days
219765309|NCT03899155|DRUG|Relatlimab|Specified dose on specified days
218836032|NCT04545866|DRUG|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
218836033|NCT04545866|DRUG|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
218836034|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
219016545|NCT05641831|PROCEDURE|Chest Radiography|Undergo chest x-ray
219016546|NCT05641831|PROCEDURE|Echocardiography|Undergo ECHO
219444042|NCT02447068|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
219444043|NCT02447068|DEVICE|Luma Light|NBUVB light
219016547|NCT05641831|DRUG|Placebo Administration|Given SC
219444044|NCT02447068|DEVICE|Occlusive Dressing|Off-the-shelf occlusive dressing
219444045|NCT01105949|DEVICE|Marketed nasal strip|Marketed nasal strip
219444046|NCT01105949|DEVICE|NexGen AB 2R11|Nasal strip prototype
219444047|NCT01105949|DEVICE|NexGen JB Organic PET/PE|Nasal strip
219016548|NCT05641831|OTHER|Quality-of-Life Assessment|Ancillary studies
219196291|NCT06597604|DEVICE|Intraoperative use of usual sealant in lung surgery|Use of the usual scealant as a control
219444048|NCT02541500|DRUG|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
219444049|NCT02454452|PROCEDURE|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
219444050|NCT02454452|PROCEDURE|Saphenous vein stripping|Saphenous vein stripping
219444051|NCT02454452|PROCEDURE|CHIVA|conservative hemodynamic treatment venous insufficiency
219444052|NCT04837781|PROCEDURE|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
219583602|NCT05515692|PROCEDURE|High Frequency Ultrasound Imaging|Undergo HFUS
219583603|NCT05515692|OTHER|Questionnaire Administration|Ancillary studies
219583604|NCT05515692|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
219583605|NCT05515692|PROCEDURE|Skin Biopsy|Undergo biopsy
219583606|NCT05473962|DIAGNOSTIC_TEST|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
219583607|NCT04935424|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
219583608|NCT01123135|DRUG|Vaginal ERT|1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week
219583609|NCT01123135|DRUG|Placebo|Placebo
219583610|NCT06213935|DRUG|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
219583611|NCT06213935|DRUG|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
219583612|NCT02376543|DEVICE|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
219583613|NCT02376543|DEVICE|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
219583614|NCT03982979|DEVICE|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
219583615|NCT05073952|PROCEDURE|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
219583616|NCT05073952|PROCEDURE|Flapless|Implants will be placed with a flapless approach
219583617|NCT02468570|OTHER|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
219583618|NCT00918840|BIOLOGICAL|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
219583619|NCT00918840|BIOLOGICAL|Placebo|Dextrose/glucose solution
219583620|NCT00918840|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
219583621|NCT00894101|DRUG|[F-18] FLT|10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
219583622|NCT04755257|DEVICE|Isokinetic test|Using IsoMed 2000 device (D. \& R. Ferstl GmbH, Hemau, Germany) we conducted the isokinetic test of concentric (CON) and eccentric (ECC) shoulder internal (IR) and external (ER) strength at the angular velocity of 60˚/s in both Method I (scapular position) and Method II (25⁰ Abd and 20⁰ ER). There were seven days between the testing sessions, and both tests were conducted at the same time of day. The same examiner with experience in performing isokinetic testing with IsoMed 2000 tested all subjects in both testing sessions.
219765310|NCT03899155|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
219765311|NCT03899155|DRUG|Capecitabine|Specified dose on specified days
219765312|NCT03899155|DRUG|Bevacizumab|Specified dose on specified days
219444053|NCT04501172|BEHAVIORAL|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
219765313|NCT03899155|DRUG|Temozolomide|Specified dose on specified days
219765314|NCT03899155|DRUG|Rucaparib|Specified dose on specified days
219765315|NCT03899155|DRUG|Daratumumab|Specified dose on specified days
219765316|NCT03899155|DRUG|Regorafinib|Specified dose on specified days
219765317|NCT03899155|DRUG|Leucovorin|Specified dose on specified days
219765318|NCT03899155|DRUG|Fluorouracil|Specified dose on specified days
219765319|NCT03899155|DRUG|Oxaliplatin|Specified dose on specified days
219765320|NCT03899155|DRUG|Enzalutamide|Specified dose on specified days
219765321|NCT03899155|DRUG|Sunitinib|Specified dose on specified days
219444054|NCT05861557|DRUG|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
219583623|NCT05509738|BEHAVIORAL|SMS Text Messaging|"The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses."
219583624|NCT03557424|DRUG|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
219583625|NCT03557424|DRUG|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
219583626|NCT03557424|DRUG|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
219583627|NCT00467935|DRUG|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
219583628|NCT01830218|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
219583629|NCT04023643|OTHER|Ventilation Weaning|Use of different weaning strategies
219583630|NCT03249337|DRUG|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
219583631|NCT05297578|BIOLOGICAL|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
219583632|NCT05297578|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
219765322|NCT03899155|DRUG|Pemetrexed|Specified dose on specified days
219765323|NCT03899155|DRUG|Pembrolizumab|Specified dose on specified days
219765324|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
219765325|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
219765326|NCT07105709|DRUG|GSK4527226|GSK4527226 will be administered.
219016554|NCT06119529|DRUG|LY3872386|Administered IV.
219016555|NCT06119529|DRUG|Prednisone|Administered orally.
219765327|NCT02979873|DRUG|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
219765328|NCT07104630|BEHAVIORAL|Pulmonary Rehabilitation (PR)|"Participants will complete an 8-week course of PR, administered by certified respiratory therapists. For each week of the course, participants will attend two PR sessions. Each session will review topics such as physical function, nutrition, and psychosocial health. Participants will also be given an exercise prescription to complete throughout the 8-week course. The exercise prescription will include individualized cardiopulmonary activities."
219583633|NCT04005365|DRUG|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
219765329|NCT07104630|OTHER|No intervention: Usual care|Participants will receive standard-of-care, publicly available education on Nutrition and Cancer Survivors and Physical Activity and Cancer Survivors published by the American Institute for Cancer Research.
219444055|NCT05861557|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
219444056|NCT00141401|DRUG|Pregabalin|
219444057|NCT03342404|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
219444058|NCT03342404|OTHER|Placebo|Placebo, Subcutaneous, every 21 days
218836035|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
219444059|NCT03342404|OTHER|Best Supportive Care (BSC)|Best Supportive Care (BSC)
219444060|NCT01968304|OTHER|Iron status follow up|
219444061|NCT00052832|DIETARY_SUPPLEMENT|doxercalciferol|
219444062|NCT03889990|DEVICE|IQOS|"Smoke IQOS"
219444063|NCT00927329|BIOLOGICAL|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
219444064|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
219765330|NCT07103135|DEVICE|MagVenture X100 Pro transcranial magnetic stimulation system|The study intervention involves the use of the MagVenture X100 Pro transcranial magnetic stimulation system to deliver accelerated intermittent theta burst stimulation (aiTBS) to personalized targets within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain.
218836036|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
218836037|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
218836038|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
218836039|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
218836040|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
218836041|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
218836042|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
218836043|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
218836044|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
218836045|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
219016556|NCT06119529|DRUG|Placebo|Administered IV.
219444065|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
219444066|NCT06242093|DEVICE|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
219444067|NCT06242093|OTHER|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
219444068|NCT01855425|RADIATION|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
219583634|NCT06552065|OTHER|collagen with silk fibroin membrane|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
219765331|NCT06394739|DEVICE|Thrombectomy|RevCore Thrombectomy to treat in-stent thrombosis
219196292|NCT01345851|RADIATION|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
219765332|NCT06833073|BIOLOGICAL|Intismeran autogene|IM injection
219765333|NCT06833073|BIOLOGICAL|BCG|Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
219196293|NCT01345851|OTHER|laboratory biomarker analysis|Correlative studies
219196294|NCT01345851|RADIATION|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
219196295|NCT01345851|DRUG|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
219444069|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
219444070|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
219444071|NCT04066699|PROCEDURE|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
219444072|NCT03046563|OTHER|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
219444073|NCT03046563|OTHER|Pressing the Sham points|Pressing the sham points for eight minutes
219444074|NCT01961102|PROCEDURE|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
219444075|NCT06337994|DRUG|Memantine Hydrochloride|Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
219475674|NCT03914547|BEHAVIORAL|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
219765334|NCT06096844|DRUG|Carboplatin|Given IV
219765335|NCT06096844|PROCEDURE|Computed Tomography|Undergo CT scan
219765336|NCT06096844|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219765337|NCT06096844|DRUG|Nab-paclitaxel|Given IV
219765338|NCT06096844|DRUG|Paclitaxel|Given IV
219765339|NCT06096844|BIOLOGICAL|Pembrolizumab|Given IV
219765340|NCT06096844|DRUG|Pemetrexed|Given IV
219765341|NCT06096844|PROCEDURE|Positron Emission Tomography|Undergo PET
219765342|NCT06096844|OTHER|Questionnaire Administration|Ancillary studies
219196296|NCT01345851|DRUG|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
219765343|NCT07107945|DRUG|Empagliflozin|Empagliflozin
219765344|NCT07107945|DRUG|Placebo|Placebo
219196297|NCT01345851|RADIATION|stereotactic body radiation therapy|Undergo hypofractionated RT
219196298|NCT06598683|OTHER|tDCS|Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation
219196299|NCT06598683|OTHER|Conventional|ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training
219196300|NCT06841081|OTHER|Enhanced Usual Care|Offer written instructions to the patient and refer the patient to their clinical team if they have unresolved issues.
219196301|NCT06841081|OTHER|Super Supporter Support|Assist and troubleshoot with the patient including a practice video visit.
219475675|NCT03914547|BEHAVIORAL|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
219475676|NCT06058988|DRUG|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
219475677|NCT05525663|BEHAVIORAL|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
219475678|NCT02255422|DRUG|Omaveloxolone capsules, 2.5 mg|
219475679|NCT02255422|DRUG|omaveloxolone capsules, 5 mg|
219475680|NCT02255422|DRUG|omaveloxolone capsules, 10 mg|
219475681|NCT02255422|DRUG|Placebo capsules|
219475682|NCT02255422|DRUG|omaveloxolone capsules, 20 mg|
219765345|NCT06479824|DEVICE|TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)|In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.
219765346|NCT06635824|DRUG|Acasunlimab|IV infusion
219765347|NCT06635824|DRUG|Pembrolizumab|IV infusion
219765348|NCT06635824|DRUG|Docetaxel|IV infusion
219765349|NCT04579224|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219765350|NCT04579224|PROCEDURE|Bone Scan|Undergo bone scan
219765351|NCT04579224|PROCEDURE|Computed Tomography|Undergo CT
219765352|NCT04579224|DRUG|Docetaxel|Given IV
219765353|NCT04579224|DRUG|Eribulin Mesylate|Given IV
219765354|NCT04579224|DRUG|Gemcitabine Hydrochloride|Given IV
219765355|NCT04579224|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219765356|NCT04579224|DRUG|Paclitaxel|Given IV
219765357|NCT04579224|BIOLOGICAL|Sacituzumab Govitecan|Receive IV
219765358|NCT00001721|DRUG|Cholesterol Suspension|
218836046|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
219444076|NCT01522118|DEVICE|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
219583635|NCT06552065|OTHER|cross linked collagen membrane|A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
219583636|NCT05402774|DIAGNOSTIC_TEST|point-of-care ultrasound|point-of-care ultrasound
219583637|NCT04422119|PROCEDURE|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
219583638|NCT04422119|PROCEDURE|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
219583639|NCT01087489|DRUG|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
219583640|NCT01087489|DRUG|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
219583641|NCT00015340|DRUG|Buprenorphine/naloxone|
219583642|NCT01113944|BEHAVIORAL|Program 1|
219583643|NCT01113944|BEHAVIORAL|Program 2|
219583644|NCT05076240|PROCEDURE|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
219583645|NCT02640092|DRUG|[18F]GTP1|Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
219583646|NCT02770885|DRUG|Dulaglutide|Treatment with dulaglutide for 3 weeks.
219583647|NCT02770885|DRUG|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
218836047|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
219444077|NCT02527902|DEVICE|Holter|measure of ANS in IgAN patients
219583648|NCT02374489|DRUG|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
219583649|NCT04735757|OTHER|Contrast-enhanced MRI|Contrast-enhanced MRI
219583650|NCT04735757|OTHER|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
219583651|NCT04849065|DRUG|MNC (Mononuclear cells)|"* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
219583652|NCT04849065|DRUG|Placebo / Saline|\- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
219583653|NCT00056394|BEHAVIORAL|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
219583654|NCT00056394|BEHAVIORAL|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
219583655|NCT00056394|BEHAVIORAL|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
219583656|NCT02912169|PROCEDURE|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
219583657|NCT02912169|BIOLOGICAL|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
219583658|NCT00346463|DRUG|Allopurinol|
219583659|NCT02208674|OTHER|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
219583660|NCT05851625|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
219583661|NCT05851625|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
219765359|NCT00001721|DRUG|CRH|
219765360|NCT00001721|DRUG|Cholesterol|
219765361|NCT04071223|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219765362|NCT04071223|PROCEDURE|Bone Scan|Undergo bone scan
219765363|NCT04071223|DRUG|Cabozantinib S-malate|Given PO
219765364|NCT04071223|PROCEDURE|Computed Tomography|Undergo CT
219765365|NCT04071223|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219765366|NCT04071223|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET or NaF-PET
219765367|NCT04071223|OTHER|Questionnaire Administration|Ancillary studies
219765368|NCT04071223|RADIATION|Radium Ra 223 Dichloride|Given IV
219765369|NCT02535702|OTHER|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
218836048|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
219583662|NCT00117325|DRUG|GW685698X|Aqueous Nasal Spray 100mcg
219583663|NCT05951855|DRUG|Selinexor|Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
219583664|NCT05951855|DRUG|Chidamide|Chidamide 10mg/day, orally on day 1 to 28
219583665|NCT03791710|PROCEDURE|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
219583666|NCT03791710|DRUG|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
219583667|NCT03791710|PROCEDURE|split thickness skin grafting|depridment and split thickness skin grafting
219583668|NCT03184155|DRUG|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
218836049|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
219583669|NCT03184155|DRUG|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
219583670|NCT05652738|DEVICE|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
219583671|NCT05652738|DEVICE|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
219583672|NCT00416650|DRUG|erlotinib hydrochloride|All patients will receive 150 mg orally daily
219583673|NCT05748249|DRUG|Vertistop® D|Vitamin D supplementation
219583674|NCT03956121|OTHER|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
219583675|NCT04664790|DEVICE|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
219583676|NCT04664790|BEHAVIORAL|Cognitive training|Neuropsychologist guided BrainHQ training
219583677|NCT04728503|BEHAVIORAL|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
219583678|NCT04728503|BEHAVIORAL|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
219583679|NCT00759187|DRUG|Fluoride|Brush twice daily
219583680|NCT00759187|DRUG|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
219583681|NCT00759187|DRUG|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
219583682|NCT04889287|DRUG|Elinzanetant (BAY3427080)|Once daily over 12 days
219583683|NCT04889287|DRUG|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
219583684|NCT01568970|BEHAVIORAL|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
219583685|NCT01568970|BEHAVIORAL|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
219583686|NCT02674906|DRUG|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
219583687|NCT02674906|DRUG|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
219583688|NCT02808156|OTHER|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
219583689|NCT02808156|OTHER|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
219583690|NCT05982288|OTHER|Virtual Reality Software|Training of intensive care nurses with virtual reality software
219583691|NCT00317707|DRUG|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
219583692|NCT00317707|DRUG|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
219583693|NCT03454178|DIAGNOSTIC_TEST|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
219583694|NCT05490485|DRUG|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
219583695|NCT04975009|BEHAVIORAL|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
219583696|NCT01996683|DRUG|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
219765370|NCT02535702|OTHER|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
219765371|NCT02535702|OTHER|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
219765372|NCT02535702|OTHER|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
219765373|NCT02535702|OTHER|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
219765374|NCT02535702|OTHER|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
219765375|NCT01799538|DRUG|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
219765376|NCT01799538|DRUG|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1
218836050|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
218836051|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
218836052|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
218836053|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
218836054|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
218836055|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
218836056|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
219016562|NCT05628649|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
219016563|NCT06463743|DRUG|metformin|metformin
219016564|NCT06463743|DRUG|Placebo|Placebo
219016565|NCT05962320|OTHER|Education and counselling|Education and counselling of patients and their parents
219016566|NCT05962320|OTHER|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
219016567|NCT05962320|OTHER|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
219016568|NCT05962320|OTHER|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
219016569|NCT05962320|OTHER|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
219016570|NCT05962320|OTHER|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
219765377|NCT01799538|PROCEDURE|PFT|Breathing Test
219765378|NCT06408259|DRUG|Ozanimod|Specified dose on specified days
219765379|NCT06408259|DRUG|Fingolimod|Specified dose on specified days
218836057|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
218836058|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
218836059|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
218836060|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
218836061|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
218836062|NCT06446375|OTHER|Regular daily activity|Regular physical activity
219765380|NCT06408259|OTHER|Placebo|Specified dose on specified days
219765381|NCT06564142|DRUG|Povetacicept|Subcutaneous injection administration.
219765382|NCT06564142|DRUG|Placebo (matched to Povetacicept)|Placebo matched to Povetacicept subcutaneous injection administration.
219765383|NCT06118515|DRUG|Letermovir|Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
219765384|NCT06520787|COMBINATION_PRODUCT|ACDP® and pharmacological treatment for obesity|40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).
219765385|NCT04603807|DRUG|Entrectinib|Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
219765386|NCT04603807|DRUG|Crizotinib|Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
219765387|NCT00687115|BEHAVIORAL|Weight Loss|liquid diet at 50% of weight maintaining intake
219765388|NCT00687115|BEHAVIORAL|Overfeeding|Overfeeding at 150% of weight maintaining intake
219765389|NCT00687115|BEHAVIORAL|Overfeeding Low Pro|Overfeeding 150% of normal intake at \<5% protein
219765390|NCT02339571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219765391|NCT02339571|PROCEDURE|Computed Tomography|Undergo CT scan
219765392|NCT02339571|PROCEDURE|Echocardiography Test|Undergo ECHO
219765393|NCT02339571|BIOLOGICAL|Ipilimumab|Given IV
219765394|NCT02339571|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219444078|NCT00002675|BIOLOGICAL|filgrastim|
219444079|NCT00002675|DRUG|carboplatin|
219765395|NCT02339571|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219765396|NCT02339571|BIOLOGICAL|Nivolumab|Given IV
219765397|NCT02339571|BIOLOGICAL|Sargramostim|Given SC
219765398|NCT06624228|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
219765399|NCT06624228|DRUG|Risankizumab|Study participants will receive risankizumab at pre-specified time points.
219765400|NCT06624228|DRUG|Placebo|Study participants will receive placebo at pre-specified time points.
219765401|NCT02522611|DRUG|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
218836063|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
218836064|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
219016571|NCT05962320|OTHER|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
219016572|NCT05962320|OTHER|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
219765402|NCT06577454|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.
219765403|NCT07100964|DRUG|nerandomilast|nerandomilast
219016573|NCT05962320|OTHER|Management of thirsty|Management of thirsty
219016574|NCT05962320|OTHER|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
219444080|NCT00002675|DRUG|cisplatin|
219444081|NCT00002675|DRUG|cyclophosphamide|
219444082|NCT00002675|DRUG|etoposide|
219444083|NCT00002675|DRUG|mesna|
219444084|NCT00002675|DRUG|vincristine sulfate|
219444085|NCT03156413|DEVICE|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
219444086|NCT03456180|DEVICE|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
219475683|NCT02255422|DRUG|omaveloxolone capsules, 40 mg|
219475684|NCT02255422|DRUG|omaveloxolone capsules, 80 mg|
219475685|NCT02255422|DRUG|omaveloxolone capsules, 160 mg|
219765404|NCT07100964|DRUG|carbamazepine|carbamazepine
219765405|NCT07102381|DRUG|Zanidatamab|Administered intravenously (IV)
219765406|NCT07102381|DRUG|Paclitaxel|Administered intravenously (IV)
219765407|NCT07102381|DRUG|Docetaxel|Administered intravenously (IV)
219765408|NCT07102381|DRUG|Carboplatin|Administered intravenously (IV)
219765409|NCT07102381|DRUG|Trastuzumab|Administered intravenously (IV)
219765410|NCT07102381|DRUG|Pertuzumab|Administered intravenously (IV)
219765411|NCT07099092|DEVICE|TUS PirC|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting piriform cortex
219765412|NCT07099092|DEVICE|TUS Amy|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting amygdala
219765413|NCT07099092|DEVICE|TUS Sham|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting white matter
219765414|NCT04459715|DRUG|Xevinapant (Debio 1143)|Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.
219765415|NCT04459715|DRUG|Cisplatin|Cisplatin administered as an IV infusion every 3 weeks (Q3W).
219765416|NCT04459715|RADIATION|Intensity Modulation Radiation Therapy (IMRT)|70 Gy given in 35 fractions over 7 weeks.
219765417|NCT04459715|DRUG|Placebo|Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
219765418|NCT06915727|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
219765419|NCT06915727|PROCEDURE|Near Infrared Imaging|Undergo NIR fluorescent imaging
219765420|NCT06915727|DRUG|Pafolacianine Sodium|Given IV
219765421|NCT06915727|PROCEDURE|Surgical Procedure|Undergo SOC surgery
219765422|NCT07112053|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
219765423|NCT07112053|DRUG|Capecitabine|Given SOC capecitabine
219765424|NCT07112053|PROCEDURE|Computed Tomography|Undergo CT or ultrasound-guided biopsies
219765425|NCT07112053|DRUG|Cyclin-Dependent Kinase 4 Inhibitor|Given SOC CDK4/6i
219765426|NCT07112053|DRUG|Cyclin-Dependent Kinase 6 Inhibitor|Given SOC CDK4/6i
219765427|NCT07112053|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo FES PET
219765428|NCT07112053|DRUG|Hormone Therapy|Given SOC ET
219765429|NCT07112053|PROCEDURE|Positron Emission Tomography|Undergo FES PET
219765430|NCT07112053|PROCEDURE|Ultrasound Imaging|Undergo CT or ultrasound-guided biopsies
219765431|NCT07112053|PROCEDURE|Biopsy Procedure|Undergo CT or ultrasound-guided biopsies
219765432|NCT07112053|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218836065|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
218836066|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
219583697|NCT00888056|PROCEDURE|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
219583698|NCT01470911|DRUG|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
219583699|NCT01470911|DRUG|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
219583700|NCT05545371|BIOLOGICAL|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
219583701|NCT03122197|DRUG|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
219583702|NCT03122197|DRUG|Temozolomide|50 mg/m2 TMZ administered orally once daily
219583703|NCT04620928|BEHAVIORAL|Concepts|Images and sounds that are characteristic of various common objects.
219583704|NCT00296231|OTHER|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
219583705|NCT02240030|DRUG|CVT-301 Low Dose|
219583706|NCT02240030|DRUG|CVT-301 High Dose|
218836067|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
218836068|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
219444087|NCT06598163|DEVICE|Five Lives MED|"Five Lives MED is a mobile application that can be installed on smartphones and tablets using the Android and/or iOS operating systems for use at home.~The app offers structured sessions that can be completed once per day. Once the session is completed, the app also offers optional access to additional cognitive training exercises and educational articles.~The intervention sessions begins with a Habit Quest, a physical activity habit building tool delivered through a chat bot. Following the Habit Quest, the participant is guided through a series of gamified cognitive training exercises aimed at improving attention, memory, language and executive function."
218836069|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
218836070|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
218836071|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
219444088|NCT00302770|DRUG|quetiapine|
219444089|NCT00003549|DRUG|CMF regimen|
219444090|NCT00003549|DRUG|cyclophosphamide|
219444091|NCT00003549|DRUG|fluorouracil|
219444092|NCT00003549|DRUG|methotrexate|
219444093|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
219583707|NCT02240030|OTHER|Placebo|
219583708|NCT04898855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
219583709|NCT05545358|OTHER|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
219583710|NCT05545358|DEVICE|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
218836072|NCT01761006|DEVICE|NIOX MINO®|
219016575|NCT04731259|DRUG|ATR-04|ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
219444094|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
219444095|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
219444096|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
219444097|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
219444098|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
219444099|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
219444100|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
219444101|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
219444102|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
219583711|NCT05545358|OTHER|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
219583712|NCT04992429|PROCEDURE|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
219583713|NCT04810286|PROCEDURE|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
219583714|NCT00978263|DRUG|metformin-based Oral Antidiabetic Drugs|
219583715|NCT00978263|DRUG|Glargine|
219583716|NCT03507023|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
219583717|NCT03507023|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
219583718|NCT04856423|DIAGNOSTIC_TEST|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
219583719|NCT00338455|DRUG|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
219583720|NCT00338455|DRUG|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
219583721|NCT06216223|PROCEDURE|treatment of anal diseases in inflammatory bowel patients|treatment of anal diseases in inflammatory bowel patients
219583722|NCT06216223|DEVICE|Laser|laser
219583723|NCT06216223|PROCEDURE|traditional surgery|traditional surgery
219583724|NCT04273841|DIETARY_SUPPLEMENT|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
219583725|NCT04273841|DIETARY_SUPPLEMENT|Placebo Gum|Pellet form placebo gum
219583726|NCT06337097|DIAGNOSTIC_TEST|Troponin surveillance|Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
219444103|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
219583727|NCT06337097|OTHER|Standard of care|Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
219583728|NCT05084963|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
219583729|NCT05084963|DRUG|Placebo|Matching placebo for IRL201104
219583730|NCT06700109|DEVICE|Neural Ice|This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
219583731|NCT06700109|DRUG|Triamcinolone acetate|A single dose of Triamcinolone 40mg injected directly into the joint space.
219583732|NCT06572631|BIOLOGICAL|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Given IV
219583733|NCT06572631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219583734|NCT06572631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219016576|NCT04731259|OTHER|Placebo|Placebo
219016577|NCT05216731|PROCEDURE|Femoro-popliteal bypass|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
219444104|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
219583735|NCT06572631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219583736|NCT06572631|PROCEDURE|Computed Tomography|Undergo PET/CT
219583737|NCT06572631|DRUG|Cyclophosphamide|Given IV
219583738|NCT06572631|DRUG|Decitabine|Given IV
219583739|NCT06572631|PROCEDURE|Echocardiography|Undergo ECHO
219583740|NCT06572631|DRUG|Fludarabine|Given IV
219583741|NCT06572631|PROCEDURE|Leukapheresis|Undergo leukapheresis
219583742|NCT06572631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219583743|NCT06572631|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219583744|NCT05500716|OTHER|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
218836073|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
218836074|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
218836075|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
218836076|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
218836077|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
219444105|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
219444106|NCT06367049|DIAGNOSTIC_TEST|Methylation-specific PCR|"Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly."
219444107|NCT02740894|DRUG|Gefitinib|
219444108|NCT04282460|BEHAVIORAL|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
219444109|NCT04282460|BEHAVIORAL|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
219444110|NCT05711511|PROCEDURE|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
219444111|NCT05711511|DEVICE|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
219583745|NCT05500716|OTHER|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
219583746|NCT01638650|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
219583747|NCT01638650|DRUG|ritonavir|100 mg bid orally, Days 1-14
219583748|NCT01638650|DRUG|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
219583749|NCT01616953|BIOLOGICAL|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
219583750|NCT01616953|PROCEDURE|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
219583751|NCT01568320|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
218836078|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
218836079|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
218836080|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
218836081|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
218836082|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
218836083|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
218836084|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
218836085|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
218836086|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
218836087|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
218836088|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
218836089|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
219583752|NCT01847820|DEVICE|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
219765433|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
219583753|NCT00306150|DRUG|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
219583754|NCT00306150|DRUG|Placebo|Placebo is used according to the description of Arm 1
219583755|NCT02680431|OTHER|Blood sample|10 mL venous blood sample for analysis of plasma
219583756|NCT03583632|OTHER|visual acuity testing|testing of visual ycuity by ETDRS charts
219765434|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
219765435|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
219765436|NCT07103941|DEVICE|AM Aligner|"Intervention Name: AM Aligner (Interocclusal Aligner) Type: Device Manufacturer: (AM Aligner; TAP Sleep Care, Texas, USA)~Description:~The AM Aligner is a prefabricated, commercially available thermoplastic appliance designed to help patients return their mandible to a normal resting position after nighttime use of a Mandibular Advancement Device (MAD). In this study, the aligner will be used each morning immediately after removing the MAD. The participant will bite into the warmed aligner for 2-5 minutes to promote realignment of the mandible and occlusion. This approach aims to minimize or prevent occlusal changes, including posterior open bite and anterior shift, associated with prolonged MAD therapy.~This intervention is distinct from the alternative study arm, which uses a set of guided jaw exercises instead of a physical appliance to achieve the same goal.~The AM Aligner used in this study is a standard-of-care option and is FDA-cleared for this use. It is not investigational."
219765437|NCT07103941|BEHAVIORAL|Exercise|"Participants in this arm will perform a standardized set of jaw exercises for 5 minutes each morning immediately after removing their Mandibular Advancement Device (MAD). The exercises are intended to assist in reestablishing the natural occlusal relationship following overnight mandibular advancement.~This routine includes the following movements:~Side-to-side jaw movements Backward pressure to the chin (similar to a thinker's pose) Gentle simulated clenching~The exercises are performed once daily and take approximately 2-3 minutes to complete. This approach represents a standard-of-care method for minimizing occlusal changes associated with MAD therapy."
219765438|NCT06919016|BIOLOGICAL|DV700P-RNA|Intramuscular (IM) injection
218836090|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
219444112|NCT05813860|DRUG|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
219444113|NCT05813860|DRUG|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
219444114|NCT01690988|DRUG|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
219583757|NCT03583632|DEVICE|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
219583758|NCT02833376|OTHER|alcohol antisepsis|
219583759|NCT02833376|OTHER|chlorhexidine antisepsis|
219583760|NCT01587937|OTHER|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
219583761|NCT06412588|DRUG|Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days|Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
219583762|NCT06412588|DRUG|Vonoprazan+Amoxicillin|Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
219583763|NCT06412588|DRUG|Vonoprazan+doxycycline|Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
219583764|NCT04727437|OTHER|No treatment|Withholding anticoagulation for at least 3 months.
219583765|NCT04727437|DRUG|Warfarin|anticoagulation drug given for at least 3 months.
219765439|NCT06919016|BIOLOGICAL|DV701B1.1-RNA|IM injection
219765440|NCT06919224|OTHER|mHealth app + booklets|A mHealth app that has patient facing guidelines and engaging content and a booklet with the guidelines that are made to be patient-facing.
218836091|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
219444115|NCT01690988|DRUG|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
219444116|NCT01690988|DRUG|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
219444117|NCT03612674|PROCEDURE|Standard colonoscopy|Current standard of care colonoscopy.
219444118|NCT03612674|DEVICE|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
219444119|NCT00638274|PROCEDURE|Air|3 mls used for identifying epidural space
219444120|NCT00638274|PROCEDURE|Saline|3 mls of saline used to identify epidural space
219444121|NCT03878043|OTHER|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
219444122|NCT01465373|DRUG|Endometrin|100 mg per vagina TID
219444123|NCT01465373|DRUG|Progesterone in Oil|50 mg IM injection daily
219583766|NCT04727437|DRUG|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
219583767|NCT04727437|DRUG|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
219583768|NCT01394952|DRUG|Dulaglutide|Administered subcutaneously
219583769|NCT01394952|DRUG|Placebo|Administered subcutaneously
219583770|NCT02410356|DRUG|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
218836092|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
218836093|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
218836094|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
218836095|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
219364052|NCT05523973|OTHER|Lingual Endurance Training|Participants will participate in 3 training sessions per day for 8 weeks. Some participants will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session. Other participants will complete effortful swallows during their 3rd training session. These participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva.
219364053|NCT05301478|DEVICE|standard of care insole|standard of care diabetic insole
219444124|NCT01251991|DRUG|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
218836096|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
218836097|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
218836098|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
218836099|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
218836100|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
218836101|NCT06102512|DRUG|LOXO-783|Administered orally
219364054|NCT05301478|DEVICE|3D Printed Insole - pressure based|3D Printed Insole - pressure based
219364055|NCT05301478|DEVICE|3D Printed Insole - FEA|3D Printed Insole - FEA
219364056|NCT06519656|DRUG|Mazdutide|In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
218836102|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
219364057|NCT06787664|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219364058|NCT05892614|DRUG|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
219364059|NCT05892614|DRUG|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
219364060|NCT05892614|DRUG|Placebo|IV infusion over approximately 60 minutes every 4 weeks
219364061|NCT05707884|OTHER|critical care management|The different sedation methods result in considerable differences in terms of set-up costs and the management of the patient, which will be examined in a direct comparison.
219364062|NCT01806311|DRUG|Candesartan32mg|
219364063|NCT01806311|DRUG|Amlodipine10mg|
219364064|NCT06270784|PROCEDURE|Traditional Extraction|Participants in this group will undergo traditional extraction method. This method involves uncovering the impacted tooth and extracting the tooth with or without dividing it.
219364065|NCT06270784|PROCEDURE|Orthodontic Extraction|"Participants in this group will undergo orthodontic extraction method. In this method, a two-stage surgical procedure will be performed. In the first operation, the impacted tooth will be uncovered, and then a button will be placed on the tooth. For anchorage purposes, orthodontic mini screws will be placed in the mandibular ramus or zygomaticomaxillary buttress area. Elastics and/or ligature wires fixed to the button will be attached to the mini screw to provide force for the traction of the tooth.~Patients will be called for check-up appointments every two weeks, and the movement of the impacted tooth will be monitored with panoramic x-rays. The second operation will be planned when the tooth moves away from the inferior alveolar nerve. In the second operation, the tooth will be extracted in a similar way to the traditional extraction group."
219364066|NCT04528771|DRUG|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
219364067|NCT04528771|DRUG|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
219364068|NCT05959720|DRUG|Prednisone|60 mg/m2 D1 to D21
219364069|NCT05959720|DRUG|Vincristin|1.5 mg/m2 D1, D8, D15 and D22
219364070|NCT05959720|DRUG|Daunorubicin|40 mg/m2 D1, D8, D15 and D22
219364071|NCT05959720|DRUG|Peg-asparaginase|2000 UI/m2 D12 and D26
219364072|NCT05959720|DRUG|Intrathecal Suspension|MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
219364073|NCT05959720|DRUG|Cyclophosphamide|1000 mg/m2 D36 and D64
219364074|NCT05959720|DRUG|Cytarabine|75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
219364075|NCT05959720|DRUG|Mercaptopurine|30 mg/m2 D36 to D63 and D1 to D56 of consolidation
219364076|NCT05959720|DRUG|Methotrexate|3.000 mg/m2 D8, D22, D36 and D50
219364077|NCT05959720|DRUG|Doxorubicin|30 mg/m2 D1 and D22
219364078|NCT05227105|BEHAVIORAL|Physical Activity|Physical activity will be encouraged up to an amount of 150 minutes per week.
219364079|NCT05227105|BEHAVIORAL|Delayed intervention|Physical activity will be encouraged at the end of the trial.
219364080|NCT05663580|DRUG|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
219364081|NCT06437509|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219364082|NCT06437509|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
219583771|NCT02410356|DRUG|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
219583772|NCT04555850|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
219583773|NCT04555850|OTHER|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
219583774|NCT05437926|DEVICE|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index \>350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
219765441|NCT06918106|BEHAVIORAL|Simple advice, Brief-counseling and brochure|"Participants assigned to the intervention group will receive simple advice plus brief counseling and health broacher and then they will be screened for alcohol consumption at 6 months and 12 months of follow-ups."
219765442|NCT06916429|OTHER|Psychotherapeutic treatment|"The psychotherapeutic treatment will reflect the therapy practices that characterize the Danish primary sector.~Treatment: Clients are referred by their GP to receive up to 12 individual psychotherapy sessions, typically of 50-60 minutes' duration. For clients with depression and anxiety as referral reason, it is possible to get a supplementary referral by the GP ensuring 12 more sessions, totaling 24 sessions of therapy.~Procedure: Due to the Danish primary sector having relative freedom in method of choice, the psychologist carries out the psychotherapy according to the treatment principles they consider the most relevant, without clauses regarding specific models of therapy or manualization. The therapists register the therapeutic approaches and interventions used in each course of therapy on The Multitheoretical List of Therapeutic Interventions (MULTI-30)at the end of each treatment."
219765443|NCT06916429|OTHER|Waiting List for Psychotherapeutic Treatment|"Treatment: During the waiting list period, clients will not receive any psychotherapeutic treatment for their mental health issues in the Danish primary sector. However, their general practitioner may refer them to appropriate psychiatric treatment if their mental condition worsens and requires immediate treatment.~Procedure: Clients in the waiting list group will fill in questionnaires on their symptom development during the waiting period. They will complete the same set of predictor and outcome questionnaires as the psychotherapy group."
219765444|NCT07106203|BEHAVIORAL|Pursed-Lip Breathing (PLB)|Children in the intervention group will receive Pursed-Lip Breathing exercises twice daily for three days under nurse supervision. Exercises will be applied using playful techniques with a toy (e.g., saxophone ball). Physiological parameters will be measured before and after each session.
218836103|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
219765445|NCT06136650|DRUG|Opevesostat|Administered orally
218836104|NCT01822769|OTHER|Cardiopulmonary rehabilitation|See Arm Description
218836105|NCT01822769|OTHER|Standard of care|See Arm Description
218836106|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
218836107|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
219444125|NCT01251991|DIETARY_SUPPLEMENT|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
219444126|NCT01251991|DIETARY_SUPPLEMENT|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
219444127|NCT01251991|OTHER|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
219444128|NCT01634100|DRUG|Probenecid|Probenecid
219444129|NCT01634100|DRUG|Rifampicin|Rifampicin
219444130|NCT01634100|DRUG|Empagliflozin|BI Drug
219444131|NCT01634100|DRUG|Empagliflozin|BI Drug
219444132|NCT01634100|DRUG|Rifampicin|Rifampicin
219444133|NCT01634100|DRUG|Probenecid|Probenecid
219444134|NCT01634100|DRUG|Empagliflozin (BI 10773)|BI Drug
219444135|NCT04330456|RADIATION|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
219444136|NCT04330456|PROCEDURE|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
219583775|NCT05986253|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
219583776|NCT05986253|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin solution
219583777|NCT02283983|OTHER|mittens and booties|
219583778|NCT02283983|OTHER|cooling helmet|
219444137|NCT04330456|RADIATION|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
218836108|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
218836109|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
218836110|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
219444138|NCT02331316|OTHER|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
219444139|NCT05234190|DRUG|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
219444140|NCT03645811|BEHAVIORAL|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
219444141|NCT03645811|BEHAVIORAL|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
219444142|NCT01934608|BEHAVIORAL|Refill synch|
219444143|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
218836111|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
218836112|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
218836113|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
218836114|NCT06200597|DRUG|LAD603|LAD603 SC injection.
218836115|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
218836116|NCT00133159|BIOLOGICAL|Grass MATAMPL|
218836117|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
218836118|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
218836119|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
219444144|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
219444145|NCT01975376|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
219444146|NCT01975376|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
219444147|NCT01816542|OTHER|patch tests on healthy skin|Patches will be placed on healthy skin.
219444148|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
219583779|NCT05802732|DIAGNOSTIC_TEST|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
219583780|NCT04953572|GENETIC|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
219583781|NCT04953572|PROCEDURE|Microfracture|Microfracture
219583782|NCT04953572|COMBINATION_PRODUCT|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
219583783|NCT04953572|PROCEDURE|Autologous osteochondral transplantation|Autologous osteochondral transplantation
219583784|NCT03290703|DRUG|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
219583785|NCT03290703|DRUG|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
219583786|NCT00157079|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
219583787|NCT02654860|DRUG|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
219583788|NCT02654860|DRUG|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
219583789|NCT02654860|DRUG|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
219583790|NCT04453202|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
219583791|NCT04453202|OTHER|Placebo|Participants will receive a single IM injection of placebo on Day 1.
219583792|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
219583793|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
219583794|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
219583795|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
219583796|NCT02027675|OTHER|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
218836120|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
219583797|NCT02027675|OTHER|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
219583798|NCT03565458|DRUG|Gemigliptin|zemiglo 50mg,LG Chem
219765446|NCT06136650|DRUG|Dexamethasone|Administered orally
218836121|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
218836122|NCT03371576|DEVICE|intraocular lenses|
218836123|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
218836124|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
218836125|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
219016578|NCT05216731|PROCEDURE|Endovascular procedure|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
219364083|NCT06777420|OTHER|Question prompt list|The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.
219364084|NCT05617833|COMBINATION_PRODUCT|MLT+EPO|Melatonin component will be a daily dose of 30 mg/kg enteral administered in the evening in a split dose given at cares/feedings. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr subcutaneously or intravenously) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday subcutaneously or intravenously) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.
219583799|NCT03565458|DRUG|Dapagliflozin|forxiga, dapagliflozin 10mg
219583800|NCT03565458|DRUG|Empagliflozin|jardiance 25mg, empagliflozin
219765447|NCT06136650|DRUG|Fludrocortisone acetate|Administered orally
219765448|NCT06136650|DRUG|Hydrocortisone|Administered orally or IM as a rescue drug
219765449|NCT06136650|DRUG|Abiraterone acetate|Administered orally
219364085|NCT05617833|OTHER|Placebo|Placebo enteral and IV
219765450|NCT06136650|DRUG|Prednisone acetate|Administered orally
219765451|NCT06136650|DRUG|Enzalutamide|Administered orally
219765452|NCT03646214|DEVICE|Midline traction oral appliance|Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
219765453|NCT07115745|GENETIC|BMS-986515|Specified dose on specified days
219364086|NCT04259125|DIAGNOSTIC_TEST|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
219765454|NCT07115745|DRUG|Fludarabine|Specified dose on specified days
219364087|NCT04259125|OTHER|Survey|Regarding epilepsy and development.
219765455|NCT07115745|DRUG|Cyclophosphamide|Specified dose on specified days
219765456|NCT07115745|DRUG|Tocilizumab|Specified dose on specified days
219364088|NCT05734989|DIAGNOSTIC_TEST|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
219364089|NCT05734989|DIAGNOSTIC_TEST|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
219364090|NCT05734989|BEHAVIORAL|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
219364091|NCT03915145|OTHER|Kinesio tape application|Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
219364092|NCT03915145|OTHER|Sham Kinesio tape application|Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
219364093|NCT03915145|OTHER|No intervention|The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
219364094|NCT02326519|OTHER|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
219364095|NCT00352534|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
219364096|NCT00352534|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219364097|NCT00352534|PROCEDURE|Chest Radiography|Undergo chest X-ray
219583801|NCT03092063|BEHAVIORAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
219583802|NCT03092063|BEHAVIORAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
219765457|NCT07114510|OTHER|OPTI-VENT Bundle|"Provider Education: During a brief (\<2 minute) bedside education, the educator will 1) review the CPR ventilation rate targets for age, and 2) ensure the provider has a cue card of current rate recommendations on his/her person. Compliance will be defined as performance of at least 30 trainings per unit per month. We will record provider discipline and time since last training as a surrogate of training spread. Educators will leverage these two-minute trainings to review the patient's current ventilator settings as an initial target during CPR to ensure adequate chest rise.~Additionally, a focus on CPR ventilation rates will be integrated into resuscitation education or quality meetings for all disciplines. Report cards detailing unit-level performance will be generated by the study team for review during site monthly presentations.~Point-of-Care Guidance: A metronome will be deployed to all cardiac arrests using a smart phone application."
219765458|NCT07114510|OTHER|Transition|There will be a 2-month transition period for study sites beginning study enrollment using standard ICU practices as they onboard to the study intervention.
219364098|NCT00352534|PROCEDURE|Computed Tomography|Undergo CT
219364099|NCT00352534|BIOLOGICAL|Dactinomycin|Given IV
219765459|NCT07114510|OTHER|None - control|Control - no intervention
219765460|NCT06857240|DRUG|Ruxolitinib Topical Cream|1.5% cream
219364100|NCT00352534|DRUG|Doxorubicin Hydrochloride|Given IV
219364101|NCT00352534|PROCEDURE|Echocardiography Test|Undergo echocardiography
219765461|NCT06776406|DEVICE|Freedom Pursuit Robotic Platform|The Freedom Pursuit Robotic Platform is a robotic head holder device that uses data from the AlignRT system (3D surface imager) to make small movements of a patient's head to stabilize it during radiation therapy.
219765462|NCT05554393|DRUG|Azacitidine|Given IV or SC
219765463|NCT05554393|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219765464|NCT05554393|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219765465|NCT05554393|DRUG|Cytarabine|Given IV
219364102|NCT00352534|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219364103|NCT00352534|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219364104|NCT00352534|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219364105|NCT00352534|DRUG|Vincristine Sulfate|Given IV
219364106|NCT01836679|DRUG|Chidamide|Given orally
219364107|NCT01836679|DRUG|Paclitaxel|Given IV
219364108|NCT01836679|DRUG|Carboplatin|Given IV
219765466|NCT05554393|DRUG|Daunorubicin Hydrochloride|Given IV
219765467|NCT05554393|DRUG|Venetoclax|Given PO
219364109|NCT01836679|DRUG|Placebo|Given orally
219364110|NCT00408863|DRUG|tibolone|tibolone 2.5 mg/day
219364111|NCT00408863|DRUG|placebo|
219364112|NCT02304198|DRUG|Udenafil|Udenafil 50mg tablet
219364113|NCT00783016|DRUG|Morphine|
219364114|NCT00955435|OTHER|Non-interventional|Patients receive induction hormones\* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
219364115|NCT00955435|GENETIC|Protein expression analysis|
219364116|NCT00955435|GENETIC|Proteomic profiling|
219364117|NCT00955435|OTHER|Laboratory biomarker analysis|
219364118|NCT01602341|DRUG|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
219364119|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
219364120|NCT01602341|DRUG|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
219364121|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
219364122|NCT01402245|BIOLOGICAL|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
219364123|NCT01402245|BIOLOGICAL|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
219765468|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
219765469|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
219765470|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
219765471|NCT07116967|DRUG|Deucravacitinib|Specified dose on specified days
219765472|NCT07116967|DRUG|Ustekinumab|Specified dose on specified days
218836126|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
218836127|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
218836128|NCT01903122|DRUG|Cevimeline|
218836129|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
219765473|NCT07117162|OTHER|ADRD Care Delivery Protocol|1\. Included in arm/group descriptions
219765474|NCT06923527|DRUG|Elacestrant|"Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity. The pills shall be administered with food (to reduce nausea and vomiting) at approximately the same time each day, and the prescription will be provided with the standard Swallow tablets whole; do not chew, crush, or split warning label."
219765475|NCT06916806|DRUG|AZD5492|IMP: subcutaneous.
219444149|NCT02564068|DRUG|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
219765476|NCT06923072|DRUG|Baricitinib|Participants will be instructed to take baricitinib 4mg oral daily for 24 weeks (with or without food)
219765477|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218836130|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
219444150|NCT02339441|DRUG|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
219444151|NCT02339441|DRUG|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
219444152|NCT02339441|DRUG|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
219444153|NCT02738346|DRUG|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
219444154|NCT02738346|DRUG|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
219444155|NCT02738346|DRUG|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
219765478|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
219765479|NCT06918847|OTHER|Myofacial release|Myofascial release (MFR) for the calf muscle will be administered with the patient in a prone position, holding for 120 seconds. The MFR technique involves allowing the lateral aspect of the therapist's thumb to sink into the central portion of the muscle belly. MFR will be performed for 15 minutes.
219765480|NCT06918847|OTHER|Dynamic cupping therapy|In dynamic cupping therapy, patients will be comfortably positioned in a prone position, ensuring that the lower limb is exposed and accessible for treatment. Appropriately sized cups will be selected and applied to the calf and hamstrings region. Prior to application, a small amount of lubricant or oil will be applied to facilitate the smooth movement of the cups over the skin surface during the therapy. The technique of dynamic cupping will involve compressing the cups and gently situating them onto the area being treated, applying the necessary force to generate negative pressure. The duration of dynamic cupping therapy will be 10 minutes.
219765481|NCT07127783|BEHAVIORAL|Active Recovery|Participants will receive postoperative instructions to follow an active recovery protocol focused on increasing activity level, core strength exercises, and pelvic floor exercises focused on urinary and bowel symptoms. Exercises are to be completed twice per day for the 12 weeks following surgery.
219583803|NCT03092063|BEHAVIORAL|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
218836131|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
219444156|NCT02738346|DEVICE|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
219444157|NCT06949995|DEVICE|Active Recovery with Blood Flow Restriction|10-minute active recovery protocol performed with blood flow restriction using a pneumatic cuff set at 60% of the participant's total occlusion pressure.
219583804|NCT03092063|BEHAVIORAL|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
219583805|NCT02931006|OTHER|water|
219583806|NCT02931006|OTHER|bovine milk|
219583807|NCT04952636|PROCEDURE|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
219583808|NCT04952636|PROCEDURE|open Cuistow|peforming the Cuistow Procedure with the traditional open process
219583809|NCT01157897|BIOLOGICAL|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
219583810|NCT01157897|OTHER|P. vivax sporozoite challenge|P. vivax sporozoite challenge
219583811|NCT04472247|DIAGNOSTIC_TEST|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
219583812|NCT03276221|BEHAVIORAL|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
219583813|NCT05528835|PROCEDURE|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
219583814|NCT04644874|DIAGNOSTIC_TEST|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
219583815|NCT04644874|DIAGNOSTIC_TEST|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
219583816|NCT04644874|DIAGNOSTIC_TEST|30 second chair stand test|Repetitions within 30 seconds
219583817|NCT04644874|DIAGNOSTIC_TEST|Handgrip Strength Test|Measured in kilograms
219583818|NCT04059224|DRUG|Trametinib|Trametinib 2 mg once a day by mouth.
219583819|NCT04059224|DRUG|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
219583820|NCT03659097|PROCEDURE|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
219583821|NCT03809988|DRUG|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
219583822|NCT03809988|DRUG|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
219583823|NCT00424775|DRUG|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
219583824|NCT05445674|COMBINATION_PRODUCT|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
219765482|NCT07127783|BEHAVIORAL|Standard Postoperative Instructions|Standard of care postoperative instructions covering incision care, pain control, dietary instructions, and emergency precautions. Also includes guidelines regarding pelvic rest and lifting restrictions.
219444158|NCT06949995|OTHER|Active Recovery|10-minute active recovery protocol.
219444159|NCT01819194|DEVICE|senofilcon A|
219444160|NCT04603274|PROCEDURE|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
219444161|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Prophylaxis|a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
219444162|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Treatment|a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
219444163|NCT06869577|OTHER|Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma|A 12-week supportive group intervention targeted caregivers to patients with glioblastoma.
219444164|NCT01875705|DRUG|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
219444165|NCT01875705|DRUG|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
219583825|NCT05445674|OTHER|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
219583826|NCT02912650|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
218836132|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
218836133|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
218836134|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
219583827|NCT02912650|DRUG|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
219364124|NCT04183985|DEVICE|Total knee arthroplasty prosthesis|In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
219583828|NCT02912650|DRUG|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
219765483|NCT07130812|OTHER|blood flow restriction|The SAGA blood flow restriction tourniquet system will be used for each training sessions for the rowers within the light load restriction group. The 4 inch-wide tourniquet will be applied to both upper thighs during the strength and endurance exercises. Tourniquet setting will be determined as the pressure needed to achieve 40-80% arterial occlusion to the extremity (as measured by the SAGA BFR unit). The SAGA units provides a consistent amount of pressure to the extremity throughout the ROM of the exercise. The settings will be determined at baseline and then recalibrated weekly.
219444166|NCT00247572|DRUG|NRP104|
219583829|NCT02912650|DRUG|Placebo|2 caplets of Placebo
219444167|NCT01962857|BEHAVIORAL|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
219364125|NCT05480969|OTHER|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
219444168|NCT02562950|DRUG|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
219444169|NCT02562950|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
219364126|NCT06265142|PROCEDURE|Bladder catheterization|Participant will undergo the standard bladder catheterization for urine collection
219364127|NCT06265142|PROCEDURE|clean catch urine via bladder massage technique|Participant will undergo clean catch urine via bladder massage technique
219364128|NCT04439279|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219444170|NCT02562950|DRUG|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
219364129|NCT03521791|DRUG|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
219444171|NCT05059704|OTHER|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
219444172|NCT05059704|OTHER|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
219444173|NCT03442504|DIAGNOSTIC_TEST|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
219444174|NCT00005969|DRUG|Chemotherapy|
218836135|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
218836136|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
219364130|NCT03521791|OTHER|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
219444175|NCT00005969|DRUG|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
219444176|NCT03054740|DRUG|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
219444177|NCT03054740|DRUG|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
219444178|NCT00331955|DRUG|doxorubicin hydrochloride|Given IV
219444179|NCT00331955|DRUG|vorinostat|Given orally
219444180|NCT00331955|OTHER|pharmacological study|Correlative studies
219444181|NCT00331955|OTHER|laboratory biomarker analysis|Correlative studies
219444182|NCT00110123|DRUG|fotemustine|
219444183|NCT00110123|DRUG|isolated perfusion|
219444184|NCT03156855|DRUG|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
219444185|NCT03156855|DRUG|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
219444186|NCT01586650|OTHER|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
219444187|NCT01586650|OTHER|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
219444188|NCT01320813|PROCEDURE|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
219444189|NCT01320813|PROCEDURE|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
218836137|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
218836138|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
219364131|NCT05046288|OTHER|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
219444190|NCT06220552|DRUG|Sintilimab|Sintilimab 200mg D1, Q3W
219444191|NCT06220552|RADIATION|Low-dose Radiotherapy|Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W
219444192|NCT04683172|DEVICE|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
219475686|NCT06340503|DEVICE|Research-grade accelerometer|Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit. Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
219475687|NCT06340503|OTHER|National Comprehensive Cancer Network (NCCN) Education Materials|The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
219475688|NCT06340503|DEVICE|Garmin Vivofit activity tracker|This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
219475689|NCT06340503|OTHER|Exercise Consultation Calls|The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
219475690|NCT06340503|OTHER|Interview|The interviews will be conducted by a trained Q-PRO interviewer and audio recorded. Interviews are expected to last approximately 30 minutes. Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
219475691|NCT06340503|OTHER|Physical Activity Index Assessment (Intervention Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 1, 3, 6, 9 and 12 while on study
218836139|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
218836140|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
218836141|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
219583830|NCT04416620|OTHER|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
219765484|NCT07130812|OTHER|Heavy load resistance training|For the resistance prescription, rowers will do strengthening exercises at 70-80% 1 RM. Exercises will be performed in series following 6 sets by 5 reps, with 120 seconds of rest between sets for each exercise.
218836142|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
219765485|NCT07134777|DIAGNOSTIC_TEST|MRI|Functional MRI scan
218836143|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
218836144|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
218836145|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
218836146|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
218836147|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
219364132|NCT05357131|BEHAVIORAL|Hypnosis without VR (HYP)|"HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used."
219364133|NCT05357131|DEVICE|Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort.
219364134|NCT04024501|DRUG|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
219364135|NCT04024501|DRUG|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
219364136|NCT04024501|DRUG|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
219364137|NCT04024501|DRUG|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
219364138|NCT04024501|DRUG|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
219364139|NCT00388947|DEVICE|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
219364140|NCT03038308|DRUG|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
219364141|NCT02343484|DRUG|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
219364142|NCT02343484|DRUG|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
219364143|NCT03547557|DEVICE|Exablate 2000 strappable system|
219364144|NCT04187092|OTHER|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
219364145|NCT04187092|OTHER|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
219583831|NCT03966482|BEHAVIORAL|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
219583832|NCT05477160|DRUG|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
219583833|NCT05477160|DRUG|Placebo (SC)|Placebo will be administered as an SC bolus injection.
219583834|NCT05477160|DRUG|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
218836148|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
219583835|NCT05477160|DRUG|Placebo (IV)|Placebo will be administered as an IV bolus injection.
219583836|NCT01246362|DRUG|Control|Given placebo
219583837|NCT01246362|DRUG|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
219765486|NCT07135895|DEVICE|Artix Thrombectomy System|Treatment of lower extremity arterial occlusions using the Artix Thrombectomy System.
219765487|NCT07140614|DRUG|EDK060, dose A|EDK060, dose A, Single dose, IV infusion
219765488|NCT07140614|DRUG|EDK060, dose B|EDK060, dose B, Single dose, IV infusion
219765489|NCT07140614|DRUG|EDK060, dose C|EDK060, dose C, Single dose, IV infusion
219765490|NCT07140614|DRUG|EDK060, dose D|EDK060, dose D, Single dose, IV infusion
219765491|NCT07140614|OTHER|Placebo|Placebo
218836149|NCT02830854|OTHER|Molecular Hydrogen|
218836150|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
218836151|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
218836152|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
218836153|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
218836154|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
218836155|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
219364146|NCT00278876|DRUG|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
219364147|NCT00145847|DRUG|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
219364148|NCT00565994|PROCEDURE|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
219364149|NCT00945919|DRUG|Oxymorphone ER|Rapid Opioid rotation/titration
219364150|NCT01630525|OTHER|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
219364151|NCT01630525|OTHER|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
219583838|NCT04439773|DRUG|placebo|the control group will be given the same volume of saline.
219583839|NCT04439773|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
219583840|NCT01720199|OTHER|Diario della Salute (DDS)|"DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
219583841|NCT00663832|DRUG|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
219583842|NCT01483859|OTHER|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
219583843|NCT02562482|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
219765492|NCT06934044|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle.
219765493|NCT06934044|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
219765494|NCT06926868|DRUG|Iza-bren|Specified dose on specified days
219765495|NCT06926868|DRUG|Nab-paclitaxel|Specified dose on specified days
219765496|NCT06926868|DRUG|Paclitaxel|Specified dose on specified days
219765497|NCT06926868|DRUG|Capecitabine|Specified dose on specified days
219765498|NCT06926868|DRUG|Carboplatin|Specified dose on specified days
219765499|NCT06926868|DRUG|Gemcitabine|Specified dose on specified days
219583844|NCT02562482|OTHER|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
219583845|NCT00939120|DRUG|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
219583846|NCT00939120|DRUG|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
219583847|NCT00939120|DRUG|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
219583848|NCT01674413|DRUG|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
219583849|NCT01674413|DRUG|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool."
219583850|NCT01674413|DRUG|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
218836156|NCT03226249|DRUG|Dacarbazine|Given IV
218836157|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
218836158|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
219583851|NCT00916136|PROCEDURE|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
219583852|NCT01487070|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
219583853|NCT02972177|PROCEDURE|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
219583854|NCT02972177|PROCEDURE|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
219583855|NCT05697055|DRUG|Azvudine|5mg orally, once a day, for no more than 14 days
219583856|NCT05697055|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
219583857|NCT03196414|BIOLOGICAL|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
219583858|NCT02736682|DRUG|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
219583859|NCT02736682|DRUG|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
219583860|NCT00503711|DRUG|Vandetanib|100 mg every other day, 100mg once daily
219765500|NCT06934239|DEVICE|Artificial intelligence (AI) decision-support tool|"The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information).~Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system."
219765501|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
219765502|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
219583861|NCT00503711|DRUG|Vandetanib 300 mg|300mg once daily
218836159|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
218836160|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
218836161|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
218836162|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
219583862|NCT03255512|DRUG|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
219583863|NCT03255512|DRUG|Placebo|Matching placebo
219583864|NCT03255512|DRUG|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
219765503|NCT06764316|DRUG|BAY 3547926|antibody conjugate with actinium-225 label
219765504|NCT06764316|DRUG|BAY 3547922|antibody conjugate without actinium-225 label as preinjection
218836163|NCT01532921|PROCEDURE|Tricuspid valve repair|
218836164|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
218836165|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
218836166|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
218836167|NCT00070109|DRUG|trabectedin|Given IV
219196302|NCT06841432|PROCEDURE|adenoidectomy using coblatioion|One hundred and five patients underwent a Coblation-assisted adenoidectomy procedure. The child was positioned in Rose's position, which helped retract the soft palate and improve visibility of the nasopharynx. Two soft rubber catheters were inserted into the patient's mouth, with the distal and proximal ends crossed externally and secured with a clamp. The COBLATOR™ II surgery system Model EC8000-01 was used, with a power setting of nine for ablation and five for coagulation. Under general anesthesia, the adenoidectomy was performed using either a 4 mm, 70-degree angled endoscope inserted orally or a zero-degree endoscope inserted through the nose, providing effective visualization of the nasopharynx. After the procedure, hemostasis was achieved by using a combination of the coagulation and ablation modes.
219765505|NCT07139457|DEVICE|Wearable seizure prediction and alert glasses|A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.
219444193|NCT04683172|DEVICE|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
219444194|NCT05946707|DRUG|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
219444195|NCT05946707|DRUG|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
218836168|NCT00070109|OTHER|pharmacological study|Correlative studies
219765506|NCT07140484|DRUG|Sotatercept|0.7mg/kg
219765507|NCT07141914|OTHER|No treatment given|No treatment given
219444196|NCT03043209|GENETIC|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
218836169|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
219475692|NCT06340503|OTHER|Physical Activity Index Assessment (Control Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.
219475693|NCT06340503|OTHER|Health Surveys|Various health surveys will be completed to assess participant health and physical activities.
219475694|NCT00568490|PROCEDURE|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
218836170|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
218836171|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
219475695|NCT00568490|PROCEDURE|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
219475696|NCT06542614|DRUG|TQH3906 capsules|To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
219475697|NCT06542614|DRUG|Placebo of TQH3906 capsules|Placebo without drug substance.
219475698|NCT03261492|BEHAVIORAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
219475699|NCT03261492|BEHAVIORAL|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
219475700|NCT04411641|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
219475701|NCT04411641|DRUG|Placebo to match Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
219475702|NCT06176989|DRUG|Enasidenib|100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
219475703|NCT05155423|OTHER|mask for immobilization|mask for immobilization
219475704|NCT05155423|OTHER|Elekta BodyFix|Elekta BodyFix
219475705|NCT04855253|DRUG|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
219475706|NCT04855253|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV daily for 3 days. Days -5, -4 and -3. Taken in combination with Cyclophosphamide
219475707|NCT04855253|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine. Days -5, -4 and -3.
219475708|NCT04855253|DRUG|Tisagenlecleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
219475709|NCT04855253|DRUG|Axicabtagene Ciloleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
219475710|NCT04855253|DRUG|Lisocabtagene Maraleucel Intravenous Suspension|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
219765508|NCT07141914|OTHER|No treatment given|No treatment given
219765509|NCT06072651|BEHAVIORAL|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
219765510|NCT06580457|BEHAVIORAL|Personal Causal Model + Personalized Feedback|Receive a personal causal model of one's personalized causes of substance use/urges, along with a 1-hour, live clinical feedback session to suggest how to apply these insights to one's own recovery.
218836172|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
218836173|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
219444197|NCT01832857|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
219444198|NCT02343952|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
219765511|NCT06935357|DRUG|Felzartamab|Administered IV
219765512|NCT06935357|DRUG|Placebo|Administered IV
219765513|NCT06931951|PROCEDURE|Knee Pharmacoacupuncture|Physician choose the adequate type and dose of pharmacoacupuncture and needle type
219765514|NCT06931951|PROCEDURE|Oriental medicine integrated treatment|Physician choose the integrated oriental medicine treatment other than herbal acupuncture.
219765515|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
219765516|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219765517|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219765518|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
219765519|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219765520|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
219765521|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
218836174|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
218836175|NCT01252160|DRUG|QUTENZA|Cutaneous patch
219475711|NCT05917210|BEHAVIORAL|Standard TB-EC|Standard TB-EC by healthcare workers
219475712|NCT05917210|BEHAVIORAL|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
218836176|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
218836177|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
218836178|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
218836179|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
218836180|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
218836181|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
219475713|NCT05658354|OTHER|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
219475714|NCT05861284|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
219475715|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
219475716|NCT05482282|BIOLOGICAL|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
219475717|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
219475718|NCT05482282|BIOLOGICAL|Pentabio|3 doses of Pentabio
219475719|NCT04501562|OTHER|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
219475720|NCT04501562|OTHER|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
219475721|NCT04501562|OTHER|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
219475722|NCT04501562|OTHER|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
219475723|NCT03810417|DRUG|Digoxin Antibodies Fab Fragments|Digoxin antibodies
219475724|NCT03810417|OTHER|Placebo|Saline
219475725|NCT03810417|DIAGNOSTIC_TEST|Baseline EO > 360 pM|Baseline ouabain concentration \> 360 pM
219475726|NCT03810417|DIAGNOSTIC_TEST|EO < 360 pM|Baseline ouabain concentration \< 360 pM
219475727|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
219475728|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
219475729|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
219765522|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
219765523|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
219765524|NCT06935370|DRUG|vicadrostat|vicadrostat
219765525|NCT06935370|DRUG|empagliflozin|empagliflozin
219765526|NCT06935370|DRUG|Placebo|Placebo matching vicadrostat
219765527|NCT06938347|DRUG|Agitated Saline SoC|The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.
219765528|NCT06938347|DRUG|ASI-02|Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.
219016592|NCT02176681|DRUG|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
219475730|NCT05776225|PROCEDURE|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
219475731|NCT03282123|DRUG|Midomafetamine|80 to 120 mg MDMA
219475732|NCT03282123|BEHAVIORAL|Manualized therapy|Non-directive therapy conducted during MDMA-assisted therapy session
219475733|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
219475734|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
219475735|NCT04148326|OTHER|No Intervention|There is no intervention for this study.
219475736|NCT05707273|DRUG|Autologous Anti-CD19 CAR-expressing T Lymphocytes|Given IV
219475737|NCT05707273|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219475738|NCT05707273|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate
219475739|NCT05707273|DRUG|Cyclophosphamide|Given IV
219475740|NCT05707273|DRUG|Fludarabine|Given IV
219475741|NCT05707273|PROCEDURE|Leukapheresis|Undergo T-cell leukapheresis
219475742|NCT05707273|OTHER|Questionnaire Administration|Complete questionnaires
219475743|NCT06022159|RADIATION|Hypofractionated Radiation Therapy|The Hypofractionated Intensity-Modulated Radiation Therapy will be delivered in 5 fractions of 6 Gy each on the Planning Target Volume (PTV). The total dose of 30 Gy will be administered in approximately 1 week.
219475744|NCT06022159|PROCEDURE|Conservative treatment|A wide en bloc resection is required (amputation is excluded) while ensuring the best functional preservation. The surgical procedure will take place about 1,5 to 2 months after the end of the radiation therapy.
219475745|NCT04082234|BEHAVIORAL|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
219475746|NCT04082234|OTHER|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
219475747|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
219475748|NCT03589729|DRUG|Cladribine|Given IV
219475749|NCT03589729|DRUG|Cytarabine|Given IV
219475750|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
219475751|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
219475752|NCT03589729|DRUG|Idarubicin|Given IV
219444199|NCT06053970|OTHER|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
219444200|NCT01378299|DRUG|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
219444201|NCT02702947|DIETARY_SUPPLEMENT|Prunus domestica extract|Prosman 1 capsule twice a day
219765529|NCT03900845|DEVICE|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
219444202|NCT00829218|OTHER|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
219765530|NCT03900845|DEVICE|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (\~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
219444203|NCT00829218|OTHER|Placebo diet|Juice with nothing added.
219444204|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
219765531|NCT03900845|DEVICE|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
219765532|NCT05932914|PROCEDURE|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
219765533|NCT06941272|BIOLOGICAL|Patritumab Deruxtecan|IV Infusion
219765534|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
219765535|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
218836182|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
218836183|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
218836184|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
218836185|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
219196303|NCT06841432|PROCEDURE|adenoidectomy by Suction diathermy|One hundred and five patients underwent a suction diathermy adenoidectomy procedure. The soft palate was gently retracted using two suction catheters, allowing a 70-degree angled endoscope (Storz, Germany) placed in the oropharynx to provide a clear view of the adenoidal tissue and surrounding structures in the nasopharynx. Using a malleable size 10 or 12 French hand-switching suction coagulator, the adenoidal tissue was carefully ablated, starting from the uppermost part. The procedure was completed when the posterior choanae were clearly visible, and the nasopharynx had a smooth, unobstructed appearance. Great care was taken to avoid injuring the Eustachian tube orifice, posterior septum, choanae, inferior turbinate, palate, and posterior pharyngeal wall. Continuous irrigation with saline, either through the mouth or the nose, helped minimize any thermal damage caused by the diathermy machine.
219196304|NCT06841679|DRUG|Utidelone Capsule|UTD2 40 mg/m2/d, po, qd, day 1-5, q3w
219444205|NCT00901589|DIETARY_SUPPLEMENT|thistle oil|four capsules a day
219196305|NCT06841679|DRUG|Utidelone Capsule|50 mg/m2/d, po, qd, day 1-5, q3w
219196306|NCT06841679|DRUG|Utidelone Capsule|60 mg/m2/d, po, qd, day 1-5, q3w
219196307|NCT06841679|DRUG|Capecitabine|1000 mg/m2, po, bid, day 1-14, q3w
219196308|NCT06841679|DRUG|Oxaliplatin|130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles
219765536|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
219765537|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
219765538|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
219765539|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
219765540|NCT07072832|DEVICE|3D-Shelf|Treatment of hip dysplasia using novel 3D printed 3D-Shelf device.
219765541|NCT04510051|DRUG|Cyclophosphamide|Given IV
219765542|NCT04510051|DRUG|Fludarabine|Given IV
219765543|NCT04510051|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
219765544|NCT06942923|DRUG|AZD4144|AZD4144 will be administered orally as per arms they have been assigned.
219765545|NCT06942923|DRUG|Placebo|Placebo will be administered orally as per arms they have been assigned.
219765546|NCT06940752|DEVICE|VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms)|Non-surgical catheter approach called VINTAGE will be used to treat ventricular arrhythmias arising from difficult-to-reach portions of the heart.
219444206|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
219765547|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
218836188|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
218836189|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
219444207|NCT00901589|DIETARY_SUPPLEMENT|Thistle oil|Four capsules daily
219444208|NCT04589338|OTHER|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
219444209|NCT04589338|OTHER|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
219444210|NCT00456885|DRUG|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
219444211|NCT00456885|DRUG|Placebo|Twice daily injection of placebo
219444212|NCT04306978|OTHER|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
219444213|NCT04306978|OTHER|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
219444214|NCT01448707|DRUG|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
219444215|NCT01448707|DRUG|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
219444216|NCT04439812|OTHER|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
219444217|NCT05825092|DRUG|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
219765548|NCT07141121|DEVICE|Histolog Scan|Upon prostate removal, the prostate is taken to the Histolog scanner, dipped in proprietary fluorescent dye, rinsed with saline, and then scanned on five different sides. This involves simply placing the prostate on the surface of the scanner and acquiring images on each side, giving a high-resolution (cellular level) microscopic imaging of the prostate's surfaces. Once images are collected, the prostate is returned to the pathology lab to undergo the NeuroSafe procedure, which is standard of care (SOC).
219765549|NCT06944522|BIOLOGICAL|bemdaneprocel|Investigational cell therapy comprising midbrain dopaminergic neuron progenitors derived from human embryonic stem cells
219765550|NCT06944522|PROCEDURE|Sham surgery|Sham surgery will be performed on Day 0
219765551|NCT05472987|PROCEDURE|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
219765552|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
219765553|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
219765554|NCT07136168|BEHAVIORAL|Health dialogue|"1. Pre-visit 20 minutes including timed-up and go (TUG) walking test, length, weight, blood pressure, and blood tests ( HbA1C, PEth)~2. Structured health dialogue by a dedicated nurse practitioner for about 60 minutes covering living conditions, activity, everyday function, lifestyle habits and formation of a plan for improved health and referral to physician, physiotherapist or other primary care worker when appropriate~3. Follow-up call at 3 months with the nurse practitioner for evaluation and adjustment of the plan"
219765555|NCT07139132|BEHAVIORAL|Health Wellness Coaching|Health wellness coach will provide education and guidance about cultural nutrition
218836190|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
218836191|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
219765556|NCT07139132|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
219444218|NCT05825092|DRUG|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
219444219|NCT05825092|DIAGNOSTIC_TEST|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
219765557|NCT07139132|BEHAVIORAL|School-age nutritional education program|Educational program will teach students about healthy Native American food choices
219765558|NCT07139132|DIAGNOSTIC_TEST|Cognitive Testing|Participants will undergo a cognitive test.
219765559|NCT07139132|DIAGNOSTIC_TEST|Blood work|Participants will undergo blood work.
219765560|NCT07142291|DRUG|Cromolyn Sodium (34.2 mg BID)|17.1 mg, BID, oral inhalation
219765561|NCT07142291|DRUG|Cromolyn Sodium (17.1 mg BID)|34.2 mg, BID, oral inhalation via dry powder inhaler
219765562|NCT07142291|DRUG|Placebo|Placebo comparator matched to active treatment.
219765563|NCT07142291|DRUG|Riluzole (100 mg)|50 mg, oral tablet, BID, standard of care treatment
219444220|NCT05825092|DIAGNOSTIC_TEST|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
219765564|NCT06945458|DRUG|KT-621|Oral drug
219444221|NCT05825092|DIAGNOSTIC_TEST|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
219444222|NCT05825092|DIAGNOSTIC_TEST|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
219444223|NCT05825092|DIAGNOSTIC_TEST|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
219444224|NCT00650312|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
219444225|NCT00650312|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
219765565|NCT06947538|BEHAVIORAL|webSTAIR|WebSTAIR consists of 10 online modules that provide psychoeducation on trauma and emotions and teach skills to improve coping with emotions and strengthen interpersonal relationships. Modules are completed at the participants' own pace and utilize interactive exercises, and audio and video components to aid in delivery.
219765566|NCT06947538|BEHAVIORAL|WebSTAIR plus coaching|WebSTAIR with up to five 30-min coaching sessions with a CHW will focus on guiding participants through the program, discussing exercises that are valuable or problematic, and reviewing module content.
219765567|NCT06947538|BEHAVIORAL|Clinician administered Brief STAIR|Brief STAIR is a brief, low intensity, therapy that utilizes psychoeducation, coping skills training, and does not include recounting of the trauma memory, making it highly tolerable. It will be delivered by mental health clinicians in five to six 30-minute individual sessions.
219765568|NCT06947538|BEHAVIORAL|Clinician administered WET|WET is a brief, high intensity, exposure-based treatment delivered by mental health clinicians consisting of six 30-minute individual sessions that cover treatment rationale, psychoeducation about PTSD, and directing participants to write in session about their traumatic experience using scripted instructions.
219765569|NCT06946888|BEHAVIORAL|Acupressure|Participants in this group will receive instruction on how to perform self-acupressure targeting two specific acupoints on the hands: Shenmen and Neiguan. The acupressure protocol includes pressing each acupoint approximately 15 times (about 30 seconds), with a total of four acupoints per session (both hands), for approximately 2 minutes per session. Pressure should be applied until a sensation of soreness, numbness, fullness, or slight pain is felt (equivalent to about 3 kg of pressure). Participants are asked to perform self-acupressure twice daily (once in the afternoon and once before bedtime, adjustable based on personal schedule) for a total of 2 weeks. They will record their practice using a daily log and continue to complete psychological and emotional outcome questionnaires weekly over a 2-month follow-up period.
219016593|NCT02176681|DRUG|Insulin|Insulin
219016594|NCT02799212|DRUG|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
219016595|NCT02799212|DRUG|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
219016596|NCT06216977|OTHER|Clear Liquids|Participants will not take anything by mouth after midnight the day before surgery but will be given 12 ounce clear liquid (Sugar-free Gatorade) at bedside at the pre-operative holding area
219016597|NCT06216977|OTHER|Standard of Care|Participants will not take anything my mouth after midnight day before surgery
219016600|NCT02896751|DEVICE|3D printed NIV mask|use of 3D printed mask
219444226|NCT05094804|DRUG|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
219444227|NCT05094804|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
219444228|NCT05094804|DRUG|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
218836192|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
218836193|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
219444229|NCT04679714|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
219444230|NCT00133172|DRUG|Tacrolimus|IV
219444231|NCT00133172|DRUG|mycophenolate mofetil|IV
219444232|NCT00133172|DRUG|Prednisone|IV
219444233|NCT00004604|BIOLOGICAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
219444234|NCT02371018|DIETARY_SUPPLEMENT|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
219444235|NCT04930952|DRUG|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
219444236|NCT00899678|DRUG|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
219444237|NCT00899678|DRUG|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
219444238|NCT04295707|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
219444239|NCT04295707|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
219444240|NCT05154071|OTHER|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
219444241|NCT00033371|DRUG|Celecoxib|Given 400 mg PO twice a day
219444242|NCT00033371|OTHER|Placebo|Given PO to match DFMO
219444243|NCT00033371|DRUG|eflornithine|Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).
218836194|NCT00297960|DRUG|ziprasidone or olanzapine|
218836195|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
218836196|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
219444244|NCT00033371|OTHER|Laboratory biomarker analysis|Correlative studies
219444245|NCT00033371|OTHER|Questionnaire administration|Ancillary studies
219016615|NCT05145491|PROCEDURE|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
219016616|NCT05145491|PROCEDURE|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~   a. Visits must be at least one month apart~3. Participant actively requests surgery due to worsening symptoms~4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
219475753|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
219475754|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
219475755|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
219475756|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
219475757|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
219475758|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
219475759|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
219475760|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
219475761|NCT01367626|DRUG|letrozole|2.5 mg tablet
219475762|NCT01367626|DRUG|letrozole|2.5 mg tablet
219583865|NCT05624827|DIAGNOSTIC_TEST|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
219583866|NCT01490866|DRUG|Axitinib|5-mg tablets PO BID
219583867|NCT01490866|DRUG|Bevacizumab|5 mg/kg Days 1 and 15; IV
219583868|NCT01490866|DRUG|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
219583869|NCT01490866|DRUG|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
219583870|NCT01490866|DRUG|Leucovorin|400 mg/m2 Days 1 and 15; IV
219583871|NCT01490866|DRUG|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
219583872|NCT02038231|BEHAVIORAL|Parenting Mindfully Program|see Arm Description.
219583873|NCT02038231|OTHER|Parent Education Program|See Arm Description.
219583874|NCT02943967|PROCEDURE|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
219583875|NCT02943967|PROCEDURE|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
219583876|NCT03433716|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
219583877|NCT01665924|DRUG|GLPG0634 100mg capsule once a day for 10 days|
219583878|NCT04171024|DEVICE|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
219583879|NCT04171024|DEVICE|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
219583880|NCT01040884|OTHER|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
219583881|NCT03088618|PROCEDURE|Nasal septoplasty|Type of surgery
219583882|NCT02672202|DRUG|Duloxetine|"* 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2"
219583883|NCT02672202|DRUG|Pregabalin|"* 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
219583884|NCT02672202|DRUG|Placebo|"* non-active - twice before surgery~* non-active - twice a day for post operative days 1-7"
219583885|NCT02351583|DEVICE|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
219583886|NCT02351583|DEVICE|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
219583887|NCT03712982|BEHAVIORAL|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
219583888|NCT03712982|BEHAVIORAL|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
219583889|NCT03712982|BEHAVIORAL|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
219016617|NCT02446457|OTHER|Laboratory Biomarker Analysis|Correlative studies
219583890|NCT03712982|OTHER|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
219583891|NCT02722148|DEVICE|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
219583892|NCT02434432|BEHAVIORAL|music therapy selected by mothers|mothers' choice of music
219583893|NCT02434432|BEHAVIORAL|Music therapy recorded lullaby|recorded lullaby
219765570|NCT06445946|DRUG|Metformin|Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
219016618|NCT02446457|DRUG|Lenalidomide|Given PO
219765571|NCT06445946|DRUG|Insulin|Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
219765572|NCT06948097|DRUG|fostamatinib|The study intervention is fostamatinib, administered orally starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for 28 additional days and randomized to receive either fostamatinib or placebo, along with standard of care.
219765573|NCT06948097|DRUG|Placebo|Placebo tablets will match fostamatinib, starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, and then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for an additional 28 days.
219765574|NCT07149207|DRUG|Indocyanine Green (ICG)|Dose: 5 mg/kg IV injection prior to surgery
219765575|NCT06952504|BIOLOGICAL|Pembrolizumab|Intravenous (IV) Infusion
219765576|NCT06952504|DRUG|Carboplatin|During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
219765577|NCT06952504|DRUG|Paclitaxel|During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
219016619|NCT02446457|BIOLOGICAL|Pembrolizumab|Given IV
219016620|NCT02446457|BIOLOGICAL|Rituximab|Given IV
219583894|NCT04191837|OTHER|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
219583895|NCT04191837|OTHER|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
219583896|NCT03056820|OTHER|25° head-up position|Participant will be positioned at 25° angle for procedure.
219583897|NCT03056820|OTHER|55° head-up position|Participant will be positioned at 55° angle for procedure.
219583898|NCT03693573|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
219583899|NCT03693573|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
219583900|NCT06253026|OTHER|Search and rescue mission|Air search and rescue missions lasting 15 consecutive days
219583901|NCT01382745|DRUG|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
219583902|NCT01382745|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
219583903|NCT02242565|DEVICE|ShangRing|ShangRing device for male circumcision
219583904|NCT04805918|BEHAVIORAL|VIPP-SD|Parenting program
219583905|NCT01296659|DRUG|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
219583906|NCT05191303|DEVICE|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
219583907|NCT05646420|OTHER|Blood sampling|A blood sample of 15 ml will be collected for each patient.
219583908|NCT06182176|DRUG|Sulphadoxine-pyrimethamine and Amodiaquine|The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
219583909|NCT00496535|DRUG|TNFerade biologic|
219583910|NCT04275765|BEHAVIORAL|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
219583911|NCT04275765|OTHER|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
219583912|NCT00220987|OTHER|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
219583913|NCT00220987|OTHER|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
219196309|NCT06841679|DRUG|Utidelone Capsule|UTD2 po, on d1-5, q3w (dose decided after the phase II)
219196310|NCT04810624|BEHAVIORAL|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
219583914|NCT01080443|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
219583915|NCT03511443|DIAGNOSTIC_TEST|hsRDT|Testing highly sensitive RDT detection for low parasitemia
219196311|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
219196312|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
219583916|NCT04128280|PROCEDURE|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
219583917|NCT04128280|PROCEDURE|TUIB|a surgery: transurethral incision of bladder neck
219583918|NCT06322173|DIAGNOSTIC_TEST|NGS Analysis|An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
219583919|NCT04831463|BEHAVIORAL|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
219583920|NCT01104779|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219765578|NCT06952504|DRUG|Docetaxel|During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
219583921|NCT01104779|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219583922|NCT00644449|OTHER|placebo|placebo
218836197|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
218836198|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
218836199|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
219444246|NCT01505660|BEHAVIORAL|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
219765579|NCT06952504|BIOLOGICAL|Sacituzumab Tirumotecan|IV Infusion
219444247|NCT02150460|PROCEDURE|One-site peribulbar injection|injection into the inferior medial orbital compartment
219583923|NCT00644449|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
219583924|NCT00644449|OTHER|placebo|placebo
219583925|NCT00644449|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
219583926|NCT03632967|DEVICE|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
219444248|NCT02150460|PROCEDURE|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
219765580|NCT06949553|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Patients will be recruited through a registry if patients who had participated in previous OASIS trials. After this referral, the study is conducted entirely electronically.
219765581|NCT06951711|DRUG|KarXT|Specified dose on specified days
219583927|NCT03848247|OTHER|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
219583928|NCT03848247|OTHER|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
219583929|NCT04204759|DEVICE|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
219765582|NCT06951711|OTHER|Placebo|Specified dose on specified days
219016621|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
219444249|NCT00510367|DRUG|5-Fluorouracil|500 mg/m\^2 By Vein Daily x 2 Days
219583930|NCT04204759|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
219583931|NCT06928025|PROCEDURE|Preoperative Education|animation-based education for elderly patients before coronary artery bypass graft surgery Before coronary artery bypass graft surgery, the scenario prepared based on the literature information including introduction of the service, preparation for surgery, monitoring, drug treatment and applications, deep breathing and cough exercise, spirometer use, operation time, postoperative period and care, patient pain management and intubation process will be given as animation-based video training. The effects of this on postoperative pain, fear, anxiety and self-care management will be evaluated.
219765583|NCT07148973|PROCEDURE|Transcatheter Aortic Valve Replacement|The TAVR surgery mainly involves attaching an artificially-made aortic valve to a special catheter, and then using the catheter to deliver the valve to the affected area and release it. This surgery replaces the original aortic valve with an artificial one, thereby restoring the valve function. Compared with traditional open-chest surgery, it causes less trauma, has lower risks, and enables faster recovery. It is particularly suitable for patients who cannot tolerate open-chest surgery, have poor cardiac function, or are older.
219765584|NCT07145801|DIAGNOSTIC_TEST|Lumason|Following baseline ultrasound imaging, CEUS will be performed using dual B-mode and CEUS mode. For the first injection using Lumason the approximate tumor mid-line will be imaged during breath hold until complete tumor enhancement is achieved followed by imaging sweeps through the tumor. Intermittent imaging will be performed after that. Following a 10 minute Lumason wash-out period, participants will then receive a bolus injection of Sonazoid with identical imaging protocol to Lumason for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps of the tumor will then be obtained at 1 and 2 minutes to evaluate enhancement within the late vascular phase to detect early washout. After visualization in the late phase, imaging will resume to evaluate the Kupffer phase of contrast enhancement. Following completion of the exam, patients will be monitored for at least 30 minutes before being discharged and all data will be exported for later off-line analysis
219765585|NCT07145801|DIAGNOSTIC_TEST|Sonazoid|Participants will receive a bolus injection up to (0.12 µl of MB/kg) of Sonazoid, followed by 5-10 ml of normal saline. Imaging of Sonazoid will be identical to the protocol described above for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps (5-10 seconds) of the tumor will then be obtained in at 1 and 2 minutes to evaluate enhancement within the late vascular phase and detect early washout. After that imaging will resume to evaluate the Kupffer phase of contrast enhancement. Kupffer phase imaging (also called the postvascular phase) starts approximately 8-10 mins after injection when the free circulating microbubbles have been eliminated from the vasculature with Kupfer-cell enhancement persisting for up to 2 hours. Sonazoid CEUS will be performed in all patients after Lumason clearance from the circulation, usually within 15 min after injection.
219196313|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
219444250|NCT00510367|DRUG|Cyclophosphamide|500 mg/m\^2 By Vein On Day 1
219444251|NCT00510367|DRUG|Doxorubicin|50 mg/m\^2 By Vein Over 72 Hours
219444252|NCT02198560|DEVICE|RS-3000 Lite|
219444253|NCT00253929|DRUG|Intra-arterial infusion of adenosine|
219444254|NCT00253929|DRUG|intra-arterial infusion of caffeine|
219444255|NCT00253929|DRUG|intra-arterial infusion of acetylcholine|
219444256|NCT00253929|DRUG|intra-arterial infusion of sodium nitroprusside|
219444257|NCT00253929|PROCEDURE|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
219444258|NCT03796195|DRUG|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
219444259|NCT03874195|BEHAVIORAL|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
219444260|NCT03874195|BEHAVIORAL|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
219444261|NCT02894255|DEVICE|Coronary artery bypass grafting|
219444262|NCT02894255|PROCEDURE|Percutaneous coronary intervention|
219444263|NCT02923050|BEHAVIORAL|Simple Suppers|Theory-based 10-week family meals program
219444264|NCT00601679|OTHER|NT-proBNP guided care|knowledge of NT-proBNP results
219444265|NCT03123484|DRUG|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
219444266|NCT03123484|DRUG|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
219016622|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
219444267|NCT02914197|OTHER|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
219444268|NCT00333047|DRUG|Letrozole|
219444269|NCT03799627|DRUG|Vadadustat|Vadadustat Tablets 150 mg
219444270|NCT03799627|DRUG|Epoetin Alfa|Epoetin Alfa
219444271|NCT03799627|DRUG|Vadadustat TIW|Oral Vadadustat
219475763|NCT04214470|OTHER|No intervention|There is no intervention for this study
219475764|NCT00005658|DRUG|Glycine|
219475765|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
219475766|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
219475767|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
219475768|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
219475769|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
219475770|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
219475771|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
219475772|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
219475773|NCT05011357|DRUG|Saline Control|Saline infusion
219475774|NCT06967259|DRUG|ENA-001|Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.
219475775|NCT06967259|DRUG|Placebo Comparator|Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.
219765586|NCT05169047|OTHER|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
219765587|NCT05169047|OTHER|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
219765588|NCT07148414|DRUG|SPY002-072|Experimental
219765589|NCT07148414|DRUG|Placebo|Matching Placebo
219765590|NCT07150117|BEHAVIORAL|Exercise|A supervised 12-week cycling-based aerobic exercise intervention performed twice per week.
219765591|NCT07154732|DEVICE|Transcranial photobiomodulation (active)|During the active stimulation period, participants completed 11 sessions of active stimulation within 11 days in their own homes. The stimulation duration per session was 9-12 minutes, administered once daily.
219765592|NCT07154732|DEVICE|Transcranial photobiomodulation (sham)|During the sham stimulation period, participants completed 11 sessions of sham stimulation in their own homes within 11 days, with the same stimulation frequency and duration as the active stimulation group. The intervention was delivered at the same target area and wavelength; the intensity was matched to that of the active stimulation during the first 30 seconds and the last 30 seconds of each session, while no intervention was applied in the intermediate period.
219765593|NCT05963971|BEHAVIORAL|PEDALL|Twenty-six hour nutrition education intervention delivered virtually over a six month period
219444272|NCT00776698|DRUG|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
219444273|NCT00776698|DRUG|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
219444274|NCT00776698|DRUG|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
219444275|NCT02883426|BIOLOGICAL|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
219444276|NCT02883426|BIOLOGICAL|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
219444277|NCT02883426|BIOLOGICAL|Placebo|Administered by nasal spray
219444278|NCT02666040|DEVICE|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
219444279|NCT02666040|DEVICE|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
218836200|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
219444280|NCT02666040|PROCEDURE|Detecting the mode of admission to hospital|Ordinary admission or day surgery
219016624|NCT06330805|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219444281|NCT02666040|PROCEDURE|Duration of surgery|Time operating room
219444282|NCT02666040|PROCEDURE|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
219444283|NCT01211119|OTHER|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
219444284|NCT06153914|PROCEDURE|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
219444285|NCT03224260|DRUG|BMS-986177|Oral Suspension
219444286|NCT03224260|OTHER|Matched Placebo|Oral Suspension
219475776|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
219475777|NCT01215968|DRUG|Placebo|Administered subcutaneously
219475778|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
219475779|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
219475780|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
219475781|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
219475782|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
219475783|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
219475784|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
219475785|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
219475786|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
219475787|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
219475788|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
219475789|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
219475790|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
219583932|NCT06928064|PROCEDURE|Prediction of Postoperative Pain Severity Using Pain Sensitivity Questionnaire Applied in Preoperative Period in Patients Undergoing Breast-Conserving Surgery (Lumpectomy).|": This study included 74 patients over the age of 18 with American Society of Anesthesiologists (ASA) scores of I, II, or III, who were scheduled to undergo breast-conserving surgery. Ethical approval from the local ethics committee and written informed consent from each patient were obtained. Patient data, including age, ASA score, and comorbidities, were collected, and contact details were recorded for postoperative follow-up.~The PSQ was administered to all patients during the preoperative period to assess their pain sensitivity. Anesthesia induction and maintenance followed a standardized protocol on the day of surgery. The intraoperative analgesic consumption and the duration of the surgery were documented. Postoperative assessments were conducted 24 hours after the surgery in the general surgery ward, where analgesic use and short pain inventory scores were recorded. Patients were followed up one month postoperatively, and their pain levels were assessed using the Numeric Rating"
219583933|NCT06928584|RADIATION|Conventional Radiotherapy|50Gy/25Fx irradiation or 39Gy/30Fx bid reirradiation (previous pelvic radiation)
219583934|NCT06928584|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
219583935|NCT06928584|DRUG|5-fluorouracil|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
219583936|NCT06928584|DRUG|folinic acid|400 mg/m2 q2w
219583937|NCT06928584|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
219444287|NCT02512276|BEHAVIORAL|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
219444288|NCT02287662|OTHER|Vancouver 3M Clinical Pathway|
219444289|NCT04019392|DEVICE|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
219444290|NCT04019392|OTHER|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
219444291|NCT03065725|PROCEDURE|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
219444292|NCT03175016|PROCEDURE|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
219444293|NCT03175016|DRUG|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
219444294|NCT03175016|DEVICE|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
219444295|NCT05793112|DRUG|INF108F probiotic|Oral suspension
219444296|NCT05793112|DRUG|Placebo|Oral suspension
219583938|NCT06928584|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
219583939|NCT06928584|DRUG|Cetuximab|500 mg/m² q2w
219583940|NCT06928584|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
219583941|NCT06928584|RADIATION|Hypofractionated radiotherapy|25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (previous pelvic radiation)
219583942|NCT06928584|DRUG|PD-1 antibody|200mg IV q3w
219765594|NCT05963971|OTHER|Standard of care|Nutrition education per institutional standard of care
219016625|NCT06330805|OTHER|Contrast Agent|Given IV
219583943|NCT06926777|DIAGNOSTIC_TEST|Nerve Conduction Study|"This study involves two diagnostic interventions for evaluating CTS:~Ultrasound Examination (Diagnostic Intervention)~1. A high-frequency ultrasound probe will be used to assess the median nerve at the wrist.~2. Parameters measured include cross-sectional area, flattening ratio, and echogenicity.~The goal is to determine if ultrasound can accurately diagnose CTS compared to NCS.~NCS (Diagnostic Intervention)~1. Surface electrodes will be placed on the skin to stimulate and record median nerve conduction.~2. Parameters such as latency, conduction velocity, and amplitude will be recorded.~3. NCS serves as the gold standard for diagnosing CTS and will be used for comparison with ultrasound results.~Each participant will undergo both ultrasound and NCS, allowing researchers to compare their effectiveness in diagnosing CTS."
219583944|NCT06928805|OTHER|Balloon inflation exercise|Balloon inflation exercise was applied in addition to the forward-leaning position.
219583945|NCT06928805|OTHER|Pursed-lip breathing exercise|The pursed-lip breathing exercise was applied in addition to the forward-leaning position.
219765595|NCT07148206|DRUG|Dronabinol Capsules|Dronabinol is a synthetic form of THC. Dronabinol is eliminated in a biphasic manner, with an initial half-life of 25-36 hours.
219765596|NCT07148206|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is an oral solution (100 mg/mL) which rapidly appears in plasma, reaches peak plasma concentration in 3-4 hours and has a half-life of 18-32 hours.
219765597|NCT07148206|OTHER|Placebo Dronabinol|Placebo capsules
219765598|NCT07148206|OTHER|Placebo Epidiolex|Placebo oral solution
219765599|NCT07155213|BEHAVIORAL|Virtual reality exergaming|High-intensity active video gaming using head-mounted display.
219765600|NCT06460961|BIOLOGICAL|MK-6837|IV Infusion
219016626|NCT06330805|DRUG|Leuprolide|Given injection
219016627|NCT06330805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219016628|NCT06330805|OTHER|Physical Performance Testing|Undergo functional fitness tests
219016629|NCT06330805|DRUG|Relugolix|Given PO
219016630|NCT04263948|DEVICE|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
219583946|NCT06928805|OTHER|Control (Standard treatment)|Standard practice is implemented in the institution where the study is conducted.
219583947|NCT03982199|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
219583948|NCT03982199|BIOLOGICAL|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
219583949|NCT04555681|DIAGNOSTIC_TEST|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
219583950|NCT00594646|DRUG|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
219583951|NCT06927349|DRUG|BA1301|BA1301 is administered intravenously once every three weeks.
219583952|NCT06926751|DRUG|Telpegfilgrastim Injection|subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle
219583953|NCT06926751|DRUG|filgrastim|subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle
219583954|NCT06927128|DRUG|Gemcitabine, Cisplatin|Gemcitabine (1000mg/m²) and cisplatin (70mg/m²). Gemcitabine is used on the 1st and 8th days of a 21 - day cycle, and cisplatin is used on the 2nd day of the cycle. A total of 3 - 4 cycles are carried out.A dose reduction to 60% of the original dose (adjusted to 0.6 times the initial dose) will be implemented if deemed clinically necessary, contingent upon meeting either of the following criteria: 1) occurrence of grade 3 or higher treatment-related adverse events as per CTCAE v5.0 guidelines, or 2) evidence of renal impairment manifested by a ≥40% decline in glomerular filtration rate (GFR) from baseline measurements.
219444297|NCT03385434|DEVICE|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
219583955|NCT06927453|PROCEDURE|Acrylic splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site covered with the custom acrylic splint.
219583956|NCT06927453|PROCEDURE|No splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site will not be covered
218836201|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
219444298|NCT04151719|DRUG|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
219583957|NCT06895343|DRUG|ABBV-701|Subcutaneous
219583958|NCT06895343|DRUG|Placebo|Subcutaneous
219583959|NCT02984774|PROCEDURE|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
219583960|NCT02984774|PROCEDURE|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
219583961|NCT02984774|PROCEDURE|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
219583962|NCT02984774|PROCEDURE|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
219583963|NCT06927960|DRUG|AH-001 or placebo|SAD: Subjects are planned to receive a single dose of AH-001 or placebo once MAD: Subjects are planned to receive a single daily dose of AH-001 or placebo for 7 consecutive days
219583964|NCT06927336|DRUG|XinNaoJing injection|XingNaoJing injection is a kind of traditional Chinese medicine preparation, which has the effects of clearing heat and detoxifying, cooling blood and activating blood circulation, resuscitating the brain. In recent years, it has been often used in the treatment of related symptoms caused by qi and blood disturbance and cerebral blood stasis, and has achieved certain results. Xingnaojing injection contains Yujin to resuscitate phlegm, invigorate blood circulation and promote qi; Zhizi dissipates blood stasis and cleans heat; Both are subject medicine. Natural musk cleans the brain, Shujin Tongluo, Jun medicine; Borneol awaken awaken, for adjuvant. Small doses of musk restored brain function and improved cerebral circulation. Xingnaojing injection can promote the recovery of consciousness, reduce the level of plasma β-endorphin, and restore brain function. Borneol bi-dimensionally regulates the central nervous system, calms, prolongs the level of arousal, and protects the brain tissue.
219583965|NCT06927336|DEVICE|tDCS|tDCS stimulated the cerebellum for 20 minutes, once a day, 5 times a week, a total of 10 times, and the stimulation intensity was 2mA.
219765601|NCT06460961|BIOLOGICAL|Pembrolizumab|IV Infusion
219765602|NCT06460961|DRUG|Rescue Medications|Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.
219765603|NCT07151014|OTHER|blood sample collection|blood sample collection in old patients in order to study the trombophilic risk
219444299|NCT04212546|OTHER|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
219444300|NCT04212546|OTHER|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
219444301|NCT01599819|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
219765604|NCT02211768|PROCEDURE|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
219583966|NCT03544879|BEHAVIORAL|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
219583967|NCT03544879|BEHAVIORAL|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
219583968|NCT06915987|BEHAVIORAL|Exercise Intervention|Exercise snack group will be higher intensity movements designed to elevate heart rate while active movement break will have low intensity / stretching exercises assigned to them.
219583969|NCT06927570|DRUG|HS-20122（Phase 1a：Dose Escalation）|Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219583970|NCT06927570|DRUG|HS-20122（Phase 1b：Dose Expansion ）|travenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219583971|NCT05673213|OTHER|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
219583972|NCT06928233|PROCEDURE|blood sampling|Blood sampling for experimental analyses.
219583973|NCT03907462|BEHAVIORAL|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
219583974|NCT02182791|DRUG|Nevirapine|
219583975|NCT02182791|DRUG|EE/NET|
219583976|NCT02140866|OTHER|Hand Exercise|
218836202|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
219583977|NCT02140866|OTHER|Compensatory Intervention Program (CIP)|
219583978|NCT05397743|OTHER|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
219583979|NCT04797429|OTHER|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
219583980|NCT04797429|OTHER|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
219583981|NCT06112431|OTHER|Intervention|Participants randomized to the Intervention Arm and referred to ophthalmology will receive assistance from a Study Coordinator with scheduling in-office eye exam appointment and arranging transportation to these appointments over 2 years at either Columbia Ophthalmology, Harlem Hospital, or their own eye care provider.
219583982|NCT06112431|OTHER|Usual Care|Consented participants randomized to the Usual Care Arm will receive all the basic level of services including the eye health screening, optometric exam if they fail the screening, and eyeglasses at no charge. Those who require referral to ophthalmology will be scheduled for the initial in-office eye exam and their outcomes will be tracked. No additional support will be provided the Usual Care participants during the study. The Usual Care Arm represents a realistic choice currently available for participants following eye health screening.
219583983|NCT06459037|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219583984|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
218836203|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
218836204|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
219765605|NCT02211768|DRUG|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
219765606|NCT07156955|BEHAVIORAL|Electrical stimulation cue|A single 30-minute session is provided. Electrodes are attached to the cubital fossa, and stimulation is delivered at a frequency that increases up to 70 Hz as the elbow joint approaches the target angle. Target angles are set between 0 degrees and 120 degrees, based on each participant's available range of motion determined during the initial assessment. Participants adjust their elbow joint angle to match the provided target angle using feedback from the electrical stimulation. When the elbow joint angle matches the target angle, the maximum frequency is applied to the cubital fossa. Participants match their elbow joint angle to the target angle based on the given frequency.
219765607|NCT07156955|BEHAVIORAL|Visual stimulation cue|A single 30-minute session is provided. The difference between the current elbow joint angle and the pre-set target angle is displayed on a screen using two colored needles (a red needle for the target angle and a black needle for the current elbow joint angle). The target angle is set within each participant's available range of motion based on the initial assessment. Participants continue the intervention by adjusting their elbow angle using the visual feedback. When the elbow joint angle matches the target angle, the two needles overlap. Based on this visual cue, participants adjust their elbow joint angle to match the target angle.
218836205|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
218836206|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
218836207|NCT02184091|DRUG|Nevirapine|
219444302|NCT01599819|BIOLOGICAL|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
219444303|NCT01424319|DRUG|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
219444304|NCT01424319|DRUG|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
219444305|NCT01424319|DRUG|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
219444306|NCT04833790|BEHAVIORAL|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
219444307|NCT04833790|BEHAVIORAL|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
219444308|NCT04833790|BEHAVIORAL|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
219444309|NCT04833790|BEHAVIORAL|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
219444310|NCT04833790|BEHAVIORAL|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
219444311|NCT02983513|BEHAVIORAL|Early Intervention|
219444312|NCT04479449|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
219444313|NCT04479449|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
219444314|NCT03430336|OTHER|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
219444315|NCT03430336|OTHER|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
219765608|NCT07156955|BEHAVIORAL|No cue|A single 30-minute session is provided. The target angle is determined within each participant's available range of motion based on the initial assessment. Throughout the session, participants receive verbal feedback from the assessor and adjust their elbow joint angle accordingly to match the target angle.
218836208|NCT05965583|DRUG|BI 1815368|BI 1815368
218836209|NCT05965583|DRUG|Itraconazole|Itraconazole
218836210|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
218836211|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
218836212|NCT02360670|OTHER|control imaging|
218836213|NCT02360670|OTHER|additional multimodal imaging|
218836214|NCT02550288|DRUG|Ezetimibe 10 mg|
218836215|NCT02550288|DRUG|Atorvastatin 10 mg|
218836216|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
218836217|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
218836218|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
218836219|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
218836220|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
219444316|NCT03430336|OTHER|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
219444317|NCT03430336|OTHER|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
219444318|NCT03430336|OTHER|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
219444319|NCT03600870|DRUG|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
219583985|NCT06336538|OTHER|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
219583986|NCT03548064|OTHER|Placebo|Placebo
219583987|NCT03548064|OTHER|Placebo|Placebo
219583988|NCT03548064|OTHER|Placebo|Placebo
219583989|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
219583990|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
219583991|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
219583993|NCT05011123|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
219583994|NCT05011123|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
219583995|NCT03117036|DRUG|Chemotherapy|Systemic chemotherapy with curative intent
219583996|NCT06953245|OTHER|Non-Interventional Study|Non-interventional study
219583997|NCT04221789|OTHER|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
219583998|NCT05137314|DRUG|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
219583999|NCT04193475|OTHER|Analysis|No intervention planned. Novel analysis of echocardiographic data.
219584000|NCT04732221|DRUG|Frespaciguat|Frespaciguat (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
219584001|NCT04732221|DRUG|Placebo to Frespaciguat|Placebo administered as dry powder inhalation
219584002|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
219584003|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
219584004|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
219584005|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
219584006|NCT05327816|BIOLOGICAL|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
218836221|NCT02998411|OTHER|Titration|
218836222|NCT01454609|DRUG|0.9% Normal saline|Saline
218836223|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
218836224|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
219584007|NCT05327816|DRUG|Placebo|Placebo will be administered as intramuscular injection.
219584008|NCT05428826|DRUG|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
219584009|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~* EFD 0.096 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
219584010|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~* EFD 0 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
218836225|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
218836226|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
218836227|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
218836228|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
218836229|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
219584011|NCT00388076|DRUG|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
218836230|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
218836231|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
219584012|NCT00388076|DRUG|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
219584013|NCT00388076|DRUG|paclitaxel|in combination with pazopanib
219584014|NCT00388076|DRUG|carboplatin|in combination with pazopanib
218836232|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
218836233|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
218836234|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
218836235|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
218836236|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
218836237|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
218836238|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
218836239|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
218836240|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
218836241|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
219584015|NCT06402370|DIAGNOSTIC_TEST|PET scan|\[18F\]Vizamyl
219584016|NCT00193466|DRUG|Rituximab|
219584017|NCT00193466|DRUG|Fludarabine|
219584018|NCT00193466|DRUG|CAMPTH-1H|
219584019|NCT02675439|DRUG|ADU-S100|
218836242|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
218836243|NCT06406400|DRUG|AZD4041|"Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7."
218836244|NCT06406400|DRUG|Itraconazole|Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
218836245|NCT06406400|DRUG|Buprenorphine|Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
218836246|NCT06406400|DRUG|Buprenorphine / Naloxone|Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
218836247|NCT06406400|DRUG|Hydromorphone|Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
218836248|NCT06406400|DRUG|Placebo|"Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7."
218836249|NCT06435416|OTHER|No intervention|No intervention
219196314|NCT04704271|DRUG|Inhaled THC|4 mg inhaled THC
219196315|NCT04704271|DRUG|Placebo|Inhaled placebo (no active cannabinoids)
219584020|NCT02675439|BIOLOGICAL|ipilimumab|
219584021|NCT06035263|OTHER|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
219765609|NCT06052306|DRUG|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
219765610|NCT07157787|DRUG|ALXN1920|Participants will receive ALXN1920 SC infusion.
219765611|NCT07157787|DRUG|Placebo|Participants will receive Placebo SC infusion.
219765612|NCT07159971|DEVICE|School B|Nutritional therapy supported by a mobile application.
219765613|NCT07159971|OTHER|Control|Conventional nutritional treatment.
219016648|NCT06555848|DEVICE|CERAMENT G|CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
219444320|NCT02417675|OTHER|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
219584022|NCT06035263|OTHER|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
219765614|NCT07164131|DRUG|Doxycycline|Subjects will receive Doxycycline (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
219765615|NCT07164131|DRUG|Azithromycin|Subjects will receive Azithromycin (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
219584023|NCT04053049|OTHER|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
219584024|NCT06168279|PROCEDURE|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
219584025|NCT06168279|PROCEDURE|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
219584026|NCT02771795|DRUG|Herceptin (trastuzumab)|Intravenous administration
219584027|NCT02771795|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
219584028|NCT01985074|BEHAVIORAL|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
219584029|NCT04112173|BEHAVIORAL|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
218836250|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
218836251|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
218836252|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
218836253|NCT04764097|DRUG|Placebo|Placebo
218836254|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
218836255|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
218836256|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
218836257|NCT00191399|DRUG|Olanzapine|
218836258|NCT00191399|DRUG|Fluoxetine|
218836259|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
219196316|NCT05940324|DRUG|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
219584030|NCT02906930|DRUG|semaglutide|Oral administration once daily.
219584031|NCT02906930|DRUG|placebo|Oral administration once daily.
219584032|NCT03621358|OTHER|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
219584033|NCT03621358|OTHER|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
219584034|NCT03621358|OTHER|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
219584035|NCT02984618|PROCEDURE|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
219584036|NCT02984618|PROCEDURE|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
219584037|NCT04198636|DRUG|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
219584038|NCT04198636|DRUG|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
219765616|NCT07156630|DEVICE|iCare ST500|Measurement of IOP
219765617|NCT07156630|DEVICE|iCare IC200|Measurement of IOP
219765618|NCT07156630|DEVICE|GAT|Measurement of IOP
219765619|NCT07156630|DEVICE|Tonovera|Measurement of IOP
219765620|NCT07162584|DRUG|Oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
219765621|NCT07162584|DRUG|Placebo|intranasal administration of placebo (24 IU)
218836260|NCT02318368|DRUG|Ficlatuzumab|
218836261|NCT02318368|DRUG|Erlotinib|
218836262|NCT02318368|DRUG|placebo|
218836263|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
218836264|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
219584039|NCT03058419|DRUG|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
219584040|NCT03058419|DRUG|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
219584041|NCT03058419|DRUG|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
219584042|NCT03058419|DRUG|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
219584043|NCT03058419|DRUG|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
218836265|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
218836266|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
218836267|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
218836268|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
219444321|NCT02417675|OTHER|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
219444322|NCT02417675|OTHER|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
219196317|NCT05940324|DRUG|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
219196318|NCT05940324|OTHER|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
219196319|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
219444323|NCT00766064|DRUG|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
219444324|NCT02091193|DIETARY_SUPPLEMENT|Krill Oil (Supplement A)|
219444325|NCT02091193|DIETARY_SUPPLEMENT|Placebo (Supplement B)|
219444326|NCT04668547|DEVICE|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
219444327|NCT02959697|DRUG|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
219444328|NCT02959697|DRUG|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
219444329|NCT02959697|PROCEDURE|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
219444330|NCT05300854|PROCEDURE|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
219584044|NCT03058419|DRUG|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
219584045|NCT03058419|DRUG|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
219584046|NCT03058419|DRUG|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
219584047|NCT03123536|DEVICE|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
218836269|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, …). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
218836270|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
218836271|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
218836272|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
219444331|NCT05300854|PROCEDURE|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
219444332|NCT03907592|DIETARY_SUPPLEMENT|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
219444333|NCT03907592|DIETARY_SUPPLEMENT|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
219444334|NCT03907592|PROCEDURE|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
219444335|NCT05625880|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
219444336|NCT01922739|DRUG|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
219444337|NCT01922739|DRUG|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
219444338|NCT02619058|BIOLOGICAL|NKT cells|autologous natural killer T cell
219444339|NCT00481221|PROCEDURE|Observation of results from laboratory tests|Laboratory data summary only
219444340|NCT01176890|DRUG|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
219444341|NCT01176890|OTHER|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
219444342|NCT04762264|DEVICE|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
219444343|NCT06228443|DRUG|Leflunomide 20 mg Film-coated Tablet|Leflunomide 20 mg Film-coated Tablet (Test Drug)
219444344|NCT06228443|DRUG|ARAVA® 20 mg Film-coated Tablet|ARAVA® 20 mg Tablets (Reference Drug)
219444345|NCT04672070|OTHER|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
219444346|NCT04672070|OTHER|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
219444347|NCT03150199|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
219765622|NCT07161765|DEVICE|Rectal Expulsion Device (RED)|"Enrolled participants will complete surveys prior a standard of care visit at the University of Michigan.~Gastroenterology staff will perform the RED device at the time of a participant's anorectal manometry appointment."
218836273|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
218836274|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
218836275|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
218836276|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
218836277|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
218836278|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
219765623|NCT07166094|DRUG|Rina-S|Intravenous (IV) infusion.
219765624|NCT07166094|DRUG|IC|"* Paclitaxel: IV infusion~* Doxorubicin: IV bolus injection/infusion"
219765625|NCT07162038|BIOLOGICAL|mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)|CAR-T cell infusion given at four escalating dose levels (DL1: 3 x 10\^4 cells/kg, DL2: 1 x 10\^5 cells/kg, DL3: 3 x 10\^5 cells/kg, DL4: 1 x 10\^6 cells/kg) with a dose de-escalation dose (DL-1: 1 x 10\^4 cells/kg), if needed.
219765626|NCT07162038|DRUG|Fludarabine|Pre-transplant: 30 mg/m\^2 IV infusion over 30-60 minutes once daily for 5 days from day -6 through day -2
219765627|NCT07162038|DRUG|Cyclophosphamide|"Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant on day -6 and day -5.~Post-transplant: 25 mg/kg/day on day +3 and day +4."
219765628|NCT07162038|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35 post-transplant.
219765629|NCT07162038|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 post-transplant.
219444348|NCT03150199|BEHAVIORAL|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
219765630|NCT07162038|DEVICE|CD19 Flow Cytometry Assay|Assay used to determine CD19+ status
219765631|NCT07162038|DEVICE|CD19 Immunohistochemical Assay|Assay used to determine CD19+ status
219765632|NCT07162038|RADIATION|Total Body Irradiation|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice a day on Day -1 pre-transplant.
219765633|NCT07161700|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
219765634|NCT07167875|BEHAVIORAL|Personalized Digital Oral Health Coaching|All participants will use an electronic toothbrush and mobile app to record brushing behavior throughout the study. However, only the intervention arm will receive personalized digital coaching through the Oralytics app, including tailored feedback, educational messages, and motivational prompts.
219765635|NCT07164209|PROCEDURE|"Excision of the mesentery: the mesentery is fully dissected and excised to the limit of macroscopic fat wrapping, where mesenteric fat is inflamed and extends beyond its normal anatomical distribut"|The resection of mesentery could take off the inflammatory tissue who may increase the risk of anastomotic recurrence The Kono anastomosis achieves a column of support (made with the bowel ) located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lumen of the anastomosis being a barrier between anastomosis and mesentery
219444349|NCT02377908|OTHER|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
218836279|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
218836280|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
218836281|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
218836282|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
218836283|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
218836284|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
218836285|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
219196320|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
219196321|NCT04028414|OTHER|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
219444350|NCT02395289|BEHAVIORAL|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
219444351|NCT02395289|BEHAVIORAL|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
219444352|NCT03623906|PROCEDURE|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
219444353|NCT03623906|PROCEDURE|Air insufflation colonoscopy|Room air insufflation colonoscopy
218836286|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
218836287|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
218836288|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
218836289|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
218836290|NCT06005012|DRUG|Placebo|Placebo
218836291|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
218836292|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
218836293|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
219444354|NCT01494025|BEHAVIORAL|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
219444355|NCT02418728|OTHER|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
219444356|NCT05076331|DIAGNOSTIC_TEST|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
219444357|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of darifenacin
219444358|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
219444359|NCT01793090|DRUG|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
219444360|NCT01793090|OTHER|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
219444361|NCT01616069|DRUG|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
219444362|NCT01898962|PROCEDURE|Complete Surgical Removal|
219444363|NCT01898962|RADIATION|Stereotactic Radiosurgery|
219444364|NCT01898962|RADIATION|Ablative external beam radiation dose|
219444365|NCT01898962|PROCEDURE|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
219444366|NCT01898962|RADIATION|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
219444367|NCT01995422|OTHER|Physical activity program|One hour sessions of active walking occurring three times a week during three months
219444368|NCT03237429|DIAGNOSTIC_TEST|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
219444369|NCT03536273|OTHER|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
219444370|NCT04185662|DIETARY_SUPPLEMENT|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
219444371|NCT04489940|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
219444372|NCT03694067|OTHER|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
219444373|NCT04843072|DEVICE|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
219444374|NCT04843072|DEVICE|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
219444375|NCT04498468|DRUG|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
219444376|NCT04498468|OTHER|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
218836294|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
218836295|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
218836296|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
219584048|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
219584049|NCT04796779|DEVICE|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
219584050|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
219584051|NCT06394843|OTHER|Ultrafiltration|Patients are selected depending on need of ultrafiltration
218836297|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
219584052|NCT03244943|PROCEDURE|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
218836298|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
218836299|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
218836300|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
219584053|NCT03230799|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
218836301|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
219444377|NCT05936372|BEHAVIORAL|Acute intense aerobic exercise|The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
219444378|NCT02725268|DRUG|Paclitaxel|Paclitaxel intravenous solution.
219444379|NCT02725268|DRUG|Sapanisertib|Sapanisertib capsules.
219444380|NCT02725268|DRUG|MLN1117|MLN1117 capsules.
219444381|NCT04737967|DRUG|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
219444382|NCT04737967|DRUG|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
219444383|NCT00668772|DRUG|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
219584054|NCT03230799|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
219584055|NCT02868918|DRUG|biodentine|tricalcium silicate cement used to replace the carious dentin
218836302|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
218836303|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
219016659|NCT05407480|OTHER|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
218836304|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
219584056|NCT02868918|DRUG|glass ionomer cement|high viscosity glass ionomer used as a base material
218836305|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
218836306|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
218836307|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
218836308|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
218836309|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
218836310|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
218836311|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
219584057|NCT02868918|DEVICE|DigoraH optium|digital Xray for follow up
218836312|NCT02078024|DRUG|IVM plus ALB|
218836313|NCT02078024|DRUG|IVM|
218836314|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
218836315|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
218836316|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
218836317|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
218836318|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
218836319|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
218836320|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
218836321|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
218836322|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
218836323|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
218836324|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
219584058|NCT04603170|OTHER|DRUG|taking drug medication prescribed by psychiatrists for at least one month
219584059|NCT00497952|BIOLOGICAL|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
219584060|NCT05355649|DEVICE|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
219584061|NCT02894437|OTHER|qualitative interviews|semi-structured interviews as a conceptual frame work
219584062|NCT02570113|DEVICE|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
219765636|NCT07164209|PROCEDURE|Kono S Anastomosis|ono-S anastomosis: the mesentery is not removed but cutted close to the bowel. The bowel is then divided transversely by placing a linear stapler perpendicular to the intestinal lumen and the mesentery. The corners of the two staple lines are reinforced and the two stumps are approximated using 5-7 sutures to create the column. If the caliber of the two intestinal segments differs significantly, the sutures should be spaced to evenly distribute the surplus tissue of the larger segment, in order to achieve good approximation and stable support for the anastomosis. To create the anastomosis, an antimesenteric longitudinal enterotomy (or colostomy) is performed on each stump to allow a transverse lumen of 7 cm in diameter for the small bowel or closer to 8 cm for the colon. In this way the supporting column is located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lum
219584063|NCT00842478|PROCEDURE|Toothbrushing|
219584064|NCT03627507|BIOLOGICAL|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
219765637|NCT07168044|BEHAVIORAL|CAN-DO|usual programing offered as part of the congregate meal program plus 18 weekly group education sessions related to CVD risk reduction and nutrition.
219765638|NCT07169630|DRUG|18F-PF974|Injected IV followed by PET scanning
219444384|NCT00668772|DRUG|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
219444385|NCT00668772|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
219444386|NCT00668772|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
219444387|NCT00668772|DRUG|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
219444388|NCT03186872|BEHAVIORAL|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
219444389|NCT03696004|DRUG|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
219444390|NCT03365440|DEVICE|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
219444391|NCT00744640|DRUG|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
219444392|NCT01838304|DEVICE|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
219444393|NCT01838304|DEVICE|Monitoring|Manual recording of drug doses determined by CRNA
219444394|NCT03674541|DRUG|Pyridostigmine Bromide|Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
219444395|NCT03674541|DRUG|Placebo|Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
219444396|NCT05706818|OTHER|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
219444397|NCT02035241|DIETARY_SUPPLEMENT|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444398|NCT02035241|DIETARY_SUPPLEMENT|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444399|NCT02035241|DIETARY_SUPPLEMENT|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444400|NCT02035241|DIETARY_SUPPLEMENT|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444401|NCT02035241|DIETARY_SUPPLEMENT|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444402|NCT02035241|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219444403|NCT00003519|DRUG|cyclophosphamide|
219444404|NCT00003519|DRUG|docetaxel|
219584065|NCT03627507|BIOLOGICAL|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
219765639|NCT07169630|DRUG|18F-florbetaben|Injected IV followed by PET scanning
219444405|NCT00003519|DRUG|doxorubicin hydrochloride|
219444406|NCT05258981|DIAGNOSTIC_TEST|MRI|Brain MRI
219444407|NCT06482255|OTHER|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
219444408|NCT06482255|OTHER|manual therapy and therapeutic exercise and virtual reality|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality"
219584066|NCT04100785|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
219584067|NCT02564211|DRUG|Ipragliflozin|one 50 mg tablet QD
219584068|NCT02564211|DRUG|Sitagliptin|one 50 mg tablet QD
219584069|NCT06358170|BEHAVIORAL|Circuit Training Combine with Square-Stepping Exercise|Circuit Training Combine with Square-Stepping Exercise
219196322|NCT06832501|OTHER|Henna|The day-care unit of the University of Hacettepe's oncology hospital is being trained by educational nurses on the treatment of patients receiving capecitabine a day before the application of chemotherapy. All the patients were questioned about their individual and disease-related characteristics using the Patient Information Form, and The National Cancer Institute common terminology criteria for adverse events - version 4.03 (NCICTCAE v4.03), EORTC C30 Cancer Quality of Life Scale, and The Hand-Foot Syndrome-14 (HFS-14) were used by face-to-face interview technique.On the 21st day and the 63rd day after the first treatment course, patients who developed hand-foot syndrome constituted the case-control group, including patients who applied henna and patients who did not apply henna.
219196323|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
219444409|NCT03169114|DRUG|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
219765640|NCT07173504|OTHER|Intermittent enteral nutrition|Participants will receive intermittent enteral nutrition in four separate portions between 8:00 a.m. and 8:00 p.m. Each portion will be administered over a one-hour period.
219765641|NCT07160725|DRUG|BMS-986517|Specified dose on specified days
219765642|NCT07170202|OTHER|Mindfulness Smartphone Application|A mindfulness mobile health smartphone application that has mindfulness information and practice videos.
219765643|NCT07177040|PROCEDURE|Maitland|Maitland technique therapy, which consists of passive mobilizations applied to the lumbar facet joints in an anterocranial direction while the patient is in a prone lying position
219765644|NCT07177040|PROCEDURE|SNAG|The technique involves applying a sustained glide to the lumbar facet joints while the patient is in a sitting position, and the pelvic girdle will be stabilized by a belt. Then the therapist will ask the patient for active forward flexion of the spine while the pressure on the facet joint is maintained during the movement till its end
219765645|NCT05335941|DRUG|Pemetrexed|Given by vein (IV)
219196324|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
219196325|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
219444410|NCT03169114|PROCEDURE|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
219444411|NCT05560295|PROCEDURE|Naser Al-Husban|uterine surgery
219584070|NCT00982176|OTHER|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
219584071|NCT05944601|BEHAVIORAL|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
219584072|NCT00910091|DRUG|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
219765646|NCT05335941|DRUG|Zimberelimab|Given by vein (IV)
219765647|NCT05335941|DRUG|Etrumadenant|Given by PO
219196326|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
219444412|NCT05482555|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
219584073|NCT00910091|DRUG|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
219584074|NCT03102801|DRUG|Humulin S|Humulin S used to induce hypoglycaemia
219584075|NCT00622466|DRUG|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
219584076|NCT00622466|DRUG|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
219765648|NCT07177976|PROCEDURE|Pilates Breathing Technique along with standard pharmacological management|"Patients in this group will receive pilates breathing technique along with pharmacological management.~A total 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home.~Pilates breathing will be performed in sitting or supine position. The patient will place a hand over the Lower Posterior rib Cage and inhale through the nose.~While breathing they will actively contract the Transverse Abdominis (TrA) as if preparing for punch or holding in urine and engaging the pelvic floor muscles."
219444413|NCT05482555|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
219444414|NCT05579795|PROCEDURE|Detethering of the spinal cord|Release of the tethered spinal cord
218836325|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
218836326|NCT03794440|DRUG|Sintilimab|200mg IV d1， Q3W
218836327|NCT03794440|DRUG|IBI305|15mg/kg IV d1， Q3W
218836328|NCT03794440|DRUG|Sorafenib|400mg PO BID
218836329|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
218836330|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
218836331|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
218836332|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
218836333|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
219196327|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
219444415|NCT05882123|OTHER|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
219444416|NCT03870906|BEHAVIORAL|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
219444417|NCT03870906|BEHAVIORAL|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
219444418|NCT03870906|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
219444419|NCT03870906|BIOLOGICAL|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
219444420|NCT05104749|DRUG|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
219444421|NCT05104749|OTHER|Placebo|Inert lactose pellets
219444422|NCT05225506|BEHAVIORAL|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
219444423|NCT04072536|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
219444424|NCT04072536|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
219444425|NCT02360449|BEHAVIORAL|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
219444426|NCT06373536|DIAGNOSTIC_TEST|Thermoacoustic imaging, MRI and Ultrasound imaging|This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
219444427|NCT02980549|OTHER|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
219444428|NCT04884906|BIOLOGICAL|Camrelizumab|200mg/m2, iv, d1, Q3W, a total of 6 cycles
219444429|NCT04884906|RADIATION|radiotherapy|1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
219444430|NCT04884906|DRUG|Albumin Paclitaxel|260mg/m2, iv, d1, Q3W, a total of 6 cycles
219584077|NCT01908816|DRUG|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
219584078|NCT05209217|DRUG|Ketamine|Intranasal administration of their customary prescribed dose
219584079|NCT00658749|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
219584080|NCT00658749|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
219584081|NCT06049836|OTHER|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
219584082|NCT06049836|OTHER|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
219584083|NCT02902536|OTHER|No interventions|
218836334|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
219016667|NCT06133413|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
219016668|NCT06133413|OTHER|Alert generation by remote plateform|Alert will be generated from weight regain \> 5% of baseline weight
219016672|NCT04423484|OTHER|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
219444431|NCT04884906|DRUG|Cisplatin|80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
219584084|NCT01633736|OTHER|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
219584085|NCT02286596|DEVICE|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
219444432|NCT04130100|BIOLOGICAL|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
219196328|NCT06658080|DIAGNOSTIC_TEST|organoid drug test|Before initiating therapy, patients diagnosed with metastatic breast cancer patients with hydrothorax and ascite fluid. The hydrothorax and ascite fluid is utilized to establish organoids and conduct drug testing.
219196329|NCT06859944|OTHER|Embryo transfer|Frozen embryo transfer
219444433|NCT04130100|BIOLOGICAL|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
219444434|NCT04130100|DRUG|Sodium Hyaluronate|Sodium Hyaluronate injection
219444435|NCT01639300|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
219584086|NCT02286596|DEVICE|dextran sulfate adsorption|Lipid apheresis for 3 hours
219765649|NCT07177976|PROCEDURE|Pursed-lip breathing along with pharmacological management|"Patient in this group will receive pursed-lip breathing along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days at home.~The patient will sit comfortably with straight back and relaxed shoulders. They will inhale slowly through the nose, with a deep relaxed breath, and then exhale slowly through the pursed lips, as if blowing out a candle. The exhalation should take 2-3 times longer than inhalation. This breathing cycle will be repeated with a focus on slow and relaxed breathing.~Pharmacological management: Patient will receive medications as per prescribed by pulmonologist"
219765650|NCT07173803|BIOLOGICAL|AADvac1|Active immunotherapy
218836335|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
218836336|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
218836337|NCT00001335|DRUG|ADR-529|
218836338|NCT00001335|DRUG|Topotecan|
218836339|NCT00001335|DRUG|G-CSF|
218836340|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
218836341|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
218836342|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
218836343|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
218836344|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
219765651|NCT07173803|DRUG|Treatment B|Tau-directed, neuroprotective or other therapy
219765652|NCT07172438|OTHER|P2611222|Menthol flavor
219196330|NCT06859944|OTHER|Embryo transfer|Frozen Embryo transfer
219196331|NCT06658301|OTHER|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
219444436|NCT01639300|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
219444437|NCT03964493|DRUG|TNP-2092|TNP-2092 100mg/vial
219444438|NCT03964493|DRUG|Vancomycin|Vancomycin 1g/vial
219444439|NCT02748278|PROCEDURE|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
219444440|NCT02748278|PROCEDURE|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
219444441|NCT03557736|BEHAVIORAL|Training mode|type of exercise training completed for 12 weeks
219444442|NCT03632551|OTHER|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
219444443|NCT02799628|BEHAVIORAL|intervention|intervention with recommendation and therapist introduction
219444444|NCT02799628|OTHER|placebo|low back pain education, and physical therapy 3 times per week
219765653|NCT07172438|OTHER|P2615022|Non-tobacco non-menthol flavor
219584087|NCT01425918|BEHAVIORAL|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
219584088|NCT01425918|BEHAVIORAL|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
219584089|NCT02296021|DRUG|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
219765654|NCT07172438|OTHER|P2615122|Non-tobacco non-menthol flavor
219444445|NCT03961893|DEVICE|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
219444446|NCT03961893|DEVICE|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
219444447|NCT04998292|DEVICE|Piezo-surgery with low level laser therapy|Low level laser therapy
219765655|NCT07172438|OTHER|P2613422|Tobacco flavor
219196332|NCT06658301|OTHER|swiss ball push up exercises|. The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
219765656|NCT07179458|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
219765657|NCT07182838|BIOLOGICAL|HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix"
219765658|NCT07183709|BIOLOGICAL|PepGNP-COVID19|A synthetic T cell priming setpoint-modifying SARS-CoV-2 vaccine composed of ultrasmall carbohydrate-coated gold nanoparticles carrying covalently bound MHC class I-binding SARS-CoV-2 peptides.
219196333|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
219444448|NCT04998292|DEVICE|Piezo-surgery only|Piezo-surgery only
219196334|NCT06825663|BIOLOGICAL|Blood punction|At each annual visit (+/- 3 months), 4X10 mL blood will be taken (1 dry tube, 1 heparinised tube, 2 EDTA tubes)
219196335|NCT06858358|PROCEDURE|Robotic assisted total knee arthroplasty|• ROSA RATKA with Zimmer Biomet Persona Medial Congruent
219196336|NCT06858358|PROCEDURE|Conventional total knee arthroplasty (cTKA)|cTKA with Microport Evolution Medial-Pivot
219444449|NCT03195686|DEVICE|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
219444450|NCT00182013|DRUG|Risperidone|Open treatment with Risperidone
219444451|NCT00182013|DRUG|Olanzapine|Open treatment with Olanzapine
219444452|NCT00182013|DRUG|Quetiapine|Open treatment with Quetiapine
219444453|NCT03094494|OTHER|none intervention|none intervention
219444454|NCT00966680|OTHER|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
219444455|NCT04601844|DRUG|Pozelimab|Single dose administered subcutaneously
219444456|NCT04601844|DRUG|Cemdisiran|Single dose administered SC
219444457|NCT00675662|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
219444458|NCT00675662|BEHAVIORAL|waiting list control|waiting list control
219444459|NCT05740891|DRUG|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
219444460|NCT00850265|DEVICE|Volumatic spacer|A spacer is a plastic device to inhaler medication
219444461|NCT02470429|DEVICE|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
219584090|NCT02296021|DRUG|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
219765659|NCT07183709|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
219765660|NCT07174856|DRUG|Misoprostol-only medication abortion regimen|This intervention is an updated misoprostol-only regimen that involves being counseled on and receiving medications for a medication abortion using 3-4 doses of 800μg misoprostol administered sublingually every 3 hours.
219765661|NCT07174856|DRUG|Combined regimen|This intervention will involve participants being counseled on and receiving medications for a medication abortion regimen of mifepristone (200mg orally) followed 24-48 hours later by misoprostol (800μg b/v) with a second dose of misoprostol (800μg b/v) taken 3 hours later only for those 64-77 days.
219584091|NCT02296021|DRUG|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
219584092|NCT02296021|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
218836345|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
218836346|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
219765662|NCT07159386|OTHER|EHR alert|Diagnoses of MASLD (based on ICD 9/10 code) in a patient's EHR history, visit, or problem list, will cue a non-interruptive alert to appear and prompt clinicians to use the integrated EPIC© FIB-4 calculation SmartPhrase. The tool displays the FIB-4 risk score, the advanced fibrosis risk, and the clinical guidance. LSM by ultrasound with elastography will be recommended for patients with FIB-4 \>1.3 (FIB-4 \>2.0 if age \>65) and the decision support will urge clinicians to order US with elastography through the SmartSet. LSM results will be documented in the EHR and categorized as low-risk MASLD (LSM \<8 kPa) or advanced fibrosis (LSM \>8 kPa). Results will be disseminated to the ordering PCPs and the patients. PCPs will receive information on patient counseling for MASLD, and the expanding roles of weight loss, reduced alcohol use, and exercise on disease management. PCPs will be encouraged to refer patients with advanced fibrosis to a hepatology specialist, in accordance with guidelines.
219444462|NCT02470429|DEVICE|Hyabak 0.15% eye drops|Preservative-free
219444463|NCT02470429|DRUG|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
219444464|NCT02915692|DEVICE|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
219444465|NCT02915692|DEVICE|Comparator Silver Coated Catheter|Foley catheter coated with silver
219444466|NCT06506292|DRUG|Adebrelimab|Adebrelimab:1200 mg, iv, d1
219584093|NCT02296021|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
219584094|NCT02134743|PROCEDURE|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
219584095|NCT00037102|DRUG|interferon beta 1a|
219444467|NCT06506292|DRUG|XELOX|oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
219584096|NCT00037102|DRUG|methotrexate|
219584097|NCT02916043|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
219584098|NCT04162132|DEVICE|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
219584099|NCT02212288|OTHER|Blood sample|Blood samples are for metabolic and genetic and biological investigation
219584100|NCT02212288|OTHER|Urine sample|Urine sample for biological investigation
219584101|NCT00183937|DRUG|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
219584102|NCT00183937|DRUG|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
219584103|NCT04719520|BEHAVIORAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
219584104|NCT00567866|DRUG|Quetiapine|50 or 100 mg of quetiapine orally
219584105|NCT01533766|DRUG|CombiflexOmega|intravenously over 5 days infusion
219584106|NCT01533766|DRUG|SmofKabiven|intravenously over 5 days infusion
219584107|NCT05042050|BEHAVIORAL|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
218836347|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
218836348|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
218836349|NCT01301287|DRUG|Chlorella|
218836350|NCT01168830|DEVICE|AMS-3.0|
218836351|NCT02463396|BEHAVIORAL|MBCT for ADHD|
219444468|NCT03401476|DRUG|Morphine Sulfate|Morphine Sulfate Tablets
219444469|NCT00074620|DRUG|PEG-hirudin|
219444470|NCT05177289|DEVICE|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
219444471|NCT05177289|DEVICE|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
219444472|NCT02498327|OTHER|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
219584108|NCT01081535|DRUG|ketorolac, fentanyl|intravenous PCA
218836352|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
218836353|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
218836354|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
218836355|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
218836356|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
219196337|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
219196338|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
219444473|NCT02498327|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
219444474|NCT06086457|RADIATION|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
219444475|NCT06086457|DRUG|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
219444476|NCT06086457|BIOLOGICAL|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
219444477|NCT01300767|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
219444478|NCT01300767|DEVICE|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
219444479|NCT01300767|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
219444480|NCT04247789|OTHER|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
219444481|NCT05892536|PROCEDURE|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
219444482|NCT00963313|DRUG|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
219444483|NCT05280236|DRUG|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
219444484|NCT05280236|DRUG|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
219444485|NCT04862741|DRUG|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
219444486|NCT04862741|DRUG|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
219444487|NCT04862741|DRUG|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
219444488|NCT04862741|DRUG|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
219444489|NCT04024449|OTHER|Group A|ovarian function test in control group
219444490|NCT00863941|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
219444491|NCT00863941|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
219444492|NCT00398138|BIOLOGICAL|WT-1 analog peptide vaccine|
219444493|NCT00398138|BIOLOGICAL|incomplete Freund's adjuvant|
219444494|NCT00398138|BIOLOGICAL|sargramostim|
219444495|NCT00398138|GENETIC|polymerase chain reaction|
219444496|NCT00398138|OTHER|flow cytometry|
219444497|NCT00398138|OTHER|immunoenzyme technique|
219444498|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Probiotics|6 Billion CFU
219444499|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|0 CFU per day
219765663|NCT07160075|BEHAVIORAL|Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs|Simultaneous administration of OAT and oral PrEP (direct observed therapy or home supply) at existing pharmacy-based programs
218836357|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
218836358|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
218836359|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
219196339|NCT06856135|DRUG|Vedolizumab IV|"Participants will continue to receive vedolizumab IV at the same dose administered at the end of Trial Vedolizumab-2005 (NCT03196427), at a frequency of every 8 weeks.~• Other Names:~* MLN0002~* ENTYVIO~* KYNTELES"
219444500|NCT02244008|OTHER|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
219444501|NCT02244008|OTHER|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
219444502|NCT00006190|DRUG|Nelfinavir mesylate|
219444503|NCT00006190|DRUG|Stavudine|
219444504|NCT00006190|DRUG|Lamivudine|
219444505|NCT00006190|DRUG|Efavirenz|
219584109|NCT05183217|BEHAVIORAL|Online Continence promotion program without tailoring|The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
219584110|NCT05183217|BEHAVIORAL|Online Continence promotion program with tailoring|"The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention."
219584111|NCT04619719|DEVICE|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
219584112|NCT03300544|DRUG|Capecitabine|Given PO
219584113|NCT03300544|DRUG|Fluorouracil|Given IV
219584114|NCT03300544|DRUG|Leucovorin|Given IV
219584115|NCT03300544|DRUG|Oxaliplatin|Given IV
219584116|NCT03300544|RADIATION|Radiation Therapy|Undergo chemoradiation
219584117|NCT03300544|BIOLOGICAL|Talimogene Laherparepvec|Given intralesionally
219584118|NCT03994601|DRUG|BMS-986288|Specified dose on specified days
219584119|NCT03994601|DRUG|Nivolumab|Specified dose on specified days
219584120|NCT03994601|DRUG|Regorafenib|Specified dose on specified days
219584121|NCT04902092|BEHAVIORAL|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at \>80% VO2max and \<60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
219765664|NCT07186543|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
218836360|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
218836361|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
218836362|NCT00356772|DRUG|Azithromycin|
219444506|NCT00528008|OTHER|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
219444507|NCT00528008|OTHER|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
218836363|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
219196340|NCT06856434|DIETARY_SUPPLEMENT|Lactobacillus plantarum sp Probiotic|Once daily consumption
219475791|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
219475792|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
219475793|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
219475794|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
219475795|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
219475796|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
219475797|NCT03804554|OTHER|Non-Interventional|Non-Interventional
219475798|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
219475799|NCT05798325|OTHER|2MWT|Two minutes walk tests.
219475800|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
219475801|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
219475802|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
219475803|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
219475804|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
219475805|NCT05798325|OTHER|10mWT|10 meters walking Test.
219475806|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
219475807|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
219475808|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
219475809|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
219475810|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
219475811|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
219475812|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
219475813|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
219475814|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
219584122|NCT04902092|BEHAVIORAL|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
219765665|NCT07186543|BEHAVIORAL|Practice Experiences for School Reintegration (PrESR)|Participants will receive an overview of cognitive behavioral therapy skills in virtual reality (VR) and then have the opportunity to practice using skills in a brief immersive experience designed to mimic difficult school and social experiences. Session begin with goal setting and conclude with a debrief summary following the VR experience. Prior to discharge and following the conclusion of the VR sessions, participants will be invited to collaborate on a safety planning intervention informed by their experiences in VR that addresses school and social experiences.
219765666|NCT07186101|DRUG|LY4268989|Administered PO
219765667|NCT07186101|DRUG|Mirikizumab|Administered IV then SC
219765668|NCT07186101|DRUG|LY4268989 Placebo|Administered PO
219196341|NCT06856434|OTHER|Placebo Group|Group who received a placebo intervention
219444508|NCT01947647|BEHAVIORAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
219765669|NCT07191327|DEVICE|HD-tDCS sessions|This project translates decades of observational neuroimaging research into a biologically plausible stimulation target (i.e., DAN) and uses functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) to plan personalized brain stimulation and to ensure target engagement. When available; those not MRI compatible will receive a standard montage with per channel amplitudes of up to 5 milliamperes (mA) or a montage derived from other imaging methods. Participants will receive 4 days of HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
219444509|NCT01947647|BEHAVIORAL|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
219444510|NCT01154322|DEVICE|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
218836364|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
219444511|NCT03366974|DRUG|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
219765670|NCT07191327|DEVICE|Sham HD-tDCS sessions|Participants will receive 4 days of sham HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
219444512|NCT03366974|DRUG|Clarithromycin|Clarithromycin 500 mg bid
219444513|NCT03366974|DIETARY_SUPPLEMENT|Grapefruit juice|Grapefruit juice 500 mL
219444514|NCT03844139|DEVICE|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
219444515|NCT04826029|OTHER|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
219584123|NCT05986721|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
219584124|NCT05986721|DRUG|Placebo|Placebo oral tablet
219584125|NCT01155024|DEVICE|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
218836365|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
219584126|NCT01155024|DEVICE|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
219765671|NCT07191327|DEVICE|HD-tDCS sessions - Open-label (after randomized treatment)|Optional 26 weeks of additional HD-tDCS sessions. Participants can complete up to 5 days per week, but most people will complete about 3 days per week. The study team may also collect audio recordings of these sessions. Participants can complete this in person or at-home via using a secure, HIPAA-compliant videoconferencing with the supervision of a research staff member. Participant's that decide to complete the additional sessions at home, a research staff member will train a study partner during the first 4 HD-tDCS sessions in the office. This option may not be available or appropriate for all participants and the study team member will discuss this with participant's and study partners.
219765672|NCT07184086|DRUG|CagriSema (Cagrilintide B + semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously.
219765673|NCT07184086|BEHAVIORAL|Low Energy Diet|Participants will receive dietary intervention as per diet intervention manual.
218836366|NCT01160133|OTHER|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
218836367|NCT01160133|OTHER|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
218836368|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
219444516|NCT04826029|OTHER|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
219444517|NCT03135639|OTHER|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
219444518|NCT03135639|OTHER|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
219444519|NCT00117572|DRUG|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
219444520|NCT00117572|DRUG|cisplatin|75 mg/m2 on day 1
219444521|NCT00117572|DRUG|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
219444522|NCT00117572|DRUG|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
219444523|NCT00117572|PROCEDURE|chemotherapy|See protocol for details
219444524|NCT00117572|PROCEDURE|radiotherapy|See protocol for details
219444525|NCT03619850|DRUG|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
219584127|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
219584128|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
219584129|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
219584130|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
219584131|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
218836369|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
218836370|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
218836371|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
218836372|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
218836373|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
218836374|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
218836375|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
219444526|NCT03619850|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
219444527|NCT01755338|DRUG|Methylprednisolone|Methylprednisolone 15mg/kg
219444528|NCT01755338|DRUG|Placebo|Placebo
219444529|NCT03903913|DRUG|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
219444530|NCT03256136|DRUG|Carboplatin|Chemotherapy
219444531|NCT03256136|DRUG|Nivolumab|will allow the body's immune system to work against tumor cells
219444532|NCT03256136|DRUG|pemetrexed|Chemo therapy
219444533|NCT03256136|DRUG|Ipilimumab|will allow the body's immune system to work against tumor cells
218836376|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
218836377|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
219444534|NCT03929406|DEVICE|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
218836378|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
218836379|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
218836380|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
219196342|NCT06859996|BEHAVIORAL|Tools for Rehabilitation and Cognitive Care (On-TRACC)|The On-TRACC intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the On-TRACC intervention will review various health and lifestyle factors that can affect cognitive functioning, learn and practice skills for managing cognitive and emotional symptoms, and develop personalized goals to support optimal cognitive functioning.
219444535|NCT04011306|DEVICE|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
219444536|NCT02048852|OTHER|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
219444537|NCT02048852|OTHER|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
219444538|NCT02048852|OTHER|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
219444539|NCT02048852|OTHER|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
219444540|NCT00722475|DRUG|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
219444541|NCT00722475|DRUG|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
219584132|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
219584133|NCT03198975|DIAGNOSTIC_TEST|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
219584134|NCT04178070|BIOLOGICAL|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
219584135|NCT04178070|BIOLOGICAL|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
218836381|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
219584136|NCT04178070|BIOLOGICAL|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
218836382|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
218836383|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
218836384|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
218836385|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
218836386|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
219444542|NCT04973085|DEVICE|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
219444543|NCT04973085|DEVICE|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
219444544|NCT04483752|OTHER|CHEST CT SCAN|Chest CTscan at 3 and 12 months
219584137|NCT04178070|BIOLOGICAL|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
219584138|NCT04178070|BIOLOGICAL|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
219584139|NCT04178070|BIOLOGICAL|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
219584140|NCT04178070|OTHER|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
219584141|NCT04178070|OTHER|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
219765674|NCT07192458|BIOLOGICAL|Fluzone High Dose Inactivated Influenza Vaccine|Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus- containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus containing hemagglutinin (HA) antigen is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step to obtain a higher HA antigen concentration. The purified split virus from the three strains included in the vaccine are produced separately and then combined to make the trivalent formulation.
219765675|NCT07192458|BIOLOGICAL|Fluzone Standard Dose Inactivated Influenza Vaccine|Fluzone Standard Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.
219444545|NCT00071214|BIOLOGICAL|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
219444546|NCT06287931|DRUG|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
219765676|NCT07187362|BIOLOGICAL|Use iliac bone graft|
219765677|NCT07187362|BIOLOGICAL|use bone morphogenetic protein|
219765678|NCT07187362|BIOLOGICAL|use bone derived allograft MSCs|
219765679|NCT07187362|BIOLOGICAL|Use adipose tissue derived MSCs|
219765680|NCT07187362|BIOLOGICAL|Use amnion/placental derived MSCs|
219765681|NCT07193082|DEVICE|Experimental Inspiratory Muscle Training (IMT Group)|Experimental (IMT Group): Inspiratory Muscle Training (POWERbreathe® device, twice daily, 30 breaths per session, 5 days/week, 4 weeks, resistance starting at 40% of MIP and increased weekly).
218836387|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
218836388|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
219444547|NCT06287931|DRUG|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
219444548|NCT04818489|DRUG|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
219444549|NCT04818489|OTHER|the standard protocol only|the local standard protocol for COVID19
219444550|NCT02947334|BIOLOGICAL|Bococizumab|Bococizumab PFS
219444551|NCT02947334|DRUG|Placebo|Placebo
219444552|NCT00029289|DRUG|Lutein (10 or 30 mg/day) capsules|
219444553|NCT03534713|DRUG|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
219444554|NCT03534713|DRUG|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
219444555|NCT03534713|DRUG|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
219444556|NCT03534713|RADIATION|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
218836389|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
218836390|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
218836391|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
218836392|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
218836393|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
219016681|NCT06183398|OTHER|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
219444557|NCT02224274|DRUG|Clopidogrel|
219444558|NCT02224274|DRUG|Ticagrelor|
219444559|NCT00903994|DRUG|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
219444560|NCT01333462|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
219444561|NCT01333462|OTHER|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
219444562|NCT04556201|DEVICE|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
219444563|NCT02745041|DRUG|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
219444564|NCT02745041|OTHER|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
219444565|NCT00187044|BIOLOGICAL|PolyEnv1 vaccine|administered subcutaneously as 10\*7 pfu in 0.8 mL
219765682|NCT07193082|DEVICE|Control Group: No inspiratory muscle training.|Control Group: No inspiratory muscle training.
219765683|NCT07192133|DIAGNOSTIC_TEST|CT scan|Dynamic contrast-free chest CT scan
219765684|NCT07190287|DEVICE|NEUSleeP system (FUS-EEG wearable device)|"The NEUSleeP system is a wearable FUS-EEG device integrating hydrogel-based EEG and focused ultrasound neuromodulation. The intervention includes:~1. Device testing in 4 healthy volunteers to assess EEG signal and impedance over 4 weeks vs. wet electrodes;~2. STN targeting validation in up to 20 participants using MRI-guided tFUS with NEUSleeP and BrainSonix Pulsar 1002, with fMRI analysis of BOLD activation in stress-related areas (amygdala, insula);~3. REM sleep modulation in 16 healthy participants across two nights, evaluating REM sleep architecture and stress-related fMRI changes following STN stimulation during REM;~4. A similar protocol in 12 individuals with self-reported poor sleep and moderate stress, assessing subjective stress (PSS), sleep dynamics, and connectivity changes post-tFUS."
219584142|NCT04178070|OTHER|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
219584143|NCT04178070|OTHER|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
219584144|NCT04178070|OTHER|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
218836394|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
218836395|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
219444566|NCT02422394|DRUG|Eltrombopag|
218836396|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
218836397|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
218836398|NCT02771574|DRUG|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
219444567|NCT01976624|DRUG|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
219444568|NCT03931980|PROCEDURE|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
219444569|NCT02628899|DEVICE|Transfemoral TAVR|
219444570|NCT02628899|DEVICE|SAVR|
219444571|NCT03079518|DRUG|Ferric Carboxymaltose|single shot infusion
219444572|NCT03079518|OTHER|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
219444573|NCT03944551|DEVICE|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
219444574|NCT03944551|OTHER|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
219584145|NCT04178070|OTHER|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
219444575|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
219444576|NCT01025297|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
219444577|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 5 mg
219444578|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
219444579|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 10 mg
219444580|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
219584146|NCT03751956|DRUG|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
219584147|NCT00769093|DRUG|Ferumoxytol|2 mg/kg
219584148|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
219584149|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
219584150|NCT01571076|OTHER|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
219584151|NCT01571076|OTHER|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
219584152|NCT01753466|DIETARY_SUPPLEMENT|Hydration|
219584153|NCT01371266|DIETARY_SUPPLEMENT|Honey|60.7 grams orally daily times 14 days
218836399|NCT02771574|DRUG|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
218836400|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
218836401|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
218836402|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
218836403|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
219584154|NCT01371266|DIETARY_SUPPLEMENT|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
219584155|NCT01371266|DIETARY_SUPPLEMENT|CHO (sugar)|50 grams daily orally times 14 days
219584156|NCT00778024|DRUG|fluoxetine HCL 40 mg capsules|
219584157|NCT00894738|PROCEDURE|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
219584158|NCT00148824|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (vaccine)|
219584159|NCT00148824|BIOLOGICAL|23-valent pneumococcal conjugate vaccine (vaccine)|
219584160|NCT00866736|DRUG|dasatinib|100mg QD
219584161|NCT00070096|DRUG|ixabepilone|
218836404|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
218836405|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
219584162|NCT04040608|OTHER|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
219584163|NCT04009512|DEVICE|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
219584164|NCT00222521|DRUG|Glargine insulin|
218836406|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
219584165|NCT06483321|DIETARY_SUPPLEMENT|Creatine Supplementation|"Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)"
219584166|NCT06483321|DIETARY_SUPPLEMENT|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
219584167|NCT04413864|OTHER|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
218836407|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
219364152|NCT01630525|OTHER|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
219584168|NCT05841303|DRUG|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
218836408|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
218836409|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
218836410|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
218836411|NCT00776542|DRUG|Minocycline 100mg Tablets|
219364153|NCT04607395|RADIATION|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
219364154|NCT03695913|OTHER|Normal Diet|"Phase I (regular diet):~all participants will eat their normal diet and will log their food."
219364155|NCT03695913|OTHER|Low carb diet|"Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food"
218859917|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
218859918|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
218859919|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
218859920|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
218859921|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
219765685|NCT07190287|DEVICE|BrainSonix Pulsar 1002|The BrainSonix Pulsar 1002 is a research-grade focused ultrasound device used to evaluate STN targeting in up to 20 healthy participants. COMSOL 2D acoustic simulations and structural MRI are used to localize the STN. The BrainSonix system is tuned and installed for STN stimulation during fMRI scanning. Pre- and post-stimulation fMRI is conducted to verify BOLD signal changes in the STN and related regions. These responses are compared with those from NEUSleeP stimulation, using identical imaging protocols. Ultrasound parameters are iteratively adjusted to optimize targeting while adhering to FDA diagnostic ultrasound safety limits. A linear mixed model is used to assess stimulation-induced changes.
219765686|NCT07191964|PROCEDURE|Supra-Sartorial Subcutaneous Infiltration (SSSI)|20 mL ropivacaine or saline infiltrated lateral-to-medial subcutaneously above sartorius at femoral triangle apex using inject-as-you-advance technique, avoiding hyperechoic nerves.
219765687|NCT07191964|PROCEDURE|intermittent adductor canal block (iACB)|An adductor canal catheter is inserted proximal-to-distally over a distance of 6-10 cm at femoral triangle apex, with an initial bolus of 10 mL of 0.3% ropivacaine administered in PACU. The following doses start at 9:00 PM on the day of surgery and are repeated every 12 hours,
219016683|NCT02383316|OTHER|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
219196343|NCT06859996|BEHAVIORAL|Brain Health psychoeducation|The Brain Health intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the Brain Health psychoeducation treatment will learn about various health and lifestyle factors that can affect brain health and cognitive functioning. In addition, they will be provided with resources and strategies for managing relevant factors and supporting optimal cognitive functioning.
219196344|NCT06859671|DRUG|Standard of Care (SOC)|14 days of antifungal therapy after the 1st negative blood culture
219196345|NCT06859671|DRUG|Shortened duration of antifungal therapy|7 days of antifungal therapy after the 1st negative blood culture
219444581|NCT01948349|OTHER|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
219444582|NCT01948349|OTHER|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
219444583|NCT05730127|OTHER|Conditioning stimulus|Pain stimulus on non-dominant side
219444584|NCT04961827|BEHAVIORAL|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
219765688|NCT07191964|PROCEDURE|posterior capsule local infiltration analgesia (PC-LIA)|PC-LIA consists of two 10 mL injections of 0.3% ropivacaine delivered intraoperatively to the posteromedial and posterolateral aspects of the posterior capsule before cementation. The target injection plane is the potential space between the posterior capsule and the popliteal artery.
219765689|NCT07187453|BEHAVIORAL|Personalized Oral Hygiene Advice using AI assisted mHealth Tool by Non-Dental Personnel|The intervention involve the delivering personalized oral hygiene advice using AI assisted gum disease screening tool by non-dental personnel social workers. Our proposed intervention involve AI to assist in the self-detection of gum disease, and emphasizes the use of mHealth for disease prevention and monitoring. Moreover, the proposed project focuses on providing personalized oral hygiene instruction, which can be utilized or provided by non-dental personnel volunteers. This combination of AI, mHealth, and personalized instruction in addition with regular service of non-dental personnel volunteers is a novel approach in managing periodontal health among older adults.
219765690|NCT07192614|DRUG|AZD6621|A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8
219765691|NCT07189897|DRUG|Enoxaparin|For DVT prophylaxis
219196346|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
219444585|NCT04961827|BEHAVIORAL|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
219444586|NCT03513250|DRUG|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
219444587|NCT03513250|DRUG|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
219444588|NCT02859987|PROCEDURE|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
219196347|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
219196348|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
219196349|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
219196350|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
219196351|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
219196352|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
219196353|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
219444589|NCT02859987|PROCEDURE|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
219444590|NCT02859987|DEVICE|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
219475815|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
219765692|NCT07189897|DRUG|Apixaban|For DVT prophylaxis
219765693|NCT07196722|DRUG|Icotrokinra|Icotrokinra will be administered orally, daily.
218836412|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
218836413|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
218836414|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
218836415|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
219444591|NCT01190020|DRUG|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
219444592|NCT01190020|DRUG|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
219444593|NCT00925691|DEVICE|RV lead|The RV lead is implanted at the apex or at the interventricular septum
219444594|NCT06916624|RADIATION|18F-NY104 PET/CT|The radionuclide ¹⁸F will serve as the tracer in this study. NY104 will be labeled with \[¹⁸F\]AlF to form the ¹⁸F-NY104 injection for use in this research.All participants will undergo ¹⁸F-NY104 PET scan.
219444595|NCT05676801|DRUG|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
219196354|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
219444596|NCT03441555|DRUG|Venetoclax|tablet, oral
219444597|NCT03441555|DRUG|Alvocidib|Intravenous
219444598|NCT03991468|DIAGNOSTIC_TEST|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
219444599|NCT03991468|DIAGNOSTIC_TEST|Light Microscopy|Use of traditional light microscopy per institutional standard practice
219444600|NCT01820767|DRUG|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
219584169|NCT05841303|OTHER|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
219584170|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
219584171|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
219584172|NCT00045903|BEHAVIORAL|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
219584173|NCT00045903|BEHAVIORAL|Stress Management Therapy (Cognitive Behavior Therapy)|
219584174|NCT01984203|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
218836416|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
218836417|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
218836418|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
218836419|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
218836420|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
218836421|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
218836422|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
218836423|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
218836424|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
219765694|NCT07196722|DRUG|Placebo|Matching placebo will be administered orally, daily.
219765695|NCT07199504|DRUG|Dipyridamole 50mg tid|Participants will take dipyridamole daily (50mg each time, three times a day) for 6 months
219765696|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Placebo Product (PP)|1 capsule (placebo)
219765697|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Active Control (AC)|1 capsule (melatonin)
219765698|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Test Product (TP)|1 capsule (valerian root extract)
219765699|NCT07200076|PROCEDURE|Quadratus Lumborum (QL) Block|"In the QLB-2 approach, a needle will be inserted in-plane from anterior to posterior, directed towards the posterior QL muscle border, and a 20 ml solution of 0.25% ropivacaine will be injected.~For the QLB-3 approach, the needle will be inserted in-plane from anterior to posterior, traversing the QL muscle's proper fascia to target the plane between the QL and PM muscles, and a 20 ml solution of 0.25% ropivacaine will be injected."
219765700|NCT07197983|DEVICE|Automated Vitrification|The PRESERVE-CR system performs automated vitrification (ultra-rapid freezing) of human oocytes and embryos using robotic manipulation and computer-controlled timing.
219765701|NCT07197983|DEVICE|Manual Vitrification|Control specimens are vitrified by standard vitrification protocol.
219444601|NCT01820767|DRUG|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
219444602|NCT01820767|DRUG|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
219765702|NCT07198100|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
219765703|NCT07198100|DEVICE|Sham stimulation|The control intervention consists of a sham stimulation. The electrode will be placed at the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.
219765704|NCT07198100|DIAGNOSTIC_TEST|Oral glucose tolerance test (oGTT)|"The oGTT will be conducted as a standardized metabolic challenge to assess glucose metabolism and insulin sensitivity. After an overnight fast, participants ingest a 75 g glucose solution. Venous blood samples are collected at five time points (0, 30, 60, 90, and 120 minutes) to measure plasma glucose and insulin concentrations. The primary variable of interest will be the peripheral insulin sensitivity index (ISI) according to Matsuda and DeFronzo as 10,000/(G0 × I0 × Gmean × Imean)1/2 with G = glucose and I = insulin.~Additionally we will investigate the correspondence of ISI with other measures of insulin sensitivity (HOMA-IR), and Insulin secretion indices (Insulinogenic index (IGI), Corrected insulin response (CIR), Areas under the curve (AUC)), and HbA1c."
219765705|NCT07198282|PROCEDURE|Conventional Suturing|Wound edges are approximated using 3/0 braided, non-absorbable silk sutures (Doğsan®, Turkey). Standard oral surgery closure technique.
218836425|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
218836426|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
218836427|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
218836428|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
219444603|NCT05412836|DEVICE|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
219475816|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
218836429|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
218836430|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
218836431|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
218836432|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
218836433|NCT00641355|PROCEDURE|No intervention|No intervention
218836434|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
218836435|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
218836436|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
218836437|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
218836438|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
218836439|NCT03255889|DRUG|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
218836440|NCT03255889|OTHER|Placebo|Sunflower oil emulsion of equal calories.
219584175|NCT01984203|OTHER|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
219584176|NCT01154816|DRUG|Alisertib|Given orally
219584177|NCT01154816|OTHER|Laboratory Biomarker Analysis|Correlative studies
219584178|NCT01154816|OTHER|Pharmacological Study|Correlative studies
219584179|NCT04737070|BIOLOGICAL|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
219584180|NCT00152737|PROCEDURE|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
219584181|NCT00152737|PROCEDURE|Ankle and arm pressure values|one test before and one test after surgery
219584182|NCT05876988|DEVICE|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
219584183|NCT03397771|DRUG|Litoxetine|oral study medication provided in a dose titration manner
219584184|NCT03397771|DRUG|placebo|placebo medication provided in a dose titration manner
219584185|NCT05477498|DRUG|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
219765706|NCT07198282|PROCEDURE|Sutureless Technique|The wound is left to heal by secondary intention without using any suturing material.
219765707|NCT07198282|PROCEDURE|Surgical Drain|A biocompatible sterile plastic drain is placed in the surgical site to facilitate drainage of blood and fluids, helping to reduce edema and hematoma formation.
219765708|NCT07198282|PROCEDURE|Cyanoacrylate Tissue Adhesive|Cyanoacrylate-based medical tissue adhesive (PeriAcryl®90 High Viscosity) is applied to the wound edges, providing rapid polymerization and effective closure.
219196355|NCT06864390|PROCEDURE|genicular nerve neurolysis|The superior medial genicular nerve (SMGN), superior lateral genicular nerve (SLGN), and inferior medial genicular nerve (IMGN) will be blocked either by phenol neurolysis or radiofrequency ablation
219364156|NCT03695913|DEVICE|CGM with no real time feedback|Phase I will collect CGM without real time feedback
219584186|NCT05477498|DRUG|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
219584187|NCT03208361|DRUG|Penicillin V|
219584188|NCT03208361|DRUG|Amoxicillin|
219584189|NCT04062656|DRUG|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
219584190|NCT04062656|DRUG|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
219584191|NCT04062656|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
219584192|NCT04062656|DRUG|Docetaxel|Docetaxel 50mg/m² IV over 1 h
219584193|NCT04062656|DRUG|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
219584194|NCT04062656|DRUG|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
219584195|NCT02991677|BEHAVIORAL|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
219584196|NCT02991677|OTHER|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
219765709|NCT07202091|DRUG|Trimethoprim Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
219364157|NCT03695913|DEVICE|CGM with real time feedback)|Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
219364158|NCT03695913|BEHAVIORAL|Education material|"Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make."
219364159|NCT00239850|BEHAVIORAL|lifestyle changes|
219364160|NCT00544869|DRUG|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
219364161|NCT01903265|DRUG|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
219364162|NCT01903265|DRUG|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
219364163|NCT03607279|PROCEDURE|NGAL|
219364164|NCT03712826|DRUG|Anti-TNF Drug|Crohn patient with antiTNF treatment
219364165|NCT03712826|DRUG|Ustekinumab|Crohn disease with ustekinumab treatment
219584197|NCT02991677|BEHAVIORAL|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
219584198|NCT03474497|DRUG|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
218836441|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
219364166|NCT04574596|OTHER|no Intervention|This is an observational study. There is no intervention
219584199|NCT03474497|DRUG|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
219584200|NCT03474497|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
219765710|NCT07202091|DRUG|Amoxycillin/clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.
219364167|NCT04175145|OTHER|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
219364168|NCT02303431|DRUG|Edoxaban low dose|Edoxaban low dose
219364169|NCT02303431|DRUG|Edoxaban high dose|Edoxaban high dose
219475817|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
218836442|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
218836443|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
218836444|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
218836445|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
219475818|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
219475819|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
219475820|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
219475821|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
219475822|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
219475823|NCT03125707|OTHER|Registry study|
219584201|NCT02936453|PROCEDURE|Device implantation|"* Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator"
219584202|NCT06345365|DRUG|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
219584203|NCT06345365|DRUG|Daunorubicin,Ara-Cytarabine, azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
218836446|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
218836447|NCT03835481|DRUG|BI 730357|Film-coated tablet
218836448|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
218859922|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
218859923|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
218859924|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
218859925|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
218859926|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
218859927|NCT04688541|DEVICE|Foley catheter|Foley catheter
218859928|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
218859929|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
218859930|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
218859931|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
219584204|NCT03801265|PROCEDURE|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
219584205|NCT03801265|PROCEDURE|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
219584206|NCT03801265|DRUG|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
219584207|NCT00601874|DRUG|Pilocarpine|
219584208|NCT04078126|COMBINATION_PRODUCT|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
219584209|NCT04078126|COMBINATION_PRODUCT|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
218836449|NCT04180098|BEHAVIORAL|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
218836450|NCT04180098|OTHER|No intervention|Participants in the control group are placed on a waiting list.
218836451|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
219584210|NCT04968665|DIAGNOSTIC_TEST|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
219584211|NCT01727466|BEHAVIORAL|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
219444604|NCT05401903|OTHER|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
219444605|NCT05394012|BIOLOGICAL|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
219584212|NCT04602065|DRUG|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
219584213|NCT04793048|DEVICE|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
219584214|NCT04793048|DEVICE|a sham device|a sham device to be used at-home for 20 minutes a day
219584215|NCT04811586|PROCEDURE|coronary revascularization|to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
219584216|NCT03321630|DRUG|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
219444606|NCT05394012|BIOLOGICAL|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
219584217|NCT03321630|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
219584218|NCT00130455|DRUG|escitalopram|
219584219|NCT05224310|PROCEDURE|PECS block, SAP block|performing either PECS block or SAP block
219444607|NCT01433692|BEHAVIORAL|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
219584220|NCT01760525|DRUG|CGM097|Patients treated with CGM097
219584221|NCT02323516|DRUG|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
219584222|NCT02323516|DRUG|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
219444608|NCT02813434|BIOLOGICAL|florbetapir|18F-AV-45 or 18F-Florbetapir
219584223|NCT02669758|DRUG|ALKS 3831|Tablets were administered for daily dosing
219584224|NCT06013839|DRUG|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
219584225|NCT03250559|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
218836452|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
218836453|NCT02727816|DEVICE|ocufilcon D|test lens
218836454|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
219584226|NCT04573764|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
219584227|NCT04573764|DIETARY_SUPPLEMENT|Placebo|Taste-matched water
218836455|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
218836456|NCT02727816|DEVICE|somofilcon A|test lens
218836457|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
218836458|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
218836459|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
218836460|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
219584228|NCT00072592|DRUG|Rituximab|
219584229|NCT02740387|DRUG|OTO-104|
219584230|NCT02069431|DRUG|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
219765711|NCT07202091|BIOLOGICAL|Immune Globulin Intravenous|Participants will continue treatment with their current Ig replacement schedule. Participants will receive monthly (every 4 weeks ± 1 week) intravenous immunoglobulin at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range. For patients who have already had their Ig dose titrated to IgG trough level, they may continue on their current monthly dose of Ig replacement. SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.
219444609|NCT04421612|BEHAVIORAL|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
219444610|NCT06939582|DRUG|Hydroxychloroquine Sulfate Tablets|the trial group use the hydroxychloroquine sulfate tablets (200mg/time, bid)
218836461|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
218836462|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
219444611|NCT06939582|OTHER|Placebo|the control group use the Placebo
219584231|NCT02069431|OTHER|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
219584232|NCT01267721|PROCEDURE|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
219584233|NCT01775852|BEHAVIORAL|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
219584234|NCT05084703|OTHER|Functional tests|"* Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
219584235|NCT02118090|DRUG|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
219584236|NCT02118090|DRUG|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
219584237|NCT04317859|BEHAVIORAL|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
219584238|NCT05136300|BEHAVIORAL|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
219584239|NCT03462849|OTHER|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
219584240|NCT05967052|DRUG|Pregabalin|Pregabalin pharmacotherapy
219584241|NCT05967052|BEHAVIORAL|Independent walking training|Independent walking training
219444612|NCT06942702|DRUG|Genicular blocks (bupivakain)|Genicular block is a regional analgesic technique performed with USG
219584242|NCT05967052|DRUG|Placebo|Placebo
219584243|NCT05967052|BEHAVIORAL|Gradual movement therapy in the ward|Gradual movement therapy in the ward
218836463|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
219584244|NCT05967052|BEHAVIORAL|Telerehabilitation|Telerehabilitation
219584245|NCT05967052|BEHAVIORAL|Psychotherapy|Psychotherapy
218836464|NCT02725476|BIOLOGICAL|XmAb5871|
218836465|NCT00191945|DRUG|Atomoxetine Hydrochloride|
219584246|NCT04319185|OTHER|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
219584247|NCT02826837|DRUG|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
219584248|NCT03779737|BEHAVIORAL|Muscular Resistance training|
219584249|NCT03779737|BEHAVIORAL|Cardiorespiratory training|
218836466|NCT00191945|DRUG|placebo|
219016688|NCT05428488|DRUG|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
219016689|NCT05428488|DRUG|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
219584250|NCT03779737|BEHAVIORAL|Habitual training|
219584251|NCT00441506|DRUG|daily interruption of sedatives|
219584252|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
219584253|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
219584254|NCT01633411|DEVICE|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
219584255|NCT02605993|BIOLOGICAL|Ravulizumab|All treatments were given as IV infusions.
219584256|NCT01454271|PROCEDURE|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
219584257|NCT02603393|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
219584258|NCT02603393|DRUG|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
219584259|NCT02603393|DRUG|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
219584260|NCT00927693|OTHER|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
219584261|NCT00468260|DRUG|Patupilone|
219584262|NCT00667901|DRUG|riluzole|
219584263|NCT00667901|GENETIC|protein expression analysis|
219016690|NCT05428488|DRUG|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
219016691|NCT06435819|OTHER|Embodied Conversational Agent (ECA)|A computer-animated character that can explain a medical illustration to laypersons.
219016692|NCT04735016|DEVICE|DiamondTemp™ Ablation System|A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
219584264|NCT00667901|GENETIC|reverse transcriptase-polymerase chain reaction|
219584265|NCT00667901|GENETIC|western blotting|
219584266|NCT00667901|OTHER|immunohistochemistry staining method|
219584267|NCT00667901|OTHER|laboratory biomarker analysis|
219584268|NCT00667901|OTHER|pharmacological study|
219584269|NCT00667901|PROCEDURE|neoadjuvant therapy|
219584270|NCT00667901|PROCEDURE|therapeutic conventional surgery|
218836467|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
218836468|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
218836469|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
219584271|NCT01383213|OTHER|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
219584272|NCT01383213|OTHER|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
219584273|NCT03472417|DEVICE|Active partial rebreathing device|
219584274|NCT03472417|DEVICE|Dummy partial rebreathing device|
219584275|NCT04234932|DRUG|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
218836470|NCT05713981|PROCEDURE|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
218836471|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
219196356|NCT06864910|DEVICE|anodal transcranial Direct Current Stimulation|Transcranial direct current stimulation was administered following standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures . None of the participants reported significant adverse effects.
218836472|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
219444613|NCT06942702|DRUG|Patient Control Analgesia (PCA) Morphine group|this group consists of the patients no any intervention preoperatively and they will be given morfin with PCA (Patient controlled analgesia) and paracetamol 3x1000 mg intravenous and diclofenac 75 mg intramuscular (if needed)
219444614|NCT06942702|DRUG|Paracetamol (acetaminophen) + Diclofenac Sodium|All patients are given paracetamol (3x1000 mg) and diclofenac (if needed)
219444615|NCT06942871|DEVICE|Remote Dielectric Sensing|The lung fluid monitor Remote Dielectric Sensing (ReDS™) is the world's first non-invasive device for heart failure monitoring and management. It directly reflects lung fluid content by measuring changes in thoracic dielectric constants, with a detection range of 15% \~ 60%. The device can sensitively identify pathological states ranging from mild compensation to severe pulmonary edema. ReDS™ technology cannot directly measure pulmonary artery pressure, but changes in lung fluid content may indirectly reflect disease progression in certain types of pulmonary hypertension.
219444616|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
219444617|NCT06940258|PROCEDURE|ultrasound measurement of caval aorta index|ultrasound measurement of caval aorta index
219444618|NCT06940258|OTHER|control group|fixed fluid prescription
218836473|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
218836474|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
218836475|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
218836476|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
218836477|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
218836478|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
218836479|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
218836480|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
219584276|NCT00668161|BEHAVIORAL|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
219584277|NCT01868893|DRUG|Obinutuzumab|
219584278|NCT01868893|DRUG|Chlorambucil|
219584279|NCT05316883|DRUG|Clozapine|clinical doses adjusted to sideeffects and clinical effect
218836481|NCT01267864|DRUG|Metoclopramide|10mg IVSS
218836482|NCT01267864|DRUG|Ketorolac|30g IVSS
218836483|NCT01267864|DRUG|Valproate|1gm IVSS
218836484|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
218836485|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
218836486|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
218836487|NCT02763813|DEVICE|Retention type appliance (ORM)|
218836488|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
218836489|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
218836490|NCT00333411|DRUG|BIRT 2584 XX|
218836491|NCT00333411|DRUG|Placebo|
218836492|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
219584280|NCT03002129|OTHER|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
219584281|NCT00967291|DRUG|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
219584282|NCT00967291|DRUG|mitomycin C|8 mg/mq on day 1 every 28 days
219584283|NCT01905748|OTHER|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
219584284|NCT03244501|OTHER|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
219584285|NCT03244501|OTHER|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
219765712|NCT07202182|BEHAVIORAL|Creative Drama-Based Stress Management Program|A creative drama-based stress management program is an intervention that aims to reduce nursing students' stress levels and increase their coping and emotional intelligence skills.
219765713|NCT07202182|BEHAVIORAL|Training|In the study, the control group will receive training on a topic different from the experimental intervention for three weeks. This method aims to prevent any loss of motivation that might result from the control group not receiving any training. It also helps determine whether the effects observed in the experimental group are due solely to the creative drama-based stress management program or to the overall training process.
219444619|NCT06943547|BEHAVIORAL|Arm 2: Patient Navigator|The patient navigation model used in the study is aligned with the conceptual model for cervical cancer screening proposed by the Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium. The initial contact, as well as most navigation activities, will occur mostly over the phone. In our study, the roles of the patient navigator (Arms 2 and 4) will include: exploring individual barriers to screening, use of motivational interviewing to educate and encourage patients to perform screening, performing reminder calls, and coordinating of referral and clinical services if needed. Also, providing other services to identify and overcome access barriers encountered during the cancer care process, including linkage to community resources. In arm 4, the patient navigator will also facilitate the explanation of the use of the self-collection kits by study participants.
219584286|NCT04364425|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
219584287|NCT04364425|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
219584288|NCT04364425|DRUG|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
219584289|NCT06633822|DIAGNOSTIC_TEST|Digital planning|The digital methodology will consist of obtaining a digital scan and a computed tomography (CBCT) that will be aligned using a digital program for the elaboration of a digital wax-up and fabrication of a printed surgical template.
219584290|NCT06633822|DIAGNOSTIC_TEST|Analogic planning|The analog wax-up will be elaborated based on a silicone impression and periapical radiographs with parallel technique, which will allow us to elaborate an essix-type surgical splint.
219584291|NCT02878122|PROCEDURE|Cancer treatment|Chemotherapy and laparoscopic surgery
219584292|NCT03009630|PROCEDURE|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
219584293|NCT03009630|DEVICE|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
219584294|NCT02141425|DRUG|ASP015K|oral
219584295|NCT02141425|DRUG|Placebo|oral
219584296|NCT01783548|DRUG|BDP Nasal Aerosol|
219765714|NCT07202273|RADIATION|simulation-free, single-fraction palliative radiation therapy|Radiation will be delivered in a single fraction. The recommended prescription dose is 8 Gy with external beam radiation therapy.
219765715|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin|(IVIg) intravenous immunoglobulin every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an (IgG) immunoglobulin G trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
219765716|NCT07202052|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
218836493|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
218836494|NCT02012855|BEHAVIORAL|Exercise|
219584297|NCT01783548|DRUG|Placebo|
218836495|NCT02012855|OTHER|Diet (meal type)|
219584298|NCT03056586|DEVICE|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
219584299|NCT03499886|DRUG|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
218836496|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
218836497|NCT03954548|DEVICE|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
218836498|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
219584300|NCT03499886|DRUG|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
219584301|NCT02923986|DRUG|BP1001 (varying dose)|BP1001 (varying dose)
219584302|NCT02923986|DRUG|BP1001 (fixed dose)|BP1001 (fixed dose)
219584303|NCT02923986|DRUG|Dasatinib|Dasatinib
219584304|NCT01097525|PROCEDURE|WFG PRK|
219584305|NCT01097525|PROCEDURE|WFG LASIK|
219584306|NCT01097525|PROCEDURE|WFO PRK|
219584307|NCT01097525|PROCEDURE|WFO LASIK|
219584308|NCT04221139|BEHAVIORAL|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
219584309|NCT05760586|DRUG|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
219196357|NCT06864559|OTHER|To Compare 3 different suture materials used in oral surgery|To compare bacterial colonization, tissue reaction and clinical characteristics such as wound healing and patient postoperative outcomes in 3 different suture materials used in oral surgery.
219765717|NCT07202052|DRUG|Amoxicillin clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical. Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin. Ciprofloxacin is omitted for participants with hypersensitivity.
218836499|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
219584310|NCT04589416|OTHER|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
219584311|NCT01140555|DEVICE|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
219584312|NCT00149812|BEHAVIORAL|Family Functioning Intervention|
218836500|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
219444620|NCT06943547|BEHAVIORAL|HPV self-collection kit|Each HPV testing kit will include an invitation letter, information sheet, one FLOQSwabs552C® and one sealable plastic bag to put the swab. Because home high risk (HR) HPV self-screening is not standard of care in the US, the kit will also include a letter advising women to receive routine Pap tests, regardless of their HR-HPV self-sampling results. Detailed instructions on how to collect the cervical sample and how to mail the kit back to the study site or bring it to the clinical visit (depending on their preference) will be included.
219444621|NCT05514925|DRUG|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
219444622|NCT05514925|PROCEDURE|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
219444623|NCT01455233|DRUG|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
219444624|NCT01455233|DRUG|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
219584313|NCT02599038|DIETARY_SUPPLEMENT|Serine supplementation|Serine supplementation (200 mg/kg/day)
219584314|NCT04605224|BEHAVIORAL|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
219584315|NCT03598335|DEVICE|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
219584316|NCT03321435|OTHER|placenta previa patient|women had placenta previa either major or minor degree
219584317|NCT03321435|OTHER|normal women|those women had not placenta previa
218836501|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
218836502|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
218836503|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
218836504|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
218836505|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
218836506|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
218836507|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
218836508|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
218836509|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
218836510|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
218836511|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
218836512|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
218836513|NCT00025792|DRUG|Pramipexole|
218836514|NCT03180333|DRUG|PNA|
218836515|NCT03180333|DRUG|PNA placebo|
218836516|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
218836517|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
218836518|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
219444625|NCT03573804|OTHER|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
219444626|NCT01425307|DRUG|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
219444627|NCT02793804|DEVICE|Oraquick (made in Thailand)|
219444628|NCT04553978|DRUG|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
219444629|NCT02578095|DRUG|VK5211|Capsule
219444630|NCT02578095|DRUG|Placebo|Capsule
219444631|NCT02741089|PROCEDURE|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
219444632|NCT06942676|BEHAVIORAL|Core Exercise Program|This intervention consists of a 4-week core training program including exercises like planks, side planks, bird-dogs, bridges, and dead bugs, performed 3 days per week alongside regular soccer training. Each session lasted approximately 25-30 minutes.
219444633|NCT06949852|DRUG|Nalbuphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
219444634|NCT06949852|DRUG|Morphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
218836519|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
218836520|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
218836521|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
218836522|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
218836523|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
218836524|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
219444635|NCT06948357|DRUG|BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo|BRIMOCHOL PF eye drops, CARBACHOL PF eye drops, Brimonidine eye drops and Placebo were administered in 7 treatment sequences in various combinations and doses
219444636|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active|The study will utilize the H7 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
219444637|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham|The study will utilize an identical protocol using the H7 coil to administer a sham condition.
219444638|NCT06949917|DIETARY_SUPPLEMENT|body mass index for age|different body mass index according to age (normal weight,overweight,obeiece)
219584318|NCT03682458|GENETIC|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
219584319|NCT03804502|DEVICE|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
219584320|NCT04333108|DRUG|Masitinib|Masitinib 6 mg/kg/day
219584321|NCT04333108|OTHER|Placebo|Matching placebo
219584322|NCT04333108|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
219765718|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"Arm A: Low dose (IgRT) immunoglobulin replacement therapy: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.25g/kg. No dose adjustment for trough serum IgG levels is required.~Arm B: Usual dose: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range."
219765719|NCT07200973|BEHAVIORAL|Adapted LINK LA Peer Navigator|Our study will adapt the LINK LA peer navigation intervention (NCT01406626) for the current context (e.g., HIV care provision, substance use risk environments, etc.) and measure its effects on participants' HIV and substance care engagement.
219765720|NCT07200778|PROCEDURE|umbilico-uterine trunk occlusion|participants will undergo umbilico-uterine trunk occlusion during laparoscopic myomectomy
219765721|NCT07200778|PROCEDURE|local epinephrine infiltration|participants will undergo local injections of epinephrine into the serosal and/or myometrium, covering the myoma before the uterine incision during laparoscopic myomectomy
219765722|NCT07199218|DRUG|Terpenes-Enriched CBD-Predominant Oil|Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD/THC: 280/10 mg per g) produced by Bazelet Group, Israel.
219444639|NCT06948370|BEHAVIORAL|Intervention Name: PARADIGM-Q Diabetes Self-Management Education Program|PARADIGM-Q Diabetes Self-Management Education Program This is a culturally sensitive, structured education intervention tailored for adults with Type 2 Diabetes in Qatar. Developed using the PARADIGM model and delivered through a Case-Based Learning (CBL) approach, the program comprises three weekly group sessions of 3.5 hours each. Each session targets key self-management attributes: problem-solving, decision-making, taking action, resource utilization, and patient-provider relationships. The program emphasizes real-life applicability, cultural relevance, and skill-building to support sustainable diabetes self-care.
219444640|NCT06948370|BEHAVIORAL|Control Arm (DESMOND): DESMOND Diabetes Self-Management Education Program|The DESMOND Diabetes Self-Management Education Program is the standard diabetes education intervention currently offered to newly diagnosed patients with Type 2 Diabetes in Qatar. It is a UK-developed, theory-driven program delivered over two group sessions, each lasting approximately four hours. The program provides structured education on diabetes, lifestyle management, and risk reduction strategies. It does not incorporate case-based learning or cultural tailoring, distinguishing it from the experimental PARADIGM-Q intervention. DESMOND is used here as an active comparator to evaluate the added value of culturally sensitive, problem-based education.
219765723|NCT07199218|DRUG|Placebo|Oral olive oil with added flavors to mimic the appearance, texture, and taste of the study drug, administered in two daily doses.
219765724|NCT07199218|DRUG|Terpenes-Enriched CBD Oil (THC-Free)|Oral cannabidiol (CBD; 7.2 mg/kg/day) and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD- 280 mg per g) produced by Bazelet Group, Israel.
219765725|NCT07198334|OTHER|Heat acclimation|Passive heat acclimation was designed to induce adaptation in participants through 14 consecutive days of controlled 5-minute whole-body immersion in water at 45°C.
219584323|NCT06107504|DRUG|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
219584324|NCT00988442|BEHAVIORAL|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
219584325|NCT00988442|BEHAVIORAL|Standard care|Usual ACTG site care.
219584326|NCT04167293|RADIATION|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
219765726|NCT07199335|DRUG|APRETUDE (cabotegravir)|All participants will be prescribed APRETUDE based on APRETUDE's FDA approved indication, which is sexual risk of HIV transmission.
218836525|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
218836526|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
218836527|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
218836528|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
218836529|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
218836530|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
218836531|NCT01143363|BEHAVIORAL|resting - control|
218836532|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
219584327|NCT04167293|DRUG|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
219584328|NCT01894035|DRUG|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
219765727|NCT07198542|DEVICE|gammaCore Sapphire|This intervention utilizes transcutaneous cervical Vagus Nerve Stimulation (tcVNS). A conductive gel is applied to the device's stimulation surfaces. The device is then placed on the neck over the vagus nerve. The daily treatment protocol consists of three consecutive 2-minute stimulations on the left side of the neck, with a 30-60 second interval between each stimulation. After a brief rest of approximately one minute, the same procedure is repeated on the right side of the neck. The total daily session duration is approximately 20 minutes. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
219444641|NCT06949189|PROCEDURE|Nail Bed Repair with Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be replaced and secured with a figure-of-eight suture using Prolene. A low-adherent dressing will be applied. If the fingernail is unavailable (e.g., due to damage or loss), a substitute material (such as foil) will be chosen by the operating surgeon
219444642|NCT06949189|PROCEDURE|Nail Bed Repair without Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be discarded. A low-adherent dressing will be applied without any covering of the nail bed
219444643|NCT06950086|DRUG|TYK-00540|Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +Fulvestrant)
218836533|NCT01143363|BEHAVIORAL|High intensity intermittent training|
219584329|NCT01103622|DRUG|AZD1656|Oral tablet bd, step-wise increased dosage
219584330|NCT01103622|DRUG|Digoxin|Oral tablet od on Day 4
219584331|NCT01103622|DRUG|Placebo|Oral tablet bd, step-wise increased dosage
218836534|NCT01143363|BEHAVIORAL|Short sprint|
219584332|NCT02776579|OTHER|Girls-only resistance training|
219584333|NCT05658978|OTHER|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
219584334|NCT05658978|OTHER|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
219584335|NCT05690503|DRUG|CI-581a|Medication infusion intravenously over 90 minutes.
218836535|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
218836536|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
218836537|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
219196358|NCT06864052|DRUG|Administration of Apixaban|Apixaban 2.5mg BID or Apixaban 5mg BID
219196359|NCT06864052|DRUG|Administration of Edoxaban|Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD
219196360|NCT06863532|DRUG|Cofrogliptin+SGLT2i+Metformin|The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.
219196361|NCT06863532|DRUG|Metformin dose escalation|The metformin dose escalation group will have their metformin dose gradually increased to the target dose.
219196362|NCT06862999|BEHAVIORAL|No Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. However, this email will not include any promised compensation for future participation in the hypothetical wellbeing study in the neighbourhood. This group serves as the control group to compare the effects of incentives on participation rates.
219196363|NCT06862999|BEHAVIORAL|Financial Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&amp;amp;#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a financial compensation, which is a chance of enter a prize draw to win a 4 X £100 voucher which can be used to purchase goods and services within the King\&amp;amp;#39;s Cross neighbourhood in London.
219196364|NCT06862999|BEHAVIORAL|Social Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a non-financial compensation, which is an invitation to participate in a social event that will be organised by the researchers and the neighbourhood asset manager team at the end of the research project. This event will be exclusive and it will be an opportunity for participants to socialize with other study participants in the neighbourhood. It will also be an opportunity for the study participants to feel they are contributing a change to the neighbourhood and will be able to articulate their views about the wellbeing research findings which is expected to be used to inform future interventions in the neighbourhood.
219584336|NCT05690503|DRUG|CI-581b|Medication infusion intravenously over 90 minutes.
219584337|NCT01557361|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
219584338|NCT01557361|OTHER|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
219016710|NCT05104476|DRUG|Lu AF82422|Solution for infusion
219016711|NCT05104476|DRUG|Placebo|Solution for infusion
218836538|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
218836539|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
218836540|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
219196365|NCT06863584|DRUG|Lenalidomide (Revlimid)|10mg po for 21 days, followed by a 7-day rest period.
219196366|NCT06863584|RADIATION|SBRT|PTV 30Gy/5f and/or PGTV 35Gy/5F.
219196367|NCT06863909|BEHAVIORAL|Journaling|In the journaling condition, participants will be asked to keep a therapy journal twice a day in addition to the content of the cognitve behavioral therapy. At the beginning of the day, patients are to set a daily goal that aligns with their therapy goals (e.g., remaining calm when negative thoughts arise), and at the end of the day, they will reflect on the day itself and the work done on their therapy goals.
219364170|NCT01973309|DRUG|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
219364171|NCT02688517|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
219364172|NCT02688517|OTHER|Laboratory Biomarker Analysis|Correlative studies
219364173|NCT03729778|BIOLOGICAL|Prevnar-13|One time administration of prevnar-13 vaccine
219364174|NCT01777763|DRUG|Posaconazole 200 mg|
219364175|NCT01777763|DRUG|Posaconazole 300 mg|
219364176|NCT04887571|OTHER|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
219364177|NCT00321165|DRUG|taurolidine|
219364178|NCT01601899|DRUG|Stavudine|30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg
219364179|NCT01601899|DRUG|Stavudine|20 mg po BD if wt \< 60kg, or 30 mg po BD if wt \> 60kg
219016716|NCT05984888|BEHAVIORAL|MIND Diet Intervention Group|Participants will receive individually tailored nutrition counseling on adopting the MIND diet pattern from a registered dietitian nutritionist (RDN) for a total of 8 sessions spanning 12 weeks. After completing the counseling sessions participants will be followed up 6 months later to collect additional questionnaires and assessments.
219016717|NCT05984888|BEHAVIORAL|General Health Curriculum (GHC) Group|Participants will meet with trained study staff for 8 sessions spanning 12 weeks covering content on non-diet related health topics. After these sessions, participants will be followed up 6 months later to collect additional questionnaires and assessments. Once 6-month follow-up has been completed, participants will be offered to receive the MIND diet intervention offered in the MIND Diet Intervention Group.
219444644|NCT06949267|BIOLOGICAL|iMSC|1× 10\^6/kg each time, twice a week
218836541|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
218836542|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
218836543|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
219444645|NCT06949267|COMBINATION_PRODUCT|conventional aGVHD prophylaxis|Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）
219444646|NCT06949904|DRUG|Melatonin|1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days
219444647|NCT06948383|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|administer 30 mL %0.25 bupivacain between third costa and serratus posterior superior muscle
219444648|NCT06948383|PROCEDURE|Serratus Anterior Plane Block|administer 30 mL %0.25 bupivacain between 5th costa and serratus anterior muscle in midaxiller line
219444649|NCT00373906|DRUG|Bortezomib (Velcade)|
219444650|NCT01766765|PROCEDURE|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
218836544|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
218836545|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
218836546|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
218836547|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
218836548|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
219444651|NCT01766765|OTHER|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
219444652|NCT06949670|DIAGNOSTIC_TEST|18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06|Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET/CT or MRI imaging within the specificed time.
219444653|NCT06439485|DRUG|Pemigatinib|Given by PO
219444654|NCT06439485|DRUG|Atezolizumab|Given by PO and IV
219444655|NCT06439485|DRUG|Bevacizumab|Given by PO and IV
219444656|NCT03619083|OTHER|SAE battery|The SAE battery yields 12 variables.
219444657|NCT03619083|BEHAVIORAL|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
219444658|NCT04507360|BEHAVIORAL|Study 1, Demographics Survey|Participants will be shown a demographics survey (e.g., age range, gender, income).
219444659|NCT04507360|BEHAVIORAL|Study 1, Next Steps Survey|Participants will be shown the Next Steps Survey, which includes 2 items assessing intended next steps on the Mental Health America (MHA) website (e.g., take another mental health test, find a treatment provider near you) and perceived need (yes, no, or I don't know) in addition to the Demographics Survey items.
219444660|NCT04507360|BEHAVIORAL|Study 1, Generic Response|Participants will be provided with the generic/current response to screening.
219444661|NCT04507360|BEHAVIORAL|Study 1, Generic Resources|Participants will be provided with links to a list of 4 generic Mental Health America (MHA) resources.
219444662|NCT04507360|BEHAVIORAL|Study 1, Tailored Response|Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes, no, or I don't know).
219444663|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Demographics|Participants will be provided with links to Mental Health America (MHA) resources tailored to sexuality (Lesbian, Gay, Bisexual, Transgender, or Queer) status and age range.
219444664|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Desired Resources|Participants will be provided with links to Mental Health America (MHA) resources aligned with their expressed interest (e.g., additional screening, self help tools).
219444665|NCT04507360|BEHAVIORAL|Study 2, Control|Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY).
219444666|NCT04507360|BEHAVIORAL|Study 2, DIY tool without AI|Participants in the Do-It-Yourself (DIY) tool without Artificial Intelligence (AI) group will be instructed to use the DIY tool 3 times a week.
219765728|NCT07198542|DEVICE|Nurosym|This intervention utilizes transcutaneous auricular Vagus Nerve Stimulation (taVNS). The device consists of an earpiece electrode that is clipped onto the left tragus. A small amount of water is applied to the skin for conductivity. The daily treatment protocol consists of one continuous 30-minute stimulation session. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
219016722|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
219765729|NCT07203079|DRUG|Acetaminophen Oral Tablet|Participants take 1000mg by mouth every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
219765730|NCT07203079|DRUG|placebo oral tablet|Participants take one placebo tablet (matchable to tylenol) by mouth every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
219765731|NCT07203079|DRUG|Acetaminophen infusion|Participants take 1000mg by intravenous infusion over 15 minutes every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
219765732|NCT07203079|DRUG|Placebo infusion|Participants take 1000mg placebo by intravenous infusion over 15 minutes every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
219765733|NCT07195955|OTHER|Cold Spray Application|A cold spray is applied to the skin at the planned injection site immediately before LMWH administration to reduce pain and ecchymosis.
219765734|NCT07199660|BEHAVIORAL|Human-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed by humans without using artificial intelligence.
219765735|NCT07199660|BEHAVIORAL|Voluntary warning|Participants will view a message suggesting user take a break from scrolling on social media. The message was developed by humans without using artificial intelligence.
218836549|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
219444667|NCT04507360|BEHAVIORAL|Study 2, DIY tool with AI|Participants in the Do-It-Yourself (DIY) tool with Artificial Intelligence (AI) group will be instructed to use the DIY tool with AI 3 times a week.
219475824|NCT06288607|DEVICE|High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)|Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. Patients are to be treated with two macro-focused handpieces with focal depths at 3.0 mm (D3.0) and 4.5 mm (D4.5) on both side. Following the treatment, local cooling with an ice pack was performed for 10 min to reduce redness and swelling. Patients were followed up at 2, 4, 6, and 8 weeks. Clinical images and non-invasive skin assessments were collected at baseline and during each visit.
219475825|NCT00667069|DRUG|triptorelin|
218836550|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
218836551|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
219016723|NCT02653001|OTHER|Stool sample collection|Collection of complete stool sample
219016724|NCT06497569|BEHAVIORAL|Dietitian Consultation|"Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention."
219016725|NCT06497569|BEHAVIORAL|Survey|"Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention."
219364180|NCT01601899|DRUG|Tenofovir|300 mg po QD
219364181|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
219364182|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
219364183|NCT05228366|OTHER|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
219364184|NCT05228366|OTHER|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
219475826|NCT00667069|PROCEDURE|adjuvant therapy|
219475827|NCT00667069|RADIATION|3-dimensional conformal radiation therapy|
218836552|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
218836553|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
218836554|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
218836555|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
218836556|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
218836557|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
218836558|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
218836559|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
219765736|NCT07199660|BEHAVIORAL|Human-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed by humans without using artificial intelligence.
219765737|NCT07199660|BEHAVIORAL|Human-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed by humans without using artificial intelligence.
219765738|NCT07199660|BEHAVIORAL|Human-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed by humans without using artificial intelligence.
219444668|NCT05844254|PROCEDURE|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
219444669|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
219444670|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
219444671|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
219444672|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
219444673|NCT00027404|DRUG|Fluoxetine|
219444674|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
219444675|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
219444676|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
219444677|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
218836560|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
218836561|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
218836562|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
218836563|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
218859932|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
219475828|NCT04394858|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219475829|NCT04394858|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
219475830|NCT04394858|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219475831|NCT04394858|DRUG|Olaparib|Given PO
219475832|NCT04394858|OTHER|Quality-of-Life Assessment|Ancillary studies
219475833|NCT04394858|DRUG|Temozolomide|Given PO
219475834|NCT05754632|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
219475835|NCT06279273|DEVICE|Transcranial direct current stimulation|Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
219475836|NCT05891834|DRUG|INV-202|tablet, once daily, oral
219475837|NCT05891834|DRUG|Placebo|tablet, once daily, oral
219475838|NCT04963777|DIETARY_SUPPLEMENT|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
219475839|NCT04963777|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
219765739|NCT07199660|BEHAVIORAL|Human-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed by humans without using artificial intelligence.
218836564|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
218836565|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
219016726|NCT06497569|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
218836566|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
218836567|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
219016727|NCT06497569|BEHAVIORAL|Referral to Dietitian|Usual Care condition referral to a dietitian based on physician discretion.
219196368|NCT06863909|BEHAVIORAL|Treatment as Usual (TAU)|Patients in this arm receive standard treatment (cognitive behavioral therapy) for their individual diagnosis. The study participation spans a period of 24 sessions (short-term psychotherapy KZT1\&2), during which the severity of symptoms will be assessed at the beginning of each session (duration approx. 2 minutes). Additionally, participants will be asked to answer some questions about basic documentation (diagnoses, symptoms) at the beginning and end of the study (duration approx. 20 minutes).
219196369|NCT06863597|OTHER|Video content|Video content produced by media professionals using expert opinions.
219196370|NCT06863597|OTHER|Written content|Written content produced by healthcare professionals with experience in health education.
219584339|NCT03456583|DEVICE|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
219584340|NCT06344936|DRUG|HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules|Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
219584341|NCT05420870|BEHAVIORAL|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
219584342|NCT01265433|BIOLOGICAL|Galinpepimut-S + Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
219765740|NCT07199660|BEHAVIORAL|Human-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed by humans without using artificial intelligence.
219765741|NCT07199660|BEHAVIORAL|Control message|Participants will view a message about encouraging seatbelt use while traveling in a vehicle.
219765742|NCT07199660|BEHAVIORAL|California's proposed social media warning|Participants will view a message warning about the harms of social media use that mirrors the language the state of California has proposed for mandatory social media warnings.
219765743|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed using artificial intelligence.
219765744|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed using artificial intelligence
219584343|NCT01265433|BIOLOGICAL|Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
219584344|NCT01212588|DRUG|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
219584345|NCT01212588|DRUG|Placebo|3 tablets once daily for seven days
219584346|NCT02430285|PROCEDURE|Endoscopic Ultrasound|Endoscopic Ultrasound
219584347|NCT02430285|DEVICE|Olympus 180 series echoendoscope|
219584348|NCT04832893|DIAGNOSTIC_TEST|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
219765745|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed using artificial intelligence.
219765746|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed using artificial intelligence.
219765747|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed using artificial intelligence.
219765748|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed using artificial intelligence.
219765749|NCT07200752|BEHAVIORAL|Telerehabilitation-Based Neck Exercise Training|Participants received a 6-week Telerehabilitation exercise program delivered via video calls and digital platforms, three sessions per week. The program included stretching, active range of motion, isometric strengthening, and postural correction exercises with progressive intensity.
219765750|NCT07200752|BEHAVIORAL|Supervised physiotherapy exercise training|Participants received the same 6-week exercise program as the Telerehabilitation group, but delivered face-to-face in a supervised clinical setting by a physiotherapist, three sessions per week.
219444678|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
219765751|NCT07201506|DEVICE|PVC and VT ablation with ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation with intracardiac echocardiography (ICE)
219584349|NCT05174494|DIAGNOSTIC_TEST|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
219584350|NCT00151138|DRUG|Atenolol (drug), Lisinopril (drug)|
219584351|NCT02276014|DIETARY_SUPPLEMENT|Beta-carotene|
219584352|NCT00357123|DRUG|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
219765752|NCT07201506|DEVICE|PVC and VT ablation without ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation without intracardiac echocardiography (ICE)
219765753|NCT07201116|DEVICE|Health-GIS Rehabilitation Coordination Platform|Participants receive access to a specialized mobile application with integrated Geographic Information System (GIS) components for rehabilitation service coordination. While hospitalized, patients submit rehabilitation requests through the platform, indicating their location, desired time, and specific rehabilitation needs. Registered rehabilitation centers within the platform receive these requests and can submit counter-proposals with available slots, services offered, and estimated costs. The platform provides real-time visualization of available rehabilitation facilities on an interactive map, displays facility ratings, services offered, current capacity, and waiting times. Patients receive automated notifications about new proposals and can compare options based on location proximity, service quality ratings, and availability. Technical support is available through in-app messaging and a dedicated helpline during business hours.
219765754|NCT07201116|OTHER|Standard Rehabilitation Referral|Upon discharge, patients receive written recommendations stating that rehabilitation is advised as part of their post-operative care plan. No specific rehabilitation facilities are recommended or contacts provided by the surgical team. Patients are instructed to contact their assigned primary care physician (general practitioner) at their local polyclinic for further referral coordination. The primary care physician is responsible for identifying available rehabilitation facilities, making referrals, and coordinating the rehabilitation timeline based on their knowledge of local resources and current availability. This intervention represents routine clinical practice typically provided to patients after total hip arthroplasty.
218859933|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
219444679|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
219444680|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
219444681|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
219444682|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
219444683|NCT01807676|DEVICE|ET View Double Lumen Tube|
219444684|NCT01807676|DEVICE|conventional Double Lumen Tube|
219584353|NCT04896814|PROCEDURE|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
219584354|NCT04896814|PROCEDURE|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
219584355|NCT02971735|OTHER|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
219584356|NCT03194841|OTHER|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
219584357|NCT03317834|DEVICE|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
219584358|NCT04271579|PROCEDURE|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
219765755|NCT07203053|DRUG|Tarlatamab|"Protocol treatment consists of tarlatamab, administered as an intravenous (i.v.) infusion:~* 1 mg on day 1 (C1D1),~* 10 mg on day 8 (C1D8) and~* 10 mg on day 15 (C1D15),~* then 10 mg every two weeks (Q2W) until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first."
219765756|NCT07195734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219765757|NCT07195734|DRUG|Carboplatin|Given IV
219765758|NCT07195734|BIOLOGICAL|Cemiplimab|Given IV
219765759|NCT07195734|DRUG|Cisplatin|Given IV
219765760|NCT07195734|PROCEDURE|Computed Tomography|Undergo CT scan
219444685|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
219444686|NCT01177826|PROCEDURE|Sample collection|Stool sample
219444687|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
219765761|NCT07195734|DRUG|Paclitaxel|Given IV
219765762|NCT07195734|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219765763|NCT07195734|RADIATION|Radiation Therapy|Undergo radiation therapy
219765764|NCT07195734|PROCEDURE|Salvage Surgery|Undergo standard of care salvage surgery
219765765|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
219765766|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
218859934|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
218859935|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
218859936|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
218859937|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
218859938|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
219444688|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
219444689|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
219444690|NCT06262646|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Trained FACT interventionists will be guided by manualized FACT intervention to identify how many psychopathological processes need support and which ACT process(es) need to work on first, then offer parents process-matched ACT intervention strategies following the principles of FACT. The intervention strategies include ACT metaphors, experiential exercises, audio-guided mindfulness exercises, guided imagery exercises and value clarification exercises. The FACT steps in each session depend on the client's situation/stage.
219444691|NCT06262646|OTHER|Control Group|Both study groups will receive standard family support from collaborating NGOs.
219765767|NCT07205107|DRUG|clindamycin phosphate, adapalene and benzoyl peroxide|Topical treatment
219765768|NCT07195695|DRUG|Zongertinib|Zongertinib
219765769|NCT07195695|DRUG|Pembrolizumab|Pembrolizumab
219765770|NCT07195695|DRUG|Atezolizumab|Atezolizumab
219765771|NCT07195695|DRUG|Durvalumab|Durvalumab
219765772|NCT07195695|DRUG|Nivolumab|Nivolumab
219765773|NCT07196748|DRUG|Icotrokinra|Icotrokinra tablet will be administered orally.
219765774|NCT07196748|DRUG|Placebo|Placebo tablet will be administered orally.
219765775|NCT07203677|DRUG|Initiation of tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
219765776|NCT07203677|DRUG|Initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
219444692|NCT04058990|DEVICE|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
219444693|NCT04058990|DEVICE|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
218836568|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
218836569|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
219196371|NCT06863597|OTHER|Podcast content|Podcast content created by media experts based on expert opinions.
219196372|NCT06863597|OTHER|Illustration (information leaflet) content|Illustration-based content created by media experts using expert opinions.
219196373|NCT06861738|DRUG|Paracetamol (acetaminophen)|oral paracetamol 500mg three times per day
219196374|NCT06861738|DRUG|Paracetamol Placebo|placebo tab three time per day
219444694|NCT01415973|DIETARY_SUPPLEMENT|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
219444695|NCT01415973|DIETARY_SUPPLEMENT|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
219444696|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
219444697|NCT05441124|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
219444698|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
219444699|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
219444700|NCT04772651|OTHER|dietary coaching|dietary coaching
219444701|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
219444702|NCT03050307|DRUG|TAK-438|TAK-438 tablets
219444703|NCT03050307|DRUG|Lansoprazole|Lansoprazole capsules
219444704|NCT03050307|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
219444705|NCT03050307|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
219444706|NCT03050307|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
219444707|NCT00470977|DRUG|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
219444708|NCT04949633|DRUG|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
219444709|NCT04949633|DRUG|Oxytocin|Induction of labor with oxytocin.
219444710|NCT04849195|OTHER|No intervention|No intervention
219444711|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
219444712|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
219444713|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
219444714|NCT02158000|OTHER|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
219444715|NCT01048164|PROCEDURE|Massage|Chair Massage
219444716|NCT02094196|OTHER|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
219444717|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
219444718|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
219444719|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
219475840|NCT04988724|BEHAVIORAL|Exercise training|Exercise training with aerobic and strength training, 30 min per session
219475841|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
219475842|NCT04723264|BEHAVIORAL|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
218836570|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
219765777|NCT07197905|DRUG|Intravenous iron|The Intravenous iron infusion will be administered according to standard clinical care. The provider will choose the dosage and formulation of IV iron.
219765778|NCT07199465|DRUG|Letermovir|Administered orally (as tablets/pellets) or via gastrostomy or nasogastric tube (as pellets) for 7 consecutive days.
219765779|NCT07198074|BIOLOGICAL|Bevacizumab|Given IV
218836571|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
218836572|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
218836573|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
218836574|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
218836575|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
219765780|NCT07198074|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219765781|NCT07198074|DRUG|Carboplatin|Given IV
218836576|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
218836577|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
218836578|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
219016728|NCT06497569|BEHAVIORAL|Social Determinants of Health Survey (SDOH)|"Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy)."
219016729|NCT05557877|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219016730|NCT05557877|DRUG|Low-Dose Aspirin|Given PO
219016731|NCT05557877|OTHER|Questionnaire Administration|Ancillary studies
219196375|NCT06671184|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
219765782|NCT07198074|PROCEDURE|Computed Tomography|Undergo CT
218836579|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
218836580|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
218836581|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
219016732|NCT05557877|PROCEDURE|Biopsy|Undergo breast biopsy
219765783|NCT07198074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219016734|NCT06191978|DRUG|ASTX727|Given by PO
219765784|NCT07198074|DRUG|Paclitaxel|Given IV
219765785|NCT07198074|BIOLOGICAL|Pembrolizumab|Given IV
219016735|NCT06191978|DRUG|Venetoclax|Given by PO
219196376|NCT06400719|BIOLOGICAL|AVT16|Single intravenous administration of 300mg of AVT16
219765786|NCT07201363|DIAGNOSTIC_TEST|Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples|In all patients, peripheral venous blood samples will be collected before the TAVI procedure for analysis and calculation of prespecified inflammatory and fibrosis biomarkers. In a subpopulation of 40 individuals, four specific microRNAs (miR-21, miR-29b, miR-155, and miR-146b) will be additionally analysed. The level of each biomarker will be correlated with rates of new-onset TAVI-related CDs and compared between patients with detected and patients without detected new-onset CDs.
218836582|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
218836583|NCT02791035|DRUG|Oral administration of Ipragliflozin|
218836584|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
218836585|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
218836586|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
219016736|NCT05626712|BIOLOGICAL|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
219016737|NCT05626712|OTHER|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
219765787|NCT07201363|DIAGNOSTIC_TEST|Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS|The echocardiographic stage of extravalvular cardiac damage related to AS and myocardial deformation parameters will be analysed in each patient before TAVI procedure and compared between the group with detected new-onset CDs and the group without new-onset CDs with a goal to examine their predictive value for the development of TAVI-related CDs.
219765788|NCT07198139|DRUG|CDI-988|Antiviral to treat norovirus
219765789|NCT07198139|DRUG|Placebo|Matching placebo
219765790|NCT07198139|OTHER|Snow Mountain Virus|Challenge with Snow Mountain Virus
219765791|NCT07204977|DRUG|Acamprosate calcium|tablet
218836587|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
219196377|NCT06770686|OTHER|Intervention Group|"A nursing care bundle will be applied to patients in the intervention group. The implementation status of the nursing interventions included in the care bundle for each patient will be observed by the researcher and recorded on the Care Bundle Observer Form. Recording of the applications performed on the monitoring form will be encouraged."
219196378|NCT06770686|OTHER|Control Group|They will receive standard care
219444720|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
219444721|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
219444722|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
219444723|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
219444724|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
219444725|NCT01144091|DRUG|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
219444726|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
218836588|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
219444727|NCT01144091|DRUG|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
219765792|NCT07205796|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
219765793|NCT07205796|BIOLOGICAL|Shingrix|Sterile suspension for injection
218836589|NCT04305509|OTHER|no intervention|no intervention
218836590|NCT06041009|DIAGNOSTIC_TEST|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
219765794|NCT07200687|OTHER|Music therapy|this research hopes to offer new insights into the benefits of combining music therapy with occupational therapy.
219765795|NCT07200687|OTHER|occupational therapy|standard treatment
218836591|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
218836592|NCT04767581|DRUG|KHK7791|oral administration
218836593|NCT04767581|DRUG|Placebo|oral administration
219196379|NCT05215197|DRUG|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
219444728|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
218836594|NCT05139953|OTHER|No intervention|No intervention
218836595|NCT06367166|DRUG|"Venarus® (diosmin and hesperidin)"|"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
218859939|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
218859940|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
218859941|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
218859942|NCT01964599|DIETARY_SUPPLEMENT|Control|
218859943|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
218859944|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
218859945|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
218859946|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
218859947|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
219196380|NCT06349980|DRUG|HLX53 (1000mg)|HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
219196381|NCT06349980|DRUG|HLX53 (2000mg)|HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
219196382|NCT06349980|DRUG|HLX10|HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
219196383|NCT06349980|DRUG|HLX04|HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219444729|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
219444730|NCT02973997|DRUG|Lenvatinib|Given PO
219444731|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
219444732|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
219444733|NCT03638518|OTHER|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
219444734|NCT03638518|OTHER|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
219444735|NCT02620124|DRUG|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
219765796|NCT07200739|DIAGNOSTIC_TEST|Mini-mental State Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
219765797|NCT07200739|DIAGNOSTIC_TEST|Addenbrooke's Cognitive Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
219444736|NCT02620124|DRUG|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
218836596|NCT06367166|PROCEDURE|Endovenous laser ablation (EVLA) with miniphlebectomy|Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
219444737|NCT02165644|DRUG|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
219444738|NCT02165644|DRUG|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
218836597|NCT06367166|OTHER|Elastic compression|All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
218836598|NCT06367166|OTHER|Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores|The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
218836599|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
219016738|NCT05683756|BEHAVIORAL|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
219016739|NCT05683756|BEHAVIORAL|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
219444739|NCT00131534|BEHAVIORAL|Individual therapy|Stage-based individual therapy for trauma survivors
219444740|NCT00131534|BEHAVIORAL|Group therapy|Stage-based group therapy for trauma survivors
219475843|NCT06971094|GENETIC|GC101 adeno-associated virus injection|Self-complementary recombinant adeno-associated viral vector (scAAV) containing a single-stranded transgene encoding a codon-optimized human SMN1 gene
219475844|NCT06116890|DRUG|KHK4951|KHK4951 eye drop for 44 weeks until end of the trial
219475845|NCT06116890|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
219475846|NCT05477901|OTHER|Supplemental cash transfer|Supplemental cash transfer ($40/month)
219475847|NCT05643573|DRUG|Asundexian (BAY2433334)|Once a day
219475848|NCT05643573|DRUG|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
219475849|NCT05643573|DRUG|Asundexian matching placebo|Placebo to asundexian, once a day
219475850|NCT05643573|DRUG|Apixaban matching placebo|Placebo to apixaban, twice a day
219475851|NCT05163353|DEVICE|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
219475852|NCT03643133|DRUG|Mifamurtide|48 doses overall over 36 weeks
219475853|NCT03643133|COMBINATION_PRODUCT|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
219475854|NCT02308085|OTHER|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
219475855|NCT04026867|OTHER|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
219475856|NCT04026867|OTHER|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
219475857|NCT05768880|BIOLOGICAL|SC-CAR4BRAIN|Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
219475858|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
219475859|NCT06199531|GENETIC|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
219475860|NCT06087822|DEVICE|IMD SiPore21®|The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c
219475861|NCT06080490|DRUG|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
219475862|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
219475863|NCT05718336|OTHER|Integrated care|multi-discipline care program
219475864|NCT04946994|BEHAVIORAL|HIIT|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
219475865|NCT04946994|BEHAVIORAL|CME|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
219475866|NCT06244212|OTHER|Demonstration of applying triamcinolone cream|Live demonstration of applying 1 fingertip unit of triamcinolone cream
219475867|NCT06244212|BEHAVIORAL|Mobile App Use|Additional mobile application that provides amount dispensed and adherence data.
219475868|NCT06244212|OTHER|Standard of Care|Written/verbal instructions only
219475869|NCT06108947|DRUG|Aspirin|Aspirin discontinuation
219475870|NCT03583255|DRUG|Dexamethasone|Given PO
219475871|NCT03583255|BEHAVIORAL|Exercise Intervention|Complete resistance training and moderate intensity walking
219765798|NCT07200739|OTHER|Speech task - Picture Description|Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
219765799|NCT07200739|OTHER|Speech task - Story Retellling|"Participants will be asked to retell the fairy-tale Cinderella, based on pictures that summarize the fairy-tale. In case Cinderella is not known, participants are asked to tell a story with a start, a middle and an end based on the provided pictures. The task will take 4 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns."
219765800|NCT07200739|OTHER|Fluency tasks|"Two fluency tasks from the Addenbrooke's Cognitive Examination. First, the participant is asked to name as many animals as possible within 1 minutes. Next the participant is asked to name as many words starting with S as possible within 1 minute.~Participants will be recorded during the tasks in order to allow the AI to learn and analyze speech patterns."
219444741|NCT06433024|DIAGNOSTIC_TEST|PPG Diagnostic|The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
219444742|NCT01326390|DEVICE|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
219444743|NCT01326390|PROCEDURE|DSA arteriogram- hepatic arteries|Standard of care
219765801|NCT07200739|DIAGNOSTIC_TEST|MRI|"For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions).~For participants in the follow-up or new referral cohorts, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
219444744|NCT01326390|PROCEDURE|CO2 aortogram|Standard of care
219475872|NCT03583255|OTHER|Placebo Administration|Given PO
219765802|NCT07200739|DIAGNOSTIC_TEST|blood sampling|"Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment.~For participants in the follow-up or new referral cohorts, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
219016741|NCT06445530|BEHAVIORAL|MFeast ENHANCED|Intervention group will initially receive prepared MTF (low carbohydrate, low-fat meals, which have been shown to improve glycemia in people with prediabetes) delivered by MFeast (10 meals weekly); Tailored Medical Nutrition Therapy (MNT) delivered by dieticians from MFeast via monthly phone calls and focused on only: ↓sugar-sweetened beverages and ↑fruit and vegetable consumption; Lactation snack bundles to boost milk supply + structural support for breastfeeding/pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (via study team-crafted virtual grocery store) for 16 more weeks.
219016742|NCT06445530|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive prepared MTF delivered by MFeast and as needed MNT from 1 to 24 weeks postpartum."
219196384|NCT06349980|OTHER|Placebo|Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
219364185|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
219364186|NCT03242954|OTHER|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
219364187|NCT03242954|OTHER|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
219475873|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
219475874|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
219475875|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
219475876|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
219475877|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
219475878|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
219475879|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
219475880|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
219196385|NCT06616402|DEVICE|prototype prosthetic group|"These 3 sessions will commence only upon successful completion of the prosthesis safety and reliability tests conducted in the preceding sessions.~For each module combination, a session will be conducted to assess motor performance through the acquisition of spatiotemporal parameters and energy efficiency parameters of gait. Motor performance will be evaluated using functional assessment tests and data will be recorded during the following activities:~* parallel bar walking on flat ground~* parallel bar walking on an inclined surface~* treadmill walking with a safety harness~* stair climbing/descending with a handrail~* standing up and sitting down from a chair within parallel bars At the end of each session, satisfaction questionnaires (ad hoc questionnaire) will be completed. At the end of the experiment, a usability scale for the devices (ad hoc System Usability Scale) will be completed.~Each session is expected to last approximately 2.5 hours."
219196386|NCT03825601|DIAGNOSTIC_TEST|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
219444745|NCT05385913|OTHER|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
219196387|NCT04078152|DRUG|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
219196388|NCT02510235|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
218836600|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
218836601|NCT00229697|DRUG|Gefitinib|
218836602|NCT00229697|DRUG|Tamoxifen|
218836603|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
219444746|NCT01481766|DIETARY_SUPPLEMENT|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
219444747|NCT01481766|DIETARY_SUPPLEMENT|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
219444748|NCT01481766|BEHAVIORAL|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
219444749|NCT02138162|DRUG|enzalutamide|oral
219444750|NCT03737396|PROCEDURE|Self-administered electronic health screening|Health assessment using an electronic device
219444751|NCT05493436|DIAGNOSTIC_TEST|MII pH-meter|using multichannel impedance pH-meter
219444752|NCT00684463|DRUG|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
219444753|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
219444754|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
219444755|NCT00325949|DRUG|placebo|2 tablets BID
219444756|NCT04295668|BEHAVIORAL|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
219444757|NCT04295668|BEHAVIORAL|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
219444758|NCT02230787|DEVICE|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
219444759|NCT02230787|DEVICE|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
219444760|NCT00673218|DRUG|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
219444761|NCT00673218|DRUG|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
219444762|NCT04527536|DIAGNOSTIC_TEST|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
219444763|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
219444764|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
219444765|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
219444766|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
219444767|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
219444768|NCT01902654|OTHER|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
219444769|NCT01902654|OTHER|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
219444770|NCT01902654|OTHER|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
219444771|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
219444772|NCT00444951|BIOLOGICAL|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
219444773|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
219444774|NCT05126654|DIETARY_SUPPLEMENT|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
219475881|NCT06620744|DEVICE|Sponsor MCG deivce|Unshielded device measuring cardiac magnetic fields.
219765803|NCT07200739|DIAGNOSTIC_TEST|Depression screening|"Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients \> 65 year of age or the Major Depression Index (MDI) for patiens \<65 year of age.~For participants in the follow-up or new referral cohorts, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
219584359|NCT02476240|BEHAVIORAL|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
219584360|NCT04020757|DEVICE|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
219584361|NCT04020757|DIETARY_SUPPLEMENT|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
219584362|NCT00971776|DEVICE|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
219444775|NCT06139445|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)
219584363|NCT02229123|DRUG|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
219584364|NCT01162746|DRUG|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
219765804|NCT07200739|OTHER|Somatic- and neurological examination|"Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status.~For participants in the follow-up or new referral cohorts, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal"
219765805|NCT07204158|DEVICE|Spray pompe nasal confort|Seawater solution with hyaluronan
219765806|NCT07202078|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
219765807|NCT07202078|BIOLOGICAL|Immune Globulin Intravenous|IVIg every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
219196389|NCT02510235|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
219196390|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
219765808|NCT07208669|DIAGNOSTIC_TEST|ACT-BP Intervention|In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.
219765809|NCT07208890|DEVICE|Methotrexate Iontophoresis/a low-intensity electric current|: Application of methotrexate solution via iontophoresis using a low-intensity electric current (5-10 mA) for 15 minutes per session, once weekly for 4 weeks, then biweekly for another 4 weeks
219765810|NCT07207564|OTHER|Non-Interventional Study|Non-interventional study
219765811|NCT07207941|DIETARY_SUPPLEMENT|Hexbio|HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.
219765812|NCT07207941|OTHER|Placebo|Matching placebo sachets, identical in appearance and schedule
219444776|NCT06139445|OTHER|Plasebo Group|random superficial touches not involved in any manual technique
219444777|NCT01998906|DRUG|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
219444778|NCT01998906|DRUG|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
219444779|NCT01998906|DRUG|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
219444780|NCT01998906|DRUG|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
219765813|NCT07207577|OTHER|Maximal incremental exercise test|Participants will perform a symptom-limited maximal incremental exercise test on a cycle ergometer.
219765814|NCT07209046|DIETARY_SUPPLEMENT|UltraFlora® Triplebiotic|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of probiotic ( UltraFlora® Triplebiotics, 2 capsules/day) are taken daily with a glass of water.
219765815|NCT07209046|DIETARY_SUPPLEMENT|Placebo|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of placebo (2 capsule/day) are taken daily with a glass of water.
219765816|NCT07209189|DRUG|Toripalimab + Chemotherapy|"Toripalimab is the study drug and will be given via IV in all arms except Rad+/-Chem : Adjuvant radiation or chemoradiotherapy"
219444781|NCT05148559|BEHAVIORAL|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
219444782|NCT05148559|BEHAVIORAL|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
219765817|NCT07209189|DRUG|Toripalimab|Study drug
219765818|NCT07209189|RADIATION|Chemoradiotherapy or radiation|In the adjuvant phase, either radiation or chemoradiotherapy is used for treatment
219765819|NCT07208799|DRUG|Dexamethasone|single dose of dexamethasone 8 mg (2 mL) administered submucosally at the surgical site 30 minutes before incision.
219765820|NCT07208799|DRUG|Methylprednisolone (Corticosteroid)|a single dose of methylprednisolone 40 mg (2 mL) will be administered submucosally at the surgical site 30 minutes before incision.
219765821|NCT07209111|DRUG|MK-1084|Oral administration
219765822|NCT07209111|BIOLOGICAL|Cetuximab|Intravenous administration
219765823|NCT07207421|PROCEDURE|Ultra-Fast-Track Anesthesia|General anesthesia for cardiac surgery followed by planned extubation in the operating room or within the first postoperative hour before ICU transfer.
218836604|NCT03334708|DIAGNOSTIC_TEST|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~* For draw amounts up to 50mL, there is no required hemoglobin threshold.~* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing \< 50kg~* For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
218836605|NCT03334708|DIAGNOSTIC_TEST|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
218836606|NCT03334708|DIAGNOSTIC_TEST|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
218836607|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
218836608|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
218836609|NCT01709552|BEHAVIORAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
218836610|NCT01709552|BEHAVIORAL|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
218836611|NCT05305898|DRUG|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
218836612|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
218836613|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
218836614|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
219765824|NCT07207421|PROCEDURE|Standart care anesthesia|Extubation will be targeted in the ICU according to respiratory effort.
219765825|NCT07207876|DRUG|Ceftriaxon|Ceftriaxone will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider
219444783|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
219444784|NCT00230373|DRUG|imiquimod 5% cream (Aldara)|
219444785|NCT04115891|OTHER|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
219584365|NCT01162746|DRUG|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
219584366|NCT04300140|DRUG|Batiraxcept|Batiraxcept is experimental drug
219584367|NCT04300140|DRUG|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
219584368|NCT04300140|DRUG|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
219584369|NCT01751932|DEVICE|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
219444786|NCT04115891|OTHER|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
219444787|NCT04115891|OTHER|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
219444788|NCT04115891|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
219765826|NCT07207876|DRUG|Benzathine penicillin G|Benzathine penicillin G will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider
219765827|NCT07208214|DIAGNOSTIC_TEST|TXI|"Participants allocated to the TXI group undergo withdrawal using Texture and Colour Enhancement Imaging, while those in the Dye group receive withdrawal with Dye chromoendoscopy. Both procedures follow standardized protocols outlined in the study design."
219765828|NCT07209098|DEVICE|Cardiac Contractility Modulation (CCM)|CCM is a therapy delivered via the Optimizer System, which is implanted in eligible heart failure patients. The device delivers non-excitatory electrical signals to the heart during the absolute refractory period, enhancing the strength of cardiac contractions without increasing myocardial oxygen consumption.
219765829|NCT07207694|BEHAVIORAL|WhatsApp-based education group|Participants in the intervention group will receive the same routine face-to-face diabetes education and insulin injection training as the control group, plus a structured WhatsApp-based educational program. The WhatsApp intervention will be delivered over four weeks and include booklets/brochures, photos, and videos on diabetes definition and symptoms, complications, recognition and management of hypoglycemia and hyperglycemia, foot care, nutrition, exercise, oral antidiabetic and insulin therapy, and insulin injection demonstration. Participants' questions will be answered through WhatsApp to provide interactive support.
218836615|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
218836616|NCT00153595|DRUG|EWO1|
218836617|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
219444789|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
218836618|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
218859948|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
219584370|NCT03713775|OTHER|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
218859949|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
218859950|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
218859951|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
218859952|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
219444790|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
219444791|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
219444792|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
219584371|NCT03713775|OTHER|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
219584372|NCT06483568|BEHAVIORAL|Pathways to Happiness Intervention|Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
219584373|NCT06483568|BEHAVIORAL|Personal Organization Activities|"Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities."
219584374|NCT05200897|DEVICE|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
219584375|NCT02852720|DRUG|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
219584376|NCT02852720|PROCEDURE|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
219765830|NCT07207694|BEHAVIORAL|Active Comparator: Routine Education|Participants in the control group will receive routine face-to-face diabetes education and insulin injection training provided during hospitalization. The education is delivered verbally to patients and their caregivers by the clinical staff. After the follow-up period and data collection are completed, participants in the control group will also be offered access to the WhatsApp-based educational materials used in the intervention group.
218836619|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
218836620|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
218836621|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
219016744|NCT05870111|DRUG|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
219016745|NCT05870111|DRUG|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
219016748|NCT05799287|BIOLOGICAL|Telitacicept|Subcutaneous injection
219016749|NCT05799287|DRUG|Placebo|Placebo to Telitacicept
219444793|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
219444794|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
219444795|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
219444796|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
219444797|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
219444798|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
219444799|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
219444800|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
219444801|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
219444802|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
219444803|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
219444804|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
219444805|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
219444806|NCT06058351|BEHAVIORAL|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
219444807|NCT05724069|DRUG|Velusetrag 15 mg once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
219444808|NCT05724069|DRUG|Placebo once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
219444809|NCT03552289|DEVICE|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
219444810|NCT03552289|DEVICE|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
219444811|NCT02749786|OTHER|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
219444812|NCT01609491|DRUG|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
219444813|NCT01609491|DRUG|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
218836622|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
218836623|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
219444814|NCT04594889|PROCEDURE|angioplasty|Balloon releasing a drug inflated in the target vessel
219444815|NCT00062972|DRUG|donepezil|
219444816|NCT00062972|DRUG|glucose|
219765831|NCT07207356|DEVICE|true transcutaneous pulsed radiofrequency|participants will receive ultrasound guidance to localize the target cervical nerve root (e.g., C5-C7) before treatment. A high-frequency linear transducer will be used with the patient in a sitting position. Transcutaneous pulsed radiofrequency (TCPRF) will be applied using the StimOn™ Pain Relief System (GM2439, Gimer Medical Co., Ltd, Taiwan; FDA 510(k) No. K213802). The device delivers a 500-kHz symmetric biphasic sine wave at 2 Hz with a 25-ms pulse. Each session lasts 30 minutes, divided into two 15-minute phases, with treatment administered 3 times per week for 4 weeks (12 sessions in total).
219765832|NCT07207356|DEVICE|Sham device|participants will receive ultrasound guidance to localize the target cervical nerve root (e.g., C5-C7) before treatment. A high-frequency linear transducer will be used with the patient in a sitting position. Sham device will be applied. No active current will be delivered. Each session lasts 30 minutes, divided into two 15-minute phases, with treatment administered 3 times per week for 4 weeks (12 sessions in total).
219444817|NCT00004256|BIOLOGICAL|sargramostim|
219444818|NCT00004256|PROCEDURE|quality-of-life assessment|
219444819|NCT00004256|RADIATION|radiation therapy|
219016750|NCT06441006|DRUG|Bedaquiline|Frequency: daily Route of administration: oral
219016751|NCT06441006|DRUG|Linezolid|Frequency: daily Route of administration: oral
219444820|NCT02996110|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219444821|NCT02996110|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
219444822|NCT02996110|BIOLOGICAL|Relatlimab|Specified Dose on Specified Days
219444823|NCT02996110|DRUG|BMS-986205|Specified Dose on Specified Days
219444824|NCT02996110|DRUG|BMS-813160|Specified Dose on Specified Days
219584377|NCT02852720|PROCEDURE|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
219584378|NCT02852720|PROCEDURE|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
219584379|NCT02852720|DEVICE|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
219584380|NCT02767882|DRUG|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
219584381|NCT02767882|DRUG|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
219584382|NCT03260985|OTHER|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
219444825|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
219444826|NCT04825106|OTHER|Diagnostic context|A life-threatening situation occurs in 3 different contexts
219444827|NCT04409340|DEVICE|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
219444828|NCT04409340|DEVICE|QUS|QUS
219444829|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
219444830|NCT01008436|DRUG|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
219444831|NCT01008436|DRUG|Control|Traditional surgical Hemostasis
219444832|NCT01938391|DEVICE|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
219584383|NCT03576482|OTHER|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
219584384|NCT03963986|DEVICE|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
219584385|NCT02188186|DRUG|Initial triple combination|Initial triple combination arm
219584386|NCT02188186|DRUG|Conventional treatment|Conventioanl treament with dose escalation
219584387|NCT05563376|DIAGNOSTIC_TEST|Univentricular Hearts|Prevention when factors are recognized
219444833|NCT05574478|BEHAVIORAL|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
219444834|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
219444835|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
219444836|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
219584388|NCT04098900|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
219584389|NCT00714961|DRUG|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
218836624|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
218836625|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
218836626|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
218836627|NCT01735734|DEVICE|Air cooling to CM site|
219584390|NCT00714961|DRUG|Placebo|plus acetylsalicylic acid (ASA)
219584391|NCT03671616|BIOLOGICAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
219584392|NCT03581409|DRUG|Aspirin|Aspirin protect tablet
219584393|NCT03581409|DRUG|Prasugrel|Prasugrel tablet
219584394|NCT03581409|DRUG|Clopidogrel|Clopidogrel 75mg tablet
219584395|NCT03581409|DRUG|Cilostazol|Cilostazol tablet
219444837|NCT05857215|DRUG|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
219584396|NCT06002841|BIOLOGICAL|intravenous treatment with EVs|intravenous treatment with extracellular vesicles
219584397|NCT06002841|BIOLOGICAL|intravenous treatment with placebo solution|intravenous treatment with placebo solution (without extracellular vesicles)
219584398|NCT01381666|DRUG|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
219584399|NCT01381666|DRUG|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
219584400|NCT05668130|PROCEDURE|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
219584401|NCT05668130|PROCEDURE|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
219584402|NCT05910112|PROCEDURE|Pleural interventions|eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
219584403|NCT03570671|DIAGNOSTIC_TEST|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
219584404|NCT03570671|DIAGNOSTIC_TEST|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
218836628|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
218836629|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
218836630|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
218836631|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
218836632|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
218836633|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
219444838|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
219584405|NCT02906761|DRUG|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
219584406|NCT02906761|DRUG|Placebo|Placebo (2 tablets) twice daily for 6 months
219584407|NCT04709211|PROCEDURE|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
219584408|NCT04709211|PROCEDURE|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
218836634|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
218836635|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
219444839|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
219444840|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
218836636|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
218836637|NCT02470585|DRUG|Veliparib|Capsules for oral administration
218836638|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
218836639|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
218836640|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
218836641|NCT05771129|DEVICE|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
218836642|NCT05726331|OTHER|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
219016752|NCT06441006|DRUG|Pretomanid|Frequency: daily Route of administration: oral
219444841|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
219444842|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
219444843|NCT00004580|DRUG|Lopinavir/Ritonavir|
219444844|NCT00004580|DRUG|Nevirapine|
219444845|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
219444846|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
219444847|NCT06048809|OTHER|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
219444848|NCT06048809|OTHER|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
219444849|NCT06370338|OTHER|Delphi Questionnaire|Experts will be approached to participate in the research via email. If the experts agree to participate they will check 'yes' in the email with the informed consent and will be directed to the Qualtrics survey. If the expert decides to decline consent they will check 'no' in the email and will not be enrolled. Subjects who agree to participate will undergo 2 phases of questions with three rounds of the same questions in each phase. This Delphi survey research involves Phase 1 and Phase 2 of questioning, each phase involves up to 3 rounds of questions to determine agreement or disagreement. Each round will take approximately 20 minutes to complete, and your responses will remain completely confidential. For both phases, the questions will either be 7-point Likert or multiple choices. For both phases, the group of questions will be sent up to three times until we obtain agreement (up to 80% of agreement consensus). Questions that have obtained agreement will be removed in each round.
219444850|NCT06476795|OTHER|Chardonnay Marc|Food product made from Chardonnay wine grapes
219444851|NCT03775603|DEVICE|TOFscan|comparison of TOFscan over TOF-Watch SX
219444852|NCT02325089|DEVICE|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
219444853|NCT02325089|DEVICE|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
219444854|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4|
219444855|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, before cooking|
219444856|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, after cooking|
219444857|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4 + ascorbic acid|
219584409|NCT04709211|DRUG|bupivacaine|bupivacaine
219584410|NCT03893565|DRUG|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
219584411|NCT03893565|DRUG|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
219444858|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, before cooking|
219444859|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, after cooking|
219444860|NCT05715840|DRUG|SG001 injection|360 mg，Q3W，IV infusion
218836643|NCT05726331|OTHER|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
219444861|NCT05715840|DRUG|Paclitaxel|175 mg/m\^2，Q3W，IV infusion
219444862|NCT05715840|DRUG|Cisplatin|50 mg/m\^2，Q3W，IV infusion
219444863|NCT05715840|DRUG|Carboplatin|AUC=5，Q3W，IV infusion
218836644|NCT05726331|OTHER|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
219444864|NCT05715840|DRUG|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
219444865|NCT05715840|DRUG|SG001 placebo|Q3W，IV infusion
218836645|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
218836646|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
218836647|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
218836648|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
218836649|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
218836650|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
218836651|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
218836652|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
218836653|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
218836654|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
218836655|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
219444866|NCT02840734|OTHER|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
219444867|NCT04510155|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
219444868|NCT06442085|OTHER|Teaching of trauma resuscitation by using virtual reality simulation|"The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator."
219444869|NCT06442085|OTHER|Teaching of trauma resuscitation by using mannequin based simulation|Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
218836656|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
218836657|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
218836658|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
218836659|NCT00167375|DRUG|eszopiclone 3 mg qHS|
218836660|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
219016753|NCT06441006|DRUG|Moxifloxacin|Frequency: daily Route of administration: oral
219016754|NCT06441006|DRUG|Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 24 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest international guidelines and the local SOC.
219444870|NCT02026934|DEVICE|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
219444871|NCT06411106|DRUG|IMIQUIMOD cream 50mg/g|5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber
219444872|NCT00469040|DRUG|GW642444M for 14 days|M salt
219444873|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
219444874|NCT02416765|OTHER|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
219444875|NCT02416765|DRUG|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
219444876|NCT02416765|DRUG|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
219444877|NCT02416765|OTHER|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
218836661|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
218836662|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
219444878|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
219444879|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
219444880|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
219444881|NCT02401776|DIETARY_SUPPLEMENT|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
219444882|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
219444883|NCT02401776|DIETARY_SUPPLEMENT|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
219444884|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
219444885|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
219584412|NCT03893565|DRUG|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
219584413|NCT02707445|DRUG|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
219584414|NCT02811432|OTHER|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
219584415|NCT02811432|OTHER|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
219584416|NCT02332837|BEHAVIORAL|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
219584417|NCT02332837|BEHAVIORAL|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
219584418|NCT02332837|BEHAVIORAL|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
219584419|NCT02697240|DRUG|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
219584420|NCT02681211|OTHER|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
219584421|NCT02681211|DRUG|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
219584422|NCT02681211|DRUG|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
219584423|NCT02681211|DRUG|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
219584424|NCT02681211|DRUG|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
219584425|NCT05875103|DIAGNOSTIC_TEST|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
219584426|NCT05008601|DEVICE|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
219584427|NCT00513136|BEHAVIORAL|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
219765833|NCT07208162|BEHAVIORAL|5+1 Adapted, early-stage dyadic care planning intervention|The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
218836663|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
218836664|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
219444886|NCT03262064|COMBINATION_PRODUCT|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
219444887|NCT03500536|BEHAVIORAL|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
219584428|NCT00513136|BEHAVIORAL|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
218836665|NCT02146131|DEVICE|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
219444888|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
219444889|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
219444890|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
219444891|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
219444892|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
219584429|NCT04380090|DRUG|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
219584430|NCT04380090|DRUG|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
219765834|NCT07208162|BEHAVIORAL|Counseling session and printed resources|Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
219765835|NCT07208032|PROCEDURE|Irregular Pulsed Radiofrequency (STP)|Flouroscopic guided irregular pulsed Radiofrequency (STP) for dorsal root ganglion
219765836|NCT07208032|PROCEDURE|regular pulsed Radiofrequency|Fluoroscopic guided regular pulsed Radiofrequency for the dorsal root ganglion
219196391|NCT06611618|OTHER|Muscle power assessment|Isokinetic dynamometry test Stair ascent/descent on instrumented stairs
219196392|NCT06611618|OTHER|Muscle force assessment|Isometric dynamometry (Maximal Voluntary Isometric Contraction)
219444893|NCT05452187|DRUG|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
218836666|NCT02146131|DEVICE|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
218836667|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
218836668|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
219016761|NCT06088121|DEVICE|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
219016762|NCT06088121|DEVICE|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
219016763|NCT06088121|DEVICE|ATNC BN-V1|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
219016764|NCT06088121|DEVICE|ATNC BN-V2|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
219584431|NCT04585880|OTHER|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
219444894|NCT05452187|DRUG|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
219584432|NCT05659693|BEHAVIORAL|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
219584433|NCT02387983|DRUG|Posaconazole|Posaconazole 300 mg solid oral tablet
219584434|NCT05301153|DIAGNOSTIC_TEST|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
219475882|NCT06395649|DEVICE|Classical rTMS to M1|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.
219475883|NCT06395649|DEVICE|rTMS to the High connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.
219584435|NCT05403255|OTHER|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
219584436|NCT02974647|DRUG|Ruxolitinib|
219584437|NCT04636242|PROCEDURE|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
219584438|NCT04636242|DRUG|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
219584439|NCT05380076|OTHER|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
219584440|NCT05380076|OTHER|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
219584441|NCT05380076|OTHER|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
219584442|NCT01551225|DRUG|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
219584443|NCT02684708|DRUG|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
219584444|NCT02684708|DRUG|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
219584445|NCT03724526|BEHAVIORAL|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
219765837|NCT07208981|DRUG|Orelabrutinib|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Orelabrutinib (150 mg, d1-d28). Maintenance phase (a total of 24 cycles, each cycle lasting 28 days), Orelabrutinib (150 mg, d1-d28). Patients who achieve complete remission (CR) or partial remission (PR) after 6 cycles will decide whether to undergo maintenance therapy based on the investigator's choice.
219765838|NCT07208981|DRUG|Zebetuzumab|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Zebetuzumab (375 mg/m2, d1/C1-C6).
219765839|NCT07208981|DRUG|Lenalidomide|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Lenalidomide (20 mg, d1-d21).
219765840|NCT07208981|DRUG|Bendamustine + Rituximab|Treatment period (a total of 6 cycles, each cycle lasting 28 days), Bendamustine (90 mg/m2, d1-2), Rituximab (375 mg/m2, d1/C1-6).
219196393|NCT06611618|OTHER|Home-based mobility monitoring|Mobility monitoring with wearable sensors
219196394|NCT06611618|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Full lower limb MRI
219196395|NCT06611618|OTHER|Gait assessment|Motion capture, surface EMG and gorund reaction force data
219196396|NCT05970601|DIETARY_SUPPLEMENT|Soup|Intake of a single soup with different sodium chloride and potassium chloride content
219196397|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
219444895|NCT05452187|OTHER|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
219444896|NCT04443257|OTHER|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
219444897|NCT06118008|DRUG|HS-20094 5mg|Administrated by subcutaneous injection
219444898|NCT06118008|DRUG|HS-20094 10mg|Administrated by subcutaneous injection
219444899|NCT06118008|DRUG|HS-20094 15mg|Administrated by subcutaneous injection
219444900|NCT06118008|DRUG|HS-20094 20mg|Administrated by subcutaneous injection
219444901|NCT06085703|DRUG|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219444902|NCT06085703|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219444903|NCT04428788|DRUG|CC-94676|Specified dose on specified days
219444904|NCT04428788|DRUG|CC1083611|Specified dose on specified days
219444905|NCT04428788|DRUG|CC1083610|Specified dose on specified days
219444906|NCT04935567|OTHER|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
219444907|NCT04574869|DRUG|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
219444908|NCT04574869|DRUG|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
219444909|NCT04574869|DRUG|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
219444910|NCT04574869|DRUG|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
219444911|NCT04574869|DRUG|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
219444912|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
219444913|NCT03766113|OTHER|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
219444914|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
219444915|NCT03409575|OTHER|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
219444916|NCT03409575|OTHER|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
219765841|NCT07207499|OTHER|"control group (standard regulation device)"|"Evaluate the time spent in the emergency room of patients referred to the emergency room by the standard regulation system"
219444917|NCT04692896|DRUG|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
219444918|NCT00628134|DRUG|calfactant|single inhaled dose by nebulizer
219444919|NCT00628134|DRUG|isotonic saline|single inhaled dose by nebulizer
219765842|NCT07207499|OTHER|"intervention group Access to Care Service SAS"|Evaluate the time spent in the emergency room of patients referred to the emergency room by the Emergency Care Access Service (SAS)
219196398|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
219444920|NCT04712643|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
219444921|NCT04712643|DRUG|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
219584446|NCT05335733|DIAGNOSTIC_TEST|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
219584447|NCT02553902|DEVICE|Sleep position trainer|
219584448|NCT02553902|DEVICE|Mandibular advancement device|
219584449|NCT02553902|DEVICE|Continuous positive airway pressure|
219765843|NCT07207460|PROCEDURE|Comparison of three different injection techniques using hydrodissection with 5% dextrose in the treatment of CTS|Comparison of three different injection techniques with D5W
218836669|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
218836670|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
219584450|NCT00548171|BIOLOGICAL|Boostrix™|Intramuscular injection, 1 dose
219765844|NCT07203326|BIOLOGICAL|Alloderm|Alloderm is a ready to use tissue graft, made from donated allograft human dermis, processed to remove cells while preserving biologic components and structure of the dermal matrix.
219765845|NCT07203326|BIOLOGICAL|MicroDerm|MicroDerm is an acellular dermal matrix sourced from donated human tissue. Cytoplast™ MicroDerm is micro-surfaced.
219765846|NCT07202598|DRUG|Emapalumab|Emapalumab will be administered via IV infusion once a month. The initial dose of emapalumab is 3 mg/kg followed by a second dose of 3 mg/kg after 3 days. Subsequently, the dose is 3 mg/kg once a month for five additional doses.
219765847|NCT07207746|BEHAVIORAL|Behavioral: Music Listening|Participants listened to slow-tempo instrumental classical music (40-60 dB) via headphones during the entire urodynamic procedure.
219444922|NCT04712643|DEVICE|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
218836671|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
218836672|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
218836673|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
218836674|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
218836675|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
218836676|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
218836677|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
218836678|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
218836679|NCT00465972|DRUG|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
219444923|NCT05554055|BIOLOGICAL|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
219584451|NCT01103466|DEVICE|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
219584452|NCT01103466|DEVICE|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
219584453|NCT01103466|DEVICE|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
219584454|NCT01216852|DRUG|Losartan Potassium|100 mg tablet
219584455|NCT01019928|DRUG|AZD1386|95 mg, oral solution, single dose
219584456|NCT01019928|DRUG|Placebo to AZD1386|Placebo, oral solution, single dose
219584457|NCT03446911|RADIATION|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
219584458|NCT03446911|COMBINATION_PRODUCT|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
219584459|NCT06967714|BEHAVIORAL|Exercise|25 min cycling exercise at 75% of hear rate reserve. Physical use of one upper-limb will be restricted with a sling.
219584460|NCT05873010|DIAGNOSTIC_TEST|Manual Compression and Stretching|Manual Compression and Stretching for The Myofascial Trigger Points
219584461|NCT02331368|PROCEDURE|Autologous Stem Cell Transplant|
219584462|NCT02331368|DRUG|Melphalan|140-200 mg/m\^2
219584463|NCT02331368|DRUG|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
219584464|NCT02331368|DRUG|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
219584465|NCT04300010|DRUG|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
219584466|NCT04300010|DEVICE|Blue Light Therapy|Blue light therapy treatment for acne
218836680|NCT00465972|DRUG|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
218836681|NCT00465972|DRUG|Placebo|Placebo capsule nightly for duration of study
219444924|NCT04369222|OTHER|Observational|Maternal consumption of mild analgesics
219444925|NCT05740293|PROCEDURE|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
219444926|NCT03687827|DRUG|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
218836682|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
219196399|NCT06858891|PROCEDURE|Transversus abdominis plane (TAP) block|Under ultrasound guidance, 20 cc of 0.25% bupivacaine was planned to be administered between the internal oblique and transversus abdominis fascial planes on both lateral aspects of the anterior abdominal wall.
219196400|NCT06862843|OTHER|Collecting questionnaires and biological samples|For each family member will be collected a 3-days food diary, a food frequencies questionnaire and a questionnaire assessing the adherence to the mediterranean diet. Additionally, a blood sample for trascriptomic analysis and a fecal sample for gut microbiota analysis will be collected
219444927|NCT03687827|DRUG|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
219444928|NCT03208075|OTHER|normal diet|Diet containing 1500mg of phosphorus
219444929|NCT03208075|OTHER|low-phosphorus diet|Diet containing 500mg of phosphorus
219584467|NCT03123510|DIETARY_SUPPLEMENT|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
219584468|NCT03123510|DIETARY_SUPPLEMENT|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
218836683|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
219584469|NCT02838810|DRUG|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
219584470|NCT02838810|DRUG|Nucleoside analogues|Nucleoside analogues
219584471|NCT03450395|OTHER|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
219584472|NCT03670264|BEHAVIORAL|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
219584473|NCT03670264|BEHAVIORAL|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
219584474|NCT03670264|BEHAVIORAL|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
219584475|NCT03670264|BEHAVIORAL|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
219584476|NCT03073785|DRUG|Capecitabine|Given by mouth (PO)
219584477|NCT03073785|DRUG|Fluorouracil|Given Intravenously (IV)
219584478|NCT03073785|OTHER|Laboratory Biomarker Analysis|Correlative studies
219584479|NCT03073785|OTHER|Pharmacological Study|Correlative studies
219584480|NCT03073785|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
218836684|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
219444930|NCT03208075|OTHER|high-phosphorus diet|Diet containing 2300mg of phosphorus
219584481|NCT03073785|DRUG|Zoledronic Acid|Given IV
219444931|NCT00917137|PROCEDURE|TBNA + transbronchial lung biopsy + bronchial washing|
219444932|NCT04819867|DRUG|Propolis|propolis is an extract derived from bee hives
219444933|NCT04819867|DRUG|Gluma Desensitizer|Gluma is a desensitizer agent
219584482|NCT02214784|DEVICE|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
219444934|NCT04044313|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
219444935|NCT04044313|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219444936|NCT04044313|DRUG|Toripalimab|240mg intravenously every 3 weeks
219444937|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
219444938|NCT00561301|DRUG|GemDOx|gemcitabine oxliplatin
219444939|NCT01578525|OTHER|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
219444940|NCT03209986|PROCEDURE|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
219444941|NCT03209986|OTHER|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
219444942|NCT02382965|DEVICE|transcranial focused ultrasound|
219584483|NCT02214784|DEVICE|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
219584484|NCT03720379|DEVICE|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
219584485|NCT03720379|DEVICE|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
219584486|NCT04751084|DRUG|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
218836685|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
218836686|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
218836687|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
219444943|NCT03986567|BEHAVIORAL|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
219444944|NCT04723004|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
219444945|NCT04723004|DRUG|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
219444946|NCT02128204|DEVICE|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
219444947|NCT02128204|DEVICE|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
219444948|NCT00023205|BEHAVIORAL|11th grade reading level arthritis materials|
219444949|NCT00023205|BEHAVIORAL|Interactive in-person arthritis education|
219444950|NCT04559997|OTHER|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
219444951|NCT04559997|OTHER|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
219444952|NCT05799547|OTHER|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
219444953|NCT00244777|DRUG|Hypo-osmolar ORS|
219444954|NCT05243147|DEVICE|nasal stents|using nasal stents after septoplasty
219444955|NCT05243147|DEVICE|merocel|using merocel after septoplasty
219444956|NCT01957085|OTHER|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
219444957|NCT02650167|BIOLOGICAL|Colostrum feeding|
219444958|NCT02650167|BIOLOGICAL|formula for preterm infants|
219444959|NCT01966276|DRUG|Methyl-P plus Nutrient Formula|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula"
218836688|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
219444960|NCT01966276|DRUG|Methyl-P plus Nutrient matched placebos|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo"
219196401|NCT06865235|PROCEDURE|360º goniotomy assisted transluminal trabeculotomy|Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
219444961|NCT01168375|DRUG|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
219444962|NCT01168375|DRUG|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
219444963|NCT04247321|DEVICE|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
218836689|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
218836690|NCT00861692|DRUG|argatroban|
218836691|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
218836692|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
219196402|NCT06865235|PROCEDURE|Phacoemulsification|Cataract Surgery
219196403|NCT06865235|PROCEDURE|180º gonioscopy assisted transluminal trabeculotomy|Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.
219364188|NCT03242954|OTHER|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
219364189|NCT04690699|BIOLOGICAL|Lerapolturev|Lerapolturev administered via intravesical instillation once
219364190|NCT04690699|OTHER|5% DDM|5% DDM and saline washes
219364191|NCT00410176|BEHAVIORAL|sanitation and personal hygiene|
219364192|NCT01653730|DEVICE|Eclipse 3 portable oxygen concentrator|
219364193|NCT01653730|DEVICE|EverGo portable oxygen concentrator|
219364194|NCT01653730|DEVICE|iGo portable oxygen concentrator|
219364195|NCT03446495|DRUG|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
219364196|NCT00925600|BIOLOGICAL|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
219364197|NCT00925600|BIOLOGICAL|Placebo|Prefilled syringe for subcutaneous (SC) injection
219364198|NCT04785612|BIOLOGICAL|RSVPreF|A single dose of 120 mcg RSVpreF for intramuscular injection
219364199|NCT04785612|OTHER|Placebo|A single Placebo dose for intramuscular injection to match experimental vaccine
219364200|NCT00646295|DEVICE|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
219364201|NCT06958367|DRUG|Dexmedetomidine|the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.
219364202|NCT06958367|DRUG|Normal Saline (Placebo)|Group (B): the control group will receive an infusion of an equivalent volume of a 0.9% saline for the same duration
219364203|NCT03396328|BEHAVIORAL|conventional low salt education|conventional low salt education
219364204|NCT03396328|BEHAVIORAL|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
219364205|NCT00120614|BEHAVIORAL|Premature infant behavior and development information|
219364206|NCT00120614|BEHAVIORAL|Parental activities to support premature infant information|
219364207|NCT01682005|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
219364208|NCT01974817|BIOLOGICAL|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
219364209|NCT05512949|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
219364210|NCT05020379|PROCEDURE|Perioperative and postoperative multimodal analgesia|"Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day."
219364211|NCT05020379|PROCEDURE|ESP Block|Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
219364212|NCT01536444|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
219584487|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
219584488|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
219584489|NCT01401621|BEHAVIORAL|Control|No scratch-off element
219584490|NCT06152952|PROCEDURE|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
219584491|NCT02352545|DRUG|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
219584492|NCT05240170|DEVICE|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
219584493|NCT05240170|DEVICE|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
219765848|NCT07207798|PROCEDURE|Epidural Electrical Stimulation|Epidural Electrical Stimulation (EES) is a medical technology that involves delivering controlled electrical impulses to the spinal cord through electrodes implanted in the epidural space-the area between the outermost membrane of the spinal cord (dura mater) and the vertebrae. This technique aims to modulate the activity of spinal neural networks, thereby regulating neurological functions and promoting functional recovery, particularly in individuals with spinal cord injuries or certain neurological disorders.
219765849|NCT07207798|PROCEDURE|Standard Rehabilitation Therapy|A structured, multidisciplinary rehabilitation program designed to improve motor function, mobility, and independence in participants with paralysis. The therapy typically includes physical Therapy and occupational Therapy.
219765850|NCT07207798|RADIATION|positron emission tomography-computed tomography (PET-CT)|PET-CT is an advanced hybrid imaging modality that combines metabolic information from positron emission tomography with anatomical details from computed tomography.
219765851|NCT07207798|RADIATION|Diffusion Tensor Imaging (DTI)|DTI is an advanced MRI technique that maps white matter tracts by measuring the directionality (anisotropy) and magnitude of water molecule diffusion in neural tissues. It provides quantitative metrics of fibers.
219765852|NCT07207798|PROCEDURE|Somatosensory Evoked Potentials (SEPs)|SEPs are electrophysiological responses recorded from the central or peripheral nervous system following electrical stimulation of sensory nerves. They assess the functional integrity of somatosensory pathways.
219444964|NCT04247321|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
219444965|NCT05001776|PROCEDURE|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
219444966|NCT05001776|DRUG|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
219444967|NCT03748420|OTHER|Adherence Intervention|The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
219444968|NCT00373880|DRUG|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
219584494|NCT02192749|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
219584495|NCT04016441|OTHER|Survey|Participants will complete a survey online
219584496|NCT02257541|DRUG|BGJ398|
219584497|NCT02257541|DRUG|Imatinib Mesylate|
219584498|NCT02302859|DRUG|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
219584499|NCT02302859|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
219584500|NCT02302859|OTHER|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
219765853|NCT07207798|PROCEDURE|Motor Evoked Potentials (MEPs)|MEPs are electrophysiological responses elicited by transcranial magnetic stimulation or electrical stimulation of the motor cortex, recorded from peripheral muscles or the spinal cord. They evaluate the integrity of corticospinal tracts.
218836693|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
218836694|NCT00061854|DRUG|soblidotin|
218836695|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
218836696|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
218836697|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
218836698|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
219444969|NCT00373880|DRUG|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
219444970|NCT02844140|PROCEDURE|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
219444971|NCT01706120|DRUG|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
219444972|NCT01706120|DRUG|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
219444973|NCT01706120|DRUG|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
219444974|NCT02330601|PROCEDURE|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
218836699|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
218836700|NCT00192764|DRUG|high-dose cyclophosphamide|
218836701|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
218836702|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
218836703|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
218836704|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
218836705|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
218836706|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
218836707|NCT05602454|OTHER|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
218836708|NCT04136587|OTHER|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
219364213|NCT03551548|DRUG|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
219364214|NCT03551548|DRUG|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
219364215|NCT00594477|RADIATION|IMRT|
219444975|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
219444976|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
218836709|NCT04380753|DRUG|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
219364216|NCT04836949|DEVICE|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
219364217|NCT04836949|DEVICE|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
219364218|NCT03156803|BEHAVIORAL|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
219364219|NCT04366999|PROCEDURE|SG|SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.
219364220|NCT04366999|PROCEDURE|RYGB|RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
219584501|NCT02302859|BEHAVIORAL|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
219584502|NCT02302859|OTHER|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
218836710|NCT05892419|OTHER|No intervention|There is no intervention
218836711|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
218836712|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
219444977|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
219444978|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
219444979|NCT03987867|BIOLOGICAL|CIK cell|CIK cell injection
219584503|NCT02302859|DEVICE|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
219584504|NCT03003949|DRUG|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
219584505|NCT03003949|DRUG|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
219584506|NCT03003949|DRUG|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
219584507|NCT03003949|DRUG|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
219584508|NCT00397059|DRUG|Escitalopram|
219584509|NCT01520532|OTHER|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
218836713|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
218836714|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
218836715|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
218836716|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
219444980|NCT03987867|BIOLOGICAL|Sintilimab Injection|IBI308 injection
219444981|NCT03987867|DRUG|Pemetrexed|Pemetrexed injection
219444982|NCT03987867|DRUG|Liposome paclitaxel|Liposome paclitaxel injection
219444983|NCT03987867|DRUG|Carboplatin|Carboplatin injection
219444984|NCT02044315|DEVICE|ICD programming|
219444985|NCT05155839|DRUG|MRG001|Administrated intravenously
219444986|NCT03067064|OTHER|no intervention|Clinical examination
219444987|NCT03304392|BEHAVIORAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
219584510|NCT05476952|PROCEDURE|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
219584511|NCT05813314|COMBINATION_PRODUCT|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
219584512|NCT05813314|DRUG|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
219444988|NCT03304392|BEHAVIORAL|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
219444989|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
219444990|NCT00298285|DRUG|enoxaparin|
219444991|NCT04281108|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
219444992|NCT04281108|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet.
218836717|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
219444993|NCT04281108|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
219444994|NCT01501162|DRUG|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
219444995|NCT01501162|DRUG|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
219444996|NCT05346861|DRUG|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
219444997|NCT05346861|DRUG|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
219444998|NCT00028964|DIETARY_SUPPLEMENT|Chinese herbs|
219444999|NCT00028964|DRUG|cyclophosphamide|
219445000|NCT00028964|DRUG|doxorubicin hydrochloride|
219445001|NCT00028964|PROCEDURE|adjuvant therapy|
219445002|NCT02868151|DRUG|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
219445003|NCT02868151|DRUG|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
218836718|NCT00460460|DRUG|AZD4877|
218836719|NCT01948479|DEVICE|Optimised instant offloading insole|
219445004|NCT04259346|DRUG|Ixekizumab|Administered SC.
219445005|NCT01487863|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
218836720|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
218836721|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
218836722|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
218836723|NCT04105959|DRUG|RIST4721|RIST4721 oral solution
218836724|NCT04105959|DRUG|Placebo|Placebo oral solution
218836725|NCT04068948|DRUG|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
218836726|NCT04068948|DRUG|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
218836727|NCT04068948|DRUG|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
218836728|NCT03306433|DEVICE|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
219445006|NCT01487863|DRUG|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
219445007|NCT06026423|OTHER|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
218836729|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
219016771|NCT06295731|DRUG|INBRX-106|INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
219016772|NCT06295731|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
219445008|NCT06026423|OTHER|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
219445009|NCT02805894|DRUG|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
219584513|NCT05735041|BEHAVIORAL|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
219584514|NCT05735041|BEHAVIORAL|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
219584515|NCT04671186|DIETARY_SUPPLEMENT|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
219765854|NCT07208435|BEHAVIORAL|Web-Based Therapeutic Exercise Program|Participants complete an 8-week web-based therapeutic exercise program via Physitrack, with 30-45 minute sessions twice weekly. The program targets core strengthening, spinal mobility, posture correction, and pain reduction. Exercises progress weekly from basic core engagement and breathing techniques to advanced trunk control, dynamic movements, and integration. The platform provides instructional videos, reminders, educational content, and self-monitoring tools to enhance adherence, engagement, and self-management.
219765855|NCT07208435|BEHAVIORAL|Traditional Home Exercise Program|Participants follow a 6-week traditional home exercise program with 30-40 minute sessions, twice weekly. The program focuses on flexibility, basic trunk and core strengthening, balance, and ergonomic practice. Exercises progress weekly, including cat-cow stretches, pelvic tilts, glute bridges, partial curl-ups, bird-dog, lunges, and posture training. Participants perform exercises independently at home using printed instructions, aiming to reduce pain, improve spinal mobility, and enhance functional outcomes.
219765856|NCT07209202|OTHER|High fructose meal|Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.
218836730|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
218859953|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
219445010|NCT02805894|DRUG|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
219445011|NCT01718366|DRUG|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
219445012|NCT06177223|BEHAVIORAL|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
219445013|NCT06019091|DEVICE|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
219765857|NCT07209202|OTHER|Low fructose meal|55% total carbohydrate (6% fructose), 30% fat, 15% protein.
219765858|NCT07209202|OTHER|13C labeled fructose, oral|Tracer amount of 13C labeled fructose administered orally in the meals.
219765859|NCT07209202|OTHER|13C labeled fructose, intravenous|Tracer amount of 13C fructose administered intravenously
219765860|NCT07208942|DEVICE|Rectal Stimulation|"The stimulation balloon was lubricated with paraffin oil and inserted until the distal end of the balloon was 10 cm from the anal verge, so as to eliminate the influence of different stimulation sites on the subjects.~At the start of stimulation, the dilatable balloon was rapidly inflated to 60/80 mL, with a stimulation duration of 150 milliseconds. Concurrently with stimulation, the onset time of stimulation was marked on the electroencephalogram (EEG), and the time window for cortical potentials evoked by rapid rectal balloon distension stimulation was recorded. During the experiment, 35 stimulations were administered to the subjects; however, the first and last stimulations were excluded due to setup issues with the precision inflation-deflation control device for the intestinal balloon. Each stimulation was delivered as a 150-millisecond inflation pulse, providing 35 identical rectal stimulations. The inter-stimulus interval was randomly set to 12 ± 4 seconds, and EEG signals were"
219445014|NCT03058263|DRUG|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
219445015|NCT06059274|OTHER|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
219445016|NCT04555811|DRUG|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
219584516|NCT04671186|OTHER|Placebo|Placebo group will take 1 capsule of placebo orally once daily
218836731|NCT05712980|DEVICE|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
219445017|NCT04555811|DRUG|Rituximab|Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
219445018|NCT00623766|DRUG|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
219445019|NCT00623766|DRUG|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
219584517|NCT04376762|DRUG|Fibrinogen|Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
219584518|NCT04376762|DRUG|Cryoprecipitate|Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
218836732|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
218836733|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
218836734|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
218836735|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
218836736|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
218836737|NCT04171505|DRUG|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
218836738|NCT00002108|DRUG|Lamivudine|
218836739|NCT00002108|DRUG|Zidovudine|
218836740|NCT04150289|DRUG|Farydak|non-interventional study
218836741|NCT02242058|OTHER|Quantitative sensory testing|
218836742|NCT01769976|OTHER|Periodic fasting|
218836743|NCT01769976|OTHER|Energy restriction|
218836744|NCT01769976|OTHER|Energy balance diet|
218836745|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
218836746|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
218836747|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
219584519|NCT00300508|DRUG|Anastrozole|
219584520|NCT01798355|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
219584521|NCT01798355|BEHAVIORAL|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
219584522|NCT04713150|OTHER|No Intervention|No Intervention
218836748|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
218836749|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
218836750|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
218836751|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
218836752|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
219196404|NCT06863948|OTHER|Teribenin method|"Intervention: Terebenin's Method~* Format:~* Duration: 8 weeks, 1 session/week (2-3 hours).~* Group size: 8-12 participants + 1-2 facilitators.~* Structure of Each Session:~* Introduction (10-15 min): Check-in, brief emotional reflection.~* Main Phase (90-120 min): Psychodrama-like enactments, systemic constellation exercises, body-oriented practices, directive interpretation by the therapist.~* Conclusion (15-20 min): Group reflection, integration, feedback.~* Quality Assurance:~* Audio/video recording (with consent) for supervision.~* A standard protocol/manual specifying core techniques"
219196405|NCT06863948|OTHER|Control Interventions|"1\. Active Control (Preferred):~* Group psychotherapy (CBT, Gestalt, or another recognized approach) matching the same 8-week schedule. 2. Waitlist Control (If Active Control Unavailable):~* Participants receive no active intervention during the 8 weeks, then are offered therapy afterward (if applicable)"
219196406|NCT06863792|OTHER|ChatGPT|Students in the intervention group will answer the questions from the Hypertension Prevention Attitude Scale using ChatGPT.
219196407|NCT06865040|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|"Administration in the interventional arm of long-acting inhaled ß-2 mimetics:~FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7."
219196408|NCT06865040|OTHER|Usual treatment|usual treatment
219196409|NCT06861426|DRUG|Ginkgo Diterpene Lactone Meglumine|The specific administration protocol (including time of initiation, dosage, and treatment duration) should be strictly adhered to as per the physician's prescription and meticulously documented in the case report forms (CRFs).
219196410|NCT02287090|OTHER|Observational Cohort|
219364221|NCT04366999|PROCEDURE|OAGB|OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
219364222|NCT02135536|BIOLOGICAL|NGM282|NGM282
219584523|NCT06008743|BEHAVIORAL|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
219584524|NCT06008743|BEHAVIORAL|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
219584525|NCT06008743|BEHAVIORAL|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
219364223|NCT06957639|OTHER|Standard physiotherapy intervention and home exercises|Various physical agents such as electrotherapy, hotpack (warm compress) and ultrasound therapy will be used within the standard physiotherapy intervention. These approaches are effective methods to reduce pain, relax muscles and accelerate healing. Home exercises are daily neck exercises recommended by a specialist physiotherapist.
218836753|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
218836754|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
218836755|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
218859954|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
218859955|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
219364224|NCT06957639|OTHER|Trigger point therapy and home exercises|Trigger point therapy is a common method used in patients with myofascial pain syndrome. This method involves manually releasing trigger points. Approaches such as pressure applications and stretching techniques are used. Muscle functions are improved by loosening painful muscle knots. Muscle flexibility and endurance are increased with home exercises.
219364225|NCT06957639|OTHER|Kinesiology Taping therapy and home exercises|"Kinesiology taping is an elastic band technique used for pain management and muscle activity support. It accelerates healing by increasing blood circulation. It supports and protects the muscles in the neck and shoulder area.~It provides supportive stabilization without restricting joint movements. It facilitates movement by reducing pain. It targets muscle strengthening and mobilization with home exercises"
219364226|NCT06957639|OTHER|Cervical - Scapular Mobilization and home exercises|Cervical and scapular mobilization includes manual therapy techniques aimed at increasing the range of motion of the joints in the spine and shoulder area. Mobilization is applied to the cervical spine and shoulder joints. Relaxation is provided in the muscles around the shoulder and neck. Cervical and scapular stability is improved. Postural disorders are corrected and range of motion is increased. Sustainability of mobilization is ensured with home exercises.
219364227|NCT06155175|DRUG|NSAIDs|The exposure to NSAIDs: NSAIDs was used at least once within the first day after surgery
219364228|NCT05038683|BEHAVIORAL|Holbæk Obesity Treatment|"Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
219584526|NCT03021109|DEVICE|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
219584527|NCT04948164|DRUG|sumatriptan 85mg and naproxen sodium 500mg|Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
219765861|NCT07208539|DRUG|Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1|The cohort A (borderline resectable) and cohort B (locally advanced) both received treatment with gemcitabine, albumin paclitaxel (administered on days 1, 8, and 15, with 4 weeks as one cycle) and adalimumab (administered once every 4 weeks, with 4 weeks as one cycle). After completing 2 cycles of treatment, they were sequentially given liposomal irinotecan combined with 5-FU/LV, oxaliplatin (administered once every 2 weeks, with 4 weeks as one cycle) and adalimumab (administered once every 4 weeks, with 4 weeks as one cycle). After completing 2 cycles of sequential treatment, surgical evaluation was conducted: for patients who could undergo radical surgical resection, surgery was performed within 2-4 weeks after the end of the conversion treatment stage, and the postoperative treatment plan was selected based on the investigator's judgment; for patients who could not undergo radical surgical resection, subsequent treatment plans could be selected based on the investigator's judgment.
219765862|NCT07208864|DIAGNOSTIC_TEST|AI-assisted EGGIM scoring|Endoscopists will evaluate the videos with the assistance of the AI system via EGGIM score.
219765863|NCT07208864|DIAGNOSTIC_TEST|Conventional EGGIM scoring|Endoscopists will evaluate the videos without the assistance of the AI system via EGGIM score.
218836756|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
219445020|NCT00623766|DRUG|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
219445021|NCT00623766|DRUG|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
219445022|NCT00623766|DRUG|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
219445023|NCT00623766|DRUG|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
219445024|NCT00623766|DRUG|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
219445025|NCT00623766|DRUG|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
219445026|NCT00623766|DRUG|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
219445027|NCT00623766|DRUG|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
219445028|NCT05714254|DRUG|MEDI0618|Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
219445029|NCT05714254|DRUG|Placebo|Four doses of IV placebo or SC placebo administered once every two weeks.
219445030|NCT00486889|BIOLOGICAL|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
219445031|NCT00421590|DRUG|SMC021|
219445032|NCT00893763|PROCEDURE|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
219445033|NCT00893763|PROCEDURE|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
219445034|NCT03884127|DRUG|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
219765864|NCT07208682|PROCEDURE|retropubic hydrodissection|subjects would receive retropubic hydrodissection prior to passage of the trocars. A total of 60cc of sterile injectable saline would be injected in the retropubic space with a 20g spinal needle along the anticipated path of the trocar.
219445035|NCT03884127|DRUG|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
219445036|NCT05249803|COMBINATION_PRODUCT|Patients with COVID-19 Pneumonia|Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
219445037|NCT00000895|DRUG|Nelfinavir mesylate|
219445038|NCT00000895|DRUG|Nevirapine|
219445039|NCT00000895|DRUG|Azithromycin|
219445040|NCT01358006|DRUG|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
219445041|NCT01358006|DRUG|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
219445042|NCT04085991|DRUG|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
219445043|NCT02251028|BEHAVIORAL|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
219445044|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
218836757|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
218836758|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
219445045|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
218836759|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
219445046|NCT03518775|DEVICE|Biometry|Measurement of Cornea
219445047|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
219445048|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
219445049|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
219445050|NCT02384928|PROCEDURE|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
219445051|NCT02384928|DEVICE|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
219445052|NCT02384928|DRUG|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
219445053|NCT02384928|PROCEDURE|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
219445054|NCT02384928|BEHAVIORAL|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
219445055|NCT02044367|DRUG|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
219445056|NCT02044367|DRUG|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
219445057|NCT02044367|DRUG|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
219445058|NCT00899366|GENETIC|microarray analysis|
219445059|NCT00899366|GENETIC|mutation analysis|
219445060|NCT00899366|OTHER|immunologic technique|
219445061|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
219445062|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
219445063|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
219445064|NCT05257915|DRUG|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
219445065|NCT00491751|DRUG|atorvastatin|atorvastatin 40 or 80 mg/day
219445066|NCT00491751|DRUG|ascorbic acid|ascorbic acid 500 mg/day
219445067|NCT00491751|DRUG|Placebo|matching placebo
219445068|NCT02291328|OTHER|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
219445069|NCT02291328|OTHER|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
219445070|NCT03420157|OTHER|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
219445071|NCT06949280|DIETARY_SUPPLEMENT|Peanut Snack Experimental|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
219445072|NCT06949280|DIETARY_SUPPLEMENT|Nut-free Snack|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
219445073|NCT03960372|BEHAVIORAL|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
219584528|NCT04948164|DRUG|Placebo|"subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg)."
219584529|NCT04301908|DRUG|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
219584530|NCT01470495|OTHER|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
219584531|NCT01470495|OTHER|RFA|treat Recurrent HCC with RFA
219584532|NCT00735605|OTHER|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
219584533|NCT00735605|PROCEDURE|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
219765865|NCT07207811|DRUG|NNC6019-0001|NNC6019-0001 will be administered IV.
219765866|NCT07207811|DRUG|Placebo (NNC6019-0001)|Placebo matched to NNC6019-0001 will be administered IV.
219765867|NCT07208812|PROCEDURE|Conventional open -tray impression|Primary impression with irreversible hydrocolloid, custom tray with open window, and final impression with silicone material around impression copings to fabricate a 3D-printed implant overdenture
219584534|NCT00735605|OTHER|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
219445074|NCT05514106|DRUG|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
219445075|NCT05514106|DIAGNOSTIC_TEST|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
219445076|NCT03012282|DIAGNOSTIC_TEST|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
219584535|NCT04796753|OTHER|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
219584536|NCT01459562|DRUG|NI-0501|
219584537|NCT01459562|DRUG|Placebo|
219445077|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
219445078|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
219584538|NCT03055650|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
219445079|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
219445080|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
219445081|NCT03489850|DRUG|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
219584539|NCT00040768|DRUG|bortezomib|Given IV
219584540|NCT00837772|DEVICE|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
219584541|NCT00837772|DEVICE|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
219584542|NCT01442428|DRUG|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
219584543|NCT01442428|DRUG|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
219584544|NCT01442428|DRUG|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
219584545|NCT01442428|DRUG|Placebo|Atorvastatin placebo
219765868|NCT07208812|PROCEDURE|Functionally generated reline impression|Interim prosthesis relieved and reline impression taken during centric closure with border molding, scanned to construct a 3D-printed implant overdenture
219765869|NCT07208812|PROCEDURE|Mucostatic base with functional borders impression|Intraoral scan of edentulous arch, 3D-printed baseplates for occlusion rim, functional border molding, and digital workflow to fabricate 3D-printed implant overdenture
219765870|NCT07209254|OTHER|High-touch blood pressure management|Twelve weeks of text-based home blood pressure monitoring with BP self-management and team-based care
219765871|NCT07209254|OTHER|Low-touch blood pressure management|10 days of text-based home blood pressure monitoring
219584546|NCT02870400|DRUG|REGN2477|Participants will receive ascending doses of REGN2477
219584547|NCT02870400|DRUG|Placebo|Participants will receive matching placebo
219765872|NCT07208955|PROCEDURE|heat application|Heat application in the early postoperative period affects gastrointestinal function and mental well-being
219765873|NCT07208955|PROCEDURE|abdominal massage|Abdominal massage administered in the early postoperative period has an effect on gastrointestinal function and mental well-being.
219765874|NCT07208955|OTHER|control group|control group
219445082|NCT03489850|OTHER|Placebo|Placebo is matched to ibudilast active medication.
219584548|NCT04076488|OTHER|Dividat Fit|tablet based, remote assisted home-training
219584549|NCT04760392|BEHAVIORAL|Goal-directed mobilization|"* A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
219765875|NCT07208149|DRUG|MR001 Bispecific Antibody for Injection|Intravenous infusion
219765876|NCT07207603|OTHER|No intervention|No intervention
219445083|NCT00422903|DRUG|lapatinib|1500 mg administered orally daily
219445084|NCT00422903|DRUG|letrozole|2.5 mg administered orally daily
219445085|NCT00422903|OTHER|placebo|1500 mg administered orally daily
219584550|NCT01483469|DRUG|RO4917523|orally daily, 14 days
219765877|NCT07209124|OTHER|Experimental: Intervention 1 (AB): Engagement in Motion-Based Activities (Wii & Magic Table)|Group to receive treatment/intervention in the AB schedule - Wii first and then magic table
219584551|NCT01483469|DRUG|RO5011232|\[11C\]-RO5011232 intravenously
219765878|NCT07209124|OTHER|Experimental: Intervention 2 (BA): Engagement in Motion-Based Activities (Magic Table BA)|Group go receive treatment in the BA schedule -- magic table first and then Wii
219196411|NCT06769802|BEHAVIORAL|Experimental|"The children in this group and their mothers will be informed about the research and their written consent will be obtained. The scale will be filled in before the application. Before the application, Nebul will introduce the teddy bear to the mother and child. The teddy bear cannot be washed because it contains an electronic device. Therefore, it will be disinfected with a solution containing 60-70% alcohol before and after use. The recorded voice will then be played to the child and mother. Then, routine nebulizer treatment will be applied and the second audio recording will be played at the end of the treatment. The researcher will be with the child.~At the end of the nebulizer treatment, after the mask is removed, the Child Fear Scale and the Child Anxiety Scale-State Scale will be filled out. The Child Fear Scale will be filled in by both the mother and the nurse and the average will be taken."
219765879|NCT07209241|BIOLOGICAL|CART-EGFR-IL13Ra2 T cells|CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2.
219765880|NCT07208994|OTHER|Description|No intervention
219765881|NCT07207473|BEHAVIORAL|Behavioral strategy program X plus Y|Brief 4 session education program with sleep specialist focused on behavioral strategies for improving use of sleep apnea therapy. Tests behavioral strategy program X plus Y.
219584552|NCT04784910|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
219765882|NCT07207473|BEHAVIORAL|Behavioral strategy program X|Brief 4 session education program with sleep specialist focused on behavioral strategies for improving use of sleep apnea therapy Tests behavioral strategy X.
219765883|NCT07207655|OTHER|HPV Card Game|HPV Card Game Group: Twenty individuals in the intervention group will receive HPV education using the card game method.
219765884|NCT07209176|OTHER|Provider-level|The provider level component will involve an email to each of the genitourinary medical oncologists at Johns Hopkins with their NGS testing rate from preliminary data and compare this rate to the mean. The initial email will also include the 2025 ASCO guideline recommending somatic testing in virtually all metastatic prostate cancer patients. Providers who do not have baseline NGS testing rates available will also be emailed. Providers will subsequently be emailed their updated NGS testing rate at the conclusion of the study period.
219765885|NCT07209176|OTHER|Provider-level and patient-level|In addition to the provider component, patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing. The email will be sent by the MyChart Recruitment Innovation team. Those without email on file will have the same message and attachment sent via mail by our study coordinator.
219765886|NCT07208695|DRUG|Antiplatelet or Anticoagulant Drugs|The goal of this observational study is to assess the effect of postoperative continuous use of standard-dose oral antiplatelet (e.g., aspirin, clopidogrel) or anticoagulant drugs (e.g., warfarin, direct oral anticoagulants) on key postoperative outcomes in patients with primary lower extremity varicose veins who have undergone endovenous radiofrequency ablation (RFA) of the great saphenous vein. Unlike studies focusing on preoperative medication adjustment or single-drug cohorts, this study specifically targets routine postoperative medication use without protocol-mandated dose changes, and distinguishes between two major classes of antithrombotic agents while including a non-user control group. The main questions it aims to answer are: 1) Whether postoperative oral antiplatelet/anticoagulant use correlates with increased 30-day bleeding risk (defined by standardized criteria: minor = localized ecchymosis needing no intervention; major = bleeding requiring transfusion or surgical hemo
219765887|NCT07207395|DRUG|JBI-802|LSD1/HDAC6 Inhibitor
219765888|NCT07207395|DRUG|Pembrolizumab|PD-1
219765889|NCT07208383|OTHER|Questionnaire|Questionnaire to examine awareness, knowledge, and help-seeking behaviors among gynecological patients and the general public
219765890|NCT07208344|BIOLOGICAL|Intravenous infusion of mononuclear cells from umbilical cord blood|When performing cell infusion, it is essential to use an infusion set and follow the standard blood transfusion procedures. Before, during, and after the infusion, monitor the patient's body temperature, pulse, breathing, and blood pressure. When infusing cells, first flush the tube with 20-30 ml of 0.9% sodium chloride, and start the infusion at a rate of 20-30 drops per minute. After half an hour, if there are no adverse reactions, increase the rate to 30-50 drops per minute. During the cell infusion process, gently shake the cell bag once every 15 minutes. After the infusion is completed, flush the cell preservation bag with 20 ml of 0.9% sodium chloride and gently shake it. After that, use 0.9% sodium chloride to rinse the infusion set to remove the cells completely, to ensure the quantity of cell infusion.
219765891|NCT07208344|DRUG|Conventional medical treatment：donepezil, rivastigmine or galantamine|The treatment is carried out using drugs such as cholinesterase inhibitors (ChEI) which are suitable for mild to moderate Alzheimer's disease. For example, donepezil, rivastigmine, galantamine, etc. The frequency and dosage of drug administration should be in accordance with the instructions provided by the drug manufacturer.The patient should maintain the stability of the medication regimen throughout the entire study period.
219765892|NCT07209293|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Transesophageal echocardiography images will be taken prior to and post oral gastric suction.
219765893|NCT07202065|BIOLOGICAL|Immune Globulin Intravenous|Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week).
219584553|NCT04784910|DRUG|Lansoprazole 15 mg|Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
219584554|NCT04784910|DRUG|DWP14012 20mg placebo|DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
219584555|NCT04784910|DRUG|Lansoprazole 15 mg placebo|Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
219584556|NCT01095042|BEHAVIORAL|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
219584557|NCT00242736|DRUG|Esomeprazole|
219584558|NCT04173299|PROCEDURE|early tips|patients with early tips
218836760|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
218836761|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
218836762|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
218836763|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
218836764|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
218836765|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
218836766|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
218836767|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
219445086|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
219445087|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
219445088|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
219475884|NCT06395649|DEVICE|rTMS to the low connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
219475885|NCT06395649|DEVICE|Sham rTMS|Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
219475886|NCT04036942|PROCEDURE|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
219475887|NCT04036942|PROCEDURE|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
219475888|NCT06051474|DRUG|Nicotine Replacement Product|Adults will receive a 2-week supply of nicotine patches to place on skin (14mg or 21mg; dosing depending on tobacco use per package insert) and oral nicotine mini-lozenges (2mg, 4mg, dosing depending on tobacco use per package insert). All participants will also receive a single smoking cessation counseling session with a physician. Surveys will be completed pre-intervention, within 24 hours of hospital discharge, and 2-weeks after hospital discharge.
218836768|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
218859956|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
218859957|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
219475889|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
218859958|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
218859959|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
218859960|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
218859961|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
218859962|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
218859963|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
218859964|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
218859965|NCT04333953|OTHER|No intervention|No intervention, observational study
219475890|NCT06805370|BEHAVIORAL|Mailed Additional FIT Kit|Mailed additional FIT Kits in November 2024.
219475891|NCT06805370|OTHER|Usual Care|This group was sent an annual FIT Kit per usual care.
219765894|NCT07201168|OTHER|Structured Multimodal Educational Program for Critical Limb Ischemia|A comprehensive 12-month educational program combining face-to-face and digital learning modalities. Components include: weekly interactive group sessions (4 weeks) led by vascular specialists covering disease pathophysiology, risk factor modification, and treatment options; digital platform access with multimedia educational materials, printed educational materials for home reference; peer support group participation; medical hotline access for patient-initiated consultations and urgent questions; smoking cessation counseling; supervised exercise program recommendations; wound care training. The program emphasizes patient self-management skills, early recognition of complications, and adherence to medical therapy alongside standard clinical care.
219765895|NCT07201168|OTHER|Standard medical care|Routine clinical management for critical limb ischemia according to current standard of care guidelines. Includes vascular surgery consultation, standard medical therapy (antiplatelet agents, statins, antihypertensive medications as indicated), routine wound care instructions, general lifestyle counseling typically provided during clinical encounters, and scheduled follow-up appointments as clinically indicated. No structured educational materials, formal patient education sessions, or additional follow-up contacts beyond routine clinical care are provided. Patients receive standard verbal and written discharge instructions and have access to the same medical and surgical treatments as the intervention group when clinically warranted.
218836769|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
218836770|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
218836771|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
218836772|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
218836773|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
219445089|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
218836774|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
218836775|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
219445090|NCT02082028|DEVICE|BGStar|
219445091|NCT02082028|DEVICE|glucose meter|
219445092|NCT00428883|DRUG|N-acetylcysteine (NAC)|
218836776|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
219196412|NCT06769802|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their written consent will be obtained. Scales will be filled in before application. Children in this group will receive routine nebulizer treatment and routine application will be performed. At the end of the treatment, the scales will be filled in again.
219445093|NCT03023605|BEHAVIORAL|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day"
219445094|NCT00228189|BIOLOGICAL|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
219445095|NCT04191213|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
219445096|NCT04191213|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
219445097|NCT01671891|RADIATION|radiation therapy|45-55Gy
219445098|NCT01671891|DRUG|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
219445099|NCT03423862|OTHER|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
219445100|NCT04904315|OTHER|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
218836777|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
218836778|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
218836779|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
218836780|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
218836781|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
218836782|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
218836783|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
218836784|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
218836785|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
218836786|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
219196413|NCT06676891|DRUG|RZ-001|Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
219445101|NCT00205751|DRUG|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
218836787|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
219445102|NCT01526005|DRUG|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
219445103|NCT01526005|DRUG|Transdermal Placebo Patch|1 patch per day; 8 weeks total
219445104|NCT03658798|PROCEDURE|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
219445105|NCT02327312|DEVICE|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
219445106|NCT02327312|PROCEDURE|Laser|Laser Trabeculoplasty
219445107|NCT02327312|DEVICE|Laser Trabeculoplasty|
218836788|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
218836789|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
218836790|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
218836791|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
218836792|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
218836793|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
218836794|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
218836795|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
218836796|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
218836797|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
218836798|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
219196414|NCT05224869|DEVICE|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
218836799|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
219196415|NCT05224869|PROCEDURE|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
219196416|NCT05224869|PROCEDURE|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
219445108|NCT00946023|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
219445109|NCT00946023|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
219445110|NCT00946023|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
219445111|NCT00946023|DRUG|Tacrolimus|Start on Day 5 through Day 180
219445112|NCT00946023|DRUG|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
219445113|NCT00946023|DRUG|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
219445114|NCT00946023|BIOLOGICAL|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
219475892|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
219475893|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
219445115|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
219445116|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
219445117|NCT02457299|PROCEDURE|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
219445118|NCT02457299|PROCEDURE|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
219445119|NCT03898388|PROCEDURE|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
219445120|NCT04925947|DRUG|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
219445121|NCT04319445|BEHAVIORAL|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
219445122|NCT04379947|PROCEDURE|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
219445123|NCT00735098|OTHER|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
219445124|NCT00735098|OTHER|strength training exercise|strength training exercise, 3 times per week for 8 weeks
219445125|NCT00735098|OTHER|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
219445126|NCT00735098|OTHER|Control group|8 week control group
219765896|NCT07210866|OTHER|no physical or medical interventions|Data from patients after successive rescucitaion will be evaluated by machine learning programs.
218836800|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
218836801|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
218836802|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
218836803|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
218836804|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
219016775|NCT05201547|DRUG|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
219445127|NCT02561780|BEHAVIORAL|Curriculum|A mental health educational resource delivered in the classroom by trained educators
219445128|NCT02561780|BEHAVIORAL|eLearning Follow-up|An online mental health education module that students access individually
219445129|NCT02324712|DEVICE|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
219445130|NCT02324712|DEVICE|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
219445131|NCT00441480|DIETARY_SUPPLEMENT|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
219445132|NCT00441480|DIETARY_SUPPLEMENT|placebo|4 gr of corn oil
219445133|NCT03771495|OTHER|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
219445134|NCT03771495|OTHER|Laying on of Hands|Sham Hip Joint Mobilization
219445135|NCT01956994|DIETARY_SUPPLEMENT|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
219765897|NCT07207902|BEHAVIORAL|Explainer video|2 minute explainer video on treatment options
218836805|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
218836806|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
219196417|NCT05224869|RADIATION|Brachytherapy|one month after completing SBRT
219445136|NCT01956994|DIETARY_SUPPLEMENT|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
219445137|NCT05823792|DIAGNOSTIC_TEST|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
219445138|NCT02705222|PROCEDURE|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
219445139|NCT02705222|PROCEDURE|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
219584559|NCT04339920|DIAGNOSTIC_TEST|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
219584560|NCT02773199|OTHER|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
219445140|NCT03785444|OTHER|WHODAS 2.0|WHO Disability Score
219445141|NCT03785444|OTHER|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
219584561|NCT02773199|OTHER|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
219584562|NCT02773199|DRUG|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
219584563|NCT01791153|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
219584564|NCT01791153|DRUG|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
219584565|NCT01791153|DRUG|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
219584566|NCT01791153|DRUG|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
219584567|NCT01791153|DRUG|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
219584568|NCT01791153|DRUG|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
219584569|NCT02876926|BEHAVIORAL|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
219584570|NCT02876926|BEHAVIORAL|Home-based testing only|A standard home-based HIV test kit.
219584571|NCT02876926|BEHAVIORAL|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
218836807|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
218836808|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
219016776|NCT05201547|DRUG|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
219445142|NCT03785444|OTHER|IADL|The Lawton Instrumental Activities of Daily Living
219584572|NCT04557306|BIOLOGICAL|CBT101 cells, every 2 weeks|CBT101 cells, every 4 weeks
219445143|NCT03785444|OTHER|Barthel-Score|Barthel Score of the patient
219445144|NCT03785444|OTHER|SF-36|Short Form Health 36
219445145|NCT03785444|OTHER|MoCA Blind|Montreal Cognitive Assessment
219445146|NCT02411513|DEVICE|CEFALY|
219445147|NCT00351806|DRUG|Erigeron breviscapus injection|
219445148|NCT00351806|DRUG|hua tuo zai zao wan (a herbal medicine pill)|
219445149|NCT00351806|DRUG|Compound stroke herbal medicine (8 herbal)|
219445150|NCT03577951|PROCEDURE|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
219445151|NCT03577951|PROCEDURE|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
219445152|NCT02699125|DRUG|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
219584573|NCT04557306|BIOLOGICAL|CBT101 cells, every 4 weeks|CBT101 cells, every 4 weeks
219584574|NCT06989840|DRUG|TVB-3567|Orally administered capsule
218836809|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
218836810|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
218836811|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
219196418|NCT05224869|PROCEDURE|Post-implant dosimetry scan|one month after brachytherapy
219584575|NCT06989840|DRUG|Placebo|Orally administered capsule
219584576|NCT00975286|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219584577|NCT00975286|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219584578|NCT00975286|DRUG|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
219584579|NCT00975286|DEVICE|Pen auto-injector|Lantus® SoloStar® OptiClik®
218836812|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
219196419|NCT06290583|DRUG|Bupivacaine|Spinal anesthesia with standard dose of bupivacaine
219196420|NCT06290583|DRUG|Prilocaine|Spinal anesthesia with 50 mg dose of Prilocaine.
219196421|NCT06681558|DEVICE|Group Nasal Cannula|"Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a conventional oxygen mask.~The nasal cannula is a device that provides oxygen to patients through the nasal passages."
219196422|NCT06681558|DEVICE|Group Procedural Oxygen Mask|Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a Procedural Oxygen Mask (POM® ELITE MF). The procedural oxygen mask is a device that covers both the mouth and nose to deliver oxygen to the patient. Its reservoir feature increases the concentration of delivered oxygen
219196423|NCT03591003|DIAGNOSTIC_TEST|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
219196424|NCT06372314|DRUG|Total parenteral nutrition (TPN): this is total nutrition provided by central vein.|isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
219196425|NCT06450444|DEVICE|PRIMUS|The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
219196426|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
219445153|NCT02699125|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
218836813|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
219196427|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
219196428|NCT03367156|DRUG|Dexamethasone|Given PO
219196429|NCT03367156|OTHER|Placebo|Given PO
219196430|NCT03367156|OTHER|Questionnaire Administration|Ancillary studies
219196431|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
219196432|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
219196433|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
219196434|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
219196435|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
219196436|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
219196437|NCT05843578|DRUG|AGMB-129|Oral capsule
219196438|NCT05843578|DRUG|Placebo|Matching oral capsule
219445154|NCT03787095|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
219445155|NCT03787095|BIOLOGICAL|Placebo|Diluent for REGN2810, administered as an IV infusion
219445156|NCT06328855|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218836814|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
218836815|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
218836816|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
218836817|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
219196439|NCT05507437|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Recombinant human CD39 enzyme
219196440|NCT05507437|OTHER|Placebo|0.9% sterile sodium chloride solution
219196441|NCT05454566|GENETIC|ICM-203|Intra-articular injection
219196442|NCT05895981|DEVICE|G132 system, Beijing PINS Medical Co., China|Neuromodulation was performed according to the usual protocol
219196443|NCT04276805|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.
219196444|NCT04276805|BEHAVIORAL|cognitive training|A program of regular mental activities purported to maintain or improve one's cognitive abilities.
219475894|NCT06056505|PROCEDURE|partial kidney nephrectomy|surgery for partial nephrectomy
219475895|NCT06056505|DEVICE|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
219196445|NCT06952595|BEHAVIORAL|five exercises prescribed and taught to carers and participants|Up to five exercises prescribed and taught to carers and participants in an acute hospital setting fort hem to continue to practice as able.
219196446|NCT06954181|DRUG|Voltaren® Schmerzgel forte; 2.32% (Test Product)|Voltaren® Schmerzgel forte; 2.32% containing 2.32% Diclofenac-N-Ethylethanamin.
219196447|NCT06835712|OTHER|The virtual reality|During the PIK application, 3D visual and audio videos of the beach will be played with an Oculus Go brand virtual reality (VR) headset until the procedure is completed. The video that starts at the beginning of the procedure is planned to last approximately 2-3 minutes during the application. During this time, patients will be asked to close their eyes and take a comfortable position. The VR headset will be disinfected after each application and used on the other patient.
219765898|NCT07209956|PROCEDURE|Echocardiographic assessment of TAPSE|"Non interventional study (study of a prognostic factor). The study procedure is the echocardiographic assessment of TAPSE at every admission in PICU for acute bronchiolitis.~Transthoracic echocardiography is a non invasive, non radiative examination, that is usually performed at every admission in PICU, however not mandatory. Inclusion in the study will lead to a systematic echocardiographic assessment at admission, potentially adding this examination to the patient's course.~As transthoracic echocardiography is systematically monitored in intubated children, no additional examination will be necessary for those requiring invasive mechanical ventilation."
219765899|NCT07209371|DRUG|Rifaximin|Given PO
219765900|NCT07209371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219445157|NCT06328855|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219445158|NCT06328855|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219445159|NCT02394223|PROCEDURE|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
219445160|NCT03944304|DRUG|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
219445161|NCT00259519|PROCEDURE|Induction of delivery|Induction of delivery
219445162|NCT02154334|DRUG|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
219445163|NCT02154334|DRUG|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
219475896|NCT06056505|DEVICE|Innersight 3D software|investigational product to generate the 3D model
219475897|NCT05921604|DRUG|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
219475898|NCT05921604|DRUG|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
219475899|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
219475900|NCT04550260|DRUG|Durvalumab|Durvalumab intravenous infusion
219765901|NCT07209384|PROCEDURE|Transarterial chemoembolization|Transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab
219765902|NCT07208461|BIOLOGICAL|Low dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
219475901|NCT04550260|DRUG|Placebo|Durvalumab matching placebo for intravenous infusion
219475902|NCT04550260|DRUG|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
219475903|NCT04550260|DRUG|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
219475904|NCT04550260|RADIATION|Radiation|50-64Gy in total
219475905|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
219475906|NCT05959551|DEVICE|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
219475907|NCT04049474|DEVICE|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
219475908|NCT03547661|OTHER|P-Dragees rosa Lichtenstein|Placebo dragées
219475909|NCT06502821|OTHER|questtionnaire|questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
219475910|NCT04832009|DRUG|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
219475911|NCT04832009|DRUG|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
219475912|NCT04832009|DRUG|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
219584580|NCT00975286|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
219584581|NCT00975286|DRUG|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
219196448|NCT06835712|OTHER|The guided imagery|Patients in this group will be played an audio clip that helps them imagine walking on a beach and gives instructions during the walk until the procedure is completed, using an MP3 player and headphones. The audio clip aims to activate the imagination of patients by allowing them to use their senses. For example, the temperature of the sun (feeling), the texture of the sand (touching), the color of the sea (seeing), the sound of the waves (hearing), and the smell of the sea (smell) are some examples of this. The audio clip will be voiced by a professional voice artist with good diction. It is planned that the audio clip will be played for approximately 2-3 minutes during the application. During this time, patients will be allowed to close their eyes and take a comfortable position. The headphones of the MP3 player will be disinfected after each application and used on the other patient.
219584582|NCT00027079|DRUG|ondansetron (Zofran)|
219584583|NCT00027079|DRUG|naltrexone (ReVia)|
219584584|NCT00027079|BEHAVIORAL|Cognitive Behavioral Therapy|
219584585|NCT02357342|DRUG|Sirolimus|intravitreal injection
219196449|NCT06964269|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Study intervention is twice weekly injections of Acthar Gel via single-dose pre-filled SelfJect injector for 12 weeks.
219445164|NCT02154334|DRUG|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
219445165|NCT03395041|DIAGNOSTIC_TEST|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
219445166|NCT02092324|OTHER|Laboratory Biomarker Analysis|Correlative studies
219445167|NCT02092324|OTHER|Quality-of-Life Assessment|Ancillary studies
219445168|NCT02092324|OTHER|Questionnaire Administration|Ancillary studies
219445169|NCT02092324|DRUG|Ruxolitinib Phosphate|Given PO
219445170|NCT02758041|DEVICE|Sebacia Microparticles|
219445171|NCT00000314|DRUG|M-CPP|
219445172|NCT01617928|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
219584586|NCT02357342|DRUG|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
219584587|NCT02373670|BEHAVIORAL|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
219584588|NCT02373670|BEHAVIORAL|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
219584589|NCT02620215|DEVICE|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
219584590|NCT02620215|DRUG|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
219445173|NCT01617928|DRUG|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
219445174|NCT01617928|DRUG|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
219445175|NCT01039428|DIETARY_SUPPLEMENT|HS219|Chewing for 30 min three time a day far after meal
219445176|NCT01039428|DIETARY_SUPPLEMENT|Placebo|Chewing for 30 min three times a day far after meal
219445177|NCT03594461|DRUG|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
219445178|NCT05051176|DIAGNOSTIC_TEST|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
219445179|NCT06056401|BEHAVIORAL|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
219584591|NCT03959215|BEHAVIORAL|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
219584592|NCT03959215|OTHER|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
219584593|NCT03359577|DIETARY_SUPPLEMENT|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
219765903|NCT07208461|BIOLOGICAL|Low dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
219765904|NCT07208461|BIOLOGICAL|Middle dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
219765905|NCT07208461|BIOLOGICAL|Middle dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
219765906|NCT07208461|BIOLOGICAL|High dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
219765907|NCT07208461|BIOLOGICAL|High dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
219765908|NCT07208461|BIOLOGICAL|Placebo|0.5 mL 0.9% sodium chloride (normal saline) injection per dose
219765909|NCT07211113|DIETARY_SUPPLEMENT|Fonte Essenziale® mineral water|400 ml/day of Fonte Essenziale® mineral water, taken every morning on an empty stomach for 12 consecutive months, in addition to a specialist-prescribed controlled nutritional regimen
219765910|NCT07210749|RADIATION|External Beam Radiation Therapy|12 Gy in 6 fractions of external beam radiation therapy
218836818|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
218836819|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
218836820|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
218836821|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
218836822|NCT02013557|BEHAVIORAL|Text-message reminder|
218836823|NCT02912494|DRUG|JR-131|
219196450|NCT04756856|OTHER|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
219445180|NCT00861094|DRUG|cisplatin|
219445181|NCT00861094|DRUG|5-FU|
218836824|NCT02912494|DRUG|Darbepoetin alfa|
218836825|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
218836826|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
218836827|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
218836828|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
218836829|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
219445182|NCT00861094|DRUG|oxaliplatin|
219445183|NCT00861094|RADIATION|radiation therapy|
219445184|NCT00861094|DRUG|Folinic Acid|
219445185|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
219445186|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
219445187|NCT06454162|OTHER|Modified Ketogenic Diet|the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
219445188|NCT06454162|OTHER|exercise program|the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
219445189|NCT01339780|RADIATION|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
219445190|NCT02262676|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
219445191|NCT02139267|BIOLOGICAL|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
219445192|NCT02393222|OTHER|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
219445193|NCT00053222|DRUG|arsenic trioxide|
219445194|NCT03587922|DEVICE|Fantom|Treatment of den ovo coronary lesions
219445195|NCT02637804|DEVICE|stenfilcon A|contact lens
219445196|NCT02637804|DEVICE|narafilcon A|contact lens
219445197|NCT02637804|DEVICE|delefilcon A|contact lens
219445198|NCT03708757|OTHER|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
219445199|NCT03708757|OTHER|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
219445200|NCT06115057|DIETARY_SUPPLEMENT|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
219445201|NCT06101316|DRUG|CB06-036|CB06-036 Capsule
219445202|NCT01468038|DRUG|Trazodone|active trazodone and sentra pm-like placebo
219445203|NCT01468038|OTHER|Sentra PM|Active Sentra PM and trazodone-like placebo
219445204|NCT01468038|DRUG|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
219445205|NCT01468038|DRUG|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
219584594|NCT03359577|DIETARY_SUPPLEMENT|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
219584595|NCT05393505|DRUG|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
219584596|NCT05393505|DRUG|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
218836830|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
218836831|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
219584597|NCT05393505|DRUG|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
219765911|NCT07210463|DRUG|NT 201|Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
219765912|NCT07210463|DRUG|NT 201 Placebo|NT 201 matching-placebo.
219765913|NCT07211061|DRUG|Stannous Fluoride Dentifrice|brush 2x a day in using a power brush (2 minutes of brushing)
219445206|NCT04841850|OTHER|Clinical and biological characteristics|"* Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose"
218836832|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
218836833|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
218836834|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
218836835|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
218836836|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
218836837|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
218836838|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
218836839|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
218836840|NCT01995526|DRUG|Insulin Peglispro|
219584598|NCT05393505|DRUG|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
219584599|NCT01674647|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
219584600|NCT01674647|DRUG|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
219765914|NCT07211061|DRUG|Sodium Fluoride Dentifrice|brush in their customary manner
219765915|NCT07211061|DEVICE|electric toothbrush|brush using a electric brush (2 minutes of brushing)
219765916|NCT07211061|DRUG|Cetylpyridinium Chloride (CPC)|use 20 ml of mouth rinse for 30 seconds
219765917|NCT07211061|DEVICE|manual toothbrush|brush in their customary manner
219765918|NCT07208786|DEVICE|PEVT|"PEVT Procedures~After the anastomosis is completed and endoscopy confirms that the anastomotic site is intact and without bleeding, the following procedures are carried out immediately (usually within 30 minutes after the completion of the anastomosis):~1. EVT device selection: Use an open-pore polyurethane sponge (OPPS) connected to a 16Fr nasogastric tube, with the sponge cut to a size of 2 cm × 3 cm.~2. Placement method: Insert the sponge through the anus to the anastomotic site in the intestinal lumen, set the negative pressure to low intensity (-50 to -100 mmHg), and connect to an external negative pressure suction device for continuous suction."
219765919|NCT07211334|PROCEDURE|Exercise Training|Adapted High Intensity Interval Training (HIIT), Moderate-Intensity Continuous training (MICT), therapeutic education workshops to help people become independent regarding their program
218836841|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
218836842|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
219445207|NCT02680106|DEVICE|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
219445208|NCT02680106|DEVICE|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
219765920|NCT07210580|BEHAVIORAL|MBC-IBD Intervention|Measurement Based Care for Inflammatory Bowel Disease - Intervention group. Veteran participants who are randomized to 12-months of MBC-IBD will be enrolled for 12 months. They will each complete surveys at baseline, 6-months, and 12-months post-randomization. After baseline completion, participants will be asked to complete weekly surveys. These assessments require completion of self-report questionnaires (PROs) which will be completed by phone or electronically using VA REDCap. MBC in IBD will not replace but rather provide care continuity between clinic visits. Patients allocated to MBC in IBD will receive automated reminders to complete weekly questionnaires. Further, patients will receive quarterly reports of their PRO data trends.
219765921|NCT07210580|OTHER|Enhanced Treatment as Usual (E-TAU)|E-TAU will receive standard of care, including monitoring and treatment as directed at the discretion of their gastroenterologist. Participants will also receive educational videos and fact sheets on various IBD-specific topics.
219765922|NCT07207967|OTHER|END INSPIRATORY PAUSE DURING CONTROLLED VENTILATION|PATIENTS WILL BE VENTILATED WITH END-INSPIRATORY PAUSE AND HIGH INSPIRATORY FLOW DURING CONTROLED VENTILATION
219765923|NCT07207967|OTHER|NO PAUSE VENTILATION|PATIENTS WILL BE VENTILATED IN VOLUME CONTROLLED VENTILATION WITHOUT END-INSPIRATORY PAUSE
219765924|NCT07207889|DRUG|morphine chlorhydrate in intrasite gel|The use of Morphine gel to treat painfull perineal radiodermatitis is new. None clinical study was conducted to explore the efficacy of the morphine gel as local analgesic for these cutaneous toxicity due to radiotherapy
218836843|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
218836844|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
218836845|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
219445209|NCT01789749|OTHER|Snare Tip Soft Coagulation|
219445210|NCT01789749|OTHER|No Snare Tip Soft Coagulation|
219445211|NCT00669513|BEHAVIORAL|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
219445212|NCT01553721|DRUG|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
219445213|NCT01553721|DRUG|placebo|Phase IIa - placebo Phase IIb - placebo
219445214|NCT03013959|DRUG|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
219445215|NCT01562678|DRUG|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
219445216|NCT01562678|DRUG|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
219445217|NCT06508398|DIAGNOSTIC_TEST|Microbiological Diagnostic Testing|"This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs."
219445218|NCT00320294|DRUG|irinotecan|
219445219|NCT00320294|DRUG|cisplatin|
219445220|NCT03681834|OTHER|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
219445221|NCT06453863|OTHER|Greater plantar feedback shoes|Shoes providing enhanced plantar feedback
219445222|NCT06453863|OTHER|Neutral gym shoes|Regular gym shoes
219445223|NCT06453863|OTHER|Barefoot|For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
219445224|NCT01526317|DRUG|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
219765925|NCT07207434|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
219765926|NCT07207434|DRUG|VE818|VE818 is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women.
218836846|NCT02755662|DEVICE|Mandibular Retention Device|
218836847|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
219445225|NCT00910013|DRUG|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
219445226|NCT01352013|DIETARY_SUPPLEMENT|Omega-3 (oil)|5ml daily with breakfast for 56 days.
219445227|NCT01352013|DIETARY_SUPPLEMENT|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
219445228|NCT02288442|OTHER|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
219445229|NCT05757024|DEVICE|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
219445230|NCT00303576|DRUG|dapivirine (TMC120) vaginal gel|
219445231|NCT04460365|DIETARY_SUPPLEMENT|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
219584601|NCT06863545|DRUG|PCSK9 inhibitors and background lipid-modifying therapy|Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.
219445232|NCT04460365|OTHER|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
219445233|NCT04892680|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
218836848|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
219445234|NCT00321360|DRUG|Propofol|
219445235|NCT00321360|DEVICE|Patient maintained sedation|
219445236|NCT01374191|DRUG|onabotulinum toxin type-A|1 injection of Btx-A
219445237|NCT01374191|OTHER|placebo|1 injection of saline solution
219445238|NCT01374191|DRUG|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
219445239|NCT04021576|OTHER|preventative training program|complementary training of leg-, hip- and core-strength/stability
219445240|NCT03647748|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
219445241|NCT01637857|DIETARY_SUPPLEMENT|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
219445242|NCT01637857|DIETARY_SUPPLEMENT|oligoantigenic diet|oligoantigenic diet associated to life style counseling
218836849|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
218836850|NCT02082444|OTHER|Skipping lunch|
218836851|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
219445243|NCT05461157|DEVICE|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
219445244|NCT05461157|OTHER|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
219584602|NCT06863545|DRUG|Placebo plus background lipid-modifying therapy|Patients will receive subcutaneous injections of placebo and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with placebo administered every 2 weeks. After the first 12 months, patients will discontinue the placebo but continue background LMT for the remainder of the trial.
219584603|NCT05755152|OTHER|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
219584604|NCT05755152|OTHER|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
218836852|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
218836853|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
218836854|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
218836855|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
218836856|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
218836857|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
218836858|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
219584605|NCT04917718|DRUG|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
219584606|NCT02487381|DRUG|delta-9-tetrahydrocannabinol|
219584607|NCT02487381|DRUG|Cannabidiol|
219584608|NCT02487381|DRUG|Placebo|
219584609|NCT00944749|DRUG|h-ATG (ATGAM )|
219584610|NCT00944749|DRUG|Cyclosporine (Gengraf )|
219584611|NCT00004890|BIOLOGICAL|aldesleukin|
219584612|NCT00004890|DRUG|Biomed 101|
219584613|NCT06412237|DEVICE|RELab tenoexo|The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.
219584614|NCT01613950|DRUG|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
219584615|NCT01613950|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
218836859|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
218836860|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
218836861|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
218836862|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
218836863|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
218836864|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
218836865|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
218836866|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
218836867|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
218836868|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
219584616|NCT03052413|DIETARY_SUPPLEMENT|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
219584617|NCT03052413|DIETARY_SUPPLEMENT|placebo|Eligible subjects will receive Placebo to take daily for 180 days
219584618|NCT03996161|OTHER|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
219584619|NCT03512951|OTHER|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
218836869|NCT05689918|OTHER|No intervention|No intervention
219584620|NCT03489161|DRUG|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
219584621|NCT01264159|DEVICE|Lung impedence-guided therapy|
219584622|NCT01264159|OTHER|Usual treatment of patients with developing acute heart failure|
219584623|NCT02083237|BEHAVIORAL|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
219445245|NCT05944029|DIETARY_SUPPLEMENT|Pomegranate seed powder|10 g powder / day
219445246|NCT05783492|DRUG|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
219445247|NCT00422240|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
219445248|NCT00422240|DRUG|Adapalene Gel, 0.1%|0.1% of adapalene gel topically daily in the evening for 12 Weeks.
219445249|NCT00422240|DRUG|Benzoyl Peroxide Gel 2.5%|2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
219445250|NCT00422240|DRUG|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
219445251|NCT00287846|DRUG|imatinib mesylate|
219445252|NCT02341404|DRUG|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
219445253|NCT00625040|OTHER|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
219584624|NCT02852642|OTHER|Exercise|Plyometric training
219584625|NCT00005965|DRUG|bryostatin 1|
219584626|NCT00005965|DRUG|cisplatin|
219584627|NCT04156620|DRUG|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
219584628|NCT04156620|DRUG|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
218836870|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
219445254|NCT05896410|DEVICE|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
219445255|NCT05950555|OTHER|Saline|We used 0.9% isotonic sodium chloride.
219445256|NCT05950555|OTHER|Dexmedetomidine|We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
219445257|NCT05950555|OTHER|Ketamine|We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
219445258|NCT05328414|DRUG|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
219445259|NCT04437810|BIOLOGICAL|Albumin|\- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
219445260|NCT04437810|OTHER|Standard Medical Treatment|standard medical therapy
219445261|NCT04822441|OTHER|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
219584629|NCT05444322|DRUG|RD14-01 cell infusion|Autologous CAR T cells
219584630|NCT00456430|DRUG|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
219584631|NCT00560430|DRUG|telmisartan|80 mg per day, orally, weeks 1-14
219584632|NCT00560430|DRUG|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
219584633|NCT00560430|DRUG|placebo|placebo; orally weeks 1-14
219584634|NCT03961022|DIETARY_SUPPLEMENT|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
219584635|NCT00395174|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
219445262|NCT02957110|BEHAVIORAL|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
219584636|NCT03817801|DEVICE|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
218836871|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
219584637|NCT03817801|DEVICE|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
219584638|NCT04751292|OTHER|Exposure to high altitude|permanence at high (\>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
219584639|NCT02872363|OTHER|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
219445263|NCT04836923|BEHAVIORAL|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
219445264|NCT04836923|BEHAVIORAL|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
219584640|NCT02872363|OTHER|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
219584641|NCT03570086|DIAGNOSTIC_TEST|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
218836872|NCT00004215|BIOLOGICAL|filgrastim|
218836873|NCT00004215|BIOLOGICAL|leridistim|
219765927|NCT07207434|DRUG|Placebo|Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)
219765928|NCT07209280|OTHER|Cannulated Bone Bolt® Screw System|Patients treated with the Cannulated Bone Bolt® screw system for Lateral Compression Type -1 (LC-1) fractures.
219445265|NCT04771481|DRUG|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
219584642|NCT05077371|BEHAVIORAL|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
219584643|NCT00677079|DRUG|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
219584644|NCT06167590|DIAGNOSTIC_TEST|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
218836874|NCT00004215|DRUG|cytarabine|
218836875|NCT00004215|DRUG|daunorubicin hydrochloride|
218836876|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
219584645|NCT05056610|OTHER|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
219584646|NCT04274023|DRUG|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
219584647|NCT00862238|BEHAVIORAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
218836877|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
218836878|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
218836879|NCT05432596|DRUG|Vehicle|Vehicle topical solution
218836880|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
218836881|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
218836882|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
219765929|NCT07209280|OTHER|Standard Cannulated Screw System|Patients treated with the Standard Cannulated Screw System for Lateral Compression Type -1 (LC-1) fractures.
219445266|NCT04771481|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
219445267|NCT00159614|DRUG|KW-3902IV|
219445268|NCT00441012|BIOLOGICAL|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
219445269|NCT00441012|BIOLOGICAL|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
218836883|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
219445270|NCT05768893|DEVICE|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
219445271|NCT05768893|DEVICE|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
219445272|NCT04831593|OTHER|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
218836884|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
218836885|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
218836886|NCT00005987|DRUG|carmustine|
219445273|NCT04831593|OTHER|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
219445274|NCT00196807|BEHAVIORAL|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
219445275|NCT03627000|OTHER|failure after reimplantation|description of cinical and microbiological failure
219445276|NCT00887068|DRUG|Azacitidine|32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
219445277|NCT05310760|DRUG|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
219445278|NCT04333992|DRUG|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
218836887|NCT00005987|DRUG|cyclophosphamide|
218836888|NCT00005987|DRUG|dexamethasone|
218836889|NCT00005987|DRUG|etoposide|
218836890|NCT00005987|DRUG|filgrastim|
218836891|NCT00005987|DRUG|mitoxantrone hydrochloride|
218836892|NCT00005987|DRUG|recombinant interferon alfa|
218836893|NCT00005987|DRUG|sargramostim|
218836894|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
218836895|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
218836896|NCT00005987|PROCEDURE|radiation therapy|
218836897|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
218836898|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
218836899|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
219196451|NCT06953635|PROCEDURE|Quadratus Lumborum (QL) Block|"The intervention arm will receive bilateral quadratus lumborum blocks in the preoperative holding area prior to surgery. The syringe will contain a total of 60 mL of 0.25% Ropivacaine with 4 mg of Decadron. The anesthesiology pain team provider will administer 30 mL on the left side and 30 mL on the right side of the abdominal wall. The patient will receive one injection site per flank. During the procedure, the patient is placed in the left and then right lateral decubitus position and the ultrasound probe is placed above the iliac crest at the mid axillary line. The pain team provider will move the probe posteriorly to identify the shamrock sign. Under ultrasound guidance, a needle is inserted in an in- plane approach through the quadratus lumborum (QL) muscle until reaching the middle of the thoracolumbar fascia layer between QL and psoas muscle. After negative aspiration for blood, injection will allow the spread of local anesthetic between the QL and psoas muscle on each side."
219445279|NCT04333992|DRUG|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
218836900|NCT02160249|OTHER|Facility based care|
219445280|NCT02090673|DRUG|Exenatide|
218836901|NCT02229825|DRUG|Duloxetine|Capsule
218836902|NCT02229825|DRUG|Placebo|Capsule
218836903|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
218836904|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
219584648|NCT00862238|OTHER|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, \& C
219584649|NCT00309764|BEHAVIORAL|Telemedicine|
219584650|NCT00626314|BIOLOGICAL|myoblast|autologous myoblast
219584651|NCT00626314|BIOLOGICAL|sham|sham injection procedure
219765930|NCT07208721|BEHAVIORAL|The Key to Emotional Balance|"The Key to Emotional Balance (KBA) program consists of eight sessions, each lasting 40-50 minutes, and aims to help participants develop emotional balance. The first session introduces the individual, introduces group rules, provides information about the program, and supports the client in identifying and expressing their emotions. The second session encourages the client to assess their energy-time intensity in their current and future balance models and, if deviations occur, to restructure them. The third session will help participants recognize their abilities in coping with bipolar illness and its symptoms and to use these abilities effectively. They will also be encouraged to identify factors that hinder their ability to use their abilities and focus on their developed abilities. The fourth session will focus on developing a positive perspective, enabling them to approach bipolar illness and its symptoms from a positive perspective. The fifth session will support participants"
219765931|NCT07208019|OTHER|Acupuncture|Electroacupuncture group: After local routine disinfection.Select the main acupoints of bilateral frontoparietal line (MS2), Tianzhu (BL10), Fengchi (GB20), blood supply, parietal midline (MS5), and parietal midline (MS8). Connect the wires of the electroacupuncture instrument to the same side of the bilateral frontoparietal line(MS2) and Tianzhu acupoint (BL10), and perform head electroacupuncture treatment on both sides with a pair on each side.There are two groups of electroacupuncture, with a continuous frequency of 100Hz, and each electroacupuncture stimulation lasts for 30 minutes. After enrollment, treatment will be conducted 5 times a week for 8 weeks.
219445281|NCT01503892|DIETARY_SUPPLEMENT|Metanx|Metanx- one tablet twice daily for twelve months
219584652|NCT05032313|DIAGNOSTIC_TEST|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
219196452|NCT06953635|PROCEDURE|Placebo|"The placebo control group will receive the same quadratus lumborum (QL) block procedure as the intervention group, with the only difference being the injection of 60 mL of saline instead of local anesthetic. The anesthesiology team will administer 30 mL on each side of the abdominal wall, with one injection site per flank. The patient will be positioned in the left and right lateral decubitus positions, and the ultrasound probe will be placed above the iliac crest at the mid-axillary line to identify the shamrock sign. The needle will be inserted through the QL muscle to the thoracolumbar fascia layer, between the QL and psoas muscle. After negative aspiration for blood, saline will be injected, allowing spread between the QL and psoas muscle on each side."
219445282|NCT01503892|DRUG|Placebo|Placebo- one tablet twice daily for twelve months.
219445283|NCT03190967|DRUG|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
219445284|NCT03190967|DRUG|TMZ|Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
219445285|NCT04681365|OTHER|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
219445286|NCT01456520|DRUG|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
219445287|NCT01456520|DRUG|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
219445288|NCT04104841|BEHAVIORAL|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
219445289|NCT04104841|BEHAVIORAL|Usual Care|Referral to school mental health provider, social worker, or community care.
219445290|NCT00997555|PROCEDURE|bronchoscopy|Scheduled bronchoscopy.
219445291|NCT03021590|DRUG|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
219445292|NCT03021590|DRUG|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
219445293|NCT04739241|DRUG|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
219445294|NCT04739241|DRUG|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
219445295|NCT01188811|DRUG|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
219584653|NCT05161806|DRUG|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
219584654|NCT05161806|DEVICE|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
219584655|NCT00238875|PROCEDURE|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
219584656|NCT05957419|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
219584657|NCT01753336|BIOLOGICAL|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
219765932|NCT07208019|OTHER|Acupuncture|Sham electroacupuncture group: After local routine disinfection. Choose the same acupoints as the electroacupuncture group, but use a specially designed electroacupuncture instrument that cannot output current, with only indicator lights or parameter displays when in use.
219196453|NCT06952738|OTHER|Not applicable- observational study|The investigators are only looking to see the rate of positivity of the cultures as well as what the organisms that are found in the cultures are.
219584658|NCT03721536|DIAGNOSTIC_TEST|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
218836905|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
219584659|NCT03721536|DIAGNOSTIC_TEST|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
219584660|NCT03195036|BEHAVIORAL|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
218836906|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
218836907|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
218836908|NCT00104416|DRUG|Placebo|Placebo control
219196454|NCT06965231|DRUG|Toripalimab combined with Endostar|"1. Neoadjuvant Phase: 2 doses of toripalimab (240 mg IV, Q2W) before surgery.~2. Surgery: Tumor resection within 2 weeks after the last neoadjuvant dose.~3. Adjuvant Phase: 1) Toripalimab: 240 mg IV every 2 weeks (up to 11 cycles); 2) Endostar: 210 mg (72-hour continuous IV infusion) every 4 weeks (up to 6 cycles)."
218836909|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
218836910|NCT03637361|DRUG|Placebo|
218836911|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
218836912|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
218836913|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
218836914|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
218836915|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
218836916|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
218836917|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
218836918|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
218836919|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
219196455|NCT03610789|DEVICE|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
219196456|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
219765933|NCT07207512|BEHAVIORAL|Emotion-Focused Therapy for Grief|"The EFT intervention will follow the model described in EFT for grief. Its main goal is to transform core emotional pain (e.g., chronic shame) by activating change-inducing emotions (e.g., assertive anger), a process described as changing emotion with emotion. This work takes place within a safe and supportive therapeutic relationship, characterized by the therapist's empathic, accepting, and compassionate stance. Therapists remain attuned to emotional markers (e.g., self-criticism, unfinished business) that signal opportunities for targeted work on specific affective problems, which are usually addressed through experiential tasks such as the Empty-Chair for Unfinished Business. Although EFT is transdiagnostic, grief work has certain distinctive features, such as the central role of experiencing grief-related sadness and fostering a sense of connection with the deceased."
219584661|NCT01501136|OTHER|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
219765934|NCT07207512|BEHAVIORAL|Self-help intervention based on EFT|The self-help intervention consists of 10 written exercises designed to address different aspects of grief. These include psychoeducation, emotional regulation, focusing on bodily awareness, softening self-criticism, reducing avoidance, managing anxiety and fear, clarifying confusing emotional reactions, processing trauma, imaginal dialogues with the deceased, and cultivating compassion.
219584662|NCT01501136|OTHER|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
219584663|NCT01501136|OTHER|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
219584664|NCT01501136|OTHER|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
219584665|NCT01501136|RADIATION|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
219584666|NCT03025490|DEVICE|Capnographic monitoring|Capnographic monitoring is used during the sedation.
219765935|NCT07207538|OTHER|Other: Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
219765936|NCT07207538|OTHER|Other: Normal life|Description: Normal life and carry out all the activities they have been doing previously.
219765937|NCT07208526|DRUG|GOLP regimen|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
219765938|NCT07208526|PROCEDURE|Surgery|R0 resection
219016789|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
219584667|NCT04019184|DRUG|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
219584668|NCT04019184|DRUG|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
219196457|NCT04866940|OTHER|Sequences test|the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols
219584669|NCT03896984|DRUG|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
219584670|NCT03896984|DRUG|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
219584671|NCT03896984|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
219584672|NCT05884879|BEHAVIORAL|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
219765939|NCT07208526|DIAGNOSTIC_TEST|TDTP-RECIST|Treatment selection between continued GOLP therapy and surgical R0 resection based on TDTP-RECIST criteria.
219765940|NCT07207629|DIAGNOSTIC_TEST|Transthoracic Echocardiography measurements|TTE will be performed before, just after and 15 minutes after a blood donation, with measurement of aortic VTI, E wave, e' wave, A wave and left ventricle global longitudinal strain
219445296|NCT01188811|DRUG|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
219584673|NCT05901259|DEVICE|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
219584674|NCT00914459|BIOLOGICAL|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
219445297|NCT03893851|BEHAVIORAL|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
219584675|NCT00914459|PROCEDURE|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
219584676|NCT02103270|DRUG|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
219584677|NCT02103270|DRUG|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
219584678|NCT02103270|DRUG|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
219584679|NCT00453778|DRUG|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
219584680|NCT03722355|RADIATION|Conventional RT|Radiation therapy
219584681|NCT03722355|RADIATION|Hyperfractionated RT|Radiation therapy
219584682|NCT03722355|DRUG|Carmustine|Chemotherapy
219584683|NCT04219683|PROCEDURE|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
219584684|NCT03605654|BIOLOGICAL|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
219584685|NCT03605654|DRUG|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
219445298|NCT06059833|DIAGNOSTIC_TEST|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
219445299|NCT03418220|OTHER|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
219445300|NCT01378845|DRUG|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
219445301|NCT01378845|DRUG|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
219445302|NCT05944445|DRUG|Linezolid 600 mg|Linezolid 600mg injection
219445303|NCT04426292|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
219584686|NCT03175289|OTHER|Best Practice|Undergo therapy session conducted by a speech pathologist
219584687|NCT03175289|OTHER|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
219584688|NCT03175289|OTHER|Exercise Intervention|Perform prescribed home exercises
219584689|NCT03175289|OTHER|Expiratory Muscle Strength Training|Participate in EMST
219584690|NCT03175289|OTHER|Quality-of-Life Assessment|Ancillary studies
219584691|NCT03175289|OTHER|Questionnaire Administration|Ancillary studies
219584692|NCT05210244|DIETARY_SUPPLEMENT|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
219584693|NCT05210244|DIETARY_SUPPLEMENT|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
219584694|NCT01661179|DRUG|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
219584695|NCT01946191|BEHAVIORAL|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
219584696|NCT01946191|BEHAVIORAL|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
219584697|NCT01946191|BEHAVIORAL|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
219584698|NCT01629966|DRUG|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
219584699|NCT01629966|DRUG|Vilazodone|Vilazodone, 20mg, oral administration once per day.
219584700|NCT01629966|DRUG|Vilazodone|Vilazodone, 40mg, oral administration once per day.
219584701|NCT00204165|PROCEDURE|MRI of the small bowel|
219196458|NCT06424587|BEHAVIORAL|Music intervention|: In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
219445304|NCT03199131|PROCEDURE|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
219445305|NCT01602744|OTHER|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
219196459|NCT01659606|BIOLOGICAL|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
219445306|NCT02766972|PROCEDURE|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
219445307|NCT02891772|PROCEDURE|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
219445308|NCT03299452|DRUG|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
219445309|NCT03299452|DRUG|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
219445310|NCT03299452|DRUG|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
219445311|NCT00085358|DRUG|carboplatin|Given intraperitoneally
219445312|NCT00085358|DRUG|paclitaxel|Given IV or intraperitoneally
219445313|NCT00085358|DRUG|docetaxel|Given IV
219445314|NCT00085358|BIOLOGICAL|bevacizumab|Given IV
218836920|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
218836921|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
218836922|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
219196460|NCT01659606|DRUG|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
219196461|NCT01659606|DRUG|Cyclosporins|
219196462|NCT01659606|DRUG|Mycophenolate mofetil|
219445315|NCT04129190|BIOLOGICAL|Glucose|Oral Intake of Glucose
219445316|NCT05455840|DEVICE|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
219445317|NCT04019236|OTHER|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
219584702|NCT03936673|PROCEDURE|Percutaneous nephrostomy|
219584703|NCT03344926|BEHAVIORAL|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life"
219584704|NCT03138226|PROCEDURE|uterus transplantation|
219584705|NCT02107326|DEVICE|Webdia Software|
219584706|NCT01019473|DRUG|AFQ056|
219584707|NCT01019473|DRUG|Placebo|
219584708|NCT00173537|PROCEDURE|for BMPR II study|
219584709|NCT00173537|GENETIC|BMPRII|
219584710|NCT02010788|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
219584711|NCT04866277|OTHER|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
219584712|NCT04395651|DEVICE|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
219584713|NCT05726760|BEHAVIORAL|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
219445318|NCT03148184|DIAGNOSTIC_TEST|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
219584714|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
219445319|NCT05319223|BEHAVIORAL|patient blood management|three pillars of patient blood management will be applied
219445320|NCT02363855|DRUG|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
219445321|NCT03348813|BEHAVIORAL|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
219445322|NCT03348813|BEHAVIORAL|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
219445323|NCT01159821|DRUG|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
219445324|NCT00940849|DIETARY_SUPPLEMENT|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
219445325|NCT00940849|DIETARY_SUPPLEMENT|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
219445326|NCT04459442|PROCEDURE|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
219445327|NCT03966352|OTHER|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
219445328|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
219445329|NCT00003000|DRUG|fentanyl citrate|
219445330|NCT00003000|DRUG|morphine sulfate|
219445331|NCT03491280|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
219445332|NCT03625960|DRUG|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
219445333|NCT03625960|DRUG|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
219584715|NCT05726760|DEVICE|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
219584716|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
219584717|NCT06231394|OTHER|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
219584718|NCT02811263|DRUG|Normal saline placebo|Equal volume of normal saline to be used as placebo
219584719|NCT02811263|DRUG|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
219016790|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
219196463|NCT01659606|DRUG|Tacrolimus|
219445334|NCT01751360|DRUG|SYR-472|
219445335|NCT03418376|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
219445336|NCT03418376|OTHER|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
219584720|NCT04269564|DEVICE|stepwise PEEP|"* a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
219584721|NCT04840966|DIAGNOSTIC_TEST|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
219584722|NCT04840966|OTHER|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
219584723|NCT00000660|DRUG|Etoposide|
219445337|NCT03028467|DRUG|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
219445338|NCT03028467|DRUG|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
219445339|NCT03028467|DRUG|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
219584724|NCT02833766|DRUG|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
219584725|NCT04979273|DRUG|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
219584726|NCT04979273|DRUG|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
219584727|NCT04979273|PROCEDURE|argon plasma coagulation|Thermocoagulation
219584728|NCT04979273|PROCEDURE|Hemoclip|Hemoclip
219584729|NCT03947424|DEVICE|LP Er:YAG|LP Er:YAG applied to oral mucosa
218836923|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
218836924|NCT01309997|DRUG|imatinib mesylate|Given PO
218836925|NCT01309997|BIOLOGICAL|rituximab|Given IV
218836926|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
218836927|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
218836928|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
218836929|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
218836930|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
218836931|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
219016791|NCT04557956|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219445340|NCT03028467|DRUG|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
219584730|NCT03947424|DEVICE|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
219584731|NCT03947424|DEVICE|sham|Er:YAG laser applied to oral mucosa with no energy
219584732|NCT04979286|OTHER|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
219584733|NCT04979286|OTHER|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
219584734|NCT02567318|DEVICE|MRI-scan|Magnetic resonance imaging scan of the brain
219584735|NCT01046266|DRUG|RO5083945|700mg iv weekly
219584736|NCT01046266|DRUG|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
219584737|NCT01142479|DRUG|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
218836932|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
219584738|NCT02240342|DRUG|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
219445341|NCT03028467|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
219445342|NCT03028467|DRUG|Folic acid|Folic acid tablet 5 mg per week is given orally.
219445343|NCT03975517|BEHAVIORAL|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
219445344|NCT00031135|DRUG|Choline Chloride|
219445345|NCT00281567|DRUG|Tiotropium|
219445346|NCT00281567|DEVICE|Respimat SMI|
219445347|NCT00281567|DEVICE|HandiHaler|
219584739|NCT00819975|DIETARY_SUPPLEMENT|Casein|
219584740|NCT00819975|DIETARY_SUPPLEMENT|Whey Isolate|
218836933|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
218836934|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
218836935|NCT00243945|DRUG|Rotigotine|
219016792|NCT04557956|PROCEDURE|Computed Tomography|Undergo CT scan
219016793|NCT04557956|DRUG|Dabrafenib Mesylate|Given PO
219445348|NCT03422055|DRUG|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
219445349|NCT05889169|OTHER|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
219445350|NCT03506113|DRUG|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
219445351|NCT03506113|DRUG|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
219445352|NCT00020449|BIOLOGICAL|recombinant interleukin-12|
219445353|NCT00020449|DRUG|paclitaxel|
219445354|NCT00020449|DRUG|pegylated liposomal doxorubicin hydrochloride|
219445355|NCT00002394|DRUG|Terbinafine hydrochloride|
219445356|NCT01905904|DRUG|sevorane|Sevorane 4% Sevorane 7%
219445357|NCT01387594|PROCEDURE|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
219445358|NCT01387594|DRUG|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
219445359|NCT03959345|DRUG|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
219445360|NCT03959345|DRUG|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
219445361|NCT04996524|DRUG|epidural analgesia|Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
219445362|NCT04350372|DEVICE|MitraClip Procedure|MitraClip procedure with MitraClip NT System
219445363|NCT01886352|DRUG|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
219445364|NCT01886352|DRUG|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
219584741|NCT00819975|DIETARY_SUPPLEMENT|Whey Hydrolysate|
219584742|NCT00819975|DIETARY_SUPPLEMENT|Alphalact-Albumin|
219584743|NCT04154306|DIETARY_SUPPLEMENT|Red clover|2 weeks of Red clover
219584744|NCT04154306|DIETARY_SUPPLEMENT|Placebo|2 weeks of Placebo
219584745|NCT00317252|DRUG|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
218836936|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
219016794|NCT04557956|PROCEDURE|Echocardiography Test|Undergo ECHO
219016795|NCT04557956|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219016796|NCT04557956|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219016797|NCT04557956|DRUG|Tazemetostat Hydrobromide|Given PO
219016798|NCT04557956|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219445365|NCT01886352|DRUG|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
219445366|NCT06401252|BEHAVIORAL|Mindfulness-based intervention|"• The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting)"
219445367|NCT02845999|BIOLOGICAL|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
219445368|NCT02845999|BIOLOGICAL|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
219445369|NCT02845999|DRUG|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
219445370|NCT02845999|DRUG|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
219445371|NCT02845999|DRUG|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
219445372|NCT03054298|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
219445373|NCT05488925|DRUG|Vitamin E|Evion, 400 mg
219584746|NCT04696107|BEHAVIORAL|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
219584747|NCT02849327|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
218836937|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
219584748|NCT02849327|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219445374|NCT05488925|DRUG|Diclofenac Sodium|Voltral SR100, 100 mg
218836938|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
219016799|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Maintenance Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
219016800|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Withdrawal Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
219196464|NCT06574035|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
219445375|NCT05488925|DRUG|Piroxicam|Feldene, 20 mg
219445376|NCT05488925|DRUG|Tramadol|Tramal, 50 mg
219445377|NCT02702167|DEVICE|High-frequency rTMS|10 Hz active stimulation, once daily
219445378|NCT02702167|DEVICE|Low-frequency rTMS|1 Hz active stimulation, once daily
219445379|NCT02702167|DEVICE|Sham rTMS|Sham stimulation, once daily
219445380|NCT02544204|BIOLOGICAL|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
219445381|NCT02544204|BIOLOGICAL|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
219445382|NCT00411970|DEVICE|20- and 23 gauge vitreoretinal surgery systems|
219445383|NCT03669107|DRUG|Gum|no gum
219445384|NCT06409507|GENETIC|FKBP12 expression|The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
219445385|NCT05627791|DRUG|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
219445386|NCT05627791|DRUG|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
219445387|NCT04929691|DEVICE|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
219445388|NCT04929691|OTHER|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
218836939|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
219445389|NCT00832689|DRUG|Irinotecan and Gemcitabine|
218836940|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
218836941|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
218836942|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
218836943|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
218836944|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
218836945|NCT03462641|DRUG|Placebo|10 cc normal saline
218836946|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
218836947|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
218836948|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
218836949|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
218836950|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
219445390|NCT04363463|OTHER|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
218836951|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
218836952|NCT02402504|OTHER|Control|Non pulse extruded snack
218836953|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
218836954|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
218836955|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
218836956|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
218836957|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
218836958|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
218836959|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
218836960|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
218836961|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
218836962|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
219445391|NCT04534049|OTHER|Intensive Strength Training (IST)|
219445392|NCT04534049|OTHER|Strength Endurance Training (SET)|
219445393|NCT04534049|OTHER|Flexibility Training (FT)|
219445394|NCT00801710|DEVICE|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
219445395|NCT03607149|DRUG|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
218836963|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
219445396|NCT03144089|DEVICE|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
219584749|NCT03801382|DEVICE|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
219584750|NCT03801382|DIAGNOSTIC_TEST|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
219584751|NCT03533127|DRUG|LY01008|LY01008+Carboplatin/Paclitaxel
219445397|NCT03144089|DEVICE|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
219584752|NCT03533127|DRUG|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
219584753|NCT00727727|DRUG|Piribedil|
219584754|NCT06157762|PROCEDURE|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
219765941|NCT07207837|OTHER|Stress Ball Use|The stress ball suppresses most of the nerves and muscles around the wrist and hand, which are directly connected to the brain, and stimulates the nerves and muscles. This mechanism reduces the release of stress hormones and regulates blood pressure by providing relaxation and relaxation (Dinis \& Sousa, 2023; Soltani et al., 2023). Stress ball, which is easy to apply, inexpensive, has no side effects on the patient, and is an effective method in physical and emotional recovery, is an intervention that can be preferred in nursing practices (Gezginci, Iyigun, Kibar, \& Bedir, 2018; Kasar, Erzincanli, \& Akbas, 2020). Stress ball application is effective on pain, anxiety and vital signs in different patient groups (Genç, Korkmaz, \& Akkurt, 2022; Gezginci, Iyigun, Kibar, \& Bedir, 2018; Karatas \& Gezginci, 2023), but no randomised controlled study has been found in which stress ball application was performed in intensive care patients.
219445398|NCT04306302|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
219584755|NCT06157762|PROCEDURE|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
219765942|NCT07208253|DRUG|Bupivacaine + Dexamethasone|20 mg bupivacaine (4 mL of 0.5%) combined with 8 mg dexamethasone, sprayed locally over the mesh and surrounding tissues after placement during laparoscopic TEP hernioplasty.
219584756|NCT04971265|BEHAVIORAL|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
219765943|NCT07209072|BEHAVIORAL|Street medicine follow up|This intervention will use electronic health record builds to automatically send a referral to a street medicine clinic, who will attempt to contact the patient within 2 weeks.
219445399|NCT04306302|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo.
219584757|NCT04971265|BEHAVIORAL|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
219584758|NCT04971265|BEHAVIORAL|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
219584759|NCT04971265|BEHAVIORAL|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
219584760|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
218836964|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
218836965|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
218836966|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
218836967|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
218836968|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
218836969|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
219584761|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
219196465|NCT06574035|BEHAVIORAL|Exercise|Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
219584762|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)|Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
219584763|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)|Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
218836970|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
218836971|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
219584764|NCT06314880|BIOLOGICAL|Placebo control|Placebo control. 20 people/group.
219584765|NCT05174676|DEVICE|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
219584766|NCT00415844|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
219584767|NCT03683368|DEVICE|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
219584768|NCT03683368|DEVICE|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
219584769|NCT04331444|DEVICE|CGM|Using the CGM during the entire study period of 12 months.
219584770|NCT04331444|BEHAVIORAL|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
219584771|NCT04331444|BEHAVIORAL|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
219584772|NCT04884867|BEHAVIORAL|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
219765944|NCT07208630|DEVICE|Instrument-assisted soft tissue mobilization|IASTM will be delivered using stainless-steel instruments with beveled edges, applied to the target muscle groups for approximately 20 minutes per session, two times per week, over four weeks. A licensed physical therapist trained in IASTM will perform the procedure. Lubricant will be applied to the skin, and strokes will be delivered in multiple directions with pressure adapted to patient tolerance.
218836972|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
218836973|NCT05143528|DRUG|Placebo|placebo capsule
218836974|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
218836975|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
218836976|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
218836977|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
218836978|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
218836979|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
219584773|NCT04188301|DRUG|IVM w/ ALB|Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
218836980|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
218836981|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
218836982|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
219584774|NCT04188301|DRUG|Single dose of IDA|Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
219584775|NCT04188301|DRUG|Three daily doses of IDA|Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
219584776|NCT01200264|DRUG|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
219584777|NCT01204450|DRUG|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
219584778|NCT01204450|DRUG|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
219584779|NCT05499013|DRUG|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
219584780|NCT05499013|DRUG|Placebo|sodium chloride, solution for injection
219584781|NCT02642536|BEHAVIORAL|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
219584782|NCT02642536|BEHAVIORAL|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
219584783|NCT00486564|DRUG|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
219584784|NCT03035721|DIETARY_SUPPLEMENT|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
219584785|NCT03035721|DIETARY_SUPPLEMENT|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
219765945|NCT07208630|BEHAVIORAL|Traditional physical therapy|The control group will receive a traditional physical therapy program focusing on strength, balance, flexibility, and functional mobility training, combined with simple cognitive stimulation tasks. Sessions will last 30 minutes, two times per week, for four weeks, supervised by a licensed physical therapist.
219765946|NCT07208422|BEHAVIORAL|Video-based Task-specific Training|Video-based self-administered TST
218836983|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
218836984|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
218836985|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
218836986|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
218836987|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
219584786|NCT04076384|BEHAVIORAL|Guided Self-Determination|Structured team-based consultations
219584787|NCT04076384|BEHAVIORAL|Standard care|Standard consultations
219584788|NCT02511899|DIETARY_SUPPLEMENT|Mango fruit powder|Dietary supplement; Mango fruit powder
219584789|NCT06927024|DEVICE|Active taVNS|Active taVNS delivered via the TENS Device 7000.
219584790|NCT06927024|DEVICE|Sham taVNS|Sham taVNS delivered via the TENS Device 7000.
219584791|NCT01124344|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
219584792|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
219584793|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
219584794|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
219584795|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
219584796|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
219584797|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
219584798|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
219584799|NCT06929052|DEVICE|ADL-018 Autoinjector|Test product (A): ADL-018 Injection 150 mg/mL solution in a single dose pre-filled autoinjector manufactured/supplied by Kashiv BioSciences LLC, USA.
219584800|NCT06929052|DRUG|ADL-018 Injection|Reference Product (B): ADL-018 Injection 150mg/mL solution in a single dose pre-filled syringe manufactured/supplied by Kashiv BioSciences LLC, USA
219584801|NCT01648504|OTHER|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
219584802|NCT06929000|OTHER|the supine head-lateral position group|the supine head-lateral position group: during the perioperative period, keep the patient's head tilted to the left or right
219584803|NCT06929000|OTHER|the adjustable headrest group|the adjustable headrest group: placing an adjustable pillows on the patient's head to align the patient's external auditory canal horizontally with the sternum
219584804|NCT06929000|OTHER|the supine head-straight position group|the supine head-straight position group: during the perioperative period, keep the patient's head upright
219584805|NCT06928129|DIAGNOSTIC_TEST|BinaxNOW™ COVID-19/Flu A&B Combo Self-Test|"Diagnostic Test: BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test~The BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test is a visually read lateral flow in vitro immunoassay for the qualitative detection and differentiation of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B directly in anterior nasal swab specimens from individuals with signs and symptoms of respiratory infection."
219584806|NCT01829087|DRUG|Botox|
219584807|NCT01829087|DRUG|placebo|
218836988|NCT00954564|OTHER|medical chart review|Observational only
218836989|NCT00954564|OTHER|questionnaire administration|Observational only
218836990|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
218836991|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
218836992|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
219584808|NCT04262661|DRUG|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
219584809|NCT04262661|DRUG|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
219584810|NCT04262661|DRUG|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
219765947|NCT07208422|BEHAVIORAL|Manual-based Task-specific Training|Manual-based self-administered TST
219765948|NCT07209059|DRUG|Nivolumab|Monoclonal antibody targeting PD-1; administered in combination regimens
219765949|NCT07209059|OTHER|N-EACOPD-14|14-day regimen. Combination of Nivolumab with Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, and Dacarbazine; given for 2 cycles as initial therapy.
219445400|NCT04808492|DEVICE|CureWave High Intensity Laser|"* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
218836993|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
218836994|NCT06400589|DRUG|tanfanercept|TNF inhibitor
219584811|NCT05460559|PROCEDURE|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
219584812|NCT05460559|PROCEDURE|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
219445401|NCT04808492|OTHER|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
219584813|NCT02288390|PROCEDURE|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
219584814|NCT06726161|DIAGNOSTIC_TEST|RYZ811|Ga-68
219445402|NCT02023541|RADIATION|Proton beam therapy|
219765950|NCT07209059|OTHER|N-AVD|Combination of Nivolumab with Doxorubicin, Vinblastine, and Dacarbazine; used as de-escalated therapy after negative interim PET (2 cycles).
219445403|NCT00802880|DRUG|Dacarbazine|
219445404|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
219445405|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
219445406|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
219584815|NCT06726161|DRUG|RYZ801|Ac-225
219445407|NCT01006213|BEHAVIORAL|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
219584816|NCT05740982|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
219584817|NCT00006721|BIOLOGICAL|rituximab|Given IV
219584818|NCT00006721|DRUG|cyclophosphamide|Given IV
219584819|NCT00006721|DRUG|doxorubicin|Given IV
219584820|NCT00006721|DRUG|prednisone|Given orally
219584821|NCT00006721|DRUG|vincristine|Given IV
219765951|NCT07207824|DRUG|Active Comparator: BCG induction and maintenance|"Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer~Other Names:~BCG"
219584822|NCT00006721|RADIATION|tositumomab|Given IV
219765952|NCT07207824|DRUG|DV + BCG induction and maintenance|"Drug: Disitamab vedotin(RC48) •An antibody-drug conjugates (ADCs) targeting HER2, has been approved in China for chemotherapy-refractory advanced UC with HER2-expression.~Other Names:~• RC48, DV~Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer~Other Names:~BCG"
219765953|NCT07206056|DRUG|Tulmimetostat DL1 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
219765954|NCT07206056|DRUG|Tulmimetostat DL2 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
219765955|NCT07206056|DRUG|Tulmimetostat DL3 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
219765956|NCT07206056|DRUG|Tulmimetostat Doses 1 or 2 QD|"Part 1b (dose expansion and optimization):~tulmimetostat doses 1 or 2 QD"
219765957|NCT07206056|DRUG|Tulmimetostat RP2D QD|"Part 2:~tulmimetostat Recommended Phase 2 Dose (RP2D) QD"
218836995|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
218836996|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
218836997|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
219765958|NCT07206056|DRUG|JSB462 Dose 1 QD|JSB462 Dose 1 QD
219584823|NCT03778060|DEVICE|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
219584824|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
219584825|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
219584826|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
219584827|NCT04578665|BEHAVIORAL|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
219584828|NCT04578665|DEVICE|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0\~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0\~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0\~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
219584829|NCT04578665|BEHAVIORAL|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error \[difference of the desired trajectory and actual trajectory\] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
219584830|NCT04578665|DEVICE|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
219584831|NCT03747601|DEVICE|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
219584832|NCT06099444|DEVICE|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
219584833|NCT06099444|DEVICE|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
219584834|NCT06099444|DEVICE|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
219584835|NCT06099444|DEVICE|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
219584836|NCT04731155|DRUG|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
219765959|NCT07206056|DRUG|JSB462 Dose 2 QD|JSB462 Dose 2 QD
219584837|NCT04731155|DRUG|standard medications|standard medications was giving to subjects according guidelines
219765960|NCT07206056|DRUG|JSB462 QD|The dose of JSB462 QD will be determined based on the totality of data from Part 1a
219765961|NCT07206056|DRUG|Standard of Care (SoC)|Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator
218836998|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
218836999|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
218837000|NCT00392158|DEVICE|Closed-loop anesthesia system|
218837001|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
219445408|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
219445409|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
218837002|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
218837003|NCT00372619|DRUG|clofarabine|Given IV for 5 days
218837004|NCT00372619|DRUG|cytarabine|Given IV
218837005|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
218837006|NCT00372619|OTHER|laboratory biomarker analysis|
218837007|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
218837008|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
218837009|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
218837010|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
219445410|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
219584838|NCT04696029|DRUG|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
219584839|NCT04441619|BEHAVIORAL|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
219584840|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
218837011|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
218837012|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
218837013|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
218837014|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
218837015|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
218837016|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
219016808|NCT06207006|BEHAVIORAL|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
219016809|NCT06207006|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
218837017|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
218837018|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
218837019|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
219584841|NCT03782415|DRUG|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
218837020|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
218837021|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
218837022|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
218837023|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
218837024|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
218837025|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
218837026|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
218837027|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
218837028|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
218837029|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
219016810|NCT02597699|DRUG|Remifentanil + Lidocaïne|
219445411|NCT03182621|BEHAVIORAL|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
219445412|NCT03182621|BEHAVIORAL|SPARK|traditional YMCA program
219016811|NCT02597699|DRUG|Sufentanil + Lidocaïne|
219445413|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
219445414|NCT04480346|BEHAVIORAL|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
219445415|NCT02058251|DRUG|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
219584842|NCT03782415|DRUG|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
219584843|NCT05217459|DEVICE|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
219584844|NCT06541002|BEHAVIORAL|SHIFT Intervention Group|Participants assigned to SHIFT will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and start using SHIFT at their desired pace over 8 weeks to complete five modules.
219445416|NCT02058251|DRUG|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
219445417|NCT06882408|DEVICE|Photorefraction device under investigation|Objective refraction measurement with and without cyclopegia
219445418|NCT06882408|DEVICE|Comparator device, Tabletop auto-refractometer|Objective refraction measurement with and without cyclopegia
219445419|NCT06882408|DEVICE|Comparator device, portable photorefraction device|Objective refraction measurement with and without cyclopegia
218837030|NCT02579421|DRUG|Progesterone|generic progesterone
218837031|NCT02579421|DRUG|placebo|placebo
219584845|NCT06541002|BEHAVIORAL|Enhanced Usual Care Group|Participants assigned to the enhanced usual care group will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and maybe referred to a psychologist, urologist, or gynecologist at the participants' request or at the discretion of the HCT clinician.
218837032|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
218837033|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
218837034|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
218837035|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
219584846|NCT05619146|DEVICE|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
219584847|NCT05949164|BEHAVIORAL|Insomnia|The primary exposure is insomnia
219445420|NCT06882408|OTHER|Distance visual acuity assessments|Distance visual acuity is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
219445421|NCT06882408|OTHER|Subjective refraction and far visual acuity|Subjective refraction is assessed and far visual acuity is assessed with the found refraction measures
219445422|NCT06882408|OTHER|Strabismus assessment|Strabismus is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
219445423|NCT05941676|DIAGNOSTIC_TEST|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
218837036|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
218837037|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
219445424|NCT02737176|OTHER|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
219445425|NCT02882165|OTHER|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
219584848|NCT05874193|DRUG|Belantamab mafodotin|Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first
219584849|NCT05634057|DRUG|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
219584850|NCT03811613|OTHER|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
219584851|NCT05199311|DRUG|Carfilzomib|20 mg/m2 C1D1; 56 mg/m2 thereafter
219584852|NCT05199311|DRUG|Iberdomide|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
218837038|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
219016817|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
218837039|NCT00146016|DRUG|Amantadine|
218837040|NCT03660865|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
218837041|NCT03660865|DEVICE|Control IOL|Fellow eye will receive control IOL
218837042|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
218837043|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
218837044|NCT00235235|PROCEDURE|Biopsy|core biopsy
218837045|NCT00235235|PROCEDURE|Serum Collection|serum collection
218837046|NCT00235235|PROCEDURE|Urine Collection|urine collection
218837047|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
218837048|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
218837049|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
218837050|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
218837051|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
219016822|NCT03755895|OTHER|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
219016823|NCT03755895|DRUG|Kalinox|patients will have brachytherapy detachment under Kalinox
219016825|NCT05100069|DRUG|Brigatinib|Brigatinib Tablets
219445426|NCT04633031|DEVICE|Boston|
219445427|NCT04633031|DEVICE|Cheneau|
219765962|NCT07208097|PROCEDURE|Stereotactic thrombolysis with Tenecteplase|Stereotactic thrombolysis with Tenecteplase for ICH is a minimally invasive method for evacuation hematoma. The hematoma puncture target is identified via CT imaging before surgery. After local anesthesia and sedation, stereotactic minimally invasive surgery is performed with the Leksell stereotactic frame. A postoperative CT scan is immediately conducted to confirm the absence of intracranial rebleeding before administering tenecteplase into the hematoma. Tenecteplase is fully diluted in 2 mL of saline and injected into the hematoma cavity via an irrigation catheter. The drainage tube is clamped for 1 hour before opening (early opening is permitted if necessary). The single dose of TNK is 0.5 mg and can be administered with a maximum of 2 dose in every 24 hours. The target hematoma clearance criteria is: residual hematoma volume ≤10 mL or ≤20% of the initial volume.
218837052|NCT04102800|DRUG|Benralizumab|subcutaneous injection
218837053|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
218837054|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
218837055|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
218837056|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
219016826|NCT00757302|DEVICE|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
219196466|NCT06574035|BEHAVIORAL|Group Discussions - Ongoing Support|Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
219445428|NCT06887803|DRUG|Roginolisib|IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD
219445429|NCT05134597|GENETIC|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
219445430|NCT00796224|DRUG|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
219445431|NCT00796224|DRUG|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
219584853|NCT05199311|DRUG|Oral Dexamethasone|40 mg (\<=75 years old); 20 mg (\>75 years old)
219584854|NCT06242704|BEHAVIORAL|Working Memory Training|A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
219584855|NCT06242704|BEHAVIORAL|Working Memory|A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
219584856|NCT06616896|DEVICE|vibration|Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
219584857|NCT06577532|DRUG|ABO2102|mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
219584858|NCT06577532|DRUG|Toripalimab|Anti-PD-1 antibody, administered intravenously
219584859|NCT05122377|DRUG|3M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
219584860|NCT05122377|DRUG|1M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
219584861|NCT00112866|DRUG|cilengitide|Given IV
219584862|NCT00112866|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection
219584863|NCT00112866|OTHER|pharmacological study|Correlative studies
218837057|NCT02293967|DRUG|MT-1303|
218837058|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
218837059|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
218837060|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
218837061|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
218837062|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
218837063|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
218837064|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
219445432|NCT03953885|OTHER|Fire needle|"1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
219584864|NCT00112866|OTHER|laboratory biomarker analysis|Correlative studies
218837065|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
218837066|NCT01823159|DRUG|placebo|Single oral administration of a tablet
218837067|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
218837068|NCT01555853|DRUG|Abraxane|
218837069|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
218837070|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
218837071|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
218837072|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
218837073|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
218837074|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
218837075|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
218837076|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
218837077|NCT02888691|OTHER|Low carbohydrate diet|
218837078|NCT02888691|OTHER|High carbohydrate diet|
218837079|NCT00000149|DRUG|Beta Blocker|
218837080|NCT00000149|PROCEDURE|Trabeculectomy|
218837081|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
218837082|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
218837083|NCT03037359|BIOLOGICAL|Other|Human immune globulin
218837084|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
218837085|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
218837086|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
218837087|NCT03122678|DRUG|Thiamine|
218837088|NCT03122678|DRUG|Placebos|
218837089|NCT04082845|OTHER|Education|Web-based patient education
218837090|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
218837091|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
218837092|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
218837093|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
218837094|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
218837095|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
219584865|NCT04487938|OTHER|No intervention utilised|No intervention utilised
218837096|NCT01524224|DRUG|LY2495655|administered intravenously
218837097|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
219445433|NCT03953885|OTHER|Fire needle Placebo|"1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
219445434|NCT00661167|DRUG|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
219445435|NCT03940014|OTHER|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
219445436|NCT01285336|GENETIC||
219445437|NCT02232724|DEVICE|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
219584866|NCT00671918|DRUG|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
218837098|NCT02746887|OTHER|Preterm/term cohort|
218837099|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
219584867|NCT02845141|PROCEDURE|Actifuse|bone tunnel filled with Actifuse
219584868|NCT02845141|PROCEDURE|bone graft|bone graft to fill bone tunnel
218837100|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
218837101|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
219584869|NCT03422939|OTHER|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
218837102|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
218837103|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
218837104|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
218837105|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
218837106|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
219445438|NCT06039280|DRUG|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
219445439|NCT06039280|DRUG|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
219445440|NCT06039280|OTHER|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
218837107|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
218837108|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
218837109|NCT05578989|DEVICE|Virtual reality glasses|watching a video with music with virtual reality glasses.
218837110|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
218837111|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
218837112|NCT05416164|RADIATION|Omission of radiotherapy|Omission of radiotherapy
218837113|NCT05976815|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
219445441|NCT05103241|DRUG|[14C] GP681|40 mg suspension containing 100μCi of \[14C\]GP681
219445442|NCT06743620|OTHER|iltamiocel|This is an observational study with no intervention.
218837114|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
218837115|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
218837116|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
218837117|NCT05300477|DRUG|Acetazolamide|Carbonic Anhydrase Inhibitor
219445443|NCT06743165|BEHAVIORAL|Pelvic floor muscle training with ultrasound biofeedback|Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.
219445444|NCT06743165|BEHAVIORAL|Dynamic neuromuscular stabilization exercise|Dynamic neuromuscular exercises (DNS) involve the joint activation of the intrinsic muscle group of the spine, which includes the cervical flexors and extensors, diaphragm, transversus abdominis, multifidus and pelvic floor, which form the integrated spinal stabilization system. The application principles are joint centering, core stabilization - Integrated spinal stabilization system and stabilization function of the diaphragm. DNS training will be applied in three stages. Preparation for exercises, IAB regulation and application of exercises according to developmental kinesiology positions. Exercises will start with preparatory training. In preparatory training, stroking, brushing and tapping techniques will be taught and self-facilitation will be demonstrated in order to increase proprioceptive input to the lower extremity, upper extremity, trunk and pelvic region. Fascial mobilizations will be performed to the foot and hand regions.
219445445|NCT00033111|DRUG|Cabergoline|
219445446|NCT00033111|DRUG|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
219445447|NCT00418899|BEHAVIORAL|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
218837118|NCT05300477|DRUG|Erythropoietin|Hormone for red blood cell
218837119|NCT03078543|DEVICE|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~* Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~* Titanium primary tibial components~* Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~* Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
218837120|NCT05735704|DIAGNOSTIC_TEST|Blood sampling for HemaChip screening/diagnostic testing|"Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA, and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom-targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed."
218837121|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
218837122|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
218837123|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
218837124|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
218837125|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
218837126|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
218837127|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
218837128|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
218837129|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
218837130|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
218837131|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
218837132|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
218837133|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
218837134|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
219445448|NCT05309395|COMBINATION_PRODUCT|FoodRx|Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
218837135|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
218837136|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
218837137|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
218837138|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
218837139|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
219584870|NCT06276049|OTHER|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
218837140|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
218837141|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
218837142|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
218837143|NCT02441907|DRUG|aflibercept|
218837144|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
218837145|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
218837146|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
218837147|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
218837148|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
218837149|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
218837150|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
218837151|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
218837152|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
219445449|NCT06759233|PROCEDURE|endoscopic cryoballoon ablation treatment(ECAT)+PD-1|"ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice.~PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions."
219765963|NCT07209150|DRUG|antibiotic prophylaxis|we will compare varying durations of antibiotic prophylaxis prior to prostate enucleation surgery
219765964|NCT07208760|DRUG|Single dose of 1800 mg L9LS SC (12mL)|A human monoclonal antibody to protect against Plasmodium falciparum.
219765965|NCT07208760|OTHER|Placebo 12 mL SC|Normal saline.
218837153|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
219765966|NCT07208760|DRUG|Single dose of 225 mg L9LS SC (1.5mL)|A human monoclonal antibody to protect against Plasmodium falciparum.
219765967|NCT07208760|OTHER|Placebo 1.5 mL SC|Normal saline.
219765968|NCT07208448|DEVICE|Voll Degradable Shoulder Spacer|Voll Degradable Shoulder Spacer
218837154|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
218837155|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
218837156|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
218837157|NCT01442337|DRUG|ASP8597|one time IV dose
218837158|NCT01442337|DRUG|Placebo|one time IV dose
218837159|NCT01741233|GENETIC|VitDgen|
218837160|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
218837161|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
219765969|NCT07208396|OTHER|Upper cervical mobilization|"All patients in group A will receive Grades I and II mobilizations in the first two sessions to reduce pain. In subsequent sessions, patients will receive Grades III and IV mobilizations; typically will be utilized to stretch the joint capsule and passive tissues, which provide stability to the joint, thereby increasing ROM. Maitland usually performs treatment techniques in an oscillatory manner. These oscillations can be performed with different amplitudes in different positions in the range of movement.~The mobilizations will be delivered in the prone position. The duration of mobilization will be 30-s bouts given for three sets. The therapist places a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand will be placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force will be directed dorsally from the shoulder until the therapist"
218837162|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
218837163|NCT02284256|DRUG|Fibrocaps|
218837164|NCT02284256|DRUG|TachoSil|
218837165|NCT01995500|DEVICE|BioNIR|drug-eluting stent
218837166|NCT01995500|DEVICE|Resolute|drug-eluting stent
218837167|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
218837168|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
218837169|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
218837170|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
218837171|NCT02096250|OTHER|NaFeEDTA|
218837172|NCT02096250|OTHER|Ferrous fumarate|
219765970|NCT07208396|OTHER|Integrated neuromuscular inhibition technique|"An integrated approach to myofascial trigger point release is achieved by combining several manual therapy techniques under the name INIT (Integrated Neuromuscular Inhibition Technique). The technique combines MET and SCS with ischemic compression in one coordinated technique .~First, intermittent compression(IC) was initiated by using the thumb and index finger to apply a pincer grip to the TrP in the middle of the UT.~Second, the strain counter strain (SCS) began by applying pressure to the trigger point . The participants' heads were passively flexed laterally to the affected side. and then asked the patient about pain.~Third, the MET begins with one of the investigator's hands stabilizing the affected shoulder and the other on the head side. The participant was asked to move the stabilized shoulder and head in the direction of the other. This contraction lasted 7 seconds and had a maximum voluntary contraction of 20%. After that, the muscle was lengthened for 30 seconds"
218837173|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
218837174|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
218837175|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
218837176|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
218837177|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
218837178|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
218837179|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
218837180|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
218837181|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
218837182|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
218837183|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
218837184|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
218837185|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
218837186|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
218837187|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
219196467|NCT04980872|DRUG|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
219196468|NCT05285358|DRUG|Cisplatin|Given IV
219445450|NCT04459104|OTHER|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
219584871|NCT05122936|COMBINATION_PRODUCT|XRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
218837188|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
218837189|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
218837190|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
218837191|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
219584872|NCT05673330|OTHER|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
219584873|NCT05673330|OTHER|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
218837192|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
219584874|NCT01167257|DRUG|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
219584875|NCT01167257|DRUG|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
219584876|NCT02512653|BIOLOGICAL|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
218837193|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
219584877|NCT00496353|DRUG|MK2461|MK2461 treatment, bid, 28-day
219584878|NCT04305587|DRUG|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
219584879|NCT04305587|OTHER|Placebo|Placebo once daily for up to 42 days.
218837194|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
219584880|NCT04305587|DRUG|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
218837195|NCT00488020|PROCEDURE|stem cells transplant|
218837196|NCT02728648|DRUG|Oxycodone|Pain Management
218837197|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
218837198|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
219584881|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Intranasal insulin will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
218837199|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
218837200|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
218837201|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
219584882|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Placebo spray will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over ten minutes starting at time point -15 minutes on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
219584883|NCT00045292|DRUG|acyclovir|
219584884|NCT00045292|DRUG|acyclovir sodium|
219584885|NCT00045292|DRUG|valacyclovir|
219584886|NCT05854394|BEHAVIORAL|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
219584887|NCT00182468|OTHER|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
219584888|NCT01367665|DRUG|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
218837202|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
219584889|NCT06006065|BEHAVIORAL|Upper limb somatosensory discrimination therapy|"Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch)."
219765971|NCT07208396|OTHER|Conventional treatment|"1. Hot packs Hot pack will be applied at the beginning of the treatment session for all patients participated in the study. The participants will be in prone lying position. The neck and upper thoracic region will be exposed. The hot pack then will be applied for 10 minutes on cervical and upper thoracic region.~2. Dynamic neck exercise: Dynamic neck exercises include lifting head up with the chin tucked in from supine lying for neck flexion, lifting head backwards in prone lying for neck extension lifting head sideways from pillow in side lying position for neck side flexion which will be also repeated for the other side.~3. Isometric Neck Exercises The exercises will be performed in sitting position, by holding the theraband directly forwards for neck flexion, backwards for neck extension and obliquely towards right and left and by crossing over the band for neck side flexion and rotation. All these will be done for all patients participated in the study for about 5-10 repetition"
219765972|NCT07208617|DEVICE|RED-light device using LED light source|The light source type of red light is LED light source.
218837203|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
218837204|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
218837205|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
218837206|NCT02593903|DRUG|Septra|
218837207|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
218837208|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
219445451|NCT04459104|OTHER|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
219445452|NCT00611988|BEHAVIORAL|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
219445453|NCT00611988|OTHER|Control group|Attention control group will receive routine follow-up phone calls
219445454|NCT03039569|BEHAVIORAL|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
219445455|NCT00002413|DRUG|Emivirine|
219445456|NCT05455255|OTHER|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
219445457|NCT06124092|OTHER|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
219445458|NCT03408886|DRUG|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
219445459|NCT03408886|DRUG|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
219445460|NCT03408886|BIOLOGICAL|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
219445461|NCT00074867|DRUG|CP-547,632|
218837209|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
218837210|NCT03263910|DRUG|NPO-11|20 ml NPO-11
218837211|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
218837212|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
218837213|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
218837214|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
218837215|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
218837216|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
219445462|NCT06031181|PROCEDURE|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
218837217|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
218837218|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
219584890|NCT06006065|BEHAVIORAL|Upper limb motor therapy|Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
219016854|NCT04008030|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219016855|NCT04008030|DRUG|Oxaliplatin|Specified dose on specified days
219445463|NCT02254304|DRUG|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
219445464|NCT02762760|BIOLOGICAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
219445465|NCT02762760|BIOLOGICAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
218837219|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
219584891|NCT01589965|BEHAVIORAL|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
218837220|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
218837221|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
218837222|NCT02269813|OTHER|MammaPrint|
218837223|NCT02269813|OTHER|BluePrint|
218837224|NCT02269813|OTHER|TargetPrint|
218837225|NCT02091362|DRUG|LY2409021|Administered orally
218837226|NCT02091362|DRUG|Placebo|Administered orally
218837227|NCT02091362|DRUG|Metformin|Administered as background therapy.
218837228|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
218837229|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
218837230|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
218837231|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
218837232|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
218837233|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
218837234|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
218837235|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
218837236|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
219016856|NCT04008030|DRUG|Leucovorin|Specified dose on specified days
218837237|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
219016857|NCT04008030|DRUG|Fluorouracil|Specified dose on specified days
219016858|NCT04008030|DRUG|Irinotecan|Specified dose on specified days
219016859|NCT04008030|DRUG|Bevacizumab|Specified dose on specified days
219016860|NCT04008030|DRUG|Cetuximab|Specified dose on specified days
219016861|NCT04008030|BIOLOGICAL|Nivolumab|Specified dose on specified days
219445466|NCT05182541|OTHER|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
219445467|NCT05182541|OTHER|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
219445468|NCT05182541|OTHER|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
219445469|NCT05182541|OTHER|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
218837238|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
219445470|NCT05016440|DRUG|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
218837239|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
218837240|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
218837241|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
218837242|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
218837243|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
218837244|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
218837245|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
218837246|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
219584892|NCT04229459|DRUG|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
219584893|NCT04229459|DRUG|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
219584894|NCT04229459|RADIATION|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
219584895|NCT04229459|DRUG|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
219584896|NCT04229459|DRUG|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
219584897|NCT02752906|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
219584898|NCT02752906|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219584899|NCT00822406|DRUG|homeopathic medicine|individualized homeopathic medicine
219584900|NCT00822406|DRUG|placebo|placebo - 6 months
219584901|NCT03153761|OTHER|CSD170201AA|A moist snuff product
219584902|NCT03153761|OTHER|CSD170201AB|A moist snuff product
219584903|NCT00106067|BEHAVIORAL|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
219584904|NCT00002282|DRUG|Clotrimazole|
219584905|NCT00002282|DRUG|Fluconazole|
219584906|NCT01717716|DIETARY_SUPPLEMENT|water with Sucralose|
219584907|NCT01717716|DIETARY_SUPPLEMENT|water with HFCS|
218837247|NCT04807088|OTHER|Placebo|
218837248|NCT04322331|OTHER|no intervention|no intervention
218837249|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
218837250|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
218837251|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
219445471|NCT06937047|PROCEDURE|cold snare polypectomy|Cold snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
219445472|NCT06937047|PROCEDURE|hot snare polypectomy|Hot snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
219445473|NCT06935630|DIETARY_SUPPLEMENT|Folic Acid|Participants in this group will receive a daily oral dose of 600 mcg (1.35 μmol) of folic acid in film-coated tablet form for a duration of three months. This synthetic form of folate will be administered to assess its impact on red blood cell folate levels compared to 5-MTHF.
219584908|NCT01717716|DIETARY_SUPPLEMENT|water with glucose|
219584909|NCT01717716|DIETARY_SUPPLEMENT|water with sucrose|
219584910|NCT04136457|OTHER|Endurance training|Subjects perform a period of endurance training
219584911|NCT04136457|OTHER|Resistance training|Subjects perform a period of resistance training
219584912|NCT04136457|OTHER|Sprint training|Subjects perform a period of sprint training
219584913|NCT03673657|DIETARY_SUPPLEMENT|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
219584914|NCT03673657|RADIATION|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
219584915|NCT03673657|DRUG|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
219584916|NCT00963781|DEVICE|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
219584917|NCT00963781|DRUG|Reduced duration (6 months) DAPT|
219765973|NCT07208617|DEVICE|Control|Fake light, with a light source power that is one-tenth of that of real LED light
219765974|NCT07211087|BEHAVIORAL|COMBEX|The intervention (COMBEX) is a combined approach to routine psychotherapy (including CBT and medication management) with additional ERIC strategies incorporated.
219765975|NCT07211087|BEHAVIORAL|COMB|COMB is a combined approach to routine psychotherapy (including CBT and medication management).
219765976|NCT07211282|DEVICE|Activity score|4 month follow-up and feedback from a heart rate and personal characteristics based activity score.
219765977|NCT07209033|DEVICE|FlexiOss®|Bone reconstruction with FlexiOss® biocomposite.
219765978|NCT07209033|PROCEDURE|Allogenic human bone grafting|Implantation of allogenic human bone graft.
218837252|NCT04963855|DRUG|GT300|SIngle oral dose
218837253|NCT04963855|DRUG|Microcrystalline cellulose|placebo
219445474|NCT06935630|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|Participants in this group will receive a daily oral dose of 1100 mcg (1.35 μmol) of 5-methyltetrahydrofolate (5-MTHF) glucosamine salt, specifically HY-FOLIC®, in film-coated tablet form for a duration of three months. This active form of folate will be administered to assess its impact on red blood cell folate levels compared to folic acid
219445475|NCT06939608|DIETARY_SUPPLEMENT|Yohimbine|A single oral dose of 50 µg yohimbine, administered as 2 x 1 tablets of Yohimbinum hydrochloricum D4® will be co-administered with 25 mg of ¹³C₃-caffeine as drinking solution with 240mL of still water under overnight fasting conditions. A total of 19 blood samples will be collected at defined time points (baseline; 10; 20; 30; 40; 50; 60; 70; 80; 90; 100; 110 min; 2; 3; 4; 6; 8; 10; 24 h). At each time point, 4.9 mL of blood will be drawn for plasma separation to determine yohimbine, the primary metabolite 11-OH-yohimbine and ¹³C₃-caffeine with associated CYP1A2 dependent metabolites.
219445476|NCT06939608|OTHER|¹³C₃-caffeine|A single oral dose of 25 mg of ¹³C₃-caffeine as a drinking solution will be co-administered with yohimbine with 240 mL of still water under overnight fasting conditions. ¹³C₃-caffeine is a stable isotope-labeled standard probe for phenotyping CYP1A2 activity and assessing potential interactions between CYP2D6 and CYP1A2. Plasma concentrations of ¹³C₃-caffeine with associated CYP1A2 dependent metabolites will be measured at predefined time points, following the sampling schedule outlined for yohimbine.
219445477|NCT02814799|OTHER|bone removal|
219445478|NCT01780207|DEVICE|PFO Closure|
219445479|NCT03084432|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
219445480|NCT06943456|PROCEDURE|Transversus Abdominis Plane (TAP) Block for Postoperative Pain Management|The intervention involves the administration of a Transversus Abdominis Plane (TAP) block performed at the end of an open appendectomy surgery. A mixture of 10 ml of 1% lignocaine and 10 ml of 0.5% bupivacaine is injected into the transversus abdominis plane, located between the transversus abdominis and internal oblique muscles, under direct vision. This procedure aims to provide localized pain relief by blocking the sensory nerves of the anterior abdominal wall, reducing the need for systemic opioid analgesics during post-operative recovery
219765979|NCT07210190|DEVICE|Microneedeling with topical application of VAMP™ ADVANCED Topical Multivitamin Serum|VAMP™ ADVANCED Topical Multivitamin Serum is not indicated for use in pregnancy, lactation, or in individuals under the age of 18. Female participants of childbearing potential will be required to undergo urine pregnancy testing at baseline and prior to each treatment session. They will also be instructed to use an acceptable form of effective contraception for the duration of the study.
218837254|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
218837255|NCT05641012|OTHER|data collection|helioderma evaluation
219765980|NCT07208708|OTHER|Scalloped margin retainer|Patient satisfaction was assessed during 2 weeks of whitening with a scalloped orthodontic retainer. Colour change, TS and IG were also measured. No studies have evaluated the effect of different margin designs in orthodontic retainers used in for tooth bleaching. Therefore, the present study aimed to clinically assess the impact of scalloped and straight margin design in orthodontic retainers employed for at-home bleaching, considering patient satisfaction, bleaching efficacy, tooth sensitivity (TS), and gingival irritation (GI).
219016883|NCT04631029|BIOLOGICAL|Atezolizumab|Given IV
219016884|NCT04631029|DRUG|Carboplatin|Given IV
219016885|NCT04631029|DRUG|Entinostat|Given PO
218837256|NCT00244868|OTHER|counseling intervention|
218837257|NCT00244868|OTHER|educational intervention|
219016886|NCT04631029|DRUG|Etoposide|Given IV
219196469|NCT05285358|DRUG|Gemcitabine|Given IV
218837258|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
218837259|NCT02125838|DEVICE|Endotracheal Tube|ETT
219196470|NCT05285358|DRUG|Nab-paclitaxel|Given via PIPAC
219445481|NCT06943456|PROCEDURE|Standard Open Appendectomy with Postoperative Pain Management|The intervention involves the standard open appendectomy surgical procedure without the addition of a Transversus Abdominis Plane (TAP) block. Postoperative pain management in this group is managed using standard opioid analgesics. No local anesthetic block is performed, and pain management is entirely reliant on systemic medications, including opioids, for post-operative recovery
219445482|NCT06944717|BIOLOGICAL|VXA-G1.1-NN|Legacy vaccine, administered orally.
219445483|NCT06944717|BIOLOGICAL|VXA-G2.4-NS|Legacy vaccine, administered orally.
219445484|NCT06944717|BIOLOGICAL|VXA G1.1 NN-T|Next generation vaccine, administered orally.
219445485|NCT06944717|BIOLOGICAL|VXA G2.4 NS-T|Next generation vaccine, administered orally.
218837260|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
218837261|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
218837262|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
218837263|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
218837264|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
218837265|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
218837266|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
219445486|NCT01226472|BIOLOGICAL|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
219445487|NCT04347616|BIOLOGICAL|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
219445488|NCT04347616|DRUG|IL-2|In vivo cytokine support
219445489|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
219445490|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
218837267|NCT05195086|DRUG|endoxan|Immunosuppressant
218837268|NCT05195086|DRUG|cellcept|Immunosuppressant
218837269|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
218837270|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
218837271|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
218837272|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
218837273|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
219196471|NCT05285358|OTHER|Quality-of-Life Assessment|Ancillary studies
219445491|NCT00952419|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
219445492|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
219445493|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
219445494|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
219445495|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
218837274|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
218837275|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
219445496|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
219445497|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
219445498|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
219445499|NCT06102330|OTHER|HomeVENT decision support tool|Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation
219445500|NCT00534664|DEVICE|TheraBionic device|Daily outpatient treatment with theraBionic device
219445501|NCT04884633|PROCEDURE|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
219445502|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
219445503|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219445504|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219445505|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
219445506|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
219445507|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219445508|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
218837276|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
218837277|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
219765981|NCT07208708|OTHER|Straight orthodontic retainer|Patient satisfaction was assessed during two weeks of whitening with a straight orthodontic retainer. Colour change, TS and IG were also measured. No studies have evaluated the effect of different margin designs in orthodontic retainers used in for tooth bleaching. Therefore, the present study aimed to clinically assess the impact of scalloped and straight margin design in orthodontic retainers employed for at-home bleaching, considering patient satisfaction, bleaching efficacy, tooth sensitivity (TS), and gingival irritation (GI). The null hypotheses were that no significant differences would be observed in: (1) patient satisfaction, (2) bleaching efficacy, (3) tooth sensitivity, and (4) gingival irritation, when different margin designs are used in orthodontic retainers for at-home tooth bleaching.
218837278|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
218837279|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
218837280|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
219445509|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
219445510|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
219445511|NCT01786499|BEHAVIORAL|Relaxation Response Training|
219445512|NCT00312390|PROCEDURE|Flicker|
218837281|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
218837282|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
219584918|NCT03097510|BEHAVIORAL|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
219765982|NCT07208071|OTHER|Augmented reality headset use|Use of a Microsoft HoloLens 2 headset with augmented reality assistance
219445513|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
219445514|NCT00312390|PROCEDURE|Retinal Blood Flow|
219584919|NCT00788138|DIETARY_SUPPLEMENT|Vitamin D3|250,000 IU of vitamin D3
219765983|NCT07208656|BEHAVIORAL|Medical TV Drama Episode (House M.D.)|Participants in the experimental group will watch a selected episode of the medical drama House M.D. (Season 1, Episode 1), which includes a dramatized storyline relevant to neurocysticercosis. The episode is intended to deliver narrative-based health education. After viewing, participants will complete post-test questionnaires assessing changes in knowledge, motivation, and credibility compared to pre-test results.
219765984|NCT07208500|PROCEDURE|RIPC|Inflate a standard blood pressure cuff on one upper arm to 200 mmHg, maintain this pressure for 5 minutes, then deflate the cuff and keep it deflated for another 5 minutes. Repeat this process for 4 cycles.
219765985|NCT07209137|DIETARY_SUPPLEMENT|Dietary Supplement|The supplement is intended to support improvements in skin health, hair strength, nail strength, joint health, and overall well-being.
219765986|NCT07207590|OTHER|web-based gamification application|Subject review and case analysis will be performed through a web-based gamification application on postpartum hemorrhage management, which will be prepared and developed by the game developer.
218837283|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
218837284|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
218837285|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
218837286|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
218837287|NCT04342676|DEVICE|k ras|K ras
218837288|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
218837289|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
219445515|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
219445516|NCT03978793|DEVICE|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
219445517|NCT04640012|DRUG|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
219445518|NCT04640012|DRUG|Placebo|Placebo orally administered
219445519|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
219445520|NCT04959474|OTHER|Best Practice|Given standard dietary recommendations
219445521|NCT04959474|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
219445522|NCT04959474|PROCEDURE|Resection|Undergo surgical resection
219445523|NCT04959474|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
219445524|NCT04959474|OTHER|Dietary Intervention|Undergo a caloric restriction diet
219445525|NCT04959474|OTHER|Questionnaire Administration|Ancillary studies
219445526|NCT04959474|OTHER|Quality-of-Life Assessment|Ancillary studies
219445527|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
219445528|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
219584920|NCT00788138|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
219584921|NCT01480843|DRUG|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
219584922|NCT02743338|BEHAVIORAL|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
219584923|NCT02743338|BEHAVIORAL|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
218837290|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
219445529|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
219445530|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
219445531|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
219445532|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
219445533|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
219765987|NCT07207590|OTHER|control group: traditional classroom learning techniques|Students in the control group will be taught topic review and case analysis using traditional classroom learning techniques
218837291|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
219765988|NCT07207707|DRUG|KQB548|Oral KQB548
219445534|NCT00483431|DIETARY_SUPPLEMENT|MK7|
219445535|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
219584924|NCT02743338|BEHAVIORAL|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
219584925|NCT04607161|OTHER|no intervention|no intervention
219765989|NCT07208188|DEVICE|Transcutaneous spinal cord stimulation (tESCS) active group|Participants in the active arm will receive 60 min of tESCS alongside the conventional occupation therapy, 20 sessions for 4 weeks, 5 times per week
219765990|NCT07208188|DEVICE|Sham transcutaneous spinal cord stimulation (tESCS)|The control group will receive only 1 min of tESCS while doing conventional occupational therapy for 60 min. Number of session 20, 4 weeks, 5 times a week
219765991|NCT07208916|DIETARY_SUPPLEMENT|Grape Powder|All participants will consume two 36g packets of grape powder (mixed with water) daily for two, 2-week periods during the study. Participants will mix pre-measured grape powder with water and drink twice a day (once in the morning and in the afternoon/evening) for two weeks.
219765992|NCT07208227|OTHER|Face Cream RV4983A LA3365|Cosmetic face cream product applied once a day on face, neck and neckline.
219765993|NCT07207993|OTHER|Fitness app for self-efficacy|AI-driven personalized exercise prescription via a fitness app. This targets self-efficacy.
219765994|NCT07207993|OTHER|Social network via app for social support|Participants will be provided access to a social network via app. This targets social support.
219765995|NCT07207993|OTHER|Health education app targeting outcome expectations|Participants are provided with an app-based health education. This targets outcome expectations.
219765996|NCT07208825|DEVICE|rTMS|2 weeks starting period (10 treatment days) followed by 5 treatment once a month.
219765997|NCT07208825|OTHER|Basic physical therapy treatment|10 sessions with physical (or occupational) therapist with special education for treating CRPS
219765998|NCT07208825|OTHER|Functional neurology|4 to 6 sessions with specialized OMT-physical therapist who will aim to improve the neurological deficits of the CRPS patient
219765999|NCT07208825|DRUG|Optimizing the medication|Aim is to optimize the medication of the CRPS patient according the the medication guidelines
219766000|NCT07207733|DEVICE|PcyCare: Self-Directed Education Platform for Pregnant Women|This intervention involves the use of the PcyCare self-directed education platform by pregnant women for one week. Participants will access educational modules on nutrition, pregnancy warning signs, mental health, and childbirth preparation. The platform includes interactive content, instructional videos, and quizzes to enhance participants' understanding. Data on ease of use, satisfaction, and increased understanding will be collected through questionnaires. In addition, midwives/practicing midwives and information technology/media experts will assess the quality of the platform's content and features through expert reviews to evaluate the platform's suitability and improvements before wider trials.
218837292|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
218837293|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
218837294|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
218837295|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
218837296|NCT00068315|DRUG|bortezomib|Given IV
218837297|NCT00068315|DRUG|fludarabine phosphate|Given IV
218837298|NCT00068315|BIOLOGICAL|rituximab|Given IV
218837299|NCT05243979|RADIATION|DEXA scan|bone study
218837300|NCT02538536|DRUG|PBI4050|
219445536|NCT05620160|DRUG|Placebo|placebo （tablet）
219445537|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
219445538|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
219445539|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
219445540|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
219445541|NCT06787248|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 4.2 software (Brain Innovation, Maastricht, The Netherlands)
219445542|NCT00352404|DEVICE|Endomicroscope|
218837301|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
218837302|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
218837303|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
218837304|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
218837305|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
219445543|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
218837306|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
218837307|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
218837308|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
219445544|NCT06379087|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
219445545|NCT06379087|DRUG|Tislelizumab Injection|Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
219445546|NCT06379087|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
219445547|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
218837309|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
218837310|NCT01786382|DRUG|PPI-668|
219445548|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
219445549|NCT00278044|PROCEDURE|blood sampling and medical records|
219584926|NCT04791878|DRUG|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
219445550|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
219445551|NCT04687475|OTHER|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
219445552|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
219445553|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
219445554|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
219445555|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
218837311|NCT01786382|DRUG|Midazolam|
218837312|NCT01786382|DRUG|Omeprazole|
218837313|NCT01786382|DRUG|Telaprevir|
218837314|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
218837315|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
218837316|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
218837317|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
218837318|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
218837319|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
218837320|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
219584927|NCT04430478|DIAGNOSTIC_TEST|Volume flow guided angioplasty|Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
219584928|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
219584929|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
218837321|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
218837322|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
219196472|NCT05285358|OTHER|Questionnaire Administration|Ancillary studies
219445556|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
219445557|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
219445558|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
219445559|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
219445560|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
219584930|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
218837323|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
219445561|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
219584931|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
219584932|NCT02048930|DEVICE|Budesonide Easyhaler|
219584933|NCT02048930|DEVICE|Budesonide dry powder inhaler|
219584934|NCT02492880|DEVICE|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
219584935|NCT03533738|OTHER|Food sequence 1|Vegetables first then meat \& rice together
219584936|NCT03533738|OTHER|Food sequence 2|Meat first then vegetables \& rice together
219766001|NCT07208084|BEHAVIORAL|Project SOAR Awakenings arm|Four Project SOAR Awakenings sessions will be conducted electronically (Zoom) by experts in a group format (12-18 participants/group) with Black American women diagnosed with breast cancer. The Strong Black Woman concept and other culturally curated topics will be discussed as they apply to group members' experience of breast cancer. All women in the study will receive a care box with resources for Black American women diagnosed with breast cancer.
219766002|NCT07208084|BEHAVIORAL|Project SOAR comparison group|Black American women diagnosed with breast cancer in this arm will receive a care box with resources for Black American women diagnosed with breast cancer.
219766003|NCT07207681|DRUG|KXV01 TCR Lentinvivo Injection|KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.
218837324|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
218837325|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
218837326|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
218837327|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
218837328|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
218837329|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
219196473|NCT04890236|DRUG|Duvelisib|Given PO
219196474|NCT04890236|BIOLOGICAL|Tisagenlecleucel|Given via infusion
219196475|NCT04276935|OTHER|Interview|Participate in cognitive interview
219196476|NCT04276935|OTHER|Quality-of-Life Assessment|Ancillary studies
219196477|NCT04276935|OTHER|Questionnaire Administration|Ancillary studies
219196478|NCT04282980|DRUG|DCC-2618|Oral kinase inhibitor
219196479|NCT05660629|OTHER|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
219196480|NCT04801381|PROCEDURE|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
219584937|NCT03533738|OTHER|Food sequence 3|Vegetables first then meat followed by rice
219584938|NCT03533738|OTHER|Food sequence 4|Vegetables first followed by meat and rice together
219584939|NCT03533738|OTHER|Food sequence 5|Rice first followed by vegetables \& meat together
219584940|NCT01560650|DEVICE|CRRT|Difference dose of CRRT
219584941|NCT05331196|DIAGNOSTIC_TEST|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
219766004|NCT07208838|DIAGNOSTIC_TEST|To test visual acuity in 150 Bulgarian patients over 18 years of age using Snellens visual acuity chart and DDIVAT optotypes|The study compares newly developed visual acuity test (DDIVAT) with standart method for visual acuity testing used worldwide
219766005|NCT07209163|DRUG|Tazemetostat|Tazemetostat 800mg, twice once daily (BID), orally
218837330|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
219196481|NCT04801381|PROCEDURE|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
219445562|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
219445563|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
219445564|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
219445565|NCT06300437|PROCEDURE|jaw thrust|children who will receive jaw thrusting during fiberoptic intubation
219445566|NCT06300437|PROCEDURE|control (sub laxed jaw)|children who will not receive jaw thrusting (just sub laxed open mouth)
219445567|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
219445568|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
219445569|NCT05452876|OTHER|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
219445570|NCT05452876|OTHER|Usual Care|Standard of care treatment
219445571|NCT05171816|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
219445572|NCT05171816|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
219445573|NCT06514105|OTHER|Physiotherapy program|All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
219445574|NCT06514105|OTHER|High intensity laser|High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.
219445575|NCT06514105|OTHER|Sham high intensity laser|In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
219445576|NCT06793709|OTHER|No Intervention|This is a non-interventional study.
219445577|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
219445578|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
219445579|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
219445580|NCT06636669|DRUG|Probiotic|Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.
219445581|NCT06636669|OTHER|Standard of care|Standard of care (SOC) treatment includes surgery and antimicrobials.
219445582|NCT04667949|DRUG|Fingolimod 0.5mg|Subjects received fingolimod 0.5mg capsule QD up to month 24
219445583|NCT05053139|DRUG|NNC0365-3769 (Mim8)|Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
219766006|NCT07209163|DRUG|Linperlisib|"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Linperlisib: 60 mg once daily (QD) and 60 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Linperlisib RP2D in patients with peripheral T-cell lymphoma with co-RHOA/TET2mut."
219766007|NCT07209163|DRUG|Golidocitinib|"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Lgolidocitinib: 150 mg every other day (QOD) and 150 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Golidocitinib RP2D in patients with peripheral T-cell lymphoma without co-RHOA/TET2mut."
219766008|NCT07207616|OTHER|educational intervention for nursing|A quasi-experimental study was carried out between February and October 2023 in the Valencian Community. This non-randomized intervention followed the TREND guidelines and targeted nurses registered in one of the three official nursing colleges of the region. The educational intervention included an asynchronous online phase hosted on a Google Sites platform, where participants accessed interactive learning materials and completed a pre-test. This was followed by a four-hour in-person session that included a brief theoretical review and hands-on workshops practicing various ALS techniques. A post-intervention test was administered immediately afterward. The intervention led to a noticeable improvement in ALS knowledge, demonstrating its effectiveness.
219584942|NCT00554190|DEVICE|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
219584943|NCT00554190|DEVICE|Merogel Injectable|Bioresorbable hyaluronic acid product
219584944|NCT00616798|DRUG|RO4917838|10mg po daily
219445584|NCT06343558|OTHER|Questionnaires, clinical scales and instrumental tests|Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
219584945|NCT00616798|DRUG|RO4917838|30mg po daily
219445585|NCT06432569|DIETARY_SUPPLEMENT|ButirBioma + PeaBioma|randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.
219584946|NCT00616798|DRUG|RO4917838|60mg po daily
219584947|NCT00616798|DRUG|Placebo|po daily
219584948|NCT00616798|DRUG|Standard antipsychotic therapy|As prescribed
219584949|NCT04820530|DRUG|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
219584950|NCT06083012|DEVICE|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~* 3D mapping of the atria and location of areas of interest;~* Catheter ablation at the operator\&amp;#39;s discretion."
219584951|NCT06355011|DEVICE|Total Elbow Replacement|Total elbow replacement is a procedure that involves replacing the elbow joint with an implanted device to alleviate pain and improve function.
219584952|NCT04903951|DEVICE|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
218837331|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
219445586|NCT06432569|DIETARY_SUPPLEMENT|Placebo|Placebo( 3+3 cps/die)
219445587|NCT06639997|DRUG|AZD5148|Participants will receive AZD5148 as IM injection or IV bolus
218837332|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
218837333|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
218837334|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
218837335|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
218837336|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
219445588|NCT06639997|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
219445589|NCT04518228|DRUG|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445590|NCT04518228|DRUG|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219584953|NCT04903951|OTHER|Best medical treatment|Best medical treatment for stroke, including rehabilitation
218837337|NCT00191568|DRUG|Gemcitabine|
218837338|NCT00191568|DRUG|Oxaliplatin|
218837339|NCT00191568|PROCEDURE|Radiotherapy|
219445591|NCT04518228|DRUG|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445592|NCT04518228|DRUG|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445593|NCT04518228|DRUG|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445594|NCT04518228|DRUG|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219584954|NCT01811316|OTHER|Probiotics|
219584955|NCT04241315|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
219584956|NCT04241315|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
219584957|NCT04522115|OTHER|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
219584958|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
219584959|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
219584960|NCT03906552|OTHER|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
219766009|NCT07208357|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
218837340|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
218837341|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
218837342|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
218837343|NCT01564212|OTHER|laminar airflow with surgical drapes|
219445595|NCT04518228|DRUG|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445596|NCT04518228|DRUG|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445597|NCT04518228|DRUG|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445598|NCT04518228|DRUG|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
219445599|NCT04518228|DRUG|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
219445600|NCT04518228|DRUG|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
219445601|NCT05406583|DRUG|Dolutegravir 0.5 mg/kg oral suspension|DTG 0.5 mg/kg liquid suspension administered orally
219445602|NCT05406583|DRUG|Dolutegravir 5 mg Dispersible Tablets|DTG 5 mg DT administered orally
219445603|NCT04357704|OTHER|S0N0|(no ITD)
219445604|NCT04357704|OTHER|S0N500|(ITD +500µs on noise)
219445605|NCT04357704|OTHER|S-500N500|(ITD -500µs on signal and +500 µs on noise)
219445606|NCT04357704|OTHER|S0N1000|(ITD + 1000 µs on noise)
219445607|NCT04357704|OTHER|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
219445608|NCT05275868|DRUG|MGY825|investigational drug
219445609|NCT04829734|DEVICE|Active PBMT-sMF|The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
219445610|NCT04829734|DEVICE|Placebo PBMT-sMF|The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
219445611|NCT02791477|DEVICE|Attune FB PS knee arthroplasty|
219445612|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
219445613|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
219445614|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
219445615|NCT06699849|BIOLOGICAL|CSL889|CSL889 is a solution for infusion to be administered by the IV route.
219445616|NCT06699849|DRUG|Placebo|Volume and regimen matched to CSL899 will be administered.
219445617|NCT02000622|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
219445618|NCT02000622|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
219445619|NCT00273806|BEHAVIORAL|Intervention for 4 behavioral risks by medical assistants.|
219445620|NCT00424840|DRUG|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
219445621|NCT00424840|DRUG|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
219445622|NCT00424840|DRUG|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
219445623|NCT00424840|DRUG|Carboplatin AUC 6|Carboplatin AUC6
219445624|NCT00424840|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
219445625|NCT00424840|DRUG|Taxotere|Taxotere 70 + G-CSF
219584961|NCT02929524|DRUG|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
219584962|NCT02929524|DRUG|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
219766010|NCT07208357|DRUG|Pregabalin with toludesvenlafaxine|In the pregabalin with toludesvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Toludesvenlafaxine will be administered at 40 mg daily initially. If the initial dose is well-tolerated, the dose could be further escalated by 40 mg per day after 7 days, up to a maximum of 160 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and toludesvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
219445626|NCT01405027|PROCEDURE|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
219766011|NCT07207642|BEHAVIORAL|Music intervention - passive listening|Diffusion of familiar music in the bedrooms and living room before bedtime; passive and individual listening.
219766012|NCT07207642|BEHAVIORAL|Audio books intervention - active listening|Dynamic audio book listening, akin to active listening while respecting the rhythm of the evening . This type of listening involves concentrating specifically .
219766013|NCT07208058|DRUG|Plonmarlimab|Subjects will receive Plonmarlimab 10 mg/kg by intravenous injection once weekly from Week 1 to Week 3, and Plonmarlimab 6 mg/kg by intravenous injection once weekly from Week 4 to Week 8 (10 mg/kg QW×3 + 6 mg/kg QW×5).
219766014|NCT07209085|DEVICE|FastWave Artero™ Peripheral IVL System|The FastWave Artero™ Peripheral IVL System includes a generator and a balloon-based catheter designed to treat calcified blockages in peripheral arteries. During a single endovascular index procedure, the catheter is positioned within the target femoropopliteal artery and inflated at low pressure. The device emits short bursts of pulsatile sonic pressure waves that fracture calcium deposits, improving vessel flexibility and allowing dilation at low balloon pressures to restore blood flow. Multiple inflations may be performed as needed. Adjunctive angioplasty or stenting may be used at the investigator's discretion.
219766015|NCT07207850|BEHAVIORAL|Parents Helping Parents program|Our innovative vaping cessation program will include two key components: 1) online training for parents and their offspring, and 2) parent-helping-parent coach sessions. Parents and children in the control setting will receive no treatments during the intervention (Baseline to Month 3). Dyads will be provided online training materials after the 6 month follow up.
219445627|NCT01405027|OTHER|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
219766016|NCT07207954|DRUG|LFD-200|2 mL glass vials, as 150 mg/mL concentrated solution
219766017|NCT07207954|OTHER|Placebo|0.9% NaCl
219766018|NCT07207954|DRUG|Oral Prednisone|Tablet
219766019|NCT07207954|OTHER|Placebo|Placebo tablet to match Prednisone
219766020|NCT07209748|DIAGNOSTIC_TEST|sCD163 level|The significance of soluble CD163 level in the early detection and severity assessment of HELLP Syndrome
219445628|NCT04825704|DRUG|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
219445629|NCT04825704|DRUG|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
219445630|NCT05085327|DRUG|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
219445631|NCT05085327|DRUG|ChapStick Lip Moisturizer Mint|Sunscreen lip balm.
219445632|NCT05085327|DRUG|ChapStick Lip Moisturizer Black Cherry|Sunscreen lip balm.
219445633|NCT05085327|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
219584963|NCT02657265|DEVICE|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
219766021|NCT07208318|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
219445634|NCT01786278|RADIATION|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
219584964|NCT02657265|DEVICE|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
219766022|NCT07208240|DRUG|Tb-PSMA-I&T (Tb-PSMA)|Terbium-161 produce beta emission with the addition of Auger electrons which have higher linear energy transfer and a very short range. By that it has the potential to improve local and distal (micro-metastatic disease) efficacy with a similar safety profile. It will be given to patients with high risk locally advanced prostate cancer prior to Radical prostatectomy
219766023|NCT07209982|BEHAVIORAL|Dual-Task Training (DTT)|This intervention combines gait and balance practice with a simultaneous secondary task to mimic real-world multitasking demands. Participants complete 60-minute sessions, three times per week for six weeks. Secondary tasks include simple cognitive activities (such as serial subtraction, word recall, or visual scanning) or light motor tasks (such as carrying an object or tossing a ball). Task complexity is increased gradually according to participant tolerance. All sessions are supervised by a trained physiotherapist, with rest breaks and safety precautions provided.
219766024|NCT07209982|BEHAVIORAL|Single-Task Training (STT)|This intervention provides gait and balance training without any added secondary tasks. Participants complete 60-minute sessions, three times per week for six weeks. Exercises include level walking, directional changes, obstacle negotiation, static and dynamic balance activities, and surface progressions (such as standing on foam). Progression is achieved by altering the physical task difficulty only. Sessions are supervised by a physiotherapist with safety measures in place and rest breaks as needed.
219445635|NCT01786278|PROCEDURE|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
219445636|NCT05727631|OTHER|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
219445637|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
218837344|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
218837345|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
218837346|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
218837347|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
218837348|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
218837349|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
218837350|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
218837351|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
218837352|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
218837353|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
218837354|NCT00626886|DRUG|placebo collagen sponge|collagen
218837355|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
218837356|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
218837357|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
219445638|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
219445639|NCT00264628|DRUG|GW679769|
219445640|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
219445641|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
219445642|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
219445643|NCT03357328|OTHER|Therapy light room|See group description
219445644|NCT03357328|OTHER|Standard light|See group description
219445645|NCT06212466|DEVICE|CardioFlux|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.
219445646|NCT05896423|BEHAVIORAL|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
219584965|NCT00394524|DEVICE|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
219584966|NCT00394524|OTHER|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
219584967|NCT00492986|DRUG|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
219584968|NCT05808153|RADIATION|radiotracer injection|MRI with radiotracer injection
219766025|NCT07208110|OTHER|Exposed to trauma|Patients exposed to trauma previous to the admission to the ICU.
219766026|NCT07208110|OTHER|Not exposed|Patients not exposed to trauma previous to the admission to the ICU.
219584969|NCT01710553|OTHER|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
219584970|NCT01710553|OTHER|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
219584971|NCT00505089|DRUG|ACZ885|
219766027|NCT07208279|DIETARY_SUPPLEMENT|Axolt Brain Supplement|https://axoltbrain.com/ Axolt is a brain health supplement. It includes native ingredients, formulated to help the brain perform at its best.
219584972|NCT00505089|DRUG|ACZ885|
219584973|NCT00505089|DRUG|ACZ885|
219766028|NCT07208279|DIETARY_SUPPLEMENT|Bolero - Flavored Drink Placebo|The control group will be asked to consume 1 packet of Bolero flavored water mix hydration enhancement also in about 16 oz of water once a day for 45 days.
219766029|NCT07207980|BEHAVIORAL|CREDOenAP intervention|Intervention program with intensive lifestyle counseling, added to standard pharmacological treatment subsequently adjusted according to clinical needs and outcomes. The intervention will last 6 months and consists of biweekly in-person and telephone visits. Patients will follow a personalized dietary plan with carbohydrate restriction, based on the recommendations of the American Diabetes Association; engage in moderate and accessible physical activity; implement circadian rhythm regularization; and receive psychological counseling and support.
219584974|NCT00505089|DRUG|ACZ885|
219584975|NCT06493604|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
219584976|NCT06493604|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
219584977|NCT01998672|DRUG|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
219766030|NCT07207785|DRUG|Pirtobrutinib|Patients will receive pirtrobrutinib at a starting dose of 200 mg once daily (q.d). All treatment will be administered orally and a cycle will be defined as 28 days in length and should be maintained regardless of dose interruptions. Treatment is meant to be administered until tumor progression, unacceptable adverse event, or patient decision for interruption.
219584978|NCT01998672|DRUG|Placebo|Drinking solution
219584979|NCT05244395|OTHER|Duchenne Muscular Dystrophy Gait Assessment Scale|a special gait assessment scale for Duchenne Muscular Dystrophy patients
219766031|NCT07208903|BEHAVIORAL|focus group discussions|"These sessions will address:~* emotional reactions to the disclosure of the result~* perceptions and representations of the disease and its treatment~* the impact on the parent-child relationship~* the lived experience of neonatal screening and the perception of the support provided"
218837358|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
218837359|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
218837360|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
218837361|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
218837362|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
218837363|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
218837364|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
218837365|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
218837366|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
219445647|NCT04252391|PROCEDURE|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
219584980|NCT00003916|RADIATION|radiation therapy|
219584981|NCT00003916|RADIATION|stereotactic radiosurgery|
218837367|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
219584982|NCT04310618|OTHER|No intervention|No intervention
219584983|NCT01345175|DRUG|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
219584984|NCT01345175|DRUG|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
219584985|NCT05411588|DRUG|PF-07275315|Active drug
219584986|NCT05411588|DRUG|Placebo|Placebo
219584987|NCT05752682|DIAGNOSTIC_TEST|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
219584988|NCT00642694|DRUG|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
219584989|NCT00642694|DRUG|Ramelteon|Ramelteon 8 mg qd
219766032|NCT07208903|BEHAVIORAL|Interview with the psychologist|"These sessions will address:~* emotional reactions to the disclosure of the result~* perceptions and representations of the disease and its treatment~* the impact on the parent-child relationship~* the lived experience of neonatal screening and the perception of the support provided"
218837368|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
218837369|NCT00003321|PROCEDURE|psychosocial assessment and care|
218837370|NCT00003321|PROCEDURE|quality-of-life assessment|
219445648|NCT04252391|PROCEDURE|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
219445649|NCT01680991|DRUG|Obinutuzumab|Multiple doses of obinutuzumab.
219584990|NCT00642694|OTHER|Placebo|Matching placebo qd
219584991|NCT03688282|DEVICE|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
219584992|NCT03688282|DEVICE|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
219584993|NCT05483725|BIOLOGICAL|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
219584994|NCT01736241|DRUG|LY3053102|
219584995|NCT01736241|DRUG|Placebo|
219584996|NCT01070459|BEHAVIORAL|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
219584997|NCT01070459|BEHAVIORAL|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
219584998|NCT01070459|BEHAVIORAL|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
219584999|NCT01070459|BEHAVIORAL|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
219585000|NCT01070459|BEHAVIORAL|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
219585001|NCT00814918|DRUG|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
219585002|NCT00814918|DRUG|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
218837371|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
219445650|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
219445651|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
218837372|NCT05793801|OTHER|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change."
218837373|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
218837374|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
218837375|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
218837376|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
218837377|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
218837378|NCT03539393|DRUG|Fremanezumab|For patients who enter this program, the monthly dose of fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the patient's weight every 3 months.
218837379|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
219445652|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
219445653|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
219445654|NCT05628194|OTHER|Observational/Survery|MSM participants will complete a one-time survey, delivered in an e-format. Survey will be accessible via Meta-based social media platforms (Facebook, Instagram).
219445655|NCT03728881|BIOLOGICAL|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Given IM
219445656|NCT03728881|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
219445657|NCT05547620|DEVICE|LIFUS Online Real|Stimulation using NeuroFUS device while standing
219445658|NCT05547620|DEVICE|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
219445659|NCT05547620|DEVICE|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
219445660|NCT06073054|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
219445661|NCT06499857|DRUG|Semaglutide|3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
219445662|NCT06499857|DRUG|Placebo|3ml pen-injector containing placebo solution for subcutaneous use.
219585003|NCT04316507|PROCEDURE|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
219585004|NCT03537599|BIOLOGICAL|Daratumumab|Given IV
218837380|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
218837381|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
219445663|NCT04307277|DRUG|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
219445664|NCT04307277|OTHER|Standard of care|Surgical excision with external radiotherapy (if applicable)
219445665|NCT04574570|DEVICE|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
219445666|NCT03601078|BIOLOGICAL|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
219445667|NCT03601078|DRUG|Lenalomide|Specified dose on specified days
219445668|NCT03601078|DRUG|Talquetamab|Specified dose on specified days
219445669|NCT05738603|DEVICE|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
219445670|NCT03145506|DEVICE|Multimodal Spectroscopy|optical measurement of excised tissue
219585005|NCT03537599|PROCEDURE|Donor Lymphocyte Infusion|Given via infusion
219585006|NCT03537599|OTHER|Laboratory Biomarker Analysis|Correlative studies
219585007|NCT05190809|PROCEDURE|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
219585008|NCT01484262|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
219585009|NCT01484262|DRUG|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
219585010|NCT01659866|DRUG|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
218837382|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
219585011|NCT01659866|DRUG|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
219585012|NCT01659866|DRUG|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
219585013|NCT01659866|DRUG|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
219585014|NCT01659866|DRUG|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
219445671|NCT03630185|DEVICE|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
219585015|NCT01659866|DRUG|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
219585016|NCT01659866|DRUG|aztreonam|500 mg intramuscularly 2 hours before the procedure
219445672|NCT03630185|DEVICE|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
218837383|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
218837384|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
218837385|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
218837386|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
218837387|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
218837388|NCT00631813|DRUG|Prucalopride|0.5 mg bid
218837389|NCT00631813|DRUG|Prucalopride|1 mg bid
218837390|NCT00631813|DRUG|Prucalopride|2 mg bid
218837391|NCT00631813|DRUG|Placebo|bid
218837392|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
218837393|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
218837394|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
218837395|NCT00375505|DRUG|Zoledronic acid|
218837396|NCT00375505|DRUG|Placebo|Placebo
218837397|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
218837398|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
219445673|NCT02079415|OTHER|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
219445674|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
219445675|NCT00141167|DRUG|varenicline|
219445676|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
219445677|NCT05211492|OTHER|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
219445678|NCT02986165|DIETARY_SUPPLEMENT|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
219585017|NCT01659866|DRUG|imipenem|500 mg intramuscularly 2 hours before the procedure
219585018|NCT01659866|DRUG|ceftriaxone|2000 mg intravenously 1 hour before the procedure
219585019|NCT01659866|DRUG|gentamicin|2 mg/kg intravenously 1 hour before the procedure
219585020|NCT01659866|DRUG|amikacin|5 mg/kg intravenously 1 hour before the procedure
219585021|NCT01659866|DRUG|aztreonam|2000 mg intravenously 1 hour before the procedure
219585022|NCT01659866|DRUG|imipenem|1000 mg intravenously 1 hour before the procedure
219585023|NCT05569603|BEHAVIORAL|Chronobiology-guided lifestyle interventions|1\) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
219585024|NCT00058721|DRUG|I-123-5-IA85380|
219585025|NCT01294826|DRUG|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
219585026|NCT01294826|DRUG|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
219585027|NCT01383135|DRUG|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
219585028|NCT03734406|OTHER|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
218837399|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
218837400|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
218837401|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
218837402|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
218837403|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
218837404|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
218837405|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
218837406|NCT06299865|OTHER|Ungrouped|Ungrouped
218837407|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
218837408|NCT00002050|DRUG|Thymopentin|
218837409|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
218837410|NCT03907176|DRUG|HTX-011|300 mg
218837411|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
218837412|NCT03907176|DRUG|Ibuprofen|600 mg
219445679|NCT02986165|DIETARY_SUPPLEMENT|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
219445680|NCT02986165|DIETARY_SUPPLEMENT|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
219196482|NCT06804720|BEHAVIORAL|Mindfulness based Self compassion|All participants in the test group completed the 8-week MBCL (Mindfulness-Based Compassionate Living) training, consisting of 2-hour sessions per week, in accordance with the MBCL training protocol. Training was conducted by one expert periodontist who is also an internationally certified MBCL instructor
219196483|NCT06242834|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219445681|NCT06186622|DRUG|Orforglipron|Administered orally.
219445682|NCT06186622|DRUG|Simvastatin|Administered orally.
219445683|NCT06186622|DRUG|Digoxin|Administered orally.
219445684|NCT06186622|DRUG|Rosuvastatin|Administered orally.
219445685|NCT06186622|DRUG|Acetaminophen|Administered orally.
219445686|NCT06186622|DRUG|Midazolam|Administered orally.
219445687|NCT06186622|DRUG|Sodium Bicarbonate|Administered orally.
219445688|NCT00002852|DRUG|paclitaxel|Given IV
219445689|NCT00002852|DRUG|carboplatin|Given IV
219445690|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219445691|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
219445692|NCT01712191|DEVICE|NUsurface Meniscus Implant|
219445693|NCT04582539|DRUG|INCB000928|INCB000928 will be administered once daily.
219445694|NCT05685849|DEVICE|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
219445695|NCT01490333|DIETARY_SUPPLEMENT|Vitamin D3|The vitamin D3 will be taken daily.
219475913|NCT04832009|DRUG|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
219475914|NCT04513015|DIETARY_SUPPLEMENT|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
218837413|NCT03907176|DRUG|Acetaminophen|1 g
219196484|NCT06242834|PROCEDURE|Computed Tomography|Undergo CT scan
219475915|NCT04513015|DIETARY_SUPPLEMENT|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
219475916|NCT06805383|BEHAVIORAL|Phone call|Phone call to patients randomized to experimental arm.
219475917|NCT06805383|OTHER|Mailed FIT Kit|FIT Kit mailed to patient address in EMR.
219475918|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
219475919|NCT04089566|DRUG|Nusinersen|Administered as specified in the treatment arm
219475920|NCT02478281|DRUG|Methylene Blue|
219475921|NCT00056472|DRUG|Olanzapine|10-20mg/day
219475922|NCT00056472|DRUG|Sertraline|150-200mg/day
218837414|NCT04174859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
218837415|NCT04895930|DRUG|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
218837416|NCT04895930|DRUG|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
218837417|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
218837418|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
218837419|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
218837420|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
218837421|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
218837422|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
218837423|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
218837424|NCT00364650|OTHER|Placebo|placebo
218837425|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
218837426|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
218837427|NCT00348998|BIOLOGICAL|bevacizumab|
218837428|NCT00348998|DRUG|bicalutamide|
218837429|NCT00348998|DRUG|goserelin acetate|
218837430|NCT00348998|RADIATION|radiation therapy|
218837431|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
218837432|NCT00349349|DRUG|ofatumumab|Intravenous infusion
218837433|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
218837434|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
218837435|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
218837436|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
218837437|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
218837438|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
218837439|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
218837440|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
218837441|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
218837442|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
218837443|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
218837444|NCT05053399|DEVICE|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
218837445|NCT06399315|DRUG|ZE46-0134 or placebo|The patients will receive ZE46-0134 or placebo
218837446|NCT06399315|DRUG|Rabeprazole, 20mg oral|Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
218837447|NCT06399315|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg BID
218837448|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
219196485|NCT06242834|PROCEDURE|Echocardiography|Undergo echocardiography
219196486|NCT06242834|BIOLOGICAL|Pembrolizumab|Given IV
218837449|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
219585029|NCT04792775|BEHAVIORAL|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
219585030|NCT00463242|DRUG|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
219585031|NCT00463242|DRUG|paroxetine|
219585032|NCT00463242|DRUG|placebo|
219585034|NCT01612299|DRUG|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml."
219766033|NCT07208201|PROCEDURE|bronchoscopy|"BAL is performed with the fiberoptic bronchoscope in a wedge position within the selected bronchopulmonary segment.~The total instilled volume of normal saline should be no less than 100 ml and should not exceed 300 ml.~Three to five sequentially instilled aliquots are generally withdrawn after each aliquot instillation.~For optimal sampling of distal airspaces, the total volume (pooled aliquots) retrieved should be greater than or equal to 30% of the total instilled volume.~A total volume of retrieved fluid less than 30% may provide a misleading cell differential, especially if total retrieved volume is less than 10% of total instilled volume.~If less than 5% of each instilled aliquot volume is recovered during the procedure due to retention of most of the fluid in the lavaged segment, the procedure should be aborted to avoid increased risk of tissue disruption and/or inflammatory mediator release due to overdistention of the lavaged segment."
218837450|NCT03377179|DRUG|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
218837451|NCT03377179|DRUG|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
218837452|NCT06107530|OTHER|semi structured interview|Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
218837453|NCT04196530|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
218837454|NCT04196530|DRUG|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
218837455|NCT00000325|BEHAVIORAL|Gonadorelin|
218837456|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
219016973|NCT06132893|DRUG|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
219016974|NCT06132893|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
219016975|NCT06132893|DRUG|Placebo|Matching placebo taken once daily
219016976|NCT05677971|DRUG|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
219016977|NCT05677971|OTHER|Placebo|Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
219196487|NCT06242834|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219585035|NCT06063265|BEHAVIORAL|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
219585036|NCT03944174|PROCEDURE|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
219585037|NCT00114166|DRUG|topotecan hydrochloride|
219585038|NCT00150891|PROCEDURE|Kidney transplantation|
219585039|NCT00150891|DRUG|cyclosporine A|
219585040|NCT00150891|DRUG|tacrolimus|
218837457|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
218837458|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
219585041|NCT00150891|DRUG|azathioprine|
219585042|NCT00150891|DRUG|mycophenolate mofetil|
219585043|NCT05521139|DIAGNOSTIC_TEST|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
219585044|NCT05379816|PROCEDURE|5% DW perineural injection|5% DW perineural injection to intercostal nerve
218837459|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
218837460|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
219445696|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
219445697|NCT02548091|PROCEDURE|Non invasive ventilation|
219766034|NCT07209215|DRUG|Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)|Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer.
219766035|NCT07208591|DRUG|STSA-1002 injection|basal treatment + STASA-1002 intravenous infusion
219766036|NCT07208591|DRUG|STSA-1002 Injection Placebo|basal treatment + STSA-1002 Injection Placebo
219766037|NCT07210528|DRUG|Emtricitabine (FTC)|"Capsule, 200mg FTC. White Opaque Body / Light Blue Opaque Cap with GILEAD and Gilead logo on body. 200 mg on cap printed in black."
219766038|NCT07210528|DRUG|Descovy® (TAF/FTC)|Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg. Tablets, Rectangular-Shaped, Debossed, Film-coated blue.
219445698|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
219445699|NCT02548091|PROCEDURE|Computed tomography (CT)|
219445700|NCT05505734|DRUG|BDA MDI|Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
218837461|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
218837462|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
218837463|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
219445701|NCT05505734|DRUG|AS MDI|Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
218837464|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
219445702|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
218837465|NCT00132990|DEVICE|Deep brain stimulation|
218837466|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
218837467|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
218837468|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
218837469|NCT05461586|DEVICE|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
218837470|NCT05461586|DEVICE|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
218837471|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
218837472|NCT00851890|DRUG|ABT-333|50 mg capsules
219445703|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
219445704|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
219445705|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
219445706|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
218837473|NCT00851890|OTHER|Placebo for ABT-333|Capsule
218837474|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
219445707|NCT05848336|BEHAVIORAL|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
219445708|NCT02985489|DIETARY_SUPPLEMENT|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
219585045|NCT00001365|DRUG|dextromethorphan|
219585046|NCT01191983|DRUG|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
219585047|NCT01049711|DRUG|erythropoietin|
219585048|NCT03614897|BEHAVIORAL|Education|Education on guidelines for care of individuals at risk of falling
219585049|NCT00301093|BIOLOGICAL|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
219585050|NCT00301093|DRUG|imatinib mesylate|Participants will continue on current dose
219585051|NCT01155453|DRUG|BKM120|
219585052|NCT01155453|DRUG|GSK1120212|
219585053|NCT03251495|DRUG|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
218837475|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
219016979|NCT05058651|BIOLOGICAL|Atezolizumab|Given IV
219016980|NCT05058651|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219016981|NCT05058651|DRUG|Carboplatin|Given IV
219445709|NCT02762045|BIOLOGICAL|Ad5-gag|Ad5-gag is used as vaccine in all arms.
219445710|NCT02762045|BIOLOGICAL|Placebo|Preservation Solution is used as control in all arms.
219445711|NCT00554853|DRUG|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
218837476|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
218837477|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
218837478|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
218837479|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
218837480|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
218837481|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
218837482|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
218837483|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
218837484|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
218837485|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
218837486|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
218837487|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
218837488|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
218837489|NCT02254044|DRUG|bivatuzumab mertansine|
218837490|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
218837491|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
218837492|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
218837493|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
218837494|NCT00777595|DRUG|Placebo|Inhaled solution, single dose of placebo
218837495|NCT00777595|DRUG|Moxifloxacin|Tablet, oral, 400mg, single dose
218837496|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
219016982|NCT05058651|DRUG|Cisplatin|Given IV
219016983|NCT05058651|PROCEDURE|Computed Tomography|Undergo CT scan
219016984|NCT05058651|DRUG|Etoposide|Given IV
219016985|NCT05058651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219016986|NCT05058651|OTHER|Patient Observation|Undergo observation
219445712|NCT00554853|DRUG|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
219445713|NCT00948285|PROCEDURE|MRI|magnetic resonance imaging (MRI)
219445714|NCT05247060|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
219445715|NCT02108522|BIOLOGICAL|Multivirus Specific T cells|
219445716|NCT01556789|BIOLOGICAL|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
219445717|NCT00349024|DRUG|polyvinylpyrrolidone-sodium hyaluronate gel|
219445718|NCT05553262|BEHAVIORAL|Behavioral support|Behavioral support as described under 'Arm description'.
218837497|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
218837498|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
218837499|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
218837500|NCT02997696|DRUG|ONO-4474|
219445719|NCT02681640|OTHER|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
219445720|NCT02681640|DEVICE|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
219445721|NCT03660280|DIETARY_SUPPLEMENT|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
219445722|NCT03660280|OTHER|Placebo|Placebo
219445723|NCT00674024|DRUG|Pazopanib|
219445724|NCT00674024|DRUG|Pazopanib (GW786034)(GW786034)|
219445725|NCT02384785|DEVICE|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
219445726|NCT01160224|DRUG|GW766944|Drug: GW766944 (Active Drug Treatment)
219445727|NCT01160224|OTHER|Placebo|This is placebo to match.
219585054|NCT02770677|OTHER|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
218837501|NCT02997696|DRUG|Placebo matching ONO-4474|
218837502|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
218837503|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
218837504|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
218837505|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
218837506|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
219017004|NCT05706077|DEVICE|active tDCS|The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.
219196488|NCT06242834|DRUG|Tazemetostat|Given PO
219196489|NCT05794139|DRUG|NMD670|Tablets
219445728|NCT00407641|DRUG|Tinzaparin administration|Patients will receive tinzaparin during the HD session
219445729|NCT00407641|DRUG|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
219445730|NCT01600105|DRUG|Perfusion MRI|1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
219445731|NCT04708340|DRUG|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
219445732|NCT04708340|DRUG|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
219445733|NCT02891252|PROCEDURE|outpatient procedure|
219445734|NCT03928444|PROCEDURE|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
219445735|NCT03928444|PROCEDURE|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
219445736|NCT05148689|DRUG|Oxymetazoline hydrochloride Cream, 1%|Cream
219445737|NCT05148689|DRUG|Rhofade™ (oxymetazoline) cream, 1%|cream
219445738|NCT05148689|DRUG|Placebo|cream
219445739|NCT01066650|DEVICE|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
219585055|NCT05990153|OTHER|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
219585056|NCT05990153|DRUG|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
219585057|NCT05990153|OTHER|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
218837507|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
219445740|NCT01066650|DEVICE|Xience V (Everolimus-eluting stent)|Drug eluting stent
219445741|NCT02233608|BEHAVIORAL|Advanced Pelvic Floor Muscle Exercise (APFX)|
219445742|NCT02056756|DRUG|Carfilzomib|
219445743|NCT03774836|DRUG|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
219766039|NCT07210528|DRUG|Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg.|Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25mg. Tablets, Rectangular-Shaped, Debossed, Film-Coated Blue.
219766040|NCT07210528|DRUG|Placebo Capsules to Match Emtricitabine Capsules, 200mg.|"White Opaque Body/Light Blue Opaque Cap with GILEAD and Gilead logo on body, 200 mg on cap printed in black."
219766041|NCT07208305|DRUG|Olanzapine|Oral olanzapine (2.5mg per night, oral, 30 minutes before taking opioids on the first day of treatment), for 7 consecutive days.
219766042|NCT07208305|DRUG|Metoclopramide|Metoclopramide (10mg/ time, orally, 3 times a day) was taken orally for 7 days.
219766043|NCT07208604|DEVICE|Quantitative refractive crosslinking|Non-invasive corneal cross-linking device delivering controlled UV light through a contact lens platform for biomechanical stabilization of the cornea.
218837508|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
218837509|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
218837510|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
218837511|NCT01872975|RADIATION|regional nodal XRT|
218837512|NCT01872975|RADIATION|chestwall XRT|
218837513|NCT01872975|RADIATION|WBI|
218837514|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
219017005|NCT05706077|DEVICE|sham tDCS|The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.
219017006|NCT05706077|OTHER|real Physical Therapy|Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.
219196490|NCT05794139|DRUG|Placebo|Tablets
219445744|NCT03774836|DRUG|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
219445745|NCT03774836|OTHER|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
219445746|NCT04007367|DRUG|SAGE-217|SAGE-217 capsule
219445747|NCT04007367|DRUG|Placebo|SAGE-217 matching placebo capsule
219475923|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
219475924|NCT02278042|OTHER|Beverage Consumption|
219475925|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
219475926|NCT06560658|DRUG|Psilocybin|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period.
219475927|NCT06560658|BEHAVIORAL|Meditation|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period. In addition to meditating during their sessions, participants will also meet online five days a week for meditation instruction and practice.
219475928|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
219475929|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
219475930|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
219475931|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
219475932|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
219475933|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
219475934|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
219475935|NCT05852301|OTHER|no intervention|no intervention, observational study only
219475936|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
218837515|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
218837516|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
218837517|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
219766044|NCT07210970|DIAGNOSTIC_TEST|Tuberculin Skin Test (TST)|Intradermal injection of 5 unit (0.1 mm) of purified protein derivative (PPD) with measurement of induration after 48-72 hours.
218837518|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
218837519|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
218837520|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
219445748|NCT03647462|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
219445749|NCT01611662|DRUG|gemcitabine hydrochloride|Given IV
219196491|NCT06804512|DEVICE|Visual Occlusion Goggles|The visual occlusion goggles alternate between sight and visual occlusion in a regular and programmable pattern. Based on the electrical properties of the goggles, they are also able to have the tint adjusted instead of blacking out entirely for the occlusion times during the programmed timings.
219445750|NCT01611662|DRUG|cisplatin|Given IV
218837521|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
218837522|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
218837523|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
218837524|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
218837525|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
219445751|NCT01611662|PROCEDURE|therapeutic conventional surgery|Undergo radical cystectomy
219445752|NCT01611662|OTHER|laboratory biomarker analysis|Correlative studies
219445753|NCT05689749|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
219445754|NCT01561040|DIETARY_SUPPLEMENT|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
219475937|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
219475938|NCT05810415|DIAGNOSTIC_TEST|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
219475939|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
219475940|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
219475941|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
219475942|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
219475943|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
219475944|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
219475945|NCT00001658|DRUG|Amoxicillin|
219475946|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
219475947|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
219475948|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
219475949|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
219585058|NCT05990153|OTHER|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
219585059|NCT04040322|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
219766045|NCT07210203|PROCEDURE|Neural mobilization with Balance training with conventional physical Therapy|"( HOT pack 10 mins + TENS 10 mins)~Neural Moblization Includes the following protocol:~Hot Pack 10 mins TENS 10 mins Upper limb and lower limb sliding techniques . (10 reps) Upper limb lower limb tentioning technique (10 reps) Tibial Nerve sliding,Siatic Nerve Sliding,Median nerve Sliding, (10 reps) Combine sliding plue Tensioning,(10 reps) Balance Training Sitting to standing (10 reps × 2 sets) Standing unsupported (Hold 30s × 3) Standing to sitting (10 reps × 2 sets) Transfers ( 10 reps) Standing with eyes closed( Hold 10-20s ×3) Standing with feet together (Hold 10-20s × 5) Reaching forward with outstretched arm (10 reps) Retrieving object from floor (8-10 reps) Turning to look behind (10 reps each side) Turning 360 degrees (3 reps each) Placing alternate foot on stool(10 reps each) Standing with one foot in front (Hold 15-30s × 3) Standing on one foot( Hold 15-30s × 3) Repetitions will increase gradually week wise"
219766046|NCT07210203|PROCEDURE|Balance Training only with conventional physical therapy|"balance training program combines conventional physical therapy with hot pack (10 min) and TENS (10 min), delivered over 4-6 weeks, 3-4 sessions per week, 30-40 minutes each. Training begins with easier Berg Balance Scale (BBS) tasks and progresses as the patient improves.~In Weeks 1-2, basic static and supported tasks are practiced, including sit-to-stand, standing unsupported (wide to narrow base), supervised transfers, reaching forward, and standing with eyes closed. Weeks 3-4 focus on dynamic stability with picking objects from the floor, head/torso turns, 360° turns, step-ups, and heel-to-toe stance. Weeks 5-6 progress to advanced functional tasks such as alternating foot placement on a stool, tandem stance, one-leg standing, gentle perturbations, and walking 5-10 m with head turns."
219017007|NCT05706077|OTHER|placebo Physical Therapy|The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
219585060|NCT04040322|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
219585061|NCT00466453|BEHAVIORAL|knowledge-adaptive Web-based instruction|
219585062|NCT04145453|BEHAVIORAL|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
219585063|NCT04145453|BEHAVIORAL|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
219585064|NCT04145453|BEHAVIORAL|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
219585065|NCT02195453|DRUG|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
219766047|NCT07211178|OTHER|There are no interventions in this observational study.|There are no interventions in this observational study.
218837526|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
218837527|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
218837528|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
218837529|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
219766048|NCT07209592|OTHER|AI gamification|The treatment program for AI gamification group will be in the form of cognitive tasks accompanied by cognitive driven motor tasks ( integrating cognitive strategies into motor tasks) exercises of the upper limb (shoulder, elbow, hand) in the form of AI gamification model. For each patient in study group, session will be for 6 minutes , three times per week for 4 weeks. The patients Will receive AI gamification via X-box with 3 D kinetic motion analysis giving the patient real time feedback, visual and auditory feedback about the range and task .Using this technology we will gain the benefits of both AI and Gamification, the patients will be engaged in the exercise intensively and for a longer time with out getting bored and the tasks will be enjoyable to capture their attention , in addition to traditional training plus conventional therapy
219445755|NCT03795636|OTHER|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
219017018|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
219017019|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
218837530|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
218837531|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
219017020|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
219445756|NCT03795636|OTHER|NaOCl (COLTENE®)|Sodium hypochlorite
219445757|NCT00862524|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
219445758|NCT00862524|DRUG|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
219445759|NCT01764022|DRUG|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
219445760|NCT01764022|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
219445761|NCT00474006|DRUG|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
219445762|NCT01207804|DEVICE|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
219445763|NCT04722380|PROCEDURE|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
219445764|NCT00626340|DRUG|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
219445765|NCT00626340|DRUG|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
219445766|NCT00626340|DRUG|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
219445767|NCT00626340|DRUG|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
219445768|NCT00291746|DRUG|Esomeprazole|
219445769|NCT00291746|PROCEDURE|Bravo technique|
219445770|NCT01899768|DRUG|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
219445771|NCT01899768|DRUG|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
219445772|NCT02092506|DRUG|10 day triple therapy|10 day triple therapy
219445773|NCT02092506|DRUG|10 day sequential therapy|10 day sequential therapy
219445774|NCT02092506|DRUG|10 day concomitant therapy|10 day concomitant therapy
219445775|NCT02245880|DEVICE|Glidescope|videolaryngoscope
219445776|NCT02245880|DEVICE|ILMA|handling of the device till the optimal ventilation achieved
219445777|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
219445778|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
219445779|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
219445780|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
219445781|NCT04247529|OTHER|Exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
219445782|NCT04247529|OTHER|No exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
219445783|NCT01728649|OTHER|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
219445784|NCT04933253|PROCEDURE|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
219445785|NCT00432640|PROCEDURE|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
219585066|NCT02195453|DRUG|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
219585067|NCT03417193|DRUG|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
219766049|NCT07209592|OTHER|conventional therapy|"the patiens will receive conventional therapy exercises in the form of flexibility exercises, strengthening exercises, Aerobic training exercise~* flexibility exercises , it will be in the form of functional stretching for shoulder adductors and flexors, elbow flexors ,wrist and finger flexors~* strengthening exercises , it will be mainly strengthening exercises for upper limb (shoulder extensors, elbow , wrist and finger extensors) in addition to trunk control exercises targeting proximal stability for distal mobility.~Aerobic training exercise, as a form of cognitive training exercises"
218837532|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
218837533|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
218837534|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
218837535|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
218837536|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
218837537|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
219017021|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
219017022|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
219017023|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
219445786|NCT00432640|PROCEDURE|Surgical staging|Surgical staging
219445787|NCT05355324|OTHER|no intervention|no intervention
219445788|NCT04028024|DRUG|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
219445789|NCT04626570|OTHER|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
219445790|NCT02158962|BEHAVIORAL|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
219585068|NCT05898321|DRUG|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
219585069|NCT05898321|DRUG|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
218837538|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
218837539|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
218837540|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
218837541|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
218837542|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
218837543|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
218837544|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
218837545|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
219585070|NCT03056157|BEHAVIORAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
219445791|NCT02921906|OTHER|High protein meal|Breakfast with high protein / low carbohydrate content
219585071|NCT03056157|BEHAVIORAL|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
219585072|NCT02077439|DEVICE|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
219585073|NCT02077439|DEVICE|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
219585074|NCT02077439|OTHER|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
219585075|NCT04013230|BEHAVIORAL|Usual care|Visit doctor and nurse at the clinic.
219585076|NCT04013230|BEHAVIORAL|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
219585077|NCT02879357|BEHAVIORAL|Training|"1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
219585078|NCT02286310|OTHER|Kinetic Chain Exercises|Exercises include kinetic chain segments.
219585079|NCT02286310|OTHER|Traditional Exercises|Stretching, strengthening exercises.
219766050|NCT07209735|DEVICE|Ultrasound|Participants in this arm will receive the structured MINUTES bundle during the first 30 minutes of shock management in the emergency department. The bundle includes: continuous monitoring, intravenous access and fluid resuscitation, early initiation of norepinephrine when indicated, point-of-care ultrasound assessment (cardiac, IVC, and lung ultrasound) to guide diagnosis and resuscitation, essential laboratory tests, early antibiotics if infection is suspected, and source control or stabilization measures.
218837546|NCT04608383|OTHER|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"* Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~* Swab from the laparoscopy filter"
218837547|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
218837548|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
218837549|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
218837550|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
219445792|NCT02921906|OTHER|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
219445793|NCT02921906|DRUG|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
219445794|NCT02921906|OTHER|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
219585080|NCT02336035|PROCEDURE|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
219585081|NCT06192836|PROCEDURE|Manual Removal 1|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
219585082|NCT06192836|PROCEDURE|Manual Removal 2|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
219585083|NCT06192836|PROCEDURE|Controlled Cord Traction 1|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
219766051|NCT07207382|DRUG|MTA group|MTA group is considered the control group
219766052|NCT07207382|DRUG|Premixed Bioceramic material|Premixed Bioceramic material is test group B
219766053|NCT07207382|DRUG|Treated Dentin Matrix|Treated Dentin Matrix is test group C
219766054|NCT07209878|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods.
219766055|NCT07209865|DRUG|68Ga-P16-093|Intravenous injection of Ga-P16-093 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods.
218837551|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
218837552|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
219445795|NCT04142840|DRUG|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
219445796|NCT04142840|DRUG|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
219445797|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
219445798|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
219766056|NCT07209553|DEVICE|Mobi|Mobi is a conversational AI coach that serves as an occupational health coach for employees. Through coaching conversations, Mobi gets to know each employee and help them set micro-goals to work towards their overall health goal/objective. Mobi suggests small, personalized activities for the micro-breaks that align with these goals. To ensure ease of use it is integrated into Slack and MS Teams.
219766057|NCT07210359|PROCEDURE|human treated dentin matrix hydrogel|material used for regenerative dentistry
219766058|NCT07210359|PROCEDURE|Theracal LC - Demineralized dentin matrix combination|material used for regenerative dentistry
219766059|NCT07210359|PROCEDURE|Retro Mta|material used for regenerative dentistry
219585084|NCT06192836|PROCEDURE|Controlled Cord Traction 2|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
219585085|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 1|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery"
219585086|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 2|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed"
219445799|NCT02233894|DRUG|Atrovent® - inhalets|
219445800|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
219445801|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
219585087|NCT04325763|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219585088|NCT04325763|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219585089|NCT04325763|DRUG|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
219585090|NCT04325763|DRUG|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
219585091|NCT04638335|BIOLOGICAL|Blood test|blood test for Anti-HAV antibodies
219585092|NCT04041349|DRUG|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
219585093|NCT03218059|PROCEDURE|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
219585094|NCT03712215|OTHER|Rehabilitation|diaphragmatic electrical stimulation
219445802|NCT04043416|OTHER|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
219445803|NCT01245127|DRUG|Ilaris|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
219445804|NCT04098016|BEHAVIORAL|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
219445805|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
219445806|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
219585095|NCT06033300|BIOLOGICAL|blood sample|blood sample
219585096|NCT03554044|DRUG|Anastrozole|Given PO
219585097|NCT03554044|DRUG|Exemestane|Given PO
219585098|NCT03554044|DRUG|Fulvestrant|Given IM
219585099|NCT03554044|DRUG|Letrozole|Given PO
219585100|NCT03554044|DRUG|Paclitaxel|Given IV
219585101|NCT03554044|BIOLOGICAL|Talimogene Laherparepvec|Given IT
219585102|NCT03554044|DRUG|Tamoxifen|Given PO
219585103|NCT03554044|DRUG|Nab paclitaxel|Given IV
219585104|NCT03554044|DRUG|Gemcitabine|Given IV
219585105|NCT03554044|DRUG|Carboplatin|Given IV
219585106|NCT00331240|DRUG|travoprost/timolol fixed combination|
219585107|NCT00331240|DRUG|placebo (artificial tears)|
219585108|NCT03527381|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
219585109|NCT03527381|OTHER|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
219585110|NCT01270165|DRUG|telbivudine|600mg, oral daily over 12 months
219585111|NCT03560986|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
219585112|NCT03560986|DRUG|Placebo|Glass vials with matching placebo.
219585113|NCT02807168|OTHER|NT-proBNP (Cardiac Biomarkers)|
219585114|NCT00708786|DEVICE|ICD|Ventricular arrhythmia treatment
219585115|NCT00708786|DEVICE|CRT-D|Ventricular arrhythmia treatment
219585116|NCT04060043|DRUG|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
219585117|NCT02183207|PROCEDURE|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
219585118|NCT02355483|DEVICE|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
218837553|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
218837554|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
218837555|NCT05799391|DRUG|SJC|Soothing cream jel
218837556|NCT05799391|OTHER|Placebo|Placebo cream jel
218837557|NCT02477917|BIOLOGICAL|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
218837558|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
218837559|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
218837560|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
218837561|NCT02509364|OTHER|No intervention|
218837562|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
218837563|NCT00375674|DRUG|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
218837564|NCT00375674|OTHER|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
218837565|NCT03269539|OTHER|MRI Imaging|
218837566|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
218837567|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
218837568|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
218837569|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
218837570|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
218837571|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
219445807|NCT03236506|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
219445808|NCT03236506|BEHAVIORAL|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
219445809|NCT03236506|DRUG|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
219445810|NCT06092840|DIETARY_SUPPLEMENT|Transform Burn|Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
219445811|NCT01832844|PROCEDURE|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
219445812|NCT01832844|PROCEDURE|"Group  without scan "|
219445813|NCT03616470|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
219445814|NCT03616470|DRUG|Placebo|Saline, 0.9% Sodium Chloride
219445815|NCT03827967|BIOLOGICAL|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
218837572|NCT03744910|BIOLOGICAL|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
218837573|NCT03744910|DRUG|Physiologic saline solution|Normal saline
218837574|NCT05631769|DRUG|Dual antiplatelet agent duration|"Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria)."
219585119|NCT02958982|DRUG|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
219585120|NCT02958982|DRUG|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
219766060|NCT07210645|OTHER|Gerofit Power Training|Gerofit Power Training will include a power training exercise prescription which will focus on having participants perform concentric portions of each resistance exercise as fast and as safely as possible with the eccentric component performed in a slow and controlled manner. The target dose of the power training intervention is 40-60% of the participant's 1-repetition maximum for 4-6 repetitions across 3-6 sets for each exercise. Exercises will focus on the major groups of the upper and lower body. All other Gerofit program components (balance, aerobic, and flexibility) will be consistent with the standard of care group. Sessions will be the same duration as the standard of care Gerofit group (60-75 minutes). The power training and standard of care groups will only differ in the form of resistance training performed.
218837575|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
218837576|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
218837577|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
219585121|NCT03870282|BEHAVIORAL|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
219585122|NCT02642848|PROCEDURE|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
219585123|NCT02642848|PROCEDURE|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
219585124|NCT02642848|PROCEDURE|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
219585125|NCT03633734|DRUG|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
219585126|NCT00152724|DEVICE|pressure strain system, iontophoresis|
219766061|NCT07210645|OTHER|Gerofit Standard of Care|Gerofit standard of care is a 60-75 minute multimodal exercise program which includes 20-30 minutes of aerobic training, traditional strength training of the major upper and lower body muscle groups (1-3 sets of 8-12 repetitions at moderate load), flexibility training and balance training.
219766062|NCT07209566|DIAGNOSTIC_TEST|Visceral Pain Stimulus|Participants will receive a visceral pain stimulus while being monitored for heart rate variability (HRV), and will have hip mobility and dorsiflexor strength assessed before and after.
219766063|NCT07209605|PROCEDURE|Group A Pull-out Suture Technique|A Brunner volar incision will be made, and the volar plate avulsion fragment will be identified. A 2-0 nonabsorbable braided suture will be passed through the volar plate using Kessler pattern, and Keith needles will be used to exit the sutures dorsally . .
219766064|NCT07209605|PROCEDURE|Group B- Mini-anchor Technique|Using the same volar approach, the volar plate will be reattached with two Mitek Micro QuickAnchors (1.3 x 3.7 mm), placed at the distal phalanx. Anchors will be inserted under fluoroscopic guidance to avoid dorsal cortex penetration. A hemimodified Kessler stitch pattern will be used with 3-0 polyester sutures.
218837578|NCT04234529|OTHER|Placebo|1.35g of microcellulose
218837579|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
219017029|NCT06829979|BEHAVIORAL|Access to napping/relaxation room|During the night shift, study participants will have access to the hospital unit's napping/relaxation room with a sound machine, diffusers for aromatherapy, a massage chair that can be used for napping, and snacks.
219017030|NCT06829979|OTHER|Blue and green light blocking glasses|During the night shift, participants will be asked wear study-provided blue and green light blocking glasses.
219585127|NCT00152724|DRUG|scopolamin|
219585128|NCT00152724|DRUG|emla|
219585129|NCT00152724|DRUG|capsaicin|
219585130|NCT00152724|DRUG|aspirin|
219585131|NCT00152724|DRUG|clopidogrel|
219585132|NCT00152724|DRUG|celecoxib|
219585133|NCT00152724|DRUG|indomethacin|
219585134|NCT00152724|DRUG|acetylcholine|
219585135|NCT00152724|DRUG|sodium nitroprusside|
219585136|NCT00152724|DRUG|brethyllium|
219585137|NCT00152724|DEVICE|general and local heating|
218837580|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
218837581|NCT04328753|OTHER|Distilled water|act as a negative control in this study
218837582|NCT06785454|DRUG|Lorundrostat|Lorundrostat tablet.
219585138|NCT06490237|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression, vestibular neurotomy, meningioma or schwannoma removal), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests in noise and in silence. During the operation, stimuli are delivered in silence and in noise, under the same conditions as during the preoperative auditory exploration."
218837583|NCT06785454|DRUG|Placebo|Lorundrostat matching placebo tablet.
218837584|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
218837585|NCT00064259|DRUG|cisplatin|Given IV
219445816|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
218837586|NCT00064259|DRUG|fluorouracil|Given IV
218837587|NCT02953093|DRUG|Acarbose|see arm description
218837588|NCT02953093|OTHER|Placebo|See arm description
218837589|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
219445817|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
219445818|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
219445819|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
219445820|NCT01606332|PROCEDURE|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
219445821|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
219445822|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
219445823|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
219445824|NCT00822640|DEVICE|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
219445825|NCT05575583|DEVICE|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
219445826|NCT05575583|DEVICE|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
219445827|NCT03808844|DRUG|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
219445828|NCT03808844|DRUG|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
219445829|NCT04739995|DRUG|Low-dose naltrexone|4.5 mg LDN/day for 1 year
219445830|NCT01599949|DRUG|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
219445831|NCT01541540|BEHAVIORAL|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
218837590|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
218837591|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
218837592|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219445832|NCT01541540|BEHAVIORAL|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
219585139|NCT03256331|DRUG|BEL-X-HG|"This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
218837593|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
218837594|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
218837595|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
219585140|NCT04471025|PROCEDURE|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
219585141|NCT05321225|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
219766065|NCT07209228|BEHAVIORAL|Haptic-Integrated Interactive Virtual Reality Experience|Participants will use haptic gloves to interact with the virtual reality experience
219766066|NCT07209228|BEHAVIORAL|Traditional Virtual Reality Experience (Hand Controllers)|Participants will use traditional hand controllers to interact with the virtual reality experience
219585142|NCT03995186|BEHAVIORAL|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
219766067|NCT07209436|PROCEDURE|Paravertebral block (single injection)|Paravertebral block at preop
219766068|NCT07209436|PROCEDURE|Pectoral block|Pectoral block at preop
219766069|NCT07209410|DRUG|Brimonidine Tartrate Ophthalmic 0.025%|Lumify is an approved eye drop to minimize ocular hyperemia.
219766070|NCT07210723|DRUG|danicamtiv|Danicamtiv will be administrated twice daily for up to 26 weeks
219766071|NCT07210723|DRUG|Placebo|Placebo will be administrated twice daily for up to 26 weeks
219766072|NCT07210554|BIOLOGICAL|Stapokibart injection|subcutaneous injection
219766073|NCT07210554|DRUG|Placebo|subcutaneous injection
219585143|NCT03995186|BEHAVIORAL|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
219585144|NCT04689919|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
219585145|NCT00593736|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
219585146|NCT00593736|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
219585147|NCT00593736|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
219585148|NCT00593736|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
219766074|NCT07210073|BEHAVIORAL|Video Education|Videos were created using deepfake technology, utilizing AI to replicate the voice of the patients' primary physician.
219766075|NCT07210073|OTHER|Control|Standard treatment
219766076|NCT07209683|DEVICE|transcranial photobiomodulation|"The Vielight Neuro Gamma TPBM devices (©Vielight Inc.) will be used to transmit pulsed near-infrared (NIR) energy through the cranium. Device emits NIR photons at 810 m wavelength generating \~100 mW/cm2 pulsed NIR power modulated at 40 Hz frequency. The six NIR light sources are positioned along the midline over the frontal, pariatel and occipital cortices, bilaterally over the temporal cortex, and intranasally. Due to its portable design, Vielight Neuro TBPM instruments can be used in the laboratory, bedside, or at the participant's home.~Active / sham photobiomodulation sessions last for 20 minutes and will be administered at a laboratory-, home-, or office-based setting depending on the preference of the participant. TPBM will be performed three or four times a week for four weeks, maximum once every other day. Participants will complete a questionnaire of adverse events after each photobiomodulation session."
219766077|NCT07210047|BIOLOGICAL|HuL001-10 mg/kg|Anti-ENO1 monoclonal antibody
219766078|NCT07210047|BIOLOGICAL|HuL001-15 mg/kg|Anti-ENO1 monoclonal antibody
219766079|NCT07210047|DRUG|Lenalidomide and Dexamethasone|Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM)
219766080|NCT07209345|DRUG|FA+Ropivacaine|0.5 mL FA (50 mg; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline
219766081|NCT07209345|DRUG|Normal (0.9%) saline|Control group:
219766082|NCT07209345|DRUG|Ropivacaine|15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline
219766083|NCT07209462|DRUG|Low dose of MRM-3379|Oral capsule
218837596|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
218837597|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
218837598|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
218837599|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
218837600|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
218837601|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
218837602|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
219766084|NCT07209462|DRUG|Middle Dose of MRM-3379|Oral capsule
219766085|NCT07209462|DRUG|High dose of MRM-3379|Oral capsule
219766086|NCT07209462|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
219766087|NCT07209462|DRUG|Low dose of MRM-3379 Open-Label|Oral capsule
219766088|NCT07210697|DRUG|Xylitol Gum|1 gram of xylitol per piece of gum with one serving being 2 pieces of gum
218837603|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
218837604|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
219445833|NCT06313749|DEVICE|Minimally Invasive Micro Sclerostomy Device|During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
219445834|NCT01869452|BEHAVIORAL|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
219445835|NCT02017067|PROCEDURE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
219445836|NCT03080701|BEHAVIORAL|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
219445837|NCT03080701|BEHAVIORAL|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
219445838|NCT03930927|DRUG|Self Assembling peptide|enamel regeneration
219445839|NCT03930927|DRUG|remineralizing agent|enamel regeneration
219445840|NCT03842761|DRUG|BI 685509|Tablet
219445841|NCT03842761|DRUG|Placebo|Tablet
219445842|NCT03887325|DRUG|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
219445843|NCT03887325|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
219445844|NCT03621124|PROCEDURE|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
219445845|NCT03621124|OTHER|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
219445846|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
219445847|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
219445848|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
219445849|NCT04327895|BEHAVIORAL|evaluation of the need for training|analyse of results of survey
219445850|NCT04837690|PROCEDURE|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
219445851|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
219445852|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
219445853|NCT01037140|DRUG|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
219445854|NCT01037140|DRUG|placebo|oral placebo tablets similar to active comparator
219445855|NCT01466062|DRUG|Palivizumab|
219445856|NCT00676728|DRUG|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
219585149|NCT05379049|BIOLOGICAL|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
219585150|NCT05442710|BIOLOGICAL|ARTICE|Extracorporal treatment with purified granulocyte concentrate
219585151|NCT01268332|DRUG|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
219585152|NCT05227911|PROCEDURE|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
219585153|NCT01857271|DRUG|Erlotinib Hydrochloride|Given PO
219585154|NCT01857271|PROCEDURE|Therapeutic Conventional Surgery|Undergo thoracotomy
219585155|NCT01857271|OTHER|Laboratory Biomarker Analysis|Correlative studies
219585156|NCT02390609|DRUG|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
219585157|NCT02390609|DRUG|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
219585158|NCT02390609|DRUG|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
218837605|NCT02897037|DRUG|heparin|heparin monotherapy
219445857|NCT00865202|DRUG|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
219445858|NCT00865202|DRUG|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
219585159|NCT02390609|DRUG|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
219585160|NCT02390609|DRUG|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
219585161|NCT02390609|DRUG|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
219585162|NCT02192320|DRUG|Atorvastatin|20 mg (every evening orally) for 5 weeks
219585163|NCT02192320|DRUG|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
219196492|NCT06804512|BEHAVIORAL|Balance Beam Walking|Participants will walk on a treadmill mounted balance beam to assess their balance
218837606|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
219196493|NCT06805266|DRUG|Vortioxetine (tablet)|Vortioxetine will be used with the aim of treating freezing of gait in subjects with Parkinson Disease and depressive symptoms
219196494|NCT06805487|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|0.5 ml of TV003 delivered via subcutaneous injection. TV003 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31- 7164 and 10\^3.3 PFU/mL of rDEN4Δ30
219196495|NCT06805487|BIOLOGICAL|Plasmalyte|0.5 mL of PlasmaLyte delivered via subcutaneous injection
219445859|NCT02865928|DRUG|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
219445860|NCT02865928|DRUG|Normal Saline|Same injection technique as intervention arm with normal saline
219445861|NCT03531710|BIOLOGICAL|UB-311|Intramuscular injection
219445862|NCT03531710|DRUG|Placebo|Intramuscular injection
219445863|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
219445864|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
219445865|NCT03152110|OTHER|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
219445866|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
219445867|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
219445868|NCT03609710|DEVICE|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
219445869|NCT03609710|PROCEDURE|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
219445870|NCT03609710|PROCEDURE|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
219445871|NCT03609710|DEVICE|Robotic surgery|Robotic low anterior resection for rectal cancer
219445872|NCT02082665|DRUG|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
219445873|NCT02082665|DRUG|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
219445874|NCT02082665|DRUG|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
219445875|NCT04584944|RADIATION|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
219445876|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
219445877|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
219445878|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
219445879|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
219445880|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
219445881|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
219445882|NCT04743869|DEVICE|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
219445883|NCT04743869|DEVICE|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
219445884|NCT05762965|DIETARY_SUPPLEMENT|GOS 1|1 sachet each morning
219445885|NCT05762965|DIETARY_SUPPLEMENT|GOS 2|1 sachet each morning
219445886|NCT05580237|PROCEDURE|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
219445887|NCT03813199|DRUG|ABX464 50mg|ABX464 is a new anti-inflammatory drug
219445888|NCT03813199|DRUG|Matching Placebo|placebo matching with ABX464
219445889|NCT03813199|DRUG|ABX464 100mg|ABX464 is a new anti-inflammatory drug
219445890|NCT03813199|DRUG|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
219445891|NCT05987514|DIAGNOSTIC_TEST|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
219445892|NCT02264652|DEVICE|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
219585164|NCT04581174|DIAGNOSTIC_TEST|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
219585165|NCT03031886|OTHER|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
219585166|NCT03031886|OTHER|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
219585167|NCT06264401|OTHER|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
219585168|NCT06264401|OTHER|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
219585169|NCT02532725|PROCEDURE|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
219766089|NCT07209995|OTHER|retroclavicular infraclavicular brachial plexus block for|The patient will be placed supine, head facing the contralateral side. A high- frequency 13-6 MHz linear array transducer probe will be placed medial to the coracoid process below and perpendicular to the clavicle to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will be inserted in the supraclavicular fossa, approximately one cm posteriorly to the clavicle, and advanced in plane parallel to the probe. After passing the initial blind zone of about 2 cm caused by the clavicle's acoustic shadow, the needle tip will be continuously seen, until it appears posterior to the axillary artery. A single injection of the local an esthetic will be performed without needle repositioning unless paresthesia is elicited
219766090|NCT07209995|OTHER|axillary block|The axillary nerve block is performed from behind the patient with the patient seated. The axillary nerve will be identified within the quadrilateral space by placing high frequency linear probe parallel to the long axis of the humeral shaft. The nerve was identified next to the circumflex artery
219766091|NCT07208773|DRUG|YL201|YL201 will be administered as IV infusion
219766092|NCT07208773|DRUG|Ivonescimab|Ivonescimab will be administered as IV infusion.
219585170|NCT02532725|PROCEDURE|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
219766093|NCT07210775|DRUG|Imiquimod (topical use)|Participants will be prescribed imiquimod 5% cream, with instructions to apply the cream with soft tray or gauze daily for one hour, five days a week (Monday to Friday). 6 week as one course and additional course may be added based on participant's conditions and consent. 2 follow up biopsies are scheduled 6 months and 12 months after the start of the treatment course.
219766094|NCT07211204|PROCEDURE|Physical examination|Physical examination and interview for obtaining a medical record
219766095|NCT07211204|OTHER|Liquid-based cytology|Screening test for cervical precursor lesions and/or cancer. LBC is a procedure in which a cervical smear is examined under the microscope.
219766096|NCT07211204|OTHER|Molecular screening|The molecular screening detects three human biomarkers associated with cervical precursor lesions and/or cervical cancer. Biomarker detection is done by Western blot and ELISA in human sera.
219766097|NCT07211204|OTHER|HPV DNA test|HPV DNA detection is performed using a cervical swab.
219766098|NCT07211204|DIAGNOSTIC_TEST|Colposcopy|A diagnostic procedure to visually examine the cervix, vagina, and vulva with a colposcope.
219766099|NCT07211204|DIAGNOSTIC_TEST|Histopathology|Is the definitive diagnosis of cervical precursor lesions and cervical cancer. It is the microscopic study of diseased cells and tissues stained with hematoxylin and eosin.
219766100|NCT07207369|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
219766101|NCT07207369|DEVICE|Saline Control|Intradermal Injections
219017060|NCT06294067|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.
219017061|NCT06294067|DIETARY_SUPPLEMENT|soybean oil placebo|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks. The 0mg group will receive only placebos.
219766102|NCT07211048|DRUG|Anti-CD19 gene injection|Intravenous infusion of Anti-CD19 gene injection （three dosage groups）
219585171|NCT02532725|PROCEDURE|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
219585172|NCT02532725|PROCEDURE|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
219585173|NCT03493386|DRUG|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
219445893|NCT02950311|DRUG|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
219445894|NCT02950311|OTHER|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
219445895|NCT05726643|OTHER|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
219445896|NCT05726643|OTHER|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
219445897|NCT01191138|PROCEDURE|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
219445898|NCT01191138|PROCEDURE|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
219445899|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
219445900|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
219445901|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
219445902|NCT03961139|OTHER|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
219445903|NCT02269982|DEVICE|AR-v7 assays|
219445904|NCT03278444|OTHER|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
219445905|NCT03278444|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
219445906|NCT03278444|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
219445907|NCT05770739|BEHAVIORAL|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
219445908|NCT05770739|BEHAVIORAL|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
219585174|NCT03493386|DRUG|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
219585175|NCT02357563|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
219585176|NCT02357563|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
219585177|NCT01020955|DRUG|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
219585178|NCT01020955|DRUG|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
219585179|NCT00201955|DRUG|Rebamipide|
219766103|NCT07209787|DEVICE|SIS-reinforced anastomosis|This intervention uses a porcine small intestinal submucosa (SIS) reinforcement patch during rectal anastomosis. The sterile, biologic, acellular mesh is mounted onto the stapler anvil and cartridge. When fired, it encircles and externally reinforces the staple line. This provides immediate mechanical support and promotes healing by serving as a scaffold for tissue integration. It is a single-use, resorbable material intended to reduce anastomotic leakage by improving seal integrity, distinguishing it from standard unreinforced stapling or other synthetic/biologic grafts.
219766104|NCT07211022|PROCEDURE|Digital impression using intraoral scanner|Digital impression of complete- arch edentulous patients using intraoral scanner
219766105|NCT07211022|PROCEDURE|Digital impression using intraoral photogrammetry|Digital impression of complete-arch edentulous patients using intraoral photogrammetry
219017064|NCT06692907|OTHER|B7A (ETEC challenge strain)|A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.
219017065|NCT06692907|BIOLOGICAL|CssBA|A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.
219017066|NCT06692907|BIOLOGICAL|dmLT|An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.
219196496|NCT06805487|BIOLOGICAL|Challenge virus ZIKV-SJRP/2016-184|0.5 ml of ZIKV-SJRP/2016-184 delivered via subcutaneous injection. ZIKV-SJRP/2016-184 contains a dose of 10\^2 plaque-forming units (PFU).
219585180|NCT01604135|DEVICE|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
219445909|NCT04493944|BEHAVIORAL|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
219445910|NCT00515944|DRUG|Botulinum neurotoxin type A, free of complexing proteins|
219445911|NCT05909462|DRUG|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine|ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
219445912|NCT00481689|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
219585181|NCT01468818|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
219585182|NCT01468818|DRUG|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219585183|NCT01468818|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
218837607|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
218837608|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
218837609|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
218837610|NCT00585442|DRUG|calcitriol|1.0 mcg daily
218837611|NCT00585442|DRUG|Placebo|Placebo
218837612|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
218837613|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
218837614|NCT00006447|PROCEDURE|Social Support|
218837615|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
219017067|NCT06692907|OTHER|Placebo|Placebo
219017068|NCT06095089|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
219017069|NCT06095089|DRUG|JNJ-87189401|JNJ-87189401 will be administered.
219445913|NCT00312728|DRUG|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
219445914|NCT00312728|DRUG|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
219445915|NCT00312728|DRUG|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
218837616|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
218837617|NCT02973204|DRUG|Sorafenib|
218837618|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
218837619|NCT02973204|DRUG|Everolimus|
218837620|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
218837621|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
219585184|NCT01607307|DRUG|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
219585185|NCT01607307|DRUG|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
219585186|NCT06455007|DRUG|Propolis|Propolis 3x10 drops (7 days)
219445916|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
219445917|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
219445918|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
219445919|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
219585187|NCT00935688|OTHER|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
219585188|NCT00540683|DEVICE|Diffuse Optical Spectroscopy|Muscle properties
219585189|NCT01568060|OTHER|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
219585190|NCT01735955|DRUG|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
219766106|NCT07210333|DEVICE|non-invasive intracranial pressure monitoring|non-invasive intracranial pressure monitoring that provides continuous bedside monitoring.
219766107|NCT07210385|PROCEDURE|anterior horizontal maxillary bone augmentation using autogenous and bovine sticky bone|Participants in this group will undergo maxillary horizontal ridge augmentation using a mixture of autogenous bone chips and S1 Bovine Bone Graft in a 70:30 ratio. The graft will be prepared as Sticky Bone and applied to the defect site for augmentation.
219766108|NCT07210385|PROCEDURE|anterior horizontal maxillary bone augmentation using autogenous and bovine bone shell technique (khoury)|Participants in this group will undergo maxillary horizontal ridge augmentation using the Khoury Bone Shell Technique, combining autogenous bone blocks and Bovine Bone Graft to reconstruct the alveolar ridge. The graft will be fixed and stabilized to provide a rigid shell for bone regeneration.
219766109|NCT07208409|DEVICE|14 Fr chest tube|Chest tube size of 14Fr will be inserted
219766110|NCT07208409|DEVICE|12 Fr chest tube|Chest tube of 12 Fr will be inserted
219766111|NCT07208409|DEVICE|8 Fr chest tube|Chest tube size of 8Fr will be inserted
219766112|NCT07209358|DEVICE|EDX110|EDX110 wound dressing system EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
219766113|NCT07210918|PROCEDURE|Blood Product|Collecting 5 ml of blood sample from individuals in the study group and obtaining serum from it.
218837622|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
218837623|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
218837624|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
218837625|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
218837626|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
218837627|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
218837628|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
218837629|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
218837630|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
218837631|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
218837632|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
218837633|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
218837634|NCT02727387|DRUG|BUMEL|Consolidation phase
218837635|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
219585191|NCT01906450|DRUG|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
219585192|NCT01906450|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
219585193|NCT05084716|BEHAVIORAL|Enhanced PrEP provision|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
219585194|NCT02890654|OTHER|First time measure|"* Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale"
219585195|NCT02890654|OTHER|Second time measure|"* Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale"
219585196|NCT02890654|OTHER|Third time measure|"* Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review"
219585197|NCT00362544|DRUG|Ambisome|
219585198|NCT05042544|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
219585199|NCT01930565|OTHER|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
219585200|NCT01930565|OTHER|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
219585201|NCT03503526|BEHAVIORAL|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
219585202|NCT00879957|DRUG|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
219585203|NCT00879957|DRUG|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
219585204|NCT03373773|PROCEDURE|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
218837636|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
219766114|NCT07208851|BEHAVIORAL|Problem Management Plus booster session|A 60-minute session designed to refresh participants on the PM+ strategies (diaphragmatic breathing, problem management, behavioral activation, strengthening social support). Session consists of practicing strategies and developing plans for the future.
219766115|NCT07210541|PROCEDURE|aortic valve/root replacement|Aortic valve or aortic root replacement with stented biological prosthesis or aortic allograft
218837637|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
219585205|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
219585206|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
219585207|NCT00001110|PROCEDURE|Bronchoalveolar lavage|
219585208|NCT01846910|BEHAVIORAL|Tooth Whitening|1\. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
219766116|NCT07211256|DEVICE|tDCS of the motor cortex|Home-delivered tDCS device
219766117|NCT07209514|DEVICE|Implantable SCS with Closed Loop mechanism|Participants will be treated with an implantable spinal cord stimulation system programmed to deliver differentially multiplexed targeting pulse program with closed-loop adjustment using evoked compound action potential feedback. All subjects will first undergo a short percutaneous trial phase of spinal cord stimulation. Those who meet trial success criteria will then receive permanent implantation with a paddle lead and the implantable pulse generator. After implantation, closed-loop DTM therapy will be enabled and optimized at each follow-up visit. The goal of the intervention is to evaluate feasibility, safety, and effectiveness of closed-loop DTM spinal cord stimulation in patients with painful diabetic peripheral neuropathy.
219766118|NCT07209423|OTHER|Strength and Range of Motion|Shoulder external rotation and internal rotation strength will be measured with a dynamometer at the end range, as well as at retroverted shoulder neutral and zero degrees for three times. Grip strength will also be measured three times using the dynamometer after the shoulder strength assessments.
219585209|NCT01846910|BEHAVIORAL|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
219585210|NCT02176408|BEHAVIORAL|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
219585211|NCT02176408|BEHAVIORAL|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
219585212|NCT02176408|BEHAVIORAL|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
219585213|NCT03204708|DEVICE|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
219585214|NCT03204708|DRUG|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
219585215|NCT00650208|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
219766119|NCT07211165|DRUG|[14C]Clifutinib|The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.
219766120|NCT07211347|PROCEDURE|Stellate Ganglion Block|There is no randomized clinical study in the literature that evaluated the efficacy and safety of the stellate ganglion infiltration procedure in patients with electrical storm.
219585216|NCT00650208|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
219766121|NCT07210632|DRUG|Nivolumab|Participants will receive a combination dose of nivolumab followed by nivolumab-IRDye800 (nivo800) for a total dose of 240 mg. Nivo800 has never been assessed in patients before and therefore cohort 1 will receive only a test dose to determine the safety (n=3). Cohorts 2-4 will receive escalating doses of nivo800, keeping the overall dose nivolumab + nivo800 no more than 240 mg. Participants will undergo planned Standard of Care surgical resection at 1-4 days after infusion.
218837638|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
219445920|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
219585217|NCT05428410|OTHER|IL-4R|IL-4R was injected subcutaneously.
219445921|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
219585218|NCT05428410|OTHER|Placebo|Placebo was injected subcutaneously.
219585219|NCT03934411|DRUG|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
219585220|NCT03934411|OTHER|Placebo|The subjects will orally ingest 100 mg calcium powder
219585221|NCT06132932|DRUG|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
219585222|NCT05568901|BEHAVIORAL|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
218837639|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
218837640|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
218837641|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
219445922|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
219445923|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
218837642|NCT03608371|DRUG|BTRX-246040|oral capsule
218837643|NCT03608371|DRUG|Placebo|oral capsule matching BTRX-246040 capsule
218837644|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
218837645|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
218837646|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
219445924|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
219445925|NCT01807494|DEVICE|Total hip replacement components|All patients will receive the same implants
219766122|NCT07210632|DRUG|Nivolumab-IRDye800|Participants will receive a combination dose of nivolumab followed by nivolumab-IRDye800 (nivo800) for a total dose of 240 mg. Nivo800 has never been assessed in patients before and therefore cohort 1 will receive only a test dose to determine the safety (n=3). Cohorts 2-4 will receive escalating doses of nivo800, keeping the overall dose nivolumab + nivo800 no more than 240 mg. Participants will undergo planned Standard of Care surgical resection at 1-4 days after infusion.
219766123|NCT07210424|PROCEDURE|Mesh Fixation|Mesh fixation during Lichtenstein inguinal hernia repair.
219445926|NCT02458742|DRUG|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
219445927|NCT02458742|DRUG|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
219445928|NCT02711410|DRUG|Clopidogrel|
219445929|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
219445930|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
219445931|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
219445932|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
219445933|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
219445934|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
219445935|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
219445936|NCT01922986|DEVICE|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
219445937|NCT01922986|DEVICE|sham rTMS|20 minutes of sham rTMS stimulation
219445938|NCT01922986|BEHAVIORAL|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
219445939|NCT00671476|DRUG|pegylated liposomal doxorubicin hydrochloride|
219445940|NCT00671476|GENETIC|DNA methylation analysis|
219445941|NCT00671476|GENETIC|TdT-mediated dUTP nick end labeling assay|
219445942|NCT00671476|GENETIC|fluorescence in situ hybridization|
219445943|NCT00671476|GENETIC|loss of heterozygosity analysis|
219445944|NCT00671476|GENETIC|polymerase chain reaction|
219445945|NCT00671476|OTHER|immunoenzyme technique|
219445946|NCT00671476|OTHER|immunohistochemistry staining method|
219445947|NCT00671476|OTHER|laboratory biomarker analysis|
219445948|NCT00671476|PROCEDURE|breast duct lavage|
219445949|NCT00671476|PROCEDURE|neoadjuvant therapy|
219445950|NCT00671476|PROCEDURE|therapeutic conventional surgery|
219445951|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
219445952|NCT04857606|DRUG|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
219445953|NCT04857606|DRUG|Placebo|Single dose of placebo administered as a subcutaneous injection.
219445954|NCT05382806|DRUG|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
219445955|NCT00723086|DRUG|docetaxel (XRP6976)|combined treatment with prednisolone
219445956|NCT00662285|DIETARY_SUPPLEMENT|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
219445957|NCT05153564|DRUG|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
219445958|NCT05153564|DRUG|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
219445959|NCT05153564|DRUG|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
219445960|NCT05153564|DRUG|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
219445961|NCT05153564|DRUG|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
219445962|NCT00125697|PROCEDURE|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
219445963|NCT02213081|DRUG|Ulipristal|Patient will take 15mg every other day, or every 4 days per week.
219585223|NCT05568901|BEHAVIORAL|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
219445964|NCT01401985|DRUG|TD-1211|Capsules
218837647|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
219445965|NCT01401985|DRUG|Placebo|Capsules
219445966|NCT00113906|DRUG|melatonin|
219445967|NCT01674972|OTHER|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
219445968|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
219445969|NCT03045640|OTHER|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
219585224|NCT04708548|OTHER|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
219585225|NCT04708548|OTHER|Psychological Distress|Measured of the distress experienced by patients
219585226|NCT04708548|OTHER|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
219585227|NCT04708548|OTHER|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
219585228|NCT03514849|PROCEDURE|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
219585229|NCT03514849|PROCEDURE|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
219585230|NCT03514849|DRUG|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
218837648|NCT05244603|BEHAVIORAL|Ideal binary mask|Speech in noise processed by ideal binary mask to reduce background noise
218837649|NCT06349343|BIOLOGICAL|CD19/BCMA CAR-T cell therapy|CD19/BCMA CAR-T cell will be infused intravenously at 3 doses: Dose A, Dose B, Dose C.
219585231|NCT03599830|OTHER|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
219585232|NCT00405886|DRUG|Neramexane|Oral tablets, duration: 16 weeks
219585233|NCT00405886|DRUG|Placebo|Oral tablets, duration: 16 weeks
219585234|NCT04380363|DEVICE|Honda Walk Assist (HWA) device|Use of HWA for 2 months in the home setting
219585235|NCT04380363|OTHER|SRALab fitness center membership|Membership to Shirley Ryan AbilityLab fitness center for 2 months
219585236|NCT01434186|DRUG|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
219585237|NCT01434186|DRUG|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
219585238|NCT01434186|DRUG|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
219585239|NCT01434186|DRUG|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
219585240|NCT00831766|DRUG|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
219585241|NCT00831766|DRUG|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
219585242|NCT00831766|DRUG|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
219585243|NCT05604248|OTHER|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
219585244|NCT01762930|DRUG|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
218837650|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
218837651|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
218837652|NCT00708136|BEHAVIORAL|water based training program to improve balance|
218837653|NCT02752919|DRUG|Galunisertib|Administered orally
218837654|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
218837655|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
219017116|NCT06745921|BIOLOGICAL|HydroVax-001B WNV|A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells. The vaccine contains 10 mcg of inactivated purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.10% aluminum hydroxide, 10% D-sorbitol, 0.001% Polysorbate 80 (Tween80) in 10 mM phosphate-buffer with 350 mM NaCl.
219017117|NCT06745921|OTHER|Placebo|Placebo
219017118|NCT06745921|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
219445970|NCT02237144|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
219445971|NCT02237144|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
219445972|NCT02237144|OTHER|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
219445973|NCT02237144|BEHAVIORAL|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
219445974|NCT04630444|DRUG|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
219445975|NCT00658866|PROCEDURE|Microdialysis|PK measurements with microdialysis
219445976|NCT05098249|DRUG|Verum|The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
219445977|NCT05098249|DRUG|Placebo|The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
219445978|NCT00836316|DRUG|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
219445979|NCT02640430|DEVICE|standard treatment|20 minutes, twice a day for 10 sessions
219445980|NCT02640430|DEVICE|Free Aspire|20 minutes, twice a day for 10 sessions
219445981|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
219445982|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
219445983|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
219445984|NCT03284151|RADIATION|Cyberknife|
219445985|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
219445986|NCT00311090|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
219445987|NCT00311090|DRUG|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
219445988|NCT00311090|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
219445989|NCT00311090|DRUG|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
219445990|NCT02022891|BEHAVIORAL|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
219445991|NCT04265092|DRUG|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
219445992|NCT02327728|PROCEDURE|Botulinum toxin A injection (5 sites: 12.5U)|
219445993|NCT02327728|PROCEDURE|Botulinum toxin A injection (4 sites: 10U)|
219445994|NCT02327728|DRUG|Botulinum toxin A 12.5U|
219445995|NCT02327728|DRUG|Botulinum toxin A 10U|
219445996|NCT00438490|DRUG|Recombinant Human Prolactin|
218837656|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
218837657|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
218837658|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
218837659|NCT05984745|DRUG|Coenzyme Q10 Forte® capsules|Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
218837660|NCT06358573|DRUG|INT230-6|"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."
218837661|NCT06358573|OTHER|neoadjuvant immuno-chemotherapy|Standard of care
218837662|NCT06788106|BEHAVIORAL|high-intensity aerobic exercise + synchronous music|This group will be intervened under high-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
218837663|NCT06788106|BEHAVIORAL|medium-intensity aerobic exercise + synchronous music|This group will be intervened under medium-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
218837664|NCT06788106|BEHAVIORAL|low-intensity aerobic exercise + synchronous music|This group will be intervened under low-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
218837665|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 1|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
219766124|NCT07210905|BEHAVIORAL|3-step Assess-Advice-Refer|Four implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all site facilitators will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the FitARise protocol is standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
219766125|NCT07209852|DEVICE|Pacemaker lead|The pacemaker lead under investigation is a bipolar, steroid-releasing pacemaker electrode with active fixation (IS-1 connection) designed for chronic stimulation and sensing in the right atrium, right ventricle or left bundle branch area (LBBA). In this study, the lead is implanted in the LBBA and connected to a single- or dual-chamber pacemaker. Implantation is performed using a compatible, CE-marked catheter for pacemaker implantation.
219766126|NCT07209332|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
219766127|NCT07211269|OTHER|Real-time fMRI neurofeedback training|Real-time neurofeedback information is computed using the Turbo Brain voyager (TBV) 4.0 software (Brain Innovation, Maastricht, The Netherlands). Functional images are collected and processed in real time based on contrasts of regulation vs. rest conditions. The BOLD signal of the target region is then transformed into visual bars and displayed to participants via the projector screen while participants keep using regulation strategy (heartbeat interoception in our study) to upregulate the target region.
218837666|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 2|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
219017128|NCT05407441|DRUG|Tazemetostat|oral, twice daily, dosage per protocol
219017129|NCT05407441|DRUG|Nivolumab|IV, dosage and schedule per protocol
219017130|NCT05407441|DRUG|Ipilimumab|IV, dosage and schedule per protocol
219017131|NCT04931095|DRUG|Cannabis|Cannabis will be orally ingested via a brownie
219017132|NCT04931095|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
219017133|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
219017134|NCT05466786|OTHER|Standard Management|Standard Management
219445997|NCT03644589|BIOLOGICAL|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
219445998|NCT03644589|DRUG|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
219445999|NCT04407286|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3 capsules
219446000|NCT04135391|BEHAVIORAL|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
219446001|NCT05953103|DRUG|Synbixin/Placebo|Synbixin/Placebo
219446002|NCT01307228|OTHER|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
219446003|NCT00744991|DRUG|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
219446004|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
219446005|NCT02515851|DRUG|Exparel|
219446006|NCT02515851|DRUG|Placebo|
219446007|NCT01858506|PROCEDURE|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
219446008|NCT01858506|PROCEDURE|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
219446009|NCT00665691|OTHER|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
219446010|NCT05299151|OTHER|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
219446011|NCT05299151|OTHER|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
219446012|NCT01215786|DRUG|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
219446013|NCT01215786|DRUG|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
219446014|NCT01215786|DRUG|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
219446015|NCT05265390|OTHER|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
219475950|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
219475951|NCT01042431|OTHER|No Intervention|No intervention
219017142|NCT06441968|BIOLOGICAL|MPV/S-2P|A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.
219766128|NCT07209930|OTHER|Exercise|"After a 12h overnight fast, baseline measurements are collected. Participants are then provided with a standardized breakfast meal (60g carbohydrate). After consumption of the breakfast, participants remain seated seated for 30 minutes, before cycling on a cycle ergometer for 30 minutes at an intensity equivalent to 10% above the first ventilatory threshold (VT1). Sixty minutes of rest sitting on a chair will follow the 30-minute cycle.~During the total 120 minute test, various measurements are collected at regular intervals, including: blood glucose measurements via finger prick, CGM measurements, RPE, HR, measures of heart rate variability (HRV) (RMSSD (Root Mean Square of Successive Differences) and SDNN (Standard Deviation of NN intervals)), and intensity of any hypoglycaemia-related symptoms using a Visual Analogue Scale (VAS)."
218837667|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 3|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
219766129|NCT07209930|OTHER|Rest|The procedure for the resting condition visits is identical to that of the exercise condition, with the only difference being that the 30-minute cycling session will be replaced by an additional 30 minutes of seated rest. This will ensure that the total duration of the session and the timing of all measurements will remain consistent across conditions.
219766130|NCT07210567|BEHAVIORAL|Mindfulness|Participants will complete 4 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 4 online surveys (baseline, quit date, end of treatment, and 3-month follow-up), and a brief phone call at the end of treatment to provide feedback. Participants will use the app every day to complete daily diaries and ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-30 minutes). Participants will also be provided with nicotine patches.
219766131|NCT07210567|BEHAVIORAL|Quitline|Participants will be referred to Quitline to receive standard care smoking cessation treatment, including counseling and nicotine patches. Participants will complete 4 online surveys (baseline, quit date, end of treatment, and 3-month follow-up) and a brief phone call at the end of treatment to provide feedback. Participants will use the app every day to complete daily diaries.
219766132|NCT07211308|DEVICE|Spinal Cord Stimulation|Differential target multiplexed stimulation
218837668|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 4|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
219766133|NCT07210281|DRUG|received an ossein-hydroxyapatite complex|Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
218837669|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 5|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
219766134|NCT07210619|DRUG|d-MAPPS|Ophthalmic Solution for oGVHD
219766135|NCT07210060|OTHER|hip + knee joint exercise group|Hip: squat, glute bridge and gluteus medius exercise Knee: knee flexor and extensor, isometric squat hold
219766136|NCT07210060|OTHER|ankle + knee joint exercise group|Knee: knee flexor and extensor, isometric squat hold Ankle: plantar flexor, dorsi flexor and lunge
219766137|NCT07210060|OTHER|Stretching group|Education Handout on Lower Limb Stretching
218837670|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 6|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
218837671|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 7|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
219017156|NCT06848478|BEHAVIORAL|Exercise Intervention|In addition to the standard of care, participants engage in exercise coaching and a 12-week exercise program, encompassing three 60-minute supervised sessions per week.
219017157|NCT06848478|BEHAVIORAL|Nutritional Intervention|In addition to the standard of care, participants receive dietary coaching and engage in a 12-week daily dietary program enriched with a blend of fruits and vegetables.
219475952|NCT06722898|DIETARY_SUPPLEMENT|Supplement|Contains ingredients believed to reduce Blood Alcohol Concentration and symptoms of alcohol impairment.
219766138|NCT07210099|DIETARY_SUPPLEMENT|Concentrated olive fruit water|Supplementation of OliPhenolia twice daily for eight days. Dose equivalent to ≤1.0mg∙kg-1 of hydroxytyrosol.
219766139|NCT07210099|DIETARY_SUPPLEMENT|Placebo|Placebo matched for taste and appearance consumed twice daily for eight days in the equivalent volume to the experimental product.
219766140|NCT07210099|DIETARY_SUPPLEMENT|Anhydrous caffeine|A single bolus of flavoured water (150mL) containing 6mg/kg anhydrous caffeine taken as a pre-exercise beverage
219766141|NCT07210099|DIETARY_SUPPLEMENT|Placebo beverage|A single bolus of flavoured water (150mL) containing 6mg/kg microcrystalline cellulose
219017158|NCT05064878|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
219585245|NCT05080101|OTHER|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
219766142|NCT07208734|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Gamma TranscraniaThis intervention uses a personalized transcranial alternating current stimulation (tACS) protocol specifically designed for older adults with cognitive impairment. Unlike standard brain stimulation approaches, this protocol is individualized through artificial intelligence-based modeling of each participant's brain imaging data to optimize electric field distribution. The study will evaluate both safety and effectiveness in a multicenter randomized controlled trial.l Alternating Current Stimulation (tACS)
219766143|NCT07208734|OTHER|AI-based Cognitive Training|This intervention provides a personalized cognitive training program tailored to multiple cognitive domains. Using algorithm-based task matching, the system delivers training exercises adapted to each participant's cognitive profile. The program is designed to target memory, attention, executive function, and language, and will be validated through a multicenter randomized controlled trial.
219017159|NCT05064878|DRUG|Matching ZX008 Placebo|Matching ZX008 placebo is supplied as an oral solution.
219446016|NCT03593564|BEHAVIORAL|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
219766144|NCT07208734|OTHER|Sham intervention|The sham stimulation group will undergo the same setup procedures as the active tACS group, including electrode placement and device operation. However, no effective current will be delivered beyond an initial brief sensation, ensuring participants cannot distinguish sham from active stimulation. This allows blinding of participants and investigators to treatment allocation.
219766145|NCT07211217|OTHER|Time Restricted Eating|See arms description
219446017|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
219766146|NCT07210138|DRUG|PeriGuard regimen|0.45% Stannous Fluoride Toothpaste, CPC-Zinc Fluoride Mouthwash, Gummy Toothbrush
219766147|NCT07210138|DRUG|Colgate Dental Cream regimen|Colgate Cavity Protection Toothpaste, Fluoride Mouthwash,Colgate Extra Clean Soft-Bristled Toothbrush
219766148|NCT07209449|DRUG|Abemaciclib|orally only in the evening
219766149|NCT07209449|DRUG|Elacestrant|orally once daily in the morning
219766150|NCT07210021|DEVICE|AK+ Guard™ ECG Application|An investigational Software as a Medical Device (SaMD) that analyzes Lead I electrocardiogram (ECG) data using artificial intelligence to detect moderate to severe hyperkalemia (serum potassium ≥ 6.5 mmol/L). ECG inputs may be obtained from standard 12-lead ECGs, clinical-grade ECG devices with Lead I capability, or consumer wearable devices (e.g., Apple Watch, HeartBeam).
219766151|NCT07209631|OTHER|Serum Lipoprotein-a level|A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.
219766152|NCT07210411|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
219766153|NCT07210411|DIAGNOSTIC_TEST|Tests of above level sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
219766154|NCT07210411|DIAGNOSTIC_TEST|Testing of below level sympathetic activation|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
219766155|NCT07210411|DEVICE|Epidural stimulation|Currently implanted epidural stimulation will be used during diagnostic testing.
219017160|NCT05206994|BEHAVIORAL|Close to Home|Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
219766156|NCT07210411|DEVICE|Transcutaneous stimulation|Transcutaneous stimulation will be used for participants with spinal cord injury without an implanted stimulator during diagnostic testing.
219446018|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
219446019|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
218837672|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 8|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
218837673|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 9|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
218837674|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 10|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
218837675|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 11|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
218837676|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 12|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
218837677|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 13|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
218837678|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 14|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
218837679|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 15|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
218837680|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 16|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
218837681|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 17|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
218837682|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 18|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
219446020|NCT04224909|DIAGNOSTIC_TEST|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
219446021|NCT02139280|DRUG|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
219446022|NCT03477864|BIOLOGICAL|Ipilimumab|Given via intraprostatic injection
219446023|NCT03477864|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
219446024|NCT03477864|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219446025|NCT03477864|BIOLOGICAL|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
219446026|NCT04157751|DRUG|Empagliflozin|Film-coated tablet
219446027|NCT04157751|DRUG|Placebo to Empagliflozin|Film-coated tablet
219475953|NCT06722898|DIETARY_SUPPLEMENT|Placebo|Placebo
219475954|NCT06722638|OTHER|Use of Virtual Reality Headset|Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
219475955|NCT06722508|BEHAVIORAL|exercise and nutritional prehabilitation|The study involves a behavioral intervention (exercise and nutritional prehabilitation) designed to assess outcomes related to feasibility, acceptability, and safety in head and neck cancer patients. Outcomes are being measured following the intervention over a defined period (from diagnosis through 1-month post-surgery).
218837683|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 19|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
218837684|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 20|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
219196497|NCT06804564|OTHER|Cold Water Immersion (CWI)|Standard immersion baths with temperature monitoring and ice supplementation. Lower limbs immersed up to the hip. Water temperature maintained at 10-12°C. Duration: 15 minutes per session. Participants perform active ankle flexion/extension to promote circulation.
219196498|NCT06804564|OTHER|Hot Water Immersion (HWI)|Controlled immersion baths. Lower limbs immersed up to the hip. Water temperature maintained at 40°C. Duration: 15 minutes per session.
219196499|NCT06804564|OTHER|Simulated Laser Therapy|Deactivated low-level laser therapy (LLLT) device. Applicator positioned over quadriceps muscle belly. Duration: 15 minutes, with no active laser output to simulate treatment conditions.
219446028|NCT00524667|DRUG|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
219446029|NCT00427791|DRUG|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
219446030|NCT00427791|RADIATION|Total Body Irradiation|3 Gy Daily for 4 Days
219446031|NCT00427791|DRUG|Rituximab|375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
219446032|NCT04282369|DEVICE|HHHFNC|noninvasive ventilation modality
219446033|NCT04282369|DEVICE|NCPAP|noninvasive ventilation modality
219446034|NCT04282369|DEVICE|NIPPV|noninvasive ventilation modality
219446035|NCT04282369|DEVICE|NHFO|noninvasive ventilation modality
219446036|NCT01395966|DRUG|DF289|Ear drops
219446037|NCT01395966|DRUG|DF277|Ear drops
219446038|NCT01395966|DRUG|DF289 plus DF277|Ear drops
219446039|NCT02664389|GENETIC|Genetic analysis|Sequencing of 200 selected genes in the different study populations
219446040|NCT03374813|DEVICE|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
219446041|NCT03374813|DEVICE|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
219446042|NCT06316687|OTHER|questionnaire for food consumption frequency|questionnaire about Food consumption frequency, Screen time , Dental neglect scale
219446043|NCT02688725|DEVICE|post mastectomy ultrasound|post mastectomy ultrasound
219446044|NCT05008549|DIETARY_SUPPLEMENT|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
219446045|NCT06394076|DEVICE|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
219446046|NCT05965531|DRUG|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
219446047|NCT05965531|RADIATION|intensity-modulated radiotherapy|intensity-modulated radiotherapy
219446048|NCT00254878|DRUG|Methylphenidate hydrochloride|
219446049|NCT01302691|DRUG|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
219446050|NCT01302691|DRUG|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
219446051|NCT01302691|DRUG|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
219446052|NCT01302691|DRUG|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
219446053|NCT01302691|DRUG|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
219446054|NCT01302691|DRUG|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
219446055|NCT04309357|DRUG|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
219446056|NCT06158282|OTHER|Voluntary apnoea|Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
219446057|NCT06033690|BEHAVIORAL|multidisciplinary guide|use of the food guide for education, clarification of doubts
219446058|NCT01335490|OTHER|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
219446059|NCT02426112|DRUG|Azithromycin|
219446060|NCT02426112|DRUG|Placebo|
218837685|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 21|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
218837686|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 22|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
218837687|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 23|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
219017166|NCT05858359|BEHAVIORAL|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
219446061|NCT04858503|OTHER|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
219446062|NCT04321278|DRUG|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
219446063|NCT04321278|DRUG|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
219446064|NCT02251067|DRUG|VPI-2690B low dose|Comparison of different doses of study drug
219446065|NCT02251067|DRUG|VPI-2690B medium dose|Comparison of different doses of study drug
219446066|NCT02251067|DRUG|Placebo to match VPI-2690B|
219446067|NCT02251067|DRUG|VPI-2690B high dose|Comparison of different doses of study drug
219446068|NCT02989311|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
219446069|NCT02989311|DIETARY_SUPPLEMENT|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
219446070|NCT00124332|DRUG|Rimonabant (SR141716)|
219446071|NCT00124332|DRUG|Placebo|
219446072|NCT05730101|OTHER|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
219446073|NCT05730101|OTHER|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
219446074|NCT01458795|PROCEDURE|Endovenous laser ablation|
219446075|NCT01462968|DEVICE|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
219446076|NCT03582969|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
219446077|NCT03582969|OTHER|Placebo|Placebo capsules
219446078|NCT02882022|DEVICE|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
219446079|NCT04348786|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
219446080|NCT04348786|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
219446081|NCT04720339|GENETIC|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
219446082|NCT02280486|DRUG|Saxagliptin|5 mg/d
219446083|NCT02280486|DRUG|Glimepiride|1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
219446084|NCT01292525|DRUG|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
219446085|NCT01292525|DRUG|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
219446086|NCT04134169|OTHER|Not applicable(observational study)|Not applicable(observational study)
219446087|NCT00423592|DRUG|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
219446088|NCT03446612|DRUG|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
219446089|NCT03446612|DRUG|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
219446090|NCT03446612|DRUG|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
219446091|NCT03446612|DRUG|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
219446092|NCT03446612|DRUG|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
219446093|NCT04315597|DRUG|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
219446094|NCT04315597|DRUG|Placebo|1 x daily, 1 tablet, 900 mg
219446095|NCT05022043|DIAGNOSTIC_TEST|Serum Presepsin|Estimation of Serum Presepsin at time of admission
219446096|NCT04039789|BEHAVIORAL|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
219446097|NCT04039789|PROCEDURE|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
219446098|NCT04199546|OTHER|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
219446099|NCT03314012|DEVICE|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
219446100|NCT05698108|DEVICE|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
219446101|NCT05698108|OTHER|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
219446102|NCT03261570|DRUG|Pyridostigmine|60mg by mouth
219446103|NCT03261570|DRUG|Digoxin|0.5 (500mcg) by mouth
219446104|NCT03261570|DRUG|Placebo|Lactulose 50mg by mouth
219446105|NCT05765552|OTHER|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
219446106|NCT05765552|OTHER|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
219446107|NCT01690819|PROCEDURE|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
219446108|NCT01690819|PROCEDURE|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
219446109|NCT05185284|DRUG|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
219446110|NCT05185284|DRUG|Favipiravir|200 mg coated tablets
219585246|NCT05080101|OTHER|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
219585247|NCT03517696|PROCEDURE|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
218837688|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 24|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
219585248|NCT03630107|OTHER|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
218837689|NCT05355909|PROCEDURE|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
219585249|NCT00752011|DRUG|TAS-106|Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
218837690|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
218837691|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
218837692|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
218837693|NCT00497419|PROCEDURE|fast track|
218837694|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
218837695|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
218837696|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
218837697|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
218837698|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
218837699|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
218837700|NCT06959264|OTHER|Virtual reality|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggles (VR Shinecon G12 3d Virtual Reality Goggles Black 4.5-7.0 Inch) compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system in supine position and minimizing sound loss. With the virtual reality goggles, nature landscapes with a relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
218837701|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
218837702|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
218837703|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
218837704|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
218837705|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
219585250|NCT00752011|DRUG|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
219585251|NCT04140435|DEVICE|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
219585252|NCT00110526|GENETIC|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
219585253|NCT00430820|PROCEDURE|per intervention|per intervention
219585254|NCT02208635|OTHER|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
219585255|NCT02208635|OTHER|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
218837706|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
219585256|NCT02208635|OTHER|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
218837707|NCT02574078|DRUG|Nivolumab|
218837708|NCT02574078|DRUG|Bevacizumab|
218837709|NCT02574078|DRUG|Pemetrexed|
218837710|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
218837711|NCT02574078|DRUG|nab-Paclitaxel|
219585257|NCT00446901|DIETARY_SUPPLEMENT|Selenium|Selenized yeast, 300 ug/day
219585258|NCT04257149|DIAGNOSTIC_TEST|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
219585259|NCT04257149|DIAGNOSTIC_TEST|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
219585260|NCT04257149|DIAGNOSTIC_TEST|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
219585261|NCT06014905|DRUG|Hyperpolarized carbon C 13 pyruvate|Given Intravenously (IV)
219585262|NCT06014905|PROCEDURE|Magnetic Resonance Image (MRI)|Imaging procedure
219585263|NCT06014905|OTHER|Saline|Given IV
218837712|NCT02574078|DRUG|Paclitaxel|
218837713|NCT02574078|DRUG|Docetaxel|
219446111|NCT05185284|DRUG|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
218837714|NCT02574078|DRUG|Gemcitabine|
218837715|NCT02574078|DRUG|Erlotinib|
218837716|NCT02574078|DRUG|Crizotinib|
218837717|NCT02574078|DRUG|Carboplatin|
218837718|NCT00193011|DRUG|Docetaxel|Docetaxel
218837719|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
218837720|NCT00193011|DRUG|Methotrexate|Methotrexate
218837721|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
218837722|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
218837723|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
218837724|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
218837725|NCT04806061|DRUG|standard care|standard care
218837726|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
219446112|NCT02251171|DRUG|Tipranavir|
219446113|NCT02251171|DRUG|Ritonavir|
219446114|NCT02251171|DRUG|Rifabutin|
219446115|NCT00044993|BIOLOGICAL|Ad5CMV-p53 gene|
219446116|NCT00044993|DRUG|docetaxel|
219446117|NCT00044993|DRUG|doxorubicin hydrochloride|
219446118|NCT00044993|PROCEDURE|conventional surgery|
219446119|NCT00044993|PROCEDURE|neoadjuvant therapy|
219446120|NCT01882192|BEHAVIORAL|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
219446121|NCT02019498|BEHAVIORAL|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
219446122|NCT02019498|OTHER|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
219446123|NCT03348566|OTHER|fish|fish intkae
219446124|NCT04553367|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
219446125|NCT04553367|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
219446126|NCT04553367|DEVICE|ventilator|ventilator
219446127|NCT01437267|BIOLOGICAL|Vi-CRM197 vaccine|
219446128|NCT01437267|BIOLOGICAL|Pneumococcal conjugate vaccine|
219446129|NCT01437267|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
219446130|NCT00838695|DRUG|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
219446131|NCT04746781|BEHAVIORAL|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
219446132|NCT04746781|BEHAVIORAL|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
218837727|NCT05516797|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
219585264|NCT00997204|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
219585265|NCT05674903|DEVICE|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
219585266|NCT05674903|DEVICE|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
219585267|NCT05909865|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
219585268|NCT05909865|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
219585269|NCT01653717|PROCEDURE|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
219585270|NCT01653717|DRUG|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
218837728|NCT05641961|BEHAVIORAL|Survivorship mobile application|Mobile phone application
218837729|NCT05641961|OTHER|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
218837730|NCT06844058|BEHAVIORAL|Islamic-Oriented Ericksonian Hypnotherapy (IEH)|"This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate:~Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression."
219446133|NCT04746781|BEHAVIORAL|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
219446134|NCT03934203|DRUG|BI 409306|Film-coated tablet
219585271|NCT01653717|DRUG|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
219585272|NCT01653717|PROCEDURE|T-cell Infusion|Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
219585273|NCT05788289|DRUG|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
218837731|NCT06844058|BEHAVIORAL|Standard Ericksonian Hypnotherapy (SEH)|"Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes:~Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements."
218837732|NCT04113044|OTHER|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
218837733|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
218837734|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
218837735|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
218837736|NCT04433741|DRUG|Placebo|Placebo administered intravenously
219446135|NCT03934203|DRUG|Moxifloxacin|Film-coated tablet
219446136|NCT03934203|DRUG|Placebo matching to BI 409306|Film-coated tablet
219585274|NCT05788289|DRUG|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
219446137|NCT01944488|DRUG|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
219446138|NCT05021172|OTHER|Best Practice|Receive usual care
219446139|NCT05021172|OTHER|Informational Intervention|Receive Passport to Health booklet
219446140|NCT05021172|OTHER|Questionnaire Administration|Complete ePrognosis
219446141|NCT05021172|OTHER|Survey Administration|Ancillary studies
219585275|NCT05301413|BEHAVIORAL|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
219585276|NCT05301413|BEHAVIORAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
219585277|NCT05301413|BEHAVIORAL|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
219585278|NCT01974440|DRUG|Bendamustine|90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
219585279|NCT01974440|DRUG|Rituximab|375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
219585280|NCT01974440|DRUG|Cyclophosphamide|750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
219585281|NCT01974440|DRUG|Doxorubicin|50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
219585282|NCT01974440|DRUG|Vincristine|1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
219585283|NCT01974440|DRUG|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
219585284|NCT01974440|DRUG|PCI-32765 (Ibrutinib)|560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
219446142|NCT00608842|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
219446143|NCT00608842|DRUG|Placebo|Matching vehicle placebo administered via intralipomal injection.
219446144|NCT06301594|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week"
219446145|NCT02406339|DEVICE|NMES|Neuromuscular Electrical Stimulation
219585285|NCT01974440|DRUG|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
218837737|NCT06525402|OTHER|Sodium Bicarbonate Group (Usual care)|In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.
218837738|NCT06525402|OTHER|Saline Group|The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.
219766157|NCT07211009|OTHER|Patient-Reported Outcome (PRO)-Based Symptom Management|Postoperative esophageal cancer patients will receive a PRO (patient-reported outcome) symptom self-report system via a WeChat mini-program/electronic form. The system covers 12 target symptoms-pain, fever, cough with sputum, dyspnea, palpitations, fatigue and activity limitation, nausea/vomiting, acid reflux/heartburn, abdominal bloating, diarrhea, swallowing obstruction (dysphagia), and hoarseness with coughing when drinking-and uses a five-level severity scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe). If any of the 12 symptom scores entered in the mini-program reaches the predefined intervention threshold (≥2, indicating moderate to very severe), the system sends a real-time alert to the surgeon, who is required to respond within a specified time window. After discharge, interventions are delivered via WeChat, text message, or telephone. Interventions mainly include counseling, patient education, prescription medication.
219585286|NCT00762437|DEVICE|Zeltiq Dermal Cooling Device|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219585287|NCT05203718|BEHAVIORAL|Food Response Training (FRT)|All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
219766158|NCT07211009|OTHER|Conventional Management|Patients in the control arm receive conventional postoperative symptom management. The electronic questionnaires use the same content and time points as the intervention arm, but reported symptoms do not trigger alerts, and surgeons cannot view the symptom scores. During the postoperative inpatient stay, surgeons typically assess symptom severity based on patient reports during morning and afternoon rounds and manage symptoms according to the same guidelines and consensus as the intervention arm. After discharge, patients do not receive proactive symptom management from their primary surgeon unless they actively seek medical care.
219446146|NCT02406339|DEVICE|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
219585288|NCT05817929|OTHER|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
219585289|NCT03569228|DEVICE|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
219585290|NCT03569228|DEVICE|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
219585291|NCT03569228|DEVICE|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
219585292|NCT03569228|DEVICE|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
219585293|NCT03569228|DEVICE|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
218837739|NCT06525402|OTHER|Black Mulberry Syrup Group|The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.
218837740|NCT04150640|DRUG|Nal-IRI|chemotherapy drug
218837741|NCT04150640|DRUG|Oxaliplatin|chemotherapy drug
218837742|NCT04150640|DRUG|5-FU|chemotherapy drug
218837743|NCT04150640|DRUG|Trastuzumab|immunotherapy
218837744|NCT04150640|DRUG|Pembrolizumab|immunotherapy
218837745|NCT04150640|DRUG|Nivolumab|immunotherapy
218837746|NCT04071340|DEVICE|non-contrast MSCT|non-contrast multi-slice computed tomography
218837747|NCT04071340|DEVICE|Abdominal ultrasonography|Abdominal ultrasonography
218837748|NCT04071340|DIAGNOSTIC_TEST|Urine analysis|Urine analysis
218837749|NCT04071340|DIAGNOSTIC_TEST|Urine culture|Urine culture
218837750|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
218837751|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
219446147|NCT02734095|DEVICE|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
219446148|NCT04445051|DEVICE|SpeediCath® Standard male or female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
219446149|NCT04445051|DEVICE|New intermittent Variant 1 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
219446150|NCT04445051|DEVICE|New intermittent Variant 2 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
219446151|NCT02939651|DRUG|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
219446152|NCT01067651|DEVICE|Plaster of Paris (POP) casting using the Ponseti Method|
219446153|NCT01067651|DEVICE|Semi-Rigid Fiberglass softcast using the Ponseti Method|
219446154|NCT03699904|DRUG|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
219446155|NCT03699904|DRUG|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
219446156|NCT06244719|DEVICE|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
219446157|NCT03024710|BEHAVIORAL|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
219446158|NCT02820558|DRUG|Substance P|
219446159|NCT04803019|COMBINATION_PRODUCT|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
219446160|NCT04803019|DEVICE|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
219446161|NCT04594018|DRUG|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
219446162|NCT04594018|DRUG|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
219446163|NCT00647907|DRUG|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
219446164|NCT02259946|DRUG|BI 1744 CL|
219446165|NCT02259946|DRUG|Placebo|
219446166|NCT02259946|DRUG|Tiotropium bromide|
219446167|NCT04157075|DRUG|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
219446168|NCT01041391|PROCEDURE|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
219446169|NCT02349204|BEHAVIORAL|Music - Mozart's sonata for 2 pianos in D-440|
219446170|NCT01953367|DRUG|Vantobra (tobramycin)|Inhalation
219446171|NCT01953367|DRUG|TOBI (tobramycin)|Inhalation
219446172|NCT01624467|BIOLOGICAL|Necitumumab|800 mg necitumumab, administered once per week IV
219446173|NCT02201472|DEVICE|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
219446174|NCT04705350|DRUG|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
219446175|NCT04705350|DRUG|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
219585294|NCT03569228|DEVICE|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
219585295|NCT06354998|BIOLOGICAL|Investigational mRNA-1273.815|Sterile solution for injection
219585296|NCT06354998|BIOLOGICAL|Licensed Spikevax Vaccine|Commercially available formulation
219196500|NCT05860114|DRUG|Givinostat|"Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening."
219585297|NCT01758055|BIOLOGICAL|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
219585298|NCT02039466|PROCEDURE|volume controlled ventilation|
219585299|NCT02039466|PROCEDURE|pressure controlled ventilation|
219585300|NCT03690882|OTHER|systematic review of medical imaging|
219585301|NCT02880657|DIETARY_SUPPLEMENT|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
219585302|NCT02880657|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
219585303|NCT04795908|DEVICE|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
219585304|NCT04795908|BEHAVIORAL|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
219585305|NCT00762931|DEVICE|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
219585306|NCT00657228|DRUG|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
219585307|NCT00657228|DRUG|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
219585308|NCT05372783|DRUG|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
219585309|NCT05372783|DRUG|Placebo|Diluent solution
219585310|NCT01802749|DRUG|Bevacizumab|
219585311|NCT01802749|DRUG|Paclitaxel|
219585312|NCT01802749|DRUG|Carboplatin|
219585313|NCT01802749|DRUG|pegylated liposomal doxorubicin|
219585314|NCT01802749|DRUG|Gemcitabine|
219585315|NCT05682846|DRUG|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
219585316|NCT02508753|DRUG|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
219585317|NCT02508753|DRUG|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
219585318|NCT02508753|DRUG|Moxifloxacin|400 mg tablet
219585319|NCT02508753|DRUG|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
219585320|NCT00115297|DRUG|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
219585321|NCT00115297|DRUG|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
219585322|NCT01555008|DRUG|LX4211|Subjects will receive LX4211 once daily for 7 days
219585323|NCT01555008|DRUG|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
219585324|NCT00085423|BIOLOGICAL|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
219585325|NCT00085423|BIOLOGICAL|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
219585326|NCT00085423|DRUG|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
219585327|NCT00085423|DRUG|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
219585328|NCT03227614|BEHAVIORAL|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
219585329|NCT00589030|RADIATION|brachytherapy|The target dose of TheraSphere® is 80-150Gy
219585330|NCT00589030|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
219585331|NCT03107143|DEVICE|Q2 System|
219585332|NCT02735850|DRUG|L19-IL2|L19-IL2 added to SBRT
219585333|NCT02735850|RADIATION|SBRT|
219585334|NCT02735850|OTHER|No intervention|
219585335|NCT02800213|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
219585336|NCT02800213|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
219585337|NCT02390141|DRUG|ZP4207|
219585338|NCT02390141|DRUG|Placebo|
219585339|NCT02440568|DRUG|Cytarabine|Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
219585340|NCT02440568|DRUG|Idarubicin|Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
219585341|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
219446176|NCT05009238|OTHER|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
219446177|NCT03338036|DEVICE|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
219585342|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
219585343|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
219766159|NCT07209657|BEHAVIORAL|Live Music Therapy|The recorded music interventions will consist of the presentation of commercially available recordings of participant preferred music. The songs utilised in the recorded music interventions will be the same as those presented during the live music therapy interventions, and only the presentation format will be different. The same music therapist who facilitates the live music therapy interventions will be present in the participant's room during the presentation of the recorded music intervention and will present the recorded music via iPad and small portable speaker.
219766160|NCT07209657|BEHAVIORAL|Recorded Music|The recorded music interventions will consist of the presentation of commercially available recordings of participant preferred music. The songs utilised in the recorded music interventions will be the same as those presented during the live music therapy interventions, and only the presentation format will be different. The same music therapist who facilitates the live music therapy interventions will be present in the participant's room during the presentation of the recorded music intervention and will present the recorded music via iPad and small portable speaker.
219766161|NCT07210164|DIETARY_SUPPLEMENT|Ocoxin|"Food Supplement based on Amino Acids, Plants, Vitamins and Minerals. Composition: Maltodextrin, L-Arginine, L-Cysteine, Microcrystalline cellulose, Talcum, Vitamin C (L-ascorbic acid), Zinc sulfate, Green Tea Extract (Camellia sinensis (L.) Kuntze), Manganese sulphate, Extracto de Canela (Cinnamomum verum J. Presl.), Vitamin B6 (pyridoxine hydrochloride).~Ocoxin utilizes Catalysis' Molecular Activation Technology (MAT) to enhance the biological activity of its natural antioxidant ingredients, such as green tea polyphenols (EGCG), to increase their antitumoral and immunomodulatory effects. This patented technology is applied to boost the efficacy of compounds within Ocoxin, such as EGCG, enabling them to exert more potent effects on cancer cells by inducing apoptosis, inhibiting tumor growth and metastasis, and supporting the body's immune response."
219766162|NCT07210164|PROCEDURE|Structured self-guided exercise|"The patient exercises in a structured manner with the help of a relevant interactive form/guide and simple aids (e.g. chair, step, water bottle, broomstick) by performing six categories of exercises: 1. Breathing exercises, 2. Pelvic floor exercises-pelvic mobility, 3. Upper trunk exercises, 4. Lower trunk exercises, 5. Aerobic exercises, 6. Stretching exercises, at a predetermined pace (number of repetitions) of each exercise and a limit of not exceeding the value 5-6 on the ten-point modified Borg fatigue scale. The intern records her activity on a form-exercise log. The recommendation is the maximum implementation of the exercise program but in any case not less than 3 times a week."
219585344|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
219585345|NCT00944268|DRUG|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
219585346|NCT04752046|PROCEDURE|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
219585347|NCT01948986|DRUG|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
219585348|NCT02833701|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
219446178|NCT03338036|DEVICE|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
219446179|NCT06076239|OTHER|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
219585349|NCT02833701|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
219585350|NCT02833701|OTHER|Laboratory Biomarker Analysis|Correlative studies
219585351|NCT02833701|OTHER|Quality-of-Life Assessment|Ancillary studies
219585352|NCT04659252|OTHER|n/a - samples collected along routine care samples only|This is a non-interventional study.
219585353|NCT00536263|DRUG|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
219196501|NCT06551519|OTHER|ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
219585354|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
219585355|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
219585356|NCT03907384|BEHAVIORAL|Mat Pilates training|This group completed 12-weeks of training
219585357|NCT00569621|DRUG|Moxaverine|intravenous administration
219585358|NCT00569621|DRUG|physiological saline|intravenous administration
219585359|NCT02550730|BEHAVIORAL|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
219585360|NCT02550730|OTHER|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
219585361|NCT05656521|DRUG|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
219585362|NCT05656521|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
219585363|NCT04263402|DRUG|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
219585364|NCT04263402|DRUG|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
219585365|NCT02548611|DRUG|Prasugrel|see arm description
219585366|NCT02548611|DRUG|Clopidogrel|see arm description
218837752|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
219585367|NCT03392493|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
219585368|NCT03392493|BEHAVIORAL|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
219585369|NCT00195637|DRUG|Immune Globulin|
219585370|NCT04371328|OTHER|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
219585371|NCT01172483|PROCEDURE|general practice in primary care and education|education of chronic disorders in PC
219585372|NCT01172483|OTHER|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
219585373|NCT03695861|DIAGNOSTIC_TEST|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
219585374|NCT03966248|OTHER|Chinese Tuina therapy|"1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
219585375|NCT03966248|OTHER|Physical Manual therapy|"1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
219585376|NCT05051202|OTHER|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
219585377|NCT05051202|OTHER|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
219585378|NCT06148168|DRUG|Bupivacaine plus normal saline|"Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
219585379|NCT06148168|DRUG|Bupivacaine plus normal saline containing MgSO4|Bupivacaine plus normal saline containing MgSO4
219585380|NCT03415061|DRUG|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
219585381|NCT03415061|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
219585382|NCT03285308|DRUG|Placebo|Placebo injected subcutaneously twice daily.
219585383|NCT03285308|DRUG|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
219766163|NCT07209501|OTHER|Aromatherapy inhaler|Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. They will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (total of six days). Given the subjective nature of scents, participants in the intervention group will be given a choice between two therapeutic aroma blends - N1 and N2 - before commencing the study. This approach aims to minimize the risk of negative associations with a particular scent and enhance participant adherence to the intervention.
219196502|NCT06551519|OTHER|DMT category 1|This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
219446180|NCT06076239|OTHER|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
219585384|NCT02191631|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
219585385|NCT02829294|DEVICE|E002 - cerumen removal aid|topical treatment
219766164|NCT07209501|OTHER|Aromatherapy inhaler (placebo)|Participants in the control group will receive the placebo intervention in addition to standard care. They will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has littleto- no scent and no known therapeutic or anxiolytic effects when inhaled.
219446181|NCT04389268|DIAGNOSTIC_TEST|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
219446182|NCT02782247|DEVICE|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal \< 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis \>11.5kPa. It cannot be used in patients with ascites."
219446183|NCT02782247|DEVICE|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
219446184|NCT01431469|DIETARY_SUPPLEMENT|Cow's milk|Powdered Whole Cow's Milk
219446185|NCT01431469|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
219446186|NCT03411434|DRUG|Methylphenidate Oral Tablet|cf arm group description
219446187|NCT06360497|OTHER|mindfulness meditation intervention and loving-kindness and compassion meditation intervention|Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
219446188|NCT06244524|OTHER|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
219446189|NCT04488549|OTHER|Survey|International E-survey
219446190|NCT04487418|PROCEDURE|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
219585386|NCT04530708|RADIATION|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
219585387|NCT02553083|DRUG|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
219585388|NCT02553083|DRUG|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
219585389|NCT02553083|DRUG|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
219585390|NCT02553083|DRUG|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
219585391|NCT02553083|DRUG|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
219585392|NCT02553083|DRUG|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
219585393|NCT01169428|BEHAVIORAL|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
219585394|NCT01169428|BEHAVIORAL|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
219585395|NCT03885479|DIAGNOSTIC_TEST|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
219585396|NCT06050161|DEVICE|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
219446191|NCT04487418|PROCEDURE|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
219585397|NCT06050161|DEVICE|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
219585398|NCT06050161|DEVICE|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
219585399|NCT04012151|OTHER|Physical measurement|Parturients of gestational week \>= 32 weeks will have their arms and fingers measured to generate the conicity index.
219585400|NCT04012151|OTHER|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
219446192|NCT03156725|DRUG|Ferrous Sulfate|
219446193|NCT03156725|DIETARY_SUPPLEMENT|Aspiron|
219446194|NCT01589692|PROCEDURE|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
219446195|NCT01589692|PROCEDURE|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
219446196|NCT01589692|PROCEDURE|Percutaneous Pinning|Pinning with any number of Kirschner wires
219446197|NCT01589692|PROCEDURE|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
219446198|NCT05942677|PROCEDURE|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
219446199|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
219446200|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
219446201|NCT06437548|DEVICE|Percutaneous spinal cord stimulation|The parameters of percutaneous cervical spinal cord stimulation leads will be adjusted for optimal upper extremity motor function.
219446202|NCT04865224|DIAGNOSTIC_TEST|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
219446203|NCT00901394|DRUG|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
219446204|NCT00901394|DRUG|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
219446205|NCT00901394|OTHER|Placebo|Saline
219446206|NCT00901394|OTHER|oxygen nitrogen|60% air and oxygen mix.
219446207|NCT00024206|DRUG|orantinib|Given orally
219446208|NCT00024206|OTHER|laboratory biomarker analysis|Correlative studies
219446209|NCT00024206|OTHER|pharmacological study|Correlative studies
219585401|NCT05459454|DEVICE|A digital health program for patients with Breast Cancer|A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
219585402|NCT00168311|DEVICE|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
219585403|NCT00168311|DEVICE|sham TMS|
219585404|NCT02353052|OTHER|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
219585405|NCT02158312|DEVICE|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
219585406|NCT00004450|DRUG|glyceryl trierucate|
219446210|NCT05097976|DRUG|Methylprednisolone|21 x 4mg tablets beginning on POD 1
219446211|NCT05097976|DRUG|Placebo|21 sugar tablets beginning on POD 1 with standard management
219446212|NCT05187572|BEHAVIORAL|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
219446213|NCT03864627|DRUG|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
219446214|NCT03864627|DRUG|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
219446215|NCT01388491|DRUG|desogestrel/ethinyl estradiol and ethinyl estradiol|
219446216|NCT01388491|DRUG|desogestrel/ethinyl estradiol|
219446217|NCT02147106|OTHER|Videoconsultation|
219446218|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
219446219|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
219446220|NCT00782301|DRUG|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
219446221|NCT00782301|DRUG|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
219446222|NCT00864123|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
219446223|NCT00864123|DRUG|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
219446224|NCT00864123|DRUG|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
219446225|NCT06113172|OTHER|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
219585407|NCT00004450|DRUG|glyceryl trioleate|
219446226|NCT06861829|DRUG|BI 3731579|BI 3731579
219446227|NCT06747390|DRUG|Lidocaine 1% Injectable Solution|1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
219446228|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
219585408|NCT00004450|DRUG|interferon beta|
219446229|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
219585409|NCT00004450|DRUG|thalidomide|
219585410|NCT04405895|OTHER|Breakfast Diet|Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
219446230|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
219446231|NCT04511338|DEVICE|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
219446232|NCT02116361|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
219446233|NCT02116361|DRUG|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
219446234|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
219446235|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
219446236|NCT02428933|DRUG|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
219766165|NCT07210814|PROCEDURE|saliva and plaque sample collection for analysis|"For collection of plaque two different gingival sites are selected for sampling in each participant. Prior to sampling, supragingival plaque is removed with a sterile instrument. Subgingival plaque is then collected from the same site using a sterile Gracey curette.~Saliva samples are collected using a commercially available saliva collection kit (Sallivete®, SARSTEDT AG, Germany). Participants should open the Sallivete® tube, remove the synthetic swab, and place it in their mouth for 1-2 minutes, ensuring it moves around to facilitate optimal saliva collection while avoiding chewing."
219446237|NCT03485963|BIOLOGICAL|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
219446238|NCT06805162|OTHER|Normal training|Athletes should continue their normal training
219446239|NCT06805162|OTHER|Specific training|Athletes should consider i) watching the educational videos on injury prevention, ii) perform the neuro-muscular exercises, iii) practice the techniques against stress and anxiety, and iv) consider the injury prognostic feedback.
218837753|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
219585411|NCT04405895|OTHER|Allday Diet|Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
219585412|NCT03452332|BIOLOGICAL|Durvalumab|Given IV
219446240|NCT06833047|BEHAVIORAL|Emotional intervention|Participants will receive different emotional interventions such as boredom, positive valence, mind-wandering.
219446241|NCT03227224|DRUG|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
219446242|NCT03227224|DRUG|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
219446243|NCT06781593|DEVICE|Light therapy|The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.
219446244|NCT04195750|DRUG|Belzutifan|Oral tablets
219446245|NCT04195750|DRUG|Everolimus|Oral tablets
219585413|NCT03452332|OTHER|Laboratory Biomarker Analysis|Correlative studies
219585414|NCT03452332|RADIATION|Stereotactic Radiosurgery|Undergo SABR
219585415|NCT03452332|BIOLOGICAL|Tremelimumab|Given IV
219585416|NCT00273390|DRUG|Remicade (infliximab)|
219766166|NCT07210814|OTHER|using commercial mouthwash|Participants use the commercial mouthwash octenident (cosmetic) twice daily after their normal dental routine for 30 seconds for consecutive seven days
219766167|NCT07210762|OTHER|Early space closure|Space closure will be started 1 week after extraction
219766168|NCT07210762|OTHER|Delayed space closure|Space closure will be started 8 weeks after extraction
219766169|NCT07209475|BIOLOGICAL|Amnio-Maxx® Dual Layer Amnion Patch|Application of Amnio-Maxx® Dual Layer Amnion Patch
218837754|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
219446246|NCT06927154|OTHER|Mobilization with movement|Group A will receive Mobilization with movement in which therapist manually applies a gentle mobilizing force to the joint while the patient actively performs a movement (2 to 3 sets) 6 to 10 repetitions per set in sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.
219446247|NCT06927154|OTHER|Facet joint oscillatory mobilization|Group B will receive Facet joint oscillatory mobilization on the cervical spine C2-C7 (6 to 10 repetitions in each session) in the sitting position.Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.
219446248|NCT02406027|DRUG|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
219446249|NCT02406027|DRUG|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
219585417|NCT01321619|DRUG|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
219766170|NCT07209475|OTHER|Standard of Care (Investigator Choice)|Cleansing, debridement, wound documentation, off-loading
219766171|NCT07210489|PROCEDURE|Reconstructive surgery after anterior cruciate ligament rupture|surgical technique for repairing the cruciate ligament
218837755|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
218837756|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
218837757|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
219446250|NCT02406027|DRUG|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
219446251|NCT02406027|DRUG|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
219585418|NCT01321619|DRUG|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
219585419|NCT01718548|DIETARY_SUPPLEMENT|Cordyceps Sinensis (CS) and Lingzhi|
219585420|NCT01718548|DIETARY_SUPPLEMENT|Tea and Flour|Placebo
219585421|NCT04857463|OTHER|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
219585422|NCT04857463|OTHER|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
219585423|NCT02468752|DRUG|Oxygen|
219585424|NCT02468752|OTHER|Air|
219585425|NCT00920894|DIETARY_SUPPLEMENT|plant stanol ester|the effect of plant stanol esters on plasma lipids
219766172|NCT07210489|OTHER|sessions from a physical therapist|sessions from a physical therapist in accordance with standard practice
218837758|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
218837759|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
219585426|NCT06214533|DRUG|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
219585427|NCT06214533|DRUG|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
219585428|NCT05291832|OTHER|Brain.fm Music|Experimental arm
219446252|NCT02497287|DRUG|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.
219446253|NCT02497287|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
219446254|NCT02497287|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
219446255|NCT02497287|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
219585429|NCT05291832|OTHER|Spectrally-matched Noise|Active control arm
219585430|NCT04950959|DEVICE|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
219585431|NCT01859767|DRUG|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
219585432|NCT03842579|OTHER|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
219585433|NCT03842579|OTHER|High-protein diet|Daily supplementation with milk-based protein-rich products
219585434|NCT03842579|OTHER|Recommendations|Provided with the official national recommendations on nutrition
219585435|NCT05701644|DRUG|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
219585436|NCT05701644|DRUG|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
219585437|NCT05701644|DRUG|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
219585438|NCT05701644|DRUG|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
219585439|NCT05701644|DRUG|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
219585440|NCT05701644|DRUG|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
219585441|NCT05701644|DRUG|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
219585442|NCT05701644|DRUG|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
219585443|NCT05701644|DRUG|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
219585444|NCT02540759|DIETARY_SUPPLEMENT|Buglossoides oil|
219585445|NCT02540759|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|
219585446|NCT05114382|PROCEDURE|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
219585447|NCT02651454|DRUG|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219585448|NCT02651454|DRUG|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
219585449|NCT02651454|DRUG|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219585450|NCT03734666|BEHAVIORAL|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
219585451|NCT03734666|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
219585452|NCT00001026|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219585453|NCT00001026|BIOLOGICAL|rgp120/HIV-1IIIB|
219585454|NCT00001026|BIOLOGICAL|rgp120/HIV-1MN|
219585455|NCT00001026|BIOLOGICAL|rgp120/HIV-1 SF-2|
219585456|NCT00001026|BIOLOGICAL|HIVAC-1e|
219585457|NCT02991170|PROCEDURE|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
219585458|NCT02991170|PROCEDURE|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
219585459|NCT02459548|OTHER|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
219446256|NCT02497287|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
219446257|NCT06369038|BEHAVIORAL|observation of level of dental anxiety in children|analysis of children's drawings using CD:H index
219446258|NCT03238079|BIOLOGICAL|10% IGIV|300-900 mg/kg
219446259|NCT00509938|DRUG|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
219446260|NCT03782376|DRUG|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
219446261|NCT03782376|DRUG|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
219446262|NCT03782376|DRUG|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
219446263|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
219446264|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
219585460|NCT02459548|OTHER|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
219585461|NCT00026364|DRUG|fluorouracil|
219585462|NCT00026364|DRUG|gefitinib|
219585463|NCT00026364|DRUG|irinotecan hydrochloride|
219585464|NCT00026364|DRUG|leucovorin calcium|
219585465|NCT00671138|BIOLOGICAL|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
218837760|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
218837761|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
219446265|NCT04614467|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34+ cells
219446266|NCT04614467|BIOLOGICAL|Placebo|isotonic solution (no CD34+ cells)
219446267|NCT04220567|OTHER|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
219585466|NCT00671138|OTHER|Sham inoculation|A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
219585467|NCT03303183|DEVICE|Standard Impression technique|Silicone impression technique
219585468|NCT03303183|DEVICE|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
219585469|NCT01592305|DRUG|atazanavir|multiple oral doses
219446268|NCT04220567|OTHER|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
219446269|NCT05620069|OTHER|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
219446270|NCT03559192|DRUG|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
219446271|NCT03559192|DRUG|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
219446272|NCT03517722|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
219446273|NCT03517722|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
219446274|NCT03517722|DRUG|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
219585470|NCT01592305|DRUG|danoprevir|multiple oral doses
219585471|NCT01592305|DRUG|ritonavir|multiple oral doses
219585472|NCT01592305|DRUG|tenofovir disoproxil fumarate|single oral doses
219585473|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|400 IU daily (low dose)
219585474|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|2000 IU daily (high dose)
219585475|NCT03697265|DRUG|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
219585476|NCT03697265|DRUG|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
219585477|NCT03697265|DRUG|Placebo|Subcutaneous (SC) adminstration
219585478|NCT02812979|DEVICE|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
219585479|NCT02812979|DEVICE|Mask|Usual nebulization of salbutamol with mask
219585480|NCT02812979|DEVICE|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
219585481|NCT01727882|BEHAVIORAL|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
219766173|NCT07210710|BEHAVIORAL|CKD Awareness, Referrals, Education, and Support (CARES)|We will target diabetic patients eligible for an early-stage CKD diagnosis with a nurse-delivered, pre-PCP-visit 1:1 virtual session including 1) tailored, evidence-based CKD education 2) motivational interviewing with self-management goal setting, and 3) social determinants of health screening with referrals to services as needed.
219446275|NCT02863705|DRUG|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
219446276|NCT02863705|DRUG|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
219446277|NCT02625389|DRUG|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
219446278|NCT01961128|BEHAVIORAL|Exercise Intervention|
219446279|NCT06930170|DEVICE|Cochlear implantation|During surgery at 8 weeks after inclusion, cochlear implant is implanted
219446280|NCT06930170|DEVICE|CROS or BiCROS device fitting|At 8 weeks after inclusion, CROS or BICROS (depending on the type of hearing loss) is fitting
219446281|NCT06930170|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat is an adaptive test that measures speech intelligibility in noise. It consists of 14 sentences of 3 words each, recorded in the presence of background noise. The FraSimat will be performed in two different configurations in relation to the source of the signal and noise before implantation or fitting, and 1, 2, 3 and 4 months after.
219446282|NCT06930170|DIAGNOSTIC_TEST|Sound localization test (ERKI)|"ERKI for German Erfassung des Richtungshörens für Kinder is an automated test that assesses spatial localization skills. The test is performed with the child seated facing a semi-circular table, surrounded by a set of 5 loudspeakers arranged 1 meter apart.~The test consists of 5 stimuli, followed by 42 trials. Following the presentation of each stimulus, the child must turn a control knob and direct the LED light to the point where he or she has perceived it. The child validates his or her response by pressing the button.~ERKI is evaluated before implantation or fitting, and 1, 2 and 3 months after."
219446283|NCT06930170|DIAGNOSTIC_TEST|Cortical Auditory Evoked Potentials (PEAc)|"The recording of Auditory Cortical Evoked Potentials provides an objective means of assessing the maturation of the auditory system and its ability to process auditory signals. AEPs consist of a series of cortical responses to an auditory stimulus.~PEAc are assessed using a non-invasive EEG recording, made under quiet wakefulness. Four surface electrodes are glued to the patient's skull: one on the vertex, one on the forehead, and one on each mastoid. The latency (msec) and amplitude (mV) values of each of the four component waves will be analyzed.~PEAc is evaluated before implantation or fitting, and 3 and 4 months after."
219446284|NCT06930170|OTHER|Speech, Spatial and Qualities of Hearing Scale (SSQ)|"The Speech, Spatial and Qualities of Hearing Scale is a questionnaire for subjective evaluation of listening performance in everyday listening situations. The parent version is adapted for parents of hearing-impaired children.~SSQ is evaluated before implantation or fitting, and 4 months after."
219446285|NCT06930170|OTHER|Peabody Picture Vocabulary Scale (PPVT or EVIP in french)|"Peabody Picture Vocabulary Scale assesses the extent of French listening vocabulary acquired by the child.~The PPVT is designed for patients aged from 2 years and 6 months to 18 years. The raw score is the number of images correctly identified.~Peabody Picture Vocabulary Scale is evaluated before implantation or fitting, and 4 months after."
219446286|NCT06930170|OTHER|NEPSY-II (A Developmental Neuropsychological Assessment)|"The NEPSY-II (A Developmental Neuropsychological Assessment) is a battery of neuropsychological tests designed to assess children's skills in 6 major neuropsychological domains. The various tests are validated for the age range indicated in brackets, and will be used for patients aged 5 and over.~NEPSY-II is evaluated before implantation or fitting, and 4 months after."
219585482|NCT01727882|BEHAVIORAL|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
219585483|NCT03267420|DIAGNOSTIC_TEST|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
218837762|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
218837763|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
219585484|NCT03267420|DIAGNOSTIC_TEST|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
219585485|NCT03267420|DIAGNOSTIC_TEST|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
219585486|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
219585487|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
219766174|NCT07210710|BEHAVIORAL|Attention control|The control group will receive an attention control session of general education about diabetes-related health behaviors (e.g., diet and physical activity) that does not refer to CKD, based on American Diabetes Association materials.
219766175|NCT07209943|DEVICE|Cognixion + Apple Vision Pro|An Apple Vision Pro device, integrated with Cognixion's brain sensing band and Assisted Reality software. The integrated device enables users to construct AI assisted communication and computer control commands using a combination of attention, eye gaze and head pose.
219766176|NCT07210346|OTHER|fairy tales|The children's stories will be selected by child psychologists. The stories will be read by a story therapist and recorded on a voice recorder. The story playback will begin five minutes before the request begins and continue throughout the request process. The stories will be played for five days. Afterward, there will be a one-week detoxification period before moving on to the next intervention.
219446287|NCT06930170|OTHER|Pediatric Quality of Life Inventory™ Multidimensional Fatigue Scale (PedsQL MFS)|PedsQL MFS is a questionnaire used to assess subjective experiences of fatigue. The questionnaire consists of 18 items The parent version is adapted for parents of hearing-impaired children. PedsQL MFS is evaluated before implantation or fitting, and 4 months after.
219446288|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
219446289|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
219446290|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
219585488|NCT05683327|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
219585489|NCT04346966|OTHER|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
219585490|NCT05927831|DRUG|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
219585491|NCT05927831|DEVICE|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
219585492|NCT00209989|DRUG|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
219585493|NCT00209989|PROCEDURE|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
219766177|NCT07210346|OTHER|mother's voice|Children's stories will be selected by child psychologists. The stories will be read by the children's mothers and recorded on a voice recorder. Story repetition will begin five minutes before the request begins and continue throughout the request period. The stories will be listened to for five days. Following this, there will be a one-week detoxification period before moving on to the next intervention.
219446291|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
218837764|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
218837765|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
218837766|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
219446292|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
219446293|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
219446294|NCT06904196|COMBINATION_PRODUCT|Lenvatinib plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD will be started at 3-7 days after the first SIRT.
219446295|NCT06904196|DRUG|Lenvatinib|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD.
219446296|NCT00321009|DRUG|Enoxaparin|
219446297|NCT01990703|DRUG|Levonorgestrel IUD|Timing of IUD insertion
219446298|NCT06903988|PROCEDURE|laparoscopic lateral suspension|Laparoscopic lateral suspension: Place a 1/2 T4 mesh in the vesicovaginal space. The two lateral slings are passed out from the outer upper side of the bilateral anterior superior iliac spine, and the prolapsed organs are suspended to the abdominal wall.
219446299|NCT06903988|PROCEDURE|Transvaginal sacrospinous ligament fixation|Transvaginal sacrospinous ligament fixation: Dissect the rectovaginal space to expose the right sacrospinous ligament, and fix the cervix or vaginal cuff to the right sacrospinous ligament.
219446300|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
219446301|NCT03277794|BEHAVIORAL|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
219585494|NCT06332001|OTHER|Experimental Group|Listening of music of patient's choice during WB-MRI
219585495|NCT06332001|OTHER|Control Group|Standard care condition during WB-MRI
218837767|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
218837768|NCT01162954|DRUG|DA-6034|
218837769|NCT01162954|DRUG|Placebo|
219585496|NCT04283916|DRUG|Botulinum Toxins|Botulinum toxin injection to abdominal wall
219585497|NCT02575612|PROCEDURE|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
218837770|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
219585498|NCT01051713|BEHAVIORAL|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
219585499|NCT01051713|BEHAVIORAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
219585500|NCT02251119|DRUG|Tipranavir|
219585501|NCT02251119|DRUG|Ritonavir|
219585502|NCT02251119|DRUG|Loperamide|
219585503|NCT01782508|DRUG|imatinib|a selectively inhibits the KIT protein tyrosine
219585504|NCT01782508|DRUG|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
219585505|NCT03916523|PROCEDURE|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
219585506|NCT03916523|PROCEDURE|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
219585507|NCT03916523|PROCEDURE|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
219446302|NCT03277794|BEHAVIORAL|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
219585508|NCT05044884|OTHER|Otago Exercise training|"1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles."
219585509|NCT05044884|OTHER|Circuit training|"1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles"
219585510|NCT01181271|DRUG|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
219766178|NCT07210346|OTHER|Cartoons|The cartoons children will watch will be selected by child psychologists. Children will be shown cartoons on tablets. Watching will begin five minutes before the request period and continue throughout the request period. Children will be shown cartoons for five days.
218837771|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
218837772|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
219766179|NCT07210177|OTHER|Bio-C Temp Intracanal Medication|Bio-C Temp (Angelus, Paraná, Brazil) is a ready-to-use calcium silicate-based material designed for use between appointments. Bio-C Temp is indicated for use as a substitute for calcium hydroxide, as a medicament for necrotic teeth or root canal resurfacing treatments, and for the treatment of internal and external root resorption and immature teeth.
218837773|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
218837774|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
218837775|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
219446303|NCT03971292|GENETIC|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
219446304|NCT03140657|DRUG|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
219446305|NCT03140657|DRUG|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
219446306|NCT02912741|DRUG|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
219766180|NCT07210177|OTHER|Metapaste Intracanal Medication|Metapaste (Meta Bıomed Co.,Ltd., Chungcheongbuk-do,Korea) is a ready-to-use calcium hydroxide-based material designed for use between appointments.Metapaste is indicated for use as a medicament for necrotic teeth or root canal resurfacing treatments, and for the treatment of internal and external root resorption and immature teeth.
219766181|NCT07210398|BEHAVIORAL|Quiet Focus|Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression
218837776|NCT00002848|PROCEDURE|psychosocial assessment and care|
219446307|NCT02912741|DRUG|resin infiltration|low viscous light cure resin applied in layers and cured
219446308|NCT02168660|DRUG|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
219446309|NCT06719102|BEHAVIORAL|MAGIC-FEED|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.
218837777|NCT00002848|PROCEDURE|quality-of-life assessment|
218837778|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
218837779|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
219446310|NCT06719102|BEHAVIORAL|MAGIC-SAFE|Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
219446311|NCT00004360|DRUG|chlorothiazide|
219446312|NCT05274594|RADIATION|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
219446313|NCT05258513|DIETARY_SUPPLEMENT|Placebo Supplementation|8 weeks of placebo supplementation
219446314|NCT05258513|DIETARY_SUPPLEMENT|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
219446315|NCT04661267|DIETARY_SUPPLEMENT|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
219446316|NCT04661267|DIETARY_SUPPLEMENT|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
219446317|NCT05671237|OTHER|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
219766182|NCT07210658|DIETARY_SUPPLEMENT|Oral nutritional supplementation|As directed by the HCP
219766183|NCT07209891|DEVICE|Kinesio Tape|Cotton elastic tape applied along the full length/width of the target hypertrophic scar with \~25-50% stretch while the scar is on gentle lengthening. Continuous wear; replaced every 2-3 days.
219446318|NCT00545467|DRUG|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
219446319|NCT00458367|DRUG|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
219446320|NCT00000405|PROCEDURE|Exercise intervention|
219446321|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
219446322|NCT02150291|DRUG|Neurobion|
219446323|NCT02150291|DRUG|placebo|
219585511|NCT01181271|DRUG|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
219585512|NCT01181271|DRUG|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
219585513|NCT01181271|DRUG|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
219766184|NCT07209891|DEVICE|Low-Level Laser Therapy (LLLT), 905-nm pulsed Ga-As|Fluence 16.2 J/cm² at skin; pulse frequency 3000 Hz; session duration \~15 min at standardized distance (\~10 cm) using an orange medical filter; protective eyewear for patient and staff.
219766185|NCT07209891|OTHER|Standardized Scar Care (concomitant for all arms)|Uniform background care applied across all groups; recorded in CRFs; prohibited co-interventions (e.g., intralesional steroids, microneedling, ablative lasers, new pressure garments during the study).
219766186|NCT07208474|OTHER|Laughter yoga|Laugher yoga
219446324|NCT06942793|DRUG|CsA-PG Ophthalmic Gel|Administer to eyes
219446325|NCT06942793|DRUG|CsA Ophthalmic Gel|Administer to eyes
219446326|NCT01831011|DRUG|mildronate injection|
219446327|NCT01831011|DRUG|cinepazide maleate injection|
219585514|NCT01181271|OTHER|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
219585515|NCT01181271|DRUG|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
219585516|NCT01181271|DRUG|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
219585517|NCT01181271|DRUG|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
218837780|NCT01827436|BEHAVIORAL|Conventional physical therapy|
218837781|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
218837782|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
219446328|NCT01831011|DRUG|aspirin|
219446329|NCT01251822|DRUG|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
219446330|NCT01251822|DRUG|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
219475956|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
219585518|NCT01181271|OTHER|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
218837783|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
219446331|NCT06949839|DEVICE|Therapeutic exercise program combined with RMT|"For the RMT protocol, the Orygen-dual valve® device will be used. Each participant will start with a load of 30% of the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Once every 10 days, the performance will be reviewed and the resistance will be increased by 10cmH2O of the initial MIP/MEP of each patient. Each session will consist of breathing through the device for 20 minutes (10 minutes dedicated to each muscle group). This process will be repeated once a day, five days a week, for eight weeks.~The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down."
219446332|NCT06949839|DEVICE|Therapeutic exercise program combined with sham RMT|The sham RMT protocol will have the same frequency as in the intervention group. The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down.
219446333|NCT06948539|DRUG|TQB2101 for injection|TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.
219446334|NCT06948240|OTHER|AF related coronary embolism|AF related coronary embolism
219446335|NCT06949501|OTHER|virtual patient simulation|Students in this group are expected to provide sexual counseling to a virtual patient model following theoretical training. In this context, a virtual patient model has been developed with whom the students will engage for the counseling process.
219446336|NCT06949501|OTHER|peer simulation conducted in a virtual environment|Students in this group are expected to provide sexual counseling to their peers in a virtual environment following theoretical training. In the virtual peer simulation, students will see the same background displayed in the virtual patient simulation; however, instead of interacting with a virtual patient, they will connect with a peer via an online platform to conduct the counseling session.
219446337|NCT06949501|OTHER|face-to-face peer simulation|Students in this group are expected to provide sexual counseling to their peers following theoretical training. In the peer simulation, students will conduct their sessions in a communication skills laboratory designed to resemble a clinical consultation room.
219475957|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
219475958|NCT06523166|PROCEDURE|Transesophageal echocardiography (TEE)|TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
219475959|NCT06523166|PROCEDURE|Cardiac CTA|Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
218837784|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
218837785|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
218837786|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
218837787|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
218837788|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
218837789|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
219475960|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
219475961|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
219475962|NCT06518616|BEHAVIORAL|10-day meditation intervention|prerecorded meditation units delivered by smartphone app
219475963|NCT06518616|BEHAVIORAL|10-day health education intervention|prerecorded health education units delivered by smartphone app
219475964|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
218837790|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
219475965|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
219475966|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
219475967|NCT06929507|DRUG|Intravitreal injection of Faricimab or Aflibercept 2 mg|Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally
219475968|NCT01441882|DRUG|Dasatinib|Given PO
219475969|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
219475970|NCT01441882|OTHER|Pharmacological Study|Correlative studies
219475971|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
219475972|NCT02010359|DRUG|Placebo|Placebo pill
219475973|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
219475974|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
219475975|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
219475976|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
219475977|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
219196503|NCT02572141|DRUG|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
219446338|NCT06949878|DRUG|Antivet|"Complete stain removal from the Enamel-Use a compact cotton swab (3 mm) to apply Antivet solution (Dental Continental, México)to the stained dental piece according to manufacturer's instructions.-Replace the swab as it becomes stained and continue until the stain is removed.  This may take 1-5 minutes per tooth, but do not exceed 15 minutes in total.  - We will keep the tooth moist during the process for effective results and avoid reusing stained cotton swab.-Then we will apply the neutralizing solution to the tooth with a brush or micro brush, ensuring it reaches the gingival margin. Leave it on for 2 minutes.-Once the antivet solution is neutralized, rinse the area and remove the rubber dam."
219446339|NCT06949878|DRUG|opalustre|Complete stain removal from the Enamel. Product will be applied to the surface with a 1 mm thick layer; ten applications of 60s to help penetration of the gel into the enamel.- Using an abrasive rubber cup (OpalCup™ Ultradent) in contra-angle low-speed handpiece at low revolution.- Then will be rinsed with injectable water for 30 seconds between each application.
219585519|NCT01181271|DRUG|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
219585520|NCT01181271|DRUG|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
219585521|NCT01181271|DRUG|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
219446340|NCT06949943|BEHAVIORAL|Behavioral Intervention|Listen to guided meditation
219446341|NCT06949943|BEHAVIORAL|Behavioral Intervention|Wear noise cancelling headphones
219446342|NCT06949943|OTHER|Electronic Health Record Review|Ancillary studies
219446343|NCT06949943|OTHER|Survey Administration|Ancillary studies
219446344|NCT06948201|DIETARY_SUPPLEMENT|70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice)|70mL Nitrate Rich Beetroot Juice for 14 days followed by placebo (Nitrate depleted beetroot juice) for 14 days
219446345|NCT06948201|DIETARY_SUPPLEMENT|Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice|Placebo (70 mL Nitrate depleted beetroot juice) for 14 days followed by 70mL Nitrate Rich Beetroot Juice for 14 days
219475978|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
218837791|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
218837792|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
219475979|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
218837793|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
218837794|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
218837795|NCT04379479|DRUG|Placebo oral|Placebo
219475980|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
219475981|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
219475982|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
219475983|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
219475984|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
219475985|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
219475986|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
219475987|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
219475988|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
219475989|NCT02696837|DEVICE|ETT|
219475990|NCT02696837|DEVICE|Proseal LMA|
219475991|NCT02696837|DRUG|Rocuronium|
219475992|NCT02696837|OTHER|No Muscle Relaxant|
219475993|NCT02696837|DRUG|Rocuronium|
219475994|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
219475995|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
219475996|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
219196504|NCT02572141|DRUG|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
219196505|NCT06168019|OTHER|Exposures|COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
219446346|NCT06949488|PROCEDURE|Group A (DT): Dexmedetomidine group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 100 µg Dexmeditomidine and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
219446347|NCT06949488|PROCEDURE|Group B (MG): Magnesium group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 150 mg of magnesium sulfate and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
219446348|NCT06949488|PROCEDURE|Group C (DM): Dexamethasone group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 8 mg dexamethasone and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
219446349|NCT06948253|OTHER|Erector Spinae Plane Block|The correct location of the needle tip in the fascial plane deep to the erector spinae muscle will be conﬁrmed by injecting 0.5-1 ml of saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process while avoiding muscle distension (hydro dissection)
219446350|NCT06948253|OTHER|Caudal Block Anesthesia|"The needle will be advanced at a 20-degree angle with needle tip and length visualization. A pop can be appreciated as the needle passes through the sacrococcygeal ligament.~Once the needle will be confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood."
219446351|NCT06948253|OTHER|External Oblique Intercostal Plane Block|the needle will be advanced until the tip lay in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs
219446352|NCT06948461|BIOLOGICAL|ORAL-LYO-FMT|An oral capsule formulation of lyophilized fecal microbiota. Participants receive 7 capsules, three times per week (Monday, Wednesday, Friday), for either 4 or 7 weeks depending on treatment allocation. The product aims to restore healthy gut microbiota for treatment of IBS-D or prevention of rCDI.
219446353|NCT06948461|OTHER|Placebo|Double-coated oral capsules visually identical to ORAL-LYO-FMT but containing no active material. Participants receive 7 capsules, three times per week, for either 3 or 7 weeks depending on treatment allocation.
219446354|NCT06948123|OTHER|Educational intervention|The experimental group was trained with educational material prepared by the researcher using a computer at home for 15 days after hospital discharge.
219446355|NCT06948123|OTHER|control group|The control group was visited at home 15 days after discharge and the scales were applied. The final scales were applied to the patient who came to the hospital for 3 months. The patient was told that the study was over and given educational materials.
219446356|NCT06949527|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|A custom-made acrylic open bite activator was fabricated for each participant, with the bite registered 3-4 mm above freeway space. Miniscrews were placed between the lateral and canine teeth in both jaws. Vertical elastics (150g force) were applied bilaterally between miniscrews and the appliance. The intervention aimed to reduce vertical growth in posterior regions and stimulate anterior dentoalveolar development while improving masseter muscle morphology.
219446357|NCT03399786|DRUG|evinacumab|IV administration of evinacumab
219446358|NCT03399786|DRUG|Placebo|IV administration of placebo
219446359|NCT06062810|DRUG|Raloxifene - Usual|"* Generic-1 - raloxifene hydrochloride tablet~* Raloxifene 60 mg taken orally daily"
219446360|NCT06062810|DRUG|Raloxifene - Study|"* Generic-2 - Raloxifene tablet~* Raloxifene 60 mg taken orally daily"
219446361|NCT00277823|DRUG|DVS-SR 50 mg|
219446362|NCT00277823|DRUG|DVS-SR 100 mg|
219446363|NCT00277823|DRUG|Placebo|
219446364|NCT06449612|DEVICE|TeleRehaStroke: Training programme using the 'Blended Clinic' mobile application|Primary end users (patients after stroke) will be familiarised with the application and the 'TeleRehaStroke' programme in two to three sessions during their last two to three weeks prior to discharge from the inpatient rehabilitation centre. This includes performing daily exercises, wearing an activity tracker and measuring blood pressure daily. Following discharge from rehabilitation, they will continue to use the application for 12 weeks.
219446365|NCT05921552|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
219446366|NCT05921552|BEHAVIORAL|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
219585522|NCT04385966|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
219196506|NCT05929859|BEHAVIORAL|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
219196507|NCT04290663|DRUG|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
219446367|NCT00636155|DRUG|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
219446368|NCT00636155|DRUG|Rituximab|375 mg/m2 on day 2
219585523|NCT04385966|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
219585524|NCT01193036|BEHAVIORAL|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
219585525|NCT01193036|BEHAVIORAL|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
219585526|NCT02885649|DRUG|Enzalutamide|Given PO
219585527|NCT02885649|OTHER|Laboratory Biomarker Analysis|Correlative studies
219585528|NCT02885649|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
219585529|NCT04624347|BEHAVIORAL|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
219585530|NCT05507762|BIOLOGICAL|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
219446369|NCT00636155|DRUG|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
219446370|NCT00636155|DRUG|Fludarabine|25 mg/m2 on days 2, 3, and 4
219446371|NCT01922518|PROCEDURE|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
219446372|NCT01922518|PROCEDURE|Apex pacing|Put RV lead around the apex
219446373|NCT06309563|DIETARY_SUPPLEMENT|Aminoacid supplementation|Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
219446374|NCT06309563|DIETARY_SUPPLEMENT|Placebo|Low-calorie and low-protein diet + placebo for 2 weeks
219446375|NCT06097468|DRUG|NisinZ® P|NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
219446376|NCT06097468|PROCEDURE|Surgery (non-interventional, standard of care)|Surgical removal of tumor as part of standard of care treatment
219446377|NCT00400946|DRUG|asparaginase|
219446378|NCT00400946|DRUG|cyclophosphamide|
219446379|NCT00400946|DRUG|cytarabine|
219446380|NCT00400946|DRUG|dexamethasone|
219446381|NCT00400946|DRUG|dexrazoxane hydrochloride|
219446382|NCT00400946|DRUG|doxorubicin hydrochloride|
219446383|NCT00400946|DRUG|etoposide|Given IV
219446384|NCT00400946|DRUG|leucovorin calcium|
219446385|NCT00400946|DRUG|mercaptopurine|Given orally
219446386|NCT00400946|DRUG|methotrexate|
219446387|NCT00400946|DRUG|methylprednisolone|
219446388|NCT00400946|DRUG|pegaspargase|Given IV
219446389|NCT00400946|DRUG|prednisolone|
219446390|NCT00400946|DRUG|therapeutic hydrocortisone|
219446391|NCT00400946|DRUG|vincristine sulfate|
219446392|NCT00400946|RADIATION|radiation therapy|
219446393|NCT03932903|BEHAVIORAL|ADAPTS (ADherence Assessments and Personalized Timely Support).|ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.
219585531|NCT05507762|BIOLOGICAL|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
219585532|NCT00181220|DRUG|valproic acid|
219585533|NCT00769626|OTHER|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
219585534|NCT00769626|OTHER|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
219585535|NCT03118570|DRUG|setrusumab|Intravenous infusion
219585536|NCT03118570|DIETARY_SUPPLEMENT|Calcium|tablets
219766187|NCT07209618|PROCEDURE|utogenous mandibular ramus block grafting with simultaneous dental implant placement|Horizontal alveolar ridge augmentation performed using autogenous block grafts harvested from the mandibular ramus. The graft was fixed to reconstruct the buccal wall, followed by immediate placement of dental implants in the same surgical session. Prosthetic loading was initiated 4 months postoperatively.
219766188|NCT07209618|PROCEDURE|Autogenous mandibular ramus block graft with simultaneous implant placement|Horizontal alveolar ridge augmentation performed using autogenous block grafts harvested from the mandibular ramus. The graft was fixed to reconstruct the buccal wall, followed by immediate placement of dental implants in the same surgical session. Prosthetic loading was initiated 4 months postoperatively.
218837796|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
219446394|NCT06955910|OTHER|questionnaires|"Anamnestic and socio-demographic information will be collected through a generic self-designed questionnaire including the following data: age, sex, residence (within or outside the Veneto region), marital status (married, divorced, cohabiting, single, widowed), employment status (employed, unemployed, retired), presence of dependents (yes/no), level of education (defined as primary, middle or high school, university degree), concomitant pathologies.~Additional data on the oncological history are also reported: histology and staging of the disease, presence or absence of metastatic disease, additional treatments before or after surgery (e.g. neoadjuvant treatments, adjuvant treatments, radiotherapy)."
219446395|NCT06834217|DEVICE|Active transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning and end of a 20-minute stimulation period.
219446396|NCT06834217|DEVICE|Sham transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning of a 20-minute period.
218837797|NCT00002249|DRUG|Levofloxacin|
218837798|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
219585537|NCT03118570|DIETARY_SUPPLEMENT|Vitamin D|capsules
219585538|NCT03118570|DRUG|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
219585539|NCT03036553|OTHER|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
219585540|NCT05981820|DIETARY_SUPPLEMENT|Creatine|To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.
219766189|NCT07210008|DRUG|Prednisolone|"Active Comparator: prednisolone. Oral prednisolone will be administered and tapered over 6 months, according to the following schedule\*:~0.5 mg/kg/day (not exceeding 40mg/day) x 4 weeks, 0.25 mg/kg/day (not exceeding 20mg/day) x 4 weeks, 15 mg/day x 4 weeks, 10 mg/days x 4 weeks, 5 mg/day x 10 weeks"
219766190|NCT07210008|DRUG|Placebo|Dispersible placebo administered and tapered over 6 months according to the schedule detailed in the protocol
218837799|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
218837800|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
218837801|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
218837802|NCT02603237|OTHER|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
218837803|NCT02603237|OTHER|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
218837804|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
218837805|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
218837806|NCT01675297|DRUG|Risedronate|Risedronate once a week
218837807|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
218837808|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
218837809|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
219585541|NCT05981820|OTHER|HIIT training|"In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
219766191|NCT07210840|PROCEDURE|Virtual Reality treatment|Exercises delivered via a VR system simulating balance tasks and environments
219766192|NCT07210840|PROCEDURE|Traditional Vestibular Rehabilitation Therapy|Customized vestibular exercises (gaze stabilization, balance, habituation, gait training).
219446397|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
219446398|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
219585542|NCT01045174|DEVICE|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
219585543|NCT05706194|DIAGNOSTIC_TEST|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
219766193|NCT07209397|DEVICE|Detrusor nerve radiofrequency ablation|A single, vaginal radiofrequency (RF) treatment. The procedure is performed with a bipolar RF applicator and requires no anesthesia. Delivered in a single session in an outpatient setting.
219446399|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
219446400|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
219766194|NCT07209397|DEVICE|Simulated (sham) detrusor nerve radiofrequency ablation|A simulated (sham) radiofrequency (RF) treatment, but with no energy delivered. The procedure mimics the appearance, duration, and positioning of the active device, without therapeutic effect.
219446401|NCT02306291|DRUG|Etoposide|induction chemotherapy
219446402|NCT02306291|DRUG|Cytarabine|induction chemotherapy
219446403|NCT02306291|DRUG|Idarubicin|induction chemotherapy
219446404|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
219585544|NCT00836329|BEHAVIORAL|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
219766195|NCT07209722|BEHAVIORAL|PrEP acronym (pre-exposure prophylaxis)|Tracked PrEP prescriptions over 8 months among patients who completed the survey
219766196|NCT07210931|BEHAVIORAL|Self-managed exercise in a fitness center|The participants are offered a 6-month membership of a local fitness club at no cost (paid by the trial). They will receive an introduction to the fitness centre and receive instructions from a personal trainer in the centre to create a personalized exercise programme
218837810|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
218837811|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
218837812|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
219766197|NCT07210931|BEHAVIORAL|Supervised Exercise|The particiopants are offered participation in the usual care exercise delivered at municipal rehabilitation centers or private physiotherapy clinics, aat the discretion of the referring doctor.
218837813|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
219446405|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
219446406|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
219446407|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
219446408|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
219446409|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
219446410|NCT02624661|DRUG|Glycerol|
219446411|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
219446412|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
219585545|NCT00836329|BEHAVIORAL|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
219585546|NCT03330912|DEVICE|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
219585547|NCT03330912|DEVICE|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
219585548|NCT03330912|DEVICE|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
219585549|NCT03330912|DEVICE|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
219585550|NCT03330912|DEVICE|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
219585551|NCT00477295|DRUG|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
219766198|NCT07208266|BEHAVIORAL|contingency management|Participants with opioid use disorder admitted to the inpatient addiction management unit will receive a contingency management (CM) program as a behavioral intervention. The program consists of providing positive reinforcement (small rewards or incentives) contingent upon objective evidence of desired behaviors, primarily drug abstinence verified by urine toxicology screening. The intervention will be delivered throughout the inpatient stay (approximately two weeks). Participants' adherence and abstinence will be monitored, and rewards will be adjusted based on performance.
219766199|NCT07209826|OTHER|Trios 5|Each patient's edentulous ridges are planned to be scanned three times with Trios 5.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
219766200|NCT07209826|OTHER|iTero Lumina|Each patient's edentulous ridges are planned to be scanned three times with iTero Lumina.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
219766201|NCT07209826|OTHER|Medit i700|Each patient's edentulous ridges are planned to be scanned three times with Medit i700.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
219766202|NCT07209826|OTHER|E4 Lab Scanner|Conventional measurements will be taken from each patient, and the resulting master model (reference scan) will be scanned using an industrial scanner with high scanning accuracy (E4 lab scanner, 3shape, Denmark) to obtain digital data.
219766203|NCT07209267|DRUG|Antiretroviral Therapy (ART)|"Antiretroviral Therapy (ART): A treatment regimen for HIV infection that uses a combination of antiretroviral drugs to suppress viral replication, reduce HIV-related morbidity, and prevent transmission.~In Step 1, participants will continue their current ART regimen for 26 weeks.~In Step 2, participants will interrupt ART.~In Step 3, participants will restart ART treatment early if they meet the ART restart criteria before the end of Step 2 (24-week maximum). Otherwise, they will resume ART at the end of Step 2."
219766204|NCT07209267|DRUG|Baricitinib (LY3009104) 2 mg|"Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients.~During Step 1, Baricitinib will be taken at a dose of 2 mg orally daily for 26 weeks.~During Step 2, Baricitinib alone will be continued at a dose of 2 mg orally daily for up to an additional 24 weeks"
219585552|NCT00477295|DRUG|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
219585553|NCT05136118|PROCEDURE|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
219585554|NCT04568031|DRUG|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
219585555|NCT04568031|DRUG|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
219585556|NCT01180439|DEVICE|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
219585557|NCT05918224|DRUG|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
219585558|NCT05918224|DRUG|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
219585559|NCT05320341|PROCEDURE|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
219766205|NCT07209761|DRUG|BPaQM|Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 15 weeks + Pretomanid 200 mg QD for 17 weeks + Quabodepistat 30 mg once daily for 17 weeks + Moxifloxacin 400 mg once daily for 17 weeks
219766206|NCT07209761|DRUG|BPaLM|Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks + Moxifloxacin 400 mg once daily for 26 weeks
219585560|NCT05320341|PROCEDURE|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
219585561|NCT00545675|DRUG|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
219585562|NCT00545675|DRUG|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
219585563|NCT05068375|DIAGNOSTIC_TEST|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
219585564|NCT03939299|PROCEDURE|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
219766207|NCT07209761|DRUG|BPaQ|Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Quabodepistat 30 mg once daily for 26 weeks
219766208|NCT07209761|DRUG|BPaL|Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks
219766209|NCT07209696|BEHAVIORAL|Tell-Show-Do|The conventional behavior guidance technique in pediatric dentistry, where the dentist explains and demonstrates dental procedures before performing them.
219766210|NCT07209696|BEHAVIORAL|Storybook Preparation|Home-based preparation using a child-friendly storybook that introduces the dental visit, instruments, and procedures in simple language and illustrations.
219766211|NCT07209696|BEHAVIORAL|Animation Video Preparation|The conventional behavior guidance method where the dentist explains and demonstrates dental procedures before performing them, to reduce anxiety and improve cooperation.
219766212|NCT07211100|BEHAVIORAL|Mobile Health Application|A mobile health application developed by the research team to support hemodialysis patients. The application includes modules on treatment adherence (medication, diet, fluid restriction, dialysis attendance), symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, reminder notifications, expert Q\&A, and personal tracking. The aim is to improve adherence to treatment, reduce symptom burden, and support patient self-care.
219766213|NCT07209813|BIOLOGICAL|GKL-006|GKL-006（3.0±0.9）×108 iNKT cells/m2 IV single infusion on Day 1 of each 14-day cycle for up to 11 cycles (≈6 month) in the absence of disease progression or unacceptable toxicity.
219766214|NCT07210437|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
219766215|NCT07210437|DIAGNOSTIC_TEST|Tests of above level sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
219766216|NCT07210437|DIAGNOSTIC_TEST|Testing of below level sympathetic activation|Cold pressor test of the foot and bladder pressor response will be tested.
219766217|NCT07209527|DEVICE|Truway Portable Ultrasound Device|Participants in the intervention group will use the Truway Portable Ultrasound Device, a FDA-regulated diagnostic tool, to perform non-invasive imaging for early detection of chronic conditions such as cardiovascular disease. The device will be used under supervised primary care protocols over a 6-month period, with training provided to care providers. Calibration and maintenance will be managed by Truway Health, Inc.
219766218|NCT07209527|DEVICE|Truway Blood Glucose Monitor|Participants in the intervention group will utilize the Truway Blood Glucose Monitor, an FDA-regulated device, to measure blood glucose levels for early detection and management of diabetes. The device will be employed under supervised primary care protocols over 6 months, with follow-ups at 3 and 6 months to assess accuracy and clinical outcomes. Training and support will be provided by Truway Health, Inc.
219766219|NCT07209527|DRUG|Standard Oral Hypoglycemic Agent|Participants in the intervention group with diagnosed prediabetes or Type 2 Diabetes Mellitus may receive a standard oral hypoglycemic agent (e.g., metformin) as prescribed by their primary care provider, in conjunction with the Truway diagnostic devices. The drug will be administered according to FDA-approved guidelines over the 6-month study period, with dosages adjusted based on blood glucose monitoring results obtained from the Truway Blood Glucose Monitor. Follow-ups at 3 and 6 months will assess glycemic control and safety.
219766220|NCT07210957|OTHER|Manual Therapy|"Myofascial Release:~Myofascial techniques will be implemented to masseter, temporalis, suboccipital, scalene, levator scapula and trapezius muscles. These techniques will be lasted for 90 seconds and using with a sliding motion between the origin and insertion of the muscles.~Trigger Point Therapy:~The ischemic compression approach will be implemented for 45-60 seconds to stretch the soft tissue over the trigger points of muscles. The emphasis will be on masseter, temporalis and scalene muscles~. The emphasis will be on the fascial chains of cranio-cervical and cranio-mandibular transition areas."
219766221|NCT07210957|OTHER|Sham manual therapy|The duration of each session will be lasted around 40-45 minutes (same as the therapy in the intervention group). The sham techniques will be implemented such as light contact by the therapist's hands, the impression of tissue manipulation, the touches with the effect of gravity and the performing non-therapeutic pressure to muscles. These sham techniques will not be implemented to the actual treatment points; however, they will be on the neck and jaw regions.
219766222|NCT07210112|DRUG|Psilocybin 25 mg per os|Caps of psilocybin administered orally once (V3) under medical and psychologist supervision in group 1, 2, and 3 and in an open-label setting for group 4
219585565|NCT04310956|DEVICE|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
219585566|NCT04310956|DEVICE|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
219585567|NCT00283491|BEHAVIORAL|Active Lactobacillus plantarum 299v|10\^11 cfu/meal in 2 meals on 2 consecutive days
219585568|NCT00283491|DIETARY_SUPPLEMENT|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
219585569|NCT04940260|DIAGNOSTIC_TEST|Renal function|measure eGFR at one year post partum
219585570|NCT04940260|DIAGNOSTIC_TEST|proteinuria|measure urine protein creatinine ratio at one year postpartum
219585571|NCT03015727|DRUG|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
219585572|NCT03015727|DRUG|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
219446413|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
219585573|NCT03015727|RADIATION|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
219585574|NCT03015727|DRUG|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
219446414|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
219446415|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
219446416|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
219446417|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
219446418|NCT00779181|DRUG|Placebo|Placebo taken three times a day
219446419|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
219446420|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
219446421|NCT02845284|BEHAVIORAL|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
219446422|NCT02845284|BEHAVIORAL|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
219446423|NCT04413344|DRUG|Bromocriptine Mesilate|Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
219446424|NCT04413344|DRUG|Placebos|Identical tablets which contain no active ingredient
219446431|NCT00863434|DRUG|clofarabine|Given IV
219446432|NCT00863434|DRUG|cytarabine|Given IV
219446433|NCT00863434|BIOLOGICAL|filgrastim|Given SC
219446439|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
219446440|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
219446441|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
219446442|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
219446443|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
219585575|NCT05145582|BEHAVIORAL|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
219585576|NCT05145582|BEHAVIORAL|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
219766223|NCT07210112|DRUG|Trazodone 5mg|Oral preparation of trazodone administered orally once (V3) with psilocybin in Group 2
219446444|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
219446445|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
219446446|NCT06793566|DEVICE|Repeated Muscle Vibration (rMV)|rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (impaired upper limb), interspersed with a 1-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
219446447|NCT06840756|BIOLOGICAL|Sex-mismatched red blood cell transfusions|Sex-mismatched red blood cell transfusions
219446448|NCT06840756|BIOLOGICAL|Sex-matched red blood cell transfusions|Sex-matched red blood cell transfusions
219446449|NCT06834789|DRUG|AGN-151586|Intramuscular injection
219446450|NCT06834789|DRUG|OnabotulinumtoxinA|Intramuscular injection
219446451|NCT06834789|DRUG|Placebo|Intramuscular injection
219585577|NCT03566576|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
219585578|NCT03566576|DRUG|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
219585579|NCT03566576|DRUG|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
219766224|NCT07210112|DRUG|Trazodone 30 mg|Oral preparation of trazodone administered orally once (V3) with psilocybin in Groups 3 \& 4
219766225|NCT07210112|DRUG|Placebo of psilocybin|Caps of psilocybin placebo will be administered at V3 in group 4
219766226|NCT07210112|DRUG|Placebo of trazodone|A placebo of trazodone will be administered orally at V3 in group 1
219766227|NCT07210255|DEVICE|SAINT Neuromodulation System|SAINT will be delivered via a MagPro X100 edition (MagVenture, Skovlunde, Denmark) TMS device equipped with a Cool-B65 A/P coil. The stimulation paradigm consists of 10 daily sessions (50 total over 5-days) of SAINT® stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be administered at 90% of the participant's resting motor threshold, with depth correction applied to adjust for the measured distance between the scalp and cortical surface. The stimulation target, the left dorsolateral prefrontal cortex (DLPFC), will be identified and localized by the study investigator using the Localite neuronavigation system.
219585580|NCT04691180|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
219585581|NCT04691180|DRUG|Placebo|Placebo given intravenously
219585582|NCT01362127|DRUG|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
219585583|NCT01362127|RADIATION|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
219766228|NCT07210255|DEVICE|Sham SAINT Stimulation|Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil and targeted to the L-DLPFC. The stimulation paradigm will be identical to the active SAINT stimulation with the exception that active stimulation will not be delivered.
219766229|NCT07211321|OTHER|No Intervention: Observational Cohort|No Intervention
219766230|NCT07209917|BEHAVIORAL|ASHA-Health HPV Intervention|The ASHA-Health HPV program will include three components: 1) Individual 1:1 weekly ASHA support; 2) 8 group sessions for the 42 W-Co-V in the ASHAHealth cohort, covering content in Modules 1-4; and 3) referral to life skills classes. The assigned ASHA will provide services to support the W-Co- V in accessing and/or adhering to HPV and ART appointments (arrange transportation, provide counseling, promote healthy lifestyle choices, and link with community resources). ASHA will also promote positive coping, social support, and aid in dealing with stigma. The 8 group sessions will be held over the six months, based on the needs identified by the women. Overall, the intervention content targets the provision of emotional support, skill building, HPV/ HIV and nutrition education, and protein-enriched food supplements, and ways to deal with stress, stigma, and the importance of engagement and retention in care. Food selections will be guided by our nutrition experts.
219766231|NCT07209917|BEHAVIORAL|Enhanced Standard of Care (SOC+)|"Selecting our base at the Belgaum ART Centers will provide the most up to date services for the SOC~\+ group. Yet, there is no typical standard of care in India as it relates to HPV screening for W-Co-V and stigma associated with both diseases is high. Further, in India, screening services are lacking at most ART centers. Since it would be unethical to withhold potentially lifesaving information about HPV, we will offer an enhanced standard of care to include usual care + 3 (1.5 hour) group sessions on wellness, basic nutrition, coping with mental health issues, and HIV/ HPV information. Thus, women will meet as a group three times over the six-month period. In addition, the women have access to our SOC+ nurse and ASHA to respond to questions."
219766232|NCT07210944|DEVICE|Repetitive transcranial magnetic stimulation|Transcranial magnetic stimulation applied a figure-8 coil to the premotor area at 80%-100% of the healthy-side MEP threshold. Treatment lasted 20 min in two phases: weeks 1-2 on the ipsilateral M1 (1Hz, 10s on/5s off), and weeks 3-4 on the contralateral M1 (10Hz, 3s on/12s off). Treat once a day, 5 days a week, for a total of 4 weeks.
219585584|NCT00872482|DRUG|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
219766233|NCT07210944|PROCEDURE|Scalp acupuncture|Scalp acupuncture selected bilateral upper-limb cortical MEP points (2 points total). The healthy-side hot spot was identified first; if the affected side had no MEP, its mirror point was used. Needles were inserted from point A (affected) to B (healthy) and beyond along the AB line. After insertion, needles were rotated for 2-3 min, manipulated every 10 min, and retained for 30 min. Treat once a day, 5 days a week, for a total of 4 weeks.
219766234|NCT07210944|COMBINATION_PRODUCT|Conventional rehabilitation treatment|Conventional drug therapy included secondary stroke prevention, neurotrophy, and improved cerebral circulation. Routine rehabilitation involved exercise, occupational, and physical therapies, with a total daily treatment time of 90 minutes.
219766235|NCT07212790|BEHAVIORAL|REAL-Fam Occupational Therapy Family Coaching|The REAL-Fam draws on the expertise of occupational therapy in evaluating the fit between the demands of everyday activities and the skills and abilities of the parent-child dyads. The dyad and the occupational therapist will be equipped to co-develop personalized strategies to enable participation in these meaningful occupations. It facilitates the family's consistent, habitual, and effective performance of their child's diabetes management tasks into their personalized daily routines. Emphasis is on the creation or modification of family-centered diabetes management and routines and catered to the child's developmental needs. Due to the complexity of diabetes management cares and the child's age, the caregiver will be present for all sessions. When working towards a caregiver-centered outcome, the caregiver will participate with little child involvement. When working toward a child-centered outcome, the child will be the focus of that session.
219766236|NCT07212725|BEHAVIORAL|Solving SCI Pain: Peer-Led Pain Self-Management Pain Tools Program|Solving SCI Pain Tools is a 7-week, peer-led, neuroscience-informed pain self-management program uniquely designed for individuals with spinal cord injury (SCI) and chronic pain. It integrates cognitive and body-based tools not commonly combined in other interventions, such as red light therapy, percussion massage, Graston technique, and guided movement, alongside education on pain neurobiology and behavior change. The program is delivered virtually and emphasizes participant autonomy, optionality, and personal relevance. Distinctively, it includes multiple individualized coaching sessions led by a peer with lived experience of SCI and pain. The program does not prescribe a fixed protocol but encourages flexible, self-paced exploration supported by structured check-ins. The integration of optional, non-clinical somatic tools with behavior-change coaching and SCI-specific education distinguishes this intervention from traditional rehabilitation or pain management programs.
219585585|NCT01102062|DIETARY_SUPPLEMENT|orange juice|
219585586|NCT04427644|PROCEDURE|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
219766237|NCT07213401|DEVICE|ComfTech HOWDY BABY|The Comftech HOWDYBABY medical device is a device for monitoring vital physiological parameters, in particular for monitoring heart rate and respiratory rate, consisting of a sensor-equipped belt. Blood oxygen saturation can also be monitored using a compatible accessory.
219585587|NCT04427644|PROCEDURE|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
219585588|NCT04427644|DIAGNOSTIC_TEST|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
219585589|NCT04427644|DIAGNOSTIC_TEST|Computed tomography|Admitted to observe leakage
219585590|NCT04557202|DRUG|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
219585591|NCT04557202|DRUG|Placebo|Placebo - control group
219585592|NCT00228423|DRUG|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
219585593|NCT00228423|DRUG|water pill daily|Daily dose of water pill (placebo)
219585594|NCT06526455|DRUG|Vonoprazan|oral drug 3-56 days after ESD.
219446452|NCT01748149|DRUG|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
219446453|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
219446454|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
219446455|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
219585595|NCT06526455|DRUG|Esomeprazole|oral drug 3-56 days after ESD.
219585596|NCT04614623|DEVICE|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
219585597|NCT04614623|OTHER|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
218837814|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
219446456|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 600 mg on Day1 to Day673
219585598|NCT00777413|DRUG|Minocycline 100mg Tablets|
219585599|NCT06438536|BEHAVIORAL|Virtual Reality-based Social Cognitive Training|Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
219446457|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673
219446458|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589
219585600|NCT03500653|DIETARY_SUPPLEMENT|Curcumin|4 gr curcumin
219585601|NCT03500653|DIETARY_SUPPLEMENT|Placebo|4 gr placebo
219585602|NCT01918540|PROCEDURE|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
219585603|NCT01918540|PROCEDURE|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
219585604|NCT01918540|DEVICE|MS-30 femoral stem|This is the stem used in the study.
219585605|NCT04673513|OTHER|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
219585606|NCT05197218|DIETARY_SUPPLEMENT|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
219585607|NCT06417138|OTHER|biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)|This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
218837815|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
218837816|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
219585608|NCT03041649|OTHER|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
219585609|NCT03041649|OTHER|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
219766238|NCT07211685|BIOLOGICAL|BAY 3401016|BAY 3401016
219766239|NCT07211685|OTHER|Placebo|Placebo to BAY 3401016
219585610|NCT02876575|DEVICE|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
219585611|NCT00199771|DRUG|7.5% NaCl in 6% dextran 70 solution|
219585612|NCT04559971|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
219446459|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
219446460|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
219446461|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
219446462|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
219446463|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
219446464|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
219446465|NCT05426460|BEHAVIORAL|Approach/Avoidance Task|The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.
219585613|NCT04559971|DRUG|Placebo|Sodium chloride for s.c. injection
219585614|NCT03787576|DEVICE|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
219585615|NCT00193427|DRUG|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
219585616|NCT00193427|DRUG|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
219585617|NCT00193427|DRUG|Carboplatin|AUC = 1.5 weekly x 7
219585618|NCT00193427|RADIATION|Radiation|To 63 Gy
219585619|NCT04099173|BEHAVIORAL|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
219585620|NCT04213976|PROCEDURE|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
219585621|NCT03170427|DEVICE|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
219766240|NCT07208006|DRUG|Standard Lipid-Lowering Therapy|Participants will receive lipid-lowering therapy according to current clinical guidelines. Treatment will be initiated with statins. Based on follow-up lipid levels, ezetimibe may be added, and PCSK9 inhibitor therapy may be considered if LDL-C goals are not met.
218837817|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
218837818|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
219585622|NCT03170427|DIAGNOSTIC_TEST|Sensory levels|Sensory levels are checked using ice test cold
219585623|NCT03170427|DIAGNOSTIC_TEST|Motor block|motor block is measured by modified Bromage scale
219585624|NCT03170427|DIAGNOSTIC_TEST|Sensory level|Sensory levels are checked using touch with alcohol puffs
219585625|NCT01072474|PROCEDURE|Capnography|Capnographic monitoring
219585626|NCT01072474|PROCEDURE|Standard monitoring|Standard monitoring
219585627|NCT06420791|OTHER||
219585628|NCT05294939|DIETARY_SUPPLEMENT|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
219766241|NCT07208006|DRUG|Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)|Participants will receive early intensive lipid-lowering therapy with a PCSK9 monoclonal antibody, initiated during the index hospitalization, in addition to statins. Ezetimibe may be added if clinically indicated. The PCSK9 inhibitor will be administered regardless of baseline lipid levels.
218837819|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
218837820|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
218837821|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
218837822|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
219585629|NCT05294939|DIETARY_SUPPLEMENT|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
219585630|NCT02683265|DRUG|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
219585631|NCT02683265|DRUG|Placebo|Placebo capsules
219446466|NCT05426460|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
219585632|NCT04682730|BEHAVIORAL|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
219585633|NCT04241991|RADIATION|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
219585634|NCT04241991|RADIATION|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
219585635|NCT05031689|BIOLOGICAL|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
219585636|NCT05031689|BIOLOGICAL|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
219585637|NCT02261844|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
219585638|NCT02261844|DRUG|Placebo|Placebo 1 pill daily X 10 days
219585639|NCT01233921|BIOLOGICAL|palifermin|Given IV
219585640|NCT01233921|OTHER|flow cytometry|Correlative studies
218837823|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
219585641|NCT01233921|OTHER|laboratory biomarker analysis|Correlative studies
219766242|NCT07209904|BEHAVIORAL|mindline.sg|mindline.sg is a polydigital mental health platform with resources, wayfinding, and peer support via a forum. The website was built by the MOH Office for Healthcare Transformation together with Ministry of Social and Family Development, National Council of Social Service and Institute of Mental health. The content was cureated by the mindline.sg team and vetted by a clinical review panel which included clinicians from IMH and Fei Yue Community Services.
219585642|NCT01233921|OTHER|pharmacological study|Correlative studies
218837824|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
219196508|NCT04290663|OTHER|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4\>1 ng/mL or rhTSH-sTg\>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
219766243|NCT07210450|DRUG|L-glutamine|Oral L-glutamine powder, administered at a dose of 0.1 g/kg/day for 60 days in adult patients with non-transfusion-dependent thalassemia (NTDT). The supplement is given in addition to each participant's standard care regimen (e.g., hydroxyurea or iron chelation therapy, as clinically indicated).
219446467|NCT05426460|BEHAVIORAL|AC|During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
219766244|NCT07212179|DEVICE|AID + InsuLearn-SMA|Automated insulin delivery (AID) system with InsuLearn simplified meal announcement bolus calculator
219766245|NCT07212179|DEVICE|AID + CC|Automated insulin delivery (AID) system using usual carbohydrate counting bolus calculator
218837825|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
218837826|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
218837827|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
218837828|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
219585643|NCT04917653|DEVICE|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
219585644|NCT04917653|OTHER|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
219446468|NCT05426460|DEVICE|Sham tDCS|Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
219446469|NCT04607590|OTHER|Best Practice|Receive usual care
219446470|NCT04607590|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219446471|NCT04607590|OTHER|Questionnaire Administration|Ancillary studies
219446472|NCT04607590|PROCEDURE|Yoga|Participate in yoga sessions
219446473|NCT06334354|OTHER|Assessments|Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
219766246|NCT07213297|OTHER|clinical assessments and complementary examinations|"Evaluation Plan~Comprehensive Examination: Complete medical history and physical examination of all body systems, including height and weight measurements.~Clinical Parameters: Pulse/heart rate, respiratory rate, and SpO2 will be monitored. The NYHA classification will be used to assess heart failure if applicable.~Neurological Examination: Includes motor strength testing, sensory testing (pinprick, light touch, temperature, proprioception), deep tendon reflexes, and gait assessment.~Electrocardiogram (ECG): A 12-lead ECG will be performed with the subject at rest for at least 5 minutes in a supine position.~24-hour Holter Monitoring: Conducted in cases of suspected arrhythmias or echocardiographic findings indicating arrhythmias.~Color Dosments and complementary examinations"
219766247|NCT07212608|DEVICE|Soft robotic exosuit|A soft robotic exosuit is a textile-based system worn on the waist and paretic lower limb that provides assistive torques via cables connecting the front and back of the ankle to anchor points on the shank. The exosuit provides dorsiflexion assistance during swing phase for foot clearance and plantarflexion assistance during stance phase for propulsion delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
219766248|NCT07212608|DEVICE|Propulsion neuroprosthesis|A neuroprosthesis is a textile-based, surface electrical stimulation system worn on the waist and paretic lower limb that delivers stimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides coordinated dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
219766249|NCT07209020|DEVICE|HealiAid Collagen Wound Dressing|Within the surgery procedure, the tumor is completely removed and the wounds are cleaned properly before applying the HealiAid Collagen Wound Dressing. HealiAid is soft and pliable. It can be adjusted to the size of the wound, and it is recommended to apply one to four pieces per wound. HealiAid Collagen Wound Dressing will be kept in place until absorbed completely.
219766250|NCT07211880|DRUG|Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin|7 days therapy
219446474|NCT06334354|OTHER|Assessment (Survivors Only)|\*Tumor/Treatment Variables (Survivors Only)
219446475|NCT06334354|OTHER|APOE and DNA Isolation|Biospecimens procurement and processing
219446476|NCT02014545|DRUG|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
219446477|NCT02014545|OTHER|Placebo|Only standard treatment of whole brain radiation therapy is done.
219446478|NCT06030193|DRUG|QLS-111 ophthalmic solution (0.015%)|QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
219446479|NCT06030193|DRUG|Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)|Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
219446480|NCT00654394|DRUG|Rosuvastatin|
219446481|NCT04718402|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
219446482|NCT04334044|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
219585645|NCT05971654|DRUG|azithromycin|azithromycin.:500 mg PO once for 5 days every month
219585646|NCT02584400|DRUG|Injection with the hypoxia tracer [18F]HX4,|The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
219585647|NCT00786994|DRUG|Oleogel-S10 100 mg/g|topical use once or twice daily
219446483|NCT05001269|DRUG|nedosiran|Monthly subcutaneous dosing throughout study period
219446484|NCT02064829|DRUG|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
219446485|NCT02064829|DRUG|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
219585648|NCT00786994|DRUG|Placebo (petroleum jelly)|topical use once or twice daily
219446486|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
219585649|NCT01674127|DRUG|Methyldopa|
219585650|NCT01674127|DRUG|Placebo|
219585651|NCT03564444|BIOLOGICAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
219585652|NCT03564444|OTHER|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
219585653|NCT03524989|DEVICE|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
219766251|NCT07211880|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer)|Endoscopic examinations were conducted using a GIF-150 endoscope in combination with the CV150 system (Olympus Co., Tokyo, Japan).
219766252|NCT07211880|DEVICE|Urea Breath Test for the prevalence of H pylori|After eradication of the H pylori with drug success of the therapy was assessed 6 to 8 weeks after treatment using the UBT(C13 Urea Breath Test: Beijing Richen-Force Science \& Techinology Co. Ltd.)
219766253|NCT07210151|DEVICE|VERAFEYE Anatomic Guidance System|The VERAFEYE Anatomical Guidance System will be used during standard of care, catheter-based treatments for atrial flutter and/or atrial fibrillation.
219766254|NCT07210320|DRUG|Epinephrine Auto-Injector 0.3 mg/0.3 mL|Epinephrine injection
219766255|NCT07210320|DRUG|Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle|Epinephrine injection
219766256|NCT07210320|DRUG|IN-001 9.06 mg Sublingual Spray|Sublingual Spray
218837829|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
218837830|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
219446487|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
219446488|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
219446489|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
219446490|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
219446491|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
219446492|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
219446493|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
219585654|NCT03524989|DEVICE|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
219585655|NCT03823495|OTHER|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
219585656|NCT01709253|RADIATION|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
219585657|NCT01540773|DRUG|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
219585658|NCT01540773|DRUG|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
219585659|NCT00147849|BEHAVIORAL|mailing of printed educational materials|
219585660|NCT00147849|BEHAVIORAL|a combination of interactive educational meetings, educational outreach visits, and reminders|
219585661|NCT00147849|BEHAVIORAL|identification of local opinion leaders and establishment of local consensus processes|
219585662|NCT00192270|BIOLOGICAL|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
219585663|NCT04776837|BEHAVIORAL|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
219585664|NCT03753763|DRUG|Safinamide Methanesulfonate|100 mg (free base)
219585665|NCT03753763|DRUG|Safinamide Methanesulfonate matching placebo|100 mg placebo
219766257|NCT07210320|DRUG|IN-001 13.59 mg Sublingual Spray|Sublingual Spray
218837831|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
218837832|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
218837833|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
218837834|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
218837835|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
219446494|NCT02422160|OTHER|No interventions are planned|No interventions are planned
219446495|NCT00564915|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
219446496|NCT02514213|BIOLOGICAL|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
219446497|NCT02514213|BIOLOGICAL|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
219446498|NCT02514213|BIOLOGICAL|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
219446499|NCT02514213|BIOLOGICAL|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
219446500|NCT02514213|DEVICE|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
219446501|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
219446502|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
219585666|NCT06309654|BEHAVIORAL|12-week home-based circuit training (HBCT)|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.
219585667|NCT06309654|BEHAVIORAL|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
219766258|NCT07211724|OTHER|MUD Management (contingency management +/- adjunctive MUD pharmacotherapy)|Management of MUD will be individualized for each study patient. All patients will receive behavioral counseling utilizing motivational interviewing and education and offered a contingency management (CM) plan incentivizing abstinence from meth. Several pharmacotherapies are recommended for the treatment of MUD: mirtazapine, bupropion and naltrexone, or bupropion monotherapy. If required, adjunctive MUD pharmacotherapy will be added to the CM guided by comorbid conditions, patient characteristics, and characteristics of use.
219766259|NCT07211724|OTHER|HF GDMT management|As per standard clinical care, patients will be followed by a cardiologist for HF management including assessment for GDMT optimization.
219766260|NCT07212413|PROCEDURE|Snow-plow restorative technique|The snow-plow technique involves placing a thin layer of uncured flowable bulk-fill resin on the gingival floor of a Class II cavity, immediately followed by placement of a packable bulk-fill composite. Both materials are light-cured simultaneously, allowing the flowable resin to fill voids and improve marginal adaptation.
219766261|NCT07212413|PROCEDURE|Resin coating restorative technique|The resin coating technique involves applying and light-curing a thin layer of flowable bulk-fill resin after adhesive application to create a stress-absorbing layer on dentin (resin coating), followed by restoration with packable bulk-fill composite. This approach aims to protect the dentin, enhance bond stability, and reduce postoperative sensitivity
219446503|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
219446504|NCT02916628|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
219446505|NCT02916628|DEVICE|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
219446506|NCT02916628|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
219446507|NCT04770090|OTHER|Blood samples|Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.
219446508|NCT05897424|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
219446509|NCT04464668|BEHAVIORAL|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
219446510|NCT04464668|BEHAVIORAL|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
219446511|NCT03539614|DRUG|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
219446512|NCT03539614|DRUG|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
219446513|NCT04997850|DRUG|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
219585668|NCT05346783|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
219585669|NCT05346783|OTHER|Placebo (vehicle)|1 drop 6 times a day
219766262|NCT07212335|BIOLOGICAL|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.
219585670|NCT05346783|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
218837836|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
219446514|NCT04997850|PROCEDURE|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
219446515|NCT02996305|DRUG|OV101 Regimen 1|
219446516|NCT02996305|DRUG|OV101 regimen 2|
219446517|NCT02996305|OTHER|Placebo|
219446518|NCT05230511|DRUG|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
219446519|NCT05230511|DRUG|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
219446520|NCT05924178|BEHAVIORAL|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
219446521|NCT05924178|BEHAVIORAL|routine treatment|The control group receives conventional treatment preoperative.
219446522|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
219446523|NCT04891757|DRUG|FHD-286|FHD-286 administered orally
219585671|NCT00389831|DRUG|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
219585672|NCT00389831|OTHER|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
219585673|NCT05058534|DEVICE|Multiline Neo®|Multiperfusion neonatal system
219585674|NCT00249691|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
219585675|NCT00249691|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
219766263|NCT07213258|BEHAVIORAL|CHAMPION Intervention|MHealth intervention to enhance PrEP adherence, combined with computer-administered cognitive behavioral therapy for a 6-month period for the intervention arm.
218837837|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
219446524|NCT04891757|DRUG|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
219446525|NCT04891757|DRUG|Decitabine|Decitabine administered intravenously
219446526|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
219446527|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
219446528|NCT02718664|OTHER|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
219446529|NCT01285752|DRUG|AK106-001616|
219446530|NCT01285752|DRUG|AK106-001616|
219446531|NCT01285752|DRUG|Active comparator|
219446532|NCT01431521|DRUG|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
219446533|NCT01431521|DRUG|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
219585676|NCT01850095|DRUG|treatment azelaic acid (azelan)|treatment for 6 months
219585677|NCT01850095|DRUG|dorspirenone/ethynil estradiol|
219585678|NCT03433755|DRUG|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
219585679|NCT03433755|DRUG|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
219585680|NCT00000117|DRUG|Immunoglobulin|
219585681|NCT00044980|PROCEDURE|nutritional support|
219585682|NCT00044980|PROCEDURE|quality-of-life assessment|
219585683|NCT03485053|DRUG|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
218837838|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
218837839|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
218837840|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
218837841|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
219196509|NCT05492448|DIETARY_SUPPLEMENT|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
219766264|NCT07213258|BEHAVIORAL|Delayed CHAMPION Package|Informational resources for first 3-months of study, followed by CHAMPION intervention for final 3-months.
218837842|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
218837843|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
219446534|NCT01431521|DRUG|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
219446535|NCT01431521|DRUG|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
219446536|NCT05907772|OTHER|No intervention|No intervention
219446537|NCT06631989|DRUG|WSD0922-FU|"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
219446538|NCT01996228|DEVICE|Stem Cell Educator|
219446539|NCT04482621|DRUG|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)"
219446540|NCT04482621|OTHER|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
219446541|NCT00223613|DRUG|daily intranasal administration of insulin|
219446542|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
219446543|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
219446544|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
219446545|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
219446546|NCT01731275|DRUG|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
219446547|NCT01731275|DRUG|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
219585684|NCT00125411|DRUG|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
219585685|NCT05486455|DIAGNOSTIC_TEST|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
219585686|NCT01176214|PROCEDURE|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
219585687|NCT01176214|PROCEDURE|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
218837844|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
219446548|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
219446549|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
219446550|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
219585688|NCT00303394|DRUG|IL-1Ra|
219585689|NCT06928090|DRUG|DTG + 3TC FDC|None(Non-interventional, retrospective chart review, single-arm study )
219585690|NCT03202901|DIETARY_SUPPLEMENT|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
219766265|NCT07209007|OTHER|No Intervention: Observational Cohort|This is an observational cohort study with no interventions administered. Skin swabs, stool samples, blood samples, and skin physiological measurements will be collected at baseline, 3, 6, 12, and 24 months after burn injury to investigate longitudinal changes in the skin and gut microbiome.
219766266|NCT07211451|PROCEDURE|Breast conserving surgery with axillary surgery|In this study, all patients received breast conserving surgery with axillary surgery.
219766267|NCT07212322|DRUG|CD19 UCAR-T cells|CD19 UCAR-T cells treatment
219766268|NCT07212101|BEHAVIORAL|Sleep and diet|Participants will be asked to increase their fruit and vegetable consumption, time in bed, and modify light exposure across the day
218837845|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
219196510|NCT05492448|DIETARY_SUPPLEMENT|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
219196511|NCT05492448|DIETARY_SUPPLEMENT|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
219446551|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
219446552|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
219446553|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
219446554|NCT02444689|BEHAVIORAL|Standard of care education|
219446555|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
219446556|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
219446557|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
219446558|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
219446559|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
219446560|NCT00366444|DRUG|Placebo|Placebo every 6 hours
219446561|NCT00171067|DRUG|valsartan|
219446562|NCT00171067|DRUG|lisinopril|
219446563|NCT01989936|DRUG|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
219446564|NCT01989936|DRUG|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
219446565|NCT01989936|DRUG|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
219446566|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
219446567|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
219446568|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
219446569|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
219446570|NCT00519571|DEVICE|ImplantLock device|dental implant
219446571|NCT00397449|BIOLOGICAL|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
219446572|NCT00242944|DRUG|Pitavastatin|Pitavastatin 4mg per day
219446573|NCT00242944|DRUG|Atorvastatin|Atorvastatin 20mg per day
219446574|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
219446575|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
219446576|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
219446577|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
219446578|NCT00585104|DRUG|levosimendan|10-minute infusion
219446579|NCT04949139|DRUG|Dextrose 5% in water|Reducing the sodium concentration
219446580|NCT03979495|OTHER|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
219446581|NCT00212667|DRUG|ONO-5920|
219446582|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
219446583|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
219446584|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
219446585|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
219446586|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
219446587|NCT04403802|DEVICE|Voxx Human Performance Technology Socks|"Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
219446588|NCT04403802|DEVICE|Placebo Socks|"Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
219446589|NCT00965744|DEVICE|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
219446590|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
219446591|NCT05547594|BEHAVIORAL|Multimodal surgical prehabilitation|Participants will be encouraged to engage in regular physical activity (endurance and resistance exercise), eat healthily and undergo cognitive behavioural therapy (the latter only if required) during the weeks prior to surgery.
219446592|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
219446593|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
219446594|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
219446595|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
219446596|NCT02337075|DEVICE|Activity Mentor|
219446597|NCT02334813|DRUG|Prednisone|Continuous daily therapy
219446598|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
219446599|NCT02726204|OTHER|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
219446600|NCT02726204|OTHER|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
219446601|NCT02726204|OTHER|Path Assistance and Gravity Elimination|
219446602|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
219446603|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
219446604|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
219446605|NCT02784496|OTHER|Long-term Follow-up|Undergo follow-up assessment
219446606|NCT02784496|OTHER|Quality-of-Life Assessment|Ancillary studies
219766269|NCT07208175|OTHER|Ultrasound-Guided Peripheral Intravenous Catheter Insertion|In this arm, PIVC insertion is performed by oncology nurses who have completed a structured ultrasound training program. Nurses use real-time ultrasound imaging to identify and select a suitable vein, guide the advancement of the catheter, and confirm placement. This method contrasts with the standard touch-and-feel approach by incorporating ultrasound technology and specialized nurse training to improve first-time insertion success and reduce complications.
219766270|NCT07208175|OTHER|Traditional Peripheral Intravenous Catheter Insertion|PIVC insertion performed by oncology nurses using the conventional touch-and-feel landmark technique, relying on visual inspection and palpation of veins. Represents current standard clinical practice in oncology.
218837846|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
218837847|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
219446607|NCT02784496|DRUG|Ruxolitinib|Given PO
219446608|NCT05611671|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
219446609|NCT05611671|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
219446610|NCT05220358|DRUG|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
219446611|NCT05396001|BEHAVIORAL|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
219446612|NCT05396001|BEHAVIORAL|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
219585691|NCT03202901|DIETARY_SUPPLEMENT|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
219196512|NCT06375655|BEHAVIORAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
219196513|NCT06375655|BEHAVIORAL|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
219446613|NCT02346409|DEVICE|tACS of the cerebellum|tACS of the cerebellum
219446614|NCT02552823|OTHER|Group1|
219446615|NCT02552823|OTHER|Group2|
219585692|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
219017182|NCT04790344|DEVICE|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
219017183|NCT04393103|DRUG|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
219017184|NCT04393103|DRUG|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
219017186|NCT04931498|OTHER|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
219017187|NCT04931498|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
219017188|NCT04931498|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
219017189|NCT04931498|PROCEDURE|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry"
219017190|NCT04931498|PROCEDURE|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays"
219196514|NCT03571386|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
219196515|NCT03571386|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
219446616|NCT04021628|OTHER|No intervention- not applicable|No intervention - not applicable
219446617|NCT04835051|BEHAVIORAL|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
219585693|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
219766271|NCT07211152|BIOLOGICAL|Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV|Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
219766272|NCT07211152|BIOLOGICAL|Vaxigrip QIV|Participants will receive one dose of vaccine (0.5 mL) of Vaxigrip QIV
219766273|NCT07212348|BEHAVIORAL|Laughter Yoga|Students in the experimental group will participate in laughter yoga sessions conducted twice a week (Thursday and Friday) for four weeks, outside of class hours and in an indoor setting.
219766274|NCT07213427|OTHER|data collection|Collection of relevant medical data (clinical data, imaging, treatment, follow-up, toxicities), performed locally by investigators or authorized members of the medical team.
219766275|NCT07211906|OTHER|Control Group: oral hygiene education standard|oral hygiene education Standard care: oral hygiene education standard care, which involved providing participants with printed oral health education leaflets without additional personalized instruction or digital support. Specifically, participants were assessed at baseline, and then, at one-month intervals, they received printed oral care instructions and completed follow-up assessments. This group was not provided oral education or interactive guidance via digital platforms during the study period.
219585694|NCT00121160|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
219475997|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
219585695|NCT06927752|DEVICE|PelviGYNious|Patient received PelviGYNious implant.
219585696|NCT06927752|DEVICE|EndoGYNious|Patient received EndoGYNious implant.
219585697|NCT06926712|DRUG|Vitamin E|dose of vitamin E in an appropriate dose for age during hospital stay for intervention group
219585698|NCT03926481|BEHAVIORAL|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
219585699|NCT06928961|OTHER|Patient portal with patient-reported outcome measure administration, appointment calendar and reminders, access to lab test results, and educational material|Patients in the intervention will be trained to register on and use the patient portal. The following portal features will be used and studied in this project: the appointment calendar, PROMs administration, reminders (e.g., for appointments), educational materials, and access to personal lab results. Educational materials in the portal will include information on what to expect during HIV clinic visits, how to interpret HIV lab reports, and instructional videos on using the portal. Prior to visiting their HIV physician, patients will have continuous access to several portal features (calendar, education, and lab results, if applicable), and receive reminders (within 48 hours) of their clinic appointment and to complete the PROMs. Physicians will acquire their patients' PROM scores via the patient portal and receive training on how to do so. Patients and physicians are expected to review the PROM results and consider them during each clinic visit.
219585700|NCT00240942|DRUG|Letrozole|
219585701|NCT00486616|DEVICE|electrical impedance tomography|
219585702|NCT00486616|PROCEDURE|double-lumen tube placement|
219585703|NCT05463263|DRUG|STP938|Small molecule
219585704|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
218837848|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
219585705|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
219585706|NCT05052515|DIETARY_SUPPLEMENT|Dihydromiricetin, Vitamin C, E and Choline|Patients with MASLD will be randomly allocated to receive capsules with Dihydromiricetin, Vitamin C, E and Choline
219585707|NCT05052515|OTHER|Placebo|Patients with MASLD will be randomly allocated to receive placebo capsules
219585708|NCT06193928|DRUG|Livmarli|The recommended dosage is 380 mcg/kg once daily.
219585709|NCT06193928|DRUG|Livmarli|The recommended dosage us 570 mcg/kg twice daily.
219585710|NCT03190330|DRUG|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
219585711|NCT03190330|DRUG|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
219585712|NCT04295473|PROCEDURE|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
219196516|NCT05361408|DRUG|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
219585713|NCT05413915|DRUG|Asciminib|Tyrosine kinase inhibitor
219585714|NCT05413915|DRUG|Imatinib|Tyrosine kinase inhibitor
219585715|NCT04197258|OTHER|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
218837849|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
218837850|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
219446618|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
219446619|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
219585716|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
219766276|NCT07211906|OTHER|oral hygiene education program|"Oral hygiene education program:~The oral hygiene education program includes a Line-based oral care guidance program, which involves personalized, one-on-one oral health education facilitated through the Line communication platform. The process began with an initial pre-test assessment, including interviews and questionnaire evaluations. Then, the participants engaged in the Line-guided oral care intervention, where they received tailored guidance and demonstrated"
219766277|NCT07212868|DRUG|REMD-477 versus Placebo|Placebo versus glucagon receptor antagonist using a human monoclonal antibody with a high level of antagonistic effect against human glucagon receptor.
219766278|NCT07212868|OTHER|Exogenous glucagon versus saline infusion|The effect of increased glucagon concentrations in plasma on glucose metabolism during glucose clamp will be studied.
218837851|NCT02448992|RADIATION|hippocampal-sparing WBRT|
219196517|NCT05361408|DRUG|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
219196518|NCT04734730|DRUG|Abiraterone Acetate|Given PO
219196519|NCT04734730|DRUG|Bicalutamide|Given PO
219196520|NCT04734730|DRUG|Degarelix|Given SC
219196521|NCT04734730|DRUG|Goserelin Acetate|Given SC
219196522|NCT04734730|DRUG|Leuprolide Acetate|Given IM
219196523|NCT04734730|DRUG|Prednisone|Given PO
219196524|NCT04734730|OTHER|Questionnaire Administration|Ancillary studies
219446620|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
219446621|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
219446622|NCT01794546|BEHAVIORAL|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
219585717|NCT05104073|BEHAVIORAL|Intervention|Provided with educational materials, guidelines and instructions.
219585718|NCT05705128|DRUG|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
219196525|NCT04734730|DRUG|Talazoparib|Given PO
219585719|NCT05376696|BEHAVIORAL|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
219585720|NCT05376696|BEHAVIORAL|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
219766279|NCT07210593|BEHAVIORAL|FAMS|"PWD participants will receive FAMS components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment.~Co-enrolled SP participants will receive high-quality print materials upon enrollment and receive text message support tailored to the goal set by the linked PWD."
219766280|NCT07210593|BEHAVIORAL|PEER|PWD participants will receive PEER components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment PWD participants assigned to PEER will be matched with another PWD participant assigned to peer to provide peer support to each other.
219446623|NCT01652222|OTHER|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
219446624|NCT01652222|OTHER|Socio-educational training only|4 socio-educative training sessions during 8 weeks
219446625|NCT00354484|DRUG|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
219446626|NCT00354484|DRUG|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
219446627|NCT04161313|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
219446628|NCT04161313|OTHER|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
219446629|NCT04161313|OTHER|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
219446630|NCT04161313|OTHER|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
219446631|NCT04161313|OTHER|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
219446632|NCT05683483|OTHER|WEsleep Interventions|1\) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
219446633|NCT02508363|BEHAVIORAL|questionnaires|
219446634|NCT06043271|BEHAVIORAL|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
218837852|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
219446635|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
219475998|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
219475999|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
219476000|NCT03174457|DRUG|Micafungin|Intravenous
219476001|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
219476002|NCT00040001|DRUG|DTI-0009|
219476003|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
219476004|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
219476005|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
219476006|NCT01782638|BEHAVIORAL|deep brain stimulation|
219476007|NCT01977131|OTHER|Cells|
219476008|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
219476009|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
219476010|NCT00001080|DRUG|Lamivudine|
219476011|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
219476012|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
219476013|NCT00470301|DRUG|tipifarnib|Given orally
219476014|NCT00470301|DRUG|paclitaxel|Given IV
219476015|NCT00470301|DRUG|doxorubicin|Given IV
219476016|NCT00470301|DRUG|cyclophosphamide|Given IV
219476017|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
219476018|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
219446636|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
219446637|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
219446638|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
219446639|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
219446640|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
219446641|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
219446642|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
219446643|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
219446644|NCT03537937|OTHER|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
219446645|NCT03537937|OTHER|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
219446646|NCT03537937|OTHER|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
219446647|NCT03671148|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
219446648|NCT03671148|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
219446649|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
219446650|NCT05788978|OTHER|Scale development|Scale development
219585721|NCT06193772|BEHAVIORAL|Internet-delivered psychodynamic therapy (IPDT)|"IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions."
219585722|NCT05257213|DRUG|Heparin solution|3 ml saline solution containing 5000 IU heparin.
219585723|NCT05257213|DRUG|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
219585724|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
219585725|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
219585726|NCT05297760|BIOLOGICAL|Polvac Grass+Rye|Suspension of micro crystalline tyrosine with grass and rye pollen allergen
219585727|NCT05297760|DRUG|Saline 0.9%|Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
219585728|NCT04395001|DRUG|duloxetine|All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.
219585729|NCT04395001|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (CBT)|The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.
219446651|NCT05065866|DRUG|BMS-986345|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
219585730|NCT04395001|OTHER|Nurse-delivered Motivational Interviewing|Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
219585731|NCT00365313|DRUG|celecoxib, esomeprazole|
219585732|NCT06531395|DRUG|Abiprubart|humanized monoclonal antibody
219446652|NCT05065866|DRUG|Duvelisib|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
219585733|NCT06531395|DRUG|Placebo|sterile preservative-free solution
219585734|NCT05844761|RADIATION|Triggered imaging on TrueBeam with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
219585735|NCT05844761|RADIATION|Synchrony MLC tracking on fiducials with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
219585736|NCT05844761|RADIATION|Synchrony MLC tracking and lung adaptive model with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
219585737|NCT06138899|OTHER|Club 25|The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
219585738|NCT04347122|DRUG|Tranexamic Acid (TXA)|Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
219585739|NCT02664935|DRUG|AZD4547|FGFR Inhibitor
219585740|NCT02664935|DRUG|Vistusertib|MTORC1/2 Inhibitor
219585741|NCT02664935|DRUG|Palbociclib|CDK4/6 Inhibitor
219585742|NCT02664935|DRUG|Crizotinib|ALK/MET/ROS1 Inhibitor
219446653|NCT01250899|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
219446654|NCT00246285|DRUG|risperidone|
219446655|NCT00673816|DRUG|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
219585743|NCT02664935|DRUG|Selumetinib|MEK Inhibitor
219585744|NCT02664935|DRUG|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
219585745|NCT02664935|DRUG|AZD5363|AKT Inhibitor
219585746|NCT02664935|DRUG|Osimertinib|EGFRm+ T790M+ Inhibitor
219585747|NCT02664935|DRUG|Durvalumab|Anti-PDL1
219585748|NCT02664935|DRUG|Sitravatinib|VEGFR Inhibitor
219585749|NCT02664935|DRUG|AZD6738|ATR inhibitor
219585750|NCT04424511|DRUG|Placebo|Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
219585751|NCT04424511|DRUG|Azithromycin|Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
219585752|NCT06381973|BEHAVIORAL|ELTGOL_Physio|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will accompany the subject by gently applying manual pressure on the chest wall and the abdomen during expiratory phases.
219585753|NCT06381973|BEHAVIORAL|ELTGOL_Auto|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will not intervene in this arm.
219585754|NCT06381973|DEVICE|PEP|The subject will be asked to exhale through a positive expiratory pressure (PEP) device (Threshold PEP) while being in the right lateral posture.
219585755|NCT06381973|BEHAVIORAL|1L-Tidal-Breathing|The subject will be asked to breath with a fixed tidal-breathing of 1 liter per breath (monitored via a spirometer) while being in the right lateral posture.
219585756|NCT06381973|BEHAVIORAL|Spontaneous Breathing|The subject will be asked to breath spontaneously while being in the right lateral posture.
219585757|NCT06450028|DRUG|10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine|Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
219585758|NCT06450028|DRUG|6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine|Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
219585759|NCT05466461|PROCEDURE|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
219585760|NCT05466461|PROCEDURE|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
219585761|NCT05906810|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
219585762|NCT04533958|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
219446656|NCT05479136|DRUG|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
219446657|NCT05042570|OTHER|Instrument Assisted Soft Tissue Mobilization|"* This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
219446658|NCT05042570|OTHER|Stretching Exercises|"* The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
219446659|NCT05042570|OTHER|Control Group / NDT program|"* Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance."
219446660|NCT04829006|DEVICE|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
219446661|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
219446662|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
219446663|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
219446664|NCT00533780|PROCEDURE|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
219585763|NCT06364696|DRUG|ASP4396|Intravenous (IV) infusion
219585764|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
219585765|NCT06526182|OTHER|Placebo|Lebrikizumab Matching placebo solution for injection administered subcutaneously.
219585766|NCT05526300|DEVICE|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
219585767|NCT05526300|OTHER|The standard care|The standard care
219585768|NCT04270175|DRUG|Daratumumab SC|Given as 1800mg via injection
219585769|NCT04270175|DRUG|Pomalidomide|Given as 4mg oral capsule
219585770|NCT04270175|DRUG|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
219585771|NCT06244745|DRUG|Administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
219585772|NCT04994483|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
218837853|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
219585773|NCT04994483|DRUG|Placebo|Matching placebo given b.i.d. for 52 weeks.
219585774|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
219585775|NCT05474846|DRUG|Melatonin|Given by PO
219585776|NCT05474846|OTHER|Placebo for Melatonin|Given by PO
219446665|NCT05017987|DRUG|ATB-101, ATB-1011, ATB-1012|"1. Test drug~   \- Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin"
219446666|NCT04300842|DEVICE|smart bracelet|to measure the stress, fatigue, and activity.
219446667|NCT00343395|DRUG|AVANDAMET|2/500 mg
219446668|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
219446669|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
219446670|NCT03437993|OTHER|Recollect, the game|"Recollect is a working memory training game"
219446671|NCT03437993|OTHER|Tetris|App-based video game where shapes are rotated and placed to fit a grid
219446672|NCT02401685|OTHER|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
219446673|NCT02401685|PROCEDURE|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
219446674|NCT06520345|DRUG|177Lu-TLX591|Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
219446675|NCT06520345|DRUG|Enzalutamide|Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
219585777|NCT05474846|DRUG|Melatonin|Given by PO
219585778|NCT05474846|DRUG|Methylphenidate|Given by PO
219446676|NCT06520345|DRUG|Abiraterone|Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
219446677|NCT06520345|DRUG|Docetaxel|Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
219446678|NCT06415656|DEVICE|TempTraq|TempTraq (Blue Spark Technologies, Westlake, OH) is an FDA 510K cleared wearable, wireless temperature monitoring patch designed to continuously monitor and track body temperature.
219446679|NCT06415656|DEVICE|VitalTraq|VitalTraq (Blue Spark Technologies, Westlake, OH) is an experimental and novel multi-vital sign monitoring platform that allows for interval measurements of heart rate, heart rate variability, and blood pressure.
219585779|NCT01565655|DRUG|peficitinib|oral
219585780|NCT01565655|DRUG|Placebo|oral
219585781|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
219585782|NCT03299088|DRUG|Trametinib|Given PO
219585783|NCT06170450|DEVICE|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
219585784|NCT06170450|DEVICE|Continuous SNM|Continuous SNM: on continuously, no 'off' period
219585785|NCT04809740|OTHER|Evaluate implementation of navigator-delivered Home ePRO for all cancer patients|evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
219585786|NCT05568264|OTHER|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
219585787|NCT05828745|DRUG|CB06-036|CB06-036 capsule
219585788|NCT05828745|DRUG|Placebo|Placebo capsule
219585789|NCT03589768|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
219585790|NCT03589768|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
219585791|NCT06530290|DRUG|Mirtazapine 15 MG|Mirtazapine (15 mg), once a day for 12 weeks
219585792|NCT06530290|DRUG|Placebo|Placebo, once a day, for 12 weeks
219766281|NCT07209800|OTHER|Sensory integration therapy|Sensory integration therapy (SIT) was delivered individually in a play-based format, three times per week for four weeks, totaling 12 sessions. Each session lasted 60 minutes, and parents were instructed to reinforce the activities at home as homework. All interventions were administered one-on-one by an experienced therapist in a therapy room. The therapist who administered the intervention did not take part in the evaluation process; therefore, the study was conducted in a single-blind manner. Before the intervention, a trust-based relationship was established with the children, and sensory activities were performed within a play context. The interventions were not limited to oral activities but aimed to support overall sensory development \[8\]. Based on this program, sensory integration procedures were applied at regular intervals.
219446680|NCT05480306|DRUG|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
219446681|NCT05480306|DRUG|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
219446682|NCT05480306|DRUG|Bevacizumab|90-min IV infusion (5mg)
219446683|NCT05480306|DRUG|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
219446684|NCT02234050|DRUG|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
219585793|NCT05804916|DEVICE|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
219585794|NCT05575258|OTHER|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
219585795|NCT05575258|OTHER|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
219766282|NCT07210892|OTHER|Measurement of needle insertion angles|Individualization of needle insertion angle depending on the skin to dural sac distance
219766283|NCT07212166|OTHER|Patient-Reported Outcome Surveys|PRO-AYA , Patient-Reported ECOG PS, EORTC QLQ-C30, Demographic/Clinical Characteristics
219446685|NCT02234050|OTHER|Local standard of care|Left to the discretion of the investigator
219446686|NCT02365805|DRUG|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
219446687|NCT02365805|DRUG|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
219446688|NCT02365805|DRUG|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
219446689|NCT05064085|DRUG|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
219446690|NCT05064085|DRUG|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
219585796|NCT06647394|PROCEDURE|Matrix Dressing|extracellular matrix dressing soaked in 4% topical lidocaine to the skin graft donor site
219585797|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill|Pomegranate extract pill
219585798|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill placebo|Pomegranate pill placebo
219585799|NCT04391530|BEHAVIORAL|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
219446691|NCT02365506|DRUG|Eleclazine|Tablets administered orally in a single dose
219446692|NCT02365506|DRUG|Placebo|Placebo to match tablets administered orally in a single dose
219585800|NCT03465826|BEHAVIORAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
219585801|NCT03465826|BEHAVIORAL|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
219585802|NCT03898089|OTHER|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
219585803|NCT03898089|OTHER|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
219446693|NCT00592176|DRUG|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
219446694|NCT06179355|PROCEDURE|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
219446695|NCT06179355|PROCEDURE|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
219446696|NCT01335438|DEVICE|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
219446697|NCT01335438|DEVICE|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
219446698|NCT00766181|BEHAVIORAL|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
219446699|NCT00599222|BIOLOGICAL|ranibizumab|0.5 mg intravitreal injection
219766284|NCT07212166|OTHER|Spanish version of PRO-AYA and the cognitive interview|Revised Spanish PRO-AYA, Demographic/Clinical Characteristics
219585804|NCT01806766|PROCEDURE|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
219446700|NCT00599222|PROCEDURE|TTT|Transpupillary thermotherapy (TTT)
219446701|NCT00599222|PROCEDURE|Sham TTT|Sham Transpupillary thermotherapy (TTT)
219446702|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
219585805|NCT01806766|PROCEDURE|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
219585806|NCT03402555|OTHER|Stool pattern|Collection of stool images
219585807|NCT02155543|DRUG|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
219585808|NCT02155543|DRUG|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
219585809|NCT02155543|DRUG|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
219585810|NCT02155543|DRUG|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
218837854|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
218837855|NCT00140179|DRUG|valnoctamide|
218837856|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
219446703|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
219446704|NCT02597686|BEHAVIORAL|SD-PB training|
219585811|NCT03543436|DRUG|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
219446705|NCT01852591|BIOLOGICAL|PCV 13|
219585812|NCT03543436|DRUG|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
219585813|NCT00104143|DRUG|A4I Antagonist|
219585814|NCT06408948|DRUG|[14C]SHR7280|Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
219585815|NCT02213510|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
219585816|NCT02213510|DEVICE|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
219585817|NCT02263950|DRUG|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
219446706|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
219446707|NCT03968107|OTHER|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
219446708|NCT05405842|DEVICE|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
219446709|NCT02375880|DRUG|DKN-01|Administration by intravenous (IV) infusion.
219446710|NCT02375880|DRUG|gemcitabine|Administered by IV infusion.
219766285|NCT07210983|DEVICE|Low-Intensity Pulsed Ultrasound|The LIPUS therapy protocol was administered by a trained nurse following standardized procedures. Starting on the third day post-enucleation, patients in the ultrasound group underwent LIPUS therapy using the OSTEOTRON IV device (Japan), set at a frequency of 1.5 MHz and an intensity of 30 mW/cm², with 20-minute sessions for 10 consecutive days (Fig. 1). Treatments were conducted in a temperature-controlled environment, with patients positioned supine. Prior to each session, the skin over the cyst site was cleansed and coated with ultrasound transmission gel (Hinuo, Qingdao, China).
219766286|NCT07210996|DRUG|pimicotinib capsules|pimicotinib capsules
219766287|NCT07212985|PROCEDURE|Autogenous Bone Block + Xenograft + Collagen Membrane|Autogenous chin bone block graft combined with particulate bovine xenograft (Bio-Oss, Geistlich Pharma AG) and covered with an absorbable collagen membrane (Bio-Gide).
219766288|NCT07210606|DRUG|Trazodone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: trazodone or placebo. In addition, participants will get PAP therapy during both the conditions.
219766289|NCT07210606|DRUG|Oxygen + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: oxygen or room air. In addition, participants will get PAP therapy during both the conditions.
219766290|NCT07211854|OTHER|Anticoagulant Treatment|Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.
219766291|NCT07213414|DIETARY_SUPPLEMENT|Probiotics|The intervention is giving probiotic supplementation that contains Bifidobacterium longum BB536, Bifidobacterium breve M-16V, Bifidobacterium longum subs.infantis M-63 from Morinaga.
219766292|NCT07213102|OTHER|Integrated Whole-Household Programming|Treatment participants receive both Compassion International's Survival and Early Childhood Program (holistic child development through health support, educational programming, social development, and spiritual formation via local community partners) plus International Care Ministries' Transform + Family Academy intervention. The Transform component is a 15-week household-level program including health education covering malnutrition prevention, sanitation, respiratory infections, infant care; livelihood training focused on income diversification and business development with savings group formation; and values formation addressing personal character, family relationships, and decision-making. The Family Academy component provides home-based early numeracy and phonics instruction (one hour per topic) to children aged 3-5 with concurrent caregiver capacity building for school readiness support, delivered over 8 weeks.
219766293|NCT07213102|OTHER|Standard Child-Focused Programming|Compassion International's Survival and Early Childhood Program provides holistic child development through health support, nutritional assistance, educational programming, social development, and spiritual formation delivered via local community partners.
219766294|NCT07210229|DIETARY_SUPPLEMENT|ashwagandha root|This substance is extracted from the root of the plant.
219766295|NCT07210229|DIETARY_SUPPLEMENT|ashwagandha root and leaf|This substance is extracted from both the root and leaves of the plant.
219766296|NCT07210229|OTHER|Placebo|The inert placebo does not contain any of the plant matter.
219766297|NCT07210086|DRUG|ADT|Androgen Deprivation Therapy
218837857|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
218837858|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
218837859|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
219446711|NCT02375880|DRUG|cisplatin|Administered by IV infusion
219446712|NCT04300946|DEVICE|TMS targeted on the cerebellum|Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
219446713|NCT06448585|DRUG|Specific immunotherapy (SIT) treatment|Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
219446714|NCT06448585|DIETARY_SUPPLEMENT|Dietary Supplement: ABB C1|"Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams"
219446715|NCT06448585|DIETARY_SUPPLEMENT|Mini-tablets with pork extract|Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
219766298|NCT07210086|DRUG|ARSI|Androgen Receptor Signaling Inhibitor
219766299|NCT07210086|OTHER|No ADT/ARSI -decline|Recurrent prostate cancer with oligometastatic disease who decline ADT/ARSI and are treated with ablative intent RT alone and who have \<=5 extrapelvic lesions detected on a baseline PSMA-PET and have rising PSA.
219766300|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (30 minutes per session, 3 sessions per week, for a 12-week period)
219585818|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
219446716|NCT06629233|PROCEDURE|Tumor resection|As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
219446717|NCT04657432|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
219446718|NCT06553898|BIOLOGICAL|anti-BCMA/CD70 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
219585819|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
219585820|NCT04055038|DRUG|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
219585821|NCT04055038|DRUG|Conventional chemotherapy|Conventional chemotherapy
219585822|NCT04890301|BEHAVIORAL|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
219585823|NCT00125840|DRUG|clofarabine (IV formulation)|
219585824|NCT04113863|DRUG|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
219766301|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (45 minutes per session, 3 sessions per week, for a 12-week period)
219766302|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (60 minutes per session, 3 sessions per week, for a 12-week period)
218837860|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
218837861|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
218837862|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
218837863|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
218837864|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
219585825|NCT04113863|DRUG|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
219585826|NCT04773301|DRUG|Levobupivacaine|Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
219585827|NCT04773301|DRUG|Ropivacaine|Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
219585828|NCT00828737|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
219585829|NCT06548815|DRUG|GZR4|Ascending single doses - 4 dose levels.
219585830|NCT06548815|DRUG|Placebo|Ascending single doses - 4 dose levels.
219585831|NCT05958888|BEHAVIORAL|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
219766303|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (30 minutes per session, 5 sessions per week, for a 12-week period)
219766304|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (45 minutes per session, 5 sessions per week, for a 12-week period)
219766305|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (60 minutes per session, 5 sessions per week, for a 12-week period)
219766306|NCT07213063|OTHER|Nutrition education|Participants and their families will also take part in nutrition education sessions to promote healthy eating and lifestyle habits.
219766307|NCT07209670|PROCEDURE|peripherally inserted central catheter insertion|Neonates who received peripherally inserted central catheters within the first 28 days of life.
219766308|NCT07209670|PROCEDURE|umbilical venous catheters insertion|Neonates who received umbilical venous catheters within the first 28 days of life
218837865|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
219585832|NCT05958888|BEHAVIORAL|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
219585833|NCT05958888|BEHAVIORAL|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
219585834|NCT05958888|BEHAVIORAL|Barcode label|Barcode is shown in white square label on the can of soup
219585835|NCT05252598|DRUG|Psilocybin|1mg encapsulated psilocybin
219585836|NCT05252598|DRUG|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
219585837|NCT06633432|OTHER|Acupuncture|Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
219585838|NCT06633432|OTHER|Sham-acupuncture stimulation|The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
219446719|NCT06420193|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
219446720|NCT05563272|DIAGNOSTIC_TEST|89Zr-girentuximab for PET/CT imaging of CAIX positive tumors|On Day 0, participants will receive a single administration of 89Zr-girentuximab (37 Megabecquerel (MBq) \[1mCi\] ± 10%, containing a mass dose of 10 mg of girentuximab).
219446721|NCT04270565|BEHAVIORAL|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
219446722|NCT04270565|BEHAVIORAL|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
219585839|NCT03190213|DRUG|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
219585840|NCT02024113|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
219585841|NCT03244644|DRUG|RBX2660|RBX2660 is a rectally administered microbiota suspension
219766309|NCT07209306|OTHER|Experimental: Self-Help Plus and booster session|"The SH+ programme, developed by WHO is a five-session stress management course. Supervised non-specialist facilitators will deliver it in a group setting in person. SH+ is intended to be transdiagnostic, easily adaptable to different cultures and languages and both meaningful and safe for people with and without mental disorders.~Booster session:~The booster session of SH+ will be provided individually to participants in an online format. It will last approximately 45 minutes, and it will contain a summary of the main contents of the five sessions. The booster session has been developed according to WHO manuals and will be delivered by a trained facilitator.~All participants in the three arms will receive ECAU that will include an information flyer about locally available services for migrants (education, health, social and legal support), and may include community care, social/legal support, etc."
219446723|NCT02186340|PROCEDURE|Inspiratory muscle training|
219585842|NCT03244644|DRUG|Placebo|Placebo is normal saline solution administered rectally
219585843|NCT03244644|DRUG|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
219585844|NCT04087434|DEVICE|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
219446724|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
219585845|NCT01879163|BIOLOGICAL|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
219585846|NCT01879163|BIOLOGICAL|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
219585847|NCT01997216|DEVICE|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
219585848|NCT01997216|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
219585849|NCT01931696|DEVICE|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
219585850|NCT01931696|DEVICE|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
218837866|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
219446725|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
219446726|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
219446727|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
219446728|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
219446729|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
219585851|NCT05353387|OTHER|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
219585852|NCT03929991|OTHER|Observational|To record social and clinical characteristics
219585853|NCT01998724|BEHAVIORAL|Tai Chi|24 week tai chi intervention designed for individuals with COPD
219585854|NCT01998724|BEHAVIORAL|Group Walking|24 week group walking intervention
219585855|NCT01398514|DRUG|Escitalopram|Escitalopram 10mg/day or matched pill placebo
219585856|NCT00072020|DRUG|zoledronic acid|
219585857|NCT00072020|PROCEDURE|adjuvant therapy|
219446730|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
219446731|NCT04833140|DRUG|Estradiol patch|The patch will provide 100mcg of estradiol daily.
219446732|NCT04833140|DRUG|Placebo|Placebo patch will contain no estradiol.
219585858|NCT00072020|PROCEDURE|neoadjuvant therapy|
219585859|NCT04015323|DEVICE|Interferential current|An electrotherapy current with different carrier frequencies
219585860|NCT00673153|DRUG|gemtuzumab ozogamicin|Given IV
219585861|NCT00673153|DRUG|vorinostat|Given orally
219585862|NCT00673153|OTHER|laboratory biomarker analysis|Correlative studies
219766310|NCT07209306|OTHER|Doing What Matters in Times of Stress and booster session|Arm Description: The DWM program has been developed by WHO as a stress management guide for coping with adversity. DWM contains the same content as the SH+ illustrated guide, training the five basic stress management skills with standalone audio. Additionally, participants are guided by a briefly trained helper. In this study, the DWM program will be delivered individually as an online guided intervention. The DWM intervention has been adapted for use on a smartphone or other device with internet access. In the online application tool, a new module (i.e., section) is released every week so participants will be asked to go through the entire DWM intervention within five weeks, with guidance from a helper through brief we brief weekly phone or text-based contacts of approximately 15 minutes. Booster session: The booster session will be provided online individually. It has been developed according to the WHO manual, and it contains a summary of the main contents of the online sessions.
218837867|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
219446733|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
219446734|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
219585863|NCT04799873|DRUG|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
219585864|NCT06445114|DRUG|Cisplatin|"Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation."
219585865|NCT01007942|DRUG|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
219585866|NCT01007942|DRUG|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
219585867|NCT01007942|DRUG|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
219585868|NCT01007942|DRUG|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
219585869|NCT02275130|PROCEDURE|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
219585870|NCT02275130|DEVICE|Radiesse Voice (Calcium Hydroxyapatite)|
219585871|NCT00266396|BEHAVIORAL|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
219585872|NCT00266396|BEHAVIORAL|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
219585873|NCT04549935|DRUG|Dextenza|Dextenza 0.4mg
219585874|NCT04549935|DRUG|Topical Prednisolone|Standard of care topical drop treatment
218837868|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
218837869|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
219585875|NCT01020344|PROCEDURE|Lung volume reduction surgery|Lung volume reduction surgery
219585876|NCT02301195|OTHER|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
219585877|NCT02301195|OTHER|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
219585878|NCT04170556|DRUG|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
219585879|NCT04170556|DRUG|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
219585880|NCT01104909|PROCEDURE|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
218837870|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
219446735|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
219446736|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
219446737|NCT04088331|DEVICE|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
219446738|NCT01451567|BEHAVIORAL|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
219446739|NCT03278925|PROCEDURE|Biopsy|Undergo biopsy
219446740|NCT03278925|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219446741|NCT03278925|PROCEDURE|Computed Tomography|Undergo CT
219446742|NCT03278925|DRUG|Defined Green Tea Catechin Extract|Given PO
219446743|NCT03278925|OTHER|Laboratory Biomarker Analysis|Correlative studies
219446744|NCT03278925|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219446745|NCT03278925|OTHER|Pharmacological Study|Correlative studies
219446746|NCT03278925|OTHER|Questionnaire Administration|Ancillary studies
219446747|NCT03278925|PROCEDURE|Ultrasound|Undergo ultrasound
219446748|NCT05942872|OTHER|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
219446749|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
219446750|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
219446751|NCT01511549|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
219446752|NCT01511549|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
219446753|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
219446754|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
219446755|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
219446756|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
219446757|NCT01994109|DRUG|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
219446758|NCT01994109|OTHER|PLACEBO|
219446759|NCT01265173|DRUG|Cefotaxime|3 g
219446760|NCT01265173|DRUG|Ceftriaxone|2 g
219585881|NCT01104909|DEVICE|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
219585882|NCT02713386|DRUG|Carboplatin|Given IV
219585883|NCT02713386|DRUG|Paclitaxel|Given IV
219585884|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
219446761|NCT01265173|DRUG|Ciprofloxacin|400 mg
219446762|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
219446763|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
219446764|NCT03491852|BEHAVIORAL|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
219446765|NCT03491852|BEHAVIORAL|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
219446766|NCT01172054|BIOLOGICAL|VAX128|one IM injection
219446767|NCT01172054|BIOLOGICAL|Placebo|One IM injection
219446768|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
219446769|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
219446770|NCT01165294|DRUG|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
219446771|NCT01165294|DRUG|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
219446772|NCT00564265|OTHER|Observation|Not applied
219446773|NCT00435929|DRUG|Ritonavir|100mg po bid
219446774|NCT00435929|DRUG|saquinavir [Invirase]|1000mg po bid
219585885|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
219585886|NCT05083585|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
219446775|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
219446776|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
219446777|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
219446778|NCT02931955|OTHER|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
219446779|NCT02253680|PROCEDURE|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
219446780|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
219446781|NCT00506740|DEVICE|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
219446782|NCT00506740|DEVICE|monopolar electrosurgery generator and tip|
219446783|NCT04642274|OTHER|Preoperative Strategies|Patient Education Preoperative Oral Carbohydrate Loading Nutritional Optimization Glycemic Control Anemia Correction Preoperative Hair Removal
219446784|NCT04642274|OTHER|Intraoperative Strategies|Anesthetic Technique (Multimodal Analgesia) Antibiotics Glycemic Control Blood Transfusion Blood Conservation Optimization of Hemodynamics Protective Lung Ventilation Strategy Optimization of Anesthetic Depth Optimization of CPB Management
219446785|NCT04642274|OTHER|Postoperative Strategies|Postoperative Analgesia Temperature Management Renal Protection Glycemic Control Early Extubation Early Oral Intake Maintain Drain Patency and Early Removal Early Ambulation Thromboprophylaxis
219585887|NCT01751035|BEHAVIORAL|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
219585888|NCT01751035|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
219766311|NCT07209306|OTHER|Psychological Placebo|Psychological placebo will consist of a phone call or online meetings with a helper, of the same duration of the DWM sessions. In the first part of the call participants will be reminded about locally available social, health, legal and education services. In the second part of the call participants will choose a discussion topic from topics presented in a list prepared by the research team . Additional session: The additional session of psychological placebo will be provided individually in an online format. It will contain neutral contents and will be facilitated by a helper. It will have the same duration as the booster sessions.
219446786|NCT03137888|RADIATION|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
219766312|NCT07210801|DEVICE|CIEDimplantation|Compare current procedural CIED practice at AUHH to recent ESC guidelines.
219766313|NCT07208136|DRUG|JMKX005425|JMKX005425 administered orally.
219766314|NCT07207915|OTHER|Observational retrospective cohort study|Observational retrospective cohort study, data collection was performed via structured extraction from electronic medical records: Includingclinical characteristics, metabolic indicators, laboratory parameters, prognosis, and outcomes.
219766315|NCT07210502|RADIATION|4D Low Dose Rate Prostate Brachytherapy|Permanent implantation of radioactive seeds in the prostate gland which slowly deposit half their dose approximately every 60 days. Prescription dose 145 Gy.
219766316|NCT07210502|RADIATION|Ultra-hypofractionated Radiotherapy|The prescription dose is 36.25 Gy given in 5 fractions over 1-2 weeks (i.e. daily or alternate daily at department discretion) delivered on linear accelerator
219446787|NCT03137888|PROCEDURE|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
219446788|NCT03137888|DRUG|Temozolomide|Given PO
219446789|NCT05776355|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
219446790|NCT02394860|OTHER|echo Doppler lower limbs|
219446791|NCT06331325|PROCEDURE|Frenotomy|Partial thickness procedure aiming to relocate high frenum attachment to a more apical level.
219446792|NCT06331325|PROCEDURE|Frenectomy|Full-thickness excision of the frenum down to the bone level and suturing by achieving primary closure.
219446793|NCT00976963|DRUG|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
219446794|NCT00976963|DRUG|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
219446795|NCT04587973|PROCEDURE|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
219585889|NCT02016313|OTHER|physiotherapy|
219446796|NCT04587973|PROCEDURE|Group Ropivacaine|Plain ropivacaine group
219446797|NCT04587973|PROCEDURE|Group Control|Control group
219446798|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
219446799|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
219446800|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
219446801|NCT02583828|DRUG|Cyclophosphamide 50mg|
219446802|NCT02583828|DRUG|Letrozole 2.5 mg|
219446803|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
219446804|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
219585890|NCT03929757|BIOLOGICAL|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
219585891|NCT03929757|BIOLOGICAL|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
219446805|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
219446806|NCT04124224|OTHER|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
219446807|NCT01775800|OTHER|Treatment modification|
219446808|NCT01755260|OTHER|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
219446809|NCT00085345|DRUG|arsenic trioxide|
219446810|NCT00085345|DRUG|ascorbic acid|
219446811|NCT00085345|DRUG|melphalan|
219446812|NCT00085345|PROCEDURE|chemosensitization/potentiation|
219446813|NCT00085345|PROCEDURE|chemotherapy|
219446814|NCT06408519|OTHER|Placebo (open-label)|P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
219585892|NCT03929757|BIOLOGICAL|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
219585893|NCT04941521|DRUG|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
219585894|NCT04941521|BEHAVIORAL|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
219446815|NCT06408519|DRUG|Ibuprofen 400 mg|Ibuprofen pills 3x/day
219446816|NCT00622570|DRUG|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
219446817|NCT00622570|DRUG|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
219446818|NCT06384300|OTHER|Financial Incentives|In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
219446819|NCT06384300|OTHER|Motivational Intervention|For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
219446820|NCT06384300|OTHER|Mixed Intervention|Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
219585895|NCT04096508|BEHAVIORAL|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
219585896|NCT01157559|DRUG|Ziprasidone|8 week prospective study
219585897|NCT00806286|DRUG|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
219585898|NCT00806286|DRUG|Paclitaxel|Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
219585899|NCT00806286|DRUG|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
219585900|NCT00806286|DRUG|Placebo Tablets|Placebo tablets matching CS-7017 tablets
219585901|NCT04575766|DRUG|FT-7051|"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."
219585902|NCT03402750|BEHAVIORAL|Meds to Beds|Medications will be delivered to patient bedside before discharge
219585903|NCT03402750|BEHAVIORAL|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
219585904|NCT03257514|DRUG|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
219585905|NCT03257514|DRUG|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
219585906|NCT06015243|DRUG|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
219585907|NCT04914858|OTHER|Education|Its validity and reliability is a reliable scale in Turkey
219585908|NCT02416024|DEVICE|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
219585909|NCT00146341|DRUG|Telmisartan/HCTZ|
219446821|NCT05668325|OTHER|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
219446822|NCT05668325|OTHER|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
219446823|NCT02331654|OTHER|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
219446824|NCT02331654|OTHER|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
219446825|NCT02756845|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
219446826|NCT03030014|BEHAVIORAL|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
219585910|NCT00146341|DRUG|Telmisartan|
219585911|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
219585912|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
219585913|NCT02621918|OTHER|Progressive resistance training|
219585914|NCT02621918|OTHER|Aerobic training|
219585915|NCT02621918|OTHER|Placebo training|
219585916|NCT03469336|DRUG|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
219585917|NCT03469336|OTHER|Vehicle|Vehicle matching PF-06763809.
219585918|NCT03469336|DRUG|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
219766317|NCT07207772|DEVICE|Group P-eit|"The Recruitment Maneuver - PEEP Titration - Recruitment Maneuver (RM-T-R) Strategy will be implemented 5 minutes after endotracheal intubation. The patient will receive an RM (peak pressure 50cm H2O, PEEP 25cmH2O, respiratory rate 6 bpm, for 10 cycles) followed by a decremental PEEP titration, during which PEEP is set to 25cm H2O and decreased stepwise by 2cm H2O every 3min until reaching 5 cmH₂O. Meanwhile, the ventilator parameters (tidal volume, respiratory rate, and inspiratory-to-expiratory ratio) will be adjusted back to their pre-recruitment settings. EIT-based optimal PEEP is defined as the crossing point of the overdistension and collapse curves during a decremental PEEP trial."
219766318|NCT07207772|DEVICE|Group P-8|In group p-8, mechanical ventilation will be administered in volume-controlled mode with a tidal volume of 8 ml/kg (based on ideal body weight). Additional settings include a PEEP of 8 cmH₂O, FiO₂ of 0.5, an inspiratory-to-expiratory ratio of 1:2, and a respiratory rate of 12 breaths/min. A recruitment maneuver (RM) will be performed 5 minutes after intubation and again after surgery, using the same protocol as in group P-eit. The respiratory rate will be adjusted as needed to maintain end-tidal CO₂ between 35 and 45 mmHg throughout the procedure.
219585919|NCT03469336|DRUG|Betamethasone|Betamethasone 1 mg/g solution
219585920|NCT02519335|DRUG|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
219585921|NCT03876418|DIAGNOSTIC_TEST|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
219585922|NCT02109419|OTHER|HHT-G|Helping Hands Technology global cognitive function assessment
219585923|NCT02109419|OTHER|HHT-D|Helping Hands Technology depression assessment
219585924|NCT02109419|OTHER|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
219585925|NCT02109419|OTHER|MMSE|Mini Mental State Exam
219585926|NCT02628743|DRUG|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
219585927|NCT06320808|OTHER|FDA template PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
219585928|NCT06320808|OTHER|Decision Critical PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
219446827|NCT03030014|OTHER|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
219585929|NCT06320808|OTHER|Standard Information|The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
219446828|NCT03234270|DEVICE|Core temperature measurements|Core temperature measurements with coretemp pill
219446829|NCT01878227|DRUG|Coenzyme A|Coenzyme A 400mg per day
219446830|NCT01878227|DRUG|Fenofibrate 200mg|Fenofibrate 200mg per day
219446831|NCT01328769|DRUG|Febuxostat|
219446832|NCT01328769|DRUG|Placebo|
219446833|NCT00134953|DRUG|Rivastigmine|
219446834|NCT01688999|DRUG|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
219446835|NCT04967911|OTHER|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
219446836|NCT04967911|OTHER|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
219446837|NCT00394693|GENETIC|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
219446838|NCT02768103|BEHAVIORAL|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
219446839|NCT02951455|BEHAVIORAL|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
219446840|NCT02951455|BEHAVIORAL|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
219446841|NCT02951455|BEHAVIORAL|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
219446842|NCT02951455|BEHAVIORAL|PF|Whether the intervention is delivered by a peer facilitator.
219446843|NCT02951455|BEHAVIORAL|LC|Whether the intervention is delivered by a licensed clinician.
219446844|NCT05849545|DEVICE|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
219446845|NCT05849545|PROCEDURE|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
219446846|NCT06358976|OTHER|Vibration plus anti-spastic hand splint|vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
219446847|NCT06358976|OTHER|Anti-spastic hand splint|the use of anti-spastic hand splint alone.
219446848|NCT06358976|OTHER|Vibration|The use of hand vibrator alone
219446849|NCT04574141|DIETARY_SUPPLEMENT|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
219585930|NCT03320200|OTHER|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
219585931|NCT03320200|OTHER|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
219585932|NCT04275206|OTHER|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
219585933|NCT04275206|OTHER|Tap water (placebo control)|The control group is treated with tap water.
219446850|NCT04024241|DEVICE|Flow Cytometer|high dose
219766319|NCT07213219|OTHER|PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).|"The PET-MRI will be performed using a Siemens Biograph mMR hybrid PET-MRI scanner. A 60-minute dynamic PET acquisition will begin following the intravenous injection of \\\[¹¹C\]raclopride (a radiotracer agonist of dopamine D2/D3 receptors) synthesized in the radiopharmaceutical laboratories of CERMEP. Simultaneously with the PET acquisition, brain MRI sequences will be acquired: 3D anatomical T1 and 3D T2, SWI, diffusion MRI (DTI), resting-state functional MRI, and arterial spin labeling (ASL) perfusion MRI.~Patients will undergo two PET-MRI scans on two consecutive days under two pharmacological conditions: Off and On dopamine:~* Day 1:\*\* The first PET-MRI session (TEPDopaOff) will be performed after a 12-hour withdrawal from usual dopaminergic treatment (Off dopamine).~* Day 2:\*\* The second PET-MRI session (TEPDopaOn) will be similar to the first, except it will take place 1 hour after administration of immediate-release Levodopa"
219766320|NCT07212114|DRUG|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension) is formulated as a sterile, non-pyrogenic, white to off-white, preservative-free homogenous suspension of bupivacaine encapsulated into multivesicular liposomes (pMVL drug delivery system). For this study, EXPAREL will be provided in 20 mL (266 mg) EXPAREL single-use, clear glass vials.
219585934|NCT02889471|PROCEDURE|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
219585935|NCT02889471|PROCEDURE|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
219585936|NCT02534844|DRUG|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
219585937|NCT02534844|OTHER|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
219446851|NCT04024241|DRUG|Mitoxantrone|high dose
219585938|NCT04948060|OTHER|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
219446852|NCT04024241|DRUG|Cytarabine|high dose
219446853|NCT01666990|DRUG|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
219766321|NCT07212114|DRUG|0.25% bupivacaine (HCl): 50 ml|The reference product is 50 mL (125 mg) 0.25% bupivacaine HCl administered via a combined sciatic (in the popliteal fossa) and saphenous nerve block (in the adductor canal)
219585939|NCT04142957|OTHER|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
219585940|NCT00003174|DRUG|bryostatin 1|
219446854|NCT01666990|DRUG|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
219585941|NCT00003174|DRUG|cladribine|
219585942|NCT03881020|DRUG|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
219585943|NCT03881020|PROCEDURE|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
219585944|NCT04636060|DIETARY_SUPPLEMENT|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
219585945|NCT05918731|BEHAVIORAL|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
219585946|NCT04645966|BIOLOGICAL|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
219585947|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
218837871|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
219446855|NCT05089188|OTHER|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
219446856|NCT05336019|BEHAVIORAL|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
219446857|NCT05336019|OTHER|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
219585948|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
219585949|NCT04645966|BIOLOGICAL|Bexsero|Bexsero - Meningococcal Group B vaccine
219585950|NCT04645966|DRUG|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
219585951|NCT04645966|BIOLOGICAL|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
219585952|NCT04645966|OTHER|Placebo|Normal Saline
219585953|NCT04645966|DRUG|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
219585954|NCT04645966|DRUG|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
219585955|NCT04938323|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
219585956|NCT04938323|DRUG|Placebo|.1 mL of diluent (saline) given intradermally at baseline
219585957|NCT03825341|DRUG|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
219766322|NCT07212114|DRUG|0.25% bupivacaine (HCl): 30 ml|EXPAREL admixed with 30 mL (75 mg) 0.25% bupivacaine HCl
219446858|NCT04348188|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
219446859|NCT06590207|DRUG|plasma rich with WNV neutralizing antibodies|200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
219446860|NCT06590207|DRUG|Saline|Placebo
219446861|NCT05267938|DRUG|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
219446862|NCT05267938|DRUG|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
219446863|NCT05401604|DIETARY_SUPPLEMENT|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
219446864|NCT05401604|DIETARY_SUPPLEMENT|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
219766323|NCT07211126|DEVICE|t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)|Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.
219585958|NCT03825341|DRUG|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
219585959|NCT04248218|BEHAVIORAL|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
219446865|NCT01048047|DRUG|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
218837872|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
219446866|NCT04724772|DRUG|Tranexamic acid injection|Injection of tranexamic acid preoperatively
219446867|NCT01962467|DRUG|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
219446868|NCT01962467|DRUG|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
219446869|NCT01962467|DRUG|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
219446870|NCT02128919|DEVICE|tDCS|Transcranial Direct Current Stimulation
219446871|NCT03906201|DIETARY_SUPPLEMENT|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
219446872|NCT03906201|OTHER|Placebo|no pharmacologic effect
219446873|NCT04104204|DRUG|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
219446874|NCT04104204|DRUG|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
219766324|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 1
218837873|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
219446875|NCT04543630|PROCEDURE|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
219446876|NCT05224752|OTHER|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
219446877|NCT00381108|DRUG|Placebo Tablet|Two tablets, twice daily.
219446878|NCT00381108|DRUG|Pomegranate Tablet|Two tablets, twice daily.
219446879|NCT03778580|DIETARY_SUPPLEMENT|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
219446880|NCT03778580|DRUG|placebo|placebo
219446881|NCT01045876|DRUG|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
219446882|NCT01045876|OTHER|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
219585960|NCT04146116|DRUG|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
219585961|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
219585962|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
219585963|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
219585964|NCT04013321|DEVICE|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
219766325|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 2
219766326|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 3
219766327|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 4
219766328|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 5
219766329|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 6
219766330|NCT07212959|OTHER|CXCR4-PET/CT|CXCR4-PET/CT for the detection of inflammatory activity in patient with active systemic sclerosis
219585965|NCT04013321|BEHAVIORAL|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
219585966|NCT03272464|DRUG|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
219585967|NCT03272464|DRUG|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
219585968|NCT03272464|DRUG|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
219585969|NCT00057421|DRUG|prednisolone|
219585970|NCT05131243|PROCEDURE|Chemotherapy time|6 months of chemotherapy
219585971|NCT05131243|PROCEDURE|Chemotherapy time|3 months of chemotherapy
219585972|NCT00829803|DEVICE|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
219585973|NCT00002608|DRUG|cisplatin|
219585974|NCT00002608|DRUG|doxorubicin hydrochloride|
219446883|NCT03966092|PROCEDURE|Quadratus lumborum block|"* Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
219446884|NCT02433691|OTHER|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
219446885|NCT02433691|OTHER|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
219446886|NCT02433691|OTHER|stretching and toning|anaerobic stretching and toning followed by memory training.
219446887|NCT06595576|DRUG|Cannabis - Placebo Dose (0 mg)|Participants will consume placebo cannabis edibles.
219585975|NCT00002608|DRUG|tamoxifen citrate|
218837874|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
219446888|NCT06595576|DRUG|Cannabis - Low Dose (2 mg)|Participants will consume a low dose (2 mg) of cannabis edibles.
219446889|NCT06595576|DRUG|Cannabis - Medium Dose (10 mg)|Participants will consume a medium dose (10 mg) of cannabis edibles.
218837875|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
218837876|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
219446890|NCT06595576|DRUG|Cannabis - High Dose (20 mg)|Participants will consume a high dose (20 mg) of cannabis edibles.
219446891|NCT02283840|DRUG|BIA 2-093|
219446892|NCT01603706|PROCEDURE|Echo guided implantation group|Lead placement according echo strain imaging result
219446893|NCT03369704|DRUG|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
218837877|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
219585976|NCT00002608|PROCEDURE|conventional surgery|
219585977|NCT00002608|RADIATION|radiation therapy|
219585978|NCT02116608|DRUG|Betadine|Apply locally as needed.
219585979|NCT02116608|DRUG|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
219585980|NCT02116608|DRUG|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
219585981|NCT03468075|DRUG|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
219585982|NCT03468075|DRUG|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
219585983|NCT04283500|DRUG|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
219585984|NCT00348452|DRUG|tramadol HCl ER; celecoxib|
219585985|NCT01008332|BIOLOGICAL|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
219585986|NCT01008332|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
219585987|NCT05552170|OTHER|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
219585988|NCT00006199|DRUG|R115777 (farnesyl transferase inhibitor)|
219446894|NCT03369704|DRUG|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
219446895|NCT05471024|PROCEDURE|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
219446896|NCT05471024|PROCEDURE|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
219446897|NCT05471024|PROCEDURE|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
219446898|NCT01855490|DRUG|Exenatide|
219446899|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219446900|NCT03812783|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
219446901|NCT03812783|DRUG|Sorafenib|administration of Sorafenib
219446902|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219446903|NCT03812783|DRUG|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
219446904|NCT01116804|PROCEDURE|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
219446905|NCT01116804|PROCEDURE|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
219446906|NCT01116804|PROCEDURE|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
219446907|NCT01116804|PROCEDURE|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
219446908|NCT02348840|DEVICE|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
219446909|NCT02325440|DRUG|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
219585989|NCT00006199|DRUG|Topotecan|
219585990|NCT03599271|DEVICE|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
219585991|NCT03599271|DEVICE|Control Device|Sinus dilation device without drug
219585992|NCT02006693|DEVICE|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
219585993|NCT02006693|PROCEDURE|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
219585994|NCT06207188|OTHER|Non-Interventional Study|Non-interventional study
219585995|NCT03682224|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
219585996|NCT03682224|DRUG|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
219585997|NCT01119508|DRUG|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
219585998|NCT01119508|DRUG|Temozolomide|Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
219585999|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
219586000|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
219586001|NCT02312518|DEVICE|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
219586002|NCT02312518|OTHER|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
219586003|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
219586004|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
219586005|NCT01172119|DEVICE|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
219586006|NCT02013479|DIETARY_SUPPLEMENT|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
219586007|NCT02013479|DIETARY_SUPPLEMENT|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
219586008|NCT06317090|PROCEDURE|guided bone regeneration|a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
219586009|NCT00190190|PROCEDURE|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
219586010|NCT00190190|PROCEDURE|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
219586011|NCT00271154|DEVICE|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
219586012|NCT01910779|PROCEDURE|100 joule as first biphasic shock energy|
219586013|NCT01910779|PROCEDURE|120 joule as first biphasic shock energy|
219586014|NCT02734654|PROCEDURE|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
219586015|NCT05109806|BEHAVIORAL|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
219196526|NCT05339477|OTHER|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
219446910|NCT02325440|DRUG|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
219446911|NCT02505802|DRUG|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
219446912|NCT02148952|BEHAVIORAL|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
219446913|NCT01025232|DRUG|Ranibizumab|Intravitreal Injection of 2.0mg formulation
219446914|NCT01699776|DRUG|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
219446915|NCT01699776|DRUG|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
219446916|NCT02021149|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
219446917|NCT02021149|BEHAVIORAL|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
219446918|NCT02021149|OTHER|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
219446919|NCT02021149|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
219446920|NCT04629365|OTHER|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
219446921|NCT04629365|OTHER|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
219446922|NCT04343391|BEHAVIORAL|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
219446923|NCT04343391|DRUG|Pharmacological treatment|Treatment as usual in PC
219446924|NCT00197340|DRUG|Epidural ropivacaine|
219446925|NCT01263444|DRUG|Brinzolamide 1% / timolol 0.5% Fixed Combination|
219586016|NCT05254600|BEHAVIORAL|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
219196527|NCT06551012|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Participants will consume 2 x 70 ml bottles of nitrate-rich beetroot juice for a 7 day period prior to exercise testing
219196528|NCT06551012|DIETARY_SUPPLEMENT|Beetroot juice with nitrate extracted|Participants will consume 2 x 70 ml bottles of beetroot juice with nitrate extracted for a 7 day period prior to exercise testing
219196529|NCT06040801|BEHAVIORAL|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~* Functional status~* Nutrition~* Comorbidity~* Mobility/Falls~* Mood~* Cognition~* Polypharmacy~* Social support."
219196530|NCT04311632|BIOLOGICAL|TCD601|Investigational Product
219196531|NCT04311632|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
219196532|NCT04311632|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
219446926|NCT01263444|DRUG|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
219446927|NCT00467948|DRUG|cefazolin|
219446928|NCT06408987|PROCEDURE|arthroscopically assisted|Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
219446929|NCT06408987|PROCEDURE|open surgical reduction|Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
219446930|NCT04682795|DEVICE|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
219446931|NCT04682795|DEVICE|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
219446932|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
219446933|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
219446934|NCT01919086|DRUG|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
219446935|NCT01919086|DRUG|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
219446936|NCT01919086|DRUG|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
219586017|NCT02498106|DIETARY_SUPPLEMENT|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
219586018|NCT04832516|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
219446937|NCT02644694|DRUG|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
219446938|NCT00572065|DRUG|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
219446939|NCT00572065|DRUG|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
219446940|NCT03021928|OTHER|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
219446941|NCT00085644|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
219446942|NCT00085644|BIOLOGICAL|placebo|Placebo every other week, subcutaneous
219446943|NCT03685929|PROCEDURE|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
219446944|NCT03330106|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
219586019|NCT04832516|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
219586020|NCT01928706|OTHER|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
219586021|NCT01928706|OTHER|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
219586022|NCT04257552|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
219586023|NCT04257552|BEHAVIORAL|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
219586024|NCT04257552|OTHER|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
219586025|NCT06149715|DEVICE|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
219586026|NCT06149715|DEVICE|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
219766331|NCT07211555|DEVICE|LARC Robotic System (Micromate™ Version 3.0)|The LARC Robotic System (Version 3.0) is an investigational configuration of the Micromate™ robotic platform by iSYS Medizintechnik GmbH (Austria). It uses fluoroscopy-based surgical navigation to assist urologists in obtaining precise renal access during percutaneous nephrolithotomy (PCNL). This version is not FDA-cleared and is being evaluated for feasibility, safety, and potential clinical benefit.
219586027|NCT06149715|DEVICE|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
219586028|NCT05597137|DIETARY_SUPPLEMENT|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
219586029|NCT00001474|DRUG|Interleukin-2|
219586030|NCT06468293|OTHER|Psychological support|Psychological support intervention
219586031|NCT03308266|DIAGNOSTIC_TEST|electromyography|
219586032|NCT05369468|DRUG|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
219586033|NCT05369468|DRUG|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
219586034|NCT01799525|PROCEDURE|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
219586035|NCT03872934|BEHAVIORAL|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
219766332|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 1: 3 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7/m\^2 of C7R.GD2.CAR T cells given 5 days later.
219766333|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 2: 6 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
219196533|NCT04311632|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
219196534|NCT04311632|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
219586036|NCT00749021|DRUG|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
219586037|NCT00749021|DRUG|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
219196535|NCT01736059|DRUG|CD34+ bone marrow stem cells intravitreal|
219586038|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
219586039|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
219446945|NCT03330106|DRUG|Docetaxel|Docetaxel intravenous infusion.
219446946|NCT03330106|DRUG|Carboplatin|Carboplatin intravenous infusion.
219446947|NCT03330106|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
219446948|NCT01404806|DRUG|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
219446949|NCT02958033|RADIATION|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
219446950|NCT05071911|PROCEDURE|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
219446951|NCT00036946|BIOLOGICAL|ziv-aflibercept|
219446952|NCT04202432|DIAGNOSTIC_TEST|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
219446953|NCT01283178|RADIATION|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
219446954|NCT01283178|DRUG|cisplatin|Given IV
219446955|NCT01283178|RADIATION|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
219446956|NCT01283178|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
219446957|NCT01283178|PROCEDURE|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
219446958|NCT01283178|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
219446959|NCT05513092|DIAGNOSTIC_TEST|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
219586040|NCT03595631|OTHER|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
219766334|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 3: 12 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
219766335|NCT07212712|DRUG|GnRH antagonist|blockade of hormone production
219766336|NCT07212712|DRUG|Estradiol (E2)|Estrogen add-back in females
219446960|NCT02387073|OTHER|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
219446961|NCT02772991|OTHER|troponin measurement|Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
219586041|NCT03595631|OTHER|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
219586042|NCT05502965|OTHER|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
219766337|NCT07212712|DRUG|Testosterone|testosterone add-back in males
219766338|NCT07212712|DRUG|Anastrozole (Arimidex)|Prevention of testosterone conversion to estrogen in males
219766339|NCT07211581|PROCEDURE|total thyroidectomy|both lobes removed and observe the calcemic level
219766340|NCT07212595|DRUG|Amino Acid infusion|Amino acid infusion of 2 grams/kilogram of participant weight/day for up to 72 hours
219196536|NCT06752278|DRUG|Pilocarpine|Pilocarpine is a muscarinic agonist
219446962|NCT06283303|BIOLOGICAL|T3011 hepatic artery infusion|The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
219766341|NCT07212595|DRUG|Lactated ringers solution|Placebo infusion to match the volume of the amino acid infusion in grams/kilogram/day
219766342|NCT07213375|DRUG|Dexamethasone|Patients will receive either low dose (8mg) or high dose (1mg/kg)
219766343|NCT07212088|BIOLOGICAL|ALC01 therapy|Bilateral implantation
219196537|NCT06752278|DRUG|artificial tears|artificial tears used for the treatment of Dry eye
219196538|NCT04605159|BIOLOGICAL|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
219446963|NCT06283303|DRUG|toripalimab|The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
219446964|NCT06283303|DRUG|regorafenib|The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
219446965|NCT06229808|DEVICE|Multifunctional Birthing ball|"In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
219446966|NCT00033449|DRUG|gefitinib|Given orally
219446967|NCT00033449|RADIATION|radiation therapy|Undergo radiation therapy
219446968|NCT00033449|DRUG|cisplatin|Given IV
219446969|NCT00033449|OTHER|laboratory biomarker analysis|Correlative studies
219446970|NCT00039091|BIOLOGICAL|ipilimumab|Given IV
219446971|NCT04729595|DRUG|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
219586043|NCT05502965|OTHER|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
219586044|NCT04576299|OTHER|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
219586045|NCT00001049|DRUG|Zidovudine|
219586046|NCT00001049|DRUG|Didanosine|
219586047|NCT04053465|OTHER|Heat acclimation|14 days of aerobic exercise in a hot environment
218837878|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
219586048|NCT04053465|OTHER|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
219446972|NCT04729595|OTHER|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
219446973|NCT04804111|DRUG|arm 0|placebo group
219446974|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
219586049|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
219586050|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
219586051|NCT00548509|DRUG|Menatetrenone (Vitamin K2)|
219586052|NCT02925507|OTHER|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
218837879|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
218837880|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
218837881|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
218837882|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
218837883|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
218837884|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
219446975|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
219446976|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
219446977|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
219446978|NCT02324049|DRUG|SBC-103|
219196539|NCT04605159|DRUG|Placebo|One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
219446979|NCT06377436|BEHAVIORAL|Experimental training|Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
219446980|NCT03640728|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
219446981|NCT03640728|DRUG|Entecavir|Entecavir 0.5 mg/day orally
219446982|NCT03640728|DRUG|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
219446983|NCT01537289|DEVICE|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
219446984|NCT01537289|DEVICE|chest tube (28-French)|inserting chest tube to decompress pneumothorax
219446985|NCT00777686|PROCEDURE|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
219446986|NCT02039128|DIETARY_SUPPLEMENT|Krill oil or Fish oil|
219446987|NCT02039128|DIETARY_SUPPLEMENT|Placebo|
219586053|NCT02013011|PROCEDURE|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
219586054|NCT05321511|DRUG|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
219586055|NCT05321511|DRUG|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
219586056|NCT05321511|DRUG|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
219586057|NCT01521065|DEVICE|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
219586058|NCT04515082|DIAGNOSTIC_TEST|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
219586059|NCT04515082|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test
219586060|NCT00002883|DRUG|cisplatin|
219586061|NCT00002883|DRUG|fluorouracil|
219586062|NCT00002883|PROCEDURE|adjuvant therapy|
219586063|NCT00002883|PROCEDURE|conventional surgery|
219586064|NCT00002883|PROCEDURE|neoadjuvant therapy|
219586065|NCT04136691|OTHER|simulation training|Burn patient scenario was performed with the intervention group.
219586066|NCT02507544|DRUG|TRX-818 capsules|
219586067|NCT05121792|BEHAVIORAL|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
219766344|NCT07212517|BEHAVIORAL|benson relaxation exercise|BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.
219766345|NCT07213232|OTHER|Core Stability Training|Core stability training will be designed to prepare participants for subsequent balance and gait exercises by promoting normal proprioceptive input through activation of deep core muscles. This training will be performed in the supine position at the beginning of each session for both groups.
219766346|NCT07213232|OTHER|Dual-Task Balance and Gait Training|Dual-task balance and gait training will be provided with task-oriented motor-cognitive and motor-motor exercises with the augmented and virtual reality system C-Mill VR+ (Motek Medical, Amsterdam, The Netherlands). Sessions will be individualized based on each participant's current abilities and the difficulty level of the tasks to address specific patient needs. Each training session will have a duration of 30 minutes for both groups.
219766347|NCT07213232|OTHER|Cognitive Training|"Cognitive training will be provided with RehaCom software, a program that emphasizes learning principles, provides task-specific exercises, delivers positive feedback, and allows individualized progression based on patient-specific difficulty levels. In the present study, the cognitive training will target the Attention, Memory, and Executive Functions domains, which are known to be affected from the early stages of Parkinson's disease. Exercises will be initiated at a level appropriate to each participant's cognitive abilities and will gradually increase in difficulty. Each training session will have a duration of 30 minutes."
219766348|NCT07212998|BIOLOGICAL|Plasma|urgent release early plasma resuscitation following burn/thermal injury
219766349|NCT07212998|BIOLOGICAL|Standard care|Standard resuscitation as dictated by institutional protocol
219766350|NCT07211490|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.
219766351|NCT07211490|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.
219766352|NCT07211438|DRUG|Psilocybin|25 mg Psilocybin
219766353|NCT07212673|BEHAVIORAL|CBT-based Mindful Courage|Self-guided online intervention
219766354|NCT07212673|BEHAVIORAL|Coached Self-Monitoring|Participants will log meals in recovery record
219196540|NCT05387525|DRUG|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).
219196541|NCT05387525|DRUG|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
219196542|NCT01982890|OTHER|Control|No intervention as this group is simply followed prospectively.
219196543|NCT06256640|DEVICE|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
219196544|NCT06768346|DEVICE|Hyperthermia will be delivered in combination with each instillation using the Combat BRS system|The Combat BRS system is a temperature controlled fluid recirculation system for the delivery of hyperthermic intravesical chemotherapy. The chemotherapy fluid is circulated in a closed system and warmed by an external isolated dry system using a novel innovative laminated aluminium foil heat exchanger with a small priming volume.
219196545|NCT06765031|DIAGNOSTIC_TEST|Furosemide|Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
219196546|NCT06347380|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
219766355|NCT07213336|OTHER|Exercise, massage|trigger point massage and stretching exercise
219766356|NCT07212231|DIETARY_SUPPLEMENT|GI Product Placebo Control|Participants will use their GI Product Placebo Control as directed for a period of 6 weeks.
219766357|NCT07212231|DIETARY_SUPPLEMENT|Active Product 1|Participants will use their GI Active Product 1 as directed for a period of 6 weeks.
219766358|NCT07212231|DIETARY_SUPPLEMENT|Active Product 2|Participants will use their GI Active Product 2 as directed for a period of 6 weeks.
219766359|NCT07212231|DIETARY_SUPPLEMENT|Active Product 3|Participants will use their GI Active Product 3 as directed for a period of 6 weeks.
219766360|NCT07212231|DIETARY_SUPPLEMENT|Active Product 4|Participants will use their GI Active Product 4 as directed for a period of 6 weeks.
219446988|NCT03862586|DRUG|N-acetyl cysteine|
219446989|NCT03862586|DRUG|Placebos|
219446990|NCT02618512|DRUG|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
219446991|NCT00995189|DEVICE|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
219446992|NCT00995189|DEVICE|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
219446993|NCT00995189|DEVICE|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
219446994|NCT01946568|DRUG|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
219446995|NCT04132128|OTHER|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
219446996|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
219446997|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
219586068|NCT05830149|OTHER|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
219586069|NCT05830149|OTHER|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
219586070|NCT03361475|BEHAVIORAL|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
219586071|NCT03265418|DEVICE|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
219586072|NCT03265418|OTHER|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
219446998|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
219196547|NCT04968366|BIOLOGICAL|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
219446999|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
219447000|NCT02809391|DEVICE|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
219196548|NCT04968366|DRUG|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
219196549|NCT04165772|DRUG|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
219196550|NCT04165772|DRUG|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
219586073|NCT03265418|PROCEDURE|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
219586074|NCT04360096|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
219586075|NCT04360096|DRUG|Placebo|Normal Saline Inhalation
219586076|NCT04360096|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
219586077|NCT06244849|BIOLOGICAL|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
219586078|NCT06244849|BIOLOGICAL|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
219447001|NCT02809391|DEVICE|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
219447002|NCT01836029|DRUG|VTX-2337|TLR8 Agonist
219447003|NCT01836029|DRUG|Carboplatin|
219586079|NCT06244849|BIOLOGICAL|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
218837885|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
219447004|NCT01836029|DRUG|Cisplatin|
219447005|NCT01836029|DRUG|5-fluorouracil|
219447006|NCT01836029|DRUG|Placebo|
219447007|NCT04476706|DRUG|canakinumab|canakinumab
219586080|NCT01714232|DEVICE|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219196551|NCT04165772|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
219196552|NCT06401954|DEVICE|High-intensity focused electromagnetic therapy|"High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
219447008|NCT01785290|DRUG|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
219447009|NCT01785290|DRUG|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
219447010|NCT01785290|DRUG|Placebo|Sodium Chloride 0.9%
219586081|NCT01714232|DEVICE|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219586082|NCT01714232|DEVICE|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219586083|NCT01714232|DEVICE|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219447011|NCT02776306|OTHER|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
219447012|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
219447013|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
219447014|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
219586084|NCT01714232|DEVICE|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219586085|NCT02338193|DRUG|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
219586086|NCT02338193|DRUG|DAPA|10 mg dapagliflozin QD for 20-24 weeks
219586087|NCT02338193|DRUG|MET XR|1000 mg Metformin XR BID for 20-24 weeks
218837886|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
219586088|NCT03715361|DIAGNOSTIC_TEST|SL-ECG|additional SL-ECG measurement
219586089|NCT03283462|DIETARY_SUPPLEMENT|Mitopure|Mitopure (Urolithin A) containing softgels
219586090|NCT03283462|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
219586091|NCT02076373|DRUG|recombinant human Erythropoietin|i.v. administration
219586092|NCT02076373|DRUG|Placebo|i.v. administration
218837887|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
218837888|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
219586093|NCT04229173|DIAGNOSTIC_TEST|MRI acquisition|MRI acquisition
219447015|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
219447016|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
219447017|NCT03250819|OTHER|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
219447018|NCT00004205|DRUG|letrozole|Letrozole 2.5 mg daily oral administration.
219447019|NCT00004205|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
219447020|NCT03388554|DEVICE|tDCS|
219586094|NCT04229173|DIAGNOSTIC_TEST|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
219586095|NCT04229173|DIAGNOSTIC_TEST|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
219586096|NCT04229173|BEHAVIORAL|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
218837889|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
218837890|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
218837891|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
219447021|NCT01396031|BEHAVIORAL|Physical Therapy|Standard of care
219447022|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
219447023|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
218837892|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
218837893|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
219447024|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
219447025|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
219447026|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
219447027|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
219447028|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
219447029|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
219447030|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
219447031|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
218837894|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
219447032|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
219447033|NCT05071794|DRUG|saline 0.9%|Placebo
219447034|NCT00736450|BIOLOGICAL|oblimersen sodium|Given IV
219447035|NCT00736450|BIOLOGICAL|rituximab|Given IV
219447036|NCT00736450|DRUG|cyclophosphamide|Given IV
219447037|NCT00736450|DRUG|doxorubicin hydrochloride|Given IV
219447038|NCT00736450|DRUG|vincristine sulfate|Given IV
219447039|NCT00736450|DRUG|prednisone|Given orally
219447040|NCT00736450|PROCEDURE|biopsy|Correlative studies
219447041|NCT00736450|GENETIC|microarray analysis|Correlative studies
219447042|NCT00736450|OTHER|immunohistochemistry staining method|Correlative studies
219586097|NCT04229173|BEHAVIORAL|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
219586098|NCT00123474|DRUG|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
219586099|NCT00123474|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
219586100|NCT00123474|DRUG|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
219586101|NCT00123474|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
219586102|NCT05386940|OTHER|PKN1 level|different PKN1 level after on-pump cardiac surgery
219586103|NCT02345629|PROCEDURE|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
219586104|NCT02345629|BEHAVIORAL|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
219766361|NCT07212231|DIETARY_SUPPLEMENT|Active Product 5|Participants will use their GI Active Product 5 as directed for a period of 6 weeks.
219447043|NCT00736450|GENETIC|gene expression analysis|Correlative studies
219447044|NCT00736450|GENETIC|cytogenetic analysis|Correlative studies
219586105|NCT02345629|PROCEDURE|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
219447045|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
219447046|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
219447047|NCT06543121|OTHER|Translating the Stroke Knowledge Test into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the test and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
219447048|NCT06543121|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of 10 expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Stroke Knowledge Test. For face validity, the final version of the form will be provided with opinions from 3 stroke patients.
219586106|NCT02345629|PROCEDURE|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
219586107|NCT01059344|DRUG|Mesalamin|4.8g/day, 800 mg tablets
219447049|NCT06543121|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
219447050|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
218837895|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
219586108|NCT02902367|OTHER|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
219586109|NCT02902367|OTHER|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
219586110|NCT02174380|OTHER|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
219586111|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
219586112|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
219586113|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
219586114|NCT01739348|DRUG|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
219447051|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
219586115|NCT01739348|DRUG|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
219586116|NCT05180916|DEVICE|TVNS|Cerbomed NEMOS
219586117|NCT01963143|BIOLOGICAL|Gammaplex (5%)|
219586118|NCT01963143|BIOLOGICAL|Gammaplex 10|
219586119|NCT02531750|OTHER|Immobilization due to an Achilles tendon rupture|
218837896|NCT01138085|DRUG|GSK1120212|MEK inhibitor
218837897|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
218837898|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
218837899|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
218837900|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
219586120|NCT02752763|DRUG|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
219586121|NCT02752763|DRUG|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
219586122|NCT02326441|DRUG|KX2-361|
219586123|NCT00742924|DRUG|cisplatin|Given IV
219586124|NCT00742924|DRUG|dexrazoxane hydrochloride|Given IV
219586125|NCT00742924|DRUG|doxorubicin hydrochloride|Given IV
218837901|NCT05377476|OTHER|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
219447052|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
219447053|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
219447054|NCT06106308|DRUG|Onvansertib|Oral capsule
219447055|NCT06106308|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
219447056|NCT06106308|DRUG|Bevacizumab|IV Infusion
219447057|NCT06106308|DRUG|FOLFOX|FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
219447058|NCT04629976|DRUG|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
219447059|NCT04629976|DRUG|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
219447060|NCT04629976|DRUG|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
219447061|NCT05124067|DRUG|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
219447062|NCT05124067|DRUG|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
219447063|NCT05124067|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
219447064|NCT05124067|DRUG|normal Saline|patients will receive normal saline.
219447065|NCT05957328|DRUG|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
219447066|NCT05957328|DRUG|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
219447067|NCT06859632|OTHER|3-hour educational intervention|"A 3-hour educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
219447068|NCT06859632|OTHER|45-minute educational intervention|"A 45-minute educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
219447069|NCT06015568|DRUG|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
218837902|NCT05377476|OTHER|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
219196553|NCT06401954|BEHAVIORAL|Foot core training|"Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks."
219447070|NCT06015568|DRUG|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
219447071|NCT05186012|DRUG|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
219447072|NCT05186012|DRUG|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
219447073|NCT01425853|DRUG|Chondroitin/Glucosamine (Droglican)|Experimental
219447074|NCT01425853|DRUG|Celecoxib|Active comparator
219447075|NCT05376995|DIAGNOSTIC_TEST|Graston technique|Graston technique among patient of knee osteoarthritis
219586126|NCT00742924|DRUG|etoposide|Given IV
219586127|NCT00742924|DRUG|ifosfamide|Given IV
218837903|NCT05377476|OTHER|standard rehabilitation|40 minutes of standard rehabilitation.
219586128|NCT00742924|DRUG|leucovorin calcium|Given IV or orally
219586129|NCT00742924|DRUG|methotrexate|Given IV
219586130|NCT00742924|DRUG|zoledronic acid|Given IV
219586131|NCT00742924|PROCEDURE|adjuvant therapy|
219586132|NCT00742924|PROCEDURE|neoadjuvant therapy|
218837904|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
219196554|NCT06401954|DEVICE|Sham high-intensity focused electromagnetic therapy|"Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
219196555|NCT04881461|DRUG|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
219196556|NCT04881461|DRUG|Placebo|Placebo
219196557|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
219586133|NCT00742924|PROCEDURE|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
219447076|NCT05376995|DIAGNOSTIC_TEST|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
219447077|NCT06095544|PROCEDURE|Enhanced recovery for SPK recipients|Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
219447078|NCT01937624|DEVICE|Diagnostic Ultrasound|
219447079|NCT01937624|RADIATION|X-ray imaging|
219447080|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
219447081|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
219447082|NCT03585465|DRUG|Vinblastine|"* Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
219447083|NCT03585465|DRUG|Cyclophosphamide|"* Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
219447084|NCT03585465|DRUG|Capecitabine|"* Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
219586134|NCT00742924|BIOLOGICAL|filgrastim|Given SC
219196558|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r ATLL
219447085|NCT03585465|DRUG|Nivolumab|"* Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle"
219447086|NCT03885674|OTHER|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
219447087|NCT03885674|OTHER|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
219447088|NCT03051269|DRUG|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
219447089|NCT03051269|DEVICE|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
219586135|NCT00742924|DRUG|Mesna|Given IV
219447090|NCT00801138|DRUG|saline|2 ml 0.9% saline (placebo)
219447091|NCT00801138|DRUG|Dexamethasone|dexamethasone 8 mg (2 ml)
219447092|NCT00801138|DRUG|ropivacaine|30 ml 0.5% ropivacaine
219447093|NCT00801138|DRUG|Bupivacaine|30 ml 0.5% bupivacaine
219447094|NCT00788918|DRUG|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
219447095|NCT06081699|DRUG|TNP-2198|Oral
219447096|NCT06081699|DRUG|TNP-2198 Placebo|The placebo for TNP-2198 active drug
219447097|NCT01947894|OTHER|Non Interventional Study|Non Interventional Study
219447098|NCT01817660|PROCEDURE|Open repair of popliteal artery|
219586136|NCT00660400|DRUG|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
219586137|NCT00660400|PROCEDURE|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
219586138|NCT04290975|OTHER|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
219586139|NCT04290975|OTHER|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
219586140|NCT03107312|PROCEDURE|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
219586141|NCT00482183|DRUG|Pioglitazone|
219196559|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL
219586142|NCT02387515|OTHER|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
219586143|NCT01447420|DRUG|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
219586144|NCT01447420|DRUG|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
219586145|NCT02822495|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
219586146|NCT00097903|DRUG|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
219586147|NCT05308082|BEHAVIORAL|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
219586148|NCT05640219|DEVICE|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
219766362|NCT07212816|DEVICE|Sauti|Investigational, software-only device that acquires short voice samples during automated phone calls and analyzes cardiopulmonary signals to estimate heart rate (HR), heart-rate variability (HRV), and rhythm status (regular vs irregular). In this study, three calls are initiated via the Vital Audio web platform (pre-, post-cardioversion, and 1-month follow-up). Results are available only to study staff and are compared with ECG obtained at the same time points. The device is used for data collection/assessment only and does not guide clinical care. IDE: G230147.
219766363|NCT07213193|PROCEDURE|colon-rectal resection|The patients who underwent colon rectal resection, would be evaluated for stomia or not.
219447099|NCT01817660|PROCEDURE|Endovascular repair of popliteal artery|
218837905|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
219447100|NCT04666025|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
219447101|NCT04666025|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219447102|NCT04666025|OTHER|Electronic Health Record Review|Medical charts are reviewed
219586149|NCT04312386|OTHER|OPTIMAT|Baseline menue, not optimized
219586150|NCT02592135|OTHER|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
219586151|NCT01989962|OTHER|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
219586152|NCT03628625|DRUG|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
219586153|NCT03628625|DRUG|Placebo|Folic acid for 3 days
219586154|NCT03628625|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
219586155|NCT02256527|OTHER|Observational|compare data
219586156|NCT03839030|OTHER|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
219586157|NCT02150135|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
219586158|NCT00024284|DRUG|carboplatin|
219586159|NCT00024284|DRUG|irinotecan hydrochloride|
219586160|NCT05367583|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
219586161|NCT01025115|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
219586162|NCT01025115|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
218837906|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
219447103|NCT04666025|OTHER|Questionnaire Administration|Complete questionnaire
219447104|NCT01231126|DRUG|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
219447105|NCT00005806|DRUG|carboplatin|
219447106|NCT00005806|DRUG|gefitinib|
219447107|NCT00005806|DRUG|paclitaxel|
219447108|NCT03672357|PROCEDURE|Laparoscopic liver resection|Laparoscopic hepatectomy
219447109|NCT03672357|PROCEDURE|Open liver resection|Traditional open hepatectomy
219447110|NCT00987610|DEVICE|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
219447111|NCT02959112|DRUG|Epinephrine|
219447112|NCT02959112|OTHER|Sterile water|
219586163|NCT03437226|DRUG|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
219586164|NCT03437226|DRUG|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
219586165|NCT04026386|BEHAVIORAL|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
219586166|NCT00025012|DRUG|isotretinoin|
219586167|NCT02643355|DRUG|Olanzapine|
219447113|NCT02959112|DRUG|Indomethacin Rectal Suppository|
219447114|NCT01686100|PROCEDURE|No touch technique|The vein graft is harvested with its surronding tissues.
218837907|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
219586168|NCT02643355|DRUG|Clonidine|
219586169|NCT05736653|DEVICE|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (\~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
219586170|NCT05736653|DEVICE|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed \~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
219586171|NCT05736653|DEVICE|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (\~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS \~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
219586172|NCT03122288|BEHAVIORAL|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
219586173|NCT03122288|OTHER|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
219586174|NCT03495349|OTHER|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
219447115|NCT01686100|PROCEDURE|Conventional technique|The vein graft is stripped from its surrounding tissues.
219447116|NCT07018635|DRUG|INCB161734|Oral; Tablet
219447117|NCT07018635|DRUG|Itraconazole|Oral; Tablet
219447118|NCT07018635|DRUG|Rifampin|Oral; Tablet
219447119|NCT07018635|DRUG|Esomeprazole|Oral; Tablet
219447120|NCT07018635|DRUG|Famotidine|Oral; Tablet
219447121|NCT04084405|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
219447122|NCT00035477|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
219447123|NCT00035477|DRUG|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
219586175|NCT04420273|BEHAVIORAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
219586176|NCT04420273|BEHAVIORAL|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
218837908|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
218837909|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
218837910|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
218837911|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
219447124|NCT04134299|DIETARY_SUPPLEMENT|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
218837912|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
218837913|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
219586177|NCT01687972|COMBINATION_PRODUCT|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
219447125|NCT02901080|DEVICE|Alpha Stim AID cranial electrotherapy stimulation|\- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
219447126|NCT02901080|BEHAVIORAL|Pregnancy test|\- Pregnancy test x 1 (day 1)
219447127|NCT02901080|OTHER|Anxiety questionnaire|\- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
219447128|NCT02901080|OTHER|Quality of life questionnaire|\- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
219447129|NCT02901080|OTHER|Work and social questionnaire|\- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
219447130|NCT02901080|OTHER|Sleep questionnaire|\- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
219447131|NCT02901080|OTHER|Depression questionnaire|\- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
219447132|NCT02901080|OTHER|Quality of life and financial questionnaire|\- CSRI questionnaire x 3 (day 1, week 12 and week 24)
219447133|NCT01779804|PROCEDURE|OFAR|OFAR
219447134|NCT06142968|DIAGNOSTIC_TEST|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
219447135|NCT05226143|OTHER|Gel Cream|Gel Cream
219447136|NCT00333970|BEHAVIORAL|cognitive remediation|individual cognitive training
219447137|NCT03766542|DEVICE|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
219586178|NCT01687972|COMBINATION_PRODUCT|Absorbable sutures|placement of absorbable sutures at cesarean section
219586179|NCT00000139|BEHAVIORAL|Stress|
219196560|NCT04007848|DRUG|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
219447138|NCT03766542|DEVICE|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
219447139|NCT03260283|DRUG|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
219447140|NCT03260283|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
219447141|NCT03260283|DRUG|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
219447142|NCT05337345|DRUG|Cendakimab|Specified Dose on Specified Days
219447143|NCT02836080|BEHAVIORAL|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
219447144|NCT02836080|OTHER|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
219447145|NCT03290794|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
219447146|NCT00901862|DEVICE|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
219447147|NCT00901862|DEVICE|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
219447148|NCT05076994|OTHER|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
219447149|NCT05076994|OTHER|Standard Care|An exercise prescription and verbal instructions in clinic
219447150|NCT05838794|OTHER|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
218837914|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
219196561|NCT04007848|DRUG|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
219196562|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
219196563|NCT06810115|OTHER|Viral PCR test|Viral PCR test regardles of symptoms
219586180|NCT00000139|DRUG|Acyclovir|
219586181|NCT03144310|OTHER|lung ultrasound|lung ultrasound and blood gas
219586182|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
219586183|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
219586184|NCT04524364|DEVICE|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
219447151|NCT05838794|OTHER|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
219447152|NCT00829062|DEVICE|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
219447153|NCT05241665|DEVICE|SpectraWAVE Imaging System|Coronary imaging
219447154|NCT04884529|BEHAVIORAL|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
219586185|NCT04007432|OTHER|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
219586186|NCT06160193|BEHAVIORAL|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
219586187|NCT06160193|OTHER|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
219586188|NCT05626855|DRUG|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
219586189|NCT05124977|DRUG|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
219586190|NCT05124977|DRUG|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
219586191|NCT03706833|DEVICE|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
219586192|NCT03706833|DEVICE|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
219586193|NCT06966050|BEHAVIORAL|Quality-of-life Questionnaire|Participants will be asked to fill out a quality-of-life questionnaire, which will take about 10-15 minutes to complete.
219196564|NCT06810206|OTHER|Bilateral Ultrasound Guidance M-TAPA|transversus abdominis, internal oblique, and external oblique muscles will be identified on the costochondral angle in the sagittal plane at the 10th costal margin. deep angle will be given to the costochondral angle at the edge of the 10th costa with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. The needle will be inserted in the cranial direction using the in-plane technique, and the needle tip will be moved to the posterior aspect of the 10th costal cartilage, and saline (5 ml) will be injected to confirm the location by observing dissection between internal oblique muscle and transversus abdominis muscle under the 10th costal cartilage, and local anesthetic will be injected into the lower surface of the chondrium. The local anesthetic to be used is bupivacaine 0.25% with Ultrasound Siemens® ACUSON X300 portable scanner with a high frequency linear transducer (10 MHz) using A Quincke 22 G . x 3½ in. (0.7x88 mm) A spinal needle
219586194|NCT05438459|BIOLOGICAL|Phase I part|Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.
219447155|NCT03814681|OTHER|Colorectal Surgery|elective Colorectal Surgery
219447156|NCT04231032|OTHER|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
219447157|NCT04231032|OTHER|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
219447158|NCT02829775|DRUG|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
219447159|NCT02829775|DRUG|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
219447160|NCT00087048|DRUG|topotecan hydrochloride|
219447161|NCT01844427|DRUG|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
219447162|NCT01844427|DRUG|Placebo|
219586195|NCT05438459|BIOLOGICAL|Phase II part|Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment
219586196|NCT03806842|DEVICE|Easytech group|total shoulder replacement
219586197|NCT03185442|DEVICE|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
219586198|NCT00752830|DRUG|AZD0328|Oral capsule, single dose
219586199|NCT06633250|OTHER|Test Formula|Hydrolyzed rice protein formula
219586200|NCT06633250|OTHER|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
219586201|NCT00826449|DRUG|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
219586202|NCT00826449|DRUG|Erlotinib|150 mg by mouth daily every 21 day cycle.
219586203|NCT02994940|DRUG|Acetaminophen|already included in arm/group descriptions
219586204|NCT03233230|DRUG|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
219586205|NCT03233230|DRUG|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
219586206|NCT03233230|DRUG|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
219447163|NCT00390429|DRUG|docetaxel|Given IV
219447164|NCT00390429|DRUG|erlotinib hydrochloride|Given orally
219447165|NCT02353689|DIETARY_SUPPLEMENT|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
219586207|NCT03233230|DRUG|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
219586208|NCT03490448|BEHAVIORAL|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
219586209|NCT02930486|DEVICE|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
219586210|NCT02930486|DEVICE|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
219586211|NCT00475150|DRUG|cediranib maleate|Given orally
219447166|NCT02353689|DIETARY_SUPPLEMENT|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
219447167|NCT02353689|DIETARY_SUPPLEMENT|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
219447168|NCT01313039|DRUG|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
219447169|NCT01816386|OTHER|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
219447170|NCT01816386|OTHER|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
219447171|NCT04500223|OTHER|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
219447172|NCT04500223|OTHER|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
219586212|NCT00475150|OTHER|laboratory biomarker analysis|Correlative studies
219586213|NCT02327741|DRUG|plavix|taking plavix more than 12 months
219586214|NCT02327741|DRUG|plavix|taking plavix less than 12 months
219586215|NCT00134693|DRUG|Prednisolone|
219586216|NCT00134693|DRUG|SB-681323|
219586217|NCT02987959|DRUG|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
219586218|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
219586219|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
219586220|NCT05581290|DEVICE|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
219586221|NCT04390659|PROCEDURE|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
219447173|NCT05490498|OTHER|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
219447174|NCT02296294|DRUG|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
219447175|NCT02296294|DEVICE|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
219447176|NCT01405378|DEVICE|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
219447177|NCT06003452|PROCEDURE|surface treatment with Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
219447178|NCT01833390|DRUG|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
219447179|NCT06004089|PROCEDURE|V NOTES Sacrocolpopexy|The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
219586222|NCT02853370|DRUG|Bendamustine and Rituximab|
219586223|NCT03851926|RADIATION|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
219586224|NCT02589314|DEVICE|Mechanical periodontal therapy|
219586225|NCT02589314|PROCEDURE|nonsurgical periodontal therapy|
219586226|NCT00117208|DRUG|mannitol|400mg BD for 12 weeks
219586227|NCT00117208|DRUG|mannitol + pulmozyme|combination
219586228|NCT00117208|DRUG|Dornase alpha|2.5mg daily for 2 weeks
219586229|NCT02831608|BIOLOGICAL|Influenza vaccine|
219586230|NCT02831608|BIOLOGICAL|Placebo|
219586231|NCT01439230|DRUG|Donepezil|10 mg Tablet
219586232|NCT01439230|DRUG|Aricept®|10 mg Tablet
219586233|NCT03915730|OTHER|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
219586234|NCT00415441|PROCEDURE|Physiotherapy program|
219586235|NCT00415441|PROCEDURE|Placebo physiotherapy treatment|
219586236|NCT04311788|DEVICE|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
219586237|NCT04311788|DEVICE|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
219586238|NCT00000583|BIOLOGICAL|hepatitis B vaccines|
219586239|NCT00675753|GENETIC|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
219766364|NCT07209709|DEVICE|Conventional exercises with dual task training (cognitive task)|"Individuals in this group will undergo exercise sessions under the supervision of a physiotherapist, with cognitive tasks added to conventional exercises, 3 days a week for a total of 8 weeks.~EXERCISES~1. Sit-Reach in Bed (15 seconds each)~2. Hip Flexor Stretch Exercise (15 seconds each)~3. Cat-Camel Exercise~4. Bridge Exercise~5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair~6. Sit-to-Stand in a Chair~7. One-Legged Stand~8. Mini Squat 9. Tandem Walk Cognitive Tasks to be Used in the Dual-Task Training Group Weeks 1 and 2 Simple single-digit addition Generate random numbers between 1 and 100 Count the days of the week Count the months of the year Repeat two spoken words Count from 0 to 100, incrementing by 10 Generate words starting with the specified letter Count from 1 to 100 The remaining cognitive task examples are in the study description. The exercises and cognitive tasks will be conducted sequentially and simultaneous"
219586240|NCT03607526|OTHER|Barriers|NGT sessions identifying barriers to vegetable intake.
219586241|NCT03607526|OTHER|Facilitators|NGT sessions identifying facilitators to vegetable intake.
219586242|NCT06053918|OTHER|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
219586243|NCT05947110|OTHER|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
219586244|NCT05947110|OTHER|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
219586245|NCT04601610|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
219586246|NCT04601610|DRUG|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
219586247|NCT03856112|DRUG|Dexamethasone|Given PO
219586248|NCT03856112|DRUG|Ixazomib|Given PO
219586249|NCT03856112|DRUG|Ixazomib Citrate|Given PO
219586250|NCT03856112|DRUG|Venetoclax|Given PO
219586251|NCT02755155|DRUG|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
219586252|NCT02755155|DRUG|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
219586253|NCT02854592|DRUG|rtPA|intravenous thrombolysis with rtPa
219586254|NCT02854592|DRUG|urokinase|intravenous thrombolysis with urokinase
219447180|NCT03834480|OTHER|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
219447181|NCT04984070|DRUG|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
219447182|NCT04984070|DRUG|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
219447183|NCT04984070|OTHER|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
219447184|NCT01144741|OTHER|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
219196565|NCT06810206|PROCEDURE|Bilateral Ultrasound Guidance EOIPB|"The patients will be positioned in the supine position with the ipsilateral arm in abduction. The transducer will be positioned in a cephalad to caudad parasagittal plane at the anterior axillary line at the level of the sixth and seventh ribs in line with the xiphoid process. Using the in-plane technique, the needle will be advanced from cephalad to caudad until the tip lies in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs. Following hydro-dissection with 2 ml of 0.9% saline to confirm the correct needle tip position, LA injection will be given. The same procedure will then be repeated on the contralateral~* Local anesthetics to be injected: iBupivacaine (0.25%)~* Dose : 25ml on each side~* Device to be used: Ultrasound Siemens® ACUSON X300 portable scanner with a high-frequency linear transducer (10 MHz) that is covered in sterile plastic.~* Needle to be used : A Quincke 22 G . x 3½ inch (0.7x88 mm) spinal needle"
219586255|NCT02650479|DRUG|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
219447185|NCT01144741|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
219447186|NCT01144741|OTHER|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
219447187|NCT01144741|OTHER|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
219447188|NCT01144741|OTHER|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
219586256|NCT02650479|DRUG|Placebo|6 hour IV infusion.
219586257|NCT02650479|DRUG|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
219586258|NCT02650479|DRUG|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
219586259|NCT02205983|DRUG|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
219586260|NCT02205983|DRUG|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
219586261|NCT02205983|DRUG|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
219586262|NCT02205983|DRUG|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
219586263|NCT05231538|OTHER|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
219586264|NCT05231538|OTHER|Routine physical therapy|stretching, passive range of motion, and active range of motion).
219586265|NCT03764761|DEVICE|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
219586266|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
219586267|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
219586268|NCT04173624|DIAGNOSTIC_TEST|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
219586269|NCT04173624|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
219586270|NCT00239044|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219586271|NCT04775420|DIAGNOSTIC_TEST|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
219586272|NCT03148561|DRUG|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
219586273|NCT00753220|BIOLOGICAL|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"
219447189|NCT01144741|OTHER|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
219586274|NCT00753220|DRUG|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
219586275|NCT01898650|OTHER|MR scan|
219766365|NCT07209709|DEVICE|Conventional Exercise With Action Observation Therapy|Individuals in this group will watch exercises on a computer screen in three sessions (in bed, sitting, and standing), three days a week for a total of eight weeks. Each exercise in each session will be monitored for two minutes, and each session will be performed under the supervision of a physical therapist for one minute. A one-minute break will be provided between sessions. Each session will last approximately 40-50 minutes. EXERCISES 1. Sit-Reach in Bed (15 seconds each) 2. Hip Flexor Stretch Exercise (15 seconds each) 3. Cat-Camel Exercise 4. Bridge Exercise 5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair 6. Sit-to-Stand in a Chair 7. One-Legged Stand 8. Mini Squat 9. Tandem Walk For Example: After watching the video of the exercise period in which you sit and stand on a chair on the computer, do the same exercise by imitating it. (1 set, 10 repetitions) Device: Handheld dynanometer, chair, stopwatch, computer
219196566|NCT06809478|PROCEDURE|Pulpotomy using Chitosan liquid|"1. After complete hemostasis, a cotton pellet damp with chitosan liquid will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
219447190|NCT01144741|OTHER|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
219586276|NCT04641793|DEVICE|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
219586277|NCT06218121|DIAGNOSTIC_TEST|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
219766366|NCT07209709|DEVICE|Conventional Exercise (Control Group)|"Individuals in this group will perform conventional exercise sessions under the supervision of a physical therapist three days a week for a total of eight weeks. Each session will last approximately 40-50 minutes. No cognitive tasks or action monitoring therapy will be used during the exercises. EXERCISES 1. Sit-Reach in Bed (15 seconds each) 2. Hip Flexor Stretch Exercise (15 seconds each) 3. Cat-Camel Exercise 4. Bridge Exercise 5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair 6. Sit-to-Stand in a Chair 7. One-Legged Stand 8. Mini Squat 9. Tandem Walk.~Device: Handheld dynanometer, chair, stopwatch"
219766367|NCT07209969|BEHAVIORAL|CBT-I group|Refer to the arm description
219766368|NCT07212933|BIOLOGICAL|RetroNectin active Killer cells|RetroNectin-Activated Killer (RAK) cells, derived from autologous peripheral blood mononuclear cells (PBMCs), are induced in vitro by RetroNectin along with anti-CD3 monoclonal antibody and Interleukin-2 (IL-2). These cells consist of various cytotoxic effectors, primarily CD8+ T (cytotoxic T, Tc) cells and natural killer T cells, which exhibit minimal cytotoxicity to normal cells but substantial specificity to tumor cells, thereby demonstrating both safety and potent anti-tumor activity.
219766369|NCT07212933|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Based on the results of the RECOURSE \[16\] and TERRA \[17\] studies, TAS-102 (Trifluridine/Tipiracil Hydrochloride) will be administered orally at a dose of 35mg/m², twice daily, Days 1-5, with each cycle lasting 3 weeks.
219766370|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
219766371|NCT07212699|OTHER|KneeApp|"Our app collects patient-authorized mobility data that are already stored on the patient's smartphone and those that will be recorded in the future, and analyzes these data with respect to their temporal patterns. Each study participant can decide individually which data they wish to share.~In addition, participants are prompted at regular intervals to perform and document functional tests, such as gait assessments (once per month) and knee function tests (weekly).~Furthermore, subjective health data are regularly collected using standardized PROMs: KOOS and SF-36 every three weeks, patient-reported satisfaction with health status on a monthly basis, and user satisfaction with the app every three months.~The collected data can be accessed both by the patient and the study team and can be downloaded and stored as a PDF file if needed.~Participation in the study requires a single on-site visit at the Department and Outpatient Clinic of Orthopedics and Sports Orthopedics. No further in-pe"
219766372|NCT07210515|DRUG|Neridronate|neridronate 100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.
219766373|NCT07210515|DRUG|Placebo|placebo comparator
219766374|NCT07211867|BEHAVIORAL|Enhearten with EMI|Enhearten is a digital intervention that is designed to foster adherence to medications for addiction treatment (MAT) and treatment retention while considering the unique needs of pregnant and postpartum women, and recently it has been adapted to include features designed to decrease self-stigma among app-users
219766375|NCT07211867|BEHAVIORAL|Waitlist Control Group|Participants will receive access to Enhearten with EMI following the trial.
219447191|NCT00609167|DRUG|bortezomib|"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"
219447192|NCT00609167|DRUG|cyclophosphamide|300mg/m\^2 PO days 1, 8, 15 \& 22
219586278|NCT06339320|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
219586279|NCT06339320|DEVICE|Apollo OverStitch endoscopic suturing device|Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
219447193|NCT00609167|DRUG|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
219447194|NCT01307046|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
219447195|NCT01307046|DRUG|Losartan|Tablet containing losartan potassium (100 mg), once daily
219447196|NCT01307046|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
219447197|NCT01307046|DRUG|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
219447198|NCT01307046|DRUG|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
219586280|NCT00134173|DRUG|torcetrapib/atorvastatin|
219586281|NCT00134173|DRUG|atorvastatin|
219586282|NCT03026972|BIOLOGICAL|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
219766376|NCT07209488|BEHAVIORAL|Phono-Motor Therapy|Orthographic stimuli (letters) are introduced from the beginning as each phoneme is being trained. This maintains the focus on phonology, while emphasizing its relevance to reading. PMT consists of an initial phase focused on training of individual phonemes and phoneme sequences in spoken language, followed by written language tasks. English phonemes are first trained in isolation, followed by phoneme sequences in words and pseudowords. They are trained multi-modally through emphasis on auditory, motor, tactile-kinesthetic, visual, and orthographic representations for each consonant and vowel. When sequences are introduced, focus on phonology is maintained by training on pseudowords first before real words are introduced. Participants work on identifying, repeating, parsing, blending, and manipulating phonemes that make up the pseudoword and word stimuli. To maintain focus on phonology, pictures and definitions of the stimuli are never shown or discussed.
219196567|NCT06809478|PROCEDURE|Pulpotomy using Formocresol|"1. After complete hemostasis, a cotton pellet damp with formocresol will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
219447199|NCT00367705|DIETARY_SUPPLEMENT|VSL#3®|1-2 sachets/day per os, 6 months
219447200|NCT00367705|DIETARY_SUPPLEMENT|Placebo|1-2 sachets/day per os, 6 months
219447201|NCT04288297|PROCEDURE|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
219447202|NCT03801798|DRUG|GC1102|NAs antivirals+GC1102 180,000 IU
219586283|NCT03026972|BIOLOGICAL|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
219447203|NCT03801798|OTHER|GC1102 Placebo|NAs antivirals+GC1102 Placebo
219447204|NCT02574520|DRUG|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
219447205|NCT02574520|DRUG|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
219586284|NCT03026972|BIOLOGICAL|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
219586285|NCT03026972|BIOLOGICAL|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
219586286|NCT03026972|BIOLOGICAL|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
219447206|NCT02574520|DRUG|Saline Placebo|5 ml once at end of surgery
219447207|NCT02574520|DRUG|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
219447208|NCT02003768|DRUG|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
219447209|NCT02003768|DRUG|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
219447210|NCT02835235|DRUG|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
219447211|NCT02835235|DRUG|placebo|Administered daily subcutaneously (s.c., under the skin)
219447212|NCT05570136|BEHAVIORAL|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
219447213|NCT05570136|BEHAVIORAL|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
219447214|NCT06249880|OTHER|Observation|This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
219447215|NCT01492816|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
219447216|NCT03935594|BIOLOGICAL|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
219447217|NCT03935594|DRUG|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
219447218|NCT01435122|DRUG|Axitinib|Axitinib Administration as outlined in Arm description
219447219|NCT00372294|DRUG|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
219447220|NCT00372294|DRUG|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
219447221|NCT01804647|OTHER|No study treatments administered - blood draws only|
219586287|NCT04135196|OTHER|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
219586288|NCT00911807|DRUG|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
219447222|NCT02482389|RADIATION|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
219447223|NCT02132689|DRUG|Actilyse (Thrombolytic therapy)|
219447224|NCT02132689|DRUG|Heparine (Standard anticoagulation therapy)|
219447225|NCT03557229|DRUG|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
219447226|NCT03557229|DRUG|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
219447227|NCT03557229|DRUG|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
219447228|NCT03557229|DRUG|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
219447229|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
219447230|NCT01808365|PROCEDURE|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
219447231|NCT01808365|OTHER|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
219447232|NCT05135182|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
219447233|NCT05135182|DRUG|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
219447234|NCT02758561|BEHAVIORAL|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
219447235|NCT04188210|OTHER|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
219447236|NCT01153568|DIETARY_SUPPLEMENT|Vitamin D 3|Patients will bew given a single capsule to take once daily
219447237|NCT01153568|OTHER|placebo|placebo tablets
219447238|NCT00198367|DRUG|Cisplatin-Gemzar|
219447239|NCT00198367|DRUG|Cisplatin-Navelbine-Radiotherapy|
219447240|NCT00198367|DRUG|Carboplatin-Taxol-Radiotherapy|
219447241|NCT03333512|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
219447242|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
219447243|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
219447244|NCT05021666|DRUG|Placebo|matching placebo
219447245|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
219586289|NCT00911807|DRUG|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
219586290|NCT00911807|DRUG|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
219447246|NCT00965549|DRUG|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
219586291|NCT02489019|DRUG|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
219766377|NCT07209488|BEHAVIORAL|Semantic Feature Analysis|"SFA activates semantic features of the target word to help retrieve the spoken form of the word. To target reading, a modified SFA is used with written words rather than pictures as the primary materials. Pictures are instead included for each word as a semantic feature. Stimuli will consist of 80 highly imageable nouns with a range of word frequencies. During treatment the therapist will present a written noun and ask the participant a series of questions about the features of that noun. For example, if the presented noun is juice, the therapist would have the participant select the corresponding picture from an array of pictures. The therapist then would ask, what do you do with it? (eliciting a feature from the function category) and where do you store it in your home? (eliciting a feature from the context category). This is done for a total of 6 categories of semantic features. The process is repeated until the participant reads the noun correctly three times in a row."
219447247|NCT00965549|DRUG|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
219447248|NCT00965549|DRUG|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
219447249|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
219447250|NCT02050672|OTHER|untreated|
219447251|NCT02451254|PROCEDURE|circumferential ablation|circumferential ablation of the pulmonary veins
219447252|NCT02451254|DEVICE|SVT ablation|SVT ablation
219447253|NCT06074718|OTHER|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
219447254|NCT03476928|DRUG|Vilaprisan (BAY1002670)|2mg, once daily, oral
219447255|NCT06926491|DRUG|KK8398|KK8398 will be administered.
219447256|NCT06949137|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal stem cell|Intravenous infusion of hMSC100 at 20-25 drops per minute
219447257|NCT06948526|DRUG|Moringa Oleifera Leaf Extract|A plant-based extract derived from Moringa Oleifera leaves, used as an intracanal irrigant during pulpectomy procedures in primary molars. It is administered using a 3 ml syringe with a side-vented needle following canal preparation and working length determination. This intervention aims to evaluate the clinical and radiographic efficacy of a natural, biocompatible alternative to conventional chemical irrigants.
219447258|NCT06948526|DRUG|Sodium Hypochlorite 1%|A 1% concentration of Sodium Hypochlorite solution used as a standard intracanal irrigant in pediatric endodontics. It is administered using a 3 ml syringe with a side-vented needle after canal instrumentation. Known for its strong antimicrobial and tissue-dissolving properties, Sodium Hypochlorite serves as the active comparator in this study.
219447259|NCT06948474|DRUG|Dachengqi decoction|experimental Participants received Dachengqi decoction (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
219447260|NCT06948474|PROCEDURE|modified gastrointestinal dual-lumen feeding tube|experimental and control group participants underwent intraoperative placement of modified gastrointestinal dual-lumen feeding tubes with distal ends positioned 15-20 cm distal to the gastrojejunostomy anastomosis (all devices were uniformly procured by China-Japan Friendship Hospital).
219586292|NCT02489019|DRUG|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
219447261|NCT06948474|DRUG|Normal Saline (0.9% NaCl)|control group participants were administered glucose and sodium chloride injection (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
219447262|NCT05375825|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
219447263|NCT05375825|DRUG|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
219447264|NCT05375825|DIAGNOSTIC_TEST|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
219447265|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
219447266|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
219447267|NCT04888507|DRUG|Cemdisiran|SC administration
219447268|NCT06431334|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d
219447269|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
219447270|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
219447271|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
219447272|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
219447273|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
219447274|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
219447275|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
219447276|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
219447277|NCT03782467|BIOLOGICAL|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
219447278|NCT00311012|DRUG|Aliskiren|
219447279|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
219447280|NCT02940353|DEVICE|TREFOIL concept|
219586293|NCT03144102|BEHAVIORAL|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
219447281|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
219447282|NCT02241356|DEVICE|single vision glasses|single vision glasses
219586294|NCT03144102|DEVICE|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
219586295|NCT03144102|BEHAVIORAL|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
219586296|NCT03144102|DEVICE|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
219586297|NCT00001713|DRUG|Recombinant Tissue Plasminogen Activator|
219586298|NCT00001713|DRUG|Heparin|
219586299|NCT00001713|DRUG|Warfarin|
219586300|NCT00809159|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
219586301|NCT00809159|DRUG|Placebo|Placebo to AIN457
219586302|NCT02944942|PROCEDURE|General anesthesia|Patients undergoing general anesthesia
219586303|NCT03201211|BIOLOGICAL|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
219586304|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219447283|NCT06745479|BEHAVIORAL|Positive Emotion Upregulation|Participants will identify personal goals or activities that they would like to engage in more and describe these goals/activities in a written format with research staff. Participants will then complete a gambling task during functional MRI scanning. Prior to making some gambling decisions, participants are instructed to mentally imagine achieving a goal or engaging in an enjoyable activity. Prior to the other decisions participants are instructed to respond naturally (i.e., not use the cognitive strategy).
219447284|NCT01712776|DEVICE|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
219447285|NCT01712776|DEVICE|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
219447286|NCT04807530|DEVICE|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
219447287|NCT03956745|BEHAVIORAL|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep \~12h opposite their usual sleep time.
219447288|NCT03956745|BEHAVIORAL|constant routine|Study participants will spend \~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
219447289|NCT02737605|DRUG|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
219447290|NCT02737605|DRUG|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
219447291|NCT02737605|DRUG|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
219586305|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219447292|NCT02737605|DRUG|Oral Placebo|Participants will receive matching placebo orally.
219447293|NCT02737605|DRUG|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
219447294|NCT02737605|DRUG|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
219447295|NCT05802290|DRUG|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
219447296|NCT04011137|OTHER|Exercise|Arm-cranking exercise
219447297|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
219447298|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
219447299|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
219586306|NCT03201211|DRUG|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219586307|NCT02612220|PROCEDURE|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
219586308|NCT02612220|OTHER|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
219586309|NCT03347760|DRUG|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
219586310|NCT03347760|DRUG|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
219586311|NCT03347760|BIOLOGICAL|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
219586312|NCT05215080|DIETARY_SUPPLEMENT|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
219586313|NCT04407091|DRUG|14C]AZD4831 Oral Solution|10 mg dose of \[14C\]AZD4831 Oral Solution
219196568|NCT06122168|OTHER|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
219196569|NCT06122168|OTHER|Standard care|verbal interview and standard health care
219196570|NCT06805045|PROCEDURE|augmented reality|To provide augmented reality (AR) guidance during robotic-assisted and laparoscopic surgeries, by overlaying the preoperative 3D virtual anatomical models to intraoperative surgical images (3D AR guidance).
219447300|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
219447301|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
219447302|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
219447303|NCT06305000|PROCEDURE|Non-surgical treatment|Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.
219447304|NCT06305000|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
219447305|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
219447306|NCT01462422|DRUG|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
219447307|NCT01462422|DRUG|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
219447308|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
219447309|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
219447310|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
219447311|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
219447312|NCT06382012|DRUG|Fosaprepitant 150 mg|Fosaprepitant 150mg IV administered over 15 minutes
219447313|NCT06382012|DRUG|Ondansetron 4 mg|Ondansetron 4mg IV administered over 15 minutes
219447314|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
219447315|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
219447316|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
219447317|NCT04541654|GENETIC|Data and Specimen Collection|"* Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional)."
219447318|NCT00177606|BEHAVIORAL|withdrawal of life sustaining treatments|
219447319|NCT02894788|OTHER|ICU admission|
219447320|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
219447321|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
219447322|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
219447323|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
219586314|NCT01083810|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
219586315|NCT03063762|DRUG|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
219766378|NCT07213024|BEHAVIORAL|Facilitated group-structured active play at the hospital|"The hospital-based part of the intervention includes daily facilitated group-structured active play sessions during the weekdays (i.e., Monday-Friday) at the hospital for 40 weeks. All sessions will be 45 minutes long and structured using the RePlay Model following four core principles: 1) ritual practices; 2) reinforcement of movement through repetition; 3) devel-opment through appropriate challenges; and 4) adjusting activities to accommodate treat-ment-related side effects. All activities are performed together, where healthcare pro-fessionals, parents, and children all participate to support social development.~The group-structured active play sessions will take place at the pediatric oncology ward and will be facilitated by a health professional (i.e., an exercise professional or physiother-apist)."
219447324|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
219447325|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
219447326|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
219447327|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
219586316|NCT03063762|DRUG|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
219447328|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
219447329|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
219586317|NCT03063762|DRUG|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
219447330|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
219447331|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
219447332|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
219447333|NCT01485185|DRUG|Donepezil|Repeat, oral dose
219447334|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
219447335|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
219447336|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
219447337|NCT00544193|DRUG|gemcitabine hydrochloride|
219447338|NCT00544193|GENETIC|polymerase chain reaction|
219447339|NCT00544193|OTHER|immunohistochemistry staining method|
219447340|NCT00544193|PROCEDURE|conventional surgery|
219447341|NCT00544193|RADIATION|intraoperative radiation therapy|
219447342|NCT00544193|RADIATION|radiation therapy|
219447343|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
219447344|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
219447345|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
219447346|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
219447347|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
219447348|NCT06366503|PROCEDURE|Fractional Ablative CO2 Laser|A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
219586318|NCT01174082|BIOLOGICAL|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
219586319|NCT01174082|BIOLOGICAL|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
219586320|NCT01174082|DRUG|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
219586321|NCT01174082|PROCEDURE|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
219586322|NCT01174082|PROCEDURE|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
219447349|NCT06366503|OTHER|Facial Cleanser|Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
219447350|NCT06366503|OTHER|Facial Moisturizer|A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
219447351|NCT06366503|OTHER|Sunscreen|During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
219447352|NCT06366503|OTHER|Basic Ointment|The basic ointment was used only on the comparator side for three days (72 hours) post-procedure. This was a requirement of the comparator anhydrous formulation.
219447353|NCT05955274|BEHAVIORAL|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
219447354|NCT05955274|BEHAVIORAL|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
219447355|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219447356|NCT05789862|BEHAVIORAL|Counseling Sessions|Virtual sessions
219447357|NCT05789862|BEHAVIORAL|Quality of Life Questionnaires|Self administered questionnaires
219586323|NCT02991430|DEVICE|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
219447358|NCT04327609|DEVICE|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
219447359|NCT04327609|DEVICE|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
219447360|NCT05836324|DRUG|INCA33890|INCA33890 will be administered at protocol defined dose.
219447361|NCT05836324|DRUG|bevacizumab|Bevacizumab will be administered at protocol defined dose.
219447362|NCT05836324|DRUG|FOLFIRI|FOLFIRI will be administered at protocol defined dose.
219447363|NCT05836324|DRUG|FOLFOX|FOLFOX will be administered at protocol defined dose.
219447364|NCT05836324|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
219586324|NCT02991430|DEVICE|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
219586325|NCT01938404|BIOLOGICAL|Octaplas|Octoplas infusion solution for IV administration
219586326|NCT01938404|DRUG|Standard Plasma|Plasma given as replacement fluid
219586327|NCT04860596|BEHAVIORAL|collaborative health management model|nursing education program
219586328|NCT05596721|DRUG|Azithromycin|Treat patient with azithromycin for 12w.
219586329|NCT05596721|DRUG|ICS/LABA|Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
219586330|NCT04335175|OTHER|None - observational study|None - observational study
219586331|NCT04732936|DEVICE|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
219586332|NCT04063488|DRUG|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
219586333|NCT03970837|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
219586334|NCT03970837|DRUG|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
219586335|NCT03970837|DRUG|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
219586336|NCT01997229|BIOLOGICAL|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
219586337|NCT01997229|DRUG|Placebo|Placebo
219586338|NCT01207505|BEHAVIORAL|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
219447365|NCT05874635|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
219447366|NCT06246552|BIOLOGICAL|JTM201|"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
219447367|NCT06246552|BIOLOGICAL|Placebo|"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
219447368|NCT06568497|OTHER|Food|Food
219447369|NCT05330611|DEVICE|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
219586339|NCT02304991|DRUG|Liquid Peanut Extract|5000mcg/ml peanut protein
219586340|NCT02304991|DRUG|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
219586341|NCT01157780|DRUG|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
219586342|NCT00907127|BEHAVIORAL|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
219586343|NCT03370731|PROCEDURE|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
219586344|NCT03370731|OTHER|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
219586345|NCT02122120|DIETARY_SUPPLEMENT|HEN|Patients with tube feeding with FSMP for at least twelve months
219766379|NCT07213024|BEHAVIORAL|Parents educational program|"The parent educational program consists of two educational sessions within the first three months of the child's treatment trajectory. The sessions have the aim of providing the par-ents with knowledge and skills to facilitate structured active play at home:~1. A 30-60-minute session with general information on gross motor function development, common physical side effects of cancer treatment, and the importance of physical activity and active play.~2. A 60-minute practical, interactive introduction to structured active play and the RePlay Model - including inspiration for active play activities they can do at home that challenge different gross motor skills.~The parents will receive practical material on gross motor development stages and skills as well as descriptions of active play activities that target gross motor functions."
219586346|NCT00234182|DRUG|Interferon alpha-2b|
219586347|NCT05931666|OTHER|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
219586348|NCT05931666|OTHER|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
219586349|NCT03287973|BEHAVIORAL|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
219586350|NCT03287973|DEVICE|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
219586351|NCT04430855|DRUG|Upadacitinib|Tablet; Oral
219586352|NCT04430855|DRUG|Placebo|Tablet; Oral
219586353|NCT04334486|OTHER|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
219586354|NCT06104241|BIOLOGICAL|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
219586355|NCT03704402|OTHER|Alcohol policy|Introduction of new mutual alcohol policy
219586356|NCT02375919|OTHER|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
219586357|NCT00317421|DRUG|Sildenafil citrate|
219586358|NCT06229821|DEVICE|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
219586359|NCT01425723|BIOLOGICAL|rFIXFc|Administered as specified in the treatment arm.
219586360|NCT01544738|OTHER|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
219586361|NCT01544738|OTHER|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
219586362|NCT01689818|OTHER|exercise training|exercise training program which included aerobic exercise for 3 times per week.
219586363|NCT02273336|OTHER|cytology specimen collection procedure|Undergo tissue and blood sample collection
219586364|NCT02273336|OTHER|laboratory biomarker analysis|Correlative studies
219586365|NCT05020613|PROCEDURE|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
219447370|NCT05330611|OTHER|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
219447371|NCT03728972|DRUG|Pembrolizumab|200mg IVPB every 3 weeks
219586366|NCT05020613|PROCEDURE|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
219017218|NCT03729804|DRUG|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
219017219|NCT03729804|DRUG|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
219017220|NCT03729804|DRUG|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
219017221|NCT03729804|DRUG|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
219586367|NCT01529918|OTHER|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
219447372|NCT05914311|DEVICE|Suture|secures SCS trial leads with a suture
219447373|NCT05914311|DEVICE|Dermabond|secures SCS trial leads with dermabond
219447374|NCT04960202|DRUG|PF-07321332|PF-07321332 (tablet)
219447375|NCT04960202|DRUG|Ritonavir|Ritonavir (capsule)
219586368|NCT00186043|DRUG|Quetiapine/Seroquel|Quetiapine/Seroquel
219586369|NCT00186043|DRUG|Placebo|Placebo
219586370|NCT02497313|DRUG|Isotonic saline|
219586371|NCT02497313|DRUG|Metformin placebo|
219586372|NCT02497313|DRUG|Cholecystokinin|
219586373|NCT02497313|DRUG|Metformin|
219586374|NCT06404164|PROCEDURE|Wedge resection under watershed analysis method|"* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery;~  * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule"
219586375|NCT06048666|BIOLOGICAL|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
219586376|NCT04874636|DRUG|LY3556050|Administered orally
219447376|NCT04960202|DRUG|Placebo|Placebo (tablet or capsule)
219586377|NCT04874636|DRUG|Placebo|Administered orally
219586378|NCT02754466|OTHER|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
219586379|NCT02754466|OTHER|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
219586380|NCT05060133|PROCEDURE|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
219447377|NCT05113251|DRUG|Trastuzumab Deruxtecan|administered by intravenous infusion
219586381|NCT04238988|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
219586382|NCT04238988|DRUG|Carboplatin|Chemotherapy medication
219447378|NCT05113251|DRUG|Paclitaxel|administered by intravenous infusion
219586383|NCT04238988|DRUG|Taxol|Chemotherapy medication
219586384|NCT04350320|DRUG|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
219586385|NCT04350320|DRUG|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
219586386|NCT02737527|PROCEDURE|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
219586387|NCT02737527|DEVICE|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
219586388|NCT02737527|DEVICE|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
219586389|NCT02737527|DEVICE|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
219586390|NCT02737527|DRUG|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
219586391|NCT02737527|PROCEDURE|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
219766380|NCT07213024|BEHAVIORAL|Online facilitated structured active play at home|The online facilitated structured active play sessions at home are provided daily during the weekdays (i.e., Monday-Friday) in the afternoon (e.g., 16.00-17.00). A healthcare profes-sional (i.e., an exercise professional or physiotherapist) facilitates these sessions, guiding the families through active play activities following the RePlay Model structure. When the families log on for the online sessions, a healthcare professional will instruct them through different play activities. Each family will receive basic essential home-structured active play equipment (e.g., bean bags, balls, bingo games, items for an obstacle course) for the online sessions. The sessions will be conducted through video connections (Teams or Skype). Families who do not have an iPad or suitable computer will receive an iPad from the research group for the nine-month intervention.
219447379|NCT05113251|DRUG|Trastuzumab|administered by intravenous infusion
219447380|NCT05113251|DRUG|Pertuzumab|administered by intravenous infusion
219447381|NCT05113251|DRUG|Doxorubicin|administered by intravenous infusion
219447382|NCT05113251|DRUG|cyclophosphamide|administered by intravenous infusion
219447383|NCT05626907|OTHER|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
219447384|NCT05626907|OTHER|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
219586392|NCT02737527|PROCEDURE|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
219586393|NCT04359576|DIAGNOSTIC_TEST|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
219586394|NCT01770392|DRUG|Nintedanib|single dose administration
219586395|NCT01770392|DRUG|Rifampicin|single dose once daily for 7 days
219586396|NCT01770392|DRUG|Nintedanib|single dose administration
219586397|NCT03476863|PROCEDURE|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
219447385|NCT05626907|OTHER|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
219447386|NCT04934748|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
219447387|NCT04934748|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
219447388|NCT04934748|DRUG|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
219447389|NCT04934748|DRUG|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
219447390|NCT06465953|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
219586398|NCT03476863|PROCEDURE|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
219586399|NCT02099695|DRUG|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
219586400|NCT02099695|DRUG|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
219586401|NCT01580813|DRUG|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
219447391|NCT06465953|DRUG|Azacitidine|Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
219586402|NCT01580813|DRUG|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
219586403|NCT04625595|DRUG|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
219586404|NCT04625595|DRUG|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
219586405|NCT04625595|DRUG|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
219586406|NCT04625595|DRUG|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
219586407|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
219447392|NCT05242627|BEHAVIORAL|Clinical Firearm Safety Counseling Module|"The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program."
219447393|NCT06483698|OTHER|Sublobar resection|Sublobar resection is a series of surgical approaches for lung cancer.
219447394|NCT06483698|OTHER|Lobectomy|Lobectomy is the surgical approach for lung cancer.
219447395|NCT01518673|PROCEDURE|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
219447396|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
219586408|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
219586409|NCT04639713|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
219586410|NCT04068636|PROCEDURE|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
219586411|NCT02165865|PROCEDURE|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
219586412|NCT00106236|BEHAVIORAL|exercise|
219586413|NCT00955136|DEVICE|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
219586414|NCT05228821|DRUG|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
219586415|NCT00390221|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
219447397|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
219447398|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
219447399|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
219447400|NCT05861050|PROCEDURE|Biopsy|Undergo tumor biopsy
219447401|NCT05861050|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219586416|NCT00390221|DRUG|Placebo|Placebo SC injection
219586417|NCT00808964|DRUG|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
219586418|NCT05652959|DEVICE|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
219586419|NCT04791475|PROCEDURE|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
219586420|NCT02533375|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
219586421|NCT01294475|BEHAVIORAL|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
219586422|NCT03727659|BEHAVIORAL|SHADE therapy + CONNECT FaceBook support|"See study arms description."
219586423|NCT06462859|OTHER|Sensory Integration Therapy Group|The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
219586424|NCT06462859|OTHER|Neurodevelopmental Treatment Group|The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
219196571|NCT06808724|PROCEDURE|implant with ozonated oil|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Ozonated oil (Surgy O3) will be applied to the implant surface and then the implant will be inserted into the prepared osteotomy site. A 3 mm high transepithelial abutment will be then screwed using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
219447402|NCT05861050|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219447403|NCT05861050|PROCEDURE|Computed Tomography|Undergo CT scan
219447404|NCT05861050|BIOLOGICAL|Glofitamab|Given IV
219447405|NCT05861050|DRUG|Lenalidomide|Given PO
219447406|NCT05861050|BIOLOGICAL|Obinutuzumab|Given IV
219447407|NCT05861050|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219447408|NCT05861050|DRUG|Venetoclax|Given PO
219447409|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
219586425|NCT04731870|OTHER|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
219586426|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
219586427|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
219447410|NCT03935828|DRUG|Oral versus topical antibioitics|Previously described in two arms
219586428|NCT05376670|DRUG|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
219586429|NCT02606175|OTHER|Taking questionnaires and tests|"At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge"
219586430|NCT02397642|PROCEDURE|IVF/ICSI|
219586431|NCT02397642|DRUG|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
219586432|NCT06123442|BEHAVIORAL|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
219586433|NCT05259878|OTHER|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
219586434|NCT00429156|DEVICE|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
219586435|NCT00429156|DEVICE|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
219586436|NCT01270737|DIETARY_SUPPLEMENT|Whole soy (soy flour)|40g soy flour per day for six months
219586437|NCT01270737|DIETARY_SUPPLEMENT|daidzein|66mg daidzein per day for six months
219586438|NCT01270737|DIETARY_SUPPLEMENT|milk powder|40g low-fat dry milk per day for six months
219766381|NCT07211984|DEVICE|Dalia Monitoring|All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For iInterventional arm: Patients will benefit from Dalia telemonitoring, in addition to conventional care.
218837915|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
219447411|NCT00378534|DEVICE|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
219447412|NCT00378534|DRUG|Fludarabine|Therapeutic
219447413|NCT00378534|DRUG|Cyclosporine|Therapeutic
219447414|NCT00378534|DRUG|Cyclophosphamide|Therapeutic
219447415|NCT00378534|OTHER|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
219447416|NCT04969900|OTHER|Placebo oil|The placebo group will receive placebo oil.
219447417|NCT04969900|OTHER|Lavender oil.|Investigational Product. This group will receive Lavender oil.
219447418|NCT06632769|DEVICE|No intervention|No intervention
219447419|NCT04168905|DEVICE|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
219586439|NCT04040153|BEHAVIORAL|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
219586440|NCT02823483|OTHER|Sunscreen Lotion (BAY987521)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
219586441|NCT02823483|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
219586442|NCT05341297|BEHAVIORAL|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
219586443|NCT00495547|DRUG|Azacitidine|Azacitidine
219586444|NCT00495547|DRUG|Beta Erythropoietin|Beta Erythropoietin
219447420|NCT04572685|DRUG|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
219586445|NCT00539227|PROCEDURE|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
219586446|NCT00539227|BEHAVIORAL|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
219586447|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
219586448|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
219586449|NCT00003079|DRUG|bryostatin 1|
219586450|NCT00003079|DRUG|cytarabine|
219586451|NCT02351544|DRUG|Botulinum Toxin Type A|
219586452|NCT02351544|PROCEDURE|Surgery|
219447421|NCT03774875|DRUG|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
219447422|NCT03774875|DRUG|Placebo|Placebo tablets taken orally twice a day
219447423|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide
219447424|NCT02013154|DRUG|DKN-01 150 mg|Administered by IV infusion
219447425|NCT02013154|DRUG|Paclitaxel|Administered by IV infusion
219447426|NCT02013154|DRUG|Pembrolizumab|Administered by IV infusion
219586453|NCT02351544|OTHER|Daily headache diary|
219586454|NCT02351544|OTHER|Migraine Disability Assessment Test (MIDAS)|
219586455|NCT02351544|OTHER|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
219586456|NCT02351544|OTHER|Migraine-Specific Quality of Life Questionnaire (MSQ)|
218837916|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
218837917|NCT00163241|DRUG|celecoxib|
219447427|NCT02013154|DRUG|DKN-01 300 mg|Administered by IV infusion
219447428|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
219586457|NCT05600504|OTHER|no intervention|no intervention
219586458|NCT00368901|DRUG|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
219586459|NCT01412372|DRUG|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
219586460|NCT01412372|DRUG|Placebo|This is an inactive pill
219586461|NCT00786279|OTHER|ethanol|15 gm ethanol daily for 6 months
219586462|NCT00786279|OTHER|Ethanol-free beverage|0 grams ethanol daily for 6 months.
219586463|NCT03905564|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
219586464|NCT03905564|DRUG|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
219586465|NCT05623943|PROCEDURE|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
219586466|NCT01700166|BIOLOGICAL|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
219586467|NCT01431859|BIOLOGICAL|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
219586468|NCT01431859|OTHER|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
219586469|NCT00521027|DEVICE|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
219586470|NCT00521027|PROCEDURE|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
219586471|NCT04067427|OTHER|Mental training|App-based mental training
219586472|NCT05476120|BEHAVIORAL|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
219586473|NCT04271020|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
219586474|NCT05386082|OTHER|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
219586475|NCT06706427|BIOLOGICAL|NGGT001|Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
219586476|NCT01622686|BEHAVIORAL|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
219586477|NCT02243267|OTHER|sample collection|
219586478|NCT05953974|OTHER|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
219586479|NCT00030992|DRUG|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
219586480|NCT00030992|DRUG|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
219586481|NCT00030992|DRUG|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
219196572|NCT06808724|PROCEDURE|non-activated implant|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. In the control group, the implant will be inserted without any treatment. A 3 mm high transepithelial abutment will be then attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
219447429|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
219447430|NCT03348293|PROCEDURE|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
219586482|NCT03984292|PROCEDURE|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
219586483|NCT06477484|DIAGNOSTIC_TEST|Blood biomarker|Blood biomarker
219586484|NCT03647683|OTHER|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
219586485|NCT03647683|OTHER|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
219766382|NCT07211984|OTHER|Conventional healthcare|All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For Control arm: Patients in this group will benefit from the conventional care pathway.
219766383|NCT07211841|DEVICE|MRS study|"Thirty patients newly diagnosed with GBM will be included in this study. The study will be conducted without any major modification of the standard management of GBM.~The MRS study will be performed at the time of the initial MRI examination (morphological MRI sequences performed on 3T Philipps). The MRS will be performed on the most agressive part of the tumor : monovoxel PRESS MRS sequence with 3 echo times : 35, 144 and 288 ms. Spectra processing with Philipps software returns relative quantifications \> 7 ratios (choline/creatin, Glucose/creatin, glutamine/creatin, N-Acetyl aspartate/creatin, myoinositol/creatin, phsopholipids/creatin, lactate/creatin, acetate/creatin). With this experimental design, the additional time required for MRS acquisition is 10 min /patient."
219766384|NCT07211841|BIOLOGICAL|blood samples|Routine basic clinical and biological analyses will be collected during the project. In addition, 2 blood samples (5 mL each time) will be obtained at the time of inclusion (pre-therapeutic) and one month after completion of the initial therapeutic cycle (surgery + radiochemotherapy). The plasma samples will be used to measure fibrinogen, lactate and choline concentrations. In addition, a metabolomic study of plasma will be performed w
219766385|NCT07211542|DRUG|SHR-1905 Injection|SHR-1905 injection.
219766386|NCT07211542|DRUG|SHR-1905 Injection Blank Preparation|SHR-1905 injection blank preparation.
219766387|NCT07211711|DEVICE|Stabilizing occlusal splint|Maxillary stabilizing occlusal splint, made of acrylic with 2mm thickness in the posterior region. Installed and evaluated monthly for 4 months.
219766388|NCT07211711|DEVICE|placebo splint|Maxillary placebo non-occlusal splint, installed and evaluated monthly for 4 months.
219447431|NCT05718557|DRUG|PYX-106|Intravenous (IV) infusion
219447432|NCT04090710|DRUG|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
219766389|NCT07211763|OTHER|No Interventions|No intervention, solely data collection
219447433|NCT04090710|RADIATION|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
219447434|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
219447435|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
219586486|NCT03647683|OTHER|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
219586487|NCT03647683|OTHER|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
219586488|NCT00818129|DRUG|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
219586489|NCT00818129|DRUG|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
219586490|NCT03870477|DEVICE|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
219586491|NCT03906162|BEHAVIORAL|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
219586492|NCT03906162|BEHAVIORAL|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
219586493|NCT03258853|DEVICE|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
219586494|NCT03258853|OTHER|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
218837918|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
218837919|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
218837920|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
218837921|NCT00231686|BEHAVIORAL|Supervised aerobic training|
218837922|NCT00231686|BEHAVIORAL|Supervised strength training|
219196573|NCT06808724|PROCEDURE|implant with plasma activation|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Implant will undergo vacuum-plasma activation immediately before insertion (Plasma X Motion, Megagen, Gyeongbuk, South Korea) and then it will be inserted into the prepared osteotomy site. A transepithelial abutment will then be attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
219196574|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
219447436|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
219447437|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
219447438|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
219447439|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
219586495|NCT00402454|DRUG|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
219586496|NCT06284577|DIETARY_SUPPLEMENT|Multistrain Probiotic|Participants will recieve a multi-strain probiotic daily for 6 months
219586497|NCT06284577|DIETARY_SUPPLEMENT|Placebo - maltodextrin|Participants will recieve placebo/ maltodextri daily for 6 months
219586498|NCT03709459|DRUG|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
219586499|NCT06514690|OTHER|Sedation|Different degrees of intravenous sedation according to the Ramsay scale
219586500|NCT05285670|BEHAVIORAL|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
219586501|NCT04565613|DIETARY_SUPPLEMENT|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
219586502|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
219196575|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
219447440|NCT05507541|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219447441|NCT05507541|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
219447442|NCT05507541|DRUG|Ontorpacept|Given IV
219447443|NCT05507541|BIOLOGICAL|Pembrolizumab|Given IV
219447444|NCT05507541|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
219447445|NCT05507541|DRUG|Maplirpacept|Given IV
219447446|NCT05507541|PROCEDURE|Biopsy|Undergo tumor biopsy
219447447|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
219447448|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
219447449|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
219447450|NCT06245044|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
219586503|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
219766390|NCT07211893|OTHER|Send myopia-related health education message|Guardians of students in the intervention group will receive regular myopia-related health education messages, comprising text and images, from the MyopiaEd information repository via class-based WeChat groups. The intervention will last for 12 months.
219766391|NCT07212686|DRUG|Angiotensin-II|Angiotensin-II will be given per the titration protocol.
219766392|NCT07211932|DRUG|Tofacitinib|Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
219766393|NCT07213089|BIOLOGICAL|Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine|A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml will be given by intramuscularly at Day 0
218837923|NCT00231686|BEHAVIORAL|Unsupervised training|
218837924|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
219196576|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
219196577|NCT06653114|OTHER|Education in Chronic Musculoskeletal Pain|Improving Knowledge and Skills in Chronic Musculoskeletal Pain (Assessment and Management)
219447451|NCT06245044|BEHAVIORAL|Scenario #1|Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
219447452|NCT06245044|BEHAVIORAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
219447453|NCT06792461|BEHAVIORAL|Physical activity and nutritional behavioural intervention|"The ePro-Schools intervention includes two digital platforms designed to promote physical activity and healthy nutrition among adolescents:~1. The Intervention Platform, which provides interactive content for both students and PE teachers.~2. The Information Platform, which offers educational resources for students, teachers, and families.~The intervention content-currently being refined through a co-creation process-will feature engaging modules focused on physical activity and healthy eating. Adolescents will have access to more than 15 interactive modules, while PE teachers will benefit from 8 targeted pedagogical modules aimed at enhancing their lessons and encouraging greater student participation in physical activity.~Control group will have access to the information platform"
219447454|NCT05412693|DEVICE|Functional orthosis|See arm descriptions
219447455|NCT05412693|DEVICE|Cast immobilization|See arm descriptions
219447456|NCT03908463|DEVICE|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
219586504|NCT04995705|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
218837925|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
219447457|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
219447458|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
219447459|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
219447460|NCT05400811|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
219447461|NCT05400811|BIOLOGICAL|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
219447462|NCT06357429|OTHER|Cold Application|Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
219447463|NCT06488014|PROCEDURE|Erector spina plan block (ESP)|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
219447464|NCT06488014|PROCEDURE|Paravertebral block|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
219447465|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
219586505|NCT05341882|BEHAVIORAL|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
219586506|NCT05341882|BEHAVIORAL|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
219586507|NCT01725776|DRUG|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
219586508|NCT00105976|DRUG|MM-093|
219586509|NCT03810755|OTHER|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
218837926|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
218837927|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
219196578|NCT06653114|OTHER|Education in Communication Skills|Developing Communication Skills (Empathy, Motivational Interviewing, Shared Decision-making)
219586510|NCT05498402|DEVICE|i-gel ® device|Ventilations will be delivered through an i-gel ® device
219447466|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
219447467|NCT06442514|BEHAVIORAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
219447468|NCT06442514|OTHER|Treatment as Usual|Referral to the local smoking cessation VA clinic.
219447469|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
219447470|NCT03659708|PROCEDURE|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
219586511|NCT05498402|DEVICE|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
219196579|NCT06310161|DEVICE|Bright light|Bright light treatment will consist of using the Re-timer device 3 times per week during dialysis sessions for 4 weeks. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Participants will be instructed to use the device for 60 minutes at the beginning of each dialysis session.
219447471|NCT03659708|PROCEDURE|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
219447472|NCT00576147|DEVICE|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
219447474|NCT06645834|DEVICE|Smart MDI System|"The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal"
219447475|NCT03736590|BEHAVIORAL|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
219447476|NCT06012097|DRUG|Diclofenac gel|using diclofenac as a comparator
219447477|NCT06012097|DRUG|Aromatherapy gel|using Aromatherapy gel as an experimetnal treatment
219196580|NCT06310161|DEVICE|Dim Light|Dim light treatment will use non-light emitting glasses that look identical to Re-Timer for 4 weeks at each dialysis session following baseline assessments. Participants will use the device for 60 minutes at the beginning of their dialysis session.
219196581|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
219196582|NCT04513054|GENETIC|Blood collection for genetic analysis|Blood collection for genetic analysis
219196583|NCT06604208|DEVICE|Binaural Beats|"The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night."
219196584|NCT06604208|DEVICE|Placebo|Placebo
219196585|NCT06828016|OTHER|foot reflexology|foot reflexology, each session lasting 45 minutes to 1 hour
219196586|NCT06828016|OTHER|usual foot care|usual foot care, with each session lasting 45 minutes to 1 hour
219196587|NCT03866837|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
219196588|NCT03866837|DIETARY_SUPPLEMENT|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
219447478|NCT04693806|OTHER|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
219447479|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
219586512|NCT05865821|PROCEDURE|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
219586513|NCT05865821|OTHER|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
219447480|NCT02155712|DEVICE|Triathlon Knee|Cemented
218837928|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
218837929|NCT04461873|OTHER|Reiki|Reiki by touching
218837930|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
218837931|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
219586514|NCT03378050|BEHAVIORAL|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
219196589|NCT03866837|DIETARY_SUPPLEMENT|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
219447481|NCT05016037|BEHAVIORAL|Lexically based speech recast|"A child's spontaneous or elicited word production containing phonological errors is immediately followed with a clinician verbal model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as \[be\] would be the whole lexeme bake \[bek\] rather than production drill on \[k\] in isolation."
219447482|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219447483|NCT04527991|DRUG|Paclitaxel|Administered intravenously
219586515|NCT03378050|OTHER|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
219586516|NCT01709838|DRUG|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
219586517|NCT00295295|DEVICE|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
219586518|NCT00295295|OTHER|Standing|Standing 10 min/day
219586519|NCT04625426|DEVICE|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
219586520|NCT04625426|DEVICE|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
219586521|NCT04625426|DEVICE|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
219586522|NCT05813366|OTHER|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
219586523|NCT05813366|OTHER|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
219447484|NCT04527991|DRUG|Docetaxel|Administered intravenously
219447485|NCT04527991|DRUG|Vinflunine|Administered intravenously
219447486|NCT06576661|DEVICE|INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™.
219586524|NCT05813366|OTHER|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
219586525|NCT03775720|BEHAVIORAL|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
219766394|NCT07213089|BIOLOGICAL|Licensed DTaP|A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0
219586526|NCT04223531|DRUG|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
219586527|NCT00969631|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
219586528|NCT00969631|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
219586529|NCT00968786|DEVICE|Home monitoring|automated measuring devices for patients using at home
219766395|NCT07213115|PROCEDURE|Gastrectomy+ chemotherapy|
219766396|NCT07212829|DEVICE|Active tDCS|tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). For active tDCS, the current is ramped up for 30 seconds until the center electrode reaches a target intensity of 2 mA, then remains for 29 minutes before dropping for another 30s.
219766397|NCT07212829|BEHAVIORAL|Aerobic exercise|Participants will perform a moderate aerobic exercise (AE, known as aerobic power index), using a cycle er-gometer. The exercise intensity is moderate and individually tailored based on each participant's estimated maximum heart rate (HRmax), calculated using the validated formula: HRmax = 211 - (0.64 × age).
219766398|NCT07212829|DEVICE|Sham tDCS|"tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site).~In the sham condition, current is ramped up to 2.0 mA for 30 seconds and then ramped down to 0 mA, with the total session duration matched to the active condition. This procedure was used to mimic the tingling sensa-tions typically experienced at the beginning of stimulation. Participants received identical instructions, session timing, and room setup across conditions."
219196590|NCT03770416|DRUG|Ibrutinib|Given PO
219196591|NCT03770416|BIOLOGICAL|Nivolumab|Given IV
219766399|NCT07211412|OTHER|Cryotherapy|A cold (-5°C) cold-pack for 15 minutes every 24 hours for 5 days
219447487|NCT01095939|DRUG|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
219447488|NCT01095939|DRUG|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
219447489|NCT06027541|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
219447490|NCT05476380|DRUG|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
219447491|NCT02219516|DRUG|RDEA3170|
219447492|NCT06039384|DRUG|INCB099280|Administered as specified in the treatment arm description
219447493|NCT06039384|DRUG|adagrasib|Administered as specified in the treatment arm description
219447494|NCT05630118|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
219447495|NCT05630118|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
219447496|NCT00852098|PROCEDURE|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
219447497|NCT00852098|PROCEDURE|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
219447498|NCT05553587|DRUG|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
219447499|NCT00757081|DRUG|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
219447500|NCT03669744|OTHER|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
219447501|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
219447502|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
219447503|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
219447504|NCT01805674|DIETARY_SUPPLEMENT|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
219447505|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
219447506|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
219447507|NCT06261476|DIETARY_SUPPLEMENT|Ashwagandha (Withnia somnifera)|Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
219447508|NCT02380482|OTHER|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
219447509|NCT02380482|OTHER|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
219017239|NCT06016517|DRUG|Etanercept|50 mg subcutaneously weekly
219017240|NCT06016517|DRUG|Adalimumab|40 mg subcutaneously every 2 weeks
219017241|NCT06016517|DRUG|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
219017242|NCT06016517|DRUG|Tocilizumab|162 mg administered SQ every 2 weeks
219447510|NCT01249157|DEVICE|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
219447511|NCT04804904|DRUG|TQ-B3101|TQ-B3101 oral capsule
219447512|NCT02608125|DRUG|PRN1371|
219447513|NCT00396825|BEHAVIORAL|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
219447514|NCT03949127|OTHER|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
219447515|NCT00062647|DRUG|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
219447516|NCT00062647|DRUG|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
219447517|NCT00904176|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
219447518|NCT00904176|DRUG|Warfarin|Tablets, Oral, 25 mg, Single Dose
219447519|NCT00904176|DRUG|Digoxin|Tablets, Oral, 0.25, Single Dose
219447520|NCT05321693|DEVICE|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
219447521|NCT05376189|DIETARY_SUPPLEMENT|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
219447522|NCT05376189|DIETARY_SUPPLEMENT|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
219447523|NCT05376189|DIETARY_SUPPLEMENT|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
219447524|NCT05376189|DRUG|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
219586530|NCT05061186|OTHER|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
219586531|NCT05061186|OTHER|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
219447525|NCT01711580|OTHER|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
219447526|NCT01711580|OTHER|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
219447527|NCT01711580|OTHER|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
219447528|NCT01711580|OTHER|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
219447529|NCT01711580|OTHER|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
219447530|NCT01711580|OTHER|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
219447531|NCT01711580|OTHER|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
219447532|NCT01711580|OTHER|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
219447533|NCT06225804|DRUG|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
219447534|NCT02392468|DRUG|Placebo matching BI 409306 25 mg|Film-coated tablet
219586532|NCT01391741|OTHER|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
218837932|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
219447535|NCT02392468|DRUG|Placebo matching BI 409306 50 mg|Film-coated tablet
219447536|NCT02392468|DRUG|BI 409306 25 mg|Film-coated tablet
219447537|NCT02392468|DRUG|BI 409306 50 mg|Film-coated tablet
219447538|NCT06195904|OTHER|NA (No intervention)|NA (No intervention)
219447539|NCT02106104|DRUG|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
219447540|NCT02106104|DRUG|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
219447541|NCT01012804|GENETIC|western blotting|
219447542|NCT01012804|OTHER|immunohistochemistry staining method|
219447543|NCT01012804|OTHER|laboratory biomarker analysis|
219447544|NCT04516824|PROCEDURE|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
219447545|NCT02070341|DRUG|Polyethylene Glycol|
219447546|NCT02070341|DRUG|Picosalax|
219447547|NCT03081572|DIAGNOSTIC_TEST|Platelet aggregation|Platelet aggregation
219447548|NCT02353676|DRUG|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
219447549|NCT02353676|OTHER|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
219447550|NCT04509401|DRUG|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
219447551|NCT04509401|DRUG|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
219447552|NCT02005510|BEHAVIORAL|Mailed in-home high-risk HPV testing kit|
219447553|NCT02005510|OTHER|Usual care|
219447554|NCT03185312|DIAGNOSTIC_TEST|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
219447555|NCT01300949|DIAGNOSTIC_TEST|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
219447556|NCT01300949|DIAGNOSTIC_TEST|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
219447557|NCT05083949|DRUG|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
219447558|NCT05083949|DRUG|Empagliflozin|empagliflozin 10mg (R1)
218837933|NCT01834950|OTHER|Blood test|
218837934|NCT01861691|PROCEDURE|Open surgery|Conventional technique
218837935|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
218837936|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
218837937|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
218837938|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
219447559|NCT05083949|DRUG|Glifage®|Glifage® 850mg (R2)
219447560|NCT02049788|BEHAVIORAL|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
219447561|NCT02049788|BEHAVIORAL|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
219447562|NCT00261794|BEHAVIORAL|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
219447563|NCT00261794|BEHAVIORAL|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
219447564|NCT01160263|DRUG|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
219447565|NCT00776334|DRUG|Fosinopril 40mg Tablets|
219447566|NCT00087386|DRUG|tanespimycin|Given IV
219447567|NCT00087386|OTHER|laboratory biomarker analysis|Correlative studies
219447568|NCT01678560|DEVICE|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
219447569|NCT01678560|DEVICE|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
219586533|NCT01391741|OTHER|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
219586534|NCT01712737|OTHER|Dietary intervention|
218837939|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
218837940|NCT05634694|OTHER|No interventions.|No interventions.
219447570|NCT03437629|PROCEDURE|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
219447571|NCT03437629|PROCEDURE|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
219586535|NCT04452253|DIETARY_SUPPLEMENT|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
219586536|NCT04452253|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
219586537|NCT04452253|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
218837941|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
218837942|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
218837943|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
218837944|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
218837945|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
218837946|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
218837947|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
218837948|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
219017243|NCT06059820|OTHER|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
219447572|NCT00925067|PROCEDURE|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
219447573|NCT00925067|DEVICE|lightweight TiMesh|
219447574|NCT00925067|DEVICE|lightweight VyproII|
219586538|NCT04452253|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
219766400|NCT07211412|OTHER|Eccentric exercise-induced muscle damage|3 sets of 15 repetitions of eccentric contractions at 80% of 1RM. This is to induced a controlled muscle damage in 2 of the 3 arms.
219766401|NCT07213141|OTHER|Data extraction|Data extraction from medical records
219766402|NCT07213245|OTHER|Meal high in energy density, high in ultra-processed food|Meal high in energy density, high in ultra-processed food
219766403|NCT07213245|OTHER|Meal high in energy density, low in ultra-processed food|Meal high in energy density, low in ultra-processed food
218837949|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
218837950|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
218837951|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
218837952|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
218837953|NCT00091741|DRUG|Etanercept (Enbrel)|
218837954|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
218837955|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
218837956|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
218837957|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
218837958|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
218837959|NCT01094977|DRUG|Saline Placebo|
219017244|NCT06059820|PROCEDURE|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
219017245|NCT05247177|DRUG|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
219017246|NCT05247177|DRUG|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
219017247|NCT00401141|PROCEDURE|Blood samples|
219017248|NCT04425434|OTHER|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
219196592|NCT06741007|PROCEDURE|Retroperitoneal pelvic lymphatic and uterine vessel dissection|ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.
219447575|NCT00925067|DEVICE|Heavyweight Marlex|
219447576|NCT04180917|OTHER|Survey|survey
219447577|NCT04904341|DRUG|Cerebrolysin|neuroprotection treatment
218837960|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
219447578|NCT03675919|DEVICE|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
219447579|NCT03675919|DEVICE|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
219447580|NCT03675919|DEVICE|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
219447581|NCT03675919|OTHER|Access to the online portal|self-monitoring of health parameters
219447582|NCT03675919|OTHER|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
219447583|NCT02685618|DRUG|Iloprost|
219447584|NCT02685618|DRUG|Saline|
219447585|NCT02685618|DEVICE|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
219447586|NCT02685618|DEVICE|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
219447587|NCT03189810|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
219447588|NCT03189810|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
219447589|NCT03189810|BEHAVIORAL|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
219586539|NCT05094245|PROCEDURE|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
219586540|NCT05899751|DRUG|High-dose methotrexate|High-dose methotrexate
219586541|NCT05899751|DRUG|Glucarpidase|Glucarpidase
219586542|NCT01573169|DRUG|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
219586543|NCT01573169|OTHER|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
219586544|NCT02439931|BEHAVIORAL|Remote psychosocial intervention|
219766404|NCT07213245|OTHER|Meal low in energy density, high in ultra-processed food|Meal low in energy density, high in ultra-processed food
219766405|NCT07213245|OTHER|Meal low in energy density, low in ultra-processed food|Meal low in energy density, low in ultra-processed food
219447590|NCT05540210|DEVICE|measurement of PSP|one or two blood samples
219447591|NCT04173390|DRUG|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
219447592|NCT04173390|DRUG|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
219447593|NCT05840523|OTHER|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
219447594|NCT05840523|OTHER|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
219017251|NCT05826184|BEHAVIORAL|Time restircted eating|8 hour time restricted eating alone
219017252|NCT05826184|BEHAVIORAL|Time restricted eating + prebiotic|8 hour TRE with a prebiotic supplement
219766406|NCT07212504|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 2-5 consecutive days.
219447595|NCT05522855|DEVICE|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
219447596|NCT01429155|GENETIC|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
219447597|NCT01835314|DRUG|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
219447598|NCT02545452|DRUG|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
219447599|NCT02545452|DRUG|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
219447600|NCT02545452|DRUG|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
219447601|NCT02545452|DRUG|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
219447602|NCT02545452|OTHER|Tampon|
219447603|NCT03122652|DRUG|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
219447604|NCT03122652|DRUG|Placebo Oral Tablet|1 tablet once a day
219447605|NCT01126294|DIETARY_SUPPLEMENT|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
219586545|NCT00896155|DRUG|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
219766407|NCT07212504|DEVICE|Sham Brainsway H1-Coil Deep TMS System|In addition to the active H7-coil, a sham coil is included in the H1-coil helmet.The sham treatment will be administered using the H1-coil helmet 6-8 times a day for 2-5 consecutive days.
219766408|NCT07212478|OTHER|PFMT|O PFMT consistirá em 10 contrações voluntárias máximas que devem ser mantidas por pelo menos 6 segundos. Os participantes serão incentivados a sustentar a contração máxima por um tempo maior a cada semana. O intervalo entre as contrações será de segundos. Os participantes realizarão 4 séries de 10 contrações e, ao final de cada série de 10 contrações, serão realizadas cinco contrações rápidas. Cada série será realizada em uma posição: deitado em decúbito lateral; sentado; de quatro apoios e em pé.
218837961|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
218837962|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
219447606|NCT01126294|DIETARY_SUPPLEMENT|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
219447607|NCT01126294|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
219586546|NCT00896155|RADIATION|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
219586547|NCT01949961|OTHER|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
219586548|NCT01949961|OTHER|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
219447608|NCT00533351|DRUG|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
219447609|NCT00533351|DRUG|placebo|placebo 50 mg capsules three-times daily for 2 weeks
219766409|NCT07212478|OTHER|Pilates exercises|The Pilates group will perform 10 solo exercises, containing stretching and strengthening for the main muscle groups, with a single series of 10 repetitions.
219447610|NCT04509557|DRUG|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
219447611|NCT00628342|DRUG|Esomeprazole|20mg Oral tablet once daily
219447612|NCT00628342|DRUG|Esomeprazole|40mg Oral tablet once daily
219447613|NCT00628342|DRUG|Placebo|Oral once daily
219447614|NCT03362489|PROCEDURE|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
219447615|NCT03362489|PROCEDURE|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
219447616|NCT06427148|OTHER|"The biofeedback-assisted VR game Golden Breath"|"The biofeedback-assisted VR game Golden Breath that we presented in this study was designed to meet children's healthcare needs quickly and efficiently while reducing pain and fear during medical procedures in the pediatric population. Golden Breath u"
219447617|NCT04298749|DRUG|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
219447618|NCT04298749|DRUG|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
219447619|NCT04298749|DRUG|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
219447620|NCT05578313|DRUG|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
219447621|NCT02823236|DRUG|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
219447622|NCT02823236|DRUG|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
219447623|NCT02823236|DRUG|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
219447624|NCT01963936|DEVICE|Supreme LMA|
219447625|NCT01963936|DEVICE|Facial mask|
219447626|NCT05798819|DRUG|GLS-010|IV infusion
219447627|NCT05798819|DRUG|Placebo|IV infusion
219447628|NCT05798819|DRUG|paclitaxel|IV infusion
219447629|NCT05798819|DRUG|cisplatin|IV infusion
219447630|NCT05798819|DRUG|carboplatin|IV infusion
219447631|NCT05798819|DRUG|bevacizumab|IV infusion
219586549|NCT06928792|OTHER|Experimental interventional group A, (MET).|10-minute hot pack application, followed by MET on the Quadratus Lumborum (3 repetitions with a 7-second hold). Flexibility exercises include William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times) and static stretching of the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises comprise isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The intervention will be performed once daily, consisting of 3 sets per session, continued for 4 weeks to enhance flexibility, core stability, and muscular balance, ultimately contributing to pain relief and improved functional mobility in CLBP patients
219196593|NCT05422885|DRUG|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
219447632|NCT03638713|BEHAVIORAL|colonoscopy first|Received water exchange colonoscopy followed by EGD
219447633|NCT03638713|BEHAVIORAL|EGD first|Received EGD followed by water exchange colonoscopy
219447634|NCT02410590|DRUG|Rocuronium|
219447635|NCT02410590|DRUG|Sugammadex|
219447636|NCT02410590|DRUG|Cisatracurium|
219586550|NCT06928792|OTHER|Control: group B (conventional intervention exercises)|10-minute hot pack application, followed by William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times). Flexibility exercises consist of static stretching for the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises include isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The protocol will be performed once daily, with 3 sets per session, continued for 4 weeks to improve flexibility, core stability, and pain management in CLBP patients.
219447637|NCT02410590|DRUG|Neostigmine/Atropine|
219447638|NCT02410590|DRUG|Succinylcholine|
219447639|NCT06455384|BEHAVIORAL|Genetics Navigator|The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
219447640|NCT06455384|BEHAVIORAL|Standard Care with Genetics Professionals|Standard care for the delivery of genetic services, including receiving genetic counselling and test results
219447641|NCT02863861|DRUG|Dexmedetomidine-ketamine|
219447642|NCT02863861|DRUG|propofol-ketamine|
219447643|NCT04434261|DIAGNOSTIC_TEST|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
219447644|NCT00691977|RADIATION|Radiation Therapy followed by prostatectomy|Radiation Therapy
219447645|NCT03382327|PROCEDURE|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
219447646|NCT02773472|DEVICE|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
219447647|NCT02773472|DRUG|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
219447648|NCT01611922|OTHER|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
219447649|NCT01611922|DEVICE|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
219447650|NCT05688540|OTHER|e book|e book
219447651|NCT05688540|OTHER|traditional education booklet|traditional education booklet
219447652|NCT00056550|BIOLOGICAL|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
219447653|NCT03243955|DEVICE|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
218837963|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
218837964|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
218837965|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
218837966|NCT03517371|OTHER|mHealth delivered exercise program|"Participants in the mobile health condition have up to 8 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
218837967|NCT03517371|OTHER|Exercise only|Participants in the control group have up to 8 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
218837968|NCT05358886|DRUG|BPN14770/ zatolmilast|25mg BID BPN14770
218837969|NCT05358886|DRUG|Placebo|Placebo
218837970|NCT06544785|DRUG|Zanubrutinib Oral Product|"Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day."
219766410|NCT07213284|BEHAVIORAL|MI MOM App|Participants enrolled in the Michigan Healthy Moms (MI MOM) app will receive initial interactive app content followed by regular text messages with information related to pregnancy health, designed to increase patient awareness of warning signs, help them with self-advocacy, and otherwise improve health in pregnancy and postpartum. They will also have online live chat (text) access to a community healthcare worker who can assist them in enrolling in services to improve their health. They will also have the option of enrolling support persons (partners, family members, close friends, etc.) in the MI MOM app to receive similar information designed to help them support the pregnant participant. Providers at intervention sites will also receive information designed to improve their awareness of techniques for preventing maternal morbidity and mortality.
219766411|NCT07212972|OTHER|Hemodialysis or peritoneal Dialysis|Hemodialysis or peritoneal Dialysis
219766412|NCT07211529|PROCEDURE|Paravertebral Block (PVB)|Participants in this arm will receive a paravertebral nerve block (PVB) performed intraoperatively under ultrasound guidance prior to the thoracic surgical procedure. The block will target the relevant thoracic vertebral levels corresponding to the surgical site. Standard local anesthetic agents will be administered according to institutional protocols. This intervention aims to provide perioperative analgesia, reduce postoperative pain, and potentially decrease the incidence of postoperative complications. All participants will also receive standard intraoperative monitoring and anesthesia management as per routine clinical practice.
219766413|NCT07211659|BIOLOGICAL|THEO-260|Oncolytic virus
219586551|NCT00923000|DRUG|Nalbuphine|Nalbuphine 10mg with oral administration
219586552|NCT00923000|DRUG|Morphine|Morphine 10mg with oral administration
219586553|NCT00923000|DRUG|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
219586554|NCT00923000|DRUG|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
219586555|NCT00923000|DRUG|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
219766414|NCT07211776|DRUG|ZL-1109 (VRDN-003)|ZL-1109 subcutaneous injection
219766415|NCT07211776|DRUG|Placebo|Matching placebo subcutaneous injection
218837971|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
218837972|NCT05486884|PROCEDURE|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
218837973|NCT05486884|PROCEDURE|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
219196594|NCT05422885|DRUG|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
219196595|NCT04619173|OTHER|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
219586556|NCT00084448|DRUG|celecoxib|
219586557|NCT00084448|DRUG|paclitaxel|
219586558|NCT01943721|DRUG|VISION5 Product|
219586559|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
219586560|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
219586561|NCT03145077|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
219586562|NCT03145077|OTHER|Questionnaire Administration|Ancillary studies
219586563|NCT06488001|DRUG|pantoprazole|Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
219586564|NCT06488001|DRUG|Placebo|Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
219586565|NCT04810871|PROCEDURE|Brain Surgery|Undergo surgery
219586566|NCT06959407|DRUG|oral dexamethasone|Patients in group A will receive oral dexamethasone which will be administered at 0.6mg/kg as single dose
218837974|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
218837975|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
218837976|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219447654|NCT03243955|DEVICE|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
219447655|NCT02826655|DEVICE|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
218837977|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
219447656|NCT02636738|DEVICE|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
219447657|NCT01376895|BEHAVIORAL|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
219196596|NCT04619173|OTHER|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
218837978|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
218837979|NCT06378918|PROCEDURE|puncture|Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
219196597|NCT06854679|RADIATION|Radiotherapy dose escalation|All patients will receive 45Gy in 25# to mesorectum and elective nodal volumes, and 52.5Gy in 25# as standard to primary gross tumour volume which includes primary tumour, visible nodal disease and extramural vascular invasion if present. Boost dose escalation to a maximum of 60Gy will be delivered to patients with ongoing visible disease from week 2 of treatment onwards.
219447658|NCT01376895|BEHAVIORAL|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
219586567|NCT06959407|DRUG|intramuscular dexamethasone|Patients in group B will receive intramuscular dexamethasone which will be administered in 0.6mg/kg strength as intra-gluteal injection as single dose
219586568|NCT02081209|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219586569|NCT06633419|DRUG|Opevesostat|Administered via oral tablet per dosing regimen.
219586570|NCT06633419|DRUG|Prednisone|Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
219447659|NCT04781049|PROCEDURE|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
219586571|NCT06633419|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
219766416|NCT07212855|PROCEDURE|Professional oral hygiene with glycine powder|Professional removal of hard and soft deposits using titanium curettes, spongy interdental floss, and air-polishing with glycine powder. The glycine powder used had a particle size of 25 μm and was applied using a supragingival nozzle positioned 3 mm from the prosthetic restoration, with particular attention given to the areas in direct contact with the mucosa.
219586572|NCT06633419|DRUG|Carbamazepine|Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
219586573|NCT05768178|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960 mg orally (4 tablets of 240 mg) on a twice daily schedule throughout a 28-day cycle. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
218837980|NCT06378918|PROCEDURE|incision of the abscess|This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
218837981|NCT04283656|DRUG|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
218837982|NCT04283656|DRUG|Spironolactone 100mg|200mg orally for two doses, twice-daily
219447660|NCT04781049|PROCEDURE|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
219447661|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
219447662|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
219447663|NCT05977803|RADIATION|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~* The CEST sequence~* The ASL infusion sequence~* The IVIM sequence"
219447664|NCT03650036|DRUG|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
219447665|NCT03650036|DRUG|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
219447666|NCT00322387|DRUG|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
219447667|NCT02518542|PROCEDURE|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
219447668|NCT02518542|PROCEDURE|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
219447669|NCT02518542|PROCEDURE|Endoscopic intervention C|Endoscopic balloon dilatation
219447670|NCT02518542|PROCEDURE|Laparoscopic Surgery|Laparoscopic Heller myotomy
218837983|NCT04283656|DRUG|Estradiol 2mg|4mg orally for two doses, twice-daily
218837984|NCT04283656|OTHER|Placebo|Placebo for one dose, daily
219447671|NCT05628987|OTHER|no intervention|Observational studies, no intervention
219447672|NCT01609738|DEVICE|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
219447673|NCT06248242|DRUG|Edaravone dexborneol|edaravone 10 mg and dexborneol 2.5 mg twice daily
219586574|NCT05768178|DRUG|Cobimetinib|Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
219586575|NCT00946816|BEHAVIORAL|Nutritional Intervention|Nutritional Intervention
219586576|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
218837985|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
218837986|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
219447674|NCT00674687|DRUG|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
219447675|NCT00674687|DRUG|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
219447676|NCT01171742|PROCEDURE|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
219447677|NCT00767299|DRUG|arzoxifene|20 mg, QD, PO,24 weeks
219447678|NCT00767299|DRUG|Placebo|QD, PO, 24 weeks
219447679|NCT03229304|OTHER||
219447680|NCT01086449|BIOLOGICAL|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
219447681|NCT01151176|DRUG|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
219766417|NCT07212855|DEVICE|Domiciliary oral hygiene with angle toothbrush|Patients were motivated and instructed to use an angled-handle toothbrush (Specialist Implant, Curasept S.p.A., Saronno, Italy), in addition to a standard toothbrush and implant floss. The specific design of the angled handle was intended to facilitate access to areas that are difficult to clean. In patients rehabilitated with full-arch implant-supported prostheses, these areas typically include distal cantilevers and surfaces in direct contact with the mucosa.
218837987|NCT04896047|PROCEDURE|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
218837988|NCT05279040|DRUG|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
218837989|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
218837990|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
219447682|NCT01151176|DRUG|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U"
219447683|NCT01924195|DRUG|Anlotinib|Anlotinib QD po.
219447684|NCT01924195|DRUG|Placebo capsule|Placebo QD po.
219447685|NCT05832060|DEVICE|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
219447686|NCT05832060|DEVICE|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
219586577|NCT06556251|DEVICE|PIPPEP App|"Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan)."
219586578|NCT06340893|BEHAVIORAL|Exercise|Participants will participate in cardiovascular, agility, balance, strength and coordination training.
219586579|NCT06340893|BEHAVIORAL|Restful Play|This group will engage in restful play activities such as coloring and playing with legos.
219586580|NCT04060017|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
219586581|NCT04060017|OTHER|Placebo|Placebo
219586582|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
219586583|NCT04702542|DRUG|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
219586584|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
219766418|NCT07208929|RADIATION|MRI|Brain and Spinal Cord MRI
219766419|NCT07211802|DRUG|Sotagliflozin Low Dose|200 mg Sotagliflozin, once daily for 6 weeks
218837991|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
219447687|NCT05832060|DEVICE|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
219586585|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
219766420|NCT07211802|DRUG|Sotagliflozin High Dose|400 mg Sotagliflozin, once daily for 6 weeks
219766421|NCT07211802|DEVICE|Dual Continuous Glucose and Ketone Monitor|Abbott Libre X dual continuous glucose and ketone monitor (DGK) device.
219766422|NCT07211633|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
219766423|NCT07211633|BIOLOGICAL|Ublituximab|Administered as an SC injection.
219766424|NCT07212452|DRUG|Tranexamic Acid (TXA)|In this study we are comparing the effect of tranexamic acid on hemoptysis when given through IV route and nebulization
219766425|NCT07212946|DRUG|Ayahuasca|Ayahuasca (oral)
219766426|NCT07212946|DRUG|Esketamine|oral esketamine (2 mg/kg)
219766427|NCT07207447|PROCEDURE|Improving the stability and re-fixation with different modalities|Improving the stability and re-fixation with different modalities such as exchange plate with longer plate, intramedullary nailing, exchange nailing with larger diameter, plating over nail or dynamization of intramedullary nail.
218837992|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
219447688|NCT00348491|DRUG|Lumiracoxib|
219447689|NCT05433974|BIOLOGICAL|Blood sample collection|Blood sample collection : 2 X 6 mL
219447690|NCT05255627|OTHER|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
219447691|NCT05255627|OTHER|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
219447692|NCT05021380|OTHER|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
219447693|NCT04110444|DRUG|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
219447694|NCT02092168|DRUG|BIA 9-1067|
219447695|NCT05620173|DEVICE|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
219447696|NCT05620173|DEVICE|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
219447697|NCT05125991|PROCEDURE|Prepectoral reconstruction|Prepectoral breast reconstruction
219766428|NCT07207447|PROCEDURE|Re-fixation with biological stimulation|Re-fixation with biological stimulation such as bone grafting, either with plate and bone graft, plate over nail and graft, or with external fixation with LRS or Ilizarov and grafting in one stage or two stages.
219766429|NCT07207447|PROCEDURE|complex care with non-union resection and bone reconstruction|complex care with non-union resection and bone reconstruction, including resection of the non-union and dealing with the defect with bone transport, either direct transport or staged with cement spacer and later bone transport, Masquelet technique or acute compression and lengthening with another osteotomy.
219447698|NCT05125991|PROCEDURE|Submuscolar reconstruction|Submuscolar breast reconstruction
219447699|NCT03930667|PROCEDURE|clips|
219766430|NCT07207447|PROCEDURE|Amputation|Amputation with consideration of prosthesis.
218837993|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
219447700|NCT03930667|PROCEDURE|knotting|
219447701|NCT06262672|OTHER|Evaluation form|This form is a form of demographic information, questions that question the habits of COVİD-19 era, and evaluation scales.
219447702|NCT00195624|BIOLOGICAL|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
219447703|NCT00195624|DRUG|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
219447704|NCT02803814|PROCEDURE|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
219766431|NCT07208370|OTHER|clinical assessment|standraized clinical evaluation to assess disease sevirity and progration
219447705|NCT02803814|PROCEDURE|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
219447706|NCT00345514|BEHAVIORAL|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
219447707|NCT00345514|BEHAVIORAL|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
219447708|NCT00723853|BEHAVIORAL|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
219447709|NCT00723853|BEHAVIORAL|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
219447710|NCT02195947|DRUG|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
219447711|NCT04673461|DRUG|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
219766432|NCT07212257|PROCEDURE|Gait analysis with surface electromyography (EMG)|Each participant undergoes a standardized gait analysis session. After skin preparation, 28 surface electrodes are placed bilaterally on seven lower limb muscles according to SENIAM recommendations. The child completes 10 walking trials (five round trips of 10 meters) at a comfortable, self-selected speed while being recorded by synchronized cameras. Data collected include EMG signals and video recordings. This procedure is non-invasive and performed in a single session lasting approximately one hour
219586586|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
218837994|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
218837995|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
218837996|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
218837997|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
218837998|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
218837999|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
218838000|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
218838001|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
218838002|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
218838003|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
219447712|NCT04673461|DRUG|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
219447713|NCT04673461|DRUG|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
219447714|NCT00000345|DRUG|Lofexidine|
219586587|NCT03672487|DRUG|Benznidazole|Benznidazole tablet
219586588|NCT03672487|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
219586589|NCT06636240|DIETARY_SUPPLEMENT|Mulberry fruit juice|Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including topical Mometasone furoate cream 0.1%
219586590|NCT06636240|OTHER|Mometasone furoate 0.1% cream|Standard therapy for atopic dermatitis including Mometasone furoate cream 0.1%
218838004|NCT00442494|DRUG|intravenous hydrocortisone|
218838005|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
218838006|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
218838007|NCT00935493|DRUG|Placebo|Placebo po qhs
218838008|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
218838009|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
218838010|NCT01060748|BIOLOGICAL|Placebo|Placebo
218838011|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
218838012|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
218838013|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
218838014|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
218838015|NCT03715140|DRUG|Placebo|Placebo
218838016|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
218838017|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
219447715|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
218838018|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
218838019|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
218838020|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
218838021|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
218838022|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
218838023|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
218838024|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
218838025|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
219447716|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
219447717|NCT04745247|PROCEDURE|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
219447718|NCT00090766|DRUG|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
219447719|NCT02278380|OTHER|Low GI Standard Breakfast|Low GI Standard Breakfast
218838026|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
218838027|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
218838028|NCT00083954|DRUG|Quetiapine Fumarate|
218838029|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
218838030|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
218838031|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
218838032|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
219447720|NCT02278380|OTHER|Medium GI Standard Breakfast|Medium GI Standard Breakfast
218838033|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
218838034|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
218838035|NCT00140153|DRUG|testosterone gel (Androgel)|
218838036|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
218838037|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
218838038|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
218838039|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
218838040|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
218838041|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
218838042|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
218838043|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
218838044|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
218838045|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
219017255|NCT06963086|BEHAVIORAL|Eating disorder prevention program (the Body Project)|The Body Project is an eating disorder prevention program for girls and young women aged 15-22 years old. The program will be delivered in groups of 6-10 youth by peer mentors, and in two formats: in-person and virtual. We are assessing two versions of the program - a 6-session version (6 weekly 45-minute sessions) and a 2-session version (2 weekly 2-hour sessions). Participants will be divided into 4 cohorts: high school in-person, university in-person, high school-aged (15-18 years) virtual, and university-aged (19-22 years) virtual. The high school in-person groups will do the 6-session version, and the university in-person groups as well as all virtual groups will do 2 weekly 2-hour sessions. Both versions cover similar content, and use a scripted intervention manual.
219447721|NCT02278380|OTHER|Enfamama A+|Nutritional pregnant milk supplement
218838046|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
218838047|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
218838048|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
219447722|NCT02278380|OTHER|Glucerna Triple Care|Nutritional product for diabetics
219447723|NCT02278380|OTHER|Dumex Precima|Pregnant and lactation women milk powder
219586591|NCT04911738|OTHER|Virtual Reality , immersion in a virtual titlted room|The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
219586592|NCT06770712|OTHER|Mirror therapy|The patients were asked to sit in front of a table at an appropriate height and rest their arms on the table. A mirror was placed between both arms. The mirror was positioned so that the reflection of the healthy extremity overlapped with the paralytic extremity. In this way, the movements of the healthy upper extremity were viewed through the mirror, creating a visual movement illusion for the hemiplegic upper extremity. During the mirror therapy, exercises including forearm supination-pronation, wrist flexion-extension, finger flexion-extension, finger counting, grasping and releasing a cup, grasping and releasing a ball, and writing with a pen were performed. First, 30 minutes of bilateral TENS therapy were applied, followed by 30 minutes of mirror therapy
219586593|NCT06770712|DEVICE|Transcutaneous Electrical Nerve Stimulation|Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The intensity of the current was adjusted to a level that produced a visible, comfortable muscle contraction. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
219586594|NCT05635383|OTHER|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
219586595|NCT03226028|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
219586596|NCT04899388|PROCEDURE|Pericapsular Nerve Block|regional anaesthia
219586597|NCT04899388|PROCEDURE|Lumbar Erector Spinae Plane Block|regional anaesthia
219766433|NCT07213154|PROCEDURE|Quantitative Oblique Back-Illumination Microscopy|Undergo qOBM
219766434|NCT07213154|RADIATION|Radiation Therapy|Undergo SOC RT
219017260|NCT04502030|BIOLOGICAL|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
219017261|NCT04502030|OTHER|Placebo|Placebo
219447724|NCT02278380|OTHER|Diasip|Nutritional drinks for diabetics
219447725|NCT02278380|OTHER|Test product|Test product not patented yet
219766435|NCT07211997|DEVICE|FebriDx|Bacterial/Non-Bacterial Point-of-Care Assay that detects the presence of MxA and CRP in fingerstick blood
219766436|NCT07211750|OTHER|integrated care intervention tailored to the needs of older adults leaving at home with mood disorders and multimorbidity in Leuven|The six guiding principles are translated into practice through a structured six-step care model. Each step operationalizes one or more principles, ensuring that the model is consistently applied across patient trajectories. The program takes 12 months, with flexible contacts depending on patient's needs.
219766437|NCT07211620|OTHER|Kinetics|Initiation of the AB therapy is recommended for the clinician if PCT ≥ 0.5 ng/ml and PCT elevation ≥100% from the previous day's value.
219766438|NCT07211620|OTHER|Absolute|According to the antibiotic protocol, starting ABs is recommended if PCT ≥ 0.5 ng/ml.
219447726|NCT00944957|DRUG|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
219447727|NCT00944957|DRUG|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
219447728|NCT00944957|DRUG|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
219447729|NCT00944957|DRUG|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
219447730|NCT02031757|OTHER|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
219447731|NCT02031757|OTHER|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
218838049|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
219447732|NCT02482792|OTHER|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
219447733|NCT02482792|OTHER|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
219447734|NCT00920946|DRUG|Dimebon|20 mg Dimebon orally TID
219447735|NCT00920946|OTHER|Placebo|Orally TID
219447736|NCT06152692|DEVICE|SHAM Continuous positive airway pressure|Placebo treatment
219447737|NCT06152692|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
219447738|NCT00034892|DRUG|Olanzapine, risperidone|
219447739|NCT00396422|DRUG|RWJ-445380|
219586598|NCT04899388|DRUG|Fentanyl|intavenous
219586599|NCT04759053|PROCEDURE|FNB|Fine needle aspiration from the nodules
219586600|NCT04759053|PROCEDURE|Core biopsy|Core biopsy from thyroid nodules
219586601|NCT01539135|DRUG|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
219586602|NCT03521466|BEHAVIORAL|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
218838050|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
218838051|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
219447740|NCT04403620|RADIATION|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
219447741|NCT02708004|DRUG|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
219447742|NCT02708004|OTHER|Placebo|Matching active drug
219447743|NCT00804986|DRUG|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
219447744|NCT00804986|DRUG|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
219447745|NCT04304404|BEHAVIORAL|Breast Cancer Risk Reduction Program (BrCaRRP)|Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
219447746|NCT03296072|DRUG|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
219447747|NCT03296072|DRUG|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
219447748|NCT03296072|DRUG|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
219586603|NCT04170751|DRUG|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
219586604|NCT04170751|DRUG|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
218838052|NCT00335738|DRUG|carboplatin|Given IV
218838053|NCT00335738|DRUG|etoposide|Given IV
218838054|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
218838055|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
219447749|NCT00654368|BIOLOGICAL|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
219766439|NCT07211672|DEVICE|Multichannel functionnal electrical stimulation|"The participants completed 24 gait rehabilitation sessions over the course of 8 to 12 weeks. Each session lasted between 30 minutes and 1 hour. A minimum of 2 days seperated two consecutive sessions. The number of sessions was used for standardization of the protocol instead of duration of treatment.~Four evaluations were completed throughout the protocol. Baseline evaluation(V1) was completed between 2 and 7 days before the first rehabilitation session. Intermediate evaluation(V2) was completed between 2 and 7 days after the 12th rehabilitation session, in other words 4 to 6 weeks after the baseline evaluation (V1) . Post-treatment evaluation(V3) was completed between 2 and 7 days after the 24th rehabilitation session, in other words 8 to 12 weeks after the baseline evaluation (V1). Follow-up evaluation(V4) was completed 2 months(60 days) after the 24th rehabilitation session, in other words 16 to 20 weeks after the baseline evaluation (V1)."
219766440|NCT07213388|BEHAVIORAL|VRPA|Effects of virtual reality physical activity on outcomes
219766441|NCT07213388|BEHAVIORAL|Treadmill|Effects of treadmill walking with music on outcomes
219766442|NCT07213388|BEHAVIORAL|Control|Effects of music while sitting on outcomes
219766443|NCT07212205|OTHER|Visual & Auditory Cueing Walker|"Intervention Name:~Visual \& Auditory Cueing Walker~Other Intervention Names (varsa):~Cueing Walker Walker with Visual \& Auditory Cues~Intervention Description:~Participants in this arm were assessed under two within-subject conditions: walking on a 7-meter path without cues (control condition) and walking on the same path using a visual and auditory cueing walker (intervention condition). Each participant completed both conditions in a single session. Pre- and post-walking evaluations were conducted for walking speed (Timed Up and Go Test), fall risk (Tinetti Balance and Gait Assessment), and gait adaptation (Dynamic Gait Index). The 'no cues' condition represents a repeated-measures control within the same arm. Participants were included based on the presence of freezing of gait.~Planned Enrollment: 18"
219766444|NCT07212777|PROCEDURE|Medial Open Wedge Hight Tibial Osteotomy using patient-specific instrumentation|Medial Open Wedge Hight Tibial Osteotomy using 3D printed patient-specific instrumentation as a guide for the osteotomy
219196598|NCT06855303|OTHER|Muscle Energy Teqnique using post isometric relaxation (PIR) principle|The contralateral leg may be either flexed or may lie straight on the plinth. The affected leg will be flexed at both the hip and knee joints, and then slowly straightened by the therapist until the restriction barrier is identified. The limb will be moved a little away from the restriction barrier and the isometric contraction against resistance is introduced. The patients will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb. On exhalation, the knee joint will be straightened (extended) towards its new barrier, and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions
219447750|NCT00654368|DRUG|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
219447751|NCT00014586|DRUG|bicalutamide|
219447752|NCT00014586|DRUG|goserelin acetate|
219447753|NCT00014586|PROCEDURE|orchiectomy|
219447754|NCT02340572|DRUG|PRS-080#022-DP|hepcidin antagonist
219447755|NCT02340572|DRUG|PRS-080-Placebo#001|Placebo treatment
219447756|NCT00815776|DEVICE|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
219447757|NCT00815776|DEVICE|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
219447758|NCT00815776|OTHER|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
219447759|NCT02927184|DRUG|VK2809|
219447760|NCT02927184|DRUG|Placebo|
219447761|NCT03327363|DEVICE|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
219447762|NCT01204424|DEVICE|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
219586605|NCT03963024|DRUG|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
219586606|NCT03963024|PROCEDURE|SCT|Stem Cell Transplant
219586607|NCT03963024|DRUG|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
219586608|NCT04197817|DRUG|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
219586609|NCT04197817|DRUG|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
219586610|NCT01451086|BIOLOGICAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
219447763|NCT01204424|DEVICE|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
219447764|NCT00559013|DEVICE|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
219447765|NCT03606655|DRUG|Kava|Kava: 75 mg three times daily (3 capsules)
219447766|NCT02584023|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
219447767|NCT05333536|OTHER|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
219447768|NCT05333536|OTHER|No Intervention: Control group|control only participates in their yearly swimming trainings.
219447769|NCT05609136|OTHER|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
219447770|NCT01059890|DRUG|cefotaxime|
219447771|NCT01059890|DRUG|Metronidazole|
219447772|NCT01059890|DRUG|Ciprofloxacin|
219447773|NCT01059890|DRUG|Fosfocine|
219447774|NCT06082349|PROCEDURE|Lymphaticovenous anastomosis|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
219447775|NCT06082349|PROCEDURE|Sham surgery|Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.
219586611|NCT01451086|BIOLOGICAL|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
219766445|NCT07212777|PROCEDURE|Medial Open Wedge Hight Tibial Osteotomy using conventional surgery techniques|Conventional Medial Open Wedge Hight Tibial Osteotomy
218838056|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
219447776|NCT05666206|PROCEDURE|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
219447777|NCT00959699|DRUG|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
219447778|NCT00959699|DRUG|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
219447779|NCT00959699|DRUG|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
219447780|NCT00959699|DRUG|Boceprevir|Boceprevir (800 mg, orally, three times per day)
219586612|NCT04326621|OTHER|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
219586613|NCT04326621|OTHER|Control|exercises
219586614|NCT05256524|DRUG|The effect of LMWH|Quantified by aFXa-levels
219586615|NCT05256524|DIAGNOSTIC_TEST|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
219586616|NCT01200992|BIOLOGICAL|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
219447781|NCT05891470|DEVICE|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
219447782|NCT05891470|DEVICE|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
219447783|NCT02583360|DIAGNOSTIC_TEST|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
219447784|NCT01061645|DRUG|MOC31-PE|Immunotoxines
219586617|NCT01200992|BIOLOGICAL|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
218838057|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
218838058|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
218838059|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
218838060|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
218838061|NCT05070312|DRUG|Placebo|Placebo
219447785|NCT04583345|BEHAVIORAL|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
219447786|NCT04228445|DRUG|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
219447787|NCT04228445|DRUG|Saline spray|Placebo
219447788|NCT00606294|RADIATION|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
219586618|NCT02808689|BEHAVIORAL|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
219447789|NCT00606294|DEVICE|18F-FMISO PET scan|
218838062|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
218838063|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
218838064|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
218838065|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
218838066|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
218838067|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
218838068|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
218838069|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
218838070|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
218838071|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
218838072|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
219447790|NCT00606294|DEVICE|MRI|
219447791|NCT00606294|DEVICE|FDG PET/CT scan|
218838073|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
219447792|NCT06153394|DRUG|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
219196599|NCT06855303|OTHER|Muscle Energy Teqnique using receprocal inhibition (RI) principle|The supine patient will ask to fully flex the hip and knee on the affected side. The affected leg will then be slowly straightened by the therapist until the restriction barrier is identified. The calf of the affected leg will then be placed on the practitioner's shoulder that stands facing the head of the table on the side of the affected leg. Then the patient will be asked to attempt to straighten the lower leg utilizing the antagonists to hamstrings, employing approximately 20 percent of the strength of the quadriceps. This will be resisted by the practitioner for 5 to 7 seconds. Appropriate breathing instructions will be given. On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions)four repetition
219447793|NCT06153394|DRUG|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
219447794|NCT03879460|DRUG|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
219586619|NCT02808689|OTHER|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
219586620|NCT02808689|OTHER|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
219586621|NCT00186095|PROCEDURE|autologous followed by nonmyeloablative allogeneic transplant|
219447795|NCT04969627|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
219447796|NCT04969627|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
219447797|NCT02823613|DIETARY_SUPPLEMENT|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
219586622|NCT02183181|DRUG|Meloxicam capsule|
219586623|NCT02183181|DRUG|Meloxicam tablet|
218838074|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
218838075|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
218838076|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
219586624|NCT04645836|BEHAVIORAL|New management mode|"New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
219586625|NCT04465695|DRUG|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
218838077|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
218838078|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
218838079|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
218838080|NCT00992056|DRUG|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
219447798|NCT02823613|DIETARY_SUPPLEMENT|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
219447799|NCT05108961|PROCEDURE|Acupuncture|one session with precise acupunture points
219447800|NCT05108961|BEHAVIORAL|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
219447801|NCT05108961|BEHAVIORAL|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
219447802|NCT05108961|DIAGNOSTIC_TEST|Bispectral Index|BIS is based on an EEG analysis algorithm
219447803|NCT02887365|DRUG|tegafur-uracil|
219447804|NCT02421146|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
219447805|NCT02421146|DEVICE|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
219447806|NCT00002097|DRUG|Nystatin|
219447807|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)"
219447808|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)"
218838081|NCT00992056|DRUG|Metoprolol|Metoprolol 50 mg titrated to 100 mg
219447809|NCT03924427|DRUG|BMS-986165|Oral tablet administration
219447810|NCT05068076|DRUG|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
218838082|NCT00075855|DRUG|therapeutic testosterone|
219196600|NCT06855303|OTHER|Conventional Treatment group|This group will receive a 10 minutes application of high-frequency TENS. Hot moist pack: The patient will be made to lay in a supine position with the affected knee in slight flexion A hot moist pack will be applied around the knee for 15 minutes. Ankle pumps, Heel slides, Open chain knee flexion and extension exercises, Straight leg raise, Quad isometrics and Calf stretch. All these exercises were given 10 repetitions x1 set, three days/week
219196601|NCT06812702|OTHER|Observational|Observational
219447811|NCT01063946|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
219586626|NCT04465695|DRUG|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
219447812|NCT00663689|DRUG|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
219447813|NCT00019214|BIOLOGICAL|MART-1 antigen|
218838083|NCT00075855|OTHER|placebo|
218838084|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
219447814|NCT00019214|BIOLOGICAL|aldesleukin|
219447815|NCT00019214|BIOLOGICAL|gp100 antigen|
219447816|NCT01574261|DRUG|Placebo|Placebo for four months
219447817|NCT01574261|DRUG|Inositol|Inositol 4g/die for four months
219447818|NCT03797157|DIETARY_SUPPLEMENT|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
219447819|NCT03797157|DIETARY_SUPPLEMENT|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
219447820|NCT01651234|DRUG|GCC-4401|"* Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C"
219447821|NCT01651234|DRUG|GCC-4401C|"* Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo"
219447822|NCT00003991|BIOLOGICAL|aldesleukin|
219447823|NCT00003991|DRUG|histamine dihydrochloride|
219447824|NCT00069017|BIOLOGICAL|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
218838085|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
218838086|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
218838087|NCT04308655|OTHER|Interview|Semi-structured interviews
218838088|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
218838089|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
218838090|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
218838091|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
219447825|NCT00069017|OTHER|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
219447826|NCT04308408|BEHAVIORAL|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
219447827|NCT04308408|BEHAVIORAL|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
218838092|NCT00002032|DRUG|Rifabutin|
218838093|NCT06365255|OTHER|questionnaires|filling in questionnaires
218838094|NCT00057759|DRUG|sildenafil citrate|
219196602|NCT06812702|PROCEDURE|Skin Biopsy|Participants may consent to additional skin biopsy at baseline and at the one-year follow-up. Skin will be taken paravertebrally at approximately the C8 level.
219196603|NCT06854926|BEHAVIORAL|Helping relationship from significant others|Helping relationship from significant others is the intervention of this study. We will use four strategies, including warning mechanisms, target setting, encouragement, and feedback.
219196604|NCT06854926|BEHAVIORAL|Usual team|Patients of this team accept usual care
219196605|NCT06854263|DEVICE|skin marking for radiotherapy treatment|skin marking for radiotherapy treatment
219447828|NCT04308408|BEHAVIORAL|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
219447829|NCT04308408|BEHAVIORAL|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
219447830|NCT01902836|BIOLOGICAL|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
219447831|NCT01902836|BIOLOGICAL|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
219586627|NCT05699486|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
219586628|NCT05699486|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
219586629|NCT02098239|DRUG|G17DT|
218838095|NCT00057759|OTHER|Placebo|Placebo
218838096|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
218838097|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
219586630|NCT00191113|DRUG|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
218838098|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
219447832|NCT00700349|OTHER|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
219447833|NCT04443036|DRUG|Albumin-Bound Paclitaxel|"* 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity"
219586631|NCT00191113|DRUG|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
219586632|NCT00191113|DRUG|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
219586633|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
219586634|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
219586635|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
219586636|NCT04129229|DEVICE|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
219586637|NCT05460481|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
219586638|NCT01466010|PROCEDURE|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
219017270|NCT06960902|OTHER|Coronary CT scan with CAC score measurement|Coronary CT scan with CAC score measurement (on the same day or within 6 months after the inclusion visit).
219586639|NCT00773630|DRUG|Cilostazol|100 mg Cilostazol
219586640|NCT04638530|OTHER|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
218838099|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
218838100|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
218838101|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
218838102|NCT01001767|DRUG|Placebo|Placebo
218838103|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
218838104|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
219017272|NCT06168409|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
219017273|NCT06168409|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
219017274|NCT06962215|OTHER|Paramedic training|"Nurses and care assistants at the centers randomized to the with training arm will undergo a day-and-a-half of training to help them support patients diagnosed with brain tumors. Training consists of half a day of theory, followed by a day of simulation."
219017275|NCT04727723|DRUG|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
219017276|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
219447834|NCT04443036|DRUG|Toripalimab|"* 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
219447835|NCT02982642|DRUG|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
218838105|NCT05076773|DRUG|IV morphine|given when VAS\>3
218838106|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
219447836|NCT02982642|DRUG|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
219447837|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
219447838|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
219447839|NCT03966664|DIAGNOSTIC_TEST|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
219447840|NCT00998036|DRUG|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
219447841|NCT00998036|DRUG|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
219447842|NCT00998036|DRUG|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
219447843|NCT00510770|DEVICE|CPAP application|
219447844|NCT01891604|DIETARY_SUPPLEMENT|breast milk with Bifidobacterium Longum subp. Infantis R0033|
219447845|NCT01891604|DIETARY_SUPPLEMENT|breast milk|
219447846|NCT05905861|PROCEDURE|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
219447847|NCT05905861|PROCEDURE|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
219447848|NCT01392768|DRUG|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
219586641|NCT03112330|DEVICE|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
219586642|NCT03112330|DEVICE|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
219586643|NCT04658017|DEVICE|GARNET device|Use of new filter in conjunction with standard of care dialysis.
219586644|NCT05955196|PROCEDURE|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
219766446|NCT07212894|OTHER|DemensiaKITA mobile health application|A mobile health application developed to support dementia caregivers. It provides structured educational modules, attitude-shaping content, and practical caregiving tips, along with self-monitoring features to reduce caregiver stress and burden. Participants in the intervention group will use the app regularly during the study period.
219766447|NCT07212894|OTHER|Usual Care|Participants assigned to the control group will continue with usual caregiving practices and community-based resources available to dementia caregivers. They will not be given access to the DemensiaKITA mobile health application during the study period. This group provides a comparator for evaluating the added benefit of th
219766448|NCT07212192|DRUG|Lidocain spray|Applying 3 spray of 10% Lidocaine to the IV insertion site in women before their C-section
218838107|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
218838108|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
218838109|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
218838110|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
218838111|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
219586645|NCT03052010|OTHER|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
219447849|NCT01392768|DRUG|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
219447850|NCT02702284|BEHAVIORAL|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
219447851|NCT02702284|BEHAVIORAL|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
219447852|NCT01316380|DRUG|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
219447853|NCT01316380|DRUG|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
219447854|NCT01316380|DRUG|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
219586646|NCT03052010|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
219447855|NCT00651768|DRUG|budesonide/formoterol|
219447856|NCT00651768|DRUG|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
218838112|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
218838113|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
218838114|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
218838115|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
218838116|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
218838117|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
218838118|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
218838119|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
219447857|NCT02253160|DEVICE|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
219447858|NCT02253160|DEVICE|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
219447859|NCT02253160|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
219447860|NCT00565240|DRUG|Marvelon|oral contraceptive
218838120|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
218838121|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
218838122|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
219586647|NCT03052010|DRUG|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
219586648|NCT04996550|DRUG|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
218838123|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
218838124|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
218838125|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
218838126|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
218838127|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
219447861|NCT00565240|DRUG|Nuvaring|contraceptive vaginal ring
219447862|NCT00565240|DRUG|Letrozole|Aromatase Inhibitors
219447863|NCT02756546|DRUG|Cyclophosphamide|
219447864|NCT02756546|DRUG|Hydroxychloroquine|
219447865|NCT02756546|DRUG|Hydrocortisone|
219447866|NCT02240992|BIOLOGICAL|PBSC|
219447867|NCT02240992|BIOLOGICAL|MSCs|
218838128|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
219447868|NCT05180604|BEHAVIORAL|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
219447869|NCT03258944|OTHER|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
219447870|NCT00000767|BIOLOGICAL|TBC-3B Vaccine|
219447871|NCT00000767|BIOLOGICAL|Smallpox Vaccine|
219447872|NCT04594304|BEHAVIORAL|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
219447873|NCT00149890|DRUG|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
219447874|NCT00149890|DRUG|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
219447875|NCT00149890|DRUG|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
219447876|NCT05838820|DIAGNOSTIC_TEST|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
219447877|NCT05838820|DIAGNOSTIC_TEST|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
218838129|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
218838130|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
218838131|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
219447878|NCT01894776|DRUG|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
219447879|NCT01894776|DRUG|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
219447880|NCT00988377|OTHER|dietary intervention|whey protein 10-40 g
219447881|NCT00988377|OTHER|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
219447882|NCT03395860|DRUG|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
219447883|NCT04929847|OTHER|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
219447884|NCT04917731|DRUG|Botulinum toxin type A|Botox injected at digital artery
219447885|NCT05447260|DRUG|Ruxolitinib|Dosage based on platelet count
219447886|NCT02485860|DEVICE|Melectis G|
219447887|NCT01695460|DRUG|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
219447888|NCT01695460|DRUG|Placebo|
218838132|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
219447889|NCT04117594|DIAGNOSTIC_TEST|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
219447890|NCT02332876|BEHAVIORAL|Exercise|
219447891|NCT02332876|BEHAVIORAL|Control|
219447892|NCT05142176|OTHER|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
219447893|NCT05142176|DRUG|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
219447894|NCT02853786|BEHAVIORAL|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
219447895|NCT02853786|OTHER|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
219447896|NCT01895634|DEVICE|Rev-01|Treatment arm patients have used Rev-01 at least once
219447897|NCT04171063|DEVICE|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
219447898|NCT01381224|OTHER|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
219586649|NCT04996550|DRUG|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
219586650|NCT02087995|DEVICE|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
219586651|NCT00006395|DRUG|St. John's Wort|
219586652|NCT02058550|OTHER|survey administration|Receive reminder email survey
219586653|NCT02058550|OTHER|computer-assisted intervention|Receive reminder email survey
218838133|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
219447899|NCT04871386|BEHAVIORAL|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
219447900|NCT04871386|BEHAVIORAL|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
219586654|NCT02058550|BEHAVIORAL|telephone-based intervention|Receive reminder phone call
219586655|NCT01844466|PROCEDURE|Physiotherapy and speech therapy|
219586656|NCT05978908|DRUG|FC-12738|Retro enversio pentapeptide of thymopentin
219586657|NCT05978908|DRUG|Saline|placebo
219586658|NCT02969265|DRUG|Amlodipine|Amlodipine Capsules
219447901|NCT00017524|DRUG|pelitrexol|
219447902|NCT00493714|BEHAVIORAL|Questionnaire|Surveys lasting 30 minutes or more.
219447903|NCT02382614|DEVICE|Spiration Valve System|
219447904|NCT02415595|DRUG|BMS-955176|HIV Maturation Inhibitor
219586659|NCT02969265|DRUG|TCV-116CCB|TCV-116CCB Tablets
219586660|NCT02969265|DRUG|Amlodipine Placebo|Amlodipine placebo-matching capsules
219586661|NCT02969265|DRUG|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
219586662|NCT03223792|OTHER|Control|Routine cow's milk-based infant formula
219586663|NCT03223792|OTHER|Investigational|Partially-hydrolyzed cow's milk protein infant formula
219586664|NCT04258462|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219586665|NCT04258462|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219447905|NCT02415595|DRUG|EFV|EFV
219447906|NCT02415595|DRUG|TDF/FTC|TDF/FTC
219447907|NCT06204510|OTHER|complex decongestive therapy|This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
219447908|NCT02402881|BEHAVIORAL|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
219447909|NCT03325010|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219586666|NCT04258462|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
219586667|NCT04335786|DRUG|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
219766449|NCT07212192|COMBINATION_PRODUCT|Sterilized saline solution|Participants will be given three sprays sterilized saline solution 3 minutes before the interventionist performed the insertion of a catheter into their vein
218838134|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
218838135|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
218838136|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
218838137|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
218838138|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
218838139|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
218838140|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
218838141|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
219447910|NCT03325010|DRUG|Placebo oral capsule|non-active dosage form
219447911|NCT00962481|DRUG|Bimosiamose|
219447912|NCT00962481|DRUG|Placebo|
219447913|NCT03942549|DEVICE|Retropubic midurethral sling|Midurethral sling
219447914|NCT05855213|DEVICE|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
219447915|NCT05855213|DEVICE|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
219447916|NCT05764811|DRUG|Canagliflozin 100mg|100 mg daily for a month
219447917|NCT04915105|DIAGNOSTIC_TEST|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
219447918|NCT05642793|DRUG|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
219447919|NCT05642793|DRUG|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
219447920|NCT02614261|DRUG|Galcanezumab|Administered SC
219586668|NCT04335786|DRUG|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
219586669|NCT05881746|PROCEDURE|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
219586670|NCT05881746|PROCEDURE|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
218838142|NCT02846792|DRUG|Plinabulin|Given IV
218838143|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
218838144|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
218838145|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
218838146|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
219447921|NCT02614261|DRUG|Placebo|Administered SC
219447922|NCT00938093|BEHAVIORAL|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
219447923|NCT00938093|BEHAVIORAL|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
219447924|NCT01462591|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
219447925|NCT00108277|BEHAVIORAL|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
219447926|NCT00108277|BEHAVIORAL|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
219447927|NCT01848795|DEVICE|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
219447928|NCT01848795|DEVICE|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
219447929|NCT00275041|BIOLOGICAL|cetuximab|
219447930|NCT00275041|DRUG|irinotecan hydrochloride|
219447931|NCT02089867|OTHER|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
219447932|NCT02089867|DRUG|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
219447933|NCT02089867|DIETARY_SUPPLEMENT|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
218838147|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
218838148|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
218838149|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
218838150|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
218838151|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
219447934|NCT03479658|BEHAVIORAL|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
219447935|NCT03479658|BEHAVIORAL|Nutritional education|School-based nutritional education on healthy dietary habits
219447936|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
219447937|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
219447938|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
218838152|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
219447939|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
219447940|NCT00926263|BIOLOGICAL|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
219447941|NCT05793372|OTHER|Retrospective study of clinical features|Retrospective study of clinical features
219447942|NCT03050606|OTHER|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
219447943|NCT03050606|OTHER|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
219447944|NCT01426724|DRUG|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
219447945|NCT00125892|DRUG|duloxetine|
219447946|NCT02315833|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
219447947|NCT02315833|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
219447948|NCT05791773|PROCEDURE|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
219447949|NCT05791773|PROCEDURE|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
219447950|NCT00036231|DRUG|RG1068 (Synthetic Human Secretin)|
219447951|NCT03824457|DRUG|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
219447952|NCT03824457|DRUG|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
219447953|NCT00200889|DEVICE|active TEAS|non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
218838153|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
218838154|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
218838155|NCT01014936|DRUG|MSC2156119J|
218838156|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
218838157|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
219447954|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
219447955|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
219447956|NCT04556929|DIAGNOSTIC_TEST|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
219447957|NCT00460525|BIOLOGICAL|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
219447958|NCT00460525|BIOLOGICAL|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
219447959|NCT03440892|DRUG|methotrexate|folate antagonist
219447960|NCT03440892|DRUG|sulfasalazine|Immunomodulatory
219447961|NCT03440892|DRUG|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
219447962|NCT03440892|DRUG|tocilizumab|IL-6 receptor antagonist
219447963|NCT03440892|DRUG|tofacitinib/baricitinib|JAK inhibitor
219447964|NCT06417268|PROCEDURE|Caudal epidural analgesia|"patient will be placed in the left lateral position with flexed hips.After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture is performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, the needle is inserted immediately below the spinous process S4.~After perforating the membrane, the needle will be advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection, The confirmation of the correct position of the caudal needle before injection by performing the modified 'swoosh' test performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of saline. Bupivacaine 0.25% at a dose of 1 ml/kg will be injected, with care taken not to exceed the maximum recommended dose (2 mg/kg)."
219447965|NCT06417268|PROCEDURE|Ultrasound-guided Combined Pericapsular Nerve Group Block|"With supine position, the probe will be put in a transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral nerve, and femoral artery (FA).~Then the probe will be rotated counter clockwise to align with the pubic ramus to visualize the AIIS, iliopsoas prominence (IPE), FA, iliopsoas, and iliopsoas notch.~Under direct vision, a 22-gauge, 50-mm echo needle will be advanced in the lateral-medial plane between the psoas tendon and the pubic ramus until the needle tip touches the IPE. The needle will be withdrawn, and after negative aspiration, 1 ml/kg (Bupivacaine 0.25%) is injected"
219447966|NCT06417268|PROCEDURE|Ultrasound-guided Lateral Femoral Cutaneous Nerve Block|patient remains supine, and the transducer is parallel to the inguinal ligament. With the femoral artery and vein as guidance, the lateral part of the sartorius muscle and fascia lata is visualized. Approximately 3 cm inferior from this point, the branches of the lateral femoral cutaneous nerve are visualized in the hypoechoic fat-filled subfascial space between the sartorius muscle medially and the tensor fascia lata muscle laterally. A 22-gauge, 50-mm needle is inserted with in plane approach at a shallow angle to reach the area of the nerve and after negative aspiration, 0.1 ml/kg (Bupivacaine 0.25%) is injected.
219447967|NCT06417268|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
219447968|NCT06417268|DRUG|Morphine|If a FLACC pain Score is ≥ 4/10, the patient in the PACU will receive morphine (intravenous, 0.03 mg/kg), and the maximum allowed dose is 0.1mg/kg every 4 hours.
219447969|NCT06417268|DRUG|Acetaminophen|P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
219447970|NCT02460172|DEVICE|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
219447971|NCT02460172|DEVICE|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
219447972|NCT05094882|PROCEDURE|pulmonary lobectomy|resection of lung lobe
219447973|NCT00241657|BIOLOGICAL|BCG|
218838158|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
219447974|NCT00641459|OTHER|Observational BPSD treatment study|Observational BPSD treatment study
219447975|NCT00510575|DEVICE|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
219447976|NCT03073200|DRUG|Ixekizumab|Administered SC
219447977|NCT03073200|DRUG|Placebo|Administered SC
219447978|NCT03073200|DRUG|Etanercept|Administered SC
219447979|NCT03104959|DIETARY_SUPPLEMENT|N-acetyl cysteine|
219447980|NCT03104959|OTHER|placebo|
219447981|NCT03512275|DRUG|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
219447982|NCT04197206|OTHER|costotransverse block|patient controlled analgesia devices with tramadol
219447983|NCT02194452|RADIATION|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
218838159|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
218838160|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
218838161|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
218838162|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
218838163|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
218838164|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
219447984|NCT02194452|PROCEDURE|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
219447985|NCT02194452|PROCEDURE|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
218838165|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
219447986|NCT02194452|OTHER|laboratory biomarker analysis|Correlative studies
219447987|NCT02333136|DEVICE|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
219447988|NCT02421640|DRUG|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
219447989|NCT02421640|DRUG|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
219447990|NCT06014021|BEHAVIORAL|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
219447991|NCT06014021|BEHAVIORAL|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
219447992|NCT06014021|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
219447993|NCT00427375|PROCEDURE|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
219447994|NCT00427375|PROCEDURE|total mesorectal excision|standard surgery
219447995|NCT00067444|DRUG|Paroxetine CR|
219447996|NCT00720720|DIETARY_SUPPLEMENT|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
219447997|NCT00720720|DIETARY_SUPPLEMENT|placebo margarine|
219447998|NCT04757376|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
219447999|NCT04757376|BIOLOGICAL|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
219448000|NCT05810376|BEHAVIORAL|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
219448001|NCT05810376|OTHER|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
219448002|NCT00096304|DRUG|docetaxel|
219448003|NCT00096304|DRUG|epirubicin hydrochloride|
219448004|NCT00374101|DRUG|omeprazole|
219448005|NCT00374101|DRUG|pantoprazole|
219448006|NCT00428103|PROCEDURE|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
219448007|NCT01997138|DRUG|Anakinra 100 mg in 2 ml saline IA|
219448008|NCT04746313|BIOLOGICAL|blood test|"* to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin"
218838166|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
218838167|NCT00601614|DRUG|temozolomide|
218838168|NCT00601614|DRUG|vandetanib|
218838169|NCT00601614|OTHER|immunoenzyme technique|
219448009|NCT00713557|DEVICE|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
219448010|NCT00713557|DRUG|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
219448011|NCT02550093|PROCEDURE|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
218838170|NCT00601614|OTHER|laboratory biomarker analysis|
219448012|NCT02550093|BEHAVIORAL|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
219448013|NCT02550093|PROCEDURE|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
219448014|NCT00128362|PROCEDURE|Radio-guided sentinel node biopsy|
219448015|NCT00128362|PROCEDURE|Axillary sampling|
219448016|NCT00740194|DRUG|Aromatase inhibition|Letrozole
219448017|NCT00740194|DRUG|Estradiol|Dermestril
219448018|NCT00224497|DRUG|SB-742457|
219448019|NCT04684160|DEVICE|Fixed-bearing TKA|
219448020|NCT04684160|DEVICE|Mobile-bearing TKA|
219448021|NCT02903745|OTHER|observational|
219448022|NCT03426644|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
219448023|NCT00993980|PROCEDURE|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
219448024|NCT00993980|PROCEDURE|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
219448025|NCT02467660|BEHAVIORAL|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
219448026|NCT02467660|BEHAVIORAL|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
219448027|NCT04941976|DRUG|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
219448028|NCT04941976|DRUG|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
219448029|NCT05724381|DIAGNOSTIC_TEST|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
219448030|NCT02250391|DRUG|NPB-06|5 days continuous-infusion
219448031|NCT02250391|DRUG|Placebo|5 days continuous-infusion
219448032|NCT01375439|OTHER|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
219448033|NCT00583830|BIOLOGICAL|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
219448034|NCT00583830|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
219448035|NCT00583830|DRUG|Paclitaxel|200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
219448036|NCT00583830|DRUG|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
219448037|NCT04052412|DRUG|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
219448038|NCT02583464|DRUG|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
219448039|NCT01992328|DRUG|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
219448040|NCT03875833|DEVICE|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
219448041|NCT04927351|BEHAVIORAL|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
219448042|NCT01269827|DRUG|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
219448043|NCT01269827|DRUG|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
219448044|NCT05116683|DRUG|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
219448045|NCT00392951|DRUG|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
219448046|NCT05255497|DEVICE|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
219448047|NCT01660997|DRUG|MLN9708|
219448048|NCT01660997|DRUG|Dexamethasone|
219448049|NCT03026205|DRUG|ARMS-I|
219448050|NCT06694233|OTHER|Aspirin prescription on outpatient basis|Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
219586671|NCT05443581|BEHAVIORAL|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
219586672|NCT03795038|DEVICE|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
219586673|NCT03795038|DEVICE|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
219586674|NCT04312295|BEHAVIORAL|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
219586675|NCT05498181|DRUG|Sacubitril-valsartan|sacubitril/valsartan
219586676|NCT05498181|DRUG|Placebo|Placebo
219586677|NCT02590250|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
219586678|NCT02903030|DRUG|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
219586679|NCT02903030|DRUG|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
219586680|NCT02826538|DEVICE|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
218838171|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
219586681|NCT02826538|DEVICE|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
219586682|NCT01502410|DRUG|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
219586683|NCT01502410|OTHER|pharmacological study|Optional correlative studies
219586684|NCT01502410|OTHER|laboratory biomarker analysis|Optional correlative studies
218838172|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
219448051|NCT01474889|DEVICE|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
219448052|NCT04245657|OTHER|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
219448053|NCT04245657|OTHER|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
219448054|NCT04245657|OTHER|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
219448055|NCT04245657|OTHER|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
218838173|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
219448056|NCT04245657|OTHER|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
219448057|NCT04245657|OTHER|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
219448058|NCT04245657|OTHER|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
219448059|NCT04245657|OTHER|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
219586685|NCT02068664|BEHAVIORAL|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
219586686|NCT06017310|DIAGNOSTIC_TEST|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
219586687|NCT05176795|OTHER|Stool sample|Comparaison of the gut microbiota composition
219586688|NCT03309995|DEVICE|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
219586689|NCT03309995|DEVICE|Placebo lozenges|Placebo lozenges
219586690|NCT03582748|PROCEDURE|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
218838174|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
218838175|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
218838176|NCT02443246|DRUG|Placebo|
218838177|NCT00429676|DRUG|Haloperidol|
218838178|NCT00602225|DRUG|clofarabine|Given IV
218838179|NCT00602225|DRUG|cytarabine|Given IV
218838180|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
218838181|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
219448060|NCT04245657|OTHER|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
219448061|NCT03298048|BIOLOGICAL|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
219448062|NCT03298048|BIOLOGICAL|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
219448063|NCT03298048|BIOLOGICAL|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
219448064|NCT00726310|DEVICE|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
219448065|NCT05056636|DIAGNOSTIC_TEST|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
219448066|NCT04856215|DRUG|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
219448067|NCT04229082|OTHER|observational|
218838182|NCT00009880|BIOLOGICAL|filgrastim|
218838183|NCT00009880|DRUG|cisplatin|
218838184|NCT00009880|DRUG|fluorouracil|
218838185|NCT00009880|DRUG|paclitaxel|
218838186|NCT00009880|RADIATION|radiation therapy|
218838187|NCT01894724|DEVICE|NeuroSave device|
218838188|NCT01696981|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
218838189|NCT01696981|PROCEDURE|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
218838190|NCT04306562|DIETARY_SUPPLEMENT|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
218838191|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
218838192|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
218838193|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
218838194|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
218838195|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
218838196|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219448068|NCT01803529|OTHER|heat-pack with massage|
219448069|NCT01803529|OTHER|heat-pack only|
219448070|NCT03993301|OTHER|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
218838197|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
218838198|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
219448071|NCT03993301|OTHER|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
219448072|NCT03993301|OTHER|Regular formula|Feeding baby two meals a day with regular formula at least.
219448073|NCT04412668|DRUG|Efzofitimod 1 mg/kg|Concentrate for solution for infusion
219448074|NCT04412668|DRUG|Efzofitimod 3 mg/kg|Concentrate for solution for infusion
219448075|NCT04412668|DRUG|Placebo|Concentrate for solution for infusion
219586691|NCT03582748|PROCEDURE|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
219586692|NCT00253695|DEVICE|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
218838199|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
218838200|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
218838201|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
218838202|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
218838203|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
218838204|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
218838205|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
219448076|NCT05203744|DRUG|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
219448077|NCT06335160|DRUG|Mebendazole|mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
219448078|NCT02159989|DRUG|Sapanisertib|Given PO
219448079|NCT02159989|BIOLOGICAL|Ziv-Aflibercept|Given IV
219448080|NCT00005629|BIOLOGICAL|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
219448081|NCT01614522|DRUG|ASLAN001|ASLAN001 500mg BID
219448082|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
219448083|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
218838206|NCT03102515|DRUG|USG-TAP block|
218838207|NCT03102515|DRUG|CIC|
219448084|NCT02834494|PROCEDURE|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
219586693|NCT06299930|PROCEDURE|Neoadjuvant chemotherapy|Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
219586694|NCT06299930|PROCEDURE|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
219586695|NCT05272748|OTHER|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
219586696|NCT05272748|OTHER|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
219586697|NCT03715504|DRUG|TP-3654|oral PIM inhibitor
219586698|NCT01404923|DRUG|anti spasmodic agents|best standard of care prescriptions
219586699|NCT01404923|DRUG|alverine citrate, simeticone|on-demand therapy
218838208|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
218838209|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
218838210|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
218838211|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
218838212|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
218838213|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
218838214|NCT01854775|DRUG|E/C/F/TAF|Tablets administered orally with food.
219448085|NCT02834494|BIOLOGICAL|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
219448086|NCT02371694|OTHER|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
219448087|NCT04394013|BEHAVIORAL|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
219448088|NCT04394013|BEHAVIORAL|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
219448089|NCT03960385|BIOLOGICAL|CYD-TDV|Dengue vaccine
219448090|NCT03699527|BEHAVIORAL|Multiple questionnaires administered|This is an observational trial
219448091|NCT03631394|OTHER|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
219448092|NCT03631394|OTHER|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
219586700|NCT05984186|DEVICE|High Velocity Therapy|FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
219586701|NCT04074629|DIAGNOSTIC_TEST|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
219586702|NCT05101681|DIAGNOSTIC_TEST|Teledentistry|Teledentistry using mobile photographs
219448093|NCT05455645|OTHER|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
218838215|NCT01854775|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
218838216|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
219448094|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
219448095|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
219448096|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
219448097|NCT02456571|DEVICE|CTC biomarker expression prevalence|
219448098|NCT04964557|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
219448099|NCT04964557|DRUG|Placebo|Placebo solution
219448100|NCT04756349|OTHER|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
219448101|NCT06722664|DRUG|Recombinant Human Chymotrypsin(OsrhCT) 4000U|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder
219448102|NCT06722664|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder
219448103|NCT06722664|DRUG|Dimethicone emulsion 4ml|Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.
218838217|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
218838218|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
218838219|NCT02822183|OTHER|Online Survey|
218838220|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
218838221|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
219448104|NCT03607604|GENETIC|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
219448105|NCT00962468|OTHER|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
219448106|NCT00826709|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
219448107|NCT04142944|DEVICE|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
219448108|NCT04142944|DEVICE|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
219448109|NCT05884268|DRUG|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
219448110|NCT05884268|DRUG|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
219448111|NCT02369211|DRUG|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
219448112|NCT02369211|OTHER|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
219586703|NCT01960712|DEVICE|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
218838222|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
218838223|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
218838224|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
219448113|NCT05956262|DEVICE|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
219448114|NCT05956262|BEHAVIORAL|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
219448115|NCT06942572|GENETIC|SB-007|Subretinal Administration of SB-007
219448116|NCT05104086|DEVICE|ultrasound elastography|strain ratio and resistivity index
218838225|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
218838226|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
218838227|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
218838228|NCT02059629|DEVICE|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
218838229|NCT02059629|DEVICE|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
219448117|NCT04339725|OTHER|DNA extraction|Extraction fecal DNA and compare disease group to normal group
219448118|NCT03649815|COMBINATION_PRODUCT|App4Independence|"The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations"
219448119|NCT00874224|PROCEDURE|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
219448120|NCT00874224|PROCEDURE|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
219448121|NCT06949306|OTHER|"Bracelet, assistant, APP: the golden triangle of smart life"|The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.
219448122|NCT06949332|DEVICE|electromyography|In this study, surface Electromyography (EMG) was employed to assess the electrical activity of the masseter muscles. Surface EMG is a physiological measurement technique that allows for the recording of electrical potentials generated by muscle fiber depolarization through non-invasive electrodes placed on the skin. This method is widely accepted for objectively determining muscle activation levels and timing, enabling the quantitative analysis of changes in masseter muscle activity during the performance of various Rocabado exercises in this study. The validity and reliability of the EMG device utilized (Noraxon USA Inc., Scottsdale, AZ, USA) have been established in the literature.
219448123|NCT06948058|OTHER|Electronic Cigarettes (EC)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to EC for 8 weeks, with EC provided.
219448124|NCT06948058|OTHER|Nicotine replacement therapy (NRT)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to combination NRT (transdermal + oral) for 8 weeks, with NRT provided.
219448125|NCT06948071|OTHER|Discharge on oral antibiotics|Patients will be discharged to home on an oral antibiotic regimen for 3 days instead of being admitted for intravenous antibiotics.
219448126|NCT06948162|DEVICE|dental-dedicated MRI (ddMRI)|This descriptive observational research is comparative in design, that is comparing existing standard clinical dental images, not obtained in this study, to test (i.e., ddMRI) images.
218838230|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
218838231|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
218838232|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
218838233|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
218838234|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
218838235|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
218838236|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
218838237|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
219448127|NCT06949397|OTHER|Change in VAS voice performance score following the characteristics of the menstrual cycle of two women|application of menstrual belt and stress ball to women in the research group
219448128|NCT04901104|DRUG|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
219448129|NCT00479934|DRUG|imatinib mesylate|6 month treatment with 400mg/day (per os)
219448130|NCT06067295|OTHER|Non-Interventional Study|Non-interventional study
218838238|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
218838239|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
219448131|NCT06486805|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
219448132|NCT06486805|OTHER|normal saline|the same volume of normal saline
218838240|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
218838241|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
218838242|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
218838243|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
218838244|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
219448133|NCT03695471|BIOLOGICAL|Pembrolizumab|Given IV
219448134|NCT04776252|DRUG|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
219586704|NCT05456555|PROCEDURE|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
219586705|NCT05456555|PROCEDURE|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
219586706|NCT05585879|DEVICE|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps"
219586707|NCT03398070|OTHER|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care"
218838245|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
218838246|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838247|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838248|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838249|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838250|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838251|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
218838252|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
219448135|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
219448136|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
219448137|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
219448138|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
219448139|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
218838253|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
218838254|NCT00271921|BEHAVIORAL|Calorie controlled diet|
218838255|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
218838256|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
218838257|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
218838258|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
218838259|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
219448140|NCT02859558|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
218838260|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
218838261|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
218838262|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
218838263|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
218838264|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
218838265|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
218838266|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with Letermovir
219448141|NCT05176223|PROCEDURE|Computed Tomography|Undergo 68Ga PSMA PET/CT
219448142|NCT05176223|DRUG|Gallium Ga 68 Gozetotide|Undergo 68Ga PSMA PET/CT
219448143|NCT05176223|PROCEDURE|Positron Emission Tomography|Undergo 68Ga PSMA PET/CT
219448144|NCT05665595|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
218838267|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with LTV
218838268|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
219448145|NCT05665595|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
219448146|NCT02342964|OTHER|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
219448147|NCT04645602|DRUG|Lenvatinib|Pill taken by mouth, once daily.
219448148|NCT04645602|DRUG|Pembrolizumab|Intravenous injection through a vein (IV).
219448149|NCT06423352|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
219448150|NCT06423352|DRUG|Placebo|Placebo administered by SC injection
219448151|NCT05651282|DRUG|Provera|Progesterone Challenge Test
219448152|NCT05485961|DRUG|CSL300|IV administration
219448153|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
219448154|NCT05485961|DRUG|Placebo|Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
219196606|NCT06853600|DIETARY_SUPPLEMENT|Rhodiola Rosea Capsules|One of the most practical and accessible options for mitigating the occurrence of mental fatigue is the strategic use of nutritional supplements. Several nutritional supplements have been shown to reduce behavioural or subjective markers of mental fatigue, including caffeine, creatine, panax ginseng, and various vitamins or minerals. Among these, Rhodiola Rosea (RR), a supplement with purported adaptogenic and ergogenic properties, has gained attention. Several randomized controlled trials have reported reductions in mental fatigue after RR supplementation without adverse effects. The main objective of this study was to explore the effects of four days of Golden Root Extract (RR) supplementation on mental fatigue, visuo-cognitive processing, strength performance, and perceived exertion in young, healthy individuals.
219196607|NCT06812182|BEHAVIORAL|nurse guided clinical pathway|"Educational training sessions were provided to care providers for one week. Pre-operative; counseling and education of patient for chest physiotherapy, using spirometry, bowel preparation, early mobilization and how to predict common complications with learning to cooperate with nurses. Emphasis on patients to co-operate postoperatively was strongly stressed in spite of the pain and weakness.~Intra-operative: Optimal fluid management, short acting anesthetics, regional analgesia, opioids-sparing anesthesia, small incisions, avoiding drains, maintaining normothermia, venous thrombo-embolism \[VTE\] prophylaxis and antibiotic prophylaxis were routinely done.~Post-operative: Early oral nutrition, optimal fluid management, multimodal non-opioid analgesia, postoperative nausea and vomiting PONV prophylaxis, stimulation of gut motility, early removal of catheters and drains, early mobilization, chest physiotherapy and using spirometry effectively."
219196608|NCT06812273|BEHAVIORAL|STM Training|This condition consists of an up/down spectral-temporal modulations (STM) presented both in quiet and with competing background noise
219196609|NCT06812273|BEHAVIORAL|Speech Training|Participants will train on the identification of three sets of speech stimuli of increasing linguistic complexity: individual phonemes (vowels), spondaic words, and matrix sentences.
219196610|NCT06812273|BEHAVIORAL|Mixed Training|This condition involves both the STM and the speech training, described above, and an additional module training localization.
219196611|NCT06812273|BEHAVIORAL|Gamified Training|"This uses auditory training within a game experience where players control a game avatar (the wisp) that appears to fly through a landscape. Players were asked to help the wisp avoid obstacles or choose from among options based on a variety of sound cues."
219448155|NCT04962087|BEHAVIORAL|Experimental: Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioral treatments for insomnia (2,5,6) and adapted to fit an automated interactive platform available via an internet enabled device. Previous research has found that CBT for insomnia can be delivered via a web-based platform (15,16). The program is divided into a series of treatment modules or levels that will be delivered over the course of 8 weeks. The content of these 8 levels includes the following components, a sleep diary, Introduction to Health EnSuite Insomnia, Sleep restriction clock, Medications, Herbal Remedies \& Sleep, Chronobiology \& Sleep Timing, Sleep hygiene, Relaxation techniques, Changing Negative Thoughts Related to Sleep, Light and Sleep.
219766450|NCT07211399|DRUG|Opioid-free anesthesia|Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and dexmedetomidine (12-20 mcg IV) and ketamine (25-50 mcg) prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, dexmedetomidine and ketamine will be administered as needed. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC).
219766451|NCT07211399|DRUG|Opioid-based anesthesia|Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and fentanyl 50-100 mcg IV prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, each patient in the opioid group will receive IV-fentanyl (50 - 100 mcg) as needed.
219766452|NCT07212387|PROCEDURE|Sacral neurostimulation|Sacral neurostimulation (SNS), or sacral neuromodulation (SNM), is a minimally invasive, reversible treatment for bladder and bowel control problems, including overactive bladder and fecal incontinence.
219766453|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
218838269|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
218838270|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
219766454|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
219766455|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
219766456|NCT07212751|DIAGNOSTIC_TEST|CTCA|"Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment~\- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen."
219766457|NCT07212634|DEVICE|Transcranial Direct Current Stimulation|"Different experimental groups received tDCS stimulation at the following distinct sites: bilateral cerebellar hemispheres, bilateral cortical areas corresponding to the suprahyoid muscles, and combined bilateral cerebellar hemispheres alongside bilateral cortical areas corresponding to the suprahyoid muscles.~Stimulation parameters: 2 mA constant current, 20 minutes per session Treatment regimen: 5 sessions per week for 2 consecutive weeks"
219017292|NCT04095676|PROCEDURE|VATS group|VATS procedure with drainage, including rinse with NaCl
219017293|NCT04095676|PROCEDURE|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
218838271|NCT06982261|OTHER|Voice-activated smart speakers|"Participants will attend a single 90 to 120-minute in-person baseline visit to complete standardized questionnaires and review a list of smart speaker-based tasks. They will select three tasks; all will receive an Echo Show and a Fitbit Versa. Additional digital health devices (e.g., blood pressure monitor, in-home motion sensors) will be provided based on their selections. Participants will learn to interact with Alexa, followed by a second home visit one week later for task-specific setup and device installation.~The team will conduct weekly or bi-weekly check-in calls for two months, with additional home visits as needed. At two months, a home visit will include questionnaires and a 30-60 minute interview on intervention feasibility. Participants will then use the devices independently for one month, with a final home visit at three months for questionnaires and a closing interview."
218838272|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
218838273|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
219448156|NCT05339022|OTHER|Best Practice|Receive standard of care
219017296|NCT06361537|DRUG|OCTA-C1-INH|OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
219448157|NCT05339022|OTHER|Exercise Intervention|Undergo exercise intervention
219448158|NCT05339022|PROCEDURE|Physical Therapy|Undergo physical therapy
219448159|NCT05339022|OTHER|Quality-of-Life Assessment|Ancillary studies
219448160|NCT05339022|OTHER|Questionnaire Administration|Ancillary studies
219448161|NCT05339022|PROCEDURE|Relaxation Therapy|Undergo progressive muscles relaxation exercises
219448162|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
219448163|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
219448164|NCT05581810|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
219448165|NCT05581810|BEHAVIORAL|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
219586708|NCT04129359|BEHAVIORAL|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
219586709|NCT04129359|OTHER|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
219586710|NCT00261092|DRUG|Oxaliplatin|
219586711|NCT02553759|OTHER|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
219586712|NCT01354379|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
219586713|NCT01354379|BIOLOGICAL|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
219017297|NCT06361537|OTHER|Placebo|0.1 mL/kg BW 0.9% sodium chloride injection
219448166|NCT05193825|DEVICE|Remote Programming|Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
219448167|NCT05193825|DEVICE|Standard Programming|Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
219448168|NCT00766142|BIOLOGICAL|cetuximab|
219448169|NCT00766142|DRUG|fluorouracil|
219448170|NCT00766142|DRUG|leucovorin calcium|
219448171|NCT00766142|DRUG|oxaliplatin|
219448172|NCT00766142|PROCEDURE|adjuvant therapy|
219448173|NCT00766142|PROCEDURE|therapeutic conventional surgery|
219448174|NCT06033365|BEHAVIORAL|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
219448175|NCT05909488|BIOLOGICAL|1.5 x 10^6 UC-MSC + CM|1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
219448176|NCT05909488|BIOLOGICAL|5 x 10^6 UC-MSC + CM|5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
219448177|NCT05756829|OTHER|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
219448178|NCT06207162|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
218838274|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
218838275|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
219448179|NCT06617390|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
219448180|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
219448181|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
219448182|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
219448183|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
219448184|NCT04978727|BIOLOGICAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
219586714|NCT02068235|DRUG|Ponesimod 5mg i.v.|
219017303|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
219017305|NCT06245681|DRUG|gender affirming hormone therapy|both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
219448185|NCT06203002|DRUG|Placebo (blinded)|LX9211 matching placebo tablets
219448186|NCT06203002|DRUG|LX9211 (blinded)|LX9211 (blinded) tablets
219448187|NCT06963840|DIETARY_SUPPLEMENT|Theronomic Ova-All Care|Two capsules of Theronomic Ova-All Care, one a day, for 12 weeks. Ova-All Care is a tribiotic, a health product that includes prebiotics, probiotics, and postbiotics. Ova-All Care affects ovarian health by regulating the gut microbiome, which affects oestrogen production and other factors.
219448188|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
219448189|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
219586715|NCT02068235|DRUG|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
219586716|NCT02068235|DRUG|Ponesimod 10 mg tablet|
219586717|NCT00003602|DRUG|cytarabine|
219586718|NCT00003602|DRUG|etoposide|
219586719|NCT00003602|DRUG|idarubicin|
218838276|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
218838277|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
219448190|NCT01670487|DEVICE|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
219586720|NCT00003602|DRUG|mitoxantrone hydrochloride|
219586721|NCT02205190|DRUG|Fimasartan|
219586722|NCT02205190|DRUG|Rosuvastatin|
219586723|NCT02205190|DRUG|Fimasartan/Rosuvastatin combination|
219586724|NCT01509703|PROCEDURE|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
219586725|NCT02478203|DEVICE|Airtraq|videolaryngoscope for difficult airway
219586726|NCT02478203|DEVICE|Glidescope|videolaryngoscope for difficult airway
219586727|NCT02478203|DEVICE|direct laryngoscopy|gold standart for intubation
219586728|NCT06232798|OTHER|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
219586729|NCT06232798|OTHER|catheter ablation|catheter ablation
219586730|NCT02598687|DRUG|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
219586731|NCT02598687|OTHER|HX4 scan|HX 4 scan day 1 and day 8
219586732|NCT02598687|DRUG|Carboplatin|2mg/ml/min
219586733|NCT02598687|DRUG|Paclitaxel|50 mg/m2
219586734|NCT02598687|RADIATION|Radiotherapy|23 x 1.8 Gy
218838278|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
218838279|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
219448191|NCT01670487|DEVICE|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
219448192|NCT04902833|PROCEDURE|Blood Draw|Blood specimen 2-4 teaspoons
219448193|NCT04675333|DRUG|evorpacept|IV Q3W
219448194|NCT04675333|DRUG|pembrolizumab|IV Q3W
219448195|NCT04675333|DRUG|Cisplatin/Carboplatin; 5FU|IV Q3W
218838280|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
218838281|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
218838282|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
218838283|NCT00025207|DRUG|gefitinib|Given orally
218838284|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
218838285|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
218838286|NCT03828760|BEHAVIORAL|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
218838287|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
219196612|NCT06812273|BEHAVIORAL|Foraging Training|This adds a component to the game where participants navigate the wisp to the location on the screen that relates to the target stimulus. The concept here is that searching for targets with manual movements, ecologically stimulates sensori-motor loops where the actions of the participants generates the auditory stimuli that are heard.
219448196|NCT04275557|OTHER|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
218838288|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
218838289|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
218838290|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
218838291|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
218838292|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
218838293|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
218838294|NCT00993863|DRUG|Placebo|single dose
218838295|NCT00993863|DRUG|ADL5859 30 mg|single dose
218838296|NCT00993863|DRUG|ADL5859 100 mg|single dose
218838297|NCT00993863|DRUG|ADL5859 200 mg|single dose
218838298|NCT00993863|DRUG|ibuprofen 400 mg|single dose
218838299|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
218838300|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
218838301|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
219448197|NCT04275557|OTHER|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
219448198|NCT04275557|OTHER|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
219448199|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
219448200|NCT06384352|DRUG|YL211|Patients will be treated with YL211 intravenous (IV) infusion.
218838302|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
218838303|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
218838304|NCT00475085|DRUG|aprepitant|Given orally or IV
219196613|NCT04084574|BEHAVIORAL|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
219448201|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
219448202|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
219448203|NCT00003899|BIOLOGICAL|filgrastim|
218838305|NCT00475085|DRUG|dexamethasone|Given orally or IV
218838306|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
218838307|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
219196614|NCT06815549|DRUG|Fluorothiazinone, tablets 300 mg|patients will receive Fluorothiazinone, tablets 300 mg at a dose 1200 mg/day (2 tablets twice a day) for 14 days
219196615|NCT06815549|DRUG|Nitrofurantoin 100 MG|Comparison arm patients will receive Nitrofurantoin in accordance with the instructions for medical use.
219196616|NCT06814522|DRUG|Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate|25 mg, single dose of synthetic psilocybin
219196617|NCT06815679|DRUG|salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)|To evaluate the patient's respiratory effort, the pressure-time product (PTPes) and the delta of Pes oscillations during inspiration (∆ Pes) will be obtained from the analysis of the Pes curve. Global and regional pulmonary tidal volumes will be evaluated with Electrical Impedance Tomography
219448204|NCT00003899|DRUG|cyclophosphamide|
219448205|NCT00003899|DRUG|melphalan|
219448206|NCT00003899|DRUG|paclitaxel|
219448207|NCT00003899|DRUG|thiotepa|
219448208|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
219448209|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
219448210|NCT02425813|DRUG|Budesonide|Given PO
219448211|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
219448212|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
219586735|NCT02598687|PROCEDURE|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
219586736|NCT02470533|RADIATION|Radiation therapy|6 fractions of 8-9Gy
219586737|NCT02470533|DEVICE|chemoembolization|Up to 4 sessions
219448213|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
219586738|NCT00991705|DRUG|Atorvastatin|
219586739|NCT00991705|DRUG|Fimasartan|
219586740|NCT06425497|OTHER|The dosage of dnDSA|Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
219586741|NCT02591186|PROCEDURE|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
219586742|NCT05339334|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
219586743|NCT00284024|DRUG|domperidone|
218838308|NCT00475085|DRUG|prochlorperazine|Given orally or IV
219448214|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
219448215|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
219448216|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
219448217|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
219448218|NCT06436300|BEHAVIORAL|Motivational text messaging|Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
219448219|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
219586744|NCT00368979|DRUG|Dutasteride|once daily
219586745|NCT00368979|DRUG|Placebo|once daily
219586746|NCT05258903|PROCEDURE|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
218838309|NCT00475085|DRUG|placebo|Given orally
218838310|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
218838311|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
219586747|NCT05258903|PROCEDURE|Radial artery cannulation|Radial artery will be cannulated under USG guidance
219586748|NCT06349590|DIETARY_SUPPLEMENT|High-fiber/low-fat meals|Meals with Low fat/High fiber
219586749|NCT03987321|DEVICE|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
219586750|NCT03786718|OTHER|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
219448220|NCT04362696|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
219448221|NCT06740708|BEHAVIORAL|SCALE-NCD|"1. FCHV home visits every three months, including~   * For hypertension i. Blood pressure measurement with digital BP devices ii. Lifestyle counseling iii. Referral if uncontrolled BP (≥140/90 mmHg) for 3 months~  * For type 2 diabetes i. Fasting blood glucose measurement with glucometer ii. Lifestyle counseling focusing on diabetes management iii. Referral if uncontrolled diabetes (≥126mg/dl) for 3 months~  * For current smokers i. Smoking cessation counseling ii. Referral for nicotine replacement therapy if request by participants~2. Mobile phone messages, including~   * Lifestyle modification~  * Conveyed as voice or text messages, depending on participant preference"
218838312|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
219448222|NCT05769153|DRUG|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
219766458|NCT07212634|OTHER|Sham tDCS|The patients in this group will receive sham stimulation applied to the same area for the same duration.
219766459|NCT07211698|OTHER|Qualitative study|"Semi-structured interviews will enable an in-depth conversation between the researcher and the participant, delving deeply into personal and sometimes sensitive issues that participants are unable to talk about in a focus group.~Focus groups allow participants to share their thoughts and experiences as part of a group, bouncing off each other instead of answering questions alone. People can discuss with each other and the researcher can learn not just what people think, but also how and why they think that way.~Both semi-structured interviews and focus groups will be audio recorded with participants consent, which may influence what participants say or do not say during the conversations. This could also make people uncomfortable, and therefore, they may decide not to participate in the study.~Therefore, an informal conversational interview is needed as an option. Informal conversations will not be recorded, creating a more friendly and comfortable atmosphere for people to share their"
218838313|NCT06171139|OTHER|Counseling Tool|Non-therapeutic educational intervention
218838314|NCT06171139|OTHER|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
218838315|NCT06688006|OTHER|climate change short animation film|For the short animated film, a scenario will be created that describes climate change, risk factors that threaten human health as a result of climate change, adverse health effects of climate change, adverse effects on maternal and foetal health, precautions to be taken to protect against and adapt to the adverse effects of climate change. In the short animation film, visual materials will be created that show the adverse effects of climate change by using developing technology. The created scenario will be prepared as a two-dimensional (2D) animation film with the support of Selçuk University SERATEM (Selçuk University Radio and Television Application Center). All lines, colours, decorations and characters used in the creation phase of the short animation film will be determined by the researchers. Once the drawing and animation phases are complete, the voice-over actors will be selected after a further review. The short animated film should be about 2-3 minutes long.
218838316|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
218838317|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
219196618|NCT06814379|BEHAVIORAL|Rehabilitation|"30-60 minutes. A total of 3 session/week at home. 4 weeks.~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
219448223|NCT05769153|DRUG|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
219448224|NCT05769153|DRUG|AR-14034 SR implant|AR-14034 SR administered as an intravitreal implant
219448225|NCT05769153|DRUG|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
219448226|NCT05769153|DRUG|Sham procedure|Needleless syringe used to simulate an intravitreal injection
219448227|NCT02670213|DRUG|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
219448228|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
219448229|NCT06031584|DRUG|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
219448230|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
219448231|NCT00003309|BIOLOGICAL|filgrastim|
219448232|NCT00003309|DRUG|cisplatin|
219448233|NCT00003309|DRUG|cyclophosphamide|
219448234|NCT00003309|DRUG|etoposide|
219448235|NCT00003309|DRUG|vincristine sulfate|
219448236|NCT00003309|PROCEDURE|adjuvant therapy|
219448237|NCT00003309|RADIATION|radiation therapy|
219448238|NCT06464276|OTHER|No intervention|No intervention
219448239|NCT05076617|DRUG|Staccato alprazolam|"* Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
219448240|NCT06150560|DRUG|Losartan|50mg administered orally once daily for 52 weeks.
219448241|NCT06150560|DRUG|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
219766460|NCT07212023|DRUG|Revumenib|Participants will receive revumenib orally.
219766461|NCT07212023|DRUG|Intensive Chemotherapy Regimen|Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.
219766462|NCT07212023|DRUG|Placebo|Participants will receive placebo (non-active agent) orally.
219766463|NCT07212296|PROCEDURE|Conventional total knee replacement|Knee replacement without robotic technology
219766464|NCT07212296|PROCEDURE|Robotic TKR|Total knee replacement WITH robotic technology
218838318|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
218838319|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
218838320|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
219766465|NCT07212127|DEVICE|Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture theory（TENS-WAA)|Based on the theory of wrist and ankle needles, transcutaneous electrical nerve stimulation is a kind of analgesic treatment device that combines wrist and ankle needles with transcutaneous electrical nerve stimulation, and can be worn on the human wrist and ankle. Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture Theory uses low-frequency electronic pulses to stimulate the entry point of the wrist-ankle needle, which has the advantages of easy to wear, concentration of the treatment site, safety of the treatment, and no needles.
218838321|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
218838322|NCT06873633|DRUG|Remdesivir|Remdesivir (RDV) has shown potent antiviral activity against RSV A in an animal model. Remdesivir has been also shown to be a safe treatment option in pediatric patients hospitalized with COVID-19. Based on previous clinical evidence and preclinical data, to address the unmet medical need for safe and effective RSV therapy, this study is being conducted to investigate remdesivir in infants and children (aged 0 days to \<2 years) as a potential treatment for RSV infection.
218838323|NCT06415760|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
218838324|NCT00343005|BIOLOGICAL|AMA1-C1|
218838325|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
218838326|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
218838327|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
218838328|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
218838329|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
218838330|NCT06440252|DRUG|Grape Seed Extract|One daily dose of 1 capsule containing 600mg grape seed extract
218838331|NCT06440252|DRUG|Maltodextrin|One daily dose of 1 capsule
218838332|NCT06712706|PROCEDURE|Feeding jejunostomy placement|Placement of feeding jejunostomy at staging laparoscopy
218838333|NCT06712706|PROCEDURE|Feeding jejunostomy placement at esophagectomy|Placement of feeding jejunostomy at esophagectomy
218838334|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
219448242|NCT06150560|DRUG|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
218838335|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
218838336|NCT04912089|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
218838337|NCT04784663|BEHAVIORAL|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
218838338|NCT04784663|OTHER|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
218838339|NCT06893224|OTHER|Coastal exposure|"This is a real-life exposure to the coastal environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
218838340|NCT06893224|OTHER|Urban exposure|"This is a real-life exposure to the urban environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
219448243|NCT06518473|DIAGNOSTIC_TEST|Skin prick test|"Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold.~Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)"
218838341|NCT07071090|DRUG|DC50292A|DC50292A tablet
218838342|NCT06878001|DIETARY_SUPPLEMENT|Carotenoids|CaroRite capsule containing carotenoids with sunflower oil. 1 capsule to be taken each day for 12 weeks.
218838343|NCT06878001|OTHER|Placebo|Placebo capsule containing sunflower oil. 1 capsule to be taken each day for 12 weeks.
218838344|NCT07061496|BEHAVIORAL|Moderately intense exercise|Structured moderate-intensity aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
218838345|NCT07061496|DRUG|MetFORMIN 500 Mg Oral Tablet|Participants will receive oral metformin 500 mg twice daily for 12 weeks.
218838346|NCT06895863|DEVICE|MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|"Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administered over five consecutive days.~On each intervention day, patients will undergo five high frequency iTBS sessions (each lasting approximately 10 minutes, excluding preparation) with about 50 minutes of rest between sessions. Each iTBS session delivers 1,800 pulses, resulting in a total of 25 sessions and 45,000 pulses over the course of a standard work week."
219448244|NCT04681248|DRUG|DKN-01|Administered by IV infusion
218838347|NCT06895863|DEVICE|Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|Intermittent theta burst stimulation (iTBS) targeting the left inferior parietal lobule (IPL) will be administered over five consecutive days using the stimulation pattern described in the active DLPFC arm.
218838348|NCT06895863|DEVICE|Sham stimulation of the MagVenture MagPro XP Orange Edition Prototype flipping the active side of the MagVenture Cool-B65 coil|"Device: Sham stimulation of the left DLPFC or IPL will be administered using the same stimulation duration and repetition as the active iTBS.~To match the subjective experience of iTBS, the sham CoMPACT uses a dedicated (Active/Placebo) stimulation coil that has both active and sham functions, generating the same sound level regardless of the type of stimulation."
218838349|NCT07070765|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|Dapagliflozin 10mg in addition to standard clinical care
219448245|NCT06496854|DRUG|Lorazepam 1 mg|1 mg oral lorazepam, a sedative used to relieve anxiety
219448246|NCT06496854|DRUG|Ibuprofen 800 mg|800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
219586751|NCT02873741|PROCEDURE|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
219586752|NCT02873741|PROCEDURE|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
219586753|NCT02873741|PROCEDURE|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
218838350|NCT07070765|OTHER|Standard medical treatment|Standard clinical care
218838351|NCT07062549|DRUG|111In-XYIMSR-01|Unite Dose: 10.5±1 mCi of 111In-XYIMSR-01 Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access
218838352|NCT07073456|DIAGNOSTIC_TEST|Viscoelastic Coagulation Monitoring measurements|Peripheral venous blood samples will be obtained for the assessment of the eight following parameters utilizing the VCM (Viscoelastic Coagulation Monitor) device: clot time, clot formation time, alpha angle, amplitude at 10 minutes, amplitude at 20 minutes, maximum clot formation, lysis index at 30 minutes, and lysis index at 45 minutes. These parameters will be measured at the Emergency Department and subsequently on a daily basis for three consecutive days, if the patient is hospitalised.
218838353|NCT05227976|BEHAVIORAL|Patient education (Theory)|"Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks."
218838354|NCT05227976|BEHAVIORAL|Physical training|"Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks."
219448247|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
219448248|NCT04481997|OTHER|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
218838355|NCT05227976|BEHAVIORAL|Mindfulness and medical yoga in group|"Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks."
218838356|NCT07071454|BEHAVIORAL|Patient intervention|Patient intervention has 2 components. 1) The investigators will send patients a letter that promotes screening and contains targeted messages based on the individual's demographic characteristics. 2) Study staff who is trained in patient navigation will call each patient up to 3 times to confirm receipt of the letter and conduct one-on-one education about screening using a standardized script.
219448249|NCT05673928|DRUG|Trastuzumab emtansine|Given by IV (vein)
219448250|NCT05673928|DRUG|Tucatinib|Given by PO
219448251|NCT03793010|DRUG|FX006|Single Intra-articular injection
219448252|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
219448253|NCT02804685|OTHER|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
218838357|NCT07071454|BEHAVIORAL|PCP intervention|PCP intervention has 2 components. 1) PCPs of patients who are randomized to this group will receive an initial email that provides a list of all patients assigned to the PCP who are randomized to the PCP intervention. PCPs will be specifically informed which patients are high-risk. The email will also include a personal report card with the percentage of patients assigned to the provider who are up-to-date with CRC screening in two age groups: 45-49 years and 50-75 years. Subsequently, PCPs will receive weekly emails with a list of patients randomized to the PCP intervention who are scheduled for a clinic visit with them. 2) The investigators will design a local clinical dashboard using Microsoft Power BI that allows PCPs to view a list of their patients who are randomized to the PCP intervention as well as provide a link to this in each email. High-risk patients will be specifically marked.
218838358|NCT03606291|RADIATION|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
218838359|NCT01070134|BEHAVIORAL|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
218838360|NCT01070134|BEHAVIORAL|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
218838361|NCT05629312|PROCEDURE|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
218838362|NCT05629312|PROCEDURE|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
218838363|NCT06895226|BEHAVIORAL|Exercise|Exercise and physical activity program and usual care
218838364|NCT06895226|OTHER|Usual Care|Usual cara and Exercise and PA recommendations
218838365|NCT06895473|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
218838366|NCT06895473|DRUG|Cytarabine|Given IT
218838367|NCT06895473|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219448254|NCT05247398|OTHER|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
219448255|NCT06042933|OTHER|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
219448256|NCT06042933|OTHER|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
219448257|NCT05661916|DRUG|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
219448258|NCT05661916|DRUG|Placebo|Placebo will be administered by SC injection.
218838368|NCT06895473|DRUG|Methotrexate|Given IT
218838369|NCT06895473|DRUG|Therapeutic Hydrocortisone|Given IT
218838370|NCT04088968|BEHAVIORAL|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
218838371|NCT03262805|DIETARY_SUPPLEMENT|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
218838372|NCT03262805|OTHER|Placebo|Microcrystalline cellulose
218838373|NCT06899737|OTHER|MOMS Postpartum Course|Online professional development training for CHWs on outreach and support for high-risk postpartum mothers
219448259|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
219448260|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
219448261|NCT03807765|DRUG|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
218838374|NCT06896058|OTHER|Written and verbal training given to caregivers|Education was provided with a brochure containing information on practices regarding care of stroke patients with PEG, prepared by the researcher in line with literature information.
218838375|NCT01308840|DRUG|Panitumumab|Day 1 and 15 = 6 mg/kg IV
218838376|NCT01308840|DRUG|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
218838377|NCT01308840|DRUG|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
218838378|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
219448262|NCT03807765|RADIATION|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
219448263|NCT05087641|DEVICE|IAB System|Bronchoscopic implantation of one or multiple IABs
219448264|NCT02230072|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
219448265|NCT00867464|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219448266|NCT00867464|OTHER|Laboratory Biomarker Analysis|Correlative studies
219448267|NCT00867464|OTHER|Long-term Follow-up|Undergo extended follow-up
219448268|NCT00867464|OTHER|Questionnaire Administration|Ancillary studies
219448269|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
219448270|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
219448271|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
219448272|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
219586754|NCT02873741|PROCEDURE|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
219586755|NCT06328179|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；|VHEA -Induction Phase Regimen/Consolidation therapy after remission
219586756|NCT01385449|PROCEDURE|interscalene catheter|interscalene catheter
219586757|NCT01385449|PROCEDURE|interscalene block|interscalene block
219586758|NCT00620399|OTHER|lumbar corset|
218838379|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
218838380|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
218838381|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
218838382|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
218838383|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
218838384|NCT03281629|DEVICE|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
218838385|NCT03281629|DEVICE|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
218838386|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
218838387|NCT01088295|DRUG|Telmisartan|
218838388|NCT06926946|OTHER|Intervention Arm- Cerebral Oximetry + Treatment Guideline|if the cerebral oximeter shows low values, a pre designed treatment guideline will be followed and corrective actions taken.
218838389|NCT06928545|DEVICE|Side-to-side duodenal-ileal anastomosis|Side-to-side duodenal-ileal anastomosis formed by magnetic compression using the GT Metabolic MagDI System.
218838390|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
219448273|NCT05334316|DRUG|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm
219448274|NCT03692195|DEVICE|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
219448275|NCT03692195|OTHER|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
219448276|NCT05980611|DIAGNOSTIC_TEST|IL B,IL 3 in nasal swap and serum|Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
219586759|NCT05408936|DRUG|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
219586760|NCT05013437|DRUG|Evomela|16 mg/m\^2 Evomela administered one time via a central line
218838391|NCT02175277|DRUG|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
218838392|NCT00652275|BIOLOGICAL|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
218838393|NCT00652275|BIOLOGICAL|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
218838394|NCT01968538|RADIATION|Radiation Therapy|
218838395|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
218838396|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
218838397|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
218838398|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
218838399|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
218838400|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
218838401|NCT03974932|DRUG|Ibuprofen|NSAID.
218838402|NCT03974932|DRUG|Acetaminophen|Analgesic.
218838403|NCT03974932|DRUG|Celecoxib|NSAID.
219448277|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
219448278|NCT06231654|DEVICE|Remote photoplethysmography for physiological parameters|"Patients participating in the study will be recruited from our emergency department.~The child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient. The whole device is connected to our standard device. Once the child is immobile and ready, the Caducy® application is launched. At the same time, our standard device is activated. After 30 seconds, we will collect the HR and FR values revealed by the Caducy® application via the non-contact plethysmography method. On the other hand, it will collect the HR and FR values revealed by our standard device (Mindray® scope)."
218838404|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
218838405|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
218838406|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
218838407|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
218838408|NCT01163396|DRUG|Bevacizumab|
218838409|NCT01163396|DRUG|Irinotecan|
218838410|NCT01163396|DRUG|Oxaliplatin|
218838411|NCT01163396|DRUG|5-fluorouracil/leucovorin|
218838412|NCT04001439|DRUG|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
218838413|NCT04122846|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
218838414|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
218838415|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
218838416|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
218838417|NCT04051294|OTHER|Control: Water|Tap water
218838418|NCT07081269|OTHER|observation alone|No interventions will be conducted during the observation period, maintaining participants' normal daily living conditions.
218838419|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
218838420|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
218838421|NCT00284635|PROCEDURE|Fast track vs conventional|
218838422|NCT05455580|BEHAVIORAL|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
218838423|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
218838424|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
218838425|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
218838426|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
219448279|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
218838427|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
218838428|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
218838429|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
218838430|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
218838431|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
218838432|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
218838433|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
218838434|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
218838435|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
218838436|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
218838437|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
218838438|NCT00025064|BIOLOGICAL|bleomycin sulfate|
218838439|NCT00025064|DRUG|chlorambucil|
218838440|NCT00025064|DRUG|cisplatin|
218838441|NCT00025064|DRUG|dacarbazine|
218838442|NCT00025064|DRUG|doxorubicin hydrochloride|
218838443|NCT00025064|DRUG|etoposide|
218838444|NCT00025064|DRUG|ifosfamide|
218838445|NCT00025064|DRUG|melphalan|
218838446|NCT00025064|DRUG|prednisolone|
218838447|NCT00025064|DRUG|procarbazine hydrochloride|
218838448|NCT00025064|DRUG|vinblastine sulfate|
218838449|NCT00025064|DRUG|vincristine sulfate|
219448280|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
219448281|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
219448282|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
218838450|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
218838451|NCT00025064|RADIATION|radiation therapy|
218838452|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
218838453|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
218838454|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
218838455|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
218838456|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
218838457|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
218838458|NCT00395824|PROCEDURE|anticoagulation procedure|
218838459|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
218838460|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
218838461|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
218838462|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
218838463|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
218838464|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
218838465|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
218838466|NCT01882556|DRUG|onabotulinumtoxinA|
218838467|NCT01882556|DRUG|Placebo|
219448283|NCT04924114|DRUG|MK-6194|Subcutaneous injection
219448284|NCT04924114|DRUG|MK-6194-matching placebo|Subcutaneous injection
219448285|NCT00692393|PROCEDURE|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
219448286|NCT00692393|PROCEDURE|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
219448287|NCT01620801|BIOLOGICAL|AAV8-hFIX19|One-time IV vector administration.
219586761|NCT05013437|DEVICE|Next Generation Sequencing|Next Generation Sequencing
219586762|NCT05013437|DRUG|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
219586763|NCT05013437|DRUG|Acetaminophen|650 mg once orally within 30 minutes before Evomela
218838468|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
218838469|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
218838470|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
218838471|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
218838472|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
218838473|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
218838474|NCT04622891|DRUG|Azithromycin|azithromycin group
218838475|NCT04622891|DRUG|Placebo|control group
218838476|NCT05010486|PROCEDURE|rectal surgery|
218838477|NCT03023579|OTHER|The star excursion balance test|
218838478|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
218838479|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
219586764|NCT05013437|DRUG|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
219586765|NCT00945100|DEVICE|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
218838480|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
219448288|NCT06114511|DRUG|BL-M07D1|Administration by intravenous infusion
219448289|NCT06961786|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
219448290|NCT06961786|BIOLOGICAL|TIL|Adoptive T cell therapy with TILs
219586766|NCT00945100|DEVICE|Eye Patch|2 hours patching daily
219448291|NCT06961786|DRUG|Cyclophosphamide|Lymphocyte-depleting chemotherapy
219448292|NCT06961786|DRUG|Fludarabine|Lymphocyte-depleting chemotherapy
219448293|NCT02743975|DRUG|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
219448294|NCT06098794|DIETARY_SUPPLEMENT|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
219448295|NCT06098794|DIETARY_SUPPLEMENT|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
219586767|NCT01853800|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|
219586768|NCT05938907|OTHER|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
219586769|NCT05938907|OTHER|bone substitute|Implanting bone substitute into the area of root apical bone defect
219586770|NCT05938907|COMBINATION_PRODUCT|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
219586771|NCT01697553|OTHER|home automation pack coupled to teleassistance service|
219586772|NCT01697553|OTHER|Home without automation pack coupled to teleassistance service|
219586773|NCT02905747|BEHAVIORAL|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
219196619|NCT06814379|BEHAVIORAL|Virtual reality based rehabilitation|"30-60 minutes. A total of 3 session/week (2 sessions at home and 1 session at the University of Granada). 4 weeks.~The 2 sessions at home will be the same as the sessions in the rehabilitation group (group 2).~The session at the University of Granada will be done with virtual reality (Nintendo Switch) and will follow the same outline as the rest of the sessions:~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
219448296|NCT05411224|OTHER|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
219448297|NCT02095249|DRUG|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
219448298|NCT05516940|OTHER||
219448299|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
219448300|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
219448301|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
219448302|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
219448303|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
219448304|NCT01430910|DRUG|CAZ104|IV infusion
219448305|NCT01430910|DRUG|Avibactam|IV infusion
219448306|NCT01430910|DRUG|Ceftazidime|IV infusion
219448307|NCT02098655|OTHER|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
219448308|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
219448309|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
219448310|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
219448311|NCT01594463|OTHER|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
219448312|NCT01594463|OTHER|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
219448313|NCT01731808|BEHAVIORAL|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
218838481|NCT06641115|BEHAVIORAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
218838482|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
218838483|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
219448314|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
218838484|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218838485|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
218838486|NCT00501592|DRUG|Placebo|Placebo
218838487|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
219196620|NCT06809998|DRUG|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).
219196621|NCT06809998|OTHER|Band-Aid|Band-Aid
219196622|NCT06808867|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for six weeks
219448315|NCT02138734|BIOLOGICAL|BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
219448316|NCT02138734|BIOLOGICAL|BCG( 50mg/Instillation)|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
219448317|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
219448318|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
219448319|NCT03922334|BEHAVIORAL|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
219448320|NCT05032755|OTHER|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
219448321|NCT05032755|OTHER|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
219448322|NCT04944420|BEHAVIORAL|Health enSuite Caregivers|"Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access."
219448323|NCT02330926|OTHER|standard care|Routine oncology and palliative care
219448324|NCT02330926|DIETARY_SUPPLEMENT|nutritional supplements and advice|n-3 PUFA enriched supplements, dietary advice
219448325|NCT02330926|BEHAVIORAL|home-based self-assisted exercise program|Strength and aerobic
219448326|NCT02330926|DRUG|Ibuprofen|400mgx3
219448327|NCT05031390|PROCEDURE|Physiotherapist-led training|Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
219448328|NCT00814905|DRUG|saline|A saline infusion after delivery (one dose)
219448329|NCT00814905|DRUG|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
219448330|NCT00814905|DRUG|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
219448331|NCT00814905|DRUG|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
219448332|NCT04284787|DRUG|Azacitidine|Given IV or SC
219448333|NCT04284787|PROCEDURE|Biopsy Procedure|Undergo biopsy
219448334|NCT04284787|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219448335|NCT04284787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219448336|NCT04284787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219448337|NCT04284787|PROCEDURE|Echocardiography Test|Undergo ECHO
219586774|NCT03724214|COMBINATION_PRODUCT|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
219586775|NCT03724214|COMBINATION_PRODUCT|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
219586776|NCT02516943|OTHER|Control|The patient's ABGs were test according to a 4 - hour routine
219586777|NCT02516943|OTHER|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
219586778|NCT00375895|DRUG|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
219586779|NCT02668588|DRUG|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
219586780|NCT02668588|DRUG|extended release of placebo|1 intramuscular injection of extended release of placebo
218838488|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
218838489|NCT05946044|BEHAVIORAL|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
218838490|NCT05417451|OTHER|Acupuncture|All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)
218838491|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
218838492|NCT04898894|DRUG|Venetoclax|Given orally (PO)
218838493|NCT04898894|DRUG|Selinexor|Given Orally (PO)
218838494|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
218838495|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
218838496|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
218838497|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
218838498|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
218838499|NCT01525862|DEVICE|Balloon sinus dilation|
218838500|NCT04193709|DEVICE|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
219017331|NCT06370780|OTHER|EPI LOVE|Observational cohort only
219017334|NCT00576134|DEVICE|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
219448338|NCT04284787|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219448339|NCT04284787|BIOLOGICAL|Pembrolizumab|Given IV
219448340|NCT04284787|DRUG|Venetoclax|Given PO
219448341|NCT03613532|DRUG|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
219448342|NCT03613532|DRUG|Fludarabine|Given once daily for 4 days
219017335|NCT06637072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
219448343|NCT03613532|DRUG|Busulfan|Given twice daily for 4 days
219448344|NCT03613532|DRUG|Venetoclax|Part 2, Part 3, and Part 4: 14 doses for 8-12 cycles depending on dose level assigned
219448345|NCT03613532|DRUG|Azacitidine|Part 2 and Part 4: 5 doses for 8-12 cycles depending on dose level assigned
219448346|NCT03613532|DRUG|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
219448347|NCT06798337|OTHER|Conventional Physiotherapy group|Participants in the regular physical therapy group performed balance and coordination exercises three times a week without the use of rewards. These subjects completed only physical exercises, without engaging in game-like interactive tasks using virtual reality (VR) glasses. Each session was conducted at the same time for each subject, with a potential variation of ±1 hour.
219448348|NCT06798337|OTHER|Reward based physiotherapy group|Subjects in the reward group performed balance and coordination exercises three times a week, with the inclusion of rewards. At the end of each exercise session, participants engaged in game-like interactive tasks using virtual reality (VR) glasses. Exercise sessions were conducted at the same time for each subject, with a permissible variation of ±1 hour.
219448349|NCT01874353|DRUG|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
218838501|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
218838502|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
218838503|NCT04719481|DRUG|Placebo|daily oral administration
218838504|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
218838505|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
218838506|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
218838507|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
218838508|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
218838509|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
218838510|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
218838511|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
218838512|NCT00408707|PROCEDURE|local infiltration analgesia|
218838513|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
218838514|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
218838515|NCT01208324|DRUG|Placebo Patch|placebo
218838516|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
218838517|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
218838518|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
218838519|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838520|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838521|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838522|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838523|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838524|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
219017336|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
219017337|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
219448350|NCT01874353|DRUG|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
219017338|NCT06641726|OTHER|Not applicable- observational study|This is non-interventional, cross-sectional observational study and thus there is no intervention.
219448351|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
219448352|NCT03059823|DRUG|retifanlimab|Anti-PD-1 monoclonal antibody
219448353|NCT05240300|BIOLOGICAL|BX005-A|phage gel
219196623|NCT06808867|DIETARY_SUPPLEMENT|Dietary Supplement with Active Ingredient Blend|Eligible subjects will receive Active supplement to take daily for six weeks
219448354|NCT05240300|OTHER|Placebo|vehicle gel
219448355|NCT06628869|DIETARY_SUPPLEMENT|Fructanase|Participants will consume one capsule containing 400 INU inulinase (325 mg, includes maltodextrin) with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The fructanase was obtained from Aspergillus tubingensis.
219586781|NCT01596660|DRUG|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
218838525|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838526|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
218838527|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
218838528|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
218838529|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
218838530|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
218838531|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
218838532|NCT00079261|DRUG|CHOP regimen|
219448356|NCT06628869|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing 300 mg maltodextrin with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The maltodextrin was obtained from tapioca.
218838533|NCT00079261|DRUG|cyclophosphamide|
218838534|NCT00079261|DRUG|doxorubicin hydrochloride|
218838535|NCT00079261|DRUG|gemcitabine hydrochloride|
218838536|NCT00079261|DRUG|prednisone|
219448357|NCT06085495|PROCEDURE|mechanical thrombectomy (PMT)|After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
219448358|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
219448359|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
219196624|NCT06808841|DRUG|Sufentanil injection|Different concentrations of sufentanil were administered to three different subgroups of patients in the same way
219448360|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
219196625|NCT06808841|DRUG|Placebo|Placebo
219448361|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
219448362|NCT04195945|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219448363|NCT04195945|DRUG|Cladribine|Given IV
219586782|NCT01596660|DRUG|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
219586783|NCT04899544|BEHAVIORAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
219586784|NCT04899544|BEHAVIORAL|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
219586785|NCT05060744|DEVICE|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
219586786|NCT05060744|OTHER|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
218838537|NCT00079261|DRUG|vincristine sulfate|
218838538|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
218838539|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
218838540|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
218838541|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
219586787|NCT01531439|DRUG|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
219586788|NCT01531439|DRUG|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
219586789|NCT00476775|BEHAVIORAL|after school ethnic dance program - ballet folklorica|
218838542|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
219586790|NCT00476775|BEHAVIORAL|culturally-tailored, home-based screen time reduction|
219586791|NCT00476775|BEHAVIORAL|culturally-tailored health and nutrition education|
219586792|NCT03796598|DRUG|Fecal Microbial transplant Capsules|Oral capsules of FMT
219586793|NCT03796598|DRUG|Fecal Microbial Transplant Enema|FMT enema
219586794|NCT03796598|OTHER|Placebo|Placebo
219586795|NCT04358055|DEVICE|WET® gel|In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
219448364|NCT04195945|DRUG|Cytarabine|Given IV
219448365|NCT04195945|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
219586796|NCT00754650|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
219586797|NCT00805675|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
218838543|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
218838544|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
218838545|NCT03292549|PROCEDURE|Robotic partial surgery|Robotic partial surgery
218838546|NCT02789345|DRUG|Ramucirumab|Administered IV
218838547|NCT02789345|DRUG|Necitumumab|Administered IV
218838548|NCT02789345|DRUG|Osimertinib|Administered orally
218838549|NCT00046761|DRUG|ONO-2506|
218838550|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
218838551|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
218838552|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
218838553|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
219448366|NCT04195945|DRUG|Mitoxantrone|Given IV
219448367|NCT04195945|OTHER|Questionnaire Administration|Ancillary studies
219448368|NCT04195945|OTHER|Quality-of-Life Assessment|Ancillary studies
219448369|NCT04413994|DIETARY_SUPPLEMENT|Humavant|"Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
219586798|NCT00805675|DRUG|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
219586799|NCT00805675|DRUG|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
219586800|NCT01911897|DEVICE|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
219586801|NCT00823121|PROCEDURE|freezing embryos by vitrification|vitrification by Cryotop method
219586802|NCT00823121|PROCEDURE|fresh embryo transfers|fresh embryo transfers
219586803|NCT00823121|DRUG|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
219586804|NCT00823121|DRUG|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
218838554|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
218838555|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
219196626|NCT06812728|DRUG|mFOLFIRINOX|Neoadjuvant chemotherapy
219448370|NCT04919369|BIOLOGICAL|Atezolizumab|Given IV
219448371|NCT04919369|DRUG|Tretinoin|Given PO
219448372|NCT03567733|DEVICE|XIENCE Sierra|Percutaneous coronary intervention
219448373|NCT04561453|DIAGNOSTIC_TEST|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
219448374|NCT05187611|DEVICE|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
218838556|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
218838557|NCT02245269|DRUG|Tipranavir|
218838558|NCT02245269|DRUG|Ritonavir|
218838559|NCT02245269|DRUG|Atorvastatin|
219448375|NCT05187611|DEVICE|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
218838560|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
218838561|NCT01163357|DRUG|bortezomib|Given IV
218838562|NCT01163357|DRUG|fludarabine phosphate|Given IV
218838563|NCT01163357|OTHER|melphalan|Given IV
218838564|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
218838565|NCT01163357|DRUG|tacrolimus|Given IV and orally
218838566|NCT01163357|DRUG|sirolimus|Given orally
218838567|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
219448376|NCT01797055|DRUG|Human apotransferrin|intravenous infusion
219586805|NCT00823121|DRUG|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
219586806|NCT00801359|PROCEDURE|Phacoemulsification|
219586807|NCT00801359|DRUG|BSSPlus solution|
219448377|NCT06803602|DEVICE|EMSELLA®|Subjects will receive 100% intensity of the EMSELLA® (BTL Industries, Marlborough, MA) High-Intensity Focused Electromagnetic (HIFEM) treatment, in a single 30-minute session, twice per week for 3 weeks.
219448378|NCT06803602|DEVICE|Sham Comparator Device|Subjects will be asked to sit on the EMSELLA® (BTL Industries, Marlborough, MA) treatment head which will be powered off and instead have a small remote control vibration device that will simulate active treatment, in a single 30-minute session, twice per week for 3 weeks.
219448379|NCT05848895|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
219586808|NCT00801359|DRUG|Lactated Ringer's solution|
219586809|NCT02328742|BIOLOGICAL|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
219586810|NCT02328742|OTHER|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
218838568|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
218838569|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
218838570|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
218838571|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
218838572|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
218838573|NCT04338178|BEHAVIORAL|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
218838574|NCT04338178|BEHAVIORAL|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
218838575|NCT04338178|BEHAVIORAL|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
218838576|NCT04338178|PROCEDURE|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
218838577|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
218838578|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
218838579|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
218838580|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
218838581|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
218838582|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
219448380|NCT05848895|BEHAVIORAL|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
219448381|NCT06085443|OTHER|Ear Hygiene|2 sprays in each ear, every 3 days at home
219448382|NCT03502785|BIOLOGICAL|INO-5401|INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
219448383|NCT03502785|BIOLOGICAL|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
219448384|NCT03502785|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
219586811|NCT02328742|BIOLOGICAL|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
219586812|NCT02328742|BIOLOGICAL|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
218838583|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
218838584|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
218838585|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
218838586|NCT00301145|BEHAVIORAL|smoking cessation intervention|
218838587|NCT00301145|DRUG|varenicline|
218838588|NCT00301145|OTHER|counseling intervention|
218838589|NCT00301145|OTHER|internet-based intervention|
218838590|NCT02854436|DRUG|Niraparib|Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
218838591|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
219196627|NCT06812728|DRUG|mFolfox6|Neoadjuvant chemotherapy
219196628|NCT06842290|PROCEDURE|Botulinum toxin-A injection|Botulinum toxin-A Injection Mentalis muscle in lower anterior teeth
218838592|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
218838593|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
218838594|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
219448385|NCT03502785|DEVICE|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
219448386|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
218838595|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
218838596|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
218838597|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
218838598|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
218838599|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
218838600|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
218838601|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
218838602|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
218838603|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
218838604|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
218838605|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
218838606|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
219448387|NCT05243875|BEHAVIORAL|LEAP Education + Navigation|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE; and (2) navigation, which involves individual tailoring of information about where and how to get tested, and where to get vaccinated, and when appropriate, guiding participants in scheduling testing and vaccination appointments.
219448388|NCT05243875|BEHAVIORAL|LEAP Education|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE.
218838607|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
218838608|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
218838609|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
218838610|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
218838611|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
218838612|NCT00003065|BIOLOGICAL|filgrastim|
218838613|NCT00003065|DRUG|paclitaxel|
218838614|NCT00003065|DRUG|topotecan hydrochloride|
219448389|NCT05426083|OTHER|Physiological Assessment|Observational only
219448390|NCT04992507|PROCEDURE|Anesthesia Procedure|Given TIVA
219448391|NCT04992507|DRUG|General Anesthesia Procedure|Given inhaled volatile anesthetics
219448392|NCT04992507|PROCEDURE|Resection|Undergo surgical resection
219448393|NCT02945852|DRUG|apatinib|apatinib 500mg/d until progressive Disease
219448394|NCT06305819|BEHAVIORAL|self-management support program|The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.
218838615|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
218838616|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
218838617|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
218838618|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
218838619|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
219017373|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
219017374|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
219448395|NCT06305819|OTHER|Control group|Treatment as usual
219448396|NCT04893395|OTHER|Pharmacogenomic Screening|"First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations"
219448397|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
219448398|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
219448399|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
219448400|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
219448401|NCT05222373|BEHAVIORAL|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
219448402|NCT04170894|OTHER|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
219448403|NCT04170894|OTHER|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
219448404|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
219448405|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
219017375|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
219017376|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
219017377|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
219017378|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
219017379|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
219017380|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
219017381|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
219017382|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
218838620|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
218838621|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
218838622|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
218838623|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
219448406|NCT05624710|DRUG|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
219448407|NCT05705401|RADIATION|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
219448408|NCT05705401|DRUG|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
219448409|NCT05645692|DRUG|Atezolizumab|Participants will receive 1200 mg IV atezolizumab Q3W.
219448410|NCT05645692|DRUG|Tobemstomig|Participants will receive 600 mg IV tobemstomig Q3W.
218838624|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
218838625|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
218838626|NCT01707680|OTHER|SOC|Patient are given standard of care
218838627|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
218838628|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
218838629|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
218838630|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
218838631|NCT02422693|OTHER|Aquatic Exercises|Exercises performed in the water.
218838632|NCT02422693|OTHER|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
218838633|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
218838634|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
218838635|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
218838636|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
218838637|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
218838638|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
219448411|NCT05645692|DRUG|Tiragolumab|Participants will receive 600 mg IV tiragolumab Q3W.
219448412|NCT03250247|DEVICE|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices \> 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
219448413|NCT01239134|BIOLOGICAL|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
219448414|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
219448415|NCT04250155|DRUG|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
219448416|NCT04250155|DRUG|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
219448417|NCT04250155|DRUG|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
219448418|NCT06225141|OTHER|Clinical Data reuse|Clinical Data reuse
219586813|NCT05035342|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
218838639|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
219017395|NCT06319339|DRUG|Vumerity|diroximal fumarate 462 mg (2 capsules)
219017396|NCT06319339|OTHER|Placebo|Microcrystalline cellulose 462 mg (2 capsules)
219017397|NCT05996523|BIOLOGICAL|PRGN-2009|PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
219017398|NCT05996523|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
219017399|NCT05445778|DRUG|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
218838640|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
218838641|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
218838642|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
219448419|NCT05371795|DEVICE|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
219448420|NCT05371795|DEVICE|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
218838643|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
218838644|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
218838645|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
218838646|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
219017400|NCT05445778|DRUG|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
219017402|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
219448421|NCT03995121|DRUG|[11C]APP311|It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
219448422|NCT04440085|DRUG|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
219586814|NCT05035342|BIOLOGICAL|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
219586815|NCT01916590|DRUG|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
219586816|NCT01916590|DRUG|placebo|
219586817|NCT00486317|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
219586818|NCT00712738|DRUG|Nifedipine|
219448423|NCT04440085|DRUG|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
219448424|NCT04488991|OTHER|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
219448425|NCT00166244|DRUG|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
219586819|NCT00712738|PROCEDURE|Phlebotomy|
219586820|NCT00712738|PROCEDURE|Urinalysis|
219586821|NCT00712738|PROCEDURE|Echocardiogram|
219586822|NCT00712738|PROCEDURE|Electrocardiogram|
219586823|NCT02208232|PROCEDURE|cataract surgery|cataract surgery with implantation of intraocular lens
219586824|NCT03279211|OTHER|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
219196629|NCT06842290|PROCEDURE|Coronally advanced flap|Coronally Advanced Flap andDe-epithelized Free Gingival Graft
219448426|NCT02844322|DRUG|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
219448427|NCT02844322|DRUG|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
219448428|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
219448429|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
219448430|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
219448431|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
219448432|NCT05010564|GENETIC|Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy|"Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10\^6 cells/m2~DL1: 1×10\^7 cells/m2~DL2: 3×10\^7 cells/m2~DL3: 1×10\^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells."
219448433|NCT05965713|DEVICE|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline and at 12 weeks completion of IpsiHand use.
219448434|NCT05965713|OTHER|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized standard of care home exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks.
219448435|NCT05951439|DIETARY_SUPPLEMENT|CRE + HMB|3 g/day of CRE and 3 g/day of HMB
219448436|NCT05951439|DIETARY_SUPPLEMENT|Placebo|6 g/day of inulin
219448437|NCT04920539|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
219448438|NCT02974621|BIOLOGICAL|Bevacizumab|Given IV
219448439|NCT02974621|DRUG|Cediranib|Given PO
219448440|NCT02974621|DRUG|Cediranib Maleate|Given PO
219448441|NCT02974621|DRUG|Olaparib|Given PO
219448442|NCT03218137|DRUG|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
219448443|NCT02549521|DIETARY_SUPPLEMENT|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
219448444|NCT02549521|DIETARY_SUPPLEMENT|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
218838647|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
218838648|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
218838649|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
218838650|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
219448445|NCT04685486|OTHER|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
219448446|NCT03580785|GENETIC|genetic analysis|saliva is collected for DNA extraction
219448447|NCT03580785|RADIATION|panoramic radiography|panoramic radiography
219448448|NCT03580785|RADIATION|teleradiography|teleradiography
219448449|NCT03580785|RADIATION|intraoral X-rays|intraoral X-rays
219448450|NCT03580785|RADIATION|CT scan of maxillary and mandible|CT scan of maxillary and mandible
219448451|NCT06253065|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model (developed)|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
219448452|NCT06103565|OTHER|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
219448453|NCT03936335|DRUG|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
219586825|NCT03279211|OTHER|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
219586826|NCT03279211|OTHER|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
219586827|NCT00097877|DRUG|biphasic insulin aspart|
219017404|NCT06558279|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
219017405|NCT06558279|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
219017406|NCT06162221|DRUG|RMC-6291|Oral tablet
219017407|NCT06162221|DRUG|RMC-6236|Oral tablet
219017408|NCT06162221|DRUG|Pembrolizumab|IV Infusion
219017409|NCT06162221|DRUG|Cisplatin|IV Infusion
219017410|NCT06162221|DRUG|Carboplatin|IV Infusion
219017411|NCT06162221|DRUG|Pemetrexed|IV infusion
219017412|NCT06162221|DRUG|RMC-9805|Oral Tablet
219017413|NCT05837897|DRUG|Vedolizumab IV|Vedolizumab IV infusion
219017414|NCT05837897|DRUG|Placebo|Vedolizumab placebo-matching IV infusion
219017415|NCT06641310|PROCEDURE|Endurance Exercise Therapy|"* Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study."
218838651|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
218838652|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
218838653|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
218838654|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
218838655|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
219448454|NCT04685356|OTHER|IBAIP : Infant Behaviour Assessment and Intervention Program|The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
219448455|NCT04685356|OTHER|Standard Support|One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
218838656|NCT02173639|DRUG|BI 1356|
218838657|NCT02173639|DRUG|Metformin|
218838658|NCT01260688|DRUG|cediranib maleate|Given orally
218838659|NCT01260688|DRUG|dasatinib|Given orally
218838660|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
218838661|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
218838662|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
219448456|NCT04685356|OTHER|Ages and Stages Questionnaire (ASQ)|Global development screening tool
219448457|NCT04685356|OTHER|Parenting Stress Index (PSI)|Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
219448458|NCT04685356|OTHER|Bayley Scales of Infant and Toddler Development (BSID-IV)|This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
218838663|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
218838664|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
218838665|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
218838666|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
218838667|NCT06106009|DRUG|Midazolam|Midazolam oral solution
218838668|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
218838669|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
219017419|NCT06179472|DEVICE|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
219017420|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
219017421|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
219017422|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219017423|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
219017424|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
219448459|NCT03786354|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
219448460|NCT03786354|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219586828|NCT00097877|DRUG|insulin glargine|
218838670|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
218838671|NCT00140907|DRUG|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
218838672|NCT00140907|DRUG|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
218838673|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
218838674|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
218838675|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
218838676|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
218838677|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
218838678|NCT02924441|OTHER|Lidocaine|Applied to breast skin
218838679|NCT02924441|OTHER|Calming Music|Played during mammography
218838680|NCT02924441|OTHER|No Music|No music played during mammography
218838681|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
218838682|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
219448461|NCT01172990|PROCEDURE|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
219448462|NCT01172990|PROCEDURE|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
219586829|NCT06018974|DEVICE|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
219586830|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
219586831|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
218838683|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
218838684|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
218838685|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
218838686|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
218838687|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
218838688|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
218838689|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
218838690|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
218838691|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
218838692|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
218838693|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
218838694|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
218838695|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
218838696|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
218838697|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
218838698|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
218838699|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
218838700|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
218838701|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
218838702|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
218838703|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
218838704|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
218838705|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
218838706|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
219448463|NCT06618911|OTHER|5 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 5 Hz"
219448464|NCT06618911|OTHER|Sham electroacupuncture|Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce \&#34;deqi.\&#34; A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm serves as a placebo control to evaluate the true effect of electroacupuncture.
219448465|NCT06618911|OTHER|100 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 100 Hz"
218838707|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
218838708|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
218838709|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
218838710|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
218838711|NCT00022763|DRUG|Enfuvirtide|
218838712|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
218838713|NCT04829786|DRUG|palovarotene low-dose|oral capsules
218838714|NCT04829786|DRUG|palovarotene high-dose|oral capsules
218838715|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
218838716|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
218838717|NCT04607512|OTHER|moxifloxicin|positive control
218838718|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
218838719|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
218838720|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
218838721|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
218838722|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
218838723|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
218838724|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
219448466|NCT04313673|DIAGNOSTIC_TEST|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
218838725|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
218838726|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
218838727|NCT06637306|DRUG|Dupilumab|Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
218838728|NCT06637306|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
218838729|NCT06637306|DRUG|Paclitaxel|Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
218838730|NCT06637306|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
218838731|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
218838732|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
218838733|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
218838734|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
218838735|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
218838736|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
218838737|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
218838738|NCT04840485|DRUG|Placebo|Placebo
218838739|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
218838740|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
218838741|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
218838742|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
218838743|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
218838744|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
218838745|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
218838746|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
218838747|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
218838748|NCT01326884|DEVICE|ZLP|ZLP Graft
218838749|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
218838750|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
218838751|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
219448467|NCT01641224|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
219448468|NCT01641224|DEVICE|Atractylodes|Atractylodes (\~10-15g)
219448469|NCT01641224|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
219448470|NCT01641224|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
219448471|NCT01641224|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
219448472|NCT01641224|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
219448473|NCT01641224|DRUG|Radix curcumae|Radix curcumae (\~10g)
219448474|NCT01641224|DRUG|Fingered citron|Fingered citron (\~10g)
218838752|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
218838753|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
218838754|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
218838755|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
218838756|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
218838757|NCT02384473|PROCEDURE|SWE|Undergo SWE
218838758|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
218838759|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
218838760|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
218838761|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
219448475|NCT01641224|DRUG|Tuckahoe|Tuckahoe (15g)
219586832|NCT05494645|DRUG|Exparel|Liposomal bupivicaine
218838762|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
218838763|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
218838764|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
218838765|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
218838766|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
218838767|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
219017431|NCT05064410|BEHAVIORAL|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
218838768|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219586833|NCT05494645|DRUG|Peripheral Nerve Block|Peripheral nerve block without Exparel
219586834|NCT00054574|BIOLOGICAL|panitumumab|
218838769|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
218838770|NCT01035463|DRUG|Carmustine|Given IV
218838771|NCT01035463|DRUG|Cytarabine|Given IV
218838772|NCT01035463|DRUG|Etoposide|Given IV
218838773|NCT01035463|DRUG|Lenalidomide|Given PO
218838774|NCT01035463|DRUG|Melphalan|Given IV
218838775|NCT01035463|BIOLOGICAL|Rituximab|Given IV
218838776|NCT04924101|BIOLOGICAL|Pembrolizumab|IV infusion
218838777|NCT04924101|BIOLOGICAL|MK-4830|IV infusion
218838778|NCT04924101|BIOLOGICAL|Boserolimab|IV infusion
218838779|NCT04924101|DRUG|Lenvatinib|Oral capsule
218838780|NCT04924101|DRUG|Etoposide|IV infusion
218838781|NCT04924101|DRUG|Cisplatin|IV infusion
218838782|NCT04924101|DRUG|Carboplatin|IV infusion
218838783|NCT00737217|BEHAVIORAL|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
218838784|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
218838785|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
218838786|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
218838787|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
218838788|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
218838789|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
219448476|NCT01641224|DRUG|Placebo|Placebo is blindly given to patients.
219448477|NCT04684849|OTHER|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
219448478|NCT04684849|OTHER|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
219448479|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
219448480|NCT00926562|DRUG|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
219448481|NCT00926562|DRUG|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
219586835|NCT05396378|DIETARY_SUPPLEMENT|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
219586836|NCT04645264|DEVICE|Foley Catheter|The patient is catheterized during surgery.
218838790|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
219448482|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
219448483|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
219448484|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
219448485|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
219448486|NCT06312046|OTHER|HiBalance-MS|See arm description for intervention group.
219448487|NCT02049294|BIOLOGICAL|Omalizumab (Xolair)|
219448488|NCT02049294|DRUG|Placebo|
219448489|NCT05422222|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
219448490|NCT04097080|DRUG|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
219448491|NCT04097080|DRUG|Standard of Care|Placebo group will receive reconstituted air given three times a week.
219448492|NCT04955301|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
219448493|NCT02972281|BIOLOGICAL|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
218838791|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
218838792|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
218838793|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
218838794|NCT00178074|BEHAVIORAL|total sleep deprivation|
218838795|NCT00178074|PROCEDURE|PET imaging|
218838796|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
218838797|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
218838798|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
218838799|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
219448494|NCT03037112|BEHAVIORAL|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
219448495|NCT03037112|BEHAVIORAL|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
219448496|NCT00255996|DRUG|linezolid|
219448497|NCT00534560|DRUG|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
219448498|NCT00534560|DRUG|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
219448499|NCT00534560|DRUG|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
219448500|NCT02415504|BEHAVIORAL|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
219448501|NCT02415504|BEHAVIORAL|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
219448502|NCT01505140|OTHER|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
218838800|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
218838801|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
218838802|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
218838803|NCT00158249|DRUG|placebo|matched for physical appearance
219586837|NCT02330536|DEVICE|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
218838804|NCT05583318|OTHER|Data collection|Data from hematological malignancy registries
218838805|NCT05583318|OTHER|Questionnaires|"9 questionnaires were sent out:~1. QLQ-C30 and SF-12 Quality of Life Questionnaire.~2. Oral quality of life questionnaire QLQ-OH15~3. Sexuality questionnaire SHQ-C22~4. Anxiety and depression questionnaire HADS,~5. Rosenberg Self-Esteem Questionnaire~6. RNLI Reintegration to Normal Life Questionnaire~7. Social Support Questionnaire SSQ6,~8. Socio-economic status questionnaire EPICES,~9. Complementary questionnaire collecting data on socio-professional status."
219448503|NCT04783376|DRUG|: Insulin, lispro and regular insulin|"* A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
218838806|NCT05103605|DRUG|Osimertinib|Single arm treated by osimertinib
218838807|NCT06477393|OTHER|Regular rehababilitation|Subjects of the experimental and control groups will receive routine procedures applied in the resort sanatorium: physiotherapy (28-32), occupational therapy (12-18), dry hydromassage (7-8), psychotherapy or audiovisual relaxation (3-4), social worker's visit ( 1-2), physiotherapy (magnetotherapy, ultrasound therapy (8-9).
218838808|NCT06477393|OTHER|Heat procedures|"The bath is filled with 200 litres of warm tap water at 36-38°C. The participant lies in the prepared bath, ensuring the chest area remains uncovered. While in the bath, the participant performs gentle movements. The procedure lasts 12-15 minutes. Air is pumped into the water to increase the oxygen saturation in the bath environment.~A prepared gel pack will be placed in another bag and heated to 50-55°C. The heated pack will be delivered to the treatment area using pumps. For applications, the gel pack is used at 40-42°C. Temperature of the gel pack can range between 38-43°C."
218838809|NCT06477393|OTHER|Healing mud application|"Therapeutic mud applications: peat brought from the quarry is sifted, ground, and mixed with natural mineralisation of 20-22g/l with mineral water in a ratio of at least 4:1 until the consistency of thick sour cream. The prepared peat mud is heated to 50-55 degrees. The heated mud is fed to the place where the procedures are performed with the help of pumps. Mud mass at 40-42 degrees is used for applications. A mud temperature range of 38-43 degrees is possible.~Before the procedure, it is recommended not to eat, go to the toilet, or take a warm shower. A polyethene film is laid on a special heated couch, and a 2-4 cm thick layer of mud is poured into the area of the hands and feet, covered with a blanket. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel, and rests. Peloids are not reused."
218838810|NCT06477393|OTHER|Mineral water bath|The pearl bath is prepared by a physical method. The bath is filled with 200 l of warm 36-38 C mineral water, the subject lies in the prepared bath, leaving the heart area open, while lying in the bath he performs light movements. The duration of the procedure is 12-15 minutes. Air is blown into the water, which increases oxygen saturation in the bath environment. Before the procedure, it is recommended not to eat, go to the toilet, take a warm shower. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel and rests. Mineral waters are not reused.
218838811|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
219448504|NCT05324956|OTHER|No intervention|Individuals will not receive any interventions
219448505|NCT02876484|DRUG|Colesevelam|
219448506|NCT02876484|DRUG|Chenodeoxycholic Acid|
218838812|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
218838813|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
218838814|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
218838815|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
218838816|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
218838817|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
218838818|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
218838819|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
218838820|NCT06248164|OTHER|No intervention|We will not carry out any type of intervention, just observe the behaviors and health parameters of parents and children.
218838821|NCT05014646|DRUG|Cholestyramine|Given PO
218838822|NCT05014646|DRUG|Leflunomide|Given PO
218838823|NCT03943901|DRUG|Rituximab|Rituximab is a monoclonal antibody
218838824|NCT03943901|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent
218838825|NCT03943901|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic
218838826|NCT03943901|DRUG|Vincristine|Chemotherapy drug, plant alkaloid
218838827|NCT03943901|DRUG|Prednisone|Steroid, anti-inflammatory
218838828|NCT03943901|BIOLOGICAL|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier
218838829|NCT05646446|BEHAVIORAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
218838830|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
218838831|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
219448507|NCT02876484|OTHER|Water|
218838832|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
218838833|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
218838834|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
218838835|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
219766466|NCT07212283|BEHAVIORAL|Wise Intervention LGB-TNB|The intervention will be designed to reduce aggressive behaviors based on sexual orientation and gender identity and to promote prosocial behaviors toward these individuals. This intervention will include three components: (1) reading scientific studies about people's ability to change. In addition, they will read other studies about how thoughts and emotions influence behavior through brain pathways, and that these pathways can be modified under certain circumstances; (2) reading testimonials that support the idea that people can change. These testimonials include accounts of people who were victims or perpetrators based on sexual orientation and gender identity, including important components of empathy and prosocial behaviors toward the victims. To give credibility to the intervention, they will be informed that these stories were written by other young people who previously participated; and (3) self-persuasion exercises that involve an active commitment to change.
219766467|NCT07212283|BEHAVIORAL|Values alignment wise intervention|This intervention will be based on the same strategies as the experimental intervention, but it will not address aspects related to prosocial behaviors or aggression toward LGB-TNB individuals; instead, it will be applied to improve adolescents' eating habits.
219448508|NCT05535270|DIAGNOSTIC_TEST|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
219766468|NCT07210294|DEVICE|The press needle and medication|"Press needles using the needle sizes 0.17mm x 0.9mm on auricular acupuncture points (MA-IC6 (Stomach) bilaterally) and the needle sizes 0.20 mm x 1.5mm on body acupuncture points (ST36 bilaterally). After that, apply an adhesive patches on top of the press needle. The press needle is attached for 14 days (on the 7th day the press needle is replaced).~Medication using proton pump inhibitor drugs"
219448509|NCT00593775|PROCEDURE|assisted hatching|assisted hatching with laser
219448510|NCT03797144|DEVICE|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
219766469|NCT07210294|DEVICE|The sham press needle and medication|"Sham press needle uses adhesive patches without needles on auricular acupuncture points (MA-IC6 (Stomach) bilateral) and body acupuncture points (ST36 bilateral). The sham press needle is attached for 14 days (on the 7th day the sham press needle is replaced).~Medication using proton pump inhibitor drugs"
218838836|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
218838837|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~\- peripheral venous"
218838838|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
218838839|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
218838840|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
218838841|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
219448511|NCT05823428|PROCEDURE|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
219448512|NCT05823428|PROCEDURE|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
219766470|NCT07212270|PROCEDURE|periodontal flap surgery|Open flap debridement with intra-sulcular incisions or flaps with para-marginal incisions were performed by lifting the mucoperiosteal flap and debriding the periodontal defect under visual control.
218838842|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
218838843|NCT04153981|DRUG|Insulin Glargine|Administered SC
218838844|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
219017437|NCT03280862|DEVICE|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
219017438|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
218838847|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
219448513|NCT02573506|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
219448514|NCT02573506|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
219448515|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
219448516|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
219448517|NCT04728880|DRUG|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
219448518|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
219448519|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
219448520|NCT00827125|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
219448521|NCT05049642|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
219448522|NCT00345956|BIOLOGICAL|Human rotavirus liquid vaccine|
219448523|NCT03083470|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
219448524|NCT03083470|OTHER|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
219448525|NCT05399589|COMBINATION_PRODUCT|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
219448526|NCT05399589|COMBINATION_PRODUCT|use healing cap in control group|use healing cap in control group
219448527|NCT04502199|OTHER|non interventional study|observational study
219448528|NCT00955344|BEHAVIORAL|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
219448529|NCT00955344|BEHAVIORAL|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
219448530|NCT06984263|PROCEDURE|Circumcision|Circumcision performed as part of standard clinical care in patients with phimosis, which may be caused by lichen sclerosus. The procedure is not assigned by the study but observed as part of routine treatment
219448531|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
219448532|NCT00041535|DRUG|OGT 918|
219017439|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
219448533|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
219766471|NCT07212270|PROCEDURE|gingivectomy and gingivoplasty|surgical methods for the excision of hyperplastically enlarged gingiva.
218838848|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
218838849|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
219017440|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
219017441|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
219017442|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
219017444|NCT04458909|DRUG|Carboplatin|Given IV
219017445|NCT04458909|DRUG|Cisplatin|Given IV
219017446|NCT04458909|DRUG|Gemcitabine|Given IV
219017447|NCT04458909|BIOLOGICAL|Nivolumab|Given IV
219586838|NCT05715983|PROCEDURE|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
218838850|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
218838851|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
219586839|NCT05715983|PROCEDURE|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
218838852|NCT05302869|OTHER|None intervention|None intervention
219448534|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
219586840|NCT05250466|PROCEDURE|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
219586841|NCT05250466|PROCEDURE|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
219586842|NCT00541216|DRUG|Ephedrine|
219586843|NCT00886223|PROCEDURE|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
219586844|NCT01955837|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
218838853|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
218838854|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
218838855|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
218838856|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
218838857|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
218838858|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
218838859|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
218838860|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
218838861|NCT00002297|DRUG|Inosine pranobex|
218838862|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
218838863|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
218838864|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
218838865|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
218838866|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
218838867|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
218838868|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
218838869|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
219448535|NCT02670187|BIOLOGICAL|GLS-5300|
219448536|NCT04688827|OTHER|Exercise therapy|15 weeks of resistance training (additional to endurance training)
219448537|NCT00606229|DRUG|Aripiprazole|oral, 24mg/day
218838870|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
219586845|NCT01955837|DRUG|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219586846|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
219586847|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
218838871|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
218838872|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
218838873|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
218838874|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
218838875|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
218838876|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
218838877|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
219448538|NCT03077711|DRUG|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
219448539|NCT03077711|DRUG|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
219448540|NCT00298311|BEHAVIORAL|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
219448541|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
218838878|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
218838879|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
219017448|NCT04458909|OTHER|Questionnaire Administration|Ancillary studies
219017449|NCT06317662|DRUG|Asparaginase Erwinia chrysanthemi|Given recombinant crisantaspase IM or crisantaspase IM or IV
219017450|NCT06317662|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219448542|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
219448543|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
219586848|NCT06423443|BEHAVIORAL|Digital Cognitive Behavioral Therapy|digital cognitive behavioral therapy app
219586849|NCT06423443|BEHAVIORAL|Health Education|traditional on-line health education app
219586850|NCT06423443|DRUG|TAU|treatment as usual
219586851|NCT01455311|PROCEDURE|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
219586852|NCT01455311|PROCEDURE|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
218838880|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
218838881|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
218838882|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
218838883|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
218838884|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
218838885|NCT00002028|DRUG|Didanosine|
218838886|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
218838887|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
218838888|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
218838889|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
218838890|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
218838891|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
219448544|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
218838892|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
218838893|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
219017451|NCT06317662|BIOLOGICAL|Blinatumomab|Given IV
219017452|NCT06317662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219017453|NCT06317662|DRUG|Calaspargase Pegol|Given IV
219448545|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
219017454|NCT06317662|PROCEDURE|Computed Tomography|Undergo CT
219017455|NCT06317662|DRUG|Cyclophosphamide|Given IV
219448546|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
219448547|NCT01110928|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
219448548|NCT04519476|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
218838894|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
218838895|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
218838896|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
218838897|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
218838898|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
218838899|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
219017456|NCT06317662|DRUG|Cytarabine|Given IT or IV
219017457|NCT06317662|DRUG|Daunorubicin|Given IV
219017458|NCT06317662|DRUG|Dexamethasone|Given PO or NG or IV
219017459|NCT06317662|DRUG|Doxorubicin|Given IV
219766472|NCT07212582|DRUG|Human Albumin 20% Solution|Intravenous 20% human albumin solution (50 mL per vial). In the experimental arm, patients receive 50 mL over 2 hours on admission, followed by additional doses for up to 72 hours, titrated to maintain serum albumin \>3.5 g/dL. If albumin is 2.5-3.4 g/dL, 1 vial every 12 hours is given; if \<2.5 g/dL, 1 vial every 6 hours is given. Infusion is withheld if there is fluid overload, pulmonary edema, or severe hypernatremia.
219766473|NCT07212582|OTHER|Standard Care (in control arm)|Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.
219766474|NCT07212842|DRUG|Methylene Blue|"This protocol was designed to perform intraoperative blood lavage with methylene blue at the end of surgery, with a duration of 20 minutes. A low dose of 1 mg/kg of body weight was administered. The objective was not to elicit hemodynamic effects, which require higher doses, but rather to exploit the anti-inflammatory and antioxidant properties of methylene blue.~Methylene blue was diluted in 1000 mL of 0.9% saline. An equivalent volume of fluid was removed simultaneously by zero-balance ultrafiltration, maintaining a fluid-equilibrium state throughout the 20-minute procedure. For this purpose, a dedicated circuit was developed to enable concurrent blood lavage and ultrafiltration. Blood was withdrawn through a dedicated port integrated into the SORIN oxygenator and directed by a centrifugal pump to a small reservoir containing the methylene blue solution. From this reservoir, the blood passed through a hemoc"
219766475|NCT07212842|PROCEDURE|Conventional ultrafiltration|Conventional ultrafiltration (CUF). CUF during cardiopulmonary bypass (CPB) is performed to remove excess fluid and solutes from the patient's blood during cardiac surgery, thereby limiting fluid accumulation and attenuating pro-inflammatory effects. This technique increases hematocrit, improves cardiopulmonary function, and reduces the need for blood transfusions. Unlike modified ultrafiltration (MUF), which is performed after weaning from CPB, CUF is carried out simultaneously with CPB while the heart-lung machine remains in operation.
219766476|NCT07212842|PROCEDURE|Zero-balance ultrafiltration|Zero-balance ultrafiltration (Z-BUF). Z-BUF is performed during cardiopulmonary bypass (CPB) to maintain fluid equilibrium by removing plasma water and solutes while simultaneously infusing an equal volume of replacement fluid, thereby achieving a net zero fluid balance. This technique has been shown to decrease urine output, reduce tissue edema and the inflammatory response, improve arterial oxygenation (PaO₂), and lower the need for postoperative blood transfusions.
219017460|NCT06317662|PROCEDURE|Echocardiography Test|Undergo ECHO
219017461|NCT06317662|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
219017462|NCT06317662|DRUG|Leucovorin|Given PO or NG or IV
219017463|NCT06317662|DRUG|Levoleucovorin|Given IV
219017464|NCT06317662|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219017465|NCT06317662|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219017466|NCT06317662|DRUG|Mercaptopurine|Given PO or NG
219017467|NCT06317662|DRUG|Methotrexate|Given IT or IV or PO or NG
219017468|NCT06317662|DRUG|Methylprednisolone|Given IV
219017469|NCT06317662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219017470|NCT06317662|DRUG|Prednisolone|Given PO or NG
219017471|NCT06317662|DRUG|Prednisone|Given PO or NG
219017472|NCT06317662|DRUG|Therapeutic Hydrocortisone|Given IT
219017473|NCT06317662|DRUG|Thioguanine|Given PO or NG
219017474|NCT06317662|DRUG|Venetoclax|Given PO or NG
219017475|NCT06317662|DRUG|Vincristine|Given IV
219017476|NCT06798831|BIOLOGICAL|Pertussis containing vaccine|Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),
219586853|NCT04310969|DEVICE|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
218838900|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
218838901|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
218838902|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
218838903|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
218838904|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
218838905|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
218838906|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
218838907|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
219196630|NCT06813625|BEHAVIORAL|Shared book reading intervention|The intervention involved us pairing each teen DS with a college student to form a duo. Each group consists of one person with DS and at least one college student who will work together throughout the shared reading intervention. A weekly event hosted by a graduate student. It begins with ice-breaking activities such as color and music games to promote social interaction between participants. After the game, participants chose from a selection of 20 books suitable for different age groups. They can choose their own reading method, such as reading aloud or assigning roles, and are encouraged to share experiences in their own duos or in a large group of multiple duos. The session ends with a sharing and reflection activity where participants can discuss what they have read and plan for the next session.
218838908|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
219448549|NCT04519476|DRUG|Lenalidomide|Immunomodulatory drug
219586854|NCT04310969|PROCEDURE|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
219586855|NCT04310969|DEVICE|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
218838909|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
218838910|NCT02036580|OTHER|Placebo|
219196631|NCT06811701|PROCEDURE|Scalp nerve block|Patient in this group will receive a scalp nerve block using bupivacaine before skull pin fixation to manage to pain.
219196632|NCT06811701|DRUG|Opioid Anesthetics|Patient in this group will receive IV opioid for pain management before skull pin fixation
219448550|NCT04519476|DRUG|Methylprednisolone|Glucocorticoid, steroid
219448551|NCT05299216|OTHER|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
219586856|NCT01209130|DRUG|DCDT2980S|Intravenous repeating dose
219586857|NCT01209130|DRUG|rituximab|Intravenous repeating dose
219586858|NCT01036139|DRUG|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
219586859|NCT02029014|DEVICE|LAA closure system|
219586860|NCT05213455|BIOLOGICAL|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
219586861|NCT00000114|DRUG|Vitamin E|
219586862|NCT00000114|DRUG|Vitamin A|
219586863|NCT00128050|DRUG|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
219586864|NCT00128050|DRUG|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
219586865|NCT00128050|OTHER|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
218838911|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
218838912|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
218838913|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
218838914|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
219448552|NCT05299216|OTHER|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
219448553|NCT05299216|OTHER|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
219448554|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
219448555|NCT00836953|BIOLOGICAL|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
219448556|NCT05474924|DRUG|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
219448557|NCT05474924|DRUG|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
219448558|NCT05474924|DRUG|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
219448559|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
218838915|NCT00295334|DRUG|alcohol|
219448560|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
219448561|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
219586866|NCT04851938|DEVICE|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
219586867|NCT03322735|DRUG|Fludarabine|25-30mg/m2/day IV for 3 days
219586868|NCT03322735|DRUG|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
219586869|NCT03322735|BIOLOGICAL|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
219586870|NCT04500418|DRUG|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
218838916|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
218838917|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
218838918|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
218838919|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
218838920|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
218838921|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
218838922|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
218838923|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
218838924|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
218838925|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
218838926|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
218838927|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
219586871|NCT04500418|DRUG|Placebo|Optically identical pills without CVC.
219586872|NCT01774552|DEVICE|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
219586873|NCT02702661|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
219586874|NCT02702661|PROCEDURE|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
219586875|NCT02702661|DRUG|Levobupivacaine|Levobupivacaine 0.125% - 40ml
219586876|NCT04668911|OTHER|Swab|PCR test for SARS-CoV2, oral and nasal swab
219586877|NCT02346591|BEHAVIORAL|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
218838928|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
218838929|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
219017481|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
219017482|NCT04974086|OTHER|Sexually transmitted infection (STI) testing clinical decision support (CDS) tool|The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
219448562|NCT03052634|DRUG|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
219448563|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
219448564|NCT03052634|DRUG|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
219448565|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
219448566|NCT04249791|PROCEDURE|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
219586878|NCT02346591|BEHAVIORAL|Online stress management information|Online educational information about stress management
219586879|NCT06021535|OTHER|No intervention|No intervention
219586880|NCT02089035|DIETARY_SUPPLEMENT|MUFA-rich dairy products (UHT milk, cheese and butter)|
219586881|NCT02089035|DIETARY_SUPPLEMENT|Conventional dairy products (UHT milk, cheese, butter)|
219586882|NCT02618135|OTHER|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
219017485|NCT03233282|OTHER|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
219017486|NCT03233282|OTHER|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
219017487|NCT03233282|OTHER|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
219017488|NCT03233282|OTHER|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
219448567|NCT00376675|DRUG|methylphenidate hydrochloride|Given orally
219448568|NCT00376675|OTHER|placebo|Given orally
219448569|NCT01833026|DEVICE|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
219448570|NCT01833026|DRUG|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
219448571|NCT00419237|DRUG|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
218838930|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
218838931|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
218838932|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
218838933|NCT00407368|PROCEDURE|Blood Sample|
218838934|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
218838935|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
218838936|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
218838937|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
219448572|NCT00995215|PROCEDURE|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
219448573|NCT00995215|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
219586883|NCT02618135|OTHER|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
218838938|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
218838939|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
218838940|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
218838941|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
218838942|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
218838943|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
219017489|NCT03233282|OTHER|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
219196633|NCT06811701|PROCEDURE|Local Anesthetic Injection|"Patients in this group will receive a local anesthetic (such as lidocaine) injection at the pin site before skull pin fixation."
218838944|NCT02177721|BIOLOGICAL|Sample Collection|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for lethal factor (LF) levels."
218838945|NCT05535504|DEVICE|Low-frequency rTMS (experimental)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / Location: motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: tangential to scalp
219448574|NCT03570190|OTHER|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect"
219448575|NCT03317912|DRUG|Lidocaïne 2%|Continuous infusion during per and postoperative periods
219448576|NCT03317912|DRUG|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
219448577|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
219448578|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
219448579|NCT04787263|BIOLOGICAL|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR\_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
219448580|NCT05480631|PROCEDURE|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
219448581|NCT05480631|PROCEDURE|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
219448582|NCT05480631|PROCEDURE|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
219448583|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
218838946|NCT05535504|DEVICE|Low-frequency rTMS (sham comparator)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: vertical to scalp
218838947|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
218838948|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
218838949|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
218838950|NCT02916069|DEVICE|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
218838951|NCT02916069|DEVICE|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
218838952|NCT02916069|DEVICE|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
218838953|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
218838954|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
218838955|NCT04170088|DRUG|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
218838956|NCT04170088|DRUG|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
218838957|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
218838958|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
219017490|NCT03233282|OTHER|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219017491|NCT03233282|OTHER|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219448584|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
219448585|NCT02943668|DRUG|Deferasirox|Given PO
219448586|NCT02943668|OTHER|Laboratory Biomarker Analysis|Correlative studies
219448587|NCT04771104|DIETARY_SUPPLEMENT|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
219448588|NCT06066190|OTHER|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
219448589|NCT03583112|DRUG|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
219586884|NCT06548308|DIAGNOSTIC_TEST|Corneal Incision|Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
219586885|NCT06548308|OTHER|Toric Intraocular|Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
219586886|NCT00000693|DRUG|Zidovudine|
218838959|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
219766477|NCT07210268|DEVICE|TI-NDBS|In the active TI-NDBS condition, participants receive transcranial stimulation for 60 minutes through scalp electrodes using temporal interference (TI). Two electrode sets deliver high-frequency alternating currents (e.g., 2000 Hz and 2020 Hz), generating a 20 Hz beat frequency at depth to stimulate targeted brain regions. Stimulation is delivered in six 10-minute blocks with 30-second ramp-up and ramp-down periods to minimize discomfort. Electrode configurations differ by group to target either the nucleus accumbens or anterior insula, based on finite element modeling. The maximum current is up to 2 mA per electrode, and no single region receives more than 2 mA.
219766478|NCT07210268|DEVICE|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
219448590|NCT03583112|DRUG|Placebo Tablet|oral one placebo tablet before MRI scan.
219448591|NCT01487694|DRUG|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
219448592|NCT01487694|DRUG|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
219448593|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
219448594|NCT04955574|OTHER|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
219586887|NCT00000693|DRUG|Acyclovir|
219766479|NCT07212374|OTHER|Graduation|"Graduation is a multifaceted approach that aims to support ultra-poor households in permanently escaping poverty traps. The standard version of Graduation tested in this study includes: a one-time asset transfer; monthly cash transfers; life skills coaching on topics like health and nutrition; technical skills training on topics like financial literacy; and access to savings services."
219766480|NCT07211646|OTHER|sham tES|short 30s sham stimulation
219766481|NCT07211646|OTHER|Fixed tES|Fixed stimulation parameters for all participants
219448595|NCT04955574|DRUG|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
219766482|NCT07211646|OTHER|Personalized tES|Stimulation parameters personalized for each participant
218838960|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
218838961|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
218838962|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
219017492|NCT03233282|OTHER|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219586888|NCT01716715|DRUG|Cabozantinib S-malate|Given PO
219586889|NCT01716715|OTHER|Laboratory Biomarker Analysis|Correlative studies
219586890|NCT01716715|DRUG|Paclitaxel|Given IV
219586891|NCT03343444|DRUG|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
219586892|NCT03343444|DRUG|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
219586893|NCT00704574|DRUG|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
219766483|NCT07212803|DIETARY_SUPPLEMENT|Energy Drink A + Placebo Capsule|1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule
219766484|NCT07212803|DRUG|Placebo Drink + Moxifloxacin Capsule|Placebo drink with 400 mg moxifloxacin capsule
219766485|NCT07212803|DIETARY_SUPPLEMENT|Placebo Drink + Caffeine Capsule|Placebo drink with 320 mg caffeine capsule
219766486|NCT07212803|OTHER|Placebo Drink + Placebo Capsule|Placebo drink with placebo capsule
219766487|NCT07212803|DIETARY_SUPPLEMENT|Energy Drink B|568 mL caffeine- and taurine-containing commercially available beverage (Formula B)
219766488|NCT07212803|DIETARY_SUPPLEMENT|Control Product + Taurine|Control product with 4000 mg taurine powder
219586894|NCT03327792|DRUG|Mavoglurant|200 mg Mavoglurant
219586895|NCT03327792|DRUG|Placebo|Placebo
219586896|NCT00626392|DRUG|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
219586897|NCT00626392|DRUG|aspirin (ASA)|325 mg tablets administered once daily
219586898|NCT00626392|DRUG|aspirin placebo (ASA Pbo)|Tablets administered once daily
219586899|NCT03624686|OTHER|peripheral blood|draw peripheral blood
219586900|NCT02123810|OTHER|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
219586901|NCT03062423|DRUG|Sofodelevier|1 tablet contains 400 mg sofosbuvir
218838963|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
218838964|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
218838965|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
218838966|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
219448596|NCT04955574|OTHER|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
219448597|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
219448598|NCT05822960|DEVICE|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
219448599|NCT06612268|DRUG|Etavopivat|Etavopivat will be administered orally.
219448600|NCT06612268|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
219586902|NCT03062423|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
219586903|NCT03062423|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
219586904|NCT05395455|PROCEDURE|Non-surgical periodontal treatment|Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
219586905|NCT00050323|DRUG|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
219586906|NCT02299024|BEHAVIORAL|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
219586907|NCT00592618|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
218838967|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
219586908|NCT02866006|DRUG|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
219586909|NCT02866006|DRUG|Topotecan|
218838968|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
218838969|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
218838970|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
218838971|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
218838972|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
218838973|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
218838974|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
218838975|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
218838976|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
218838977|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
218838978|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
218838979|NCT04470050|DRUG|Placebo|Sublingual Placebo film
218838980|NCT03098433|DRUG|Liothyronine|Single dose
218838981|NCT03098433|DRUG|Levothyroxine|Active comparator
219448601|NCT02201251|DRUG|Topiramate|Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
219448602|NCT02201251|DRUG|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
218838982|NCT03098433|DRUG|Placebos|Placebo
218838983|NCT01104545|DRUG|MK-3614|
218838984|NCT01104545|DRUG|Comparator: Placebo|
219448603|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
219448604|NCT03592589|DEVICE|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
219586910|NCT01782300|BIOLOGICAL|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
219586911|NCT01782300|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
219766489|NCT07212803|DIETARY_SUPPLEMENT|Control Product + Caffeine + Taurine|Control product with 320 mg caffeine + 4000 mg taurine powder
219766490|NCT07212803|DIETARY_SUPPLEMENT|Lower Dose Energy Drink A|591 mL caffeine- and taurine-containing commercially available beverage (Formula A)
219448605|NCT05393570|BEHAVIORAL|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
219448606|NCT06614361|BEHAVIORAL|Health education on COVID and flu vaccination|1 session (30 min) with a health educator on vaccination
219448607|NCT06614361|BEHAVIORAL|Nurse-led shared decision-making|1 session and FU calls with a trained nurse
219448608|NCT06614361|BEHAVIORAL|Text messages|Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)
219448609|NCT06614361|BEHAVIORAL|Lottery prize for vaccination|Modest lottery prize for COVID vaccination
219448610|NCT06614361|BEHAVIORAL|Peer navigation|Peer navigation (4 months duration, contact as needed).
219448611|NCT06341569|OTHER|Respiratory breathing techniques group|"Target group: subjects in the respiratory breathing techniques group. Program duration: the program lasts for 14 weeks.~Breathing techniques: the program includes various breathing exercises, including:~Diaphragmatic breathing teaches participants to breathe deeply, engaging the diaphragm muscle, which can improve lung capacity and relaxation.~Pursed-lips breathing: this technique involves inhaling through the nose and exhaling slowly through pursed lips, which can help slow down breathing and manage shortness of breath.~Alternate nostril breathing: this technique involves closing one nostril while inhaling and exhaling through the other nostril alternately.~Relaxation techniques: the program incorporates progressive muscle relaxation techniques. This involves progressively tensing and relaxing different muscle groups.~Medical education: topics like the anatomy of the respiratory system, the importance of proper breathing, potential benefits of specific breathing exercises."
219448612|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed.
219448613|NCT06997393|BEHAVIORAL|Prevention programme|The prevention programme consists of a validated educational video and training in the basic recognition and prevention of hand eczema.
219448614|NCT06996444|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
218838985|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
218838986|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
218838987|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
218838988|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
219448615|NCT01914939|DRUG|Oxytocin|
219448616|NCT01914939|BEHAVIORAL|Social Skills focused CBT|
219448617|NCT01914939|BEHAVIORAL|Stress management/relaxation training|
219448618|NCT01914939|DRUG|placebo drug|
219448619|NCT06993675|DRUG|Talquetamab|Talquetamab is a GPRC5DxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
219448620|NCT06993675|DRUG|Teclistamab|Teclistamab is a BCMAxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
219448621|NCT06541990|BEHAVIORAL|HARMONY|A psychoeducational intervention for patients with HCC
218838989|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
218838990|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
218838991|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
218838992|NCT03585764|DRUG|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
218838993|NCT03585764|DEVICE|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
218838994|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
218838995|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
219448622|NCT06541990|OTHER|Enhanced usual care|A supportive care resource guide
219448623|NCT06427967|BEHAVIORAL|Project Dream Team|Five total sessions, 60-minutes each, with one session every 7 days (+/- 21 days between sessions), Session activities include discussion prompts, interactive learning methods, skill rehearsals, mindfulness / somatic exercises and lecture slides facilitated by a trained facilitator.
219448624|NCT06538064|OTHER|No Intervention|This is a non-interventional study.
219448625|NCT06541678|DRUG|Danuglipron|MR Tablet
219448626|NCT06541678|DRUG|Cyclosporine|Capsule
219448627|NCT06541678|DRUG|Itraconazole|Oral solution
219448628|NCT03595189|DRUG|Cilastatin|Dose escalation 3-hour single intravenous administration
219448629|NCT03595189|DRUG|Placebo|3-hour single intravenous administration
219448630|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
219448631|NCT03313752|OTHER|Placebo|placebo
219448632|NCT02877134|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
219448633|NCT02877134|DRUG|Placebo|Participants will receive placebo Subcutaneously.
218838996|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
218838997|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
218838998|NCT03953248|DRUG|L-Carnitine|
218838999|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
218839000|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
218839001|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
218839002|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
218839003|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
219017493|NCT03233282|OTHER|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219766491|NCT07211243|DEVICE|PHMB-impregnated biocellulose wound dressing with additional polyethylene film on top, compression therapy, systemic antomicrobial therapy (optional)|Application of a wound dressing with additional polyethylene film on top and compression therapy. Optional usage of the systemic antimicrobial therapy.
219448634|NCT02877134|DRUG|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
219586912|NCT05935111|BEHAVIORAL|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
218839004|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
219017494|NCT03233282|OTHER|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219448635|NCT01332851|BEHAVIORAL|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
219448636|NCT01332851|BEHAVIORAL|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
219448637|NCT04205474|DIAGNOSTIC_TEST|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
218839005|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
219017495|NCT03233282|OTHER|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
219017496|NCT05783622|DRUG|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
219448638|NCT07005986|DIAGNOSTIC_TEST|Plasmatic PPi level|Plasmatic PPi level dosage at visit 1
219448639|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
218839006|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
218839007|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
218839008|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
218839009|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
218839010|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
218839011|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
219586913|NCT04717765|DEVICE|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
219586914|NCT04717765|DEVICE|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
219448640|NCT05292573|DRUG|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
219448641|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
219448642|NCT03865849|DEVICE|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
219448643|NCT03865849|DEVICE|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
219448644|NCT06623409|BIOLOGICAL|GARDASIL®9 (G9)|Suspension administered via intramuscular (IM) injection
219448645|NCT06623409|BIOLOGICAL|V540B|Experimental vaccine and adjuvant administered via IM injection
219448646|NCT06625905|DIAGNOSTIC_TEST|Ultrasound imaging|Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).
219448647|NCT06685679|DRUG|Melatonin|oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
219448648|NCT06685679|OTHER|Placebo|Equivalent amount of distilled water will be given every hours as combined therapy to milrinone
219448649|NCT00546936|DRUG|ranibizumab|0.5mg ranibizumab
219448650|NCT00546936|DRUG|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
219448651|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
219448652|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
219448653|NCT00502619|PROCEDURE|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
219586915|NCT04717765|DEVICE|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
219586916|NCT04717765|DEVICE|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
219586917|NCT01801631|OTHER|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
219586918|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
219766492|NCT07211243|DEVICE|PHMB-impregnated biocellulose wound dressing without additional polyethylene film on top, compression therapy, systemic antomicrobial therapy (optional)|Application of a wound dressing without additional polyethylene film on top and compression therapy. Optional usage of the systemic antimicrobial therapy.
219448654|NCT00502619|OTHER|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
219448655|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
219448656|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
219448657|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
219448658|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
219586919|NCT00405444|DRUG|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
218839012|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
218839013|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
218839014|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
219448659|NCT00881699|BEHAVIORAL|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
219586920|NCT00405444|DRUG|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
219586921|NCT00498901|DRUG|goserelin|
219586922|NCT00498901|DRUG|letrozole|
219586923|NCT00498901|DRUG|leuprolide acetate|
219586924|NCT00498901|PROCEDURE|conventional surgery|
219586925|NCT01302522|BEHAVIORAL|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
219586926|NCT02767830|BEHAVIORAL|Excercise and Nutrition Program|
219586927|NCT02066948|OTHER|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
219586928|NCT02066948|OTHER|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
219448660|NCT00881699|BEHAVIORAL|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
219448661|NCT00319683|DRUG|ADH300004|
219448662|NCT04710992|PROCEDURE|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
219586929|NCT02066948|OTHER|meal pattern|skew or even
219586930|NCT02066948|DIETARY_SUPPLEMENT|even|even amount of protein distributed between each meal
219586931|NCT02066948|DIETARY_SUPPLEMENT|skew|a skewed amount of protein is distributed between each meal
219586932|NCT02005263|PROCEDURE|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
219586933|NCT01234922|DRUG|lisinopril|Given orally
219586934|NCT01234922|DRUG|losartan potassium|Given orally
219586935|NCT01234922|OTHER|laboratory biomarker analysis|Correlative studies
219448663|NCT04710992|PROCEDURE|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
219448664|NCT04710992|PROCEDURE|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
219448665|NCT00971360|OTHER|conversion disorder|Proinflammatory cytokine levels in conversion disorder
219586936|NCT01234922|DRUG|benazepril hydrochloride|Given orally
219586937|NCT01234922|DRUG|ramipril|Given orally
219586938|NCT05893810|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
219586939|NCT04122066|DRUG|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
219586940|NCT03666650|DRUG|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
219586941|NCT03466255|OTHER|Ultrasound|Contrast-enhanced ultrasound (CEUS)
219586942|NCT04066595|DRUG|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
219586943|NCT01085734|DRUG|Avastin|1.25mg intravitreally
219586944|NCT01085734|DRUG|Osurdex|0.7mg intravitreally
219586945|NCT01085734|DRUG|Avastin|1.25mg intravitreally
219586946|NCT02135835|DRUG|Shenfu Zhusheye|
219586947|NCT02135835|DRUG|5% glucose injection|
219586948|NCT01759732|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -4
219586949|NCT01759732|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
219586950|NCT01759732|BIOLOGICAL|anti-thymocyte globulin|
219586951|NCT01759732|BIOLOGICAL|filgrastim|
219586952|NCT01759732|RADIATION|Total body irradiation|200 cGy per day on D-5 \& -4
219586953|NCT01759732|PROCEDURE|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
219586954|NCT01269333|DRUG|omeprazole|omeprazole 20mg for 7 days
219586955|NCT01269333|DRUG|fluvoxamine|fluvoxamine 50mg for 7 days
219586956|NCT01269333|DRUG|placebo|placebo for 7 days
219586957|NCT03090607|DEVICE|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
219586958|NCT03090607|DRUG|Saline|Endoscopic injection of saline
219586959|NCT04808180|OTHER|Biorepair Shock Treatment|Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
219586960|NCT04808180|OTHER|No treatment|Teeth from this group will not be treated with the experimental toothpaste.
219586961|NCT06551571|OTHER|Intrapartum Care Model|\- The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations
219766493|NCT07212543|OTHER|Routine anesthesia care (desflurane at different low-flow rates: 0.5, 1.0, 1.5 L/min); no intervention assigned as part of the study.|Routine anesthesia care (desflurane at different low-flow rates: 0.5, 1.0, 1.5 L/min); no intervention assigned as part of the study.
219586962|NCT02644005|DEVICE|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG \& Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
218839015|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
219448666|NCT02136550|BEHAVIORAL|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
219448667|NCT05369793|DRUG|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
219448668|NCT05369793|DRUG|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
219448669|NCT04450641|OTHER|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
219448670|NCT01722357|BEHAVIORAL|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
219448671|NCT01722357|BEHAVIORAL|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
219448672|NCT05475444|DEVICE|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
219448673|NCT05475444|DEVICE|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
219448674|NCT04010812|OTHER|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
219448675|NCT02996500|DRUG|PF-06650833|Investigational
219448676|NCT02996500|DRUG|Placebo|Placebo
219448677|NCT02996500|DRUG|Tofacitinib|Investigational
219448678|NCT05639829|BEHAVIORAL|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
219448679|NCT00004772|DRUG|Immune globulin|
219448680|NCT03978572|BEHAVIORAL|Resistance Training|Exercise intervention designed to improve muscular strength and power
219448681|NCT03978572|BEHAVIORAL|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
219586963|NCT00252200|DRUG|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
219586964|NCT04769414|DRUG|Gemcitabine fluorouracil|"chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
219586965|NCT05949710|BEHAVIORAL|aerobic exercise(AE)|The participants will receive AE three times per week.
219017497|NCT05754528|DRUG|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
219017498|NCT05754528|DRUG|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
219448682|NCT03978572|BEHAVIORAL|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
219448683|NCT01770886|DRUG|UE2343|Oral capsule
219586966|NCT04856410|OTHER|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
219586967|NCT04856410|OTHER|Controls|No intervention
219586968|NCT02513030|PROCEDURE|Defibrillation testing during ICD replacement|
219766494|NCT07207668|PROCEDURE|Open Flap Debridement (OFD)|Standard periodontal surgical procedure involving full-thickness flap elevation, scaling, and root planing to eliminate inflamed tissue and reduce periodontal pocket depth.
219448684|NCT01770886|DRUG|Placebo|Oral capsule
219448685|NCT00068484|DRUG|topotecan hydrochloride|Given IV
219448686|NCT00068484|DRUG|bortezomib|Given IV
219448687|NCT00068484|OTHER|pharmacological study|Correlative studies
219448688|NCT00068484|OTHER|laboratory biomarker analysis|Correlative studies
219448689|NCT03108300|DRUG|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
219448690|NCT03108300|DRUG|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
219448691|NCT01853852|DRUG|GR181413A/AT1001 solution|Powder for reconstitution
219448692|NCT01853852|DRUG|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
219448693|NCT01853852|OTHER|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
219448694|NCT01853852|DRUG|Placebo capsule|Solution matched
219448695|NCT02892175|PROCEDURE|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
219448696|NCT03322085|PROCEDURE|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
219448697|NCT03821480|DRUG|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
219448698|NCT03821480|DRUG|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
219448699|NCT01977807|DEVICE|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
219448700|NCT02725736|DRUG|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
219448701|NCT02725736|DRUG|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
219586969|NCT01715571|DEVICE|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
219586970|NCT02135471|DRUG|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
219586971|NCT02135471|DRUG|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
219586972|NCT06968325|DEVICE|AI-based TruRoot group:|Participants in this group will receive clear aligner treatment designed using an artificial intelligence (AI)-based system called TruRoot
219586973|NCT06968325|DEVICE|Conventional clear aligner group|Participants in this group will receive clear aligner treatment planned manually by expert orthodontists based only on intraoral scans.
218839016|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
218839017|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
218839018|NCT06485713|DRUG|fufuquitinib|fufuquitinib
218839019|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
218839020|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
219448702|NCT00645203|DRUG|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
219448703|NCT01555736|DRUG|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
219448704|NCT01715090|DEVICE|Web-based insulin titration|
219448705|NCT01659359|DEVICE|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
219586974|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
219586975|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
219586976|NCT00643136|DRUG|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
219586977|NCT00643136|DRUG|Placebo|Matching placebo capsules twice daily for 28 days
219586978|NCT00392236|DEVICE|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
219586979|NCT00392236|BEHAVIORAL|Treatment as usual|Participants will receive treatment as usual.
219448706|NCT01659359|DRUG|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
219448707|NCT05928104|OTHER|Medication review|Pharmacist-led medication review in primary care using a co-designed document
219448708|NCT05579223|DRUG|Intrathecal Hydromorphone Mono Injection|Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s
219586980|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
219448709|NCT05579223|DRUG|Intrathecal Placebo Mono Injection|Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
218839021|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
218839022|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
218839023|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
219448710|NCT00774969|DRUG|Metronidazole|Metronidazole 10% ointment three times a day 7 days
219448711|NCT06039657|OTHER|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
219448712|NCT06039657|OTHER|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
219448713|NCT01353183|PROCEDURE|colonoscopy or rectosigmoidoscopy|Usual procedure
219448714|NCT02746445|OTHER|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
219448715|NCT03105245|OTHER|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
219448716|NCT02566876|DRUG|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
219448717|NCT04528394|RADIATION|Photon|Photon combined with Carbon ion in Arm 1
219448718|NCT04528394|RADIATION|Proton|Proton combined with Carbon ion in Arm 2
219448719|NCT04528394|RADIATION|Carbon ion|Same dose and fractionation will be used in both arms.
219448720|NCT02048657|DEVICE|Foley Airway Stylet Tool|
219448721|NCT02048657|DEVICE|introducer-tool|
218839024|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
219448722|NCT00707486|DEVICE|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
219448723|NCT00707486|DEVICE|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
219448724|NCT04552626|BEHAVIORAL|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
219586981|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
219586982|NCT03230500|PROCEDURE|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
218839025|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
218839026|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
218839027|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
218839028|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
218839029|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
218839030|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
218839031|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
218839032|NCT01642056|DRUG|Placebo|
218839033|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
218839034|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
219448725|NCT04552626|BEHAVIORAL|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
219448726|NCT04552626|BEHAVIORAL|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
218839035|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
219448727|NCT00831857|OTHER|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
219448728|NCT02797769|DRUG|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
219448729|NCT02797769|DRUG|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
219448730|NCT04259034|OTHER|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
219448731|NCT04259034|OTHER|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
219448732|NCT04878276|DEVICE|Dimet 5|The application is carried out according to the enclosed instructions for use.
219448733|NCT05177224|OTHER|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
219448734|NCT02233582|DRUG|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
219448735|NCT02233582|DRUG|Sugar pill|
219448736|NCT04962490|PROCEDURE|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
219448737|NCT06309498|PROCEDURE|blood test|11 DOC levels will be measured in enrolled patients
219448738|NCT05925400|DEVICE|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
219448739|NCT05213676|DRUG|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
219448740|NCT05213676|OTHER|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
219448741|NCT00835276|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
219448742|NCT00835276|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
219448743|NCT00871676|BEHAVIORAL|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
219448744|NCT00871676|BEHAVIORAL|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
219448745|NCT04189380|OTHER|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
219448746|NCT04189380|OTHER|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
219448747|NCT02565862|DRUG|Daclatasvir|
219448748|NCT02565862|DRUG|Metformin|
219586983|NCT00406744|DRUG|Intravitreal injection of Bevacizumab|
219586984|NCT02196701|DRUG|Adalimumab|Administered by subcutaneous injection every other week.
219586985|NCT02196701|DRUG|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
218839036|NCT02168062|OTHER|Educational Intervention|Review educational modules
218839037|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
218839038|NCT02168062|DRUG|Goserelin Acetate|Given SC
218839039|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
218839040|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
218839041|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
218839042|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
218839043|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
218839044|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
219586986|NCT05418530|OTHER|with pause- without pause|start with pause expiration
219586987|NCT05418530|OTHER|without pause-with pause|start without pause expiration
219448749|NCT04922710|BEHAVIORAL|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
219586988|NCT02608138|OTHER|Iodine status among portuguese school children|
219586989|NCT06417736|DRUG|Megestrol Acetate 40 MG|160mg/one time/day
219586990|NCT02424643|BEHAVIORAL|Monetary Incentive|$20 Amazon.com gift card
219448750|NCT01574417|DIETARY_SUPPLEMENT|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
219448751|NCT01574417|DIETARY_SUPPLEMENT|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
219448752|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
219448753|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
219448754|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
219448755|NCT02832817|DEVICE|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
219448756|NCT04985513|PROCEDURE|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
219448757|NCT02858713|DRUG|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
219448758|NCT02858713|DEVICE|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
219448759|NCT06016335|DIAGNOSTIC_TEST|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
219586991|NCT02424643|BEHAVIORAL|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
219586992|NCT02424643|BEHAVIORAL|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
219586993|NCT03681236|PROCEDURE|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
219766495|NCT07207668|OTHER|24% EDTA Root Conditioning|Application of 24% neutral pH EDTA gel for 3 minutes on root surfaces to remove the smear layer and expose collagen fibers before closure.
219766496|NCT07207668|BIOLOGICAL|Injectable Platelet-Rich Fibrin (i-PRF)|Autologous platelet concentrate prepared by low-speed centrifugation of venous blood (\~700 rpm, 3 minutes). The upper plasma fraction rich in platelets and leukocytes was aspirated and applied to defect surfaces for approximately 5 minutes before flap closure.
219766497|NCT07210125|DRUG|Lenacapavir long-acting|Until recently, only oral formulations of PrEP were available. With the availability of long-acting PrEP injectables, new strategies will need to be developed to deliver this new treatment option. The availability of L4P offers an opportunity to expand PrEP access outside traditional healthcare settings. However, data on the feasibility and acceptability of L4P in community pharmacies is lacking. Community pharmacies are ideal for L4P due to their accessibility and the ability to utilize both pharmacy and medical billing for reimbursement of medication and clinical services, unlike traditional healthcare settings. Pharmacists are one of the most highly accessible healthcare professionals in the community. There are over 60,000 community pharmacies across the U.S. The study will evaluate implementation outcomes (feasibility, acceptability), real-world effectiveness, and whether L4P can be used for same day starts or treatment switches.
219448760|NCT06016335|DIAGNOSTIC_TEST|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
219448761|NCT06016335|OTHER|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
219586994|NCT05919121|OTHER|Therapeutic exercise|"1. Stretching exercise of posterior shoulder capsule~2. Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~3. The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
219586995|NCT05919121|OTHER|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
219586996|NCT05919121|OTHER|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
218839045|NCT00976716|DRUG|Celecoxib|"Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~\- Celecoxib 200mg twice daily"
218839046|NCT01740921|DRUG|Liraglutide|Administered once daily
218839047|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
218839048|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
219448762|NCT05859906|OTHER|mechanical power measurement|"Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]"
219448763|NCT03581799|OTHER|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
219448764|NCT02774291|BIOLOGICAL|Aldesleukin|Given IV
219448765|NCT02774291|BIOLOGICAL|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
219448766|NCT02774291|DRUG|Cyclophosphamide|Given IV
219448767|NCT02774291|BIOLOGICAL|Filgrastim|Given SC
218839049|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
218839050|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
218839051|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
218839052|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
219448768|NCT02774291|DRUG|Fludarabine Phosphate|Given IVPB
219448769|NCT02774291|OTHER|Laboratory Biomarker Analysis|Correlative studies
219448770|NCT00126425|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single dose
219448771|NCT02556580|DRUG|Albumin 20%|Intervention: intravenious infusion Drug: albumin
219448772|NCT03965546|COMBINATION_PRODUCT|Sorafenib combined with ET140202-T cell|"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
219448773|NCT03965546|COMBINATION_PRODUCT|TAE combined with ET140202-T cell|"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
219448774|NCT03965546|BIOLOGICAL|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
219448775|NCT05295940|DRUG|LY3841136|Administered SC.
219766498|NCT07210125|OTHER|Standard of Care (SOC)|In aim 2, subjects enrolled in the L4P cohort will have the option of conducting STI testing every 6 months versus every 3 months. A retrospective matched cohort study will be conducted to assess the differences in retention and STI positivity rates between groups. All participants will be able to get tested in between monitoring visits.
218839053|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
218839054|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
218839055|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
218839056|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
218839057|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
218839058|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
218839059|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
219448776|NCT05295940|DRUG|Placebo|Administered SC.
219448777|NCT00236405|DRUG|epoetin alfa|
219448778|NCT00471315|DRUG|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
219586997|NCT01108211|DEVICE|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
219766499|NCT07212738|OTHER|Delayed mobilization (DeM)|Delayed mobilization (group 1): active therapy beginning ≥3 days from symptom onset.
218839060|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
218839061|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
219448779|NCT04631367|BEHAVIORAL|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
219448780|NCT04631367|DEVICE|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
219448781|NCT06078306|DRUG|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
219448782|NCT06078306|DRUG|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
219448783|NCT06078306|DRUG|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
219448784|NCT04474366|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
219448785|NCT04474366|OTHER|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
219448786|NCT03364062|PROCEDURE|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
219448787|NCT04064372|BEHAVIORAL|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
219448788|NCT04064372|BEHAVIORAL|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
219448789|NCT03288623|DIETARY_SUPPLEMENT|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
219448790|NCT03288623|DIETARY_SUPPLEMENT|White/Milk chocolate (<35% cocoa)|white or milk chocolate (\<35% cocoa) in tablet
219448791|NCT03258450|BEHAVIORAL|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
219448792|NCT00320190|DRUG|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
219448793|NCT00320190|DRUG|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
218839062|NCT02016495|DRUG|Placebo|
218839063|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
218839064|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
219017508|NCT05896293|DRUG|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
219448794|NCT05129683|OTHER|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
219017509|NCT05896293|DRUG|leuprolide acetate|Single SC bolus
219017510|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
218839065|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
218839066|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
218839067|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
219448795|NCT05129683|OTHER|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
219448796|NCT05129683|OTHER|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
219448797|NCT00712270|DRUG|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
219448798|NCT00712270|DRUG|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
219448799|NCT06247449|DIAGNOSTIC_TEST|Brain imaging|Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
219448800|NCT06247449|DIAGNOSTIC_TEST|Analysis of circulating tumor DNA|One single blood draw for analysis of circulating tumor DNA
219448801|NCT06247449|BEHAVIORAL|Testing Morbidities Index|Questionnaire regarding the participant's perception of brain imaging.
219448802|NCT04915872|PROCEDURE|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
219586998|NCT05912361|BEHAVIORAL|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
219586999|NCT02138058|DRUG|Topiramate|
219587000|NCT02138058|BEHAVIORAL|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
219587001|NCT03275064|BIOLOGICAL|LNA043|LNA043 intra-articular injection
219587002|NCT03275064|OTHER|Placebo|Placebo intra-articular injection
218839068|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
218839069|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
219017513|NCT04215978|DRUG|BGB-A445|Administered as specified in the treatment arm
219017514|NCT04215978|DRUG|tislelizumab|Administered as specified in the treatment arm
219587003|NCT04159935|DEVICE|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
219587004|NCT02340130|BIOLOGICAL|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
219587005|NCT02340130|BIOLOGICAL|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
219587006|NCT00077753|DRUG|enoxaparin sodium|
219766500|NCT07212738|OTHER|Standard Care (in control arm)|"Standard care (group 2): allied health assessment by 48 hours post-stroke followed by initiation of therapy at routine intensity (approximately 20 minutes/day of occupational and 20 minutes/day of physiotherapy). Therapy will depend on the level of disability of the participant, but will include working on standing, stepping, walking, balancing, self-care (i.e., grooming, dressing), functional task training (i.e., self-feeding), and addressing any cognitive and/or perceptive deficits.~Active therapy will be conducted by the Foothills Medical Centre stroke unit (Calgary, AB, Canada) certified physiotherapists and occupational therapists. The allied health team will not be blinded to the randomization of participants."
219766501|NCT07213037|DRUG|Dexmedetomidine|patients will receive dexmedetomidine(D) in dose 0.2 μg/kg/h infusion via syringe pump during surgery
219766502|NCT07213037|DRUG|Magnesium sulfate|patients will be given intravenous dose 30mg/kg.
219766503|NCT07213037|DRUG|lidocaine|patients will be given in one dose 1.5 mg/kg.
219448803|NCT04915872|PROCEDURE|other samplings (T1)|"\- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
219448804|NCT02828995|OTHER|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
219448805|NCT02852291|BEHAVIORAL|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
219448806|NCT02852291|BEHAVIORAL|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
219448807|NCT01041040|DRUG|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
219448808|NCT00005640|PROCEDURE|Preoperative Endoscopy|
219448809|NCT00005640|RADIATION|Technetium Tc 99m Sulfur Colloid|
219448810|NCT00005640|PROCEDURE|Gamma Probe|
219448811|NCT00005640|PROCEDURE|Biopsy of Sentinel Lymph Nodes|
219448812|NCT04573491|GENETIC|Pharmacogenetic test|genotyping for genes that affect drug metabolism
219448813|NCT04573491|OTHER|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
219587007|NCT00615654|OTHER|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
219587008|NCT01627353|PROCEDURE|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
218839070|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
219017515|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-087|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
219017516|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-088|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
219448814|NCT04429074|PROCEDURE|Minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy
219448815|NCT04443868|DRUG|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
219448816|NCT01755104|DIETARY_SUPPLEMENT|Stablor|
219448817|NCT01755104|DIETARY_SUPPLEMENT|Placebo|
219448818|NCT05885906|DRUG|Aloevera|Mouthwash
219448819|NCT05885906|DRUG|Thyme honey|Mouthwash
219448820|NCT05885906|DRUG|Saline|Mouthwash
219448821|NCT01611311|DRUG|BI 409306|Film-coated tablet
219448822|NCT01611311|DRUG|Placebo|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
219448823|NCT01376505|BIOLOGICAL|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
219587009|NCT01627353|PROCEDURE|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
219587010|NCT05986591|COMBINATION_PRODUCT|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
219587011|NCT05986591|COMBINATION_PRODUCT|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
219587012|NCT05986591|COMBINATION_PRODUCT|Placebo|Placebo Product
218839071|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
218839072|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
219448824|NCT01376505|BIOLOGICAL|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
219448825|NCT03780088|BEHAVIORAL|mTranS-C|mobile health
219448826|NCT02391298|BEHAVIORAL|Mindfulness Meditation|
219448827|NCT03119922|OTHER|No intervention|
219448828|NCT03421262|DIAGNOSTIC_TEST|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
219587013|NCT04781192|DRUG|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
219587014|NCT04781192|DRUG|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
219587015|NCT05345743|PROCEDURE|Surgery|All types of surgery requiring general anesthesia
219587016|NCT04600102|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
219766504|NCT07212530|BEHAVIORAL|EmoTIChealth|The EmoTIChealth technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself. The game is composed of 6 areas, each of which refers to one of the variables that are analysed or considered important in promoting health related quality of life and adaptation to chronic illness: Area 1. Psychoeducation; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication.
218839073|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
218839074|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
218839075|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
218839076|NCT04873258|DIAGNOSTIC_TEST|Bioimpedence Vector Analysis|Bioimpedence vector analysis
218839077|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
218839078|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
218839079|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
218839080|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
218839081|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
219448829|NCT03421262|DIAGNOSTIC_TEST|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
219448830|NCT00886691|BIOLOGICAL|Bevacizumab|Given IV
219448831|NCT00886691|DRUG|Everolimus|Given PO
219448832|NCT00886691|OTHER|Laboratory Biomarker Analysis|Correlative studies
219448833|NCT00886691|OTHER|Placebo|Given PO
219448834|NCT00433927|DRUG|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
219587017|NCT05962203|DIAGNOSTIC_TEST|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
219587018|NCT02545348|PROCEDURE|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
219766505|NCT07212361|DIETARY_SUPPLEMENT|Probiotic|Specific infant-adapted commercially available strains or strains isolated from the infant's mother.
219448835|NCT00433927|DRUG|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
219448836|NCT00433927|DRUG|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
219448837|NCT00433927|DRUG|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
219448838|NCT00433927|DRUG|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
219587019|NCT01341782|DRUG|paricalcitol|
219587020|NCT01341782|DRUG|maxacalcitol|
219587021|NCT01341782|DRUG|paricalcitol placebo|
219587022|NCT01341782|DRUG|maxacalcitol placebo|
219587023|NCT00230074|DRUG|TCH346|
218839082|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
218839083|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
218839084|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
218839085|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
218839086|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
218839087|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
219196634|NCT06813209|DEVICE|tDCS|For true tDCS, the technique will be performed with the anode over the right dorsolateral prefrontal cortex and the cathode over the left dorsolateral prefrontal cortex, positioned at F4 and F3, respectively, according to the International 10/20 Electrode Placement System. The current intensity will be set to 2 milliamperes (mA) for 20 minutes over five consecutive days.
219448839|NCT05908929|PROCEDURE|SRP and concomitant insertion of PRF membrane|The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane. Blood samples were drawn without anticoagulants in 10 mL tubes, which were immediately centrifuged at 4000 rpm for 8 minutes. Upon centrifugation, the blood showed three distinct layers: the uppermost layer contained platelet poor plasma, the middle layer consisted of a fibrin clot, and the lowermost band appeared bright red due to the presence of red blood cells. The fibrin clot polymerized in a diffuse manner within the tube, which was then cut with sharp scissors and squeezed between two glass slides to obtain a thick membrane. The PRF membrane was carefully handled using a carrier and isolated with a periodontal pack dressing (Coe-Pak). All patients were followed up at one week and six weeks after the treatment.
219448840|NCT05908929|PROCEDURE|SRP|The pockets were treated using the conventional procedure of scaling and root planing (SRP) utilizing curettes and an ultrasonic device. All patients were followed up at one week and six weeks after the treatment.
219448841|NCT03822780|DRUG|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
219448842|NCT01365091|DRUG|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
219448843|NCT01365091|DRUG|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
219448844|NCT01365091|DRUG|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
219448845|NCT01365091|DRUG|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
219448846|NCT01365091|DRUG|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
219448847|NCT04341025|BEHAVIORAL|Mindfulness based psychosexual therapy ( MBPST)|The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
219448848|NCT05478967|PROCEDURE|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
219448849|NCT01739374|OTHER|reduced mesh implants|mesh for pelvic floor reinforcement
219448850|NCT01428986|DRUG|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
219448851|NCT00655239|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
219448852|NCT00655239|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
219766506|NCT07212361|OTHER|Placebo|Infant formula without bacteria.
218839088|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
218839089|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
218839090|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
219017524|NCT00213915|DRUG|12 g of L-arginine glutamate during 6 weeks twice a day|
219196635|NCT06813209|DEVICE|tVNS|For true tVNS stimulation, the technique will be performed with the electrodes positioned on the upper concha of the left ear, using gel for better current distribution.
219017526|NCT05407675|DRUG|BMS-986408|Specified dose on specified days
219017527|NCT05407675|BIOLOGICAL|Nivolumab|Specified dose on specified days
218839091|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
219448853|NCT01228838|DRUG|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
219448854|NCT01228838|DRUG|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
219448855|NCT01238276|DRUG|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
219448856|NCT01238276|DEVICE|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
219448857|NCT00216229|BIOLOGICAL|Combined vaccine against hepatitis A and B (Twinrix)|
219448858|NCT05746689|DRUG|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
218839092|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
218839093|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
219448859|NCT02282488|OTHER|Low protein formula|
218839094|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
219448860|NCT02282488|OTHER|High protein formula|
219448861|NCT06216769|DRUG|Rivaroxaban|"Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours."
219448862|NCT01963962|DRUG|Copper IUD|
219448863|NCT01963962|DRUG|Levonorgestrel IUD|
219448864|NCT03455504|DRUG|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
218839095|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
218839096|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
218839097|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
218839098|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
218839099|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
218839100|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
219448865|NCT00721357|BEHAVIORAL|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
219587024|NCT05882994|BEHAVIORAL|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
219587025|NCT00685672|DRUG|adrenalin|adrenalin 2 microgram pr ml placebo
219587026|NCT00685672|DRUG|placebo|Saline instead of adrenaline in the epidural mixture
219587027|NCT00620555|DRUG|gabapentin|Orally administered gabapentin
219587028|NCT00581087|DRUG|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
219587029|NCT00581087|DRUG|Placebo|Treatment : 200 mg/day hard gelatine capsule
219587030|NCT04175444|DIAGNOSTIC_TEST|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
219587031|NCT04175444|DIAGNOSTIC_TEST|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
219587032|NCT01140503|DRUG|Apremilast|Apremilast 20mg PO BID
219587033|NCT00928161|DRUG|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
219017528|NCT05407675|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219587034|NCT05363514|DRUG|Low Dose Naltrexone|Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
219587035|NCT05363514|DRUG|Microcrystalline cellulose|Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
219587036|NCT02678650|DRUG|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
219587037|NCT02678650|DRUG|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
219587038|NCT02548130|OTHER|MELD score|introduction of MELD score
218839101|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
219766507|NCT07213128|OTHER|Training|"home-based inspiratory muscle training (IMT) will be delivered using a portable IMT device connected via Bluetooth to a smartphone application that provides real-time feedback, adherence monitoring, and telemonitoring by the study team. Patients will train for 365 days following hospital discharge due to an acute exacerbation of COPD:~* Intensive phase (Day 0-90): 2 daily sessions, each consisting of 30 breaths against an inspiratory load set by thetelemonitor, with regular online supervised IMT sessions, 7 sessions in total~* Maintenance phase (Day 91-180): One daily session of 30 breaths, with sporadic online supervised IMT sessions, 2 sessions in total.~* Follow-up phase (Day 181-365): Participants may continue IMT unsupervised. Supervision includes both in-person sessions at hospital visits and online sessions with telemonitors."
219448866|NCT00721357|OTHER|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
219448867|NCT00438776|DRUG|olanzapine|2.5mg to 15mg daily
219448868|NCT00438776|DRUG|sugar pill|matching placebo to olanzapine
219587039|NCT00724048|DRUG|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
219196636|NCT06811688|OTHER|Two mobile applications: Brushout and Brush teeth reminder applications|These applications were adjusted to send notifications twice daily in the morning and night as reminders to practice oral hygiene.
219587040|NCT00724048|OTHER|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
219587041|NCT06059664|DRUG|Finerenone Oral Tablet|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
219587042|NCT06059664|DRUG|Placebo|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
219766508|NCT07211971|DIAGNOSTIC_TEST|retrospective study including neonates who underwent flexible fiberoptic bronchoscopy over a period of 10 years from January 2015 to January 2025.|retrospective study including neonates who underwent flexible fiberoptic bronchoscopy over a period of 10 years from January 2015 to January 2025.
219766509|NCT07213453|DEVICE|Digital Smile Design|Digital Smile Design workflows used for virtual planning and fabrication of laminate veneer restorations.
219766510|NCT07213011|OTHER|Neck static stretching|The neck static stretching (SS) protocol consisted of four sets, each lasting 45 seconds, interspersed with 45-second recovery periods (total intervention time: 3 minutes). While seated on a chair, participants performed the stretch by gently inclining the head forward and to the left in an antero-lateral direction and assisting the movement with the contralateral (left) hand to specifically elongate the right posterolateral neck region.
219448869|NCT00003992|BIOLOGICAL|trastuzumab|
219448870|NCT00003992|DRUG|cyclophosphamide|
219448871|NCT00003992|DRUG|doxorubicin hydrochloride|
219448872|NCT00003992|DRUG|paclitaxel|
219448873|NCT00003992|DRUG|tamoxifen citrate|
219448874|NCT01343576|DIETARY_SUPPLEMENT|milk fat|45 g milk fat per day in 4 weeks
219448875|NCT03828565|PROCEDURE|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
219448876|NCT00909194|BEHAVIORAL|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
219587043|NCT06262282|BIOLOGICAL|mycobacteriophage|mycobacteriophage phage that has been found effective in killing participants NTM infection
219587044|NCT02141035|DRUG|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
219587045|NCT02141035|DRUG|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
219587046|NCT00561561|BEHAVIORAL|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
219587047|NCT03833479|OTHER|No Further Treatment|No further treatment
219587048|NCT03833479|DRUG|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
219587049|NCT02754544|PROCEDURE|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
219587050|NCT02754544|OTHER|Electrocorticography|Undergo electrocorticography
219587051|NCT06982924|DRUG|Limertinib+bevacizumab|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive the combination of Limertinib with bevacizuma in first-line treatment
218839102|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
218839103|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
218839104|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
218839105|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
218839106|NCT05535023|DRUG|SAR444245|Given by vein (IV)
218839107|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
219448877|NCT03233672|RADIATION|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
219448878|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
219448879|NCT03954704|DRUG|mFOLFOX6 Regimen|Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
219448880|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
219448881|NCT03628040|DRUG|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
219448882|NCT03628040|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane
219587052|NCT06982924|DRUG|Limertinib|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive Limertinib in first-line treatment
219587053|NCT06984523|RADIATION|Varian Eclipse|Varian TrueBeam linear accelerator with photon beam Volumetric Modulated Arc Therapy (VMAT) capability. Subjects will receive 3000 centigray (cGy) in 10 fractions at 300 cGy per fraction.
219587054|NCT04801667|BIOLOGICAL|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
218839108|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
218839109|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
218839110|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
218839111|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
218839112|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
218839113|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
218839114|NCT01221753|DRUG|docetaxel|
218839115|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
218839116|NCT01221753|DRUG|5-FU|
218839117|NCT01221753|RADIATION|IMRT|
218839118|NCT01221753|DRUG|cetuximab|
218839119|NCT01221753|DRUG|carboplatin|
218839120|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
218839121|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
219017529|NCT05407675|BIOLOGICAL|Platinum-doublet chemotherapy|Specified dose on specified days
219017530|NCT05407675|DRUG|Rabeprazole|Specified dose on specified days
219448883|NCT00916396|DRUG|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
219448884|NCT00916396|DRUG|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
219448885|NCT00102804|DRUG|Pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
219448886|NCT00102804|DRUG|Placebo|IV administration, q 21 days
219448887|NCT00102804|OTHER|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
219448888|NCT02669446|DEVICE|Medical devices|
219448889|NCT02669446|DEVICE|traditional household remedy|
219448890|NCT04273568|OTHER|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
219448891|NCT04273568|OTHER|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
219587055|NCT01358552|OTHER|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
219587056|NCT05217706|DRUG|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
218839122|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
219448892|NCT03017040|DEVICE|CT scan|A CT scan of the wrist
219448893|NCT03017040|DEVICE|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
219587057|NCT05217706|DRUG|normal Saline|The placebo group will receive normal saline IV in a matched syringe
219587058|NCT06990243|OTHER|Evaluation Group|An evaluation form will record the participants' socio-demographic characteristics and information about their disease/treatment. Consciousness and cognitive tests will be performed. Then, pain will be assessed with the Visual Analog Scale, 4-Question Neuropathic Pain Questionnaire,, and the Spinal Cord Injury Pain Instrument (SCIPI).
219587059|NCT06990971|OTHER|No Intervention: Observational Cohort|No interventions will be performed specifically for this study. Samples will be collected from menstrual fluid naturally shed or from biopsies and/or operations that are already taking place.
219448894|NCT00058773|DRUG|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
219448895|NCT02094664|DEVICE|Heated and humidified oxygen|
219448896|NCT02507050|DRUG|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
219448897|NCT01886495|OTHER|nutrition intervention|
219448898|NCT04137055|DRUG|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
219448899|NCT04137055|DRUG|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
219448900|NCT04137055|DRUG|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
219448901|NCT04137055|DRUG|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
219448902|NCT04137055|DRUG|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
219448903|NCT04137055|DRUG|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
219448904|NCT04137055|DRUG|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
219448905|NCT04137055|DRUG|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
219448906|NCT04137055|DRUG|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
219448907|NCT04137055|DRUG|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
219587060|NCT03131492|DIAGNOSTIC_TEST|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
219587061|NCT06156189|DIETARY_SUPPLEMENT|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
219587062|NCT06105827|DRUG|Control group|Give antibiotics or diclofenac sodium suppository as needed.
218839123|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
218839124|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
218839125|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
218839126|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
219448908|NCT04137055|DRUG|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
219448909|NCT04137055|DRUG|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
219448910|NCT01428414|DRUG|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
219448911|NCT01428414|DRUG|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
219448912|NCT01428414|DRUG|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
219448913|NCT01428414|DRUG|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
219448914|NCT05202002|BEHAVIORAL|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
219448915|NCT05202002|BEHAVIORAL|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
219587063|NCT06105827|DRUG|Ningmitai capsule|Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
219587064|NCT06105827|DRUG|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
219587065|NCT06989996|DEVICE|Images Acquisition|Acquisition of useable video images
219587066|NCT06988995|OTHER|Information|Participants provided handouts with information on self-compassion
218839127|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
218839128|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
219448916|NCT01722214|BIOLOGICAL|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
219448917|NCT01722214|OTHER|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
219448918|NCT01896414|DIETARY_SUPPLEMENT|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
219448919|NCT01896414|DIETARY_SUPPLEMENT|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
219448920|NCT01001143|DRUG|Decitabine|
219448921|NCT01001143|DRUG|Bexarotene|
219587067|NCT06988995|BEHAVIORAL|Meeting|Participants meet with a psychological provider to receive information on self-compassion and training on how to utilize self-compassion
219587068|NCT06988670|DRUG|EXT608|Modified version of parathyroid hormone attached to vitamin D to extend half-life
219587069|NCT06988670|OTHER|Placebo|Placebo for injection
219587070|NCT06990932|DEVICE|High Intensity Laser|The therapeutic dose of laser therapy depends on power density, tissue color, and type. Darker skin may absorb the laser in the epidermal layer, but HILT can pass through without absorption. Research has improved power density and dose, with the World Association of Laser Therapy recommending a 5-7 J/cm2 dose for optimal therapeutic outcomes.
219587071|NCT06990932|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is a popular alternative to traditional manual therapy techniques, derived from Cyriax cross-friction massage. It uses hard tools to manipulate soft tissue, varying in direction, force, and pattern, and allowing pressure to disperse to underlying tissues. Modern Instrument-assisted soft tissue mobilization instruments vary in material and design, and are used to improve musculoskeletal conditions and outcomes. Patients receive Instrument-assisted soft tissue mobilization with an M2T blade, positioned at a 45° angle, and instructed to apply an ice pack if experiencing burning sensations.
219587072|NCT06990932|OTHER|Conventional treatment|conventional physical therapy, which includes ultrasound, isometric neck exercises, chin tucks, stretching of neck muscles, and neck stabilization exercises, were used for groups A, B and C
218839129|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
219448922|NCT04120480|DIAGNOSTIC_TEST|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
219448923|NCT00985140|RADIATION|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
219448924|NCT03327246|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
219448925|NCT03253029|DIETARY_SUPPLEMENT|Pure Encapsulations Branched Chain Amino Acid powder|
219448926|NCT03253029|DIETARY_SUPPLEMENT|control group (no BCAAs provided)|
219448927|NCT03377829|PROCEDURE|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
219448928|NCT03377829|PROCEDURE|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
219448929|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
219448930|NCT03371589|DRUG|Dexamethasone|Solution for otic injection
219448931|NCT00755391|BEHAVIORAL|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
219448932|NCT00755391|BEHAVIORAL|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
219448933|NCT02021474|DRUG|AGX-201|Subcutaneous injection
218839130|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
218839131|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
218839132|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
219448934|NCT02021474|DRUG|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
219448935|NCT00833612|DEVICE|Counterpulsation with IAB|IABC pre-reperfusion PCI
219448936|NCT05405569|OTHER|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
218839133|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
218839134|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
218839135|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
218839136|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
218839137|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
218839138|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
218839139|NCT04552288|DRUG|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
219448937|NCT05405569|OTHER|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
219448938|NCT03729908|BEHAVIORAL|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
219587073|NCT05120206|PROCEDURE|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
218839140|NCT05285644|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
218839141|NCT05285644|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
218839142|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
218839143|NCT03001193|DRUG|DF 01|
218839144|NCT03001193|DRUG|Oxytocin|
218839145|NCT03001193|DRUG|Placebo|
219587074|NCT02044549|DRUG|carbetocin|Oxycontin analogue
219587075|NCT02044549|DRUG|Syntometrine|Uterotonins
219448939|NCT03729908|BEHAVIORAL|Anti-stress program|A mindfulness based intervention with no reference to animals
219448940|NCT00658450|BEHAVIORAL|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
219448941|NCT03256006|OTHER|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
219448942|NCT03677544|OTHER|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
219448943|NCT01312285|DEVICE|Resonator device|low level magnetic fields
219448944|NCT00139633|DRUG|carboplatin, 5FU, Taxol and radiation|
219448945|NCT03769389|DIETARY_SUPPLEMENT|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
219448946|NCT03769389|DIETARY_SUPPLEMENT|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
219448947|NCT03769389|DIETARY_SUPPLEMENT|placebo|50g of pure glucose dissolved in 100ml of water
219448948|NCT04105595|DEVICE|Septal defect closure|Device closure of atrial septal defect
219448949|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
219448950|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
219448951|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
219448952|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
219448953|NCT00683774|DRUG|diazoxide|100mg orally three times per day for 10 days
219448954|NCT00691054|DRUG|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
219448955|NCT02735044|DRUG|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
219448956|NCT02735044|DRUG|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
219448957|NCT02735044|DRUG|Background therapy|Fast-acting mealtime insulin analogs
219448958|NCT00441194|DEVICE|Visual Field (Octopus 311 and the HFA 700 series)|
219448959|NCT04669509|DIAGNOSTIC_TEST|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
219448960|NCT06186895|DRUG|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
219448961|NCT06186895|DRUG|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
219587076|NCT06991127|DEVICE|MAIA|MAIA is an automatic microperimeter with fundus imaging capabilities that measures retinal sensitivity, fixation stability and locus of fixation, and allows the acquisition of confocal images of the retina, thanks to its confocal scanning imaging system which uses infrared and visible light.
219587077|NCT06989073|PROCEDURE|Muscle Energy Technique|METs are soft tissue or joint techniques that are employed in the treatment of musculoskeletal dysfunctions.
219587078|NCT06989073|PROCEDURE|Convenional treatment|Hot pack, Range of Motion Exercises, Stretching Exercises and Strengthening exercises.
218839146|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
218839147|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
218839148|NCT04318678|DRUG|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
219448962|NCT07102355|OTHER|Experimental: Group A = Dry Cupping|Dry cupping, originating in Middle Eastern and Asian countries, gained popularity in the United States after the 2016 Summer Olympics. It has two main forms: wet and dry cupping. Wet cupping involves laceration of the skin, while dry cupping uses negative pressure to pull the skin into the cup. Cupping is used to reduce musculoskeletal or myofascial pain, with the most accepted mechanism being localized hyperemia, which improves microcirculation and promotes healing
219587079|NCT06988891|OTHER|'Evidence-based practice' training based on the flipped learning model|The evidence-based practice training, developed using the flipped learning model, was delivered once a week for four weeks. Each session was delivered as an offline training (3-24 February 2025) and a face-to-face training three days later (6-27 February 2025). The offline part of the training was delivered via the Edpuzzle platform. The training duration for each session was 75 minutes in total, 15 minutes offline and 60 minutes face-to-face.
219587080|NCT06988891|OTHER|'Evidence-based practice' training based on web-based education model|Evidence-based practice training, developed based on a web-based training model, was implemented once a week for two weeks (March 17-24, 2025). Each session was conducted offline. The first session was 20.10 minutes, and the second session was 17.44 minutes.
218839149|NCT04318678|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
219448963|NCT07102355|OTHER|Experimental: Group B = Graston Technique|Instrument-assisted soft tissue mobilization (IASTM), derived from Cyriax cross-friction massage, is a popular alternative to traditional manual therapy techniques, with its first controlled study published in 1997 (Seffrin \&amp; Gardiner-Shires, 2019) .The Graston Technique(GT), also known as instrument-assisted soft tissue mobilization (IASTM), is used by chiropractors, doctors, and therapists to alleviate pain and range-of-motion restrictions caused by musculoskeletal injuries and scar tissue. (McKivigan, J. M., \&amp; Tulimero, G. et al. , 2020) . The Graston technique, is also used to alleviate upper cervical pain.
218839150|NCT04318678|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
218839151|NCT04318678|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
219448964|NCT06727032|DEVICE|Brain Metastasis AI|There will be no intervention
218839152|NCT04318678|DRUG|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
219448965|NCT06725004|DRUG|Oxytocin|Injection Oxytocin 10 mg intramuscular as trigger for ovulation induction
219448966|NCT06725004|DRUG|Human Chorionic Gonadotropin|Injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
219448967|NCT07057817|DEVICE|Cerament G|Partial Calcanectomy plus cerament G
219587081|NCT06988891|OTHER|'Evidence-based practice' training based on traditional education model|The evidence-based practice training, developed based on the traditional/face-to-face education model, was delivered once a week for three weeks (7-21 April 2025). Each session consisted of two teaching hours (one teaching hour: 45 minutes).
218839153|NCT04295759|DRUG|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
218839154|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
218839155|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
218839156|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
218839157|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
219448968|NCT07057817|OTHER|Standard Surgical Managment|Partial Calcanectomy as standard of care
219448969|NCT03219476|DRUG|Anastrozole|1 mg once daily.
219448970|NCT03219476|DRUG|Letrozole|2.5mg once daily.
219448971|NCT03219476|DRUG|Exemestane|25 mg once daily.
219587082|NCT04222374|PROCEDURE|Intervention in the UroCCR sites|"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~   * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~  * 1 aliquot for the UroCCR biobank.~  * For patients from other UroCCR centers, only 1 aliquot will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
219587083|NCT04222374|PROCEDURE|Intervention in the CRB of Bordeaux University Hospital|"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
219587084|NCT04222374|PROCEDURE|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
219587085|NCT04222374|PROCEDURE|Subsequent intervention at the NCI (for information)|"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
219587086|NCT02951442|BIOLOGICAL|Biological sample|
219587087|NCT02951442|PROCEDURE|Non invasive Arterial investigations|
219587088|NCT02951442|PROCEDURE|Abdominal tomodensitometry|
218839158|NCT00156104|DRUG|Asenapine|5 mg BID
218839159|NCT00156104|DRUG|Asenapine|10 mg BID
218839160|NCT00156104|DRUG|Haloperidol|4 mg BID
218839161|NCT00156104|OTHER|Placebo arm|
218839162|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
218839163|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
218839164|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
218839165|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
218839166|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
218839167|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
218839168|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
218839169|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
219448972|NCT03219476|DRUG|Tamoxifen|20 mg once daily.
219448973|NCT01105468|DEVICE|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
219448974|NCT01105468|DEVICE|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
219448975|NCT06917651|DRUG|sufentanil sublingual 30 mcg tablet|"patient randomized in the SST 30mcg arm will receive a 30-microgram sublingual sufentanil tablet"
218839170|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
218839171|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
218839172|NCT02299141|DRUG|Nintedanib|
218839173|NCT05152524|DEVICE|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
219448976|NCT06917651|OTHER|Standard of Care (SOC)|"patients randomized in the SOC arm will receive analgesic treatment according to the department's internal pain management protocol."
219448977|NCT06932822|OTHER|Mental Imagery|Placement of a peripheral venous catheter on a simulation mannequin after a mental visualization session
218839174|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
218839175|NCT05278845|DRUG|SLC-391|SLC-391 is an AXL inhibitor
218839176|NCT02020798|OTHER|Dietary Intervention|
218839177|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
219587089|NCT06395376|OTHER|Bikram Hot Yoga Intervention|"Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)"
219587090|NCT06395376|OTHER|Hot Yoga Washout|"The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga."
219587091|NCT01687348|DRUG|lidocaine aguettant|
219587092|NCT03923530|DRUG|Eplerenone|Eplerenone 50 mg daily
218839178|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
218839179|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
218839180|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
218839181|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
218839182|NCT03690986|BIOLOGICAL|VX15/2503|Given IV
218839183|NCT03690986|BIOLOGICAL|Ipilimumab|Given IV
218839184|NCT03690986|BIOLOGICAL|Nivolumab|Given IV
218839185|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
218839186|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
218839187|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
218839188|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
218839189|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
218839190|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
219448978|NCT06932380|PROCEDURE|Talus prosthesis|The Episealer Talus is an individualised resurfacing implant intended for use on either the medial or lateral talus. It aims to treat patients suffering from pain and reduced mobility due to focal osteochondral lesions in the talus.
219448979|NCT05434936|PROCEDURE|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
219448980|NCT05136040|DRUG|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
219587093|NCT00407758|DRUG|enzastaurin hydrochloride|
219587094|NCT00273234|PROCEDURE|Autologous Platelet Gel (APG)|
218839191|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
218839192|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
218839193|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
219587095|NCT02098421|DRUG|Oxytocin|Use of oxytocin while the Foley bulb is in place
219587096|NCT04154150|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
219587097|NCT04154150|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
218839194|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
218839195|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
218839196|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
219587098|NCT04154150|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
219587099|NCT01742520|DRUG|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
219587100|NCT01742520|DRUG|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
218839197|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
218839198|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
219448981|NCT02112461|BEHAVIORAL|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
219448982|NCT06949787|PROCEDURE|Membrane sweeping|Participants in the membranes sweeping group will receive membrane sweeping. If labor will not initiate within 48 hours, the procedure will be repeated up to a maximum of three times at 48-hour intervals.
219448983|NCT06949384|OTHER|observational study|This observational study focuses on the measurement of self-esteem in medical students using the Rosenberg Self-Esteem Scale. There is no intervention or treatment applied, and participants are only assessed for their self-esteem levels based on their demographic information.
219448984|NCT06948838|BEHAVIORAL|RBPM|Standardized blood pressure measurement and treatment protocols in clinical practice.
219448985|NCT06948838|OTHER|MII|Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.
219448986|NCT06132529|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
219448987|NCT06132529|OTHER|Speech Sample|Recorded reading aloud of pre-written words and sentences
219448988|NCT06132529|OTHER|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
219448989|NCT02621021|BIOLOGICAL|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
219448990|NCT02621021|DRUG|Pembrolizumab|(Cohort 1, Arm 2 ,Cohort 2 and Cohort 3, Arm 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes.
219448991|NCT02621021|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
219448992|NCT02621021|DRUG|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
218839199|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
218839200|NCT03737955|DRUG|Gemtuzumab Ozogamicin|Receive IV
219448993|NCT02621021|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
219448994|NCT06447220|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
219448995|NCT05365685|BEHAVIORAL|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
219587101|NCT00515931|RADIATION|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
219587102|NCT02245061|OTHER|paired pulses cortical electrical stimulation|
219587103|NCT01955655|DRUG|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
219587104|NCT01955655|OTHER|Placebo|
219587105|NCT05189938|DIAGNOSTIC_TEST|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
219587106|NCT04455178|DRUG|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
219587107|NCT04455178|DRUG|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
218839201|NCT03737955|OTHER|Quality-of-Life Assessment|Ancillary studies
218839202|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
218839203|NCT05060016|DRUG|Tarlatamab|Intravenous (IV) infusion
219448996|NCT04567732|COMBINATION_PRODUCT|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
219448997|NCT04567732|DRUG|Placebo|Single injection of Placebo
219448998|NCT06458998|BEHAVIORAL|Patient Navigation|Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.
219448999|NCT06458998|BEHAVIORAL|Implementation Facilitation|Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
219449000|NCT05744713|OTHER|Observational|Observational
219449001|NCT01711671|DRUG|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
219449002|NCT01711671|DRUG|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
219449003|NCT01711671|DRUG|Standard of Care|Current approved standard of care
219449004|NCT05974202|DEVICE|Active H7-coil repetitive transcranial magnetic stimulation (rTMS)|A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.
219449005|NCT05974202|DEVICE|Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)|A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
219449006|NCT05755269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219449007|NCT05755269|PROCEDURE|Genotyping|Undergo genotyping
219587108|NCT00599898|DRUG|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
218839204|NCT03215719|RADIATION|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.
218839205|NCT03215719|RADIATION|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
218839206|NCT03215719|DRUG|Cisplatinum|Standard of care chemotherapy
218839207|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
219449008|NCT05755269|OTHER|Survey Administration|Complete surveys
219587109|NCT00599898|DRUG|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
219587110|NCT01222390|DEVICE|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
218839208|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
218839209|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
218839210|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
219587111|NCT03757975|PROCEDURE|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
219587112|NCT00146887|PROCEDURE|coronary catheterization|
218839211|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
218839212|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
218839213|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
218839214|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
218839215|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
218839216|NCT01795976|GENETIC|NY-ESO-1 T cells|
218839217|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
218839218|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
219449009|NCT04685408|BEHAVIORAL|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
219449010|NCT04685408|BEHAVIORAL|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
219449011|NCT05761899|COMBINATION_PRODUCT|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
219449012|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
219449013|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
219449014|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
219449015|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
218839219|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
218839220|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
218839221|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
219449016|NCT00142818|DRUG|Modafinil|400 mg daily
218839222|NCT04859101|OTHER|Gum|2 minutes of gum chewing prior to procedure
218839223|NCT04859101|OTHER|Control|2 swallows prior to procedure
219449017|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
219449018|NCT02051088|PROCEDURE|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
219449019|NCT02051088|PROCEDURE|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
219449020|NCT02051088|DEVICE|drug-coated balloons and/or drug-eluting stents|
219587113|NCT05190653|OTHER|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
218839224|NCT02855879|OTHER|Collection of biological data|
218839225|NCT02855879|OTHER|Collection of clinical data|
218839226|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
218839227|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
218839228|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
218839229|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
219587114|NCT01822275|DRUG|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
219587115|NCT01822275|RADIATION|Radiation therapy|
219587116|NCT05034276|OTHER|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
219587117|NCT02468492|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
218839230|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
219449021|NCT06366425|DIAGNOSTIC_TEST|Blood sample then fibroscan|"The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan."
219449022|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
219449023|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
219587118|NCT02468492|OTHER|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
219587119|NCT05011630|OTHER|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
219587120|NCT00703573|DRUG|S-777469 400 mg|S-777469 400 mg BID
219587121|NCT00703573|DRUG|S-777469 800 mg|S-777469 800 mg BID
219587122|NCT00703573|DRUG|Placebo|Placebo BID
219587123|NCT04321798|BEHAVIORAL|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
219587124|NCT05426304|DRUG|Agomelatine|agomelatine 25 mg/day for 180 days
219587125|NCT05426304|DRUG|Placebo Tablets|placebo 25 mg/day for 180 days
219587126|NCT03610568|BEHAVIORAL|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
219587127|NCT01594450|BIOLOGICAL|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
219587128|NCT01594450|PROCEDURE|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
219587129|NCT02119117|DIETARY_SUPPLEMENT|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
218839231|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
218839232|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
219587130|NCT02119117|DIETARY_SUPPLEMENT|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
219587131|NCT03465917|COMBINATION_PRODUCT|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
219587132|NCT00069186|DRUG|Creatine Monohydrate|
219587133|NCT00228241|DEVICE|AAI vs. DDD vs. BIV pacing in different patients groups|
219587134|NCT03814941|OTHER|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
219587135|NCT03814941|OTHER|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
219587136|NCT04003584|PROCEDURE|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
218839233|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
218839234|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
219587137|NCT00073021|DRUG|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
219587138|NCT00073021|DRUG|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
219587139|NCT01458106|DRUG|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
219449024|NCT05501405|OTHER|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
219449025|NCT06771869|DIAGNOSTIC_TEST|Sodium balance|cumulative sodium balance and cumulative fluid balance will be estimated in the first three days after admission
219449026|NCT06797076|BEHAVIORAL|Health enSuite Headache|"The program consists of treatment modules delivered over 8 weeks. Modules include topics such as Headaches and Triggers, Relaxation, Breathing, Changing Thoughts, Imagery, Problem Solving, Nutrition, Sleep, Exercise, Medication, and more. Each module features sections like Goals, Getting Started, Let's Talk, and a Quiz, with Let's Practice in four modules. Intervention participants track headaches using a structured tracker to log impacts, daily events (e.g., exposure, strategies, medication), and notes. Control group participants track headaches only at baseline, two months, and five months post-randomization. Weekly reminders (nudges) encourage app usage, with the same frequency for all users. Reports summarizing daily headache data are available to participants."
219449027|NCT05442060|BIOLOGICAL|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
218839235|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
218839236|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
218839237|NCT06661811|DRUG|CAR-T|CAR-T cells
218839238|NCT06660043|OTHER|physical activity|40 min circuit training session
219449028|NCT05442060|DRUG|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
219587140|NCT01458106|DRUG|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
219587141|NCT04650113|COMBINATION_PRODUCT|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
219587142|NCT06989918|DRUG|MHB018A|MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
219587143|NCT06989918|DRUG|MHB018A placebo|6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
219587144|NCT01644136|PROCEDURE|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
218839239|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
218839240|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
218839241|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
218839242|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
218839243|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
218839244|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
218839245|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
218859966|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
219587145|NCT01644136|PROCEDURE|regional lymph node dissection|Undergo pelvic lymph node dissection
219587146|NCT01644136|DEVICE|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
219587147|NCT00362921|DRUG|Gliadel wafers in combination with O6-benzylguanine|
218839246|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
219449029|NCT06793449|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
219449030|NCT06793449|BIOLOGICAL|ASCT|Autologous stem cell infusion
218839247|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
218839248|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
218839249|NCT06078527|DEVICE|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
218839250|NCT06078527|PROCEDURE|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
218839251|NCT06078527|OTHER|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
218839252|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
218839253|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
218839254|NCT02106572|DRUG|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
218839255|NCT02106572|DRUG|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
218859967|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
219449031|NCT06959160|OTHER|Atlanto-occipital manipulation|Participants in the first group received atlanto-occipital manipulation. The patient was positioned in a supine position, with the head rotated to one side. The therapist placed the middle and ring fingers of one hand on the patient's mastoid process, while the palm of the other hand made contact with the patient's jawline and cheek. A gentle traction force was applied to the cranial region using both hands. When the therapist sensed joint tension, a high-velocity, low-amplitude thrust was delivered in the direction of the traction with a slight rotational force. The procedure was performed bilaterally and lasted approximately 5 minutes.
219449032|NCT06959160|OTHER|Cervical mobilization|Participants in the second group underwent Grade II-III cervical mobilization techniques, administered over a period of 10 minutes. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
219587148|NCT04470336|OTHER|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
219587149|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
219587150|NCT04470336|OTHER|Placebo|Three capsules post-breakfast Three capsules post-dinner
219587151|NCT01601366|DEVICE|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
219587152|NCT01601366|DRUG|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
218839256|NCT06842381|OTHER|Telerehabilitation Program|A support system for the treatment of cervical pain based on Web technologies will be used, accredited as a health website. This system has a structure based on 4 sections: database treatment, database user profiles, recommendations, and feedback/biofeedback procedures. This system allows the registration and introduction of a subject, and modification of a treatment with electroanalgesia and exercises, according to the symptomatic evolution of the pain. It is based on an initial patient assessment system.
219766511|NCT07213011|OTHER|Neck self-myofascial release|For the self-myofascial release (SMR) intervention, a Theraband® roller massager was employed. The device consists of a rigid plastic core surrounded by dense foam, designed with a grooved surface to facilitate both superficial and deeper tissue stimulation. The SMR protocol comprised four sets (total intervention time: 3 minutes), during which participants executed 45 rhythmic rolling movements per set at a cadence of one roll per second. The tempo was standardized using a metronome application. For the SMR condition, the protocol included 45-second recovery intervals between sets. Participants, seated on a chair, were instructed to perform self-administered rolling on the right posterolateral neck region using the massage roller and to cover the largest possible area of the posterolateral neck region during the rolling, with the head gently inclined forward and to the left in an antero-lateral direction.
219766512|NCT07211464|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each 1.5-hour session will consist of a 1-hour ACT intervention and 30 minutes of exercise training. The ACT group was led by a trained ACT counsellor and a trained exercise trainer.
219766513|NCT07211464|BEHAVIORAL|back exercise|30-minute exercise class
219766514|NCT07211464|BEHAVIORAL|back care education|1-hour interactive lesson on back care
219766515|NCT07210684|DIETARY_SUPPLEMENT|Placebo 400 mg|Participants will receive 4 placebo capsules daily for 6 weeks. Each capsule contains 100 mg of microcrystalline cellulose, which serves as a inactive control substance.
219766516|NCT07210684|DIETARY_SUPPLEMENT|Dihydroberberine（DHB）400 mg|Participants will receive 4 capsules of DHB (Dihydroberberine) 100 mg each, orally, once daily for 6 weeks. The total daily dose is 400 mg of DHB.
219449033|NCT06959160|OTHER|Trigger point therapy|Participants in the third group received trigger point therapy, which included ischemic compression followed by myofascial stretching on the upper trapezius muscle. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
219449034|NCT06114043|OTHER|Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus|60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.
219449035|NCT06114043|OTHER|Operation for mild to moderate hallux valgus|60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
219449036|NCT06794073|DEVICE|Multimodal Thermal Therapy|The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
219449037|NCT04547816|PROCEDURE|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
219449038|NCT04547816|PROCEDURE|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
219449039|NCT04547816|BEHAVIORAL|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
219587153|NCT00855803|RADIATION|radiation|Given in 1 or 5 fractions
218839257|NCT06842381|OTHER|Face to Face Program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience in both procedures. This program will be developed in the Health Sciences clinical units of the Universities of Almeria, Granada and Malaga.
218839258|NCT01847612|PROCEDURE|indocyanine green fluorescent cholangiography|
218839259|NCT01847612|DRUG|methylene blue|
218839260|NCT07020650|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and bone graft.
218839261|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
218839262|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
218839263|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
218839264|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
219587154|NCT02839421|DRUG|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
219587155|NCT00166270|DEVICE|ExAblate 2000|
219587156|NCT03316378|DRUG|Ropivacaine injection|single dose, subcutaneous injection
219587157|NCT01693627|DEVICE|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
218839265|NCT06831851|BEHAVIORAL|Storytelling Sessions|Children will participate in structured storytelling sessions, held once a week for 30 minutes per session. The sessions will use interactive narrative techniques, including voice modulation, gestures, and visual aids, to enhance cognitive, linguistic, and socio-emotional development. The intervention is designed to promote active engagement, stimulate imagination, and improve attention and language skills in early childhood.
218839266|NCT06831851|BEHAVIORAL|Music Education Sessions|Children will participate in structured music education sessions, conducted twice per week for 40 minutes each. The sessions will include rhythm exercises, vocalization, body percussion, and instrumental exploration using age-appropriate musical instruments. Activities will be designed to enhance cognitive, motor, and socio-emotional development by fostering auditory discrimination, fine and gross motor coordination, and social interaction. The intervention follows an interactive and play-based methodology, ensuring active engagement and progressive learning.
219449040|NCT04547816|BEHAVIORAL|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
219449041|NCT06479811|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.
219449042|NCT06479811|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET will be given IV 7 days prior to \[212Pb\]VMT-alpha-NET.
219449043|NCT06479811|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
219449044|NCT03662685|OTHER|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
219449045|NCT03662685|DRUG|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
219449046|NCT03662685|DEVICE|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
219449047|NCT03738878|DRUG|Valsartan|oral valsartan
219587158|NCT01693627|DEVICE|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
219766517|NCT07213271|OTHER|Dance classes|Participants will attend supervised sessions three times per week, each lasting 60 minutes. Classes were instructed by certified professional dancers and incorporated structured choreographies from three dance genres: folkloric, Latin American, and contemporary.
218839267|NCT06831851|BEHAVIORAL|Parental Guidance Sessions|Parents or guardians will attend 8 biweekly training sessions (60 minutes each) designed to equip them with strategies for cognitive, linguistic, and socio-emotional stimulation in early childhood. The sessions will include practical guidance on storytelling techniques, musical interaction, and play-based learning to reinforce the intervention at home. The goal is to create continuity between structured intervention activities and the home environment, maximizing developmental outcomes for the children. Sessions will be interactive, combining theoretical content with practical exercises and demonstrations
218839268|NCT06831851|BEHAVIORAL|Standard Daycare Activities|Children in this group will participate in regular daycare activities, including artistic and pedagogical tasks such as drawing, painting, and modeling. These activities are part of the standard curriculum and do not include structured storytelling or music education interventions
218839269|NCT03108521|DRUG|Sitagliptin|100mg.QD for 3 months
218839270|NCT06897228|DRUG|PANK-003 cell injection|PANK-003 cell injection
218839271|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
218839272|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) Online|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of an online family dyadic skills training and in-person core behavioral weight loss sessions.
219449048|NCT03738878|DRUG|LCZ696|oral LCZ696
219449049|NCT03738878|DRUG|Bradykinin|Intra-arterial bradykinin at three graded doses
219449050|NCT03738878|DRUG|Substance P|Intra-arterial substance P at three graded doses
219449051|NCT03738878|DRUG|BNP|Intra-arterial BNP at three graded doses
219449052|NCT03738878|DRUG|Sitagliptin|oral sitagliptin
219587159|NCT01693627|DEVICE|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
219766518|NCT07212647|OTHER|Home Exercise Group|Patient education + structured, video-based home exercise program Participants instructed to perform exercises 5 days per week for 6 weeks Adherence monitored via logs and telephone follow-up at week 3
219766519|NCT07212647|OTHER|Topical Therapy Group|Patient education + 1.5% diclofenac sodium gel Participants applied gel to anterior, medial, and lateral aspects of the knee, once daily, without massage techniques, for 6 weeks
219449053|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
218839273|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) In-Person|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of in-person family dyadic skills training and core behavioral weight loss sessions.
219449054|NCT06198959|DEVICE|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
219449055|NCT06198959|DEVICE|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
219449056|NCT06198959|DEVICE|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
219449057|NCT06198959|DEVICE|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
219449058|NCT06198959|DEVICE|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
219449059|NCT03872947|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
219449060|NCT03872947|BIOLOGICAL|TRK-950|5 mg/kg administered intravenously over 60 minutes (weekly)
219449061|NCT03872947|BIOLOGICAL|TRK-950|Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)
219449062|NCT03872947|DRUG|Irinotecan|Intravenously over 30 - 90 minutes
219449063|NCT03872947|DRUG|Leucovorin|Intravenously over 30 - 90 minutes
219449064|NCT03872947|DRUG|5-FU|Intravenously bolus and intravenously for two days
219449065|NCT03872947|DRUG|Gemcitabine|Intravenously over 30 minutes
219449066|NCT03872947|DRUG|Cisplatin|Intravenously over 60 minutes
219449067|NCT03872947|DRUG|Carboplatin|Intravenously per package insert
218839274|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
219449068|NCT03872947|DRUG|Ramucirumab|Intravenously over 60 minutes
219587160|NCT01693627|DEVICE|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
219587161|NCT06131827|OTHER|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
218839275|NCT02744612|DRUG|Ibrutinib|Given PO
218839276|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
218839277|NCT06786780|COMBINATION_PRODUCT|Drug: Cisplatin|Organoids were constructed prior to simultaneous radiochemical therapy
218839278|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
218839279|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
218839280|NCT02712983|DRUG|TIP|TIP dose regimen
219449069|NCT03872947|DRUG|Paclitaxel|Intravenously
219449070|NCT03872947|DRUG|Nivolumab|Intravenously over 30 minutes
219449071|NCT03872947|DRUG|Pembrolizumab|Intravenously over 30 minutes
219449072|NCT03872947|DRUG|Imiquimod Cream|Topically
219449073|NCT03872947|DRUG|Bevacizumab|Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
219449074|NCT03872947|DRUG|PLD|Intravenously over 60 minutes
219449075|NCT05810402|BIOLOGICAL|Liquid Biopsy|"30mL blood sample:~* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
219449076|NCT05611242|PROCEDURE|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
219449077|NCT05611242|PROCEDURE|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
219449078|NCT05611242|PROCEDURE|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
219587162|NCT06131827|OTHER|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
219587163|NCT05100979|OTHER|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
218839281|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
218839282|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
218839283|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
218839284|NCT04235816|DRUG|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
218839285|NCT04235816|DRUG|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
218839286|NCT05225233|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
218839287|NCT05225233|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
219196637|NCT06814990|DIAGNOSTIC_TEST|Cardiac MRI|Additional to standard clinical practice Patients will receive a cardiac magnetic resonance imaging without contrast. Measured parameters are enddoastolic and endsystolic volume (in ml oder ml/body surface area (BSA)), stroke volume (in ml) of right and left ventricle absolute and relatvie to body surface area (BSA), ejection fraction in % of right and left ventricle, myocardial Strain in % of right and left ventricle if applicable. T1 and T2 relaxation times are obtained and aortic and pulmonary artery flow parameters are measured.
218839289|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
219766520|NCT07211373|DEVICE|Jaspr|With assistance from a research staff, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subjects will continue to have access to the coping skills and videos via a mobile app.
219449079|NCT06845345|OTHER|early time restricted Mediterranean diet|Participants will start with a calorie restricted Mediterranean diet, with an eating window between 8AM till 6PM (early time-restricted eating) for a period of six months. Participants are asked to stop eating at 6PM. This results in a daily fasting window of approximately 14 hours. A daily caloric intake of 500 kcal compared to the calculated energy requirement is assumed to stimulate weight loss.
219449080|NCT06845345|DRUG|Mysimba|Participants will take Mysimba twice daily at a total dose of 32 mg/360 mg naltrexone/bupropion per day for a duration of six months. The dosage will be built up in the first month following the stepped care approach used in the SmPC. Participants receive usual care, including the advice of 60 minutes of exercise per day and standard dietary recommendations according to the guidelines for the Dutch population.
219449081|NCT02632344|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
218839290|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
218839291|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
219196638|NCT06814990|DIAGNOSTIC_TEST|Blood samples|We will take additional blood samples for the analysis of markers of bacterial translocation (e.g. LBP, EndoCAb, 16S rRNA), detection of bacterial markers (bacterial extracellular vesicles), inflammatory markers (e.g. IL-1ß, TNF-α, TGF-ß, IL-6, CXCL8, IL1-RA, IL-10, IL-18) and monocyte/macrophage activation markers (sCD14, sCD163, sCD87, sCD206), bile acids (including TCA, GCA, GCDCA, TCDCA, TLCA, GLCA, TDCA, GDCA, CA, CDCA, UDCA, DCA, TUDCA, LCA), lipids and lipoproteins (triglyerides, cholesterol, LDL/HDL cholesterol), coagulation factors (e.g. VWF, ADAMTS13, fibrinogen), markers of cardiac remodeling (e.g. NT-proBNP; troponin, VEGF-D, cleaved Gasdermin D, HMGB1) and Immunophenotyping of monocytes/macrophages, T and B cells (e.g. CD14, CD16, MERTK, CD4, CD127, CD25, TREM1/2).
219449082|NCT03144206|DRUG|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
218839292|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
218839293|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
219449083|NCT02171104|BIOLOGICAL|Stem Cell Transplantation|Infusion given on Day 0
219449084|NCT02171104|DRUG|IMD Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan"
219449085|NCT02171104|DRUG|Osteopetrosis Only Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa"
219449086|NCT02171104|DRUG|Osteopetrosis Haploidentical Only Preparative Regimen|"* Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine"
219449087|NCT02171104|DRUG|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
219449088|NCT02171104|DRUG|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
219449089|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
219449090|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
219449091|NCT04065295|DRUG|BI 1356225|Oral Dose
218839294|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
218839295|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
218839296|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
218839297|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
218839298|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
218839299|NCT06833931|DRUG|IV infusion|IV infusion
218839300|NCT06833931|OTHER|Placebo|IV infusion
218839301|NCT02965963|DRUG|Dopamine|
218839302|NCT02965963|DRUG|Metoclopramide|
218839303|NCT02965963|DRUG|Placebos|
219449092|NCT04065295|DRUG|Placebo|Oral dose
219449093|NCT05509699|DRUG|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
218839304|NCT02965963|OTHER|Rest|
218839305|NCT02965963|OTHER|Exercise - 60%|60% of VO2max
218839306|NCT02965963|OTHER|Exercise - 85%|85% of VO2max
218839307|NCT05360966|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
218839308|NCT05360966|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
218839309|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
218839310|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
219449094|NCT05509699|DRUG|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
219449095|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
219449096|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
219449097|NCT05110963|BEHAVIORAL|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
218839311|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
218839312|NCT06360900|DEVICE|taVNS|Electrical transcutaneous auricular vagus nerve stimulation
218839313|NCT06360900|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
218839314|NCT06360900|BEHAVIORAL|Education Control|Education of FD condition
218839315|NCT06360900|DEVICE|Sham taVNS|Sham (no current) transcutaneous auricular vagus nerve stimulation
218839316|NCT05396014|BEHAVIORAL|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
219449098|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
219449099|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
219449100|NCT06319534|BEHAVIORAL|Comprehensive rehabilitation|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
218839317|NCT05396014|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
218839318|NCT05396014|BEHAVIORAL|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
218839319|NCT05396014|DRUG|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
218839320|NCT06963905|DRUG|Relatlimab FDC + Nivolumab|Relatlimab: 360 IV Q3W (Dose level 1) and 120mg IV Q3W (Dose level -1) Nivolumab: 360mg IV Q3W
218839321|NCT06963905|DRUG|Sacituzumab Govitecan (SG)|10 mg/kg IV D1 \& D8 every 21-day cycles (Dose level 1); 7.5 mg/kg IV D1 \& D8 every 21-day cycles (Dose level -1); 5 mg/kg IV D1 \& D8 every 21-day cycles 21-day cycles (Dose level -2)
219587164|NCT05200962|DEVICE|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
219587165|NCT05541991|DIETARY_SUPPLEMENT|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
218839322|NCT06963905|DRUG|Nivolumab|360mg IV Q3W
218839323|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
218839324|NCT04591639|DRUG|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
218839325|NCT04591639|DRUG|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
218839326|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
218839327|NCT04894877|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
218839328|NCT04894877|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
218839329|NCT04894877|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
218839330|NCT04894877|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
218839331|NCT04894877|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
218859968|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
218859969|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
218859970|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
219196639|NCT06814990|DIAGNOSTIC_TEST|Echocardiography|Patients will receive an extended echocardiographic protocol. In addition to standard clinical parameters, we will collect study specific parameters such as LV EF in %, global longitudinal strain in %, septal e' velocity (cm/s), E/e' ratio, left atrial volume index (LAVI) (in ml/m2), tricuspid regurgitation velocities (m/s).
219449101|NCT06319534|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
219449102|NCT06319534|DRUG|Lidocaine Hydrochloride|the patients are provided with Stellate ganglion block, using 2.8ml of 0.8% Lidocaine hydrochloride and 0.2 ml of 0.5% vitamin B12. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
219587166|NCT05541991|DIETARY_SUPPLEMENT|placebo coated tablet|coated tablet without active principle
219587167|NCT05541991|DIETARY_SUPPLEMENT|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
219587168|NCT04048343|DRUG|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
219587169|NCT02384694|OTHER|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
219587170|NCT01918826|DEVICE|TENS|
219587171|NCT04393766|DRUG|Normal Saline|normal saline(crystalloids)
219587172|NCT03780231|OTHER|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
219587173|NCT02254369|DRUG|GC021109|
219587174|NCT02254369|OTHER|Placebo|
219587175|NCT00004755|DRUG|allopurinol|
219587176|NCT00004755|DRUG|glucantime|
219587177|NCT05187702|OTHER|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
218859971|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
218859972|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
218859973|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
218859974|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
218859975|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
218859976|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
219587178|NCT05187702|OTHER|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
219587179|NCT01703936|OTHER|Agricultural and life skills training program|
219587180|NCT00990587|DRUG|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
219587181|NCT01044654|GENETIC|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
219587182|NCT00609388|DRUG|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
219587183|NCT00609388|OTHER|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
219587184|NCT04481178|OTHER|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
219587185|NCT02132754|BIOLOGICAL|MK-4166|
219587186|NCT02132754|BIOLOGICAL|Pembrolizumab|
219587187|NCT04801953|DRUG|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
218839332|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
218839333|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
218839334|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
218839335|NCT06679192|DEVICE|Milled thickness varied soft upper surface, based on plantar pressure measurement|"This custom made shoe insole is milled, with a thickness varied soft upper surface ranging from 0-6mm in thickness. The base of the insole is 45 shore Ethylene-vinyl acetate (EVA).~This intervention makes the insole from an individual foot scan, a plantar pressure measurement from the individual and the shoe model to mill a finished custom made shoe insole with a soft upper surface. It is difficult in clinical practice of making shoe inserts to create a thickness varied soft upper with different zones all over the insole. Furthermore, a soft upper requires a physical positive model to be made of the foot and staff must spend time to grind the insole to an acceptable shape. A milled version would be more effective since it require no physical foot model, little to no work grinding the insole and enables the use of thickness-variations. It also enables the use of data-based insole-manufacturing, such as data from plantar pressure measurements."
218839336|NCT06679192|DEVICE|3mm soft upper surface|This intervention has a 3mm soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
218839337|NCT06679192|DEVICE|No soft upper surface|This intervention has a no soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
218839338|NCT05642455|GENETIC|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
218839339|NCT06349954|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
218839340|NCT06349954|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
218839341|NCT01894854|PROCEDURE|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
218839342|NCT06788561|DEVICE|Transauricular Nerve Stimulation|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
218839343|NCT06788561|DEVICE|s-taVNS|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
219196640|NCT06842862|DEVICE|GGED|This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
219449103|NCT06319534|BEHAVIORAL|placebo injection|2.8 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
219449104|NCT04248127|OTHER|Honey sweetened yogurt|2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
219766521|NCT07211373|BEHAVIORAL|Behavioral support|"Jaspr conversations will be augmented human-driven behavioral support. Conversations will be guided by motivational interviewing principles. Subjects can sign up to receive JAH mobile app.~Subjects will be prompted with their personalized goals as reminders to use the Jaspr app."
219449105|NCT04248127|OTHER|Sugar sweetened yogurt|sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
219449106|NCT04923659|DRUG|Carbamazepine|600 mg reconstituted as one table. Administered once
218839344|NCT06782932|DRUG|AGEN2373|"1. Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be tested in Phase I to determine the dose to be used in Phase II. AGEN2373 will be administered as a 60 minute IV infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
218839345|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
218859977|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
219449107|NCT04923659|DRUG|Lorazepam|2.5 mg mg reconstituted as one table. Administered once
219449108|NCT04923659|DRUG|Dextromethorphan|150 mgmg reconstituted as one table. Administered once
219449109|NCT04923659|DRUG|Nimodipine|30 mg reconstituted as one table. Administered once
219449110|NCT04923659|DRUG|Placebo|Administered once
219449111|NCT01980381|OTHER|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
219449112|NCT05957549|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
218859978|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
219196641|NCT06841068|BIOLOGICAL|Amniotic fluid or placental CD117 stem cells|CD117 (c-Kit) positive stem cells, extracted from ethical fetal sources such as amniotic fluid and placental tissue.
219766522|NCT07212153|DIETARY_SUPPLEMENT|Oral Carbohydrate Drink (Maltodextrin)|Participants receive 400 mL of a clear beverage containing 50 g of maltodextrin (carbohydrate) 2 hours before anesthesia induction. The drink is used to lower insulin resistance and improve perioperative recovery.
219449113|NCT05706909|DEVICE|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
219449114|NCT06525389|DRUG|Liposomal Amphotericin B (LAmB)|Antifungal dosed at 10 mg/kg/day IV x one single dose.
219449115|NCT06525389|DRUG|Flucytosine (5FC)|Antifungal dosed at 25mg/kg oral 3x daily.
219449116|NCT06525389|DRUG|Flucytosine (5FC) placebo pill|Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
218839346|NCT06782932|DRUG|Cyclophosphamide|"1. 200 mg/m2 will be administered as a 30 minute IV infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 200 mg/m2 IV"
218839347|NCT06782932|DRUG|GVAX|"1. Vaccine (5 × 108 cells) will be administered on Day 2 of each cycle for a total of 6 cycles of treatment. Six intradermal injections will be given in the upper thighs and non-dominant arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: GVAX"
219449117|NCT06525389|DRUG|Deoxycholate Amphotericin B (DAmB)|Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
219449118|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
219449119|NCT02474368|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|
219449120|NCT02474368|DRUG|Cisplatin|
219449121|NCT02474368|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
219449122|NCT03724994|DRUG|Gemcitabine|Adjuvant or palliative chemotherapy according to national guidelines
219449123|NCT06057207|DIAGNOSTIC_TEST|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
219449124|NCT06057207|DIAGNOSTIC_TEST|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
218839348|NCT06782932|DRUG|AGEN2373 (RP2D)|"1. Drug: Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be administered as a 60 minute IV. Infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
219196642|NCT06596018|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy using 6MV-X rays, administered once a day for three consecutive days.
219196643|NCT06596018|DRUG|Chemotherapy|Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
219196644|NCT06841965|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
219449125|NCT06057207|OTHER|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.
219449126|NCT06057207|OTHER|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic or laparotomic dehiscence, wound/local infection, postoperative bleeding, reoperation and nonsurgical site complications: sepsis, pneumonia, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure, postoperative delirium. Length of ICU and overall hospital stay with after discharge from hospital will be documented.
219449127|NCT04076579|DRUG|Olaparib|Olaparib taken by mouth twice daily
219449128|NCT04076579|DRUG|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
219449129|NCT05067764|PROCEDURE|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
219449130|NCT05067764|PROCEDURE|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
219449131|NCT06309550|DIAGNOSTIC_TEST|exercise test|exercise test
219449132|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
219196645|NCT06841237|OTHER|Xiang Lei Ointment plus Clinical standard treatment protocols|A therapy for chronic wound healing
219449133|NCT02918734|DEVICE|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
219449134|NCT02918734|DEVICE|Metal interference screw|ACL reconstruction with metal interference screw
219449135|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
219449136|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
219449137|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
219449138|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
219449139|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
219449140|NCT05487092|OTHER|Placebo|Placebo
219449141|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
219449142|NCT06481241|DRUG|Venetoclax|VEN
219449143|NCT00638768|OTHER|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
219449144|NCT05405114|DRUG|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
219449145|NCT05405114|DRUG|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
218839349|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV. Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
218839350|NCT06782932|DRUG|mKRASvax|"1. mKRASvax will be administered on Day 1 of each cycle and on Day 8 of Cycle 1 only. mKRASvax is given as 5 subcutaneous injections administered in the upper thighs and arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
219196646|NCT06841237|OTHER|Clinical standard treatment protocols|A therapy for chronic wound healing
219766523|NCT07212153|OTHER|Placebo (Water)|Participants receive 400 mL of plain water 2 hours before anesthesia induction, following the same protocol and timing as the carbohydrate drink group.
219196647|NCT06777576|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
219196648|NCT06753747|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.
219196649|NCT06753747|DRUG|Afatinib(30mg)|Afatinib will be administered orally at a dose of 30 mg once daily (QD) in each 4-week cycle.
219587188|NCT04801953|OTHER|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
219587189|NCT02310282|DEVICE|Telemedicine|In-hospital telemedicine
219587190|NCT06709807|DRUG|CKD-378 25/1000mg|QD, PO
219587191|NCT02881060|DIETARY_SUPPLEMENT|Alcohol|
219587192|NCT02881060|DIETARY_SUPPLEMENT|Placebo|
218859979|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
219587193|NCT01333280|BEHAVIORAL|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
219587194|NCT01333280|BEHAVIORAL|Treatment as usual|Receive usual treatment at the programs
219449146|NCT05405114|DRUG|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
219587195|NCT02098096|OTHER|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
218839351|NCT05929703|BEHAVIORAL|HELP|This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
218839352|NCT05929703|BEHAVIORAL|FAM-HELP|Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
219587196|NCT02098096|OTHER|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
219587197|NCT01170910|PROCEDURE|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
218839353|NCT06839131|DRUG|SPH9788|SPH9788 tablets administered orally
218839354|NCT06839131|DRUG|Placebo|Matching placebo administered orally
218839355|NCT05314179|BEHAVIORAL|Doula - Patient engagement|"Ubuntu ambassador/Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2) practical assistance, 3) family support, and/or 4) legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
218839356|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
218839357|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
218839358|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
218839359|NCT04299308|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
219196650|NCT06753747|DRUG|Afatinib(40mg)|Afatinib will be administered orally at a dose of 40 mg once daily (QD) in each 4-week cycle.
219449147|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
219449148|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
219449149|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
219587198|NCT01170910|PROCEDURE|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
219587199|NCT00361114|DRUG|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
219587200|NCT00361114|DRUG|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
219587201|NCT00361114|DRUG|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
219587202|NCT03039179|DEVICE|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
219587203|NCT06455436|DEVICE|Standard healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
219587204|NCT06455436|DEVICE|Individualized healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
218839360|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
219196651|NCT06753747|DRUG|Afatinib(RP2D)|In the Phase 2 study, the recommended Phase 2 dose (RP2D) of Afatinib, determined during the Phase 1b portion, will be utilized.
218839361|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
218839362|NCT06069362|OTHER|Manual physiotherapy and neurodynamic exercises|"* Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability."
219017532|NCT04265053|DRUG|Indomethacin 25 MG/50 MG|Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin is used to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
219449150|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|participants performed moderate intensity soleus push-ups with ankle weights, calculated as 30-40% of individuals 1RM of soleus muscle's strength. The single set of MSPU was performed 15 minutes after the meal for time till the point where the muscle started to fatigue. The participants were in sitting position with legs positioned at 90 degree angle relative to floor and feet flat on ground performed continuous planter flexion against the ankle weight. Three sets of MSPU was performed at every 15 and Session lasted in 60 minutes.
219449151|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
219449152|NCT01351714|PROCEDURE|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
219449153|NCT04970433|PROCEDURE|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
219449154|NCT04970433|PROCEDURE|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
219449155|NCT04970433|PROCEDURE|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
219449156|NCT02903966|DRUG|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
219449157|NCT02903966|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
219587205|NCT02244879|DIETARY_SUPPLEMENT|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
219587206|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
219449158|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
219766524|NCT07212218|BEHAVIORAL|Health Promotion Model-Based Education and Motivational Interviewing|Structured education sessions based on the Health Promotion Model will be delivered, followed by motivational interviewing techniques to enhance parental engagement and support diabetes management and quality of life.
219766525|NCT07211828|DRUG|high dose of alfentanil|The initial dose is alfentanil cet 10ng/mL and propofol 1ug/mL. Dose of alfentanil will be increased by 10ng/mL each until PSI reach to 25-50. If alfentail has been adjusted to 50 but PSI is still too high, increase propofol cet by 0.5-1ug/mL till target PSI is reached. If propofol is adjusted to 0 but PSI is still too low, decrease alfetanil by 10ng/mL The range of dosage of alfentanil is 0-50ng/mL while propofol is 0-5ug/mL.
219449159|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
219449160|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
219587207|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
219587208|NCT06309277|DRUG|GM-1020|N-methyl-D-aspartate (NMDA) receptor antagonist
219587209|NCT01303705|DRUG|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
219587210|NCT01303705|RADIATION|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
219587211|NCT01303705|DRUG|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
219587212|NCT01383798|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
219587213|NCT01383798|DIETARY_SUPPLEMENT|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
219587214|NCT01745705|OTHER|Cervical Spine Manipulation|
219587215|NCT01745705|OTHER|Manual Contact|
219449161|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
219449162|NCT06388200|GENETIC|Sub-Retinal Administration of OCU400-301|Sub-Retinal Administration of OCU400-301
219449163|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
219449164|NCT03057106|DRUG|Durvalumab|MEDI4736
219587216|NCT05124197|OTHER|prone position|extension of prone position duration
219587217|NCT02178280|OTHER|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
219587218|NCT01884662|BEHAVIORAL|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
219587219|NCT01884662|BEHAVIORAL|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
219587220|NCT01698827|OTHER|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
219587221|NCT01965392|OTHER|Health education intervention|'Health education intervention'
219587222|NCT02171676|DRUG|Docetaxel|
219587223|NCT02171676|DRUG|BIBW 2992|
219449165|NCT03057106|DRUG|Tremelimumab|Tremelimumab
219449166|NCT03057106|DRUG|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
219449167|NCT05127356|DEVICE|DIAGNOdent|Laser fluorescence device
219587224|NCT03276780|BEHAVIORAL|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
219587225|NCT03276780|DRUG|combination NRT|Both groups will receive combination NRT to help with smoking cessation
219587226|NCT01150617|DRUG|Insulin glargine plus insulin analogues|"* Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up."
219587227|NCT00427713|DRUG|capecitabine|
219587228|NCT00427713|DRUG|oxaliplatin|
219587229|NCT00427713|PROCEDURE|adjuvant therapy|
219587230|NCT00427713|PROCEDURE|standard follow-up care|
219587231|NCT03134443|DRUG|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
219587232|NCT03134443|DRUG|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
218839363|NCT02423525|DRUG|Afatinib|
218859980|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
219449168|NCT05127356|DIAGNOSTIC_TEST|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
218859981|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
218859982|NCT02833792|OTHER|Placebo|Intravenous administration
219449169|NCT03289494|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
219449170|NCT03289494|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
219449171|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
219449172|NCT04974411|OTHER|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
219449173|NCT04974411|OTHER|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
219449174|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
219587233|NCT02426047|DIETARY_SUPPLEMENT|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
219587234|NCT03375294|DRUG|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
219587235|NCT05335291|OTHER|Questionnaire study|The Turkish validity and reliability of the questionnaire will be examined.
219587236|NCT03250494|DRUG|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
219587237|NCT03250494|DRUG|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
219766526|NCT07211828|DRUG|low dose of alfentanil with propofol|Adjust dose of propofol to the upper limit before adjusting dose of alfentanil. Increase dose of propofol 0.5-1 ug/mL in order to have PSI valued 25-50. The initial dose of propofol is 1ug/mL, alfentanil 10 ng/mL. If propofol was adjusted to cet=5 ug/mL but PSI is still too high, increase alfentanil by 10 ng/mL instead. If alfentanil was adjusted to 0 but PSI is still too low, decrease propofol by 0.5-1 ug/mL instead . The range of dosage of propofol is 0-5 ug/mL while alfentanil is 0-50ng/mL.
219766527|NCT07212309|BEHAVIORAL|Board Game-Based Hydration Education Program|A six-week educational program delivered through board games, designed to improve hydration knowledge, practices, and status among school children. The program includes interactive sessions, quizzes, and games that teach the importance of adequate water intake. It is integrated into regular school activities and monitored for engagement and adherence.
218839364|NCT05258890|OTHER|Social Network Group Counseling|Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
218839365|NCT05258890|OTHER|Individual Counseling|The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
219017533|NCT04265053|DRUG|Placebo - Lactose|Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
219766528|NCT07213310|DRUG|DWP16001|Tablets, Oral
219449175|NCT02119611|DEVICE|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
219449176|NCT05220098|DRUG|TAK-280|Participants will receive TAK-280 as IV infusion.
219449177|NCT06003387|GENETIC|CSL222 (AAV5-hFIXco-Padua)|Administered as a single IV infusion.
219587238|NCT03250494|DRUG|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
219766529|NCT07212140|BEHAVIORAL|Adapted STAIR-NT|An adapted version of STAIR-NT that utilizes components from GMT in order to treat PTSD and TBI.
219449178|NCT06849310|BEHAVIORAL|Group that will receive emotional regulation training|The content of the program is based on the current literature (Dennison, 2024; Holmqvist Larsson et al., 2020; Kara \& Yüksel, 2022; Kılıçarslan \& Varol, 2023; Siegel \& Brayson, 2021; Vafaei et al., 2021) for four weeks, once a week (average 50 minutes/week). The module on noticing emotions, which will be applied in the first week, is aimed at adolescents to think about and notice emotions. The content of the training will include determining the beliefs and effects of the group members about emotions, teaching the nature of all emotions and the function of adaptation, distinguishing between emotions and thoughts, teaching similar and opposite emotions, and situations that contribute to the positivity of the emotional state.
219587239|NCT04001101|COMBINATION_PRODUCT|RT and Anti-PD-1|limited metastatic site radiation
219587240|NCT04001101|DRUG|Anti-PD-1|anti-PD-1 therapy alone
219766530|NCT07211503|OTHER|blood sampling|The study involves the collection of an additional aliquot of cord blood and an additional aliquot of maternal venous blood.
219766531|NCT07213349|DRUG|Daridorexant 50 mg|Study drug (Daridorexant 50 mg) taken orally each night 30 minutes before bedtime, for the 1 year duration of the study
218839366|NCT06366789|DRUG|ZE46-0134|oral capsules QD
219587241|NCT02362984|DRUG|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
219587242|NCT02362984|DRUG|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
218839367|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
219587243|NCT02582866|DRUG|Lacosamide|"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
219587244|NCT02901613|DEVICE|Negative-pressure wound therapy|
219766532|NCT07213349|DRUG|Placebo|Study drug (Placebo) will be taken orally each night, 30 minutes before bedtime, for the 1 year duration of the study
219766533|NCT07212660|DEVICE|Fast curing mode|Composite restoration is cured with Turbo mode (5 seconds with 2000 mW/cm²).
219449179|NCT06430840|BEHAVIORAL|CostCOM (Cost Communication, Financial navigation and counseling)|"Patients will receive two 1-hour, phone or video sessions with a remote financial counselor, each session will cover each of these 3 components of CostCOM.~Out-of-pocket cost communication (OOPC): A review of insurance benefits and education of the patient-specific OOPC for anticipated treatment regimen if any (i.e., medication). The OOPC is provided as a total estimate and will be updated at 3-month session in case of changes in treatment or insurance.~Financial navigation: Real-time professional guidance to identify financial assistance programs (e.g., co-pay, living expenses) that alleviate costs of care and discuss information to improve insurance coverage.~Financial counseling: To address the range of patients' financial concerns and enroll patients in financial assistance programs."
219449180|NCT06430840|BEHAVIORAL|Provision of local and national resources to address financial and social needs|Patients will be provided with a comprehensive list of local resources (in patients' preferred language) in Orange County that can help with food insecurity, ir transportation, as well as contact information for national non-profit organization where patients can self-refer for financial navigation (e.g., Patient Advocate Foundation (PAF)
219449181|NCT06430840|BEHAVIORAL|Financial Education|Patient will receive online and paper educational materials on topics such as health insurance and health insurance literacy, navigating hospitals' price estimator tool.
219449182|NCT06430840|OTHER|Usual care|Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.
219449183|NCT06430840|OTHER|Screening for financial and social needs|Patients will be screened for financial hardship and health-related social risks.
219449184|NCT06491368|PROCEDURE|Cesarean Delivery|A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
219449185|NCT05711693|DEVICE|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
219449186|NCT05711693|PROCEDURE|Blood pressure and heart rate measurement|"To all patients:~\- blood pressure and heart rate will be measured"
219449187|NCT05711693|DEVICE|carotid to femoral PWW measurement|"To all patients:~\- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
219449188|NCT05711693|PROCEDURE|Questionnaire completion|All patients will complete a questionnaire of acceptability
219449189|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
219449190|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
219449191|NCT04319835|DEVICE|OnZurf Probe|
219449192|NCT03733106|DIAGNOSTIC_TEST|digital breast tomosynthesis|pseudo three dimension mammography
219449193|NCT03733106|DIAGNOSTIC_TEST|standard two dimension digital mammogram|standard two dimension mammogram
219449194|NCT06128629|BIOLOGICAL|NTLA-2001|NTLA-2001 (55mg) by IV infusion
219449195|NCT06128629|DRUG|Placebo|Normal saline (0.9% NaCl) by IV infusion
219449196|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
219449197|NCT04423718|DRUG|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
219449198|NCT04423718|DRUG|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
219449199|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 1|single infusion of rapcabtagene autoleucel
219587245|NCT04754126|BEHAVIORAL|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
219587246|NCT00523965|DRUG|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
219587247|NCT00523965|DRUG|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
219587248|NCT00523965|DRUG|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
219587249|NCT00523965|DRUG|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
219587250|NCT01708629|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
219587251|NCT01708629|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
219587252|NCT01708629|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
219587253|NCT01708629|DRUG|placebo|placebo administered SC
218839368|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
218839369|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
218839370|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
218839371|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
219587254|NCT00415766|DRUG|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
218839372|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
218839373|NCT04935697|OTHER|SOC|Standard of care patient management.
218839374|NCT04493424|DRUG|Spesolimab|Spesolimab
218839375|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
219017534|NCT04265053|DRUG|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
219766534|NCT07212660|DEVICE|Conventional curing mode|Composite restoration is cured with High mode (10 seconds with 1200 mW/cm²).
219766535|NCT07211386|PROCEDURE|Erector Spinae Plane Block|The abdominal viscera, from the stomach to midway through the sigmoid colon, derives its sensory innervation from afferent fibers that travel with, but are distinct from, the sympathetic nerve fibers from the 5th thoracic (T5) to the 2nd lumbar (L2) spinal levels (Moore et al). These fibers converge at the celiac plexus, located near the celiac artery and the aorta. From there, they bifurcate into the paravertebral sympathetic chain and subsequently ascend to the spinal cord and integrate into the central nervous system (Lohse et al). The celiac plexus block is an invasive procedure performed by an interventional anesthesiologist or palliative care specialist to lyse the celiac plexus and has been shown to reduce pain and opiate use in patients suffering from GI malignancy (Ashlock et al). While there are multiple methods to perform a celiac plexus block, it involves a steep needle trajectory either posteriorly through the retroperitoneum or anteriorly through the abdominal wall close
219766536|NCT07208045|BEHAVIORAL|Es tu juego: decide bien (IYG)|Affective-sexual education for adolescents through an gamified online and school-based program.
219766537|NCT07212907|DIETARY_SUPPLEMENT|Symbiosys® Stomalex (commercial name)|One oral capsule per day for 8 weeks. Each capsule contains Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger root extract (50 mg, titrated to 20% gingerols).
219449200|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 2|single infusion of rapcabtagene autoleucel
219449201|NCT06581198|OTHER|Standard of Care|The treatment regimen must be in line with KDIGO guidelines for treatment of class III/IV LN.
219449202|NCT00425945|DRUG|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
219449203|NCT01377324|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
219766538|NCT07211607|DRUG|selonabant|Intravenous infusion of selonabant
219766539|NCT07211607|DRUG|placebo|Placebo infusion which looks the same as the selonabant infusion
219017535|NCT04265053|DRUG|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
219017536|NCT04265053|DRUG|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
219449204|NCT00741767|DRUG|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
219449205|NCT03991936|DRUG|Placebos|Normal saline intralesional injection
219017537|NCT04265053|DRUG|Antacid|Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
219017538|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
219017539|NCT04655755|DRUG|Venetoclax|Given PO
219017540|NCT02020005|OTHER|Non-flavored 2mg nicotine gum|
219017541|NCT02020005|OTHER|Non-flavored 4mg nicotine gum|
219449206|NCT03991936|DRUG|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
218839376|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
218839377|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
219449207|NCT03991936|DRUG|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
219449208|NCT03991936|DRUG|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
219449209|NCT03991936|DRUG|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
218839378|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
218839379|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
219449210|NCT03783013|OTHER|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
219449211|NCT03783013|OTHER|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
219449212|NCT02090218|DEVICE|I-Gel|I-Gel supraglottic airway device
219449213|NCT02090218|DEVICE|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
219449214|NCT04905810|DRUG|Azacitidine|Given IV
219449215|NCT04905810|DRUG|Decitabine|Given IV
219017542|NCT02020005|OTHER|Mint-flavored 2mg nicotine gum|
219017543|NCT02020005|OTHER|Mint-flavored 4mg nicotine gum|
219017544|NCT02020005|OTHER|Non-flavored nicotine inhaler|
219017545|NCT02020005|OTHER|Mint-flavored nicotine ihaler|
219449216|NCT04905810|DRUG|Venetoclax|Given PO
219449217|NCT04950933|DRUG|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
219449218|NCT04950933|DRUG|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
219449219|NCT00551967|PROCEDURE|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
219449220|NCT02233140|DEVICE|Extra-corporeal pulsed-activated therapy or shockwave therapy|
219449221|NCT00939055|DEVICE|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
219449222|NCT00939055|PROCEDURE|Sham procedure|False procedure
219449223|NCT02462811|DRUG|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
219449224|NCT02462811|DRUG|Placebo|
219449225|NCT02462811|DRUG|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
218839380|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
219449226|NCT03139435|PROCEDURE|Biopsy|Undergo skin biopsy
219449227|NCT03139435|OTHER|Questionnaire Administration|Ancillary studies
219449228|NCT03139435|DIAGNOSTIC_TEST|Ultrasound Tomography|Undergo peripheral nerve ultrasound
219449229|NCT01128452|DRUG|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
219449230|NCT01128452|DRUG|Placebo|HPMC Placebo capsules, once daily for 28 days
218839381|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
218839382|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
218839383|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
218839384|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
218839385|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
219766540|NCT07213206|DRUG|CDK 4/6 inhibitor combined therapy (omit chemo)|CDK 4/6 inhibitor and endocrine therapy combined with Trastuzumab ( without chemotherapy)
219449231|NCT00584987|DRUG|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
219449232|NCT00584987|DRUG|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
219449233|NCT00584987|DRUG|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
219449234|NCT00584987|DRUG|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
219449235|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
219449236|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
219449237|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
219449238|NCT05997173|OTHER|Control|Investigation of scale of control
219449239|NCT05997173|OTHER|Non erosive OLP|Investigation of cale of non erosive OLP patients
218839386|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
218839387|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
219449240|NCT05997173|OTHER|Erosive OLP|Investigation of cale of erosive OLP patients
218839388|NCT05644665|DRUG|Ozanimod|Specified dose on specified days
218839389|NCT05644665|DRUG|Placebo|Specified dose on specified days
218859983|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
218859984|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
219449241|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219449242|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
219449243|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
219449244|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
219449245|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
219449246|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
219449247|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
219449248|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
219449249|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
219449250|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
219449251|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
219449252|NCT02542566|PROCEDURE|Physiotherapy rehabilitation|Physiotherapy rehabilitation
219449253|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
219587255|NCT00415766|DRUG|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
219587256|NCT00415766|DRUG|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
219766541|NCT07213206|DRUG|standard of care|four cycles of docetaxel and cyclophosphamide or four cycles of weekly paclitaxel Combined with Trastuzumab followed by standard endocrine therapy( aromatase inhibitors or tamoxifen，Ovarian function suppression agents may be added if premenopausal)
219766542|NCT07211568|DRUG|Pancreatic Enzyme Replacement Therapy|Enteric coated pancreatic enzyme preparation
219766543|NCT07211568|DRUG|Placebo|Similar appearing glucose capsules
218839390|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
218839391|NCT05143749|OTHER|video tutorial|get video tutorial
219766544|NCT07213323|DIETARY_SUPPLEMENT|Probiotics (Natural product)|"Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of a probiotic with water at room temperature with the first meal.~Dosage levels: 1 capsule Digestive Quality of life during the study will be assessed."
218839392|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
218839393|NCT00964665|DRUG|albinterferon alfa-2b|
218839394|NCT00964665|DRUG|albinterferon alfa-2b|
218839395|NCT00964665|DRUG|albinterferon alfa-2b|
219449254|NCT03258593|DRUG|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
219449255|NCT03258593|DRUG|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
219449256|NCT03258593|DRUG|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
219449257|NCT03258593|DRUG|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
219449258|NCT03258593|PROCEDURE|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
219449259|NCT03258593|PROCEDURE|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
219449260|NCT03258593|PROCEDURE|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
218839396|NCT00964665|DRUG|albinterferon alfa-2b|
218839397|NCT00964665|DRUG|Pegasys®|
218839398|NCT01791049|DRUG|TD-1607|
218839399|NCT01791049|DRUG|Placebo|
218839400|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
218839401|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
218839402|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
218839403|NCT00438126|BEHAVIORAL|A lifestyle educational program|
218839404|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
218839405|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
218839406|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
218839407|NCT05924165|DRUG|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
218839408|NCT05924165|DRUG|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
218839409|NCT05049772|BEHAVIORAL|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
218839410|NCT05049772|BEHAVIORAL|Stabilization exercises group|10 weeks of stabilization exercises.
218839411|NCT05959447|DRUG|Camlipixant|Camlipixant will be administered
218839412|NCT05959447|DRUG|Dabigatran etexilate|Dabigatran etexilate will be administered
218839413|NCT05959447|DRUG|Gemfibrozil|Gemfibrozil will be administered.
218839414|NCT05278039|BEHAVIORAL|Respiratory-Swallow Phase Training|Participants will complete 6 respiratory-swallow phase training sessions that will last approximately one hour.
219449261|NCT03258593|DIAGNOSTIC_TEST|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
219449262|NCT03258593|DIAGNOSTIC_TEST|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
219449263|NCT03258593|DIAGNOSTIC_TEST|CT|Computed tomography (CT) at screening and every 12 months while on study.
219449264|NCT03258593|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
219766545|NCT07213323|OTHER|Placebo|"Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of PLACEBO with water at room temperature with the first meal.~Digestive Quality of life during the study will be assessed."
219766546|NCT07213167|OTHER|None-placebo|No interventions.
218839415|NCT05278039|OTHER|Swallow Practice|"Participants will complete 6 swallow practice sessions that will last approximately one hour."
218839416|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
218839417|NCT06429072|BEHAVIORAL|Mindfulness training|• I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).
218839418|NCT06429072|OTHER|Acupuncture|This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.
219449265|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
219449266|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
219449267|NCT06624475|DRUG|Nivolumab|Nivolumab is a fully humanized monoclonal antibody that binds to the PD-1 receptor, blocking its interactions with PD-L1 and PD-L2, and thus additionally inhibiting PD1-driven immune suppression. Nivolumab 490 mg via IV administration 28 day cycle
219449268|NCT06624475|DRUG|Opdualag|Opdualag (Opdualag) is supplied as a single dose vial containing 240 mg of Nivolumab and 80 mg. Relatlimab per 20 mL for intravenous administration ; 28 day cycle.
219449269|NCT05763693|DRUG|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
219449270|NCT05763693|DRUG|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
219449271|NCT05763693|OTHER|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
219449272|NCT05763693|OTHER|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
219449273|NCT06136195|DRUG|Mavoglurant|The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
219449274|NCT04574076|DRUG|Turoctocog alfa pegol (N8-GP)|Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
219449275|NCT04224350|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
219587257|NCT01302613|DRUG|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
219449276|NCT04224350|DRUG|Tacrolimus cap.|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
219449277|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
219449278|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
218839419|NCT06429072|BEHAVIORAL|Enhanced education|• The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
219449279|NCT05614700|RADIATION|Brachytherapy|High Dose-Rate Brachytherapy
219449280|NCT05614700|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
219449281|NCT04076904|DIAGNOSTIC_TEST|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
219449282|NCT03857464|DIAGNOSTIC_TEST|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
218839420|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
218839421|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
218839422|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
219449283|NCT03857464|DIAGNOSTIC_TEST|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
219449284|NCT05318183|OTHER|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
219449285|NCT05318183|OTHER|White Bread (control)|Standardized white bread (128 g daily)
219449286|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
219449287|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
219587258|NCT01302613|DRUG|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
219587259|NCT01302613|DRUG|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
218839423|NCT00107432|DRUG|sorafenib tosylate|Given orally
218839424|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
218839425|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
218839426|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
218839427|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
218839428|NCT03154515|DRUG|Ingavirin|
218839429|NCT03154515|DRUG|Placebo|
218839430|NCT02181491|OTHER|[11C]-P943|
218839431|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
218839432|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
218839433|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
218839434|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
219587260|NCT01302613|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
218839435|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
218839436|NCT00070876|BEHAVIORAL|Mental health communication skills training|
218839437|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
218839438|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
219587261|NCT01302613|RADIATION|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
219587262|NCT01302613|PROCEDURE|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
219587263|NCT00030043|DEVICE|Penetrating auditory brainstem implant|
219587264|NCT03763552|OTHER|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
219587265|NCT00003179|DRUG|medroxyprogesterone|
219587266|NCT01666197|DRUG|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
219449288|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
219449289|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
219587267|NCT01666197|DRUG|placebo|placebo
219449290|NCT02875353|DEVICE|Doppler Endoscopic Probe|A colon length catheter (probe).
219587268|NCT01159197|BEHAVIORAL|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
219196652|NCT06408038|OTHER|For each patient included, the samples described below will be collected:|"* A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study."
219196653|NCT02641730|DRUG|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
218839439|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
218839440|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
218839441|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
219196654|NCT02641730|DRUG|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
219196655|NCT05862298|DIAGNOSTIC_TEST|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, \>50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
219196656|NCT06813521|OTHER|NaP1%+VitCG3% leave-on lotion (formula 1256103)|leave-on lotion
219196657|NCT06813521|OTHER|vehicle (formula 1256145)|vehicle lotion
219196658|NCT06813521|OTHER|reference Octopirox 0.25% (formula 1256149).|lotion reference Octopirox 0.25%
219449291|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
219449292|NCT03880123|DRUG|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
219449293|NCT03880123|DRUG|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
219449294|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
219449295|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
219449296|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
219449297|NCT04502095|DRUG|Clindamycin|Given PO
219449298|NCT04502095|OTHER|Diary|Complete drug diary
219449299|NCT04502095|DRUG|Ertapenem|Given PO
219449300|NCT04502095|DRUG|Levofloxacin|Given PO
219449301|NCT04502095|DRUG|Nitrofurantoin|Given PO
219449302|NCT04502095|DRUG|Trimethoprim-Sulfamethoxazole|Given PO
218839442|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
218839443|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
218839444|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
218839445|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
218839446|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
218859985|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
218859986|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
218859987|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
218859988|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
218859989|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
218859990|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
218839447|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
218859991|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
218859992|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
218859993|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
219449310|NCT06083857|DRUG|Amivantamab|Given by IV (vein)
219449311|NCT06083857|DRUG|Tepotinib|Given by PO
219449312|NCT00945269|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219587269|NCT00630097|DRUG|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
219587270|NCT04971798|BIOLOGICAL|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
219587271|NCT03550573|DEVICE|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
219587272|NCT05217719|DRUG|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
219587273|NCT05217719|DRUG|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
219587274|NCT03055702|OTHER|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
219587275|NCT05975138|PROCEDURE|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
219587276|NCT00658645|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
219587277|NCT00658645|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
218859994|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
218859995|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
219449313|NCT00945269|BIOLOGICAL|aldesleukin|Given SC
219449314|NCT00945269|BIOLOGICAL|denileukin diftitox|Given IV
219449315|NCT00945269|PROCEDURE|biopsy|Optional correlative studies
219449316|NCT00945269|OTHER|immunohistochemistry staining method|Correlative studies
219449317|NCT00945269|OTHER|laboratory biomarker analysis|Correlative studies
219449318|NCT00945269|GENETIC|polymerase chain reaction|Correlative studies
219449319|NCT06643988|BEHAVIORAL|MemFlex|MemFlex employs cognitive training exercises in self-led sessions to improve 1) switching between specific and general AMs, 2) access to positive AMs, and 3) vividness of positive AMs.
219449320|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
219449321|NCT06144229|DIAGNOSTIC_TEST|Self-Collection HPV testing kit from Abbott|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
219449322|NCT06471608|OTHER|Ambulatory management|"* Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home."
219587278|NCT00658645|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
219587279|NCT02359747|GENETIC|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
219587280|NCT00578669|DRUG|Fluoxetine|20mg once daily for 16 weeks
219587281|NCT00578669|DRUG|Dextrose|Once daily for 16 weeks
219449323|NCT06471608|OTHER|Standard Care|"Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
218839448|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
219449330|NCT04334057|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
219449331|NCT04217447|DRUG|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
219449332|NCT04217447|DRUG|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
219449333|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
219449334|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
219449335|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
219449336|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
219449337|NCT03596268|DIAGNOSTIC_TEST|Imaging|3T Prisma MRI
219449338|NCT03596268|DIAGNOSTIC_TEST|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
219449339|NCT03596268|DIAGNOSTIC_TEST|Lumbar Puncture|CSF will be collected
219449340|NCT06509568|RADIATION|Neoadjuvant chemoradiotherapy followed by immunotherapy|Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose tislelizumab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.
219449341|NCT06509568|DRUG|Neoadjuvant chemoimmunotherapy|Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and tislelizumab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
218839449|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
219587282|NCT02753491|BEHAVIORAL|Motivational short interview|New designed motivational short interview model
219587283|NCT03030820|PROCEDURE|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
219587284|NCT03035344|OTHER|Metabolome study|Metabolome study in ALL patients compared to healthy controls
219587285|NCT03033082|OTHER|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
219587286|NCT01193127|DRUG|OMS302 Solution|
219587287|NCT01193127|DRUG|OMS302 Mydriatic Solution|
219587288|NCT01193127|DRUG|OMS302 Anti-inflammatory Solution|
219587289|NCT01193127|DRUG|Balanced Salt Solution (BSS) Solution|
219587290|NCT02314091|PROCEDURE|onlay mesh hernioplasty|
218839450|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
219449342|NCT03381274|BIOLOGICAL|Oleclumab|Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
219449343|NCT03381274|DRUG|Osimertinib|Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
219449344|NCT03381274|DRUG|AZD4635|Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
219449345|NCT02566122|OTHER|measurements|
219449346|NCT05805839|DRUG|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
219449347|NCT05805839|DRUG|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
219449348|NCT05805839|DIAGNOSTIC_TEST|PET/CT scan|Imaging of entire brain
219449349|NCT05805839|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging of the Brain
219449350|NCT06097832|BIOLOGICAL|NXC-201 CAR-T|NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
219449351|NCT06016738|DRUG|Palazestrant|Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
219449352|NCT06016738|DRUG|Fulvestrant|Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
219449353|NCT06016738|DRUG|Anastrozole|Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
219449354|NCT06016738|DRUG|Letrozole|Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
219449355|NCT06016738|DRUG|Exemestane|Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
219449356|NCT05124912|PROCEDURE|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
219449357|NCT05124912|DRUG|Steroid Therapy|Best medical management with steroid therapy
219587291|NCT03246646|BEHAVIORAL|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
219449358|NCT05124912|PROCEDURE|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
219449359|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
219449360|NCT06030505|OTHER|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
219449361|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
219449362|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
219449363|NCT04042701|DRUG|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
219449364|NCT05879653|DRUG|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
219449365|NCT05879653|DRUG|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
219587292|NCT00532038|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
219587293|NCT02688426|DEVICE|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
219449366|NCT05879653|PROCEDURE|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
219587294|NCT02688426|DEVICE|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
219587295|NCT03889366|DRUG|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
219587296|NCT01331226|BEHAVIORAL|telephone counseling 3 sessions|3 sessions of telephone counseling
219587297|NCT01331226|BEHAVIORAL|telephone counseling 1 session|1 session of telephone counseling
218839451|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
218859996|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
219587298|NCT01331226|BEHAVIORAL|written materials only|written materials only
219587299|NCT00739986|DRUG|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
219587300|NCT00739986|DRUG|Semapimod|Semapimod 60 mg IV x 3 days
219587301|NCT00739986|DRUG|Placebo|placebo IV x 3 days
218859997|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
218859998|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
218859999|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
218860000|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
218860001|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
219449367|NCT05879653|RADIATION|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
219449368|NCT05977686|DEVICE|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
219449369|NCT05977686|DEVICE|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
219449370|NCT02502955|PROCEDURE|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
219449371|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
219449372|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
219449373|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
219449374|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
219449375|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
219449376|NCT00099840|PROCEDURE|Procalcitonin guided antibiotic therapy|
219449377|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
219449378|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
219449379|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
219449380|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
219449381|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
219449382|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
219587302|NCT04860063|DRUG|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
219587303|NCT04860063|DRUG|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
219449383|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
219449384|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
219449385|NCT06967675|PROCEDURE|Low-Flow Anesthesia (LFA)|General anesthesia with a fresh gas flow rate of 1 L/min (50% oxygen + 50% air).
219449386|NCT05180721|BEHAVIORAL|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
219587304|NCT04919863|DRUG|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
219587305|NCT04919863|DRUG|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
219587306|NCT00397163|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
219587307|NCT00397163|PROCEDURE|Placebo|Deflated cuff on upper arm and thigh for 20 min
219587308|NCT05912439|BEHAVIORAL|SidekickHealth|Usage of mobile application called SidekickHealth.
218860002|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
218860003|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
218860004|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
219017554|NCT04221542|DRUG|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
219587309|NCT02569112|DEVICE|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
219587310|NCT02569112|DEVICE|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
219587311|NCT06309927|PROCEDURE|Operative hysteroscopy (by tissue removal device)|Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
219587312|NCT06309927|PROCEDURE|Suction curettage|Surgical evacuation of the uterine cavity with electrical vacuum suction curette
219587313|NCT02352779|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO
219587314|NCT02352779|OTHER|Placebo|Given PO
218839452|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
219449387|NCT05846282|BEHAVIORAL|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
219587315|NCT02352779|OTHER|Questionnaire Administration|Ancillary studies
219587316|NCT02352779|OTHER|Laboratory Biomarker Analysis|Correlative studies
218839453|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
218839454|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
218839455|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
218839456|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
218839457|NCT01436656|DRUG|LGX818|
218839458|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
218839459|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
218839460|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
218839461|NCT02636504|DEVICE|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
218839462|NCT04729972|COMBINATION_PRODUCT|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye
218839463|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
218839464|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
219017555|NCT04221542|DRUG|Abiraterone|Abiraterone administered as oral tablets.
219017556|NCT04221542|DRUG|Enzalutamide|Enzalutamide administered as oral tablets.
219017557|NCT04191499|DRUG|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
219017558|NCT04191499|DRUG|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
219017559|NCT04191499|DRUG|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
219017560|NCT04191499|DRUG|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
219587317|NCT00306423|PROCEDURE|Other: Exercise|exercise 3 times per week for 12 weeks
219587318|NCT02185651|DRUG|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
219587319|NCT05695677|PROCEDURE|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
219017563|NCT04644289|DRUG|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
219017564|NCT04644289|DRUG|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
219587320|NCT00324480|DRUG|alvocidib|Given IV
219587321|NCT00324480|DRUG|vorinostat|Given orally
219587322|NCT00324480|OTHER|pharmacological study|Correlative studies
219587323|NCT00485420|OTHER|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
219449388|NCT05846282|BEHAVIORAL|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
219449389|NCT04870099|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
219449390|NCT04081558|DEVICE|Electronic patient reported outcomes tool|Electronic patient reported outcomes
219449391|NCT01996865|DRUG|Lenalidomide|
219449392|NCT01996865|DRUG|Rituximab|
219449398|NCT06399952|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Participants will undergo a 5-10 minute non-anesthesia brain MRI in order to evaluate for changes in brain structure. A 20 to 30 minutes 20 channel surface electroencephalography will be performed in the wake and sleep states.
219449399|NCT06399952|GENETIC|Whole Genome Sequencing|15 milliliters of blood will be collected at the initial visit. Blood samples will be centrifuged, and plasma stored in the University of Missouri Next Gen Precision Health building. Next generation whole genome sequencing and proteomics will be performed on plasma samples. Additional blood will be collected for the DNA biobank.
219449400|NCT06399952|OTHER|Induced Pluripotential Stem Cells|A 3 mm skin punch biopsy will be collected for developing induced pluripotential stem cells.
219449401|NCT06342843|PROCEDURE|Total Hip Arthroplasty|a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.
219449402|NCT06217575|BEHAVIORAL|Alpha neurofeedback training|Alpha neurofeedback training affords the participant the ability to monitor cortical EEG waves and entrain to a specific rhythm using visual feedback. Alpha is measured between 8-12Hz and is associated with cortical inhibition. Aging related changes in alpha have been associated with loss of modulation ability. However, alpha training may afford increased perception of visual details.
219449403|NCT06217575|BEHAVIORAL|Visual Attention Training|"Visual attention training involves repeated testing on the location and identity of objects in the visual field. Also called the Dual Decision task training, objects are briefly presented in a radial field of view surrounding a gaze fixation point. The participant is asked to remember the location and object presented within the field. The test progressively increases in difficulty by limiting the amount of time the object is presented on screen. Accuracy is measured by either a correct or incorrect response (binary response)."
219449404|NCT05667623|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
219449405|NCT05667623|OTHER|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
219766547|NCT07212920|DIAGNOSTIC_TEST|Physiotherapy digital assessment|This study involves three types of knee assessments to evaluate diagnostic reliability and validity: (1) a video-based function-based examination without specific knee tests, (2) traditional in-person function-based examination without specific knee tests and to control with (3) a traditional in-person examination including specific knee tests. The video-based assessment includes standardized history taking and functional evaluation conducted via clinic software, with the physiotherapist and participant in separate rooms. Physiotherapists provide diagnostic judgments after each assessment phase. All procedures follow standardized protocols, pilot-tested and conducted at a public rehabilitation clinic in Västra Götaland.
218839465|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
219449406|NCT05455294|DRUG|Navitoclax|See Arm Description
219449407|NCT05455294|DRUG|Venetoclax|See Arm Description
219449408|NCT05455294|DRUG|Decitabine|See Arm Description
219449409|NCT04934956|OTHER|Split-belt walking|These will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.
219449410|NCT04934956|OTHER|Multiple transitions between split-belt and tied-belt walking|This intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018).
218839466|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
219449411|NCT03044210|OTHER|Metabolic evaluation|"* diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)"
219449412|NCT06206746|DEVICE|May Health System|The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
219449413|NCT04571684|OTHER|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
219449417|NCT03575351|DRUG|Standard of Care|Standard of Care
219449418|NCT03575351|GENETIC|JCAR017|JCAR017
219587324|NCT04326465|DEVICE|Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage|Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
219587325|NCT03457467|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
218839467|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
218839468|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
218839469|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
218839470|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
219587326|NCT03457467|RADIATION|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
219587327|NCT04896749|OTHER|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
218839471|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
218839472|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
218839473|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
218839474|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
218839475|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
218839476|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
218839477|NCT03702959|DRUG|Betamethasone|Corticosteroids
218839478|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
218839479|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
218839480|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
218839481|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
218839482|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
218839483|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
218839484|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
218839485|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
218839486|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
218839487|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
218839488|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
218839489|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
219449419|NCT06295991|DEVICE|Lycra garment|Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
218839490|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
218839491|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
218839492|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
218839493|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
218839494|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
218839495|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
219449420|NCT06976437|DRUG|RN1101 injection|RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.
219449421|NCT06976554|PROCEDURE|weaning|gradual weaning from the mechanical ventilator
219449422|NCT03733132|DRUG|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
219449423|NCT03733132|DRUG|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
219449424|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
219449425|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
219587328|NCT04896749|OTHER|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
219587329|NCT01414049|PROCEDURE|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
219587330|NCT01414049|PROCEDURE|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
219449426|NCT02968277|DEVICE|Standard Rollator|A control rollator device
219449427|NCT04288089|DRUG|Palbociclib (75, 100, 125 milligram [mg])|Palbociclib orally, once daily (QD).
219449428|NCT04288089|DRUG|H3B-6545 (150, 300, 450 mg)|H3B-6545 orally, QD.
219449429|NCT06519682|DRUG|Nivolumab|All patients will be administered Nivolumab with or without radiation
219449430|NCT06519682|RADIATION|Radiation|Radiation
219449431|NCT06322238|DIAGNOSTIC_TEST|PGx panel test|In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mayo Clinic Health System), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
219449432|NCT03715205|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
219449433|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
219449434|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
219449435|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
219449436|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
219449437|NCT06435806|OTHER|Medical Illustration design|We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
219449438|NCT02836548|DRUG|Vorinostat|vorinostat 360 milligram once daily
219449439|NCT05273996|DRUG|Sertraline, bupropion, desvenlafaxine|Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
219449440|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219449441|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
219449442|NCT06198829|OTHER|Physical examination tests and surveys|Patients'hip joint range of motion range of motion, pain levels, pressure-pain threshold levels, kinesiophobia levels, and hip dysfunction levels will be measured, and the alpha angle will be evaluated on hip radiographs.
219449443|NCT06190717|DEVICE|EchoMark/EchoSure|Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
219449444|NCT06190717|PROCEDURE|Standard of Care|Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
219449445|NCT04774419|RADIATION|Intensity modulated radiation therapy (IMRT)|To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
219449446|NCT04774419|DRUG|Dostarlimab|IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
218839496|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
219449447|NCT04774419|RADIATION|Hypofractionated IMRT|Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
219449448|NCT03554174|DRUG|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
219449449|NCT03554174|DRUG|Placebo|microcrystalline cellulose capsule
219449450|NCT03554174|DRUG|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
219587331|NCT01398943|DRUG|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
219587332|NCT01398943|DIETARY_SUPPLEMENT|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
219587333|NCT06072495|OTHER|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
219587334|NCT00871741|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
218839497|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
218839498|NCT05081518|DRUG|Placebo|Placebo - capsule
218839499|NCT01050920|BIOLOGICAL|Blood collection|
218839500|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
218839501|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
218839502|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
218839503|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
218839504|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
218839505|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
219449451|NCT06570603|BEHAVIORAL|Self-Efficacy|Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.
219449452|NCT06570603|BEHAVIORAL|Willingness|Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.
218839506|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
218839507|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
218839508|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
218839509|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
218839510|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
219449453|NCT06570603|BEHAVIORAL|Psychoeducation|Psychoeducation about the components and functions of emotion.
219449454|NCT04432324|BIOLOGICAL|Intravenous Immune Globulin|IVIG Intravenous infusion
219449455|NCT04432324|DRUG|Standard Medical Treatment|SMT
219449456|NCT00236574|DRUG|Galantamine hydrobromide|
219449457|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
219449458|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
219449459|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
219449460|NCT06975293|COMBINATION_PRODUCT|STC-15 in combination with toripalimab|STC-15 in combination with toripalimab in 21-day cycles
219449461|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
219449462|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
219449463|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
219449464|NCT01426009|DRUG|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
219449465|NCT01426009|DRUG|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
219587335|NCT00871741|BIOLOGICAL|Infanrix hexa|Intramuscular, three doses
219587336|NCT00871741|BIOLOGICAL|Menjugate|Intramuscular, two doses
218839511|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
218839512|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
219449466|NCT01426009|DRUG|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
219449467|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
219449468|NCT01478178|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
219449469|NCT02283333|BEHAVIORAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
219449470|NCT02283333|BEHAVIORAL|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
219449471|NCT02192619|OTHER|observational|
219449472|NCT04462978|OTHER|Non IgE-mediated food allergy|
219449473|NCT04063540|DRUG|Amiloride|Treatment by Amiloride vs placebo in crossover
219449474|NCT04063540|DRUG|Placebos|Treatment by Amiloride vs placebo in crossover
219449475|NCT05126550|BIOLOGICAL|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
219449476|NCT03438760|BEHAVIORAL|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
219449477|NCT03438760|BEHAVIORAL|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
219449478|NCT03438760|BEHAVIORAL|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
219449479|NCT05103995|OTHER|no intervention|no intervention, just observation
219449480|NCT01938560|OTHER|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
219449481|NCT00557323|DRUG|Lanthanum carbonate|
219449482|NCT03003130|DEVICE|Restylane Defyne|Intradermal injection
219449483|NCT03003130|DEVICE|Restylane|Intradermal injection
219587337|NCT02635581|DEVICE|Delta TT acetabular cup|
219587338|NCT03894748|DRUG|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
219587339|NCT04667260|PROCEDURE|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
219587340|NCT04667260|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
218839513|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
218839514|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
218839515|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
218839516|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
218839517|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
218839518|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
218839519|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
218839520|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
218839521|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
218839522|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
218839523|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
219449484|NCT03872336|DRUG|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
218839524|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
218839525|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
218839526|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
218839527|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
218839528|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
218839529|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
218839530|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
218839531|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
218839532|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
219449485|NCT03872336|OTHER|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
219587341|NCT01565850|DRUG|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
218839533|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
218839534|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
218839535|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
218839536|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
219587342|NCT01565850|DRUG|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
219587343|NCT01565850|DRUG|COBI|COBI 150 mg tablet administered orally once daily
219449486|NCT05724147|BEHAVIORAL|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
219449487|NCT01863901|DEVICE|Treatment with Cryo-Touch III device|
219449488|NCT04164849|DRUG|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
219449489|NCT04164849|PROCEDURE|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
219449490|NCT04164849|PROCEDURE|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
219449491|NCT04164849|PROCEDURE|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
219449492|NCT00748306|DRUG|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
219449493|NCT00748306|DRUG|Placebo|Matching Intervention Drug
219449494|NCT01821885|BEHAVIORAL|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
219449495|NCT01821885|BEHAVIORAL|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
219449496|NCT04099836|DRUG|Atezolizumab|1200 mg IV every 3 weeks
219449497|NCT04099836|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks
219449498|NCT00776581|PROCEDURE|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
219587344|NCT01565850|DRUG|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
218839537|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
218839538|NCT04220463|OTHER|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
219449499|NCT00776581|PROCEDURE|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
219449500|NCT00776581|PROCEDURE|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
219449501|NCT00776581|PROCEDURE|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
219449502|NCT02455440|DRUG|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
219449503|NCT02455440|DRUG|Placebo|
219449504|NCT02455440|DRUG|Propofol and sevoflurane|
219449505|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
219449506|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
219449507|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
219449508|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
219587345|NCT01565850|DRUG|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
219587346|NCT01565850|DRUG|DRV Placebo|DRV placebo tablet administered orally once daily
219587347|NCT01565850|DRUG|COBI Placebo|COBI placebo tablet administered orally once daily
219587348|NCT01565850|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
219587349|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
219587350|NCT05849038|DRUG|Baricitinib|Patients will receive baricitinib at a dose of 2 mg oral daily.
219587351|NCT05849038|OTHER|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
219587352|NCT02375620|BIOLOGICAL|PEG-somatropin|
219587353|NCT06218030|DRUG|L-methylfolate|Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
219587354|NCT06451926|OTHER|Escape room game|Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
219587355|NCT04685109|DEVICE|Alocross 0.2% Unit Dose|Eye Drops
218839539|NCT04220463|OTHER|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
218839540|NCT05096247|DEVICE|TempSure|This device is an RF device.
218839541|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
218839542|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
218839543|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
218839544|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
218839545|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
218839546|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
219196659|NCT05727280|BEHAVIORAL|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
219587356|NCT04685109|DEVICE|Vismed|Eye drops
219196660|NCT04068792|OTHER|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
218839547|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
218839548|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
218839549|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
218839550|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
219196661|NCT04068792|DRUG|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
219196662|NCT04068792|DRUG|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
219196663|NCT04068792|DRUG|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
219196664|NCT04068792|DRUG|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
219449509|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
219449510|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
219449511|NCT05789914|PROCEDURE|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
219587357|NCT04941729|DEVICE|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
219587358|NCT04941729|DEVICE|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
218839551|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
218839552|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
218839553|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
219449512|NCT01814449|OTHER|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
219449513|NCT01814449|DRUG|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
219449514|NCT01905514|DEVICE|internet mobile application|
219587359|NCT05676918|BEHAVIORAL|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
219587360|NCT05676918|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
219587361|NCT03964532|DRUG|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
219587362|NCT03964532|DRUG|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
219587363|NCT05742347|DEVICE|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
219587364|NCT06559176|BIOLOGICAL|PM359|Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
218839554|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
218839555|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
218839556|NCT00232999|DRUG|Nebulized IVX-0142|
218839557|NCT06547645|OTHER|Sub-Acute Rehab at Home|Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
218839558|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
218839559|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
218839560|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
218839561|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
218839562|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
218839563|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
218839564|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
218839565|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
218839566|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
218839567|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
218839568|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
219766548|NCT07212920|DIAGNOSTIC_TEST|Physiotherapy assessment - only functional tests|This study involves three types of knee assessments to evaluate diagnostic reliability and validity: (1) a video-based function-based examination without specific knee tests, (2) traditional in-person function-based examination without specific knee tests and to control with (3) a traditional in-person examination including specific knee tests. The in-person assessments (2 and 3) includes the same functional tests plus specific tests targeting knee structures (ligaments, meniscus etc). Physiotherapists provide diagnostic judgments after each assessment phase. All procedures follow standardized protocols, pilot-tested and conducted at a public rehabilitation clinic in Västra Götaland.
218839569|NCT01756573|DRUG|Dexamthsone|
218839570|NCT01756573|DRUG|Bupivacaine|
218839571|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
218839572|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
218839573|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
219449515|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
218839574|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
218839575|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
219766549|NCT07212062|DRUG|X/T + X-EC|Xanomeline and Trospium Chloride Capsules
219587365|NCT06145737|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|"One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module."
218839576|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
218839577|NCT01863069|DRUG|Interferon beta 1a|
218839578|NCT01863069|DRUG|(IM) AVONEX®|
219196665|NCT04614948|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
219587366|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
219196666|NCT04614948|OTHER|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
219587367|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
219587368|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
219587369|NCT06314048|OTHER|CGM and RPM|1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
219587370|NCT04351737|DRUG|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
219196667|NCT06565247|DRUG|[18F]PSMA-PET|Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.
219587371|NCT04351737|DRUG|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
219587372|NCT04018664|DRUG|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
219587373|NCT04018664|DRUG|Placebo solution|Placebo
219587374|NCT05960266|BIOLOGICAL|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
219587375|NCT04582279|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
219587376|NCT03845296|DRUG|Rucaparib|Given PO
219587377|NCT06411899|DRUG|Sonelokimab|Sonelokimab
219587378|NCT06411899|DRUG|Placebo|Placebo
219766550|NCT07212062|DRUG|Placebo|Placebo
219766551|NCT07212062|DRUG|Lecanemab 10 mg/kg|Participants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo.
218839579|NCT06412835|OTHER|cooperative learning|Students working in groups
218839580|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
218839581|NCT00086983|DRUG|becatecarin|Given IV
218839582|NCT00086983|DRUG|oxaliplatin|Given IV
218839583|NCT00086983|OTHER|pharmacological study|Correlative studies
218839584|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
218839585|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
218839586|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
218839587|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
218839588|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
218839589|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
218839590|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
218839591|NCT01844297|DRUG|TDF+3TC+EFV|
218839592|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
218839593|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
218839594|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
218839595|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
218839596|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
218839597|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
218839598|NCT03985943|DRUG|Placebo|Placebo
218839599|NCT03985943|DRUG|Nemolizumab|Nemolizumab
218839600|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
218839601|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
218839602|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
218839603|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
218839604|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
218839605|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
218839606|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
218839607|NCT02604602|OTHER|blood exam|laboratory test
218839608|NCT01825148|OTHER|radiolabeled Exendin|
218839609|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
219196668|NCT06565247|DEVICE|MRI sequences optimized for prostate cancer examinations|T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
219196669|NCT06440304|DRUG|Fosfomycin|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
218839610|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
218839611|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
218839612|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
218839613|NCT06075134|PROCEDURE|Botox injection|Botox injection
218839614|NCT06075134|DEVICE|EMG|Quantitative Electromyography
218839615|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
218839616|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
218839617|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
218839618|NCT05822804|DEVICE|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
218839619|NCT05822804|DEVICE|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
218839620|NCT06479083|OTHER|New Intervention form including|The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
218839621|NCT06479083|OTHER|Standard treatment|The standard treatment which all compulsory insured patients get.
218839622|NCT06403098|DEVICE|External Nasal Dilator Strip|Participants will wear an extra strength Breathe Right nasal strip overnight.
218839623|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
218839624|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
219449516|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
218839625|NCT04670523|PROCEDURE|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
218839626|NCT04670523|PROCEDURE|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
218839627|NCT04135807|COMBINATION_PRODUCT|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
219449517|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
218839628|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
219196670|NCT06440304|DRUG|Eravacycline|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
219196671|NCT06440304|DRUG|ampicillin/sulbactam|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
218839631|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
218839632|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
218839633|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
218839634|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
218839635|NCT05764720|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
218839636|NCT06546202|OTHER|No Drug|This is an non-interventional, observational study. No drug was administered during this study.
218839637|NCT06348615|DEVICE|Anti-cellulite cream-gel Medical Device (DEFBODY)|one bottle of 400 ml, twice a day
218839638|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
218839639|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
218839640|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
218839641|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
218839642|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
218839643|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
219196672|NCT00317486|DRUG|bosentan|
218839644|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
219196673|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
219196674|NCT06592248|DEVICE|Coc Knee|Implementation of a ceramic on ceramic knee prosthesis
218839645|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
218839646|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
218839647|NCT02889497|BIOLOGICAL|the first batch vaccine|
218839648|NCT02889497|BIOLOGICAL|the second batch vaccine|
218839649|NCT02889497|BIOLOGICAL|the third batch vaccine|
218839650|NCT01732029|OTHER|Normobaric hypoxia chamber|
218839651|NCT00021567|DRUG|Interferon Gamma for Aerosol|
218839652|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
218839653|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
219449518|NCT03607240|PROCEDURE|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
219449519|NCT03607240|PROCEDURE|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
219449520|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
219449521|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
219449522|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
219449523|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
219449524|NCT01196091|DRUG|Standard of Care|
219449525|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
218839654|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
218839655|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
218839656|NCT04964505|DRUG|Azacitidine|Given IV or SC
218839657|NCT04964505|DRUG|Uproleselan|Given IV
219449526|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
219017570|NCT06123546|OTHER|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
219449527|NCT03733249|DRUG|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
219449528|NCT03733249|BIOLOGICAL|rivogenlecleucel|donor T-cells modified with iCasp safety switch
219449529|NCT00806650|GENETIC|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
219449530|NCT00806650|GENETIC|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
218839658|NCT04964505|DRUG|Venetoclax|Given PO
218839659|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
219449531|NCT00806650|DIAGNOSTIC_TEST|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
219449532|NCT00806650|OTHER|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
219587379|NCT06956430|DEVICE|Battery-powered rickshaw|A battery-powered rickshaw is a rickshaw where the wheels are turned by a small electric motors powered by a battery.
219587380|NCT06795997|BEHAVIORAL|Tax Conditions|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to 4 conditions with 5 trials each, where products will increase in price: Tobacco Parity, Nicotine-Content, Harm- Reduction, and Modified Risk Tobacco Product-related taxes.
219587381|NCT06795997|BEHAVIORAL|Control Condition|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to a control trial.
218839660|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
218839661|NCT03489772|DRUG|ITI-214|Oral
218839662|NCT03489772|DRUG|Placebo|Oral
218839663|NCT01731158|DRUG|Avastin in combination with Roferon-A|
218839664|NCT01731158|DRUG|Afinitor|
218839665|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
218839666|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
218839667|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
218839668|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
218839669|NCT02244307|DRUG|alpha-adrenergic blocker|
219449533|NCT00806650|OTHER|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
219449534|NCT04476108|DRUG|LY3016859|Administered IV
219449535|NCT04476108|DRUG|Placebo|Administered IV
219449536|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
219449537|NCT05009836|DRUG|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
219449538|NCT05009836|DRUG|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
219449539|NCT01637844|DRUG|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
219449540|NCT00883792|PROCEDURE|Colonoscopy|Once-only colonoscopy screening
219449541|NCT03219554|DRUG|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
219449542|NCT02253992|BIOLOGICAL|Urelumab|
219449543|NCT02253992|BIOLOGICAL|Nivolumab|
219449544|NCT02968966|OTHER|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
219449545|NCT03683095|PROCEDURE|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
219449546|NCT06141889|DRUG|Azelaprag|oral, apelin receptor (APJ) agonist
219449547|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
219449548|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
219449549|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
219449550|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
219449551|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
219449552|NCT03206983|DEVICE|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
219449553|NCT03323086|BEHAVIORAL|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
219449554|NCT03323086|OTHER|Brochure|Brochures provided one time
219449555|NCT00149006|PROCEDURE|Cell therapy|
219449556|NCT02812329|BEHAVIORAL|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
219449557|NCT02911051|DEVICE|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
219449558|NCT01537523|PROCEDURE|community-care program|community nurse care, physiotherapy
219587382|NCT03611543|DEVICE|Standard of Care Flat Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a 4-view 2D plus 3D combination imaging: Left Cranial Caudal (LCC), Left Medial Oblique (LMO), Right Cranial Caudal (RCC), and Right Medial Oblique (RMLO) with the current standard of care (SOC) flat paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the SOC flat paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
218839670|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
218839671|NCT00964002|DRUG|efavirenz|
218839672|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
219449559|NCT03283891|OTHER|Educational intervention - humanistic nursing practice|"Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
218839673|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
218839674|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
219449560|NCT01866306|BIOLOGICAL|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
219449561|NCT01866306|DRUG|LABA|Asthmatic participants were treated with LABA as part of their standard of care
219449562|NCT03873428|OTHER|FES PET|FES injection
219449563|NCT05155410|DIETARY_SUPPLEMENT|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
218839675|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
218839676|NCT00479817|DRUG|AMG 386|10mg/kg
218839677|NCT00479817|DRUG|AMG 386|3 mg/kg
218839678|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
218839679|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
218839680|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
218839681|NCT04181593|DRUG|Placebos|Mineral oil Softgels
218839682|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
219449564|NCT05155410|DIETARY_SUPPLEMENT|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
219449565|NCT02516891|DEVICE|Drug-Eluting Stents implantation in bifurcation lesions|
218839683|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
218839684|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
218839685|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
218839686|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
218839687|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
218839688|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
218839689|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
218839690|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
218839691|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
218839692|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
218839693|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
218839694|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
218839695|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
218839696|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
219449566|NCT00820963|DRUG|temozolomide|Given orally
219449567|NCT00820963|RADIATION|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
219449568|NCT00820963|RADIATION|radiation therapy|Patients undergo standard radiotherapy
219449569|NCT02980263|DRUG|Canakinumab|
219449570|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
218839697|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
218839698|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
218839699|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
218839700|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
218839701|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
218839702|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
218839703|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
218860005|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
218839704|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
219449571|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
219449572|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
219449573|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
219449574|NCT05560074|DEVICE|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
219449575|NCT05560074|OTHER|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
218839705|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
218839706|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
218839707|NCT03597204|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for up to five years and follow-up colonoscopy was arranged for those with FIT positive result
218839708|NCT03597204|DIAGNOSTIC_TEST|Colonoscopy|Subjects in the retrospective cohort were allowed to choose one-off colonoscopy for CRC screening
219449576|NCT04247828|DEVICE|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
219449577|NCT04247828|DEVICE|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
219449578|NCT03140046|PROCEDURE|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
219449579|NCT05634837|BEHAVIORAL|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
219766552|NCT07212764|OTHER|mobile application|Patients will be instructed to record any symptoms suggestive of infectious diseases-such as fever, cough, nasal discharge, or myalgia-directly into the mobile application whenever they occur. The app will provide simple checklists and entry fields, allowing patients (or their caregivers) to promptly log these symptoms in real time. By systematically documenting infection-related manifestations alongside routine follow-up data, we will be able to prospectively evaluate whether infectious episodes act as potential triggers for Familial Mediterranean Fever (FMF) attacks. The collected data will then be analyzed to determine temporal and clinical associations between infection symptoms and subsequent disease flares, thereby clarifying whether infections precipitate or overlap with FMF attacks.
219766553|NCT07212465|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.
219766554|NCT07212465|DEVICE|Sham Brainsway H1-Coil Deep TMS System|In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.
219449580|NCT05634837|BEHAVIORAL|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
219449581|NCT06396130|DEVICE|Photobiomodulation by low level diode laser|Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
218839709|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
218839710|NCT00056576|DRUG|Zonisamide|
219449582|NCT06396130|OTHER|Mock Laser Application|Placebo for control group
219449583|NCT06432491|BEHAVIORAL|Drinking cold water|Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
219449584|NCT03988790|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
219449585|NCT02159365|DRUG|Elotuzumab|
219449586|NCT02159365|DRUG|Lenalidomide|
219449587|NCT02159365|DRUG|Dexamethasone|
218839711|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
219017571|NCT06123650|DEVICE|Repetitve transcranial magnetic stimulation|"The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days."
219017572|NCT06123650|DEVICE|Sham transcranial magnetic stimulation|Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
218839712|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
218839713|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
219017573|NCT06807099|DEVICE|Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)|Target Lesion treated with WRAPSODY CIE
219449588|NCT05141565|OTHER|No intervention|No intervention
219449589|NCT02460094|DRUG|BIIB092|See Arm Descriptions for dosing information.
219587383|NCT03611543|DEVICE|Investigational Curved Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a CC and an MLO in one of her breasts as determined by a randomization scheme with the investigational (INV) curved paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the INV curved paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
219766555|NCT07213440|PROCEDURE|lumbar puncture|After information and consent by the investigator, clinical data will be collected using a CRF and biological samples (Blood sampling, Urine sample, cephalo spinal fluid), lacrimal fluid sampling, and a smell test will be taken from all subjects at baseline and at 12 months.
219766556|NCT07213050|PROCEDURE|Radiofrequency|achieve a target temperature of 90-110°C for 4-12 minutes, ensuring an ablative margin of at least 0.5-1.0 cm around the tumor.
219766557|NCT07213050|PROCEDURE|Microwave|Antennas will be placed under imaging guidance, and ablation will be performed for 5-10 minutes per antenna activation to achieve the desired margin.
218839714|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
219766558|NCT07212491|OTHER|Non-Interventional Study|Non-interventional study
219766559|NCT07211958|DRUG|Revumenib|Participants will receive revumenib orally.
219766560|NCT07211958|DRUG|Placebo|Participants will receive placebo (non-active agent) orally.
219766561|NCT07211958|DRUG|Intensive Chemotherapy Regimen|Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.
219766562|NCT07211425|DRUG|BI 3031185|BI 3031185
219766563|NCT07211425|DRUG|Itraconazole|Itraconazole
219766564|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
219766565|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218839715|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
218839716|NCT03556670|OTHER|Control|Usual practice control
218839717|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
219449590|NCT02460094|DRUG|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
219449591|NCT01095328|OTHER|screening|screening for Q-fever with a single blood sampling
219449592|NCT00245349|PROCEDURE|F-18 Fluorothymidine|
219449593|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
219449594|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
218839718|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
218839719|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
218839720|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
219766566|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219196675|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
219196676|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
219449595|NCT00796549|DRUG|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
219449596|NCT04311437|PROCEDURE|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
219196677|NCT06595628|PROCEDURE|Lichtenstein Mesh-Based Hernioplasty|This is a tension-free hernioplasty procedure that uses a synthetic mesh to reinforce the inguinal canal floor. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, creating a barrier to prevent hernia recurrence. It is considered the gold standard for inguinal hernia repair and is widely used for its effectiveness in reducing recurrence rates and postoperative complications.
219449597|NCT04311437|PROCEDURE|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
219449598|NCT01102946|DRUG|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
219449599|NCT01102946|PROCEDURE|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
219449600|NCT02719210|BIOLOGICAL|High Volume Plasma Exchange|
219449601|NCT02719210|DRUG|Hypertonic 3% saline|
219449602|NCT02719210|DRUG|Mannitol|
219449603|NCT02719210|DEVICE|Elective positive pressure ventilation|
219449604|NCT00004194|DRUG|fludarabine phosphate|
219587384|NCT06185959|BEHAVIORAL|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
219587385|NCT06847633|BEHAVIORAL|Digital lifestyle intervention|The digital lifestyle intervention provides support to the patient through digital lectures, home assignments and digital group meetings as well as provides the possibility for the healthcare provider to provide personalized digital support and feedback to the patient
219587386|NCT06580925|DEVICE|sham tape|sham
219587387|NCT06580925|DEVICE|kinesio tape|Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators
219587388|NCT06580925|DEVICE|dynamic tape|Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators
219766567|NCT04301076|DRUG|Cyclophosphamide|Given IV
219766568|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
219766569|NCT04301076|DRUG|Etoposide|Given IV
219766570|NCT04301076|DRUG|Lenalidomide|Given PO
219449605|NCT02966899|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
219449606|NCT00474773|DRUG|Celecoxib|
219449607|NCT02661256|DEVICE|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
219449608|NCT02661256|DIETARY_SUPPLEMENT|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
219449609|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
219449610|NCT03426761|DRUG|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
219449611|NCT03426761|DRUG|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
219449612|NCT00747708|DRUG|Granulocyte-colony stimulating factor|5 days subcutaneous injection
219449613|NCT00747708|PROCEDURE|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
219766571|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219766572|NCT04301076|DRUG|Prednisone|Given PO
219766573|NCT04301076|DRUG|Vincristine Sulfate|Given IV
219449614|NCT00747708|PROCEDURE|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
219449615|NCT03868475|PROCEDURE|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
218839721|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
218839722|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
218839723|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
218839724|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
218839725|NCT03520686|DRUG|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])"
219449616|NCT03868475|PROCEDURE|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
219017592|NCT03233347|DRUG|Brentuximab Vedotin|Given IV
219017593|NCT03233347|DRUG|Dacarbazine|Given IV
219449617|NCT04143490|OTHER|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
219017594|NCT03233347|DRUG|Doxorubicin|Given IV
219017595|NCT03233347|OTHER|Laboratory Biomarker Analysis|Correlative studies
219017596|NCT03233347|BIOLOGICAL|Nivolumab|Given IV
219017597|NCT03233347|DRUG|Vinblastine|Given IV
219449618|NCT01878175|BEHAVIORAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
219449619|NCT04591873|OTHER|telemedicine|Using telemedicine system to communicate
219449620|NCT04591873|OTHER|traditional communication tools|Use telephone or direct verbal communication
219449621|NCT03102463|DIETARY_SUPPLEMENT|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
219449622|NCT03102463|DIETARY_SUPPLEMENT|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
219449623|NCT03102463|DIETARY_SUPPLEMENT|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
218839726|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
218839727|NCT03520686|DRUG|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
218839728|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
218839729|NCT03520686|DRUG|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
218839730|NCT03520686|DRUG|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
218839731|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab|The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
218839732|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
219449624|NCT03102463|OTHER|Lipid Load|100mL oral lipid load
219449625|NCT04611204|OTHER|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
219449626|NCT01498497|DRUG|EUR-1100|
219449627|NCT01498497|DRUG|Placebo|
219587389|NCT05105490|DRUG|PerQdisc|Observational trial to collect post-market safety and efficacy information in a limited number of human patients
219587390|NCT04163432|DRUG|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
219587391|NCT04163432|DRUG|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.
219587392|NCT04163432|DRUG|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
219449628|NCT07007806|DRUG|Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting|On day 1 single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions.
219449629|NCT07007806|DRUG|Treatment B-Omeprazole 20 mg dose administered fasting|On Day 4 to Day 13, a 20 mg dose omeprazole (1 × 20 mg) will be administered QD under fasting conditions.
219449630|NCT07007806|DRUG|Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting|On Day 8, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions simultaneously with a 20 mg dose omeprazole (1 × 20 mg).
219449631|NCT07007806|DRUG|Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole|On Day 13, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 0.5 hour before the administration of a 20 mg dose omeprazole (1 × 20 mg).
218839733|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
218839734|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
219587393|NCT04220255|DEVICE|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
219587394|NCT00536692|DRUG|mecamylamine|topical ocular drops
219587395|NCT01711463|DRUG|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
219587396|NCT01711463|DRUG|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
219587397|NCT06222320|OTHER|Kinesiotaping|Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.
219449632|NCT07007806|DRUG|Treatment E-Omeprazole 40 mg administered fasting|On Day 14 to Day 22, a 40 mg dose omeprazole (2 × 20 mg) will be administered QD under fasting conditions.
219449633|NCT07007806|DRUG|Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole|On Day 18, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 2 hours after the administration of a 40 mg dose omeprazole (2 × 20 mg).
219449634|NCT00255606|DRUG|docetaxel|Given in 3- or 4- week courses
219449635|NCT00255606|DRUG|prednisone|Given in 3- or 4- week courses
219449636|NCT06373978|DRUG|Diclofenac|50mg every 8hours as needed for pain
218839735|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
218839736|NCT00654225|DRUG|Rosuvastatin|
218839737|NCT00654225|DRUG|Atorvastatin|
218839738|NCT00851552|BIOLOGICAL|rituximab|Given IV
218839739|NCT00851552|DRUG|bortezomib|Given IV
218839740|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
218839741|NCT00851552|GENETIC|gene expression analysis|Correlative Study
218839742|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
218839743|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
218839744|NCT00851552|GENETIC|proteomic profiling|Correlative Study
218839745|NCT00851552|OTHER|flow cytometry|Correlative Study
219449637|NCT06373978|DRUG|Tramadol|50mg every 8hours as needed for pain
219449638|NCT06373978|OTHER|Acetaminophen|1000mg every 8hours as needed for pain
219449639|NCT07011667|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.
219449640|NCT07011667|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
218839746|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
218839747|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
218839748|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
218839749|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
218839750|NCT01281384|OTHER|Advanced Imaging|
218839751|NCT01281384|OTHER|Standard Imaging|
218839752|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
218839753|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
218839754|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
218839755|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
218839756|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
218839757|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
219449641|NCT06867575|OTHER|Progressive Relaxation Exercise|Progressive Relaxation Exercise Steps
219449642|NCT07012148|DEVICE|UNEEG SubQ device|Subjects will be implanted with the UNEEG SubQ device in the neurosurgical operating suite under general anesthesia. Electrodes will be placed over the temporal lobe of the hemisphere established as the origin of seizures by previous EEG monitoring. Only one UNEEG device will be placed, and only the seizure onset hemisphere will be covered.
219449643|NCT00552994|DEVICE|Cypher Select plus|Drug eluting stent
219449644|NCT00552994|DEVICE|Xience V stent|Drug eluting stent
219449645|NCT03049930|DRUG|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
219449646|NCT03049930|DRUG|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
218839758|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
218839759|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
218839760|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
218839761|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
219449647|NCT03511300|BEHAVIORAL|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
218839762|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
218839763|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
218839764|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
218839765|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
219196678|NCT06595628|PROCEDURE|Combined Modified Guarnieri-Desarda Tissue-Based Hernioplasty|This technique combines elements of the Guarnieri and Desarda tissue-based repairs. It does not involve the use of synthetic mesh, relying instead on the patient's own tissues to reinforce the inguinal canal. The Guarnieri technique reshapes the internal ring to improve the inguinal canal's shutter mechanism, while the Desarda technique reinforces the posterior wall using the external oblique aponeurosis. This approach aims to preserve natural anatomy and minimize complications associated with mesh use.
219449648|NCT03511300|BEHAVIORAL|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
219449649|NCT00778310|DRUG|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
219449650|NCT00778310|DRUG|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
219449651|NCT00995605|DRUG|AMAP102|AMAP102 or Placebo
219449652|NCT03163173|DRUG|GC4419|30 mg (\~100 μCi) dose of \[14C\]GC4419
219449653|NCT02455362|DRUG|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
219449654|NCT02455362|DRUG|Placebo|
219449655|NCT00698776|DRUG|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
219449656|NCT00698776|BIOLOGICAL|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
219449657|NCT05964712|PROCEDURE|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
219449658|NCT01197794|DRUG|AZD1981|AZD1981 twice daily
219449659|NCT01197794|DRUG|AZD1981|AZD1981 once daily
219587398|NCT06222320|DRUG|Painkillers|Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
219587399|NCT02991690|OTHER|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification \[510(k), K030421\]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
218839766|NCT01712581|OTHER|Magnetic Resonance Imaging|
218839767|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
218839768|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
218839769|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
218839770|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
219017613|NCT06188507|DRUG|GSK4347859|GSK4347859 will be administered
219017614|NCT06188507|DRUG|Placebo|Placebo will be administered
219449660|NCT01197794|DRUG|Placebo|Placebo to match AZD1981
219449661|NCT01055457|DEVICE|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
218839771|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
218839772|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
218839773|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
218839774|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
218839775|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
218839776|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
218839777|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
218839778|NCT00644072|DRUG|SNX-5422|
218839779|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
218839780|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
218839781|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
218839782|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
219449662|NCT01055457|DEVICE|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
219449663|NCT02732184|DRUG|Co-ArgI-PEG modified human arginase I|
219449664|NCT04598841|DIETARY_SUPPLEMENT|supplement nutritional supporting|Special medical formula for the purpose of formula food
219449665|NCT04716010|OTHER|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
219449666|NCT04716010|OTHER|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
219449667|NCT04716010|OTHER|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
218839783|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
218839784|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
218839785|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
218839786|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
218839787|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
219196679|NCT03663205|DRUG|Tislelizumab|Administered intravenously
219196680|NCT03663205|DRUG|Cisplatin|Administered intravenously
219196681|NCT03663205|DRUG|Carboplatin|Administered intravenously
219196682|NCT03663205|DRUG|Pemetrexed|Administered intravenously
219196683|NCT06814899|DRUG|Fosfomycin|In this retrospective study, the investigators want to analyze the medical records of all patients admitted to the Lecco ASST from 04/01/2020 to 12/31/2023 treated with IV fosfomycin in order to evaluate different clinical outcomes.
219196684|NCT06815770|DRUG|Terlipressin Injectable Product|Terlipressin Injectable Product
219196685|NCT06813495|BEHAVIORAL|Eastern Principles Acceptance and Commitment Therapy for Nurses and Nursing Aids (EPACT NNA)|The EPACT intervention will be group-based with 5-10 participants per group. The group-based format has been shown to be an effective delivery method for NNAs (O'Brien, et al., 2019b). The EPACT protocol is comprised of two 2.5-hour sessions spaced one week apart.
219449668|NCT04716010|OTHER|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
219449669|NCT03777397|OTHER|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
219449670|NCT00679380|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
219449671|NCT00679380|DRUG|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
219449672|NCT00679380|DRUG|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
219449673|NCT00679380|DRUG|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
219449674|NCT00679380|DRUG|Placebo|Placebo
219449675|NCT00656760|OTHER|PET/CT|PET/CT is being performed on all patients in the study.
219449676|NCT02715596|DIETARY_SUPPLEMENT|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
219449677|NCT02715596|OTHER|Placebo|placebo in 15 cc emulsion stick-pack
219587400|NCT06318780|OTHER|three-phase CT angiography|three-phase CT angiography
219587401|NCT06318780|OTHER|CEUS ultrasound|CEUS ultrasound
218839788|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
218839789|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
218839790|NCT02534012|PROCEDURE|Major abdominal surgery|
218839791|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
218839792|NCT05723692|OTHER|Placebo|formulation buffer
218839793|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
218839794|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
218839795|NCT02746588|OTHER|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
218839796|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
218839797|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
218839798|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
219196686|NCT06813495|BEHAVIORAL|Acceptance and Commitment Therapy for Nurses and Nursing Aids (ACT NNA)|The ACT for NNA intervention has been previously tested for NNAs. It contains only the six core processes identified above and omits the added EPACT components of acceptance of suffering, common humanity, impermanence, self- and other-compassion, and non-self-attachment. It will be delivered in a similar group-based format of 5-10 participants in two 2.5 -hour sessions.
219196687|NCT06811337|PROCEDURE|Open Sinus Elevation|Open Sinus Elevation
219449678|NCT03630016|DIAGNOSTIC_TEST|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
219449679|NCT01833806|DEVICE|ExAblate MRgFUS|Focused Ultrasound Ablation
219587402|NCT06638450|PROCEDURE|Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)|"DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
219449680|NCT02724111|DRUG|sufficient dose of rocuronium|
219449681|NCT02724111|DRUG|sugammadex 10 min after position change|
219449682|NCT01828567|BEHAVIORAL|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
219587403|NCT06638450|PROCEDURE|Minimal Acupuncture Stimulation (MAS)|"MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. After that, electrical stimulation is performed on bilateral Tongtian (BL07), with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
219587404|NCT02799095|DRUG|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
219587405|NCT02799095|DRUG|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
218839799|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
218839800|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
218839801|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
218839802|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
218839803|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
219196688|NCT06811337|PROCEDURE|Closed Sinus Elevation|Closed Sinus Elevation
218839804|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
219449683|NCT01427660|BEHAVIORAL|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
219449684|NCT01427660|BEHAVIORAL|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
219449685|NCT01210976|DRUG|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
219449686|NCT01210976|DRUG|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
219449687|NCT03336476|DEVICE|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
219449688|NCT03336476|DEVICE|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
219449689|NCT02419586|OTHER|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
219449690|NCT00895908|BEHAVIORAL|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
219449691|NCT00895908|BEHAVIORAL|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
219449692|NCT04046601|DEVICE|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
219449693|NCT05265104|DRUG|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
219449694|NCT05265104|DEVICE|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
219449695|NCT05265104|OTHER|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
219449696|NCT03253185|DRUG|SC-007|intravenous
219449697|NCT03053973|DEVICE|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
219449698|NCT03053973|OTHER|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
219449699|NCT04063865|DRUG|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
218839805|NCT00489320|DEVICE|Cypher Stent|
218839806|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
218839807|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
218839808|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
219196689|NCT06589726|DRUG|Placebo|Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
219196690|NCT06589726|DRUG|Moxifloxacin|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
219196691|NCT06589726|DRUG|Enpatoran low dose|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
219196692|NCT06589726|DRUG|Enpatoran high dose|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
219449700|NCT04063865|DRUG|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
218839809|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
219196693|NCT06769776|OTHER|No Drain i.e. Omission of abdominal drain placement|Omission of abdominal drain placement in intervention arm. The No-drain arm will be compared to drain arm
219449701|NCT05409092|DIETARY_SUPPLEMENT|Astaxanthin|8 mg/day in one capsule for 4 weeks
219449702|NCT05409092|DIETARY_SUPPLEMENT|Placebo|8 mg/day in one capsule for 4 weeks
219449703|NCT03659240|OTHER|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
219449704|NCT03659240|OTHER|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
219449705|NCT03898323|DEVICE|Alcohol Approach Bias Modification|Computerized training
218839810|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
218839811|NCT04217811|OTHER|No intervention|No intervention
219196694|NCT06768840|DRUG|Baricitinib|oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
219196695|NCT06768840|DRUG|oral mini pulse|pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
219449706|NCT01948323|BEHAVIORAL|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
218839812|NCT02959853|DRUG|Anastrazole|
218839813|NCT02959853|BEHAVIORAL|weight loss|
218839814|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
219196696|NCT06768840|RADIATION|Narrow Band UVB Treatment|narrowband ultraviolet rays B phototherapy two sessions per week
219196697|NCT06603519|DIETARY_SUPPLEMENT|Modified Plant-Based Mediterranean Diet|Two-week dietary intervention after the participants' scheduled colonoscopy consisting of vegetarian high-fiber meals. These meals are designed to provide a substantial intake of dietary fiber through a variety of plant-based foods, including whole grains, legumes, fruits, vegetables, nuts, and seeds. Meals will be delivered bi-weekly, and compliance will be monitored through regular check-ins with a study dietitian.
219449707|NCT06455423|PROCEDURE|Thoracic Manipulation|Thoracic manipulation will be administered at hypomobile or stiff segments.
219449708|NCT06455423|PROCEDURE|Chin tuck in exercises|Chin tuck in exercises
219449709|NCT06455423|PROCEDURE|Thoracic Extension Exercise|Thoracic Extension Exercise
219449710|NCT06455423|PROCEDURE|Scapular Retraction Exercises|Scapular Retraction Exercises
219449711|NCT06455423|DEVICE|Hot Pack|Hot Pack
219449712|NCT06455423|DEVICE|TENS|Trans Cutaneous Electric Nerve Stimulation (TENS)
219449713|NCT06455423|PROCEDURE|ELDOA|ELDOA exercises
219449714|NCT03175250|BEHAVIORAL|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
219449715|NCT03175250|BEHAVIORAL|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
219449716|NCT03175250|BEHAVIORAL|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
219449717|NCT01547806|DRUG|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
219449718|NCT01547806|DRUG|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
219449719|NCT01547806|PROCEDURE|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
219449720|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
219449721|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|"1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
219449722|NCT06503133|OTHER|Birth preparation training|Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).
219449723|NCT06503133|OTHER|Prenatal yoga practice|Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
219449724|NCT00620737|BIOLOGICAL|Autologous Human Fibroblasts (Isolagen TherapyTM)|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
219449725|NCT00620737|BIOLOGICAL|Placebo|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
219449726|NCT00515554|DRUG|Rituximab|addition of Rituximab to BEACOPP escalated
219449727|NCT00515554|DRUG|BEACOPP escalated|chemotherapy with BEACOPP escalated
219449728|NCT02448797|DRUG|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
219449729|NCT02448797|DRUG|Chemotherapy|Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
219449730|NCT00000703|DRUG|Bleomycin sulfate|
219449731|NCT00000703|DRUG|Vincristine sulfate|
219449732|NCT00000703|DRUG|Doxorubicin hydrochloride|
219449733|NCT00000703|DRUG|Cyclophosphamide|
219449734|NCT00000703|DRUG|Allopurinol|
219449735|NCT00000703|DRUG|Methotrexate|
219449736|NCT00000703|DRUG|Cytarabine|
219449737|NCT00000703|DRUG|Leucovorin calcium|
219449738|NCT00000703|DRUG|Zidovudine|
219449739|NCT00000703|DRUG|Dexamethasone|
219449740|NCT02626299|DRUG|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
219449741|NCT02626299|DRUG|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
219449742|NCT02626299|OTHER|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
219449743|NCT06870019|BEHAVIORAL|GPS tracker device|GPS tracker device
219449744|NCT02159001|DEVICE|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
219449745|NCT02307604|GENETIC|Tumour markers testing|
219449746|NCT05307081|DRUG|Artificial Tears|Artificial Tears are an FDA approved intervention
219449747|NCT03882866|PROCEDURE|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
219449748|NCT03882866|PROCEDURE|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
219449749|NCT04501965|COMBINATION_PRODUCT|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
219449750|NCT04501965|COMBINATION_PRODUCT|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
219587406|NCT05644873|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
219587407|NCT05644873|DRUG|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
219587408|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
218839815|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
219449751|NCT04501965|COMBINATION_PRODUCT|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
219449752|NCT04844567|DEVICE|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
219449753|NCT04844567|DEVICE|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
219449754|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
219449755|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
219449756|NCT04060433|BEHAVIORAL|Family Therapy|Swedish version of the evidence based manualized Family Therapy
219476019|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
219449757|NCT06388356|OTHER|Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care|"Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive."
219449758|NCT06220188|DRUG|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
219449759|NCT00877227|DRUG|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
219449760|NCT00374127|DRUG|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
219449761|NCT00374127|DRUG|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
219449762|NCT05736042|DEVICE|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
219449763|NCT03419351|DIAGNOSTIC_TEST|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
219449764|NCT03419351|DIAGNOSTIC_TEST|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
219449765|NCT03419351|DIAGNOSTIC_TEST|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
219449766|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
219449767|NCT01145404|DRUG|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
219449768|NCT01145404|DRUG|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
219449769|NCT02484040|RADIATION|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
219449770|NCT02484040|DRUG|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
219449771|NCT03623204|OTHER|Dyspnea evaluation|
219449772|NCT03053713|BEHAVIORAL|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
219449773|NCT03053713|BEHAVIORAL|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
219449774|NCT03148249|OTHER|interview|control group: interview, study group: explanation and exploration
219476020|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
219476021|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
219476022|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
219476023|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
219476024|NCT00058994|DRUG|anecortave acetate|
219476025|NCT01473602|DRUG|Teriparatide|Administered by SC injection
219476026|NCT01473602|DRUG|Placebo|Administered by SC injection
219476027|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
219476028|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
219476029|NCT04463771|DRUG|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
219476030|NCT04463771|DRUG|epacadostat|epacadostat will be administered orally BID.
219476031|NCT04463771|DRUG|pemigatinib|pemigatinib will be administered orally QD.
219476032|NCT04463771|DRUG|INCAGN02385|INCAGN2385 will be administered every 2 weeks
219476033|NCT04463771|DRUG|INCAGN02390|INCAGN2390 will be administered every 2 weeks
218839816|NCT06036602|BIOLOGICAL|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
219449775|NCT07025382|OTHER|Home-based pulmonary rehabilitation|"An eight-week (three sessions per week) telerehabilitation home-based program, including:~Twenty-four PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations. Participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application (TELEREHAPP) for guidance throughout the program, remote monitoring, and communication. Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Physical activity coaching, including a daily step goal."
219449776|NCT07025382|OTHER|Center-based pulmonary rehabilitation|"An eight-week (three sessions per week) center-based pulmonary rehabilitation program, including:~Twenty-four center-based PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations."
219449777|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
219449778|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
219449779|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
219449780|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
219449781|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
219449782|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
219449783|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
219449784|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
219449785|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
219449786|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
219449787|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
219449788|NCT03374891|OTHER|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
219449789|NCT01868594|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
219449790|NCT01868594|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
219449791|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
219476034|NCT04238624|DRUG|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
219476035|NCT04238624|DRUG|Trametinib|Participants will receive trametinib 2 mg orally once a day
218839817|NCT06036602|OTHER|Placebo|0.9% NaCl solution for injection.
218839818|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
218839819|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
219476036|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
219476037|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
219476038|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
219476039|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
218839820|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
218839821|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
218839822|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
218839823|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
218839824|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
219196698|NCT04741230|DEVICE|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
219196699|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
219196700|NCT06655636|DEVICE|Device tuned to Assistance|The device spring components will be tuned to produce an assistive supination torque on the forearm.
219196701|NCT06655636|DEVICE|Device tuned to Sham (Slack Springs)|The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
219196702|NCT06655636|DEVICE|Device tuned to Anti-Assistance|The device spring components will be tuned to produce a resistive supination torque on the forearm.
219196703|NCT06655220|DRUG|Metformin hydrochloride|Metformin hydrochloride
219196704|NCT06655220|DRUG|BI 1815368|BI 1815368
219196705|NCT06655870|DRUG|mRNA-0184|SC injection
219449792|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
219449793|NCT07032272|DRUG|remibrutinib|Tablet with oral route of administration
219449794|NCT06878131|BEHAVIORAL|Colorectal Cancer|Participants that take part in this research, will be responsible for following study directions and allowing blood samples to be collected every 3 months for correlative studies.
219449795|NCT05976685|PROCEDURE|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
219449796|NCT05976685|DRUG|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
219449797|NCT05412667|DIETARY_SUPPLEMENT|TWK10|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
219196706|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
219196707|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
219449798|NCT05412667|OTHER|Placebo|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
219449799|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
219449800|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
219449801|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
219449802|NCT01201967|OTHER|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
219449803|NCT01201967|OTHER|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
219449804|NCT06706869|DRUG|PF-07258669|Tablet
218839825|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
219449805|NCT06706869|DRUG|Itraconazole|Solution
219449806|NCT05844657|OTHER|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
219449807|NCT05844657|OTHER|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
219449808|NCT05844657|OTHER|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
219449809|NCT05844657|OTHER|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
219449810|NCT05844657|OTHER|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
219449811|NCT05844657|OTHER|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
219449812|NCT05844657|OTHER|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
219196708|NCT06655428|DEVICE|Endobronchial Therman Liquid Ablation (ETLA)|The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.
219449813|NCT05844657|OTHER|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
219449814|NCT05844657|OTHER|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
219449815|NCT05844657|OTHER|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
219449816|NCT05844657|OTHER|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
219449817|NCT05844657|OTHER|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
219476040|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
219476041|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
219476042|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
218839826|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
218839827|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
218839828|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
218839829|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
219476043|NCT00006049|DRUG|carboplatin|
219476044|NCT00006049|DRUG|gefitinib|
219476045|NCT00006049|DRUG|paclitaxel|
219476046|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
219476047|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
218839830|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
219449818|NCT05844657|OTHER|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
219449819|NCT05844657|OTHER|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
218839831|NCT02665663|DEVICE|medical device|
218839832|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
218839833|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
218839834|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
219449820|NCT05844657|OTHER|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
219449821|NCT05844657|OTHER|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
219476048|NCT00070070|BIOLOGICAL|sargramostim|
219476049|NCT02052206|PROCEDURE|Shoulder replacement surgery|
219476050|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
219476051|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
219476052|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
219449822|NCT05844657|OTHER|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
219449823|NCT05844657|OTHER|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
218839835|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
219476053|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
219476054|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
218839836|NCT01339819|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
218839837|NCT01339819|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
218839838|NCT01594723|DRUG|120 mg LY2784544|Administered orally
218839839|NCT05511610|PROCEDURE|Sevoflurane uptake and supply|"Phase sevo 1)~* Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~* M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels \>\> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels\>\> increase SEVOdel by 0.25-0.5%."
218839840|NCT05511610|PROCEDURE|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2\>5\>10 liters per minute (LPM), until the etSEVO% is \<0.2 MAC.
218839841|NCT05511610|PROCEDURE|Desflurane uptake and supply|"Phase desflu 1)~* Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~* M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels \>\> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels\>\> increase DESFLUdel by 0.25-0.5%."
218839842|NCT05511610|PROCEDURE|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% \< 0.2 MAC."
218839843|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
218839844|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
218839845|NCT04837885|DRUG|LUTATHERA® by intra-arterial hepatic (IAH) injection|One treatment dose of LUTATHERA® by IAH injection. The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
218839846|NCT04837885|PROCEDURE|Scan|Scans after completion of LUTATHERA® treatment injection
218839847|NCT06632587|PROCEDURE|Early cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.
219476055|NCT05981365|DRUG|Voxelotor|Drug drug interaction
219476056|NCT05981365|DRUG|Bupropion|Drug drug interaction
219476057|NCT05981365|DRUG|Repaglinide|Drug drug interaction
219476058|NCT05981365|DRUG|Flurbiprofen|Drug drug interaction
219476059|NCT05981365|DRUG|Omeprazole|Drug drug interaction
219476060|NCT05981365|DRUG|Midazolam|Drug drug interaction
219476061|NCT05981365|DRUG|Metformin|Drug drug interaction
219476062|NCT05981365|DRUG|Furosemide|Drug drug interaction
219587409|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
219587410|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
219587411|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
219587412|NCT02839915|DRUG|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
219587413|NCT02839915|OTHER|Placebo|Inactive placebo comparator
219587414|NCT06540963|DRUG|Tipifarnib|Tablet
219587415|NCT06540963|DRUG|Naxitamab|IV
219587416|NCT00901212|DEVICE|Device programming|6-month period
219587417|NCT06520592|BEHAVIORAL|With AR guided CPAP therapy|Participants will received AR training course to utilize the AR guided CPAP therapy
219587418|NCT04809168|OTHER|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
219587419|NCT03060434|DRUG|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
219587420|NCT03060434|DRUG|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
219587421|NCT06185023|BEHAVIORAL|Low-intensity physical exercise|As an active control intervention, a low-intensity non-aerobic exercise program was selected that mirrors more closely the standard-of-care physical therapy currently provided to stroke patients. This control intervention will offer the same level of participant involvement and type of exercises, but without the intensity element, i.e., it will not incorporate the cardiovascular and the strengthening components.
219587422|NCT06185023|BEHAVIORAL|High-intensity physical exercise|We have developed a new exercise program specifically designed for individuals with post-stroke aphasia, Aphasia Physical EXercise (APEX), to provide a safe, stroke- and aphasia-friendly physical exercise intervention to achieve optimal physical fitness and cognitive/language gains. This intervention, based on published research and clinical practice recommendations, is a high-intensity interval training full-body workout optimized to accommodate the range of motor abilities and general deconditioning observed in stroke survivors.
219017622|NCT02855034|OTHER|Blood samples|Blood samples for dosage: copeptin and protein S100B
218839848|NCT06632587|PROCEDURE|Standard-of-care cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
219476063|NCT05981365|DRUG|Rosuvastatin|Drug drug interaction
219476064|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
219476065|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
219476066|NCT05053581|OTHER|Survey|Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
219476067|NCT03113760|DRUG|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
219476068|NCT03113760|OTHER|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
219476069|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
219476070|NCT03927989|BEHAVIORAL|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
218839849|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
218839850|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
218839851|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
218839852|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
218839853|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
218839854|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
218839855|NCT04050072|OTHER|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
218839856|NCT04050072|OTHER|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
219449824|NCT05844657|OTHER|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
219449825|NCT05844657|OTHER|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
219449826|NCT05844657|OTHER|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
219587423|NCT06551441|BEHAVIORAL|High Intensity Interval Training (HIIT)|"The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed."
219587424|NCT04190069|BEHAVIORAL|Behavioral interventions/modifications|UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.
218839857|NCT04050072|OTHER|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
218839858|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
218839859|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
219449827|NCT05844657|OTHER|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
219449828|NCT05844657|OTHER|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
219587425|NCT04186923|OTHER|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
218839860|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
219449829|NCT03709940|DRUG|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
219449830|NCT06880393|BIOLOGICAL|anti-BCMA-CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg
219449831|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 5|The number of family skills training sessions administered: 5 sessions
218839861|NCT02270528|BEHAVIORAL|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
218839862|NCT02270528|BEHAVIORAL|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
218839863|NCT03815149|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
218839864|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
218839865|NCT00673231|DRUG|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
218839866|NCT00673231|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
219196709|NCT06654206|OTHER|Exercise|"Supervised strength exercise sessions: There will be two sessions per week, each lasting 50 minutes. Each session will consist of three distinct parts:~Warm-up: 10 minutes of global strength and aerobic exercises at 6/10 on the Rating Perceived Exertion (RPE) scale.~Strength training: 6 strength exercises targeting the major muscle groups, lasting 30 minutes. The initial load will be set at 70% of the estimated 1-RM (assessed in the first session and based on the individual patient). When the participant is able to complete 3 sets of 12 repetitions with the established weight in two consecutive sessions, the weight will be increased by 10%. The exercises will be performed in a circuit format with 30 seconds of rest between exercises and 90 seconds of rest between sets.~Cool-down/stretching: 10 minutes of a combination of breathing exercises and stretching for the major muscle groups.~Promotion of physical activity: Participants"
219196710|NCT06654206|OTHER|Home exercise|Participants will complete three weekly home training sessions that will not coincide with supervised training days. Each session will last 20 minutes, they will complete two sets of five exercises, with one minute of work and one minute of rest.
219449832|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: In-person|The mode of administration of family skills training sessions: in person or online
219449833|NCT06724406|BEHAVIORAL|Family Skills Training Content: Communication|The content of family skills training sessions administered focused on communication and conflict resolution : communication and conflict resolution
218839867|NCT00673231|DRUG|Placebo|Placebo
219196711|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
219196712|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
219449834|NCT06724406|BEHAVIORAL|Family Skills Training Content: Cohesion|The content of family skills training sessions administered focused on cohesion: cohesion or no cohesion
219449835|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 10|The number of family skills training sessions administered: 10 sessions
219449836|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: Online|The mode of administration of family skills training sessions: online
219449837|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Communication|The content of family skills training sessions administered focused on communication and conflict resolution : no communication and conflict resolution
219449838|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Cohesion|The content of family skills training sessions administered focused on cohesion: no cohesion
219449839|NCT03796871|DEVICE|Dermapol|Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
219476071|NCT03927989|OTHER|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
219476072|NCT05960461|BEHAVIORAL|FMF (Families Moving Forward) Connect Pro|"FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app"
218839868|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
218839869|NCT00673231|DRUG|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
218839870|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
218839871|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
219449840|NCT06885827|DIETARY_SUPPLEMENT|Vitamin B-mix|"Daily oral supplementation with:~Vitamin B6 (pyridoxine, 25 mg), 1 capsule Vitamin B9 (folic acid, 400 µg) + Vitamin B12 (cyanocobalamin, 1 mg), 2 capsules.~Choline (choline bitartrate, 500 mg), 2 capsules Administered alongside standard glaucoma care."
219449841|NCT06885827|OTHER|Standard Care|Usual glaucoma management (e.g., monitoring and/or IOP-lowering treatments) without additional supplementation.
219587426|NCT03537716|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
218839872|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
218839873|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
218839874|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
218839875|NCT01396590|DRUG|Perampanel|6 x 2 mg perampanel once per day
218839876|NCT01396590|DRUG|Perampanel|12 mg perampanel once per day
218839877|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
218839878|NCT03028415|DEVICE|AMPLEX|A bone graft substitute
218839879|NCT03028415|PROCEDURE|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
218839880|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
218839881|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
218839882|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
219196713|NCT04159012|DEVICE|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
219587427|NCT04428216|OTHER|Group RIB|In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219196714|NCT06756529|OTHER|hand massage|Hand massage was applied to the patients before surgery, on the morning of surgery and after surgery.
219196715|NCT06043531|OTHER|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
219587428|NCT02185716|DRUG|Levobupivacaine 0.25 %|
219587429|NCT02185716|DRUG|Levobupivacaine 0.5%|
219587430|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 90 days)|90 days
219587431|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 180 days)|180 days
219587432|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 270 days)|270 days
219587433|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 90 days)|90 days
219587434|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 180 days)|180 days
219587435|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 270 days)|270 days
218839883|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
218839884|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
218839885|NCT05838950|OTHER|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
218839886|NCT06649253|OTHER|Sampling bone tissue and blood|Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
218839887|NCT06031285|DRUG|Sintilimab|sintilimab (200 mg intravenous infusion), a bevacizumab biosimilar (15 mg/kg intravenous infusion), and TACE-HAIC (c-TACE, FOLFOX-based HAIC).
218839888|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
218839889|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
218839890|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
218839891|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
218839892|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
218839893|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
218839894|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
218839895|NCT02644369|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
218839896|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
219449842|NCT07045519|DEVICE|Local Vibration Therapy|Local vibration (LV) will be applied using the Vibrasens© device (Techno Concept, Mane, France). Vibrasens© is a non-invasive therapeutic mechanical vibrator used for transcutaneous vibratory stimulation in sensorimotor rehabilitation. The system includes one pilot unit, one manual vibrator (VB200), four flat skin contactors for tendon applications, four round skin contactors for surface applications, a power supply, a user manual, and a protocol guide.
219449843|NCT07045519|DEVICE|Sham Vibration|Participants will receive sham stimulation by placing the Vibrasens© device on the same area as the treatment group for 10 minutes, without activating the vibration function. They will be informed that they will only feel the contact of the device.
219449844|NCT06731075|DRUG|ORMD-0801 8 mg|1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
219449845|NCT06731075|OTHER|Placebo capsule|Placebo capsule
219449846|NCT06731075|DRUG|ORMD-0801 16 mg|2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
219449847|NCT06926530|OTHER|No intervention|Participants will complete a one-time 33-question survey. The survey is comprised of three sections: (1) Section A includes 12 questions related to demographic information, (2) Section B consists of 2 questions addressing treatment characteristics, \& (3) Section C contains 19 questions focusing on supplement usage.
219449848|NCT06925321|DRUG|Fosmanogepix IV infusion|Fosmanogepix will be administered IV
219449849|NCT06925321|DRUG|Standard of care antifungal therapy|Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines
219587436|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
219587437|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
218839897|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
218839898|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
218839899|NCT02091531|DRUG|MLN0128|
218839900|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
219449850|NCT06925321|DRUG|Fosmanogepix oral tablet|Fosmanogepix will be administered orally.
219449851|NCT06922656|DRUG|Dapagliflozin (DAPA)|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
219449852|NCT06922656|DRUG|Pioglitazone 45 mg|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
219449853|NCT06922656|DRUG|Placebo|Placebo
219476073|NCT05960461|BEHAVIORAL|ECHO (Extension of Community Healthcare Outcomes) implementation.|Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.
219587438|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
219587439|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 90 days)|90 days
219587440|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 180 days)|180 days
219587441|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 270 days)|270 days
219587442|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 90 days)|90 days
219587443|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 180 days)|180 days
218839901|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
218839902|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
218839903|NCT02082080|OTHER|Education|
218839904|NCT02082080|OTHER|Social support|
218839905|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
218839906|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
218839907|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
218839908|NCT05361720|DRUG|Cabozantinib|Given PO
219587444|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 270 days)|270 days
218839909|NCT05361720|BIOLOGICAL|Ipilimumab|Given IV
218839910|NCT05361720|BIOLOGICAL|Nivolumab|Given IV
218839911|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
218839912|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
218839913|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
218839914|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
219587445|NCT03450174|DIETARY_SUPPLEMENT|Placebo|In control group, participants will receive only a placebo product
219449854|NCT07041723|BEHAVIORAL|Visual-acoustic biofeedback for Sibilants|Participants will view a real-time FFT spectrum and will be cued to match a visual target for /s/ where the spectral energy is concentrated to the right side of the display, primarily in the 5000-10,000 Hz region of the spectrum. Practice will occur in blocks of 10 consecutive trials on the same item (e.g., 10 /sa/), after which a new item will be addressed (e.g., 10 /se/). Within each block, the clinician will provide qualitative (knowledge of performance) feedback as prompted by the research team's custom open-source software, Challenge Point Program (CPP). The CPP software prompts clinician actions such as delivery of knowledge of performance (KP) feedback. Following each block of ten trials, the software automatically tallies the scores entered by the clinician and uses the summed scores to make adaptive changes in practice difficulty.
219449855|NCT06732362|OTHER|Different DPN ratings|According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
218839915|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
218839916|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
218839917|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
219587446|NCT03450174|BEHAVIORAL|Formative messgaes|In this group, participants will only receive daily formative messages
219587447|NCT03450174|DIETARY_SUPPLEMENT|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
219587448|NCT03450174|COMBINATION_PRODUCT|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
219587449|NCT04061031|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
219587450|NCT04061031|BEHAVIORAL|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
219587451|NCT03283319|BIOLOGICAL|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
219587452|NCT03283319|BIOLOGICAL|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
219587453|NCT03283319|BIOLOGICAL|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
219587454|NCT03283319|BIOLOGICAL|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
219587455|NCT03283319|BIOLOGICAL|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
219587456|NCT05261295|DIAGNOSTIC_TEST|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
219587457|NCT05261295|DIAGNOSTIC_TEST|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
219587458|NCT05210478|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
219587459|NCT03958565|BIOLOGICAL|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
219587460|NCT03958565|DRUG|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
218839918|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
218839919|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
218839920|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
218839921|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
218839922|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
218839923|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
218839924|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
218839925|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
218839926|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
218839927|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
219449856|NCT06724913|OTHER|specialized food product based on ice cream|Day 1: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 3: standard ice cream (12% fat)
218839928|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
218839929|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
218839930|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
219449857|NCT06724913|OTHER|specialized food product based on ice cream 2|Day 1: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: standard ice cream (12% fat)
219449858|NCT06724913|OTHER|specialized food product based on ice cream 3|Day 1: standard ice cream (12% fat) Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin
218839931|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
218839932|NCT01328028|OTHER|Data collection|Log sheet
219017630|NCT06801574|OTHER|Erector Spinae Plane Block|After the surgical team places the final suture, while the patient is in the prone position, an ultrasound-guided ESP (Erector Spinae Plane) block will be administered bilaterally using a block needle. A total of 40 mL of 0.25% bupivacaine will be injected.
219017631|NCT06801574|OTHER|infiltration|Before the surgical team closes the incision, local infiltration with 40 mL of 0.25% bupivacaine will be performed at the surgical site.
219017633|NCT06676579|DRUG|Avacopan|Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
219017634|NCT06676579|DRUG|Prednisone|0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
219017635|NCT06676579|DRUG|Methylprednisolone (drug)|Methylprednisolone 1g intravenous on day +1
219017636|NCT06676579|DRUG|Prednisolone|Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
219476074|NCT05960461|BEHAVIORAL|Self-Directed Learning implementation.|Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
219476075|NCT04632485|DEVICE|Ultrasound imaging|Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.
219476076|NCT04632485|DEVICE|Magnetic Resonance Imaging (MRI)|Head and Neck MRI exam with contrast
219449859|NCT06733506|DRUG|Chlorhexidine gluconate|"Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml)."
218839933|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
218839934|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
218839935|NCT03349138|DEVICE|Conventional Therapy|
218839936|NCT03349138|DEVICE|Robotic Glove|
218839937|NCT03349138|DEVICE|Electrical Stimulation|
218839938|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
219587461|NCT03958565|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
218839939|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
218839940|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
218839941|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
218839942|NCT00136695|DRUG|anastrozole|1 mg QD
218839943|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
218839944|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
218839945|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
218839946|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
218839947|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
218839948|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
219196716|NCT06493994|OTHER|transaxillary (TAX) transcatheter aortic valve replacement|Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
219196717|NCT02326974|DRUG|T-DM1|Neoadjuvant treatment is for a total of 18 weeks.
219196718|NCT02326974|DRUG|Pertuzumab|Neoadjuvant treatment is for a total of 18 weeks.
219587462|NCT04505748|DEVICE|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
219587463|NCT06370130|DRUG|Esketamine 0.2mg/kg|"Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
219196719|NCT02326974|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
218839949|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
218839950|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
219449860|NCT06733506|DRUG|Isopropyl Alcohol 70% Topical Application Solution|Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
218839951|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
218839952|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
218839953|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
218839954|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
218839955|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
218839956|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
218839957|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
218839958|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
219196720|NCT04370431|DRUG|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
219196721|NCT04370431|DRUG|Placebo|Placebo control for Part A of the study
219196722|NCT04370431|DRUG|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
219196723|NCT04370431|DRUG|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
219449861|NCT06733506|BEHAVIORAL|Skin Prep Before Injecting Recreational/Street Drugs|During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
219449862|NCT06738485|BIOLOGICAL|Recombinant single-chain factor VIII (rVIII-SingleChain)|Lyophilized powder for solution for intravenous injection
219449863|NCT07048808|COMBINATION_PRODUCT|XC001|XC001 administered by percutaneous catheter delivery using the Extroducer® Infusion Catheter System.
219449864|NCT07048808|COMBINATION_PRODUCT|Sham (No Treatment)|Subjects randomized to the sham catheterization procedure group will receive the same procedure as the treatment group (with introduction of an iliofemoral or radial sheath, positioning of the pigtail catheter in the left ventricle, generation of ventriculograms, and mimicking of the injection procedure by the interventional team following a Cath Lab script), except they will not have the delivery catheter inserted and will not receive any endocardial injections
219449865|NCT07050589|BEHAVIORAL|Exercise and art|Weekly SMARTfit dual-task exergaming and group art-making
219476077|NCT04632485|OTHER|Neurocognitive testing|Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills
219196724|NCT04370431|DRUG|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
219196725|NCT04370431|DRUG|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
219476078|NCT04632485|DEVICE|Transcranial Doppler (TCD)|Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes
218839959|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
218839960|NCT02015481|DRUG|Cabaletta|
218839961|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
218839962|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
218839963|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
218839964|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
219449866|NCT07047300|DIAGNOSTIC_TEST|Record EMG maximum amplitude from bilateral erector spinae, rectus femoris, and medial and lateral gastrocnemius muscles.|"Conduct measurements under two conditions:~Condition 1: Standing with standardized flat shoes. Perform three trials for each participant. Calculate and record the mean as baseline data. Condition 2: Standing with a standardized heel lift insole inside the flat shoes.~Conduct three trials. Record the mean for comparative analysis."
219449867|NCT07047300|DIAGNOSTIC_TEST|Photograph participants from anterior and lateral views to assess knee valgus angle and lumbosacral angle.|"Capture two sets of photographs for each participant:~Set 1: Wearing flat shoes. Set 2: Wearing the heel lift insole inside the flat shoes. Compare knee valgus angle and lumbosacral angle under both conditions. Ensure consistency and reliability by following standardized protocols and performing repeated measurements.~Analyze the effects of heel lift insoles on muscle activity and postural alignment."
219449868|NCT07044388|BEHAVIORAL|Coping with asthma through life management program|Participants will complete surveys, learn stress coping strategies, receive asthma education information, and obtain access local community financial resources.
219449869|NCT07044388|BEHAVIORAL|Waitlist Control (CALM)|Participants in this group will complete surveys but will not receive the CALM intervention. Upon completing the study after 12 weeks they will be able to complete the program if they would like the resources/materials to learn healthy stress coping strategies, asthma health education, and access to financial resources.
219449870|NCT07048262|BIOLOGICAL|CSL787|CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of \>= 6 months but not exceeding 12 months.
219449871|NCT07048262|DRUG|Placebo|Participants will receive a matching volume of placebo QD over a period of \>= 6 months but not exceeding 12 months.
219449872|NCT07048262|DEVICE|Nebulizer|The nebulizer is a CE-marked device.
219449873|NCT06745882|DRUG|Cisplatin|Given on day 1 of every 21-day cycle.
219449874|NCT06745882|DRUG|Carboplatin|Given on day 1 of every 21-day cycle.
219449875|NCT06745882|DRUG|Pemetrexed|Given on day 1 of every 21-day cycle.
219449876|NCT06745882|DRUG|Pembrolizumab|Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.
219449877|NCT06745882|DRUG|Abraxane|Given on days 1, 8, and 15 of each 21-day cycle.
219449878|NCT06745882|DRUG|Paclitaxel|Given on day 1 of every 21-day cycle.
219449879|NCT04737707|OTHER|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
218839965|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
218839966|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
218839967|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
218839968|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
219196726|NCT04370431|DRUG|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
218839969|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
218839970|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
219196727|NCT06788821|DIAGNOSTIC_TEST|Description of the trend of major thyroid ultrasound biometric parameters|Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.
219196728|NCT04186650|BIOLOGICAL|COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
219449880|NCT07052552|OTHER|osteopathic manipulative tratment only|focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome
219449881|NCT07052552|OTHER|ujjayi pranayama and osteopathic manipulative treatment|"Ujjayi pranayama, often called ocean breath, can be a helpful practice for individuals with Upper Cross Syndrome (UCS) by promoting relaxation and improving breath control. While not a direct cure, it can alleviate some symptoms and improve overall posture and body awareness.~Osteopathic manipulative treatment focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome"
219449882|NCT02466204|DRUG|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
219449883|NCT02466204|DRUG|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
219449884|NCT07054684|DRUG|BHV-1400|BHV-1400 is delivered subcutaneously (SC)
219476079|NCT04632485|DEVICE|Pulse Wave Doppler|Pulse wave Doppler will be used to acquire a Doppler waveform in the right common carotid artery and the right femoral artery
219449885|NCT06853210|DEVICE|Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
219449886|NCT06853210|DEVICE|Human Amnion/Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
219449887|NCT06860815|PROCEDURE|Biopsy|Undergo tumor biopsy
219449888|NCT06860815|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219449889|NCT06860815|BIOLOGICAL|Cemiplimab|Given IV
219449890|NCT06860815|PROCEDURE|Computed Tomography|Undergo CT
219449891|NCT06860815|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219449892|NCT06860815|RADIATION|Transarterial Radioembolization|Undergo TARE
219449893|NCT06860815|RADIATION|Yttrium Y 90 Resin Microspheres|Given intratumorally
219587464|NCT06370130|DRUG|Esketamine 0.3mg/kg|"Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
219587465|NCT02290301|DRUG|gemigliptin|
219587466|NCT00721630|DRUG|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
219587467|NCT00224926|PROCEDURE|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
219196729|NCT06819774|DRUG|Cetirizine Hydrochloride Injection|The subjects received a single dose of 1-2 ml of the injection of cetirizine hydrochloride (administered by intravenous push) and a 1 ml dose of the injection simulant of diphenhydramine hydrochloride (administered by deep intramuscular injection), both as a simulation of a single administration.
218839971|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
218839972|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
219449894|NCT07060456|DRUG|HRS953|HRS953-low dose
219449895|NCT07060456|DRUG|HRS953|HRS953-high dose
219449896|NCT07060456|DRUG|Placebo|Placebo
219449897|NCT07061691|DEVICE|WIM Robotic Exoskeleton|Wearable hip-powered exoskeleton
219449898|NCT06898450|DRUG|NDI-219216|NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
219449899|NCT06784791|DRUG|Amivantamab Intravenous|Stage 1: Pre-operative amivantamab monotherapy Stage 2: Pre-operative amivantamab treatment plus chemotherapy (carboplatin/pemetrexed)
219449900|NCT06784791|DRUG|Carboplatin/Pemetrexed|Stage 2: Pre-operative amivantamab plus chemotherapy (carboplatin/pemetrexed)
219449901|NCT02978638|DEVICE|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
219449902|NCT07063069|OTHER|Abdominal ultrasound|All patients included will have an abdominal ultrasound scan to mesure anterior/posterior external diameter of gastric antrum upstream of pyloru and external diameter upper/lower of gastric antrum upstream of pylorus
219449903|NCT05977322|DRUG|68Ga-FF58|Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection
219196730|NCT06819774|DRUG|Diphenhydramine Hydrochloride Injection|The subjects received 1 ml of the injection of Diphenhydramine Hydrochloride (for deep intramuscular injection) and 1 ml of the injection of Simulated Cetirizine Hydrochloride (administered by rapid intravenous injection over 1 to 2 minutes), each as a single dose.
219449904|NCT05977322|DRUG|177Lu-FF58|Solution for injection/infusion
219449905|NCT02659098|DRUG|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
219449906|NCT02659098|DEVICE|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
219476080|NCT06237855|OTHER|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
219476081|NCT06256900|OTHER|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
219476082|NCT06256900|OTHER|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
219476083|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
219476084|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
219476085|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
219476086|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
219476087|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
219476088|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
219476089|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
219476090|NCT00007735|DRUG|Doxycycline (200mg/day) or Placebo|
219476091|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
219476092|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
218839973|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
218839974|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
218839975|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
218839976|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
218839977|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
218839978|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
219449907|NCT04363944|DEVICE|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
218839979|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
218839980|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
218839981|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
218839982|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
218839983|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
219449908|NCT06823193|BEHAVIORAL|Mental Time Travel task|"A psychophysical task (D'Angelo et al., 2023) will be adopted. In this task, a projection in time will be induced by faces of different ages. Face stimuli will be presented with a short sentence describing a particular life event, commonly occurring around 60. Participants will perform a two-alternative forced-choice task under two experimental conditions. In the past projection condition, they will indicate whether it is likely or unlikely that the person of the face shown could have experienced the indicated event 10 years earlier. In the future projection, they will indicate whether it is likely or unlikely that the person depicted will experience the indicated event in 10 years."
219587468|NCT05960812|PROCEDURE|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
218839984|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
218839985|NCT02216916|DRUG|HM781-36B|
219196731|NCT06820931|DRUG|Xuandi Ziyin Mixture|Treatment is given only with the hospital preparation 'Xuandi Ziyin Mixture' with a dosage of 30ml per administration three times a day.
218839986|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
218839987|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
218839988|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
218839989|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
219196732|NCT06817317|OTHER|Model Based Training|experimental group
219196733|NCT06817317|OTHER|Peer and Self-Learning Group|experimental group
219196734|NCT06819241|BEHAVIORAL|AI chatbot support|Integrating the practice of self-monitoring of HBP with the use of AI chatbot responses. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
218860006|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
218860007|NCT00018382|DRUG|rosiglitazone|
218860008|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
218860009|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
218839990|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
219449909|NCT06823193|BEHAVIORAL|Age Estimation control task|In this task participants will estimate the age of the faces adopted as stimuli.
219449910|NCT06823193|BEHAVIORAL|Lifeline task|In this task participants will be instructed to associated each event with the age at which they believe it typically occurred.
219449911|NCT06748144|DRUG|Intraosseous Vancomycin|The intervention is specific to the method of administration that will be used when giving the dose of antibiotic vancomycin which is done to prevent infection following surgery.
219449912|NCT06748144|DRUG|Intravenous Vancomycin|This is the standard method of giving the antibiotic vancomycin to patients undergoing surgery across many specialties in order to prevent infection.
219449913|NCT07085975|DRUG|Adenosine 5'-triphosphate|Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
219449914|NCT00353327|PROCEDURE|Plasma infusion|
219449915|NCT06466876|BEHAVIORAL|retrieval-based word learning|Word learning intervention that compares two strategies for teaching novel words
219449916|NCT07085468|DRUG|LY3549492|Administered orally
219449917|NCT07085468|DRUG|Placebo|Administered orally
219449918|NCT07094087|BIOLOGICAL|BE1116|A single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.
219449919|NCT07094087|BIOLOGICAL|FFP|A single dose of FFP will be administered as investigational product (IP) by IV infusion intraoperatively.
219449920|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
219449921|NCT03083106|DEVICE|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
219449922|NCT06910813|GENETIC|DFT383|DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.
219587469|NCT05960812|PROCEDURE|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
219449923|NCT07137611|BEHAVIORAL|Low Exercise|• Low-Intensity Continuous Training (LICT): Participants will run continuously for 24 minutes at 50-60% of their MAS without breaks.
218860010|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
218860011|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
219449924|NCT07137611|BEHAVIORAL|Moderate-Intensity Exercise|Moderate-Intensity Continuous Training (MICT): Participants will run at a speed corresponding to 70-80% of their MAS. The protocol consists of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants performed light jogging. This pattern totaled 24 minutes of exercise.
219449925|NCT07137611|BEHAVIORAL|HIIT Exercise|High-Intensity Interval Training (HIIT): Participants will run at 110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they will rest passively for 15 seconds and returned to their starting point. This will be repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets will be completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
219587470|NCT03186781|BIOLOGICAL|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
218860012|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
218860013|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
218860014|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
218860015|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
218839991|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
219196735|NCT06819241|BEHAVIORAL|telemonitoring and case management|Combining self-monitoring of HBP with telemonitoring and case management. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
219449926|NCT07137741|BEHAVIORAL|FICare nursing method guided by Swanson's caring theory|"encompasses the following five dimensions: Understanding: A neonatologist provided a comprehensive explanation regarding the developmental progress of premature infants, potential complications, and essential aspects of nursing care to ensure the family gained a thorough understanding of the care requirements for premature infants.~Accompaniment: Two nursing guides provided essential support to parents of newborns in the NICU, helping to alleviate the anxiety and sense of helplessness among family members and fostering a relationship of trust between the medical staff and the families.~Help: A neonatal nurse played a guiding role in facilitating parental involvement in the daily care of premature infants, which encompassed feeding guidance, introduction of complementary foods, skin care, and related aspects.~Empowerment: A psychological counselor was assigned to provide psychological counseling and guidance to new parents, offering appropriate emotional support and assisting them in ac"
219449927|NCT07088718|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
219449928|NCT07088718|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the reference.
219587471|NCT03186781|BIOLOGICAL|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
219587472|NCT00792935|DRUG|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
219587473|NCT00792935|DRUG|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
219587474|NCT00792935|DRUG|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
218839992|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
219587475|NCT04663295|DEVICE|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
219587476|NCT03925350|DRUG|Niraparib|300 mg PO daily
219587477|NCT03168581|DRUG|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
219587478|NCT04125849|PROCEDURE|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
219449929|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
219587479|NCT04125849|PROCEDURE|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
219449930|NCT06794554|DRUG|Rezafungin Acetate|IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
219587480|NCT04953936|DIETARY_SUPPLEMENT|HMB-enriched Nutritional Supplements|The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
219587481|NCT04953936|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
219587482|NCT04953936|BEHAVIORAL|Caloric Restrition Diet|Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
219587483|NCT03335449|OTHER|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
219587484|NCT05783830|DRUG|ACD856|IV injection 100 mcg
219587485|NCT05930457|DRUG|2.5-3.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
218839993|NCT03500016|OTHER|High intensity interval training|See under arm description.
218839994|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
218839995|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
218839996|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
219449931|NCT07070323|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
218839997|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
218839998|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
218839999|NCT05073484|DRUG|BAT6021|Ⅳ infusions
218840000|NCT05073484|DRUG|BAT1308|Ⅳ infusions
218840001|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
219449932|NCT07070323|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
219449933|NCT07070323|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
219449934|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
219449935|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
218840002|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
218840003|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
218840004|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
218840005|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
218840006|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
218840007|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
218840008|NCT02400606|OTHER|Solving VP cases|See above
218840009|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
218840010|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
218840011|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
218840012|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
218840013|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
218840014|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
218840015|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
218840016|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
218860016|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
219449936|NCT06481228|DRUG|Olverembatinib|TKI
219449937|NCT06831734|DRUG|Concizumab|Participants will be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Alhemo is made at the physician's discretion before and independently from this study.
219587486|NCT05930457|DRUG|3.5-4.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.
219587487|NCT05930457|DRUG|4.5-5.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
219587488|NCT06634342|DIAGNOSTIC_TEST|HCV RNA Rapid testing|Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
218860017|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
219587489|NCT02101593|DRUG|ADI-PEG 20|
219587490|NCT02051400|DEVICE|the McGrath® MAC video laryngoscope|
219587491|NCT02051400|DEVICE|the GlidesScope® Ranger video laryngoscope|
219587492|NCT02051400|DEVICE|the Macintosh laryngoscope|
219449938|NCT07099274|DRUG|lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib|lparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, q3w; Lenvatinib: 8 mg once daily for patients weighing \<60 kg, or 12 mg once daily for those weighing ≥60 kg, administered orally, continuous daily dosing； TACE: Administered 4-6 times, using a combination of anthracyclines, lipiodol, and microspheres. The procedure should be performed within one week before or after QL1706 administration.
219449939|NCT01394211|DRUG|anastrozole|Given PO
219449940|NCT01394211|DRUG|pazopanib hydrochloride|Given PO
219449941|NCT01394211|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
219449942|NCT07096063|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
219449943|NCT07096063|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the comparator.
219449944|NCT07096063|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure/comparator.
219449945|NCT07096063|DRUG|Sitagliptin|New use of sitagliptin dispensing claim is used as the comparator.
219449946|NCT07102446|OTHER|Opioid Stewardship Program|The Opioid Stewardship Program (OSP) includes pain and functional assessments, opioid prescription review and coordination, patient education, and counseling provided by trained pharmacists.
219449947|NCT07101627|DRUG|Hetrombopag Tablets|"Stage 1: After screening and enrollment, patients will receive oral administration of hetrombopag, 7.5 mg/day, for 14 days from the first day after the end of chemotherapy in this cycle.~Stage 2: Patients who met the inclusion criteria were randomized 1:1 to the experimental group and the control group after enrollment. Patients in the experimental group began to orally take hetrombopag 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle; patients in the control group began to orally take hetrombopag simulated tablets 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle. Randomization was stratified by concomitant immunotherapy (yes versus no) and chemotherapy with gemcitabine plus platinum (yes versus no)."
219587493|NCT01746459|OTHER|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
218840017|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
218860018|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
219449948|NCT07101822|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
219449949|NCT07101796|DEVICE|continous positive airway pressure (CPAP)|using CPAP to treat OSA
219449950|NCT07101913|BIOLOGICAL|Incidence of acute kidney injury|"* Creatinine measurement before lymphodepletion chemotherapy, before CAR-T cells injection (day 0) and at day 1, day 3, day 5, day 7, day 10, day 14, day 21 and day 28.~* AKI according to 2012 KDIGO."
219449951|NCT07101913|OTHER|Describe risk factors in AKI occurrence.|"Comparison of caracteristics between participants with AKI and participants without AKI :~* Baseline caracteristics of participants : age, gender, BMI (Body mass index), medical history…~* Caracteristics of hematology disease : severity of lymphoma, previous treatments (chemotherapy, autologous/allogenic stem cell transplant), type of CAR-T cells (axi-cel, tisa-cel)~* Other adverse affects : cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS)~* Use of nephrotoxic medications Informations found in medical field."
219449952|NCT07101913|OTHER|Focus on patient with chronic kidney disease at baseline|Looking at the subgroup with chronic kidney disease at baseline : are the outcomes different in this population ? Efficacity of CAR-T ? More adverse effects ?
219587494|NCT01746459|OTHER|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
219587495|NCT02977312|DRUG|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
219587496|NCT04096755|DIAGNOSTIC_TEST|Procedure|serum and urine samples will be taken for analysis
219587497|NCT04914221|DRUG|JLP-2002|administration of JLP-2002
219587498|NCT04914221|DRUG|Comparator|administration of comparator
219587499|NCT04395014|DIAGNOSTIC_TEST|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
219587500|NCT00670163|BEHAVIORAL|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
219449953|NCT07101913|OTHER|Long term evolution after treatment by CAR-T cells|Creatinine measurement 1 year after CAR-T treatment. Informations found in medical field.
219449954|NCT07100899|OTHER|Dual task training|Dual motor task training for 30 minutes. The dual motor training was divided into two phases. The first part involved a single task condition in which the stroke patient was instructed to stand up from a seated position at a self-selected speed without the use of upper limb assistance. Cognitive and physical tasks, is the second part of training. In addition to a 30-minute selected physiotherapy program.
218840018|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
218840019|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
218840020|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
218840021|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
218840022|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
219449955|NCT07100899|OTHER|Task-specific training|Began with a highchair before switching to a low one. In addition to a 30-minute selected physiotherapy program.
219449956|NCT07100899|OTHER|Selected physiotherapy program|Consisting of trunk control, trunk stabilization, balance training and lower extremity strengthening exercises (primarily for the hip adductors and abductors) for 60 minutes.
219449957|NCT07100262|OTHER|Effortful swallow exercise|"The participants will be practiced effortful swallow exercises as follows:~When you are ready to swallow your saliva, squeeze your tongue against the roof of your mouth.~B) As you swallow squeeze all the muscles in your throat. Imagine you are trying to swallow a large tablet or a golf ball.~C) If it has been recommended by your speech and language therapist, this exercise may be repeated when eating and drinking.~Frequency of exercise:~Exercises will be two 30-minutes sessions of effortful swallow practice daily, 5 days/week.~For every patient: 4 sets (1 set = 8-12 repetitions) 5 days/week, for 18 weeks."
219587501|NCT00670163|BEHAVIORAL|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
218840023|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
218840024|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
218840025|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
218840026|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
219196736|NCT06819917|OTHER|Identification of liver fibrosis biomarkers|"Patients will be recruited in the study using 2 different approaches. The first is patients who are referred to clinical centers as part of an existing assessment where a decision to perform a liver biopsy has been made (routine biopsy). This decision can be based on standard liver function tests AST, ALT, FIB-4 (performed up to 8 months before biopsy), fibroscan (performed up to 6 months before biopsy) or other factors.~In addition, patients F0-F2 who underwent a biopsy within the last 6 months but at least 1 month ago, can be recalled to join the study. If patients agree to participate in the study, they will be recalled to the site for a blood draw and ultrasound scan."
219449958|NCT07100262|DEVICE|Pulsed electromagnetic therapy|"The participants will receive pulsed electromagnetic therapy as the following:~Position of patient: supine lying position with head supported by pillow. Sleeve of device: above anterior neck area.~Parameters of application of device: according to programs for sarcopenia and muscular pain as the following:~Power: 30 GAUSS. Frequency: in first 6weeks: 5Hz - second 6weeks: 10Hz - last 6weeks: 15Hz. Time of session: 30 min. Sessions frequency: 3 sessions per week. Time of treatment course: 18 weeks."
219449959|NCT07100626|DEVICE|BlueCheck|Caries Detection and Monitoring
219449960|NCT07101991|OTHER|Standard monitoring|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
219449961|NCT07101991|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
219449962|NCT07101315|PROCEDURE|Laparoscopic Cholecystectomy|Standard four-port laparoscopic cholecystectomy was performed by a specialist or resident surgeon.
219449963|NCT07101497|DRUG|BN104 monotherapy|BN104 will be started at 200 mg or 300mg, to a target dose of 400mg, twice daily, orally, 28 days a cycle, for a total of 24 to 36 cycles . When used in combination with posaconazoles and voriconazole, the dose of BN104 should be reduced by 50%.
219449964|NCT07100509|OTHER|Major Vascular Injury During Elective Thoracic Surgery|This exposure refers to patients who experienced major vascular injuries during elective thoracic surgery. Injuries involved central vessels such as the subclavian artery, brachiocephalic vein, superior vena cava, and innominate vein. No experimental intervention was applied. The study retrospectively evaluated the surgical management, transfusion requirements, preoperative planning, and clinical outcomes associated with these intraoperative events.
219449965|NCT07101549|DRUG|R-Star001|"Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (R-Star001).~The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase."
219449966|NCT00024544|DRUG|anti-IL-4 monoclonal antibody (pascolizumab)|
219449967|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
219449968|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
218840027|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
218840028|NCT02720055|OTHER|Psychological workbook|
218840029|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
219196737|NCT06820541|DEVICE|Double plastic pigtail stent plus fully covered self-expandable metal stent|After contrast injection, the cystic duct orifice will be detected. Using a sphincterotome, a 0.035-inch hydrophilic angled guidewire will be negotiated into the gallbladder. Dilation of the cystic duct will be performed using standard devices designed for biliary intervention, including pneumatic dilators or dilation progressive catheters. After dilation, a 7Fr plastic, double pigtail stent, length of 12 or 15 cm, will be deployed across the papilla. Finally, a fully-covered self-expandable metal stent will be placed alongside the gallbladder drainage for biliary drainage.
219449969|NCT05157685|DRUG|Azithromycin Oral Tablet|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
219449970|NCT05157685|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
219449971|NCT03871075|DEVICE|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
219196738|NCT06820541|DEVICE|Fully covered self-expandable metal stent|After biliary cannulation, a fully covered self-expandable metal stent will be placed for biliary drainage
219449972|NCT03871075|BEHAVIORAL|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
219449973|NCT03871075|DEVICE|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
219449974|NCT03871075|BEHAVIORAL|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
219449975|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
219449976|NCT06481150|OTHER|Placebo|Placebo
219449977|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
219587502|NCT00670163|BEHAVIORAL|Standard Care|Standard care will consist of usual care for STIs.
219587503|NCT05200546|DIAGNOSTIC_TEST|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
219587504|NCT05267743|DRUG|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
218860019|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
219449978|NCT06397131|COMBINATION_PRODUCT|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.
219449979|NCT00050570|BEHAVIORAL|Web-based intervention to reduce eating disorder risk factors|
219449980|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
219587505|NCT05267743|DRUG|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
218840030|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
219196739|NCT06820801|OTHER|pelvic floor muscles strength and function|using pressure perineometer to evaluate pelvic floor muscles strength and using PFDI to evaluate pelvic floor muscles function
218840032|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
219449981|NCT02890940|BEHAVIORAL|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
219449982|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
219449983|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
219449984|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
219449985|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
219449986|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
218840033|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
219449987|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
219587506|NCT05193643|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
218840034|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
218840035|NCT05083208|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
219587507|NCT05076695|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
219587508|NCT05076695|DRUG|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
219587509|NCT05076695|DRUG|pyrotinib|Pyrotinib 400mg, PO daily, continuously
218840036|NCT05083208|DRUG|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
218840037|NCT06981390|DRUG|Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy
219196740|NCT02561611|BEHAVIORAL|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
219449988|NCT06097299|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219449989|NCT06097299|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219449990|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
219449991|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
219587510|NCT05076695|DRUG|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
219587511|NCT02080169|DRUG|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
219587512|NCT02080169|DRUG|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
219587513|NCT02080169|DRUG|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
218840038|NCT06981390|DRUG|Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy
218840039|NCT06981390|DRUG|Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy
218840040|NCT06981143|BEHAVIORAL|Quantitative study|A validated questionnaire will be used to investigate the knowledge and perceptions of physical activity and exercise of specialists and residents in Pathological Oncology
219449992|NCT03898752|DIETARY_SUPPLEMENT|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
219449993|NCT06801639|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
218840041|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
218840042|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
219449994|NCT06801639|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
219449995|NCT05618808|DRUG|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
219449996|NCT05618808|DRUG|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
219449997|NCT05618808|DRUG|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
219449998|NCT03874052|DRUG|Azacitidine|Given IV or SC
218840043|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
218840044|NCT06602310|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application. Telematic non-face-to-face preoperative assessment.
218840045|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
218840046|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
219449999|NCT03874052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219450000|NCT03874052|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
218840047|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
218840048|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
218840049|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
218840050|NCT06652412|DRUG|Sintilimab|200 mg q3w
218840051|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
218840052|NCT06652412|DRUG|Raltitrexed|Raltitrexed
219450001|NCT03874052|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219450002|NCT03874052|PROCEDURE|Echocardiography Test|Undergo ECHO
219450003|NCT03874052|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
219450004|NCT03874052|OTHER|Questionnaire Administration|Ancillary studies
219450005|NCT03874052|DRUG|Ruxolitinib|Given PO
219450006|NCT03874052|DRUG|Venetoclax|Given PO
219450007|NCT06799286|DRUG|BMS-986489|Specified dose on specified days
219450008|NCT04228276|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
219450009|NCT06431126|OTHER|Nature and animal-assisted activities|Supervised activities on a farm, 2 half day/week for 12 weeks
218840053|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
218840054|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
218840055|NCT05517486|DRUG|GTX-101|Bupivacaine HCl metered spray
218840056|NCT05517486|DRUG|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
218840057|NCT03226847|PROCEDURE|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
218840058|NCT00249587|DRUG|Methadone|dosed to effect, every six hours
218840059|NCT00395499|DRUG|Risperidone|
218840060|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
218840061|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
219196741|NCT06816355|PROCEDURE|Orchiectomy|CPT:54520
219196742|NCT06816355|PROCEDURE|Hysterectomy|CPT:1013911
219450010|NCT04526938|DEVICE|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
219450011|NCT03527472|DRUG|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
219450012|NCT03527472|DRUG|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
219450013|NCT06803771|DEVICE|Avantect Pancreatic Cancer Test|Avantect test
219450014|NCT03825536|DRUG|Oral Methamphetamine|An initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
218840062|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
218840063|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
219450015|NCT03825536|OTHER|Placebo oral capsule|One placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
219587514|NCT06032650|OTHER|Calisthenics exercise and High intensity interval training|"1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
219587515|NCT05253963|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
218840064|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
218840065|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
218840066|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
218840067|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
218840068|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
218840069|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
218860020|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
219196743|NCT06816355|PROCEDURE|Augmentation mammoplasty|CPT:19325
219450016|NCT02498600|BIOLOGICAL|Ipilimumab|Given IV
219450017|NCT02498600|BIOLOGICAL|Nivolumab|Given IV
219450018|NCT05602363|DRUG|Docirbrutinib|oral tablet, twice daily
219450019|NCT05298774|DEVICE|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
219450020|NCT01492036|OTHER|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
219450021|NCT01492036|BEHAVIORAL|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
219450022|NCT04269239|BEHAVIORAL|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
218840070|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1\. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
219450023|NCT04269239|BEHAVIORAL|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
219450024|NCT06563596|DRUG|Zanubrutinib|Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
219450025|NCT06563596|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
219450026|NCT06563596|DRUG|Epcoritamab|Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
219450027|NCT06285071|DRUG|Concizumab|Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
219587516|NCT06484842|OTHER|The combined psychological resilience and self-efficacy intervention|Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
218840071|NCT05894889|BIOLOGICAL|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
218840072|NCT06290505|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
218860021|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
219450028|NCT05999435|DRUG|LAU-7b for 3 cycles|Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.
219450029|NCT05999435|DRUG|LAU-7b for 1 cycle, then placebo|One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.
219450030|NCT05999435|OTHER|Placebo for 3 cycles|Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of14 days
219450031|NCT05085275|DRUG|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
218840073|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
218840074|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
218840075|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~\- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
218840076|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
219450032|NCT05085275|DRUG|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
219450033|NCT03713151|OTHER|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
218840077|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
218840078|NCT05909176|BEHAVIORAL|GYN Residency Training|The combined care model will be implemented and during months 5-14.
218840079|NCT05909176|BEHAVIORAL|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
218840080|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
219450034|NCT01081262|BIOLOGICAL|Bevacizumab|Given IV
219450035|NCT01081262|DRUG|Capecitabine|Given PO
219450036|NCT01081262|DRUG|Carboplatin|Given IV
219450037|NCT01081262|OTHER|Laboratory Biomarker Analysis|Correlative studies
219450038|NCT01081262|DRUG|Oxaliplatin|Given IV
219450039|NCT01081262|DRUG|Paclitaxel|Given IV
219450040|NCT01081262|OTHER|Quality-of-Life Assessment|Ancillary studies
219450041|NCT04331522|DIAGNOSTIC_TEST|Oral provocation test|Titrated provocation with allergen
219450042|NCT06575387|PROCEDURE|Partogram|to evaluate the utility of partogram in management and progress of active labor in Primigravidae.
219450043|NCT04428580|OTHER|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
219450044|NCT04428580|OTHER|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
219450045|NCT06083077|OTHER|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
219450046|NCT05302986|DRUG|Tranexamic acid injection|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes during the shoulder surgery.
218840081|NCT06868641|BEHAVIORAL|TAIL-PrEP|The TAIL-PrEP intervention is comprised of two components: (1) monthly cab-LA monitoring with specimens self-collected by patient and mailed to a lab for processing; and (2) monthly HIV prevention coaching with personalized cab-LA feedback.
218840082|NCT01526941|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
218840083|NCT01526941|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
218840084|NCT02747459|BEHAVIORAL|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
218840085|NCT07028528|DIETARY_SUPPLEMENT|Levagen+|Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA
218840086|NCT07028528|OTHER|Placebo|Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]
218840087|NCT07034300|DRUG|Lidocaine (drug)|40 ml of 0.5% lidocaine
218840088|NCT07034300|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 μg/kg)
219450047|NCT05302986|DRUG|Placebo|Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
218840089|NCT07033390|OTHER|survey|validity and reliability study of MOS
219587517|NCT06484842|OTHER|The mindfulness intervention|The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
219587518|NCT01162707|DEVICE|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
219587519|NCT06633809|OTHER|Immediate endovascular therapy|The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.
219587520|NCT03596814|OTHER|No Interventional study|Retrospective data
218840090|NCT07032779|OTHER|simulation|the students in the intervention group will have the Tag Team Patient Safety Simulation application. The students in the simulation group will be divided into 2 groups and each group will have the Tag Team Patient Safety Simulation application with the same scenario. The students in the labeling group will be included in the scenario as the scenario progresses. It will start with 4 students at the beginning, but with labeling, 7-8 students in each group will take the role of the actors, and the other students will take the role of the audience.
218840091|NCT07081321|BEHAVIORAL|Lithotomy position|Participants in the lithotomy decubitus position group were in the lithotomy position at the second stage of labor of delivery.
219587521|NCT00306930|DEVICE|Acetabular cup|Acetabular cup replacement
218840092|NCT07081321|BEHAVIORAL|Lateral Position|Participants in the lateral position group were in the lateral position at the second stage of labor of delivery.
218840093|NCT07081321|BEHAVIORAL|Upright Position|Participants in the upright position group were in the upright position at the second stage of labor of delivery.
218840094|NCT07080502|OTHER|Application for the creation of a questionnaire on alterations in vaginal penetration|"Development of domains and items:~Through the judgment of 10 experts, the set of items of each domain will be identified.~Development of the scale:~A pilot will be carried out to guarantee the viability and feasibility of what was created in the previous stage; The questionnaire will be applied to 30. participants.~Evaluation of the scale:~At this stage, the Questionnaire will be applied to a larger sample: 10 participants for each item create. In the same way as the previous stage, the Female Sexual Function Index will be applied together with the created questionnaire."
218840095|NCT07080840|BEHAVIORAL|Nursing education A+1|Dietary education once
218840096|NCT07080840|BEHAVIORAL|Nursing education A+2|Dietary education twice
218840097|NCT07080840|BEHAVIORAL|Nursing education A+3|Dietary education three times
218840098|NCT07080840|BEHAVIORAL|Nursing education B+1|Medication education once
218840099|NCT07080840|BEHAVIORAL|Nursing education B+2|Medication education twice
218840100|NCT07080840|BEHAVIORAL|Nursing education B+3|Medication education three times
218840101|NCT07080840|BEHAVIORAL|Nursing education AB+1|Combined dietary and medication education once
218840102|NCT07080840|BEHAVIORAL|Nursing education AB+2|Combined dietary and medication education twice
218840103|NCT07080840|BEHAVIORAL|Nursing education AB+3|Combined dietary and medication education three times
219450048|NCT06048367|DRUG|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
219587522|NCT06505070|BEHAVIORAL|Recreational Games|"40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played."
219587523|NCT05337371|DEVICE|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
219587524|NCT03083652|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
219587525|NCT03083652|OTHER|Sham|Conventional physiotherapy with NMES device NOT activated
219587526|NCT05021718|OTHER|Strengthening exercises|Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
218840104|NCT07081126|DRUG|Daratumumab (Subcutaneously)|Kidney transplant recipients with late ABMR and de novo DSA treated with daratumumab (1800mg subcutaneous, weekly x 4, then monthly x 6).
218840105|NCT07081126|OTHER|control group|Kidney transplant recipients with late ABMR and de novo DSA treated with standard therapies (IVIG, plasmapheresis, rituximab, etc.) prior to the start of the daratumumab study.
218840106|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
218840107|NCT02147197|DRUG|Placebo|Matching placebo tablet.
218840108|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
218840109|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
218840110|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
218840111|NCT06951464|DRUG|BL-B01D1|BL-B01D1 (2.2 or 2.5mg/kg) to be administered on Day 1 and Day 8 of every 3-week cycle for 2 cycles.
218840112|NCT06951464|DRUG|Almonertinib|Almonertinib 100mg QD
218840113|NCT06853990|DEVICE|twiist insulin delivery system|twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm
218840114|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
218840115|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
218840116|NCT06501638|DRUG|Memantine Hydrochloride 10 MG|Take Memantine Hydrochloride for intervention First week, 5mg(half the tablet), p.o.，bid. Second to Sixth week, 10mg(one tablet), p.o., bid
218840117|NCT06501638|DRUG|Placebo|Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
218840118|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
218840119|NCT06534541|BEHAVIORAL|Attentional bias to food cues|Measurement of the amount of attention given to food cues
218840120|NCT03179982|BEHAVIORAL|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills"
218840121|NCT04230811|DIAGNOSTIC_TEST|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
218840122|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
218840123|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
218840124|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
218840125|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
218840126|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
218840127|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
218840128|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
218840129|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
218840130|NCT05815550|DRUG|PPI|Use of PPI defined as PPI mentioned in the safety report
219450049|NCT06048367|DRUG|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
219587527|NCT05021718|DRUG|Pharmacological therapy|Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
219587528|NCT05021718|OTHER|Hot compression|Hot moist compression from week 4 to week 6.
219587529|NCT05021718|BEHAVIORAL|Activities to daily living instructions|"* Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position."
218840131|NCT06781931|DEVICE|DG1 Spectacle Lens|DG1 spectacle lens, daily wear for 36 months
219587530|NCT01589289|DEVICE|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
218840132|NCT06781931|DEVICE|Single Vision Spectacle Lens|Single vision spectacle lens, daily wear for 36 months
218840133|NCT04991870|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
218840134|NCT04991870|PROCEDURE|Resection|Undergo surgical resection
218840135|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
218840136|NCT06506903|DEVICE|Medtronic Avalus Ultra|Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
218840137|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
218840138|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
218840139|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
218840140|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
218840141|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
218840142|NCT06298214|BEHAVIORAL|Her Health Program|Addition of a community health worker navigator to assist subject in navigating their health in the first year postpartum.
218840143|NCT03797625|DRUG|Irinotecan|60mg/m2，D1，8
218840144|NCT03797625|DRUG|DDP|60mg/m2，D1
218840145|NCT03797625|DRUG|Endostar|15mg/d，d1-d7 civ
218840146|NCT02128906|DRUG|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
218840147|NCT02128906|RADIATION|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
218840148|NCT02128906|DRUG|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
218840149|NCT02128906|DRUG|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
218840150|NCT02112188|BEHAVIORAL|In-depth Patient Interviews|
218840151|NCT02112188|BEHAVIORAL|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
218860022|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
219450050|NCT06048367|DRUG|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
219587531|NCT01589289|DEVICE|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
219587532|NCT01589289|DEVICE|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
219587533|NCT01589289|DEVICE|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
219587534|NCT01589289|DEVICE|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
218860023|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
218860024|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
218860025|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
219450051|NCT06048367|DRUG|CNSI-Fe(II) 120 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
219450052|NCT06048367|DRUG|CNSI-Fe(II) 150 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
219450053|NCT05374564|DRUG|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
219450054|NCT02906098|BEHAVIORAL|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
219450055|NCT02906098|BEHAVIORAL|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
219450056|NCT05403385|DRUG|inupadenant|Adenosine 2a receptor antagonist
219450057|NCT05403385|DRUG|Placebo|matched placebo capsule to inupadenant
219450058|NCT05403385|DRUG|Carboplatin|standard of care chemotherapeutic, alkylating agent
219450059|NCT05403385|DRUG|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
219587535|NCT05134857|DRUG|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
219587536|NCT05134857|DRUG|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
219587537|NCT02684630|DEVICE|Trima Accel System|Platelet Apheresis Procedure
218840152|NCT02112188|BEHAVIORAL|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
218840153|NCT04953806|BEHAVIORAL|Step-CBT|Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
218840154|NCT05011006|DIAGNOSTIC_TEST|NT3 blood draw|blood draw
218840155|NCT04148482|OTHER|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
218840156|NCT05318534|DRUG|GL-0719|Administration route: intravenous infusion and subcutaneous injection
219587538|NCT04593576|OTHER|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
218840157|NCT05318534|DRUG|Placebo|Administration route: intravenous infusion and subcutaneous injection
218840158|NCT06375421|BEHAVIORAL|MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval|Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.
218840159|NCT06375421|BEHAVIORAL|Blocked Retrieval|Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.
218840160|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
219587539|NCT04593576|OTHER|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
218840161|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
218840162|NCT05926544|BEHAVIORAL|Standard implementation webinar and online training|"The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients."
218840163|NCT05926544|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
218840164|NCT05006937|PROCEDURE|Dusting|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
218840165|NCT05006937|PROCEDURE|Basket extraction|Basket extraction is when a small wire basket is used to remove stone fragments.
218840166|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
218840167|NCT05722197|BEHAVIORAL|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
218840168|NCT02891148|DRUG|BI 690517|
218840169|NCT03522246|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
218840170|NCT03522246|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
218840171|NCT03522246|DRUG|Placebo Oral Tablet|Placebo tablets will be administered twice daily
218840172|NCT03522246|DRUG|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
218840173|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
218840174|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
218840175|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
218840176|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
218840177|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
218840178|NCT06027255|DIAGNOSTIC_TEST|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
218840179|NCT06027255|DIAGNOSTIC_TEST|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
218840180|NCT06027255|BEHAVIORAL|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
218840181|NCT06438120|BEHAVIORAL|Chatbot-based positive psychology intervention|Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
218840182|NCT06830889|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
218840183|NCT06830889|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
218840184|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
218840185|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
218840186|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
218840187|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
218840188|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
218840189|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
218840190|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
218840191|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
218840192|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
219450060|NCT04849676|OTHER|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
219450061|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
219450062|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
219450063|NCT04303169|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219450064|NCT04303169|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
218840193|NCT05658627|OTHER|active release technique|Hamstring active release technique-
219450065|NCT04303169|BIOLOGICAL|Gebasaxturev|Administered via IT injection at a specified dose on specified days
219450066|NCT04303169|BIOLOGICAL|MK-4830|Administered via IV infusion at a specified dose on specified days
219450067|NCT04303169|BIOLOGICAL|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219450068|NCT04303169|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
219450069|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
219450070|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
219450071|NCT01327573|DRUG|eculizumab|"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
219587540|NCT04251572|OTHER|Blood sampling|Blood sampling
219587541|NCT04251572|OTHER|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
219587542|NCT04647565|OTHER|interviews|interviews (human and social sciences)
219587543|NCT03624959|DRUG|Ozanimod|ozanimod
219587544|NCT03624959|DRUG|Gemfibrozil|Gemfibrozil
219587545|NCT03624959|DRUG|Itraconazole|Itraconazole
218840194|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
219196744|NCT06816953|DIAGNOSTIC_TEST|HEAD-US|HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)
219450072|NCT01748006|OTHER|Standard of care therapy for severe decompensated heart failure|
219450073|NCT03923829|DRUG|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
219450074|NCT03923829|PROCEDURE|scaling and root planing|scaling and root planing
219450075|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
219587546|NCT03624959|DRUG|Rifampin|Rifampin
219587547|NCT04792762|OTHER|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
219587548|NCT04792762|OTHER|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
219587549|NCT04792762|OTHER|Saline|Intravenous administration of saline during a stepwise glucose clamp
219587550|NCT00631657|DRUG|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
219587551|NCT00631657|DRUG|Placebo|One placebo tablet once a day
219587552|NCT01670617|OTHER|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
219587553|NCT02131350|PROCEDURE|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
219587554|NCT02131350|DRUG|Ranibizumab|
219587555|NCT00663026|DRUG|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
219587556|NCT00663026|DRUG|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
219587557|NCT00663026|DRUG|placebo|Placebo subcutaneous injection once per week for 6 months
218840195|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
218840196|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
218840197|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
218840198|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
218840199|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
218840200|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
218840201|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
218840202|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
218840203|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
218840204|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
218840205|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
218840206|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
218840207|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
218840208|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
219450076|NCT05609500|BEHAVIORAL|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
218840209|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
219450077|NCT05490043|DRUG|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
219450078|NCT05848557|BEHAVIORAL|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
219450079|NCT06527456|OTHER|participation of the general practitioner|participation of the general practitioner in encouraging cervical cancer screening
219587558|NCT03360955|PROCEDURE|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
219587559|NCT02904941|BIOLOGICAL|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
218840210|NCT00093197|DRUG|Placebo|
218840211|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
218840212|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
218840213|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
218840214|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
218840215|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
218840216|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
218860026|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
218840217|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
218840218|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
219450080|NCT03894657|DIAGNOSTIC_TEST|Nasal brushing|Nasal scrapping at visit V0
219450081|NCT03894657|OTHER|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study"
219450082|NCT03894657|OTHER|blood sample|"Visit V0 : Additional 14 mL~* 5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~* 3 mL in Dry tube for Serum biobank~* 6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~* 2x3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~* 3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank"
219450083|NCT03894657|DRUG|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
219450084|NCT05815862|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
219450085|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
219450086|NCT01364948|OTHER|No oil application|Oil application was not done
219450087|NCT05722288|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219450088|NCT05722288|OTHER|Informational Intervention|Receive nutritional counseling
219450089|NCT05722288|OTHER|Quality-of-Life Assessment|Ancillary studies
219450090|NCT05722288|OTHER|Questionnaire Administration|Ancillary studies
219450091|NCT05722288|BEHAVIORAL|Short-Term Fasting|Undergo time-restricted eating
219450092|NCT04053114|OTHER|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
219450093|NCT02136134|DRUG|Daratumumab|Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
219450094|NCT02136134|DRUG|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
219450095|NCT02136134|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
219450096|NCT05674838|OTHER|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
219450097|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219450098|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
219450099|NCT06639958|BEHAVIORAL|Compliance Monitoring|Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits
219196745|NCT06816953|DIAGNOSTIC_TEST|Urinary carboxy-terminal cross linked telopeptide of type II collagen|Cartilage biomarker represent cartilage degradation
219450100|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
219450101|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
219450102|NCT06639958|OTHER|Media Intervention|View MIPE program videos
219450103|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
219450104|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
219450105|NCT06639958|DRUG|Mercaptopurine|Given PO
219450106|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
218840219|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
218840220|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
219196746|NCT06816953|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers included CBC, Ferritin, ESR, CRP
219196747|NCT06817447|PROCEDURE|Pulmonary vein isolation plus cavo-tricuspid isthmus ablation|For those who are randomized to CTI+CPVI Arm, additional CPVI should be performed after finishing CTI ablation. CPVI could be performed using open-irrigated contact-force catheter, cryoballoon catheter or pulse-field ablation catheter. The endpoint is defined as both entrance and exit block in the pulmonary veins.
219450107|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
219450108|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminders
219450109|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Manually activate daily smartphone reminders with successive alerts (using the snooze function)"
219450110|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
219450111|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
219450112|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
219450113|NCT06821425|DRUG|Melatonin gel mixed with xenograft|This study will be conducted to evaluate the effect of melatonin (5% gel) when used as an adjunct to xenograft for the surgical management of intrabony periodontal defects.
219450114|NCT06821425|OTHER|Xenograft|Application of Xenograft alone for the surgical management of intrabony periodontal defects.
219450115|NCT06821802|DIETARY_SUPPLEMENT|Moltein PURE Protein Powder|80 g protein supplementation per day (two bottles, each containing 40 g protein)
218840221|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
218840222|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
218840223|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
218840224|NCT00467545|DRUG|telbivudine|
219450116|NCT06821802|BEHAVIORAL|Fluid restriction|total daily fluid intake to a maximum of 1000 ml
219450117|NCT06177535|DIETARY_SUPPLEMENT|Kavalactones|Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
219450118|NCT06177535|DRUG|Placebo|Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
219450119|NCT05196867|BEHAVIORAL|Intervention Group|Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.
219450120|NCT05196867|BEHAVIORAL|Control Group|Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
219450121|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
219450122|NCT06378099|OTHER|Patient guided and followed by the pharmacist|"The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~This training will cover both pharmacological and non-pharmacological aspects of MA management. The pharmacological component will emphasize the appropriate selection and safe use of nonprescription drugs, with a focus on identifying potential drug interactions, contraindications, and moderate and serious ADRs. Pharmacy staff will also be equipped with tools to apply proper criteria for referral to a GP when necessary.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Consensus-based Protocols."
219450123|NCT04255693|BEHAVIORAL|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
219450124|NCT04255693|BEHAVIORAL|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
219450125|NCT04255693|BEHAVIORAL|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
218840225|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
218840226|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
218840227|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
218840228|NCT06326450|BEHAVIORAL|Augmented Reality simulation|Augmented simulation of medical crisis scenarios
218840229|NCT06326450|BEHAVIORAL|In Person simulation|In Person simulation of medical crisis scenarios
218840230|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
218840231|NCT04585542|DRUG|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
218840232|NCT04585542|DRUG|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
218840233|NCT04585542|DRUG|Patiromer|Potassium binder to treat hyperkalemia.
218840234|NCT04585542|DRUG|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
218840235|NCT03451981|PROCEDURE|mechanical instrumentation|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned
218840236|NCT03451981|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
218840237|NCT03451981|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, an Air-Powder treatment will be provided on the implant surface.
218860027|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
219587560|NCT02904941|DEVICE|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
219450126|NCT04255693|BEHAVIORAL|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
219450127|NCT04255693|BEHAVIORAL|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
219450128|NCT04255693|BEHAVIORAL|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
218840238|NCT06087991|BEHAVIORAL|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
218840239|NCT05844618|DRUG|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
218840240|NCT05844618|DRUG|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
218840241|NCT06519773|PROCEDURE|Modified periosteal inhibition|"After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A soft bone lamina will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone. Then the jumping gap between the dental implant and the buccal plate of bone will be filled using either collagen sponge or xenograft."
218840242|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
218840243|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
218840244|NCT06523010|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
218840245|NCT06523010|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
218840246|NCT03350126|DRUG|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
218840247|NCT03350126|DRUG|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
218840248|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
218840249|NCT03665766|DRUG|Cycloserine,Tacrolimus|
218840250|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
218840251|NCT02516995|DEVICE|Functional magnetic resonance imaging|
218840252|NCT02516995|DEVICE|Ultrasound|
218840253|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
218840254|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
218840255|NCT05960578|DRUG|Apalutamide|Given PO
218840256|NCT05960578|PROCEDURE|Biopsy|Undergo tumor biopsy
218840257|NCT05960578|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218840258|NCT05960578|PROCEDURE|Computed Tomography|Undergo CT scan
218840259|NCT05960578|DRUG|Golimumab|Given SC
218840260|NCT05960578|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218840261|NCT05960578|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
218840262|NCT05960578|PROCEDURE|Bone Scan|Undergo bone scan
218840263|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
219587561|NCT02904941|PROCEDURE|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
218840264|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
218840265|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
218840266|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
218840267|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
218840268|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
218860028|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
219587562|NCT01570686|DRUG|Aliskiren|Aliskiren 300 mg once daily
218840269|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
218840270|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
218840271|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
218840272|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
219196748|NCT06817447|PROCEDURE|Cavo-tricuspid isthmus ablation|"In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl.~CTI ablation should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter. Radiofrequency should be delivered at 30-50 W with a contact-force between 5-30 g in a point-by-point fashion until the CTI line is completed. Touch-up radiofrequency should be performed as needed. The endpoint of ablation is termination of AFL, if present, and the demonstration of bidirectional block across the CTI by using differential pacing."
219196749|NCT06814210|DEVICE|Cerebral Embolic Protection|Subjects will undergo M-TEER following placement of the cerebral embolic protection device.
219450129|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
219450130|NCT02381886|DRUG|IDH305|
219450131|NCT06038578|BIOLOGICAL|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
219450132|NCT06038578|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
219450133|NCT06038578|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
219587563|NCT04528030|DEVICE|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
219587564|NCT04708639|DRUG|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
219587565|NCT00325195|OTHER|placebo|placebo by intravenous infusion every 2 weeks
219587566|NCT00325195|BIOLOGICAL|pegloticase|8 mg pegloticase by intravenous infusion
219587567|NCT01892124|BEHAVIORAL|Motivational Interviewing/Cognitive Behavioral-based Therapy|
219450134|NCT03070119|DRUG|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
219450135|NCT05232929|DRUG|Risdiplam|Risdiplam taken by participants as prescribed by their physician.
219450136|NCT05232929|DEVICE|SMA-DAT Application and ADAM Sensor|Participants will perform a programmed selection of SMA-DAT tasks while wearing the ADAM Sensor.
219450137|NCT05978557|OTHER|Biospecimen collection|Biospecimen will be collected during surgery.
219587568|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
219587569|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
219587570|NCT00613535|DEVICE|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
219587571|NCT00613535|DEVICE|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
219587572|NCT00613535|PROCEDURE|Lavage debridement|Remove loose chondral fragments
219587573|NCT00613535|DEVICE|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
219587574|NCT00613535|DEVICE|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
219587575|NCT01536158|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
219587576|NCT01536158|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
219587577|NCT03801889|DRUG|SP-420|Self-administered by mouth
218840273|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
218840274|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
218840275|NCT03239951|DEVICE|iTind|temporary implant
219450138|NCT03217318|DEVICE|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
219450139|NCT00732472|DRUG|GSK573719|7 day repeat dose
219450140|NCT00255983|DRUG|Faropenem medoxomil|600 mg BID for 5 days
219587578|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
219587579|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
219587580|NCT05686083|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
218840276|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
218840277|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
218840278|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
218840279|NCT00459875|DRUG|sunitinib malate|
219450141|NCT00255983|DRUG|placebo|placebo tablets BID for 5 days
218840280|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
218840281|NCT03898297|RADIATION|[18F]FPEB|Radiotracer: \[18F\]FPEB
218840282|NCT03898297|RADIATION|[11C]APP311|Radiotracer: \[11C\]APP311, \[11C\]UCB-J
219196750|NCT06818305|DRUG|Finerenone (BAY 94-8862)|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Finerenone (10mg/d or 20mg/d)."
219450142|NCT02159768|DEVICE|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
219587581|NCT05686083|DIETARY_SUPPLEMENT|Novel ketone di-ester|Novel ketone di-ester
219587582|NCT05066672|DRUG|NV-5138|NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
219196751|NCT06818305|DRUG|Empagliflozin 10 mg|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Empagliflozin (10mg/d)."
219196752|NCT06817551|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
219450143|NCT06053281|DRUG|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
219587583|NCT05066672|DRUG|matched placebo|matched placebo oral capsules
219587584|NCT01248689|OTHER|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
219587585|NCT01248689|OTHER|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
218840283|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
218840284|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
218840285|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
218840286|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
218860029|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
218860030|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
218860031|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
219450144|NCT06053281|OTHER|Placebo|Placebo
219450145|NCT05044351|DEVICE|Fluobeam LX|See arm description
219450146|NCT05044351|OTHER|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
219450147|NCT03833349|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
219450148|NCT03833349|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
219450149|NCT03833349|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
219450150|NCT00554346|DRUG|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
219450151|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
219450152|NCT04691531|DEVICE|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
219587586|NCT01248689|OTHER|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
219587587|NCT00000386|BEHAVIORAL|Exposure and Response Prevention|
219587588|NCT00000386|BEHAVIORAL|Family Treatment Program|
219587589|NCT00000386|BEHAVIORAL|Relaxation Training|
218840287|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
219450153|NCT04691531|DEVICE|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
219450154|NCT05544214|DRUG|CKD-371|PO
219450155|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
219450156|NCT02446028|DRUG|BIOD-531|
219450157|NCT02446028|DRUG|Humalog® Mix 75/25|
219450158|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
219450159|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
219450160|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
219450161|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
219450162|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
219450163|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
219450164|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
219450165|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
219450166|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
219450167|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
219450168|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
219587590|NCT00000386|BEHAVIORAL|Behavior therapy|
219196753|NCT06817551|OTHER|Supportive Care|\*Please see description for supportive care arm.
219450169|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
219450170|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
218840288|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
218840289|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
218840290|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
218840291|NCT00335283|DRUG|lansoprazole|40mg bid
218840292|NCT00335283|DRUG|placebo|one tablet bid
218840293|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
219196754|NCT06818760|DIAGNOSTIC_TEST|Masimo Smart Wristband|Continuous wear of Masimo Smart Wristband
219450171|NCT05058859|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
219450172|NCT04084795|BEHAVIORAL|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
219450173|NCT04084795|OTHER|transcranial Direct Current Stimulation|tDCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; Fp1, F7, Fc5, AF3, Fc1, Fz, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 2mA tDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
219450174|NCT05438004|OTHER|Ambulatory nice birth|discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
219450175|NCT06630585|DRUG|Tirzepatide|"Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks."
219450176|NCT06105970|OTHER|No intervention|cross sectional study#no intervention
219450177|NCT04783506|OTHER|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
219587591|NCT00000386|BEHAVIORAL|Family Counseling|
219587592|NCT05989113|OTHER|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
219587593|NCT02901964|OTHER|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
219587594|NCT02901964|OTHER|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
218840294|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
219450178|NCT04083781|DRUG|Concizumab|Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
219450179|NCT05103501|DRUG|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
219450180|NCT05120284|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
219450181|NCT05120284|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
218840295|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
218840296|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
219450182|NCT05674955|DIAGNOSTIC_TEST|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
219450183|NCT00807443|DRUG|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
219450184|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|Administered one time via subcutaneous route.
219450185|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Administered one time via intravenous route.
219587595|NCT06430359|DIAGNOSTIC_TEST|urine and blood test|3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
219587596|NCT01299259|BEHAVIORAL|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
219587597|NCT05808192|DRUG|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
219587598|NCT02029573|DRUG|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
219587599|NCT02029573|DRUG|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
219587600|NCT02029573|RADIATION|Radiotherapy|60 Gy in 30 fractions
219587601|NCT00329472|DRUG|gemcitabine, cisplatin|
219587602|NCT01751763|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
218840297|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
218840298|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
218840299|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
218840300|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
218840301|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
218840302|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
218840303|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
218840304|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
218840305|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
219587603|NCT02815358|OTHER|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
219587604|NCT02815358|OTHER|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
219587605|NCT03407235|DEVICE|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
219587606|NCT03407235|DEVICE|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
219587607|NCT03543241|DIAGNOSTIC_TEST|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
219587608|NCT01090921|DRUG|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
219587609|NCT05000879|BEHAVIORAL|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
219450186|NCT05304611|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
219450187|NCT06281314|DEVICE|Vespa software|The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
219450188|NCT01165463|BEHAVIORAL|SOPT basic training|10 hours of basic training
219450189|NCT01165463|BEHAVIORAL|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
219450190|NCT01165463|BEHAVIORAL|SOPT booster training|4 hours of subsequent booster-training
219450191|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
219450192|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
219450193|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
219587610|NCT06116084|OTHER|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
219587611|NCT06116084|OTHER|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
219587612|NCT06223243|OTHER|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
219587613|NCT06223243|OTHER|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
219587614|NCT06223243|OTHER|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
219587615|NCT01561508|DRUG|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
219587616|NCT01561508|DIETARY_SUPPLEMENT|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
219587617|NCT01752543|DRUG|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
219587618|NCT01752543|DRUG|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
218840306|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
219450194|NCT03239769|PROCEDURE|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
219450195|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
219450196|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
219450197|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
219450198|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
219450199|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
219450200|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
219450201|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
219450202|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
219450203|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
219450204|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
219450205|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
219450206|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
219450207|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
219450208|NCT04796012|DRUG|Atezolizumab|Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle
219450209|NCT04796012|DRUG|Vincristine|Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle
219450210|NCT04796012|DRUG|Irinotecan|Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle
219450211|NCT04796012|DRUG|Temozolomide|Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
219450212|NCT06299111|DRUG|REGN9933|Intravenous (IV) single dose administered
219450213|NCT06299111|DRUG|REGN7508|IV single dose administered
219450214|NCT06299111|DRUG|Placebo|IV single dose administered
219450215|NCT05064007|BEHAVIORAL|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
219450216|NCT05064007|BEHAVIORAL|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
219450217|NCT05064007|BEHAVIORAL|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
219450218|NCT06563479|DIAGNOSTIC_TEST|FMISO-PET Scan|Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
219450219|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
219450220|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
219450221|NCT06563479|OTHER|Assessments|EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
219450222|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
219450223|NCT05164341|DRUG|Placebo|Placebo
219450224|NCT04577313|BEHAVIORAL|Behavioral Self-Regulation Adherence Counseling|Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
219450225|NCT06287814|BIOLOGICAL|Blood sample/lliquid biopsy|ctDNA analysis
219450226|NCT05393362|PROCEDURE|Cardiac Rehabilitation Program (CR)|"Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end."
219450227|NCT05393362|BEHAVIORAL|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
219450228|NCT02682511|DRUG|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
219450229|NCT02682511|DRUG|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
219450230|NCT04316117|PROCEDURE|Computed Tomography|Undergo PET/CT
219450231|NCT04316117|OTHER|Fludeoxyglucose F-18|Given IV
219450232|NCT04316117|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219450233|NCT06807957|DEVICE|Group with IMT|Group with IMT + CrossFit training
219587619|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
219587620|NCT00686075|OTHER|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
219450234|NCT06807957|BEHAVIORAL|CrossFit® Training|The training routine will occur seven days a week, with participants encouraged and motivated to attend at least five training sessions. CrossFit® classes will include: warm-up exercises, strength training (with a focus on Olympic weightlifting and free weights), strength endurance (body weight and external loads), aerobic capacity (across multiple domains), maximal aerobic power (across multiple domains), anaerobic capacity (across multiple domains), cool-down activities, and mobility exercises. Each training session will be designed and supervised by a team of certified physical educators.
219450235|NCT04556175|BEHAVIORAL|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
219450236|NCT04556175|BEHAVIORAL|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
219587621|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
219587622|NCT00686075|OTHER|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
219450237|NCT04430894|DRUG|Carfilzomib|"* Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
218840307|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
218840308|NCT00140296|BEHAVIORAL|Contraceptive counseling|
219450238|NCT04430894|DRUG|Isatuximab|"* Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  \-- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
219450239|NCT04430894|DRUG|Lenalidomide|\- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
219450240|NCT04430894|DRUG|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
219450241|NCT05549505|DRUG|ARV-471|100 mg tablet
219450242|NCT05549505|DRUG|Anastrozole|1 mg tablet
219450243|NCT05549505|PROCEDURE|Surgical resection of breast tumor|Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
219450244|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
219450245|NCT06408818|BEHAVIORAL|Media Aware Parent - Tween|Media Aware Parent - Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
219587623|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
219587624|NCT00686075|OTHER|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
218840309|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
218840310|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
218840311|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
219450246|NCT06408818|BEHAVIORAL|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
218840312|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
218840313|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
219450247|NCT01602822|DRUG|Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
219450248|NCT03739892|BEHAVIORAL|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
219450249|NCT03288311|OTHER|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
219450250|NCT03288311|OTHER|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
219450251|NCT02960308|RADIATION|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
219587625|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
219587626|NCT00686075|OTHER|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
219587627|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
219587628|NCT00686075|OTHER|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
218840314|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
219450252|NCT02110550|OTHER|IPS.emmax endocrown|
219587629|NCT03884452|DRUG|Atorvastatin|Tablets taken orally once daily in the morning
218840315|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
218840316|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
219450253|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
219450254|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
219450255|NCT00854061|DRUG|T-Pred|sterile ophthalmic solution
219450256|NCT00854061|DRUG|Pred Forte|sterile ophthalmic solution
219450257|NCT05322083|DRUG|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
219587630|NCT03884452|DRUG|Simvastatin|Tablets taken orally once daily in the morning or evening
219450258|NCT05022706|OTHER|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
218840317|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
219450259|NCT05022706|BEHAVIORAL|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
219450260|NCT05022706|BEHAVIORAL|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
219450261|NCT04711915|DRUG|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
219450262|NCT04711915|DRUG|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
219450263|NCT05492877|DRUG|Mitiperstat (AZD4831)|Oral dosage, once daily.
219450264|NCT05492877|OTHER|Placebo|Oral dosage, once daily.
219450265|NCT02286089|BIOLOGICAL|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
219587631|NCT03884452|DRUG|Ezetimibe|Tablet taken orally once daily in the morning or evening
219587632|NCT03884452|DRUG|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
219587633|NCT05164887|PROCEDURE|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
219587634|NCT02928718|PROCEDURE|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
219587635|NCT03052218|DEVICE|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
219587636|NCT04715932|DRUG|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
219587637|NCT04715932|DRUG|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
219587638|NCT02828306|OTHER|Patient Specific Implant|Implantation of Patient Specific Implant
219587639|NCT00993837|PROCEDURE|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
219587640|NCT00367549|DIETARY_SUPPLEMENT|Energy-containing soft drink|Commercial energy/sports drink
219587641|NCT00002149|DRUG|Clavulanate potassium|
219587642|NCT00002149|DRUG|Pseudoephedrine hydrochloride|
219196755|NCT06307574|BEHAVIORAL|bpMedManage|In this 16-week RCT, a total of 100 older adults with MCI will be recruited. There are two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
219587643|NCT00002149|DRUG|Amoxicillin trihydrate|
218840318|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
218840319|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
218840320|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
219587644|NCT00051987|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
219196756|NCT06817811|DRUG|Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)|One tablet of the test drug was given orally under fasting condition
218840321|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
218840322|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
219450266|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
219450267|NCT03413228|OTHER|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
218840323|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
219450268|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
218840324|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
219587645|NCT01108406|DEVICE|Sonitus SoundBite System|Non Surgical Bone Conduction Device
219587646|NCT01108406|DEVICE|SoundBite Hearing System|
219587647|NCT02740699|DRUG|Rosuvastatin|Participants will receive 20-40 mg once daily
219587648|NCT02740699|DRUG|Atorvastatin|Participants will receive 40-80 mg once daily.
218840325|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
218840326|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
218840327|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
218840328|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
218840329|NCT03818607|DRUG|ABP 959|intravenous infusion
219450269|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
219450270|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
219450271|NCT05835167|PROCEDURE|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
219587649|NCT02740699|RADIATION|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
219587650|NCT02740699|RADIATION|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
219587651|NCT03881956|BEHAVIORAL|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
219587652|NCT00175188|DEVICE|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
219587653|NCT02649985|DRUG|[F-18]PBR06|PET radiopharmaceutical
219587654|NCT02649985|DRUG|[C-11]PBR28|PET radiopharmaceutical
219587655|NCT03046407|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
219587656|NCT05961865|DIAGNOSTIC_TEST|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
219587657|NCT04137016|OTHER|Mobile application|
219587658|NCT01467414|DRUG|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
218840330|NCT03818607|DRUG|Eculizumab|intravenous infusion
218840331|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
218840332|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
218840333|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
219196757|NCT06817811|DRUG|Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)|One tablet of the reference drug was given orally under fasting condition
218840334|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
218840335|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
218840336|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
218840337|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
219450272|NCT05835167|PROCEDURE|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
219450273|NCT00129376|DRUG|Doxorubicin|
219196758|NCT06336148|DRUG|ACTM-838|Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
219196759|NCT06656754|OTHER|Isometric Reaching|"The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation"
219196760|NCT06476600|DRUG|Dexmedetomidine injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
219196761|NCT06476600|DRUG|Nalbuphine Injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
219450274|NCT00129376|DRUG|Cyclophosphamide|
219587659|NCT04302558|BEHAVIORAL|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
219587660|NCT04302558|BEHAVIORAL|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
219196762|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
219196763|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
219196764|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
219450275|NCT00129376|DRUG|Docetaxel|
219450276|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
219450277|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
219450278|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
219450279|NCT00136461|DRUG|All-trans retinoic acid|
219587661|NCT05199519|DRUG|IBI345|IBI345 CAR-T cell injection by intravenous infusion
219587662|NCT00944619|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
219450280|NCT00136461|DRUG|Bryostatin 1|
219587663|NCT00944619|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
219587664|NCT01050608|DEVICE|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
219587665|NCT01050608|DRUG|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
219587666|NCT01050608|BEHAVIORAL|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
219587667|NCT01050608|BEHAVIORAL|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
219450281|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
219450282|NCT00000515|BEHAVIORAL|diet, reducing|
219450283|NCT00536094|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
219587668|NCT05819723|OTHER|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
219587669|NCT01616108|DRUG|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
219587670|NCT06160570|RADIATION|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
219587671|NCT06160570|RADIATION|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
219587672|NCT01545661|PROCEDURE|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
219587673|NCT01545661|PROCEDURE|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
219587674|NCT04431583|PROCEDURE|Bariatric surgery- single surgeon service|
219450284|NCT00536094|BEHAVIORAL|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
219587675|NCT04431583|PROCEDURE|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
219196765|NCT05043064|PROCEDURE|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
219196766|NCT06855992|DEVICE|Laser|60-minute 635 nm red laser intervention 3 times per week for 8 weeks
219196767|NCT06855992|DEVICE|Red Light|60-minute red light sham intervention three times per week for 8 weeks
219196768|NCT06820736|DEVICE|Drain|A drain is a small flexible tube that is placed next to where the spine was operated upon.
219587676|NCT04431583|PROCEDURE|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
219587677|NCT03544424|OTHER|No intervention|No intervention
219587678|NCT04915482|DRUG|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
219587679|NCT04915482|DRUG|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
219196769|NCT06815978|DIAGNOSTIC_TEST|DXA|Dual energy X-ray absorptiometry
219196770|NCT06815978|DIAGNOSTIC_TEST|ultrasonography|ultrasonography
219450285|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
219450286|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
219450287|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
219450288|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
219450289|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
219450290|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
219450291|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
219587680|NCT02316665|DEVICE|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
219587681|NCT02316665|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
219587682|NCT03627520|DRUG|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi \[14C\]
219587683|NCT01303757|BEHAVIORAL|Dietary counselling|
218840338|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
219450292|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
219450293|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
219450294|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
219450295|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
219450296|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
219450297|NCT02404909|OTHER|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
219587684|NCT06273930|DRUG|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
218840339|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
218840340|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
218840341|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
219196771|NCT06815978|DIAGNOSTIC_TEST|indirect calorimetry|indirect calorimetry
219196772|NCT06815978|DIAGNOSTIC_TEST|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
219196773|NCT06815978|DIAGNOSTIC_TEST|bioimpedentiometry|bioimpedentiometry
219450298|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
219450299|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
218840342|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
218840343|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
219450300|NCT07126600|OTHER|No investigational intervention administered|No investigational intervention administered
218840344|NCT02924246|OTHER|raw milk|raw milk
218840345|NCT02924246|OTHER|pasteurized milk|pasteurized milk
218840346|NCT02924246|OTHER|UHT milk|UHT milk
218840347|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
218840348|NCT00434447|DRUG|Zoledronic acid|
218840349|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
218840350|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
218840351|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
218840352|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
218840353|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
218840354|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
219196774|NCT06857318|BIOLOGICAL|Colostrum Nasal Spray|24 hours use of nasal spray of colostrum from MERS-CoV positive camels- 6 doses total
219450301|NCT06648655|DRUG|TMP-301|Daily (QD) x 14 weeks.
219450302|NCT06648655|DRUG|Placebo|Daily (QD) x 14 weeks.
219450303|NCT06827275|PROCEDURE|Feeding process|Nutritional therapy is administered according to the feeding procedure
219587685|NCT06273930|DRUG|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
219587686|NCT00684892|DEVICE|Chartis System|Assessment of airway flow and pressure
219587687|NCT06133283|BEHAVIORAL|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
219587688|NCT06133283|BEHAVIORAL|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
219587689|NCT06133283|BEHAVIORAL|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
218840355|NCT06792760|OTHER|Physiotherapy|The intervention will consist of 10 individual physiotherapy sessions delivered by a single physiotherapist trained in FMD. The physiotherapy programme will include education, movement retraining and a self-management plan.
218840356|NCT06792760|OTHER|Specific Breathing Techniques|The intervention will include education and training in specific breathing techniques, which will be exercised by the patient as a self-management plan for over 5-10 minutes daily.
218840357|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
218840358|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
218840359|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
218840360|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
218840361|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
219450304|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
218840362|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
218840363|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
218840364|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
218840365|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
218840366|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
218840367|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
219587690|NCT03783039|DEVICE|SURGICEL Powder|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
218840368|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
218840369|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
219196775|NCT06857318|OTHER|Water for injection|24 hours use of a nasal spray of water for injection- 6 doses total
219450305|NCT06479278|BEHAVIORAL|Talk with Me Baby|Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
219450306|NCT06813365|DRUG|DZD6008|Daily dose of DZD6008
219587691|NCT03783039|DEVICE|SURGICEL Original|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
219587692|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
218840370|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
218840371|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
219196776|NCT06855888|PROCEDURE|Modified Blumgart suture method|During pancreaticoduodenectomy, the modified Blumgart suture method is used for pancreaticojejunostomy. For anastomosis, 5-0PDS is used for pancreatic duct mucosal anastomosis, and 3-0 or 4-0 monofilament non-absorbable suture is used for pancreaticojejunal mattress anastomosis.
219450307|NCT05941052|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
219450308|NCT06338631|OTHER|Diet|Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
219450309|NCT06842147|DEVICE|7-day single-lead long-term ECG monitoring device.|Participants in the long-term screening group will undergo baseline data collection and a 12-lead ECG at baseline, followed using a 7-day single-lead long-term ECG monitoring device. This device continuously collects dynamic ECG data for seven days and allows participants to view and store ECGs through the accompanying software (registration number: 20192070163).
218840372|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
218840373|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
218840374|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
218840375|NCT04952753|DRUG|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
218840376|NCT04952753|DRUG|Bevacizumab|Bevacizumab will be administered IV
219450310|NCT06842147|DEVICE|Standard Screening Group|Patients in the standard screening group will undergo baseline data collection and a standard 12-lead ECG at the start of the study, with follow-up including opportunistic ECG checks as needed. Those diagnosed with AF will receive anticoagulation and antiarrhythmic therapy according to clinical guidelines.
219450311|NCT04921865|DEVICE|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
219450312|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
219450313|NCT04112992|PROCEDURE|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
219450314|NCT06806657|BIOLOGICAL|Garadacimab|Participants will receive a loading dose of garadacimab, followed by once monthly garadacimab administration for 2 months. Garadacimab will be given as a subcutaneous injection. The timing for the administration of the loading dose (first administration of garadacimab) is determined by the dosing schedule of the current HAE prophylactic treatment. No washout necessary.
219450315|NCT01081028|OTHER|First-line therapy|As prescribed by treating physician
218840377|NCT04952753|DRUG|Modified FOLFOX6|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
218840378|NCT04952753|DRUG|FOLFIRI|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
218840379|NCT04952753|DRUG|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
218840380|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
218840381|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
219450316|NCT01081028|DRUG|Second-line Multiple Myeloma treatments|As prescribed by the treating physician
219450317|NCT03218826|DRUG|Docetaxel|Given IV
219450318|NCT03218826|OTHER|Laboratory Biomarker Analysis|Correlative studies
219450319|NCT03218826|OTHER|Pharmacological Study|Correlative studies
219450320|NCT03218826|DRUG|PI3Kbeta Inhibitor AZD8186|Given PO
219450321|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
219450322|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
219450323|NCT06421415|DRUG|Allergen Immunotherapy Extract|Patients will be treated as usual. The study is an observation of the long term effect of the treatment
219587693|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
218840382|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
218840383|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
219450324|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
219450325|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
219450326|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
219450327|NCT04996277|PROCEDURE|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
219450328|NCT04996277|PROCEDURE|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
219450329|NCT04996277|PROCEDURE|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
219450330|NCT04996277|BEHAVIORAL|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
219450331|NCT02497053|DRUG|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
219450332|NCT02497053|DRUG|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
219450333|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
219450334|NCT03426449|PROCEDURE|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
219450335|NCT03426449|PROCEDURE|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
219450336|NCT02974660|DRUG|Protamine sulfate|
219450337|NCT02974660|DRUG|0.9% NaCl|
219450338|NCT04883099|DEVICE|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
219450339|NCT04955652|BEHAVIORAL|Health Maintenance Topic|Alert
219450340|NCT04955652|BEHAVIORAL|Actionable Sidebar Item|Alert
219450341|NCT04955652|BEHAVIORAL|Best Practice Alert|Alert
219450342|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
219450343|NCT01378676|DRUG|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
219587694|NCT01682863|DRUG|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
219587695|NCT01682863|DRUG|Placebo|To mimic QAB149
219587696|NCT04549714|PROCEDURE|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
219587697|NCT04549714|PROCEDURE|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
218840384|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
218840385|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
219450344|NCT01378676|DRUG|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
219587698|NCT04549714|PROCEDURE|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
219450345|NCT01378676|DRUG|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
219450346|NCT01378676|DRUG|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
219450347|NCT01378676|DRUG|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
219450348|NCT01378676|DRUG|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
219450349|NCT01378676|DRUG|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
219450350|NCT01378676|DRUG|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
219450351|NCT01378676|DRUG|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
219450352|NCT02482415|OTHER|Psycho-educational|
219450353|NCT04372979|DRUG|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
219450354|NCT04372979|DRUG|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
219450355|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
218840386|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
218840387|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
218840388|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
218840389|NCT05731817|OTHER|Observational study|N/A - observational study.
218840390|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
219196777|NCT06855888|PROCEDURE|Three-sided mattress suture|At the time of pancreaticoduodenectomy, the three-sided mattress suture is used as the pancreaticojejunostomy method. In addition to the conventional Blumgart modified suture, the three-sided mattress suture method adds a mattress anastomosis with 3-0 or 4-0 monofilament non-absorbable suture to the cranial and caudal sides of the pancreaticojejunostomy site.
219196778|NCT06857331|PROCEDURE|Erector Spinae Plane Block using 0.2% ropivacaine|Bilateral thoracic ESP block on the day of the transplantation with a subsequent catheterization will be suggested for the patients. In case of their written consent for the participation in the study this procedure will be performed on the day of the operation. 0.2% ropivacaine is going to be used throughout all the perioperative period.
219196779|NCT06816238|OTHER|Interactive education|interactive education based on a medical knowledge model, utilizing intelligent medical agents and interactive Q\&A
219196780|NCT06816238|OTHER|Traditional health education|traditional health education methods without the use of the interactive medical model and intelligent Q\&A system
219196781|NCT05224440|BEHAVIORAL|Veteran Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
219196782|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
219450356|NCT03629483|DRUG|Dexmedetomidine|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
219450357|NCT03629483|DRUG|Placebo|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
219450358|NCT00909883|DRUG|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
219450359|NCT00909883|DRUG|Placebo|Placebo injection
219450360|NCT06816368|DEVICE|Catheter ablation using sequential radiofrequency and pulsed field ablation|We are using sequential application of radiofrequency and pulsed field ablation to increase lesion depth and better treat ventricular arrhythmias.
219450361|NCT01501734|DEVICE|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
219450362|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
219196783|NCT04924400|BEHAVIORAL|CHIP Program|"GHP members randomized to the intervention arm will participate in the following activities:~* Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~* Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
219196784|NCT04924400|BEHAVIORAL|Usual Care|"GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
218840391|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
218840392|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
218840393|NCT04277325|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Couples Therapy (EFT) is an empirically supported, attachment-based model of couples therapy that combines experiential, systems, and attachment theories with the goal of fostering the development of safe contact, accessibility, and responsiveness in both partners.
218840394|NCT05318469|DRUG|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
218840395|NCT05318469|DRUG|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
218840396|NCT05318469|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle
219450363|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
218840397|NCT05730335|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
218840398|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
218840399|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
218840400|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
219196785|NCT06660446|OTHER|Exercise|The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
219450364|NCT04461145|BEHAVIORAL|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
218840401|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
218840402|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
218840403|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
218840404|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
218840405|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
218840406|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
218840407|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
219450365|NCT04639505|DIAGNOSTIC_TEST|ELISA|ELISA kit detecting the serum AMH level
219450366|NCT04639505|DIAGNOSTIC_TEST|Chemiluminescence|CLIA method detecting the serum AMH level
219450367|NCT05633160|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
219450368|NCT05633160|DRUG|67Cu-SAR-BBN|67Cu-SAR-BBN
219450369|NCT00513370|BIOLOGICAL|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
219450370|NCT01492166|DRUG|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
219450371|NCT01856855|RADIATION|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
219450372|NCT04103203|DIAGNOSTIC_TEST|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
219450373|NCT03598660|GENETIC|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
219450374|NCT03598660|OTHER|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
219450375|NCT01122823|BEHAVIORAL|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
219450376|NCT02394990|BEHAVIORAL|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
219450377|NCT02394990|BEHAVIORAL|ABI|
219450378|NCT00809055|DRUG|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
219450379|NCT02353338|PROCEDURE|Surgical intervention|Surgical management of radial fracture
219450380|NCT02353338|PROCEDURE|Conservative management|Immobilized/cast for 6 weeks
219450381|NCT02353338|DEVICE|cast|
219450382|NCT02576093|DRUG|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
219587699|NCT01381250|BEHAVIORAL|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
219587700|NCT00737750|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
219587701|NCT00737750|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
219450383|NCT02576093|DRUG|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
219450384|NCT02576093|DRUG|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
219450385|NCT02576093|DRUG|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
219587702|NCT00737750|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
219587703|NCT01673438|DRUG|aldoxorubicin|
219587704|NCT04269538|DRUG|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
219587705|NCT04269538|DRUG|Placebo|Placebo SC dosing
219587706|NCT02037035|DRUG|Ketamine|
219196786|NCT06663189|DRUG|treatment withdrawal|Patients will STOP their DMT
219196787|NCT06663189|DRUG|Usual DMT continuation|Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
219587707|NCT02003521|DEVICE|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
218840408|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
219196788|NCT06663189|OTHER|MRI|Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
219587708|NCT00918138|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
219587709|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
219587710|NCT00918138|DRUG|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
219196789|NCT06663189|BEHAVIORAL|Quality of Life questionnaires|EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
219196790|NCT06663189|OTHER|Disability evaluation tests|EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
219196791|NCT06826248|DRUG|Darqeen Capsule|Effect of Darqeen capsule on Thyroid hormones
219587711|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
219587712|NCT00918138|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
219587713|NCT03568279|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
219587714|NCT03568279|PROCEDURE|Control|The intubation was done without two-handed jaw thrust.
219587715|NCT03653117|DEVICE|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
219587716|NCT00457899|DRUG|Quetiapine IR (Immediate Release)|oral
219476093|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
219587717|NCT05500118|OTHER|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
219587718|NCT06048432|OTHER|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
219587719|NCT02592083|DRUG|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
219587720|NCT02592083|DRUG|Palbociclib|
219587721|NCT05033093|DRUG|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
219587722|NCT00699374|DRUG|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
219587723|NCT00699374|DRUG|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
219196792|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel one time a day during Day 3-Day 12.
219196793|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo one time a day during Day 3-Day 12.
219196794|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 2 times a day during Day 3-Day 12.
219587724|NCT05973266|BEHAVIORAL|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
219587725|NCT00196625|DRUG|Amprenavir (drug)|
219587726|NCT00196625|DRUG|ABT-378/r (drug)|
219587727|NCT00196625|DRUG|Ritonavir (drug)|
219587728|NCT02043587|DRUG|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
219587729|NCT02043587|DRUG|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
219587730|NCT02043587|DRUG|PEG-asp|2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
219587731|NCT02043587|DRUG|CTX|750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
219587732|NCT02043587|DRUG|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
219587733|NCT02043587|DRUG|Liposomal AraC|25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
219587734|NCT02043587|DRUG|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
219587735|NCT02043587|DRUG|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
219587736|NCT02043587|DRUG|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
219587737|NCT02043587|DRUG|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
219587738|NCT02043587|DRUG|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
219587739|NCT02043587|DRUG|Rituximab|375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
219587740|NCT02043587|DRUG|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
219587741|NCT05358470|OTHER|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
219587742|NCT00899990|OTHER|Laboratory Biomarker Analysis|Correlative studies
219587743|NCT01788618|OTHER|Cognitive exams|"Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~\- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
219196795|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 2 times a day during Day 3-Day 12.
218840409|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
218840410|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
218840411|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
219450386|NCT03239262|PROCEDURE|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
219450387|NCT03239262|PROCEDURE|No intervention|No intervention was performed in patients without ganglionated plexi.
219450388|NCT05394181|OTHER|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
218840412|NCT00883168|DRUG|Placebo|Placebo
218840413|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
218840414|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
219196796|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 3 times a day during Day 3-Day 12.
219196797|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 3 times a day during Day 3-Day 12.
219450389|NCT05274009|OTHER|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
219450390|NCT05274009|OTHER|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
219450391|NCT05274009|OTHER|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
219450392|NCT00218569|DRUG|Naltrexone|Naltrexone
219450393|NCT00218569|DRUG|Placebo|Placebo
219450394|NCT05431335|OTHER|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
219450395|NCT05431335|OTHER|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
219450396|NCT00011375|DRUG|Rolipram|
219450397|NCT00355615|DRUG|Rosuvastatin|oral
219450398|NCT00355615|DRUG|Placebo|oral
219450399|NCT02608294|DEVICE|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
219476094|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
219476095|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
219476096|NCT06635408|DIAGNOSTIC_TEST|cystatin c|a biomarker to assess renal function
219476097|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
219476098|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
219476099|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
219476100|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219450400|NCT02608294|DEVICE|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
219450401|NCT03523715|DIETARY_SUPPLEMENT|Prunes|12 oz of prunes daily
219450402|NCT03523715|DRUG|Docusate Sodium|Oral docusate sodium twice daily
219450403|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
219450404|NCT00151528|DRUG|Pregabalin|
219450405|NCT06009406|OTHER|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
219450406|NCT01654328|DRUG|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
219450407|NCT01654328|DRUG|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
219450408|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
219450409|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
219450410|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
219450411|NCT00276224|DRUG|ferrous sulphate (drug)|
219450412|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
219450413|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
219450414|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
218840415|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
218840416|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
218840417|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
218840418|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219450415|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
219450416|NCT01751373|BEHAVIORAL|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
219450417|NCT01751373|BEHAVIORAL|Standard Therapy|
219450418|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
219450419|NCT02347202|OTHER|Telephone support as needed|
219450420|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
219450421|NCT05467072|DEVICE|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
219450422|NCT03712995|PROCEDURE|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
219450423|NCT04272814|OTHER|Compression therapy|Compression application
219476101|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
219476102|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
219476103|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
219476104|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
219476105|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
219476106|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
218840419|NCT00262886|DRUG|cyclophosphamide|
219476107|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
218840420|NCT00262886|DRUG|fludarabine phosphate|
218840421|NCT00262886|DRUG|mycophenolate mofetil|
218840422|NCT00262886|DRUG|tacrolimus|
218840423|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
219476108|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
219476109|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
219450424|NCT04272814|DIAGNOSTIC_TEST|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
219450425|NCT03814460|DIAGNOSTIC_TEST|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
219450426|NCT05801172|PROCEDURE|ketoprofen for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
219450427|NCT05801172|PROCEDURE|ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
219450428|NCT05801172|PROCEDURE|ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
219450429|NCT05790902|DRUG|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
219450430|NCT05790902|DRUG|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
219450431|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
219450432|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
219450433|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
219450434|NCT05581927|DEVICE|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
219450435|NCT05581927|DEVICE|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
219450436|NCT06612008|DEVICE|Mandibular Advancement Device|MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
219450437|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
218840424|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
218840425|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
219196798|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)
219196799|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
219450438|NCT06989463|OTHER|12 Week Exercise Intervention|Participants will be provided with the results of their physical functioning and fitness assessments and will receive an individually tailored exercise prescription, written by an exercise specialist and approved by the study physician. The prescription will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity and twice weekly strengthening106 over 12 weeks.
219476110|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
219476111|NCT00396357|DRUG|Vildagliptin|
219476112|NCT00396357|DRUG|metformin|
219476113|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
219476114|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
219476115|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
219476116|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
219476117|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
219476118|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
219476119|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
219476120|NCT01716546|DRUG|Pazopanib|
219196800|NCT06824883|DRUG|Immunochemotherapy|"P-P-GemOx regimen Sintilimab 200mg iv D1; Pegaspargase 3750U im D1; GemOx regimen: Gemcitabine 1000mg/m2 iv D1, Oxaliplatin 100mg/m2 iv D1 This regimen is administered every 3 weeks.~For patients with stage I-II (localized) disease:~A sandwich approach incorporating radiotherapy is employed. Patients initially receive 2 cycles of the P-P-GemOx regimen. If the interim evaluation demonstrates a complete response (CR) or partial response (PR), patients will proceed to intensity-modulated radiotherapy (IMRT). Following radiotherapy, an additional 2 cycles of the P-P-GemOx regimen are administered.~For patients with stage III-IV (advanced) disease. Patients are planned to receive 6 cycles of the P-P-GemOx regimen. For those achieving CR or PR following 6 cycles of immunochemotherapy, subsequent treatment options include autologous hematopoietic stem cell transplantation (auto-HSCT) or PD-1 monoclonal antibody maintenance therapy, determined based on age and overall physical condition."
219196801|NCT06824961|OTHER|5-second ventilation pause duration during mechanical CPR|The intervention is a 5-second lasting ventilation pause during mechanical CPR
219450439|NCT06989463|OTHER|Cognitive Training Intervention|"Participants will complete cognitive training with Lumosity (Lumos Labs, Inc.; San Francisco, California; cognitive training program). This computer-based training consists of games focused on specific executive function skills (shifting attention, working memory, verbal fluency, problem solving). Each 20-minute session includes five games focused specifically on these executive functioning skills.~Participants will be prescribed three 20-minute sessions each week for 12-weeks."
219450440|NCT06989463|OTHER|Mindfulness practice intervention|"The mindfulness practice intervention is a modified version of the University of California at Los Angeles Mindfulness Awareness Research Center's Mindful Awareness Practices designated to be remotely delivered.~during odd weeks, participants will watch the educational lecture video once and practice meditation daily. During even weeks, they will review the educational video as needed and continue daily meditation practice."
219450441|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
219450442|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
219450443|NCT05248529|OTHER|Education booklet|Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
219450444|NCT03531918|DRUG|Cladribine|Given IV
219450445|NCT03531918|DRUG|Cytarabine|Given IV
219450446|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
219450447|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
219450448|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
219450449|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
219450450|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
219450451|NCT06666764|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
219450452|NCT06666764|OTHER|Control|Best medical care
219450453|NCT06675188|DRUG|PF-07275315|PF-07275315 solution for injection (single use only)
219450454|NCT06675188|OTHER|Placebo|Placebo solution for injection (single use only)
218840426|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
219196802|NCT06824961|OTHER|3-second ventilation pause duration during mechanical CPR|The intervention is a 3-second lasting ventilation pause during mechanical CPR
219196803|NCT06824454|DRUG|Dipyridamole 75 MG|Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
219196804|NCT04424316|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
219196805|NCT04424316|BIOLOGICAL|Placebo|Placebo
219450455|NCT03820479|OTHER|Protocol|Best practice of protocol
219450456|NCT07001852|OTHER|Endovascular Therapy (Mechanical Thrombectomy)|Endovascular therapy performed with CE-approved thrombectomy devices, initiated within 6 to 72 hours after stroke onset in patients with anterior circulation large vessel occlusion. The procedure is guided by an automated non-contrast CT detection tool and follows standard device-specific instructions for use.
219450457|NCT07001852|OTHER|Standard Medical Management|Standard medical management including therapies such as antiplatelet agents, anticoagulants, blood pressure control, and general supportive care. Delivered in accordance with institutional guidelines for acute ischemic stroke.
219450458|NCT01563406|OTHER|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
219450459|NCT01563406|OTHER|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
219450460|NCT01563406|DRUG|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
219450461|NCT01563406|DRUG|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
219450462|NCT06390150|DEVICE|Spinal Cord Stimulator|The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
219450463|NCT03299166|DRUG|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
218840427|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
218840428|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
218840429|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
218840430|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
218840431|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
218840432|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
218840433|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
218840434|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
218840435|NCT03438279|OTHER|Non-Interventional|Non-Interventional
218840436|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
218840437|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
218840438|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
218840439|NCT01243372|GENETIC|mutation analysis|
218840440|NCT01243372|OTHER|laboratory biomarker analysis|
218840441|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
218840442|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
218840443|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
218840444|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
218840445|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
218840446|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
219450464|NCT03299166|DRUG|Placebo|Matching capsule once daily (QD)
218840447|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
218840448|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
218840449|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
218840450|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
218840451|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
218840452|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
218840453|NCT03704480|DRUG|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
218840454|NCT03704480|DRUG|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
218840455|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
218840456|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
218840457|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
218840458|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
219450465|NCT05277116|OTHER|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
219450466|NCT05464498|DEVICE|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
219450467|NCT05464498|OTHER|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
219450468|NCT02521740|OTHER|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
219450469|NCT06687278|BEHAVIORAL|Interpersonal Relationship Psychotherapy-Based Intervention Program|The Interpersonal Relationship Psychotherapy-Based Intervention Program is based on IPR and developed with reference to relevant literature and a previously published study (Cort et all., 2014). Subsequent to the development of the program, a series of expert opinions were obtained from seven specialists in the field. The Interpersonal Relationship Psychotherapy-Based Intervention Program is a 2.5-3 month program comprising eight individual sessions. The program is designed to be administered on a weekly basis, with each session lasting approximately 45-60 minutes. The participants in this group will receive an Interpersonal Relationship Psychotherapy Based Intervention Programme, which consists of eight individual sessions.
219450470|NCT04111653|OTHER|Mud therapy|Application of sludge poultice
219450471|NCT04815876|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
219587744|NCT01788618|OTHER|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
219587745|NCT01788618|OTHER|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
219587746|NCT01788618|OTHER|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
219587747|NCT06113926|OTHER|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist… acknowledgment of the participants experience, …this shouldn't have happened, and I'm really sorry it did… an apology, and …I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
219587748|NCT02226757|DRUG|Paclitaxel-trastzumab|"Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~\- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
219587749|NCT05211414|BEHAVIORAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
219450472|NCT04815876|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
219450473|NCT04815876|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
219450474|NCT05263544|OTHER|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
219450475|NCT00043004|BIOLOGICAL|bevacizumab|
219450476|NCT00043004|DRUG|FOLFOX regimen|
219450477|NCT00043004|DRUG|fluorouracil|
219450478|NCT00043004|DRUG|leucovorin calcium|
219450479|NCT00043004|DRUG|oxaliplatin|
219450480|NCT00043004|PROCEDURE|conventional surgery|
219450481|NCT00043004|PROCEDURE|radiofrequency ablation|
219450482|NCT04055844|DRUG|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
219450483|NCT04055844|DRUG|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.
219450484|NCT04055844|DRUG|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
218840459|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
218840460|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
218840461|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
218840462|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
218840463|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
218840464|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
218840465|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
218840466|NCT06351345|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
218840467|NCT05221840|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219017637|NCT06058169|DEVICE|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
219450485|NCT03538990|OTHER|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
219450486|NCT06013319|DRUG|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
219450487|NCT03732521|OTHER|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
219450488|NCT00307814|DRUG|Epoetin Alfa|
219450489|NCT00572728|PROCEDURE|CT|Undergo 18F-FLT PET/CT
219450490|NCT00572728|DRUG|18F-FLT|Undergo 18F-FLT PET/CT
219450491|NCT00572728|PROCEDURE|PET|Undergo 18F-FLT PET/CT
219450492|NCT04356872|DRUG|Sintilimab|immune check point inhibitor, 200mg, iv, d1
219587750|NCT01996449|DRUG|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
218840468|NCT05221840|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
219450493|NCT04356872|DRUG|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
219587751|NCT01996449|DRUG|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
218840469|NCT05221840|DRUG|Monalizumab|Monalizumab IV (intravenous infusion)
218840470|NCT05221840|OTHER|Placebo|Placebo IV (intravenous infusion)
219450494|NCT04356872|DRUG|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
219450495|NCT02615262|DRUG|Dexamethasone|
219450496|NCT02615262|DRUG|Placebo|0.9% Sodium Chloride
219450497|NCT06435962|DEVICE|sonography|measurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
219450498|NCT02719457|OTHER|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
218840471|NCT05411822|DEVICE|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention. Blue light (λmax = 451 nm) on axis and off axis.
218840472|NCT05411822|DEVICE|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention. Green light (λmax = 522 nm) on and off axis
218840473|NCT05411822|OTHER|Dim-light control condition|(\< 5 lux at the eye) for 30 min
218840474|NCT03352141|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
218840475|NCT04715568|DRUG|Losartan|50 mg tablets taken orally
218840476|NCT04715568|DRUG|Placebo|Tablets taken orally
218840477|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
218840478|NCT01864148|DRUG|BIIB033|
218840479|NCT01864148|OTHER|Placebo|
219450499|NCT02719457|OTHER|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
219450500|NCT04113512|OTHER|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
219450501|NCT04407624|OTHER|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
219450502|NCT04407624|OTHER|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
219450503|NCT00002981|PROCEDURE|positron emission tomography|
219450504|NCT00002981|RADIATION|fludeoxyglucose F 18|
219450505|NCT00002981|RADIATION|methionine C 11|
219450506|NCT01529450|DRUG|LDE225|800-mg (4 200-mg capsules/day) capsule
218840480|NCT01864148|DRUG|Avonex|
218840481|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
218840482|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
218840483|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
218840484|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
218840485|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
218840486|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
219450507|NCT02142855|BEHAVIORAL|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
219450508|NCT02142855|BEHAVIORAL|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
219450509|NCT03457636|DRUG|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
219450510|NCT03457636|DRUG|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
218840487|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
218840488|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
218840489|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
218840490|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
219450511|NCT00358709|BEHAVIORAL|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
218840491|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
219450512|NCT02230839|BEHAVIORAL|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
219450513|NCT02230839|BEHAVIORAL|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
219450514|NCT04431804|OTHER|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
219450515|NCT04823741|GENETIC|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
219450516|NCT03465046|COMBINATION_PRODUCT|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
219450517|NCT00540527|DRUG|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
219450518|NCT00540527|DRUG|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
219450519|NCT00731952|DRUG|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
219587752|NCT01996449|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
218840492|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
218840493|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
218840494|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
218840495|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
218840496|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
218840497|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
218840498|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
218840499|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
218840500|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
218840501|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
218840502|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
218840503|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
219017638|NCT05649306|OTHER|Additional Education|Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
219017639|NCT05649306|OTHER|Questionnaires|Female Sexual Function Index, Demoralization Scale-II
218840504|NCT04698564|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
218840505|NCT06233110|DRUG|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
218840506|NCT06233110|DRUG|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
218840507|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
218840508|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
218840509|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
218840510|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
218840511|NCT02414945|DRUG|Cyclophosphamide|
218840512|NCT02414945|DRUG|Fludarabine|
218840513|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
218840514|NCT02414945|BIOLOGICAL|Interleukin-2|
218840515|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
218840516|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
218840517|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
218840518|NCT03456349|DRUG|HTL0018318|HTL0018318
218840519|NCT03456349|DRUG|Placebo|Placebo
218840520|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
218840521|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
218840522|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
218840523|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
218840524|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
219450520|NCT04001660|PROCEDURE|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
219450521|NCT03815760|DEVICE|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
218840525|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
218840526|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
218840527|NCT06079281|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
218840528|NCT06079281|DRUG|Placebo|Placebo will be administered via SC injection.
218840529|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
218840530|NCT00150215|DRUG|PF-00184562|
218840531|NCT00150215|DRUG|Olanzapine|
218840532|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
218840533|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
218840534|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
218840535|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
218840536|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
219450522|NCT06338852|OTHER|Socio demographic and evaluation questionnaires|Socio demographic and evaluation questionnaires Used to measure the awareness of gynaecologists about role of physical therapy in genital prolapse
218840537|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
218840538|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
219450523|NCT02683460|PROCEDURE|Patella resurfacing|
219450524|NCT02683460|PROCEDURE|Patella retention|
219450525|NCT01885104|DRUG|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
219450526|NCT01885104|DRUG|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
219450527|NCT01885104|DRUG|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
219450528|NCT00654576|DRUG|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
219587753|NCT01996449|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
219587754|NCT01996449|PROCEDURE|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
219587755|NCT01996449|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
219587756|NCT01996449|PROCEDURE|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
219587757|NCT01996449|PROCEDURE|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
218840539|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
218840540|NCT02173483|PROCEDURE|Quadriceps graft|
218840541|NCT00684710|DRUG|PAZ-417|
218840542|NCT00684710|DRUG|Placebo|
218840543|NCT03245411|BEHAVIORAL|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
218840544|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
218840545|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
218840546|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
218840547|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
218840548|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
219450529|NCT00654576|BEHAVIORAL|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
219450530|NCT04236531|OTHER|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
219450531|NCT00991367|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
219450532|NCT00991367|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
219450533|NCT00944580|BIOLOGICAL|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
219450534|NCT04369586|DRUG|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
219450535|NCT04369586|DRUG|Placebo|placebo
219450536|NCT05622656|DRUG|Dexmedetomidine|Dexmedetomidine 0.0005%
219587758|NCT05275803|DIETARY_SUPPLEMENT|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
218840549|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
218840550|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
219450537|NCT05622656|DRUG|Placebo|0.9% Sodium Chloride Solution
219450538|NCT03304093|DRUG|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
219450539|NCT04925830|BEHAVIORAL|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
219450540|NCT05437692|DRUG|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
219450541|NCT02469584|PROCEDURE|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
219450542|NCT00113555|DEVICE|ACT (Adjustable Continence Therapy)|surgically implanted device
219450543|NCT02602704|DRUG|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
219450544|NCT02602704|DRUG|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
219450545|NCT03202368|DRUG|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
219450546|NCT02374073|OTHER|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
219587759|NCT05275803|DIETARY_SUPPLEMENT|Control|The participant does not use probiotics after non-surgical periodontal treatment.
219587760|NCT00553306|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219587761|NCT00553306|BIOLOGICAL|aldesleukin|Given subcutaneously
219017640|NCT05649306|OTHER|Attendance Diary|Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
219017641|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
219587762|NCT00553306|DRUG|cyclophosphamide|Given IV
219587763|NCT00553306|PROCEDURE|biopsy|Optional correlative studies
219017642|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
219450547|NCT02374073|OTHER|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
219450548|NCT04426240|DRUG|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
219450549|NCT01703715|DEVICE|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
219450550|NCT01636167|DEVICE|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
219450551|NCT01576224|DEVICE|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
219587764|NCT00553306|OTHER|immunohistochemistry staining method|Optional correlative studies
219587765|NCT00553306|OTHER|flow cytometry|Correlative studies
219587766|NCT00553306|GENETIC|polymerase chain reaction|Correlative studies
219587767|NCT06263712|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
219450552|NCT01864486|DEVICE|Intelligent Retinal Implant System|
218840551|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
218840552|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
219017648|NCT05070403|DRUG|Afatinib 40 MG|Participants will receive 40 mg Afatinib, once daily.
219450553|NCT03336203|DRUG|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
219450554|NCT06168981|OTHER|Chewing Gum|The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
218840553|NCT03708315|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
218840554|NCT03708315|DRUG|Placebos|Placebo
218840555|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
218840556|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
219450555|NCT06302608|GENETIC|NGGT001|Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
219450556|NCT06690255|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
219476121|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
219476122|NCT04148274|OTHER|No intervention|There is no intervention for this study.
219476123|NCT06717256|BEHAVIORAL|training|The diabetes education booklet is a collection of information designed by the researcher. These interventions will continue for 1.5 months, with a total of 6 sessions for each type 2 DM individual, lasting approximately 120 minutes (2 hours per week and 12 hours in total after 6 weeks), and will be carried out as reminders afterwards. In these sessions, agendas will be created appropriately on regular eating habits, physical activity, regular monitoring of blood sugar, compliance with treatment, problem-solving ability, coping strategies and minimizing risks, conflicts regarding self-management and skin care behaviors of the patient will be tried to be resolved, the patient's suitability and adaptation to the change phase will be determined, their willingness to change will be questioned, and the change plan will be helped in the matters of care and self-management.
219476124|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
219476125|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
219476126|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
219476127|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
219476128|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
219476129|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
219476130|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
219476131|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
219476132|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
219476133|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
219476134|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
219476135|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
219476136|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
219476137|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
219476138|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
219450557|NCT06902246|DRUG|Regorafenib|"Participants will orally self-administer Regorafenib tablets for the first 21 days of each 28-day cycle as follows. Dose-escalation will occur only if there are no significant drug-related adverse events:~* Safety Run-in Phase: For the first six (6) participants enrolled. The starting dose is 80 mg/day during Cycles 1 and 2. In Cycle 3, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose of 160 mg/day on Days 15 to 21. Participants will continue to receive the maximum tolerated dose determined at the end of Cycle 3.~* Phase 2: For participants enrolled after the Safety Run-in phase. In Cycle 1, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose 160 mg/day on Days 15 to 21. From Cycle 2 onward, participants will take 160 mg/day (or maximum tolerated dose from Cycle 1), on Days 1 to 21."
219450558|NCT06902246|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Y-90 absorbed glass microspheres will be administered standard of care once via the percutaneous trans-arterial approach after the first 3 weeks of Regorafenib treatment but before Day 28. Additional Y-90 absorbed glass microsphere administration is allowed for treatment of baseline disease in the absence of disease progression within 6 months of the initial Y-90 TARE treatment.
219450559|NCT02244125|DRUG|PCD|"STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~\- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]"
219450560|NCT02244125|PROCEDURE|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
219450561|NCT05637567|DRUG|Acetylsalicylic acid|100 mg per os once daily
219450562|NCT05637567|DRUG|Placebo|Placebo pill per os once daily
219450563|NCT03551106|OTHER|Web based learning module|Web based learning module available on a especially designed website
219450564|NCT02725749|RADIATION|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
219450565|NCT02725749|OTHER|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
219450566|NCT02725749|RADIATION|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
219450567|NCT03028532|DRUG|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
218840557|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
218840558|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
218840559|NCT05064501|OTHER|Asthma control test|Asthma control test
219587768|NCT06263712|BEHAVIORAL|Standard of care plus resource interview group (STAR)|The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
219587769|NCT00042536|DRUG|Naltrexone HCL/ Yohimbine HCL|
219587770|NCT05915975|BEHAVIORAL|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
218840560|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
218840561|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
218840562|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
218840563|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
219587771|NCT05915975|BEHAVIORAL|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
219587772|NCT04859543|DEVICE|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
218840564|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
218840565|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
218840566|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
218840567|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
219450568|NCT03137056|DEVICE|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
219450569|NCT03137056|DEVICE|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
219450570|NCT03137056|DEVICE|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
219450571|NCT06507215|DIAGNOSTIC_TEST|Protein analysis|The investigator enrolled 149 healthy volunteers and collected peripheral blood samples for protein analysis. While 18 of these individuals with protein levels in the range of 40%-64% were predicted to be carriers by the monocyte assay, subsequent DYSF sequencing analysis in 14 of 18 detected missense variants in only four. Analysis of DNA methylation patterns at the DYSF locus showed no changes in methylation levels at CpG islands and shores between samples.
219450572|NCT01251315|DRUG|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
219450573|NCT01251315|DRUG|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
219587773|NCT00442039|DRUG|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing \< 20 kg
218840568|NCT00615693|DRUG|AEB071|
218840569|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
218840570|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
219450574|NCT01251315|DRUG|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
219450575|NCT01251315|DRUG|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
218840571|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
218840572|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
218840573|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
219587774|NCT00442039|DRUG|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
218840574|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
218840575|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
218840576|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
218840577|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
218840578|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
218840579|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
219587775|NCT00442039|DRUG|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
219587776|NCT00442039|DRUG|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
218840580|NCT05970341|BEHAVIORAL|1. Welcome package|"At the end of the baseline data collection visit at the clinic, the Research Staff will hand the participant a welcome packet that includes:~* educational and motivational written materials (about such topics as CKD and healthy eating for early CKD stages)~* a collection of recipes featuring kidney-friendly vegetables"
218840581|NCT05970341|BEHAVIORAL|2. Welcome information (phone or text)|"Those allocated to the intervention arm will receive a welcome call from the Program Staff to provide further details and expectations about the program (such as delivery details and schedule).~Those allocated to the control arm will receive an SMS text that informs them of their arm allocation, what to expect and a phone number to call for questions."
218840582|NCT05970341|BEHAVIORAL|3. Produce delivery + Recipes customized to produce|"* Content: Bags with kidney-friendly produce will include 2 vegetables sufficient for 2 meals for 4 people, 1 type of fruit, and 1 dried fruit. The total cost is estimated at USD 20, excluding delivery, for prices in June 2022.~* Delivery: Bags will be delivered to the participant's preferred location (e.g. home or work) and period of the day (e.g., morning, evening).~* Recipes: SMS texts will precede each delivery to share an URL to recipes customized to the items being delivered, and to inform of an upcoming produce bag, its content.~* Frequency:~  1. Weeks 1-2 (2 weeks): No bags delivered.~ 2. Weeks 3-10 (8 weeks): Delivered weekly, for a total of 8 bags.~ 3. Weeks 11-18 (8 weeks): Delivered every two weeks, for a total of 4 bags.~ 4. Weeks 19-26 (8 weeks): No bags delivered."
218840583|NCT05970341|BEHAVIORAL|4. E-gift cards to a grocery store of choice|"Five (5) e-gift cards to a major local grocery retailer chosen by the participant (from 3 options) at the following frequency:~1. Weeks 1-6: No e-gift card.~2. Week 7: One card of USD 30.00 value.~3. Week 11 \& 15: One card of USD 40.00, for a total of USD 80.00.~4. Week 19 \& 23: One card of USD 60.00, for a total of USD 120.00."
218840584|NCT05970341|BEHAVIORAL|5. Personalized practical & emotional support through a dedicated health partner|"* Each participant is assigned a program staff (dedicated health partner) who call them briefly (15 min or so) over the phone for empathy-based support on the participant's health journey, and practical suggestions for shopping and food preparation.~* The Health Partner will share periodically via SMS text a curated list of evidence-based, trustworthy online educational resources.~* Health partners are not trained to answer medical or health-related questions and will not provide medical guidance or advice of any kind. For such questions, they will encourage participants to contact the clinic or physician.~* Frequency:~  1. Weeks 1-2 (2 weeks): No calls.~ 2. Weeks 3-7 (4 weeks): 2 calls a week, for a total of 8 calls.~ 3. Weeks 8-26 (18 weeks): 1 call every 2 weeks, for a total of 10. But during weeks 7, 11, and 19, participants will be given the choice to keep at 1x/week or decrease to 1x every 4 weeks."
218840585|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
218840586|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
219450576|NCT01251315|DRUG|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
219450577|NCT01251315|DRUG|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
219450578|NCT02672644|DEVICE|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
219450579|NCT02672644|DEVICE|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
219450580|NCT04552067|DRUG|Lovenox|patients given curative dose of Lovenox
219587777|NCT06351436|BEHAVIORAL|Mindfulness|The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
219587778|NCT04758975|DRUG|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
219450581|NCT04552067|DRUG|Enoxaparin|patients given curative dose of Enoxa
219450582|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
219587779|NCT04758975|DRUG|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
219587780|NCT04758975|DRUG|Ibrutinib|IBRUTINIB 420 mg QD
219587781|NCT02469259|DRUG|Oxytocin|
219587782|NCT02469259|OTHER|Placebo|
219450583|NCT05758974|PROCEDURE|dental treatment|Extraction, pulp therapy or both
219450584|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
219476139|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
219476140|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
219476141|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
219476142|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
219476143|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
219476144|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
218840587|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
218840588|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
218840589|NCT05270148|OTHER|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
219450585|NCT04330989|BEHAVIORAL|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
218840590|NCT05270148|OTHER|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
218840591|NCT00038090|DRUG|Thalidomide|100 mg capsules by mouth daily each evening
218840592|NCT00038090|DRUG|Dexamethasone|20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
218840593|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
218840594|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
218840595|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
218840596|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
218840597|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
218840598|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
218840599|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
218840600|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
218840601|NCT00000696|DRUG|Interferon alfa-2a|
218840602|NCT00000696|DRUG|Zidovudine|
218840603|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
219450586|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
219450587|NCT05616572|BEHAVIORAL|OncoWhiz|OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
219450588|NCT00112840|DRUG|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
219450589|NCT00112840|DRUG|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
219476145|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
219476146|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
219476147|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
219476148|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
219476149|NCT02010671|OTHER|Survey|Survey
219476150|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
219476151|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
218840604|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
218840605|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
218840606|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
218840607|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
218840608|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
218840609|NCT01270880|GENETIC|RNA analysis|Correlative studies
218840610|NCT01270880|OTHER|spectrophotometry|Correlative studies
218840611|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
218840612|NCT01270880|GENETIC|gene expression analysis|Correlative studies
218840613|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
218840614|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
218840615|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
218840616|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
218840617|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
218840618|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
218840619|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
218840620|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
219450590|NCT02299206|DRUG|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
219450591|NCT02299206|DRUG|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
219450592|NCT00407251|DRUG|Patupilone|
219450593|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
218840621|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
218840622|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
218840623|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
218840624|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
218840625|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
218840626|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
218840627|NCT01153711|DRUG|Ketoconazole|400 mg tablet
218840628|NCT01153711|DRUG|Ketoconazole|400 mg tablet
218840629|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
218840630|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
218840631|NCT03222362|OTHER|Surgery|
218840632|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
218840633|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
218840634|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
218840635|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
218840636|NCT01668446|DRUG|estradiol valerat|
218840637|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
218840638|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
218840639|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
218840640|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
218840641|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
218840642|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
218840643|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
219450594|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
219450595|NCT05254925|DRUG|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
219450596|NCT05254925|OTHER|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
219450597|NCT05254925|DRUG|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
219450598|NCT05254925|OTHER|Petrolatum vehicle|Petrolatum vehicle
219450599|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
219450600|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
219450601|NCT00166621|DRUG|Buspirone|
219450602|NCT03566498|DIETARY_SUPPLEMENT|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
219587783|NCT01915706|PROCEDURE|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
219587784|NCT02485171|DEVICE|SAFEWALKER|Medical device walking aids.
219587785|NCT01136967|DRUG|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
218840644|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
218840645|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
219450603|NCT03566498|DIETARY_SUPPLEMENT|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
219450604|NCT02875366|DRUG|LUM/IVA|
219587786|NCT02885181|DRUG|GS-9876|One tablet administered orally once daily
219587787|NCT02885181|DRUG|Filgotinib|Two tablets administered orally once daily
219587788|NCT02885181|DRUG|GS-9876 placebo|One tablet administered orally once daily
219587789|NCT02885181|DRUG|Filgotinib placebo|Two tablets administered orally once daily
218840646|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
218840647|NCT05891080|DRUG|JS004|Specified dose on specified days.
218840648|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
218840649|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
219450605|NCT02875366|DRUG|Placebo|
219450606|NCT01453686|DRUG|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
219587790|NCT02885181|DRUG|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
219587791|NCT00570895|DIETARY_SUPPLEMENT|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
218840650|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
218840651|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
218840652|NCT03138460|OTHER|standard medications crossed over to cannabis|
218840653|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
218840654|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
218840655|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
218840656|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
218840657|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
218840658|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
219450607|NCT01453686|DRUG|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
219450608|NCT00001302|DRUG|PSC 833|
219450609|NCT03249441|BEHAVIORAL|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
218840659|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
218840660|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
218840661|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
218840662|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
219450610|NCT01531933|DRUG|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
219476152|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
219476153|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
219476154|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
219476155|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
219476156|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
219476157|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
218840663|NCT01814397|DRUG|Anastrozole|1 mg orally daily
218840664|NCT01814397|DRUG|exemestane|25 mg orally daily
218840665|NCT01814397|DRUG|letrozole|2.5 mg orally daily
219476158|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
218840666|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
219450611|NCT01531933|DRUG|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
219450612|NCT02551328|DRUG|sevofluorane|Continuous infusion of sevofluorane
219450613|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
219450614|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
219450615|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
219450616|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
219450617|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
219450618|NCT01250392|BEHAVIORAL|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
219450619|NCT02308904|OTHER|Blood Draw/Semen Exam|"Females:~1\. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
219450620|NCT02308904|OTHER|Retrospective data/Chart Review/Relevant Clinical Results|"1. 1\. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1\. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1\. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
219450621|NCT02308904|OTHER|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
219450622|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
219450623|NCT03592173|DIAGNOSTIC_TEST|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
219450624|NCT06700291|PROCEDURE|Surgery|Patient undergoing Anesthesia and Surgery
218840667|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
218840668|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
218840669|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
218840670|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
218840671|NCT03302884|OTHER|biological sampling|Tumor and blood samples
218840672|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
218840673|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
219587792|NCT04930419|DEVICE|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
218840674|NCT01178944|DRUG|Oxaliplatin|Given IV
218840675|NCT01178944|DRUG|Pralatrexate|Given IV
218840676|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
218840677|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
219450625|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
219450626|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
219450627|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
219450628|NCT00685828|DRUG|imatinib mesylate|By mouth
219450629|NCT00004728|DRUG|Warfarin|
219450630|NCT00004728|DRUG|Aspirin|
219450631|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
219450632|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
218840678|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
218840679|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
218840680|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
218840681|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
218840682|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
218840683|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
218840684|NCT06549166|OTHER|Experimental: VR and exercise|Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
219450633|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
219450634|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
219450635|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
219587793|NCT04930419|DEVICE|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
218840685|NCT06549166|OTHER|Sham Comparator: exercise|The control group will perform a 40-minute same neck exercises.
218840686|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
219450636|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
219450637|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
219450638|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
218840687|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
218840688|NCT05090163|OTHER|PREP|Group based exercise
219450639|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
219450640|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
219450641|NCT02462200|OTHER|Indocyanine green|
219450642|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
219450643|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
219450644|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
219450645|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
218840689|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
219450646|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
219450647|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
219450648|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
218840690|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
218840691|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
218840692|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
218840693|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
218840694|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
218840695|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
218840696|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
219450649|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
219450650|NCT05625659|DIAGNOSTIC_TEST|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
219450651|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 5-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 5 ounces.
219450652|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 1-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the control group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 1 ounce.
219450653|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|Tested positive
218840697|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
218840698|NCT02177331|DRUG|Lacidipine|
218840699|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
218840700|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
218840701|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
218840702|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
218840703|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
219450654|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|tested negative
219450655|NCT06706778|BEHAVIORAL|Music intervention|Based on the NIH toolkit and MBIs reporting guidelines, the engagement in this pilot study will be receptive by providing participants with prerecorded, preselected playlists. Participants will also receive a guided video on maximizing music's therapeutic benefits. The playlists will be purely instrumental, with a 60-80 bpm tempo, and feature melodies and harmonies designed for stress relief, including soothing, grounding, meditation, emotional release, etc. This approach is resource-efficient and easily accessible, allowing participants to integrate it into daily pain self-management strategies. Participants will be asked to engage in the MBI in the morning and at night for 30 minutes each, wearing the abdominal belt and smartwatch.
218840704|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
218840705|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
219450656|NCT07135388|DIETARY_SUPPLEMENT|Food for special medical purposes|Oral supplementation with a protein supplement high in branched-chain amino acids and β-hydroxy-β-methyl-butyrate (HMB)
219450657|NCT06763627|OTHER|Gamification ( Board game )|"A three- or four-player board game will be designed to teach acute cholecystitis and pancreatitis. The game has two stages: educational (houses 1-9) and reinforcement (houses 10-30). Players roll dice and move their pieces to answer various questions such as multiple-choice, true/false, matching, puzzles, and scenario-based problem-solving. Each player starts with three hearts, and if they land on one of the three red trap spaces and answer incorrectly, they lose one heart. Yellow spaces introduce random events like gaining or losing hearts. One space features a general knowledge question for variety. Players must achieve a point threshold in the educational section to move to the reinforcement section, and the highest scorer at the end of the hour wins. Groups of 3 or 4 students will play for one hour under the supervision of the investigator."
219450658|NCT06763627|OTHER|Traditional lecture-based teaching|Students will attend a standard one-hour lecture delivered by a general surgery faculty member, covering the same topics. PowerPoint presentations prepared by the research team will ensure consistency with the game content.
219450659|NCT07069179|BEHAVIORAL|Choose to Move Replacement Ready|As described under study arm description.
219450660|NCT06853470|DEVICE|VA-ECMO circulatory support|Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a percutaneous mechanical circulatory support device that can provide short-term hemodynamic support during high-risk PCI.
219450661|NCT06853470|DEVICE|SynFlow 3.0 circulatory support|The SynFlow 3.0 is a novel percutaneous left ventricular-assist device that can provide temporary hemodynamic support during high-risk procedure.
219450662|NCT06853470|PROCEDURE|percutaneous coronary intervention|The percutaneous coronary intervention is a percutaneous endovascular intervention technique that can restore coronary blood flow by various intervention methods such as angioplasty and stent implantation.
219450663|NCT07077213|COMBINATION_PRODUCT|18F-FAPI-74|10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan, performed during the first 6 weeks of treatment and a second dose of 10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan within 6 weeks after tuberculosis treatment completion.
219450664|NCT05681442|DRUG|continuous pivotal βL-AB|continuous pivotal βL-AB
219450665|NCT05681442|DRUG|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
219450666|NCT05681442|DRUG|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
219450667|NCT05681442|DRUG|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
219476159|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
218840706|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
218840707|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
218840708|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
218840709|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
218840710|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
218840711|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
218840712|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
218840713|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
219476160|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
219476161|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
219476162|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
218840714|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
219476163|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
219476164|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
218840715|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
218840716|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
218840717|NCT03114111|DRUG|aminolevulinic acid (ALA)|
218840718|NCT03114111|DRUG|Placebo|
218840719|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
218840720|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
218840721|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
218840722|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
218840723|NCT02952313|DEVICE|Nasal Implant|
218840724|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
218840725|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
218840726|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
218840727|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
218840728|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
218840729|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
218840730|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
218840731|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
218840732|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
218840733|NCT05882045|DRUG|Retatrutide|Administered SC
218840734|NCT05882045|DRUG|Placebo|Administered SC
218840735|NCT04734860|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
218840736|NCT04734860|DRUG|Placebo|Diluent solution
219450668|NCT07084467|OTHER|EF1 guided CRT optimisation|In the EF1-guided optimisation group, the settings of the CRT device are adjusted to maximise early heart pumping efficiency, measured by a parameter called first-phase ejection fraction (EF1). Depending on the patient's heart rhythm, either the timing between heart chambers (AV or VV delay) is adjusted in small steps. The device setting that gives the best EF1 reading is chosen to help improve the heart's response to CRT.
219450669|NCT07084467|OTHER|Standard of Care (SOC)|This group will receive standard of care for their health condition and CRT management.
218840737|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
218840738|NCT01310946|OTHER|Database|Database
218840739|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
218840740|NCT01925040|DEVICE|Placement of restoration|Placement of restorations
218840741|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
218840742|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
218840743|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
218840744|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
218840745|NCT06563466|OTHER|Treatment as usual|See arm description
218840746|NCT05275478|DRUG|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
218840747|NCT03168737|PROCEDURE|Computed Tomography|Undergo PET-CT scan
218840748|NCT03168737|RADIATION|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
218840749|NCT03168737|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
218840750|NCT04394416|DRUG|Imatinib|Therapeutic
218840751|NCT04394416|DRUG|Placebo oral tablet|Placebo
218840752|NCT05893225|DRUG|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
218840753|NCT05893225|DRUG|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
218840754|NCT05788432|DEVICE|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
218840755|NCT04255849|BIOLOGICAL|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
218840756|NCT04255849|OTHER|Saline Placebo|Saline Placebo
218840757|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
218840758|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
219450670|NCT07076342|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)
218840759|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
219450671|NCT07076342|DRUG|PET Scan with [11C]ABP688|Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \[11C\]ABP688) to quantify hippocampal mGluR5 density.
218840760|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
218840761|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
218840762|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
218840763|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
218840764|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
218840765|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
219450672|NCT07086560|DRUG|IV adenosine|Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment
219450673|NCT07086560|DRUG|IV diltiazem|Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment
219450674|NCT06853860|OTHER|reflexology massage|classic hand massage
219450675|NCT06853860|OTHER|classic hand massage|classic hand massage
219450676|NCT07087743|BEHAVIORAL|VR-Based Gait Training with End-Effector Robot|A single-session gait training protocol using the Morning Walk® end-effector robot with real-time virtual reality visual feedback to encourage paretic limb propulsion and symmetrical gait. This intervention is intended to study participants' behavioral and biomechanical responses to the VR feedback, not to evaluate the robot as a device.
219450677|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
219587794|NCT04475835|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
219587795|NCT04475835|DRUG|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
219587796|NCT05837013|PROCEDURE|Spinal anesthesia (with nerve block)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
218840766|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
218840767|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
218840768|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
218840769|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
218840770|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
218840771|NCT06512779|OTHER|Control Group|sleep hygiene education
219450678|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219450679|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219450680|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219450681|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
219450682|NCT06343376|DRUG|Cyclophosphamide|Given IV
219450683|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
219450684|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
219450685|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
219450686|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
219450687|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219450688|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
219450689|NCT01412762|BEHAVIORAL|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
219450690|NCT01412762|BEHAVIORAL|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
219450691|NCT07094971|DEVICE|Pure Impact|Pure Impact is an EMS module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.
219450692|NCT06360718|BEHAVIORAL|"Who is Luke Eemia? Storybook"|"Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later)."
219450693|NCT07096167|BEHAVIORAL|Voucher for Afterschool Care|Intervention includes a voucher for afterschool care and enrollment assistance
219450694|NCT07101848|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. Patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
219450695|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were given orally as a single dose
219450696|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were taken orally multiple times
219450697|NCT07102537|DEVICE|Hyaluronic acid combined with calcium hydroxyapatite injection|The filler was injected in nasolabial folds in a before-after setting
219450698|NCT07100977|DIETARY_SUPPLEMENT|Bragg ACV Supplement|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
219450699|NCT07100977|OTHER|Placebo|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
219450700|NCT07100561|OTHER|Extensive post discharge counselling and phone-based follow up|Counselling by their attending physicians plus Extensive post-discharge counselling from a study doctor/pharmacist/a trained nurse and telephone follow-ups in addition to their normal outpatient reviews. The telephone follow-ups will be weekly for the first 30 days and then 4 weekly till day 90.
219450701|NCT07101354|DRUG|0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
219450702|NCT07101354|DRUG|0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
219450703|NCT07101354|DRUG|0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
219450704|NCT07101354|DRUG|0.08mg/kg DGPR1008 Injection Dose Group 4 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
219587797|NCT05837013|PROCEDURE|General anesthesia (GA)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
219587798|NCT03839823|COMBINATION_PRODUCT|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
218840772|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
219450705|NCT07101354|DRUG|Dose Group 0 (n=8)|Within the specified time frame, dose escalation will be conducted. Intravenous infusions will be administered according to randomization, with subjects receiving either the corresponding dose or placebo.
219450706|NCT07095972|DEVICE|Abbot Freestyle Libre CGM|Participants assigned to the CGM group will receive the Libre 2+ systems (Abbott Diabetes Care, Alameda, CA) upon randomization. This will include comprehensive training provided by a qualified healthcare professional. The training will cover detailed instructions on sensor placement, how to download and use the associated smartphone application, and guidance on interpreting the glucose data effectively. To ensure continuous and accurate monitoring, the CGM sensor will be routinely replaced every 14 days following randomization. Additionally, in the event of sensor detachment or loss, immediate replacement will be arranged to maintain uninterrupted glucose tracking. Regular sessions are conducted to analyze glucose trends, refine management strategies, and provide additional support or education on device usage.
219450707|NCT07099742|DRUG|Tirzepatide|Exposure
218840773|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
218840774|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
218840775|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
219450708|NCT07099742|BEHAVIORAL|Life Style Modification|Referent group - Lifestyle interventions, exercise, and diet control
219450709|NCT07100210|BIOLOGICAL|IL-22BP mRNA vaccine injection|During the injection of IL-22BP/LNP compound, there were three dose groups, namely 25 μg, 50 μg, and 100 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP/LNP compound formulation. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL-22BP/LNP compound injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be administered 1 month after the 4th dose.The entire treatment period lasts for 2 months.
218840776|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
218840777|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
219450710|NCT07101120|DRUG|KH607 tablets|oral 30mg , once daily for 14 days
218840778|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
218840779|NCT02620033|BEHAVIORAL|Yoga therapy|
218840780|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
219450711|NCT07101120|DRUG|placebo|oral, once daily for 21 days
219450712|NCT07101120|DRUG|KH607 tablets|oral 20mg, once daily for 21 days
219450713|NCT07101120|DRUG|KH607 tablets|oral 30mg, once daily for 21 days
219450714|NCT06909422|BEHAVIORAL|Mobile Intervention for Biased Thinking|This intervention will be delivered via a mobile application.
219450715|NCT07102511|BIOLOGICAL|lerodalcibep 300 mg Monthly SC|lerodalcibep or placebo
219450716|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
219476165|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
218840781|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
218840782|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
219476166|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
219476167|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
219476168|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
219476169|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
219476170|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
219476171|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
219476172|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
219476173|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
219476174|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
219476175|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
219476176|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
219450717|NCT06535932|DEVICE|Amara View Minimal Contact Full Face Mask|The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
219450718|NCT06535932|DEVICE|F40 Minimal Contact Full Face Mask|The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
218840783|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
219450719|NCT06911723|BEHAVIORAL|Brief Activities|The activities will be completed online.
219450720|NCT07101081|DIAGNOSTIC_TEST|HER-2 Test|Samples from patients with gynecological tumors eligible to the study will be retrospectively identified and the paraffin slides will be sent to central laboratory to perform HER2 IHC testing using the automated protocols (Dako and Ventana). Expert pathologists will select primary tumor samples from surgery or excisional biopsies with enough material to perform HER2 testing using both antibodies without exhausting the cancer tissue. The entire cohort will be tested with both Dako HercepTest and Roche Ventana 4B5 antibody using gastric cancer and breast cancer criteria for positivity (3+, 2+ and 1+, 0).
219450721|NCT06756685|OTHER|Core Strengthening Exercises|The Core Strengthening Program participants will have supervised gym-based sessions for 8 weeks. In the first 4 weeks , participants will attend two 1 hour training sessions, followed by self-selected one or two sessions per week. The session will begin with 20min of aerobic conditioning of walking or running on a treadmill, starting at 65% and moving to 85% of HR max. The 5 key elements of focus are i. Centering ii. Breathing iii. Head and neck placement iv. Shoulder placement v. Chest wall placement
219450722|NCT06756685|OTHER|Motor Control Training|"Participants in Motor Control group will receive two physiotherapy sessions of 1hour / week in the first 4 weeks, during stage 1. i. Abdominal drawing-in maneuver (ADIM) : isometric contraction of the local stability muscles (e.g., lumbar multifidus, transversus abdominis) in minimally loading positions (supine lying, quadruped, sitting, and standing) by maintaining a neutral spine while maintaining normal breathing. During Phase 2, One 1 hour session / week in the second 4 weeks.~Activation and facilitation of transversus abdominis, lumbar multifidus and pelvic floor motor control(36).Exercises target the transversus abdominis, multifidus and pelvic floor muscles plus postural correction to restore optimal motor control during non-weight-bearing activities. Exercises and progressions will follow previous protocols of motor control exercise."
219450723|NCT07102186|DRUG|use of adapalene gel 0.1% and hyaluronic acid at bedtime|in this intervention a combination of adapalene gel 0.1% and hyaluronic acid will be used
219450724|NCT07102186|DRUG|use of adapalene gel 0.1% once daily at bedtime|in this intervention involves the use of adapalene gel 0.1% once daily only topically at bedtime
219450725|NCT07100808|PROCEDURE|Using the tunnel technique in the treatment of gingival recession|Microsurgical periodontal instruments were used during surgical procedures. In this study, specially developed tunnel instruments (Helmunt Zepf, Seitingen-Oberflacht, Germany) were used to mobilize the gingivo-papillary unit and prepare the supraperiosteal tunnel bed. After passing the coronal edge of the alveolar bone with the tunnel instrument placed in the soft tissue, it was advanced towards the apical mucogingival junction with small, circular movements. This procedure was repeated by entering from the sulcus of each tooth. Care was taken to ensure that the prepared flaps were in the same layer and opened towards each other. In the interdental areas, the papillary complex was carefully separated from the periosteum and mobilized in the buccal direction. Thus, mobilization of the entire buccal soft tissue complex was achieved in the coronal direction. After these procedures, it was checked whether the flap covered the recession areas without tension.
219450726|NCT06287047|PROCEDURE|Epidural analgesia|Epidural analgesia alone or with dural puncture with different sizes of spinal needles
219450727|NCT04443842|BEHAVIORAL|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
219476177|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
219476178|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
219587799|NCT03839823|COMBINATION_PRODUCT|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]"
218840784|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
218840785|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
218840786|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
218840787|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
219450728|NCT06364709|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
219450729|NCT01171313|DRUG|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
219450730|NCT01171313|DRUG|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
219450731|NCT01171313|DRUG|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
219450732|NCT01171313|DRUG|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
219450733|NCT00683501|DRUG|DNB-001|four dosages of DNB-001, one placebo dosage
219450734|NCT04341311|DRUG|Marizomib|\- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
219450735|NCT04341311|DRUG|Panobinostat|\- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
219450736|NCT07140861|OTHER|Conventional|"patients will receive conventional therapy that include~1. Short foot exercises~2. Towel-curl exercise~3. Heel raise exercise~4. Calf stretch"
219450737|NCT07140861|OTHER|Experimental|"Core stability exercises:~The training programs will last 6 weeks and comprise 3 training sessions per week. Each training session lasted 30 min, starting with a brief, standardized warm-up program mainly consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, research group will conduct the big 3 exercises as described by McGill (Mcgill, 2001). These include the curl-up, side bridge, and quadruped position. In other words, every single training session consisted of frontal, dorsal, and lateral core exercises. Training intensity will be progressed and individually increased over the 6-week training program by modulating lever lengths, movement velocity"
218840788|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
218840789|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
219450738|NCT07138651|OTHER|Aspiration care bundle|Evidence-based aspiration care protocol
219450739|NCT05829811|DEVICE|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
219450740|NCT03128307|DEVICE|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
219450741|NCT07148648|PROCEDURE|Chest Wall Reconstruction|there are many methods described in literature for reconstruction of chest wall after chest wall resection. The investigators are focusing on chest wall reconstruction using steel wires in this study.
219450742|NCT07149285|OTHER|Mandala coloring|"Intervention Group:~The content of the study and the mandala application will be explained to women diagnosed with menopause, and after obtaining consent, a personal information form and scales regarding menopause symptoms and quality of life will be applied. Participants will be given a sample and blank mandala, 12 colored crayons and a follow-up form. The mandala application will be done for 20-30 minutes every day for 15 days, and will be monitored by phone every other day. At the end of the process, the scales will be re-applied and the follow-up forms will be collected. Their routine treatments will continue."
219476179|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
219476180|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
219476181|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
219476182|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
219476183|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
218840790|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
218840791|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
218840792|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
218840793|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
218840794|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
218840795|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
218840796|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
218840797|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
218840798|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
218840799|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
219450743|NCT07147517|OTHER|Component A0|It will be implemented as a recruitment strategy. This strategy will enable members of the community to access no cost testing for respiratory infections. If a participant feels sick or thinks they have been exposed to a respiratory infection and wants to be tested, they can complete a symptoms and exposure survey in the PREVENT APP, retrieve a PCR test kit from a vending machine using a unique code received through the PREVENT APP, self-collect an anterior nares nasal swab following instructions provided, and return the test kit at one of the vending machines or drop off locations for the EXCITE lab to pick up and process. The anterior nares nasal swab will be tested for SARS-CoV-2, influenza, Respiratory Syncytial Virus, and other germs (viruses or bacteria) that cause respiratory infections. At the time of consent and registration for the Community Testing Component, participants will be used to screen for Cohorts A/B.
219450744|NCT07147517|OTHER|Component A1|Participants will be invited to 'test' out the PREVENT App and a provide a 'baseline' sample to ensure competency for requesting a nasal swab, retrieving the test kit from a vending machine, self-collecting a sample, and returning the test for PCR testing, with the assistance of study staff. Weekly Symptom Surveys, Annual Surveys, and immunization status.
219587800|NCT03839823|COMBINATION_PRODUCT|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
218840800|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
219587801|NCT03839823|DRUG|Ribociclib|Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
219587802|NCT03839823|DRUG|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
219587803|NCT03839823|DRUG|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
218840801|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
218840802|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
218840803|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
218840804|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
218840805|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
218840806|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
218840807|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
218840808|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
218840809|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
218840810|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
218840811|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
218840812|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
218840813|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
218840814|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
218840815|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
218840816|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
218840817|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
218840818|NCT03545087|DRUG|Lanabecestat|Administered orally
218840819|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
218840820|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
218840821|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
218840822|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
219017650|NCT02828618|PROCEDURE|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
219587804|NCT04436887|PROCEDURE|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
219587805|NCT01152151|DEVICE|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
219587806|NCT01152151|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
219587807|NCT01152151|DEVICE|Reminder letters|up to four reminder letters in september - december 2010
219587808|NCT02419144|BEHAVIORAL|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
219587809|NCT05371860|OTHER|Omit breast radiation|Omit breast radiation for 3 years after surgery
219587810|NCT04228783|BIOLOGICAL|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
219587811|NCT04228783|BIOLOGICAL|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
218840823|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
218840824|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
219587812|NCT04228783|BIOLOGICAL|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
219587813|NCT00635063|DRUG|AD 923|
219587814|NCT05546112|DEVICE|Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B|A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
219587815|NCT05546112|DEVICE|Sham Stimulation using YPS-401B|A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
219587816|NCT02483208|DRUG|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
219587817|NCT02483208|DRUG|Advate|Advate infusion to analyze pharmacokinetics.
219587818|NCT05268835|DRUG|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
219587819|NCT01211938|RADIATION|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
219587820|NCT01211938|RADIATION|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
219587821|NCT00996775|BEHAVIORAL|brief alcohol intervention|this intervention consists of brief assessment and feedback
218840825|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
218840826|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
218840827|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
218840828|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
218840829|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
219587822|NCT00996775|BEHAVIORAL|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
219587823|NCT00304837|GENETIC|pVGI.1 (VEGF-2)|
218840830|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
218840831|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
218840832|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
218840833|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
219450745|NCT07147517|OTHER|Component A2|Investigators will collect immunologic specimens from a subset of participants in Component A (the subset herein referred to as Component A immunologic sub-study). Investigators will combine testing data from these immunologic specimens with multiple data elements already captured in Component A (such as data from pathogen testing and sequencing, survey data, medical records, or immunization services) and Component B (serum obtained at enrollment and 28 post-enrollment) to meet sub-study objectives. Overall, the Component A sub-study will provide critical insight into the immune response to respiratory pathogen infections and immunizations.
219450746|NCT07147517|OTHER|Component B|"Participants will be asked to complete the enrollment survey after enrolling in Component B if the survey has not already been completed as part of Component A. They will also be asked to complete:~1. Daily anterior nares nasal swab collection~2. All household participants, including the index case, will be asked to self-collect an enrollment swab and daily nasal swab specimens for 14 days and return them for testing.~3. Mucosal specimen collection~4. Survey data collection"
219450747|NCT07148622|DRUG|Antibiotic regimen 1: sulbactam + ampicillin + azithromycin|For the first 48 hours, 4×2 g IV sulbactam + ampicillin, 1 g oral azithromycin on day 1, and from days 3-7, 3×500 mg oral amoxicillin
219450748|NCT07148622|DRUG|Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin|For the first 48 hours, 1×1 g IV ceftriaxone + 2×500 mg oral clarithromycin, and from day 3 onwards, 3×500 mg oral amoxicillin + 2×500 mg oral clarithromycin.
219587824|NCT03151811|DRUG|Melflufen|Intravenous infusion
219587825|NCT03151811|DRUG|Pomalidomide|Oral capsules
219587826|NCT03151811|DRUG|Dexamethasone|Oral tablets
219587827|NCT03002571|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
219587828|NCT03002571|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
218840834|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
219476184|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
219587829|NCT02676583|PROCEDURE|Tonsillectomy|Closure or not closure of tonsil fossa
219587830|NCT01086397|PROCEDURE|Urine sample collection|All subjects have non-invasive urine sample collection performed
219587831|NCT01069276|OTHER|No intervention in this study|No intervention in this study
218840835|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
218840836|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
218840837|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
219017651|NCT02828618|PROCEDURE|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
219017652|NCT02828618|PROCEDURE|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
219017653|NCT02828618|PROCEDURE|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
219017654|NCT02828618|DRUG|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
219476185|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
219476186|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
219476187|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
219476188|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
219476189|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
219450749|NCT07148154|DEVICE|Cytology|Two cervical samples are collected using a cervical brush or swab, following the standard procedure for cervical cytology. Cells are taken from the cervix using a brush/spatula during a gynecological exam. (1) The first sample is kept in the clinical center's pathology department for examination. (2) The second sample is sent to MiMARK's facilities for the investigational project, where it will be processed and stored for future cohort selection and analysis.
219450750|NCT07149103|OTHER|Percutaneous Tibial Nerve Stimulation|By wearing the Confidanz Smart Patch, the Tibial Nerve will be stimulated
219450751|NCT07149103|OTHER|Placebo|No active stimulation will be provided
219450752|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training is an adaptive N-back task in which participants respond to colors and/or shapes.
219450753|NCT07147894|BEHAVIORAL|Gamified N-back training|Participants train on a gamified version of the N-back task, specifically, players control an astronaut that collects resources (target stimuli) needed to feed a colony and keep the technology working, while avoiding non-targets and other obstacles.
219450754|NCT07147894|BEHAVIORAL|Multiple Domain Training|Participants train on a gamified versions of the N-back task, Complex span, Set-shifting and Inhibitory control task.
219450755|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training trains a visual, adaptive N-back task in which participants respond to colors and/or shapes.
219450756|NCT07147894|BEHAVIORAL|Coaching Session|Participants in coaching conditions receive weekly, motivational coaching sessions via videoconference to (i) provide encouragement taking into account individual training performance and self-reported engagement (strength-based feedback), (ii) set realistic goals for training (time management, scheduling, and session completion plan, performance goals) while emphasizing autonomy and choice, and (iii) re-explain task and provide corrective feedback as needed.
219450757|NCT07148141|OTHER|Ovarian stimulation|Ovarian stimulation before oocytes retrieval
219450758|NCT07148479|OTHER|Telerehabilitation group|The telerehabilitation group participated in balance training sessions delivered through secure virtual platforms such as WhatsApp video calls. Participants completed 3 sessions per week, each lasting 45-60 minutes, over a total of 6 weeks (18 sessions). The program target static, dynamic, anticipatory, and reactive balance. participants will use households items.session began with warm-up exercises such as gentle marching, arm circles, and hamstring stretches, followed by balance training targeting static, dynamic, anticipatory, and reactive components. Exercises included heel-to-toe standing, single-leg stance, tandem stance, obstacle walking, heel-to-toe walking, side stepping, functional reach, weight shifting, caregiver-assisted perturbations, and foam surface standing. All exercises were performed in 3 sets with specified holds or repetitions. Sessions concluded with cool-down activities including tricep stretches, forward bends, and deep breathing.
219450759|NCT07148479|OTHER|Traditional balance training group|Same as telerehabilitation group but it will concluded in a clinical setting.
219450760|NCT06948448|DRUG|ONO-4578|ONO-4578 tablets once a day
219450761|NCT06948448|DRUG|Opdivo®|Specified dose on specified days
219450762|NCT06948448|DRUG|Oxaliplatin|Specified dose on specified days
219450763|NCT06948448|DRUG|5-Fluorouracil|Specified dose on specified days
219450764|NCT06948448|DRUG|Bevacizumab|Specified dose on specified days
219587832|NCT01517373|DRUG|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
219587833|NCT01517373|DRUG|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
219450765|NCT06948448|DRUG|Leucovorin|Specified dose on specified days
219450766|NCT06949579|BIOLOGICAL|blood sampling for DNA|Blood sampling for DNA and serum and plasma colection and PBMC
219450767|NCT06949215|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration."
219450768|NCT06949696|OTHER|Dual Task Training|In dual task training, patients will be given cognitive exercises such as counting backwards from 100 by 3, counting the names of cities, girls and boys while walking.
219450769|NCT06949696|OTHER|Cognitive Rehabilitation|In cognitive rehabilitation, patients will be given paper-and-pencil activities and exercises to find the difference between two pictures.
219450770|NCT06949696|OTHER|Conventionel Physiotherapy|In conventionel physiotherapy, patients will be given posture exercises for balance and strengthening.
219450771|NCT06948409|DRUG|Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])|The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.
219450772|NCT06949826|DRUG|Buprenorphine Transdermal System|The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
219587834|NCT01517373|DRUG|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
219587835|NCT01517373|DRUG|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
219587836|NCT01517373|DRUG|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
219587837|NCT02164474|BEHAVIORAL|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
219587838|NCT02712060|OTHER|No intervention|
218840838|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
219450773|NCT06949826|DRUG|Placebo Patch|The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
219450774|NCT06948513|DRUG|Naproxen|Naproxen given immediately post-operatively following Mohs surgery reconstruction
219450775|NCT06948513|DRUG|Acetaminophen (Standard of Care)|Acetaminophen alternated with ibuprofen on an as needed, patient directed basis
219450776|NCT06948513|DRUG|ibuprofen|Ibuprofen alternated with acetaminophen in a patient directed manner for as needed pain control
219450777|NCT06948994|COMBINATION_PRODUCT|autologous NK cell plus GD2 antibody|Combination of autologous NK cells and GD2 monoclonal antibody
219450778|NCT07147244|OTHER|Treatment 1: Full GRIN course (Lessons 1-8)|multi module online training
219587839|NCT01284946|DRUG|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
219587840|NCT04447950|PROCEDURE|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
218840839|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
218840840|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
219587841|NCT04447950|PROCEDURE|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
219587842|NCT06232330|DEVICE|Group A|This group will receive TOA which include Weight transfers from a standing position and stepping in various star-type directions, Sit-ups from different heights with the hemiplegic lower limb behind the normal lower limb, From a kneeling position alternately projecting the lower limb forward, From a standing position with a limited base of support turning head and trunk right to left, Continuous walking on a treadmill for 10 minutes, Ascending and descending of stairs, Crossing 4 obstacles with continuous walking, Walking while simultaneously pushing a stroller, Walking while holding an object, Walking on different surfaces and slopes, The intervention took place for 5 days a week for 6 week for 20 minutes. Pre measurement was taken before the intervention and after 6 weeks post measurement was taken.
219587843|NCT06232330|DEVICE|Group B|This group will receive PNF techniques for trunk control. Rhythmic initiation and Rhythmic stabilization for a span of 20 minutes on both sides. In rhythmic initiation patient will move passively from trunk flexion into extension and then back to the flexed position When the patient is relaxed and moving easily, ask for active assisted motion Then begin resisting the motion then patient will perform independently in rhythmic stabilization Resist an isometric contraction of the patient's trunk flexor muscles patient will match the resistance in front and then in back
219587844|NCT04024839|OTHER|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
219587845|NCT04024839|OTHER|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
219587846|NCT00375830|PROCEDURE|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
219587847|NCT00375830|DRUG|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
219587848|NCT00375830|PROCEDURE|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
219587849|NCT00375830|DRUG|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
219587850|NCT00375830|PROCEDURE|Computed Tomography (CT) scan|Scan to detect \& analyze X-rays
218840841|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
218840842|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
218840843|NCT03823287|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
219450779|NCT07147244|OTHER|Treatment 2: Part 1 of GRIN (Lessons 1-4)|multi module online training
219450780|NCT07147244|OTHER|Treatment 3: Part 2 of GRIN (Lesson 1, 5-8)|multi module online training
219587851|NCT00375830|DRUG|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
219587852|NCT00375830|PROCEDURE|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
218840844|NCT03823287|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
218840845|NCT03823287|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
218840846|NCT05202262|DRUG|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
218840847|NCT05202262|DRUG|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
218840848|NCT05202262|DRUG|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
218840849|NCT05202262|DRUG|Open-label Symbicort TBH 320/9 μg|Open-label Symbicort Turbuhaler 320/9 μg
219587853|NCT00375830|DRUG|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
218840850|NCT06992713|DRUG|H1710 for Injection|Injection.
218840851|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
218840852|NCT05396846|BEHAVIORAL|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
218840853|NCT05396846|BEHAVIORAL|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
218840854|NCT05396846|BEHAVIORAL|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
218840855|NCT07011173|DEVICE|Exotendon assistance|Assistive devices with distinct assistance dynamics
218840856|NCT07011173|DEVICE|End-effector assistance|Finger will be moved by the actuators connected to the fingertip
218840857|NCT07028957|PROCEDURE|Group A; Low volume local anesthetic in Ultrasound guided combined Supraclavicular and Interscalene block for Upper limb surgery|Group A; will receive ultrasound guided combined Supraclavicular Block (SCB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%) and Interscalene Block (ISB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%).
218840858|NCT07028957|PROCEDURE|Group B; High volume local anesthetics (30-40ml) ultrasound guided combined Supraclavicular Block (SCB) and Interscalene Block (ISB)|Group B; High volume local anesthetics in ultrasound guided combined Supraclavicular Block (SCB) with 15-20 ml (7.5-10ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%) and Interscalene Block (ISB) with 15-20 ml (7.5-10 ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%).
218840859|NCT06880055|DIAGNOSTIC_TEST|Shield Blood Test for colo-rectal cancer Screening|Shield Blood Test for colo-rectal cancer Screening
218840860|NCT07033507|DIAGNOSTIC_TEST|MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions|Compare MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions
218840861|NCT07033000|DIETARY_SUPPLEMENT|Placebo|Placebo
219587854|NCT00375830|DRUG|Gadofosveset|A gadolinium-based contrast agent for MRI
219587855|NCT00375830|DRUG|Gadobutrol|A gadolinium-based contrast agent for MRI
218840862|NCT07033000|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing blend of Digestive Enzymes, Dandelion, Ginger \& Fennel Extracts
218840863|NCT07033442|DRUG|Sevoflurane (Volatile Anesthetic)|Inhalational anesthetic used for maintenance of anesthesia. Administered at 2-3% concentration in a 40% oxygen-air mixture to maintain BIS values between 40-60.
218840864|NCT07033442|DRUG|Propofol 1%|Intravenous hypnotic agent used for induction (2-3 mg/kg) and maintenance (50-150 μg/kg/min) of anesthesia. Titrated to maintain BIS values between 40-60.
218840865|NCT07033442|DRUG|Remifentanil 2 MG|Short-acting opioid used for induction and maintenance of anesthesia at a dose of 1 μg/kg IV (induction) and 0.05-0.25 μg/kg/min (maintenance).
218840866|NCT07033442|DRUG|Rocuronium 50 mg/5 ml|Neuromuscular blocker administered IV at 0.6-1.2 mg/kg for induction and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
219587856|NCT04226326|OTHER|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
219587857|NCT04330716|BEHAVIORAL|Standard Genetic Counseling|Standard of care genetic counseling
219587858|NCT04330716|BEHAVIORAL|Educational Video|Video tutorial about genetic testing
219587859|NCT00236366|DRUG|fentanyl|
218840867|NCT07033442|DRUG|Lidocaine %2 ampoule|Administered intravenously at 1-1.5 mg/kg before anesthesia induction to reduce injection pain and facilitate induction.
218840868|NCT07033442|DRUG|Thiopental 500 mg vial for injection|Intravenous anesthetic agent used for induction of anesthesia at 4-6 mg/kg.
218840869|NCT07033442|DRUG|Neostigmine 0,5 mg/ml ampoule|Administered IV at 0.04 mg/kg for reversal of neuromuscular blockade at the end of the procedure.
218840870|NCT07033442|DRUG|Atropine Sulphate 0.5mg/ml ampoule|Administered intravenously (0.4 mg per 1 mg neostigmine) to counteract muscarinic effects during neuromuscular blockade reversal; also 0.5 mg IV in cases of intraoperative bradycardia (HR \< 45 bpm).
218840871|NCT07033442|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|Used intravenously at 0.1 mg/kg to manage intraoperative hypotension unresponsive to fluid and anesthetic dose adjustment.
219450781|NCT07148830|PROCEDURE|Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)|"* All patients undergo pancreaticoduodenectomy with total mesopancreatic excision (TMpE) and Adjuvant chemotherapy.~* Meticulous dissection and en bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels (superior mesenteric artery and portal vein) and the celiac axis, performed during pancreaticoduodenectomy."
219450782|NCT07148596|OTHER|It is an observational study without any intervention measures.|All patients will fast for 6 hours and will abstain from drinking for 2 hours preoperatively, with no premedication. Preoxygenation will be performed with an oxygen flow rate of 6 L/min. Ciprofol will be continuously infused via a micropump at a rate of 12 mg/kg/h. During preoxygenation with a facemask, if respiratory depression occurs during ciprofol infusion, assisted ventilation via facemask will be initiated. After LOC and completion of observation indices, the anesthesiologist may administer midazolam (1-3 mg), sufentanil (0.2-0.5 μg/kg), and rocuronium (0.3-0.6 mg/kg) sequentially based on the patient's age, physical condition, and BIS values to complete anesthesia induction. If hypotension (systolic blood pressure \<90 mmHg or \<80% of baseline) or bradycardia (heart rate \<50 beats/min) occurs during induction, vasoactive agents such as ephedrine or atropine will be administered for management.
219450783|NCT07147543|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
218840872|NCT07033442|PROCEDURE|CO₂ Pneumoperitoneum|Creation of pneumoperitoneum with CO₂ insufflation for robotic prostatectomy; monitoring and recording of intra-abdominal pressures.
219450784|NCT07139223|BEHAVIORAL|laughter yoga|Intervention arm: Laughter yoga group sessions will be implemented twice a week for 4 weeks (8 sessions in total); the first session will be \~45 min, the subsequent sessions \~30 min. Sessions will be conducted face-to-face in a suitable room within the institution. Following the interim measurement in week 4, the intervention arm will continue structured individual laughter practices daily for 4 weeks.
219587860|NCT01054235|BEHAVIORAL|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
219587861|NCT05826795|PROCEDURE|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
218840873|NCT07033442|DEVICE|Bispectral index (BIS) Monitoring|Monitoring of depth of anesthesia using bispectral index values; frontal placement preoperatively and throughout surgery. BIS maintained between 40-60.
218840874|NCT07033442|PROCEDURE|intraocular pressure measurement|Measurement of intraocular pressure (IOP) in both eyes at multiple intraoperative and postoperative time points (T0-T9).
218840875|NCT07033442|PROCEDURE|intraarterial cannulation and pressure measurement|Invasive arterial blood pressure measurement and blood gas measurements via an 18G catheter inserted into the radial artery
218840876|NCT07033442|PROCEDURE|Mechanical Ventilation|Ventilation initiated after intubation with volume-controlled settings (TV 6-8 ml/kg, RR 12, FiO₂ 50%), adjusted to maintain ETCO₂ between 30-36 mmHg.
218840877|NCT07033442|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
218840878|NCT07033442|DRUG|Crystalloid solutions|Participants received calculated maintenance fluids with crystalloids through intravenous infusion prior to and during surgery.
218840879|NCT07033442|PROCEDURE|Endotracheal Intubation|After induction of anesthesia and neuromuscular blockade, endotracheal intubation was performed using standard technique in all participants.
219017661|NCT03798223|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
219017662|NCT01496313|DRUG|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
218840880|NCT07033442|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine ASA monitoring, including noninvasive blood pressure, ECG (D2 derivation), End-tidal carbon dioxide (ETCO₂) and Peripheral Oxygen Saturation (SpO₂), was performed in all patients, starting from the preoperative period and continuing throughout the surgery.
218840881|NCT07033442|PROCEDURE|Ventilatory Pressure and Compliance Monitoring|Throughout the procedure, the following lung mechanics were continuously measured: PEEP, peak airway pressure (PEAK), mean airway pressure (Pmean), plateau pressure (Pplato), and dynamic compliance.
219450785|NCT07148219|BEHAVIORAL|Embrace Your Power: A VR Journey to Overcome Negative Emotions|"EYP-VR represents a virtual reality (VR) educational tool to combat bullying. Using Meta Quest 3 passthrough technology, the app combines real-world classroom elements with immersive virtual scenarios, enabling safe and interactive experiences that simulate bullying situations but that do not place students in the roles of victims or aggressors but heroes or protectors.~The app guides participants through narrative episodes focused on building empathy, practicing assertiveness, and learning conflict resolution techniques. AI-driven characters dynamically respond to students' actions as they engage in puzzles, and sensory feedback (visual, auditory, and haptic) reinforces key socio-emotional learning outcomes.~The program will take place in classrooms during instructional hours. Each session will end with a feedback phase so that the school counselor can manage any issues that interest them."
219450786|NCT07149129|DEVICE|Electromyographic Biofeedback|"This intervention phase will last 30 minutes of training, during which the participant will be encouraged to actively and voluntarily relax their spastic muscles and will receive visual feedback through the software when this occurs. Two modes will be used in the software: the first, called Recovery, which consists of a game in which the participant is encouraged to contract and relax their muscles in order to guide a rocket in a specific direction to earn points. The second, called Maestro, in which the participant's objective is to keep the rocket below the specified line while maintaining their muscles relaxed. The participant will perform each mode for 15 minutes, totaling the proposed 30 minutes. There may be a break between each mode if the participant experiences fatigue. Afterward, they will receive standard occupational therapy."
219450787|NCT07149129|DEVICE|Sham (No Treatment)|The intervention with the placebo group will have an identical structure to that of the intervention group, but during the biofeedback phase, the software screen will be a simulation, not corresponding to the patient's muscle activity. The patient will receive occupational therapy as usual, in a manner identical to that of the intervention group after the placebo biofeedback therapy.
219450788|NCT07149259|DEVICE|At Home Use|Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.
219450789|NCT07147712|BEHAVIORAL|Psychological Group Intervention|6-session psychological group intervention, delivered once per week over six weeks. The intervention is designed to promote well-being and improve the quality of social relationships. It includes psychoeducational content, experiential exercises, and guided group discussions focused on emotional expression, social connection, and mutual support. A follow-up session will be offered after 4 weeks. Sessions will be led by trained psychologists and conducted in a university setting.
218840882|NCT05506982|DRUG|Psilocybin|Given PO
218840883|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
218840884|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
218840885|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
218840886|NCT07033546|BEHAVIORAL|Toy bracelets|The intervention involves the use of colorful, child-friendly toy bracelets worn by children during procedures requiring physical restraint in the pediatric intensive care unit. These bracelets are designed to offer a sense of familiarity, distraction, and emotional comfort during potentially distressing experiences. Unlike standard care, which involves restraint without any therapeutic distraction tools, the toy bracelets serve as a non-pharmacological, low-cost, and easily applicable intervention aimed at reducing emotional distress. The intervention is distinguished by its simplicity, immediate usability, and focus on integrating play-based elements into clinical care to address the psychological needs of hospitalized children.
218840887|NCT07033923|DIAGNOSTIC_TEST|Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional)|Brain MRI with structural (anatomical) and functional sequences (without contrast injection) will be collected. The cognitive tests will be carried out during the recording of the functional MRI (optional) in order to highlight the neural correlates of mood variations.
218840888|NCT07033923|BEHAVIORAL|Computerized cognitive tests|"Cognitive tests can be administered during the recording of a functional MRI, in order to highlight the neural correlates of mood variations.~Cognitive data from a computerized experimental psychology experiment: this test involves different tests on a computer or tablet, including a test evaluating the minimal variations in the subject's mood and motivational state during the task, as well as its decision-making abilities."
218840889|NCT07033923|DEVICE|Daily longitudinal monitoring by mobile MOODELING application|Daily longitudinal monitoring by mobile MOODELING application (mood, energy, events) with self-monitoring tools (calendar, mood curve) at home. Follow-up duration on the application: 12 months
218840890|NCT06879041|DRUG|AZD2287|AZD2287 is administered through intravenous injection.
218840891|NCT06879041|DRUG|AZD2275|AZD2275 is administered through intravenous infusion.
218840892|NCT06879041|DRUG|AZD2284|AZD2284 is administered through intravenous injection.
218840893|NCT07034833|BEHAVIORAL|Ventriloquist Puppet Interaction|children allocated to the Ventriloquist Puppet group were introduced to a Ventriloquist Puppet inside the clinic and were allowed to play, talk, and interact with the puppet for 5-10 minutes.
218840895|NCT06086392|DRUG|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
218840896|NCT06086392|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
218840897|NCT06086392|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
219450790|NCT07147998|OTHER|Oral hygiene instruction|Oral hygiene and gingival health of all patients were assessed using the Turesky Modification of the Quigley-Hein Plaque Index and the Gingival Index. Tooth brushing frequency was recorded. The 2D:4D ratio was calculated by dividing the second digit length by the fourth, with three measurements taken per finger to ensure reliability. A cut-off value of 1 was used to evaluate prenatal androgen influence, and participants were grouped by 2D:4D ratio (≥1 or \<1). All participants received standardized oral hygiene instructions from the same instructor, including Modified Bass brushing and interdental cleaning. A second clinical exam was performed one week later by the same examiner, and both indices were re-scored.
219450791|NCT07149311|BEHAVIORAL|Intervention|The intervention group will receive the usual consultation from their doctor and referral to a diabetes educator for individualised structured DSME training. A clinical sheet will be used while delivering the education to ensure that all core topics are covered. For this study, 2 diabetes educators will offer the individualised DSME sessions using the American Association of Diabetes Education (AADE) 7 self-care behaviour model. The participants are scheduled to attend a 1-hour individualised session at the hospital every 3 months as well as telephone consultations lasting up to 15 minutes every 2 weeks at the convenience of the participant to reinforce DSME for 6 months. The first session is arranged on the first day after consultation with the doctor. At the end of the sessions, the participants will receive a patient guide to diabetes booklet and graphic material illustrating several self-care activities such as foot care
218840898|NCT06883903|OTHER|day-night cycle application|In this group, colostrum delivered to the unit within the first 5 days of life was administered by the nurse every three hours for 14 days. In order to create a day/night cycle, a white incubator cover was used routinely in the unit during the day (between 08.00-20.00 hours) and a dark colored incubator cover was used at night (between 20.00-08.00 hours).
218840899|NCT06883903|OTHER|routine practice|"In this group, colostrum delivered to the unit within the first 5 days of life was administered every three hours for 14 days by the nurse.~is the group whose covers are used."
218840900|NCT05767047|DRUG|Apremilast|Oral tablets or liquid suspension
218840901|NCT07053046|OTHER|Standard engagement approach|"Large group meetings led by PRECIDENTD PIs; composed of \~20 sites (with \~25 site investigators and \~40 study staff). PRECIDENTD PIs will share updates and facilitate discussion around any problems.~Problem identification and steps toward solution occur sequentially. A problem is identified in the data (e.g., slow recruitment), then brought to the Stakeholder Advisory Council (SAC) for advisement, then back to site investigators and study staff to implement recommended changes, the PIs look at data to see if changes improved the problem. PIs and the Stakeholder Engagement Core broker information and relationships with SAC partners."
218840902|NCT07053046|OTHER|Agile methods engagement approach|"Small group meetings led by a coordinator trained in agile methods; composed of \~4 sites each (representing 4-6 investigators and 6-10 study staff), plus 2-3 Stakeholder Advisory Council (SAC) patient partners. Meetings will focus on problem-solving around specific topics and apply agile tools and principles.~Sites in each small group will review process data together and each site will identify a specific topic (recruitment, retention, medication adherence) to focus on improving over the next month. Research partners at sites and patient partners will contribute to discussion and reflection on barriers, challenges, successes, and facilitators. Steps toward solutions occur on a rapid timeframe, iteratively using data as a guidepost."
218840903|NCT07058922|DIAGNOSTIC_TEST|evaluation of systemic microvascular reactivity|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging.
218840904|NCT07058922|DIAGNOSTIC_TEST|ABPM|Ambulatory blood pressure measuring: systolic, diastolic and mean arterial pressures
219450792|NCT07148180|DRUG|Tagraxofusp|A CD123-directed cytotoxin, Single-use vial, via intravenous (into the vein) infusion per protocol.
219450793|NCT07148180|DRUG|Azacitidine (AZA)|A cytidine nucleoside analog, single-use vial, via intravenous infusion or subcutaneous (under the skin) injection per standard of care.
219450794|NCT07148180|DRUG|Venetoclax|A BCL-2 inhibitor, tablet, via orally per standard of care.
219450795|NCT07147972|DRUG|Propranolol 80 mg|Propranolol 40-80 mg/day
219450796|NCT07147972|DRUG|Magnesium 400Mg|Magnesium 400 mg daily
219450797|NCT07148609|BEHAVIORAL|Video game-facilitated group activity|The intervention is a 12-week group activity program for each participant in the intervention group, and the program consists of three 50-minute video game facilitated group activity sessions per week. Participants in the intervention group will engage in those group activity session which will be mediated by the game of Super Mario Party on Nintendo Switch.
219450798|NCT07148882|DRUG|fentanyl|"Intra nasal fentanyl group: will receive intranasal fentanyl using nasal dose of INF is 1.5µg/kg/dose, and typically one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment (maximum two doses per procedure).~Intravenous fentanyl group: will receive intravenous fentanyl 1 µg/kg/dose and typically, one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment maximum two doses per procedure.~Measure MDA Malondialdehyde level as oxidative stress marker in pain response , venous blood sample 0.5 ml will be collected twice, just before and 30 minutes after the procedure.~Monitor adverse events after fentanyl use as apnea cessation of breathing for \>20 s, bradycardia heart rate \< 100 beats/minute, desaturation oxygen saturation \< 80%"
218840905|NCT07058922|DIETARY_SUPPLEMENT|beetroot supplement|A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.
218840906|NCT06774131|DRUG|UGN-104|UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
218840907|NCT07066397|BIOLOGICAL|ARM011|ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process
219450799|NCT06948149|DIETARY_SUPPLEMENT|Creatine monohydrate|Participants will consume one serving of creatine daily (0.10g of creatine/kg of body weight). This relative dosing approach ensures that smaller participants do not receive excessive doses, while larger participants receive an adequate amount. There is currently limited evidence to conclude the effectiveness of timing daily creatine intake, but it is recommended that creatine be consumed at mealtime for optimal absorption. Participants will choose what meal they will take the supplement and will be asked to keep timing consistent throughout the study. This daily low dose method was chosen because other methods (high-dose loading) may have negative side effects (e.g., water retention, cramping).
219450800|NCT06948149|BEHAVIORAL|Resistance training|Participants will use the programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. The investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
219450801|NCT07147257|BIOLOGICAL|CHS-1420|Dose of 40 mg will be subcutaneously administered to participants in
219450802|NCT07147257|BIOLOGICAL|HUMIRA®|Dose of 40 mg will be subcutaneously administered to participants in
219450803|NCT07149077|DRUG|Echo-guided scalp blocks|Classic anesthetic strategy in association with echo-guided scalp blocks
219450804|NCT07149077|DRUG|Classic anesthetic strategy|classic anesthetic strategy with postoperative analgesia associating Paracetamol and Morphine with standardized dose.
219450805|NCT03757260|DEVICE|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
219450806|NCT03757260|DEVICE|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
219450807|NCT01820494|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
219450808|NCT00168168|DRUG|G-CSF/Filgrastim|
219450809|NCT03853252|OTHER|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
219450810|NCT06156293|BEHAVIORAL|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
219450811|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
219450812|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
218840908|NCT07066397|DRUG|Fludarabine|Administered prior to infusion of ARM011
218840909|NCT07066397|DRUG|Cyclophosphamide|Administered prior to infusion of ARM011
218840910|NCT06875388|OTHER|Task specific Training|Group A will receive a basic protocol of 40 minutes involving 10 minutes of warm up 10 10 mins of task-specific training 10 mins of leg strength exercises and 10 mins of cool-down exercises.
218840911|NCT06875388|OTHER|Specific Yoga Poses|For group B, a series of yoga poses will be applied. Each training session consists of a 10-minute warm-up, 20 minutes of yoga exercises, and a 10-minute cool-down.
219450813|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
218840912|NCT06875388|OTHER|Tasl specific Training with perturbation|GGroup C will be 40 minutes involving 10 minutes of warm-up 10 minutes of task-specific training involving perturbation 10 mins of leg strength exercises involving perturbation and 10 mins of cool-down exercises.
218840913|NCT06875388|OTHER|Specific yoga poses with perturbation|Group D training session consists of a 10-minute warm-up, 20 minutes of yoga exercises with perturbation, and a 10-minute cool-down
218840914|NCT07071116|OTHER|Communication skills training|See Detailed Description
218840915|NCT07071116|OTHER|Communication skills training-Facilitator|See Detailed Description
218840916|NCT04750486|DEVICE|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
218840917|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
219450814|NCT04370574|DIAGNOSTIC_TEST|Soluble Biomarkers dosage|"1. CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~2. Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
219450815|NCT03787355|COMBINATION_PRODUCT|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
219450816|NCT04495673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
219450817|NCT04495673|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
219450818|NCT04495673|BEHAVIORAL|Cognitive Training|Executive functioning tasks
219450819|NCT05110157|DRUG|Placebo|Oral capsules
219196806|NCT06817746|BEHAVIORAL|FIRRST|FIRRST is based on the principles of Naturalistic Developmental Behavioral Interventions (NDBIs), and more specifically on the principles of Infant Start and iBASIS. FIRRST targets ASD prodromes including diminished eye contact, diminished communicative intent, diminished social orientation, and unusual pattern of object exploration. Additionally, it also targets motor immaturity, frequent in infants at risk for ASD. FIRRST is a systemic approach, integrated within the family dynamics and culture. The program will address the five elements identified in efficacious very early intervention: 1) parent involvement, 2) frequency and length of intervention, 3) individualized, developmentally appropriate activities, 4) beginning the interventions as early as possible, and 5) increasing parental sensitivity and responsivity to infant cues. FIRRST will be delivered by experienced licensed health professionals trained by the developer of the intervention.
219450820|NCT05110157|DRUG|Valbenazine|Oral capsules
219450821|NCT05560009|DRUG|Fluorodopa F 18|Given IV
219450822|NCT05560009|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219450823|NCT05560009|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219450824|NCT05560009|RADIATION|Radiation Therapy|Receive standard of care radiation therapy
219450825|NCT05560009|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
219450826|NCT05248789|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
219450827|NCT06799377|BEHAVIORAL|Restricted Activity Reccomendations|"Patients in this respective group will be given restricted activity recommendations over the casting period. They will be told Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the restricted activity group. We ask that you limit sprinting, jumping, and organized sports during the time of cast immobilization. As a rule of thumb, we recommend feet on the floor activities while playing and avoiding playgrounds and gym class if possible. While it is not realistic to restrict a young child entirely, do your best to avoid strenuous or intense exercise until cleared by your physician or nurse practitioner"
219587862|NCT00759850|DEVICE|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
219587863|NCT04842838|DEVICE|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
219587864|NCT04842838|DEVICE|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
219587865|NCT00002825|BIOLOGICAL|filgrastim|
219587866|NCT00002825|DRUG|docetaxel|
219587867|NCT04187417|DRUG|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
219587868|NCT04187417|DRUG|Placebo|Placebo
219587869|NCT05999058|PROCEDURE|Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation|The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
219587870|NCT00715936|BEHAVIORAL|Control|
219587871|NCT00715936|BEHAVIORAL|ECD|
218840918|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
218840919|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
219450828|NCT06799377|BEHAVIORAL|Full Activity/Limited Activity Reccomendations|"Patients in this respective group will be allowed to engage in most activities. They will be read Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the activity as tolerated group. Your child may participate in all desired activities except contact sports. Your child does not need to increase his/her activity level but should participate in activities as they feel comfortable doing so. Sprinting, jumping, and organized sports are acceptable as long as your child is not experiencing pain. Your child may use playgrounds and participate in gym class as desired. Do your best to avoid restricting your child from activities unless they are experiencing pain or you have concerns about their safety."
219450829|NCT05471609|DRUG|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
218840920|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
218840921|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
219450830|NCT05471609|DRUG|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
219450831|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
219450832|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
219450833|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
219450834|NCT04809467|DRUG|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
219450835|NCT04809467|DRUG|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
219450836|NCT04884802|PROCEDURE|Tight blood pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
219450837|NCT04884802|PROCEDURE|Routine blood pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
219450838|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
219450839|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
219450840|NCT05031182|PROCEDURE|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
219450841|NCT05031182|PROCEDURE|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
219587872|NCT00715936|BEHAVIORAL|Enhanced Nutrition|
219587873|NCT04032236|OTHER|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
219587874|NCT03216070|DRUG|Dasatinib 50 MG|50mg of dasatinib orally daily
219587875|NCT05178433|COMBINATION_PRODUCT|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
219587876|NCT05149859|OTHER|Observational|(no intervention)
219587877|NCT02169700|PROCEDURE|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
219587878|NCT05984875|OTHER|Collection of tumor samples, blood and vaginal and rectal swabs|The following biological samples will be collected at different time points, according to the specified cohort and after signing the inform consent form: tumor tissue (fresh and archival) or normal tissue (cohort E), ascites (when present), peripheral blood, rectal swab, vaginal swab.
219587879|NCT04470687|DEVICE|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
219450842|NCT05890599|BEHAVIORAL|Yoga Therapy|"The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume."
219450843|NCT05890599|BEHAVIORAL|Health Education|Health education courses are conducted on-site once a week for 90 minutes over a 12-week period by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
219450844|NCT06464679|BIOLOGICAL|anti-CD19 CAR NK cells|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
219587880|NCT02449096|DEVICE|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
219587881|NCT02449096|OTHER|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
219587882|NCT06158256|OTHER|Voluntary apnoea|Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
219587883|NCT06148415|BEHAVIORAL|Fetal Heartbeat Monitoring Group|Fetal Heartbeat Monitoring Group
219587884|NCT02875015|DRUG|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
219587885|NCT02875015|DRUG|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
219587886|NCT02875015|PROCEDURE|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
219587887|NCT04471337|DRUG|BAY1817080|BAY1817080 will be administered orally as tablet.
219587888|NCT03201432|DEVICE|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
219587889|NCT03201432|DEVICE|Bare metal stent (BES)|Bare metal stent
219587890|NCT05665829|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
219587891|NCT05665829|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
219587892|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
218840922|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
219587893|NCT01103830|DRUG|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
219587894|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
219587895|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
218840923|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
218840924|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
218840925|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
218840926|NCT01627626|DRUG|saline|0.9% saline solution
218860032|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
219450845|NCT06013449|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|Pulsed Electromagnetic Field (PEMF) Device BEMER Device consist of a total body mat (B. BODY) plus a targeted pelvic mat (B.PAD), and a Control Unit which powers the device and logs usage. Both B.BODY and B.PAD must be plugged into the Control Unit simultaneously and activated individually. B. Body must be placed on a flat surface (i.e. bed, floor, reclining chair etc.) for best results.
219450846|NCT06013449|DEVICE|Sham Pulsed Electromagnetic Feild (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
219450847|NCT05534126|PROCEDURE|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
219450848|NCT05534126|PROCEDURE|Placebo|Sham
219450849|NCT06631820|DIETARY_SUPPLEMENT|Epicatechin extract|In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
219450850|NCT02170558|DEVICE|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
219450851|NCT02911337|DIETARY_SUPPLEMENT|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
218840927|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA\_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
218840928|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
218840929|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
218840930|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
218840931|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
218840932|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
218840933|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
218840934|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
218840935|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
219450852|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
219450853|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
218840936|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
219450854|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
219450855|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
219587896|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
219017663|NCT01496313|DRUG|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
219017670|NCT06444880|DRUG|Ubamatamab|Given by IV
219017671|NCT06444880|DRUG|Cemiplimab|Given by IV
219587897|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
218840937|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
219450856|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
219450857|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
219450858|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
219450859|NCT02125812|OTHER|scaling and root planing|scaling and root planing
219450860|NCT02966106|DEVICE|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
219450861|NCT02966106|OTHER|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
219450862|NCT02362256|DRUG|Naltrexone|
219450863|NCT02362256|DRUG|Clonidine|
219450864|NCT02362256|DRUG|Lorazepam|
219450865|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
219450866|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
219450867|NCT06548074|BEHAVIORAL|H-PACE Behavioral Intervention|Participate in the H-PACE program
219450868|NCT06548074|OTHER|Accelerometer|Wear an accelerometer
219450869|NCT06548074|OTHER|Questionnaire Administration|Ancillary studies
219450870|NCT06548074|OTHER|Supportive Care|Parents may participate in an optional virtual peer support group
219450871|NCT00236210|BEHAVIORAL|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
219450872|NCT00236210|BEHAVIORAL|VIP program|Risk assessment, lifestyle counselling, exercise program
219450873|NCT00949806|DRUG|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
219450874|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
219450875|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
219450876|NCT05815758|DRUG|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
219587898|NCT05495672|PROCEDURE|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
219587899|NCT02804022|DEVICE|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
219587900|NCT02804022|DRUG|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
219587901|NCT02973230|OTHER|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
219587902|NCT02398630|RADIATION|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
219450877|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
219450878|NCT03837301|PROCEDURE|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
219450879|NCT01924260|DRUG|alisertib|Given PO
219450880|NCT01924260|DRUG|gemcitabine|Given IV
219450881|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
219587903|NCT02398630|OTHER|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
219587904|NCT02398630|OTHER|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
219587905|NCT02398630|OTHER|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
219587906|NCT04562155|DRUG|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
219450882|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
219450883|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
219450884|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
219450885|NCT03682042|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
219450886|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
219450887|NCT02987205|DEVICE|Restylane|NLF Correction
219450888|NCT04803006|BIOLOGICAL|TCD601|Investigational Product
219450889|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
219450890|NCT04675632|PROCEDURE|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
219450891|NCT06113471|DRUG|Povorcitinib|Oral, Tablet
219450892|NCT06113471|DRUG|Placebo|Oral, Tablet
219587907|NCT04562155|DRUG|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
219587908|NCT00790335|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
219587909|NCT00459901|DRUG|Erlotinib and capecitabine|
219587910|NCT05094492|COMBINATION_PRODUCT|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
219587911|NCT05094492|OTHER|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
219587912|NCT04385121|OTHER|Questionnary|Family member's will answer the questionnaires by phone
219587913|NCT02405884|OTHER|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
219587914|NCT04986384|DRUG|Atoderm SOS spray Aerosol 200ml|A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
219587915|NCT00001705|DRUG|GP100 peptide|
219587916|NCT00001705|DRUG|IL-2|
219587917|NCT00422552|DRUG|Indacaterol (QAB149)|
219587918|NCT05110482|DRUG|Syntocinon|uterotonic drugs
219587919|NCT05110482|DRUG|Carbetocin|uterotonic drug
219587920|NCT01085201|DRUG|Lexiscan|Given as an infusion
219587921|NCT03143426|PROCEDURE|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
219587922|NCT05010616|DEVICE|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
219587923|NCT03516110|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
219450893|NCT06436599|OTHER|plane block with %0.25 30 ml bupivacaine|evaluation of the efficacy of two different plan blocks for postoperative analgesia
219450894|NCT03292835|DEVICE|LeiProtect®|Filmogenic dressing gel
219450895|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
219450896|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
219450897|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
219450898|NCT02627196|DEVICE|BAROSTIM NEO® System|
219450899|NCT02627196|DRUG|Medical Management|
219450900|NCT02088736|DEVICE|Intraosseous|
219450901|NCT02088736|DEVICE|Intravenous|
219450902|NCT00633425|DRUG|GLIMEPIRIDE|
219450903|NCT05623059|DRUG|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
219450904|NCT02362594|BIOLOGICAL|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
218840938|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
218840939|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
218840940|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
218840941|NCT07081464|OTHER|MRI, EEG, Pupillometry|Comparison of P300 wave amplitude, pupillometric responses, functional and structural brain connectivity, socio-adaptive function, cardiac autonomic balance between two phenotypic severity groups of young patients with Ondine Syndrome.
219450905|NCT02362594|DRUG|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
218840942|NCT07079501|OTHER|Test Eye Cream (Formula# 899675 44A)|A white cream formulated as eye cream (Formula# 899675 44A) provided by L'Oréal R\&I China. Participants will apply 1ml of the product on the full face and neck twice daily for 8 weeks. The aim is to evaluate its efficacy on facial wrinkles, eye bags, dark circles, and other skin aging signs in healthy Chinese women.
218840943|NCT07081750|BEHAVIORAL|Dyadic tailored home-based activity program intervention|"1. During hospitalization, caregivers receive health education on managing behavioral and psychological symptoms of dementia. Patient-caregiver dyads participate in structured ward activities to assess activity preferences and capabilities, forming the basis for co-developing individualized home activity plans with training for caregivers.~2. A customized home activity kit is provided at discharge.~3. Post-discharge, a 12-week tailored home intervention is implemented, using a patient-centered model with caregiver support. Caregivers record participation and behavioral responses, which inform dynamic adjustments to activity content, difficulty, and methods."
218840944|NCT07081750|OTHER|Routine care|Participants will receive routine care consisting of standard hospitalization treatment, basic caregiver education on behavioral and psychological symptoms of dementia (BPSD), routine discharge instructions (including general home activity recommendations without personalized intervention assessment, planning or implementation), and routine post-discharge follow-up for 12 weeks.
218840945|NCT07081503|DRUG|ADX-626|siRNA duplex oligonucleotide
219450906|NCT04167514|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
219450907|NCT04167514|DRUG|Placebo|Albumin solution administered intravenously
219450908|NCT05719064|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
219450909|NCT06528496|BIOLOGICAL|DANYELZA|DANYELZA is a humanized monoclonal antibody of the IgG1 subclass
219450910|NCT06528496|BIOLOGICAL|Sargramostim|Yeast derived recombinant human Sargramostim (GM-CSF)
219450911|NCT06528496|DRUG|Cytoxan|Cyclophosphamide is an alkylating agent related to nitrogen mustard
219450912|NCT06528496|DRUG|Topotecan|Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
219450913|NCT06528496|DRUG|Vincristine|Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
219450914|NCT06528496|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic
219450915|NCT06528496|DRUG|Ifosfamide|Ifosfamide is a structural analogue of cyclophosphamide
219450916|NCT06528496|DRUG|Etoposide|Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
219450917|NCT06528496|DRUG|Carboplatin|Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
219450918|NCT06528496|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
219450919|NCT06528496|DRUG|Temozolomide|Temozolomide is administered intravenously
219450920|NCT04305041|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219450921|NCT04305041|BIOLOGICAL|Quavonlimab|Administered via IV infusion at a specified dose on specified days
219450922|NCT04305041|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
219450923|NCT04305041|DRUG|Lenvatinib|Administered via oral capsules at a specified dose on specified days
219450924|NCT04305041|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
219450925|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
219450926|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
218840946|NCT07081503|DRUG|Placebo|Saline
219450927|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
218840947|NCT07080801|DRUG|RAG-21|Intrathecal bolus administration of RAG-21 will be initiated at a dose of 120 mg, prepared with a dedicated solvent into a 10 mL sterile aqueous solution. Dosing will occur every 2 weeks, with the dose escalating to 180 mg after 3 administrations. Subsequently, the dosing interval will be extended to every 4 weeks. The investigator will then select an optimal dose from the completed dose cohorts or continue dose escalation until the maximum tolerated dose (MTD) is reached, with a predefined maximum dose of 210 mg. For continued treatment, the investigator-determined optimal dose will be administered as a fixed dose every 4 weeks, with a total treatment duration of 6 months (8 administrations).
218840948|NCT07080892|PROCEDURE|distal iPACK|● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
218840949|NCT07080892|PROCEDURE|proximal iPACK|● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
218840950|NCT07080658|DRUG|[14C]-WPV01|Single oral dose of 600 mg \[14C\]-WPV01
218840951|NCT07080463|PROCEDURE|vasculens and cta|using vasculens and cta for one group and cta for the second group (control)
219587924|NCT02699060|PROCEDURE|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
218840952|NCT07081529|DEVICE|Direct Restoration with Microhybrid Composite|Direct Class I restorations were placed in molar teeth using a microhybrid universal composite (Aelite All-Purpose Body, Bisco) and an adhesive system according to the manufacturer's instructions.
218840953|NCT07081529|DEVICE|Indirect Restoration with Reinforced Microfill Composite|Indirect Class I restorations were fabricated using a reinforced microfill composite system (Tescera Indirect Composite System Body, Bisco) in the laboratory and cemented into molar teeth using resin cement.
219196807|NCT06817746|BEHAVIORAL|Parent Education|Families will receive written educational material focused on supporting child development and targeting ASD specific immaturities and atypicalities. Additionally, parent education families will receive counseling once per month for 6 months delivered by a licensed health professional aiming at supporting the family well being and helping the family to connect with the local public health services.
218840955|NCT07079527|DEVICE|Manual Positive End Expiratory Pressure (PEEP) Therapy|Participants in this group receive Manual Positive End Expiratory Pressure (PEEP) therapy. The intervention is delivered using a tight-fitting mask that applies positive pressure at the end of expiration, helping to keep the alveoli open, enhance oxygenation, and prevent airway collapse. The therapy is administered according to a structured protocol over a 4-week period, aiming to reduce breathlessness, improve lung function, and support ventilation. Along with PEEP, participants also receive baseline Active Cycle of Breathing Techniques (ACBTs) for airway clearance and breathing control.
219017679|NCT05556720|BIOLOGICAL|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
219017680|NCT05556720|BIOLOGICAL|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
219587925|NCT02699060|PROCEDURE|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
219587926|NCT03490760|DRUG|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
219587927|NCT03490760|RADIATION|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
219587928|NCT00384644|DEVICE|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
219587929|NCT00711438|BEHAVIORAL|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
219587930|NCT00711438|BEHAVIORAL|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
219587931|NCT04516759|DRUG|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
219587932|NCT04516759|OTHER|Placebo|Matched placebo tablets
218840956|NCT07079527|DEVICE|Non-Invasive CPAP Therapy|Participants in this group receive Non-Invasive Continuous Positive Airway Pressure (CPAP) therapy. CPAP provides a constant level of positive pressure throughout the entire breathing cycle using a non-invasive ventilator and a full-face or nasal mask. This therapy improves gas exchange, reduces the work of breathing, and eases symptoms such as dyspnea. Like Group A, CPAP therapy is delivered following a standardized protocol for 4 weeks, and participants also perform baseline ACBTs to support respiratory function.
218840957|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
218840958|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
218840959|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
218840960|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
218840961|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
218840962|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
219450928|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
219450929|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
219450930|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
219450931|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
219450932|NCT00397644|BEHAVIORAL|Prompting (survey instrument/resources list) (behavior)|
219450933|NCT06156306|BEHAVIORAL|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
219450934|NCT06156306|BEHAVIORAL|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
219450935|NCT02483351|OTHER|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
218840963|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
218840964|NCT05377489|DRUG|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
218840965|NCT06895603|DEVICE|Philips Advanced Monitoring Cuff (AMC)|The Philips AMC is a Class II (USA) and Class IIb (EU) medical device that is a non-invasive, semirigid disposable upper arm cuff with an integrated pneumatic actuator enabling hydraulic coupling of tissue pressure waveforms from the upper arm tissue.
219450936|NCT02483351|OTHER|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
219450937|NCT01370772|DRUG|Rituximab|"* Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
219450938|NCT01370772|DRUG|Rituximab|"* Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
219450939|NCT01370772|DRUG|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
219450940|NCT01370772|DRUG|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
219450941|NCT06282302|OTHER|Group control|Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
219587933|NCT05462171|DIAGNOSTIC_TEST|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
219587934|NCT06443411|OTHER|Monitoring of cerebral hemodynamics|A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
218840966|NCT06914245|DIAGNOSTIC_TEST|Electronic bowel diary|This bowel diary will be available on the smartphone in the form of an application.
218840967|NCT06914245|DIAGNOSTIC_TEST|Faecal Incontinence Quality of Life questionnaire (FIQL)|This questionnaire will be available online.
218840968|NCT06914245|DIAGNOSTIC_TEST|EuroQoL 5 dimensions, 5 levels (EQ-5D-5L)|This questionnaire will be available online.
218840969|NCT00006003|DRUG|semaxanib|Given IV
218840970|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
218840971|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
219450942|NCT06282302|OTHER|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
219450943|NCT06282302|OTHER|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
219450944|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
219450945|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
219450946|NCT01873196|BEHAVIORAL|Receive extra oil|
219450947|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
219450948|NCT03942640|OTHER|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
219450949|NCT03942640|OTHER|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
219450950|NCT04400669|OTHER|Mechanical Bowel Preparation|oral sodium phosphate (NaP) enema
219450951|NCT04400669|DIETARY_SUPPLEMENT|Low fibre diet|3 days
219450952|NCT04400669|OTHER|MBP plus low-fibre diet|3 days low fibre diet preoperative mechanical bowel preparation
219587935|NCT00528411|DRUG|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
219587936|NCT00528411|DRUG|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
219587937|NCT00528411|DRUG|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
219587938|NCT04916444|DEVICE|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
219587939|NCT03247192|DIETARY_SUPPLEMENT|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
219587940|NCT03247192|DIETARY_SUPPLEMENT|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
219450953|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
219450954|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
219450955|NCT02110472|DEVICE|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
219587941|NCT03247192|DIETARY_SUPPLEMENT|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
219450956|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
219450957|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
219450958|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
219450959|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
219450960|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
219450961|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
219450962|NCT01633372|DRUG|itacitinib|
219450963|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
219450964|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
219450965|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
218840972|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
219450966|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
219450967|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
219450968|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
219450969|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
219450970|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
219450971|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
219450972|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
219450973|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
219450974|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
218840973|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
218840974|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
218840975|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
218840976|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
219450975|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
219450976|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
219450977|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
219450978|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
219450979|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
219450980|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
219450981|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
219450982|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
219450983|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
219450984|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
219450985|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
219450986|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
218840977|NCT03753685|DRUG|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
218840978|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
219450987|NCT02696590|DIETARY_SUPPLEMENT|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
218840979|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
218840980|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
218840981|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
219450988|NCT01207921|DRUG|Lenalidomide|
219450989|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
219587942|NCT06187558|PROCEDURE|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
219587943|NCT00734396|PROCEDURE|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
219587944|NCT02201212|DRUG|Everolimus|
219587945|NCT02182635|DRUG|Ba253BINEB|
219587946|NCT04881019|DEVICE|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
219587947|NCT03292159|DEVICE|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
218840982|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
218840983|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
218840984|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
219587948|NCT03292159|DEVICE|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
219587949|NCT02951975|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
219587950|NCT02598856|DRUG|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
219587951|NCT02598856|DRUG|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
218840985|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
218840986|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
218840987|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
219450990|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
219450991|NCT04437511|DRUG|Donanemab|Given IV
219450992|NCT04437511|DRUG|Placebo|Given IV
219450993|NCT05088460|DRUG|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
219450994|NCT05088460|DRUG|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
218840988|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
218840989|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
218840990|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
218840991|NCT06239480|DRUG|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel
218840992|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
218840993|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
219450995|NCT05879822|DRUG|INCB099280|Administered as specified in the treatment arm description
219450996|NCT04146285|DRUG|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
219450997|NCT04601233|DRUG|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
219450998|NCT02073604|OTHER|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
219450999|NCT02073604|OTHER|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
219451000|NCT05422573|BEHAVIORAL|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
219451001|NCT05422573|BEHAVIORAL|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
219451002|NCT05422573|BEHAVIORAL|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
219451003|NCT06109935|DRUG|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
219451004|NCT03093350|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
219451005|NCT04934683|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
219451006|NCT04934683|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
219451007|NCT04934683|DRUG|Etomidate Induction|Anesthetic induction with etomidate.
219451008|NCT04934683|DRUG|Propofol Induction|Anesthetic induction with propofol.
219451009|NCT05165160|DIAGNOSTIC_TEST|Blood sample|Pre- and postoperative blood sample
219451010|NCT05898802|DIETARY_SUPPLEMENT|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
219451011|NCT05898802|DIETARY_SUPPLEMENT|Placebo|Lactose with kimchi flavor
219451012|NCT05798247|OTHER|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
219451013|NCT06441643|DRUG|AR-17043 Ophthalmic Solution|Investigational monotherapy supplied in three concentration levels: low, medium, high
218840994|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
219451014|NCT06441643|DRUG|PG043 Ophthalmic Solution|Investigational fixed dose combination supplied in two concentration levels: low and high
219451015|NCT06441643|DRUG|Latanoprost 0.005% Ophthalmic Solution|Marketed monotherapy
219451016|NCT06441643|DRUG|Netarsudil 0.02% Ophthalmic Solution|Marketed monotherapy
219451017|NCT06441643|DRUG|Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution|Marketed fixed dose combination
219451018|NCT06441643|DRUG|AR-17043 Vehicle|Placebo comparator
219451019|NCT04134598|RADIATION|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
219451020|NCT04134598|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
219451021|NCT04039243|BEHAVIORAL|Being Brave|Up to 12 weekly sessions
219451022|NCT04039243|OTHER|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
219451023|NCT01319045|DRUG|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
219451024|NCT00058006|DRUG|celecoxib|
219451025|NCT00058006|PROCEDURE|adjuvant therapy|
219451026|NCT06239675|DEVICE|tDCS|tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.
219451027|NCT06239675|BEHAVIORAL|CIMT|CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
219451028|NCT06239675|DEVICE|sham tDCS|sham tDCS
219451029|NCT03537378|PROCEDURE|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
219451030|NCT06254950|DRUG|TAK-279|TAK-279 capsules.
219451031|NCT06254950|DRUG|Placebo|TAK-279 placebo-matching capsules.
219451032|NCT05381818|BEHAVIORAL|Daily Inspiratory Muscle Training (dIMT)|Daily IMT training sessions for 2-4 weeks prior to surgery
218840995|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
218840996|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
218840997|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
218840998|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
218840999|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
218841000|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
218841001|NCT05246839|BEHAVIORAL|Brief Video|Videos about colorectal cancer screening.
218841002|NCT05246839|BEHAVIORAL|Brief Video Plus|Videos about colorectal cancer screening and modalities.
218841003|NCT03556228|DRUG|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
218841004|NCT03947164|OTHER|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
218841005|NCT04937400|OTHER|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
219361097|NCT05825872|PROCEDURE|internal superior laryngeal nerve block|"A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly"
219451033|NCT05381818|BEHAVIORAL|Acute Inspiratory Muscle Training (aIMT)|A single session of IMT provided within 30 minutes prior to anesthesia induction.
218841008|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
218841009|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
218841010|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
218841011|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
219451034|NCT05381818|OTHER|Standard of Care (SOC)|Standard of care only pre and post-operatively.
219451035|NCT06246513|BIOLOGICAL|SRP-9003|Solution for single IV infusion
219451036|NCT06246513|DRUG|Glucocorticoid|Oral tablet (prophylactic)
219451037|NCT05485948|DRUG|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
219451038|NCT05370911|DRUG|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
219587952|NCT02598856|DRUG|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
219587953|NCT02598856|DRUG|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
219587954|NCT00519688|DRUG|Thalidomide|100 mg, BID
219587955|NCT00519688|DRUG|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
218841012|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
218841013|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
218841014|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
218841015|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
218841016|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
218841017|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
218841018|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
218841019|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
218841020|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
218841021|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
218841022|NCT03392389|OTHER|Placebo|Saline
218841023|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
218841024|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
219451039|NCT05451524|BEHAVIORAL|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
218841025|NCT00137137|PROCEDURE|Placement of the mini-screw|
218841026|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
218841027|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
218841028|NCT00005636|DRUG|cisplatin|
218841029|NCT00005636|DRUG|pemetrexed disodium|
218841030|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
218841031|NCT06762613|COMBINATION_PRODUCT|Generative AI Based Puncture Surgery Navigation System|Participants will receive percutaneous lung puncture under the guidance of GPS.
218841032|NCT06762613|DEVICE|Cone beam CT|Participants will receive percutaneous lung puncture under the guidance of cone beam CT.
218841033|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
218841034|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
218841035|NCT00002955|DRUG|fluorouracil|
218841036|NCT00002955|DRUG|leucovorin calcium|
218841037|NCT00002955|DRUG|trimetrexate glucuronate|
218841038|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
219451040|NCT05451524|BEHAVIORAL|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
219451041|NCT01368055|RADIATION|70 Gy/CGE|Low Risk
219451042|NCT01368055|RADIATION|72.5 Gy/CGE|Intermediate Risk
218841039|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
219361098|NCT05825872|DRUG|Lidocaine 2% Injectable Solution|0.5 ml will be injected
219451043|NCT05306964|PROCEDURE|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
218841040|NCT06007677|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
218841041|NCT06735872|PROCEDURE|Non invasive ventilation (NIV)|"This group will receive a unique 10-minute session of non invasive ventilation with standard parameters directly on the CT table. The treatment will be delivered via a naso-buccal mask.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
218841042|NCT06735872|PROCEDURE|High flow oxygen therapy (HFO)|"This group will receive a unique 10-minute session of high flow oxygen directly on the CT table. The treatment will be delivered via a nasal cannula.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
218841043|NCT04829825|DIAGNOSTIC_TEST|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
218841044|NCT04874220|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
218841045|NCT02383888|DRUG|BI 425809|
218841046|NCT02383888|DRUG|BI 425809|
218841047|NCT02383888|DRUG|Placebo|
218841048|NCT02383888|DRUG|BI 425809|
218841049|NCT05381428|DRUG|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
219361099|NCT05825872|DRUG|Bupivacaine 0.5% Injectable Solution|1.5 ml will be injected
219361100|NCT00006093|DRUG|cilengitide|
219361101|NCT05963763|BEHAVIORAL|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs."
219451044|NCT05306964|PROCEDURE|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
219451045|NCT04632589|DRUG|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
218841050|NCT05381428|COMBINATION_PRODUCT|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
218841051|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
218841052|NCT04628169|OTHER|no intervention applied|no intervention applied
218841053|NCT02189720|DRUG|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients \> 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age \< 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
218841054|NCT03793426|BIOLOGICAL|Fibryga|Human plasma-derived fibrinogen concentrate
218841055|NCT06562166|RADIATION|online adaptive radiotherapy|Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
218841056|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
218841057|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
218841058|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
218841059|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
218841060|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
218841061|NCT06472141|OTHER|Cervical stabilization exercises|Cervical Stabilization Exercises will be performed 3 days a week for 8 weeks.
218841062|NCT06472141|OTHER|Standard treatment (Education + home exercises)|Individuals will be informed about TMJ disorders, parafunctional activities (chewing gum, nail/pen biting, etc.) and recommendations. In addition, Rocabado exercises will be given as a home program.
218841063|NCT04904471|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
218841064|NCT04904471|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
218841065|NCT05887492|DRUG|TNG260|CoREST inhibitor, administered orally
218841066|NCT05887492|DRUG|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
218841067|NCT05765604|BIOLOGICAL|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
218841068|NCT05765604|BIOLOGICAL|Recombinant COVID-19 vaccine(CHO cell)|IM
219451046|NCT04632589|DRUG|Placebo|subjects ingest placebo tablet daily for 6 weeks
218841069|NCT05532722|DRUG|ABC008|Given subcutaneous injection
218841070|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
218841071|NCT02975167|OTHER|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
218841072|NCT02975167|OTHER|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
218841073|NCT02975167|PROCEDURE|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
218841074|NCT02975167|BEHAVIORAL|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
219451047|NCT06388759|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
219451048|NCT06648486|DEVICE|With the assistance of wearable isokinetic training robot （ 7 children with SMA type II）|A child with SMA will use a wearable isokinetic training robot to train the knee joint for three stages. ( Stage 1: 1.5 months=30 sessions; Stage 2 (follow up): 1.5 months=18 sessions, Stage 3(follow up) = 0 session)
219451049|NCT04168866|PROCEDURE|Operative management|Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
219451050|NCT04168866|OTHER|Drainage or antibiotics|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
218841075|NCT02975167|BEHAVIORAL|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
218841076|NCT02975167|PROCEDURE|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
218841077|NCT04075292|DRUG|Acalabrutinib|acalabrutinib 100 mg twice daily orally
218841078|NCT04075292|DRUG|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
218841079|NCT04075292|DRUG|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
219451051|NCT05852600|BEHAVIORAL|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
218841080|NCT06006702|DRUG|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
219587956|NCT05729685|OTHER|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
219587957|NCT05729685|OTHER|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
219587958|NCT01808820|BIOLOGICAL|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
219587959|NCT01808820|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
219587960|NCT01808820|DRUG|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
219587961|NCT01808820|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
219587962|NCT02481362|OTHER|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
219587963|NCT02481362|OTHER|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
219587964|NCT01939574|OTHER|Chemoradiation Therapy|"* Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
218841081|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
218841082|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
218841083|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
218841084|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
218841085|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
218841086|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
218841087|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
218841088|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
218841089|NCT05598125|DEVICE|conventional tobacco cigarette|
218841090|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
218841091|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
218841092|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
218841093|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
218841094|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
218841095|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
218841096|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
218841097|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
218841098|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
218841099|NCT03680781|DEVICE|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
218841100|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
218841101|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
219451052|NCT05852600|BEHAVIORAL|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
219451053|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
219451054|NCT06247384|DEVICE|Hypotension Prediction Index Hemodynamic Monitoring|The application of the perioperative hemodynamic management according to the hypotension prediction index algorithm.
218841102|NCT06513546|DRUG|PLL001 or placebo daily subcutaneous injections|PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
219196808|NCT06816290|OTHER|"This research uses a qualitative method called photovoice. Participants express their experience of being a nursing student in a foreign country through visuals and share their feelings and"|"Photovoice is a participant-centered research method that allows participants to convey their experiences through visual data. This method is particularly used to understand social issues and the challenges individuals face. Participants take photos that they find meaningful related to the research topic and express their feelings, thoughts, and experiences through these images.~In this study, the Photovoice method is used to visualize the experiences of being a nursing student in a foreign country. Participants share their cultural adaptation, educational processes, personal challenges, and overall life experiences through photos taken with their smartphones. The photos are then analyzed in-depth during face-to-face interviews with the participants, where they discuss the meaning of the photo, the reason for choosing it, and their personal experiences."
219196809|NCT06265207|OTHER|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
219196810|NCT06265207|OTHER|routine maintenance|routine maintenance
219196811|NCT06819124|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and their caregiver will work together. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
219196812|NCT06819124|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and their caregiver will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
219196813|NCT06280560|PROCEDURE|Controlled Ovarian Stimulation + Luteal Phase Support|Short COS protocol with GnRH antagonist followed by progesterone supplementation. Will be initiated after a negative vaginal ultrasonographic scans to define ovarian quiescence, on days 1 and 2 of the menstrual period. For ovarian stimulation, 150-225 UI /day of FSHrec (GONAL F) will be administered along or in combination with 75 UI/day of HMG (Menopur). From day 6 onwards, HMG/FSHrec will be administered on an individual basis according to the serum E2 levels and transvaginal ovarian ultrasound scans and GnRH antagonist (Orgalutran) 0.25 mg /day is introduced as soon as a follicle of 14 mms diameter has achieved. hCGrec (6500 IU, Ovitrelle) will be administered when 7 or 8 follicles with a maximum diameter of \>17-18 mms will observed. 400 mg of micronized vaginal progesterone will be administered (200 mg twice a day vaginal route), during 5 days. An endometrial biopsy and a blood sample will be obtained 7 days after hCG administration (hCH+7)
219451055|NCT05379686|DRUG|GlucaGen|150 ug glucagon will be administered to the participants before exercise.
219451056|NCT04517253|DRUG|Baricitinib|Administered orally
219451057|NCT04979429|BEHAVIORAL|Perioperative Pain Self-management (PePS)|4 sessions of telephone CBT-based pain self-management.
219451058|NCT03811535|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
219451059|NCT03811535|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
219451060|NCT00271180|DEVICE|Device|
219451061|NCT05564039|DRUG|Tirzepatide|Administered SC
219451062|NCT05564039|DRUG|Dulaglutide|Administered SC
219451063|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
219451064|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
219451065|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
219451066|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
219451067|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
219451068|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
219451069|NCT05841355|OTHER|Educate|Education sessions
219451070|NCT05841355|OTHER|Empower|Empowerment sessions
219451071|NCT03493048|DRUG|Irinotecan|Irinotecan 130 mg/m²
219451072|NCT03493048|DRUG|Cetuximab|Cetuximab, iv, 500mg/m2
219451073|NCT03493048|DRUG|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
219451074|NCT03493048|DRUG|Oxaliplatin|oxaliplatin 85 mg/m²
219451075|NCT03493048|DRUG|Leucovorin|leucovorin 200 mg/m²
219451076|NCT04972825|BEHAVIORAL|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
219451077|NCT05664113|DRUG|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
219451078|NCT06206421|DRUG|Fezolinetant|oral
219451079|NCT06206421|DRUG|Placebo|oral
219587965|NCT01939574|OTHER|Adjuvant Therapy|"* Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
219587966|NCT01221363|BEHAVIORAL|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
218841103|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
218841104|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
218841105|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
218841106|NCT02290782|RADIATION|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
218841107|NCT00000805|DRUG|Ganciclovir|
218841108|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
218841109|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
218841110|NCT00328887|GENETIC|CD40 Gene Transfer|gene transfer, intratumoral administration
218841111|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
218841112|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
219587967|NCT04261907|DRUG|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
219587968|NCT04261907|DRUG|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
219587969|NCT00525447|DRUG|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
219587970|NCT00525447|DRUG|lenalidomide|Up to 25 mg daily of a 21-day cycle.
219587971|NCT00525447|DRUG|dexamethasone|40 mg administered weekly.
219587972|NCT02430831|DIETARY_SUPPLEMENT|Nidina|
219587973|NCT02430831|DIETARY_SUPPLEMENT|Placebo|
219587974|NCT02186626|BIOLOGICAL|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
218841113|NCT00878254|BIOLOGICAL|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4.
219587975|NCT02186626|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
218841114|NCT00878254|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenously (IV) on Day 1 for 4 Cycles during induction therapy. Participants achieving complete remission will then receive Rituximab maintenance therapy every 6 months for up to three years.
219361102|NCT02640963|OTHER|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
218841115|NCT00878254|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3.
218841116|NCT00878254|DRUG|Cytarabine|Cytarabine (AraC) 2 grams/m\^2 IV on Days 1 and 2 of Cycles 2 and 4.
218841117|NCT00878254|DRUG|Doxorubicin|Doxorubicin 45 mg/m\^2 IV bolus on Day 1 of Cycles 1 and 3.
218841118|NCT00878254|DRUG|Etoposide|Etoposide (VP16) 60 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
218841119|NCT00878254|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
219361103|NCT02640963|OTHER|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
219361104|NCT04213859|BEHAVIORAL|VRET - Virtual Reality Exposure Therapy|VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
219361105|NCT05836376|PROCEDURE|Mitral valve annuloplasty|implantation of a prosthetic ring to treat mitral valve regurgitation
218841120|NCT00878254|DRUG|Leucovorin|Leucovorin 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3.
218841121|NCT00878254|DRUG|Mesna|Mesna 360 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
218841122|NCT00878254|DRUG|Methotrexate|Methotrexate (MTX) 1,200 mg/m\^2 in 250 mL with Dextrose 5% in water (D5W) IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3.
218841123|NCT00878254|DRUG|Vincristine|Vincristine 1.5 mg/m\^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3.
218841124|NCT04819087|BEHAVIORAL|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
218841125|NCT06837077|DRUG|SHR-1209 single-site subcutaneous injection|SHR-1209 single-site subcutaneous injection.
218841126|NCT06837077|DRUG|SHR-1209 multiple-site subcutaneous injections|SHR-1209 multiple-site subcutaneous injections.
218841127|NCT05120895|DRUG|Mevalotin|Oral tablets (starting dose 5 mg)
218841128|NCT06849765|BEHAVIORAL|Rehabilitation|The rehabilitation program will utilize the MORA app to create individualized interventions based on each patient's physical capabilities.
218841129|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
218841130|NCT03872778|DRUG|[177Lu]-NeoB|\[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
218841131|NCT03872778|DRUG|[68Ga]-NeoB|\[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation
218841132|NCT03872778|DRUG|LCZ696|dose strength 49/51 mg, film-coated tablets for oral use
218841133|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
218841134|NCT02944708|DRUG|Conventional chemotherapy|
219196814|NCT06280560|PROCEDURE|Hormonal Replacement Therapy programmed artificial cycle|6 mg of oestradiol orally administered starting the first day of the menstrual period, followed by an endometrial scan 10-days later, and when a 7 mms triple line endometrium has seen by vaginal ultrasound scan, 800 mg of micronized vaginal progesterone (400 mg twice a day vaginal route), during five days, will be added to the oestrogen therapy. An endometrial biopsy and a blood sample will be obtained on day 5 of progesterone administration (P+5)
218841135|NCT02944708|DRUG|Maintenance chemotherapy 1|
218841136|NCT02944708|DRUG|Maintenance chemotherapy 2|
218841137|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
218841138|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
218841139|NCT03367403|DRUG|Donanemab|Administered IV
218841140|NCT03367403|DRUG|Placebo|Administered IV
218841141|NCT03367403|DRUG|LY3202626|Administered orally
219451080|NCT04785144|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
219451081|NCT04785144|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
219451082|NCT00949104|DRUG|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
219451083|NCT00949104|DRUG|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
219451084|NCT06128733|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
219451085|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
219451086|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
219451087|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
219451088|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
219451089|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
219451090|NCT06128733|BIOLOGICAL|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
218841142|NCT00213941|DEVICE|Echocardiography|
218841143|NCT02934841|DRUG|Conbercept|
218841144|NCT02934841|DRUG|sham|
218841145|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
218841146|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
218841147|NCT03704844|OTHER|non applicable|non applicable
218841148|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
218841149|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
218841150|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
218841151|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
218841152|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
218841153|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
218841154|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
218841155|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
218841156|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
218841157|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
218841158|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
218841159|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
218841160|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
218841161|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
218841162|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
218841163|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
218841164|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
218841165|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
218841166|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
218841167|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
219196815|NCT06280560|PROCEDURE|Natural Cycle (NC)|No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
219451091|NCT06128733|BIOLOGICAL|MenABCYW conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
219451092|NCT04453722|DEVICE|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
219451093|NCT04453722|DEVICE|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
219451094|NCT02691923|DRUG|Fluorescein|
219451095|NCT02691923|DRUG|Fluorescein + ALA|
219451096|NCT03947099|DRUG|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
219451097|NCT01263470|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
219451098|NCT01263470|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
219451099|NCT01263470|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
218841168|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
219451100|NCT01263470|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
219451101|NCT01263470|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
219451102|NCT01263470|DRUG|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
219451103|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
219451104|NCT00610714|DRUG|AZD0530|oral once daily dose
219451105|NCT00610714|DRUG|Carboplatin|intravenous injection
219451106|NCT00610714|DRUG|Paclitaxel|intravenous infusion
219196816|NCT06280560|PROCEDURE|Endometrial receptivity reference group|Recruited among women belonging to the oocyte donation program and will follow the procedures described above for the Natural Cycle group. No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
219451107|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
219451108|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
219451109|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
219451110|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
219451111|NCT05275127|OTHER|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
219451112|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
219451113|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
219451114|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
219451115|NCT01197872|OTHER|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
219451116|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
219451117|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
219451118|NCT00712712|DRUG|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
219451119|NCT00712712|DRUG|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
219451120|NCT00712712|OTHER|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~* The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~* the background morphine analgesic treatment during the last 24 hours,~* the morphine analgesic treatment taken during painful attacks,~* the possible undesirable effects of morphine treatment.~* the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
219451121|NCT00712712|PROCEDURE|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
219587976|NCT05773248|PROCEDURE|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
218841169|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
218841170|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
219451122|NCT00712712|PROCEDURE|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
219451123|NCT05681780|BIOLOGICAL|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
219451124|NCT05681780|DRUG|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
218841171|NCT02628405|DRUG|Carboplatin|Given IV
218841172|NCT02628405|DRUG|Etoposide|Given IV
218841173|NCT02628405|DRUG|Ifosfamide|Given IV
218841174|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
218841175|NCT02628405|DRUG|Lenalidomide|Given PO
218841176|NCT02628405|BIOLOGICAL|Rituximab|Given IV
219451125|NCT05681780|DRUG|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
218841177|NCT02782234|BEHAVIORAL|Contract management|
218841178|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
219451126|NCT05681780|DRUG|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
219451127|NCT05681780|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
219451128|NCT05681780|DRUG|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
219451129|NCT02966236|DRUG|Tranexamic Acid|
219587977|NCT01336452|RADIATION|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
219587978|NCT04245241|OTHER|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
218841179|NCT02840318|OTHER|Compassion Intervention|See arm description
218841180|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
218841181|NCT00575107|OTHER|Exercise|Standard training of leg extension
218841182|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
219451130|NCT02966236|DRUG|Placebos|
219451131|NCT03698214|OTHER|reversed shock index < 1|Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
219451132|NCT03698214|OTHER|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
218841183|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
218841184|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
218841185|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
218841186|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
218841187|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
218841188|NCT00296049|DRUG|daptomycin|
219451133|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
219451134|NCT03927820|OTHER|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
219451135|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
219451136|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
219451137|NCT06364943|OTHER|with/without dry eye syndrome|compare tear ferning structure between dry eye and non-dry eye patients
218841189|NCT00296049|DRUG|vancomycin|
218841190|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
219451138|NCT05081245|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
219451139|NCT05081245|DRUG|ML-004 Placebo|Participants will receive matching placebo once daily.
219451140|NCT06380556|DEVICE|ShotBlocker|The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
219587979|NCT04318223|DRUG|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
219451141|NCT06380556|DEVICE|Mechanical vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
219451142|NCT04331028|DEVICE|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
219587980|NCT03277118|DEVICE|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
219451143|NCT03353441|DIETARY_SUPPLEMENT|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
219451144|NCT03353441|DIETARY_SUPPLEMENT|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
219451145|NCT02432690|DRUG|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
219451146|NCT05415865|COMBINATION_PRODUCT|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
219451147|NCT05415865|DRUG|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
219451148|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
219451149|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
219451150|NCT05841277|DRUG|LY3819469|Administered SC.
219451151|NCT02106845|DRUG|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
218841191|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
218841192|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
218841193|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
218841194|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
219196817|NCT06816680|PROCEDURE|APF + FGG|In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS\*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization. To eliminate muscle and frenum attachment at recipient site, vestibuloplasty and a periosteal incision were performed. A 4 mm or 6 mm healing abutment was then screwed onto the implants. FGG was harvested from palate in a 7-8 mm width and trimmed to an even thickness of 1 to 1.5 mm. A resorbable hemostatic sponge (Spongostan, Ethicon, Johnson \& Johnson) was placed at donor site for wound coverage. For graft fixation, a loop suture with 6-0 (PROLENE, ETHICON) was first placed at the center of recipient site, additional sutures were added to enhance stabilization.
218841195|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
218841196|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
218841197|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
218841198|NCT03636893|DRUG|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
218841199|NCT03636893|DRUG|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
218841200|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
218841201|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
218841202|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
218841203|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
218841204|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
218841205|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
218841206|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
219451152|NCT02106845|DRUG|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
219451153|NCT02106845|DRUG|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
219451154|NCT02954861|OTHER|No intervention|No intervention
219451155|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
219451156|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
219451157|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
218841207|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
218841208|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
218841209|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
218841210|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
218841211|NCT00002134|DRUG|Ganciclovir|
219451158|NCT00693563|BEHAVIORAL|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
219451159|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
219587981|NCT03587324|DRUG|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
219587982|NCT02390128|OTHER|observational only|
219587983|NCT03928210|DRUG|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
219587984|NCT05782881|BEHAVIORAL|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
219587985|NCT05782881|DRUG|Statin|Treatment and management according to the guidelines
219587986|NCT03016819|DRUG|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
219587987|NCT03016819|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
219587988|NCT03016819|DRUG|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
219587989|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^7 pfu /2mL administered in each deltoid
219587990|NCT00083603|BIOLOGICAL|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
219587991|NCT00083603|BIOLOGICAL|Empty TBC-FPV|Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
219587992|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^8 pfu /2mL administered in each deltoid
219587993|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^9 pfu /2mL administered in each deltoid
219587994|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^7 pfu/2mL administered into each deltoid
219587995|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^8 pfu/2mL administered into each deltoid
219587996|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^9 pfu/2mL administered into each deltoid
219587997|NCT02695537|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
219587998|NCT06223087|OTHER|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
219017695|NCT01329302|PROCEDURE|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
219587999|NCT03335215|OTHER|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
219588000|NCT02032797|DRUG|Progesterone|
219588001|NCT04538183|OTHER|WO 5000|WO 5000
219588002|NCT04538183|OTHER|WO 5001|WO 5001
219588003|NCT01339338|PROCEDURE|warming the contrast media|warm the contrast media with 37℃ water-bathing
219588004|NCT04263324|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
219588005|NCT00115830|DRUG|Atorvastatin|
219588006|NCT00115830|DRUG|Rosuvastatin|
218841212|NCT00006144|DRUG|Lopinavir/Ritonavir|
218841213|NCT00006144|DRUG|Emtricitabine|
218841214|NCT00006144|DRUG|Stavudine|
219451160|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
219451161|NCT00667940|BEHAVIORAL|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
219451162|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
218841215|NCT05778864|DRUG|LY3473329|Administered orally.
218841216|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
219451163|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
218841217|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
219588007|NCT05786716|DRUG|Trastuzumab|An initial loading dose of 8 mg/kg body weight, followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
219588008|NCT05786716|DRUG|Pertuzumab|An initial loading dose of 640 mg, followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive an initial loading dose of 14 mg/kg (maximum 840 mg), followed thereafter by a maintenance dose of 7 mg/kg (maximum 420 mg) administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
218841218|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
219451164|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
219451165|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
218841219|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
218841220|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
218841221|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
218841222|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
218841223|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
218841224|NCT04333979|OTHER|Drainage|Using drain after operation
218841225|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
218841226|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
219017705|NCT04493853|DRUG|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
219017706|NCT04493853|OTHER|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
219017707|NCT04493853|DRUG|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
219451166|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
219451167|NCT05879484|DRUG|pembrolizumab|"Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks."
219451168|NCT05879484|DRUG|valemetostat|"Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose."
219451169|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
219451170|NCT01003340|BEHAVIORAL|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
219451171|NCT04617639|BEHAVIORAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
219588009|NCT04501133|DEVICE|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
219588010|NCT04501133|DEVICE|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
218841227|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
218841228|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
219017708|NCT06073171|BIOLOGICAL|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
219017709|NCT06073171|BIOLOGICAL|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
219017710|NCT06073171|GENETIC|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
219017715|NCT00694655|BIOLOGICAL|Yellow Fever Vaccine|Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
219451172|NCT04617639|BEHAVIORAL|Standard care|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
219588011|NCT02578030|DRUG|SHP465 12.5mg|
219588012|NCT02578030|DRUG|SHP465 25mg|
219588013|NCT06152406|PROCEDURE|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
219588014|NCT05418504|DRUG|Dental anesthesia|Dental anesthesia, used to do any dental procedure
219588015|NCT04480710|DRUG|CRV431 75mg|1 x 75mg softgel capsule
219588016|NCT04480710|DRUG|Placebo (1 softgel)|1 x placebo softgel capsule
219588017|NCT04480710|DRUG|CRV431 225mg|3 x 75mg softgel capsule
219588018|NCT04480710|DRUG|Placebo (3 softgels)|3 x placebo softgel capsule
218841229|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
218841230|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
219451173|NCT04617639|BEHAVIORAL|Observation group|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
219451174|NCT03727633|DRUG|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
219451175|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
219451176|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
219588019|NCT06971367|BEHAVIORAL|Risk assessment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category.
218841231|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
218841232|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
218841233|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
218841234|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
218841235|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
218841236|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
218841237|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
218841238|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
218841239|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
218841240|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
218841241|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
218841242|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
218841243|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
219451179|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
219451180|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
219451181|NCT02871791|DRUG|Palbociclib|
219451182|NCT02871791|DRUG|Everolimus|
219451183|NCT02871791|DRUG|Exemestane|
219451184|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
219451185|NCT06977321|OTHER|Kinesiotaping|Kinesiotaping, unlike wrist splints, which are frequently used in the treatment of carpal tunnel syndrome, does not restrict daily living activities. Space correction technique will be applied while performing kinesio taping.
219451186|NCT06977321|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
219451187|NCT06977321|OTHER|Home exercise|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
219451188|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
219588020|NCT06971367|BEHAVIORAL|U=U messaging|Participants will be shown a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category.
218841244|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
218841245|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
218841246|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
218841247|NCT01241188|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
218841248|NCT01241188|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
218841249|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
219451189|NCT00984919|OTHER|high performance liquid chromatography|
218841250|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
218841251|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
218841252|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
219451190|NCT00984919|OTHER|laboratory biomarker analysis|
219451191|NCT00984919|OTHER|mass spectrometry|
218841253|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
219451192|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
219451193|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
219451194|NCT04917328|OTHER|compression ultrasound|performing a compression ultrasound
219451195|NCT00585507|DRUG|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
219451196|NCT05182294|DEVICE|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
218841254|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
218841255|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
218841256|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
218841257|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
218841258|NCT02931513|OTHER|Blood samples|
218841259|NCT02931513|DEVICE|Fibroscan|
218841260|NCT02931513|OTHER|Questionnaires|
218841261|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
219451197|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
219451198|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
219588021|NCT06971367|BEHAVIORAL|Community benefits messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category.
218841262|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
219451199|NCT03307473|BEHAVIORAL|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
219451200|NCT05999240|DRUG|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
219451201|NCT05999240|DRUG|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
219451202|NCT06654336|RADIATION|Recurrence-directed therapy (RDT)|RDT options include radiotherapy or surgical resection.
219451203|NCT06654336|DRUG|ELIGARD 22.5mg|ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
219451204|NCT04005755|DRUG|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
218841263|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
218841264|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
218841265|NCT03179930|DRUG|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
219196818|NCT06816680|PROCEDURE|PPF group|For the PPF group, the palatal sliding flap was a modified version of modified roll technique, as described in previous cohort study. Unlike the original technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG). Following buccal pouch flap preparation, a slight APF was required in cases with limited vestibular depth. When the palatal pedicle CTG was rolled in buccal pouch flap, a loop suture with 6-0 (PROLENE, ETHICON) was used for flap stabilization.
218841266|NCT03179930|DRUG|Pembrolizumab|pembrolizumab 200 mg IV on D1
218841267|NCT02214888|DRUG|BIRB 796 BS, low dose|
218841268|NCT02214888|DRUG|BIRB 796 BS, high dose|
218841269|NCT02214888|DRUG|Placebo|
218841270|NCT05523167|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
218841271|NCT05523167|OTHER|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
218841272|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
218841273|NCT06455566|DEVICE|Leadless pacemaker implantation through right internal jugular vein|Leadless pacemaker implantation through right internal jugular vein
218841274|NCT00431522|DRUG|Valproic acid, sodium salt|
218841275|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
219361106|NCT04244565|BEHAVIORAL|Self-directed model of clinical learning for nurses|the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources \& decide whether learning method can be used, and engaging in self-reflection \& evaluation.
219361107|NCT03285256|BEHAVIORAL|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
218841276|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
219361108|NCT03285256|BEHAVIORAL|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
219361109|NCT03285256|BEHAVIORAL|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
219361110|NCT03649295|OTHER|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
219361111|NCT03649295|OTHER|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
219361112|NCT01916629|DRUG|Photocil for Psoriasis|Photocil for Psoriasis
219361113|NCT01916629|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
219361114|NCT02082678|DRUG|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
219361115|NCT02082678|DRUG|Placebo|Inactive ingredient matching the active medication in appearance
219361116|NCT03034395|PROCEDURE|Wide Local Excision|Surgery
219361117|NCT03301181|DRUG|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
219361118|NCT03301181|DRUG|Rifampin|600 mg rifampin once daily
219361119|NCT03301181|DRUG|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
219361120|NCT03301181|DRUG|Itraconazole|200 mg itraconazole once daily
219361121|NCT04202731|BEHAVIORAL|PBS Study|Sleep extension intervention
219361122|NCT04182867|OTHER|Dietary intervention|Dietary modification (provision of diet).
219361123|NCT03708055|BEHAVIORAL|Exercise Intervention|Undergo weight bearing exercise program
219361124|NCT00603915|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) day 1 and day 8
219361125|NCT00603915|DRUG|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
219361126|NCT00603915|DRUG|erlotinib|150mg daily (post GC therapy)
219361127|NCT03891901|DRUG|Imatinib|Tablets, administered orally
219361128|NCT03891901|DRUG|Isoniazid|300 mg tablets, administered orally
219361129|NCT03891901|DRUG|Rifabutin|300 mg capsules, administered orally
218841277|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
218841278|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
218841279|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
218841280|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
218841281|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
218841282|NCT04998318|DEVICE|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
218841283|NCT04998318|PROCEDURE|Standard of Care Colposcopy|VIA and VILI as previously described,
218841284|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
218841285|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
218841286|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
218841287|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
219451205|NCT00705380|BEHAVIORAL|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
219451206|NCT00705380|BEHAVIORAL|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
218841288|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
219017716|NCT00694655|PROCEDURE|Leukapheresis|In leukapheresis blood is drawn and then the white blood cells are separated from the blood sample in a laboratory procedure. Once the white blood cells are returned the blood is returned back to the bloodstream of the participant who provided the sample.
219017717|NCT00694655|PROCEDURE|Fine-needle aspiration (FNA)|In fine-needle aspiration a cell sample is collected using a needle and syringe. Fine-needle aspiration is typically used as a minimally invasive method of sample collection used to confirm a diagnosis.
219451207|NCT02789072|OTHER|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
219451208|NCT06986317|OTHER|Positional release techniques|Positional release techniques apply for 90 second with the frequency of 3. This protocol will given 2 times in a week.
219451209|NCT06986317|OTHER|Graston technique|Graston technique will apply at 45 degree to muscle fiber for 60 sec with the frequency of three. 2 session will be given per week
219451210|NCT06085937|DRUG|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
219451211|NCT02723019|BEHAVIORAL|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
219451212|NCT01453933|DRUG|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
218841289|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
218841290|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
218841291|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
218841292|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
218841293|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
218841294|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|25 μg p.o.
218841295|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|100 or 200 μg p.o.
218841296|NCT04908865|DRUG|Belimumab|Belimumab will be administered.
218841297|NCT04908865|DRUG|Standard therapy|Standard therapy will be continued.
218841298|NCT06127836|PROCEDURE|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
219451213|NCT03012360|DRUG|ceftriaxone|2 g iv every 24h
219451214|NCT03012360|DRUG|ciprofloxacin|400 mg iv every 8h
219451215|NCT03012360|DRUG|imipenem|1 g iv every 8h
219451216|NCT03012360|DRUG|linezolid|600 mg iv every 12h
219451217|NCT03012360|DRUG|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
218841299|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
218841300|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
218841301|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
218841302|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
218841303|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
219588022|NCT06971367|BEHAVIORAL|Fresh start effect|Participants will be shown a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category.
219588023|NCT06971367|BEHAVIORAL|Education-based messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based content category.
219588024|NCT06971367|BEHAVIORAL|Default appointment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category.
218841304|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
218841305|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
218841306|NCT06640517|DRUG|Netakimab|netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
218841307|NCT06640517|DRUG|Placebo|placebo will be administered subcutaneously at a scheme masking netakimab treatment
218841308|NCT06640517|DRUG|Adalimumab|adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
218841309|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
218841310|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
218841311|NCT05947175|BIOLOGICAL|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
219361130|NCT01182831|PROCEDURE|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
219361131|NCT01182831|PROCEDURE|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
219361132|NCT01569685|DRUG|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
219361133|NCT01569685|DRUG|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
219361134|NCT01069497|OTHER|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
219361135|NCT01407549|BEHAVIORAL|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
219361136|NCT02547480|DEVICE|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
219361137|NCT00864266|DRUG|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
219361138|NCT03686501|DRUG|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections
219361139|NCT03757832|DEVICE|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
219451218|NCT05017168|DRUG|CT-P63|CT-P63 will be administered
219451219|NCT05017168|DRUG|Placebo|Placebo-matching CT-P63
219451220|NCT05448937|PROCEDURE|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
219451221|NCT05448937|PROCEDURE|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
219451222|NCT05379192|OTHER|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
219451223|NCT00515099|DRUG|Antithymocyte globulin|Daily 4-day escalating dose
219451224|NCT00515099|DRUG|Placebo|Daily 4-day saline solution
219451225|NCT01905306|PROCEDURE|computer guided implant planning|
219451226|NCT01905306|PROCEDURE|free hand implants placement|
219361140|NCT02129946|OTHER|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
219361141|NCT00911846|OTHER|interview|interview using questionnaires
219361142|NCT03473132|DRUG|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
219361143|NCT04186026|OTHER|Saline + saline|Double saline infusion followed by an ad libitum meal
219361144|NCT04186026|OTHER|Neurotensin + saline|Neurotensin + saline infusion followed by an ad libitum meal
219361145|NCT04186026|OTHER|GLP-1 + saline|GLP-1 + saline infusion followed by an ad libitum meal
219361146|NCT04186026|OTHER|GLP-1 + Neurotensin|GLP-1 + Neurotensin infusion followed by an ad libitum meal
219451227|NCT03639688|PROCEDURE|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
219361147|NCT05350059|DEVICE|High Intensity Focused Ultrasound (HIFU) to the Breast Cancer|Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
219361148|NCT01314300|DRUG|Lidocaine|Lidocaine 5% plaster
219361149|NCT02903537|DRUG|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
219361150|NCT02903537|DRUG|Interferon-beta|Subcutaneous administration interferon-beta
219361151|NCT02105415|DRUG|Ketamine / Propofol Admixture|
219361152|NCT02105415|DRUG|Etomidate|
219451228|NCT03639688|PROCEDURE|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
219451229|NCT05105529|BEHAVIORAL|Exercise|Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
219451230|NCT05105529|OTHER|Ozone|Breathing 170ppb ozone
219451231|NCT05105529|OTHER|Filtere Air|Breathing filtered air
219451232|NCT05002036|DEVICE|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
219451233|NCT01071291|DRUG|Niaspan|Niaspan™
219451234|NCT01071291|DRUG|Comparator: Placebo|Placebo
219451235|NCT00475072|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
219451236|NCT00475072|DRUG|ribavirin|1000/1200mg po daily for 48 weeks
219451237|NCT01149525|DRUG|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
219451238|NCT01149525|DRUG|Placebo|oral solution, twice per day (morning/evening), during 3 months
219451239|NCT05678504|DEVICE|The phlebotomy procedure|The process of blood collection with a vascular imaging device
219451240|NCT02630394|DRUG|Azithromycin|
219451241|NCT04732780|OTHER|No intervention|No intervention
219451242|NCT03035422|DRUG|Sequential Packaging (SET)|"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
219451243|NCT03035422|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at D0
219451244|NCT03035422|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
219451245|NCT03035422|DRUG|Care supports|According to the protocols of each center
219451246|NCT03035422|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
219451247|NCT05402111|DRUG|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
219451248|NCT05402111|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
218841312|NCT05947175|OTHER|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
219196819|NCT06820892|OTHER|Survey|The study utilised a 16-item questionnaire to evaluate the quality of information received during antenatal diagnosis consultations and its congruence with subsequent experiences following birth and hospitalisation of the infant. The questionnaire encompassed seven questions pertaining to consultation arrangements, including duration, frequency and unit visits, six questions addressing the received information, and three questions exploring the long-term outcomes of the child.
219196820|NCT06818175|PROCEDURE|Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia|The injection of a fluid solution to separate facial or tissue layers in the body. Usually guided by ultrasound.
219196821|NCT06818175|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|The therapeutic application of manually guided forces by an osteopathic physician (US Usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques.
219196822|NCT06819384|OTHER|Movement Pattern Training|The group A Movement Pattern Training 2set each set 20 repition lasting for eight weeks.
219196823|NCT06819384|OTHER|propioceptive neuromuscular facilitation|The group B propioceptive neuromuscular facilitation 2set each set 20 repition lasting for eight weeks.
219196824|NCT06816602|BEHAVIORAL|education|Receiving structured education
219196825|NCT06816407|DRUG|Prucalopride 2mg|Prucalopride 2mg taken preoperatively
219196826|NCT06816407|DRUG|Prucalopride 4mg|Prucalopride 4mg taken preoperatively
219196827|NCT06816407|OTHER|Standard Care|Standard Supportive care
218841313|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
218841314|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
219196828|NCT03752892|OTHER|intervention -1-leg cycle training|partitioned aerobic exercise training
219196829|NCT03752892|OTHER|usual care - 2-leg cycle training|conventional aerobic exercise training
219451249|NCT05333289|BIOLOGICAL|mRNA-1030|Sterile liquid for injection
219451250|NCT05333289|BIOLOGICAL|mRNA-1020|Sterile liquid for injection
218841315|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
218841316|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
218841317|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
218841318|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
219196830|NCT06825923|OTHER|Clinical and Endotypic Assessmen|This observational study involves a detailed clinical and endotypic assessment of patients diagnosed with Obstructive Sleep Apnea (OSA). Assessments include polysomnography (PSG) to measure sleep patterns and disturbances, drug-induced sleep endoscopy (DISE) to evaluate upper airway obstruction, and various biomarker analyses to characterize endotypic traits. The study aims to collect comprehensive phenotypic and endotypic data to develop predictive models for OSA patient characterization and management.
219196831|NCT06820268|DRUG|XS-04 tablet|Each treatment cycle is 28 days, with continuous oral administration, twice daily.
219451251|NCT05333289|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219451252|NCT05333289|BIOLOGICAL|Active Comparator|Sterile liquid for injection
219451253|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
219451254|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
218841319|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
218841320|NCT05722938|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
219451255|NCT03888976|PROCEDURE|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
219451256|NCT02381262|BEHAVIORAL|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
219451257|NCT00221689|DRUG|baclofen (drug)|
219451258|NCT00979862|DRUG|Cediranib Maleate|Given PO
219588025|NCT06971367|BEHAVIORAL|Reserved for you messaging|"Participants will be shown a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
218841321|NCT05722938|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
218841322|NCT05549297|DRUG|Tebentafusp|Soluble gp100-specific T cell receptor with anti-CD3 scFV
219451259|NCT00979862|DRUG|Cilengitide|Given IV
219451260|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
219451261|NCT06119568|DEVICE|Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).|Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
219451262|NCT04340687|DEVICE|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
219451263|NCT01859884|BEHAVIORAL|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
219451264|NCT03714789|OTHER|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
219451265|NCT01680562|OTHER|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
219451266|NCT05825365|DRUG|Selumetinib|Selumetinib
219451267|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
219451268|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
219451269|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
219451270|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
219588026|NCT06971367|BEHAVIORAL|Social norms (default) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by the default avatar. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
219588027|NCT06971367|BEHAVIORAL|Social norms (varied) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by an avatar that approximately matches each participant's age and sex. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
219588028|NCT06971367|BEHAVIORAL|Goal-setting messaging|Participants will be shown a brief video message at their baseline visit, containing information related to goal-setting core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the goal-setting content category.
219588029|NCT06971367|BEHAVIORAL|Incentive|Participants will be informed that they will receive a small financial incentive if they return for repeat HIV testing in 3-6 months after enrollment.
219588030|NCT05980741|PROCEDURE|high-quality nursing|High-quality nursing
219588031|NCT05980741|PROCEDURE|Clinical Care Pathway|Clinical Care Pathway
219588032|NCT05980741|PROCEDURE|Roy Adaptation Model|Roy Adaptation Model
219588033|NCT04126213|BIOLOGICAL|RSV MAT 60 µg|One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
219588034|NCT04126213|BIOLOGICAL|RSV MAT 120 µg|One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
219588035|NCT04126213|DRUG|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
219588036|NCT02160275|DEVICE|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
219588037|NCT02160275|DEVICE|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
219588038|NCT04532359|DEVICE|Implant placement|Implant placement
218841323|NCT05549297|DRUG|Tebentafusp with Pembrolizumab|Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab
219451271|NCT03676465|OTHER|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
219451272|NCT03676465|OTHER|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
219588039|NCT06483841|BEHAVIORAL|Parents as Partners|The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
219588040|NCT05965453|DEVICE|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
219588041|NCT03254381|BEHAVIORAL|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
218841324|NCT05549297|DRUG|Investigators Choice|Investigators choice of therapy
218841325|NCT06643377|DRUG|Enlicitide|Oral tablet
218841326|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
219451273|NCT02952430|PROCEDURE|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
219588042|NCT03254381|BEHAVIORAL|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
219588043|NCT04431882|PROCEDURE|optic nerve sheath fenestration|A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
219588044|NCT03050060|DRUG|Atezolizumab|Given IV
219588045|NCT03050060|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218841327|NCT04122911|DRUG|Temozolomide|pharmacological
218841328|NCT00439543|DRUG|Iloprost inhalation|
218841329|NCT03663504|OTHER|No Preparation|No preparation before surgery
218841330|NCT03663504|DRUG|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
218841331|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
218841332|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
218841333|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
218841334|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
218841335|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
218841336|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
218841337|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
219451274|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
219451275|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
218841338|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
218841339|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
219451276|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
218841340|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
218841341|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
218841342|NCT06267937|OTHER|type of intitution|public or private health care facility
219017727|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
219017728|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
219451277|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
219451278|NCT06218628|DRUG|Talazoparib|pacritinib in combination with talazoparib
219451279|NCT06218628|DRUG|pacritinib|pacritinib in combination with talazoparib
219451280|NCT04797494|DEVICE|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
219588046|NCT03050060|OTHER|Laboratory Biomarker Analysis|Correlative studies
219451281|NCT01936428|OTHER|interview|
219451282|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
219451283|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
219588047|NCT03050060|DRUG|Nelfinavir Mesylate|Given PO
219588048|NCT03050060|BIOLOGICAL|Nivolumab|Given IV
219588049|NCT03050060|BIOLOGICAL|Pembrolizumab|Given IV
218841343|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
218841344|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
218841345|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
218841346|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
219017729|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
219017730|NCT04442022|DRUG|Placebo matching for Selinexor (combination therapy)|Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
219017731|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
219017732|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
219017733|NCT04442022|DRUG|Gemcitabine (combination therapy)|Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
219451284|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
218841347|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
219451285|NCT02750501|DEVICE|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
219451286|NCT02750501|OTHER|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
219451287|NCT03685643|BEHAVIORAL|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
219588050|NCT05499780|DEVICE|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
219588051|NCT00003592|DRUG|methotrexate|
219588052|NCT00003592|DRUG|paclitaxel|
219588053|NCT03245957|OTHER|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
219588054|NCT03245957|OTHER|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
219588055|NCT01826786|DRUG|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
218841348|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
218841349|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
218841350|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
218841351|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
218841352|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
219588056|NCT01826786|DRUG|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
219588057|NCT02681146|OTHER|Multimodal intervention|Educational advice + physiotherapist treatment
218841353|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
218841354|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
218841355|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
218841356|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
218841357|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
219451288|NCT03685643|BEHAVIORAL|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
219451289|NCT04916301|BEHAVIORAL|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
219451290|NCT02789189|DRUG|nedaplatin and gemcitabine|
219588058|NCT03252418|DRUG|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
218841358|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
218841359|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
218841360|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
218841361|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
218841362|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
218841363|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
218841364|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
219017734|NCT04442022|DRUG|Dexamethasone (combination therapy)|Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
219017735|NCT04442022|DRUG|Cisplatin (combination therapy)|Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
219017736|NCT04442022|DRUG|Selinexor (continuous therapy)|Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
219451291|NCT00718991|DEVICE|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
219588059|NCT03252418|DEVICE|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
219588060|NCT03835221|DEVICE|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
219451292|NCT04196049|PROCEDURE|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
218841365|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
219451293|NCT04752631|DRUG|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
218841366|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
219451294|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
219451295|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
219451296|NCT00403390|DRUG|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
219451297|NCT00403390|DRUG|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
219451298|NCT02081911|PROCEDURE|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
219451299|NCT02081911|PROCEDURE|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
219451300|NCT02081911|PROCEDURE|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
219588061|NCT03835221|DEVICE|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
219588062|NCT01258166|PROCEDURE|Surgery or immobilization|
219588063|NCT01647672|DRUG|Abraxane|Abraxane for neoadjuvant chemotherapy
219588064|NCT04384744|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
218841367|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
218841368|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
218841369|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
218841370|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
218841371|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
218841372|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
218841373|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
218841374|NCT02043106|OTHER|plantar vibration|
218841375|NCT02930382|OTHER|Baroreflex assessment|
218841376|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
218841377|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
218841378|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
218841379|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
218841380|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
218841381|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
218841382|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
219017737|NCT04442022|DRUG|Placebo matching for Selinexor (continuous therapy)|Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
219017738|NCT05185258|DRUG|Enstilar|Topical foam
219451301|NCT02617199|DRUG|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
219451302|NCT02617199|DRUG|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
219588065|NCT06708364|OTHER|Virtual Reality Training|"Virtual reality training (X-BOX). Table tennis~* Frequency: 3 day per week~* Intensity: Mild to moderate as per Game. Exer-game ( River Rush)~* Time: total 30 minute of training with 5 min warm and 5 min cool down.~* Type: aerobic exercise"
219588066|NCT06708364|OTHER|Cycle Ergometer|"* Frequency: 3 days per week.~* Intensity: 40-60% of HRR~* Time: total 30 minutes with 5 min warm up and 5 min cool down~* Type: aerobic exercise"
219588067|NCT01088802|RADIATION|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
219588068|NCT01088802|DRUG|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
219588069|NCT01088802|DRUG|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
219588070|NCT05177172|OTHER|High beta glucans|higher dose betaglucans
219588071|NCT05177172|OTHER|Low beta glucans|lower dose beta glucans
218841383|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
218841384|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
218841385|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
218841386|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
218841387|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
219451303|NCT06659744|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
218841388|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
218841389|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
218841390|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
218841391|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
218841392|NCT04113707|BEHAVIORAL|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
218841393|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
218841394|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
218841395|NCT05949255|DIETARY_SUPPLEMENT|Probiotic|10 subject will receive a probiotic daily for 12 weeks.
218841396|NCT05949255|DIETARY_SUPPLEMENT|Placebo|10 subjects will receive a placebo daily for 12 weeks.
218841397|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
218841398|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
219017739|NCT05185258|DRUG|Placebo-vehicle|Topical foam
219017740|NCT05986916|DIAGNOSTIC_TEST|Liverscope® exam|Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
219017741|NCT05986916|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
219017742|NCT05986916|DIAGNOSTIC_TEST|FibroScan® exam (optional)|Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.
219017743|NCT05986916|OTHER|Blood draw|Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.
219451304|NCT06659744|DRUG|New initiation of sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
219017744|NCT05986916|OTHER|Body measurements|Participants will have their height, weight, waist circumference, and hip circumference measured.
219017745|NCT05986916|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
219451305|NCT03931889|DIETARY_SUPPLEMENT|Vitamin D3|Cap. Cholecalciferol 40,000 IU
219451306|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
219017748|NCT06645873|DEVICE|Continuous glucose monitoring (CGM) device|All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
219196832|NCT06826222|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
219451307|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
219451308|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
219451309|NCT01941212|BEHAVIORAL|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
219451310|NCT04760691|DRUG|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
219451311|NCT04760691|DRUG|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
219451312|NCT04760691|DRUG|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
219451313|NCT04760691|DRUG|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
219451314|NCT04760691|DRUG|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
219451315|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
219451316|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
219451317|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
219451318|NCT04686929|DRUG|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
219451319|NCT00428285|PROCEDURE|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
219451320|NCT00605228|DRUG|MOVIPREP|2L Drug
219451321|NCT00605228|DRUG|COLOPEG|4L Drug
219451322|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
219451323|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
219451324|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
219451325|NCT03830463|DRUG|CTP-692|Single oral dose
218841399|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
218841400|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
218841401|NCT00182052|OTHER|Placebo|Given orally twice daily.
219451326|NCT03830463|DRUG|Placebo|Single oral dose
219451327|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
219588072|NCT05177172|OTHER|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
219588073|NCT05177172|OTHER|Polar lipids|low dose polar lipids
219588074|NCT05177172|OTHER|Control|No beta glucans or polar lipids
219588075|NCT03261765|OTHER|Assessment of adhesions|Modified Nair scoring system
219588076|NCT06352229|BEHAVIORAL|Playful Learning in Infancy Program|Research-based knowledge on play with babies delivered to the parents systematically by public health visitors based on a manual, activity cards, and video clips at four time points from 0 to 12 months postpartum.
218841402|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
218841403|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
218841404|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~\- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
219451328|NCT01369667|OTHER|Placebo|
218841405|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
219196833|NCT06826222|DIETARY_SUPPLEMENT|Sodium Chloride|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
219451329|NCT03698929|OTHER|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
219451330|NCT03698929|OTHER|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
219451331|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
218841406|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
218841407|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
218841408|NCT02543177|PROCEDURE|coronary angiography|
218841409|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
218841410|NCT02543177|PROCEDURE|prior kidney irrigation|
219451332|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
219588077|NCT06352229|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
219588078|NCT02823652|OTHER|standard genetic education|Undergo usual care
219588079|NCT02823652|OTHER|Genetic Counseling|Complete remote counseling
219588080|NCT02823652|OTHER|Genetic Testing|Undergo germline testing
219588081|NCT02823652|OTHER|Internet-Based Intervention|Complete on-line genetic education
219588082|NCT02823652|OTHER|Survey Administration|Ancillary studies
219588083|NCT01367652|DRUG|Letrozole|2.5 mg tablet
219588084|NCT01367652|DRUG|Letrozole|2.5 mg Tablet
219588085|NCT06002737|DEVICE|Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel|Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
218841411|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
218841412|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
218841413|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
218841414|NCT05452031|BEHAVIORAL|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
218841415|NCT05452031|BEHAVIORAL|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
219451333|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
219451334|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
219588086|NCT01385982|OTHER|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
219588087|NCT03567382|DRUG|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
219020718|NCT07205393|OTHER|Cardiac rehabilitation|"The intervention group underwent the cardiac rehabilitation program from the first day following surgery regarding the clinical guideline for rehabilitation in patients with cardiovascular disease.17 This rehabilitation exercise program formed of breathing exercises, lower and upper extremity exercises in bed, sitting on the edge of the bed, standing at the bedside, and walking around the bed and for 100 m in the ward. The patient performed three sessions per day, with approximately 20 minutes each time. After the rehabilitation exercise, patients continued with gait practice for up to 500 m and carried out endurance training by using a stationary bike in the rehabilitation center of the hospital.~The essions continued until they were discharged from the hospital (approximately 5 to 6 days post operative). The intensity of physical activity was limited by clinical conditions and activity tolerance, and monitored and assessed by physical therapists. Plus routine clinical care"
219451335|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
219451336|NCT05018091|DRUG|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
219451337|NCT05018091|DRUG|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
219451338|NCT05018091|DRUG|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
219451339|NCT00645736|OTHER|No intervention|No intervention
219451340|NCT05017727|DEVICE|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
219451341|NCT01393665|DRUG|PENNEL capsule|"hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
219451342|NCT01393665|DRUG|Placebo|Placebo
219451343|NCT05259800|OTHER|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
219451344|NCT05259800|OTHER|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
219451345|NCT01487707|BEHAVIORAL|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
219451346|NCT01487707|BEHAVIORAL|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
219588088|NCT03567382|BIOLOGICAL|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
219588089|NCT01099527|DRUG|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
219588090|NCT01099527|DRUG|Capecitabine|dose escalation of capecitabine, everolimus
219588091|NCT02671227|DRUG|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
218841416|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
219451347|NCT01487707|BEHAVIORAL|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
219451348|NCT00329459|DRUG|sumatriptan succinate/naproxen sodium|
219588092|NCT02671227|DRUG|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
219588093|NCT02175576|DEVICE|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
219588094|NCT02175576|DEVICE|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
219588095|NCT00039962|DRUG|thymalfasin (thymosin alpha 1)|
219588096|NCT00039962|DRUG|PEGinterferon alfa-2a|
218841417|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
219451349|NCT00329459|DRUG|placebo|placebo to match
219451350|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
219451351|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
219588097|NCT03183492|BIOLOGICAL|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219588098|NCT05215717|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
219588099|NCT05215717|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
219588100|NCT06047392|DIAGNOSTIC_TEST|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
219588101|NCT00131872|DEVICE|Expedial Vascular Access Graft|
219588102|NCT05919316|DEVICE|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
219588103|NCT05919316|DRUG|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
219588104|NCT04060316|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
219588105|NCT04060316|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
219588106|NCT02972918|DRUG|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
218841418|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
218841419|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
218841420|NCT01904474|OTHER|Standard treatment protocol|
218841421|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
218841422|NCT02907983|DRUG|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
219020719|NCT07205393|OTHER|Routine clinic care|The control group did not joined any rehabilitation program and only received routine clinical care during the duration of the hospital stay (approximately 5 to 6 days post operative).
219020720|NCT07206407|DIETARY_SUPPLEMENT|Placebo|Four capsules.
219020721|NCT07206407|DIETARY_SUPPLEMENT|Nutraceutical blend|Four capsules.
219588107|NCT03601650|BEHAVIORAL|Mindful eating|Attending to the sensory properties of food as it is eaten
219588108|NCT03601650|BEHAVIORAL|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
219588109|NCT06248541|DEVICE|treatment with low-level laser therapy|low-level laser therapy (wavelength of 620 - 640nm)
219451352|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
219451353|NCT05823649|DIETARY_SUPPLEMENT|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
219451354|NCT01099761|BIOLOGICAL|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
219451355|NCT01099761|BIOLOGICAL|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
219451356|NCT01099761|OTHER|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
219588110|NCT06248541|DEVICE|treatment with conventional light diodes|conventional light diodes
219588111|NCT00211120|DRUG|Epoetin Alfa|
219588112|NCT00620659|DRUG|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
219588113|NCT00620659|DRUG|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
219588114|NCT00620659|DRUG|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
219588115|NCT01974336|DRUG|ursodeoxycholic acid|
218841423|NCT02907983|DRUG|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
219451357|NCT05859867|OTHER|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
219451358|NCT06041191|DIAGNOSTIC_TEST|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
219451359|NCT03580525|DRUG|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
219451360|NCT03580525|DRUG|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
219451361|NCT03580525|DRUG|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
219451362|NCT03580525|DRUG|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
219451363|NCT03580525|DRUG|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
219451364|NCT01638676|DRUG|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
219451365|NCT01638676|DRUG|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
219451366|NCT01223690|DRUG|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
219588116|NCT02784353|BEHAVIORAL|Perioperative rehabilitation program|"Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation"
219588117|NCT02784353|BEHAVIORAL|Conventional|conventional perioperative management without rehabilitation program
219588118|NCT06297954|DRUG|Metoclopramide|Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
219588119|NCT06297954|DRUG|Placebo|Patients will receive placebo 10 ml IV in a single dose prior to randomization.
219588120|NCT04366427|COMBINATION_PRODUCT|L-HBO|as previously described.
219588121|NCT04366427|COMBINATION_PRODUCT|HBO|as previously described.
219588122|NCT04366427|COMBINATION_PRODUCT|30% O2|as previously described
219588123|NCT04366427|COMBINATION_PRODUCT|50% O2|as previously described
219588124|NCT06390644|DIAGNOSTIC_TEST|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.
218841424|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
218841425|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
218841426|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
218841427|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
218841428|NCT00070928|DRUG|valerian|
219451367|NCT01223690|DRUG|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
219451368|NCT03749850|DRUG|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
219451369|NCT03749850|PROCEDURE|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~\- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
219451370|NCT03749850|DRUG|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~\- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
219451371|NCT04152668|PROCEDURE|Titanium curette.|Implant debridement.
219451372|NCT04152668|PROCEDURE|Ultrasonic|Implant debridement.
219451373|NCT04152668|PROCEDURE|Air-polishing|Implant debridement and polishing.
218841429|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
218841430|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
219196834|NCT06825026|BEHAVIORAL|Pragmatic exercise trial|As part of the broader Observatory of the Older Person cohort, we aim to conduct a pragmatic exercise trial in a subgroup of nursing home residents. This trial seeks to evaluate the effectiveness of a concurrent exercise intervention on frailty, functional capacity, independence in activities of daily living and falls rate in real-world settings.
219451374|NCT05959915|DEVICE|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
219451375|NCT03398824|DRUG|metformin HCl|Receive metformin HCl
219451376|NCT01060124|DRUG|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
219451377|NCT05307523|DEVICE|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
219451378|NCT05307523|OTHER|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
219451379|NCT01359111|DEVICE|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
219451380|NCT00417833|DRUG|Intravitreal Bevacizumab|
218841431|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
219451381|NCT01562197|DRUG|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
219451382|NCT01562197|DRUG|Axitinib plus Lomustine|Lomustine 90mg/m²
219451383|NCT04063397|DIAGNOSTIC_TEST|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
219451384|NCT04063397|DIAGNOSTIC_TEST|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
219451385|NCT00174889|DRUG|Pregnenolone|
219451386|NCT04135664|PROCEDURE|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
219588125|NCT06390644|OTHER|Control Group (Standard Care)|"Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy."
219451387|NCT04135664|COMBINATION_PRODUCT|chemoradiation|concurrent chemotherapy and radiotherapy
219451388|NCT04135664|OTHER|active surveillance|No further adjuvant therapy
219451389|NCT03044743|DRUG|Fludarabine|To modify immune micro-environment
219588126|NCT00698880|PROCEDURE|Right hepatic vein embolization|Embolization of the right hepatic vein
219588127|NCT00004089|BIOLOGICAL|filgrastim|
219588128|NCT00004089|DRUG|fluorouracil|
218841432|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
218841433|NCT05001984|DRUG|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
218841434|NCT06299163|BIOLOGICAL|NM32-2668|Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody
218841435|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
218841436|NCT01667497|DRUG|Fampridine SR|
218841437|NCT01667497|DRUG|Placebo|
218841438|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
218841439|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
219196835|NCT06824025|DRUG|lidocaine group ( nebulized lidocaine + saline) total volume 4 ml|nebulization of 60 mg lidocaine in 4ml saline 0.9%
219451390|NCT03044743|DRUG|Cyclophosphamide|To modify immune micro-environment
219451391|NCT03044743|DRUG|Interleukin-2|To sustain the survival of infused T cells
219451392|NCT05937490|DRUG|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
219451393|NCT05937490|DRUG|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
219451394|NCT05937490|DRUG|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
219588129|NCT00004089|DRUG|hydroxyurea|
219588130|NCT00004089|DRUG|paclitaxel|
219588131|NCT00004089|PROCEDURE|conventional surgery|
219588132|NCT00004089|RADIATION|radiation therapy|
219451395|NCT05937490|DRUG|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
219451396|NCT02111070|BIOLOGICAL|IL-YANG FLU Vaccine|0.5mL
219451397|NCT04071808|DIAGNOSTIC_TEST|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
219588133|NCT02777112|OTHER|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
218841440|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
218841441|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
218841442|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
218841443|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
218841444|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
218841445|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
218841446|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
218841447|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
218841448|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
218841449|NCT01780337|OTHER|Saline|Intranasal dose of saline
219451398|NCT00957190|DRUG|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
219588134|NCT02777112|OTHER|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
218841450|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
218841451|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
218841452|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
218841453|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218841454|NCT05770089|OTHER|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
218841455|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
218841456|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
218841457|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
218841458|NCT02283905|DRUG|amphotericin-B|continuously infused
219451399|NCT00275106|DRUG|asparaginase|
218841459|NCT02283905|DRUG|voriconazole|intravenously or orally administered
218841460|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
218841461|NCT00019968|DRUG|melphalan|
218841462|NCT00019968|DRUG|tumor necrosis factor|
218841463|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
218841464|NCT04736290|OTHER|NLR|Calculation of NLR
218841465|NCT04736290|OTHER|PLR|Calculation of PLR
218841466|NCT01323088|OTHER|Control|Standard care control (no exercise)
218841467|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
218841468|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
218841469|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
219451400|NCT00275106|DRUG|cyclophosphamide|
219451401|NCT00275106|DRUG|cytarabine|
219451402|NCT00275106|DRUG|daunorubicin hydrochloride|
219451403|NCT00275106|DRUG|dexamethasone|
219451404|NCT00275106|DRUG|doxorubicin hydrochloride|
219451405|NCT00275106|DRUG|leucovorin calcium|
219588135|NCT02777112|OTHER|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
218841470|NCT06423456|DRUG|Lidocaine IV|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
218841471|NCT06423456|DRUG|Saline|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
219451406|NCT00275106|DRUG|mercaptopurine|
219451407|NCT00275106|DRUG|methotrexate|
219451408|NCT00275106|DRUG|prednisolone|
219451409|NCT00275106|DRUG|thioguanine|
219451410|NCT00275106|DRUG|vincristine sulfate|
219451411|NCT00275106|PROCEDURE|radiation therapy|
219451412|NCT03273699|DEVICE|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
219451413|NCT04662645|OTHER|Palliative Therapy|Undergo embedded palliative care
219451414|NCT04662645|OTHER|Questionnaire Administration|Ancillary studies
219451415|NCT00906828|DRUG|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
219451416|NCT00906828|DRUG|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
219451417|NCT00906828|DRUG|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
219451418|NCT01666015|OTHER|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
219451419|NCT01666015|OTHER|Standard Care|This group will be under standard care without any EX intervention.
219451420|NCT05242809|BEHAVIORAL|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
219451421|NCT05651074|DRUG|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
219588136|NCT00813527|DRUG|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
218841472|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
218841473|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
219451422|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
218841474|NCT04268121|DRUG|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
218841475|NCT04268121|DRUG|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
218841476|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
218841477|NCT02443116|BIOLOGICAL|NGM282|
218841478|NCT02443116|OTHER|Placebo|
218841479|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
218841480|NCT00330408|BEHAVIORAL|GP training|
219588137|NCT00813527|DRUG|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
219588138|NCT00681512|DIETARY_SUPPLEMENT|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
218841481|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
218841482|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
218841483|NCT06145581|BEHAVIORAL|Supportive Care (home-based physical activity)|Receive health coaching
218841484|NCT06145581|OTHER|Exercise Intervention|Participate in home-based physical activity
219588139|NCT03584984|PROCEDURE|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
219588140|NCT03584984|PROCEDURE|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
218841485|NCT06145581|OTHER|telephone interview|Participate in a telephone interview
218841486|NCT06145581|OTHER|Remote Monitoring|Undergo remote monitoring
218841487|NCT06145581|PROCEDURE|Patient Monitoring|Monitor physical activity
218841488|NCT06145581|OTHER|Questionnaire Administration|Ancillary studies
218841489|NCT06145581|OTHER|Electronic Health Record Review|Ancillary studies
218841490|NCT04069468|DEVICE|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
219451423|NCT05086094|DRUG|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
219451424|NCT04856969|DRUG|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
218841491|NCT05070351|DRUG|PPI deprescribing|Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
218841492|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
218841493|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
219451425|NCT04856969|DRUG|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
218841494|NCT01917929|DEVICE|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
219451426|NCT06146140|DIETARY_SUPPLEMENT|Oral herbal supplement|Take one capsule daily
219451427|NCT06146140|DIETARY_SUPPLEMENT|Oral placebo supplement|Take one capsule daily
219451428|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
219451429|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
219451430|NCT04738240|DIAGNOSTIC_TEST|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
219451431|NCT03858686|DRUG|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
219451432|NCT03858686|DRUG|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
219451433|NCT02002624|DEVICE|PSI|
219451434|NCT02002624|DEVICE|Conventional instrumentation|
219451435|NCT03651128|BIOLOGICAL|bb2121|bb2121
219451436|NCT03651128|DRUG|Daratumumab|Daratumumab
219451437|NCT03651128|DRUG|Pomalidomide|Pomalidomide
219451438|NCT03651128|DRUG|Dexamethasone|Dexamethasone
219451439|NCT03651128|DRUG|Bortezomib|Bortezomib
219451440|NCT03651128|DRUG|Ixazomib|Ixazomib
219451441|NCT03651128|DRUG|Lenalidomide|Lenalidomide
219451442|NCT03651128|DRUG|Carfilzomib|Carfilzomib
218841495|NCT06249061|DIETARY_SUPPLEMENT|oral sodium bicarbonate|Those in the oral sodium bicarbonate intervention group will be encouraged to sip a solution of 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water throughout labour with other drinks. If the first solution is fully consumed, a second solution will be prepared and offered. Thus, each participant can receive a maximum dose of 2 imperial teaspoons (\~10g) of sodium bicarbonate.
218841496|NCT06387290|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.
218841497|NCT06387290|BEHAVIORAL|Patient-Centered Chronic Pain Management Visits|Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).
219451443|NCT03651128|DRUG|Elotuzumab|Elotuzumab
219451444|NCT01045551|DRUG|Apremilast|20mg taken orally twice per day for 12 weeks
219451445|NCT02415829|DRUG|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
219451446|NCT00290680|DRUG|bortezomib|
219451447|NCT00290680|DRUG|celecoxib|
219451448|NCT04453891|DEVICE|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
219451449|NCT03832023|OTHER|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
219451450|NCT01626755|PROCEDURE|Sciatic name block|Ultrasound-guided sciatic nerve block.
219451451|NCT03231228|DRUG|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
219451452|NCT03231228|DRUG|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
219451453|NCT03061227|DRUG|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
218841498|NCT06368739|BEHAVIORAL|Nurture program|"1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided."
219451454|NCT03061227|DRUG|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
219451455|NCT02033291|PROCEDURE|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
219451456|NCT04033380|DEVICE|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
219588141|NCT03584984|PROCEDURE|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
219588142|NCT00398255|BEHAVIORAL|self-management program|
219588143|NCT01240213|DIETARY_SUPPLEMENT|Vitamin D|2000 IU per day of Vitamin D
219588144|NCT01240213|DIETARY_SUPPLEMENT|Placebo|1 Placebo per day
219588145|NCT00804713|DRUG|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
218841499|NCT06368739|OTHER|Regular benefits|Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
218841500|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
218841501|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
218841502|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
218841503|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
219020722|NCT07206069|BEHAVIORAL|Standard Care (in control arm)|This Standard Care involves a recorded video education and in-person visit.
219451457|NCT04033380|DEVICE|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
219451458|NCT00781183|OTHER|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
219588146|NCT00804713|DRUG|TST|Administer TB Skin test (TST)
219588147|NCT00804713|OTHER|QFT|Perform QFT TB test
219588148|NCT00804713|OTHER|T-spot|Perform T-Spot TB test
219588149|NCT04993014|DRUG|Pertuzumab|Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
219588150|NCT04993014|DRUG|Trastuzumab|Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
219588151|NCT04993014|OTHER|Circulating tumor cells|Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
219588152|NCT01214915|DRUG|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
219588153|NCT06399809|DRUG|Fisetin|Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
219588154|NCT06399809|DRUG|Placebo|The placebo will be matched to the Fisetin intervention
219588155|NCT02935205|DRUG|Enzalutamide|Given PO
219588156|NCT02935205|DRUG|Indomethacin|Given PO
219588157|NCT04784754|DRUG|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
219451459|NCT06166251|BEHAVIORAL|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
219451460|NCT06166251|BEHAVIORAL|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
219588158|NCT04784754|DRUG|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
219588159|NCT03039660|BEHAVIORAL|RefreshMD|Online Sleep Improvement Course
219588160|NCT03039660|BEHAVIORAL|Bond Between Us|Online Educational Course
219588161|NCT02056392|DRUG|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
219588162|NCT02056392|DRUG|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
219588163|NCT02056392|DRUG|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
218841504|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
218841505|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
219451461|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
219451462|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
219451463|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
219451464|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
219451465|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
219588164|NCT05255874|OTHER|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
219451466|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
219451467|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
218841506|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
219451468|NCT01682759|DRUG|Omarigliptin|
219451469|NCT01682759|DRUG|Placebo to Omarigliptin|
219451470|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
219588165|NCT06506162|OTHER|Flavor|The study will compare sweet vs. cool flavors
219588166|NCT06506162|OTHER|Nicotine concentration|The study will compare low vs. high strength Oral Nicotine Products
219588167|NCT02280668|OTHER|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
219588168|NCT02280668|OTHER|the eccentric muscle damage exercise|
218841507|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
219588169|NCT04346420|OTHER|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
218841508|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
218841509|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
218841510|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
218841511|NCT00332085|DRUG|Chromium Picolinate|
218841512|NCT00302354|DRUG|OROS methylphenidate HCl|
218841513|NCT00302354|DRUG|SODAS methylphenidate HCl|
218841514|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
218841515|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
218841516|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
218841517|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
218841518|NCT00741897|DRUG|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
219020723|NCT07206069|BEHAVIORAL|Telemedicine Shared Decision-Making|This intervention involves two live telemedicine video visits.
219020724|NCT07207174|BEHAVIORAL|Brief Mindfulness Oriented Recovery Enhancement|B-MORE is a 2-hour adaptation of the traditional MORE program.
219451471|NCT01682759|DRUG|Glimepiride Placebo|
219451472|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
218841519|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
218841520|NCT03367923|OTHER|Communication Intervention|Receive email/text
219451473|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
219451474|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
219451475|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
219451476|NCT06873789|DRUG|INCB177054|INCB177054 will be administered at protocol defined dose.
219451477|NCT06873789|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
219451478|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
219451479|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
219451480|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
219451481|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
218841521|NCT03367923|OTHER|Counseling|Undergo exercise counseling
219017765|NCT06096116|DRUG|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
219017766|NCT06096116|DRUG|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
219451482|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
219451483|NCT02336880|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|
219451484|NCT06709430|OTHER|Classical education group|Students will be divided into standardized patient and Classical education group. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.
219451485|NCT06709430|OTHER|Standardized Patient Group|Students will be divided into standardized patient group and control groups. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the
219451486|NCT06720896|DRUG|APT-001 topical ophthalmic ointment (spinosad)|APT-001 topical ophthalmic ointment, administered once daily
219451487|NCT06720896|DRUG|Vehicle control for APT-001 topical ophthalmic ointment|Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
219451488|NCT06727279|OTHER|Specialized food - Plant-Based Meat Analog|Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.
218841522|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
218841523|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
218841524|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
218841525|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
218841526|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
218841527|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
219451489|NCT06727279|OTHER|standard isocalorie diet|Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
218841528|NCT06539754|BEHAVIORAL|Music|Participants will have bone conducting headphones available to listen to the music of their choice from premade Spotify playlists.
218841529|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
218841530|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
219451490|NCT07047014|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
219451491|NCT07047014|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
219451492|NCT06728540|OTHER|Investigation of Physical Activity Levels, Respiratory and Pelvic Floor Muscle Function|The sociodemographic and clinical characteristics of the children participating in the study will be evaluated with an evaluation form, respiratory muscle strength with an RP Check brand electronic pressure measurement device, and body composition with a Tanita MC-580 brand bioelectrical impedance analyzer. Pelvic floor muscle functions of children with LUTD will be evaluated with a 632 Myomed biofeedback device. The survey questions and the evaluation form will be filled out by the parents.
219451493|NCT06372327|BEHAVIORAL|Daily Exercise Snacks|Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
219451494|NCT06720597|DRUG|Daily low-dose PDE5 inhibitor therapy|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
219451495|NCT06720597|DRUG|Testosterone therapy as per clinical guidelines.|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
219451496|NCT06075498|PROCEDURE|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
218841531|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
218841532|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
219451497|NCT07047820|DRUG|Zuranolone|Administered as specified in the treatment arm
219451498|NCT07052279|OTHER|water based burpee exercises|water based burpee exercises ( Aquatic exercise ) is one method that has previously been shown to improve muscle strength, balance, and coordination in those of advancing age Although the evidence supports the effectiveness of both water-based burpee exercise in middle-aged and elderly individuals, has, to our knowledge, never been investigated. Thus, the objective of this study was to assess the long-term effect of water-based burpee exercises
219588170|NCT04346420|DEVICE|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
219588171|NCT05323331|OTHER|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
219588172|NCT05323331|OTHER|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
219588173|NCT04142892|DRUG|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
219588174|NCT04771663|OTHER|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
219588175|NCT01846013|BEHAVIORAL|Stand|Stand at least half of the workday at work.
219588176|NCT01846013|BEHAVIORAL|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
219588177|NCT01846013|BEHAVIORAL|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
219588178|NCT03467880|OTHER|Clinical Observation|No treatment given but observation with IOS
219588179|NCT00529282|DRUG|Ceftobiprole Medocaril|500 mg every 8 hours
218841533|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
218841534|NCT06971978|OTHER|Online decision support platform to support evidence-based heat health risk assessment and extreme heat event preparedness planning|The intervention group will receive facilitated engagement with Chart. Chart is an online decision support platform designed to support evidence-based risk assessment and planning for extreme heat risk mitigation. Chart has a risk assessment platform that provides estimates of heat-health risks at a census tract level under various hazard conditions. It also has a decision support platform that links drivers of risk in a given location with information about potential risk reduction activities and includes information useful to policymakers regarding intervention efficacy, timing, and cost. Facilitated engagement includes an initial introduction to the platform, real-time questions and answers, and focused discussion regarding priority interventions and planning and implementation needs. This engagement comprises about five hours of time that can be provided over the course of a couple weeks or several months, depending on the needs of the health department.
219588180|NCT00529282|DRUG|Cefepime with or without vancomycin|120-minute infusion \[250 mL\]
219588181|NCT03598868|DRUG|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
219588182|NCT03598868|DRUG|Placebo|Augmentation : Placebo for week 1,2,4,6
218841535|NCT06971978|OTHER|Heat and health risk assessment and preparedness information|Study participants in the control group will be provided with a package of information supportive of heat-health vulnerability and risk assessment and planning for risk reduction activities through built environment hazard mitigation and public health programming. This package will include an annotated list of online resources, including those available on Heat.gov and the CDC website, and a selected set of review papers on heat-health vulnerability, heat-health risk assessment, heat hazard mitigation through built environment strategies, and heat action planning and preparedness.
218841536|NCT06055309|DRUG|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
218841537|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
218841538|NCT06384131|DRUG|ABI-4334|10 mg or 50 mg tablets for oral administration
218841539|NCT06384131|DRUG|Placebo|10 mg or 50 mg tablets for oral administration
218841540|NCT04555577|DRUG|Peposertib|Given PO
218841541|NCT04555577|RADIATION|Radiation Therapy|Undergo radiation therapy
218841542|NCT04555577|PROCEDURE|Resection|Undergo surgical resection
218841543|NCT04555577|DRUG|Temozolomide|Given PO
218841544|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
218841545|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
218841546|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
218841547|NCT05738967|BEHAVIORAL|Transdiagnostic cognitive behavioral therapy (CBT)|Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation. It will also include flexible incorporation of emotion-focused coping and adaptations for autism.
218841548|NCT05738967|BEHAVIORAL|Treatment as usual|Adolescent-caregiver dyads will participate in coordinated referrals to the community. They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
218841549|NCT06160687|PROCEDURE|PSV mode during NIV|NIV will be delivered using PSV mode of ventilation
219451499|NCT07052279|OTHER|aerobic exercises|Traditional aerobic exercises for post-menopause include activities like brisk walking, jogging and cycling. These exercises help improve cardiovascular health, boost metabolism, and enhance mood. They can also be beneficial for maintaining bone density, especially weight-bearing exercises like walking and jogging.
219451500|NCT06795009|DRUG|Zanzalintinib|Taken by mouth.
219588183|NCT05220189|DIAGNOSTIC_TEST|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
219588184|NCT04555720|BEHAVIORAL|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
219017768|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
218841550|NCT06160687|PROCEDURE|ASV intellisync|ASV intellisync mode will be used to deliver NIV
218841551|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
218841552|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
218841553|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
218841554|NCT05692518|DEVICE|MAGNET System, DI Bio-fragmentable|Anastomoses achieved by magnetic compression.
219017769|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
219017770|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
219020725|NCT07207174|BEHAVIORAL|Brief Cognitive-Behavioral Therapy|B-CBT is a 2-hour adaptation of a traditional 8-week CBT for Chronic Pain manual.
219020726|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 1|Participants will use their Hydration Active Product 1 as directed for a period of 1 week.
219451501|NCT06795009|DRUG|Paclitaxel|175 mg\^m2 intravenous over 3 hours.
219451502|NCT07054983|OTHER|Qualitative Research Interview|Qualitative research interview of parents of pediatric patients seen in an interdisciplinary feeding clinic who underwent a tube weaning program
218841555|NCT03865589|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
218841556|NCT06093880|DEVICE|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
218841557|NCT04793204|DRUG|fezolinetant|oral
218841558|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
218841559|NCT06338748|DEVICE|Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode|Dexcom G7 used in blinded mode
219451503|NCT06751589|DRUG|Tirzepatide|2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
219588185|NCT02249312|DRUG|BIIL 284 BS|
219588186|NCT02249312|DRUG|Placebo|
219588187|NCT00521469|DEVICE|Pro Adjuster|
219451504|NCT07057531|PROCEDURE|Tubeless thoracic surgery|Tubeless thoracic surgery is a minimally invasive procedure performed without tracheal intubation or mechanical ventilation, allowing for spontaneous breathing. Anesthesia combines conscious sedation with local nerve blocks to ensure pain relief while preserving diaphragmatic movement. The surgical approach is similar to conventional video-assisted thoracic surgery (VATS), used for procedures like lung resections and mediastinal mass excisions. Post-operative care focuses on early mobilization and quick discharge.
219451505|NCT06369285|DRUG|Alisertib|Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
219451506|NCT06369285|DRUG|Endocrine therapy|"Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter"
219451507|NCT05768347|BIOLOGICAL|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
219451508|NCT07069309|BIOLOGICAL|BNT162b2 (Omi LP.8.1)|BNT162b2 monovalent (Omicron LP.8.1)
219451509|NCT07136883|DEVICE|POBA|The intervention consists of preparing the artery with a traditional/regular angioplasty balloon before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
219451510|NCT07136883|DEVICE|Scoring Balloon|The intervention consists of preparing the artery with a scoring balloon (Angiosculpt™; Manufacturer: Spectranetics Corporation, Fremont, California, USA) before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
219451511|NCT07137845|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
219451512|NCT07137845|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
219451513|NCT07137845|PROCEDURE|Sham CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
219588188|NCT01899443|OTHER|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
219588189|NCT01043835|PROCEDURE|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
219588190|NCT01043835|PROCEDURE|Open gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
219588191|NCT04418843|PROCEDURE|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
219588192|NCT04418843|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
219588193|NCT00968799|PROCEDURE|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
219588194|NCT00968799|PROCEDURE|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
219588195|NCT00968799|DRUG|Cisplatin|Cisplatin is applied as chemotherapy during surgery
218841560|NCT03829969|BIOLOGICAL|Toripalimab|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
218841561|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
218841562|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
218841563|NCT06545929|DRUG|Sunobinop|1 tablet taken orally at bedtime
218841564|NCT06545929|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
218841565|NCT04576455|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
219451514|NCT06889571|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session.
219451515|NCT06102382|DRUG|Norepinephrine (0.1)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
219451516|NCT06102382|DRUG|Norepinephrine (0.075)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
219451517|NCT07125534|DRUG|Alcohol beverage|This intervention involves the administration of an alcohol beverage (vodka mixed with juice or soda) in a controlled laboratory setting, targeting a blood alcohol concentration (BAC) of 0.08%. The alcohol is consumed over a 36-minute period in three equal parts.
219451518|NCT07125534|OTHER|Control - non alcoholic beverage|This intervention involves the administration of a non-alcoholic control beverage in a controlled laboratory setting. The beverage is matched in volume and palatability to the alcohol condition but co
219451519|NCT06931080|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 6 weeks
219451520|NCT06931080|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 6 weeks
219451521|NCT06931080|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
219451522|NCT07089459|DEVICE|Low-Level Laser Therapy (LLLT)|Low-Level Laser Therapy (LLLT) will be administered using an 830 nm wavelength and 150 mW power output with 5 W/cm² power density. The laser probe will be applied 2-3 times per week for 6 weeks over the affected knee. Treatment is performed using a direct skin contact method with 3-4 minutes of exposure per point around the knee joint. The goal is to reduce inflammation, enhance collagen synthesis, and support ligament healing in patients with partial anterior cruciate ligament (ACL) tears. This intervention is provided in addition to standard physiotherapy and shortwave diathermy.
219451523|NCT07089459|BEHAVIORAL|Shortwave therapy|Participants in this group will receive standard physiotherapy exercises combined with shortwave diathermy (SWD), without the application of Low-Level Laser Therapy (LLLT). The exercise protocol includes heel slides, supported partial knee bends, quadriceps sets, and step-ups, performed in 2 sets of 10 repetitions with 3-5 second rest intervals. SWD will be delivered 2-3 times, using a 27.12 MHz frequency for 20-30 minutes per session, targeting pain relief and enhanced soft tissue healing. This group functions as an active comparator to assess the additional therapeutic value of LLLT used in the intervention group.
219451524|NCT07089797|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app (i.e., WeChat mini program) delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session (up to 20 minutes each) across a 6 week intervention period.
219451525|NCT07089797|BEHAVIORAL|Sleep hygiene education|The participants in the control group will receive only sleep hygiene (one-page handout) via WeChat. Access to the CBT-I WeChat mini program will be offered to these participants after the completion of the 3-month follow-up assessment.
219451526|NCT06893341|DEVICE|The Sensing Device|Children diagnosed with diabetes that wear a continuous glucose monitor will be given the Sensing Device. The subjects will provide breath samples into the device during euglycemia, hypoglycemia, and hyperglycemia, and the breath data will be analyzed to draw correlations with blood glucose levels.
219451527|NCT07102342|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain
219451528|NCT07101432|DRUG|Fludarabine|Given by infusion
219020727|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 2|Participants will use their Hydration Active Product 2 as directed for a period of 1 week.
219020728|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 3|Participants will use their Hydration Active Product 3 as directed for a period of 1 week.
219196836|NCT06824558|OTHER|primiparous pregnant woman following virgin mary|It is thought that the application of the motherwort during birth shortens the duration of labor and reduces pain and fear during birth. In the study, the pregnant women in the intervention group watched the opening of the motherwort in water during birth.
219451529|NCT07101432|DRUG|Cyclophosphamide|Given by infusion
219451530|NCT07102498|BEHAVIORAL|BG mmol/L|BG presented in mmol/L (the standard presentation in Canada)
219451531|NCT07102498|BEHAVIORAL|BG mg/dl|BG presented in mg/dl
219196837|NCT06824558|OTHER|primiparous pregnant|Only midwifery care was applied to pregnant women in the control group.
219451532|NCT07102498|BEHAVIORAL|A1c percent|HbA1c presented in percent (the standard presentation in Canada)
219451533|NCT07102498|BEHAVIORAL|A1c mmol/mol|HbA1c presented in mmol/mol
219451534|NCT07102017|DEVICE|Passive Robotic Support for Enhanced Well-Being|Previous research primarily compared scenarios with robots versus without robots, while this study examines how differences in robot activity levels and interaction levels affect older adults' well-being. In this study, this intervention includes a passive robot that would not initiate any interactions with older adults. In this arm, we employed LOVOT as a passive comfort object that only reacts to older adults when being triggered. Besides, this robot has no voice (i.e. the device was muted).
219451535|NCT07102017|DEVICE|Proactive Robotic Support for Enhanced Well-Being|This intervention differs significantly from the Passove Robotic Support for Enhanced Well-Being primarily through its proactive social engagement capabilities and autonomous agency. This intervention actively seeks interaction by enabling free movement, approaching individuals, and following them. Furthermore, the robot in this intervention responds dynamically to auditory stimuli with sounds and head tilts, offering a richer, reciprocal interaction compared to Arm 1's limited reactive purring and eye blinks. This shift transforms the LOVOT's role from a passive comfort object into an active social catalyst designed to stimulate engagement and reciprocity.
219451536|NCT07101068|DEVICE|Dental Anesthesia Injector|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using Dental Anesthesia Injector.
218841566|NCT04576455|DRUG|Fulvestrant or an Aromatase Inhibitor (Physician Choice)|Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
218841567|NCT04576455|DRUG|LHRH Agonist|Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
218841568|NCT00394758|PROCEDURE|CO2 laser surgery|
218841569|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
218841570|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
218841571|NCT02059499|DRUG|imiquimod|Given intra-anally
218841572|NCT02059499|DRUG|fluorouracil|Given intra-anally
219451537|NCT07101068|OTHER|conventional syringe|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using conventional syringe
219451538|NCT06911970|OTHER|Exercise|"Moderate-Intensity Continuous Exercise (MOD):~The MOD condition will consist of a 37-minute continuous aerobic exercise session on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 32-minute period at moderate intensity at a power corresponding to 50% of the last stop completed in the modified YMCA test completed in the preliminary visit.~High-Intensity Interval Exercise (HIIE):~The HIIE condition will consist of a 35-minute high-intensity aerobic exercise session on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (110% of power highest poweroutput reached during the submaximal test) and 2 minutes of active rest (25% of highest power output)."
219451539|NCT07102056|DIAGNOSTIC_TEST|18F-AlF-NOTA-Octreotide PET-CT or PET-MR|18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging
219451540|NCT07101952|OTHER|Braded Suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
219451541|NCT07101952|OTHER|Multifilament vicryl suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
219451542|NCT07102290|BEHAVIORAL|Free Help|Text message offering free quitline coaching. FREE HELP: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. A Quit Coach can double your chances of quitting. For more info call 1-844-XXXXXXX.
218841573|NCT02059499|OTHER|questionnaire administration|Ancillary studies
218841574|NCT02059499|OTHER|laboratory biomarker analysis|Correlative studies
218841575|NCT06440200|BEHAVIORAL|group gamed-based activity|Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
218841576|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
218841577|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
219451543|NCT07102290|BEHAVIORAL|Free NRT|Text message for free nicotine patches with free quitline counseling. FREE NRT: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. You may be able to get nicotine patches mailed to your home at no cost. For more info call 1-844-XXXXXXX.
218841578|NCT03645278|DRUG|Placebo|Ascending dose oral administration
218841579|NCT05016310|DIETARY_SUPPLEMENT|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
218841580|NCT05016310|DIETARY_SUPPLEMENT|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
218841581|NCT02134561|BEHAVIORAL|psychological interview|
218841582|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
218841583|NCT02134561|OTHER|cognitive tests|
218841584|NCT02134561|OTHER|neurological tests|
218841585|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
218841586|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
218841587|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
218841588|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
219196838|NCT06825156|DRUG|Empagliflozin 10 MG|Patients receive 10mg Empagliflozin(SLGT-2i) daily from 3 days prior to surgery untill 2 days post-surgery which includes day of surgery.
218841589|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
218841590|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
219451544|NCT07101185|DEVICE|VIRTUAL REALITY|"The interventional part of the study is limited to 3 centers. It explores SOCIAL COGNITION throught a newly developed paradigm in Virtual Reality.~In detail: an adapted version of the Virtual Reality Social Prediction Improvement and Rehabilitation Intensive Training (VR-SPIRIT) using a VR Head Mounted Display (HMD) will be implemented on a portable HMD, the Oculus Quest, equipped with two controllers with motion sensors that are used to track hand position.~In a VR-SPIRIT session, participants are immersed in the playground scenario and engaged in a competition with four avatars. Each avatar has a pre-established probability to move toward one of the three described games.~Different indices about a partecipant's performance are recorded automatically by the system during the session, such as the duration of each trial and the prediction score (percentage of trials in which the participant correctly predicted an avatar's intention)."
219451545|NCT07100197|DEVICE|continuous Theta-burst stimulation|Treatment parameters: each cTBS session consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 s, totaling 600 pulses, and every set simulation includes 3 sessions. Electrodes are attached to designated head regions (right dorsolateral prefrontal cortex).
219451546|NCT07100197|DEVICE|Sham|the treatment mode was with sham coil.
219451547|NCT06832982|DRUG|FS-8002 injection|Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first
219451548|NCT04867616|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
219451549|NCT04867616|BIOLOGICAL|Bepranemab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
219451550|NCT04191096|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
219451551|NCT04191096|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
219451552|NCT04191096|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
219451553|NCT04191096|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
219451554|NCT07100704|DRUG|Nivolumab|240 mg will be administered on Day 1 and Day 15 of each cycle, or 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and the site principal investigator or site co-investigator.
219588196|NCT05940753|OTHER|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
218841591|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
218841592|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
219451555|NCT05954065|DEVICE|Erchonia CFL Laser|405nm violet and 520nm green laser light therapy.
219451556|NCT07102251|DRUG|HEC-007 injection|Single dose escalation of HEC-007 injection in healthy subjects
219451557|NCT07102251|DRUG|Placebo|Single dose of placebo in healthy adults
219451558|NCT07102251|DRUG|HEC-007 injection|Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects
219451559|NCT07102251|DRUG|Placebo|Multiple dose of placebo in Overweight or Obese Subjects
219451560|NCT07100925|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection
219451561|NCT07115732|DEVICE|Total Hip Replacement|Primary elective total hip replacement
219451562|NCT06921837|DRUG|BDC-4182|Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
218841593|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
218841594|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
219588197|NCT04642651|DRUG|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
218841595|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
218841596|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
218841597|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
218841598|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
218841599|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
218841600|NCT06991348|DRUG|Tegoprazan|Tegoprazan 50 mg daily for 28 days
219451563|NCT06921941|DRUG|Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR|"Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions.~Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions.~Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions."
219451564|NCT06921941|DRUG|Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR|"Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions.~Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions.~Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions."
219588198|NCT04642651|DRUG|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
219588199|NCT03173144|OTHER|Primary exposure variable|"1. Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~2. Low intake of red and processed meat (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of dietary fibres (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
218841601|NCT06991348|DRUG|Pantoprazole|Pantoprazole 40 mg daily for 28 days
218841602|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
218841603|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
218841604|NCT06992843|OTHER|Goal-directed care bundle for neuroprotection|"Reducing lactate (Lac) to \<2 mmol/L within 24 hours.Maintaining systolic arterial pressure at 120-140 mmHg.~Elevating the head-of-bed to 30 degrees. Maintaining body temperature ≤37.7°C. Maintaining PaO₂ at 70-100 mmHg. Maintaining PaCO₂ at 35-45 mmHg. Maintaining blood glucose at 7.8-10.0 mmol/L. Maintaining serum sodium level at 140-150 mmol/L. If any management parameter falls outside the target range, immediate correction is required within 24 hours of enrollment and must be sustained for 72 hours. Given the dynamic nature of some targets (e.g., mean arterial pressure, body temperature), a degree of flexibility is permitted in achieving these goals. Patients are considered to have successfully implemented the neuroprotection bundle if the achievement rate of individual targets is ≥80% and all targets are met. The medications(antipyretics, vasopressor agents) is acceptable to achieve these targets."
218841605|NCT06992843|OTHER|Usual Care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
218841606|NCT04601038|DRUG|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
218841607|NCT04601038|DRUG|Placebo|Placebo taken as 2 tablets daily for 2 weeks
218841608|NCT07002996|BEHAVIORAL|SMIP|Participants will undergo a 3-month-long regimen of 60 minutes spatial memory training sessions held twice a week, consisting of a series of computerized virtual reality tasks.
218841609|NCT07002996|OTHER|No intervention|Control participants will not receive spatial memory intervention training. They will watch documentaries and then complete multiple choice quizzes on its content to ensure they are paying attention. The placebo condition will match the experimental condition in terms of duration and visit frequency.
218841610|NCT07019571|DEVICE|Wireless Multichannel Transcranial Current Stimulator (tDCS)|tDCS will be delivered for 13 minutes (active) or only at the beginning and end of the 13 minute period (sham) using Neuroelectrics Instrument Controller software and a battery-driven Starstim 8-channel transcranial direct current stimulator with 1cm2 ceramic electrodes and SIGNAGEL conductive saline gel.
218841611|NCT07019571|BEHAVIORAL|Cue exposure|Participants will undergo three, twenty-second trials of exposure to individualized cues at the top of the established urge hierarchy, previously determined to precede picking or biting behaviors before and after tDCS.
218841612|NCT07019571|BEHAVIORAL|Boredom induction|Participants will be left in the testing room without access to a cellphone or reading materials for 2 different 6 minute periods.
218841613|NCT06072833|BEHAVIORAL|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
218841614|NCT07030010|OTHER|Breakfast meal challenge with tonic drink|High-carbohydrate containing breakfast meal with the addition of the tonic drink
218841615|NCT07030010|OTHER|Breakfast meal challenge with placebo drink|High-carbohydrate containing breakfast meal with the addition of the placebo drink
218841616|NCT07026695|DEVICE|transcutaenous vagal nerve stimulation|Low level Stimulation of the Auricular Branch of the Vagal Nerve at the tragus
218841617|NCT07026695|DEVICE|Sham transcutaenous vagal nerve stimulation|Sham treatment
218841618|NCT07029503|DRUG|Eplerenone|"Participants will receive eplerenone 25 mg once daily or every other day, based on baseline potassium levels, eGFR, systolic blood pressure, and concomitant use of weak or moderate CYP3A4 inhibitors.~The study will implement a safety protocol with predefined procedures for managing significant hyperkalemia, worsening renal function, and hypotension. These will include temporary or permanent dose reduction or discontinuation of eplerenone, and, if necessary, administration of the potassium binder sodium zirconium cyclosilicate (SZC, Lokelma®)."
219451565|NCT05964413|DRUG|vilobelimab|vilobelimab infusion
219588200|NCT03173144|OTHER|Other (exploratory) exposure variables|"* Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~* Pretreatment lifestyle-associated biomarkers~* Combinations of lifestyle factors and lifestyle-associated biomarkers~* Gene-environment interaction analyses~* Pretreatment levels of inflammatory molecules"
219588201|NCT03382730|OTHER|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
219588202|NCT03382730|OTHER|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
219588203|NCT00719849|BIOLOGICAL|anti-thymocyte globulin|30mg/Kg Days -6 to -4
218841619|NCT07035015|OTHER|VR UGRA|The simulator applied principles of cognitive task analysis, which is a method aimed at describing the knowledge, cognitive process, and goal structures experts rely upon while performing a complex procedure
218841620|NCT07035015|OTHER|Mannequin-based simulation|The hybrid simulator will consist of a 3G mannequin and a gel-based part-task trainer.
218841621|NCT07034326|OTHER|Electroacupuncture combined with immunotherapy|Connect the electroacupuncture therapy instrument, select the density wave 2 Hz/100 Hz, the current intensity should be tolerated by the patient, leave the needle for 20 min.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
218841622|NCT07034326|DRUG|Zilongjin tablet combined with immunotherapy|Take Zilongjin tablets orally, 4 tablets each time, 3 times a day.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
218841623|NCT07034326|DRUG|Immunotherapy|Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
218841624|NCT07034729|BEHAVIORAL|training to develop emotional intelligence skills|2 hours in a week, 6 week training
218841625|NCT07033780|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-s (experimental study intervention), which will be delivered to the left DLPFC. Following iTBS-s, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
218841626|NCT07033780|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-c (active comparator), which will be delivered to the left DLPFC. Following iTBS-c, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
218841627|NCT07036419|DRUG|Remimazolam Tosilate for injection|Remimazolam Tosilate for injection.
218841628|NCT07036419|DRUG|Propofol Injection|Propofol injection.
218841629|NCT07034690|OTHER|Educational Material|Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
218841630|NCT07034690|OTHER|Standard of care|Standard of care
218841631|NCT07034209|DRUG|Plonmarlimab|Subjects receive Plonmarlimab 6 mg/kg or 10 mg/kg, administered intravenously, once weekly for 8 weeks.
218841632|NCT07033754|DIETARY_SUPPLEMENT|Propionibacterium freudenreichii P.UF1|one capsule once a day with/beforebreakfast for 120 days
219451566|NCT05964413|DRUG|Placebo|Placebo Infusion
219451567|NCT00404638|DRUG|Desmopresin|
218841633|NCT07033754|DIETARY_SUPPLEMENT|Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia|one capsule once a day with/beforebreakfast for 120 days
219196839|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
219451568|NCT00404638|BEHAVIORAL|Paula Method of Circular Muscle Exercise|
219451569|NCT07120477|DRUG|Intravenous Esketamine|Single-session intravenous esketamine infusion (0.5 mg/kg) administered over 40 minutes in a medical setting with continuous monitoring of vital signs, blood pressure, ECG, and oxygen saturation for 4 hours post-infusion. Administration supervised by trained medical staff with emergency protocols available. Participants will be discharged 24 hours post-infusion if no clinical complications arise, with ambulatory evaluations at 48 hours, 72 hours, and 7 days post-infusion.
219451570|NCT07120477|OTHER|Crisis Response Planning intervention (structures safety planning)|Collaborative safety planning intervention delivered by trained clinical psychologists in 20-45 minute sessions. Participants create personalized, written crisis response plans identifying warning signs of emotional distress, internal coping strategies, social support contacts, professional resources, and means restriction methods. The intervention follows a structured format focusing on practical crisis management tools that participants can implement during suicidal crises.
219451571|NCT07122219|BEHAVIORAL|NIATx|The Network for the Improvement of Addiction Treatment (NIATx) model uses a bundle of implementation tools that include expert facilitation (coaching) and quality process improvement specifically for behavioural healthcare settings to improve access and retention in treatment.
219451572|NCT06932146|DRUG|LLX-424|Tablets for oral administration
219588204|NCT00719849|DRUG|cyclophosphamide|50 mg/Kg Day -6
219588205|NCT00719849|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
219588206|NCT00719849|DRUG|fludarabine phosphate|40mg/m2 Days -6 to -2
218841634|NCT07034508|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
219451573|NCT07124832|BEHAVIORAL|Socratic Questioning Method|"Socratic questioning is a method in which behaviour is examined through questions such as what, where, which, who, when, how, and why. It consists of four stages: defining the problem, evaluating and identifying alternatives, redefining, and discussing feasible outcomes. Through this process, individuals develop their critical thinking skills and make self-evaluations."
219451574|NCT07134101|DRUG|Serplulimab|Serplulimab 300 mg IV on Day 1
219451575|NCT07134101|DRUG|Bevacizumab|Bevacizumab 5 mg/kg IV on Day 1
219588207|NCT00719849|DRUG|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
219588208|NCT00719849|PROCEDURE|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
219588209|NCT00719849|RADIATION|total body irradiation|200 cGy Day -1
219588210|NCT01323049|PROCEDURE|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
219588211|NCT01323049|PROCEDURE|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
219588212|NCT03048253|BIOLOGICAL|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
218841635|NCT07034508|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
218841636|NCT07034508|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm
218841637|NCT07034508|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219451576|NCT07134101|RADIATION|Short-Course Radioterapy|25 Gy in 5 fractions over 1 week
219451577|NCT07134101|DRUG|Chemotherapy (CAPOX or capecitabine)|Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle
219451578|NCT07139886|DRUG|Stillen® Tab|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
219451579|NCT07139886|DRUG|Stillen® Tab Placebo|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
219588213|NCT06895902|DEVICE|Polypropylene Suture Eyelid Spring for Paralytic Lagophthalmos|The polypropylene loop eyelid suture spring will be centrally placed without fixation to the bone unlike a metal lid spring.
219588214|NCT03867097|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
219588215|NCT03867097|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
219588216|NCT01372774|RADIATION|stereotactic radiosurgery|Undergo RT
218841638|NCT07034508|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
218841639|NCT07039955|BEHAVIORAL|Daily Chlorhexidine Bathing|Daily bathing using no-rinse, 4% chlorhexidine gluconate (CHG)-impregnated washcloths will be implemented in ICUs assigned to the intervention group. The purpose is to reduce CPE colonization and infection by maintaining effective residual CHG skin concentrations. Bathing will be performed by trained nursing staff following standardized protocols.
218841640|NCT07039955|BEHAVIORAL|Antimicrobial and PPI Stewardship Program|A targeted stewardship program will be implemented to reduce unnecessary carbapenem use and inappropriate proton pump inhibitor (PPI) prescriptions. The program includes audit and feedback, education of ICU physicians, and monthly monitoring of antimicrobial and PPI usage. Stewardship activities will be uniformly applied across both intervention and control ICUs.
218841641|NCT07039955|BEHAVIORAL|Standard Bathing|Patients in ICUs assigned to the control group will receive standard daily bathing without the use of chlorhexidine. No CHG-containing products will be applied. This represents usual care in the participating hospitals.
219588217|NCT01372774|RADIATION|whole-brain radiation therapy|Undergo radiotherapy (RT)
219588218|NCT04328857|DEVICE|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
219588219|NCT05551819|DIETARY_SUPPLEMENT|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
218841642|NCT07034170|BEHAVIORAL|Enhanced Rehabilitation Program|Participants in the intervention group receive an enhanced rehabilitation program, including muscular electrical stimulation, guided active rehabilitation sessions, and structured physical engagement during periods of consciousness. The intervention is designed to promote functional improvement in post-cardiac arrest patients.
218841643|NCT07033234|DRUG|HS-20118|HS-20118
219196840|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
218841644|NCT07042386|BEHAVIORAL|CROWN Intervention|"CROWN Intervention includes:~1. Private BP screenings in salon Heart Health Stations by trained Heart Health Stylists~2. Free Omron home BP monitor paired with a mobile app for twice-daily telemonitoring~3. In-depth coaching sessions + monthly check-ins with a community health worker~4. Bi-weekly medication review and adherence support by a clinical pharmacist~5. Digital social-needs screening (AHC HRSN) with referral to community resources"
219451580|NCT06932731|BEHAVIORAL|Mind-body Intervention|The Mind-Body Intervention group designed to included several elements with mind and body involvement such as mindful breathing, body scan, stretching, mindful movement as well as adapting mindful practice in their routine. Mind-Body Intervention group will join the activities in a group setting for 5 sessions. Each session 45 to 60 minutes. Intervention is led by a registered nurse. Each session (except for the first session) will start by sharing of practice from the past week. Followed by mind-body practices. Before the end of session, a group discussion on the practice of that day and reflection will be done.
219451581|NCT06932731|BEHAVIORAL|Befriending Intervention|In this group, volunteer will spend time with the participants, engaging in conversation and join their routine activities by the time of visit or other scheduled activities in the institution (such as arts and crafts, playing board games or reminiscing activities).
219451582|NCT07142486|DRUG|Omeprazole 20 mg|"Omeprazole 20mg capsule~1 dose = 1 capsule~Participants will consume one dose per day for 5 days prior to their study visit. They will also consume one dose the day of the study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
219451583|NCT07142486|OTHER|Placebo|"Placebo~1 dose of placebo = 1 capsule filled with maltodextrin~Participants will consume 1 dose per day for 5 days prior to their study visit. They will then consume 1 dose the day of their study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
219451584|NCT03285061|DEVICE|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
219588220|NCT05551819|DIETARY_SUPPLEMENT|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
219588221|NCT02828059|DRUG|Ropivacaine|Surgical wound Infiltration over 48 hours
218841645|NCT07042386|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care include:~1. Private BP screenings in salon Heart Health Stations by Heart Health Stylists~2. Printed cardiovascular health brochures~3. Free home blood pressure monitor (no app integration)~4. Standard referrals to social and health services"
219451585|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
219451586|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
219451587|NCT01287767|BEHAVIORAL|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
219451588|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
219451590|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
219451591|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
219451592|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
219451593|NCT06949150|DIAGNOSTIC_TEST|coronary angiography|Invasive coronary angiography (ICA), with or without percutaneous coronary intervention (PCI), intravascular ultrasound (IVUS), optical coherence tomography (OCT), or fractional flow reserve (FFR).
219451594|NCT06949150|OTHER|Medical therapy|Patients do not undergo invasive coronary angiography (ICA), recieving medical treatment, lifestyle intervention or further test
219451595|NCT06948890|OTHER|Music intervention|"Subjects will listen to two songs of their choosing. They will be prompted: Please choose two songs that you really enjoy and that make you feel relaxed or take away stress."
219451596|NCT06948890|OTHER|Silence|Subjects will listen to 10 minutes of silence through high quality noise canceling headphones
219451597|NCT06950021|DEVICE|Magnetic seed|All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.
219451598|NCT07148661|PROCEDURE|Removal of PPcT|Iatrogenic Pulmonary Parenchymal Chest Tube is removed as a staged procedure in which gradual retraction of 2cm of chest tube is done from lung parenchyma keeping an eye on the hemodynamic status of Patient.
219451599|NCT07147959|DRUG|[89Zr]Zr-CIT|radiolabelled CIT-013
219451600|NCT07147738|BEHAVIORAL|Kapot Sterk (translate as Incredibly Strong)|The program consists of five lessons of approximately 60 minutes long, delivered over a period of four to eight weeks. The lessons are facilitated by trained pedagogical staff (e.g., youth workers), while the school's own teachers are always present during the sessions. Lessons include active learning strategies such as role-playing, group discussions, and reflection exercises, often based on realistic and recognizable scenarios. The program focuses on strengthening key social-emotional skills, such as self-esteem, self-control, and resistance to peer pressure.
219451601|NCT07148193|OTHER|No intervention (observational study)|No intervention (observational study)
219588222|NCT02201290|DRUG|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
219588223|NCT02201290|DRUG|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
218841646|NCT07045649|DIAGNOSTIC_TEST|1-minute sit-to-stand test|The 1-minute sit-to-stand test will be assessed upon discharge from the Cardiac Intensive Care Unit. It may be assessed up to 48 hours after discharge from the unit. It will be performed on a standardized 46.0 cm chair without armrests, placed against the wall. Participants will be seated in the chair, without support, with their knees and hips at 90° flexion, with their feet parallel to the floor and their arms crossed over their chest. Participants will be instructed to stand up and sit down as quickly as possible without using their arms for 1 minute and will be instructed to stop whenever they wish. However, they must return as quickly as possible, since the goal is to complete as many repetitions as possible in 1 minute. Vital signs and dyspnea and leg fatigue will be assessed using the Modified Borg Scale before and after the test. A repetition will be identified as standing up completely straight and returning to the sitting position.
218841647|NCT07048860|OTHER|ICOPE intense intervention|The ICOPE-intense intervention (45 hours centre-based (in-group and in-person) multidomain intervention, everyday home-based lifestyle improvement, and weekly individual phone/video call for support)
218841648|NCT07048860|DIETARY_SUPPLEMENT|Ketone Ester (KE) supplementation|12.5g once a day of KE for week 1, and 25g once a day of KE supplementation week 2 to week 8.
218841649|NCT07048860|DIETARY_SUPPLEMENT|Placebo|2.5 g of nonketogenic canola oil
218841650|NCT07048860|DIETARY_SUPPLEMENT|Vitamin D3|2 sprays (i.e. 2000 iu) per day in the morning for 60 days
219451602|NCT07148037|GENETIC|Atorvastatin|10mg once a day for 2 months
219451603|NCT07147686|BEHAVIORAL|Slow tempo basic motor skills exercises with music (30 BPM)|Participants performed basic motor skills exercises synchronized with slow-tempo music at 30 beats per minute (BPM). The slow tempo was intended to enhance internal timing, cognitive inhibition, controlled movement coordination, and sustained attention. Each session lasted 10-15 minutes per exercise, using traditional Turkish music (e.g., Erik Dali, Horon, Sari Zeybek) to provide culturally relevant rhythmic patterns.
219451604|NCT07147686|BEHAVIORAL|Fast tempo basic motor skills exercises with music (60 BPM)|Participants performed basic motor skills exercises synchronized with fast-tempo music at 60 BPM. The faster tempo aimed to increase reaction speed, attention demand, processing speed, decision-making, and cognitive flexibility. Each session lasted 10-15 minutes per exercise, using traditional Turkish music with asymmetric rhythms to challenge timing and planning skills.
218841651|NCT07048860|DIETARY_SUPPLEMENT|OMega 3|1000 mg: 1 table per day in the morning during 60 days
218841652|NCT07048860|DIETARY_SUPPLEMENT|vitamin B9|5 mg cp: 1 tablet morning and 1 tablet evening for 60 days
218841653|NCT07048860|DIETARY_SUPPLEMENT|Vitamin B12|250 microgram: 1 tablet per day in the morning for 30 days, then 1 tablet every 10 days for 30 days
218841654|NCT07048860|DIETARY_SUPPLEMENT|Leucin-rich whey|In case of Sarcopenia or low protein intake (\<1.2 g/kg/day), Oral Nutritional Supplementation enriched in essential amino acid (leucin)
218841655|NCT07048860|OTHER|ICOPE Step 1|usual ICOPE Step 1
218841656|NCT06743425|OTHER|RAMP Reports|Participants will receive text-based requests for reports with embedded links to select radio button questionnaires directly on their mobile device. Questions include current inattention/hyperactivity symptoms, school performance, and any engagement in behavioral therapy. Inattention/hyperactivity symptom questions and scoring is taken directly from the publicly available Vanderbilt Rating Scales, which is a commonly used, guideline-recommended tool for both diagnosis and management of ADHD for use by parents and teachers.
218841657|NCT06743425|OTHER|Digital Education Handouts|The digital education handouts will be sent via email to the control group and will serve as an attention control. They will consist of information regarding a general pediatric health topic and will be emailed at intervals matching the RAMP requests in the intervention group.
219451605|NCT07147647|DEVICE|Direct Selective Laser Trabeculoplasty|DSLT using the Belkin Vision Eagle Device
219451606|NCT07148089|DRUG|SGT-501|IV for infusion
219451607|NCT07147335|DIAGNOSTIC_TEST|serum AKR1B10 levels|Investigators collected blood from the patients every three months to test their serum AKR1B10 levels.
218841658|NCT06899152|DIAGNOSTIC_TEST|HepQuant DuO|HepQuant DuO is a quantitative liver function test. It assesses cholate uptake, a liver specific function. Cholate is a naturally occurring substance that is cleared by the liver. Cholate uptake reflects the health of liver cells.
219451608|NCT07148817|BEHAVIORAL|Noise canceling earplugs|Modifiable noise cancelling earplugs will be used to attempt to limit individual noise exposure in those with high levels of exposure or high levels of annoyance related to noise
219451609|NCT07148817|BEHAVIORAL|Usual care|No behavioral changes to limit noise exposure
219451610|NCT07147283|BEHAVIORAL|Educational film and volitional help sheet|The intervention consists of a bespoke online gynaecological cancer awareness educational film and a volitional help sheet to plan future gynaecological help seeking and monitoring based on implementation intention principles \[24\]. The intervention will be delivered online using Qualtrics™.
219588224|NCT00094081|DRUG|tirapazamine (SR259075)|
218841659|NCT06899152|OTHER|Multiparametric MRI Scans|Standard of care
218841660|NCT07071012|DRUG|Bupivacaine|Used for regional anesthesia during nephrectomy procedure (e.g., paravertebral or external oblique intercostal block)
219451611|NCT07147699|DEVICE|cardiostory|measure the pressure of remplissage
219588225|NCT00094081|DRUG|cisplatin|
219588226|NCT00094081|PROCEDURE|Radiation Therapy|
218841661|NCT07071012|DRUG|morphine|Used for postoperative pain control via PCA device
218841662|NCT07071012|DRUG|paracetamol|Used as part of postoperative multimodal analgesia
218841663|NCT07071012|DRUG|Diclofenac|Administered for postoperative pain management
218841664|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
218841665|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
218841666|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
218841667|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
218841668|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
218841669|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
218841670|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
218841671|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
218841672|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
219451612|NCT07149064|DIETARY_SUPPLEMENT|Nextida GC-B|One liquid shot contains 5 g of collagen hydrolysate.
219451613|NCT07149064|OTHER|Placebo|One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).
218841673|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
218841674|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
219451614|NCT07149220|DRUG|Mucoadhesive fenretinide-releasing system (FMS)|All persons with premalignant oral epithelial lesions will receive active intervention. The intervention consists of b.i.d. application of the FMS to the premalignant lesion for a total of six weeks. Please note that the intervention title Drug and intervention titled Other are the same entity.
218841675|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
218841676|NCT01673854|DRUG|Ipilimumab|
219451615|NCT07147413|BEHAVIORAL|Behavioral/Digital Health Intervention|Participants in this group will utilize an AI-powered digital health management platform designed to optimize blood pressure control. The platform provides personalized medication and blood pressure measurement reminders, tailored health education, and interactive quizzes to improve hypertension awareness and engagement. Data from blood pressure monitors will be scanned and uploaded, and the system will alert participants and case managers to abnormal readings, enabling timely interventions.
218841677|NCT01673854|BIOLOGICAL|Vemurafenib|
218841678|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
219451616|NCT07149272|DEVICE|Virtual Reality Exercise (VRE) using VRAGMENT software|Adjuvant Virtual Reality Exercise (VRE) delivered via Oculus Quest 2 headset with VRAGMENT software, a culturally adapted VR program simulating daily activities (e.g., grocery shopping, phone calls) to induce physical movement. Participants received VRE alongside conventional multimodal exercise (breathing, resistance, aerobic) during hospitalization. Sessions were tailored to individual clinical conditions and aimed to improve fatigue and mobility through gamified rehabilitation
219588227|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
218841679|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
218841680|NCT00285155|DRUG|Bupropion|
218841681|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
218841682|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
219588228|NCT00661011|PROCEDURE|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
219588229|NCT04149795|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
219588230|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 .|
219588231|NCT01632761|DRUG|omega-3 fatty acids (fish oil)|
219588232|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
219588233|NCT01632761|DIETARY_SUPPLEMENT|Fish oil placebo|
219588234|NCT05933343|PROCEDURE|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
219588235|NCT05933343|PROCEDURE|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
219588236|NCT04004156|DEVICE|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
219588237|NCT05675306|BEHAVIORAL|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
219588238|NCT05102721|DRUG|Avelumab and Pepinemab|IV Infusions every two weeks.
219588239|NCT05999396|DRUG|Administration of CC-3|Accelerated titration phase, Standard 3+3 titration phase, expansion phase
219588240|NCT06848010|DEVICE|Automated endotracheal cuff controller|The automated endotracheal tube cuff pressure controller will continously assess and maintain the endotracheal tube cuff pressure at pre-specifed pressure level of 25 cmH20.
219588241|NCT06844305|OTHER|Prosthetic foot|The most- and least-preferred prosthetic foot
219588242|NCT06844305|OTHER|Physical therapy|Personalized physical therapy
219588243|NCT04682964|DRUG|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
218841683|NCT07081802|DRUG|Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)|"Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)was administered orally twice daily from preoperative day 3 to postoperative day 3. The decoction aims to warm the middle jiao and promote gastrointestinal recovery, with dose adjustments based on syndrome differentiation."
219451617|NCT07148687|BEHAVIORAL|Conventional Exercise Program|Exercise protocol targeting subacromial pain syndrome, including shoulder mobility, strengthening, and posture correction exercises based on established clinical guidelines.
219451618|NCT07148687|BEHAVIORAL|ChatGPT-Guided Rehabilitation|AI-generated exercise recommendations from ChatGPT-4 tailored to the patient's profile and applied under physiotherapist supervision.
218841684|NCT07081802|PROCEDURE|Transcutaneous Electrical Acupoint Stimulation (TEAS)|TEAS was delivered at acupoints ST36/ST37 (10Hz continuous wave, 30min/session) once daily from intraoperative day to postoperative day 4. On surgery day, stimulation started 30min preoperatively for 1 hour. Intensity was adjusted to elicit deqi sensation.
219451619|NCT07148687|BEHAVIORAL|DeepSeek-Guided Rehabilitation|Personalized rehabilitation exercises generated by DeepSeek-R1 and implemented under physiotherapist guidance.
219451620|NCT07148804|DRUG|Fermented Deglycyrrhizinated Licorice|Oral capsules containing 500 mg of fermented deglycyrrhizinated licorice root extract standardized to 2500 IU/gm of α-amylase enzyme and naturally occurring flavonoids and acid-lipase. Administered twice daily (1000 mg/day).
219451621|NCT07148804|DIETARY_SUPPLEMENT|Non-fermented Deglycyrrhizinated Licorice|500 mg non-fermented deglycyrrhizinated licorice root extract capsules, matching FDGL in appearance, color, weight, and excipients. Administered twice daily.
219588244|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
219451622|NCT07148778|BEHAVIORAL|Educational intervention|"In this study, a web-based postpartum care package program supported by a chatbot will be administered to the intervention group.~A pre-test will be administered to participants in the intervention group within 24-48 hours after birth.~Participants in this group will be informed that they must watch the videos in the educational modules until the sixth week postpartum. Reminder messages will also be sent to participants via the website, email, and phone calls (between days 7 and 14 postpartum and week 3 postpartum). Participants who have completed the module training will be eligible for post-tests at 6 weeks postpartum and 3 months postpartum."
219451623|NCT07148050|BIOLOGICAL|SC-CAR.GPC3xIL15.21 CAR T cells|Autologous SC-CAR.GPC3xIL15.21 T cell products infusion
219451624|NCT07148557|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (400 mg/dose) was SC
219451625|NCT07148557|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (600 mg/dose) was SC
219451626|NCT07147920|DEVICE|Chest-Worn ECG Monitoring Device|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor electrocardiogram (ECG) signals using dry conductive adhesive electrodes. In this validation study, the device will be evaluated for its ability to accurately measure ECG parameters including heart rate, QT interval, QRS duration, and R-R intervals compared to FDA-cleared Holter monitors.~The study intervention involves three components: (1) simultaneous ECG recording with the patch and reference Holter monitor for 15 minutes while participants remain seated, (2) placement tolerance testing where the patch is positioned at various locations (±20mm from optimal placement) to assess performance under suboptimal positioning, and (3) long-term wear evaluation where participants wear the patch continuously for 15 days with periodic assessments. The intervention is limited to device application and ECG data collection under controlled conditions, with no therapeutic treatment provided."
219588245|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
218841685|NCT07081802|OTHER|ERAS|"Standardized ERAS protocol included: (1) Preoperative carbohydrate loading; (2) Intraoperative goal-directed fluid therapy; (3) Minimally invasive surgery; (4) Multimodal opioid-sparing analgesia; (5) Early oral feeding (semi-liquid diet at 6h post-op); (6) Early ambulation (first mobilization at 8h post-op). Implemented by a multidisciplinary team."
219451627|NCT07148323|DEVICE|HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor|Subjects with planned monitoring with a pulmonary artery catheter in the operating room, will be monitored with the above listed devices.
219451628|NCT07149155|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|The intervention was a 2-hour, in-person SFA/HRW training followed by 30-minute monthly learning collaboratives to address occupational stress of harm reduction workers.
219451629|NCT07148856|OTHER|Conventional Physiotherapy|A standard physiotherapy program provided after Achilles tendon surgery, including stretching, strengthening, mobility, and functional training exercises
219588246|NCT04740476|DRUG|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
219588247|NCT05192876|RADIATION|Radiotherapy|Outcomes and adverse events using radiation therapy
219588248|NCT04616430|DRUG|Topical endoxifen|topical solution
219588249|NCT04616430|DRUG|Placebo|topical
219588250|NCT00633243|PROCEDURE|Modified Directly Observed Therapy (mDOT)|
219588251|NCT00633243|PROCEDURE|Self-Administered Therapy (SAT)|
218841686|NCT07081802|OTHER|Multimodal Prehabilitation Program|(1) Exercise: Daily aerobic/resistance training (30min, 5×/week); (2) Nutrition: High-protein diet (1.5g/kg/day) + oral supplements if needed; (3) Psychological Support: Cognitive-behavioral therapy sessions (2×/week). Tailored to individual patient risk profiles.
218841687|NCT07079423|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
218841688|NCT07079592|DIAGNOSTIC_TEST|AI-ECG Guidance|Participants undergo screening using the AI-ECG system. Those identified as high-risk for pulmonary hypertension receive echocardiography to confirm the diagnosis and guide subsequent management.
218841689|NCT07080372|DIAGNOSTIC_TEST|assesment|This study aims to assess the role of early arterial phase in detecting and differentiating hepatocellular carcinoma from dysplastic nodules in chronic liver disease patients.
218841690|NCT07081763|DRUG|Baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
219451630|NCT07148856|OTHER|Myofascial Release Technique|A manual therapy technique applied to the lower limb and ankle region, aiming to release fascial restrictions, improve soft tissue flexibility, and enhance ankle range of motion.
219451631|NCT06950112|DEVICE|lung ultrasound|The lung ultrasound score between 0 and 3 (0 = normal A lines, 1 = multiple separated B lines, 2 = coalescing B lines or light beam, 3 = consolidation). The aeration score will be built by the sum of the scores of the 12 segments, with a minimum of 0 and a maximum of 36 according to the aeration loss.
219451632|NCT06949865|OTHER|video recording|The patient's motor symptoms were recorded via video for assessment purposes.
219451633|NCT07148492|PROCEDURE|Antireflux suture|Antireflux suture will be taken in this intervention group
219451634|NCT07148492|PROCEDURE|No Antireflux suture|Antireflux suture will not be taken in this intervention group
219451635|NCT07148869|BEHAVIORAL|LAUGHTER YOGA|Patients will be divided into groups of at least 5 people according to the sample size. Laughter yoga sessions will be conducted under the leadership of the researcher in a suitable room / hall determined within the hospital. A total of 8 sessions will be applied, 2 sessions per week for 4 weeks, with each session lasting an average of 40 minutes.
219451636|NCT07148869|OTHER|control group|there will be no application to this group
219451637|NCT07147322|OTHER|Medical education, basic life support training|One basic life support training session / participant. Duration of educational session aprox. 30min.
219451638|NCT07148284|OTHER|Isolation of EVs + RNA sequencing|Isolation of EVs + RNA sequencing
219451639|NCT07149025|PROCEDURE|Osteopathic Manipulative Therapy|1 session of OMT
218841691|NCT07081763|DRUG|Sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
218841692|NCT07081763|OTHER|Placebo of baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
218841693|NCT07081763|OTHER|Placebo of sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
218841694|NCT07081035|DRUG|Warfarin (low-intensity anticoagulation)|"Low-intensity INR group (Experimental):~Participants will receive anticoagulation therapy with warfarin, aiming for a reduced INR range of 1.5-2.0, which is lower than the current standard recommendation. Warfarin dosing will be regularly adjusted based on INR monitoring throughout the 6-month study period."
218841695|NCT07081035|DRUG|Warfarin (standard anticoagulation)|"Standard INR group (Active Comparator):~Participants will receive anticoagulation therapy with warfarin, maintaining an INR within the standard therapeutic range of 2.0-3.0. Warfarin dosing adjustments will be made regularly according to standard clinical practice and INR monitoring throughout the 6-month study period."
219451640|NCT07147595|PROCEDURE|Isometric handgrip exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with a handgrip device for each arm, with 1-minute rest intervals between sets and between arms.
219451641|NCT07147595|PROCEDURE|Isometric knee extension exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with adjustable ankle weights for each leg, with 1-minute rest intervals between sets and between legs.
219451642|NCT07149090|DRUG|Lenvatinib|"Description: Lenvatinib: 12 mg (for body weight ≥ 60 kg) or 8 mg (for body weight \< 60 kg) per oral once daily~* Dose level 1: 8mg per oral once daily (for \<60kg) 12mg per oral once daily (for ≥ 60kg)~* Dose level 2: 4mg per oral once daily (for \<60kg) 8mg per oral once daily (for ≥ 60kg) Nivolumab: 360 mg administered intravenously every 3 weeks Chemotherapy(Oxaliplatin+Capecitabine) every 3 weeks~* Capecitabine 1000 mg/m² per oral twice daily on Days 1-14~* Oxaliplatin 130 mg/m² administered intravenously on Day 1"
219451643|NCT07148635|PROCEDURE|Electrical Dry Needling (EDN)|Electrical dry needling will be performed at active myofascial trigger points in lumbar muscles (quadratus lumborum, multifidus, iliocostalis lumborum). Fine monofilament needles are inserted into trigger points and connected to a low-frequency stimulator (2-10 Hz) for 10-15 minutes per session. Treatment is delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program.
219451644|NCT07148635|PROCEDURE|Sham Dry Needling (SDN)|Sham dry needling will be administered at the same anatomical sites as the experimental group, using superficial or blunt needle placement without penetration into muscle tissue and without electrical stimulation. Sessions are delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive the same standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program to maintain consistency with the experimental arm.
218841696|NCT07079358|BEHAVIORAL|Veterans Cardiac Rehabilitation Referral Program|"1. A CDS tool that identifies Veterans hospitalized with CR-eligible conditions and prompts physicians to refer them to CR.~2. Educational materials that explain to Veterans the benefits and importance of participating in CR.~3. Defined responsibilities for a facility-based CR referral coordinator who will support development and oversight of the referral process."
218841697|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive anodal HD-tDCS targeting the left or right DLPFC (F3/F4).
218841698|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive sham HD-tDCS targeting the left or right DLPFC (F3/F4). The device mimics the sensation of stimulation without delivering active current.
218841699|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive anodal HD-tDCS targeting the left DLPFC (F3) and cathodal stimulation targeting the right DLPFC (F4).
219451646|NCT07148531|BEHAVIORAL|Seeds for Attachment (translated version)|"Developed by, and base at Universidad de los Andes, this is a community-based psychosocial model for caregivers of young children in conflict-affected settings.~The program is implemented through a 15-week group-based model with approximately 15 caregivers per group, and led by community facilitators (non-professionals).~The program follows four sequential goals: (1) promoting awareness of and tools for emotional regulation of the psychological consequences of conflict and forced displacement; (2) understanding children's emotional needs and the caregiver-child relationship; (3) developing responsive caregiving practices that foster secure attachment; and (4) strengthening social support networks. The approach integrates psychosocial support with attention to the social determinants of caregiving and mental health."
219451647|NCT07147881|DEVICE|IpsiHand|IpsiHand is a therapeutic device that uses a brain-computer interface system which detects neural signals associated with motor intent and translates them into assisted hand movements in individuals with upper extremity impairment following a stroke.
219451648|NCT07148921|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a psychophysical test procedure. With the help of calibrated stimuli and subjective sensory information, the functional state of the somatosensory system of a subject or patient is examined with regard to the expression of clinical signs.~The test includes:~* Cold detection threshold~* Warm detection threshold~* Paradoxical heat sensation~* Cold pain threshold~* Heat pain threshold~* Mechanical detection threshold~* Mechanical pain threshold~* Mechanical pain sensitivity~* Dynamic mechanical allodynia~* Wind-up phenomena~* Vibration threshold~* Pressure pain threshold"
219588252|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
219588253|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
218841700|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive sham HD-tDCS targeting the left DLPFC (F3) and right DLPFC (F4). The device mimics the sensation of stimulation without delivering active current.
218841701|NCT07080294|OTHER|extended platelet rich fibrin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used.
218841702|NCT07080294|OTHER|albumin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared.
218841703|NCT07080294|OTHER|scaling and root planing|removes plaque and calculus above and below the gumline using manual or ultrasonic instruments.
218841704|NCT07080190|DRUG|Early N-Acetylcysteine|Patients received N-acetyl cysteine early (at admission) in the course of treatment of acute hair dye poisoning.
218841705|NCT07080190|DRUG|Late N-Acetylcysteine|Patients received the standard treatment of N-acetyl cysteine after starting organ affection in the course of treatment of acute hair dye poisoning.
218841706|NCT07081698|OTHER|Infant walnut intake|The intervention group will receive walnuts at 10 g/day, and the control group will be advised to avoid walnuts/tree nuts during the intervention. The purpose of this research is to learn more about how walnuts as a first food in infants impact immunity and the development of bacteria living in your baby's gut.
218841707|NCT07081828|DEVICE|Surgery|Patients who undergo surgery utilising the Senhance Surgical System.
218841708|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
219588254|NCT02022748|DRUG|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
218841709|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
218841710|NCT06890988|OTHER|Care Navigator|"The Care Navigator will be added to the dental team as an added resource to:~1. Champion the use of the multicomponent HIV intervention in the dental clinic among clinic administrators, residents, dental hygienists, dental assistants, and other dental team staff.~2. Provide technical assistance~3. Provide logistical assistance ; and~4. Support dental team in educating patients about HIV prevention and treatment options"
218841711|NCT06890988|OTHER|Multicomponent HIV Service Package|"Multicomponent HIV Service Package consisting of:~1. Clinical Decision Support (CDS) within electronic medical record (EMR) system to help providers identify patients who would benefit from HIV screening or re-engagement in HIV care.~2. Point-of-care HIV testing in the dental clinic.~3. Patient and provider-facing educational materials to support providers in discussing HIV prevention options (for patients who test HIV negative) and treatment (for patients who test HIV positive or are out of HIV care) options."
218841712|NCT07079644|BIOLOGICAL|Nivolumab + Relatlimab|As per product label
218841713|NCT07079644|BIOLOGICAL|Nivolumab + Ipilimumab|As per product label
218841714|NCT07079644|BIOLOGICAL|Immunotherapy monotherapy|As per product label
218841715|NCT07079644|DRUG|BRAF/MEK inhibitors|As per product label
219451649|NCT07148921|DIAGNOSTIC_TEST|Patient Health Questionnaire 9|The Patient Health Questionnaire 9 (PHQ-9), a validated and internationally used health questionnaire, will also be completed twice at the first study day before the sex hormone therapy is initiated and during the last study day in month 6. The questionnaire consists of 9 items on the topic of mental well-being.
218841716|NCT07079540|DRUG|X842|X842 capsules
218841717|NCT07079540|DRUG|X842 Placebo|X842 placebo-matching capsules
218841718|NCT07079540|DRUG|Lansoprazole|Lansoprazole capsules
218841719|NCT07079540|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
218841720|NCT07081048|OTHER|Buzzy®.Group|The ice pack, which has been removed from the deep freezer in advance, should be left at room temperature for 10 minutes, and the hole in the ice pack should be placed on the hook behind the Buzzy® will be placed on the lateral side of the left heel and activated for 30 seconds. After 30 seconds, Buzzy® will be pulled up 1 centimetre (cm), and the heel will be punctured with a sterile lancet to collect blood on the Guthrie card. After the heel blood collection procedure, Buzzy® will be pulled back to the punctured heel area and left for another 30 seconds.
218841721|NCT07081048|OTHER|ShotBlocker Group|"ShotBlocker will be placed on the designated area for collecting the baby's heel blood. After ensuring that the protrusions of the ShotBlocker are in contact, pressure will be applied for 20 seconds.~The heel will be punctured with a sterile lancet in the area designed for applying the ShotBlocker, and the ShotBlocker will be removed from the area. The blood collected will be collected on Guthrie paper."
218841722|NCT07080827|BEHAVIORAL|TTM-Based Online Psychoeducation Program|A 5-week structured psychoeducation program based on the Transtheoretical Model (TTM), delivered via WhatsApp. Educational content was tailored to the participant's stage of change and included videos, texts, and interactive materials to promote treatment adherence in individuals with psychosis.
219451650|NCT07148921|DIAGNOSTIC_TEST|Hormone concentrations|"Blood concentrations of the following laboratory parameters will be determined:~* Follicle stimulating hormone (FSH)~* Luteotropic hormone (LH)~* Prolactin (PRL)~* Oestradiol (E2)~* Sex hormone-binding globulin (SHBG)~* Testosterone"
219588255|NCT06511648|DRUG|Erdafitinib monotherapy|Patients will receive treatment with erdafitinib alone (cohort 1)
219588256|NCT06511648|DRUG|Cetrelimab and Erdafitinib combination|Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
219588257|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
219588258|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
219588259|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
219588260|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
219451651|NCT07148167|OTHER|Magnetic resonance imaging|use Magnetic Resonance Imaging (MRI) to evaluate the cervical muscle planes in AS patients in more detailed and objective ways. In this study, in addition to cervical muscle volumes in AS patients, we also aimed to evaluate cervical fat infiltration and cervical alignment, which have not been previously evaluated in AS patients.
219451652|NCT07147660|OTHER|Compensatory scanning training|Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
219451653|NCT07147660|OTHER|Delayed Compensatory scanning training|Delayed track start. Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
219588261|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
219588262|NCT06554873|DRUG|Nicoderm|Depending on responder status and group assignment the maximum amount of time nicotine patches will be used is 24 weeks. The final four weeks of nicotine patch treatment will comprise 2 weeks of 14 mg patches and two weeks of 7 mg patches.
218841723|NCT07080827|BEHAVIORAL|Standard Face-to-Face Psychoeducation Program|A 3-week conventional psychoeducation program delivered face-to-face at the Community Mental Health Center. The program focused on general treatment adherence without utilizing the Transtheoretical Model and included verbal education, printed materials, and discussions.
218841724|NCT07080827|OTHER|TTM-Based Online Psychoeducation Program|The intervention was provided after a 3-month delay following initial observation. Participants received the same 5-week online psychoeducation program as the main intervention group
218841725|NCT07081776|DEVICE|OptiNIV|"Patients assigned to the OptiNIV group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with an optimized mask (OptiNIV) and in the second session they will receive NIV with a traditional oronasal mask (Visairo). The study will follow a crossover design, meaning each patient will undergo both sessions, In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
219451654|NCT07147582|OTHER|Transcranial alternating current stimulation with two electrodes placed on scalp|Transcranial alternating current stimulation with anode and cathode electrodes and frequency ranged from 8 to 13 HZ
219451655|NCT03893630|DRUG|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
219451656|NCT03893630|DRUG|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
219451657|NCT03893630|OTHER|Control|Standard of Care
219451658|NCT05230355|DEVICE|standard technique|The probe was moved over each hemisphere for 120 seconds (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
219451659|NCT05230355|DEVICE|modified pattern|The probe was moved over 3 quadrants for 80 seconds for each quadrant (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
219451660|NCT05238324|BIOLOGICAL|Genetic HMI-203|HMI-203 delivered intravenously
219451661|NCT04826640|OTHER|Observational|Observational
219451662|NCT06296667|OTHER|core muscles training exercises|The sessions will be conducted three times per week for four weeks and each exercise will be performed two sets of 10 repetitions. For the static exercises, the final position will be held for 6 second. There will be a pause of 3 second between repetitions, and a 60 sec rest between each exercise. The exercise will be performed in three forms: abdominal bracing, dynamic stabilization, and advanced core strengthening.
219588263|NCT06554873|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 24 weeks.
218841726|NCT07081776|DEVICE|Visairo|"Patients assigned to the Visairo group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with a traditional oronasal mask (Visairo) and in the second session they will receive NIV with an optimized mask (OptiNIV). The study will follow a crossover design, meaning each patient will undergo both sessions. In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
218841727|NCT07079891|OTHER|MINS|MINS
218841728|NCT07081230|COMBINATION_PRODUCT|SRP with hyaluronic acid|patients will receive hyaluronic acid mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
219451663|NCT00002624|PROCEDURE|adjuvant therapy|
219451664|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
219451665|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
219451666|NCT00002624|PROCEDURE|video-assisted surgery|
219451667|NCT00002624|RADIATION|radiation therapy|
219451668|NCT02554721|DRUG|Cilostazol|
219451669|NCT02554721|DRUG|Acetylsalicylic acid|
219451670|NCT02554721|DRUG|Clopidogrel|
219451671|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
219451672|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
219451673|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
219588264|NCT06554873|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 24 weeks.
219588265|NCT06554873|OTHER|NJOY e-cigarette|Each NJOY Classic Tobacco and Menthol pod is pre-filled with 1.9 mL of e-liquid with 5% nicotine (by weight); as needed maximum usage 24 weeks.
219451674|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
219451675|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
219451676|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
219588266|NCT06554873|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 24 weeks.
219588267|NCT03103789|DIAGNOSTIC_TEST|single catheter mucosal impedance testing|
219588268|NCT03103789|DIAGNOSTIC_TEST|balloon assembly mucosal impedance testing|
219588269|NCT02616432|DEVICE|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
219588270|NCT04713475|BIOLOGICAL|PBGM01|AAVhu68 viral vector
219588271|NCT03887494|DEVICE|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
218841729|NCT07081230|COMBINATION_PRODUCT|SRP + Injectable Platelet-Rich Fibrin|patients will receive Albumin gel mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
218841730|NCT07079852|DRUG|Placebo|This is an inactive control condition.
218841731|NCT07079852|DRUG|Psilocybin 15mg|This is a moderate psychoactive dose.
218841732|NCT07081919|PROCEDURE|femtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery|"1. 5-year follow-up assessing stability of astigmatism correction. Most FSAK studies track ≤2 years. This addresses critical evidence gaps in durability~2. Combines topographic data with patient-reported visual function (VF-14/QoV questionnaires at all visits. Links anatomical changes to real-world visual experiences"
218841733|NCT07080736|BEHAVIORAL|E-learning|"The training consists of an e-learning module created on the RISE - Articulate platform, and is based on previously developed e-learning modules (SP-reflex) and physical training aimed at other target groups, but was adapted to the specific context of detention.~This specific training will consist of sensitising information, theoretical knowledge, as well as some concrete tools and tips for suicide prevention within detention. Relevant examples and cases will be discussed. The following topics, among others, will be discussed:~* How common is suicide?~* What myths exist about suicide?~* Why do people contemplate suicide?~* What is the process from suicidal thoughts to suicide?~* How do I recognise signs of suicidal thoughts?~* What can I do if I notice signs?~* What if someone attempts suicide or a suicide occurs?~* How do I take care of myself?"
218841734|NCT07081113|OTHER|Cyriax Mobilization|Deep transverse friction massage applied to the wrist and forearm muscles, 3 sessions/week for 4 weeks, along with TENS and hot packs.
218841735|NCT07081113|OTHER|Muscle Energy Technique (MET)|Isometric contractions performed against therapist resistance to improve range of motion and reduce pain, 3 sessions/week for 4 weeks.
218841736|NCT07079696|DRUG|ATRA|"Treatment Phase (Duration: 18 months) Intervention: ATRA oral administration using a stepwise titration protocol (detailed below). Patients may discontinue treatment if intolerable adverse events occur; post-withdrawal symptom exacerbation is monitored.~\*Titration Protocol\*~Treatment Cycle (C): 3 weeks per cycle. Dose escalation follows:~Cycle Dosage Duration C1.1 15 mg/m²/day 2 weeks on / 1 week off C1.2 20 mg/m²/day 2 weeks on / 1 week off C1.3 25 mg/m²/day 2 weeks on / 1 week off Blinded Assessments: primary endpoints: ADOS-2 SA score, CARS, SRS, ATEC, Gesell, and Sensory Motor (SM) scales.~Biomarker/Diagnostic tests: blood tests (CBC, liver/kidney function, vitamin panels, ATRA levels, hepatitis markers), neuroimaging (cranial fMRI), neurophysiology (EEG, audiometry), skeletal imaging (limb long-bone radiographs, growth monitoring), and biobanking: 1 blood tube for proteomics (baseline, 6/12/18 months). Repeat all assessments at 6, 12, and 18 months after ATRA treatment."
218841737|NCT07080437|DRUG|Immunotherapy Therapy|"Patients will receive concurrent chemoradiotherapy (CCRT) combined with immunotherapy. The treatment includes:~Radiotherapy: Individualized radiotherapy targeting the tumor. Concurrent Chemotherapy: Platinum-based doublet chemotherapy (e.g., cisplatin + fluorouracil or S-1) administered during radiotherapy.~Immunotherapy: PD-1 inhibitor (e.g., tislelizumab) used to enhance the immune response against cancer cells.~The treatment will be tailored to each patient's condition, with regular follow-up assessments every 3 months for up to 2 years to monitor efficacy and safety."
218841738|NCT07081685|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
218841739|NCT07081685|DEVICE|sham repetitive Magnetic Transcranial Stimulation (rTMS)|sham robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
218841740|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
218841741|NCT07080359|DRUG|Isavuconazole treatment|Administer isavuconazole as follows: Loading dose: 200 mg every 8 hours (q8h) for three times, Maintenance dose: 200 mg once daily (qd)
218841742|NCT07081334|BIOLOGICAL|PV-001|9-valent vaccine containing antigens for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
218841743|NCT07081334|BIOLOGICAL|PEV-001|PEV-001 is a formulation of the PV-001 vaccine that excludes the HPV antigens and contains only aluminum phosphate.
218841744|NCT07079943|OTHER|Self-questionnaire : satisfaction and quality of life|Patient satisfaction and quality of life outcomes assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
218841745|NCT07079943|OTHER|Self-reported questionnaire : educational or professional|Patient educational or professional outcomes, assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
218841746|NCT07080541|OTHER|Physical literacy and life satisfaction|Participants in the technology experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via social media
218841747|NCT07080541|OTHER|Analogic information|Participants in the analogic experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via paper sheets.
218841748|NCT07079917|PROCEDURE|subperiosteal tunneling for horizontal alveolar ridge augmentation|subperiosteal dissection through horizontal incision only
218841749|NCT07079917|PROCEDURE|conventional alveolar ridge augmentation|horizontal alveolar ridge augmentation through trapezoidal flap
219451677|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
219451678|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
219451679|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
219588272|NCT01025544|BIOLOGICAL|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
218841750|NCT07081724|BEHAVIORAL|Online Parent Training in Early Behavioral Intervention (OPT-In-Early)|"the Online Parent Training in Early Behavioral Intervention (OPT-In-Early; Dai et al., 2018, 2021,2022) is a self-directed online resource for caregivers of children with autism or high likelihood of autism. The OPT-In-Early program includes 14 modules (6 mandatory, 8 optional) comprising text and video demonstrations to teach caregivers effective methods for improving their children's language, social, and adaptive skills (e.g., using utensils, toilet training), and reducing their children's disruptive behavior. Parents are taught how to facilitate joint attention, imitation, pretend play, language, sharing, emotional engagement, social play, and self-help skills such as feeding and dressing in their child using behavioral principles (e.g. prompting, shaping and fading) during play and naturalistic daily routines. The optional modules cover such topics as picky eating and toilet training."
218841751|NCT07081217|DIAGNOSTIC_TEST|Intravenous Radiocaine|Intravenous injection of Radiocaine
218841752|NCT07080385|DRUG|Encaleret|Oral tablets, age-appropriate pediatric formulation (currently under development).
218841753|NCT07079956|DEVICE|TUBE Flow Diverter|TUBE Device
218841754|NCT07079488|DIAGNOSTIC_TEST|Motor proficiency scales|AIMS, PDMS-2, HINE
218841755|NCT07081061|OTHER|BetterHelp|Use program as needed for 16 weeks
218841756|NCT07080970|OTHER|observation of incidence of early vascular events|observation of difference incidence of early vascular events in the two cohorts
219451680|NCT05359991|OTHER|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
219451681|NCT04814355|DRUG|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
218841757|NCT07081906|DRUG|Oral Oxybutynin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
218841758|NCT07081906|DRUG|transdermal oxybutinin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
218841759|NCT07080424|PROCEDURE|Fistulectomy with Marsupialization|Patients with fistula in ano treated with Fistulectomy with Marsupialization and were compared for wound healing with other group
218841760|NCT07080424|PROCEDURE|Fistulectomy|Patients with fistula in ano treated with Fistulectomy and were compared for wound healing with other group
218841761|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH PASSIVE SENSORY TRAINING|"Bimanual intensive therapy Bimanual coordination training ,Functional training of the hands ,Trask oriented training, Bilateral arm training,~Passive sensory training:~Electrical stimulation."
219451682|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
219451683|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
219451684|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
219451685|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
219451686|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
219451687|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
218841762|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH ACTIVE SENSORY TRAINING|"Bimanual intensive therapy:~* Bimanual coordination training ,Functional training of the hands~* Trask oriented training, bilateral arm reaching~Active sensory training:~sensory re education techniques ,touching different objects, massage, identifying different temperatures, and sensory locating."
218841763|NCT07079553|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation (TEDS)|TEDS was applied using surface electrodes placed over the diaphragm region. The stimulation protocol was set at 50 Hz frequency, 300 μs pulse width, with 6 seconds of stimulation followed by 5 seconds of rest, daily for 12 weeks. It was combined with ACBT sessions.
218841764|NCT07079553|BEHAVIORAL|Active Cycle of Breathing Techniques (ACBT)|ACBT sessions included breathing control, thoracic expansion exercises, and forced expiration techniques (huffing). Sessions were performed daily for 12 weeks to aid in secretion clearance and improve lung function.
218841765|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
219451688|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
219451689|NCT06536101|DRUG|GIM-407|GIM-407 oral dose
219451690|NCT06536101|DRUG|Placebo|Matching placebo oral dose
219451691|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
219451692|NCT01030757|RADIATION|Tomotherapy treatment|"* A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%"
219451693|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 326.3 µg RE of vitamin A/day. This would fulfill \~59.3% of the RNI of vitamin A for children aged 7-12 years old.
219588273|NCT01025544|BIOLOGICAL|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
218841766|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
218841767|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
218841768|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
218841769|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
218841770|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
218841771|NCT01034982|DRUG|AZD9668|20 mg
218841772|NCT01034982|DRUG|AZD9668|60 mg
219451694|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
218841773|NCT07080853|OTHER|Exercise with Overdressing|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing overdressing ensemble.
219451695|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
219451696|NCT05846919|PROCEDURE|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
219451697|NCT05846919|PROCEDURE|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
219588274|NCT04111055|DEVICE|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
218841774|NCT07080853|OTHER|Control Exercise|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing control clothing ensemble.
218841775|NCT07080333|BIOLOGICAL|biopsy|After verifying the patient's identity, obtaining their informed consent and confirming that there are no immediate contraindications to performing biopsies (haemorrhagic and infectious), the patient will be prepared for RTUV, which will be performed by cystoscopy under anaesthesia in the operating theatre.
218841776|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
218841777|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
218841778|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
219451698|NCT05846919|PROCEDURE|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
219451699|NCT06455800|DIAGNOSTIC_TEST|lung function measurements|Patients will once a year be monitored with different lung function methods
219588275|NCT03665441|DRUG|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
219588276|NCT03665441|DRUG|Gemcitabine plus Abraxane|gemcitabine, Abraxane
219588277|NCT03665441|DRUG|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
219588278|NCT03996135|DEVICE|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
218841779|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
218841780|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
218841781|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
218841782|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
218841783|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
218841784|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
218841785|NCT02242214|DRUG|Misoprostol|
219451700|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
219588279|NCT01600690|OTHER|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
219588280|NCT03659292|OTHER|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
219588281|NCT03659292|OTHER|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
219588282|NCT03659292|OTHER|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
219588283|NCT03659292|OTHER|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
219588284|NCT05471492|DRUG|Investigational Product|PF-06480605 150 mg
219588285|NCT05471492|DRUG|Placebo|Placebo
219588286|NCT04354116|DEVICE|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
219588287|NCT04354116|DEVICE|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
219588288|NCT03954834|DRUG|Tirzepatide|Administered SC
219588289|NCT03954834|DRUG|Placebo|Administered SC
219588290|NCT05055830|DRUG|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
219588291|NCT04051034|DIETARY_SUPPLEMENT|Omega 3|"Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]"
219588292|NCT04051034|OTHER|Placebo|Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
219588293|NCT03358186|PROCEDURE|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
218841786|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
218841787|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
218841788|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
219451701|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
219451702|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
219451703|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
219588294|NCT03295981|DRUG|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
219588295|NCT04322110|OTHER|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
219588296|NCT04322110|OTHER|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
219588297|NCT01917981|DEVICE|Personal Heart Rhythm Monitor|
219588298|NCT04776538|BIOLOGICAL|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
219588299|NCT04776538|BIOLOGICAL|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
218841789|NCT01696019|OTHER|Contact and testing only|
219451704|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
219451705|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
219451706|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
219451707|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
219451708|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
219451709|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
219451710|NCT04427228|RADIATION|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
219451711|NCT04427228|RADIATION|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
219588300|NCT03957070|DEVICE|Liver Incyte|Ultrasound elasticity imaging
219588301|NCT06324110|OTHER|Electronic Health Record Review|Ancillary studies
219588302|NCT06324110|OTHER|Interview|Ancillary studies
219588303|NCT06324110|BEHAVIORAL|Patient Navigation|Receive lung cancer screening care coordination services
219588304|NCT04202003|DRUG|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
218841790|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
218841791|NCT00960791|DEVICE|AZD1656|Oral single dose
218841792|NCT07081620|OTHER|Physical examination of chest skin|soft touch and thermal (cold and warm) examination
218841793|NCT07079774|DEVICE|Transverse Bone Transport System|"This is a prospective, international, multicentre, observational post-market clinical follow-up (PMCF) study. Adult subjects will be treated according to the manufacturer's Instructions for Use, with follow-up extending to 12 months post-device removal. Participating sites include centres in the US, Europe, the UK, and South Africa.~Subjects will be followed using a phased framework:~T0: Index Surgery (baseline data, operative details, ulcer status) T1: End of Distraction (device parameters, adverse events, ulcer status) T2: End of Compression (similar to T1) T3: Device Removal (confirmation of union, ulcer status)~Post-removal visits:~F3: 3 months F6: 6 months F12: 12 months"
218841794|NCT07079787|DEVICE|TeleRehab DSS Pilot Test|Participants will perform an individualised multisensory balance rehabilitation program via augmented reality, while wearing motion sensors. The program will consist of multisensory balance exercises, cognitive games, and exergames. All participants will perform 2 sessions per week, carried in at each clinical site, over the course of 3-week.s
218841795|NCT07079657|PROCEDURE|Thulium laser + growth factor serum + LED|3 sessions at intervals of 6 weeks
218841796|NCT07079657|PROCEDURE|Thulium laser + growth factor serum|3 sessions at intervals of 6 weeks
218841797|NCT07079657|PROCEDURE|Thulium laser|3 sessions at intervals of 6 weeks
218841798|NCT07080918|PROCEDURE|Irrigation|Irrigation procedures were performed with needles of different designs, each 30 G, for three different groups
218841799|NCT07080606|BEHAVIORAL|Brief exposure therapy and exercise|Treatment provided in this study includes an open label brief imaginal exposure therapy for Post Traumatic Stress Disorder (PTSD) and moderate intensity aerobic exercise (i.e., 70-75% max heart rate). Participants all receive 30 minutes of psychotherapy and 25 minutes of exercise.
218841800|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
218841801|NCT01766804|DIETARY_SUPPLEMENT|placebo|
218841802|NCT05269225|OTHER|Organic diet|Organically produced foods.
218841803|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
219451712|NCT00232050|DRUG|Omalizumab|
219451713|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
218841806|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
218841807|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
218841808|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
218841809|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
218841810|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
219451714|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
219451715|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
219451716|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
219451717|NCT03501615|DRUG|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
219451718|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
219451719|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
219451720|NCT02829606|OTHER|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
218841811|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
218841812|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
218841813|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
218841814|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
219451721|NCT02829606|OTHER|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
219451722|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
219451723|NCT01913652|DRUG|Cabazitaxel|
219451724|NCT01449344|DRUG|Rituximab|Rituximab 375mg/m² IV , day 1
219451725|NCT01449344|DRUG|High dose Ara-C|Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
219451726|NCT01449344|DRUG|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
219451727|NCT01449344|DRUG|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
219451728|NCT03363789|BIOLOGICAL|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
219451729|NCT03363789|PROCEDURE|Physical Therapy|Patients will receive a prescription for physical therapy.
219451730|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
219451731|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
219451732|NCT04576273|DIAGNOSTIC_TEST|Pathology examination|Gross and microscopic evaluation
218841815|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841816|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841817|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841818|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841819|NCT04500171|BEHAVIORAL|Colocare Instruction Video: Modified SAM + CAM -Superior rating|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
219451733|NCT00865358|BEHAVIORAL|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
219588305|NCT05373004|DRUG|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
219588306|NCT05373004|DRUG|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
219588307|NCT04077190|DEVICE|Adipose-derived stem cells|5cc adipose derived stem cells.
219588308|NCT04077190|DEVICE|cortisone injection|cortisone injection
219588309|NCT06172244|OTHER|Applying with whole body vibration device|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
219588310|NCT05160233|BEHAVIORAL|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
219588311|NCT05160233|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
218841820|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
219451734|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
219451735|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
219451736|NCT00017225|BIOLOGICAL|filgrastim|
219588312|NCT05160233|BEHAVIORAL|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
219451737|NCT00017225|DRUG|carboplatin|
219588313|NCT05707754|DRUG|Bupivacaine|Topically applied to sphenopalatine ganglion
219588314|NCT05707754|DEVICE|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
219588315|NCT03443830|DRUG|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
219588316|NCT05726903|DRUG|Depo-subQ Provera Injectable Product|SC Injection at Home
219588317|NCT03700385|DEVICE|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
219588318|NCT00658515|DRUG|Dalcetrapib (RO4607381)|600mg po daily
219451738|NCT00017225|DRUG|cisplatin|
219588319|NCT00658515|DRUG|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
219588320|NCT00658515|DRUG|Placebo|po daily
219588321|NCT04086407|DEVICE|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
218841821|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841822|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841823|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
218841824|NCT06955416|DRUG|Reamberin|Infusion of study drug REAMBERIN®, solution for infusion 1.5%, in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
219451739|NCT00017225|DRUG|cyclophosphamide|
219588322|NCT01555671|DRUG|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
219588323|NCT01555671|DRUG|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
219588324|NCT00372411|DEVICE|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
218841825|NCT06955416|DRUG|Placebo|Infusion of 0,9% normal saline in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
218841826|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
218841827|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
218841828|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
218841829|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
219451740|NCT00017225|DRUG|dacarbazine|
219451741|NCT00017225|DRUG|doxorubicin hydrochloride|
219451742|NCT00017225|DRUG|etoposide|
219451743|NCT00017225|DRUG|ifosfamide|
219451744|NCT00017225|DRUG|melphalan|
219451745|NCT00017225|DRUG|tretinoin|
219451746|NCT00017225|DRUG|vincristine sulfate|
219451747|NCT00017225|DRUG|vindesine|
219451748|NCT00017225|PROCEDURE|autologous bone marrow transplantation|
219451749|NCT00017225|PROCEDURE|conventional surgery|
219451750|NCT00017225|PROCEDURE|peripheral blood stem cell transplantation|
219451751|NCT00017225|RADIATION|radiation therapy|
219451752|NCT02432911|DRUG|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
219451753|NCT02432911|DRUG|low dose cytarabine|cytarabine 20mg bid for 10 days.
219451754|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
219451755|NCT00069251|DRUG|Bupropion|
219451756|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
219451757|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
219451758|NCT03934515|OTHER|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values."
219451759|NCT03934515|OTHER|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values."
219451760|NCT00118924|BIOLOGICAL|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
219451761|NCT00118924|BIOLOGICAL|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
219451762|NCT00765830|DRUG|vildagliptin|50mg qd
219451763|NCT00765830|DRUG|Placebo|qd
219451764|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
219451765|NCT02045979|DRUG|BI 695501|BI 695501 single s.c. injection
219451766|NCT02045979|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
219451767|NCT02045979|DRUG|adalimumab-US source|adalimumab-US source single s.c. injection.
218841830|NCT05126030|DEVICE|Topaz TTVR System|Transcatheter tricuspid heart valve replacement
218841831|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
218841832|NCT02756962|DRUG|Cytarabine|
218841833|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
219451768|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
219451769|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
219451770|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
219451771|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
219451772|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
219451773|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
219451774|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
219451775|NCT03196206|DRUG|BMS-986177|Oral Suspension
219451776|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
219451777|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
219451778|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
219451779|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
219451780|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
219451781|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
219451782|NCT02086760|RADIATION|Scintigraphy|
219451783|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
219451784|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
219451785|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
219451786|NCT02447393|DRUG|levocetirizine|levocetirizine
218841834|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
219451787|NCT02447393|DRUG|cetirizine|cetiridine
219451788|NCT02447393|DRUG|placebo|placebo
219451789|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
219451790|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
219451791|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
219451792|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
218841835|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
218841836|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
218841837|NCT04829643|DIAGNOSTIC_TEST|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
218841838|NCT06282471|BEHAVIORAL|Expressive Writing and Problem-Solving Therapy (EW+PST)|Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
218841839|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
218841840|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
218841841|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
218841842|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
218841843|NCT03530995|DRUG|Belumosudil|Development candidate
218841844|NCT03530995|DRUG|Itraconazole|Perpetrator drug
219451793|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
219451794|NCT04124952|DEVICE|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
218841845|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
218841846|NCT03530995|DRUG|Rifampicin|Perpetrator drug
218841847|NCT03530995|DRUG|Omeprazole|Perpetrator drug
218841848|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
218841849|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
218841850|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
219196841|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
219196842|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
219196843|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
219451795|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
219451796|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
219588325|NCT00372411|OTHER|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
219451797|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
219451798|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
219451799|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
219588326|NCT00372411|OTHER|Usual Care|The usual chronic stroke care as delivered at each participating medical center
218841851|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
218841852|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
218841853|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
218841854|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
218841855|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
218841856|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
218841857|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
219451800|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
219588327|NCT03070587|BEHAVIORAL|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
219588328|NCT05159167|OTHER|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
219588329|NCT05001217|DRUG|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
219588330|NCT05001217|DRUG|Chinese herbal medicine treatment|"1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction"
219451801|NCT00421616|BEHAVIORAL|High protein diet study|
219451802|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
219451803|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
219451804|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
219451805|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
219451806|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
219451807|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
219451808|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
219451809|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
219451810|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
219451811|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
219451812|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
219451813|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
219588331|NCT01915758|DRUG|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
219588332|NCT01915758|DRUG|vehicle gel|vehicle gel
219588333|NCT01028924|DRUG|Teduglutide|subcutaneous (SC), single dose
219588334|NCT00052299|DRUG|cytarabine|
219588335|NCT00052299|DRUG|etoposide|
219588336|NCT00052299|DRUG|gemtuzumab ozogamicin|
219588337|NCT00052299|DRUG|idarubicin|
219588338|NCT00052299|DRUG|mitoxantrone hydrochloride|
219588339|NCT03047629|DRUG|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
219588340|NCT03047629|OTHER|Placebo|Daily dosing with a placebo
218841858|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
219588341|NCT04590040|OTHER|Placebo|0% nano-HAP toothpaste
219588342|NCT04590040|DEVICE|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
219588343|NCT04590040|DEVICE|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
219588344|NCT03916029|BEHAVIORAL|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
219588345|NCT03268707|DEVICE|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
219588346|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
219588347|NCT04539327|DRUG|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
219588348|NCT02056912|GENETIC|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
219588349|NCT02056912|BIOLOGICAL|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
219588350|NCT06028880|BEHAVIORAL|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
219588351|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
218841859|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
219017775|NCT06084611|DEVICE|Provox Life|Compliant use of Provox Life HMEs
219588352|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
219588353|NCT05458882|BEHAVIORAL|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
219588354|NCT01404286|BEHAVIORAL|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
219588355|NCT04660240|DEVICE|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
219588356|NCT04660240|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
219588357|NCT04545320|BEHAVIORAL|Usual care control group|Health education
219588358|NCT04545320|BEHAVIORAL|HIIT group|Once-a-week HIIT
219588359|NCT04545320|BEHAVIORAL|MICT group|Once-a-week MICT
219588360|NCT01284361|DEVICE|30 cm Intermittent Catheter|Randomized cross-over
219588361|NCT01284361|DEVICE|40 cm Intermittent Catheter|randomized cross-over
219588362|NCT05830344|DEVICE|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
219588363|NCT05830344|DEVICE|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
219588364|NCT04905940|DRUG|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
219451814|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
219451815|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
219451816|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 0|10 (8-12) x 10\^6 MSCs
219451817|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 1|20 (16-24) x 10\^6
219451818|NCT03750344|DEVICE|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
219451819|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
219451820|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
219451821|NCT02094612|DEVICE|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
219451822|NCT02094612|BEHAVIORAL|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
219588365|NCT05279911|RADIATION|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode \[Ga-Al-As\]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
219588366|NCT05907239|DEVICE|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
219588367|NCT05907239|DEVICE|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
219588368|NCT04003896|DRUG|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
219588369|NCT01843738|RADIATION|Radiation therapy|Per standard of care
219588370|NCT01843738|DRUG|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
218841860|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
219451823|NCT05929937|DRUG|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
219451824|NCT05929937|OTHER|No opioids|Standard of care, patients will not receive a prescription for opioids.
219588371|NCT02274506|DRUG|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
219588372|NCT02274506|DRUG|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
219588373|NCT02274506|PROCEDURE|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
219588374|NCT03104478|PROCEDURE|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
219588375|NCT05861297|DRUG|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
219588376|NCT05861297|DRUG|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
219588377|NCT05861297|DRUG|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
218841861|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
218841862|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
219451825|NCT03261037|OTHER|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
219451826|NCT03261037|OTHER|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
219451827|NCT03261037|OTHER|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
219451828|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
219451829|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
219451830|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
219588378|NCT05861297|DRUG|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
219588379|NCT05861297|DRUG|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
219588380|NCT01957397|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
219588381|NCT01957397|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
219588382|NCT01957397|DEVICE|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
218841863|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
218841864|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
218841865|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
218841866|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
218841867|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
218841868|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
219451831|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
219451832|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
219451833|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
219588383|NCT01857141|DRUG|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
219588384|NCT01857141|DRUG|normal saline|patients in the control groups received the equivalent volume of normal saline.
219588385|NCT03043404|DEVICE|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
219588386|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
219588387|NCT00324649|DRUG|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
219588388|NCT00324649|DRUG|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
219588389|NCT05721287|DRUG|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
219588390|NCT05721287|DRUG|Placebo|Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
219451834|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
219451835|NCT04708769|BEHAVIORAL|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
219451836|NCT04708769|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
219451837|NCT01355224|GENETIC|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
219451838|NCT01355224|BEHAVIORAL|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
219451839|NCT05422690|DRUG|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
219451840|NCT05422690|RADIATION|Concurrent Y-90 treatment|Patients will undergo a Y-90 treatment planning consultation by the treating interventional radiologist during cycle 1. One or two cycles (depending on tumor size) of cisplatin, 25 mg/m2 and gemcitabine 300 mg/m2 given on day 1 and day 8 in combination with Yttrium-90 (Y-90) microspheres which will be given on day 3-7 or day 10-21 at the discretion of the interventional radiologist, separated in time by at least 2 days from a chemo infusion during that cycle
219451841|NCT05422690|DRUG|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
219451842|NCT04576663|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
219451843|NCT04576663|DRUG|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
219451844|NCT03537001|OTHER|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
219451845|NCT06491992|DRUG|Chitosan Phonophresis|Chitosan Phonophresis, three times per week for four weeks.
219451846|NCT06491992|OTHER|selected physical therapy exercise|selected neck exercise and electrotherapy on cervical region
219451847|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
219588391|NCT01185197|DRUG|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
219588392|NCT01185197|DRUG|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
219451848|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
219588393|NCT01006798|OTHER|Placebo|enteric coated capsule containing no vaccine virus
219588394|NCT01006798|BIOLOGICAL|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
219451849|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
219451850|NCT05522543|OTHER|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
219451851|NCT05522543|OTHER|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
219588395|NCT01006798|BIOLOGICAL|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
219588396|NCT01988129|OTHER|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
219588397|NCT04848922|OTHER|Hot shower intervention|Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
218841869|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
218841870|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
218841871|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
218841872|NCT00168636|DRUG|Vitamin A|
218841873|NCT01772524|BIOLOGICAL|ALD403|
218841874|NCT01772524|DRUG|Placebo|
218841875|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
218841876|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
218841877|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
219588398|NCT05552079|OTHER|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
219588399|NCT05968599|DRUG|Enzalutamide|As provided in real-world setting
219588400|NCT05968599|DRUG|Abiraterone acetate|As provided in real-world setting
218841878|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
218841879|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
218841880|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
218841881|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
218841882|NCT00408382|DRUG|atorvastatin, Lipitor|
218841883|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
218841884|NCT00789594|BEHAVIORAL|Result management module|Result management module
218841885|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
218841886|NCT03673085|DRUG|CN128|CN128
218841887|NCT03673085|OTHER|placebo|The tablets without CN128
218841888|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
218841889|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
218841890|NCT04458441|OTHER|warm group/cold group|sequential randomization
219451852|NCT02373891|DRUG|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
219451853|NCT02373891|DRUG|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
219451854|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
219451855|NCT02085486|OTHER|Standard|Standard inspection, palpation.
219451856|NCT05211973|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
219451857|NCT05211973|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
219451858|NCT05211973|DEVICE|Chair Scale|a wheel-chair compatible scale to measure body weight
219451859|NCT05211973|DEVICE|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
219451860|NCT05211973|DEVICE|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
219451861|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
219451862|NCT00470873|DRUG|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
219451863|NCT04725604|DEVICE|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
219451864|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
219451865|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
219451866|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
219451867|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
219451868|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
219451869|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
219451870|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
219451871|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
219451872|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
219451873|NCT02023892|DRUG|atorvastatin|
219451874|NCT02023892|DRUG|placebo|
219451875|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
219451876|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
219451877|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
219451878|NCT04838340|OTHER|Standart care|This group will leave in the hospital's usual care and no intervention will be applied.
219588401|NCT00027248|DRUG|MBI 226|
219588402|NCT04901169|DRUG|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
219451879|NCT04838340|BEHAVIORAL|Hypnobirthig training|"Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor."
219451880|NCT03760302|OTHER|analgesics|analgesics given to a patient treated from HEMS
219451881|NCT03760302|OTHER|hypnotics|hypnotics given to a patient treated from HEMS
219451882|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
219451883|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
219451884|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
219451885|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
219451886|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
219451887|NCT03033992|DEVICE|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
219588403|NCT04901169|DRUG|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
218841891|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
219451888|NCT03033992|COMBINATION_PRODUCT|Concurrent Optune and RT followed by Optune System alone|In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
219451889|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219451890|NCT06538389|DRUG|BRC-001|Given PO
219451891|NCT06538389|DRUG|Placebo Administration|Given PO
219451892|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
219451893|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
219451894|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
219451895|NCT06377605|PROCEDURE|ESPB|the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
219588404|NCT04713553|BIOLOGICAL|BNT162b2|Intramuscular injection
219588405|NCT04713553|BIOLOGICAL|BNT162b2.B.1.351|Intramuscular injection
219588406|NCT04060030|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
218841892|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
218841893|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
218841894|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
218841895|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
218841896|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
218841897|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
218841898|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
219451896|NCT06377605|PROCEDURE|local anaesthetic infiltration|the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
219451897|NCT06377605|DRUG|midazolam and lidocaine|midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
219451898|NCT06377605|DRUG|Bupivacain|bupivacaine infiltration
219451899|NCT00911183|BIOLOGICAL|filgrastim|Given subcutaneously
219451900|NCT00911183|BIOLOGICAL|pegfilgrastim|Given subcutaneously
219451901|NCT00911183|BIOLOGICAL|rituximab|Given IV
219451902|NCT00911183|DRUG|cyclophosphamide|Given IV
219451903|NCT00911183|DRUG|liposome-encapsulated doxorubicin citrate|Given IV
219451904|NCT00911183|DRUG|prednisone|Given orally
219451905|NCT00911183|DRUG|vincristine sulfate|Given IV
219451906|NCT04654468|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight between 40 and 100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100 kg) or 1020 mg SC (for participants with body weight ≥ 100 kg). Dosing schedule will be as described above.
219588407|NCT04060030|OTHER|Placebo|Placebo
219588408|NCT00810316|DRUG|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
219588409|NCT00810316|DRUG|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
219588410|NCT00810316|DRUG|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
219451907|NCT05852925|OTHER|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
219451908|NCT05852925|DEVICE|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
219451909|NCT03803553|DRUG|FOLFIRI Protocol|FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
219451910|NCT03803553|OTHER|ACTIVE SURVEILLANCE|Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
219451911|NCT03803553|DRUG|Nivolumab Protocol|Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.
219451912|NCT03803553|DRUG|Encorafenib/Binimetinib/Cetuximab Protocol|Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.
219451913|NCT03803553|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
219451914|NCT03900026|DRUG|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
219451915|NCT03900026|OTHER|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
219451916|NCT05741346|DRUG|BCX9930|Taken orally at 400 mg twice daily (BID)
219451917|NCT06530927|DIAGNOSTIC_TEST|3D rotational digital tomography|DHTM is label-free and records the phase shift of low-energy light passing through the specimen on a transparent surface with minimal perturbation. DHTM measures the refractive index (RI) and computes the refractive index gradient (RIG), unveiling optical heterogeneity in cells. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots.
219588411|NCT01235832|OTHER|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
219588412|NCT01235832|OTHER|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
219588413|NCT01235832|OTHER|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
219588414|NCT05117983|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
219588415|NCT03967171|OTHER|before uterine incision oxytocin|blood loss during elective cesarean section
218841899|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
219451918|NCT06530927|DIAGNOSTIC_TEST|Atomic Force Microscopy|The atomic force microscope (AFM) is widely used in materials science and has found many applications in biological sciences but has been limited in use in vision science. The AFM can be used to image the topography of soft biological materials in their native environments. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots
219588416|NCT03967171|OTHER|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
218841900|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
218841901|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
218841902|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
218841903|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
218841904|NCT03379857|OTHER|Drug urinal test|Non Applicable
218841905|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
218841906|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
218841907|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
218841908|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
218841909|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
219017782|NCT03914794|DRUG|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
219588417|NCT01853930|BEHAVIORAL|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
219588418|NCT00459121|DRUG|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
219588419|NCT00459121|DRUG|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
219588420|NCT00459121|DRUG|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
219588421|NCT00459121|PROCEDURE|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
219588422|NCT02315196|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
219588423|NCT02315196|DRUG|epirubicin hydrochloride|Given IV
219588424|NCT02315196|DRUG|carboplatin|Given IV
219588425|NCT02315196|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
219588426|NCT02315196|DRUG|paclitaxel|Given IV
219588427|NCT02315196|OTHER|laboratory biomarker analysis|Correlative studies
219588428|NCT02315196|OTHER|quality-of-life assessment|Ancillary studies
219588429|NCT05484037|OTHER|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
218841910|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
219451919|NCT06530927|DIAGNOSTIC_TEST|Micro-Computertomography|"Micro-CT is a 3D imaging technique utilizing X-rays to see inside an object, slice by slice. Micro-CT, also called microtomography or micro computed tomography, is similar to hospital CT or CAT scan imaging but on a small scale with greatly increased resolution. Samples can be imaged with pixel sizes as small as 100 nanometers and objects can be scanned as large as 200 millimeters in diameter. We will use micro-CT to analyze blood clots from patients with large vessel occlusion."
219451920|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
219451921|NCT05994482|OTHER|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
219451922|NCT05994482|OTHER|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
219451923|NCT05994482|OTHER|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
219451924|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
219451925|NCT06127173|OTHER|Positive End Expiratory Pressure PEEP|children will receive different levels of PEEP during induction of anesthesia
219451926|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
219451927|NCT02749552|BEHAVIORAL|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
219451928|NCT00081263|DRUG|Celecoxib|Given orally
218841911|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
219451929|NCT00081263|OTHER|Laboratory Biomarker Analysis|Correlative studies
219451930|NCT00081263|OTHER|Placebo|Given orally
219451931|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
219451932|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
219451933|NCT02912572|DRUG|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
219451934|NCT02912572|DRUG|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
219451935|NCT02912572|DRUG|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
219451936|NCT06216964|DIAGNOSTIC_TEST|Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)|Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
218841912|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
219451937|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
218841913|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
218841914|NCT01097265|DRUG|capecitabine|
218841915|NCT01097265|DRUG|oxaliplatin|
218841916|NCT01097265|OTHER|active surveillance|
218841917|NCT01097265|OTHER|laboratory biomarker analysis|
218841918|NCT01097265|PROCEDURE|adjuvant therapy|
218841919|NCT01097265|PROCEDURE|lymph node mapping|
218841920|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
219451938|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
219451939|NCT05018208|OTHER|Computer-Assisted Intervention|Use smartphone app
219451940|NCT05018208|PROCEDURE|Patient Monitoring|Wear Biofourmis wearable device(s)
219451941|NCT05018208|OTHER|Questionnaire Administration|Complete questionnaires
219451942|NCT03467516|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
219451943|NCT06549400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
219588430|NCT03058094|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
219588431|NCT03058094|DRUG|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
219451944|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
219451945|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
219451946|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
219451947|NCT05219955|BEHAVIORAL|Morning Action Plan Execution|Each day, participants are asked to track if they do the morning activity plan.
219451948|NCT05219955|BEHAVIORAL|Activity Strategy-based Session with Therapist|Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
219451949|NCT05219955|BEHAVIORAL|Attention-based Session with Therapist|Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
219451950|NCT05219955|BEHAVIORAL|Advance sleep-wake time|Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
219451953|NCT04757220|OTHER|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
219451954|NCT06060561|OTHER|Non-Interventional Study|Non-interventional study
219451955|NCT04931251|BEHAVIORAL|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
219451956|NCT05690256|BEHAVIORAL|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
219451957|NCT05690256|BEHAVIORAL|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
218841921|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
219588432|NCT03058094|DRUG|AC0010|300mg, orally, BID
219588433|NCT04770467|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
219588434|NCT04770467|DRUG|Placebo|Placebo given by intravenous administration
219588435|NCT04164225|BEHAVIORAL|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
219588436|NCT04164225|BEHAVIORAL|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
219588437|NCT05974436|OTHER|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
218841922|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
218841923|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
218841924|NCT02557100|DRUG|Abatacept|
218841925|NCT02557100|DRUG|Adalimumab|
219451958|NCT06171945|BEHAVIORAL|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
219451959|NCT06171945|BEHAVIORAL|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
219451960|NCT06171945|BEHAVIORAL|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
219451961|NCT01381731|DRUG|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
219451962|NCT01381731|DRUG|placebo|opthalmic solution 2 drops in each eye QID
219451963|NCT04564027|DRUG|Ceralasertib|Tablets will be administered orally
219451964|NCT05292521|OTHER|Best Practice|Receive usual care
219451965|NCT05292521|OTHER|Informational Intervention|Receive QOL fact sheet
219451966|NCT05292521|OTHER|Questionnaire Administration|Ancillary studies
219451967|NCT06578819|BEHAVIORAL|doll therapy|Doll therapy applied to the experimental group 4 days a week.
219451968|NCT00777036|DRUG|Dasatinib|
219451969|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
219451970|NCT06436534|DRUG|Ganciclovir Oral Capsule|2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
219451971|NCT06436534|DRUG|Ganciclovir Simulant Oral Capsule|2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
218841926|NCT02557100|DRUG|Methotrexate|
218841927|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
218841928|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
218841929|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
218841930|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
218841931|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
218841932|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
218841933|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
218841934|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
219451972|NCT06436534|DRUG|Mometasone Nasal|From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
219451973|NCT05346536|OTHER|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
219451974|NCT01267955|OTHER|Laboratory Biomarker Analysis|Correlative studies
219451975|NCT01267955|OTHER|Pharmacogenomic Study|Correlative studies
219451976|NCT01267955|DRUG|Vismodegib|Given PO
218841935|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
218841936|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
218841937|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
218841938|NCT00616811|DRUG|vildagliptin|
218841939|NCT00616811|DRUG|Sitagliptin|
219451977|NCT04334109|BEHAVIORAL|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
218841940|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
218841941|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
218841942|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
219451978|NCT04334109|BEHAVIORAL|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
219451979|NCT03801083|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
219451980|NCT05465538|DRUG|[11C]UCB-J PET|Single PET scan using the radioligand \[11C\]UCB-J
219451981|NCT03534453|DRUG|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
219451982|NCT06194929|DRUG|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
219588438|NCT03924206|DEVICE|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
219588439|NCT00246142|BIOLOGICAL|Botulinum toxin type A|
219588440|NCT04764136|DEVICE|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
219588441|NCT04098289|PROCEDURE|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
219588442|NCT04098289|PROCEDURE|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
219588443|NCT04917289|DRUG|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
219588444|NCT05539430|BIOLOGICAL|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
219588445|NCT01366430|PROCEDURE|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
219451983|NCT06194929|DRUG|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
219451984|NCT06194929|DRUG|Encorafenib|Encorafinib administered orally per arm description.
219451985|NCT05920343|DRUG|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
219451986|NCT05920343|OTHER|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
219588446|NCT01366430|PROCEDURE|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
218841943|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
218841944|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
218841945|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
219451987|NCT05868668|DEVICE|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
219451988|NCT05868668|DEVICE|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
219451989|NCT05868668|DEVICE|Sham treatment|Handheld sham probe
219451990|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 1
219451991|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 3
219451992|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
219451993|NCT04003649|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
219451994|NCT04003649|BIOLOGICAL|Ipilimumab|Given IV
219451995|NCT04003649|BIOLOGICAL|Nivolumab|Given IV
219451996|NCT04003649|OTHER|Quality-of-Life Assessment|Ancillary studies
219451997|NCT04003649|OTHER|Questionnaire Administration|Ancillary studies
219451998|NCT04278235|DRUG|Elezanumab|Solution for intravenous (IV) infusion
219451999|NCT05814042|DRUG|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
219452000|NCT05814042|DRUG|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
219452001|NCT05827978|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219452002|NCT05827978|BIOLOGICAL|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
219452003|NCT06524908|BEHAVIORAL|Exercise and dietary calorie restriction|The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
219452004|NCT06065449|DRUG|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
219588447|NCT01366430|PROCEDURE|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
219588448|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
218841946|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
219017783|NCT06151223|OTHER|Bio-specimen Collection: Blood|At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.
219017784|NCT06151223|OTHER|Bio-specimen Collection: Pancreatic Juice|This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.
219452005|NCT04651777|DRUG|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
219452006|NCT04566445|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
219452007|NCT02421939|DRUG|gilteritinib|tablet, oral
219452008|NCT02421939|DRUG|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
219452009|NCT02421939|DRUG|Azacitidine|SC or IV injection
219452010|NCT02421939|DRUG|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
219452011|NCT02421939|DRUG|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
219452012|NCT03336606|DRUG|MEDI0562|Surgical resection of tumor
219452013|NCT04752228|OTHER|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
219588449|NCT01397643|OTHER|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
219588450|NCT01045538|DRUG|Vorinostat, capecitabine, and cisplatin|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
218841947|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
218841948|NCT01314170|DEVICE|Susanna Implant|device
218841949|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
218841950|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
218841951|NCT01511614|DEVICE|sham|Sham Comparator
218841952|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
218841953|NCT01511614|DRUG|Placebo patch|Nicotine deprived
218841954|NCT01511614|DRUG|Varenicline Pill|Treatment
218841955|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
219452014|NCT04752228|OTHER|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
219452015|NCT00579462|OTHER|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
219452016|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
219588451|NCT05408234|OTHER|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
219588452|NCT02879734|OTHER|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
219588453|NCT03219619|DEVICE|Cap-EGD|Undergoing cap-assisted endoscopy
219588454|NCT03219619|DEVICE|Duo|Undergoing side-viewing duodenoscope
219588455|NCT03555006|OTHER|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
219017785|NCT06151223|DIAGNOSTIC_TEST|MRI|"A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia/anxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.~Clinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.~If a clinical MRI/MRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI/MRCP could be used to obtain baseline imaging data."
219588456|NCT03555006|OTHER|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
219588457|NCT02730117|DEVICE|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
219588458|NCT02730117|DEVICE|Mechanical ventilator|Invasive or noninvasive form of respiratory support
219588459|NCT02730117|DRUG|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
219588460|NCT02730117|DRUG|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
219017788|NCT05051475|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
219452017|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
219588461|NCT01310270|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
219588462|NCT01310270|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|4.4 gm/day for 1 month
218841956|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
218841957|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
218841958|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
218841959|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
218841960|NCT00489424|DRUG|Placebo|
218841961|NCT00489424|DRUG|Acetaminophen|
218841962|NCT00489424|DRUG|Fluvastatin|
218841963|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
218841964|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
218841965|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
218841966|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
218841967|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
219452018|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
219452019|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
219452020|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
219452021|NCT03140033|DRUG|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
219452022|NCT03140033|DRUG|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
219452023|NCT03606707|DRUG|Steroids|intra-articular steroid injection for atlantoaxial joint
219452024|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
219452025|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
219452026|NCT03072368|OTHER|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
219452027|NCT00729560|DRUG|Flutamide|250 mg twice daily for 4 weeks
219452028|NCT00729560|DRUG|Placebo|Placebo twice daily for 4 weeks
219588463|NCT02984085|DRUG|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
218841968|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
219588464|NCT04918498|BEHAVIORAL|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
219588465|NCT04918498|BEHAVIORAL|routine treatment|provide routine nursing and rehabilitation program
219452029|NCT04709094|DRUG|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
219452030|NCT04709094|DRUG|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
219452031|NCT04709094|DRUG|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
219588466|NCT02212613|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
218841969|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
218841970|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
218841971|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
218841972|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
219017789|NCT05051475|PROCEDURE|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
219588467|NCT00095316|DRUG|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
218841973|NCT04612348|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound to measure gastric contents.
218841974|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
218841975|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
218841976|NCT06376669|RADIATION|Proton Stereotactic Body Radiation therapy (SBRT)|Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks
219452032|NCT04709094|DRUG|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
219452033|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
219452034|NCT00249522|BEHAVIORAL|Contingency management|
219588468|NCT00095316|OTHER|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
219588469|NCT00527553|DIETARY_SUPPLEMENT|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
219588470|NCT00527553|DIETARY_SUPPLEMENT|lutein|daily lutein enriched egg
219588471|NCT00527553|DIETARY_SUPPLEMENT|zeaxanthin|daily zeaxanthin enriched egg
219588472|NCT00527553|DIETARY_SUPPLEMENT|egg product from enriched eggs|daily egg product from lutein enriched eggs
219588473|NCT05727371|COMBINATION_PRODUCT|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
219588474|NCT05727371|DEVICE|Hylan G-F 20|Single intra-articular injection at Day 0
219588475|NCT05727371|DRUG|Placebo|Single intra-articular injection at Day 0
219588476|NCT05645159|OTHER|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
219588477|NCT03849287|DRUG|CKD-333, formula I|Test drug
218841977|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
218841978|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
218841979|NCT02733822|DRUG|Naloxone|
218841980|NCT01696994|OTHER|Laboratory Biomarker Analysis|Correlative studies
218841981|NCT01696994|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
218841982|NCT01696994|PROCEDURE|Ultrasound Imaging|Undergo TVU
218841983|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
218841984|NCT05438719|DEVICE|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
219452035|NCT01732133|DEVICE|Nexfin|
219452036|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
219452037|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
219452038|NCT01256957|DEVICE|HEPA filter|
219588478|NCT03849287|DRUG|CKD-333, formula II|Test drug
219588479|NCT03849287|DRUG|CKD-330, D090|Reference Drug
219588480|NCT02107365|DRUG|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
219588481|NCT02107365|DRUG|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
219588482|NCT02107365|DRUG|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
219588483|NCT02107365|DRUG|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
219588484|NCT03453801|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
219588485|NCT03453801|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
219588486|NCT01348412|DRUG|oxaliplatin|130 mg/m²Every 21 days
219588487|NCT01348412|DRUG|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
219588488|NCT01348412|DRUG|other intravenous chemotherapy drugs|
219588489|NCT02976324|DEVICE|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
219588490|NCT02459535|OTHER|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
219588491|NCT02459535|OTHER|oral stimulation saccharin|
219452039|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
219452040|NCT00172003|DRUG|Zoledronic acid|
219452041|NCT00103207|BIOLOGICAL|cetuximab|
219452042|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
219452043|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
219452044|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
219452045|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
219452046|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
219588492|NCT02459535|OTHER|oral stimulation aspartame|
218841985|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
218841986|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
218841987|NCT00368680|DEVICE|Early Bubble CPAP|
218841988|NCT04682223|BEHAVIORAL|Semantically-focused therapy tasks|1\) Semantic feature analysis (SFA; Boyle \& Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis \& Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
219452047|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
218841989|NCT04682223|BEHAVIORAL|Phonologically-focused therapy tasks|1\) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
219452048|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
219588493|NCT02459535|OTHER|oral stimulation sucralose|
219588494|NCT00010621|PROCEDURE|Acupuncture|
219588495|NCT00010621|PROCEDURE|chiropractic therapy|
219588496|NCT00010621|PROCEDURE|bodywork therapy|
219588497|NCT00054808|DRUG|gallium nitrate|
219588498|NCT03908879|PROCEDURE|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
218841990|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
219452049|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
219452050|NCT06022432|OTHER|Video of a patients testimonial|The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.
219452051|NCT06022432|OTHER|Writing Task|Participants write freely about their current treatment expectations / apprehensions to seek treatment
219588499|NCT03908879|PROCEDURE|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
218841991|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
218841992|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
219588500|NCT03908879|PROCEDURE|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
219588501|NCT00735306|DRUG|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
219588502|NCT00735306|DRUG|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
219588503|NCT00735306|RADIATION|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
219588504|NCT05228028|PROCEDURE|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
219588505|NCT05228028|PROCEDURE|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
219588506|NCT00054665|DRUG|PS-341|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
219588507|NCT00054665|DRUG|Etoposide|50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
218841993|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
218841994|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
218841995|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
219452052|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
219452053|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
219452054|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
219452055|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
219588508|NCT00054665|DRUG|Doxorubicin|10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
219588509|NCT00054665|DRUG|Vincristine|0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
219588510|NCT00054665|DRUG|Cyclophosphamide|750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
219588511|NCT00054665|DRUG|Prednisone|60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
219588512|NCT00054665|DRUG|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
219588513|NCT04181073|DEVICE|Jet Nebuliser|Jet Nebuliser
218841996|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
218841997|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
218841998|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
218841999|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
218842000|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
218842001|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
218842002|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
218842003|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
218842004|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
218842005|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
218842006|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
218842007|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
218842008|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
218842009|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
218842010|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
218842011|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
219452056|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
219452057|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
219452058|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
219452059|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
219452060|NCT03662789|DRUG|Iron Isomaltoside 1000|Intravenous infusion
219452061|NCT03662789|OTHER|Placebo: NaCl 0,9%|Intravenous infusion
219452062|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
219452063|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
219452064|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
219588514|NCT04181073|DEVICE|Vibrating Mesh Nebuliser|Aerogen Device
219588515|NCT06574360|DRUG|S1RA plus NMDAE|Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
219452065|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
219452066|NCT05103631|GENETIC|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219588516|NCT06574360|DRUG|S1RA plus Placebo Cap|Use of an S1R agonist plus placebo as a comparator
218842012|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
218842013|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
218842014|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
218842015|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
218842016|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
218842017|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
218842018|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
219588517|NCT06621004|DRUG|Patients will receive propranolol 1-2 mg.|Patients will receive propranolol 1-2 mg. prepared in a 10 ml syringe (100 ug/ml).
219588518|NCT06621004|DRUG|Patient receives magnesium sulphate|Magnesium sulphate 10%: 1g ampoule (10ml), will be prepared in a syringe pump to be given at a rate of 40 ml/hr . Another syringe of 10 ml 0.9% sodium chloride will be prepared to be given in group (P).
219588519|NCT05485701|DIAGNOSTIC_TEST|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
218842019|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
218842020|NCT02926027|DRUG|placebo|placebo
218842021|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
218842022|NCT02377752|DRUG|Doxorubicin|Administered IV
218842023|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
218842024|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
218842025|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
218842026|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
218842027|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
218842028|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
218842029|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
218842030|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
219452067|NCT06647433|OTHER|Observation|case study will be observed participants, methods will include observation, interview and video reflexive ethnography
219452068|NCT03602235|OTHER|Ascorbate|Ascorbate is in the vitamin drug class
219452069|NCT03602235|DRUG|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
219588520|NCT01243112|DRUG|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
219588521|NCT01243112|DRUG|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
219588522|NCT01243112|DRUG|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
218842031|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
218842032|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
219588523|NCT01243112|DRUG|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
219588524|NCT04892225|BEHAVIORAL|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
218842033|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
219452070|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
219452071|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
219452072|NCT00486590|PROCEDURE|Prolact-Plus Human Milk Fortifier|
219588525|NCT03824496|DIAGNOSTIC_TEST|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
219588526|NCT01001624|OTHER|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
219588527|NCT01001624|OTHER|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
219588528|NCT01081834|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
219588529|NCT01081834|DRUG|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
219588530|NCT01081834|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
219588531|NCT02444117|OTHER|functional rehabilitation of social communication|
219452073|NCT03447067|PROCEDURE|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
219452074|NCT03447067|PROCEDURE|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
219452075|NCT03447067|DEVICE|CBCT|For measuring the bone removeal
219452076|NCT03447067|DEVICE|CBCT|for identifed the nerve
219452077|NCT05655416|PROCEDURE|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
219452078|NCT01023516|DRUG|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
219588532|NCT01118897|RADIATION|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
219588533|NCT03710993|DEVICE|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
219588534|NCT04389892|DIAGNOSTIC_TEST|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
219588535|NCT02621749|DEVICE|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
218842034|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
218842035|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
219588536|NCT01001988|OTHER|Blood sample|Blood sample for immunogenicity assessment
219588537|NCT01001988|BIOLOGICAL|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
218842036|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
218842037|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
218842038|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
218842039|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
218842040|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
218842041|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
218842042|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
218842043|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
219452079|NCT01023516|DRUG|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
219452080|NCT02559115|RADIATION|68Ga-RM2 (RM2)|
219452081|NCT02559115|DEVICE|PET/CT Scan|
219452082|NCT05060081|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
219452083|NCT05060081|OTHER|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
219452084|NCT03617471|PROCEDURE|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
219452085|NCT03330093|BEHAVIORAL|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
219452086|NCT03330093|BEHAVIORAL|Health and Safety Intervention|In-person, family-based behavioral intervention
218842044|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
218842045|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
218842046|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
218842047|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
218842048|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
219452087|NCT06138704|PROCEDURE|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
219588538|NCT03908515|DEVICE|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
218842049|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
219588539|NCT03340207|DEVICE|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
219588540|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
219588541|NCT02465294|BEHAVIORAL|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
218842050|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
218842051|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
218842052|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
218842053|NCT01222091|DRUG|Placebo to Match Propranolol|
218842054|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
218842055|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
219588542|NCT02465294|OTHER|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
219588543|NCT02465294|OTHER|Blood Test|All subjects will have blood tests performed.
219588544|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
219588545|NCT01345916|DRUG|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
219588546|NCT01345916|DRUG|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
219588547|NCT01345916|DRUG|BDP DPI 2 months|BDP DPI 2 months
219588548|NCT01420471|DRUG|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
219588549|NCT01420471|OTHER|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
219588550|NCT00002393|DRUG|Indinavir sulfate|
219588551|NCT00002393|DRUG|Efavirenz|
219588552|NCT00150761|DRUG|Levocetirizine (drug)|
219588553|NCT02665845|DRUG|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
219588554|NCT02665845|DRUG|Corticosteroids|Corticosteroids will be given to all patients.
219588555|NCT04618783|BIOLOGICAL|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
219588556|NCT04618783|BIOLOGICAL|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
218842056|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
219452088|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
219452089|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
219452090|NCT00369564|OTHER|placebo|Given orally 3 times daily
219452091|NCT04507516|OTHER|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
219452092|NCT00002274|DRUG|Didanosine|
219452093|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
219452094|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
219452095|NCT02060903|DRUG|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
219452096|NCT02060903|DRUG|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
219452097|NCT05576415|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
219452098|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
219588557|NCT04618783|BIOLOGICAL|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
219588558|NCT04618783|BIOLOGICAL|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
219588559|NCT04618783|BIOLOGICAL|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
218842057|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
218842058|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
218842059|NCT00395187|PROCEDURE|Photodynamic Therapy|
218842060|NCT01280058|DRUG|Carboplatin|Given IV
219588560|NCT04204291|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
219588561|NCT01565057|OTHER|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
219588562|NCT03351465|BEHAVIORAL|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
218842061|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
218842062|NCT01280058|DRUG|Paclitaxel|Given IV
218842063|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
219452099|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
219452100|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
219452101|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
218842064|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
218842065|NCT05985993|DEVICE|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
218842066|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
219452102|NCT02400840|PROCEDURE|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
219452103|NCT02400840|DRUG|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
219452104|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
219452105|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
219452106|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
219452107|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
219588563|NCT04201691|OTHER|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
218842067|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
219452108|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
219452109|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
219452110|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
219452111|NCT06445400|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219452112|NCT06445400|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
219452113|NCT06445400|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
219452114|NCT03445962|DIAGNOSTIC_TEST|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity"
219452115|NCT03501979|DRUG|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
219452116|NCT03501979|DRUG|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
219452117|NCT03501979|DRUG|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
219452118|NCT06804811|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219452119|NCT06804811|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
219452120|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
219588564|NCT04201691|OTHER|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
219588565|NCT02425163|DEVICE|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
219588566|NCT02425163|PROCEDURE|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
219588567|NCT04951986|DRUG|Rifampin|Rifampicin up to 35 mg/kg/day for 14 days
219588568|NCT04951986|DRUG|Levofloxacin|Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days
219452121|NCT05448807|DRUG|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
219452122|NCT06624150|DEVICE|Active tDCS sessions, StarStim device|10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
219452123|NCT06624150|DEVICE|Sham (fake) tDCS sessions|10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
219588569|NCT04951986|DRUG|Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
219588570|NCT04951986|DRUG|Prednisone|Prednisone 1.5mg/kg/day for 14 days
219588571|NCT04951986|DRUG|Placebo|Placebo identical to Prednisone
219588572|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 1
219588573|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 2
219588574|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 3
219588575|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 4
219588576|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 5
218842068|NCT05433441|PROCEDURE|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
218842069|NCT06554886|DEVICE|Cryoneurolysis|Cryoneurolysis
218860033|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
219588577|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 6
219588578|NCT04187339|OTHER|Placebo|Placebo
219452124|NCT06574555|DRUG|Norepinephrine|"The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30."
219452125|NCT04332848|DRUG|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
219452126|NCT04332848|DRUG|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
219452127|NCT05501457|DEVICE|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
219452128|NCT04106180|DRUG|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
219452129|NCT04106180|DRUG|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
219452130|NCT04106180|RADIATION|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
219452131|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
219452132|NCT06358430|DRUG|Cyclophosphamide|Given by IV
219452133|NCT06358430|DRUG|Cetuximab|Given by IV
219452134|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
219452135|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
219452136|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
219452137|NCT03993119|DRUG|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
219452138|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
219452139|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
219452140|NCT05029193|BEHAVIORAL|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
219452141|NCT06069999|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
219452142|NCT06202027|DRUG|FGF23-related hypophosphataemic rickets and osteomalacia|FGF23-related hypophosphataemic rickets and osteomalacia
219452143|NCT05398068|OTHER|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
219452144|NCT05398068|OTHER|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
219452145|NCT05664126|DRUG|VST infusion|single intravenous (IV) infusion.
219452146|NCT05664126|DEVICE|CliniMACS|Cells infusions are prepared using the ClinMACS
219452147|NCT05889273|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
219452148|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
219452149|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
219452150|NCT06980181|OTHER|Graded Motor Imagery|Graded Motor Imagery typically 1 to 3 times per day for 5 to 10 minutes for each phase. No physical movement at first only cognitive task, mental rehearsal and visual motor.
219588579|NCT04604886|DIAGNOSTIC_TEST|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
219588580|NCT04604886|DIAGNOSTIC_TEST|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
219588581|NCT03902886|DIAGNOSTIC_TEST|gait analysis|gait analysis using an optoelectronic system and a surface EMG
219588582|NCT05502081|DRUG|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
219588583|NCT05502081|DRUG|Remdesivir|antiviral drug
219588584|NCT05502081|DRUG|Favipiravir|antiviral drug
219588585|NCT00176423|DRUG|galantamine|see arm/group description
219452151|NCT06980181|OTHER|Mirror Therapy|Mirror Therapy typically involves 1 to 3 sessions per day for 10 to 15 minutes gradually increases as tolerated.Visual and motor training using a mirror placed at the midline.
219452152|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
219452153|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
219452154|NCT06647485|PROCEDURE|PF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only PF energy for ablation
219452155|NCT06647485|PROCEDURE|Hybrid PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing both PF and RF energy for ablation. Specifically, PF energy is used for the posterior segments and RF energy for the anterior segments of the pulmonary veins
219452156|NCT06647485|PROCEDURE|RF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only RF energy for ablation
219452157|NCT06599073|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest
219017798|NCT03282266|PROCEDURE|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
219452158|NCT06599073|DEVICE|Rescue|RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
219452159|NCT04173481|OTHER|Rood's Group|"ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
219452160|NCT04173481|OTHER|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
219452161|NCT06981741|BIOLOGICAL|BP CC 001|10-20 x 10\^6 UC-MSC in 1 ml suspension, applied to a collagen carrier structure (Chondro-Gide®)
219452162|NCT00367627|DRUG|Albendazole|
219452163|NCT01756365|PROCEDURE|Surgical transplantation of ACCE|The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
219452164|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
219452165|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
219452166|NCT02204111|OTHER|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
219452167|NCT05529862|GENETIC|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
219452168|NCT05529862|GENETIC|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
219452169|NCT05529862|GENETIC|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
219452170|NCT05529862|GENETIC|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
219452171|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
219452172|NCT00681902|DRUG|Placebo|Jet saline
219452173|NCT06594627|DEVICE|Smart pillow|Utilize a smart pillow that is designed to reduce snoring issues and OSA symptoms during sleep
219017799|NCT03282266|PROCEDURE|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
219017800|NCT05511792|PROCEDURE|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
219452174|NCT06662994|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
219588586|NCT04538625|DRUG|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
219588587|NCT04538625|DRUG|Placebo|Matching placebo tablets
219588588|NCT05452122|OTHER|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
219588589|NCT02556463|DRUG|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
219017801|NCT05511792|PROCEDURE|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
219017802|NCT04124406|DEVICE|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
219452175|NCT06490536|DRUG|Oxaliplatin|"Oxaliplatin is used as part of the chemotherapy regimens for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Oxaliplatin 130 mg/m² is given intravenously on day 1, in combination with capecitabine 1000 mg/m² taken orally twice daily on days 1-14 of each 21-day cycle.~FOLFOX Regimen: Oxaliplatin 85 mg/m² is administered intravenously on day 1, alongside folinic acid 400 mg/m² and fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~Dosages are standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
219452176|NCT06490536|DRUG|Capecitabine|"Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months."
219588590|NCT02556463|BIOLOGICAL|durvalumab|Subjects will receive durvalumab every 4 weeks
219588591|NCT02397187|BEHAVIORAL|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
219588592|NCT02529644|BEHAVIORAL|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
219588593|NCT02529644|BEHAVIORAL|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
219452177|NCT06490536|DRUG|Folinic acid|"Folinic acid is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1, in combination with oxaliplatin 85 mg/m² IV on day 1 and fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of folinic acid is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
219452178|NCT06490536|DRUG|Fluorouracil|"Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results."
219588594|NCT04492644|OTHER|No intervention|No intervention
219588595|NCT05523024|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
219196844|NCT03958539|DEVICE|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
219196845|NCT00560118|DRUG|fotemustine|
218842070|NCT06836245|OTHER|Measure the patient's body temperature intraoperatively using instruments|"1. Core Body Temperature Measurement:~   Nasopharyngeal Temperature Probe: Insert the probe into the patient's nasal cavity to measure the temperature of the nasopharynx.~   Esophageal Probe: Insert the probe through the esophagus to measure the temperature of the lower esophagus.~   Bladder Temperature Probe: Insert the probe into the bladder to measure the temperature of the urine.~   Tympanic Temperature Probe: Place the probe in the ear canal to measure the temperature near the tympanic membrane.~2. Peripheral Body Temperature Measurement:~Axillary: Place the thermometer under the armpit, suitable for routine temperature monitoring, but may not be as accurate as core temperature measurement.~Oral: Place the thermometer under the tongue, suitable for conscious and cooperative patients.~Rectal: Insert the thermometer into the rectum to provide an accurate temperature measurement, but may not be suitable for all patients, especially those with rectal diseases or immunosuppressed conditions."
218842071|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
218842072|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
219017803|NCT05301998|OTHER|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
219017804|NCT02680821|PROCEDURE|ALL reconstruction (Anterolateral ligament)|
219017805|NCT02680821|PROCEDURE|ACL revision (Anterior cruciate ligament )|
219452179|NCT06490536|DRUG|Temozolomide|"Temozolomide is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial, specifically for those with MGMT-negative tumors. It is administered in the following way:~TEMIRI Regimen: Temozolomide 150-200 mg/m² is taken orally once daily on days 1-5 of each 28-day cycle, in combination with irinotecan 250 mg/m² administered intravenously on day 1 of each cycle.~The dosage of temozolomide is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452180|NCT06490536|DRUG|Irinotecan|"Irinotecan is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~TEMIRI Regimen: Irinotecan 250 mg/m² is administered intravenously on day 1 of each 28-day cycle, in combination with temozolomide 150-200 mg/m² taken orally once daily on days 1-5.~FOLFIRI Regimen: Irinotecan 180 mg/m² is given intravenously on day 1, in combination with folinic acid (leucovorin) 400 mg/m² IV, fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of irinotecan is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452181|NCT06490536|DRUG|Nivolumab|"Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452182|NCT06490536|DRUG|Ipilimumab|"Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219588596|NCT05523024|DIETARY_SUPPLEMENT|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
219588597|NCT05523024|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
219017806|NCT04830202|DRUG|Telisotuzumab vedotin|Intravenous Infusion
219588598|NCT05523024|DIETARY_SUPPLEMENT|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
219588599|NCT00462124|DEVICE|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
219588600|NCT06505941|DRUG|umbilical cord mesenchymal stem cell|umbilical cord mesenchymal stem cell
219588601|NCT06505941|DRUG|Placebo|non-cell-containing placebo
219588602|NCT01329549|DRUG|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
219588603|NCT01329549|DRUG|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
219588604|NCT01329549|DRUG|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
219588605|NCT03337243|PROCEDURE|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
219588606|NCT05054478|DRUG|Daratumumab|Daratumumab added to induction, first consolidation and second consolidation
219452183|NCT06490536|DRUG|Trastuzumab|"Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452184|NCT06490536|DRUG|Pertuzumab|"Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452185|NCT06490536|DRUG|Panitumumab|"Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
219452186|NCT02324036|DEVICE|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
219452187|NCT02324036|BEHAVIORAL|Coached Care|Community health worker provides participation training to patient
219452188|NCT00941707|DRUG|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
219452189|NCT00941707|DRUG|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
218842073|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
218842074|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
219452190|NCT00608491|DRUG|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
219452191|NCT00608491|DEVICE|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
219452192|NCT04717050|BEHAVIORAL|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
219452193|NCT04717050|BEHAVIORAL|Attention Control (AC)|12 month stretching program
219452194|NCT03648411|GENETIC|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
219588607|NCT06549283|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation|Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
219452195|NCT00592072|DIETARY_SUPPLEMENT|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
218842076|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
219452196|NCT00592072|OTHER|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
219588608|NCT00788320|DRUG|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
219588609|NCT00788320|DRUG|Placebo|Placebo three times a week for 8 weeks
219588610|NCT06625567|OTHER|Animated video|Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
218842077|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
218842078|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
218842079|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
218842080|NCT01918605|DEVICE|Diluted spacer|
219452197|NCT01047462|PROCEDURE|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
218842081|NCT01918605|DEVICE|Non-diluted spacer|
218842082|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
218842083|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
218842084|NCT05594225|BEHAVIORAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
218842085|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
218842086|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
218842087|NCT04882878|OTHER|Placebo|Placebo will be administered intravenously.
218842088|NCT04882878|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
218842089|NCT04882878|DRUG|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
218842090|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
218842091|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
218842092|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
219452198|NCT03148899|DRUG|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
219452199|NCT03148899|DRUG|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
219452200|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
219588611|NCT06252220|DRUG|DA-1726|Active
219588612|NCT06252220|DRUG|Placebo to DA-1726|Placebo
219588613|NCT02264912|DRUG|antiplatelet drugs - P2Y12 antagonists|
219588614|NCT02208739|PROCEDURE|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
219588615|NCT02208739|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
219588616|NCT05174195|DRUG|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
219588617|NCT05174195|DRUG|Implanon NXT® subdermal implant|Inserted immediately
219588618|NCT04890912|RADIATION|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
218842093|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
219588619|NCT04890912|RADIATION|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
219588620|NCT03271723|OTHER|Observational study|No intervention
219588621|NCT05546008|DEVICE|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
219588622|NCT02904824|BIOLOGICAL|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
218842094|NCT02314156|OTHER|Placebo|Given PO
218842095|NCT02314156|DRUG|Telapristone Acetate|Given PO
218842096|NCT02314156|OTHER|Placebo|Given transdermally
218842097|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
218842098|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
218842099|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
219452201|NCT03644316|DEVICE|BandGrip skin closure device|topical skin closure device
219452202|NCT03678506|DRUG|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
218842100|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
218842101|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
219452203|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
219452204|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
219452205|NCT03160066|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
219452206|NCT03160066|DIETARY_SUPPLEMENT|Placebo|Placebo
219452207|NCT01738594|DRUG|carfilzomib|Given IV
219452208|NCT01738594|DRUG|romidepsin|Given IV
219452209|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
219452210|NCT01481428|BEHAVIORAL|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
219452211|NCT01481428|BEHAVIORAL|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
219452212|NCT03510728|BEHAVIORAL|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
219452213|NCT03510728|BEHAVIORAL|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
219452214|NCT03510728|BEHAVIORAL|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
219452215|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
219452216|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
219452217|NCT05130229|BEHAVIORAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
219452218|NCT05620485|PROCEDURE|laparoscopic-assisted CDC excision and hepaticojejunostomy|After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
219452219|NCT06594185|DEVICE|enVista Aspire EA or Aspire Toric ETA IOLs|enVista Aspire EA or Aspire Toric ETA IOLs
219588623|NCT02904824|BIOLOGICAL|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
219588624|NCT05019599|OTHER|low protein diet|Low protein diet (\<0.8g/kg/BW/day)
219588625|NCT04371094|DEVICE|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
219452220|NCT06864650|OTHER|Ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
219452221|NCT06864650|OTHER|exercise program|stretching exercises strengthening exercises waist exercises core exercises relaxation exercises
219588626|NCT06175988|OTHER|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
219588627|NCT02609074|PROCEDURE|Minimally invasive internal fixation surgeries|
219588628|NCT02609074|DEVICE|CPC/rhBMP-2 micro-scaffolds|
219588629|NCT02609074|DEVICE|CPC paste|
219588630|NCT05580965|OTHER|20 N pressure for 1 minute|After blood collection, 20 N pressure applied for 1 minute
219588631|NCT05580965|OTHER|20 N pressure for 3 minute|After blood collection, 20 N pressure applied for 3 minute
219588632|NCT05580965|OTHER|20 N pressure for 5 minute|After blood collection, 20 N pressure applied for 5 minute
219588633|NCT04163510|BEHAVIORAL|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
219588634|NCT05324410|DRUG|VX-840|Solution for oral administration.
219588635|NCT05324410|DRUG|Placebo|Placebo matched to VX-840 for oral administration.
219452222|NCT07000162|RADIATION|Lattice radiation therapy|"A total dose will be 20 Gy, with a simultaneous boost to selected tumor regions (hot spots) reaching a minimum median dose of 50 Gy.~Peripheral blood (PB) samples for the immune cell characterization and quantification of immune-related circulating factors will be collected at baseline (pre-therapy) and within 7 -14 days after the end of the treatment (post-therapy)."
218842102|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
219452223|NCT06204926|DIAGNOSTIC_TEST|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
219452224|NCT06001892|BEHAVIORAL|Tennessee Youth Prepared for Success|both 5 day classroom interventions.
218842103|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
219452225|NCT07009119|PROCEDURE|laparoscopic Pancreaticoduodenectomy|The patient is positioned in French position (right arm in, left arm abducted 90°), with a suprapubic area reserved for Pfannenstiel incision. A 6-port technique is used: sub-umbilical (12 mm), four semi-circular trocars (two 12 mm, two 5 mm), and a sub-xiphoid trocar for liver retraction. Laparoscopic pancreaticoduodenectomy (LPD) proceeds if no vascular invasion/metastasis is found. Key steps include Kocher's maneuver, vessel ligation (gastroepiploic, gastric, gastroduodenal), lymphadenectomy (stations 5-17), pancreatic neck transection, and jejunal division. Reconstruction involves duct-to-mucosa pancreaticojejunostomy (or invaginating if duct unfound), hepaticojejunostomy, and stapled gastrojejunostomy. Margins are examined post-resection. Harmonic scalpel/Ligasure and staplers are used.
219452226|NCT04655963|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
219452227|NCT06627816|DRUG|Nefopam|efficacy of 3 drugs in preventing post-spinal anesthesia shivering
219452228|NCT01368952|DEVICE|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
219452229|NCT04192760|PROCEDURE|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
219452230|NCT06043934|OTHER|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
219452231|NCT06043934|OTHER|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
219452232|NCT02758912|DRUG|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
219588636|NCT02421224|BEHAVIORAL|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
219588637|NCT02421224|BEHAVIORAL|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
219588638|NCT02421224|BEHAVIORAL|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
219588639|NCT02421224|BEHAVIORAL|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
218842104|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
218842105|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
218842106|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
218842107|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
218842108|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
218842109|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
219452233|NCT04720560|DIAGNOSTIC_TEST|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
218842110|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
218842111|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
219452234|NCT00215189|BEHAVIORAL|In SHAPE (Pilot Health Promotion Intervention)|
219452235|NCT02120560|PROCEDURE|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
219452236|NCT03374436|BEHAVIORAL|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
219452237|NCT03374436|BEHAVIORAL|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
219452238|NCT03374436|BEHAVIORAL|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
219452239|NCT01503619|OTHER|laboratory biomarker analysis|Correlative studies
219452240|NCT05856279|PROCEDURE|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
219452241|NCT00810251|DEVICE|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
219452242|NCT07020702|DEVICE|Implantation of an ICD|Implantation of an ICD
219588640|NCT02421224|BEHAVIORAL|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
219588641|NCT02421224|BEHAVIORAL|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
219588642|NCT05969249|DEVICE|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
218842112|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
219452243|NCT03435276|DRUG|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
219452244|NCT03435276|OTHER|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
219196846|NCT06411054|DEVICE|Acu-TENS|After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
218842115|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
218842116|NCT02088879|BEHAVIORAL|chest compression with standing position|
219452245|NCT05381389|DRUG|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
219452246|NCT05381389|DRUG|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
219452247|NCT04568876|DIETARY_SUPPLEMENT|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
219452248|NCT04568876|COMBINATION_PRODUCT|Standard Therapy|Standard therapy established for individual patients
219452249|NCT06245304|DEVICE|Dual chamber Medtronic pacemaker implantation.|"All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830."
219452250|NCT06245304|OTHER|DDD-50 pacing program|This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
219452251|NCT06245304|OTHER|AAI-DDD 50 pacing program|This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
219452252|NCT01159886|PROCEDURE|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
219452253|NCT06144567|DRUG|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
219452254|NCT02315417|DRUG|gevokizumab|
219452255|NCT02315417|DRUG|Placebo|
218842117|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
218842118|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
218842119|NCT02846389|OTHER|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
218842120|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
218842121|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
218842122|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
218842123|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
219452256|NCT02315417|DRUG|gevokizumab open-label|
219452257|NCT00366938|DRUG|Lumiracoxib|
219452258|NCT03228849|PROCEDURE|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
218842124|NCT04425967|RADIATION|pre-operative radiotherapy|pre-operative radiotherapy
219452259|NCT03228849|PROCEDURE|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
218842125|NCT05962242|RADIATION|Radiation Therapy|External Beam Radiation to Head and Neck
218842126|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
218842127|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
218842128|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
218842129|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
218842130|NCT04071262|DRUG|Abemaciclib|Administered orally
218842131|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
218842132|NCT04071262|DRUG|Prednisolone|Administered orally
218842133|NCT01598883|DRUG|Heparin|150 U/kg
218842134|NCT01598883|DRUG|ATryn|1000 IU
219452260|NCT04101370|DRUG|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
218842135|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
218842136|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
219452261|NCT04101370|DRUG|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
219452262|NCT03527303|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
219452263|NCT04173403|DRUG|450mg AK102|AK102 Q4W
219452264|NCT04173403|DRUG|300mg AK102|AK102 Q4W
219452265|NCT04173403|DRUG|150mg AK102|AK102 Q2W
219452266|NCT04173403|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
219452267|NCT02031627|DEVICE|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
219452268|NCT02031627|DEVICE|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM \& PM (2 hours)
219452269|NCT02031627|DEVICE|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
219452270|NCT00906334|DRUG|ON 01910.Na|The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
219452271|NCT00906334|DRUG|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
219452272|NCT00373464|DRUG|etoricoxib|
219452273|NCT01925482|DRUG|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
219452274|NCT01925482|DRUG|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
219452275|NCT01925482|DRUG|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
218842137|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
218842138|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
219452276|NCT01925482|DRUG|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
219452277|NCT01925482|DRUG|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
219452278|NCT01925482|DRUG|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
219452279|NCT02094625|DRUG|N-Acetylcysteine|"NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
219452280|NCT00044694|DRUG|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
219452281|NCT00044694|DRUG|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
219452282|NCT00044694|DRUG|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
219452283|NCT00044694|DRUG|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
219452284|NCT00044694|DRUG|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
219452285|NCT00044694|DRUG|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
219452286|NCT00044694|DRUG|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
219452287|NCT00044694|DRUG|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
219452288|NCT01804660|OTHER|No study treatments administered|
219452289|NCT02377076|DIETARY_SUPPLEMENT|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
219452290|NCT02377076|DIETARY_SUPPLEMENT|Control|Control (Whey protein, vitamin D, sugar and salt)
219452291|NCT05375240|DRUG|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
219452292|NCT05375240|DRUG|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
219452293|NCT03193944|DRUG|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
219452294|NCT03193944|DRUG|Placebo vitamin D3|vitamin D as a placebo
219452295|NCT00484367|BEHAVIORAL|Adolescent group therapy|Adolescent group therapy
219452296|NCT00484367|BEHAVIORAL|Transitional family therapy|Transitional family therapy
219452297|NCT05007340|OTHER|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
219452298|NCT05007340|OTHER|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
219452299|NCT05007340|OTHER|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
219452300|NCT05007340|OTHER|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
219452301|NCT00928304|DRUG|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
219452302|NCT03402360|OTHER|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
219452303|NCT03402360|OTHER|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
219452304|NCT01386229|DRUG|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
219452305|NCT01386229|DRUG|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
219452306|NCT03622216|DRUG|Bradanicline|Three different doses over the course of the study
219588643|NCT03451552|BEHAVIORAL|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
219452307|NCT03622216|DRUG|Placebo|Matching placebo for Bradanicline
219452308|NCT03131011|OTHER|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
219452309|NCT04222257|DRUG|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
219452310|NCT04222257|DRUG|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
219452311|NCT06331273|PROCEDURE|"Liver transplantation with No-touch technique"|"The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues."
219452312|NCT00004889|BIOLOGICAL|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
219588644|NCT01114100|DRUG|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
218842139|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
219452313|NCT00824967|OTHER|Training and valuation of the treating personnel|Training and valuation of the treating personnel
219452314|NCT02545972|DRUG|tacrolimus extended release|daily dosing of tacrolimus
218842140|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
218842141|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
219452315|NCT01761942|DIETARY_SUPPLEMENT|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
219452316|NCT01512329|BEHAVIORAL|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
219452317|NCT01512329|BEHAVIORAL|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
219452318|NCT02825940|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
219452319|NCT02825940|DRUG|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.
219452320|NCT02825940|DRUG|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
219452321|NCT00576368|DRUG|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
219452322|NCT03942172|DEVICE|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
219452323|NCT02812615|DIETARY_SUPPLEMENT|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
219452324|NCT02812615|DIETARY_SUPPLEMENT|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
219452325|NCT02812615|DRUG|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
219452326|NCT02812615|BEHAVIORAL|Nutritional counselling|Parents/caregivers will be given nutritional counselling
219452327|NCT02812615|DIETARY_SUPPLEMENT|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
219452328|NCT02237898|BEHAVIORAL|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
219452329|NCT02237898|BEHAVIORAL|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
219452330|NCT02237898|DEVICE|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
219452331|NCT02237898|DEVICE|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
219452332|NCT00442130|BIOLOGICAL|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
219452333|NCT00442130|PROCEDURE|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
219452334|NCT06330766|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
219452335|NCT04884386|DEVICE|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
219452336|NCT04884386|BEHAVIORAL|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
219452337|NCT04432181|OTHER|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
218842142|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
219452338|NCT04261218|DRUG|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
219452339|NCT04261218|DRUG|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
219452340|NCT05557136|DEVICE|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
218842143|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
218842144|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
219452341|NCT05557136|DEVICE|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
219452342|NCT00057928|DRUG|cisplatin|
219452343|NCT00057928|DRUG|gemcitabine hydrochloride|
219452344|NCT00057928|DRUG|paclitaxel|
219452345|NCT01186315|BEHAVIORAL|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
219452346|NCT01186315|BEHAVIORAL|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
219452347|NCT03846076|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
219452348|NCT04864327|BEHAVIORAL|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
219452349|NCT06156462|DEVICE|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
219452350|NCT05708729|DEVICE|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
219452351|NCT05708729|DEVICE|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
219452352|NCT01855867|DRUG|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
219452353|NCT06691698|OTHER|The Cognitive Orientation to Daily Occupational Performance Approach|CO-OP is a client-centred, performance-based, problem-solving focused, occupation-focused and occupation-based intervention. In CO-OP the person is guided to use a meta-cognitive strategy to find his or her own strategies for specific activities. The main purpose is to enable meta-cognitive thinking in every day activities, leading to enhanced self-efficacy, occupational performance and independency.
219452354|NCT00182234|BEHAVIORAL|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
219452355|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
219452356|NCT00678249|PROCEDURE|PTA|Percutaneous Transluminal Angioplasty
219452357|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
219452358|NCT01572636|DRUG|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
219452359|NCT03828864|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
219452360|NCT03828864|DEVICE|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
219452361|NCT03458403|PROCEDURE|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
219452362|NCT02920879|PROCEDURE|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
219452363|NCT02052908|OTHER|Laboratory Biomarker Analysis|Correlative studies
219452364|NCT02052908|DRUG|Naproxen|Given PO
218842145|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
218842146|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
218842147|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
219452365|NCT02052908|OTHER|Placebo Administration|Given PO
218842148|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
218842149|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
219452366|NCT01708915|DRUG|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
219452367|NCT01708915|DRUG|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
219452368|NCT01708915|DRUG|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
219588645|NCT01114100|DRUG|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
219588646|NCT03597529|DRUG|Melatonin|melatonin
219588647|NCT01683292|DRUG|Inhaled VR040|
219588648|NCT01683292|DRUG|Placebo for VR040|Placebo arm
218842150|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
218842151|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
219452369|NCT01708915|DRUG|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
219452370|NCT02907411|OTHER|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
219452371|NCT02171156|DRUG|nintedanib|soft gelatin capsule
219452372|NCT00108615|DRUG|Metformin|
219452373|NCT00108615|DRUG|Pioglitazone|
219452374|NCT00108615|DRUG|Metformin|
219452375|NCT00108615|DRUG|Pioglitazone|
219452376|NCT00108615|RADIATION|CT scans|To measure changes in adipose tissue volumes
219452377|NCT00108615|PROCEDURE|Oral glucose tolerance test|To detect a change in glucose tolerance
219452378|NCT02072733|OTHER|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
219452379|NCT02802657|PROCEDURE|Treat-and-Extend regimen|For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
219588649|NCT03680989|DEVICE|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~10,000 lux at 22."
219588650|NCT03680989|DEVICE|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~500 lux at 22."
219588651|NCT04876365|OTHER|Non-Interventional|This is a Non-Interventional Study.
218842152|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
218842153|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
218842154|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
218842155|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
218842156|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
218842157|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
218842158|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
218842159|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
219588652|NCT00381160|BEHAVIORAL|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
219588653|NCT06194760|PROCEDURE|Vitrectomy with ILM peeling|Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
219588654|NCT00916760|BIOLOGICAL|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
219588655|NCT00916760|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
219588656|NCT03769714|DRUG|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
219452380|NCT02802657|PROCEDURE|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
219452381|NCT02802657|DRUG|Conbercept|
219452382|NCT04742140|DRUG|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
219452383|NCT04742140|DRUG|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
219452384|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
219452385|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
219452386|NCT03414268|OTHER|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
219452387|NCT03414268|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
219452388|NCT04272762|PROCEDURE|Cryoablation|Pulmonary vein isolation with cryoablation
219452389|NCT04272762|PROCEDURE|Placebo|Placebo procedure
219452390|NCT04892394|OTHER|Information Types Before Endodontic Treatment|The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
218842160|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
218842161|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
218842162|NCT00057733|PROCEDURE|psychosocial assessment and care|
218842163|NCT00057733|PROCEDURE|quality-of-life assessment|
218842164|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
218842165|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
218842166|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
218842167|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
218842168|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
218842169|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
219452391|NCT00353340|DRUG|n acetylcysteine|
219452392|NCT00353340|DRUG|sodium bicarbonate|
219452393|NCT00353340|DRUG|sodium chloride|
219452394|NCT06412640|DRUG|Keverprazan|Potassium-competitive acid blocker
219452395|NCT06412640|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219452396|NCT05699044|DIAGNOSTIC_TEST|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
219452397|NCT01432938|BIOLOGICAL|dulaglutide|Administered subcutaneously
219452398|NCT01432938|DRUG|Warfarin|Administered orally
219588657|NCT03769714|DRUG|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
219588658|NCT05412238|DIETARY_SUPPLEMENT|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
219588659|NCT01140399|DRUG|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
219588660|NCT01140399|DEVICE|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
219588661|NCT04191850|PROCEDURE|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
219588662|NCT02538380|PROCEDURE|EUS-B-FNA followed by EUS-FNA for LAG analysis|
219588663|NCT03819894|DIAGNOSTIC_TEST|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
219588664|NCT05205343|OTHER|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
219588665|NCT05205343|OTHER|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
219588666|NCT00401609|DRUG|gemcitabine|
218842170|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
219452399|NCT04951817|DRUG|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
219452400|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
219452401|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
219452402|NCT07028385|DRUG|Bariticinib 2 mg|Commercially available tablets containing 2 mg of barticiinib will be used. The tablets will be re-capsulated to keep the study blind.
219452403|NCT07028385|OTHER|Placebo|Maltodextrin capsules with identical weight and appearance (shape, size, colour and flavour) as the bariticinib-containing capsules.
219452404|NCT06564051|OTHER|Non-Interventional Study|Non-interventional study
219452405|NCT07063277|DEVICE|Preoperative Evaluation with ORI and Spirometry|"All participants in this single-arm diagnostic study will undergo preoperative evaluation involving two non-invasive respiratory assessment methods: the Oxygen Reserve Index (ORI) and spirometry. ORI will be measured using a multi-wavelength pulse co-oximetry sensor placed on the patient's fingertip. This sensor provides a continuous, real-time index (ranging from 0.00 to 1.00) that reflects the patient's oxygen reserve within a PaO₂ range of approximately 100-200 mmHg.~Spirometry will be performed using standard pulmonary function testing protocols. Each patient will be instructed to perform forced expiratory maneuvers to obtain parameters including forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and the FEV₁/FVC ratio. These values will be recorded prior to surgery and interpreted according to internationally accepted reference ranges."
219588667|NCT00401609|DRUG|vinorelbine|
219588668|NCT00401609|DRUG|cisplatin|
219588669|NCT00401609|DRUG|etoposide|
219588670|NCT00401609|DRUG|carboplatin|
219588671|NCT00237653|DRUG|Valganciclovir|
219588672|NCT06453369|PROCEDURE|Y shaped Tunnel with Connective tissue graft|Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
219588673|NCT01755767|DRUG|Tivantinib|Tivantinib tablets
219588674|NCT01755767|DRUG|Placebo|Matching placebo tablets
219588675|NCT04665466|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
219588676|NCT02211196|BEHAVIORAL|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
219588677|NCT02211196|OTHER|survey administration|Ancillary studies
219588678|NCT02211196|OTHER|questionnaire administration|Ancillary studies
219452406|NCT07077460|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
219452407|NCT07077460|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is applied in Mirror therapy.
219452408|NCT07077460|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
219452409|NCT07077460|DEVICE|Graded-Pressure Haptic Device (Passive press-feedback cushion)|A passive press-feedback cushion (Graded-Pressure Haptic Device) would deliver force pulses to the subjects' non-dominant fingertips in synchrony with the TiPR game's force output (matched amplitude)
219452410|NCT07124117|DRUG|OBI-902|OBI-902 is an antibody-drug conjugate study drug
219452411|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
219452412|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
219452413|NCT05076760|DRUG|Docetaxel|75 mg/m2 intravenous administration every 3 weeks
219452414|NCT06313593|DRUG|INCB160058|Oral; Tablet
219452415|NCT06060613|BIOLOGICAL|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide."
219452416|NCT07091565|OTHER|Qualitative interview/Focus group|Participants will take part in a 1:1 interview or focus group
219452417|NCT07091344|BEHAVIORAL|VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments|"VR-Based Avatar Therapy is a 12-week intervention designed to help patients with psychosis manage distressing auditory hallucinations. The therapy consists of 7 individual sessions using virtual reality (VR) technology to externalize the auditory hallucinations, allowing patients to interact with a computer-generated avatar representing their dominant voice.~In addition to standard therapy, participants will undergo assessments of cognition, metacognition, and social cognition to explore their impact on treatment outcomes. These assessments include measures of emotion recognition, attributional style, theory of mind, cognitive flexibility, and trauma history. Sessions are conducted using VR headsets and noise-canceling headphones to enhance immersion, and patients receive ongoing therapeutic guidance throughout the process."
219452418|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
219452419|NCT07101770|OTHER|A combined retrospective and prospective observational follow-up|A combined retrospective and prospective observational follow-up
219452420|NCT07101718|OTHER|No intervention|No intervention
219452421|NCT07101666|RADIATION|Short course radiation therapy|25 Gy in 5 fractions
219452422|NCT07101666|DRUG|Standard of care neoadjuvant chemotherapy|Recommended options are CAPOX, FOLFOX, or FLOT but other standard of care chemotherapy may be given given at the discretion of the treating medical oncologist after consultation with the study Principal Investigator.
219452423|NCT07100860|PROCEDURE|One-Lung ventilation|In this observational study, the naturally occurring duration of intraoperative single-lung ventilation (SLV) during thoracic surgery will be recorded. No intervention is applied or modified for research purposes. The exposure of interest is the total duration (in minutes) of SLV, which will be timed from initiation to termination during surgery. This variable will be analyzed in relation to postoperative pulmonary complications.
219452424|NCT07100613|DRUG|Clobetasol Patch|A mucoadhesive patch containing clobetasol propionate 0.05%. Applied once daily for 30 days to the oral lesion.
219452425|NCT07100613|DRUG|Clobetasol + Resveratrol Patch|A mucoadhesive patch containing clobetasol propionate 0.05% and resveratrol. Applied once daily for 30 days to the oral lesion.
219452426|NCT07100613|DRUG|Clobetasol in Orabase|Clobetasol propionate 0.05% in orabase-type adhesive paste. Applied once daily for 30 days to the oral lesion.
219452427|NCT07100717|BEHAVIORAL|2-days workshop and self-mindfulness practices|Participants will attend 2-days face-to-face workshop on mindfulness-based self-care (MBSC) program. After the completion of the 2-days workshop, the participants will be required to complete self-mindfulness practices within a period of 4 weeks
219452428|NCT07100431|PROCEDURE|Articulating (experimental group)|1\. Surgical procedure On the day of surgery, random allocation to either the experimental or the control group will be perfored just before the start of the procedure. All of the surgery will be conducted laparoscopically. The control group will undergo surgery using a conventional straight laparoscopic instrument, while the experimental group will use an articulating instrument. The surgical procedure will be the same for both groups. The total time of surgery and the time spent on the supra-pancreatic lymph node dissection will be recorded during the procedure. The estimated blood loss during surgery will be also measured.
219588679|NCT04774744|OTHER|Educational Intervention|Receive digital health coaching program
219452429|NCT07100431|PROCEDURE|Control (control group)|"2\. Postoperative follow-up Patients participating in this study will have the same postoperative care as those not participating in this study. To compare the degree of pancreatic injury, amylase and lipase levels will be measured in the serum and the peritoneal fluid frome the drainage on postoperative days 1 and 3.~Postoperative complications will be classified and recorded according to the Clavien-Dindo classification for all complications occurring within 30 days after surgery. The dissected lymph nodes will be categorized by region, and the number of dissected lymph nodes will also be confirmed."
219588680|NCT04774744|OTHER|Questionnaire Administration|Ancillary studies
219588681|NCT04774744|OTHER|Supportive Care|Receive standard of care support services
219588682|NCT00191165|DRUG|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
219588683|NCT00191165|DRUG|Somatropin|In-label dosage
219588684|NCT03007238|BIOLOGICAL|Aldesleukin|Given SC
219588685|NCT03007238|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
219588686|NCT03007238|OTHER|Laboratory Biomarker Analysis|Correlative studies
219588687|NCT03007238|OTHER|Quality-of-Life Assessment|Ancillary studies
219588688|NCT01273896|DRUG|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
218842171|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
218842172|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
218842173|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
218842174|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
218842175|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
218842176|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
218842177|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
218842178|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
218842179|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
218842180|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
218842181|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
218842182|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
218842183|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
218842184|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
218842185|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
219452430|NCT07100548|BEHAVIORAL|"ich bin alles (English: I am everything)"|"The web-based information platform ich bin alles (www.ich-bin-alles.de) on depression and mental health in youth as well as its social media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the Ludwig-Maximilians-University Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e., short videos with overlays of text and music; https://www.instagram.com/ich.bin.alles/). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
219452431|NCT07100184|DRUG|Disitamab Vedotin combined with Radiotherapy|Disitamab Vedotin (RC-48) injection 2mg/kg, Q2w for 4 circles before radiotherapy and 2mg/kg, Q3w for 8 circles after radiotherapy; Radiotherapy (Whole bladder dose: 25 Gy in 5 doses, QD)
218842186|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
218842187|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
218842188|NCT00002540|OTHER|Laboratory Biomarker Analysis|Correlative studies
218842189|NCT00002540|PROCEDURE|Medical Examination Assessment|Undergo DRE
219452432|NCT07102550|BIOLOGICAL|MiMedx AmnioFix|MiMedx Amniofix to be placed on biliary anastomosis of the recipient during living donor liver transplant.
218842190|NCT00002540|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
218842191|NCT05903898|DEVICE|AI software StrokeSens (Circle NVI)|Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
218842192|NCT06471491|OTHER|Driving pressure-guided positive end-expiratory pressure|Driving pressure-guided positive end-expiratory pressure during the surgical procedure
218842193|NCT06189963|BIOLOGICAL|SNK01|SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
218842194|NCT06189963|OTHER|Placebo|Sodium Lactate Hartmann's Solution
218842195|NCT05312697|BIOLOGICAL|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
219452433|NCT07100795|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
219452434|NCT07100457|DIAGNOSTIC_TEST|Blood Biomarker Profiling and Prognostic Follow-up|Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.
219452435|NCT07101614|DRUG|JS004 in combination with toripalimab and chemotherapy|"BTLA inhibitor (JS004):200mg, IV infusion , d1, Q3W;(1-24 week)~Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
219452436|NCT07101614|DRUG|Toripalimab and chemotherapy|"Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
219452437|NCT07101614|DRUG|Chemotherapy|"Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
219452438|NCT07100652|PROCEDURE|Threshold FiO₂|"Group 1 (Intervention Group) received the initial dose of pulmonary surfactant immediately upon reaching an inhaled oxygen concentration (FiO₂) \>0.25.~Group 2 (Control Group) received the initial dose of pulmonary surfactant as early as possible within 48 hours, but only when FiO₂ was titrated to \>0.3 based on the infant's clinical condition."
219452439|NCT07114276|OTHER|Machine learning models predictions of acute kidney injury and acute kidney disease|Comparison of the performances of machine learning models and clinicians in predicting AKI within 14 days and AKD within 89 days
219452440|NCT07132489|DIAGNOSTIC_TEST|HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio|"1. To investigate whether the HbA1c to C-peptide ratio can serve as a predictive marker for no-reflow, reflecting the impact of chronic glycemic control and pancreatic beta-cell function.~2. To evaluate the neutrophil-to-HDL ratio as a potential indicator of no-reflow, representing the balance between systemic inflammation and endogenous vascular protection.~3. To examine the prognostic value of the albumin-bilirubin (ALBI) score in identifying patients at higher risk for no-reflow, considering the systemic influence of hepatic function and inflammation."
219452441|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
219452442|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
219452443|NCT05505669|OTHER|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
219452444|NCT07140224|OTHER|Korfball-Based Movement Training|"The weekly training content was structured as follows:~* Week 1: Chest pass, overhead pass, right-left hand pass, moving pass, cool-down (15 repetitions).~* Week 2: One-handed pass, penalty shot, defensive follow-up run, lay-up shot, cool-down (20 repetitions).~* Week 3: One-handed pass, diagonal passing, penalty shot, lay-up shot, short and long-distance shooting (25 repetitions).~* Week 4: Lay-up shot, V-cut shot, stationary short-distance shot, defensive follow-up run,penalty shot, cool-down (20 repetitions).~* Week 5: V-cut shot, stationary short-distance shot, front-of-the-basket shot, behind-the-basket short-distance shot (15 repetitions).~* Week 6: V-cut shot, lay-up shot, stationary shot, defensive follow-up run, penalty shot (20 repetitions).~* Week 7: One-handed pass, penalty shot, lay-up shot (right-left), shooting, V-cut shot (10 repetitions).~* Week 8: One-handed pass penalty shot, lay-up shot (right-left), stationary shot, V-cut shot (10 repetitions)."
219452445|NCT07137767|DEVICE|Quantitative refractive crosslinking|Non-invasive corneal crosslinking device delivering controlled UV light through a contact lens platform for refractive reshaping of the cornea.
219588689|NCT05690490|PROCEDURE|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
219196847|NCT06411054|DEVICE|Sham acu-TENS|"After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed)."
218842196|NCT06482671|DRUG|Rikkunshi-to|Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
218842197|NCT06482671|OTHER|Placebo|inactive drug, The matching placebo contains Corn Starch (vehicle), Lactose Hydrate (vehicle), Dextrin (vehicle), Magnesium Stearate (lubricant), FD\&C Blue No.1 Aluminum Lake (coloring agent), FD\&C Yellow No.5 Aluminum Lake (coloring agent), and Red Ferric Oxide (coloring agent).
218842198|NCT04869007|DEVICE|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
218842199|NCT05902910|DEVICE|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
219452446|NCT06939946|DEVICE|Parathyroid auto-fluorescence imaging|All enrolled patients for thyroid surgery, once the thyroid gland is removed the device will be used to identify the parathyroid glands.
219452447|NCT06939946|DRUG|Indocyanine green|For a select group of patients when deemed necessary by the surgeon, and when one or more parathyroid gland appear to be de vascularized ICG will be administered, A dosage of 5 mg will be injected into a peripheral IV line, followed by fluorescence imaging to determine the perfusion status of the gland.
219452448|NCT07148466|OTHER|Scapular PNF|scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment . It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
219452449|NCT07148466|OTHER|Conventional treatment|Conventional treatment. It includes closed kinematic chain exercises of upper limb, upper and lower extremity range of motion exercises, stretching and strengthening exercises for upper limb, trunk and lower limb, balance \& coordination, manual dexterity exercises (e.g., grasp release), and teaching of ADLs.. It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
219452450|NCT07149051|BEHAVIORAL|Gamified Sensory Integration Exercise Program|This study implemented a gamified physical activity intervention aimed at improving sensory integration abilities among first-grade students with sensory processing difficulties. The intervention program incorporated game narratives, mechanisms, and components into physical education activities, guided by the Octalysis Framework to strategically engage both extrinsic (e.g., rewards, rankings) and intrinsic (e.g., creativity, social interaction, meaning) motivational drives.
219452451|NCT07148843|DRUG|Cannabidiol (CBD)|Cannabidiol
219452452|NCT07148843|DRUG|Placebo|placebo
219452453|NCT07147491|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
219452454|NCT07147452|PROCEDURE|Dual tracer: The infiltration of the Supermagnetic Iron Oxide (SPIO) and Methylene Blue|"Participation in the study did not alter the indications or standard surgical technique. The only additional intervention consisted of intraoperative administration of SPIO, performed either laparoscopically or conventionally, as appropriate.~Immediately after removal of the surgical specimen : Submucosal instillation of methylene blue was then performed at the tumour periphery"
219452455|NCT07147452|DIAGNOSTIC_TEST|OSNA AND H-E|Analysed the performance of one-step nucleic acid amplification (OSNA) versus conventional histology and applied pooling analysis with OSNA in non-sentinel nodes
218842200|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
218842201|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
218842202|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
218842203|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
218842204|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
218842205|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
219017817|NCT02763917|DEVICE|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
219017818|NCT02763917|DEVICE|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
219452456|NCT07147179|RADIATION|Short Course Radiotherapy|Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions).
219452457|NCT07148453|OTHER|Experimental Group|The experimental group will receive training through a smartphone-based brain training program using the Lumosity app, as well as aerobic exercise on a bicycle ergometer for 18 sessions other days for 6 weeks, 3 times per week, every session for 40 minutes (20 minutes aerobic training on a stationary bicycle ergometer followed by 20 minutes for Lumosity training application on the smartphone).
219452458|NCT07148453|OTHER|Control Group|The control group will participate in aerobic training on a bicycle ergometer as well as mental exercises for 18 sessions every other day for 6 weeks, 3 sessions/week, each for 40 minutes
219452459|NCT07148258|OTHER|Project ImPACT Training As Usual|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The typical training model for Project ImPACT includes a 6-hour, interactive online tutorial that walks providers through the core Project ImPACT intervention strategies. After completing the online tutorial, providers attend a live interactive workshop virtually that is spread across 4, 3.5-hour days (14 hours total). Providers receive 1 hour of consultation once every other week for an hour from a trained Project ImPACT consultant (research staff member) following training."
219452460|NCT07148258|OTHER|Project ImPACT Training Plus Co-Production|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The second cohort for Project ImPACT training is a model in which providers receive the same typical Project ImPACT training activities, in addition to three supplemental modules on other common areas of concern for families and how best to integrate other topics within Project ImPACT to meet the diverse needs of families."
219452461|NCT07148258|BEHAVIORAL|Routine Project ImPACT|Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills. Project ImPACT is delivered with parents meeting once or twice each week for one hour over 12- 16 weeks. In each session, parents receive: 1) didactic instruction in intervention strategies; 2) modeling of the intervention techniques by the therapist; 3) live coaching from the therapist while practicing the strategies with their child; and 4) homework to practice the strategies at home with their child, 20 minutes each day across meaningful home routines.
219452462|NCT07147387|BEHAVIORAL|Lion Hearts Family-Based Physical Activity Program|The Lion Hearts Family-Based Physical Activity Program is a 12-week, community-based intervention designed to improve cardiovascular health and physical activity behaviors among mother-child dyads. The program consists of twice-weekly, 60-minute group exercise sessions delivered at local CrossFit affiliates. Each session includes scalable functional movement exercises, strength training, cardiovascular conditioning, and flexibility activities appropriate for both adults and children. In addition to physical activity, sessions incorporate goal-setting, family teamwork activities, and health education components to promote sustainable behavior change. The program was co-designed with community members during earlier study phases and is tailored to support engagement, feasibility, and family bonding.
219452463|NCT07147400|BIOLOGICAL|10µg of R21 with 50µg Matrix-M1|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
219588690|NCT05690490|PROCEDURE|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
219588691|NCT05340829|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
219588692|NCT01023048|OTHER|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
219588693|NCT00670202|DRUG|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
219588694|NCT00670202|DRUG|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
219588695|NCT00400699|OTHER|counseling intervention|
219588696|NCT00400699|OTHER|study of socioeconomic and demographic variables|
219588697|NCT00400699|PROCEDURE|psychosocial assessment and care|
218842206|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
219196848|NCT06817733|PROCEDURE|Transurethral Thermal Vaporization of the Prostate|After anesthesia, the patient is placed in the lithotomy position, and standard aseptic preparation and draping are performed. A cystoscope and a transrectal ultrasound (TRUS) probe are inserted. Following real-time image fusion and localization according to the preoperative plan, needles are inserted to deliver thermal vaporization to the prostate. Each needle treatment lasts 8 seconds, and the entire procedure is completed within 200 seconds after activation of the needle pathway.
218842207|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
218842208|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
218842209|NCT06424743|OTHER|exercise|exercise programs with different volumes
218842210|NCT05241691|DEVICE|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
218842211|NCT04445519|DRUG|NCX 470 0.065% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
218842212|NCT04445519|DRUG|Latanoprost 0.005% (initial phase of trial)|Latanoprost Ophthalmic Solution, 0.005%
219452464|NCT07147400|BIOLOGICAL|6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation|"R21 Malaria antigen is expressed in a recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.~Recombinant CRM197 is a recombinant protein, and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India.~Recombinant Pfs230D1M drug substance lots/batches of cGMP were manufactured using Hansenula Polymorpha and manufactured at the SIIPL.~A single vial coformulation containing 10µg R21 and 6µg Pfs230D1-CRM197 conjugate mixed with 50µg Matrix-M1 has been developed and is manufactured by SIIPL."
219452465|NCT07147400|BIOLOGICAL|RABIVAX-S|Sterile, purified inactivated rabies vaccine prepared on vero cells, indicated for the prevention of rabies in children and adults.
219452466|NCT07147400|BIOLOGICAL|Conjugated Pfs230D1 Vaccine (Pfs230D1-CRM197) For Bedside Mixing|"Recombinant Pfs230D1M drug substance lots/batches cGMP manufactured using Pichia pastoris manufactured at the Pilot Bioproduction Facility, Walter Reed Army Institute of Research (Silver Spring, Maryland), and at SIIPL respectively.~Recombinant CRM197 is a recombinant protein and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India."
219588698|NCT05705037|OTHER|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
219588699|NCT05705037|OTHER|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
219196849|NCT06589791|OTHER|No treatment given|Online self-completion survey
219196850|NCT06816914|DRUG|NALIRIFOX|Patient in upfront surgery arm will receive operation followed by adjuvant chemotherapy with NALIRIFOX; patient in experimental arm will receive neoadjuvant NALIRIFOX followed by operation than adjuvant NALIRIFOX after operation.
218842213|NCT04445519|DRUG|NCX 470 0.1% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.1%
218842214|NCT04445519|DRUG|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1%
218842215|NCT04445519|DRUG|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005%
219017823|NCT04562870|DRUG|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
219017824|NCT04562870|OTHER|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
219017826|NCT04378790|OTHER|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
219017827|NCT04378790|OTHER|Glasses|Eye Glasses are created and worn by patient to improve vision
218842216|NCT04254562|BEHAVIORAL|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
219452467|NCT07147400|BIOLOGICAL|R21 Malaria Vaccine (Recombinant) For Bedside Mixing|R21 is a fusion protein of hepatitis B surface antigen (HBsAg) to the C-terminus and central repeats of the circumsporozoite (CS) protein of Plasmodium falciparum. R21 VLP, recombinant HBsAg spontaneously self-assembled \& formed a virus-like particle, wherein circumsporozoite protein (CSP) from Plasmodium falciparum is presented on the VLP of recombinant HBsAg particles. R21 Malaria antigen expressed in recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.
219452468|NCT07147400|BIOLOGICAL|MATRIX-M1 (Adjuvant) For Bedside Mixing|active ingredient in Matrix-M1 are saponin-based fractions. Matrix-M1 has a ratio of Matrix-A and Matrix-C of 85:15 (by weight). Both Matrix-A and Matrix-C are individual fractions (separated by chromatography) derived from extracts from the Quillaja saponaria tree. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
219452469|NCT07147270|OTHER|side to side and front to back rotation 30 minutes each|side to side and front to back rotation 30 minutes each after pleurodesis
219452470|NCT07148388|DEVICE|Repetitive transcranial magnetic stimulation|Patients in the AiTBS group received 5 consecutive days of AiTBS treatment, with 6 sessions of iTBS interventions per day (1800 pulses per trial, with a 50-minute interval between trials). Patients in the 10Hz rTMS group received 10 consecutive days of 10Hz rTMS treatment within 10 days, with 1500 pulses per day, totaling 15 minutes.
219452471|NCT07149012|OTHER|Artificial Intelligence Awareness and Feasibility Assessment|"A sequential explanatory mixed-methods assessment of surgeons' awareness, readiness, and perceived barriers to adopting artificial intelligence in surgical care during the ongoing Sudan conflict. The intervention consisted of:~A validated, structured online questionnaire adapted from established AI awareness tools, assessing familiarity, perceived benefits, barriers, and ethical concerns.~Semi-structured interviews with senior surgical residents and consultants to explore contextual and ethical perspectives in greater depth.~The study did not implement AI tools in practice but focused on measuring feasibility and identifying requirements for future AI deployment in conflict-affected surgical systems."
219452472|NCT07147218|DEVICE|TMS|transcranial magnetic stimulation - DASH 36 treatment delivered in 5 days
219452473|NCT07147608|OTHER|actimeter wearing|actimeter wearing during 7 days : recording of physical activity over 7 days using a non-invasive external sensor
219452474|NCT07147608|OTHER|physical activities questionnaires|IPAQ and SAPHIR questionnaires
219452475|NCT07148102|DEVICE|Diaphragmatic US|Diaphragmatic thickening fraction (DTF) and diaphragmatic excursion (DE) were measured by ultrasound within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
219452476|NCT07148102|DEVICE|EC|TFC was assessed using electrical cardiometry (EC). Measurements were obtained within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
219588700|NCT05705037|OTHER|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
219588701|NCT00998309|DRUG|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
218842217|NCT04254562|BEHAVIORAL|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
218842218|NCT04254562|BEHAVIORAL|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
218842219|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
218842220|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
218842221|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
218842222|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
218842223|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
218842224|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
218842225|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
218842226|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
218842227|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
218842228|NCT00004573|DRUG|ganciclovir|
218842229|NCT06626529|BEHAVIORAL|Guided mindfulness meditation|Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
219452477|NCT07148427|DRUG|Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy|Iparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX
219452478|NCT07148739|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.
219452479|NCT07148739|OTHER|therapeutic drug monitoring|Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.
219452480|NCT07149233|DEVICE|Inspiratory Muscle Training|Inspiratory muscle training (IMT) was performed for 4 weeks in patients with moderate to severe OSA. The intervention group used a threshold device with resistance: training occurred twice daily, 7 days per week, with 3 sets of 30 fast inspiratory efforts and 1-minute rest between sets. Load started at 50% of maximal inspiratory pressure (MIP), increased to 60% in week 3, and 75% in week 4. Weekly visits were held for load adjustment. The sham group followed the same schedule using the same device without resistance (spring removed). Both groups recorded adherence in training diaries and received daily follow-up calls from the principal investigator
219452481|NCT07149116|DEVICE|Tracheostomy sealing|A non-classified silicone-based prototype device designed to temporarily seal the tracheostomy tract from within the airway for up to 7 days after decannulation.
219452482|NCT07147985|BEHAVIORAL|162 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 162 steps per minute crossover to 180 steps per minute and 198 steps per minute.
219452483|NCT07147985|BEHAVIORAL|180 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 180 steps per minute crossover to 162 steps per minute and 198 steps per minute.
219452484|NCT07147985|BEHAVIORAL|198 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 198 steps per minute crossover to 162 steps per minute and 180 steps per minute.
219452485|NCT07149168|DRUG|Dexmedetomidin|The PENG block will be performed using a mixture of 0.25% bupivacaine (1.25 to 2.5 mg/kg.) combined with dexmedetomidine at a dose of 1.25 mcg/kg
218842230|NCT06626529|BEHAVIORAL|Scenery video|Watching a ten-minute video of calming music and images
218842231|NCT00505973|DRUG|SCA-136|
218842232|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
218842233|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
219452486|NCT07149168|DRUG|Bupivacain|a typical dose of 0.5% hyperbaric bupivacaine ranges from 0.1 to 0.15 mg/kg (2 to 3 mL), depending on the patient's height and clinical condition. Lower doses are used for shorter or elderly patients, while taller patients may require higher doses
219452487|NCT07148570|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Delivery Room Nursing Care Based on Kolcaba's Comfort Theory
219452488|NCT07100223|OTHER|EDUCATION|"Assignment to the intervention and control groups will be made by randomization method.~Before training is given to the intervention and control groups, Parental Introduction Form, Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~After parents attend a 1-week birth preparation training at Kayseri City Hospital Pregnancy School, they will participate in a 9-week Awareness-Based Parenting and Birth Preparation Training.~After the training is completed; Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~Wijma Birth Expectation/Experience Scale Version B will be administered to mothers on the 1st postpartum day."
219452489|NCT07148674|DEVICE|Positive Expiratory Pressure (10cmH2O) in hypobaric hypoxia|The intervention under investigation will be the application of positive expiratory pressure (PEP) at 10 cmH₂O using an Ambu mask. The mask will allow participants to inspire freely while generating a controlled expiratory pressure. The PEP device is a non-pharmacological medical device whose uses in both hospital and pre-hospital settings are part of everyday medical practice.
219588702|NCT01425411|DRUG|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
219588703|NCT04260555|DRUG|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
219588704|NCT04260555|DRUG|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
219588705|NCT04260555|DRUG|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
219588706|NCT05566184|DEVICE|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
218842234|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
218842235|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
218842236|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
219452490|NCT07147569|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|The target patients are those who were attempted to implant the AC during the enrollment period of this surveillance. Patients will also be targeted even if all components of the TAMBE device (devices that can be used in combination with AC specified in IFU) were not used, or if a device other than the component of the TAMBE device was used.
219452491|NCT07148401|DEVICE|Hall technique|Hall technique for placement of crowns on carious primary molars
219452492|NCT07148947|DRUG|Pacritinib|Given PO
219452493|NCT07148947|DRUG|Decitabine|Given IV
219452494|NCT07148947|DRUG|Decitabine and Cedazuridine|Given PO
219452495|NCT07148947|DRUG|Azacitidine|Given IV or SC
219452496|NCT07148947|OTHER|Survey Administration|Ancillary studies
219452497|NCT07148947|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218842237|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
218842238|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
218842239|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
218842240|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
219196851|NCT06818162|OTHER|normative data|Ultra sonography of ulnar nerve along its course to obtain normative values for the CSA
219452498|NCT07148947|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219452499|NCT07148947|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219452500|NCT04223778|DRUG|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
219452501|NCT04223778|DRUG|ART|Baseline ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
219452502|NCT06547112|DRUG|Motixafortide|Dose = 1.25 mg/kg via subcutaneous injection
219452503|NCT06547112|DRUG|G-CSF|Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
219452504|NCT06109363|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I intervention will be provided to participants once their districts are exposed.
219452505|NCT05119231|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
219452506|NCT05119231|OTHER|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
219452507|NCT06956508|OTHER|Targeted Brain Rehabilitation|"Patients will be given a virtual reality headset that is pre-loaded with the targeted brain rehabilitation (TBR) software at the time of their major amputation.~The Virtual Reality (VR) environment will consist of a high-fidelity virtual representation of the participant's phantom limb. Participants will use a mounted head display (MHD) to interact with a virtual avatar, with the phantom limb represented as a realistic 3D limb model matching the remaining anatomy and skin tone. The VR system will be set up either in the clinic or at the participant's home, depending on individual circumstances and preferences.~The VR protocol will be standardized and include exercises designed to mimic typical occupational therapy session."
219452508|NCT05374512|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
219452509|NCT05374512|DRUG|Paclitaxel|IV Infusion. Active comparator
219452510|NCT05374512|DRUG|Nab-paclitaxel|IV infusion. Active comparator
219452511|NCT05374512|DRUG|Carboplatin|IV infusion. Active comparator
219452512|NCT05374512|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
219452513|NCT05374512|DRUG|Eribulin mesylate|IV infusion. Active comparator
219452514|NCT04422847|DEVICE|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
219452515|NCT04085406|DEVICE|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
219452516|NCT04418427|BIOLOGICAL|6E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
219452517|NCT04418427|BIOLOGICAL|2E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
219452518|NCT04418427|BIOLOGICAL|Aflibercept|Commercially available Active Comparator
219452519|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
219452520|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
219452521|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
219452522|NCT00189059|DRUG|amitriptyline|
219452523|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
219452524|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
219452525|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
219452526|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
219452527|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
219452528|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
219452529|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219452530|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219452531|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219452532|NCT01662752|DRUG|Indocyanine green|Please see arm description
219452533|NCT06229093|DEVICE|Gamma|For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
219588707|NCT05543343|DRUG|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
219588708|NCT05543343|DRUG|Placebo|8 placebo tablets 3 times daily
218842241|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
218842242|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
219452534|NCT06229093|DEVICE|Synchrony|For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
219452535|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
219452536|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
219452537|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
219452538|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
219452539|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
218842243|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
218842244|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
219452540|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
219452541|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
219452542|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
219452543|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219588709|NCT01667237|BEHAVIORAL|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
219588710|NCT01667328|PROCEDURE|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
219588711|NCT01667328|PROCEDURE|Standard of care|Control group will receive standard of care with no massage therapy
219588712|NCT04643561|OTHER|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
218842245|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
218842246|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
218842247|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
218842248|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
218842249|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
218842250|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
218842251|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
218842252|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
218842253|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
219452544|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
219452545|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
219452546|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
219452547|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
219588713|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^9 CFU/day)|
219588714|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^8 CFU/day)|
219588715|NCT02032056|OTHER|Placebo|
219588716|NCT02865460|DRUG|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
218842254|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
218842255|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
219588717|NCT02865460|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
218842256|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
218842257|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
218842258|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
219588718|NCT06500793|DRUG|PF614 capsule|PF614 capsules (25-100 mg)
219588719|NCT06500793|DRUG|Nafamostat Mesylate|Nafamostat IR/ER solution/beads (total 1-10 mg)
219588720|NCT01497808|DRUG|Ipilimumab|
219588721|NCT01497808|RADIATION|Stereotactic Body Radiation Therapy|
219588722|NCT02816008|BEHAVIORAL|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
218842259|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
218842260|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
218842261|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
219452548|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
219452549|NCT02306148|OTHER|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
219452550|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
219452551|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
219452552|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
219452553|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
219588723|NCT02816008|BEHAVIORAL|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
219588724|NCT05784532|DEVICE|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
219588725|NCT04553016|BIOLOGICAL|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
219588726|NCT04553016|BIOLOGICAL|Placebo|IM administration of 0.9% sterile sodium chloride solution
219588727|NCT03983915|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
219588728|NCT03983915|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
219588729|NCT03983915|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
219588730|NCT00555152|OTHER|Laboratory Biomarker Analysis|Correlative studies
219196852|NCT06596980|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
219588731|NCT00555152|DRUG|Lapatinib Ditosylate|Given PO
219588732|NCT00555152|OTHER|Placebo|Given PO
219588733|NCT01015937|DRUG|Turmeric extract|turmeric 500 mg TID for 45 days
219588734|NCT01015937|DRUG|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
219196853|NCT06601127|DRUG|Tiprogrel|Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
219196854|NCT06601127|DRUG|Tiprogrel|Drug: Tiprogrel and Aspirin Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
219588735|NCT04558918|DRUG|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
219588736|NCT04558918|DRUG|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
219588737|NCT04558918|DRUG|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
219588738|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
219588739|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
219588740|NCT02467478|DRUG|Linagliptin|5 mg tablet once daily for 12 weeks
219588741|NCT02467478|DRUG|Placebo|1 tablet daily for 12 weeks
219588742|NCT01869985|DRUG|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
218842262|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
219196855|NCT06601127|DRUG|Clopidogrel|Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.
219196856|NCT06586970|BEHAVIORAL|Meals + RD services|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
219196857|NCT06586970|BEHAVIORAL|Meals + OT services|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
219452554|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
219588743|NCT06583473|BEHAVIORAL|Interactive digital health application|The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
219588744|NCT01722201|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
219588745|NCT01722201|DRUG|Risperidone|1 mg tablet once a day
219588746|NCT05076019|DRUG|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
219588747|NCT05076019|DRUG|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
219588748|NCT05578183|DEVICE|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
219588749|NCT05578183|DEVICE|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
219196858|NCT06586970|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
219452555|NCT06292429|OTHER|Control Group|No intervention given
219452556|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
219452557|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
219452558|NCT01952041|BEHAVIORAL|Device: Smartphone|
219588750|NCT02304497|OTHER|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
219588751|NCT05986227|DRUG|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
219588752|NCT05585021|DIETARY_SUPPLEMENT|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
218842263|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
218842264|NCT04521946|DRUG|Etoposide|Given IV
218842265|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
219452559|NCT01952041|BEHAVIORAL|Treatment as usual|
219452560|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
219452561|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
219452562|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
219452563|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
219452564|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
219452565|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
219452566|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
219452567|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
219452568|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
219452569|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
219452570|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
219452571|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
219452572|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
219452573|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
219452574|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
219452575|NCT01370499|DRUG|LY2216684|
219452576|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
218842266|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
218842267|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
218842268|NCT04521946|DRUG|Melphalan|Given IV
219452577|NCT00532233|DRUG|QAX576|
219452578|NCT06485661|DRUG|Captopril Tablets|Patients will be given captopril to see effect on global longitudinal strain
219452579|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
218842269|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
218842270|NCT04521946|DRUG|Tacrolimus|Given IV
218842271|NCT04521946|DRUG|Thiotepa|Given IV
218842272|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
218842273|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
218842274|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
219452580|NCT01118585|PROCEDURE|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
219452581|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
219452582|NCT04770259|OTHER|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
219588753|NCT05585021|DIETARY_SUPPLEMENT|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
219588754|NCT01831102|OTHER|none- observational study|
219588755|NCT05817682|OTHER|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
218842275|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
218842276|NCT03544489|BEHAVIORAL|E-ICD Intervention|Home walking 3 days/week x 12 weeks
218842277|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
218842278|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
218842279|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
218842280|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
218842281|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
219196859|NCT06599099|DEVICE|Medtronic Percept RC System|"Medtronic Percept RC System includes:~Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module"
219452583|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
218842282|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
219452584|NCT01741584|BEHAVIORAL|stationary bike exercise|
219452585|NCT01741584|BEHAVIORAL|aerobic|
219452586|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
219452587|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
219452588|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
219452589|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
219588756|NCT01314937|DRUG|Mebendazole|Single-dose 500 mg mebendazole tablet
219588757|NCT01314937|OTHER|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
219588758|NCT04113785|DEVICE|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
219588759|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
218842283|NCT06403982|OTHER|Continuation of oxytocin after ELA|"The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery."
219588760|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
218842284|NCT06403982|OTHER|Discontinuation of oxytocin after ELA|The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
218842285|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
218842286|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
218842287|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
219588761|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
219588762|NCT06692400|PROCEDURE|endotracheal tube suctioning|Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
219588763|NCT06349577|OTHER|Non-pulsatile blood flow|Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass
219588764|NCT06349577|OTHER|Pulsatile blood flow|Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass
218842288|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
218842289|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
218842290|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
218842291|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
218842292|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
218842293|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
218842294|NCT00152828|DRUG|Celecoxib|
219452590|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
218842295|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
218842296|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
219452591|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
219452592|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
219452593|NCT06447935|OTHER|No intervention|not applicable - no intervention required
219452594|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
219452595|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
219452596|NCT02299128|OTHER|Physical Therapy Treatment|
219452597|NCT00499161|BEHAVIORAL|New model of nursing care|
219452598|NCT00039546|DRUG|cyclophosphamide|
219452599|NCT00039546|DRUG|epirubicin hydrochloride|
219452600|NCT00039546|DRUG|gemcitabine hydrochloride|
219452601|NCT00039546|DRUG|paclitaxel|
219452602|NCT00039546|PROCEDURE|adjuvant therapy|
219452603|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
219452604|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
219452605|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
219452606|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
219452607|NCT06379672|OTHER|Resonance breathing|Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
219452608|NCT02306928|OTHER|Blood draw|
219452609|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
219452610|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
219452611|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
219452612|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
219452613|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
218842297|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
218842298|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
218842299|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
218842300|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
218842301|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
219196860|NCT06599099|BEHAVIORAL|One Month Blinded Discontinuation Period|The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
219196861|NCT04265807|DEVICE|Active Remote Ischemic Conditioning|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
219452614|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
219452615|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
219452616|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
219452617|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
218842302|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
218842303|NCT05319600|BEHAVIORAL|Diabetes behavior change skills training|Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.
218842304|NCT05319600|BEHAVIORAL|Physical activity promotion program|The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.
218842305|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
218842306|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
218842307|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
218842308|NCT02497365|DRUG|Besifloxacin|
218842309|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
218842310|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
218842311|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
218842312|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
218842313|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
219017833|NCT06771635|OTHER|concurrent|"The concurrent training program is divided into three types of training: endurance, cardiovascular and neuromotor.~Resistance training sessions were performed in a circuit format with \>30 rest periods between exercises. The volume of work ranged from 8 to 12 repetitions at 60% of the estimated 1 maximum repetition (RM).~The cardiovascular work time per session ranged from 25-50 min depending on the intensity of the exercise and the intensity was regulated according to the maximum heart rate (FHR) estimated for each subject between 60-75%~The neuromotor training intensity of the sessions was low. The participants wore a heart rate monitor and were instructed not to exceed 60% of their HRF"
219017834|NCT06771635|BEHAVIORAL|Health Education Session|Single formative session on healthy lifestyle and nutrition provided to both groups. Control group received only this session without concurrent training.
218842314|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
218842315|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
218842316|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
218842317|NCT03768089|DRUG|IVA|Tablet for oral administration.
218842318|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
218842319|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
218842320|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
218842321|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
218842322|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
218842323|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
218842324|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
218842325|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
218842326|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
219196862|NCT04265807|DEVICE|Sham Remote Ischemic Conditioning|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
219452618|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
218842327|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
218842328|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
218842329|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
218842330|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
218842331|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
218842332|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
218842333|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
218842334|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
219452619|NCT04835389|DRUG|Placebo|0.9% normal saline
218842335|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
218842336|NCT00961740|OTHER|Waitlist condition|See Summary
219017835|NCT06263075|PROCEDURE|Intraoperative monitoring|"ANESTHESIOLOGICAL MANAGEMENT accords to usual practice. Participants underwent preoperative fasting (3 h for breast milk, 4 h for formula milk, and 1 h for clear liquids), no premedication, induction and maintenance by sevoflurane, fentanyl boluses for analgesia, mechanical ventilation (PEEP 4 cm H2O, target tidal volume 6-8 ml/Kg, end tidal CO2 32-40 mmHg), 10 ml/Kg/h of intraoperative fluids. Scalp block is performed before surgery.~MONITORING DURING SURGERY: monitor devices routinely used are connected to the participant: Dräger Infinity Delta XL®, Masimo® for pulse oximetry (Rainbow SET), regional cerebral oximetry (O3TM), and (optional) brain function monitoring (Masimo® SedLine). Arterial blood gas test is sampled at the anesthesiologist's discretion. After the artery catheterization, the MostCare® system is simultaneously connected to the patient monitoring devices. Data are collected every 3 minutes, 6 minutes for the noninvasive blood pressure measurement."
219588765|NCT03490344|DRUG|Daratumumab|"* Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
219588766|NCT03490344|DRUG|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
219588767|NCT05816590|OTHER|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
219588768|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
218842337|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
218842338|NCT01375816|DRUG|fluorouracil|
218842339|NCT01375816|DRUG|irinotecan hydrochloride|
218842340|NCT01375816|DRUG|leucovorin calcium|
218842341|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
218842342|NCT01375816|DRUG|Bevacizumab|
218842343|NCT06308601|OTHER|Laughter yoga|Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
218842344|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
219452620|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
219452621|NCT00120029|BEHAVIORAL|weight loss counseling|
219452622|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
219452623|NCT01087151|DRUG|ABT-263|Oral repeating dose
219452624|NCT01087151|DRUG|rituximab|Intravenous repeating dose
219452625|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
219588769|NCT04977986|DRUG|ZYN002 - transdermal gel|Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
218842345|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
218842346|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
218842347|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
218842348|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
218842349|NCT06310941|DEVICE|Mechanical insufflation-exsufflation|Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection
218842350|NCT06310941|OTHER|Standard of Care|systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines
219196863|NCT00412607|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
219196864|NCT06592807|OTHER|Perioperative Warm Socks|The socks to be used in the study were provided by the researcher. The socks were suitable for foot sizes 36-45. The socks were white and made of cotton fabric. The socks were sterilized in an autoclave before use. The socks were put on the patients just before the surgery. The socks were heated to 40 degrees with an intravenous fluid warming machine.The socks remained on the patients feet throughout the surgery. After the surgery, the patients socks were removed and new heated socks were put on. The socks were kept on the patients feet for 1 hour. All socks were used for single use.
219588770|NCT04977986|DRUG|Placebo|"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
219588771|NCT02174432|DRUG|nalbuphine HCl ER|nalbuphine HCl ER BID for up to 50 weeks
219588772|NCT06578442|OTHER|Magnetic Field Treatment|Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.
219588773|NCT06578442|OTHER|Constipation Coping Training|"The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation."
219588774|NCT03066739|DRUG|Remifentanil|0.1 micrograms/kg/mL
219588775|NCT03066739|DRUG|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
219588776|NCT03066739|DRUG|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
218842351|NCT06310941|OTHER|Hypertonic saline with hyaluronic acid|Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
218842352|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
218842353|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
218842354|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
218842355|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
218842356|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
218842357|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
218842358|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
218842359|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
218842360|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
218842361|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
218842362|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
218842363|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
218842364|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
218842365|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
218842366|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
218842367|NCT03981107|OTHER|Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions only~* Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing."
219452626|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
219452627|NCT00784680|DRUG|Anastrozole|1mg, orally, once daily
219452628|NCT00784680|DRUG|Tamoxifen|20mg, orally, once daily
219452629|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
219588777|NCT06369831|DIAGNOSTIC_TEST|68Ga-NOTA-ABSCINT-HER2 PET/CT|68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
219588778|NCT06853197|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
219588779|NCT05728047|PROCEDURE|Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam)|The 'Cytocam' is a hand held computer-controlled device, a third generation video-microscope, which enables real time visualisation of the in vivo microcirculation, based upon the principle of incident dark field (IDF) illumination.
219588780|NCT02737748|DRUG|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
219588781|NCT02737748|DRUG|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
219588782|NCT01018589|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
219588783|NCT00723723|DRUG|Statin|Statin
219588784|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
219588785|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
218842368|NCT03981107|OTHER|Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions and rescue breathing~* Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute."
218842369|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
218842370|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
219588786|NCT00662623|BEHAVIORAL|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
218842371|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
219452630|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
219452631|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
219452632|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
219452633|NCT01967082|OTHER|Survey Administration|Complete survey
219452634|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
219452635|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
219452636|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
219452637|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
219452638|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
219452639|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
219452640|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
219452641|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
219452642|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
219452643|NCT05587439|GENETIC|Data and Specimen Collection|"* Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members"
219452644|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
219588787|NCT00662623|BEHAVIORAL|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
219588788|NCT01152619|DRUG|Placebo|Subcutaneous repeated dose
218842372|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
218842373|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
218842374|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
219452645|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
219452646|NCT02473016|DRUG|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
219452647|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
219588789|NCT01152619|DRUG|RO4989991|Subcutaneous repeated dose
219588790|NCT04480021|BEHAVIORAL|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
219588791|NCT04480021|BEHAVIORAL|EUC|Group education on depression by community health workers
218842375|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
219452648|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
219452649|NCT03686462|DEVICE|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
219452650|NCT03686462|DEVICE|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
219452651|NCT05754372|DIAGNOSTIC_TEST|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
219452652|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
219452653|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
219452654|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
219452655|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
219452656|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
219452657|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
219452658|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
219452659|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
219452660|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
219452661|NCT05248646|DRUG|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
219452662|NCT05248646|DRUG|Placebo|Placebo s.c. q 4 weeks
219452663|NCT05053867|DRUG|tranexamic acid|Inhaled
219452664|NCT05053867|OTHER|Usual Care|Standard of Care
219452665|NCT03062670|OTHER|Retreat|Full day off-site training session
219452666|NCT05465668|DRUG|DWP16001 Drug A|DWP16001 Drug A
219452667|NCT05465668|DRUG|DWP16001 Drug C|DWP16001 Drug C
219452668|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
219452669|NCT04547491|DEVICE|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
218842376|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
218842377|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
218842378|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
218842379|NCT05803161|DRUG|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
218842380|NCT05803161|DRUG|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
218842381|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
219452670|NCT04547491|DEVICE|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
218842382|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
219452671|NCT03416517|DRUG|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
219452672|NCT03416517|DRUG|Irinotecan|Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
219452673|NCT05481944|DIAGNOSTIC_TEST|MRI in patients|Injected MRI
219452674|NCT05481944|DIAGNOSTIC_TEST|MRI in healthy volunteers|non injected MRI
219452675|NCT04888182|DIETARY_SUPPLEMENT|intervention|a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
219452676|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
219452677|NCT04918069|DRUG|Capsaicin|Topical capsaicin ointment
219452678|NCT04918069|DRUG|Placebo|Topical placebo ointment
219452679|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
219452680|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
219452681|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
219452682|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
219452683|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
219452684|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
219452685|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
219452686|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
219588792|NCT03761264|DRUG|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
218842383|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
219452687|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
219452688|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
219452689|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
219452690|NCT05836428|OTHER|no intervention|no intervention
219452691|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
219452692|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
219452693|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
219588793|NCT03761264|DRUG|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
219588794|NCT03761264|DRUG|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
218842384|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
218842385|NCT01308255|DRUG|Infliximab|"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
218842386|NCT01308255|DRUG|Methylprednisolone|Steroid
218842387|NCT01308255|DRUG|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
218842388|NCT01308255|DIETARY_SUPPLEMENT|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
218842389|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
218842390|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
218842391|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
219588795|NCT05655221|DRUG|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
219588796|NCT05655221|OTHER|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
219452694|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
219452695|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
219452696|NCT04768920|BEHAVIORAL|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
219452697|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
219452698|NCT00723489|DRUG|YFV-17D Placebo|
219452699|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
219452700|NCT05427058|PROCEDURE|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
219452701|NCT05427058|PROCEDURE|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
219452702|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
219452703|NCT02171806|DRUG|BI 1744 CL|
219452704|NCT02171806|DRUG|Placebo|
219452705|NCT05736302|OTHER|Doubly-Labeled Water|All eligible participants will receive a dose of doubly-labeled water.
219452706|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
219588797|NCT04686552|DIETARY_SUPPLEMENT|cinnamon|6 g of ground cinnamon
218842392|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
218842393|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
218842394|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
219452707|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
219452708|NCT06272942|OTHER|An ICU admission and a temporally related ARDS diagnosis|"This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome."
219452709|NCT05857150|DIAGNOSTIC_TEST|Treadmill Test|Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
219452710|NCT05857150|DIAGNOSTIC_TEST|Strength Test|Measure the strength of leg muscles by kicking against a machine with resistance.
219452711|NCT05857150|DIAGNOSTIC_TEST|Dual-Energy X-Ray Absorptiometry|Body composition measurement.
219452712|NCT05857150|PROCEDURE|Muscle Biopsy|Obtain a small piece of muscles from the upper part of the legs
219452713|NCT05857150|PROCEDURE|Fat Biopsy|Fat sample taken from abdomen
219452714|NCT05857150|DIAGNOSTIC_TEST|Resting Energy Expenditure|Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
219452715|NCT05857150|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI on upper leg to look at fat and muscle
219452716|NCT06037954|OTHER|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
219452717|NCT06037954|OTHER|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
219588798|NCT04823975|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group description\]
219588799|NCT01292226|DRUG|mycophenolate mofetil|1 g PO BID for 24 weeks
219588800|NCT01292226|DRUG|antibody induction|According to manufacturer recommendation
219588801|NCT01292226|DRUG|Cyclosporine|According to manufacturer recommendation
219588802|NCT01292226|DRUG|corticosteroid|According to manufacturer recommendation
219588803|NCT05468424|OTHER|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
219452718|NCT06037954|OTHER|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care"
219452719|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
219452720|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219452721|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219452722|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219452723|NCT02422381|DRUG|MK-3475|Investigational drug.
219452724|NCT02422381|DRUG|Gemcitabine|Standard care drug.
219452725|NCT06390371|OTHER|Spotlight AQ Survey platform|A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
219452726|NCT04683952|DEVICE|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
219452727|NCT04683952|OTHER|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
219452728|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
219452729|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
219452730|NCT06972004|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|"Preventing Loss of Independence through Exercise (PLIÉ) is a multi-domain, mind-body, group movement program for people with dementia that improves quality of life.~Classes begins and ends with fully body tapping/massaging and breathing exercises that bring participants into awareness of their bodies in the present moment and create a calming ritual. Participants are invited to share appreciations of things in their lives that make them feel happy or grateful. Instructors lead participants through progressive, functional movement sequences that are designed to be repetitive (to build procedural or muscle memory) and to build slowly in functional complexity over time. Movements are tailored to the ability levels of the group. Resting, breathing and mindful body awareness exercises are incorporated throughout each class to provide breaks and to improve focus and attention. A non-judgmental errorless learning process is used, and all movements are performed slowly and purposefully."
219452731|NCT04771390|DRUG|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
218842395|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
218842396|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
218842397|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
218842398|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
218842399|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
218842400|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
219452732|NCT04771390|DRUG|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
219452733|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
219452734|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
219452735|NCT01985204|DIETARY_SUPPLEMENT|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
219452736|NCT01985204|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet without iodine
218842401|NCT00080834|DRUG|DJ-927|
218842402|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
218842403|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
218842404|NCT00395486|DRUG|Rosuvastatin|10mg
218842405|NCT00395486|DRUG|Atorvastatin|10mg
218842406|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
218842407|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
218842408|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
218842409|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
218842410|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
218842411|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
218842412|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
218842413|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
218842414|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
218842415|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
218842416|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
218842417|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
218842418|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
218842419|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
219452737|NCT02098915|DRUG|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
219452738|NCT02098915|OTHER|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
219452739|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
219017850|NCT06238596|PROCEDURE|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
219017851|NCT05564169|DRUG|Placebo|treatment per os
219017852|NCT05564169|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
219017853|NCT05564169|DRUG|Standard of care|Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
218842420|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
218842421|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
218842422|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
218842423|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
218842424|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
219452740|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
219452741|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
219452742|NCT05550857|OTHER|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
219452743|NCT05550857|OTHER|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
219452744|NCT05379933|OTHER|Remote health coaching to improve self-care behaviors|Participants will be asked to wear an activity tracker, complete brief surveys, and participate in weekly health coaching sessions remotely for 8 weeks
219452745|NCT00141622|DRUG|Slow sodium|
219452746|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
219452747|NCT06549699|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
219452748|NCT06549699|OTHER|Usual Care|Usual care plus healthy recipes provided
219452749|NCT02126384|DRUG|pneumovax vaccination|vaccination
219452750|NCT02955940|DRUG|Ruxolitinib|5 mg BID
219452751|NCT02955940|DRUG|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
219452752|NCT02955940|DRUG|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
219452753|NCT03980340|BEHAVIORAL|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
219452754|NCT03980340|BEHAVIORAL|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
219452755|NCT03805789|BIOLOGICAL|AAT|AAT is a lyophilized product for IV administration.
219452756|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
219588804|NCT05468424|OTHER|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
219588805|NCT06154200|DRUG|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
219588806|NCT06154200|DRUG|Vehicle gel|Vehicle gel applied to eyelids twice per day
219588807|NCT01844505|BIOLOGICAL|Nivolumab|
219452757|NCT05898659|DEVICE|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
219452758|NCT05898659|DEVICE|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
219452759|NCT06371404|DRUG|Bavarostat|Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
219452760|NCT04717414|DRUG|ACE-536|Subcutaneous Injection
219452761|NCT04717414|OTHER|Placebo|Subcutaneous Injection
219452762|NCT06810544|DRUG|TNG456|A selective PRMT5 inhibitor
219452763|NCT06810544|DRUG|abemaciclib|A kinase inhibitor
219452764|NCT00879047|DRUG|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
219452765|NCT00879047|DRUG|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
219452766|NCT00986804|DRUG|Decitabine|
219452767|NCT00853112|DRUG|PF-00489791|tablet form, 1 mg, single dose (Day 1)
219452768|NCT00853112|DRUG|PF-00489791|tablet form, 2 mg, single dose (Day 1)
219452769|NCT00853112|DRUG|PF-00489791|tablet form, 4 mg, single dose (Day 1)
219452770|NCT00853112|DRUG|PF-00489791|tablet form, 10 mg, single dose (Day 1)
219452771|NCT00853112|DRUG|PF-00489791|tablet form, 20 mg, single dose (Day 1)
219452772|NCT00853112|DRUG|placebo|tablet form, single dose (Day 1)
219452773|NCT00853112|DRUG|sildenafil|tablet form, 20 mg, single dose (Day 1)
219588808|NCT01844505|BIOLOGICAL|Ipilimumab|
219588809|NCT01844505|BIOLOGICAL|Placebo for Nivolumab|
219588810|NCT01844505|BIOLOGICAL|Placebo for Ipilimumab|
219588811|NCT05990478|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Participants will have pre- and post-treatment CEM of the affected breast
219588812|NCT05990478|DIAGNOSTIC_TEST|Breast MRI|Pre- and post-NAT breast MRI will be performed for all participants
219588813|NCT06666309|BEHAVIORAL|SBCM-PrEP + Text Messaging|Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting
219452774|NCT01762592|DRUG|Iodine (124I) Girentuximab|i.v.
219452775|NCT02788825|PROCEDURE|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
219452776|NCT00537459|DRUG|16448|
219452777|NCT05535790|OTHER|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
219452778|NCT05535790|OTHER|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
219452779|NCT05439304|OTHER|No intervention|No intervention
219452780|NCT01553591|DRUG|Eluxadoline|Oral tablets twice daily
219452781|NCT01553591|DRUG|Placebo|Oral tablets twice daily
219452782|NCT04660006|PROCEDURE|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
219452783|NCT01770119|BIOLOGICAL|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
219452784|NCT02329860|DRUG|Apatinib|
219452785|NCT02329860|DRUG|Placebo|
219452786|NCT05306262|PROCEDURE|Hypnosis session|Comfort hypnosis: accompaniment of a pleasant memory.
219588814|NCT06666309|BEHAVIORAL|CDC-PrEP + Text Messaging|1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings
219588815|NCT06666309|BEHAVIORAL|T-SBCM|Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2
219588816|NCT06666309|BEHAVIORAL|Mobile Outreach|Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
219588817|NCT04232683|DRUG|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
219588818|NCT04232683|DRUG|Placebo oral tablet|Placebo pill given preoperatively
219588819|NCT04375722|DEVICE|tACS|Active or Sham tACS will be applied.
219452787|NCT05306262|OTHER|Catalepsy|Catalepsy of the hand.
219452788|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
219452789|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
219452790|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
219452791|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
219452792|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
219452793|NCT04951219|DRUG|Resmetirom|Tablet
219452794|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
219452795|NCT06983782|OTHER|Exercise and education programme|Participants will complete 8-week online exercise programme consisting of an online exercise class once per week. The exercises will target improving strength, balance and range of movement. In addition, participants will receive educational materials on exercise, nutrition, walking changes, fatigue, optimizing bone health, pain management, mental health, sleep and physical activity maintenance.
219452796|NCT06983782|OTHER|control group|The control group will receive educational materials over 8 weeks
219452797|NCT02881086|DRUG|Rituximab|
219452798|NCT02881086|DRUG|Nelarabine|
219452799|NCT02881086|DRUG|PEG-Asparaginase|
219452800|NCT02881086|PROCEDURE|Cranial irradiation|
219588820|NCT06039371|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219588821|NCT06039371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219588822|NCT06039371|PROCEDURE|Bone Scan|Undergo bone scan
219452801|NCT02881086|DRUG|Imatinib|
219452802|NCT02881086|DRUG|Idarubicin|
219452803|NCT02881086|DRUG|Dexamethasone|
219452804|NCT02881086|DRUG|Cyclophosphamide|
219452805|NCT02881086|DRUG|Fludarabine|
219452806|NCT02881086|DRUG|Vincristine|
219452807|NCT02881086|DRUG|Mercaptopurine|
219452808|NCT02881086|DRUG|VP16|
219452809|NCT02881086|DRUG|Daunorubicin (DNR)|
219452810|NCT02881086|DRUG|Methotrexate|
219452811|NCT02881086|PROCEDURE|Stem cell transplantation|
219452812|NCT02881086|DRUG|Cytarabine|
219452813|NCT02881086|DRUG|Vindesine|
219452814|NCT02881086|DRUG|Adriamycin|
219452815|NCT02881086|DRUG|Prednisolone|
219452816|NCT01952613|DEVICE|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
219452817|NCT01184339|DEVICE|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
219588823|NCT06039371|DRUG|Carboplatin|Given IV
219588824|NCT06039371|PROCEDURE|Computed Tomography|Undergo CT
219588825|NCT06039371|DRUG|Etoposide|Given PO
219588826|NCT06039371|OTHER|Quality-of-Life Assessment|Ancillary studies
219588827|NCT06039371|OTHER|Questionnaire Administration|Ancillary studies
218842425|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
219452818|NCT05929677|DRUG|Placebo|Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.
219452819|NCT05929677|DRUG|Alcohol|Participants receive alcohol intravenously, clamped at BrACs of 20mg%, 40mg%, and 60mg%. They will also have the opportunity to self-administer alcohol (up to 120mg% BrAC) during the 60-minute free-access IV self-administration period in session 3.
219452820|NCT05728749|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
219452821|NCT04128072|DRUG|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
219452822|NCT04128072|RADIATION|Total Skin Electron Beam Therapy (TSEB)|"* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration."
219452823|NCT04128072|DRUG|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
219452824|NCT00135993|DRUG|Rotigotine|
219452825|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
219452826|NCT05837234|DEVICE|ULF SCS|Ultra low frequency spinal cord stimulation
219588828|NCT06039371|DRUG|Testosterone Cypionate|Given IM
219588829|NCT06039371|OTHER|Radioconjugate|Given LuPSMA IV
219588830|NCT06039371|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
219588831|NCT06039371|OTHER|Gallium Ga 68-PSMA-617|Given gallium 68Ga-PSMA-617
218842426|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
218842427|NCT06176794|DRUG|Immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
218842428|NCT06176794|DRUG|Extended release torsemide 24mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
218842429|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
218842430|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
218842431|NCT00143624|DRUG|Placebo|See detailed description.
219196865|NCT06878014|PROCEDURE|Spinal Anesthesia (bupivacaine)|Patients were positioned in sitting position on operating table, interspinous space was identified using anatomical landmarks (intercristal line) and palpation. Entire procedure was conducted with aseptic technique, puncture site was prepared with izopropyl alcohol solution. Skin was anesthetized with subcutaneous injection of 1% lidocaine. Spinal puncture was achieved using median or paramedian technique with 27G pencil-point spinal needle. After confirmation of free flow of cerebrospinal fluid 15 mg of 0,5% bupivacaine was administered intrathecaly. Block level was assessed by lack of sensation to alcohol swab in periumbilical area and complete motor block (Bromage 3).
219452827|NCT03272880|BEHAVIORAL|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
219452828|NCT04255368|OTHER|Water-soluble choline|600 mg choline as choline bitartrate
219452829|NCT04255368|OTHER|Fat-soluble choline|600 mg choline as phosphatidylcholine
219452830|NCT04255368|OTHER|No choline control|No choline
219452831|NCT01818765|PROCEDURE|Trans-ventricular-septal placement of LV pacing lead|
219452832|NCT01818765|OTHER|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
219452833|NCT01818765|OTHER|Acute response assessment|Cardiac output monitoring
219452834|NCT00004147|DRUG|incyclinide|
219588832|NCT06039371|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA PET
219588833|NCT06039371|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219588834|NCT04097158|OTHER|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
219588835|NCT06499805|DEVICE|Audiologist-based fitting|Description hearing aids will be fitted by audiologists using established procedures.
219196866|NCT06878014|DRUG|Postoperative pain management with acetaminophen|Postoperatively patients received 1,0g of paracetamol every 6 hours,
219588836|NCT06499805|DEVICE|Over-the-counter fitting|In this group, over-the-counter hearing aids will be used by subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
219588837|NCT06263842|PROCEDURE|modified Elamrousy approach for socket shield technique|the jumping gap will be filled with AWTG
219452835|NCT05935475|PROCEDURE|Anatomical landmark guided dialysis catheter insertion|.: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
219452836|NCT05935475|PROCEDURE|ECG guided dialysis catheter insertion|after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
219452837|NCT06108440|OTHER|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
219588838|NCT06263842|PROCEDURE|conventional socket shield|the jumping gap will be left ungrafted
219588839|NCT06263842|PROCEDURE|combined socket shild with xenograft|the jumping gap will be filled with xenograft
219452838|NCT06108440|OTHER|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
219452839|NCT02010567|DRUG|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
219452840|NCT02010567|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
219452841|NCT02010567|RADIATION|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
219452842|NCT02010567|PROCEDURE|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
219452843|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
219452844|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
219452845|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
219452846|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
219452847|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
219588840|NCT06975943|DRUG|Progesterone 200 mg vaginal capsules|Participants in this group will receive daily vaginal micronized progesterone (Microgest®) of dose 200 mg for a duration of two weeks following arrested preterm labor. This micronized progesterone will be administered to assess its impact on pregnancy prolongation and changes of cervical length following arrested preterm labor.
219588841|NCT06273475|OTHER|Robot-assisted Training|Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.
219588842|NCT06273475|OTHER|Standard Training|Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
219588843|NCT06125951|DRUG|Xanamem|Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
219588844|NCT06125951|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
219588845|NCT05818241|PROCEDURE|Treatment of fracture by forearm cast|Patient that are not surgically treated for DRF
219452848|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
219452849|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
219452850|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
219452851|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
219452852|NCT02005211|DRUG|AZD3293|Oral solution
219452853|NCT02005211|DRUG|Placebo|Oral solution
219452854|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
219452855|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
219452856|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
219452857|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
219452858|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
219452859|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
219452860|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
219452861|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
219452862|NCT04214106|DRUG|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
219588846|NCT05818241|PROCEDURE|Surgical treatment of fracture|Patients that are surgically treated for DRF
219588847|NCT03384654|DRUG|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
219588848|NCT03384654|DRUG|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
219588849|NCT03384654|DRUG|Prednisone|Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
219588850|NCT03384654|DRUG|Doxorubicin|Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
219588851|NCT03384654|BIOLOGICAL|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
219588852|NCT03384654|DRUG|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
219588853|NCT03384654|DRUG|Cytarabine|Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
219017858|NCT06474676|DRUG|Cyclophosphamide|Given by IV
219452863|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
219452864|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
219452865|NCT04589832|DRUG|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
219452866|NCT04589832|DRUG|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
219452867|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
219588854|NCT03384654|DRUG|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
219588855|NCT03384654|DRUG|Methotrexate|Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
218842432|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
218842433|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
218842434|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
218842435|NCT06506474|DIAGNOSTIC_TEST|Provision of any of six different low-value health services for treatment of bronchiolitis|This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
218842436|NCT05101629|DRUG|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
218842437|NCT05101629|DRUG|Lenvatinib Capsules|Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
219452868|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
219452869|NCT00397631|DRUG|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
218842438|NCT03554356|DEVICE|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
219588856|NCT03867955|OTHER|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
219588857|NCT05114837|DRUG|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
218842439|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
218842440|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
218842441|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
218842442|NCT00153140|DRUG|polyethyleneglycol3350|
218842443|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
219017859|NCT06474676|DRUG|T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy|Given by IV
219588858|NCT05114837|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
219588859|NCT05114837|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
219588860|NCT01443936|BIOLOGICAL|Ad4-H5-VTN vaccination-tonsillar route|
219588861|NCT01443936|BIOLOGICAL|Ad4-H5-vaccination-oral route|
219588862|NCT01062737|DRUG|ASU|
219588863|NCT02180126|OTHER|Follow-up|Follow-up of of patients with borderline positive ANCA test results
219588864|NCT06270212|DEVICE|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
219588865|NCT06270212|DEVICE|NO DEVICE|Evaluation of NO DEVICE during sedation
219588866|NCT06141161|DRUG|corticosteroids|inhailed or oral corticosteroids
219588867|NCT02922881|OTHER|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
219588868|NCT00423319|DRUG|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
219588869|NCT00423319|DRUG|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
219588870|NCT00423319|DRUG|Enoxaparin-matching placebo|Administered as injection
219588871|NCT00423319|DRUG|Apixaban-matching placebo|Administered as oral tablets
219588872|NCT02373748|DEVICE|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
219588873|NCT01584843|DRUG|GSK1358820|IM injection of Botulinum Toxin Type A
219588874|NCT03666559|DRUG|Azacitidine|Chemotherapy
218842444|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
219452870|NCT00397631|DRUG|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
219452871|NCT05319886|DRUG|Anlotinib and Penpulimab|Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
219452872|NCT01666353|RADIATION|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
219452873|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
219452874|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
219452875|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
219452876|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
219452877|NCT00003716|BIOLOGICAL|rituximab|
219452878|NCT04211857|DEVICE|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
219452879|NCT00832091|DRUG|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
219588875|NCT01157806|RADIATION|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
219588876|NCT00009009|DRUG|immunosuppressive regimen designed to complement HAART|
218842445|NCT04168008|BEHAVIORAL|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
218842446|NCT04168008|BEHAVIORAL|WISH Parenting|The educational sessions will focus on parenting and baby care.
218842447|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
219452880|NCT00832091|DRUG|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
219452881|NCT01782612|PROCEDURE|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
219452882|NCT01782612|PROCEDURE|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
219588877|NCT01254266|BEHAVIORAL|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
219588878|NCT01254266|BEHAVIORAL|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
219588879|NCT01254266|PROCEDURE|bariatric surgery|bariatric surgery.
219588880|NCT01254266|BEHAVIORAL|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
218842448|NCT04106219|DRUG|LY3295668 Erbumine|Administered orally.
218842449|NCT04106219|DRUG|Topotecan|Administered IV.
218842450|NCT04106219|DRUG|Cyclophosphamide|Administered IV.
218842451|NCT06305806|DRUG|Ivabradine|Participants will receive ivabradine for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).
218842452|NCT06305806|DRUG|Ivabradine Placebo|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months)."
218842453|NCT06305806|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
218842454|NCT06305806|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
218842455|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
218842456|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
219452883|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
219452884|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
219452885|NCT06359886|PROCEDURE|B-Lynch Transverse Compression Suture|closure of uterine and utero ovarian arteries bilaterally with one suture
219452886|NCT04759612|OTHER|Action Observation|Participants will watch an upper extremity functionality test.
219452887|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
218842457|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
218842458|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
218842459|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
218842460|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
218842461|NCT00066599|DRUG|voriconazole|
218842462|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
218842463|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
218842464|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
218842465|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
218842466|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
218842467|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
218842468|NCT06967337|BEHAVIORAL|Microsteps|Microsteps (behavioral nudges) are a series of short, written messages that were developed by the Thrive Global Wellbeing and Behavior Change Platform, based in the US. The Microsteps messages deliver step-wise, small health behavioral nudges that align with research on behavior change strategies. The behavioral nudges focus on health behaviors that could be useful adjunct interventions for GLP-1RA users, (improved food choices, exercise, sleep and stress management).
219017860|NCT04596644|DRUG|Active Cannabis|6.58% THC + \<0.01% CBD cannabis (in one cigarette)
219017861|NCT04596644|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
219017863|NCT05558904|DRUG|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
219017864|NCT05558904|PROCEDURE|Computed Tomography|Undergo PET/CT
219017865|NCT05558904|OTHER|Laboratory Biomarker Analysis|Correlative studies
219017866|NCT05558904|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219452888|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
219452889|NCT02508506|DRUG|ALKS 5461|Single dose, given orally
219452890|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
219452891|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
219452892|NCT04145505|PROCEDURE|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
219452893|NCT06135142|OTHER|Connective Tissue Massage|It involves manipulating the soft and deep tissues of the body.
219452894|NCT06135142|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
219452895|NCT06135142|OTHER|Classical Massage|It involves manipulating the soft tissues of the body.
219452896|NCT06135142|DEVICE|Therapatic Ultrasound|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
219452897|NCT06135142|OTHER|Heat Treatment|Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
219452898|NCT04146870|OTHER|not have|not have
219452899|NCT06859281|DRUG|Grammidin neo|Grammidin neo, lozenges, 1 lozenge to be taken once under fed conditions.
219452900|NCT06859281|DRUG|Grammidin, a metered dose topical spray|Grammidin, a metered dose topical spray, 4 sprays to be taken once under fed conditions.
218842469|NCT06967337|BEHAVIORAL|Storytelling video|The storytelling video is a short, 2D animated, wordless storytelling video, of 2:21 minutes duration. The humorous, animated story features a minion-like character who, with the help of their dog, learns to adopt better health behaviors after experiencing an episode of burnout. The video mirrors the written Microsteps messages, conveying them through comical demonstration, rather than through instructional language. The animated characters are free of cultural identifiers, with the intention of increasing the accessibility of the video by overcoming barriers associated with culture, education, language and literacy. The video is intended to underscore and complement the written Microsteps messages, enhance their durability and boost hope and happiness in viewers.
218842470|NCT06967337|BEHAVIORAL|Instructional Video|The Instructional Video is a short 2:27min video demonstrating the microsteps and presenting additional information about the rationale for adopting them. The video features an educator who explains these points in a didactic format, and a second educator who demonstrates performing a microstep (stretching at a desk).
218842471|NCT05817422|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
218842472|NCT05817422|OTHER|Placebo|0.9% NaCl solution for injection.
218842473|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
218842474|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
218842475|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
218842476|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
218842477|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
218842478|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
218842479|NCT00750841|DRUG|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
218842480|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
219196867|NCT06878014|DEVICE|PCA IV Oxycodone|All patients were equipped with PCA capable syringe pump (Perfusor Space, B. Braun) with 40 milligrams of oxycodone. Care provider explained thoroughly how to operate the device and educated about possible adverse effects.
219452901|NCT01522196|DRUG|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
219196868|NCT06878014|DRUG|Postoperative pain management with dexketoprofen|Postoperatively patients received 50mg of dexketoprofen intravenously every 8 hours.
219196869|NCT06878014|DRUG|Postoperative pain management with metamizole|Postoperatively patients received 1,0g of metamizole intravenously every 6 hours.
219196870|NCT06878014|DRUG|Preemptive Analgesics|After securing intravenous line each patient received preemptive analgesia with 1,0g paracetamol and 1,0g metamizole.
219452902|NCT01522196|OTHER|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
219452903|NCT02180464|DRUG|LAS41004|
219452904|NCT02180464|DRUG|control|
219452905|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
219452906|NCT05162833|DEVICE|TheraNova Neuromodulation Device|TENS device
219452907|NCT04829864|BEHAVIORAL|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
219452908|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
219452909|NCT06246864|OTHER|Hydrocolloid dressing|After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
219452910|NCT06246864|OTHER|Hypoallergenic Flexible|After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
219452911|NCT00152841|DRUG|Iron supplement 300-600 mg/day|
219452912|NCT00152841|DRUG|Vitamin E 800IU|
219452913|NCT02061163|DEVICE|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
219452914|NCT02061163|DRUG|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
219452915|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
219452916|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219452917|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
219452918|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
219452919|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
219452920|NCT00124384|BEHAVIORAL|CBT-I|
219452921|NCT00124384|DRUG|modafinil|
219452922|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
219452923|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
219452924|NCT05246007|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
219452925|NCT05246007|DRUG|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
219452926|NCT04237610|BEHAVIORAL|behavioral assessment|Probabilistic learning task
219452927|NCT03602521|OTHER|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1\) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2\) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
219452928|NCT06602869|OTHER|Scheduled visit (V1)|During the scheduled visit (V1), as part of routine care, a blood draw will be performed. On this occasion, an additional 7 ml tube will be collected to perform serology and culture. This will help define the group (NTM+ Cases/NTM- Controls) and measure cellular biomarkers.
219452929|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
219452930|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
219452931|NCT06615349|BEHAVIORAL|DigiPall|DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.
219452932|NCT06992934|DRUG|Gilteritinib|Administration of Gilteritinib
219588881|NCT01962480|PROCEDURE|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
219588882|NCT03401359|GENETIC|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
219196871|NCT06878014|DEVICE|Patient monitor|Postoperatively each patient's vital signs were monitored continuously using patient monitor for 48 hours.
219452933|NCT06996730|DRUG|Donanemab|IV Infusion
219452934|NCT06996730|DRUG|RG6289|Oral tablet
219588883|NCT04622215|DIAGNOSTIC_TEST|ICIQ questionnaire|questionnaire
219196872|NCT06587256|DEVICE|Mouth Tape|A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
218842481|NCT06452394|DRUG|Doxycyclin|Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
218842482|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
218842483|NCT05278000|OTHER|Presence of scarcity mindset|"This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
218842484|NCT05360160|DRUG|SNDX-5613|Given by PO
218842485|NCT05360160|DRUG|Venetoclax|Given by PO
218842486|NCT05360160|DRUG|ASTX727|Given by PO
218842487|NCT00736749|PROCEDURE|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
219452935|NCT06996730|DRUG|Donanemab placebo|IV placebo
219452936|NCT06996730|DRUG|RG6289 placebo|Oral tablet placebo
219452937|NCT05442515|BIOLOGICAL|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
219452938|NCT05442515|DRUG|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
219452939|NCT05442515|DRUG|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
219452940|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
219452941|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
218842488|NCT00736749|OTHER|Questionnaire Administration|"Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)"
218842489|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
218842490|NCT04724369|DRUG|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
218842491|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
218842492|NCT06414460|DRUG|ISM3412|ISM3412 will be administered orally once daily.
218842493|NCT04075591|DEVICE|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
218842494|NCT04017650|BIOLOGICAL|Cetuximab|Given IV
218842495|NCT04017650|DRUG|Encorafenib|Given PO
218842496|NCT04017650|BIOLOGICAL|Nivolumab|Given IV
219017867|NCT06660368|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
218842497|NCT04777435|DIAGNOSTIC_TEST|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
218842498|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
219017868|NCT06660368|DRUG|Venetoclax|Venetoclax will be administered orally, once daily, with food.
219196873|NCT06590077|OTHER|Aromatherapy|The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
219452942|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
219452943|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
219452944|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks
219452945|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
219452946|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
219452947|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
219452948|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
219452949|NCT06997627|BIOLOGICAL|GC3111B|0.5 mL, Intramuscular injection
219452950|NCT06997627|BIOLOGICAL|Boostrix®|0.5 mL, Intramuscular injection
219452951|NCT06865014|OTHER|Intermittent Ramadan Fasting|Intermittent fasting during the month Ramadan
219452952|NCT06517732|OTHER|Secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
219452953|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
219452954|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
218842499|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
218842500|NCT02191657|DRUG|Deferiprone|Oral iron chelator
219452955|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
219196874|NCT06590077|OTHER|Control (placebo) group|Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
219452956|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
219452957|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
219452958|NCT06300788|OTHER|PPI and T50 dosing|Sampling for PPI determination and T50 in blood and urine.
219452959|NCT02711553|DRUG|Ramucirumab|Administered IV
219452960|NCT02711553|DRUG|Merestinib|Administered orally
219452961|NCT02711553|DRUG|Cisplatin|Administered IV
219452962|NCT02711553|DRUG|Gemcitabine|Administered IV
219588884|NCT01877226|DRUG|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
219588885|NCT06013410|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
219588886|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
218842501|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
218842502|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
218842503|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
218842504|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
218842505|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
219452963|NCT02711553|DRUG|Placebo Oral|Administered orally
219452964|NCT02711553|DRUG|Placebo IV|Administered IV
219452965|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
219452966|NCT06996574|OTHER|Randomization|The all-in-one (NTG) procedure versus the established two-phase closed-loop SCS procedure with at-home screening trials (TG) under everyday clinical practice, that can be used for clinical decision-making and to inform health policy decisions.
219452967|NCT01771718|DEVICE|Multiphoton microscopy-based tomograph.|non-invasive optical biopsy
219452968|NCT00648492|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
219588887|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
219588888|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
219588889|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
218842506|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
219452969|NCT00648492|DRUG|Glucophage® XR 500 mg|500mg, single dose fed
219452970|NCT03100006|DRUG|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
218842507|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
218842508|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
219452971|NCT03100006|DRUG|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
219452972|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
219452973|NCT04346368|BIOLOGICAL|Placebo|Placebo
219588890|NCT04244123|COMBINATION_PRODUCT|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
219588891|NCT05980195|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy for 30 times within 50 days
219588892|NCT05980195|DRUG|Standard medical treatment|"Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months"
219588893|NCT05980195|BEHAVIORAL|Risk factor management|Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
219588894|NCT04810403|BEHAVIORAL|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
219452974|NCT07004751|DIAGNOSTIC_TEST|Additional laboratory analysis|Additional lab tests will be done to establish the diagnosis of Murine typhus, Bartonellosis, Q-fever, Chikungunya, Zika, Japanese B encephalitis, West Nile virus
219452975|NCT07004751|DIAGNOSTIC_TEST|Standard of Care (SOC)|Standard of care evaluation of a febrile patient is done by the treating medical team as Standard of care evaluation of a febrile patient is done by the treating medical team which includes clinical, basic laboratory, radiological and microbiological evaluations
219452976|NCT06861647|OTHER|sample collection|sample collection of surplus samples not needed for diagnostic or pathological requirements
219588895|NCT02724930|BEHAVIORAL|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
219588896|NCT00311402|DRUG|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
218842509|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
218842510|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
218842511|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
218842512|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
218842513|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
218842514|NCT03989349|DRUG|Placebo|Placebo
218842515|NCT03989349|DRUG|Nemolizumab|Nemolizumab
218842516|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
218842517|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
219452977|NCT06861647|OTHER|Discussing study/seeking consent|An NHS or CRN staff member will inform patients of the nature and objectives of the study, go through the participant information sheet, highlighting possible risks associated with their participation and reiterate the voluntary nature of this study. Patients will be given opportunities to ask questions pertaining to the study. If the potential participant is still interested in taking part, written informed consent for the study will then be received and a copy of the informed consent will be given to the participant to keep.
219452978|NCT06861647|OTHER|Completion of Study Questionnaire|Patient will complete in own time. To take place in a routine outpatient clinic appointment
219452979|NCT06861647|OTHER|Blood Sample|To take place in an outpatient clinic.
219452980|NCT05605041|DEVICE|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
219452981|NCT04272801|DRUG|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
219452982|NCT04272801|BEHAVIORAL|Patient reported outcomes|"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
219452983|NCT06998784|DEVICE|taVNS|"Patients will receive taVNS at left tragus (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows:~* Duty circle: 30s on periods alternating with 30s off periods;~* Frequency: 25 Hz;~* Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient);~* Pulse width: 0.5 ms."
219452984|NCT06998784|DEVICE|Sham-taVNS|"Patients will receive taVNS at left earlobe (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows: \*Duty circle: 30s on periods alternating with 30s off periods; \*Frequency: 25 Hz; \*Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient); \*Pulse width: 0.5 ms."
219452985|NCT07006064|DEVICE|SUPERNOVA|In the intervention group, oxygen is delivered using the SuperNO2VA™ nasal positive airway pressure mask (Vyaire Medical, USA), which differs from conventional nasal oxygen delivery systems by providing continuous positive airway pressure (CPAP) through a sealed nasal interface. This mask also includes an integrated sampling port for accurate end tidal carbon dioxide (EtCO2) monitoring. The aim is to reduce the incidence of hypoxia and allow for better detection and prevention of hypo/hypercapnia during sedation in elderly patients undergoing TAVI without intubation. The use of positive pressure is intended to prevent upper airway collapse, maintain functional residual capacity, and improve gas exchange during sedation.
219452986|NCT07006064|DEVICE|NASAL MASK|Traditional nasal cannulas only provide passive oxygen flow. End-tidal CO2 measurement is being conducted with Capnostream™ 35 Portable Respiratory Monitor.
219452987|NCT04060706|RADIATION|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
219452988|NCT01742663|DRUG|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
219452989|NCT01742663|DRUG|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
219452990|NCT01742663|DRUG|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
219452991|NCT05559203|BEHAVIORAL|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
219452992|NCT06625073|DRUG|Empagliflozin|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
219452993|NCT06625073|DRUG|Placebo|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
219588897|NCT00311402|OTHER|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
219588898|NCT05713851|DRUG|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
219588899|NCT00073619|BEHAVIORAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
218842518|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
218842519|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
218842520|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
218842521|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
218842522|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
218842523|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
218842524|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
218842525|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
218842526|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
218842527|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
218842528|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
218842529|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
218842530|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
218842531|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
218842532|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
219452994|NCT07009886|OTHER|Communication|Participants meet with clinician
219452995|NCT07012915|DIAGNOSTIC_TEST|Blood testing|Blood sample will be collected twice for each participants procedding and following dental implant removal. Cone Beam Computed Tomography will be applied to evaluate the shape, severity of bone defect in direct viscinity of the implant.
218842533|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
219588900|NCT02823418|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
219588901|NCT02823418|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
219588902|NCT03082287|DEVICE|Fecal Calprotectin Level|Measurement of calprotectin in feces
218842534|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
218842535|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
219452996|NCT03117309|DRUG|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
219452997|NCT03117309|DRUG|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
219452998|NCT03117309|DRUG|Nivolumab 3mg/kg|In combination with Ipilimumab
219452999|NCT03117309|DRUG|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
219588903|NCT05241028|DRUG|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
219588904|NCT02640053|PROCEDURE|Cryotherapy|Applied topically
219588905|NCT02640053|DRUG|Paclitaxel|Given IV
218842536|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
218842537|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
218842538|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
218842539|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
218842540|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
218842541|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
218842542|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
218842543|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
219453000|NCT01089075|DRUG|Hydrocortisone|20 mg po for 7 days (2 tablets)
219453001|NCT01089075|DRUG|Placebo|2 tablets po
219453002|NCT01818128|DEVICE|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
219453003|NCT01818128|DEVICE|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
218842544|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
218842545|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
218842546|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
218842547|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
218842548|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
218842549|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
218842550|NCT06991270|DEVICE|OMNI 3.0 Surgical System|Canaloplasty and trabeculotomy.
218842551|NCT06611163|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
218842552|NCT06611163|DRUG|Placebo|Placebo SC injection at Day 1 and Week 4
218842553|NCT05906134|PROCEDURE|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
218842554|NCT05906134|PROCEDURE|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
219453004|NCT05007301|DEVICE|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
218842555|NCT05906134|PROCEDURE|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
218842556|NCT05906134|PROCEDURE|Thoracic epidural catheter|"The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will likely consist of a thoracic epidural catheter.~Any additional pain control will be added as an adjunct to the study arm and will be noted in the data set."
218842557|NCT07003893|OTHER|Diaphragmatic Proprioceptive Neuromuscular Facilitation + Aerobic exercises|Control group will perform aerobic exercises only Experimental group will perform diaphragmatic proprioceptive neuromuscular facilitation in addition to aerobic exercises
218842558|NCT06872489|BIOLOGICAL|SL-28.|Allogeneic, non-HLA matched, Leucocyte-Tells-based therapy
218842559|NCT05812924|BIOLOGICAL|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
218842560|NCT06689007|OTHER|Implementation Intervention|The intervention employs four established implementation strategies according to the Expert Recommendations for Implementing Change: conduct educational meetings, provide ongoing consultation, provide technical assistance, and change physical structure and equipment. The first component is a six-week online course led by the PI that combines weekly pre-recorded lectures, hands-on activities, group mentoring sessions and a reflective assignment. The second component of the intervention is ensuring access to the equipment needed for FES. The third component of the intervention is access to the FES Toolkit.
219453005|NCT04048876|DRUG|CC-90001|oral
219453006|NCT04048876|DRUG|Placebo|oral
219453007|NCT02227901|DRUG|Tipifarnib|Given PO
219453008|NCT02227901|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219453009|NCT02227901|DRUG|Temozolomide|Given PO
219453010|NCT02227901|OTHER|Laboratory Biomarker Analysis|Correlative studies
219453011|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
219453012|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
219453013|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
219453014|NCT05046236|OTHER|Interactive POWER rehabilitation|Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
219453015|NCT05046236|OTHER|Conventical physical training|Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
219453016|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
219453017|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
219453018|NCT01573286|DRUG|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
219588906|NCT02640053|OTHER|Quality-of-Life Assessment|Ancillary studies
219588907|NCT02640053|OTHER|Questionnaire Administration|Ancillary studies
219588908|NCT01794026|PROCEDURE|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
218842561|NCT06877299|DRUG|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
218842562|NCT07034560|DRUG|Tranexamic Acid (TXA)|500 mg oral tranexamic acid (Transamin®), taken once daily at bedtime for 12 weeks.
218842563|NCT07034560|DRUG|melatonin (Circadin)|2 mg oral melatonin (Circadin®), taken once daily at bedtime for 12 weeks.
218842564|NCT07034560|DRUG|Placebo|Placebo capsule identical in appearance, taken once daily at bedtime for 12 weeks.
218842565|NCT07033650|OTHER|Bulk-fill composite (X-tra Fil)|Bulk fill resin composite
218842566|NCT07033650|OTHER|flowable Bulk-fill composite (X-tra Base)|flowable resin composite
218842567|NCT07033650|DEVICE|compothixo oscillating packing|oscillating packing device
218842568|NCT07034937|OTHER|Combination of aerobic training (treadmill walking) and resistance training|Combination of aerobic training (treadmill walking) and resistance training using resistance bands for deltoid, biceps, triceps, and quadriceps muscles. Conducted twice weekly for 6 weeks (12 sessions). Tools include treadmill and theraband loop bands.
218842569|NCT07034235|PROCEDURE|Dentin Wet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on wet dentin in the etch-and-rinse application strategy.
218842570|NCT07034235|PROCEDURE|Dentin Overwet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on overwet dentin in the etch-and-rinse application strategy.
218842571|NCT07034235|DEVICE|Ambar Universal APS Plus; FGM|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
218842572|NCT07034235|DEVICE|Prime&Bond Active; Dentsply Sirona|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
218842573|NCT07033910|DEVICE|sepsis adsorption column|after the initiation of fluid and antibiotic therapy according to the Surviving Sepsis Campaign 2021 Guidelines, an additional routine sepsis adsorption column (Biosky® MG350) was used within 48-72 hours.
218842574|NCT07034846|OTHER|High-intensity intermittent IMT and Otago Exercises Group|Patients in the experimental group will perform 7 sets of high-intensity intermittent inspiratory muscle training (IMT) for eight weeks, one day a week face-to-face with the researcher and two days at home, for a total of three days, each set consisting of 2 minutes of loading and 1 minute of rest for a total of 21 minutes. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
218842575|NCT07034846|OTHER|Sham IMT and Otago Exercises Group|Patients in the control group will perform 7 sets of sham inspiratory muscle training (IMT), consisting of 2 minutes of loading and 1 minute of rest in each set for a total of 21 minutes, one day a week face-to-face with the researcher and two days at home, for eight weeks. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
218842576|NCT07034287|OTHER|Telehealth physical therapy and pharmacy consultation|Telehealth physical therapy and pharmacy consultation at baseline emergency department visit.
218842577|NCT07034105|DIAGNOSTIC_TEST|Gait Analysis|"* Overground Walking: Stroke patients walk in a natural environment, collecting data on their gait parameters such as stride length, cadence, and gait speed.~* Treadmill: Patients walk on a treadmill at their comfortable pace, allowing for more control over their walking speed while measuring the same gait parameters as in overground walking.~* Body-Weight Supported Treadmill: Patients walk on a treadmill with a body-weight support system that reduces the load on the legs, enabling patients with more severe impairment to perform walking tasks safely while recording gait parameters."
218842578|NCT07033208|DEVICE|Feasibility to obtain thermal variance measurements using a wireless thermal capsule|A total of 10 healthy volunteers will be enrolled in this study all consented participants will receive the same intervention.
218842579|NCT07035938|OTHER|observational study|observational study
218842580|NCT07033702|DEVICE|Airway-Exchange Broncholaryngoscope (AEBLScope)|Airway Exchange Broncholaryngoscope (AEBLScope) - A modified disposable flexible bronchoscope designed to allow visualization during airway tube exchange procedures.
218842581|NCT07033143|DRUG|Adebrelimab+SOX|"Adebrelimab: 1200mg, intravenous drip, day 1, 21 days as one cycle, treatment duration is 1 year.~SOX: Eight cycles after the operation, intravenous infusion of oxaliplatin at 130 mg/m2. On the first day, oral administration of S-1 at 40-60 mg twice a day. From the first to the 14th day, 21 days constitute one cycle.~Enhanced CT examinations of the chest, abdomen and pelvis were conducted every 9-12 weeks in the first year of treatment. Then have a check-up every 24 weeks."
219453019|NCT01573286|DRUG|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
219588909|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
218842582|NCT07032948|DEVICE|FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter、Columbus™ 3D EP Navigation System|All patients were treated withFireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter and Columbus™ 3D EP Navigation System for rapid arrhythmia.
219453020|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
219453021|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
219588910|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
218842583|NCT06883409|PROCEDURE|Interval Cytoreduction Surgery|"The procedure started with the cytoreduction of highest complexity (determined at the time of initial inspection), after which, if necessary, the patient underwent a complete hysterectomy, bilateral salpingo-oophorectomy, omentectomy, or partial peritonectomy and excision of any peritoneal implants present. The magnitude of the surgical procedures will be classified as:~1. Standard surgery: minimal hysterectomy, adnexectomy y omentectomy~2. Radical Surgery: included resection of the ovaries, of the rectouterine excavation (pouch of Douglas) and or the peritoneum between the bladder and uterus, hysterectomy, rectosigmoid colectomy, and complete omentectomy~3. Supra-radical Surgery: included other procedures such as splenectomy, diaphragm resection, or other intestinal resection."
218842584|NCT07032974|DEVICE|Franseen|Franseen needle
218842585|NCT07032974|DEVICE|Forward-bevel|Forward-bevel needle
218842586|NCT07032974|DEVICE|Fork-tip|Fork-tip needle
218842587|NCT07043270|DRUG|Nab-paclitaxel + Gemcitabine|Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).
218842588|NCT07043270|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).
218842589|NCT07050654|DEVICE|Dual-task cycling|"Pairs of participants are formed, who will be the SocialBike players; these pairs consist of users from the same center. The two players are in the same room where two replicas of the SocialBike system are installed.~The participants can each view, on their own screen, the virtual scenario, either a park or a city environment. Movement within these VR environments is synchronized with the patient's actual pedaling speed, measured in revolutions per minute (RPM) from the cycle ergometer. Movement occurs along a predefined path. The participant's heart rate will always be monitored.~The therapist chooses the optimal ergometer workload, the type of exercise, and social/single-player mode. Each session (either single- or multi-player mode) lasts 10 minutes. The available exercise are: Find the intruder (go/no-go task); Prepare your Meal (spatial attention); Watch the road (working memory)."
218842590|NCT07052669|RADIATION|Hypofractionated Radiation Therapy|All patients will receive split-course hypofractionated radiotherapy. First course of radiotherapy: Total dose of 4000 cGy in 10 daily fractions (400 cGy per fraction) or 3000 cGy in 6 daily fractions (500 cGy per fraction). Three weeks after the completion of the first course of hypofractionated radiotherapy, tumor response and toxicity will be evaluated. For patients who achieve a partial response and without grade 2 or higher respiratory toxicity, a second course of radiotherapy will be planned for the residue disease at a total dose of 2000 \~2400 cGy in 5\~6 fractions (400 cGy per fraction). The interval between the two courses of radiotherapy will be 28 days.
218842591|NCT07052669|RADIATION|Conventionally Fractionated Radiation Therapy|Patients in this group will receive a total dose of 6000- 6400 cGy in 30- 32 fractions, with 200 cGy per fraction.
219453022|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
219453023|NCT06145763|OTHER|Survey Administration|Ancillary studies
219453024|NCT02685124|DIETARY_SUPPLEMENT|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
219588911|NCT01600430|DIETARY_SUPPLEMENT|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
219588912|NCT03506906|DIAGNOSTIC_TEST|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
218842592|NCT07052669|DRUG|Concurrent Chemotherapy|Paclitaxel plus platinum-based chemotherapy.
218842593|NCT07052669|DRUG|concurrent chemotherapy|Paclitaxel plus platinum-based chemotherapy or pemetrexed plus platinum-based chemotherapy.
218842594|NCT07052669|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, PD-1/PD-L1 immune checkpoint inhibitor consolidation therapy will be administered for up to 12 months.
218842595|NCT06749236|DRUG|test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).
218842596|NCT06749236|DRUG|reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).
218842597|NCT07066306|DRUG|Ketamine|In the ketamine group, 0.2 mg/kg of ketamine will be administered locally. This application will be performed twice: once during the Le Fort I osteotomy and once during the sagittal split osteotomy. After calculating the total dose, it will be equally divided and administered locally to both the maxilla and the mandible.
219017873|NCT06481592|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
219588913|NCT03506906|DIAGNOSTIC_TEST|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
219588914|NCT04502823|PROCEDURE|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."
219588915|NCT02260297|DEVICE|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
219588916|NCT03283761|DRUG|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
218842598|NCT07066306|DRUG|Articaine Hydrochloride + Epinephrine|A total of 4 ampoules of articaine hydrochloride will be used. Two ampoules will be administered prior to the incision during the Le Fort I osteotomy, and the remaining two ampoules will be used prior to the incision during the sagittal split osteotomy.
218842599|NCT06817707|OTHER|Evaluation of urinary dysfunction in patients with CANVAS|Urinary dysfunction will be evaluated with neurologic exam, interrogation, urinary dairy report, self-questionnaires, biologic analysis, Sudoscan and urological exams
219453025|NCT02177214|PROCEDURE|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
219453026|NCT01861613|BIOLOGICAL|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
219453027|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
219453028|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
219453029|NCT01028040|DRUG|AZD3043|Intravenous, single dose
219453030|NCT01028040|DRUG|AZD3043|Infusion, single dose
219453031|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
219453032|NCT01297023|DIETARY_SUPPLEMENT|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
219453033|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
219453034|NCT01297023|OTHER|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
219588917|NCT03283761|DRUG|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
219453035|NCT03103776|OTHER|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
219453036|NCT03764462|DRUG|AD-101 45mg|Raloxifene 45mg tablet
219453037|NCT03764462|DRUG|Raloxifene 60mg|Raloxifene 60mg tablet
219453038|NCT03949010|OTHER|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
219453039|NCT03949010|OTHER|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
219453040|NCT03949010|OTHER|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
219453041|NCT01524926|DRUG|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
219453042|NCT03874104|DIETARY_SUPPLEMENT|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
219588918|NCT03283761|DRUG|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
218842600|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
218842601|NCT00322413|DRUG|Epoetin|
219017876|NCT05670080|BEHAVIORAL|Motor Imagery|Motor imagery is the imagining of action without its physical execution and motor imagery elicits activity in brain regions that are normally activated during actual task performance. The brain perceives real experiences and the visualization process as similar. For this reason, imagery is considered a mental exercise
219017877|NCT05670080|BEHAVIORAL|Physical Therapy|Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.
219453043|NCT02187224|DRUG|Progesterone|
219453044|NCT02187224|DRUG|Placebo (for Progesterone)|
219453045|NCT00006062|DRUG|oxaliplatin|
219453046|NCT01208818|DRUG|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
219453047|NCT01208818|DRUG|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
219453048|NCT01208818|DEVICE|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
219453049|NCT01208818|DEVICE|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
219453050|NCT01039038|RADIATION|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
219588919|NCT03283761|DRUG|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
219588920|NCT05041881|DEVICE|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
219588921|NCT05041881|DEVICE|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
219588922|NCT05041881|DEVICE|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
219588923|NCT00148642|DEVICE|silver salts coated endotracheal tube|intubation with silver coated tube
219588924|NCT00148642|DEVICE|uncoated endotracheal tube|intubation
218842602|NCT07079436|DRUG|0.25% ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.25% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
218842603|NCT07079436|DRUG|0.375% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.375% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
218842604|NCT07079436|DRUG|0.5% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.5% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
218842605|NCT07080242|DRUG|BL-M14D1|BL-M14D1 will be administered on D1 every 3 weeks.
219017878|NCT06385015|BEHAVIORAL|Tailored DPP Intervention|The intervention includes 19 sessions (18 in-person and 1 on-demand) covering 24 DPP modules; each session is approximately an hour in length and will be moderated by a trained lifestyle coach. Lifestyle coaches are accessible, collaborative, and culturally competent diabetes care and education specialists trained and certified in the CDC's National DPP curriculum to provide effective guidance and support for program participants. Each group will meet regularly during the academic year, with six in-person sessions delivered per 10-week quarter (for each of three quarters) to allow for breaks during final exams and scheduled school recess (e.g., spring break). It will take place on UCLA campus.
219017880|NCT02026895|GENETIC|Genetic blood sample|
219017881|NCT05030428|DRUG|Inclisiran sodium 300 mg|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
219453051|NCT05748236|DRUG|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
219453052|NCT05748236|DRUG|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
219453053|NCT00388375|PROCEDURE|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
219453054|NCT02237365|DRUG|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
219453055|NCT02237365|DRUG|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
219453056|NCT02237365|DRUG|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
219453057|NCT04162912|BEHAVIORAL|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
219453058|NCT01010776|DRUG|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
219453059|NCT06687876|DRUG|Metformin|Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
219453060|NCT06693726|DRUG|Angiotensin II Infusion|Angiotensin II continuous infusion
218842606|NCT07081399|COMBINATION_PRODUCT|ETT cuff pressure monitoring, ETT suctioning, cough augmentation technique, swallowing exercises,: Nebulized budesonide 1mg and IV methylprednisolone 40 mg we|cough augmentation, larson maneuver, swallowing rehabilitation
218842607|NCT07079475|DRUG|DZD6008|DZD6008 will be administered orally at 40/60 mg QD or selected dose.
218842608|NCT07079475|DRUG|Sunvozertinib|Sunvozertinib will be administered orally at 100 mg QD or selected dose.
218842609|NCT07079475|DRUG|Osimertinib|Osimertinib will be administered orally at 80 mg QD
218842610|NCT07081542|DEVICE|IotaSoft Robotic Insertion System|The IotaSoft robotic insertion device is an FDA-approved tool designed to provide precise and controlled insertion of the cochlear implant electrode array to minimize trauma during implantation.
219453061|NCT04655846|BEHAVIORAL|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
218842611|NCT07081542|PROCEDURE|Manual Cochlear Implant Insertion|Standard surgical technique for manually inserting the cochlear implant electrode array. This method reflects the current standard of care without the assistance of robotic tools.
218842612|NCT07081477|DRUG|Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients|Cirpropofol is a 2,6-disubstituted phenol derivative that introduces a cyclopropyl group based on the chemical structure of propofol, increasing its affinity with GABA receptors and stereoeffect, thus its effect is 4-5 times that of propofol. Studies have found that the incidence of hypotension, injection pain, and respiratory depression during cirpropofol anesthesia is lower than that of propofol.
218842613|NCT07081477|DRUG|Propofol Intravenous Anesthesia Induction for Painless Colonoscopy in Elderly Patients|Propofol has favorable pharmacokinetic properties with minimal residue. Currently, it is widely used for endoscopic procedure sedation, but there are still many limitations, such as a narrow therapeutic window, injection pain, hypotension, and respiratory depression.
218842614|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
218842615|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
218842616|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
218842617|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
218842618|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
218842619|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
218842620|NCT07081789|BEHAVIORAL|Music Listening|Participants will listen to a 24 min 54 sec music track for 4 days (starting 3 days before menstruation).
218842621|NCT07081789|BEHAVIORAL|Puzzle Activity|Participants will do puzzles for the same duration and timing.
219453062|NCT04655846|BEHAVIORAL|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
218842622|NCT07079618|DRUG|SGC001|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug SGC001 should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
218842623|NCT07079618|DRUG|Placebo|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug placebo should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
218842624|NCT07081295|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
218842625|NCT07079462|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Radiotherapy: Low-dose radiotherapy to the abdominal cavity region, 5-10 Gy/5 fractions. For visible local lesions, large fraction radiotherapy is administered, 15-30 Gy/5 fractions, once daily.~Immunotherapy: One week after the completion of radiotherapy, cadonilimab, 6 mg/kg, is administered every two weeks."
218842626|NCT07079462|DRUG|Chemotherapy (control)|Standard second-line treatment regimen: (XELOX/FOLFOX or XELIRI/FOLFIRI + bevacizumab/ cetuximab)
219017882|NCT05030428|DRUG|Placebo|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
218842627|NCT05571644|DRUG|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
218842628|NCT05571644|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
218842629|NCT05571644|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
218842630|NCT05571644|DRUG|mFOLFOXIRI+AK104+fruquintinib|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles, and fruquintinib (3mg Qd, D1-21, Q4W for 3 months) before surgery
218842631|NCT07079709|BEHAVIORAL|Workfocused CBT|In WCBT, the central idea is that CBT techniques can be applied in a work context with the aim of achieving both usual treatment goals related to symptoms and RTW. To ensure positive effects at both symptomatic and functional levels, a work perspective must be fully integrated into the intervention to optimize the treatment effect which demands collaboration with the sick leave prescribing doctor and the patient's employer. The protocol is based on principles of increasing return-to-work self-efficacy (RTW-SE). Work-specific components, such as work anamnesis, adjusting the difficulty of work tasks, and developing a return-to-work plan that includes recommendations for workplace accommodations, are integrated into all treatment sessions.
219453063|NCT01229410|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
218842632|NCT07079709|OTHER|Standard Care (in control arm)|Standard Care is defined as care by the sick leave prescribing physician and the rehab coordinator. Other interventions such as psychological treatment, physiotherapy etc. may also be included in this arm.
218842633|NCT07080749|OTHER|Vagal nerve stimulation through deep exhalation exercise|Deep Exhalation Treatment: Participants will receive a set of standard balloons to use for deep exhalation. They will sit in a comfortable position, take a deep breath in and blow their breath continuously out into the balloon. They repeat the deep exhalation process for a total of 4 consecutive breaths. They perform this breathing exercise once every hour during waking hours each day.
218842634|NCT07080749|OTHER|Vagal nerve stimulation through ear electrical stimulation|Ear Electrical Stimulation Treatment: Participants will receive a small electrical stimulator and electrode set to be applied to their left ear. The investigators will train the participants to use the device safely and effectively. Once they are comfortable with the procedure, they will perform the procedure at home for 20 minutes twice daily.
218842635|NCT07080749|OTHER|No intervention (observational study)|The no intervention group will not receive treatment immediately after their baseline assessments, they will be scheduled for another visit after two weeks, then a new set of baseline measurements will be recorded as the post intervention data.
218842636|NCT06456008|OTHER|Standard of care|Standard of care
219453064|NCT01229410|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
219453065|NCT04485936|DEVICE|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
219453066|NCT03334656|BIOLOGICAL|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
218842637|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
218842638|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
218842639|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
218842640|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
218842641|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
218842642|NCT06907888|DEVICE|Rhythm Express Wearable System|The Rhythm Express Wearable System consists of the FDA-cleared RX-1 mini Cardiac Monitor, an FDA-cleared pulse oximeter, and a cellular gateway to relay data from the pulse oximeter to the cloud-based RS-1 Server. The RS-1 Sleep Algorithm is a cloud-based software as a medical device (SWMD) that receives inputs from the two FDA-cleared wearable devices. The Algorithm, together with the two wearable devices, comprises the Rhythm Express Wearable System.
218842643|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
218842644|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
218842645|NCT06838351|BEHAVIORAL|Guided Drawing Intervention|The guided drawing activity is a 20 minute session which integrates mindfulness and drawing elements. Participants were given a pencil and blank paper to use while they watched a pre-recorded video guiding them through a mindfulness and drawing activity. In the pre-recorded video, participants are instructed to draw elements of nature from exemplar photographs (e.g., leaves, twigs). The activity incorporates drawing with aspects of mindfulness meditation (i.e., being non-judgmental of thoughts and behaviors, focusing on breathing, and embodiment).
218842646|NCT06838351|BEHAVIORAL|Free Drawing Control|Participants are instructed to draw freely for about 20 minutes.
218842647|NCT06838351|BEHAVIORAL|Basic Control|Participants are instructed to complete simple paper and pencil activities (e.g., mazes, connect the dots) for about 20 minutes.
218842648|NCT06924918|OTHER|Scalp Acupuncture Treatment|"Acupoint Selection:~Baihui (GV20), Sishencong (EX-HN1), Frontal Midline Line (MS1), Vertex Midline Line (MS5), Lateral Line 1 of Vertex (MS7), Shenting (GV24), Yintang (EX-HN3), Shuaigu (GB8)~Acupuncture Manipulation:~Needles with a diameter of 0.18-0.35 mm and length of 13-25 mm are selected. After routine disinfection of the acupoint skin, the practitioner holds the micro-needle and quickly inserts it into the subcutaneous tissue at an insertion angle of 15°-30°, primarily using superficial horizontal insertion. The insertion depth is maintained at 15-20 mm, adjusted according to the child's head circumference, body size, and body mass. Needles are retained for 30 minutes.~Course of treatment:~2 times a week for 12 weeks"
219453067|NCT03334656|OTHER|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
219453068|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
219196875|NCT05181748|BIOLOGICAL|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
219453069|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 3mcg
219453070|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 15mcg
219453071|NCT00902057|DRUG|placebo|saline subcutaneous
219453072|NCT03286881|OTHER|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
219453073|NCT03286881|OTHER|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
219453074|NCT03286881|OTHER|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
219453075|NCT03286881|OTHER|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
219453076|NCT03286881|OTHER|Usual treatment|Medication provided by a general practitioner.
219453077|NCT05232292|BIOLOGICAL|Ultrix Quadri|vaccination by Ultrix Quadri against flu
219453078|NCT04140682|DEVICE|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
219453079|NCT04140682|DEVICE|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
219453080|NCT02929381|DEVICE|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
219453081|NCT02929381|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
219453082|NCT00169767|OTHER|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
219453083|NCT04446767|RADIATION|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
219453084|NCT04446767|OTHER|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
219453085|NCT03019172|COMBINATION_PRODUCT|Lactobacillus reuteri|Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
219453086|NCT03019172|DIETARY_SUPPLEMENT|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
219453087|NCT03294772|OTHER|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
219453088|NCT03294772|OTHER|liquid soap|DCCs received liquid soap and a program educational.
219453089|NCT01637090|DRUG|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
219453090|NCT00952952|DRUG|Mesalamine|
219453091|NCT02822352|OTHER|Chromoendoscopy|High definition virtual chromoendoscopy
219453092|NCT04600453|OTHER|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
219453093|NCT01815905|OTHER|Mobile program for occupational and speech therapy|
219453094|NCT01815905|OTHER|Traditional rehabilitation therapy|
219453095|NCT01665898|PROCEDURE|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
219453096|NCT01665898|PROCEDURE|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
219453097|NCT02931747|DIETARY_SUPPLEMENT|Placebo|Subjects are received Placebo once daily for 16 weeks.
219453098|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
219453099|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
219453100|NCT04386473|DEVICE|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
219453101|NCT00198731|BEHAVIORAL|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
219017889|NCT04519645|DRUG|Lacosamide intravenous|Study participants will receive lacosamide (LCM) as an intravenous (iv) infusion during the Treatment Period.
219017890|NCT04519645|DRUG|Lacosamide oral|Study participants may receive lacosamide (LCM) as an oral solution during the Extension Period.
219453102|NCT00922038|BEHAVIORAL|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
219453103|NCT02280525|DRUG|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
219453104|NCT02280525|DRUG|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
219453105|NCT02280525|DRUG|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
219453106|NCT02280525|DRUG|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
218842649|NCT06924918|OTHER|Tuina Treatment Group|"Prescription:~Spleen Meridian (Pi Jing), Small Heavenly Heart (Xiao Tianxin), Five Finger Joints (Wu Zhi Jie), Internal Bagua (Nei Bagua), Hand Yin-Yang (Shou Yin Yang), Upper Three Passes (Shang San Guan), Gushing Spring (Yongquan, KI-1), Leg Three Miles (Zusanli, ST-36) Manipulation Techniques~Pushing/Kneading the Spleen Meridian (Tonifying Pi Jing):~Tapping Small Heavenly Heart (Xiao Tianxin):~Kneading the Five Finger Joints (Wu Zhi Jie):~Moving the Internal Bagua (Nei Bagua):~Separating Yin and Yang (Separating Shou Yin Yang):~Pushing Up the Upper Three Passes (Pushing San Guan):~Kneading Gushing Spring (Yongquan, KI-1):~Kneading Leg Three Miles (Zusanli, ST-36):~2 times a week for 12 weeks"
219453107|NCT02280525|PROCEDURE|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
219453108|NCT02280525|DRUG|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
218842650|NCT07080723|OTHER|Algorithm guided treatment (AGT)|"AGTs consist of strategies (which treatments to use), tactics (how to implement each treatment) and treatment steps (in what order to implement the different treatments). Furthermore, AGTs also define critical decision points during the treatment at which the effects of a certain treatment are assessed and based on this assessment recommend specific treatment revisions according to preset if-then rules. This is most often done by implementing measurement-based care."
219453109|NCT02913833|OTHER|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
218842651|NCT07080723|OTHER|Treatment as usual (TAU)|TAU includes the standard clinical care for patients with TRD as determined by a senior consultant.
218842652|NCT06906549|DRUG|Rituximab 200mg/6months|perfusion of Rituximab 200mg
218842653|NCT06906549|DRUG|Rituximab 1g/6months|perfusion of Rituximab 1g
219453110|NCT03832166|OTHER|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
219588925|NCT05375526|DEVICE|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
219588926|NCT05783544|DIAGNOSTIC_TEST|Interleukin-1B|Level of serum interleukin-1B will be detected
219588927|NCT05783544|DIAGNOSTIC_TEST|Interleukin-4|Level of serum interleukin-4 will be detected
218842654|NCT04183465|OTHER|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
218842655|NCT04183465|OTHER|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
218842656|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
218842657|NCT06948006|DRUG|AZD4144|Participants will receive AZD4144 orally.
218842658|NCT06948006|DRUG|Omeprazole|Participants will receive omeprazole orally.
219453111|NCT03832166|OTHER|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
219453112|NCT03903276|OTHER|rehabilitation|Tens
219453113|NCT05354973|DEVICE|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
219453114|NCT01542294|DRUG|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
219453115|NCT01542294|DRUG|Oxaliplatin|130mg/m2 d1 repeated every 21 days
219453116|NCT04520867|OTHER|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
219453117|NCT04050475|DIETARY_SUPPLEMENT|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
219588928|NCT05783544|DIAGNOSTIC_TEST|Interleukin-6|Level of serum interleukin-4 will be detected
219588929|NCT05783544|DIAGNOSTIC_TEST|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
219588930|NCT05783544|DIAGNOSTIC_TEST|interferon- gamma|Level of serum interferon- gamma will be detected
219588931|NCT05590832|BEHAVIORAL|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
219588932|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
219588933|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
218842659|NCT06950177|BIOLOGICAL|CoV-RBD-scNP-001 and 3M-052-AF|All subjects will receive the investigational vaccine CoV-RBD-scNP-001 adjuvanted with 3M-052-AF.
218842660|NCT05878951|DRUG|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
219453118|NCT03890497|BIOLOGICAL|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
219453119|NCT03746145|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
219453120|NCT03746145|DIETARY_SUPPLEMENT|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
218842661|NCT06283459|BIOLOGICAL|IMNN-101|IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.
218842662|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
218842663|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
218842664|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
218842665|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
218842666|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
218842667|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
218842668|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
218842669|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
218842670|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
219588934|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
219588935|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
219588936|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
218842671|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
218842672|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
218842673|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
218842674|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
218842675|NCT05386719|OTHER|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.
218842676|NCT05386719|OTHER|Screening and Enrollment|Consent
219588937|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
219588938|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
219588939|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219588940|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219588941|NCT02036775|DRUG|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219588942|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
219588943|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
219588944|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219453121|NCT04537572|DIAGNOSTIC_TEST|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
219453122|NCT05469152|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
219453123|NCT03566992|PROCEDURE|Gastric|Placement of a nasoenteric tube
219453124|NCT02152540|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
219453125|NCT02152540|DEVICE|Sham rTMS|Placebo Device that simulates active rTMS treatment
219453126|NCT01012037|DRUG|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
219453127|NCT01012037|DRUG|placebo|patient to receive placebo tablet(s) matching linagliptin
219453128|NCT01012037|DRUG|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
219453129|NCT02583711|DEVICE|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
219588945|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
219588946|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219588947|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
219588948|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
219588949|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
219588950|NCT01268501|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
218842677|NCT05386719|BEHAVIORAL|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
218842678|NCT05386719|BEHAVIORAL|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
218842679|NCT05386719|OTHER|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
218842680|NCT05386719|OTHER|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c \<5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol \>200, family history of Coronary Artery Disease/Heart Attack in first degree family \<55 year old male or \<65 year old female, systolic blood pressure \>130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
218842681|NCT05386719|BEHAVIORAL|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
218842682|NCT05386719|BEHAVIORAL|Recommendations|Provide individual patient handout based on all above interventions
218842683|NCT05386719|BEHAVIORAL|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
218842684|NCT05873192|DRUG|ADT|Given by PO
218842685|NCT05873192|DRUG|Enzalutamide|Given by PO
218842686|NCT05873192|DRUG|Talazoparib|Given by PO
218842687|NCT05873192|DRUG|Degarelix|Given PO or given INJ
218842688|NCT05873192|DRUG|Luprolide|Given PO or given INJ
218842689|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
219453130|NCT04853056|DEVICE|virtual reality|wearing virtual reality glasses
219453131|NCT04853056|DEVICE|Cold vibration|Buzzy
219453132|NCT05675475|OTHER|Exposure|Higher education students from health technologies field exposed to digital devices.
219588951|NCT05913089|DRUG|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
219588952|NCT05913089|DRUG|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
219588953|NCT00769990|DIETARY_SUPPLEMENT|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
219588954|NCT00769990|RADIATION|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
219588955|NCT05495828|DRUG|Orelabrutinib|Orelabrutinib, 150mg, po, qd
219588956|NCT02131961|DRUG|Collagenase ointment|250 collagenase units/g
219588957|NCT02131961|DEVICE|Modified Contact Cast System|1 Unit
219588958|NCT06209567|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scans|Participants will be injected intravenously with 68Ga-PSMA-11 via intravenous catheter. PET scans will first be interpreted without information on the results of other imaging modalities. Following the blinded read of the 68Ga-PSMA-11 PET scans, all recorded findings will be correlated with the results of CE CT and MR studies and 18F-FDG PET/CT or PET/MR performed as part of standard clinical care.
219588959|NCT00718913|DRUG|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
219588960|NCT00718913|DRUG|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
218842690|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
218842691|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
218842692|NCT01837446|DRUG|2% morphine solution|
218842693|NCT01837446|DRUG|Magnesium aluminum hydroxide|
218842694|NCT01837446|DRUG|2% viscous lidocaine|
218842695|NCT01837446|DRUG|Diphenhydramine|
219453133|NCT05675475|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
219588961|NCT00718913|DRUG|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
219588962|NCT00718913|RADIATION|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
219588963|NCT00718913|DRUG|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
218842696|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
218842697|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
219588964|NCT02959424|OTHER|Spanish Northwestern Esophageal Quality of Life questionnaire|
219588965|NCT00678886|BIOLOGICAL|otelixizumab infusion plus physician determined standard of care|infusion
219588966|NCT00678886|BIOLOGICAL|placebo infusion plus physician determined standard of care|infusion
219588967|NCT03680066|OTHER|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
218842698|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
218842699|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
219017891|NCT04519645|OTHER|Active Comparator|Active Comparator treatment will be chosen and dosed based on StOC (per local practice and treatment guidelines).
219017892|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
219017893|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
219017894|NCT04643444|DIAGNOSTIC_TEST|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
219196876|NCT06530589|OTHER|Tupler's Technique|Patient will wear diastasis rehab splint and will follow Tupler's techniqe protocol for 6 weeks. In the first 2 weeks both elevator and contracting exercises will be performed and after 2 weeks in the 3rd week only contracting exercises will be perform and for these exercises we divide abdomen into 6 floors and will patient have to contract her tummy towards the 3rd to 5th floor in first week, towards the 4th to 5th floor in 2nd week and from 5th to 6th floor in the 3rd week. in the wek 4 to week 6 head lifts will also be started along with contracting exercises from 5th to 6th floor.
219017895|NCT04643444|OTHER|Online Questionnaire|Questions on working place, risk profiles and PPE
219196877|NCT06530589|OTHER|Traditional Exercises|The traditional treatment includes traditional abdominal exercises that patient will be perform for 6 weeks and three times per week with 15 repetitions of each exercise. These exercises includes posterior pelvic tilt' static abdominal contractions', reverse sit up exercise, kegals, russian twist , trunk twist and reverse trunk twist.
219453134|NCT05675475|DIAGNOSTIC_TEST|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
219453135|NCT02282930|DRUG|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
219588968|NCT06227026|BIOLOGICAL|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
219588969|NCT00206323|DRUG|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
219588970|NCT00206323|DRUG|placebo/sugar pill|placebo
219588971|NCT04151901|OTHER|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
219588972|NCT04151901|OTHER|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
219588973|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
219196878|NCT06843135|DEVICE|Ventricular pacing|Participants will undergo conductionsystem pacing and right ventricular pacing in a randomized sequence, each for six months. After each phase, patients will undergo a CMR scan and advanced ECG imaging
219453136|NCT01480791|DRUG|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
219453137|NCT01480791|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
219453138|NCT01832389|DEVICE|PiCCO|
219453139|NCT06343129|BEHAVIORAL|Dietary education program|"Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/"
219453140|NCT02149186|DEVICE|iCTuS-L|
219453141|NCT05740267|PROCEDURE|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
219453142|NCT03876704|DRUG|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
219453143|NCT03876704|DRUG|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
219453144|NCT04969458|OTHER|survey application|"Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)"
219453145|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with investigational device
219453146|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with reference device
219453147|NCT00164567|BEHAVIORAL|Onsite IPV specialist|
219453148|NCT00164567|BEHAVIORAL|Empowerment focused intervention|
219453149|NCT00419835|DRUG|enalapril|
219453150|NCT00419835|DRUG|losartan|
219453151|NCT00415623|DRUG|Amlodipine|Amlodipine 5mg/ day
219453152|NCT00415623|DRUG|Amlodipine|Amlodipine 10mg/ day
219453153|NCT00896350|DRUG|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
219453154|NCT03248817|DRUG|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
219453155|NCT03248817|DRUG|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
219453156|NCT03248817|DRUG|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
219453157|NCT03248817|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
219453158|NCT00177008|DRUG|Aripiprazole|
219453159|NCT00233181|BEHAVIORAL|Home-based adherence monitoring|
219453160|NCT06695858|DRUG|ESPB|Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
219453161|NCT04251195|BEHAVIORAL|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
219453162|NCT04251195|BEHAVIORAL|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
219588974|NCT06474715|BEHAVIORAL|Arms|The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
218842700|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
218842701|NCT00025298|DRUG|amifostine trihydrate|
218842702|NCT00025298|DRUG|carboplatin|
218842703|NCT00025298|DRUG|cisplatin|
218842704|NCT00025298|DRUG|paclitaxel|
218842705|NCT00025298|RADIATION|radiation therapy|
219453163|NCT04174872|DRUG|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
219453164|NCT04174872|DRUG|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
219453165|NCT02663245|OTHER|Intervention 1|"* Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
219453166|NCT02663245|OTHER|Intervention 2|"* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
219588975|NCT05580653|OTHER|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
219588976|NCT05580653|OTHER|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
218842706|NCT02285582|OTHER|Registry study|No intervention.
218842707|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
218842708|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
218842709|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
218842710|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
219196879|NCT06843122|BIOLOGICAL|A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC|ADSC/ASC will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
219588977|NCT01943994|DRUG|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
219588978|NCT01943994|DRUG|Nicotine Replacement Therapy (NRT)|
219588979|NCT04969510|DRUG|10 mg PRAX-114|Once daily oral treatment
218842711|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
218842712|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
218842713|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
218842714|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
218842715|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
218842716|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
218842717|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
218842718|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
219453167|NCT04697108|OTHER|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
218842719|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
218842720|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
218842721|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
218842722|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
219453168|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
219453169|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
219453170|NCT03943940|BIOLOGICAL|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg"
219453171|NCT03943940|OTHER|Control|Standard medicine
219453172|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
219453173|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
218842723|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
219453174|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
219453175|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
218842724|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
219453176|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
219453177|NCT04862650|DRUG|Carboplatin|Given IV
219453178|NCT04862650|BIOLOGICAL|Cemiplimab|Given IV
219453179|NCT04862650|DRUG|Paclitaxel|Given IV
219453180|NCT00566332|DRUG|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
219453181|NCT00566332|DRUG|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
219453182|NCT01563952|DEVICE|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
219453183|NCT01563952|DEVICE|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
219453184|NCT01563952|DEVICE|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
219453185|NCT01563952|DEVICE|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
218842725|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
218842726|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
218842727|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
218842728|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
218842729|NCT06789042|DRUG|0.9%NaCl|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
218842730|NCT06789042|DRUG|Dexamethasone 4mg|20ml 0.2% Ropivacaine + 4mg Dexamethasone
218842731|NCT00087776|DRUG|Taxoprexin|Administered by intravenous infusion over 2 hour infusion on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
218842732|NCT00087776|DRUG|Dacarbazine|Administered by intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
218842733|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
218842734|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
218842735|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
218842736|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
218842737|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
218842738|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
218842739|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
218842740|NCT03045406|DRUG|Apixaban|Tablets
218842741|NCT03045406|DRUG|Dalteparin|Injections
219453186|NCT04602299|OTHER|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
219453187|NCT01510561|DRUG|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
218842742|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
218842743|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
218842744|NCT06252961|DRUG|Placebo|Placebo for 5 days
218842745|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
218842746|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
218842747|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
218842748|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
219453188|NCT01510561|DRUG|90Y-hPAM4|
218842749|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
218842750|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
218842751|NCT05838625|DEVICE|Digital Therapeutic|A prescription digital therapeutic in the form of a smartphone app.
219453189|NCT01510561|DRUG|90Y-hPAM4 + gemcitabine|
218842752|NCT05100017|DRUG|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
218842753|NCT05100017|DRUG|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
218842754|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
219453190|NCT02098928|BEHAVIORAL|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
219453191|NCT02098928|DEVICE|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
219453192|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
219453193|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
219453194|NCT02930811|DRUG|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
219453195|NCT02930811|DRUG|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
219453196|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
219453197|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
219453198|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
219453199|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
219453200|NCT01601873|DEVICE|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
219453201|NCT01601873|DEVICE|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
219453202|NCT00268476|DRUG|Celecoxib|
219453203|NCT00268476|DRUG|Docetaxel|
219588980|NCT04969510|DRUG|20 mg PRAX-114|Once daily oral treatment
219588981|NCT04969510|DRUG|40 mg PRAX-114|Once daily oral treatment
219588982|NCT04969510|DRUG|60 mg PRAX-114|Once daily oral treatment
219588983|NCT04969510|DRUG|Placebo|Once daily oral treatment
219453204|NCT00268476|DRUG|Prednisolone|
219453205|NCT00268476|DRUG|ADT|
219453206|NCT00268476|DRUG|Zoledronic Acid|
219453207|NCT00268476|DRUG|Abiraterone|
219453208|NCT00268476|RADIATION|Radiotherapy to the prostate|
219453209|NCT00268476|DRUG|Enzalutamide|
219453210|NCT00268476|DRUG|Metformin|
219588984|NCT05054413|OTHER|Questionnaire Administration|Complete questionnaires
219453211|NCT00268476|DRUG|Transdermal Oestradiol|
219588985|NCT01404832|DRUG|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
219453212|NCT03727776|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
219453213|NCT04961502|BIOLOGICAL|Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly|3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers): the first carried out before the anti-Coronavirus Disease 2019 (COVID-19) vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
219453214|NCT00269620|DRUG|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
219453215|NCT00269620|DRUG|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
219453216|NCT01847872|DRUG|IPV IM Needle|
219453217|NCT01847872|DRUG|IPV ID Needle|
219453218|NCT01847872|DRUG|IPV IM Device|
219453219|NCT01847872|DRUG|IPV ID Device|
219453220|NCT04220658|OTHER|Biomarker study|Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation
219453221|NCT05399836|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
219453222|NCT02096471|DRUG|PD-0325901|
219453223|NCT07057856|BIOLOGICAL|Ustekinumab (UST)|The first sufficient dose of UST (6mg/kg) was administered intravenously at weeks 0
219453224|NCT07059156|DRUG|Induction Therapy Regimen|"VICP+VEN regimen:~* Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22.~* Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.~* Cyclophosphamide (CTX): 500 mg/m², days 7, 21.~* Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28~* Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day"
219588986|NCT00827632|DRUG|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
219588987|NCT00827632|DRUG|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
219588988|NCT04265430|OTHER|Contrast Agent|Given IV
219588989|NCT04265430|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219588990|NCT04265430|OTHER|Quality-of-Life Assessment|Ancillary studies
219588991|NCT04265430|OTHER|Questionnaire Administration|Ancillary studies
218842755|NCT06500013|BEHAVIORAL|Self-designed messages|Messages designed by participants
218842756|NCT06500013|BEHAVIORAL|Standardized messages|Messages designed by researchers based on behavioral change theories
218842757|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
218842758|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
218842759|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
219453225|NCT07059156|DRUG|Pre-Treatment Regimen|"Indications for pre-treatment:~* WBC ≥30×10⁹/L, or significant hepatosplenomegaly/lymphadenopathy.~* Laboratory signs of tumor lysis syndrome (e.g., electrolyte abnormalities).~Pre-treatment protocol:~* Glucocorticoids (e.g., prednisone or dexamethasone): Prednisone 1 mg/kg/day (PO/IV) for 3-5 days.~* Optional addition of CTX: 200 mg/m²/day IV for 3-5 days."
219453226|NCT07059156|OTHER|Post-CR Treatment|"Principles:~1. MRD-positive or rising: Administer blinatumomab (CD19/CD3 bispecific antibody) for residual disease clearance, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).~2. MRD-negative/unknown: Continue multi-agent chemotherapy ± blinatumomab consolidation. Allo-HSCT for patients with high-risk clinical/genetic features."
219453227|NCT07059156|DRUG|Post-CR Consolidation Regimens|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO)."
219588992|NCT06981338|COMBINATION_PRODUCT|Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs)|This experimental treatment combines intrathecal administration of allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs) with transcutaneous spinal cord stimulation (tSCS) and neurorehabilitation. Participants will receive three doses of cryopreserved WJ-MSCs (30×10⁶±30% viable cells per dose) derived from umbilical cord tissue, delivered via lumbar puncture at 6-week intervals in a saline-albumin solution. The intervention includes concurrent tSCS, a non-invasive electrical stimulation technique, paired with standardised neurorehabilitation. As the first clinical study evaluating this specific combined therapy for chronic spinal cord injury (AIS A-C grades), safety monitoring incorporates regular cerebrospinal fluid analysis to assess potential immune responses.
219588993|NCT01736748|BEHAVIORAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
219588994|NCT01736748|BEHAVIORAL|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
219588995|NCT02102516|DRUG|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
218842760|NCT03679546|DRUG|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
218842761|NCT03679546|DRUG|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
218842762|NCT05591768|PROCEDURE|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
218842763|NCT05591768|PROCEDURE|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
218842764|NCT01628029|OTHER|Counseling|Undergo CBT
218842765|NCT01628029|DRUG|Methylphenidate Hydrochloride|Given PO
218842766|NCT01628029|PROCEDURE|Phototherapy|Undergo light therapy
218842767|NCT01628029|OTHER|Placebo Administration|Given PO
218842768|NCT01628029|OTHER|Quality-of-Life Assessment|Ancillary studies
218842769|NCT01628029|PROCEDURE|Sham Intervention|Undergo sham light therapy
218842770|NCT01628029|DRUG|Therapeutic Melatonin|Given PO
218842771|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
219453228|NCT07059156|OTHER|Transplant-Eligible Subsequent Therapy|"* Allo-HSCT for eligible patients after induction.~* Conditioning regimen: TBI-VP16-CY.~* Donor priority: HLA-matched sibling donor (MSD), Matched unrelated donor (MUD), Haploidentical donor (Haplo).(Consider age/donor health status)."
219453229|NCT07059156|OTHER|Allo-HSCT Protocol|"1.6.1 Conditioning Regimen (TBI-VP16-Cy/ATG):~* TBI: 5 Gy (Days -7 to -6).~* VP16: 10 mg/kg/day (Days -5 to -4).~* CTX: 30 mg/kg/day (Days -3 to -2).~* ATG: 7.5 mg/kg/day (Days -5 to -2). 1.6.2 GVHD Prophylaxis:~* Basiliximab (anti-CD25 mAb): 50 mg (Days +1, +4).~* Standard regimen: Cyclosporine (CsA): IV: 2 mg/kg/day (start Day -9; target level 150-250 μg/L). PO: 3-5 mg/kg/day BID (switch delayed until Day +10 if no aGVHD); Mycophenolate mofetil (MMF) + short-course methotrexate."
219453230|NCT07059156|OTHER|Non-Transplant Maintenance Therapy Options|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO).~  * Maintenance (6-MP/MTX alternating with V-Dex): 6-MP: 75 mg/m²/day at bedtime (Days 1-21); MTX: 20 mg/m² IM weekly × 3 weeks.\*Adjust doses to maintain WBC \~3×10⁹/L, ANC 1.0-1.5×10⁹/L.\*"
219453231|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
219453232|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
219453233|NCT07058896|BEHAVIORAL|High intensity task oriented circuit training + Telerehabilitation|"Participants will receive 12 sessions of high-intensity, task-oriented circuit training, three times a week for four weeks. Each session will last 180 minutes, with 108 minutes of active training. Each session will include three rounds, each lasting 51 minutes. During each round, participants will rotate between stations working for six minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including sit-to-stand transitions, walking, standing, bed mobility and transfers, stepping, and wheelchair use. If participants are unable to walk, the walking station will be replaced by upper limb function station.~After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. Including monthly televisits with the physiotherapist. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring."
219453234|NCT02449915|DRUG|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
219453235|NCT02449915|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
219453236|NCT06757218|OTHER|empty socket|Patients will be left socket empty without any graft materials for spontaneous healing process after tooth extraction
219453237|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and platelet rich fibrin in the socket after extraction.
219453238|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Albumin Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and Albumin Platelet Rich Fibrin in the socket after extraction.
219453239|NCT07063446|DEVICE|sTMS|Single pulses of TMS will be delivered over the motor cortex to quantify and map the motor evoked potentials
219453240|NCT07063446|DEVICE|taVNS|taVNS will be used to stimulate the auricular branch of the vagus nerve and paired with CIMT for a total of 40hours of CIMT
219453241|NCT06771648|DEVICE|Daxxin Psoriasis Shampoo|Daxxin Psoriasis Shampoo at least 3 times a week and at most once a day as per instructions for use
219453242|NCT02407691|OTHER|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
219453243|NCT02407691|OTHER|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
219196880|NCT06843122|BIOLOGICAL|B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo|ADSC/ASC will be administered once, at the time of the second application patients will receive a placebo - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed weekly, up to V6 visit (up to 6 weeks after V0)
219453244|NCT06814041|OTHER|Chatbot as an informational coach|"The chatbot acts as an empathic informational coach, performing three main functions: (1) offering short conversation sessions about key topics on living with HIV; (2) responding to users' ad-hoc questions on HIV; (3) reminding users of medical appointments and drug taking.~The chatbot comprises a conversational system, utilizing WhatsApp for user interaction, with messages routed through the backend Voiceflow. User can access the chatbot system via WhatsApp. That means that they access the chatbot like any other contact in their WhatsApp chat list. The bot incorporates mostly text-based input- and output modalities, and a few images, which are more protective of users' privacy than speech. Concretely, chatbot users interact with the chatbot on WhatsApp by selecting from pre-defined options (buttons) or, in some parts, writing text."
219588996|NCT01910389|DRUG|Tadalafil|
219196881|NCT06843122|OTHER|C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Placebo will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
219453245|NCT07070440|DRUG|DZD6008|DZD6008 was administered orally at 40/60/90 mg QD.
219453246|NCT07070440|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.
219453247|NCT07070440|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.
219453248|NCT07070440|DRUG|Docetaxel|Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.
219588997|NCT01910389|DRUG|Placebo for tadalafil|
219588998|NCT00511095|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
219588999|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
219453249|NCT07074184|OTHER|Radiofrequency 448khz with manual therapy|The intervention in consisted of a total of 12 sessions (twice a week) of treatment. The set duration for each session was 45 minutes, except for those sessions where variable measurements were required, which lasted 60 minutes. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
219453250|NCT07074184|OTHER|Turn off radiofrequency 448khz|Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
219453251|NCT07074184|OTHER|Manual therapy|Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
219589000|NCT02415569|DRUG|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
219589001|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
219589002|NCT04331561|BEHAVIORAL|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
219589003|NCT00589329|DRUG|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
219589004|NCT00589329|DRUG|placebo|IV and pill placebo
218842774|NCT05624931|BEHAVIORAL|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
219453252|NCT06812286|OTHER|Less-volume|In the first 10-week cycle, the less-volume group will perform around 1500 repetitions per intervention. Participants will perform 1-3 sets of 4-7 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
219453253|NCT06812286|OTHER|More-volume|In the first 10-week cycle, the more-volume group will perform around 2000 repetitions per intervention. Participants will perform 1-3 sets of 6-10 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
219453254|NCT06812286|OTHER|Control|Participants in the control group will undergo sham training twice weekly for 30 weeks, consisting of stretching exercises supervised by two exercise physiologists.
219453255|NCT07081360|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (mFOLFIRINOX) followed by pancreaticoduodenectomy
219453256|NCT07081360|PROCEDURE|Upfront Surgery Group|Pancreaticoduodenectomy followed by adjuvant chemotherapy
219453257|NCT07083817|DRUG|[14C]Xeruborbactam|Carbon Radiolabeled Xeruborbactam
219453258|NCT07125183|DRUG|Doxorubicin|Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium. It has widespread use as a chemotherapeutic agent since the 1960s. Doxorubicin is part of the anthracycline group of chemotherapeutic agents. Doxorubicin may be used to treat soft tissue and bone sarcomas and cancers of the breast, ovary, bladder, and thyroid. It is also used to treat acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and small cell lung cancer.
219453259|NCT07123597|OTHER|5mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 5mm bioceramic putty coronal plug.
219453260|NCT07123597|OTHER|3mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 3mm bioceramic putty coronal plug.
219453261|NCT06924164|OTHER|Progressive resistance training|The progressive resistance program consist of a five-minute aerobic warm-up on either an ergometer bike, treadmill or rowing machine followed by six resistance training exercises: landmine twist, walking lunges, leg press, hip abduction, hip adduction and hip flexion. All training sessions (three per week) will be supervised for the first two weeks. After that, there will be one weekly supervised training session and two self-directed sessions. The subjects will be scheduled for 36 training sessions over 12 weeks, of which 16 will be supervised. Each training session is designed based on the findings from the feasibility study and is expected to last approximately one hour. If a subject cannot perform all scheduled sessions in a week, additional sessions will be planned for the following week to obtain the 16 supervised sessions.
219453262|NCT06924164|BEHAVIORAL|Waiting time|12 weeks of waiting time
219453263|NCT06924164|BEHAVIORAL|Self guided exercise|12 weeks of self guided exercise
219453264|NCT06853847|OTHER|The bed levels of the patients in the experimental group changed the patient's position|The bed levels of the patients in the experimental group changed the patient's position
219453265|NCT06779994|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
219453266|NCT06779994|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
219453267|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
219453268|NCT05083546|OTHER|Placebo|sugar pill
218842775|NCT05624931|OTHER|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
219196882|NCT06842225|OTHER|reduced physical activity|Each participant will undergo a three-week study. For the first week (day -7 to day 0), participants will be instructed to maintain their normal level of physical activity. For the second week (day 0 to day 7), the reduced physical activity (RPA) week, participants' schedules will be examined, and strategies designed to reduce steps (by at least 2000 steps) and physical activity (by taking elevators and short-cuts, etc.) by increasing sitting time \>10%. To assist in reducing walking and increased sitting, participants will be given seated electric scooters to use whenever they normally walk. The scooters will be returned on the third week (day 7 to day 14), and participants will be instructed to resume their normal physical activity. During the entire three weeks, participants will wear a continuous glucose monitor (CGM) and a physical activity monitor (ActivPal).
218842776|NCT01673906|DRUG|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
219453269|NCT06858332|DRUG|Atorvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
219453270|NCT06858332|DRUG|Simvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
219589005|NCT00420459|DRUG|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
219589006|NCT01324674|OTHER|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
219589007|NCT01324674|OTHER|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
219589008|NCT03048188|OTHER|wound dressing|Manuka honey wound dressing
218842777|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
218842778|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
218842779|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
218842780|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
218842781|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
219453271|NCT06858332|DRUG|Rozuvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
219453272|NCT06858332|DRUG|Ezetimibe|Ezetimibe
219453273|NCT06858332|DRUG|Niacin|Niacin
219453274|NCT06858332|DRUG|Ciprofibrate|Fibrates
219453275|NCT06858332|DRUG|Fenofibrate|Fibrates
219589009|NCT00872638|PROCEDURE|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
219589010|NCT00872638|PROCEDURE|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
219589011|NCT06824350|DEVICE|chlorination for water disinfection and surface disinfection|"* Installation of inline chlorine doser(s) for automated water disinfection.~* Provision of chlorine solution for water and surface disinfection (half of treatment facilities randomized to receive electrochlorinator, half receive bulk chlorine solution deliveries).~* Provision of mop(s), bucket(s), and spray bottles for surface cleaning."
219589012|NCT06824350|BEHAVIORAL|infection prevention and control messaging|Infection prevention and control guidance and messaging
219589013|NCT06982742|OTHER|Mobile Health App for Neuropathic Pain Management in MS|This intervention is a self-management mobile health application specifically designed for patients with Multiple Sclerosis who experience neuropathic pain. Unlike general symptom tracking apps, this application provides structured educational content on anti-inflammatory nutrition, physical activity, sleep hygiene, stress management, and smoking cessation. It includes goal-setting features, personalized reminders, symptom tracking tools, and feedback mechanisms to promote behavior change and self-efficacy. The intervention is designed based on Social Cognitive Theory, aiming to empower patients to actively manage their pain and improve their quality of life. T
219589014|NCT06990022|OTHER|Carbohydrate|CHO solution was a maltodextrin-based mixture containing 6.4% maltodextrin (Protein Ocean, Türkiye). An CHOMR was performed prior to SSGs. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before SSGs and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz
218842782|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
218842783|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
218842784|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
218842785|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
218842786|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
218842787|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
218842788|NCT05160415|DRUG|Sevasemten|Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).
218842789|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
219453276|NCT06858332|DRUG|Bezafibrate|Fibrates
219453277|NCT06858332|DRUG|Evolocumab|PCSK9 inhibitor
219453278|NCT06858332|DRUG|Alirocumab|PCSK9 inhibitor
219453279|NCT06858332|DRUG|Inclisiran|Small interfering RNA
219453280|NCT07093684|OTHER|Kidney disease|This is a registry-based observational study investigating the association between kidney disease and dementia-related outcomes. Kidney disease is not assigned or manipulated by the researchers but is classified as an exposure based on diagnostic codes (e.g., ICD codes), and related laboratory test recorded in health registers.
219453281|NCT07093437|DEVICE|GRIP-LOK FOLEY SECUREMENT DEVICE ®|"* Used device: adhesive~* Specific Skin protection: with non alcohol barrier film"
218842790|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
219453282|NCT07093437|DEVICE|CONVEEN, ELASTIC LEG WRISTBAND FOR URINARY CATHETER|The elastic wristband will be adjusted appropriately to minimize catheter movement while allowing normal blood circulation in the limb.
219453283|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
219453284|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
219453285|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
219453286|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
219453287|NCT04960397|OTHER|Placebo|Physiological saline, i.e., 0.9% sodium chloride.
219453288|NCT04960397|BIOLOGICAL|Sing2016 M2SR H3N2|Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.
219453289|NCT07101601|DRUG|DM5167|Once daily for 28 days
219589015|NCT06990022|OTHER|Placebo|The PLA solution consisted of purified water. Both solutions were made indistinguishable by adding 50 mg of non-calorific artificial sweetener and 50 mg of sucralose (Fibrelle, Turkey). A 25 ml bolus of 6.4% maltodextrin solution was used in a pre-weighed plastic container and sucralose water was tested as PLA for each rinse solution.
219589016|NCT06989008|OTHER|Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences|This is a single group observational study with no interventions.
219453290|NCT07102004|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).
219453291|NCT07101731|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|Participants in the control group will receive an individualized home-based pelvic floor muscle exercise program. Exercises will be performed once daily for 8 weeks, focusing on voluntary pelvic floor contractions in various positions (supine, sitting, standing). Participants will receive initial training and written instructions from a physiotherapist, and will be contacted weekly to monitor adherence.
219453292|NCT07101731|BEHAVIORAL|Hypopressive Exercises|Participants in the experimental group will attend supervised hypopressive exercise sessions twice per week for 8 weeks. These sessions involve specific postural sequences combined with breathing and apnea techniques aimed at reducing intra-abdominal pressure while activating pelvic floor and abdominal muscles. Sessions will be led by a physiotherapist and adapted based on individual performance and posture tolerance.
219453293|NCT07101055|DRUG|Letermovir 480 mg [PREVYMIS]|A single 480 mg oral dose of letermovir (2 x 240 mg tablets).
219453294|NCT07102472|BEHAVIORAL|"Using the term community immunity instead of herd immunity"|"In the intervention arm, participants are shown the less traditional term community immunity in place of the more traditional herd immunity"
219453295|NCT07102472|BEHAVIORAL|Herd immunity|"Using the traditional term herd immunity"
219453296|NCT07101939|DRUG|(S)-pindolol benzoate|(S)-pindolol benzoate (ACM-001.1) immediate release tablet containing (S)-pindolol benzoate administered BID.
219589017|NCT06990685|DRUG|Salidroside|In the salidroside group, oral administration of rhodiola capsules (Xizang Gaoyuan 'an Biotechnology Development Co., LTD.) was started on the day of entering the COS cycle, once a day, 2 pills at a time, and the drug was stopped on the trigger day.
219453297|NCT07101939|DRUG|Semaglutide|Semaglutide, solution for injection in pre-filled pen
219453298|NCT07101939|DRUG|Placebo to (S)-pindolol benzoate|Placebo to ACM-001.1 immediate release tablet administered BID
219453299|NCT07100327|PROCEDURE|Band|Laparoscopic sleeve gastrectomy with the placement of a 1.5 x 5.5 cm polypropylene band around the proximal gastric pouch to enhance restriction.
219453300|NCT07100327|PROCEDURE|Non-Band|Standard laparoscopic sleeve gastrectomy where approximately 75-80% of the stomach is resected to form a tubular structure
219453301|NCT07100873|DRUG|ADI-001|Anti-CD20 CAR-T
219453302|NCT07100873|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
219453303|NCT07100873|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
219589018|NCT06990230|DEVICE|Radiofrequency Transseptal Puncture System and Auxiliary Device|"The intervention in this study stands out due to its specific focus on evaluating the safety and efficacy of a radiofrequency transseptal puncture system designed exclusively for use in the atrial septum, with the purpose of establishing a passage from the right atrium to the left atrium. This system incorporates an auxiliary radiofrequency puncture device, which serves as a crucial supportive component, enhancing the overall functionality and precision of the primary transseptal puncture system.~What further distinguishes this intervention from others is its utilization of radiofrequency energy to facilitate the transseptal puncture. Unlike traditional mechanical puncture methods, which can have a steep learning curve, potentially cause serious complications such as pericardial tamponade and cardiac rupture, and may be time-consuming and imprecise in predicting the puncture site, the radiofrequency puncture device provides a more controlled and predictable approach. The radiofrequenc"
218842791|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
218842792|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
219589019|NCT06990750|PROCEDURE|15 mmHg|Insufflation pressure was set to 15 mm Hg at the time of single port robotic sacrocolpopexy.
219589020|NCT06990750|PROCEDURE|12 mmHg|Insufflation pressure was set to 12 mm Hg at the time of single port robotic sacrocolpopexy.
219589021|NCT06989411|OTHER|Clinical pilates exercises +Interferential current therapy (real current)|All treatments were given three times a week for 8 weeks. The current intensity was determined as the mA CC level that the patient felt at the maximum but did not feel any discomfort.
219589022|NCT06989411|OTHER|Clinical pilates exercises+ Interferential current therapy (Placebo current)|All treatments were given three times a week for 8 weeks. The current intensity was set to 0.1 mA CC (necessary for the machine to work)
219589023|NCT06989697|DRUG|Cilostazol / Ginko Leaf Dried Ext.|Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
218842793|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
218842794|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
218842795|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
219589024|NCT06989697|DRUG|Placebo|Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
219589025|NCT06991036|OTHER|Gastric emptying test|"After the radiolabeled breakfast meal is ingested, the participant is positioned upright between the two detectors of the Brightview system (Phillips Medical Systems, Cleveland, OH). Detector height is adjusted to include esophageal uptake, the stomach, and the small bowel. Anterior and posterior static images are acquired at 2 minutes per image using a 256 x 256 word mode matrix. Anterior and posterior images are again acquired at 1 and 2 hours post-ingestion of the radiolabeled breakfast meal.~The participant is then given the designated 'push' meal after completion of the 2-hour images. At 4 hours post-ingestion, images are acquired in the same manner as at previous time points."
219589026|NCT06990061|RADIATION|Radiation therapy|Radiation therapy will be given in 20 fractions of 2.75 Gy (total dose of 55 Gy) covering the whole bladder over 4 weeks in combination.
219589027|NCT06990217|DRUG|Oxytocin Grindeks 10 IU/ml- solution for injection|our study is aims to compare two oxytocin regimens - low VS high dose among obese women who need induction or augmentation of labor
219589028|NCT06989931|DEVICE|Intracranial Distal Access Catheter|Patients with mechanical thrombectomy for acute ischemic stroke, treatment of intracranial aneurysms and other ischemic and hemorrhagic diseases, requiring the use of Intracranial Distal Access Catheter(X-Track) to complete the procedure
218842796|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
218842797|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
218842798|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
219453304|NCT07100574|OTHER|atheroma plaque|During the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
219453305|NCT07100574|OTHER|dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
219453306|NCT07102173|PROCEDURE|Intercostal nerve block|Before final lung re-expansion, involving the administration of 20 mL of 0.5% levobupivacaine using a 27G needle into the subpleural space of the thoracotomy access site and adjacent intercostal spaces.
219453307|NCT07102173|PROCEDURE|Ultrasound-guided ESPB|After identifying the target transverse process, a linear ultrasound probe is placed sagittally approximately 2 cm from the midline. The needle (22G, 50 mm) is inserted in-plane in a cranio-caudal direction until contacting the transverse process. After confirming proper injection by observing anesthetic spread between the erector spinae muscle and transverse process, a total of 30 mL of 0.375% ropivacaine is administered.
219453308|NCT07101133|DIETARY_SUPPLEMENT|Control group: Energy-limited balanced diet group|"Based on clinical phenotype + energy-restricted diet group：Based on the baseline dietary quality assessment of the subjects and baseline clinical data , a dietary plan was formulated, and the types and proportions of food were adjusted specifically .~Intervention group based on genetic susceptibility：Integrate deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimpose obesity nutrition gene data and nutrient metabolism genes, and customize the macronutrient ratio.~Based on genetic susceptibility + intestinal flora intervention group: Integrating deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimposing obesity nutrition gene + intestinal flora genomic data, including 33 obesity nutrition-related genes and 170 intestinal obesity nutrient metabolic bacterial genera/species test results, to customize the proportion of macronutrients."
219453309|NCT07101003|PROCEDURE|single visit instrumentation|root canal instrumentation will be done on single visit treatment
219453310|NCT07101003|PROCEDURE|multiple visit instrumentation|root canal treatment will be done on two visits
219453311|NCT07100275|BEHAVIORAL|Patient education|In addition to the procedures in the control group, the patient will be informed about the surgery while he/she is at home the day before the surgery. Information will be provided about the hospital and surgical process. If there are any questions, the patient will be asked and their concerns will be resolved. T0-T1-T2 procedures will be performed on patients in the intervention group, respectively.
219453312|NCT07100275|BEHAVIORAL|Follow-up via Mobile Health Application|The researcher will create a video depicting the process of transferring patients from the ward to surgery. The video will be created with a volunteer mannequin. It will not be created with a real patient. This video will be recorded during a non-busy Sunday at the hospital. This video will be shown to patients the evening before surgery, following online education, and their questions will be answered.
219453313|NCT05543252|DRUG|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
219453314|NCT05337137|DRUG|Relatlimab|Specified dose on specified days
219589029|NCT06990048|DEVICE|AFX2 System|"The AFX2 System comprises of the following:~AFX2 Bifurcated Endograft System and delivery system AFX Vela Proxmal Endograft System and delivery system AFX Stand Alone Endograft System and delivery system"
219589030|NCT06989892|DEVICE|Super High-flux dialyzer (Elisio 19HDx)|Dialysis with Super High-flux dialyzer for intervention group
219589031|NCT06989892|DEVICE|High-flux dialyzer (Elisio 19H)|Dialysis with High-flux dialyzer for control group
219589032|NCT00942695|OTHER|1.5PD|average American diet plus 1.5 oz per day pistachios
219589033|NCT00942695|OTHER|3.0PD|average American diet plus 3.0 oz per day pistachios
219589034|NCT00942695|OTHER|control|average American diet without pistachios
218842799|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
218842800|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
219453315|NCT05337137|DRUG|Nivolumab|Specified dose on specified days
219589035|NCT02608151|OTHER|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
219589036|NCT02608151|OTHER|massage without oil|
219589037|NCT02953951|OTHER|blood transfusion|blood transfusion different sources
219589038|NCT05761925|BEHAVIORAL|COMA-F|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.
219589039|NCT00004421|DEVICE|implanted pulse generator|
219589040|NCT06676306|OTHER|Non-Interventional Study|Non-Interventional Study
219589041|NCT03718052|PROCEDURE|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
219589042|NCT03718052|PROCEDURE|Conventional Care|Conventional care according to the 2015 European guidelines.
218842801|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
218842802|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
218842803|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
219453316|NCT05337137|DRUG|Bevacizumab|Specified dose on specified days
219589043|NCT06988852|COMBINATION_PRODUCT|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion. The FOLFOX regimen involving oxaliplatin (130mg/m2, day 1, 0-2h), leucovorin (400 mg/m2, day 1, 2-3h), 5-Fu (400mg/m2, day 1, bolus at 3h, then 2400 mg/m2, day 1-3, 3-49h), was administered via the microcatheter. The microcatheter and sheath were removed after HAIC finished. We didn't implanted port catheter system and repeated percutaneous femoral artery puncture and catheterization once every 3
218842804|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
218842805|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
219453317|NCT05337137|OTHER|Placebo|Specified dose on specified days
219453318|NCT07101562|DEVICE|Tissue-engineered bone|Tissue-engineered bone with autologous bone marrow mesenchymal stem cells
219453319|NCT07100834|DEVICE|Single-Shot Pulsed Field Ablation (FARAPULSE™ Pulsed Field Ablation System)|The FARAPULSE™ Pulsed Field Ablation System (Boston Scientific, Inc.) is a CE-marked system consisting of the FARASTAR™ Pulsed Field Ablation Generator that is used with the FARAWAVE™ Pulsed Field Ablation Catheter for cardiac tissue ablation
219453320|NCT07100834|DEVICE|Single-Shot Cryoballoon Devices (Arctic Front Advance PRO, Medtronic Inc., Minneapolis, MN, USA; POLARx and POLARx FIT Balloon Catheter, Marlborough, MA, USA)|The Arctic Front Advance PRO, POLARx and FIT Balloon Catheters are CE-marked cryoablation systems consisting of a cryoballoon device, which is used in conjunction with a CryoConsole, a steerable sheath, and a circular mapping catheter
219453321|NCT07100535|BEHAVIORAL|Education and Literacy for an Active Life|This study will assess the effectiveness of a school-based health literacy intervention on the four dimensions of health literacy (i.e., access, understanding, evaluation, and application) on diet, sedentary behaviour, physical activity, sleep, and mental health in 5th and 6th graders (aged 9-12), and explored its implementation feasibility.
219453322|NCT07101211|BEHAVIORAL|Video-Based Educational Animation|A short, Turkish-dubbed educational animation video explaining the cystoscopy procedure, including steps of the procedure, expected sensations, and post-procedure care. The video is viewed by patients via QR code on their mobile devices before the cystoscopy to enhance patient understanding and reduce anxiety, stress, and depression.
219453323|NCT07101211|OTHER|Standard Written Informed Consent|A standard written informed consent form describing the cystoscopy procedure, including the purpose, steps, possible sensations, and post-procedure care, provided to all participants before the procedure.
219589044|NCT06988852|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC)|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion.
219589045|NCT06988852|DRUG|Bevacizumab|We would inject bevacizumab at the dose of 7.5mg/kg once every 3 weeks if the primary tumors located from right-side to splenic flexure colon or the genotype of RAS or RAF was mutational.
218842806|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
218842807|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
218842808|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
219453324|NCT07101653|OTHER|Exercise|According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minute sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period
219453325|NCT07100743|DIETARY_SUPPLEMENT|Probiotic Agent|HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg
219453326|NCT07100743|DIETARY_SUPPLEMENT|Placebo|The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.
219453327|NCT01877005|DRUG|Ruxolitinib|
219589046|NCT06988852|DRUG|Cetuximab (Erbitux)|We would inject cetuximab at an initial dose of 400mg/m2 and maintained a dose of 250mg/m2 once every week if we didn't choose bevacizumab.
219589047|NCT06988852|PROCEDURE|liver resection|If patients reached potential resectable state, we would perform liver resection.
219589048|NCT06990100|DEVICE|ACL surgery|ligamentoplasty surgery - ACL reconstruction surgery
219589049|NCT01923194|DRUG|Highly Purified Urofollitropin|for Injection
219589050|NCT01923194|DRUG|Recombinant Human Follitropin Alfa|for Injection
218842809|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
219453328|NCT07102420|OTHER|Questionnaire and Physical Exam|Artificial Intelligence Anxiety Scale, Exercise Benefits/Barriers Scale
219453329|NCT07101861|BEHAVIORAL|Survivors RESET|16-session adaptation of the Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training
219453330|NCT06933095|DIETARY_SUPPLEMENT|LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)|apsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
218842810|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
218842811|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
219453331|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 4 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
219453332|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 2 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 2 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
219453333|NCT07148128|DRUG|WEF-001|Starting dose of 0.3 mg/m2 q4wks IV, dose escalation
219453334|NCT07147907|DEVICE|Chest Worn Respiratory Rate Monitor|The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including respiratory rate and other health metrics. In this study, the device will be evaluated for its ability to accurately measure respiratory rate during controlled breathing exercises in healthy adult volunteers. The respiratory rate values recorded by the Perin Health Patch will be compared against respiratory rate measurements obtained via manually scored end tidal carbon dioxide (EtCO2) waveforms from a GE Datex-Ohmeda monitor, following Element Laboratory protocols aligned with clinical validation standards. The intervention in this study is limited to the application and use of the device for data collection during controlled respiratory rate conditions, where participants perform paced breathing exercises at various rates (5-50 breaths per minute) using a breathing app while positioned sitting or lying supine.
219453335|NCT07148544|OTHER|Sedo analgesia protocol|Nurse-Controlled Sedo-Analgesia Protocol
219453336|NCT07148544|OTHER|control group|The clinic's routine sedation analgesia management plan will be implemented.
219453337|NCT07147205|OTHER|Therapy|MCGP will be delivered in 8 weekly sessions for 90 minutes over Zoom by a licensed doctoral level psychologist.
219453338|NCT06949514|OTHER|guided imagery|Participants in this group will receive the guided imagery intervention. They will be approached after being hospitalized for at least 24 hours. The guided imagery audio recording will be played for the pregnant women every evening before sleep for three consecutive days.
219453339|NCT06948955|DRUG|Bezuclastinib|Drug: Bezuclastinib
219453340|NCT06948955|DRUG|Sunitinib|Drug: Sunitinib (locally sourced)
219453341|NCT06951165|BEHAVIORAL|Parent Supported Psychosocial Development Programme|A six-module online program was developed for parents of children ages 1 to 3. The program was provided to parents as a PDF, one module per week, and each module was discussed online.
219453342|NCT07149194|OTHER|CBC derived markers|CBC derived markers against CRP and ESR in detecting active Rheumatoid arthritis
219589051|NCT05387538|PROCEDURE|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
219453343|NCT07148908|DIETARY_SUPPLEMENT|Yeast Protein Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
219453344|NCT07148908|DIETARY_SUPPLEMENT|Whey Protein Isolate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
219453345|NCT07148908|DIETARY_SUPPLEMENT|Collagen Hydrolysate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
218842812|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
218842813|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
218842814|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
218842815|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
218842816|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
218842817|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
218842818|NCT04748757|DRUG|Placebo|Normal saline 50 ml
219453346|NCT07147842|DRUG|Rutin 500 MG|Rutin 500 mg capsules twice daily for 30 days
219453347|NCT07147842|OTHER|Placebo|Placebo Tablets
219453348|NCT07147842|DIAGNOSTIC_TEST|fecal calprotectin|Fecal calprotectin level was measured using an ELISA kit .
218842819|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
218842820|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
218842821|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
218842822|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
219453349|NCT07148375|PROCEDURE|Anterograde screws for medial Malleolus fractures|Fixation of medial Malleolus fracures by anterograde headless screws
219453350|NCT07149181|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
219589052|NCT05387538|PROCEDURE|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
219589053|NCT04375683|DRUG|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
219589054|NCT04658836|DRUG|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
219589055|NCT04669691|BIOLOGICAL|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
219589056|NCT04841252|DEVICE|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
219589057|NCT04841252|DEVICE|Alpinion clinical ultrasound machine|Ultrasound
219589058|NCT00825136|BEHAVIORAL|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
219589059|NCT00825136|BEHAVIORAL|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
218842823|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
218842824|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
218842825|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
218842826|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
218842827|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
219017897|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
219453351|NCT07149181|DRUG|SOX Chemotherapy|SOX or XELOX
219453352|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
219453353|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
219453354|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
218842828|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
218842829|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
219453355|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
218842830|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
218842831|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
219453356|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
218842832|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
218842833|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
218842834|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
218842835|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
218842836|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
218842837|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
218842838|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
218842839|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
218842840|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
218842841|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
219453357|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
219453358|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
219589060|NCT05841446|DRUG|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
218842842|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
219453359|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
219453360|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
219453361|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
219453362|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
219453363|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
219453364|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
219589061|NCT05841446|DRUG|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
219589062|NCT02304458|BIOLOGICAL|Ipilimumab|Given IV
219589063|NCT02304458|OTHER|Laboratory Biomarker Analysis|Correlative studies
219589064|NCT02304458|BIOLOGICAL|Nivolumab|Given IV
219589065|NCT02304458|OTHER|Pharmacological Study|Correlative studies
219589066|NCT04231734|OTHER|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
218842843|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
218842844|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
219453365|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
218842845|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
219453366|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
219589067|NCT01796158|BEHAVIORAL|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
219589068|NCT01796158|BEHAVIORAL|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
219589069|NCT01109563|BEHAVIORAL|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
219453367|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
219589070|NCT03516214|DRUG|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
219589071|NCT03516214|DRUG|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
219589072|NCT05504590|DEVICE|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
218842846|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
219453368|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
219453369|NCT01855919|DRUG|Duloxetine|Administered orally
219453370|NCT01855919|DRUG|Placebo|Administered orally
219453371|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
219453372|NCT04459416|OTHER|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
219453373|NCT04459416|DRUG|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
219453374|NCT04459416|OTHER|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
219453375|NCT05953961|DEVICE|Therasphere 90Y|Transarterial Radioembolization
219453376|NCT05953961|DEVICE|Microwave Ablation|Microwave Ablation
219453377|NCT05910320|DEVICE|Wearable Vital Signs Monitoring Device|The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
219453378|NCT05680545|OTHER|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
219017908|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
219017909|NCT05958342|DRUG|Calcium Gluconate|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
219453379|NCT05493982|BEHAVIORAL|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
219453380|NCT04083963|DRUG|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
219453381|NCT04083963|DRUG|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
219453382|NCT04083963|DRUG|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
219453383|NCT04083963|DRUG|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
219453384|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
219453385|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
219453386|NCT01747447|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219453387|NCT01747447|DIETARY_SUPPLEMENT|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219453388|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
219453389|NCT04898153|DEVICE|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
219453390|NCT06506097|BEHAVIORAL|Family-school Partnership Intervention (FSPI)|"FSPI includes implementation activities across multiple levels.~FSPI Planning Team Meetings will be held monthly to plan project activities, practice staff and parent coaching strategies, and troubleshoot implementation challenges.~FSPI Staff Training (3 hours) will be provided during a single professional development day (3 hours), and attended by members of the FSPI Planning Team and teachers.~FSPI Playgroups. Over the course of the school year, each parent-child dyad will be invited to participate in three FSPI Playgroup events. Typically, teachers from two classrooms will collaborate in hosting playgroup events, and each playgroup will be attended by four parent-child dyads (i.e., two per classroom). Teachers will be provided with a curriculum and learning outcomes to target.~FSPI Debrief Meetings are held after each FSPI Playgroup to debrief, reflect, and improve FSPI implementation."
219453391|NCT06213649|DRUG|Polyhexamethylene biguanide (PHMB)|PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
219453392|NCT06213649|DRUG|Topical corticosteroid|Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
219453393|NCT06213649|OTHER|Topical placebo|An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
219453394|NCT05200715|OTHER|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
219453395|NCT04713657|OTHER|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
219453396|NCT04713657|OTHER|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
219453397|NCT04713657|PROCEDURE|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in Tetrology of Fallot/ Pulmonary Stenosis (ToF/PS) and is non-invasive.
219589073|NCT05504590|DEVICE|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
219589074|NCT03401450|DRUG|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
219589075|NCT03401450|DRUG|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
219589076|NCT03353623|DEVICE|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
219017910|NCT05958342|DRUG|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
219017911|NCT05958342|DRUG|saline placebo|saline placebo volume matched to prehospital or in hospital phase
218842847|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
218842848|NCT02819258|OTHER|Endodontic treatment|
218842849|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
219589077|NCT03353623|OTHER|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
219589078|NCT01463436|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
219589079|NCT01463436|DIETARY_SUPPLEMENT|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
219589080|NCT03143608|DEVICE|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
219589081|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
219589082|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
219589083|NCT00675064|DRUG|GSK369796|Anti-malarial
219589084|NCT00675064|DRUG|Placebo|Placebo matching GSK369796
219589085|NCT06198036|OTHER|Hold-Relax Technique|Participants in this group will be treated with hold-relax PNF Technique
218842850|NCT02412891|DEVICE|Sham UroShield device|
219017917|NCT06262269|OTHER|Home-based adapted physical activity program supervised by an APA teacher via individual video conference.|Participants will follow a 12-week tele-rehabilitation programme involving high-intensity interval training (HIIT) adapted to their AIS. The programme includes three 45-minute individual sessions per week. The exercises are selected from a database designed for AIS patients. The APA teacher will systematically document the patient's presence or absence at each tele-rehabilitation session, thus assessing their adherence to the programme.
219017918|NCT06262269|OTHER|First period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet of specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
219017919|NCT06262269|OTHER|Second period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
219589086|NCT06198036|OTHER|Muscle Energy Technique|Participants in this group will be treated with Muscle Energy Technique via Reciprocal Inhibition Mechanism
219589087|NCT03792087|DRUG|SmofKabiven Peripheral|Total Parenteral Nutrition
219589088|NCT03792087|DRUG|Hospital compounded emulsion|Total Parenteral Nutrition
218842851|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
219453398|NCT04713657|PROCEDURE|Cardiac MRI (CMR)|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
218842852|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
219453399|NCT04713657|DRUG|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
219453400|NCT04713657|DRUG|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.
219589089|NCT05769933|DEVICE|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
219589090|NCT05769933|DEVICE|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
219453401|NCT04713657|PROCEDURE|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
219453402|NCT04713657|OTHER|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
219453403|NCT03093116|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
219589091|NCT06444932|PROCEDURE|Joint Mobilization|Patellofemoral and tibiofemoral joint mobilization
219589092|NCT06444932|PROCEDURE|Resistance Exercise Training|Lower limb resistance exercise training
219589093|NCT06444932|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|Transcutaneous Electric Nerve Stimulation (TENS)
219589094|NCT06444932|DEVICE|Heating Pad|Heating pad for heat therapy
219589095|NCT03121378|OTHER|Blood sample 1|Blood taken before prosthesis implantation
219589096|NCT03121378|OTHER|Blood sample 2|Blood taken after prosthesis implantation
219589097|NCT02288182|DEVICE|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
219589098|NCT02288182|DEVICE|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
218842853|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
218842854|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
218842855|NCT00374946|DEVICE|THA|
219017920|NCT03665831|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
219017921|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
219589099|NCT01058720|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU orally once daily for 12 weeks
219589100|NCT05276882|OTHER|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
219589101|NCT05276882|OTHER|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)"
219017924|NCT05507424|PROCEDURE|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
219017925|NCT05507424|PROCEDURE|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
219453404|NCT06835842|OTHER|rib mobilization technique|"rib mobilization technique The patient in experimental group will be relaxed in semi- fowler position while connected to mechanical ventilator, therapist will seat at the patient side, his fingers pads are placed at the position of the patient's rib angles , pulling upward and the lateral position the position is held while wait for the soft tissues to release this take from 15 seconds .Release of the diaphragm through manual contact with hypothenar region of therapist thumb inferior laterally xiphoid process and rest along Antero lateral costal margin below rib7 during exhalation the therapist thumb give pressure posteriorly repeat this steps for 3 to5 respiratory cycle • routine chest physiotherapy percussion on chest wall its frequency should be 3-7 beats per sec. vibration applying a light pressure with hand on affected segment for about 5 min modified postural drainage R. and L. side. U\&L limb passive ex. for R.10 x3 set~.this program for 30 minutes once daily for ten days"
219453405|NCT06835842|OTHER|routine chest physiotherapy|"routine chest physiotherapy the patient will be laid in half supine position connected to a ventilator applying~* percussion on chest wall its frequency should be 3-7 beats per second or 180-420 beats per minute~* vibration applying a light pressure with flattened hand on affected segment for about 5 minutes~* modified postural drainage (right and left sidling 10 min for each side~* upper and lower limb exercise for 4 limbs (3 sets and each set has 10 repetition~* this program for 30 minutes once daily~* for 10 consecutive days"
219453406|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
219453407|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
219589102|NCT04787874|BEHAVIORAL|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
219589103|NCT03106649|DEVICE|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
218842856|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
218842857|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
218842858|NCT01748812|DRUG|Osteomalacia|
218842859|NCT00125463|DRUG|Candesartan cilexetil|
218842860|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
218842861|NCT01601106|DRUG|Placebo|
218842862|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
219589104|NCT03106649|DEVICE|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
219589105|NCT04946396|DRUG|dexmedetomidine intravenous infusion|Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
219589106|NCT04946396|DRUG|0.9%sodium chloride|0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
219589107|NCT02647801|BEHAVIORAL|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
219589108|NCT03574350|BEHAVIORAL|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
219589109|NCT03574350|BEHAVIORAL|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
219589110|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
219589111|NCT01638598|DRUG|Test drug|BI 1021958
219589112|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
218842863|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
218842864|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
218842865|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
218842866|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
218842867|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
219589113|NCT01638598|DRUG|Test drug|BI 1021958
219589114|NCT01638598|DRUG|Test drug|BI 1021958
219589115|NCT01638598|DRUG|Test drug|BI 1021958
218842868|NCT04266301|DRUG|Sabatolimab|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
218842869|NCT04266301|DRUG|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
218842870|NCT04266301|DRUG|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
218842871|NCT05001152|DRUG|Ozanimod|Taste assessment
218842872|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
219589116|NCT01638598|DRUG|Test drug|BI 1021958
218842873|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
218842874|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
218842875|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
218842876|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
218842877|NCT06567028|DIAGNOSTIC_TEST|OSPM-Enhanced AI Model|Analyze tumor images using the model developed in our study
219589117|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
219589118|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
219589119|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
219589120|NCT06376851|DIAGNOSTIC_TEST|AI-enabled quantitative coronary plaque analysis (AI-QCPA)|The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
219589121|NCT01447277|PROCEDURE|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
219589122|NCT01447277|PROCEDURE|Femoral Block only|Performing a preoperative sciatic nerve block only
219589123|NCT02297399|DRUG|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
219589124|NCT02297399|DRUG|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
219589125|NCT03851029|OTHER|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
219589126|NCT03851029|OTHER|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
219589127|NCT00461253|DEVICE|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
219589128|NCT00461253|DEVICE|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
219589129|NCT02051712|BEHAVIORAL|exercise training|individualized exercise training
219589130|NCT02051712|BEHAVIORAL|Adherence measures|Measures to increase adherence to exercise training
219589131|NCT06633653|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
218842878|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
218842879|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
218842880|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
218842881|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
218842882|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
218842883|NCT00345566|PROCEDURE|Nutrition composition|
218842884|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
218842885|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
218842886|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
219453408|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
218842887|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
218842888|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
219589132|NCT04240392|BEHAVIORAL|Collaborative Care (CC)|"The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner."
218842889|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
219453409|NCT06318481|DRUG|Ticagrelor 90 MG|Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
219589133|NCT04240392|BEHAVIORAL|Extension for Community Healthcare Outcomes (ECHO)|The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
218842890|NCT02767726|DEVICE|non-invasive multimodal imaging|
219589134|NCT05093777|OTHER|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
219589135|NCT05093777|OTHER|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
219589136|NCT01523457|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
219589137|NCT01038440|DIETARY_SUPPLEMENT|Safflower Oil|One softgel consumed daily with food
219589138|NCT01038440|DIETARY_SUPPLEMENT|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
219589139|NCT01038440|DIETARY_SUPPLEMENT|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
218842891|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
219453410|NCT06318481|DRUG|Clopidogrel|Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
218842892|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
218842893|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
218842894|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
218842895|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
219453411|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
219453412|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
218842896|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
219453413|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
219453414|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
219453415|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
219589140|NCT05475886|DRUG|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
219589141|NCT06633081|DEVICE|handheld dynamometer|handheld dynamometer is a device that measure muscle strength
219589142|NCT04878848|OTHER|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
219589143|NCT04878848|OTHER|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
219589144|NCT04782674|DIAGNOSTIC_TEST|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
219589145|NCT00000130|DRUG|Intravitreal Antibiotics|
218842897|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
218842898|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
218842899|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
218842900|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
219453416|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
219453417|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
219453418|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
219453419|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
219453420|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
219453421|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
219589146|NCT00000130|PROCEDURE|Initial Pars Plana Vitrectomy|
219453422|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
219453423|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
219589147|NCT04345601|BIOLOGICAL|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
219589148|NCT04345601|OTHER|Supportive Care|Patients will receive supportive care per their treating physician
219589149|NCT00521534|DEVICE|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
219589150|NCT05478512|DRUG|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
219589151|NCT02358135|OTHER|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
219589152|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
219589153|NCT00403507|BEHAVIORAL|Participation in a monitored exercise program|No contact with control group during 20 weeks.
218842901|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
218842902|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
218842903|NCT03215758|DRUG|QAW039|QAW039 once daily
218842904|NCT03215758|DRUG|Placebo|Placebo once daily
219453424|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
219453425|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
218842905|NCT01942668|DRUG|Estradiol|
218842906|NCT01942668|DRUG|Progesterone|
218842907|NCT01942668|DRUG|Placebo|
218842908|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
218842909|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
218842910|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
218842911|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
218842912|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
219453426|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
219453427|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
218842913|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
218842914|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
219453428|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
218842915|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
218842916|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
218842917|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
218842918|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
218842919|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
218842920|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
218842921|NCT03764631|DRUG|Empagliflozin|Drug
218842922|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
218842923|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
218842924|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
218842925|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
218842926|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
218842927|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
218842928|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
218842929|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
218842930|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
219589154|NCT00403507|BEHAVIORAL|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
219589155|NCT03330054|DEVICE|fundoscope|Fundoscope for eye examination
219589156|NCT04608123|OTHER|none (observational study)|DBS
219589157|NCT05360485|BEHAVIORAL|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
219589158|NCT05360485|BEHAVIORAL|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
219589159|NCT04932161|PROCEDURE|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
219589160|NCT04932161|PROCEDURE|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
219589161|NCT01499459|GENETIC|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
219589162|NCT01291394|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
219589163|NCT01886196|DRUG|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
219589164|NCT01886196|OTHER|placebo|placebo designed to mimic experimental drug (ibuprofen)
219589165|NCT01886196|BEHAVIORAL|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
219589166|NCT01886196|BEHAVIORAL|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
219589167|NCT00602368|OTHER|histological technique|
219589168|NCT00602368|OTHER|laboratory biomarker analysis|
219589169|NCT00602368|PROCEDURE|colposcopic biopsy|
219589170|NCT00602368|PROCEDURE|colposcopy|
219589171|NCT00602368|PROCEDURE|light-scattering spectroscopy|
218842931|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
218842932|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
218842933|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
219589172|NCT00602368|PROCEDURE|loop electrosurgical excision procedure|
218842934|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
218842935|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
218842936|NCT06959862|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
219453429|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
219453430|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
219453431|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
219453432|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
219453433|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
219589173|NCT04011605|PROCEDURE|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
219589174|NCT02897245|OTHER|No intervention|
219589175|NCT00357253|DRUG|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
219589176|NCT00357253|RADIATION|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
219589177|NCT04127630|PROCEDURE|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
218842937|NCT05464914|DRUG|CEO Pack|is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
219453434|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
218842938|NCT06004895|DEVICE|Actual IPL|Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse
219453435|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
219017944|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
219017945|NCT05799755|DRUG|Placebo|Placebo comparator
219453436|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
219453437|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
219453438|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
219453439|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
219453440|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
219453441|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
219453442|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
219453443|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
219589178|NCT03251339|DRUG|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
219453444|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
219589179|NCT03251339|DRUG|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
218842939|NCT06004895|DEVICE|Sham IPL|Simulated five light pulses along lower lid region of the other eye of the same participant
218842940|NCT06004895|DEVICE|LLLT|Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
219453445|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
219453446|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
218842941|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
218842942|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
218842943|NCT05849675|DRUG|Placebo|Single dose placebo
218842944|NCT04457206|BEHAVIORAL|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
218842945|NCT06468605|BIOLOGICAL|JCXH-211|JCXH-211 is a lipid nanoparticle (LNP) encapsulated srRNA, encoding the human IL-12 protein.
218842946|NCT05107635|DEVICE|AtriCure Commercially Available Devices|Epicardial and endocardial hybrid ablation procedure used to treat the IST or POTS using AtriCure commercially available devices.
218842947|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
218842948|NCT03159676|RADIATION|Proton beam|Proton beam
218842949|NCT02964884|DRUG|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
218842950|NCT02964884|BEHAVIORAL|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
218842951|NCT02964884|DRUG|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
219017946|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
219453447|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
219453448|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
219589180|NCT03047330|DRUG|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
219589181|NCT03047330|OTHER|Fragmented sleep|Fragmented sleep will be experimentally induced.
219453449|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
219453450|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
219453451|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
219453452|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
219453453|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
219453454|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
219589182|NCT00004137|BIOLOGICAL|filgrastim|
219589183|NCT00004137|DRUG|carboplatin|
219589184|NCT00004137|DRUG|paclitaxel|
219589185|NCT00004137|DRUG|topotecan hydrochloride|
219453455|NCT00526760|DRUG|Dexmedetomidine|
219453456|NCT03031327|DEVICE|Lubricin 20µg/ml|Lubricin 20µg/ml eye drops
219453457|NCT03031327|DEVICE|Lubricin 50µg/ml|Lubricin 50µg/ml eye drops
219453458|NCT03031327|DEVICE|Sodium hyaluronate 0.18%|Sodium hyaluronate (HA) 0.18% eye drops
219453459|NCT02274987|OTHER|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
219453460|NCT02274987|RADIATION|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
219453461|NCT01226758|BIOLOGICAL|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
219453462|NCT01226758|BIOLOGICAL|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
219453463|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
219453464|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
219589186|NCT01345578|DRUG|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
219589187|NCT01345578|RADIATION|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
219453465|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
219589188|NCT03980574|DIETARY_SUPPLEMENT|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
219589189|NCT04123626|DRUG|QR-1123|unilateral IVT injection
219589190|NCT04123626|OTHER|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
219453466|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
219453467|NCT03942029|DRUG|Placebo|Administered orally as tablet
219453468|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
219453469|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
219453470|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
219453471|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
219453472|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
219453473|NCT04177940|DRUG|DMAB Discontinuation and Switching|"Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
219453474|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
219589191|NCT05016609|DEVICE|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
219453475|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
219453476|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
219453477|NCT04361695|DRUG|Placebo|Placebo
219453478|NCT01678469|OTHER|blood sample|
219453479|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
219453480|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
219453481|NCT01842282|DRUG|Amlexanox|
219453482|NCT03930225|BEHAVIORAL|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
219453483|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
219589192|NCT05016609|DEVICE|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
219589193|NCT05016609|DRUG|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
219589194|NCT03762044|OTHER|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"* Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression."
219589195|NCT03762044|OTHER|Complete Decongestive Therapy (CDT)|"* Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
219589196|NCT01704274|OTHER|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
219589197|NCT01704274|OTHER|High Dose GTN 0.057 mg/hr|High Dose GTN
219589198|NCT01704274|OTHER|Placebo|Placebo
219589199|NCT05659212|DRUG|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
219589200|NCT05659212|DRUG|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
219589201|NCT05659212|DRUG|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
218842952|NCT02964884|BEHAVIORAL|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
218842953|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
218842954|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
219196883|NCT06841484|PROCEDURE|Arm I (Assistant-Controlled Laparoscopic Instrumentation)|In this group, robotic distal gastrectomy is performed with assistant-controlled laparoscopic instrumentation. The assistant conducts vascular clipping using articulating Hemolock clip appliers (Livsmed) or Challenger® clip appliers (B.Braun). For gastrointestinal anastomosis, the assistant operates an Echelon stapling system (Johnson \& Johnson) via the assistant port. The surgeon controls the robotic console for all other surgical steps. This method utilizes a hybrid approach, combining robotic precision with laparoscopic efficiency.
218842955|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
218842956|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
219196884|NCT06841484|PROCEDURE|Arm II (Assistant-Controlled Laparoscopic Instrumentation)|"In this group, all surgical steps, including vascular clipping and anastomosis, are performed using the robotic system. The surgeon utilizes the Da Vinci Xi system and switches robotic instruments as needed. Vascular clipping is performed with robotic Hemolock or Hemoclip appliers, and anastomosis is conducted using the SureForm robotic stapler. This fully robotic technique eliminates laparoscopic assistance and utilizes only robotic arms for the entire procedure.~Both groups follow the same postoperative care protocols, including standardized pain management and recovery assessments."
219589202|NCT00381914|DRUG|Vitamin D|400 IU vitamin D / day
219589203|NCT00381914|DRUG|Vitamin D|800 IU vitamin D / day
219589204|NCT00381914|DRUG|Vitamin D|1200 IU vitamin D / day
219589205|NCT03376061|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
219589206|NCT01386255|DRUG|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
219589207|NCT01386255|DRUG|placebo|placebo. No other names
219589208|NCT06123455|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.
219589209|NCT06123455|BIOLOGICAL|Sintilimab|Sintilimab
219589210|NCT06123455|DRUG|XELOX regimen|Oxaliplatin + capecitabine
219589211|NCT06123455|DRUG|SOX regimen|Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
219589212|NCT06123455|DRUG|FOLFOX regimen|Oxaliplatin + leucovorin + fluorouracil
218842957|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
218842958|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
218842959|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
219589213|NCT02466841|PROCEDURE|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
219589214|NCT00438061|BEHAVIORAL|Weight loss by dietary restriction|
219589215|NCT00792961|DEVICE|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
219453484|NCT03790267|OTHER|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
219589216|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
219589217|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
219453485|NCT04605068|PROCEDURE|Transverse preputial island flap (Duckett's technique)|
219589218|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
219589219|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
219589220|NCT06490679|PROCEDURE|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
219589221|NCT06490679|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"(a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
219589222|NCT00362466|DRUG|Dasatinib|Tablets, Oral, Once daily, 5-7 years
218842960|NCT05875207|BEHAVIORAL|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
219589223|NCT00362466|DRUG|Imatinib|Tablets, Oral, Once daily, 5-7 years
219589224|NCT03168230|PROCEDURE|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
218842961|NCT05875207|BEHAVIORAL|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
218842962|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
218842963|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
218842964|NCT02317601|DRUG|placebo saline|
219453486|NCT04605068|PROCEDURE|Double-faced preputial flap (DFPF)|
218842965|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
219453487|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
218842966|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
218842967|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
218842968|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
218842969|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
219453488|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
219453489|NCT00686699|DRUG|Preladenant|capsules
219453490|NCT00686699|DRUG|Placebo|capsules
219453491|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
218842970|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
218842971|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
218842972|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
219453492|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
219453493|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
219589225|NCT06151769|OTHER|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
219589226|NCT06151769|OTHER|Sesame oil|Sesame oil
219589227|NCT04604340|PROCEDURE|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
219589228|NCT04604340|PROCEDURE|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
218842973|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
218842974|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
218842975|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
218842976|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
219453494|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
219589229|NCT06202729|OTHER|Questionnaire|GAD-7, VAS-A, NRS
219589230|NCT00757211|GENETIC|polymorphism analysis|
219589231|NCT00757211|OTHER|laboratory biomarker analysis|
219589232|NCT00757211|OTHER|questionnaire administration|
219589233|NCT06550739|OTHER|Randomization|Randomly divide the data into a training set and a validation set in a 7:3 ratio
219589234|NCT00336076|OTHER|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
219589235|NCT02289443|OTHER|complete denture|Comparison of different procedures
218842977|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
218842978|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
218842979|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
218842980|NCT02982434|DRUG|0.9% normal saline|
218842981|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
218842982|NCT00853242|DRUG|Placebo|
218842983|NCT00853242|DRUG|Genz-644470|
218842984|NCT00853242|DRUG|Sevelamer carbonate|
219196885|NCT06843005|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Based on the assessment of plaque progression after follow-up CCTA examination, patients will be given either intensive treatment or routine treatment.
219196886|NCT06843005|OTHER|Current clinical guidelines|Patients will be treated according to the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.
219453495|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
219453496|NCT06028906|DIAGNOSTIC_TEST|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
219589236|NCT06178003|BIOLOGICAL|Tpdelansbsalbac|Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
218842985|NCT05850130|OTHER|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
218842986|NCT05850130|OTHER|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
218842987|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
218842988|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
218842989|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
218842990|NCT03497975|DRUG|Placebo Tablets|Placebo matching NAL ER with no active substance
218842991|NCT05495243|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
218842992|NCT05495243|DRUG|Placebo|Isotonic saline (0.9%)
218842993|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
218842994|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
218842995|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
218842996|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
218842997|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
218842998|NCT01651065|BEHAVIORAL|Control|
218842999|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
218843000|NCT05422495|OTHER|non intervention|non intervention
218843001|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
218843002|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
218843003|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
219453497|NCT05765721|BEHAVIORAL|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
219589237|NCT02026687|DRUG|Epidural|
219589238|NCT02026687|DRUG|Intrathecal|
219589239|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
219589240|NCT03335826|PROCEDURE|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
219589241|NCT03335826|PROCEDURE|General anesthesia|General anesthesia and postoperative intravenous analgesia.
219589242|NCT01574690|DEVICE|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
219589243|NCT01574690|PROCEDURE|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
219453498|NCT05214365|DEVICE|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
218843004|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
218843005|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
219453499|NCT05214365|DEVICE|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
219589244|NCT01574690|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
219589245|NCT00540293|DRUG|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
219589246|NCT00511641|BEHAVIORAL|Questionnaire|Questionnaires lasting up to 30 minutes.
219453500|NCT00122824|DRUG|duloxetine hydrochloride|
219453501|NCT00122824|DRUG|placebo|
219453502|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
219589247|NCT04684238|DRUG|Midazolam|Solution for Injection/Infusion
219589248|NCT04684238|DRUG|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
219589249|NCT01560741|DEVICE|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
219589250|NCT01560741|DEVICE|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
219589251|NCT01377818|PROCEDURE|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
219589252|NCT01377818|PROCEDURE|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
219589253|NCT01377818|PROCEDURE|Both|both types of intervention
218843006|NCT00397761|DRUG|capecitabine|
218843007|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
218843008|NCT00397761|PROCEDURE|neoadjuvant therapy|
219589254|NCT04847518|DRUG|Kan Jang capsules|"One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate)."
219589255|NCT04847518|OTHER|Placebo capsules|Inactive excipients
218843009|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
218843010|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
219196887|NCT06841783|PROCEDURE|nerve block|ultrasound guided nerve block
219196888|NCT05670782|DRUG|KM-819|Participants will receive oral doses of KM-819 once-daily
218843011|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
218843012|NCT02672059|OTHER|Observation|No intervention
218843013|NCT02253563|BEHAVIORAL|Resistance Training|
218843014|NCT02253563|BEHAVIORAL|Balance Training|
218843015|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
218843016|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
218843017|NCT01097317|DRUG|carboplatin|
218843018|NCT01097317|DRUG|vinorelbine tartrate|
218843019|NCT01097317|OTHER|neuromuscular electrical stimulation|
218843020|NCT01097317|OTHER|physiologic testing|
218843021|NCT01097317|PROCEDURE|fatigue assessment and management|
219453503|NCT02411669|OTHER|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
219453504|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
219589256|NCT02171871|OTHER|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
219589257|NCT05239546|DRUG|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks for 8 cycles until 1.5 years
219589258|NCT00309725|DRUG|galantamine|
219589259|NCT00775905|DRUG|amlodipine 10 mg tablet|
219589260|NCT04779515|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
219589261|NCT04779515|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
219589262|NCT03522610|BEHAVIORAL|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
219589263|NCT02241421|DRUG|Amoxicillin|
219589264|NCT02241421|DRUG|Vancomycin|
219589265|NCT02241421|OTHER|Placebo|
219589266|NCT00000718|DRUG|Zidovudine|
219589267|NCT00000718|DRUG|Zalcitabine|
219589268|NCT03889067|BIOLOGICAL|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
218843022|NCT01097317|PROCEDURE|quality-of-life assessment|
218843023|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
218843024|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
218843025|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
218843026|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
218843027|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
218843028|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
218843029|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
218843030|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
218843031|NCT00378625|DRUG|Artesunate|
218843032|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
218843033|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
218843034|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
218843035|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
218843036|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
218843037|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
218843038|NCT00369174|DRUG|rosiglitazone maleate|Given orally
218843039|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
218843040|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
218843041|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
218843042|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
218843043|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
218843044|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
218843045|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
219453505|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
219453506|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
219453507|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
219453508|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
219453509|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
219589269|NCT02585934|DRUG|RVT-101|once daily, oral, 35 mg tablets
219589270|NCT02585934|DRUG|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
219589271|NCT00782574|DRUG|AZD2281|Tablets Oral BID
219589272|NCT00782574|DRUG|Cisplatin|IV every 3 weeks
219589273|NCT02448706|DEVICE|Hearing Aid Fitting A|
219589274|NCT02448706|DEVICE|Hearing Aid Fitting B|
219589275|NCT01476618|OTHER|No Intervention|No Intervention
219589276|NCT00599378|BEHAVIORAL|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
219589277|NCT01344278|BEHAVIORAL|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
219589278|NCT00020371|DRUG|BMS-247550|
219589279|NCT00020371|DRUG|filgrastim|
219589280|NCT03860662|DIAGNOSTIC_TEST|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
219589281|NCT03860662|DRUG|Botox|botox
219589282|NCT03860662|DRUG|Baclofen|baclofen
219589283|NCT01458730|DRUG|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
219589284|NCT01359969|DRUG|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
219589285|NCT02067468|DEVICE|HPV test|QIAGEN - The Digene HPV test®
218843046|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
218843047|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
218843048|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
218843049|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
219589286|NCT02067468|PROCEDURE|COLPOSCOPY|Colposcopy routine health services
219589287|NCT02067468|DEVICE|cytology|Cytology routine health services
218843050|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
219589288|NCT02174419|DRUG|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
219589289|NCT02174419|DRUG|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
219589290|NCT02174419|DRUG|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
219589291|NCT03174262|BEHAVIORAL|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
219589292|NCT04062474|PROCEDURE|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
219453510|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
219453511|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
218843051|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
218843052|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
218843053|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
218843054|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
219453512|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
219453513|NCT01935622|DRUG|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
219453514|NCT01935622|DRUG|placebo|Placebo 1 tablet every 12 hours for 14 days
218843055|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
218843056|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
218843057|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
219453515|NCT00025194|DRUG|estramustine phosphate sodium|
219453516|NCT00025194|DRUG|ixabepilone|
219453517|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219453518|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
219453519|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
219453520|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
219589293|NCT05939635|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
218843058|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
218843059|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
218843060|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
218843061|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
218843062|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
218843063|NCT01880294|DRUG|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
219453521|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219453522|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219453523|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
219453524|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219453525|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
219453526|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
218843064|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
218843065|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
218843066|NCT03070171|DRUG|dabigatran etexilate|single dose
218843067|NCT02182661|DRUG|Ba253BINEB|
218843068|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
218843069|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
218843070|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
219453527|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
218843071|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
219453528|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
219589294|NCT05939635|PROCEDURE|Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block|"Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
218843072|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
218843073|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
218843074|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
218843075|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
218843076|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
218843077|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
219453529|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
219589295|NCT05939635|DRUG|IV morphine patient-controlled analgesia (PCA)|Morphine will be administered via PCA device for the first 24 hours after surgery
218843078|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
218843079|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
218843080|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
219196889|NCT05670782|DRUG|Placebo|Participants will receive matching placebo once-daily
219453530|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219589296|NCT05876663|OTHER|Kinesio Taping|Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
219589297|NCT05876663|OTHER|Conventional physiotherapy protocol|"Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks."
219589298|NCT03126617|BIOLOGICAL|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
218843081|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219453531|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219453532|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
219589299|NCT00110136|DRUG|St. John's Wort|St. John's Wort 300mg tablet three times per day
219589300|NCT03322618|BIOLOGICAL|blood samples|7 tubes of 6 ml (42 ml of blood )
219589301|NCT00154271|DRUG|Valsartan, Valsartan HCT|
219589302|NCT06031233|DRUG|Nivolumab|Gradual shortening of infusion times
219589303|NCT06031233|DRUG|Pembrolizumab|Gradual shortening of infusion times
219589304|NCT06031233|DRUG|Ipilimumab|Gradual shortening of infusion times
219589305|NCT06031233|DRUG|Durvalumab|Gradual shortening of infusion times
219017958|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
219017959|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
219017961|NCT06150742|DEVICE|Niyad (nafamostat mesylate)|Niyad (nafamostat mesylate) lyophilized
219453533|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
219453534|NCT00601510|DRUG|capecitabine|
219453535|NCT00601510|DRUG|cisplatin|
219453536|NCT00601510|DRUG|imatinib mesylate|
219453537|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
219453538|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
219589306|NCT06031233|DRUG|Atezolizumab|Gradual shortening of infusion times
219589307|NCT06031233|DRUG|Bevacizumab|Gradual shortening of infusion times
219589308|NCT06031233|DRUG|Trastuzumab|Gradual shortening of infusion times
219589309|NCT04540406|DRUG|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
219453539|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
219453540|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
219453541|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
219453542|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
219453543|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
219453544|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
219453545|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
219453546|NCT01901809|DRUG|Furosemide|
219453547|NCT01901809|DRUG|Dopamine|
219453548|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
219589310|NCT04540406|OTHER|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
219589311|NCT03875859|DRUG|Remetinostat|Topical 1% remetinostat gel
219589312|NCT02887456|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
219589313|NCT02887456|DRUG|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
218843082|NCT01788839|BEHAVIORAL|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
219589314|NCT04365777|OTHER|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
219017962|NCT06150742|DEVICE|Placebo (0.9% NaCl)|0.9% NaCl
219453549|NCT03968523|PROCEDURE|TAP block|TAP block technique
219453550|NCT03040479|DRUG|lasmiditan 200 mg|single dose
219453551|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
219453552|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
219589315|NCT04365777|OTHER|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
219589316|NCT04365777|OTHER|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
219589317|NCT00470067|DRUG|carboplatin|IV
219589318|NCT00470067|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
219589319|NCT02480868|DEVICE|ARTEBONE|4,3 g Bone Void Filler
219589320|NCT00460135|BEHAVIORAL|resistance training|2 times a week resistance training
219589321|NCT03400943|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
219589322|NCT03400943|DRUG|Placebo|Matching placebo was administered to group B1 and B2.
219589323|NCT04863599|OTHER|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
219589324|NCT02563106|DRUG|SYN-004|
219589325|NCT02563106|DRUG|Placebo|
218843083|NCT01788839|OTHER|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
219453553|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
219453554|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
218843084|NCT01788839|DEVICE|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
218843085|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
218843086|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
218843087|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
218843088|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
218843089|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
219453555|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
219453556|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
219453557|NCT04657003|DRUG|Tirzepatide|Administered SC
219453558|NCT04657003|OTHER|Placebo|Administered SC
219453559|NCT01768624|PROCEDURE|dialysis, kidney transplant|
219453560|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
219589326|NCT00005983|RADIATION|radiation therapy|
219589327|NCT00005983|PROCEDURE|surgery|surgery
219589328|NCT04260971|DEVICE|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
219589329|NCT04729309|DRUG|[12C] RO7049389|Participants will receive oral \[12C\] RO7049389.
219589330|NCT04729309|DRUG|[13C] RO7049389|Participants will receive IV \[13C\] RO7049389.
219589331|NCT04729309|DRUG|[14C] RO7049389|Participants will receive an oral suspension of \[14C\] RO7049389.
219589332|NCT01515930|BEHAVIORAL|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
219589333|NCT01515930|BEHAVIORAL|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
219589334|NCT01515930|BEHAVIORAL|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
219589335|NCT03914911|DEVICE|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
219589336|NCT04558268|DRUG|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
219589337|NCT04558268|DRUG|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
219589338|NCT04558268|DIETARY_SUPPLEMENT|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
219589339|NCT04558268|DIETARY_SUPPLEMENT|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
219589340|NCT04558268|DIETARY_SUPPLEMENT|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
219453561|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1\) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
218843090|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
218843091|NCT04821375|DRUG|bazedoxifene plus conjugated estrogens|6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
218843092|NCT05157113|DRUG|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
218843093|NCT05157113|DRUG|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
218843094|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
218843095|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
218843096|NCT01812213|DRUG|[18F]NAV4694|
218843097|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
218843098|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
218843099|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
218843100|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
219017963|NCT04648969|DRUG|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
219017964|NCT04648969|DRUG|GnRH|1 intravenous dose of GnRH
219017966|NCT06311214|PROCEDURE|Biopsy Procedure|Undergo biopsy
219589341|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
219589342|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
219589343|NCT03924089|OTHER|Dietary recommendations|Dietary recommendations
219589344|NCT01290562|RADIATION|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
219589345|NCT01584557|DRUG|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
219589346|NCT01584557|DRUG|placebo or sugar pill|sugar pill
219589347|NCT00326560|PROCEDURE|Pterygium excision and conjunctival autograft|
219589348|NCT01059539|DRUG|Cariprazine|Cariprazine was supplied in capsules.
219589349|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
219589350|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
219589351|NCT00941148|DRUG|Insulin Glargin|
219589352|NCT00941148|DRUG|NPH insulin|
219589353|NCT00941148|DRUG|Insulin detemir|
219589354|NCT00941148|DRUG|metformin|metformin (2000 mg/day)
219589355|NCT03122925|DEVICE|MR|MR
219589356|NCT00537303|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
219589357|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
219589358|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
219017967|NCT06311214|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219017968|NCT06311214|PROCEDURE|Computed Tomography|Undergo CT
219017969|NCT06311214|PROCEDURE|Echocardiography Test|Undergo ECHO
219017970|NCT06311214|OTHER|Electronic Health Record Review|Undergo review of SOC RNA testing results
219017971|NCT06311214|DRUG|Enfortumab Vedotin|Given IV
219017972|NCT06311214|OTHER|Immunohistochemistry Staining Method|Undergo IHC assay
219017973|NCT06311214|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219453562|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
219453563|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
219453564|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
219453565|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
219453566|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
219453567|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
219453568|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
219453569|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
219453570|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
219589359|NCT03717025|PROCEDURE|SUCTION BLISTER EPIDERMAL GRAFTING|"1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
219589360|NCT03717025|PROCEDURE|MINI PUNCH GRAFTING|"1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
219589361|NCT03717025|PROCEDURE|NON CULTURED EPIDERMAL CELL SUSPENSION|"1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
219589362|NCT05362838|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
219589363|NCT05362838|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
219453571|NCT02949414|PROCEDURE|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
219453572|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
219453573|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
219453574|NCT00162799|DRUG|Triflusal (DCI)|
219589364|NCT04197050|DRUG|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
219589365|NCT01110135|DRUG|bendamustine hydrochloride|Given IV
219589366|NCT01110135|DRUG|dexamethasone|Given PO
219589367|NCT01110135|BIOLOGICAL|filgrastim|Given SC
219589368|NCT01110135|PROCEDURE|leukapheresis|Given IV
219589369|NCT01110135|OTHER|laboratory biomarker analysis|Correlative studies
219589370|NCT01110135|OTHER|flow cytometry|Correlative studies
219589371|NCT01110135|DRUG|etoposide|Given IV
219589372|NCT00196924|BIOLOGICAL|HPV-16/18 L1/AS04|
219589373|NCT03156335|DEVICE|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
219196890|NCT06824766|OTHER|Visual Analogue Scale|The pain intensity of the participants will be assessed using the Visual Analogue Scale, which is a simple, reliable and short-term method commonly used to measure pain intensity in the clinic. The participant is told that the most severe pain he/she experiences is 10 and if there is no pain, the pain intensity is 0. The participant will be asked to tick a number between 0 and 10 corresponding to the intensity of pain felt in the masticatory muscles at rest and during chewing.
219589374|NCT02085135|DRUG|ALKS 5461|Sublingual tablet taken once daily
219589375|NCT03552835|PROCEDURE|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
219589376|NCT03552835|PROCEDURE|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
219589377|NCT03552835|PROCEDURE|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
219589378|NCT05251519|OTHER|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
219453575|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
219453576|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
219453577|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
219453578|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
219453579|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
219453580|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
219453581|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
219453582|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
219453583|NCT01886144|DEVICE|Knee OA Brace|
219589379|NCT05251519|OTHER|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
218843101|NCT02843035|DRUG|venglustat (GZ402671)|"Pharmaceutical form: capsule or tablet~Route of administration: oral"
219196891|NCT06824766|OTHER|Autonomic nervous system activity assessment|All participants included in the study will undergo a 5-minute test with the Polar H10 chest strap device for autonomic nervous system activity assessment (heart rate variability assessment). The data obtained after the measurement will be analysed with Kubios software. Stress index (cardiovascular system stress), PNS index (parasympathetic nervous system dominance), SNS index (sympathetic nervous system dominance), LF power (sympathetic activity), HF power (parasympathetic activity) and LF/HF ratio (sympathetic/parasympathetic balance) parameters will be used in the evaluation of HRV in Kubios programme.
219453584|NCT06241937|BEHAVIORAL|Expanded Clinical Firearm Safety Counseling Training|Members of the DGSOM class of 2027 will participate in a mandatory 3.5 hour training session as a part of the regular curriculum that will include: (1) didactic information on firearm violence epidemiology; (2) suicide epidemiology and introduction to lethal means restriction; (3) firearm safety counseling techniques; (4) a panel of firearm violence survivors / trauma interventionists; and (5) a small group session with discussions of the aforementioned topics and a demonstration of a patient encounter using a standardized patient actor depicting a clinical scenario warranting firearm safety counseling. The training will be taught by faculty members, invited subject matter experts, senior medical students, and the DGSOM Standardized Patient Program.
219453585|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
219453586|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
219453587|NCT06333535|OTHER|foot massage|foot massage
219453588|NCT06333535|OTHER|abdominal massage|abdominal massage
219453589|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
219453590|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
219589380|NCT05394649|DEVICE|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
219589381|NCT05394649|DEVICE|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
219589382|NCT05763108|DIAGNOSTIC_TEST|genetic test|COL1A1 or COL5A1 genetic test
219589383|NCT05763108|OTHER|Beighton joint laxity test|Based on Beighton scale.
219017974|NCT06311214|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219017975|NCT06311214|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219017976|NCT06311214|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219017977|NCT04268849|DRUG|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
219589384|NCT04851652|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
219589385|NCT04720118|OTHER|No Intervention|There is no intervention for this study.
219589386|NCT05305482|DEVICE|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
219589387|NCT05305482|DEVICE|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
219589388|NCT02535871|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
218843102|NCT02843035|DRUG|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
218843103|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
219017978|NCT04268849|DRUG|Saline|Placebo for Ferumoxytol
219017979|NCT04268849|DRUG|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
219017980|NCT04268849|DRUG|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
219017981|NCT05011084|DEVICE|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
219589389|NCT02535871|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
219589390|NCT00883909|DRUG|dutasteride|A follow-up study in adult male subjects who have received investigational product
219589391|NCT00446537|PROCEDURE|Methylphenidate|
219589392|NCT06627491|BEHAVIORAL|Imagined muscle contractions|The intervention involved imagining, with no physical movement, of muscle contractions.
219589393|NCT03177174|DRUG|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
219589394|NCT03177174|DRUG|Docetaxel|Docetaxel
219589395|NCT01830894|DEVICE|MRI|3 MRI on different times during the study for each arm.
219589396|NCT05043844|DEVICE|abdominal binder|Wearing an abdominal binder postoperatively
218843104|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
218843105|NCT04826094|BIOLOGICAL|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
218843106|NCT04826094|BIOLOGICAL|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
218843107|NCT04826094|DRUG|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
218843108|NCT04826094|BIOLOGICAL|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
218843109|NCT04826094|BIOLOGICAL|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
218843110|NCT04826094|DRUG|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
218843111|NCT04826094|DRUG|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
218843112|NCT05604560|DRUG|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
219589397|NCT01838668|DRUG|Placebo|Two placebo capsules orally BID
219589398|NCT01838668|DRUG|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
219589399|NCT04023162|BEHAVIORAL|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
219589400|NCT04023162|BEHAVIORAL|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
219589401|NCT04023162|BEHAVIORAL|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
219589402|NCT04689867|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
219589403|NCT06361979|DRUG|SHR-A1811|SHR-A1811: intravenous
219589404|NCT06361979|DRUG|Bevacizumab|Bevacizumab:intravenous
219589405|NCT05144490|OTHER|Exercise|A single session of bodyweight exercise
219589406|NCT03775759|PROCEDURE|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
218843113|NCT05604560|DRUG|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
218843114|NCT04753970|DRUG|Cilostazol|Cilostazol 100mg BID
218843115|NCT06342024|OTHER|Pistachio group|Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
218843116|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
218843117|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
218843118|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
219017982|NCT05011084|OTHER|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
219017983|NCT05777928|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
219589407|NCT03775759|OTHER|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
219589408|NCT04091659|OTHER|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
219589409|NCT04091659|OTHER|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
219589410|NCT00205244|BEHAVIORAL|Healing images, relaxation and distraction materials|
219589411|NCT01173081|DRUG|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
219589412|NCT01173081|DRUG|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
219589413|NCT04934410|DRUG|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
219589414|NCT04934410|DRUG|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
219589415|NCT04934410|DRUG|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
219589416|NCT05532124|BIOLOGICAL|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
219589417|NCT05532124|OTHER|normal saline|Intravenous Injection
218843119|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
218843120|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
218843121|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
218843122|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
218843123|NCT02989818|OTHER|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
218843124|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
218843125|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
218843126|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
219589418|NCT05670535|OTHER|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
219589419|NCT05670535|OTHER|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
218843127|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
218843128|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
218843129|NCT00399217|DEVICE|ICD|
218843130|NCT03309033|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218843131|NCT03309033|OTHER|Questionnaire Administration|Complete questionnaire
218843132|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
219017984|NCT05777928|PROCEDURE|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
219589420|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
219589421|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
219589422|NCT00772421|DEVICE|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
219589423|NCT04675619|DRUG|Oral pirfenidone|Treatment
219589424|NCT04675619|DRUG|Standard care|Treatment
218843133|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
218843134|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
218843135|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
218843136|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
218843137|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
219453591|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
219453592|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
219589425|NCT01410500|DRUG|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
219589426|NCT04169542|OTHER|Questionnaire Administration|Complete questionnaires
218843138|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
218843139|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
218843140|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
218843141|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
218843142|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
219589427|NCT02926482|BEHAVIORAL|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
219589428|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
219589429|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
219589430|NCT01507363|DRUG|Placebo|Placebo tablets for 7 days, starting on the day of surgery
218843143|NCT02733770|PROCEDURE|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
218843144|NCT02733770|PROCEDURE|Laparoscopic mini gastric bypass|Doppler ultrasound.
218843145|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
218843146|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
218843147|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
218843148|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
218843149|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
219589431|NCT04451681|OTHER|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
218843150|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
219589432|NCT05487534|OTHER|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
219589433|NCT04297319|PROCEDURE|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
219589434|NCT04297319|PROCEDURE|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
219589435|NCT02040506|DRUG|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
219453593|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
219453594|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
219453595|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
219453596|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
219453597|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
219453598|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
219453599|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
219453600|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
219453601|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
219453602|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
219453603|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
219453604|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
219453605|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
219453606|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
219453607|NCT00270010|DRUG|epoetin alfa|
219453608|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
219453609|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
219453610|NCT02015858|PROCEDURE|Chest drain withdrawal|
219453611|NCT02015858|DEVICE|Pain Monitor|
219453612|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
219589436|NCT02651259|DRUG|Rifapentine (RPT)|900 mg of RPT
219453613|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
219453614|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
219453615|NCT01108224|BEHAVIORAL|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
219453616|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
219453617|NCT04443205|OTHER|Data record|Data record
219453618|NCT02008461|PROCEDURE|radiofrequency ablation|
219453619|NCT02008461|DRUG|botulinum toxin injection|
219453620|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
219453621|NCT00495508|DRUG|Quinine|
219453622|NCT00495508|DRUG|artemether / lumefantrine|
219453623|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
219453624|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
219453625|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
219453626|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
219453627|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
219453628|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
219453629|NCT01776372|DEVICE|Medela Thopaz Thoracic Drainage System|
219453630|NCT01776372|DEVICE|Atrium Express Dry Seal Chest Drain|
219453631|NCT03896087|DIAGNOSTIC_TEST|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
219589437|NCT02651259|DRUG|Isoniazid (INH)|900 mg of INH
219589438|NCT02651259|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
218843151|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
219453632|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
219453633|NCT03896087|DIAGNOSTIC_TEST|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
219453634|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
219453635|NCT00065221|DRUG|Ginger|
219453636|NCT02274311|DRUG|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
219589439|NCT03756506|DEVICE|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
218843152|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
218843153|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
219453637|NCT06258161|PROCEDURE|Spinal Fusion|Realignment and fusion of adult spinal deformity
219453638|NCT06258161|OTHER|No intervention|No intervention for control group.
219453639|NCT05840393|OTHER|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
219453640|NCT05260190|DEVICE|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
219589440|NCT00562237|BIOLOGICAL|S205 placebo|2 i.m. injections per subject (0.5 mL each)
218843154|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
218843155|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
219017989|NCT06355791|DEVICE|Minuteman G5 Device|The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
219453641|NCT05260190|DEVICE|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
219453642|NCT02940158|OTHER|1/4 cup- Small red lentil|
219453643|NCT02940158|OTHER|1/4 cup- Small green lentil|
219453644|NCT02940158|OTHER|1/4 cup- corn|
219453645|NCT02940158|OTHER|1/4 cup- macaroni|
219453646|NCT02940158|OTHER|1/4 cup- white potato|
219453647|NCT02940158|OTHER|1/4 cup- white rice|
218843156|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
218843157|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
219453648|NCT02940158|OTHER|1/2 cup- small red lentil|
219453649|NCT02940158|OTHER|1/2 cup- small green lentil|
219453650|NCT02940158|OTHER|1/2 cup- corn|
219453651|NCT02940158|OTHER|1/2 cup- macaroni|
219453652|NCT02940158|OTHER|1/2 cup- white potato|
219453653|NCT02940158|OTHER|1/2 cup- white rice|
219453654|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
219453655|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
219453656|NCT05727891|DRUG|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
219589441|NCT00562237|BIOLOGICAL|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
219589442|NCT00562237|BIOLOGICAL|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
219589443|NCT00562237|BIOLOGICAL|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
218843158|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
218843159|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
219453657|NCT05727891|OTHER|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
219453658|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
219453659|NCT01110486|DRUG|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
219453660|NCT01110486|DRUG|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
219453661|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
219453662|NCT01110486|DRUG|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
219453663|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
219453664|NCT05458492|DRUG|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
219453665|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
219453666|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
219453667|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
219453668|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
219453669|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
219589444|NCT00562237|BIOLOGICAL|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
219589445|NCT00562237|BIOLOGICAL|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
219589446|NCT00562237|BIOLOGICAL|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
219589447|NCT02031718|BEHAVIORAL|Virtual Counseling|
219589448|NCT03293407|DRUG|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
219589449|NCT03293407|DEVICE|Breelib nebulizer|Used for inhalation of Ventavis
219589450|NCT06426615|DEVICE|Intracranial electrodes|Placement of intracranial electrodes in the cortico-subcortical system
219589451|NCT03678285|OTHER|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
219589452|NCT00534807|DRUG|Vinflunine|
219589453|NCT00534807|DRUG|Rifampin|
219589454|NCT04641585|DIAGNOSTIC_TEST|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
219589455|NCT01345487|OTHER|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
218843160|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
218843161|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
219453670|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
218843162|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
218843163|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
219453671|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
219453672|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
219453673|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
219453674|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
219453675|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
219453676|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
219453677|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
219453678|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
219453679|NCT03109288|DRUG|Pioglitazone|15-45 mg po qd
219453680|NCT03109288|DRUG|clemastine fumarate|8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
219453681|NCT03109288|DRUG|Dantrolene|Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
219589456|NCT01345487|OTHER|Animal protein|Protein in the form of minced pork/beef
219589457|NCT04359511|DRUG|Prednisone|prednisone 0.7 mg/kg/d (PO)
219589458|NCT04359511|DRUG|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
219589459|NCT05744180|OTHER|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
219589460|NCT06498440|DRUG|Ketorolac 0.5% Eye Drops|Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.
219589461|NCT06498440|DRUG|Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops|Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
219589462|NCT00616629|DRUG|AZD1305|Intravenous infusion
219589463|NCT04232280|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
219589464|NCT04232280|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
219589465|NCT05927948|DEVICE|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
219589466|NCT03157648|OTHER|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
219453682|NCT03109288|DRUG|Pirfenidone|"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid"
219453683|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
219453684|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
218843164|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
218843165|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
218843166|NCT02185560|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
218843167|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
218843168|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
218843169|NCT02152371|DRUG|Dulaglutide|Administered SQ
218843170|NCT02152371|DRUG|Placebo|Administered SQ
218843171|NCT02152371|DRUG|Insulin Glargine|Administered SQ
218843172|NCT02152371|DRUG|Metformin|Administered orally
218843173|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
218843174|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
219017990|NCT04998201|DRUG|ARO-APOC3|ARO-APOC3 Injection
218843175|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
219589467|NCT06633172|PROCEDURE|laparoscopic ventral mesh rectopexy|performing ventral mesh rectopexy via laparoscopic surgery to correct the anterior rectocele.
219589468|NCT06633172|PROCEDURE|Trans vaginal repair|performing repair of the rectocele through the recto vaginal septum repair.
218843176|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
218843177|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
218843178|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
218843179|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
218843180|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
218843181|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
218843182|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
218843183|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
218843184|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Patients|Patients will be randomized to the shared decision making aid intervention.
218843185|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Providers|Providers of patients randomized o the shared decision making aid intervention.
218843186|NCT06730867|BEHAVIORAL|EMDR Therapy Protocol|The intervention involves an eight-week program that details a specific EMDR protocol and questionnaire for people living with HIV. The EMDR sessions occur once a week for eight weeks under the supervision of the investigator.
218843187|NCT06359028|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2
218843188|NCT06359028|DRUG|Crest cavity protection toothpaste|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
218843189|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
218843190|NCT06235632|BEHAVIORAL|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
218843191|NCT06235632|BEHAVIORAL|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
218843192|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
218843193|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
218843194|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
218843195|NCT00002552|BIOLOGICAL|filgrastim|
218843196|NCT00002552|BIOLOGICAL|sargramostim|
218843197|NCT00002552|DRUG|carmustine|
218843198|NCT00002552|DRUG|cyclophosphamide|
218843199|NCT00002552|DRUG|cytarabine|
218843200|NCT00002552|DRUG|etoposide|
218843201|NCT00002552|DRUG|leucovorin calcium|
218843202|NCT00002552|DRUG|methotrexate|
218843203|NCT00002552|DRUG|perfosfamide|
218843204|NCT00002552|DRUG|therapeutic hydrocortisone|
218843205|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
218843206|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
218843207|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
218843208|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
218843209|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
218843210|NCT00002552|RADIATION|radiation therapy|
219017991|NCT04998201|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
219589469|NCT05255848|DRUG|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
219589470|NCT03560648|DEVICE|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
219589471|NCT05811806|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
219589472|NCT04519034|OTHER|no intervention|There will be no intervention
219589473|NCT00235196|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
219589474|NCT06124495|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
219589475|NCT00823108|DRUG|GIK|12 hour infusion of GIK solution
219453685|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
219589476|NCT02594670|OTHER|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
219589477|NCT02594670|OTHER|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
219589478|NCT02594670|OTHER|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
218843211|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
218843212|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
218843213|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
218843214|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
218843215|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
218843216|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
218843217|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
218843218|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
219453686|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
219453687|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
219453688|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
219453689|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
219589479|NCT05384639|DEVICE|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
219589480|NCT05384639|DEVICE|Cycling Group|Participant will cycle only.
218843219|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
218843220|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
218843221|NCT04616326|DRUG|Galcanezumab|Administered SQ
218843222|NCT04616326|DRUG|Placebo|Administered SQ
218843223|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
218843224|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
218843225|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
218843226|NCT01943058|DRUG|megestrol acetate|Given PO
218843227|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
218843228|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
218843229|NCT01943058|OTHER|questionnaire administration|Ancillary studies
218843230|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
218843231|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
218843232|NCT06094244|OTHER|No drugs|No drugs
218843233|NCT06971614|BIOLOGICAL|T3011|T3011 will be administered at a dose of 1x10\^10 PFU intravesically.
218843234|NCT01866111|DRUG|YKP3089|
218843235|NCT01866111|DRUG|Placebo|
218843236|NCT06081179|DRUG|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
218843237|NCT06081179|DRUG|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
218843238|NCT06081179|DRUG|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
218843239|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
219453690|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
219453691|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
219453692|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
219453693|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
219589481|NCT05384639|DEVICE|Cognitive Group|Participant will perform cognitive training only.
219453694|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
219453695|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
219453696|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
219453697|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
219453698|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
219589482|NCT04292665|BEHAVIORAL|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
219589483|NCT04292665|BEHAVIORAL|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
219589484|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
219453699|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
219453700|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
219453701|NCT00232531|DRUG|Niaspan|
219453702|NCT03211546|PROCEDURE|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
219589485|NCT01777620|BIOLOGICAL|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
219589486|NCT01777620|DRUG|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
219589487|NCT02988024|DRUG|LY03005|LY03005
219589488|NCT02988024|DRUG|Pristiq|
219589489|NCT01740726|BEHAVIORAL|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
219589490|NCT01740726|DRUG|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
219589491|NCT05151666|OTHER|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
219589492|NCT01434082|BEHAVIORAL|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
218843240|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
218843241|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
218843242|NCT00257582|DRUG|Cetirizine Dry Syrup|
218843243|NCT03958864|DRUG|CC-90001|CC-90001
219453703|NCT03211546|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
219453704|NCT04981860|DRUG|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
219453705|NCT04981860|DRUG|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
219453706|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
219453707|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
219453708|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
219453709|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
219453710|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
219453711|NCT03720067|DRUG|Rosuvastatin|20mg / day
219453712|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
219453713|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
219453714|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
219453715|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
219453716|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
219453717|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
219453718|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
219453719|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
219453720|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
218843244|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
218843245|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
218843246|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
218843247|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
218843248|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
218843249|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
219453721|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
219453722|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
219453723|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
218843250|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
218843251|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
218843252|NCT05976646|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
219453724|NCT02319564|DRUG|Beclomethasone|
219453725|NCT02319564|DRUG|Beclomethasone and Salbutamol|
219453726|NCT02319564|DRUG|Placebo|
218843253|NCT05976646|DRUG|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
218843254|NCT01027494|DRUG|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
218843255|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
219453727|NCT02319564|DEVICE|Aerochamber Max®|
219453728|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
219453729|NCT05925829|BIOLOGICAL|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
219453730|NCT03809195|BEHAVIORAL|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
219453731|NCT03350802|DIAGNOSTIC_TEST|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
219453732|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
219453733|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
219453734|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
219453735|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
219453736|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
219453737|NCT02477800|DRUG|Placebo|Placebo
218843256|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
218843257|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
218843258|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
218843259|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
218843260|NCT01802580|BEHAVIORAL|Internet Survey|
218843261|NCT01802580|DRUG|fluocinonide 0.05% ointment|
218843262|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
218843263|NCT01931488|DEVICE|SPECT imaging|
218843264|NCT03401944|DRUG|TPN|
218843265|NCT03401944|OTHER|Control|
218843266|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
218843267|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
218843268|NCT02066831|BEHAVIORAL|Telemedical coaching|
218843269|NCT02066831|OTHER|Telemedicine|
218843270|NCT03216343|DRUG|Chiauranib|CS2164
218843271|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
218843272|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
218843273|NCT00121758|BIOLOGICAL|LIPO-5|
218843274|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
218843275|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
218843276|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
219453738|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
219453739|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
219589493|NCT04557020|DRUG|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
219589494|NCT04557020|DRUG|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
219589495|NCT04557020|DRUG|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
219589496|NCT04557020|RADIATION|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
219589497|NCT00482651|RADIATION|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
219589498|NCT00482651|PROCEDURE|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
219589499|NCT00482651|PROCEDURE|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
219589500|NCT00482651|PROCEDURE|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
219589501|NCT03929341|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
219589502|NCT03929341|OTHER|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
219589503|NCT02789618|OTHER|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
219589504|NCT02789618|OTHER|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
219589505|NCT02789618|OTHER|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
218843277|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
218843278|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
218843279|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
218843280|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
219453740|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
219453741|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
219589506|NCT05158036|OTHER|Classic massage group|Classic massage application will be given to the Classic massage group
219589507|NCT05158036|OTHER|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
219589508|NCT04709770|DRUG|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
219589509|NCT04709770|DRUG|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
219589510|NCT04709770|DIETARY_SUPPLEMENT|Low-residue diet|Diet before colonoscopy.
218843281|NCT02674919|OTHER|Nordic Hamstring|
219589511|NCT02202070|DRUG|onabotulinumtoxinA|
219589512|NCT00727870|DEVICE|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
218843282|NCT02674919|OTHER|Control|
218843283|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
218843284|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
218843285|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
219453742|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
219453743|NCT05939219|BIOLOGICAL|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
219453744|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
219453745|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
218843286|NCT03236909|DEVICE|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
218843287|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
218843288|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
218843289|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
218843290|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
219453746|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
218843291|NCT06797856|DIAGNOSTIC_TEST|Refractive Error|"* Refractive error centrally (on-axis) and peripherally in both nasal and temporal visual fields~* Ocular wavefront measured centrally (on-axis) and peripherally in both nasal and temporal visual fields"
218843292|NCT06814886|BEHAVIORAL|wearable devices to initiate behavioral intervention|12 week wearable devices to initiate behavioral intervention including line APP recruited participants and give some behavior change advises, also give a APP-based motivational interviewing 15 minutes per week.
219196892|NCT06824766|OTHER|Masticatory muscles assessment|The Myoton PRO device will be used to objectively assess the biomechanical properties of the participants' masticatory muscles such as tone, stiffness and elasticity. The masseter and temporalis muscles will be evaluated bilaterally in the sitting position. Three measurements will be recorded at one second intervals and the average value will be used for analysis.
219196893|NCT06825065|BEHAVIORAL|PAPE Protocol|In this intervention, participants perform a warm-up consisting of 3 repetitions at 90% of 1RM. After a 10-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is designed to enhance performance through the post-activation potentiation effect.
219453747|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
219453748|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
219453749|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
219453750|NCT02709239|DIETARY_SUPPLEMENT|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
219589513|NCT00727870|DEVICE|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
219589514|NCT00727870|DEVICE|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
219589515|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
219589516|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
219589517|NCT02701270|DIETARY_SUPPLEMENT|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
219589518|NCT02701270|DIETARY_SUPPLEMENT|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
219589519|NCT01475097|DRUG|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
219589520|NCT01475097|DRUG|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
219589521|NCT03149445|DRUG|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
219589522|NCT03149445|DRUG|Placebos|Study medication will be administered for 91 days.
219589523|NCT02784873|OTHER|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
219589524|NCT05594264|BEHAVIORAL|HBPStories|The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
219589525|NCT03083080|PROCEDURE|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
219589526|NCT03083080|DRUG|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
219589527|NCT03083080|DRUG|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
219589528|NCT03173326|PROCEDURE|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
219589529|NCT03173326|PROCEDURE|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
219589530|NCT02194348|DRUG|BIBN 4096 BS - in single rising doses|
219589531|NCT02194348|DRUG|Placebo|
219589532|NCT04810026|BEHAVIORAL|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
219589533|NCT04810026|BEHAVIORAL|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
219589534|NCT04810026|BEHAVIORAL|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
219589535|NCT02074917|PROCEDURE|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
219589536|NCT02759601|DRUG|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
219453751|NCT02709239|DIETARY_SUPPLEMENT|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
219589537|NCT03101644|DRUG|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
219589538|NCT04005235|DEVICE|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
219589539|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
219196894|NCT06825065|BEHAVIORAL|Control Protocol|In this intervention, participants perform a warm-up consisting of 8 repetitions at 50% of 1RM. After a 4-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is used as a baseline for comparison with the PAPE protocol.
219453752|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
219453753|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
219453754|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
219589540|NCT01548118|BIOLOGICAL|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
219589541|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
219453755|NCT02258191|DEVICE|telemonitoring|
219453756|NCT02258191|DEVICE|sham telemonitoring|
219589542|NCT01548118|BIOLOGICAL|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
219589543|NCT02634359|DEVICE|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
219589544|NCT02634359|PROCEDURE|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
219589545|NCT02634359|PROCEDURE|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
219589546|NCT04308707|OTHER|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
219589547|NCT00752648|DRUG|TMC435350|
219589548|NCT04639804|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
219589549|NCT04639804|DRUG|Naproxen|Naproxen 500 mg tablet
219589550|NCT04639804|DRUG|Aceclofenac|Aceclofenac 100 mg tablet
219196895|NCT06825689|DEVICE|Self-sampling with urine|Urine is self-collected at home using a urine sample cup.
219196896|NCT06825689|DEVICE|Self-sampling with swab|A vaginal cell sample is self-collected at home using a swab and collection tube.
219196897|NCT06825689|DEVICE|In-clinic Pap/HPV co-testing|Cervico-vaginal cell samples are collected by a clinician during a Pap smear/HPV co-test appointment.
219453757|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
219453758|NCT06593379|BEHAVIORAL|Safety planning|Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.
219453759|NCT06593379|BEHAVIORAL|Treatment as usual|This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans
219453760|NCT06593379|BEHAVIORAL|MIST Intervention|This is a mobile intervention designed to target and modify suicidal cognitions. Veteran in this condition will be asked to use the intervention 5 times a week for 4 weeks.
219453761|NCT00263406|DRUG|Administration of an ACE-inhibitor or not|
219589551|NCT04639804|DRUG|Celecoxib|Celecoxib 200 mg capsule
219589552|NCT04005352|BIOLOGICAL|Brolucizumab 6 mg|Intra-vitreal injection
219589553|NCT04005352|BIOLOGICAL|Aflibercept 2 mg|Intra-vitreal injection
219589554|NCT02965040|DRUG|Roxadustat|Oral
219453762|NCT05482594|DIAGNOSTIC_TEST|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
219453763|NCT05482594|DIAGNOSTIC_TEST|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
219453764|NCT04419597|DEVICE|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
218843293|NCT06814886|BEHAVIORAL|12 week wearable devices monitor|12 week wearable devices monitor physical activity and sleep quality only
218843294|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
218843295|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
218843296|NCT01783197|DRUG|Paclitaxel|
218843297|NCT01783197|DRUG|Carboplatin|
219453765|NCT04419597|DEVICE|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
219589555|NCT06017479|DRUG|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
219589556|NCT06017479|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
219589557|NCT05900258|DRUG|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
218843298|NCT01783197|DRUG|Selumetinib|
218843299|NCT01783197|DRUG|Pemetrexed|
218843300|NCT01783197|DRUG|Cisplatin|
219453766|NCT01076270|DRUG|plerixafor|Given SC
219453767|NCT01076270|BIOLOGICAL|filgrastim|Given SC
219453768|NCT01076270|PROCEDURE|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
219453769|NCT01076270|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
219453770|NCT00675311|BEHAVIORAL|DM-Standard|Device/t+ Medical Diabetes Management System
219453771|NCT00675311|BEHAVIORAL|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
219453772|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
218843301|NCT05500573|PROCEDURE|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
218843302|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
218860034|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
219453773|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
219589558|NCT02623283|OTHER|No intervention given|Participants will have a full dental examination but no operative intervention
219589559|NCT01016327|DRUG|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
219589560|NCT06019598|OTHER|Licorice|Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
219589561|NCT00936897|DRUG|Ibandronate|Ibandronate 150mg PO QM (tablet)
219589562|NCT00936897|DRUG|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
219589563|NCT03670693|DIAGNOSTIC_TEST|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
219589564|NCT03670693|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
219589565|NCT03670693|DIAGNOSTIC_TEST|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
218843303|NCT06855654|BEHAVIORAL|Promoting Resilience in Women with Breast Cancer (PRISM)|PRISM is a brief, skills-based intervention targeting 4 core resilience resources (stress management, goal setting, cognitive reframing, and meaning-making) followed by an optional family session. This adapted version of the PRISM intervention will be delivered1:1 by trained coaches who speak English or Spanish via HIPAA-compliant video conference.A single coach conducts the program with a single patient. Each session is 30-60 minutes, for a total of 2- 4 hours. Sessions are delivered every 1-2 weeks per patient's preference. To facilitate on-demand skills-practice between sessions, all participants have access to the PRISM app, available for iOS/Android, and thus available to the \>90% of U.S. adults who own a smartphone. Participants will be assisted to download the PRISM app to their device at the time of registration; however, coaches can also provide assistance with app access during intervention sessions.
218843304|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
218843305|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
218843306|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
218843307|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
219453774|NCT05477251|PROCEDURE|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
219453775|NCT05477251|PROCEDURE|lobectomy|lobectomy for GGOs located in hilar regions
219453776|NCT01948518|DRUG|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
219453777|NCT03975049|RADIATION|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
219018009|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
219018010|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
219453778|NCT03975049|DRUG|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
219453779|NCT03975049|DRUG|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
218843308|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
218843309|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
218843310|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
218843311|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
218843312|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
218843313|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
218843314|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
219018011|NCT04300855|DRUG|Sunphenon|The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
219018012|NCT04300855|DRUG|Placebo|Matching placebo
219453780|NCT03793790|BEHAVIORAL|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
219453781|NCT03793790|BEHAVIORAL|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
219453782|NCT03793790|BEHAVIORAL|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
219453783|NCT03793790|BEHAVIORAL|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
219453784|NCT03793790|BEHAVIORAL|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
219453785|NCT00169338|PROCEDURE|Deep brain stimulation|internal pallidal deep brain stimulation
219453786|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
219453787|NCT04473495|DEVICE|educational video|educational video before intervention
219453788|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
219453789|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
219453790|NCT02196090|BEHAVIORAL|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
219453791|NCT02196090|DEVICE|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
219453792|NCT00958191|DEVICE|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
219453793|NCT03216668|DRUG|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
219453794|NCT03216668|DRUG|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
218843315|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
218843316|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
219453795|NCT05518136|BEHAVIORAL|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
219453796|NCT00611767|DRUG|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
219453797|NCT00611767|DRUG|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
219453798|NCT01898000|BEHAVIORAL|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
219453799|NCT01898000|BEHAVIORAL|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
219453800|NCT04940741|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
219589566|NCT03670693|DIAGNOSTIC_TEST|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
218843317|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
218843318|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
218843319|NCT03838601|DRUG|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
218843320|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
218843321|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
219589567|NCT03670693|DIAGNOSTIC_TEST|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
219589568|NCT04482673|DRUG|Daily Vitamin D3|6000 IU vitamin D3 daily
219589569|NCT04482673|DRUG|Daily placebo|Placebo daily
219589570|NCT04482673|DRUG|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
219589571|NCT04482673|DRUG|Bolus placebo|Bolus placebo daily for 3 days
219589572|NCT06349551|BIOLOGICAL|Patients of intensive care unit|Patients of intensive care unit having an arterial catheter undergoing arterial blood sampling
219589573|NCT04058067|DRUG|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
219589574|NCT04058067|DRUG|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
219589575|NCT06229678|DRUG|Empagliflozin 25 MG Oral Tablet|Empagliflozin 25MG will be administered orally once per day for 3 months
219589576|NCT06229678|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
219589577|NCT06229678|DRUG|Acipimox 250 Mg Oral Capsule|subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
218843322|NCT06850363|DEVICE|ExaStim Stimulation System|Transcutaneous Spinal Cord Stimulation
219196898|NCT06820788|OTHER|music therapy|Local music will be played in the patient room 2 hours after the patient is transferred from the postoperative care unit to the clinic, which is the most appropriate time after surgery, when vital signs have stabilized and clinical adaptation has been achieved.
219453801|NCT04940741|OTHER|Placebo|comparator without active ingredient
219453802|NCT04743401|OTHER|Tele-exergaming Tablet|"The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program."
219453803|NCT03166657|PROCEDURE|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
219453804|NCT00598806|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
219453805|NCT00598806|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
219453806|NCT00598806|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
219453807|NCT06587490|RADIATION|stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
219453808|NCT01908049|DIETARY_SUPPLEMENT|Probiotic.|
219453809|NCT01908049|DIETARY_SUPPLEMENT|Placebo|
219453810|NCT05185219|DRUG|Valerian|A natural plant
219589578|NCT00417170|DRUG|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
218843324|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
218843325|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
219589579|NCT00417170|DRUG|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
219589580|NCT00417170|DRUG|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
219589581|NCT00417170|DRUG|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
219589582|NCT02702570|BEHAVIORAL|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
219589583|NCT04728009|DIETARY_SUPPLEMENT|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
219589584|NCT05180201|DIETARY_SUPPLEMENT|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
219589585|NCT05180201|DIETARY_SUPPLEMENT|Probiotic|Lactiplantibacillus plantarum ATCC 202195
219589586|NCT05180201|OTHER|Placebo|Maltodextrin
219589587|NCT01932723|BEHAVIORAL|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
218843326|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
218843327|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
219589588|NCT01085123|DRUG|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
218843328|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
219589589|NCT01085123|DRUG|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
219589590|NCT05005312|DRUG|PF-07321332|Tablet
219589591|NCT05005312|DRUG|Ritonavir|PK Boosting agent
219453811|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
219453812|NCT04600427|PROCEDURE|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
219453813|NCT02238236|DRUG|Alesion®|Dry Syrup
219453814|NCT01730001|PROCEDURE|Early Intubation|
219453815|NCT01730001|PROCEDURE|Late intubation|
219453816|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
219453817|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
219453818|NCT01228149|DRUG|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
219453819|NCT01228149|DRUG|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
219453820|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
218843329|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
218843330|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
218843331|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
218843332|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
218843333|NCT06995339|DRUG|Febuxostat Tablets|Febuxostat is a selective xanthine oxidase inhibitor (XOI) that targets uric acid generation. It has been used as a SUA lowering agent in patients not responding to allopurinol
218843334|NCT06995339|DRUG|Metformin|Metformin is an oral antihyperglycemic drug widely used in type 2 diabetes (T2DM) treatment. Most of its effects are exerted via an indirect induction of the phosphorylated activation of AMP-activated protein kinase (AMPK)
218843335|NCT06152172|DRUG|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
218843336|NCT06152172|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
218843337|NCT06152172|DRUG|Fludarabine|Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
218843338|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
218843339|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
218843340|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
218843341|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
219453821|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
219453822|NCT05412160|DRUG|Arginine|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
219589592|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cemented Fixation|
219589593|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cementless Fixation|
219589594|NCT04182724|DRUG|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
219589595|NCT06633939|BEHAVIORAL|Behavioral Treatment|The theoretical framework for the Move \&amp; Eat 2 Live intervention is guided by the health belief model (HBM), socioecological model (SEM) and motivational interviewing (MI) approach. Tailoring to the target community will include a standard cultural adaptation that will replace curriculum content and examples with Native American relevant foods, physical activities, and representation in materials. For this study, the intervention will be piloted in the target population and will include the first 5 sessions of the original 12-session program.
219589596|NCT01890135|DRUG|Zibotentan (ZD4054)|10 mg
219589597|NCT01890135|DRUG|placebo|randomized double blind
218843342|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
218843343|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
218843344|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
218843345|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
218843346|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
218843347|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
218843348|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
218843349|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
218843350|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
218843351|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
218843352|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
219453823|NCT05412160|DRUG|Placebo|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
218843353|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
218843354|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
218843355|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
218843356|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
218843357|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219453824|NCT00896662|OTHER|immunologic technique|immunologic technique
219453825|NCT00896662|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219589598|NCT06550258|OTHER|Equine-assisted therapy|Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
218843358|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
219453826|NCT00896662|OTHER|pharmacological study|pharmacological study
219453827|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
219453828|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
219589599|NCT06550258|OTHER|Traditional Pediatric Physiotherapy|In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
218843359|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218843360|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
218843361|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
218843362|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
218843363|NCT02279433|DRUG|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
218843364|NCT07000136|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
218843365|NCT07000136|DRUG|Placebo|Participants will receive daily oral dose of placebo
218843366|NCT06613711|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
218843367|NCT07001618|DRUG|MaaT033 capsule|MaaT033 capsule will be taken orally once a day for a week before every Cemiplimab cycle for the first 6 months of treatment.
218843368|NCT07001618|DRUG|Cemiplimab|CB will be administered 350 mg IV over 30 minutes every 21 days up to 2 years
218843369|NCT07001618|DRUG|Cisplatin|75mg/m2 at day 1 (d1) every 21 days (q21)
218843370|NCT07001618|DRUG|Carboplatine|Area Under the Curve (AUC) 5-6 at d1 q21
218843371|NCT07001618|DRUG|Pemetrexed (Alimta)|500mg/m2 at day 1 (d1) q21
218843372|NCT07001618|DRUG|Bevacizumab|10mg/kg at d1 and day 15 (d15) every 28 days (q28)
218843373|NCT07001618|DRUG|Paclitaxel|175mg/m2 at d1 q21 or 80 mg/m2 at d1, day 8 (d8), day 15 q28
218843374|NCT07001618|DRUG|gemcitabine|1250 or 1000 mg/m2 d1, d8 q21
218843375|NCT07001618|DRUG|Docetaxel|75 mg/m2 d1 q21 or 33mg/mq d1, d8 q21 q21
218843376|NCT07001618|DRUG|Vinorelbine i.v. 25 mg/m²|25-30 mg/m2 d1, d8 q21
218843377|NCT07001618|DRUG|Vinorelbine oral|30 mg/50 mg per os 3 days per week (metronomic)
218843378|NCT06808451|DEVICE|DNA PCR|Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.
218843379|NCT06808451|DIAGNOSTIC_TEST|Urine Culture|Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.
218843380|NCT07001215|DEVICE|In the intervention group, patients will be treated with auto-adjusting APAP, providing variable pressures throughout the sleep hours.|AutoCPAP will be prescribed to patients undergoing bariatric surgery.
218843381|NCT07001215|DEVICE|CPAP|In the control group, patients will be treated with CPAP.
218843382|NCT07019389|OTHER|Turkish Version of the Scale of Food Allergy Anxiety (SOFAA)|Participants will complete the Turkish-translated versions of the Scale of Food Allergy Anxiety (SOFAA). Children will complete the SOFAA-C; their parents will complete the SOFAA-P. The study aims to evaluate the reliability and validity of the translated scales through internal consistency, factor analysis, and test-retest reliability methods.
219453829|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
219589600|NCT02955758|BIOLOGICAL|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
219589601|NCT01283035|DRUG|Akt Inhibitor MK2206|Given PO
219589602|NCT01283035|OTHER|Laboratory Biomarker Analysis|Correlative studies
218843383|NCT07021040|DIAGNOSTIC_TEST|olfactory testing|"Patients will undergo smell testing, using the Smell Identification Test (Sensonics), a validated widely-used 40-item scratch-and-sniff style psychophysical test to determine olfactory function."
218843384|NCT07021040|OTHER|Odor stimulation|"subset of patients will be asked to sniff a specific odor for about an hour, using commercially available odor pens (Sniffin' Sticks or Sensonics). These odor pens are widely used for olfactory training therapy, a treatment designed to help people with some forms of smell loss; they are also used in psychophysical olfactory testing."
218843385|NCT07021040|PROCEDURE|Olfactory biopsy|Biopsy involves a simple cytology brush technique of the lining of the nose in a region called the olfactory cleft, using a nasal endoscope, and can be done in clinic or in the operating room at the time of a nasal surgery. Topical oxymetazoline and tetracaine spray is applied to the nasal cavity, a rigid nasal endoscopy (0-degree 4 mm endoscope, Karl Storz) is performed to visualize the olfactory cleft, and a small nasal cytology brush biopsy (Hobbs Medical)is performed by swabbing and rotating brush gently in the olfactory cleft. Cytology sample is placed into a buffer (Hibernate-E, Thermo Fisher)on ice for transport to the research lab.
218843386|NCT07029022|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|This intervention consisted of three 90-minute in-person workshops delivered monthly over a three-month period. Content included psychoeducation, guided stretching, and focused-attention meditation. Participants were also encouraged to practice mindfulness at home for 10 minutes daily and to follow lifestyle guidance on diet and physical activity.
218843387|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
218860035|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
219453830|NCT03371394|OTHER|no intervention|no intervention
219453831|NCT00034697|DRUG|temozolomide|
219453832|NCT04801355|PROCEDURE|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
219453833|NCT04801355|PROCEDURE|laparoscopic colon resection|Standard laparoscopic colon resection
219453834|NCT05346380|DEVICE|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
219589603|NCT04530435|DEVICE|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
219589604|NCT02083718|BIOLOGICAL|PBSC|
219589605|NCT02083718|BIOLOGICAL|MSCs|
219589606|NCT01680003|DRUG|Hepar-P|
219589607|NCT01680003|DRUG|Placebo for Hepar-P|
219589608|NCT05847803|OTHER|No intervention, questionnaire survey|No intervention, questionnaire survey
219589609|NCT00867503|DRUG|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
219589610|NCT06363903|DIAGNOSTIC_TEST|mesh allergy test|a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
219589611|NCT06363903|DIAGNOSTIC_TEST|blood tests|Blood tests for diagnosis of autoimmune diseases will be performed
219589612|NCT06363903|PROCEDURE|Mesh removal|If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
219589613|NCT02704403|DRUG|Elafibranor|
219589614|NCT02704403|DRUG|Placebo|
219589615|NCT03259659|OTHER|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
219589616|NCT05682859|DRUG|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
218843388|NCT03479541|BEHAVIORAL|Timing of Rehabilitation|Participants in the Earlier Physical Therapy group will start physical therapy within a week of enrollment and baseline testing. Participants allocated to the Later Physical Therapy group will wait 6 weeks after enrollment and baseline testing before starting physical therapy, and re-test on study outcomes before starting physical therapy. Both groups will see a physical therapist in person twice per week for 2 weeks and once per week for 4 weeks for a total of 8 sessions over 6 weeks. Each session will last 60 minutes and consist of cardiovascular, cervical spine, and vestibular therapy exercises (static and dynamic balance). Participants will perform daily home exercises for 30 minutes with similar subcategories from the in-person sessions. Both the in-person physical therapy and home exercises will be individualized and progressive at the discretion of the physical therapist depending on the performance of the participant.
218843389|NCT03479541|BEHAVIORAL|Biofeedback|Wearable sensors measure movement during the home exercise program for later feedback.
218843390|NCT06875609|DIAGNOSTIC_TEST|Blood and Tissue Collection|Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.
218843391|NCT07033767|DRUG|genistein|Participants will receive genistein treatment (10-15 mg/kg/day with a maximum dose of 1500mg/day) for 3 months. From the 3-month- to 6-month follow-up, participants will receive a dose of 20-25 mg/kg/day (with a maximum dose of 1500mg/day). According to participant preference, Genistein will be provided as a capsule (250mg per capsule). For participants that are unable to swallow the capsule the capsule may be opened and the powder from the capsule can be mixed with a beverage or food. Interim clinical evaluations will occur at 3 and 6 months to assess, tolerability, adherence and efficacy.. Post-treatment assessment after a 3-month washout will occur at 9 months to determine delayed adverse effects and persistence of beneficial effects after genistein discontinuation.
218843392|NCT07034651|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
218843393|NCT07032987|OTHER|Not an intervention study|This is not an intervention study
218843394|NCT07033325|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT) for Trypanosoma cruzi infection.|Rapid diagnostic tests (RDTs) for the detection of Trypanosoma cruzi infection are performed in university facilities, outside of a clinical care setting, using a point-of-care approach. The study population includes adult male and female participants from the university community. This intervention differs from most existing strategies that target exclusively women of reproductive age and/or newborns to control vertical transmission; instead, it focuses on broader population-based screening and linkage to care for chronic infections.
218843395|NCT07034625|OTHER|Low Level Laser Therapy|940 nm wavelength diode laser was applied to the wound area on the surgery day, 3rd, 5th and 7th days postoperatively. The power of the laser was set to 3W, power density 1.07 W/cm2, probe spot size 2.8 cm2, application mode continuous wave, application distance 1mm and application type stable.
218843396|NCT07034625|OTHER|Gengigel Spray|Patients were given a high molecular weight hyaluronic acid spray and instructions for use were explained. Accordingly, the patients applied the spray to the wound area twice a day for the first 7 days.
218843397|NCT07034521|DEVICE|HIWIN MRG-P110|HIWIN MRG-P110 is a robotics for lower limbs rehabilitation
218860036|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
219453835|NCT05346380|DRUG|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
219453836|NCT04062006|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
219453837|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
219453838|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
219453839|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
219453840|NCT02111954|DIAGNOSTIC_TEST|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
219589617|NCT05682859|DRUG|Placebo|Placebo tablets
218860037|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
218860038|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
218860039|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
218860040|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
219453841|NCT00170846|DRUG|Everolimus (RAD001)|
219453842|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
219453843|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
219453844|NCT00170846|DRUG|Steroids|
219453845|NCT00118040|DRUG|Genistein|Given orally
219453846|NCT00118040|OTHER|Laboratory Biomarker Analysis|Correlative studies
219589618|NCT04888559|OTHER|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
219589619|NCT04888559|OTHER|Breakfast product: Reference|This intervention is a rice-based breakfast product.
219589620|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
219589621|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
219589622|NCT00851318|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
219453847|NCT00118040|OTHER|Pharmacological Study|Correlative studies
219589623|NCT00851318|DRUG|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
218843398|NCT07033884|BEHAVIORAL|Peer Engagement and Exploration of Responsibility and Safety|PEERS involves a one-on-one session with a firearm-owning Veteran peer interventionist. The appointment will last between 15 minutes and one hour, and the modality (i.e., in-person or virtual) will be based on Veteran participant preference. Principal components of the PEERS session will include: 1) engaging - initiating conversation in a non-confrontational manner; 2) focusing - quickly concentrating the discussion on the topic of firearms and means safety; 3) evoking - reflecting the participants' reasons both for and against engaging in means safety, leveraging the participants' own rationale for change as a tool for increasing behavior change; and 4) planning - once a plan is agreed upon, this information is put into writing. Participants will also be provided the same psychoeducational materials provided to the participants in the active control condition.
218843399|NCT07033884|OTHER|Active Control|"Veterans will receive no treatment and will not interact with peers. A no treatment control condition was selected due to the preventative nature of PEERS, as well as the early stage of evaluation for this intervention. However, given the varied recruitment outlets and subsequent lack of standardized usual care, as well as ethical concerns with not providing important resources to firearm owning Veterans, two informational handouts will be added to this control condition. Specifically, Veterans in this condition will be provided with an informational handout developed by the National Sports Shooting Foundation, which includes a variety of secure firearm storage options, as well as a handout listing national mental health and suicide prevention resources."
218860041|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
219453848|NCT00118040|OTHER|Placebo Administration|Given orally
219453849|NCT00118040|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
219453850|NCT03839056|DEVICE|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
219453851|NCT03839056|DEVICE|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
219453852|NCT03839056|DEVICE|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
219453853|NCT01550614|GENETIC|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
219453854|NCT01968915|DRUG|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
219453855|NCT01968915|DRUG|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
219453856|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
219589624|NCT04077918|DIETARY_SUPPLEMENT|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
219589625|NCT03063918|OTHER|Informational Intervention|Receive a workbook
219589626|NCT03063918|OTHER|Quality-of-Life Assessment|Ancillary studies
219589627|NCT03063918|OTHER|Questionnaire Administration|Ancillary studies
219589628|NCT03063918|OTHER|Survey Administration|Ancillary studies
219589629|NCT03063918|BEHAVIORAL|Telephone-Based Intervention|Receive personalized dietary intervention
219589630|NCT01734200|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
218860042|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
218860043|NCT00022724|DRUG|temsirolimus|
218860044|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
218860045|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
219589631|NCT01734200|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
219589632|NCT01839318|DEVICE|Nelfilcon A contact lenses|
219589633|NCT01839318|DEVICE|Omafilcon A contact lenses|
219589634|NCT01839318|DEVICE|Etafilcon A contact lenses|
219589635|NCT04400032|BIOLOGICAL|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
219589636|NCT00644852|OTHER|Retrospective chart review study|Retrospective study chart review long acting risperidone
219589637|NCT03183336|PROCEDURE|ridge split interpositional block graft|
219589638|NCT03183336|PROCEDURE|decortication Onlay block graft|
219453857|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
219453858|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
219453859|NCT05843344|DRUG|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
219453860|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
218843400|NCT07034079|DEVICE|complete dentures|"Participants were randomly allocated into two intervention sequences using a computer-generated randomization list. The two sequences were:~* Group A: Received maxillary complete denture with palatal rugae first, followed by a smooth polished palatal surface denture after a 2-month adaptation period.~* Group B: Received a smooth polished palatal surface denture first, followed by a rugae-enhanced denture after a 2-month adaptation period."
218843401|NCT07034196|OTHER|Primary Care Treatment in lieu of Rheumatologist|RA patients will be randomized to receive their RA care via their established PCP who completed a structured training course in RA and who has monthly case review/consultation sessions with the rheumatology team in this study
218843402|NCT07034716|PROCEDURE|CORONARY BYPASS SURGERY USING CARDIOPULMONARY BYPASS|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with nonpulsatile flow during cardiopulmonary bypass
218843403|NCT07034716|PROCEDURE|cardiac surgical patients who will undergo isolated elective cardiopulmonary bypass|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with pulsatile flow during cardiopulmonary bypass
219453861|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
219589639|NCT04495036|OTHER|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users"
219589640|NCT04495036|OTHER|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
219589641|NCT01844856|DRUG|Eravacycline|
218843404|NCT07032519|BEHAVIORAL|Mindfulness Intervention|Participants will use the smartphone app daily for pain tracking and weekly to engage with mindfulness content and complete additional assessments.
218843405|NCT07068191|COMBINATION_PRODUCT|"Dietary supplement Gepaktiv"|"Dietary supplement Gepaktiv 60 minutes before meals 2 capsules × 3 times/day"
218843406|NCT07068191|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 10-15 mg/kg/day
218843407|NCT07068191|DRUG|Ademetionine|Ademetionine 800-1600 mg/day.
219589642|NCT01844856|DRUG|Ertapenem|
219589643|NCT01844856|DRUG|Placebo|Administered IV to maintain the blind.
218843408|NCT06767098|OTHER|theraputic exercises for neck muscles and smartphone holder|strech and strength exercises for neck muscles. and using smartphone holder daily.
218843409|NCT06767098|OTHER|theraputic exercises for neck muscles|strech and strength exercises for neck muscles.
218843410|NCT06222827|DRUG|Satralizumab Prefilled Syringe|Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
218843411|NCT06222827|DRUG|Placebo Comparator|Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
219453862|NCT00706264|DEVICE|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
219453863|NCT00532064|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219453864|NCT00532064|OTHER|Questionnaire Administration|Ancillary studies
219453865|NCT05749874|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
219453866|NCT05749874|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
219453867|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
219453868|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
219453869|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
219453870|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
219453871|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
219453872|NCT02607865|DRUG|semaglutide|Oral administration once-daily
219453873|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
219453874|NCT02607865|DRUG|placebo|Oral administration once-daily
219453875|NCT04814706|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
219453876|NCT00528840|BIOLOGICAL|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
219453877|NCT03177954|BEHAVIORAL|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
219453878|NCT03720106|OTHER|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
219453879|NCT00126386|DRUG|Zoledronic acid (Zometa)|
219453880|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
219453881|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
219453882|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
219453883|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
219453884|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
219453885|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
219453886|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
219453887|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
219453888|NCT03245944|PROCEDURE|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
219589644|NCT03906578|DIETARY_SUPPLEMENT|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
219589645|NCT03906578|OTHER|Placebo|Placebo with similar appearance to probiotic
219589646|NCT05369728|OTHER|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
219589647|NCT01442688|DRUG|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
219589648|NCT01442688|DRUG|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
219589649|NCT05691088|DEVICE|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
219589650|NCT02720874|BEHAVIORAL|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
219589651|NCT02720874|BEHAVIORAL|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
219589652|NCT02720874|BEHAVIORAL|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
218843412|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
218843413|NCT03486301|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
218843414|NCT03486301|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
218843415|NCT06889090|DRUG|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as conti|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as continuous infusion.
218843416|NCT06889090|DRUG|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.
218843417|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
218843418|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
218843419|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
218843420|NCT07081867|PROCEDURE|Supra-inguinal Fascia Iliaca Block (SIFIB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
218843421|NCT07081867|PROCEDURE|Sacral Erector Spinae Plane Block (SESPB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
218843422|NCT04362800|OTHER|MRI|MRI at baseline and J90
219453889|NCT03245944|PROCEDURE|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
219453890|NCT04022291|BIOLOGICAL|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
219589653|NCT02720874|BEHAVIORAL|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
218843423|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
218843424|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
218843425|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
218843426|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
218843427|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
218843428|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
218843429|NCT04061616|BEHAVIORAL|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
218843430|NCT07081659|DRUG|sildosin 4mg|ondemand sildosin 4mg
218843431|NCT07081659|DRUG|dapoxetine 60mg|ondemand dapoxetine 60mg
218843432|NCT07079670|BIOLOGICAL|NVX-CoV2705|Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.
218843433|NCT07080697|PROCEDURE|Splenectomy|Open Debridement combined with distal pancreatectomy and total splenectomy
219453891|NCT04022291|BIOLOGICAL|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
219453892|NCT01416506|OTHER|No Drug|It's a surveillance
219453893|NCT03667573|DEVICE|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
218843434|NCT07080697|PROCEDURE|Control|Open Debridement alone
218843435|NCT07080645|OTHER|Pain Relieving|aim to relieve tooth pain with HMI Biosilicate
218843436|NCT07080645|OTHER|topical application|the operator will apply a solution to all the free surfaces of the selected teeth using a microapplicator. The solution will either be 10% Biosilicate® solution, fluoride varnish (Duraphat®), or distilled water . All products will be removed from their original containers and placed in identical 10ml plastic bottles, white and standardized. The different products will be applied equally for 15 seconds according to the application protocol.
218860046|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
218860047|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
218860048|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
218860049|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
218843437|NCT07079293|OTHER|Preparation of Extended PRF|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used .
219196899|NCT06818526|DEVICE|Huandao Conditioning Application|"Mobile Application Intervention: Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
219453894|NCT03667573|DEVICE|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
219589654|NCT02720874|BEHAVIORAL|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
219589655|NCT00630929|DRUG|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
219589656|NCT00630929|DRUG|Placebo|Matched placebo orally for 6 weeks
219589657|NCT00630929|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
219589658|NCT00927394|DRUG|Aliskiren|Aliskiren 150 mg tablet
219589659|NCT00927394|DRUG|Valsartan|Valsartan 160 mg capsules
219453895|NCT03667573|OTHER|textured shoe insoles|textured shoe insoles
219453896|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
219589660|NCT00927394|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
219589661|NCT00927394|DRUG|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
219589662|NCT00274820|DIETARY_SUPPLEMENT|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
219589663|NCT00274820|DRUG|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
219589664|NCT00274820|DRUG|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
219453897|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
219453898|NCT01756833|DRUG|Doxycycline|100 mg po bid
219453899|NCT01756833|DRUG|Placebo|capsule identical to the doxycycline capsule
219589665|NCT00274820|DRUG|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience \< grade 1 thalidomide-attributed toxicity using CTC criteria.
219589666|NCT05508841|OTHER|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
219589667|NCT02875652|BIOLOGICAL|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
218843438|NCT07079293|PROCEDURE|Harvesting of Free Gingival Graft and preparation of CTG|The region distal from the canines, commencing at least 2 mm from the gingival margin with a width of 5-8 mm and a desirable length to cover the entire recipient site is an ideal site for harvesting a FGG from the hard palate for root coverage. Harvesting of FGG is performed as follows: The graft is prepared by outlining with two parallel longitudinal incisions that are interconnected with vertical incisions. Graft deliberation is initiated along the paramarginal incision in a split-thickness fashion with a goal of removing an FGG of 1.5-2-mm thickness without touching the periosteum. The harvested free gingival graft will be de-epithelialized to obtain an DFGG. The donor site wound will be covered by gel foam which will be sutured in place and then healing will occur by secondary intention .
218843439|NCT07079293|PROCEDURE|VISTA technique|Following Zadeh's (2011) protocol, under local anesthesia, a vestibular access incision is made depending on the treatment site (midline frenum for maxillary anterior, frenal area between canine and lateral incisor for maxillary posterior, and similar for mandibular regions). The incision passes through the periosteum to create a subperiosteal tunnel exposing the facial bone and root dehiscence. In the test group, the extended platelet-rich fibrin (e-PRF) membrane is inserted into the tunnel and secured to the flap with horizontal sutures; in the control group, a de-epithelialized free gingival graft (DFGG) is used similarly. Each tooth's facial enamel is briefly acid-etched, washed, and dried to attach vicryl sutures fixed with flowable composite resin to prevent apical relapse during healing. Finally, the access incision is closed and sutured with vicryl sutures
218843440|NCT07081451|OTHER|Guided ımagery supported psychoeducation|Guided Imagery Technique is an effective, economical and therapeutic technique that can be easily used in nursing practices. Guided Imagery Technique is a set of stories that individuals create by visualising the symbols given by the practitioner after relaxation exercises. Within the scope of this technique, which is a window to the inner world of the person, the creation of his/her own unique story through symbols is encouraged
218843441|NCT07079605|OTHER|Standard treatment for sepsis of any focus|This group of patients will be treated for the sepsis of any focus as per standard.
218843442|NCT07079605|OTHER|Treatment for the sepsis with standard management of cardiac failure|This group of patients will be treated for the sepsis and management of cardiac failure with additional supportive care cocktails based on the specific indication.
218843443|NCT00006459|DRUG|gemcitabine hydrochloride|
218843444|NCT00006459|DRUG|paclitaxel|
218843445|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
218843446|NCT00107900|DRUG|DU-176b|
219453900|NCT02664740|DRUG|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
219453901|NCT02664740|DRUG|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
218843447|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
218843448|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
218843449|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
218843450|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
218843451|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
219589668|NCT04821700|BIOLOGICAL|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
219589669|NCT02792699|DRUG|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
218843452|NCT06789328|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
218843453|NCT06789328|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
218860050|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
218860051|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
219453902|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|Given via injection
219453903|NCT06661902|DRUG|Lidocaine|Given via injection
219453904|NCT06661902|PROCEDURE|Biopsy of Prostate|Undergo SOC prostate biopsy
219453905|NCT06661902|OTHER|Questionnaire Administration|Ancillary studies
219589670|NCT02792699|DRUG|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
218860052|NCT00228046|DRUG|Divalproex Sodium|
218860053|NCT00228046|DRUG|Methylphenidate|
219589671|NCT02792699|DRUG|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
219589672|NCT06277232|OTHER|Nutrition care|Nutrition care is designed to include nutrition assessment (e.g., malnutrition screening, monitoring weight changes, etc.), optimization of individual dietary patterns, and evaluation. Through the Diet4painrelief platform, a dietician will follow up the progress of each participant in different timepoints and also plan meetings with other professionals in IPRP. A dietitian together with a physician in rehabilitation are responsible for the administration of the procedure.
218843454|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
218843455|NCT00531440|DRUG|Everolimus (RAD001)|
218843456|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
218843457|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
218843458|NCT00540241|DRUG|Pemetrexed|in-label use
218843459|NCT07080411|RADIATION|short course radiotherapy using MR-linac|Patients in the MRgART group will receive standard total neoadjuvant therapy (TNT) and surgical treatment, including short-course radiotherapy and chemotherapy, with the addition of immunotherapy at the investigator's discretion based on individual patient characteristics.
218843460|NCT07079878|OTHER|Group with Bed Head Height 30°|30 minutes before feeding, the bed head height of the preterm newborn is adjusted to 30° and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
218843461|NCT07079878|OTHER|Group with Bed Head Height 45°|The bed head height of the preterm newborn is adjusted to 45° 30 minutes before feeding and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
218843462|NCT07080788|BEHAVIORAL|Smoking Cessation|Investigators will provide financial incentives for biochemically verified abstinence at 4 weeks following treatment. This incentive is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
218843463|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
218843464|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
218843465|NCT07076992|PROCEDURE|Circumcision by Plastibell|Patients will undergo circumcision by Plastibell (PB).
218843466|NCT07076992|PROCEDURE|Circumcision by Gomco|Patients will undergo circumcision by the Gomco (GM).
218843467|NCT07080047|OTHER|Mackenzie exercise for lateral shift|Participants in the McKenzie group will perform standing side glide exercises, where they stand perpendicular to a wall (painful side away), press their hips toward the wall, and hold for 2-3 seconds, repeated 30 times
218843468|NCT07080047|OTHER|Traditional physical therapy|Participants in the traditional therapy group will receive posteroanterior lumbar mobilizations (30 repetitions × 3), 10-minute hot pack application, myofascial release of paraspinal muscles, and core stability exercises (plank and bridging).
218843469|NCT07080112|BEHAVIORAL|Peer education|The study was designed as a randomized controlled trial. The population consisted of third-year nursing students (84 students) enrolled in the spring semester of the 2024-2025 academic year. The entire population was included in the study. For randomization, the class list of 84 students was used based on their order, and randomization was performed via the website https://www.random.org/ to form the experimental and control groups.
218843470|NCT07081854|OTHER|Land-Based Plyometric Training|"Participants will perform traditional plyometric exercises on land aimed at improving lower-body power and neuromuscular performance.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air."
218860054|NCT00228046|DRUG|Dextroamphetamine|
219453906|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
219453907|NCT01960764|DRUG|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
218860055|NCT00228046|DRUG|Mixed Amphetamine Salts|
218860056|NCT00228046|BEHAVIORAL|Family Counseling|
219453908|NCT01960764|OTHER|Control|
219453909|NCT01697189|BEHAVIORAL|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
219453910|NCT01087073|BEHAVIORAL|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
218860057|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
218860058|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
218860059|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
218843471|NCT07081854|OTHER|Aquatic Plyometric Training|"Participants will perform plyometric exercises in a shallow pool, with the water depth fixed at the xiphoid process level (chest height). Greater peak mechanical power was observed for jumps performed in the water and was influenced by immersion depth.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air.~Key Points:~* Encouraged to perform movements explosively while applying maximal effort.~* Proper execution is emphasized to maintain biomechanical integrity even in the water environment.~* Water temperature: 25-28 °"
218843472|NCT07081854|OTHER|General conditioning exercises|"Participants will follow a general conditioning routine that does not include plyometric exercises.~Exercises:~1. Bodyweight squats.~2. Lunges.~3. Core stability exercises (e.g., planks, bridges).~4. General cardio activities such as light jogging or cycling."
218843473|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
219453911|NCT01087073|BEHAVIORAL|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
219453912|NCT01087073|BEHAVIORAL|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
219589673|NCT06277232|BEHAVIORAL|Dialogue and education (part of Interdisciplinary Pain Rehabilitation Program)|Dialogue and education consists of patient education, training in wellness and healthy living habits, meetings with families, video feedback, and couples therapy and self-training (e.g., home lessons, activity diary, physical self-training, reflection time, and self-analysis. . In addition, lectures in basic pain science and pain management are offered for both patients as well as for relatives, friends, and colleagues.
219589674|NCT06277232|BEHAVIORAL|activity training (part of Interdisciplinary Pain Rehabilitation Program)|Activity training includes graded activity training, and exposure training, which are delivered by an interdisciplinary team (i.e., a physiotherapist, an occupational therapist, and a psychologist).
219589675|NCT06277232|BEHAVIORAL|meetings (part of Interdisciplinary Pain Rehabilitation Program)|The meetings consist of conferences with patients, rehabilitation team, vocational guidance, rehabilitation coordinator, goal-setting meetings, and meetings to check goal achievement.
218843474|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
218843475|NCT07080138|DRUG|All kinds of INSTI medications|All kinds of INSTI medications, such as Bictegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Dolutegravir/Emtricitabine/Tenofovir alafenamide Fumarate for PLWH
218843476|NCT07080138|DRUG|All kinds of conventional medications|All kinds of conventional medications, such as Abacavir, Efavirenz for PLWH
219589676|NCT06277232|BEHAVIORAL|Cognitive behavioral therapy (part of Interdisciplinary Pain Rehabilitation Program)|Acceptance and Commitment Therapy (ACT, e.g., goal compass, training in ACT principles, and mindfulness) is mainly delivered by psychologist in a group-treatment (e.g., training in coping strategies). The cognitive behavioral principles are also used in physiotherapy, ergonomics, and education in pain management.
219589677|NCT06277232|BEHAVIORAL|Relaxation techniques (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist and psychologist in an interdisciplinary team.
219589678|NCT06277232|BEHAVIORAL|Physical exercise (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist in an interdisciplinary team.
219589679|NCT03464630|BEHAVIORAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
218843477|NCT00002412|DRUG|Emivirine|
218843478|NCT00002412|DRUG|Hydroxyurea|
218843479|NCT00002412|DRUG|Stavudine|
218843480|NCT00002412|DRUG|Didanosine|
219589680|NCT03464630|BEHAVIORAL|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
219589681|NCT03152734|PROCEDURE|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
218843481|NCT02461290|RADIATION|Chemotherapy|
218843482|NCT02461290|DRUG|Rituximab|
218843483|NCT07074990|DRUG|conventional sepsis therapy alone|fluid resuscitation a minimum of 30 mL/kg of intravenous (IV) crystalloid fluid administered during the initial 3 hours of resuscitation, along with empiric antibiotic therapy aimed at the suspected pathogens and infection sites, ideally starting within the first hour.
218843484|NCT07074990|DRUG|colchicine 500 mcg oral twice daily plus conventional sepsis therapy.|colchicine 500 mcg oral twice daily plus conventional sepsis therapy for 5 days.
218843485|NCT07081282|BEHAVIORAL|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)
218843486|NCT07081282|BEHAVIORAL|Centre-Based Exercise Health Session|Participants will receive one time centre-based exercise health programme each week.
218843487|NCT07079566|BEHAVIORAL|Primal Reflex Release Technique (PRRT)he Primal Reflex Release Technique (PRRT) is a hands-on, non-invasive therapeutic approach designed to deactivate overactive protective reflexes believed to contr|The Primal Reflex Release Technique (PRRT) is a non-invasive, manual therapy that targets specific neurogenic reflex points to reduce muscle tension, pain, and dysfunction. It works by modulating the autonomic nervous system to interrupt hyperactive primal reflexes such as withdrawal and startle reflexes, which are often involved in chronic musculoskeletal pain conditions like plantar fasciitis. In this study, PRRT was applied to participants in the experimental group over a 3-week period, consisting of multiple sessions per week. Each session included a series of gentle manual techniques such as the sternocleidomastoid (SCM) release, startle reflex inhibition, and positional reflex modulation. These techniques aim to reset the body's reflex-driven pain responses and promote functional mobility. PRRT was performed by trained physiotherapists following a standardized protocol to ensure consistency throughout the study.
218843488|NCT07079566|BEHAVIORAL|Conventional Physiotherapy Treatment This reflects the standard care or routine treatment used as a comparison in your randomized controlled trial on plantar fasciitis. Let me know if your control gr|"The control group in this randomized controlled trial received standard conventional physiotherapy treatment for plantar fasciitis. This treatment protocol consisted of traditional evidence-based physiotherapy interventions commonly used in clinical practice. Participants received supervised sessions including static and dynamic stretching exercises targeting the plantar fascia, Achilles tendon, and calf muscles. In addition, the intervention included modalities such as cryotherapy (application of ice packs), ultrasound therapy for soft tissue healing, and patient education on activity modification, proper footwear, and home exercise programs.~The conventional treatment was administered for 3 sessions per week over a period of 3 weeks. Each session lasted approximately 30 to 40 minutes. The objective of this intervention was to reduce inflammation, relieve pain, and improve foot function through mechanical and thermal means, without involving neuromuscular reflex reprogramming. This a"
218860060|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
218860061|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
219453913|NCT01087073|BEHAVIORAL|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
218860062|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
219453914|NCT01766401|DRUG|Placebo|
219453915|NCT01766401|DRUG|Vilazadone|Viibryd
219453916|NCT00000642|DRUG|CD4-IgG|
219453917|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
219453918|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
219589682|NCT05554081|DEVICE|Peezy urine collection device|use peezy collection to obtain urine sample
219589683|NCT00073710|DRUG|Zemplar|
218860063|NCT01532544|DRUG|low molecular weight heparin.|
218860064|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
218860065|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
219453919|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
219589684|NCT00073710|PROCEDURE|42 Ca carbonate absorption via single tracer method|
219589685|NCT00073710|DRUG|Calcijex|
219589686|NCT02033538|DRUG|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
219589687|NCT00735618|OTHER|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
219589688|NCT03196635|DEVICE|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
219589689|NCT03196635|DEVICE|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
218843489|NCT07081373|DRUG|A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.|At surgical closure, a single dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered without concurrent analgesics. The total 20 mL volume is divided into six equal aliquots (≈3.3 mL each) and infiltrated circumferentially around the incision using a 25-gauge or larger-bore needle. Injections target tissue layers above and below the fascia and within the subcutaneous plane, with frequent aspiration during administration to mitigate intravascular injection risk. Seventy-two hours postoperatively, a repeat dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered. Prior to infiltration, topical lidocaine cream is applied to the per-incisional skin for ≥20 minutes. The full 20 mL volume is then injected uniformly around the incision via circumferential needle advancement into pericicatricial tissues.
219453920|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
218843490|NCT07079384|OTHER|The patient will be instructed about wearing the prosthesis. First, seat the prosthesis in a posterior undercut, then rotate the prosthesis slightly superiorly in the defect area and engage the anteri|"* The obturator will then be printed using Denture Base Resin and teeth.~* The printed obturator will be tried in, two magnets, one anteriorly and another posteriorly will be picked up then inserted into the patient mouth.~* The patient will be again instructed regarding the care of the prosthesis and hygiene maintenance as formerly. The patient will also be instructed to wear the obturator plate first, and once this is comfortably seated, the denture part will be inserted. During removal, the patient will be instructed to first remove the denture part gently to disengage the magnetic attraction after the obturator part as formerly instructed. The patient will be recalle"
218843491|NCT07080164|OTHER|mini implant retained overdenture|mini implant retained overdenture
218843492|NCT07074015|DEVICE|Use of IntelliWell to identify and localize sperm for ICSI|The experimental arm will have surgically extracted testicular sperm processed with IntelliWell. If identified and confirmed by embryology, cryopreservation of sperm will occur. On day of ICSI, thaw of testicular sperm will occur and be processed by IntelliWell for identification and localization for use in ICSI.
218843493|NCT07081581|DRUG|Bupivacain|In Group B( control group), bupivacaine was given as additional medication in the serratus block application.
218843494|NCT07081581|DRUG|Bupivacaine and Magnesium sulfate|In Group M, bupivacaine and magnesium were given as additional medication in the serratus block application.
218843495|NCT07081581|DRUG|Bupivacaine and Dexmedetomidine ile Blokaj|In Group D, bupivacaine and dexmedetomidine were given as additional medication in the serratus block application.
218843496|NCT07080073|OTHER|Maitland Mobilization Group|"Participants in this group will receive Maitland Grade III central posterior-anterior spinal mobilizations targeting the lumbar spine. The intervention will be administered by a licensed physiotherapist with the patient in a prone position, applying oscillatory mobilization for 3 sets of 40 seconds with 1-minute rest intervals.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
218843497|NCT07080073|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan spinal mobilizations with lower limb movement (SNAGs). The therapist will apply sustained passive glides to the lumbar spinous process while the patient actively elevates the leg in a pain-free range. Mobilizations will be performed in 3 sets of 7-10 repetitions.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
218843498|NCT07079319|OTHER|MET + Biofeedback Strengthening + Kinesiotaping|Participants in this group will receive the same treatment protocol as Arm 1 (MET and biofeedback strengthening), with the addition of Kinesiotaping (KT) applied across the shoulder girdle. KT will be applied with 50-70% stretch from the anterior acromion to the opposite scapula, 3 times per week for 4 weeks. The tape will be worn for 14-16 hours per application. Standard physiotherapy (heat, ultrasound, neck isometrics, and stretching) will also be administered as part of the protocol.
218843499|NCT07079319|OTHER|MET + Biofeedback Strengthening|Participants in this group will receive Muscle Energy Technique (MET) for the upper trapezius, levator scapulae, pectoralis major, and pectoralis minor using post-isometric relaxation technique. Additionally, they will perform biofeedback-based cranio-cervical flexion exercises using a pressure biofeedback unit (PBU). The intervention will be administered 3 times per week for 4 weeks, with a total of 12 sessions. Standard physiotherapy (heat application, ultrasound, neck isometrics, and stretching exercises) will also be provided.
218843500|NCT07080710|PROCEDURE|Immediate implant placement|Immediate implant placement with socket grafting and soft tissue augmentation. In cases with a buccal dehiscence \>3mm only this technique is applied. In cases with a buccal dehiscence between 4-6mm a collagen membrane is applied prior to socket grafting. In cases with a buccal dehiscence \> 6 mm, a collagen membrane is also applied and a mixture of C-DBBM and autogenous bone chips (1:1 ratio) is used as grafting material.
219589690|NCT03997279|DRUG|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
219589691|NCT03997279|DRUG|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
219589692|NCT05801718|DIAGNOSTIC_TEST|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
219589693|NCT01316315|DRUG|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
219589694|NCT01316315|DRUG|Placebo|Same as active
219589695|NCT02525237|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
218843501|NCT07080814|DEVICE|Tecnobody ProKin Balance Training|Balance training using Tecnobody ProKin dynamometric platform, administered 5 sessions per week for 3 weeks in addition to standard rehabilitation.
218843502|NCT07080814|BEHAVIORAL|Standard rehabilitation|The standard rehabilitation protocol includes cold pack application to the knee region, transcutaneous electrical nerve stimulation (TENS), quadriceps muscle stimulation, knee stretching, active-assisted and active range of motion (ROM) exercises, strengthening exercises for the knee extensors and hip abductors/extensors, gait training, and balance exercises. Each patient will undergo a total of 15 physical therapy sessions.
218843503|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a test device at 12 week and 12 month|"T-PTNS treatment will be performed at home with an external generator and two surface electrodes SmartUric medical device. Each T-PTNS session will consist of test and treatment sections. The treatment will be planned and carried out by researchers.~The treatment dose is 1 day/week, 30 minutes/session, totaling 12 sessions. Treatment Pulse Frequency: 20 Hz, Treatment Pulse Width: 200us (microsecond)."
218860066|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
218860067|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
219453921|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
219453922|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
219453923|NCT00485121|DRUG|Ezetimibe|
219453924|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
219453925|NCT00398086|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
219453926|NCT00398086|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
219453927|NCT01432665|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
219453928|NCT01432665|DRUG|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
219453929|NCT01432665|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
219453930|NCT01950364|DRUG|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
219453931|NCT01950364|DRUG|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
219453932|NCT05384990|DEVICE|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
219453933|NCT05747664|DRUG|DWP16001|0.3mg
219453934|NCT02118402|DIETARY_SUPPLEMENT|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
218860068|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
218860069|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
218860070|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
218860071|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
218860072|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
218843504|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a placebo device at 12 week|These are devices that have the same physical appearance, interface and feedback features, but are prepared in a way that they will not provide electrical stimulation during the treatment session. They are delivered to the Contract Research Organization (CRO) by the project manager and are randomized through the CRO and given to the researchers with a code. The duration and frequency of treatment will be the same as the treatment group.
218843505|NCT07079514|DRUG|Placebo|normal saline in 100ml piggy bag
218843506|NCT07079514|DRUG|Magnesium|Magnesium Sulphate will be given as doses of 20-50mg/kg in 2 -3 minutes. In order to standardize the dose in every patient we will be using 3g
218843507|NCT07080281|DEVICE|Oculus Meta Quest 2 All In-One model virtual reality glasses|"During the caesarean section, Meta Quest 2 All In-One model virtual reality glasses from Oculus were used for 15 minutes. In this virtual environment, the licensed product video Breathe- Relax and Meditate was watched via the Meta Horizon application."
218843508|NCT02227069|DRUG|M518101|
218843509|NCT02227069|DRUG|M518101 Vehicle|
219453935|NCT00006463|DRUG|ECTEINASCIDIN 743|
218843510|NCT02227069|OTHER|sodium lauryl sulfate|
218843511|NCT02227069|OTHER|saline|
218843512|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
218843513|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
218843514|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
218843515|NCT06895915|PROCEDURE|dynamic navigation surgery|immediate implant placement assisted by dynamic navigation
218843516|NCT06895915|PROCEDURE|robotic surgery|immediate implant placement assisted by robotic surgery
218843517|NCT07079579|DRUG|Enarodustat 2mg|initial phase：2mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
218843518|NCT07079579|DRUG|Enarodustat 3mg|initial phase：3mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
218843519|NCT07079579|DRUG|Enarodustat 4mg|initial phase：4mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
218843520|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
218843521|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
218843522|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
218860073|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
219453936|NCT05398341|DEVICE|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy \[BSE\] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
219453937|NCT06256575|COMBINATION_PRODUCT|Diosmin|A medical food of diosmin and alka4-complex
219453938|NCT06256575|OTHER|Placebo|Corn starch one (1) capsule twice daily
219453939|NCT05919511|OTHER|Non-Interventional|This is an observational study
219453940|NCT03678389|OTHER|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
219453941|NCT04368741|DIETARY_SUPPLEMENT|SANZ®KINGWILL|20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
219453942|NCT04368741|DIETARY_SUPPLEMENT|GLUCERNA SR®|17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
219589696|NCT02525237|DRUG|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
219589697|NCT03769207|DEVICE|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
219589698|NCT01680107|DRUG|d-cycloserine|
219589699|NCT01680107|DRUG|placebo|
219589700|NCT01680107|BEHAVIORAL|cognitive-behaviour therapy|
219589701|NCT06453252|OTHER|we are aiming to develop a Scoring system based on certain variables derived from both groups|We are aiming to develop a Scoring system based on certain variables derived from both group
219589702|NCT05233852|OTHER|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
218843523|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
218843524|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
218843525|NCT07080060|OTHER|Niel-Asher Technique|"Participants in this group will receive the Niel-Asher Technique, a manual therapy approach focusing on trigger point release and myofascial decompression of the shoulder girdle. Treatment will involve structured pressure techniques applied to specific muscular trigger points including the infraspinatus, supraspinatus, subscapularis, and levator scapulae. The intervention will be delivered in side-lying and sitting positions.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
218860074|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
218860075|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
218860076|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
218860077|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
218860078|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
218860079|NCT02907853|BEHAVIORAL|Contingency Management|as described above
218860080|NCT01789528|DRUG|CAZ-AVI|IV infusion
218860081|NCT01789528|DRUG|CXL|IV infusion
218860082|NCT04533542|OTHER|Measurement|Undergo sensory measurements
219453943|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
219453944|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
219453945|NCT01662128|DRUG|Xeloda|Xeloda as Adjuvant Therapy
219453946|NCT00961558|PROCEDURE|Varicocelectomy|Varicocelectomy
219453947|NCT02724280|DEVICE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
219453948|NCT02724280|DEVICE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
219453949|NCT01546090|DRUG|Alprazolam|preoperative administration of an orally 0.50 mg single dose
219453950|NCT01546090|DRUG|placebo|placebo capsules were filled with starch
219589703|NCT06136000|OTHER|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
219589704|NCT06136000|OTHER|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
219589705|NCT01040598|BIOLOGICAL|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
219453951|NCT01438359|DRUG|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
219453952|NCT01438359|DRUG|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
219453953|NCT01438359|DRUG|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
219453954|NCT00333931|DRUG|Phenytoin|
219589706|NCT00380744|DRUG|LY2189102|
219589707|NCT00380744|DRUG|placebo|
219589708|NCT03936595|OTHER|Core exercises protocol|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
219589709|NCT03936595|OTHER|Structural exercises protocol|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
218860083|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
219453955|NCT00333931|BEHAVIORAL|Cognitive Behavioral Therapy|
218860084|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
219453956|NCT04277052|DEVICE|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
219453957|NCT01318928|DRUG|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
219453958|NCT00155467|PROCEDURE|CT|
219453959|NCT06107790|DRUG|HS022|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
218843526|NCT07080060|OTHER|Spencer Technique|"Participants in this group will receive the Spencer Technique, an osteopathic manual therapy consisting of eight mobilization steps: extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction with external rotation, internal rotation, and traction stretch. Each movement will be performed with patient participation using muscle energy techniques.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
218843527|NCT07080684|DRUG|Ticagrelor 60 mg|"Patients in this arm will receive dual antiplatelet therapy (DAPT) consisting of low-dose ticagrelor (60 mg twice daily) plus aspirin (75-100 mg once daily) for 1 month, followed by ticagrelor 60 mg monotherapy for 5 additional months (total 6 months of therapy).~This strategy aims to reduce ischemic events while minimizing bleeding risk by leveraging the potent antiplatelet effect of ticagrelor at a lower maintenance dose."
218843528|NCT07080684|DRUG|clopidogrel 75 mg|"Patients in the control group will receive standard DAPT consisting of clopidogrel 75 mg once daily plus aspirin 75-100 mg once daily for 6 months.~This represents the current standard of care in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents."
218843529|NCT07079722|BEHAVIORAL|Exercise|This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.
218843530|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
218843531|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
218843532|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
218843533|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
218843534|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
218843535|NCT01787396|DRUG|Gemigliptin 50mg|
218843536|NCT01787396|DRUG|Placebo(Metformin)|
218843537|NCT01787396|DRUG|Metformin|
218843538|NCT01787396|DRUG|Placebo(Gemigliptin)|
218843539|NCT06827886|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
218843540|NCT04488159|DRUG|Capecitabine|Tablet
218843541|NCT04488159|DRUG|Oxaliplatin|Infusion
219589710|NCT03936595|OTHER|Accentuated eccentric load exercises protocol|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM"
218843542|NCT04488159|DRUG|Fluorouracil|Infusion
218843543|NCT04488159|DRUG|Leucovorin|Infusion
219589711|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
219589712|NCT06287138|DRUG|ciprofol|Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
219589713|NCT02005835|OTHER|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
218843544|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
218843545|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
218843546|NCT04884490|DRUG|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
218843547|NCT04884490|DRUG|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
218843548|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
218843549|NCT00161577|OTHER|Placebo|Placebo Comparator
218843550|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
218843551|NCT02658747|OTHER|No intervention|No intervention administered in this study
218843552|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
218843553|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
218843554|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
218843555|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
218843556|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
219589714|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
219589715|NCT03412799|DRUG|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
219589716|NCT03412799|DRUG|nab-paclitaxel|Administered as intravenous (IV) infusion
219589717|NCT03412799|DRUG|Gemcitabine Injection|Administered as intravenous (IV) infusion
219589718|NCT06104943|OTHER|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
218843557|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
218843558|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
219589719|NCT06104943|OTHER|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
219589720|NCT06104943|OTHER|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
219589721|NCT06104943|OTHER|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
219589722|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
219589723|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
219589724|NCT01971437|PROCEDURE|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
219589725|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
219589726|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
219589727|NCT01338870|DRUG|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
219589728|NCT01338870|DRUG|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
219589729|NCT01338870|DRUG|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
219589730|NCT01338870|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
219589731|NCT01338870|DRUG|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
219589732|NCT01338870|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
219589733|NCT04150770|DRUG|infliximab|
219589734|NCT01115478|DIETARY_SUPPLEMENT|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
219589735|NCT01115478|DIETARY_SUPPLEMENT|Zinc|Daily oral dose of 25 mg from enrollment until delivery
219589736|NCT01115478|OTHER|Placebo|Daily oral dose from enrollment until delivery
219589737|NCT00709488|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
219589738|NCT00709488|PROCEDURE|Placement of device in prostate urethra|Placement of device in prostate urethra
219589739|NCT00709488|DEVICE|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
219589740|NCT00258128|DRUG|Salsalate|Active
219589741|NCT00258128|DRUG|Placebo|Placebo for salslate, used only in the third trial
219589742|NCT03986411|OTHER|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
219589743|NCT03986411|OTHER|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
219589744|NCT03986411|OTHER|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
219589745|NCT04409483|DRUG|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
219589746|NCT04409483|COMBINATION_PRODUCT|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
219589747|NCT03977714|DEVICE|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
219589748|NCT03977714|DEVICE|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
218843559|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
219453960|NCT06107790|DRUG|Trastuzumab|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
218843560|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
218843561|NCT06543498|DIAGNOSTIC_TEST|Lactulose/Mannitol Ratio Test|To test for gut permeability, Urine collected over 8hrs after ingestion of lactulose/mannitol drink.
218843562|NCT06543498|DIAGNOSTIC_TEST|Serum biomarkers of intestinal permeability|Phlebotomy and subsequent lab tests to analyse concentration of LPS, LPB, sCD14, Zonulin and Occludin.
219589749|NCT03977714|DEVICE|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
218843563|NCT06543498|OTHER|Rome IV questionnaire|Diagnositic questionnaire for IBS-D
218843564|NCT06543498|OTHER|Irritable bowel severity scoring system|Questionnaire to determine severity of abdominal and bowel symptoms
219453961|NCT06107790|DRUG|Vinorelbine Bitartrate|"Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first."
219589750|NCT03977714|DEVICE|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
219589751|NCT03977714|DEVICE|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
218843565|NCT06543498|OTHER|Bowel Habit diary|Assess bowel habit at baseline and changes in bowel habit over the study
218843566|NCT06543498|OTHER|3 day dietary record|Used to verify compliance to exclusion criteria #5.
219589752|NCT04982302|PROCEDURE|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
218843567|NCT06543498|DIETARY_SUPPLEMENT|NCT and NFT|N-transcaffeoyltyramine and N-transferuloyltyramine supplement taken once per day.
219589753|NCT02940808|DIETARY_SUPPLEMENT|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
218843568|NCT06543498|OTHER|Placebo|Placebo supplement taken once per day.
218843569|NCT02511834|DEVICE|VEST External Support|
218843570|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
218860085|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
218860086|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
218860087|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
219453962|NCT02793206|DEVICE|Imaging|
219589754|NCT02940808|OTHER|Placebo|Oral consumption of capsule containing a placebo substance.
219589755|NCT02348255|PROCEDURE|Electric Field Therapy|Undergo NovoTTF-100A
219589756|NCT02348255|BIOLOGICAL|Bevacizumab|Given IV
219589757|NCT02348255|DRUG|Carmustine|Given IV
219589758|NCT02348255|OTHER|Quality-of-Life Assessment|Ancillary studies
218843571|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
218843572|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
218843573|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
218843574|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
218843575|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
218843576|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
218843577|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
218843578|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
218843579|NCT05897242|BEHAVIORAL|Smartphone app|Use ACT on Vaping smartphone app
218843580|NCT05897242|OTHER|Text Message|Receive text messages
218843581|NCT05897242|OTHER|Survey Administration|Ancillary studies
218843582|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
218843583|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
219453963|NCT07022457|BIOLOGICAL|Encorafenib + Binimetinib|Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics
219589759|NCT03147625|BEHAVIORAL|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
219589760|NCT04731792|OTHER|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
218860088|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
219589761|NCT02004015|DRUG|injection of placebo|0.5 mg/kg milligram(s)/kilogram
219589762|NCT02004015|DRUG|injection of NMBA|
219589763|NCT05865418|OTHER|Loaded high intensity training|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.
219589764|NCT05865418|OTHER|High intensity circuit training (HICT)|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
218860089|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
219453964|NCT01700140|DRUG|SyB D-0701|Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
218843584|NCT06224998|BEHAVIORAL|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
218843585|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
218843586|NCT00680979|BEHAVIORAL|Health Education|
219453965|NCT01700140|DRUG|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
219453966|NCT02663947|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
219589765|NCT06970262|OTHER|Fecal suspension (provided by SShanghai Chengge Pharmaceutical Technology Co., Ltd.)|Prepare 300 ml of intestinal flora suspension from 100-150 g of feces. Administer vancomycin 500 mg via nasogastric tube every 12 hours for 48-72 hours before FMT. Clean the intestines with 2000 ml of polyethylene glycol 24 hours before FMT (except for patients with diarrhea). Subjects can eat and drink freely during preparation but must fast for at least 2 hours before FMT (water allowed). No food or water is permitted within 2 hours after FMT. Stop all antibiotics (intravenous, oral, nebulized) at least 24 hours before FMT.
219589766|NCT06283862|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
219589767|NCT06971016|OTHER|Mulligan Mobilization technique|"i. Mulligan Mobilization for Medial Glide: During the treatment, the patient will be positioned in a prone (face-down) posture. To execute a medial glide, the therapist will position themselves on the side opposite to the target knee. They will place a belt around the patient's waist and lower leg, aligning the upper edge of the belt with the margin of the tibial joint. Using one hand to stabilize the thigh above the knee and the other hand to support the lower leg, the therapist will apply a medial force to the knee using the belt. The therapist will then instruct the patient to flex their knee while maintaining the glide.~ii. Mulligan Mobilization for Lateral Glide: To administer a lateral glide to the knee, the therapist will position themselves next to the affected knee. They will employ the belt to facilitate the glide by applying force from the opposite side."
219589768|NCT06971016|OTHER|Proprioceptive Exercises|"i. One leg balance- It requires flexing the opposite leg at the knee, hip, and ankle while standing on the affected foot. This position will be hold for one minute (60 seconds), followed by rest for 10 to 20 seconds, then continue this process twice more. Three repetitions of the same exercise will be performed with the unaffected leg after a brief break.~ii. Blind advanced one leg balance- The task will resemble one-legged balance, but the participant will be required to close their eyes while executing the routine, and then repeat it two more times.~iii. Toe walking- In this activity, the participant will be instructed to walk a 20-meter distance while balancing on their toes with their toes pointing straight ahead. They will then be asked to walk the same distance again, but this time with their toes pointing outward. After a brief rest, the entire procedure will be repeated once more."
219589769|NCT06971016|OTHER|Traditional Physical therapy|"• Stretching of the Gastrocnemius and Soleus Muscles~* Frequency: 3-5 times per week.~* Intensity: Stretch to the point of mild discomfort, not pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Gastrocnemius Stretch: Stand facing a wall with one foot forward (slightly bent) and the other foot back (straight). Press the back heel into the floor and lean forward to feel the stretch in the calf.~Soleus Stretch: From the same position, slightly bend the back knee while keeping the heel on the ground to target the lower calf (soleus muscle).~• Stretching of the Hamstrings~* Frequency: 3-5 times per week.~* Intensity: Stretch to a tolerable point of tension without causing pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Seated Hamstring Stretch: Sit on the floor with one leg straight and the other bent."
219589770|NCT05642130|OTHER|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
219589771|NCT05642130|OTHER|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
219589772|NCT00653679|OTHER|exercise|1 hour of endurance or resistance exercise
219589773|NCT02539862|OTHER|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
219589774|NCT02539862|OTHER|psychoeducation|the psychoeducation is delivered by a doctor
218843587|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
218843588|NCT02920528|DRUG|Placebo|Normal Saline
218843589|NCT02483793|DRUG|Tamsulosin|
218843590|NCT02483793|DRUG|Oxybutynin|
218860090|NCT00047333|OTHER|pharmacological study|Correlative studies
218860091|NCT02798770|OTHER|No Intervention Foreseen|
218860092|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
218843591|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
218843592|NCT02481648|OTHER|Exercise|
218843593|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
218843594|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
219453967|NCT01899001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
218843595|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
219453968|NCT01899001|BEHAVIORAL|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
219453969|NCT05474768|OTHER|no intervention|no intervention
219453970|NCT04019197|DRUG|Semaglutide Injectable Product|semaglutide subcutaneous injection
218843596|NCT04463342|COMBINATION_PRODUCT|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
218843597|NCT04463342|COMBINATION_PRODUCT|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
218843598|NCT05400473|OTHER|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
218843599|NCT05400473|OTHER|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
218843600|NCT00066703|DRUG|exemestane|
218843601|NCT00066703|DRUG|tamoxifen|
218843602|NCT00066703|DRUG|triptorelin|
218843603|NCT06473831|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
218843604|NCT06346483|PROCEDURE|Dusting without Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
218843605|NCT06346483|PROCEDURE|Dusting with Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
218843606|NCT06346483|OTHER|Moses 2.0 Modulation|Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology used for lithotripsy and BPH treatments
218843607|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
218843608|NCT04314193|DRUG|Prednisone|Oral prednisone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
219453971|NCT04019197|DRUG|Placebo|placebo injection
219453972|NCT02573012|DRUG|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
219453973|NCT02573012|DRUG|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
219453974|NCT02573012|BIOLOGICAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
219453975|NCT03518580|OTHER|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
219453976|NCT05315973|DEVICE|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
219453977|NCT02587104|OTHER|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
218843609|NCT01696968|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
218843610|NCT01696968|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
218843611|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
218843612|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
218843613|NCT05290246|BEHAVIORAL|Time restricted eating|Limiting daily eating time to an 8 hour window
218843614|NCT05290246|BEHAVIORAL|Caloric reduction|Cut caloric intake by 15%
218843615|NCT03165240|DRUG|BI 690517|Film-coated tablet
218843616|NCT03165240|DRUG|Eplerenone|Film-coated tablet
218843617|NCT03165240|DRUG|Placebo|Film-coated tablet
219453978|NCT03773601|OTHER|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
219453979|NCT03773601|OTHER|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
219453980|NCT03773601|OTHER|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
219453981|NCT02268760|DRUG|BILN 2061 ZW single rising doses|
219453982|NCT02268760|DRUG|Placebo|
219453983|NCT02268760|DRUG|BILN 2061 ZW fixed dose|
219453984|NCT02268760|OTHER|Standardized breakfast|
218843618|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
218843619|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
218843620|NCT05240157|DRUG|Corticosteroid Derivatives|observational
218843621|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
218843622|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
218843623|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
218843624|NCT03155087|DRUG|Metformin|
218843625|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
218843626|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
219453985|NCT04317898|PROCEDURE|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
219453986|NCT04317898|PROCEDURE|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
219453987|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
218843627|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
218843628|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
218843629|NCT02348879|DRUG|Placebo|contains no active drug
218843630|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
218843631|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
219453988|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
219453989|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
219453990|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
219453991|NCT01281774|BIOLOGICAL|CSL112|reconstituted high density lipoprotein
219453992|NCT01281774|BIOLOGICAL|Placebo|Normal saline (0.9%)
219453993|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
219453994|NCT03508973|OTHER|Sculpta|
218843632|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
218843633|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
218843634|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
218843635|NCT00182715|BIOLOGICAL|cetuximab|
218843636|NCT00182715|DRUG|capecitabine|
218843637|NCT00182715|DRUG|fluorouracil|
218843638|NCT00182715|DRUG|leucovorin calcium|
218843639|NCT00182715|DRUG|oxaliplatin|
218843640|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
218843641|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
218843642|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
218843643|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
218843644|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
218843645|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
218843646|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
218843647|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
218843648|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
218843649|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
218843650|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
218843651|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
218843652|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
218843653|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
218843654|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
218843655|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
218843656|NCT00426595|DRUG|Administration of omeprazole suspension|
218843657|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
218843658|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
218843659|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
218843660|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
218843661|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
218843662|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
218843663|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
218843664|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
218843665|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
218843666|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
218843667|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
218843668|NCT02503358|DRUG|Paclitaxel|Given IV
218843669|NCT02503358|OTHER|Pharmacological Study|Correlative studies
218843670|NCT02503358|DRUG|Selumetinib|Given PO
218843671|NCT02118181|DIETARY_SUPPLEMENT|HMB|
219453995|NCT03324867|DRUG|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
218843672|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
218843673|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
218843674|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
218843675|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
218843676|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
218843677|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
218843678|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
218843679|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
218843680|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
218843681|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
218843682|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
218843683|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
218843684|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
218843685|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
218843686|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
218843687|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
218843688|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
218843689|NCT03289910|DRUG|Carboplatin|Given IV
219196900|NCT06818526|DEVICE|Placebo Huandao Conditioning App|"Mobile Application Intervention: Placebo Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
218843690|NCT03289910|DRUG|Topotecan|Given IV
218843691|NCT03289910|DRUG|Topotecan Hydrochloride|Given IV
218843692|NCT03289910|DRUG|Veliparib|Given PO
218843693|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
218843694|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
218843695|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
218843696|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
218860093|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
219196901|NCT05371132|PROCEDURE|Positron Emission Tomography|Undergo PET
219196902|NCT05371132|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219196903|NCT05371132|DRUG|Zirconium Zr 89-Df-Crefmirlimab|Given IV
219196904|NCT05371132|RADIATION|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
218843697|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
218843698|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
218843699|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
218843700|NCT02304913|OTHER|Hypoglossal acupuncture|
218843701|NCT02304913|OTHER|Sham acupuncture|
218843702|NCT02304913|BEHAVIORAL|Dietary recommendations|
218843703|NCT05389423|DRUG|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
218843704|NCT05389423|DRUG|Prednisone|60 mg/m2/day administered orally on days 1 to 5
218843705|NCT05389423|DRUG|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
218843706|NCT05389423|DRUG|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
218843707|NCT05389423|DRUG|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
218843708|NCT05389423|DRUG|Cyclophosphamide|750 mg/m2 administered IV on day 5
218843709|NCT05389423|DRUG|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
218843710|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
218843711|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
218843712|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
218843713|NCT00880269|DRUG|Panobinostat/LBH589|
218843714|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
219453996|NCT03324867|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
218843715|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
218843716|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
218843717|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
218843718|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
219453997|NCT01337791|DRUG|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
218843719|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
218843720|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
218843721|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
218843722|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
218843723|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
218843724|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
218843725|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
218843726|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
218843727|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
218843728|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
218843729|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
218843730|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
218843731|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
218843732|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
219453998|NCT05469880|OTHER|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
219453999|NCT05469880|OTHER|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
219454000|NCT00369889|DRUG|bevacizumab|iv every 21 days
219454001|NCT00369889|DRUG|Erlotinib|oral daily
219454002|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
219454003|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
219454004|NCT04570982|BIOLOGICAL|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
219454005|NCT03520426|DEVICE|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
219454006|NCT03603574|DEVICE|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
219454007|NCT03603574|DEVICE|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
219454008|NCT04574765|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
219454009|NCT04574765|OTHER|Questionnaire collection (CITF)|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
219454010|NCT04574765|OTHER|Optional blood collection|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
218843733|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
218860094|NCT01694277|DRUG|Masitinib|12 mg/kg/day
218860095|NCT01694277|DRUG|Sunitinib|50 mg/day
219454011|NCT04574765|OTHER|Optional questionnaire completion (mental health)|Fill out an optional mental health questionnaire.
219454012|NCT04574765|DIAGNOSTIC_TEST|Optional saliva sample (for validation)|Provide saliva sample anonymously.
219454013|NCT04574765|DIAGNOSTIC_TEST|Nasal Swab (rapid antigen test)|Panbio nasal swab rapid antigen test
218843734|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
218843735|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
218843736|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
218843737|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
218843738|NCT02182206|DRUG|BIBF 1120|
218843739|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
218843740|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
218843741|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
218843742|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
218843743|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
219454014|NCT01339104|DRUG|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
219589775|NCT04081766|BEHAVIORAL|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
219589776|NCT03272061|OTHER|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
218843744|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
218843745|NCT05295901|DEVICE|mKOAH application|mobile app installed group
218843746|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
218843747|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
218843748|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
218843749|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
218843750|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
218843751|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
218843752|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
218843753|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
218843754|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
218843755|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
218843756|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
218843757|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
219454015|NCT04272372|DRUG|Ketoprofen|PO and local therapy
219454016|NCT03663972|BEHAVIORAL|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
219454017|NCT03663972|BEHAVIORAL|phonologic treatment|children receive instruction in producing new sounds at the word level
219589777|NCT02445274|PROCEDURE|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
218843758|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
218843759|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
218843760|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
218843761|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
218843762|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
218843763|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
218843764|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
218843765|NCT00620178|DRUG|Losartan|once daily oral dose
218843766|NCT02842515|OTHER|teeth avulsion|
218843767|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
218843768|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
218843769|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
218843770|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
218843771|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
218843772|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
218843773|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
218843774|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
218843775|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
218843776|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
218843777|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
218843778|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
218843779|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
219454018|NCT04520295|GENETIC|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
218843780|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
219454019|NCT00803296|OTHER|Oral glucose tolerance test (OGTT)|
218843781|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
218843782|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
218843783|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
218843784|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
218843785|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
218843786|NCT06266468|BEHAVIORAL|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
218843787|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
218860096|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
218843788|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
219454020|NCT00803296|OTHER|Isoglycemic intravenous glucose infusion|
219589778|NCT06633237|OTHER|Core training program in female amateur basketball players|The intervention consists of a core training program specifically designed to improve core and trunk stability in female amateur basketball players. The program is integrated into the warm-up routine and is applied twice a week over an 8-week period. Each session lasts approximately 12-15 minutes and includes five exercises. The training program is divided into three phases of progression, gradually increasing the difficulty of the exercises over the 8 weeks by incorporating more dynamic and functional movements.
218843789|NCT00416065|DEVICE|PET/CT imaging|
218843790|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
218843791|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
218843792|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
218843793|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
218843794|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
218843795|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
218843796|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
219454021|NCT01321658|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
219454022|NCT00409396|PROCEDURE|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
219454023|NCT00409396|PROCEDURE|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
219454024|NCT00073034|DRUG|EAA-090|
219589779|NCT05109338|DEVICE|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
219589780|NCT02052050|OTHER|core stability|
219589781|NCT02299115|DRUG|Prednisolone|Corticosteroid
219589782|NCT02299115|DRUG|Vigabatrin|Antiepileptic
219589783|NCT02348723|DRUG|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
218843797|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
218860097|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
218860098|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
219454025|NCT01610414|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
219454026|NCT01610414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
219589784|NCT02348723|DRUG|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
219589785|NCT02069483|BEHAVIORAL|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
219589786|NCT02069483|BEHAVIORAL|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
219589787|NCT01064050|DEVICE|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
219589788|NCT00355810|DIETARY_SUPPLEMENT|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
219589789|NCT00355810|DIETARY_SUPPLEMENT|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
219589790|NCT03891030|OTHER|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
219454027|NCT05388734|OTHER|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
219454028|NCT03305913|DRUG|TAS 102|TAS-102 tablet
219454029|NCT03305913|DRUG|Regorafenib|Regorafenib tablet
219454030|NCT03973632|DRUG|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
218843798|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
218843799|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
219454031|NCT02074761|DEVICE|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
219454032|NCT02736474|DRUG|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
219454033|NCT02736474|DRUG|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
219454034|NCT02736474|DRUG|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
219454035|NCT02736474|DRUG|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
219454036|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
219454037|NCT02409264|OTHER|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
219454038|NCT03227601|DEVICE|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
219454039|NCT04432168|PROCEDURE|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
219589791|NCT00899041|PROCEDURE|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
219589792|NCT04874155|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
219589793|NCT04874155|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
219589794|NCT04874155|DEVICE|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
219454040|NCT04432168|OTHER|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
219454041|NCT00454350|DRUG|Hectorol (doxercalciferol injection)|
219454042|NCT00454350|DRUG|Zemplar (Paricalcitol injection)|
219454043|NCT05947695|BEHAVIORAL|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
219589795|NCT04733703|OTHER|questionnaire|assessment of postoperative quality of recovery with the QoR-15
219454044|NCT02540655|BIOLOGICAL|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
219454045|NCT02540655|PROCEDURE|Excipients|Patients will receive excipients through intravenous infusion
219454046|NCT06245395|DEVICE|Virtual Reality|Meta Quest 2 Headset
219454047|NCT01550770|DRUG|propofol|peripheral IV of propofol at increasing dose levels
219589796|NCT05513846|DEVICE|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
219589797|NCT05513846|DEVICE|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
219589798|NCT00683579|DRUG|Early Treatment with HAART|HAART with possibility of de-intensification
218843800|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
218843801|NCT03560752|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
218843802|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
218843803|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
218843804|NCT05247970|DRUG|S-309309|Capsule administered orally
218843805|NCT05247970|DRUG|Midazolam|Syrup administered orally
218843806|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
218843807|NCT06602674|OTHER|Observe the medical images|Observe the medical images via work station or local image analysing software
218843808|NCT06602674|OTHER|Feature extraction|Extracting image feature via radiomics or deep learning methods
218843809|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
218843810|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
218843811|NCT00080080|DRUG|talabostat (PT-100) tablets|
218843812|NCT00080080|DRUG|Docetaxel|
219454048|NCT02649075|OTHER|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
219454049|NCT02649075|OTHER|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
218843813|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
218843814|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
218843815|NCT05618041|BIOLOGICAL|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
218843816|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
218843817|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
219454050|NCT02587975|DRUG|Evogliptin|10 mg
219454051|NCT01172704|BEHAVIORAL|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
219454052|NCT01079208|OTHER|test starter infant formula|infants are fed for 6 months with this starter formula
219454053|NCT01079208|OTHER|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
219454054|NCT01079208|OTHER|control standard formula|infant are fed 6 months with this formula
219454055|NCT02483611|DRUG|Magnesium Sulfate|
219454056|NCT02483611|DRUG|Lidocaine|
219454057|NCT02483611|DRUG|Isotonic Solution|
218843818|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
218843819|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
218843820|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
218843821|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
218843822|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
219454058|NCT02483611|DRUG|Cisatracurium|
219454059|NCT01353066|DRUG|Intensive Medical Treatment|
219454060|NCT01353066|OTHER|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
219454061|NCT05830240|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
218843823|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
218843824|NCT01626118|DRUG|Placebo|capsules
219454062|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
218843825|NCT05754151|BEHAVIORAL|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
218843826|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
218843827|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
219454063|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
219454064|NCT02382276|DRUG|Nalmefene hydrochloride|
219454065|NCT01222416|RADIATION|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
219454066|NCT01222416|RADIATION|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
219454067|NCT01748903|DEVICE|Target 360°, 2D Coils, Nano Coils|
219454068|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
219454069|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
219454070|NCT03784326|DRUG|Atezolizumab|Given IV (vein)
219454071|NCT03784326|PROCEDURE|Conventional Surgery|Undergo surgical resection
219454072|NCT03784326|DRUG|Fluorouracil|Given IV (vein)
219454073|NCT03784326|DRUG|Oxaliplatin|Given IV (vein)
219454074|NCT03784326|DRUG|Tiragolumab|Given IV (vein)
219454075|NCT02685449|DRUG|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
219454076|NCT02685449|DRUG|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
219454077|NCT02685449|DRUG|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
218843828|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
218843829|NCT06440980|DRUG|Orforglipron|Administered orally
218843830|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
218843831|NCT04314531|DRUG|TILD|one 1 mL injection of study medication
218843832|NCT04314531|DRUG|matching placebo injections|one 1 mL injection of placebo
218843833|NCT04450771|BEHAVIORAL|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
218843834|NCT04450771|BEHAVIORAL|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
218860099|NCT01256463|BEHAVIORAL|HIV prevention intervention|
219454078|NCT01758367|DRUG|Deciatbine(DAC)|
219454079|NCT05661838|PROCEDURE|transfusion|transfusion
219454080|NCT03008928|BEHAVIORAL|Alcooquizz|
219454081|NCT05391412|DRUG|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
219454082|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
219454083|NCT05569356|OTHER|Retrospective|None (only data collection)
219454084|NCT00518336|PROCEDURE|Blood sampling|Blood sampling at Visit 3, 5 and 7.
219454085|NCT00518336|PROCEDURE|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
219589799|NCT00683579|OTHER|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
219589800|NCT00683579|DRUG|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
219589801|NCT02329847|DRUG|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
219589802|NCT02329847|DRUG|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
219454086|NCT00518336|BIOLOGICAL|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
219454087|NCT00238160|DRUG|cisplatin|
219589803|NCT05293639|DEVICE|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
219589804|NCT05067621|DRUG|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
219589805|NCT05067621|DRUG|Placebo|Injection pen contains excipients.
218843835|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
218843836|NCT05467410|BEHAVIORAL|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
218843837|NCT05467410|BEHAVIORAL|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
218843838|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
218843839|NCT05817058|DRUG|AFM28|AFM28 dose escalation
218843840|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
218843841|NCT03910751|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
218843842|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
218843843|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
218843844|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
219454088|NCT00238160|DRUG|fluorouracil|
219454089|NCT00238160|PROCEDURE|adjuvant therapy|
219589806|NCT05066334|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal cells
219589807|NCT05066334|PROCEDURE|Sham|local anaesthesia, no disc injection, no placebo injection
218843845|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
218843846|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
218843847|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
218843848|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
218843849|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
218843850|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
218860100|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
218860101|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
218860102|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
218860103|NCT00205842|DRUG|alvimopan|
219454090|NCT00238160|PROCEDURE|chemotherapy|
219454091|NCT00238160|PROCEDURE|conventional surgery|
219454092|NCT00238160|PROCEDURE|hepatic arterial infusion|
219454093|NCT00238160|PROCEDURE|surgery|
219454094|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
219589808|NCT06323525|BIOLOGICAL|TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
219589809|NCT06323525|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
219454095|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
219454096|NCT04479306|DRUG|Alisertib|Given PO
219454097|NCT04479306|DRUG|Osimertinib|Given PO
219454098|NCT04479306|DRUG|Sapanisertib|Given PO
218860104|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
218860105|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
218860106|NCT00048815|DRUG|Placebos|Placebo pill
218860107|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
219454099|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
219454100|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
219589810|NCT06323525|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
219589811|NCT05694780|BEHAVIORAL|Sleep intervention|Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
219589812|NCT06595303|DRUG|Nitrous oxide for labour analgesia|Any woman may choose to have nitrous oxide inhalation as a standard protocol for labour analgesia
219589813|NCT04646941|OTHER|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
218843851|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
218843852|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
219196905|NCT03995979|OTHER|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
219196906|NCT06147232|DRUG|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
219454101|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
219454102|NCT03628391|DRUG|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
219454103|NCT03628391|DRUG|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
219454104|NCT04166955|BEHAVIORAL|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
219454105|NCT06700551|OTHER|Psychoeducation|Each week, the investigator will send participants one topic through the chat function on the Zalo app. Before receiving the topic, participants will vote on which topic they would like to learn about. The topics will be presented as videos and will cover the following seven areas: providing everyday care, being a caregiver, self-care, knowledge about dementia, fall prevention, pressure injury prevention and care, and managing behavior changes.They may ask questions related to providing dementia care or share their feelings via the chat on the Zalo app.
219454106|NCT07030608|BEHAVIORAL|Exercise|Pelvic Floor Muscle Exercise Program Week 1: Contract the pelvic floor muscles for 6 seconds, then relax for 6 seconds. Repeat 25 times. Perform 3 sessions per day (total of 75 contractions per day). Week 2: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day). Week 3: Contract for 6 seconds, relax for 6 seconds. Repeat 75 times. Perform 3 sessions per day (total of 225 contractions per day). Weeks 4-24: Contract for 6 seconds, relax for 6 seconds. Repeat 100 times. Perform 3 sessions per day (total of 300 contractions per day). After Week 24: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day).
219196907|NCT06147232|DRUG|Placebo|Placebo tablet
219196908|NCT04823689|PROCEDURE|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
219196909|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
219454107|NCT07138430|OTHER|İntervention|Patients participating in the study will be informed about the purpose of the study. Participants will be included in the study after verbally and in writing confirming the informed consent form. Patients will receive training and information about the virtual reality headset before the procedure. Patients will complete a personal information form 1 hour before the coronary angiography procedure. Pain and anxiety levels will be measured using the Visual Analog Scale (VAS) and the State Anxiety Scale 10 minutes before the procedure. Patients in the intervention group will wear virtual reality headsets during coronary angiography. Local anesthesia will not be administered to the femoral intervention site in these patients. Pain and anxiety will be assessed after the coronary angiography procedure (10 minutes later). Patients will also be questioned about their satisfaction with the virtual reality application after the procedure. One week after discharge, the patient will be re-evaluate
218843853|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
219196910|NCT06610903|DRUG|Hemay005|In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
219454108|NCT07138430|OTHER|Control|Ten minutes before the coronary angiography procedure, patients will be assessed for pain and anxiety using the Visual Analog Scale (VAS) and the State Anxiety Scale. During the coronary angiography, control group patients will undergo routine interventional procedures. Following the coronary angiography procedure (10 minutes later), patients will be assessed for pain and anxiety. One week after discharge, the patient will be re-evaluated at the hospital for an interventional site examination. The femoral area will be examined for edema, hematoma, pain, and difficulty walking. These assessments will be recorded on forms.
219454109|NCT01723176|PROCEDURE|Echocardiography|
219454110|NCT00879788|DRUG|Ramipril 10mg capsules|
219454111|NCT00000231|DRUG|Buprenorphine|
219454112|NCT06713499|DRUG|SHR-1819 injection|SHR-1819 injection.
219454113|NCT05979363|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
219454114|NCT05979363|DRUG|VRD-based regimen|Bortezomib, Lenalidomide and Dexamethasone
218843854|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
218843855|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
219454115|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
219454116|NCT00716040|BEHAVIORAL|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
219454117|NCT00716040|OTHER|Usual care|The control group will be submitted to the usual care of the health service
219454118|NCT06721975|DEVICE|Thulio pulsed Thulium:YAG (p-Tm:YAG)|A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG.
219454119|NCT06721975|DEVICE|Thulium Laser Fiber (TFL)|The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
219454120|NCT06723405|BIOLOGICAL|EVO301|Intravenous EVO301
219454121|NCT06723405|BIOLOGICAL|Placebo|Placebo
219454122|NCT05282186|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
219454123|NCT05282186|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
219589814|NCT04084600|OTHER|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
219589815|NCT04084600|OTHER|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
219589816|NCT04084600|OTHER|Traditional Massage|Traditional Massage is a gentle and superficial massage.
219589817|NCT05400408|DIAGNOSTIC_TEST|VOX|Breath Biopsy Analysis
219589818|NCT02264470|OTHER|Not relevant|Not relevant
219589819|NCT03460314|DRUG|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
219589820|NCT06979635|DEVICE|Tandem Mobi Hybrid Closed Loop (HCL) pump|Tandem Mobi Hybrid Closed Loop (HCL) pump with an integrated Control-IQ algorithm (CIQ), the Dexcom G7 continuous glucose monitoring sensor (CGM ) and Tandem Mobi Mobile App
218843856|NCT05271253|DRUG|normal Saline|injection of normal Saline
218843857|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
218843858|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
219589821|NCT06983314|OTHER|Observation|Observation of pharmacological prescriptions in patients with ABI
219589822|NCT06982196|DRUG|Sulodexide|Sulodexide group：Starting after the last injection of secukinumab, oral treatment with sulodexide soft capsule (Alpha Weissmann Pharmaceuticals, Italy, approval number H20140119, specification 250 LSU) was given as 1 tab bid for 120 days or discontinued after judged to be a relapse.
219589823|NCT06982196|DRUG|Placebo|Control group: Oral treatment with placebo capsule, 1 tab bid starting after the last injection of secukinumab, discontinued after 120 days of continuous oral administration or judged to be discontinued for relapse.
219589824|NCT06983626|PROCEDURE|micro-dissection testicular sperm extraction|dissection of the seminefrous tubules under microscope to extract sperms
219589825|NCT06983795|PROCEDURE|PFO closure using approved PFO closure devices, Surgical PFO closure|PFO closure using approved PFO closure devices, Surgical PFO closure
219589826|NCT06983795|DRUG|Medical management|"Antiplatelet therapy~* ASA, also called acetylsalicylic acid (Aspirin, Asaphen, Entrophen, Novasen)~* clopidogrel (Plavix)~* ticagrelor (Brilinta)~* dipyridamole (Persantine)~* cilostazol~Anticoagulation therapy~* apixaban (Eliquis)~* dabigatran (Pradaxa)~* edoxaban (Lixiana)~* rivaroxaban (Xarelto)~* warfarin (Coumadin)"
218843859|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
218843860|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
218843861|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
218843862|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
218843863|NCT00100074|DRUG|Lobeline|
218843864|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
218843865|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
218843866|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
218843867|NCT06237127|DIETARY_SUPPLEMENT|Goji berry|Participants will be instructed to consume 14 grams of goji berries 5 days a week for 6 months
218843868|NCT06237127|DIETARY_SUPPLEMENT|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
219454124|NCT06925776|OTHER|CHOOSE Home Intervention|Integration of a CHW (Community Health Worker) in the CKD (Chronic Kidney Disease) care process to augment patient engagement and address HRSNs (Health-Related Social Needs) within the context of an IDC (Interdisciplinary Care) CKD clinic. The multifaceted components of the intervention are tailored to address key care delivery and social barriers to home dialysis utilization before implementation.
219454125|NCT06925776|OTHER|Usual Care|This is the usual interdisciplinary care that patients would typically receive for their chronic kidney disease. A key missing factor here is the lack of a community health worker. Patients in this group will be screened for health-related social needs and receive general information on ways to access social services from a study coordinator. Patients will not receive facilitated peer support and social care navigation from the Community Health Worker.
219454126|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
219454127|NCT05439876|DRUG|Melatonin|Melatonin 2 mg daily for 4 weeks
219454128|NCT05439876|DRUG|Placebo|Placebo daily for 4 weeks
219454129|NCT01718119|DRUG|r-hCG|r-hCG(250mcg) injection subcutaneously
219589827|NCT06984315|OTHER|The effects of the groups on perioperative inflammation changes were compared.|Between January 2020 and April 2025, data from 849 patients who underwent total knee arthroplasty were retrospectively reviewed. Preoperative hemogram values were obtained during routine anesthesia clinic evaluation, typically one day prior to surgery. Postoperative hemogram samples were collected on the day of surgery (postoperative day 0), within 4 to 12 hours after the procedure. Blood parameters included neutrophil, lymphocyte, monocyte, and platelet counts. Based on these values, inflammatory indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammatory response index (SIRI) were calculated.
219589828|NCT06983977|OTHER|Measurement of physical activity|Measurement of physical activity by accelerometer
218843869|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
218843870|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
218843871|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
218843872|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
218843873|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
218843874|NCT02274480|DEVICE|cardiac MRI with DWI|
218843875|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
218843876|NCT00203866|DRUG|G250 peptide|
218843877|NCT00203866|DRUG|IL-2|
218843878|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
218843879|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
218843880|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
218843881|NCT01731340|OTHER|Low Dietary Calcium|450 mg
218843882|NCT01731340|OTHER|High Dietary Calcium|1200 mg
218843883|NCT00711230|BIOLOGICAL|DermaVir|
218843884|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
218843885|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
218843886|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
218843887|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
218843888|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
218843889|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
218843890|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
218843891|NCT02110654|DRUG|Montelukast|
218843892|NCT02110654|DRUG|mometasone furoate nasal spray|
218843893|NCT02030925|DRUG|IW-3718|
218843894|NCT02030925|DRUG|Matching Placebo|
218843895|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
218843896|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
218843897|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
218843898|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
218843899|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
219454130|NCT06534164|DEVICE|Full/High Tech Telerehabilitation decision support system|"The TeleRehaB DSS intervention includes balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
219454131|NCT06534164|DEVICE|Basic/Low Tech Telerehabilitation decision support system|"The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
219589829|NCT06983977|OTHER|Digital nudging|Digital feedback and nudging to participants (patients) and staff, based on participants' physical activity measurements, aiming to increase patients' physical activity and reduce sedentary time
218843900|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
218843901|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
219454132|NCT06534164|PROCEDURE|OTAGO Home exercise program|balance rehabilitation program
219454133|NCT06534164|PROCEDURE|Vestibular rehabilitation program|vestibular rehabilitation and dizziness program
219589830|NCT06977620|OTHER|Closed kinetic chain exercises|Closed kinetic chain (CKC) exercises emphasize weight-bearing movements where the distal segment of the extremity is fixed, and motion occurs as the proximal segment moves over the stabilized distal segment.
219589831|NCT06977620|OTHER|Weight shifting exercises|Weight-shifting is a crucial aspect of dynamic postural control, which refers to the ability to maintain one's bodyweight within the base of support. Lateral weight-shifting, in particular, is essential for maintaining posture under dynamic conditions and is commonly performed in various activities of daily living
219589832|NCT06977620|OTHER|Complete Decongestive Therapy|CDT includes (skin care, manual lymphatic drainage, compression bandages, compression garments and exercises).
219589833|NCT06683573|BEHAVIORAL|3D Kidney model|Brief provider led counseling and education on Chronic Kidney Disease (CKD) and hypertension guided by use of 3D kidney model visual aid
218843902|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
218843903|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
218843904|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
219589834|NCT06683573|BEHAVIORAL|Standard medical treatment|Standard provider led counseling and education on CKD and hypertension
219589835|NCT03469505|BEHAVIORAL|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
219589836|NCT03469505|BEHAVIORAL|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
219589837|NCT06185608|DRUG|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
219589838|NCT06185608|DRUG|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
218843905|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
218843906|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
218843907|NCT06187194|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
218843908|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
218843909|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
218843910|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
219454134|NCT07048587|DIAGNOSTIC_TEST|Beta-hCG levels in the uterine cavity lavage for differential diagnosis in pregnancy of unknown locations and ectopic pregnancy|The intervention in this study centers on utilizing beta-hCG levels in uterine cavity lavage as a diagnostic tool to differentiate between ectopic pregnancy and early pregnancy loss.The procedure includes females aged 18-45 with positive serum beta-hCG, inconclusive clinical findings, and transvaginal ultrasound results, focusing on beta-hCG levels below 1500-2000 mIU/mL and abnormal progression.The intervention performed before probe curettage (P/C). Before the intervention beta-hCG is measured in venous blood. Patients undergo uterine cavity lavage with 5 ml of saline solution administered and 3 ml of aspirated liquid collected for beta-hCG measurement. Data collection involves beta-hCG levels from lavage fluid and venous blood, pathology results.After the samples were collected, each one was frozen at -80 ºC. All uterine lavage samples were then analyzed later on the same day.
219454135|NCT06890559|BEHAVIORAL|financial incentive intervention based on a digital platform|The intervention will span a duration of 12 months. All residents in the 8 intervention subdistricts/townships are available for participation; each participant household needs to register a household account on the digital platform. Each family member who completes targeted vaccine uptake or related health behaviors can earn points through two point-recording routes. Reward points will be accumulated on a household basis to encourage family members' engagement. Points can be redeemed for gifts on the digital platform and are only valid once.
219454136|NCT05911945|PROCEDURE|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
219454137|NCT05911945|PROCEDURE|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
219454138|NCT07052942|DRUG|Inhaled corticosteroid (ICS)|Participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy.
219454139|NCT07052942|DRUG|Azithromycin|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects.
218843911|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
218843912|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
218843913|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
218843914|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
218843915|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
218843916|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
219196911|NCT06610955|OTHER|High intensity interval training|After a 10 minutes warm up exercise, participants will exercise with a bicycle ergometry device at 80% of their maximum heart rate for 4 minutes, and the active recovery period will be 3 minutes (4x4 minutes). During the recovery period, the participant will exercise with the Ergoline bicycle ergometry system for 4 sets at 60% of their maximum heart rate for 3 minutes. A total of 45 minutes exercise session will be completed with a 10 minutes cool down exercise. Exercise will be done 5 days a week for a total of 8 weeks. In the first 4 weeks, exercise will be done at 80% intensity, and in the following weeks, the exercise intensity will be increased by 5% each week, respectively, to 85%, 90%, 95%, and 100% in the last week.
219196912|NCT06610955|OTHER|Moderate intensity continuous training|Following a 10 minutes warm up exercise, participants will exercise continuously for 30 minutes at 65% of their maximum heart rate with the Ergoline bicycle ergometry system. A 5 minutes cool down exercise will end the 45 minutes exercise session. The exercise duration is 5 days a week for a total of 8 weeks.
219196913|NCT06668597|BEHAVIORAL|Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP|Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
219454140|NCT07052942|OTHER|Asthma Symptom Monitoring Web-based Application|All participants will be provided access to the Asthma Symptom Monitoring (ASM) tools. ASM can be integrated with electronic health records (EHR) or used as a stand alone application. Participants will answer 5 questions about their asthma each week. If symptoms are problematic, participants can request a call back from a person on their care team. Participants can view a graph of their data, watch videos, and record peak flows. Clinicians and members of the care team can view data in the EHR (not for stand alone web app).
219454141|NCT07057674|DRUG|HS-20094 AI pen;|Arm 1: Administered SC The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
219454142|NCT07057674|DRUG|HS-20094 MDV pen|The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
219454143|NCT07057895|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM) Criteria Assessment|Malnutrition was diagnosed according to the GLIM consensus criteria. This required at least one phenotypic criterion (non-volitional weight loss, low BMI, or reduced muscle mass) and one etiologic criterion (reduced food intake/assimilation or inflammation/disease burden). Reduced muscle mass was assessed by bioelectrical impedance analysis (BIA). The assessment was performed once for each patient within 24 hours of hospital admission.
219454144|NCT07057895|DIAGNOSTIC_TEST|Patient-Generated Subjective Global Assessment (PG-SGA)|A comprehensive nutritional assessment administered by trained clinical staff. The tool comprises patient-reported sections (weight history, food intake, symptoms, activities/function) and clinician-assessed sections (disease, metabolic demand, physical exam). For this study, a total score of ≥2 was considered indicative of malnutrition. The assessment was performed once for each patient within 24 hours of hospital admission.
219589839|NCT06185608|DRUG|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
219589840|NCT06983912|BEHAVIORAL|Preoperative Rehabilitation Training|"Initiate preoperative Physical Rehabilitation Training (PRT) starting from the preoperative period, with training five days a week up until the day before surgery. This includes:~Muscle Strength Training: Isometric contractions of the quadriceps, straight leg raises, etc., for 15-20 minutes per session, twice daily.~Joint Mobility Training: Flexion and extension exercises of the knee joint, ankle pump exercises, etc., for 10-15 minutes per session, twice daily.~Balance Training: One-legged standing, center of gravity shifting exercises, etc., for 10-15 minutes per session, twice daily.~Activities of Daily Living Training: Transfer training from sitting to standing, walking exercises, etc., for 10-15 minutes per session, twice daily."
219589841|NCT04314414|OTHER|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
219589842|NCT04314414|OTHER|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
218843917|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
218843918|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
218843919|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
218843920|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
218843921|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
219589843|NCT05974917|DEVICE|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle."
219589844|NCT06454396|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
219196914|NCT06609486|DEVICE|Blood pressure measurement group|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."
219196915|NCT06609512|DRUG|Enlicitide|Oral Tablet
219196916|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
219454145|NCT07058636|DRUG|2% Lidocaine HCl + saline|The intervention consists of injecting a mixture of 1 ml 2% lidocaine and 1 ml normal saline into trigger points located in the upper trapezius muscle.
219454146|NCT07058636|DRUG|Steroid+lidocaine|The GON block involves injecting a mixture of 1 ml 2% lidocaine and 1 ml betamethasone.
219454147|NCT07057518|BEHAVIORAL|emotional freedom technique|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
219454148|NCT07059247|BIOLOGICAL|Application of Enamel Matrix Derivatives|After the extraction of the impacted lower third molar, EMD will be applied on the distal site of the second molar
219454149|NCT07059247|PROCEDURE|Extraction of the impacted third molar|Extraction of the impacted third molar
219454150|NCT07058025|BIOLOGICAL|Human Allogenic Umbilical Cord Mesenchymal Stromal Cells|IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded
219454151|NCT07058025|OTHER|Sham procedure control|Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks
219454152|NCT07059286|BEHAVIORAL|Maternal Frailty Inventory (MaFra) Questionnaire|A validated psychometric inventory designed to assess maternal clinical, psychological, and lifestyle risk factors during pregnancy. The composite risk score is used to stratify participants into low- or medium/high-risk categories. Administered during pregnancy, the inventory informs classification and predictive modeling of fetal and child neurodevelopmental outcomes.
219454153|NCT07059286|DIAGNOSTIC_TEST|Fetal Resting-State Functional MRI|Non-invasive resting-state functional MRI scans performed during gestation (fetal) life to assess functional connectivity across sensorimotor, auditory, visual, language, and attention networks. Imaging data are analyzed to derive local and global connectivity measures and indices of segregation and integration among functional brain systems. Structural MRI is used to confirm normal brain morphology.
219454154|NCT07059286|BEHAVIORAL|Maternal Emotional Reactivity|During fetal rs-fMRI acquisition, mothers listen to emotionally evocative musical excerpts while rating their emotional responses. These self-reported ratings (valence and arousal) are later correlated with fetal brain connectivity responses.
219589845|NCT06983483|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
219589846|NCT06983483|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)~6. External Renders"
219589847|NCT06659679|DRUG|New use of oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
219589848|NCT06659679|DRUG|New initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
219589849|NCT06506214|OTHER|Questionnaires|"Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)"
218843922|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
218843923|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
218843924|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
218843925|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
218843926|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
218843927|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
218843928|NCT04590404|BEHAVIORAL|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
218843929|NCT04590404|DRUG|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
218843930|NCT04590404|DRUG|Varenicline|FDA-approved smoking cessation medication.
219589850|NCT03178032|BIOLOGICAL|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
219589851|NCT00294463|DRUG|Tibolone|
219589852|NCT00294463|DRUG|Estradiol|
218843931|NCT04590404|OTHER|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
219589853|NCT00294463|DRUG|Estradiol + Medroxy Progesterone Acetate|
219589854|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|Stone needle therapy follows the Belt channel involves the use of stones by the intervener to follow the path of the Belt channel by pushing and rubbing the abdomen of patients with postpartum diastasis rectus abdominis.
219589855|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
219589856|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
219589857|NCT06990945|DEVICE|Hi-Bond Universal Adhesive|"A bioactive glass adhesive containing mesoporous bioactive glass designed to promote dentin remineralization, manufactured by Mediclus, Korea. It releases calcium and phosphate ions to enhance dentin sealing and reduce hypersensitivity~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of HI Bond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
218843932|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
218843933|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
218843934|NCT04827147|DEVICE|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
218843935|NCT04827147|DEVICE|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
218843936|NCT04154605|DEVICE|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
218843937|NCT04154605|DEVICE|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
218843938|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
218843939|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
218860108|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
218843940|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
219454155|NCT07059286|DIAGNOSTIC_TEST|Neonatal Resting-State Functional MRI|Non-invasive MRI scanning protocol conducted during the neonatal period to acquire resting-state functional MRI (rs-fMRI) data. The scan is performed while the newborn is in a natural sleep state, using motion-optimized sequences to assess functional connectivity between brain regions. The focus is on sensorimotor, auditory, visual, language, and attention networks. Structural MRI is also acquired to verify normative brain morphology. Imaging outcomes are used in longitudinal analyses to link early brain connectivity with cognitive and behavioral development.
219454156|NCT07059286|BEHAVIORAL|Longitudinal Neurodevelopmental Testing Battery|Standardized neuropsychological and behavioral assessments are administered at multiple timepoints between birth and 72 months of age. Domains evaluated include sensorimotor skills, cognitive abilities, language development, executive function, social-emotional regulation, and adaptive behaviors. Data are used to compute specific and composite scores that reflect neurocognitive and behavioral profiles. These are later integrated with prenatal and neonatal brain imaging and maternal risk data to model individual neurodevelopmental trajectories.
219454157|NCT07059468|DIAGNOSTIC_TEST|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA)|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method
219454158|NCT07058246|OTHER|Mime therapy with Conventional therapy|"Experimental group was given mime therapy along with conventional therapy. Mirror therapy, Raising eyebrows as if surprised, Widening eyes in shock, blinking rapidly, Extreme smiling, Eye closure with dramatic expressions, exaggeration nose wrinkling. pouting and mouth opening, expression transitions.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
219454159|NCT07058246|OTHER|Conventional therapy|"Raising and lowering eyebrows, Wrinkling nose, smiling, frowning, massage.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
218843941|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
218843942|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
218843943|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
218843944|NCT05288790|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement
218843945|NCT05288790|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
219454160|NCT07060716|DIAGNOSTIC_TEST|donor-derived cell-free DNA test|A donor-derived cell-free DNA (dd-cfDNA) test used to measure the concentration of total cell-free DNA and the fractional abundance of the dd-cfDNA.
219454161|NCT07059494|DRUG|Atezolizumab|Atezolizumab is an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. It is indicated for usage in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS).
219454162|NCT07059494|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It is also indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in participants who have progressed on a first-line bevacizumab product-containing regimen.
219454163|NCT07059494|RADIATION|Y^90 Radioembolization|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat cancers in the liver. Tiny beads filled with a radioactive isotope are placed inside the blood vessels that supply a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. It can help extend the lives of participants with inoperable tumors and improve their quality of life.
219454164|NCT07058688|DRUG|NTRX-07|Orally administered CB2 agonist
219454165|NCT07058688|DRUG|Placebo|Inactive matched comparator
219454166|NCT07058337|PROCEDURE|parsplana vitrectomy|23 gauge parsplana vitrectomy
218843946|NCT04972396|DRUG|Pemvidutide|Injected subcutaneously (SC)
218843947|NCT04972396|DRUG|Metformin|Taken by mouth (PO)
218843948|NCT04972396|DRUG|Atorvastatin|Taken by mouth (PO)
218843949|NCT04972396|DRUG|Warfarin|Taken by mouth (PO)
218843950|NCT04972396|DRUG|Digoxin|Taken by mouth (PO)
218843951|NCT04972396|DRUG|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
218843952|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
218843953|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV\_P. bGTV\_P will then be used as an adjunct to help us delineate the GTV\_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV\_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
218860109|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
218843954|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV\_P and bGTV\_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
219454167|NCT07058337|PROCEDURE|adjunctive use of Methotrexate|intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively
218843955|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
218843956|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
218843957|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
219454168|NCT07058415|OTHER|Stool sample 1|Stool sampling at D0 for having baseline reference
219454169|NCT07058415|OTHER|Stool sample 2|Stool sampling at D5 to study the impact of antibiotics on microbiota
219454170|NCT07058415|OTHER|Stool sample 3|Stool sampling at DX+28 to study the impact of antibiotics on microbiota
219454171|NCT07058285|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. o ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
219454172|NCT07058285|OTHER|SDTT+ anteroposterior perturbations|The SDTT+ anteroposterior perturbations program will trigger reactive gait adaptations by accelerations and decelerations of one of the belts of a split-belt treadmill.
219454173|NCT07058571|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participating Veterans will engage in bi-weekly, telehealth mediated resistance exercise session. Aerobic exercise will be monitored passively through FitBit data collection. Telehealth exercise sessions will last approximately 45-90 minutes pending the individual Veteran's progress. Participants will also undergo a one-time dietary consultation and recommendations by a Leukemia and Lymphoma Society (LLS) member.
219454174|NCT04873843|BEHAVIORAL|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
219454175|NCT04873843|BEHAVIORAL|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
219454176|NCT02422563|PROCEDURE|hysterectomy|radical hysterectomy
219454177|NCT02422563|RADIATION|Radiation|
219454178|NCT02422563|DRUG|Cisplatin|
219454179|NCT02422563|DRUG|Paclitaxel|
219589858|NCT06990945|DEVICE|OptiBond Universal Adhesive|"conventional universal adhesive designed for bonding composite restorations to enamel and dentin.~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of OptiBond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
219589859|NCT06989125|BEHAVIORAL|Internet-based cognitive behavioral therapy|"The internet-based CBT treatment arm is delivered via the online treatment platform SpilleFri and consists of nine internet-delivered modules delivered over 10-12 weeks. Modules contain written assignments and multiple-choice lists, combined with psychoeducation delivered in text, illustrations, and videos. The treatment is assisted by a therapist. The therapist contact is primarily written and takes place in an embedded secured message system on the platform. Participants can use the written message function whenever they want, and the therapist will respond on a specific day each week. Further, participants are offered up to three sessions of face-to-face or video-based therapist support during the treatment, depending on their preference.~Treatment is regarded as completed if the participant has worked actively (logged in to the module and filled in at least one interactive exercise) in the first 6 modules of the treatment program."
218843958|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
218843959|NCT01581021|DEVICE|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
218843960|NCT01581021|DEVICE|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
218843961|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
218843962|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
219196917|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
219454180|NCT02422563|DRUG|Carboplatin|
219454181|NCT02422563|DRUG|Ifosfamide|
218843963|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
218843964|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
218843965|NCT00392587|DRUG|GW856553|
218843966|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
218843967|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
218843968|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
218843969|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
218843970|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
218843971|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
219454182|NCT07058584|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is administered using a figure-of-eight coil from MagVenture positioned over the left primary motor cortex (M1) in an anteroposterior direction. High-frequency rTMS is delivered at 10 Hz, consisting of 100 trains of 10-second duration (3000 pulses), with 20-second inter-train intervals, at \~90% of resting motor threshold (RMT) depending on participant tolerance and TMS-EEG brain response.
219454183|NCT07058584|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|This intervention involves high-frequency repetitive transcranial magnetic stimulation (rTMS) applied over the primary motor cortex (M1), using a figure-of-eight coil. In the sham condition, the same coil is used, but it is oriented away from the scalp at an angle that prevents effective magnetic stimulation of the brain, while still producing similar auditory and tactile sensations. This allows participants to remain blinded to the intervention type, maintaining the single-blind nature of the study. The active stimulation is delivered at 10 Hz, comprising 30 trains of 10 seconds (9900 milliseconds)(3000 pulses in total), with 20-second inter-train intervals, at \~110% of the individual's resting motor threshold (rMT). Stimulation is delivered while the participant is seated at rest, and the full rTMS protocol takes approximately 15 minutes to complete.
218843972|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
218843973|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
218843974|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
218843975|NCT03730233|PROCEDURE|Hiatal hernia repair by tension-free mesh closure|
218843976|NCT03730233|PROCEDURE|Hiatal hernia repair by simple suturing|
218843977|NCT00256360|DRUG|dose dense with neulasta|
219454184|NCT06751251|DIAGNOSTIC_TEST|IHC: Immunohistochemistry|Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.
219454185|NCT06751251|GENETIC|RNA-seq|RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.
218843978|NCT00599534|DRUG|Montelukast|4 mg oral tablets
218843979|NCT00599534|DRUG|Placebo|5mg tablets
218843980|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
218843981|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
218843982|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
219454186|NCT07058233|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Oral Nutritional Supplement (ONS) in the form of a soy-based drink (235 kcal/200mL: 10.34 g protein, 7.9 g fat, 30.61 g carbohydrate; Protein)
218843983|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
218843984|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
218843985|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
218843986|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
218843987|NCT00054327|DRUG|cyclophosphamide|Given IV
218843988|NCT00054327|DRUG|cytarabine|Given IV
219454187|NCT07058675|DRUG|Metformin Hydrochloride 500 MG|metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.
218843989|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
218843990|NCT00054327|DRUG|Etoposide|infusion
218843991|NCT00054327|PROCEDURE|Stem Cell Transfusion|
218843992|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
218843993|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
218843994|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
218843995|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
218860110|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
218843996|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
218843997|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
218843998|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
218843999|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
218844000|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
219454188|NCT07058675|DRUG|Myoinositol|myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily
219454189|NCT06760156|DRUG|Tafasitamab|The recommended dose of tafasitamab is 12 mg/kg.
219454190|NCT06760156|DRUG|Lenalidomide|The starting dose for lenalidomide will be 25 mg PO daily.
219454191|NCT02717962|DRUG|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
219454192|NCT05227612|DRUG|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg).
219454193|NCT05227612|BEHAVIORAL|Cognitive behavioral therapy|Twelve total sessions of therapy, including manualized cognitive behavioral therapy for major depressive disorder, including psychoeducation about depression, cognitive skills, and behavioral skills as well as preparation for psilocybin.
218844001|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
218844002|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
219454194|NCT05227612|BEHAVIORAL|Minimal therapeutic support|Six total therapy sessions. Preparation for psilocybin in the first three sessions plus supportive, nondirective psychotherapy in the final three sessions.
219454195|NCT06899945|DEVICE|a percussion massage gun (Hypervolt device (Hyperice, CA, USA))|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the deltoid, supraspinatus, infraspinatus, and teres minor muscles with a percussion massage gun (Hypervolt device (Hyperice, CA, USA)) along the origo-insertio line for 3 minutes for each muscle group. Vibration application will be performed using the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
218844003|NCT01803100|OTHER|No intervention|There is no intervention in this trial
218844004|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
218844005|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
218844006|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
218844007|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
218844008|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
218844009|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
218844010|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
218844011|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
218844012|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
218844013|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
218844014|NCT00140049|DRUG|Xalacom|
218844015|NCT00140049|DRUG|Cosopt|
218844016|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
218844017|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
219589860|NCT06989125|BEHAVIORAL|Synchronous cognitive behavioral therapy|In the sCBT condition, participants receive 9 individual sessions spread over 14-20 weeks, in a 1 to 1 format with a therapist, delivered either face-to-face or via video connection, depending on the participant's preference (there may be a mix). Treatment sessions take place weekly at the start of the course. After week 4, the aim is to have sessions at least every other week to maintain continuity in treatment. Further, participants are offered up to three additional sessions that can be included on request of participant or when therapists deem it necessary. Treatment is regarded as completed if the participant has attended 6 sessions of the treatment program.
218844018|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
219454196|NCT06899945|OTHER|conventional physiotherapy program|"Participants in the conventional physiotherapy program will follow a 3-week exercise plan, with sessions 5 days per week, each lasting 30 minutes under physiotherapist supervision.~Treatment includes:~TENS therapy (20 min, 100 Hz) on the painful area. Wand exercises for flexion, abduction, extension, internal, and external rotation (10 reps/set).~Codman exercises for flexion, abduction, and circular movements (10 reps/set). Active \& passive stretching for flexion, abduction, internal, and external rotation (10 reps/set).~Finger ladder exercises for flexion and abduction (10 reps/set). Strengthening with a theraband for flexion, abduction, external/internal rotation, and extension, adjusted based on progress (10 reps/set).~This exercise program will be applied to all study groups."
219454197|NCT07147530|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
219454198|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
219454199|NCT04716920|DEVICE|FitBit|Wear FitBit
219454200|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
219454201|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
219454202|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
219589861|NCT06990334|GENETIC|Whole genome sequencing analysis|RNAseq
219589862|NCT06989034|OTHER|Child Sensory Profile 2 (SP2) for Sensory processing abilities|Sensory processing abilities are evaluated using the Child Sensory Profile 2 (SP2), an 86-item caregiver questionnaire assessing six sensory systems (auditory, visual, touch, movement, body position, and oral) and three behavioral domains (conduct, social-emotional, and attentional).
219589863|NCT06989034|OTHER|HUMAC Balance System for Postural stability evaluation|"Postural stability is assessed using the HUMAC Balance System, incorporating tests such as:~* The Modified Clinical Test of Sensory Integration of Balance (mCTSIB)~* Limits of Stability (LOS) at difficulty levels 4 and 6~* Center of Pressure (COP) metrics"
219589864|NCT06989034|OTHER|Selective Motor Control Evaluation for the upper and lower extremities|"Selective voluntary motor control is evaluated using the following tools:~* Test of Arm Selective Control (TASC) for the upper extremities~* Selective Control Assessment of the Lower Extremity (SCALE) for the lower extremities"
218844019|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
219454203|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
219454204|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
219454205|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
218844020|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
218844021|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
218844022|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
218844023|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
218844024|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
218844025|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
218844026|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
218844027|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
218844028|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
218844029|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
219454206|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
219454207|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Expanding retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. This practice schedule is repeated the next day (Day 2).
219454208|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).
218844030|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
218844031|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
218844032|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
218844033|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
218844034|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
218844035|NCT02540187|OTHER|blood specimen|
218844036|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
218844037|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
218844038|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
218844039|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
218844040|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
218844041|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
219454209|NCT05726747|DIAGNOSTIC_TEST|Quality of Life surveys|QoL and sarcopenia assessments
219454210|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
219454211|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
219454212|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
219454213|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
218844042|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
218844043|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
218844044|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
218844045|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
218844046|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
218844047|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
218844048|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
218844049|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
219454214|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
219454215|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
219454216|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
219454217|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
219589865|NCT06988696|OTHER|The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention.|"The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention. Eligible patients will be informed about the study by reading the voluntary informed consent form, which includes information about the purpose, content, and methodology of the research. Both verbal and written consent will be obtained from patients who agree to voluntarily participate in the study.~Initially, the Descriptive Characteristics Form will be administered to the patients. One group will be given heated socks, one group will be given regular socks, and one group will not receive any intervention. The effect of these interventions on hypothermia will be examined."
219589866|NCT06990516|DRUG|SHR-A1811|"Dose: 3.2 mg/kg, 4 mg/kg, or 4.8 mg/kg, administered intravenously (IV) every 3 weeks (Q3W).~Infusion Duration:~First infusion: 90 ± 10 minutes. Subsequent infusions: May be shortened to approximately 30 minutes (minimum 20 minutes, maximum 60 minutes, including flush phase) if no infusion-related reactions occur after the first dose."
219589867|NCT06990516|DRUG|Carboplatin|"Dose: Area Under the Curve (AUC) 5 mg/mL/min, administered IV Q3W.~Infusion Duration:~Should be completed within 30-60 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
219589868|NCT06990516|DRUG|Oxaliplatin|"Dose: 85 mg/m², administered IV Q3W.~Infusion Duration:~Should be infused over \>120 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
218844050|NCT05686746|DRUG|MMF|1000 mg oral daily
218844051|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
218844052|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
218844053|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
218844054|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
218844055|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
218844056|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
218844057|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
218844058|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
218844059|NCT06009237|DRUG|ABBV-903|Tablet; oral
218844060|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
218844061|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
218844062|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
219454218|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
218844063|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
218844064|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
218844065|NCT02952508|DRUG|Iopofosine I 131 single dose|Radiopharmaceutical
218844066|NCT02952508|DRUG|Iopofosine I 131 multiple dose|Radiopharmaceutical
218844067|NCT02952508|DRUG|Iopofosine I 131 fractionated dose|Radiopharmaceutical
218844068|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
219454219|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
219454220|NCT01814189|DRUG|Sumatriptan+Promethazine (SPr)|
219589869|NCT06990516|DRUG|Bevacizumab|"Dose: 15 mg/kg, administered IV Q3W.~Infusion Duration:~First dose: 90 minutes. Second dose: If the first infusion is well-tolerated, may be shortened to 60 minutes.~Subsequent doses: If the 60-minute infusion is well-tolerated, all following infusions may be administered over 30 minutes (including flush phase)."
219589870|NCT06990191|BEHAVIORAL|Partnered Prolonged Exposure (PPE)|The PPE condition adapts the PE protocol with strategies from Integrative Behavioral Couples Therapy (an evidence-based couple therapy. PPE involves twice-weekly 60-minute sessions, with some sessions completed by both the Veteran and their partner while others are with the Veteran only.
219589871|NCT06990191|BEHAVIORAL|Prolonged Exposure (PE)|The PE condition will follow the standardized PE manual and involve weekly 90-minute sessions and a 30-minute check-in attended only by the Veteran and the therapist.
219454221|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
219589872|NCT06990126|DRUG|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid(BALF)
218844069|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
219454222|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
219589873|NCT06990165|DEVICE|Photobiomodulation|Photobiomodulation applications will be performed within 1 hour after the radiotherapy session, covering the entire irradiated area, three times per week, starting from the first day of radiotherapy. The procedure will be conducted using the Antares/IBRAMED® device, with a cluster applicator featuring a 20 cm² contact area and two distinct wavelengths: four infrared laser diodes (808 nm), each with a power of 180 mW, and three red light diodes (630 nm), each with a power of 150 mW. Each diode will deliver 3 J of energy, with the wavelengths applied separately and sequentially.
218844070|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
218844071|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
218844072|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
218844073|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
218844074|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
218844075|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
219589874|NCT06990165|OTHER|Sham Control|Group B will have the device in contact with the irradiated area, following the same protocol as Group A, but with the device turned off, receiving no therapeutic light and, therefore, experiencing no biological effects from the light.
219454223|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
218844076|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
218844077|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
219454224|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
219454225|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
219454226|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
219454227|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
219454228|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
218844078|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
218844079|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
218844080|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
218844081|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
218844082|NCT06241924|PROCEDURE|High Resolution Electroencephalogram (EEG-HR)|Local field potentials (LFP) recording using EEG-HR
218844083|NCT06241924|PROCEDURE|Stereo-electro-encephalography (SEEG)|Local field potentials (LFP) recording using sEEG
218844084|NCT06007339|DEVICE|PerQseal ELITE|"The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
218844085|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
218844086|NCT04677595|DRUG|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
218844087|NCT04021108|DRUG|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
219454229|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
218844088|NCT05364684|DRUG|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
218844089|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
219454230|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
219454231|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
219454232|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
219454233|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
219454234|NCT01032057|DRUG|capecitabine|
219454235|NCT01032057|DRUG|gemcitabine hydrochloride|
219454236|NCT01032057|PROCEDURE|quality-of-life assessment|
219454237|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
219454238|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
219454239|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
219454240|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
219454241|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
219454242|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
219454243|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
219454244|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
219589875|NCT03347006|DIETARY_SUPPLEMENT|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
219589876|NCT03045471|DRUG|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
219589877|NCT03045471|DRUG|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
219589878|NCT03504280|DRUG|Cholecalciferol|
219454245|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
219454246|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
219454247|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
219454248|NCT01685372|BIOLOGICAL|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
219454249|NCT01685372|BIOLOGICAL|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
219454250|NCT05790967|OTHER|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
219589879|NCT03918109|DRUG|OTO-313|single intratympanic injection of gacyclidine
219589880|NCT03918109|DRUG|Placebo|single intratympanic injection of placebo
219589881|NCT04499365|DRUG|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
219589882|NCT04499365|DIAGNOSTIC_TEST|PET/CT scan|PET/CT scan
219589883|NCT05993117|DEVICE|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
218844090|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
218844091|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
218844092|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
218844093|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
219018047|NCT02998333|PROCEDURE|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
218844094|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
219454251|NCT03224832|PROCEDURE|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
219454252|NCT03224832|PROCEDURE|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
218844095|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
218844096|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
218844097|NCT05307640|BEHAVIORAL|CG-Well|CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support
219454253|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
219454254|NCT06054594|OTHER|Resistance exercise|After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
219454255|NCT02055872|DRUG|Intravenous albumin|
219454256|NCT02055872|DRUG|Normal saline|
219454257|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
218844098|NCT05307640|BEHAVIORAL|Information Support & Referral (ISR)|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
219454258|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
219454259|NCT04966806|PROCEDURE|LASIK refractive surgery|laser vision correction for myopic eyes
219454260|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
219454261|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
219454262|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
219454263|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
219454264|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
219454265|NCT02136264|OTHER|PCFA interventional dietary counselling|
219454266|NCT02136264|OTHER|conventional DASH diet counselling|
219454267|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
219454268|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
219454269|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
218844099|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in cases group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
218844100|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in control group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
218844101|NCT02265536|DRUG|LY3022855|Administered IV
219454270|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
219454271|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
218844102|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
219454272|NCT02089191|DEVICE|Nelfilcon A contact lenses|
219454273|NCT02089191|DEVICE|Stenfilcon A contact lenses|
219454274|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound and neurostimulator|
218844103|NCT05975619|DEVICE|HyperSight imaging|Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
218844104|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
219454275|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound|
219454276|NCT02721290|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
219454277|NCT02789800|BEHAVIORAL|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
219454278|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
219454279|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
218844105|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
218844106|NCT02905539|DRUG|Iron Isomaltoside 1000|
219454280|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
219454281|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
219454282|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
219454283|NCT06234891|DRUG|Nsaid|Medical treatment
219454284|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
219454285|NCT00005066|DRUG|O6-benzylguanine|
219454286|NCT00005066|DRUG|carmustine|
219454287|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
219454288|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
218844107|NCT02905539|DRUG|Ferric Carboxymaltose|
218844108|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
218844109|NCT02048137|DEVICE|Transcranial direct current stimulation|
219454289|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
219454290|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
219454291|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
219454292|NCT06976775|BIOLOGICAL|"Rush regimen"|"The rush regimen consists of the administration of several incremental doses daily, every day, over the first week of the Induction Phase (Part 1)"
219454293|NCT06976775|BIOLOGICAL|"Conventional regimen"|"The conventional regimen consists of the administration of only one incremental dose every 2 weeks, throughout all the Induction Phase (Part 1)"
219454294|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
219454295|NCT05594667|DRUG|Psilocybin|25mg of psilocybin provided by Filament Health
219454296|NCT02061540|DRUG|LUM001|LUM001 oral dose
219454297|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
219454298|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
219454299|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
219454300|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
219454301|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
219454302|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
219589884|NCT02983136|BEHAVIORAL|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
219589885|NCT01501864|BEHAVIORAL|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
219589886|NCT06137690|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
218844110|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
218844111|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
218844112|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
218844113|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
218844114|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
218844115|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
218860111|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
219454303|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
219454304|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
219454305|NCT00004064|BIOLOGICAL|oregovomab|
219454306|NCT04198311|BEHAVIORAL|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
219454307|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
219454308|NCT00068549|DRUG|Cisplatin|Given IV
219454309|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
219454310|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
219454311|NCT03042494|DIETARY_SUPPLEMENT|Control|Isocaloric food without the test prebiotic.
219454312|NCT03042494|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
219454313|NCT03955120|BEHAVIORAL|Dayzz mobile sleep training|"1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
219454314|NCT03955120|OTHER|Treatment as usual|Standard medical care for specific sleep condition
219454315|NCT05562700|OTHER|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~* Socio-demographic questions: age, height, weight, smoking status, etc.~* Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~* Functional results"
219589887|NCT02799368|DRUG|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
219454316|NCT02289833|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
218844116|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
219589888|NCT02799368|DRUG|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
219589889|NCT02320760|BEHAVIORAL|Physical activity on prescription|
219589890|NCT02733926|OTHER|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
219589891|NCT00839592|OTHER|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
218844117|NCT05822570|DIAGNOSTIC_TEST|Assessment of Oxygen Dissociation Curve (ODC)|ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery
218844118|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
218844119|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
218844120|NCT06078592|DRUG|BRIDIN-plus Eye drops|BRIDIN-plus Eye drops
218844121|NCT06078592|DRUG|Combigan Eye drops|Combigan Eye drops
218844122|NCT06149520|DRUG|BAY3018250|Dose 1 or dose 2 of BAY3018250
218844123|NCT06149520|DRUG|Placebo to BAY3018250|Matching placebo to BAY3018250
218844124|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
218844125|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
219454317|NCT03526692|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
219454318|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
219454319|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
219454320|NCT00005555|BEHAVIORAL|Exercise|
219454321|NCT01227252|DRUG|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
219454322|NCT01227252|DRUG|Placebo|Administered orally as capsules, daily for 14 days
219454323|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
219589892|NCT00378404|DRUG|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
219589893|NCT00378404|RADIATION|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
219589894|NCT03473769|OTHER|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
219589895|NCT03473769|OTHER|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
219454324|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
219589896|NCT04063436|DEVICE|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
219454325|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
219589897|NCT02448264|DRUG|BCX7353|
219589898|NCT02448264|DRUG|Placebo to match BCX7353|
219589899|NCT04549753|DEVICE|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
219589900|NCT03220347|DRUG|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
219589901|NCT02078427|BIOLOGICAL|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
219589902|NCT02078427|BIOLOGICAL|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
219589903|NCT06009627|DRUG|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
218844126|NCT06579404|DEVICE|CamAPS HX|"The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm"
219196918|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
219454326|NCT03501381|DRUG|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
219454327|NCT03501381|DRUG|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
219454328|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
219454329|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
219454330|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
219454331|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
219454332|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
219454333|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
219454334|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
219454335|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
219454336|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
219454337|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
219454338|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
219454339|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
219454340|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
219454341|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
219589904|NCT06009627|DRUG|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5\. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6\. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
219589905|NCT03677076|OTHER|Ancillary/Correlative|Collection of research blood and urine
219589906|NCT04651894|DEVICE|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
218844127|NCT06579404|OTHER|Standard insulin therapy with glucose sensor|Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
218844128|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
218844129|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
218844130|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
218844131|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
218844132|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
218844133|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
219196919|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
219196920|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
219196921|NCT05652010|DEVICE|New 2-piece Coupling|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with new 50mm Ø coupling.
219196922|NCT05652010|DEVICE|SenSura Mio Click|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with 50mm Ø coupling.
219196923|NCT04513951|DRUG|5Fluorouracil|phase II
219196924|NCT04513951|DRUG|L-leucovorin|phase II
218844134|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
218844135|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
219589907|NCT01023191|PROCEDURE|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
218844136|NCT04113018|DRUG|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
218844137|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
218844138|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
218844139|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
218844140|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
218844141|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
219454342|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
219454343|NCT02561273|DRUG|Cyclophosphamide|Given IV
219454344|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
219454345|NCT02561273|DRUG|Etoposide|Given IV
219454346|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
219454347|NCT02561273|DRUG|Lenalidomide|Given PO
219454348|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
219589908|NCT01023191|PROCEDURE|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
219589909|NCT05004584|OTHER|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
219589910|NCT05004584|OTHER|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
219589911|NCT05004584|OTHER|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
219589912|NCT05004584|OTHER|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
219589913|NCT05004584|OTHER|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
218844142|NCT03016624|DEVICE|OCT guided PCI|oct guided
218844143|NCT03016624|DEVICE|Angiography guided PCI|angio guided
218844144|NCT06678139|OTHER|physiotherapy|Bilateral gastrosoleus stretching, iliopsoas and hamstring stretching (if a shortness is detected), foot intrinsic and extrinsic muscle strengthening, lower extremity muscle strengthening and parkour walking training will be performed. Therapeutic exercises will be performed once a week for 12 weeks under the supervision of a physiotherapist. Parents will be asked to follow a 12-week home exercise program at home during the five days. The home exercise program will include the exercises performed in the pediatric physiotherapy and research laboratory. Parents will be instructed to perform each exercise twice a day at home. Children will be given a weekly exercise diary to increase adherence to the exercise program.
218844145|NCT05047913|DRUG|18F-FTX|Given By IV
218844146|NCT05005013|OTHER|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
219454349|NCT02561273|DRUG|Prednisone|Given PO
219454350|NCT02561273|DRUG|Vincristine Sulfate|Given IV
219454351|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
219454352|NCT03017833|OTHER|Laboratory Biomarker Analysis|Correlative studies
219454353|NCT03017833|DRUG|Metformin|Given PO
219454354|NCT03017833|OTHER|Pharmacological Study|Ancillary studies
219454355|NCT03017833|DRUG|Sapanisertib|Given PO
219454356|NCT01071369|DRUG|Xylocaine|0.5% Xylocaine
219454357|NCT01071369|DRUG|Xylocaine and Celestone|non-particulate Celestone
219454358|NCT00724646|OTHER|Survey|3 individual surveys
219454359|NCT00724646|OTHER|Focus group|Focus group discussions facilitated by a psychologist
218844147|NCT05005013|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
218844148|NCT05005013|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
218844149|NCT06073457|DEVICE|MagGJ System|Anastomoses achieved by magnetic compression.
218844150|NCT06651853|DRUG|Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab|"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."
218844151|NCT06977113|OTHER|High Fibre Fermented Food Diet|Participants will be provided with and asked to consume specific foods high in various types of fibre to promote a variety of substrates for gut bacteria including inulin, galactooligosaccharides (GOS), and β-glucan. Participants will also be asked to consume 2 fermented items, yogurt and kefir. Study foods will be commercially available including a high-fibre bar made from chicory-derived inulin (1 bar of 35 g/d), oat-containing cakes (4 oatcakes of 35 g/d) or oat porridge (1 sachet of 38.5 g/d), shredded wheat cereal biscuits (2 biscuits of 45 g/d), hummus (½ pot of 100 g/d), and/or baked beans (½ can of 100 g/d) or lentil soup (1 can of 400 g/d), and low fat yogurt (1/3 pot of 150 g/d) and kefir (½ bottle of 250 ml/d). The total amount of fibre study foods will provide is approximately 25 g/day which will be consumed in addition to the habitual diet. The total amount of fibre will be expected to reach the 30 g/day recommendation and will range between 25 - 40 g/day.
218844152|NCT06977113|OTHER|Control Habitual Diet|Participants will follow their habitual diet and will not consume any of the study foods (i.e., high-fibre fermented foods). The population average fibre intake for women in Scotland is 16 g/day (The Scottish Health Survey 2021).
218844153|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
218844154|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
218844155|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
218844156|NCT03981094|DRUG|BMS-986278|suspension
218844157|NCT03981094|DRUG|Pirfenidone|capsule
218844158|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
218844159|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
218844160|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
218844161|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
218844162|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
219454360|NCT00262353|DEVICE|Dialysis with different artificial devices|
219454361|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
219454362|NCT01608555|DRUG|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
219454363|NCT03527836|DRUG|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
219454364|NCT03527836|DRUG|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
219454365|NCT03527836|DRUG|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
219454366|NCT01619527|DRUG|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
219454367|NCT01619527|DRUG|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
219454368|NCT03442595|OTHER|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
219589914|NCT02771886|BEHAVIORAL|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
218844163|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
219454369|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
218844164|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
218844165|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
218844166|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
218844167|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
218844168|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
218844169|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
218844170|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
218844171|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
218844172|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
218844173|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
218844174|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
218844175|NCT03435120|OTHER|No intervention|No intervention
219454370|NCT04705428|OTHER|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
219454371|NCT06302868|BEHAVIORAL|Telemedicine Exposure Therapy Using Photos and Videos|Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
219454372|NCT06302868|BEHAVIORAL|Telemedicine-Based Virtual Reality Exposure Therapy|Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
219589915|NCT03945669|PROCEDURE|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
218844176|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
218844177|NCT02604368|DRUG|SC411|Soft gelatin capsule
218844178|NCT02604368|DRUG|Placebo|Soft gelatin capsule
218844179|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
218844180|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
218844181|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
218844182|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
218860112|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
219196925|NCT04513951|DRUG|Irinotecan|phase II
219454373|NCT03817749|DIETARY_SUPPLEMENT|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
219589916|NCT03945669|PROCEDURE|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
219589917|NCT01980966|DRUG|MHAA549A|IV dose
219589918|NCT01980966|DRUG|Placebo|IV dose
219589919|NCT01980966|DRUG|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
219589920|NCT00229983|BEHAVIORAL|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
219589921|NCT03346486|OTHER|Control diet|Regular diet
219454374|NCT02077972|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
218844183|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 \_\_\_ Dyspepsia: 1 \_\_\_ Uncomplicated ulcer: 2 \_\_\_ Complicated ulcer 3 \_\_\_ NSAID 2 \_\_\_ Steroids 2 \_\_\_ SSRI 2 \_\_\_ Anticoagulant Tx 2 \_\_\_"
218844184|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
218844185|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
218844186|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
218844187|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
219454375|NCT04739917|BIOLOGICAL|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
219454376|NCT04739917|OTHER|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
219454377|NCT05165004|BEHAVIORAL|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
219454378|NCT05165004|BEHAVIORAL|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
218844188|NCT04734483|RADIATION|MRI and CT|MRI and CT
218844189|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
218844190|NCT04734483|OTHER|electromyography|electromyography
218844191|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
218844192|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
218844193|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
218844194|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
218844195|NCT01555034|BEHAVIORAL|movement therapy|exercise, nutrition, movement therapy
218844196|NCT01555034|OTHER|exercise plus nutrition|exercise, nutrition
218844197|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
219196926|NCT04513951|DRUG|Oxaliplatin|phase II
219196927|NCT04513951|DRUG|Cetuximab|phase II
219196928|NCT04513951|DRUG|Avelumab|phase II
219454379|NCT05165004|BEHAVIORAL|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
219454380|NCT06593626|DRUG|[18F]Florbetazine|Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
219454381|NCT05135468|DRUG|CU-40102 Spray|topical application, 1\~4 sprays each time, once daily
219454382|NCT05001581|PROCEDURE|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
219454383|NCT05001581|PROCEDURE|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
219454384|NCT04233840|DRUG|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
219589922|NCT03346486|OTHER|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
219589923|NCT00638027|DRUG|placebo|matched tablets bid
219589924|NCT00638027|DRUG|memantine|10 mg bid
218844198|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
218844199|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
218844200|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
218844201|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
218844202|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
218844203|NCT02832557|OTHER|Medical history questionaire|
219454385|NCT04233840|DRUG|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
219454386|NCT04099225|DIAGNOSTIC_TEST|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
219454387|NCT01126567|OTHER|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
219589925|NCT00370812|PROCEDURE|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
219589926|NCT04008654|BEHAVIORAL|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
219589927|NCT04008654|BEHAVIORAL|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
219589928|NCT00593047|DRUG|KB2115|tablet formulation given once daily for 12 weeks
218844204|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
219589929|NCT03139227|PROCEDURE|Bio specimen Collection|Patients undergo collection of blood and urine
219589930|NCT03139227|DIETARY_SUPPLEMENT|Dietary Intervention|Consume celery-banana bread
218844205|NCT02832557|OTHER|Mullen Scales of Early Learning|
218844206|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
219454388|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
219454389|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
219454390|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
219454391|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
219454392|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
219589931|NCT03139227|OTHER|Laboratory Biomarker Analysis|Correlative studies
219589932|NCT03463473|DRUG|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
219589933|NCT03463473|DRUG|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
219589934|NCT03463473|DRUG|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
219589935|NCT03463473|DRUG|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
219589936|NCT03014180|DEVICE|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
218844207|NCT02504398|OTHER|Fast injection speed by immunizer|
218844208|NCT02504398|OTHER|Slow injection speed by immunizer|
218844209|NCT02791516|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
218844210|NCT02791516|DRUG|Placebo|Administered by subcutaneous injections once a month
218844211|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
218844212|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
218844213|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
218844214|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
218844215|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
219454393|NCT06336447|OTHER|Experimental: Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
219454394|NCT06336447|OTHER|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
219454395|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219454396|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
218844216|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
219454397|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
219589937|NCT03261986|RADIATION|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
219589938|NCT03261986|PROCEDURE|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
218844217|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
218844218|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
218844219|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
218844220|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
219454398|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
219589939|NCT04592835|DRUG|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
218844221|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
218844222|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
218844223|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
218844224|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
219454399|NCT04324476|DRUG|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
219454400|NCT00102336|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
219454401|NCT00102336|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
219454402|NCT03031990|BEHAVIORAL|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
219589940|NCT02392351|DEVICE|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
219589941|NCT02392351|DEVICE|Renal Angiography|Percutaneous renal angiography
219589942|NCT02802631|DRUG|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
219589943|NCT02802631|OTHER|Placebo|Placebo - Normal Saline
219589944|NCT04579016|OTHER|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
219589945|NCT04579016|OTHER|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
219589946|NCT05224934|RADIATION|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
219589947|NCT06955091|OTHER|contrast strength training|For eight weeks players performed Contrast strength training included bench press, pull-over, half squat, and forward lunge. Each session began with a 10-minute warm-up (jogging, dynamic stretching, and basic weightlifting exercises) and ended with a 5-minute cool-down. Training was performed twice a week for 8 weeks on non-consecutive days (Tuesday and Thursday). Exercises were done using free weights at 40-80% of 1-repetition maximum, in 3-4 sets of 2-4 repetitions
219589948|NCT03395405|DRUG|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
219589949|NCT03395405|OTHER|Placebo|One tablet twice daily with food for 56 consecutive doses
218844225|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
218844226|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
218844227|NCT06061705|PROCEDURE|Tumor Biopsy|"Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination."
219454403|NCT03031990|BEHAVIORAL|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
219454404|NCT03031990|BEHAVIORAL|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
219454405|NCT01253941|OTHER|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
219454406|NCT03249480|BIOLOGICAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
219589950|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
219589951|NCT05499286|OTHER|Mindfulness Program|Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
219589952|NCT02713919|BEHAVIORAL|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
219454407|NCT04509297|DIETARY_SUPPLEMENT|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
219454408|NCT04509297|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
219454409|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
219454410|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
219454411|NCT02114918|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
219454412|NCT02114918|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
219454413|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
219454414|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
219589953|NCT01364181|DRUG|Udenafil|Udenafil 50mg qd po
219589954|NCT00315887|DRUG|Buprenorphine transdermal delivery system|
219589955|NCT00000378|DRUG|Sertraline|12 week trial dose up to 200mgs
219589956|NCT00000378|DRUG|Nortriptyline|12 week trial dose adjusted to therapeutic level
219589957|NCT05158088|DEVICE|Borescope|Endotracheal intubation using borescope
219589958|NCT05158088|DEVICE|Video laryngoscope|Endotracheal intubation using video laryngoscope
219589959|NCT05746598|DRUG|Cisplatin injection|Cisplatin 75mg/m2
219454415|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
219454416|NCT05008367|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
219454417|NCT05008367|DRUG|Isotonic saline|6 ml of isotonic saline
219589960|NCT04556071|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
219589961|NCT04556071|DRUG|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
219589962|NCT00009815|DRUG|etoposide|
219589963|NCT00009815|DRUG|leucovorin calcium|
219589964|NCT00009815|DRUG|tegafur-uracil|
219589965|NCT06344585|OTHER|Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation|"A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries."
219589966|NCT01129687|PROCEDURE|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
219589967|NCT01129687|PROCEDURE|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
219589968|NCT03035929|DRUG|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
219589969|NCT02886624|DRUG|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
219589970|NCT05496244|DEVICE|Laparoscopy|Laparoscopic surgery
219589971|NCT05496244|DEVICE|Robotic-assisted surgery|Robotic-assisted surgery
219589972|NCT06490185|OTHER|Clinical data collection|Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
219589973|NCT01235481|DEVICE|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
219589974|NCT01235481|BEHAVIORAL|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
219589975|NCT06626464|DRUG|[14C]MK-8189|Oral administration
219018057|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
219454418|NCT02240524|PROCEDURE|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
219454419|NCT02240524|PROCEDURE|Systemic chemotherapy|
219454420|NCT02240524|PROCEDURE|HIPEC|
219454421|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
219454422|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
219454423|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
219454424|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
219454425|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
219454426|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
219454427|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
219454428|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
219454429|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
219454430|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
219454431|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
219454432|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
219454433|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
219454434|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
219454435|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
219454436|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
219589976|NCT06633705|DRUG|Vaginal Cream with Applicator|Vaginal Cream that contains estriol (1mg estriol in 1 g cream)
219589977|NCT01047514|BEHAVIORAL|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
219589978|NCT03972163|BEHAVIORAL|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
219454437|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
219454438|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
219454439|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
219454440|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
219454441|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
219454442|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
219454443|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
219454444|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
219454445|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
219454446|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
219454447|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
219454448|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
219454449|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
219454450|NCT03227692|DEVICE|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
219454451|NCT03227692|PROCEDURE|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
219454452|NCT03227692|DEVICE|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
219454453|NCT02448095|DRUG|Ponatinib|Observation of tolerability and safety profiles
219454454|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
219454455|NCT02108795|DRUG|Placebo|
219454456|NCT05064943|DIAGNOSTIC_TEST|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
219454457|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
218844228|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
218844229|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
218844230|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
219454458|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
219454459|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
219454460|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
218844231|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
218844232|NCT06669507|BEHAVIORAL|Chronotherapy|"1. The effect of light exposure follows a phase-response curve where circadian phase advancement is strongest in the biological morning, whereas light in the biological evening/night may lead to a phase delay. Light therapy is provided by 30 min light exposure using 10 000 lux light boxes.~2. Melatonin 3 milligram is prescribed in tablet forms (not depot), usually 12 hours before the planned rise time.~3. Additionally, blue-light-blocking glasses are used to block light exposure at night, which has been found to advance circadian rhythms. Patients are advised to wear their blue-blocking glasses 12 hours before rise time.~Which chronotherapeutic interventions that are used, is considered individually by the clinicians in the Sleep Clinic, but often all three treatment components are used at the same time. Duration of chronotherapy given in the Sleep Clinic vary from 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment."
219454461|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
219454462|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
219454463|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
219454464|NCT03710291|DRUG|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
219589979|NCT03972163|BEHAVIORAL|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
219454465|NCT03710291|DRUG|Placebo|Placebo comparator
219454466|NCT04323917|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
219454467|NCT04456803|DRUG|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
219454468|NCT04456803|DRUG|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
219454469|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
219454470|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
219454471|NCT06084065|DEVICE|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
219454472|NCT04731194|BEHAVIORAL|Performance-based financial incentive program|"1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
219589980|NCT03972163|BEHAVIORAL|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
219589981|NCT03972163|BEHAVIORAL|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
219589982|NCT01260519|DRUG|Heparin|unfractionated heparin 2000 unites
219589983|NCT00799448|DRUG|repaglinide|
219589984|NCT00799448|DRUG|biphasic human insulin 30|
219589985|NCT00799448|DRUG|insulin NPH|
219589986|NCT01119183|BEHAVIORAL|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
218844233|NCT06669507|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|All participants will receive treatment as usual. CBT-I has several components and consists of the following interventions including psychoeducation about sleep: sleep hygiene, sleep restriction therapy, stimulus control, and challenging beliefs and perceptions of sleep. Special emphasis is placed on providing a rationale for behavior change as a primary means of improving sleep as well as addressing dysfunctional beliefs the patients may hold about sleep. During treatment, tapering sleep medication is not necessary. However, if the patients are motivated to do so, this is discussed and a plan for tapering is provided. Treatment duration is typically between 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment.
219454473|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
218844234|NCT06669442|BEHAVIORAL|Guided Imagery|Guided imagery is a mindfulness based therapeutic technique that involves utilizing positive imagery allowing one to cultivate awareness of their mental state and shift their attention from ruminative thought patterns to the present moment. Evidence-based research shows that benefits of Guided imagery include relaxation, stress reduction, anxiety reduction, immune system enhancement, and overall well-being.
218844235|NCT06681818|OTHER|carbon monoxide measurement via smokerlyzer|participants in this study will provide breath samples for carbon monoxide measurements pre and post liver resection
219454474|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
219454475|NCT00952588|DRUG|AZD1152|1200 mg, iv, 7 day infusion
218844236|NCT00211757|DRUG|Divalproex sodium|Study drug.
218844237|NCT00211757|DRUG|Placebo|Placebo comparator.
218844238|NCT06625385|DEVICE|3M™ V.A.C.® Peel and Place Dressing|Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
218844239|NCT07013916|DIETARY_SUPPLEMENT|fructose|Fructose powder
218844240|NCT07013916|DIETARY_SUPPLEMENT|glucose|Glucose powder
218844241|NCT06657794|DEVICE|Implantation of Physician-Modified Terumo Aortic TREO abdominal stent graft system|A Physician Modified Endograft is a commercially available, off-the-shelf endograft that has been altered at the time of the procedure by creating fenestrations in the seal zone of the graft to preserve blood flow into vital branch vessels. These fenestrations are marked with medical grade gold markers to facilitate fluoroscopic visualization during the procedure. In order to prevent branch vessel occlusion, these branch vessels are typically stented with covered balloon expandable stents using standardized techniques.
218844242|NCT07020923|DRUG|Atacicept|Drug: Atacicept
218844243|NCT07024953|OTHER|Chronic Kidney Disease Structured Agenda-Setting Tool|Chronic Kidney Disease (CKD) Topics is a novel clinical visit agenda-setting intervention developed through participatory research methods for people with CKD living in rural areas. CKD Topics includes structured discussion topic areas.
218844244|NCT07023328|BEHAVIORAL|A structured ball exercise program|Pre-frail older adults will undergo a structured ball exercise program
218844245|NCT07023471|DEVICE|Group A (Trainee --> expert)|The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.
218844246|NCT07023471|DEVICE|Group B (Trainee +AI --> expert)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
219018058|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
219454476|NCT00952588|DRUG|LDAC|20 mg, sc, bd, 10 days
219454477|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
219589987|NCT01119183|BEHAVIORAL|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
218844247|NCT07023471|DEVICE|Group C (Trainee --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
219196929|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
219196930|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
219454478|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
219454479|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
219454480|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
219589988|NCT05430984|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|"Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh."
219589989|NCT04177784|OTHER|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
219589990|NCT00513279|DRUG|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
219589991|NCT00513279|DRUG|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
219589992|NCT04701086|DEVICE|Cationorm Pro|Eye Drops
219018061|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
219454481|NCT03596320|PROCEDURE|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
219454482|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
219454483|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219454484|NCT00515866|DRUG|Gemcitabine|intravenous injection
219454485|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
219589993|NCT04701086|DEVICE|Vismed|Eye Drops
219589994|NCT00093873|DRUG|Anti-angiogenesis|Anti-angiogenesis
219589995|NCT00093873|DRUG|AMG 706|Anti-angiogenesis
219454486|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
219454487|NCT05972122|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219454488|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
219454489|NCT05647928|OTHER|no intervention|no intervention
219589996|NCT01944176|DRUG|simvastatin, placebo|
219589997|NCT05119348|OTHER|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
219454490|NCT02795182|DRUG|Zanubrutinib|
218844248|NCT07023471|DEVICE|Group D (Trainee + AI --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
218844249|NCT04066504|DRUG|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
218844250|NCT07027059|BEHAVIORAL|median nerve mobilization|An exercise to increase median nerve mobility by flexing and extending fingers, wrist, elbow, shoulder, and neck
219454491|NCT02795182|DRUG|Tislelizumab|
219454492|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
219454493|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
219454494|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
219454495|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
219454496|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
219454497|NCT02280109|DRUG|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
219454498|NCT02280109|DRUG|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
219454499|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
218844251|NCT07027059|BEHAVIORAL|routine exercises for lateral epicondylisits|eccentric strengthening exercises
218844252|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
218844253|NCT07028346|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a first-line, non-medication treatment for insomnia that helps individuals identify and change the thoughts and behaviors that contribute to their sleep problems.
218844254|NCT07028346|BEHAVIORAL|Sleep Education|Sleep Education group comprises psychoeducation sessions on sleep hygiene.
219589998|NCT05658458|DRUG|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
219589999|NCT03257865|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
219454500|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
218844255|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
218844256|NCT07034482|DRUG|Intralesional Triamcinolone 5 mg/ml|Solution containing 5 mg TAC was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
219454501|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
218844257|NCT07034482|DRUG|Intralesional 5-fluorouracil|Solution containing 45 mg 5-FU was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
218844258|NCT07034391|DRUG|denosumab combined anti-PD-1 inhibitor with chemotherapy|120mg of denosumab，d1 in a 28-days cycle；200mg of anti-PD-1 inhibitor, d1 in a 21-days cycle；500mg/m2 of pemetrexed, d1 in a 21-days cycle; AUC4-5 of carboplatin, d1 in a 21-days cycle, for 4-6 cycle
218844259|NCT07032792|DRUG|FEIBA|Subjects randomized to FEIBA will receive up to 2 vials of 500U of FEIBA through a preexisting central line at a rate that does not exceed 2 units per kg of body weight per minute for the study intervention.
218844260|NCT07032792|DRUG|FFP|Subjects randomized to FFP will receive up to 2 units of FFP intravenously through a preexisting central line.
219454502|NCT00348192|DRUG|SB-742457|
219590000|NCT03257865|DRUG|Placebo|Administered orally daily for 3 weeks.
219590001|NCT04444674|BIOLOGICAL|ChAdOx1 nCoV-19|Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
219590002|NCT04444674|BIOLOGICAL|Normal saline 0.9%|Normal saline 0.9% as placebo
219590003|NCT00111826|DEVICE|Celacade™ system|
219590004|NCT00002960|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
219590005|NCT02991326|OTHER|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;"
219590006|NCT02991326|OTHER|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
218844261|NCT07034599|DEVICE|Negative pressure ventilation|All participants are ventilated with negative pressure ventilation first
218844262|NCT07034599|DEVICE|positive pressure ventilation|All participants are ventilated using positive pressure ventilation after negative pressure ventilation
219590007|NCT02021357|BEHAVIORAL|hyperbolid combined with tongue exercises on the palate|
219590008|NCT02021357|OTHER|hyperbolid|
219590009|NCT04380766|PROCEDURE|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
219590010|NCT04675814|OTHER|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
218844263|NCT07034040|BEHAVIORAL|SmaRTWork|The SmaRTWork app provides weekly individually tailored self-management plans by matching the participant's health information and sick leave status with targeted educational messages, physical activity advice, and exercise recommendations. In addition, participants with specific problems regarding i) work accommodations, ii) workplace conflicts, iii) large responsibilities as caregivers, iv) financial problems, or v) who do not think they will return to the old workplace are offered to be set in contact with a caseworker at the social insurance office. The intervention is given in addition to usual care.
219454503|NCT00348192|DRUG|donepezil|
219454504|NCT02737371|DRUG|F901318 Dose level A oral|Adverse events days 1-10
219454505|NCT02737371|DRUG|Placebo dose level A oral|Placebo adverse events days 1-10
219454506|NCT02737371|DRUG|F901318 Dose level B oral|F901318 adverse events days 1-10
219454507|NCT02737371|DRUG|Placebo dose level B oral|Placebo adverse events days 1-10
219454508|NCT02737371|DRUG|F901318 Dose level C oral|F901318 adverse events days 1-10
219454509|NCT02737371|DRUG|Placebo Dose level C oral|Placebo adverse events days 1-10
219590011|NCT03429010|PROCEDURE|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
219590012|NCT03792295|DRUG|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
219590013|NCT03792295|DRUG|Oxycodone|Classic opiod pain treatment group
219590014|NCT01366950|BEHAVIORAL|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
219590015|NCT01496300|PROCEDURE|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
219590016|NCT01496300|PROCEDURE|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
219454510|NCT00261378|DEVICE|Transarterialchemoembolisation (TACE)|
219454511|NCT00261378|DEVICE|DC Bead with Doxorubicin|
219454512|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
219454513|NCT00095134|DRUG|risperidone|
219454514|NCT06980168|OTHER|kabat technique|kabat technique include diagonal movements to activate weak muscles through resistance . 3-5 repetetion per muscle for 2-3 sets .session conducted 5 days per week for three weeks each lasting 30 minutes .
218844264|NCT07032753|DEVICE|eOPRA|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system for transhumeral amputees.
219454515|NCT06980168|OTHER|facial nerve mobilization|neural mobilization involves manual traction and circular movement around ear to enhance nerve mobility and function .5-10 repetetions .Session conduted 5 days per week for 3 weeks lasting 30 minutes facial exercises include raising eyebrows-eye closure-lip raising-smiling-snarling flaring of nose-forehead wrinkling-lipspuckering-pouting. 5-10 repetetions 3 times a day .7 days for 3 weeks
219454516|NCT01021553|DRUG|GSK557296|50 mg GSK557296
219454517|NCT01021553|DRUG|GSK557296|150 mg GSK557296
219454518|NCT01021553|DRUG|placebo|placebo
219454519|NCT00006493|DRUG|Rosiglitazone|
219454520|NCT00997607|BIOLOGICAL|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
219454521|NCT00997607|BIOLOGICAL|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
219590017|NCT04182282|BEHAVIORAL|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
219454522|NCT00997607|OTHER|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
219454523|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
219454524|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
219454525|NCT01579526|DRUG|FP01|comparison of different dosages
219454526|NCT02744781|DEVICE|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
219454527|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
219590018|NCT06079346|DRUG|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
218844265|NCT07032753|DEVICE|OPRA|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations
218844266|NCT07032753|DEVICE|eOPRA with sensory feedback|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations with sensory feedback.
218844267|NCT07032753|DEVICE|eOPRA without sensory feedback|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations without sensory feedback.
218844268|NCT07033377|OTHER|Self-administered paper-based questionnaires|Participants will complete the Persian version of the CBQ-NSCLBP and other self-report measures as part of a psychometric validation study. No clinical or therapeutic intervention is involved.
218844269|NCT07034157|PROCEDURE|Percutaneous Coronary Intervention|Coronary stenting performed as part of routine care for patients with coronary artery stenosis.
218844270|NCT07034157|PROCEDURE|Cerebrovascular Intervention (CAS ）|Patients with intervention-indicated head and neck artery stenosis will receive carotid artery stenting based on clinical evaluation.
218844271|NCT07034157|OTHER|No Intervention / Observation|Clinical observation or standard follow-up in patients without significant disease
218844272|NCT07034872|OTHER|Control Group|Participants in the control group will receive two face-to-face physiotherapy sessions and one asynchronous video-based exercise training session per week for eight weeks. Following the baseline assessments, a conventional exercise program will be individually planned by the physiotherapist for each child. Each 60-minute session will include strengthening exercises for upper and lower extremity muscles, active and passive stretching exercises for spastic muscles, static and dynamic balance training in standing, and gait exercises.
218844273|NCT07034872|OTHER|Intervention Group|Following baseline assessments, a personalized 60-minute exercise program will be developed by the physiotherapist for each child in the intervention group, consisting of two face-to-face sessions and one asynchronous video-based session per week for eight weeks. Each session will include 30 minutes of multidimensional trunk-focused exercises-such as static and dynamic trunk control (e.g., reaching, rotational movements), scapular and pelvic mobilizations, isolated muscle training, proprioceptive activities, and core strengthening-followed by 30 minutes of conventional therapy, including upper and lower extremity strengthening, stretching for spastic muscles, balance training in standing, and gait exercises.
218844274|NCT07032805|PROCEDURE|personalized outpatient rehabilitation treatment after TKA|personalized outpatients rehabilitation treatment after TKA, including posturographic assessment, psychomotivational framing, and telemedicine-based rehabilitation interventions
218844275|NCT07032805|PROCEDURE|standard outpatient rehabilitation treatment after TKA|standard outpatient rehabilitation treatment after TKA
218844276|NCT06713798|DRUG|Atezolizumab 1200 mg IV|atezolizumab (intravenous 1200mg Q3W)
219196931|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
218844277|NCT06713798|DRUG|Tiragolumab 600 mg IV|Tiragolumab (intravenous 600mg Q3W)
219196932|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
219454528|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
219454529|NCT00033293|OTHER|Clinical Observation|Undergo observation
219590019|NCT06079346|DRUG|mFOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
219590020|NCT06515236|BEHAVIORAL|Strategic Treatment Assessment for Youth (STAY)|Culturally tailored measurement based care
219196933|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
219454530|NCT00033293|DRUG|Cyclophosphamide|Given IV
219454531|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
219454532|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
219454533|NCT00033293|DRUG|Prednisone|Given orally
219454534|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
219454535|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
219590021|NCT06515236|BEHAVIORAL|Measurement Based Care As Usual|Measurement based care as usual
219590022|NCT05267730|BEHAVIORAL|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
218844278|NCT07034443|DEVICE|High Intensity Focused Electromagnetic Stimulation|Patients will sit on the device, the high intensity for 28 minutes, twice a week for three weeks
218844279|NCT07032740|DIAGNOSTIC_TEST|Bruce test|In the Bruce test, a breath pattern was obtained by means of an OEP (once with a respirator and once without a respirator).
218844280|NCT06729502|OTHER|Questionnaire - Pictorial Fit-Frail Scale|All patients over 60 years old, or their caregivers, will be asked to fill the PFFS questionnaire
219196934|NCT04729751|DRUG|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
219590023|NCT06338761|BEHAVIORAL|Smoking cessation|Stop smoking
219590024|NCT06338761|BEHAVIORAL|Switching to E-cigarette|Switching to E-cigarette
219590025|NCT02538965|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
219196935|NCT06613243|DRUG|Esketamine 0.2 mg/kg|Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
219590026|NCT06359639|BEHAVIORAL|Cognitive restructuring|Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
218844281|NCT00050830|DRUG|CI 1033|
218844282|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
218844283|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
218844284|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
218844285|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
218844286|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
218844287|NCT07075510|DRUG|Daratumumab Injection|Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
218844288|NCT01198210|DRUG|saline|local peritonsillar infiltration of 2 ml saline,
218844289|NCT01198210|DRUG|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
218844290|NCT01198210|DRUG|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
218844291|NCT01198210|DRUG|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
218844292|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
218844293|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
218844294|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
218844295|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
218844296|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
219454536|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
219454537|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
219454538|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
219454539|NCT01592942|DEVICE|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
219454540|NCT01592942|DEVICE|Progrip|self-gripping mesh
219454541|NCT01592942|DEVICE|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
219454542|NCT02657109|OTHER|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
219454543|NCT03529175|DRUG|Abraxane (nab-paclitaxel)|
218844297|NCT07080398|DIAGNOSTIC_TEST|serum bilirubin level measurement|Total serum bilirubin levels and concurrent transcutaneous bilirubin measurements will be done and the results will be evaluated comperatively.
218844298|NCT07081490|OTHER|Virtual Escape Room Game|Virtual escape rooms are digital versions of physical escape rooms that can be accessed remotely. Virtual escape rooms are adaptations of physical escape rooms that use online interactive environments where participants aim to solve puzzles within a set timeframe.
218844299|NCT07080346|DRUG|Upadacitinib 15 MG|All the BS patients discontinued other biologic agents and received oral upadacitinib treatment at a dose of 15mg per day with background glucocorticoids and immunosuppressants for 48 weeks. All the patients will be followed up prospectively for 48 weeks.
218844300|NCT07081737|OTHER|Interdisciplinary treatment (IDT) + Clinical Decision Support System (CDSS)|Interdisciplinary treatment (IDT) combined with Clinical Decision Support System (CDSS)
218844301|NCT07081737|OTHER|Interdisciplinary treatment (IDT)|Interdisciplinary treatment (IDT)
218844302|NCT07079410|DRUG|Sintilimab+Cetuximab|Neoadjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week/cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles. Adjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week cycle, a total of 17 cycle) for a total of one year.
218844303|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
218844304|NCT06896656|BEHAVIORAL|Marigold Mobile Peer Support Intervention|"The MPS App is a secure platform that allows text-based peer support for individuals in recovery from OUD. Participants assigned to this condition will be enrolled on a rolling basis into a peer support group on the app. All participants will receive onboarding assistance and will have access to the app for 6 months.~The app will include live moderation from a certified Peer Recovery Support Specialist and trained research assistants. Moderators will begin discussions with prompts and regulate the flow of conversation with standardized text language. Moderators will be able to respond in real-time to malicious messages or other flags that could impact participant safety. Built in natural language processing algorithms will also detect language requiring intervention and automatically alter the moderators and on-call clinicians."
218844305|NCT06896656|BEHAVIORAL|Resources|A list of online peer support and mental health resources, drawn from SAMSHA and equivalent websites, will be provided to all participants, as an enhanced adjunct to their standard recovery plans.
218844306|NCT06895330|OTHER|Virtual Reality Group|A brief orientation regarding the use of the virtual reality headset will be provided to the children. One minute prior to the vaccination procedure, the selected video-either a roller coaster or Formula 1 experience, based on the child's preference-will be initiated through the virtual reality headset. Throughout the procedure, the children will continue to watch the video using the virtual reality headset.
218844307|NCT06895330|OTHER|Helfer Skin Tap Group|"The Helfer Skin Tap technique is applied to reduce pain and muscle tension during intramuscular injection by stimulating large nerve fibers through rhythmic tapping. After determining the injection site and preparing the skin with alcohol, the area is tapped for approximately 5 seconds using the dominant hand. The syringe is then held in the dominant hand while a V shape is formed with the non-dominant hand to tap the skin firmly three times. On the count of three, the needle is inserted at a 90° angle. After aspiration, the medication is injected slowly while gentle tapping continues to maintain muscle relaxation. The procedure concludes with simultaneous needle withdrawal and a final V-shaped tap to minimize discomfort."
218844308|NCT06749847|OTHER|Women receive invitation letter with HPV self-sampling kit|Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.
218844309|NCT06749847|OTHER|Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider|Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.
218844310|NCT07079371|PROCEDURE|Micellar Water Application (No Rinse)|Participants apply micellar water to the forehead once daily and leave it on the skin without rinsing for 21 days.
219454544|NCT03529175|DRUG|Gemcitabine|
218844311|NCT07079371|PROCEDURE|Micellar Water Application (With Rinse)|Participants apply micellar water to the forehead once daily and rinse it off after application for 21 days.
219454545|NCT05068427|DRUG|Chidamide|20mg or 30mg orally twice per week(BIW)
219454546|NCT05068427|DRUG|Envafolimab|400mg subcutaneous infusions every 4 weeks
219454547|NCT00878306|DRUG|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
219454548|NCT00878306|DRUG|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
219454549|NCT00878306|DRUG|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
219454550|NCT00878306|DRUG|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
219454551|NCT02946151|DEVICE|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
219454552|NCT02211950|DRUG|BI 44847|
219454553|NCT02211950|DRUG|Acarbose|
219454554|NCT02211950|OTHER|Japanese diet|
219454555|NCT04623255|DRUG|OCTAPLAS|plasma exchange
219454556|NCT06507098|OTHER|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.
219454557|NCT06507098|OTHER|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
219454558|NCT03850704|DRUG|Selinexor|
219454559|NCT06090929|DEVICE|STN-DBS|STN-DBS was implanted according normal process
219454560|NCT01518634|DRUG|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
219454561|NCT01518634|DRUG|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
218844312|NCT07080983|PROCEDURE|Crosslinking|Corneal Cross-Linking (CXL) is a minimally invasive procedure used to strengthen the cornea by increasing the chemical bonds between collagen fibers. It is primarily used to treat keratoconus and corneal ectasia, conditions where the cornea becomes progressively thinner and weaker.
218844313|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
218844314|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
218844315|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
218844316|NCT03296748|PROCEDURE|anterior colporraphy|
219454562|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
219454563|NCT01092949|DEVICE|MRI|MRI, 45 minutes
219590027|NCT06359639|BEHAVIORAL|Supportive counselling|Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
219590028|NCT00551018|DRUG|Vicriviroc|one 30 mg tablet QD
218844317|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
218844318|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
218844319|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
219590029|NCT00551018|DRUG|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
219590030|NCT06402760|OTHER|TCM comprehensive treatment|"1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted."
218844320|NCT04742803|DEVICE|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
218844321|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
219454564|NCT06063525|OTHER|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
219454565|NCT00184067|BIOLOGICAL|Montanide ISA 51|
219590031|NCT06402760|DRUG|Western medicine|The treatment methods prescribed in the guidelines.
219590032|NCT04928092|PROCEDURE|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
219590033|NCT02006225|DRUG|Plerixafor|
218844322|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
218844323|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
218844324|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
218844325|NCT04732702|OTHER|no intervention|There will be no intervention.
219454566|NCT04369872|PROCEDURE|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
219454567|NCT00186472|BEHAVIORAL|Brief Cognitive Behavioral Treatment|
219454568|NCT04921410|DEVICE|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
219454569|NCT04921410|DEVICE|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
219454570|NCT04869189|DEVICE|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
219590034|NCT03364543|OTHER|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
219590035|NCT03364543|OTHER|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
219590036|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
218844326|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
218844327|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
218844328|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
218844329|NCT01244789|OTHER|observation|active observation
218844330|NCT06206720|DRUG|Deuremidevir Hydrobromide for Suspension|"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
218844331|NCT06206720|DRUG|Placebo|"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
218844332|NCT06242847|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
218844333|NCT06242847|PROCEDURE|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
218844334|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
218844335|NCT06025734|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) treatment|Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
218844336|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
218844337|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
219454571|NCT02257112|DEVICE|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
219454572|NCT00384449|DRUG|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
219590037|NCT06010186|OTHER|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
219590038|NCT05190692|DEVICE|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation \& Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
219590039|NCT04621019|DEVICE|BTL-785F|Treatment with study device.
219590040|NCT03844256|COMBINATION_PRODUCT|nivolumab 480mg|Immuno-chemoradiotherapy
219590041|NCT03844256|COMBINATION_PRODUCT|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
218844338|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
218844339|NCT05978102|DRUG|approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines or the corresponding drug Labeling.
219454573|NCT03976193|BEHAVIORAL|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
219454574|NCT03976193|BEHAVIORAL|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
219454575|NCT04976478|DRUG|Nimotuzumab|Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
219590042|NCT03844256|COMBINATION_PRODUCT|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
219590043|NCT05939583|OTHER|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
219590044|NCT05939583|OTHER|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
218844340|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
218844341|NCT03255577|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
218844342|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
218844343|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
218844344|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218844345|NCT05756166|DRUG|Celecoxib|Given PO
218844346|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
218844347|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
218844348|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218844349|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
218844350|NCT05756166|DRUG|Rintatolimod|Given IV
218844351|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
218844352|NCT05879354|OTHER|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
218844353|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
218844354|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
218844355|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
218844356|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
218844357|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
218844358|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
218844359|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
218844360|NCT03224403|DRUG|Placebo|2 placebo caplets
218844361|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
218844362|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
218844363|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
218844364|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
218844365|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
218844366|NCT03840772|DRUG|Eribulin|Treatment with eribulin
218844367|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
218844368|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
218844369|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
218844370|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
218844371|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
218844372|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
218844373|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
218844374|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
218844375|NCT04460339|OTHER|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
218844376|NCT04847258|OTHER|Standard rehabilitation|Patients follow standard municipal rehabilitation
218844377|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
218844378|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
218844379|NCT06447337|DIAGNOSTIC_TEST|Continous body temperature monitoring|The investigational product will be placed on the participants' body in axilar joint and connected to the mobile phone. The values of the current temperature will apear on the monitor and it will be recorded in the database with date and time for each record. In parallel, study staff will occasionally measure the temperature using standard hospital thermometer.
218844380|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
219196936|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
218844381|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
218844382|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
218844383|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
218844384|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
218844385|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
218844386|NCT05980130|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|The RFCBT exclusively addresses one possible mechanism underlying depression, rumination. In general, a participant and their therapist will identify when the participant ruminates in an unhelpful manner, what triggers the rumination, what function the rumination fulfills for the participant, and how the participant already does to stop ruminating. Building on this knowledge both together will change the environment to reduce the likelihood of the participant to ruminate, use consciously strategies to stop rumination when it occurs, and replace rumination by more helpful strategies. In the proposed single subject study, the participant and the therapist will meet in person or using a UofL approved video platform up to 18 times for 50-minutes.
218844387|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
219590045|NCT04546724|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
219590046|NCT04546724|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
219590047|NCT03101865|DEVICE|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
218844388|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
218844389|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
218844390|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
218844391|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
218844392|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
218844393|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
218844394|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
218844395|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
218844396|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
218844397|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
218844398|NCT03019328|OTHER|Peanut in diet|
218844399|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
219196937|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
219590048|NCT02213653|DRUG|ARM A : IV iron + epoietin zeta|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
218844400|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
219454576|NCT04976478|RADIATION|EBRT combined with brachytherapy|"IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy.~Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80\~85Gy (EQD2); If the tumor diameter is ≥4cm, HR-CTV D90 cumulative dose is ≥87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks."
218844401|NCT05081167|DRUG|REL-1017|REL-1017 tablet
218844402|NCT05081167|DRUG|Placebo|Placebo tablet
218844403|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
218844404|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
218844405|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
218844406|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
218844407|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
218844408|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
218844409|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
218844410|NCT03441997|OTHER|Mind-body exercise|Exercise program.
218844411|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
218844412|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
218844413|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
218844414|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
218844415|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
218844416|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
218844417|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
218844418|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
218844419|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
218844420|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
218844421|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
218844422|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
218844423|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
218844424|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
218844425|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
219196938|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
219196939|NCT00761124|BEHAVIORAL|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
219196940|NCT00761124|BEHAVIORAL|Printed Material|General prostate cancer pamphlet
219196941|NCT04681638|DRUG|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
219454577|NCT04974957|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
218844426|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
218844427|NCT00053976|BIOLOGICAL|Daclizumab|
218844428|NCT00053976|DRUG|methylprednisolone|
218844429|NCT00053976|DRUG|Placebo|
219018067|NCT06622629|OTHER|Nature based Therapy (NbT): Planned therapeutic techniques performed in natural settings and based on nature-human active participation and connection|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application App, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
219454578|NCT05839236|COMBINATION_PRODUCT|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
219454579|NCT03338452|BEHAVIORAL|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
219454580|NCT06382740|PROCEDURE|Liver transplantation|Liver transplantation
219454581|NCT01836367|DRUG|Ingenol Mebutate 0.015%|Picato
219454582|NCT03616249|OTHER|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
219454583|NCT03616249|OTHER|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
218844430|NCT02589665|DRUG|Mirikizumab|
218844431|NCT02589665|DRUG|Placebo|
218844432|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
219454584|NCT00382551|BEHAVIORAL|Moderate daily consumption of Red wine|
219454585|NCT00382551|BEHAVIORAL|Moderate daily consumption of beer|
219454586|NCT00382551|BEHAVIORAL|Moderate consumption of fruit juice rich in polyphenolics|
219454587|NCT00998985|DRUG|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
219454588|NCT00998985|DRUG|Placebo|Placebo tablet, orally, once a day for 7 days
219454589|NCT00253799|DEVICE|Hylan GF-20|
219454590|NCT01271127|RADIATION|CT coronary angiography|patient will undergo one CT coronary angiography
219454591|NCT01100762|DEVICE|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
219454592|NCT01100762|DEVICE|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
219454593|NCT01100762|DEVICE|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
219454594|NCT00017927|DRUG|Pegvisomant|
219454595|NCT05093569|DEVICE|K'watch|Patients
218844433|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
218844434|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
218844435|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
218844436|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
218844437|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
218844438|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
218844439|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
218844440|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
218844441|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
218844442|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
218844443|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
218844444|NCT03114579|DEVICE|NEXFIN HD|
218844445|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
218844446|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
218844447|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
218844448|NCT04960059|OTHER|No intervention|This is an observational study
218844449|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
218844450|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
218844451|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
219018068|NCT06622629|OTHER|Nature based Therapy (NbT)|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application MyCap app, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
219018069|NCT03742037|DRUG|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
219018070|NCT03742037|DRUG|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
219454596|NCT02637167|DRUG|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
219454597|NCT02637167|DRUG|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
218844452|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
218844453|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
219454598|NCT03649386|DEVICE|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
219454599|NCT03649386|DEVICE|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
219454600|NCT01995786|DEVICE|Goal Directed Fluid Therapy FloTrac/Vigileo|
219454601|NCT01595308|DIETARY_SUPPLEMENT|Pomegranate juice|Pomegranate juice
219454602|NCT03824964|BIOLOGICAL|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
219454603|NCT01167088|DRUG|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
219454604|NCT01167088|DRUG|Placebo|Placebo
219454605|NCT01623856|OTHER|laboratory biomarker analysis|Correlative studies
219454606|NCT01701856|DRUG|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
219454607|NCT00549406|PROCEDURE|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
219454608|NCT00549406|PROCEDURE|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
219454609|NCT00549406|PROCEDURE|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
219454610|NCT02062970|BIOLOGICAL|blood draw|
219454611|NCT01040728|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
218844454|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
218844455|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
218844456|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
218844457|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
219590049|NCT02213653|DRUG|ARM B: IV iron + epoietin zeta sequence|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
219590050|NCT02213653|DRUG|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
218844458|NCT00284284|DEVICE|Use of a rehabilitation brace|
218844459|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
218844460|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
218844461|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
218844462|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
218844463|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
218844464|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
218844465|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
218844466|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
219018071|NCT03742037|DRUG|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
219018072|NCT03742037|DRUG|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
219018073|NCT03742037|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
219018074|NCT03742037|DRUG|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
219590051|NCT04238260|BEHAVIORAL|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
219590052|NCT04238260|BEHAVIORAL|Physical Therapy Usual Care|Usual physical therapy
219590053|NCT04996914|PROCEDURE|TACE|1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.
219590054|NCT04996914|RADIATION|SBRT|"SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.~Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) EQD2 (α/β 10Gy) 5x 8-6 Gy @ 83% isodose = 40-30 Gy (60-40 Gy) 8 x 6-4.5 Gy @ 83% isodose = 48-36 Gy (64-43.5 Gy)"
219454612|NCT01040728|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
218844467|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
218844468|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
218844469|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
218844470|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
219454613|NCT01040728|DRUG|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
219454614|NCT01040728|DRUG|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
219454615|NCT01040728|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
219454616|NCT01958268|PROCEDURE|Pretest and validation of a translated questionnaire|
219590055|NCT06968208|DRUG|Puerarin|75 mg of puerarin injection, dissolved in 0.9% sodium chloride solution. The puerarin injection is manufactured under Good Manufacturing Practice (GMP) conditions by \[Harbin Medisan Pharmaceutical Co., Ltd.\], with identical appearance, size, and packaging to the blank 0.9% sodium chloride solution to ensure blinding. Stability testing confirms integrity under standard storage conditions (25°C, 60% RH).
219590056|NCT06968208|DRUG|Placebo|0.9% sodium chloride solution formulated to match the appearance, size, and taste of the active puerarin solution, with no other active pharmaceutical ingredients. 0.9% sodium chloride solution is manufactured under identical Good Manufacturing Practiceconditions by \[Shijiazhuang No.4 Pharmaceutical Co., Ltd.\] and changed to the same batch processes and packaging as the intervention group. Stability testing confirms equivalent integrity under standard storage conditions (25°C, 60% RH). Blinding is ensured through indistinguishable outer packing characteristics and labeling.
219590057|NCT02143973|DRUG|nalbuphine HCl ER|nalbuphine HCl ER
219590058|NCT00077857|DRUG|capecitabine (Xeloda®)|825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
219590059|NCT00077857|DRUG|docetaxel (Taxotere®)|75 mg/m\^2 intravenous on day 1 of each 3 week cycle
219590060|NCT00351884|DRUG|Vildagliptin AM|
219590061|NCT00351884|DRUG|vildagliptin pm|
219590062|NCT00351884|DRUG|placebo|
219590063|NCT05229003|DRUG|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
219590064|NCT05229003|DRUG|Penpulimab|Penpulimab 200mg, d6, q2w
219590065|NCT05229003|DRUG|Irinotecan|Irinotecan 180mg/m2, d6, q2w
219590066|NCT06823804|DRUG|10ml of 10% saline is injected centrally|"The first phase of the study is an observational study that does not alter the clinical treatment plan.~The experimental group（Sample size of 48 cases） in the second phase of the study needs to receive a central venous injection of 10ml of 10% saline to demonstrate pulmonary blood flow, while the control group （Sample size of 48 cases）requires no intervention.~The experimental group select the optimal pulmonary blood flow PEEP By Electrical impedance tomography.Change in ventilation-perfusion ratio measured by EIT during PEEP trials from baseline to 30 minutes at each PEEP level (5, 10, 15 cmH2O).~The control group was selected Best PEEP according to the PEEP table ."
219590067|NCT05838430|DRUG|Solriamfetol 75 MG|Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of \~2 hours (range 1.25-3.0 hours) and a T1/2 of \~7.1 hours.
218844471|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
219018075|NCT06548230|DRUG|Nadunolimab|Give by IV
219018076|NCT06548230|DRUG|Azacitidine|Given by IV
219018077|NCT06548230|DRUG|Venetoclax|Given by mouth (PO
219454617|NCT02141529|PROCEDURE|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
219454618|NCT02141529|PROCEDURE|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
219454619|NCT04930172|DEVICE|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
219454620|NCT03445611|DRUG|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
218844472|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
219454621|NCT03445611|DRUG|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
219454622|NCT05362461|DIAGNOSTIC_TEST|Near Infrared Transillumination|Caries imaging detection technology.
219454623|NCT03276260|DEVICE|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
218844473|NCT05665660|BEHAVIORAL|CARE|CARE is a culturally tailored mammography education module.
218844474|NCT05665660|BEHAVIORAL|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
218844475|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
218844476|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
218844477|NCT00320554|BEHAVIORAL|Durometer analysis|
219454624|NCT03345173|DRUG|CI-581-a|Two infusions in the context of naltrexone induction protocol.
219454625|NCT03345173|DRUG|CI-581-b|Two infusions in the context of naltrexone induction protocol.
219454626|NCT04717167|OTHER|Dry Needling|
219454627|NCT04717167|OTHER|Sham Needling|
219454628|NCT00432289|PROCEDURE|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
219454629|NCT07022002|DRUG|SSGJ-705|anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody
219454630|NCT07022002|DRUG|PD-1/L1 inhibitor combined with chemotherapy|Immune checkpoint inhibitors
219454631|NCT07022002|DRUG|SSGJ-705 combined with chemotherapy|anti-PD-1 and anti-HER2 bispecifc antibody
219454632|NCT02029391|OTHER|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
219454633|NCT02029391|OTHER|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
219454634|NCT03605225|DEVICE|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
219590068|NCT05838430|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Treatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer).~Each session will be conducted individually and have a singular focus per session.~All sessions following the delivery of sleep restriction therapy \& stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration."
219590069|NCT05838430|OTHER|Monitoring|No CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
219590070|NCT05838430|OTHER|Placebo|Placebo, identical in appearance to the active drug.
219590071|NCT06552572|DRUG|Glofitamab|Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
219590072|NCT06173947|DEVICE|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
219590073|NCT06509893|DRUG|aspirin 80 mg and clopidogrel 75 mg daily|post PCI patients received these two drugs as dual antiplatelet regimen
219590074|NCT06509893|DRUG|Ticagrelor 90 MG|Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
219590075|NCT04997226|DEVICE|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
218844478|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
218844479|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
218844480|NCT00077714|DRUG|Paliperidone ER|
219196942|NCT04681638|DRUG|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
219454635|NCT01736930|DEVICE|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
219454636|NCT04207125|BEHAVIORAL|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
218860113|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
219454637|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
219454638|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
219454639|NCT00431223|BEHAVIORAL|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
219454640|NCT01759628|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
219590076|NCT04997226|DEVICE|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
219590077|NCT02543619|OTHER|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
219590078|NCT02877459|DEVICE|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
219590079|NCT00276861|DRUG|gemcitabine hydrochloride|
219590080|NCT00276861|DRUG|oxaliplatin|
219454641|NCT04851327|BEHAVIORAL|High Energy preload|Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
218860114|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
219454642|NCT04851327|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
219454643|NCT04851327|BEHAVIORAL|Test meal|Test meal to follow low or high energy preload
219454644|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
219454645|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
219590081|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
219590082|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
219590083|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
218844481|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
218844482|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
218844483|NCT02855866|PROCEDURE|thyroidectomy|
218844484|NCT02855866|OTHER|cryotherapy|
218844485|NCT02855866|DRUG|cortisone aerosol|
218844486|NCT02855866|DRUG|Dexamethasone acetate|
218844487|NCT02855866|DRUG|paracetamol|
218844488|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
219454646|NCT04162262|OTHER|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
219590084|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
219590085|NCT04056286|DIETARY_SUPPLEMENT|Whey|45 g whey protein + 20 g maltodextrin
219590086|NCT04056286|DIETARY_SUPPLEMENT|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
219590087|NCT06438809|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|MSC suspension single does injection.
219590088|NCT05302830|BEHAVIORAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
219590089|NCT05302830|BEHAVIORAL|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
218844489|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
218844490|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
218844491|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
218844492|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
218844493|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
219590090|NCT05532371|OTHER|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
219590091|NCT05532371|OTHER|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
219590092|NCT05532371|OTHER|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
218844494|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
218844495|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
218844496|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
218844497|NCT00538967|DRUG|doxycycline|2 weeks once daily
218860115|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
219590093|NCT05532371|OTHER|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
219454647|NCT04162262|OTHER|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
219454648|NCT04162262|OTHER|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
219454649|NCT03024229|DEVICE|LifePort® perfusion machine|Renal perfusion on LifePort® machine
219590094|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Ropivacaine|
219590095|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Saline|
219590096|NCT04058249|DEVICE|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
219590097|NCT00785460|DRUG|Benfotiamine|
218844498|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
218844499|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
219196943|NCT06612723|OTHER|high-intensity gait training|Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
219590098|NCT03467139|OTHER|Abdominal breathing exercise|Deep Breathing Exercise
219590099|NCT06050889|OTHER|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
219590100|NCT06050889|OTHER|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
219590101|NCT03573778|BEHAVIORAL|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
219590102|NCT03573778|BEHAVIORAL|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
219454650|NCT02388672|DIETARY_SUPPLEMENT|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
219454651|NCT02388672|DIETARY_SUPPLEMENT|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
219454652|NCT02388672|DIETARY_SUPPLEMENT|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
219590103|NCT02475330|DIETARY_SUPPLEMENT|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
219590104|NCT03833401|PROCEDURE|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
219590105|NCT03833401|PROCEDURE|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
219590106|NCT03750292|DEVICE|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
219590107|NCT03750292|DEVICE|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
219590108|NCT03961490|OTHER|No interventional study|No interventional study
219590109|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
219590110|NCT06105801|PROCEDURE|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
219590111|NCT06105801|PROCEDURE|Bronchoscopy|Participants will undergo Bronchoscopy
218844500|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
218844501|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
219454653|NCT02388672|DIETARY_SUPPLEMENT|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
219454654|NCT03116841|DRUG|Vonoprazan|Vonoprazan 20 mg
219454655|NCT04520919|OTHER|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
219590112|NCT06105801|PROCEDURE|Cryobiopsy|Participants will undergo Cryobiopsy
219590113|NCT05002777|DRUG|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
219590114|NCT04171206|OTHER|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
219590115|NCT04171206|OTHER|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
219196944|NCT06612723|BEHAVIORAL|Physical activity coaching|Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
219454656|NCT03398174|BEHAVIORAL|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
219454657|NCT03398174|BEHAVIORAL|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
219454658|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
219454659|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
219454660|NCT01693289|DRUG|metformin plus letrozole|
219196945|NCT06288386|DEVICE|GrandioSO Heavy Flow|Attachment will be performed with GrandioSO Heavy Flow.
219454661|NCT01693289|PROCEDURE|ovarian drilling|
219454662|NCT05589623|OTHER|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
219590116|NCT01308905|DEVICE|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
219590117|NCT06978140|BEHAVIORAL|Personalized feedback|Material includes feedback on alcohol-related consequences with elements from Acceptance Commitment Therapy, Relapse Prevention, Cognitive Behavioral Therapy, and Behavioral Activation. Focus of the intervention is learning about personal environmental cues.
219590118|NCT06978556|DIAGNOSTIC_TEST|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated.|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated. Including data from testing refraction, visual acuity, biometry, tomography, and OCT.
219590119|NCT06983119|OTHER|Case-finding for Neurocognitive Disorders|The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.
219590120|NCT06982651|DRUG|MI078|"Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, once daily;~* 2 capsules per dose, once daily;~* 3 capsules per dose, once daily;~* 4 capsules per dose, once daily; Duration of Treatment: 1 day .~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, twice daily;~* 2 capsules per dose, twice daily; Duration of Treatment: 7 days .~Dosage Form: Capsule Specification: 50mg~Administration and Dosage: Oral. Options include:~\- 5 capsule per dose, Three times a day Duration of Treatment: 3 days ."
219590121|NCT06982651|DRUG|Placebo|Placebo of MI078 Capsule
219590122|NCT06983145|OTHER|Olive Leaf tea|Individuals will consume 2-3 pieces of biscuits with caramel coloring (total 120 g) and a glass (250 mL) of tea (natural mineral water with 1.25 g. dried olive leaves)
219590123|NCT06982053|DIAGNOSTIC_TEST|Received 68Ga-NOTA-GZP PET scanning|Received twice 68Ga-NOTA-GZP PET scanning before neoadjuvant therapy and radical surgery.
219590124|NCT06981728|PROCEDURE|Mid point transverse to pleura block|"TPVB and MTPB was performed at a spinal level midway between the uppermost and the lowest fractured rib, with the patient in a sitting position, and under complete aseptic conditions, a linear ultrasound probe (GE Healthcare-Logiq F6) will be placed oblique parasagittally 3 cm lateral to spinous process used to identify the transverse process, pleura, superior costotransverse ligament, and the paravertebral space at the target vertebral level.~After skin and subcutaneous tissue infiltration with 2-3 mL of 2% lignocaine, an 18-gauge Touhy needle was inserted under ultrasound guidance until the needle tip reaches :~* the midpoint between the transverse process and the pleura (group M).~* the paravertebral space (group P). A bolus dose (0.3mL/kg) of plain bupivacaine 0.5% plus 8 mg of dexamethasone was injected after negative aspiration to blood and air."
219590125|NCT06982547|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
219590126|NCT06983054|DRUG|ertugliflozine|SGLT2i versus placebo
219590127|NCT06983054|BEHAVIORAL|low salt diet|comparing low salt versus high salt diet
219590128|NCT06983054|DRUG|placebo|placebo tablet
219590129|NCT06983054|BEHAVIORAL|high salt diet|high salt diet
219590130|NCT06438263|DRUG|Rocatinlimab|Vial supplied as a single-use preservative free solution for SC injection.
219590131|NCT06438263|DRUG|Rocatinlimab|Autoinjector for SC injection.
219454663|NCT05589623|OTHER|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
219454664|NCT04484038|RADIATION|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
218844502|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
218844503|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
219454665|NCT03234075|OTHER|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator"
219454666|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
219454667|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
218860116|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
219454668|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
219590132|NCT06982976|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
219590133|NCT06983873|BEHAVIORAL|adapted Canadian C-Spine rules|The CCRa are decision rules for pre-hospital cervical spine collar immobilization. They include three high-risk criteria indicating imaging, 5 low-risk criteria allowing assessment of cervical spine rotation, and finally the ability of patients to achieve limited active rotation. They have been designed and validated to avoid immobilization during transport to the emergency department without any significant cervical injury being missed.
219590134|NCT06982664|PROCEDURE|High Tie of Inferior Mesenteric Artery|IMA was ligated approximately 1 cm from its origin after dissection of the surrounding tissue to ensure clear visualization of the IMA root. Using this technique, the LCA and the inferior mesenteric vein were ligated near the lower border of the pancreas
219590135|NCT06982664|PROCEDURE|Low Tie of Inferior Mesenteric Artery|During this procedure, the LCA was identified and preserved, and the superior rectal artery was ligated. Before colonic transection or anastomosis, the preserved LCA underwent temporary, controlled occlusion. After assessing perfusion changes using LSCI, the occlusion was released to restore blood flow.
219590136|NCT06983197|DIAGNOSTIC_TEST|blood test|Blood samples are drawn every 3-5 days in the RRT group but only once in the control group
219590137|NCT06593054|DRUG|Ceftibuten|Ceftibuten dihydrate, formulated in capsules
219590138|NCT06593054|DRUG|Avibactam prodrug|Avibactam prodrug, formulated in capsules
219590139|NCT06593054|DRUG|CTB-AVP in Tablet|ceftibuten and avibactam prodrug, in Tablet formulation
219454669|NCT01875874|BIOLOGICAL|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
219590140|NCT06980233|BEHAVIORAL|reentry assistance mobile health app|R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.
219590141|NCT01943110|DEVICE|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
219590142|NCT01943110|DEVICE|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
218844504|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
218844505|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
218844506|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
218844507|NCT02745782|OTHER|Observational Study|Observational Study
219454670|NCT04583267|DRUG|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
219454671|NCT00002749|DRUG|carboplatin|
219454672|NCT00572312|DRUG|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
218844508|NCT01152255|DRUG|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
218844509|NCT01152255|DRUG|Comparator: Placebo|Placebo tablets taken orally for seven day
218844510|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
219454673|NCT03270618|DEVICE|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
219454674|NCT06376435|DRUG|Herombopag Olamine Tablets|Herombopag Olamine；combined rhTPO;combined IL-11
218844511|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
218844512|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
219454675|NCT03827070|DRUG|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%
218844513|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
218844514|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
219454676|NCT03827070|DRUG|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
219590143|NCT03996642|BEHAVIORAL|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
219590144|NCT02032095|DRUG|GB-0998|
219590145|NCT02768714|DRUG|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
218844515|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
219196946|NCT06288386|DEVICE|Filtek Z350XT Flowable|Attachment will be performed with Filtek Z350XT Flowable.
219454677|NCT01607749|BEHAVIORAL|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
219454678|NCT01607749|OTHER|Usual Asthma Information for teachers|Common asthma information for teachers
218844516|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
218844517|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
218844518|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
218844519|NCT01952548|DRUG|K-312|
218844520|NCT01952548|DRUG|Placebo|
218844521|NCT02965183|OTHER|Temperature measurements|
218844522|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
218844523|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
218844524|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
218844525|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
219454679|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
219454680|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
218844526|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
218844527|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
218844528|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
219454681|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
219454682|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
219454683|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
218844529|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
218844530|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
218844531|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
218844532|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
218844533|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
218844534|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
218844535|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
218844536|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
218844537|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
218844538|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
219196947|NCT06177613|PROCEDURE|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
219454684|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
219454685|NCT01018615|DRUG|silymarin|capsules, 700 mg, twice daily, 12 days
219454686|NCT01018615|DIETARY_SUPPLEMENT|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
219454687|NCT04880460|DIETARY_SUPPLEMENT|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
219454688|NCT04880460|DIETARY_SUPPLEMENT|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
219454689|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
219454690|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
219454691|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
218844539|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
218844540|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
218844541|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
218844542|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
218844543|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
218844544|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
218844545|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
219454692|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
219454693|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
219590146|NCT02768714|DRUG|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
219590147|NCT00426712|BIOLOGICAL|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
219590148|NCT00426712|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
219590149|NCT00369317|DRUG|asparaginase|Given IM
219590150|NCT00369317|DRUG|daunorubicin hydrochloride|Given IV
219590151|NCT00369317|DRUG|cytarabine|Given IV or IT
219590152|NCT00369317|DRUG|thioguanine|Given orally
219590153|NCT00369317|DRUG|etoposide|Given IV
219590154|NCT00369317|OTHER|laboratory biomarker analysis|Correlative studies
218844546|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
218844547|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
219590155|NCT01004094|BEHAVIORAL|simple goal setting|This group will set goals only
219590156|NCT01004094|BEHAVIORAL|goal setting plus action intentions|This group will set goals and form action intentions (plans)
218844548|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
218844549|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
218844550|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
219454694|NCT01755390|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
219454695|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
219454696|NCT00603876|DIETARY_SUPPLEMENT|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
219454697|NCT01935167|DRUG|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
219454698|NCT01935167|DRUG|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
219454699|NCT01935167|DRUG|Placebo|Placebo 2 tablets b.i.d.
219590157|NCT01004094|BEHAVIORAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
219590158|NCT01004094|BEHAVIORAL|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
219590159|NCT02365558|DRUG|Evacetrapib|Administered orally
219590160|NCT02365558|DRUG|Omeprazole|Administered orally
219590161|NCT00000717|DRUG|Primaquine|
218844551|NCT06511596|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
218844552|NCT06511596|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
218844553|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
218844554|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
219590162|NCT00000717|DRUG|Clindamycin|
219590163|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
219590164|NCT03240237|DEVICE|Optimizer SMART|Cardiac Contractility Modulation
218844555|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
218844556|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
218844557|NCT00000467|BEHAVIORAL|diet|
218844558|NCT00000467|BEHAVIORAL|exercise|
218844559|NCT00000467|BEHAVIORAL|smoking cessation|
218844560|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
218844561|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
218844562|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
218844563|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
218844564|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
219454700|NCT03932591|PROCEDURE|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
218844565|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
218844566|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
218844567|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
219454701|NCT03932591|PROCEDURE|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
219454702|NCT01728766|OTHER|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
219454703|NCT01728766|OTHER|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
219454704|NCT00826540|DRUG|sorafenib tosylate|Given orally
219454705|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
219590165|NCT01330420|BEHAVIORAL|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting."
219590166|NCT03322930|DIAGNOSTIC_TEST|Rod sensitivity|diagnostic test for rod loss in central retina
219590167|NCT01687244|DRUG|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
219590168|NCT02819050|DEVICE|NCPAP|Nasal Continuous Positive Airway Pressure
218844568|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
219454706|NCT01166386|BEHAVIORAL|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
218844569|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
218844570|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
218844571|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
219454707|NCT01166386|BEHAVIORAL|FANCI|Watching DVDs chosen by participants on various topics.
219454708|NCT00542217|BIOLOGICAL|Imprime PGG|
219454709|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
219454710|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
219454711|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
219454712|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
218844572|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
218844573|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
218844574|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
218844575|NCT03153644|BEHAVIORAL|Observation|Field Observation
218844576|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
219454713|NCT00675129|BEHAVIORAL|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
219454714|NCT00675129|BEHAVIORAL|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
219454715|NCT02640924|RADIATION|Proton radiotherapy|
218844577|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
219454716|NCT02640924|PROCEDURE|Radiofrequency Ablation|
218844578|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
219454717|NCT04225936|DRUG|BMS-986263|Single Dose
219454718|NCT01341236|OTHER|different nutrional regimen|compare bolus versus intermittent nutrition
219454719|NCT01341236|OTHER|comparison of different feeding regimens|compare intermittent versus bolus nutrition
219454720|NCT00975442|OTHER|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
219454721|NCT00975442|DEVICE|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
219454722|NCT00975442|DEVICE|Forearm band|All patients were instructed to use a forearm band during all daily activities.
219454723|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
219454724|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
219454725|NCT04993430|DEVICE|HRS8807、SHR6390|HRS8807 in combination with SHR6390
219454726|NCT04993430|DRUG|HRS8807、SHR6390|HRS8807 in combination with SHR6390
219454727|NCT05528562|OTHER|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
219454728|NCT05528562|OTHER|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
219454729|NCT05528562|OTHER|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
219454730|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
219454731|NCT01138462|OTHER|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
218844579|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
218844580|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
218844581|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
219590169|NCT02373189|DEVICE|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
219590170|NCT03596892|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
219590171|NCT03596892|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
219590172|NCT03596892|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
219590173|NCT01449448|DRUG|Ketorolac|Subacromial injection
219590174|NCT01449448|DRUG|Triamcinolone|Subacromial Injection
218844582|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
218844583|NCT00961246|BEHAVIORAL|general health information|participants received general health information
218844584|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
218844585|NCT03713294|DRUG|Dexamethasone|Given IV and PO
218844586|NCT03713294|BIOLOGICAL|Elotuzumab|Given IV
218844587|NCT03713294|DRUG|Pomalidomide|Given PO
218844588|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
218844589|NCT03458910|BEHAVIORAL|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
218844590|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
218844591|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
218844592|NCT06381063|DRUG|pain management|o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
218844593|NCT06381063|DRUG|ketoprofen|Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
218844594|NCT06381063|DRUG|PLacebo|Placebo twice a day, during 48 h after surgery, intravenous administration
218844595|NCT05023980|DRUG|Pirtobrutinib|Oral
218844596|NCT05023980|DRUG|Bendamustine|IV
218844597|NCT05023980|DRUG|Rituximab|IV
218844598|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
218844599|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
218844600|NCT03548311|DRUG|methylcobalamin|Patients receive methylcobalamin 50mg intramuscular injection twice a week.
218844601|NCT03548311|DRUG|saline solution|Patients receive saline solution intramuscular injection twice a week.
218844602|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
218844603|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
218844604|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
218844605|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
218844606|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
218844607|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
218844608|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
218844609|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
218844610|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
219590175|NCT06634251|OTHER|No intervention|This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
218844611|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
218844612|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
218844613|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
218844614|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
218844615|NCT06434363|DRUG|Tafasitamab|Given by vein (IV)
218844616|NCT06434363|DRUG|Fludarabine phosphate|Given by vein (IV)
218844617|NCT06434363|DRUG|Cyclophosphamide|Given by vein (IV)
218844618|NCT06434363|DRUG|Tafasitamab and NK cells|Given by vein (IV)
219590176|NCT02828241|DRUG|DFD-04 Ointment|
219590177|NCT02828241|OTHER|Placebo Ointment|
219590178|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
218844619|NCT04265651|DRUG|Infigratinib 0.016 mg/kg|"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
218844620|NCT04265651|DRUG|Infigratinib 0.032 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
219590179|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
219590180|NCT03849183|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
218844621|NCT04265651|DRUG|Infigratinib 0.064 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
218844622|NCT04265651|DRUG|Infigratinib 0.128 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
218844623|NCT04265651|DRUG|Infigratinib 0.25 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
218844624|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
218844625|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
218844626|NCT03356834|DRUG|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
219590181|NCT03849183|DRUG|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
219590182|NCT02542553|PROCEDURE|Bilateral BAL|
219590183|NCT06016491|BEHAVIORAL|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
219590184|NCT06016491|BEHAVIORAL|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
219590185|NCT02977897|DRUG|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
219590186|NCT02990780|RADIATION|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
219590187|NCT02990780|RADIATION|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
219590188|NCT01177475|OTHER|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
219590189|NCT01177475|OTHER|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
219590190|NCT02917070|OTHER|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
218844627|NCT03356834|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
219590191|NCT04614415|DEVICE|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
219590192|NCT04614415|OTHER|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
219590193|NCT06456905|BEHAVIORAL|Contingency Management|Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
219590194|NCT00185445|DRUG|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
218844628|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
218844629|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
218844630|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
218844631|NCT00346658|DRUG|magnesium|
218844632|NCT04909606|OTHER|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
219196948|NCT06177613|PROCEDURE|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
219590195|NCT02838121|DRUG|Aclasta|Aclasta once annually for 2 years
219590196|NCT02838121|DRUG|Placebo|No IV aclasta
219590197|NCT04504305|OTHER|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
219590198|NCT04504305|OTHER|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
219454732|NCT03631849|PROCEDURE|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
219454733|NCT03631849|OTHER|Care|descaling and maintenance of implants
219454734|NCT02071329|DRUG|Vaccine FP-01.1|
219454735|NCT02071329|DRUG|Placebo|
218844633|NCT04909606|OTHER|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
218844634|NCT06002477|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
218844635|NCT06002477|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
218844636|NCT05547503|DRUG|AFA-281|Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
219454736|NCT02071329|OTHER|Virus Challenge|
219454737|NCT06332183|GENETIC|Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
219454738|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
219454739|NCT03851224|PROCEDURE|control group|immediate implant with immediate loading using no graft
219454740|NCT03851224|PROCEDURE|study group|immediate implant with immediate loading using autogenous bone graft
219454741|NCT03851224|PROCEDURE|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
219454742|NCT02871570|DRUG|Rivipansel|A single dose of IV Rivipansel over 20 minutes
219454743|NCT06386367|BEHAVIORAL|Monastery-based health education by Buddhist monks|During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
218844637|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
218844638|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
218844639|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
218844640|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
218844641|NCT01764269|OTHER|text message surveillance for fever|
218844642|NCT00020098|PROCEDURE|evaluation of cancer risk factors|
218844643|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
218844644|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
219196949|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219454744|NCT02178592|DRUG|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
219454745|NCT02178592|DRUG|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
219454746|NCT06227416|OTHER|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
219454747|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
219454748|NCT01476553|PROCEDURE|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
219454749|NCT03390127|OTHER|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
219454750|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
219454751|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
219454752|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
218844645|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
218844646|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
219590199|NCT02151877|DRUG|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
218844647|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
218844648|NCT01935323|OTHER|High Intensity Interval Training|
218844649|NCT01935323|OTHER|Moderate Intensity Training|
218844650|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
218844651|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
218844652|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
218844653|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
218844654|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
218844655|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
218844656|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
218844657|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
218844658|NCT05306834|OTHER|Walking speed measurement|over 5 meters
219454753|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
219454754|NCT02045225|BEHAVIORAL|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
219454755|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
219454756|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
219590200|NCT02151877|DRUG|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
219196950|NCT06611891|DRUG|68Ga-DOTATOC|Slow direct intravenous injection
219454757|NCT01628458|PROCEDURE|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
219590201|NCT02505087|DRUG|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
219590202|NCT02505087|DRUG|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
219590203|NCT00217555|DRUG|gemcitabine hydrochloride|
218844659|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
218844660|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
218844661|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
218844662|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
218844663|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
218844664|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
218844665|NCT06245109|DRUG|Duloxetine|60 mg, oral
218844666|NCT06245109|DRUG|Celecoxib|200 mg, oral
218844667|NCT06245109|DRUG|Placebo|Matching placebo, oral
218844668|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
218844669|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
218844670|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
218844671|NCT00630006|GENETIC|TNF-alpha and IL-10|
218844672|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
218844673|NCT03783000|DRUG|BI 425809|Treatment T
219454758|NCT02520141|OTHER|Laboratory Biomarker Analysis|Correlative studies
219454759|NCT02520141|BIOLOGICAL|Ramucirumab|Given IV
219454760|NCT01640067|BIOLOGICAL|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
218844674|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
218844675|NCT04963244|OTHER||
218844676|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
218844677|NCT02690688|DEVICE|determination of dynamic preload variables|
218844678|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
218844679|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
218844680|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
218844681|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
218844682|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
218844683|NCT05742646|BEHAVIORAL|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
218844684|NCT05742646|BEHAVIORAL|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
218844685|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
218844686|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
218844687|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
218844688|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
218844689|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
218844690|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
218844691|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
218844692|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
218844693|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
218844694|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
218844695|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
218844696|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
218844697|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
218844698|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
218844699|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
218844700|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
218844701|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
218844702|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
218844703|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
218844704|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
219454761|NCT00192712|DRUG|irinotecan, gemcitabine|
219454762|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
219454763|NCT00703781|DRUG|placebo|sterile ophthalmic solution
219590204|NCT00217555|DRUG|topotecan hydrochloride|
219454764|NCT01228695|OTHER|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
218844705|NCT06467955|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
218844706|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
218844707|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
218844708|NCT02814240|OTHER|NMR|
218844709|NCT02814240|BIOLOGICAL|Blood samples|
218844710|NCT02814240|OTHER|fibroscan|
218844711|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
218844712|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
218844713|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
218844714|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
218844715|NCT06084182|OTHER|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
218844716|NCT02182063|DRUG|BIBF 1120 low dose|
218844717|NCT02182063|DRUG|BIBF 1120 high dose|
218844718|NCT01835288|DRUG|arsenic trioxide|Given IV
219454765|NCT03714256|DEVICE|Device, patient mobility, powered|Pediatric mobility device
219454766|NCT00112554|DRUG|cytarabine|Given IV
218844719|NCT01835288|OTHER|laboratory biomarker analysis|Correlative studies
218844720|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
218844721|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
218844722|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
218844723|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
218844724|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
218844725|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
218844726|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
218844727|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
218844728|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
218844729|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
218844730|NCT05034497|DRUG|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
218844731|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
218844732|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
218844733|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
218844734|NCT00003191|DRUG|fenretinide|
218844735|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
218844736|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
219454767|NCT00112554|DRUG|laromustine|Given IV
219454768|NCT00112554|OTHER|placebo|Given IV
219454769|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
219454770|NCT03797794|DEVICE|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
219454771|NCT03797794|DEVICE|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
218844737|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
218844738|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
218844739|NCT06111040|OTHER|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
218844740|NCT06297317|DIAGNOSTIC_TEST|Ultrasound measurement of triceps surae muscle-tendon architecture|The resting plantar-flexors MTU architecture assessment was performed using a conventional B-mode and extended-field-of-view (EFOV) ultrasound imaging. Achille tendon cross-sectionnal area, Medial gastrocnemius thickness, pennation angle, fascicle length and muscle length were collected on the dominant lower limb.
218844741|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
218844742|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
218844743|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
219454772|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
219454773|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
219454774|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
219454775|NCT03756142|DIAGNOSTIC_TEST|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
219454776|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
219454777|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
218844744|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
218844745|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
218844746|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
218844747|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
218844748|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
218844749|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
218844750|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
218844751|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
218844752|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
218844753|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
218844754|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
218844755|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
219454778|NCT02901106|DRUG|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
219454779|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
219454780|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
218844756|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
219454781|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
219454782|NCT07022639|PROCEDURE|Total pancreatectomy|Total pancreatectomy for any kind of disease
219454783|NCT07022639|PROCEDURE|Proximal pancreatectomy|Proximal pancreatectomy for any kind of disease
219454784|NCT07022639|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy for any kind of disease
219454785|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
219454786|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
219454787|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
218844757|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
218844758|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
218844759|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
218844760|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
218844761|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
218844762|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
219454788|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
218844763|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
218844764|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
218844765|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
218844766|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
218844767|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
218844768|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
218844769|NCT05587296|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
218844770|NCT05587296|DRUG|Placebo|Matching placebo orally once daily
218844771|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
218844772|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
218844773|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
218844774|NCT01328535|DRUG|temozolomide|Given PO
218844775|NCT01328535|OTHER|flow cytometry|Correlative studies
218844776|NCT01328535|OTHER|staining method|Correlative studies
218844777|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
218844778|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
219196951|NCT06612151|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
219454789|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
219454790|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
219454791|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
219454792|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
219454793|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
219454794|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
219454795|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
218844779|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
218844780|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
218844781|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
218844782|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
218844783|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
218844784|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
218844785|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
218844786|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
218844787|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
218844788|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
218844789|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
218844790|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
218844791|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
218844792|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
219454796|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
219590205|NCT06665204|OTHER|Clinical Practice Guideline-adherent Care|Clinical examination procedures will be used to identify all appropriate impairment subcategories (Overuse/Overload without Other Impairment, PFP with Movement Coordination Deficits, PFP with Muscle Performance Deficits, PFP with Mobility Impairments) and create a subcategory-specific or multimodal (for patients classified to \>1 subcategory) plan of care. Research physical therapists will target all applicable impairment subcategories using the corresponding CPG-recommended interventions, all of which are recommended for use as part of standard-of-care physical therapy practice. The duration and length of care will not be prespecified or standardized across participants to allow flexibility pending participant's care needs and schedule (e.g., vacation, short-term TDY status); however, research PTs will be trained to target providing no more than 10-12 visits over no more than 6-8 weeks to promote generalizability of the CPG-adherent intervention.
218844793|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
218844794|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
218844795|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
218844796|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
218844797|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
218844798|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
218844799|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
218844800|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
218844801|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
218844802|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
218844803|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
218844804|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
218844805|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
219454797|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
219454798|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
219454799|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
219454800|NCT01943695|BEHAVIORAL|Aerobic Training|
219454801|NCT01943695|BEHAVIORAL|Educational Information|Subjects will be given material regarding cancer and it's impact.
218844806|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
218844807|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
218844808|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
218844809|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
218844810|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
218844811|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
218844812|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
218844813|NCT00051012|DRUG|ONTAK|
219454802|NCT01943695|BEHAVIORAL|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
219454803|NCT05335993|BIOLOGICAL|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
219590206|NCT06665204|OTHER|Usual Care|Usual physical therapy care will be provided by a licensed outpatient staff physical therapist who is not associated with the research team. The outpatient physical therapists will not treat participants in the CPG-adherent group and will be free to treat their participants based on their current personal and organizational clinical practice standards. The research team will neither influence nor restrict the evaluations conducted or interventions provided.
219590207|NCT03148106|DEVICE|Somatosensory Electrical Stimulation|The investigators will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
219590208|NCT06985368|DRUG|SIBP-A18|"SIBP-A18 formulation for injection, Claudin18.2-ADC. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
219590209|NCT06982586|DEVICE|Repetitive transcranial magentic stimulation|Low frequencey repetitive transcranial magentic stimulation
218844814|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
218844815|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
219454804|NCT05335993|DRUG|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
219454805|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
219454806|NCT04937127|OTHER|usual care|usual care
219454807|NCT03357770|DRUG|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
218844816|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
218844817|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
218844818|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
218844819|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
218844820|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
218844821|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
219454808|NCT04227119|DEVICE|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
218844822|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
218844823|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
218844824|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
218844825|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
218844826|NCT00685269|DRUG|Placebo|Placebo tablet
218844827|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
218844828|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
218844829|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
218844830|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
218844831|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
219454809|NCT04227119|DEVICE|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
219454810|NCT02691468|DEVICE|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
218844832|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
218844833|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
218844834|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
218844835|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
218844836|NCT00144469|DRUG|peginterferon alfa-2a|
218844837|NCT00144469|DRUG|rivavirin|
218844838|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
218844839|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
218844840|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
218844841|NCT00406874|DRUG|folic acid|800 micrograms daily
218844842|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
218844843|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
219454811|NCT02691468|DEVICE|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
218844844|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
218844845|NCT00346606|DRUG|Denosin® and Xyzal®|
219454812|NCT05742789|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
219454813|NCT05742789|DRUG|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
218844846|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
218844847|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
218844848|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
218844849|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
218844850|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
218844851|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
219454814|NCT05742789|DRUG|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
219454815|NCT01917591|DEVICE|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
219454816|NCT01917591|DEVICE|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
219454817|NCT02052154|BIOLOGICAL|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
219454818|NCT06875973|DRUG|Pelacarsen (TQJ230)|pelacarsen 80mg s.c. monthly
219454819|NCT07102134|PROCEDURE|Suturing-LIFT procedure|This group received conventional ligation with absorbable sutures
219454820|NCT07102134|PROCEDURE|Clipped-LIFT procedure|This group was treated with absorbable clips commonly used for vascular or biliary duct occlusion
219454821|NCT04839328|DRUG|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
219454822|NCT04839328|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
219454823|NCT06711302|DEVICE|Sham RIC|Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
219454824|NCT06711302|DEVICE|Remote Ischemic Conditioning treatment instrument|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
219454825|NCT07030868|DRUG|LY6249492|Administered orally
218844852|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
218844853|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
218844854|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
218844855|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
219196952|NCT06612151|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
219454826|NCT07030868|DRUG|Placebo|Administered orally
219454827|NCT00256646|DRUG|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
219454828|NCT05874336|DRUG|Aramchol|Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
219454829|NCT06881290|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab combined with glucocorticoid therapy: Vunakizumab is administered subcutaneously at 240 mg at weeks 0, 2, and 4, followed by maintenance dosing every 4 weeks at 240 mg per dose.
219454830|NCT07044518|DEVICE|Over-the-Counter Hearing Aid|This intervention involves a self-fit, over-the-counter (OTC) hearing aid that is set up by the user with limited to no help from a hearing professional. Amplification is personalized through an app-based hearing test on a smartphone. The device is used during a single study visit (90 minutes) to assess hearing and provide amplification.
219454831|NCT07044518|DEVICE|Hearing aid, air conduction|This intervention uses a prescription hearing aid that is programmed and fitted based on results from a standard hearing test. The device is also used during a single study visit (90 min) for comparison purposes.
218844856|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
219454832|NCT07047482|BIOLOGICAL|Immunohistochemical staining|Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
219454833|NCT07046468|DEVICE|Ingestion of sensor capsule (twice)|Ingestion of the GISMO GEN1 System, an ingestible sensor capsule which measures pH, temperature and oxidation reduction potential (ORP) in the intestines.
218844857|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
218844858|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
218844859|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
218844860|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
218844861|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
218844862|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
218844863|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
218844864|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
219590210|NCT06983574|OTHER|MIA|"Through a collaborative co-creation process, MIA, a mHealth app was developed and refined over multiple iterations with the goal of promoting physical activity and fostering a lifestyle centred around an active and healthy approach. Content and design were derived from both the co-creative workshops and based on the theoretical framework of the intervention functions of the BCW. The final mHealth app is composed by five major features:~* Tailor-made tips~* Literacy aiming to improve awareness about PA and an active healthy lifestyle~* Exercise workouts~* Community calendar aiming to enhance social connections~* A diary consisting of daily activities (MIA workouts and self-registration) To customize the user experience, a brief personal description was created as the start screen, which prompts older adults to answer questions related to their baseline physical activity level, motivation, and medical history."
218844865|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
218844866|NCT00320905|BEHAVIORAL|Observational|No intervention
218844867|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
219454834|NCT07046468|BEHAVIORAL|Device evaluation questionnaire|A 16-item online questionnaire to assess participant's experiences with the ingestible sensor capsule after the study measurements.
218844868|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
219454835|NCT07046468|DEVICE|Wearing device|Participants will wear a small device on a soft belt around their waist during study measurements with the sensor capsules.
219454836|NCT07046468|BEHAVIORAL|Monitoring sensor capsule exit|Participants are instructed to press a button on the wearable device when they use the toilet for defaecation and wait with flushing to toilet until the wearable device indicates (using colored LEDs) that the toilet can be flushed and 1) that the sensor capsule is still in the body and study measurements continue or 2) that the sensor capsule has likely been excreted via the feces and the participant has to contact the research team to confirm exit.
219454837|NCT07046468|DEVICE|Placement of devices at home|Participants do not have to wear the device around the waist during sleeping. For optimal monitoring of sensor capsule exit during the nights, a second device will be placed on the participant's bedside table/close to the bed and a third device will be placed close to the toilet that the participant usually uses during the night.
219454838|NCT07046468|DIAGNOSTIC_TEST|Follow-up intestinal ultrasound|At 3 months after treatment initiation, participants with ulcerative colitis will undergo a follow-up intestinal ultrasound (IUS) (non-endoscopic) outside of routine care to assess treatment response.
219454839|NCT06334055|DEVICE|Masimo INVSENSOR00073|Noninvasive blood pressure monitor
218844869|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
218844870|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
218844871|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
218844872|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
218844873|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
218844874|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
218844875|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
218844876|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
218844877|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
218844878|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
218844879|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
218844880|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
218844881|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
218844882|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
218844883|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
218844884|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
218844885|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
218844886|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
218844887|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
218844888|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
218844889|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
219454840|NCT06196905|DRUG|MT-2990|i.v. infusion
219454841|NCT02545049|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
219454842|NCT02545049|DRUG|Placebo|Matching placebo to be taken orally, once daily.
219454843|NCT07051642|BEHAVIORAL|Incredible Years Dinosaur Child Program|The Incredible Years Dinosaur Child Program is a structured, manualized group intervention designed for children aged 4 to 8 years with elevated or (sub)clinical conduct problems. The program consists of 18 weekly group sessions lasting approximately two hours each. Sessions are delivered in small groups (5-6 children per group) by certified trainers and follow a developmentally appropriate, play-based curriculum. Intervention components include storytelling with puppets, role-play, video modeling, and group discussions. The program aims to enhance emotional regulation, social competence, and problem-solving skills. The Dutch version of the program is used in this study and implemented in both clinical and preventive settings.
219454844|NCT07059338|DRUG|Trastuzumab +Cetuximab β+Irinotecan|Trastuzumab 4 mg/kg , Cetuximab β: 500 mg/m² ,Irinotecan 180 mg/m², repeat once every 2 weeks
219454845|NCT07057973|DRUG|Ferric carboxymaltose|The experimental group was treated with 1000 mg of ferric carboxymaltose
219454846|NCT07059481|OTHER|Root Canal Treatment and Sample Collection|Single session root canal treatment procedure will be performed with VDW Gold Reciproc device and reciprocal files (Endo T-Must, Dentac, Turkey). Endodontium Samples will be collected from each patient's root canal, with 15 Hedström files (Dentsplay).
219454847|NCT07059481|DIAGNOSTIC_TEST|PAI Score Comparasion|PAI scores of the patients will be determined with periapical films taken before treatment and compared with oxidative stress markers before and after treatment for the epoxyamine group and bioceramic group.
219590211|NCT06374862|OTHER|mobilization|specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
218844890|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
218844891|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
218844892|NCT06439433|DRUG|Placebo|once a week for 6 weeks
218844893|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
218844894|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
218844895|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
219454848|NCT07059364|BEHAVIORAL|CAST Treatment|Activity completion will be evaluated based the number of consecutive and total activities completed, duration of sustained activity engagement, prompts or redirection, and adult proximity at baseline and post-trial.
219454849|NCT07057687|OTHER|Conventional Physical Therapy Group|Conventional physical therapy applied to patients consists of Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound (US) and Hot Pack. TENS will be applied for 20 minutes at a frequency of 100 hertz. US will be applied for 5 minutes at an intensity of 1.2-1.5 W/cm2. Hot Pack will be applied for 20 minutes. Treatment will be applied to the lumbar region. Application will be made 3 days a week for 4 weeks.
219454850|NCT07057687|OTHER|Relaxation Techniques Group|The individual will be in a sitting or lying position without muscle tension, and progressive relaxation will be provided with verbal commands given for each body part in order. The patient is asked to place their hand on their abdomen and by applying light resistance, they are provided with the direction in which the breath will go. During diaphragmatic breathing, the person breathes deeply and slowly through the nose and out through the mouth for 5-7 seconds, holds it for 2 seconds and exhales for 6-8 seconds. During this time, the abdomen is inflated in 4 directions and care is taken to ensure that there is no auxiliary muscle activity. First, after taking a deep breath, the muscles are tensed, this tension is maintained for 5-7 seconds and then the muscles are relaxed (8-10 seconds). This application will be applied in 3 sets, with 5/6 repetitions and then returning to calm/normal breathing. The treatment will be applied 3 days a week and will last for 4 weeks.
219454851|NCT07057687|OTHER|Mulligan Treatment Group|Application of the Technique: The direction of the technique will be shaped according to the direction of movement of the patient's pain. If the patient's pain occurs during flexion, flexion will be applied, if it occurs during extension, extension SNAGS will be applied. In the flexion SNAGS application, the physiotherapist places the mobilization belt at the patient's spina iliaca anterior superior (SIAS) level while the patient is sitting or standing. The physiotherapist places his hand, thumbs or the hypothenar part of the hand parallel to the spinous processes one level above the relevant segment. Then, he asks the patient to flex until he feels pain. The physiotherapist continues the flexion by applying force towards the cranium with his hand. After waiting for a while at the end point, the starting position is returned. During this time, the physiotherapist maintains the natural shift in the facet joint. If the pain does not disappear, the application is applied unilaterally.
219454852|NCT07058701|OTHER|Investigational Serum, Standard Cleanser|"Mode of Group Serum application : On-site single use~Standard cleanser + Investigational Serum (random half-face) \[FLA #2039128 50\]~\- subjects should wash face with standard cleanser \[FLA #730457 36\] on site before measurements.~The technician will apply the Investigational Serum \[FLA #2039128 50\] on the subject's half face (according to the Annex 11.6) at the test site, keep another half face as blank control."
219454853|NCT07058701|DEVICE|Infrared Light for Redness Induction on Face|"Infrared light has high radiation frequency, its permeability is strong, the wavelength of infrared light can penetrate the human dermis to promote blood circulation and induce skin redness.The redness induction process will be done after baseline measurements for each subject.The subject's face was exposed at a distance of 20cm from infrared lamp for minimum 5 - 10 minutes at a temperature of 30-40°C and a wavelength of 760-5000 nm. In general, the skin will not be burned during the induction process. Due to individual differences, if the subjects cannot tolerate or feel uncomfortable during the process, the investigators will stop the process according to the situation; If there is any burn during the process, the on-site dermatologist will treat it in time, and the subject needs to follow the dermatologist's advice for follow-up treatment.~Infrared light type: PHILIPS, IR250 RH IR2, 230-250V, 250W, wave length 760-5000nm, T 30\~40°C"
219590212|NCT06374862|OTHER|no effect|"a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect."
219590213|NCT04661891|OTHER|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
219590214|NCT04661891|OTHER|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
219590215|NCT04661891|DEVICE|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
219590216|NCT04661891|DEVICE|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
219590217|NCT04661891|DEVICE|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
219590218|NCT04661891|OTHER|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
219590219|NCT06988865|OTHER|Clinical evaluation|treatment methods, associated symptoms, evolution and clinical presentation
219590220|NCT06989827|DRUG|Preservative free artificial tear|After diagnosing patients with dry eye disease we prescribed them preservative free artificial tears and scheduled them for a follow-up keratometry.
218844896|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
219454854|NCT07057843|BEHAVIORAL|Sequential Nutrition Intervention|"Participants received a structured, sequential nutrition intervention guided by nutritional risk screening (NRS2002). A multidisciplinary team provided the intervention, which included:~* Pre-CyberKnife phase: Calculation of energy requirements using the Harris-Benedict formula, dietary guidance, and initiation of oral nutritional supplements (ONS). If oral intake was less than 60% of target, partial enteral (PEN) or parenteral nutrition (PPN) was administered for 7-10 days.~* Post-CyberKnife phase: Phased re-introduction of feeding, starting with enteral nutrition via nasojejunal tube (Day 1-2) and transitioning to an oral diet (Day 3 onwards).~* Post-discharge phase: Home energy targets were recalculated, with telephone/WeChat follow-up to ensure adherence. ONS prescribed if intake fell below 60% of targets."
218844897|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
219454855|NCT07057843|DRUG|Enteral Nutrition Emulsion|Fresubin (500 mL/bottle) administered at 30 mL/kg/day during the initial post-CyberKnife phase if required.
219590221|NCT06990035|BEHAVIORAL|Mediterranean diet lessons program|Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.
219454856|NCT07057843|BEHAVIORAL|Routine Nutritional Intervention|Participants received routine nutritional intervention, which consisted of dietary education focused on balanced, soft, and easily digestible meals rich in protein and other nutrients (e.g., high-protein soups).
219454857|NCT07059169|DRUG|JY231 (JY231 injection)|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.
219454858|NCT07057869|PROCEDURE|5-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 5 minutes per session, 4 weeks duration.
219454859|NCT07057869|PROCEDURE|10-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 10 minutes per session, 4 weeks duration.
219454860|NCT07057869|PROCEDURE|15-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 15 minutes per session, 4 weeks duration.
219454861|NCT07059195|PROCEDURE|cervical collar or cervical-thoracic orthosis.|postoperative cervical spine flexion maintained using non-invasive techniques, such as a cervical collar or cervical-thoracic orthosis.
219454862|NCT07059195|DEVICE|chin-to-chest (Grillo) suturing|cervical spine flexion maintained using traditional chin-to-chest (Grillo) suturing
218844898|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
218844899|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
218844900|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
218844901|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
219590222|NCT06990035|BEHAVIORAL|Physical activity|Participants will undergo a 12-week physical exercise program guided by specified personal trainers.
219590223|NCT06988982|DRUG|Intravenous Lipid Emulsion 20%|patients will receive 1.5 ml/kg bolus of intravenous lipid emulsion 20 % followed by 0.25 ml/kg/hr infusion over 30 minutes at the end of surgery
219590224|NCT06988982|DRUG|Control (placebo) group|patients will receive equal volume of normal saline at the end of surgery
218844902|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
218844903|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
218844904|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
218844905|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
218844906|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
218844907|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
219196953|NCT06611644|OTHER|Erector Spinae Plane Block|Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.
219454863|NCT07058129|PROCEDURE|Deep cervical lymphatic venous anastomosis|The intervention requires to perform bilateral deep cervical lymphatic venous anastomosis (DC-LVA). Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
219454864|NCT07058493|DRUG|Dexmedetomidine|dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
219454865|NCT07058493|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%.
218844908|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
218844909|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
218844910|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
219454866|NCT07057752|OTHER|Virtual Reality|Virtual reality (VR) will be applied to patients in this group in addition to painkillers. VR is a non-pharmacological method that uses special glasses to create an immersive visual and auditory experience. It helps distract patients from the procedure and may reduce pain and anxiety.
219454867|NCT07057752|DRUG|dexketoprofen + midazolam|Patients in this group will be treated with dexketoprofen as a painkiller and midazolam as an anxiolytic, if needed. This combination aims to reduce both pain and anxiety during the procedure.
219454868|NCT07057778|DRUG|Iguratimod|oral iguratimod at 25mg twice daily for 26 weeks
219454869|NCT07057778|DRUG|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
219454870|NCT07057700|DEVICE|welwalk training|welwalk training group 30 min of welwalk robot-assisted training + 15 min of walking training + 15 min of other training per session.The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
219454871|NCT07057700|OTHER|physical therapy|45 min of walking training + 15 min of other training per session. The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
219454872|NCT07058545|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
219454873|NCT07058545|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
219454874|NCT07054866|BEHAVIORAL|Speech-Gesture combinations|this is a pretest, test, posttest evaluation of language comprehension with and without gestures, to see if gestures can improve language comprehension
219454875|NCT07054632|GENETIC|LX101|Subretinal administration of LX101 to the study eye
219454876|NCT07054801|DRUG|Lidocaine hydrochloride|A total of 20 mg injected in 10 mg doses will be administered over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 40 mg per MMA. The injection will be performed bilaterally, yielding a total dose of 80 mg per patient.
219454877|NCT07054801|DRUG|Methylprednisolone sodium succinate|A total of 10 mg were injected over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 20 mg per MMA, yielding a total dose of 40 mg per patient.
219454878|NCT07058779|DRUG|SSS55|SSS55 is an injection targeting complement C3b
219454879|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
219454880|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
219454881|NCT07058090|DRUG|Silymarin 420 mg|silymarin group received silymarin 140mg thrice daily along with antituberculous drugs for 14 days
219454882|NCT07058090|DRUG|N Acetyl Cysteine|N- acetylcysteine group will receive N-acetylcysteine 900mg once daily with antituberculous drugs for 14 days
219454883|NCT07058090|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|Antituberculous drugs only
219454884|NCT07059143|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
219590225|NCT06988930|DIAGNOSTIC_TEST|Control group|The non-operation group was treated with rehabilitation therapy for 6 weeks, and the operation group was treated with arthroscopic surgery and the pathological tissue of cartilage and subchondral bone was taken. Assessment was performed at three months, one year, and two years after treatment and recorded in the database.
218844911|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
218844912|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
218844913|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
218844914|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
218844915|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
218844916|NCT02354131|DRUG|Bevacizumab|
218844917|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
218844918|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
218844919|NCT02007057|PROCEDURE|Suprascapular nerve block|
218844920|NCT02007057|PROCEDURE|Interscalene nerve block|
218844921|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
218844922|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
218844923|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
218844924|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
218844925|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
219590226|NCT06990763|DRUG|Remimazolam|Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance
219590227|NCT06990763|DRUG|propofol|Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance
218844926|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
218844927|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
218844928|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
218844929|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
219018086|NCT04682652|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
219018087|NCT04447755|DRUG|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m\^2 QD
219590228|NCT06990646|BEHAVIORAL|VR-ACT|8 MODULES OF 3D VIRTUAL REALITY Modules 1 \& 2: Awareness Regulation Skills Modules 3, 4 \& 5: Acceptance of Pain and Internal Experiences Modules 6, 7 \& 8: Behavior Change and Valued Action
219590229|NCT06990646|BEHAVIORAL|Sham-VR|8 2D non-immersive distracting video-animations delivered through a VR headset.
218844930|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
218844931|NCT02126553|DRUG|Lenalidomide|Given PO
218844932|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
218844933|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
218844934|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
218844935|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
219018088|NCT05712720|DRUG|Experimental: Group 1 - 50mg RZ402|RZ402 50 mg oral tablet, once daily for 3 months
219018089|NCT05712720|DRUG|Experimental: Group 2 - 200mg RZ402|RZ402 200mg oral tablet, once daily for 3 months
219018090|NCT05712720|DRUG|Experimental: Group 3 - 400mg RZ402|RZ402 400mg oral tablet, once daily for 3 months
219018091|NCT05712720|OTHER|Placebo: Group 4 - Placebo|Placebo oral tablet, once daily for 3 months
219018092|NCT06963671|BEHAVIORAL|Blood Flow Restriction|The treatment group will receive standard rehabilitation as a home program plus low-load resistance training with BFR application while at the hand therapy clinic for their appointments
218844936|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
218844937|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
218844938|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
218844939|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
218844940|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
218844941|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
218844942|NCT06635785|DRUG|AI-081|AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
218844943|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
218844944|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
218844945|NCT02182024|DRUG|Dabigatran etexilate high dose|
218844946|NCT02182024|DRUG|Dabigatran etexilate low dose|
218844947|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
218844948|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
218844949|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
219454885|NCT07058831|DEVICE|Home ECG monitoring|The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.
219454886|NCT07059260|DIAGNOSTIC_TEST|Early referral|The intervention involves early referral, allowing patients to be assessed by a cardiologist prior to the standard referral process. During this visit, the cardiologist will perform a comprehensive medical history and a detailed physical examination to assess signs of central and peripheral congestion. A standardized echocardiogram will also be conducted, including a series of objective measurements.
219454887|NCT07058116|DRUG|L-Boronophenylalanine intravenous administration|L-BPA will be complexed with fructose to form L-BPA-fructose (L-BPA-F) to increase solubility, and 400 mg/kg of L-BFA as complexed with fructose (L-BPA-F) will then be administered intravenously at a concentration of L-BPA 30 g/L over 2 hours before neutron irradiation.
219590230|NCT06989372|PROCEDURE|serratus posterior superior block|patients were placed in the lateral decubitus position for SPSIPB. The blocks were performed under the guidance of ultrasonography (USG), a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) transducer was placed at the level of the spine scapula in the transverse plane, and the upper medial border of the scapula, trapezius muscle, serratus posterior superior muscle (SPSM), 2nd and 3rd ribs were visualized. The ultrasound probe is rotated 90 degrees in a parasagittal orientation to identify the first rib. After its identification, the second and third ribs are confirmed. An 80 mm sono visible needle (type) was inserted in the caudocranial direction just medial to the scapula with the in-plane technique and driven between the 2nd and 3rd ribs targeting the inferior part of the SPSM. The target was confirmed by injecting the test dose with saline. Thirty ml of 0.25% bupivacaine was subsequently injected
218844950|NCT01961284|DEVICE|Zygomatic implant placement|
218844951|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
218844952|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
218844953|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
218844954|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
218844955|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
218844956|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
218844957|NCT00888329|DRUG|Placebo|Placebo
218844958|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
218844959|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
218844960|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
218844961|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
218844962|NCT02621541|DEVICE|PET/CT|
218844963|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
218844964|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
218844965|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
219454888|NCT06843967|DRUG|Mirdametinib|Mirdametinib (PD-0325901) is a highly selective non-ATP-competitive inhibitor of MEK1 and MEK2. It significantly inhibits the phosphorylation of the MAP kinases ERK1 and ERK2, leading to impaired tumor cell growth in vitro and in vivo in a broad spectrum of human tumors
219454889|NCT06843967|DRUG|Palbociclib|Palbociclib (IBRANCE®) is a kinase inhibitor FDA approved for the following indications: treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men or fulvestrant in patients with disease progression following endocrine therapy.
219454890|NCT07057622|DRUG|177Lu-DOTATATE injection|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the test group are treated with 177Lu-DOTATATE injection, 7.4GBq±0.74GBq (200mCi±20mCi)/cycle, once every 8 to 12 weeks, 4 times in total.
218844966|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
218844967|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
218844968|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
218844969|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
218844970|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
218844971|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
218844972|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
218844973|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
218844974|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
218844975|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
218844976|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
218844977|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
218844978|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
218844979|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
218844980|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
218844981|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
218844982|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
218844983|NCT06003777|DRUG|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
218844984|NCT06003777|DRUG|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
219454891|NCT07057622|DRUG|Octreotide LAR (Long-acting release)|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the treatment group are treated with 60mg of long-acting octreotide once every 4 weeks±3 days.
218844985|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
218844986|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
218844987|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
218844988|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
219454892|NCT07057739|DRUG|Superficial cervical plexus block|Patients received superficial cervical plexus block with 1 ml of normal saline with 7ml bupivacaine 0.25% per side without adjuvants.
219454893|NCT07057739|DRUG|Superficial cervical plexus block + Fentanyl|Patients received superficial cervical plexus block with fentanyl 1 ml (50 microgram) as an adjuvant to 7ml bupivacaine 0.25% per side.
219454894|NCT07057739|DRUG|Superficial cervical plexus block + Dexmedetomidine|Patients received superficial cervical plexus block with dexmedetomidine 0.5mcg/kg in 1 ml of normal saline as an adjuvant to 7ml bupivacaine 0.25% per side.
219454895|NCT06769633|DRUG|Givinostat Hydrochloride|Cohort 1 - from 4 to 6 years old
219454896|NCT06769633|DRUG|Givinostat Hydrochloride - Cohort 2|Cohort 2 - from 2 to 4 years old
219454897|NCT07059299|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
219454898|NCT07059299|DRUG|FLOT Chemotherapy|docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W
219454899|NCT07058532|OTHER|Therapeutic Writing Intervention in Pain Rehabilitation|The therapeutic writing intervention is designed to support emotional processing and regulation in individuals with chronic pain and comorbid mental health disorders. It has been developed specifically for use in a clinical rehabilitation setting and is delivered in two phases over a four-week period at the Pain Clinic of Satasairaala Hospital. Sessions are conducted in person, with clinical staff available to support participants. The intervention is non-pharmacological, low-risk, and integrated into the broader multidisciplinary care pathway.
219454900|NCT07058870|BEHAVIORAL|High Intensity Task Oriented Circuit Training + Telerehabilitation|Participants will receive 10 sessions of high-intensity, task-oriented circuit training, three times a week. Each session will last 60 minutes, with minutes of active training. Each session will include three rounds, each lasting 55 minutes. During each round, participants will rotate between stations working for four minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including supine to stand transitions, walking speed and functional capacity, walking adaptability and stepping. After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring.
219454901|NCT07058818|BEHAVIORAL|Resistance training|Full-body physical therapy and resistance training intervention
219454902|NCT07058259|BEHAVIORAL|Acupuncture|Acupuncture will be administered twice weekly for 5 weeks (10 sessions total) at predefined bilateral acupoints: LU1, LU9, LI18, ST36, GB12, BL13, BL20, and BL23. Single-use, sterile 25 mm × 0.25 mm needles will be inserted at each point for 20 minutes per session.
218844989|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
218844990|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
218844991|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
218844992|NCT00602004|DRUG|losartan|losartan 50 mg a day
218844993|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
219018093|NCT01143454|DEVICE|NSR IDE-MRI: Research pulse sequences|NSR IDE-MRI: Research pulse sequences, Device Manufacturer NIH. Research pulse sequences are customized pulse sequences and analysis software developed by NIH scientists.
219590231|NCT06989372|PROCEDURE|erector spinae block|US-guided ESPB, a commonly performed interfascial plane block, was first defined by Forero et al. (21). In this technique, LA is injected in the plane between the erector spinae muscles and the thoracic transverse processes. Thus, multiple thoracic levels are anesthetized by the LA spreading in a craniocaudal direction. The transducer was then placed approximately 3 cm lateral to the midline parasagittally. The T5 transverse process and the erector spinae, rhomboid major, trapezius muscles were viewed (i.e., from deep to superficial). The block needle was advanced in a craniocaudal direction using an in-plane approach through the trapezius, rhomboid major, and erector spinae muscles. After establishing contact with the hyperechoic transverse process, 30 mL of 0.25% bupivacaine was injected in small aliquots after hydrodissection (2-3 mL, 0.9% NaCl) and checking for negative blood aspiration after every 5 mL of injection.
218844994|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
218844995|NCT00151684|DRUG|Diazoxide|
218844996|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
218844997|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
218844998|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
218844999|NCT00190021|DRUG|donepezil|
218845000|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
218845001|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
218845002|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
218845003|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
218845004|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
218845005|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
218845006|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
218845007|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
218845008|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
218845009|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
218845010|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
218845011|NCT00386750|DRUG|Artemether-lumefantrine|
218845012|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
218845013|NCT02745678|DRUG|Thermosensitive gel rectal formulation|
218845014|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
218845015|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
218845016|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
218845017|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
218845018|NCT00118248|DRUG|tanespimycin|Given IV
218845019|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
218845020|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
218845021|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
218845022|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
219590232|NCT06989801|BEHAVIORAL|Urban Walk|"For each session, participants will take a 30-minute walk in an urban environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
218845023|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
218845024|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
218845025|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
218845026|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
218845027|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
218845028|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
218845029|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
218845030|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
218845031|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
218845032|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
218845033|NCT03734640|OTHER|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
218845034|NCT03734640|OTHER|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
218845035|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
218845036|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
218845037|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
218845038|NCT05040503|BIOLOGICAL|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion"
218845039|NCT05040503|BIOLOGICAL|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
218845040|NCT05040503|OTHER|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
218845041|NCT03482648|DRUG|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
218845042|NCT03482648|DRUG|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
218845043|NCT03482648|DRUG|Placebo|Placebo matched to BBT-401-1S, oral capsule
218845044|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
219018094|NCT06550128|DRUG|AHB-137|AHB-137 injection will be administered subcutaneously.
219018095|NCT06550128|DRUG|AHB-137 and Placebo|AHB-137and placebo will be administered subcutaneously.
219018096|NCT06550128|DRUG|AHB-137 (16weeks)|AHB-137 injection will be administered subcutaneously.
218845045|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
218845046|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
218845047|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
218845048|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
218845049|NCT02765815|DRUG|Ketorolac 30mg|
218845050|NCT02765815|DRUG|Morphine 10mg|
218845051|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
218845052|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
218845053|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
218845054|NCT04867720|DRUG|Everolimus|\- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
218845055|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
218845056|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
218845057|NCT00695916|PROCEDURE|Breast MRI|
218845058|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
218845059|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
218845060|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
219454903|NCT07058259|DRUG|Standard COPD Pharmacological Therapy (LAMA + LABA or LAMA + LABA + ICS)|"Patients in this group receive standard pharmacological treatment for COPD according to current clinical guidelines. Treatment includes either dual or triple inhaler therapy:~Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a long-acting muscarinic antagonist (LAMA) such as Tiotropium bromide, Umeclidinium, or Glycopyrronium.~Triple Therapy (LABA + LAMA + ICS): Patients receive the above combination of LABA and LAMA plus an inhaled corticosteroid (ICS) such as Budesonide, Fluticasone, or Beclometasone.~These medications may be administered either as fixed-dose combination inhalers or as separate inhalers, depending on patient needs and physician discretion. The treatment regimen is individualized based on clinical condition, prior therapy, and symptom severity."
218845061|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
218845062|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
218845063|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
218845064|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
218845065|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
218845066|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
218845067|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
218845068|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
218845069|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
218845070|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
218845071|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
218845072|NCT00488449|DRUG|GSK256073A tablets|
218845073|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
218845074|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
218845075|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
218845076|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
218845077|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
218845078|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
218845079|NCT02661737|DEVICE|YVOIRE volume s|
218845080|NCT00171457|DRUG|Tegaserod|
218845081|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
218845082|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
218845083|NCT00348699|DRUG|AFP464|Given IV
218845084|NCT00348699|OTHER|pharmacological study|Correlative studies
218845085|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
219454904|NCT07059442|DIAGNOSTIC_TEST|anal HPV screening|From all included women samples will be collected at the out-patient HIV departments including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA.
218845086|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
218845087|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
218845088|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
218845089|NCT01404403|DEVICE|Rapid System|
218845090|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
218845091|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
218845092|NCT01292356|DRUG|cetuximab|
218845093|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
218845094|NCT02365610|DRUG|GWP42006|
218845095|NCT02365610|DRUG|Placebo Control|
218845096|NCT00311740|DRUG|Valsartan|
218845097|NCT00311740|DRUG|Hydrochlorothiazide|
218845098|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
218845099|NCT06105775|DIETARY_SUPPLEMENT|Inorganic Nitrate Capsule|Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing 400 mg of inorganic nitrate. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
218845100|NCT06105775|DIETARY_SUPPLEMENT|Placebo Capsule|From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing sodium chloride with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
218845101|NCT00004112|BIOLOGICAL|rituximab|
218845102|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
218845103|NCT00004112|DRUG|cyclophosphamide|
218845104|NCT00004112|DRUG|doxorubicin hydrochloride|
218845105|NCT00004112|DRUG|prednisone|
218845106|NCT00004112|DRUG|vincristine sulfate|
219454905|NCT07058766|BEHAVIORAL|positively affects the physical and psychological health of pregnant women in the disaster area.|As time passes after the earthquake, psychological first aid services are not sufficient. Developing a care protocol to provide physical and psychosocial support to pregnant women who are earthquake victims, especially those in the vulnerable group, during the post-disaster disappointment period (months 2-36), is an important unique value of this project.
219454906|NCT01154738|DRUG|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
219454907|NCT01154738|DRUG|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
219454908|NCT06899620|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 60 days.
219454909|NCT06899620|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 60 days.
218845107|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
218845108|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
218845109|NCT04038632|OTHER|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
218845110|NCT05262530|BIOLOGICAL|BNT142|Intravenous bolus/infusion
218845111|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
218845112|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
218845113|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
218845114|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
218845115|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
219454910|NCT06856057|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|CAARE is a technology-enhanced stepped model of care that is designed to deliver education at the bedside to caregivers of children under age 12 years hospitalized for pediatric injury about mental health recovery after pediatric injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and reinforcement of coping skills via mHealth tools (Step 2), screen for caregivers' and children's PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm hand-off to mental health services if needed (Step 4).
219454911|NCT06879327|BIOLOGICAL|R21 Matrix-M (R21/MM) Malaria Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
219454912|NCT06879327|BIOLOGICAL|Placebo|Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
219454913|NCT06879327|BIOLOGICAL|Hexavalent Vaccine|"Administered by intramuscular injection. Each dose of 0.5 mL contains:~* Diphtheria Toxoid \> 30 IU~* Tetanus Toxoid \> 40 IU~* B. pertussis (whole cell) \> 4 IU~* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg~* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU~* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]"
219454914|NCT06879327|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
219454915|NCT06879327|BIOLOGICAL|Rotavirus, Live Attenuated (Oral) Vaccine|Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
219590233|NCT06989801|BEHAVIORAL|Nature Walk|"For each session, participants will take a 30-minute walk in a natural environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
219590234|NCT06989801|BEHAVIORAL|Active Nature Walk|"For each session, participants will take a 30-minute walk in a natural area, following a designated looped route. Unlike a regular walk, participants will be encouraged to engage with nature (e.g., listening to natural sounds, looking for birds, and touching flowers).~To make the most of the walk, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just letting it run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
219590235|NCT06988839|PROCEDURE|Microneedling followed by coronally advanced flap|Microneedling will be performed using a 30 gauge lancet needles, inserted until hard tissue is felt. It will be performed in 4 sessions at 10 day intervals, followed by coronally advanced flap procedure, 2 months post microneedling.
219590236|NCT06988839|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap operation will be performed with connective tissue graft harvested from palate after phase 1 therapy.
219590237|NCT06989619|BEHAVIORAL|Sleep health and mindfulness intervention|This educational, healthy lifestyle intervention will include several modules detailing sleep health and mindfulness strategies. In addition, opinion leaders will be identified in the population to help diffuse messages through each housing facility.
219590238|NCT06990672|OTHER|Standard care|Receiving standard dietary and regular recommendations such as education profile and counseling to achieve a fluid intake ≥ 2500 ml, providing verbal health education counseling regarding urological calculi prevention during the hospitalization, and adequate fluid intake in person on the day of discharge. Prepare a fixed-capacity water bottle. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
218845116|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
219590239|NCT06990672|OTHER|Experimental|Receive the same standard dietary counseling and education handout but also the WeChat applet intervention. A WeChat-based applet will be developed for fluid intake adherence improvement and self-monitoring to prevent urinary calculi, including fluid intake reminders, fluid value recording, urine value and coluor recording, and health education, an interactive platform for communication among post-operative patients with urinary stones. The applet will tailor the daily notification to participants of fluid intake to increase their fluid consumption to more than 2,500 ml. Extra education information regarding the benefits of adherence will be provided to the experimental group only via the applet. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
219590240|NCT06990568|DRUG|Lacidofil|1 capsule twice daily.
219590241|NCT06990568|DRUG|Placebo|1 capsule twice daily.
219590242|NCT06990958|PROCEDURE|Erector Spinae Plane Block (ESPB) group|ultrasound guided erector spinae plane block (at lumbar level) in lateral position .
219590243|NCT06990958|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound guided suprainguinal approach in supine position
219590244|NCT06990178|RADIATION|Neoadjuvant concurrent chemoradiotherapy|Non-cCR group will continue with neoadjuvant concurrent chemoradiotherapy (2Gy\*20f) followed by radical surgery
218845117|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
219590245|NCT06990607|PROCEDURE|Pars plana Vitrectomy|Pars plana Vitrectomy using 23 Gauge
219590246|NCT06990607|PROCEDURE|Silicone Oil|Silicone Oil injection after PPV
219454916|NCT06879327|BIOLOGICAL|Measles and Rubella Vaccine|Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
219454917|NCT06879327|BIOLOGICAL|Meningococcal A conjugate vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
219454918|NCT06879327|BIOLOGICAL|Yellow Fever vaccine|Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
219454919|NCT06879327|BIOLOGICAL|Typhoid Conjugate vaccine|Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
219590247|NCT06988878|OTHER|Evidence-based practice competence training based on the flipped learning model|This training was carried out for six weeks (11 September 2024 - 16 October 2024). Once a week, participants first watched the videos uploaded by the researcher to the Edpuzzle application and participated in the offline training. Participants who had watched the videos then attended the face-to-face/traditional training. The nurse information form, the evidence-based practice knowledge test and the evidence-based practice evaluation competence questionnaire were administered to the participants before the training (4 September 2024), at the end of the training (16 October 2024) and two months after the training (18 December 2024).
219590248|NCT06988709|OTHER|Real-time Visual Feedback|Runners will visualize their real-time ground contact time (GCT) measured by the RunScribe on a TV screen. They will be instructed to run with a goal of matching their target GCT. Their target GCT will be 5% less than their baseline.
219590249|NCT06988709|OTHER|Real-time Auditory Feedback|Runners will be instructed to match their step rate to a target step rate, 10% above their baseline step rate. A metronome will be played over a speaker to provide real-time auditory feedback of the target step rate.
219590250|NCT06988709|OTHER|Real-time Verbal Feedback|"The clinician will provide real-time verbal feedback to runner to pull your foot off the ground as quickly as you can, every 15 seconds during the retraining condition."
219590251|NCT06990893|DRUG|Oliceridine|a loading dose of 1.5 mg of oliceridine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.01 mg.kg-1.h-1 oliceridine was connected with normal saline to 100 ml at a rate of 2 ml per hour
219590252|NCT06990893|DRUG|Morphine|a loading dose of 4 mg of morphine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 mg.kg-1.h-1 morphine was connected with normal saline to 100 ml at a rate of 2 ml per hour
219590253|NCT06990893|DRUG|Sufentanil|A 4 ug loading dose of sufentanil was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 ug.kg-1 h-1 was connected. sufentanil was mixed with normal saline to 100 ml at a rate of 2 ml per hour
219454920|NCT04561284|DIETARY_SUPPLEMENT|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
219454921|NCT04561284|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
219454922|NCT01846689|DRUG|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
219454923|NCT01801189|DRUG|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
218845118|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
218845119|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
219454924|NCT01801189|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
219454925|NCT02364661|BEHAVIORAL|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
219454926|NCT01731756|OTHER|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
219454927|NCT01731756|DRUG|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
219454928|NCT01731756|OTHER|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
219454929|NCT03300557|DRUG|Exemestane|Given PO
219454930|NCT03300557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219454931|NCT03300557|OTHER|Pharmacokinetic Study|Correlative studies
219454932|NCT03300557|OTHER|Questionnaire Administration|Ancillary studies
219454933|NCT06107452|OTHER|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
219454934|NCT06107452|OTHER|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
219454935|NCT04305054|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219454936|NCT04305054|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
219454937|NCT04305054|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
219454938|NCT04305054|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
219454939|NCT04305054|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
219454940|NCT04305054|DRUG|ATRA|Administered via oral capsule at a specified dose on specified days
219590254|NCT06989398|BEHAVIORAL|Advancing Supervisors' Capacity for Mental Health at Work (ASCEND)|"The intervention will consist of a training that incorporates evidence-based content and interactive exercises. Advancing Supervisors' Capacity for Mental Health at Work (ASCEND) covers five core topics designed to equip supervisors with the knowledge and practical skills needed to effectively support the mental health of their employees. The full training is delivered over approximately 8 hours in an in-person group setting. Trainings are facilitated by a trained professional.~To support learning and skill application, participants will also receive a Manager Reference Booklet during the training. This booklet consolidates key information from the ASCEND training, serving both as a learning aid during the sessions and a practical, quick-reference tool afterward. It includes summaries of key concepts, tips, and exercises, along with space for participants to record notes."
219590255|NCT06989333|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|Bronchoscopy under general anesthesia or sedation; The predetermined dose of recombinant GM-CSF was dissolved in normal saline. The diseased lung segments were located through bronchoscopy and the liquid medicine was sprayed.
219590256|NCT06989554|DEVICE|mechanical feedback insole|A 3-mm rubber insole containing four 15-mm spring-steel snap buttons aligned along the heel-mid-foot axis. Each insole is statically calibrated on a hydraulic press so that the buttons collapse at 20 % ± 1 % of the individual's body weight, producing an unmistakable plantar cue when the load limit is exceeded. The device is purely mechanical, requires no batteries, and is fitted on postoperative day 1. Participants wear the insole during every supervised walking session until discharge (≈ 14 days).
218845120|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
219454941|NCT07072325|DRUG|CD-001|CD-001 administered as an intravenous (lV)infusion.
219454942|NCT06587932|OTHER|brain gym exercises|It is comprised very easy body movements which have been designed to coax the two hemispheres of the brain.
219454943|NCT06587932|OTHER|Traditional treatments|traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other
219454944|NCT06843577|DEVICE|Zona Plus Device|Use of the Zona Plus device involves performing isometric handgrip exercise therapy. Isometric exercise is the type of exercise in which you tense or tighten your muscle without seeing it change in length.
219454945|NCT06843577|OTHER|Relaxing Music App|Relaxing music will be made available through a mobile app that users access via their smart phone or tablet. Subjects will have the option to listen to 5 different music genres that support relaxation (Classical, Nature, Movie Soundtracks, Jazz, Reggae).
219454946|NCT04470024|DRUG|INCAGN01876|agonistic antihuman GITR mAb
219454947|NCT04470024|DRUG|INCMGA00012|humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
219590257|NCT06989554|PROCEDURE|Standard physiotherapy without feedback device|Routine inpatient physiotherapy consisting of verbal instruction to limit loading to 20 % body weight, initial bathroom-scale training, and assisted ambulation with walker or crutches. No tactile, visual, or electronic feedback device is provided. Session frequency, walking aids, analgesia, and discharge criteria are identical to the intervention arm; duration ≈ 14 days.
219590258|NCT06989151|BEHAVIORAL|Cognitive Remediation Therapy|8 session psychological intervention.
218845121|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
219454948|NCT04470024|BIOLOGICAL|DPV-001|autophagosome cancer vaccine
219454949|NCT06740214|DRUG|0.5% standard bupivacaine only|20ml 0.5% standard bupivacaine only
219454950|NCT06740214|DRUG|1.33% liposomal bupivacaine with 0.5% standard bupivacaine|10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
219454951|NCT06740214|DRUG|1.33% liposomal bupivacaine only|20ml 1.33% liposomal bupivacaine (266mg)
219454952|NCT06926829|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 52 weeks
219454953|NCT06926829|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 52 weeks
219454954|NCT07137182|OTHER|8-week physical activity program|Individuals in the experimental group will be administered an eight-week physical activity program. The researcher who will administer the activity is a specialist in Sports Sciences and holds the necessary certifications. The activity program includes cardio exercises, jumping, stretching, and stretching exercises.
219454955|NCT00502398|PROCEDURE|Blood test|
219454956|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
219454957|NCT04975997|DRUG|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
219590259|NCT06988787|BEHAVIORAL|webSTAIR|"Ten web-based modules that are completed independently by participants (\~2 modules per week) and receive therapist support via video-telehealth after the completion of every 2 skill modules (1x per week for a total of 5 meetings).~The first five modules review emotional awareness, emotion management, and distress tolerance while the final five modules raise awareness about relationship patterns and provide interpersonal skills training regarding effective assertiveness, interpersonal flexibility, and compassion for self and others."
219590260|NCT06988787|BEHAVIORAL|ExpoTx|A real-time, present-focused, intervention that does not require participants to relive or focus on past trauma(s), but rather on current social functioning; ie, how they are doing in day-to-day life, and current cognitive and psychological functioning. Therapist will meet individually with the participant for 5 sessions, 60 minutes each conducted virtually. During the 5 sessions, participants will be guided to use in vivo or in the moment ExpoTx to identified fear-based triggers. In each consecutive session, the therapist will engage the Veteran to explore cognitions that interfered with, reinforced, or diminished fear responses. Participants will be asked about their use of coping skills during exposure practice. Intentional participation in exposure for one target at least 30 minutes per day, or until SUDs lower by half. At the end of ExpoTx, the therapist will engage the Veteran in self-determining future goals and offer referrals in the community or at VA for additional support.
219590261|NCT06988787|OTHER|PsychoEd|Psycho-education (PsychEd) orientation that provides an overview of PsychEd as a process for learning about mental health symptoms and disease management related to trauma. During PsychEd sessions, therapists will focus on the following 5 areas: 1) Defining trauma and PTSD. 2) Brain Basics and Brain Injury. 3) Understanding the Role of Stress and Its impact on trauma symptoms. 4) The Role of Nutrition and Exercise in Disease Management. 5) Information on other Programs.
219590262|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery
219590263|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery, designed to provide superior precision and increase the safety profile of the current standard of care.
219590264|NCT06988631|OTHER|Sensory treatment|Participants were asked to practice the foot sole sensory training program at home every day for 2 weeks.
219590265|NCT06988631|OTHER|foot care booklet|Participants were given a booklet about healthy feet and were informed.
219590266|NCT06990308|PROCEDURE|Inflated Cuff Extubation|The adjustable pressure limiting valve will be set to 20 centimeters water pressure. To blind the Anesthesiologist Associate Investigator from the patient's group allocation, sham deflation of the endotracheal tube cuff pilot balloon will be performed with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure. In the rare event significant resistance is met with attempted extubation, the principal investigator will deflate the cuff in one milliliter increments until extubation is possible. This process does not unblind the Anesthesiologist Associate Investigator.
219590267|NCT06990308|PROCEDURE|Deflated Cuff Extubation|The adjustable pressure-limiting valve will be set to 20 centimeters water pressure. All air will be removed from the endotracheal tube cuff pilot balloon with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel, to prevent the Anesthesiologist Associate Investigator from identifying the patient's allocation, while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure.
219590268|NCT06990438|DRUG|TDF (Tenofovir)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
219590269|NCT06989723|DRUG|Pioglitazone 15 MG [Actos]|Participants will receive pioglitazone 15 mg, administered orally once daily. The tablet may be taken with or without food.
219454958|NCT04975997|DRUG|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
219590270|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance]|Participants will receive empagliflozin 10 mg, administered orally once daily. The tablet may be taken with or without food.
219590271|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]|Participants will receive one tablet of pioglitazone 15 mg and one tablet of empagliflozin 10 mg, administered orally once daily. Both tablets may be taken with or without food.
219590272|NCT06990802|BEHAVIORAL|Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)|LTP+CaCBT has two components. LTP is underpinned by Piaget's theory of cognitive development and Bowlby's theory of attachment. The CBT component uses active listening techniques, changing negative thinking, and guided discovery (i.e., Socratic questioning style to gently probe for cultural beliefs on mental health and stimulate alternative positive thinking). This includes a culturally adapted pictorial calendar devised for women, depicting successive stages of child well-being from 0-3 years, with illustrations of mother-child play and other culturally relevant activities that promote healthy parenting and mother-child attachment.
219590273|NCT06990802|DRUG|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the health care sites of intervention (e.g. diagnosis, management, antidepressant prescription and/or other forms of mental health care).
218845122|NCT06205381|DRUG|AV078|Oral solution containing active ingredient, AV078
218845123|NCT06205381|DRUG|Placebo|Oral solution with no active ingredients
219454959|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
219454960|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
218845124|NCT06205381|DRUG|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
218845125|NCT06205381|DRUG|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
218845126|NCT06205381|DRUG|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
219454961|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
219454962|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
219454963|NCT04975997|DRUG|Daratumumab|Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
218845127|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
218845128|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
218845129|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
218845130|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
218845131|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
218845132|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
218845133|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
218845134|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
219454964|NCT06692673|DRUG|Use of Linaclotide as a single agent Colonoscopy prep|We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
219454965|NCT04581109|BIOLOGICAL|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
219590274|NCT06990503|DRUG|SHR-A1811|"Injection SHR - A1811 (hereinafter referred to as SHR - A1811) is an antibody - drug conjugate (ADC) targeting the HER2 protein, independently developed by Suzhou Shengdeya Biopharmaceutical Co., Ltd. (hereinafter referred to as the sponsor). It is composed of a recombinant humanized anti - HER2 IgG1 monoclonal antibody (SHR - 1805) conjugated with a small molecule component, SHR169106."
219590275|NCT06990503|DRUG|Chemotherapy|"The treatment regimens for the control group are as follows:~Liposomal doxorubicin: Administered intravenously on Day 1 of each 4 - week treatment cycle at a dose of 40 mg/m².~Paclitaxel: Given intravenously on Days 1, 8, 15, and 22 of each 4 - week treatment cycle at a dose of 80 mg/m² per administration.~Topotecan: Intravenously infused on Days 1, 8, and 15 of each 4 - week treatment cycle at a daily dose of 4 mg/m².~Gemcitabine: Infused intravenously on Days 1 and 8 of each 3 - week treatment cycle at a daily dose of 1000 mg/m²."
219590276|NCT06991075|DEVICE|High frequency transcutaneous electrical nerve stimulation|TENS 7000 digital TENS unit will be used.
219590277|NCT06990659|OTHER|Ambulatory care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an outpatient basis: hospitalization in an outpatient unit, followed by systematic telephone and on-demand nursing follow-up for 48 hours for REH and 72 hours for CEH. A dedicated re-hospitalization circuit has also been set up in the event of complications.
219590278|NCT06990659|OTHER|Conventional inpatient care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an inpatient basis: conventional hospitalization.
219590279|NCT06981949|DRUG|Dexmedetomidine|"Dexmedetomidine added to ropivacaine in the bilateral single-shot Ultrasound-guided erector spinae plane block that will be applied to each side (bilateral):~20ml/side of 0.375% ropivacaine+0.5 μg/kg/side of dexmedetomidine (lean body weight if BMI \>30)"
219590280|NCT06981949|DRUG|Ropivacaine|"Ropivacaine only in the Bilateral single-shot Ultrasound-guided Erector Spinae Plane Block:~20ml/side of 0.375% ropivacaine"
219590281|NCT04769687|BIOLOGICAL|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
219590282|NCT04769687|BIOLOGICAL|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
219590283|NCT04769687|OTHER|Placebo|Placebo
219590284|NCT06429579|PROCEDURE|Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy|Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
219454966|NCT04929288|DRUG|Alcohol|Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.
219454967|NCT05690906|DEVICE|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
218845135|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
219590285|NCT06429579|DRUG|Only conventional drug therapy|Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
219590286|NCT06988501|BEHAVIORAL|Goal setting with mobile-based self-management tool|In addition to the nutrition education provided to both groups, the participants of the intervention group will work with the dietitian to make behavior-change goals based on SMART goal setting strategy. They will also have access to diet tracking function and weekly report on smart phone application. The dietitian will also meet with the participants virtually to track their progress and provide suggestions.
219590287|NCT06988501|OTHER|Nutrition education|The control group will receive nutrition education about blood pressure management by the dietitian
219590288|NCT06989476|OTHER|CARELOOP Intervention|"CARELOOP Intervention (Clinics cAtch needs, REfer, Link to services, and close the lOOp using an equitable family-centered Process).~CARELOOP is a way of enhancing psychosocial screenings through PSM methodology and Implementation Science, and grounded in the Clinical-Community Relationships Evaluation framework"
218845136|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
218845137|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
218845138|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219454968|NCT05690906|DEVICE|gauze packing|The subjects of both groups will be given gauze packing
219454969|NCT06929403|BEHAVIORAL|Diet|Low-fat, low-cholesterol heart-protective diet
218845139|NCT00499291|PROCEDURE|gene expression analysis|
218845140|NCT00499291|PROCEDURE|laboratory biomarker analysis|
218845141|NCT00499291|PROCEDURE|pharmacological study|
218845142|NCT00499291|PROCEDURE|polymerase chain reaction|
218845143|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
218845144|NCT03718884|DRUG|Mirikizumab|Administered SC
218845145|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
218845146|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
218845147|NCT00382421|DRUG|bisoprolol|
219454970|NCT06929403|DIETARY_SUPPLEMENT|Diet supplementation|2 tablets/daily bergamot and plant sterol/stanol supplement (375 mg bergamot fruit extract, 800 mg plant sterols and 150 mg flavonoids) for 12 weeks
219454971|NCT07086222|BIOLOGICAL|NVX-CoV2705|NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant
219454972|NCT07086222|BIOLOGICAL|Placebo|Placebo (normal saline) in a 0.5 mL injection volume.
219590289|NCT06989736|DIAGNOSTIC_TEST|Taste Test|Participants received nine solutions (tasteless, sweet, salty, sour, and bitter; each in two concentrations) before treatment and six weeks later.
219590290|NCT06989047|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Assigned Interventions:~Procedure/Surgery: Pericapsular Nerve Group (PENG) Block An ultrasound-guided nerve block targeting articular branches of the femoral, obturator, and accessory obturator nerves. Performed under aseptic technique using a curved low-frequency ultrasound probe to visualize the iliopsoas plane and pubic ramus.~Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used to provide analgesia in nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct used to enhance analgesic efficacy of the block."
218845148|NCT00382421|DRUG|amlodipine|
218845149|NCT00382421|DRUG|molsidomine|
219590291|NCT06989047|PROCEDURE|Femoral Nerve Block (FNB)|An ultrasound-guided nerve block targeting the femoral nerve to provide analgesia before spinal anesthesia in proximal femur fracture surgery. Administered using 30 ml of 0.25% bupivacaine and 5 ml of 10% magnesium sulfate (500 mg). The block is performed with an in-plane ultrasound approach, identifying the femoral nerve lateral to the femoral artery under sterile conditions.
219590292|NCT06991062|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a non-invasive procedure in which a coil is placed over the scalp, and focused magnetic pulses are applied to parts of the brain through the coil.
219590293|NCT06981637|DRUG|Pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg / m2 every 4 weeks for a maximum of 12 cycles.
219590294|NCT06983509|DRUG|Regiocit|"Regiocit can be used as a replacement fluid for CRRT with RCA. It will be used in pre-dilution mode only.~At least 200 mL of post-replacement solution is recommended to minimize clotting in the de-aeration chamber. A replacement/dialysate solution with 22 to 26 mEq/L bicarbonate buffer is advised as the first choice. A higher concentration of bicarbonate may be required in severe cases of acidosis. The use of a non-calcium-containing dialysate or replacement fluid is advised. The rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Regiocit will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 to 4 mmol/L. A BFR between 100 to 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight."
218845150|NCT00382421|DRUG|acetylsalicylic acid|
218845151|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
218845152|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
219454973|NCT05172973|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
218845153|NCT05359003|BEHAVIORAL|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
218845154|NCT04700540|DEVICE|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
218845155|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
218845156|NCT05337124|DRUG|LUPKYNIS|LUPKYNIS treatment per the approved US Prescribing Information
218845157|NCT06853301|OTHER|Blood culture sampling|Patients with blood culture sampling as standard of care. Two to four additional blood culture bottles sampled that will be spiked with known bacterial species to determine their electrochemical profiles
218845158|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
218845159|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
218845160|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
218845161|NCT02342847|OTHER|N/A (non-interventional study)|
218845162|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
218845163|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
218845164|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
218860117|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
219454974|NCT04267887|DRUG|Abiraterone Acetate|Given PO
219454975|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
219454976|NCT04267887|DRUG|Apalutamide|Given PO
219454977|NCT04267887|DRUG|Prednisone|Given PO
219454978|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
219454979|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
219454980|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219454981|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
219454982|NCT05118789|DRUG|Zidesamtinib (NVL-520)|Oral tablet of zidesamtinib (NVL-520)
219454983|NCT07095855|DRUG|ZM-H1505R 100mg|ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.
219454984|NCT07095855|OTHER|ZM-H1505R Placebo|ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.
219454985|NCT07095855|COMBINATION_PRODUCT|"NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments"|"All eligible subjects will be use NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments during the study for 148 weeks, including Part A and Part B.~Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions."
219454986|NCT07095543|BEHAVIORAL|Low-fat, vegan diet|All participants will be asked to follow a low-fat vegan diet for the duration of the study. Participants will attend weekly classes where they we receive education and support.
219454987|NCT07099209|BEHAVIORAL|Delta-Wave Hypnoanalgesia|Binaural beat audio tracks at delta frequencies (1-4 Hz) to induce deep relaxation and reduce perioperative anxiety.
219454988|NCT01365169|BEHAVIORAL|Exercise Intervention|Participate in walking and/or strengthening program
219454989|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
219454990|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
219454991|NCT01365169|OTHER|Health Telemonitoring|Use smart phone
219454992|NCT01365169|OTHER|Health Telemonitoring|Use CO monitor and smart phone
219454993|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
219454994|NCT01365169|OTHER|Quality-of-Life Assessment|Ancillary studies
219454995|NCT01365169|OTHER|Questionnaire Administration|Ancillary studies
219454996|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit and Actigraph
219454997|NCT07095751|DEVICE|AI Uro-Cam|As stated in AI Uro-Cam arm description
219454998|NCT07096401|DEVICE|Reverse Curve of Spee Archwire|Orthodontic treatment using a 0.016 × 0.022 NiTi reverse curve of Spee archwire to correct deep bite through posterior extrusion and anterior intrusion.
219454999|NCT07096401|DEVICE|Anterior Bite Turbos|Orthodontic treatment using anterior bite turbos bonded to the palatal surfaces of the upper central incisors to promote posterior extrusion and correct deep bite.
219455000|NCT07096401|DEVICE|Clear Aligners|Orthodontic treatment using clear aligner therapy designed for anterior intrusion and leveling of the curve of Spee to correct deep bite.
219455001|NCT07096908|DRUG|Tirzepatide|weekly injections
219455002|NCT07096908|DRUG|Placebo|weekly injections
219455003|NCT07096739|DIETARY_SUPPLEMENT|High protein shake|Subjects in this study will consume the study product for 1 week. Participants will record GI symptoms over the past 24h on 3 days during the week prior to the intervention, and on days 3, 5, and 7 during the intervention. On the first day, overnight fasted participants will be given the product and symptoms will be followed for 2h. 24h dietary recalls will be collected at the beginning and end of the 7-day treatment period.
219590295|NCT06983509|DRUG|Biphozyl|"Biphozyl is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter. After the initiation of RRT, Biphozyl is used for late treatment of the acute condition when pH, potassium, and phosphate concentrations return to normal. Biphozyl can also be used if any other buffer is in use or during RCA.~The volume and rate of administration of Biphozyl depend on the blood concentration of phosphate and other electrolytes, acid-base balance, body fluid balance, and overall clinical condition of the patient. The volume of replacement fluid given also depends on the expected intensity (dosage) of treatment."
219455004|NCT03579446|DRUG|Hydrocodone|Given by PO
219455005|NCT03579446|DRUG|Hydromorphone|Given by PO
219455006|NCT03579446|DRUG|Levorphanol|Given PO
219455007|NCT03579446|DRUG|Morphine|Given by PO
219455008|NCT03579446|DRUG|Oxycodone|Given by PO
219455009|NCT03579446|DRUG|Oxymorphone|Given by PO
219455010|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
218845165|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
218845166|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
218845167|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
219455011|NCT07100769|PROCEDURE|Real-time ultrasound-guided thoracic epidural placement|"Real-time ultrasound-guided thoracic epidural catheter placement is performed by an attending anesthesiologist using paramedian-cross view to approach thoracic epidural space.~The patient is placed in the prone position with a pillow under the upper abdomen. The probe is placed to identify the rib, then moved medially to identify key anatomical structures: costotransverse joint, transverse process, lamina, superior articular process. The probe is rotated clockwise toward the midline to visualize the lamina and base of the spinal process.~A 18G Tuohy needle is advanced under ultrasound guidance from inferior to superior aiming for the interspace between the lamina and base of the upper spinal process.~After the tip of Tuohy needle approaches the interspace, the anesthesiologist will perform a loss-of-resistance test to identify the epidural space. Then a catheter will be inserted into epidural space."
218845168|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
218845169|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
218845170|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
219455012|NCT07101380|DEVICE|Tablet-based Physical SuperBrain BOOM|"This intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI).~Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function.~Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting.~The app also helps track progress and encourage adherence to the exercise regimen."
219590296|NCT06983509|DRUG|Prismasol 2|"Prismasol 2 is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter.~The volume and rate of administration of Prismasol 2 depend on the blood concentration of electrolytes, acid-base balance, fluid balance, and overall clinical condition of the patient. The volume of replacement fluid administered also depends on the required intensity (dosage) of the treatment."
218845171|NCT00044837|DRUG|Medroxyprogesterone acetate|
218845172|NCT00044837|DRUG|Estradiol|
218845173|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
218845174|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
218845175|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
218845176|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
218845177|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
218845178|NCT00189800|DRUG|Solifenacin succinate|
218845179|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
218845180|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
218845181|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
218845182|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
218845183|NCT06232746|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
218845184|NCT05617508|OTHER|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
218845185|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
218845186|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
218845187|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
218845188|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
218845189|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
218845190|NCT04084366|DRUG|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
218845191|NCT04084366|DRUG|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
218845192|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
218845193|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
218845194|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
218845195|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
218845196|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
218845197|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
218845198|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
218845199|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
218845200|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
219455013|NCT07101380|DEVICE|Smartphone-based SuperBrain BOOM|This intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen.
219455014|NCT07101276|OTHER|No intervention|No intervention will be performed in this study.
219455015|NCT07102225|DRUG|prolotherapy solution of 20% dextrose|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
219455016|NCT07102225|DRUG|Hyaluronic Acid (HA)|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
219455017|NCT07100730|COMBINATION_PRODUCT|TLX-101-Tx + Lomustine|Combination therapy with TLX-101-Tx + Lomustine
219455018|NCT07100730|RADIATION|TLX101-Tx|TLX101-Tx
219455019|NCT07101016|DRUG|Diclofenac Sodium Gel|I1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity
219455020|NCT07100470|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI is used to detect early metabolic alterations in neurodegenerative diseases
218845201|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
218845202|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
218845203|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
218845204|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
218845205|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
218845206|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
218845207|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
218845208|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
218845209|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
218845210|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
218845211|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
218845212|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
218845213|NCT02108717|DEVICE|Remote CT reading using the iPhone|
218845214|NCT02108717|DEVICE|CT reading using LCD monitor|
218845215|NCT00130143|DRUG|Ethyol (Amifostine)|
219455021|NCT07101341|PROCEDURE|Traditional aerobic training|5 minutes of warm-up at increasing intensity up to 60% of maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cool-down at decreasing intensity (30-60% HRmax)
218845216|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
218845217|NCT03359707|OTHER|survey|no intervention just survey
218845218|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
218845219|NCT00002598|BIOLOGICAL|sargramostim|
218845220|NCT00002598|DRUG|cyclophosphamide|
218845221|NCT00002598|DRUG|cytarabine|
218845222|NCT00002598|DRUG|etoposide|
218845223|NCT00002598|DRUG|methotrexate|
218845224|NCT00002598|DRUG|mitoxantrone hydrochloride|
218845225|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
218845226|NCT00002598|RADIATION|radiation therapy|
218845227|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
218845228|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
218845229|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
218845230|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
218845231|NCT00197145|DRUG|GW873140|400 mg twice daily
218845232|NCT04670458|OTHER|no intervention|no intervention
218845233|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
218845234|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
218845235|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
218845236|NCT00018330|BEHAVIORAL|Weight Loss|
219590297|NCT06990906|DEVICE|BAIBYS Sperm selection|Software based decision support device for sperm selction based on morphology and motility
218845237|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
218845238|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
218845239|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
218845240|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
218845241|NCT00822705|DRUG|Placebo tablet|Control arm
218845242|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
218845243|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
218845244|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
219018105|NCT03460483|OTHER|Genetic Counseling|Undergo genetic counseling
219455022|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT)|5 minutes warm-up at increasing intensity up to 60% maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax)
219455023|NCT07101341|PROCEDURE|Aerobic training performed with a immersive virtual reality application|5 minutes of warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cooling at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses and an immersive virtual reality application
219455024|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT) performed with a immersive virtual reality application|5 minutes warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses for an immersive virtual reality application
219455025|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
219455026|NCT02803437|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
219455027|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
219455028|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
219455029|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
219590298|NCT06990906|PROCEDURE|Intra cytoplasmatic sperm injection|Sperm injection into oocytes for ferilization
219590299|NCT06990906|PROCEDURE|Conventional manual sperm selection|selection beased on motility at low magnification
219590300|NCT06498739|DRUG|Erector spinae plane block(15 ml bupivacaine 0.5%)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
219590301|NCT06498739|DRUG|Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
219590302|NCT06624709|DRUG|Iron Supplement|The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
219590303|NCT02442583|OTHER|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
219590304|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
219590305|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
219590306|NCT05966220|DEVICE|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
219590307|NCT01781520|BIOLOGICAL|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
219590308|NCT01781520|DRUG|S1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
219590309|NCT01781520|OTHER|Best supportive care|Best supportive care
219590310|NCT03483168|BEHAVIORAL|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
218845245|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
218845246|NCT02518958|DRUG|RRx-001|
218845247|NCT02518958|DRUG|Nivolumab|
218845248|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
218845249|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
219455030|NCT02972658|DRUG|Lanabecestat|Administered orally
219590311|NCT03483168|BEHAVIORAL|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
219590312|NCT00140660|DRUG|rituximab|375 mg/m2 on D1
219455031|NCT02638285|DRUG|LH|
219590313|NCT01833091|OTHER|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
219590314|NCT06205329|DRUG|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
219590315|NCT06205329|DRUG|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
219590316|NCT06205329|DRUG|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
219590317|NCT06205329|DRUG|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
219590318|NCT06205329|DRUG|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
219590319|NCT04473521|DEVICE|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
219590320|NCT04473521|DEVICE|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
219590321|NCT01664221|DRUG|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
219590322|NCT04461366|DEVICE|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
219590323|NCT04461366|DEVICE|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
219590324|NCT03786133|DIAGNOSTIC_TEST|Analysis of microbiological tests|Collection and comparison of microbiological data
219590325|NCT02365259|DEVICE|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
219590326|NCT02121275|DEVICE|Ultrasound of the lungs|Ultrasound examination of the lungs
219590327|NCT02121275|DEVICE|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
219455032|NCT02638285|DRUG|HCG|
219455033|NCT02638285|DRUG|Clomiphene|
219455034|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
219590328|NCT02610387|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
219590329|NCT02610387|DEVICE|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
219590330|NCT00500175|DEVICE|TempTouchRM|
219590331|NCT00500175|DEVICE|Offloading|
219590332|NCT04128475|OTHER|N/A - observational study.|N/A - observational study.
219590333|NCT03457649|BIOLOGICAL|ARGX-113|
219590334|NCT03457649|BIOLOGICAL|Placebo|
218845250|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
218845251|NCT02968160|DRUG|Rosuvastatin 20mg|
219590335|NCT01467206|BEHAVIORAL|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
219590336|NCT01467206|BEHAVIORAL|Standard care|Standard care as it is given to all stoke patients after stroke
219455035|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
219455036|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
219455037|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
219455038|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
219455039|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
219590337|NCT06150456|PROCEDURE|extraction|extraction: in all groups, extraction will be performed
219590338|NCT06150456|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
219590339|NCT06150456|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
219590340|NCT00438477|DRUG|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
219590341|NCT00438477|PROCEDURE|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
219590342|NCT00438477|RADIATION|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
219590343|NCT01678053|DRUG|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
219590344|NCT01678053|DRUG|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
218845252|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
218845253|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
218845254|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
218845255|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
219018106|NCT03460483|OTHER|Genetic Testing|Undergo genetic testing
219018107|NCT03460483|OTHER|Laboratory Biomarker Analysis|Correlative studies
219018108|NCT03460483|PROCEDURE|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
219590345|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
219590346|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
218845256|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
218845257|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
219455040|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
219455041|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
219455042|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
219455043|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
219455044|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
219455045|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
219455046|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
219455047|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
219455048|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
219590347|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
218845258|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
219590348|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
219590349|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
218845259|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
219590350|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
219590351|NCT05865080|DRUG|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
219590352|NCT05865080|DRUG|Placebo|Normal saline
219018122|NCT04962867|DRUG|E7090|140 mg of E7090 is orally administered once daily.
218845260|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
219455049|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
218845261|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
218845262|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
219455050|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
219455051|NCT02499172|BIOLOGICAL|Shanchol|
218845263|NCT06178289|DEVICE|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
218845264|NCT06178289|DEVICE|Standard hospital wound treatment protocol|Comparator: Standard hospital wound treatment protocol
218845265|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
218845266|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
218845267|NCT04439539|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
218845268|NCT04439539|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
218845269|NCT04439539|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
218845270|NCT04439539|DRUG|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
218845271|NCT04439539|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally.
218845272|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
218845273|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
218845274|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
218845275|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
218845276|NCT02578680|DRUG|Cisplatin|IV infusion
219455052|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
219590353|NCT00943462|RADIATION|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
219590354|NCT00943462|DRUG|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
219590355|NCT03729076|OTHER|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
218845277|NCT02578680|DRUG|Carboplatin|IV infusion
218845278|NCT02578680|DRUG|Pemetrexed|IV infusion
218845279|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
218845280|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
218845281|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
218845282|NCT02578680|DRUG|Saline solution|IV infusion
219455053|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
219455054|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
219590356|NCT03729076|OTHER|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
219590357|NCT01689662|DRUG|Tc 99m EC20|
219590358|NCT00000569|DRUG|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
219590359|NCT00000569|OTHER|Placebo|Placebo
219590360|NCT01775436|BEHAVIORAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
219455055|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
219455056|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
219455057|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
219455058|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
218845283|NCT05760313|DRUG|Linaclotide|Capsule; oral
219455059|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
218845284|NCT05760313|DRUG|Placebo|Capsule; oral
218845285|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
218845286|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
218845287|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
218845288|NCT00073411|DRUG|duloxetine|
218845289|NCT00073411|DRUG|escitalopram|
218845290|NCT00073411|DRUG|placebo|
218845291|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
218845292|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
218845293|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
218845294|NCT05427136|DIAGNOSTIC_TEST|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~* Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~* Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
218845295|NCT05427136|DIAGNOSTIC_TEST|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
219455060|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
218845296|NCT05427136|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
218845297|NCT05427136|OTHER|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
218845298|NCT05427136|OTHER|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
218845299|NCT05427136|OTHER|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
218845300|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
219455061|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
219455062|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
218845301|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
218845302|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
218845303|NCT00451009|DEVICE|Viacell's product Media Kits|
219455063|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
218845304|NCT01234740|DRUG|bafetinib|Given orally
218845305|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
218845306|NCT01234740|OTHER|pharmacological study|Correlative studies
218845307|NCT01234740|OTHER|liquid chromatography|Correlative studies
218845308|NCT01234740|OTHER|mass spectrometry|Correlative studies
219455064|NCT01226602|DRUG|Placebo|
218845309|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
218845310|NCT01234740|GENETIC|protein expression analysis|Correlative studies
218845311|NCT01234740|GENETIC|western blotting|Correlative studies
218845312|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
218845313|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
218845314|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
218845315|NCT02879591|OTHER|Social Skills training with Avatar therapist|
218845316|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
218845317|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
218845318|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
218845319|NCT05013918|OTHER|Observational study|No intervention
218845320|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
218845321|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
218845322|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
218845323|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
218845324|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
218845325|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
218845326|NCT06402279|DEVICE|Efferon CT therapy|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886. Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion.
218845327|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
218845328|NCT05255549|PROCEDURE|ESWT + Stretching|"3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week"
218845329|NCT05255549|PROCEDURE|ESWT and SHAM + Stretching|"3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week"
218845330|NCT00195052|DIAGNOSTIC_TEST|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
218845331|NCT05280158|DRUG|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
219018129|NCT04574167|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
219018130|NCT04574167|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
219018137|NCT03204370|DRUG|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
219018140|NCT06853288|BEHAVIORAL|Diet containing 80% ultra processed foods|Very high ultra-processed food diet where 80% of calories are coming from ultra processed food
219018141|NCT06853288|BEHAVIORAL|Diet containing 20% ultra processed foods|Low ultra processed food diet where 20% of the calories are coming from ultra processed food
218845332|NCT04610645|DEVICE|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
218845333|NCT04610645|DEVICE|Dermatoscope|2x2 pictures taken with a dermatoscope
218845334|NCT04610645|GENETIC|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
218845335|NCT05187884|DRUG|Darovasertib|Oral Darovasertib 300 mg tablets twice daily
218845336|NCT04770545|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
218845337|NCT06472128|BEHAVIORAL|DREAMLAND|Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
218845338|NCT06472128|BEHAVIORAL|VITAL WELLNESS|Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
218845339|NCT06458920|BEHAVIORAL|Social regulation|Participants will regulate emotion with the help of a friend
218845340|NCT06458920|BEHAVIORAL|Cognitive regulation|Participants will regulate emotion on their own
218845341|NCT04506164|OTHER|Multicomponent Implementation Strategy|The eScreening MCIS was developed over the past seven years and consists of: 1) eScreening software provision, 2) training, 3) RPIW, and 4) ongoing blended facilitation. The investigators developed our MCIS to address specific eScreening implementation barriers found in the investigators' prior research.
219455065|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
219455066|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
218845342|NCT04506164|OTHER|eScreening|eScreening is a clinical patient self report system that allows Veterans to complete clinical reminders and other self report screens using a secure connection from any internet connected device.
218845343|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
218845344|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
218845345|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
218845346|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
218845347|NCT00332384|DRUG|brimonidine/timolol fixed combination|
218845348|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
218845349|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
218845350|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
218845351|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
219455067|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
218845352|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
218845353|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
218845354|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
218845355|NCT05865340|BEHAVIORAL|oral health|oral health education
218845356|NCT05865340|BEHAVIORAL|MED diet|MED diet education
218845357|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
218845358|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
218845359|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
218845360|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
218845361|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
218845362|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
219590361|NCT01775436|BEHAVIORAL|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
219590362|NCT03185013|BIOLOGICAL|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
219590363|NCT03185013|BIOLOGICAL|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
219590364|NCT03185013|DEVICE|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
219590365|NCT04842136|OTHER|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
219590366|NCT06233084|DRUG|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
219590367|NCT06233084|DRUG|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
218845363|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
218845364|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
218845365|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
218845366|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
219590368|NCT03343613|DRUG|LY3381916|IDO-1 inhibitor administered orally
219590369|NCT03343613|DRUG|LY3300054|PD-L1 inhibitor administered IV
219590370|NCT05072197|DEVICE|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
219590371|NCT03248453|OTHER|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
219590372|NCT06713382|COMBINATION_PRODUCT|Pleural Saline Irrigation|This intervention, Pleural Saline Irrigation, involves the administration of up to 250 mL of sterile saline solution into the pleural cavity through a chest tube immediately following each intrapleural tPA/DNase (IPFT) therapy session. The saline irrigation is intended to aid in clearing infected pleural fluid and reducing pleural effusion volume. This maneuver is repeated based on the treating physician's criteria, differentiating it from standard care, which includes only antibiotics, chest tube placement, and IPFT without saline irrigation. The irrigation is expected to enhance infection resolution and may impact chest tube duration and the frequency of pleural interventions.
219590373|NCT02575976|BEHAVIORAL|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
219590374|NCT02575976|OTHER|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
219590375|NCT02575976|OTHER|wait list control|No cardiac rehabilitation.
219590376|NCT03530176|RADIATION|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
219590377|NCT05211076|OTHER|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
218845367|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
218845368|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
218845369|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
218845370|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
218845371|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
218845372|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
218845373|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
218845374|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
218845375|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
218845376|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
218845377|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
218845378|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
218845379|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
219196954|NCT06611644|OTHER|SPSIPB blcok|Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.
219196955|NCT06611644|OTHER|Control|Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
219196956|NCT06612346|DEVICE|Minimally Invasive Micro Trabeculostomy|The MINT system is a surgical device designed to create a trabeculostomy within the eye.
219196957|NCT06611605|BEHAVIORAL|Storytelling with metaphor toys|"There is evidence of the effectiveness of various methods such as using different types of balls as tactile stimulation and active distraction methods during the management of pain, anxiety, and fear, watching cartoons, using virtual reality (VR) as a method of distracting attention, and using virtual reality hypnosis (VRH). However, no scientific study has been found on storytelling with a metaphoric toy during venous blood collection.~Before the children in the intervention group start the blood collection process, the story will be told to the child by the researcher in the waiting room of Akdeniz University Hospital Blood Collection Unit. The child and the parent will be together during the story telling. Expert opinions were received from five academics who completed their doctorate in Child Health and Disease Nursing for the content of the story."
219196958|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
219196959|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
219455068|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
219455069|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
218845380|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
218845381|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
218845382|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
218845383|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
218845384|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
218845385|NCT04051710|DRUG|Placebo|Placebo Product
218845386|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
218845387|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
218845388|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
218845389|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
218845390|NCT01681069|OTHER|Placebo|
218845391|NCT01697423|DRUG|platelet-rich plasma|
218845392|NCT01697423|DRUG|durolane|
218845393|NCT02292082|DRUG|Bupivacaine|
218845394|NCT02292082|DRUG|Morphine|
218845395|NCT02292082|DRUG|Methylprednisolone|
218845396|NCT02292082|DRUG|Cefazolin|
218845397|NCT02292082|DRUG|Normal saline|
218845398|NCT02292082|DRUG|Midazolam|
219455070|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
219455071|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
219455072|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
219455073|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
219455074|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
219455075|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
219455076|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
219455077|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
219455078|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
219590378|NCT05211076|OTHER|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
219455079|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
219455080|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
219455081|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
219455082|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
219455083|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
219455084|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
219455085|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
218845399|NCT02292082|DRUG|Propofol|
218845400|NCT02292082|DRUG|Dexamethasone|
218845401|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
218845402|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
218845403|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
218845404|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
218845405|NCT01683747|DRUG|Tranexamic Acid|
218845406|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
218845407|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
219455086|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
219455087|NCT02735876|DRUG|acalabrutinib|
219455088|NCT02735876|DRUG|ibrutinib|
219455089|NCT02735876|DRUG|rituximab|
219455090|NCT00003389|DRUG|Doxorubicin|given IV
219455091|NCT00003389|DRUG|Bleomycin|given IV
219455092|NCT00003389|DRUG|Vinblastine|given IV
219455093|NCT00003389|DRUG|Dacarbazine|given IV
219455094|NCT00003389|DRUG|Vincristine|given IV
219455095|NCT00003389|DRUG|Mechlorethamine|given IV
219455096|NCT00003389|DRUG|Etoposide|given IV
219455097|NCT00003389|DRUG|Prednisone|taken orally
219455098|NCT00003389|DRUG|Cyclophosphamide|given IV
219455099|NCT00003389|RADIATION|Radiotherapy|
219455100|NCT01234558|DRUG|GLYX-13|single IV dose
218845408|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
218845409|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
218845410|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
219590379|NCT05211076|OTHER|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
218845411|NCT03831191|DRUG|LY3375880|Administered SC
218845412|NCT03831191|DRUG|Placebo|Administered SC
218845413|NCT02300558|DRUG|Eleclazine|Tablets administered orally
218845414|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
218845415|NCT05474781|DRUG|Epclusa|HCV treatment
218845416|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
218845417|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
218845418|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
219590380|NCT04599127|OTHER|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
218845419|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
218845420|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
219455101|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
219455102|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
219455103|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
219590381|NCT04599127|OTHER|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
219590382|NCT00570882|DRUG|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
218845421|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
218845422|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
218845423|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
219455104|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
219455105|NCT05385172|OTHER|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
219455106|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
219455107|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
218845424|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
219455108|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
219455109|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
219455110|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
219455111|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
219455112|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
219455113|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
219455114|NCT03247712|DRUG|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
219455115|NCT03247712|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
219590383|NCT00570882|DRUG|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
219590384|NCT00510289|DRUG|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
219590385|NCT00658931|DRUG|Drug treatment with Cymbalta|Drug treatment with Cymbalta
219590386|NCT03077035|OTHER|glass ionomer sealants|
219590387|NCT03077035|OTHER|resin-based sealant|
219590388|NCT03602963|DEVICE|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
219590389|NCT04161014|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
219590390|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|2000 IU per day
219590391|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|400 IU per os once daily
219590392|NCT00725114|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days
219590393|NCT00725114|BIOLOGICAL|Placebo|2 mL subcutaneous injection twice daily for 4 days
218845425|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
218845426|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
219455116|NCT03247712|RADIATION|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
219455117|NCT03247712|RADIATION|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
219455118|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
219455119|NCT00908050|DRUG|Botulinum toxin type A|Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
219455120|NCT00908050|DRUG|Placebo arm|Placebo comparator
219590394|NCT05534308|PROCEDURE|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
219590395|NCT05534308|OTHER|No trasoperative taping|Patients will received only compression stockings after surgery
219590396|NCT03150823|PROCEDURE|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
219455121|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
219455122|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
219590397|NCT03150823|PROCEDURE|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
219590398|NCT03150823|PROCEDURE|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
219590399|NCT04834843|OTHER|Observational study, no intervention|Observational study, no intervention
219590400|NCT03222752|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
219590401|NCT03222752|DEVICE|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
219590402|NCT04158700|DRUG|LY3200882|LY3200882 administered orally
219590403|NCT04158700|DRUG|Pembrolizumab|Pembrolizumab administered IV
219590404|NCT06163599|BEHAVIORAL|Transdiagnostic Telenovela Intervention|The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
219590405|NCT02257294|DRUG|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
219590406|NCT02257294|OTHER|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
219590407|NCT01684163|DRUG|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
219590408|NCT01684163|DRUG|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
219590409|NCT01684163|DRUG|Placebo|Intravenous administration of normal saline into arm.
219590410|NCT01881113|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
219590411|NCT01881113|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
218845427|NCT01059682|DRUG|Placebo|Placebo orally once daily
218845428|NCT05669755|DRUG|Cagrilintide|Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
218845429|NCT05669755|DRUG|Semaglutide|Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
218845430|NCT05669755|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
218845431|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
219590412|NCT01458821|BEHAVIORAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
219590413|NCT00673387|DRUG|pramlintide acetate|subcutaneous injection, twice a day
219590414|NCT00673387|DRUG|metreleptin|subcutaneous injection, twice a day
218845432|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
218845433|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
218845434|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
218845435|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
219590415|NCT00673387|DRUG|placebo-P|subcutaneous injection, twice a day
219590416|NCT00673387|DRUG|placebo-M|subcutaneous injection, twice a day
219590417|NCT06877819|OTHER|Motor Imaginary Technique alongwith task-oriented training|Motor imaginary technique followed by task oriented trunk control training alongwith conventional physiotherapy.Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins. First of all task based exercises will be assumed by patient. To make imaginations more strong an audio demonstration of each exercise will be recorded by therapist and will be administered to patients hearing via headphones. This will make it easy for patients to assume as they are performing theses exercises in their head. Motor imagination will be followed by practical performance of same tasks. The experimental group will receive motor imagery technique for 15 minutes followed by task-specific training for 45minutes along with conventional physiotherapy to improve postural control and balance in stroke patients. .
219590418|NCT06877819|OTHER|Task Oriented Training|Control group will receive task oriented trunk control training exercises followed by conventional physiotherapy. .Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins.
219590419|NCT00200759|DRUG|Cranberry juice and capsules|
218845436|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
218845437|NCT02570724|BIOLOGICAL|blood patch|
218845438|NCT00284505|DRUG|thalidomide|
218845439|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
218845440|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
218845441|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
218845442|NCT02018848|BEHAVIORAL|Attention Training Program|
218845443|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
218845444|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
218845445|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
218845446|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
218845447|NCT00086801|DRUG|vinblastine|given IV
218845448|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
219590420|NCT05553899|RADIATION|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
219590421|NCT01882075|DRUG|Open loop|
219590422|NCT01882075|DEVICE|Closed-loop|
219590423|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 1)|
218845449|NCT00086801|PROCEDURE|CT scan|
218845450|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
219455123|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
218845451|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine
218845452|NCT06135350|DRUG|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
218845453|NCT06135350|OTHER|Placebo|"Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
218845454|NCT05292092|DRUG|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
218845455|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
218845456|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
218845457|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
218845458|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
218845459|NCT02522182|BEHAVIORAL|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
219455124|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
219455125|NCT05195619|BIOLOGICAL|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
219455126|NCT05195619|DRUG|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
219455127|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
219455128|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
219455129|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
219455130|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
219590424|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 2)|
219590425|NCT00406042|DRUG|prednisolone acetate 1%|
219590426|NCT00960115|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
219590427|NCT00960115|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
219590428|NCT00960115|BIOLOGICAL|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
219018149|NCT02759419|DRUG|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
219455131|NCT01855139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
218845460|NCT02522182|BEHAVIORAL|Usual Treatment|Information related to intervention description have been already included in arm/group description
218845461|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
219455132|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
218845462|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
218845463|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
218845464|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
218845465|NCT01947621|OTHER||
218845466|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
218845467|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
218845468|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
219590429|NCT00960115|OTHER|Saline|A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
218845469|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
218845470|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
218845471|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
218845472|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
218845473|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
218845474|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
218845475|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
219455133|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
219455134|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
219455135|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
219455136|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
219590430|NCT00861198|OTHER|ERCP as per medical indication|ERCP as per medical indication
219590431|NCT04298645|OTHER|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
218845476|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
218845477|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
218845478|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
218845479|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
218845480|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
218845481|NCT01421303|DRUG|Enbrel|Enbrel
218845482|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
218845483|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
218845484|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
218845485|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
218845486|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
218845487|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
218845488|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
218845489|NCT01986192|DRUG|rivaroxaban|
218845490|NCT01986192|DRUG|Warfarin|
219455137|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
219455138|NCT01381289|DRUG|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
219455139|NCT05753124|OTHER|Observational|This is an observational study
219455140|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
219455141|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
219455142|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
218845491|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
218845492|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
218845493|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
218845494|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
218845495|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
218845496|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
218845497|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
219455143|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
219455144|NCT05320640|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
219455145|NCT05320640|DRUG|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
219455146|NCT05320640|DRUG|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
219455147|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
219455148|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
219455149|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
219455150|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
218845498|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
218845499|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
218845500|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
218845501|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
218845502|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
218845503|NCT03466099|OTHER|Sham Procedure|Sham Procedure
218845504|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
218845505|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
218845506|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
218845507|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
218845508|NCT00048022|DRUG|Dual Integrin Antagonist|
218845509|NCT06045793|DRUG|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
218845510|NCT06045793|DRUG|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
219018153|NCT03313908|PROCEDURE|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
219455151|NCT04044625|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
219455152|NCT04044625|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
219455153|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
219018154|NCT06099457|BEHAVIORAL|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
219018157|NCT02260271|OTHER|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
219455154|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
219455155|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
219455156|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
219455157|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
219455158|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
219455159|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
219455160|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
219455161|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
219455162|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
219455163|NCT00935766|DRUG|Placebo|
219455164|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
219455165|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
219455166|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
219590432|NCT03137927|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
219590433|NCT03137927|OTHER|Placebo|Placebo
219590434|NCT03332927|OTHER|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
219590435|NCT03332927|OTHER|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
219590436|NCT00260169|BEHAVIORAL|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
219590437|NCT00260169|BEHAVIORAL|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
219590438|NCT04617054|DRUG|AB-106|600mg QD for each subjects.
219590439|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily
219455167|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
219455168|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
219455169|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
219455170|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
219455171|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
219455172|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
219455173|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
219590440|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
219590441|NCT01197755|DRUG|placebo|Placebo twice daily
219590442|NCT00888823|RADIATION|Stereotactic Radiotherapy|Stereotactic Radiotherapy
219590443|NCT03040323|DRUG|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
219590444|NCT03040323|DRUG|Placebos|Placebos injected prior to ultrasound-guided biopsy
219590445|NCT00796679|DRUG|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
219455174|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
219455175|NCT00768040|DRUG|Aliskiren|300 mg once daily
219590446|NCT06299852|DRUG|Trastuzumab emtansine|SRT for metastatic foci
218845511|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
218845512|NCT05448573|DIAGNOSTIC_TEST|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
218845513|NCT06049225|BEHAVIORAL|High-Tech|Access to technological platform and weekly health coaching
218845514|NCT06049225|BEHAVIORAL|Low-Tech|Weekly email with educational content and weekly health coaching
218845515|NCT06049225|BEHAVIORAL|Attention Control|No technology access or health coaching
218845516|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
218845517|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
218845518|NCT02693080|DRUG|Isovue-200|Contrast agent
218845519|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
218845520|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
218845521|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
218845522|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
218845523|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
218845524|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
218845525|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
218845526|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
218845527|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
218845528|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
218845529|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
218845530|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
218845531|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
218845532|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
218845533|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
218845534|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
218845535|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
218845536|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
218845537|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
218845538|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
218845539|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
218845540|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
218845541|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
218845542|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
218845543|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
218845544|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
219455176|NCT00768040|DRUG|Placebo|Matching placebo once daily
219455177|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
219455178|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
219455179|NCT01790451|PROCEDURE|Irreversible Electroporation|
219455180|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
219590447|NCT05364060|OTHER|Questionnaires|Different questionnaires detailed in the objectives part
219590448|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
219590449|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
219590450|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
219590451|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
219590452|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
219196960|NCT05864040|DEVICE|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved.
218845545|NCT06080893|DRUG|Ferric carboxymaltose|"FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
218845546|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
218845547|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
218845548|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
218845549|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
218845550|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
218845551|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
218845552|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
218845553|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
218845554|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
218845555|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
218845556|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
218845557|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
218845558|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
218845559|NCT03208660|DRUG|Fycompa|Oral suspension
218845560|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
218845561|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
218860118|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
218845562|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
218845563|NCT01997606|OTHER|placebo|
218845564|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
219455181|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
219455182|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
219455183|NCT00012870|BEHAVIORAL|Behavioral Management|
219590453|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
219590454|NCT05027243|PROCEDURE|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
219590455|NCT05027243|DRUG|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
218845565|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
218845566|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
218845567|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
218845568|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
218845569|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
219455184|NCT00000529|DRUG|tamoxifen|
219455185|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
219455186|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
219455187|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
219455188|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
219455189|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
219455190|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
219455191|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
219455192|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
219455193|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
219455194|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
219455195|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
219455196|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
219455197|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
219590456|NCT02512926|DRUG|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
219590457|NCT02512926|DRUG|Cyclophosphamide|
219590458|NCT02512926|DRUG|Etoposide|
219590459|NCT00370357|DRUG|3% w/w SPL7013 Gel (VivaGel™)|
219590460|NCT00499174|PROCEDURE|conventional surgery|Radical prostatectomy
218845570|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
218845571|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
218845572|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
218845573|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
218845574|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
219455198|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
219455199|NCT02763605|OTHER|no intervention|
218845575|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
219455200|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
219455201|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
219455202|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
219455203|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
219455204|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
219455205|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
219590461|NCT00499174|RADIATION|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
218845576|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
218845577|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
218845578|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
218845579|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
218845580|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
219455206|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
218845581|NCT05409560|OTHER|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
218845582|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
219196961|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
219455207|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
219455208|NCT04874129|DRUG|YYC506 (phase 1)|Test
219455209|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
219455210|NCT04874129|DRUG|YYC506 (phase 2)|Test
219455211|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
219590462|NCT00499174|RADIATION|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
219590463|NCT00499174|PROCEDURE|Biopsies|Periodic repeat biopsies
219590464|NCT02788682|GENETIC|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
219590465|NCT03891966|PROCEDURE|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
218845583|NCT03069248|DRUG|Rituximab|
218845584|NCT03069248|DRUG|Alpha Interferon|
218845585|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
219455212|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
218845586|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
218845587|NCT06458764|OTHER|Questionnaire|none, it's a incidence-prevalence study
219455213|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
219455214|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
218845588|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
219455215|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
219455216|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
219455217|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
218845589|NCT00568763|BIOLOGICAL|sargramostim|
218845590|NCT00568763|OTHER|immunoenzyme technique|
218845591|NCT00568763|OTHER|immunohistochemistry staining method|
219455218|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
219590466|NCT03891966|PROCEDURE|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
218845592|NCT00568763|OTHER|immunologic technique|
218845593|NCT00568763|OTHER|laboratory biomarker analysis|
218845594|NCT00568763|PROCEDURE|biopsy|
218845595|NCT00568763|PROCEDURE|cryosurgery|
218845596|NCT00568763|PROCEDURE|radiofrequency ablation|
218845597|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
218845598|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
218845599|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
218845600|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
219455219|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
219455220|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
219455221|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
219455222|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
219455223|NCT00537251|DRUG|Insulin glargine|
219455224|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
219196962|NCT05741294|DRUG|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
219196963|NCT05070247|DRUG|TAK-500|TAK-500 intravenous infusion.
219455225|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
219590467|NCT00039520|DRUG|docetaxel|
219590468|NCT00039520|DRUG|sulindac|
219590469|NCT03131674|OTHER|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
219590470|NCT03761680|DIETARY_SUPPLEMENT|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
219590471|NCT03761680|DIETARY_SUPPLEMENT|Control Intervention|Patients receive ONS between meals or at their request as usual
219590472|NCT02269163|BIOLOGICAL|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
218845601|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
219455226|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
219455227|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
219455228|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
219455229|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
219455230|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
219590473|NCT02269163|BIOLOGICAL|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
219590474|NCT01133886|DRUG|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
219590475|NCT03296384|OTHER|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
219590476|NCT05433727|DIAGNOSTIC_TEST|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
219590477|NCT03253523|PROCEDURE|Occipital neurolysis|Surgical occipital nerve decompression
219590478|NCT01413516|BEHAVIORAL|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
219590479|NCT01413516|DRUG|Placebo|Sugar pill without any active medication
219590480|NCT01413516|DRUG|Varenicline|Varenicline (an approved medication for smoking cessation)
219590481|NCT03542955|DEVICE|ActiPatch|A Pulsed Shortwave Therapy Device
218845602|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
218845603|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
218845604|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
218845605|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
218845606|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
218845607|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
218845608|NCT06290466|DRUG|Low dose group|300 mg,single dose.
218845609|NCT06290466|DRUG|High dose group|400 mg, single dose.
218845610|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
218845611|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
219196964|NCT05070247|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
219590482|NCT03542955|DRUG|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
219590483|NCT01072955|BIOLOGICAL|Bovine Heparin|5.000UI/mL bottle with 5mL
219590484|NCT01072955|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
219590485|NCT01026155|OTHER|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
219590486|NCT01523223|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
219590487|NCT05277623|DRUG|Mannitol|During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
219590488|NCT05277623|OTHER|0.9% normal saline|the same amount of 0.9% normal saline
219590489|NCT03802955|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
218845612|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
218845613|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
219455231|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
218845614|NCT00632047|OTHER|active surveillance|
218845615|NCT00632047|OTHER|educational intervention|
218845616|NCT00632047|PROCEDURE|examination|
218845617|NCT00632047|PROCEDURE|long-term screening|
218845618|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
218845619|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
219590490|NCT02632513|DEVICE|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
218845620|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
218845621|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
219455232|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
219455233|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
219455234|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
219590491|NCT04856150|DRUG|Q-1802|Q-1802 will be administered intravenously.
219590492|NCT05295238|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
219590493|NCT04284995|DRUG|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
219590494|NCT00630019|DRUG|1.5% levofloxacin ophthalmic solution|Topical application
219590495|NCT00630019|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
219590496|NCT01414595|GENETIC|DNA analysis|
219590497|NCT01414595|GENETIC|DNA methylation analysis|
218845622|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
218845623|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
218845624|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
218845625|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
219455235|NCT02185040|DRUG|Placebo|Matching oral placebo daily
218845626|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
218845627|NCT00350870|DRUG|Placebo|Placebo plus CBT
218845628|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
218845629|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
218845630|NCT01969383|OTHER|Heated pool training|
218845631|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
218845632|NCT02072135|DRUG|Exparel|
218845633|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
218845634|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
218845635|NCT06718036|OTHER|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
219455236|NCT01713257|DIETARY_SUPPLEMENT|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
219455237|NCT01713257|DIETARY_SUPPLEMENT|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
219455238|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
219590498|NCT01414595|GENETIC|RNA analysis|
219590499|NCT01414595|GENETIC|gene expression analysis|
219590500|NCT01414595|GENETIC|polymorphism analysis|
219590501|NCT01414595|OTHER|laboratory biomarker analysis|
219590502|NCT01414595|OTHER|medical chart review|
219590503|NCT02821052|DRUG|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
219455239|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
218845636|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
218845637|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
218845638|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
218845639|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
218845640|NCT05627570|BEHAVIORAL|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
218845641|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
218845642|NCT06826690|PROCEDURE|Group 1: ultrasound guided wrist block with bupivacane alone|Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
218845643|NCT06826690|PROCEDURE|Group 2 : ultrasound guided wrist block with bupivacane and dexamethasone|Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
218845644|NCT06826690|PROCEDURE|Group 3: ultrasound guided wrist block with bupivacane and dexametmiodine|Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
218845645|NCT06826690|PROCEDURE|Group 4: patients will receive ultrasound guided wrist block with bupivacane and dexamethasone and dexametmiodine|Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e and 8 mg dexamethasone and 50 mcg dexametmiodine
218845646|NCT05248997|DRUG|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
219455240|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
219455241|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
219455242|NCT05427864|DIAGNOSTIC_TEST|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
219455243|NCT02543606|DRUG|Esomelone|powder for injection/ infusion Esomeprazole 40mg
219455244|NCT02543606|DRUG|Nexium|powder for injection/ infusion Esomeprazole 40mg
219455245|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
219455246|NCT06425406|DEVICE|high-flow nasal cannula|In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
219455247|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
219455248|NCT04506879|PROCEDURE|Popliteal Sciatic nerve block|Patients schedule for lower limb surgery under regional anesthesia will receive ultrasound guided subparaneural popliteal sciatic nerve block. After identification of the common peroneal nerve and tibial nerve, local anesthetic agents will be injected close to each nerve below the point of divergence at the popliteal fossa. The spread of the drug and the sensory and motor function of that limb will be assessed regularly till it is ready for surgery.
219455249|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
219455250|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
219455251|NCT05392101|DRUG|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
219455252|NCT00944476|PROCEDURE|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
219455253|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
219455254|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
219455255|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
219455256|NCT06232187|BEHAVIORAL|Artificial Intelligence feedback for ultrasound EFW standard plane images|AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
219455257|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
219455258|NCT02029365|OTHER|semi-structured interview|phone interview
219455259|NCT03787901|OTHER|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
219455260|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
219455261|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
219455262|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
218845647|NCT05248997|DRUG|Matching placebo|One dose of matching placebo
218845648|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
218845649|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
218845650|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
218845651|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
218845652|NCT06150365|BIOLOGICAL|KSX01-TCRT cell therapy|Patient autologous T cell therapy
218845653|NCT05447650|DEVICE|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
218845654|NCT05447650|DEVICE|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
218845655|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
218845656|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
218845657|NCT05465070|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
218845658|NCT05465070|DEVICE|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
218845659|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
218845660|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
218845661|NCT02291783|DRUG|HTL0009936|Single dose
218845662|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
218845663|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
218845664|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
218845665|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
219455263|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
219590504|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
219590505|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
219590506|NCT02287207|DEVICE|transcranial direct current stimulation (tDCS)|
218845666|NCT01396824|OTHER|No intervention|No intervention
218845667|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
218845668|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
218845669|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
219455264|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
219455265|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
219455266|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
219455267|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
219455268|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
219455269|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
219455270|NCT00003684|DRUG|theophylline|
219455271|NCT00003684|PROCEDURE|quality-of-life assessment|
219455272|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
219455273|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
219455274|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
219455275|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
219455276|NCT01930396|DRUG|Tinzaparin|
219590507|NCT04822233|DEVICE|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
219590508|NCT04822233|DEVICE|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
219590509|NCT04822233|DEVICE|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
219590510|NCT02938754|BEHAVIORAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
219590511|NCT02938754|BEHAVIORAL|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
219590512|NCT06719011|DRUG|NNC0174-1213 A|"Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
218845670|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
219455277|NCT01930396|DRUG|Unfractionated Heparin|
218845671|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
219455278|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
219455279|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
219455280|NCT02198313|DRUG|BIIX 1 XX - D1|
219455281|NCT02198313|DRUG|BIIX 1 XX - D2|
219455282|NCT02198313|DRUG|BIIX 1 XX - D3|
219455283|NCT02198313|DRUG|Placebo|
219455284|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
219455285|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
219455286|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
219455287|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
218845672|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
218845673|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
218845674|NCT00724685|DRUG|Naropeine (Ropivacaine)|
218845675|NCT00724685|DRUG|Placebo|saline
218845676|NCT05783063|DEVICE|Active iTBS|Mag-TD
218845677|NCT05783063|DEVICE|Sham iTBS|Mag-TD
218845678|NCT04105920|DEVICE|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
218845679|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
219196965|NCT05852808|DRUG|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
219455288|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
219455289|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
219455290|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
219455291|NCT01921959|BEHAVIORAL|Intervention|Postpartum women are randomized to intervention or control group
219455292|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
219455293|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
219590513|NCT06719011|DRUG|Cagrilintide B|"Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
219590514|NCT06719011|DRUG|Placebo A (NNC0174 1213 A)|"Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
219590515|NCT03550105|DEVICE|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
219590516|NCT02426853|BEHAVIORAL|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
218845680|NCT05747209|OTHER|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
218845681|NCT05849207|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
218845682|NCT05021133|BEHAVIORAL|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS using a video or telephone call
218845683|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
218845684|NCT02602275|DRUG|Neurexan|0.6 mg / tablet
218845685|NCT02602275|DRUG|Placebo|Neurexan-matched Placebo tablet
219590517|NCT02426853|OTHER|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
218845686|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
218845687|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
218845688|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
218845689|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
218845690|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
218845691|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
218845692|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
218845693|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
218845694|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
218845695|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
218845696|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
218845697|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
218845698|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
218845699|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
218845700|NCT02566187|DRUG|Fimasartan|
218845701|NCT02566187|DRUG|Atorvastatin|
218845702|NCT00014443|DRUG|thalidomide|
218845703|NCT00014443|DRUG|topotecan hydrochloride|
218845704|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
218845705|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
218845706|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
218845707|NCT06036706|RADIATION|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
218845708|NCT06036706|RADIATION|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
218845709|NCT06036706|RADIATION|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
218845710|NCT06036706|OTHER|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
218845711|NCT00002389|DRUG|Abacavir sulfate|
218845712|NCT00002389|DRUG|Lamivudine|
218845713|NCT00002389|DRUG|Zidovudine|
219455294|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
219455295|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
219455296|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
219455297|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
219455298|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
219455299|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
219455300|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
219455301|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
219455302|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
219455303|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
219455304|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
219455305|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
219455306|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
219590518|NCT02426853|BEHAVIORAL|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
218845714|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
218845715|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
218845716|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
218845717|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
218845718|NCT00868140|DRUG|Placebo|placebo daily
218845719|NCT04047433|GENETIC|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
218845720|NCT04047433|GENETIC|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
218845721|NCT05453500|DRUG|Cyclophosphamide|Given IV
218845722|NCT05453500|DRUG|Doxorubicin|Given IV
218845723|NCT05453500|DRUG|Etoposide|Given IV
218845724|NCT05453500|DRUG|Prednisone|Given PO
218845725|NCT05453500|BIOLOGICAL|Rituximab|Given IV
218845726|NCT05453500|BIOLOGICAL|Tafasitamab|Given IV
218845727|NCT05453500|DRUG|Vincristine|Given IV
218845728|NCT05453500|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219455307|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
219455308|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
219455309|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
219590519|NCT00761865|DEVICE|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
219590520|NCT01208220|DEVICE|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
219590521|NCT01208220|BIOLOGICAL|Collagenase Ointment|Apply TIW
219590522|NCT00758680|DRUG|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
219590523|NCT00758680|DRUG|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
218845729|NCT05453500|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218845730|NCT05453500|PROCEDURE|Computed Tomography|Undergo CT scan
218845731|NCT05453500|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218845732|NCT05453500|PROCEDURE|Biospecimen Collection|Undergo blood sample and cerebrospinal fluid collection
218845733|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
218845734|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
218845735|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
218845736|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
218845737|NCT05239143|BIOLOGICAL|P-MUC1C-ALLO1 CAR-T cells|P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
218845738|NCT05239143|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
218845739|NCT06974929|DRUG|HRS-6209 Capsules|Oral HRS-6209 capsules.
218845740|NCT06974929|DRUG|Letrozole Tablets|Oral Letrozole tablets.
218845741|NCT05819541|DRUG|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
218845742|NCT05819541|DRUG|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
218845743|NCT05819541|DRUG|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
218845744|NCT06069856|DIETARY_SUPPLEMENT|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
218845745|NCT06069856|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
218845746|NCT02187887|BEHAVIORAL|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
218845747|NCT06046859|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
218845748|NCT06046859|DRUG|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
218845749|NCT05666778|DEVICE|Menstrual Cup|Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
218845750|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
218845751|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
218845752|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
218845753|NCT03352466|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
218845754|NCT03352466|BIOLOGICAL|BioThrax|Commercially available anthrax vaccine
218845755|NCT03352466|OTHER|Placebo|Normal saline
218845756|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
218845757|NCT02333396|OTHER|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
218845758|NCT02333396|OTHER|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
218845759|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
218845760|NCT05481502|PROCEDURE|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
218845761|NCT05481502|PROCEDURE|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
218845762|NCT05481502|PROCEDURE|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
219455310|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
219455311|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
219590524|NCT04174976|PROCEDURE|wall hernia repair|Wall hernia repair with mesh
218845763|NCT05493254|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
218845764|NCT05493254|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
218845765|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
218845766|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
218845767|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
218845768|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
219018180|NCT05574439|BEHAVIORAL|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
219018181|NCT05574439|DRUG|Semaglutide 3 mg/ml|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
219590525|NCT02565173|DRUG|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
218845769|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
218845770|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
218845771|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
218845772|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
219455312|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
219455313|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
219455314|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
219455315|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
219455316|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
219455317|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
219455318|NCT02491593|DEVICE|fecal occult blood test|
219455319|NCT04290767|DIAGNOSTIC_TEST|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
219455320|NCT05465967|PROCEDURE|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
219455321|NCT00290355|BIOLOGICAL|GSK 249553 vaccine|Intramuscular injection, 13 doses
219455322|NCT00290355|BIOLOGICAL|Placebo|Intramuscular administration, 13 doses
219455323|NCT00381524|BEHAVIORAL|Increase condom use|Voluntary increase in condom use
219455324|NCT01173822|OTHER|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
219455325|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
219455326|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
219455327|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
219455328|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
219455329|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
219455330|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
219455331|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
219455332|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
219455333|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
218845773|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
218845774|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
218845775|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
218845776|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
218845777|NCT04210245|BIOLOGICAL|aldafermin|aldafermin
219455334|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
219455335|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
219455336|NCT02827487|DRUG|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
218845778|NCT04210245|OTHER|Placebo|Placebo for aldafermin
218845779|NCT01892722|DRUG|Interferon beta-1a|Administration once weekly via i.m. injections.
218845780|NCT01892722|DRUG|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
218845781|NCT01892722|DRUG|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
218845782|NCT01892722|DRUG|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
218845783|NCT06977594|OTHER|Proactive immune tolerance induction|Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles
219455337|NCT02827487|DRUG|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
219455338|NCT02827487|DRUG|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
219455339|NCT02827487|DRUG|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
219455340|NCT02827487|PROCEDURE|IUD|IUD insertion
219455341|NCT00809575|OTHER|questionnaire administration|
219455342|NCT00809575|OTHER|fatigue assessment and management|
218845784|NCT06977594|OTHER|Standard Treatment|Standard treatment throughout all chemotherapy cycles
218845785|NCT06977594|DRUG|Paclitaxel and carboplatin|A chemotherapy regimen for gynecologic cancers.
219455343|NCT00809575|OTHER|observation|
219455344|NCT00809575|OTHER|quality-of-life assessment|
219455345|NCT03502941|DIETARY_SUPPLEMENT|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
219455346|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
219455347|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
218845786|NCT06977594|DRUG|Standard premedication (20 mg)|Premedication includes 20 mg of dexamethasone.
218845787|NCT06977594|DRUG|Reduced premedication (10 mg)|Premedication includes 20 mg of dexamethasone.
219455348|NCT00218452|BEHAVIORAL|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
219455349|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
219455350|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
219455351|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
219455352|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
218845788|NCT06977594|DRUG|Reduced premedication (5 mg)|Premedication includes 5 mg of dexamethasone.
218845789|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
218845790|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
218845791|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
219455353|NCT00618865|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
219590526|NCT02565173|DRUG|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
219590527|NCT02565173|DRUG|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
219590528|NCT02565173|DRUG|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
219590529|NCT02565173|DRUG|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
219590530|NCT03463382|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
219590531|NCT03463382|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
219590532|NCT03463382|DRUG|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
219590533|NCT00943267|DRUG|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
219590534|NCT00943267|DRUG|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
219590535|NCT00943267|DRUG|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
219590536|NCT00943267|PROCEDURE|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
219590537|NCT00943267|PROCEDURE|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
219590538|NCT03158974|DRUG|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
218845792|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
218845793|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
218845794|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
218845795|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
218845796|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
218845797|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
218845798|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
218845799|NCT00298623|DRUG|XP13512 (GSK1838262)|
219455354|NCT05617248|BEHAVIORAL|Self-efficacy App|The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
219455355|NCT00057265|DRUG|telbivudine or lamivudine|
219455356|NCT00881686|DRUG|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
219455357|NCT00040911|PROCEDURE|electroacupuncture therapy|
219455358|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
219455359|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
219455360|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
219455361|NCT00161746|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
218845800|NCT00298623|OTHER|placebo|
218845801|NCT00221000|DRUG|Methoxsalen|
218845802|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
218845803|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
218845804|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
218845805|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
218845806|NCT02353702|DRUG|Infusion of placebo during 48 hours|
218845807|NCT02353702|DRUG|NaCl|
218845808|NCT00189579|DRUG|Herceptin|
218845809|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
219590539|NCT00386763|DRUG|Artemether-lumefantrine|
219590540|NCT05480163|OTHER|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
219590541|NCT01094886|DRUG|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
219590542|NCT02955381|DEVICE|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
219590543|NCT02955381|DEVICE|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
219590544|NCT04748523|DRUG|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
219590545|NCT04748523|DRUG|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
218845810|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
218845811|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
218845812|NCT00116675|DRUG|Resiquimod|
218845813|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
218845814|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
218845815|NCT02524275|DRUG|Capecitabine|Given PO
218845816|NCT02524275|DRUG|Docetaxel|Given IV
218845817|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
218845818|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
218845819|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
218845820|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
218845821|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
218845822|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
219018182|NCT05574439|DRUG|Placebo (Semaglutide 3 mg/ml)|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
219018183|NCT01347697|PROCEDURE|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
219018184|NCT01347697|PROCEDURE|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
219455362|NCT01914991|PROCEDURE|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
219455363|NCT01914991|PROCEDURE|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
219455364|NCT04444323|OTHER|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
218845823|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
218845824|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
218845825|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
218845826|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
218845827|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
218845828|NCT00467194|DRUG|Rapamycin|
218845829|NCT00467194|DRUG|Bevacizumab|
218845830|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
218845831|NCT03614481|GENETIC|Sampling|Sampling
218845832|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
218845833|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
219455365|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
218845834|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
218845835|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
218845836|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
218845837|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
218845838|NCT05699993|DRUG|IBI351|IBI351 was administered orally
219455366|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
219455367|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
218845839|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
219455368|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
219455369|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
219455370|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
219455371|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
218845840|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
218845841|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
218845842|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
218845843|NCT06282406|OTHER|Transcutaneous Electrical Stimulation|Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.
218845844|NCT06282406|OTHER|Sham|Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
218845845|NCT06811103|OTHER|patient reported outcome|after enrollment, patient will have to answer to several patient reported outcome (PRO) to evaluate their pain, and well being. They will also answer to the MacCatT PRO to assess their understanding, reasoning, appreciation and choice expression
218845846|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
218845847|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
218845848|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
218845849|NCT06267872|BIOLOGICAL|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
218845850|NCT06267872|BIOLOGICAL|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
219455372|NCT06041230|DEVICE|Ozone Generator|Ultrasound guided ozone therapy
219455373|NCT06041230|DEVICE|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
219455374|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
219455375|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
219455376|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
218845851|NCT06267872|BIOLOGICAL|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
218845852|NCT06267872|BIOLOGICAL|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
218845853|NCT06267872|BIOLOGICAL|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
218845854|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
218845855|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
218845856|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
218845857|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
219455377|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
219455378|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
219455379|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
219455380|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
219455381|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
219455382|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
219455383|NCT04018716|DEVICE|MTA|Indirect capping with MTA
219455384|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
219455385|NCT00036816|BIOLOGICAL|MART-1 antigen|
219455386|NCT00036816|BIOLOGICAL|NA17-A antigen|
219455387|NCT00036816|BIOLOGICAL|gp100 antigen|
219455388|NCT00036816|BIOLOGICAL|tyrosinase peptide|
218845858|NCT06811675|DRUG|Dexamethasone and N-acetylcysteine (NAC)|Dexamethasone 10mg IV STAT +QD for 3 days+NAC IV 200mg/kg over 4 hours, then 100 mg/kg over 16 hours
219455389|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
219590546|NCT04681066|DRUG|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
219590547|NCT04681066|OTHER|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
218845859|NCT06811675|DRUG|Placebo|Placebo
218845860|NCT06652386|OTHER|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
218845861|NCT02601638|OTHER|Demographics and Health History Questionnaire|
218845862|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
218845863|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
218845864|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
218845865|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
218845866|NCT02601638|OTHER|Day of Discharge Practicum|
218845867|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
219455390|NCT02146885|OTHER|Weight Control|Weight Control
219455391|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
218845868|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
218845869|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
218845870|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
218845871|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
219455392|NCT02196389|DEVICE|Nasal dilator Nozovent|
219455393|NCT02196389|DEVICE|Nasal dilator Breath Right|
219455394|NCT02196389|DEVICE|Nasal dilator Airmax|
219455395|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
219455396|NCT05334329|BIOLOGICAL|Antineoplastic Immune Cell|Given COH06 IV
219455397|NCT05334329|BIOLOGICAL|Atezolizumab|Given IV
219455398|NCT05334329|PROCEDURE|Biospecimen Collection|Correlative studies
219455399|NCT05334329|DRUG|Cyclophosphamide|Given IV
219455400|NCT05334329|DRUG|Fludarabine|Given IV
218845872|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
219455401|NCT04828850|PROCEDURE|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
219455402|NCT00267657|DRUG|Reserpine|
218845873|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
218845874|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
218845875|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
218845876|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
218845877|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
218845878|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
218845879|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
218845880|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
218845881|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
218845882|NCT04613492|BIOLOGICAL|MEDI9253|Participants will receive either single or multiple dose of MEDI9253; sequentially or concurrent with Durvalumab
218845883|NCT04613492|BIOLOGICAL|Durvalumab|Participants will receive durvalumab treatment sequentially or concurrently with MEDI9253
219455403|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
219590548|NCT04943484|PROCEDURE|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
219455404|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
219590549|NCT03866902|BEHAVIORAL|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
219590550|NCT03866902|OTHER|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
219590551|NCT00362479|DRUG|DR-1021|1 tablet daily
219590552|NCT06349252|PROCEDURE|Radical resection|Patients should undergo radical resection.
218845884|NCT06654284|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at predeifined time points (baseline, 3 months, 1 year, 3 year, 6 year, 9 year and 12 year) collecting a complete overview of different aspects of quality of life, including: - Florida patient acceptance score (FPAS) - Short Form Health Survey (SF-12) - Kansas City Cardiomyopathy Questionnaire (KCCQ-12) - Hospital Anxiety and Depression Scale (HADS) - Florida Shock Acceptance score (FSAS) - Steinke Sexual Concerns Inventory - the Good Death questionnaire"
218845885|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
219455405|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
218845886|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
218845887|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
218845888|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
218845889|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
218845890|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
218845891|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
218845892|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
218845893|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
218845894|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
218845895|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
218845896|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
218845897|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
218845898|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
219590553|NCT04275882|DIAGNOSTIC_TEST|Electrocardiogram|There will be no new intervention performed for the patients.
219590554|NCT06283576|DIAGNOSTIC_TEST|Liquid biopsy|"Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth"
219590555|NCT05525793|OTHER|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
219590556|NCT00049582|DRUG|decitabine|Given IV
218845899|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
218845900|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
218845901|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
218845902|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
219590557|NCT00049582|OTHER|laboratory biomarker analysis|Correlative studies
219590558|NCT00049582|OTHER|pharmacological study|Correlative studies
219590559|NCT01069991|BEHAVIORAL|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
219590560|NCT01069991|BEHAVIORAL|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
219590561|NCT04180163|DRUG|Lanadelumab|Lanadelumab solution, SC
219590562|NCT05392335|OTHER|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
218845903|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
218845904|NCT06659081|PROCEDURE|implant placement|implant placement
218845905|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
218845906|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
218845907|NCT06658223|OTHER|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
218845908|NCT05691062|DEVICE|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
218845909|NCT05691062|DEVICE|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
218845910|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
218845911|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
218845912|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
218845913|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
218845914|NCT00256035|PROCEDURE|Measuring IL-4 levels|
218845915|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
218845916|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
218845917|NCT04420598|DRUG|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed"
218845918|NCT06598540|BEHAVIORAL|Kindness-focused|This mindset intervention frames food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include sharing their experiences about considering food choices as an act of self-kindness with other study participants or writing an encouraging letter to a study participant and physician colleague through the private and secure message board of a web-based educational platform.
219455406|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
219455407|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
219455408|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
219455409|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
219455410|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
219455411|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
219455412|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
219455413|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
219590563|NCT05392335|OTHER|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
219590564|NCT04730349|BIOLOGICAL|Nivolumab|Specified dose on specified days
219590565|NCT04730349|BIOLOGICAL|NKTR-214|Specified dose on specified days
219590566|NCT04352387|BEHAVIORAL|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
219590567|NCT04352387|BEHAVIORAL|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
219590568|NCT05060354|OTHER|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
219590569|NCT03613727|DRUG|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
219590570|NCT03630250|BIOLOGICAL|N. lactamica|Genetically modified N. lactamica
219590571|NCT01284621|DRUG|BI 10773|medium dose, oral administration
219590572|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
219590573|NCT01284621|DRUG|BI 10773|medium dose oral administration
219590574|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
219590575|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
219590576|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
218845919|NCT06598540|BEHAVIORAL|Health-focused|Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include writing a brief statement about their perspective on the usefulness of healthy eating and sharing it with physician colleagues in their group through the private and secure message board of a web-based educational platform.
219590577|NCT01377376|DRUG|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
219590578|NCT01377376|DRUG|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
219590579|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
219590580|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
219590581|NCT05596565|OTHER|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
219590582|NCT02418663|DRUG|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
219590583|NCT02342639|DRUG|Rifaximin|550mg pills
219590584|NCT02342639|DRUG|Placebo|Placebo pill
219590585|NCT01129843|DRUG|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
219590586|NCT02804711|BIOLOGICAL|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
219590587|NCT02804711|BIOLOGICAL|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
219590588|NCT02804711|BIOLOGICAL|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
219590589|NCT02804711|BIOLOGICAL|Placebo|
219590590|NCT01274676|DEVICE|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
219590591|NCT01274676|DEVICE|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
219455414|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
219455415|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
219590592|NCT04632160|DEVICE|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
219590593|NCT02318238|OTHER|6 minutes walking test|
219590594|NCT02318238|OTHER|6 minutes step test|
219590595|NCT02318238|OTHER|4 meters gait speed|
219590596|NCT03155945|DRUG|Olorinab|Olorinab active treatment for 8 weeks.
219590597|NCT04186351|BEHAVIORAL|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
219590598|NCT01090830|DRUG|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
219590599|NCT00810576|DRUG|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
219590600|NCT00810576|DRUG|Bortezomib|Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
219590601|NCT04719260|BEHAVIORAL|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
219590602|NCT04719260|BEHAVIORAL|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
219590603|NCT02968849|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
219590604|NCT02968849|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
219590605|NCT02968849|BIOLOGICAL|Placebo|Sodium Chloride for injection, 0.9% delivered IM
219590606|NCT02254161|DRUG|Matching placebo|Tablet
219590607|NCT02254161|DRUG|BI 1181181 healthy elderly|Tablet
219590608|NCT02254161|DRUG|BI 1181181 Healthy young|Tablet
219590609|NCT02832180|DRUG|OC containing EE and NET|
219590610|NCT02832180|DRUG|BMS-986142|
219590611|NCT03510780|PROCEDURE|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
219590612|NCT03510780|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
219455416|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
219455417|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
219455418|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
218845920|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
218845921|NCT04283994|BEHAVIORAL|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
218845922|NCT04283994|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
218845923|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
218845924|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
218845925|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
218845926|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
218845927|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
219455419|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
219455420|NCT05488977|BEHAVIORAL|Exercise training|8 weeks of supervised high-intensity interval training (HIIT).
219455421|NCT02689544|OTHER|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
219455422|NCT02689544|OTHER|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
219455423|NCT02689544|OTHER|Control|The control group volunteers no received intervention
219455424|NCT01642004|BIOLOGICAL|Nivolumab|
219455425|NCT01642004|DRUG|Docetaxel|
219455426|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
219455427|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
219455428|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
219455429|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
218845928|NCT00487942|DRUG|placebo|placebo
218845929|NCT06362876|BEHAVIORAL|Breastfeeding Counseling Based on Motivational Interviewing|Breastfeeding Counseling Based on Motivational Interviewing Program The breastfeeding counseling based on motivational interviewing program consists of 6 sessions and 4 hours. It includes information about breastfeeding, motivational preparation for the breastfeeding experience.
218845930|NCT06362876|BEHAVIORAL|Standard Breastfeeding Consultancy|Standart Breastfeeding Consultancy The standard breastfeeding consultancy program consists of 6session and 4 hours. It contains only information and applications about breastfeeding
218845931|NCT06996145|OTHER|dynamic 4D scanner|dynamic 4D scanner
219455430|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
219455431|NCT01128855|OTHER|Placebo|Weekly Placebo
219455432|NCT01832051|DRUG|89Zr-trastuzumab injection|
219455433|NCT03075930|DEVICE|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
218845932|NCT07004244|BIOLOGICAL|KRAS-mutated mRNA vaccine|"Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose.~Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery"
218845933|NCT07004244|BIOLOGICAL|TORIPALIMAB|intravenous injection
218845934|NCT07004244|DRUG|Pemetrexed+carboplatin|intravenous injection
218845935|NCT07003217|BEHAVIORAL|Virtual Reality-based practical education|VR-based practical education is an interactive learning method that utilizes virtual reality, where participants engage in a 3D environment for learning.
218845936|NCT07003217|BEHAVIORAL|Video Watching-based practical education|Video Watching-based practical education is a passive learning method, where information is delivered solely through video viewing.
218845937|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
218845938|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
218845939|NCT05034627|DRUG|Cobimetinib|Given PO
218845940|NCT06828029|BEHAVIORAL|Problem-Solving|The problem-solving training consists of five modules, blending theory and practice. Module 1 covers the basics of problem-solving, including key steps like identification, analysis, and evaluation, with group activities for hands-on practice. Module 2 focuses on creative techniques, such as brainstorming and mind mapping, to develop innovative solutions. Module 3 teaches decision-making and prioritization, using tools like SWOT analysis and decision trees, with applied exercises. Module 4 emphasizes teamwork and communication, highlighting conflict resolution and effective collaboration through team-based problem-solving activities. Module 5 integrates all techniques, applying them to real-life scenarios, particularly clinical cases, with group discussions and solution evaluations. The training incorporates interactive learning, simulations, and structured feedback, aiming to enhance problem-solving and leadership skills. Evaluation includes self-assessment and performance observation
219455434|NCT03075930|DEVICE|Body surface potential map|ECG with 184 leads and a 5 minute recording
219455435|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
219455436|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
219455437|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
219455438|NCT05714852|BEHAVIORAL|Healthy eating|Promotion of healthy eating
219455439|NCT05592444|DIAGNOSTIC_TEST|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
219455440|NCT06348862|BEHAVIORAL|Listening to either Quran, Music, and or Natural sound|Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
219590613|NCT04778553|DIAGNOSTIC_TEST|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
219590614|NCT02125162|DRUG|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
219590615|NCT00704847|DRUG|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
219590616|NCT00704847|DRUG|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
219590617|NCT02013674|BIOLOGICAL|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
219590618|NCT06632431|OTHER|Endometrial cancer (EC)|"Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm."
219590619|NCT01462773|DRUG|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
218845941|NCT05544227|DRUG|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
218845942|NCT07014085|PROCEDURE|"Histomorphometric Evaluation of Bone Augmentation Using Xenografts Versus Autologous Bone Grafts in Dental Implant Patients: A Comparative Clinical Study"|Split mouth comparative clinical prospective study xenograft vs autologous graft
218845943|NCT06682728|DRUG|Sacituzumab Govitecan (SG)|Given IV
218845944|NCT06682728|DRUG|Nivolumab|Given IV
218845945|NCT07011082|OTHER|Stress preventative measures|These studies will address fundamental gaps in our current knowledge and establish a scientific framework to investigate the long-term effects of early childhood adversity, physical or emotional trauma, child maltreatment, or other adverse experiences in early childhood, as well as the preventive and protective effects of loving, nurturing, and consistent caregiving offered to young children during their early childhood
218845946|NCT06773130|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
218845947|NCT06773130|DRUG|Nimotuzumab|400mg，ivgtt，d1，qw
218845948|NCT06692348|DRUG|Orforglipron|Administered orally
218845949|NCT06875635|OTHER|Pre and Post op pelvic floor muscle training|pre op exercises: Breathing exercise ,Kegel exercise ,Abdominals exercise include pelvic tilt ,knee rolling with abdominal contraction post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op exercise
218845950|NCT06875635|OTHER|Only post op pelvic floor muscle training|post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op protocol
219455441|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
219455442|NCT04583228|DRUG|HLX71|Single-dose, intravenous infusion
219455443|NCT04583228|OTHER|Placebo|Single-dose, intravenous infusion
219455444|NCT03232502|DIAGNOSTIC_TEST|Pharmacogenetic testing|Basic pharmacogenetic panel
219455445|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
219455446|NCT02192190|OTHER|Placebo- oral|Administered orally
218845951|NCT06875635|OTHER|Routine medical care|Circulatory exercise Breathing exercise Administrating analgesic Nursing care
218845952|NCT06076551|DIAGNOSTIC_TEST|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
218845953|NCT07022405|DRUG|Pramipexole Immediate Release|The intervention involves taking pramipexole immediate release (IR) for 8 weeks followed by 2 weeks of down titration and follow up.
218845954|NCT07025746|DEVICE|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
218845955|NCT07029217|RADIATION|Radiation (Standard)|24 Gy in 12 fractions
218845956|NCT07029217|RADIATION|Radiation (Very low dose)|4 Gy in 1-2 consecutive daily fractions
218845957|NCT07026539|DRUG|Finerenone (BAY 94-8862)|Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L
218845958|NCT07026539|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
219455447|NCT02192190|OTHER|Placebo - SC|Administered SC
219455448|NCT02192190|DRUG|Celecoxib|Administered orally
219455449|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
219455450|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
219455451|NCT00005623|DRUG|cyproterone acetate|
219455452|NCT00005623|PROCEDURE|quality-of-life assessment|
219590620|NCT01462773|DRUG|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
218845959|NCT07028372|OTHER|Short Form Health Survey (SF-36)|Heath-related quality-of-life is assessed using the SF-36 questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
218845960|NCT07028372|OTHER|Modified Rankin Score (mRS)|The degree of disability/dependence is evaluated using the mRS scale at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
219455453|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
219455454|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
219455455|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
219590621|NCT02334592|RADIATION|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
219590622|NCT05367050|BEHAVIORAL|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
218845961|NCT07028372|OTHER|Activity of Daily Living (ADL) questionnaire|Level of independence is evaluated using the ADL questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
218845962|NCT07028372|OTHER|New York Heart Association (NYHA) Classification|The extent of heart failure is assessed using the NYHA functional classification at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
218845963|NCT07028372|OTHER|St George's Respiratory Questionnaire (SGRQ)|Respiratory status is assessed using the SGRQ questionnaire at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
218845964|NCT07033260|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive ultrasonographic measurement of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
218845965|NCT07034807|DRUG|the traditional Chinese medicine prescription ' Shenzhuo Decoction '|The traditional Chinese medicine prescription ' Shenzhuo Decoction ' is composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort. It is a traditional Chinese medicine prescription for the treatment of diabetic kidney disease, which was founded by Tong Xiaolin, an academician of the Chinese Academy of Sciences.
218845966|NCT07034807|COMBINATION_PRODUCT|basic treatment|Basic treatment includes six aspects : nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, and control of other risk factors, which are implemented in accordance with clinical standard treatment specifications.
218845967|NCT07033715|OTHER|Exercise|"The exercise sessions will have a frequency of 3 times a week and a duration of 60 minutes per session. Exercise intensity will be gradually increased throughout the program and will be monitored every session using Borg's Rated Perceived Exertion scale, aiming at levels of 12-13 (fairly light to somewhat hard). The program will be mainly composed of cardiorespiratory exercises and resistance exercises. It will also comprise flexibility exercises to improve joint range of motion and neuromotor exercises involving motor skills (balance, agility, coordination, gait...), proprioceptive training and multifaceted activities (tai ji, yoga...)."
219590623|NCT05367050|BEHAVIORAL|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
219590624|NCT00960635|DRUG|1,25-dihydroxy-vitamin D3 (calcitriol)|
218845969|NCT07034573|OTHER|context adapted air filtration system for operating theatre|"This observational pilot study combines a retrospective design (technical data) and a prospective design (microbial data) to evaluate a new air filtration system adapted to the context. For this research, the technical data of the system concerning air velocity, temperature, etc. will be used retrospectively. Microbial sampling in the operating theatre will be carried out prospectively.~No patient contact will take place."
218845970|NCT07035041|DRUG|D-2570|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
218845971|NCT07035041|DRUG|Placebo|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
218845972|NCT07033039|DEVICE|Photobiomodulation|The photobiomodulation device used in this study will be the ECCO Reability (Ecco Fibras, Campinas, SP, Brazil), which is approved for clinical use by the Brazilian Health Regulatory Agency (ANVISA) under registration number 80323310001. The equipment is also certified by INMETRO, ensuring adherence to nationally established safety and performance standards.
218845973|NCT07033039|OTHER|Simulation of Photobiomodulation|In the sham group, the photobiomodulation procedure will be simulated with the device turned off. To preserve blinding, the equipment will be positioned as in the active treatment and its operational sound will be reproduced during the simulation, ensuring that the intervention remains indistinguishable from the actual PBM application.
219590625|NCT00960635|DRUG|placebo|pill without agent
219590626|NCT00416884|DRUG|Campath|30 mg on day -8 over 5-6 hours
219590627|NCT00416884|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 on day -4 through day -2
219590628|NCT00416884|RADIATION|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
219590629|NCT00416884|OTHER|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
219590630|NCT02819700|BEHAVIORAL|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
219590631|NCT06884514|DRUG|Psilocybin|A moderate dose of 20 mg psilocybin will be administered.
219590632|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
219590633|NCT06884514|DRUG|Psilocybin placebo|Mannitol capsules instead of capsules containing psilocybin.
219590634|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine placebo|Mannitol capsules instead of capsules containing MDMA.
218845974|NCT07033039|PROCEDURE|Standard treatment protocol|Participants in the control group will receive the standard medical protocol. No medication will be given preoperatively. Intraoperatively, dexamethasone 4 mg and tranexamic acid 1 g will be administered IV. Postoperative hospital care will include hydrocortisone 200 mg IV, tranexamic acid 250 mg IV, dipyrone 1 g IV, and cefazolin 1 g IV every 8 hours, plus ketorolac 10 mg sublingual as needed. At home, patients will take cefuroxime axetil 500 mg orally every 12 hours for 10 days, prednisolone 40 mg orally in the morning for 3 days, and dipyrone 1 g orally as needed. They will also apply a fibrinolysin and chloramphenicol ointment twice daily for 30 days and perform nasal irrigation with 0.9% sodium chloride six times daily for 60 days.
218845975|NCT07033611|DIETARY_SUPPLEMENT|Creatine|Five grams of creatine were administered to each patient daily for eight weeks.
218845976|NCT07034781|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
218845977|NCT07034781|DRUG|Comparator 2|Metformin 1000mg
218845978|NCT07034781|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
218845979|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
218845980|NCT04415749|OTHER|Placebo|Normal saline
218845981|NCT07033819|DRUG|Neoadjuvant therapy with fluazoparib in combination with apatinib|"Neoadjuvant Treatment Period Furazopanib: 150 mg, twice daily, orally, either before or after meals. It is recommended to take it within 0.5 hours after breakfast and dinner. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles.~Apatinib: 250 mg, once daily, orally, recommended to be taken within 0.5 hours after breakfast. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles."
219455456|NCT02447952|DEVICE|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
219455457|NCT02447952|DEVICE|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
219455458|NCT02447952|PROCEDURE|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
218845982|NCT07033819|PROCEDURE|Preoperative Period|Discontinue Furazopanib 7 days before surgery. Discontinue Apatinib 14 days before surgery. The specific timing will be assessed by the investigator based on postoperative wound healing.
218845983|NCT07033819|DRUG|Chemotherapy|Postoperative Adjuvant Chemotherapy Period (≥4 cycles) Paclitaxel: 150-175 mg/m², intravenous infusion, every 3 weeks (Q3W). Carboplatin: AUC 4-5, intravenous infusion, every 3 weeks (Q3W).
218845984|NCT07033819|DRUG|Maintenance treatment|"Maintenance Treatment Period Furazopanib: 150 mg, twice daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Apatinib: 250 mg, once daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Treatment will continue until disease progression, intolerable toxicity, or other reasons as specified in the protocol."
218845985|NCT07034222|DRUG|Administer Leqemi 10 mg/kg, every two weeks.|Receive 10 mg/kg of Leqembi once every two weeks. Dissolve Leqembi in normal saline and administer it intravenously over 60 minutes. The infusion system must use a 0.2-μM terminal line filter for administration.
218845986|NCT07033741|BEHAVIORAL|EMDR|The EMDR process follows an eight-phase protocol that includes (1) history taking: gathering patient's background information and planning treatment, (2) preparation: preparing the patient for processing target, (3) assessment: accessing target of the traumatic memories, (4) desensitization: processing target memories using dual task , (5) installation: strengthening the alternative positive cognition, (6) body scan: noting any physical sensations related to the target memory, (7) closure: ensuring patient's stability at the end of the session, and (8) revaluation: assessing effectiveness of the session and future planning.
218845987|NCT06829849|DIAGNOSTIC_TEST|Landing error assessment during a SHD task using the SHD-LESS scale|Participants will perform a 2D-camera-recorded SHD task, with the SHD-LESS scored by two sports medicine physicians. Additional tests include isokinetic muscle testing, as well as functional and psychological status assessments, following standard clinical practice.
219455459|NCT05143736|DIAGNOSTIC_TEST|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
219455460|NCT03247010|OTHER|Blood sampling|Blood samples are taken before each cycle of Radium 223
219455461|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
219590635|NCT06882811|BIOLOGICAL|CD83-positive MSC|90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
219590636|NCT06882811|BIOLOGICAL|regulatory MSC|45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
219590637|NCT06882811|OTHER|control solution|45 patients are infused with equal volume of control solution and receive regulatory treatment
219590638|NCT02203331|DRUG|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
219590639|NCT02203331|DRUG|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
219590640|NCT02203331|DRUG|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
218845988|NCT07033273|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Inferior Vena Cava Collapsibility Index (IVCCI) using ultrasound and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
218845989|NCT07033637|OTHER|Dietary Supplement|A daily oral capsule containing 1 x 10⁹ CFU of Lactiplantibacillus plantarum CECT 7481 (32.5 mg), microcrystalline cellulose (304.1 mg), and magnesium stearate (3.4 mg). Administered once daily before the main meal for 6 weeks. Used to evaluate its effects on gut microbiota and physical health in older adults.
218845990|NCT07033637|OTHER|Placebo|A daily oral capsule identical in appearance to the probiotic capsule, containing maltodextrin instead of Lactiplantibacillus plantarum. Administered once daily before the main meal for 6 weeks. Used to control for placebo effects in the assessment of probiotic efficacy.
218845991|NCT07033637|BEHAVIORAL|Structured Physical Activity Program|A 12-week supervised physical activity program conducted at municipal sports centers. Participants engage in moderate-intensity exercise at least 2 times per week. Designed to assess the impact of physical activity on gut microbiota, physical condition, and quality of life in older adults.
218845992|NCT06722989|BEHAVIORAL|mobile-guided exercise|"Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000."
218845993|NCT06722989|BEHAVIORAL|Unguided physical activity|In this group, pregnant women will be physically active at their discretion.
218845994|NCT07034547|PROCEDURE|Botulinum toxin infiltration|Botulinum toxin is a medication that is injected directly into the muscles selected by a physiatrist, based on a clinical evaluation. The doses are determined according to the clinical condition of the spasticity, the patient's age, and weight. The procedure is performed under deep sedation and uses ultrasound and electrostimulation to ensure greater safety and precision.
218845995|NCT07034898|DRUG|Dexmedetomidine|Participants in this arm will receive dexmedetomidine at a dose of 0.5 mcg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
218845996|NCT07034898|DRUG|Labetalol|Participants in this arm will receive labetalol at a dose of 0.5 mg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
218845997|NCT07032883|OTHER|Benson relaxation technique|"It will be performed every day, twice daily (in the morning and evening), for 4weeks, the Benson relaxation technique instruction included these steps.~1. Sit in a comfortable position.~2. Close their eyes.~3. Relax all their muscles beginning from the soles of the feet, moving forward up, and relax all parts of their body.~(4 ) Breath through their nose, pay attention to the sound of their breathing, and say the word ''one'' quietly to themselves when the breath is out.~(5) Continue for 20 min. the patients were instructed to check the time by opening their eyes. However, using an alarm was prohibited. The training sessions were held during the patients hospitalization period after one week from surgery, the technique continued during the hospitalization and after discharge from the hospital."
219455462|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
219455463|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
219455464|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
219455465|NCT01138293|DEVICE|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
219455466|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
219455467|NCT04809649|DRUG|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
219455468|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
219455469|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
219455470|NCT00058448|DRUG|docetaxel|
219590641|NCT02203331|DRUG|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
219590642|NCT02091466|DEVICE|pre-warming|warming patients 30 minutes prior to anesthesia
219455471|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
219455472|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
219590643|NCT03560180|DIAGNOSTIC_TEST|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
219590644|NCT03560180|DIAGNOSTIC_TEST|Serum C-reactive Protein|see study protocol
219590645|NCT03560180|DIAGNOSTIC_TEST|serum Procalcitonin|see study protocol
219455473|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
219455474|NCT04958551|OTHER|No intervention|No intervention
219455475|NCT06355206|COMBINATION_PRODUCT|endoscopic intervention, surgery or conservative treatment|Personal information and treatment of the enrolled subjects will be collected.
218845998|NCT07032883|OTHER|Routine physiotherapy program|The participants will receive routine physical therapy program (gentle stretching, manual therapy, mobility and strengthening exercises and posture training) for 40 minutes , for 4 weeks.
219455476|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
219455477|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
218845999|NCT07032883|DRUG|Medications|"the participants will receive the following medications:~1. Antibiotic: Ancef 1 g intravenous (IV) ( cefazolin) intravenous post-surgery every 8 hours for 24 hours. If allergic to ampicillin /cephalosporins clindamycin IV 600\_900 mg every 8 hours for 24 hours. Then continue oral with keflex 1g tablets (cephalexin) twice daily for 7 days.~2. Anti-inflammatory:~   Adolor ( ketorolac) 15\_30 mg IV every 6 hours up to 5 days post-operation ( not exceed 120 mg/day) then followed by oral celecoxib 200 mg once or twice daily till pain subsides.~3. paracetamol 500\_1000 mg I.V every 6 hours for 5 days (Not exceed 4000 mg / day) Then followed by oral paracetamol tablets till pain subsides.~4. Zurcal 40 mg IV (pantoprazol) then followed by oral zurcal tablets."
218846000|NCT06721689|DRUG|PEEL-224|PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor
218846001|NCT06721689|DRUG|Vincristine|Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.
218846002|NCT06721689|DRUG|Temozolomide (TMZ)|Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.
218846003|NCT07034417|OTHER|Exercise|Cognitive Exercise Therapy Approach
218846004|NCT07034417|OTHER|Home exercise|Home exercise
218846005|NCT06888258|PROCEDURE|Ultrasound guided Erector Spinae Plane block|"Group E: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse process of the 5th thoracic vertebra and erector spine muscle.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. The puncture will be performed using the intra-plane needling technique after local anaesthesia infiltration. A 20-gauge Tuohy needle connected to a syringe containing the anesthetic mixture or saline will be advanced. When the puncture needle touch the transverse process, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered between the erector spine muscle and transverse process.~Local anesthetic diffusion between the transverse process and erector spinae muscle is an indication of a successful puncture."
219455478|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
218846006|NCT06888258|PROCEDURE|Ultrasound guided Mid-point to Pleura block|"Group M: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse processes of the 4th and 5th thoracic vertebrae and pleura.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. Using the in plane needling technique in the space between the transverse processes of the 4th and 5th thoracic vertebrae, the puncture needle needle tip will be placed at the mid-point between the transverse process and pleura, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered. The local anesthetic spread will be noted in the area midway between the transverse process and pleura is an indication of a successful puncture."
219455479|NCT04025749|OTHER|Care as usual|Care as usual
219455480|NCT00348075|DEVICE|Neurovision|
219455481|NCT00000175|DRUG|Estrogen|
219455482|NCT00000175|DRUG|Testosterone|
219455483|NCT03439722|OTHER|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
219455484|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
219455485|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
219455486|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
219455487|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
219455488|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
219455489|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
219455490|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
219455491|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
219455492|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
219455493|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
219455494|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
219455495|NCT02846766|DRUG|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
218846007|NCT06727903|OTHER|laboratory biomarker analysis|Results of laboratory biomarker analysis will be analyzed as predictors for mortality
218846008|NCT06886828|DEVICE|Virtual reality goggles during HFNC|HFNC oxygen therapy will be started with video demonstration accompanied by virtual reality glasses. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the study, only the behaviours of the child during the procedure should be video recorded by a mobile phone. For the participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study. The study will continue until the 30-person intervention group is completed.
218846009|NCT06886828|DEVICE|HFNC oxygen therapy with routine service application|HFNC oxygen therapy will be started with routine ward practice. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the research, only the behaviours of the child during the procedure should be video-recorded by means of a mobile phone. For participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study
218846010|NCT06725927|BIOLOGICAL|Influenza vaccination|Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
218846011|NCT06732141|BEHAVIORAL|Personalized Telephone-Based Psychological Support|"This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components:~1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects.~2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being.~3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change.~4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels."
219455496|NCT01406366|BEHAVIORAL|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
219455497|NCT01406366|BEHAVIORAL|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
219455498|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
219590646|NCT06341829|OTHER|Prismatic adaptation|Participants will fit with prismatic goggles that deviate their visual field by 13° either leftward or rightward. They will seat in front of a white horizontal board on which three target dots (5 mm diameter) were positioned at 0, -10 and +10° from their body midline at a distance of 57 cm from their eyes. They will perform a total of 150 verbally instructed pointing movements with their right index finger towards the right (+10°) and left (-10°) targets in a pseudorandom order.
219590647|NCT05258448|OTHER|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
219590648|NCT01919788|DRUG|Insulin (Insuman Rapid)|
219590649|NCT01919788|DRUG|Glucose|
219590650|NCT01919788|OTHER|Saline|
219590651|NCT03749083|OTHER|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
219590652|NCT03558061|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
219455499|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
219455500|NCT00396344|OTHER|Çontrol|Intravenous saline
219455501|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
219455502|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
219455503|NCT04488601|DRUG|Rapamycin|Rapamycin in 2 different dosage forms.
219455504|NCT04488601|DRUG|Placebo|Placebo capsules
219455505|NCT04853264|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
219455506|NCT04853264|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
219455507|NCT03938558|OTHER|MS-Dance|The experimental group will perform 10 weeks of dance training
219455508|NCT03938558|OTHER|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, …)
219455509|NCT02411006|BEHAVIORAL|Prediction mailing|Ask people to predict their upcoming medication adherence
219590653|NCT06733142|DIETARY_SUPPLEMENT|Test Product: Yoghurt|High protein spoonable yoghurt
218846012|NCT06732141|BEHAVIORAL|Standard Care with Weekly Follow-Up Calls|Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
218846013|NCT06885385|BIOLOGICAL|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days
219455510|NCT02411006|BEHAVIORAL|Commitment mailing|Ask people to commit to their upcoming medication adherence
219455511|NCT02411006|BEHAVIORAL|Reminder|Remind people to take their medicine
219455512|NCT02411006|BEHAVIORAL|Anonymity|Keep patient predictions and commitment anonymous
219455513|NCT02411006|BEHAVIORAL|Identification|Ask patients to report their predictions and commitments
219455514|NCT00004127|DRUG|FOLFOX regimen|
219455515|NCT00004127|DRUG|fluorouracil|
218846014|NCT06885385|BIOLOGICAL|JS015|JS015 will be administered every 3 weeks for a treatment cycle of 21 days
219455516|NCT00004127|DRUG|leucovorin calcium|
219455517|NCT00004127|DRUG|oxaliplatin|
219590654|NCT06733142|DIETARY_SUPPLEMENT|Micellar casein drink|Micellar casein drink made from water, casein powder and fruit syrup
218846015|NCT06885385|DRUG|Capecitabine|Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle
219455518|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
218846016|NCT06885385|DRUG|Oxaliplatin|Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle
218846017|NCT06738082|BIOLOGICAL|Influenza vaccine|Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.
218860119|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
219455519|NCT02087241|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
219455520|NCT02087241|DRUG|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
219455521|NCT02087241|DRUG|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
219455522|NCT02087241|DRUG|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
219455523|NCT01725919|BEHAVIORAL|CI therapy|constraint induced movement therapy
219455524|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
219455525|NCT06990828|OTHER|Frenkel Stabilization Exercises|Participants included in the study will undergo a program of Frenkel Stabilization Exercises.
219455526|NCT01296464|DRUG|Carbidopa|Capsules
219455527|NCT02181504|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
219455528|NCT02181504|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
219590655|NCT06733142|DIETARY_SUPPLEMENT|Placebo|Placebo sugar free jelly
219590656|NCT00497913|DRUG|NaCl 0.9%|
219590657|NCT00497913|DRUG|Botulinum Toxin A|
219590658|NCT03134118|DRUG|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
219590659|NCT04335318|DEVICE|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
219590660|NCT05260580|OTHER|No Intervention: Routine care|
219455529|NCT02181504|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
219455530|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
219455531|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
219455532|NCT03068182|OTHER|Exercise|
219455533|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
219455534|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
219455535|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
219455536|NCT04849260|BIOLOGICAL|Pexa-Vec combined with ZKAB001|"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."
219455537|NCT04849260|BIOLOGICAL|ZKAB001 monotherapy|ZKAB001 monotherapy
219455538|NCT02897011|DRUG|Methotrexate|
219455539|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
219455540|NCT03944811|PROCEDURE|Summers technique|Summers technique
219455541|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
219455542|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
219455543|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
219455544|NCT02303470|BEHAVIORAL|Moderate Exercise|
219455545|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
219455546|NCT01006915|PROCEDURE|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
219455547|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
219455548|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
219455549|NCT00614042|DRUG|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
219455550|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
219455551|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
219455552|NCT06989242|DEVICE|Yoga-Based Therapeutic Device (incorporating guided breathing and movement)|The Fluere™ Therapeutic Device is a computer-guided, electro-mechanical system designed to simulate yoga-inspired spinal movement and rhythmic breathing. Resembling a dental chair, the device dynamically adjusts spinal curvature to replicate motion patterns associated with deep abdominal breathing, similar to Kundalini or Qi Gong breathwork. The device operates automatically, with optional manual adjustments by the researcher.
219455553|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
219455554|NCT03200418|OTHER|P-4|This patch is made of new adhesive
219455555|NCT03200418|OTHER|P-15|This patch is made of new adhesive
219455556|NCT03200418|OTHER|P-16|This patch is made of new adhesive
219455557|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
219455558|NCT02223949|DEVICE|Cook double balloon catheter|
219455559|NCT02223949|DRUG|PGE1 tablet|
219455560|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
219455561|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
219455562|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
219455563|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
219590661|NCT03483363|DRUG|topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)|Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
219590662|NCT03483363|DRUG|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure.
219590663|NCT03483363|DRUG|intravenous (IV) prophylactic antibiotic|All arms with receive standard parenteral (IV) prophylactic antibiotic.
219590664|NCT01987310|DRUG|atorvastatin|atorvastatin 20 mg per day for 6 months
219590665|NCT01987310|BEHAVIORAL|lifestyle counseling|lifestyle modification by dietician counseling and follow up
219590666|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
219590667|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
219590668|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
219590669|NCT04726176|BIOLOGICAL|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
218846018|NCT06885320|BEHAVIORAL|IMPROVE|IMPROVE is an individual manualized intervention. Session1 includes: • psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations • guided discussion of maladaptive thoughts about bodily sensations related to anxiety • how to challenge bodily sensations cognitively • generating three takeaways about the benign nature of anxiety Session 2 includes: • review of homework • psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty. • when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty. Session 3 includes: • review interoceptive exposure (IE) and behavioral exercises (BE) for progress • revisit beliefs related to cognitive biases • discuss areas where skills can be used moving forward
218846019|NCT06885320|BEHAVIORAL|HET|"Clinicians will administer HET using a PowerPoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. HET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
218846020|NCT06891495|OTHER|Expert Evaluation of Adapted Questionnaire|This intervention involves inviting a group of subject matter experts-including dental specialists, public health professionals, and communication experts-to evaluate the adapted questionnaire. The questionnaire, derived from the Questionnaire for Assessing Educational Podcasts (QAEP) and tailored for assessing an AI-generated health podcast, covers four dimensions: Access and Use, Design and Structure, Content Adequacy, and Value as an Aid to Learning. Experts will complete a structured online survey (via Google Form) to rate each item's clarity, relevance, and necessity. Their feedback is integral to refining and validating the instrument prior to its use with the general public.
218846021|NCT06891495|OTHER|AI-Generated Health Podcast Evaluation|Participants in this group will first listen to a 4-minute AI-generated health podcast on gum health and prevention. The podcast was produced using Google NotebookLM and is based on publicly available information from the American Academy of Periodontology, with appropriate source credit. After listening, participants will complete a validated questionnaire (administered via Google Form) that assesses the podcast's accessibility, design, content adequacy, and educational value. This intervention is designed to measure public perception, engagement, and overall feasibility of using AI-generated podcasts as an educational tool for health communication.
218846022|NCT06890754|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|Diagnostic hysteroscopy. An IHC study of the expression of the plasma cell marker CD138 was systematically performed for all samples studied
218846023|NCT06632405|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
218846024|NCT06632405|DRUG|Nab paclitaxel|Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
218846025|NCT06632405|DRUG|Levocetirizine Hydrochloride|5mg daily, start 3 days before the 1st administration
218846026|NCT06890676|OTHER|Comprehensive Oral Evaluation|A thorough check-up of teeth, gums, and surrounding tissues, including medical and dental history, to assess overall oral health and identify any infections.
218846027|NCT06890676|OTHER|Intraoral Complete Radiographic Series|A series of x-rays of the whole mouth intended to display the, teeth, roots, periapical areas, bone, and areas without teeth.
218846028|NCT06890676|OTHER|• Teledentistry-synchronous and asynchronous|The delivery or coordination of care for a patient using synchronous; real-time or aysnchronous communication between care providers or between care providers and a patient.
219455564|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
219455565|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
219455566|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
219455567|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
219455568|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
218846029|NCT06890676|PROCEDURE|Periodontal Therapy|A therapeutic procedure designed to remove plaque and calculus (hardened plaque) causing gum infections that can lead to tooth loss and other medical complications.
218846030|NCT06890676|PROCEDURE|Periodontal Maintenance Procedure|A periodic evaluation and therapeutic support procedure for patients with a history of gum infections.
218846031|NCT06890676|PROCEDURE|Application of Caries Arresting Medicament|Topical application of decay arresting or inhibiting medicament.
218846032|NCT06890676|OTHER|Oral Hygiene Assistance|Dental procedures aimed at educating patients on, and assisting patients with ,proper oral hygiene practices removing food debris, germ-laden plaque, and soft tartar using cloth wipes, toothbrush, floss, and using oral hygiene aids.
218846033|NCT06890676|PROCEDURE|Referral for Treatment of Acute Oral Infection|Diagnosis and treatment of oral infection outside the scope of a dental hygienist or Expanded Function Dental Assistant.
218846034|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
218846035|NCT06896786|OTHER|dialysis assisted with the sodium management tool|"Sodium management tool is a modul of the fresenius 6008 dialysis machine. This model approximates changes in plasma electrolyte concentrations during dialysis and allows the estimation of sodium concentration based on dialysate conductivity. Na control biosensor continuously (every minute) monitors the dialysate side sodium balance based on measurements of fresh and spent dialysate conductivities and the application of a kinetic model to account for the typical influence of other ions on dialysate conductivity. In activated Na control, as zero diffusive mode, dialysate sodium is then adjusted continuously to minimize diffusive Na transfer. SMT is part of the 6008 Machine and its certification is included in the Fresenius 6008 Machine certification. Untill now there is no data if this modul benefits. in this study the investigator compares standard of care dialysis (Arm 1) with dialysis assisted with the SMT (Arm ) on clinical outcome"
218846036|NCT06895668|OTHER|None (cohort study)|None (cohort study)
218846037|NCT06895278|DRUG|Methotrexate|Prevalent use of methotrexate in pediatric age
218846038|NCT06895278|DRUG|Biological Drug|Prevalent use of biological drugs in pediatric age
218846039|NCT06896071|BEHAVIORAL|Project SOLVE|"Project SOLVE is a 30-minute self-guided online activity that includes an introduction to problem solving and which types of problems might be most appropriate for this skill; a description of how the brain facilitates problem solving; vignettes demonstrating how older adolescents have solved their problems; scientific evidence that problem solving can work; practice exercises; and activities to encourage the use of problem solving in daily life. The intervention teaches students how to solve problems via the SOLVE framework (i.e., Saying what the problem is; One goal to aim for; Listing some solutions; Voting for the best solution; Exploring what works)."
219455569|NCT06315322|DRUG|Brivaracetam Film-coated tablet|Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
219455570|NCT06315322|DRUG|Brivaracetam oral solution|Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
219455571|NCT04533360|DIAGNOSTIC_TEST|VITROS Anti-SARS-CoV-2 IgG test|The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
219455572|NCT01071941|BIOLOGICAL|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
219455573|NCT02558452|DRUG|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
219455574|NCT01677676|BIOLOGICAL|FP-01.1|IM injection
219455575|NCT01677676|BIOLOGICAL|FP-01.1-Adjuvant|IM injection
219455576|NCT00003804|BIOLOGICAL|dactinomycin|
219455577|NCT00003804|DRUG|vincristine sulfate|
219455578|NCT00003804|PROCEDURE|conventional surgery|
219455579|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
219455580|NCT05111184|BEHAVIORAL|Education groupe|Education
219455581|NCT00389805|DRUG|bortezomib|
219455582|NCT00389805|DRUG|pemetrexed disodium|
218846040|NCT06896071|BEHAVIORAL|Project Success|Project Success is comparable to Project SOLVE in format and length (i.e., a 30 minute online, self-guided intervention) and teaches young people three strategies to reach their academic goals: how to take effective notes, how to break big assignments down into smaller tasks, and how to ask trusted others for help.
219455583|NCT00389805|GENETIC|gene expression analysis|
219455584|NCT00389805|GENETIC|mutation analysis|
219455585|NCT00389805|GENETIC|protein expression analysis|
218846041|NCT06845579|PROCEDURE|Renal sympathetic denervation|All procedures will be carried out by highly experienced interventional cardiologists, each having performed a minimum of 20 RDN prior to treating study patients. All interventions will be performed with the CE-marked Symplicity SpyralTM (Medtronic, Minneapolis, MN, USA) renal denervation system following current treatment standards. Procedures will be performed as stated in the IFU. The specific ablation points will be determined by the discretion of the interventionalist.
218846042|NCT06880042|DRUG|Tacrolimus|Tacrolimus is calcineurin inhibitor that will act as immunomodulator
218846043|NCT06880042|DRUG|Calcipotriol|Calcipotriol is a vitamin D analogue that will act as immunomodulator
218846044|NCT01777503|DRUG|prasugrel|prasugrel 5 mg o.d.
218846045|NCT01777503|DRUG|Clopidogrel|75 mg o.d.
218846046|NCT06755632|DIAGNOSTIC_TEST|TROD (rapid diagnostic orientation test) and FibroScan®|"Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient :~* with Fibroscan® ≥ 9.6 KPa or~* positive hepatitis C serology or~* HBsAg positive"
218846047|NCT05325736|PROCEDURE|sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery
218846048|NCT05325736|PROCEDURE|gastric bypass surgery|participants undergoing gastric bypass surgery
218846049|NCT05325736|PROCEDURE|control|cholecystectomy
218846050|NCT05325736|PROCEDURE|Pancreatectomy|Collecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample
218846051|NCT06893549|DIETARY_SUPPLEMENT|Lactobacillus plantarum GKK1 Probiotic|Participants in the probiotic group will receive a daily oral supplementation of Lactobacillus plantarum GKK1 probiotic capsules for 28 days. Each capsule contains 50 billion CFU, with a total daily intake of 100 billion CFU. The probiotic strain Lactobacillus plantarum GKK1 has been selected for its potential benefits in reducing exercise-induced fatigue and enhancing physical performance. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
218846052|NCT06893549|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a daily oral supplementation of placebo capsules for 28 days. The placebo capsules are identical in appearance, taste, and weight to the probiotic capsules but contain only microcrystalline α-cellulose, magnesium stearate, and silicon dioxide. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
218846053|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
218846054|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
218846055|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
218846056|NCT02204046|DRUG|BIWA 4|
219455586|NCT00389805|GENETIC|reverse transcriptase-polymerase chain reaction|
219455587|NCT00389805|OTHER|flow cytometry|
219455588|NCT00389805|OTHER|immunoenzyme technique|
218846057|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
218846058|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
218846059|NCT06890221|DIETARY_SUPPLEMENT|B-Crobes intake complete nutrition|Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.
218846060|NCT06890221|DIETARY_SUPPLEMENT|Placebo|Contains full cream dairy milk
218846061|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
218846062|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
218860120|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
219455589|NCT00389805|OTHER|immunohistochemistry staining method|
219455590|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
219455591|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
219455592|NCT07007091|DRUG|Risankizumab|Subcutaneous (SC) Injection
219455593|NCT07007091|DRUG|Risankizumab|On-Body Injector (OBI)
219455594|NCT06868173|DEVICE|Electro-acupuncture|Electroacupuncture at Trigger Points is electroacupuncture at predetermined trigger points. Electroacupuncture at traditional acupoints is electroacupuncture at the following points: Jiaji (L2-L5), Yaoyangguan (GV3), Shendu (BL23), Dachangdu (BL25), and Weizhong (BL40).
219455595|NCT01289028|DRUG|Nilotinib|
219455596|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
218860121|NCT03745352|DRUG|Azacitidine|Given IV or SC
219455597|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
219455598|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
219455599|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
219455600|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
219455601|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
219455602|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
219455603|NCT04669106|OTHER|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
219455604|NCT01657214|DRUG|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
219455605|NCT03208504|DEVICE|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
219590670|NCT06988904|OTHER|Energy2MOB|"Intervention: The Energy2MOB programme will take place at three primary healthcare centres in Berguedà:~Baix Berguedà (Puig-Reig CAP) Berga Centre (Berga CAP) Alt Berguedà (Guardiola de Berguedà CAP)~The programme will include:~One pre-intervention visit 8 weekly group sessions One post-intervention visit One-month telephone follow-up In-person follow-ups at three and six months~The control group will continue with standard care at their usual primary healthcare centre and will only attend pre-intervention, post-intervention, and six-month follow-up visits. They will not receive group sessions or telephone follow-ups. If the Energy2MOB programme proves effective, control group participants will be invited to participate in the intervention sessions."
219590671|NCT06219278|DEVICE|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
219590672|NCT01910974|PROCEDURE|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
219590673|NCT01723579|DRUG|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
219590674|NCT01723579|DRUG|Estradiol (E2)|Daily release of 1.5 mg
218846063|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
218846064|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
218846065|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
218846066|NCT00050206|DRUG|Olanzapine|
218846067|NCT00050206|DRUG|Placebo|
218846068|NCT06644482|OTHER|Exercise group in a hospital setting|Participants will exercise in a group once a week for 16 weeks in a hospital setting.
218846069|NCT00501722|DRUG|satavaptan (SR121463B)|
218846070|NCT01794208|DRUG|Follitropin Epsilon|
218846071|NCT01794208|DRUG|Follitropin Alfa|
218846072|NCT07080931|DRUG|5% minoxidil foam|Participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
218846073|NCT07080931|DRUG|Placebo for 5% Minoxidil Foam|Participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
218846074|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
218846075|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
218846076|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
218846077|NCT07079748|DIETARY_SUPPLEMENT|Yeast Postbiotics|Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide.
218846078|NCT07079748|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals.
218846079|NCT06902701|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Endoscopic excision of the rectal lesion by submucosal injection and circumferential mucosal incision using an electrosurgical knife with en-bloc resection intent
218846080|NCT06902701|PROCEDURE|Transanal Endoscopic Surgery (TES)|Transanal endoscopic surgery procedures include Transanal Minimally Invasive Surgery (TAMIS) and Transanal Endoscopic Operation (TEO). TAMIS will be performed using a single-port transanal access platform with standard laparoscopic instruments, including a high-definition camera, an insufflation system, and endoscopic graspers. The lesion will be circumferentially excised using electrocautery or an energy device, ensuring full-thickness resection when necessary. The defect will be managed based on its size, with primary closure using absorbable sutures or left to heal by secondary intention. TEO will be conducted using a rigid transanal endoscopic platform with a stereoscopic optical system to enhance visualization. The lesion will be marked, and a full-thickness or submucosal excision will be performed using endoscopic instruments and electrosurgical devices. Post-resection, the rectal wall defect will be assessed, and primary closure will be performed when indicated to minimize post
218846081|NCT00322452|DRUG|Gefitinib|oral tablet
218846082|NCT00322452|DRUG|Carboplatin|IV
219590675|NCT03481218|OTHER|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
218846083|NCT00322452|DRUG|Paclitaxel|IV
219590676|NCT03481218|OTHER|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
218846084|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
218846085|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
218846086|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
218846087|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
218846088|NCT07080879|DEVICE|Linear Anastomat|The product registration certificate numbers of linear anastomat is Su Wei registered 20202021581.
218846089|NCT07080879|DEVICE|Tubular Anastomat|The product registration certificate numbers of tubular anastomat is Su Wei registered 20182020305.
218846090|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
218846091|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
218846092|NCT07081607|DRUG|golidocitinib with azacytidine and chidamide|"In Phase I, a 3+3 dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).~In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma"
218846093|NCT07080593|BEHAVIORAL|Novel Physical Activity Program|A structured phase and a self-directed phase, involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aligns with the participants' goals and motivations to increase physical activity levels.
218846094|NCT07080593|BEHAVIORAL|Standard of Care Physical Activity Program|"Those in the control group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)"
218846095|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
218846096|NCT02497144|OTHER|Control Group|Breathing exercises
218846097|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
218846098|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
218846099|NCT06896149|DIAGNOSTIC_TEST|Obstetric ultrasound|Ultrasound focus on fetal renal pelvis, amniotic fluid assessment, and fetal weight estimation.
218846100|NCT06889779|DIETARY_SUPPLEMENT|MIX 1|Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-Ofucosyllactose 300 mg 1 capsule per day Orally
218846101|NCT06889779|DIETARY_SUPPLEMENT|MIX 2|Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day Orally
218846102|NCT06889779|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose 1 capsule per day Orally
218846103|NCT07079267|DRUG|Olpasiran|
218846104|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
218846105|NCT03284333|DEVICE|other|no arm
218846106|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
218846107|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
218846108|NCT01794078|OTHER|Placebo|
218860122|NCT03745352|DRUG|Pevonedistat|Given IV
219455606|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
219455607|NCT06321640|GENETIC|Cohort A: primarily operable disease, candidate to adjuvant|This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint
219455608|NCT06321640|GENETIC|Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.
219455609|NCT06321640|GENETIC|Cohort C: metastatic disease|In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.
219590677|NCT03481218|OTHER|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
218860123|NCT00070252|DRUG|Capecitabine|Given PO
218860124|NCT00070252|DRUG|Docetaxel|Given IV
218860125|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
218860126|NCT00070252|OTHER|Pharmacological Study|Correlative studies
219455610|NCT06321640|GENETIC|Cohort D: Progressive disease|In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.
219455611|NCT06321640|GENETIC|Cohort E: Hematological neoplasms|Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.
219455612|NCT06321640|GENETIC|Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
219455613|NCT01709604|PROCEDURE|CVVH|Ultrafiltration at 35ml/h/Kg
218860127|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
218860128|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
219455614|NCT01709604|PROCEDURE|Standardized therapy regimens|"Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care"
219455615|NCT00382655|PROCEDURE|Education and referral|
219455616|NCT05254587|DEVICE|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
219455617|NCT03515616|DIAGNOSTIC_TEST|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
219455618|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
218860129|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
219455619|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
219455620|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
219455621|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
218860130|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
219455622|NCT02120469|DRUG|everolimus|Given PO
219455623|NCT02120469|DRUG|eribulin mesylate|Given IV
219455624|NCT02120469|OTHER|pharmacological study|Correlative studies
219455625|NCT02120469|OTHER|laboratory biomarker analysis|Optional correlative studies
219455626|NCT02980991|DRUG|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
219455627|NCT02980991|DRUG|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
219455628|NCT04143789|DRUG|AP-002|Dose escalation
219455629|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
219455630|NCT04235088|OTHER|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
219455631|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
219455632|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
219455633|NCT05391620|OTHER|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
219455634|NCT05391620|OTHER|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
219590678|NCT05233930|PROCEDURE|TKR with augmented reality-based navigation system|Surgery
219590679|NCT05233930|PROCEDURE|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
219590680|NCT06897644|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
219590681|NCT06897644|DRUG|Irinotecan (CPT-11)|150 mg/sqm iv over 60 minutes day 1
219590682|NCT06897644|DRUG|Leucovorin|Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1
219455635|NCT04469257|BEHAVIORAL|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
219455636|NCT05570357|DIETARY_SUPPLEMENT|Berberine+Cinnamon (TDS)|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
219455637|NCT05570357|OTHER|Placebo (TDS)|Placebo contains Maltodexterin
219455638|NCT06231004|PROCEDURE|glucocorticosteroid and surgery|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
219455639|NCT06102928|DRUG|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
219455640|NCT05609162|PROCEDURE|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
219455641|NCT03104829|BEHAVIORAL|Motivational interviewing|
219455642|NCT03104829|DRUG|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
219455643|NCT02597972|PROCEDURE|Fracture repair|
219455644|NCT02597972|PROCEDURE|Fracture repair with joint replacement|
218846109|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
218846110|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
218846111|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
219455645|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device|
219590683|NCT06897644|DRUG|5-FU (5-fluorouracil)|2400 mg/sqm 46-hours infusion
218846112|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
218846113|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
219590684|NCT06897644|DRUG|gemcitabine|1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
219590685|NCT06897644|DRUG|Nab-paclitaxel|125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
219590686|NCT06841822|OTHER|SCTL superficial plane block|The purpose of this study was to evaluate whether thoracic paravertebral nerve block performed on superficial SCTL (puncture needle did not break SCTL) was more beneficial to maintaining hemodynamic stability during the induction period of thoracoscopic lobectomy compared with SCTL deep plane (puncture needle break SCTL). We performed an ultrasound-guided paravertebral nerve block while keeping the puncture needle did nit to break through the SCTL. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
218846114|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
218860131|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
218860132|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
219455646|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device in placebo mode|
219455647|NCT06124352|DIAGNOSTIC_TEST|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
219455648|NCT06124352|DIAGNOSTIC_TEST|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
219455649|NCT06124352|DIAGNOSTIC_TEST|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 \[24, 25\].
219455650|NCT00250029|DRUG|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
219590687|NCT06841822|OTHER|SCTL deep plane block group|Ultrasound-guided thoracic paravertebral nerve block was routinely performed. SCTL was broken by a puncture needle during the ultrasound-guided thoracic paravertebral block. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
219590688|NCT00596037|DRUG|Growth hormone - LB03002|
219590689|NCT06812611|DEVICE|High Energy Laser Group|"The multimodal high energy laser therapy treatment with thermal control (THEAL) will be delivered with an Ixyon XP device (Mectronic, Bergamo, Italy) which allows the delivery of 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, average power up to 30 W, administering 10 sessions every other day.~The patients will simultaneously carry out the rehabilitation treatment exercises, as was expected in the control group."
219590690|NCT06812611|OTHER|Exercise|Daily exercise
218846115|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
218846116|NCT00898300|OTHER|biologic sample preservation procedure|
218846117|NCT00898300|PROCEDURE|biopsy|
218846118|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
218846119|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
218846120|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
218846121|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
218846122|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
218846123|NCT00258232|DRUG|capecitabine|
218846124|NCT00258232|DRUG|celecoxib|
218846125|NCT00258232|DRUG|irinotecan hydrochloride|
218846126|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
218846127|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
218846128|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
218846129|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
218846130|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
219590691|NCT00802594|DRUG|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
218846131|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
218846132|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
219455651|NCT02076243|DRUG|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
218846133|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
218846134|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
218846135|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
218846136|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
218846137|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
218846138|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
219455652|NCT06198504|PROCEDURE|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
219590692|NCT06908876|BIOLOGICAL|IBI302|4 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by Pro re nata (PRN) regimen.
218846139|NCT00063895|OTHER|pharmacological study|Correlative studies
218846140|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
218846141|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
218846142|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
218846143|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
218846144|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
218846145|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
218846146|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
218846147|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
219455653|NCT00456924|DRUG|VA2914|
219455654|NCT06022224|BIOLOGICAL|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.
219455655|NCT06022224|BIOLOGICAL|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
219455656|NCT05384795|OTHER|Lung ultrasound|Lung atelectasis score
219455657|NCT01183481|DRUG|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
219455658|NCT01183481|RADIATION|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
219455659|NCT01183481|DRUG|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
218846148|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
218846149|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
218846150|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
218846151|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
218846152|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
218846153|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
219455660|NCT01725295|OTHER|NST|A form of physical therapy
219455661|NCT01725295|OTHER|Hydrotherapy|
219590693|NCT06908876|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by PRN regimen.
219590694|NCT06908876|DRUG|Faricimab|6 mg faricimab will be administered by intravitreal injection into the study eye once every 4 weeks for 4 consecutive months, followed by PRN regimen.
219590695|NCT06830044|DRUG|Milsaperidone|Oral milsaperidone
219590696|NCT06830044|DRUG|Placebo|Oral placebo
218846154|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
219455662|NCT04454749|DIAGNOSTIC_TEST|Blood test|Mesurement of E2, P4, LH, FSH hormones
219455663|NCT04454749|DIAGNOSTIC_TEST|Ultrasound|Follicular measurement and endometrium measurement
218846155|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
218846156|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
218846157|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
218846158|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
218846159|NCT00952445|DRUG|Placebo|Once daily, oral
218846160|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
218846161|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
218846162|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
218846163|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
218846164|NCT01905345|PROCEDURE|Training|
218846165|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
218846166|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
218846167|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
218846168|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
218846169|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
218846170|NCT00269269|DRUG|antihypertensive drug|
218846171|NCT00269269|BEHAVIORAL|placebo|
218846172|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
219361153|NCT04696588|OTHER|Complex set of kinesiotherapy of cervical spine and delicate massage|"Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~1. Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~2. Massage of cervical interspinales muscles performed by therapist 3 minutes.~3. Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~4. Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes."
219455664|NCT00122070|DRUG|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
218846173|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
219455665|NCT04396327|DRUG|SM-1|diphenhydramine, zolpidem and lorazepam
219455666|NCT04396327|DRUG|Active Comparator|diphenhydramine and lorazepam
219590697|NCT05940623|DEVICE|Standard care and home IOP telemonitoring with smart phone-based intervention|We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
219590698|NCT00278252|DRUG|etoposide|
218846174|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
218846175|NCT03626636|OTHER|Sham|Sham injection
218846176|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
218846177|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
219590699|NCT00278252|PROCEDURE|conventional surgery|
219590700|NCT06912152|BIOLOGICAL|MT027 CAR-T cells|"Prior to MT027 cell infusion, lymphodepleting chemotherapy with fludarabine and cyclophosphamide was administered.~Dose Group 1: 1×10⁷ cells per administration; Dose Group 1: 3×10⁷ cells per administration; Dose Group 1: 6×10⁷ cells per administration; Based on the data obtained, adjustments to the specific number of cells in the established dosage groups and/or the addition of dosage groups may be made after discussion between the collaborators and researchers. A dose reduction titration may also be conducted based on the completed dosage groups."
219455667|NCT04114773|OTHER|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
219455668|NCT02828189|OTHER|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
219455669|NCT02828189|BEHAVIORAL|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
219455670|NCT02828189|OTHER|Therapeutic exercise-Physiotherapy|"1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises"
219590701|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
219590702|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
218846178|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
218846179|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
218846180|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
218846181|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
218846182|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
219455671|NCT03905525|DRUG|CFZ533|Biological
218846183|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
218846184|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
218846185|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
218846186|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
218846187|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
219455672|NCT03905525|OTHER|Placebo|liquid placebo for injections
218846188|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
218846189|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
218846190|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
219590703|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
219455673|NCT03973567|DRUG|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
219455674|NCT03973567|OTHER|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
219455675|NCT02591836|DRUG|Gemcabene|Gemcabene
219455676|NCT02591836|DRUG|Atorvastatin|Atorvastatin
219455677|NCT02591836|DRUG|Placebo|
219455678|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
219455679|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
219455680|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
219455681|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
219455682|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
219590704|NCT06914102|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure.
219590705|NCT06914102|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
219590706|NCT06917326|DEVICE|Monitoring|Lung monitoring with the Neola device
219590707|NCT00704730|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
219590708|NCT00704730|DRUG|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
219590709|NCT01767961|PROCEDURE|diagnostic imaging|Undergo MBS
218846191|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
218846192|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
218846193|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
219455683|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
219455684|NCT01369069|DRUG|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
219455685|NCT01369069|DRUG|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
219455686|NCT04363723|OTHER|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
219455687|NCT04168151|OTHER|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
219455688|NCT06070727|OTHER|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
219590710|NCT01767961|OTHER|questionnaire administration|Correlative studies
218846194|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
218846195|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
218846196|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
218846197|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
218846198|NCT00420004|DRUG|Placebo|
219590711|NCT01767961|PROCEDURE|quality-of-life assessment|Correlative studies
219590712|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
219590713|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
218846199|NCT00420004|DRUG|Escitalopram|10-mg capsules
219590714|NCT06913153|BEHAVIORAL|Diet|
219590715|NCT05345613|DRUG|Tranexamic acid|Submucosal injection of standard solution including TXA during EMR procedure
218846200|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
218846201|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
218846202|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
218846203|NCT00362583|DRUG|Fentanyl|
219455689|NCT05069389|OTHER|Data collection|"Some data will be collected for all patients included :~* specific treatment administered in COVID unit~* dosages of treatment~* inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
219590716|NCT05345613|DRUG|Standard|Injection of standard solution
219590717|NCT04313049|DEVICE|JACO2|Performing tasks using joystick control
219590718|NCT04313049|DEVICE|VOCAL CONTROL|Performing tasks using vocal control
219455690|NCT03952689|DEVICE|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
219455691|NCT02820480|DEVICE|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
219455692|NCT02249260|BEHAVIORAL|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
219455693|NCT00882362|DRUG|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
219455694|NCT00411840|PROCEDURE|intraarterial and intramuscular injection of BMCs|
219455695|NCT04451694|OTHER|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
219455696|NCT05233423|DEVICE|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
219455697|NCT01942395|BEHAVIORAL|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
219455698|NCT01942395|BEHAVIORAL|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
219455699|NCT01846208|DRUG|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
219455700|NCT01846208|DRUG|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
219455701|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
219455702|NCT03371303|OTHER|collection of prescription data|collection of prescription data before and after a hospitalization
219455703|NCT01424306|OTHER|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
219455704|NCT01424306|OTHER|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
219455705|NCT01424306|OTHER|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
219455706|NCT03105375|DRUG|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
219455707|NCT03105375|DRUG|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
219455708|NCT03105375|DRUG|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
219455709|NCT01961999|PROCEDURE|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
219455710|NCT01961999|PROCEDURE|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)"
219455711|NCT03739099|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
219455712|NCT02203942|OTHER|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
219455713|NCT00369928|DRUG|PG-760564|100 mg BID, of oral PG-760564
219455714|NCT00369928|DRUG|Placebo dose|placebo, BID, oral for 12 weeks
219455715|NCT00369928|DRUG|PG-760564|25 mg BID, of oral PG-760564
219455716|NCT00193128|DRUG|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
219455717|NCT00193128|DRUG|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
219455718|NCT00193128|DRUG|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
219455719|NCT00193128|RADIATION|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
219455720|NCT02530827|DRUG|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
219455721|NCT04868331|BEHAVIORAL|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
218846204|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
219455722|NCT00487994|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
218846205|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
218846206|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
218846207|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
218846208|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
218846209|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
218846210|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
219455723|NCT00487994|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
219455724|NCT00487994|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
219455725|NCT02812394|DRUG|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
219455726|NCT02812394|DRUG|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
219590719|NCT06937294|DRUG|Metformin|Participants are administered metformin with an initial dose of 500 mg/day, which was incrementally increased by 500 mg/day each week until the maximum tolerated dose. The maximum dose of metformin is set at 2000 mg/day.
218846211|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
218846212|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
219455727|NCT02812394|DRUG|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
219455728|NCT04126460|DRUG|Toripalimab|Toripalimab is a type of PD-1 antibody
219455729|NCT04527666|DRUG|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
218846213|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
219455730|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
219455731|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
219455732|NCT03201744|PROCEDURE|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
219590720|NCT06937294|DRUG|Placebo|Participants are administered a placebo, starting with one tablet per day, followed by an incremental increase of one tablet per week. In the absence of adverse reactions, the dosage is escalated up to a maximum of four tablets per day.
218846214|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
219455733|NCT01528436|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
219455734|NCT01528436|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
219455735|NCT01528436|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
219455736|NCT00004056|BIOLOGICAL|filgrastim|
219455737|NCT00004056|DRUG|asparaginase|
219455738|NCT00004056|DRUG|cytarabine|
219455739|NCT00004056|DRUG|daunorubicin hydrochloride|
219455740|NCT00004056|DRUG|melphalan|
219455741|NCT00004056|DRUG|thioguanine|
219455742|NCT00004056|PROCEDURE|peripheral blood stem cell transplantation|
219455743|NCT02663115|OTHER|Biopsy of the diaphragmatic muscle|
218846215|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
219455744|NCT02663115|OTHER|Skeletal muscle biopsy|
218846216|NCT00441649|DRUG|Methylphenidate|
219590721|NCT06943196|OTHER|Structured physical activity break|"The structured physical activity breaks in classroom will include 5-30 minutes physical activities sequenced as: Week 1,4,7: 5-mintue stretch break, 5-minute marching in place, 30-sec jumping an invisible rope, 30-sec Flap arms like a bird, 5-minute mirror each other's actions and guess, 5-minute hop on one foot/ jump on both feet, draw on board, guess the color, make a circle and play a game of throw a ball in class. Week 2,5,8: 5-minute stretch break, 2-3 laps throughout the classroom, jumping in and out a circle on command, rock-paper-scissors-jump, paint or sketch on book, guess the animal, up-down-stop-go opposites, make a circle and play a game of throw a ball and clap in class.~Week 3,6: 5-minute stretch break, 30-sec balance on one foot, 30-sec hopping, 5-jumping jacks, 5-claps turn around and guess the shape, play a game on board or notebook, make a circle and play a game of throw a ball and jump in class."
219590722|NCT02551666|OTHER|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
218846217|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
218846218|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
218846219|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
219455745|NCT04460300|OTHER|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
218846220|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
218846221|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
219455746|NCT04460300|OTHER|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
219455747|NCT04090515|BEHAVIORAL|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
219590723|NCT02551666|OTHER|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
219590724|NCT00600808|DRUG|BPLG-003|
219455748|NCT04090515|OTHER|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
219455749|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
219455750|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
219455751|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
219455752|NCT03196973|DRUG|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
219590725|NCT03173638|PROCEDURE|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
218846222|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
218846223|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
218846224|NCT00470093|BIOLOGICAL|recombinant interferon-α|
218846225|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
218846226|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
218846227|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
218846228|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
218846229|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
218846230|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
218846231|NCT04205851|DRUG|Placebo|Saline
218846232|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
218846233|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
218846234|NCT00989521|DRUG|PUR003|PUR003 for inhalation
218846235|NCT00989521|DRUG|Placebo|Normal saline for inhalation
218846236|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
219361154|NCT02260518|BEHAVIORAL|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
219455753|NCT03196973|DRUG|DF289|1 vial into the affected ear twice daily for 7 days
219455754|NCT03196973|DRUG|DF277|1 vial into the affected ear twice daily for 7 days
219455755|NCT02717429|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
219455756|NCT02717429|BEHAVIORAL|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
219455757|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
219455758|NCT03344562|DEVICE|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
219455759|NCT03344562|DEVICE|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
219455760|NCT01802294|BEHAVIORAL|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
219455761|NCT03602638|DRUG|Sitagliptin|Sitagliptin 100mg QD
219455762|NCT03602638|DRUG|Acarbose|Acarbose
218846237|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
219361155|NCT02260518|BEHAVIORAL|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
219361156|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
219361157|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
219361158|NCT03491410|DRUG|Aspirin Low Dose|Low-Dose Aspirin is to be added in the standard patient´s treatment
219361159|NCT03491410|DRUG|Placebo Oral Tablet|Placebo is to be added in the standard patient´s treatment
219455763|NCT02039089|DRUG|E2006 2.5 mg|
219455764|NCT02039089|DRUG|E2006 10 mg|
219455765|NCT02039089|DRUG|E2006 25 mg|
219455766|NCT02039089|DRUG|Placebo|
219455767|NCT05990140|OTHER|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
219455768|NCT01635244|DEVICE|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
219455769|NCT01329172|OTHER|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
219455770|NCT01329172|OTHER|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
219455771|NCT00408772|BIOLOGICAL|bevacizumab|
219455772|NCT00408772|DRUG|capecitabine|
219455773|NCT00408772|DRUG|oxaliplatin|
219455774|NCT00408772|PROCEDURE|conventional surgery|
218846238|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
218846239|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
218846240|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
218846241|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
218846242|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
218846243|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
218846244|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
219590726|NCT06945926|DRUG|oxytocin nasal spray|Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia.Before the end of anesthesia, the experimenter administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and 24 IU in the evening.Until 7 days after surgery or discharge.
218846245|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
218846246|NCT01431937|DRUG|GSK2018682|Active Drug
218846247|NCT01431937|DRUG|Placebo|Placebo
219455775|NCT00408772|PROCEDURE|neoadjuvant therapy|
219455776|NCT00408772|PROCEDURE|radiofrequency ablation|
219590727|NCT01177059|GENETIC|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
219590728|NCT04401865|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
219590729|NCT06955065|OTHER|battle rope training|Battle rope training is a dynamic, high-intensity exercise involving heavy ropes to improve strength, endurance, and coordination. It primarily targets the upper body, including the shoulders, arms, and core, through rhythmic, wave-like movements. This training is adaptable and effective for enhancing functional fitness in both general and adaptive athletes.
219590730|NCT06955065|OTHER|Bocce Throwing|Participants in the control group will engage in regular bocce training sessions as per their usual routine. These sessions will focus on standard bocce drills and techniques without additional battle rope exercise. A warm- up activity used in every training session and a proper warm-up should include Aerobic activity and Dynamic stretching . 15 to 20 repetitions of each exercise.
219590731|NCT06955429|DEVICE|Dental restorative or endodontic treatment requiring Biodentine XP use|In this observational and prospective study, the patients are included since this intervention is schedulded as part of their routine care.
219590732|NCT00229320|BEHAVIORAL|Group therapy|
219590733|NCT06989944|BEHAVIORAL|Physical Activity (PA) program|"Participants assigned to the PA-arm will participate in at least three weekly 30-minute sessions of PA for a total of 12 weeks.~The PA program will be tailored to individuals' characteristics, skills and preferences, based on information collected in connection with the baseline assessment and physical examination. A PA program could preview some forms of aerobic/relaxation/anaerobic exercises"
219590734|NCT06990113|OTHER|three dimensional lumbar myofascial release|Three-dimensional (3D) MFR is a novel approach toward reducing fascial restrictions. It recognizes that fascia exists not only in a linear plane but also in complex multidirectional networks throughout the body.
219590735|NCT06990113|OTHER|conventional treatment.|conventional treatment, including selected physical therapy, flexibility exercise for the back, static back and abdomen exercises, and electrotherapy
219590736|NCT05103189|OTHER|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
218846248|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
218846249|NCT05752227|RADIATION|CT chest|Computed tomography
218846250|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
218846251|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
218846252|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
218846253|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
219455777|NCT02647372|PROCEDURE|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
219455778|NCT02647372|PROCEDURE|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
219455779|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
219455780|NCT01555541|DRUG|Ofatumumab|1000 mg IV days 0, 7, 14, 21
219455781|NCT01555541|DRUG|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
219455782|NCT01555541|DRUG|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
219455783|NCT00002041|DRUG|Amphotericin B|
219455784|NCT02772835|DEVICE|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
219455785|NCT00236106|DRUG|tacrolimus ointment 0.1%|
219455786|NCT00236106|DRUG|mometasone furoate 0.1%|
219455787|NCT05488106|DIETARY_SUPPLEMENT|Placebo|Placebo
219455788|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
219455789|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 5mg/d|Riboflavin 5mg/d
219455790|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 20mg/d|Riboflavin 20mg/d
219455791|NCT03381352|RADIATION|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
219455792|NCT03381352|DRUG|Capecitabine|Capecitabine 825mg/m2 PO BID
219455793|NCT03381352|DRUG|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
218846254|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
219361160|NCT05697458|OTHER|computerized tomography scanning|In all patients the investigators will perform CT for determination of iliac arteries calcifications
219455794|NCT01965028|DEVICE|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
219455795|NCT02176005|DEVICE|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
219455796|NCT02176005|DRUG|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
219455797|NCT02176005|OTHER|Negative Control|Moxifloxacin is used alone
219455798|NCT04913792|DEVICE|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
219455799|NCT00481377|PROCEDURE|ablation|
219455800|NCT00374062|BEHAVIORAL|relaxation therapy 1|relaxation therapy 1
219455801|NCT00374062|BEHAVIORAL|relaxation therapy 2|relaxation therapy 2
218846255|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
219361161|NCT03370497|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
219361162|NCT03370497|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
219361163|NCT05156541|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
219361164|NCT03589404|DEVICE|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
219361165|NCT04033419|DRUG|Memantine|"memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
219361166|NCT00742469|DRUG|Rifaximin|
219361167|NCT00742469|DRUG|Placebo|
219361168|NCT02662647|DRUG|Decitabine 20 mg/m²/day for 5 days|
219361169|NCT01055535|DRUG|Microplasmin|125 µg intravitreal injection
219361170|NCT01132209|PROCEDURE|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
219361171|NCT05227339|DEVICE|RAE|Subjects in the interventional group will have access to the RAE Health mobile app which receives continuous physiologic data from a wearable device. Algorithms embedded in the RAE app detect stress and craving events, and trigger mobile phone notifications when detected. Notifications are paired to real-time mindfulness based interventions.
219361172|NCT05365165|DRUG|Sevoflurane|Sevoflurane will be applied during aortic cross- clamping in cardiac surgery
219361173|NCT03778086|PROCEDURE|gonioscopy|gonioscopic observation and grading of iridocorneal angle
219361174|NCT00347828|DRUG|Moxifloxacin ophthalmic solution 0.5%|
219361175|NCT00347828|DRUG|Gatifloxacin ophthalmic solution 0.3%|
219361176|NCT03663088|OTHER|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
219361177|NCT03663088|OTHER|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
219361178|NCT02095743|DEVICE|implanted port for chemo administration (X-port isp)|
219361179|NCT02095743|DEVICE|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
219361180|NCT03079479|DIAGNOSTIC_TEST|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
219361181|NCT03079479|DIAGNOSTIC_TEST|2D Kinematics Analysis|2D Kinematics Analysis of the gait
219361182|NCT06196086|DIAGNOSTIC_TEST|Echocardiography examination|Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
219455802|NCT00374062|BEHAVIORAL|relaxation therapy 3|relaxation therapy 3
219455803|NCT05774574|DIETARY_SUPPLEMENT|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
219455804|NCT05774574|DIETARY_SUPPLEMENT|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
219455805|NCT01740765|OTHER|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
219455806|NCT02463331|DRUG|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
219455807|NCT02463331|DRUG|prednisone|Prednisone 5-15 mg/day until the end of the study
219455808|NCT02463331|DRUG|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
219455809|NCT02239029|DRUG|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
219455810|NCT02239029|DRUG|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
219455811|NCT02274766|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
219455812|NCT02274766|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
219455813|NCT06747858|BIOLOGICAL|ARCT-032|CFTR mRNA formulated in lipid nanoparticles
219455814|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and atropine infusion|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Atropine infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
218846256|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
218846257|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
218846258|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
218846259|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
218846260|NCT00664560|DRUG|Placebo|sugar pill bid
219455815|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Saline infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
219455816|NCT07093983|OTHER|Constraint-Induced Movement Therapy (CIMT)|Participants in this group will receive modified CIMT in combination with conventional physical therapy. The unaffected arm will be restrained to encourage use of the affected upper limb. Task-specific exercises will include fine motor tasks, strengthening, reaching, and functional movement training. Each session will last approximately 45-60 minutes and will be conducted three times per week for 12 weeks.
219455817|NCT07093983|OTHER|Coupling Rehabilitation|Participants in this group will receive Coupling Rehabilitation in addition to conventional physical therapy. This method involves bilateral arm training and functional tasks designed to improve coordination between both upper limbs, using the unaffected limb to guide movement in the affected one. Exercises will include trunk-supported reaching, object retrieval, and posture-supported task practice. Sessions will occur three times per week for 12 weeks, each lasting approximately 45-60 minutes.
219455818|NCT07101237|DIAGNOSTIC_TEST|Multi-modal ultrasonic imaging system for liver cancer|Conventional ultrasound, SMI, shear wave /strain elastography, and CEUS will be conducted for HCC/ICC patients. All above the imaging examinations will be conducted at 1/2/3/4/5/6, 9/12/15/18/21/24, and 30/36/42/48/54/60 months after the postoperative/post-conversion therapy.
219455819|NCT07102485|OTHER|disease-induced immunity|"Using a different label for natural immunity, specifically, disease-induced immunity"
219455820|NCT07102485|OTHER|natural immunity|"Using standard label natural immunity"
219455821|NCT07101692|BEHAVIORAL|Virtual Reality-Based NGT Training|Participants will be given nasogastric catheter application training accompanied by a PowerPoint presentation and then they will be provided with three individual applications on the model.
219455822|NCT07100067|BIOLOGICAL|LCAR- F33S cells intravenous infusion|Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219455823|NCT07101029|DRUG|Bio-C Temp Intracanal Medication|Bio-C Temp Bioceramic intracanal dressing in the form of injectable premixed paste
219455824|NCT07101029|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide intracanal dressing in the form of injectable premixed paste
219455825|NCT07100379|PROCEDURE|Endoscopic Balloon Dilation|Endoscopic balloon dilation is a routine procedure in which a catheter with a balloon is introduced into the esophagus to help treat esophageal strictures via endoscope. The catheter is placed directly across the span of the esophageal stricture and the balloon is inflated to pre-determined volume in order to dilate the esophageal stricture. Balloon will remain inflated for either 30 or 180 seconds based on patient's randomization.
219455826|NCT07100301|OTHER|Proximal/distal protocol|Proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
219361183|NCT06500247|DRUG|Dalpicilib|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
218846261|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
218846262|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
218846263|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
218846264|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
218846265|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
218846266|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
218846267|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
218846268|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
218846269|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
219590737|NCT03664518|DRUG|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
218846270|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846271|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846272|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
219361184|NCT06500247|DRUG|Abiraterone Acetate (II)|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
219361185|NCT06500247|DRUG|Androgen Deprivation Therapy|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
219361186|NCT06500247|DRUG|Prednisone|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
219361187|NCT02026063|DRUG|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
219361188|NCT03116945|DRUG|68Gallium Citrate|Procedure: PET/CT Imaging
219361189|NCT00052195|BIOLOGICAL|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
219361190|NCT05170711|PROCEDURE|hypotensive anesthesia|hypotensive anesthesia
219361191|NCT05170711|PROCEDURE|normotensive anesthesia|normotensive anesthesia group
219361192|NCT00639938|DRUG|Nevirapine|200 mg Nevirapine tablet
219361193|NCT00639938|DRUG|HIV immune globulin solution|5% intravenous HIV immune globulin solution
219361194|NCT01154647|DRUG|citalopram|intravenous
219361195|NCT01154647|DRUG|1 ml 0.9 % NaCl|intravenous
219361196|NCT02810028|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
219361197|NCT04208854|DRUG|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
219361198|NCT03695068|BEHAVIORAL|RISE Intervention|Described in Arms description.
219361199|NCT02154087|BIOLOGICAL|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
219361200|NCT06046703|OTHER|Daily nutritional intake|Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
219361201|NCT02182349|DRUG|BI 201335 NA soft gelatin capsule|
219361202|NCT02182349|DRUG|[14C]-BI 201335 NA radiolabelled drug|
219361203|NCT01044186|DRUG|ICL670|
218846273|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846274|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846275|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846276|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846277|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846278|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
219361204|NCT00604968|DRUG|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).
219361205|NCT03378063|DRUG|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
219361206|NCT03378063|DRUG|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
219361207|NCT05519345|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response during stimulation.
219361208|NCT05519345|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
219361209|NCT01116544|DEVICE|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
219361210|NCT03704129|OTHER|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
219196966|NCT05852808|RADIATION|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
219196967|NCT02768038|OTHER|Observational|Blood, stool ja biopsy specimens
219196968|NCT06860282|DRUG|Remdesivir|Intravenous remdesivir 100 mg
219455827|NCT07100301|OTHER|Distal protocol|Distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
219455828|NCT07101887|PROCEDURE|Implantation of thumb prosthesis|Replacing the articular surface of the trapezo-metacarpal joint with a socked-ball prosthesis.
219196969|NCT06860282|DRUG|CX2101A|CX2101A enteric-coated tablet
219196970|NCT06860282|DRUG|Placebo|CX2101A placebo enteric-coated tablet
219455829|NCT07101887|PROCEDURE|Burton-Pellegrini technique|Remove the trapezium bone and perform a suspensionplasty using a hemi-slip of the flexor carpi radialis tendon
218846279|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
218846280|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
218846281|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
218846282|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
218846283|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
218846284|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
218846285|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
219455830|NCT07100756|DEVICE|AI vertebral fracture diagnostics (Flamingo)|The AI (name: Flamingo from Image Biopsy Lab, IBL, Vienna, Austria) screens thoracic and abdominal CT scans for vertebral fractures.
219455831|NCT07101146|OTHER|Quality of life questionnaire|The NEI-RQL-42 (National Eye Institute Refractive Quality of Life) questionnaire will be self-administered via a secure online platform to assess the impact of pathological myopia on quality of life.
219455832|NCT07101146|OTHER|Performance Outcomes (PerfO)|"Three tests are planned to assess the impact of high myopia on critical aspects of mobility and safety, with the possibility of adjusting their scope based on pilot data.~* The first test involves an assessment of driving on a simulator, designed to evaluate the performance of detecting pedestrians in peripheral vision, with and without glare.~* The second test focuses on assessing mobility and obstacle avoidance under six levels of brightness.~* The third test evaluates visual search ability. It consists of finding spheres in everyday scenes in an apartment with six levels of contrast tested."
219590738|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
219590739|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
219590740|NCT04232111|DEVICE|Heat|Heat applied to hand
219590741|NCT04232111|DEVICE|Vacuum|vacuum applied to hand
219590742|NCT04232111|DEVICE|sham|neither heat nor vacuum
218846286|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
218846287|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
219196971|NCT06860919|OTHER|Follow-up of the patients during 3 years|"Evaluation of PTSD prevalence, anxiety-depressive state, quality of life, look for a correlation between their clinical history and PTSD.~Analysis of the nutritional, gastrointestinal and respiratory status."
219196972|NCT04707768|DRUG|Vadadustat|oral tablets
219196973|NCT04707768|DRUG|Mircera®|intravenous administration
219196974|NCT06860217|OTHER|Robotic Nipple-Sparing Mastectomy|Patient will undergo to nipple sparing mastectomy and breast reconstruction, conducted using robot
219196975|NCT06860841|DRUG|D-Chiro-Inositol Combined with Metformin|D-chiro-Inositol will be administered for 14 days,1 cp after lunch and 1 cp after dinner in addition to preexisting metformin therapy
219196976|NCT06860841|DRUG|Placebo in combination with metformin|placebo will be administerd for 14 days, 1 cp after lunch and 1 cp after dinner in addition to pre-existing metformin therapy
219196977|NCT06862141|DEVICE|bendable suction ureteral access sheath|flexible ureteroscopy will be done using bendable suction ureteral access sheath
219196978|NCT06862141|DEVICE|conventional suction ureteral access sheath|flexible ureteroscopy will be done using conventional suction ureteral access sheath
219196979|NCT06860659|DRUG|0.28% Sodium Hyaluronate , preservative free eye drops|0.28% Sodium Hyaluronate , preservative free eye drops
218846288|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
218846289|NCT03350035|DRUG|IV Ganaxolone active|IV
218846290|NCT03350035|DRUG|IV Placebo, non-active|IV
218846291|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
219455833|NCT07101146|OTHER|Semi-structured interviews|Semi-structured interviews will only be offered to patients recruited in Phase 1 Qualitative and aim to further explore the information gathered from the NEI-RQL-42 questionnaire responses and the difficulties encountered during the performance tasks in the laboratory, by exploring in more detail the limitations encountered by patients with pathological myopia in their daily activities. These interviews will help identify the specific causes of the difficulties encountered, as well as the environmental conditions that may create discomfort or increased hardship.
219455834|NCT07100886|OTHER|long-term follow up visit|Phone call questionnaire- retrospective treatment arm Phone call questionnaire- retrospective control arm
219455835|NCT07101588|COMBINATION_PRODUCT|Ruxolitinib, Decitabine|"1. Decitabine: 20 mg/m²/day, administered from Day -15 to Day -10.~2. Ruxolitinib:~   * 10 mg twice daily (bid), Day -15 to Day -5~  * 5 mg twice daily (bid), Day -4 to Day -3~  * 5 mg once daily (Qd), Day -2"
219590743|NCT06189638|DRUG|Antimicrobial Peptide PL-5 Topical Spray and Placebo|Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
219590744|NCT05307510|DEVICE|Prefabricated splint|Subjects will be provided either a prefabricated splint
218846292|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
218846293|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
218846294|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
218846295|NCT00150319|DRUG|Vfend®; I.V.|
218846296|NCT02269176|DRUG|Low dose of telmisartan|
219590745|NCT05307510|DEVICE|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
219590746|NCT05969613|PROCEDURE|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
219590747|NCT05969613|PROCEDURE|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
219590748|NCT05969613|PROCEDURE|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
219590749|NCT03038841|DEVICE|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
219590750|NCT01331629|OTHER|ART-THERAPIE|8 sessions of art therapy during radiotherapy
218846297|NCT02269176|DRUG|High dose of telmisartan|
218846298|NCT02269176|DRUG|Low dose of losartan|
218846299|NCT02269176|DRUG|High dose of losartan|
218846300|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
218846301|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
218846302|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
218846303|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
218846304|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
218846305|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
218846306|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
218846307|NCT02379221|DRUG|Topical|4% Topicaine gel
218846308|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
218846309|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
218846310|NCT00100997|DRUG|tanespimycin|
218846311|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
218846312|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
218846313|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
219196980|NCT06860659|DRUG|0.18% Sodium Hyaluronate , preservative free eye drops|0.18% Sodium Hyaluronate , preservative free eye drops
219455836|NCT07102303|BEHAVIORAL|Online Group Cognitive-Behavioral Therapy (CBT)|"12-session group online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and in a group format. The program consists of twelve sessions of approximately 2,5 hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
219590751|NCT04949360|BEHAVIORAL|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
219590752|NCT04949360|BEHAVIORAL|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
219590753|NCT04949360|BEHAVIORAL|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by SleepUp app.
219590754|NCT05326282|DIAGNOSTIC_TEST|Multi-parametric ultrasound|Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
219590755|NCT02333656|OTHER|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
219018198|NCT04600414|OTHER|Collaborative Care for Mental Health Symptoms|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
219018199|NCT04600414|OTHER|Collaborative Care for Opioid Use Disorder and Mental Health Symptoms|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
219018203|NCT06472830|OTHER|Non-Interventional Study|Non-interventional study
219590756|NCT04952818|DIAGNOSTIC_TEST|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
219590757|NCT05954221|PROCEDURE|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
219590758|NCT05954221|PROCEDURE|Conventional processing|The tissue is fixed with 10% formalin.
219590759|NCT06298019|BIOLOGICAL|KYV-101|The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.
219590760|NCT00995280|DEVICE|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
219590761|NCT00995280|DEVICE|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
219590762|NCT00019864|BIOLOGICAL|filgrastim|
219590763|NCT00019864|DRUG|cisplatin|
219590764|NCT00019864|DRUG|dexrazoxane hydrochloride|
219590765|NCT00019864|DRUG|doxorubicin hydrochloride|
219590766|NCT00019864|DRUG|leucovorin calcium|
219590767|NCT00019864|DRUG|methotrexate|
219590768|NCT00019864|PROCEDURE|adjuvant therapy|
219590769|NCT00019864|PROCEDURE|conventional surgery|
219590770|NCT00019864|PROCEDURE|neoadjuvant therapy|
219590771|NCT02784444|DRUG|MSDC-0602K|MSDC-0602K capsules
219590772|NCT02784444|DRUG|Placebo|Placebo capsules
219590773|NCT05328336|DRUG|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
219590774|NCT05235945|BEHAVIORAL|Online exercise intervention|Described in arm descriptions
219590775|NCT04144478|OTHER|Web based education|Web based education
218846314|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
218846315|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
218846316|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
218846317|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
218846318|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
218846319|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
218846320|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
218846321|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
218846322|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
218846323|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
218846324|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
218846325|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
218846326|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
218846327|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
218846328|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
218846329|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
219361211|NCT06269250|OTHER|Policy Change|There will be a change with the digitalization in the health care system with the beginning of the year 2024 and between Wave 1 and Wave 2
219361212|NCT03805893|PROCEDURE|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
219361213|NCT00486278|DRUG|eptacog alfa (activated)|90 mcg/kg, injected i.v.
219361214|NCT00486278|DRUG|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
219361215|NCT00486278|DRUG|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
219361216|NCT00486278|DRUG|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
219361217|NCT00486278|DRUG|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
219361218|NCT00486278|DRUG|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
219361219|NCT04947176|DIETARY_SUPPLEMENT|Supplement|200mg C15:0 once daily
219361220|NCT04947176|OTHER|Placebo|Matching placebo once daily
219361221|NCT03463590|DEVICE|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
219361222|NCT00930215|DRUG|D961H|Oral gelatin capsule
219361223|NCT00930215|DRUG|D961H|Oral HPMC capsule
219196981|NCT06857409|PROCEDURE|pulsed radiofrequency|All patients will be monitored with electrocardiography, non-invasive blood pressure, and peripheral oxygen saturation, and peripheral intravenous vascular access will be performed before the procedure. Patients will be placed in a sitting position. The physician will stand behind the patient for the posterior approach. The skin area to be injected will be prepared and covered in a sterile manner using a povidone-iodine-based solution. The operator will use ultrasound (a TOSHIBA Aplio 500 Ultrasound) guidance to perform suprascapular nerve radiofrequency. The suprascapular notch will be visualized. A twenty-two gauge, 10 cm long, and 10 mm active-tipped radiofrequency cannula will be introduced to the suprascapular notch. Motor stimulation will be performed at 2 Hz at a setting of 1 V, and sensory stimulation will be performed at 50 Hz at a setting of 0.5 V. After the needle tip confirmation, pulsed radiofrequency will be applied to the suprascapular nerve for 360 seconds.
219196982|NCT06862739|COMBINATION_PRODUCT|Empagliflozin+Linagliptin+Metformin|Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
219196983|NCT06860438|DRUG|Vasoconstrictor Agents|vasopressor agents will be started in patients with sepsis who will not improved using the resuscitation fluids
219196984|NCT06666296|BEHAVIORAL|Digital collection of recipes|The digital recipe collection is created for private use. This collection contains recipes for every meal of the day to ensure a Planetary Health Diet throughout the day. This includes digital weekly plans with corresponding dishes, including shopping lists, to simplify implementation in everyday life. This enables participants to make quick meal choices and simplify their shopping. Employees are encouraged to use this digital recipe collection to prepare their meals over a defined period of time. In addition, the kitchen management of the university hospital will be asked to assist with the creation of the recipes. The project benefits from the experience of the kitchen staff. Popular recipes can be used across projects.
219196985|NCT06666296|BEHAVIORAL|E-Mail-Newsletter|"The e-mail newsletter contains information on the Planetary Health Diet (background, urgency, goals, etc.). Regular contact by e-mail enables a fast, uncomplicated and personal exchange with the participants, uncomplicated and personal exchange with the participants. The e-mail support encourages participants to actively engage with the topic. The newsletter is supplemented by instructional kitchen videos (one person cooks a recipe from the recipe collection), checklists (e.g. How sustainable am I already acting?), tasks (e.g. three possible measures for a more sustainable diet) or food information (e.g. seasonal plan for fruit and vegetables). This provides participants with important information at regular intervals and ensures compliance."
219455837|NCT07102303|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
219455838|NCT07100951|BEHAVIORAL|Brief Psychoanalytic Couple Therapy|Brief Psychoanalytic Couple Therapy (BPCT) consists of 12 weekly online sessions (50 minutes each) focused on uncovering unconscious relational dynamics, symbolic conflict meanings, and early attachment schemas. Techniques include relational interpretations, exploration of projective identification and transference, and analysis of emotional defenses. Therapists maintain a neutral, reflective stance to promote insight and self-awareness within the couple dynamic.
219455839|NCT07100951|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Therapy (EFT) involves 12 weekly online sessions (50 minutes each) focusing on repairing emotional bonds and enhancing attachment security. The intervention targets maladaptive emotional interaction cycles and promotes the expression of primary emotions and attachment needs. Therapists actively guide couples through restructuring emotional responses and rebuilding secure, responsive communication patterns.
218846330|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
218846331|NCT04924894|OTHER|no intervention|no intervention
219455840|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 100 mg orally, daily on days 1-21 of a 28-day cycle, for 3 years.
219455841|NCT07101159|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitor), as per physician's choice.
218846332|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
218846333|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
218846334|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
218846335|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
218846336|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
218846337|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
218846338|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
218846339|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
219590776|NCT01406483|OTHER|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
219590777|NCT03151291|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
219590778|NCT03151291|DIETARY_SUPPLEMENT|L-carnitine (LC)|daily intake of 4 g LC
219590779|NCT03151291|DIETARY_SUPPLEMENT|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
219590780|NCT03151291|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
218846340|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
218846341|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
218846342|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
218846343|NCT02715024|DRUG|Tamsulosin|Oral
218846344|NCT02715024|DRUG|Solifenacin|Oral
218846345|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
218846346|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
218846347|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
218846348|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
218846349|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
218846350|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
218846351|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
218846352|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
218846353|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
218846354|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
218846355|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
219455842|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 125 mg orally, daily on days 1-21 of a 28-day cycle, for 2 years.
219455843|NCT07102576|DRUG|MDMA Hydrochloride|Initial dose of 120 mg MDMA HCl in a therapeutic setting, followed 1.5 to 2 hours later by a supplemental dose of 40 mg MDMA HCl. Supplemental doses may be withheld if tolerability issues emerge or it is declined by the participant.
219455844|NCT07100288|OTHER|resection of infundibulopelvic ligament|Therefore, this study also aims to perform bilateral infundibulopelvic ligament resection (at least 8 cm in length) during surgery for ovarian cancer patients
219590781|NCT05788614|DEVICE|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
219590782|NCT06209541|BEHAVIORAL|Internet-based cognitive behavioral therapy (ICBT)|All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
219018206|NCT06067841|DRUG|BMS-986460|Specified dose on specified days.
219590783|NCT06632470|DRUG|Secretome injection|Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
219590784|NCT06632470|DRUG|Vitamin B12 Injection|Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
219590785|NCT03848637|DRUG|CKD-375|Test drug
219590786|NCT03848637|DRUG|D387|Reference drug
219590787|NCT03173430|DRUG|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
219590788|NCT01664130|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219590789|NCT01664130|PROCEDURE|quality-of-life assessment|Ancillary studies
219590790|NCT01664130|OTHER|laboratory biomarker analysis|Correlative studies
219590791|NCT03590912|DRUG|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
219590792|NCT03590912|DRUG|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
219590793|NCT03590912|DRUG|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
219590794|NCT04749238|DEVICE|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
219590795|NCT03133338|DEVICE|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
219590796|NCT02336724|DRUG|Famitinib|
219590797|NCT03357835|OTHER|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
219590798|NCT00554606|DRUG|Canakinumab|Canakinumab
219590799|NCT00956800|OTHER|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
219590800|NCT00956800|OTHER|Normal care|Control group will receive 5 routine office visits in one year
219590801|NCT05782959|BIOLOGICAL|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
219590802|NCT05379907|OTHER|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
219590803|NCT00372151|DIETARY_SUPPLEMENT|L-Theanine|400 mg/day, caps.
219590804|NCT00372151|OTHER|Placebo|caps.
219590805|NCT03214029|DIAGNOSTIC_TEST|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
219590806|NCT04249869|DRUG|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
219590807|NCT06450795|BEHAVIORAL|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.|HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
219590808|NCT03086759|PROCEDURE|platelet rich plasm|intra-articular infiltration with platelet rich plasm
219590809|NCT03086759|DRUG|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
219590810|NCT03086759|PROCEDURE|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
219590811|NCT01161407|DIETARY_SUPPLEMENT|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
219590812|NCT01161407|DIETARY_SUPPLEMENT|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
219590813|NCT03910387|DRUG|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
219590814|NCT03910387|DRUG|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
219590815|NCT03910387|DRUG|Telotristat Ethyl|Given PO
219590816|NCT00537420|DRUG|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
219590817|NCT00537420|DRUG|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
219590818|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
219590819|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
219590820|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
219590821|NCT00537420|DRUG|Sibutramine|Sibutramine will be taken once daily with or without food
219590822|NCT04914455|DIAGNOSTIC_TEST|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
219018207|NCT03587961|DRUG|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
219196986|NCT06666296|BEHAVIORAL|digital/hybrid teaching kitchen|Recipes, cooking techniques, shopping tips and recommendations for implementing the Planetary Health Diet are taught in the digital/hybrid teaching kitchen. The focus here is on fun, good taste and interesting experiences. A shared experience can be created through such cooking events. The teaching kitchen events can be supplemented by the participation of the kitchen management in order to benefit from their special cooking skills and wealth of experience. The positive aspect of the digital training kitchen is the easy access to information, as this does not have to be read, but is conveyed visually.
219361224|NCT02183519|DRUG|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
219361225|NCT02183519|OTHER|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
219018208|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
219018209|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
219018210|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
218846356|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
218846357|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
218846358|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
218846359|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
218846360|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
218846361|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
218846362|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
218846363|NCT00608023|DRUG|Tesamorelin|
218846364|NCT00608023|DRUG|Placebo for Tesamorelin|
219455845|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
219455846|NCT00175422|BEHAVIORAL|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
219455847|NCT05013788|OTHER|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
219455848|NCT05013788|OTHER|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
219590823|NCT06396767|DIAGNOSTIC_TEST|DIA measured via Ultrasonography|Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
219590824|NCT03012984|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
218846365|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
218846366|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
218846367|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
218846368|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
218846369|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
219590825|NCT03012984|DRUG|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
219590826|NCT06634121|DEVICE|Transcatheter mitral valve edge-to-edge repair (M-TEER)|M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
219590827|NCT00096603|DRUG|Raptiva (efalizumab)|
219590828|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
219590829|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
219455849|NCT06935331|DRUG|Opioid-Free/Opioid-Avoidant|"Managed post-operatively with an opioid-free pain regimen which will include:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Aromatherapy, Music therapy, Pet therapy, Early mobilization and PT"
219455850|NCT06935331|DRUG|Opioid-Containing|"Managed post-operatively with a traditional opioid containing pain regimen including:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Post-operative morphine IV for breakthrough pain~Oral narcotic (hydrocodone/acetaminophen)~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Early mobilization and PT"
219455851|NCT06940596|OTHER|FODMAP Diet|The intervention is an online diet program. The diet is the low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet. It is a 3-phase diet which involves: 1.Phase 1 FODMAP restriction: restrict foods high or moderate in FODMAPs and swap these for low FODMAP alternatives; 2. Phase 2 FODMAP reintroduction: continue to follow a low FODMAP diet and complete a series of food challenges to understand which foods and FODMAPs are tolerated and which trigger symptoms; 3. Phase 3 FODMAP personalization: include well-tolerated foods and FODMAPs back into the diet, and restrict poorly tolerated foods and FODMAPs to a level needed to maintain symptom relief. The online FODMAP program is a self-directed diet program with support from an online clinician (Accredited Practicing Dietitian \[APD\]). The content is delivered over 12 weeks. After each module participants will complete homework activities and questions and submit them to the dietitian for feedback.
219590830|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
219590831|NCT04987385|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
218846370|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
218846371|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete an overnight polysomnogram.
218846372|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
218846373|NCT04093323|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
218846374|NCT04093323|DRUG|Celecoxib|Given PO
218846375|NCT04093323|DRUG|PD-1 Ligand Inhibitor|Given IV
219590832|NCT04987385|DIETARY_SUPPLEMENT|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, …) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
219590833|NCT01226771|DRUG|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
218846376|NCT04093323|DRUG|PD1 Inhibitor|Given IV
218846377|NCT04093323|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
218846378|NCT04093323|DRUG|Rintatolimod|Given IV
218846379|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
218846380|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
218846381|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
218846382|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
218846383|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
218846384|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
219455852|NCT06940596|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|The intervention is an online behavioral therapy program. The behavioral therapy is Exposure-based Cognitive Behavioral Therapy (E-CBT) Program. The E-CBT program is organised into six steps to be completed over 12 weekly modules with support from an online clinician (Psychologist). The first step contains a rationale for the treatment and instructions on self-observation. Steps 2, 3 and 4 contain a presentation of a psychological model of IBS and continued self-observation exercises. The fifth step covers exposure exercises, divided into three categories; (1) exercises that provoke symptoms, (2) abolishment of behaviors that serve to control symptoms, (3) exposure to situations where symptoms were unwanted. The final step (Step 6) includes how to handle relapses into avoidance behaviors and how to maintain a widened behavioral repertoire. After each module participants will be directed to complete homework activities and questions and submit them to the psychologist for feedback.
219455853|NCT06939075|DIAGNOSTIC_TEST|ROLE OF Cross sectional imaging modalities in the diagnosis and characterization of colonic masses|"Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):~* CT Scan: To evaluate mass morphology, size, and lymph node involvement.~* MRI: To assess tissue composition, characterization and diffusion restriction.~* Colonoscopy and Biopsy: Gold standard reference to assess the diagnostic accuracy for different"
219455854|NCT05996809|DEVICE|Coseal|Adhesion reduction
219455855|NCT03030157|DRUG|pirarubicin(THP)|
219455856|NCT05931068|OTHER|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
219455857|NCT07101978|BEHAVIORAL|serial whole body hyperthermia|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermiatreatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
219455858|NCT07100340|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
219455859|NCT07101536|BIOLOGICAL|EBV mRNA vaccine|EBV mRNA vaccine
219455860|NCT07101536|BIOLOGICAL|Immune Checkpoint Inhibitors, ICIs|Immune Checkpoint Inhibitors, ICIs
219590834|NCT01226771|DRUG|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
218846385|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
219590835|NCT01226771|DRUG|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
219590836|NCT00952211|DEVICE|CPAP|CPAP at therapeutic pressure during nighttime
218846386|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
219590837|NCT00952211|DEVICE|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
219590838|NCT00552851|DRUG|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
219590839|NCT02857751|BEHAVIORAL|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
218846387|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
218846388|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
218846389|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
218846390|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
218846391|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
218846392|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
218846393|NCT04506593|OTHER|no intervention|
219590840|NCT03893097|DRUG|Praziquantel|40 mg/kg at baseline
219590841|NCT03893097|DRUG|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
219590842|NCT01056042|DRUG|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
219590843|NCT01056042|DRUG|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
219455861|NCT07101393|PROCEDURE|Intraoperative Epiaortic Ultrasound (EAU)|Intraoperative epiaortic ultrasound (EAU) is a real-time imaging technique used during coronary artery bypass grafting (CABG) to evaluate the presence, location, and severity of atherosclerotic plaques in the ascending and arch aorta. In this study, EAU was performed after median sternotomy but prior to aortic manipulation, using a high-frequency linear transducer directly applied to the exposed aorta. Plaques were classified by thickness, and findings were used to guide surgical strategy, including modification of cannulation site, avoidance of cross-clamping, or alteration of grafting technique. This intervention differs from conventional CABG, in which such imaging is not routinely employed.
219455862|NCT03649581|OTHER|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
219455863|NCT03649581|OTHER|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
219455864|NCT06169488|PROCEDURE|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
219455865|NCT06169488|BEHAVIORAL|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training, but the protocol is somewhat compressed in terms of time and additionally updated in line with recent years' research in cognitive functional rehabilitation.
219455866|NCT04901273|PROCEDURE|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
219455867|NCT04901273|PROCEDURE|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
219455868|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
219455869|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
219455870|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455871|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455872|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455873|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455874|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455875|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219455876|NCT00308568|BEHAVIORAL|Mailed educational brochure|
219455877|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
219455878|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
219455879|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
219455880|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
219455881|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
218846394|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
219455882|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
219590844|NCT02935621|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
219590845|NCT02935621|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
219590846|NCT00872794|DEVICE|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
219590847|NCT00674349|PROCEDURE|surgery|staging surgery
219590848|NCT06353568|DEVICE|Photobiomodulation|The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
219590849|NCT06353568|DEVICE|Simulation of Photobiomodulation|The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
219590850|NCT06353568|BEHAVIORAL|Therapeutic education|Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
219590851|NCT04117919|DRUG|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
219590852|NCT04117919|DRUG|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
218846395|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
218846396|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
218846397|NCT00763191|OTHER|examination of ocular movements|
218846398|NCT00763191|OTHER|MATTIS test|
218846399|NCT00763191|OTHER|UPDRS test|
218846400|NCT00763191|OTHER|CRST test|
218846401|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
218846402|NCT05336929|OTHER|Roy adaptation model-based nursing education|
218846403|NCT03883165|OTHER|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
218846404|NCT03883165|OTHER|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
218846405|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
218846406|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
218846407|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
218846408|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
219455883|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
218846409|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
218846410|NCT04478071|DRUG|vadadustat|Participants will receive vadadustat once daily for 14 days.
218846411|NCT04478071|DRUG|placebo|Participants will receive matching placebo once daily for 14 days.
218846412|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
219455884|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
219455885|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
219590853|NCT04918485|OTHER|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
219590854|NCT04505956|DEVICE|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
219590855|NCT04505956|DEVICE|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
218846413|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
218846414|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
218846415|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
219455886|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
219455887|NCT00396968|DRUG|AMD3100|
219455888|NCT00396968|PROCEDURE|Allogeneic Stem Cell Transplantation|
219455889|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
219196987|NCT06666296|BEHAVIORAL|Digital events (digital cafés)|"Events are planned that will be set up via the digital café for in-depth discussions and exchanges about the content. Fixed dates are planned at which the study participants can meet digitally. In this protected setting, the topics of the study will be discussed in a convivial atmosphere. The personal exchange enables a deeper examination of the topic. The online events give participants the opportunity to interact directly with the study coordinators and other participants in order to effectively and sustainably change the participants' perception and awareness of sustainable nutrition through the various intervention points."
218846416|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
218846417|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
218846418|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
218846419|NCT00515606|DRUG|helium:oxygen|
218846420|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
218846421|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
219196988|NCT06666296|BEHAVIORAL|Social-Media|A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
219196989|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily following first 2 weeks
218846422|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
218846423|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
218846424|NCT04713345|OTHER|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
219455890|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
219455891|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
219455892|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
219455893|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
218846425|NCT04713345|OTHER|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
218846426|NCT04370483|DRUG|Leflunomide|Gievn PO
219196990|NCT03579836|DRUG|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
219196991|NCT03579836|COMBINATION_PRODUCT|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
219196992|NCT04293523|DRUG|ELOCTA|Extended half-life factor VIII product
219455894|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
219455895|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
218846427|NCT04370483|OTHER|Quality-of-Life Assessment|Ancillary studies
219455896|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
219455897|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
218846428|NCT02776462|DEVICE|EyeBox CNS|
218846429|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
218846430|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
219455898|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
219455899|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
219455900|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
219455901|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
219455902|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
219455903|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
219455904|NCT04547127|DRUG|Standard Medical Treatment|SMT
219455905|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
218846431|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
218846432|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
218846433|NCT00222235|DRUG|d-cycloserine|
218846434|NCT00222235|DRUG|glycine|
218846435|NCT00222235|DRUG|placebo|
218846436|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
218846437|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
218846438|NCT00351767|DRUG|placebo|Topically applied
218846439|NCT00351767|DRUG|telbermin|Topically applied
218846440|NCT02340247|OTHER|Water|
218846441|NCT02340247|DRUG|Ursodeoxycholic Acid|
218846442|NCT02340247|DRUG|Chenodeoxycholic Acid|
218846443|NCT02704702|DRUG|Fimasartan|
218846444|NCT02704702|DRUG|Rosuvastatin|
218846445|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
219018238|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with VR-IOMSs|Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs
219018239|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with COMS|Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)
219018240|NCT04639531|BEHAVIORAL|No Orientation and Mobility Training|No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
219018241|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
219018242|NCT04340180|DRUG|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
219018243|NCT04340180|DRUG|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
219018246|NCT05901545|BIOLOGICAL|Panitumumab|Given by IV
219018247|NCT05901545|OTHER|Indium In 111 Panitumumab|Given by IV
219018248|NCT05901545|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219018249|NCT05901545|PROCEDURE|Computed Tomography|Undergo SPECT/CT
219018250|NCT05901545|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
219455906|NCT04330794|OTHER|NMFACT|caries index
219455907|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
219455908|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
219455909|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
219455910|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
219455911|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
218846446|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
219455912|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
219455913|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
219455914|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
219455915|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
219455916|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
218846447|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
218846448|NCT04533971|OTHER|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
219018251|NCT05901545|OTHER|Imaging agent|Receive local injection of optical dye
219455917|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
219455918|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
219455919|NCT02134912|DRUG|crizotinib|Given PO
219455920|NCT02134912|DRUG|pemetrexed disodium|Given IV
219455921|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
219455922|NCT02134912|OTHER|pharmacological study|Correlative studies
219455923|NCT00561067|DRUG|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
219455924|NCT00561067|DRUG|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
219455925|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
219018252|NCT05901545|PROCEDURE|Intraoperative Imaging|Undergo Intraoperative Imaging
219018253|NCT05901545|PROCEDURE|Near Infrared Imaging|Undergo Near Infrared Imaging
219018254|NCT05901545|PROCEDURE|Electrocardiography|Undergo Electrocardiography
219018255|NCT05901545|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219455926|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
218846449|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
218846450|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
218846451|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
218846452|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
218846453|NCT00579618|OTHER|Saliva or Blood samples|Extracting sample of saliva or blood only once.
219455927|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
218846454|NCT02193737|PROCEDURE|Early oral fluid recovery.|
218846455|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
218846456|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
219455928|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
219455929|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
219455930|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
219455931|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
218846457|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
218846458|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
219018256|NCT03081260|OTHER|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
219018257|NCT03081260|OTHER|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
219018263|NCT05322577|DRUG|Bemarituzumab|Intravenous (IV) infusion
219018264|NCT05322577|DRUG|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
219018265|NCT05322577|DRUG|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
219018266|NCT05322577|DRUG|Nivolumab|IV infusion.
219455932|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
219455933|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
219455934|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
218846459|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
218846460|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
218846461|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
218846462|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
218846463|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
218846464|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
218846465|NCT02516098|DRUG|hyoscine butylbromide|
218846466|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
218846467|NCT01057576|OTHER|Placebo|capsule, daily dosage
218846468|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
218846469|NCT04571424|DRUG|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
219455935|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
219455936|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
219455937|NCT01646151|DRUG|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
219455938|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
219455939|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
219455940|NCT03272009|DRUG|Entecavir|Tablets administered orally
219455941|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
219455942|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
219455943|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
219455944|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
219455945|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
219455946|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
218846470|NCT04571424|DRUG|Placebo|Administered as specified in the treatment arm
218846471|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
218846472|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
218846473|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
218846474|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
218846475|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
218846476|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
218846477|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
218846478|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
218846479|NCT00149136|DRUG|imatinib|
218846480|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
218846481|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
218846482|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
218846483|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
218846484|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
218846485|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
218846486|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
218846487|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
218846488|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
219455947|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
219455948|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
219455949|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
219455950|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
219455951|NCT02033252|DEVICE|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
219455952|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
218846489|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846490|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846491|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846492|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846493|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846494|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846495|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846496|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
218846497|NCT00139295|DEVICE|Hylastan|
218846498|NCT06014606|DRUG|placebo|oral formulation
218846499|NCT06014606|DRUG|haloperidol 2mg|oral formulation
218846500|NCT06014606|DRUG|propranolol 40mg|oral formulation
218846501|NCT01676753|DRUG|Dinaciclib|Given IV
218846502|NCT01676753|DRUG|Pembrolizumab|Given IV
219196993|NCT04975607|BEHAVIORAL|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
219455953|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
219455954|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
219455955|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
219455956|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
218846503|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
218846504|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
219196994|NCT06752473|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
218846505|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
218846506|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
218846507|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
218846508|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
218846509|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
218846510|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
218846511|NCT06279364|DRUG|SKB264|IV Infusion
218846512|NCT06279364|DRUG|Paclitaxel|IV Infusion.
218846513|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
218846514|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
218846515|NCT06279364|DRUG|Eribulin|IV infusion.
218846516|NCT06279364|DRUG|Carboplatin|IV infusion.
218846517|NCT00022360|DRUG|taurolidine|
218846518|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
218846519|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
218846520|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
218846521|NCT02084706|DRUG|2% Lidocaine|
218846522|NCT02084706|DRUG|Triamcinolone (20 g)|
218846523|NCT02084706|PROCEDURE|J-tip lidocaine administration|
218846524|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
218846525|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
218846526|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
218846527|NCT02049827|OTHER|participation in the study|
218846528|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
219455957|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
219590856|NCT05860205|BEHAVIORAL|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
219590857|NCT05860205|OTHER|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
219590858|NCT05860205|OTHER|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
219590859|NCT04632511|DEVICE|MetaSAMP|Rectal Sampler
219590860|NCT02730026|DRUG|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
219590861|NCT02730026|DRUG|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
219455958|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
219455959|NCT01228084|OTHER|Pharmacological study|Correlative studies
219455960|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
219455961|NCT00340938|PROCEDURE|Blood testing|
218846529|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
219455962|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
219455963|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
219590862|NCT06247397|DEVICE|Added high-flow oxygen therapy|Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
218846530|NCT00000593|PROCEDURE|blood transfusion|
218846531|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
218846532|NCT00875238|BIOLOGICAL|trastuzumab|
218846533|NCT00875238|DRUG|doxorubicin hydrochloride|
218846534|NCT00875238|GENETIC|polymorphism analysis|
218846535|NCT00875238|OTHER|laboratory biomarker analysis|
218846536|NCT00875238|OTHER|questionnaire administration|
218846537|NCT00875238|PROCEDURE|assessment of therapy complications|
218846538|NCT00875238|PROCEDURE|magnetic resonance imaging|
218846539|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
218846540|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
219018318|NCT02985307|BEHAVIORAL|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
219018319|NCT02985307|BEHAVIORAL|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
219018320|NCT04626232|PROCEDURE|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
219018321|NCT04626232|PROCEDURE|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
219018323|NCT01422772|BIOLOGICAL|VM202-0.5 mg|0.5 mg intramyocardial injection
219018324|NCT01422772|BIOLOGICAL|VM202-1.0 mg|1 mg intramyocardial injection
219018325|NCT01422772|BIOLOGICAL|VM202-2.0 mg|2 mg intramyocardial injection
219018326|NCT06965257|OTHER|Continuous non-invasive blood pressure monitoring|Addition prior to anaesthetic induction of the non-invasive monitoring device (digital sleeve available at the investigation site) for blood pressure measurement on the side ipsilateral to the arterial catheter
219455964|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
219455965|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
219455966|NCT02182505|DRUG|Berodual® Respimat®, low dose|
219590863|NCT06247397|OTHER|Standard care|Standard care with low-flow oxygen therapy in accordance with clinical routine.
219590864|NCT04314648|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
219590865|NCT03803930|DEVICE|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
219455967|NCT02182505|DRUG|Berodual® Respimat®, high dose|
219455968|NCT02182505|DRUG|Berodual® MDI|
219455969|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
219455970|NCT04844970|DRUG|Placebo|Anamorelin placebo
219455971|NCT05352321|DRUG|Gemcitabine|for induction chemotherapy
219455972|NCT05352321|DRUG|Cisplatin|for induction and concurrent chemotherapy
219455973|NCT05352321|RADIATION|regular intensity-modulated radiotherapy|in active comparator arm
219455974|NCT05352321|PROCEDURE|surgery|in experimental arm
219455975|NCT05352321|RADIATION|Target-reduction intensity-modulated radiotherapy|in experimental arm
218846541|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
218846542|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
219455976|NCT03061149|OTHER|Low-level laser therapy|
219455977|NCT03061149|OTHER|Ultrasound treatment|
219455978|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
219196995|NCT06614738|OTHER|Sampling of feces and duodenal fluids|"* Blood sampling (plasmotheque and serotheque): 2 tubes (EDTA (5mL) and dry (5mL)) during hospitalization~* Fecal sampling (fecal library): A stool sample (approx. 2g) will be taken 48 hours before the endoscopy at home for outpatient or during hospitalization~* Duodenal aspiration fluid (6-10 mL in total): before and after mucosal lavage with sterile isotonic saline on the day of endoscopy.~* Food and Lifestyle Questionnaire (FFQ) during inclusion"
219455979|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
219455980|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
219455981|NCT05613491|DRUG|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
219590866|NCT03803930|DEVICE|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
219590867|NCT03803930|DEVICE|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
219018341|NCT04130997|BIOLOGICAL|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
219018342|NCT04745559|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
219455982|NCT05613491|DRUG|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
219455983|NCT01430364|DEVICE|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
219455984|NCT01430364|DEVICE|BIOSS Lim|
219455985|NCT01430364|DEVICE|CarloS|
219455986|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
219455987|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
219455988|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
219455989|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
219455990|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
219455991|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
219590868|NCT03803930|DEVICE|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
218846543|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
219018343|NCT04745559|BIOLOGICAL|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
219018344|NCT05392946|DRUG|Bortezomib|Given SC
219018345|NCT05392946|BIOLOGICAL|Daratumumab|Given SC
219018346|NCT05392946|DRUG|Dexamethasone|Given PO
219018347|NCT05392946|DRUG|Iberdomide|Given PO
219196996|NCT06781554|DEVICE|MD-Small Joints Collagen Medical Device|The infiltrations will be performed using 2.5ml syringes and 26 gauge/13mm needles under complete aseptic conditions. The first 3 infiltrations will be carried out at both intra- and peri-articular levels by injecting MD-Small Joints Collagen Medical Device into the trapeziometacarpal joint until a counter-pressure is felt, preventing further penetration of the liquid; the remaining quantity (usually about 1ml) will be injected at the peri-articular level by retracting the needle tip. The fourth and fifth infiltrations will be performed only at the peri-articular level.
219196997|NCT06781034|OTHER|None, pure observational study|None, pure observational study
219455992|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
219455993|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
219455994|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
219590869|NCT05180357|OTHER|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
219590870|NCT01804348|DEVICE|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
219590871|NCT01708148|DIETARY_SUPPLEMENT|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
219196998|NCT06862167|PROCEDURE|Desarda's technique|Patients will undergo Desarda's technique.
219455995|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
219455996|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
219455997|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
219455998|NCT00636038|DIETARY_SUPPLEMENT|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
219590872|NCT01708148|OTHER|Placebo|control group would receive a oral lactose placebo
219590873|NCT02784041|DRUG|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
219590874|NCT02784041|DRUG|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
219590875|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 1: 50 ug
219590876|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
219590877|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
219018348|NCT05963698|DEVICE|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
218846544|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
218846545|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
218846546|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
218846547|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
218846548|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
218846549|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
218846550|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
218846551|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
219455999|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
219590878|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
218846552|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
218846553|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
219590879|NCT01415102|DRUG|Placebo|Inhaled
218846554|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
218846555|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
219590880|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
218846556|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
218846557|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
218846558|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
219590881|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
219590882|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
219590883|NCT01415102|DRUG|Placebo|Inhaled
218846559|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
219196999|NCT06862167|PROCEDURE|Lichtenstein's technique|Patients will undergo Lichtenstein's technique.
219456000|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
219456001|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
219456002|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
219456003|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
219456004|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
219456005|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
219456006|NCT03011424|DEVICE|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
219456007|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
219590884|NCT01392625|BIOLOGICAL|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
219590885|NCT01392625|BIOLOGICAL|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
219456008|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
219456009|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
219456010|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
219456011|NCT00004795|DRUG|dehydroepiandrosterone|
219456012|NCT02325128|BEHAVIORAL|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
219456013|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
219456014|NCT05353881|OTHER|No intervention|No intervention
219456015|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
219456016|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
219456017|NCT06990776|DRUG|TQA3605 tablets Placebo|Placebo contains no active substance.
219590886|NCT03518801|BEHAVIORAL|Prolonged Exposure|psychotherapy
219590887|NCT03518801|DRUG|Cannabidiol|active medication
219590888|NCT03518801|DRUG|placebo|non-active medication
219590889|NCT04939220|PROCEDURE|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
219590890|NCT04939220|PROCEDURE|TEE with Deep Sedation|Deep sedation with propofol and natural airway
219590891|NCT01919021|OTHER|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
219590892|NCT01919021|OTHER|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
219590893|NCT01919021|PROCEDURE|Assessment of Gastric motor and sensory function|
219590894|NCT00849186|DRUG|sunitinib malate|oral
219590895|NCT00849186|PROCEDURE|neoadjuvant therapy|IV
219590896|NCT00849186|PROCEDURE|therapeutic conventional surgery|Surgery
218846560|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
218846561|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
218846562|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
219197000|NCT06857630|OTHER|Observational|Postoperative acute kidney injury and hemoglobin level relationship observation
218846563|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
218846564|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
218846565|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
218846566|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
218846567|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
218846568|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
218846569|NCT02512874|DEVICE|Dynamometer|Grip Test
218846570|NCT02512874|RADIATION|DEXA|Body Composition Testing
218846571|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
218846572|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
218846573|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
218846574|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
218846575|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
219197001|NCT06615037|OTHER|Assess Hip joint strength by Biodex isokinetic dynamometer (System 4 Pro)|"Assessment of the strength of hip flexors and extensors muscles:~* Participants will be in a supine-lying position, the highest reliability (ICC = 0.90) according to the results of the meta-analysis (Contreras et al., 2021).~* Seat orientation 0°.~* Dynamometer tilt 0° and orientation 0°.~* The axis of the dynamometer on the greater trochanter of the femur.~* The test parameters included a 0-90 degree range of motion.~* During the isokinetic testing movement, the hip was first flexed from a neutral (starting) position to 90° (for hip flexion) and then the direction of the movement was reversed (for hip extension)~* Angular speed at 120°/s which shows excellent reliability (ICC = 95%) with concentric contraction mode (Contreras et al., 2021) ."
219197002|NCT06400602|BEHAVIORAL|Usual ED Care plus Health Coaching|Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.
219197003|NCT06400602|BEHAVIORAL|Usual ED Care plus Education|Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
219456018|NCT06990776|DRUG|TQA3605 Tablets|TQA3605 tablets is core protein allosteric modulators
219456019|NCT06990776|DRUG|Entecavir dispersible tablets|Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.
219456020|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
218846576|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
218846577|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
218846578|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
218846579|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
218846580|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
218846581|NCT02854488|DRUG|Yervoy|
218846582|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
218846583|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
218846584|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
218846585|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
218846586|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
218846587|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
218846588|NCT05562674|BEHAVIORAL|Support group|"This is a group-based, peer specialist and clinician co-facilitated psychosocial intervention for Veterans with SMI, called Veteran Voices and Visions (VVV). VVV is an adaptation of a community-based support group model called the Hearing Voices (HV) approach. The approach facilitates group cohesion around and normalization of the common psychotic symptoms of SMI: hallucinations, delusions, and social isolation."
218846589|NCT01906385|DRUG|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
218846590|NCT03888235|PROCEDURE|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
218846591|NCT03888235|DEVICE|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
218846592|NCT03888235|OTHER|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
218846593|NCT00666653|DRUG|pramipexole|
219018350|NCT05740566|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
219456021|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
219456022|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
219456023|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
219456024|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
219456025|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
219456026|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
219456027|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
219456028|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
219456029|NCT07002008|OTHER|Scapular Stabilization Exercise|"Intervention Description:~The intervention consists of a structured, physiotherapist-supervised scapular stabilization exercise program developed specifically for athletes engaged in traditional archery. The program is designed to enhance scapular alignment, motor control, and dynamic stability by targeting key stabilizing muscles such as the serratus anterior and lower trapezius.~Participants in the intervention group will continue their standard traditional archery training and will additionally perform the scapular stabilization protocol three times per week for 8 consecutive weeks, with each session lasting approximately 40 minutes.~The exercise regimen includes:~Scapular Retraction Exercise (prone position with arm elevation)~Push-Up Plus Exercise (with scapular protraction emphasis)~Scapular Retraction and Depression with Elastic Band Resistance~Dipping Exercise (shoulder elevation and scapular control in seated position)~Forward Lean Exercise on Therapy Ball (scapular pro"
219018351|NCT05740566|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SOC.
219018352|NCT05740566|DRUG|Topotecan|Topotecan will be administered per local SOC.
219018353|NCT05740566|DRUG|Amrubicin|Amrubicin will be administered per local SOC.
219456030|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
219456031|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
219590897|NCT04447339|PROCEDURE|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
219590898|NCT01926574|BEHAVIORAL|long rehabilitation program|
219590899|NCT01926574|BEHAVIORAL|short rehabilitation program|
219590900|NCT01926574|BEHAVIORAL|Acceptance and commitment therapy (ACT)|
219590901|NCT00492024|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
219456032|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
218846594|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
218846595|NCT05282108|DRUG|Carcemia|Generic Imatinib
218846596|NCT05282108|DRUG|Glivec|Imatinib
218846597|NCT06401746|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
218846598|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
218846599|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
218846600|NCT06806241|DRUG|Tranexamic acid|in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
218846601|NCT06806241|DRUG|saline irrigation|In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
218846602|NCT03314974|BIOLOGICAL|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
218846603|NCT03314974|BIOLOGICAL|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
218846604|NCT06409871|OTHER|Physiotherapy treatment.|-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
218846605|NCT06409871|OTHER|Physiotherapy treatment and modification of the biorhythm.|"* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime."
218846606|NCT03887988|PROCEDURE|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
218846607|NCT03887988|OTHER|Nonsurgical|Nonsurgical treatment of fracture
218846608|NCT03887988|PROCEDURE|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
218846609|NCT03887988|PROCEDURE|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
219018358|NCT06522906|BEHAVIORAL|Muscle Strengthening|Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
219018359|NCT06522906|BEHAVIORAL|General Physical Activity|The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
219018360|NCT06522906|BEHAVIORAL|Education|Administered by a promotora, treatment will include 4 live video educational sessions about OA
219456033|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
219456034|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
218846610|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
218846611|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
219456035|NCT04539665|PROCEDURE|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
219456036|NCT00152789|PROCEDURE|Oxygen measurement - Eppendorf machine|
219456037|NCT03099304|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219456038|NCT03099304|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
218846612|NCT03200834|PROCEDURE|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
218846613|NCT03200834|PROCEDURE|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
218846614|NCT04824911|DRUG|Clopidogrel|300mg loading and 75mg/day from day 2
218846615|NCT04824911|DRUG|Aspirin|Aspirin(100-300mg/day)
218846616|NCT04824911|DRUG|Atorvastatin|Atorvastatin 40-80mg/day
219456039|NCT03248960|DIAGNOSTIC_TEST|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
219456040|NCT03248960|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
219456041|NCT03248960|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
219456042|NCT03248960|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
219456043|NCT00947089|DEVICE|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
219456044|NCT00947089|DEVICE|iodoform gauze|one iodoform gauze
219590902|NCT00492024|DRUG|Placebo|Placebo - 380 mg Microcrystalline Cellulose
219590903|NCT03303196|DEVICE|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
218846617|NCT04824911|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day.
218846618|NCT02357472|DIETARY_SUPPLEMENT|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.
218846619|NCT04704505|RADIATION|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
219018374|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
219018375|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
218846620|NCT04704505|DRUG|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
218846621|NCT05230667|OTHER|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
218846622|NCT05230667|OTHER|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
218846623|NCT05230667|OTHER|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
218846624|NCT00719498|DRUG|Epo-alpha|
218846625|NCT06491745|OTHER|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
218846626|NCT06491745|OTHER|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
218846627|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
218846628|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
218846629|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
219456045|NCT06189625|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
219590904|NCT05738317|DRUG|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
219590905|NCT05446012|DIAGNOSTIC_TEST|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
218846630|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
218846631|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
218846632|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
218846633|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
218846634|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
218846635|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
218846636|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
218846637|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
218846638|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
218846639|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
219590906|NCT03782909|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
219590907|NCT05396521|OTHER|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
219590908|NCT05396521|OTHER|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
219590909|NCT03167268|DRUG|Lycopene|
219590910|NCT03167268|OTHER|Placebo|
218846640|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
218846641|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
218846642|NCT06501092|DEVICE|Point Mini|Patient is fit with the Point Mini finger prosthetic system, which consists of 1-4 ratcheting mechanical digits and mounting brackets
218846643|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
219456046|NCT06189625|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
218846644|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
219456047|NCT06154759|OTHER|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
219590911|NCT01837524|BEHAVIORAL|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
218846645|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
218846646|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
218846647|NCT01195376|DRUG|BEZ235|
218846648|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
218846649|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
218846650|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
218846651|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
218846652|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
218846653|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
218846654|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
218846655|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
219197004|NCT06670092|OTHER|Vojta Therapy|"The intervention is carried out using Vojta therapy for one month, with one session per day, 5 days a week. This therapy is carried out by an expert physiotherapist. Vojta therapy is a non-experimental, painless, non-invasive therapy with no adverse effects, which is based on triggering repeated motor reactions or innate movement patterns (reflex locomotion patterns) in the trunk and limbs based on defined stimuli and starting from specific postures.~Both groups will undertake a pre-treatment assessment, a post-treatment assessment at the end of the one-month intervention period, and a final follow-up assessment one month after the end of the intervention."
219590912|NCT01837524|BEHAVIORAL|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
218846656|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
218846657|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
218846658|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
219197005|NCT06670092|OTHER|No intervetion|No intervetion group
219197006|NCT06668961|DRUG|SI-B001|Administration by intravenous infusion
219197007|NCT06668961|DRUG|SI-B003|Administration by intravenous infusion
218846659|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
218846660|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
218846661|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
218846662|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
218846663|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
218846664|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
219197008|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
219456048|NCT04966611|DRUG|Anlotinib|This is an observational study
219456049|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
219456050|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
218846665|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
218846666|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
218846667|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
219018376|NCT04615013|DRUG|Capecitabine|Not applicable to this study
219018377|NCT04615013|DRUG|Carboplatin|Not applicable to this study
219197009|NCT02728635|OTHER|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
219197010|NCT02728635|PROCEDURE|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
219456051|NCT04096404|GENETIC|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
219456052|NCT04096404|BEHAVIORAL|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
219456053|NCT04383171|DEVICE|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
219590913|NCT02530658|OTHER|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
219197011|NCT02728635|OTHER|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
219197012|NCT04691323|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
219197013|NCT03525587|OTHER|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
219197014|NCT06258811|DRUG|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
219197015|NCT03117972|DRUG|FOLFOXIRI|12 cycles
218846668|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
218846669|NCT02584543|BIOLOGICAL|HEV vaccine|
219197016|NCT03117972|DRUG|FOLFOX|12 cycles
219197017|NCT03117972|DRUG|FOLFIRI|12 cycles
218846670|NCT02584543|BIOLOGICAL|HBV vaccine|
219197018|NCT03117972|DRUG|Bevacizumab|12 cycles
219197019|NCT03117972|DRUG|LV5FU2|Maintenance chemotherapy
218846671|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
218846672|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
218846673|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
218846674|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
218846675|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
218846676|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
218846677|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
219018378|NCT04615013|DRUG|Docetaxel|Not applicable to this study
219018379|NCT04615013|DRUG|Fluorouracil|Not applicable to this study
219018380|NCT04615013|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
219018381|NCT04615013|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219018382|NCT04615013|DRUG|Leucovorin|Not applicable to this study
219018383|NCT04615013|DRUG|Oxaliplatin|Not applicable to this study
219018384|NCT04615013|DRUG|Paclitaxel|Not applicable to this study
219018385|NCT06852872|OTHER|CRET Therapy|Diathermy therapy with a protocol to preheat the back extensor muscle
219018386|NCT06852872|OTHER|ILEX training|Isolated lumbar Extension Training
219018387|NCT06852872|OTHER|CRET therapy sham|Diathermy therapy withouth any radiofrequency as a sham intervention
219456054|NCT01661725|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
219456055|NCT04474392|OTHER|N/A (Observational Study)|Observational study, no intervention will be administered.
219456056|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
219456057|NCT05813405|OTHER|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
219456058|NCT03894267|DEVICE|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
218846678|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
218846679|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
218846680|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
218846681|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
218846682|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
219018392|NCT06511908|DRUG|(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)|Arm 1 and 2 Experimental Intervention
219018393|NCT06511908|DRUG|Placebo|Arm 1 and 2 Control Intervention
219197020|NCT03117972|DRUG|Capecitabine|Maintenance chemotherapy
219197021|NCT06513182|OTHER|No Alexis orthopaedic protector|No Alexis orthopaedic protector will be used during the course of the surgery.
219197022|NCT06513182|DEVICE|Alexis orthopaedic protector|Alexis orthopaedic protector will be inserted after making an initial superficial approach to the shoulder.
219456059|NCT02728310|DRUG|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
219456060|NCT02728310|DRUG|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
219456061|NCT02437721|OTHER|infant formula containing folic acid|
218846683|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
219456062|NCT02437721|OTHER|infant formula containing MTHF|
218846684|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
218846685|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
218846686|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
218846687|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
218846688|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
218846689|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
218846690|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
219456063|NCT03726749|DRUG|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
218846691|NCT00349921|DRUG|placebo|inactive substance
218846692|NCT00349921|DRUG|placebo|inactive substance
219018401|NCT03244020|DRUG|Aspirin 325mg|Aspirin 325 mg by mouth once daily
219018402|NCT03244020|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
219018403|NCT06083636|OTHER|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
219197023|NCT04483739|DRUG|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
219456064|NCT03726749|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
218846693|NCT05521854|BEHAVIORAL|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
218846694|NCT05521854|BEHAVIORAL|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
218846695|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
218846696|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
219456065|NCT04957745|BEHAVIORAL|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
219456066|NCT04957745|BEHAVIORAL|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
219456067|NCT04957745|BEHAVIORAL|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
218846697|NCT02202915|BEHAVIORAL|Behavioral Checklist|
218846698|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
218846699|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
218846700|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
218846701|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
219456068|NCT03906591|PROCEDURE|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
219456069|NCT03906591|PROCEDURE|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
219590914|NCT02530658|OTHER|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
219590915|NCT02530658|OTHER|Informed Consent Follow-Up Visit|At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
219590916|NCT02530658|OTHER|Return of Results Conversation|Participants will complete the assessment questionnaires.
218846702|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
218846703|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
218846704|NCT05076409|DRUG|BI 425809|Period 1 and period 2
218846705|NCT05076409|DRUG|fluconazole|Period 2
218846706|NCT06980272|DRUG|SSGJ-707|Subjects receive SSGJ-707 intravenously.
218846707|NCT06980272|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
218846708|NCT01926041|DRUG|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
218846709|NCT01926041|BEHAVIORAL|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
218846710|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
218846711|NCT06601218|DRUG|Oral cannabis low THC|4 months daily dosing with oral cannabis low THC
218846712|NCT06601218|DRUG|Placebo Comparator|4 months of daily dosing with oral placebo
218846713|NCT06601218|DRUG|Oral cannabis high THC|4 months of daily dosing with oral cannabis with high THC
218846714|NCT06601218|DRUG|Oral cannabis THC/CBD|4 months of daily dosing with oral cannabis with THC and CBD
219456070|NCT01646346|RADIATION|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
219456071|NCT06259604|OTHER|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
219456072|NCT06259604|OTHER|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
219590917|NCT02530658|OTHER|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
219590918|NCT02530658|PROCEDURE|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
218846715|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
219456073|NCT01315340|PROCEDURE|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
219456074|NCT05976906|BIOLOGICAL|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
219456075|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
219456076|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
219456077|NCT02676050|OTHER|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
219456078|NCT02676050|DEVICE|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
219456079|NCT02676050|DEVICE|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
219456080|NCT01437059|DRUG|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
219456081|NCT01437059|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219456082|NCT00086242|BEHAVIORAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
218846716|NCT06987604|DEVICE|High-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 45-55 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
218846717|NCT06987604|DEVICE|Conventional-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 25-35 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
219197024|NCT04483739|DRUG|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
219197025|NCT04857827|DRUG|QLS-101|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
219197026|NCT04857827|DRUG|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
218846718|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility, plus specific training of the inspiratory muscles, 3 times a week, at a load between 50 and 80% of the maximum inspiratory pressure of each participant, after re-education of their diaphragmatic ventilation.
218846719|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility.
218846720|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
218846721|NCT06857214|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
218846722|NCT06857214|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
218846723|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
219197027|NCT05122962|DIAGNOSTIC_TEST|Remote Heart Rhythm Monitoring|We will be looking to see if remote heart rhythm monitoring for 30 days at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.
218846724|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
218846725|NCT06861010|OTHER|Placebo|Placebo tablets will have the same look and appearance of ondansetron.
218846726|NCT06861010|DRUG|Ondansetron|ondansetron is commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea
219197028|NCT06865157|OTHER|Healthy Wallet|The Healthy Wallet program is a mobile-based initiative designed to promote healthy eating among low-income families by incentivizing the purchase of fruits and vegetables at open markets. Over a two-month period, 30 families received monthly benefits to use at a designated open market.
219197029|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
219197030|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
219197031|NCT06616311|DEVICE|Radiofrequency microneedling|The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
219197032|NCT05827874|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
219456083|NCT02698852|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
218846727|NCT06865768|DRUG|Flotufolastat F-18 Gallium|Given IV
218846728|NCT06865768|PROCEDURE|Magnetic Resonance Imaging|Undergo TRUS-MR fusion biopsy
218846729|NCT06865768|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
218846730|NCT06865768|PROCEDURE|Positron Emission Tomography|Undergo PET
218846731|NCT06865768|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-MR fusion biopsy
218846732|NCT07009418|DIAGNOSTIC_TEST|Coronary CT Angiography (CCTA)|In the surveillance by CCTA group, patients will be evaluated by CCTA at 1 year from index hospitalization. CCTA will be done according to current acquisition guidelines. Downstream management according to the results from CCTA will be performed under recommendations from current guidelines.
218846733|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Subepithelial Connective Tissue Graft (SCTG)|The modified coronally advanced tunnel (MCAT) technique is performed to prepare a recipient site. A subepithelial connective tissue graft (SCTG), harvested from the palate, is inserted into the tunnel using guiding sutures and stabilized. The flap is advanced coronally to completely cover the graft and achieve primary closure.
218846734|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Enamel Matrix Derivative (EMD)|This intervention involves the application of enamel matrix derivative (EMD; Emdogain, 0.15 ml gel form) in conjunction with the modified coronally advanced tunnel (MCAT) technique. Following tunnel preparation, EMD is applied to the exposed root surface to enhance periodontal tissue regeneration.
219456084|NCT02630485|BEHAVIORAL|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
219456085|NCT02630485|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
219456086|NCT02630485|DRUG|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
218846735|NCT07011654|DRUG|Sacituzumab govitecan|Given by IV
218846736|NCT07011654|DRUG|Naxitamab|Given by IV
218846737|NCT07012772|DEVICE|The COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
218846738|NCT07012954|DRUG|Cetuximab (Erbitux, C225)|cetuximab 500 mg/m² repeated every two weeks.
218846739|NCT07012954|DRUG|trifluridine/tipiracil|Trifluridine/tipiracil 35 mg/m² (orally for 5 days, followed by 9 days off)
218846740|NCT07012954|DRUG|Bevacizumab ( Avastin)|bevacizumab 5 mg/kg
218846741|NCT07014891|DEVICE|Intelligent Visual Feedback Motor Control Training|Patients receive motor control training using the intelligent training system (Monitored Rehab Systems B.V., 2031 CW Haarlem, The Netherlands). The Monitored Rehab Systems-Functional Squat is selected for lower - limb motor control training. The patient assumes a supine position, with both feet fixed at the correct position on the pushing - training board. The relative position of the patient can be displayed on the computer screen. The system represents the degree of joint flexion and extension and the duration of muscle contraction through the height, length, and size of images, while the speed of moving images reflects the speed of joint movement during exercise. Patients complete various simulated actions through interactive video games. During the training, the load of exercise training can be adjusted according to the patient's functional status and tolerance. The training is conducted once a day, 20 minutes per session, five times a week, for a total of four weeks.
218846742|NCT07014891|DEVICE|Bobath Ball Training|Bobath Ball Training Specific operations include: ① In the supine position, the heel controls the ball to move back and forth; ② In the supine position, both feet step on the ball to perform stepping movements, etc. The training is conducted 1 session daily, 20 minutes per session, 5 days per week, for a total of 4 weeks.
218846743|NCT07016386|PROCEDURE|Group A: will receive an ultrasound-guided interscalene block (ISB)|Group A: will receive an ultrasound-guided interscalene block (ISB) using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
218846744|NCT07016386|PROCEDURE|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
218846745|NCT03111550|DEVICE|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
219456087|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
218846746|NCT03111550|DEVICE|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
218846747|NCT03111550|DEVICE|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
218846748|NCT07013656|OTHER|L-tryptophan|L-tryptophan, an aromatic amino acid and one of the building blocks of protein, is a part of our daily diet. The load of L-tryptophan (0.1 kcal/minute) is based on our previous study, in which L-tryptophan represented a submaximal load.
219018404|NCT06083636|OTHER|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
219456088|NCT01564485|DIAGNOSTIC_TEST|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
219456089|NCT01564485|BEHAVIORAL|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
218846749|NCT07013656|OTHER|Combination of L-tryptophan + Ca-500|Calcium, an essential mineral and a key component of dairy products, is a regular part of our daily diet. In this condition, both L-tryptophan and calcium will be administered as 'active'. Recent studies have shown that calcium in a dose of 500 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'lower dose'.
218846750|NCT07013656|OTHER|Combination of L-tryptophan + Ca-1000|In this condition, both L-tryptophan and calcium will be administered. In our study calcium in a dose of 1000 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'higher dose'.
218846751|NCT07013656|OTHER|Control|An isotonic solution containing 2.5 g of NaCl, dissolved in 225 mL of distilled water.
218846752|NCT04291105|BIOLOGICAL|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
218846753|NCT04291105|BIOLOGICAL|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
218846754|NCT07033182|DRUG|Levornidazole Disodium Phosphate for Injection|Single dose, IV
218846755|NCT07033104|OTHER|us guided Transversalis fascia plane block|addition of calcitonin to pubivacaine
218846756|NCT07032441|DEVICE|PSG|"Polysomnography (PSG) is a comprehensive test used to assess sleep disorders and monitor sleep quality. PSG is typically conducted in specialized sleep laboratories and can simultaneously record various physiological parameters to help doctors diagnose different types of sleep disorders, such as obstructive sleep apnea, insomnia, and periodic limb movement disorder.~The monitored components of PSG usually include:~Electroencephalogram (EEG): Records the electrical activity of the brain to determine different sleep stages.~Electrooculogram (EOG): Records eye movements to identify rapid eye movement (REM) sleep stages.~Electromyogram (EMG): Records muscle activity, typically monitoring the muscles of the jaw or legs.~Electrocardiogram (ECG): Monitors the electrical activity of the heart. Respiratory flow monitoring: Records the flow and frequency of breathing. Oxygen saturation monitoring: Monitors blood oxygen levels using a pulse oximeter."
218846757|NCT07034378|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of pulmonary veins
218846758|NCT07034378|PROCEDURE|Extended cryoballoon ablation|Cryoablation of pulmonary veins + posterior wall isolation
218846759|NCT07034378|PROCEDURE|Standard cryoballoon ablation|Standard cryoablation of pulmonary veins
218846760|NCT07035002|BIOLOGICAL|transfusion of 5×10^8 PD-1 knockout TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
219456090|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
219456091|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
218846761|NCT07035002|BIOLOGICAL|transfusion of 1×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
218846762|NCT07035002|BIOLOGICAL|transfusion of 2×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
219456092|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
218846763|NCT07035002|BIOLOGICAL|transfusion of maximum dose without side effects among group A, B and C|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
218846764|NCT07034118|RADIATION|Proton radiotherapy|Patients enrolled would receive proton radiotherapy with chemoimmunotherapy.
218846765|NCT07034118|DRUG|Immune Checkpoint Inhibitors|Patients enrolled would receive proton radiotherapy and chemoimmunotherapy
218846766|NCT07035080|OTHER|interferential therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
218846767|NCT07035080|OTHER|tradional physical therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
218846768|NCT07032662|DRUG|IMVT-1402|Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
218846769|NCT07032662|DRUG|Placebo|Matching placebo SC QW for 24 weeks (Period 1)
218846770|NCT07035028|DIAGNOSTIC_TEST|Digital fetal scalp stimulation dFSS|Digital fetal scalp stimulation will be performed for a period of 30 seconds, prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and rubbing the fetal scalp with pressure for 30 to 60 seconds.
219456093|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
219456094|NCT03665987|BEHAVIORAL|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
218846771|NCT07034859|DRUG|Cabergoline 0.5 MG|Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).
218846772|NCT07034742|DRUG|Intraperitoneal chemotherapy PLUS systemic chemotherapy|Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)
218846773|NCT07033299|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
218846774|NCT06894407|DEVICE|Device: Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy.
218846775|NCT06896890|DRUG|CIS-DPI|"* Administration of cisplatin by inhalation (pulmonary route) using single-use RS01 capsule-based device and CIS-DPI hard capsules containing 2.5 mg, 5 mg, and 10 mg cisplatin.~* CIS-DPI, administered once-a-day, 5-days on followed by 2-days off. Daily dose to be administered will range from an initial dose of 2.5 mg cisplatin to a maximal theoretical dose of 30 mg (i.e., dose 1 to dose 7)."
218846776|NCT06896305|COMBINATION_PRODUCT|CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapy|"Patients in the experimental group will receive professional dietary advice on how to adhere to CDED for 12 weeks, in addition to anti-TNF therapy while patients in the control group will receive only anti-TNF therapy for the entire duration of the study.~Diet adherence is completely voluntary and is not enforced in any way. CDED is divided into 3 phases, the first two, grouped as the induction phase, with 6 weeks of strict diet and 6 weeks to gradual food reintroduction, followed by 12 weeks of patients follow-up.~Five foods (chicken, eggs, potatoes, apple and bananas) are permitted at the start of the diet; the patient can then choose to consume a range of permitted foods at will, the variability of which increases after the first six weeks"
218846777|NCT06896305|DRUG|Anti-TNF Therapy|The control group will receive only anti-TNF therapy as per standard of care. This therapy is recommended by guidelines and is the cornerstone of treatment of Crohn's disease and ulcerative colitis.
219197033|NCT05827874|BIOLOGICAL|Tdap|Tdap will be administered as an IM injection.
219456095|NCT05677854|OTHER|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
219456096|NCT05677854|OTHER|Health literacy based health education|Health education based on health literacy was used.
219456097|NCT02227433|DRUG|Brentuximab Vedotin|
218846778|NCT06896461|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"The test consists of physical exertion performed on a stationary bike with a progressively increasing workload, continuing until specific electrocardiographic and/or clinical criteria are met or muscle fatigue occurs. The rate of workload increase (ramp) will be personalized and adjusted to ensure the exercise reaches its peak in approximately 10 minutes.~Throughout the test, a continuous electrocardiogram (ECG) will be recorded, and various physiological parameters will be measured. These include ventilation, oxygen consumption, carbon dioxide production, and related derived parameters, which will be assessed using a mouthpiece or a face mask through which you will need to breathe for the entire duration of the test. Blood pressure will also be measured at two-minute intervals."
218846779|NCT06896461|DIAGNOSTIC_TEST|Lung function|"Assessment of both static lung volumes (vital capacity, total lung capacity, functional residual capacity, and residual volume) and dynamic lung volumes (forced vital capacity and forced expiratory volume in one second, or FEV1).~Additionally, the flow-volume curve is measured, generated by continuously recording airflow and volume using an electronic spirometer during a foThe diffusion capacity for carbon monoxide (DLCO) can be measured using the single-breath method (DLCOSB). The patient inhales a small, known concentration of carbon monoxide (CO), holds their breath for 10 seconds, and then exhales. A sample of alveolar gas (from the end of expiration) is analyzed to determine the amount of CO absorbed during the breath, expressed in ml/min/mm Hg.~By repeating the test with inhalation of gas mixtures containing different oxygen concentrations (approximately 20%, 40%, and 60%), it is possible to assess the diffusion subcomponents: the membrane component and capillary blood volume."
219197034|NCT05827874|BIOLOGICAL|PPSV23|PPSV23 will be administered as an IM injection.
219456098|NCT02339454|DEVICE|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
219456099|NCT02339454|DEVICE|Placebo group|Placebo Applicator
219456100|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
219456101|NCT05664828|DRUG|SN132D|Manganese-based macromolecular MRI contrast agent
219456102|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
219456103|NCT01841164|DRUG|Montelukast|
219456104|NCT01841164|DRUG|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
219456105|NCT01841164|OTHER|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
219456106|NCT02462889|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection
219456107|NCT02462889|DRUG|Placebo|Sham injection
219456108|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
219456109|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
219456110|NCT00885729|PROCEDURE|stem cells|Stem cells or chondrocytes under a commercial available membrane
219456111|NCT00885729|PROCEDURE|Chondrocytes|Implantation of chondrocytes
219456112|NCT00885729|OTHER|Rehabilitation program|Strength exercises, neuromuscular exercises
219456113|NCT00294229|PROCEDURE|manipulative therapy|
219456114|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
219456115|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
219456116|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
219456117|NCT03450486|OTHER|exercise|one 30 minute bout of mild exercise
219456118|NCT01855204|RADIATION|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
219456119|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
219456120|NCT03238040|OTHER|None, observational study|Observational study, no interventions
219456121|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
219456122|NCT04009824|BIOLOGICAL|AGS-v PLUS Vaccine|Administered by subcutaneous injection
219456123|NCT04009824|BIOLOGICAL|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
219456124|NCT04009824|BIOLOGICAL|Alhydrogel® Adjuvant|Administered by subcutaneous injection
219456125|NCT04009824|BIOLOGICAL|Saline Placebo|Administered by subcutaneous injection
219456126|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
219456127|NCT02311140|OTHER|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
219456128|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
219456129|NCT00391495|PROCEDURE|Blood drawing|
219456130|NCT03452995|PROCEDURE|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
219456131|NCT06096012|DRUG|Anti-MRSA therapy|chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
219590919|NCT02530658|PROCEDURE|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
218846780|NCT06896461|DIAGNOSTIC_TEST|Biomarkers evaluation|"Samples of plasma will be collected for bimarkers quantification in heart failure.~Speecifically, plasma levels will be quantitatively assessed using plasma obtained from venous blood. Blood will be collected in tubes containing 0.129 M Na-citrate (9 volumes of blood to 1 volume of Na-citrate), immediately centrifuged at 3000 g for 15 minutes at 4°C. Circulating levels of both immature and mature SP-B will be analyzed via Tricine gel electrophoresis followed by immunoblotting with an anti-SP-B antibody, allowing for the detection of all SP-B isoforms (proprotein 42 kDa, intermediate 23 kDa, and mature 8 kDa).~To validate potential heart failure biomarkers, a quantitative, scalable, and cost-effective method-Multiple Reaction Monitoring (MRM)-will be used. MRM, based on triple quadrupole mass spectrometry, enables precise quantification of proteins/peptides and their isoforms in complex biological samples."
218846781|NCT05949697|DIETARY_SUPPLEMENT|Dry Eye Drink|Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
218846782|NCT06895694|OTHER|examine the impact of education|Children in the research group were trained to create a positive hospital perception.
219456132|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
219456133|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
219456134|NCT03731910|DIAGNOSTIC_TEST|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
219456135|NCT06019390|DEVICE|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
219456136|NCT01381809|DRUG|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
219456137|NCT01381809|DRUG|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
218846783|NCT06896357|PROCEDURE|Limbal relaxing incisions|A fixed depth diamond-guarded knife (Gemcision LRI 600 Microns Blade, Katalyst Surgical, chesterfield, MO, USA) will be used to create a paired circumferential corneal incision, following the limbal curvature, 1-1.5mm anterior to the limbus centered on the steep corneal meridian. The incision arc length will be ninety degree according to the Nichamin Age and Pachymetry Adjusted (NAPA) nomogram.
219456138|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
218846784|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in trained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
218846785|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the IHT group|The participants in IHT group will live in normoxic conditions, but part of their training will be performed in normobaric hypoxia in a hypoxic chamber. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
219197035|NCT06370702|OTHER|Handgrip Exercises|Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
219197036|NCT06071286|PROCEDURE|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
219197037|NCT05825079|BEHAVIORAL|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
219197038|NCT05825079|DEVICE|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
219197039|NCT06674408|OTHER|Traditional physical therapy|"Control group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Finger Ladder Exercise, Codman's Pendulum Exercise, Towel Stretch Exercise and Wand Exercises 10 reps x 2 sets per session,~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week of treatment for outcome measures."
218846786|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the NRT group|The participants in the NRT group will perform resistance training in normoxia. The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
218846787|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in untrained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
218846788|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the LHTL group|The participants from the LHTL group will be exposed to normobaric hypoxia (FIO2 = 14.4%, corresponding to an altitude of 3000 m a.s.l.) in a hotel room for 11 to 12 hours a day (evenings and nights). Participants in this group will perform interval training under normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
219456139|NCT00976261|DRUG|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
218846789|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the Control group|The participants in the C group will live and train in normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
218846790|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the HRT group|The participants in the HRT group will perform resistance training in normobaric hypoxia (FIO2 = 14.4%, 3000 m a.s.l.). The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
218846791|NCT06895785|DEVICE|Exalt Model D|Exalt Model D single-use duodenoscope will be used in ERCP
218846792|NCT06895785|DEVICE|Reusable|Standard reusable duodenoscope will be used in ERCP
219197040|NCT06674408|OTHER|Prioprioceptive group|"Experimental group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Plyometric CKC shoulder exercise 10 seconds each x 5 reps x 2 sets per session, CKC exercise on the ball 10 seconds each x 5 reps x 2 sets per session, Open KC exercises 10 seconds each x 5 reps x 2 sets per session, Hand-eye coordination exercises for 30 minutes/per day for 5x/per week, Hand Function Exercises for 30 minutes/per day for 5x/per week.~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week"
219456140|NCT00976261|DRUG|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
219456141|NCT00976261|OTHER|Placebo|Comparator
219456142|NCT04770428|DRUG|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
219456143|NCT04770428|DRUG|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
219456144|NCT04176328|DRUG|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
219456145|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
219456146|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
219456147|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
219456148|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
219456149|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
219456150|NCT03988894|DEVICE|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
219456151|NCT03817931|DRUG|Anticholinergic|Tablet taken once daily.
219456152|NCT03817931|DRUG|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
219456153|NCT03817931|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
219456154|NCT03817931|DIAGNOSTIC_TEST|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
219590920|NCT06453135|DRUG|Eculizumab|On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
219590921|NCT02351271|DEVICE|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
219590922|NCT02351271|DEVICE|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
219590923|NCT03067597|DRUG|Dinoprostone|The DVI contains 10 mg dinoprostone
219590924|NCT01711892|BEHAVIORAL|Soccer training|
219197041|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
218846793|NCT06897098|BIOLOGICAL|Implantation of autologous cartilage mini-grafts (Cartibeads)|"1. st surgery: cartilage biopsy harvest by minimally invasive surgery (arthroscopy or mini arthrotomy).~2. nd surgery: Implantation of autologous cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant)."
218846794|NCT06896097|PROCEDURE|Ridge preservation|extraction of non restorable tooth in a traumatic way and socket preservation with the selected group
218846795|NCT06000683|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
219197042|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
219197043|NCT06674681|DIAGNOSTIC_TEST|HPV Self-Collection|HPV self-collection program for in-clinic and mailed cervical cancer screening.
219197044|NCT05640375|DRUG|Methylprednisolone|Single dose, 1 mg/kg
219197045|NCT05890105|DRUG|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
219197046|NCT05890105|DRUG|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
219456155|NCT02180191|OTHER|Comparison of the gut microbiota composition|
219456156|NCT03184766|DRUG|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
219456157|NCT03184766|DRUG|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
219456158|NCT03184766|DRUG|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
219456159|NCT02902692|OTHER|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
219590925|NCT05831371|DIAGNOSTIC_TEST|TEP FDG|FDG TEP peformed in clinical routine
219590926|NCT05908630|OTHER|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C"
219590927|NCT01786889|BIOLOGICAL|blood and urine|Blood collection and urine collection after consent of the patient
219590928|NCT01786889|BEHAVIORAL|Questionnaire|The patient complete the questionnaire alone at home
219590929|NCT01786889|BEHAVIORAL|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
219590930|NCT04063423|PROCEDURE|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
219590931|NCT04126590|BIOLOGICAL|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
219590932|NCT03960203|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
219197047|NCT04678336|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
219456160|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
219456161|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
219456162|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
219456163|NCT04807244|PROCEDURE|Selective Caries Removal with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
219456164|NCT04807244|PROCEDURE|Partial Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
219456165|NCT04807244|PROCEDURE|Full Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
219456166|NCT04807244|PROCEDURE|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
219456167|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
219456168|NCT04526444|OTHER|Online training|Les Mills On Demand
218846796|NCT06000683|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
219456169|NCT04526444|OTHER|Peer support via social media|Facebook group
219590933|NCT04132700|DEVICE|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
219590934|NCT02287818|DRUG|Placebo|Placebo twice daily from Day 1 to Week 12
219590935|NCT02287818|DRUG|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
219197048|NCT06549023|PROCEDURE|Single-session panretinal PRP (SS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
219197049|NCT06549023|PROCEDURE|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
219456170|NCT06178458|OTHER|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
219590936|NCT02287818|DRUG|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
219590937|NCT04708574|BEHAVIORAL|Lifestyle intervention|
219590938|NCT04708574|OTHER|Placebo - Control|
219590939|NCT04241926|DIAGNOSTIC_TEST|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
219590940|NCT01121848|DRUG|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
219590941|NCT01121848|DRUG|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
218846797|NCT06000683|BEHAVIORAL|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
218846798|NCT06000683|BEHAVIORAL|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
218846799|NCT06897280|DEVICE|SCS Device Program Setting|A Pulse Dose setting specifies a brief duration of stimulation 'on' and stimulation 'off' durations, applied in a continuously cycled manner
219456171|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
218846800|NCT06896747|BIOLOGICAL|Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes|"Mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) are isolated from umbilical cord-derived mesenchymal stem cells (UCMSCs) subjected to mechanical stress conditioning during in vitro expansion. This process enhances exosome yield, bioactivity, and regenerative capacity. The exosomes are purified via ultracentrifugation and characterized for size, protein markers, and RNA content.~In this study, ME-UCMSC-Exo is administered via intra-endometrial injection under hysteroscopic guidance. Each participant in this intervention group will receive 1-1.5 mL of exosome solution (containing approximately5\*10\^10 particles/mL) per injection site during the proliferative phase (Day 3-7 of the menstrual cycle). The aim is to enhance endometrial thickness, receptivity, and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions."
218846801|NCT06896747|BIOLOGICAL|Umbilical cord mesenchymal stem cell-derived exosomes|Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning. These exosomes undergo identical purification and characterization procedures as ME-UCMSC-Exo but lack biomechanical priming. UCMSC-Exo is also administered intra-endometrially via hysteroscopic injection at a dose of 1-1.5 mL (5\*10\^10 particles/mL) per site.
218846802|NCT06896747|BIOLOGICAL|platelet-rich plasma|"Platelet-rich plasma (PRP) is an autologous biological preparation obtained from centrifuged whole blood. It contains a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote endometrial regeneration.~In this study, PRP will be administered via hysteroscopically guided intra-endometrial injection at a dose of 1-1.5 mL per injection site, following standard PRP preparation protocols. This group serves as a positive control for evaluating the efficacy of exosome-based therapies."
218846803|NCT06898502|DEVICE|Electrotherapy ( TENS, hot pack, and therapeutic ultrasound )|"Each participant will receive electrotherapy treatment three times a week for four weeks. Each treatment session will consist of 20 minutes of TENS, 20 minutes of hot pack, and 6 minutes of ultrasound therapy. Twelve weeks after the treatment, participants will be contacted by phone and asked about their improvement using the Global Rating of Change Scale (GRC). Pain intensity and disability level will be reassessed through phone interviews using the Numeric Pain Scale, the Oswestry Disability Index for low back pain, and the Neck Disability Index for neck pain at the 12th week. Thus, it will be evaluated whether there is any difference in patient satisfaction, pain intensity, and disability at the 12th week between participants who selected electrotherapy as the most effective method and those who chose other treatments."
219456172|NCT04905836|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
219456173|NCT04905836|DRUG|Placebo|Excipient solution
219456174|NCT01528618|DRUG|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
219456175|NCT01528618|DRUG|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
219456176|NCT01620437|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
219590942|NCT01121848|DRUG|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
219590943|NCT01616030|OTHER|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
219590944|NCT03574948|DRUG|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
219590945|NCT03574948|DRUG|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
219590946|NCT05405348|BEHAVIORAL|Intervention|The patients did not eat anything during hemodialysis.
219590947|NCT04223557|DEVICE|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
219590948|NCT04223557|DEVICE|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
219590949|NCT02677714|RADIATION|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
219590950|NCT00400816|DRUG|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
219456177|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
219456178|NCT02334137|BEHAVIORAL|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
219456179|NCT02334137|BEHAVIORAL|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
219456180|NCT02334137|BEHAVIORAL|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
219456181|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
219456182|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
219456183|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
219456184|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
219456185|NCT06423001|DIETARY_SUPPLEMENT|PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.|Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).
219456186|NCT02378610|OTHER|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
218846804|NCT06896448|DIAGNOSTIC_TEST|Specialized sleep consultation and overnight recording using the APNEAL application|"A sleep consultation with a clinical examination. Completion of several questionnaires: Snoring and sleep quality questionnaire (AFSORL), EORTC Qulity of Life questionnary -C30, and H\&N35.~Providing the Apneal application pre-installed on a loaned smartphone for the patient to use at home for overnight recording."
219456187|NCT04959786|DRUG|Ivermectin,ribavirin ,nitazoxanide and zinc|oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
219197050|NCT05966805|BEHAVIORAL|Exercise training group|12-Week Exercise intervention on mentaL, metabolic, physicaL, spiritual, social, and occupational well-being among shift-working acute care NURSE
219197051|NCT05966805|BEHAVIORAL|Wait-List Control Group|Control group
219197052|NCT05699837|DEVICE|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
218846805|NCT06895434|OTHER|Balneotherapy with physical therapy|"Balneotherapy applied in the thermal pools to patients for 20 minutes, at a temperature of 38-40°C. After resting for 30 minutes,physical therapy was applied.~A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity."
219590951|NCT05998512|OTHER|Observational register|This is a non-interventional observational registry on patients
219590952|NCT00335114|DRUG|cyclosporine ophthalmic emulsion|
219197053|NCT00450216|DRUG|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
219197054|NCT00450216|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
219197055|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
219456188|NCT06375694|DIETARY_SUPPLEMENT|Herbiotics Oral + Ent Probiotic|Chewable Tablets containing Lactobacillus species.
219456189|NCT06375694|DIETARY_SUPPLEMENT|Placebo|Honest Placebo Pills by Zeebo
219456190|NCT01142791|DEVICE|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
219456191|NCT04582162|OTHER|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
219456192|NCT04582162|OTHER|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
219456193|NCT00656994|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
219456194|NCT00656994|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
219456195|NCT01212120|BIOLOGICAL|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
219590953|NCT01303770|BEHAVIORAL|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
219590954|NCT01303770|BEHAVIORAL|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
219590955|NCT02455037|OTHER|Neck Strengthening|Targeted neck strengthening exercises
219590956|NCT03486691|OTHER|Routine measurement of left lobe|Routine preoperative measurement of left lobe
219590957|NCT03486691|OTHER|control group|no routine preoperative measurement of left lobe
219590958|NCT05798026|DRUG|EU103|EU103 will be administered via intravenous infusion.
219590959|NCT05742763|COMBINATION_PRODUCT|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
219197056|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
218846806|NCT06895434|OTHER|Physical therapy|A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.
218846807|NCT06895655|DEVICE|MRI and Ultrasound Elastography|transcutaneous ultrasound elastography and MRI abdomen with diffusion to evaluate pancreatic mass as regard of probability of mass to be malignancy ,size of the mass ,relation to pancreatic duct and bile duct evaluation with their result will be compared to the pathologic finding.
219456196|NCT04051489|OTHER|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
219456197|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
219456198|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
219456199|NCT03450824|OTHER|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
219456200|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
219456201|NCT03032523|DIAGNOSTIC_TEST|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
219456202|NCT02590406|PROCEDURE|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
219456203|NCT02590406|PROCEDURE|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
219456204|NCT01982669|OTHER|No Intervention|
219456205|NCT04840849|BIOLOGICAL|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
219456206|NCT04840849|OTHER|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
219456207|NCT04562038|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
219456208|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
219456209|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
219456210|NCT02839655|DEVICE|Da Vinci Xi|
219456211|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
219456212|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
219456213|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
219456214|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
219456215|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
219456216|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
219456217|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219456218|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219590960|NCT05742763|COMBINATION_PRODUCT|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
218846808|NCT06885216|PROCEDURE|Anterior cervical discectomy and fusion/ posterior decompression|
218846809|NCT06896214|OTHER|Standardised nursing care intervention|Standardised nursing care intervention
218846810|NCT06897787|PROCEDURE|manuel positioning group|As Prof. Reyneke does, mandibular base and proximal segment leveling are performed first, followed by fixation.
218846811|NCT06897787|PROCEDURE|mandibular basis osteotomy|After the mandibular sagittal split, secure the proximal segment in its preoperative position and remove the bone piece for leveling. After that, fixation is performed.
219456219|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
218846812|NCT04696276|OTHER|ERAS protocol|special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
218846813|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
218846814|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
218846815|NCT06751602|DRUG|Belumosudil 200 mg QD|Belumosudil 200 mcg oral daily
219456220|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
218846816|NCT06751602|DRUG|Placebo|Placebo (once daily)
218846817|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
218846818|NCT06895876|PROCEDURE|Deep parasternal intercostal plane block|The block is performed bilaterally in the 4th intercostal space. The probe is placed in the latero-median axis and a needle is placed latero-medially between the intercostal and transverse thoracic muscle. The solution is then injected under ultrasound control
218846819|NCT06895889|DEVICE|EB-OC Graft Implantation|The implantation of the EB-OC graft is completed via an arthrotomy, which is categorized as a minor surgery and is done on an outpatient basis, which means you can go home the same day. It is completed under general anesthesia and may last between one to two hours.
219456221|NCT00740818|OTHER|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
219456222|NCT00740818|PROCEDURE|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
219456223|NCT00740818|PROCEDURE|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
219456224|NCT03307213|DEVICE|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
219456225|NCT03307213|DEVICE|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
219456226|NCT01243203|DRUG|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
219456227|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
219456228|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
219590961|NCT05742763|COMBINATION_PRODUCT|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
218846820|NCT06895889|PROCEDURE|Abrasion chondroplasty|Abrasion chondroplasty is a minimally invasive procedure in which the surgeon uses a rotary burr to scrape off the bone tissue from the surface of the joint.
218846821|NCT06896227|DIAGNOSTIC_TEST|transthoracic echocardiography|Each study patient will undergo transthoracic echocardiography, transesophageal echocardiography, and cardiac magnetic resonance imaging following transcatheter aortic valve replacement.
218846822|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
218846823|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
219197057|NCT05466838|DRUG|PERT at discharge|Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
219456229|NCT06064552|DIAGNOSTIC_TEST|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
219590962|NCT02558348|DRUG|AL3818|Administered orally
219590963|NCT03242200|OTHER|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
219590964|NCT03781037|BEHAVIORAL|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
219590965|NCT06332989|OTHER|stroke-APP|Ambulane paramedics will use an online application to fill in several observations on scen
219590966|NCT03288701|DEVICE|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
218846824|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
218846825|NCT06895733|DRUG|Pazopanib Oral Tablet|Orally administered once daily (100mg)for 21 consecutive days, followed by a 7-day cessation of medication; Every 28 days is a treatment cycle.
219456230|NCT01163695|BEHAVIORAL|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
219456231|NCT00935662|DRUG|AZD8329|Oral solution, single ascending doses
219456232|NCT00935662|DRUG|Placebo|Oral solution, placebo
219456233|NCT02907801|BEHAVIORAL|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
219456234|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
219456235|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
219456236|NCT02349776|OTHER|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
219456237|NCT00302575|BEHAVIORAL|Collaborative Behavioral Management|
219456238|NCT00302575|PROCEDURE|Integrated parole and outpatient addiction treatment|
219456239|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
219456240|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
219590967|NCT03741712|DRUG|SHR3680|Tablet. Specifications of 80mg
219456241|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
219590968|NCT03741712|DRUG|SHR2554|Tablet. Specifications of 50mg and 200mg
219456242|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
219456243|NCT02292888|OTHER|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
219456244|NCT06117956|DIAGNOSTIC_TEST|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
219456245|NCT03821350|OTHER|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
219590969|NCT03337958|DEVICE|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
219590970|NCT04322565|DRUG|Colchicine|Cochicine 1mg/day
219590971|NCT00991419|DRUG|[18F]AZD4694|\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
219590972|NCT03183596|DRUG|Bupivacaine|20-60cc of 0.25% Bupivacaine
219590973|NCT03183596|DRUG|Dexamethasone|2-4mg of Dexamethasone
219590974|NCT01422187|DRUG|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
219590975|NCT03777618|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
219590976|NCT04015908|DRUG|Celecoxib|Celecoxib 100mg
219590977|NCT04015908|DRUG|Acetaminophen|Acetaminophen 325mg
219590978|NCT04015908|DRUG|Pregabalin|Pregabalin 50 mg
219590979|NCT04015908|DRUG|Oxycodone|oxycodone 5-10 mg
219590980|NCT04015908|DRUG|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
218846826|NCT06895733|DRUG|Palbociclib|Oral treatment once a day, with a cycle of 28 days. In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.
218846827|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
219456246|NCT05129111|DEVICE|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
219456247|NCT06193837|DRUG|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
219456248|NCT02385591|BEHAVIORAL|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
219456249|NCT02385591|BEHAVIORAL|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
219456250|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
219456251|NCT00281528|DRUG|bevacizumab|infusions
219456252|NCT01758640|DRUG|Warfarin|Low dose warfarin of 5mg or less per day
219456253|NCT01758640|DRUG|phenindione|Phenindione of 100mg or less per day
219456254|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
219456255|NCT05512195|RADIATION|New delineation approach|New delineation approach
219456256|NCT04812665|BEHAVIORAL|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
219456257|NCT04081051|OTHER|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
219456258|NCT02133144|BEHAVIORAL|overeating fat|
219456259|NCT02133144|BEHAVIORAL|overeating carbohydrate|
219456260|NCT03486769|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
219456261|NCT03486769|DEVICE|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
219456262|NCT03486769|DEVICE|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
219590981|NCT05801952|DEVICE|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
219590982|NCT02257697|DRUG|Mizoribine (MZR)|
219590983|NCT02257697|DRUG|Cyclophosphamide (CTX)|
219590984|NCT01866046|BEHAVIORAL|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
218846828|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
218846829|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
218846830|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
219456263|NCT03486769|BEHAVIORAL|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
219456264|NCT00291460|DEVICE|inspiratory muscle training|
219590985|NCT02227446|DRUG|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
218846831|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
219197058|NCT05466838|OTHER|Standard of Care|Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
219456265|NCT02652572|DRUG|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
219456266|NCT05057884|BEHAVIORAL|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
219456267|NCT04396106|DRUG|AT-527|One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
219456268|NCT04396106|OTHER|Placebo|One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
219456269|NCT04396106|DRUG|AT-527|Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
219456270|NCT04396106|OTHER|Placebo|Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
219456271|NCT03781154|BEHAVIORAL|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
219456272|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
219456273|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
219456274|NCT02783651|OTHER|Other|No intervention other than routine medical care
219590986|NCT04623086|DRUG|Insulin Degludec|Insulin Degludec injection
219590987|NCT04623086|DRUG|Insulin Glargine|Insulin Glargine injection
218846832|NCT07081893|OTHER|Conventional care with semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
218846833|NCT07081893|OTHER|In-depth interviews with patients and relatives|The objective is to thoroughly understand what PEC means in rehabilitation. Although PEC can be understood as 'being responsive to the unique wishes and needs of the individual person', there still is a lack of consensus about its exact conceptualization in the rehabilitation context (Yun and Choi 2019). Prior work often only considers PEC in terms of shared decision making and goal setting, while the holistic perspective on the patient as a whole person is largely neglected (Yun and Choi 2019). This qualitative phase thus focuses on understanding PEC, its dimensions and the unique wishes and needs of patients in rehabilitation services. In addition, we gather insights regarding the potential enhancement of PEC in rehabilitation. The interviews are based on the Trajectory Touchpoint Technique (TTT; Sudbury-Riley et al. 2020a; 2020b) which allows us to uncover the unique experiences of respondents (i.e., patients, relatives, informal caregivers). The TTT is especially suited fo
218846834|NCT07081893|OTHER|Semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
218846835|NCT07081893|OTHER|Conventional care with additional focusgroups|In semi-structured individual interviews, students of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. The focus groups will be supported by the Lego® Serious Play (LSP) will be used to collect in-depth insights from students. This design allows flexibility in questioning, while still following a consistent structure to explore common themes across focus groups. The use of Lego encourages participants to think in new ways.
219197059|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
219197060|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
219361226|NCT05768490|RADIATION|brain radiotherapy|Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.
219361227|NCT05768490|DRUG|Almonertinib|almonertinib po 110mg QD
219361228|NCT00982904|DRUG|Fexinidazole/Placebo|
219361229|NCT01612715|OTHER|Segmental Allergen Challenge|segmental allergen challenge
219361230|NCT03754907|PROCEDURE|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson \& Johnson K.K., Tokyo, Japan)
219361231|NCT03754907|PROCEDURE|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
219361232|NCT04945798|OTHER|OMT|OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds
219361233|NCT01401504|DRUG|ASP3026|oral
219361234|NCT04804592|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
219361235|NCT04804592|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
219361236|NCT04804592|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
219361237|NCT02752100|PROCEDURE|Percutaneous transluminal angioplasty|
218846836|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
218846837|NCT07079280|OTHER|Low Intensity Aerobic Exercise with Blood Flow Restriction (LIAE+BFR)|"In the LIAE+BFR condition, participants will walk on a treadmill for 20 minutes at 30-40% of heart rate reserve (HRR), with a pneumatic cuff inflated to 1.3 times the individual's ankle systolic blood pressure, using a 5cm wide x 75cm long commercial cuff around each upper thigh.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
218846838|NCT07079280|OTHER|High Intensity Interval Exercise (HIIE)|"In the HIIE condition, participants will perform a 20 minutes treadmill-based HIAE, alternating between 60-seconds high-intensity intervals at 60-89% HRR and 60-second active recovery intervals at 40-50% HRR.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
219590988|NCT04623086|DRUG|Placebo|9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
218846839|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
219361238|NCT06233695|DRUG|Potassium sparing diuretic|Starting Spironolactone or Eplerenone at the time of enrollment.
219590989|NCT04131738|DRUG|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
219590990|NCT00875797|DIETARY_SUPPLEMENT|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
219590991|NCT00875797|DIETARY_SUPPLEMENT|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
219361239|NCT06066892|PROCEDURE|Impression techniques|3 types of impression techniques for all on four
219361240|NCT03090685|PROCEDURE|True auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
219361241|NCT03090685|PROCEDURE|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
219361242|NCT01733017|BEHAVIORAL|Sodium reduction|Teaching and skill building to reduce dietary sodium
219361243|NCT01733017|DIETARY_SUPPLEMENT|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
219361244|NCT01733017|DIETARY_SUPPLEMENT|rice bran oil capsules|placebo capsules
219361245|NCT01733017|BEHAVIORAL|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
219361246|NCT04102969|BEHAVIORAL|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
219361247|NCT04102969|OTHER|Nutrition Package Session|A nutrition package session will be given to the control group.
219361248|NCT02312492|OTHER|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
219361249|NCT02312492|OTHER|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
219361250|NCT02312492|OTHER|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
219361251|NCT02288273|DRUG|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
219361252|NCT02288273|DRUG|Placebo|Placebo
219456275|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
218846840|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
218846841|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
218846842|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
218846843|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
219456276|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
219456277|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
219456278|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
219456279|NCT05592145|DEVICE|ViOptix|ViOptix machine
219456280|NCT01930669|OTHER|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
219456281|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
219456282|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
219197061|NCT05819931|DEVICE|Mechanical In-Exsufflator treatment|"The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit."
219456283|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
219590992|NCT01291771|PROCEDURE|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
219456284|NCT06220240|OTHER|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
219456285|NCT06220240|OTHER|Routine Training Programme|A routine training program will be used.
219456286|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
218846844|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
218846845|NCT03319953|DRUG|TAK-041|TAK-041 suspension
218846846|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
219197062|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
219456287|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
219456288|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
218846847|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
219456289|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
218846848|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
218846849|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
218846850|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
219456290|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
219456291|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
219456292|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
219456293|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
219456294|NCT00859716|BIOLOGICAL|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
219456295|NCT00859716|BIOLOGICAL|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
219456296|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
219456297|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
219456298|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219456299|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
219456300|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
219590993|NCT05213039|OTHER|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
219590994|NCT00715624|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219590995|NCT00715624|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219590996|NCT00715624|DRUG|Basal Insulin|Dose to be kept stable.
219590997|NCT00715624|DRUG|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
219197063|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
219590998|NCT00715624|DEVICE|Pen auto-injector|
218846851|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
218846852|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
219197064|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
219590999|NCT00203710|DEVICE|Concentric Retriever Device|
219591000|NCT03200912|DRUG|Ingenol Mebutate (Picato®)|Brand product
218846853|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
219456301|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
219197065|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
219197066|NCT04898400|PROCEDURE|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
219591001|NCT03200912|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
219591002|NCT03200912|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
218846854|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
218846855|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
218846856|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
218846857|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
218846858|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
218846859|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
218846860|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
218846861|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
218846862|NCT00729495|DRUG|celecoxib|dose form
219197067|NCT06746857|DEVICE|repetitive transcranial magnetic stimulation|Bilateral dorsolateral prefrontal cortex Intermitten Theta Burst Stimulation to
219197068|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
219456302|NCT00921908|OTHER|2 mBq radioactive technetium diluted in 20 mL saline|
219456303|NCT00381836|DRUG|Darbepoetin Alfa|
219591003|NCT03316274|DRUG|Nivolumab|Given via intralesional injection
219591004|NCT02264860|DIETARY_SUPPLEMENT|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
219591005|NCT02572414|BEHAVIORAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
219591006|NCT02572414|BEHAVIORAL|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
219591007|NCT03645239|PROCEDURE|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
218846863|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
218846864|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
218846865|NCT01795495|DRUG|Remifentanil|
219456304|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
219018412|NCT04017299|OTHER|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
219591008|NCT03645239|OTHER|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
218846866|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
218846867|NCT04577300|OTHER|Sham comparator|Sham implantation
218846868|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
218846869|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
218846870|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
218846871|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
218846872|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
218846873|NCT04994912|DRUG|EI-001|EI-001 IV infusion
219018428|NCT06024928|DEVICE|Control-IQ use in Type 2 Diabetes under basal insulin injections|Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
219018429|NCT05840211|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219018430|NCT05840211|DRUG|Paclitaxel|Administered intravenously
219018431|NCT05840211|DRUG|Nab-paclitaxel|Administered intravenously
219018432|NCT05840211|DRUG|Capecitabine|Administered orally
219018433|NCT05378880|BEHAVIORAL|Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission|The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
219456305|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
219591009|NCT03645239|OTHER|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
218846874|NCT04994912|OTHER|Placebo|Placebo IV infusion
218846875|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
219456306|NCT00003687|DRUG|dextromethorphan hydrobromide|
219456307|NCT00003687|DRUG|morphine sulfate|
218846876|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
219456308|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
219591010|NCT03645239|OTHER|Headspace|The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
219591011|NCT02399319|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
219591012|NCT02399319|PROCEDURE|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
219591013|NCT03526159|DRUG|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
219591014|NCT06633159|DEVICE|MitraClip|surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
219591015|NCT00819637|DRUG|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
219591016|NCT00819637|DRUG|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
219591017|NCT00819637|DRUG|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
218846877|NCT06837961|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks
218846878|NCT06837961|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 4 weeks
218846879|NCT06894719|DRUG|tranexamic acid Oral-Short Arm|1.95g Tranexamic acid daily for post op days 1 to 3
218846880|NCT06894719|DRUG|tranexamic acid Oral-Long Arm|1.95g tranexamic acid daily post op days 1-7
218846881|NCT06894719|DRUG|Control group placebo|Placebo for 3 days post-op
218846882|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
218846883|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
218846884|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
219018448|NCT04170283|DRUG|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
219018449|NCT04170283|DRUG|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
219018450|NCT04817488|OTHER|Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea
219018451|NCT04817488|OTHER|Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
219456309|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
219456310|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
219456311|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
219456312|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
219456313|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
218846885|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
218846886|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
219018452|NCT01498211|PROCEDURE|Biopsy|3 mm punch biopsy of the skin at the distal leg.
219018456|NCT06032533|DEVICE|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
219456314|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
218846887|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
218846888|NCT06907680|DIETARY_SUPPLEMENT|M-Gard|One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.
218846889|NCT06907680|OTHER|Placebo|One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.
218846890|NCT07080008|DEVICE|Lumitrace|Administered as a bolus intravenous injection over 30 - 60 seconds
218846891|NCT07080008|DEVICE|KARL STORZ POWER LED BLUE System|Imaging will be acquired within 30 minutes post Lumitrace administration. Following the initial endoscopic surgical incision, the surgeon will record the image assessments based on Likert Scales.
218846892|NCT03626688|DRUG|Ralinepag|Active
218846893|NCT03626688|DRUG|Placebo|Placebo
219456315|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
219456316|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
219456317|NCT02036476|DRUG|Cabozantinib|oral administration
219591018|NCT03207737|BEHAVIORAL|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
219591019|NCT03207737|BEHAVIORAL|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
219591020|NCT02186288|OTHER|High-flow nasal cannula oxygen|
218846894|NCT06821061|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
218846895|NCT06821061|BIOLOGICAL|Investigational COVID-19 Vaccine|Investigational COVID-19 Vaccine
218846896|NCT06821061|COMBINATION_PRODUCT|Investigational Influenza and COVID-19 Combination Vaccine|Investigational Combined Influenza and COVID-19 Vaccine
218846897|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
218846898|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
218846899|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 3|Licensed Influenza Vaccine 3
218846900|NCT06821061|BIOLOGICAL|Licensed COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
218846901|NCT06066918|DRUG|Pregabalin 75mg|Pregabalin 75 mg twice a day
218846902|NCT06828185|PROCEDURE|Radical inguinal orchiectomy|External oblique fascia will be incised during orchiectomy
218846903|NCT06828185|PROCEDURE|Radical external oblique fascia sparing orchiectomy|External oblique fascia will be spared during orchiectomy
218846904|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
218846905|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
218846906|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
218846907|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
218846908|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
218846909|NCT06929806|DRUG|Ferric Derisomaltose|100 mg/mL
218846910|NCT04028167|DRUG|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
219456318|NCT04448340|DIAGNOSTIC_TEST|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
219456319|NCT01768702|BIOLOGICAL|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
219456320|NCT01768702|BIOLOGICAL|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
219456321|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
218846911|NCT06942429|BEHAVIORAL|Internet-delivered cognitive-behavioral therapy|Internet-delivered cognitive behavioral therapy (ICBT) is a 12-module intervention delivered over a maximum of 14 weeks. Two age-specific versions are available: \[1\] for children aged 8-12 years and \[2\] for adolescents aged 13-17 years. Both versions share the same core content, but the texts, illustrations, videos, and exercises are adapted to be developmentally appropriate. Each version focuses on exposure, along with psychoeducation, coping strategies, and relapse prevention. Caregivers have access to a parallel program that mirrors the structure of the youth program. Both patients and caregivers engage with a therapist through a secure digital platform, communicating via text messages similar to emails. Two scheduled telephone or videoconference calls are conducted approximately 3-4 and 7-8 weeks into treatment, respectively, to follow up on adherence and address questions related to the intervention. Additional telephone support will be available on demand.
219018457|NCT06032533|DEVICE|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
219456322|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
219456323|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
219456324|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
219591021|NCT05810688|OTHER|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
219591022|NCT03150407|DEVICE|VR101 Device (Efficacy)|Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
219591023|NCT03150407|OTHER|Sham Control Ring|Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
219591024|NCT03150407|DEVICE|VR101 Device (Safety)|Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
219591025|NCT02975778|DEVICE|Pain Monitor™|Pain measured by Pain Monitor™
219591026|NCT05950178|DIAGNOSTIC_TEST|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
219591027|NCT01165528|PROCEDURE|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
219591028|NCT05373628|DIAGNOSTIC_TEST|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
219591029|NCT00423371|DEVICE|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
219591030|NCT00423371|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
219591031|NCT03108378|PROCEDURE|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
219591032|NCT03369197|DEVICE|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
219591033|NCT03369197|DEVICE|Control: Nasal Cannula|Nasal cannula as per usual care
219591034|NCT03421730|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
219591035|NCT03421730|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
219591036|NCT03847298|OTHER|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
219591037|NCT00311324|BEHAVIORAL|Special Intervention|
219591038|NCT00311324|BEHAVIORAL|Delayed Intervention|
219591039|NCT00118534|BEHAVIORAL|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
219591040|NCT00118534|BEHAVIORAL|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
219591041|NCT00961402|BEHAVIORAL|Wellness Control|6-month wellness control
219456325|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
219591042|NCT00961402|BEHAVIORAL|Exercise Intervention|6 month exercise intervention
219018464|NCT02955485|OTHER|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
219456326|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
219456327|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
218846912|NCT06942429|BEHAVIORAL|Personalized in-person cognitive-behavioral therapy|Personalized in-person cognitive-behavioral therapy (CBT) follows a manual drawing on previously published protocols and meta-analyses on effective components of CBT for pediatric anxiety disorders and results from our pilot study. It consists of 12 weekly one-hour sessions delivered over a maximum of 14 weeks. It follows a disorder-specific CBT approach, with a strong emphasis on therapist-led exposure tailored to the patient's principal anxiety disorder. Participants receive workbooks containing information on anxiety disorders, the treatment rationale, and the rationale for exposure therapy. The intervention has three phases: \[1\] 1-2 sessions of psychoeducation and symptom identification, \[2\] 8-10 sessions of therapist-led exposure with homework, and \[3\] 1-2 sessions of relapse prevention planning. Caregiver involvement is tailored to the individual needs of each participant, with a maximum of 2 additional hours allocated for caregivers beyond the standard treatment time.
218846913|NCT06943781|DIAGNOSTIC_TEST|Fecal Helicobacter pylori gastric cancer susceptibility gene test|In the early stage of the study, the team used genome-wide association analysis (GWAS) to identify H. pylori specific SNP that are significantly associated with gastric cancer in gastric cancer patients and controls; according to the mutation or not of the SNP loci, the strains were categorized into the high-risk group of gastric cancer (mutated group) and the low-risk group (un-mutated group). The mutation status of the SNP locus was detected in portable and non-invasive fecal samples from patients using molecular biology assays for early non-invasive screening and risk assessment of gastric cancer in H. pylori infected patients.
218846914|NCT06943794|DRUG|recommendations for eradication treatment|"A high-risk Hp subtype guidance group consisting of the receiving physician + trial-related personnel conducts individualized assessment based on Hp infection, SNP test results, gastric mucosa condition, medical history and other factors, and provides subjects with medical explanations and recommendations for eradication treatment.~Eradication group protocol: standard quadruple therapy for H. pylori eradication program (PPI + bismuth + two antibiotics)~1. Omeprazole (or esomeprazole): 20mg, 2 times/day~2. Bismuth citrate: 220mg, 2 times/day~3. Metronidazole: 400mg, 3 times/day~4. Tetracycline: 500mg, 3 times/day~5. Treatment cycle: 10-14 days Eradication success was assessed after 1 month by urea breath test (UBT) or Hp fecal antigen test."
218846915|NCT06943768|DIAGNOSTIC_TEST|fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing|To establish an early diagnostic test system for gastric cancer based on the methylation site detection technology in feces, with or without the combination of Helicobacter pylori gastric cancer susceptibility gene detection, and then to evaluate the clinical diagnostic value of this test system.
218846916|NCT06950125|OTHER|Placebo|Bottle of 15 mL liquid (non-effective product) will be taken once a day for 12 weeks.
218846917|NCT06950125|OTHER|JUICE HA® supplement|Bottle of 15 mL JUICE HA® supplement will be taken once a day for 12 weeks.
218846918|NCT06949657|OTHER|the conventional treatment group|Patients received conventional mental health education once weekly for 6 weeks, covering schizophrenia symptoms, treatment, and prognosis. Standard nursing care and antipsychotic medications (e.g., olanzapine, quetiapine) were maintained without additional psychological interventions.
219197069|NCT06855693|BEHAVIORAL|Delivering better oral health: an evidence-based toolkit for prevention|"The PHE Delivering Better Oral Health toolkit has been developed with the support of the 4 UK Chief Dental Officers. This is a general population approach to Oral Hygiene advice and includes the following:~Effective toothbrushing with a fluoride toothpaste is important to support oral health. The physical action of brushing removes plaque, which prevents gingivitis and periodontitis, and the fluoride in toothpaste is effective against tooth decay. The following key messages for the population include when and how to brush, specific habits associated with brushing, and, where necessary, assistance with brushing. There may be adaptations of toothbrushes, such as special grip handles, that are helpful to people who have limited manual dexterity."
219197070|NCT06855693|BEHAVIORAL|Mini Mouth Care Matters guide for special Education Settings|"2\. Oral hygiene guidance from a Clinical standard for autistic children and young people and/or those with a learning disability in special educational settings (Mini Mouth Care Matters Special Education Settings resources.~This is a specific approach to providing Oral Hygiene for children with sensory challenges.~This clinical standard supports the vision of universal access whereby everyone receives quality health services that meet their specific needs.~The clinical standard is designed to be used by all those involved in improving health outcomes and quality of life, including eating, speaking and socialising, for autistic children and young people, and those with a learning disability in England.~It is accompanied by a supporting package of tools, resources, and modules to support the delivery of the oral healthcare assessment (either face to face or remote) and to support teams in the development of complementary tailored mouthcare plans."
219197071|NCT06856824|PROCEDURE|injection in the bicipital groove guided by anatomic landmarks|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
219456328|NCT02034539|DEVICE|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
219456329|NCT05956990|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
219456330|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
219456331|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
219456332|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
219456333|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
219456334|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
219456335|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
219456336|NCT02227290|DRUG|Naftin Cream|
218846919|NCT06949657|OTHER|the ACT group|"Patients received ACT-based nursing interventions tailored to risk factors (e.g., age ≥70, long disease duration), including:~ACT modules: Acceptance, cognitive defusion, mindfulness, values clarification, and committed action.~Adjunct strategies: Family therapy, Tai Chi, and crisis planning. Frequency: Daily practice + 1-2 group sessions/week for 6 weeks. Goal: Enhance psychological flexibility, reduce stigma, and improve cognitive function."
218846920|NCT06947928|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
218846921|NCT06947928|DRUG|Placebo|"Route of Administration:~• Intralesional"
218846922|NCT06947928|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpoint inhibitor)~Route of administration:~• Intravenous (IV) infusion"
218846923|NCT06950775|OTHER|Residence in Agrihood Neighborhood|We are examining the effects of individuals who move into an agrihood neighborhood.
218846924|NCT06954584|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 15 months
218846925|NCT06954584|DRUG|Fluzoparib Monotherapy|150 mg orally bid (50 mg/capsule, 3 capsules/dose)
218846926|NCT06954584|BEHAVIORAL|Dietary Intervention|Control carbohydrate intake in the daily diet
218846927|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
218846928|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
218846929|NCT06525896|DEVICE|NSSD|A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
218846930|NCT06525896|DEVICE|Sham NSSD|A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
219018466|NCT05212012|DRUG|Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)|Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
219197072|NCT06856824|PROCEDURE|injection in the bicipital groove guided by ultrasound|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
219456337|NCT02227290|DRUG|Placebo Cream|
219456338|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
219591043|NCT02901548|DRUG|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
219591044|NCT02901548|PROCEDURE|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
218846931|NCT06518655|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
218846932|NCT06470204|DRUG|Ropivacaine|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)
218846933|NCT06470204|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
218846934|NCT05945732|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
218846935|NCT06052878|OTHER|"Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)"|"The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions."
218846936|NCT06052878|OTHER|Parental questionnaire about their child's cognitive functioning in their daily life and medical history.|Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.
218846937|NCT00790868|DRUG|d-cycloserine|50mg
218846938|NCT00790868|DRUG|placebo|50mg
218846939|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
218846940|NCT02179736|DEVICE|Restylane|
218846941|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
218846942|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
219591045|NCT02942030|OTHER|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
219591046|NCT02882308|DRUG|Olaparib|50/25 mg BD split x 5 days
219591047|NCT02882308|DRUG|Cisplatin|60 mg/m\^2 d1-d5
219591048|NCT02882308|DRUG|Olaparib|300 mg BD x 21-28 days.
219591049|NCT02882308|DRUG|Durvalumab|1500 mg d1
218846943|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
219456339|NCT03113799|DEVICE|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
219456340|NCT02523742|DEVICE|IMRf|
219456341|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
219456342|NCT04337528|OTHER|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
219456343|NCT04337528|OTHER|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
219456344|NCT04337528|OTHER|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
219456345|NCT02149628|DRUG|propofol|
219456346|NCT02149628|DRUG|Desflurane|
219456347|NCT03708029|OTHER|Revita Allograft|Human placental allograft
219456348|NCT00688389|OTHER|case/control|case: infected dengue fever people control:healthy people
219456349|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
219456350|NCT01660529|BIOLOGICAL|hTERT|
219456351|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
219456352|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
219456353|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
219456354|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
219456355|NCT03035058|DRUG|Vedolizumab|Vedolizumab intravenous infusion
219456356|NCT03035058|DRUG|Placebo|Placebo
219456357|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
219456358|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
219456359|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
219456360|NCT02005718|DRUG|Cholecalciferol|
219456361|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
219456362|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
219591050|NCT02113618|BEHAVIORAL|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
219591051|NCT02113618|BEHAVIORAL|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
219456363|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
219456364|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
219456365|NCT02685839|OTHER|general physical therapy|
218846944|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
219456366|NCT06256094|DIETARY_SUPPLEMENT|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
218846945|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
219456367|NCT06256094|DIETARY_SUPPLEMENT|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
219456368|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
218846946|NCT02359357|DRUG|FDL169|
218846947|NCT02359357|DRUG|Placebo|
218846948|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
219456369|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219456370|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
219456371|NCT02161224|DRUG|FG-4592|Oral
219456372|NCT02438670|DEVICE|PID control algorithm|
219456373|NCT02438670|DEVICE|MPC control algorithm|
219456374|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
219456375|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
219456376|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
219456377|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
219591052|NCT03897985|DEVICE|Narcotrend TM|Measurement of anesthesia depth
219591053|NCT02976285|PROCEDURE|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
218846949|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
218846950|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
218846951|NCT04022785|DRUG|Azacitidine|Given IV or SC
218846952|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
218846953|NCT06357871|OTHER|No intervention|No intervention
218846954|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
218846955|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
219456378|NCT01814228|PROCEDURE|transcatheter ablation of ganglionated plexi in right atrium|
219456379|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
219456380|NCT00005054|DRUG|temozolomide|
218846956|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
218846957|NCT01845584|DRUG|NPB-01|
218846958|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
218846959|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
218846960|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
218846961|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
218846962|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
218846963|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
218846964|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
218846965|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
218846966|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
218846967|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
218846968|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
218846969|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
218846970|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
218846971|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
218846972|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
218846973|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
218846974|NCT05519501|PROCEDURE|Standard of Care|Offloading
218846975|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
219591054|NCT01955083|DEVICE|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
218846976|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
219591055|NCT01955083|DEVICE|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
219591056|NCT04833530|DIAGNOSTIC_TEST|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
219591057|NCT00693043|DRUG|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
218846977|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
218846978|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
219456381|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
219456382|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
219456383|NCT02993783|DRUG|Vedolizumab|Vedolizumab IV infusion
219456384|NCT02117492|PROCEDURE|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
219456385|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
219456386|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
219456387|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
219456388|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
219456389|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
219456390|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
219456391|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
219456392|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
219456393|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
219456394|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
219456395|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
219456396|NCT01371799|DRUG|Drug|Placebo
219456397|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
219456398|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
219456399|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
219456400|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
219456401|NCT01393561|DRUG|Group 2|Placebo
219456402|NCT01987609|DRUG|Hylenex|
219456403|NCT01987609|DRUG|Normal Saline|
219456404|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
219456405|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
219456406|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
219456407|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
219456408|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
219456409|NCT01774838|DRUG|Prasugrel|3 months treatment
219456410|NCT01774838|DRUG|Clopidogrel|3 months treatment
219456411|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
219456412|NCT04737551|OTHER|Follow-up only|Only routine follow-up but no treatment
218846979|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
218846980|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
218846981|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
218846982|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
218846983|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
219456413|NCT04737551|DRUG|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
219456414|NCT04737551|RADIATION|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
218846984|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
218846985|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
218846986|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
218846987|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
219456415|NCT04737551|RADIATION|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
219456416|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
218846988|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
218846989|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
218846990|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
218846991|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
219018467|NCT06386133|DEVICE|MS Boost|remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision
219018468|NCT06386133|OTHER|Standard of care|General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
219456417|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
219456418|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
219456419|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
219456420|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
219456421|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
218846992|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
218846993|NCT06442358|DEVICE|Pulsenmore ES home ultrasound device|Pulsenmore ES device is a portable home used ultrasound device which allow the patient to perform an ultrasound scan from the comfort of their home under the supervision of a healthcare provider
219456422|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
219456423|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
219456424|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
219456425|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
219456426|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
219456427|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
218846994|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
218846995|NCT04753658|DRUG|lorlatinib|Oral
218846996|NCT03900949|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
218846997|NCT03900949|DRUG|Cytarabine|Given IV
218846998|NCT03900949|DRUG|Daunorubicin Hydrochloride|Given IV
218846999|NCT03900949|DRUG|Gemtuzumab Ozogamicin|Given IV
218847000|NCT03900949|DRUG|Midostaurin|Given PO
218847001|NCT05888467|OTHER|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
218847002|NCT05888467|OTHER|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
219456428|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
219456429|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
219456430|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
219456431|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
219456432|NCT02709889|DRUG|Rovalpituzumab tesirine|
219456433|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
219456434|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
218847003|NCT05888467|OTHER|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
218847004|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
218847005|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
218847006|NCT05515588|DRUG|BI 690517|BI 690517
218847007|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
219456435|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
219456436|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
219456437|NCT01729481|DRUG|Erlotinib|100mg, once per day
218847008|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
218847009|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
219456438|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
219456439|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
218847010|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
218847011|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
218847012|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
219456440|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
219456441|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
219456442|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
219456443|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
219018481|NCT06274801|DRUG|Seralutinib|Capsule containing seralutinib
219018482|NCT06274801|DEVICE|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
219018483|NCT02014883|DRUG|GLUT1 DS|
219456444|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
219456445|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
219456446|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
219456447|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
219456448|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
219456449|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
219456450|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
219456451|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
218847013|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
218847014|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
218847015|NCT05949970|PROCEDURE|Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.
218847016|NCT06528418|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
218847017|NCT00113204|DRUG|IPI-504|
218847018|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
218847019|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
218847020|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
218847021|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
218847022|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
218847023|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
218847024|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
219456452|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
219456453|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
219456454|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
218847025|NCT00002705|DRUG|topotecan hydrochloride|
218847026|NCT00306293|DRUG|valacyclovir|valacyclovir
219456455|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
219456456|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
219456457|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
219456458|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
219456459|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
219456460|NCT01711359|DRUG|Baricitinib|Administered orally
219456461|NCT01711359|DRUG|Methotrexate|Administered orally
219456462|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
219456463|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
219591058|NCT06571513|BEHAVIORAL|Written Exposure Therapy|During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
219591059|NCT06571513|BEHAVIORAL|Unemotional Writing|During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
218847027|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
218847028|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
218847029|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
219456464|NCT01711359|DRUG|Folic Acid|Administered orally every day
219456465|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
219456466|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
219456467|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
219456468|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
219456469|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
219456470|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
219456471|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
219456472|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
218847030|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
218847031|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
218847032|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
218847033|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
218847034|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
218847035|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
219456473|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
219456474|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
219456475|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
219456476|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
219456477|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
218847036|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
218847037|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
218847038|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
218847039|NCT04543266|PROCEDURE|Surgery|Resection of tumors
218847040|NCT01120236|DRUG|Bicalutamide|Given PO
218847041|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
218847042|NCT01120236|DRUG|Goserelin Acetate|Given SC
218847043|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
218847044|NCT01120236|DRUG|Leuprolide Acetate|Given IM
218847045|NCT01120236|OTHER|Pharmacological Study|Correlative studies
219456478|NCT00795717|DRUG|Placebo|2 capsules given twice daily
219456479|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
218847046|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
218847047|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
218847048|NCT00606541|DRUG|Placebo|Placebo
218847049|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
219456480|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
218847050|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
219591060|NCT04574440|DEVICE|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
219591061|NCT05523791|DIETARY_SUPPLEMENT|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
219591062|NCT05523791|DIETARY_SUPPLEMENT|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
219591063|NCT02763826|DEVICE|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
219591064|NCT01233739|DRUG|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
219591065|NCT01233739|DRUG|Placebo|Administration of 2 capsules of placebo orally.
219591066|NCT01272492|OTHER|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
218847051|NCT00372372|DRUG|risedronate|
218847052|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
218847053|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
218847054|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
218847055|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
218847056|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
218847057|NCT00116701|DRUG|Aranesp®|
218847058|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
219018503|NCT05655858|OTHER|Management of allergic rhinitis|Collection of patient data in real-life
218847059|NCT01044745|DRUG|rituximab|Given IV
218847060|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
218847061|NCT01044745|DRUG|tacrolimus|Given IV
218847062|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
218847063|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
218847064|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
218847065|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
218847066|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
218847067|NCT01044745|DRUG|fludarabine phosphate|Given IV
218847068|NCT01044745|DRUG|busulfan|Given IV
218847069|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
219456481|NCT01477073|DRUG|FSH-GEX™|
219456482|NCT01477073|DRUG|recombinant FSH|
219456483|NCT01477073|DRUG|urinary FSH|
219456484|NCT01477073|DRUG|Placebo|
219456485|NCT01800162|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
218847070|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
218847071|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
218847072|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
218847073|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
218847074|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
218847075|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
219456486|NCT01800162|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
219456487|NCT01800162|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
219456488|NCT04481711|PROCEDURE|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
219456489|NCT06722781|BEHAVIORAL|Unified Protocol|The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.
219456490|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
218847076|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
218847077|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
218847078|NCT06488170|DRUG|Tildrakizumab|As provided in real world clinical practice.
218847079|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
219018506|NCT06973187|DRUG|BGB-16673|BGB-16673 will be administered orally
219018507|NCT06973187|DRUG|Pirtobrutinib|Pirtobrutinib will be administered orally
219456491|NCT07043868|DEVICE|Low Level Laser Therapy|Painless, non-invasive treatment
218847080|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
218847081|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
218847082|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
218847083|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
218847084|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
218847085|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
218847086|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
218847087|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
218847088|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
218847089|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
218847090|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
218847091|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
218847092|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
218847093|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
219456492|NCT07046676|DRUG|sodium valproate|All three groups are administered twice a day via oral administration. Patients are given different doses based on their body weight and the therapeutic effect in controlling epilepsy.
218847094|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
219456493|NCT02985684|DEVICE|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
219456494|NCT04140474|DEVICE|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
218847095|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
218847096|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
218847097|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
218847098|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
218847099|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
218847100|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
218847101|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
219456495|NCT07052591|BEHAVIORAL|Zumba Exercise|Participants in the Zumba Exercise group engaged in supervised aerobic dance sessions lasting 60 minutes, twice per week, over an 8-week period. The exercise intensity was set to match aerobic-level activity suitable for improving body composition, muscle strength, and balance. Sessions included warm-up, main Zumba dance routines, and cool-down phases, all conducted by certified instructors.
219456496|NCT07052591|OTHER|Control Group|Participants in this arm did not receive any structured exercise intervention. They continued their usual daily activities throughout the 8-week study period. No physical training or behavioral program was applied.
219456497|NCT07052656|OTHER|Observational study, participants are not assigned an intervention as part of the study.|Observational study, participants are not assigned an intervention as part of the study.
219456498|NCT07052656|OTHER|Transport modality|Transfer modality to tertiary centers
218847102|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
219456499|NCT07053397|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs).~It has a wide range of use for postoperative pain management in trauma surgery, cardiac surgery, thoracic surgery and breast surgery."
219456500|NCT07053397|PROCEDURE|DSAPB|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs). Following hydrodissection between the serratus anterior and intercostal muscles, a single-shot injection is administered. Subsequently, a peripheral nerve block catheter is placed in the same region under ultrasound guidance."
219456501|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Patients with Rheumatoid Arthritis|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. Both the prevalence of osteosarcopenia and the subgroups of sarcopenia will be compared with the healthy control group. Through this comparison, we will explain the relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the changes in fall and fracture risk using various questionnaires and tests.
219456502|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Healthy Control Group|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. The relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the risk of falls and fractures will be evaluated using various questionnaires and tests.
219591067|NCT05015283|PROCEDURE|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
219591068|NCT05015283|PROCEDURE|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
218847103|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
218847104|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
218847105|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
218847106|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
218847107|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
218847108|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
218847109|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
219018515|NCT06972979|BEHAVIORAL|Text Message Gamification and Remote Support|Participants in the intervention arm consists of several components: (I) medication check-ins with the ability to set the time(s) for daily medication reminders, (II) a gamification experience to drive behavior change, (III) ability to identify a support partner who receives weekly updates on the patient's game status; (IV) access to an RN team for clinical questions and care coordination, and (V) patients' providers can see real-time progress within an electronic health record (EHR) integrated application.
218847110|NCT02759107|DRUG|Tirzepatide|Administered SC
218847111|NCT02759107|DRUG|Placebo|Administered SC
218847112|NCT02759107|DRUG|Dulaglutide|Administered SC
218847113|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
218847114|NCT02104596|DEVICE|Xylitol|
218847115|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
218847116|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
219456503|NCT07058181|BEHAVIORAL|Meaning-centered intervention for individuals who tend to feel down or anxious|"Meaning-centered intervention for internalizing symptoms adapted from the intervention Meaning-centered intervention for youth worrying about their weight and shape.~* Six 1-hour individual online sessions, approximately every 4 days~* Sessions led by a certified trainer based on intervention manual~* Four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* Participants follow intervention using intervention workbook~* Homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
219456504|NCT07058610|DEVICE|Amplifi Vein Dilation System|An investigational extracorporeal blood pump and catheter system designed to promote vein dilation prior to AVF creation.
219456505|NCT07059416|BEHAVIORAL|Oncology nurses carried out hand hygiene awareness activities with positive affirmation words and breathing exercises while washing hands or providing hand hygiene with hand antiseptic.|positive affirmation, focus on the moment
219591069|NCT05980689|DRUG|AK104|During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.
219591070|NCT05980689|DRUG|Capecitabine|During neo-CRT: 825mg/m2 bid Monday-Friday per week
218847117|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
218847118|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
218847119|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
218847120|NCT00000273|DRUG|opiates|prescription opioids
218847121|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
218847122|NCT04861467|DRUG|Camrelizumab|IV
218847123|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
218847124|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
218847125|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
218847126|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
218847127|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
218847128|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
218847129|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
218847130|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
218847131|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
218847132|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
219591071|NCT05980689|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
218847133|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
218847134|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
219591072|NCT02871492|DRUG|Pritelivir 5% w/w ointment|
219591073|NCT02871492|DRUG|Pritelivir ointment matching placebo|
218847135|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
219591074|NCT02871492|DRUG|Zovirax® cream|
219591075|NCT06173141|OTHER|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
219591076|NCT06173141|OTHER|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
219591077|NCT06173141|OTHER|hemodialysis sessions only|hemodialysis sessions only
219591078|NCT02256436|BIOLOGICAL|pembrolizumab|IV infusion
219456506|NCT07058389|OTHER|8-week outdoor physical activity program|"EXT group will perform aerobic and resistance exercises with a coach in adapted physical activities on a green environment in a parc.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) EXR group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
219456507|NCT07058389|OTHER|8-week indoor physical activity program|"INT group will perform aerobic and resistance exercises with a coach in adapted physical activities, inside a conventional gym.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) INT group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
219456508|NCT07059390|BEHAVIORAL|Nature Immersion Therapy|During the length of inpatient stay at Changi General Hospital (CGH), which ranges from 5 to 10 days, the patients and caregivers will be enrolled for a set of 3 nature-based sessions. Each session will be conducted in groups of 4 to 6 patients incorporating a relational multi-sensory experience as well as mind-body connectedness while spending time in nature. Each of the 3 sessions will be 45 minutes each. The nature-based therapy/green social prescription plan will be conducted in groups guided by a trained CGH staff (Allied Health Professionals/Nurse). This Green social prescribing plan (Playbook) will be integrated into inpatient's care plan. Caregivers of the enrolled patients will also be part of the therapy group following the necessary consent.
219456509|NCT07058012|DRUG|Cemiplimab|Cemiplimab 350mg intravenously
219456510|NCT07058012|DRUG|cemiplimab plus fianlimab|Cemiplimab 350mg + Fianlimab 1600mg intravenously
219456511|NCT07058012|DRUG|cemiplimab + REGN7075|Cemiplimab 350mg + REGN7075 2700mg intravenously
219456512|NCT07058012|OTHER|ctDNA testing|Eligible patients using results for ctDNA-positivity as obtained from a commercial assay run in any CLIA-certified lab will proceed to enrollment and begin treatment. All patients will have confirmation of ctDNA-positivity via the Signatera\^TM assay (Clinical Trial Assay), but treatment may proceed while awaiting confirmatory results.
219456513|NCT07057804|DIAGNOSTIC_TEST|Lung Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Lung ultrasound was conducted across 12 zones (anterior and posterior) to evaluate aeration and calculate the lung ultrasound score (LUS).
219456514|NCT07057804|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Diaphragmatic excursion and thickening fraction were measured on the right hemidiaphragm.
219456515|NCT07058142|BEHAVIORAL|Interaction Standard Theory-Based Multi-Care Program|A comprehensive nursing program based on King's Theory of Goal Attainment and Satir's model, focusing on structured nurse-patient communication, shared goal-setting, and multi-dimensional care addressing cognitive, psychological, behavioral, and dietary aspects. Delivered daily during hospitalization (30-45 min sessions) with post-discharge follow-up.
219456516|NCT07058142|BEHAVIORAL|Conventional Nursing Intervention|Standard hospital protocol for postpartum hemorrhage management including physiological monitoring, emergency measures as needed, and basic postpartum care education.
219456517|NCT07057713|PROCEDURE|Total Arterial Grafting|Coronary artery bypass grafting using only arterial conduits in the left coronary artery system. The left internal thoracic artery (LITA) is grafted to the LAD, and the radial artery is anastomosed to the obtuse marginal or diagonal branches. This approach avoids the use of saphenous vein grafts for the left coronary system.
219456518|NCT07057713|PROCEDURE|Conventional Mixed Grafting|A standard coronary artery bypass grafting (CABG) procedure where the left internal thoracic artery (LITA) is grafted to the LAD, and saphenous vein grafts are used for the obtuse marginal or diagonal branches of the left coronary system. This approach represents the conventional mixed arterial-venous strategy.
219591079|NCT02256436|DRUG|paclitaxel|IV infusion
219591080|NCT02256436|DRUG|vinflunine|IV infusion
219591081|NCT02256436|DRUG|docetaxel|IV infusion
219197073|NCT06857162|BEHAVIORAL|Positioninng during Cs|"1. Group A (N=72): Immediate Supine Position (Control):~   Immediately after administering spinal anesthesia, participants will be placed in a supine position. To reduce the risk of aortocaval compression, a slight left lateral tilt (approximately 15 degrees) will be applied. This is the traditional positioning method and serves as the control group for comparison.~2. Group В (N=72): Sitting Position:~   After spinal anesthesia, participants will be positioned in a sitting position with the ack supported at a 90-degree angle for the first 2 minutes. Knees will be bent, and feet will be supported.~3. Group С (N=72): Semi-Sitting Position:~After spinal anesthesia, participants will be positioned in a semi-sitting position with the back supported at the back supported at for the first 2 minutes.~Similar to the sitting position, knees and feet will be flat."
218847136|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
218847137|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
218847138|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
219197074|NCT06862180|OTHER|Meal replacement therapy|A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving
219591082|NCT01564264|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
219591083|NCT03583086|DRUG|Vorolanib|Given by mouth
219591084|NCT03583086|BIOLOGICAL|Nivolumab|Given by IV
219591085|NCT01696279|DRUG|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
218847139|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
219456519|NCT07058480|BEHAVIORAL|Combined MET and MFC-Based Pelvic Stabilization Training|This intervention consisted of a combination of Muscle Energy Technique (MET) for iliac and sacral dysfunctions (20 minutes per session) and myofascial chain-based pelvic stabilization training (including curl-ups, planks, and anti-rotation exercises; 30 minutes per session), targeting pelvic alignment and neuromuscular control. Sessions were conducted 3 times per week, 50 minutes per session, for 4 consecutive weeks.
218847140|NCT00182780|OTHER|Placebo|
218847141|NCT02120170|PROCEDURE|Colon polypectomy|
218847142|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
218847143|NCT02715882|DRUG|CBLB502|
218847144|NCT02715882|DRUG|Placebo|
218847145|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
218847146|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
218847147|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
218847148|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
219456520|NCT07058480|DEVICE|Interferential current therapy (ICT)|Interferential current therapy (ICT) was applied to the lumbar (lower back), sacroiliac, and iliac crest regions, 3 sessions per week, 20 minutes per session, for 4 weeks.
219456521|NCT07058480|BEHAVIORAL|Deep Friction Massage (DFM)|Deep friction massage was administered to the lumbar, sacroiliac, and iliac crest regions for 30 minutes per session, 3 sessions per week, for 4 weeks.
218847149|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
219456522|NCT07059533|OTHER|Verum|anodal transcranial direct current stimulation: 20 minutes of stimulation with 1 mA (ramp-up/ramp-down times of 8 seconds)
218847150|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
219456523|NCT07059533|OTHER|Placebo|anodal transcranial direct current stimulation with 40 seconds of stimulation delivered at the beginning of training (with 8 seconds ramp-up and 5 seconds ramp-down times)
219456524|NCT04714554|DRUG|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
219456525|NCT04714554|DRUG|Relugolix|Relugolix 120-mg tablets; oral administration.
219591086|NCT01696279|DRUG|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
218847151|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
218847152|NCT02526524|DRUG|Placebo|
218847153|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
218847154|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
218847155|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
218847156|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
218847157|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
218847158|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
218847159|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
218847160|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
218847161|NCT04371640|DRUG|Placebo|Oral solution
218847162|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
218847163|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
218847164|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
218847165|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
218847166|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
218847167|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
218847168|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
218847169|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
218847170|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
219456526|NCT04714554|DRUG|Erythromycin|Erythromycin 500-mg tablets; oral administration.
219456527|NCT05263401|DIETARY_SUPPLEMENT|3-hydroxybutyrate|Orally administered pre-meal drinks.
219456528|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
219456529|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
219456530|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
219456531|NCT07058402|PROCEDURE|Retrograde Intrarenal Surgery (RIRS) with Tip-Flexible Suction Access Sheath|Participants undergo retrograde intrarenal surgery (RIRS) using a tip-flexible suction access sheath. The procedure involves the insertion of a flexible ureteroscope through the urethra and ureter into the kidney. A novel access sheath with tip-flexible and suction capabilities is used to facilitate stone fragmentation and removal. The goal is to improve stone clearance and reduce intrarenal pressure during the procedure.
219456532|NCT07058402|PROCEDURE|Standard Percutaneous Nephrolithotomy (PCNL)|Participants undergo standard percutaneous nephrolithotomy (PCNL). The procedure involves creating a percutaneous tract into the renal collecting system under imaging guidance, followed by nephroscope insertion to fragment and extract 2-3 cm renal stones. This represents the current standard of care for large renal calculi.
219456533|NCT06843018|DRUG|Grammidin with anesthetic|Grammidin with anesthetic, a metered dose topical spray
219456534|NCT06843018|DRUG|Septolete Total|Septolete Total, lozenges 3 mg + 1 mg
219456535|NCT01749865|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
219456536|NCT07058363|OTHER|Progressive Relaxation Exercises|"Progressive Relaxation Exercises are defined as a method that provides relaxation throughout the body by voluntary, regular relaxation of large muscle groups in the human body. The main purpose of relaxation exercises is for individuals to feel the difference between tension and relaxation in the muscles and to learn to relax on their own in cases of tension."
219456538|NCT01436357|BIOLOGICAL|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
218847171|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
219456539|NCT01436357|BIOLOGICAL|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
219456540|NCT01436357|OTHER|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
219591087|NCT03258203|OTHER|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
219197075|NCT06861218|DRUG|pemetrexed|The pemetrexed is administrated by intrathecal injection with a dose of 50mg, once per week for 4 weeks, followed by every four weeks thereafter. The cerebrospinal fluid(CSF) samples are collected every 4 weeks and the cytology examination will be performed. If CSF cytology was negative, CSF cytology was tested again 1 week later. Two negative tests were considered as negative CSF cytology. If the cytology of cerebrospinal fluid was negative after 4 consecutive intrathecal injections, the intrathecal injection should be stopped. If positive, continue to give a intrathecal injection every 4 weeks until CSF cytology is negative. If CSF cytological positivity or worsening of neurological symptoms occurs again during discontinuation, or if new symptoms appear, the intrathecal injection should be resumed every 4 weeks.
218847172|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
219197076|NCT06861218|DRUG|vometinib|double dose of vometinib (160mg)
219456541|NCT06099678|BEHAVIORAL|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
219456542|NCT06099678|BEHAVIORAL|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
219456543|NCT04626050|BEHAVIORAL|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
219456544|NCT04626050|BEHAVIORAL|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
219456545|NCT04626050|BEHAVIORAL|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
219456546|NCT04626050|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
219456547|NCT06287749|BIOLOGICAL|Blood sample/Liquid Biopsy|ctDNA analysis
219456548|NCT01657227|BEHAVIORAL|Intervention to patients|"Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
219591088|NCT01881984|DRUG|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
219591089|NCT04941079|OTHER|no intervention|no intervention
218847173|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
218847174|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
218847175|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
218847176|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
218847177|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
218847178|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
218847179|NCT01657890|DRUG|isavuconazole|oral
218847180|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
218847181|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
218847182|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
218847183|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
219197077|NCT06861114|DIAGNOSTIC_TEST|Urine proteomics|Patients with hepatocellular carcinoma amenable to radical resection were included according to the inclusion exclusion criteria, and preoperative urine and postoperative urine from consecutive patients were collected at the marker time (before receiving postoperative adjuvant therapy after radical surgery for hepatocellular carcinoma) and at the longitudinal time (at the time point of 3 months after radical surgery), and the different samples were preprocessed, followed by mass spectrometry-based urinary proteomics to detect the differences in urinary proteins, and the data were recorded to compare the differences.
219456549|NCT01657227|BEHAVIORAL|Intervention to professionals|"Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
219456550|NCT01657227|OTHER|Usual care|Usual care for T2DM received in primary health care
219456551|NCT03786276|BEHAVIORAL|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
218847184|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
218847185|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
219456552|NCT03786276|BEHAVIORAL|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
219456553|NCT03786276|BEHAVIORAL|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
218847186|NCT06345482|DRUG|MHB039A|a bispecific antibody
218847187|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
218847188|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
218847189|NCT00519376|DRUG|GW642444M|drug
218847190|NCT00519376|DRUG|GW642444H|drug
218847191|NCT00519376|DRUG|placebo|
218847192|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
218847193|NCT00549263|DRUG|SB797620|
218847194|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
218847195|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
219456554|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
218847196|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
218847197|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
218847198|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
219456555|NCT01271049|OTHER|Control Food Product|Control food product
219456556|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
219456557|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
219456558|NCT05954845|OTHER|biopsies|Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
219456559|NCT00468624|DRUG|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
219456560|NCT00468624|PROCEDURE|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
218847199|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
219456561|NCT00468624|PROCEDURE|blood sampling before and after pegvisomant/placebo|
219456562|NCT00468624|PROCEDURE|arginine stimulation test after each limb|
219456563|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
219456564|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
219456565|NCT04936529|DIETARY_SUPPLEMENT|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
219456566|NCT04936529|DRUG|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
219197078|NCT06861179|DRUG|The formulation of Compound Phellinus igniarius decoction|The formulation of Compound Phellinus igniarius decoction is manufactured by Hangzhou Qianjifang Technology Co., Ltd, the composition includes Phellinus igniarius 12g, jujube 3g, wolfberry 3g, tangerine peel 1g. The dosage regimen was as follows: 4 Packs of the formulation of Compound Phellinus igniarius decoction (Phellinus igniarius Herbal Decoction Pieces) + 1 Pack of the formulation of Compound Phellinus igniarius decoction(Excipients) per day, administered twice daily throughout the entire course of radiotherapy until its completion.
218847200|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
219456567|NCT04936529|BIOLOGICAL|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
219456568|NCT07087769|BEHAVIORAL|Treadmill Walking with Split-Belt and/or Tied-Belt Conditions|Participants will walk on an instrumented treadmill under split-belt and/or tied-belt conditions depending on their walking capacity. The belt speeds will be adjusted to facilitate locomotor adaptation and evaluate propulsion symmetry.
218847201|NCT00134992|DRUG|Prednisolone acetate|
218847202|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
219456569|NCT07087769|BEHAVIORAL|Mechanical Resistance (Pelvis and/or Ankle) depending on participant's walking capacity|Participants will walk on a treadmill (Split-belt and/or Tied-belt) with backward-directed resistance applied at the pelvis, ankle, or both. The resistance is used to challenge paretic leg propulsion and assess adaptive gait responses.
218847203|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
219456570|NCT07087769|BEHAVIORAL|Sensory Feedback Training|Real-time feedback-visual, auditory, or combined-will be provided based on the propulsive force generated during split-belt and/or tied-belt treadmill walking, with or without mechanical resistance.
219591090|NCT03555383|DIAGNOSTIC_TEST|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
219591091|NCT01912378|DRUG|Oxytocin|
219591092|NCT01912378|DRUG|Placebo nasal spray|
219456571|NCT01841086|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
219456572|NCT01841086|DRUG|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
219456573|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
219591093|NCT06446258|OTHER|Manual therapy (myofascial release, soft tissue mobilization)|Soft tissue mobilization will be performed by a team of experienced manual therapists.
219591094|NCT01441947|DRUG|Cabozantinib|Given orally daily with a starting dose of 40 mg
219591095|NCT01441947|DRUG|Fulvestrant|Given intramuscularly 500 mg on Days 1 and 15 of the first 28 day cycle, then on Day 1 only each cycle after
219591096|NCT05775211|BIOLOGICAL|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
219456574|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
219456575|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
219456576|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
219197079|NCT06861803|DRUG|Letrozole tablets|The intervention in this study is ovulation induction using letrozole, an aromatase inhibitor commonly used in women with polycystic ovary syndrome (PCOS) to stimulate ovulation. Participants will receive letrozole at an initial dose of 2.5 mg/day for five days, starting on day 3 of the menstrual cycle. If ovulation is not achieved, the dose will be incrementally increased up to a maximum of 7.5 mg/day over a maximum of three cycles. Ovulation will be monitored through serial transvaginal ultrasounds to assess follicular development, and confirmed by measuring mid-luteal serum progesterone levels (\>3 ng/mL). Based on the response to letrozole, participants will be classified as either letrozole-sensitive (ovulatory) or letrozole-resistant (anovulatory) to identify potential predictors of resistance and improve individualized treatment strategies for PCOS-related infertility.
218847204|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
218847205|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
218847206|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
218847207|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
218847208|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
218847209|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
218847210|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
219456577|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
219456578|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
218847211|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
219591097|NCT06851442|DRUG|TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules|Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists.
219591098|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
218847212|NCT02537587|OTHER|Control 1|67g of control bar
218847213|NCT02537587|OTHER|Control 2|86g of control bar
219591099|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
219591100|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
218847214|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
218847215|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
218847216|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
218847217|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
218847218|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
218847219|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
218847220|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
218847221|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
218847222|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
218847223|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
218847224|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
218847225|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
218847226|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
218847227|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
219456579|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
219456580|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
219456581|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
219456582|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
219456583|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
218847228|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
218847229|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
219197080|NCT06592742|BEHAVIORAL|Pulmonary rehabilitation (alone)|The Pulmonary Rehabilitation (PR) program for the control group includes daily aerobic exercises such as treadmill walking or cycling for 20-30 minutes at moderate intensity, tailored to improve cardiovascular fitness and respiratory function. Strength training focuses on major muscle groups with resistance exercises lasting 15-20 minutes, promoting muscle strength and endurance. Airway clearance techniques are performed for 15-20 minutes daily, using methods like chest physiotherapy or positive expiratory pressure (PEP) to clear mucus from the lungs. Breathing exercises, including diaphragmatic and pursed-lip breathing, are practiced for 10-15 minutes to improve breathing efficiency. Participants also receive education on disease management and nutritional support to meet caloric needs.
219456584|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219456585|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
219456586|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
219456587|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219456588|NCT07100236|OTHER|Observational study of 29 - gene - defined HCC subtypes and immunotherapy responsiveness correlation|This is a non - interventional observational study. We will stratify patients with hepatocellular carcinoma (HCC) based on transcriptome sequencing of their tumor samples, specifically using a 29 - gene signature to classify them into different subtypes. Without interfering with patients' existing immunotherapy regimens (which are determined by clinical practice), we will retrospectively collect and analyze data on treatment responses. The goal is to explore the correlation between the 29 - gene - based HCC subtypes and responsiveness to immunotherapy, focusing on differences in outcomes like objective response rate (ORR) and progression - free survival (PFS) across subtypes. This study distinguishes itself by emphasizing observational analysis of pre - existing treatment patterns rather than implementing active interventions, aiming to provide insights into personalized immunotherapy for HCC through genetic subtyping.
219456589|NCT07102199|OTHER|Internal focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
219197081|NCT06592742|BEHAVIORAL|Intervention group (PR + PMR)|The intervention group will follow a Pulmonary Rehabilitation (PR) program combined with Progressive Muscle Relaxation (PMR). Daily aerobic exercises like treadmill walking or cycling will be performed for 20-30 minutes at moderate intensity, improving cardiovascular fitness and lung function. Strength training for major muscle groups will be included, with 15-20 minutes of resistance exercises to enhance muscle strength. Airway clearance techniques, such as chest physiotherapy or PEP, will help clear mucus from the lungs in daily 15-20 minute sessions. Breathing exercises, including diaphragmatic and pursed-lip breathing, will be practiced for 10-15 minutes to improve breathing efficiency. The PMR component involves daily 20-30 minute guided sessions to reduce stress and anxiety through muscle relaxation techniques.
219197082|NCT06596668|DRUG|bomedemstat|Oral tablet
219197083|NCT06596668|DRUG|carbamazepine|Oral extended-release capsule
218847230|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
219197084|NCT06587607|BEHAVIORAL|VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.|VA CALM is a 9 week mindfulness curriculum typically delivered at a once/week module pace in group settings during sessions that last approximately 60-90 minutes. Module topics include: Program Introduction, Why mindfulness, Perception, What Makes Something a Pleasant Experience?, Being Stuck, Getting Unstuck, Communication, Mindfulness in Daily Life, and Today is the First Dat of the Rest of Your Life.
219197085|NCT06673082|DRUG|Oral zinc supplementation|Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
219456590|NCT07102199|OTHER|External focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
219456591|NCT07102199|OTHER|Home exercises|Participants' home exercise program includes cervical and scapulothoracic stabilization exercises and self-mobilization exercises with the self-sustained natural apophyseal glide (SNAG) method.
218847231|NCT00129701|PROCEDURE|Telephone consultation|
219197086|NCT06673082|OTHER|Placebo|Oral
219197087|NCT06590870|DRUG|Fentanyl|The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
219197088|NCT06590870|DRUG|Normal saline|The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
219197089|NCT06865196|BEHAVIORAL|Positive Parenting Seminar Series|Selected Teen Triple P Positive Parenting Seminar Series Delivered Through Telehealth
219197090|NCT06863363|DRUG|PEG-rhGH Injection + Semaglutide Injection|"Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH Injection), 54 IU/9.0 mg/1.0 mL/amp.; Subcutaneous injection using pen-injector, once weekly at a dose of 2 mg per week (weeks 1-40).~Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks"
219456592|NCT02020304|DRUG|combined spinal epidural|Combined Spinal Epidural
219456593|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo posterior spinal tumor resection
218847232|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
218847233|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
219456594|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
218847234|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
219456595|NCT01308489|PROCEDURE|quality-of-life assessment|Ancillary studies
219456596|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
219456597|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
219197091|NCT06863363|DRUG|Semaglutide Injection|Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks
219197092|NCT06863896|PROCEDURE|Hartmann's reversal|Colostomy reversal with laparoscopic technique after Hartmann's procedure ( procto-sigmoidectomy with end colostomy)
219197093|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
219197094|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
219197095|NCT06219616|DIAGNOSTIC_TEST|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
219197096|NCT06767995|DEVICE|Flexible fiberoptic bronchoscopy|If Flexible Intubation Video Endoscope® (FIVE) will be used, the appropriate endotracheal tube is loaded into the bronchoscope and made ready. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started when the FFB started to pass through the patient's mouth/nose, and as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, the stopwatch was stopped and this time was recorded as the successful intubation time. The time between passing FFB through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. The endotracheal tube passage time was defined as the intubation time minus the best glottic visualization time and recorded. Complications during the procedure were recorded.
219197097|NCT06767995|DEVICE|Glidescope|If GlideScope® Titanium is to be used, a 50-60° angle is applied with the appropriate stylet, and the appropriate one from 3 pediatric blade sizes is selected according to the clinical experience of the relevant practitioner. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started as soon as the videolaryngoscope started to pass through the patient's mouth, and the stopwatch was stopped as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, and this time was recorded as the successful intubation time. The time between passing the videolaryngoscope through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. Endotracheal tube transit time was defined as intubation time minus best glottic visualization time and recorded. Complications during the procedure were recorded.
219197098|NCT05347069|DRUG|Aspirin|Aspirin 100 mg/day
219197099|NCT05347069|DRUG|No aspirin|No aspirin administered
219456598|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
219456599|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
219591101|NCT04636164|DIAGNOSTIC_TEST|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
219197100|NCT04206787|DRUG|Afatinib|drug
219197101|NCT06670196|DRUG|SKB264|4mg/kg, intravenous (IV) infusion
219197102|NCT06670196|DRUG|Osimertinib|80mg, QD
219456600|NCT07101484|DRUG|GD007 Low-dose drug group|"o Eligible patients who provide informed consent will receive:~* First exosome perfusion: 24 hours post-operatively~* Subsequent perfusions: Every 3 days (total 3 perfusions)"
219456601|NCT07101484|DRUG|GD007 Mid-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
219456602|NCT07101484|DRUG|GD007 High-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
219591102|NCT00235404|OTHER|Multicomponent treatment|Specialized care in preparing recharge to home
219591103|NCT00235404|OTHER|usual care|Usual recharge directly from hospital to home
219591104|NCT03243058|BIOLOGICAL|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
219591105|NCT03243058|OTHER|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
218847235|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
219456603|NCT07101484|DRUG|GD007 Blank Control drug Group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
219456604|NCT07100093|PROCEDURE|Drug serum levels|Ustekinumab trough levels (prior to administration of the next dose of the drug) will be determined by enzyme-linked immunoadsorption assay (ELISA) methodology.
219456605|NCT07102238|PROCEDURE|muscoloskeletal ultrasound and synovial biopsy|Use of a standardized US evaluation according with OMERACT definition and scoring system; Synovial biopsy; To identify systemic and synovial disease biomarkers in SLE patients that can predict different joint patterns, systemic manifestations and response to therapy through multi-omics technologies.
219456606|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
219456607|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
219456608|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
219456609|NCT06522438|COMBINATION_PRODUCT|Hyaluronic Acid (HA) and Octenidine gel|A thermosensitive gel with Hyaluronic Acid (HA) and Octenidine (Pocket-X®, Geistlich, Wolhusen, Switzerland) will be applied in the periodontal pockets ≥5mm immediately after the subgingival PMPR, by means of a pre-filled syringe bearing a thin plastic tip and following manufacturer's instructions.
219456610|NCT06522438|PROCEDURE|Non-surgical periodontal treatment (NSPT)|Full mouth supragingival professional mechanical plaque removal (PMPR) and subgingival PMPR at sites with PPD ≥4mm will be performed with the aid of manual and power-driven instruments under local anaesthesia.
219197103|NCT06677164|PROCEDURE|Gluteus Maximus strengthening exercise|Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks
219197104|NCT06677164|DEVICE|high-intensity laser therapy|A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
219197105|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.
219197106|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP
219456611|NCT05234463|OTHER|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
219456612|NCT00938197|DRUG|Fimasartan|Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
219456613|NCT00938197|DRUG|Amlodipine|Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
219456614|NCT00508469|DRUG|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
219456615|NCT00508469|DRUG|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
219456616|NCT00508469|DRUG|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
219456617|NCT00508469|DEVICE|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
219456618|NCT02912962|BEHAVIORAL|Self-Regulation Intervention adapted from the Alert Program ®|
219456619|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
219456620|NCT06443177|DEVICE|Sham|No electrode is placed.
219456621|NCT06953752|OTHER|Music intervention|Music group patients select preferred genres (classical/pop/rock/jazz; classical default) delivered at 50-60 dB during the procedure.
219456622|NCT06953752|OTHER|Control|Controls receive no music.
219456623|NCT06766604|OTHER|Super-GDF9 supplementation during CAPA-IVM|Group 1: donated COCs will be exposed to Super-GDF9 at 50 ng/ml in both the CAPACITATION and MATURATION culture steps.
219456624|NCT06766604|OTHER|Conventional CAPA-IVM|Group 2: The subject's remaining COCs will be cultured in the CAPA step and the IVM step without the addition of Super-GDF9 during CAPA-IVM.
219456625|NCT05421546|DIETARY_SUPPLEMENT|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
219456626|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
218847236|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
218847237|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
218847238|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
218847239|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
218847240|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
218847241|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
218847242|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
218847243|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
218847244|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
218847245|NCT01447485|DRUG|Valsartan (VAL489)|
218847246|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
219197107|NCT06677502|DRUG|Cerebrolysin|Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.
219197108|NCT06677502|OTHER|Saline Solution - IV|Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
219591106|NCT03243058|OTHER|Placebo Arm|Participants in this group will receive a placebo injection for two years.
219591107|NCT05656872|PROCEDURE|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
218847247|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
218847248|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
218847249|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
218847250|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
218847251|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
218847252|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
218847253|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
218847254|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
218847255|NCT02947178|DRUG|Bupivacaine|
218847256|NCT02947178|DRUG|Liposomal Bupivacaine|
218847257|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
218847258|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
218847259|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
218847260|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
218847261|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
218847262|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
218847263|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
218847264|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
218847265|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
218847266|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
218847267|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
218847268|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
218847269|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
218847270|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
218847271|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
218847272|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
218847273|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
218847274|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
218847275|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
218847276|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
218847277|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
218847278|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
218847279|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
218847280|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
218847281|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
218847282|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
218847283|NCT06038526|OTHER|Survey Administration|Ancillary studies
219591108|NCT05656872|PROCEDURE|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
219591109|NCT03299946|DRUG|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
219591110|NCT03299946|DRUG|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
218847284|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
218847285|NCT05250050|DRUG|Esomeprazole|20mg bid
218847286|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
218847287|NCT05250050|DRUG|Metronidazole|0.4g qid
218847288|NCT05250050|DRUG|Clarithromycin|0.5g bid
218847289|NCT05250050|DRUG|Levofloxacin|0.5g qd
218847290|NCT05250050|DRUG|Amoxicillin|1g bid
218847291|NCT05250050|DRUG|Tetracycline|0.5g qid
218847292|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
218847293|NCT00461864|PROCEDURE|ultrasound examination of the hip|
218847294|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
218847295|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
218847296|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
218847297|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
218847298|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
218847299|NCT05385887|DRUG|Placebo|Placebo tablets
218847300|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
218847301|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
218847302|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
218847303|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
218847304|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
218847305|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
218847306|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
218847307|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
218847308|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
218847309|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
218847310|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
218847311|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
218847312|NCT06837935|DEVICE|Aluminum Foil Reflector|"The hyperbilirubinemia newborns will receive phototherapy with an Aluminum Foil Reflector around an incubator. The aluminum foil reflector, sewn inside a cloth that is 30 cm long and 3 mm thick, will be hung from the three sides of the phototherapy unit. The reflector will cover the whole incubator except for the foot part to allow infant observation during treatment. While receiving phototherapy, the lights will be continuously on, except during feeding, physical examination, and blood taking. All participants will dress only in nappies and eye masks during phototherapy treatment.~Serum bilirubin will be taken every 24 hours until phototherapy can be stopped according to AAP guidelines."
218847313|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
218847314|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
218847315|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
218847316|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
218847317|NCT02172573|DRUG|Pramipexole|
219197109|NCT05557578|DRUG|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
219456627|NCT06954857|DEVICE|Cuff pressure monitor|"Participants were allocated to the experimental group and the control group using block randomization.~Experimental group: A pressure monitor was used to continuously monitor and promptly adjust the cuff pressure, seal pressure, and leakage pressure of the laryngeal mask."
219456628|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
219456629|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
219456630|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
219456631|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
219456632|NCT05186363|DRUG|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
218847318|NCT02172573|DRUG|Bromocriptine|
218847319|NCT02172573|DRUG|Placebo pramipexole|
218847320|NCT02172573|DRUG|Placebo bromocriptine|
218847321|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
218847322|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
218847323|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
218847324|NCT05294289|OTHER|Alpelisib|There was no treatment allocation. Patients administered alpelisib by prescription that were involved in Novartis' alpelisib managed access program were enrolled
218847325|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
218847326|NCT03130439|DRUG|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
218847327|NCT06157697|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.
218847328|NCT06259006|DRUG|Dexamethasone Oral|Dexamethasone suspension (1mg/ml) 20mg/m2/day (maximum dose 24mg/day) given in three divided doses
218847329|NCT06259006|DRUG|Placebo|Matching capsules taken orally three times daily for three days
218847330|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
218847331|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
218847332|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
218847333|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
218847334|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
218847335|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
218847336|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
218847337|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
218847338|NCT00634725|DRUG|capecitabine|
218847339|NCT00634725|DRUG|erlotinib hydrochloride|
218847340|NCT00634725|DRUG|gemcitabine hydrochloride|
218847341|NCT00634725|OTHER|laboratory biomarker analysis|
218847342|NCT00634725|RADIATION|radiation therapy|
218847343|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
218847344|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
218847345|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
219456633|NCT05186363|DRUG|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
219456634|NCT03109535|BEHAVIORAL|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
219456635|NCT03109535|BEHAVIORAL|Fitbit only|Users receive a Fitbit Zip to wear daily.
219456636|NCT00284726|DEVICE|Celsior Cold Storage Solution|
219591111|NCT06682546|DRUG|ET-26HCl 0.6mg/kg group|The initial dose is 0.6 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
219591112|NCT06682546|DRUG|ET-26HCl 0.8mg/kg group|The initial dose is 0.8 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
218847346|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
218847347|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
218847348|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
218847349|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
218847350|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
218847351|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
219591113|NCT06682546|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose is 0.3 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion).Infusion time was 1minute ± 5second.
219456637|NCT04794075|OTHER|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
218847352|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
218847353|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
218847354|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
219456638|NCT05315297|DEVICE|PEMF device|PEMF device wear overnight daily for four weeks
219456639|NCT05315297|DEVICE|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
219456640|NCT05949632|DRUG|INCB099280|Administered as specified in the treatment arm description
219456641|NCT05949632|DRUG|axitinib|Administered as specified in the treatment arm description
219456642|NCT05244733|BEHAVIORAL|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
219456643|NCT05244733|BEHAVIORAL|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
218847355|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
219197110|NCT06675942|DEVICE|Oscillation and Lung Expansion|The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.
219197111|NCT06675942|DEVICE|High-frequency chest wall oscillation|High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
219197112|NCT05097885|OTHER|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
219456644|NCT05524584|DRUG|Fulvestrant|Given intramuscularly
219456645|NCT05524584|DRUG|Anastrozole|Given orally
219456646|NCT05524584|DRUG|Abemaciclib|Given orally
219456647|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
219456648|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
219456649|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
219456650|NCT04362514|BEHAVIORAL|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
219456651|NCT04362514|OTHER|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
219456652|NCT01150149|BEHAVIORAL|No face touch|
219456653|NCT01150149|DEVICE|Surgical face mask|
219456654|NCT01150149|DEVICE|Surgical face mask + no face touch|
219456655|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
219456656|NCT01376115|DRUG|Nelarabine|
219456657|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
219456658|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
218847356|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
219456659|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
218847357|NCT00620256|DRUG|Latanoprost ophthalmic solution|
219456660|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
219456661|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
219456662|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
219456663|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
219456664|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
219456665|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
219456666|NCT00491062|PROCEDURE|Biopsies|
219456667|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
219591114|NCT06972030|BEHAVIORAL|Motivational interviewing|After the pre-test, motivational interviewing-based training consisting of six sessions, once a week, will be applied to the students in the experimental group. A pre-test, post-test (after 6 weeks) and control test will be applied to both groups. At the end of the training, training materials will be shared with the students.
219591115|NCT06416787|DRUG|placebo|IBI355 7.5mg/kg Q4W
219197113|NCT05117008|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
219197114|NCT04452500|DRUG|CORT108297|CORT108297- 180mg daily for 7 days
219197115|NCT04452500|DRUG|Placebo|Placebo- 180mg daily for 7 days
219456668|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
219456669|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
219456670|NCT01240629|OTHER|questionnaire administration|Correlative study
219456671|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
219456672|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
219456673|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
219456674|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
219456675|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
219456676|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
219456677|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
219456678|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
219591116|NCT06416787|DRUG|IBI355|IBI355 1mg/kg Q4W
219591117|NCT03504163|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
219591118|NCT03504163|DRUG|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
219591119|NCT06243601|BIOLOGICAL|Aloe vera Gel|A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
219591120|NCT03898908|DRUG|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
219591121|NCT03898908|DRUG|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
218847358|NCT03150004|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5."
218847359|NCT03150004|DRUG|Cladribine and Cytarabine (CLLDAC) Regimen|"* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;"
218847360|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
218847361|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
218847362|NCT01140100|DRUG|propofol|
218847363|NCT01140100|DRUG|thiopental,propofol|
219197116|NCT04987060|DEVICE|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
219197117|NCT04938609|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
219456679|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
219456680|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
219456681|NCT02879968|OTHER|Non-interventional study|
219456682|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
219197118|NCT04938609|RADIATION|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
219591122|NCT03898908|RADIATION|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
218847364|NCT03940638|OTHER|Data collection|Data collection
219197119|NCT04938609|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
219456683|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
218847365|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
219456684|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
219456685|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
219591123|NCT03898908|RADIATION|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
218847366|NCT03544476|BEHAVIORAL|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
218847367|NCT03544476|OTHER|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
218847368|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
218847369|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
218847370|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
219456686|NCT04408105|BEHAVIORAL|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
219456687|NCT04408105|BEHAVIORAL|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
219456688|NCT04408105|BEHAVIORAL|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
219456689|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
219456690|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
219456691|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
219456692|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
219456693|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
219456694|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
219456695|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
219456696|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
219456697|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
219456698|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
219456699|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
219456700|NCT06722313|DIAGNOSTIC_TEST|Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband|"1. Targeted deep sequencing for mosaicism detection for patients with suspected gonadal mosaicism, eg. Repeated similar abortion due to the same variant while the couple were tested negative for the variant in the peripheral blood.~2. Ovarian stimulation, embryo culture, biopsy and vitrification as routinely used in the IVF clinical practice.~3. Gametes and arrested embryo preservation by the embryo laboratory during embryo culture.~4. Genetic testing, including multiple displacement amplification for WGA, variant sequencing in WGA products and Infinium Chip protocol for amplified DNA and haplotype analysis"
219456701|NCT00452166|DRUG|rosiglitazone|
219456702|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
218847371|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
218847372|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
218847373|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
218847374|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
219456703|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
218847375|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
218847376|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
218847377|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
219456704|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
219456705|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
219456706|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
219456707|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
219456708|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
219456709|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
219456710|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
219456711|NCT06199193|DIETARY_SUPPLEMENT|Personalized diet|Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets
219456712|NCT06199193|DIETARY_SUPPLEMENT|Dietary counseling|Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
219456713|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
219456714|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
219456715|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
219456716|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
219456717|NCT01986166|DRUG|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
219456718|NCT01986166|DRUG|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
219456719|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
219456720|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
219456721|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
219456722|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
219456723|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
219456724|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
219456725|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
219456726|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
218847378|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
218847379|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
218847380|NCT02885740|BIOLOGICAL|Blood sample|
218847381|NCT02628431|DEVICE|Elfi tech monitor|
218847382|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
218847383|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
218847384|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
219456727|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
219591124|NCT06975085|BEHAVIORAL|Presentation of a personal breast cancer risk estimate|Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.
219591125|NCT06971783|OTHER|CT- control group|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
219591126|NCT06971783|OTHER|NP- Potassium nitrate gel|The gels will be applied to the sensitive lesions according to the experimental group and will be rubbed for 20 seconds using a microbrush, remaining on the lesions for 10 minutes.
218847385|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
218847386|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
218847387|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
218847388|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
218847389|NCT01684696|BEHAVIORAL|Virtual experience|
218847390|NCT01684696|BEHAVIORAL|Videos|
219456728|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
219456729|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
219456730|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
218847391|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
218847392|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
218847393|NCT06379802|BEHAVIORAL|Individualized physical activity and diet|Precision health
218847394|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
219456731|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
219456732|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
219456733|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
219456734|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
219456735|NCT00003855|PROCEDURE|axillary lymph node dissection|
219456736|NCT00003855|RADIATION|whole breast irradiation|
219456737|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
219456738|NCT06037863|OTHER|Best Practice|Undergo bladder filling prior to CT
219456739|NCT06037863|PROCEDURE|Computed Tomography|Undergo CT
219456740|NCT06037863|OTHER|Electronic Health Record Review|Ancillary studies
219456741|NCT06037863|PROCEDURE|Imaging Procedure|Undergo bladder emptying prior to CT
219456742|NCT06037863|OTHER|Questionnaire Administration|Ancillary studies
219456743|NCT06037863|RADIATION|Radiation Therapy|Undergo radiation therapy
218847395|NCT00022204|DRUG|pentoxifylline|
218847396|NCT00022204|PROCEDURE|quality-of-life assessment|
219018522|NCT06973928|DEVICE|Measures of jaw activity using the Jawac|At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements of jaw activity. Patients will undergo adenotonsillectomy during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires.
219591127|NCT06971783|OTHER|AO - Acmella Oleracea Extract Gel|The Acmella oleracea gel will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
218847397|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
218847398|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
218847399|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
218847400|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
218847401|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
219456744|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
219456745|NCT05366686|BEHAVIORAL|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
219456746|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
219456747|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
219456748|NCT00247052|DRUG|matching placebo|
219456749|NCT02132169|DRUG|Drug: AC-170 0.24%|
219456750|NCT02132169|DRUG|AC-170 0%|
219456751|NCT03724799|DEVICE|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
219456752|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
219456753|NCT02841254|OTHER|Non interventional study|
219456754|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
219456755|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
219456756|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
218847402|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
218847403|NCT00005841|BIOLOGICAL|MART-1 antigen|
218847404|NCT00005841|BIOLOGICAL|gp100 antigen|
218847405|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
218847406|NCT00005841|BIOLOGICAL|progenipoietin|
218847407|NCT00005841|BIOLOGICAL|tyrosinase peptide|
218847408|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
218847409|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
218847410|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
218847411|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
218847412|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
219456757|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
219456758|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
219456759|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
219456760|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
219456761|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
219456762|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
219456763|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
219456764|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
219456765|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
219456766|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
218847413|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
218847414|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
218847415|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
218847416|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
219197120|NCT04175327|DEVICE|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
219456767|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
219456768|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
219456769|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
219456770|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
219456771|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
219456772|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
219456773|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
219456774|NCT03607461|DEVICE|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
219456775|NCT03607461|COMBINATION_PRODUCT|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
219456776|NCT02267460|BIOLOGICAL|AA4500|
219456777|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
219456778|NCT02267460|PROCEDURE|Investigator Modeling|
218847417|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
218847418|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
218847419|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
218847420|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
219456779|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
219456780|NCT01621581|GENETIC|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
219456781|NCT02318082|DRUG|Interleukin-2|
219456782|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
219197121|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
219456783|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
219456784|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
219456785|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
219456786|NCT00336466|DRUG|Human recombinant erythropoietin|
219456787|NCT03231592|OTHER|CSA Group|Already included in the arm descriptions.
219456788|NCT03231592|OTHER|Enhanced Usual Care Group|Already included in the arm descriptions.
219456789|NCT05637073|DRUG|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
219456790|NCT05637073|PROCEDURE|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
219197122|NCT06609460|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
219456791|NCT05637073|OTHER|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
219456792|NCT00278967|DRUG|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
219456793|NCT00278967|DRUG|HalfLytely - Reformulation|
219456794|NCT02531919|DRUG|Sodium Bicarbonate|Given PO
219456795|NCT00443534|DRUG|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
219456796|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
219456797|NCT03362216|DRUG|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
219456798|NCT03362216|DRUG|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
219456799|NCT01773616|DRUG|Oral prednisolone|
219456800|NCT01773616|DRUG|Rituximab|
219456801|NCT01773616|DRUG|Mycophenolate mofetil|
218847421|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
218847422|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
219018529|NCT04287192|OTHER|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
219197123|NCT06609460|COMBINATION_PRODUCT|Placebo|Placebo to match
219197124|NCT04195984|DEVICE|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
219197125|NCT05531058|BEHAVIORAL|AI-driven Vaccine Communicator|The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.
219197126|NCT05531058|BEHAVIORAL|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
219197127|NCT03011034|DRUG|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
219197128|NCT03011034|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
219197129|NCT04497428|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
218847423|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
219197130|NCT04497428|OTHER|cTBS|continuous theta-burst stimulation
219456802|NCT01773616|DRUG|Methyl prednisolone|
219456803|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
219456804|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
219197131|NCT06398470|DIAGNOSTIC_TEST|NeuroSAFE procedure|Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.
219197132|NCT06398470|DIAGNOSTIC_TEST|LaserSAFE procedure|The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
219456805|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
219456806|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
219456807|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
219456808|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
218847424|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
219591128|NCT06971783|OTHER|AF - Gel of Acmella Oleracea extract associated with Fluoride.|The Acmella oleracea gel associated with fluoride will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
219591129|NCT06396858|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
218847425|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
219591130|NCT06396858|DRUG|Colchicine 0.5 MG|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
219591131|NCT06396858|DRUG|Placebo Rivaroxaban|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
219591132|NCT06396858|DRUG|Placebo Colchicine|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
219456809|NCT00364611|DRUG|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
219456810|NCT00364611|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
218847426|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
218847427|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
218847428|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
218847429|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
218847430|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
219456811|NCT00364611|DRUG|Trastuzumab|"* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
219456812|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
219018530|NCT05098665|COMBINATION_PRODUCT|Telemonitoring service|Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
218847431|NCT00059943|DRUG|docetaxel|
219456813|NCT04607291|OTHER|Survey Administration|Ancillary studies
218847432|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
219456814|NCT04765176|DEVICE|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
218847433|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
219456815|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
219591133|NCT05436028|DEVICE|Transcatheter Tricuspid Valve Intervention|"Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb).~Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement."
219591134|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
219591135|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
219591136|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
218847434|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
218847435|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
219591137|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
219591138|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
219591139|NCT04512365|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
219591140|NCT04512365|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
219591141|NCT06213233|DRUG|Placebo|Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
219456816|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
219456817|NCT02450240|BEHAVIORAL|standardized diagnostic assessment|
219456818|NCT02450240|BEHAVIORAL|self-report questionnaires|
218847436|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
218847437|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
219456819|NCT02450240|BEHAVIORAL|behavioral tasks|
219456820|NCT02450240|OTHER|physiological measurements|
219456821|NCT02450240|OTHER|structural and functional magnetic resonance imaging and EEG|
219456822|NCT02450240|OTHER|biomarker and microbiome assessments|
219456823|NCT02450240|OTHER|blood to derive induced pluripotent stem cells|
219456824|NCT02450240|OTHER|genetic and epigenetic assessments|
219456825|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
218847438|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
218847439|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
218847440|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
218847441|NCT01974557|OTHER|Exercise|
219456826|NCT04471532|BEHAVIORAL|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
219456827|NCT04191252|DIAGNOSTIC_TEST|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
218847442|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
218847443|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
219456828|NCT06399068|DRUG|CKD-387|1 Tablet
218847444|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
218847445|NCT00673205|DRUG|Placebo|
218847446|NCT02803177|BIOLOGICAL|BMC2012|
219591142|NCT06213233|DRUG|Cannabidiol|Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
219591143|NCT06338956|DRUG|LDL reduction therapy|LDL reduction therapy
219591144|NCT05830838|PROCEDURE|Computed Tomography|Undergo PET/CT
219591145|NCT05830838|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
219591146|NCT05830838|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219591147|NCT05830838|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219591148|NCT05830838|OTHER|Questionnaire Administration|Ancillary studies
219591149|NCT05830838|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219591150|NCT03221348|BIOLOGICAL|CHO-H01|Glyco-engineered anti-CD20 antibody
219591151|NCT06968533|DIAGNOSTIC_TEST|AI-ECG guided diagnosis|Participants undergo screening using the AI-ECG system. Participants identified as medium- to high-risk for LV dysfunction (LVEF \<50%) are recommended for echocardiography to confirm the diagnosis and guide subsequent management.
218847447|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
218847448|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
218847449|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
218847450|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
218847451|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
218847452|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
218847453|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
218847454|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
218847455|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
218847456|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
218847457|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
218847458|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
218847459|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
218847460|NCT04313374|DRUG|Placebo|the PCA will contain placebo
218847461|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
218847462|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
218847463|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
218847464|NCT00370760|DRUG|placebo|
218847465|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
218847466|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
219456829|NCT06399068|DRUG|D484|1 Tablet
219591152|NCT00468650|DRUG|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
218847467|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
218847468|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
218847469|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
218847470|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
218847471|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
219456830|NCT03748875|BEHAVIORAL|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
219456831|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
219591153|NCT06509477|DEVICE|Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
218847472|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
218847473|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
219018538|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
219018539|NCT05442086|BEHAVIORAL|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24-27 minutes
219018540|NCT05442086|BEHAVIORAL|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
219018541|NCT05814458|DEVICE|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
219018542|NCT05814458|DEVICE|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
219456832|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
219456833|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
218847474|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
218847475|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
218847476|NCT05291988|OTHER|Educational Intervention|Receive S2S education
219591154|NCT06509477|DEVICE|Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
218847477|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
218847478|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
218847479|NCT00262236|DRUG|Aliskiren|
218847480|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
218847481|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
218847482|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
218847483|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
218847484|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
218847485|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
218847486|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
218847487|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
219591155|NCT02639052|DRUG|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
218847488|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
218847489|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
218847490|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
218847491|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
218847492|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
218847493|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
218847494|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
218847495|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
218847496|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
218847497|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
219197133|NCT04751903|BEHAVIORAL|oral motor stimulation|Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
219197134|NCT04575883|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
219591156|NCT02639052|DRUG|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
219591157|NCT04926948|OTHER|Immunotherapy|Immunotherapy
219591158|NCT04926948|OTHER|Quality-of-Life Assessment|Ancillary studies
219591159|NCT04926948|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219591160|NCT01340326|DRUG|high dose of valsartan|comparison of different dosages of drug
219591161|NCT01340326|DRUG|usual dose of valsartan|comparison of different dosages of drug
219591162|NCT00399256|DRUG|Acetylcysteine|
219591163|NCT00399256|DRUG|Zinc|
219591164|NCT04975893|BIOLOGICAL|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
219591165|NCT04975893|OTHER|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
219591166|NCT02337296|BEHAVIORAL|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
219456834|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
219456835|NCT05466240|DRUG|AT-752|AT-752 for 5 days
218847498|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
219456836|NCT05466240|DRUG|Placebo|Placebo for 5 days
219456837|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
219456838|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
219456839|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
219456840|NCT01813630|DRUG|DA-3002|
219456841|NCT01813630|DRUG|Genotropin®|
219456842|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
219456843|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
219197135|NCT06853392|COMBINATION_PRODUCT|Demineralized freeze dried allograft with collagen sponge|Demineralized freeze dried allograft,filling 2/3 of the socket covered with collagen sponge ,six months, one time
219456844|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
218847499|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
219456845|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
219456846|NCT05993585|OTHER|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
219456847|NCT05993585|OTHER|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
219456848|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
218847500|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
218847501|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
218847502|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
219018549|NCT04370704|DRUG|INCAGN02385|INCAGN02385 administered intravenously
219018550|NCT04370704|DRUG|INCAGN02390|INCAGN02390 administered intravenously
219456849|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
219456850|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
219456851|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
219456852|NCT00154895|DRUG|intrapleural minocycline instillation|
219456853|NCT02143336|PROCEDURE|subcuticular suture|
219456854|NCT02143336|PROCEDURE|Skin staples|
219456855|NCT02355860|BEHAVIORAL|assessment|assessment
219456856|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
219456857|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
219456858|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
219456859|NCT00184366|DRUG|efalizumab|efalizumab
218847503|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
218847504|NCT02899650|OTHER|exercise|acute downhill running
218847505|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
219018551|NCT04370704|DRUG|INCMGA00012.|INCMGA00012 administered intravenously
219456860|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
219456861|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
219456862|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
219591167|NCT03065218|DRUG|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
219456863|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
218847506|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
219018552|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (low dose)|Low dose MVA strain monkeypox attenuated live vaccine
219018553|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (high dose)|High dose MVA strain monkeypox attenuated live vaccine
219456864|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
219456865|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
219456866|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
219456867|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
219591168|NCT02676362|OTHER|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
219591169|NCT01455363|PROCEDURE|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
219591170|NCT01455363|OTHER|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
218847507|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
218847508|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
218847509|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
218847510|NCT02858986|PROCEDURE|3D laparoscopy|
218847511|NCT02858986|PROCEDURE|4K laparoscopy|
218847512|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
218847513|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
218847514|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
219018554|NCT06771479|OTHER|Placebo|Vaccine excipient
219456868|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
219456869|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
219456870|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
219456871|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
219456872|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
219456873|NCT00025090|DRUG|cisplatin|
219456874|NCT00025090|DRUG|fluorouracil|
219591171|NCT01455363|OTHER|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
219591172|NCT04672486|BEHAVIORAL|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
218847515|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
218847516|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
218847517|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
218847518|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
218847519|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
218847520|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
218847521|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
218847522|NCT01220973|DRUG|atorvastatin calcium|
218847523|NCT01220973|DRUG|celecoxib|
218847524|NCT01220973|OTHER|laboratory biomarker analysis|
218847525|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
218847526|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
219018558|NCT04057872|PROCEDURE|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
218847527|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
218847528|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
218847529|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
219197136|NCT06853392|COMBINATION_PRODUCT|autogenous dentin graft with collagen sponge|autogenous mineralized dentin graft, filling 2/3 of the socket covered with collagen sponge , six months, one time
218847530|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
218847531|NCT03691844|DRUG|AMZ001|diclofenac gel
218847532|NCT03691844|DRUG|Placebo|Placebo
218847533|NCT03691844|DRUG|Comparator|diclofenac gel
218847534|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
218847535|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
219456875|NCT00025090|DRUG|mitomycin C|
219456876|NCT00025090|RADIATION|radiation therapy|
218847536|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
219456877|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
219456878|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
219456879|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
219456880|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
219591173|NCT04791423|BIOLOGICAL|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
219456881|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
219456882|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
219591174|NCT04791423|OTHER|Placebo|Saline solution
219591175|NCT03938714|PROCEDURE|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
218847537|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
218847538|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
218847539|NCT01215110|DRUG|TMC207|
218847540|NCT01215110|DRUG|Rifafour e-275 mg|
218847541|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
218847542|NCT05333666|OTHER|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
218847543|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
219456883|NCT02959736|BEHAVIORAL|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
219456884|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
219456885|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
218847544|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
218847545|NCT05501886|DRUG|Gedatolisib|Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
218847546|NCT05501886|DRUG|Palbociclib|Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
218847547|NCT05501886|DRUG|Fulvestrant|Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
218847548|NCT05501886|DRUG|Alpelisib|Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
218847549|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
219456886|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
219456887|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
219456888|NCT00478530|PROCEDURE|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
219456889|NCT00305773|DRUG|vorinostat|Given orally once daily
219456890|NCT00305773|DRUG|vorinostat|Given orally three times daily
219456891|NCT03313440|OTHER|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
219456892|NCT03313440|OTHER|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
219456893|NCT03095157|DIETARY_SUPPLEMENT|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
219456894|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
219456895|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
219591176|NCT01781741|COMBINATION_PRODUCT|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
219591177|NCT01781741|OTHER|quality-of-life assessment|Ancillary studies
219591178|NCT00732550|PROCEDURE|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
219591179|NCT00732550|PROCEDURE|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
219591180|NCT04838548|DRUG|MRG003|Administered intravenously
218847550|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
218847551|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
218847552|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
218847553|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
218847554|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
218847555|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
218847556|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
218847557|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
218847558|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
218847559|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
218847560|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
218847561|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
219456896|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
219456897|NCT00501930|DRUG|GSK189075|
219591181|NCT00128830|DRUG|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
219591182|NCT00128830|DRUG|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
218847562|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
218847563|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
219456898|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
219591183|NCT00128830|DRUG|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
219591184|NCT00128830|DRUG|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
219591185|NCT02730351|DRUG|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
219591186|NCT02730351|DRUG|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
219591187|NCT02730351|DRUG|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
218847564|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
218847565|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
218847566|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
218847567|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
218847568|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
219456899|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
219456900|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
219456901|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
219456902|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
219456903|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
219456904|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
219456905|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
219456906|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
219456907|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
219456908|NCT00073541|DRUG|EMD 72000|
218847569|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
218847570|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
218847571|NCT02791932|BEHAVIORAL|Exercise|See description above.
219197137|NCT03419052|BEHAVIORAL|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
218847572|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
218847573|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
219456909|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
219456910|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
219456911|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
219456912|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
219456913|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
219456914|NCT00409149|BEHAVIORAL|CALM Approache|
219456915|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
219456916|NCT00958230|DEVICE|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
219456917|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
219591188|NCT02730351|DRUG|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
219591189|NCT03058653|PROCEDURE|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
219591190|NCT03058653|DEVICE|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
219591191|NCT05739552|OTHER|Telerehabilitation program|Application of customised respiratory and/or motor rehabilitation exercises to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.
219591192|NCT04955535|PROCEDURE|Arthroscopic synovectomy|Arthroscopic synovectomy
219591193|NCT00063219|DRUG|MAC-321|
219591194|NCT02528513|DRUG|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
219591195|NCT02528513|DRUG|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
219591196|NCT02528513|DRUG|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
219591197|NCT02528513|DRUG|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
218847574|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
218847575|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
218847576|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
219456918|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
219456919|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
219456920|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
219197138|NCT03419052|BEHAVIORAL|MIND foods|"The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
219456921|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
219456922|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
219456923|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
219456924|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
219591198|NCT02528513|PROCEDURE|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
219591199|NCT02528513|PROCEDURE|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
219591200|NCT02528513|DRUG|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
219591201|NCT04521582|DRUG|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
219591202|NCT04521582|BEHAVIORAL|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
219591203|NCT03822065|DRUG|LY03005|80 mg oral tablet single dose
219591204|NCT04361149|DRUG|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
219591205|NCT04361149|DEVICE|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
219591206|NCT04361149|DEVICE|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
219591207|NCT04361149|OTHER|Placebo Cream|Placebo cream will be administered as a topical skin cream
219591208|NCT00838435|DRUG|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
219591209|NCT05783518|DRUG|desflurane|Intraoperative anesthesia maintenance
219591210|NCT05783518|DRUG|propofol|Intraoperative anesthesia maintenance
219591211|NCT02496936|OTHER|SFA|High saturated fatty acid/SFA oil source
219591212|NCT02496936|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
219591213|NCT02496936|OTHER|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
219591214|NCT02496936|OTHER|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
219591215|NCT02496936|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
219591216|NCT00093561|DIETARY_SUPPLEMENT|lycopene|
219591217|NCT02747550|PROCEDURE|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
218847577|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
218847578|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
218847579|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
218847580|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
218847581|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
218847582|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
218847583|NCT00813865|DRUG|afegostat tartrate|
218847584|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
218847585|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
218847586|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
218847587|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
219456925|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
219456926|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
219456927|NCT04598100|BEHAVIORAL|FOCUS-EC|
219456928|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
218847588|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
218847589|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
218847590|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
219456929|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
219456930|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
219456931|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
219456932|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
218847591|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
219456933|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
219456934|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
219456935|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
219456936|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
219456937|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
219456938|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
219456939|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
219456940|NCT03178591|DRUG|vildagliptin|
219456941|NCT03178591|DRUG|Dapagliflozin|
219456942|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
219456943|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
219456944|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
218847592|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
219018565|NCT04577755|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219018566|NCT04577755|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219018567|NCT04577755|PROCEDURE|Computed Tomography|Undergo CT
219018568|NCT04577755|DRUG|Pomalidomide|Given PO
219456945|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
219591218|NCT02747550|PROCEDURE|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
219591219|NCT05145686|DIAGNOSTIC_TEST|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
218847593|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
218847594|NCT04295681|DRUG|MMH-MAP|Oral administration
218847595|NCT04295681|DRUG|Placebo|Oral administration
219456946|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
219456947|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
218847596|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
218847597|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
218847598|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
218847599|NCT04402632|PROCEDURE|Surgical Management|SDH Evacuation (Control)
218847600|NCT04402632|DEVICE|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
218847601|NCT04402632|OTHER|No Treatment|Observation Only (Control)
218847602|NCT04402632|DEVICE|Treatment|Onyx™ LES Embolization
218847603|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
218847604|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
218847605|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
219591220|NCT04731753|DEVICE|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
219591221|NCT04571151|DRUG|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
219591222|NCT04571151|DRUG|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
218847606|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
218847607|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
218847608|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
219018569|NCT04577755|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219456948|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
219456949|NCT04686539|DRUG|Placebo|Placebo Oil
219456950|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
219591223|NCT04571151|OTHER|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
219591224|NCT02497651|DIETARY_SUPPLEMENT|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
219591225|NCT02497651|OTHER|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
218847609|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
218847610|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
219018575|NCT01499563|DRUG|ITI-007|Capsules containing ITI-007 for 28 days
219018576|NCT01499563|DRUG|Placebo|Capsules containing inactive placebo for 28 days
219018577|NCT01499563|DRUG|Risperidone|Capsules containing risperidone for 28 days
219456951|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
219456952|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
219456953|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
219456954|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
219591226|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)|Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
219591227|NCT02422589|DRUG|ceritinib|
219591228|NCT02422589|DRUG|warfarin|
219591229|NCT02422589|DRUG|midazolam|
219591230|NCT02361294|OTHER|Blood samples|
219591231|NCT05716386|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet less than 2 gram per day
219591232|NCT01135186|DRUG|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
219591233|NCT05749250|DEVICE|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
218847611|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
219456955|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
219456956|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
219456957|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
219456958|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
219456959|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
219456960|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
219456961|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
219456962|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
219456963|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
219456964|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
219456965|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
218847612|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
218847613|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
218847614|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
218847615|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
219197139|NCT03419052|BEHAVIORAL|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
219197140|NCT03419052|BEHAVIORAL|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
219197141|NCT05646680|PROCEDURE|two step adnexectomy|instead of standard resection of salpinx and ovary, they are now separately excised
219456966|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
219456967|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
219456968|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
219456969|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
219456970|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
219456971|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
219456972|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
219456973|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
219456974|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
219456975|NCT00712764|DRUG|Adenosine|
219456976|NCT00712764|DRUG|Placebo|
219456977|NCT04829591|OTHER|observational|Heart failure, non interventional
219456978|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2\. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
219456979|NCT05804071|DRUG|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
219456980|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
219456981|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
219456982|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
219591234|NCT04755933|BEHAVIORAL|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
219591235|NCT06178432|GENETIC|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
219591236|NCT03878667|DIETARY_SUPPLEMENT|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
219591237|NCT03878667|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
219591238|NCT03878667|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
218847616|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
218847617|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
218847618|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
219456983|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
219456984|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
219591239|NCT03470168|DEVICE|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
219591240|NCT03470168|DEVICE|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
219591241|NCT05670574|PROCEDURE|Surgery with extended (D3) mesenterectomy for small bowel tumors|
219591242|NCT03796039|BEHAVIORAL|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
219591243|NCT01333774|DRUG|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
219591244|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
219591245|NCT03840369|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
219591246|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
219591247|NCT05234372|BEHAVIORAL|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
219591248|NCT03728855|BEHAVIORAL|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
218847619|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
218847620|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
218847621|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
218847622|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
218847623|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
219456985|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
219456986|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
219456987|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
219591249|NCT05396261|DEVICE|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
219591250|NCT03915028|OTHER|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water"
219591251|NCT04008628|DRUG|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
218847624|NCT02450461|OTHER|no intervention|
218847625|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
218847626|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
218847627|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
219018587|NCT06975423|DEVICE|Active lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis provides real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
219018588|NCT06975423|DEVICE|Inactive lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis does not provide real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
219456988|NCT03309722|OTHER|biomarker study|
218847628|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
218847629|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
218847630|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
218847631|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
219591252|NCT03093389|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
219456989|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
219456990|NCT06292026|OTHER|standard of care|apply non adherent dressing
219456991|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
219456992|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
219456993|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
219456994|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
219456995|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
219456996|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
219456997|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
219456998|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
219591253|NCT03093389|DRUG|Placebo|Matching placebo capsules
219591254|NCT02927366|DRUG|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
219591255|NCT02927366|DRUG|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
219591256|NCT01679639|DRUG|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
219591257|NCT01679639|DRUG|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
219591258|NCT01648660|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
219591259|NCT03953989|DRUG|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
219591260|NCT05387850|OTHER|no intervention|no intervention
219591261|NCT06000943|OTHER|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
218847632|NCT00227669|DRUG|docetaxel|
218847633|NCT00227669|DRUG|gemcitabine hydrochloride|
218847634|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
218847635|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
218847636|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
218847637|NCT00054951|DRUG|MTC-DOX for Injection|
218847638|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
218847639|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
218847640|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
218847641|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
218847642|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
219591262|NCT02472223|DRUG|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
218847643|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
219456999|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
219457000|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
219457001|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
219457002|NCT02367157|PROCEDURE|Kenzo Kase Method|
218847644|NCT00192049|DRUG|Gemcitabine|
218847645|NCT00192049|DRUG|mitomycin C|
218847646|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
218847647|NCT01408550|DRUG|Placebo|Physiological saline
219457003|NCT02367157|DEVICE|Kinesio Taping|
219591263|NCT02472223|DRUG|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
219591264|NCT02969681|DRUG|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
219591265|NCT02969681|DRUG|Chemotherapy|"* mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
219018589|NCT06620289|BEHAVIORAL|Dental Desensitization Clinic|The goal of offering desensitization visits is to reduce the dental anxiety and distress of patients and enhance their cooperation during future appointments. The specifics of the desensitization are individualized to meet the unique needs of each patient based on information provided by the parent/caregiver. A standard desensitization visit involves providing the patient the opportunity to sit in the exam chair; touch the toothbrush and rubber prophy cup, mouth mirror, fluoride applicator brush, air-water syringe tip and saliva ejector tip; gain exposure to the dental lights and sounds commonly experienced in the dental visit; practice opening their mouth; and tolerate toothbrush and rubber prophy cup, mirror, explorer, fluoride applicator brush, air-water syringe, and salvia ejector in the mouth. If the child is unable or unwilling to participate, these activities are modeled on the parent or by the CCLS.
219018598|NCT06806176|BEHAVIORAL|Cognitive analytic therapy guided self-help (CAT-GSH)|Six session CAT-GSH treatment
219018599|NCT06806176|BEHAVIORAL|Cognitive behavioural therapy guided self-help (CBT-GSH)|Six session CBT-GSH treatment
219591266|NCT00855179|DRUG|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
219591267|NCT00855179|DRUG|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
219591268|NCT04699851|BEHAVIORAL|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
219591269|NCT04699851|BEHAVIORAL|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
218847648|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
218847649|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
219457004|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
219457005|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
219457006|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
219457007|NCT01520727|DRUG|Placebo|single-dose
219457008|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
219457009|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
219457010|NCT03597789|BEHAVIORAL|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
219591270|NCT02373033|OTHER|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
218847650|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
218847651|NCT03927482|BEHAVIORAL|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
219457011|NCT04145193|DRUG|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
218847652|NCT03927482|BEHAVIORAL|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
218847653|NCT05764759|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
218847654|NCT05764759|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
218847655|NCT06755034|DEVICE|c-SIMO|Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.
218847656|NCT06755034|DEVICE|m-SIMO|Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.
218847657|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
218847658|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
218847659|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
218847660|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
218847661|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
218847662|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
218847663|NCT06593184|DEVICE|Trans-spinal magnetic stimulation|Trans-spinal magnetic stimulation activates afferent spinal roots and increases cortical excitability.
218847664|NCT06593184|DEVICE|Sham Comparator|Sham trans-spinal magnetic stimulation involves masking, where the sound of stimulation persists even though no magnetic pulses are delivered
219457012|NCT04145193|DRUG|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
218847665|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
218847666|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
218847667|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
219457013|NCT04145193|DRUG|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
219457014|NCT04145193|DRUG|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
218847668|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
219457015|NCT04989140|DRUG|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
219591271|NCT02373033|OTHER|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
218847669|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
218847670|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
218847671|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
218847672|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
218847673|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
218847674|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
218847675|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
218847676|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
218847677|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
218847678|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
218847679|NCT04448392|DRUG|Valacyclovir|Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
219457016|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
219457017|NCT00440102|DRUG|Ketamine|Ketamine
219457018|NCT00440102|DRUG|Etomidate|Etomidate
219457019|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
218847680|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
218847681|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
218847682|NCT07034469|PROCEDURE|air|use of sterile air as a tamponade
218847683|NCT07034469|PROCEDURE|Gas SF6 (Sulfur Hexafluoride) and others|use of fluorinated gases such as SF6, C2F6 or C3F8 as a tamponade agent
218847684|NCT06887244|OTHER|Tele-consultation|Tele-consultation procedure is defined as a telephone consultation with the patient conducted by nursing staff with an appropriate level of experience in digestive endoscopy
219457020|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
219457021|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
219457022|NCT02777034|OTHER|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
219457023|NCT02777034|OTHER|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
219457024|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
219457025|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
219457026|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
219457027|NCT01551485|DRUG|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
219457028|NCT01551485|DRUG|Placebo|Pacebo tablet, blinded given on the first night after surgery
218847685|NCT06895369|DRUG|Pucotenlimab|patients will receive 3 cycles of pucotenlimab combined with TP (cisplatin + docetaxel) as neoadjuvant therapy, followed by standard surgical treatment
218847686|NCT06895642|OTHER|Exercise|After all of the participants perform a symptom-limited cardiopulmonary exercise test, they included a single session high intensity interval exercise created according to test results. They randomized to two gorups as video and treadmill-based or only treadmill-based high intensity interval exercise.
218847687|NCT06896409|COMBINATION_PRODUCT|PuraStat® combined with Adrenaline|PuraStat® application (mL) combined with Adrenaline injection (mL)
218847688|NCT06896409|COMBINATION_PRODUCT|Standard of Care|Adrenaline injection + second hemostasis modality (contact thermal, mechanical therapy, or injection of a sclerosing agent).
218847689|NCT06897345|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block is a regional anesthesia technique used primarily to provide pain relief for patients undergoing surgery in the abdominal region. The TAP block targets the nerves that supply sensations to the skin and muscles of the abdominal wall.
218847690|NCT06897345|PROCEDURE|rectus sheat block|The rectus sheath block is a type of regional anesthesia used primarily for pain management in the abdominal area. It involves injecting local anesthetic into the rectus sheath, which is the fibrous sheath that envelops the rectus abdominis muscle. This block targets the lower intercostal nerves as they traverse through the sheath, thereby providing analgesia to the anterior abdominal wall.
218847691|NCT06895954|DIETARY_SUPPLEMENT|Genistein|Hyperlipidemia patients take a 125mg Genistein capsule daily, once a day.
218847692|NCT06896851|OTHER|Su Jok|a type of acupressure includs hand massage
219457029|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
219457030|NCT03279146|DRUG|Tenofovir exalidex (TXL)|Oral formulations
219457031|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
219591272|NCT02373033|OTHER|Apple juice|Received apple juice containing no folate or folic acid.
219591273|NCT01337258|DRUG|Dutasteride|dutasteride 0.5mg daily.
219591274|NCT01337258|DRUG|Placebo|Men taking placebo daily
219591275|NCT06402617|PROCEDURE|Pulmonary vein isolation|Standard clinical radio-frequency ablation isolation of pulmonary veins
219591276|NCT06402617|DIAGNOSTIC_TEST|RETRO-Mapping without adjunctive ablation|RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation
219591277|NCT06402617|PROCEDURE|Adjunctive ablation guided by RETRO-Mapping|Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping
219591278|NCT01675843|PROCEDURE|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
219591279|NCT03179215|DIAGNOSTIC_TEST|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
219591280|NCT01381315|PROCEDURE|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur \<3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
219591281|NCT01381315|PROCEDURE|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is \<0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
219591282|NCT06118606|OTHER|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
219591283|NCT03735316|DRUG|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
219591284|NCT03735316|PROCEDURE|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
219591285|NCT03735316|DRUG|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
219591286|NCT03620968|OTHER|cognitive training|15 minutes day of brain training by an APP
219591287|NCT04251520|DIAGNOSTIC_TEST|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
218847693|NCT06896851|OTHER|Sham point using|unrelated point using for acupressing
218847694|NCT06762626|OTHER|Frozen embryo transfer according to endometrial receptivity analysis result|Frozen embryo transfer will be arranged according to endometrial receptivity analysis result, which will be shown in the form of P+X hours
218847695|NCT06086873|DEVICE|Implant Type|"Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)."
218847696|NCT06895395|BEHAVIORAL|High intensive combined phonetic-phonological intervention|High intensity speech intervention 5 times 30' per week for 2 times 4 weeks
218847697|NCT06895395|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|low intensity speech intervention 2 times 30' per week for 20 weeks
218847698|NCT06896721|DRUG|Preoperative sedation with dexmedetomidine was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of dexmedetomidine were administered intranasally (1-2ug/kg) with conventional open venous access
218847699|NCT06896721|DRUG|Preoperative sedation with normal saline was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of normal saline were administered intranasally (equal volume) with conventional open venous access
218847700|NCT06896864|PROCEDURE|cochlear implantation|After the surgery, patients typically undergo a period of recovery and healing. several factors including age at implantation, pre- and post-operative therapy, and parental involvement
218847701|NCT06896487|OTHER|Surface EMG Biofeedback Muscle and Relaxation Training|We think that 6 weeks of superficial EMG Biofeedback muscle training and relaxation training given to the participants in this study will improve the patient's upper trapezius activation and voluntary contraction performance.
218847702|NCT06896487|OTHER|Conventional Rehabilitation|The conventional rehabilitation group of this study received ultrasound, TENS and hot pack application 3 days a week for 6 weeks.
218847703|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
218847704|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
218847705|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
219457032|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
218847706|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
218847707|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
218847708|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
218847709|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
218847710|NCT00003783|BIOLOGICAL|filgrastim|
218847711|NCT00003783|DRUG|asparaginase|
218847712|NCT00003783|DRUG|cyclophosphamide|
218847713|NCT00003783|DRUG|cytarabine|
218847714|NCT00003783|DRUG|daunorubicin hydrochloride|
218847715|NCT00003783|DRUG|dexamethasone|
218847716|NCT00003783|DRUG|etoposide|
219457033|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
218847717|NCT00003783|DRUG|idarubicin|
219457034|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
219457035|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
219457036|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
218847718|NCT00003783|DRUG|leucovorin calcium|
219457037|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
219457038|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
218847719|NCT00003783|DRUG|mercaptopurine|
218847720|NCT00003783|DRUG|methotrexate|
218847721|NCT00003783|DRUG|prednisone|
218847722|NCT00003783|DRUG|vincristine sulfate|
218847723|NCT00003783|RADIATION|radiation therapy|
218847724|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
218847725|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
219457039|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
219457040|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
219457041|NCT02411266|OTHER|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
218847726|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
218847727|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
219018616|NCT05784480|DIAGNOSTIC_TEST|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
218847728|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
218847729|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
218847730|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
218847731|NCT00491946|DRUG|Actinomycin-D|
218847732|NCT00491946|DRUG|Vincristine|
218847733|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
218847734|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
218847735|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
218847736|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
218847737|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
218847738|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
218847739|NCT03315793|DRUG|Placebo|Administered orally
218847740|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
218847741|NCT04481061|GENETIC|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
219457042|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
219457043|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
219457044|NCT03442933|OTHER|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
219457045|NCT03442933|OTHER|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
218847742|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
219457046|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
219457047|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
219457048|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
218847743|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
218847744|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
218847745|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
218847746|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
218847747|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
218847748|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
218847749|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
218847750|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
218847751|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
218847752|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
218847753|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
218847754|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
218847755|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
218847756|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
218847757|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
219457049|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
219457050|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
219457051|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
218847758|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~\- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
218847759|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~\- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~\- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
218847760|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
218847761|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
218847762|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
218847763|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
218847764|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
218847765|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
218847766|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
218847767|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
218847768|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
218847769|NCT02524015|OTHER|Novel physical therapy|
218847770|NCT02524015|OTHER|Standard physical therapy|
218847771|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
218847772|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
218847773|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
219457052|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
219457053|NCT03087474|OTHER|Non-Interventional|Non-Interventional
218847774|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
218847775|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
218847776|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
218847777|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
218847778|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
219457054|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
219457055|NCT04220645|OTHER|Standard of care|Referral at discharge
219457056|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
219457057|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
219457058|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
219457059|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
218847779|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
219457060|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
218847780|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
218847781|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
218847782|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
218847783|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
218847784|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
218847785|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
218847786|NCT03369041|DRUG|Irinotecan-Eluting Beads|
218847787|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
218847788|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
218847789|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
218847790|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
218847791|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
218847792|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
218847793|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
218847794|NCT05209295|DRUG|Onureg|Specified dose on specified days
218847795|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
218847796|NCT04525859|BIOLOGICAL|Safety|See previous Safety group description
218847797|NCT04525859|BIOLOGICAL|Expansion Cohort|See previous Expansion Cohort
218847798|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
218847799|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
218847800|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
218847801|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
218847802|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
219457061|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
218847803|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
218847804|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
218847805|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
218847806|NCT02513290|DRUG|Bilastine|
218847807|NCT02513290|DRUG|Loratadine|
218847808|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
218847809|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
218847810|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
218847811|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
218847812|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
218847813|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
218847814|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
219457062|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
219591288|NCT04251520|OTHER|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
218847815|NCT02791191|DRUG|LY3202626|Administered orally
219591289|NCT06476951|BEHAVIORAL|Parent-Child Physical Activity Program|The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
219591290|NCT04972110|DRUG|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
218847816|NCT02791191|DRUG|Placebo|Administered orally
218847817|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
218847818|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
218847819|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
218847820|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
218847821|NCT01851486|DRUG|placebo|
218847822|NCT01851486|OTHER|saline|
218847823|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
219018626|NCT02007044|DRUG|Ibrutinib|Given PO
219018627|NCT02007044|OTHER|Quality-of-Life Assessment|Ancillary studies
219018628|NCT02007044|OTHER|Questionnaire Administration|Ancillary studies
219018629|NCT02007044|BIOLOGICAL|Rituximab|Given IV
218847824|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
218847825|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
218847826|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
218847827|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
218847828|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
218847829|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
218847830|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
218847831|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
218847832|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
218847833|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
218847834|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
218847835|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
218847836|NCT00771732|DEVICE|light therapy|6 minute light therapy
218847837|NCT00771732|DEVICE|light therapy|combination of wavelengths
218847838|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
218847839|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
218847840|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
218847841|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
218847842|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
218847843|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
218847844|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
218847845|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
219457063|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
219457064|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
219457065|NCT02169466|DRUG|Placebo|PLC, Placebo
218847846|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
218847847|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
218847848|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
218847849|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
218847850|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
218847851|NCT01777555|DRUG|CVT-301|
218847852|NCT01777555|DRUG|Placebo|
218847853|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
218847854|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
218847855|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
218847856|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
219018639|NCT05587842|PROCEDURE|Early Weightbearing management post operation|Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.
219018640|NCT05587842|PROCEDURE|Delayed Weightbearing management post operation (Traditional)|Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
219018643|NCT06419374|BIOLOGICAL|Pegozafermin|Subcutaneous injection
219018644|NCT06419374|DRUG|Placebo|Subcutaneous injection
219457066|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
219457067|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
219457068|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
218847857|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
219457069|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
219197142|NCT05045820|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
219197143|NCT05045820|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
219197144|NCT06862882|BEHAVIORAL|Community-Based Primary Health Care|Mediation between citizens and health workers to allow an orderly and appropriate use of social and health services
219197145|NCT06858852|DRUG|ET-26HCl 0.8mg/kg group|The initial dose was 0.8 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
219197146|NCT06858852|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose was 0.3 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
219197147|NCT06856642|OTHER|Conservative Physical Therapy|"Transcutaneous Electrical Nerve Stimulation (TENS):It is an electrotherapy modality commonly used in pain management. Conventional TENS will be applied to our patients. The frequency of Conventional TENS will be 50 Hz, the pulse duration will be 80 µs, the amplitude will be of mild to moderate intensity as perceived by the patient, and the duration will be 20 minutes.~Hot Pack:It is a superficial heat therapy method commonly used to reduce muscle spasms, increase circulation, and alleviate pain.The packs, which are kept in hydrocollator tanks, will be applied at a temperature that will not harm the patient.The application time is 20 minutes.~Therapeutic Ultrasound:This method, which uses sound waves to support tissue healing, creates heating and healing effects in deep tissues and is commonly used to reduce pain and relieve muscle spasmsThe frequency of the applied ultrasound will be 1 MHz, with an intensity of 1.5 W/cm², and it will be applied for 8 minutes in continuous mode"
218847858|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
218847859|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
218847860|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
218847861|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
218847862|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
218847863|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
218847864|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
218847865|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
218847866|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
218847867|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
218847868|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
218847869|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
219457070|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
218847870|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
218847871|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
218847872|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
218847873|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
218847874|NCT03831906|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
218847875|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
218847876|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
218847877|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
218847878|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
218847879|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
218847880|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
218847881|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
218847882|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
218847883|NCT01468948|DRUG|Octanoic Acid|
218847884|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
218847885|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
219457071|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
218847886|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
218847887|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
218847888|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
218847889|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
218847890|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
218847891|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
218847892|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
218847893|NCT00024024|DRUG|rebimastat|
218847894|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
218847895|NCT04140695|DRUG|Tradipitant|BID
218847896|NCT04140695|DRUG|Placebo|BID
218847897|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
218847898|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
218847899|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
218847900|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
218847901|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
219457072|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
218847902|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
218847903|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
218847904|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
218847905|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
219457073|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
218847906|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
218847907|NCT02834585|OTHER|Ultrasound|
218847908|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
218847909|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
218847910|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
218847911|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
218847912|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
218847913|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
219457074|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
219457075|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
219457076|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
218847914|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
218847915|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
219457077|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
219457078|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
219457079|NCT04576390|DRUG|Ondansetron 4 mg|Antiemetic drug
219457080|NCT04576390|DRUG|Palonosetron 75 mcg|Antiemetic drug
219457081|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
219457082|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
219457083|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
219457084|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
219457085|NCT01881724|BEHAVIORAL|Sleep education|
218847916|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
218847917|NCT01559259|DRUG|Placebo|Two caplets of placebo
218847918|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
218847919|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
218847920|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
218847921|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
218847922|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
218847923|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
219457086|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
218847924|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
218847925|NCT01530035|OTHER|physical training|training
219457087|NCT00372580|PROCEDURE|blood test|
219457088|NCT00171327|DRUG|valsartan, fluvastatin|
218847926|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
218847927|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
218847928|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
218847929|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
218847930|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
219457089|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
219457090|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
219457091|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
219457092|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
219457093|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
219457094|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
218847931|NCT00515658|DEVICE|theta-burst rTMS|
219457095|NCT05143645|OTHER|Plasma vancoymcin measurements|
219457096|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
218847932|NCT02199314|DRUG|Desflurane|
218847933|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
218847934|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
218847935|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
218847936|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
218847937|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
219457097|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
219457098|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
219457099|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
219457100|NCT03564210|BEHAVIORAL|Screen time permitted|Cohort will not be directed to abstain from screen time
219457101|NCT03564210|BEHAVIORAL|Screen Time Abstain|Cohort will be directed to abstain from screen time
219457102|NCT00436722|DRUG|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
219361253|NCT00803179|DRUG|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
218847938|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
218847939|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
219457103|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
219457104|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
219457105|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
218847940|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
218847941|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
218847942|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
219457106|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
219457107|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
219457108|NCT04241536|PROCEDURE|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
219457109|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
219457110|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
219457111|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
219457112|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
218847943|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
218847944|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
218847945|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
218847946|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
218847947|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
218847948|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
218847949|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
218847950|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
218847951|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
218847952|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
218847953|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
218847954|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
218847955|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
218847956|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
218847957|NCT00052611|DRUG|Celecoxib|
218847958|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
219018655|NCT05133427|DEVICE|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
219018656|NCT02927041|DEVICE|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
219457113|NCT00003958|DRUG|vincristine sulfate|Given IV
219457114|NCT00003958|DRUG|cyclophosphamide|Given IV
219457115|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219457116|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
218847959|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
218847960|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
218847961|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
218847962|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
218847963|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
218847964|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
218847965|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
219361254|NCT03084640|DRUG|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
218847966|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
218847967|NCT01892436|DRUG|Placebo|Placebo
218847968|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
218847969|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
218847970|NCT00461149|DRUG|Octreotide-LAR|
218847971|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
218847972|NCT00886886|DRUG|MDMA|125 mg, single dose
218847973|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
218847974|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
218847975|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
218847976|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
218847977|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
218847978|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
218847979|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
218847980|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
218847981|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
219361255|NCT03084640|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
219457117|NCT00003958|DRUG|topotecan hydrochloride|Given IV
218847982|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
218847983|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
218847984|NCT02242435|DRUG|4 mL Injection of Placebo|
219457118|NCT00003958|BIOLOGICAL|filgrastim|Given SC
219457119|NCT00003958|BIOLOGICAL|sargramostim|Given SC
219457120|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
219457121|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
219457122|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
219457123|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
219457124|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
218847985|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
219457125|NCT00688194|DRUG|fulvestrant|Given intramuscularly
219457126|NCT00688194|DRUG|lapatinib ditosylate|Given orally
219457127|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
219457128|NCT00688194|OTHER|placebo|Given orally
219457129|NCT00006037|DRUG|fluorouracil|
219457130|NCT00006037|DRUG|irinotecan hydrochloride|
219457131|NCT00006037|DRUG|oglufanide disodium|
219457132|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
219457133|NCT02983851|PROCEDURE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
219457134|NCT02983851|PROCEDURE|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
219457135|NCT02442765|DRUG|AVP-786|
219457136|NCT02442765|DRUG|Placebo|
218847986|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
218847987|NCT02402894|OTHER|no intervention|
218847988|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
219457137|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
219457138|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
219457139|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
219457140|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
219457141|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
219457142|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
219457143|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
219457144|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
219457145|NCT01825759|DRUG|danshen dripping pill|
219457146|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
219457147|NCT03033290|DRUG|placebo|placebo control
219457148|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
218847989|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
218847990|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
219457149|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
218847991|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
219361256|NCT03084640|DRUG|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
219457150|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
218847992|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
219361257|NCT02419508|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
219361258|NCT02419508|DRUG|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
219361259|NCT02419508|DRUG|Prostaglandin analogue|
219361260|NCT03110900|DRUG|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
219361261|NCT03110900|DRUG|Loxapine|loxapine + placebo
219361262|NCT00163332|DRUG|Ciclesonide|
219361263|NCT02877173|DRUG|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
219361264|NCT02877173|DRUG|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
219361265|NCT04583397|OTHER|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
219361266|NCT04103801|DIETARY_SUPPLEMENT|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
219361267|NCT02674438|OTHER|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
219361268|NCT04545346|OTHER|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
219361269|NCT01016639|OTHER|oxaliplatin, capecitabine, radiotherapy|
219457151|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
219457152|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
219457153|NCT00169273|BEHAVIORAL|Structured behavioral weight loss group|Structured group weight loss program
219457154|NCT00169273|BEHAVIORAL|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
219457155|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
219457156|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
219457157|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
219457158|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
219457159|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
219457160|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
219457161|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
219457162|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
219457163|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
219457164|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
219457165|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
219457166|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
219457167|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
219457168|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
219457169|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
219457170|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
219457171|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
218847993|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
218847994|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
218847995|NCT00003671|DRUG|asparaginase|
218847996|NCT00003671|DRUG|cyclophosphamide|
218847997|NCT00003671|DRUG|cytarabine|
218847998|NCT00003671|DRUG|daunorubicin hydrochloride|
218847999|NCT00003671|DRUG|dexamethasone|
218848000|NCT00003671|DRUG|leucovorin calcium|
218848001|NCT00003671|DRUG|mercaptopurine|
218848002|NCT00003671|DRUG|methotrexate|
218848003|NCT00003671|DRUG|thioguanine|
218848004|NCT00003671|DRUG|vincristine sulfate|
218848005|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
219457172|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
218848006|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
218848007|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
219018693|NCT06293053|DRUG|Dupilumab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous"
219018694|NCT03279692|DRUG|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
219018695|NCT04414475|DRUG|Selinexor|Participants will receive Selinexor oral tablets.
219457173|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
219457174|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
218848008|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
218848009|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
218848010|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
218848011|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
218848012|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
218848013|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
218848014|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
218848015|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
218848016|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
218848017|NCT00116064|DRUG|intranasal lorazepam|
218848018|NCT00116064|DRUG|intramuscular paraldehyde|
218848019|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
218848020|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
218848021|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
218848022|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
218848023|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
219018696|NCT04414475|DRUG|Dexamethasone|Participants will receive Dexamethasone oral tablets.
219018697|NCT04414475|DRUG|Bortezomib|Participants will receive Bortezomib SC injection.
218848024|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
218848025|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
218848026|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
219457175|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
219457176|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
219457177|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
219457178|NCT05327309|DRUG|Bleomycin|
218848027|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
218848028|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
219457179|NCT00002102|DRUG|Trimetrexate glucuronate|
219457180|NCT00002102|DRUG|Leucovorin calcium|
219457181|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
219457182|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
219457183|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
219457184|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
219457185|NCT01322711|DRUG|Placebo|Diet
219457186|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
218848029|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
218848030|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
218848031|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
218848032|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
219457187|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
219457188|NCT02960802|PROCEDURE|kidney transplantation|
219457189|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
218848033|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
218848034|NCT04660825|OTHER|Control|Maintained usual physical activity
218848035|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
218848036|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
218848037|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
218848038|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
218848039|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
218848040|NCT01888536|DRUG|Limaprost|
218848041|NCT01888536|DRUG|Pregabalin|
218848042|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
218848043|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
218848044|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
218848045|NCT01084278|DRUG|Colchicine|Colchicine tablets
218848046|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
219197148|NCT06856642|OTHER|Abdominal Draw-in Manuever|Starting Position: The patient lies in a supine position with knees bent and feet flat on the ground. The neck and spine are kept in a neutral position. Breath Control: The patient focuses on abdominal expansion while inhaling and flattening the abdomen while exhaling. Transversus Abdominis Activation: The patient attempts to draw the abdominal muscles inward (pulling the navel toward the spine). During this movement, care should be taken to avoid pressing the lower back against the ground or contracting the hip muscles. The goal is to activate only the deep abdominal muscles. Checking for Proper Muscle Activation: The patient can place their fingertips on the lower abdominal region (just above the pelvic bone) to feel whether the transversus abdominis muscle is activating correctly. Maintaining the Position: The patient holds this activation for 5-10 seconds while continuing to breathe naturally, then relaxes. Muscles should be fully relaxed between repetitions.
219361270|NCT05683444|DRUG|Octreotide infusion|Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
218848047|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
219361271|NCT05683444|DRUG|Saline infusion|Saline Infusion
219361272|NCT00502216|DRUG|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
219361273|NCT00502216|DRUG|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
219018712|NCT05483868|DRUG|AU-011|Administration of AU-011 intratumorally and intramurally
219018713|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Adminstration|AU-011 Intratumorally and Intramurally
219361274|NCT01007578|DEVICE|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
219361275|NCT06372132|PROCEDURE|G-POEM|Gastric Per-Oral Endoscopic Pyloromyotomy
219361276|NCT02549755|DRUG|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
219361277|NCT04856709|PROCEDURE|Abdominal Pectopexy|Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.
219361278|NCT04856709|PROCEDURE|Abdominal Sacral Hysteropexy|Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
219361279|NCT02001376|OTHER|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
219361280|NCT02001376|OTHER|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
218848048|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
218848049|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
218848050|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
218848051|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
218848052|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
218848053|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
218848054|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
218848055|NCT01466660|DRUG|Afatinib|afatinib once daily
218848056|NCT01466660|DRUG|gefitinib|Gefitinib once daily
218848057|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
218848058|NCT01742910|PROCEDURE|intraocular lens implantation|
219457190|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
218848059|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
218848060|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
218848061|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
218848062|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
218848063|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
218848064|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
219197149|NCT06856642|OTHER|Real-Time Ultrasound Biofeedback with Abdominal Draw-In Manuever|The patient, who has been instructed on the abdominal drawing-in exercise, assumes a supine position with knees bent. The ultrasound screen is positioned so that both the practitioner and the patient can see it. The researcher places the linear ultrasound probe on the patient's transversus abdominis muscle to obtain an image, which is then shown to the patient for awareness. The patient is instructed to keep their eyes on the screen and follow their muscle activity throughout the exercise. During the exercise, the patient's muscle is displayed on the screen, and they are asked to hold the contraction at its maximum level for 10 seconds. After the contraction phase, the patient is instructed to relax and rest for 2 minutes. The treatment is completed with a total of 10 repetitions.
219197150|NCT06858722|DRUG|ripertamab|On Day 1 of the treatment period, an intravenous infusion of Ripertamab at a dose of 375 mg/m² body surface area will be administered.
219457191|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
218848065|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
218848066|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
218848067|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
218848068|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
218848069|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
218848070|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
218848071|NCT00474864|DRUG|GW856553|
218848072|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
218848073|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
219457192|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
219457193|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
219457194|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
219457195|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
219457196|NCT00003159|DRUG|carboplatin|
219457197|NCT00003159|DRUG|cisplatin|
219457198|NCT00003159|DRUG|docetaxel|
218848074|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
218848075|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
219197151|NCT06858722|DRUG|Placebo|On Day 1 of the treatment period, an intravenous infusion of Placebo at a dose of 375 mg/m² body surface area will be administered.
219197152|NCT05565209|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
219457199|NCT00003159|DRUG|gemcitabine hydrochloride|
219457200|NCT00003159|DRUG|ifosfamide|
219591291|NCT05864963|PROCEDURE|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
218848076|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
218848077|NCT02068690|DRUG|Placebo|Placebo
218848078|NCT02068690|DRUG|Placebo|Placebo
218848079|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
218848080|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
218848081|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
218848082|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
218848083|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
219457201|NCT00003159|DRUG|mitomycin C|
219457202|NCT00003159|DRUG|paclitaxel|
219457203|NCT00003159|DRUG|vinblastine sulfate|
219457204|NCT00003159|DRUG|vinorelbine tartrate|
219457205|NCT00003159|PROCEDURE|conventional surgery|
219457206|NCT00003159|PROCEDURE|neoadjuvant therapy|
219591292|NCT00210990|DRUG|doripenem|
218848084|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
218848085|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
218848086|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
218848087|NCT00280618|DRUG|Oxaliplatin|
219018714|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Administration|AU-011 Intratumorally
219457207|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
219591293|NCT03541980|DRUG|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
218848088|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
218848089|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
218848090|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
218848091|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
218848092|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
218848093|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
219197153|NCT06860997|DIAGNOSTIC_TEST|Tissue Doppler Imaging (TDI) S' Wave Echocardiography|This intervention involves bedside echocardiographic assessment using TDI S' wave velocity to evaluate its diagnostic accuracy for acute coronary syndrome (ACS) in patients presenting with acute chest pain in the emergency department (ED).
219197154|NCT06672666|DRUG|Hemp Derived Cannabidiol Extract|Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
219591294|NCT03541980|DRUG|Normal saline|Normal saline volume equivalent
219197155|NCT06672666|DRUG|Placebo|Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
218848094|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
218848095|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
218848096|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
218848097|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
219197156|NCT04066881|BIOLOGICAL|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
219591295|NCT00541879|BEHAVIORAL|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
219591296|NCT00541879|OTHER|comparison|
219591297|NCT03477903|DRUG|TAK-954|TAK-954 infusion
219591298|NCT03477903|DRUG|Metoclopramide|Metoclopramide infusion
218848098|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
218848099|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
218848100|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
218848101|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
218848102|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
219361281|NCT02001376|OTHER|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
219361282|NCT02586792|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
219591299|NCT03477903|DRUG|Normal Saline|0.9% sodium chloride for injection
219361283|NCT05309863|BEHAVIORAL|Lifestyle management|Increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
219591300|NCT04766164|BEHAVIORAL|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
219591301|NCT04378738|BEHAVIORAL|survey|all people in the cohort
219457208|NCT05992051|BEHAVIORAL|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
218848103|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
218848104|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
218848105|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
218848106|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
218848107|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
218848108|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
218848109|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
218848110|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
218848111|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
218848112|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
218848113|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
218848114|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
218848115|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
218848116|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
218848117|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
218848118|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
218848119|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
218848120|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
218848121|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
218848122|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
218848123|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
219361284|NCT05083637|DRUG|L- carnitine oral solution|The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
219361285|NCT05083637|OTHER|Placebo|The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
219361286|NCT01501058|BEHAVIORAL|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
219361287|NCT01501058|BEHAVIORAL|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
219361288|NCT04199325|DIETARY_SUPPLEMENT|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
219361289|NCT04199325|DRUG|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
219361290|NCT05649995|OTHER|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
219457209|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
219457210|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
219457211|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
219457212|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
219457213|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
219457214|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
219457215|NCT02528461|PROCEDURE|Gastroscopy|
219457216|NCT02528461|PROCEDURE|Liver biopsy|
219457217|NCT02528461|PROCEDURE|Fibroscan|
219457218|NCT02528461|PROCEDURE|Liver vein catheterization|
219457219|NCT02528461|DRUG|Sofosbuvir|
219457220|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
219457221|NCT03006952|DRUG|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
219457222|NCT03006952|DRUG|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
218848124|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
218848125|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
218848126|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
219457223|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
219457224|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
219457225|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
219457226|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
219457227|NCT05233319|OTHER|There is no intervention|There is no intervention
219457228|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
219457229|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
219457230|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
219457231|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
219457232|NCT06594406|DIETARY_SUPPLEMENT|Creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks, and administration of a placebo.
219457233|NCT06594406|DIETARY_SUPPLEMENT|Bifidobacterium and creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks. In parallel, the dosing schedule of bifidobacterium administration is 200 million colony-forming units (CFU) /day for 4 weeks.
218848127|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
219457234|NCT06594406|DIETARY_SUPPLEMENT|Placebo|Administration of creatine placebo and bifidobacterium placebo for 4 weeks,
219457235|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
219457236|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
219457237|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
219457238|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
219457239|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
219457240|NCT01563224|DRUG|placebo|placebo
219591302|NCT05976126|OTHER|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
219591303|NCT01031030|DRUG|cyclophosphamide|
219591304|NCT01031030|DRUG|epirubicin hydrochloride|
219591305|NCT01031030|DRUG|fluorouracil|
218848128|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
219457241|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
219457242|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
219457243|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
218848129|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
218848130|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
218848131|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
218848132|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
218848133|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
218848134|NCT03645525|DRUG|placebo|saline
218848135|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
218848136|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
218848137|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
218848138|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
218848139|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
218848140|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
219591306|NCT01031030|DRUG|methotrexate|
219591307|NCT01031030|OTHER|laboratory biomarker analysis|
219591308|NCT01031030|PROCEDURE|adjuvant therapy|
219591309|NCT01233895|DRUG|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
219591310|NCT01233895|DRUG|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
218848141|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
218848142|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
218848143|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
218848144|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
218848145|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
218848146|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
218848147|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
218848148|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
219591311|NCT05090488|BEHAVIORAL|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
219591312|NCT05232266|DRUG|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
219591313|NCT05232266|DRUG|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
219591314|NCT03845803|OTHER|Reducing sedentary behaviour|Implementing sit/stand workstations at work
218848149|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
218848150|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
218848151|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
218848152|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
219591315|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
219591316|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
218848153|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
218848154|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
218848155|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
218848156|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
218848157|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
219457244|NCT06617689|OTHER|Various levels of patient education|"The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them."
218848158|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
218848159|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
219591317|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
219591318|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
219591319|NCT03813810|OTHER|Non|There would be no interventions. Only measurements will be performed.
219197157|NCT04066881|BIOLOGICAL|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
219591320|NCT06061068|PROCEDURE|Hernia belt compression|Use the hernia belt to compress the inguinal region
218848160|NCT05912881|OTHER|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
219197158|NCT04066881|BIOLOGICAL|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
218848161|NCT05912881|OTHER|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
218848162|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
219197159|NCT04066881|DRUG|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
219197160|NCT04066881|DRUG|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
219197161|NCT06671262|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.
218848163|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
219457245|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
219457246|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
219457247|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
219591321|NCT06170905|DIETARY_SUPPLEMENT|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
219591322|NCT02143648|DRUG|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
219591323|NCT02143648|DRUG|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
219591324|NCT02143648|DRUG|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
219591325|NCT06062043|BEHAVIORAL|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
219457248|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
219197162|NCT06671262|DRUG|Immuno-chemotherapy|Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
218848164|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
218848165|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
219591326|NCT06581055|DRUG|Luspatercept|As per COMMANDS Trial (NCT03682536) study protocol
219591327|NCT06581055|DRUG|Epoetin Alfa|As per COMMANDS Trial (NCT03682536) study protocol
219197163|NCT06155916|DRUG|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
219591328|NCT06657456|DIETARY_SUPPLEMENT|Phytosterol-rich extract|Experimental product: extract rich in phytosterols
219591329|NCT06657456|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
219591330|NCT06982872|DIAGNOSTIC_TEST|artificial intelligence|Different AI assisted diagnostic systems are used to diagnose lesions.
219591331|NCT06982560|DEVICE|electrical cardiometry|use of cardiometry parameters as cardiac output, thoracic fluid content, systemic vascular resistance
218848166|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
218848167|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
218848168|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
218848169|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
218848170|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
219197164|NCT06544863|OTHER|Data collection and blood sample|In addition to collecting medical data, additional blood samples will be collected in order to create a biological collection and identify biomarkers associated with the occurrence of cirrhosis-related complications, progression to TH and follow-up.
219197165|NCT06857123|BEHAVIORAL|Exercise with Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include two 45 minute rest periods between exercises and take about two and a half hours.
219197166|NCT06857123|BEHAVIORAL|Exercise without Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include minimal resting periods between exercises and take about one hour.
219591332|NCT06982560|OTHER|traditonal methods|clinical examination, lung ultrasound, inferior vena cava
219591333|NCT06982729|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
219591334|NCT06983431|BEHAVIORAL|technology driven self coaching|subject will be provided with the technology driven lifestyle coaching based on the real time data from the wearables
219591335|NCT06983431|BEHAVIORAL|Health coaching|participants will be provided with the health coach (expert) driven lifestyle coaching based on the real-time data from the wearables
219591336|NCT06983431|BEHAVIORAL|Peer coaching|participants will be provided with the peer coach (expert) driven lifestyle coaching based on the real-time data from the wearables
219591337|NCT06983431|BEHAVIORAL|Active Control|participants will be provided with the wearable, but not exposed to any of the coaching strategies. Real-time data provided by the wearable will be available to them.
219591338|NCT06982313|DRUG|Tamoxifen (Nolvadex)|5 mg per day for 3 years during TAM-01 phase III trial
219591339|NCT06982313|DRUG|Tamoxifen (Nolvadex) placebo|Tamoxifen (Nolvadex) placebo per day for 3 years during TAM-01 phase III trial.
218848171|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
218848172|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
218848173|NCT01558362|DRUG|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections. All volunteers had a rest dose first followed by a stress dose.
218848174|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
218848175|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
219457249|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
219457250|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
218848176|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
218848177|NCT01557777|DRUG|Navitoclax|QD
219197167|NCT06544941|DEVICE|Smart Bassinet|The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
218848178|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
219457251|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
219457252|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
219457253|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
219457254|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
218848179|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
218848180|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
218848181|NCT00140283|PROCEDURE|Educational interactive intervention|
218848182|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
218848183|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
219197168|NCT06544941|DEVICE|HALO|The HALO is a commercially available bassinet
219197169|NCT06547632|DEVICE|ClearPetra Ureteral access sheath|Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
219457255|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
219457256|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
219457257|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
219457258|NCT01336257|OTHER|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
219457259|NCT01003067|DEVICE|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
219457260|NCT00002590|BIOLOGICAL|filgrastim|
219457261|NCT00002590|DRUG|cyclophosphamide|
219457262|NCT00002590|DRUG|cytarabine|
219457263|NCT00002590|DRUG|daunorubicin hydrochloride|
219457264|NCT00002590|DRUG|doxorubicin hydrochloride|
219457265|NCT00002590|DRUG|etoposide|
219457266|NCT00002590|DRUG|leucovorin calcium|
219457267|NCT00002590|DRUG|methotrexate|
219457268|NCT00002590|DRUG|pegaspargase|
219591340|NCT06983600|OTHER|alternative therapy:sujok therapy|As of the first day of the menstrual period for a total of 10 days, the researcher will provide sensitization of the points and painful point detection with the ring and in-hand spiral in the hand macro insect and mini system. Then, moxa will be applied to the uterus and ovary reflection point between 2 minutes and 5 minutes. Moxa is a method that burns wormwood and treats it with the heat emitted to the skin by the smoke with perforated apparatus. It is one of the oldest treatment methods based on heat and plant healing. After the Moxa application, the black pepper seed will be fixed to the painful spot with the help of an air-tight plaster. The black pepper seed will be kept for at least 4 hours and maximum 8-10 hours.
219018735|NCT04742751|DRUG|Metformin|To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily
219457269|NCT00002590|DRUG|prednisone|
219197170|NCT06618898|OTHER|online questionnaire|The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
219457270|NCT00002590|DRUG|thioguanine|
219457271|NCT00002590|DRUG|vincristine sulfate|
219457272|NCT00002590|RADIATION|radiation therapy|
219457273|NCT03194204|DRUG|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
219457274|NCT01401101|OTHER|PCM|Care Manager (CM) intervention
219457275|NCT01401101|OTHER|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
219457276|NCT05680090|DIAGNOSTIC_TEST|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
219457277|NCT02822924|PROCEDURE|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
219457278|NCT00715949|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
219457279|NCT00789659|OTHER|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
219591341|NCT06981845|DRUG|Immunosuppressive therapy|prednisone + sirolimus
219591342|NCT06981845|DRUG|Placebo|Placebo
219591343|NCT06983756|DRUG|Erythropoietin|EPO resistance
219591344|NCT03441932|PROCEDURE|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
219591345|NCT04053920|BEHAVIORAL|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
219591346|NCT04053920|BEHAVIORAL|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
218848184|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
218848185|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
218848186|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
218848187|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
219457280|NCT03998995|DEVICE|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
219457281|NCT05206682|DRUG|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
219457282|NCT05822284|DIAGNOSTIC_TEST|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
218848188|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
218848189|NCT02121106|BEHAVIORAL|Cognitive Remediation|
218848190|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
218848191|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
218848192|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
218848193|NCT02262026|DRUG|Placebo|Placebo
218848194|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
218848195|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
218848196|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
218848197|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
219018736|NCT04742751|BEHAVIORAL|Digital Intervention|"Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24."
219018740|NCT05781269|OTHER|VLCKD|VLCKD diet treatment with medical food
219018741|NCT05781269|OTHER|r-MedDiet|Mediterranean diet treatment
219457283|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
219457284|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
219457285|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
219457286|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
219457287|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
219457288|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
219457289|NCT06305169|DIAGNOSTIC_TEST|Gastropanel|Gastropanel is a commercially available blood test which given serum levels of pepsinogen I and II and gastrin 17 along with helicobacter pylori infection status
218848198|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
218848199|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
219457290|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1\. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
219457291|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
219457292|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
219457293|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
219457294|NCT05237414|DEVICE|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
219457295|NCT05237414|DEVICE|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
219457296|NCT05237414|BEHAVIORAL|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
219457297|NCT05237414|BEHAVIORAL|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
219457298|NCT02396264|OTHER|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
219457299|NCT02396264|OTHER|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
219457300|NCT04691011|OTHER|Muscular MRI|MRI (1.5T)
219457301|NCT04691011|OTHER|Electrophysiological exam|MUNIX
219457302|NCT04691011|OTHER|Brain MRI|MRI (7T)
219457303|NCT04691011|OTHER|Spinal cord MRI|7T and 3T MRI
219457304|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
218848200|NCT02183480|DRUG|Linagliptin, low dose|
218848201|NCT02183480|DRUG|Linagliptin, medium dose|
218848202|NCT02183480|DRUG|Linagliptin, high dose|
218848203|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
218848204|NCT02186652|DRUG|Pantoprazole|
219457305|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
219457306|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
219457307|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
219457308|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
219457309|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
219457310|NCT00304681|DRUG|OROS*-Methylphenidate|
219457311|NCT00537810|DRUG|Sibutramine|15 mg daily
219457312|NCT00537810|DRUG|Placebo|Daily
218848205|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
218848206|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
219457313|NCT00537810|BEHAVIORAL|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
219457314|NCT00537810|BEHAVIORAL|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
219457315|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
219457316|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
219457317|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
219457318|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
219457319|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
219457320|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
219457321|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
219457322|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
219457323|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
219457324|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
219457325|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
219457326|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
219457327|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
219591347|NCT00525551|DRUG|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
219591348|NCT00525551|DRUG|Placebo (NaCl)|300 mL 0.9% NaCl
219457328|NCT01512849|DRUG|TA-7284 Low|Low
219457329|NCT01512849|DRUG|TA-7284 High|High
219457330|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
219457331|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
219457332|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
219457333|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
219457334|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
218848207|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
218848208|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
219457335|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
219591349|NCT00426361|BIOLOGICAL|Boostrix ® Polio|One dose of vaccine administered intramuscularly
219457336|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
219591350|NCT00426361|BIOLOGICAL|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
219591351|NCT01758588|DRUG|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
219591352|NCT00224471|BIOLOGICAL|GSK208141 vaccine|3 IM doses
219591353|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
219591354|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
219591355|NCT06988956|DRUG|Nimotuzumab|Nimotuzumab 400mg
219591356|NCT06988956|DRUG|Tegafur|S-1 60mg/m2
219591357|NCT06988956|RADIATION|radiotherapy|PTV 50Gy/2Gy
219591358|NCT06612957|PROCEDURE|Repair of uterine cicatricial diverticulum|Cut off the uterine cicatricial diverticular tissue in the lower portion of the uterus, and restore normal uterine muscle tissue.
219591359|NCT00004025|BIOLOGICAL|aldesleukin|
218848209|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
218848210|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
219457337|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
219457338|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
219457339|NCT02006394|OTHER|Market variety bread products|placebo bread products
219457340|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
219457341|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
219457342|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
219457343|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
219591360|NCT00004025|BIOLOGICAL|dendritic cell-gp100-MART-1 antigen vaccine|
219591361|NCT06990347|DRUG|Inetetamab and Pyrotinib Combined with Chemotherapy|Inetetamab and Pyrotinib Combined with Chemotherapy
219591362|NCT06989632|DEVICE|We want to know the work and sport activities that our patients are able to undertake after a total lumbar disc replacement|
219591363|NCT06990620|COMBINATION_PRODUCT|TACE+AK112|TACE+AK112 (PD-1/VEGF bi-antibody, 20mg/kg, ivgtt, Q3W)
218848211|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
218848212|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
218848213|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
218848214|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
218848215|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
218848216|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
218848217|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
218848218|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
218848219|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
218848220|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
218848221|NCT04755166|PROCEDURE|Lateral ridge augmentation|
218848222|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
218848223|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
218848224|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
218848225|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
218848226|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
218848227|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
218848228|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
219457344|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
219457345|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
219457346|NCT00404326|DRUG|Hydralazine and magnesium valproate|
219457347|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
219457348|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
218848229|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
218848230|NCT02609230|DRUG|ONC-201|
218848231|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
218848232|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
219457349|NCT00006242|DRUG|BMS-214662|Given IV
219457350|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
219457351|NCT00006242|OTHER|pharmacological study|Correlative studies
219457352|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
219457353|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
218848233|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
218848234|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
218848235|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
218848236|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
218848237|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
218848238|NCT00776672|DRUG|Fosinopril 40mg Tablets|
218848239|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
218848240|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
218848241|NCT02471560|DRUG|injectable MS DMT|As described above.
218848242|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
218848243|NCT01858142|BEHAVIORAL|Parental presence decision tool|
218848244|NCT01858142|BEHAVIORAL|Standard preparation|
219457354|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
219457355|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
219457356|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
219457357|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
218848245|NCT00626509|DRUG|sunitinib malate|
218848246|NCT00626509|PROCEDURE|adjuvant therapy|
219457358|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
219457359|NCT00026819|DRUG|Rofecoxib|
219457360|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
219457361|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
219457362|NCT00267267|DRUG|torcetrapib/atorvastatin|
218848247|NCT00626509|PROCEDURE|neoadjuvant therapy|
218848248|NCT00626509|PROCEDURE|therapeutic conventional surgery|
218848249|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
218848250|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
218848251|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
218848252|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
218848253|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
218848254|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
218848255|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
218848256|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
218848257|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
218848258|NCT01887613|DRUG|Regnite|oral
218848259|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
218848260|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
218848261|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
218848262|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
219018756|NCT06521736|DEVICE|AAC-BCI device|Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
219457363|NCT00267267|DRUG|ezetimibe/simvastatin|
219457364|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
219457365|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
219457366|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
219457367|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
219457368|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
218848263|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
218848264|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
218848265|NCT04077996|DEVICE|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
218848266|NCT04077996|DEVICE|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
218848267|NCT05129449|DEVICE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
219457369|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
219457370|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
219457371|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
219457372|NCT00517673|DRUG|GSK945237|
219457373|NCT00517673|DRUG|Sugar Pill|Placebo
219591364|NCT05775952|BIOLOGICAL|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
218848268|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
218848269|NCT01777217|DRUG|Placebo|IGRT with placebo
218848270|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
218848271|NCT03824678|DRUG|CC-220|CC-220
218848272|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
218848273|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
218848274|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
219018761|NCT03709043|DRUG|Standardized kudzu|Standardized kudzu
219018762|NCT03709043|OTHER|Placebo|Placebo
219018763|NCT03709043|DIAGNOSTIC_TEST|Sexually transmitted infection testing:|At baseline and month 3 visits, all participants will be tested for syphilis (serum RPR), Neisseria gonorrhea and Chlamydia trachomatis (urine, pharyngeal swab, and rectal swab nucleic acid amplification \[NAAT\]) through an established protocol that has been validated by our Public Health Laboratory (PHL) and others.
219457374|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
218848275|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
219457375|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
219457376|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
219457377|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
219457378|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
219457379|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
219457380|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
219591365|NCT00987753|DRUG|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
219591366|NCT04837755|DIAGNOSTIC_TEST|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
218848276|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
218848277|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
218848278|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
218848279|NCT01792713|DRUG|Sertaconazole 2% cream|
218848280|NCT01792713|DRUG|Placebo|
218848281|NCT00642434|DRUG|carvedilol|variable
218848282|NCT00642434|DRUG|metoprolol|variable
218848283|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
218848284|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
218848285|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
219018764|NCT03709043|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM has been used in a targeted pharmacotherapy trial and our team has successfully used MM in AUD trials. MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist.
219591367|NCT01438528|DEVICE|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
219591368|NCT02889055|DEVICE|patient requiring the MIRUS (mechanical ventilation)|
218848286|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
218848287|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
218848288|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
218848289|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
218848290|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
218848291|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
219591369|NCT05854823|RADIATION|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
219591370|NCT03061682|DEVICE|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
219591371|NCT00902031|DRUG|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
219591372|NCT00902031|DRUG|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
219591373|NCT00000734|DRUG|Sulfamethoxazole-Trimethoprim|
219591374|NCT00000734|DRUG|Zidovudine|
219591375|NCT04546893|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
219591376|NCT00168597|DRUG|Vitamin A|
219591377|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
219591378|NCT02446327|OTHER|Blood sampling for biomarker assessment|
219591379|NCT02478320|DRUG|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
219591380|NCT04208074|OTHER|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
219591381|NCT03673319|PROCEDURE|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
219591382|NCT03673319|PROCEDURE|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
219591383|NCT04039386|DEVICE|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
218848292|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
219457381|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
219457382|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
219457383|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
219457384|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
219457385|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
219457386|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
219457387|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
219591384|NCT04039386|OTHER|Control|Subjects in the control group will receive standard care.
218848293|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
218848294|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
218848295|NCT01818258|DRUG|ZDV+3TC+LPV/r|
218848296|NCT06362473|DRUG|Lipid-lowering treatments|
219457388|NCT01709240|DEVICE|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
219457389|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
218848297|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
219457390|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
219591385|NCT02158286|OTHER|Measuring emptying rate from the gastric tube|
219457391|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
219457392|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
219457393|NCT02253173|DRUG|Estradiol|
219457394|NCT02253173|DRUG|Placebo|
219591386|NCT01436799|DRUG|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
219591387|NCT01436799|DRUG|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
219591388|NCT01436799|DRUG|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
219591389|NCT01436799|DRUG|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
218848298|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
218848299|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
218848300|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
218848301|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
219591390|NCT01516307|BIOLOGICAL|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
219591391|NCT01516307|BIOLOGICAL|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
219591392|NCT01516307|DRUG|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
218848302|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
218848303|NCT02708849|DRUG|Placebo|oral dose placebo
218848304|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
218848305|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
218848306|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
218848307|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
218848308|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
218848309|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
218848310|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
218848311|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
218848312|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
218848313|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
218848314|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
219457395|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
218848315|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
218848316|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
218848317|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
218848318|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
218848319|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
218848320|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
218848321|NCT00002873|RADIATION|brachytherapy|
218848322|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
218848323|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
218848324|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
218848325|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
218848326|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
218848327|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
219199437|NCT06866626|BEHAVIORAL|Theory-Based Nutrition Education Intervention to Improve Infant and Young Child Feeding Practices and WASH Practices Among Turkana Caregivers|This nutrition education intervention was designed following the DESIGN procedure, informed by the Theory of Planned Behavior, and employed health literacy principles. The nutrition education sessions were held Monday through Saturday for a total of 8 weeks in a community building. This nutrition education intervention had 4 modules, module one covered the recommended breastfeeding practices, including early initiation of breastfeeding, exclusive breastfeeding and continued breastfeeding. The second module was on the young child feeding practices, with a focus on the quality and quantity of the child's meal. The third module entailed WASH practices such as disinfection of drinking water, harms of open defecation, and other personal and household hygiene practices. The fourth module served as a comprehensive review of all previous modules.
219591393|NCT04638075|DEVICE|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
218848328|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
218848329|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
218848330|NCT01882426|OTHER|Usual Care|usual step care practice
219457396|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
219457397|NCT00410514|DRUG|Mirabegron|oral
219457398|NCT00410514|DRUG|Placebo|oral
219457399|NCT05312385|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
219457400|NCT05312385|DRUG|Propofol|Intravenous infusion of propofol
219457401|NCT01661231|DEVICE|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
219457402|NCT03351062|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
219457403|NCT03351062|DRUG|Toremifene|Patients will be given 60mg Toremifene once a day.
219457404|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
219457405|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
219457406|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
219457407|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
219457408|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
219457409|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
219457410|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
219591394|NCT06718790|OTHER|Using menstrual cup|"In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire.~Women who will use menstrual cups will be trained on the use of the product and a menstrual cup will be provided for them to use. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual cup use by sharing an online form."
218848331|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
219457411|NCT06720545|DEVICE|No HGNS therapy (HGNS-off)|Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
219457412|NCT07045870|DRUG|group L : will receive lidocaine|group L : will receive 1.5 mg/kg bolus of iv lidocaine 10 minutes before anaesthesia induction then continuous iv infusion rate 1.5 mg / kg / h
219457413|NCT07045870|DRUG|group k : will receive Ketamine|patients will receive .25 mg / kg bolus of iv ketamine 10 minutes before anaesthesia induction then continuous iv infusion of ketamine at .25 mg /kg /h
219457414|NCT07045870|DRUG|group c: will recieve .9% saline|group c will be injected with equivalent volumes and rates of .9% saline using the same application scheme as the lidocaine and ketamine as a control group
219457415|NCT06719362|DRUG|M3T01|Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.
219457416|NCT06719362|DRUG|Pembrolizumab|Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.
218848332|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
218848333|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~\- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~\- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
219457417|NCT06719362|RADIATION|Chemoradiation|Subjects will be treated with standard of care chemoradiation therapy consisting of TMZ 75 mg/m2 daily with concurrent radiation therapy (60 Gy administered over 6 weeks). Following chemoradiation therapy, subjects will have a 4-week break from TMZ before starting standard adjuvant TMZ 150-200 mg/m2 days 1-5 of 28-day cycles for 6 cycles. Subjects will be treated with M3T01 at the RP2D through an IV infusion every 3 weeks that will begin concurrently with chemoradiation therapy.
219457418|NCT06719362|DRUG|FOLFOX regimen|FOLFOX will be given as standard of care on 14 day cycles. Subjects will receive oxaliplatin 85 mg/m2 IV on Day 1, leucovorin 400 mg/m2 IV on Day 1, fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles.
219457419|NCT00362141|DRUG|levetiracetam (add-on)|
219457420|NCT03378128|PROCEDURE|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
219457421|NCT05228704|BEHAVIORAL|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
219457422|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
219457423|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
219457424|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
219457425|NCT07047378|BEHAVIORAL|ACT Intervention Group|"For Parent ACT Group, parents will participate in a six-week, group-based ACT program integrated with behavioral parenting training based on positive parenting principles. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of parenting education and/or behavioral skills training.~For Children ACT Group, children (aged 6-11) will also receive a child-focused ACT intervention to help them manage emotional challenges. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of behavioral skills training."
219457426|NCT07047378|OTHER|control group|"Participants allocated to the Control Group will not receive the ACT intervention but will continue to receive the standard services originally provided by Harmony House. These services constitute usual care and include initial assessments, individual counselling, group counselling, the provision of community resource information, and referrals. Control group participants will receive these supports as usual. This study will not alter their existing service arrangements in any way, nor will it add to or reduce the support they receive.~Aside from not participating in the ACT program, the control group's experience will be identical to that of clients receiving regular services. After the intervention group completes the program, the control group will be offered the same course content (i.e., a waitlist intervention arrangement)."
219457427|NCT05743413|PROCEDURE|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
219457428|NCT05743413|PROCEDURE|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
219591395|NCT06718790|OTHER|Using menstrual pads|In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire. For women in the group who will use menstrual pads, the average number of pads they have used in their previous menstrual cycles will be asked and an appropriate number of menstrual pads will be provided. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd, and 6th menstrual cycles and asked to answer questions about their menstrual pad use by sharing an online form.
219591396|NCT00537927|PROCEDURE|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
219591397|NCT00485680|DRUG|Olanzapine Hydrochloride|
219591398|NCT00485680|DRUG|Lithium Carbonate|
219591399|NCT02011386|DRUG|Treatment|
219591400|NCT05940155|DIAGNOSTIC_TEST|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
219591401|NCT04588714|BEHAVIORAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
219591402|NCT03255655|DEVICE|Intense Therapeutic Ultrasound Treatment - ITU|
219591403|NCT05795738|BEHAVIORAL|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
219591404|NCT05795738|BEHAVIORAL|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
219591405|NCT04428333|DRUG|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
219591406|NCT04428333|DRUG|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
219591407|NCT04428333|DRUG|Placebo|Sterile normal saline
218848334|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
218848335|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
218848336|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
219199438|NCT06866626|DIETARY_SUPPLEMENT|Harvest Lentil Vegetable Blend|Harvest Lentil Vegetable Blend is a dehydrated supplemental food produced from natural ingredients namely, rice, carrots, lentils and onions. This product was prepared by mixing it with water and boiling the mixture for approximately 25-35 minutes to a mid-consistency. In this study we implemented a blanket supplementary feeding program where all the recruited children in the intervention group received a meal of Harvest Lentil Vegetable Blend. The feeding program was on-site, and participating children aged 6-12 months received three-quarters of a cup of the supplemental food, (\~ 52 kcal/d). Children aged 13-23 months received 1 cup of the supplemental food (∼69 kcal/d), whereas children aged 24-59 months received 2 cups of the supplemental food (∼138 kcal/d). The feeding was implemented for 6 days a week (Monday through Saturday) for a total of eight weeks.
219457429|NCT02289521|DEVICE|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
219457430|NCT06444997|DRUG|Oxycodone Hydrochloride|Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
219591408|NCT04428333|DRUG|Platinum based chemotherapy|Cisplatin/carboplatin
219591409|NCT04428333|DRUG|Fluorouracil (5FU)|5-fluorouracil
219591410|NCT03365011|DRUG|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
219591411|NCT03365011|DRUG|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
219591412|NCT04853992|DRUG|LEO 152020|LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
219591413|NCT04853992|DRUG|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
219591414|NCT03582826|BEHAVIORAL|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
219591415|NCT03582826|BEHAVIORAL|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
219591416|NCT02866526|OTHER|Patient questionnaire|quantitative and qualitative data collection will be proposed.
219591417|NCT00532818|DRUG|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
219591418|NCT00532818|DRUG|Placebo|Cisplatin + Topotecan plus placebo
218848337|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
219018765|NCT03709043|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers for recent alcohol use:|Urine samples will be collected at Enrollment, Month 1, Month 2 and Month 3 visits and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours.
219591419|NCT01806818|DRUG|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
219018766|NCT03709043|DIAGNOSTIC_TEST|Dried Blood Spot (DBS) Testing for PEth:|DBS samples will be collected at enrollment, weeks 12, and post-treatment visits at month 3. Samples will be dried overnight using standardized methods. PEth testing of DBS samples will be conducted at the United States Drug Testing Laboratories in Des Plaines, IL using liquid chromatography-tandem mass spectrometry system following extraction into methanol.
218848338|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
218848339|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
218848340|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
219018767|NCT03709043|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measures will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection.To minimize potential social desirability bias, staff will not have access to data during the trial.
219018768|NCT03709043|BEHAVIORAL|Ecological Momentary Assessment procedure:|Participants will receive daily SMS texts to collect data on alcohol consumption, number of drinks on drinking days, targeted medication administration prior to anticipated drinking sessions, and sexual risk behaviors
219591420|NCT03370809|RADIATION|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
219457431|NCT06444997|DRUG|Remifentanil|Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
219457432|NCT00881023|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
218848341|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
218848342|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
218848343|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
219457433|NCT00881023|DEVICE|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
219457434|NCT06099808|OTHER|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
219457435|NCT06099808|OTHER|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
219457436|NCT06099808|OTHER|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
219457437|NCT01875666|DRUG|Trastuzumab|8 mg/kg IV, single dose
219457438|NCT01875666|DRUG|pertuzumab|840 mg IV single dose
219457439|NCT01875666|DRUG|lapatinib|1000 mg daily for 7 days
219457440|NCT02481323|DRUG|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
219457441|NCT02481323|DRUG|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
219457442|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
219457443|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
219457444|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
219457445|NCT07050056|DRUG|Tislelizumab|200mg, iv, Q3W, 3-4 cycle
219457446|NCT07050056|RADIATION|3D-CRT/IMRT|40Gy in 20 fractions
219457447|NCT07050771|OTHER|Comprehensive multimodal prehabilitation (CMMP)|Components of the CMMP intervention (which will be administered for at least 3 weeks from study registration to the Preoperative Reassessment) will include: 1) Motivational interviewing: 2 sessions, 10-15 minutes each. 2) Nutritional prehabilitation (a supplement containing 18-22g high quality protein consumed 2 times/day, 7 days/week). 3) Inspiratory muscle training using a hand-held inspiratory muscle device, 5 minutes of respiratory muscle training twice/day, 5 days per week. 4) Physical prehabilitation a) aerobic exercise (20 minutes of moderate-intensity exercise at least 3 days/week) and b) strength resistance training using resistance bands (3 sets of 10 repetitions at moderate intensity at least 3 days/week).
219457448|NCT07052331|DEVICE|Birth Mobility System|Participants receive standard obstetric care and have access to a birth mobility system installed on the birthing bed. Use of the system is voluntary and guided by medical professionals. Participants view a video explaining the system's operation. Birth mobility data is collected passively.
219457449|NCT07052240|BEHAVIORAL|Gatekeeper Training Program (GTK)|"Behavioral: Gatekeeper Training Program (GTK)~The GTK program is a suicide prevention intervention for university students. It includes two sessions of 3 hours each (total: 6 hours), delivered over one week, either face-to-face or online. Content is organized into six modules:~1. Introduction to suicidal behavior.~2. Warning signs and risk/protective factors.~3. Crisis intervention and suicide first aid.~4. Safety planning and community resources.~5. Ethics and gatekeeper self-care.~6. Practical simulations and skill application.~The program includes interactive exercises, role-plays, take-home materials, and a booster session plus a focus group at the 2-month follow-up."
219457450|NCT07051707|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD)Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
219457451|NCT07051707|DRUG|Standard medical care|Continuing standard of care COPD maintenance medication that minimally includes LABA/ICS, LAMA/LABA or LABA/LAMA/ICS.
219457452|NCT07052981|DRUG|Telitacicept|The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.
219457453|NCT01041001|BIOLOGICAL|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
219457454|NCT01041001|PROCEDURE|Microfracture treatment|
219457455|NCT01586962|DRUG|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
219591421|NCT00164151|DRUG|HalfLytely|
218848344|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
218848345|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
218848346|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
218848347|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
218848348|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
218848349|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
219591422|NCT00164151|DRUG|Visicol|
219197171|NCT06867744|PROCEDURE|Extracapsular Supradiscal Subperiosteal Surgical Procedure for Temporomandibular Joint Internal Derangement Correction|Patients in a supine extended position with nasotracheal intubation; oral intubation in such cases is not suitable as it makes dissection and disc repositioning difficult and compromises the surgery results. Periauricular incision with postauricular extension; after infiltration with noradrenaline 1/200000 solution with or without zylocaine which gives better exposure and better aesthetic results. Dissection down the wound till reach the temporal fascia starting posteriorlay till the fascia blended with the zygomatic arch anteriorly; identification of temporal root of zygomatic arch using fine dissector followed by subperiosteal dissection of zygomatic arch till five mm anterior to the articular eminence of TMJ. Accurate identification of TMJ followed by meticulous subperiosteal dissection of superior margin of TMJ capsule then the dissection continued posteriorly till posterior margin; no need to dissect the bilaminar zone, and the dissection continued anteriorly down the skull base t
219197172|NCT06867302|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|An infusion given all through intraoperative time
219197173|NCT06867302|DRUG|Dexmedetomidine Injection [Precedex]|Single dose given 15 minutes before end of surgery
219197174|NCT06866808|OTHER|talocrural MWM and Therapeutic US|Mobilization with movement alongwith the therapeutic ultrasound
219197175|NCT06866808|OTHER|Conventional physiotherapy|Ankle isometrics, calf stretches, icing
219197176|NCT06866002|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
219457456|NCT07058220|OTHER|Cervical proprioceptive training|Study group will receive proprioceptive training through use of a laser pointer in a similar way to the testing. From sitting position, patients were asked to flex, extend and rotate their head and then return to the neutral position . This training was commenced with open eyes. Each direction was repeated 8 times for two sets, 30 seconds rest between sets. Progression of exercise was achieved by closing eyes, and altering the duration (trace shapes for 5 minutes and progress by increasing 2-3 minutes weekly as tolerated), repetitions (2-3 repetitions weekly), sets (1 set weekly) and the degree of difficulty of the task (different shapes and positions as standing and walking)
219457457|NCT07058220|OTHER|Advices|Patients of control group were allowed to stay active, avoid poor cervical ergonomics (poor sleeping habits, improper use of mobile/telephone),hot/cold packs, some range of motion exercises, and local medicines as prescribed by their general practitioner.
219457458|NCT07057934|PROCEDURE|ESPB Block|Under sterile conditions and ultrasound guidance, 20 mL of local anesthetic solution (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected bilaterally into the erector spinae plane at the T7-T8 level before incision. The block was performed after induction of general anesthesia but before the start of laparoscopic cholecystectomy.
219197177|NCT06866002|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (arterial stiffness) for the patients of the subgroup and others questionnaires.
219457459|NCT07057934|PROCEDURE|EOPB Block|Under ultrasound guidance, 20 mL of local anesthetic mixture (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected into the fascial plane between the external oblique and internal intercostal muscles at the level of the 6th rib. The procedure was done after anesthesia induction but prior to laparoscopic cholecystectomy.
219457460|NCT07057934|DRUG|Standard Systemic Analgesia|No regional anesthesia technique was applied. Postoperative pain was managed using systemic rescue analgesia: 50 mg dexketoprofen trometamol IV when VAS ≥4, followed by 50 mg tramadol IV if pain persisted.
219197178|NCT06867419|RADIATION|Transient Elastography|participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.
219457461|NCT07058597|DEVICE|Twinfork plate|Twinfork plate
218848350|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
219197179|NCT06865638|PROCEDURE|Intraoperative leak testing|◦After anastomosis was completed, the integrity of anastomosis was tested intraoperatively. The methods include directly observing the integrity of the anastomosis under gastroscopy, immersing the anastomosis in 500 - 1000 mL of warm saline and temporarily occluding the distal end, filling the anastomotic bowel with air, and injecting 60 mL of methylene blue through colonoscopy. Wrapping a white gauze pad around the anastomosis and observing for methylene blue leakage.
219197180|NCT06866418|DEVICE|1. Phagenyx® System Group Patients|Patients who have undergone Pharyngeal Electrical Stimulation (PES) treatment for severe dysphagia using the Phagenyx® System
219457462|NCT07058597|DEVICE|3D-interlocking plate|3D-interlocking plate
219457463|NCT07058597|DEVICE|Miniplate|Miniplate
219591423|NCT02351960|DRUG|Dexlansoprazole|Dexlansoprazole capsules
218848351|NCT01183052|OTHER|Training|20 sessions of training
218848352|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
218848353|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
218848354|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
219197181|NCT06867315|DEVICE|steep pulse therapy system|"1. Use steep pulse system to ablate the transitional zone of the prostate to treat BPH~2. The steep pulse generator employs irreversible electroporation technology, which involves inserting electrodes into the tumor and delivering high-voltage electrical pulses to create nanoscale permanent pores on the lipid bilayer of tumor cell membranes. This disrupts the intracellular balance and induces cell apoptosis"
219197182|NCT06867315|DRUG|Tamsulosin Hydrochloride|"1. use Tamsulosin Hydrochloride Sustained-Release Capsules to treat BPH~2. the brand name is Harnal®~3. the specification is 0.2mg per capsule"
219591424|NCT03337165|BIOLOGICAL|tolerogenic dendritic cells|dose-escalation
219591425|NCT00319982|DRUG|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
218848355|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
218848356|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
218848357|NCT02082457|DRUG|YKP10811 5mg|
218848358|NCT02082457|DRUG|YKP10811 20mg|
218848359|NCT02082457|DRUG|YKP10811 placebo|
218848360|NCT03791281|BEHAVIORAL|BASIS|
218848361|NCT03791281|BEHAVIORAL|Attention Control|
218848362|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
219457464|NCT07059130|BIOLOGICAL|Mirikizumab|Mirikizumab will be administered to participants according to FDA-approved dosing guidelines for moderate-to-severe Crohn's Disease and Ulcerative Colitis. Participants will receive scheduled doses throughout the study period at predefined intervals. Clinical assessments, patient-reported outcomes, biomarker analyses, and safety monitoring will occur at baseline and at Weeks 12, 24, and 48.
219457465|NCT07058857|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
219457466|NCT07058857|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
219457467|NCT06731894|PROCEDURE|Biospecimen Collection|Undergo urine sample collection
219457468|NCT06731894|DRUG|Cannabidiol|Given PO
218848363|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
218848364|NCT00503581|DRUG|Megestrol Acetate|given orally
218848365|NCT00503581|OTHER|Pharmacological Study|Correlative studies
219457469|NCT06731894|DRUG|Dronabinol|Given PO
219457470|NCT06731894|DRUG|Placebo Administration|Given PO
219457471|NCT06731894|OTHER|Survey Administration|Ancillary studies
218848366|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
218848367|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
218848368|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
218848369|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
218848370|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
218848371|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
218848372|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
218848373|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
218848374|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
218848375|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
218848376|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
218848377|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
218848378|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
218848379|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
218848380|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
219457472|NCT07057765|DRUG|Observational Assessment of Standard R-CHOP Treatment|Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.
219457473|NCT07058844|BEHAVIORAL|High-BPM Line Dance|A structured aerobic dance program set to music with tempos of 130-140 BPM, designed to improve cognitive and physical function in older adults with MCI.
219457474|NCT07058844|BEHAVIORAL|Low-BPM Line Dance|A structured aerobic dance program set to music with tempos of 90-100 BPM, using the same choreography but slower rhythm and reduced rest intervals.
219457475|NCT07058844|OTHER|Usual Daily Activity|No structured intervention will be provided. Participants will continue their routine lifestyle.
219457476|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
219457477|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
219457478|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
219457479|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
219457480|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
218848381|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
218848382|NCT04561245|DRUG|ALT-801|Injected subcutaneously (SC)
218848383|NCT04561245|OTHER|Placebo|Injected subcutaneously (SC)
218848384|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
218848385|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
218848386|NCT04221178|OTHER|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
218848387|NCT00150228|DRUG|CP-526,555 (varenicline)|
218848388|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
219197183|NCT06867224|DEVICE|Shame TUS-vmPFC|The sham stimulation protocol maintained identical parameter settings to the active treatment group with equivalent application of ultrasound coupling gel at the left vmPFC site localized via the FP1 electrode. Crucially, the ultrasound transducer's output trigger was disabled during sham sessions, ensuring identical device operation procedures without acoustic energy delivery. Participants received daily 15-minute sham sessions matching the active group's 10-day treatment schedule.
219457481|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
219457482|NCT00134199|DRUG|CP-945,598|
219457483|NCT00134199|DRUG|sibutramine|
219457484|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
219457485|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
219591426|NCT00319982|DRUG|Placebo|Placebo comparator (double-blind allocation of study medication)
219591427|NCT00472862|BEHAVIORAL|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
219591428|NCT02702479|OTHER|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
219591429|NCT02702479|OTHER|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
219591430|NCT03480386|BEHAVIORAL|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
219591431|NCT02517086|OTHER|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
219591432|NCT02517086|OTHER|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
219591433|NCT02517086|OTHER|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
219591434|NCT03506984|DEVICE|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
219591435|NCT03506984|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
218848389|NCT05695898|DRUG|XmAb22841|Given intravenously (IV)
218848390|NCT05695898|DRUG|XmAb23104|Given intravenously (IV)
218848391|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
218848392|NCT02713997|DRUG|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
218848393|NCT02713997|DRUG|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
218848394|NCT05368285|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
218848395|NCT05368285|DRUG|Matching Placebo|Subcutaneous Administration
218848396|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
218848397|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
218848398|NCT01661777|DRUG|Nasal steroid|
218848399|NCT01661777|PROCEDURE|Myringotomy tube placement|
218848400|NCT01661777|DRUG|Diuretic|
218848401|NCT01661777|DRUG|Antihistamine|
218848402|NCT01661777|BEHAVIORAL|Low salt diet|
219457486|NCT02249858|PROCEDURE|Cranial Vault Hold|
219457487|NCT02249858|PROCEDURE|Cervical HVLA|
219457488|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
219457489|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
218848403|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
218848404|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
218848405|NCT06585293|DEVICE|Mitra Microsampling Device|Microsampling tool for finger-prick blood collection
219591436|NCT00574912|DRUG|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
218848406|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
218848407|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
218848408|NCT06397703|DRUG|Leuprolide, Degarelix or Relugolix|Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
219197184|NCT06867224|DEVICE|Active TUS-vmPFC|Participants in the active stimulation group will receive the transcranial ultrasound stimulation (TUS) targeted the left ventromededial prefrontal cortex (vmPFC), localized via the FP1 electrode position of the International 10-20 EEG system. The TUS will be delivered in the form of pulsed sinusoidal waves, with a fundamental frequency of 0.5 MHz and an intensity of 8 W/cm² (spatial peak pulse average intensity \[Isppa\]). The pulse duration will be 500 microseconds, and the sonication bursts will consist of 50 tone bursts per session, with a duty cycle of 5%. Each burst (pulse repetition frequency: 100 Hz) was followed by an 8-second inter-burst interval, yielding a total session duration of 15 minutes. Participants underwent one daily session for 10 consecutive days.
219197185|NCT06866977|DRUG|Oncolytic virus VRT106|VRT106, IV
219197186|NCT06866977|DRUG|Chemotherapy|21 days/cycle
219197187|NCT06342921|DRUG|15 mg ADC189|Use only once during the whole study.
219197188|NCT06342921|DRUG|45 mg ADC189|Use only once during the whole study.
219591437|NCT00574912|DRUG|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
219591438|NCT00574912|DRUG|Insulin Glargine 1.0 u/kg body wt SC|
219591439|NCT00574912|DRUG|Insulin Glargine 1.5 u/kg body wt SC|
218848409|NCT06397703|RADIATION|Stereotactic body radiation therapy/radiosurgery (SBRT)|SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Intra-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
218848410|NCT05591066|BEHAVIORAL|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
218848411|NCT05591066|BEHAVIORAL|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
218848412|NCT05661981|DEVICE|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
218848413|NCT04934800|DRUG|Cladribine|No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
219197189|NCT06342921|DRUG|Placebo|Use only once during the whole study.
219197190|NCT06865846|DEVICE|TeleMedBot|The patient will receive a questionnaire daily containing a list of questions about blood pressure and heart rate. For this purpose, a messaging application will be installed on the patients' smartphones before the study begins. All patients will be instructed and trained to use the application. Every day at 12 noon, patients will receive a questionnaire containing 2 questions. Patients can start, pause, and continue answering for 12 hours before the next questionnaire appears. For security reasons, no personal data of patients is entered or saved in the program. The research physician will receive daily information about the patient's self-monitoring results and make decisions about the need to adjust therapy.
219197191|NCT06854497|DIAGNOSTIC_TEST|MMSE (Mini-Mental State Examination),NIHSS (NIH Stroke Scale) and mRS (Mordified Rankin Score), Confusion Assessment Methods (CAM), PSQI Pittsburgh Sleep Quality Index, Respiratory polygraphy|Respiratory polygraphy will be performed during acute stroke period, to evaluate the relationship between sleep apnea and stroke evolution.
219197192|NCT06853678|DRUG|Adebrelimab|1200mg,d1,iv,q3w
219197193|NCT06853678|DRUG|Selinexor|40mg,twice weekly,d1, d3,oral,q3w
219591440|NCT00574912|DRUG|Insulin Glargine 2.0 u/kg body wt SC|
219591441|NCT03806712|OTHER|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
219591442|NCT06207214|OTHER|Self-help book for university students.|"The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week)."
219591443|NCT01080664|DRUG|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
219591444|NCT01080664|DRUG|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
219197194|NCT06853678|DRUG|Nab-paclitaxel|100mg/m2,d1,d8,d15,iv,q3w
218848414|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
218848415|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
219197195|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
219197196|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
219197197|NCT06842433|OTHER|General healthy diet|General healthy diet based on national health dietary guidelines.
219457490|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
219457491|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
219591445|NCT02958423|DEVICE|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
219197198|NCT06842433|OTHER|Personalized diet|Personalized diet will be based on an algorithm considering the individuals' postprandial glucose, triglycerides and inflammation markers to each of the three study meals in the characterization phase (Phase I) matched with established knowledge about the effects of specific foods on such metabolic parameters.
219197199|NCT06647459|DIAGNOSTIC_TEST|EP Study|To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
219197200|NCT06804317|OTHER|telerehabilitation|"Exercise-based interventions were conducted twice weekly for three months via videoconferencing on Microsoft Teams. The program included various components:~Aerobic and strength training, Flexibility, Balance and coordination"
219197201|NCT05417282|DRUG|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
219197202|NCT06805448|DRUG|MSC|Allogeneic adipose-derived mesenchymal stromal / stem cells in 10% DMSO
218848420|NCT05897619|BEHAVIORAL|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
219197203|NCT06805448|DRUG|Saline Water (Control)|Isotonic sterile saline water
219197204|NCT06805123|OTHER|Early feeding|Begin drinking water 2 hours after the procedure. If no complications occur 2 hours after starting water intake, progress to a liquid diet. If no abnormalities are observed after the liquid diet, transition to a soft diet for the next meal.
219197205|NCT06805123|OTHER|Late feeding|Maintain fasting on the day of the procedure. Begin a liquid diet 24 hours after the procedure. If no complications occur after starting the liquid diet, transition to a soft diet at the next meal.
218848421|NCT05942053|DRUG|Placebo|Placebo match vitamin K2 capsules once per day.
218848422|NCT05942053|DRUG|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
218848423|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
218848424|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
218848425|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
218848426|NCT06078202|DRUG|ABBV-903|Tablet; oral
219197206|NCT06877416|OTHER|Non-intervention research|Non-intervention research
219457492|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
219457493|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
219457494|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
219591446|NCT02958423|DEVICE|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
219591447|NCT02958423|DEVICE|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
219591448|NCT02958423|DEVICE|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
219591449|NCT03456154|DRUG|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
219591450|NCT03456154|DEVICE|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
219591451|NCT01008982|DRUG|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
219591452|NCT00210873|DRUG|topiramate|
219591453|NCT02116426|BIOLOGICAL|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
218848427|NCT05093335|DRUG|[68Ga]-Pentixafor|An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
218848428|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
218848429|NCT05893160|OTHER|Placebo|Inert placebo formulation
218848430|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
218848431|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
218848432|NCT05808179|DEVICE|Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s
218848433|NCT05808179|BEHAVIORAL|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
218848434|NCT05808179|DEVICE|Sham Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
218848435|NCT05871476|BEHAVIORAL|Hospital Cohort Care Intervention at the hospital|There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
218848436|NCT05871476|BEHAVIORAL|, Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention|The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
218848437|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
218848438|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
218848439|NCT05413512|OTHER|Acute psychological stress|Experimental: Acute psychological stress Two, acute-psychological stress tasks known to reliably elicit a cardiovascular responses (Multi-source interference task; Stroop).
218848440|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
218848441|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
219591454|NCT02116426|BIOLOGICAL|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
219591455|NCT02116426|BIOLOGICAL|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
219591456|NCT01789827|OTHER|Laboratory Biomarker Analysis|Correlative studies
219591457|NCT01789827|PROCEDURE|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
219591458|NCT01789827|BIOLOGICAL|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
219591459|NCT00003638|BIOLOGICAL|Detox-B adjuvant|
219591460|NCT00003638|BIOLOGICAL|THERATOPE STn-KLH vaccine|
219591461|NCT00003638|BIOLOGICAL|keyhole limpet hemocyanin|
219591462|NCT00003638|DRUG|cyclophosphamide|
219591463|NCT02235038|BEHAVIORAL|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
218848442|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
219018773|NCT05198843|DRUG|Dasatinib|Given PO
219018774|NCT05198843|DIETARY_SUPPLEMENT|Icosapent Ethyl|Given PO
219018775|NCT06078020|OTHER|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
219591464|NCT02235038|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
219591465|NCT02235038|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
219197207|NCT06843291|GENETIC|Genetic Testing for hematological malignancies|combined skin punch biopsy/BM aspiration technique, followed by NGS and OGM.
219197208|NCT04678856|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219197209|NCT04678856|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219197210|NCT06809075|PROCEDURE|hematopoietic precursor transplantation (TPHa)|An apheresis is performed on the patients and a selection of CD34 hematopoietic progenitors is performed. Subsequently, conditioning is performed with cyclophosphamide, thymoglobulin, corticosteroids and rituximab to subsequently infuse the hematopoietic precursors.
219197211|NCT06857604|OTHER|Biological samples|Immunological Screening and Genetic analysis
219197212|NCT04351256|DRUG|Durvalumab Injection [Imfinzi]|Durvalumab fixed dose of 1,500 mg
219197213|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) conventionally|Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
219197214|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) hypofractionated|Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
219197215|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
219197216|NCT06329531|OTHER|Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|Given by Questionnaire
219197217|NCT04637282|DRUG|PLX-200|15 mg/mL oral solution of experimental drug
219197218|NCT04637282|DRUG|Placebo|Taste and color-matched drug-free solution
219457495|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
219457496|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
219457497|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
219457498|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
219457499|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
219457500|NCT01868126|DRUG|DE-117 ophthalmic solution|
219457501|NCT01868126|DRUG|latanoprost ophthalmic solution|
219457502|NCT01868126|OTHER|Placebo|
219457503|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
219457504|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
219457505|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
219457506|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
219457507|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
219018779|NCT06973668|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max: 1,000mg/dose) IV/PO three times daily
219018780|NCT06973668|DRUG|Ruxolitinib|5 mg PO every 12 hours
219018781|NCT06972953|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
219018782|NCT06972953|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
219457508|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
218848443|NCT06341881|BEHAVIORAL|Transitional Care Training Program|A nursing based transitional care training intervention would be carried out to prepare the family caregivers to take care of their elderly stroke survivors at home. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the family caregivers at their homes after hospitalization. The study participants would be evaluated after 8 weeks of the intervention. A structured, validated and literature based assessment checklist will be devised to assess the usefulness and feasibility of the intervention. Assistance of senior nurses and health professionals, specialized in stroke care will be taken during the training part of the program.
219457509|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
218848444|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
218848445|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
218848446|NCT06812026|OTHER|no melatonin and massage|receiving no melatonin and massage
218848447|NCT06812026|DIETARY_SUPPLEMENT|receive melatonin|receiving only melatıonin pills
218848448|NCT06812026|OTHER|receiving lymphatic drainage|receiving lymphatic drainage massage
218848449|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
218848450|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
218848451|NCT02438683|DRUG|Placebo|single dose, oral administration
218848452|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
218848453|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
218848454|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
218848455|NCT06984926|DRUG|BI 3810477|BI 3810477
218848456|NCT06984926|DRUG|Placebo|Placebo for BI 3810477
219457510|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
219457511|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
219457512|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
218848457|NCT04432064|DEVICE|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
218848458|NCT04432064|OTHER|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
218848459|NCT04432064|DEVICE|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
219197219|NCT03500328|OTHER|Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq|Early Aggressive Therapy
219197220|NCT03500328|OTHER|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
219199439|NCT06871358|DRUG|Atorvastatin 80mg|80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI
219457513|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
219457514|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
219591466|NCT02433054|DEVICE|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
218848460|NCT00453609|DRUG|long-lasting injectable naltrexone|
218848461|NCT03520751|DRUG|scAAV1.tMCK.NTF3|gene vector
218848462|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
219197221|NCT04671303|DRUG|Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
219457515|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
219457516|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
219457517|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
219457518|NCT03466528|DRUG|Pabrinex|standard treatment
219457519|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
219457520|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
219197222|NCT04705220|DIETARY_SUPPLEMENT|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
219197223|NCT04705220|OTHER|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
219197224|NCT05930509|DEVICE|Non-invasive transcranial direct current stimulation (tDCS)|Electrical stimulation
219197225|NCT06517082|OTHER|Artificial Intelligence|Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.
219197226|NCT06088381|OTHER|Experimental Observation|Patients on the experimental arm will be under observation only.
219197227|NCT06088381|OTHER|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
219197228|NCT06088381|RADIATION|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
219457521|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
219457522|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
219197229|NCT06088381|DIAGNOSTIC_TEST|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
219457523|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
219018792|NCT05099965|BIOLOGICAL|CMV-MVA Triplex|5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine
219018793|NCT05099965|BIOLOGICAL|Placebo|7.5% Lactose in phosphate-buffered saline \[PBS\]
219457524|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
219457525|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
219457526|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
219457527|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
219457528|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
219018794|NCT04415944|PROCEDURE|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
219197230|NCT05848739|DRUG|ST316|IV
219197231|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
219197232|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
219457529|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
219457530|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
219457531|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
219457532|NCT02184520|DEVICE|TRANSITION|
219457533|NCT02184520|DEVICE|REVERE|
219457534|NCT02712892|GENETIC|Non Interventional Study|
219457535|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
219457536|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
219457537|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
219457538|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
219457539|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
219457540|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
219457541|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
219457542|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
219591467|NCT02302547|DRUG|triple therapy|Dosage treatment and usual prescription
219457543|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
219457544|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
219457545|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
219457546|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
219457547|NCT04802395|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
219457548|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
219457549|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
219457550|NCT00003016|DRUG|tamoxifen citrate|
219457551|NCT00003016|PROCEDURE|adjuvant therapy|
219457552|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
219457553|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
219457554|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
219457555|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
219457556|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
219457557|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
219591468|NCT02302547|DRUG|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
219457558|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
219457559|NCT04921111|DRUG|placebo|aluminium phosphate
219457560|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
219457561|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
219457562|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
219457563|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
219457564|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
219457565|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
219591469|NCT02629354|DRUG|Ibuprofen|
219591470|NCT02629354|DRUG|Caffeine|
219591471|NCT02629354|DRUG|Ibuprofen|
219591472|NCT04422782|OTHER|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
219457566|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
219457567|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
218848463|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
219457568|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
219457569|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
219457570|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
219197233|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
219197234|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
219457571|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
219457572|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
219457573|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
219457574|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
219457575|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
219457576|NCT05249504|OTHER|Community resources|Learn about community resources
219457577|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
219457578|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
219457579|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
219457580|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
219457581|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
219457582|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
218848464|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
219197235|NCT06953362|DEVICE|Direct Neural Electrical Stimulation|We are not delivering treatment in this study. Direct neural electrical stimulation is being administered to determine its effect on neural circuit activity and connectivity.
219199440|NCT06871358|DRUG|Placebo|Only given a loading DAPT without loading Atorvastatin 80 mg
219457583|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
219457584|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
219457585|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
219457586|NCT03858855|OTHER|Subject Diary|Complete journal
219457587|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
219457588|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
219457589|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
219457590|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
219457591|NCT02397772|DRUG|albendazole|Single dose of albendazole (400 mg)
219457592|NCT00846027|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
219457593|NCT00846027|DRUG|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
219457594|NCT00846027|DRUG|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
219457595|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
219457596|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
219457597|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
219457598|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
219457599|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
219457600|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
219457601|NCT03595982|DRUG|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
219457602|NCT03595982|DRUG|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
219457603|NCT05833061|OTHER|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
219457604|NCT05833061|OTHER|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
219457605|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
219457606|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
219457607|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
219457608|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
219457609|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
219457610|NCT02278159|PROCEDURE|Peritoneal dialysis|
219457611|NCT02278159|PROCEDURE|Home hemodialysis|
219457612|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
219457613|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
219457614|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
219457615|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
219457616|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
219457617|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
218848465|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
219457618|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
219457619|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
219457620|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
219457621|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
219457622|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
219457623|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
219457624|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
219457625|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
219457626|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
219457627|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
219457628|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
219457629|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
219457630|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
219457631|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
219457632|NCT05516316|DRUG|EP395|Capsule for oral use
219457633|NCT05516316|DRUG|Placebo|Capsule for oral use
219457634|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
219457635|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
219457636|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
219457637|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
218848466|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
218848467|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
218848468|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
219199441|NCT06870955|PROCEDURE|using biomimetic abutments|The subjects recieved the biomimetic healing abutments during the second-stage surgery, and the biomimetic prosthetic abutments were used to complete the implant restoration.
219199442|NCT06869655|DEVICE|Threshold Loading device|threshold loading device for diaphragmatic resistance training
219457638|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
219457639|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
219457640|NCT02773849|BIOLOGICAL|ADSTILADRIN|
219457641|NCT02058186|DRUG|oral vitamin D|
219457642|NCT02058186|DRUG|Placebo|
219457643|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
219457644|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
219457645|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
219457646|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
219457647|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
219457648|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
219457649|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
219457650|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
219457651|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
219457652|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
219457653|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
218848469|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
219457654|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
218848470|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
219457655|NCT03331393|OTHER|Non-interventional|Non-interventional
219457656|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
219457657|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
219591473|NCT05641090|OTHER|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
218848471|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
218848472|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
218848473|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
218848474|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
218848475|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
219197236|NCT05505578|BEHAVIORAL|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
219457658|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
219457659|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
219457660|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
219591474|NCT05641090|OTHER|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
219591475|NCT03169712|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
219591476|NCT03169712|BEHAVIORAL|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
219591477|NCT03433898|DRUG|BI 754091|Solution for infusion
219591478|NCT03433898|DRUG|BI 754111|Solution for infusion
219591479|NCT04695145|BEHAVIORAL|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
219457661|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
219457662|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
219457663|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
218848476|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
219457664|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
218848477|NCT06163703|BEHAVIORAL|Family Life Skills Triple P|The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
218848478|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
218848479|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
219457665|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
219457666|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
219197237|NCT05505578|BEHAVIORAL|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
219197238|NCT04804605|DRUG|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
219591480|NCT04695145|BEHAVIORAL|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
219197239|NCT02914483|BEHAVIORAL|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
219197240|NCT02914483|BEHAVIORAL|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
219197241|NCT02914483|DIAGNOSTIC_TEST|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
219197242|NCT04337619|BEHAVIORAL|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
219457667|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
218848480|NCT06753669|BEHAVIORAL|health education and social network building|The investigators will use techniques from the social network literature to build each treatment group as a cohesive social network and will diffuse educational messages through these groups.
218848481|NCT06753669|BEHAVIORAL|dental referral and educational materials|Control arm will receive a referral to vetted dentist and educational materials on child health
219457668|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
219457669|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
219457670|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
219197243|NCT04337619|BEHAVIORAL|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
219197244|NCT04337619|BEHAVIORAL|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
219197245|NCT04337619|BEHAVIORAL|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
219197246|NCT05425615|DEVICE|Transcranial Magnetic Stimulation|Deymed DuoMag XT-100 rTMS
219197247|NCT06427590|DRUG|ASC47|single subcutaneous injection of ASC47
219197248|NCT06427590|DRUG|Matching placebo|single subcutaneous injection of Placebo
219197249|NCT06965101|RADIATION|Radiotherapy to the spine in a single appointment|8Gy/ 1# to be delivered to all participants using a single posterior direct field.
219199443|NCT06869655|DEVICE|Volumes Oriented Spirometry|group B will receive this interentions
219199444|NCT05386589|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
219457671|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
219457672|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
219457673|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
218848482|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
219457674|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
219457675|NCT02418000|DRUG|E6201|Single Group Assignment
219457676|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
219457677|NCT02772042|OTHER|Intervention Group|
219457678|NCT02772042|OTHER|Control Group|
219457679|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
219197250|NCT05647044|DEVICE|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
219197251|NCT05647044|DEVICE|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
219197252|NCT06115395|DEVICE|non- invasive ventilator|Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
219197253|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
219197254|NCT06115395|DEVICE|non- invasive ventilator|Group 3 (non- hypoxemic patients who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
218848483|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
219197255|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy without non- invasive ventilation{NIV) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
219457680|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
218848484|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
218848485|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
218848486|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
219197256|NCT05934487|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
219197257|NCT06813326|PROCEDURE|catheter insertion|success of catheter insertion
219197258|NCT06853977|BEHAVIORAL|Cognitive tasks|Cognitive tasks performed during intracerebral voltammetric recordings
219199445|NCT06868069|DIAGNOSTIC_TEST|Diagnostic tests and questionnaires|Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty
219457681|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
219457682|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
219457683|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
219457684|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
219457685|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
219457686|NCT03261739|BIOLOGICAL|Placebo|Placebo
219457687|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
219591481|NCT00371397|BEHAVIORAL|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
219591482|NCT00371397|BEHAVIORAL|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
218848487|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
218848488|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
218848489|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
218848490|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
218848491|NCT06687668|OTHER|Short Leg Walking Plaster Cast|A short leg walking plaster cast that extends from the head of the metatarsal to the mid-calf. This cast provides stability to the fracture site while allowing limited weight-bearing, and is designed to restrict inversion and eversion movements, thereby reducing the risk of fracture displacement. Applied for six weeks.
218848492|NCT06687668|OTHER|Walking Foot Plaster Cast|A walking foot plaster cast that covers the foot from the metatarsal heads but leaves the toes exposed. This cast allows weight-bearing while restricting side-to-side movement, providing support to the fracture area without immobilizing the ankle. It will be used for six weeks.
218848493|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
219197259|NCT06854198|OTHER|Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry|Participants will be called and offered a screening appointment. At the appointment, visual acuity, OCT, color fundus photography, tonometry, and visual field testing will be performed. The images will be assessed for abnormalities. Participants meeting referral criteria will be referred for a comprehensive eye examination with an eye care provider.
218848494|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
218848495|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
218848496|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
218848497|NCT06874517|OTHER|no intervention|no intervention
218848498|NCT06875518|PROCEDURE|BTLH with bilateral uterine artery ligation from its origin|The round ligament close to the pelvic side wall is first coagulated and separated before the procedure is applied. Further incision is then made in the peritoneum. The bladder fold is pulled downward by opening the anterior leaf of the wide ligament. It shows the ureters lateralized and the posterior leaf of the wide ligament. After that, the ureters' path is shown, the retroperitoneal area is revealed, and the location where the uterine artery leaves the iliac artery is seen.
218848499|NCT06875518|PROCEDURE|Conventional TLH|The conventional TLH technique involved division of the corneal pedicles and securing the uterine pedicles. Preoperative Preparation of bowel wasn't routinely done to improve enhanced recovery of patients. Antibiotic prophylaxis with 3rd generation cephalosporin and metronidazole was given one hour preoperatively. Obese patients received subcutaneous low molecular weight heparin and compression devices after surgery. Under general anesthesia, patients were placed in a Lloyd Davis position.
219197260|NCT06854198|OTHER|Educational Brochure|A brochure about glaucoma screening will be mailed to participants. The brochure will include contact information of a staff member who can schedule an appointment for a comprehensive eye examination.
219197261|NCT06812624|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional study. Only the information of the patients will be used.
219197262|NCT06811246|DRUG|Islatravir (ISL)|Oral administration of a single dose in period 1 and period 2
218848500|NCT01638013|DRUG|Peficitinib|Oral Tablet
219197263|NCT06811246|DRUG|Lamivudine (3TC)|Oral administration of multiple daily doses for 27 days
219197264|NCT06808334|OTHER|CLAIR|Subject will have retinal images obtained and uploaded to CLAiR Software. Subjects are not directly in contact with CLAiR software. There is no medical intervention.
219457688|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
219457689|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
218848501|NCT07028645|DRUG|desmopressin melt form 120 μg|Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.
218848502|NCT07028645|DRUG|Desmopressin lyophilisate (Melt)|Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.
218848503|NCT07028645|DRUG|Propiverine tablet|Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg
218848504|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
218848505|NCT07032701|OTHER|Best Practice|Undergo SOC non-adherent dressing wound care
218848506|NCT07032701|OTHER|Educational Intervention|Receive SNaP education
218848507|NCT07032701|OTHER|Educational Intervention|Receive SOC wound care education
218848508|NCT07032701|OTHER|Electronic Health Record Review|Ancillary studies
219457690|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
219457691|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
219457692|NCT01845766|OTHER|exercise rehabilitation|
219197265|NCT06654596|DRUG|Telitacicept 240mg|Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
219197266|NCT06654596|DRUG|Glucocorticoid|Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
219457693|NCT00327834|DRUG|atomoxetine|
219457694|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
218848509|NCT07032701|OTHER|Follow-Up Care|Attend SNaP device follow-up visits
218848510|NCT07032701|OTHER|Follow-Up Care|Attend SOC wound care follow-up visits
218848511|NCT07032701|OTHER|Medical Device Usage and Evaluation|Undergo dNPWT with SNaP device
219457695|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
219457696|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
218848512|NCT07032701|PROCEDURE|Negative Pressure Wound Therapy|Undergo dNPWT with SNaP device
219018795|NCT04415944|DRUG|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~* Extraperitoneal disease noted at the time of the second look procedure~* Macroscopic intraperitoneal disease which is not resectable to R1~* Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~* Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
219018796|NCT04415944|OTHER|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
219457697|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
219457698|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
219457699|NCT00946829|DRUG|telmisartan|
219457700|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
218848513|NCT07032701|OTHER|Photography|Ancillary studies
218848514|NCT07032701|OTHER|Questionnaire Administration|Ancillary studies
218848515|NCT07033312|DRUG|oral hyaluronate and injection|The patient receives oral hyaluronate and hyaluronate injection
218848516|NCT07033312|DRUG|hyaluronate injection|The patient receives hyaluronate injection only
218848517|NCT07034144|OTHER|Drop Table Technique|"The Drop Table Technique is a chiropractic intervention that utilizes a segmented treatment table with adjustable sections that can be elevated slightly and then dropped.~During the procedure, a high-velocity, low-amplitude (HVLA) thrust is applied while the specific segment of the table drops slightly in coordination with the thrust.~This technique aims to reduce the resistance experienced during the adjustment and to enhance the mechanical effect on targeted spinal joints.~In this study, the Drop Table Technique will be specifically applied to the cervical spine to address mechanical neck pain.~All applications will be performed by a licensed chiropractor using standardized positioning and adjustment protocols to ensure consistency across sessions."
219457701|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
219591483|NCT04494880|DRUG|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
219591484|NCT00517127|DRUG|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
218848518|NCT07034144|OTHER|Cervical Spine Manipulation|"Cervical spinal manipulation (SM) will be applied with the participant supine to restrictions found on motion palpation, following the technique described by Bergmann and Peterson. The participant's head and neck will be simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7)-to the end of passive range of motion (ROM).~Subsequently, a high-velocity, low-amplitude thrust will be delivered in the direction of restricted movement. Participants with greater ROM restriction in the lateral plane will receive more laterally-to-medially directed thrusts. Participants with more restriction in rotation will be given thrusts in the direction of restricted axial rotation, and those with more restriction in extension will receive more anteriorly directed thrusts."
219457702|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
219457703|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
219457704|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
219457705|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
219457706|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
219457707|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
219457708|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
219457709|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
219457710|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
219457711|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
219457712|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
219457713|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
219457714|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
219457715|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
219457716|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
219457717|NCT00114400|DRUG|folic acid|
219018810|NCT07132983|DRUG|Ensifentrine 3 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
219018811|NCT07132983|DRUG|Glycopyrrolate 42.5 mcg|Single dose, administered by oral inhalation using a standard jet nebulizer
219018812|NCT07132983|DRUG|Ensifentrine 1.5 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
219457718|NCT00114400|DRUG|vitamin B12|
219457719|NCT00114400|DRUG|vitamin B6|
219457720|NCT00848172|DRUG|Octanoic Acid|4mg/kg
219457721|NCT00848172|DRUG|Placebo|identical capsules
219457722|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
219457723|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
219457724|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
218848519|NCT06896812|DEVICE|The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling.|"The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling. The app will be installed on the participant's mobile device. The app will be used anonymously, and patients use their unique study code to activate the app.~The content and user-interface of the app-based treatment were developed in collaboration with healthcare professionals for relevant medical specialties, including orthopedic surgery, neurosurgery, neurology, physiotherapy, and rehabilitation. The content is based on expert opinion from these fields. Additionally, there is scientific evidence indicating that the treatments used within the app are safe and effective. The app has been tested for usability and functionality by both professionals and laypersons, including individuals with back pain."
218848520|NCT06897319|DEVICE|High-Flow Tracheal Therapy|Device: Airvo 2 (Fisher \& Paykel Healthcare) Settings: Flow rate start at 40L/min and will be adapted according to tolerance; temperature aimed at 37°C or 34°C according to tolerance, FiO₂ set (if needed) according to SpO2 target values.
218848521|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Polyphenol Rich Drink|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with control drink (Placebo) devoid of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the RGPD 60 minutes prior.
218848522|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Control Drink (Placebo)|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a control drink (Placebo) (150 mL) containing 0 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the Control drink (Placebo) 60 minutes prior.
218848523|NCT06897423|OTHER|Education|"Midwifery students in the intervention group of the study will receive 8 weeks of disaster midwifery training. The training content will be covered in 8 main categories: safe prenatal, delivery and postnatal period, women's reproductive health services, family planning, immunization, violence and sexually transmitted infections and newborn and infant care, reproductive health in disadvantaged groups, emergency obstetric situations."
219591485|NCT00517127|DRUG|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
219018813|NCT07132983|DRUG|Ensifentrine 3 mg (marketed formulation)|Single dose, administered by oral inhalation using a standard jet nebulizer
219018814|NCT05039281|BIOLOGICAL|Atezolizumab|Given IV
219018815|NCT05039281|DRUG|Cabozantinib|Given PO
219457725|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
219457726|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
219457727|NCT04522986|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
219457728|NCT05908162|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
219591486|NCT03547076|DIAGNOSTIC_TEST|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
219591487|NCT02837614|DRUG|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
219591488|NCT02837614|DRUG|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
218848524|NCT06895421|BEHAVIORAL|Cognitive behavior therapy based guided self help manual for psychosis plus treatment as usual|The Cognitive Behavior Therapy-Based Guided Self-Help (CBTp-GSH) manual is a structured intervention designed specifically for individuals with psychosis, particularly those diagnosed with Schizophrenia Spectrum Disorders. This manual offers a culturally adapted approach, providing participants with tools and strategies rooted in Cognitive Behavioral Therapy (CBT) principles, tailored to be delivered through guided self-help.
219457729|NCT03530059|OTHER|Home-based rehabilitation|Observational study
219457730|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
219457731|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
219457732|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
219457733|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
219457734|NCT02709941|OTHER|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
219457735|NCT02709941|OTHER|Placebo|
219457736|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
219457737|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
219457738|NCT00282607|DRUG|DA-8159|
219457739|NCT01424865|GENETIC|fluorescence in situ hybridization|
219457740|NCT01424865|OTHER|immunohistochemistry staining method|
219457741|NCT01424865|OTHER|immunologic technique|
219457742|NCT01424865|OTHER|laboratory biomarker analysis|
219457743|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
219457744|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
219591489|NCT02837614|PROCEDURE|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
219591490|NCT02837614|DRUG|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
219591491|NCT02416414|DEVICE|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
219591492|NCT02416414|DEVICE|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
219591493|NCT03777423|DEVICE|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
219591494|NCT03777423|DEVICE|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
218848525|NCT06895421|DRUG|Treatment as usual|anti psychotic drugs which they are already using
218848526|NCT06896253|DRUG|Pulse bolus corticosteroids|Treatment administration
218848527|NCT06896253|DRUG|Pulse bolus corticosteroids and IVIG|Treatment administration
218848528|NCT06896253|DRUG|Pulse bolus corticosteroids (G5%) and IVIG (G5 %)|Treatment administration
218848529|NCT05539963|DRUG|STIMULAN VG|Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
219018818|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
219018819|NCT05010122|DRUG|Gilteritinib|Given PO
219018820|NCT05010122|DRUG|Venetoclax|Given PO
218848530|NCT05539963|DRUG|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements.
218848531|NCT06896539|OTHER|Telemedicine|"Contraceptive Counselling using the LOWE Method and through Tele Health, Video Call with Midwife."
218848532|NCT06896539|OTHER|Counselling in person visit|"Contraceptive Counselling using the LOWE Method. In-person visit with midwife at Maternal Health Clinic."
218848533|NCT05463744|DRUG|Insulin Efsitora Alfa|Administered SC
218848534|NCT05463744|DRUG|Insulin Degludec|Administered SC
218848535|NCT07081880|OTHER|biological sampling|DNA and Cells will be sampled
218848536|NCT02693054|DEVICE|HALO|Laser Treatment
219197267|NCT06810791|DRUG|HVA|Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14. Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
219457745|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
219457746|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
219457747|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
219457748|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
219457749|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
218848537|NCT00432328|DRUG|Avotermin|
219457750|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
219457751|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
219457752|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
219457753|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
219457754|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219457755|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
219457756|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
219457757|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
219457758|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
219457759|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
219457760|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
219457761|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
219457762|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
219457763|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
219457764|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
219457765|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
219457766|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
218848538|NCT06943807|DIAGNOSTIC_TEST|Fecal sample methylation detection for gastric cancer|Detection of gastric cancer-associated methylation sites in fecal samples
218848539|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
219018838|NCT06142357|OTHER|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
218848540|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
219457767|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
218848541|NCT02772796|DRUG|SENS-218|Oral Administration
218848542|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
218848543|NCT01448824|DRUG|LY2484595|Administered orally
218848544|NCT01448824|DRUG|Placebo|Administered orally
218848545|NCT01448824|DRUG|Ketoconazole|Administered orally
218848546|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
218848547|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
218848548|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
218848549|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
218848550|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
218848551|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
218848552|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
218848553|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
218848554|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
218848555|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
218848556|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
218848557|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
218848558|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
218848559|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
218848560|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
218848561|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
218848562|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
218848563|NCT06006507|OTHER|control|no exercise will be given
218848564|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
218848565|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
218848566|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
218848567|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
218848568|NCT05319483|OTHER|No intervention|No intervention.
219197268|NCT06810791|DRUG|VA|VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.
219197269|NCT06810791|DRUG|Standard Chemotherapy|Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.
219197270|NCT06811753|PROCEDURE|robotic surgery|minimally invasive surgery
219197271|NCT06811883|DEVICE|LIGHTBACK|This group will perform a standard 20-minute warm-up, and the LIGHTBACK protocol is also included.
218848569|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
218848570|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
218848571|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
218848572|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
218848573|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
218848574|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
218848575|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
218848576|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
218848577|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
218848578|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
218848579|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
218848580|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
218848581|NCT00004446|DRUG|fluoxetine|
219018844|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
219018845|NCT07115329|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
219018846|NCT07119944|OTHER|Not Related|This observational study does not involve any therapeutic intervention. Instead, all participants undergo gait analysis using two different measurement methods-2D pose estimation algorithms and an inertial measurement unit (G-Walk system)-to compare their outputs. Both assessments are performed on the same individuals under standardized conditions without altering their routine care.
219197272|NCT06811883|DEVICE|Placebo|This group will perform a standard 20-minute warm-up, but the LIGHTBACK protocol is not included and a similar placebo is used.
219197273|NCT03492424|DEVICE|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
219197274|NCT00942877|DRUG|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
219197275|NCT03495128|OTHER|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
219197276|NCT03495128|OTHER|Reconditioning|daily resistance training (for 3 days) on one leg
219197277|NCT04784416|DEVICE|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
219197278|NCT04784416|DEVICE|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."
219197279|NCT04784416|DRUG|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
219197280|NCT06617416|DRUG|Cadonilimab (AK104)|AK104 ivgtt Q3W
219197281|NCT06617416|DRUG|Sugemalimab|1200mg Q3W
219591495|NCT05226546|DRUG|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
219591496|NCT05226546|OTHER|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
219591497|NCT02817945|DRUG|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
219591498|NCT02377427|DRUG|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
219591499|NCT03478527|DIETARY_SUPPLEMENT|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
219591500|NCT03478527|OTHER|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
219591501|NCT00977886|DRUG|Placebo|Oral, 10 days
219591502|NCT00977886|DRUG|ELB353|Oral, 10 days
219197282|NCT03595202|DRUG|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
219197283|NCT03595202|DRUG|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
219197284|NCT05388812|OTHER|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
219197285|NCT05388812|OTHER|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
219197286|NCT04502186|BEHAVIORAL|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
219197287|NCT04502186|OTHER|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
219197288|NCT06313060|DIETARY_SUPPLEMENT|Coca-cola|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
219197289|NCT03233854|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
219197290|NCT03233854|DRUG|Cyclophosphamide|Given IV
219197291|NCT03233854|DRUG|Fludarabine Phosphate|Given IV
219197292|NCT03233854|OTHER|Laboratory Biomarker Analysis|Correlative studies
219457768|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
218848582|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
218848583|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
219457769|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
219197293|NCT03233854|OTHER|Questionnaire Administration|Ancillary studies
219197294|NCT03233854|DRUG|NKTR-255|Given IV
219197295|NCT06774664|BIOLOGICAL|SCTC21C|Drug: SCTC21C Administered SC
219591503|NCT02212379|DRUG|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
219591504|NCT03384082|PROCEDURE|hysteroscopic treatment|treatment
219197296|NCT04175470|DRUG|Bevacizumab|10 mg/kg intravenously every three weeks
219457770|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
219591505|NCT02105974|DRUG|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
219591506|NCT02105974|DRUG|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
219591507|NCT00801580|DRUG|doxorubicin liposomal|"* Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine"
218848584|NCT03668938|OTHER|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
218848585|NCT03668938|OTHER|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
218848586|NCT01995669|OTHER|Laboratory Biomarker Analysis|Correlative studies
218848587|NCT01995669|DRUG|Lenalidomide|Given PO
218848588|NCT01995669|BIOLOGICAL|Obinutuzumab|Given IV
218848589|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
219197297|NCT04175470|DIETARY_SUPPLEMENT|Tocotrienol|Capsules, 300 mg orally three times daily
219197298|NCT06754852|DRUG|HMB-002 (Part A)|HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.
219197299|NCT06754852|DRUG|HMB-002 (Part B)|HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.
219197300|NCT06841900|DEVICE|Cochlear Implantation|Standard cochlear implantation
219591508|NCT03877991|DRUG|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
219591509|NCT03877991|DRUG|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
219591510|NCT03877991|DRUG|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
219197301|NCT06814223|DRUG|• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA|"Patients with an elevated risk of infection will be randomly assigned to two groups using stratification for new catheter placement versus catheter replacement. Fifty percent of the high-risk patients will receive prophylactic antibiotics targeting gram-positive and gram-negative bacteria. The antibiotic regimen will include:~* Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously.~* Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA colonization will receive vancomycin (2 grams)."
219197302|NCT06841367|OTHER|Mindfulness-based stress reduction training|It is expected that improvements in physiological parameters and anxiety levels will be observed in the preeclampsia group with awareness-based stress reduction training.
218848590|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
218848591|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
218848592|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
218848593|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
218848594|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
218848595|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
218848596|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
218848597|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
219197303|NCT06841601|OTHER|topical anesthetic gel|gels applied directly to the mucous membranes to provide localized relief of pain by numbing the area. They typically contain active ingredients such as lidocaine, benzocaine, or prilocaine, which work by blocking nerve signals to reduce sensation and discomfort
219197304|NCT06841601|OTHER|Vibration|The vibration generated by the Buzzy device functions as a non-pharmacological agent that can reduce pain perception in children based on the principles of the Gate Control Theory of Pain.
219197305|NCT06841601|OTHER|Cold pack|cold packs are also provided by the Buzzy device. they act as non-pharmacological agents that can reduce pain perception in children based on the Gate Control Theory of Pain.
219457771|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
219457772|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
219591511|NCT02075177|DRUG|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
219591512|NCT02075177|DRUG|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
219197306|NCT06841263|OTHER|Not applicable- observational study|Not applicable - observational study
219197307|NCT02905331|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
219591513|NCT02529891|OTHER|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
219591514|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
218848598|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
219197308|NCT02905331|DRUG|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
219197309|NCT01385202|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
219197310|NCT03368729|DRUG|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
219197311|NCT03368729|DRUG|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
219197312|NCT06594497|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
219197313|NCT06594497|OTHER|Conventional Physiotherapy + Kinesthetic motor imagery training|Conventional Physiotherapy + Kinesthetic motor imagery training
219591515|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
219591516|NCT00506584|DIETARY_SUPPLEMENT|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
219197314|NCT04860765|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
219457773|NCT01986049|DRUG|Bupivicaine|
219457774|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
218848599|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
219457775|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
219197315|NCT05677594|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
219197316|NCT04305366|OTHER|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
219197317|NCT03681262|DEVICE|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
219199446|NCT06867432|DRUG|Combination Product：t: SIRT-Y90 +HAIC+Atezolizumab + Bevacizumab|"Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.~HAIC：administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks."
219199447|NCT06867237|DEVICE|Suction cuff pressure|Use the device to do continuous management of suction cuff pressure and subglottic irrigation suction
219457776|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
219457777|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
219457778|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
219457779|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
219457780|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
219457781|NCT03880162|OTHER|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
219457782|NCT03880162|OTHER|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
219457783|NCT04560127|DRUG|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
219457784|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
219457785|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
219197318|NCT03681262|DEVICE|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
219197319|NCT06790589|DRUG|Levothyroxine Oral Tablet [Synthroid]|"Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side."
219197320|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with glucose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of glucose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
219199448|NCT06867861|DIETARY_SUPPLEMENT|Fiber|Psyllium fiber supplement capsules, 2g soluble fiber per capsule. They will be instructed to take 4 capsules twice daily for a total of 16g supplemental soluble fiber per day. This will be continued throughout pregnancy.
218848600|NCT06145204|OTHER|questionnaire|anamnesis, OMSPQ, Brief Pain Inventory-short form, lymph-ICF-LL
218848601|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
218848602|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
218848603|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
218848604|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
219591517|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
218848605|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
218848606|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
218848607|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
218848608|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
219457786|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
219457787|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
219591518|NCT00506584|DIETARY_SUPPLEMENT|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
219591519|NCT04274231|GENETIC|different effection|Analysis of the reasons for treatment
219591520|NCT06232473|BEHAVIORAL|Patient Education|Please see arm desciption
219591521|NCT06232473|DRUG|Duloxetine|Please see arm description
219591522|NCT06232473|DRUG|Benztropine Mesylate 0.5 MG and passive placebo RAP|Please see arm description
219591523|NCT06232473|BEHAVIORAL|Enhanced usual care|Please see arm description
219591524|NCT04037774|DRUG|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
219457788|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
219457789|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
219457790|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
219457791|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
218848609|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
218848610|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
218848611|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
218848612|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
218848613|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
218848614|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
218848615|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
218848616|NCT03347526|DRUG|Vigabatrin|oral
218848617|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
219197321|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with fructose|Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of fructose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
219591525|NCT04037774|OTHER|placebo|addition of placebo with local anesthetic to create a control group
219591526|NCT01181362|PROCEDURE|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
219591527|NCT00902317|PROCEDURE|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
219591528|NCT00902317|PROCEDURE|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
219591529|NCT00902317|PROCEDURE|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
219591530|NCT00902317|DEVICE|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
218848618|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
218848619|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
219457792|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
219457793|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
219457794|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
219457795|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
219457796|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
219457797|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
218848620|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
219457798|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
219457799|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
219457800|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
219457801|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
219457802|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
219457803|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
219457804|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
219457805|NCT01676649|DRUG|Carboplatin|AUC = 6
219457806|NCT01676649|DRUG|Paclitaxel|175 mg/m2
219457807|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
219457808|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
219457809|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
219457810|NCT01051856|DEVICE|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
219457811|NCT01051856|PROCEDURE|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
219591531|NCT00902317|PROCEDURE|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
219457812|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
219457813|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
219591532|NCT04332965|PROCEDURE|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
219591533|NCT03123432|DIETARY_SUPPLEMENT|immunomodulating nutrients enriched diet|
218848621|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
218848622|NCT02650804|DRUG|Gemcitabine|
218848623|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
218848624|NCT00046293|DRUG|Reopro|
218848625|NCT00046293|DRUG|Retrovase|
219457814|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
219591534|NCT03123432|DIETARY_SUPPLEMENT|standard diet|
219457815|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
219457816|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
219457817|NCT02381795|DRUG|Nasal Carbon Dioxide|
219457818|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
219457819|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
219457820|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
219457821|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
219591535|NCT03209557|OTHER|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
219591536|NCT02613702|PROCEDURE|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
218848626|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
218848627|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
219197322|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with sucrose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of sucrose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
218848628|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
219197323|NCT06751862|DIETARY_SUPPLEMENT|Short-term (7 days) fructose restriction|Subjects will receive a package of glucose and selected foods without fructose to supplement their diet. For seven days they then will adhere to the diet without fructose and keep the detailed dietary record.
218848629|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
218848630|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
219197324|NCT05774665|DRUG|Omega 3|Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
219197325|NCT05774665|OTHER|Placebo|Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
219457822|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
219457823|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
219591537|NCT02613702|PROCEDURE|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
219591538|NCT02613702|PROCEDURE|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
218848631|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
219457824|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
219457825|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
219457826|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
218848632|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
218848633|NCT00004248|BIOLOGICAL|aldesleukin|
219457827|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
218848634|NCT00004248|DRUG|doxorubicin hydrochloride|
219457828|NCT02908841|DEVICE|Surgicel Snow|
219457829|NCT02908841|OTHER|Standard of Care|
218848635|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
219197326|NCT06594055|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring is a wearable device that continuously collects glucose data from interstitial fluid.
219197327|NCT06594055|DEVICE|Self-monitoring blood glucose|The control group used self-monitoring blood glucose (SMBG) for two weeks with a manual food diary, followed by diet education. They then repeated SMBG with a food diary three months later, with a final follow-up at the 6-month mark.
219457830|NCT01611558|BIOLOGICAL|Ipilimumab|
219457831|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
219457832|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
218848636|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
218848637|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
218848638|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
218848639|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
218848640|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
218848641|NCT01255813|OTHER|Control|No stimulation applied
218848642|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
218848643|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
219457833|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
219457834|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
219457835|NCT00044811|DRUG|Fexofenadine|
219457836|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
219457837|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
219457838|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
219457839|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
219457840|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
219457841|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
219457842|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
219457843|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
219457844|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
219591539|NCT06144164|PROCEDURE|Immediate Lymphatic Reconstruction|Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
219591540|NCT06144164|DIAGNOSTIC_TEST|Volumetric arm measurements|Volumetric arm measurements will occur at each in-person postoperative visit time points.
218848644|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
218848645|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
219457845|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
219457846|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
219591541|NCT06144164|OTHER|Lymphatic massage|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
219591542|NCT06144164|OTHER|Range of motion exercises|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
218848646|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
218848647|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
218848648|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
218848649|NCT04840563|DEVICE|Precision1|Precision1
219197328|NCT06594055|DEVICE|AI food camera|The AI food camera automatically detects the contents and nutritional information of foods.
219591543|NCT06144164|OTHER|Compression garment use|Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
219591544|NCT04578444|DRUG|Zanidatamab|Administered intravenously
219591545|NCT06649240|DRUG|Statins and/or Ezetimibe|Statin ± Ezetimibe to achieve target LDL-cholesterol level
219457847|NCT01245972|PROCEDURE|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
219457848|NCT04005885|DEVICE|comfilcon A|Contact Lens
219591546|NCT06649240|DRUG|PCSK9 inhibitor|The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
219591547|NCT04511962|OTHER|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
219197329|NCT06594055|DEVICE|Food diary|A food diary is a record in which the user manually writes down the consumed foods and their amounts.
218848650|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
219457849|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
219457850|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
219457851|NCT01412333|DRUG|Interferon beta-1a|
219457852|NCT01412333|DRUG|Ocrelizumab-matching placebo|
219457853|NCT01412333|DRUG|Ocrelizumab|
219197330|NCT06592989|DRUG|sorafenib, gefitinib|Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
219197331|NCT04370834|BIOLOGICAL|Tocilizumab|Given IV
219457854|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
219457855|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
219457856|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
219457857|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
219591548|NCT06912711|DRUG|Toripalimab|Triplizumab (240mg, Q3W, 2 cycles, induction)and (240mg, Q3W, 15 cycles, adjuvant)
218848651|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
218848652|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
218848653|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
218848654|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
219197332|NCT06355986|BEHAVIORAL|Alert-based computerized decision support|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
219457858|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
219457859|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
219591549|NCT06912711|DRUG|Nimotuzumab|Triplizumab (200mg, Q3W, 2 cycles, induction) and (200mg, Q3W, 15 cycles, adjuvant)
219197333|NCT05599724|OTHER|Biocollection|"For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota."
219197334|NCT05032066|DRUG|HZN-825|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
219457860|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
219457861|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
218848655|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
218848656|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
218848657|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
218848658|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
218848659|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
218848660|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
218848661|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
218848662|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
218848663|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
218848664|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
218848665|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
219457862|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
219457863|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
219457864|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
219457865|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
219591550|NCT06912711|PROCEDURE|surgery|The complete resection of the nasopharyngeal tumor and its adequate safety boundary must be performed under general anesthesia and under the guidance of nasal endoscopy through bilateral nasal passages. The anterior incisal margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper incisal margin should reach about 0.5-1cm in front of the upper margin of the posterior nostril. The lateral incisal margin and the lower incisal margin should be individually designed according to the size and location of the tumor. A safe incisal margin of 0.5-1.0cm was obtained, and then the tumor tissue and normal tissue of the incisal margin were ablated layer by layer from the upper incisal margin to the lower incisal margin until no obvious tumor remained under the naked eye.
219591551|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
219591552|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
219591553|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
219591554|NCT06546774|DIETARY_SUPPLEMENT|Melatonin|In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
219591555|NCT06285994|PROCEDURE|High frequency jet ventilation|Use of high frequency jet ventilation during bronchoscopy
219591556|NCT01777360|DEVICE|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
219591557|NCT02969174|OTHER|zimin Lu,Guo Sa|chengzhong Liu
219591558|NCT04051619|DRUG|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
219591559|NCT05005897|BIOLOGICAL|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
219457866|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
218848666|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
218848667|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
218848668|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
218848669|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
218848670|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
218848671|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
218848672|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
218848673|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
218848674|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
218848675|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
218848676|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
218848677|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
218848678|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
218848679|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
219457867|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
219457868|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
219457869|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
219457870|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
219457871|NCT01427855|OTHER|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
219591560|NCT06634433|BEHAVIORAL|Health Personnel Attitude|The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
219591561|NCT00839553|PROCEDURE|Intrapleural Minocycline application|
219591562|NCT01442324|PROCEDURE|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
219591563|NCT04060446|DEVICE|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
219591564|NCT04060446|OTHER|Questionnaire Administration|Ancillary studies
219591565|NCT04060446|BEHAVIORAL|Tobacco Smoking|Smoke cigarettes
219591566|NCT02293980|DRUG|MK-3795|Oral administration
219591567|NCT02293980|DRUG|Nivolumab|IV infusion
219591568|NCT02293980|DRUG|Cabozantinib|Oral administration
219457872|NCT01427855|OTHER|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
219591569|NCT02293980|DRUG|Bezlutifan|Oral administration
219591570|NCT02339662|DRUG|Gabapentin|muscles pain treatment
219591571|NCT02339662|DRUG|Amitriptyline|muscles pain treatment
219591572|NCT04876105|OTHER|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
219591573|NCT02354404|BIOLOGICAL|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
219457873|NCT01427855|OTHER|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
219457874|NCT01427855|OTHER|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
219457875|NCT01427855|OTHER|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
219457876|NCT01427855|OTHER|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
219457877|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
219457878|NCT00000244|DRUG|Dynorphin 1 - 13|
219457879|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
218848680|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
218848681|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
219457880|NCT00003572|DRUG|mycophenolate mofetil|
219591574|NCT02354404|BIOLOGICAL|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
219591575|NCT02354404|BIOLOGICAL|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
219591576|NCT06277089|OTHER|Casts|According to level of scoliosis cast done and recast in a serial manner
219591577|NCT04853095|PROCEDURE|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
219591578|NCT04853095|PROCEDURE|Standard of care|ePLND without peritoneal flap fixation
219591579|NCT03831204|DEVICE|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
219591580|NCT03831204|DIAGNOSTIC_TEST|prognostic scores|Effect and GWTGHF were calculated for every patient
218848682|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
218848683|NCT01611363|DRUG|ASP1941|Oral
218848684|NCT01611363|DRUG|Placebo|Oral
218848685|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
219457881|NCT00003572|DRUG|tacrolimus|
219457882|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
219457883|NCT00003572|RADIATION|radiation therapy|
219591581|NCT03510598|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
219591582|NCT03510598|DRUG|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
219591583|NCT06325397|OTHER|High Intraocular Pressure (IOP)|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with Intraocular Pressure (IOP) ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye.
219591584|NCT06325397|OTHER|Low Intraocular Pressure (IOP)|Low Intraocular Pressure (IOP) Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye
219591585|NCT06316583|OTHER|TrP-DN and Acupuncture|Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
219197335|NCT05032066|DRUG|Placebo|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
219457884|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
219457885|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
219457886|NCT00462657|GENETIC|polymerase chain reaction|
219457887|NCT00462657|OTHER|bronchoalveolar lavage|
219457888|NCT00462657|OTHER|immunoenzyme technique|
219457889|NCT00462657|OTHER|laboratory biomarker analysis|
219457890|NCT00462657|PROCEDURE|bronchoscopy|
219457891|NCT00462657|PROCEDURE|management of therapy complications|
219457892|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
219457893|NCT00826787|DRUG|Levetiracetam|750 mg tablet
219457894|NCT00031824|DRUG|cyclosporine|
219457895|NCT00031824|DRUG|hydroxychloroquine|
219457896|NCT00031824|DRUG|prednisone|
219457897|NCT00031824|DRUG|tacrolimus|
219457898|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
219457899|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
219457900|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
219457901|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
219457902|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
219591586|NCT05915325|PROCEDURE|Physical training|"1. Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~2. Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
219591587|NCT02066103|DRUG|Paclitaxel|
219591588|NCT00993486|BIOLOGICAL|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
219591589|NCT04308226|BEHAVIORAL|Patient Navigation|The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
219457903|NCT05291741|DIETARY_SUPPLEMENT|VLCD|Advice regarding VLCD
219457904|NCT05291741|DIETARY_SUPPLEMENT|Standard care|Standard dietary advice for weight loss before bariatric surgery
219457905|NCT02718625|BIOLOGICAL|Santyl|Collagenase ointment applied topically
219457906|NCT02718625|BIOLOGICAL|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
219591590|NCT01630967|DRUG|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
219591591|NCT05994001|DRUG|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
219591592|NCT05994001|DRUG|LM-302|LM-302 :ClAUDIN 18.2-ADC
219591593|NCT01626443|DIETARY_SUPPLEMENT|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
219591594|NCT01626443|DIETARY_SUPPLEMENT|Folic acid|Folic acid (200 mcg); 2 x die
219591595|NCT06598878|PROCEDURE|AR gait training|Participants will walk on a pathway projected in augmented reality (AR), following the instructions provided on the pathway Each session will last for 60 minutes, conducted three times per week, over a period of six weeks.
219591596|NCT00935610|DIETARY_SUPPLEMENT|Immunocal|20 grams per day of Immunocal for 135 days.
219591597|NCT00935610|DIETARY_SUPPLEMENT|Casein|20 grams per day for 135 days
219591598|NCT01143766|DRUG|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
218848686|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
218848687|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
218848688|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
218848689|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
218848690|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
218848691|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
218848692|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
219457907|NCT03971019|DRUG|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
219457908|NCT03971019|BEHAVIORAL|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
219457909|NCT00860704|DRUG|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
219457910|NCT02681068|OTHER|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
219457911|NCT02828462|OTHER|CAPRI|
219457912|NCT03704090|BEHAVIORAL|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
219457913|NCT03704090|BEHAVIORAL|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
219457914|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
219457915|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
219457916|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
219457917|NCT00984152|DRUG|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
219457918|NCT00984152|DRUG|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
219457919|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
218848693|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
218848694|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
218848695|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
218848696|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
219457920|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
219457921|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
219457922|NCT00000641|DRUG|Ethambutol hydrochloride|
219457923|NCT00000641|DRUG|Amikacin sulfate|
219591599|NCT01143766|OTHER|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
219591600|NCT04321330|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
219591601|NCT06370286|BEHAVIORAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
219591602|NCT06370286|BEHAVIORAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
219591603|NCT04020289|BEHAVIORAL|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
219457924|NCT00000641|DRUG|Azithromycin|
219457925|NCT00000641|DRUG|Rifampin|
219457926|NCT00000641|DRUG|Clofazimine|
219457927|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
219591604|NCT06404658|PROCEDURE|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
219591605|NCT03610516|DRUG|CFZ533|Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
218848697|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
218848698|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
218848699|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
218848700|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
218848701|NCT02503670|OTHER|Control Group|Continue with standard care.
218848702|NCT00521690|DRUG|insulin detemir|
218848703|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
218848704|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
218848705|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
218848706|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
218848707|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
218848708|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
218848709|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
218848710|NCT01606683|OTHER|No intervention|
218848711|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
218848712|NCT01345591|PROCEDURE|Fat Grafting|
219018850|NCT06978582|BEHAVIORAL|Mindful and conscious movement-based exercise|The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month: • 15 minutes of health education. Educational content will focus on self-management, pacing, planning of activity and rest, basic theoretical framework about the conditions, and familiarization with mindful and awareness practices and their purported benefits. • 30 minutes of conscious movement-based exercise practice, increasing by 5 minutes each month and guided by pacing recommendations. Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material.
219197336|NCT04093921|BEHAVIORAL|MET-based therapy|see previous
219197337|NCT04093921|BEHAVIORAL|Standard Care|To include all recommended outpatient treatments
219457928|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
219457929|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
219457930|NCT01836549|DRUG|imetelstat sodium|Given IV
219457931|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
219457932|NCT00003465|DRUG|temozolomide|
219457933|NCT01500421|DEVICE|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
218848713|NCT02514694|DRUG|LEO32731|
218848714|NCT02514694|OTHER|Placebo|
218848715|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
218848716|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
218848717|NCT03100916|DRUG|BI 690517|once daily
218848718|NCT03100916|DRUG|Placebo|once daily
218848719|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
219591606|NCT03610516|DRUG|Placebo|multiple doses of placebo intravenous infusion
219591607|NCT05169450|DRUG|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
219591608|NCT05169450|DRUG|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
219591609|NCT00293943|PROCEDURE|Pulmonary vein ablation|
219591610|NCT04385303|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
219591611|NCT04385303|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
218848720|NCT03100916|DRUG|BI 690517|Non- fasting
218848721|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
219197338|NCT06598865|OTHER|adapted physical activity|After the initial training in adapted physical activity (APA), patients will receive regular support from an APA instructor, and they will be asked to participate in 3 sessions per week of APA, if possible in a Sport-Health center close to their home, for the entire duration of the study. The content of the additional APA sessions (up to 2 additional sessions per week) can be discussed with the APA instructor. They will also be asked to return to the study center for a visit at 3 months (Visit 3) to assess the effect of the APA conducted during this period
219197339|NCT06056011|DEVICE|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
219197340|NCT06585839|BEHAVIORAL|Digital coaching solution to improve childbirth experience|Intervention provides coaching to improve the childbirth experience and offers comprehensive perinatal mental health support to pregnant and postpartum women. It features emotion tracking and exercise customization functionality, along with an avatar-based platform. The app includes digital psychotherapy exercises and psychoeducation. These core elements are complemented by exercises in mindfulness, relaxation, and self-soothing.
218848722|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
218848723|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
218848724|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
218848725|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
218848726|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
218848727|NCT01820403|OTHER|portion size kcal of box lunch|
218848728|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
218848729|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
219197341|NCT06585839|OTHER|Application for the control group|Application for the control group including surveys.
219197342|NCT04977271|DRUG|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
219197343|NCT06590441|DEVICE|Myopia control spectacles|Myopia control spectacles fitted with temperature sensors
219197344|NCT04102111|DRUG|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
219197345|NCT04102111|DRUG|Placebo|Participants will receive oral tablets of matching placebo twice daily.
219197346|NCT06595706|DRUG|Lucid-21-302|Capsule containing a small molecule inhibitor of hypercitrullination
219197347|NCT06595706|DRUG|Placebo|Capsule containing only Silicified Microcrystalline Cellulose
219591612|NCT01653301|DRUG|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
219591613|NCT01653301|DRUG|XELOX RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
219197348|NCT00887198|DRUG|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
219197349|NCT00887198|DRUG|Placebo|4 placebo tablets per day taken orally.
218848730|NCT05302167|DEVICE|Molehill Mountain app|As above.
218848731|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
218848732|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
218848733|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
218848734|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
218848735|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
218848736|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
219197350|NCT00887198|DRUG|Prednisone|5 mg tablet orally twice daily.
219197351|NCT06588140|DEVICE|Duplicated refitted complete denture made from conventionally heat-cured polymethyl methacrylate.|The duplication of a refitted complete removable denture will be performed using conventional heat-cured polymethyl methacrylate through the conventional heat-cured polymerization technique.
218848737|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
218848738|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
218848739|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
218848740|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
218848741|NCT01150058|GENETIC|western blotting|
218848742|NCT01150058|OTHER|flow cytometry|
218848743|NCT01150058|OTHER|laboratory biomarker analysis|
218848744|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
218848745|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
218848746|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
218848747|NCT00094159|DRUG|SNS-595|
218848748|NCT01338350|DRUG|AZD5423|Inhalation, suspension
218848749|NCT01338350|DRUG|Placebo|Inhalation, solution
219018851|NCT06978582|BEHAVIORAL|Conventional exercise|"The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month:~* 15 minutes of health education. Educational content will now focus on self-management, pacing, planning of activity and rest, basic theoretical framework about the conditions, and the rationale for the impact of exercise in symptom management.~* 30 minutes of low intensity strength and aerobic exercise practice, with session duration progressively increased by increasing by 5 minutes each month and guided by pacing recommendations.~Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material."
219591614|NCT06197269|OTHER|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
219591615|NCT06197269|OTHER|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
219591616|NCT01328379|DRUG|Dalfampridine-ER 5mg|5mg, twice daily
219591617|NCT01328379|DRUG|Dalfampridine-ER 10mg|10mg, twice daily
219591618|NCT01328379|OTHER|Placebo|placebo, twice daily
219591619|NCT01820234|OTHER|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
219591620|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
219591621|NCT03523078|PROCEDURE|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
219591622|NCT00318877|BEHAVIORAL|After school team sports program|
219591623|NCT00318877|BEHAVIORAL|After school health education program|
219591624|NCT04351633|OTHER|questionnaire assesment|questionnaire assesment
219591625|NCT03706937|OTHER|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
219591626|NCT05326048|OTHER|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
219591627|NCT06416956|DRUG|Caffeine|We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
219591628|NCT04778085|BEHAVIORAL|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
219591629|NCT04778085|OTHER|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
219591630|NCT00588588|PROCEDURE|Bronchoscopy|Bronchoscopy procedure
219591631|NCT00588588|PROCEDURE|Clinical pulmonary infection score (CPIS)|Calculate CPIS
219591632|NCT00660907|DRUG|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
219591633|NCT00660907|DRUG|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
219018852|NCT02851706|OTHER|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
219591634|NCT00660907|DRUG|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
219591635|NCT00237640|DRUG|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
219591636|NCT02218801|OTHER|Evaluation of treatment for liver metastasis|
219591637|NCT03973307|DIAGNOSTIC_TEST|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
219591638|NCT02813265|DRUG|KPI-121 0.25% Ophthalmic Suspension|
219591639|NCT02813265|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
219591640|NCT00668694|BEHAVIORAL|Stimulation|Stimulation given to the child by mother
219591641|NCT04975191|BEHAVIORAL|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
219591642|NCT04975191|BEHAVIORAL|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
219591643|NCT04975191|BEHAVIORAL|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
219591644|NCT01815476|RADIATION|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
218848750|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
219457934|NCT01500421|DEVICE|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
219457935|NCT01500421|DEVICE|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
219591645|NCT05264129|DRUG|Atogepant|Oral Tablet
219457936|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
219457937|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
219457938|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
219457939|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
219591646|NCT05264129|DRUG|Ubrogepant|Oral Tablet
219591647|NCT02053337|DEVICE|Self adhesive foam dressing|Self adhesive foam dressing
219591648|NCT00618332|DRUG|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
219591649|NCT00618332|DRUG|placebo|2 puffs in each nostril once a day for 2 weeks
219197352|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM pink polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed separately with pink polymethyl methacrylate resin, and the teeth are printed as a single unit using tooth-colored resin, followed by the assembly of the two components.
218848751|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
218848752|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
218848753|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
218848754|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
218848755|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
218848756|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
219197353|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM white polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink polymethyl methacrylate resin.
218848757|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
218848758|NCT03017716|OTHER|Gluten free diet|The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
218848759|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
219197354|NCT02782676|DEVICE|Investigational Healon5 OVD|ophthalmic viscosurgical device
219197355|NCT02782676|DEVICE|Healon5 OVD|ophthalmic viscosurgical device
219197356|NCT06597786|OTHER|Exercise therapy|Patients will receive a study kit which includes a smart watch (for monitoring of mobility / lifestyle patterns), heart rate monitor, blood pressure cuff, scale, and e-tablet. Patients may receive a treadmill to perform exercise therapy sessions. The treadmills and study kits are MSK owned equipment that will be deployed to the patients' homes and returned at the end of the study.
219197357|NCT06807060|BEHAVIORAL|'Light, activity and sleep in my daily life' intervention|"The intervention is complex in that it considers multiple factors (e.g., light-related behaviour, physical activity and sleep behaviour) and multiple components (e.g., cognitive goal setting and implementation).~The intervention is delivered as a web-based course on a digital learning platform. Course material is placed in nine modules covering electric lighting, daylight, physical activity outdoors and sleep. Besides online material, the course includes a test kit containing light bulbs, a sleep mask, a checklist for the room inventory, a cap, a notebook, and a sleep diary. The purpose of the test kit is to encourage experimentation and provide handouts and printed copies to facilitate the completion of assignments."
219197358|NCT03334695|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
219197359|NCT03334695|DRUG|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
219197360|NCT04258566|DEVICE|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
219197361|NCT04258566|RADIATION|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
219197362|NCT06050720|DEVICE|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
219199449|NCT05098379|BEHAVIORAL|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
219591650|NCT02692144|OTHER|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
219591651|NCT05773794|DIETARY_SUPPLEMENT|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
219591652|NCT05773794|DIETARY_SUPPLEMENT|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
218848760|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
218848761|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
218848762|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
218848763|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
218848764|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
218848765|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
218848766|NCT01425359|DRUG|Ranolazine|
218848767|NCT01425359|DRUG|Ranolazine placebo|
218848768|NCT04678986|OTHER|ER2|No intervention, data analysis only
218848769|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
218848770|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
218848771|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
218848772|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
218848773|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
219457940|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
219457941|NCT02516306|DRUG|EV06 Ophthalmic Solution|
218848774|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
218848775|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
218848776|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
218848777|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
218848778|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
218848779|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
218848780|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
218848781|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
218848782|NCT02959541|DRUG|Leucovorin|
218848783|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
218848784|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
218848785|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
218848786|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
218848787|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
218848788|NCT01940250|DRUG|Sterile water|H2O IV infusion
218848789|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
219457942|NCT02516306|DRUG|Placebo Ophthalmic Solution|
219457943|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
219457944|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
219457945|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
219457946|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
218848790|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
218848791|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
218848792|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
218848793|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
218848794|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
218848795|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
218848796|NCT03848208|DRUG|placebo|matching placebo oral tablet
218848797|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
218848798|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
218848799|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
218848800|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
218848801|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
218848802|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
218848803|NCT02292758|DRUG|Irinotecan|Given IV
219197363|NCT02394626|PROCEDURE|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
219197364|NCT02394626|PROCEDURE|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
219457947|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
219197365|NCT05340348|OTHER|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
219197366|NCT06553131|DEVICE|Neuromuscular Transmission Monitoring|A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
219457948|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
219457949|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
219457950|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
219457951|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
219457952|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
219457953|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
219457954|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
219457955|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
219591653|NCT04993066|DEVICE|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
219591654|NCT05274555|OTHER|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
219591655|NCT05990985|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
218848804|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
218848805|NCT02292758|OTHER|Placebo|Given IV
218848806|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
219457956|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
218848807|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
219457957|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
219457958|NCT00000970|DRUG|Foscarnet sodium|
219457959|NCT00000970|DRUG|Ganciclovir|
219457960|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
219457961|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
219457962|NCT00642122|DRUG|Budesonide|0.5mg once daily
219457963|NCT00642122|DRUG|Budesonide|1mg once daily
218848808|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
218848809|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
218848810|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
218848811|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
218848812|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
218848813|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
218848814|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
219457964|NCT00642122|DRUG|Budesonide|1mg twice daily
219457965|NCT00642122|DRUG|Budesonide|2mg once daily
219457966|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
219457967|NCT00001343|DRUG|Humatrope|
218848815|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
218848816|NCT02072460|OTHER|electromyography|
218848817|NCT02072460|OTHER|electroencephalography|
218848818|NCT02072460|OTHER|approaches from psychophysics|
218848819|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
219457968|NCT00001343|DRUG|Oxandrolone|
219457969|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
219457970|NCT02749643|DEVICE|Vibrotactile feedback system|
219457971|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
219457972|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
219457973|NCT06137989|PROCEDURE|Fill-Up Class ӀӀ restoration|Bulk-fill technique
219457974|NCT06137989|PROCEDURE|QuiXfil Class ӀӀ restoration|Bulk-fill technique
219457975|NCT06137989|PROCEDURE|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
219591656|NCT05990985|DRUG|RiTUXimab Injection|RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
219591657|NCT05990985|DRUG|Cyclophosphamid|Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
219591658|NCT05990985|DRUG|Vincristine|Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
219591659|NCT05990985|DRUG|Prednisolone|Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
219591660|NCT01733810|OTHER|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
219591661|NCT04247100|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
219591662|NCT04247100|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
219591663|NCT04575064|OTHER|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
219591664|NCT04575064|DRUG|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
219591665|NCT03202979|DRUG|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
219457976|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
219457977|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
219457978|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
219457979|NCT02736149|DRUG|ubenimex|
219457980|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
219457981|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
218848820|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
218848821|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
218848822|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
218848823|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
218848824|NCT00273520|DRUG|Telithromycin|
218848825|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
218848826|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
218848827|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
219197367|NCT06589271|BIOLOGICAL|human umbilical cord mesenchymal stem cell suspension|2 \* 10\^7 cells (2ml)
219197368|NCT06589271|PROCEDURE|total endoscopic extraction of lumbar nucleus pulposus|hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
219457982|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
219457983|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
219457984|NCT01022918|DRUG|Temodal/radiotherapy|
219457985|NCT05949463|OTHER|Intermittent teaching unit|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
219457986|NCT05949463|OTHER|No intervention group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
219457987|NCT01969565|DRUG|Carfilzomib|
219591666|NCT03202979|DRUG|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
219591667|NCT03202979|DRUG|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
219591668|NCT05595148|PROCEDURE|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
219197369|NCT00319046|DRUG|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
218848828|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
218848829|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
218848830|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
218848831|NCT01480518|GENETIC|DNA analysis|
219457988|NCT01969565|DRUG|Dexamethasone|
219457989|NCT02234024|DIETARY_SUPPLEMENT|Supplementation of dairy-derived concentrated gangliosides.|
219457990|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
219457991|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
219457992|NCT00242710|DRUG|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
219457993|NCT00242710|OTHER|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
219457994|NCT01910649|DRUG|Drisapersen|Subcutaneous and Intravenous
219457995|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
219457996|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
219457997|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
219457998|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
219457999|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
219591669|NCT05595148|OTHER|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
219591670|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
219591671|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
218848832|NCT01480518|GENETIC|comparative genomic hybridization|
219458000|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
219458001|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
219458002|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
219458003|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
218848833|NCT01480518|GENETIC|gene expression analysis|
218848834|NCT01480518|GENETIC|mutation analysis|
218848835|NCT01480518|GENETIC|polymerase chain reaction|
218848836|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
218848837|NCT01480518|OTHER|laboratory biomarker analysis|
218848838|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
218848839|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
218848840|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
219458004|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
219458005|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
218848841|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
218848842|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
219591672|NCT01877746|OTHER|No intervention|No intervention, only standard medical therapy
219458006|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
219458007|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
219591673|NCT05776862|DRUG|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
219591674|NCT05776862|OTHER|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
219591675|NCT00084032|BEHAVIORAL|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
218848843|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
218848844|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
218848845|NCT00075946|BIOLOGICAL|rituximab|Given IV
218848846|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
218848847|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
219197370|NCT02874742|DRUG|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
218848848|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
219197371|NCT02874742|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
219197372|NCT02874742|DRUG|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
219197373|NCT02874742|DRUG|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
219199450|NCT06868342|PROCEDURE|High-frequency nerve conduction block|A high-frequency nerve conduction block applied to a muscular branch of the tibial nerve and assessed by intraoperative EMG, performed before the nerve is cut as a part of a standard tibial neurectomy for focal spasticity.
218848849|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
219458008|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
219458009|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
219458010|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
219458011|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
219458012|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
219591676|NCT00084032|DRUG|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
219591677|NCT02014207|OTHER|dietary treatment|
219591678|NCT01421173|DRUG|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
219591679|NCT01421173|DRUG|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
218848850|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
218848851|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
219197374|NCT04245956|PROCEDURE|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
219591680|NCT01421173|DRUG|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
219591681|NCT01421173|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
219591682|NCT01421173|PROCEDURE|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
219591683|NCT01421173|DRUG|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
219591684|NCT01421173|DRUG|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
219591685|NCT01421173|DRUG|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
219591686|NCT01421173|DRUG|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
219591687|NCT02188914|RADIATION|Positron emission tomography scan|
219591688|NCT02188914|OTHER|Magnetic resonance imaging|
219591689|NCT00003324|PROCEDURE|conventional surgery|
219591690|NCT00003324|RADIATION|radiation therapy|
219591691|NCT02619435|DRUG|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
218848852|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
218848853|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
218848854|NCT03082183|DRUG|Rifampicin|once daily
219458013|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
219591692|NCT03937336|BEHAVIORAL|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
219458014|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
218848855|NCT03082183|DRUG|BI 425809|once daily
218848856|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
218848857|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
218848858|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
218848859|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
218848860|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
218848861|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
218848862|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
219018869|NCT06979050|BEHAVIORAL|The Ronnie Gardiner Method|The intervention involves participants performing coordinated movements while saying specific cue words, synchronized to rhythmic music. The exercises are guided by a visual notation system consisting of 19 colored symbols that represent different body parts and movements. Red symbols indicate movements on the left side of the body, while blue symbols represent the right side. Each symbol corresponds to a specific movement and verbal cue. Exercises are typically performed standing to maximize balance effects and are accompanied by rhythmic, often popular, music to enhance engagement and motivation. Complexity can be increased by adjusting the tempo of the music or combining multiple symbols. Training sessions are conducted in groups, led by certified instructors, twice per week for 12 weeks (60 minutes per session), with an additional home-based practice session each week.
219458015|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
219591693|NCT06387602|PROCEDURE|Cryotherapy|Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
219591694|NCT06387602|PROCEDURE|Strengthening of adductors|"Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist."
218848863|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
219197375|NCT03589547|DRUG|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
219591695|NCT06387602|PROCEDURE|Active release technique|"Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week."
219199451|NCT06866197|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
219018872|NCT07128550|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
219018873|NCT07128550|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
219018874|NCT07128550|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
219458016|NCT03644173|BEHAVIORAL|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
219591696|NCT06387602|PROCEDURE|Post-Isometric Relaxation|"Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week."
219591697|NCT02065700|DRUG|Filgotinib|Administered as Oral Tablets
219591698|NCT06355999|BEHAVIORAL|Color Feedback|Feedback is given about the correctness of the response on the color dimension
219591699|NCT06355999|BEHAVIORAL|Shape Feedback|Feedback is given about the correctness of the response on the shape dimension
219197376|NCT03589547|RADIATION|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"
219197377|NCT06746025|BEHAVIORAL|Quit Center cessation program|Lifestyle modifications based on the Quit Center cessation program.
219197378|NCT01950234|DRUG|ACTH|Acthar gel
219197379|NCT01950234|DRUG|Placebo|Placebo
219197380|NCT06815523|OTHER|Machine learning and logistic regression for the training/testing cohort and validation cohort|Machine learning and logistic regression for the validation cohort
219197381|NCT06814938|DRUG|Semaglutide|2.4 mg subcutaneous weekly
219197382|NCT06814938|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
219197383|NCT06814912|OTHER|Survey using a questionnaire|virtual reality headset is added during treatment administration. Patient must complete a survey at the end of treatment administration and virtual headset use.
219199452|NCT06867198|DIETARY_SUPPLEMENT|Peanuts|43 g of peanut butter (1 snack cup) 3 x/week, 42 g of dry roasted peanuts (1/3 of a cup) 3x/week, or 56 g of peanut flour 1x/week for 6 months.
219458017|NCT00362440|DRUG|Leptin|
219458018|NCT00362440|DRUG|Pioglitazone or metformin|
219458019|NCT00362440|DRUG|Placebo|
219458020|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
218848864|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
218848865|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
219458021|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
219458022|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
219458023|NCT00381706|BIOLOGICAL|cetuximab|given IV
219458024|NCT00381706|DRUG|ECF|epirubicin and 5-fluorouracil given IV
219591700|NCT04864470|BEHAVIORAL|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
219458025|NCT00381706|DRUG|IC|cisplatin and irinotecan given IV
219458026|NCT00381706|DRUG|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
218848866|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
218848867|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
218848868|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
219458027|NCT00051194|DRUG|Combination IOP Lowering Therapy|
219458028|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
218848869|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
218848870|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
219458029|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
219458030|NCT02113891|DRUG|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
219591701|NCT02782793|PROCEDURE|Endoscopic Mucosal Resection|
219591702|NCT02281292|BIOLOGICAL|LKA651 ophthalmic solution|
219591703|NCT02281292|BIOLOGICAL|Ranibizumab ophthalmic solution|
219591704|NCT02281292|BIOLOGICAL|Sham injection|Mock injection administered as an empty hub without needle
219591705|NCT03612557|DRUG|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
219591706|NCT05824416|DEVICE|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
219591707|NCT05824416|BEHAVIORAL|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
219591708|NCT03842813|DEVICE|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
219018884|NCT05365035|DRUG|Cladribine|Given by Vein (IV)
219018885|NCT05365035|DRUG|Cytarabine|Given under the skin; subcutaneous injection (SQ)
219018886|NCT05365035|DRUG|Venetoclax|Given by PO
219018887|NCT05365035|DRUG|Azacitidine|Given by IV or subcutaneous injection (SQ)
219018888|NCT06655155|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
219458031|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
219458032|NCT00005577|DRUG|gemcitabine hydrochloride|
219591709|NCT04181749|DRUG|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
219018889|NCT06655155|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
219018891|NCT06437184|DIAGNOSTIC_TEST|ODP|se previously
219199453|NCT06865625|BEHAVIORAL|mobile application|In this study, unlike similar studies in the literature, participants were grouped based on their oral hygiene status.
219199454|NCT06865625|BEHAVIORAL|traditional oral hygiene motivation|The group demonstrating the brushing technique on a braces model
218848871|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
218848872|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
218848873|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
218848874|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
218848875|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
218848876|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
218848877|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
218848878|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
218848879|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
218848880|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
218848881|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
218848882|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
218848883|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
218848884|NCT00799227|DRUG|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
218848885|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
219458033|NCT05458869|PROCEDURE|HPV Self-Collection|Use HPV self-collection kit
219458034|NCT05458869|OTHER|Interview|Attend interview
219458035|NCT05458869|OTHER|Survey Administration|Complete surveys
219458036|NCT00310063|PROCEDURE|acupressure therapy|Acupressure wristband
218848886|NCT04845009|BEHAVIORAL|Usual care|Usual care
218848887|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
219458037|NCT00310063|PROCEDURE|sham intervention|Sham wristband
219197384|NCT06808919|OTHER|Whole Body Vibration Exercise|The participants underwent a prescribed exercise protocol involving both static and dynamic exercises on the designated platform. Specifically, static squats at a 30º angle, dynamic deep squats ranging from 30 to 60º, toe raises, weight transfer maneuvers during squats, as well as static and dynamic squat exercises performed unilaterally were implemented as part of the program
218848888|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
219197385|NCT06808919|OTHER|Aerobic Exercise|The participants assigned to the aerobic exercise group were directed to engage in running activity on a conventional treadmill. The participants engaged in aerobic exercise, specifically moderate-to-high-intensity running at 65-80% of their maximal heart rate, for durations of 30-45 minutes per session, three times weekly. Heart rate was monitored with a portable pulse oximetry device.
219458038|NCT00472043|DRUG|PDT with Metvix 160 mg/g cream|
219458039|NCT00472043|DRUG|Placebo|
219458040|NCT01339676|DRUG|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
219458041|NCT01339676|DRUG|Placebo capsules|Identically appearing once weekly peroral placebo capsules
219458042|NCT03822546|OTHER|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
219458043|NCT03822546|OTHER|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
219458044|NCT03822546|OTHER|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
219458045|NCT03822546|OTHER|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
219458046|NCT03822546|OTHER|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
219458047|NCT03822546|OTHER|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
219458048|NCT03922711|DRUG|Pridopidine|Oral capsule
219458049|NCT03922711|DRUG|Placebo|Oral capsule
218848889|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
218848890|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
218848891|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
218848892|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
218848893|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
218848894|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
218848895|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
219018892|NCT06655337|DEVICE|Smartphone Application for Post-Discharge Symptom Monitoring|This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
219458050|NCT00852761|DRUG|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
219458051|NCT00852761|DRUG|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
219458052|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
219458053|NCT04992000|OTHER|4-free app + PHN intervention|same mentioned in groups
219458054|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
219458055|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
219458056|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
219458057|NCT02375464|DRUG|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
219458058|NCT01170468|DRUG|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
219458059|NCT01170468|DRUG|Placebo|Placebo orally, daily for 2 years
219458060|NCT03170492|OTHER|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
219458061|NCT03170492|OTHER|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
219458062|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
219458063|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
219591710|NCT00000259|DRUG|15 % Nitrous oxide|
219591711|NCT00000259|DRUG|0.3 % Sevoflurane|
219591712|NCT00000259|DRUG|30% Nitrous oxide|
219591713|NCT00000259|DRUG|0.6% Sevoflurane|
219591714|NCT00000259|OTHER|Placebo|
219591715|NCT06394700|BEHAVIORAL|written exposure therapy|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
218848896|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
218848897|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
218848898|NCT01755962|OTHER|Glycemic Load|
218848899|NCT01755962|OTHER|Resistance Training|
218848900|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
218848901|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
218848902|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
218848903|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
218848904|NCT06117969|DRUG|Tibolone|1.25mg po qd
218848905|NCT06117969|DRUG|Xiangshao granules|4g po tid
218848906|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
218848907|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
218848908|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
218848909|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
218848910|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
218848911|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
218848912|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
219458064|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
218848913|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
218848914|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
218848915|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
219458065|NCT06106685|DRUG|High-dose washed microbiota suspension|The high-dose group will be administered a high dose of washed microbiota suspension。
218848916|NCT01382303|DRUG|Placebo|placebo tablet three times a day
218848917|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
218848918|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
219018893|NCT06368947|BEHAVIORAL|Therapeutic Play|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
219018894|NCT05027997|DRUG|Dipraglurant|Oral tablet
219018895|NCT05027997|DRUG|Placebo|Oral matching placebo tablet
218848919|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
219458066|NCT06106685|DRUG|Low-dose washed microbiota suspension|The low-dose group will be administered a low dose of washed microbiota suspension.
218848920|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, … \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
218848921|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
218848922|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
219197386|NCT06808919|OTHER|Strengthening Exercise|Strengthening group, participants engaged in various lower extremity strengthening activities such as straight leg raises, abduction and adduction movements, knee flexion-extension, ankle plantar-dorsiflexion exercises. These exercises were performed both on a bed and in standing positions, utilizing resistance exercise bands.
219197387|NCT06810830|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (iCBT)|A structured 7-week program focusing on cognitive restructuring, stress management, and emotional regulation.
219018902|NCT06980025|DRUG|162mg Aspirin|"Two 81mg aspirin tablets in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
219197388|NCT06810830|BEHAVIORAL|Internet-Based EMDR Flash Technique (iEMDR-FT)|A 3-session protocol adapted to minimize re-exposure to distressing cancer-related memories through rapid bilateral stimulation and positive imagery.
219458067|NCT06106685|DRUG|Placebo|The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
218848923|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
218848924|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
218848925|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
219458068|NCT02324413|DRUG|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
219458069|NCT02324413|DRUG|Placebo|
219197389|NCT06813196|BEHAVIORAL|Forest Bathing|Forest bathing intervention is a group structured psychosocial intervention. Its core therapeutic element is its nature-based activities that took place in an outdoor green space. During the session, participants would be guided by a trained forest therapy guide to engage in nature-based activities, such as walking in the woods, listening to the nature, and interacting with objects in the nature through different sensations.
219197390|NCT06813196|BEHAVIORAL|Art activity|Art activity intervention is a group semi-structured psychosocial intervention. Its main therapeutic element is its engagement in art-based activites. During the session, participants would be guided in individual or collaborative art activities of different forms, such as painting, paper arts, and dried flower art, by an experienced interventionist in an activity room.
219197391|NCT06808958|BEHAVIORAL|Experimental (Bathtub Bath) Group|The newborn's eyes will be covered with a phototherapy eye patch and placed in the baby's jeans and the treatment will be started. The position (face down and back down) is changed every two hours. And phototherapy is paused every three hours for feeding. Therefore, the bath will be given half an hour after the phototherapy application is completed before the two phototherapy sessions. The physiological parameters of the newborns will be evaluated 0 minutes before the bath. Then the bathtub bath application will be started. The bath application will be completed in a time not exceeding 5 minutes. Physiological parameters, stress and comfort will be assessed 15 minutes after bathing. Then, 15 minutes after starting the phototherapy session and 15 minutes before ending the phototherapy session, physiological parameters, stress and comfort will be assessed. The measured physiological parameters (respiratory rate, heart rate, oxygen saturation and body temperature), stress and comfort scor
219197392|NCT06814314|DIAGNOSTIC_TEST|Transcriptomic investigation|Transcriptomic investigation followed by ontology classification
219197393|NCT06815133|DRUG|Zilbrysq|Zilbrysq is a medicine used to treat generalized myasthenia gravis anti-AChR (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against a protein called the acetylcholine receptor. It is given as a subcutaneous injection (under the skin) once daily in a prefilled syringe that can be self-injected, and the dose depends on the patient's body weight. There are 3 available doses: 16.6 mg/0.416 mL for patients weighing less than 56 kg (123 lbs); 23 mg/0.574 mL for patients between 56 kg and less than 77 kg (123-170 lbs); and 32.4 mg/0.81 mL for patients weighing 77 kg and above (\>170 lbs). This can be injected into the abdomen, front of the thighs, and back of the upper arms (only if administered by a caregiver),
219197394|NCT04142307|DEVICE|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
219458070|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
219458071|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
219458072|NCT05391295|OTHER|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
219458073|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
219458074|NCT06352502|DRUG|Furmonertinib|Patients treated with Furmonertinib mesilate tablets orally
219458075|NCT01160042|DRUG|Metformin|Metformin Tablets 1000 mg
219458076|NCT01160042|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
219458077|NCT03166228|DRUG|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
219458078|NCT03166228|DRUG|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
219458079|NCT03271411|BEHAVIORAL|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
219458080|NCT03271411|BEHAVIORAL|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
219458081|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
219458082|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
219458083|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
218848926|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
218848927|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
218848928|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
219018903|NCT06980025|DRUG|81mg Aspirin|"One 81mg aspirin tablet in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
219458084|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
219458085|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
219458086|NCT03431623|BIOLOGICAL|CKD-11101(Darbepoetin alfa)|
219458087|NCT03431623|BIOLOGICAL|NESP(Darbepoetin alfa)|
219199455|NCT06869772|PROCEDURE|Closure of sternotomy|In group I, spreading of BW on the sternal surfaces by digital pressure immediately after sternotomy and before closing the chest. In group II ORC will be cut and laid along the sternotomy over the intramedullary area immediately after sternotomy and it will be removed before closing the chest.
219458088|NCT03686579|RADIATION|chest trauma|clinical and radiological study
219458089|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
219458090|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
219458091|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
219458092|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
219458093|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
219458094|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
219458095|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
218848929|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
218848930|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
219458096|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
219458097|NCT00933387|DRUG|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
219458098|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
219458099|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
219458100|NCT04335357|DRUG|Placebo|Placebo
219458101|NCT02845115|DEVICE|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
219458102|NCT02845115|DEVICE|optimized implantation with laser velocimetry|
219458103|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
219458104|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
219458105|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
219458106|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
219458107|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
219458108|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
219458109|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
219458110|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
219458111|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
218848931|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
219458112|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
219018913|NCT06255886|DRUG|Protein pump inhibitor.|1 mg/kg /day
219018914|NCT06255886|BEHAVIORAL|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
219018915|NCT06255886|DRUG|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
219458113|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
219458114|NCT02335567|OTHER|there is no intervention|
218848932|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
218848933|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
219458115|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
218848934|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
218848935|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
219458116|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
219458117|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
219458118|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
219458119|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
219458120|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
219458121|NCT02217449|OTHER|Prediction of histology|
219458122|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
219458123|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
219458124|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
218848936|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
218848937|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
219018930|NCT05367960|DRUG|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
219018931|NCT06628622|DRUG|BI 1356225|BI 1356225
219018932|NCT06628622|DRUG|Placebo|Placebo
219018933|NCT03564873|DRUG|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
219018934|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
219018935|NCT03564873|DRUG|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
219197395|NCT04142307|DEVICE|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
218848938|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
218848939|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
218848940|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
218848941|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
218848942|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
218848943|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
218848944|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
218848945|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
218848946|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
219197396|NCT05830201|BEHAVIORAL|No Dog Present|Dog is not present during pin removal
219197397|NCT05830201|BEHAVIORAL|Dog is Present|Dog is present during pin removal
219458125|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
219458126|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
219458127|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
218848947|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
219197398|NCT06502782|DIAGNOSTIC_TEST|digital assesment|Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
219197399|NCT06807827|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
219458128|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
218848948|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
219458129|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
219458130|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
219458131|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
219458132|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
219458133|NCT01901679|DRUG|Celebrex|200 mg PO BID
219458134|NCT00266149|DRUG|Oral contraception|
219458135|NCT00266149|DRUG|Lamotrigine|
219458136|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
218848949|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
218848950|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
219458137|NCT03453346|DRUG|Sofosbuvir|Generic sofosbuvir tablet 400 mg
219458138|NCT03453346|DRUG|Ribavirin|Ribavirin was provided in 100-mg tablets.
219458139|NCT05910983|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Bipolar enucleation of the prostate (BipolEP)
219458140|NCT05910983|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
219458141|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
219458142|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
218848951|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
218848952|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
218848953|NCT02493257|DRUG|Capsaicin|
218848954|NCT02493257|DRUG|Placebo|
218848955|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
218848956|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
218848957|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
218848958|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
218848959|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
218848960|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
219197400|NCT06807827|OTHER|Basic Education|Basic Education about lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.
219197401|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
219458143|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
218848961|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
219197402|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
219197403|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
219197404|NCT05493280|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
219197405|NCT06656676|BEHAVIORAL|WePrEP: A shared decision-making tool|WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.
218848962|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
218848963|NCT02980146|OTHER|Non interventional study|
218848964|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
218848965|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
218848966|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
218848967|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
218848968|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
218848969|NCT05564884|OTHER|no intervantion|no intervention
219458144|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
218848970|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
218848971|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
219458145|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
219458146|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
219458147|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
219458148|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
219458149|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
219458150|NCT05034029|DRUG|Placebo|Placebo
219458151|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219458152|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
219458153|NCT05061758|DRUG|LY3056480|LY3056480 is an inhibitor of gamma-secretase
219458154|NCT02563886|OTHER|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
219458155|NCT02563886|OTHER|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
219458156|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
219458157|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
219458158|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
219458159|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
219458160|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
219458161|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
219458162|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
219458163|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
219197406|NCT06656676|BEHAVIORAL|Active comparator: CDC recommendations for discussing PrEP|Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
219197407|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
219458164|NCT04805606|DRUG|CKD-843 A|Single Dose
219458165|NCT04805606|DRUG|CKD-843 B|Single Dose
219458166|NCT04805606|DRUG|CKD-843-R|QD, PO
219458167|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
218848972|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
218848973|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
219197408|NCT06581029|OTHER|The multidimensional peer victimization scale (PVS)|The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
219197409|NCT06657196|OTHER|No Intervention: Observational Cohort|No intervention.
218848974|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
218848975|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
218848976|NCT03022097|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
219197410|NCT05378373|BEHAVIORAL|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
219197411|NCT06806306|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis is one of the most widely performed refractive surgeries for correcting myopia, hyperopia, and astigmatism
219458168|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
218848977|NCT03022097|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
218848978|NCT03022097|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
218848979|NCT03022097|DRUG|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
218848980|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
219458169|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
218848981|NCT05126797|OTHER|Questionnaire Administration|Ancillary studies
219458170|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
219591716|NCT06394700|BEHAVIORAL|Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
219591717|NCT06394700|BEHAVIORAL|Minimal Contact Control (MCC)|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
219591718|NCT02509299|OTHER|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
219197412|NCT06631079|BIOLOGICAL|NECVAX-NEO1|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
219197413|NCT06638203|OTHER|The 2-hour Exemplary Leadership Course (ELC)|"This two-hour course, based on the Five Exemplary Leadership Model, aims to refresh participants' theoretical understanding of leadership while providing insights into effective leader-follower interactions through practical scenarios. The session will begin with an exploration of the nature of leadership, including its philosophical and historical context. The significance of leadership in nursing will be emphasized, highlighting its impact on education, clinical practice, and the profession overall. Participants will examine the key roles of nurse leaders, focusing on modeling the way, inspiring a shared vision, challenging the process, enabling others to act, and encouraging the heart. Content Outline:~1. The Nature and Definition of Leadership (5 minutes)~2. Leadership and Its Importance in Nursing (15 minutes)~3. Transformational Leadership and Its Components (40 minutes)~4. Positive Leader-Follower Interactions (15 minutes)~5. Case Study Discussions (45 minutes)"
219591719|NCT02509299|OTHER|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
218848982|NCT05126797|DEVICE|Stent Device|Wear customized 3D printed oral stent
218848983|NCT03306979|DRUG|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
218848984|NCT03306979|OTHER|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
218848985|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
218848986|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
218848987|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
219458171|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
219458172|NCT04250610|OTHER|Survey|On-line survey.
218848988|NCT06508177|OTHER|İnterfascial plane block|Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.
218848989|NCT06508177|OTHER|Standart analgesia plan|This is the routine analgesia plan applied in our clinic.
218848990|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
218848991|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
218848992|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
218848994|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
218848995|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
218848996|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
218848997|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
218848998|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
218848999|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
218849000|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
219018936|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
219018937|NCT04657081|DRUG|Decitabine and Cedazuridine (ASTX727)|Route of administration: oral in the form of a tablet
219018938|NCT04657081|DRUG|Venetoclax|Route of administration: oral in the form of a tablet
218849001|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
218849002|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
218849003|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
218849004|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
218849005|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
218849006|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
219018939|NCT04573140|BIOLOGICAL|Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)|RNA-LP vaccines will be administered intravenous. Three RNA-LP vaccines will be administered every 2 weeks followed by 12 cycles of adjuvant monthly RNA-LP vaccines for a total of 15 vaccines.
219458173|NCT02184390|OTHER|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
219458174|NCT02393989|PROCEDURE|posterior restoration|restorations for caries effected teeth
219458175|NCT01518140|DEVICE|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
219458176|NCT01518140|BEHAVIORAL|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
219458177|NCT00262561|DRUG|Aspirin|The effect of Aspirin on platelet function was assessed.
219458178|NCT05597111|DIAGNOSTIC_TEST|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
219458179|NCT07058103|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
219458180|NCT07058506|DEVICE|Comparison of 5 interfaces used to capture user intent to operate a neuroprosthesis|No intervention
219458181|NCT07058272|OTHER|Comprehensive corrective exercise protocol|"Initial phase exercises include lying supine on a foam roll with the arms in 3 different abduction angles, side-lying external rotation, side-lying forward flexion, standing diagonal flexion , and military press .Initial phase lasts for 2 weeks, with exercises progressing from 7 Reps of 10-second holds to 10 Reps of 15-second hold.~Improvement phase consist of exercises including side-lying external rotation with a dumbbell , side-lying forward flexion with a dumbbell , standing diagonal flexion with a dumbbell, standing external rotation with Thera-Band, standing diagonal flexion with Thera-Band, abduction while sitting on a training ball, prone lying V, T, and W exercises, and standing abduction on a balance board. The improvement phase lasts for 2 weeks, with exercises progressing from seven sets of 10-seconds hold to 10 sets of 15 secs hold.~The exercises in the maintenance phase are the same as those in the improvement phase, with no increase in intensity and frequency"
219591720|NCT02509299|DRUG|Standard medical treatment|"The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
218849007|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
219591721|NCT00422578|DRUG|tadalafil|
219591722|NCT05149677|BEHAVIORAL|Music therapy|Music therapy intervention + Standard of Care for labor pain
219591723|NCT04673682|DRUG|D309|D309(Testosterone) 1 vial, Once, IM injection
219591724|NCT04673682|DRUG|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
219591725|NCT01902368|OTHER|gluten free diet|
219018950|NCT06982300|OTHER|[68Ga]Ga-DOTA-TOC PET imaging|"Patients will undergo \[68Ga\]Ga-DOTA-TOC PET imaging before and 3 weeks after start of standard of care treatment with induction chemotherapy or CRT, unless the baseline scan shows no tracer uptake in the tumor, in that case the scan will not be repeated.~Patients will receive 120 MBq \[68Ga\]Ga-DOTA-TOC intravenously and will be scanned up to 20 minutes, 60 minutes after tracer injection, after acquisition of a low dose CT for attenuation correction.~The investigators will use archival tissue of the diagnostic biopsy for SSTR2 staining. If there is not sufficient tumor tissue available, a new biopsy will be performed after the baseline PET scan.~Blood samples will be drawn before the start, during and after finishing therapy at 3 or 4 different time points, depending on the treatment schedule."
218849008|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
218849009|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
218849010|NCT01956747|PROCEDURE|venapunction|
218849011|NCT01956747|PROCEDURE|bone marrow punction|
218849012|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
218849013|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
218849014|NCT02063867|DRUG|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
218849015|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
218849016|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
218849017|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
218849018|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
218849019|NCT01335724|DRUG|Placebo gel|Placebo gel
218849020|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
218849021|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
219458182|NCT07058272|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) Techniques|"In this study following PNF Stretching techniques are used~* Hold-relax or Contract-relax~* Hold-relax with agonist contraction In the Hold-Relax or Contract-Relax technique, stretching is performed 4sessions per week for each muscle group, with each session lasting 40 min. The protocol includes a 10-sec hold phase followed by a 10-sec contraction phase, repeated for 7 reps . The total duration of this program is 8weeks including 6 weeks of treatment phase and last 2 weeks of detraining.~In Hold-Relax with Agonist contract, the same procedure is followed as in Hold-Relax method, with 4sessions per week for each muscle group. The patient is asked to hold the initial stretch for 10 sec, followed by a relaxation phase. Afterward, the agonist muscle is contracted to actively move further into the stretch, which is then held for 10 sec. This protocol is performed for 7 reps per session, and the total duration of study is 8 weeks including 6 weeks of treatment program with last 2 weeks"
219458183|NCT07058753|PROCEDURE|Prehabilitation. An intensive prehabilitation for NACT patients|Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided.
219458184|NCT02074475|OTHER|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
219458185|NCT03039907|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty
218849022|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
218849023|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
218849024|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
218849025|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
218849026|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
218849027|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
219458186|NCT01960556|OTHER|Simulation Training|Simulation training provided to one group
219458187|NCT06892925|DRUG|QL1706|Eligible participants will receive QL1706 at 5.0 mg/kg intravenously every 3 weeks, lenvatinib at 8 mg orally once daily every 3 weeks, oxaliplatin at 85 mg/m², and gemcitabine at 1000 mg/m² (on days 1 and 8 of each cycle) for up to 8 cycles. Then, they will continue with QL1706 and lenvatinib until clinical progression, imaging progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met.
219458188|NCT06899815|DRUG|F230 tablets|"SAD： A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg .~MAD： B1: F230 tablets 6mg; B2: F230 tablets 12mg; B3: F230 tablets 20mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach."
219458189|NCT06349473|DRUG|SR604|SR604 will be administered as SC injection.
218849028|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
218849029|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
218849030|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
218849031|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
218849032|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
218849033|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
218849034|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
218849035|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
219458190|NCT06349473|DRUG|Placebo|Placebo will be administered as single SC injection.
219458191|NCT05880160|OTHER|Phased withdrawal of heart failure medications|As per arm/group description
219591726|NCT03285100|DIAGNOSTIC_TEST|Venipuncture|"* Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~* At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
219591727|NCT06007911|DRUG|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
219591728|NCT06007911|DRUG|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
219591729|NCT06007911|DRUG|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
218849036|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
218849037|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
218849038|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
218849039|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
218849040|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
218849041|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
218849042|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
219591730|NCT06007911|DRUG|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
219591731|NCT06007911|DRUG|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
219591732|NCT06007911|DRUG|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
219591733|NCT06007911|DRUG|Cladribine|5 mg/m\^2 intravenously days 1-5.
219591734|NCT06007911|DRUG|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m\^2 subcutaneous days 1-10.
219591735|NCT06007911|DRUG|Cytarabine (CLAG-M Backbone)|1.5 g/m\^2 intravenously days 1-5.
219591736|NCT06007911|DRUG|Mitoxantrone|10 mg/m\^2 intravenously days 1-3.
219591737|NCT06007911|DRUG|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
219591738|NCT00010426|DRUG|cysteamine hydrochloride|
219591739|NCT03844217|DRUG|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
219591740|NCT03844217|DRUG|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
219591741|NCT03634475|DRUG|PP-001|Drug - no placebo
218849043|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
218849044|NCT03326921|BIOLOGICAL|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
219458192|NCT07072962|DEVICE|home-based self-administered interactive exercise|The Tele-Exergame system delivers a structured foot and ankle exercise program tailored for individuals with cognitive impairment or mild dementia to support balance and cognitive function. Exercises such as leg raising and foot flexion are guided through audio, visual, and text prompts on a tablet. A foot-mounted motion sensor provides real-time feedback to ensure proper range of motion, while exercise data are securely streamed to the cloud for remote monitoring of adherence. The system also includes a telemedicine interface to enable remote support and education when needed.
218849045|NCT03326921|OTHER|Laboratory Biomarker Analysis|Correlative studies
219591742|NCT04990700|PROCEDURE|Partial rib resection|1 cm partial rib resection during thoracotomy opening
218849046|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
218849047|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
218849048|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
218849049|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
218849050|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
218849051|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
218849052|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
218849053|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
218849054|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
218849055|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
219591743|NCT04293796|PROCEDURE|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
219591744|NCT03323437|DRUG|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
219458193|NCT06049706|DEVICE|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
219458194|NCT06049706|DEVICE|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
219458195|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
218849056|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
218849057|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
219458196|NCT07078838|DRUG|Tirzepatide|Patients will receive a subcutaneous dose of 5 mg weekly for the 4 weeks prior to surgical staging.
219458197|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
219458198|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
219458199|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
219458200|NCT03080532|OTHER|dietary habits|
218849058|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
218849059|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
218849060|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
219458201|NCT06911008|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
219458202|NCT06911008|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219458203|NCT06911008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219458204|NCT06911008|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219458205|NCT06911008|OTHER|Questionnaire Administration|Ancillary studies
219458206|NCT06911008|BIOLOGICAL|SCD1 Inhibitor MTI-301|Given PO
219458207|NCT02729402|OTHER|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
219458208|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
218849061|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
218849062|NCT02370485|DRUG|LY2801653|Administered orally
218849063|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
218849064|NCT05666843|BEHAVIORAL|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
218849065|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
218849066|NCT04363697|DRUG|Placebo|Matched placebo
218849067|NCT06107803|DRUG|Roluperidone 64 mg|64 mg/day oral
218849068|NCT06107803|DRUG|Olanzapine 10 MG|10 mg/day oral
218849069|NCT05392114|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
218849070|NCT05129072|DEVICE|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
219018982|NCT05934526|DRUG|Placebo|Matching capsule containing placebo
219018983|NCT05934526|DRUG|Seralutinib|Capsule containing seralutinib
219018984|NCT05934526|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
219018985|NCT04425421|OTHER|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
219018987|NCT04171440|PROCEDURE|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
218849071|NCT02380664|DEVICE|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
219458209|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
219458210|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
218849072|NCT02380664|BEHAVIORAL|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
218849073|NCT02378298|DRUG|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
219458211|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
219458212|NCT06908395|OTHER|10-day ambulatory assessment in everyday life combined with two laboratory office days|Participants undergo a 10-day ambulatory assessment period wearing a continuous glucose monitor and a light logger as a necklace as well as completing short questionnaires through a smartphone app at regular intervals every day. On the first day, participants also undergo an extensive eye examination. Day 11 and 12 are spent in either dim or bright office lighting in randomized order.
219018988|NCT06599697|BIOLOGICAL|Intravenously administered pooled human immunoglobulin (IVIG)|IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)
219018989|NCT06605924|OTHER|Tobacco-free|Ad contains baseline language + language that product is tobacco-free
219018990|NCT06605924|OTHER|Discrete|Ad contains baseline language + language that product is discrete
219458213|NCT07101042|OTHER|Cold Stimulation|Ice massage using circular movements over the suprapubic and inner thigh areas to stimulate sensory afferents. Each session lasted 20 minutes, delivered 3 times per week for 4 weeks.
219458214|NCT07101042|OTHER|Paraspinal Electrical Stimulation|Surface electrodes applied bilaterally to the T12-L2 region. Parameters: 20 Hz frequency, 200 µs pulse width, intensity set below motor threshold. Sessions were administered 3 times per week for 4 weeks.
219458215|NCT05281549|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
219458216|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
218849074|NCT02378298|DRUG|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
218849075|NCT02378298|DRUG|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
218849076|NCT04934254|OTHER|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
218849077|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
218849078|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
219197414|NCT06638203|OTHER|The NurseLead in Progress Game|Developed collaboratively by the author and a company, this unpublished game focuses on role-playing leader-follower interactions to navigate scenarios effectively. Designed for five students per session, the game consists of five sections, lasting approximately one hour, with each section corresponding to one of the Five Practices of Exemplary Leadership. In each section, one student takes on the role of leader while the other four act as followers. The main objective is to guide a newly appointed charge nurse in making sound decisions when facing challenges to achieve key goals. Following the game, a debriefing session will allow participants to analyze responses with experts. Performance will not be formally evaluated, as the game serves as a learning experience, enabling students to lead and engage as followers. This activity aims to activate the experiential learning phase of Kolb's Learning Model.
219197415|NCT06551142|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
219458217|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
219458218|NCT06442176|DIAGNOSTIC_TEST|OCT|Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
219197416|NCT06551142|DRUG|Cisplatin|Cisplatin will be administered
219458219|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
219458220|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
219591745|NCT04416165|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
219591746|NCT02276950|PROCEDURE|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
219591747|NCT02276950|PROCEDURE|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
219197417|NCT06551142|DRUG|Carboplatin|Carboplatin will be administered
219458221|NCT02814812|PROCEDURE|CT scan|
219458222|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
219591748|NCT00294775|DRUG|Candesartan|
219591749|NCT06389695|DRUG|68Ga-NYM032 injection|The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
219591750|NCT05377892|OTHER|Dietary protein|High protein followed by reduced protein diet
219591751|NCT05991648|PROCEDURE|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
218849079|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
218849080|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
218849081|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
218849082|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
218849083|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
218849084|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
218849085|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
218849086|NCT06433505|DRUG|BMS-986365|Specified dose on specified days
218849087|NCT06433505|DRUG|[14C] BMS-986365|Specified dose on specified days.
218849088|NCT06433505|DRUG|[14C] BMS-986409 + BMS-986410|Specified dose on specified days
219197418|NCT06551142|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered
219197419|NCT06551142|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
219197420|NCT06551142|BIOLOGICAL|Durvalumab|Durvalumab will be administered
219197421|NCT06551142|BIOLOGICAL|Cetuximab|Cetuximab will be administered
219197422|NCT06551142|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered
219197423|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
219458223|NCT00477867|PROCEDURE|quality-of-life assessment|
219458224|NCT06909578|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
219458225|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing (PIRS) with peritoneal cauterization|Percutaneous Internal Ring Suturing with peritoneal cauterization at the internal ring.
219458226|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing|Percutaneous Internal Ring Suturing (PIRS) without peritoneal cauterization.
219197424|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
218849089|NCT06433505|DRUG|[14C] BMS-986410 + BMS-986409|Specified dose on specified days
218849090|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
218849091|NCT01974206|DRUG|Placebo|intramuscular injection
218849092|NCT05849584|OTHER|Transperineal ultrasound|A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
218849093|NCT06315140|OTHER|Nutrition|The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.
219458227|NCT06412198|DRUG|Cetuximab|Given by IV
219458228|NCT06412198|DRUG|Cemiplimab|Given by IV
219458229|NCT06412198|DRUG|Adagrasib|Given by PO
218849094|NCT05235971|BEHAVIORAL|Episodic Future thinking|"During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected"
219018991|NCT06605924|OTHER|Convenient|Ad contains baseline language + language that product is convenient
219197425|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
219197426|NCT05564637|DRUG|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
219458230|NCT07101744|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab combined with Nimotuzumab , administered on Day 1 every 3 weeks (D1 Q3W), until disease progression or unacceptable toxicity.
219458231|NCT07100171|OTHER|Biological: GM101|Neurosurgical delivery of GM101 to the putamen
219458232|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
219458233|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
219591752|NCT00421395|BIOLOGICAL|90Y-hLL2|weekly dosing for either 2 or 3 weeks
219591753|NCT02727881|DRUG|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
219591754|NCT02727881|DRUG|Placebo Ophthalmic solution|Placebo Ophthalmic solution
219591755|NCT02727881|DRUG|ranibizumab|ranibizumab
219591756|NCT03837002|OTHER|foot care protocol|foot assesment, foot care, foot care education
219591757|NCT03568097|DRUG|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
219591758|NCT01025453|DRUG|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
219591759|NCT01386983|DRUG|5ARI|Dutasteride or Finasteride
219591760|NCT01386983|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
219591761|NCT03594058|DRUG|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
219591762|NCT03594058|DRUG|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
219591763|NCT03594058|DRUG|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
219591764|NCT03881423|DRUG|Rocuronium Bromide|DEEP block to PTC 1-3
219458234|NCT06910254|DEVICE|Overground Robot-Assisted Gait Training (o-RAGT)|This group receives a combination of overground robot-assisted gait training (o-RAGT) and recumbent bicycle training. The o-RAGT is delivered using the Angel Legs M20 wearable exoskeleton with the MW10 suspension system for safety and gait assistance. Each o-RAGT session lasts 30 minutes and is performed overground, with support gradually reduced based on patient tolerance. Recumbent bicycle training uses the TBR9000 device (DRAX, Korea) for 30 minutes per session, focusing on lower limb strength and aerobic conditioning. Resistance is progressively increased based on patient tolerance using an RPE scale (11-14). Training is provided 5 times per week for 4 weeks. The combined program aims to improve muscle mass, physical function, and cardiopulmonary endurance in subacute stroke patients with pre-sarcopenia.
218849095|NCT05235971|BEHAVIORAL|Volitional choice|"Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
219458235|NCT06910254|DEVICE|Recumbent Bicycle Training|This group receives 30-minute recumbent bicycle training sessions using the TBR9000 device (DRAX, Korea), 5 times per week for 4 weeks. Resistance is gradually increased based on patient tolerance and monitored using an RPE scale (11-14). The intervention targets lower limb muscle strengthening and aerobic conditioning to promote physical recovery. No robotic gait training is provided in this group.
219458236|NCT06857890|DRUG|Grammidin with anesthetic neo|Grammidin with anesthetic neo, lozenges, 1 lozenge to be taken once under fed conditions.
218849096|NCT05235971|BEHAVIORAL|Monitoring only|"Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
219458237|NCT06857890|DRUG|Grammidin with anesthetic, a metered dose topical spray|Grammidin with anesthetic, a metered dose topical spray, 4 sprays to be taken once under fed conditions
219458238|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
219458239|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
219458240|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
219458241|NCT02897076|DRUG|betamethasone 24 mg|
219458242|NCT02897076|DRUG|12mg betamethasone +placebo|
219591765|NCT00465465|BIOLOGICAL|MVA 85A|i.d. injection
219591766|NCT04691726|DRUG|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
218849097|NCT04356469|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
218849098|NCT05623319|DRUG|Pembrolizumab/Olaparib|Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
218849099|NCT06404515|OTHER|Telehealth Group Counseling|Group counseling for women via telehealth to provide educational materials about atherosclerotic heart disease and provide information about risk factors and modification of risk factors. Women then have an opportunity to discuss / ask questions.
218849100|NCT02517892|PROCEDURE|Biopsy|
219458243|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
219458244|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
219458245|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
219591767|NCT04691726|DRUG|Placebo|bolus i.v. + continuous i.v. infusion
219591768|NCT04691726|DRUG|Metamizole|2,5 g i.v. BD
219591769|NCT04691726|DRUG|Morphine|continuous i.v. infusion adjusted to VAS scale score
219591770|NCT04707781|DIAGNOSTIC_TEST|chest CT|assessment of interstitial lung disease using chest CT
219591771|NCT02105558|DRUG|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
218849101|NCT03192020|PROCEDURE|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
218849102|NCT03192020|DRUG|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
219458246|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
219458247|NCT01289561|DRUG|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
219458248|NCT01289561|DRUG|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
219458249|NCT02951728|DRUG|Rituximab|
218849103|NCT03192020|PROCEDURE|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
218849104|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
218849105|NCT02118766|DRUG|Matching vehicle control|
218849106|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
218849107|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
219458250|NCT02951728|DRUG|Cyclophosphamide|
219458251|NCT02951728|DRUG|Doxorubicin|
219458252|NCT02951728|DRUG|Vincristine|
219591772|NCT02105558|DRUG|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
219591773|NCT03167463|PROCEDURE|flap|Repair choanal atresia with using flap during surgery
219458253|NCT02951728|DRUG|Prednisone|
218849108|NCT06119789|DRUG|Trametinib|According to biomarkers
218849109|NCT06119789|DRUG|Dabrafenib|According to biomarkers
218849110|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
219018999|NCT06819228|DRUG|Panitumumab IRDye 800|Study participation would last approximately 60 days from screening to follow-up visits. Participants dose of Panitumumab would be based on weight and Panitumumab IRDye800 is dosed the same for all participants.
219458254|NCT02951728|DRUG|Decitabine|
219458255|NCT01247012|DIETARY_SUPPLEMENT|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
219458256|NCT01247012|DIETARY_SUPPLEMENT|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
219458257|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
219458258|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
219591774|NCT00226174|DRUG|Curcuminoids|
218849111|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
219458259|NCT04728815|BEHAVIORAL|TAU - Phase 1|4-8 weeks of TAU treatment
219458260|NCT04728815|BEHAVIORAL|CAMS - Phase 1|4-8 weeks of CAMS treatment
219458261|NCT04728815|BEHAVIORAL|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
219458262|NCT04728815|BEHAVIORAL|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
219458263|NCT04728815|BEHAVIORAL|DBT - Phase 2|Up to 8 weeks of DBT treatment
219458264|NCT06953479|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|Individuals will receive a full course (i.e., 84 tablets) of Sofosbuvir / Velpatasvir 400/100mg tablets.
219458265|NCT06953479|OTHER|Community Health Worker|Participants will receive support from a Community Health Worker which may include assistance with basic needs (transportation, housing, employment, vital documents, insurance re-activation) as well as medication adherence, patient navigation, and peer recovery support.
219458266|NCT06949033|DRUG|Neoadjuvant cadonilimab combined with perioperative SOX|Cadonilimab: 10 mg/kg, iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
218849112|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
219197427|NCT05564637|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
218849113|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
219458267|NCT06949033|DRUG|Neoadjuvant placebo plus perioperative SOX|Placebo: iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
219458268|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
219458269|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
218849114|NCT01581528|GENETIC|gene expression analysis|
219458270|NCT05573022|OTHER|Pre-consultation electronic patient decision aid|This group is invited to access an electronic version before the consultation. The group of colorectal cancer patients is also introduced to a paper-based version by the clinician in the consultation.
218849115|NCT01581528|OTHER|cell culture procedure|
218849116|NCT01581528|OTHER|flow cytometry|
219458271|NCT05573022|OTHER|In-consultation paper-based patient decision aid|This group is introduced to a paper-based version by the clinician in the consultation
219458272|NCT00957034|DRUG|placebo|placebo patch
219458273|NCT00957034|DRUG|testosterone|300 or 450 micrograms/day transdermal testosterone patch
219458274|NCT06419790|DEVICE|EIT electrode belt, spirometry|Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
219458275|NCT05700994|BEHAVIORAL|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
219458276|NCT05700994|BEHAVIORAL|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
219458277|NCT05670132|OTHER|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
219458278|NCT05670132|OTHER|Standard of care|No intervention during the neurocardiac rehabilitation program
219458279|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
219458280|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
218849117|NCT01581528|OTHER|laboratory biomarker analysis|
218849118|NCT01581528|OTHER|metabolic assessment|
218849119|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
218849120|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
219019003|NCT04975347|DRUG|Naloxone|One bolus and one infusion of naloxone
218849121|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
218849122|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
218849123|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
218849124|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
218849125|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
218849126|NCT02521233|DRUG|losartan+hydrochlorothiazide|
219458281|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
219458282|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
219458283|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
219458284|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
219458285|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
219458286|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
219458287|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
219591775|NCT04100720|DEVICE|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
219591776|NCT04122144|BEHAVIORAL|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
219591777|NCT03972735|OTHER|Psychiatric interview|PANSS, MADRS, PSP, YMRS
219591778|NCT03972735|OTHER|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
219591779|NCT03972735|OTHER|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
219591780|NCT03972735|OTHER|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
219591781|NCT01639196|OTHER|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
219591782|NCT01639196|OTHER|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
218849127|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
218849128|NCT02684877|OTHER|Questionnaire|
218849129|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
218849130|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
218849131|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
218849132|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
218849133|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
218849134|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
218849135|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
218849136|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
218849137|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
218849138|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
218849139|NCT06981065|PROCEDURE|Simple Sling and Physiotherapy|Non-surgical treatment with a simple sling and physiotherapy according to standardized program.
218849140|NCT06981065|PROCEDURE|Surgical treatment|Surgical treatment with plate and screws (lateral clavicle plate, clavicle plate or hook plate with/without coracoclavicular fixation).
218849141|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
218849142|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
218849143|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
218849144|NCT06658990|DRUG|control|Sufentanil is used after surgery
218849145|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
218849146|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
218849147|NCT06658444|OTHER|sham ultrasound|sham ultrasound
218849148|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
218849149|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
218849150|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
218849151|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
219458288|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
219458289|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
219458290|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
219458291|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
218849152|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
218849153|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
219458292|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
219458293|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
219458294|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
219197428|NCT05564637|DIAGNOSTIC_TEST|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
218849154|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
219458295|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
218849155|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
218849156|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
218849157|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
219197429|NCT06128252|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
219197430|NCT06128252|BIOLOGICAL|Serplulimab|Serplulimab
219458296|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
219197431|NCT06128252|DRUG|XELOX regimen|Oxaliplatin + capecitabine
219197432|NCT06128252|DIETARY_SUPPLEMENT|Placebo|Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
219197433|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
218849158|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
219197434|NCT06351761|DEVICE|Investigational Device (Withings SCT02) 30 second Electrocardiogram recording|30 second ECG recording with investigational device (Withings SCT02)
219197435|NCT06351761|DEVICE|Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording|30 second ECG recording with reference device (Schiller Cardiovit FT-1)
219197436|NCT06876298|DIAGNOSTIC_TEST|- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.|\- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.
219197437|NCT06290999|DIAGNOSTIC_TEST|multifrequential admittancemetry|"Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure."
219197438|NCT06308445|DRUG|Rapamycin|This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
219197439|NCT06651658|PROCEDURE|Pleural embolisation|Administration of pleural blood patch with tandem needle technique
219197440|NCT04062565|DRUG|Treprostinil Injectable Product|Injection
219197441|NCT04062565|DRUG|Riociguat Pill|Tablet
219197442|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
219197443|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
219197444|NCT06652425|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
219197445|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
219458297|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
219458298|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
219458299|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
219591783|NCT01890447|OTHER|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
218849159|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
218849160|NCT06821009|OTHER|mPATH-CRC|Individuals will receive an automated text message inviting them to use the mPATH-CRC WebApp. The WebApp takes approximately 5 to 8 minutes to complete. The WebApp verifies patients are due for routine CRC screening, educates them about their options, and lets them request a screening test via the program.
219591784|NCT06460207|OTHER|fMRI neurofeedback|fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
218849161|NCT06821009|OTHER|Usual Care (Control)|"Patients randomized to the control arm will receive usual care, which includes the organizations' standard procedures for addressing CRC screening. In the participating Fee-for-Service and Value-Based settings, the EHR flags patients who are overdue for CRC screening as a care gap that is visible to all primary care providers."
218849162|NCT01916252|DRUG|bortezomib (Velcade ®)|
218849163|NCT01916252|DRUG|lenalidomide (Revlimid®)|
218849164|NCT01916252|DRUG|busulfan (Busilvex ®)|
218849165|NCT01916252|DRUG|Dexamethasone acetate|
218849166|NCT01916252|DRUG|Melphalan|
218849167|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
218849168|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
219591785|NCT01631071|BIOLOGICAL|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
218849169|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
218849170|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
218849171|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219591786|NCT05631197|OTHER|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
219591787|NCT05631197|OTHER|Sensodyne Repair & Protect|Domiciliary use twice a day
219591788|NCT01181960|DRUG|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
219591789|NCT01181960|DRUG|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
219591790|NCT01181960|DRUG|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
219591791|NCT01181960|DRUG|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
219591792|NCT05022589|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
219591793|NCT04226950|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
219591794|NCT04226950|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
218849172|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
218849173|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
218849174|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
218849175|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
219591795|NCT01885026|BEHAVIORAL|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
219591796|NCT01885026|BEHAVIORAL|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
218849176|NCT04522102|DRUG|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
218849177|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
218849178|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
218849179|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
218849180|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
218849181|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
218849182|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
218849183|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
218849184|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
218849185|NCT05403437|OTHER|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
218849186|NCT05403437|DIAGNOSTIC_TEST|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
218849187|NCT05403437|OTHER|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
218849188|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
218849189|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
218849190|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
218849191|NCT04199091|PROCEDURE|Craniosacral Therapy (CST) self-help techniques|Manual self-help techniques based on Craniosacral Therapy (group setting).
218849192|NCT04199091|PROCEDURE|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation according to Jacobsen (group setting).
218849193|NCT06628284|DEVICE|Dexcom G7|The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).
219591797|NCT01885026|BEHAVIORAL|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
219591798|NCT06633848|PROCEDURE|spinal surgery|spinal surgery
219591799|NCT03511326|DRUG|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
218849194|NCT07017647|OTHER|Conservative treatment|Conventional physiotherapy treatments will be administered to patients in both groups three days a week for six weeks. This programme will include the following treatments: electrotherapy modalities for pain relief (TENS current application), moist heat application, flexibility and strengthening exercises to stretch and strengthen the back and spinal muscles, and massage and manual therapy applications to relax the back muscles and reduce pain. First, TENS current will be applied for 15 minutes using an electrical stimulation device due to its pain-relieving properties. Then, moist heat application will be performed for 15 minutes. Following this, flexibility and strengthening exercises aimed at stretching and strengthening the lower back and back muscles will be performed under the supervision of a physical therapist for approximately 20 minutes.
218849195|NCT07017647|OTHER|Patient Education|Patient education will be provided immediately after conventional physiotherapy applications in each session. Patients will be asked to pay attention to and comply with the recommendations/issues covered in this education. Comprehensive patient education includes the following: the cause of chronic back pain, negative factors that may cause discomfort and exacerbate symptoms, how to cope with back pain, ways to prevent pain, exercises and proper postures to reduce pain, and harmful movements and positions to avoid in daily life.
218849196|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
218849197|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
218849198|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
218849199|NCT07021157|DRUG|SK-08|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.
218849200|NCT07021157|DRUG|Placebo|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.
218849201|NCT07024901|BEHAVIORAL|Dance-walk|Dance-Walk is a 4-week somatic intervention combining movement, dance, and walking elements designed to enhance body awareness and emotional regulation. The program consists of 4 weekly group sessions, each lasting approximately 90-120 minutes. Sessions focus on helping participants connect with their body sensations through guided movement exercises that integrate dance movements with mindful walking practices. The intervention targets autonomic nervous system regulation and aims to improve interoceptive awareness, emotional expression, and stress management through embodied practices. Sessions are facilitated by trained practitioners and emphasize non-verbal emotional expression and somatic experiencing to promote mental health and vitality.
218849202|NCT07022392|OTHER|Technology-enhanced gender support platform|Technology-based platform to support parents
218849203|NCT07026305|PROCEDURE|Pressure-guided laminectomy (PGL)|Osseous resection of the lamina and ligamentum flavum until the epidural pressure reaches a normal value at the stenotic segment.
218849204|NCT07026305|PROCEDURE|Laminectomy without pressure guidance (LWPG)|Complete resection of both the lamina and the ligamentum flavum at the stenotic segment.
218849205|NCT06877104|OTHER|Healing @ Home Program (H@H 2.0)|Healing @ Home 2.0 is a clinically used comprehensive technology-based postpartum support program, which provides 24/7 support to individuals through use of a text message based chatbot for six weeks postpartum. Content of H@H 2.0 includes anticipatory guidance regarding physical recovery, infant care and feeding, clinical algorithms to respond to urgent patient needs.
218849206|NCT07033403|DEVICE|Low Level Laser Therapy|low-level laser therapy (LLLT) at a wavelength of 660nm (SiroLaser Blue, Dentsply Sirona, USA) after extraction
218849207|NCT07033403|BEHAVIORAL|Placebo plus Treatment As Usual|placebo (Sham) with only the aiming beam of thelow-level laser therapy (LLLT)
218849208|NCT07034014|DEVICE|Dressing|The dressing will be applied to intact skin on healthy volunteers participants to assess the self-adhesive properties of two investigational devices compared to a test specimen reference. The dressing will be worn for up to 14 days on a designated area on the health volunteers participants back.
218849209|NCT07033806|OTHER|Exercise Tabata Protocol|more effective
218849210|NCT07032896|BEHAVIORAL|Nurse-led Patient Education|The training program will be implemented in line with patient needs determined by the researcher. In order to overcome this lack of information, existing research findings and evidence-based treatment guidelines were extensively reviewed. The training program will be based on the following guidelines. The program will start with a 30-minute individual training session on patients' self-efficacy level, self-care behaviors, medication and diet compliance processes. This training will be carried out in the hospital in accordance with the patient's plan. Discharged intervention group patients will then be interviewed by telephone six times over a period of three months, and two interviews will be scheduled for each of these monthly periods. In order to measure the impact of the intervention, data will be collected twice, before and after the training for the intervention group
218849211|NCT07034456|DEVICE|Tape with mangetic particles|An elastic adhesive tape containing magnetic particles, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. The tape remains in place during standardized sensory and vascular measurements
218849212|NCT07034456|DRUG|Topical Anesthetic Cream|EMLA®, a topical anesthetic cream containing lidocaine and prilocaine, will be applied under occlusion prior to tape application during 30 minutes with the aim of anesthetize the cutaneous sensory receptors
218849213|NCT07034456|DEVICE|Control KinesioTape|An elastic adhesive tape, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. This tape does not content magnetic particles, thus is used as a comparator. The tape remains in place during standardized sensory and vascular measurements
219019027|NCT06660667|BIOLOGICAL|SAR402663|Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
219458300|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
219458301|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
219458302|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
219458303|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
219458304|NCT03220620|OTHER|GDT|individualized fluid therapy
219458305|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
219458306|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
219458307|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
219458308|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
219458309|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
219458310|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
219458311|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
219458312|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
219458313|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
219458314|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
219458315|NCT03102541|OTHER|None intervention|
219458316|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
218849214|NCT07034456|DEVICE|Moisturizing Cream (control)|A neutral moisturizing cream (control) will be applied under occlusion prior to tape application during 30 minutes. The application will be blind and use as a placebo vs the anesthetic cream.
218849215|NCT07033533|DRUG|Allopurinol Tablet|allopurinol 300
218849216|NCT07033533|DRUG|Placebo|placebo tablet
218849217|NCT07033871|DIAGNOSTIC_TEST|comprehensive geriatric assessment|The comprehensive geriatric assessment (CGA) is a multi dimensional diagnostic process used to determine the medi cal, psychological, and functional capabilities of a frail elderly person to develop a coordinated and integrated plan for treat ment and long-term follow-up.
218849218|NCT06718426|DRUG|Fertitonex capsule|Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
218849219|NCT06718426|DRUG|Placebo Oral Capsule|placebo oral capsule. the dose is twice daily for 3 months
218849220|NCT06716619|BIOLOGICAL|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells . After lymphodepletion, patients are infused with TAL-T.
219458317|NCT00205010|PROCEDURE|Lymphoscintigraphy|
219458318|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
219458319|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
219458320|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
219458321|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
219458322|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
219458323|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
219458324|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
218849221|NCT06716619|DRUG|Serplulimab Injection|Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.
218849222|NCT07034534|BEHAVIORAL|Three typical yoga poses|duration for both group includes 10 mins 5 sec, rest period will be included
218849223|NCT07034534|BEHAVIORAL|Deep breathing technique|duration for both group includes 10 mins 5 sec, rest period will be included
218849224|NCT06887920|DEVICE|Acuvue Oasys for Presbyopia|ACUVUE OASYS for PRESBYOPIA contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
218849225|NCT06887920|DEVICE|MiSight 1 Day|MiSight 1 Day contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
218849226|NCT06897332|BEHAVIORAL|Real-world manual dexterity task|Participants will perform a manual dexterity task involving the displacement of physical cubes
219458325|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
219458326|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
219458327|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
219458328|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
219591800|NCT04043130|BEHAVIORAL|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
219591801|NCT01687426|DRUG|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
219591802|NCT01687426|DRUG|Vehicle|1 drop in each eye daily four times a day for 14 days
218849227|NCT06897332|BEHAVIORAL|Immersive virtual reality with controllers|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using controllers
218849228|NCT06897332|BEHAVIORAL|Immersive virtual reality with hand-tracking|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using the hand-tracking technology
219019028|NCT06660667|DRUG|Diluent|Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
219019029|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
218849229|NCT06896760|DRUG|[14C]ABSK011|The standard meal was taken the night before administration, and the patient was fasted for at least 10 h without drinking water overnight. The next morning, eat a low-fat meal, finish the meal within 30 minutes, and take the test drug with warm water 30 minutes (±5 minutes) after the beginning of the meal. The total volume of warm water and suspension liquid is about 240 mL. Except for meals and administration, no water was allowed 1 hour before and 1 hour after medication. No food is allowed for 4 hours after taking the medication. Throughout the study, participants received meals provided by the center at approximately the same time each day.
218849230|NCT06896318|DEVICE|Virtual Reality Therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
218849231|NCT06896318|BEHAVIORAL|Cardiac rehabilitation|A three-week, hospital-based cardiac rehabilitation program for all participants, incorporating structured group exercises and activities. The conventional cardiac rehabilitation program includes morning warm-up exercises, afternoon group sessions, interval training on stationary bikes, and relaxation activities. Morning sessions consist of 20 minutes of standing cardiovascular exercises accompanied by music, while afternoon sessions include 45 minutes of seated activities, divided into cardiovascular, equipment-based, and breathing exercises.
218849232|NCT06896370|OTHER|observational study|By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
218849233|NCT06896552|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic Diet as an Adjunct to Immunotherapy: Unlike many trials focused on chemotherapy or targeted therapies, this study specifically investigates the synergistic effects of the ketogenic diet with immune checkpoint inhibitors (ICIs), a promising approach for enhancing immunotherapy efficacy. The diet's high-fat, low-carbohydrate regimen is designed to shift metabolism towards ketone bodies and fatty acid utilization, potentially modulating immune responses and tumor immunogenicity in a way that standard diets do not.
218849234|NCT06897059|OTHER|Vuka+ application|The Vuka+ smartphone app included PrEP daily reminders, tracking for pill taking, resources for sexual reproductive health including quizzes and articles, and chat access to other Vuka+ users and medical expert.
219019030|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
219197446|NCT06814626|DIETARY_SUPPLEMENT|12-week nutritional intervention with Friliver dispensing|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
219197447|NCT06814626|OTHER|12-week nutritional intervention with personalized diet|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
219458329|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
219458330|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
219458331|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
219458332|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
219458333|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
218849235|NCT06897384|DRUG|Saline (NaCl 0,9 %)|The control group involves only adding 50ml of normal saline to a 50ml syringe, without any labels to ensure identical appearance, and the method of administration and dosage are the same with vitamin C group.
218849236|NCT06897384|DRUG|Vitamin C (Ascorbic Acid)|Vitamin C at dose of 500mg/kg/24h, 2g/h
219458334|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
218849237|NCT06896084|DEVICE|da Vinci Xi System|A group of surgeons will make determinations as to the material within identical balloons while using the da Vinci Xi System
218849238|NCT06897111|BIOLOGICAL|Implantation of allogeneic cartilage mini-grafts (Allogeneic Cartibeads)|Implantation of allogeneic cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant).
218849239|NCT06897371|OTHER|Games-based education|"A 5-question trial test on Kahoot usage will be applied to the students in the intervention group (questions must be prepared in advance, students must have full internet connection, students must enter the Kahoot application with their phones, students must enter the code required to enter the platform, etc.). The questions that make up the trial test will be created independently of the subject covered in the theoretical training and students will be adapted to Kahoot. After the 2-hour theoretical training is completed, reinforcement will be provided using the 25-question game-based learning method on the Kahoot platform. Brief explanations will be made to reinforce the subject and the reinforcement session will last for 30 minutes. The Self-Confidence/Competence Scale in Patient Intervention, Postpartum Hemorrhage Management Information Form and Motivation Scale Regarding the Teaching Material will be applied to both groups as a post-test."
218849240|NCT06817512|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 (MK-7) 300µg/d for 2 year
218849241|NCT06817512|DIETARY_SUPPLEMENT|Zinc|Zinc, 15mg/d for 2 year
218849242|NCT06817512|DIETARY_SUPPLEMENT|Placebo|Placebo for 2 year
218849243|NCT04863300|BEHAVIORAL|Collaborative stepped care and peer support|"Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked."
219197448|NCT06814626|OTHER|12-week nutritional intervention with diet diary to report foods eaten.|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
219197449|NCT06814548|OTHER|ICIs(Immune checkpoint inhibitors)|N
219197450|NCT06814249|OTHER|ligation of pancreatic stump with a quantified force|After severing the pancreas, the pancreas was ligated at 5 mm from the pancreatic stump with a quantified force.
219197451|NCT06814249|OTHER|Manual suturing or stapling closure.|Handle the pancreatic stump according to conventional methods (manual suturing or stapling closure).
219197452|NCT06812572|DEVICE|Visibly Vision Test|The Visibly Vision Test is used as a digital self-administered device to measure visual acuity and to subjectively measure refractive value for a patient's eye to determine the optical prescription for the conditions of myopia and astigmatism
219197453|NCT01196715|DRUG|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
219197454|NCT01196715|DRUG|Filgrastim|300 mcg vials twice a week, 3-4 days apart
219458335|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
219458336|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
219458337|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
219458338|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
219458339|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
219458340|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
219458341|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
218849244|NCT06896591|PROCEDURE|Deep posterior post gluteal nerve block|One injection with ultrasound guidance injection of 5, 10 or 15 mL of naropeine 0.35 % Procedure : injection below the piriformis muscle in front of the head of the femur.
218849245|NCT06770673|BEHAVIORAL|TOD Great Plains|The adapted TOD intervention is rooted in the original TOD structure, delivery system, and home-visiting teaching schedule. Local enhancements include intervention topics and activities to address local adult caregivers' diabetes management and to promote families' modifiable risk and protective factors targeted by this proposal and informed by the Wicozani wellness concept and measurement. The TOD intervention includes targeted content taught approximately bi-weekly by family health coaches over a 16-week period.
218849246|NCT06770673|BEHAVIORAL|Waitlist Standard of Care|Participants who are waitlisted to receive the TOD intervention will receive Standard of Care.
218849247|NCT06769425|DRUG|HS-10502 + NHA|HS-10502 + NHA
219458342|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
219458343|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
218849248|NCT06769425|DRUG|HS-10502 + HS-20093|HS-10502 + HS-20093
219458344|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
218849249|NCT06769425|DRUG|HS-10502+ Apatinib|HS-10502+ Apatinib
219458345|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
219591803|NCT03729726|BEHAVIORAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
218849250|NCT06769425|DRUG|HS-10502 + HS-20089|HS-10502 + HS-20089
218849251|NCT06769425|DRUG|HS-10502 + Platinum + Bevacizumab|HS-10502 + Platinum + Bevacizumab
218849252|NCT06769425|DRUG|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
218849253|NCT06769425|DRUG|HS-10502 + Bevacizumab|HS-10502 + Bevacizumab
218849254|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
218849255|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
218849256|NCT02307097|OTHER|WAIT|
218849257|NCT00059930|DRUG|FOLFOX regimen|
218849258|NCT00059930|DRUG|dexamethasone|
218849259|NCT00059930|DRUG|floxuridine|
218849260|NCT00059930|DRUG|fluorouracil|
218849261|NCT00059930|DRUG|leucovorin calcium|
219019032|NCT05247229|BEHAVIORAL|Middle school education program|The intervention assessed the impact of a middle school education program (implemented as an after school program in Sitka, AK and Juneau, AK and during school hours as an elective in Hoonah, AK) on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention took place weekly during the school year. The curriculum centered around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
219019033|NCT04108026|DRUG|Durvalumab|1500 mg IV every 4 weeks
219458346|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
219458347|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
219458348|NCT00002494|DRUG|cyclophosphamide|
219458349|NCT00002494|DRUG|cytarabine|
219458350|NCT00002494|DRUG|dexamethasone|
219458351|NCT00002494|DRUG|doxorubicin hydrochloride|
219458352|NCT00002494|DRUG|etoposide|
219458353|NCT00002494|DRUG|ifosfamide|
219458354|NCT00002494|DRUG|leucovorin calcium|
219458355|NCT00002494|DRUG|mesna|
219591804|NCT02750748|DRUG|Naltrexone|
219591805|NCT02750748|OTHER|Intravail|
218849262|NCT00059930|DRUG|oxaliplatin|
219458356|NCT00002494|DRUG|methotrexate|
219458357|NCT00002494|DRUG|prednisone|
219458358|NCT00002494|DRUG|therapeutic hydrocortisone|
219458359|NCT00002494|DRUG|vincristine sulfate|
219458360|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
219458361|NCT00002494|RADIATION|low-LET photon therapy|
219458362|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
219458363|NCT04984252|BEHAVIORAL|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
219458364|NCT04984252|BEHAVIORAL|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
218849263|NCT00059930|PROCEDURE|adjuvant therapy|
218849264|NCT00059930|PROCEDURE|conventional surgery|
218849265|NCT06890689|PROCEDURE|Scaling and root planing|Retrospective study to evaluate the outcome of scaling and root planing
219458365|NCT04984252|BEHAVIORAL|Distraction group|Participants will be asked to listen recording on irrelevant topic.
219458366|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
219458367|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
218849266|NCT05557162|OTHER|AI ECG Amyloid algorithm|Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
219458368|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
219458369|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
218849267|NCT06890000|OTHER|Scapular Exercise|"Scapular exercise includes scapular clock exercise (3 sets of 10 repetitions), rowing exercise (3 sets of 10 repetitions), resisted external rotation (3 sets of 10 repetitions), resisted punching exercise (3 sets of 10 repetitions).~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 15-20 minutes."
219458370|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
219458371|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
219458372|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
219458373|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
218849268|NCT06890000|OTHER|Control (Standard treatment)|"Conventional Treatment includes TENS (100 Hz) with hotpack (20 minutes), Stretching exercises (posterior capsule and pectoral muscle), resisted flexion and abduction exercises.~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 30-45 minutes."
218849269|NCT06896955|OTHER|PMR+VR Education|PMR and VR education
218849270|NCT06896955|OTHER|PMR Education|PMR education
218849271|NCT06838663|PROCEDURE|Robotic assisted Cruciate-Retaining (CR) TKA procedures|Patients who underwent Cruciate Retaining (CR) total knee arthroplasty (TKA)
218849272|NCT06838663|PROCEDURE|Robotic assisted Bi-Cruciate Stabilized (BCS) TKA procedures|Patients who underwent Bi-Cruciate Stabilized (BCS) total knee arthroplasty (TKA)
218849273|NCT06860490|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
219458374|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
219458375|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
218849274|NCT06860490|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle.
219458376|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
219458377|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
219458378|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
219458379|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
219458380|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
219458381|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
219458382|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
219458383|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
219458384|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
219458385|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
219458386|NCT02408016|DRUG|Cyclophosphamide|Given IV
219458387|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
219458388|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219458389|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
219458390|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
219458391|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
219458392|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
219458393|NCT00216346|DRUG|Paromomycin sulfate|
219458394|NCT00216346|DRUG|Amphotericin B|
219197455|NCT01196715|PROCEDURE|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
219458395|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
219458396|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
219458397|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
219458398|NCT00003410|DRUG|motexafin gadolinium|
219019051|NCT06819007|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
219019052|NCT06819007|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15/mg/kg IV Q3W
219458399|NCT00003410|PROCEDURE|magnetic resonance imaging|
219458400|NCT00003410|PROCEDURE|surgical procedure|
219458401|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
219458402|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
219458403|NCT00284167|BEHAVIORAL|tailored web-based weight management intervention|
218849275|NCT06860490|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 3 weeks for up to four cycles. Sintilimab plus bevacizumab will be administered 1-3 days after HAIC.
218849276|NCT06888869|OTHER|Other: Clinical rehabilitation group|Rehabilitation training for twice a week, total 12 weeks in hospitals.
218849277|NCT06888869|OTHER|Other: Home-based rehabilitation group|Rehabilitation training for twice a week, total 12 weeks at home.
218849278|NCT06897176|DRUG|Cerebrolyisin|This intervention uses Cerebrolysin, which is a treatment aimed at improving language abilities and providing neuroprotection for patients with non-fluent aphasia following a stroke. Cerebrolysin is administered via intravenous injection, with the goal of improving language skills and promoting brain function recovery. The treatment is evaluated based on improvements in language abilities, neurological function recovery, and safety.
218849279|NCT06897176|DRUG|Placebo|The placebo is administered alongside standard language therapy to the patients with non-fluent aphasia following a stroke. This allows for comparison with the Cerebrolysin group to assess the impact of the treatment on language abilities and neurological function recovery. The goal is to evaluate the improvements in language skills, neurological function recovery, and safety, comparing the effects between the active treatment and placebo.
218849280|NCT06827327|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 24 weeks
218849281|NCT06827327|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 24 weeks
218849282|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
218849283|NCT06894069|DRUG|Dexamethasone|a 2 ml solution of dexamethasone (3.3mg/ml) will be flushed in the root canal and intentionally extruded to the periradicular tissues to assess its potnetial sedative effect
218849284|NCT06894069|OTHER|Placebo|2ml of normal saline will be used as placebo to be flushed and extruded through the canals to the periradicular tissues
218849285|NCT06889428|DIAGNOSTIC_TEST|CMR|No CMR
218849286|NCT05503186|OTHER|Text Message|The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.
218849287|NCT05503186|OTHER|Standard of Care|Information provided by the physician and/or pharmacist.
218849288|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
218849289|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
219458404|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
218849290|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
219458405|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
219458406|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
219458407|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
219591806|NCT01305044|BEHAVIORAL|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
219591807|NCT01305044|BEHAVIORAL|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
219591808|NCT04532801|DRUG|Kisspeptin-10|kisspeptin-10 IV infusion
218849291|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
218849292|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
218849293|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
218849294|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
218849295|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
219019059|NCT05281471|BIOLOGICAL|olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
219019060|NCT05281471|DRUG|Platinum chemotherapy: carboplatin (preferred) or cisplatin|Administered according to local practice
219197456|NCT04055012|DRUG|Metformin|500mg tabs of Metformin Extended Release
219197457|NCT04055012|DRUG|Placebo|Placebo Tabs
219197458|NCT05960032|DRUG|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
219197459|NCT04375891|RADIATION|Radiation Therapy|30 Gy in 10 fractions of 3 Gy each
219458408|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
219458409|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
219458410|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
219197460|NCT04375891|RADIATION|Radiofrequency Ablation (RFA)|Radiofrequency Ablation (RFA) / Vertebral Augmentation
218849296|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
218849297|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
218849298|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
218849299|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
218849300|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
218849301|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
218849302|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
218849303|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
218849304|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
218849305|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
218849306|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
219197461|NCT06631092|BIOLOGICAL|Oral DNA Vaccine|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
219458411|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
219591809|NCT04532801|OTHER|mixed meal tolerance test|mixed meal tolerance test
219197462|NCT03969563|BEHAVIORAL|Mindfulness-based Stress Reduction|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
219197463|NCT03969563|BEHAVIORAL|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
219197464|NCT05633147|DRUG|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
219197465|NCT05633147|DRUG|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
219197466|NCT05633147|DRUG|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
219197467|NCT05501808|PROCEDURE|cerasmart|the patient received a crown made of cerasmart ceramic
219197468|NCT05501808|PROCEDURE|enamic|the patient received a crown made of enamic ceramic
219197469|NCT06806345|DEVICE|Hyperbaric oxygen therapy|Hyperbaric Oxygen Therapy (HBOT):(Haux, Starmed 2300, Germany). A multichamper Double-lock, divided into Main chamber and Antichamber, with omega Ω-shape and all safety and CE-Certificate,
219458412|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
219458413|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
219458414|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
219458415|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
219591810|NCT06241469|DRUG|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
219591811|NCT00071292|BEHAVIORAL|stress reduction program|
219591812|NCT00071292|BEHAVIORAL|meditation|
219591813|NCT00833001|DEVICE|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
218849307|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
218849308|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
218849309|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
218849310|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
218849311|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
218849312|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
218849313|NCT01730326|DRUG|Paracetamol|1000 mg
218849314|NCT01730326|DRUG|Dexketoprofen|50 mg
218849315|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
218849316|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
218849317|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
218849318|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
218849319|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
218849320|NCT01027234|DRUG|AZD8418|Single oral dose
218849321|NCT01027234|DRUG|Placebo|single oral dose
218849322|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
218849323|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
218849324|NCT02709551|BEHAVIORAL|HRV_Bfb|
218849325|NCT02709551|BEHAVIORAL|MBI|
218849326|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
219458416|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
218849327|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
218849328|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
218849329|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
218849330|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
219019061|NCT05281471|DRUG|Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|Administered according to local practice
219019062|NCT05281471|DRUG|Bevacizumab (or biosimilar)|Administered according to local practice
219019063|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
219019064|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
219019072|NCT06517901|PROCEDURE|Software fusion prostate biopsy|Software fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
219019073|NCT06517901|PROCEDURE|Cognitive fusion prostate biopsy|Cognitive fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using visual estimation and/or measurements of lesion. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
219019078|NCT06980428|DRUG|AZD4954|AZD4954 will be administered orally.
219019079|NCT06980428|DRUG|Placebo|Placebo will be administered orally.
219458417|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
219458418|NCT01722552|BEHAVIORAL|adherence feedback|
219458419|NCT01722552|BEHAVIORAL|standard of care|
219458420|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
219591814|NCT02279134|RADIATION|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
219591815|NCT02279134|RADIATION|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
218849331|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
218849332|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
218849333|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
218849334|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
218849335|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
218849336|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
218849337|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
218849338|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
218849339|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
218849340|NCT04788797|OTHER|Placebo|Two capsules three times a day
218849341|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
218849342|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
218849343|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
218849344|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
218849345|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
218849346|NCT02825420|DRUG|trabectedin|
218849347|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
218849348|NCT02748668|OTHER|Blood specimen collection|
218849349|NCT06910761|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219591816|NCT02279134|DRUG|Paclitaxel|135-150mg/m2 (D1 and D29)
218849350|NCT06910761|RADIATION|Craniospinal Irradiation|Undergo photon-VMAT-CSI
218849351|NCT06910761|OTHER|Electronic Health Record Review|Ancillary studies
219591817|NCT02279134|DRUG|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
218849352|NCT06910761|PROCEDURE|Lumbar Puncture|Undergo LP
218849353|NCT06910761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219591818|NCT04061525|PROCEDURE|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
219591819|NCT00292058|DEVICE|Videoconference equipment (telepsychiatry)|
219591820|NCT04177446|DIETARY_SUPPLEMENT|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
219591821|NCT04177446|DIETARY_SUPPLEMENT|basic energy intake|supplement as basic energy intake
218849354|NCT06910761|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir tap
218849355|NCT06910761|OTHER|Questionnaire Administration|Ancillary studies
218849356|NCT06910761|RADIATION|Volume Modulated Arc Therapy|Undergo photon-VMAT-CSI
218849357|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
219591822|NCT04177446|DIETARY_SUPPLEMENT|maltodextrin|used as placebo in the control group
219197470|NCT06806345|DRUG|Hypoglycemic Drug|"Metformin reduces serum glucose level by several different mechanisms without increasing insulin secretion.it increases the effects of insulin so it is termed insulin sensitizer ,metformin also suppresses the endogenous glucose production by the liver ,which is mainly due to a reduction in the rate of gluconeogenesis and asmall effect on glycogenolysis. Moreover, metformin activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis and glycogen synthesis in the liver while stimulating insulin signaling and glucose transport in muscles"
218849358|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
218849359|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
218849360|NCT04910074|DEVICE|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
218849361|NCT04910074|DEVICE|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
218849362|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
219197471|NCT05259943|DRUG|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
219591823|NCT01667835|BEHAVIORAL|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
219591824|NCT04774016|OTHER|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
219197472|NCT05259943|DRUG|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
219197473|NCT05883956|DRUG|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
218849363|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
218849364|NCT00349180|DRUG|Enoxaparin sodium|
218849365|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
219197474|NCT05883956|DRUG|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
219197475|NCT06005948|OTHER|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
219197476|NCT06005948|OTHER|control|No intervention will be made.
219197477|NCT01474122|DRUG|Macitentan 3 mg|Macitentan 3-mg tablet once daily
219197478|NCT01474122|DRUG|Macitentan 10 mg|Macitentan 10-mg tablet once daily
219197479|NCT01474122|DRUG|Placebo|Placebo tablet matching macitentan tablet, once daily
219197480|NCT06587945|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral Nicotinamide Riboside, 2g daily for 4 weeks followed by 1g daily for 16 weeks
219591825|NCT04774016|OTHER|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
219197481|NCT06587945|OTHER|Placebo|Matched placebo
219197482|NCT06587945|PROCEDURE|Vitrectomy and Gas tamponade|Standard of care Vitrectomy surgery for retinal reattachment
219591826|NCT04774016|OTHER|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
219591827|NCT01794897|DRUG|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
218849366|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
218849367|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
218849368|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
218849369|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
218849370|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
218849371|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
218849372|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
218849373|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
218849374|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
218849375|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
219591828|NCT01794897|DRUG|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
218849376|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
218849377|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
218849378|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
218849379|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
218849380|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
218849381|NCT03883919|DRUG|5-FU|-Standard of care drug
218849382|NCT03883919|DRUG|Leucovorin|-Standard of care drug
218849383|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
218849384|NCT03883919|DRUG|Paricalcitol|-Investigational drug
218849385|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
218849386|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
218849387|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
218849388|NCT00408655|DRUG|paclitaxel|Given IV
218849389|NCT00408655|DRUG|carboplatin|Given IV
218849390|NCT00408655|DRUG|temsirolimus|Given IV
218849391|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
219591829|NCT01594255|DRUG|sotrastaurin|
219591830|NCT01594255|DRUG|sotrastaurin|
218849392|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
218849393|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
218849394|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
218849395|NCT01977443|DRUG|APD-209 Eye drops|
219591831|NCT01594255|DRUG|placebo to sotrastaurin|
219591832|NCT01594255|DRUG|Avelox|
218849396|NCT01977443|DRUG|APD-209 Placebo Eye drops|
218849397|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
218849398|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
218849399|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
218849400|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
218849401|NCT01328041|DRUG|dolutegravir|50 mg twice daily
219591833|NCT04267029|DIAGNOSTIC_TEST|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive"
219458421|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
219458422|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
219458423|NCT00045565|DRUG|arsenic trioxide|Given IV
219458424|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
219458425|NCT02581098|OTHER|No interventions|No interventions
219458426|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
219458427|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
219458428|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
219458429|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
219458430|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
219458431|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
219458432|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
219458433|NCT02967562|OTHER|Inflation Breaths|
219458434|NCT02967562|OTHER|Sustained Inflation|
219458435|NCT03260062|BEHAVIORAL|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
219458436|NCT03260062|OTHER|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
219458437|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
219458438|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
218849402|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
219458439|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
219458440|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
219458441|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
219458442|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
219458443|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1\) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
219458444|NCT04335552|OTHER|Standard of care|Standard of care
219458445|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
219458446|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
219458447|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
219458448|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
218849403|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
218849404|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
218849405|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
219458449|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
219458450|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
219458451|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
219458452|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
219458453|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
219458454|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
219458455|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
219458456|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
219458457|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
219458458|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
219458459|NCT04563624|DRUG|composite blocks|cad cam composite blocks
219458460|NCT04563624|DRUG|ceramic cad cam blocks|ceramic cad cam blocks
219458461|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
219458462|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
218849406|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
218849407|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
218849408|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
219591834|NCT03722667|BEHAVIORAL|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
219591835|NCT03722667|BEHAVIORAL|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
219591836|NCT01058772|OTHER|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
219591837|NCT04105140|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
219591838|NCT04105140|DRUG|Placebo|intranasal administration of placebo (24 IU)
219591839|NCT00198250|DRUG|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
219591840|NCT03653910|DEVICE|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
219591841|NCT03653910|DEVICE|Macintosh|Macintosh is a traditional laryngoscope for intubation
218849409|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
218849410|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
218849411|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
218849412|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
218849413|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
219458463|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
219458464|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
219458465|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
219458466|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
219458467|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
219458468|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
219591842|NCT03868150|DRUG|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
219591843|NCT03868150|DEVICE|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
219458469|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
219458470|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
219458471|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
219458472|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
219458473|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
219458474|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
219458475|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
219591844|NCT01903135|PROCEDURE|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
219591845|NCT01903135|PROCEDURE|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
218849414|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
218849415|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
219591846|NCT01563835|DRUG|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
218849416|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
219019099|NCT05462821|DEVICE|Eye Patch|adhesive patch to cover eye
219591847|NCT01563835|DRUG|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
219591848|NCT04730648|DRUG|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
219019104|NCT06668064|DRUG|EYP-1901|Intravitreal Injection
219591849|NCT04790708|RADIATION|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
219591850|NCT04790708|RADIATION|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
219591851|NCT04790708|RADIATION|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
219591852|NCT04790708|RADIATION|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
219591853|NCT04790708|RADIATION|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
219591854|NCT05987319|DEVICE|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
219591855|NCT04500093|PROCEDURE|Capsulotomy with Repair|Capsulotomy with Repair
219591856|NCT04500093|PROCEDURE|Capsuloectomy|Capsuloectomy
219591857|NCT04628793|DRUG|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
219591858|NCT04628793|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
218849417|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
219197483|NCT06811259|OTHER|Virtual reality (in experimental group)|Virtual reality application is performed with virtual reality glasses. Virtual reality glasses are a simulation model that provides participants with the opportunity to communicate with a dynamic environment created by computers and gives them a sense of reality. Virtual reality glasses, which have a mechanism compatible with smart phones, allow videos downloaded to mobile phones or watched directly via the internet to be viewed at a 360-degree angle. The two lenses on the device provide panoramic viewing by dividing the image into two equal parts. The bands on the front of the device that fits the face are flexible and prevent the device from slipping from the face. The buckles on the back are adjustable and provide ease of use. Thanks to the proximity sensor on the device, images can be zoomed in and out to obtain a clearer image. Thanks to the device holder on the sides, the phone can be easily placed and removed from the device. Again, videos can be advanced or changed with the tou
219458476|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
219458477|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
219197484|NCT06811259|OTHER|Standart care|Women in the control group will receive only standard care during colposcopy
218849418|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
219458478|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
219458479|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
219458480|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
219458481|NCT02870348|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
219458482|NCT06366854|PROCEDURE|Personalised fluid and haemodynamic resuscitation|individualised resuscitation
219458483|NCT00672139|DRUG|Methylnaltrexone bromide|
219591859|NCT03302026|BEHAVIORAL|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
219591860|NCT01655576|PROCEDURE|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
218849419|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
219197485|NCT06813300|PROCEDURE|Electrophysiological recordings|Addition of electrophysiological recordings performed during cognitive tasks passation in patients undergoing DBS: in pre-op, per-op, peri-op and post-op setting
219197486|NCT06290895|OTHER|women having had a second IVF cycle with AOA|The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
219197487|NCT06603025|OTHER|chewing gum|Preoperative intervention group patients will chew sugarless gum for at least 30 minutes 30-60 minutes before surgery. The gum will be removed before going to the operating room.
219197488|NCT06594900|BEHAVIORAL|resistance training intervention|"The RT intervention focuses on knee extensor muscles, following current guidelines. Children will attend two supervised 1-hour sessions per week, proven sufficient for adaptations. Trained coaches and a scientific assistant, supported by master students, will document the sessions. Sessions are spaced 48 hours apart, totaling 40 over 20 weeks, with eight sessions between PRE and MID.~Each session has three phases: warm-up, strength, and coordination. Warm-up involves whole-body games to increase heart rate and prepare for strength training. The strength phase, documented for effort and adjustments, includes squats, lunges, and step-ups, with intensity changes over time. Four sets of 8-12 repetitions per exercise are performed, aiming for strength increase and hypertrophy. Movements are done with great effort but not until voluntary failure.~The coordination phase focuses on age-appropriate strength and motor skills through a circuit of challenges."
219197489|NCT06769204|DRUG|EMLA SPRAY|2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure
219197490|NCT06769204|DRUG|Placebo|2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
219458484|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
219458485|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
219458486|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
219458487|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
219458488|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
219458489|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
219458490|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
219591861|NCT02315430|DRUG|Cabozantinib S-malate|Given PO
219591862|NCT02315430|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218849420|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
218849421|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
218849422|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
218849423|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
218849424|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
218849425|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
219458491|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
219458492|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
218849426|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
218849427|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
218849428|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
218849429|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
218849430|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
218849431|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
218849432|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
218849433|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
218849434|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
219458493|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
219458494|NCT02079701|BIOLOGICAL|Placebo|
219458495|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
219458496|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
219458497|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
219458498|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
219458499|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
218849435|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
218849436|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
218849437|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
218849438|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
219458500|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
218849439|NCT02688088|DRUG|Drug Cocktail|Administered orally
218849440|NCT02688088|DRUG|Abemaciclib|Administered orally
218849441|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
219458501|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
219458502|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
219458503|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
219458504|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
219458505|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
218849442|NCT02252549|DEVICE|WLI assisted TURB|
219458506|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
219458507|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
219458508|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
219458509|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
219458510|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
219458511|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
219458512|NCT00420823|DRUG|Taurine 4g|
219458513|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
219591863|NCT03741426|DRUG|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
219591864|NCT03741426|DRUG|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
219591865|NCT03741426|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
219591866|NCT03039426|DRUG|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
219591867|NCT03039426|DRUG|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
219591868|NCT02041065|DEVICE|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
219591869|NCT02041065|DEVICE|CUSA induced dissection|Ultrasound based destruction of the liver
219591870|NCT04712981|BEHAVIORAL|HOPE|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
219591871|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
218849443|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
218849444|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
219019105|NCT06668064|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
219019106|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
218849445|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
218849446|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
218849447|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
218849448|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
218849449|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
218849450|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
218849451|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
218849452|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
218849453|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
219197491|NCT06767644|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
219197492|NCT06767644|OTHER|no music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
219197493|NCT06810063|OTHER|Assessment only, no intervention|Participants in this study complete two visits to test the agreement of telehealth and in person assessments of arm and hand movement.
219458514|NCT05302102|OTHER|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
219458515|NCT05302102|OTHER|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
219458516|NCT05302102|OTHER|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
219458517|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
219458518|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
219458519|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
219458520|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
219458521|NCT05807191|OTHER|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
219458522|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
219458523|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
219458524|NCT00107536|DRUG|lapatinib ditosylate|
218849454|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
218849455|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
218849456|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
218849457|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
219458525|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
219591872|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
219591873|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
219591874|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
219591875|NCT00400595|DRUG|Mupirocin ointment|topical ointment (already in widespread clinical use)
219591876|NCT00400595|DRUG|Polysporin Triple|
219458526|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
219591877|NCT02076490|OTHER|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
219197494|NCT06808763|OTHER|Knee Rehabilitation Exercise Program|"Rehabilitation Program Description:~The rehabilitation program was designed to restore knee function and strength progressively in football players recovering from anterior cruciate ligament (ACL) injuries. Key elements of the program are detailed below:~Program Components:~Session Structure:~Each session lasted 60 to 90 minutes. Sessions were performed multiple times weekly, progressively adjusted throughout the program.~Session Breakdown:~Warm-Up and Jump Exercises (Part 1):~Focused on preparing the body for physical activity and improving jump dynamics.~Dynamic Exercises (Part 2):~Included drop-jumps, side-hops, and crossover-hops for dynamic knee stabilization and balance.~Strength Exercises:~Targeted muscle groups included hamstrings, quadriceps, and calves. Exercises consisted of one-legged leg press, eccentric leg press, squats, one-legged squats on a balance mat, one-legged leg curls, Nordic hamstring, one-legged toe-raises, and lunge exercises.~Resistance training was i"
219458527|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
219458528|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
219458529|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
219458530|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
219458531|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
219458532|NCT02413086|PROCEDURE|Early-stage amputation|Individuals with DFU were given early-stage amputation.
219458533|NCT02413086|PROCEDURE|Amputation|Individuals with DFU were given amputation.
219458534|NCT02413086|OTHER|External herbs chitosan|Wound was given external herbs chitosan after amputation.
219458535|NCT02413086|OTHER|Traditional gauze|Wound was given traditional gauze after amputation.
219197495|NCT06798636|DRUG|Psilocybin 5 mg with cognitive behavioural therapy intervention|This is an oral 5mg psilocybin dose preceding a mental imagery rescripting procedure
219197496|NCT06798636|DRUG|Placebo with cognitive behavioural therapy intervention|This is an oral placebo comparator preceding a mental imagery rescripting procedure
219197497|NCT06816030|DRUG|MK-4482|Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
219197498|NCT06818318|OTHER|Temporomandibular disorder|Fonseca's Anamnestic Index was used for TMJ dysfunction. The diagnostic accuracy of the Fonseca's Anamnestic Index was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
219197499|NCT06818318|OTHER|Smartphone Addiction Scale-Short Form|In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The Smartphone Addiction Scale-Short Form is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60, and an increase in the score indicates an increased risk for smartphone addiction. Although the scale does not have a cut-off score in our country, it was determined as 31 for men and 33 for women in the Korean sample.
218849458|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
219591878|NCT06634186|DIETARY_SUPPLEMENT|Dietary intervention|The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
219591879|NCT05319210|PROCEDURE|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
219591880|NCT06452667|PROCEDURE|platelet-rich fibin|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
219458536|NCT01430949|PROCEDURE|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
219458537|NCT04048057|OTHER|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
219458538|NCT00597857|DRUG|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
219458539|NCT00597857|DRUG|placebo|receipt of a placebo pill for 16 days
219458540|NCT04054219|DEVICE|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
219458541|NCT00213967|DEVICE|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
219591881|NCT06452667|PROCEDURE|platelet-rich palsma|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
218849459|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
218849460|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
218849461|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
219458542|NCT02355925|DRUG|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
219458543|NCT02355925|DRUG|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
219591882|NCT04319016|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
219591883|NCT04746794|BEHAVIORAL|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
218849462|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
218849463|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
218849464|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
218849465|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
219197500|NCT06818318|OTHER|Neck Disability Index|The Neck Disability Index was used to assess the disability caused by neck pain. This questionnaire consists of ten items, four of which are related to subjective symptoms (pain intensity, headache, concentration, sleep) and six of which are related to activities of daily living (self-care, lifting, reading, work, driving and leisure activities). Scale scoring ranges from 0-40.
218849466|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
219458544|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
218849467|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
218849468|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
218849469|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
219458545|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
219458546|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
219591884|NCT04040192|DRUG|Crisaborole 2%|Crisaborole ointment 2%
219591885|NCT04040192|DRUG|Vehicle|Vehicle ointment
219591886|NCT03207243|DRUG|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
219591887|NCT03207243|DRUG|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
219591888|NCT03207243|DRUG|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
219591889|NCT03207243|DRUG|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
219458547|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
219458548|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
219458549|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
219458550|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
219458551|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
219458552|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
219458553|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
219458554|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
219458555|NCT04454840|BIOLOGICAL|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
219591890|NCT03551288|DRUG|SUVN-911|Tablet
219197501|NCT06818318|OTHER|Temporomandibular Joint Pain|Numeric Pain Scale is a simple, reliable and short-term method commonly used in the clinic to measure pain intensity. It is a very reliable method in the evaluation of pharmacological and nonpharmacological treatments that reduce pain. The patient is told that the most severe pain he/she experiences is 10, and if he/she has no pain, the pain intensity is 0. The participant was asked to say a number between 0 and 10 corresponding to the intensity of pain felt in the TMJ region.
219458556|NCT04454840|DRUG|Riluzole|The basic treatment is Riluzole 25\~50mg twice daily
219197502|NCT06818318|OTHER|Anterior posture of the head|The anterior posture of the head was assessed with the Craniovertebral angle using a goniometer. The Craniovertebral angle was measured in degrees as the angle between the horizontal plane and the 7th cervical vertebra and the ear hole.
219197503|NCT06818318|OTHER|Pressure Pain Threshold Assessment|In our study, the pressure pain threshold measurement of the dominant and non-dominant side masseter and tenar muscles was evaluated with Baseline manual algometer.
219591891|NCT04439617|BIOLOGICAL|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
219591892|NCT02268968|DRUG|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
219591893|NCT00154869|DRUG|Peginterferon Alfa-2a plus Ribavirin|
219591894|NCT03531138|OTHER|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
219591895|NCT01635816|BIOLOGICAL|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
219591896|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
219591897|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
219591898|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
219591899|NCT05798910|OTHER|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
219591900|NCT05798910|OTHER|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
219591901|NCT05555823|DRUG|ATR-002|300 mg tablets for oral intake
219591902|NCT05555823|DRUG|Placebo|matching tablets for oral intake
219197504|NCT04173247|DEVICE|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
219458557|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
219458558|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
218849470|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
218849471|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
219458559|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
219458560|NCT04451395|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
219458561|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
219458562|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
219458563|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
218849472|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
218849473|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
219458564|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
219458565|NCT00857116|DRUG|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
219458566|NCT00857116|DRUG|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
219591903|NCT05555823|DRUG|Repaglinide|0,5 mg tablets for oral intake
219591904|NCT05555823|DRUG|Celecoxib|100 mg capsules for oral intake
219591905|NCT05171608|PROCEDURE|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
219591906|NCT01820975|DIETARY_SUPPLEMENT|High protein intake|
219591907|NCT01820975|OTHER|Placebo comparator|No protein intake
219591908|NCT05856006|OTHER|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
219591909|NCT05856006|OTHER|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
219591910|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
219019113|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
219019114|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
219019115|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
219458567|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
218849474|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
218849475|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
218849476|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
218849477|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
218849478|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
218849479|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
218849480|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
219197505|NCT04173247|OTHER|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
219197506|NCT06820918|DEVICE|Bottle PEP|Home respiratory physiotherapy using the PEP bottle for a minimum of 10 minutes to a maximum of 30 minutes, twice a day (morning and evening), every day for 30 days
219458568|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
219458569|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
219458570|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
219458571|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
219458572|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
219458573|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
219458574|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
219458575|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
219458576|NCT05119790|DRUG|[14C] BIIB122 ([14C] DNL151)|Oral dose
219591911|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
219458577|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
219458578|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
219458579|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
219458580|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
219591912|NCT05437315|BIOLOGICAL|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
219591913|NCT00354692|DRUG|Sodium Ferric Gluconate and Iron sucrose|
219458581|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
219458582|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
219458583|NCT04212611|DRUG|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
219591914|NCT00308880|DRUG|Transamin|
219591915|NCT01238380|OTHER|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
219591916|NCT04283604|DRUG|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
218849481|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
219197507|NCT06795555|BEHAVIORAL|Virtual reality food exposure|Patients in this condition are exposed to a virtual kitchen environment once/day, for 5 consecutive days (from Monday, day 1, to Friday, day 5). Each session lasts 5 minutes. The VR environment was specifically developed by the study team (Natali et al, 2024) and it consists of a kitchen with foods of different calorie contents. Patients are invited to explore the environment; they can freely move, open the cupboards and the fridge, and grab and hold the foods. Participants can choose to interact with one of three versions of the virtual kitchen environment: a) a kitchen alone, b) a kitchen with a virtual pet which participants can interact with (and aimed at inducing positive mood) and c) a kitchen with a compassionate avatar which motivates the participant to face food-related fears.
219458584|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
219458585|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
219458586|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
219458587|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
219458588|NCT03257306|PROCEDURE|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
219458589|NCT03257306|PROCEDURE|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
219458590|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
219458591|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
219458592|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
219458593|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
218849482|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
218849483|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
218849484|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
219197508|NCT06795555|BEHAVIORAL|Virtual Reality Nature Exposure|"Patients in this condition complete a session of VR exposure to a natural scenario (from the NatureTreksVR app) for 5 consecutive days (from Monday to Friday), one session/day. Each session lasts 5 minutes. Participants can choose exposure to one of three different natural environments, at the start of each session: a white sand beach (Blue Ocean), a snowy mountain (White Winter), or a forest in autumn foliage (Red Fall)."
219458594|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
219458595|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
219458596|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
219458597|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
219458598|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
219591917|NCT02583958|DEVICE|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
219591918|NCT02583958|DEVICE|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
219591919|NCT02497638|DRUG|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
219591920|NCT02497638|DRUG|Atorvastatin|Atorvastatin 20 mg once daily until progression.
219591921|NCT02497638|DRUG|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
219591922|NCT02497638|DRUG|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
219458599|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
219458600|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
219458601|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
219458602|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
219458603|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
218849485|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
218849486|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
219458604|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
219458605|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
219458606|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
219458607|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
219458608|NCT00256204|OTHER|Placebo|Placebo
218849487|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
218849488|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
219458609|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
219591923|NCT02390024|DEVICE|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
219591924|NCT01960049|PROCEDURE|ropivacaine + iv PCA|
219591925|NCT01960049|PROCEDURE|saline and IV PCA|
219591926|NCT03510390|DRUG|Metformin|850 mg, oral, twice daily, 9-14 days
219591927|NCT02341391|BIOLOGICAL|TissueGene-C(Low dose)|3.0 x 10\^6 cells
219591928|NCT02341391|BIOLOGICAL|TissueGene-C(Medium dose)|1.0 x 10\^7 cells
219591929|NCT02341391|BIOLOGICAL|TissueGene-C(High dose)|3.0 x 10\^7 cells
219591930|NCT05800067|DRUG|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
219591931|NCT01380548|DIETARY_SUPPLEMENT|Placebo|Placebo; once/day; for 12 weeks
219591932|NCT01380548|DIETARY_SUPPLEMENT|Iron alone|Iron (3 mg); once/day; for 12 weeks
219591933|NCT01380548|DIETARY_SUPPLEMENT|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
218849489|NCT05526781|DEVICE|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
218849490|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
218849491|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
218849492|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
219019146|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
219019147|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
219019148|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of vasopressin (20 IU).
219019149|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
219591934|NCT01380548|DIETARY_SUPPLEMENT|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
219458610|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
219458611|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
219591935|NCT01380548|DIETARY_SUPPLEMENT|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
219591936|NCT03960125|DEVICE|Photodynamic Therapy|Blue Light Therapy Exposure
219197509|NCT06820632|BEHAVIORAL|Enhanced physical education|"The Enhanced physical education is based on the Health and Physical Education (HPE) Curriculum Framework developed by the Bhutanese Ministry of Education and well-document in the 2022 edition, www.education.gov.bt. The enhanced PE group will follow closely the description of the HPE curriculum and receive two 90-minute sessions weekly for 5 months. According to the HEP curriculum, the enhanced PE program incorporate both PE with socio-emotional competencies, such as self-regulation, self- and social-awareness, empathy-building exercises, and cooperation activities."
219197510|NCT06820632|BEHAVIORAL|HPE Standard curriculum|Health and physical education (HPE) standard curriculum includes roughly one hour per week of general physical education, typically involving activities like football and basketball.
219197511|NCT06821308|DEVICE|Implant placement|Each patient received 4 implants to support a bar supported overdenture. One implant is commercially available, 3 implants were experimentally made by the manufacturer for this study. The implants were similar in macro-desing, surface and platform shift but differ in microthread design and implant-abutment connection.
219197512|NCT06819345|OTHER|Survey form|PPE15 (Picker Patient Experience Questionnaire) at all visit of the study KDQOL-SF (Kidney Disease Quality Of Life -short form) at inclusion and 3 months after initiation of RRT ou 24 months after inclusion SDMQ9 (Shared Decision Making Questionnaire): at inclusion and 3 months after receiving information related to RRT SDRS (Score Decision Regret Scale) : 3 months after initiation of RRT ou 24 months after inclusion HLS EU 16 (Health Literacy Survey) : at inclusion or 3 months after information on RRT
219458612|NCT03427528|BEHAVIORAL|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
219458613|NCT03427528|BEHAVIORAL|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
219458614|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
219591937|NCT03960125|DRUG|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
219591938|NCT03960125|DRUG|Base Cream|Control to 4% Imipramine
219591939|NCT00229723|DRUG|gefitinib (Iressa)|250 mg oral tablet
219458615|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
219458616|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
219458617|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
219458618|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
219458619|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
219591940|NCT00229723|DRUG|cisplatin|intravenous infusion
219591941|NCT00229723|RADIATION|radiotherapy|radiation therapy
219591942|NCT00229723|DRUG|Gefitinib (Iressa)|500 mg oral tablet
219591943|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
219591944|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
219591945|NCT04408235|DRUG|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
219591946|NCT03931525|DEVICE|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
219591947|NCT03931525|DEVICE|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
219591948|NCT03904264|DEVICE|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
218849493|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
218849494|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
218849495|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
218849496|NCT04847752|DRUG|Aspirin|the dosage and duration
218849497|NCT04847752|DRUG|Clopidogrel|the dosage and duration
218849498|NCT04847752|DRUG|Anticoagulant|the dosage and duration
218849499|NCT04847752|DRUG|Statin|the dosage and duration
218849500|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
218849501|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
218849502|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
218849503|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
218849504|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
218849505|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
218849506|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
218849507|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
219197513|NCT06817486|OTHER|RUNNİNG TRAİNİNG|Running training It was performed between 08:00 and 10:00 for morning running and between 18:00 and 20:00 for evening running (Bessot et al., 2014). The exercise intensity of each child in the running group was determined as the 50% heart rate (HR) according to the Karvonen formula (target pulse: (220-age-basal pulse) × intensity) + basal pulse). HR was determined via a telemetric heart rate monitor (PolarM400, Finland) during the first week of running training. Environmental conditions are known to influence the degree of airway epithelial disruption during high-intensity exercise (Boukelia et al., 2017). Therefore, all the participants performed continuous running exercise on a football field in Kelkit/Gümüşhane/Turkey (altitude: 1373 m). It was performed for 50 minutes (including 10 min warm-up and cool-down), 3 days a week, for 8 weeks at the set target heart rate. Each session was supervised by trainers. Running included approximately 10 minutes of warm-up and cool-down with stati
219197514|NCT06817486|PROCEDURE|TRAİNİNG|RUNNING TRAINING WAS DONE
219458620|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
218849508|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
219197515|NCT06818279|DRUG|Dabigatran|Dabigatran 150 mg BD fixed dose to be given for duration of 6 months.
219458621|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
218849509|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
219458622|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
219458623|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
218849510|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
218849511|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
218849512|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
218849513|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
218849514|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
218849515|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
218849516|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
219197516|NCT06818279|DRUG|Enoxaparin|Enoxaparin . Treatment would be given with 1 mg /Kg (100IU/Kg) dose s/c twice daily for 6 months.
218849517|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
218849518|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
218849519|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
218849520|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
219197517|NCT06819982|OTHER|BCM2.0|The BCM2.0 programme provides occupational therapy sessions and assistive devices to support older people who want to age in place.
219197518|NCT06816485|DEVICE|PTV (Percutaneous Transcatheter Valvuloplasty) Balloon|Minimally invasive medical procedure used to replace a diseased aortic valve without the need for open-heart surgery. It is commonly used to treat severe aortic stenosis, a condition in which the aortic valve becomes narrowed and restricts blood flow from the heart to the rest of the body.
219458624|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
219458625|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
219458626|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
219458627|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
219458628|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
219458629|NCT00474136|DRUG|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
219458630|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
219591949|NCT05885984|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
218849521|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
219197519|NCT01855633|DEVICE|Traditional Theta burst stimulation (TBS)|
218849522|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
218849523|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
219197520|NCT01855633|DEVICE|Modified TBS rTMS|
219458631|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
219458632|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
219458633|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
219458634|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
219458635|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
219458636|NCT02136329|DRUG|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
219458637|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
219458638|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
219458639|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
218849524|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
218849525|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
218849526|NCT04553744|OTHER|Survey Administration|Complete survey
218849527|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
218849528|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
218849529|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
218849530|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
218849531|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
218849532|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
218849533|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
218849534|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
218849535|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
218849536|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
218849537|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
219197521|NCT01855633|DEVICE|Sham rTMS|
219458640|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
218849538|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
218849539|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
218849540|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
219458641|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
219458642|NCT04111926|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
218849541|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
218849542|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
218849543|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
219458643|NCT04111926|DRUG|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
219458644|NCT03266367|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
218849544|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
218849545|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
218849546|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
219458645|NCT01585909|PROCEDURE|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
219458646|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
219458647|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
219458648|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
219458649|NCT04144933|DRUG|Dexamethasone, Ondansetron|6 mg, 4 mg
219458650|NCT04144933|DRUG|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
219458651|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
219197522|NCT06478693|DRUG|MT-303|MT-303
218849547|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
218849548|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
218849549|NCT04351464|OTHER|physical therapy and reflexology|
219458652|NCT04144933|DRUG|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
219458653|NCT03062605|DRUG|Iodine (Betadine)|
218849550|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
218849551|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
218849552|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
218849553|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
218849554|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
218849555|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
219197523|NCT06855823|DRUG|Golicitinib combined with Pomadomide|golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd
219197524|NCT06659536|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
219197525|NCT06825221|DIETARY_SUPPLEMENT|Oral Nutrition supplement|Participants received normal diet and in the interventional group received package of immune formula 2 meals per day for 10-14 days prior surgery.
219591950|NCT05885984|OTHER|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
219591951|NCT00735397|DRUG|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
219197526|NCT06608407|BIOLOGICAL|PRP group|After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
219458654|NCT03062605|BIOLOGICAL|NaOCL|
219458655|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
219458656|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
218849556|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
219458657|NCT02405091|DRUG|NBI-98854|
219458658|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
219458659|NCT00151723|PROCEDURE|treatment with 131I|
219458660|NCT01742182|OTHER|Light exposure|
219591952|NCT04767191|DRUG|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
219591953|NCT04767191|DRUG|dihydroartemisinin piperaquine|Antimalarial Combinations
219591954|NCT02404766|OTHER|C0-C1 dorsal glide manual mobilization|
219591955|NCT02404766|OTHER|C7-T1 ventral cranial glide manual mobilization|
219591956|NCT05998148|OTHER|virtual phone appointment visits|Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
218849557|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
218849558|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
218849559|NCT04700345|OTHER|Medical Management|best medical management
218849560|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
219458661|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
219591957|NCT02737904|OTHER|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
219591958|NCT02737904|OTHER|Usual care|Personalised in-patient rehabilitation programme
218849561|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
218849562|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
219458662|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
218849563|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
218849564|NCT02607917|OTHER|Mass Media plus clinic intervention.|
218849565|NCT02607917|OTHER|Media|
218849566|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
219458663|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
219458664|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
219458665|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
219458666|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
219458667|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
219458668|NCT00002024|DRUG|Ganciclovir|
219458669|NCT03424616|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
219458670|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
219458671|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
219458672|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
219458673|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
219458674|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
219458675|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
219458676|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
219591959|NCT02338804|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
218849567|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
218849568|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
218849569|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
218849570|NCT01602783|OTHER|11C Acetate Imaging|Single scan
219458677|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
218849571|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
219019160|NCT06588504|DRUG|Dasiglucagon|Participants will receive s.c. injection of dasiglucagon.
219458678|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
219458679|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
219458680|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
219197527|NCT05148117|DIAGNOSTIC_TEST|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
219197528|NCT05148117|DIAGNOSTIC_TEST|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
219197529|NCT06585917|DEVICE|7F Thin-Walled Sheath|The 7F Thin-Walled Sheath is used during coronary intervention procedures via distal radial artery access. This device has a smaller outer diameter compared to traditional 7F sheaths, designed to reduce the risk of vascular complications while allowing for the performance of complex coronary interventions.
219197530|NCT06585917|DEVICE|6F Thin-Walled Sheath|The 6F Thin-Walled Sheath is the standard device used in coronary intervention procedures via distal radial artery access. It is employed as a control in this study to compare its efficacy and safety against the 7F Thin-Walled Sheath.
219458681|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
219019161|NCT06588504|DRUG|Glucagon|Participants will receive i.m. injection of glucagon.
219458682|NCT00191438|DRUG|gemcitabine|
219458683|NCT00191438|DRUG|capecitabine|
219458684|NCT00191438|DRUG|docetaxel|
219591960|NCT02338804|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
219591961|NCT01054404|DRUG|Furosemide|Furosemide 0.3 mg/kg
218849572|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
218849573|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
218849574|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
218849575|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
218849576|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
218849577|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
218849578|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
218849579|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
218849580|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
219197531|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
218849581|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
218849582|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
218849583|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
219019163|NCT06215586|DRUG|Tovinontrine (CRD-750|Tablets administered orally
219458685|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
219458686|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
219458687|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
219458688|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
219458689|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
219458690|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
219458691|NCT01768039|DRUG|Vitamin D|
219458692|NCT01768039|DRUG|Placebo|
219458693|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
218849584|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
219019164|NCT06215586|DRUG|Placebo|Tablets administered orally
219458694|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
219591962|NCT01054404|DRUG|Placebo|Placebo (up to 5mL)
219591963|NCT00880789|BIOLOGICAL|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
219458695|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
219458696|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
219458697|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
219458698|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
219197532|NCT06826144|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 200 mmHg or exceeds baseline systolic pressure by 35 mmHg (intervention group).At least 4 sessions of actual RIC treatment before the procedure.Continued RIC treatment for a minimum of 4 weeks postoperatively.
219458699|NCT02401945|DRUG|DE-120|
219458700|NCT02401945|DRUG|Aflibercept|
219591964|NCT02518672|DIETARY_SUPPLEMENT|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
219197533|NCT06826144|PROCEDURE|Sham treatment|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 20 mmHg.At least 4 sessions of sham RIC treatment before the procedure.Continued sham RIC treatment for a minimum of 4 weeks postoperatively.
219197534|NCT06825637|DEVICE|Kandoo|Kandoo is an app that allows patients to track their activities in an engaging and gamified platform.
219458701|NCT02522091|DEVICE|functional brain MRI|
219458702|NCT02522091|OTHER|Neuropsychology tests|
219458703|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
219458704|NCT02074436|DRUG|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
219458705|NCT02074436|OTHER|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
219458706|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
219458707|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
219591965|NCT02518672|DIETARY_SUPPLEMENT|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
219591966|NCT02876757|DRUG|5ARI|Exposure to finasteride/dutasteride
219591967|NCT02630979|BEHAVIORAL|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
219591968|NCT03016975|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
219591969|NCT03016975|DRUG|Guideline Directed Medical Therapy|GDMT Only
219591970|NCT00002737|BIOLOGICAL|recombinant interferon alfa|
219591971|NCT00002737|DRUG|chemotherapy|
219591972|NCT00002737|DRUG|isotretinoin|
219019165|NCT06665672|DEVICE|Wrist worn vibro-acoustic device|The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.
219019166|NCT06855732|BEHAVIORAL|Usual Care|"Usual care refers to the standard of care that patients receive at their primary care clinic.~The standard of care for patients is to discuss chronic pain with their providers at their discretion, and for providers to offer buprenorphine for OUD and/or provide referrals to specialty addiction treatment programs in the local community.~Participants will continue to have access to usual care for chronic pain, which could include pain clinic visits, physical therapy, medication (e.g., gabapentin), and/or seeing a counselor, psychiatrist, or psychologist.~The study protocol will not interfere with usual clinical care."
219458708|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
219458709|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
219458710|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
219458711|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
219458712|NCT01694966|DRUG|Methylene Blue MMX®|
219458713|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
219458714|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
219458715|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
219458716|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
219458717|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
219458718|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
219458719|NCT04068220|OTHER|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
219458720|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
219458721|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
219458722|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
219458723|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
219458724|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
219458725|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
219458726|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
219458727|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
219458728|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
219458729|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
219458730|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
218849585|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
218849586|NCT00003946|DRUG|danazol|
219458731|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
219458732|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
219458733|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
219458734|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
219458735|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
219458736|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
219458737|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
219458738|NCT02924922|DRUG|Mannitol|
218849587|NCT00099242|DRUG|rivastigmine transdermal patch|
218849588|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
219458739|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
219458740|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
219458741|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
219458742|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
219458743|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
219458744|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
219458745|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
219458746|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
219458747|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
219458748|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
218849589|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
218849590|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
218849591|NCT00912080|GENETIC|genomic signature|genomic signature analysis
219019167|NCT06855732|BEHAVIORAL|Pain Self-Management|"PSM is a manualized behavioral intervention tailored to patients in primary care with opioid misuse/OUD. The PSM intervention that consists of ten sessions/modules.~Participants will be offered a total of 10 PSM sessions, delivered weekly over a 12-week intervention period starting from the date of study enrollment.~A trained staff interventionist will lead the 60-minute sessions using a participant study manual that outlines the content for all 10 sessions.~The first two sessions, Introduction and Navigating Conversations About Opioids, are mandatory. Participants can choose the order of the remaining 8 sessions, prioritizing those they are most interested in. Additional session topics are: Stress Management and Your Pain, Relaxation Techniques to Help Your Pain, Thinking Differently About Your Pain, Sleeping Better to Help Your Pain, Physical Activity and Your Pain, Mood and Your Pain, and Communicating with Others."
219458749|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
219458750|NCT00155246|DRUG|pentoxifylline (drug)|
219458751|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
219458752|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
219458753|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
219458754|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
218849592|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
218849593|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
218849594|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
218849595|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
218849596|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
218849597|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
218849598|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
218849599|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
218849600|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
218849601|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
218849602|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
219197535|NCT06599333|BEHAVIORAL|Adherence to Care|"Questionnaire to assess the perception and readiness of patients in Lebanon towards the effectiveness of digital marketing strategies to improve their adherence to medications they take chronically~The following sections will be considered:~* General Characteristics of the Participants~* Medical and medication history~* Assessment of adherence to chronic medications (Likert scale)~* Digital Marketing Strategies to improve adherence to chronic medications (Likert scale)~* Perceived barriers to adopting digital marketing strategies in Lebanon (Likert scale)"
219197536|NCT06817681|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium bicarbonate (NaHCO3) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
219458755|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
219458756|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
219458757|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
219458758|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
219458759|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
219591973|NCT01900561|BEHAVIORAL|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
219197537|NCT06817681|OTHER|Placebo (Sodium Chloride)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium chloride (NaCl) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
219458760|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
219458761|NCT00702949|DRUG|pregabalin|Given orally
219591974|NCT01900561|BEHAVIORAL|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
219591975|NCT01590797|DRUG|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
219591976|NCT01590797|DRUG|Placebo|Matching placebo once daily for 24 weeks
219197538|NCT06590129|PROCEDURE|hydrodissection of median nerve|Ultrasound guided hydrodissection of median nerve in carpal tunnel with 5% dextrose solution
219458762|NCT00702949|OTHER|placebo|Given orally
219458763|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
219458764|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
219458765|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
219591977|NCT01590797|BIOLOGICAL|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
219197539|NCT06590129|OTHER|Physiotherapy|5-20 sessions in rehabilitation area with physical media: paraffin glove (10 coats for 15min), mobilizations of wrist and fingers, strectching of wrist and fingers tendons/muscles, muscle stregthening whit isometric or isotonic excercises to intrinsic muscles of the hand an forearm, and occupational therapy with techniques for sensory return, nerve and tendon sliding techniques, activities aimed at improving basic hand functions and work simulation activities.
219591978|NCT01590797|DRUG|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
219591979|NCT01006018|DRUG|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
219197540|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose
219197541|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, single dose
219197542|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, three times daily for a total of 8 days
219197543|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, six times daily for a total of 8 days
219458766|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
219458767|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
218849603|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
219197544|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, multiple doses
219197545|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose, tear samples will be collected
219197546|NCT06603441|DIAGNOSTIC_TEST|Samsung Galaxy Watch|Samsung Galaxy Watch technology to monitor sleep patterns, oxygen saturation, PPG, and heart rate variability amongst other physiologic parameters.
219197547|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
219197548|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
219197549|NCT05070741|BEHAVIORAL|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
219197550|NCT06842069|BEHAVIORAL|Decision Aid Supported Education|Dialysis Education
219458768|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
219458769|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
219458770|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
219458771|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
219458772|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
219458773|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
219458774|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
219591980|NCT01006018|DRUG|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
219591981|NCT01006018|DRUG|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
218849604|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
218849605|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
218849606|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
219197551|NCT06842069|BEHAVIORAL|Dialysis Education for Urgent Dialysis Start Patient|"Education provided in two consequtive educational session. During first 30-minute session, the aim of the training program was explained with an overview of CKD, sparing time for potential patient questions. The second training day was scheduled according to patients' agenda and their next hemodialysis session.~Second Interview: RRT options were explained in the 30-minute , followed by interactive discussion with patients, ensuring that patients understood the information. When the training was completed, a guidebook (Treatment Options in Kidney Failure-Conscious Choice, Conscious Start) was distributed to participants. The third interview date and time was scheduled with the patients in the DTSEP group."
219458775|NCT02690506|DRUG|Placebo|
219458776|NCT02690506|DRUG|Pregabalin|
219458777|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
219458778|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
219458779|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
219458780|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
219458781|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
219458782|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
219458783|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
219197552|NCT05786040|PROCEDURE|Biopsy|Undergo biopsy
219197553|NCT05786040|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219197554|NCT05786040|PROCEDURE|Computed Tomography|Undergo CT
219458784|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
218849607|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
219458785|NCT00052494|DRUG|cisplatin|
218849608|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
219019171|NCT06615622|DIETARY_SUPPLEMENT|Placebo|Thiotacid 300 mg tab once/day
219197555|NCT05786040|PROCEDURE|Positron Emission Tomography|Undergo PET
219458786|NCT00052494|DRUG|imatinib mesylate|
219197556|NCT05786040|BIOLOGICAL|Rituximab|Given IV or SC
219197557|NCT05786040|BIOLOGICAL|Tafasitamab|Given IV
219458787|NCT00052494|DRUG|irinotecan hydrochloride|
218849609|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
218849610|NCT04023357|OTHER|PEEK|New polyetheretherketones material
218849611|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
218849612|NCT06629896|DIAGNOSTIC_TEST|Contrast Enhancement Mammography|In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
219458788|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
219458789|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
219458790|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
219458791|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
219458792|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
219458793|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
219197558|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with polyphenol supplement (PPS)|Test meal with polyphenol supplement
219458794|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
218849613|NCT06629896|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) and digital mammography (DM)|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
218849614|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
218849615|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with fibromyalgia|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
218849616|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
218849617|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
218849618|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
218849619|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
218849620|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
218849621|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
218849622|NCT01190475|DRUG|Placebo treatment to blind study|
218849623|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
219458795|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
219458796|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
219591982|NCT01791270|DEVICE|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. \- Respiratory Polygraphy~2. \- Ambulatory Blood Pressure Monitoring~3. \- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. \- ß1en subunit expression in peripheral blood leukocytes."
219591983|NCT04590352|PROCEDURE|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
218849624|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
218849625|NCT06397027|DRUG|Ziftomenib|Given by IV
218849626|NCT06397027|DRUG|Venetoclax|Given by PO
218849627|NCT06397027|DRUG|Azacitidine|Given by PO
218849628|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
219458797|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
218849629|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
219197559|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with placebo|Test meal with placebo (maltodextrin) supplement
218849630|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
218849631|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
218849632|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
219458798|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
219458799|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
219458800|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
219458801|NCT04989660|DRUG|6% aqueous phenol|1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
219458802|NCT04989660|DRUG|Isotonic saline|1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
219458803|NCT00834392|BEHAVIORAL|Exercise|Walking exercise
219458804|NCT02505269|DRUG|Brentuximab Vedotin|
219458805|NCT02505269|DRUG|Adriamycin|
218849633|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
219458806|NCT02505269|DRUG|Dacarbazine|
219458807|NCT00597532|DIETARY_SUPPLEMENT|Soy|soy (soy protein supplementation 50 grams/day)
219458808|NCT00597532|DIETARY_SUPPLEMENT|Milk|placebo (milk protein supplementation 50 grams/day)
219458809|NCT03904004|PROCEDURE|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
219458810|NCT03904004|PROCEDURE|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
219458811|NCT03904004|PROCEDURE|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
219458812|NCT03904004|PROCEDURE|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
219458813|NCT05687253|DRUG|BX1000|IV BX1000
219458814|NCT05687253|DRUG|Rocuronium Bromide|IV Rocuronium
219458815|NCT01451957|OTHER|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
218849634|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
219197560|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with PPS|Test drink with polyphenol supplement
219591984|NCT04590352|PROCEDURE|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
218849635|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
219197561|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with placebo|Test drink with placebo (maltodextrin) supplement
219458816|NCT01451957|OTHER|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
219458817|NCT01451957|OTHER|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
219458818|NCT03398252|DRUG|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
219458819|NCT03398252|DRUG|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
219458820|NCT00307892|DRUG|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
218849636|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
219458821|NCT00307892|DRUG|Placebo|placebo remedy
218849637|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
219458822|NCT05961397|DRUG|baxdrostat|single oral dose of baxdrostat 10 mg
219458823|NCT04012762|DEVICE|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
219458824|NCT01135004|PROCEDURE|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
219458825|NCT03727386|OTHER|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
219458826|NCT03727386|OTHER|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
219458827|NCT00150150|PROCEDURE|Interstitial laser photocoagulation|
219458828|NCT00578890|PROCEDURE|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
219458829|NCT01344304|DRUG|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
219458830|NCT03304769|DEVICE|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
219591985|NCT04590352|PROCEDURE|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
219458831|NCT02802735|DRUG|Apremilast|Tablet for oral administration
219458832|NCT02802735|DRUG|Placebo|Tablet for oral administration
219458833|NCT00190606|DRUG|Duloxetine|
219458834|NCT00190606|PROCEDURE|Pelvic Floor Muscle Training (PFMT)|
219458835|NCT00190606|PROCEDURE|Imitation PFMT|
219591986|NCT03769961|OTHER|No intervention|No interventions - Observational study
219591987|NCT01014377|DEVICE|VascuActive|
219591988|NCT02369302|DRUG|DWC20141|Tablet
219591989|NCT02369302|DRUG|DWC20142|Tablet
219591990|NCT02369302|DRUG|DWC20141, DWC20142|Tablet
219019182|NCT06994832|BEHAVIORAL|Visual Array|Single side-by-side visual array
219019183|NCT06994832|BEHAVIORAL|Narrative Visual Array|Evolving narrative with sequential visual arrays
219019184|NCT04392284|BEHAVIORAL|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
219458836|NCT00190606|DRUG|placebo|
219458837|NCT04542395|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
219458838|NCT00000756|DRUG|Lymphocytes, Activated|
219458839|NCT05063760|BEHAVIORAL|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
219458840|NCT02807155|BEHAVIORAL|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
218849638|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
218849639|NCT06571591|DRUG|Metformin|tablets, oral administration
219458841|NCT02807155|BEHAVIORAL|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
219591991|NCT06021691|BEHAVIORAL|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
218849640|NCT04154345|OTHER|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
218849641|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
218849642|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
219197562|NCT05657795|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
219591992|NCT06452901|OTHER|Progression and structured surgical training.|Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
219591993|NCT05173857|DEVICE|Advance PTX|PTA in Dysfunctional Haemodialysis Access
219591994|NCT05173857|DEVICE|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
219591995|NCT05173857|DRUG|Paclitaxel (PTX)|Paclitaxel (PTX)
219591996|NCT02849938|DEVICE|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
219591997|NCT05055583|DRUG|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
218849643|NCT05466292|OTHER|Survey1|Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.
218849644|NCT05466292|OTHER|semi-structured interview_1|the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered
218849645|NCT05466292|OTHER|semi-structured interview_2|semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.
218849646|NCT05466292|OTHER|semi-structured interview_3|semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee
218849647|NCT05466292|OTHER|survey_2|survey of 20 multiple-choice questions and supplemented by free-text questions.
218849648|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
219197563|NCT05443685|DRUG|ADX-629|"Particpants 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Participants 5-9 years old will be administered ADX-629 125 mg tablets twice daily."
219197564|NCT06824753|OTHER|oxygenator and tubing set blood transfusion|blood from the oxygenator and tubing set was collected into a 1000 cc Ringer lactate bag, originally used as the pump's priming solution, under sterile conditions using a roller pump
219197565|NCT06264232|DEVICE|Cataract Surgery|Bilateral removal of age related cataractous lenses with the implantation of intraocular lenses to improve visual acuity.
219458842|NCT02807155|BEHAVIORAL|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
219458843|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
219591998|NCT05055583|PROCEDURE|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
219458844|NCT03686527|PROCEDURE|stenosis aortic valve|"The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial"
219458845|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
218849649|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
219019185|NCT04392284|BEHAVIORAL|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
219591999|NCT05055583|DRUG|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
219592000|NCT04588493|DIAGNOSTIC_TEST|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
219592001|NCT00073697|DRUG|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
219592002|NCT00073697|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
219197566|NCT05875922|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
219197567|NCT05875922|DEVICE|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
219197568|NCT05195034|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
219197569|NCT05195034|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
219197570|NCT02768844|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
219458846|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
219458847|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
219458848|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
219458849|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
219458850|NCT04733664|DEVICE|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
219458851|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
219458852|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
219458853|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
219458854|NCT04690556|DRUG|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
218849650|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
219458855|NCT04690556|DRUG|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
218849651|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
218849652|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
218849653|NCT05584111|DRUG|STC-15|STC-15 oral capsules various dosing regimen in 3-week cycles
218849654|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
218849655|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
218849656|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
218849657|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
218849658|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
218849659|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
218849660|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
219458856|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
219458857|NCT05874947|DEVICE|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
219458858|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
219458859|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
219458860|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
219458861|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
219458862|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
219458863|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
218849661|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
218849662|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
218849663|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
218849664|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
218849665|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
218849666|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
218849667|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
218849668|NCT00204594|DRUG|rM28|
218849669|NCT00204594|DRUG|autologous PBMCs|
219458864|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
218849670|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
218849671|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
218849672|NCT03085628|DRUG|Oxytocin|40IU
218849673|NCT03085628|DRUG|Placebo|40IU
219458865|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
218849674|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
219458866|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
219458867|NCT01646736|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
219458868|NCT01646736|DRUG|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
219458869|NCT01646736|DRUG|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
219458870|NCT02599324|DRUG|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
219458871|NCT02599324|DRUG|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
218849675|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
219458872|NCT02599324|DRUG|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
219458873|NCT02599324|DRUG|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
219458874|NCT02599324|DRUG|cetuximab|Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
219458875|NCT02599324|DRUG|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
219592003|NCT00073697|OTHER|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
219592004|NCT01772797|DRUG|LDK378|LDK378 is a capsule to be taken daily by mouth.
219592005|NCT01772797|DRUG|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
219592006|NCT01559389|DRUG|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
219592007|NCT05404334|DIAGNOSTIC_TEST|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
219592008|NCT06292117|OTHER|CYP2C19 Genotype|qPCR-based genotyping assay interrogating all Association for Molecular Pathology (AMP) recommended Tier 1 and Tier 2 single nucleotide polymorphisms (SNPs) for CYP2C19 (\*2, \*3, \*4, \*5, \*6, \*7, \*8, \*9, \*10, \*17, \*35)
219592009|NCT04302636|DIETARY_SUPPLEMENT|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
219592010|NCT05242718|DIETARY_SUPPLEMENT|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
219592011|NCT05242718|DIETARY_SUPPLEMENT|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
219592012|NCT05242718|DIETARY_SUPPLEMENT|Curcumin|Health Canada Natural Product Number (NPN) 80043455
219592013|NCT05242718|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
218849676|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
218849677|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
218849678|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
218849679|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
218849680|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
218849681|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
218849682|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
218849683|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
218849684|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
218849685|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
218849686|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
218849687|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
218849688|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
218849689|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
218849690|NCT00970892|DRUG|Warfarin dose titration|Dosage
218849691|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
219458876|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
219458877|NCT00761033|BEHAVIORAL|music|
219592014|NCT01708018|PROCEDURE|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
219592015|NCT00576108|DRUG|KD7040 Topical Gel|KD7040 topical gel
219592016|NCT00576108|DRUG|Placebo gel|Placebo gel
219592017|NCT02953977|BEHAVIORAL|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
219592018|NCT05775133|DEVICE|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
218849692|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
218849693|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
218849694|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
218849695|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
219197571|NCT02768844|OTHER|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
219197572|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
219197573|NCT06667960|DRUG|JK06|Biparatopic anti-5T4 antibody
219197574|NCT06594783|OTHER|Carvedilol plus endoscopic variceal ligation|Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
219197575|NCT06594783|DRUG|Carvedilol alone|Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
219197576|NCT06667232|OTHER|Single-pulse stimulation|Investigators use single-pulse electrical stimulations at 1Hz to elicit cortico-cortical evoked potentials
219197577|NCT06667232|OTHER|Paired-pulse stimulation|The repetitive delivery of pairs of stimulation pulses is DES patten with a 5-50 ms interval between each pulse, constitutes repetitive paired-pulse stimulation.
219197578|NCT06667232|OTHER|Stepwise frequency stimulation|Stepwise incremental stimulation ranging from 5 Hz to 145 Hz following a cyclic pattern.
219458878|NCT00439699|DRUG|Memantine|Mematine administration
219458879|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
219458880|NCT05413356|DRUG|Ruxolitinib|Oral ruxolitinib twice daily
219458881|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
219458882|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
219458883|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
219592019|NCT04521387|PROCEDURE|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
219592020|NCT04521387|DRUG|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
219592021|NCT04521387|DRUG|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
218849696|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
219197579|NCT06667232|OTHER|Burst stimulation|Burst stimulation pattern consisting of short bursts delivered once a second and an intraburst frequency of 50 Hz, 100 Hz, 150 Hz, 175 Hz and 200 Hz
219197580|NCT06609083|DRUG|THC 30mg|High dose of THC (30 mg)
219197581|NCT06609083|DRUG|THC 5mg|Low dose of THC (5 mg)
219458884|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
219458885|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
219458886|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
219458887|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
219458888|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
219458889|NCT02604628|BEHAVIORAL|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
219458890|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
219458891|NCT02582151|DEVICE|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
219458892|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
219458893|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
219458894|NCT02746991|DRUG|Sham Injection|Placebo
219458895|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
219458896|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
219458897|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
218849697|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
219197582|NCT06609083|DRUG|THC 0mg|Placebo dose of THC (0 mg)
219197583|NCT06609083|DRUG|Cigarette Full Nicotine|Full nicotine cigarette
219197584|NCT06609083|DRUG|Cigarette Reduced Nicotine|Reduced nicotine cigarette
219197585|NCT05825989|BEHAVIORAL|Healthy Beat Acupunch Regimen|The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
219197586|NCT06858631|BEHAVIORAL|Physical Aerobic Exercise|30-minute net aerobic exercise sessions at moderate intensity (3-5 METS, 60%-70% of maximum heart rate) three times per week. Walking, cycling, or swimming, with the option to alternate activities to enhance adherence to the program. Each session will include 10 minutes of warm-up (gradual increase in intensity); 30 minutes of aerobic exercise and 10 minutes of cool-down (gradual reduction of intensity and optional stretching). Total weekly exercise duration will be 150 minutes
219197587|NCT06661369|OTHER|Sensory Perceptual Motor Training on Group|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
218849698|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
219458898|NCT00653198|OTHER|No intervention|
219458899|NCT01774227|PROCEDURE|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
219458900|NCT01774227|PROCEDURE|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
219458901|NCT01902927|OTHER|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
219458902|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
219458903|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
219458904|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
219458905|NCT00669591|DRUG|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
219458906|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
219592022|NCT04521387|DRUG|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
219592023|NCT04521387|OTHER|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
219592024|NCT02210845|BEHAVIORAL|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
219458907|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
219458908|NCT05546957|DRUG|Aspirin|Administered orally once per day (QD)
219458909|NCT05546957|DRUG|rivaroxaban low dose|Administered orally twice per day (BID)
219458910|NCT05546957|DRUG|rivaroxaban high dose|Administered orally QD
218849699|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219197588|NCT06661369|OTHER|Sensory Perceptual Motor Training on Individual|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
219197589|NCT06856408|BEHAVIORAL|FinnPog|The aim of the study is to find out how intervention affects the early childhood educators' self-efficacy teamwork and the changes in children's behavioral challenges. This RCT study has two parallel groups where teams of the daycare centres are randomized to intervention or control group. The research data is collected using electronic surveys and interviews.
219197590|NCT06859450|DRUG|Levofloxacin|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
219197591|NCT06859450|DRUG|Placebo|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
219197592|NCT06859905|OTHER|blood flow restriction training|"Position of the patient The vascular occlusion pressure required for the full blockage of upper extremity blood flow will be measured at rest, with the individual relaxed in a sitting position(Sieljacks et al., 2018).~Position of the of the cuff during BFRT~Placing a 5 to 6 cm wide cuff on the more proximal part of the affected upper limb, it should be around the bulk of biceps muscle above the cubital fossa .~BFRT Cuff Pressure The upper arm external pressure of the cuff (100-130 mmHg) will be selected concerning the subject's resting blood pressure as described previously by Yasuda et al. 2008 (Yasuda et al., 2008).~BFRT exercises prescription~1. Exercise frequency and duration~   -The study group (BFRT G) will be subjected to supervised exercises with low-load blood flow restriction training LIBFR (three days per week for 8 weeks),~2. Exercise intensity -Low load blood flow restriction training LIBFR (20%-40% of 10 repetition maximum (10 RM) BFR training for the study group,"
219458911|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
219458912|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
219458913|NCT02570581|OTHER|Jelly with Furosemide|
219458914|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
219458915|NCT02570581|OTHER|Jelly with Memantine|
219458916|NCT02570581|OTHER|Jelly with Zopiclone|
219458917|NCT02570581|OTHER|Jelly with Alprazolam|
219458918|NCT02570581|OTHER|Jelly with Oxazepam|
219458919|NCT02570581|OTHER|Jelly with Donepezil|
219458920|NCT02570581|OTHER|Jelly with Clopidogrel|
219458921|NCT02570581|OTHER|Jelly with Ramipril|
219592025|NCT02210845|BEHAVIORAL|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
219592026|NCT02210845|OTHER|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
219592027|NCT06350916|BEHAVIORAL|SeamlessMD® Mobile Application|Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
219592028|NCT04308057|PROCEDURE|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
218849700|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
218849701|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
218849702|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
218849703|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
218849704|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
218849705|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
219458922|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
219458923|NCT02570581|OTHER|Plain jelly control|
219197593|NCT06859905|OTHER|regular exercises|"the routine rehabilitation will be applied 3 times per week for 8 weeks, including the following training~1. Appropriate neurodevelopmental techniques as needed by each patient~2. Progressive resistance exercise for muscles in the affected upper extremity using sandbags, free weights, or elastic resistance bands according to each patient's abilities~3. prolonged stretching using splints if needed~4. Functional electrical stimulation (FES)"
219197594|NCT06856486|DIETARY_SUPPLEMENT|Sulforaphan Smart®|Fasting volunteers will intake the Sulforaphan Smart® pill, and blood and urine samples will be taken at the beginning of the intervention (Time 0 hours, before intake the pill), and 6 and 24 hours after its intake the pills (Time 6 hours and Time 24 hours) to measure the biomarkers related to the bioavailability of GSL/ITCs.
219197595|NCT06856655|DEVICE|Scorpion Portal Vein Access Kit|Procedure/Surgery: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
219197596|NCT06857552|OTHER|Visual biofeedback using transperineal ultrasound (TPUS)|The intervention (study) arm will recieve coached maternal pushing via transperineal ultrasound (US) with visual biofeedback
218849706|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
218849707|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
218849708|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
218849709|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
219197597|NCT06858293|BEHAVIORAL|Mental Imagery Open Chain|Participants will receive a paper packet with instructions to imagine themselves performing seated maximal leg extension exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
219458924|NCT02570581|OTHER|Apple compote Paracetamol|
218849710|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
219458925|NCT02570581|OTHER|Apple compote Furosemide|
219458926|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
219458927|NCT02570581|OTHER|Apple compote Memantine|
218849711|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
219458928|NCT02570581|OTHER|Apple compote Zopiclone|
218849712|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
218849713|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
218849714|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
218849715|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
219458929|NCT02570581|OTHER|Apple compote Alprazolam|
219458930|NCT02570581|OTHER|Apple compote Oxazepam|
219458931|NCT02570581|OTHER|Apple compote Donepezil|
219458932|NCT02570581|OTHER|Apple compote Clopidogrel|
219592029|NCT05378555|DRUG|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
219592030|NCT02781038|BEHAVIORAL|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
219592031|NCT02781038|BEHAVIORAL|Control|Subjects in this group will not receive the pamphlet
219592032|NCT00695058|DEVICE|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
219592033|NCT00238758|DRUG|Omega-3 Polyunsaturated Fatty Acids|
219592034|NCT04582084|DRUG|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
218849716|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
218849717|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
218849718|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
218849719|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
219458933|NCT02570581|OTHER|Apple compote Ramipril|
219458934|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
219458935|NCT02570581|OTHER|Plain apple compote control|
219458936|NCT01389895|DRUG|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
219197598|NCT06858293|BEHAVIORAL|Mental Imagery Closed Chain|Participants will receive a paper packet with instructions to imagine themselves performing maximal standing squat exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
219458937|NCT01389895|DRUG|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
219458938|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
219458939|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
219458940|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
219458941|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
219458942|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
219458943|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
219458944|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
219458945|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
219197599|NCT06858605|OTHER|Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT)|Kaltenborn's biomechanical approach to diagnosis and treatment emphasizes ergonomic principles and trial-based techniques. His mobilization methods, classified into Grades I-III, target pain relief (Grades I-II) and joint hypomobility (Grade III) by enhancing glide and tissue elasticity. The Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT) further refines this approach using arthrokinematic principles to restore physiological joint motion based on the concave-convex rule.
219197600|NCT03582033|DRUG|SEA-BCMA|Given into the vein (IV; intravenously)
219197601|NCT03582033|DRUG|dexamethasone|Given by mouth (orally) or by IV
219458946|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
219458947|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
219197602|NCT03582033|DRUG|pomalidomide|Given orally
219197603|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
219197604|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
219197605|NCT06353529|DRUG|Sham Comparator|Participants receive no additional study injections
219197606|NCT06669416|BEHAVIORAL|Taste Alteration Self-Assessment|The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to select assessment-driven interventions to manage TA symptoms.
219458948|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
219458949|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
219458950|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
219458951|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
219458952|NCT04352049|PROCEDURE|Preoxygenation|
219458953|NCT00003606|DRUG|cisplatin|
219458954|NCT00003606|DRUG|cyclophosphamide|
219458955|NCT00003606|DRUG|epirubicin hydrochloride|
219458956|NCT00003606|DRUG|etoposide|
219458957|NCT00003606|RADIATION|radiation therapy|
219458958|NCT05219006|DIETARY_SUPPLEMENT|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
219592035|NCT01228019|DRUG|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
219592036|NCT03892499|DRUG|Olinciguat|Oral Tablet
219592037|NCT03892499|DRUG|Itraconazole|Oral Capsule
219592038|NCT06339697|DRUG|different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)|Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
219592039|NCT01577550|DRUG|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
219592040|NCT01577550|DRUG|Placebo, i.v.|Single i.v. administration of placebo
219592041|NCT01577550|DRUG|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
219592042|NCT01577550|DRUG|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
219592043|NCT01577550|DRUG|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
219592044|NCT01577550|DRUG|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
219592045|NCT01577550|DRUG|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
219592046|NCT01577550|DRUG|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
218849720|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
219592047|NCT01577550|DRUG|Placebo, s.c.|Single s.c. administration of placebo
218849721|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
219458959|NCT05219006|DIETARY_SUPPLEMENT|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
218849722|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
218849723|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
218849724|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
218849725|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
219458960|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
219458961|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
219458962|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
218849726|NCT03579472|DRUG|Eribulin Mesylate|Given IV
218849727|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
218849728|NCT05499455|DEVICE|Control|Control Device
219458963|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
218849729|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
218849730|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
219458964|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
219458965|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
219458966|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
218849731|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
218849732|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
219458967|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
219458968|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
219458969|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
218849733|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
218849734|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
218849735|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
218849736|NCT01418131|DRUG|Placebo|Placebo
218849737|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
218849738|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
218849739|NCT03440567|DRUG|Avelumab|Given IV
218849740|NCT03440567|DRUG|Carboplatin|Given IV
218849741|NCT03440567|DRUG|Etoposide Phosphate|Given IV
218849742|NCT03440567|DRUG|Ibrutinib|Given PO
218849743|NCT03440567|DRUG|Ifosfamide|Given IV
219458970|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
219458971|NCT04585113|RADIATION|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
219458972|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
219458973|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
219458974|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
219458975|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
218849744|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
218849745|NCT03440567|BIOLOGICAL|Rituximab|Given IV
218849746|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
218849747|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
218849748|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
218849749|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
218849750|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
218849751|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
218849752|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
219458976|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
219458977|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
219458978|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
219458979|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
219458980|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
219458981|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
219458982|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
219458983|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
219458984|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
219458985|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
219458986|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
219458987|NCT04851522|DRUG|Di-Dak-Sol|Topical solution applied externally.
219458988|NCT04851522|OTHER|White Petrolatum|Topical ointment applied externally
219458989|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
219458990|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
219592048|NCT01577550|DRUG|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
219592049|NCT06297915|DRUG|Ketamine|Ketamine infusion was administered at 1 mg/kg (in 1 hour)
219592050|NCT06297915|DRUG|Lidocain|Lidocaine infusion was administered at 3 mg/kg (in 1 hour)
218849753|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
218849754|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
218849755|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
218849756|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
218849757|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
218849758|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
218849759|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
219019198|NCT05725057|DRUG|AX-158|Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
219019199|NCT05725057|DRUG|Placebo|Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
219197607|NCT06669416|BEHAVIORAL|Taste Alternation Self-Management|The nurse-led intervention involves teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage their symptoms. Data will be collected about the specific actions prescribed in the teaching tool and to identify which interventions were used and their overall impact.
219197608|NCT06669663|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
218849760|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
218849761|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
218849762|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
218849763|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
218849764|NCT00092703|DRUG|MK0663, etoricoxib|
218849765|NCT00092703|DRUG|Comparator: Diclofenac sodium|
219458991|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
219458992|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
219458993|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
219458994|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
219592051|NCT06421298|DRUG|Tafolecimab|450mg Q4W ≤6cycle
219197609|NCT06668935|DEVICE|To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists|All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
219197610|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
219197611|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
219197612|NCT02695940|DRUG|LEO 124249 ointment 30 mg/g|
219197613|NCT02695940|OTHER|LEO 124249 ointment vehicle|
219197614|NCT04628585|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
219458995|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
219458996|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
219458997|NCT01914510|DRUG|ENMD-2076|
219458998|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
219458999|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
219459000|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
219592052|NCT06421298|DRUG|Sintilimab|200mg Q3W ≤2years
219592053|NCT06421298|DRUG|Nab paclitaxel|130mg/m² Q3W 4-6cycles
219592054|NCT06421298|DRUG|Docetaxel|75mg/m² Q3W 4-6cycles
219592055|NCT06421298|DRUG|Gemcitabine|1250mg/m² Q3W 4-6cycles
219592056|NCT01241110|DRUG|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
219592057|NCT01241110|DRUG|azitromycin|azitromicin vs ofluxacin
218849766|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
219459001|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
219459002|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
219459003|NCT01078779|DRUG|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
219459004|NCT01078779|DRUG|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
219459005|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
219459006|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
219459007|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
219459008|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
219459009|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
219459010|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
219459011|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
219459012|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
219459013|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
219459014|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
219459015|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
219459016|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
219459017|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
219459018|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
219459019|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
219459020|NCT04052594|DRUG|LY3475766 - IV|Administered IV
218849767|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
219459021|NCT04052594|DRUG|LY3475766 - SC|Administered SC
219459022|NCT04052594|DRUG|Placebo - IV|Administered IV
219459023|NCT04052594|DRUG|Placebo - SC|Administered SC
218849768|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
218849769|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
219459024|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
218849770|NCT02667041|DEVICE|NeuroQore rTMS Device|
218849771|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
218849772|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
219019210|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
219019211|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
219019212|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
219019213|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
218849773|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
218849774|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
218849775|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
218849776|NCT02337998|OTHER|load carriage|
218849777|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
218849778|NCT02047773|OTHER|Duration|If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
218849779|NCT02047773|DRUG|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
218849780|NCT02047773|DRUG|Meropenem|
218849781|NCT01700998|DRUG|Magnesium|
218849782|NCT01700998|DRUG|Placebo|
218849783|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
218849784|NCT00521599|DRUG|Placebo|
218849785|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
219459025|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
219459026|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
219459027|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
218849786|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
218849787|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
218849788|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
218849789|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
218849790|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
218849791|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
218849792|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
218849793|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
219197615|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
219459028|NCT01808040|DRUG|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
219459029|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
219459030|NCT02485431|DRUG|Deflazacort|
219459031|NCT04559867|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
219459032|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
219459033|NCT00519558|DRUG|somatropin|
219459034|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
219459035|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
219459036|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
219459037|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
219459038|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
219459039|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
219459040|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
218849794|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
218849795|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
218849796|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
218849797|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
218849798|NCT00381511|DRUG|low molecular weight heparin|
218849799|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
218849800|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
218849801|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
218849802|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
218849803|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
218849804|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
219197616|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
219197617|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
219459041|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
219459042|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
219459043|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
219459044|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
219459045|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
219459046|NCT01654406|DEVICE|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4\_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
219459047|NCT01654406|DEVICE|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
219459048|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
219459049|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
219592058|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
218849805|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
219459050|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
219459051|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
219592059|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
219592060|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
219592061|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
219592062|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
219197618|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
219197619|NCT04727242|DRUG|Gemcitabine|Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
219197620|NCT04727242|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
219459052|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
219459053|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
219459054|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
219459055|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
219459056|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
219592063|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
219592064|NCT04366323|DRUG|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
219459057|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
218849806|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
218849807|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
219459058|NCT00779233|DRUG|Zidovudine tablets 300 mg|
219459059|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
219459060|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
218849808|NCT00151710|DRUG|Pioglitazone|
218849809|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
218849810|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
218849811|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
218849812|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
218849813|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
218849814|NCT02928029|DRUG|Placebo|Matching placebo
218849815|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
218849816|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
219459061|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
219592065|NCT01461915|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
219592066|NCT01461915|DRUG|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
219592067|NCT01461915|DRUG|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
219592068|NCT04515381|OTHER|Therapeutic Touch|Therapeutic Touch
218849817|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
218849818|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
218849819|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
219197621|NCT04727242|PROCEDURE|Cytoreductive Surgery|Surgery for cancer removal
219459062|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
219459063|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
219592069|NCT04515381|OTHER|Control group|Making measurements at the beginning of the research and 4 weeks
219592070|NCT04515381|OTHER|Sham Therapeutic Touch|Sham Therapeutic Touch
219592071|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
219592072|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
219592073|NCT05724563|DRUG|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
219592074|NCT05724563|DRUG|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
219592075|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
219592076|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
219592077|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
218849820|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
218849821|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
218849822|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
218849823|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
218849824|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
219197622|NCT04727242|BEHAVIORAL|Functional Assessment of Cancer Therapy (FACT) G questionnaire|Preoperative and Postoperative FACT G questionnaire to assess QoL
219197623|NCT04727242|PROCEDURE|Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan|Radiologic imaging after Cycle 3 and 6 and at each follow up visit
219197624|NCT04727242|DRUG|Gadolinium|Contrast Agent
219459064|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
219459065|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
219459066|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
219459067|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
219592078|NCT04331119|DRUG|Duvelisib|SecuraBio will supply duvelisib
219592079|NCT04331119|PROCEDURE|Peripheral blood draw|-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
219592080|NCT02586246|DRUG|CDP870|Self-injection
219592081|NCT05646043|BEHAVIORAL|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
219197625|NCT05419050|DRUG|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
218849825|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
218849826|NCT02778555|BEHAVIORAL|Questionnaires|
218849827|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
219197626|NCT03209791|OTHER|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
219459068|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
219197627|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
218849828|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
218849829|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
218849830|NCT01213459|OTHER|Data collection|Questionnaire completion
218849831|NCT02390440|DRUG|EXPAREL|
218849832|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
218849833|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
218849834|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
218849835|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
219197628|NCT06421324|BEHAVIORAL|Health reccommendations|Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
219197629|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
219197630|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
219197631|NCT05417828|DEVICE|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
219459069|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
219459070|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
219459071|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
218849836|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
219459072|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
219459073|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
219459074|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
219459075|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
219459076|NCT05539742|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
219459077|NCT05539742|DIETARY_SUPPLEMENT|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
219459078|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
219459079|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
218849837|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
218849838|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
218849839|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
218849840|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
218849841|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
219459080|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
219459081|NCT00417898|DRUG|Aspirin|
218849842|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
219197632|NCT06746311|DRUG|HT-101|Single dose of HT-101 administered subcutaneously.
219459082|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
219197633|NCT06746311|DRUG|HT-101|Multiple dose of HT-101 administered subcutaneously.
218849843|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
218849844|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
219197634|NCT06746311|DRUG|Placebo|Placebo, containing no active ingredient, administered subcutaneouly
219197635|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
219197636|NCT06442241|BIOLOGICAL|LYB005 low dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197637|NCT06442241|BIOLOGICAL|LYB005 middle dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197638|NCT06442241|BIOLOGICAL|LYB005 high dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197639|NCT06442241|BIOLOGICAL|LYB005 low dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197640|NCT06442241|BIOLOGICAL|LYB005 middle dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197641|NCT06442241|BIOLOGICAL|LYB005 high dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197642|NCT06442241|BIOLOGICAL|Placebo|0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197643|NCT06442241|BIOLOGICAL|Positive control|AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
219197644|NCT06530381|OTHER|Pilates Exercises With Face-to-Face|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed face to face.
219197645|NCT06530381|OTHER|Pilates Exercises With Telerehabilitation|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed as telerehabilitation.
218849845|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
218849846|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
218849847|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
218849848|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
219197646|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
219197647|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
218849849|NCT05397041|DRUG|Placebo|Matched Placebo
218849850|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
218849851|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
218849852|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
218849853|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
218849854|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
218849855|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
219197648|NCT06612229|PROCEDURE|Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue|In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
219459083|NCT02741336|BEHAVIORAL|Self-Monitoring|
219459084|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
219459085|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
219459086|NCT04884009|DRUG|SHR-1701|SHR-1701
219459087|NCT00060333|RADIATION|radiation therapy|
219459088|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
218849856|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
219459089|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
219459090|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
219459091|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
219459092|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
219459093|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
219459094|NCT04097106|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic dietary supplement in capsule form
219459095|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
219459096|NCT00122317|DRUG|eculizumab|
219459097|NCT02886338|DEVICE|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
219459098|NCT00284336|DRUG|Caelyx|
219459099|NCT00284336|DRUG|endoxan|
219459100|NCT00394654|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
219459101|NCT00394654|OTHER|Placebo|Placebo administered as a single intravenous infusion
219459102|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
218849857|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
219019214|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
219019215|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
219459103|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
219459104|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
219459105|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
219459106|NCT06263400|BEHAVIORAL|psychoeducation and follow-up study|In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
219459107|NCT04095962|OTHER|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
219459108|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
219459109|NCT03739060|DEVICE|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
219459110|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
219019216|NCT02407028|DRUG|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
219019217|NCT02407028|OTHER|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
219019218|NCT01013727|RADIATION|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
219459111|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
219459112|NCT07050212|DRUG|remimazolam group|remimazolam is administered intravenously at a dose of 0.3 mg/kg
219592082|NCT05646043|BEHAVIORAL|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
219592083|NCT00873457|DRUG|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
218849858|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
218849859|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
218849860|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
218849861|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
219459113|NCT07050212|DRUG|dexmedetomidine group|dexmedetomidine is administered intravenously at a dose of 1 μg/kg
219459114|NCT07050212|DRUG|esketamine group|esketamine is administered intravenously at a dose of 0.5 mg/kg
219459115|NCT00600249|DRUG|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
219459116|NCT00600249|DRUG|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
219592084|NCT05046964|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
219459117|NCT07058168|DIETARY_SUPPLEMENT|Other: experimental group (labor diet)|"The data collection tools Personal Information Form, Women's Perception of Supportive Care Provided at Birth Scale, and Pregnant and Infant Monitoring Form (VAS pain, anxiety, fatigue and thirst scales) were applied. The VAS scales contains numbers evenly spaced (0-10) on a line. It's an evaluation scale filled out by pregnants stating their current levels by givig a number. The cut off point of the VAS anxiety and thirst scales were found to be four.In VAS anxiety, scores above this cut-off point indicate deviation from normal and individuals must be handled by professionals. In VAS thirst, patients who score above this score are considered to be experiencing dehydration symptoms. The time of the last meal was learnt according to the information given by the pregnant woman. Spontaneous blood glucose measurement was performed. The labor diet was administered after 6 hours of fasting. Post-prandial blood glucose and tools were measured after the labor diet (at the 2nd hours)"
219459118|NCT05453006|DEVICE|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview non-intervention clinics.
219459119|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
219459120|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
219459121|NCT02216292|OTHER|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
219459122|NCT02216292|OTHER|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
219459123|NCT06517446|OTHER|Optokinetic Virtual Reality Stimulation|"The optokinetic stimulation protocol is defined as follows:~* Optokinetic stimulation sessions are planned with a balloon rotation speed of 20°/s (degrees per second) during the first four weeks. In the fifth and sixth weeks, the speed will be increased to 25°/s, and in the seventh and eighth weeks, it will be raised to 30°/s.~* The background screen will be set to rotate in the same direction as the balloons, with a rotation speed equal to 30-50% of the balloon rotation speed.~* Session duration will start at 30 seconds and will increase to 150 seconds depending on patient tolerance as the sessions progress.~* Participants will be instructed to focus on the red balloon in a moving visual scene.~Optokinetic stimuli will be applied to participants in various postures: sitting, upright posture (feet together), semi-tandem stance, or tandem stance positions."
219459124|NCT06517446|OTHER|Conventional rehabilitation program based on Cawthorne Cooksey exercises|The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
219197649|NCT06612866|DIETARY_SUPPLEMENT|Keratin hydrolysate|The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
219197650|NCT04076956|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
219197651|NCT05566964|DEVICE|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
219197652|NCT06391710|DRUG|HRS9531|subcutaneous
219197653|NCT06391710|DRUG|Placebo|subcutaneous
219197654|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
219197655|NCT05868460|DEVICE|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
219197656|NCT05868460|OTHER|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
219197657|NCT05868460|DEVICE|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
219197658|NCT06827769|DIAGNOSTIC_TEST|serum zinc and magnesium|participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).
219459125|NCT06517446|OTHER|VR+OKS|"The optokinetic stimulation protocol is defined as follows:~Optokinetic stimulation will be applied over 8 weeks with gradually increasing balloon rotation speeds: 20°/s (weeks 1-4), 25°/s (weeks 5-6), and 30°/s (weeks 7-8). The background will rotate in the same direction at 30-50% of the balloon speed. Sessions will start at 30 seconds and increase to 150 seconds based on tolerance. Participants will focus on a red balloon in a rotating visual scene, and the stimulation will be performed in various postures including sitting, feet together, semi-tandem, and tandem stance.~The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used."
219459126|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
219459127|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
219459128|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
219459129|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
219459130|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
219459131|NCT06471686|DRUG|Acamprosate|2 pills three times a day
219459132|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
219459133|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
219459134|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
219459135|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
219459136|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
219459137|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
219197659|NCT06234410|RADIATION|Computed tomography coronary angiography (CTCA)|Single CTCA scan prior to kidney transplantation
219197660|NCT05818462|DIAGNOSTIC_TEST|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
219197661|NCT05818462|DIAGNOSTIC_TEST|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
219197662|NCT05818462|OTHER|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
218849862|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
219197663|NCT05818462|DIAGNOSTIC_TEST|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
218849863|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
218849864|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
219197664|NCT05818462|DIAGNOSTIC_TEST|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
219197665|NCT06429631|DEVICE|mobile application on telephone|"when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section."
219197666|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
219459138|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
219459139|NCT00027846|PROCEDURE|therapeutic conventional surgery|
219459140|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
219459141|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
219459142|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
219459143|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
219459144|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
219459145|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
219459146|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
219459147|NCT03345927|OTHER|no intervention|no intervention
219459148|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
218849865|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
218849866|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
218849867|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
218849868|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
218849869|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
218849870|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
218849871|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
218849872|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
218849873|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
218849874|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
218849875|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
218849876|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
219019225|NCT06858514|OTHER|Virtual reality|Students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses.
219019226|NCT06858514|OTHER|Escape room|Students will perform crossword puzzles, word hunt and matching activities related to subcutaneous injection practice.
219459149|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
219459150|NCT06369402|DIAGNOSTIC_TEST|Cerebral haemodynamic testing using transcranial Doppler|Measurement of cerebral haemodynamics using transcranial Doppler to insonate the middle cerebral arteries bilaterally testing neurovascular coupling with selected domains from the Addenbrooks cognitive examination III and the digit span forward and backwards.
219459151|NCT06369402|DIAGNOSTIC_TEST|Ankle-brachial pressure index|Ratio of ankle to brachial blood pressure measured using handheld Doppler at rest and after exercise (six-minute walk test).
219459152|NCT06369402|DIAGNOSTIC_TEST|Six-minute walk test|Supervised brisk walk for six minutes. Time and distance to onset of claudication pain and total distance walked (and total time walked if did not complete the full six minutes).
219459153|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
219459154|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
219459155|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
219459156|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
219592085|NCT01832779|OTHER|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
219592086|NCT01625832|PROCEDURE|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
219592087|NCT02176785|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
219197667|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
219197668|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
219197669|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
219197670|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
219197671|NCT04325815|DEVICE|CADDIE- Computer Aided (AI) Device used in Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
218849877|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
219197672|NCT03898583|DRUG|Microarray patch A|Microarray patch
219197673|NCT03898583|DRUG|Microarray patch B|Microarray patch
219197674|NCT03898583|DRUG|Placebo|Microarray patch vehicle
219197675|NCT03898583|DRUG|Daivobet|Daivobet Gel
219199456|NCT06671730|BEHAVIORAL|8-Week Telehealth-based Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study)
219459157|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
219459158|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
219459159|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
219459160|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
219459161|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
219459162|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
219459163|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
219592088|NCT01269541|DRUG|Mupirocin|Topical in the nose 3 times daily for 5 days
219459164|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
219197676|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
218849878|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
218849879|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
219197677|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
219197678|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
219197679|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
219197680|NCT06599268|BEHAVIORAL|Survey using a questionnaire.|"Questionnaire to assess the barriers and enablers for women reaching top executive positions in pharmaceutical companies and pharmacies~The following sections will be considered:~* General Characteristics of the Participants~* Work-related characteristics~* Barriers faced by women to reach top executive positions (Likert scale)~* Enablers for women to reach top executive positions (Likert scale)~* Conception of women in the pharmaceutical sector (Likert scale)"
219197681|NCT06600438|DEVICE|Slow-SPEED app|Gamified motivational smartphone app
219197682|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
219459165|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
219459166|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
219592089|NCT01269541|DRUG|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
219592090|NCT02687217|DRUG|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
219592091|NCT04106661|OTHER|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
219459167|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
219592092|NCT04514432|OTHER|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
219592093|NCT00074828|DRUG|LY517717|
219592094|NCT00074828|DRUG|enoxaparin|
219592095|NCT06816758|OTHER|Routine Care for Corrosive Esophagitis|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients diagnosed with corrosive esophagitis who received routine clinical care. The exposure of interest includes diagnostic and treatment procedures such as endoscopic evaluation (Zargar classification), proton pump inhibitors, corticosteroid therapy, and surgical interventions for complications like strictures. The outcomes and clinical data collected reflect routine care practices over 26 years.
219592096|NCT06287528|BIOLOGICAL|19-28z/IL-18 CAR T cells|19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
219592097|NCT03503864|DRUG|Arsenic Trioxide|Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
219592098|NCT06965738|PROCEDURE|Buccal fat reconstruction|Ipsilateral buccal fat rotation flap for reconstruction of lateral oropharyngectomy defect
219592099|NCT06965738|PROCEDURE|No buccal fat reconstruction|No reconstruction of lateral oropharyngectomy defect
218849880|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
218849881|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
219197683|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
219459168|NCT00275704|DRUG|Flaxseed|
219197684|NCT06586606|DRUG|MK-1708|Oral administration
219592100|NCT06970782|DRUG|Vebreltinib|Subjects will receive Vebreltinib Enteric-coated Capsule orally twice per day (BID).
219592101|NCT06970782|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
219592102|NCT06970782|DRUG|Pemetrexed plus Carboplatin or Cisplatin|Subjects randomized to the control group received pemetrexed 500 mg/m² + platinum-based chemotherapy (carboplatin AUC 5 or cisplatin 75 mg/m²) via intravenous infusion for 4-6 cycles (determined by the investigator) as initial therapy, followed by pemetrexed maintenance therapy (500 mg/m²) until disease progression, intolerable toxicity, initiation of new antitumor therapy, death, loss to follow-up, or other treatment-terminating conditions (whichever occurred first).
219592103|NCT04521413|DRUG|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
218849882|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
219197685|NCT06586606|DRUG|Itraconazole|Oral administration
219197686|NCT06600100|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
219592104|NCT04521413|DRUG|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
218849883|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
218849884|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
218849885|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
218849886|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
219199457|NCT02911805|BEHAVIORAL|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
219199458|NCT02911805|BEHAVIORAL|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
219199459|NCT06885996|DRUG|Psilocybin|See treatment arm description.
219459169|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
218849887|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
219199460|NCT00817193|BEHAVIORAL|Physical Activity|Physical Activity program
219199461|NCT00817193|BEHAVIORAL|Wellness|Wellness program
219199462|NCT06752512|DEVICE|Remote Patient Monitoring|24/7 remote patient monitoring with a wearable thermometer
219199463|NCT06873048|DEVICE|Control Contact Lens (stenfilcon A Sphere)|One week of wear
219199464|NCT06873048|DEVICE|Test Contact Lens (stenfilcon A Toric)|One week of wear
219459170|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
219459171|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
219459172|NCT05846659|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
219459173|NCT05846659|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
219459174|NCT05846659|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
219459175|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
219592105|NCT05550532|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
219592106|NCT05550532|OTHER|Placebo|Placebo tablet will be administered orally.
219592107|NCT05107141|PROCEDURE|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
219592108|NCT05107141|DEVICE|bone graft plus a collagen membrane|
218849888|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
218849889|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
218849890|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
218849891|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
219459176|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
219459177|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
219459178|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
219459179|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
219459180|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
219459181|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
219592109|NCT00979914|OTHER|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
218849892|NCT03782207|DRUG|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
218849893|NCT03324529|DEVICE|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
219197687|NCT06600100|BEHAVIORAL|Placebo Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Here, three separate categories of non-food items (stationery, flowers and clothing) would be Go signal (associated with green 100%), No-Go signal (associated with red 100%) and control (50% red 50% green) respectively.
219197688|NCT06593197|COMBINATION_PRODUCT|Apremilast with NB-UVB|Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
219197689|NCT06593197|DEVICE|NB-UVB|NBUVB only will be given twice per week for 8 months
219199465|NCT06872619|DEVICE|PROSTest|Multianalyte Algorithm Analysis of circulating prostate cancer transcripts
218849894|NCT02745067|BEHAVIORAL|enhanced cognitive behavioral therapy|
218849895|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
218849896|NCT01124123|DRUG|Bilastine|20 mg oral tablet
218849897|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
219592110|NCT03379389|DRUG|Methenamine + Methylthioninium|Methenamine + Methylthioninium
219592111|NCT03379389|DRUG|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
219592112|NCT03379389|DRUG|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
219592113|NCT02834650|OTHER|Cardiac MRI with contrast|Cardiac MRI
219592114|NCT02834650|OTHER|Cardiac MRI without contrast|Cardiac MRI
219592115|NCT02834650|OTHER|Blood Test|Hematocrit, Creatinine, Troponin, BNP
219592116|NCT02834650|OTHER|Heart Rate|Holter Monitor
219592117|NCT02834650|OTHER|Pulmonary Function Test|Pulmonary Function Test
219592118|NCT02834650|OTHER|Genetic Testing|Genetic Testing
219592119|NCT02834650|OTHER|Repeat MRI scan|Repeat MRI scan
219592120|NCT02686645|BIOLOGICAL|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
219592121|NCT02686645|DRUG|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
218849898|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
218849899|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
218849900|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
218849901|NCT01083979|DRUG|Liposomes|Intravesical instillation
219459182|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
219459183|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
219459184|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
218849902|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
219197690|NCT06861348|DRUG|Inotuzumab Ozogamicin±Donor Lymphocyte Infusion|"Participants will receive Ino±DLI regimen:~* ① InO induction dose: the first cycle: 0.8mg/m2, intravenous infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ② If CR/CRi was reached after induction, the second cycle :0.5mg/m2, intravenous infusion, d1, d8，d15; If CR/CRi is not reached, Cycle 2 :0.8mg/m2, IV infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ③DLI dose: CD3 positive cells 1x10\^7/kg; DLI indication: no previous grade III-IV aGVHD, negative HLALOSS test and no present aGVHD and cGVHD;~* Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment."
219197691|NCT06861491|BEHAVIORAL|Non-pharmacological|This intervention will be provided by student pharmacists. It will focus on lifestyle modifications, adherence, and education of disease state.
219459185|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
219459186|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
219459187|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
219459188|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
219459189|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
219459190|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
219459191|NCT01005966|DRUG|Placebo|placebo and washout treatment
219459192|NCT01005966|DRUG|675 ppmf toothpaste|dose response
219199466|NCT06871956|DIAGNOSTIC_TEST|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma: A Prospective Multicenter Validation and Development of a Web Calculator
218849903|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
219459193|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
219459194|NCT00863564|DIETARY_SUPPLEMENT|Cod|
219459195|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
219459196|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
218849904|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
218849905|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
218849906|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
218849907|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
219459197|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
219459198|NCT01451203|DRUG|CZP|SC
219459199|NCT01451203|DRUG|methotrexate (MTX)|oral
219459200|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
219592122|NCT02686645|DRUG|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
219592123|NCT02686645|DRUG|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
219592124|NCT01922804|DIETARY_SUPPLEMENT|K2 vitamin|K2 vitamin tablet
219459201|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
218849908|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
219459202|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
219459203|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
219459204|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
219459205|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
219459206|NCT02553486|OTHER|quality of life evaluation|
219459207|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
219459208|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
219459209|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
219459210|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
219199467|NCT06867783|DEVICE|coquille|"Modalities: Elaboration of the personalized care project, follow-up parents-child single family, multi-family therapy (MFT).~Frequency: MFT weekly, bi-familial observation weekly for one month, single-parent child-parent monitoring weekly for five months, MFT father-child bimonthly for six months, three co-parents, three child psychiatric consultations to develop the personalized collaborative care project"
219592125|NCT01922804|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
218849909|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
218849910|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
218849911|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
219459211|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
219592126|NCT04702438|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
219592127|NCT05023837|DRUG|Pembrolizumab 100 MG Injection|Pembrolizumab iv 200mg q21d
219592128|NCT05569551|DEVICE|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
218849912|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
218849913|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
218849914|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
219459212|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
219459213|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
219459214|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
219459215|NCT02430064|OTHER|Low PAMP diet|
219459216|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
219459217|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
219592129|NCT02913092|BEHAVIORAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
218849915|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
218849916|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
218849917|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
218849918|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
218849919|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
218849920|NCT00350363|DRUG|Zymar|zymar qid
218849921|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
218849922|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
218849923|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
218849924|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
218849925|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
218849926|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
218849927|NCT00518648|OTHER|Usual care|Usual care
218849928|NCT02559323|OTHER|Survey|
218849929|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
218849930|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
218849931|NCT00441428|DRUG|solifenacin|
218849932|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
218849933|NCT03898466|OTHER|Matching placebo|Placebo inhaler
219459218|NCT03308799|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
219459219|NCT03308799|DRUG|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
219459220|NCT03308799|DRUG|Cream vehicle|Vehicle Cream
219459221|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
219459222|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
219459223|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
219459224|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
219459225|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
219592130|NCT01676415|DRUG|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
218849934|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
218849935|NCT00003603|DRUG|cyclophosphamide|
218849936|NCT00003603|DRUG|dexamethasone|
218849937|NCT00003603|DRUG|idarubicin|
218849938|NCT00003603|DRUG|lomustine|
218849939|NCT00003603|DRUG|melphalan|
218849940|NCT00003603|DRUG|prednisolone|
218849941|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
218849942|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
218849943|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
218849944|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
219459226|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
219459227|NCT04084444|DRUG|Placebo|Blank control.
219459228|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
219459229|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
219459230|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
219459231|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
219459232|NCT06304493|DEVICE|Alarms|"The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
219459233|NCT05534412|OTHER|Academic Detailing|"1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
219459234|NCT05534412|OTHER|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
219459235|NCT05534412|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
219459236|NCT05534412|OTHER|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
219459237|NCT01403415|DRUG|Dexamethasone|Given PO or IV
219459238|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
219459239|NCT01403415|DRUG|Methotrexate|Given IT
219459240|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
219459241|NCT01403415|DRUG|Pegaspargase|Given IV
219459242|NCT01403415|OTHER|Pharmacological Study|Correlative studies
219459243|NCT01403415|DRUG|Temsirolimus|Given IV
219592131|NCT01676415|DRUG|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
218849945|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
219459244|NCT01403415|DRUG|Vincristine Sulfate|Given IV
219592132|NCT05578456|DRUG|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
219592133|NCT05578456|DRUG|Placebo|placebo 2 starch tablets per day per os
219459245|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
219459246|NCT00000980|DRUG|Spiramycin|
219459247|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
219459248|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
219459249|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
219459250|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
219459251|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
219459252|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
219459253|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
219459254|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
219459255|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
218849946|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
219459256|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
219459257|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
219459258|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
219459259|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
219459260|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
219459261|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
219459262|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
219459263|NCT00027027|DRUG|rhuMAb 2C4|
219459264|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
219459265|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
219592134|NCT01205984|DRUG|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
218849947|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
218849948|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
218849949|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
218849950|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
218849951|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
218849952|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
218849953|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
218849954|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
218849955|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
218849956|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
218849957|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
218849958|NCT02042053|DEVICE|PET/CT|
218849959|NCT02042053|DEVICE|PET/MRI|
218849960|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
218849961|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
218849962|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
218849963|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
218849964|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
218849965|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
218849966|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
218849967|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
218849968|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
218849969|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
219199468|NCT06867159|PROCEDURE|Autogenic Inhibition (AI) MET (Post Facilitation Stretch)|"Autogenic Inhibition (AI) MET (Post Facilitation Stretch)~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
218849970|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
218849971|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
218849972|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
218849973|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
218849974|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
218849975|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
218849976|NCT02979093|DRUG|Oxytocin|All women will receive a nasal spray containing oxytocin.
218849977|NCT02979093|DRUG|Placebos|All women will receive a nasal spray containing a placebo solution.
218849978|NCT02979093|PROCEDURE|Functional MRI scanning|Study participants undergo two functional MRI scans.
218849979|NCT05083091|BEHAVIORAL|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
218849980|NCT05083091|BEHAVIORAL|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
218849981|NCT05083091|BEHAVIORAL|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
218849982|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
218849983|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
218849984|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
219459266|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
219459267|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
219459268|NCT01809158|DRUG|minocycline|
219459269|NCT01809158|DRUG|placebo|
219459270|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
219459271|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
219459272|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
219459273|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
219459274|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
219459275|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
219459276|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
219459277|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
219592135|NCT00587990|BIOLOGICAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
219197692|NCT04852601|OTHER|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
219592136|NCT00587990|GENETIC|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
219592137|NCT00587990|BIOLOGICAL|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
218849985|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
219592138|NCT02754856|BIOLOGICAL|Durvalumab|Given IV
218849986|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
219592139|NCT02754856|OTHER|Laboratory Biomarker Analysis|Correlative studies
219592140|NCT02754856|PROCEDURE|Therapeutic Conventional Surgery|Undergo liver surgery
219592141|NCT02754856|BIOLOGICAL|Tremelimumab|Given IV
218849987|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
218849988|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
218849989|NCT03099174|DRUG|Xentuzumab|Once weekly administrated through one hour intravenous infusion
218849990|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
218849991|NCT03099174|DRUG|Letrozole|Once a day
219459278|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
218849992|NCT03099174|DRUG|Anastrozole|Once a day
218849993|NCT03099174|DRUG|Fulvestrant|Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
219459279|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
219459280|NCT01829529|DRUG|Amoxicillin|Amoxicillin
219459281|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
219459282|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
219459283|NCT04115020|DRUG|Placebo|Placebo oral suspension
219459284|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
219459285|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
219459286|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
219459287|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
219459288|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
219459289|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
219459290|NCT02039687|OTHER|Placebo|Formulation buffer
219459291|NCT05959278|OTHER|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
219459292|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
219459293|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
219459294|NCT00343161|DRUG|esomeprazole|
219459295|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
219459296|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
219459297|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
219592142|NCT05567146|BEHAVIORAL|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
219592143|NCT00530218|DRUG|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
219459298|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
218849994|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
219459299|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
219459300|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
219459301|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
219459302|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
219459303|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
219197693|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
219459304|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
219459305|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
219459306|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
219459307|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
219459308|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
219459309|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
219459310|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
219459311|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
219459312|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
219459313|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
219459314|NCT00983944|BIOLOGICAL|rituximab|Given IV
219459315|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
219459316|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
219459317|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
219459318|NCT00983944|DRUG|etoposide|Given IV or orally
219459319|NCT00983944|DRUG|prednisone|Given IV or orally
219459320|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
219459321|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
219459322|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
219592144|NCT01342900|DEVICE|connected to the InSpectra Monitor|
218849995|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
218849996|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
218849997|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
218849998|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
218849999|NCT06146946|PROCEDURE|Dissection of the No.253 lymph node|The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.
218850000|NCT06146946|PROCEDURE|Omitting the dissection of the No.253 lymph node|In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
218850001|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
218850002|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
219459323|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
219459324|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
219459325|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
219459326|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
219459327|NCT00075634|DRUG|decitabine|Given IV
219592145|NCT04851535|DRUG|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
219592146|NCT01798316|DRUG|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
219592147|NCT01798316|DRUG|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
219592148|NCT02345837|DEVICE|endometrial sampling|injury to the endometrium
219592149|NCT02345837|DRUG|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
219592150|NCT05850806|DEVICE|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
219592151|NCT01147107|DRUG|Raltegravir|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
218850003|NCT01096368|DRUG|Carboplatin|Given IV
219592152|NCT01147107|DRUG|Efavirenz|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
219592153|NCT00403637|DRUG|indacaterol maleate|
219592154|NCT03885752|DRUG|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
218850004|NCT01096368|DRUG|Cisplatin|Given IV
218850005|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
218850006|NCT01096368|DRUG|Cyclophosphamide|Given IV
218850007|NCT01096368|DRUG|Etoposide|Given IV
218850008|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
219459328|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
219459329|NCT00075634|DRUG|cyclophosphamide|Given IV
219459330|NCT00075634|BIOLOGICAL|filgrastim|Given SC
219592155|NCT03885752|OTHER|swallow twice|asked to swallow twice without any additional treatment.
219592156|NCT01865942|PROCEDURE|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
219592157|NCT01865942|PROCEDURE|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
219592158|NCT01871571|BIOLOGICAL|bevacizumab|Given IV
219592159|NCT01871571|DRUG|oxaliplatin|Given IV
219592160|NCT01871571|DRUG|leucovorin calcium|Given IV
219592161|NCT01871571|DRUG|fluorouracil|Given IV
219592162|NCT01871571|OTHER|laboratory biomarker analysis|Correlative studies
218850009|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218850010|NCT01096368|DRUG|Mesna|Given IV
218850011|NCT01096368|DRUG|Vincristine|Given IV
218850012|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
218850013|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
218850014|NCT05473156|DRUG|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses."
218850015|NCT05473156|DRUG|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
218850016|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
218850017|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
218850018|NCT02308163|DRUG|Peficitinib|oral
218850019|NCT02308163|DRUG|Placebo|oral
219459331|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
219459332|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
219459333|NCT00075634|OTHER|pharmacological study|Correlative studies
219459334|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
219459335|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
219459336|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
219459337|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
219459338|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
219459339|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
219459340|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
219459341|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
219459342|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
219459343|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
219459344|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR\_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
218850020|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
218850021|NCT03496792|OTHER|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
218850022|NCT03496792|OTHER|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
218850023|NCT03496792|OTHER|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
219459345|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
219459346|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
219459347|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
219459348|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
219459349|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
219459350|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
219459351|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
219459352|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
219459353|NCT00570089|DRUG|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
219459354|NCT00570089|DRUG|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
219459355|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
219459356|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
219459357|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
219197694|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
219197695|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
219197696|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
219197697|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
218850024|NCT03496792|OTHER|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
219197698|NCT06862440|DEVICE|Kegg|Fertility status monitor
219197699|NCT06861140|DIETARY_SUPPLEMENT|Tryptophan 25mg/kg bodyweight|Tryptophan is supplemented during the treatment of chronic pouchitis with pro- and antibiotics
219197700|NCT06861140|OTHER|Placebo|standard treatment of chronic pouchitis using pro- and antibiotics.
219197701|NCT06860958|DRUG|Fluoxetine|Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
219197702|NCT06860958|DRUG|Roflumilast|Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
219197703|NCT06860958|DRUG|Placebo|Placebo
219197704|NCT06861322|BEHAVIORAL|Short Foot Exercise|"* Description: Short Foot Exercise is a therapeutic exercise designed to strengthen intrinsic foot muscles and improve medial longitudinal arch stability.~* Procedure: Participants will perform Short Foot Exercise twice daily, five times per week for four weeks. The exercise consists of progressive phases, starting with basic foot activation and advancing to resistance-based strengthening using bands.~* Purpose: To determine if strengthening the foot's intrinsic muscles positively impacts knee pain, muscle function, and balance in individuals with flexible flatfoot."
219459358|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
219459359|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
219459360|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
219459361|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
219459362|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
219459363|NCT00510406|DRUG|Placebo|Placebo
219459364|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
219459365|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
219459366|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
219459367|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
219459368|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
219459369|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
219459370|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
219459371|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
219459372|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
219459373|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
219459374|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
218850025|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
218850026|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
218850027|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
218850028|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
218850029|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
218850030|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
219197705|NCT06861322|BEHAVIORAL|Conventional Physical Therapy|"* Description: Standard non-invasive physical therapy aimed at reducing knee pain, improving muscle relaxation, and enhancing lower limb function.~* Procedure: Participants will receive twice-weekly conventional physical therapy for ten minutes per session over four weeks. Treatment includes soft tissue mobilization, muscle relaxation techniques, and neuromuscular stimulation, as appropriate for knee pain relief.~* Purpose: To evaluate its effectiveness as a standalone treatment compared to the addition of Short Foot Exercise."
219459375|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
219459376|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
219459377|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
219459378|NCT01888380|PROCEDURE|Conventional autopsy|
219459379|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
218850031|NCT05434338|DIAGNOSTIC_TEST|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
218850032|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
219197706|NCT06862921|OTHER|Control|fawler position using a standard tourniquet
219197707|NCT06861036|PROCEDURE|Biospecimen|"* 1 or 2 tumoral specimen (depending on the size of the tumor)~* 1 specimen of the healthy oral mucosa~* 1 leucoplakia specimen if applicable.~The biospecimens will be collected at the time of the surgery organised for the standard routine medical care."
219197708|NCT06861036|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam.
219459380|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
219459381|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
219459382|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
219459383|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
219459384|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
219592163|NCT00865371|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
219592164|NCT00865371|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
219592165|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
219592166|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
219592167|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
219592168|NCT02910063|DRUG|Blinatumomab|Blinatumomab monotherapy
219592169|NCT01789723|DRUG|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
219459385|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
219459386|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
219459387|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
218850033|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
218850034|NCT04414046|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
218850035|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
218850036|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
218850037|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
218850038|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
218850039|NCT05441163|OTHER|APA and nutrition intervention|"\- APA intervention: weekly supervised sessions at home with the APA professional combined with unsupervised sessions, alone or with the APA partner, for 8 weeks.~The supervised session will be broken down as follows: warm-up block (approximately 10'), aerobic block (15'), muscle strengthening/resistance block (15') and stretching/relaxation block (10'). The remaining 10' will be used to review the session and the individual sessions. This program can be adapted to the needs and abilities of the patient if necessary.~\- Nutritional intervention: dietitian weekly visits at home during 8 weeks with dietetic counseling; decision of oral, enteral and/or parenteral feeding validated by the clinical steering committee according to the Société Francophone de Nutrition Clinique et Métabolisme (SFNCM) guidelines."
218850040|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
219459388|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
219459389|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
218850041|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
219197709|NCT06604156|DEVICE|EEG monitoring|During gastrointestinal endoscopy, electroencephalogram (EEG) monitoring will be conducted using qCON and qNOX technologies to assess patients\&amp;amp;#39; sedation and analgesia status while they undergo painless gastrointestinal endoscopy. This will be combined with visual assessments (such as cough reflex, respiratory depression, and limb movement) and clinical physiological monitoring (including vital signs and pulse oximetry) to explore and establish a stable and optimal depth of sedation for anesthesia.
219197710|NCT06861023|OTHER|Patients who have undergone extensive nail resection with reconstruction|The investigators studied a population of 10 patients who underwent nail and nail matrix excision surgery as part of the treatment of subungual melanoma, as well as the reconstruction, the investigators opted for. The specific intervention of this study is based on late postoperative questions (after 3 months)
218850042|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
219197711|NCT06860412|BEHAVIORAL|Animal Assisted Intervention|This is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions through the integration of a psychoeducational intervention and animal-assisted therapy for elderly people with unwanted loneliness.
219592170|NCT01789723|DRUG|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
219592171|NCT05540028|BIOLOGICAL|IVT PCV-25|25 valent pneumococcal conjugate vaccine
219592172|NCT05540028|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
219459390|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
219459391|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
219459392|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
219197712|NCT06860412|BEHAVIORAL|Psychoeducational Intervention as Usual|This psychoeducational intervention is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions for elderly people with unwanted loneliness.
219197713|NCT04474574|DEVICE|Simultaneous recording of nocturnal SpO2|The intervention will consist in performing a simultaneous recording of nocturnal SpO2 and pulse rate for at least 4 hours with 3 different devices.
219459393|NCT00104429|DRUG|GW873140|
219459394|NCT00104429|DRUG|Combivir|
219197714|NCT06858592|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Dancers will then individually be screened for somatic dysfunctions (SD) by a physician and VCOM OMS-III student doctor under their direct supervision. OMS-III student investigators will receive training and be assessed on their abilities before performing OMT on subjects. This will take place at the dancers' place of practice in a private area equipped with an OMM table. The areas to be screened include the lumbar spine, hips, knees, ankles, and feet. All diagnoses in these areas will be documented with specific notation for the area of greatest restriction on paper. After making a diagnosis or multiple diagnoses, the dancer will be treated utilizing OMT for 15 minutes starting with the area of greatest restriction in the lower body by the OMS-III student doctor under direct supervision of a physician, should an adverse event take place. The type of treatment(s) used will be at the discretion of the supervising physician and the VCOM student doctor. They may use any OMT technique, exc
219197715|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
219592173|NCT05949411|OTHER|Screening visit|Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.
219197716|NCT06858189|BEHAVIORAL|Walk-and-talk therapy|During the 10-week intervention, clients and therapists will engage in walk-and-talk therapy outdoors in natural settings during weekly therapy sessions. In addition, therapists will work with clients to set realistic goals for increased nature-based physical activity outside of the therapy setting. Therapists will check in with clients weekly regarding their progress and assist with goal revision, barrier planning, and self-monitoring.
219459395|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
219459396|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
219459397|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
219459398|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
219197717|NCT06855667|BIOLOGICAL|Plasma Exchange|3 to 5 sessions alternate day
219197718|NCT06855667|DRUG|Steroid|Steroid
219197719|NCT06855667|DIETARY_SUPPLEMENT|Diet|Diet
219459399|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
219459400|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
219459401|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
219459402|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
219459403|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
219459404|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
219592174|NCT05949411|OTHER|Lactulose test|Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.
219592175|NCT05949411|OTHER|Administration of standardized meals with characterized dietary fiber content|Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
219459405|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
219459406|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
219459407|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
219592176|NCT01269931|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
219592177|NCT05070026|OTHER|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
219592178|NCT05070026|OTHER|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
219019233|NCT07001020|BEHAVIORAL|Technology-based Intervention|Technology-based intervention co-developed by a community board.
219019234|NCT06995378|BEHAVIORAL|Lab Result Communication Tool|A behavioral intervention delivered through a personalized EHR-integrated lab result communication tool designed to improve emotional and cognitive responses to lab results among adults aged 65+. The tool applies behavioral science principles such as risk personalization, simplified messaging, and visual framing to reduce patient anxiety, enhance understanding, and support informed decision-making.
219592179|NCT05018546|PROCEDURE|Irrigation force|RIRS with different irrigation force
219592180|NCT04693416|OTHER|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
219592181|NCT04693416|OTHER|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
219592182|NCT03510026|DEVICE|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
219592183|NCT00625053|PROCEDURE|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
219592184|NCT00625053|PROCEDURE|Open midline incisional hernia repair|"* Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
219592185|NCT00474266|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
219592186|NCT00474266|BIOLOGICAL|Priorix-Tetra|2-dose subcutaneous injection
219592187|NCT00474266|BIOLOGICAL|Meningitec|Single dose intramuscular injection
219459408|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
219459409|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
218850043|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
218850044|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
218850045|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
219459410|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
219459411|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
219459412|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
219459413|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
219459414|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
219459415|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
219459416|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
218850046|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
219459417|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
219459418|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
219459419|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
219459420|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
219459421|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
219459422|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
219197720|NCT06859892|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine 0.4 μg/kg and esketamine 0.2 mg/kg is infused over 10 minutes before anesthesia induction. Dexmedetomidine 0.20 μg/kg/h and esketamine 0.10 mg/kg/h is then infused until 60 minutes before the expected end of surgery. Patient-controlled intravenous analgesia is established with 100 μg dexmedetomidine, 50 mg esketamine, and 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
219459423|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
219197721|NCT06859892|DRUG|Placebo|Placebo (normal saline) is administered in the same rate and volume as that in the dexmedetomidine-esketamine group. Patient-controlled intravenous analgesia is established with 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
219459424|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
219459425|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
219459426|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
219459427|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
219459428|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
219459429|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
219459430|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
219459431|NCT06525337|BEHAVIORAL|STANDARDCARE (STAND) group|Will receive a device and health coaching
219459432|NCT06525337|OTHER|CONTROL (CON) group|Will not use any devices or receive health coaching
219459433|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
219459434|NCT03055806|DRUG|Placebo|Placebo caplet(s)
219592188|NCT04880603|DEVICE|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
218850047|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
219197722|NCT06859567|OTHER|Evaluation|Comparison of the 6-minute walk test and Chester step test, one of the aerobic capacity tests
219197723|NCT06859112|OTHER|logotherapy focused psychoeducation|8 sessions of online individual logotherapy focused psychoeducation program
219197724|NCT06856941|DEVICE|cerebello-spinal direct current stimulation|Cerebello-spinal direct current stimulation is an electrical stimulus in the cerebellum as well as in the spinal cord that is used to improve functional mobility. To our knowledge, this is the first study to use this setup in individuals with Parkinsons disease.
219197725|NCT06856941|DEVICE|sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation involves masking, where the total duration of stimulation is thirty seconds, which is sufficient to mimic the sensation of stimulation but without neuromodulatory effects
219459435|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
219459436|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
219459437|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
219459438|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
219459439|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
219459440|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
219459441|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
219459442|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
219459443|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
219459444|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
219459445|NCT00125138|DRUG|Placebo|Syrup formulation
219459446|NCT00041119|DRUG|AC regimen|Given IV
219459447|NCT00041119|DRUG|cyclophosphamide|Given IV
219592189|NCT04880603|PROCEDURE|Standard of Care Skin Graft|Standard of Care Skin Graft
219592190|NCT00045864|DRUG|Recombinant Human Interleukin-2 and Rituximab|
218850048|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
219459448|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
219459449|NCT00041119|DRUG|paclitaxel|Given IV
219459450|NCT02758106|DEVICE|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
219459451|NCT02758106|DEVICE|placebo intervention|CCPT for 15 minutes then sputum suction.
219459452|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219459453|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219459454|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
219459455|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
219459456|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
219459457|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
219459458|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
218850049|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
218850050|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
219459459|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
219459460|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
219459461|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
219459462|NCT00005838|OTHER|placebo|Given orally
219459463|NCT00005838|DRUG|cisplatin|Given IV
219459464|NCT00005838|DRUG|vinorelbine tartrate|Given IV
219459465|NCT00005838|DRUG|carboplatin|Given IV
219592191|NCT04110379|BEHAVIORAL|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
218850051|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
218850052|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
218850053|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
218850054|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
219019244|NCT06863142|BIOLOGICAL|VRC-FLUMOS0116-00-VP|The VRC-FLUMOS0116-00-VP (FluMos-v2) vaccine is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA ectodomain trimers from influenza strains: Influenza A (H1-H3) and Influenza B (Victoria lineage and Yamagata lineage)
219019245|NCT06863142|OTHER|ALFQ|The ALFQ adjuvant is a sterile suspension that contains monophosphoryl 3-deacyl Lipid A \[3D-PHAD(R)\] and QS-21
219019246|NCT06308653|DRUG|Psilocybin 25 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
219592192|NCT04110379|BEHAVIORAL|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
219592193|NCT03886415|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
218850055|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
218850056|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
218850057|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
219459466|NCT00005838|DRUG|paclitaxel|Given IV
219459467|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
219459468|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
219459469|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
219459470|NCT00000576|DRUG|beclomethasone|
218850058|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
218850059|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
219459471|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
219459472|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
219459473|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
219459474|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
219459475|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
219459476|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
219459477|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
219459478|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
219459479|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
219197726|NCT06857617|BIOLOGICAL|(Part C) MET097|"Participants will receive 13 once-weekly subcutaneous injections of MET097 as follows:~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 1.2mg~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 1.6 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 3.2 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 2.0 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 4.0 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 4.8 mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 2.4mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 4.8mg"
219459480|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
218850060|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
218850061|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
218850062|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
219019247|NCT06308653|DRUG|Inactive Placebo|The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
219019248|NCT06308653|DRUG|Psilocybin 5 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
219019249|NCT06308653|BEHAVIORAL|Psychosocial Support|Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
219459481|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
219459482|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
219459483|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
219459484|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
219459485|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
219459486|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
219592194|NCT02633748|BEHAVIORAL|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
219197727|NCT06857617|BIOLOGICAL|(Part C) Placebo|Participants will receive 13 once-weekly subcutaneous injections of matching placebo
219197728|NCT06858917|PROCEDURE|Ganglion Impar Block|Block of the ganglion impar is performed by injecting a mixture of steroid and local anaesthetic in front of the sacrococcygeal joint. This procedure is performed in a sterile operating theatre under ultrasound and/or fluoroscopic (X-ray) guidance. Radiopaque agents are also used during the procedure to confirm the location.
218850063|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
218850064|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
218850065|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
218850066|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
218850067|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
219197729|NCT06858917|PROCEDURE|Sacral Erector Spinae Plane Block|The sacral erector spina plan block is performed with ultrasound guidance by injecting a high volume mixture of local anaesthetic and steroid into the fascia under the erector spina muscles in the sacral region.
219459487|NCT00689611|DRUG|Placebo|Placebo
219459488|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
219459489|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
219459490|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
219459491|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
218850068|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
219197730|NCT06858943|PROCEDURE|arthroscopic meniscus reconstruction using a tendon autograft|arthroscopic meniscus reconstruction using a tendon autograft
219197731|NCT06860009|BEHAVIORAL|Multicomponent psychological intervention|The multicomponent intervention starts with 8 sessions of ACT (Acceptance and commitment therapy) once a week. After four weeks, patients start with graded activity and frequent napping. After eight weeks in the intervention period, patients will have consults with an IBD psychologist every two weeks. The intervention period is 14 weeks in total.
219197732|NCT06860009|BEHAVIORAL|Early start|Patients in the early group immediately start with the multicomponent psychological intervention
219197733|NCT06860009|BEHAVIORAL|Late start (after 28 weeks)|Patients in the late intervention group will wait 28 weeks before starting the intervention
219197734|NCT06668363|BEHAVIORAL|Treat4All|An alcohol reduction evidence-based intervention integrated with HIV status-neutral counseling
219197735|NCT06668363|BEHAVIORAL|Standard of care (control arm)|Sexual risk reduction counseling
219197736|NCT06862492|DEVICE|Open surgical cut down technique|"The technique was performed following the descriptions of Farhadi et al. The infant was positioned in 30° (Trendelenburg's position), with a roll under his shoulders for neck extension and rotated to contralateral side of the surgical side to expose the incision site. Incision was done under sedation and pulse oximeter to monitor the oxygen saturation during the technique.~Under complete aseptic technique, a small transverse incision 1cm was made on triangle bordered by the clavicle inferiorly and by the sternal and clavicular heads of the sternomastoid muscle medially and laterally. With blunt dissection we separate the two heads of the sternomastoid exposing the internal jugular vein .~Then internal jugular vein cut down was performed and catheter inserted through it, all internal jugular vein venotomies were repaired as needed by 6/0 Polypropylene (Prolene®) suture and the wound was closed by absorbable polyglactin (Vicryl) suture"
219459492|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
219592195|NCT06173856|OTHER|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
218850069|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
218850070|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
219459493|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
219459494|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
219459495|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
219459496|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
219459497|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
219459498|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
219459499|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
219459500|NCT03708926|DRUG|Placebo|placebo injection pen
219459501|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
219459502|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
219459503|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
219459504|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
219459505|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
219592196|NCT02774642|BEHAVIORAL|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
219592197|NCT02774642|BEHAVIORAL|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
218850071|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
218850072|NCT05544942|OTHER|maltodextrin|1 capsule once a day
219459506|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
219459507|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
219459508|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
219459509|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
219459510|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
219459511|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
219459512|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
219459513|NCT03676712|DEVICE|scoliosis brace|Wear at least 18 hours a day
219459514|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
219459515|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
219197737|NCT06862492|DEVICE|Modified Seldinger's technique|After proximal and distal control of the vein, a 24-G. cannula was carefully inserted directly to the internal jugular vein . The guidewire was inserted through the cannula, then the cannula was removed. A size 4-5 French short length catheter was passed and brought out through the guidewire, then the guidewire was removed. The wound was closed after the correct catheter position and good haemostasis was obtained; the area was covered with sterile dressing.
219459516|NCT03673150|OTHER|non intervention|Observational study / non intervention
219459517|NCT05959876|OTHER|Training group|Face-to-face perineal care training
219459518|NCT05959876|OTHER|Control group|No intervention
219459519|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
219459520|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
218850073|NCT03760016|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
218850074|NCT03760016|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
219459521|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
219459522|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
219459523|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
219459524|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
219459525|NCT00939861|PROCEDURE|laparotomy|colorectal resection
219459526|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
219459527|NCT04056325|DRUG|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
219459528|NCT04056325|DRUG|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
219459529|NCT04056325|DRUG|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
219459530|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
219459531|NCT05731726|DRUG|Serplilumab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits."
219459532|NCT05731726|DRUG|Capecitabine|Given PO
219459533|NCT05731726|DRUG|Oxaliplatin|Given IV
219459534|NCT05731726|DRUG|Celecoxib|celebrex
219459535|NCT05642884|OTHER|Multi-modal Exercise Regimen|Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.
219459536|NCT05642884|BEHAVIORAL|Dietary Guidelines|Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
219592198|NCT03947944|PROCEDURE|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
218850075|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
218850076|NCT06423664|BEHAVIORAL|Play and Learn Strategies (PALS) Program|Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
218850077|NCT06650878|PROCEDURE|Desarda|This technique prevent from using a mesh to surgical repair of a inguinal hernia
218850078|NCT06650878|PROCEDURE|Lichtenstein|This technique implies using a mesh to surgical repair of a inguinal hernia
219459537|NCT05949177|BEHAVIORAL|Graded Exposure and Mindfulness Meditation|Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
219459538|NCT05949177|BEHAVIORAL|Waitlist Control|Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
219459539|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
219459540|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
219459541|NCT05989815|OTHER|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
219459542|NCT05989815|DEVICE|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
219459543|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
219592199|NCT03947944|PROCEDURE|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
219592200|NCT00376038|DRUG|GSK189075 oral tablets|
219592201|NCT00376038|DRUG|metformin tablets|
219592202|NCT01529710|DRUG|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
218850079|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
218850080|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
218850081|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
218850082|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
218850083|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
219592203|NCT06551415|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
219197738|NCT06862492|DEVICE|Closed Ultrasound guided CVC insertion|Ultrasound probe was connected to ultrasound unit and focused with ultrasonic gel and wrapped in a sterile plastic sheath. By wrapping the transducer in a sterile sheath, the probe place perpendicular to the long axis of the vessel, standard US two-dimensional (2D) imaging was used to visualize the vein in the short-axis view as a circle. Catheterization was performed under continuous dynamic observation of real-time 2D images. Insertion needle was advanced through the skin under US guidance into the internal jugular vein . A guidewire was then placed through the needle into the vein, and the needle was removed. Then catheter was inserted over the wire into internal jugular vein .
219197739|NCT06860334|DRUG|Favipiravir|6-fluoro-3-hydroxypyrazine-2-carboxamide, T-705
218850084|NCT00425997|DRUG|Valsartan/HCTZ|
218850085|NCT00425997|DRUG|amlodipine|
219197740|NCT06860334|DRUG|Ribavin|1-3,4-dihydroxy-5-1,2,4-triazole-3-carboxamide
219197741|NCT06860334|OTHER|Optimised Standard of Care|Optimised standard of care will include treatment per national guidelines for CCHF case management in Turkiye and Iraq, and any other supportive medication or therapies as required.
218850086|NCT00425997|DRUG|HCTZ|
219459544|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
219459545|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
219459546|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
219459547|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
219459548|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
219459549|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
219459550|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
219197742|NCT06861400|BEHAVIORAL|Self-Reflective Resilience-Recovery Activity Promotion Training|Self-Reflective Resilience-Recovery Activity Promotion Training (SRR-RAPT) promotes finding positive meaning in stressors by building self-awareness of the coping and regulatory responses used to manage them; evaluating those responses; adapting them based upon their perceived effectiveness; and developing a plan for managing similar stressors in the future based on what can be learned from the current situation. In addition to prompting self-monitoring and active reflection on stressors and coping responses, SRR-RAPT encourages practicing recovery activities that permit a person's stressor induced strain level to return to baseline. SRR-RAPT is administered daily for 8 consecutive days.
219592204|NCT06551415|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
219592205|NCT02199886|DRUG|BIBH 1|labeled with eight to ten millicurie of 131I
219592206|NCT02308566|PROCEDURE|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
218850087|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
219197743|NCT06861907|DEVICE|Virtual Reality|Virtual Reality Modules created to simulate HAZWOPER PowerPoint scenarios
219197744|NCT06862856|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|This is a PET scan with flotufolastat F 18 injection.
219459551|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
219459552|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
219459553|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
219459554|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
218850088|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
218850089|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
218850090|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
218850091|NCT00353808|DRUG|[S,S]-Reboxetine|
218850092|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
218850093|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
218850094|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
219459555|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
219459556|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
219459557|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
219459558|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
219459559|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
219459560|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
219459561|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
218850095|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
218850096|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
218850097|NCT05712109|OTHER|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
218850098|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
219459562|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
219459563|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
219459564|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
219197745|NCT06861959|DEVICE|Device: Volume-Controlled Ventilation (VCV)|Tidal volume: 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
219459565|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
219459566|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
219459567|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
218850099|NCT00014989|DRUG|magnesium sulfate|
218850100|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
218850101|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
218850102|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
219197746|NCT06861959|DEVICE|Device: Pressure-Controlled Ventilation (PCV)|Initial peak inspiratory pressure adjusted to deliver a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
219459568|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
219459569|NCT02004457|BEHAVIORAL|ABBT|
219459570|NCT02004457|OTHER|TAU|
219459571|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
219459572|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
219592207|NCT02308566|PROCEDURE|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
219592208|NCT04445597|OTHER|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
218850103|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
219197747|NCT06861959|DEVICE|Device: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)|Pressure-controlled mode with volume guarantee to maintain a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
219197748|NCT06861296|BEHAVIORAL|Intervention Group|(Flipped Learning Model Based Training Group)-Arm Description: This group will receive training on postpartum hemorrhage management using the reverse learning
219197749|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
219197750|NCT05535816|DIAGNOSTIC_TEST|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
219197751|NCT04675034|DRUG|MEDI7352|Participants will receive SC injection of MEDI7352 as stated in arm description.
219197752|NCT04675034|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
219459573|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
219459574|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
219592209|NCT02776137|DRUG|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
219592210|NCT02776137|RADIATION|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
218850104|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
218850105|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
218850106|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
218850107|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
219197753|NCT05956574|BEHAVIORAL|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
219197754|NCT05956574|BEHAVIORAL|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
219197755|NCT05956574|BEHAVIORAL|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
219197756|NCT05956574|BEHAVIORAL|Standard Dietary plan|Receive a standard dietary plan
219197757|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
219197758|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
219197759|NCT06781164|DEVICE|telemedicine|Recording of the ear of each patient with an ear problem
218850108|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
218850109|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
218850110|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
218850111|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
219197760|NCT03494959|DRUG|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
219459575|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
219197761|NCT06661421|DEVICE|Dry Needling|This intervention combines Dry Needling Therapy (DNT) with routine physical therapy for children with spastic cerebral palsy. The experimental group will receive DNT alongside physical therapy, while the control group will undergo only physical therapy. Routine Physical Therapy includes a warm-up, stretching, and strengthening exercises like hamstring stretches and squats, adjusted over a month with increasing intensity. Dry Needling targets the gastrocnemius muscle using a fast-in, fast-out technique with sterile needles, applied weekly for 10 weeks. This combined approach aims to reduce spasticity, improve mobility, and enhance range of motion, distinguishing it from standard therapies.
219459576|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
219459577|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
219592211|NCT02003950|OTHER|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
219592212|NCT03389815|DRUG|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
218850112|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
218850113|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
218850114|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
218850115|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
218850116|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
218850117|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
218850118|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
218850119|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
218850120|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
218850121|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
218850122|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
218850123|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
218850124|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
219592213|NCT00616070|DRUG|Difluprednate|Difluprednate
219592214|NCT00616070|OTHER|Placebo|Vehicle
219197762|NCT06661421|OTHER|Cerebral Palsy conventional Treatment|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel rises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three sessions per week, focusing on hamstring stretches and progressive resistance exercises.
219197763|NCT06614218|DEVICE|Minimally Invasive Micro Sclerostomy|The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
218850125|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
218850126|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
218850127|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
218850128|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
218850129|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
219197764|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
219197765|NCT06669091|DRUG|Ecopipam tablet|A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
218850130|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
218850131|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
218850132|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
219197766|NCT06669611|DRUG|Camrelizumab combined GP chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
219197767|NCT06669611|DRUG|Camrelizumab combined TPC chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
219197768|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
219592215|NCT03172663|DEVICE|pure tone audiometry|for estimate the type and degree of hearing loss
219592216|NCT03051932|DRUG|Ofiramev® (IV Acetaminophen)|Post -op pain medication
219592217|NCT03051932|DRUG|Placebo IV administration|Post -op pain
219592218|NCT06979206|OTHER|Application of Binarual Beat|The binaural beat audio file consists of pure tones at 431 Hz in the left ear and 432 Hz in the right ear, delivered via earphones continuously until the end of anesthesia.
219592219|NCT06983548|BIOLOGICAL|semen, blood and urine tests|Patients will undergo several tests, including semen analysis, spermocytogram, blood and urine tests, serology, and RT-PCR. These tests will be conducted on days 7±2, 15±2, 30±3, 60±5, 90±5, and 180±15. (Patients will only undergo the V6 if the sperm PCR result comes back positive on D90).
219592220|NCT06981767|DIETARY_SUPPLEMENT|Topical Bromelain|A natural enzyme-based formulation derived from pineapple, bromelain in orabase is being investigated for its anti-inflammatory and wound-healing properties. As a non-steroidal alternative, it offers a potentially safer treatment option with minimal side effects.
219592221|NCT06981767|DRUG|0.1% topical triamcinolone acetonide|A corticosteroid-based standard treatment for OLP, triamcinolone acetonide in orabase is used for its strong anti-inflammatory and immunosuppressive effects. It serves as the conventional treatment versus novel therapy in this study
219592222|NCT06981767|COMBINATION_PRODUCT|Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase|This novel formulation combines the enzymatic, healing properties of bromelain with the anti-inflammatory property of triamcinolone. It is designed to provide enhanced therapeutic effects through synergistic action, potentially reducing the required corticosteroid dose while improving clinical outcomes.
218850133|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
218850134|NCT04193085|OTHER|Observational|Observational
219459578|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
219459579|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
219459580|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
219459581|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
219459582|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
219459583|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
219459584|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
219459585|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
219459586|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
219459587|NCT02393612|DRUG|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
219459588|NCT02393612|DRUG|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
219459589|NCT00159653|DRUG|Xalacom|
219459590|NCT00159653|DRUG|Xalatan|
219459591|NCT00159653|DRUG|Timolol|
219459592|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
219459593|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
219197769|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
219197770|NCT04961840|OTHER|No Intervention|This is a non-interventional study.
219459594|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
219459595|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
219459596|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
219592223|NCT06981676|DIETARY_SUPPLEMENT|DHA and EPA|Women will receive daily supplementation of LCPUFAs (DHA and EPA) from first trimester until delivery
218850135|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
218850136|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
218850137|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
219459597|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
219459598|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
219459599|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
218850138|NCT06690242|DRUG|Etelcalcetide Hydrochloride|the already-marketed therapeutic agents
218850139|NCT06690242|DRUG|Placebo|The measure does not contain the active ingredients
218850140|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
218850141|NCT07033468|DEVICE|VR-WLC|First, conduct the Virtual Reality (VR) training activity. After the evaluation is completed, proceed to the Waitlist Control (WLC) session, approximately 5 to 10 weeks later.
218850142|NCT07033468|DEVICE|CTL-VR|First, conduct the Control (CTL) session for approximately 5 to 10 weeks. After the evaluation is completed, proceed to the Virtual Reality (VR) training activity.
218850143|NCT07033975|OTHER|Flavonoid-enriched Mediterranean Diet|A set of dietary guidelines describing an adjusted Mediterranean diet focusing on the intake of flavonoid-rich products.
219459600|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
219459601|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
219459602|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
219459603|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
219459604|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
218850144|NCT04617912|DEVICE|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
218850145|NCT03532854|DRUG|Valsartan|Valsartan P.O
218850146|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
218850147|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
218850148|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
219197771|NCT06609655|OTHER|no intervention studied, it&#39;s a databank|"The AgeTeQ database Arts, health and new information and communication technologies has three objectives.~The first is to preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory.~The second objective of the database is to use the information provided by the recorded data to fuel reflection, test new research hypotheses and thus open up new avenues of research for the Arts, Health and New Information and Communication Technologies research team.~The third objective is to share the AgeTeQ database with the scientific community on a non-commercial basis, to improve access to data on the themes of arts, health and new technologies, and to increase knowledge and enable the development of research in these fields."
219197772|NCT05755191|DRUG|NEU-411|Oral Doses
219459605|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
219459606|NCT02429076|DRUG|Placebo|normal saline
219459607|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
218850149|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
218850150|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
218850151|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
218850152|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
218850153|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
218850154|NCT04710550|DRUG|F18-3F4AP|PET Scan
218850155|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
218850156|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
218850157|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
219197773|NCT05755191|DRUG|Placebo|Oral Doses
219459608|NCT02429076|DRUG|Propofol|IV anesthetic
219459609|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
218850158|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
218850159|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
219459610|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
219459611|NCT00242814|DRUG|Micardis|
219459612|NCT00242814|DRUG|Amlodipine|
219459613|NCT00242814|PROCEDURE|Abdominal biopsy|
219459614|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
219459615|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
219459616|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
219459617|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
219459618|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
219459619|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
219459620|NCT00372944|DRUG|AZD6244|oral capsule
219459621|NCT00372944|DRUG|capecitabine|oral tablet
219459622|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
219459623|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
219459624|NCT01741285|DRUG|Fluticasone|Course particle treatment
219459625|NCT04075955|DRUG|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
219459626|NCT04075955|DRUG|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
218850160|NCT00798460|DRUG|adefovir|adefovir 10mg
219197774|NCT05458622|BIOLOGICAL|Blood sample|"\- Total volume of blood (on each sampling occasion): 54,5mL.~* Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~* Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
219197775|NCT05458622|BIOLOGICAL|Urine sample|\- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
219197776|NCT05458622|BIOLOGICAL|Saliva sample|\- Saliva: will be collect in special container for saliva microbiome and methylation;
219197777|NCT05458622|BIOLOGICAL|Stood sample|\- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
219197778|NCT05458622|PROCEDURE|Tissue sample|"\- Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
219197779|NCT04214418|DRUG|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
219197780|NCT04214418|DRUG|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
218850161|NCT00798460|DRUG|clevudine|clevudine 30mg
219459627|NCT01943136|DRUG|papaya 1% extract ointment|
218850162|NCT00798460|DRUG|lamivudine|lamivudine 100mg
218850163|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
219459628|NCT01943136|DRUG|mupirocin 2% ointment|
219459629|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
219459630|NCT00271076|PROCEDURE|IVUS|
219459631|NCT00271076|DEVICE|CAS|
219459632|NCT00271076|PROCEDURE|CEA|
219459633|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
219459634|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
219459635|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
219459636|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
219459637|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
219459638|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
219459639|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
219592224|NCT06982833|OTHER|Trunk restraint|Participants were seated in a chair with a standard sitting height of 26 centimeters. After completing the 9-Hole Peg Test with their trunks free on a table of appropriate height so that their trunks would not flexion, they were secured to the chair crosswise in front of their chest with the help of a non-elastic but firm enough belt that would not cause discomfort to the person. Participants completed the 9-DPT with their trunks constrained.
218850164|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
218850165|NCT00733057|DRUG|Placebo (200 mg/day)|
218850166|NCT00138047|DRUG|zinc supplementation|
218850167|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
218850168|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
218850169|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
218850170|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
218850171|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
219592225|NCT06982014|BEHAVIORAL|cilinical simulation|he experimental group will interact with standardized patients (using moulage techniques) who exhibit signs of physical violence. This approach provides a realistic environment for students to assess the physical manifestations of violence and practice their recognition skills in a controlled, yet lifelike, setting.
218850172|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
218850173|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
219197781|NCT04214418|DRUG|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
219197782|NCT02637609|OTHER|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
219197783|NCT02637609|OTHER|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
219197784|NCT06856772|DRUG|Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their Statin daily at approx. 8PM-12AM.
219197785|NCT06856772|DRUG|Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).
219197786|NCT06331065|OTHER|Information session on mindfulness meditation and questionnaires|"The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered."
219197787|NCT06331065|DEVICE|Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group|"After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end."
219197788|NCT06865326|OTHER|Standardized CTEPH Screening Protocol|Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.
219592226|NCT06982014|OTHER|Educational Video Viewing|"The control group will watch a film titled Gözlerimde Al (translated as Take My Eyes), which addresses the issue of gender-based violence. The film aims to provide insights into the emotional and physical effects of violence against women and encourages reflection on how to recognize such violence in real-life scenarios."
219459640|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
219459641|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
219459642|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
219459643|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
219459644|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
219459645|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
219459646|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
219459647|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
219459648|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
219459649|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
219459650|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
219459651|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
219459652|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
219459653|NCT00544154|DRUG|CDP870|
219459654|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
219459655|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
219459656|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
219459657|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
218850174|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
218850175|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
218850176|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
218850177|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
219459658|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
219459659|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
219459660|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
218850178|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
218850179|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
218850180|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
218850181|NCT00164385|BEHAVIORAL|Adolescent Impact|
218850182|NCT04827797|DEVICE|balls|Birth balls to exercise
218850183|NCT00437450|DRUG|Epoetin/Atra|
219459661|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
219459662|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
219197789|NCT06862973|DIAGNOSTIC_TEST|Digital Occlusal Analysis Using Medit i700 and OccluSense in Single-Tooth Implant Restorations|This study differs from other research through the comparison of two advanced digital occlusal analysis methods-OccluSense system and MEDIT i700 intraoral scanner-to measure occlusal force distribution both before and after the insertion of single-tooth implant restorations in the posterior segment. Unlike research based upon the use of articulation paper, this study employs pressure-sensitive sensor technology (OccluSense) and scanner-based occlusion analysis (MEDIT i700) to quantitatively measure occlusal contacts and force intensity using CloudCompare and ImageJ. With the analysis of the variations that take place within the pre-and-post implant occlusion, the study provides an understanding of occlusal adaptation and how to optimize occlusal adjustments to prevent implant overload and complications, differing from the research that has previously lacked both digital force mapping and longitudinal occlusal analysis.
219197790|NCT06863623|OTHER|İmmersive Virtaul Reality Applications|To apply immersive virtual reality applications (Scenarios)
218850184|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
219459663|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
219459664|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
219459665|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
218850185|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
219459666|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
218850186|NCT01925495|OTHER|varied middle-ear pressure|
219197791|NCT06863623|OTHER|Relaxing Videos|To watch relaxing videos including pictures and sounds prepared by researcher
219459667|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
219459668|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
219459669|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
219459670|NCT06277609|DRUG|Lu AF28996|Capsule
219459671|NCT06277609|DRUG|Acetylsalicylic Acid|Tablet
219459672|NCT06277609|DRUG|Mefenamic Acid|Tablet
219459673|NCT06277609|DRUG|Amoxicillin/clavulanic acid|Tablet
219197792|NCT06540768|OTHER|Therapeutic Normothermia Group|Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
219197793|NCT06861595|DEVICE|accuvein|intravenous route with accuvein
219197794|NCT06861595|OTHER|with out accuvein|intravenous route with out accuvein
219197795|NCT06862063|DIAGNOSTIC_TEST|Genetic testing|Each eligible patient will undergo a blood sample to perform a genetic analysis through Next Generation Sequencing (NGS) technique in order to analyze a high number of genes involved in the structure/function of connective tissue
219459674|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
219459675|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
219459676|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
219459677|NCT05441436|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
219459678|NCT05441436|PROCEDURE|Solid organ transplantation|Solid organ transplantation
219459679|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
219459680|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
219459681|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
219459682|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
219459683|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
219459684|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
219459685|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
218850187|NCT01925495|DRUG|varied middle-ear gas composition|
218850188|NCT01925495|OTHER|varied ear-canal pressure|
219592227|NCT06983964|GENETIC|CD19 CART|"Dose group dosage unit (CAR+T cells/kg) Acceptable dose range Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases Dose escalation rule The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases, it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is the maximum tolerated dose (MTD)."
219592228|NCT06981624|OTHER|No heparin|Hemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization
219459686|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
219459687|NCT00352833|DRUG|catumaxomab|
219459688|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
219459689|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
219197796|NCT06862154|DRUG|IV Analgesia- Fentanyl|Patients receive intravenous fentanyl at a dose of 1 mcg/kg, diluted in 100 mL normal saline, administered as a single dose for systemic analgesia. This intervention aims to control acute pain in hip fracture patients before surgical intervention.
219459690|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
219459691|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
219459692|NCT06201585|DEVICE|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
219459693|NCT01784900|DRUG|Catumaxomab 100µg|
219459694|NCT01784900|DRUG|Catumaxomab 140µg|
219459695|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
218850189|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
219459696|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
219592229|NCT01688570|DRUG|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
219459697|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
219459698|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
219459699|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
218850190|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
218850191|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
219197797|NCT06862154|PROCEDURE|Femoral Nerve Block|Patients undergo an ultrasound-guided, single-injection femoral nerve block with 20 mL of 0.5% bupivacaine. This regional anesthesia technique targets the femoral nerve, providing effective pain relief while reducing opioid requirements.
219197798|NCT06864455|BEHAVIORAL|Guided Imagery Meditation|Audio meditation by Sheri Menelli, for 10-14minutes
219197799|NCT06864455|BEHAVIORAL|Religious Recitation|listen to Surah Ar-Rahman for 14 minutes
219197800|NCT06864455|BEHAVIORAL|Infant Video with Music|10 minutes of slides show of infant's image and video
219197801|NCT06864455|BEHAVIORAL|Distraction with News and Media|10 minutes of phone use
219197802|NCT06864455|BEHAVIORAL|Control|All participants will ask to sit for 10minutes . Minimum distraction will be applied such as minimal or no chatting.
219197803|NCT01850849|DRUG|LEO 39652 cream|
218850192|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
218850193|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
218850194|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
218850195|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
218850196|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
218850197|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
218850198|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
219197804|NCT01850849|DRUG|cream vehicle|
219197805|NCT05941377|OTHER|blood pressure lowering|For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
219197806|NCT06542653|PROCEDURE|PCI|successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
219197807|NCT06542653|DRUG|OMT|optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
219197808|NCT06615843|DEVICE|Participants will receive post-emergency gynecological follow-up at home using a connected health app|The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
219197809|NCT02293954|PROCEDURE|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
219197810|NCT02293954|PROCEDURE|positron emission tomography|Undergo PET
219197811|NCT02293954|OTHER|laboratory biomarker analysis|Correlative studies
219197812|NCT02293954|OTHER|pharmacological study|Correlative studies
218850199|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
218850200|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
219197813|NCT02293954|DRUG|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
219197814|NCT06617195|OTHER|Exercise|Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
219197815|NCT01907126|BEHAVIORAL|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
219459700|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
219459701|NCT01644812|BEHAVIORAL|Aerobic exercise|
219459702|NCT01644812|BEHAVIORAL|Stretching|
219459703|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
219459704|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
219459705|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
219459706|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
219459707|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
218850201|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
218850202|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
218850203|NCT00777530|DRUG|Bosutinib (SKI-606)|
218850204|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
218850205|NCT05179668|DRUG|Placebo|administered orally once daily
218850206|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
219197816|NCT01907126|BEHAVIORAL|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
218850207|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
218850208|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
218850209|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
218850210|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
218850211|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
218850212|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
218850213|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
218850214|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
219197817|NCT04603911|DRUG|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
219197818|NCT04603911|DRUG|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
219197819|NCT05563584|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
219197820|NCT05475678|DRUG|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
219197821|NCT05475678|DRUG|TCb regimen|docetaxel + carboplatin regimen
219197822|NCT04869488|DRUG|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
219197823|NCT04869488|DRUG|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
219197824|NCT04869488|DRUG|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
219459708|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
219459709|NCT02736487|DEVICE|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
219592230|NCT01688570|DRUG|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
218850215|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
219459710|NCT02736487|DEVICE|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
219459711|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
219459712|NCT01634087|DRUG|Placebo|Placebo administered orally
219459713|NCT00580827|DRUG|Placebo|Matched placebo.
218850216|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
218850217|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
218850218|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
218850219|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
218850220|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
218850221|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
218850222|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
219197825|NCT03717623|DRUG|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
219197826|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
219459714|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
219459715|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
219459716|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
218850223|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
219197827|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
219197828|NCT06862895|OTHER|chest physiotherapy|Chest Physiotherapy is including various techniques, in this study classical CPT was used to be applied to participants
219197829|NCT06862479|PROCEDURE|Endoscopic management of fistulas with stents or vacum therapy|A prospective registry of patients who develop fistulas after oncologic surgery on the stomach or esophagus as well as those after bariatric surgery and managed endoscopically with stents or endoscopic vacuum therapy will be evaluated to assess and compare the efficacy and safety of the Luso-Cor versus conventional partially or fully covered metallic stents or bariatric stents or endoscopic vacuum therapy.
219197830|NCT06864663|DRUG|nerve block with bupivacaine 0.25%|ultrasound guided adductor canal block and interspace between the popliteal artery and the knee capsule using bupivacaine 0.25%
219197831|NCT06864663|DRUG|Nerve Block with bupivacaine 0.25%|ultrasound guided combined adductor canal block and genicular nerve block using bupivacaine 0.25%
219459717|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
219592231|NCT01688570|DRUG|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
219592232|NCT03077555|DRUG|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
219592233|NCT03077555|DRUG|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
218850224|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
218850225|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
218850226|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
218850227|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
218850228|NCT02346331|OTHER|Oxygen delivery|
218850229|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
218850230|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
218850231|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
218850232|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
219459718|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
219459719|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
219459720|NCT03481634|DRUG|Aflibercept|Intravitreal injection
219459721|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
219459722|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
219459723|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
219459724|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
219459725|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
219459726|NCT00994890|DRUG|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
219592234|NCT02362555|OTHER|no intervention was used in this observational study|
219592235|NCT00867997|OTHER|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
219197832|NCT06858410|DRUG|lorlatinib|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 36 months during the treatment phase.
219197833|NCT06858410|OTHER|concurrent/sequential platinum-based chemoradiotherapy|The choice of chemotherapy and will be determined by the investigator prior to treatment allocation and the radiotherapy also according to the clinical therapy regimen decided by the investigator.
218850233|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
219592236|NCT00867997|OTHER|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
218850234|NCT02795507|BEHAVIORAL|conventional exercises|
218850235|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
218850236|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
219459727|NCT00994890|DRUG|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
219459728|NCT00994890|DRUG|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
219459729|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
219592237|NCT00867997|OTHER|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
219459730|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
219592238|NCT03603379|DRUG|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
219592239|NCT05648461|RADIATION|Five fraction of post operative radiotherapy|Target volume will include tumor bed \& ipsilateral level I-III levels.
219592240|NCT00637650|PROCEDURE|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
219592241|NCT00637650|PROCEDURE|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
218850237|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
218850238|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
218850239|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
218850240|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
218850241|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
219197834|NCT06768983|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|10 sessions of remotely delivered CBT; each session is about 45 minutes in length. The aim of the sessions is to cultivate skills that promote activity and reduce fatigue and its impact on daily activities.
219197835|NCT03532672|OTHER|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
219197836|NCT06676267|PROCEDURE|Laparoscopic surgery|The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
219459731|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
219459732|NCT00089206|BIOLOGICAL|sargramostim|
219459733|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
219459734|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
219459735|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
219459736|NCT03323385|DRUG|N1539|Once Daily
219459737|NCT03323385|DRUG|Placebo|Once Daily
219459738|NCT00247962|DRUG|etanercept|50 mg
219459739|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
219459740|NCT02963194|DRUG|Oxytocin|
218850242|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
218850243|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
218850244|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
218850245|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
218850246|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
218850247|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
218850248|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
219197837|NCT04856384|OTHER|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
219459741|NCT02963194|DRUG|Placebo|
219459742|NCT01087229|DRUG|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
219459743|NCT01087229|DRUG|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
219459744|NCT02538705|DRUG|Neovasculgen|
219197838|NCT05008055|DRUG|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
218850249|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
219197839|NCT06250855|DEVICE|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
219197840|NCT04635059|DRUG|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
219197841|NCT06876792|DEVICE|electrical impedance tomography|Respiratory drive assessed by flow index measured by electrical impedance tomography.
219459745|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
219459746|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
219197842|NCT06527300|DRUG|NHWD-870 HCl|Administered P.O.
219459747|NCT02142075|DRUG|Daptomycin|
219459748|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
218850250|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
219197843|NCT06252779|DEVICE|Plasma therapy equipment|The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.
219197844|NCT06252779|DEVICE|Fake therapeutic device|False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
219459749|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
219459750|NCT01469637|DRUG|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
219459751|NCT01469637|DRUG|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
219459752|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
219459753|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
219459754|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
219459755|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
218850251|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
218850252|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
218850253|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
218850254|NCT00395291|DRUG|Placebo|Placebo
218850255|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
218850256|NCT02390674|DRUG|Saline|
218850257|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
218850258|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
219197845|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
219459756|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
219459757|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
219459758|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
218850259|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
219197846|NCT00640822|DRUG|Tacalcitol Ointment|Once daily application for up to 8 weeks
218850260|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
218850261|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
218850262|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
219197847|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
219197848|NCT03248479|DRUG|Magrolimab|Administered intravenously
219197849|NCT03248479|DRUG|Azacitidine|Administered according to region-specific drug labeling either subcutaneously or intravenously
219197850|NCT06170814|OTHER|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
219197851|NCT04980924|OTHER|no intervention|no intervention
219459759|NCT02872090|DRUG|Indacaterol|inhalation
219459760|NCT02872090|DRUG|Glycopyrronium|inhalation
219459761|NCT02872090|DRUG|Tiotropium|inhalation
219459762|NCT02872090|DRUG|Placebo|
219459763|NCT02872090|PROCEDURE|photoplethysmography|inhalation
219459764|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
219459765|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
219459766|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
219459767|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
219592242|NCT03045991|BEHAVIORAL|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
218850263|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
218850264|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
218850265|NCT02093988|DRUG|Topical TXA|
218850266|NCT02093988|DRUG|Intravenous TXA|
218850267|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
218850268|NCT00199251|DRUG|RUPATADINE|
219197852|NCT01999361|DRUG|Myfortic|treatment with myfortic
219197853|NCT04699773|PROCEDURE|LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
219459768|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
219459769|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
219459770|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
219459771|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
219459772|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
219459773|NCT00846352|PROCEDURE|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
219459774|NCT05476757|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
219459775|NCT00923962|DRUG|Glucagon like peptide-1|0,1 pmol/kg/min
219459776|NCT00923962|DRUG|Adenosine|20-40 microgram/minute
219459777|NCT04275492|DRUG|Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)|Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
219459778|NCT04275492|DRUG|Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)|Siforl® is produced by Boehringer Ingelheim International Gmbh
219459779|NCT01983046|DRUG|Three different mixture of acetate, butyrate and propionate and palcebo|
219459780|NCT01525108|BEHAVIORAL|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
219459781|NCT01525108|OTHER|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
219592243|NCT03045991|BEHAVIORAL|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
219592244|NCT03045991|BEHAVIORAL|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
219592245|NCT06396065|DRUG|AK112 Injection|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
219592246|NCT06396065|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
218850269|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
219592247|NCT06123923|OTHER|no intervention|no intervention, just retrospective observation
219592248|NCT02549235|OTHER|Ultrasound|Routine 2D/3D ultrasound assessment
219592249|NCT03603548|DRUG|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
219592250|NCT03603548|DRUG|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
219592251|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
219592252|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|"These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
218850270|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
219459782|NCT06404229|DIAGNOSTIC_TEST|CardioPulmonary Exercise Testing|CardioPulmonary Exercise Testing using an arm ergometer prior to surgery
218850271|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
218850272|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
218850273|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
218850274|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
218850275|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
219459783|NCT00604357|DRUG|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
219459784|NCT00199368|DRUG|Istradefylline ( KW-6002)|
219459785|NCT01641341|DRUG|Bifidobacterium infantis|once a day for seven to eight weeks
219459786|NCT01641341|DRUG|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
219459787|NCT01641341|DRUG|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
219459788|NCT01641341|DRUG|Placebo|Placebo capsule will not contain active treatment ingredients.
219459789|NCT00641745|DRUG|Lurasidone HCl|40 - 120mg per day
219459790|NCT00641745|DRUG|Risperidone|Risperidone
219459791|NCT05917392|DIETARY_SUPPLEMENT|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
219459792|NCT05917392|DIETARY_SUPPLEMENT|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
219459793|NCT05917392|DIETARY_SUPPLEMENT|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
219459794|NCT03494946|PROCEDURE|Liver transplantation|
219459795|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
219459796|NCT03542890|DEVICE|Baska Mask|used in adult low risk females undergoing elective gynecological operations
219459797|NCT03542890|DEVICE|I-gel|used in adult low risk females undergoing elective gynecological operations
219459798|NCT04995731|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
219459799|NCT04995731|PROCEDURE|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
219459800|NCT01875068|BEHAVIORAL|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
219459801|NCT01875068|BEHAVIORAL|versus NPs and PAs who are not required to discuss patient referrals (control group).|
219459802|NCT05212467|BEHAVIORAL|AIR-program|This is a guided self management program that is added on the treatment as usual.
219459803|NCT05212467|BEHAVIORAL|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
219459804|NCT05212467|BEHAVIORAL|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
219459805|NCT05692986|DIAGNOSTIC_TEST|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of \>5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
219459806|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
218850276|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
219459807|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
218850277|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
218850278|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
219197854|NCT04699773|RADIATION|Hypofractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
219459808|NCT03518463|COMBINATION_PRODUCT|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
219459809|NCT02162264|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
219459810|NCT01701349|DRUG|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
219459811|NCT01701349|DRUG|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
219459812|NCT06279052|BEHAVIORAL|Phone interview|Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
219459813|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
218850279|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
219459814|NCT00804128|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
218850280|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
218850281|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
218850282|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
218850283|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
218850284|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
219459815|NCT00804128|DRUG|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
219459816|NCT04700228|DRUG|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
219459817|NCT04700228|DRUG|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
219459818|NCT05422833|OTHER|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
219459819|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
219459820|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
219459821|NCT05141344|DRUG|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
219459822|NCT05141344|DRUG|Placebo|sugar-coated tablets will be given one hour preoperatively
219459823|NCT02943044|DEVICE|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
219459824|NCT05554744|PROCEDURE|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
219459825|NCT00420212|DRUG|BG00012|
219592253|NCT05607641|DRUG|Neospastil, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day."
219592254|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months"
218850285|NCT00002114|DRUG|Procysteine|
219459826|NCT00420212|DRUG|Placebo|
219459827|NCT03934489|BEHAVIORAL|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
219459828|NCT03934489|BEHAVIORAL|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
219459829|NCT01499212|PROCEDURE|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
219592255|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months"
219592256|NCT00269243|DRUG|Quinapril|
219592257|NCT00006019|DRUG|azacitidine|
219592258|NCT00006019|DRUG|sodium phenylbutyrate|
219459830|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
219459831|NCT03449186|OTHER|Saliva collection|
219459832|NCT03449186|OTHER|GCF collection|
219459833|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
218850286|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
218850287|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
218850288|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
219459834|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
219459835|NCT06446050|BIOLOGICAL|MSC-L|Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
219459836|NCT05405855|BEHAVIORAL|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
219459837|NCT04111185|DEVICE|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
219459838|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
218850289|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
218850290|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
218850291|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
219459839|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
219459840|NCT05616052|DRUG|Semaglutide|treatment with different dosage regimes
219459841|NCT06296043|PROCEDURE|Progressive Muscle Relaxation Exercise Group|Exercise Group
219459842|NCT06296043|PROCEDURE|Su-Jok Intervention|Hand massage with seeds
219459843|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
219592259|NCT06200324|OTHER|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
219592260|NCT03821181|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219592261|NCT03821181|DEVICE|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
219592262|NCT06633575|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
219592263|NCT03344861|DRUG|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
219592264|NCT03344861|DEVICE|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
218850292|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
218850293|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
218850294|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
218850295|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
219197855|NCT06253871|DRUG|IAM1363|Oral, immediate release capsules of IAM1363
219459844|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
219459845|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
219459846|NCT00742391|DRUG|Vehicle gel|two day treatment
219592265|NCT03462979|DEVICE|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
219592266|NCT01117493|BEHAVIORAL|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
218850296|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
218850297|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
219459847|NCT06049628|BEHAVIORAL|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
219459848|NCT06049628|BEHAVIORAL|routine program|This program consists of jogging, and stretching exercises.
219459849|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
219459850|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
219592267|NCT01117493|BEHAVIORAL|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
219592268|NCT04642365|DRUG|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
219592269|NCT04642365|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
219592270|NCT06982755|PROCEDURE|acupuncture|acupuncture at Zusanli (ST36); sample size: 44
218850298|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
218850299|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
218850300|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
218850301|NCT00081315|DRUG|Amifostine|
218850302|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
218850303|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
218850304|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
218850305|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
218850306|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
218850307|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
218850308|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
218850309|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
218850310|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
218850311|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
218850312|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
218850313|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
219197856|NCT04262830|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
219197857|NCT04262830|OTHER|Accelerometer physical activity monitoring|Measurement of physical activity using hip-worn accelerometer.
219459851|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
218850317|NCT00004206|DRUG|FOLFOX regimen|
218850318|NCT00004206|DRUG|fluorouracil|
219459852|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
219459853|NCT01706744|OTHER|Intermediate care unit|
219592271|NCT06982755|DRUG|compound diclofenac sodium|intramuscular injection of compound diclofenac sodium injection; sample size: 44
219592272|NCT06982755|COMBINATION_PRODUCT|acupuncture combined with compound diclofenac sodium|acupuncture at Zusanli (ST36) and intramuscular injection of compound diclofenac sodium injection; sample size: 44
218850319|NCT00004206|DRUG|leucovorin calcium|
218850320|NCT00004206|DRUG|oxaliplatin|
218850321|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
218850322|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
219459854|NCT01706744|OTHER|Local health care 1|
219459855|NCT01706744|OTHER|Local health care 2|
219459856|NCT01834469|DRUG|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
219459857|NCT02239562|DRUG|sPIF|
219459858|NCT02239562|DRUG|Placebo|
219459859|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
219459860|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
219459861|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
219459862|NCT00021281|DRUG|FOLFIRI regimen|
219459863|NCT00021281|DRUG|fluorouracil|
219459864|NCT00021281|DRUG|irinotecan hydrochloride|
219459865|NCT00021281|DRUG|leucovorin calcium|
219592273|NCT06982755|COMBINATION_PRODUCT|placebo|superficial acupuncture at Zusanli (ST36) and intramuscular injection of normal saline; sample size: 44
218850323|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
218850324|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
218850325|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
219459866|NCT00021281|DRUG|semaxanib|
219459867|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
219459868|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
219459869|NCT00600236|PROCEDURE|blood sample|
219592274|NCT05521659|OTHER|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
219592275|NCT04290195|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
219592276|NCT06988917|BEHAVIORAL|the regular rehabilitation program|Each training session consists of a 10-minute warm-up (including power cycling, full-body stretching, etc.) At the same time, use the foam axis to relax the lateral oblique femoris and iliotibial band to relieve the pressure on the lateral side of the patella), 40 minutes of formal training (including wall squats with a ball, straight leg raising resistance training, terminal resistance knee extension training, bench kick ball clamping training, and balance training), and 10 minutes of relaxation (using a foam roller, foam axis and other combined techniques to relax the muscles Especially for the lower limb muscles such as the lateral femoris, iliotibial band, and tibialis anterior muscle.
218850326|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
218850327|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
218850328|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
218850329|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
218850330|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
219197858|NCT06316882|DIAGNOSTIC_TEST|Screening endoscopy|We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
218850331|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
218850332|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
218850333|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
218850334|NCT05134662|DRUG|ALT-801|Injected subcutaneously (SC)
219197859|NCT05650996|BEHAVIORAL|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
219197860|NCT05650996|BEHAVIORAL|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
219197861|NCT05211050|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
219197862|NCT05211050|DRUG|Sumatriptan|10 min infusion of 4 mg sumatriptan.
219197863|NCT05211050|DRUG|Saline|10 min infusion of isotonic saline (placebo).
218850335|NCT05134662|OTHER|Placebo|Injected subcutaneously (SC)
218850336|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
218850337|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
219459870|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
219459871|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
219459872|NCT00497159|OTHER|Placebo|Placebo TID x 90 days
219459873|NCT00497159|DRUG|Dimebon|Dimebon 20 mg TID x 90 days
218850338|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
218850339|NCT00262678|DRUG|EN3267|
219459874|NCT04383535|OTHER|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
219459875|NCT04383535|OTHER|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
219459876|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
219459877|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
219459878|NCT00381472|DRUG|Ropinirole|
219459879|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
219459880|NCT05557240|DRUG|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
219459881|NCT05557240|DRUG|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
218850340|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
218850341|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
219197864|NCT06859619|OTHER|Peripheral venous blood sample|Peripheral venous blood sampling for IgG serology against leishmaniasis, leptospirosis, brucellosis, Q fever, rickettsiosis, tularemia, psittacosis, Lyme disease, tick-borne encephalitis, hantavirus, hepatitis E virus, dengue virus, Zika virus, Chikungunya virus, West Nile virus, Usutu virus, Toscana virus, Crimean-Congo hemorrhagic fever virus.
219197865|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
219197866|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
219197867|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
219197868|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
219197869|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
219197870|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
218850342|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
218850343|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
219197871|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
219197872|NCT06598644|OTHER|Cervical SNAGS (C3-C7) + Conventional PT|Cervical SNAGS at C3-C7 with active movements of lateral flexion and rotation with overpressure at the end range. .Frequency: 10 reps 3 times/week for 3 consecutive weeks Intensity: starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-hot pack for 10 minutes 2-Cervical Stretchings for levator scapulae and sternocleidomastoid 3-cervical isometric exercises, 4. Cervical Range of motion exercises
219197873|NCT06598644|OTHER|IASTM (ergon) + Conventional PT|IASTM, ergon applied at levator scapulae and sternocleidomastoid muscle, with 30 strokes at an angle. After that icing done at the levator scapulae and sternocleidomastoid muscle for 5-10 minutes using cold pack.
219197874|NCT06863064|DRUG|Dexmedetomidine|During the surgery, target-controlled infusion (TCI) pumps were used, employing the Dyck model for continuous infusion of propofol, with the target plasma concentration maintained at 0.2 ng/ml. Postoperatively, propofol was infused at a rate of 0.2-0.4 mcg/kg/hr according to the intensive care unit's protocol, until the patient had the endotracheal tube removed.
219197875|NCT06863064|DRUG|Normal Saline|During the surgery, equal volumes of saline were injected. After the surgery, the patient was transferred to the intensive care unit, where propofol was continuously infused at a rate of 0.2-0.4 mcg/kg/hr according to the ICU protocol, until the endotracheal tube was removed.
219197876|NCT06865300|DRUG|Lidocain 40 mg|We injected 40 mg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
219197877|NCT06865300|DRUG|lidocain 1 mg/kg|We injected 1 mg/kg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
219197878|NCT06865300|DRUG|serum physiologic|We injected serum physiologic before rocuronium injection. Then we recorded pain score by using visual analog scale.
219197879|NCT06864364|OTHER|CGM feedback visualization|The subject will have CGM feedback visualization
219459882|NCT02633917|BEHAVIORAL|Motor control exercises|exercises to strength the lumbar musculature and control the posture
219459883|NCT02633917|BEHAVIORAL|Standard exercises|general exercises
219592277|NCT06988917|DEVICE|The blood flow limiting pressure band|The experimental group (LL-BFRT group) wore a flow-limiting pressure band for exercise during routine rehabilitation training. The blood flow limiting pressure band used in this study mainly consists of a 109\*10cm leg pressure band, a barometric display dial with a pressure range of 0-300mmHg, and a pressure pump. In the experiment, we fixed the blood flow restriction pressure band in the area for measuring the circumference and adjusted the blood flow restriction pressure according to the thigh circumference of the subjects to maintain it within the range of 40%-60% arterial occlusion pressure. The way to limit blood flow is intermittent inflation, that is, during the intervals of muscle strength training, the cuff deflation operation is carried out simultaneously.
219592278|NCT06990282|OTHER|microneedling|gingival microneedling (small holes in gingiva)
219197880|NCT06864364|DIETARY_SUPPLEMENT|milk supplemented with mulberry leaves extract|milk supplemented with mulberry leaves extract
219197881|NCT06864364|OTHER|blinded CGM feedback visualization|The subject will have blinded CGM feedback visualization
219592279|NCT06990282|OTHER|scaling|scaling (plaque removal)
218850344|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
218850345|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
218850346|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
219197882|NCT06862466|OTHER|Education intervention|Knowledge, Attitude, and Practice Questionnaire (KAPQ) Regarding Renal Nutrition will be used to collect the data at baseline, after the intervention, and three months follow-up, which is adjusted for clustering.
219197883|NCT06864702|BEHAVIORAL|Whether the patient received diagnosis and treatment at Zhujiang Hospital of Southern Medical University and retained medical images such as abdominal|The construction of a deep learning model for semantic segmentation of images during laparoscopic hepatobiliary and pancreatic surgery, focusing on classifying surgical stages, anatomical structures, surgical instruments, and surgical gestures, along with the validation of model performance (Intersection over Union, Dice score, accuracy, precision, recall, and F1 score).
219197884|NCT06863077|PROCEDURE|MCL Pie-Crusting|Percutaneous MCL Pie-Crusting
219197885|NCT03735979|DRUG|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
219197886|NCT03735979|DRUG|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
219197887|NCT03735979|DRUG|Placebo|IV placebo solution
219197888|NCT06862544|DEVICE|Smartwatch (Withings Scanwatch 2)|All-day monitoring of patients via smartwatch and migraine diary app
219197889|NCT05921201|BEHAVIORAL|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
219197890|NCT02531542|DEVICE|Echocardiography according to the READ method.|"* Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
219459884|NCT01981096|BEHAVIORAL|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
219459885|NCT01981096|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
219459886|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
219592280|NCT06990282|BIOLOGICAL|Ozonated olive oil|ozonated olive oil after microneedling
219592281|NCT06990633|DIAGNOSTIC_TEST|diagnostic test|"Group 1: MMR-Proficient Group Label: MMR-Proficient~Description: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.~Type: Observational Group~Group 2: dMMR Group Label: dMMR~Description: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.~Type: Observational Group"
219592282|NCT06988826|DRUG|G-CSF|G-CSF \& Antibiotic therapy in combination
219592283|NCT06988826|DRUG|Antibiotics only|Antibiotics alone
219592284|NCT06914154|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
218850347|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
219197891|NCT06618872|DIAGNOSTIC_TEST|PET/CT with RO958 (experimental)|the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)
219197892|NCT06861192|DRUG|Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy|On the 1st to 5th day, Fasudil hydrochloride (10mg of fasudil hydrochloride) was treated, and on the 5th day, PD-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip) was treated. The treatment was repeated every 21 days for a total of 4 times
219459887|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
219459888|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
219459889|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
219459890|NCT04322266|DRUG|HGP0904|Amlodipine
219459891|NCT04322266|DRUG|HGP0608|Losartan potassium
219459892|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
219459893|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
219197893|NCT06861192|DRUG|Placebo combined with androgen deprivation therapy|Days 1 to 5 were treated with placebo (0.9% sodium chloride 10mg), and days 5 were treated with placebo (0.9% sodium chloride 3mg/kg). The treatment was repeated every 21 days for a total of 4 times.
219197894|NCT06861192|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle
219197895|NCT06868095|OTHER|Surgical resection|Histologically confirmed EOCRC
219197896|NCT06867250|DIAGNOSTIC_TEST|The patients' periodontal clinical parameters were recorded. PISF samples were collected, and the evaluations of 25(OH)D and LL-37 were conducted using enzyme-linked immunosorbent assay.|In vitro studies have shown that vitamin D promotes the release of antimicrobial peptides from gingival epithelial cells, no clinical research has specifically examined its effect on LL-37 levels in peri-implant tissue diseases. This study seeks to investigate the relationship between vitamin D levels in peri-implant sulcus fluid and clinical parameters in individuals with both peri-implant health and disease. Additionally, it aims to assess the correlation between vitamin D and the antimicrobial peptide LL-37.
218850348|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
219197897|NCT06865508|DEVICE|Laser therapy|Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].
219197898|NCT06865508|DEVICE|zinc oxide eugenol dressing.|zinc oxide eugenol dressing.
219197899|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
219197900|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
219197901|NCT04930783|DRUG|CDX-301|Administered as an injection given underneath the skin
219197902|NCT04930783|BIOLOGICAL|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
219197903|NCT04930783|DRUG|Nivolumab|Administered intravenously (IV)
219197904|NCT04930783|DRUG|Pembrolizumab|Administered intravenously (IV)
219197905|NCT06865833|OTHER|Tai Chi and Relaxation Intervention|"This Tai Chi and Relaxation Intervention specifically targets adolescents with chronic somatoform disorders, utilizing a combination of mind-body practices designed to reduce pain and alleviate psychological distress. The intervention is distinct in the following ways:~Target Population: It focuses specifically on adolescents aged 12-19 years experiencing unexplained physical symptoms, such as chronic pain, headaches, and fatigue, that are not attributable to any identifiable medical condition.~Non-pharmacological Approach: Unlike traditional medical treatments that may involve medications or invasive procedures, this intervention is entirely non-medical, aiming to address both the physical and psychological aspects of chronic somatoform disorders without using drugs.~Structured Workshops: The intervention consists of weekly Tai Chi and relaxation workshops (1 hour 15 minutes per session) over a 5-week period. The approach emphasizes gentle, controlled movements, relaxation techniqu"
219197906|NCT04621006|DIAGNOSTIC_TEST|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
219197907|NCT06674980|OTHER|Standard of Care - DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219197908|NCT06674980|OTHER|AM/Single - DFU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219197909|NCT06674980|OTHER|AM/Double - DFU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219459894|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
219592285|NCT06914154|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
219592286|NCT06981988|DRUG|Linperlisib ； Rituximab|Linperlisib ； Rituximab
219459895|NCT00293319|BIOLOGICAL|filgrastim|
219459896|NCT00293319|RADIATION|iobenguane I 131|
219459897|NCT03973502|DRUG|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
219459898|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
219459899|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
219459900|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
219459901|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
219592287|NCT02519738|DRUG|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
219459902|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
219459903|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
219459904|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
219459905|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
219459906|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
219459907|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
219459908|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
219459909|NCT01225211|DRUG|Lumacaftor|Tablet
219459910|NCT01225211|DRUG|Ivacaftor|Tablet.
219459911|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
219459912|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
219592288|NCT02519738|DRUG|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
219592289|NCT02519738|OTHER|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
219592290|NCT03715075|PROCEDURE|Caesarean Section|Caesarean Section
219592291|NCT00375349|PROCEDURE|Ultrasound to demonstrate existence of fatty liver|
219592292|NCT00469911|PROCEDURE|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
219592293|NCT00469911|PROCEDURE|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
219592294|NCT06633471|DRUG|Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).|Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
219592295|NCT02854111|OTHER|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
219592296|NCT02854111|OTHER|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
219592297|NCT02149329|DRUG|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
219592298|NCT00527865|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
219592299|NCT00527865|DRUG|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
219592300|NCT04445363|DRUG|Jaktinib hydrochloride cream|Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
219592301|NCT04445363|DRUG|Placebo|Dose extension: Placebo
219592302|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
219592303|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
219592304|NCT01659086|BIOLOGICAL|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
219592305|NCT01199679|PROCEDURE|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
219592306|NCT01199679|PROCEDURE|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
219592307|NCT03688438|DEVICE|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
219592308|NCT00275938|DRUG|interferon alpha 2b plus ribavirin|
219592309|NCT00275938|DRUG|interferon alpha 2b plus placebo|
219592310|NCT01912027|PROCEDURE|Open Latarjet technique|
219592311|NCT01912027|PROCEDURE|Arthroscopic Latarjet techniques|
219592312|NCT00086827|DRUG|romidepsin|Given IV
219592313|NCT00086827|OTHER|laboratory biomarker analysis|Correlative studies
219459913|NCT00807989|DRUG|Carbamazepine|
219459914|NCT00807989|DRUG|Lamotrigine/Valproate|
219459915|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
219459916|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
219459917|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
219459918|NCT02619929|DRUG|Vinorelbine oral|
219592314|NCT00611273|DEVICE|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
219592315|NCT01841476|DRUG|POL6326|
219197910|NCT06674980|OTHER|Standard of Care - VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219197911|NCT06674980|OTHER|AM/Single - VLU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219197912|NCT06674980|OTHER|AM/Double - VLU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219197913|NCT05958927|OTHER|tear test and eye measurement|tear test and eye measurement
218850349|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
218850350|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
218850351|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
218850352|NCT06112288|OTHER|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
218850353|NCT06112288|OTHER|Ankle mobilisation|ankle mobilization is manual therapy technics.
218850354|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
219197914|NCT06071013|DRUG|Nintedanib, gefitinib, erlotinib, afatinib, osimertinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
219459919|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
219459920|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
219459921|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
219459922|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
219459923|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
219459924|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
219459925|NCT01893879|DRUG|placebo for study drug|Given PO
218850355|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
219459926|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
219459927|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
219459928|NCT00075413|DRUG|arsenic trioxide|
219592316|NCT05009680|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
219459929|NCT00002336|DRUG|Clarithromycin|
219459930|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
219459931|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
219459932|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
219459933|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
219459934|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219459935|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219592317|NCT05009680|DRUG|Placebo|Placebo is administered orally twice a day
219592318|NCT00561704|DRUG|losartan|losartan, 100mg daily,
218850356|NCT05897970|DIAGNOSTIC_TEST|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
219592319|NCT05009914|PROCEDURE|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
219459936|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219459937|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219459938|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219459939|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
219459940|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
219459941|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
219459942|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
219459943|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
219592320|NCT02292173|DRUG|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
219592321|NCT02292173|DRUG|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
219592322|NCT00683631|OTHER|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
219592323|NCT04720131|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
219592324|NCT04720131|DRUG|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
219592325|NCT04720131|DRUG|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
218850357|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
218850358|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
219459944|NCT01520675|PROCEDURE|surgery|Drainage procedure
219459945|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
219459946|NCT04904991|PROCEDURE|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
219459947|NCT01579162|DEVICE|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
219459948|NCT02355665|DRUG|Nicotine Spray|Nicotine Spray
219459949|NCT02355665|DRUG|Placebo|Placebo to match nicotine spray
219459950|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
219459951|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
219592326|NCT00664131|OTHER|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
219592327|NCT00107510|BIOLOGICAL|pegfilgrastim|
219592328|NCT00107510|DRUG|carboplatin|
219592329|NCT00107510|DRUG|docetaxel|
219592330|NCT00107510|PROCEDURE|conventional surgery|
219592331|NCT02293369|PROCEDURE|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
219592332|NCT02293369|PROCEDURE|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
219592333|NCT05204836|DRUG|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
219592334|NCT05204836|DRUG|Placebo|100 mL intravenous infusion
218850359|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
218850360|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
218850361|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
218850362|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
219459952|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
219459953|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
219459954|NCT01209117|DRUG|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
219459955|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
219459956|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
219197915|NCT06613516|DRUG|Capivasertib|Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg
219459957|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
219459958|NCT01209117|DRUG|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
219459959|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
219459960|NCT05312099|OTHER|Case control|Case control study
219459961|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
219459962|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
219459963|NCT04034069|DEVICE|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
219459964|NCT04034069|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
219592335|NCT03619681|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
219592336|NCT02099682|DRUG|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
219592337|NCT05141331|DEVICE|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
219592338|NCT02553031|DEVICE|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
219592339|NCT03874286|DIAGNOSTIC_TEST|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
218850363|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
218850364|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
218850365|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
219592340|NCT06731101|DRUG|Bupivacaine + Lidocaine +dexamethasone|Sonar guided block of Stellate Ganglion By Bupivacaine + Lidocaine
219592341|NCT06731101|DRUG|Tryptizole + Librax|Tryptizole + Librax
218850366|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
219459965|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
219459966|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
219459967|NCT02993289|OTHER|Different well-known treatments|
219459968|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
219459969|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
219459970|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
219459971|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
219459972|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
219459973|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
219459974|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
219459975|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
219459976|NCT03458234|DEVICE|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
218850367|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
218850368|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
218850369|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
218850370|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
218850371|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
218850372|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
218850373|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
219459977|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
219459978|NCT00432354|DRUG|atorvastatin|
219459979|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
218850374|NCT02937077|DEVICE|Medtronic Reveal LINQ|
218850375|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
218850376|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
218850377|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
219459980|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
219459981|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
219459982|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
219459983|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
219459984|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
219459985|NCT01354964|DRUG|Vitamin D|
219459986|NCT01354964|DRUG|Placebo|
219459987|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
218850378|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
218850379|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
219197916|NCT04956549|BEHAVIORAL|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
218850380|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
218850381|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
218850382|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
218850383|NCT01933438|OTHER|Control|Standard treatment
218850384|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
218850385|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
218850386|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
218850387|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
218850388|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
218850389|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
218850390|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
219459988|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
219459989|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
218850391|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
218850392|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
218850393|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
218850394|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
219459990|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
219459991|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
219459992|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
219459993|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
219459994|NCT03539666|OTHER|diet|dietary patterns
219459995|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
219459996|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
219459997|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
219459998|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219459999|NCT01319539|OTHER|Pharmacological Study|Correlative studies
219460000|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
219460001|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
219460002|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
219460003|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
219460004|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
218850395|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
218850396|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
218850397|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
219197917|NCT04956549|BEHAVIORAL|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
218850398|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
218850399|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
218850400|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
219197918|NCT05687344|DRUG|Nifedipine ER|Postpartum BP treatment to \<140/90 mmHg
219592342|NCT04001127|OTHER|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
219460005|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
219460006|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
219460007|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
219460008|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
219460009|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
219592343|NCT00699062|DRUG|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
219592344|NCT00699062|DRUG|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
219592345|NCT04810130|OTHER|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
219592346|NCT04810130|OTHER|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
218850401|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
218850402|NCT00900679|BEHAVIORAL|telephone-based intervention|
218850403|NCT00900679|OTHER|counseling intervention|
218850404|NCT00900679|OTHER|educational intervention|
218850405|NCT00900679|OTHER|medical chart review|
218850406|NCT00900679|OTHER|questionnaire administration|
219197919|NCT00319111|DRUG|bosentan|"Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)"
218850407|NCT00900679|PROCEDURE|psychosocial assessment and care|
219197920|NCT06087952|OTHER|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
219460010|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
219460011|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
219460012|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
218850408|NCT00900679|PROCEDURE|quality-of-life assessment|
218850409|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
219592347|NCT04810130|OTHER|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
219460013|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
219460014|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
219460015|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
219460016|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
219592348|NCT02929186|BEHAVIORAL|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
219592349|NCT02929186|BEHAVIORAL|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
219592350|NCT03515590|OTHER|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
219592351|NCT03515590|OTHER|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
219592352|NCT04941118|DRUG|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
219592353|NCT04941118|DRUG|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
219592354|NCT01909830|DRUG|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
219592355|NCT00124761|PROCEDURE|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
219592356|NCT00124761|RADIATION|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
219592357|NCT05653284|DRUG|AK130|IV infusion, specified dose on specified days.
219592358|NCT06739993|BEHAVIORAL|Resonance frequency breathing with heart rate variability biofeedback training|During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds. When the participants achieved the specified breathing frequency, resulting in an increased sinus arrhythmia, the symbols appearing on the smartphone display were green. When the participants did not achieve the specified breathing frequency, the symbols appeared in yellow (non-significant deviation), orange (significant deviation), or red (very significant deviation). The participants were instructed to adjust their breathing frequency to reach emergence of as many green symbols as possible for the entire training session.
218850410|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
219592359|NCT06739993|BEHAVIORAL|Anti-Stress program|The mobile system eSense Pulse from Mindfield Biosystems is used for the digital anti-stress program. To do this, the participants put on a chest strap with a sensor and can start training via the eSense app. The anti-stress program is carried out using a procedure generated for the study. During the anti-stress program units, the participants receive application-related information and tips to better understand the topic of stress, identify stressors in their own lives and reduce stress. The active control intervention of the anti-stress program was selected to investigate the effect of a specific stress level reduction without the direct modulation of physiological mechanisms of action as with HRV-BF-RFA.
219592360|NCT06754176|BEHAVIORAL|Alcohol Consumption Randomized Instructions|"Alcohol Avoidance: In this intervention assignment, participants will be instructed to avoid drinking alcohol for this day.~Alcohol Non-Avoidance: In this intervention assignment, participants will be allowed to drink alcohol for this day."
219460017|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
219460018|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
219460019|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
219460020|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
219460021|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
219460022|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
219460023|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
219460024|NCT00188162|DEVICE|CT|
219460025|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
219460026|NCT04450394|DRUG|LY3209590|Administered SC
219460027|NCT04450394|DRUG|Insulin Degludec|Administered SC
219460028|NCT02327182|DRUG|MT-4666|
219460029|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
219460030|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
219197921|NCT06087952|DIAGNOSTIC_TEST|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
219197922|NCT06087952|DIAGNOSTIC_TEST|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
219460031|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
219460032|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
219460033|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
219460034|NCT00124696|DRUG|Cocaethylene|
219197923|NCT06087952|OTHER|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
219197924|NCT06087952|OTHER|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
219197925|NCT06746961|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg , iv, q3w
219197926|NCT06746961|DRUG|Lenvatinib|8 mg or 12 mg QD via oral capsule
219197927|NCT03030066|DRUG|DS-1001b|Generic not assigned
219460035|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
219460036|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
219460037|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
219460038|NCT00374764|DRUG|Risperidone|
219460039|NCT00374764|BEHAVIORAL|ABA|
219460040|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
219460041|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
219460042|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
219460043|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
219197928|NCT06392945|DEVICE|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.
218850411|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
219460044|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
219460045|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
219460046|NCT01434498|DRUG|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
218850412|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
218850413|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
218850414|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
219460047|NCT01434498|DRUG|GS-9451 tablet|GS-9451 tablet, 200 mg QD
219460048|NCT01434498|DRUG|tegobuvir capsule|tegobuvir capsule, 30 mg BID
219460049|NCT01434498|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
219460050|NCT01434498|DRUG|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
218850415|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
219460051|NCT01434498|DEVICE|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
219460052|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
219460053|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
218850416|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
218850417|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
218850418|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
218850419|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
218850420|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
218850421|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
219592361|NCT04815889|BEHAVIORAL|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~* Web courses"
219592362|NCT06901336|DRUG|[14C]-STX-478|oral administration
218850422|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
218850423|NCT03784599|DRUG|Osimertinib|Tablet
218850424|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
218850425|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
218850426|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
218850427|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
219460054|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
219460055|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
219460056|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
219460057|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219460058|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219460059|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219460060|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219197929|NCT06392945|DEVICE|Cognitive Treadmill Walking Training (CTW) group|Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.
219197930|NCT06392945|DEVICE|Treadmill Walking Training (TW)|Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
219460061|NCT00002176|DRUG|Hydroxyurea|
219460062|NCT00002176|DRUG|Nelfinavir mesylate|
219460063|NCT00002176|DRUG|Stavudine|
219460064|NCT00002176|DRUG|Didanosine|
218850428|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
218850429|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
219460065|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
219460066|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
219460067|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
219460068|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
218850430|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
218850431|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
218850432|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
218850433|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
218850434|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
219460069|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
219460070|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
219460071|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
219460072|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
219460073|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
219460074|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
219460075|NCT00153699|DRUG|Topiramate|
219460076|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219460077|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219460078|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219460079|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219460080|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
218850435|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
218850436|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
218850437|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
219460081|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
219460082|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
219460083|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
219460084|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
219460085|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
219460086|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
219460087|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
219460088|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
219460089|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
219460090|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
219460091|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
219460092|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
219460093|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
219460094|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
219460095|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
218850438|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
219460096|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
219460097|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
219460098|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
219460099|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
219460100|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
218850439|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
218850440|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
218850441|NCT00642369|DRUG|haloperidol|6-40mg/day
218850442|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
218850443|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
218850444|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
219460101|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
219460102|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
219197931|NCT06858254|BIOLOGICAL|Autologous mesenchymal stem cells|"1. Participant's blood is drawn at the start of each visit.~2. Bone marrow aspirate is drawn from the posterior aspect of the pelvis and is subsequently harvested and processed.~3. The following procedures are administered in a crossover design (Day 0 and 6 months):~   * Intranasal bone marrow aspirate administration (INA BMAC) OR Sham INA~  * Intravenous bone marrow aspirate administration (IV BMA) OR Sham IVA~4. At 12 months, all participants receive IV BMA + INA BMAC"
219460103|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
219460104|NCT03934333|DRUG|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
219460105|NCT03934333|DRUG|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
219460106|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
219460107|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
219460108|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
219460109|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
219460110|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
219197932|NCT02243852|DRUG|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
219197933|NCT05138848|BEHAVIORAL|Time in Bed Restriction|Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.
219197934|NCT05138848|BEHAVIORAL|Sleep Schedule|Participants will maintain their typical sleep schedule for 4-weeks.
219197935|NCT03946358|BIOLOGICAL|Blood sample collection|"Four blood samples will be collected at:~* baseline~* 2 months from inclusion (+/- 1 week)~* 4 months from inclusion (+/- 1 week)~* the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
219197936|NCT03946358|PROCEDURE|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
219460111|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
219592363|NCT05132036|OTHER|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
219197937|NCT03946358|OTHER|CT scan|"A CT scan will be planned~* at baseline~* at tumor evaluation visit (8 weeks)~* every 8 weeks (+/- 1 week)~* at end of treatment visit."
219197938|NCT03946358|DRUG|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
219197939|NCT03946358|DRUG|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
219460112|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
219460113|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
219460114|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
219460115|NCT00133640|DRUG|cholecalciferol|
219460116|NCT00133640|BEHAVIORAL|Physiotherapy|
219460117|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
219460118|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
219460119|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
219592364|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
219592365|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
218850445|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
218850446|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
218850447|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
218850448|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
218850449|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
218850450|NCT03582553|OTHER|Placebo|Cellulose
219460120|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
219460121|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
219460122|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
219460123|NCT01745159|DRUG|tacrolimus|
219460124|NCT02050256|OTHER|continuing medical education and electronic decision support|
219460125|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
219460126|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
219460127|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
219197940|NCT06619834|BEHAVIORAL|Financial Navigation and Peer Support|A combined intervention of technology-supported financial navigation and peer support: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks. Participants will also be matched with a Peer Supporter to help improve the participants\&#39; diabetes self-management.
219197941|NCT06619834|BEHAVIORAL|Financial Navigation Only|A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks.
219460128|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
219460129|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
219460130|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
219460131|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
219460132|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
219460133|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
219460134|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
219460135|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
219460136|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
218850451|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
218850452|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
219460137|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
219460138|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
219460139|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
219460140|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
219197942|NCT06621186|OTHER|No intervention measures|No intervention measures
219460141|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
218850453|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
218850454|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
218850455|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
218850456|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
218850457|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
218850458|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
218850459|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
218850460|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
218850461|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
218850462|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
218850463|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
218850464|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
218850465|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
218850466|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
218850467|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
218850468|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
218850469|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
218850470|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
218850471|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
218850472|NCT02578966|BEHAVIORAL|Motivational Interview|
219460142|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
219460143|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
219460144|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
219460145|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
219460146|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
219460147|NCT00493909|PROCEDURE|thoracic epidural analgesia|
219460148|NCT00759993|DRUG|chromium piccolinate|1000mg tab
219460149|NCT00759993|DRUG|placebo for chromium piccolinate|
219460150|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
219460151|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
219460152|NCT02073292|PROCEDURE|c-RFA|
219460153|NCT02073292|PROCEDURE|tRFA|
218850473|NCT02578966|OTHER|Traditional health education|
219460154|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
219592366|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
218850474|NCT02172131|DRUG|BI 1744 CL|
218850475|NCT02172131|DRUG|Placebo|
218850476|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
219460155|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1\) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
218850477|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
218850478|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
219460156|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
219460157|NCT00266331|DRUG|Reduced glutathione|
219460158|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
219460159|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
219460160|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
219460161|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
218850479|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
218850480|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
218850481|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
219592367|NCT06677554|DRUG|Addition of ultrasound with contrast injection (SonoVue®)|Addition of contrast evaluation with SonoVue® injection (5 min including 1 min of acquisition) within the diagnostic strategy
219592368|NCT06677554|OTHER|Standard Care (in control arm)|No addition of ultrasound with contrast
219592369|NCT06895577|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
218850482|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
218850483|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
219460162|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
219460163|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
219460164|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
219460165|NCT01880320|DRUG|Topical Gel Vehicle|
219460166|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
219460167|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
219460168|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
219460169|NCT02502994|DRUG|GEN0101|
219460170|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
218850484|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
219197943|NCT01944332|PROCEDURE|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
219460171|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
219460172|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
219460173|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
218850485|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
218850486|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
219460174|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
218850487|NCT04662775|BEHAVIORAL|HERizon Project|"1\. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
218850488|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
219460175|NCT03511222|DRUG|Nivolumab|Standard of care
219460176|NCT03511222|DRUG|Pembrolizumab|Standard of care
219460177|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
219460178|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
219460179|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
219460180|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
219460181|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
219460182|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
219460183|NCT02176031|DRUG|Natalizumab|
219460184|NCT02176031|DRUG|Methylprednisolone|
219460185|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
219460186|NCT00055939|DRUG|exatecan mesylate|
219460187|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
219460188|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
219460189|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
219460190|NCT00167713|DRUG|Ibuprofen|
219460191|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
219460192|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
219460193|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
219460194|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
219460195|NCT02643420|DRUG|Docetaxel|Standard therapy
219460196|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
219460197|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
219460198|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
219460199|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
218850489|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
219460200|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
219460201|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
219460202|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
219460203|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
219460204|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
219460205|NCT02895477|DEVICE|hearing aid|
219460206|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
218850490|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
218850491|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
218850492|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
218850493|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
218850494|NCT04247009|OTHER|Meal based on red meat, fish products or vegan products|Three meals will be served
218850495|NCT04247009|OTHER|Meal based on red meat|Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
218850496|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
218850497|NCT00000487|DRUG|antihypertensive agents|
218850498|NCT00000487|BEHAVIORAL|smoking cessation|
218850499|NCT00000487|BEHAVIORAL|diet, fat-restricted|
218850500|NCT00000487|DRUG|diuretics|
218850501|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
218850502|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
219460207|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
218850503|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
218850504|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
219460208|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
219460209|NCT04446039|DRUG|Escitalopram|Treatment for depression
219460210|NCT04446039|DRUG|Paroxetine|Treatment for depression
219460211|NCT04446039|DRUG|Fluoxetine|Treatment for depression
219460212|NCT04446039|DRUG|Mirtazapine|Treatment for depression
219460213|NCT04446039|DRUG|Duloxetine|Treatment for depression
219460214|NCT04446039|DRUG|Sertraline|Treatment for depression
219460215|NCT04446039|DRUG|Venlafaxine|Treatment for depression
219460216|NCT04446039|DRUG|Tianeptine|Treatment for depression
219460217|NCT04446039|DRUG|Vortioxetine|Treatment for depression
219592370|NCT06891677|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (CBT) with ACT and COPD Education|Participants receive an internet-based cognitive behavioral therapy (CBT) intervention combined with education specifically developed for COPD. The CBT program includes Acceptance and Commitment Therapy (ACT) components. The intervention lasts 8-10 weeks and consists of several online modules. Modules cover topics such as coping strategies, mindfulness techniques, disease knowledge, and symptom management. Participants complete the modules at home via a secure online platform, with regular support and feedback from trained healthcare professionals. The program aims to improve mental health, reduce anxiety and depression, enhance COPD knowledge, and help participants manage symptoms and daily life more effectively.
218850505|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
218850506|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
218850507|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
218850508|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
218850509|NCT00274859|DRUG|gemcitabine hydrochloride|
219460218|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
219460219|NCT04446039|DRUG|Bupropion|Treatment for depression
219460220|NCT00472628|PROCEDURE|Blood samples collected|
219460221|NCT00072085|BIOLOGICAL|aldesleukin|
219460222|NCT00072085|BIOLOGICAL|gp100 antigen|
219460223|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
219460224|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
219460225|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
219460226|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
219460227|NCT00034801|DRUG|olanzapine|
219460228|NCT00034801|DRUG|ziprasidone|
219460229|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
218850510|NCT00274859|DRUG|oxaliplatin|
219460230|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
219460231|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
219460232|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
219460233|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
219460234|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
219460235|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
219460236|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
219460237|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
219460238|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
219460239|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
218850511|NCT00113399|BIOLOGICAL|filgrastim|
218850512|NCT00113399|DRUG|cisplatin|
218850513|NCT00113399|DRUG|docetaxel|
218850514|NCT00113399|DRUG|fluorouracil|
218850515|NCT00113399|DRUG|paclitaxel|
218850516|NCT00113399|RADIATION|radiation therapy|
218850517|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
218850518|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
218850519|NCT03729037|OTHER|CPR self-training|
218850520|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
218850521|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
218850522|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
218850523|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
219460240|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
219460241|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
219460242|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
219460243|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
219460244|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
219460245|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
219460246|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
219460247|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
219460248|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
219460249|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
219460250|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
219460251|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
219460252|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
219460253|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
219592371|NCT06902350|DRUG|CS231295|oral tablet. Only one dose on C0D1 in single-dose period. Once daily from C1D1 until disease progression, death, intolerable toxicity, loss to follow-up, withdrawal of informed consent, or the end of the trial, whichever occurs first, in multiple-dose period in both escalation and cohort expansion phases.
219592372|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
219592373|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
219460254|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
219460255|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219460256|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
219460257|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
219460258|NCT04629105|OTHER|Placebo|Placebo
218850524|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
218850525|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
218850526|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
218850527|NCT00322296|DRUG|Bexarotene 1% gel|
218850528|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
218850529|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
218850530|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
218850531|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
218850532|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
218850533|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
219592374|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
218850534|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
218850535|NCT03051412|OTHER|No Intervention|No intervention
218850536|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
218850537|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
218850538|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
219592375|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
219592376|NCT06907342|DRUG|FOLFOX or FOLFIRI|Treatment allocation from tumouroid readout
219592377|NCT06911398|OTHER|Articulate Medical Intelligence Explorer (AMIE)|AMIE is an AI system for having clinical conversations with patients
219592378|NCT04874675|DRUG|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
219592379|NCT04874675|DRUG|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
219592380|NCT06935162|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
219592381|NCT06936878|BEHAVIORAL|BOLSTER Program|This supportive care program includes six telehealth sessions led by a trained nurse to help patients with advanced gynecological or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Two additional sessions will be help support care partners. Participants will also get access to the BOLSTER website, which offers personalized educational materials to support their well-being
219592382|NCT05999812|DRUG|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
219592383|NCT05999812|DRUG|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
219592384|NCT05999812|DRUG|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
218850539|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
218850540|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
218850541|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
218850542|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
218850543|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
219460259|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
219460260|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
219460261|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
219460262|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
219460263|NCT00089505|DRUG|Nevirapine|200 mg taken orally
219460264|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
219460265|NCT05272306|OTHER|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
219460266|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
219460267|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
219460268|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
219460269|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
219592385|NCT06537388|PROCEDURE|Ventilation type|Type of ventilation used during the EBUS procedure, either HFJV or IPPV
218850544|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
218850545|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
218850546|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
218850547|NCT02502669|DRUG|Placebo tablets|
218850548|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
219197944|NCT06622252|OTHER|13-week session program|The newly designed intervention was split into three major components - Healthy Literacy, Caregiver Wellness, and Culturally Competent Care and is delivered throughout a 13-session program delivered via Zoom. Sessions are guided by a psychologist, nutritionist, spirituality specialist, social worker, case coordinator, oncologist and traditional Chinese medicine practitioner. Sessions are intended for caregivers specifically, however, other members of the family may join if they choose to.
219197945|NCT06869460|RADIATION|Stereotactic Body Radiotherapy/Radiosurgery|Stereotactic Body Radiotherapy/Radiosurgery
219460270|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
219460271|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
219592386|NCT06940310|BEHAVIORAL|Daily load-velocity-based training intensity adjustment.|At the beginning of the training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. Additionally, during the training sessions, intensity will be monitored, and load will be adjusted in real time by movement velocity.
218850549|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
219460272|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
219460273|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
219460274|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
219460275|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
219460276|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
219460277|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
219460278|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
219460279|NCT03018028|DRUG|Semaglutide|Oral administration once daily
219460280|NCT03018028|DRUG|Placebo|Oral administration once daily
219460281|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
219460282|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
219460283|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
219460284|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
218850550|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
218850551|NCT01165320|DRUG|Caspofungin|
218850552|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
218850553|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
218850554|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
218850555|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
219197946|NCT06871150|DEVICE|Flotrac sensor|"Traditional management of hemodynamic parameters and intraoperative fluids without the aid of predictive tools based on artificial intelligence.~Possibility of having advanced hemodynamic analysis tools such as SV (stroke volume), SVV (stroke volume variation), PPV (pulse pressure variation), CO (cardiac output).~The anesthetist will decide whether to administer fluids, vasopressors, or other pharmacological interventions to maintain hemodynamic stability basing on clinical hemodynamic parameters derived from pulse contour systems, in accordance with a specific flowchart.~Interventions will be applied when blood pressure decreases, or clinical signs of instability are observed"
219460285|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
219460286|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
219460287|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
219460288|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
219460289|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
218850556|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
219460290|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
219460291|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
219460292|NCT00004885|DRUG|FOLFIRI regimen|
219460293|NCT00004885|DRUG|fluorouracil|
219460294|NCT00004885|DRUG|irinotecan hydrochloride|
219199469|NCT06867159|PROCEDURE|Reciprocal Inhibition (RI) MET|"Reciprocal Inhibition (RI) MET~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
219460295|NCT00004885|DRUG|leucovorin calcium|
219460296|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
219460297|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
219460298|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
219460299|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
219460300|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
219460301|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
219460302|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
219460303|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
219592387|NCT06940310|BEHAVIORAL|Training intensity prescription based on an initial 1RM estimation using load-velocity relationship|In the first training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. This 1RM will be used to prescribe exercise intensity throughout the intervention.
219592388|NCT06940310|BEHAVIORAL|Traditional training with intensity prescription based on 1RM testing.|The traditional training group will follow a training program using the traditionally employed methodology for assessing and prescribing training intensity in breast cancer survivors. This methodology is based on an initial 1RM estimation conducted through a 1RM test, which will be used to prescribe the training load throughout the intervention.
219592389|NCT02658838|DRUG|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
219592390|NCT02658838|DRUG|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
219460304|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
219460305|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
219460306|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
219460307|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
219592391|NCT02658838|DRUG|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
219592392|NCT02658838|DRUG|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
219592393|NCT02248038|PROCEDURE|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
219592394|NCT02248038|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
219592395|NCT03679052|DRUG|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
219460308|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
219460309|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
219460310|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
219460311|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
219460312|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
219460313|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
219460314|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
219197947|NCT06871150|DEVICE|HPI|"The Hypotension Prediction Index (HPI) is an advanced arterial waveform analysis algorithm that uses machine learning to predict hypotensive episodes (defined as mean arterial pressure \[MAP\] \< 65 mmHg) five minutes in advance, achieving high sensitivity and specificity. This technology is based on patient demographic data (e.g., age, height, weight) and hemodynamic parameters derived from arterial waveform analysis.~* HPI uses demographic information and hemodynamic signals obtained via a radial arterial catheter.~* The signals are analyzed using Edwards Lifesciences' Acumen IQ software, which has been further developed to include prediction of hypotensive episodes.~The algorithm provides a numerical value (0-100) reflecting the risk of imminent hypotension. An HPI value above 85 signals a high likelihood of hypotension.~The system also provides advanced hemodynamic data, including cardiac output, dynamic arterial elastance, dP/dtmax (systolic slope), and stroke volume."
218850557|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
218850558|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
218850559|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
218850560|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
218850561|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
219460315|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
219460316|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
219460317|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
219460318|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
219460319|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
219460320|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
219460321|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
219460322|NCT00767494|DRUG|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
219460323|NCT00767494|DRUG|Azopt|Eye Drop Suspension, 1 drop BID
219460324|NCT00767494|DRUG|Travatan|Eye Drop Solution, 1 drop BID
219460325|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
218850562|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
218850563|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
219460326|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
219460327|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
219460328|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
219460329|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
219460330|NCT02543801|DRUG|Ropivacaine|Periarticular injection
219460331|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
219460332|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
219460333|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
219460334|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
219460335|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
219460336|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
219460337|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
219460338|NCT02181335|DRUG|Respimat® Budesonide low dose|
219460339|NCT02181335|DRUG|Respimat® Budesonide high dose|
219460340|NCT02181335|DRUG|Turbohaler® Budesonide|
219460341|NCT02181335|DRUG|Placebo|
219592396|NCT03679052|DRUG|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
219460342|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
219592397|NCT03679052|DRUG|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
219592398|NCT06948968|OTHER|Social Role Participation Questionnaire|Validity and Reliability of the Turkish Version of the Adapted Social Role Participation Questionnaire in Ankylosing Spondylitis
219592399|NCT06954727|OTHER|No intervention; Observational study|No intervention; observational study
218850564|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
218850565|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
218850566|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
218850567|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
218850568|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
218850569|NCT01833260|BEHAVIORAL|Music|
218850570|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
218850571|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
218850572|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
219197948|NCT06871150|DEVICE|HPI-AFM|"HPI: Provides a predictive index (from 0 to 100) based on real-time hemodynamic data, indicating the probability of the patient developing a hypotensive episode (MAP \< 65 mmHg) within the next 10-15 minutes.~AFM: In addition to hypotension prediction, continuously monitors parameters such as stroke volume and cardiac output, providing indications for optimal fluid administration. It is programmed to suggest the quantity and the speed of fluid administration based on real-time data and patient conditions.~In conjunction with the HPI system, the AFM suggests administering a specific fluid volume to correct the patient's hemodynamic status.~The AFM uses a predictive algorithm to calculate the patient's response to fluid administration, enabling anesthetists to dynamically adjust therapy.~The AFM system is based on assisted clinical decisions, where anesthetist receive algorithm-based AI recommendations to proactively administer fluids, avoiding the traditional reactive approach."
219197949|NCT06097637|OTHER|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection achieves similar rates of complete resection with comparable safety, with lower rates of recurrence and fewer repeat procedures.
219197950|NCT06097637|OTHER|hot snare polypectomy|Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
219197951|NCT05310097|BEHAVIORAL|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
219592400|NCT06955117|OTHER|Physical Therapy Exercises|"Experimental - McKenzie Technique (Group A) Intervention Type: Other: Physical Therapy Exercises~Other Names:~Intervention for low back pain~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
219460343|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
219460344|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
219460345|NCT05278611|DRUG|placebo|placebo
219460346|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
219460347|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
219460348|NCT02002637|DEVICE|Latella Knee Implant System|
219460349|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
219460350|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
219460351|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
219460352|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
219460353|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
219460354|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
219197952|NCT05310097|BEHAVIORAL|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
218850573|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
218850574|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
218850575|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
218850576|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
218850577|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
219460355|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
218850578|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
218850579|NCT04851210|OTHER|No intervention|No intervention
218850580|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
218850581|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
218850582|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
218850583|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
218850584|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
218850585|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
218850586|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
218850587|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
218850588|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
218850589|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
218850590|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
219460356|NCT03344874|DEVICE|Stethee®|Stethee® is a new wireless digital stethoscope.
219460357|NCT03344874|DEVICE|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
219460358|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
219460359|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
218850591|NCT00003914|DRUG|dolastatin 10|
218850592|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
219592401|NCT06955117|OTHER|Group B|"Manual Therapy (Group B)~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
219592402|NCT02903706|OTHER|Measure of Plasmodium prevalence (PCR)|
219592403|NCT06322784|DIETARY_SUPPLEMENT|Oat bran (dietary fiber)|"Dietary fiber, known as the seventh type of nutrients, refers to carbohydrate polymers that have health benefits for the human body, mainly derived from plant cell walls such as grains, fruits, and vegetables.Mediterranean cuisine is a dietary pattern"
219592404|NCT00549575|DRUG|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
218850593|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
218850594|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
219197953|NCT03167164|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219592405|NCT00549575|DRUG|Placebo|After double blind randomization, patients received a placebo.
218850595|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
218850596|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
218850597|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
218850598|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
218850599|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
218850600|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
218850601|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
218850602|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
218850603|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
219592406|NCT01707056|OTHER|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
219592407|NCT01707056|OTHER|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
219197954|NCT03167164|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
218850604|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
218850605|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
218850606|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
218850607|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
218850608|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
218850609|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
218850610|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
218850611|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
218850612|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
218850613|NCT01778049|DRUG|BI 10773|Empagliflozin active
219197955|NCT03167164|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219197956|NCT03167164|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219592408|NCT01707056|OTHER|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
219197957|NCT03167164|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219197958|NCT03167164|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219197959|NCT03167164|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219592409|NCT01707056|OTHER|Water|Taking Synthroid with water for a period of 6 weeks.
218850614|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
218850615|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
218850616|NCT01778049|DRUG|BI 10773|Empagliflozin active
218850617|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
219197960|NCT03167164|DRUG|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219197961|NCT03167164|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
219197962|NCT03167164|RADIATION|Stereotactic Body Radiation Therapy|radiation
219592410|NCT03283267|DRUG|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
218850618|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
218850619|NCT01778049|DRUG|BI 10773|Empagliflozin active
219197963|NCT03167164|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219197964|NCT03167164|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219197965|NCT03167164|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
219197966|NCT03167164|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
218850620|NCT01778049|DRUG|BI 10773|Empagliflozin active
218850621|NCT01778049|DRUG|BI 10773|Empagliflozin active
219460360|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
218850622|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
219460361|NCT00820313|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
219460362|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
219460363|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
219460364|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
219460365|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
219460366|NCT00682760|DRUG|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
219460367|NCT04333875|DEVICE|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
219460368|NCT03252262|OTHER|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
219460369|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
219460370|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
219460371|NCT05648006|BIOLOGICAL|OH2|Oncolytic Type 2 Herpes Simplex Virus
219460372|NCT05648006|DRUG|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
219460373|NCT05648006|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
219460374|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
219460375|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
218850623|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
218850624|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
218850625|NCT01778049|DRUG|BI 10773|Empagliflozin active
219197967|NCT03167164|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
219197968|NCT06479629|DRUG|Piracetam|800mg oral tablet of Piracetam three times every day for 3 months
218850626|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
218850627|NCT01711489|DRUG|isavuconazole|oral
218850628|NCT01711489|DRUG|Mycophenolate mofetil|oral
218850629|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
218850630|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
218850631|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
218850632|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
218850633|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
218850634|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
218850635|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
218850636|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
218850637|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
218850638|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
218850639|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219460376|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
218850640|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
218850641|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
218850642|NCT02862483|DRUG|Tamsulosin 0.2mg|
218850643|NCT02862483|DRUG|Tadalafil 5mg|
218850644|NCT02862483|DRUG|Placebo for Tamsulosin|
218850645|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
218850646|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
218850647|NCT00177567|DRUG|lithium carbonate|
218850648|NCT00177567|DRUG|Depakote-ER|
218850649|NCT00177567|DRUG|risperidone|
219460377|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
219460378|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
219460379|NCT05914233|DEVICE|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
219460380|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
219460381|NCT00001925|DRUG|Alcohol|
219460382|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
218850650|NCT00177567|DRUG|olanzapine|
218850651|NCT00177567|DRUG|paroxetine|
218850652|NCT00177567|DRUG|bupropion|
218850653|NCT00177567|DRUG|lamotrigine|
218850654|NCT00177567|DRUG|venlafaxine|
218850655|NCT00177567|DRUG|tranylcypromine|
218850656|NCT00177567|DRUG|mirtazapine|
218850657|NCT04960930|DRUG|FMX101|topically once daily
218850658|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
218850659|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
218850660|NCT00336167|DRUG|bezafibrate (drug)|
218850661|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
218850662|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
218850663|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
219197969|NCT06479629|DRUG|Placebo|starch tablet
219460383|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
219460384|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
219460385|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
219460386|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
219460387|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
219460388|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
219460389|NCT01122992|PROCEDURE|Limbal relaxing incision|
218850664|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
219197970|NCT05439018|OTHER|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
219197971|NCT05439018|OTHER|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
219197972|NCT06755762|OTHER|Organoid 3D culture|Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites
219460390|NCT06356649|PROCEDURE|extubation|Complications after extubation
218850665|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
219460391|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
219460392|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
219460393|NCT04721275|OTHER|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
219460394|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
219592411|NCT00805467|DRUG|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
219592412|NCT05779852|OTHER|self-hypnosis and dressing|self-hypnosis during dressing
218850666|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
218850667|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
218850668|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
219197973|NCT06872957|DEVICE|Surface Electromyography Noraxon MiniDTS system|Trapezius muscle activities of 19 healthy individuals were measured with surface EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) in the ascending, stationary and descending phases of the wall slide exercise under different head posture conditions: natural head posture and corrected head posture.
218850669|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
218850670|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
218850671|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
218850672|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
218850673|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
219592413|NCT05779852|OTHER|dressing|dressing without self-hypnosis
218850674|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
218850675|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
219197974|NCT06871826|DRUG|TIMP2 level|different TIMP2 level after on-pump cardiac surgery
219592414|NCT04697836|PROCEDURE|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
219592415|NCT05353010|DRUG|Tacrolimus|Tacrolimus 5mg (1 mg \* 5 capsules)
218850676|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
219197975|NCT06873282|BIOLOGICAL|TB/Flu-05E|Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis
219460395|NCT02367690|DRUG|Selinexor|Topical gel
219460396|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
219460397|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
219592416|NCT05353010|DRUG|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
218850677|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
218850678|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
218850679|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
218850680|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
218850681|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
218850682|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
218850683|NCT00260767|DRUG|HEC placebo gel|
219592417|NCT05353010|DRUG|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
218850684|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
218850685|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
218850686|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
219460398|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
219460399|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
219460400|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
219460401|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
219460402|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
219460403|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
219460404|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
219460405|NCT02698917|OTHER|High normal PaO2|20-25 kPa
219197976|NCT06873282|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer in 0.5 ml
219460406|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
218850687|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
218850688|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
219460407|NCT02698917|OTHER|High normal MAP|80-100 mmHg
219460408|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
219460409|NCT04796454|DRUG|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
219460410|NCT04796454|DRUG|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
219460411|NCT04796454|DRUG|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
219460412|NCT04796454|DRUG|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
219460413|NCT04796454|DRUG|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
219460414|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
219460415|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
219460416|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
218850689|NCT00531557|DRUG|Darunavir ritonavir|
218850690|NCT00004495|DRUG|cyanocobalamin|
219460417|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
219460418|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
219460419|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
219460420|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
219460421|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
219460422|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
219592418|NCT01761370|PROCEDURE|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
219460423|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
219460424|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
218850691|NCT00004495|DRUG|folic acid|
218850692|NCT00004495|DRUG|pyridoxine|
218850693|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
218850694|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
218850695|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
218850696|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
218850697|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
218850698|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
218850699|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
219460425|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
219592419|NCT01761370|PROCEDURE|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
219197977|NCT06869980|PROCEDURE|mitral valve replacement through limited right anterior thoractomy|The incision is placed just lateral to the nipple over the fourth intercostal space (above the nipple in men and in the inframammary crease in most women) 6-10 cm in length, the pectoralis muscles are mobilized for fourth intercostal space thoracic entry-The pericardium is opened 2-cm ventral to the phrenic nerve under direct vision and carried cephalad to the aortic reflection. The anterior edge of the pericardium is tacked to incision edges using silk sutures-To initiate cardiopulmonary bypass, Cannulation of the femoral artery and femoral vein should be prior to mediastinal dissection-. The ascending aorta occluded with an external clamp. This aortic clamp passed through the thoracotomy incision if we use the aortic cross clamp and the anterograde cardioplegia delivered through a standard cardioplegia cannula secured with purse-string sutures in the ascending aorta.
219460426|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
219460427|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
219460428|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
218850700|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
218850701|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
218850702|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
218850703|NCT00107315|BIOLOGICAL|bevacizumab|
218850704|NCT00107315|DRUG|capecitabine|
218850705|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
218850706|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
218850707|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
218850708|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
218850709|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
218850710|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
219460429|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
219460430|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
219460431|NCT01830829|DRUG|Jalyn|study drug
219460432|NCT01830829|DRUG|Placebo|Placebo
219460433|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
219460434|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
219460435|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
219460436|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
218850711|NCT00236990|DRUG|pentosan polysulfate sodium|
218850712|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
219460437|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
219460438|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
219460439|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
218850713|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
218850714|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
218850715|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
218850716|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
218850717|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
218850718|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
219592420|NCT05231330|DRUG|silvernanoparticles|silvernanoparticles in fluoride varnish
218850719|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
218850720|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
218850721|NCT01794741|DRUG|Dymista Nasal Spray|
218850722|NCT01794741|DRUG|Fluticasone propionate nasal spray|
218850723|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
218850724|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
218850725|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
218850726|NCT02089464|DEVICE|NBS-guided rTMS|
218850727|NCT02089464|DEVICE|Sham rTMS|
219460440|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
218850728|NCT02089464|PROCEDURE|Task oriented rehabilitation|
218850729|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
219460441|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
219460442|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
219460443|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
218850730|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
219460444|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
219460445|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
219460446|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
219460447|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
219460448|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
219460449|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
219460450|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
218850731|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
218850732|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
219460451|NCT01020994|DRUG|LAS41003|Once daily, topically
219460452|NCT01020994|DRUG|LAS189962|Once daily, topically
219592421|NCT05231330|DRUG|SDF|silver diamine fluoride
218850733|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
219592422|NCT03928730|PROCEDURE|resection and removal|Surgical resection or removal for histopathological examination
219592423|NCT00625625|DRUG|isosulfan blue|
219592424|NCT00625625|GENETIC|polymerase chain reaction|
219592425|NCT00625625|OTHER|diagnostic laboratory biomarker analysis|
219592426|NCT00625625|OTHER|immunohistochemistry staining method|
218850734|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
218850735|NCT01572363|DRUG|Sildenafil|50 mg once
218850736|NCT00283270|BEHAVIORAL|Brief counselling|
218850737|NCT00283270|BEHAVIORAL|Behavior|
219460453|NCT01020994|DRUG|LAS189961|Once daily, topically
219460454|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
219460455|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
219460456|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
219460457|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
219592427|NCT00625625|PROCEDURE|diagnostic lymphadenectomy|
219592428|NCT00625625|PROCEDURE|therapeutic conventional surgery|
219592429|NCT00625625|PROCEDURE|therapeutic lymphadenectomy|
219592430|NCT00213135|DRUG|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
219592431|NCT00213135|DRUG|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
219592432|NCT00213135|OTHER|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
219592433|NCT03593538|DRUG|Metformin|Metformin capsule
219592434|NCT03593538|DRUG|Placebo|Sucrose filler in gel capsules
218850738|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
218850739|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
218850740|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
218850741|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
219460458|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
218850742|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
218850743|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
218850744|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
218850745|NCT06425809|OTHER|Observation|The data collection will be carried out by the two researchers, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the athletes whose data are collected. The members of the research group will not have access to personal data that could facilitate the identity of any person on the basis of the data collected. The data collected in this study, anonymised from the outset, will be exported to an Excel file. Access to the Excel file will require password access and will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialities).
218850746|NCT00934947|DRUG|Propranolol|40 mg
218850747|NCT00934947|DRUG|Placebo|sugar pill
218850748|NCT00934947|DRUG|Propanolol|120 mg twice per day
218850749|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
218850750|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
218850751|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
218850752|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
218850753|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
218850754|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
219460459|NCT04615429|BIOLOGICAL|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
219460460|NCT04615429|OTHER|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
219460461|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
219460462|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
219460463|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
219460464|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
218850755|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
218850756|NCT02970630|DRUG|Tacrolimus|once a day
218850757|NCT02970630|DRUG|Everolimus|twice daily
218850758|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
219592435|NCT02173314|OTHER|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
218850759|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
218850760|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
218850761|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
218850762|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
219460465|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
219460466|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
219460467|NCT04139603|OTHER|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
219460468|NCT04139603|OTHER|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
219460469|NCT04139603|OTHER|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
218850763|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
218850764|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
218850765|NCT06343350|DEVICE|OPTDR01 software application|Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
219592436|NCT00999323|DEVICE|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
219592437|NCT06176729|DRUG|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
219592438|NCT00644930|DEVICE|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
219592439|NCT00644930|DEVICE|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
218850766|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
218850767|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
218850768|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
219592440|NCT02645903|DRUG|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
219592441|NCT02645903|DRUG|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
218850769|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
219197978|NCT06869980|PROCEDURE|mitral valve replacement through median sterntomy|The incision is begun approximately 2 cm below the sternal notch and extended approximately 2 cm beyond the distal tip of the xiphoid process and is usually extended with the electrocautery down to the sternal periosteum. A midline approach can be ensured by careful attention to the insertion points of the pectoralis major muscles onto the sternum; the incision should lie directly midway between these insertion points.After sternotomy, the pericardium is opened; the heart is cannulated for cardiopulmonary bypass. Arterial inflow is established by cannulation of the distal ascending aorta near the pericardial reflection. Double venous cannulation of the venae cavae by way of the right atrium is generally employed. In most adults a size 32 Fr cannula in the superior vena cava and a size 34-38 Fr cannula in the inferior vena cava provide excellent venous drainage and easy fit. Encircling of the venae cavae and their generous mobilization aid in the subsequent exposure of the mitral valve.
219592442|NCT02028741|OTHER|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
219460470|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
219460471|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
219460472|NCT02084316|BEHAVIORAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
219460473|NCT02084316|BEHAVIORAL|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
219460474|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
219460475|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
219460476|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
219592443|NCT00245687|DEVICE|Tiger Tube|
219592444|NCT01194063|DRUG|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
219592445|NCT05395286|BEHAVIORAL|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
219592446|NCT04208958|BIOLOGICAL|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
219592447|NCT04208958|DRUG|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
219592448|NCT04208958|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
219197979|NCT05564208|DRUG|elafibranor|Oral Tablet
219197980|NCT05564208|DRUG|elafibranor|Oral Tablet
219197981|NCT06628180|DEVICE|LIFU|Application of low-intensity focused ultrasound for neuromodulation
219197982|NCT06628180|DEVICE|Sham LIFU|Sham application of LIFU - will appear the same to participants.
219197983|NCT06875544|OTHER|Beautifil F00|Beautifil F00 is bioactive giomer resin composite.
219197984|NCT06875544|OTHER|G-aenial Universal Injectable Flowable Composite|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component
219197985|NCT05654662|DRUG|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
219197986|NCT05654662|DRUG|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
219197987|NCT05225792|BEHAVIORAL|Promis Physical Function Questionnaire|Patient reported physical function outcomes
219197988|NCT05225792|BEHAVIORAL|L Test|Performance based measure assessing general physical function and balance ability.
219460477|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
219460478|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
219460479|NCT00424736|PROCEDURE|whole body CT scan|
219460480|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
219460481|NCT06093321|DEVICE|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
219460482|NCT06093321|DEVICE|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
219460483|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
219460484|NCT00841854|DRUG|bismuth|bismuth 300mg qid
219460485|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
219460486|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
219460487|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
219460488|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
219197989|NCT05225792|BEHAVIORAL|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
219197990|NCT05225792|BEHAVIORAL|PEQ-A|Survey on confidence, stumbles and falls.
219197991|NCT06630260|DRUG|Avutometinib|Supplied as 0.8mg capsules.
219197992|NCT06630260|DRUG|Defactinib|Supplied as 200mg tablets.
219460489|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
219460490|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
219460491|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
219197993|NCT06630260|DRUG|Temozolomide|Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
219460492|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
219460493|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
219460494|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
219460495|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
219460496|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
219197994|NCT06695780|OTHER|survey on eating behavior, physical activity and health status|Participatory research: participants will carry out surveys, functional tests and urine and blood sampling completely independently
219197995|NCT06687070|DRUG|APG -2449|Orally once a day(QD), every 28 days as a cycle.
219197996|NCT06687070|DRUG|PLD|Injected on the first day of each cycle, every 28 days as a cycle.
219361291|NCT05649995|OTHER|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
218850770|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
219361292|NCT02851173|DEVICE|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
219361293|NCT02851173|DEVICE|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
219361294|NCT03219866|DEVICE|Nebulizers|Patients treated and discharged on nebulized bronchodilators
219361295|NCT03219866|DEVICE|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
219361296|NCT03219866|DRUG|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
219361297|NCT03219866|DRUG|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
219361298|NCT03219866|DRUG|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
219361299|NCT03219866|DRUG|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
219361300|NCT03219866|DRUG|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
219361301|NCT03682497|DRUG|AZD9977|AZD9977 capsules taken orally for 28 days.
219361302|NCT03682497|DRUG|Spironolactone|Spironolactone tablets taken orally for 28 days.
219361303|NCT00578305|BIOLOGICAL|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
219361304|NCT00578305|DRUG|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
219361305|NCT00578305|DRUG|Methylprednisolone|
219361306|NCT00578305|DRUG|Methotrexate|
219361307|NCT00578305|DRUG|Folic acid or folate|
219361308|NCT06548906|DRUG|GZR4 Injection|GZR4 Injection administered sc, once weekly.
219361309|NCT00129155|DRUG|treosulfan|
219361310|NCT03502720|DEVICE|Scaphoid fixation using 3D device|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide
219361311|NCT03502720|PROCEDURE|Scaphoid fixation using standard procedure|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
219361312|NCT03778164|OTHER|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
219361313|NCT03778164|OTHER|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
219361314|NCT02709278|BIOLOGICAL|BCG|BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
219361315|NCT02709278|OTHER|Saline placebo|Saline placebo
219361316|NCT02709278|BIOLOGICAL|BCG|BCG Bulgaria (InterVax)
219361317|NCT03796468|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
219361318|NCT03796468|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
219361319|NCT00389025|DRUG|Olopatadine (generic name)|
219361320|NCT02320487|DRUG|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
219361321|NCT02320487|DRUG|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
219361322|NCT01230879|OTHER|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
219361323|NCT03220828|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets)
219361324|NCT02392273|DRUG|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
219361325|NCT03099720|DRUG|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
219361326|NCT03099720|DRUG|Placebo|placebo fluid will be given at the site of operation locally
219361327|NCT02613728|BEHAVIORAL|Accelerated Recovery Plan|
219361328|NCT02613728|BEHAVIORAL|Early Discharge|
219361329|NCT02613728|OTHER|Telemedicine|
219460497|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
218850771|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
218850772|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
218850773|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
218850774|NCT04049266|DRUG|KSI-301|Intravitreal Injection
218850775|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
218850776|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
218850777|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
218850778|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
218850779|NCT00851981|OTHER|Placebo|TID
218850780|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
218850781|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
218850782|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
218850783|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
218850784|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
218850785|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
219361330|NCT02613728|BEHAVIORAL|Standard Enhanced Care|
219361331|NCT05832294|DEVICE|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
219361332|NCT05832294|DEVICE|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
219361333|NCT00002778|BIOLOGICAL|sargramostim|
219361334|NCT00002778|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219361335|NCT00002778|PROCEDURE|allogeneic bone marrow transplantation|
219361336|NCT00002778|PROCEDURE|in vitro-treated bone marrow transplantation|
219361337|NCT06237231|DRUG|DIT112|DIT112 tablet
219361338|NCT06237231|DRUG|DIPYRONE|Dipyrone tablet 1.000mg
219361339|NCT06237231|DRUG|TRAMADOL|Tramadol tablet 50mg
219361340|NCT06237231|DRUG|DIT112 Placebo|DIT112 placebo tablet
219361341|NCT06237231|DRUG|Dipyrone Placebo|Dipyrone placebo tablet
219361342|NCT06237231|DRUG|Tramadol Placebo|Tramadol placebo capsule
219361343|NCT05242783|DRUG|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
219361344|NCT04993378|DEVICE|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
219361345|NCT05275907|DRUG|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
219361346|NCT05275907|DRUG|Chlorthalidone|25mg capsule once daily for 6 weeks
219361347|NCT03938493|OTHER|monitoring of the endotracheal tube cuff|We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
219361348|NCT04004598|BEHAVIORAL|golf training|12 weeks of training by Professional Golf Association professional
219361349|NCT01240161|DRUG|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
219361350|NCT02161679|DRUG|IMMU-132 infusion is administered to participants in one arm for the study|
219361351|NCT02161679|DRUG|IMMU-132 plus Carboplatin infusion|
219197997|NCT06875596|OTHER|Control: Exercise Program|The entire program begins with an assessment of scapulohumeral rhythm using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. The exercise program for the experimental group lasts eight weeks and is divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. After the initial assessment, participants will undergo scapular positioning correction for the dominant extremity. They are then introduced to the first set of exercises for the first two weeks. The handball players will be given an exercise sheet explaining each exercise, which they will complete daily after completing their assigned ten minutes of exercise. They will also be given two resistance bands to provide resistance during the assigned exercises. One band is for upper scapular rotation, while the other is for resisting
219197998|NCT06875596|OTHER|Experimental: Exercise Program|Participants in the active control group will begin the program in the same manner as the experimental group, beginning with scapulohumeral rhythm assessments using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. They will also follow an eight-week exercise program divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. The key difference is that the control group will not focus on correcting scapular position for upward rotation during the exercises. Specifically, they will skip the upward rotation exercises at the beginning of each set and will not incorporate the acquired upward rotation control into other movement exercises. You will also be given a resistance band to provide resistance during the assigned exercises.
219460498|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
219460499|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
219460500|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
219460501|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
219460502|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
219460503|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
219460504|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
219460505|NCT02254694|OTHER|high heeled shoes|see detailed study description
219460506|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
219460507|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
219460508|NCT06514170|OTHER|No intervention|No intervention
219460509|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
219460510|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
219460511|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
219460512|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
219460513|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
219460514|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
219460515|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
219460516|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
219460517|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
219460518|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
219460519|NCT02365961|DRUG|ropivicaine|
219460520|NCT02365961|DRUG|clonidine|
219460521|NCT02365961|DRUG|Epinephrine|
219460522|NCT02365961|DRUG|Noropin|
219460523|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
219460524|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
219460525|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
218850786|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
218850787|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
218850788|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
218850789|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
218850790|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
218850791|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
218850792|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
218850793|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
219197999|NCT05700760|BEHAVIORAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
219361352|NCT02007707|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
218850794|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
218850795|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
218850796|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
218850797|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
218850798|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
218850799|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
218850800|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
219361353|NCT02007707|BEHAVIORAL|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
219361354|NCT01879345|DRUG|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
219361355|NCT01879345|DRUG|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
219361356|NCT01879345|DRUG|Placebo|placebo tablets
219361357|NCT05565599|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
219361358|NCT05121532|DIAGNOSTIC_TEST|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
219361359|NCT06729489|PROCEDURE|Upper Endoscopy|Endoscopy in children with refractory iron deficiency anemia
219361360|NCT00472524|PROCEDURE|Mydriasis/cycloplegia via different modes of administration|
219361361|NCT02705989|DRUG|BMS-986195|Specified dose on specified day
219361362|NCT02705989|OTHER|Placebo|Specified dose on specified day
219361363|NCT01841333|DRUG|PF-04449913|100mg given orally
219361364|NCT07076238|BIOLOGICAL|Bacteriophage Treatment|Participants who have a positive match for their NTM isolate will start on mycobacteriophage treatment per prescribed treatment regimen.
219361365|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
219361366|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
219361367|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
219361368|NCT07078994|OTHER|Placebo|injection
219361369|NCT05442853|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
219361370|NCT05442853|DEVICE|Point of care glucose monitoring|Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
219361371|NCT06814119|DRUG|MK-1084|Oral tablet
219361372|NCT07082920|DRUG|JNJ-78278343|JNJ-78278343 will be administered intravenously.
219361373|NCT07082920|DRUG|JNJ-95298177|JNJ-95298177 will be administered intravenously.
219361374|NCT07081958|DRUG|RO7795081|RO7795081 will be administered orally once daily, according to the randomized dosing regimen, during the 38-week treatment period.
219198000|NCT05700760|BEHAVIORAL|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
218850801|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
218850802|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
219460526|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
219460527|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
219460528|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
219460529|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
219460530|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
219460531|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
219460532|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
219460533|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
219460534|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
219460535|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
219460536|NCT02098291|DRUG|G17DT|
219460537|NCT04576962|OTHER|Immunization Information System Review|Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System
219460538|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
219460539|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
218850803|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
218850804|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
219460540|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
219460541|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
219460542|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
219460543|NCT02259452|PROCEDURE|Pulmonary Function Tests|
219460544|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
219460545|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
218850805|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
219460546|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
218850806|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
219198001|NCT06397820|DEVICE|Percutaneous coronary intervention (PCI)|Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
219460547|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
219460548|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
219460549|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
219460550|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
219460551|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
219460552|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
219460553|NCT02132416|DRUG|NSAID|Will be used if tolerated.
219460554|NCT02132416|DRUG|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
219460555|NCT02132416|DRUG|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
219460556|NCT02132416|DRUG|Paracetamol|1g QID will be given to all patients unless allergies.
219460557|NCT02132416|PROCEDURE|Surgical management|Fracture stabilization
219460558|NCT00006082|DRUG|rubitecan|
219460559|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
219460560|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
219460561|NCT00379873|DEVICE|ProAdjuster|
219460562|NCT02692560|BEHAVIORAL|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
219460563|NCT02692560|OTHER|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
219460564|NCT05004389|DIAGNOSTIC_TEST|MRI|white matter integrity and brain structural connectivity metrics
219460565|NCT05004389|DIAGNOSTIC_TEST|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
219460566|NCT05004389|OTHER|Clinical assessments|measures of strength, balance, and mobility
218850807|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
218850808|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
218850809|NCT05638269|OTHER|no intervention|Observational studies, no intervention
218850810|NCT02042586|OTHER|Analysis of movement before total hip replacement|
219198002|NCT03165955|DRUG|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
219460567|NCT00031915|DRUG|imatinib mesylate|
219460568|NCT00520091|DRUG|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
219460569|NCT00520091|DRUG|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
219460570|NCT00520091|DRUG|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
219460571|NCT00520091|RADIATION|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
219460572|NCT00520091|PROCEDURE|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
219460573|NCT02490904|DRUG|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
219460574|NCT02490904|DRUG|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
219460575|NCT02825238|OTHER|Supervised exercise program|
219460576|NCT03088332|PROCEDURE|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
219460577|NCT01675856|OTHER|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
219460578|NCT01675856|OTHER|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
219460579|NCT00417391|DRUG|RR110 (Tamibarotene)|1 mg RR110
219460580|NCT00417391|DRUG|RR110 (Tamibarotene)|4 mg RR110
218850811|NCT02042586|OTHER|Analysis of movement after total hip replacement|
218850812|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
218850813|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
219460581|NCT05178680|OTHER|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
219460582|NCT01326910|DRUG|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
219460583|NCT01326910|DEVICE|Topical Cream|Topical cream applied twice daily (or as needed)
219460584|NCT01723124|PROCEDURE|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
219460585|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
219460586|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
219460587|NCT01270113|BEHAVIORAL|contingency management|
219460588|NCT00001685|BIOLOGICAL|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
219460589|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
219460590|NCT02430389|DRUG|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
219460591|NCT02430389|DRUG|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
219592449|NCT00948324|DRUG|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
218850814|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
218850815|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
218850816|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
218850817|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
219460592|NCT06410729|OTHER|Observational study, no intervention|
218850818|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
218850819|NCT00123370|DRUG|Modafinil|
219460593|NCT01261494|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
219460594|NCT01261494|DRUG|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
219460595|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
219460596|NCT02807194|OTHER|spinal anesthesia|
219460597|NCT02807194|OTHER|general anesthesia|
219460598|NCT02807194|PROCEDURE|lumbar disc herniation|
219460599|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
219592450|NCT03669185|DRUG|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
218850820|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
218850821|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
218850822|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
218850823|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
218850824|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
219198003|NCT06701318|DEVICE|Ultrasound shear wave elastography|An ultrasound machine (GE LogiQ S8) equipped with SWE technology will be used. A high-frequency linear transducer will be used and The machine settings will be optimized for musculoskeletal applications.
219592451|NCT03669185|DRUG|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
219592452|NCT00506701|DRUG|Tadalafil|40 mg tablet
219592453|NCT01119781|DRUG|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
219460600|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
219592454|NCT06551714|PROCEDURE|Phase 1 cardiac rehabilitation|"Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given."
219198004|NCT06634004|OTHER|BOLD MRI|The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
219198005|NCT06701955|OTHER|Questionnaire and Physical Exam|self administered questionnaires
219198006|NCT06876324|BEHAVIORAL|HealthMPowerment App|A mobile health app designed to facilitate increased PrEP use and adherence among AYAs
219198007|NCT06879054|OTHER|Healthy lifestyle education|Healthy lifestyle education via nutritional educational modules from the Gaples Institute.
219460601|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
219460602|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
219460603|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
219460604|NCT00898690|GENETIC|cytogenetic analysis|
219460605|NCT00898690|GENETIC|gene expression analysis|
219460606|NCT00898690|GENETIC|microarray analysis|
219460607|NCT00898690|GENETIC|mutation analysis|
219460608|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
219460609|NCT00898690|OTHER|immunohistochemistry staining method|
219460610|NCT06049251|OTHER|ELDOA exercises|"The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day."
219460611|NCT06049251|OTHER|Lumbar SNAGS and motor control exercises|"The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps"
219460612|NCT00493844|OTHER|Exercise testing|Exercise testing
219460613|NCT00493844|OTHER|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
219460614|NCT05790915|COMBINATION_PRODUCT|Standardized interventions|Standardized interventions according organ dysfunction
219460615|NCT02740036|DEVICE|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
219460616|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
219460617|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
219460618|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
218850825|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
218850826|NCT02049190|DRUG|onapristone|
219198008|NCT06616623|BIOLOGICAL|Atezolizumab|Given IV
219198009|NCT06616623|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
219198010|NCT06616623|PROCEDURE|Computed Tomography|Undergo CT
219198011|NCT06616623|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219198012|NCT06616623|DRUG|Vismodegib|Given PO
219198013|NCT06878755|OTHER|Promoting Assertive Communication among Teens (PACT)|See Arm Description
219198014|NCT06878755|OTHER|Healthy Minds|See Arm Description
219198015|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
218850827|NCT02049190|DRUG|abiraterone|
218850828|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
219460619|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
219460620|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
219460621|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
219460622|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
219460623|NCT00198289|DRUG|Aurexis® (tefibazumab)|
219460624|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
219460625|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
219460626|NCT04844892|DEVICE|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
219460627|NCT02981173|DRUG|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
219460628|NCT02981173|DRUG|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
219460629|NCT02981173|DRUG|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
219460630|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
219460631|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
219460632|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
219460633|NCT00205374|DRUG|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
219460634|NCT00205374|DRUG|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
219460635|NCT00022906|DRUG|Iodine-131 Anti-B1 Antibody|
218850829|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
219198016|NCT04503694|DRUG|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~* On day 1 and 15, during the Induction treatment~* On day 29, 43 and 57, during the Consolidation treatment"
219460636|NCT02865681|DRUG|Menopur|Nasal versus injectable
219460637|NCT02865681|DRUG|Synarel|nasal
219460638|NCT02865681|DRUG|HCG trigger|injectable
219460639|NCT02865681|DRUG|Clomiphene citrate|oral
219460640|NCT02865681|DRUG|Letrozole|Oral
219460641|NCT01763632|DEVICE|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
219460642|NCT03795545|PROCEDURE|SWL|Shock wave lithotripsy
219460643|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
219460644|NCT02289118|DRUG|[18F]-T807 imaging tracer|Tau Imaging tracer
219460645|NCT02971072|PROCEDURE|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
219460646|NCT02971072|OTHER|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
219460647|NCT05588076|OTHER|no intervention|no intervention
219460648|NCT02655263|DRUG|Somatropin|Somatropin infusion (Genotropin®)
219460649|NCT02655263|OTHER|Ketone bodies|ketone bodies infusion
219460650|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
219460651|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
219460652|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
219460653|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
219460654|NCT02067546|DEVICE|Experimental toilet seat|
219460655|NCT02067546|DEVICE|Standard toilet seat|
219460656|NCT03700931|BEHAVIORAL|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
219460657|NCT03700931|BEHAVIORAL|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
219460658|NCT02476903|DRUG|Monovisc|
219460659|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
218850830|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
218850831|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
218850832|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
218850833|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
218850834|NCT00793572|DRUG|Bortezomib|Given SC
218850835|NCT00793572|DRUG|Cyclosporine|Given IV
219460660|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
219460661|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
219460662|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
218850836|NCT00793572|DRUG|Cyclosporine|Given PO
218850837|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
219460663|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
219460664|NCT00106366|DRUG|insulin detemir|
219460665|NCT00106366|DRUG|insulin glargine|
219460666|NCT00106366|DRUG|insulin aspart|
218850838|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
219460667|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
219460668|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
219460669|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
219460670|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
218850839|NCT00793572|DRUG|Melphalan|Given IV
218850840|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
218850841|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
219460671|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
219460672|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
219460673|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
219592455|NCT06551714|PROCEDURE|Neurophysiological facilitation techniques|"In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days."
219592456|NCT01027195|DEVICE|Bipolar Radiofrequency (Aquamantys 6.0)|
219592457|NCT01027195|DEVICE|Standard Bovie Electrocautery|
219592458|NCT06501716|PROCEDURE|Indocyanine Green|"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."
219592459|NCT00661895|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
219592460|NCT00661895|DRUG|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
219592461|NCT00661895|DRUG|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
219592462|NCT00661895|DRUG|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
219592463|NCT00661895|DRUG|Metoprolol tartrate|50 mg tablets \& 100 mg tablets
219592464|NCT00661895|DRUG|Atenolol|50 mg tablet
219592465|NCT00661895|DRUG|Valsartan|80 mg tablets \& 160 mg tablet
219592466|NCT00661895|DRUG|Doxazosin|4 mg tablets
219592467|NCT00661895|DRUG|Clonidine|0.2 mg tablets
219592468|NCT00661895|DRUG|Hydralazine|50 mg tablets
219592469|NCT00661895|DRUG|Metoprolol succinate|50 mg tablet \& 100 mg tablet
219592470|NCT00661895|DRUG|Amlodipine|5 mg tablets \& 10 mg tablets
219460674|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
218850842|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
218850843|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
218850844|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
218850845|NCT00309699|DRUG|Placebo|Daily for 3 weeks
219460675|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
219592471|NCT04371107|OTHER|consultation|Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months
219592472|NCT04371107|DRUG|Azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
218850846|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
218850847|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
218850848|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
219592473|NCT02387411|OTHER|High-intensity interval exercise training|High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
219592474|NCT02387411|OTHER|Combined exercise training|High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
218850849|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
218850850|NCT00269503|PROCEDURE|Prone Distraction|
218850851|NCT00269503|PROCEDURE|Side-Posture Manipulation|
218850852|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
218850853|NCT00269503|PROCEDURE|Usual Care (Control Group)|
218850854|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
218850855|NCT00221806|DEVICE|endothelialised prosthesis|
218850856|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
219460676|NCT01110889|DRUG|Agomelatine (AGO178C)|
219460677|NCT01110889|DRUG|Agomelatine (AGO178C)|
219460678|NCT01110889|DRUG|Placebo|
219361375|NCT07081958|DRUG|Placebo|Placebo matching each RO7795081 dosing regimen arm will be administered orally once daily during the 38-week treatment period.
219361376|NCT05007353|BEHAVIORAL|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
219361377|NCT05007353|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
219361378|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
219361379|NCT06357832|DEVICE|Brainsway Deep TMS System|The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.
219361380|NCT05448326|OTHER|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
219460679|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
219460680|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
219460681|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
219460682|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
218850857|NCT05076214|BEHAVIORAL|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
218850858|NCT05076214|BEHAVIORAL|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
218850859|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
218850860|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
219460683|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
219592475|NCT05108402|DIAGNOSTIC_TEST|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
219592476|NCT05108402|DIETARY_SUPPLEMENT|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
219198017|NCT04503694|DRUG|Regorafenib 30 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 60 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~* From day 1 to 14, during the Induction treatment~* From day 29 to 49, during the Consolidation treatment"
219198018|NCT04503694|RADIATION|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
219198019|NCT04503694|PROCEDURE|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
219592477|NCT06231095|DEVICE|continuous theta burst stimulation - cTBS|Continuous theta burst stimulation (cTBS) is a quicker and potentially more effective technique to reduce cortical hyperactivity than repetitive transcranial magnetic stimulation (rTMS). The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity.
219460684|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
219592478|NCT05065710|DRUG|ZL-1211|Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
218850861|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
218850862|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
218850863|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
219460685|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
219460686|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
219460687|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
219460688|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
219460689|NCT03515031|DEVICE|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
219460690|NCT03515031|DEVICE|Venturi Mask Oxygenation|delivery of high flow oxygen
219592479|NCT00609180|BEHAVIORAL|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
219460691|NCT04120025|BEHAVIORAL|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
218850864|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
219198020|NCT04503694|PROCEDURE|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~* Digital rectal examination~* Rectal endoscopy~* Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch \& wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
219198021|NCT06876051|BEHAVIORAL|Relaxation & Breastfeeding Education|"Pregnant women in this group will be trained in 10 individual interactive sessions, focusing on relaxation techniques and breastfeeding including:~1. Diaphragmatic breathing~2. Progressive muscle relaxation (PMR) - tailored for pregnant women.~3. Guided imagery~4. the analysis of the concept of stress and stress management strategies for pregnancy including Cognitive-behavioral approach (CBT principles)~5. Mindfulness-based pregnancy adaptation including positive thinking and wellbeing during pregnancy .~6. Pregnancy stages.~7. Benefits of breastfeeding.~8. Breastfeeding guide and practical applications.~9. Labor stages and childbirth preparation.~10. Newborn and infant needs at home Every relaxation technique training will last 20 minutes practice in every session Additionally pregnant women will be practiced at least 3 times weekly during pregnancy"
219361381|NCT05448326|OTHER|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
219361382|NCT05448326|BIOLOGICAL|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
219361383|NCT06909318|BEHAVIORAL|Asthma Education - Animated Video|"This intervention consists of a 7-minute and 39-second animated video titled Living with Asthma, specifically designed for children aged 7 to 11. The video features two characters, Mert and Robo, who explain asthma, its symptoms, triggers, and correct inhaler techniques in a child-friendly manner. The content is based on the latest GINA (2020) and NHLBI (2020) guidelines. The video is first watched in the clinic setting using a tablet device and then shared with parents via WhatsApp, email, or CD for home viewing. Parents are asked to watch the video with their child at least twice per week for two months and record viewing frequency using a structured observation form. This visual and engaging format distinguishes the intervention from conventional text-based education."
219361384|NCT06909318|BEHAVIORAL|Booklet Group|"This intervention involves the distribution of a 12-page, full-color, illustrated educational booklet titled Living with Asthma, developed for children aged 7 to 11. The booklet covers topics such as asthma symptoms, triggers, medication use, and device techniques using simple language and visual aids. Its content was developed in line with GINA (2020) and National Heart, Lung, and Blood Institute (2020) recommendations. During the initial clinic visit, children and parents are introduced to the booklet and instructed to review it together at least twice per week over two months. Parents are also asked to log reading sessions using a structured observation form. This printed, interactive material offers a visually supported, age-appropriate alternative to standard asthma education methods."
219361385|NCT06908005|OTHER|CT radiomic analysis|Radiomic features of tumor tissue
219361386|NCT06908005|OTHER|Fibrosis assessment|Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software (v1.5)
218850865|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
218850866|NCT05996055|DEVICE|improved version_support device|designed the NTUH version\_support device based on the clinical suggestion.
218850867|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
218850868|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
218850869|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
219361387|NCT06914752|DEVICE|TENS|transcutaneous electrical nerve stimulation
218850870|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
218850871|NCT02783040|DRUG|Midazolam|
218850872|NCT02783040|DRUG|Warfarin|
218850873|NCT02783040|DRUG|Omeprazole|
218850874|NCT02783040|DRUG|Midazolam|
218850875|NCT02783040|DRUG|Digoxin|
219361388|NCT02508805|DRUG|Neuromultivit|
219361389|NCT02508805|DRUG|Voltaren|
219361390|NCT02508805|DRUG|Sirdalud|
218850876|NCT02783040|DRUG|BI 425809|
218850877|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
219361391|NCT06916520|DRUG|Prasugrel 5 mg|Prasugrel 5 mg once daily (monotherapy)
219361392|NCT06916520|DRUG|Dual Antiplatelet (DAPT) Therapy|Dual antiplatelet therapy according to guidelines
219361393|NCT06917066|PROCEDURE|TAVR|TAVR procedure using Myval Transcatheter Heart Valve
218850878|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
218850879|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
218850880|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
218850881|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
219460692|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
219460693|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
219460694|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
219460695|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
219460696|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
219460697|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
219460698|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
219460699|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
219460700|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
219460701|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
219460702|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
219460703|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
219460704|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
219460705|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
219460706|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
219460707|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
219460708|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
218850882|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
219460709|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219460710|NCT00347685|DRUG|tramadol ER|
219460711|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
219460712|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
219460713|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
219460714|NCT00840684|DRUG|amsacrine|
219460715|NCT00840684|DRUG|busulfan|
218850883|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
219460716|NCT00840684|DRUG|cytarabine|
219460717|NCT00840684|DRUG|daunorubicin hydrochloride|
219460718|NCT00840684|DRUG|laromustine|
219460719|NCT00840684|DRUG|melphalan|
219460720|NCT00840684|DRUG|mitoxantrone hydrochloride|
219460721|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219460722|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
219460723|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
219460724|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
219460725|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
219460726|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
219460727|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
219460728|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
218850884|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
218850885|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
218850886|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
218850887|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
219460729|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
219460730|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
219592480|NCT00609180|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
218850888|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
218850889|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
219460731|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
219460732|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
218850890|NCT07033858|DRUG|Rapamune Pill|Rapamiune Tablet 1mg daily plus Advograf plus prednisolone
219460733|NCT00754312|DRUG|SNDX-275|
218850891|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219019257|NCT07132684|DRUG|Daunorubicin/Idarubicin|Daunorubicin/Idarubicin is used in Induction Therapy and Maintenance Therapy.
219019258|NCT07132684|DRUG|Cytarabine|Cytarabine is used in Induction Therapy, Consolidation Therapy and Maintenance Therapy.
219019259|NCT07132684|DRUG|Azacitidine|Azacitidine is used in VA regimen
219019260|NCT07132684|DRUG|Venetoclax|Venetoclax is used in VA regimen
219019261|NCT06868329|OTHER|Superficial moist heat|Twenty minutes of automatic moist hot pack (Besmed© BE-267, Taiwan) of suitable size was used to apply superficial heat. The heat level was adjusted to the medium level. While the moist environment was assured by placing a moist sponge layer between the pack and its cotton outer coverage. The duration was calculated after 8 minutes of warming up (when the temperature reaches its maximum level). The patient-reported sensation should be moderate warmth. A thermal sensation test using two test tubes was performed before applying heat therapy to avoid any adverse effects
219460734|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
219460735|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
219592481|NCT00609180|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
219592482|NCT00609180|DIETARY_SUPPLEMENT|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
219592483|NCT03082144|DRUG|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
218850892|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
218850893|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
219460736|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
219460737|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
219460738|NCT00155428|PROCEDURE|rapid prototyping|
219460739|NCT00155428|PROCEDURE|computed tomography|
219460740|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
219460741|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
219460742|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
219460743|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
219460744|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
219460745|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
219460746|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
219460747|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
219460748|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
219460749|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
219460750|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
219460751|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
219592484|NCT03082144|DRUG|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
219460752|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
219460753|NCT00646191|DRUG|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
219460754|NCT00646191|DRUG|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
219460755|NCT00646191|DRUG|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
219460756|NCT03262285|PROCEDURE|phacoemulsification|removal of cataract using ultrasound waves
219460757|NCT03262285|PROCEDURE|extracapsular cataract extraction|removal of cataract using surgical corneal incision
219460758|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
219460759|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
219460760|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
219460761|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
219460762|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
219592485|NCT03082144|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
218850894|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
218850895|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
218850896|NCT02358200|DRUG|BMN-673|
218850897|NCT02358200|DRUG|Carboplatin|
219361394|NCT06915922|DEVICE|Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy|Nd:YAG laser treatment(s) for Vision Degrading Myodesopsia (clinically significant vitreous floaters) in eyes with vitreous opacities due to myopic vitreopathy and posterior vitreous detachment (PVD).
219361395|NCT06917495|DRUG|Rifampin|Rifampin: once daily, 600 mg.
219361396|NCT06917495|DRUG|Isoniazid|Isoniazid: once daily, 300 mg.
219361397|NCT06917495|DRUG|Rifapentine (RPT)|Rifapentine: once daily with dosage adjusted based on body weight: 750 mg for ≤41.2 kg, 900 mg for \>41.3-48.7 kg, 1050 mg for \> 48.8-56.2 kg, 1200 mg for ≥ 56.3 kg.
219361398|NCT06917495|DRUG|Moxifloxacin|Moxifloxacin: once daily, 400 mg.
219361399|NCT06917495|DRUG|Pyrazinamide|Pyrazinamide: once daily with dosage adjusted based on body weight: 1000 mg for \< 55 kg, 1500 mg for ≥ 55-75 kg, and 2000 mg for \>75 kg.
219361400|NCT06917495|DRUG|Ethambutol|Ethambutol: once daily with dosage adjusted based on body weight: 800 mg for \< 55 kg, 1200 mg for ≥ 55-75 kg, and 1600 mg for \> 75 kg.
219460763|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
219460764|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
219460765|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
219460766|NCT05598840|OTHER|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
219460767|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
219460768|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
219460769|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
219460770|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
219460771|NCT01425242|DRUG|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
219460772|NCT01425242|DRUG|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
218850898|NCT02358200|DRUG|Paclitaxel|
219361401|NCT06917339|DEVICE|NeuroStar Advanced TMS Therapy System|non-invasive brain stimulation device
218850899|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
218850900|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
218850901|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
218850902|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
218850903|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
218850904|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
219361402|NCT06915181|DRUG|Pyridostigmine|"Subjects will participate in a double-blind randomized controlled cross-over trial. All patients will receive the study drug and placebo. Subjects and investigators will remain blinded to whether the subject receives active treatment during the first or second treatment period.~Participation in the study will last 10 weeks, with 4 weeks on active treatment and 4 weeks on placebo, with a 2-week wash-out period in between."
219361403|NCT06915818|DEVICE|Ileo-colic and colo-colonic Anastomosis with Flexagon SFM and OTOLoc|This study will investigate two types of intervention: ileo-colic and colo-colonic anastomosis creation in subjects undergoing colon surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into a portion of either the ileum or the colon that are intended to be anastomosed. An OTOLoc device will be deployed into the ileum/colon wall to provide access for the deployment of a Flexagon SFM into the bowel. The process is repeated at an intended section of colon. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
219361404|NCT06917183|OTHER|Training using the Immersive Multi- player Virtual Surgical Safety Checklist Training Simulator|Training for performing surgical safety checklist for a period of 4 weeks.
219361405|NCT06910449|RADIATION|hemithoracic Volumetric Arc Radiotherapy post Pleural decortication|post operative delivery of hemithoracic Volumetric Arc Radiotherapy
219361406|NCT06914089|DEVICE|The BioMime is an ultra-thin strut (65 µm) SES that uses a cobalt-chromium platform with a unique hybrid design of open cells in the mid segment and closed cells at the edges|testing its safety and efficacy at long term follow up after primary percutaneous intervention
219460773|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
219460774|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
219460775|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
219460776|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
219460777|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
219460778|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
219460779|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
219460780|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
219460781|NCT00337740|PROCEDURE|endoscopic variceal banding|
219592486|NCT06273501|DRUG|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
219592487|NCT00315289|PROCEDURE|Nasolacrimal balloon catheter duct dilation|
219592488|NCT00315289|PROCEDURE|Nasolacrimal intubation|
219592489|NCT00315289|PROCEDURE|Simple Nasolacrimal duct probing|
219592490|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
219592491|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
219019262|NCT06868329|OTHER|Hamstring and back muscles stretching|Patients received manual passive stretch for the hamstring and lower back muscles. Three repetitions per session with every repetition sustained for 30 s. The patient assumed a long sitting position with both knees in full extension and feet together. The patient was then asked to bend forward from the hips to reach the furthest point towards the feet. The therapist applied over pressure by pressing hands on the patient's upper back and pushing forward.
219019263|NCT06868329|OTHER|posterior pelvic tilting exercises regular procedures|Patients will be asked to assume the supine position with both knees semi-flexed. A small billow will be placed under the low back, another billow will be placed under the flexed knees for comfort. The patient will be asked to tuck the abdominal muscles inward and press with the low back on the underlying billow and hold for six seconds, then relax. after a few seconds of rest, the patient should repeat this procedure for 3 sets X 10 repetitions per session during the first 2 weeks. the number of sets will be increased according to the adaptation of each patient and his/her fatigue threshold.
219019264|NCT06868329|OTHER|Postural correction with lumbar stabilization using TBed|These exercises consisted of pelvic rocking, and activation of the upper back and interscapular muscles. TBed from Techno body©, Italy was used to assist the patient to perform these exercises through VR video gaming interface. The patients in the experimental group will be asked to contract the targeted muscles and push down on the surface of the TBed. Patient's pressure will activate the sensors inserted inside the TBed, which will be reflected on the game as triggering of the gun that targets flying fruits. The game consists of three levels, easy, medium, and hard. The patient will be asked to play the game for the lower back where pushing the lower back against the bed (posterior pelvic tilting) triggered the gun and for the upper back where pushing the scapula against the bed was the triggering action.
219460782|NCT00337740|DRUG|propranolol|
219460783|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
218850905|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
218850906|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
219460784|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
219460785|NCT02475564|DRUG|Placebo|40mg of starch
219460786|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
219460787|NCT02961400|OTHER|PUSH text messages|The intervention is designed to remind participants of treatment components.
218850907|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
219460788|NCT02961400|OTHER|PULL text messages|The intervention is designed to remind participants to recall treatment components.
219460789|NCT02961400|BEHAVIORAL|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
219460790|NCT02961400|BEHAVIORAL|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
219460791|NCT01156012|DRUG|T2345|One drop of T2345
219460792|NCT01156012|DRUG|Prostaglandin|One drop
219460793|NCT01665040|DEVICE|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
219460794|NCT01203111|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
219460795|NCT01203111|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
219460796|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
219460797|NCT02705755|DRUG|TD-9855|Administered orally.
219460798|NCT02705755|DRUG|Placebo|Administered orally.
219460799|NCT00490126|OTHER|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
218850908|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
218850909|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
218850910|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
218850911|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
218850912|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
219019270|NCT05251207|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
219019271|NCT05251207|DIETARY_SUPPLEMENT|L-leucine|L-leucine
219019272|NCT05251207|BEHAVIORAL|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
219019273|NCT04678011|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
219460800|NCT02382952|DEVICE|Differential Dissector|
219460801|NCT02382952|OTHER|Standard Dissection Method|
219460802|NCT05265585|DIAGNOSTIC_TEST|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
219460803|NCT07052708|BEHAVIORAL|No adherence group|Patients with poor adherence was defined as medication possession ratio(MPR) \<50%.
219460804|NCT07052708|BEHAVIORAL|Adherence group|Patients with good adherence was defined as medication possession ratio(MPR) ≥50%.
219460805|NCT07058428|DRUG|Bevacizumab|Bevacizumab starts on day 1 (one week before FSRT treatment), q3w，a total of 4 treatment courses, intravenous injection, with a dose of 7.5mg/kg.
219460806|NCT07058428|RADIATION|FSRT|The FSRT group received simple FSRT radiotherapy; FSRT is targeted at visible intracranial lesions, with a total dose of 30Gy, administered once a day for a total of 5 days, with a fraction dose of 6Gy.
219460807|NCT07058428|RADIATION|Whole brain radiotherapy|The WBRT group received whole brain radiotherapy and locally increased dose radiotherapy for visible intracranial lesions, with a total dose of 40Gy for local lesions and 30Gy for the whole brain, once a day for a total of 10 days.
219460808|NCT02651376|COMBINATION_PRODUCT|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
219460809|NCT01565460|OTHER|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
219460810|NCT03567590|PROCEDURE|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
219460811|NCT03567590|PROCEDURE|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
219460812|NCT04773964|DRUG|MET642|MET642 active treatment
219460813|NCT04773964|DRUG|Placebo|Placebo comparator
219460814|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
219460815|NCT03164122|DRUG|injection of microfat and plasma rich platelet PRP|intra-articular injections
219460816|NCT03164122|DEVICE|MRI|MRI 3T
218850913|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
219019276|NCT03782636|DRUG|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
219019277|NCT03782636|OTHER|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
219019283|NCT06870331|DIETARY_SUPPLEMENT|Probiotic|Participants will take one sachet BIOTICS-G (Burgerstein, Switzerland, 2.5 g) daily for eight weeks. The supplement contains 14 bacterial strains with a total viable cell count of 2.5 billion colony-forming units per sachet.
219019284|NCT06870331|DIETARY_SUPPLEMENT|Prebiotic|Participants will take 5 g of oat bran (Naturaplan Bio Haferkleie, Coop, Switzerland) daily for eight weeks.
219460817|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
219460818|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
219460819|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
219460820|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
219460821|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
219460822|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
219460823|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
219460824|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
219460825|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
219460826|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
218850914|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
218850915|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
218850916|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
218850917|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
218850918|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
219460827|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
219460828|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
219460829|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
219460830|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
219592492|NCT01056289|DRUG|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
219592493|NCT01917916|DRUG|Placebo|Solution for subcutaneous (s.c.) injection.
219592494|NCT01917916|DRUG|BI 655064|Solution for subcutaneous (s.c.) injection.
219592495|NCT00098358|DRUG|Zileuton|
219592496|NCT02918812|DRUG|Intracervical lidocaine|Intracervical lidocaine injected at four different points
219592497|NCT02918812|DRUG|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
219592498|NCT00583388|DIETARY_SUPPLEMENT|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
219592499|NCT00583388|DEVICE|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
219592500|NCT00216138|DRUG|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
219592501|NCT00216138|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
218850919|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
218850920|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
219592502|NCT00216138|DRUG|Premedication|Dexamethasone and antiemetic premedication
218850921|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
219019285|NCT06870617|OTHER|Practical Geriatric Assessment|The PGA will be administered via the electronic health record (EHR), available for patients to complete independently prior to an initial medical oncology visit, or during the visit with staff assistance. Results from the PGA will be shared automatically with clinical teams via the EHR, including a Best Practice Alert highlighting any identified geriatric impairment(s) and ASCO's recommendation for PGA-adapted care.
219019286|NCT06870617|OTHER|Correlation of body composition PGA and step count with outcomes|Monitoring of step counts (measured via FitBit) and body composition (measured via standard abdominal CT scans)
219019287|NCT02472795|DRUG|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
219592503|NCT02487303|DRUG|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
219019288|NCT02472795|DRUG|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
219361432|NCT07178990|BEHAVIORAL|Digital Contingency Management Intervention Arm|Participants will use a version of the app for 6-months. Participants in this group may earn rewards for completing recovery-related activities and for abstinence from drugs and alcohol. During the 6 months this will include: random saliva drug tests, breathalyzer tests, and video selfies, completing surveys and questionnaires through the app, and receiving rewards on a debit card for abstinent tests, surveys, and activities. Additionally, participants will complete follow-up at approximately 9 months after randomization.
219361433|NCT07178990|BEHAVIORAL|Digital Wellness Arm|Participants will use a version of the app for 6-months focussed on wellness. During the 6 months this will include: random requests to do saliva drug tests, breathalyzer tests, and video selfies, complete surveys and questionnaires through the app, and receive rewards on a debit card for completing tests, surveys, and activities. Participants in this group may also earn rewards for completing study activities like tests and surveys. Additionally, participants will complete follow-up at approximately 9 months after randomization.
219361434|NCT07178210|DEVICE|Symani Surgical System|Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.
219361435|NCT07177664|OTHER|Breastfeeding Consultation Provided through the Nurse Navigation Program|The navigator nurse will meet with the pregnant woman/mother starting at 28-32 weeks of gestation and continuing until the sixth month postpartum. During these meetings, planned breastfeeding education will be provided, women's questions about breastfeeding will be answered, and counseling will be provided to address any concerns.
219361436|NCT07178145|DRUG|GLP-1RA|Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of 0.5, 1.0, 1.7, and 2.4 mg until a target dose of 2.4mg is reached after 16 weeks.
219361437|NCT07178613|DRUG|Serine（Oral）|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
219592504|NCT02487303|DRUG|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
219592505|NCT04412278|OTHER|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
219592506|NCT01708668|PROCEDURE|Epidural analgesia|
219592507|NCT01708668|PROCEDURE|Combined spinal-epidural analgesia|
219592508|NCT01708668|PROCEDURE|Continuous epidural infusion|
219592509|NCT01708668|PROCEDURE|Intermittent epidural bolus|
219592510|NCT01741168|OTHER|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
219592511|NCT01741168|OTHER|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
219460831|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
219460832|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
218850922|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
218850923|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
218850924|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
218850925|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
218850926|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
218850927|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
218850928|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
218850929|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
218850930|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
218850931|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
218850932|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
218850933|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
218850934|NCT01165112|DRUG|Carboplatin|Given IV
218850935|NCT01165112|BIOLOGICAL|Rituximab|Given IV
218850936|NCT01165112|DRUG|Etoposide|Given IV
218850937|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
218850938|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
219460833|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
219592512|NCT05568667|BEHAVIORAL|Low risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* logbook"
219592513|NCT05568667|BEHAVIORAL|Moderate risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* logbook"
219592514|NCT05568667|BEHAVIORAL|High risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* 3 individual sessions of motivational coaching~* connected watch~* logbook"
219592515|NCT00102947|DRUG|daptomycin (up to 14 days)|
219460834|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
219460835|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
219460836|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
219460837|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
219592516|NCT04192461|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
219198022|NCT06876051|BEHAVIORAL|Active comparator|"Participants in this group will receive only interactive online education, focusing exclusively on breastfeeding and newborn care. The Programme included ten remote sessions:~1. Pregnancy stages.~2. Benefits of breastfeeding.~3. Skin-to-skin contact and rooming-in during the first days.~4. The role of breastfeeding in maternal emotional well-being.~5. Breastfeeding guide and practical applications.~6. Maternal nutrition during breastfeeding.~7. Common breastfeeding challenges.~8. The father's role in breastfeeding support.~9. Labor stages and childbirth preparation~10. Newborn and infant needs at home."
219198023|NCT06876051|OTHER|control group|This group will received only standard prenatal and postnatal care at a Baby-Friendly Hospital, which adheres to WHO and UNICEF guidelines for breastfeeding support. They did not participate in additional structured educational programs or relaxation training.
219198024|NCT06882993|DIAGNOSTIC_TEST|Panenteric capsule endoscopy|Panenteric capsule endoscopy
219198025|NCT06882993|DIAGNOSTIC_TEST|Ileocolonoscopy|Endoscopic examination of the colon and terminal ileum after bowel preparation.
219198026|NCT06882993|DIAGNOSTIC_TEST|MRI enterography|MRI of the small bowel
219198027|NCT06882993|DIAGNOSTIC_TEST|Small bowel capsule endoscopy|Capsule endoscopy of the small bowel
219198028|NCT06721572|DEVICE|TEA|Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.
219198029|NCT06884241|DIETARY_SUPPLEMENT|Probiotic supplementation|The intervention consists of a 6-week supplementation with a specific combination of probiotics: Lactiplantibacillus plantarum P17630 49x109, Lacticaseibacillus paracasei I1688 1x109, Ligilactobacillus salivarius I1794 25x106. All participants were given a gluten-free, low FODMAPs diet. After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained
219198030|NCT06884241|OTHER|Placebo|"The participants received placebo for 6 weeks. Placebo was identical in appearance, texture, taste, and packaging to the probiotic treatment. All participants were given a gluten-free, low FODMAPs diet.~After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained"
219198031|NCT06857019|OTHER|"Endotracheal Tube Position Anomaly Alerting System"|"The Endotracheal Tube Position Anomaly Alerting System (ETPAAS) is designed to assist healthcare providers in managing patients receiving mechanical ventilation via an endotracheal tube. This system integrates an artificial intelligence (AI) algorithm that automatically evaluates the appropriateness of endotracheal tube positioning whenever a patient's chest X-ray is uploaded. If the system detects that the distance between the endotracheal tube tip and the carina falls outside the optimal range, it promptly alerts healthcare providers, enabling timely intervention to correct the tube position and enhance patient safety."
219198032|NCT06648564|PROCEDURE|Bone regenerative surgery with a bone graft substitute and a resorbable membrane|Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
219198033|NCT06346704|OTHER|Digital HealthTechnology|Subject will wear the Syde® for 1 month every 6 months
218850939|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
218850940|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
218850941|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
218850942|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
218850943|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
218850944|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
218850945|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
218850946|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
218850947|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
218850948|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
218850949|NCT00433160|DRUG|Placebo|daily, subcutaneous
218850950|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
218850951|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
219361438|NCT07178613|DRUG|Fluoropyrimidine Drugs|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
219460838|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
219460839|NCT02049385|DRUG|Placebo|Placebo
219460840|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
219460841|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
219460842|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
219460843|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
219460844|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
219460845|NCT04492514|DRUG|Mavrilimumab|Treatment infusion
219460846|NCT04492514|DRUG|Placebo|Placebo infusion
219460847|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
218850952|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
218850953|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
218850954|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
218850955|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
218850956|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
218850957|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
218850958|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
219361439|NCT07178080|DEVICE|PIUR tUS Infinity Ultrasound|PIUR imaging technology, cleared by the U.S. Food and Drug Administration under 510(k) (K240036), is designed to provide advanced volumetric imaging capabilities to improve accuracy in assessing nodule size and volume reduction.
219361440|NCT07179445|OTHER|Not applicable- observational study|Not applicable- observational study
219460848|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
219460849|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
219460850|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
218850959|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
218850960|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
219460851|NCT03758612|DRUG|TBI-223 oral suspension|TBI-223 oral suspension, orally administered.
219460852|NCT03758612|DRUG|TBI-223 enteric capsule|TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.
219198034|NCT05525104|DEVICE|Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)|"This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration"
219198035|NCT06602466|DRUG|Test toothpaste|0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
219198036|NCT06602466|DRUG|Colgate Cavity Protection Toothpaste|Commercial toothpaste containing 1450 ppm fluoride.
219361441|NCT07178275|BEHAVIORAL|Baduanjin Qigong|A standardized 60-minute Baduanjin Qigong protocol (15 minutes of breathing-focused warm-up, eight movements each lasting 5 minutes, and 10 minutes of breathing-focused closing). The sessions will be conducted by a licensed occupational therapist certified in Qigong.
219460853|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 1|TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.
219460854|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 2|TBI-223 600 mg SR tablet Prototype 2, orally administered.
219460855|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 3|TBI-223 900 mg SR tablet Prototype 3, orally administered.
218850961|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
218850962|NCT03802344|DRUG|Vehicle|Vehicle cream
218850963|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
218850964|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
218850965|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
218850966|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
219460856|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet, orally administered
219460857|NCT03758612|DRUG|Placebo suspension|Placebo for TBI-223 oral Suspension; orally administered.
219460858|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
219460859|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
219592517|NCT04587999|OTHER|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~* The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~* the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~* The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~* The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
219592518|NCT04587999|OTHER|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
219592519|NCT01806571|DRUG|Cytarabine|Given IV
219592520|NCT01806571|DRUG|Daunorubicin Hydrochloride|Given IV
219592521|NCT01806571|OTHER|Laboratory Biomarker Analysis|Correlative studies
219592522|NCT01806571|DRUG|Nilotinib|Given PO
219592523|NCT01806571|OTHER|Pharmacological Study|Correlative studies
219592524|NCT04659759|OTHER|COVID-19 exposure|COVID-19 exposure during pregnancy
219592525|NCT04659759|BIOLOGICAL|COVID-19 vaccine|Receipt of any COVID-19 vaccine
219592526|NCT02198183|DEVICE|Casmed Fore-Sight Elite|
219592527|NCT02198183|DEVICE|Non-invasive Cardiac Output Monitor (NICOM)|
218850967|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
218850968|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
218850969|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
218850970|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
218850971|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
218850972|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
218850973|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
218850974|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
218850975|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
218850976|NCT01895231|DRUG|Placebo|
218850977|NCT02153424|DRUG|Apixaban|
218850978|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
218850979|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
218850980|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
218850981|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
218850982|NCT02952963|DRUG|Chenodeoxycholic Acid|
218850983|NCT02952963|DRUG|Colesevelam|
218850984|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
218850985|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
218850986|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
218850987|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
218850988|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
218850989|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
218850990|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
218850991|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
219460860|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
219460861|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
219460862|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
218850992|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
218850993|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
218850994|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
218850995|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
218850996|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
218850997|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
218850998|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
218850999|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
218851000|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
218851001|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
218851002|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
218851003|NCT00255138|DRUG|Atomoxetine|
218851004|NCT00000293|DRUG|Nefazodone|
218851005|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
218851006|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
218851007|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
218851008|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
219460863|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
219460864|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
219460865|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
219460866|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
219460867|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
219460868|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
219460869|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
219460870|NCT01603615|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
219460871|NCT02967965|OTHER|Imagery|MRI at year 3
219460872|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
219460873|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
219460874|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
219592528|NCT01947998|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
218851009|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
219460875|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
219592529|NCT01947998|DRUG|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
219592530|NCT01947998|DRUG|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
219592531|NCT01570114|DEVICE|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
219592532|NCT00337337|BEHAVIORAL|Multiple grain|
219592533|NCT00337337|BEHAVIORAL|Ordinary Asian- rice|
219592534|NCT06583161|BEHAVIORAL|Moderate drinking|Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
219592535|NCT06583161|BEHAVIORAL|Quitting|No alcohol consumption
219592536|NCT06583161|BEHAVIORAL|Social drinking|Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
218851010|NCT05270291|PROCEDURE|rectal swab|rectal swab
218851011|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
218851012|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
218851013|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
218851014|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
219592537|NCT06583161|BEHAVIORAL|Heavy/binge drinking|Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
219592538|NCT02446756|OTHER|acupuncture|
219592539|NCT02446756|OTHER|physiotherapy|
219592540|NCT02618759|DRUG|DSXS|active treatment
219592541|NCT02618759|DRUG|Placebo|placebo treatment
219592542|NCT00269230|DEVICE|Pacing Lead|Left ventricular pacing lead
219592543|NCT03074344|DEVICE|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
219592544|NCT03074344|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
219592545|NCT01823497|DRUG|Morphine|Morphine will be used to control pain post-surgery.
219592546|NCT05884944|PROCEDURE|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
218851015|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
218851016|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
219460876|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
219460877|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
219460878|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
219460879|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
219460880|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
219460881|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
219460882|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
219460883|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
219460884|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
219460885|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
219460886|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
219460887|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
218851017|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
218851018|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
219361442|NCT07178275|BEHAVIORAL|Passive Rest|Passive rest refers to a condition in which participants remain seated or lying quietly in a calm environment for a specified period of time, without engaging in any structured physical activity, therapeutic exercise, or cognitive tasks. During this period, external stimuli such as phone use, electronic devices, or reading materials are restricted in order to minimize distraction. The purpose of the passive rest condition is to provide a neutral control state that accounts for the passage of time and environmental factors, allowing valid comparison with the active intervention
218851019|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
218851020|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
218851021|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
218851022|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
218851023|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
219361443|NCT07179406|OTHER|H-Reflex|H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes.
219460888|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
219460889|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
219460890|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
219460891|NCT01970124|DRUG|KPS-0373, High dose|
219460892|NCT01970124|DRUG|KPS-0373, Low dose|
219460893|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
219460894|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
219460895|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
219460896|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
219460897|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
219460898|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
219460899|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
218851024|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
218851025|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
219460900|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
219460901|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
219460902|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
219460903|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
219460904|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
219460905|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
219460906|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
219460907|NCT00085189|DRUG|agatolimod sodium|Given SC
218851026|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
218851027|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
218851028|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
219460908|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
219460909|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
219460910|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
219460911|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
219460912|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
219460913|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
219460914|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
219460915|NCT01730768|DRUG|AQW051|
219460916|NCT01730768|DRUG|Placebo|
219460917|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
218851029|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
218851030|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
218851031|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
218851032|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
218851033|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
218851034|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
219460918|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
219460919|NCT04252872|DRUG|HCP0605|
219361444|NCT07179406|OTHER|Somatosensory evoked potential (SSEP)|A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes.
219361445|NCT07179406|OTHER|Vibratory Electrophysiological Response Potential (ERP)|stimulation is provided to the ankle with vibration sensations using a device like a buzzer and the recording of the body's responses using the EEG and/or EMG electrodes.
219460920|NCT04252872|DRUG|HGP1405|
219460921|NCT04252872|DRUG|HCP1401|
219460922|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
219460923|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
219460924|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
219460925|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
219460926|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
219460927|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
219460928|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
219460929|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
219460930|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
219361446|NCT07179406|OTHER|Transcranial Magnetic Stimulation (TMS)|A small magnetic pulse is used to provide a small amount of electrical stimulation to the nervous system. The EEG and/or EMG electrodes will be used to measure the body's reaction.
219460931|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
219592547|NCT05884944|PROCEDURE|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
218851035|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
218851036|NCT05686096|DRUG|MYK-224|Specified dose on specified days
219460932|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
219460933|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
219460934|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
219460935|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
219460936|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
219460937|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
218851037|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
218851038|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
218851039|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
219460938|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
219460939|NCT04853368|DRUG|ABBV-576|Oral capsules
219460940|NCT04853368|DRUG|Galicaftor|Oral capsules
219460941|NCT04853368|DRUG|Placebo|Oral capsules
219460942|NCT04853368|DRUG|Navocaftor|Oral capsules
219460943|NCT04853368|DRUG|ABBV-119|Oral capsules
219460944|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
219460945|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
219460946|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
219460947|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
219460948|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
219460949|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
219460950|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
219460951|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
219460952|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
219460953|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
218851040|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
218851041|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
218851042|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
218851043|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
218851044|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
218851045|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
218851046|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
218851047|NCT02263911|DRUG|Baricitinib|Administered orally
218851048|NCT02723006|DRUG|TAK-580|TAK-580 tablets
218851049|NCT02723006|DRUG|TAK-202|TAK-202 infusion
218851050|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
218851051|NCT02723006|DRUG|nivolumab|nivolumab infusion
218851052|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
218851053|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
218851054|NCT00227318|DRUG|ATACAND|
218851055|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
218851056|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
218851057|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
218851058|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
219460954|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
219592548|NCT04403828|OTHER|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
218851059|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
218851060|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
218851061|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
218851062|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
218851063|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
218851064|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
218851065|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
218851066|NCT02100163|OTHER|Standard treatment|
218851067|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
218851068|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
219361447|NCT07179406|OTHER|Spinal Cord Stimulator (SCS) manipulation|Spinal cord stimulator will be turned on/off
219361448|NCT07179237|DIETARY_SUPPLEMENT|Carminal Oral solution|Carminal is an oral dietary supplement presented in 30 ml vials, administered once daily (1 vial BID). It contains Aloe vera extract, olive extract, glutamic acid, zinc, and other components with potential antioxidant, anti-inflammatory, and immunomodulatory effects on gastric mucosa. In this study, Carminal is administered for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued treatment post-eradication to support mucosal recovery and improve dyspeptic symptoms.
218851069|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
218851070|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
218851071|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
218851072|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
218851073|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
218851074|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
218851075|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
218851076|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
218851077|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
218851078|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
218851079|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
218851080|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
218851081|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
218851082|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
218851083|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
218851084|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
219460955|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
219460956|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
219460957|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
219460958|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
219460959|NCT02298790|BEHAVIORAL|Meal schedule|
219460960|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
219460961|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
219460962|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
218851085|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
218851086|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
218851087|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
219460963|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
219460964|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
219460965|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
219460966|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
219460967|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
218851088|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
218851089|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
218851090|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
218851091|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
218851092|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
218851093|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
219019292|NCT06045962|DEVICE|Ureteral stent|Used to open the ureter and help the kidney drain
219460968|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
219460969|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
219460970|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
219460971|NCT00231621|DRUG|topiramate|
219460972|NCT03553121|OTHER|walking|walking and not walking
219592549|NCT02856555|DRUG|Firsocostat|Capsules orally once daily.
219592550|NCT02856555|DRUG|Placebo|Placebo matched to firsocostat orally once daily.
219592551|NCT03333941|DEVICE|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
219019295|NCT06872060|DRUG|Glucagon|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes.
219019296|NCT06872060|DRUG|Glucagon+Exendin9-39|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes
219019297|NCT06872060|DRUG|Sodium chloride|Placebo (0.9% NaCl).
219019298|NCT07010471|DRUG|1.0mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
219460973|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
219592552|NCT03955458|DRUG|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
219592553|NCT03955458|DRUG|Ropivacaine|FICB with continuous infusion of ropivacaine
219592554|NCT03955458|DRUG|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
219592555|NCT01342601|DEVICE|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
219592556|NCT01342601|DEVICE|Placebo products|Nasal Spray and Eye drops without Ectoin
219592557|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
219592558|NCT03155321|OTHER|It's an observational study - no intervention is planned|No intervention is planned
219592559|NCT02932306|DRUG|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
218851094|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
219460974|NCT05659875|OTHER|Standard Occupational Therapy Arm Exercise Program|Standard exercise program will be provided addressing shoulder, elbow, forearm, wrist, and hand with expectation that participant will complete 3 times a week. Exercise program will be updated at assessment timepoints as needed with change in arm function.
219460975|NCT01396811|DRUG|33525|Daily for 14 days
219460976|NCT01396811|DRUG|Placebo|Daily for 14 days
219460977|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
219460978|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
219460979|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
219460980|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
219460981|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
219460982|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
219460983|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
219460984|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
219460985|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
219460986|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
219460987|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
219592560|NCT02932306|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
219592561|NCT03163524|OTHER|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
219592562|NCT03163524|OTHER|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
219592563|NCT05462431|BEHAVIORAL|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
219592564|NCT02627248|DRUG|Huaier Granule|20g tid, orally
219592565|NCT02627248|DRUG|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
219592566|NCT02627248|DRUG|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
219592567|NCT02627248|DRUG|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
218851095|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
218851096|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
218851097|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
218851098|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
219361449|NCT07179237|OTHER|Placebo|Placebo is an oral solution presented in 30 ml vials, identical in appearance, taste, color, and smell to Carminal, but without any active ingredients. It is administered once daily (1 vial BID) for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued placebo treatment post-eradication. This comparator is used to evaluate the efficacy of Carminal in mucosal recovery and symptom improvement in patients with H. pylori positive gastritis.
219019299|NCT07010471|DRUG|1.5mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
219019300|NCT07010471|DRUG|Placebo|Once daily orally or gastronomy/jejunostomy
219019305|NCT06864936|DRUG|Ublituximab|ublituximab
219019306|NCT06864936|OTHER|Other disease modifying therapies|Other disease modifying therapies for MS (not ublituximab)
219019307|NCT04780256|PROCEDURE|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~1. Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~2. Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~3. Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
219019308|NCT06871969|DIAGNOSTIC_TEST|Dry electrode EEG|"A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. EEG data will be acquired with Strokepointer (TrianecT B.V., Utrecht, The Netherlands).~StrokePointer is a portable EEG acquisition and analysis device. The device consists of three parts: (1) StrokePointer headset with dry electrodes to measure EEG data, (2) Portable StrokePointer suitcase that contains a mobile computing device (Android phone), CE-marked (IIa) EEG amplifier and storage compartments and (3) Software to acquire, analyse and upload EEG data."
219361450|NCT07179094|OTHER|Routine Protective Oral Care|In the control group, this group will perform oral care according to the routine clinical oral care procedures applied in the oncology clinic.
219361451|NCT07179094|OTHER|Protective Oral Care Using Peppermint Oil Mouthwash|Patients in the intervention group will perform a mouth rinse three times daily using 1 mL of peppermint oil diluted in 50 mL of water. The first application will be initiated on the day of chemotherapy, and patients will continue the peppermint oil oral care for six consecutive days (Day 0, Day 1, Day 2, Day 3, Day 4, and Day 5). The peppermint oil oral care protocol is scheduled to be administered at 07:00-08:00, 15:00-16:00, and 22:00-23:00, taking into account the routine timing of antiemetic medication administration in the clinic. The detailed description of the oral care protocol is presented below.
219361452|NCT07178743|DRUG|Initiation of palbociclib plus letrozole|Initiation of palbociclib plus letrozole described in electronic health records is used as the exposure.
219361453|NCT07178743|DRUG|Initiation of letrozole|Initiation of letrozole described in electronic health records is used as the reference.
219361454|NCT07179120|DRUG|Semaglutide (Rybelsus®)|Participants receive once-weekly subcutaneous injections of Semaglutide. The dose is titrated every 4 weeks: 0.25 mg (Weeks 1-4), 0.5 mg (Weeks 5-8), and maintained at 1.0 mg from Week 9 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
219361455|NCT07179120|DRUG|Tirzepatide|Participants receive once-weekly subcutaneous injections of Tirzepatide. The dose is titrated every 4 weeks: 2.5 mg (Weeks 1-4), 5 mg (Weeks 5-8), 10 mg (Weeks 9-12), and maintained at 15 mg from Week 13 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
219361456|NCT07179120|BEHAVIORAL|Standardized Lifestyle Intervention|Participants receive individualized intensive lifestyle management, including a calorie-restricted Mediterranean diet (daily deficit of 500 kcal), structured aerobic and resistance exercise (150 mins/week), and behavioral coaching. Delivered through weekly face-to-face sessions for the first 12 weeks, followed by bi-weekly sessions for the remaining 20 weeks. No pharmacotherapy is administered.
219361457|NCT07178717|DRUG|Rechalange with bevacizumab + encorafenib|Patients will receive encorafenib 300mg once daily plus cetuximab 500mg/m2 every 2 weeks until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy or death.
219361458|NCT07177898|DRUG|Allopurinol|Group A received allopurinol with lisinopril, and Group B received lisinopril alone
219361459|NCT07177872|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
219361460|NCT07178678|DRUG|NeuroEPO|0.5 mg of NeuroEPO will be administered intranasally three times a week for 52 weeks.
219361461|NCT07178678|DRUG|Placebo|250 µL of placebo will be administered to intranasally to each nostril three times a week for 52 weeks.
219361462|NCT00684957|DRUG|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
219361463|NCT00684957|DRUG|Recombinant Human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
219361464|NCT05847322|BIOLOGICAL|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
219361465|NCT05847322|DRUG|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
218851099|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
218851100|NCT04736953|DRUG|Sirolimus|Sirolimus
218851101|NCT04736953|OTHER|Placebo|Placebo
218851102|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
218851103|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
218851104|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
218851105|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
218851106|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
219460988|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
219460989|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
219460990|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
219460991|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
219460992|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
219460993|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
219460994|NCT03724318|PROCEDURE|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
219460995|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
219460996|NCT05114031|OTHER|Placebo|Saline water
219460997|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
219460998|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
219460999|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
218851107|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
218851108|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
218851109|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
218851110|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
218851111|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
218851112|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
218851113|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
218851114|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
218851115|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
218851116|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
218851117|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1\. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4\) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
218851118|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
218851119|NCT01863251|DRUG|Atomoxetine|
218851120|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
218851121|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
218851122|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
218851123|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
218851124|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
219461000|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
219461001|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
218851125|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
219461002|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
218851126|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
219461003|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
219461004|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
219461005|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
219461006|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
219461007|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
218851127|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
219461008|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
219592568|NCT05637346|PROCEDURE|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
218851128|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
218851129|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
218851130|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
218851131|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
218851132|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
219461009|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
219592569|NCT02518516|DRUG|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date)."
219461010|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
219461011|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
219461012|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
219461013|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
218851133|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
218851134|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
218851135|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
218851136|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
218851137|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
218851138|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
218851139|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
218851140|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
219461014|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
219461015|NCT06404476|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219461016|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
219461017|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
219461018|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
219461019|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
219461020|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
218851141|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
218851142|NCT00002440|DRUG|Indinavir sulfate|
218851143|NCT00002440|DRUG|Ritonavir|
218851144|NCT00002440|DRUG|Abacavir sulfate|
218851145|NCT00002440|DRUG|Amprenavir|
218851146|NCT00002440|DRUG|Nelfinavir mesylate|
219461021|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
219461022|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
219461023|NCT04880642|DRUG|C21|C21
219461024|NCT04880642|DRUG|Placebo|Placebo
219461025|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
219461026|NCT01223560|OTHER|Exercise|Exercise on tread mill
219461027|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
219461028|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
219461029|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
219461030|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
218851147|NCT00002440|DRUG|Saquinavir|
219461031|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
219461032|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
218851148|NCT02830347|DRUG|Amoxicillin|Extraction
219461033|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
219461034|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
219592570|NCT02518516|DRUG|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
219592571|NCT02518516|DRUG|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218851149|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
219461035|NCT02906644|DRUG|lorcaserin|
219461036|NCT02906644|DRUG|nicotine patch|
219461037|NCT02906644|DRUG|placebo lorcaserin|
218851150|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
219461038|NCT01974414|DRUG|orally administered cedar honey|
219461039|NCT02452034|DRUG|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
219461040|NCT02452034|DRUG|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
219461041|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
218851151|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
218851152|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
219461042|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
219461043|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
219198037|NCT06882434|BEHAVIORAL|Local intervention program|"HI-HOPE Project introduces a three-phase intervention program Phase 1: Active Mind \& Body (12 Weeks) Focus: Cognitive enhancement, depression relief, and music-based movement therapy.~Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 2: Complete Senior Wellness (12 Weeks) Focus: Comprehensive functional improvement covering all six ICOPE domains. Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 3: Advanced Exercise Training (12 Weeks) Focus: Strengthening self-care abilities and increasing acceptance of medical interventions.~Delivery: Professional exercise coaches. Schedule: 2 sessions/week, 1 hour per session (total 24 sessions)."
219461044|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
219198038|NCT06882434|BEHAVIORAL|Referral Process|"Self-referral tracking (1-2 weeks): Participants able to visit referral sites independently will be followed up to confirm completion.~Barrier assessment: If unable to attend, interviews will identify obstacles (e.g., transport, finances, willingness).~Transportation support: Solutions include volunteer transport with fuel subsidies, local transport networks, and government-assisted group referrals.~Financial assistance: Eligibility for social welfare aid will be assessed, with support for applications.~Personal willingness \& health literacy: Health education will address concerns about treatment or social stigma.~Telehealth consultations: Remote specialist consultations will be provided if in-person visits are not possible.~Hospital-based referral support: Group hospital visits will be arranged for those with referral difficulties.~Monthly tracking: Referral completion rates and outcomes will be monitored (e.g., treatments, assistive devices, social services)."
219198039|NCT06882434|BEHAVIORAL|Telehealth Education & Digital Integration|"Live-streamed health education across multiple community sites.~Digital health platforms for real-time intervention monitoring and professional feedback:~Polypharmacy management via medication usage tracking and pharmacist analysis. Nutritional assessment with dietitian recommendations. Health consultations provided remotely by specialists based on screening results."
219198040|NCT03990883|DEVICE|Princess Filler Lidocaine|correction of nasolabial folds
218851153|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
218851154|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
218851155|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
218851156|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
219198041|NCT06809751|DRUG|melatonin 3mg|In this group, participants will be randomly assigned to take 3 mg tablets of melatonin twice a day for 1 month.
219198042|NCT06809751|DRUG|Placebo Drug|The placebo is also prepared in the form of tablets with similar packaging as melatonin by the pharmaceutical company. Participants will be randomly assigned to take placebo with the same frequency and duration as melatonin (twice a day for 1 month).
219361466|NCT04484285|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
219361467|NCT03793062|OTHER|No Interventions|Not applicable - No Interventions
218851157|NCT01024582|RADIATION|accelerated partial breast irradiation|
219361468|NCT03842696|DRUG|Vorinostat|"* HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
218851158|NCT01024582|RADIATION|image-guided radiation therapy|
218851159|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
218851160|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
218851161|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
219361469|NCT03842696|PROCEDURE|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
219361470|NCT03842696|DRUG|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
219361471|NCT03842696|DRUG|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
219361472|NCT03842696|DRUG|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
219361473|NCT03842696|DRUG|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
219361474|NCT06104306|DRUG|B/F/TAF|Tablets administered without regard to food
218851162|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
218851163|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
218851164|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
218851165|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
218851166|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
218851167|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
218851168|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
218851169|NCT00074529|DRUG|MK0677|
218851170|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
218851171|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
218851172|NCT01797848|DRUG|Peginterferon alfa 2a|
218851173|NCT01797848|DRUG|Ribavirin|
218851174|NCT01797848|DRUG|Placebo matching Daclatasvir|
218851175|NCT01797848|DRUG|Daclatasvir|
219461045|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
219461046|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
219461047|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
219461048|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
219461049|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
219461050|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
219461051|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
219461052|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
219461053|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
219592572|NCT02518516|DRUG|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
219592573|NCT02518516|DRUG|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
219592574|NCT02518516|DRUG|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
219461054|NCT05766410|DRUG|Letrozole|Endocrine therapy
219461055|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
219461056|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
219461057|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
219461058|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
219461059|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
219198043|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
218851176|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
218851177|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
219461060|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
219461061|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
219461062|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
219461063|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
219461064|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
219461065|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
219461066|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
219461067|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
219461068|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
219461069|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
219461070|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
218851178|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
219461071|NCT00066274|DRUG|FOLFIRI regimen|
219461072|NCT00066274|DRUG|FOLFOX regimen|
218851179|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
218851180|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
218851181|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
218851182|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
218851183|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
218851184|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
218851185|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
218851186|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
218851187|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
218851188|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
219461073|NCT00066274|DRUG|fluorouracil|
219461074|NCT00066274|DRUG|irinotecan hydrochloride|
219461075|NCT00066274|DRUG|leucovorin calcium|
219461076|NCT00066274|DRUG|oxaliplatin|
219461077|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
219461078|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
219461079|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
219461080|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
219461081|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
219461082|NCT01959087|PROCEDURE|Multiport surgery|
219461083|NCT04235959|DRUG|Tirzepatide|Administered SC
219461084|NCT04235959|DRUG|Placebo|Administered SC
219461085|NCT01978717|PROCEDURE|epidural anesthesia|
219461086|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
219461087|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
219461088|NCT01869920|BEHAVIORAL|Usual care|Usual care
219461089|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
219461090|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
219461091|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
219461092|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
219461093|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
219461094|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
219461095|NCT00899327|GENETIC|DNA methylation analysis|
219461096|NCT00899327|GENETIC|RNA analysis|
219461097|NCT00899327|GENETIC|cytogenetic analysis|
219461098|NCT00899327|GENETIC|gene expression analysis|
219461099|NCT00899327|GENETIC|mutation analysis|
218851189|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
218851190|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
218851191|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
218851192|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
219461100|NCT00899327|GENETIC|polymerase chain reaction|
219461101|NCT00899327|GENETIC|protein expression analysis|
219461102|NCT00899327|OTHER|laboratory biomarker analysis|
219019330|NCT06873334|DRUG|SKY-0515|"Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months~Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements."
219019331|NCT06873334|DRUG|SKY-0515 Placebo|"Route of Administration: Oral Dosage~Frequency: Once daily~Blinded Treatment Duration: 12 months~Use: Experimental~Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee~Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements"
219019334|NCT04371081|DEVICE|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
218851193|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
218851194|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
218851195|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
218851196|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
218851197|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
218851198|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
218851199|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
219461103|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
219461104|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
219461105|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
219592575|NCT02518516|DRUG|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218851200|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
218851201|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
219592576|NCT02518516|DRUG|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218851202|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
218851203|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
218851204|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
218851205|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
218851206|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
219361475|NCT03099434|BEHAVIORAL|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
219361476|NCT03099434|BEHAVIORAL|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
219361477|NCT05942144|OTHER|Exercise-snacks program|"Subjects in the exercise-snacks group will perform 4 exercise-snacks sessions per working day for 4 weeks. These sessions will consist of 80 one-to-one walks to be completed as quickly as possible. They will also receive information about their attitudes to physical activity."
219361478|NCT06960694|DRUG|L-carnitine|This group will be treated with tablet L-carnitine 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
219361479|NCT06960694|DRUG|Placebo|This group will be treated with tablet Placebo 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
219361480|NCT03196180|DRUG|Imiquimod|Given intravaginally
219361481|NCT03196180|DRUG|Topical Fluorouracil|Given intravaginally
219361482|NCT04439175|DRUG|Taselisib|Given PO
219361483|NCT04654728|PROCEDURE|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
219361484|NCT00152867|DRUG|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
219361485|NCT06312332|BEHAVIORAL|Pulmonary Embolism (PE) Care in Emergency Department (ED)|Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
219361486|NCT06467812|DIETARY_SUPPLEMENT|Salt Tablets|Three doses of 4 Salt Tablets (1gm) will be taken with 400mL of water on day 2 (1200ml total) between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm.
219361487|NCT06467812|DIETARY_SUPPLEMENT|Electrolyte Solution|"Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day.~The ingredients are included below for the two flavors offered.~Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole).~Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA."
219361488|NCT01020760|BEHAVIORAL|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
219361489|NCT03597165|OTHER|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
219361490|NCT03597165|OTHER|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
219461106|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
218851207|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
218851208|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
218851209|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
218851210|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
218851211|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
218851212|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
218851213|NCT03211026|OTHER|No intervention|No intervention
218851214|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
218851215|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
219461107|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
219461108|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
219461109|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
218851216|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
218851217|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
218851218|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
218851219|NCT00841048|DRUG|Placebo|
218851220|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
218851221|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
218851222|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
218851223|NCT00001812|DRUG|Nystatin|
218851224|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
218851225|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
218851226|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
218851227|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
218851228|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
218851229|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
218851230|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
218851231|NCT00458042|DRUG|treprostinil sodium|
219461110|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
218851232|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
218851233|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
218851234|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
219461111|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
219461112|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
219461113|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
219461114|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
219461115|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
219461116|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
219461117|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
219461118|NCT01453439|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
219461119|NCT01453439|BEHAVIORAL|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
219461120|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
218851235|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
219198044|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
219198045|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
219461121|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
219592577|NCT01730066|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
219461122|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
219461123|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
219592578|NCT04981496|OTHER|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
219461124|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
219461125|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
219592579|NCT00191971|DRUG|Gemcitabine|
219592580|NCT02760992|DRUG|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
219592581|NCT02760992|DRUG|Oral Baclofen|10 mg tablet
219592582|NCT05657392|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
219592583|NCT05657392|OTHER|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
219592584|NCT01037296|PROCEDURE|catheter ablation|ablation procedure performed with Hansen robotic navigation system
219592585|NCT01037296|PROCEDURE|catheter ablation|Ablation will be performed as normal treatment
219592586|NCT05214703|OTHER|cold therapy application|cold therapy
219592587|NCT00307918|DEVICE|acupuncture|
218851236|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
219592588|NCT04176406|DEVICE|rTMS|excitatory 5Hz rTMS will be used
218851237|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
218851238|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
219592589|NCT04176406|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
218851239|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
219461126|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
218851240|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
218851241|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
219019345|NCT06688955|PROCEDURE|Colonoscopy with Bacteriological Controlled Water|Patient with coloscopy which used Bacteriological Controlled Water : Collection of 250 ml of bacteriologically controlled water from the wash bottle at the end of each water-assisted colonoscopy to test for enterobacteria and fecal streptococci
219461127|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
219461128|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
219461129|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
219461130|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
219461131|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
219461132|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
219461133|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
219461134|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
219461135|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
219461136|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
219461137|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
219461138|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
219461139|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
219461140|NCT01557140|DRUG|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
219461141|NCT00035412|DRUG|St. John's Wort|
219461142|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
219461143|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
219461144|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
219592590|NCT01489631|DRUG|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
219592591|NCT01489631|DRUG|marcaine|bupivacaine 0,125%
219592592|NCT01489631|DRUG|sufentanil|sufentanil 1mcg/ml
219592593|NCT01489631|DRUG|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
219461145|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
219461146|NCT06326658|OTHER|Bufei Yishen Prescription Granule|The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
219461147|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2\. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
219461148|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
219461149|NCT02705339|DRUG|Rociletinib|
219461150|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
219461151|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
219461152|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
219461153|NCT01833299|PROCEDURE|TACE|
219461154|NCT03820518|DRUG|Calcitriol|
219461155|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
219461156|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
219461157|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
218851242|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
218851243|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
219592594|NCT06344663|OTHER|motivational interview|Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
219592595|NCT02763371|OTHER|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
219461158|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
219461159|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
218851244|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
218851245|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
218851246|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
218851247|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
218851248|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
218851249|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
218851250|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
218851251|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
218851252|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
218851253|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
218851254|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
218851255|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
218851256|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
219461160|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
219461161|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
219461162|NCT01017640|DRUG|Mitomycin|Given IV
219461163|NCT01017640|DRUG|Veliparib|Given PO
219592596|NCT02763371|OTHER|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
219592597|NCT05782127|DRUG|Onureg + Venetoclax|Combination of Onureg and Venetoclax
219592598|NCT04674865|OTHER|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
218851257|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
218851258|NCT02446704|DRUG|Olaparib|
218851259|NCT02446704|DRUG|Temozolomide|
218851260|NCT00303771|DRUG|fluorouracil|
218851261|NCT00303771|DRUG|irinotecan hydrochloride|
219461164|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
219461165|NCT00915226|PROCEDURE|Squatting|Squatting
219461166|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
219461167|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
219461168|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
219461169|NCT03010358|DRUG|Entospletinib|Given PO
219461170|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
219461171|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
219461172|NCT03010358|OTHER|Pharmacological Study|Correlative studies
219461173|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
219461174|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
219461175|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
219461176|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
219461177|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
218851262|NCT00303771|DRUG|leucovorin calcium|
218851263|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
218851264|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
218851265|NCT01689012|BEHAVIORAL|Facial Exercise|
219461178|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
219461179|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
219461180|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
218851266|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
218851267|NCT02241057|OTHER|Temperature Probe|
218851268|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
218851269|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
218851270|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
218851271|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
218851272|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
219461181|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
219461182|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
219461183|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
219461184|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
219461185|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
219461186|NCT04672200|OTHER|Group exercise|Weekly group exercises delivered online and face to face
219461187|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
219461188|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
219592599|NCT04674865|OTHER|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
219592600|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
219198046|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
219592601|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
219592602|NCT02036359|DRUG|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
218851273|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
219461189|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
219461190|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
218851274|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
219461191|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
219461192|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
219461193|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
219461194|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
219461195|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
219461196|NCT06065371|DRUG|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
219461197|NCT06065371|DRUG|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
219461198|NCT06538610|DEVICE|Holter monitor|"Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours."
218851275|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
219019346|NCT05908461|BEHAVIORAL|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
219461199|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
219461200|NCT00001961|PROCEDURE|MRI|
219461201|NCT02135848|DRUG|GSK1278863|GSK1278863
219461202|NCT02135848|DRUG|Placebo|Placebo
219461203|NCT04815005|OTHER|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
219461204|NCT02868801|DRUG|Placebo|same intervention as the experimental group
219198047|NCT04479514|OTHER|Warm Baths or Showers|Daily warm baths or showers
219592603|NCT02036359|DRUG|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
218851276|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
219198048|NCT04479514|OTHER|Moisturizer|moisturizers applied daily immediately after bathing
219198049|NCT04479514|DRUG|SPF 30 or Higher Suncreen|Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
219198050|NCT04479514|OTHER|Sun Protective Clothing|Sun protective clothing worn when outdoors
219461205|NCT02868801|DRUG|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
219461206|NCT02868801|DRUG|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
219461207|NCT02868801|DRUG|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
219461208|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
219461209|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
219461210|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
219461211|NCT00611351|DRUG|busulfan|
219461212|NCT00611351|DRUG|cyclophosphamide|
219461213|NCT00611351|DRUG|mycophenolate mofetil|
219461214|NCT00611351|DRUG|tacrolimus|
219461215|NCT00611351|GENETIC|polymerase chain reaction|
219461216|NCT00611351|GENETIC|polymorphism analysis|
219461217|NCT00611351|OTHER|flow cytometry|
219461218|NCT00611351|OTHER|laboratory biomarker analysis|
219461219|NCT00611351|OTHER|pharmacogenomic studies|
219461220|NCT00611351|OTHER|pharmacological study|
219461221|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
219461222|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219461223|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
219461224|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
219461225|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
219461226|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
219461227|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
219461228|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
219461229|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
219461230|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
219461231|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
219461232|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
219461233|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
219461234|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
219461235|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
218851277|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
218851278|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
218851279|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
218851280|NCT00031655|DRUG|cyclosporine|Given PO
218851281|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
219461236|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
219461237|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
218851282|NCT00031655|DRUG|fludarabine phosphate|Given IV
218851283|NCT00031655|DRUG|mycophenolate mofetil|Given PO
219461238|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
219461239|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
219461240|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
219461241|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
219461242|NCT01162967|DRUG|Benznidazole|Standard dosage
219461243|NCT01162967|DRUG|Posaconazole|
219461244|NCT00993694|DRUG|chemotherapy|
219461245|NCT00993694|DRUG|dapsone|
219461246|NCT00993694|OTHER|medical chart review|
219461247|NCT00993694|PROCEDURE|assessment of therapy complications|
219461248|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
219461249|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
219461250|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
219461251|NCT00545740|DRUG|Placebo|QD orally
219461252|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
219461253|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
219461254|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
219461255|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
219461256|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
219461257|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
219461258|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
219461259|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
219461260|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
219461261|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
219592604|NCT05584592|OTHER|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
219592605|NCT05584592|OTHER|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
219019360|NCT07009899|DRUG|Linvoseltamab|Linvoseltamab is a human IgG4-based bsAb that binds to CD3, a T-cell antigen associated with the TCR complex, and BCMA, which is expressed on the surface of malignant MM B-lineage cells, as well as late-stage B cells and plasma cells.
219198051|NCT04479514|BEHAVIORAL|Limited Sun Exposure|Limit sun exposure during peak hours of 10am-4pm
219461262|NCT02029885|DEVICE|Sham Control|
219461263|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
219461264|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
219461265|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
219461266|NCT02826083|DIETARY_SUPPLEMENT|XXS|
219461267|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
219461268|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
219461269|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
219461270|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
219461271|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
219461272|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
218851284|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
219198052|NCT04479514|OTHER|Dilute bleach baths|Warm 10-15 minute dilute bleach baths every other day
219198053|NCT01504789|BEHAVIORAL|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
219198054|NCT01504789|BEHAVIORAL|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
219198055|NCT01504789|BEHAVIORAL|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
219198056|NCT01504789|BEHAVIORAL|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
219198057|NCT06048250|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219461273|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
218851285|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
218851286|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
218851287|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
218851288|NCT00309712|DRUG|simvastatin 20 mg and placebo|
218851289|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
219461274|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
219592606|NCT04933448|OTHER|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
218851290|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
218851291|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
218851292|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
218851293|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
218851294|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
218851295|NCT00256815|DRUG|chemotherapy|
218851296|NCT00256815|PROCEDURE|Radiation|
218851297|NCT00002839|DRUG|cisplatin|
218851298|NCT00002839|DRUG|fluorouracil|
218851299|NCT00002839|PROCEDURE|conventional surgery|
218851300|NCT00002839|PROCEDURE|neoadjuvant therapy|
218851301|NCT00002839|RADIATION|radiation therapy|
218851302|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
218851303|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
218851304|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
218851305|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
218851306|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
219198058|NCT06048250|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219198059|NCT06048250|PROCEDURE|Computed Tomography|Undergo CT
219461275|NCT01433328|DRUG|Lidocaine|Lidocaine
219461276|NCT01433328|DRUG|Placebo|Placebo
219461277|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
218851307|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
218851308|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
219461278|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
219461279|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
219461280|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
219592607|NCT06632899|BEHAVIORAL|combined physical and cognitive training and 1 hour of risk factor prevention and healthy lifestyle development|"Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep) and healthy lifestyle development (Discussion and sharing on topics such as self-health management, goal setting, and the health journal.)"
219592608|NCT05551871|DRUG|Simvastatin|the patient will receive Simvastatin for 7 days
219592609|NCT05551871|DRUG|Placebo drug|the patient will receive Placebo drug for 7 days
219592610|NCT06231056|DIETARY_SUPPLEMENT|Probiotic iNatal®|iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
218851309|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
218851310|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
218851311|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
218851312|NCT04496375|OTHER|Survey|Self-completed questionnaires
218851313|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
218851314|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
218851315|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
218851316|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
218851317|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
218851318|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
219461281|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
219461282|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
219461283|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
219461284|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
219461285|NCT00316212|DRUG|INS50589 Intravenous Infusion|
219592611|NCT00359593|BEHAVIORAL|Knowledge translation intervention package|
219592612|NCT03718312|PROCEDURE|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
219592613|NCT04842786|OTHER|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
218851319|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
218851320|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
218851321|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
218851322|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
218851323|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
218851324|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
218851325|NCT02388035|DRUG|Cefotaxime|
218851326|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
218851327|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
219461286|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
219461287|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
219461288|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
219461289|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
219461290|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
218851328|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
219461291|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
219461292|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
219461293|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
219198060|NCT06048250|BIOLOGICAL|Mezigdomide|Receive PO
218851329|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
218851330|NCT00322023|DRUG|D-serine|
218851331|NCT00322023|DRUG|D-serine|
218851332|NCT00322023|DRUG|D-serine|
218851333|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
218851334|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
218851335|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
218851336|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
218851337|NCT02873065|DRUG|Ilaprazole|
218851338|NCT02873065|DRUG|Esoprazole|
219461294|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
219461295|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
218851339|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
219461296|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
219461297|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
219461298|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
219461299|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
219461300|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
219461301|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
219198061|NCT06048250|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218851340|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
218851341|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
218851342|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
218851343|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
218851344|NCT04526873|BEHAVIORAL|Postcard|Mailed
219461302|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
219461303|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
219461304|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
219461305|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
219461306|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
219461307|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
219461308|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
219461309|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
219461310|NCT03453593|OTHER|No intervention|No intervention
219461311|NCT03000413|DRUG|Ketamine|Active treatment
219461312|NCT03000413|DRUG|Fentanyl|
219461313|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
219461314|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
219461315|NCT02445352|DRUG|Rosuvastatin 5mg|
219461316|NCT02445352|DRUG|DP-R207 5/10mg|
219461317|NCT02445352|DRUG|Rosuvastatin 10mg|
219461318|NCT02445352|DRUG|DP-R207 10/10mg|
218851345|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
218851346|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
218851347|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
218851348|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
218851349|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
219461319|NCT02445352|DRUG|Rosuvastatin 20mg|
219461320|NCT02445352|DRUG|DP-R207 20/10mg|
219461321|NCT02445352|DRUG|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
219461322|NCT02445352|DRUG|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
219461323|NCT02445352|DRUG|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
219461324|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
219461325|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
219461326|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
219461327|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
219461328|NCT03955211|DRUG|HTX-011|300 mg
219461329|NCT03955211|DRUG|HTX-011|400 mg
219461330|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
219461331|NCT03955211|DRUG|Ibuprofen|400 mg
219461332|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
218851350|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
218851351|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
219461333|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
219461334|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
219592614|NCT04591223|BEHAVIORAL|Competency-based physical training (CbM)|The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
219592615|NCT04293328|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
219198062|NCT05131347|BEHAVIORAL|motor intervention|Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.
219198063|NCT05131347|BEHAVIORAL|cognitive intervention|Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
219198064|NCT05163639|PROCEDURE|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
219198065|NCT05163639|PROCEDURE|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
219198066|NCT05163639|PROCEDURE|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
219361491|NCT01820442|DRUG|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
219361492|NCT01820442|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
219361493|NCT01436721|DEVICE|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
219361494|NCT06107556|DIAGNOSTIC_TEST|Gait analysis|3D gait analysis with electromyographic measurements
218851352|NCT02868450|BIOLOGICAL|Blood Sample|
218851353|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
218851354|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
218851355|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
219361495|NCT06140979|BEHAVIORAL|Playing the game|The intervention is based on a parkour game in which the player runs forward as a cartoon character, avoiding obstacles in front of him/her while collecting gold coins and various props. In this process, players need to stay focused and operate in time to avoid obstacles or collect rewards, and as time goes on, the difficulty of the game increases until eventually they cannot avoid obstacles. As time goes on, the difficulty of the game will increase until the end of the game when you can't avoid the obstacles.
219361496|NCT06140979|BEHAVIORAL|Watching the gameplay video|"The intervention consists of a 30-minute non-therapeutic video of a parkour game, which is paused every 10 minutes and requires the patient to click continue until the end of the video. No other action is required."
219361497|NCT02554929|BEHAVIORAL|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
219361498|NCT02554929|BEHAVIORAL|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
218851356|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
218851357|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
218851358|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
218851359|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
218851360|NCT00162747|DRUG|Aquaphor|
218851361|NCT00162747|DRUG|Sunflower Seed Oil|
218851362|NCT00206128|DRUG|Seroquel SR|
218851363|NCT03449940|PROCEDURE|Immediate repair|
219198067|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
219461335|NCT01430689|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
219461336|NCT01430689|BIOLOGICAL|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
219461337|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
219461338|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
219461339|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
219461340|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
219461341|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
219461342|NCT03869489|DEVICE|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
219461343|NCT03869489|DEVICE|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
219461344|NCT03869489|DEVICE|Sham tDCS stimulation|Sham tDCS stimulation will be applied
219461345|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
219461346|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
219592616|NCT04293328|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
219592617|NCT02009514|OTHER|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
219592618|NCT02119923|BEHAVIORAL|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
219198068|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
219198069|NCT05713006|DRUG|Alectinib Oral Product|Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
219198070|NCT06790368|BIOLOGICAL|VENOX|Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
219461347|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
219461348|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
218851364|NCT03449940|PROCEDURE|Delayed repair|
219461349|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
219461350|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
219461351|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
219461352|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
219461353|NCT01085695|DRUG|rabeprazole|10 mg normal tablet
219461354|NCT01085695|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
219461355|NCT01085695|DRUG|rabeprazole|Type 2 granule containing rabeprazole 10 mg
219461356|NCT01085695|DRUG|rabeprazole|Type 3 granule containing rabeprazole 10 mg
219461357|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
219461358|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
219461359|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
219461360|NCT04145310|DRUG|Placebo + SCO|sublingual drops
219461361|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
219461362|NCT02256150|DRUG|Mizoribine (MZR)|
219461363|NCT02256150|DRUG|Cyclophosphamide (CTX)|
219461364|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
219461365|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
219461366|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
218851365|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
218851366|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
218851367|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
218851368|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
219461367|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
219461368|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
219461369|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
219461370|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
218851369|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
219461371|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
219461372|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
219461373|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
219461374|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
219461375|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
219461376|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
218851370|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
219198071|NCT06953947|PROCEDURE|Costoclavicular block|"The costoclavicular block was first described by Karmakar et al. in 2015. It is a type of brachial plexus block that targets the three cords located lateral to the axillary artery within the costoclavicular space. The costoclavicular space is defined as the area between the middle third of the clavicle and the anterior thoracic wall. Within this space, the cords of the brachial plexus are situated lateral to the axillary artery, positioned between the pectoralis major, subclavius, and serratus anterior muscles.~In contrast to the traditional infraclavicular approach, the cords in the costoclavicular block are located more superficially and are more consistently clustered lateral to the axillary artery, which may facilitate visualization and needle targeting. After the needle is placed between the three cords under ultrasound guidance, the local anesthetic (20 mL of 0.25% bupivacaine) is injected."
219198072|NCT06953947|PROCEDURE|Interscalene block|Originally described by Etienne in 1925, the technique was later refined into its modern clinical form by Alon Winnie in 1970. The interscalene approach, primarily preferred for shoulder surgeries, aims to target the upper roots of the brachial plexus (C5-C7). In interscalene block, a needle is placed under ultrasound guidance around the upper and middle trunks of the brachial plexus, which pass through the space between the anterior and middle scalene muscles, and the local anesthetic (20 mL of 0.25% bupivacaine) is injected while its spread is observed.
219461377|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
219461378|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
219461379|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
219461380|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
219461381|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
219461382|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
219461383|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
219461384|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
219461385|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
219198073|NCT06953947|DRUG|Costoclavicular block|In costoclavicular block, the course of the three cords of the brachial plexus is visualized under ultrasound guidance, adjacent to the brachial artery beneath the clavicle. Subsequently, after the needle is placed under ultrasound guidance between the three cords, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
219198074|NCT06953947|DRUG|Interscalene Nerve Block|In interscalene block, using an ultrasound probe placed on the neck, the course of the brachial plexus trunks between the anterior and middle scalene muscles is visualized. Then, after the needle is inserted under ultrasound guidance between the anterior and middle scalene muscles, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
219461386|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
219461387|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
219461388|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
219461389|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
219461390|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
219461391|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
219461392|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
219461393|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
219461394|NCT02180854|OTHER|Control group|
219461395|NCT02180854|OTHER|Increased monitoring frequency|
219461396|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
219461397|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
219461398|NCT01968629|DRUG|Eovist|
219461399|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
219461400|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
219461401|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
219461402|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
219198075|NCT06834386|OTHER|Best Practice|Receive standard of care
219198076|NCT06834386|OTHER|Electronic Health Record Review|Ancillary studies
219461403|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
219461404|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
219592619|NCT02119923|BEHAVIORAL|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
219592620|NCT05519319|PROCEDURE|RFA|RFA will be performed
218851371|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
219461405|NCT02798159|DRUG|TD0025|
219461406|NCT02798159|DRUG|Sildenafil Citrate 50mg|
219592621|NCT05519319|PROCEDURE|PDT|PDT will be performed
218851372|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
219198077|NCT06834386|OTHER|Interview|Ancillary studies
219198078|NCT06834386|OTHER|Questionnaire Administration|Ancillary studies
219198079|NCT06834386|DRUG|Suvorexant|Given PO
219461407|NCT02961153|OTHER|death|
219461408|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
219461409|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
219461410|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
219461411|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
219461412|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
219461413|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
219461414|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
219461415|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
219461416|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
219461417|NCT01646255|DRUG|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
219592622|NCT05519319|PROCEDURE|RFA combined with PDT|RFA and PDT will be performed
218851373|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
218851374|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
218851375|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
218851376|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
218851377|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
218851378|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
218851379|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
218851380|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
219461418|NCT01646255|DRUG|Placebo Patch|"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
219461419|NCT01646255|DRUG|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
219461420|NCT05136209|PROCEDURE|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
219461421|NCT05136209|PROCEDURE|PCCC+A-Vit procedure|PCCC+A-Vit procedure
219461422|NCT00846911|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
219461423|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
219461424|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
219461425|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
218851381|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
218851382|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
218851383|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
218851384|NCT00899197|DRUG|tamoxifen citrate|
218851385|NCT00899197|GENETIC|gene expression analysis|
219461426|NCT04316780|OTHER|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
219461427|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
219461428|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
219592623|NCT03858543|DRUG|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
218851386|NCT00899197|GENETIC|protein expression analysis|
218851387|NCT00899197|OTHER|immunoenzyme technique|
218851388|NCT00899197|OTHER|laboratory biomarker analysis|
218851389|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
218851390|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
218851391|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
218851392|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
218851393|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
218851394|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
219461429|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
219461430|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
219461431|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
219461432|NCT04296721|BEHAVIORAL|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
219461433|NCT04296721|BEHAVIORAL|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
219592624|NCT03858543|DEVICE|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
218851395|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
218851396|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
218851397|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
218851398|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
218851399|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
219019383|NCT07019662|DEVICE|Decannulation with a medical device|Wound Closure with a medical device
219019384|NCT07019662|PROCEDURE|Decannulation using surgical removal or manual compression|Wound closure using surgical removal or manual compression
219198080|NCT05860829|BEHAVIORAL|Educational|Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
219198081|NCT06953713|PROCEDURE|gallbladder extraction umbilical|extracting gallbladder via umbilical port site
219461434|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
219461435|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
219461436|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
219198082|NCT06953713|PROCEDURE|extracting gallbladder via epigastric port|extracting gallbladder via epigastric port
219592625|NCT04008849|OTHER|Safety and efficacy assessments|Long term safety and clinical outcomes
219592626|NCT01544179|DRUG|Gefitinib|Investigational Drug
219592627|NCT01544179|DRUG|Placebo|Matching placebo as comparator
219592628|NCT01544179|DRUG|Pemetrexed|Chemotherapy (concomitant therapy)
219592629|NCT01544179|DRUG|Cisplatin|Chemotherapy (concomitant therapy)
219592630|NCT06633484|OTHER|functional magnetic resonance imaging|non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
219592631|NCT03466268|DRUG|Gumarontinib Tablets|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
219198083|NCT04427007|DEVICE|Moisture Management Liner|A prototype prosthetic liner designed to reduce and/or remove moisture and heat that builds up on the limb.
219198084|NCT04427007|DEVICE|Control Liner|The participant's usual prosthetic liner
218851400|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
218851401|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
218851402|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
219461437|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
219461438|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
219461439|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
219461440|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
219461441|NCT02496390|BIOLOGICAL|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
219461442|NCT02496390|BIOLOGICAL|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
219461443|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
219461444|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
219592632|NCT00049530|BIOLOGICAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
218851403|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
218851404|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
218851405|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
219198085|NCT04633278|DRUG|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
219198086|NCT04633278|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
219592633|NCT01279083|DRUG|DE-112|Topical ocular solution
219592634|NCT01279083|DRUG|DE-112|Topical ocular solution
219592635|NCT01279083|DRUG|DE-112|Topical ocular solution
219592636|NCT01279083|DRUG|DE-112|Topical ocular solution
219592637|NCT01279083|DRUG|DE-112 Vehicle Solution|Topical ocular solution
218851406|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
219592638|NCT01279083|DRUG|Timolol Maleate Solution|Topical ocular solution
219592639|NCT01635283|BIOLOGICAL|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
219592640|NCT01635283|OTHER|laboratory biomarker analysis|Correlative studies
219461445|NCT01362049|OTHER|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
219461446|NCT01362049|OTHER|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
219461447|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
219461448|NCT02777008|DRUG|CTP-543|
219461449|NCT02777008|DRUG|Placebo for CTP-543|
219461450|NCT03152175|DRUG|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
219461451|NCT03152175|DRUG|Placebo|1mg / kg of matched placebo, oral capsule
219461452|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
219461453|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
219461454|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
219461455|NCT03607994|DEVICE|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
219461456|NCT03607994|DEVICE|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
219592641|NCT01438996|BIOLOGICAL|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
219592642|NCT01433549|DEVICE|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
219592643|NCT01433549|DEVICE|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
219592644|NCT00479778|DRUG|Bazedoxifene/conjugated estrogens|
219592645|NCT04496115|BEHAVIORAL|Mindfulness|Mindfulness training
218851407|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
219019392|NCT06691971|DEVICE|AeviceMD|The AeviceMD device will be placed on the patient to detect the presence of wheeze and perform auscultation.
218851408|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
219461457|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
219461458|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
219461459|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
219461460|NCT04919694|PROCEDURE|orbital compression|orbital compression
219461461|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
219461462|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
219461463|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
219461464|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
219592646|NCT02398383|OTHER|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
219592647|NCT02398383|OTHER|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
219592648|NCT02398383|OTHER|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
219592649|NCT05156905|DRUG|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
219592650|NCT00000978|DRUG|Zidovudine|
219592651|NCT00000978|DRUG|Zalcitabine|
219592652|NCT01004653|BIOLOGICAL|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
219592653|NCT03831165|COMBINATION_PRODUCT|Melatonin 3 mg|melatonin and placebo
219592654|NCT03831165|DRUG|Acyclovir|Only acyclovir 200 mg twice a day
219592655|NCT06324851|DRUG|Drospirenone / Estetrol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
219592656|NCT06324851|DRUG|Nomegestrol Acetate / Estradiol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
219592657|NCT06324851|DRUG|Ethinylestradiol / Dienogest|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
219592658|NCT02573844|DRUG|Proklama|
219019397|NCT06533657|DRUG|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)|Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
219019398|NCT03721822|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
219019402|NCT06683742|DRUG|EYP-1901|Intravitreal Injection
219019403|NCT06683742|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
219019404|NCT06624969|OTHER|virtual reality|Virtual reality program to reduce pain in orthopedic fractures
219461465|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
219461466|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
219461467|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
219461468|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
219592659|NCT02573844|DRUG|Placebo|
219592660|NCT00581126|DRUG|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
218851409|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
218851410|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
218851411|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
218851412|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
219461469|NCT02417935|DRUG|Duloxetine|Administered orally
219461470|NCT02417935|DRUG|Pregabalin|Administered orally
219461471|NCT02417935|DRUG|Placebo|Administered orally
219461472|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
218851413|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
219461473|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
219461474|NCT05189535|DRUG|Placebo|placebo
219461475|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
219461476|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
219461477|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
218851414|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
218851415|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
218851416|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
218851417|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
218851418|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
218851419|NCT02210689|OTHER|placebo|vehicle used as placebo
218851420|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
218851421|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
218851422|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
218851423|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
219461478|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
219461479|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
219461480|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
219461481|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
219461482|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
219461483|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
219461484|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
219461485|NCT00073515|DRUG|Alfimeprase|
219461486|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
219461487|NCT02850276|DRUG|Pyridostigmine|
219461488|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
219461489|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
218851424|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
218851425|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
219461490|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
219461491|NCT05248776|DRUG|Placebo|Matching placebo tablet.
219461492|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
219461493|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
219461494|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
219592661|NCT01399567|BEHAVIORAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
219592662|NCT02432053|DRUG|Advagraf|
218851426|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
218851427|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
218851428|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
218851429|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
218851430|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
218851431|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
218851432|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
218851433|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
218851434|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
219461495|NCT02358928|OTHER|Diet Intervention|
219461496|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
219461497|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
219461498|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
219461499|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
219461500|NCT04707027|DRUG|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
219461501|NCT04707027|OTHER|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
219461502|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
219461503|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
219461504|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
219592663|NCT00256113|DRUG|Saredutant succinate (SR48968C)|
219592664|NCT03551821|DRUG|ATI-50002|Topical Solution
219592665|NCT03857750|DRUG|Rocuronium|0.6 mg/kg
219592666|NCT02826772|DRUG|GT0918|anti-tumor activity
219592667|NCT01696058|DRUG|Tiotropium|marketed product
219592668|NCT01696058|DRUG|Placebo matching Olodaterol|one dose
219592669|NCT01696058|DRUG|Tiotropium|marketed product
218851435|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
219461505|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
219592670|NCT01696058|DRUG|Olodaterol|one dose
219461506|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
219461507|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
219461508|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
219461509|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
219461510|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
219461511|NCT02183792|DRUG|Tolvaptan|
219461512|NCT02183792|DRUG|Furosemide|
219461513|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
219461514|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
219461515|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
219461516|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
219461517|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
219461518|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
219461519|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
219461520|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
219461521|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
218851436|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
219461522|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
219461523|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
219461524|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
219461525|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
219461526|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
219461527|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
219461528|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
219592671|NCT03482258|DIETARY_SUPPLEMENT|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
219592672|NCT03482258|DIETARY_SUPPLEMENT|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
219592673|NCT03815734|PROCEDURE|motor imagery|motor imagery during the postoperative immobilization period
219592674|NCT01773837|DRUG|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
219592675|NCT01773837|DRUG|placebo|placebo (pill) p.o.
219461529|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
219461530|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
219461531|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
219461532|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
219461533|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
219461534|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
219461535|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
219461536|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
219461537|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
219461538|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
218851437|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
218851438|NCT03087942|DRUG|QAW039|450 mg
218851439|NCT03087942|DRUG|QAW39A|450 mg
218851440|NCT03087942|DRUG|QAW39A2107|450 mg
218851441|NCT03087942|DRUG|QAW39A2107|450 mg
218851442|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
218851443|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
218851444|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
218851445|NCT00412347|DRUG|Insulin Drip Therapy|
218851446|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
218851447|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
218851448|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
218851449|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
219461539|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
219461540|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
219461541|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
219461542|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
218851450|NCT00764257|DEVICE|PREVELLE Shape|
218851451|NCT00764257|DEVICE|Restylane|
218851452|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
218851453|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
218851454|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
218851455|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
219461543|NCT05373810|OTHER|Surgery|all interventions are allowed
219461544|NCT02701569|OTHER|Rebound exercise|Repeated jumping on a mini trampoline was administered
219461545|NCT04619381|BEHAVIORAL|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
219461546|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
219461547|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
219461548|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
219461549|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
219461550|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
218851456|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
219461551|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
219198087|NCT05937100|DRUG|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
219461552|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
219592676|NCT05284487|DEVICE|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
219592677|NCT05284487|DEVICE|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
219461553|NCT00411879|DRUG|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
219461554|NCT00411879|DRUG|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
218851457|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
218851458|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
219461555|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
218851459|NCT00410826|DRUG|cisplatin|Given IV
218851460|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
219461556|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
219461557|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
219461558|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
219592678|NCT05287256|DRUG|Oral Delta-8-THC Cannabis|Delta-8-THC cannabis will be orally self-administered by study participants
219592679|NCT05287256|DRUG|Oral Delta-9-THC Cannabis|Delta-9-THC cannabis will be orally self-administered by study participants
218851461|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
218851462|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
218851463|NCT01299857|DRUG|Rituximab|375mg/m2
219019409|NCT04112355|OTHER|Blood Collection|Blood draw
219019412|NCT06873438|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
219019413|NCT06873438|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
219019414|NCT07019883|BIOLOGICAL|H5 AC-Anhui RNA Vaccine|A nucleoside-modified mRNA vaccine encoding a stabilized, antigenically central hemagglutinin (HA) from influenza A(H5), based on A/Anhui/1/2005 (clade 2.3.4) with substitutions 222QL, 224GS, 156TA, and 134TA. The 2119-nt mRNA is encapsulated in lipid nanoparticles (LNPs) for intramuscular delivery.
219019415|NCT07019883|BIOLOGICAL|H5 Astrakhan RNA Vaccine|The vaccine product consists of a monovalent nucleoside-modified mRNA that encodes a traditionally selected avian influenza HA. The H5 Astrakhan RNA encodes the HA from the clade 2.3.4.4b A/Astrakhan/3212/2020 virus.
219019416|NCT07019883|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
218851464|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
218851465|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
218851466|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
218851467|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
218851468|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
219461559|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
218851469|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
219461560|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
219461561|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
219461562|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
218851470|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
218851471|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
218851472|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
218851473|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
219461563|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
219461564|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
219461565|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
219461566|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
219461567|NCT01431456|DRUG|Dabigatran|Dabigatran
219461568|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
219461569|NCT01431456|DRUG|Nadroparin|Nadroparin
219461570|NCT00408785|DRUG|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
219461571|NCT00408785|DRUG|sodium chloride|sodium chloride 0.9 mg
219461572|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
219592680|NCT05287256|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants
219592681|NCT05287256|DRUG|Vaporized Delta-8-THC Cannabis|Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
219592682|NCT05287256|DRUG|Vaporized Delta-9-THC Cannabis|Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
219592683|NCT05287256|DRUG|Vaporized Placebo|Placebo will be self-administered by study participants using a vaporizer
219592684|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
219198088|NCT05937100|DRUG|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
219198089|NCT05937100|DRUG|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
219198090|NCT06292091|DRUG|Captopril 12.5 Mg|12.5 mg of captopril
219198091|NCT06292091|DRUG|Sodium bicarbonate 4 G|4 g of sodium bicarbonate
219198092|NCT06292091|DRUG|Torsemide 20 MG|20 mg of torsemide
219198093|NCT05124405|OTHER|Fitbit|wearable activity tracker
218851474|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
218851475|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
218851476|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
218851477|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
218851478|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
218851479|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
218851480|NCT01180894|DRUG|Placebo|
218851481|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
218851482|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
218851483|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
218851484|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
218851485|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
218851486|NCT02894164|OTHER|No intervention|
218851487|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
218851488|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
218851489|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
219461573|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
219461574|NCT01173328|BEHAVIORAL|Normal Breathing|
219461575|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
219461576|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
219461577|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
219461578|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
219461579|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
219461580|NCT02785861|BEHAVIORAL|supervision of physical activity|
219461581|NCT02785861|BEHAVIORAL|distance supervised physical activity|
219461582|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
219461583|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
219461584|NCT00498927|DRUG|temozolomide|
219461585|NCT00498927|GENETIC|protein expression analysis|
219461586|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
219461587|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
219461588|NCT00498927|OTHER|immunoenzyme technique|
219461589|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
219461590|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
219461591|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
218851490|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
218851491|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
219198094|NCT05124405|OTHER|Continuous Glucose Monitor|wearable activity tracker
218851492|NCT02276352|DRUG|Treatment 1|
219198095|NCT04290403|DEVICE|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
218851493|NCT02276352|DRUG|Treatment 2|
218851494|NCT02276352|DRUG|Treatment 3|
218851495|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
218851496|NCT03618732|OTHER|Bilateral movement-based computer training|
218851497|NCT03618732|OTHER|Video-directed conventional training|
218851498|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
218851499|NCT00036855|BIOLOGICAL|rituximab|Given IV
219198096|NCT04290403|DEVICE|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
219198097|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
219461592|NCT04722692|DIAGNOSTIC_TEST|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
219461593|NCT04722692|DIAGNOSTIC_TEST|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
219461594|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
219461595|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
219461596|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
219461597|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
219461598|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
219461599|NCT02878135|PROCEDURE|fast application|
219461600|NCT02878135|PROCEDURE|slow application|
219461601|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
219461602|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
219461603|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
219461604|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
219461605|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
219461606|NCT01913015|DRUG|abiraterone acetate|Given PO
219461607|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive low fat breakfast
219461608|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive high fat breakfast
219461609|NCT01913015|OTHER|pharmacological study|Correlative studies
219461610|NCT01913015|OTHER|questionnaire administration|Ancillary studies
219461611|NCT01913015|OTHER|laboratory biomarker analysis|Correlative studies
219592685|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
219592686|NCT05805215|COMBINATION_PRODUCT|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
218851500|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
218851501|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
218851502|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
219461612|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
219461613|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
218851503|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
219461614|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
218851504|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
218851505|NCT02585024|DRUG|Cytisine|
219592687|NCT04028193|DIETARY_SUPPLEMENT|Calogen|Polyunsaturated liquid fat supplement
219592688|NCT04028193|DIETARY_SUPPLEMENT|Resource Energy|Carbohydrate Supplement
218851506|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
218851507|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
218851508|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
218851509|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
218851510|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
218851511|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
218851512|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
218851513|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
218851514|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
218851515|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
219198098|NCT05947422|DIAGNOSTIC_TEST|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
219461615|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
219592689|NCT01167101|DRUG|Rebamipide|Rebamipide 100mg Tid for 28days
219592690|NCT01167101|DRUG|pantoprazole|pantoprazole 40mg qd for 28days
219592691|NCT03223844|DRUG|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
219461616|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
219461617|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
219461618|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
219461619|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
219461620|NCT03056209|DRUG|Placebo|oral administration, placebo
219592692|NCT00000108|BEHAVIORAL|Exercise|
219592693|NCT02278055|DRUG|Radium-223|
219592694|NCT01934335|DRUG|Vandetanib|
219592695|NCT01934335|OTHER|Placebo|
218851516|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
218851517|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
219461621|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
219461622|NCT00258596|DEVICE|sirolimus-eluting stent|
219461623|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
219592696|NCT02360176|PROCEDURE|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
219592697|NCT02360176|PROCEDURE|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
219461624|NCT02022592|DRUG|Lormetazepam|
218851518|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
218851519|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
219461625|NCT02022592|DRUG|Midazolam|
218851520|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
218851521|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
219461626|NCT00002986|DRUG|carmustine|
219461627|NCT00002986|DRUG|topotecan hydrochloride|
219461628|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
219461629|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
219461630|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
219461631|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
219461632|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc…
219461633|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
219461634|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
219461635|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
219592698|NCT05384171|BEHAVIORAL|Measurement-Based Transition Assistance (MBTA)|Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
219461636|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
219592699|NCT01371812|DRUG|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
219461637|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
219461638|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
219461639|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
219592700|NCT01371812|DRUG|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
219592701|NCT04992208|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
219592702|NCT06130423|DRUG|Music intervention|Music therapy carried out with Music Care
219592703|NCT06130423|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
219592704|NCT02870010|BIOLOGICAL|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
219592705|NCT02870010|RADIATION|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
218851522|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
218851523|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
218851524|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
218851525|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
218851526|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
218851527|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
218851528|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
218851529|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
219198099|NCT05947422|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
219198100|NCT06563713|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 0 following protocol requirements
219461640|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
219461641|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
219461642|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
219461643|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
219461644|NCT00426842|DRUG|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
219461645|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
219461646|NCT00362297|DRUG|acyclovir|800 mg orally three times daily for 7 weeks
219461647|NCT00362297|DRUG|valacyclovir|500 mg orally once daily for 7 weeks
219592706|NCT06338124|DIAGNOSTIC_TEST|Triglyceride glucose index|To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
219592707|NCT06343064|DRUG|Vebreltinib|Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
219198101|NCT06563713|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements
219592708|NCT06343064|DRUG|PLB1004|Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
219198102|NCT04919629|BIOLOGICAL|Bevacizumab|Given IV
219198103|NCT04919629|PROCEDURE|Biopsy|Undergo tumor biopsy
219198104|NCT04919629|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219198105|NCT04919629|DRUG|Pegcetacoplan|Given IV and SC
219198106|NCT04919629|BIOLOGICAL|Pembrolizumab|Given IV
219198107|NCT04919629|OTHER|Questionnaire Administration|Ancillary studies
219198108|NCT05191823|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
219198109|NCT05191823|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
219461648|NCT00313742|DRUG|insulin detemir|
219461649|NCT00313742|DRUG|insulin glargine|
219461650|NCT00313742|DRUG|insulin NPH|
219592709|NCT01090752|DRUG|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
219198110|NCT06639633|OTHER|Anatomy Training with Enlarged %100 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 60 minutes.
218851530|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
218851531|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
218851532|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
219461651|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
219461652|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
219461653|NCT01759095|DEVICE|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
219461654|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
219461655|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
219461656|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
219461657|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
219461658|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
219461659|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
219461660|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
219461661|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
219461662|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
219461663|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
219461664|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
219461665|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
219461666|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
218851533|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
218851534|NCT00123578|DRUG|Lorazepam|Lorazepam
218851535|NCT00123578|DRUG|Pentobarbital|Pentobarbital
218851536|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
218851537|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
218851538|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
218851539|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
218851540|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
219461667|NCT01070381|DEVICE|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
219461668|NCT01070381|DEVICE|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
219461669|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
219461670|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
219461671|NCT01869686|BIOLOGICAL|Denosumab|60 mg
219461672|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
219461673|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
219461674|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
218851541|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
218851542|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
219461675|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
219461676|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
219461677|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
219461678|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
219461679|NCT04569890|DRUG|Prednisone|10mg GC orally daily
219461680|NCT00000151|DRUG|Aspirin|
219461681|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
219461682|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
219461683|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
219461684|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
219461685|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
219461686|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
219461687|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
219461688|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
219592710|NCT01090752|DRUG|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
219461689|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
219461690|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
219461691|NCT00000894|DRUG|Cidofovir|
219592711|NCT02669030|DRUG|suvorexant|an FDA-approved sleep aid
219592712|NCT02669030|DRUG|Placebo|control group
219592713|NCT04939376|PROCEDURE|IVF|In vitro fertilization
219592714|NCT06270186|DIAGNOSTIC_TEST|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
219592715|NCT02329938|PROCEDURE|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
219592716|NCT02329938|PROCEDURE|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
218851543|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
218851544|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
218851545|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
218851546|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
218851547|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
218851548|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
218851549|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
219461692|NCT00000894|DRUG|Probenecid|
219461693|NCT00000894|DRUG|Ganciclovir|
219461694|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
219461695|NCT02743494|OTHER|Placebo|Specified dose on specified days
219461696|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
219592717|NCT01756079|DRUG|boceprevir|
219592718|NCT01756079|BIOLOGICAL|PegIFN-2b|
219592719|NCT01756079|DRUG|RBV|
219592720|NCT02654119|DRUG|Cyclophosphamide|Given IV
219592721|NCT02654119|OTHER|Laboratory Biomarker Analysis|Correlative studies
219592722|NCT02654119|DRUG|Paclitaxel|Given IV
219592723|NCT02654119|BIOLOGICAL|Trastuzumab|Given IV
218851550|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
218851551|NCT00096226|DRUG|Induction Carboplatin|
218851552|NCT00096226|DRUG|Induction Paclitaxel|
218851553|NCT00096226|PROCEDURE|Resection|
218851554|NCT00096226|DRUG|Consolidation Carboplatin|
218851555|NCT00096226|RADIATION|Radiation Therapy|
218851556|NCT00096226|DRUG|Consolidation Paclitaxel|
218851557|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
218851558|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
218851559|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
218851560|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
218851561|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
218851562|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
218851563|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
219461697|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
219461698|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
219461699|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
218851564|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
219592724|NCT00106964|BIOLOGICAL|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
219592725|NCT00106964|BIOLOGICAL|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
219592726|NCT00106964|BIOLOGICAL|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
219592727|NCT02492659|PROCEDURE|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
218851565|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
218851566|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
218851567|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
218851568|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
218851569|NCT00112411|DRUG|Bronchodilator|
218851570|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
219198111|NCT06639633|OTHER|Anatomy Training with Enlarged %50 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 30 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 60 minutes.
218851571|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
219461700|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
219461701|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
219461702|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
219461703|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
218851572|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
218851573|NCT04444492|DRUG|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
218851574|NCT04444492|DEVICE|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
218851575|NCT02922764|DRUG|RGX-104|
218851576|NCT02922764|DRUG|Ipilimumab|
218851577|NCT02922764|DRUG|Docetaxel|
219461704|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
219461705|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
219461706|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
219461707|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
219461708|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
219461709|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
219461710|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
219461711|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
219461712|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
219461713|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
219592728|NCT02492659|PROCEDURE|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
219592729|NCT05390593|DEVICE|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
218851578|NCT02922764|DRUG|Pembrolizumab|
218851579|NCT02922764|DRUG|Carboplatin|
218851580|NCT02922764|DRUG|Pemetrexed|
218851581|NCT04773782|DRUG|avapritinib|oral administration
218851582|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
218851583|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
219461714|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
219461715|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
219461716|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
219461717|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
219461718|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
219461719|NCT01521494|DRUG|PA21|
219461720|NCT01521494|DRUG|PA21|
219461721|NCT01521494|DRUG|PA21|
219461722|NCT01521494|DRUG|PA21|
219461723|NCT01521494|DRUG|Placebo|
219461724|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
219461725|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
219461726|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
219461727|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
219461728|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
219461729|NCT01503229|OTHER|Pharmacological Study|Correlative studies
219461730|NCT01503229|DRUG|Prednisone|Given PO
219461731|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
219461732|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
219461733|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
219461734|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
219461735|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
219461736|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
219461737|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
219461738|NCT01973673|BEHAVIORAL|Bone health educational materials|
219461739|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
219461740|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
219461741|NCT02623569|DRUG|Ivabradine|Not Provided
219461742|NCT02623569|DRUG|Atenolol|Not Provided
219461743|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
219461744|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
219461745|NCT02609087|DRUG|Sevoflurane|
219461746|NCT02609087|DRUG|Propofol|
219461747|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
219461748|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
219461749|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
219461750|NCT00481533|DRUG|Oxytocin|
219461751|NCT03935074|DRUG|intra-arterial administration of melphalan|
219461752|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
219461753|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
219461754|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
219461755|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
219461756|NCT00004173|DRUG|oxaliplatin|
219461757|NCT00004173|DRUG|paclitaxel|
219461758|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
219461759|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
219461760|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
219461761|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
219461762|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
219461763|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
219461764|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
219461765|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
219592730|NCT05390593|DEVICE|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
219592731|NCT04868994|DIAGNOSTIC_TEST|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
219461766|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
219461767|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
219461768|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
219461769|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
219461770|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
219592732|NCT03827720|DEVICE|SENSE Device|Non-invasive radiofrequency (RF) sensor
219592733|NCT01261091|PROCEDURE|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
219592734|NCT01261091|PROCEDURE|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
219592735|NCT00245830|PROCEDURE|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
219592736|NCT01679717|OTHER|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
218851584|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
218851585|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
219461771|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
219461772|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
219461773|NCT06161766|DRUG|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
219461774|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
219461775|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
219461776|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
219461777|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
219461778|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
218851586|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
219461779|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
219461780|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
219592737|NCT06158555|DRUG|250 ML NaCl 4.5 MG/ML Injection|Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
219592738|NCT06290908|PROCEDURE|RPE-P/TLIF|patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
219592739|NCT03747510|DEVICE|CarpX Device|Transverse carpal ligament release with CarpX Device
219592740|NCT03196219|DRUG|C16G2|C16G2
218851587|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
218851588|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
219461781|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
219461782|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
219461783|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
219592741|NCT03196219|DRUG|Placebo|Varnish Placebo
219592742|NCT02079779|OTHER|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
219592743|NCT02079779|OTHER|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
219592744|NCT06187090|DIETARY_SUPPLEMENT|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
219592745|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
219592746|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
219592747|NCT00168818|DRUG|enoxaparin|40 mg once daily
219592748|NCT05408585|OTHER|Regional Anesthesia Techniques|Fascial Plane Blocks
219592749|NCT03289273|DRUG|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
219592750|NCT04379791|OTHER|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
219198112|NCT06639633|OTHER|Anatomy Training with Conventional Carpal Models|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 60 minutes practical lesson with a standard sized printed model.
219198113|NCT05989269|OTHER|Modified lab reporting|If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
219198114|NCT06495658|DIETARY_SUPPLEMENT|Prebiotic|Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
219198115|NCT06876246|BEHAVIORAL|Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication.
219461784|NCT05535452|DEVICE|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
219461785|NCT05999773|DRUG|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
219461786|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
219461787|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
219461788|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
218851589|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
219461789|NCT00219310|DRUG|Famciclovir|
219461790|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
219461791|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
219461792|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
219461793|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
219461794|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
219461795|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
219461796|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
219461797|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
219592751|NCT01994291|DRUG|Ranibizumab|"Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks"
219461798|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
219461799|NCT02515604|DRUG|Misoprostol|
219461800|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
219461801|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
219461802|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
219461803|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
219461804|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
219461805|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
219461806|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
219461807|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
219461808|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
219461809|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
219592752|NCT01994291|DRUG|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
219592753|NCT01994291|DRUG|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
219592754|NCT01994291|DRUG|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
219592755|NCT05916274|BIOLOGICAL|Blood and fecal samples|Blood and fecal samples will be performed
219592756|NCT05916274|PROCEDURE|Coolonic biopsies|colonic biopsies will be analysed
218851590|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
218851591|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
218851592|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
218851593|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
219461810|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
219461811|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
219461812|NCT00241371|DRUG|Clofarabine|
219461813|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
219592757|NCT05209165|DRUG|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
219592758|NCT05209165|DRUG|Placebo|Matching placebo and intake visit for VA MOVE
219592759|NCT06413043|DRUG|Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
219592760|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
219461814|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
219461815|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
219461816|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
219461817|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
219461818|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
219461819|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
219461820|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
219461821|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
219461822|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
218851594|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
218851595|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
218851596|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
219461823|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
219461824|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
219461825|NCT01787019|OTHER|Oral feeding|
219461826|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8\_1
219461827|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
218851597|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
218851598|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
218851599|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
218851600|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
218851601|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
219461828|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
219461829|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
218851602|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
219461830|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
219461831|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
219461832|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
218851603|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
218851604|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
218851605|NCT00822419|DRUG|ketamine|ketamine 5%
218851606|NCT00822419|DRUG|non-drug cream|will be put on the skin
218851607|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
218851608|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
218851609|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
219461833|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
219461834|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
219461835|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
219461836|NCT06040437|BEHAVIORAL|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
219461837|NCT04276493|BIOLOGICAL|Zanidatamab|Administered intravenously
219461838|NCT04276493|DRUG|Docetaxel|Administered intravenously
219461839|NCT04276493|BIOLOGICAL|Tislelizumab|Administered intravenously
219461840|NCT04276493|DRUG|Capecitabine|Administered orally
219461841|NCT04276493|DRUG|Oxaliplatin|Administered intravenously
219461842|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
219461843|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
219461844|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
219461845|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
219461846|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
219461847|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
219461848|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
219461849|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
219461850|NCT02083406|DRUG|960mg PQP|
219461851|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
219461852|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
219461853|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
219461854|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
219461855|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
219461856|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
219461857|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
219461858|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
219461859|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
219461860|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
219461861|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
219592761|NCT00085384|DRUG|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
219592762|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
219592763|NCT01017796|DRUG|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
219461862|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
219019434|NCT07029399|DRUG|NKT5097 CDK2/CDK4 dual degrader|NKT5097 will be distributed in tablet form and dosed daily or twice a day
219461863|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
219461864|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
219461865|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
219461866|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
219461867|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
219461868|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
219461869|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
219461870|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
219461871|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
219461872|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
219461873|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
219461874|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
219461875|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
219461876|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
219461877|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
219461878|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
219461879|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
219461880|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
219461881|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
219461882|NCT01247467|OTHER|Breast Tumor Blocks|
219461883|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
219461884|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219461885|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
219461886|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
219461887|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
219461888|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
219461889|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
218851610|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
218851611|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
219461890|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
219461891|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
219019437|NCT06006923|DRUG|Regorafenib|A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also have immunomodulatory affect in the tumor microenvironment.
219461892|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
219461893|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
219461894|NCT00354120|DRUG|Alentuzumab|Alentuzumab
219461895|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
219461896|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
219461897|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
219461898|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
219461899|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
219461900|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
219461901|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
219461902|NCT02457130|DRUG|Ticagrelor|
219461903|NCT02457130|DRUG|Clopidogrel|
219461904|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
219461905|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
219461906|NCT02577107|DRUG|ranibizumab|
219461907|NCT02577107|DRUG|Conbercept|
218851612|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
218851613|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
218851614|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
219461908|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
219592764|NCT05629975|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
219592765|NCT02794597|BEHAVIORAL|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
219198116|NCT06876246|BEHAVIORAL|FCU Online with Telehealth Coaching|This intervention is the Family Check-Up Online plus telehealth support from a parenting coach. The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. A coach based at the child's school meets with caregivers via telehealth modality to provide motivation and to help caregivers tailor the content of the modules to their specific child and family's needs.
219198117|NCT05247034|DIETARY_SUPPLEMENT|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
219198118|NCT05247034|OTHER|Placebo|Each capsule contains 500 mg of methylcellulose
219198119|NCT03489122|BEHAVIORAL|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
219198120|NCT03489122|BEHAVIORAL|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
219198121|NCT04510740|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
219198122|NCT05679232|DEVICE|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
218851615|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
218851616|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
218851617|NCT02242136|BEHAVIORAL|FORNET|
218851618|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
218851619|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
218851620|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
219198123|NCT05679232|PROCEDURE|Control|standard cementless hip revision arthroplasty
219461909|NCT00577382|DRUG|Sunitinib|
218851621|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
219461910|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
218851622|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
218851623|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
218851624|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
218851625|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
219198124|NCT04464564|DRUG|AVP-786|oral capsules
219198125|NCT04464564|DRUG|Placebo|oral capsules
219198126|NCT06803537|OTHER|Fiber-reinforced composite|short fiber-reinforced composite used as base covered by conventional composite
219198127|NCT06803537|OTHER|indirect lab composite|indirect lab processed resin composite inlay restorations
219198128|NCT06803537|OTHER|Conventional resin composite|conventional microhybrid resin composite posterior restorations
218851626|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
218851627|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
218851628|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
218851629|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
218851630|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
219019438|NCT06006923|DRUG|Pembrolizumab|An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.
219461911|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
219461912|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
219461913|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
219461914|NCT05108818|BIOLOGICAL|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
219461915|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
219461916|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
219461917|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
219461918|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
219461919|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
219461920|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
219461921|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
219461922|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
219461923|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
219461924|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
219461925|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
219461926|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
219461927|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
219461928|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
219461929|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
219461930|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
219461931|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
219461932|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
219461933|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
219592766|NCT04020783|OTHER|NO Intervention|NO Intervention
219592767|NCT00221377|DEVICE|Intubation using tracheal tubes with or without cuff|
218851631|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
218851632|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
218851633|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh\_NTHi-Mcat\_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
218851634|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
218851635|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
218851636|NCT00589056|DRUG|cisplatin|
219198129|NCT06571968|DEVICE|fully guided stent|All surgical procedures with drills were done through the stent., the implant was picked up from the implant holder and then installed, still with the surgical guide in situ, by using the ratchet and ratchet connector at a motor speed of 20 rpm, followed by cover screw placement without the need for sutures.
218851637|NCT00589056|DRUG|etoposide|
218851638|NCT00589056|DRUG|nelfinavir mesylate|
219461934|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
219461935|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
219461936|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
219461937|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
219198130|NCT06571968|DEVICE|semiguided stent|"The first osteotomy was performed with the surgical guide in situ using a 1.95 mm pilot-drill. Successive color coded implant drills were used to prepare implant osteotomies. When using each twist drill, a removable sleeve having a diameter to coincide with the drill and inserted into the sleeve of the surgical guide.~The stereo lithographic guide template was removed and the receptor sites were irrigated with saline solution then the final drill of the implant system 3.5 mm diameter was used to finalize the osteotomy. The implant was gripped with the placement aid, released from the implant holder by 1/4 turn and manually inserted into the prepared implant site using a finger placement tool or hand ratchet. A torque of 45 N cm should not be exceeded during insertion procedure and cover screws were screwed over it."
219461938|NCT03007472|DEVICE|CI532|Cochlear implant
219461939|NCT03007472|DEVICE|Nucleus 7|Sound processor
219461940|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
219461941|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
219461942|NCT06108531|OTHER||
218851639|NCT00589056|GENETIC|protein expression analysis|
218851640|NCT00589056|OTHER|immunohistochemistry staining method|
218851641|NCT00589056|OTHER|laboratory biomarker analysis|
219198131|NCT04511052|DIETARY_SUPPLEMENT|Probiotic|Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
219198132|NCT04511052|OTHER|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
219198133|NCT04511052|DIETARY_SUPPLEMENT|Carotenoid supplement|1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
219461943|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
218851642|NCT00589056|PROCEDURE|biopsy|
218851643|NCT00589056|RADIATION|radiation therapy|
218851644|NCT00003406|DRUG|carboplatin|
218851645|NCT00003406|DRUG|docetaxel|
218851646|NCT00003406|DRUG|ifosfamide|
219461944|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
219461945|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
219461946|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
219461947|NCT02988115|OTHER|placebo|Matching placebo tablet
219461948|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
219461949|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
218851647|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
218851648|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
219461950|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
219461951|NCT03165227|DRUG|BI 685509|Taken orally
218851649|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
219461952|NCT03165227|DRUG|Placebo|Taken orally
219461953|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
219461954|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
219461955|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
219461956|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
219461957|NCT03924960|BEHAVIORAL|Control|Usual care control group
219592768|NCT02638025|DEVICE|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
219592769|NCT01693796|OTHER|blood and urine samples ; Echography|
219592770|NCT06421883|DIETARY_SUPPLEMENT|Lactobacillus containing probiotic|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."
219592771|NCT00408083|DRUG|MultiHance|0.5 mmol/kg as a single dose administration
218851650|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
219461958|NCT02108158|DRUG|Azzalure|
219461959|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
219592772|NCT00408083|DRUG|Magnevist|0.5 mmol/kg as a single dose administration
219592773|NCT03270878|DRUG|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
218851651|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
218851652|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
218851653|NCT02198482|DRUG|Volasertib|
218851654|NCT02198482|DRUG|Cytarabine|
218851655|NCT02198482|DRUG|Daunorubicin|
218851656|NCT02198482|DRUG|Mitoxantrone|
218851657|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
218851658|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
219461960|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
219461961|NCT01466439|PROCEDURE|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
219461962|NCT01466439|PROCEDURE|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
219461963|NCT01020929|DEVICE|Blunt Coude|Type of needle tip
219461964|NCT01020929|DEVICE|Quincke|Type of needle tip
219461965|NCT01020929|DEVICE|Trucath|Type of needle tip
219461966|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
219461967|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
219198134|NCT06537648|BEHAVIORAL|Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program|Adults with Down syndrome will be asked to attend 35 minute, remotely delivered (Zoom®) group dance sessions twice weekly across 12 weeks. All sessions will be directed by an instructor experienced in leading 35 minute, group remote exercise sessions for individuals with intellectual disability as part of the ongoing exercise program for individuals with intellectual disability offered by the Division for Physical Activity and Weight Management.
219198135|NCT06318533|DRUG|anti-CD19 CAR NK cells|Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.
219198136|NCT06963489|OTHER|Not applicable- observational study|Intervention is not applicable
219198137|NCT03505710|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
218851659|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
218851660|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
218851661|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
219461968|NCT05099718|PROCEDURE|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
219461969|NCT05099718|DEVICE|Hyaluronic acid|application 3-times per day for 7 days
219461970|NCT05099718|OTHER|Saline solution (placebo)|application 3-times per day for 7 days
219461971|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
219592774|NCT03270878|DRUG|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
219592775|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
219592776|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
219592777|NCT04362553|DEVICE|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
219592778|NCT04836897|DEVICE|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
219592779|NCT00641615|BIOLOGICAL|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
219592780|NCT02006329|DEVICE|acupuncture|
219592781|NCT00637767|DRUG|melphalan|
218851662|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
219592782|NCT00637767|PROCEDURE|autologous hematopoietic stem cell transplantation|
218851663|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
218851664|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
219592783|NCT00637767|RADIATION|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
219592784|NCT03544944|DRUG|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
219461972|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
219461973|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
219592785|NCT03544944|DRUG|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
219592786|NCT03544944|DRUG|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
219592787|NCT01596309|DIETARY_SUPPLEMENT|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
219198138|NCT06965439|BEHAVIORAL|AI-delivered emotional wellbeing support|Participants in this arm will complete four 20-minute sessions with an AI-powered chatbot designed to deliver CBT-based emotional wellbeing support. The chatbot provides conversational guidance using techniques such as cognitive restructuring, behavioural activation, and emotion validation. Sessions are delivered via Zoom, and participants receive structured homework after each session to reinforce learning. The chatbot was not custom-built for this study but is an existing tool provided to NUS students as part of their digital mental health benefits.
219198139|NCT06965439|OTHER|Neutral writing tasks|Participants in this arm will complete four 20-minute sessions of neutral writing tasks unrelated to mental health. Prompts include writing factually about daily routines or describing an object in detail. The content is emotionally neutral to act as a comparison for the chatbot intervention. Sessions are conducted online via Zoom.
219198140|NCT05562310|DRUG|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
218851665|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
219198141|NCT03674723|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
218851666|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
218851667|NCT06356259|DRUG|IRX-010|Administered IV
219198142|NCT01907789|OTHER|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
219198143|NCT01907789|PROCEDURE|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
219461974|NCT02344758|BEHAVIORAL|gluten-containing diet|
219461975|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
218851668|NCT06356259|DRUG|Placebo|Administered IV
218851669|NCT06345313|PROCEDURE|Day Group|Patient group that will be operated on between 08.00-12.00
218851670|NCT06345313|PROCEDURE|Night Group|Patient group that will be operated on between 18.00-22.00
219461976|NCT03520842|DRUG|Methotrexate|Given PO
219461977|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
219461978|NCT03520842|DRUG|Regorafenib|Given PO
219461979|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
219461980|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
219461981|NCT04306003|OTHER|ERAS pathway|See ERAS pathway arm description.
219461982|NCT04306003|OTHER|Standard Perioperative Care|See control arm description.
219461983|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
218851671|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
218851672|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
218851673|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
218851674|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
219461984|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
219461985|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
219461986|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
219461987|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
219461988|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
219461989|NCT03076411|DRUG|Pepsin|
219461990|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
219461991|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
219461992|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
219461993|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
219461994|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
219198144|NCT01907789|PROCEDURE|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
219198145|NCT01907789|BEHAVIORAL|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
219198146|NCT01907789|PROCEDURE|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
219198147|NCT01907789|BEHAVIORAL|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
218851675|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
218851676|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
219461995|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
219461996|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
219461997|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
218851677|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
218851678|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
218851679|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
219198148|NCT03304717|DRUG|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
219198149|NCT03304717|OTHER|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
219198150|NCT05735652|DEVICE|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
219461998|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
219461999|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
219462000|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
219462001|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
219462002|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
219462003|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
219462004|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
219462005|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
219462006|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
219462007|NCT03547219|DRUG|Escitalopram|
219462008|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
219462009|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
219462010|NCT04846543|OTHER|MRI Scan|MRI scan
218851680|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
219462011|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
219462012|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
219592788|NCT01860352|DIETARY_SUPPLEMENT|Fish OIl|
219592789|NCT01179711|DEVICE|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
218851681|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
219462013|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
219198151|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
218851682|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
218851683|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
218851684|NCT03609385|DIAGNOSTIC_TEST|Coronary angiography|In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
218851685|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
218851686|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
218851687|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
218851688|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
218851689|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
218851690|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
218851691|NCT03554941|DEVICE|noise stimulation|noise stimulation
218851692|NCT00099944|DRUG|vildagliptin|
218851693|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
218851694|NCT00099944|DRUG|LAF237 placebo|
219198152|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
219198153|NCT06639516|DIETARY_SUPPLEMENT|Bifidobacterium longum|Bifidobacterium longum
218851695|NCT02144506|OTHER|T&E|
219198154|NCT06639516|DIETARY_SUPPLEMENT|Placebo|Placebo
219462014|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
219592790|NCT00901576|DRUG|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
219592791|NCT00901576|DRUG|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
219592792|NCT00901576|DRUG|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
219592793|NCT03420586|DRUG|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
218851696|NCT02144506|OTHER|OTAGO|
218851697|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
218851698|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
218851699|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
218851700|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
219592794|NCT01153295|PROCEDURE|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
219592795|NCT01153295|PROCEDURE|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
218851701|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
218851702|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
219198155|NCT06639516|COMBINATION_PRODUCT|Standard clinical treatment|Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
219198156|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
219198157|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219592796|NCT00003302|PROCEDURE|biopsy|
219592797|NCT00003302|DIAGNOSTIC_TEST|magnetic resonance imaging|
218851703|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
218851704|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
218851705|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
218851706|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
218851707|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
219462015|NCT01363232|DRUG|BKM120 + MEK162|
219462016|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
219462017|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
219462018|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
219462019|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
219462020|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
219462021|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
219462022|NCT01678287|DRUG|ASP1941|oral
219462023|NCT01678287|DRUG|Placebo|oral
219462024|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
219462025|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
219462026|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
219462027|NCT00304421|DRUG|rabeprazole|
219462028|NCT00304421|DRUG|pantoprazole|
219198158|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219462029|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
219462030|NCT00551694|DRUG|GSK256073A tablets|
219462031|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
218851708|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
219462032|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
219462033|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
219462034|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
219462035|NCT01977664|OTHER|no intervention|
218851709|NCT02392390|DRUG|Metvixia cream|
218851710|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
218851711|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
218851712|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
218851713|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
218851714|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
218851715|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
219462036|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
219592798|NCT00003302|DIAGNOSTIC_TEST|mammography|
219592799|NCT03201445|DRUG|Filgotinib|200 mg tablet administered orally once daily
219592800|NCT03201445|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
219592801|NCT03201445|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
218851716|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
219462037|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
219462038|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
219462039|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
219462040|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
219462041|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
219462042|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
219462043|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
219462044|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
219462045|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
219462046|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
219462047|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
219462048|NCT06415916|PROCEDURE|Cardiac ultrasound|Performed 5 times between 0 and 120 minutes
219462049|NCT06415916|PROCEDURE|Lung ultrasound|Performed 5 times between 0 and 120 minutes
219462050|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
219462051|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
219462052|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
219462053|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
219462054|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
219462055|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
219462056|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
218851717|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
218851718|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
219462057|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
219462058|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
219462059|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
219462060|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
219592802|NCT05179330|DEVICE|OMEGO®|Lower limb rehabilitation with and without visual feedback
219592803|NCT03191591|BEHAVIORAL|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
219592804|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3 + bracket|
219592805|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3|
219592806|NCT02132806|PROCEDURE|Piezosurgery|
219592807|NCT02914210|DEVICE|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
219198159|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219198160|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219198161|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
219198162|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
218851719|NCT00385281|BIOLOGICAL|FluMist|
218851720|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
218851721|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
218851722|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
219198163|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
219198164|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
219592808|NCT02914210|OTHER|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
219592809|NCT00144157|DRUG|Nevirapine|
219592810|NCT00144157|DRUG|Zidovudine|
219592811|NCT00144157|DRUG|3TC|
219592812|NCT03354260|OTHER|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
219592813|NCT03239743|DEVICE|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
219592814|NCT03239743|DRUG|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
219592815|NCT01774708|DEVICE|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
218851723|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
218851724|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
218851725|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
219198165|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-6 (il-6) concentration in blood serum|Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum
219198166|NCT06793085|DIAGNOSTIC_TEST|Measurement of fasting tumor necrosis factor α (TNF-α) concentration|Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum
219462061|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
219462062|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
219592816|NCT02588495|OTHER|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
219592817|NCT01695863|DRUG|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
219592818|NCT00813800|DRUG|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
218851726|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
218851727|NCT05629208|DRUG|Edecesertib|Tablets administered orally
218851728|NCT05629208|DRUG|Edecesertib Placebo|Tablets administered orally
218851729|NCT04246775|DEVICE|Peristeen|rectal irrigation
218851730|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
218851731|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
218851732|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
218851733|NCT06357780|OTHER|close-loop synchronization controller with spontaneous mode|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
218851734|NCT06357780|OTHER|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
218851735|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
218851736|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
218851737|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
218851738|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
218851739|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
218851740|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
219462063|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
219462064|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
218851741|NCT06356935|OTHER|RT|Resistance training
218851742|NCT06356935|OTHER|CON|Control group
218851743|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
218851744|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
218851745|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
218851746|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
218851747|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
218851748|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
218851749|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
218851750|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
218851751|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
218851752|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
218851753|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
218851754|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
218851755|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
219462065|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2\) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
218851756|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
219462066|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
219462067|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
219462068|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
219462069|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
219462070|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
219462071|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
219462072|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
219462073|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
219462074|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
219592819|NCT03456453|BEHAVIORAL|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
219592820|NCT06852755|OTHER|Blood Sample Collection|Collection of peripheral blood samples for mitochondrial analysis, including the extraction of mononuclear cells and plasma for further assessment of mitochondrial quality and quantity.
219592821|NCT06983106|OTHER|body composition calculate|The goal of this observational study is to learn about the value of body composition as predictors of pathological grading and prognosis in patients with gastroenteropancreatic neuroendocrine neoplasms. The volume of abdominal skeletal muscle and fat tissue is calculated based on CT scans at diagnosis.
219592822|NCT06982443|BEHAVIORAL|Mindfulness based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
219592823|NCT06983717|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
219592824|NCT06977490|DRUG|Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 3.0 mg/kg in each period.
219592825|NCT06977490|DRUG|Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)|Single intravenous administration of 3.0 mg/kg in each period.
219592826|NCT06983860|PROCEDURE|Application and demonstration of endoscope-assisted low-temperature plasma radiofrequency ablation resection of tonsils|Low temperature plasma radiofofency ablation of tonsil under 70° nasal endoscope can directly view the lesion area on the monitor, clearly enlarge the operating field, and has the advantages of small surgical trauma, good hemostatic effect, light postoperative pain, low probability of postoperative bleeding and quick postoperative recovery of patients, etc. It is a good surgical mode integrating surgery and teaching, and has brought great benefits to patients, and is worth promoting and applying.
219592827|NCT06982040|DRUG|NTQ5082 capsules 100 mg|NTQ5082 capsules 100 mg
219592828|NCT06982040|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
219592829|NCT06982040|DRUG|NTQ5082 capsules 300 mg|NTQ5082 capsules 300 mg
219592830|NCT06982040|DRUG|Placebo|Placebo
219592831|NCT06982989|DEVICE|use LED to treat pelvic pain|Use led to treat pelvic pain
219019455|NCT06694727|DIETARY_SUPPLEMENT|Coenzyme Q10 100 Milligrams Oral Capsule|100 mg capsules given twice daily, per oral use.
219592832|NCT06981910|BEHAVIORAL|Psychoeducation program|Each psychoeducation session included informational components, a preliminary group discussion of the topic, structured education on the discussed topic, awareness-raising activities within the group, opportunities for sharing, and emotional support. When participants' attention waned during sessions, breathing exercises were introduced. Depending on the group's preference, sessions concluded with a 2-3-minute poetry listening session and/or breathing exercises. At the end of each session, educational booklets prepared specifically for that session were distributed to the participants.
219592833|NCT06982339|OTHER|Air Conditioner|Air conditioners will be window-mounted units powered by 110v AC.
219198167|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-18 (il-18) concentration|Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum
219198168|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-4 (il-4) concentration|Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma
219462075|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
219462076|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
219462077|NCT02839590|DEVICE|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
219462078|NCT02839590|DEVICE|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
219462079|NCT02839590|DEVICE|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
219462080|NCT02839590|DEVICE|STARflo|Suprachoroidal Shunt Surgery (STARflo)
219462081|NCT02839590|DEVICE|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
219462082|NCT02839590|DEVICE|iStent implant|Trans-trabecular meshwork implants (iStent implant).
219462083|NCT02839590|DEVICE|Kahook Dual Blade|It removes part of the trabecular meshwork
219462084|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
219019456|NCT06694727|DIETARY_SUPPLEMENT|Selenium 100 Micrograms Oral Tablets|100 μg tablets given twice daily, per oral use.
219462085|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
219462086|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
219462087|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
219462088|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
219462089|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
219462090|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
219462091|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
219462092|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
219462093|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
219462094|NCT00104273|DRUG|Rasagiline|
219462095|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
219592834|NCT06982339|OTHER|Electricity subsidy|Electricity subsidies will consist of a single block subsidy of USD 100, intended to provide support for the electricity costs associated with operating an air conditioning unit.
219462096|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
219462097|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
219462098|NCT03681808|DEVICE|Control|Contact Lens
219462099|NCT03681808|DEVICE|Test|Soft Contact Lens
219462100|NCT02283801|DRUG|Eslicarbazepine acetate|
219462101|NCT02283801|DRUG|Lamotrigine|
219462102|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
219462103|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
219462104|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
219462105|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
219462106|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
219592835|NCT06983834|BEHAVIORAL|Psychoeducation|Mindfulness Based Psychoeducation
219592836|NCT06983132|DIAGNOSTIC_TEST|Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading|Cerebral MRI according to dedicated protocol, central MRI reading.
218851757|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
219198169|NCT02358187|BIOLOGICAL|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
219198170|NCT04536012|BEHAVIORAL|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
219198171|NCT05059002|DEVICE|Physiological signal monitoring and seizure detection|Data collection and as an adjunct to other methods of seizure monitoring
219462107|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
219462108|NCT02297620|DRUG|Suglat®|oral
219462109|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
219462110|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
219462111|NCT02561104|PROCEDURE|Laser-assisted cataract surgery.|
219462112|NCT02561104|PROCEDURE|Traditional manual phacoemulsification|
219462113|NCT03826316|DRUG|Nalbuphine|Pharmacokinetic study under fasting conditions
219462114|NCT00636506|DEVICE|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
219462115|NCT01822249|DRUG|EPI-743|
219462116|NCT01822249|DRUG|Placebo|
219462117|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
219462118|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
219462119|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
219462120|NCT00821756|BEHAVIORAL|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
219462121|NCT03742271|DEVICE|senofilcon A|TEST Lens
219462122|NCT01860131|BEHAVIORAL|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
219462123|NCT06136910|DRUG|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
219462124|NCT04361721|DRUG|Erenumab|First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
219019463|NCT06712316|DRUG|Pumitamig|Intravenous infusion
219462125|NCT01601990|DRUG|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
219198172|NCT04506424|OTHER|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
219198173|NCT06421376|DRUG|Cardonilizumab|Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
219198174|NCT06421376|RADIATION|Chemoradiotherapy ±immunotherapy|"Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles"
219198175|NCT06421376|PROCEDURE|Radical surgery|Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
219198176|NCT03907020|DIETARY_SUPPLEMENT|Barley|Assessing the metabolic availability of lysine in barley.
219198177|NCT04389957|OTHER|Veterans Affairs Endoscopy Quality Improvement Program (VA-EQuIP)|We created an innovative informatics framework for centralized reporting of colonoscopy quality across the VA, facilitating the implementation of the VA Endoscopy Quality Improvement Program (VA-EQuIP). The VA-EQuIP quality dashboard (updated at 6 month intervals) provided adenoma detection rates (ADR), bowel preparation quality, and cecal intubation rate to every facility.This initiative directly addressed the OIG's recommendations and the VA's urgent need for evidence-based colonoscopy quality measurement and reporting. Through VA-EQuIP, we provided bi-annual audits and feedback on colonoscopy quality for VA sites and endoscopists, along with individual provider benchmarking against local and national performance standards. Additionally, we organized collaborative learning sessions led by national experts in colonoscopy training and quality. These sessions focused on shared learning, featuring lectures, discussions, skill-building activities, and work on quality improvement projects.
219198178|NCT05079269|OTHER|Crystalloid Solutions|As above
219462126|NCT01601990|DRUG|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
219462127|NCT03810053|BEHAVIORAL|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
219462128|NCT01529827|DRUG|fludarabine phosphate|Given IV
219462129|NCT01529827|DRUG|melphalan|Given IV
219462130|NCT01529827|RADIATION|total-body irradiation|Undergo TBI
219462131|NCT01529827|DRUG|tacrolimus|Given IV or PO
219462132|NCT01529827|DRUG|mycophenolate mofetil|Given IV or PO
219462133|NCT01529827|DRUG|methotrexate|Given IV
219019464|NCT06712316|DRUG|Pembrolizumab|Intravenous infusion
219019465|NCT06712316|DRUG|Carboplatin|Intravenous infusion
219019466|NCT06712316|DRUG|Pemetrexed|Intravenous infusion
219019467|NCT06712316|DRUG|Paclitaxel|Intravenous infusion
219198179|NCT03021395|DRUG|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
219462134|NCT01529827|OTHER|laboratory biomarker analysis|Correlative studies
219462135|NCT01529827|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
219462136|NCT01529827|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
219462137|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
219462138|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
219462139|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
219462140|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
219462141|NCT01758172|DRUG|6% hydroxyethyl starch 130/0.4|
219462142|NCT01758172|DRUG|Albumin|
219592837|NCT06983132|DIAGNOSTIC_TEST|Determination of circulating biomarkers|High-throughput molecular analysis will be performed on plasma samples collected assessing a selected panel of biomarkers, associated with endothelial cell profiles using automated and high-throughput ELISA. The interactions between mutation profile, protein biomarkers, and clinical variables will be correlated with patients' outcomes.
219592838|NCT06983652|DEVICE|THz scanning using THz Imaging system.|The THz scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
218851758|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
218851759|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
219462143|NCT05431972|DEVICE|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
219462144|NCT05431972|DEVICE|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
219592839|NCT06983951|GENETIC|BCMA CART|"The cell product used in this study is a targeted BCMA autologous CART cell injection.~Research drug name: Targeted BCMA Autologous CART Cell Injection Drug code: BJBR-BCMA-006 Administration method: single intravenous injection"
219592840|NCT06804876|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
219592841|NCT06981858|DRUG|Enlonstobart Injection|Sequential Enlonstobart Injection with concurrent chemoradiotherapy
219019474|NCT06703489|DEVICE|Sphere-9 Catheter with the Affera Mapping and Ablation System|Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and undergo ablation with the Sphere-9 Catheter with the Affera Mapping and Ablation System.
219019476|NCT04166513|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
219462145|NCT00315523|DRUG|Levocetirizine|
219462146|NCT01481714|DRUG|Sodium picosulphate, magnesium oxid and citric acid|"* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
219462147|NCT01481714|DRUG|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~\- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
219462148|NCT06267495|PROCEDURE|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
219462149|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
219462150|NCT00854568|DRUG|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
219462151|NCT00854568|DRUG|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
219462152|NCT04830176|OTHER|dentifrice|use of dentifrices for brushing
219462153|NCT04142762|DRUG|ABI-H2158|ABI-H2158 tablets
219462154|NCT04142762|DRUG|Itraconazole|Itraconazole capsules
219462155|NCT04142762|DRUG|Rifampin|Rifampin capsules
219462156|NCT04142762|DRUG|Midazolam|Midazolam syrup
219462157|NCT04142762|DRUG|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
219462158|NCT04142762|DRUG|Esomeprazole|Esomeprazole capsules
219462159|NCT04142762|DRUG|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
219462160|NCT00444834|DRUG|Carvedilol|50 mg
219462161|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
219462162|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
219462163|NCT03463109|OTHER|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
219462164|NCT03463109|OTHER|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
219462165|NCT00791011|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
219462166|NCT00791011|OTHER|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
219462167|NCT00791011|OTHER|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
219019477|NCT04166513|DEVICE|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
219462168|NCT00758004|DRUG|Atorvastatin|A single dose of 80 mg atrovastatin tablet
219462169|NCT00758004|DRUG|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
219462170|NCT02996240|DIETARY_SUPPLEMENT|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
219462171|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
219462172|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
219462173|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
219462174|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
219462175|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
219462176|NCT03735017|OTHER|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
219462177|NCT03735017|OTHER|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
219462178|NCT03529734|OTHER|12 min running|This was already explained in the description of arm
219462179|NCT03529734|OTHER|Local strengthening exercises|This was already explained in the description of arm
219462180|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
219462181|NCT02513355|BIOLOGICAL|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
219462182|NCT02513355|DRUG|Changchun marina|25mg/m2,d1 and d8,q21d×4
219462183|NCT02513355|DRUG|cisplatin|80mg/m2,d1, q21d×4
219462184|NCT02513355|DRUG|Taxol|135-175mg/m2,d1,q21d×4
219462185|NCT02513355|DRUG|parapl|AUC=5-6,d1,q21d×4
219462186|NCT01590446|DRUG|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
219462187|NCT01590446|DRUG|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
219462188|NCT05202184|PROCEDURE|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
219462189|NCT01376908|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
219462190|NCT01376908|OTHER|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
219592842|NCT06982391|BEHAVIORAL|Resilience-Focused Acceptance and Commitment Therapy (ReACT) Program|The Resilience-Focused Acceptance and Commitment Therapy (ReACT) program is a structured, group-based psychological intervention specifically designed for women who have undergone mastectomy following breast cancer. The program consists of three weekly 90-minute sessions integrating core ACT processes, including acceptance, defusion, mindfulness, values clarification, and committed action, with an emphasis on building psychological resilience, self-compassion, and enhancing perceived social support. The program uniquely combines evidence-based ACT techniques with group exercises focused on post-cancer psychosocial adjustment.
219592843|NCT06982391|OTHER|No intervention|Standard Care
219592844|NCT06982534|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
219592845|NCT06982326|OTHER|MF+|During the MF+ session, before each physical testing phase, participants completed a 30-min Colour Word Stroop task (CST) to trigger MF. The paper-based version of the CST was completed in quiet rooms following the same protocol as in previous studies. This prolonged cognitive task was reported to require sustained attention and automatic response inhibition and effectively induced MF through cognitive manipulation. ThyIt had ben Four colour words (red, blue, green and yellow) were randomly printed and participants were asked to verbalise the colour of each word.
219592846|NCT06982326|OTHER|MF-|During the control session, before each physical testing phase, participants watched emotionally neutral documentaries for 30 min.
219462191|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
219462192|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
219462193|NCT00369408|DRUG|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
219462194|NCT00369408|DRUG|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
219462195|NCT04080349|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
219462196|NCT04080349|DRUG|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
219462197|NCT04080349|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
219462198|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
219198180|NCT06236503|BEHAVIORAL|Real Stimulation|"Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months."
219019478|NCT04166513|BEHAVIORAL|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
219592847|NCT06983236|BEHAVIORAL|AI-enabled patient education material|Students in the intervention group will be asked to prepare patient education material for a patient using an artificial intelligence (AI) tool on 'infection care'. First, the intervention group will receive 2 hours of training on artificial intelligence. This training will take place in a classroom environment with internet access. All students in the intervention group will be trained at the same time and their questions will be answered. The students will not receive any additional counselling after the training. It will be explained to the students in the intervention group that they will first have to prepare the educational material using the AI tool and that they can use support tools such as books, magazines and websites while preparing the educational material. Students will be given five days and will be asked to submit their patient education materials at the end of the five days and will be asked to complete the patient education information form.
219019479|NCT04166513|BEHAVIORAL|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
219462199|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
219462200|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
219462201|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462202|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462203|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462204|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462205|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462206|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
219462207|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219462208|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219462209|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219462210|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219462211|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219019482|NCT07123363|DRUG|bitopertin|bitopertin 60 mg will be taken once daily by mouth
219019484|NCT06881888|DRUG|Octreotide (drug)|Participants will administer the DDM-octreotide nasal spray without priming in one nostril three times a day.
219019485|NCT06881888|DRUG|Placebo|Participants will administer the placebo nasal spray without priming in one nostril three times a day.
219462212|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
219462213|NCT04299750|PROCEDURE|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
219462214|NCT04299750|PROCEDURE|Tooth extraction|Tooth extraction and socket natural healing
219462215|NCT02158195|BIOLOGICAL|blood samples|
219462216|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
219462217|NCT01551628|DRUG|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
219462218|NCT03610867|DRUG|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
219462219|NCT03610867|DRUG|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
219462220|NCT03610867|DRUG|Placebo (SAD)|Each subject will receive the sample once by oral administration.
219462221|NCT03610867|DRUG|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
219462222|NCT01213849|DRUG|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
219462223|NCT01213849|DRUG|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
219462224|NCT01213849|DRUG|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
219462225|NCT01213849|DRUG|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
219462226|NCT02105168|PROCEDURE|Blood sample|Optional
219462227|NCT02105168|PROCEDURE|Tumorous biopsy|Optional
219462228|NCT02105168|PROCEDURE|Healthy material sample|Optional
219462229|NCT00415246|DRUG|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
219462230|NCT02477540|DRUG|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular"
219462231|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
219462232|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
219462233|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
219462234|NCT01468844|DRUG|Placebo|Placebo
219462235|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
219462236|NCT01251081|OTHER|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
219462237|NCT01251081|OTHER|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
219462238|NCT02142712|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
219462239|NCT02142712|DRUG|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
219462240|NCT02142712|DRUG|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
219462241|NCT02142712|DRUG|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
219462242|NCT02309216|OTHER|Whol-Body MRI scan|
219462243|NCT03080441|DEVICE|pressure stockings|pressure stockings worn during dialysis throughout treatment period
219462244|NCT03080441|DRUG|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
219462245|NCT03080441|OTHER|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
219462246|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
219462247|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
219462248|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
219462249|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
219462250|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
219462251|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
219462252|NCT02220660|DRUG|BI 1744 CL|
219462253|NCT02220660|DRUG|BI 54903 XX|
219462254|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
219462255|NCT02220660|DRUG|Placebo|
219462256|NCT01408862|OTHER|venous puncture|Blood for in vitro studies will be drawn
219462257|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
219462258|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
219462259|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
219462260|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
219462261|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
219462262|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
219462263|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
219462264|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
219462265|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
219462266|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
219462267|NCT02415582|OTHER|Control|45 minutes resting sitting
219462268|NCT01886092|DEVICE|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
219462269|NCT01886092|DEVICE|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
219462270|NCT01886092|DEVICE|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
219462271|NCT01886092|DEVICE|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
219462272|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
219462273|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
219462274|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
219462275|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
219462276|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
219462277|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
219462278|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
219462279|NCT00003368|DRUG|irinotecan hydrochloride|
219462280|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
219462281|NCT01086267|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
219462282|NCT01086267|DRUG|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
218851760|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
218851761|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
218851762|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
218851763|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
218851764|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
218851765|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
218851766|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
219462283|NCT01086267|DRUG|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
219462284|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
219462285|NCT05275140|OTHER|Physical activity|Combat sports and exercise
219462286|NCT03656146|OTHER|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
219462287|NCT03656146|OTHER|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
219462288|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
219019488|NCT03480438|DRUG|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
219462289|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
219462290|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
219462291|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
219462292|NCT02853318|DRUG|Cyclophosphamide|Given PO
219462293|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
219462294|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
219462295|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~\- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
219462296|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~\- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
219462297|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
219462298|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
219462299|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
219462300|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
219462301|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
219462302|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
219462303|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
219462304|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
219462305|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
219462306|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
219462307|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
219462308|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
219198181|NCT06236503|BEHAVIORAL|Placebo Stimulation|Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
219198182|NCT06134258|OTHER|mixed meal test|mixed meal test after fasting
219198183|NCT04950894|DEVICE|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
219462309|NCT01813149|OTHER|punch biopsy|
219462310|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
219462311|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
219462312|NCT02079506|DRUG|Candesartan|
219462313|NCT02079506|DRUG|Rosuvastatin|
219462314|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
219462315|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
219462316|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
218851767|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
218851768|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
219462317|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
219462318|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
219462319|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
219462320|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
219462321|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
219462322|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
219462323|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
219462324|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
219462325|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
219462326|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
219462327|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
219462328|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
219462329|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
219462330|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
219462331|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
219462332|NCT04490499|BIOLOGICAL|HBVAXPRO™|Single 0.5 mL intramuscular dose
219462333|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
219462334|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
219462335|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
219462336|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
219462337|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
219462338|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
219462339|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
219462340|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
218851769|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
219462341|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
219462342|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
219462343|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
219462344|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
219462345|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
218851770|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
218851771|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
219462346|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
218851772|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
218851773|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
218851774|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
219462347|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
219462348|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
219019494|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
219019495|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
219198184|NCT03868826|PROCEDURE|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
219462349|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
219198185|NCT03596801|BIOLOGICAL|RSV 6120/∆NS1|Delivered as nose drops
219198186|NCT03596801|BIOLOGICAL|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
218851775|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
218851776|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
218851777|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
218851778|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
218851779|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
218851780|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
218851781|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
218851782|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
218851783|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
219198187|NCT03596801|BIOLOGICAL|Placebo|Delivered as nose drops
218851784|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
218851785|NCT06888180|OTHER|Non interventional study|"Documentation of Non-Invasive Ventilation Settings at Different Stages of Patient Management"
218851786|NCT04657367|OTHER|Observational study - registry|Observational study - registry
219198188|NCT05374538|DRUG|VIC-1911|VIC-1911 tablets for oral administration
218851787|NCT06896019|DIAGNOSTIC_TEST|Community Pneumonia|The BALF of CAP patients
219198189|NCT05374538|DRUG|sotorasib|Sotorasib tablets for oral administration
219198190|NCT06809322|DRUG|Vorasidenib|Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles
219198191|NCT06809322|DRUG|Vorasidenib Placebo|Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles
219198192|NCT05972577|OTHER|Health Promotion and Education|Undergo GO!
219198193|NCT05972577|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
219198194|NCT05972577|OTHER|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
219198195|NCT05972577|OTHER|Questionnaire Administration|Complete questionnaires
218851788|NCT06895512|DRUG|HLX15-IV|recombinant anti-CD38 human monoclonal antibody injection
219198196|NCT06651840|PROCEDURE|"bipolar diathermy Standard technique."|"The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
218851789|NCT06895512|DRUG|Darzalex|recombinant anti-CD38 human monoclonal antibody injection
218851790|NCT06897306|PROCEDURE|surgery|The patient underwent surgery.
218851791|NCT06896500|BEHAVIORAL|Kegel Exercises|Kegel exercises performed three times daily in different positions (supine, sitting, and standing) for three weeks, followed by a six-week home program
218851792|NCT06572982|DRUG|Azacitidine|300 mg Film coated tablets
218851793|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219198197|NCT06651840|PROCEDURE|coblation technique.|"The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
219198198|NCT03709966|DEVICE|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
219198199|NCT03709966|BEHAVIORAL|Routine|Physical activity promotion supported by a kinesiologist
219462350|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
219462351|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
219462352|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
219462353|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
219462354|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
219462355|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
219462356|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
219462357|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
219462358|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
219462359|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
219462360|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
219462361|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
219462362|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
219462363|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
219462364|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
219462365|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
219462366|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
219462367|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
219462368|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
219462369|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
219462370|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
219462371|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
219462372|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
219462373|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
219462374|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
219462375|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
219462376|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
219462377|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
219198200|NCT05988918|DRUG|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
219462378|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
219462379|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
219462380|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
219462381|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
219462382|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
218851794|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
218851795|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
218851796|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
218851797|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
218851798|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
218851799|NCT03020134|DRUG|Placebo|Placebo
218851800|NCT06379958|DRUG|leramistat 40mg|Oral capsule
218851801|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
218851802|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
218851803|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
218851804|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
218851805|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
218851806|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
218851807|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
218851808|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
218851809|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
219462383|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
219462384|NCT01997333|DRUG|CDX-011|
219462385|NCT01997333|DRUG|Capecitabine|
219462386|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
218851810|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
218851811|NCT02885480|BEHAVIORAL|questionnaires|
218851812|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
218851813|NCT00146809|DRUG|Minocyline|
218851814|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
218851815|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
218851816|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
218851817|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
218851818|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
218851819|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
219198201|NCT03778801|DIAGNOSTIC_TEST|kinesiophobia|The investigators assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
219462387|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
219462388|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
219462389|NCT00015015|DRUG|Dichloroacetate|
219462390|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
219462391|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
219592848|NCT06983236|BEHAVIORAL|Traditional patient education material|"Students in the control group will be interviewed and asked to prepare a patient education material about infection care for a patient. Students will be informed that they can use additional tools such as books, magazines, and websites to prepare educational materials. Students will be given five days and at the end of the five days, they will be asked to submit their patient education materials and fill out the Patient Education Information Form. Students will be asked to write down the references they used in detail and include direct links to the websites of the Internet resources."
219592849|NCT06982612|OTHER|Hot environment|Participants exercising in a 36 degrees celsius environment
218851820|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
218851821|NCT00274898|DRUG|celecoxib|
218851822|NCT00274898|DRUG|docetaxel|
218851823|NCT00274898|PROCEDURE|adjuvant therapy|
218851824|NCT00274898|RADIATION|radiation therapy|
218851825|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
218851826|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
218851827|NCT02956044|DRUG|Metformin|1000 mg metformin
218851828|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
218851829|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
218851830|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
218851831|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
219019509|NCT06688344|OTHER|fESWT|fESWT will be applied for 1 session between weeks 4-9. The device will be set to low intensity at 0.20 mJ/mm2 - 4 Hz, 500 pulses will be applied from the tibiofemoral interval to the center of the tibiofemoral joint, and 1000 pulses will be applied to the soft tissues around the patella.
219019510|NCT06688344|OTHER|Conventional Physiotherapy|"Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down"
219019511|NCT06688344|OTHER|shamfESWT|Participants in the control group will receive sham fESWT once a week in weeks 4-9. Participants will be prepared in the same way as the fESWT procedure, but the application will be done with a sham device.
219019520|NCT06721910|DRUG|Tocilizumab|Blockade of the interleukin-6 receptor
219019521|NCT06721910|OTHER|Placebo|Infusion of 100 ml normal saline
219462392|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
219462393|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
219462394|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
219462395|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
219462396|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
219592850|NCT06982612|OTHER|Temperate condition|Participants exercising in a 18 degrees celsius environment
219592851|NCT06982378|DRUG|GLP-1 receptor agonist|on and not on treatment
219462397|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
219462398|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
219462399|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
219462400|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
219462401|NCT00476515|DRUG|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
219462402|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
219462403|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
219462404|NCT01083615|DRUG|docetaxel|
219462405|NCT01083615|DRUG|cabazitaxel|
219462406|NCT01083615|DRUG|prednisone|
219462407|NCT01681537|DRUG|Lenalidomide|
218851832|NCT01728558|OTHER|Early goal Directed Sedation|
218851833|NCT01728558|OTHER|Standard care sedation|
219462408|NCT01681537|DRUG|Mitoxantrone|
219198202|NCT06356285|BEHAVIORAL|Presentation of Antimicrobial Resistance|Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
219198203|NCT04877444|DEVICE|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
219198204|NCT04877444|BEHAVIORAL|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
218851834|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
218851835|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
219462409|NCT01681537|DRUG|Etoposide|
219462410|NCT01681537|DRUG|Cytarabine|
219462411|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
219462412|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
219462413|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
219462414|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
219462415|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
219462416|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
219462417|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
219462418|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
219462419|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
219462420|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
219462421|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
219462422|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
219462423|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
218851836|NCT02975479|DRUG|ALK Diluent|
218851837|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
218851838|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
218851839|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
219462424|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
219462425|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
219462426|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
219462427|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
219462428|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
219462429|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
218851840|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
218851841|NCT02629848|DRUG|Carboplatin|Carboplatin IV
218851842|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
218851843|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
218851844|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
218851845|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
218851846|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
218851847|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
218851848|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
218851849|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
218851850|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
218851851|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
219462430|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
219462431|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
219462432|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
219462433|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
219462434|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
219462435|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
218851852|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
218851853|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
218851854|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
218851855|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
219462436|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
219462437|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
219462438|NCT01641029|OTHER|No intervention|There is no intervention
219462439|NCT00902473|DRUG|Topiramate|25mg tablets
219462440|NCT00174876|DRUG|Drug Abilify|
219462441|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
219462442|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
219462443|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
219462444|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
219462445|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
219462446|NCT04411472|OTHER|Placebo|Placebo
219462447|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
219462448|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
219462449|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
219462450|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
219462451|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
219462452|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
219462453|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
219462454|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
219462455|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
219462456|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
219462457|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
219462458|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
219462459|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
219462460|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
219462461|NCT01910142|DIETARY_SUPPLEMENT|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
219462462|NCT01910142|DIETARY_SUPPLEMENT|calcium|
219462463|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
219462464|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
219462465|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
219462466|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
219462467|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
219462468|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
219462469|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
219462470|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
219462471|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
219462472|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
219462473|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
219462474|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
219462475|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
219462476|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
219462477|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
219462478|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
219462479|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
219462480|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
219462481|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
219462482|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
219462483|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
219462484|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
219462485|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
219462486|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
219462487|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
219462488|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
219462489|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
219462490|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
219462491|NCT01531244|DRUG|melphalan|Given via ILI
219462492|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
219592852|NCT06981897|BEHAVIORAL|early cognitive therapy program in addition to selected physical therapy program (positioning, chest care exercise).|"A.Positioning for head injury patients~B.Chest clearance intervention~C.Procedure for cognitive therapy All these exercises are given to patients even when they are on ventilator support of around 20-30 minutes six days /week .~1. coma stimulation incorporated with cognition training such as : i. Multimodal Sensory stimulation, including :~   1. Visual~  2. Auditory~  3. Olfactory~  4. Gustatory~  5. Tactile- Administered by rubbing different textures like satin, silk, fur, smooth metal, sandpaper, or cool or warm items over the patient's body surfaces.~   ii. Calling out their names, using patient's relatives help for transferring were used for improving the cognition and conscious levels.~2. Kinesthetic Stimulation~   1. Passive movements~  2. Joint approximation Each movement two times, allowing 1 minute to respond. This will be performed either in bed or in the wheelchair, one extremity at a time."
219019529|NCT07033845|DEVICE|Phenylephrine|Topical Phenylephrine
219198205|NCT04877444|BEHAVIORAL|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
219462493|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
219462494|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
219462495|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
219462496|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
219462497|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
219462498|NCT02884440|DRUG|TAP block ropivacaine|
219462499|NCT02884440|DRUG|TAP block placebo|
219462500|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
219462501|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
219592853|NCT06981897|BEHAVIORAL|selected physical therapy program (Chest care exercise, passive movement of the four limbs) in addition to early cognitive therapy program|"The patient was placed in a comfortable position with a head-up position Passive range of movement for all four limbs \& positioning for head injury patients,. Joint approximation and Chest clearance intervention and Procedure for cognitive therapy~Multimodal Sensory stimulation, including :~Visual Auditory- Olfactory-. Gustatory- Tactile- Calling out their names, using patients relative help for transferring were used for improving the cognition and conscious levels."
219198206|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
219198207|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
219592854|NCT06981897|BEHAVIORAL|Control group|The patient was placed in a comfortable position with a head-up position , Passive range of movement for all four limbs and positioning for head injury patients,. Joint approximation and Chest clearance intervention
219592855|NCT00866190|DRUG|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
219592856|NCT00866190|DRUG|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
219592857|NCT01163630|DRUG|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
219592858|NCT00491140|GENETIC|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
219592859|NCT04249544|DRUG|Pramipexole|1mg of pramipexole
219592860|NCT04249544|DRUG|Placebo|1mg equivalent of placebo
219592861|NCT06284447|OTHER|Non-Interventional Study|Non interventional study
219592862|NCT03734315|DEVICE|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
219592863|NCT06662227|BIOLOGICAL|Single dose injection of certain dose of UWD-19|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells
219592864|NCT02898753|DRUG|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
219592865|NCT02898753|DRUG|RhGAA|Active comparator
219592866|NCT00642278|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
219592867|NCT00642278|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
219592868|NCT00642278|DRUG|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
219592869|NCT02635113|DEVICE|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
219592870|NCT00006043|DRUG|temozolomide|
219592871|NCT00090363|DRUG|ZD4054 15 mg|15 mg oral tablet once daily
219592872|NCT00090363|DRUG|Placebo|
219592873|NCT00090363|DRUG|ZD4054 10 mg|10mg oral tablet once daily
219592874|NCT01802450|DRUG|Dasatinib|
219592875|NCT06190418|OTHER|Loaded sit to stand strengthening exercise|This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
218851856|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
218851857|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
219198208|NCT06614270|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for conditioning. Multiple doses of anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
219462502|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
219462503|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
219462504|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
219462505|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
219462506|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
219462507|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
219462508|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
219462509|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
219462510|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
219462511|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
219462512|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
219462513|NCT02161614|DRUG|Estradiol valerate|
219462514|NCT02161614|DRUG|Placebo|
219462515|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
219462516|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
219462517|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
219462518|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
219462519|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
219462520|NCT01881906|OTHER|Usual care|
219462521|NCT01881906|OTHER|Exercise|
219462522|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
219462523|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
219462524|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
219592876|NCT06190418|OTHER|Unloaded sit to stand strengthening exercise|This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
219592877|NCT03713619|DRUG|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
219592878|NCT03713619|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
219592879|NCT03484143|DEVICE|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
219592880|NCT03484143|DEVICE|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
219592881|NCT00700297|DRUG|Colchicine|100 mg Colchicine per day for 4 months
219592882|NCT00700297|DRUG|Placebo|One tablet placebo per day for 4 months
219592883|NCT05068154|DIAGNOSTIC_TEST|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
219592884|NCT03095638|DRUG|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
219462525|NCT05751915|DEVICE|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
219462526|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
219462527|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
219462528|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
219462529|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
219462530|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
219462531|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
218851858|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
219198209|NCT06854029|DRUG|Cabotegravir Injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
219462532|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
219462533|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
218851859|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
219462534|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
219462535|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
219462536|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
219462537|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
219462538|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
219462539|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
219462540|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
218851860|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
218851861|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
218851862|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
218851863|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
218851864|NCT02031224|BEHAVIORAL|Conventional low protein diet|
218851865|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
219019530|NCT04616547|OTHER|Questionnaire Administration|Ancillary studies
219019531|NCT04616547|RADIATION|Tin Sn 117m Pentetate|Given IV
219462541|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
219462542|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
219462543|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
219462544|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
219462545|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
219462546|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
219462547|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
219462548|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
219462549|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
219592885|NCT03095638|DRUG|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
219592886|NCT03095638|DRUG|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
219592887|NCT03095638|DRUG|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
219592888|NCT00557089|DRUG|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
219019550|NCT06803147|OTHER|Discontinued endoscopic surveillance|Endoscopic surveillance is discontinued for eligible patients in line with the new guideline revision, and patients are then followed in this prospective cohort
219019552|NCT07050173|DRUG|Gamma-glutamylcysteine (GGC)|400mg tablet orally (two times) per day.
219198210|NCT06854029|DRUG|Cabotegravir Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
219198211|NCT06854029|DRUG|Buprenorphine injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
219198212|NCT06854029|DRUG|Buprenorphine Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
218851866|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
218851867|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
218851868|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
218851869|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
218851870|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
219462550|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
219462551|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
219462552|NCT02020564|BEHAVIORAL|Speed of Processing Training|
219462553|NCT02020564|BEHAVIORAL|Placebo Control|
219462554|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
219462555|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
219462556|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
219592889|NCT00557089|OTHER|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
218851871|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
219198213|NCT06810804|DRUG|NBQ72S|Patients will receive the study drug every 28 days
219198214|NCT06655818|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
219198215|NCT06655818|DRUG|Dostarlimab|Dostarlimab will be administered.
219198216|NCT06811519|DIAGNOSTIC_TEST|Body Composition Analyzer (ACCUNIQ BC720)|Body Composition Analyzer (ACCUNIQ BC720)
219198217|NCT06811077|OTHER|individual coaching|in addition to group therapeutic education, the patient participates to individual coaching session and answers several Patient Reported Outcome to assess his wellbeing
219198218|NCT06813287|DIAGNOSTIC_TEST|Electroencephalography (EEG)|Recording of electrical activity in the brain
219198219|NCT06813287|DEVICE|Upper extremity robot|Used for training and objective assessment (kinematics)
219462557|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
219462558|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
219462559|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
219462560|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
219462561|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
219462562|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
219462563|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
219462564|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
219462565|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
219592890|NCT05912270|BEHAVIORAL|Orchestra in Class|See arm/group descriptions
219592891|NCT05358080|DRUG|Entelon Tab. 50mg|twice daily for 24months
219592892|NCT05358080|DRUG|Placebo|twice daily for 24months
219462566|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
219462567|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
218851872|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
219462568|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
219462569|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
219462570|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
219462571|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
219462572|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
219462573|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
219462574|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
219462575|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
219462576|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
219462577|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
219462578|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
219462579|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
219462580|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
219462581|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
218851873|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
219462582|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
219462583|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
219462584|NCT02261402|OTHER|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
219592893|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
219592894|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
218851874|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
218851875|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
218851876|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
218851877|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
218851878|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
218851879|NCT03297073|PROCEDURE|hepatic surgery|
218851880|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
218851881|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
219462585|NCT05870397|DIAGNOSTIC_TEST|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
219462586|NCT00939094|DRUG|AZD2066|Capsule, once daily
219462587|NCT00939094|DRUG|Placebo|Capsule, once daily
219462588|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219462589|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219462590|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
219462591|NCT04146129|DRUG|CDX-0159|Single dose of one of four dosages of CDX-0159
219462592|NCT04146129|DRUG|Normal saline|Single infusion of normal saline
219462593|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219462594|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219462595|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219462596|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219462597|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219462598|NCT00518739|DRUG|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
219462599|NCT02303730|DRUG|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
219462600|NCT02303730|DRUG|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%."
218851882|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
219462601|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
219462602|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
219462603|NCT00004654|DRUG|soy protein isolate|
219462604|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
219462605|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
218851883|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
218851884|NCT00646321|DRUG|budesonide|
219462606|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
219462607|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
219462608|NCT00536354|OTHER|Postural Orientation|
219462609|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
219462610|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
218851885|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
219198220|NCT06811961|BEHAVIORAL|Exercise|Patients with lipedema will perform group exercises consisting of warm-up, loading and cool-down periods of 40-50 minutes, 2 days a week for 6 weeks, and strengthening exercises applied to the muscles around the hips and knee extensors with elastic resistance bands, determined according to the effort level perceived by the patient, 3 sets of 10 repetitions, 2 days a week for 6 weeks.
219198221|NCT06811961|BEHAVIORAL|Physical activity|The control group will be given recommendations regarding lipedema and physical activity level.
219198222|NCT06826053|OTHER|Therapeutic position|each newborn was given four different therapeutic positions in sequence.
219198223|NCT06826053|OTHER|Therapeutic position + smell breast milk|each newborn will be given four different therapeutic positions in sequence and will be made to smell the scent of breast milk.
219198224|NCT05327647|DRUG|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
219198225|NCT05327647|BIOLOGICAL|Control Arm|Induction BCG
219198226|NCT05839509|DRUG|GH001|GH001 administered via inhalation
219198227|NCT06006585|DRUG|BI 771716|BI 771716
219198228|NCT02800512|PROCEDURE|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
219198229|NCT02800512|PROCEDURE|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
219198230|NCT04105114|DRUG|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
219198231|NCT04105114|DEVICE|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
219198232|NCT04105114|DEVICE|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
219198233|NCT04105114|DEVICE|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
219198234|NCT04105114|DEVICE|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
219198235|NCT04105114|DEVICE|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
219198236|NCT05003245|DRUG|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
219198237|NCT05003245|DRUG|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
219198238|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
219198239|NCT06167655|DEVICE|Neurostimulator|Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.
219592895|NCT01144715|DEVICE|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
218851886|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
218851887|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
218851888|NCT00657839|DRUG|Placebo|Matching placebo
219198240|NCT06455085|BEHAVIORAL|Augmented-Fracture Liaison Service Arm|Patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health clinician.
219198241|NCT06455085|BEHAVIORAL|Enhanced Usual Care Arm|Patients will be mailed education materials and encouraged to follow up with their primary care physician.
219198242|NCT06094621|OTHER|Survey|For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
219198243|NCT05586308|BEHAVIORAL|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
219198244|NCT05586308|BEHAVIORAL|Financial incentive|"1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
219198245|NCT05586308|BEHAVIORAL|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
219198246|NCT06815276|OTHER|Exercise|core muscle training
219198247|NCT06813573|BIOLOGICAL|blood sampling|A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
219462611|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
219462612|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
219462613|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
219462614|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
219462615|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
219462616|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
219462617|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
219462618|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
219462619|NCT02101216|DRUG|Prurisol|Experimental Drug
219462620|NCT02101216|DRUG|Ziagen|Active comparator
219462621|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
219462622|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
219462623|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
219462624|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
219592896|NCT01144715|DEVICE|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
219592897|NCT06982079|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg will be added in addition to standard of care
219592898|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
219592899|NCT06983704|PROCEDURE|AGV plate|AGV plate using a 27-gauge needle
219592900|NCT06983704|PROCEDURE|bevacizumab injection|subconjunctival injection of bevacizumab
219592901|NCT06982690|PROCEDURE|Spinal Anesthesia|A total of 10-12 mg of 0.5% bupivacaine will be administered into the cerebrospinal fluid of the subarachnoid space using a 25-gauge Quincke spinal needle via an 18-gauge introducer (adjusted by body height). Midazolam (2-5 mg) may be used to decrease anxiety.
219592902|NCT06982690|PROCEDURE|General Anesthesia|Induction will be performed with propofol (0.5-1.5 mg/kg) and fentanyl (1-2 µg/kg), and anesthesia will be maintained with sevoflurane (1-3 vol %) via a laryngeal mask or endotracheal intubation. Rocuronium (0.5-0.6 mg/kg) will be used for induction, maintenance and occurrence of obturator jerk.
219592903|NCT06983002|BEHAVIORAL|Experimental group: AC-group therapy intervention.|"The aim is to increase Affect consciousness and Affect integration with 15 two hour group session interventions. Interview for 4 central affect categories to become familiar with the questions/techniques is used pre and post group. Group meeting 1 presents the AC affect theory, 13 affect categories and the group program related to each individual group meeting. Group meetings 2-14 lectures on the current affect category, bodily attentional signals and inner mood/mental content, exploration of impact, handling and the signal function of emotions and non-verbal body language and verbal descriptions related to the desire and ability to express oneself. Group meeting 15 is evaluation, clarification, repetition and closure of the group. On arrival focus on disturbances (internal and external) for each participant and performance of four body awareness exercises is used. Therapeutic writings and listening to a piece of music shared by the participants in rotation are methods i"
219592904|NCT06983002|BEHAVIORAL|Control group 1: Body Awareness Group.|The aim is to connect with and become more confident about the body experiences, needs and feelings, to gain an increased understanding of oneself. The Group consists of 15 group sessions. Group meeting 1 Introduces Body Awareness Therapy, group structure and content and focus on experiences and expectations. The practice of slow, simple movements for the whole body in a standing position, introduction of The Autonomous Compass model, giving an opportunity to figure out where to place themselves in the compass in the moment, exercise stimulating the feet and a relaxation exercise. Group meetings 2-14 focuses on a topic as grounding, balance, breathe, play, posture due to habitual positions, body language and emotions, self-compassion and boundaries, explored through experience by using various physical exercises, sharing body experiences and psychoeducation. Session 15 contains summary, evaluation and repetition.Reflection on the previous session and sharing homework is included.
218851889|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
218851890|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
218851891|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
219462625|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
219462626|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
219462627|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
219462628|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
219462629|NCT00136994|DRUG|Ziprasidone|
219462630|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
219462631|NCT00133276|OTHER|Placebo|
219592905|NCT06983002|BEHAVIORAL|Control group 2: Art Psychotherapy group.|"The aim is to keep an open non-directive psychodynamic and analytical approach to explore, discover and feel ownership of creativity as a form of expression. The group consists of 15 group sessions, where session 1-4 is setting the framework by presenting art mediums to be used collectively, creating security, a sense of community and solidarity sharing common challenges. Each individual is free to choose the motive and form of expression, with a high level of sharing and learning. Creative experiences made together on the use of art materials to convey the inner world, become the starting point for further creative exploration on a individual level with their inner selves in a self-developing therapeutic process. Session 1: Introduction to projection and how to read oneself into an object by using figures and sandplay. Sessions 2 - 4: How one can transfer, animate, or create personal expressions using collage, acrylic painting and clay.Groups 5-15 allows freedom to choo"
219592906|NCT06595264|PROCEDURE|embolization therapy|Embolization in the neuroradiological department is the Golden Standard for the treatment of vein of Galen malformations.
219592907|NCT06281171|OTHER|SkillTalk for Autistic Young Adults|A Microskills video training library on communication skills for autistic young adults.
219592908|NCT06281171|OTHER|Flyer Library|A collection of existing online resources on relationship skills
218851892|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
219462632|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
218851893|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
218851894|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
218851895|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
219198248|NCT06813001|OTHER|ACT-based nursing intervention|ACT-based nursing intervention is a 1:1 single online session with a nurse, which takes about 60 minutes followed by a daily self-monitoring survey for one week, which encourages patients to practice ACT.
219198249|NCT06813989|OTHER|carotid ultrasound|The investigator will perform a carotid ultrasound just 2 cm before the carotid bulb and measure the corrected flow time and flow using Doppler and pulse wave analysis. The corrected carotid flow time will be calculated according to Bazett's equation.
219462633|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
219462634|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
219462635|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
219462636|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
219462637|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
219592909|NCT06982092|DRUG|sugammadex|: patients will receive the reversal drug according to the group to which they had been randomised. in the Sugammadex Group will receive 2 mg/kg sugammadex.
219592910|NCT06982092|DRUG|Neostigmine|Patients in the NEO Group will receive 50 mic/kg neostigmine and .01-.02 mg/kg atropine
219462638|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
219462639|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
219462640|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
218851896|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
218851897|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
218851898|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
218851899|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
218851900|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
218851901|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
218851902|NCT02417116|OTHER|Saline|Application as required to improve comfort
219462641|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
219462642|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
219462643|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
219462644|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
219462645|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
219462646|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
219462647|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
219462648|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
219462649|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
219462650|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
219462651|NCT00337935|OTHER|Standard of care|
219462652|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
219592911|NCT06102291|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
218851903|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
218851904|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
218851905|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
218851906|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
219462653|NCT02974764|OTHER|No intervention/exposures|
219462654|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
219592912|NCT06102291|OTHER|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
218851907|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
219462655|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
219462656|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
219462657|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
219462658|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
219462659|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
219462660|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|\- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
219462661|NCT02873806|DRUG|Topical travoprost|\- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
219462662|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|\- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
219462663|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
219462664|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
219462665|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
219462666|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
219592913|NCT06988722|DEVICE|650 nm Diode Laser PBM|A 650 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
218851908|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
218851909|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
218851910|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
218851911|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
219198250|NCT06815016|OTHER|Reflexology ,mulligan mobilization and conventional|Reflexology is a systematic practice in which applying some pressure to any particular points on the feet and hands give impacts on the health of related parts of the body as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) Mulligan's Mobilization with Movement (MWM) apply accessory gliding force combined with active movement as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise)
219462667|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
218851914|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
218851915|NCT01510015|DRUG|Risperidone|variable dose
218851916|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
219462668|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
219462669|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
219462670|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
219462671|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
219462672|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
218851917|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
219462673|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
219462674|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
219462675|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
219462676|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
219462677|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
219462678|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
219462679|NCT04054531|BIOLOGICAL|KN046|IV infusion
219462680|NCT04054531|DRUG|Paclitaxel|IV infusion
219592914|NCT06988722|DEVICE|810 nm Diode Laser PBM|A 810 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
219592915|NCT06988722|DEVICE|Sham Laser PBM|Identical laser handpiece applied at the same locations and durations as the active PBM groups, but without laser emission. Used to maintain blinding and simulate treatment without therapeutic effect.
218851918|NCT01839019|DRUG|ODM-102|Single dose escalation
218851919|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
219198251|NCT06815016|OTHER|reflexology and conventional|Reflexology as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
219462681|NCT04054531|DRUG|Pemetrexed|IV infusion
219462682|NCT04054531|DRUG|Carboplatin|IV infusion
219462683|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
219462684|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
219462685|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
219462686|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
219462687|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
219462688|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
219462689|NCT05656729|DIETARY_SUPPLEMENT|DefensePlus|Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
219462690|NCT05656729|DIETARY_SUPPLEMENT|Placebo|Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
219462691|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
219592916|NCT06991023|DIETARY_SUPPLEMENT|Prebiotic (Bimuno®)|The prebiotic supplement (Bimuno®) is a galactooligosaccharide (GOS) supplement derived from lactose which is publicly available and sold in the UK. Subjects will consume a daily dose of 2.75g GOS (3.65g total powder) which will be administered in sachets and consumed with breakfast by mixing into water, tea or coffee, or sprinkling on top of/mixing into food.
218851920|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
218851921|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
219462692|NCT00511966|DRUG|Rabeprazole|As prescribed
218851922|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
218851923|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
218851924|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
219198252|NCT06815016|OTHER|mulligan mobilization and conventional|Mulligan mobilization as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
219462693|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
219462694|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
219462695|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
219462696|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
219592917|NCT06991023|DIETARY_SUPPLEMENT|Placebo|A matched placebo for the prebiotic intervention, containing 3.65g of maltodextrin. Consumed in the same manner as the prebiotics.
219592918|NCT06989268|DRUG|Linaclotide 290 micrograms|290 μg linaclotide once daily oral administration with 125mL of water
219592919|NCT06989268|DRUG|Placebo|Placebo, empty capsule, once daily oral administration with 125mL of water
219592920|NCT06989281|BEHAVIORAL|FLOW Lifestyle Medicine Clinic|The FLOW Lifestyle Medicine Clinic is a 12-month multidisciplinary program for improving obesity and obesity-related chronic conditions. FLOW is an evidence-based program that aligns with USPSTF recommendations for intensive behavioral counseling for obesity and cardiovascular disease risk reduction. There are at least 12 clinician/patient encounters in the FLOW clinic over 12 months including 6 with a registered dietitian and 6 with a FLOW physician. Behavioral Health assessments and visits are also offered as part of FLOW but are optional.
219592921|NCT06990451|OTHER|time pressure|a set of alternative cognitive strategies that allow patients in real-life tasks to compensate for their mental slowness
219592922|NCT06990451|OTHER|step square exercise|is a form of highly specific balance training for falls prevention which directly addresses stepping capacity-a commonly executed protective strategy for maintaining balance in the everyday environment
219592923|NCT06990451|OTHER|functional care training|Intensive functional endurance, strength, and balance exercises, and selected physical therapy interventions for balance
219592924|NCT06990412|DEVICE|NEO|a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO
219198253|NCT06815016|OTHER|Conventional treatment|Conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
219592925|NCT06989450|DEVICE|Sidekick digital patient support program for patients with breast cancer|A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
219592926|NCT06989450|OTHER|Standard of care for breast cancer patients|Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
219592927|NCT06989138|OTHER|Stabilitation Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
219592928|NCT06989138|OTHER|Conventional Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
219592929|NCT06989138|OTHER|Orthosis|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours.
219592930|NCT06989775|DEVICE|Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System|Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery
219592931|NCT06989502|BEHAVIORAL|Co-creation (2016 to 2019) + Co-design (2023 to 2024)|"It includes interventions implemented in a sequential way: a) The co-creation intervention (between 2016 and 2019), and b) the co-design intervention (between 2023 and 2024).~In this group of sequential interventions, relevant stakeholders have already been engaged in the project and they would be familiar with the intervention components. Their participation this time will enable updating and refining the previous co-creation intervention through the co-design process.~The intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
219198254|NCT06815406|PROCEDURE|Endoscopic Mucosal Resection (EMR)|atients assigned to this arm will undergo Endoscopic Mucosal Resection (EMR), a standard endoscopic technique that involves the resection of colorectal Laterally Spreading Tumors - Granular type (LST-G) using a diathermic snare with submucosal injection. The procedure may be performed en bloc or in a piecemeal fashion, depending on lesion size and characteristics. EMR is widely accepted for lesions with low submucosal invasion risk but has a higher recurrence rate than ESD.
219462697|NCT00182572|DRUG|buprenorphine|
219462698|NCT00182572|DRUG|naltrexone|
219462699|NCT00182572|PROCEDURE|behavior therapy|
219462700|NCT00182572|PROCEDURE|voucher-based contingency management|
219462701|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
219462702|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
219462703|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
219462704|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
219462705|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
219462706|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
219462707|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
219592932|NCT06989502|BEHAVIORAL|Co-design only (2023 to 2024)|"The same intervention activities of the first group (between 2023 and 2024), but without having them involved in the previous co-creation process. In consequence, relevant stakeholders in the corresponding sites are not expected to be as engaged in the project (in contrast to the intervention that includes co-creation), and they would not be very familiar with the intervention components of COHESION-I.~As in the first group, the intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
219592933|NCT06989684|PROCEDURE|Osseodensification|Osseodensification uses specially designed burs to densify osteotomy site
219592934|NCT06989684|PROCEDURE|Underdrilling|In underdrilling the osteotomy is smaller than implant diameter to be placed
219462708|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
219592935|NCT01878487|DEVICE|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
219592936|NCT02552212|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
219592937|NCT02552212|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
219592938|NCT04129671|GENETIC|No intervention was applied|No intervention was administered
219592939|NCT03565679|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
219592940|NCT03565679|DEVICE|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
219592941|NCT00654290|DRUG|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
219592942|NCT00654290|DRUG|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
219592943|NCT00654290|DRUG|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
219592944|NCT03429400|DRUG|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
219019555|NCT07049029|BEHAVIORAL|PREP-Y|The intervention is a series of behavioral health/psychoeducational modules that the participant will learn from. Participants will use the information discussed and overall impact on physical activity engagement, chronic pain management, and quality of life will be measured
219592945|NCT03263897|DEVICE|insufflation|mobile interface driven insufflation of the ear canal
219592946|NCT03263897|DEVICE|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
219592947|NCT03020589|DRUG|Tacrolimus|See description in arm/group sections
219592948|NCT00771459|DRUG|Ropivacaine 0.5 %|Local infiltration analgesia
219592949|NCT00771459|DRUG|Isotonic NaCl|Local infiltration analgesia
219592950|NCT02489253|OTHER|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
219019562|NCT07046234|DEVICE|Lung ultrasound|Lung ultrasound software.
219019563|NCT06736431|BEHAVIORAL|Text-based resource referral platform with diabetes educational materials|Text-based resource referral platform with diabetes educational materials
219592951|NCT06330272|PROCEDURE|Application of dental mousse based on CPP-ACPF|"Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks."
219592952|NCT06989385|OTHER|This is an observational study. Interventions are standard of care and include: High-flow nasal oxygen (HFNO) Non-invasive ventilation (NIV) Pnose monitoring|No experimental interventions are administered as part of the study.
218851925|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
219198255|NCT06815406|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Patients assigned to this arm will undergo Endoscopic Submucosal Dissection (ESD), an advanced endoscopic technique that allows for en bloc resection of large colorectal Laterally Spreading Tumors - Granular type (LST-G). The procedure involves the use of specialized knives to dissect the submucosal layer, ensuring complete resection with histologically clear margins (R0 resection). ESD has been associated with lower recurrence rates but requires a high level of expertise, longer procedural times, and carries a higher risk of complications.
219198256|NCT06814834|DRUG|Oral dissolution therapy|Patients received guidance for oral potassium-sodium-hydrogen-citrate (6:6:3:5) at a dosage of twenty milliequivalents three times every day, along with a daily fluid intake of two to three liters and a food plan to restrict protein and sodium consumption for a maximum of three months.
219462709|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
219462710|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
219462711|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
219462712|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
219462713|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
219462714|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
219462715|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
218851926|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
218851927|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
218851928|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
218851929|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
218851930|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
218851931|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
219198257|NCT06814834|PROCEDURE|Extracorporeal shock wave lithotripsy|Patients received extracorporeal shock wave lithotripsy utilizing a Dornier lithotripter equipped with an integrated ultrasound for stone localization. If the patient required additional sessions, up to a maximum of four sessions, at a rate of 60-90 shocks per minute, the period between sessions was three weeks.
219198258|NCT06814834|PROCEDURE|Oral dissolution therapy + extracorporeal shock wave lithotripsy|Patients received a combination of oral dissolution therapy and extracorporeal shock wave lithotripsy.
219198259|NCT06813534|DEVICE|Intravascular Ultrasound guided PCI|Intra-coronary ultrasound
219198260|NCT06813937|DEVICE|Procedure: Peripheral Magnetic Stimulation (PMS)|PMS is a non-invasive neuromodulation technique used to treat chronic pain. Procedure starts with sensory mapping, localisation of the hotspot and detection of sensory threshold. Then two protocols of PMS are implemented: 5 blocks of PMS of varying frequency and 1 block of rPMS.
219462716|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
218851932|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
218851933|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
218851934|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
218851935|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
218851936|NCT01846195|DEVICE|CM 1500|
218851937|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
218851938|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
218851939|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
219592953|NCT02302053|DIETARY_SUPPLEMENT|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
218851940|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
218851941|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
219592954|NCT02302053|DIETARY_SUPPLEMENT|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
219592955|NCT02330315|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
218851942|NCT01247363|DRUG|LY2608204|Administered orally.
218851943|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
218851944|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
218851945|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
218851946|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
218851947|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
218851948|NCT02071186|OTHER|Standard of care|
219019566|NCT07047651|COMBINATION_PRODUCT|Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), 20 people|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) with RECOVERYTRSGR (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions.
219019567|NCT07047651|COMBINATION_PRODUCT|Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants, 15 people|The combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) and TAU (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions. The control group of Group A
219462717|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
218851949|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
218851950|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
218851951|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
218851952|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
218851953|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
218851954|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
218851955|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
218851956|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
218851957|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
218851958|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
218851959|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
218851960|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
219462718|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
219462719|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
219462720|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
219198261|NCT06813937|OTHER|Electroencephalography (EEG)|EEG is a technique commonly used for the registration of brain activity. The procedure is non-invasive, electrodes are placed on the scalp of the participants. The recording is made simultaneously with the PMS.
219462721|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
219592956|NCT02330315|DEVICE|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
218851961|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
218851962|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
218851963|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
219592957|NCT00635232|DRUG|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
218851964|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
218851965|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
218851966|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
218851967|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
219462722|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
219592958|NCT00635232|DRUG|placebo|placebo capsules once daily for 12 weeks
219592959|NCT00635232|DRUG|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
219462723|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
219462724|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
219462725|NCT05620849|BEHAVIORAL|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
219462726|NCT02314299|DRUG|MTP-131|
219462727|NCT02103400|OTHER|Experimental group|Exercise Training Group
219462728|NCT02103400|OTHER|Control group|Exercise control group
219462729|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
219198262|NCT06841302|OTHER|Fibromyalgia Agents|All study participants were enrolled in a combined treatment program consisting of both a structured aerobic exercise program (swimming, cycling, or brisk walking for at least three days a week, with each session lasting two hours) and a pharmacological treatment regimen. Patients who did not adhere to the prescribed treatment regimen or who discontinued follow-up were excluded from the study.
219462730|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
219462731|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
219462732|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
219592960|NCT00635232|DRUG|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
219592961|NCT00635232|DRUG|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
219592962|NCT02093130|DIETARY_SUPPLEMENT|Pomegranate Juice|
218851968|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
218851969|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
218851970|NCT01477463|DRUG|placebo and vitamin D|
218851971|NCT00003044|DRUG|cisplatin-e therapeutic implant|
218851972|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
218851973|NCT04881500|OTHER|Routine Care|Patients will follow routine care
219019568|NCT07047651|COMBINATION_PRODUCT|Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine|A combination of pharmacotherapy with RECOVERYTRSBDGR (antipsychotics, anxiolytics, antidepressants, mood stabilizers) for patients with treatment-resistant bipolar disorder. 140 sessions, 15 people
219592963|NCT02093130|DIETARY_SUPPLEMENT|Placebo|
219592964|NCT00946686|DRUG|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
219592965|NCT00946686|DRUG|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
218851974|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
218851975|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
218851976|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
219019569|NCT07047651|COMBINATION_PRODUCT|Group D (Pharmacotherapy and TAU)Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, seropram, lithium, depakine)|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants, mood stabilizers) and TAU (psychotherapy). A control group to RECOVERYTRSBDGR. 140 sessions. 10 people
219198263|NCT06813222|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg
219462733|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
219462734|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
219462735|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
219462736|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
219462737|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
219462738|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
219462739|NCT04830813|DRUG|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
219462740|NCT04830813|DRUG|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
219462741|NCT04027127|OTHER|netrin-1 value on admission to hospital|
219462742|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
219462743|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
219462744|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
219592966|NCT01064154|DRUG|Carvedilol|Carvedilol Tablets 25 mg
219592967|NCT00205803|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
219592968|NCT00205803|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
219592969|NCT06613347|OTHER|whitening maintenance|whitening maintenance regimen
219592970|NCT06613347|OTHER|whitening maintenance MW|maintenance MW
219592971|NCT06613347|OTHER|negative control|negative control
219592972|NCT06428526|DEVICE|Continuous stimulation strategy|Participants will be administered stimulation with a constant frequency stimulation.
219462745|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
219462746|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
219462747|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
219462748|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
219462749|NCT00240331|DRUG|10mg Rosuvastatin|
219462750|NCT00240331|DRUG|Placebo|
219462751|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
219462752|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
219462753|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
219462754|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
219592973|NCT06428526|DEVICE|Closed-loop stimulation strategy|Participants will be administered with an activity-dependent stimulation.
219592974|NCT06989749|OTHER|Anodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the anodal condition, real tDCS stimulation enters from the C3 electrode, and exits at the FP2 electrode.
218851977|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
219019572|NCT06740110|DEVICE|Tooth extraction and GBR procedure|The intervention will include tooth extraction and GBR procedure. After clinical and radiographic assessment, local anaesthesia is applied. The dentist performs atraumatic extraction, cleans the socket, places investigational device (first arm) or standard of care (second arm) and applies gauze for hemostasis. The patient is given post-operative care instructions. After recovery the first and second stage of implantation will be performed.
219462755|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
219019573|NCT06737341|DRUG|Bupivacaine Liposomes(BL)|20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.
219462756|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
219462757|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
219462758|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
219019574|NCT06737341|DRUG|Bupivacaine(B)|10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
219462759|NCT01933269|DRUG|FACBC|
219462760|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
219462761|NCT00107601|DRUG|Insulin|
219462762|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
219462763|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
219462764|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
219462765|NCT00303004|DRUG|Bosentan and Sildenafil|
219462766|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
219592975|NCT06989749|OTHER|Cathodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the cathodal condition, real tDCS stimulation enters from the FP2 electrode, and exits at the C3 electrode.
219462767|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
219462768|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
219462769|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
219462770|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
219462771|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
219462772|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
219462773|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
219462774|NCT03517150|DEVICE|mandibular advancement device|
219198264|NCT06813950|OTHER|Physical activity|The intervention group will participate in a 10-week structured physical activity program consisting of 120 minutes of supervised exercise per week, led by a team of physiotherapists and physical activity professionals. Meanwhile, the control group will not participate in any organized physical activity program but will continue with their usual activities.
219462775|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
219462776|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
219592976|NCT06989749|OTHER|Sham tDCS|This is the sham (or placebo) tDCS intervention. The tDCS device is applied for one minute, for a 30-second ramp-up and 30-second ramp-down of stimulation.
219592977|NCT06990204|DRUG|Azilsartan medoxomil 80 mg tablet|1 tablet of 80 mg of azilsartan medoxomil
219592978|NCT06990204|DRUG|Edarbi® 80 mg tablets|1 tablet of 80 mg of azilsartan medoxomil.
219592979|NCT05686473|BEHAVIORAL|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done"
219592980|NCT06988800|DEVICE|Paced breathing wellness breathing sessions|The paced breathing condition used timed auditory and visual cues to guide participants through breathing cycles at a rate of five breaths per minute (Murtezani, 2018), designed to stimulate the parasympathetic nervous system and promote relaxation. The audiovisual cues included spoken instructions, music, and breath-like sounds (as described in Marentakis, Borthakur, Batchelor et al., 2021). The tonal audio cues rose in pitch during inhalation and fell during exhalation, creating a clear auditory signal for breath pacing. The same harmonic drone used in the mindfulness intervention provided a calming background, though here it was combined with the rhythmic pacing. Visually, the pacing was synchronized with the image of a lotus flower opening during inhalation and closing during exhalation, reinforcing the breathing rhythm.
218851978|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
218851979|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
218851980|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
218851981|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
218851982|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
218851983|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
218851984|NCT00354107|DRUG|ifosfamide|Given IV
218851985|NCT00354107|DRUG|carboplatin|Given IV
218851986|NCT00354107|DRUG|etoposide|Given IV
218851987|NCT00354107|DRUG|methotrexate|Given IT
218851988|NCT00354107|DRUG|cytarabine|Given IT
218851989|NCT00354107|OTHER|pharmacological study|Correlative studies
218851990|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
219462777|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
219462778|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
219198265|NCT06815510|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be followed up to find out any of these complications: pulmonary, hemodynamic complications, temperature disturbances, or pain
219462779|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
218851991|NCT04699292|PROCEDURE|Surgery|Surgery
218851992|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
218851993|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
218851994|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
218851995|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
218851996|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
218851997|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
218851998|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
218851999|NCT02267304|DRUG|Morphine 0,05mg/kg|
218852000|NCT02267304|DRUG|Naloxone 10mg|
218852001|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
218852002|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
218852003|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
218852004|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
218852005|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
219198266|NCT06842186|DRUG|WVE-007|Stereopure siRNA oligonucleotide
219462780|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
218852006|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
218852007|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
218852008|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
218852009|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
218852010|NCT00307840|DRUG|paricalcitol|
218852011|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
218852012|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
219198267|NCT05007080|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
219198268|NCT03404791|DRUG|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
219198269|NCT05814432|DRUG|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
219462781|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
219198270|NCT05814432|DRUG|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
219462782|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
219462783|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
219462784|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
219462785|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
219462786|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
219462787|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
219462788|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
219462789|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
219198271|NCT06810388|OTHER|Health education intervention program based on a family-centered empowerment model|Three sessions of approximately 15-30 min each are conducted within 3 d of the child's admission to the hospital, from the fourth day to the day before discharge, and on the day before discharge. The researcher or charge nurse assesses the caregivers' mastery every week using uniform evaluation criteria and adjusts the topic or number of interventions within each phase based on mastery, with the final intervention content and timeline remaining unchanged.Health education includes: providing family caregivers of children with malignant tumors with knowledge of the disease, guidance on dietary care, instruction on how to recognize symptoms, guidance on medication, post-implantation precautions at the port of infusion, knowledge of blood markers, monitoring of the disease, and emergency treatment.
219198272|NCT06810388|OTHER|Implementation of routine care measures|"Routine nursing care and current health education content will be provided, including the following: introduction to the department's environment, rules, and regulations; admission counselling; examination guidance; distribution of health education brochures; ongoing education on daily care, medication management, and health practices during hospitalisation; guidance on daily care, medication management, and health education by the nurse in charge; proactive support and communication by medical staff, including resolving questions and sharing caregiver experience; and discharge instructions with follow-up schedules for chemotherapy.~Participants in the control group are offered an FCEM-based intervention regimen on their second admission (at the beginning of the second course of treatment), which is appropriately adapted to the control group's second chemotherapy treatment."
219198273|NCT06302933|BIOLOGICAL|Blood sampling|Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
219462790|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
219462791|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
218852013|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
218852014|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
218852015|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
219462792|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
219462793|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
219462794|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
219462795|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
219462796|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
219462797|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
219462798|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
219462799|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
219462800|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
219462801|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
219462802|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
219462803|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
219462804|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
219462805|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
219462806|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
219462807|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
219462808|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
219462809|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
219462810|NCT04179864|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
219462811|NCT04179864|DRUG|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
219462812|NCT04179864|DRUG|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
219592981|NCT06988800|DEVICE|Mindfulness video sessions|The audio component of the mindfulness intervention featured a female narrator guiding participants through mindfulness exercises, focusing on breath awareness and cultivating non-judgmental attention to thoughts and feelings (Sibinga, 2016). Ambient tonal sounds, including a harmonic drone with slow timbral changes, played softly in the background to support relaxation. Importantly, no rhythmic audio cues were included to avoid inducing breathing entrainment. This setup emphasized passive, mindful observation rather than active breath control, encouraging participants to observe their bodily sensations and thoughts without judgment.
219462813|NCT06280079|DIETARY_SUPPLEMENT|Ultra-high-caloric fatty diet|100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g
219462814|NCT06280079|OTHER|Placebo|\<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g
219462815|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
219462816|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
219462817|NCT00231959|DRUG|Placebo|sugar pill
219462818|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
219462819|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
219462820|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
219462821|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
219462822|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
219462823|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
219019590|NCT07053423|DRUG|Dupilumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
219462824|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
219462825|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
219462826|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
219462827|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
219462828|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
219462829|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
219462830|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
219462831|NCT01069692|DRUG|SBR759A|9g daily
219462832|NCT01069692|DRUG|SBR759A|12g daily
219462833|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
219462834|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
219462835|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
219462836|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
219462837|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
219462838|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
219462839|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
219462840|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
219462841|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
219462842|NCT04563845|DRUG|Placebo|Placebo will be administered.
219462843|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
219462844|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
219019591|NCT07053423|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
219019594|NCT06785402|DRUG|Ceftriaxone treatment|9 infusions spaced out approximately every 5 days
219019595|NCT06785402|DRUG|Placebo|D5W (placebo)
219462845|NCT00207831|DRUG|Tegafur and Uracil|
219462846|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
219462847|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
219462848|NCT04731740|DRUG|Lenvatinib|PO
219462849|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
219462850|NCT04731740|DRUG|Chemotherapy|Investigators' choice
219462851|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
219462852|NCT00060320|OTHER|placebo|
218852016|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
219462853|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
219462854|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
219462855|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
219462856|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
219462857|NCT05083975|DEVICE|Buzzy System|Vibrating Device
219592982|NCT06534528|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
219462858|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
219462859|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
219462860|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
219462861|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
219462862|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
219462863|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
219462864|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
219592983|NCT06616064|BEHAVIORAL|personalised feedback and brief motivational|personalised feedback and brief motivational
219592984|NCT06616064|OTHER|routine lifestyle advice|routine lifestyle advice
218852017|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
218852018|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
218852019|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
218852020|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
218852021|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
218852022|NCT04774536|DRUG|CRISPR_SCD001|CRISPR\_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
218852023|NCT00033046|DRUG|Modafinil|
219198274|NCT06807502|DEVICE|The DM/DIV ScreenCell is the experimental product studied during this research|The product is not used directly on the subject, but on a blood sample taken from the participant.
219198275|NCT06002100|OTHER|fNIRS measurement|Kernel Flow2 measurements.
219198276|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
219198277|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
219462865|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
219592985|NCT06616064|OTHER|questionnaire CliniCAP|questionnaire CliniCAP
218852024|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
219462866|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
219462867|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
219462868|NCT02531074|BEHAVIORAL|Mobile Application|
219462869|NCT02531074|BEHAVIORAL|Food Journal|
219462870|NCT02531074|BEHAVIORAL|Usual Care|
219462871|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
219462872|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
219462873|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
219462874|NCT03824106|OTHER|Control|Participants randomized to the control arm will not receive any of the Frailty Management Interventions.
219462875|NCT03824106|BEHAVIORAL|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
219462876|NCT03824106|COMBINATION_PRODUCT|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist."
219462877|NCT03824106|DIETARY_SUPPLEMENT|Protein Supplement|Protein supplementation will be provided.
218852025|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
218852026|NCT03575065|DRUG|BGB-290|Administered orally
218852027|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
218852028|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
218852029|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
218852030|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
218852031|NCT00206050|DRUG|Esomeprazole|
218852032|NCT00206050|DRUG|pantoprazole|
218852033|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
218852034|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
218852035|NCT04697537|DRUG|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
218852036|NCT04697537|DRUG|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
218852037|NCT04071015|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
218852038|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
219198278|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
219462878|NCT03824106|DIETARY_SUPPLEMENT|Vitamin D|1000 IU of oral vitamin D
218852039|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
218852040|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
219198279|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
218852041|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
219462879|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
219462880|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
219462881|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
219462882|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
219462883|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
219462884|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
219462885|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
219462886|NCT02645682|DEVICE|anti-infection CVC|
218852042|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
218852043|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
219462887|NCT02645682|DEVICE|normal CVC|
219462888|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
219462889|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
219462890|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
219462891|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
219462892|NCT02927990|OTHER|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
219462893|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
219462894|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
219462895|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
219462896|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
219462897|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
219462898|NCT06412471|DRUG|SSGJ-707|bispecific antibody
219462899|NCT06412471|DRUG|carboplatin|chemotherapy
219462900|NCT06412471|DRUG|Pemetrexed|chemotherapy
219462901|NCT06412471|DRUG|paclitaxel|chemotherapy
219462902|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
219462903|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
219462904|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
219462905|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
219462906|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
218852044|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
218852045|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
218852046|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
218852047|NCT02312999|DRUG|Plasmalyte|
219462907|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
218852048|NCT02312999|DRUG|Volulyte|
218852049|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
218852050|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
218852051|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
218852052|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
219462908|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
219462909|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
219462910|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
218852053|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
218852054|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
218852055|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
219462911|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
219462912|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
219462913|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
219462914|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
219462915|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
219198280|NCT03652272|BEHAVIORAL|EMC2|"1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
219198281|NCT06698250|DRUG|Zanzalintinib|Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
219592986|NCT06617169|DRUG|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
218852056|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
218852057|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
218852058|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
218852059|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
218852060|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
218852061|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
218852062|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
218852063|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
218852064|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
219198282|NCT06698250|DRUG|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
219198283|NCT06698250|DRUG|Tremelimumab|Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
219198284|NCT06817954|PROCEDURE|endoscopic-assisted mastectomy and immediate breast reconstruction|endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
219198285|NCT06817954|PROCEDURE|mastectomy and immediate breast reconstruction|conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
218852065|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
218852066|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
218852067|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
219462916|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
219462917|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
219462918|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
219462919|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
219462920|NCT02540811|DEVICE|dCELL® ACL Scaffold|
219462921|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
219462922|NCT01494753|DRUG|T2345|One drop at 8.00pm.
219592987|NCT05656001|OTHER|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
219592988|NCT05656001|OTHER|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
218852068|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
219462923|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
218852069|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
218852070|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
218852071|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
218852072|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
218852073|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
218852074|NCT03960580|DRUG|OPN-375|OPN-375, BID
218852075|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
218852076|NCT02724917|DRUG|Placebo|Placebo to match
219592989|NCT02436967|OTHER|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
219592990|NCT05300828|DRUG|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
219592991|NCT06411379|DRUG|Sonelokimab|Sonelokimab
219592992|NCT06411379|DRUG|Placebo|Placebo
219592993|NCT06678854|OTHER|Training about Aphasia|Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
219592994|NCT05278650|OTHER|Senior PharmAssist^TM Program Implementation|"Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling"
219592995|NCT06870968|BEHAVIORAL|Exercise Training|The Exercise Training will follow a progressive interval-based training program designed for youth with MS. Participants will engage in three weekly exercise sessions. Participants will be given access to links to live virtual structured exercise sessions. The sessions will be scheduled weekly in partnership with a coach. A trained fitness instructor will lead the participants in a 10-minute warm-up, followed by 30 minutes of interval training, and a 10-minute stretching and cool down activity. Intervals will progress in intensity over the course of the 20-week program and progression will be based on individualized target heart rate zones. The session will be delivered via a live feed in order to foster social support from the participants peers enrolled in the program. Participants will have the option of completing the class in real-time and make up classes will also be available through a repository of sessions accessible through links to the repository cloud.
219592996|NCT06870968|BEHAVIORAL|Mobility and Flexibility Training|The Mobility and Flexibility Training will be focused on improving mobility and flexibility through three times a week stretching and mobility program. A 5-minute warm up will be followed by a series of stretches and mobility patterns that will be repeated as a circuit four times. Each session will focus on a specific muscle group - upper body, lower body or core. The classes will be led by a fitness instructor in the same manner as the exercise intervention arm with a virtual link sent to the participants.
219592997|NCT04469816|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
219592998|NCT04469816|OTHER|Services as Usual|Services/Treatment as usual.
219592999|NCT06595277|DIAGNOSTIC_TEST|Neuromuscular blockade|Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.
218852077|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
218852078|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
218852079|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
218852080|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
218852081|NCT01528891|OTHER|Placebo|
218852082|NCT01825486|BEHAVIORAL|accidental falls|
218852083|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
219019619|NCT06309966|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
219019620|NCT06309966|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
219019621|NCT06309966|DRUG|Placebo|Matching placebo taken once daily
218852084|NCT04452435|DRUG|C21|C21
218852085|NCT04452435|DRUG|Placebo|Placebo
219198286|NCT05985382|OTHER|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
219462924|NCT05696184|DIAGNOSTIC_TEST|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
219462925|NCT05696184|DIAGNOSTIC_TEST|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
218852086|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
218852087|NCT01234805|OTHER|questionnaire administration|Ancillary studies
218852088|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
218852089|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
218852090|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
218852091|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
219462926|NCT01551043|BIOLOGICAL|CART-19|
219593000|NCT06681935|PROCEDURE|Oral Cavity Reconstruction|This procedure includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
219593001|NCT06082674|DEVICE|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
219593002|NCT06082674|DEVICE|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
219593003|NCT05491876|OTHER|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
218852092|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
218852093|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
218852094|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
218852095|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
219198287|NCT05985382|OTHER|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
218852096|NCT02249299|DRUG|Placebo|
218852097|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
219462927|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
219462928|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
219462929|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
219462930|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
219462931|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
219198288|NCT06818448|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
219198289|NCT06818448|DEVICE|Rotator cuff repair with comparator device|Treatment of rotator cuff lesions with the conventional surgical technique (comparator device)
219198290|NCT06219369|PROCEDURE|Group T|"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."
219462932|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
219462933|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
219593004|NCT05491876|OTHER|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
219593005|NCT00290160|BEHAVIORAL|Protein supplementation|
219593006|NCT06680414|OTHER|Supportive Vaccine Communication Using Motivational Interviewing|Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
219593007|NCT02369458|DRUG|Mitomycin-C|
219593008|NCT02369458|DRUG|Pegfilgrastim|
219593009|NCT04572893|DRUG|danicamtiv|Myosin activator
219593010|NCT03784053|OTHER|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
219593011|NCT00121134|DRUG|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
219593012|NCT00121134|DRUG|Cyclophosphamide|Once a day for 6 months
218852098|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
218852099|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
219462934|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
219462935|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
218852100|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
218852101|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
218852102|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
218852103|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
218852104|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
218852105|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
218852106|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
218852107|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
219198291|NCT06817694|BEHAVIORAL|Cognitive-behavioral group therapy|The intervention consists of a 4-week cognitive-behavioral group therapy. Each session is given online and will last 90-minutes. The intervention has been adapted to the population of women with a cancer and a BRCA1/2 mutation from a behavioral-cognitive therapy for fear of cancer recurrence that already exists and has already been proven effective.
219198292|NCT06818292|BIOLOGICAL|Liraglutide|0.6 mg of the pre-filled solutions from pen-injector Liraglutide (GLP-1 Agonist)
219198293|NCT06818292|BIOLOGICAL|Placebo|0.1 mL NaCl
219198294|NCT06819462|DRUG|Inhaled Placebo|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups inhaled with vibrating mesh spray twice a day for 3 days. The NS group inhaled with normal saline .
219198295|NCT06819462|DRUG|inhaled corticosteroids and other asthma drugs|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups used vibrating mesh spray twice a day for 3 days. The Polymyxin E group inhaled polymyxin， 75 mg bid.
219462936|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
219462937|NCT01031368|DRUG|cytarabine|Given IV
219462938|NCT01031368|DRUG|clofarabine|Given IV
219462939|NCT01031368|DRUG|filgrastim|Given SC
219462940|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
219462941|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
219462942|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
219462943|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
218852108|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
218852109|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
218852110|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
218852111|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
218852112|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
218852113|NCT00189332|DRUG|852A|
218852114|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
218852115|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
219462944|NCT00004058|DRUG|tetradecanoylphorbol acetate|
219462945|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
219462946|NCT06580756|OTHER|Short training program|Training in the early identification of addictive disorders in primary care
219462947|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
218852116|NCT00096525|DRUG|lenalidomide|
218852117|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
218852118|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
218852119|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
218852120|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
219462948|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
219462949|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
219462950|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
219462951|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
218852121|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
218852122|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
218852123|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
218852124|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
218852125|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
219198296|NCT06818916|DRUG|Hetrombopag|Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
219198297|NCT06816719|DRUG|Treatment A: JW0106 1 tablet + C2101 1 tablet|"* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101~* Administration orally with 150 mL of water under fasting conditions"
219462952|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
219462953|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
219462954|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
219462955|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
219462956|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
219462957|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
219593013|NCT00121134|DRUG|Methotrexate|Twice daily for the first two days of every week for 6 months
218852126|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
219593014|NCT00121134|DRUG|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
218852127|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
219593015|NCT02909283|PROCEDURE|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
219593016|NCT04080544|DRUG|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
219593017|NCT04080544|PROCEDURE|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
218852128|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
218852129|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
218852130|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
218852131|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
218852132|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
219198298|NCT06816719|DRUG|Treatment B: JW0107 1 tablet|"* Administration alone of 1 tablet of JW0107~* Administration orally with 150 mL of water under fasting conditions"
219462958|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
219462959|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
219462960|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
219462961|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
219462962|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
219462963|NCT03146195|OTHER|Dynamic Magnetic resonance imaging|
219462964|NCT02478658|OTHER|exercise training|high-intensity resistance training
219462965|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
219462966|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
219462967|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
219462968|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
218852133|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
218852134|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
219198299|NCT06816316|PROCEDURE|external angular dermoid cysts surgical removal|"Skin incision was done below the eyebrow, subcutaneous and orbicularis dissection was done to remove the cysts. Upon accidental opening of the cyst then removal of the cyst walls and its contents from the surgical field as much as possible was done.~At this step, in group (A) only saline was used to wash the surgical field from any remnants. In group (B) the surgical field was cleaned with a gauze soaked with ethyl alcohol 70%. Then closure of the wound in both groups."
219462969|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
218852135|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
218852136|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
218852137|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
218852138|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
218852139|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
218852140|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
218852141|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
219462970|NCT00145379|DRUG|Tablet Metformin 500 mg|
219462971|NCT00145379|DRUG|Placebo|
219462972|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
219462973|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
219462974|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
219593018|NCT04410237|DEVICE|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
218852142|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
218852143|NCT02916641|DRUG|Fuzhenghuayu|
218852144|NCT02916641|DRUG|UDCA|
218852145|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
218852146|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
218852147|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
218852148|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
218852149|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
218852150|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
218852151|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
218852152|NCT02359045|DRUG|D1400147|Treatment A
218852153|NCT02359045|DRUG|D14000136|Treatment B
218852154|NCT02359045|DRUG|D14000137|Treatment C
218852155|NCT02359045|DRUG|Epanova®|Treatment D
219462975|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
219462976|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
219462977|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
218852156|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
219198300|NCT04576741|BEHAVIORAL|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
219198301|NCT04576741|BEHAVIORAL|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
219462978|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
219462979|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
219462980|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
219462981|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
219462982|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
219462983|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
219462984|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
219462985|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
219462986|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
219462987|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
219462988|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
219462989|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
219462990|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
219462991|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
219462992|NCT02179216|OTHER|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
219462993|NCT02179216|OTHER|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
219462994|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
219462995|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
219462996|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
219462997|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
219462998|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
219462999|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
219463000|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
219463001|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
218852157|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
218852158|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
218852159|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
219463002|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
219463003|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
219463004|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
219463005|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
219463006|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
219463007|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
219463008|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
219463009|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
219463010|NCT05593185|BIOLOGICAL|Galinpepimut-S|
219463011|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
219463012|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
219463013|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
219463014|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
219463015|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
219463016|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
219463017|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
219463018|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
218852160|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
218852161|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
218852162|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
219463019|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
219463020|NCT00237146|DRUG|Zoledronic acid|
219463021|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
219463022|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
219463023|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
219463024|NCT05707403|DRUG|BI 1015550|Treatment T
219463025|NCT05707403|DRUG|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
219463026|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
219463027|NCT03927703|DRUG|SB206 12%|Topically once daily
219463028|NCT03927703|DRUG|Placebo|Topically once daily
219463029|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
219463030|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
219593019|NCT04410237|OTHER|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
218852163|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
218852164|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
218852165|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
218852166|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
218852167|NCT04172415|OTHER|Retrospective cohort|Chart Review
219463031|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
219463032|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
219463033|NCT03854552|DRUG|BI 764198|capsule
218852168|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
218852169|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
218852170|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
218852171|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
219463034|NCT03854552|DRUG|Placebo|capsule
219463035|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
219463036|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
219463037|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
219463038|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
219463039|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
219463040|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
219463041|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
219463042|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
219463043|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
219463044|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
219463045|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
218852172|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
218852173|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
219463046|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
218852174|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|\- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
219199470|NCT06866015|OTHER|Activation-socialization intervention programme|"The proposed A-S IP (Author, 2021) includes 40 activities of three domains focusing mainly on the social-psychological level of education: the Laughter Therapy Concept (13), the Reminiscence Therapy Concept (13), and the Cognitive and Social Skills Stimulation Intervention Concept (14).~The implementation of the A-S IP activities was designed for a time period of four weeks during weekdays. In the Hriňovčan care facility for older adults, mainly in the common room, two activities were implemented daily during the morning and afternoon hours reserved for this purpose. Morning activities (active) were from 10:00 to 11:00 a.m., and afternoon activities (passive) were from 1:00 to 2:00 p.m. The application of the activities was strictly determined and organised according to a time-thematic schedule that applied rules. The participants participated in group activities, and their participation was voluntary."
219463047|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
219593020|NCT06694753|BIOLOGICAL|mRNA-1645-eODGT8|eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.
218852175|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
218852176|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
219463048|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
218852177|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
218852178|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
218852179|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
218852180|NCT01063491|PROCEDURE|bypass graft angiography|
218852181|NCT05655507|DRUG|Zuranolone|Administered as capsules
218852182|NCT02043912|DRUG|Haloperidol|
218852183|NCT00150111|DRUG|Methimazole|
218852184|NCT00150111|DRUG|Rituximab|
218852185|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
218852186|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
218852187|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
218852188|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
219463049|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
219463050|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
219463051|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
219593021|NCT06694753|BIOLOGICAL|mRNA-1645-CoreG28v2|core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
218852189|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
218852190|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
218852191|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
219463052|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
219463053|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
219463054|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
219463055|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
219463056|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
219463057|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
219463058|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
219593022|NCT06694753|BIOLOGICAL|mRNA-1645-N332GT5|"N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg."
219593023|NCT06694753|BIOLOGICAL|Placebo|Saline
219019675|NCT04727047|DEVICE|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
219019676|NCT03676218|OTHER|Elderly cancer patients|No intervention: Panel of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
219463059|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
219463060|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
219463061|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
219593024|NCT04967508|DRUG|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
219593025|NCT04967508|DRUG|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
219463062|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
219463063|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
219463064|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
219463065|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
219463066|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219463067|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219463068|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
219463069|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
219463070|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
219463071|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
219463072|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
219593026|NCT03011190|BEHAVIORAL|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
219593027|NCT03338842|DEVICE|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
219593028|NCT00002241|DRUG|Indinavir sulfate|
219463073|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
219463074|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
219463075|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
219463076|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
219463077|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
219463078|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
219463079|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
219463080|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
219463081|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
219463082|NCT02530580|DRUG|Placebo|A single oral dose
219463083|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
219463084|NCT00296569|DRUG|MK0686|
219463085|NCT06497816|OTHER|No intervention|No intervention
219463086|NCT01809717|OTHER|Weight Lifting Exercises|
219463087|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
219463088|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
219463089|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
219463090|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
219593029|NCT00002241|DRUG|Ritonavir|
219463091|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
219463092|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
219463093|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
219463094|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
219463095|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
219463096|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
219463097|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
219463098|NCT00088660|BIOLOGICAL|PANVAC™-VF|
219463099|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
219463100|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
219463101|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
219593030|NCT00002241|DRUG|Lamivudine|
219593031|NCT00002241|DRUG|Stavudine|
219463102|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
219463103|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
219463104|NCT02990273|BIOLOGICAL|Blood transfusion|
219463105|NCT02185443|RADIATION|SBRT|"* 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
219463106|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
219593032|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
219593033|NCT06876454|PROCEDURE|Gastrostomy Tube|Feeding gastrostomy tube insertion
219593034|NCT06876454|DEVICE|Self Expanding Metal esophageal Stent|Fully covered SEMS in the esophagus
219463107|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
219463108|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
219593035|NCT02954926|DRUG|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
219593036|NCT03273491|BEHAVIORAL|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
219593037|NCT03273491|BEHAVIORAL|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
219593038|NCT06695598|DRUG|CKD-383|QD, PO
219593039|NCT06464432|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
219593040|NCT02927977|OTHER|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
219593041|NCT02927977|OTHER|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
219593042|NCT00376194|DRUG|DMSA|
219463109|NCT02182856|DRUG|Ipratropium 500 µg|
219463110|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
219463111|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
218852192|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
218852193|NCT02239835|DRUG|Tipranavir (TPV) low dose|
218852194|NCT02239835|DRUG|Tipranavir (TPV) high dose|
218852195|NCT02239835|DRUG|Ritonavir low dose|
218852196|NCT02239835|DRUG|Ritonavir high dose|
218852197|NCT02239835|DRUG|Saquinavir|
218852198|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
218852199|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
219199471|NCT06871163|PROCEDURE|inspiratory muscle training|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg Participants will perform home-based IMT with a moderate load set at 50% of maximal inspiratory pressure (PImáx), adjusted weekly during in-person sessions at LACAP-UFPE. Training will use the Powerbreathe® Classic Light device, provided to participants for the study duration. The protocol includes three cycles of 10 explosive respiratory incursions, with one-minute rest intervals, performed twice daily for eight weeks. Participants will record perceived exertion (Borg scale) and any occurrences in a training log.
219463112|NCT05553652|DIETARY_SUPPLEMENT|ASTARTE™ oral capsules|1 Capsule daily for 6 months
219463113|NCT05553652|DIETARY_SUPPLEMENT|Placebo oral capsules|1 Capsule daily for 6 months
219463114|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
219463115|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
219463116|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
219463117|NCT03589794|OTHER|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
219463118|NCT03589794|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
219463119|NCT03589794|BIOLOGICAL|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
219463120|NCT00097916|DRUG|memantine HCl|
219593043|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
219593044|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
219593045|NCT00118131|DRUG|cisplatin|
219593046|NCT00118131|DRUG|docetaxel|
218852200|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
219463121|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
219463122|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
219463123|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
219463124|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
219463125|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
219463126|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
219593047|NCT04254939|DRUG|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
219593048|NCT03589235|PROCEDURE|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
219593049|NCT03589235|DEVICE|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
219463127|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
219463128|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
219463129|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
219463130|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
219463131|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
219463132|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
219593050|NCT03589235|DEVICE|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
219593051|NCT00197496|PROCEDURE|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
219198302|NCT06820684|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol will be delivered as follows:~1. Touching and applying gentle pressure to the participant's upper shoulder area (this is called Thoracic inlet direct myofascial release)~2. Touching and applying gentle pressure to the participant's midsection and abdomen (this is called Abdominal diaphragm direct myofascial release)~3. Touching and applying gentle pressure to the participant's pelvis and sacrum (this is called Muscle Energy or Counterstrain, if indicated).~4. Touching and applying gentle pressure to the participant's hips and hamstrings (this is called muscle energy) and will be done in 3 repeated rounds of 5 seconds each.~5. Touching and applying gentle pressure to the backs of the participant's knees (this is called open popliteal fossa with direct myofascial release)~6. Touching and applying gentle pressure to the participant's feet, moving them back and forth in 10 rhythmic pulses (this is called Pedal Pump)"
219198303|NCT06820502|PROCEDURE|Transurethral Resection of Prostate (TURP)|"TURP:~Transurethral resection of the prostate remains the criterion standard therapy for obstructive prostatic hypertrophy and is both the surgical treatment of choice and the standard of care when medication fails. It improves obstructive voiding symptoms and urinary flow rate with success rates ranging from 85 to 90% ."
219198304|NCT06820502|PROCEDURE|Transurethral Resection Of Bladder Tumor|"TURBT:~Trans-urethral resection of bladder tumor (TURBT), performed endoscopically, is the firstline procedure for diagnosis, staging, and treatment of visible bladder tumors,"
219198305|NCT05536245|OTHER|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
219198306|NCT06657677|DIETARY_SUPPLEMENT|40mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
219198307|NCT06657677|DIETARY_SUPPLEMENT|100mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
219198308|NCT06657677|DIETARY_SUPPLEMENT|180mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
219198309|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
219198310|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
219463133|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
219463134|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
219463135|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
219463136|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
219463137|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
219463138|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
219463139|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
219463140|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
219463141|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
219593052|NCT02606214|DRUG|TBA-354|
219593053|NCT02606214|DRUG|TBA-354 Placebo|
219463142|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
219463143|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
219463144|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
219463145|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
219593054|NCT00534014|DIETARY_SUPPLEMENT|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
219593055|NCT02803229|DRUG|Adderall-XR|
219593056|NCT02803229|DRUG|Matched placebo|matched placebo provided for placebo arm
219593057|NCT02995876|PROCEDURE|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
219593058|NCT02995876|PROCEDURE|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
219198311|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
219198312|NCT00364637|DRUG|Sevoflurane (Volatile Anesthetic)|
219198313|NCT00364637|DRUG|Total intravenous anesthesia|
219463146|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
219593059|NCT04995692|BEHAVIORAL|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
219593060|NCT04995692|BEHAVIORAL|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
219593061|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
219593062|NCT01024686|BIOLOGICAL|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
219593063|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
219593064|NCT01519986|DIETARY_SUPPLEMENT|Vitamin D3|Supplement of vitamin D3
219593065|NCT01519986|DIETARY_SUPPLEMENT|Placebo|Placebo
219593066|NCT04819035|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
219019689|NCT04350138|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
219019690|NCT04350138|OTHER|Placebo|150mM sodium chloride (0.9% saline solution).
219019698|NCT05415020|BEHAVIORAL|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
219019699|NCT05415020|BEHAVIORAL|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
218852201|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
219463147|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
219463148|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
219463149|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
219463150|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
219463151|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
219463152|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
219198314|NCT05754515|PROCEDURE|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
219198315|NCT06811597|PROCEDURE|Voco Meron Conventional Glass Ionomer|The right molars were bonded with Meron
219198316|NCT06811597|PROCEDURE|High-Q-Bond Band™ self-adhesive resin cement.|The left mandibular first molars were bonded with FSM High-Q-Bond Band™ self-adhesive resin cement.
219593067|NCT00696579|DRUG|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
219593068|NCT00696579|DRUG|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
218852202|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
218852203|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
219198317|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
219198318|NCT06807879|BEHAVIORAL|Modified Otago Exercise with Routine care Physical therapy|"To improve the efficacy of the balance improvement intervention, we modified the OEP by incorporating the additional walking, recommended by the OEP guidelines, into a single exercise session and conducting it as a group exercise program in accordance with a previous meta-analysis (Chiu et al., 2021) . As shown in Figure 1, the modified-OEP group intervention consisted of 15 min of walking followed by a 30 min Otago Exercise Program consisting of balance and strength training, followed by another 15 min of walking. The 15 min walking was accomplished through continuous walking at an individual pace in the \~15m training room. Participants were asked to walk 15 m, make a U-turn towards the left side, walk 15 m, then make a U-turn towards the right side at the next turning point, in order to achieve an equivalent effect on the promoted benefit of symmetry when turning left and right.~This was repeated until the session was complete."
219199472|NCT06871163|PROCEDURE|inspiratory muscle training (IMT) combined with manual techniques for the lower esophageal sphincter (MTLES) and diaphragmatic release (DRT)|"Volunteers allocated to the group will receive proton pump inhibitor medication at a standard dose of 20 mg.~The IMT protocol will be the same as in Group 1. Intervention: IMT Combined with Manual Techniques (MTLES \& DRT) The IMT protocol follows Group 1. DRT (Rocha et al., 2015) involves manual traction during inspiration and deepened contact during expiration, applied in two sets of ten deep breaths. MTLES (Eguaras et al., 2019) is performed with the patient seated, applying epigastric pressure to access the lower esophageal sphincter through coordinated flexion-inspiration and extension-expiration for 5 minutes."
219463153|NCT04047472|DRUG|Brolucizumab 6mg|Intravitreal injection
219463154|NCT04047472|DRUG|Aflibercept 2 mg|Intravitreal injection
219463155|NCT04741867|OTHER|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
219463156|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
219463157|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
219463158|NCT01934842|DEVICE|TAP20-C|
219463159|NCT01934842|DEVICE|SAFE-T-FILL|
219463160|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
219463161|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
219463162|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
219463163|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
219463164|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2\_Advanced All-In-One Virtual Reality Headset\_ 128 GB)).
219463165|NCT02030067|DRUG|RX-3117|
219593069|NCT00857584|DRUG|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
219593070|NCT00857584|DRUG|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
219463166|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
219463167|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
219463168|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
219463169|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
219463170|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
219463171|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
219463172|NCT01682694|DIETARY_SUPPLEMENT|placebo|
218852204|NCT02856243|DRUG|new antiviral therapy|
218852205|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
218852206|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
218852207|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
218852208|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
218852209|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
218852210|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
219463173|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
219463174|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
219463175|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
219463176|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
219463177|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
218852211|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
218852212|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
218852213|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
218852214|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
218852215|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
218852216|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
218852217|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
218852218|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
218852219|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
218852220|NCT01666535|BIOLOGICAL|Influenza vaccination|
218852221|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
218852222|NCT02193386|OTHER|Intervention period|Predefined intervention program
219463178|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
219463179|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
219463180|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
219593071|NCT00857584|DRUG|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
219593072|NCT03967587|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
219593073|NCT00612430|DRUG|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
219593074|NCT01102374|DRUG|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
219593075|NCT01102374|DRUG|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
219593076|NCT01102374|DRUG|Placebo|Placebo monthly
219593077|NCT01102374|DIETARY_SUPPLEMENT|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
219463181|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
219463182|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
219463183|NCT02288416|OTHER|questionnaire administration|Ancillary studies
219463184|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
219463185|NCT02288416|OTHER|Best Practice|
219463186|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
219463187|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
219463188|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
219463189|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
219463190|NCT05298410|OTHER|Limitless|Participants will be instructed to take Limitless for 30 days.
219463191|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
218852223|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
219199473|NCT06871163|PROCEDURE|Controle|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg, as prescribed for other participants. They will undergo a simulated treatment protocol, including inspiratory muscle training (IMT) without load to mimic device use and manual techniques where the therapist places hands on the intervention area without performing actual manipulation.
219463192|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
219463193|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
219463194|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
219199474|NCT06870929|DEVICE|The Photogrammetry-assisted intraoral scanning|The Photogrammetry-assisted intraoral scanning; will be executed using the MUA-compatible ioConnect ® photogrammetry system components exactly in the same sequence as recommended by the manufacturer
219463195|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
219463196|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
219463197|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
219593078|NCT00418821|BIOLOGICAL|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
219593079|NCT01469702|DRUG|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
219593080|NCT01469702|DRUG|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
219463198|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
219463199|NCT00062842|DRUG|Irinotecan|
219463200|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
219463201|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
219463202|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
219593081|NCT01469702|DRUG|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
219593082|NCT02071849|DEVICE|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
219593083|NCT01513382|PROCEDURE|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
218852224|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
219463203|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
219593084|NCT05318274|RADIATION|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
219593085|NCT04677296|OTHER|VS002A|Amino acid based ORS/Medical food
219593086|NCT04677296|OTHER|WHO-ORS|WHO Oral rehydration solution, which is glucose based
219593087|NCT04619992|DEVICE|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
219198319|NCT06807879|BEHAVIORAL|Routine Care Physical Therapy|The routine care physical therapy session typically involves a variety of exercises aimed at general strengthening, stretching, and basic gait training. 1 hour of standard physiotherapy exercises focusing on general strengthening, stretching, and basic gait training. The session included a combination of exercises aimed at general strengthening, such as core stability exercises, muscle-strengthening exercises with weights or resistance bands and functional movements like squats and lunges. Stretching exercises targeting key muscle groups like hamstrings will be incorporated to improve flexibility and range of motion. Gait training will focus on activities like side lunges, step-ups, and balance exercises to enhance walking ability and postural control. Additionally, the plan emphasized progressive challenges incorporating a mix of static and dynamic balance exercises using tools like foam pads or balance boards.
219198320|NCT05302219|OTHER|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
219198321|NCT05302219|OTHER|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
219198322|NCT05302219|OTHER|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
219198323|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
219198324|NCT06819501|DEVICE|hyperbaric oxygenation treatment|Administration of 100% oxygen at a pressure of 2.0ATA once daily for 60-90 minutes for a total of 30-40 times.
219198325|NCT06819501|BEHAVIORAL|routine care|Administration of pressurised ice gloves 30 minutes before, during, and 30 minutes after administering paclitaxel chemotherapy drugs.
219198326|NCT06819163|DIETARY_SUPPLEMENT|Berry leaf extract|The study foresees the intake of 2 capsules per day during 12 weeks
219198327|NCT06819163|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 12 weeks
219198328|NCT03239613|OTHER|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
219198329|NCT06857292|DRUG|Telpegfilgrastim|"Experimental group: Patients were subcutaneously injected with Telpegfilgrastim 33μg/kg (maximum dose ≤2mg) 24h after chemotherapy, 21 days for one chemotherapy cycle, and only one chemotherapy cycle was observed.~Pharmacokinetic determination: Among them, 8 patients underwent pharmacokinetic determination. The pharmacokinetic sampling time points were blood samples taken before administration, 12 h, 24 h, 48 h, 120h, 168 h, 336 h, 480h after administration. A total of 8 blood samples were collected, and the pharmacokinetic characteristics of the experimental drugs were analyzed by ELISA."
219198330|NCT04532177|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
219198331|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
219198332|NCT06855979|OTHER|Food with high antioxidant potential|The dietary intervention using fruit and nut bars with high antioxidant activity will last 1 month. Before and after the procedure, oxidative-antioxidant markers in the blood and intestinal microflora in the stool will be determined.
219463204|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
219463205|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
219463206|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
219463207|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
219593088|NCT04619992|DEVICE|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
219593089|NCT01236586|DRUG|RO4929097|
219593090|NCT01236586|DRUG|Dexamethasone|
219593091|NCT02148289|DIETARY_SUPPLEMENT|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
219593092|NCT02148289|DIETARY_SUPPLEMENT|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
219593093|NCT00674557|DRUG|SOD1 inhibitor ATN-224|
219593094|NCT00674557|DRUG|exemestane|
219593095|NCT00674557|GENETIC|protein expression analysis|
219593096|NCT00674557|GENETIC|proteomic profiling|
219463208|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
219463209|NCT00018694|DRUG|Chenodeoxycholic Acid|
219463210|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
219463211|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
219463212|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
219463213|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
219463214|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
219463215|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
219463216|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
219198333|NCT06856876|OTHER|Multidisciplinary Care Team (MDCT) Approach|A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.
219198334|NCT06856876|OTHER|Standard Breast Cancer Therapy|Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.
219198335|NCT06856603|RADIATION|stereotactic radiation therapy in ablative doses to each metastatic site|Stereotactic ablative radiation therapy will be utilized for each metastatic site in patients with 6 to 10 sites of metastasis (persistent or progressive disease).
219198336|NCT06818981|DRUG|8mg dexamethasone|Minimal research exists on how to treat pain, odynophagia, and dysphagia in sleep surgery patients. One study by Williams et al. evaluated the use of a one-time dose of intravenous or intramuscular dose of steroids versus placebo after uvulopalatopharyngoplasty but did not find a clinically significant difference between the two groups postoperatively. However this study mentioned that their current intervention was too short and that a longer-term steroid intervention could be beneficial. This is the goal of this intervention.
219198337|NCT06820112|OTHER|mechanical ventilation|patients who received mechanical ventilation
219463217|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
219463218|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
219463219|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
219463220|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
219463221|NCT02599740|OTHER|Placebo|Rice only
219463222|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
219463223|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
219463224|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
219463225|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
219463226|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
219593097|NCT00674557|OTHER|laboratory biomarker analysis|
219593098|NCT00674557|OTHER|pharmacological study|
219593099|NCT03852173|BEHAVIORAL|Wasserschulen|"Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents"
219593100|NCT06884215|OTHER|Mitopure Topical Formula 3|Topical skin cream containing Mitopure
219593101|NCT06884215|OTHER|Mitopure Topical Formula 4|Topical skin cream containing Mitopure
219593102|NCT03457155|OTHER|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~* At intensive care admission time~* 24h after admission time~* In case of FA occurrence~* In case of sinusal rhythm recovery (in patients with new onset FA)"
219463227|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
219463228|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
219593103|NCT00259272|DRUG|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
219463229|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
219463230|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
219463231|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
219463232|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
219463233|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
219463234|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
219463235|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
219463236|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
219463237|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
219463238|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
219463239|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
219463240|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
219463241|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
219463242|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
219463243|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
219463244|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
219463245|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
219463246|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
219463247|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
219463248|NCT02517502|DRUG|Placebo|Matched, blinded placebo
219593104|NCT04172116|DEVICE|Continuous glucose monitoring|see arm/group descriptions
219593105|NCT04051112|DRUG|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
219593106|NCT04164914|DIETARY_SUPPLEMENT|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
219463249|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
219463250|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
219463251|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
219463252|NCT00072215|DRUG|cisplatin|given IV
219463253|NCT00072215|DRUG|ifosfamide|given IV
219463254|NCT00072215|DRUG|paclitaxel|given IV
219463255|NCT00072215|DRUG|vinblastine|given IV
219593107|NCT00727766|DRUG|Clofarabine|
219593108|NCT00416702|DRUG|QAB149|
219593109|NCT03349008|DRUG|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
219593110|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
219593111|NCT03349008|DRUG|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
219593112|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
218852225|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
218852226|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
218852227|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
218852228|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
219463256|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
219463257|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
219463258|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
219463259|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
219463260|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
219593113|NCT03349008|DRUG|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
219463261|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
219463262|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
219463263|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
219463264|NCT00090246|DRUG|MK0869, aprepitant|
219463265|NCT00090246|DRUG|Comparator: ondansetron IV|
219593114|NCT01123837|OTHER|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
219593115|NCT01123837|OTHER|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
219593116|NCT02838654|PROCEDURE|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
219463266|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
219463267|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
219463268|NCT00807768|DRUG|Carboplatin|Given IV
219463269|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
219463270|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
219463271|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
218852229|NCT02139878|OTHER|Wild blueberry juice|
218852230|NCT02139878|OTHER|Placebo wild blueberry juice|
218852231|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
218852232|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
218852233|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
218852234|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
218852235|NCT06601517|DRUG|HDM1002|Administered orally
218852236|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
218852237|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
218852238|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
218852239|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
219463272|NCT00807768|DRUG|Paclitaxel|Given IV
219463273|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
219463274|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
219463275|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
219463276|NCT00539825|DRUG|GSK704838|
219463277|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
219463278|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
219463279|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
219463280|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
219463281|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
219463282|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
219463283|NCT00139373|DRUG|donepezil|
219463284|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
219463285|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
219463286|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
219463287|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
219463288|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
219463289|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
219463290|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
219463291|NCT06477523|DRUG|AK104|IV infusion
219463292|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219463293|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
219593117|NCT03336177|OTHER|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
219593118|NCT05653024|DRUG|Salbutamol|8 puffs of 100 mcg inhaled salbutamol administered with spacer
219593119|NCT05653024|DRUG|Placebo|8 puffs of placebo inhaler administered with spacer
219593120|NCT01558180|BEHAVIORAL|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
219593121|NCT01558180|BEHAVIORAL|Usual Care|educational handouts on pediatric insomnia
219019727|NCT06808516|DRUG|Oxytocin nasal spray|24 IU
219019728|NCT06808516|DRUG|Placebo|0.9% NaCl
219019730|NCT06758011|DEVICE|ivWatch|Patients wear ivWatch device at time of already scheduled chemotherapy on study.
219019731|NCT07063303|OTHER|Intermittent feeding|"Feeding Frequency: Enteral nutrition will be provided every 4 to 6 hours via nasogastric tube.~Feeding Volume: Each session will deliver 240 to 720 mL of enteral formula. Feeding Duration: Each feeding session will last approximately 20 to 60 minutes."
219019732|NCT07063303|OTHER|Continuous feeding|"Feeding Frequency: Enteral nutrition will be administered continuously for 20 hours per day via nasogastric tube.~Feeding Volume: The total daily volume will be divided evenly over the 20-hour infusion period, based on individual nutritional requirements.~Feeding Duration: Each 24-hour cycle includes 20 hours of continuous feeding followed by a 4-hour rest period."
219463294|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
219463295|NCT05231291|OTHER|hand grip strength|Observational study
219463296|NCT04348825|DEVICE|Electroconvulsive therapy|
219463297|NCT00287976|DRUG|irinotecan hydrochloride|
219463298|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
219463299|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
219463300|NCT00842829|DRUG|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
219463301|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
219463302|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
219463303|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
219463304|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
219463305|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
219463306|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
219463307|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
219463308|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
219463309|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
219463310|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
219463311|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
219198338|NCT06856811|PROCEDURE|tmj lavage with ringer lactate solution|tmj lavage using 150ml ringer lactate in symptomatic side of unilateral anterior disc displacement with reduction
219198339|NCT04947137|DRUG|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219463312|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
219463313|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
219463314|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
219463315|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
219463316|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
219463317|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
219198340|NCT01692366|DRUG|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
219198341|NCT04472013|OTHER|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
219463318|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
219463319|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
219463320|NCT00517634|DRUG|Placebo|Matching Placebo
219463321|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
219463322|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
219463323|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
219463324|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
219463325|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
218852240|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
218852241|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
218852242|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
218852243|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
218852244|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
218852245|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
218852246|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
218852247|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
218852248|NCT01696617|DRUG|Aripiprazole 6-week group|
219463326|NCT01551381|DRUG|EV-077|twice daily oral administration
219463327|NCT01551381|DRUG|Placebo|twice daily oral administration
219463328|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
218852249|NCT01696617|DRUG|Aripiprazole 8-week group|
219019763|NCT06898515|DEVICE|Reprieve System|The Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
219463329|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
219463330|NCT00052013|DRUG|PTK787/ZK 222584|
219463331|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
219463332|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
219463333|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
219463334|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
219463335|NCT03091920|DRUG|IW-1973|Oral Tablet
219463336|NCT03091920|DRUG|Placebo|Oral Tablet
219463337|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
219463338|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
219463339|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
219463340|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
219463341|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
219463342|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
219593122|NCT00005727|BEHAVIORAL|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
219593123|NCT00501501|PROCEDURE|Cesarean section|
219593124|NCT00501501|PROCEDURE|Vaginal delivery|
219593125|NCT04465773|PROCEDURE|general anesthesia for scheduled gynecological surgery|
219593126|NCT04465773|DRUG|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
219593127|NCT04465773|DRUG|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
219593128|NCT04465773|PROCEDURE|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
219593129|NCT04465773|DEVICE|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
219593130|NCT03008876|DRUG|Acetaminophen|infants receive acetaminophen for treatment of their PDA
219593131|NCT03008876|DRUG|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
219463343|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
219463344|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
219463345|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
219463346|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
219463347|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
219463348|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
219463349|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
219463350|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
219463351|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
219463352|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
218852250|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
218852251|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
218852252|NCT01944098|DRUG|Lidocaine|
218852253|NCT01944098|DRUG|Placebo|
219198342|NCT04472013|OTHER|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
219198343|NCT04472013|OTHER|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
219198344|NCT04472013|OTHER|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
219198345|NCT06299683|BEHAVIORAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
219463353|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
218852254|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
218852255|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
219463354|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
219463355|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
219463356|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
219463357|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
219463358|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
219463359|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
219463360|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
218852256|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
218852257|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
219463361|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
219463362|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
219463363|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
219463364|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
219593132|NCT04220931|DRUG|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
219593133|NCT02001831|DIETARY_SUPPLEMENT|Supplement|
219463365|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
218852258|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
219463366|NCT00056628|DEVICE|The COGNIShunt® System|
219593134|NCT02001831|DIETARY_SUPPLEMENT|Placebo|
218852259|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
218852260|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
218852261|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
218852262|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
218852263|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
219019764|NCT06898515|DRUG|furosemide infusion|Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy
219463367|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
219463368|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
219463369|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
219463370|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
219463371|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
218852264|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
219463372|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
218852265|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
218852266|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
218852267|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
219463373|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
219463374|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
219463375|NCT00381810|DRUG|Methylprednisolone|
219463376|NCT00381810|DRUG|Acetaminophen|
219463377|NCT00381810|DRUG|Diphenhydramine|
219463378|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
219463379|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
219463380|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
219463381|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
219463382|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
219463383|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
219593135|NCT00813631|OTHER|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
219463384|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
218852268|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
218852269|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
218852270|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
218852271|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
218852272|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
218852273|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
219463385|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
219463386|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
219593136|NCT00106340|DRUG|vildagliptin|
219593137|NCT00106340|DRUG|glimepiride|
219593138|NCT00106340|DRUG|Metformin|
219463387|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
219463388|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
219463389|NCT02628366|OTHER|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
218852274|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
218852275|NCT06542978|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
219593139|NCT00106340|DRUG|Vildagliptin matching placebo|
218852276|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
219593140|NCT00106340|DRUG|Glimepiride matching placebo|
219593141|NCT02368574|PROCEDURE|Class II hysterectomy|Class II hysterectomy
219198346|NCT06299683|OTHER|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
219463390|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
219463391|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
218852277|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
218852278|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
218852279|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
218852280|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
218852281|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
218852282|NCT06614647|DIAGNOSTIC_TEST|Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker|"IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:~1\) Recurrence risk stratification by ctDNA analysis of blood samples:~a) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging."
219019772|NCT05436418|DRUG|Melphalan|"Matched HCT: 100 mg/m\^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m\^2 IV on day -6 over approximately 20-30 minutes."
219019773|NCT05436418|DRUG|Sirolimus|Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)\^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.
219019774|NCT05436418|RADIATION|Total Body Irradiation (TBI)|Haplo HCT only: A dose of 200 cGy will be administered on day -1.
219463392|NCT00457093|DRUG|glargine|
219463393|NCT00457093|DRUG|detemir|
219593142|NCT03654469|OTHER|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
219593143|NCT03756467|BEHAVIORAL|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
218852283|NCT06614647|BEHAVIORAL|Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)|2\) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.
218852284|NCT06614647|BEHAVIORAL|Systematic treatment of organ-specific late effects and/or biopsychosocial late effects|3\) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.
218852285|NCT06614647|BEHAVIORAL|Digital care-guide for long-term follow-up after cancer treatment|Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.
218852286|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
218852287|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
218852288|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
218852289|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
218852290|NCT06869798|DRUG|zinc sulphate|"Group A (intervention) and Group B (non-intervention). The patients in Group A will receive standard therapy along with oral zinc 20mg/day OD for 2 months. While the patients in Group B will receive only Standard therapy.~Then, all the patients of both groups will be trained to maintain diary regarding questionnaire asked in asthma control test, followed up 4 weekly for 8 weeks"
218852291|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
218852292|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
218852293|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
218852294|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
218852295|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
218852296|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
218852297|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
218852298|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
218852299|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
219019775|NCT05436418|DRUG|Cyclophosphamide|based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
219019776|NCT05436418|DRUG|Mycophenolate Mofeti|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
219019777|NCT05436418|DRUG|Fludarabine|Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
219463394|NCT03066661|DRUG|Entrectinib|Open-label expanded access, capsules
219463395|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
219463396|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
219463397|NCT01922336|BIOLOGICAL|SB2|IV infusion
219463398|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
219463399|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
219463400|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
219463401|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
219463402|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
219463403|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
219463404|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
219463405|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
219463406|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
219463407|NCT00033683|DRUG|CMF regimen|
219463408|NCT00033683|DRUG|cyclophosphamide|
219463409|NCT00033683|DRUG|docetaxel|
219463410|NCT00033683|DRUG|epirubicin hydrochloride|
219199475|NCT06870929|DEVICE|The modified approach of splinting-assisted intraoral scanning|The scan bodies will be mounted over the MUA and loosely connected with a power chain before the Medit scanner single-shot scanning procedure. Using the additional scan option in the Medit scanner software, another single-shot scan will be obtained and superimposed to the first scan yielding a color map that reflects the accuracy of the obtained scan and directs a highly precise final scan.
219593144|NCT02884401|DEVICE|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
219593145|NCT02636192|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study.
219593146|NCT04682769|OTHER|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
219593147|NCT06303479|OTHER|Non-Instrumental breathing exercise group|Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.
219593148|NCT06303479|OTHER|Instrumental breathing exercise group|The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
219593149|NCT02086903|DRUG|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
219593150|NCT02086903|DRUG|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
219593151|NCT01264536|DIETARY_SUPPLEMENT|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
219019778|NCT05436418|PROCEDURE|Allogeneic HSCT|Stem cell transplant
219019779|NCT05436418|DRUG|Mesna|equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
219463411|NCT00033683|DRUG|fluorouracil|
219019780|NCT05436418|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.
219463412|NCT00033683|DRUG|methotrexate|
219463413|NCT00033683|DRUG|tamoxifen citrate|
219463414|NCT00033683|PROCEDURE|adjuvant therapy|
219463415|NCT00033683|RADIATION|radiation therapy|
219463416|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
219463417|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
219463418|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
219463419|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
219463420|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
219463421|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
219463422|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
219463423|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
219463424|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
219593152|NCT01264536|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
219198347|NCT06583213|PROCEDURE|Fractional Spinal Anaesthesia.|An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
219198348|NCT06583213|PROCEDURE|Conventional Spinal Anaesthesia|"Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes."
219199476|NCT06870929|DEVICE|Simple splinting-assisted intraoral scanning|The Medit i600 direct intraoral classical scans will be obtained while applying only a basic simple splinting
219463425|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
219463426|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
219463427|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
219463428|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
219463429|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
219463430|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
219463431|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
219463432|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
219463433|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
219463434|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
219593153|NCT05892692|BEHAVIORAL|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
219463435|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
219463436|NCT03616652|DRUG|Placebo|Placebo pill
219463437|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
219463438|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
219463439|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
219463440|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
219463441|NCT05423275|DEVICE|Negative ion therapy|Negative ion generator
219463442|NCT05423275|DEVICE|Light therapy|Fluorescent light box
219463443|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
219463444|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
219463445|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
219463446|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
219463447|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
219463448|NCT00005874|DRUG|rubitecan|
219593154|NCT04719962|PROCEDURE|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
219593155|NCT00021580|PROCEDURE|human cadaveric islet cell transplantation|
219593156|NCT04684004|OTHER|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
219463449|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
219463450|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
219463451|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
219463452|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
219463453|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
219463454|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
219463455|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
219463456|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
219463457|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
219463458|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
219463459|NCT02581657|DRUG|Placebo Injection|Placebo Injection
218852300|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
219463460|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
219463461|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
219463462|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
219463463|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
219463464|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
219463465|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
219463466|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
219463467|NCT00313716|OTHER|placebo|an inactive substance
219463468|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
219463469|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
219463470|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
219463471|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
219463472|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
219463473|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
219463474|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
219463475|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
219463476|NCT02010099|DRUG|PP110 Gel|
219463477|NCT02010099|DRUG|PP110 Medicated wipes|
218852301|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
219463478|NCT02010099|DRUG|Preparation-H Cream|
218852302|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at dental clinic|Participants will perform a self-sampling at the dental clinic using gargling kit
219463479|NCT01024270|DRUG|Misoprostol|
219463480|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
219463481|NCT00001256|DRUG|prednisone and methotrexate|
219463482|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
219463483|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
219463484|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
219463485|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
219593157|NCT04888598|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
219593158|NCT03579927|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219593159|NCT03579927|DRUG|Carmustine|Given IV
219593160|NCT03579927|DRUG|Cytarabine|Given IV
219593161|NCT03579927|DRUG|Etoposide|Given IV
219593162|NCT03579927|BIOLOGICAL|Filgrastim|Given SC
218852303|NCT07033091|OTHER|Questionnaire|Participants will answer questionnaire online/paper at their home or at the dental clinic
219463486|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
219198349|NCT06819540|BEHAVIORAL|Mindfulness-Based Stress Reduction Programme|Mindfulness involves paying attention to what is occurring in the present moment, noticing the particularity of that attention, and accepting without judgement all states of awareness. Mindfulness is important in moving individuals away from automatic thoughts, habits and unhealthy patterns of behaviour, and therefore can play an important role in promoting conscious and self-affirmed behavioural regulation, which has long been associated with enhancing well-being. Mindfulness is a way of regulating one's self, thoughts and awareness. It has been demonstrated to enhance the ability to remain present in the moment, arising through purposeful, momentary, non-judgemental attention to experience. Recently mindfulness appears to have a positive impact on helping people overcome addiction and psychological problems and providing effective techniques to manage them
219593163|NCT03579927|DRUG|Melphalan|Given IV
219198350|NCT03617237|OTHER|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~1. The research involves no more than minimal risk to the subjects.~2. The waiver will not adversely affect the rights and welfare of the subjects.~3. The research could not practicably be carried out without the waiver.~4. Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
219593164|NCT03579927|BIOLOGICAL|Rituximab|Given IV
219593165|NCT03579927|BIOLOGICAL|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
219593166|NCT05933980|DRUG|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
219463487|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
218852304|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at home|Participants will perform a self-sampling at home using gargling kit
219463488|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
219463489|NCT01041027|DRUG|Paclitaxel|Given IV
219463490|NCT01041027|DRUG|Carboplatin|Given IV
219463491|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
219463492|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219463493|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
219463494|NCT01907373|DRUG|olmesartan medoxomil|
219463495|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
218852305|NCT07033091|DIAGNOSTIC_TEST|Blood sampling|Venous blood will be collected from study participants with oral hrHPV positivity, in which the presence of circulating hrHPV DNA will be determined.
218852306|NCT07033091|DIAGNOSTIC_TEST|Self-sampling of the urogenital area|In case of a positive examination in the oropharynx, the tested individuals will be offered a self-collection HPV examination in the urogenital area (cervicovaginal swab in women or external genital swab in men).
218852307|NCT02455661|DEVICE|TR Band (TM)|
218852308|NCT02455661|DEVICE|AngioSeal|
218852309|NCT02455661|DEVICE|StarClose|
218852310|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
218852311|NCT07035054|BIOLOGICAL|low dose-1|PCV24 (low-dose 1) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, and the dosage is 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows: 4.0 μg per vial for serotypes 3, 6B, and 12F; and 2.0 μg per vial for the other 21 serotypes, namely 1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant (aluminum content: 0.125 mg per dose).
218852312|NCT07035054|BIOLOGICAL|low dose-2|"PCV24 (low-dose 2) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 4.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
219463496|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
219463497|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
219593167|NCT05527574|OTHER|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
219463498|NCT04393259|OTHER|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
219463499|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
219463500|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
219463501|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
219463502|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
219463503|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
219463504|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
219463505|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
219463506|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
219463507|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
219463508|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
219463509|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
219463510|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
219593168|NCT04175535|PROCEDURE|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
219593169|NCT04175535|PROCEDURE|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
219593170|NCT04049110|DRUG|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
219593171|NCT04049110|DRUG|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
219593172|NCT02511821|OTHER|Computer-Assisted Intervention|Complete online surveys
219593173|NCT02511821|DEVICE|Vivofit watch|Wear Vivofit watch
219593174|NCT02511821|OTHER|Quality-of-Life Assessment|Ancillary studies
219198351|NCT03884101|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
219463511|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
219463512|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
219463513|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
219463514|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
219463515|NCT02257970|DRUG|Ketoprofen|
219463516|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
219463517|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
219463518|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
219463519|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
218852313|NCT07035054|BIOLOGICAL|high dose|"PCV24 (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 8.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
218852314|NCT07035054|BIOLOGICAL|positive control|PPV23 produced by Chengdu Institute of Biological Products is a formulation with each vial containing 0.5 ml, and the dosage is 0.5 ml per person per administration. It contains polysaccharides of the following pneumococcal serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, with each serotype containing 25 μg of polysaccharide. In addition, it contains sodium chloride and water for injection.
219463520|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
219463521|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
219463522|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
219463523|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
219463524|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
219463525|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
219463526|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
219019788|NCT06745050|BEHAVIORAL|Text message mHealth Evidence-based intervention|MM! includes three messages per week in month one, then two messages per week for the six-month intervention period. Earlier messages include more informational and motivational content, while later messages include more behavioral skills.
219463527|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
219463528|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
219463529|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
219463530|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
218852315|NCT07032428|DEVICE|A new non-invasive brain stimulation tool|kTMP is a magnetic induction method that delivers continuous kHz-frequency cortical electric fields (E-fields) which may be amplitude-modulated to potentially mimic electrical activity at endogenous frequencies which will be tested on anhedonia patients in this study.
218852316|NCT07032428|DEVICE|A new non-invasive brain stimulation tool with sham setting selected|This device will counterbalance the active kTMP conditions
218852317|NCT07034911|DRUG|Ketalar|women receiving sub-anesthetic dose of ketamine of 0.5 mg/kg IV bolus in 3 ml of normal saline.
218852318|NCT07034911|DRUG|Ephedrine|women receiving bolus of 15mg of ephedrine
218852319|NCT06881953|OTHER|Questionnaire|The questionnaire will be completed on line by the participants (approx. 10 min).
218852320|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
218852321|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
218852322|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
218852323|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
218852324|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
218852325|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
218852326|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
219198352|NCT03884101|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
218852327|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
218852328|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
218852329|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
219198353|NCT03884101|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
218852330|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
218852331|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
218852332|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
218852333|NCT06892574|DEVICE|Active-VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
218852334|NCT06892574|DEVICE|Sham VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
219198354|NCT03884101|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
219198355|NCT06816277|PROCEDURE|Desbridamiento de periimplantitis|"The implant with the most severe involvement was selected, although the treatment was performed on all implants, to prevent patients with more affected implants from having greater statistical relevance.~The peri-implant surgical treatment was performed under local infiltrative anesthesia with 4% articaine with 1:100,000 adrenaline. Debridement was performed using ultrasound with irrigation, complemented using curettes. Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded. It was sutured with 4/0 monofilament in a pre-assembled 3/8 s"
219463531|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
219463532|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
219463533|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
219463534|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
219463535|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
218852335|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
218852336|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
218852337|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
218852338|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
218852339|NCT06896279|PROCEDURE|TI Stimulation|Participants will accept the TI stimulus for one month
218852340|NCT06896279|PROCEDURE|Sham Stimulation|Participants will accept the sham TI stimulus for one month
218852341|NCT06895590|DEVICE|Philips Advanced Monitoring Cuff (i.e. AMC)|Investigational, non-invasive upper arm cuff
219463536|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
219463537|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
219463538|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
219463539|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
219463540|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
219463541|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
219463542|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
219463543|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
219463544|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
219463545|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
219463546|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
219463547|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
219463548|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
219463549|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
219463550|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
219463551|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
219463552|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
219463553|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
219463554|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
219463555|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
219463556|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
219463557|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
219463558|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
219463559|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
219463560|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
219463561|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
219593175|NCT02511821|OTHER|Questionnaire Administration|Ancillary studies
219593176|NCT04689555|PROCEDURE|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
219593177|NCT04689555|PROCEDURE|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
219593178|NCT04320654|OTHER|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
219593179|NCT00000212|DRUG|Desipramine|
219593180|NCT00906386|DRUG|Varenicline|oral, 1 mg twice daily, 12 weeks
219593181|NCT00906386|DRUG|placebo|oral, 1 mg twice daily, 12 weeks
219463562|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
219463563|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
219463564|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
219463565|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
219463566|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
219463567|NCT02547064|PROCEDURE|Glidescope guided intubation|
219463568|NCT02547064|DEVICE|GlideScope®|
219463569|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
219463570|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
219463571|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
219019789|NCT06786923|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulator|Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).
219463572|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
219463573|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
219463574|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
219463575|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
219463576|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
219463577|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
219463578|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
219463579|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
219463580|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
219463581|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
219593182|NCT00085475|DRUG|imatinib mesylate|
219019790|NCT05695339|DRUG|Resiniferatoxin|An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
219593183|NCT00085475|PROCEDURE|conventional surgery|
219593184|NCT01325727|OTHER|Brief computerized feedback|Brief computerized feedback
219593185|NCT01325727|OTHER|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
219593186|NCT02472327|BEHAVIORAL|Pre-operative support|
219593187|NCT03483727|DEVICE|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
219593188|NCT00159627|DRUG|KW-3902IV|
219593189|NCT05148260|BEHAVIORAL|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
219593190|NCT05148260|BEHAVIORAL|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
219593191|NCT01470768|OTHER|Amino Acid-based Formula with high DHA and ARA|
219593192|NCT01470768|OTHER|Amino Acid-based Formula with lower DHA and ARA|
219593193|NCT04493086|DIAGNOSTIC_TEST|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR \< 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
219593194|NCT02646852|DRUG|PLX038|
219593195|NCT03805711|DEVICE|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
219463582|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
219463583|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
219463584|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
218852342|NCT06805396|BEHAVIORAL|Palliative Care Consult|Patients receive a regular consult (30-45 min) with the hospital palliative care consult team (PCCT) that is tailored to the preferences and needs of the individual patient. The following topics can be discussed: 1) physical symptoms, and, where appropriate, followed by recommendations for symptom management and transfer of handovers to the treating care team, 2) psychological, social and spiritual distress, followed by provision of counseling or referral to another specialist if needed, 3) goals of care to explore participants' values, preferences and needs (advance care planning), and 4) discussion about the needed follow-up of palliative care, and 5) care for caregivers. At baseline, patients receive a validated symptom questionnaire (Utrecht Symptom Diary (USD)-4D), which can be used as input for discussion during the consultation. If necessary, patients may have a follow up.
218852343|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on natural nails|Comparison of microbiological sampling before and after hand desinfection
219019791|NCT07071727|RADIATION|Preoperative radiotherapy|preoperative radiotherapy
219019792|NCT07061964|PROCEDURE|Biospecimen Collection|Undergo tissue, urine, and blood sample collection
219019793|NCT07061964|PROCEDURE|Computed Tomography|Undergo CT
219019794|NCT07061964|PROCEDURE|Cystoscopy|Undergo cystoscopy
219463585|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
219463586|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
219463587|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
219463588|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
219463589|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
219463590|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
219463591|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
219463592|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
219463593|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
219463594|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
219463595|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
219463596|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
219463597|NCT02463812|DRUG|Intralipid|
219463598|NCT02463812|DRUG|Saline|
219019795|NCT07061964|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219463599|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
219463600|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
219463601|NCT00372658|DRUG|1% Lidocaine intracervical injection|
219463602|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
219463603|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
219463604|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
219463605|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
219593196|NCT03086382|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
219593197|NCT03086382|DRUG|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
219593198|NCT03993782|OTHER|A19010-R|A snus product
219593199|NCT03993782|OTHER|B19010-O|A snus product
219593200|NCT01485744|DRUG|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
218852344|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on methacrylic nails|Comparison of microbiological sampling on methacrylic nails
219019796|NCT07061964|BIOLOGICAL|Pembrolizumab|Given IV
219019797|NCT07061964|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam RT
219019798|NCT07061964|PROCEDURE|Positron Emission Tomography|Undergo PET
219019799|NCT07061964|OTHER|Questionnaire Administration|Ancillary studies
219019800|NCT07061964|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
218852345|NCT06891469|DIETARY_SUPPLEMENT|Caffeine administration according to body mass (moderate intake- 7 mg/kg)|This randomized, double-blind, crossover study aimed to investigate the acute effects of caffeine consumption on physiological responses and performance during a strength-focused CrossFit workout. Participants will consume either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or placebo, 60 minutes before a CrossFit workout aiming to perform as many repetitions as possible.
218852346|NCT06891469|DIETARY_SUPPLEMENT|Placebo (Biotin Capsules)|Consumption of biotin (BIOTIN tablets by Myprotein) at the same time as caffeine.
218852347|NCT06896396|DRUG|Lenvatinib, Pembrolizumab|Pabilizumab: intravenously every three weeks Lenvatinib, with a dosage based on body weight: 8 mg (≤60 kg) or 12 mg (\>60 kg), once daily
219463606|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
219463607|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
219463608|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
219463609|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
219463610|NCT04196010|DRUG|Cladribine|Given IV
219463611|NCT04196010|DRUG|Cytarabine|Given IV
219463612|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
219463613|NCT04196010|DRUG|Mitoxantrone|Given IV
219463614|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
219463615|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
219463616|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
219463617|NCT05015959|OTHER|observation|quality
219463618|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
219463619|NCT00006382|PROCEDURE|comparison of screening methods|
219463620|NCT00006382|PROCEDURE|computed tomography|
219463621|NCT00006382|PROCEDURE|radiography|
219463622|NCT00006382|PROCEDURE|study of high risk factors|
219463623|NCT03613766|OTHER|Physical activity program|
219463624|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
219463625|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
219463626|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
218852348|NCT06896396|DRUG|Icaritin soft capsules|Starting 3-5 days after the first TACE treatment, take 6 capsules orally, twice a day, and swallow them with warm water within 30 minutes after breakfast and dinner
218852349|NCT06896396|PROCEDURE|TACE|TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
219019805|NCT06194799|DRUG|ACP-204|ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
219463627|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
219463628|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
219463629|NCT01794221|PROCEDURE|stitches only|standard of care
219463630|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
219463631|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
219463632|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
219463633|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
219463634|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
219463635|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
219463636|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
219463637|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
219463638|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
219463639|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
219463640|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
219463641|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
219463642|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
219463643|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
219463644|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
219019806|NCT06823752|DRUG|Lemborexant 10 MG|An orally ingested tablet containing 10mg Lemborexant taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
219463645|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
219463646|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
219463647|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
219463648|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
219463649|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
219463650|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
219463651|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
219463652|NCT02833142|DRUG|BIIB033 (opicinumab)|
219463653|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
219463654|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
219463655|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
219463656|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
219463657|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
219463658|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
219463659|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
219463660|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
219463661|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
219463662|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
219463663|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
219463664|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
219463665|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
219463666|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
218852350|NCT06896292|BEHAVIORAL|Hybrid care model|"Participants will receive usual antenatal care (in-person), plus the digital support tool. A co-design process was used to develop the tool based on consumer feedback.~The tool is based on the recommended Assess/ask, Advise, Help approach to preventive care for smoking, nutrition, alcohol, physical activity and gestational weight gain.~Participants will be prompted (via SMS) to use the digital support tool at regular intervals throughout their pregnancy to self-assess health risks and be reminded of recommendations and available coaching services."
219463667|NCT02013999|OTHER|standard occupational therapy|
219463668|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
219463669|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
219463670|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
219463671|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
219463672|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
218852351|NCT06896292|OTHER|Usual Care|Participants will receive usual antenatal care (in-person), which is recommended to include the delivery of preventive care using the AAH model for smoking, nutrition, alcohol, physical activity and gestational weight gain.
218852352|NCT06895980|PROCEDURE|Non-surgical periodontal treatment, glycated hemoglobin measurement and application of OHIP-14SP survey.|Non-surgical periodontal treatment will be performed, with periodontal maintenance therapy at 3, 6, 9 and 12 months, with measurement of glycated hemoglobin at each time and application of the OHIP-14SP oral health-related quality of life survey.
218852353|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
218852354|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
219463673|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
219463674|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
219463675|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
219463676|NCT00389766|DRUG|topotecan hydrochloride|
219463677|NCT00389766|PROCEDURE|chemotherapy|
219463678|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
219463679|NCT00389766|PROCEDURE|radioisotope therapy|
219463680|NCT00389766|PROCEDURE|radionuclide imaging|
219463681|NCT00389766|PROCEDURE|radiosensitization|
219463682|NCT00389766|PROCEDURE|total-body irradiation|
219463683|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
219463684|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
219463685|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
219019807|NCT06823752|DRUG|Placebo|Placebo tablets will contain similar excipients without the active ingredient (Lemborexant) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.
219463686|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
219463687|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
219463688|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
219463689|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
219463690|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
219463691|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
219463692|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
219463693|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
219593201|NCT03125980|DRUG|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)"
219593202|NCT03125980|DRUG|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W"
218852355|NCT06641713|PROCEDURE|TACE|TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.
218852356|NCT06641713|PROCEDURE|HAIC|HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
218852357|NCT06895824|OTHER|Mindfulness Meditation|Somatic tracking is one aspect of most mindfulness meditation protocols, involving paying attention to the present non-judgementally, and focusing on breath and bodily sensations (e.g., sounds in the case tinnitus). This study employs this approach as a standalone intervention, in the form of a guided meditation recording.
219463694|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
219463695|NCT06601478|BEHAVIORAL|The MedLIFE app|The intervention arm will receive the lifestyle counselling by the MEDLIFE app, and the control arm will go on with standard lifestyle recommendations in the form of a two-page written handout.
219463696|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
219593203|NCT06234202|DEVICE|Bioactive Sleeve|Pitchers will wear a bioactive sleeve immediately post-game through overnight.
219463697|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
218852358|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the neoadjuvant therapy phase before TURBT surgery.
218852359|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the B arm, the combined therapy with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2 ) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the induction phase after TURBT surgery.
218852360|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
218852361|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
218852362|NCT04005638|BIOLOGICAL|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
218852363|NCT04005638|BIOLOGICAL|urine sample|12 ml
218852364|NCT06895850|OTHER|Eccentric cycling training|The training protocol for the ECC consisted of a 5-minute warm-up on a stationary ergometer (RS1 Go, Life fitness, USA) before completion of the prescribed workout. In the first two weeks, participants completed two sets of 10 minutes of eccentric cycling at an RPE between 9-11 with 2 minutes of inter-set rest. Then, during weeks 3-8, participants completed two sets of 15 min of eccentric cycling at an RPE between 13-15 with 2 min inter-set rest.
218852365|NCT06895850|OTHER|Standar Rehabilitation|The training protocol for STD REHAB consisted of the same 5 min warm-up protocol used in ECC, followed by three sets of 8 repetitions of bicep curls, triceps extensions, shoulder abduction, bodyweight squats, deadlifts, and leg abductions with an elastic band with 2 min inter-set rest. The resistance of the elastic band tension was progressively increased according to the participant's tolerance based on RPE. ECC training was programmed for \~20-30 min, while STD REHAB lasted \~60 min per session.
219019808|NCT05423717|DRUG|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
219019809|NCT05423717|DRUG|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
219463698|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
219463699|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
219463700|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
219463701|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
219463702|NCT01483378|OTHER|Choosing to receive the vaccine|
219593204|NCT06234202|DEVICE|Control Sleeve|Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
219463703|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
219463704|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
219463705|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
219463706|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
219463707|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
219463708|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
219463709|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
219463710|NCT02026193|PROCEDURE|oocyte vitrification|
219463711|NCT02026193|PROCEDURE|embryo freezing|
219463712|NCT00040066|PROCEDURE|Cocaine (IV)|
219463713|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
219463714|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
219463715|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
219463716|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
219463717|NCT02499380|DEVICE|PneumRx Coil System|
219463718|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
219463719|NCT01927276|OTHER|Gluten Free Flour|
219463720|NCT01927276|OTHER|Wheat Flour|
218852366|NCT06597929|OTHER|Moderate-vigorous physical activity|The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
218852367|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
219463721|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
219463722|NCT02957500|DEVICE|Mediclore® (adhesion barrier)|
219463723|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
219463724|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
219463725|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
219463726|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
219463727|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
219463728|NCT03391427|DRUG|Saline|This group will receive saline infusion
219463729|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
219463730|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
219463731|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
219463732|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
219463733|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
219463734|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
219463735|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
218852368|NCT06180629|OTHER|normal treatment routine|normal treatment routine
218852369|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
218852370|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
218852371|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
218852372|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
218852373|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
218852374|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
218852375|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
218852376|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
218852377|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
218852378|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
218852379|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
218852380|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
218852381|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
218852382|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
218852383|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
218852384|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
218852385|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
218852386|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
218852387|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
219463736|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
219463737|NCT03550508|BIOLOGICAL|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
218852388|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
218852389|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
218852390|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
218852391|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
218852392|NCT00656188|DRUG|Placebo|Matching placebo
218852393|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
218852394|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
218852395|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
218852396|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
218852397|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
218852398|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
218852399|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
218852400|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
218852401|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
218852402|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
219463738|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
219198356|NCT06816277|DRUG|Aplicación de melatonina|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
219198357|NCT06816277|OTHER|Placebo application|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
219593205|NCT00604136|BIOLOGICAL|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
219593206|NCT02656888|DRUG|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
219198358|NCT06817824|OTHER|Su-jok therapy|"Su Jok therapy was developed by South Korean scientist Professor Woo Jae Woo (1942-2010) in 1986. In Korean language, 'Su' means hand and 'Jok' means foot (Friman \& Chelala, 2016; Ivanov 2018; Woo 1987, 1991, 2000, 2002, 2007; Sharma \& Sharma, 2015). In Su Jok therapy, it is argued that there are reflection points of the body in the hands and feet and that these points activate every organ and part of the body like a remote control (Woo 1987, 1991, 2000, 2002, 2007; Şimşek \& Alpar, 2020).~Holistic approaches, energy flow and meridians form the basis of Su Jok therapy (Ivanov, 2018; Seth, 2013). Su Jok is an integrated therapy method that includes many tried and trusted methods of oriental medicine (Ponni, 2011; Rodríguez et al., 2018; Seth, 2013). In particular, it is similar in content to practices such as acupuncture and acupressure, which are approaches expressed by the same philosophy (Ivanov 2018; Ponni, 2011; Rodríguez et al., 2018)."
219593207|NCT02656888|DRUG|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
219593208|NCT04513288|DIETARY_SUPPLEMENT|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
219593209|NCT04513288|OTHER|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
219593210|NCT01208987|OTHER|Medication History was printed|
219198359|NCT06825078|DEVICE|multiparametric MRI|"An MRI scan will be performed within 2 weeks of the discovery of a solid lung nodule ≥ 5mm on the screening scan.~When a follow-up scan is indicated, an MRI will be repeated on the same day as the follow-up scan.~The MRI sequences that will be performed are: SpiraleVibe UTE, T1map, T2 map and Diffusion.~A synthetic scanner image will be generated from the UTE morphological MRI image using a generative artificial intelligence (GAN) model."
219198360|NCT00160732|DRUG|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
219198361|NCT00160732|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
219198362|NCT06825975|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
219593211|NCT01908907|DIETARY_SUPPLEMENT|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
219198363|NCT06825507|BEHAVIORAL|Lifestyle-based mental health care|Participants in the LSC will access a stepped care treatment consisting of 3 steps, including self-help multicomponent LM treatment (Step 1), guided self-help based on the LM approach and low-intensity cognitive behavioural therapy for depression (Step 2), and specialist mental health services (Step 3).
219463739|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
219463740|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
219463741|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
219463742|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
219463743|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
219463744|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
219463745|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
219593212|NCT01908907|DIETARY_SUPPLEMENT|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
219593213|NCT00761657|DRUG|Roxadustat|Capsule
219593214|NCT00761657|DRUG|Placebo|Capsule
219593215|NCT02989324|DRUG|MisoprostoL|Vaginal MisoprostoL
219593216|NCT02989324|DEVICE|Foley Catheter|Misoprostol Plus Foley Catheter
218852403|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
218852404|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
218852405|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
218852406|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
218852407|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
218852408|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
218852409|NCT04703608|DRUG|Placebo|Non-identical placebo
218852410|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
218852411|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
219463746|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
219463747|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
218852412|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
218852413|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
218852414|NCT00704483|DRUG|SBR759|1.5 g tid
218852415|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
218852416|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
218852417|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
218852418|NCT00373165|DRUG|Ganciclovir|
218852419|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
218852420|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
219463748|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
219463749|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
219463750|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
219593217|NCT05329324|OTHER|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
218852421|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
218852422|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
218852423|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
218852424|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
218852425|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
218852426|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
218852427|NCT00903136|OTHER|questionnaire administration|
218852428|NCT00903136|PROCEDURE|comparison of screening methods|
218852429|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
218852430|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
218852431|NCT00903136|PROCEDURE|tethered capsule endoscopy|
218852432|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219463751|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
219463752|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
219463753|NCT02112149|BEHAVIORAL|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
219463754|NCT02194192|DRUG|Placebo|Normal saline 10 ml
219463755|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
219463756|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
219463757|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
219463758|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
219463759|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
219463760|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
219463761|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
219463762|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
219463763|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
219463764|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
219463765|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
219463766|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
219463767|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
219463768|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
219463769|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
219463770|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
219463771|NCT00004333|DRUG|NTBC|
219463772|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
219593218|NCT05329324|OTHER|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
218852433|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
218852434|NCT00017654|DRUG|anti-thymocyte globulin|
219593219|NCT01393886|PROCEDURE|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
218852435|NCT00017654|DRUG|cyclophosphamide|
218852436|NCT00017654|DRUG|cyclosporine|
218852437|NCT00017654|DRUG|methylprednisolone|
218852438|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
218852439|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
219463773|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
219463774|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
219463775|NCT03626389|OTHER|Physiotherapy|
218852440|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
219463776|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
219463777|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
219198364|NCT06825507|OTHER|Care-as-usual|Participants in the CAU will receive their baseline depressive symptom severity via text message following randomisation, and they will have unrestricted access to mental health services based on their needs and preferences, such as pharmacological treatments, psychological treatments, and complementary and alternative medicine.
219198365|NCT04906824|DEVICE|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
219463778|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
219463779|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
219463780|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
219463781|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
219463782|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
219463783|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
219463784|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
219463785|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
219463786|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
219463787|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
219463788|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
219463789|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
219463790|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
219593220|NCT05435937|BEHAVIORAL|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
219463791|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
219463792|NCT01118039|DRUG|sunitinib malate|
219463793|NCT01118039|OTHER|immunohistochemistry staining method|
218852441|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
219198366|NCT06507072|BEHAVIORAL|Adaptive Rock Climbing Program|Twelve week rock climbing program. The program will take place once per week over the course of twelve weeks.
219463794|NCT01118039|OTHER|laboratory biomarker analysis|
219463795|NCT01118039|OTHER|pharmacological study|
219463796|NCT01118039|PROCEDURE|quality-of-life assessment|
218852442|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
218852443|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
218852444|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
218852445|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
218852446|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
218852447|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
218852448|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
218852449|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
218852450|NCT00359944|DRUG|AC-3933|5mg twice daily
219463797|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
219463798|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
218852451|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
218852452|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
218852453|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
219198367|NCT03169634|PROCEDURE|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
219198368|NCT03169634|PROCEDURE|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
219198369|NCT03169634|PROCEDURE|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
219198370|NCT06824909|DEVICE|ROSE-AI diagnostic system|"All samples were obtained due to the necessity for disease treatment and in accordance with routine clinical workflows. After the pathological diagnoses were confirmed by the pathology departments of the hospitals affiliated with the respective endoscopic centers, the eligible pancreatic puncture Diff-Quik stained smears were borrowed and transferred to Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University. There, the self-developed Zhiying Shunxi system was used to capture corresponding traditional light microscope RGB images. After the imaging was completed, all specimens were returned to the endoscopic centers from which they originated. Using the RGB images as input, an artificial intelligence algorithm was developed to assist in differentiating solid pancreatic lesions."
218852454|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
218852455|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
218852456|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
218852457|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
218852458|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
218852459|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
218852460|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
218852461|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
218852462|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
219198371|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
219463799|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
219463800|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
219463801|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
219463802|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
219463803|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
219463804|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
219463805|NCT00953784|PROCEDURE|standard operating management|As previously described
219463806|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
219463807|NCT00207493|PROCEDURE|patient referral versus contract referral|
219463808|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
219463809|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
218852463|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
219463810|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
219463811|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
219463812|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
219463813|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
219463814|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
219463815|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
219463816|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
219463817|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
219463818|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
219463819|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
219463820|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
219463821|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
219593221|NCT05435937|BEHAVIORAL|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
219593222|NCT03601130|DEVICE|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
219019810|NCT05423717|DRUG|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
219019811|NCT05423717|DRUG|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
219463822|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
219463823|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
219463824|NCT01888367|DRUG|DFA-02 Placebo Gel|
219198372|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
219198373|NCT05983055|DRUG|Dexamethasone 20mg|Periarticular dexamethasone injection
219198374|NCT06610045|OTHER|No intervention|No specific intervention is assess in this study.
219198375|NCT05969223|DRUG|Risankizumab|Subcutaneous injection
219198376|NCT05969223|DRUG|Placebo for Risankizumab|Subcutaneous injection
219198377|NCT02595424|DRUG|Capecitabine|Given PO
219198378|NCT02595424|DRUG|Carboplatin|Given IV
219198379|NCT02595424|DRUG|Cisplatin|Given IV
219198380|NCT02595424|DRUG|Etoposide|Given IV
219198381|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
219198382|NCT02595424|DRUG|Temozolomide|Given PO
219198383|NCT02938520|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
218852464|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
219463825|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
219463826|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
219463827|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
219463828|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
219463829|NCT04812821|OTHER|questionnaire|questionnaire post delivery
219463830|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
219463831|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
219463832|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
219463833|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
219463834|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
219463835|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
218852465|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
218852466|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
218852467|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
218852468|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
219463836|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
219463837|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
219463838|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
219463839|NCT04916106|DEVICE|Transcutaneous Electroacupuncture|give diffrent parameter TEA treatment for 4 weeks.
219463840|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
218852469|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
218852470|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
218852471|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
218852472|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
218852473|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
219463841|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
219463842|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
219463843|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
219463844|NCT00000952|DRUG|Ritonavir|
219463845|NCT00000952|DRUG|Lamivudine|
219463846|NCT00000952|DRUG|Zidovudine|
219463847|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
219463848|NCT04006431|OTHER|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
219463849|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
219463850|NCT03232151|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
218852474|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
218852475|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
218852476|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
218852477|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
218852478|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
218852479|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
218852480|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
218852481|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
219463851|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
219463852|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
219463853|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
219463854|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
219463855|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
219463856|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
219463857|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
219463858|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
219463859|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
219463860|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
219463861|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
219463862|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
219463863|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
219463864|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
219593223|NCT03601130|DEVICE|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
219463865|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
219463866|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
219463867|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
219463868|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
218852482|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
218852483|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
218852484|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
218852485|NCT00000146|DRUG|Methylprednisolone|
218852486|NCT00000146|DRUG|Prednisone|
219198384|NCT02938520|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
219463869|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
219463870|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
219463871|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
219463872|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
219463873|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
219463874|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
219463875|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
219463876|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
219463877|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
219593224|NCT01793948|DRUG|metformin hydrochloride|Given PO
219593225|NCT01793948|OTHER|placebo|Given PO
219593226|NCT01793948|OTHER|laboratory biomarker analysis|Correlative studies
218852487|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
218852488|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
218852489|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
219463878|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
219463879|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
219463880|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
219463881|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
219463882|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
219463883|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
219463884|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
219593227|NCT04060095|PROCEDURE|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
219593228|NCT05968118|DRUG|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
218852490|NCT02227173|DRUG|BMS-986020|
218852491|NCT02227173|DRUG|Montelukast|
218852492|NCT02227173|DRUG|Flurbiprofen|
219463885|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
219463886|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
219463887|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
219463888|NCT03264976|DIAGNOSTIC_TEST|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
218852493|NCT02227173|DRUG|Digoxin|
218852494|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
218852495|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
218852496|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
218852497|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
218852498|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
218852499|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
218852500|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
218852501|NCT00174863|DRUG|SR31747A|
218852502|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
218852503|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
219593229|NCT05968118|DRUG|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
219198385|NCT02938520|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
219198386|NCT02938520|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
219198387|NCT02938520|DRUG|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
219198388|NCT02938520|DRUG|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
219463889|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
219593230|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
218852504|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
219593231|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
219593232|NCT01239108|DRUG|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
219593233|NCT06223386|BEHAVIORAL|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
218852505|NCT04029389|DEVICE|Injection|Local corticosteroid injection
218852506|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
218852507|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
218852508|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
218852509|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
218852510|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
219198389|NCT06420830|PROCEDURE|SAPIEN 3 Ultra RESILIA Valve|Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
219198390|NCT06608303|DRUG|Topical Human Granulocyte Macrophage Stimulating Factor Gel|Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
219198391|NCT06608303|DRUG|Saline (NaCl 0,9 %) (placebo)|placebo
219198392|NCT04499638|DEVICE|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
219463890|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
218852511|NCT01686750|BEHAVIORAL|Integrated care centers|
218852512|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
218852513|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
218852514|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
218852515|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
218852516|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
219463891|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
219463892|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
219463893|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
219463894|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
219463895|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
219463896|NCT00636116|BIOLOGICAL|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
219463897|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
219463898|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
219463899|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
219463900|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
219463901|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
219593234|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
218852517|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
218852518|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
218852519|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
218852520|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
218852521|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
218852522|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
218852523|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
218852524|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
218852525|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
218852526|NCT05154136|DRUG|Etrumadenant|Capsule
218852527|NCT05154136|DRUG|Itraconazole|Capsule
218852528|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
218852529|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
218852530|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
219463902|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
219463903|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
219463904|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
219463905|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
219463906|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
219463907|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
219463908|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
219463909|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
219463910|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
219463911|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
219463912|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
219463913|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
219463914|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
219463915|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
219463916|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
219463917|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
219463918|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
219463919|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
219463920|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
219463921|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
219463922|NCT01365897|DRUG|Modafinil|Modafinil 200mg
219463923|NCT04047342|BEHAVIORAL|Welcome email|Email
218852531|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
218852532|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
218852533|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
219463924|NCT04047342|BEHAVIORAL|Loss frame|Email
219463925|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
219463926|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
219593235|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
219593236|NCT06223386|BEHAVIORAL|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
218852534|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
218852535|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
219463927|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
219463928|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
219463929|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
219463930|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
219463931|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
219463932|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
219463933|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
219463934|NCT02966912|OTHER|Open label (none)|
219463935|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
219463936|NCT01742013|DRUG|Placebo|Comparator
219463937|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
219463938|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
219593237|NCT01188512|BIOLOGICAL|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
219199477|NCT06869096|PROCEDURE|Intraoperative area irrigation|After colorectal cancer surgery, flush the surgical area with chlorhexidine solution 1 minute before suturing the skin. According to abdominal cavity contamination, bleeding and tumor invasion to determine the flushing time and flush fluid volume. If the abdominal cavity infection is more serious or exudate more, the flushing time can be relatively prolonged. At last, there were no obvious blood residue, tissue fragments and suppurative secretions in abdominal cavity. Ensure that the surgical field of vision is clear, the surface of each organ is smooth, and there is no abnormal exudate.
219463939|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
219463940|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
219463941|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
219463942|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
219463943|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
219463944|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
219463945|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
219463946|NCT02554916|DEVICE|Dual-Belt Treadmill|
219463947|NCT00106496|DRUG|Protopic|topical
219463948|NCT00106496|DRUG|Corticosteroid|topical
219463949|NCT00106496|DRUG|placebo|topical
219463950|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
219463951|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
219463952|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
219463953|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
218852536|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
218852537|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
218852538|NCT01939002|DRUG|BIIB017|
218852539|NCT01939002|DRUG|naproxen|
218852540|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
219463954|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
219463955|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
219463956|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
219463957|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
219463958|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
219463959|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
219463960|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
219463961|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
219463962|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
219463963|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
219463964|NCT03060109|OTHER|Blood draw within 12 hours of injury|
219463965|NCT01701531|DRUG|RBCPF|
219463966|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
219463967|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
219463968|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
219463969|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
219463970|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
219463971|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
219463972|NCT02984228|BIOLOGICAL|PRP|
219463973|NCT02984228|DRUG|Hyaluronic Acid|
219463974|NCT02984228|DEVICE|Ultrasound|
219593238|NCT01188512|BIOLOGICAL|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
219593239|NCT02673814|BIOLOGICAL|durvalumab|
219593240|NCT02673814|BIOLOGICAL|bavituximab|
219463975|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
219463976|NCT03579862|OTHER|Blood Draw|
219593241|NCT00610610|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
218852541|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
218852542|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
218852543|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
218852544|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
218852545|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
218852546|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
218852547|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
218852548|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
219198393|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
219198394|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
219198395|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
219198396|NCT06608186|DRUG|Cetrorelix drug|a drug injection daily sc. from day 5 of stimulation till hCG trigger day
219198397|NCT06608186|DRUG|Drospirenone drug|A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
219198398|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
219198399|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
219198400|NCT06608030|DRUG|Esketamine|A single dose of 0.3mg / kg esketamine during induction of anesthesia.
219198401|NCT06608030|DRUG|normal saline|Receiving the same volume of normal saline during induction of anesthesia.
219198402|NCT04803604|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
219198403|NCT06607939|DRUG|ORB-021|ORB-021 is dosed via IV infusion
219198404|NCT06606886|DRUG|Tablet Metformin (Group A)|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
219198405|NCT06606886|DRUG|Tablet Hydroxyurea (Group B)|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
219198406|NCT05016856|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System|A personalized and adaptive text message reminder system.
219593242|NCT00610610|DRUG|Placebo|Same shape Placebo
218852549|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
219198407|NCT05016856|BEHAVIORAL|Standard Reminder System (Active Control)|A typical text message reminder system.
219198408|NCT04866641|DRUG|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
219198409|NCT01582867|DEVICE|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B\_HC01"
219198410|NCT04902872|DRUG|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
219198411|NCT05883345|DIAGNOSTIC_TEST|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levels|Endoscopic biopsy
219463977|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
219593243|NCT01635348|BEHAVIORAL|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
219198412|NCT05904691|DRUG|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
219198413|NCT05057572|DRUG|Carvedilol|\- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
219198414|NCT05057572|DRUG|Standard Medical Treatment|"* Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
219198415|NCT05614206|BEHAVIORAL|Behavioral intervention based on Applied Behavior Analysis principles|"Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors."
219198416|NCT06346171|BEHAVIORAL|Virtual Reality Integrative Psychotherapy|"Music therapy: Weightless by Marconi Union plays continuously, bridging VR distraction and psychotherapy.~Before: Patients pick a VR scene (-13 to -10 min), learn VR navigation, and practice 4-7-8 breathing with a VR flower for grounding and resilience (-10 to -9 min). They continue 4-7-8 doing Progressive Muscle Relaxation (4+7 contraction, 8 relaxation), moving from lower body to facial muscles (-8 to -5 min). Values and commitment to action are discussed (-4 to -2 min), emphasizing present-focused thoughts and acceptance (-1 min).~During: Mindfulness and relaxation are encouraged, with PMR during intense moments. Empowerment and procedural feedback are provided (0 to 30/45 min).~After: Debriefing normalizes the experience, reinforcing proactive health actions (35 to 50 min)."
219199478|NCT06870747|DEVICE|use of Transcutaneous electrical neurostimulation|in this study we would like to use for the first time TENS device during non surgical periodontal therapy
219593244|NCT01635348|BEHAVIORAL|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
219593245|NCT04063085|DEVICE|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
219593246|NCT04063085|DEVICE|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
219593247|NCT04063085|OTHER|No treatment|No anti-adhesion agent applied
219593248|NCT04063085|DEVICE|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
219593249|NCT04063085|DEVICE|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
218852550|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
219593250|NCT03900455|DEVICE|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
219593251|NCT03900455|PROCEDURE|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
218852551|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
218852552|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
218852553|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
219198417|NCT06346171|DEVICE|Virtual Reality Distraction|"Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience."
219463978|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
219463979|NCT01196065|DRUG|RO5313534|single oral dose
219463980|NCT01196065|DRUG|memantine|multiple doses to steady state
219463981|NCT00693524|DRUG|tacrolimus|oral
219463982|NCT00693524|DRUG|Anti-IL2R AB|i.v.
219463983|NCT00693524|DRUG|Mycophenolate mofetil|oral
219463984|NCT00693524|DRUG|prednisone|oral
219463985|NCT02174406|PROCEDURE|breast ultrasound|
219463986|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
219463987|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
219463988|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
219463989|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
219463990|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
219463991|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
218852554|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
219463992|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
219198418|NCT02050906|BEHAVIORAL|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
219198419|NCT02050906|BEHAVIORAL|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
219463993|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
219198420|NCT02050906|OTHER|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
218852555|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
219198421|NCT02050906|BEHAVIORAL|telephone based counseling|Undergo behavioral activity and nutritional counseling
219198422|NCT02050906|PROCEDURE|quality-of-life assessment|Ancillary studies
219463994|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
219463995|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
219463996|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
219463997|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
219463998|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
218852556|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
218852557|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
218852558|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
219463999|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
219464000|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
219464001|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
219464002|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
219464003|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
218852559|NCT04048707|DRUG|Angiotensin II|Intravenous
218852560|NCT04048707|DRUG|Midodrine|Pill
218852561|NCT04048707|DRUG|Octreotide|Subcutaneous
218852562|NCT04048707|DRUG|Albumin solution|Intravenous suspension
219464004|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
219464005|NCT00006162|BEHAVIORAL|exercise and diet|
219464006|NCT00036660|DRUG|SarCNU|
218852563|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
218852564|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219464007|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
219464008|NCT03463720|OTHER|Infected|Extremity wound, infected
219464009|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
219464010|NCT01130831|DRUG|Lanthanum carbonate|
219464011|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
219464012|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
219464013|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
219464014|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
218852565|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218852566|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219198423|NCT02050906|OTHER|questionnaire administration|Ancillary studies
218852567|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219464015|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
219464016|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
219464017|NCT00380601|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
219464018|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
219464019|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
219464020|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
219464021|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
219464022|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
219464023|NCT02204267|DEVICE|ECG|
218852568|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
218852569|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
218852570|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
218852571|NCT01868620|DEVICE|Iontophoretic CXL|
219198424|NCT06589687|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under neuraxial anesthetic.
219198425|NCT06588803|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
219464024|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
219464025|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
219464026|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
219464027|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
219464028|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
219464029|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
219464030|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
219464031|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
219464032|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
219464033|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
219464034|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
219464035|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
219464036|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
218852572|NCT01868620|DEVICE|Standard CXL|
218852573|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
218852574|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
218852575|NCT02030197|OTHER|Control Group|no treatment
218852576|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
218852577|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
218852578|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
218852579|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
218852580|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
218852581|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
218852582|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
218852583|NCT01863173|DRUG|metoprolol|using B blocker in patient group
218852584|NCT01863173|DRUG|placebo|placebo to control group
219198426|NCT04807751|DRUG|Delgocitinib cream|Cream for topical application
219198427|NCT04807751|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219464037|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
218852585|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
219198428|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Escalation)|Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.
219464038|NCT00000799|DRUG|Cidofovir|
219464039|NCT00000799|DRUG|Probenecid|
219464040|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
219464041|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
219593252|NCT03830372|DEVICE|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
219198429|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Expansion)|Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
219198430|NCT06592053|PROCEDURE|Breast Cancer Surgery Pain|Factors affecting the occurrence of chronic pain in patients undergoing elective mastectomy surgery will be investigated.
219198431|NCT06030076|DRUG|Tildrakizumab|As provided in real-world clinical practice.
219198432|NCT06593210|BIOLOGICAL|Adjuvant, non-live RSV vaccine|One dose of arexvy vaccine to transplant recipients.
219198433|NCT06470022|DEVICE|Medtronic Evolut FX|TAVI performed with Medtronic Evolut FX
219198434|NCT06470022|DEVICE|Edwards Sapien 3 Ultra Resilia|TAVI performed with Edwards Sapien 3 Ultra Resilia
219198435|NCT06601673|BEHAVIORAL|Cognitive training|The intervention consists of computer-based cognitive training in the areas of attention, processing speed, memory, emotional intelligence, reasoning and orientation. The training takes place under supervision for 120 minutes a day from the first to the fifth postoperative day.
219593253|NCT03830372|OTHER|Control|10 sessions of 20 minutes of Schultz Autogenic Training
219464042|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
219593254|NCT04934059|DRUG|Yuxuebi tablet|0.5g/ tablet
219593255|NCT04934059|DRUG|Placebo tablet|0.5g/ tablet
219593256|NCT06064578|BEHAVIORAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
219593257|NCT02690987|DRUG|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL."
219593258|NCT02690987|BIOLOGICAL|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL."
219593259|NCT02690987|BIOLOGICAL|Saline|The placebo visit will involve an intravenous infusion of normal saline.
219593260|NCT02474277|OTHER|30 sec chair stand test|diagnostic test for functional impairment
219593261|NCT02500043|DRUG|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
218852586|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
219464043|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
218852587|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
219464044|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
218852588|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
218852589|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
218852590|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
219464045|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
219464046|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
219464047|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
219464048|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
218852591|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
218852592|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
219198436|NCT06601673|BEHAVIORAL|Listen to audio book|Here, an audio book is listened to for 2h daily for the first five postoperative days (or until discharge from hospital if earlier). The audio book is brought and set up by study staff.
219198437|NCT06824571|DIETARY_SUPPLEMENT|High-Dose Taurine Supplementation (6g)|Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
219198438|NCT06824571|DIETARY_SUPPLEMENT|Medium-Dose Taurine Supplementation (4g)|Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
219198439|NCT06824571|DIETARY_SUPPLEMENT|Low-Dose Taurine Supplementation (1g)|Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
219198440|NCT06824571|DIETARY_SUPPLEMENT|Placebo (0g Taurine)|Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
219198441|NCT05869487|RADIATION|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
219198442|NCT06274853|DRUG|GS-441524|Oral GS-441524 capsules
219198443|NCT06274853|DRUG|Placebo|Placebo capsules
219464049|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
219464050|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
219464051|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
218852593|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
219464052|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
219464053|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
219464054|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
219464055|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
219464056|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
219464057|NCT02127580|PROCEDURE|BAV|
219464058|NCT02127580|PROCEDURE|without BAV|
219464059|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
219593262|NCT02500043|DRUG|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
219593263|NCT00132860|DRUG|azithromycin|
219593264|NCT04326114|DEVICE|Inspiratory training device|Inspiratory training by a Power-breath device
219593265|NCT04326114|DEVICE|Expiratory training device|Expiratory training a Winner-flow device
219593266|NCT00822796|DEVICE|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
219593267|NCT00822796|DEVICE|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
219593268|NCT03413293|DIAGNOSTIC_TEST|Diagnosis of bacterial infections|Cultures
219593269|NCT03151408|DRUG|Pracinostat|60 mg capsule
219593270|NCT03151408|DRUG|Placebos|capsule
219593271|NCT03151408|DRUG|Azacitidine|SC or IV injection
219593272|NCT02744118|OTHER|5A's Model|"The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
219464060|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
219464061|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
219464062|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
219464063|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
219593273|NCT02744118|OTHER|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication"
219593274|NCT04540679|OTHER|VIP4SCI|Technology-enabled self-management \& rehabilitation solution
219593275|NCT06359106|DRUG|80% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
219593276|NCT06359106|DRUG|40% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
219593277|NCT03730818|OTHER|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
218852594|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
218852595|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
219019819|NCT07072845|BEHAVIORAL|Enhanced Brief Cognitive Behavioral Therapy (E-BCBT) for Suicidal Inpatients|"E-BCBT is a brief, structured cognitive behavioral therapy designed for psychiatric inpatients at risk of suicide. The primary goals are to reduce the risk of suicide attempts after discharge, improve problem-solving and coping with recent stressors related to suicidal crises, and help patients shift from maladaptive suicidal modes to more adaptive cognitive and behavioral patterns. The intervention consists of five individual sessions (approximately 50-60 minutes each) delivered during hospitalization. It includes two sessions on crisis management, two sessions on cognitive and behavioral strategies, and one relapse prevention session. Each session incorporates psychoeducation, skill-building, and worksheet-based self-practice to enhance self-regulation and promote continued use after discharge."
219198444|NCT06820983|OTHER|adult questionnary for parents of children aged 8 to 13|Quality of life questionnaire for parents of children aged 8 to 13
219019820|NCT07072845|OTHER|Treatment as Usual (TAU)|TAU is based on a short-term inpatient stabilization model and includes 24-hour multidisciplinary care provided by the psychiatric ward. Individualized treatment may involve pharmacotherapy, occupational therapy, and supportive psychotherapy, depending on patient needs and hospital protocols.
219198445|NCT06820983|OTHER|Quality of life questionnaire for children aged 8 to 13|Quality of life questionnaire for children aged 8 to 13
219198446|NCT06820983|OTHER|Quality of life questionnaire for adolescents aged 14 to 17|Quality of life questionnaire for adolescents aged 14 to 17
219464064|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
219019821|NCT06769048|DRUG|Placebo-matching BI 1584862|Placebo-matching BI 1584862
219019822|NCT06769048|DRUG|BI 1584862|BI 1584862
219464065|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
219464066|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
219464067|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
219464068|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
219464069|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
219464070|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
219593278|NCT03730818|OTHER|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
219593279|NCT03578575|DRUG|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
219593280|NCT03578575|DRUG|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
219198447|NCT06820983|OTHER|Quality of life questionnaire for adults|Quality of life questionnaire for adults
219198448|NCT06820983|OTHER|A satisfaction adherence questionnaire|A satisfaction adherence questionnaire will also be distributed to patients after several months' use of oscillating PEP
219199479|NCT06870747|DEVICE|no TENS during non-surgical periodontal therapy|patients in the control group are going to have non surgical periodontal therapy without TENS
219593281|NCT01723618|DRUG|CRD007|
219593282|NCT00493415|DRUG|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
219593283|NCT00493415|DRUG|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
219464071|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
219464072|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
218852596|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
219464073|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
219464074|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
219464075|NCT02206230|RADIATION|Hypofractionated radiation therapy|
219464076|NCT02206230|RADIATION|Standard radiation therapy|
219464077|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
219464078|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
219464079|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
218852597|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
218852598|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
218852599|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
218852600|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
218852601|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
218852602|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
218852603|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218852604|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218852605|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218852606|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
218852607|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
218852608|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
219464080|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
219464081|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
219464082|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
219464083|NCT00003824|PROCEDURE|surgical procedure|
219464084|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
218852609|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
218852610|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
218852611|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
219198449|NCT06816589|BEHAVIORAL|ChatGPT-based job coaching|Using ChatGPT for creating job resumes, discussing job types, preparing and practicing for job interviews, writing job descriptions for individuals with Asperger's syndrome, and discussing workplace social interactions
219464085|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
219464086|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
219464087|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
219464088|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
219464089|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
219464090|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
219464091|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
219464092|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
219464093|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
219464094|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
219464095|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
219464096|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
219464097|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
219464098|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
219464099|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
218852612|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
219198450|NCT06820567|DRUG|Dapagliflozin (DAPA)|patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients
219464100|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
219464101|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
219464102|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
219464103|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
219464104|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
219593284|NCT04084093|DEVICE|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
219593285|NCT02346266|OTHER|SMART Education|
219593286|NCT05496660|OTHER|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
219198451|NCT06820567|DRUG|Placebo|type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks
219464105|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
219464106|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
219464107|NCT00405795|DEVICE|Envision® Patient Support System|
219464108|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
219464109|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
219464110|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
219464111|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
219464112|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
219464113|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
219464114|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
219464115|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
219464116|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
219593287|NCT05496660|OTHER|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
219593288|NCT00746876|DEVICE|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
219593289|NCT00746876|DEVICE|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
219464117|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
219464118|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
219464119|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
219464120|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
219464121|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
219464122|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
219464123|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
219464124|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
219593290|NCT02235090|OTHER|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
219593291|NCT01478165|DRUG|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
219593292|NCT01478165|DRUG|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
219593293|NCT03206463|DRUG|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
219464125|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
219464126|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
219464127|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
219464128|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
219464129|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
219464130|NCT00300794|DRUG|Ketamine|
219464131|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
219464132|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
219464133|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
219464134|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
219464135|NCT00377273|DRUG|fluorouracil cream 0.5%|
219464136|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
219464137|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
219464138|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
219464139|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
219464140|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
219464141|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
218852613|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
219464142|NCT02078674|BIOLOGICAL|Placebo|
219464143|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
219464144|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
219464145|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
219464146|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
219464147|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
218852614|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
218852615|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
218852616|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
218852617|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
218852618|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
219019830|NCT06780215|DRUG|Varenicline Tartrate Tablets|"Participants in treatment group take varenicline tartrate tablets according to the following regimen:~Days 1-3: 0.5 mg/dose, once daily. Days 4-42: 0.5 mg/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 0.5 mg/dose, once daily."
219019831|NCT06780215|DRUG|Placebo|"Days 1-3: 1 tablet/dose, once daily. Days 4-42: 1 tablet/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 1 tablet/dose, once daily."
219464148|NCT00367146|DRUG|MMF|
219464149|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
219464150|NCT00021346|DRUG|carboplatin|
219464151|NCT00021346|DRUG|gemcitabine hydrochloride|
219464152|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
219464153|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
218852619|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
219464154|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
219464155|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
219464156|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
219464157|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
219464158|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
219464159|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
219464160|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
219464161|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
219464162|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
219464163|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
219464164|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
219464165|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
219464166|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
219464167|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
219593294|NCT03206463|DRUG|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
219593295|NCT03206463|DRUG|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
219593296|NCT02771535|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
219593297|NCT02771535|BEHAVIORAL|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
219593298|NCT02936414|DRUG|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
219593299|NCT02936414|DRUG|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
219019841|NCT06781879|DRUG|Mitomycin c|Chemoablation
218852620|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
219464168|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
219464169|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
219464170|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
219593300|NCT01235195|DRUG|sertraline hydrochloride|50 mg capsule, single-dose
219593301|NCT01235195|DRUG|sertraline hydrochloride|50 mg tablet, single-dose
219593302|NCT01473524|DRUG|Obeticholic Acid (OCA)|OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
219198452|NCT06603766|DRUG|IV Magnesium Sulfate|MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
219198453|NCT06603766|DRUG|Inhalational magnesium sulfate|It gives us the same mechanism of action as IV MgSO4 with less side effects.
219198454|NCT05271097|OTHER|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
219198455|NCT05271097|OTHER|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
219198456|NCT06598657|OTHER|Mobilization with Movement MWM|Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.
219198457|NCT06598657|OTHER|Conventional Treatment|"* Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week"
219198458|NCT06586541|OTHER|Participation in attending team rounds|Family members can participate both in-person and virtually, which can vary daily if desired. If the family member wishes to participate in-person, they will be invited to be present when the team rounds in the ICU. If the family member wishes to participate virtually, they will be provided with a personalized link by email to attend rounds.
219198459|NCT06602375|OTHER|Standard care|The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
219464171|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
219464172|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
219464173|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
219464174|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
219464175|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
219464176|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
219464177|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
219593303|NCT01473524|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
219593304|NCT03870867|OTHER|No intervention|No intervention
219593305|NCT04287335|DIAGNOSTIC_TEST|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
219593306|NCT04287335|DIAGNOSTIC_TEST|FIT|fecal immunochemical test
219593307|NCT04287335|PROCEDURE|Colonoscopy|diagnostic colonoscopy
219593308|NCT00140218|DRUG|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
219593309|NCT00006216|BIOLOGICAL|PA-1-STK ovarian carcinoma vaccine|
219593310|NCT00006216|DRUG|ganciclovir|
219593311|NCT06447311|OTHER|Hyaluronic acid gel|Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
219593312|NCT06633328|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with severe aplastic anemia
219593313|NCT06633328|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
219593314|NCT02410980|DRUG|Tretinoin cream 0.1%|Assessment of the skin change
219593315|NCT02383810|DRUG|Elsiglutide|
219593316|NCT02383810|DRUG|Placebo|
219593317|NCT01046786|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
219464178|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
219464179|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
219464180|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
219464181|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
219464182|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
219464183|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
219464184|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
219464185|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
219464186|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
219464187|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
219464188|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
219464189|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
219593318|NCT01046786|DRUG|Methylprednisolone|30 mg/kg methylprednisolone
219593319|NCT01046786|DRUG|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
219593320|NCT05794360|BEHAVIORAL|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
219593321|NCT01782235|DRUG|Tocilizumab|
219464190|NCT01738906|OTHER|Orange juice|
218852621|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
219464191|NCT01738906|OTHER|maltodextrin|
219464192|NCT01738906|OTHER|Vodka|
219464193|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
219464194|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
219464195|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
219464196|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
219464197|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
219593322|NCT01782235|DRUG|Placebo|
219593323|NCT01911286|PROCEDURE|Apnea test - Standard|
219464198|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
219464199|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
219593324|NCT01911286|PROCEDURE|Apnea test - CPAP|
219593325|NCT02549586|DRUG|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
219593326|NCT01194986|OTHER|[11C]AZ12807110|Radioligand
219593327|NCT01194986|DRUG|AZD5213|
219198460|NCT06602375|OTHER|Physical Therapy (PT)|Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
219198461|NCT06592183|BEHAVIORAL|Smart-phone based, self-driven speech rehabilitation|Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
219198462|NCT06604637|OTHER|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|taVNS will be applied for a total of 12 sessions, 20 minutes each session, 3 days/week.
219198463|NCT06824792|DRUG|Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.|Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.
219198464|NCT06824935|PROCEDURE|Anesthesia|The study planned to investigate the anesthesia requirements and frequency and the risk factors that play a role in the anesthesia of patients who had completed preoperative anesthesia evaluation and were going to undergo outpatient cataract surgery.
219198465|NCT06824844|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
219198466|NCT06824844|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
219198467|NCT06825169|BIOLOGICAL|NCR101 injection|Subjects will receive one NCR101 injection in Single Ascending Dose（SAD）and receive 4 NCR101 injections in Multiple Ascending Dose(SAD).
219198468|NCT06597071|OTHER|NeuraLight PD|NeuraLight software-based platform for PD patients
219198469|NCT06597071|OTHER|NeuraLight PSP|NeuraLight software-based platform for PSP patients
219198470|NCT06597071|OTHER|NeuraLight MSA|NeuraLight software-based platform for MSA patients
219198471|NCT06597071|OTHER|NeuraLight|NeuraLight software-based platform
219198472|NCT06589297|DIAGNOSTIC_TEST|Modified Rankin scale|Acute stroke patients will undergo modified rankin scale
219199480|NCT06871345|OTHER|Semi-structured interviews SCID|"Structured Clinical Interview for DSM-5 Personality Disorder (SCID) :~The SCID is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-5. Each item is rated on a three-point scale: absent, subclinical level and present."
219464200|NCT03162380|OTHER|Date collection|Date collection
219464201|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
219464202|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
219464203|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
219593328|NCT01327508|DEVICE|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
219593329|NCT01327508|OTHER|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
219593330|NCT00282919|DRUG|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
219593331|NCT04840537|PROCEDURE|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
219593332|NCT01413607|DEVICE|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
219593333|NCT01413607|DEVICE|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
219464204|NCT06313567|OTHER|Observation|observation
219464205|NCT02218424|DRUG|Magnesium|
219464206|NCT02218424|DRUG|Normal saline|
219464207|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
219464208|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
219464209|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
219464210|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
219464211|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
219464212|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
219464213|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
219464214|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
219464215|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
219464216|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
219464217|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
219464218|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
219464219|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219464220|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219464221|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
219464222|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
219464223|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
219464224|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
219464225|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
219198473|NCT06820346|OTHER|Manual and instrumental evaluation of hip adduction|The intervention consists of a new manual test for assessing iliotibial band (ITB) tension and hip abductor extensibility. The patient lies supine on the edge of a treatment table with the non-tested leg flexed at the hip and knee, stabilizing the pelvis. The tested leg remains extended. The examiner stabilizes the non-tested leg with one hand and adducts the tested leg until a resistance is felt, ensuring no pain. The hip adduction angle is visually assessed and recorded. A subset of participants also undergoes the modified Ober test for comparison. Inertial motion sensors are used to validate the accuracy of visual assessments. The primary outcomes include intra-rater and inter-rater reliability, while secondary outcomes evaluate the test's accuracy and pelvic movement reduction.
219198474|NCT06825988|DEVICE|Grasp|Grasp system (hardware and mobile application) during first 6 postsurgical weeks of rehabilitation. Subjects are instructed to report pain through squeezing the hardware in 3 different levels regulaly during the day, and, in addition enter answers to questions on patient reported outcome meassures (sleep quality, overall well-being, use of medication, appetit, physical activity) and register exercise time into the mobile application.
219198475|NCT06825429|PROCEDURE|exercise programme for group with ECOG 0-1|exercise programme for group with ECOG 2
219464226|NCT00115622|DRUG|fluticasone furoate|
219464227|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
219464228|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
219464229|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
219464230|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
219464231|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
219464232|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
219464233|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
219464234|NCT00000662|DRUG|Zidovudine|
219593334|NCT02935153|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
219464235|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
219464236|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
219464237|NCT01213511|PROCEDURE|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
219464238|NCT01213511|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
219464239|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
219464240|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
219464241|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
219464242|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
219464243|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
219464244|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
219464245|NCT02409251|BEHAVIORAL|Education and feedback|
219464246|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
219464247|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
219464248|NCT02582008|DRUG|Nicotine Replacement|Given NRT
219198476|NCT06825429|PROCEDURE|exercise programme for ECOG 2 group|this intervention shall be proportionated to the ECOG status of the group
219198477|NCT06816862|DEVICE|SYMPHONY™ OCT System|Internal fixation system for surgical stabilisation of upper spine instabilities
219198478|NCT06819358|DEVICE|Transcranial Magnetic Stimulation|Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of TMS treatment, while patients in Group B will receive sham stimulation with the same frequency. After a 4-week washout period, the two groups cross over. Patients in Group A will receive sham stimulation, and patients in Group B will receive TMS treatment for 2 weeks (10800 Hz daily, 5 days×2).
219464249|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
219198479|NCT06593769|DIETARY_SUPPLEMENT|whey-protein microgel|The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.
219198480|NCT06593769|OTHER|Placebo|Water (isovoloumous amount)
219198481|NCT06600880|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
219198482|NCT06600880|DRUG|Lumason|New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.
219199481|NCT06871345|OTHER|Self-report questionnaires|Participants will complete a battery of self-report questionnaires, assessing emotional dysregulation (including SRD, the primary endpoint), childhood adversity, anxiety, depression, and premenstrual symptoms.
219464250|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
219464251|NCT02582008|DRUG|Varenicline|Given PO
219464252|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
219464253|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
219464254|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
219464255|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
219464256|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
219464257|NCT04591704|OTHER|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
219464258|NCT02300844|DRUG|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
219464259|NCT02300844|DRUG|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
219464260|NCT01475227|DRUG|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
219464261|NCT01475227|DRUG|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
219464262|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
219464263|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
219198483|NCT06600880|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|"A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York."
219198484|NCT06600880|RADIATION|Positron Emission Tomography (PET)|A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
219198485|NCT06600880|DRUG|Amyvid|Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.
218852622|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
219464264|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
219464265|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
218852623|NCT00444704|DRUG|PRA-027|
218852624|NCT00563069|DRUG|Midazolam|
219464266|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
219464267|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
219464268|NCT07058740|PROCEDURE|early cholangiography|We perform cholangiography on the early group in advance
219464269|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
219464270|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
219464271|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
219464272|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
219464273|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
219464274|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
219464275|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
219464276|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
219464277|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
218852625|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
219198486|NCT06600880|DRUG|MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
219198487|NCT06600880|DRUG|Dotarem|FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.
218852626|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
219464278|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
219464279|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
219464280|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
219464281|NCT03968588|DRUG|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
219464282|NCT03968588|DRUG|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
219464283|NCT04840914|DRUG|LY3461767|Administered SC.
219464284|NCT04840914|DRUG|Placebo|Administered SC.
219464285|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
219464286|NCT00078455|DRUG|ILX651|
219464287|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
219464288|NCT01197495|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
219464289|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
219464290|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
219464291|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
219464292|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
219464293|NCT00726167|DEVICE|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
219464294|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
218852627|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
219464295|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
219464296|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
219464297|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~\- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
219464298|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
219593335|NCT06048965|OTHER|No intervention to be performed|No intervention to be performed. Anonymous survey only.
219198488|NCT06600880|DIAGNOSTIC_TEST|Blood draw|Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.
219198489|NCT06600880|DEVICE|UR5e|Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.
219198490|NCT06600880|DIAGNOSTIC_TEST|Urine test|Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
219198491|NCT06594744|PROCEDURE|Endoscopic variceal ligation|EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.
219198492|NCT06594744|DRUG|Carvedilol|The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
219198493|NCT06587529|BEHAVIORAL|The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum|Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
219464299|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
219464300|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
219464301|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
219464302|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
219464303|NCT00175552|BEHAVIORAL|Psychotherapy Training|
219464304|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
219464305|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
219464306|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
219464307|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
219464308|NCT05664412|DEVICE|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
219464309|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
219464310|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
219464311|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
219464312|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
219464313|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
219464314|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
219464315|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
219464316|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
219464317|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
219464318|NCT00211133|DRUG|epoetin alfa|
219464319|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
219464320|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
219464321|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
219464322|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
219464323|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
219464324|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
219464325|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
219593336|NCT04395144|PROCEDURE|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
219593337|NCT04395144|PROCEDURE|Standard care|Patients will not receive any special instructions with regards to proning.
219593338|NCT01750489|DEVICE|non-invasive ventilation (NIV)|
219593339|NCT01967914|OTHER|PVI|Measurement of PVI (plethysmography variability index)
219593340|NCT02378792|DEVICE|Vagus Nerve Stimulation|Vagus Nerve Stimulator
219593341|NCT03479567|OTHER|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
219593342|NCT03479567|OTHER|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
219198494|NCT06600074|BEHAVIORAL|Back care advice|All patients in both groups will be advised to use proper lifting techniques, avoid prolonged sitting or standing, maintain a healthy weight, quit smoking, practice good posture, take breaks, spread housekeeping duties over the whole week, and sleep in supportive positions.
219198495|NCT06600074|OTHER|Postural correction exercises|All patients in both groups will be instructed to perform postural correction exercise. They will be performed from different positions (crock lying, supine lying, supine, sitting and standing position). They will lie in crock lying position for example and the physical therapist will instruct them to do chin in , open out ribs through costal breathing, contract abdominal muscles, contract glutei, hold for 6 seconds and relax and repeat 10 times.
219198496|NCT06600074|OTHER|Retro-walking|Patients in the experimental group only will practice walking backward on a treadmill, starting with a 5-minute warm-up at a self-selected speed, then gradually increasing speed from 1.2 to 1.6 m/s based on comfort and progress.
219198497|NCT06597682|DRUG|Prednisone|Total 4 weeks of treatment
219198498|NCT06597682|DRUG|Budesonide/Formoterol|Total 8 weeks of treatment
219198499|NCT06597682|DRUG|Vitamin C combined with Coenzyme Q10 oral treatment|Total 4 weeks of treatment
219198500|NCT06597682|DRUG|Montelukast tablets oral treatment|Total 8 weeks of treatment
219464326|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
219464327|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
219464328|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
219464329|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
219464330|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
219464331|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
219464332|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
219593343|NCT03479567|OTHER|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
219593344|NCT03479567|DIAGNOSTIC_TEST|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
218852628|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
218852629|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
219464333|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
219464334|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
219464335|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
219464336|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
219464337|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
219593345|NCT03479567|OTHER|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
219198501|NCT06599931|DEVICE|tACS Transcranial alternating stimulation|session of 20 minutes
219198502|NCT06594757|PROCEDURE|Toothbrushing with triple-headed manual toothbrush|Toothbrushing with triple-headed manual toothbrush
219198503|NCT06594757|PROCEDURE|Toothbrushing with standard manual toothbrush|Toothbrushing with tstandard manual toothbrush
219198504|NCT06444594|DRUG|TRPM8 Agonist|menthol gel 4-10%
218852630|NCT00436423|DRUG|gemcitabine, TS-1|
218852631|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
218852632|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
218852633|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
219198505|NCT06444594|DRUG|TRPV1 Agonist|camphor gel 5-20%
218852634|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
218852635|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
218852636|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
219198506|NCT06444594|DRUG|TRPV4 Agonist|capsaicin gel 0.05-1%%
219198507|NCT06444594|DRUG|TRPM8, TRPV4, TRPV1 Agonists|menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
219464338|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
219464339|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
218852637|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
218852638|NCT00132756|DRUG|Doxil and Estramustine|
218852639|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
218852640|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
218852641|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
218852642|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
219198508|NCT06444594|OTHER|Vehicle gel|Inactive vehicle gel
219464340|NCT05483062|OTHER|galla chinensis|toothpaste
219464341|NCT05483062|OTHER|Stannous fluoride|Toothpaste
219198509|NCT06097494|OTHER|No intervention|Observational analysis of usual care only.
219198510|NCT06588595|DRUG|Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
219198511|NCT06588595|DRUG|Aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
219198512|NCT06597344|DRUG|Gepotidacin|Gepotidacin will be administered.
219198513|NCT06589765|DRUG|HRS-7535 tablet|HRS-7535 tablet
219464342|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
218852643|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
218852644|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
219464343|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
219198514|NCT06589765|DRUG|dapagliflozin tablet|dapagliflozin tablet
219198515|NCT06587464|OTHER|No Intervention|This is a non-interventional study.
219464344|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
219464345|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
219464346|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
219464347|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
219464348|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
219464349|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
219464350|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
219464351|NCT01974310|PROCEDURE|Postoperative face-down positioning|
219464352|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
219464353|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
219464354|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
219464355|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
219464356|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
219464357|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
219464358|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219464359|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
218852645|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
218852646|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
218852647|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
218852648|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
218852649|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
219198516|NCT06599359|BEHAVIORAL|BLISS Questionnaire|"After extensive literature review and review from the IRB of the Lebanese University. A questionnaire was developed to assess the Intention to leave, job stress, burnout, and job satisfaction among pharmacists in Lebanon~The following sections will be considered:~* Socio-economic characteristics~* Work-related characteristics~* Job stress assessment (Likert scale)~* Burnout assessment (Likert scale)~* Intention to Leave assessment (Likert scale)"
219198517|NCT06601842|DEVICE|ICP monitoring|ICP monitoring
219198518|NCT06597409|OTHER|Standard PR|(Aerobic exercise, PLB, ACBT, Education)
219198519|NCT06597409|OTHER|Standard PR plus Respiratory Muscle Stretching (RMS)|Standard PR plus Respiratory Muscle Stretching (RMS)
219198520|NCT06857305|DRUG|Eribulin biweekly regimen|Eribulin biweekly regimen
219198521|NCT06857305|DRUG|Eribulin standard regimen|Eribulin standard regimen
219199482|NCT06871345|OTHER|Cognitive assessment|"Cognitive assessment, coupled with the recording of physiological parameters (Biopac).~Participants will complete a battery of neuropsychological tests targeting emotional processes. These tests will make it possible to evaluate the hot component of executive functioning, i.e. specifically involved in the processing of socio-emotional information. Autobiographical verbal fluences and the emotional Hayling test will be used to measure initiation and inhibition processes, respectively."
219464360|NCT02399345|DRUG|ribavirin (RBV)|tablet
219464361|NCT00039377|DRUG|imatinib mesylate|Given PO
219464362|NCT00039377|DRUG|methotrexate|Given IT and IV
219464363|NCT00039377|DRUG|vincristine sulfate|Given IV
219464364|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
219464365|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
219464366|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
219464367|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
219464368|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
218852650|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
218852651|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
218852652|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
218852653|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
218852654|NCT00118313|BIOLOGICAL|sargramostim|
218852655|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
218852656|NCT00118313|DRUG|dimethyl sulfoxide|
219464369|NCT00039377|DRUG|tacrolimus|Given IV or PO
219464370|NCT00039377|BIOLOGICAL|filgrastim|Given SC
219464371|NCT00039377|DRUG|etoposide|Given IV
219464372|NCT00039377|DRUG|cyclophosphamide|Given IV
219464373|NCT00039377|DRUG|cytarabine|Given IV
219464374|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
219464375|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
219464376|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
218852657|NCT00118313|DRUG|imiquimod|
218852658|NCT00118313|PROCEDURE|adjuvant therapy|
218852659|NCT00068913|DRUG|Dichloroacetate|
218852660|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
218852661|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
218852662|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
218852663|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
218852664|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
218852665|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
218852666|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
218852667|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
219464377|NCT04620005|OTHER|Observational|Survey
219464378|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
219464379|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
219464380|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
219464381|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
218852668|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
218852669|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
218852670|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
218852671|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
218852672|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
218852673|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
218852674|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
218852675|NCT05933642|DRUG|Frusemide|frusemide 120mg
218852676|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
218852677|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
218852678|NCT03602313|DEVICE|Body Weight Support Gait Training|
218852679|NCT03602313|OTHER|Traditional Gait Training|
219199483|NCT06871345|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed between visits V1 and V4 in order to assess the emotional and symptomatic dynamics in a context of daily life. During two menstrual cycles, subjects will be invited, via their smartphone, to take daily semi-random readings (indicated by SMS) of their subjective (4 times/day), but also spontaneous emotional experiences
219464382|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
218852680|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
218852681|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
218852682|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
219464383|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
219464384|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
219464385|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
219464386|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
219464387|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
219464388|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
219464389|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
219464390|NCT03326882|DEVICE|Endotracheal intubation|
219464391|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
219464392|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
219464393|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
219464394|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
219593346|NCT03608865|DRUG|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
218852683|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
218852684|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
218852685|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
218852686|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
218852687|NCT06767917|DEVICE|Eyefill® S.C.|Used as viscoelastic devices during cataract surgery
218852688|NCT06767917|DEVICE|Eyefill® M.B.|Used as viscoelastic devices during cataract surgery
219464395|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
219464396|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
219464397|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
219464398|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
219464399|NCT02493712|DRUG|Placebo|Placebo
219464400|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
219464401|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
219464402|NCT02452138|OTHER|Severe sepsis management|
219593347|NCT03278392|BEHAVIORAL|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
219593348|NCT03278392|BEHAVIORAL|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
218852689|NCT06826677|DRUG|Durvalumab|PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY
218852690|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
218852691|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
219464403|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
219464404|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
219198522|NCT05106036|OTHER|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
219198523|NCT06820359|OTHER|Bowel Preparation|Individuals will perform a bowel preparation using a Fleet saline enema.
219198524|NCT06820359|OTHER|No bowel preparation|Subjects will not be required to perform bowel preparation before surgery.
219198525|NCT06599528|DRUG|T-R (Test-Reference drug)|T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
219198526|NCT06599528|DRUG|R-T (Reference-Test drug)|R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
219464405|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
218852692|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
219464406|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
219464407|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
219593349|NCT05800158|DIAGNOSTIC_TEST|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
218852693|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
218852694|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
218852695|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
218852696|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
218852697|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
218852698|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
218852699|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
218852700|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
218852701|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
218852702|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
218852703|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
218852704|NCT00127309|DRUG|Glutathione|
218852705|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
218852706|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
218852707|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
218852708|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
218852709|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
218852710|NCT00303446|DRUG|Placebo|Matched placebo
219198527|NCT06589128|DIETARY_SUPPLEMENT|Astaxanthin Oral Capsule|Once daily supplementation of oral astaxanthin capsule for 24 weeks
219198528|NCT06589128|DIETARY_SUPPLEMENT|Placebo|Once daily supplementation of olive oil capsule for 24 weeks
219199484|NCT06870695|PROCEDURE|Electrocautery|Patients undergoing standard surgical de-epithelization with electrocautery.
219464408|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
219464409|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
219593350|NCT00581165|DRUG|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
219593351|NCT02456935|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
219593352|NCT02456935|DRUG|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
219464410|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
219464411|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
219464412|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
219464413|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
219464414|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
219464415|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
219464416|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
219464417|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
219464418|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
219464419|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
219464420|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
219593353|NCT02861014|BIOLOGICAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
219464421|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
219464422|NCT00002600|BIOLOGICAL|filgrastim|
219464423|NCT00002600|DRUG|carboplatin|
218852711|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
219199485|NCT06870695|PROCEDURE|Surgical blade by scalpel|Patients undergoing standard surgical de-epithelization using surgical blade by scalpel.
219199486|NCT06869668|OTHER|Correlation|Correlation between outcomes
219464424|NCT00002600|DRUG|cyclophosphamide|
219464425|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
219464426|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
219464427|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
219464428|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
219464429|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
219464430|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
219464431|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
219464432|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
219464433|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
219593354|NCT00002780|BIOLOGICAL|aldesleukin|
219593355|NCT00002780|BIOLOGICAL|cytokine therapy|
219593356|NCT00002780|BIOLOGICAL|sargramostim|
219593357|NCT00002780|DRUG|carboplatin|
219593358|NCT00002780|DRUG|cyclophosphamide|
219593359|NCT00002780|DRUG|thiotepa|
219593360|NCT00002780|PROCEDURE|peripheral blood stem cell transplantation|
219593361|NCT00926783|PROCEDURE|CFAE ablation|CFAE ablation (targeted vs. generalized)
219593362|NCT00236912|DRUG|levofloxacin; metronidazole|
219593363|NCT04321681|OTHER|no intervention|no intervention
219593364|NCT05577221|DEVICE|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
219593365|NCT00219817|DRUG|RC-1291 HCl|
219593366|NCT01819870|DRUG|Dilatrend SR capsule 32mg|"* 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)"
219593367|NCT01819870|DRUG|Dilatrend IR tablet 25mg|"* 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)"
219593368|NCT02023294|PROCEDURE|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
219464434|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
219464435|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
218852712|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
218852713|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
218852714|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
219464436|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
219464437|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
219464438|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
219464439|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
219464440|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
219464441|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
219464442|NCT02583854|DEVICE|RY-STOP hemostasis device|
219464443|NCT02583854|DEVICE|TR-Band, Terumo|
219464444|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
219593369|NCT02023294|PROCEDURE|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
219593370|NCT04522817|BIOLOGICAL|CLBS119|Peripheral blood derived autologous CD34+ cells
219593371|NCT00235209|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
219593372|NCT02546466|PROCEDURE|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
219593373|NCT02546466|PROCEDURE|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
219199487|NCT06870370|DRUG|propranolol|This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg
219199488|NCT06870370|DRUG|normal saline IV|This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days
219199489|NCT06870942|DRUG|Maintenance first-line treatment plus radiation therapy|Maintenance first-line treatment plus radiation therapy
219199490|NCT06868732|DRUG|JSKN016|Administered intravenously according to protocol.
219464445|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
219464446|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
219464447|NCT00466284|DRUG|Tarceva (erlotinib)|
219464448|NCT05141110|DRUG|NVP-1705|NVP-1705
218852715|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
218852716|NCT00428220|DRUG|sunitinib|sunitinib
218852717|NCT02691403|DRUG|levo-bupivacaine|
218852718|NCT02691403|DRUG|normal saline|
218852719|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
218852720|NCT04054804|DIAGNOSTIC_TEST|D-Foot|A digital foot check i assessed by using the software D-Foot.
218852721|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
218852722|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
219464449|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
219464450|NCT01020812|PROCEDURE|TACE|Standard of Care
219464451|NCT01020812|PROCEDURE|SBRT|Standard of Care
219464452|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
219198529|NCT06597981|BEHAVIORAL|Dyadic empowerment-based sport stacking|For the intervention group, the care dyads will receive an 18-week dyadic empowerment-based sport stacking program, which is divided into two phases: the active phase (weeks 1-12) and the maintenance phase (weeks 13-18). In the active phase, the care dyads will engage in three online sessions in small groups (3-5 dyads/group) and three check-up/support sessions. Three online sessions will be scheduled at weeks 1, 3, and 9 during the 12-week active phase. They will also be required to engage in self-practice at home for at least 30 minutes per day, five times per week during this time according to their training schedule. In the maintenance phase, there will be three online sessions in small groups (3-5 dyads/group). Three online sessions will be scheduled at weeks 13, 16, and 18. The dyads will continue their self-practice at home (at least 30 minutes/day, five times/week) for 6 weeks.
218852723|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
219464453|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
219464454|NCT00158002|DRUG|Topiramate|
219464455|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
219464456|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
219464457|NCT00042575|DRUG|Duloxetine|
218852724|NCT03879304|OTHER|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
218852725|NCT03879304|OTHER|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
218852726|NCT04204356|BEHAVIORAL|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
219464458|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
219464459|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
219464460|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
219464461|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
219464462|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
219464463|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
219464464|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
219464465|NCT02528643|DRUG|Enzalutamide|Oral capsule
219464466|NCT02528643|DRUG|Placebo|Oral capsule
219464467|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
219464468|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
219198530|NCT06597981|OTHER|Basic education|Participants in the control group will receive basic education on dementia caregiving, which will comprise three group-based (3-5 dyads/group) online meetings in the same schedule as the intervention group (1st, 3rd, 9th week).
219198531|NCT04861636|BEHAVIORAL|HealthTRAC|Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
219198532|NCT04861636|BEHAVIORAL|SBWC|Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
218852727|NCT04204356|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
218852728|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
219198533|NCT06597500|DRUG|GSK3923868|GSK3923868 will be administered.
219198534|NCT06597500|DRUG|Itraconazole|Itraconazole will be administered.
219198535|NCT04571736|OTHER|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
219198536|NCT06203327|OTHER|Esophagogastroscopy (OLGA 0-Ⅰ)|Surveillance endoscopies at years 3-5.
219198537|NCT06203327|OTHER|Esophagogastroscopy (OLGA II)|Surveillance endoscopies at years 2-3.
219198538|NCT06203327|OTHER|Esophagogastroscopy (OLGA III-IV)|Surveillance endoscopies every year.
219464469|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
219464470|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
218852729|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
218852730|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
218852731|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
218852732|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
219464471|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
219464472|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
219198539|NCT06842992|DRUG|NH102|5 mg twice daily over 6 weeks, followed by a 1-week tapering period.
219198540|NCT06842992|DRUG|NH102|10 mg twice daily over 6 weeks, followed by a 1-week tapering period.
219198541|NCT06842992|DRUG|NH102|15 mg twice daily over 6 weeks, followed by a 1-week tapering period.
219198542|NCT06842992|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|30 mg twice daily for 6 weeks, followed by a 1-week tapering period.
219198543|NCT06842992|DRUG|Placebo|Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.
219199491|NCT06868732|DRUG|Carboplatin|AUC 4, Q3W, administered intravenously according to protocol.
219199492|NCT06868732|DRUG|Furmonertinib Mesylate|160mg, qd, administered according to protocol.
219464473|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
219464474|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
219464475|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
218852733|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
219464476|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
219464477|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
219464478|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
219464479|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
219464480|NCT00003576|DRUG|cisplatin|
219464481|NCT00003576|DRUG|fluorouracil|
219464482|NCT00003576|PROCEDURE|surgical procedure|
219464483|NCT00003576|RADIATION|radiation therapy|
219464484|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
219464485|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
219464486|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
219464487|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
218852734|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
218852735|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
218852736|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
218852737|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
218852738|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
218852739|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
218852740|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
218852741|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
219199493|NCT06868732|DRUG|Ivonescimab|20mg/kg, Q3W, administered intravenously according to protocol.
219199494|NCT06868732|DRUG|Docetaxel|60mg/m\^2, Q3W, administered intravenously according to protocol.
219199495|NCT06868732|DRUG|Tislelizumab|200mg, Q3W, administered intravenously according to protocol.
219464488|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
219464489|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
219464490|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
219464491|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
219464492|NCT06724484|PROCEDURE|Surgical management of fracture|Surgical management of fracture
219464493|NCT06724484|OTHER|No intervention|No intervention
219464494|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
219464495|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
219464496|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
219464497|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
219464498|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
219464499|NCT02095834|DRUG|Carfilzomib|Given IV
219464500|NCT02095834|DRUG|Dexamethasone|Given PO or IV
219464501|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
219464502|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
219464503|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
219464504|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
219464505|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
219464506|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
219464507|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
219464508|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
219464509|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
218852742|NCT06303232|OTHER|MANUAL LYMPHATIC DRAINAGE|"MLD was performed after the moist heating of 10 minutes in supine position with both knees bent. It will start from the abdominal lymph drainage followed by the central lymph drainage.~Then, by stimulating the bilateral axillary lymph nodes, the flow of the fluid was directed to the axillary lymph node. Each session lasted for approximately 45 minutes, for 7 days"
218852743|NCT06303232|OTHER|THERAPEUTIC ULTRASOUND|The participants of group B will receive a treatment of manual lymphatic drainage and ultrasound after the moist heat of 10 minutes. After MLD of 45 minutes, ultrasound will be performed in small circular pattern from periphery to the center towards the areola with following parameters: Mode: pulsed, Frequency: 1MHz, Intensity: 1W/cm2, Time: 8 minutes. Treatment was given for 7 consecutive days
218852744|NCT00389350|DRUG|Extract of Green and Black Tea|
218852745|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
218852746|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
218852747|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
218852748|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
218852749|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
218852750|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
218852751|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
218852752|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
218852753|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
218852754|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
218852755|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
218852756|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
218852757|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
218852758|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
218852759|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
218852760|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
218852761|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
219198544|NCT05029336|BIOLOGICAL|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
219464510|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
219198545|NCT06842914|OTHER|postural training|postural training
219464511|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
219464512|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
219464513|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
219464514|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
218852762|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
218852763|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
218852764|NCT01065051|DRUG|Placebo|Single oral dose
218852765|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
218852766|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
218852767|NCT00064766|DRUG|doxycycline|
218852768|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
219464515|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
218852769|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
218852770|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
219464516|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
219464517|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
219464518|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
218852771|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
218852772|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
219198546|NCT06824831|DRUG|Patients receive microporous polysaccharide hemospheres.|Patients were randomized to receive microporous polysaccharide hemospheres, after mastectomy was done.
218852773|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
218852774|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
218852775|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
218852776|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
218852777|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
218852778|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
218852779|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
218852780|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
219198547|NCT06824831|DRUG|Patients DO NOT receive microporous polysaccharide hemospheres.|Patients were randomized to NOT receive microporous polysaccharide hemispheres after mastectomy was done.
219199496|NCT06868732|DRUG|Pembrolizumab|200mg, Q3W, administered intravenously according to protocol.
219464519|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
219464520|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
219464521|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
219464522|NCT05870423|DRUG|olaparib|18 days olaparib during each cycle of PRRT
219464523|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
219464524|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
219464525|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
219464526|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
219464527|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
218852781|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
218852782|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
218852783|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
218852784|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
219464528|NCT04010357|DRUG|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
219464529|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
219464530|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
219464531|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
219464532|NCT00000649|DRUG|Nevirapine|
219464533|NCT00000649|DRUG|Zidovudine|
218852785|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
218852786|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
218852787|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
219019842|NCT06855563|BEHAVIORAL|Community-based intervention packages|"Community-based intervention packages~* Intervention packages are expected to consist of multiple specific activities tailored to the local context. All intervention packages will be designed to be (i) multi-level (i.e. targeting at least two of individual, external and structural environments), (ii) multi-component (i.e. targeting both healthy diet and physical activity), (iii) co-created with local communities in which they are implemented and (iv) health equity oriented in terms of both access and improvement. The exact package of interventions will differ by country and is expected to evolve pragmatically over time.~* The intervention group in each country will be made up of (children in) neighbourhoods where intervention packages are implemented."
219464534|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
219464535|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
219464536|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
219464537|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
219464538|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
219198548|NCT06825351|BEHAVIORAL|Psychological First Aid versus Dialectal behavioral Intervention|"PFA is an immediate, supportive intervention aimed at helping individuals in distress. It focuses on providing emotional support and practical assistance in the aftermath of a crisis.~Key Components:~Safety and Comfort: Ensuring that participants feel safe and secure in their environment.~Active Listening: Engaging in empathetic listening to validate participants' feelings and experiences.~Assessment of Needs: Identifying immediate needs and concerns, including emotional and practical aspects.~Information and Resources: Providing clear information about available resources, such as mental health services and coping strategies.~Encouragement of Social Support: Guiding participants to connect with friends, family, or support groups."
219198549|NCT06819033|DEVICE|PBM Therapy|patients will receive PBM therapy using the Biolase Epic pro laser. An average power of 0.6w (peak power = 80w, rep. rate= 20Hz). Each aphthous ulcer will be irradiated one time for a total of 30 seconds via continuous wave.
219198550|NCT06819033|DRUG|Maalox plus Benadryl|1:1 mixture of Maalox and Benadryl will be applied to the ulcer as needed for pain. Applications typically will be applied before eating to form a dissolvable oral band-aid that lasts for up to 30 minutes. 10 milliliters of 1:1 Maalox: Benadryl solution will be provided to the family. During the presenting appointment, the patient/family will be shown how to use the 1:1 Maalox: Benadryl solution. It will be applied topically with no rinsing needed.
219198551|NCT06826235|OTHER|3 dates at the breakfast meal in the diet program|Participants in the intervention group will consume 3 dates at the breakfast meal in the diet program.
219198552|NCT06819436|DRUG|Dexamethasone|Intravenous dexamethasone 8mg given to participants before spinal anesthesia
219198553|NCT06819436|OTHER|Placebo|Intravenous placebo given to the participants before spinal anesthesia
218852788|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
218852789|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
219464539|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
219464540|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
219464541|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
219464542|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
219464543|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
219464544|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
219464545|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
219464546|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
218852790|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
218852791|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
218852792|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
219198554|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
219198555|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
219198556|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
219593374|NCT02546466|BEHAVIORAL|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
218852793|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
218852794|NCT06511739|DRUG|placebo|Oral tablet
219198557|NCT04170374|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219464547|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
219464548|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
219464549|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
219464550|NCT02382419|OTHER|Placebo|Applied vaginally
219464551|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
219464552|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
218852795|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
219464553|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
219464554|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
219464555|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
219464556|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
219464557|NCT00002021|DRUG|Foscarnet sodium|
219464558|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
219464559|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
219464560|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
219464561|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
218852796|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
219019848|NCT06790784|PROCEDURE|Vitrectomy|The vitrectomy must occur within 4 weeks of randomization. A single injection of faricimab is allowed at any point before the vitrectomy. It is recommended that this injection is within 1 week of the vitrectomy. Requirement of triamcinolone staining to assist in complete elevation and removal of the posterior hyaloid and in removal of as much peripheral vitreous as is safely possible, 20 gauge not permitted. Allows subconjunctival steroid at investigator discretion; however, sub-tenon's triamcinolone or other long-acting steroid will not be permitted.
219464562|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
219464563|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
218852797|NCT02676336|OTHER|Placebo|
218852798|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
218852799|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
218852800|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
218852801|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
218852802|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
219019849|NCT06790784|DEVICE|Endolaser|Complete panretinal photocoagulation (PRP) during vitrectomy
219019850|NCT06790784|DRUG|Faricimab|Treatment must be initiated on the day of randomization with one faricumab injection. The remainder of the randomized treatment includes 2 additional injections every 4-weeks. Injections must be completed within 90 days of randomization.
219019851|NCT06790784|DEVICE|Panretinal Photocoagulation (PRP)|Complete PRP. PRP may be completed in 1-3 sessions, with the timing at the investigator's discretion. All PRP sessions must be completed within 90 days of randomization.
219019860|NCT04665739|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219019861|NCT04665739|PROCEDURE|Computed Tomography|Undergo CT
219019862|NCT04665739|DRUG|Everolimus|Given PO
219464564|NCT00004409|DRUG|collagenase|
219464565|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
219464566|NCT04143815|DRUG|Placebo|Intramuscular injection
219464567|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
219464568|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
219464569|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
219464570|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
219464571|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
219464572|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
219464573|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
219198558|NCT04170374|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
219464574|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
219464575|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
219464576|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
219464577|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
219464578|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
219464579|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
219464580|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
219464581|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
219464582|NCT04463719|BEHAVIORAL|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
219464583|NCT04463719|BEHAVIORAL|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
219464584|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
219464585|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
219464586|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
219464587|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
219464588|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
219464589|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
219464590|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
219464591|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
219464592|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
219464593|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
219464594|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
219464595|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
219464596|NCT00021125|PROCEDURE|adjuvant therapy|
219464597|NCT00021125|RADIATION|radiation therapy|
219019863|NCT04665739|OTHER|Fludeoxyglucose F-18|Given FDG
219464598|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
219464599|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
219464600|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
219464601|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
219464602|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
219464603|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
219019864|NCT04665739|DRUG|Lutetium Lu 177 Dotatate|Given IV
219019865|NCT04665739|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219019866|NCT04665739|PROCEDURE|Positron Emission Tomography|Undergo PET
219019867|NCT04665739|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
219019868|NCT04665739|OTHER|Survey Administration|Ancillary studies
219198559|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
219198560|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
219464604|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
219464605|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
219464606|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
219464607|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
219464608|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
219464609|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
219464610|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
219464611|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
219464612|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
219464613|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
219464614|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
219464615|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
219464616|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
219464617|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
219464618|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
219464619|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
219464620|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
219198561|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
219464621|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
219464622|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
219464623|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
219464624|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
219464625|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
219464626|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
219464627|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
219464628|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
219464629|NCT01136317|DRUG|Omeprazole|
219464630|NCT01136317|DRUG|Rabeprazole|
219464631|NCT01136317|DRUG|Lactose|
219464632|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
219464633|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
219464634|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
219464635|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
219464636|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
219464637|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
219464638|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
219464639|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
218852803|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
219464640|NCT00425594|DRUG|NuLYTELY|
219464641|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
219464642|NCT02382887|DEVICE|Airtraq|
219464643|NCT02382887|DEVICE|fiberscope|
219464644|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
219464645|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
218852804|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
219593375|NCT00613886|DEVICE|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
219593376|NCT00613886|BEHAVIORAL|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
219593377|NCT03426163|DEVICE|Virtual reality|Application of knee MRI transformed virtual reality system
218852805|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
218852806|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
218852807|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
218852808|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
218852809|NCT03638908|DRUG|Fluoxetine|
219593378|NCT00753857|OTHER|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
219593379|NCT00753857|OTHER|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
218852810|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
218852811|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
218852812|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
219464646|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
219464647|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
219464648|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
219464649|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
219464650|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
219464651|NCT00212615|DRUG|Capecitabine (Xeloda)|
219593380|NCT05346926|DEVICE|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
219019876|NCT05647122|DRUG|AZD9592|Varying doses of AZD9592
219019877|NCT05647122|DRUG|Osimertinib|tablets administered orally
219019878|NCT05647122|DRUG|5-Fluorouracil (5-FU)|IV infusion
219019879|NCT05647122|DRUG|Leucovorin|IV infusion
219019880|NCT05647122|DRUG|Bevacizumab|IV infusion
219464652|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
219464653|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
219464654|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
219464655|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
219593381|NCT05346926|DEVICE|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
218852813|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
218852814|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
218852815|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
218852816|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
218852817|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
218852818|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
218852819|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
218852820|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
218852821|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
218852822|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
218852823|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
218852824|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
219464656|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
219464657|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
219464658|NCT01869231|DIETARY_SUPPLEMENT|water|
219464659|NCT00017108|DRUG|chlorambucil|
219464660|NCT00017108|DRUG|cyclophosphamide|
219464661|NCT00017108|DRUG|fludarabine phosphate|
219464662|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
219464663|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
219464664|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
219464665|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
219464666|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
218852825|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
219464667|NCT00004937|DRUG|acridine carboxamide|
219464668|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
218852826|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
219464669|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
219464670|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
219464671|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
219464672|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
219464673|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
218852827|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
218852828|NCT02253056|OTHER|Fasting / Caloric Restriction|
218852829|NCT02253056|OTHER|Healthy Diet|
218852830|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
218852831|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
218852832|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
219464674|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
219464675|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
219464676|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
219464677|NCT04541394|DEVICE|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
219464678|NCT02698020|PROCEDURE|Room-air|Provision of room-air
219464679|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
219464680|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
219464681|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
219464682|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
219464683|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
218852833|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
218852834|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
218852835|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
218852836|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
218852837|NCT01833234|OTHER|Interviews and questionnaires|
219464684|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
219464685|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
219464686|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
219464687|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
219464688|NCT02701933|DRUG|Saline|Saline, intravenous infusion
218852838|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
218852839|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
218852840|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
218852841|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
218852842|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
218852843|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
218852844|NCT02832024|DEVICE|plaque excision system|
218852845|NCT02832024|DEVICE|stent|
218852846|NCT02832024|DEVICE|Balloon|
218852847|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
218852848|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
219198562|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by robotic arm|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
219464689|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
219464690|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
219464691|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
219464692|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
219464693|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
218852849|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
218852850|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
219593382|NCT05018312|BEHAVIORAL|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
218852851|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
219464694|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
219464695|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
219464696|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
219464697|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
219464698|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
219464699|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
219464700|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
219464701|NCT00038116|PROCEDURE|placebo|sham surgery
219464702|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219464703|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
219464704|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
219464705|NCT01716585|DRUG|Placebo for ABT-333|Tablet
219464706|NCT01716585|DRUG|Placebo for ribavirin|Capsule
219464707|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
219464708|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
219464709|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
219464710|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
219464711|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
219464712|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
219464713|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
219593383|NCT05018312|BEHAVIORAL|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
219593384|NCT04855149|OTHER|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
219019885|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
219019886|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
219019889|NCT05840159|DRUG|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
219198563|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by rmanual execution|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
219198564|NCT06858618|COMBINATION_PRODUCT|FCN-338 + Azacitidine|FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle
219198565|NCT06858618|COMBINATION_PRODUCT|FCN-338 + erythromycin+ Ara-C|"Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles.~Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles"
219198566|NCT06855953|DIETARY_SUPPLEMENT|Vitamin K|Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
219198567|NCT06855953|DIETARY_SUPPLEMENT|Placebo|Participants receive daily placebo for 12 weeks
219198568|NCT06655480|DRUG|[ARNI + SGLTi + AMR]|Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet
219198569|NCT06655480|DRUG|[SGLTi + previously taken RAAS blocker]|Empagliflozin 10mg tablet, previously taken RAAS inhibitor
219464714|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
219464715|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
218852852|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
219464716|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
219464717|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
219464718|NCT02503956|PROCEDURE|Crawford tube insertion|
219464719|NCT02503956|DEVICE|Crawford lacrimal tube|
218852853|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
219464720|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
219464721|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
219464722|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
219593385|NCT02065856|BIOLOGICAL|AVANZ Salsola|AVANZ Salsola
218852854|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
218852855|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
218852856|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
219019890|NCT05840159|OTHER|Placebo|Placebo
219019893|NCT06768489|DRUG|JNJ-79635322|JNJ-79635322 will be administered subcutaneously.
219019894|NCT06768489|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
219019895|NCT06768489|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219019896|NCT06768489|DRUG|Lenalidomide|Lenalidomide will be administered orally.
219019908|NCT06443463|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
219019909|NCT06443463|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
219019912|NCT06927947|OTHER|Communication Intervention|Use relative invitation tool
219019913|NCT06927947|OTHER|Health Promotion and Education|Receive access to the VGN
219019914|NCT06927947|OTHER|Informational Intervention|Receive access to a Genetic Testing Family Letter
219019915|NCT06927947|OTHER|Survey Administration|Ancillary studies
218852857|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
218852858|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
219464723|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP\_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
219464724|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
219198570|NCT06856395|OTHER|intervention group|Robotic distraction during vaccination process
219198571|NCT06857916|OTHER|Traditional|Traditional rehabilitation course will occur.
219198572|NCT06857916|OTHER|cycle with biofeedback|Individuals will receive biofeedback about their power production and power symmetry while participating in a 32 minute recumbent cycling session in inpatient rehabilitation facility.
219198573|NCT06859216|BEHAVIORAL|AI-Generated Plain Language Summaries|Participants receive standard ophthalmology notes plus an AI-generated summary that explains medical information in simpler language. Each summary is reviewed by an ophthalmologist for accuracy before being given to the participant. The goal is to help participants better understand their diagnosis, treatment plan, and follow-up instructions.
218852859|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
218852860|NCT00045149|BIOLOGICAL|aldesleukin|
219198574|NCT06859749|OTHER|Education|"Students will be given a question-answer application. In order to perform the Escape game for students, 4 stations were prepared in the skills laboratory: Pulse, Respiration-Oxygen Saturation, Blood Pressure, Body Temperature. Separate scenarios will be prepared for each station."
219198575|NCT06859190|DRUG|estazolam 1-2 mg|oral estazolam 1-2 mg daily at bedtime for 8 weeks.
218852861|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219198576|NCT06859190|PROCEDURE|Auricular pressure bean combined with electroacupuncture|Electroacupuncture treatment will be performed on seven acupoints, including Baihui (GV20), Shenting (GV24), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6). Each session lasts for 30 minutes and is conducted twice a week.In addition, auricular point seed-pressing therapy will be applied to bilateral auricular points related to insomnia (Shenmen, Heart, and Sympathetic). Each auricular point will be pressed for 1 minute, three times a day. The total treatment course is eight weeks.
219198577|NCT06860152|DEVICE|Cochlear implant|Cochlear implant
219198578|NCT06669806|DEVICE|TIPS Stent Graft|a covered TIPS stent graft
219198579|NCT06669234|DRUG|ALN-F1202|Administered per the protocol
219198580|NCT06669234|DRUG|Matching Placebo|Administered per the protocol
219198581|NCT06248515|DRUG|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
219198582|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
218852862|NCT01926899|DRUG|Bortezomib administration|
218852863|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
219198583|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
218852864|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
218852865|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
219198584|NCT06457958|DRUG|Sevoflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
219464725|NCT02028052|DEVICE|22 gauge Vizishot needles|
219593386|NCT03301571|OTHER|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
219593387|NCT03301571|OTHER|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
219593388|NCT03301571|OTHER|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
218852866|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
218852867|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
218852868|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
218852869|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
218852870|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
219593389|NCT01707771|PROCEDURE|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
219593390|NCT01707771|BEHAVIORAL|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
219198585|NCT06457958|DRUG|Desflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
219593391|NCT02549027|DRUG|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
219198586|NCT05198648|OTHER|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
219198587|NCT05198648|OTHER|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
219593392|NCT02549027|DRUG|MK-6096|Oral MK-6096 tablets (5 mg strength)
219464726|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
218852871|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
218852872|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
218852873|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
218852874|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
218852875|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
218852876|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
219464727|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
219593393|NCT02549027|DRUG|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
218852877|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
218852878|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
218852879|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
219198588|NCT06729762|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation, microwave ablation, laser ablation
219198589|NCT02934282|DRUG|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
219198590|NCT04736810|BIOLOGICAL|AK105|IV infusion
219198591|NCT04736810|DRUG|Cisplatin|IV infusion
219198592|NCT04736810|DRUG|Gemcitabine|IV infusion
219198593|NCT04736810|DRUG|Anlotinib hydrochloride|Oral administration
219464728|NCT02118909|DRUG|Pracinostat|
219464729|NCT02118909|DRUG|Itraconazole|
219464730|NCT02118909|DRUG|Ciprofloxacin|
219593394|NCT02400853|DEVICE|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
219593395|NCT02400853|PROCEDURE|Cord blood analysis|Cord blood will be collected during deliverance and analysed
219593396|NCT03589040|DRUG|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
219593397|NCT03589040|DRUG|rilpivirine|Oral rilpvirine 25mg
219593398|NCT03589040|DRUG|darunavir|Oral darunavir+ritonavir 600/100mg
219593399|NCT05651789|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
219593400|NCT05651789|DRUG|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
219593401|NCT03450044|BIOLOGICAL|Dendritic cells|Adoptive transfer of autologous DCs
219464731|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
219464732|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
219464733|NCT04371705|OTHER|control|placebo
219464734|NCT02291952|BEHAVIORAL|Meal schedule|
219464735|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
219464736|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
219464737|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
219464738|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
218852880|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
218852881|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
218852882|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
218852883|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
218852884|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
218852885|NCT01783574|DRUG|Testosterone|
218852886|NCT01783574|DRUG|Placebo|
218852887|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
218852888|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
218852889|NCT00092872|DRUG|MK0557|
219464739|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
219464740|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
218852890|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
219198594|NCT06856694|OTHER|NLP+AI Report|A NLP model will extract key content from consultations and AI (Chat GPT) will summarize that information. Reports including the top sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within approximately 72 hours after each case. In both arms, a follow up phone call will allow for clarification any concepts that was inadequately communicated during the consultation. This call will be audio recorded and qualitatively assessed to determine whether deficiencies in risk communication observed in the consultation were rectified.
219198595|NCT06668025|OTHER|MxA tests|Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.
219464741|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
219464742|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
219464743|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
219464744|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
219464745|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
219464746|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
219464747|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
218852891|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
219198596|NCT06668025|OTHER|MxA feedback|MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
219198597|NCT06668025|OTHER|Follow-up at Day 30|A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
219198598|NCT01396408|DRUG|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
219198599|NCT01396408|DRUG|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
219198600|NCT06862258|PROCEDURE|Shehata technique|For patients whose intra-abdominal testicle cannot easily reach the contralateral internal inguinal ring due to a short testicular pedicle, the Shehata procedure will be performed. This technique involves a two-stage laparoscopic orchidopexy that preserves the testicular vessels. In the first stage, the intra-abdominal testicle is fixed above the contralateral iliac crest using prolene vascular suture. Twelve weeks later, a second procedure is performed to position the testicle lower. This approach ensures the preservation of the testicular vessels, vas deferens, and overall circulation.
219593402|NCT03021889|BEHAVIORAL|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
219198601|NCT06862830|OTHER|Virtual reality video|Virtual reality video: luna park, carousels, space, zoo, safari, dinosaurs, sightseeing, role-play
219198602|NCT06861816|OTHER|incentive spirometer and walking with dog|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks. they will additionally walked freely with a dog 30 min three times weekly (in opposite days of hemodialysis). The duration of this trial will be 12 weeks.
219464748|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
218852892|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
218852893|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
218852894|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
219464749|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
219464750|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
219464751|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
219464752|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
219593403|NCT03021889|BEHAVIORAL|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
219593404|NCT03684967|DRUG|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
218852895|NCT02567370|DRUG|AMG 581|Active drug
219198603|NCT06861816|OTHER|training by incentive spirometer only|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks.
219198604|NCT04159610|DRUG|WO3970|Application of cream to each axilla
219198605|NCT04159610|DRUG|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
219593405|NCT05026996|DRUG|Pelacarsen|Single subcutaneous injection of pelacarsen
219593406|NCT04569669|DIAGNOSTIC_TEST|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
219593407|NCT03850314|DIETARY_SUPPLEMENT|Glycine|Glycine powder to be dissolved in water.
218852896|NCT02567370|DRUG|Placebo|Placebo
218852897|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
218852898|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
218852899|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
218852900|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
218852901|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
218852902|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
219464753|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
219593408|NCT00740012|OTHER|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
219593409|NCT00740012|OTHER|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
219464754|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
219198606|NCT06664957|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.
219198607|NCT06664957|OTHER|Placebo|Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
219198608|NCT06666855|DRUG|DE-117B Eye Drops|Investigational Product: 0.002% DE-117B Eye Drops
219198609|NCT06666855|DRUG|Latanoprost|Active Control: 0.005% Latanoprost Eye Drops
219198610|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
219198611|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
219198612|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
219198613|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
219464755|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
219464756|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
219464757|NCT01122719|DEVICE|Drug Eluting Stent|
219464758|NCT02708576|BIOLOGICAL|NGM313|
219464759|NCT02708576|OTHER|Placebo|
219464760|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
219464761|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
219593410|NCT00740012|OTHER|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
219593411|NCT00740012|OTHER|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
219593412|NCT00740012|OTHER|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
219593413|NCT00740012|OTHER|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
219593414|NCT01323712|DIETARY_SUPPLEMENT|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
219593415|NCT06097455|GENETIC|ARI0003|Treatment with ARI0003 cells
219464762|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219464763|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219593416|NCT02186834|DRUG|Selinexor|Selinexor orally as outlined in the study treatment arm.
219593417|NCT02186834|DRUG|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
219198614|NCT05433103|OTHER|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
219198615|NCT05433103|OTHER|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
219464764|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219464765|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
219464766|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
219464767|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
219464768|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
219464769|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
219464770|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
219464771|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
219464772|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
219464773|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
219464774|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
219464775|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
219464776|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
219464777|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
219464778|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
219198616|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
219464779|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
219464780|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
219464781|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
219464782|NCT02336191|PROCEDURE|living donor liver transplantation|living donor liver transplantation
219464783|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
219593418|NCT02186834|DRUG|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
219593419|NCT06246214|DEVICE|Blue Light Therapy|The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
219593420|NCT06246214|DEVICE|ControlLT|The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
218852903|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
218852904|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
218852905|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
219464784|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
219464785|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
219464786|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
219464787|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
219464788|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
219464789|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
219464790|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
219464791|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
219464792|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
219593421|NCT03927014|OTHER|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
219593422|NCT03240835|DRUG|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
219593423|NCT03240835|RADIATION|IMRT|intensity modulation radiation therapy
219593424|NCT04228835|DIAGNOSTIC_TEST|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
218852906|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
218852907|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
218852908|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
218852909|NCT00006042|BIOLOGICAL|filgrastim|
218852910|NCT00006042|DRUG|cyclophosphamide|
219593425|NCT01000558|OTHER|biologic sample preservation procedure|
219593426|NCT01504958|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
219593427|NCT01504958|BEHAVIORAL|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
219593428|NCT06633341|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
219593429|NCT01343316|DEVICE|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
218852911|NCT00006042|DRUG|fludarabine phosphate|
218852912|NCT00006042|DRUG|mycophenolate mofetil|
218852913|NCT00006042|DRUG|tacrolimus|
218852914|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
218852915|NCT00006042|RADIATION|radiation therapy|
218852916|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
218852917|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
218852918|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
218852919|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
218852920|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
219593430|NCT00127218|DRUG|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
219198617|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
219198618|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
219198619|NCT06997835|BEHAVIORAL|Control group：The interactive management nursing model on the wechat platform|The intervention subjects of the control group: targeted at the pregnant and postpartum women themselves. Specifically, conduct routine outpatient prenatal examinations and health education for pregnant women. Regularly receive health education and pregnancy guidance intervention provided by the wechat platform. It includes: ① Setting specific wechat ringtones, 60-second voice messages and picture reminders every day; ② Basic knowledge education every Monday ③ Dietary guidance is provided every Tuesday. ④ Exercise guidance every Wednesday ⑤ Guidance on blood glucose monitoring every Thursday; Weight guidance is provided every Friday.
219198620|NCT06997835|BEHAVIORAL|Intervention group：Family-centered early care intervention|"The intervention subjects of the intervention group were parturients and their primary caregivers (spouses and parents).~The specific measures are as follows:~1. Establish a family-centered healthcare team (FCC) It includes one chief physician, two attending physicians, one diabetes specialist nurse, two responsible nurses, one psychotherapist, and one nutritionist. The organization members will conduct FCC concept learning and knowledge training.~2. Interactive management nursing model on the wechat platform~   * Set specific wechat ringtones, 60-second voice messages and picture reminders every day;~     * Basic knowledge education every Monday; ③. Dietary guidance every Tuesday;~       ④. Exercise guidance every Wednesday;~       ⑤ Guidance on blood glucose monitoring every Thursday;~       ⑥. Weight guidance every Friday;~       ⑦. Strengthen home care guidance every Saturday and Sunday."
219464793|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
219464794|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
218852921|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
219593431|NCT00127218|DRUG|niacin|long-acting niacin daily for 18 months
219593432|NCT00127218|DRUG|Placebo|matching placebo pill daily for 18 months
219593433|NCT05744141|PROCEDURE|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
219593434|NCT03115216|PROCEDURE|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
219593435|NCT03115216|PROCEDURE|CEIOL|Manual cataract extraction and intraocular lens placement
218852922|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
218852923|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
219593436|NCT03897803|DIAGNOSTIC_TEST|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
219593437|NCT00099879|DRUG|BMS-275183|
218852924|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
218852925|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
218852926|NCT04233658|DRUG|Placebo|3x2 capsules / day
218852927|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
218852928|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
218852929|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
218852930|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
218852931|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
218852932|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
219464795|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
219464796|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
219464797|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
219464798|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
219464799|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
219464800|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
219464801|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
219464802|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
219464803|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
219464804|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
219464805|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
218852933|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
218852934|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
218852935|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
218852936|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
218852937|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
218852938|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
219464806|NCT00266604|DRUG|Topiramate|
219464807|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
219464808|NCT04455958|DRUG|Placebo Administration|Given PO
218852939|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
219464809|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
219464810|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
218852940|NCT06115694|DEVICE|TCI Articulating Introducer|use
218852941|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
218852942|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
218852943|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
218852944|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
218852945|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
218852946|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
219464811|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
219464812|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
219464813|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
219464814|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
219593438|NCT02974179|BIOLOGICAL|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
219593439|NCT02810379|PROCEDURE|written informed consent|
219464815|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
218852947|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
218852948|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
218852949|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
218852950|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
218852951|NCT02291393|DEVICE|80 lead ECG|
218852952|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
218852953|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
218852954|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
218852955|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
218852956|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
219464816|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
219464817|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
219593440|NCT02810379|PROCEDURE|video+written informed consent|
219593441|NCT00405808|DRUG|Rimonabant|Once daily in the morning
219593442|NCT00405808|DRUG|Placebo|Once daily in the morning
219593443|NCT01236911|OTHER|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
219593444|NCT01421511|DRUG|TR-701 FA|"* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily"
218852957|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
218852958|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
218852959|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
218852960|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
218852961|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
219019930|NCT05650645|DRUG|incobotulinum toxin A|The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
219019931|NCT05650645|DRUG|Placebo-Saline|Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
218852962|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
218852963|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
218852964|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
218852965|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
218852966|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
218852967|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
219593445|NCT01421511|DRUG|Linezolid|"* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours"
219593446|NCT00163488|DRUG|Ciclesonide|
219198621|NCT06997536|PROCEDURE|Ilioinguinal/iliohypogastric Nerve Block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
219198622|NCT06997536|PROCEDURE|Transversus abdominis plane (TAP) block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
219464818|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
219464819|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
218852968|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
219593447|NCT01505153|BIOLOGICAL|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
218852969|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
218852970|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
218852971|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
218852972|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
218852973|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
218852974|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
218852975|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
218852976|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
218852977|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
218852978|NCT02154048|DRUG|Ropivacaine|
218852979|NCT02154048|DRUG|Dexamethasone|
218852980|NCT02154048|OTHER|Placebo|
218852981|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
218852982|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
218852983|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
218852984|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
219464820|NCT00261599|DRUG|Midazolam HCI|
219593448|NCT05011747|PROCEDURE|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
218852985|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
218852986|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
218852987|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
218852988|NCT00001724|DRUG|Flurbiprofen|
218852989|NCT00416715|DRUG|letrozole|Given PO
218852990|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
218852991|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
219464821|NCT00003089|DRUG|amifostine trihydrate|
219464822|NCT00003089|DRUG|carboplatin|
219464823|NCT00003089|DRUG|paclitaxel|
219593449|NCT05011747|PROCEDURE|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
219464824|NCT00003089|RADIATION|radiation therapy|
219464825|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
218852992|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
219464826|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
219464827|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
219464828|NCT03016520|DRUG|DWJ1392|
219464829|NCT03016520|DRUG|DWC20164|
219464830|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
219464831|NCT00958282|OTHER|placebo|
219464832|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
219464833|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
219464834|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
219464835|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
218852993|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
218852994|NCT00416715|DRUG|calcium gluconate|Given PO
219464836|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
219464837|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
218852995|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
218852996|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
219464838|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
219464839|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
219464840|NCT00374920|DRUG|MEM 1003|
219464841|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
219464842|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
218852997|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
218852998|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
218852999|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
218853000|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
219019935|NCT04488198|OTHER|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
219019936|NCT04488198|OTHER|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
219464843|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
219198623|NCT06997536|PROCEDURE|Quadratus Lumborum Block (QLB)|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
219593450|NCT05850585|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
219464844|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
219464845|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
219464846|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
219464847|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
219464848|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
219464849|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
219464850|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
219464851|NCT00756379|OTHER|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
219464852|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
219464853|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
219464854|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
219464855|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
219464856|NCT03006042|DRUG|Bupivacaine|
219464857|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
219464858|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
219464859|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
219464860|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
219593451|NCT05850585|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
219198624|NCT03372057|DRUG|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
219198625|NCT03372057|DRUG|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
219198626|NCT03372057|DRUG|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).
219593452|NCT03636997|PROCEDURE|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
219198627|NCT02475161|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
219198628|NCT02475161|DRUG|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
219198629|NCT06351215|DRUG|Methadone group|5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
219198630|NCT06351215|DRUG|Placebo|sugar pill that is identical look-alike to study drug
219199497|NCT06862804|BEHAVIORAL|practical group training|It is understood how important the issue is when it is considered that supporting these families, especially mothers, both socially and psychologically can be important in alleviating the difficulties they experience and that mothers with children with autism are in a risk group in terms of receiving this support. The research was designed considering that the applied training we will provide will be effective in increasing social support and developing self-compassion for the primary caregivers of children and will reduce the level of depressive symptoms.
219464861|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
219464862|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
219464863|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
219464864|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
219464865|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
219199498|NCT06862804|BEHAVIORAL|practical group training|practical group training
219464866|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
219464867|NCT00026559|DEVICE|Shock Device|Shock Device
218853001|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
218853002|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
219199499|NCT05589363|DRUG|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
219464868|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
219464869|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
219464870|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
219464871|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
219464872|NCT01909635|BEHAVIORAL|Food Feelings|
219464873|NCT01909635|BEHAVIORAL|Other Feelings|
219593453|NCT03636997|PROCEDURE|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
219593454|NCT05260060|BEHAVIORAL|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
219593455|NCT05260060|BEHAVIORAL|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
219199500|NCT05589363|DRUG|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
219199501|NCT06624592|DRUG|Sevoflurane|Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
219464874|NCT00627991|DRUG|Valsartan|
219464875|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
219464876|NCT01549327|OTHER|Oncology Interactive Navigator|
219464877|NCT01549327|OTHER|Routine Care|
219464878|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
219464879|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
219464880|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
219464881|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
219464882|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
219593456|NCT00749892|DRUG|Erlotinib Hydrochloride|Given PO
219593457|NCT01799369|BEHAVIORAL|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
219464883|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
219198631|NCT05342974|DRUG|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
219198632|NCT05342974|DRUG|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
219464884|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
219464885|NCT01984840|DEVICE|Telemedicine|
219464886|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
219464887|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
219464888|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
219464889|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
219464890|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
219464891|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
219464892|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
219198633|NCT05272163|BEHAVIORAL|Stimulus Type|Targets can be specific or categorical
219198634|NCT05272163|BEHAVIORAL|Target Presence|There is or is not a target present on each trial
219464893|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
219464894|NCT01416259|DRUG|Withdraw treatment|
219464895|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
219464896|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
219464897|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
219464898|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
218853003|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
218853004|NCT04026360|OTHER|no intervention|
219198635|NCT05272163|BEHAVIORAL|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
219198636|NCT05611372|DRUG|Rasagiline|1 mg rasagiline
219198637|NCT05495360|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|twice daily serving of the study product
219464899|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
219464900|NCT03161015|DRUG|GBT440|Oral
219464901|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
219464902|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
219464903|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
219464904|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
219464905|NCT02727452|OTHER|Skin-to-skin contact|
219464906|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
219198638|NCT05953740|DRUG|MK-5720|IM injection
219464907|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
219464908|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
219464909|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
219464910|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
219198639|NCT05953740|DRUG|Placebo to MK-5720|Placebo IM Injection matched to MK-5720
218853005|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
218853006|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
219198640|NCT05953740|DRUG|MK-8189|Oral Tablet
218853007|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
219198641|NCT05953740|DRUG|Placebo to MK-8189|Placebo oral tablet matched to MK-8189
218853008|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
218853009|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
219198642|NCT06473103|DEVICE|Two photon fluorescence microscopy imaging|Excised tissues will be imaged with two photon fluorescence microscopy prior to submission for histological processing.
219198643|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
219198644|NCT04567316|DRUG|[14C]-radiolabelled BI 1358894|Part 1
218853010|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
219464911|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
219464912|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
219464913|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
219464914|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
219464915|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
218853011|NCT00489736|DRUG|amiodarone|oral administration
218853012|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
219198645|NCT04567316|DRUG|BI 1358894|Part 2
219198646|NCT05112939|DRUG|RPV LA|RPV LA will be administered at different formulations.
219198647|NCT05112939|DRUG|CAB LA|CAB LA will be administered at formulation 3.
219464916|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
219464917|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
219464918|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
219464919|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
219198648|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
219199502|NCT06624592|DRUG|Isoflurane|Subjects will receive standard of care anesthesia Isoflurane
219464920|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
218853013|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
218853014|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
218853015|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
218853016|NCT03262207|OTHER|Extraction genomic DNA|
219464921|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
219464922|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
219464923|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
219464924|NCT03083262|OTHER|no intervention|None, there is no intervention
219464925|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
219464926|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
218853017|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
219464927|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
219464928|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
219464929|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
219464930|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
219464931|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
219464932|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
219464933|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
219464934|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
219464935|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
219464936|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
218853018|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
218853019|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
218853020|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
218853021|NCT02707393|DRUG|Fludarabine|infusion
218853022|NCT02707393|DRUG|Thiotepa|infusion
218853023|NCT02707393|DRUG|Melphalan|infusion
218853024|NCT02707393|DRUG|ATG|infusion
218853025|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
218853026|NCT02707393|DRUG|Mycophenolate mofetil|infusion
219464937|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
219464938|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
219464939|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
219464940|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
218853027|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
218853028|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
218853029|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
218853030|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
218853031|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
218853032|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
219464941|NCT01907750|DEVICE|biliary drainage tube|
219464942|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
219464943|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
219464944|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
219464945|NCT00527046|DRUG|CP-424,391|
219464946|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
218853033|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
218853034|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
218853035|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
218853036|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
218853037|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
218853038|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
218853039|NCT01684644|BEHAVIORAL|Treatment as usual|
218853040|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
218853041|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
218853042|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
219198649|NCT05197855|DEVICE|Deem 3 Headband|The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
218853043|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
218853044|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
219464947|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
219464948|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
219464949|NCT00286234|DRUG|extended release niacin|2 g qpm
219464950|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
219464951|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
219464952|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
219464953|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
218853045|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
218853046|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
218853047|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
218853048|NCT00438269|DRUG|Piperacillin/tazobactam|
218853049|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
219198650|NCT04312399|PROCEDURE|blood take|Blood is taken to analyse degradation products of the metabolism of amyloid
219198651|NCT05146284|DRUG|PXL770|Tablet
219198652|NCT06452329|DRUG|Nivolumab|As prescribed by treating physician
219198653|NCT05441618|DEVICE|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
219198654|NCT05281276|DRUG|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
219464954|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
219464955|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
219464956|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
219464957|NCT00090324|DRUG|quetiapine fumarate tablets|
219464958|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
219464959|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
219464960|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
219464961|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
219464962|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
219464963|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
219464964|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
219464965|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
219464966|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
218853050|NCT00258765|DRUG|Zoledronic Acid|
218853051|NCT00258765|DRUG|Docetaxel|
218853052|NCT02808195|OTHER|Constraint-induced therapy|
218853053|NCT02808195|OTHER|kinect-based constraint-induced therapy|
218853054|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
218853055|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
218853056|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
218853057|NCT01294306|OTHER|Pharmacological Study|Correlative studies
218853058|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
218853059|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
218853060|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
218853061|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
219198655|NCT05281276|DRUG|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
219464967|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
219464968|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
219464969|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
219464970|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
219464971|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
219464972|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
219464973|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
219464974|NCT00079157|BIOLOGICAL|sargramostim|
219464975|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
219464976|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
219464977|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
219464978|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
218853062|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
218853063|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
218853064|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
218853065|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
218853066|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
219464979|NCT00572858|PROCEDURE|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
219464980|NCT00572858|GENETIC|Blood test|Blood test for genetic testing
219464981|NCT00572858|PROCEDURE|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
219464982|NCT00572858|PROCEDURE|Saliva test|Saliva test for cotisol levels
219198656|NCT06854367|DEVICE|TBS|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neurostimulation that uses focused magnetic field pulses to directly stimulate cortical neurons. Theta burst stimulation (TBS) is a briefer form of patterned rTMS that has been shown to be effective against major depressive disorder. Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.
218853067|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
219464983|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
219198657|NCT05807724|OTHER|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
219198658|NCT05807724|OTHER|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
219198659|NCT06863987|DRUG|Valsartan Oral Solution|"Valsartan oral solution, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Halve dose:~\<35 kg: 7 mL (equivalent to valsartan 20 mg);~* 35 kg: 13 mL (equivalent to valsartan 40 mg).~Full dose:~\<35 kg: 13 mL (equivalent to valsartan 40 mg);~* 35 kg: 27 mL (equivalent to valsartan 80 mg)."
218853068|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
219198660|NCT06863987|DRUG|Placebo|"placebo, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Full dose:~\<35 kg: 13 mL ;~* 35 kg: 27 mL .~Placebo dosing during elution phase:~\<35 kg: 7 mL;~* 35 kg: 13 mL."
219198661|NCT05255133|OTHER|Liquid biopsies|Blood sampling will be done at regular intervals
219198662|NCT05255133|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
219198663|NCT06503679|DRUG|LY4100511 (DC-853) Dose 1|Administered orally
219464984|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
219464985|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
219198664|NCT06503679|DRUG|LY4100511 (DC-853) Dose 2|Administered orally
219464986|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
219593458|NCT04581369|OTHER|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
219593459|NCT04581369|OTHER|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
218853069|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
218853070|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
218853071|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
218853072|NCT02944357|DRUG|Cisplatin|Given IV
218853073|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
218853074|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
218853075|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
218853076|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
218853077|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
218853078|NCT04857437|DRUG|Placebo|Matching Placebo
218853079|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
219464987|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
219464988|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
219464989|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
219464990|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
219464991|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
219464992|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
219464993|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
219464994|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
219464995|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
219464996|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
219464997|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
219464998|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
219464999|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
219465000|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
219465001|NCT01756482|DRUG|GS-5806|GS-5806, powder for oral solution
219465002|NCT01756482|DRUG|Placebo|
219465003|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
219465004|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
219465005|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
219465006|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
219465007|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
219198665|NCT06503679|DRUG|LY4100511 (DC-853) Dose 3|Administered orally
219198666|NCT06503679|DRUG|Midazolam|Administered orally
219465008|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
219465009|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
219465010|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
219465011|NCT02557633|BIOLOGICAL|Placebo|
219465012|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
219465013|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
219465014|NCT01602627|OTHER|pharmacological study|Correlative studies
219465015|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
219465016|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
219465017|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
219198667|NCT06503679|DRUG|Repaglinide|Administered orally
219198668|NCT06503679|DRUG|Digoxin|Administered orally
219198669|NCT06503679|DRUG|Rosuvastatin|Administered orally
219198670|NCT04564209|OTHER|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
219198671|NCT06667336|PROCEDURE|intermittent suction|This suction was applied only as needed to clear secretions
219198672|NCT06667336|PROCEDURE|continuous suction|The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
219465018|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
219465019|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
219593460|NCT04581369|OTHER|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
219593461|NCT01360463|BEHAVIORAL|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
219593462|NCT01360463|BEHAVIORAL|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
218853080|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
218853081|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
218853082|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
219465020|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
219465021|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
219465022|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
219465023|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
219465024|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
219465025|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
219465026|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
219465027|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
219465028|NCT00132405|DRUG|ALGRX 3268|
219465029|NCT00072098|BIOLOGICAL|adenovirus vector|
219465030|NCT00072098|BIOLOGICAL|interleukin-12 gene|
219465031|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
219198673|NCT04155710|BIOLOGICAL|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
219465032|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
219465033|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
219465034|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
219465035|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
219465036|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
218853083|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
218853084|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
219593463|NCT04460508|DRUG|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
219593464|NCT04460508|DRUG|rhG-CSF|rhG-CSF:5ug/kg/d
218853085|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
218853086|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
219019937|NCT07069738|DEVICE|CRT-D with a Quadripolar LV lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.
219019938|NCT07069738|DEVICE|CRT-D with INGEVITY+ pace/sense lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)
219019939|NCT06483620|DIAGNOSTIC_TEST|Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)|The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \[1 item in each domains, i.e. additional 6 items (items 28-33)\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \[5\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL
219019942|NCT07076186|DRUG|Trabectedin|Given by IV Infusion
219019943|NCT07076186|DRUG|Doxorubicin Hydrochloride|Given by IV Infusion
219465037|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
219465038|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
219465039|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
219593465|NCT00780910|DRUG|MP-424|750 mg every 8 hours for 12 weeks
218853087|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
218853088|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
218853089|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
219465040|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
219593466|NCT00780910|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
219593467|NCT00780910|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
219593468|NCT06360055|DRUG|Dabigatran Etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
219465041|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
219465042|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
219465043|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
219465044|NCT01140646|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
219593469|NCT06360055|DIETARY_SUPPLEMENT|D-mannose|Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
219593470|NCT01111825|DRUG|Temsirolimus|"28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
218853090|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
218853091|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
219465045|NCT01140646|OTHER|questionnaire administration|Ancillary studies
219465046|NCT01140646|PROCEDURE|quality-of-life assessment|Ancillary studies
218853092|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
218853093|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
219198674|NCT04155710|DRUG|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
219198675|NCT04155710|DRUG|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
219198676|NCT04155710|DRUG|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
219465047|NCT03006276|DRUG|DFN-15 Active|
219465048|NCT03006276|OTHER|DFN-15 Placebo|
219465049|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
219465050|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
219465051|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
219593471|NCT01111825|DRUG|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
219593472|NCT03263975|OTHER|Gatorade or Enterade|Commercially available oral rehydration therapies
219593473|NCT04462211|PROCEDURE|Implementation of management pharmacological protocol of constipation|"first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
219593474|NCT04462211|PROCEDURE|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation."
219593475|NCT01329783|OTHER|maraviroc|No intervention is distributed during this trial.
219593476|NCT02581397|DRUG|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
218853094|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
218853095|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
218853096|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
219465052|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
219465053|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
219465054|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
219465055|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
219465056|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
219465057|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
219465058|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
219465059|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
219465060|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
219465061|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
219465062|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
218853097|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
218853098|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
219465063|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
218853099|NCT05467761|DRUG|Oral Psilocybin|25mg orally
218853100|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
218853101|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
219465064|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
219465065|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
219593477|NCT02581397|DRUG|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
219593478|NCT02581397|DRUG|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
218853102|NCT00798239|OTHER|Iliac crest autograft|autograft
218853103|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
218853104|NCT03172065|DRUG|Normal saline|intravenous flluid
218853105|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
219593479|NCT02572245|DEVICE|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
219593480|NCT02572245|DEVICE|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
219593481|NCT01620294|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
219593482|NCT01620294|PROCEDURE|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
219019946|NCT06578247|DRUG|Quizartinib|Participants will receive quizartinib at 60 mg/day orally once daily
218853106|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
218853107|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
219465066|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
219465067|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
218853108|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
219465068|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
219465069|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
219593483|NCT05204082|DEVICE|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
219593484|NCT06265194|BEHAVIORAL|EMDR|The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.
218853109|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
218853110|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
218853111|NCT01967017|DRUG|Lidocaine|
218853112|NCT01967017|DRUG|Placebo|
218853113|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
218853114|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
218853115|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
218853116|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
218853117|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
219465070|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
219465071|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
219465072|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
219465073|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
219465074|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
219465075|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
219465076|NCT00660829|DRUG|Placebo|Placebo
219465077|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
219465078|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
219465079|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
219465080|NCT03576456|DRUG|Alprazolam 0.5 mg|receive alprazolam prior to angio
219465081|NCT03576456|DRUG|Placebo Oral Tablet|receive placebo prior to angio
219019947|NCT06578247|DRUG|Placebo|Participants will receive placebo at 60 mg/day orally once daily
219019948|NCT06578247|DRUG|Chemotherapy|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
219465082|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
219465083|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
218853118|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
219465084|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
219465085|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
219465086|NCT00427687|DRUG|AGG-523|
219465087|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
219198677|NCT03873402|BIOLOGICAL|Nivolumab|Specified dose on specified days
219198678|NCT03873402|BIOLOGICAL|Ipilimumab|Specified dose on specified days
218853119|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
218853120|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
218853121|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
218853122|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
218853123|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
218853124|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
218853125|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
218853126|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
218853127|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
218853128|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
218853129|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
218853130|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
219198679|NCT03873402|OTHER|Ipilimumab placebo|Specified dose on specified days
219465088|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
219465089|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
218853131|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
218853132|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
218853133|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
218853134|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
218853135|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
218853136|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
219465090|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
219465091|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
219465092|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
219465093|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
219465094|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
219465095|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
219465096|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
219465097|NCT02297867|DRUG|ADSCs|autologous ADSCs
219198680|NCT04007055|DIAGNOSTIC_TEST|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
219465098|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
219198681|NCT04007055|DRUG|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
219465099|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
219465100|NCT05524376|OTHER|no intervention|no intervention
219465101|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
219465102|NCT02833779|OTHER|Individual exercises|
219465103|NCT02833779|OTHER|Group exercises|
219465104|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
219465105|NCT00383344|PROCEDURE|FDG PET/CT|
219465106|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
219465107|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
219465108|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
219465109|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
219465110|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
219465111|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
219465112|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
219465113|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
219465114|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
219465115|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
219593485|NCT06265194|BEHAVIORAL|TAU|Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
218853137|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
219198682|NCT04679389|DRUG|Placebo|administered orally or enterally
218853138|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
219198683|NCT04679389|DRUG|Acetazolamide|administered orally or enterally
219198684|NCT05296122|DEVICE|TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.|The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
219198685|NCT05152472|DRUG|Atezolizumab 1200 mg|(Intravenous administration)
219198686|NCT05152472|DRUG|Imatinib 400 MG|(Per os)
219465116|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
219465117|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
219465118|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
219465119|NCT00058097|DRUG|tipifarnib|Given orally
219465120|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
219465121|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
219465122|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
219465123|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
219465124|NCT03950531|OTHER|No intervention|
219465125|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
218853139|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
218853140|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
218853141|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
218853142|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
218853143|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
218853144|NCT01691885|DRUG|Vilanterol|25mcg Once daily
219465126|NCT00457951|DRUG|Open-Label|ODSH administered open-label
219465127|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
218853145|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
218853146|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
218853147|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
218853148|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
218853149|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
218853150|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
218853151|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
218853152|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
218853153|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
218853154|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
218853155|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
218853156|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
218853157|NCT02442791|OTHER|20% Human Albumin|See description of Arms
218853158|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
218853159|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
219198687|NCT05662306|DRUG|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
218853160|NCT00234481|DRUG|XL844|
218853161|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
219198688|NCT05662306|BEHAVIORAL|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
219198689|NCT06862778|DIAGNOSTIC_TEST|SERS|Spectroscopic assessment of serum samples from healthy and diabetic patients to identify characteristics for diagnosis.
219465128|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
219465129|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
219465130|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
219465131|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
219465132|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
219465133|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
219199503|NCT06624956|DRUG|glucose, insulin, and potassium (GIK)|"GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV."
219199504|NCT06624956|DRUG|Crystalloid Infusion|placebo
219199505|NCT06676189|DEVICE|total knee arthroplasty with medial pivot polyethylene|total knee arthroplasty with medial pivot polyethylene
219465134|NCT00679354|DRUG|cilengitide|Given IV
219198690|NCT06862245|DRUG|T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
219593486|NCT02691143|OTHER|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
218853162|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
218853163|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
218853164|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
218853165|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
218853166|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
219198691|NCT06862245|DRUG|Group L received propofol at 2-2,5mg/kg dose based on le|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison
219198692|NCT06860620|DRUG|Zinc supplementation plus standard treatment|children were given 5 mg of elemental zinc sulfate as a single daily dose for children less than 4 years of age and 10 mg for children more than 4 years of age for a total duration of 6 months, along with standard therapy.
219465135|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
219465136|NCT00679354|OTHER|pharmacological study|Correlative studies
219593487|NCT06422910|OTHER|Telerehabilitation|"Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)"
219593488|NCT02907255|DEVICE|Oximetry monitor|Wireless respiratory monitoring system
219593489|NCT05418114|DRUG|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
219198693|NCT06864572|DIAGNOSTIC_TEST|P17-079, P16-093, or P15-041 PET/CT|P17-079, P16-093, or P15-041 PET/CT
219465137|NCT01700218|OTHER|telemonitoring|
218853167|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
219465138|NCT01700218|OTHER|control|
218853168|NCT06233864|DRUG|Gemcitabine|Gemcitabine
218853169|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
218853170|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
219465139|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
219465140|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
219465141|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
219465142|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
219465143|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
219593490|NCT04937114|PROCEDURE|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
219465144|NCT02216539|PROCEDURE|Lung transplantation|
219465145|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
219465146|NCT02492321|DRUG|EBI-005|
219465147|NCT02492321|DRUG|Placebo Comparator|
219465148|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
219465149|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
219465150|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
219465151|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
219465152|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
219465153|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
219465154|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
219465155|NCT00081276|DRUG|triapine|Given IV
219465156|NCT00081276|DRUG|cisplatin|Given IV
219465157|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
219465158|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
219465159|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
219465160|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
219465161|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
219593491|NCT04074616|DEVICE|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
219593492|NCT04074616|DEVICE|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
218853171|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
218853172|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
219199506|NCT06676189|DEVICE|total knee arthroplasty with ultra-congruent polyethylene|total knee arthroplasty with ultra-congruent polyethylene
219199507|NCT06675539|DIAGNOSTIC_TEST|French version PAWSS|French version of the Prediction of Alcohol Withdrawal Severity Scale
219465162|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
219465163|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
219465164|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
219465165|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
219465166|NCT03210909|DRUG|BMS-986231|BMS-986231
219465167|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
219465168|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
219465169|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
219465170|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
219465171|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
219465172|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
219465173|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
219198694|NCT06861374|DRUG|Bivalirudin|"For rescued PCI, do not recommend to include patient who's ACT is more than 350s.~If fibrinolysis is successful, monitor ACT and wait till it's lower than 350s before randomization.~Monitor ACT before angiography, (1) if ACT\<180, bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (2) if 180s\<ACT\<225s, bivalirudin 0.5mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (3) if ACT\>225s, bivalirudin intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. (4) ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s, intravenous injection of 0.3 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds."
218853173|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
219465174|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
218853174|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
219465175|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
219465176|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
218853175|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
218853176|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
219198695|NCT06861374|DRUG|Unfractionated heparin|(1)If ACT\<180s, administer an intravenous bolus of unfractionated heparin at 70 U/kg before coronary angiography, with a maximum total dose of 6000U. (2)If 180\<ACT\<225s, administer an intravenous bolus of unfractionated heparin at 60 U/kg before coronary angiography, with a maximum total dose of 4000U. (3)If ACT\>225s, proceed directly with PCI and maintain 225s\<ACT\<350s.
219198696|NCT06861088|DRUG|Isoquercetin|Isoquercetin with vitamin C and vitamin B3 capsules
219198697|NCT06861088|DRUG|Placebo|Placebo
219465177|NCT00967356|DRUG|Placebo|Oral suspension
219465178|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
219465179|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
219465180|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
219465181|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
219465182|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
219198698|NCT06858215|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised lay counsellors in primary health care clinics. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the counsellor helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
219198699|NCT04099732|DRUG|Rosuvastatin|Tablet
219198700|NCT04099732|DRUG|BI 1358894|Tablet
219198701|NCT04099732|DEVICE|Dabigatran etexilate|Capsule
219465183|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
219465184|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
219465185|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
218853177|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
219198702|NCT04822350|DRUG|Avelumab|As provided in real world practice
219465186|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
219465187|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
219465188|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
219198703|NCT06617338|DIAGNOSTIC_TEST|CT scan unilateral knee|Intervention given to the Active Comparator arm
219198704|NCT06617338|DIAGNOSTIC_TEST|CT scan bilateral knee|Intervention given to the Experimental Arm
219593493|NCT02620436|OTHER|Core Mother Shelter Model|"1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
219593494|NCT02055664|DRUG|Ropivacaine 0.2%|
219593495|NCT02055664|DRUG|Chlorure de sodium 0.9%|
219198705|NCT06616142|DRUG|[18F]CETO tracer|PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
219198706|NCT06616142|DRUG|Dexamethasone oral|Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
219198707|NCT06616142|PROCEDURE|Adrenal vein sampling|Adrenl vein sampling
219198708|NCT05257603|BEHAVIORAL|RPCW|Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
219465189|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
219465190|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
219465191|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
219465192|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
219465193|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
219465194|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
219593496|NCT00159237|PROCEDURE|blood test|
219198709|NCT05257603|BEHAVIORAL|HEC|Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
219198710|NCT06091163|BEHAVIORAL|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
219199508|NCT04114136|DRUG|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
219199509|NCT04114136|DRUG|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
219465195|NCT01934101|DRUG|CHR-5154|CHR-5154
219593497|NCT05113433|OTHER|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
219593498|NCT05113433|OTHER|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
219465196|NCT01934101|DRUG|Placebo|Placebo
219465197|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
219465198|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
219465199|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
219465200|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
219465201|NCT06018766|DRUG|LAM-001|LAM-001 administered via dry powder inhaler
219465202|NCT06018766|DRUG|Placebo|Placebo administered via dry powder inhaler
219465203|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
219465204|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
219465205|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
219465206|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
219593499|NCT01401556|OTHER|case management|
219593500|NCT01401556|OTHER|Multifaceted quality improvement intervention|
219198711|NCT06091163|BEHAVIORAL|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
219198712|NCT05291507|DEVICE|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
219198713|NCT04882904|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219465207|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
219465208|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
219465209|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
219465210|NCT03802331|DRUG|BI 1323495,|single oral doses
219465211|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
219465212|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
219465213|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
219465214|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
219465215|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
219465216|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
219465217|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
219465218|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
219465219|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
219465220|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
219465221|NCT00917553|DRUG|doxycycline monohydrate|50 mg
219593501|NCT01056315|DRUG|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
219593502|NCT01056315|DRUG|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
219593503|NCT05416788|OTHER|cervical manipulation|high-velocity, low-amplitude cervical manipulation
219593504|NCT05416788|OTHER|Sham intervention|lateral flexion and cervical rotation without manipulation
219593505|NCT02482961|DRUG|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
219593506|NCT04471129|OTHER|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
219593507|NCT04471129|OTHER|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
219465222|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
219593508|NCT06629844|OTHER|The VR dementia education group|The intervention group will receive the VR dementia education program, which will be conducted once for each participant, and each session will accommodate a maximum of 20 participants. The VR dementia education program will follow the flow below, integrating video dramatizations, VR experiences, lectures, and discussions. The program is designed to simulate real-life dementia care situations, encourage reflection, and enhance nursing students' understanding of dementia management. The following are the steps for intervention: Introduction (3 minutes), Pre-Program Questionnaire (10 minutes), Lecture Introduction (2 minutes), Bad Drama (Unfriendly Communication) (10 minutes), Bad VR (10 minutes), Discussion (5 minutes), Lecture 1: What is Dementia? (10 minutes), Good VR (10 minutes), Good Drama (10 minutes), Lecture 2: What Can We Do to Support PLWD? (5 minutes), N-impro (10 minutes), Post-Program Questionnaire (10 minutes), Conclusion (5 minutes).
219465223|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
219465224|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
218853178|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
219199510|NCT04114136|DRUG|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
219465225|NCT01616173|DRUG|Dexamethasone|8mg/2mL
219465226|NCT01616173|DRUG|Saline|2mL
219465227|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
219465228|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
219465229|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
219465230|NCT00014560|BIOLOGICAL|sargramostim|
219465231|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
219465232|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
219465233|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
219465234|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
219465235|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
219465236|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
219465237|NCT01673204|DRUG|Placebo|
219465238|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
219465239|NCT05610228|OTHER|NO intervention|No intervention
219465240|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
219465241|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
219465242|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
219465243|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
219465244|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
219465245|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
219465246|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
219465247|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
219465248|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
219465249|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
219465250|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
219465251|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
219465252|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
219465253|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
219593509|NCT06629844|OTHER|The control group|The intervention begins with an introduction to the VR dementia program, outlining its objectives and setting participant expectations. A pre-program questionnaire follows to assess baseline knowledge, attitudes, and intention to assist people with dementia. A brief lecture introduces a dramatization showing ineffective communication with a PLWD, followed by a VR scenario highlighting poor care practices. After discussing these observations, participants attend a lecture explaining dementia's symptoms and progression, with culturally adapted video content for Indonesian audiences. Next, a positive VR scenario demonstrates best practices in dementia care, followed by a video on supportive communication. A second lecture offers practical strategies for caregiving and communication, complemented by an N-impro session to deepen understanding. The session concludes with a post-program questionnaire and final reflection to encourage real-world application of the learned skills.
219465254|NCT00000322|BEHAVIORAL|Tyrosine|
219465255|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
219465256|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
219465257|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
219465258|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
219465259|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
219465260|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
219465261|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
219465262|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
219465263|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
219465264|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
219465265|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
219465266|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
219465267|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
218853179|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
219465268|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
219465269|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
219465270|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
219465271|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
219465272|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
219465273|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
219465274|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
219465275|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
219465276|NCT04142697|BEHAVIORAL|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
219465277|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
219465278|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
219593510|NCT02937389|DIAGNOSTIC_TEST|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
218853180|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
219465279|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
219465280|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
219465281|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
219465282|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
219465283|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
219465284|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
219465285|NCT01957904|DEVICE|ArterX Surgical Sealant|
219593511|NCT04854044|DRUG|Akt/ERK Inhibitor ONC201|Given orally
219593512|NCT04854044|RADIATION|Radiation Therapy|Undergo radiation therapy
219593513|NCT04854044|PROCEDURE|Resection|Undergo surgical resection
219593514|NCT00469144|DRUG|Busulfan|"Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
219593515|NCT00469144|DRUG|Fludarabine|40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
219465286|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
219465287|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
219465288|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
219465289|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
219465290|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
219465291|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
219465292|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
219465293|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
219465294|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
219465295|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
219465296|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
219198714|NCT06862297|DEVICE|Ultrasonic Jaw Tracking Device|"This study investigates the effectiveness of the Ultrasonic Jaw Tracking Device, a novel non-invasive diagnostic tool designed to monitor dynamic jaw movements during sleep. The device is equipped with advanced ultrasonic sensors and proprietary algorithms to track jaw position and motion in real time.~The intervention involves placing the device on the participant's mandible during polysomnography (PSG) sessions to simultaneously measure jaw movement data alongside standard PSG parameters. The primary goal is to evaluate the accuracy and efficacy of the device in detecting sleep-related conditions such as obstructive sleep apnea (OSA) compared to traditional PSG metrics."
219198715|NCT06862505|PROCEDURE|Biopsy|Biopsy of soft tissue were taken randomly at 8 or 16 weeks to compare soft tissue
219198716|NCT06671197|DEVICE|Pulmonary vein isolation|Pulsed field ablation
219198717|NCT06671197|DEVICE|Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation|Pulsed field ablation
219198718|NCT06671171|DEVICE|Apple Watch Series 9|"Participants will wear Apple Watch Series 9 during cardiopulmonary exercise test (in Visit 1), 1-week study period and 6-Minute walk distance test (in Visit 2) to have assessment of maximal oxygen uptake and pre- and post-SaO2.~During 1-week study period, participants will measure their oxygen saturation once daily with a medical-grade pulse oximeter while wearing the smartwatch continuously."
219198719|NCT06671340|DRUG|Dorzagliatin|chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
219593516|NCT02733380|DRUG|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
219593517|NCT02733380|DRUG|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
219198720|NCT06671106|OTHER|toothbrushing|manual toothbrush (meridol)
219198721|NCT06671106|OTHER|flossing|dental floss (meridol)
219198722|NCT06671106|DEVICE|Toothpaste Product|amine and zinc lactate - containing toothpaste (meridol Gum Protection)
219593518|NCT02733380|DRUG|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
219593519|NCT02733380|DRUG|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
219593520|NCT02733380|DRUG|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
219593521|NCT05128760|DIAGNOSTIC_TEST|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
219593522|NCT02000765|DRUG|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
219198723|NCT06671106|DEVICE|Mouthrinse|amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
219198724|NCT06593847|BEHAVIORAL|Single-session VR exposure intervention|VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
219198725|NCT06678542|DRUG|GP681 tablet|GP681 tablet, 20 mg, single oral dose in each Group.
219198726|NCT06678542|DRUG|GP681 Powder for Oral Suspension|GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
219198727|NCT06679153|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
219198728|NCT06679153|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
219465297|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
219465298|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
219465299|NCT05635110|DRUG|VX-548|Tablets for oral administration.
219465300|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
219465301|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
219465302|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
219465303|NCT05311631|BEHAVIORAL|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
219465304|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
219465305|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
219465306|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
219198729|NCT06679153|DRUG|Prednisolone acetate|Prednisolone acetate, 1%, for up to 28 days
219465307|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
219465308|NCT01992146|DRUG|Target-controlled naloxone-infusion|
219465309|NCT01992146|DRUG|Placebo|
219465310|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
219465311|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
219465312|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
219465313|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
219465314|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
219465315|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
219593523|NCT02000765|DRUG|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
219593524|NCT04602546|DEVICE|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
219593525|NCT02794246|BIOLOGICAL|CART-19 cells|
219198730|NCT04362774|DEVICE|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
219465316|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
219465317|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
219465318|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
219465319|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
219465320|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
219465321|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
219465322|NCT01784094|DEVICE|StromaGlide|
219593526|NCT06455540|PROCEDURE|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
219198731|NCT05932342|BEHAVIORAL|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
219198732|NCT06678906|BEHAVIORAL|Intervention arm|All patients in the intervention group will benefit from the standard information phase on physical activity and sedentary behavior, as well as personalized support for behavior change in the form of a serious game and remote coaching.
219593527|NCT00186940|DRUG|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
219593528|NCT04467450|DRUG|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
219593529|NCT04467450|DRUG|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
219593530|NCT01722422|DRUG|oxygen and saline|
219593531|NCT03951025|DIETARY_SUPPLEMENT|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
219593532|NCT03951025|DIETARY_SUPPLEMENT|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
219593533|NCT05494476|PROCEDURE|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
218853181|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
219465323|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
219465324|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
219465325|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
219465326|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
219465327|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
219465328|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
219465329|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
219465330|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
219465331|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
219465332|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
219465333|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
218853182|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
218853183|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
218853184|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
218853185|NCT02563860|DRUG|Lovastatin|dose escallating
218853186|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
219198733|NCT06867692|OTHER|Aerobic Exercise|"Warm-Up (5 minutes): Marching in Place: 2 minutes of marching to elevate heart rate. Arm Circles: 1 minute of small and large arm circles. Side Steps with Arm Swings: 2 minutes of stepping side to side with gentle arm swings. Main Exercise Routine (35 minutes): Walking/Jogging Intervals: 10 minutes alternating between 1 minute of walking and 1 minute of jogging. Jumping rope: 10 minutes of rope jumping. As a pre-determined routine to maintain consistency. Aerobic Games: 10 minutes of structured games like:~1. Simon Says: Incorporating aerobic movements like jumping jacks, running in place, etc.~2. Obstacle Course: Pre-planned course involving stepping over objects, crawling, and balancing. Ball Activities: 5 minutes of activities such as throwing and catching, or dribbling a ball around cones.~3. Cool Down (5 minutes) Stretching: Gentle stretching of major muscle groups, holding each stretch for 20-30 seconds."
219465334|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
219465335|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
219593534|NCT03775044|DEVICE|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
219593535|NCT06362694|DRUG|Dabrafenib + Trametinib|Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
219593536|NCT01775189|DRUG|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
219593537|NCT01775189|DRUG|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
219593538|NCT01775189|DRUG|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
219593539|NCT01775189|DRUG|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
218853187|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
219465336|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
219465337|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
219465338|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
219465339|NCT03485404|DRUG|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
219465340|NCT03485404|DRUG|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
219465341|NCT03485404|OTHER|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
219465342|NCT03485404|OTHER|Placebo for folic acid|yellow tablets that looks exactly like folic acid
219465343|NCT03485404|PROCEDURE|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
219465344|NCT03485404|BEHAVIORAL|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
219593540|NCT02996292|DEVICE|Traditional brackets|Treating of crowding using traditional brackets
219593541|NCT02996292|DEVICE|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
219593542|NCT02996292|DEVICE|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
219593543|NCT04608435|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
218853188|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
219465345|NCT02020811|DEVICE|Sentinel|
219465346|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
219593544|NCT03585634|BEHAVIORAL|Dads in Gear Program|
219465347|NCT00366665|DEVICE|Legacy 20000|
219465348|NCT00366665|DEVICE|Infinit system|
219465349|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
219593545|NCT00856375|DRUG|NKTR-102|IV every 3 weeks
219593546|NCT00856375|DRUG|irinotecan|IV every 3 weeks
219593547|NCT01455298|OTHER|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
219593548|NCT03846583|DRUG|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
219593549|NCT03846583|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
219593550|NCT03846583|DRUG|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
219593551|NCT03846583|DRUG|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
219593552|NCT00442871|DRUG|eltrombopag|eltrombopag 50 mg oral
219593553|NCT04585230|DRUG|CBD|CBD oil Roll-On Stick
219593554|NCT04585230|DRUG|Mineral Oil|Mineral Oil- Roll on Stick
219465350|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
219465351|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
219465352|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
219465353|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
219465354|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
219465355|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
219465356|NCT02618681|OTHER||
219593555|NCT04585230|DRUG|Placebo|Roll- On stick with no CBD and no Mineral Oil
218853189|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
219465357|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
219465358|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
219465359|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219465360|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219465361|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219465362|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
219465363|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
219465364|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
218853190|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
218853191|NCT02051153|DRUG|Placebo|
219465365|NCT04738123|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
219465366|NCT04738123|DRUG|Placebo|Placebo Capsules
219465367|NCT03153085|BIOLOGICAL|TBI-1401(HF10)|"1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
219465368|NCT03153085|DRUG|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
219465369|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
219465370|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
219465371|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
219465372|NCT00730249|DRUG|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
219465373|NCT00730249|DRUG|Placebo|twice daily according to an individual titration schedule
218853192|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
218853193|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
218853194|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
218853195|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
219465374|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
219465375|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
219465376|NCT00006025|DRUG|irinotecan hydrochloride|
219465377|NCT00006025|DRUG|temozolomide|
219465378|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
219465379|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
219465380|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
219465381|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
219465382|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
219465383|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
219465384|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
219465385|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
218853196|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
218853197|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
218853198|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
219465386|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
218853199|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
218853200|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
218853201|NCT00196027|DEVICE|PFX Closure System|
218853202|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
218853203|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
218853204|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
218853205|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
218853206|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
218853207|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
219465387|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
218853208|NCT01887561|DRUG|dasatinib|
219465388|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
219465389|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
218853209|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
218853210|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
218853211|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
218853212|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
218853213|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
219465390|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
219465391|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
218853214|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
218853215|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
218853216|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
218853217|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
218853218|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
219465392|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
218853219|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
218853220|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
219465393|NCT01072227|PROCEDURE|Sample Collection|Tissue
219465394|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
219465395|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
218853221|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
219465396|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
219465397|NCT03223649|OTHER|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
219465398|NCT03223649|OTHER|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
219465399|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
219465400|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
219465401|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
219465402|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
219593556|NCT02121392|DEVICE|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
219199511|NCT03884439|DRUG|Infliximab [infliximab biosimilar 3]|\<Crohn's disease\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
219593557|NCT02121392|DEVICE|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
219593558|NCT02121392|DRUG|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
218853222|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
218853223|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
218853224|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
218853225|NCT00384423|DRUG|PRX-03140|
218853226|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
218853227|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
218853228|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
218853229|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
218853230|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
219199512|NCT06613763|DRUG|RAY1225|Administered SC
219465403|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
219465404|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
218853231|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
218853232|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
219465405|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
219465406|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
219465407|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
219465408|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
219465409|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
219465410|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
219465411|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
219465412|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
219465413|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
219465414|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
219465415|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
219465416|NCT01478490|DRUG|mirabegron|oral
219465417|NCT01478490|DRUG|metoprolol|oral
219465418|NCT03023124|DRUG|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
218853233|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
218853234|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
218853235|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
218853236|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
218853237|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
218853238|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
218853239|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
218853240|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
218853241|NCT02101801|OTHER|vegetables from fresh or recycled water|
218853242|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
218853243|NCT02123238|OTHER|bed positioning|
218853244|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
218853245|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
218853246|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
218853247|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
219465419|NCT03023124|DRUG|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
219465420|NCT03023124|DRUG|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
219465421|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
219465422|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
219465423|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
219465424|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
219465425|NCT03970603|OTHER|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
219465426|NCT03970603|OTHER|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
219593559|NCT03021863|BEHAVIORAL|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
219593560|NCT03021863|BEHAVIORAL|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
219465427|NCT04550143|OTHER|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
219465428|NCT04550143|OTHER|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
219465429|NCT04550143|OTHER|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
219465430|NCT04550143|OTHER|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness."
219465431|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
219465432|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
219465433|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
219465434|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
219465435|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
219465436|NCT06533176|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
219465437|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
219465438|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
219465439|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
218853248|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
219465440|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
219465441|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
219465442|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
219465443|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
219465444|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
219465445|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
219465446|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
219465447|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
218853249|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
218853250|NCT00098046|DRUG|famciclovir|
218853251|NCT00002858|DRUG|cisplatin|
218853252|NCT00002858|DRUG|cyclophosphamide|
218853253|NCT00002858|DRUG|doxorubicin hydrochloride|
218853254|NCT00002858|DRUG|etoposide|
218853255|NCT00002858|RADIATION|radiation therapy|
219593561|NCT03021863|BEHAVIORAL|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
219593562|NCT03021863|BEHAVIORAL|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
219593563|NCT03021863|BEHAVIORAL|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
219593564|NCT03021863|BEHAVIORAL|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
219465448|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
219198734|NCT06867692|OTHER|Light Physical Activity Plan|"Warm-Up (5 minutes): Gentle Walking: 2 minutes at a slow pace. Light Arm Movements: 1 minute of gently moving arms up and down. Side Steps: 2 minutes of gentle side stepping.~2\. Main Activity Routine (35 minutes): Stretching Exercises: 10 minutes of gentle stretching, focusing on flexibility. Balance Activities: 10 minutes of activities such as: Standing on One Leg: Holding balance for 10-15 seconds on each leg. Heel-to-Toe Walking: Walking in a straight line, placing the heel of one foot directly in front of the toes of the other foot. 3. Light Coordination Games: 10 minutes of low-intensity activities like: Passing a Ball: Gently passing a ball back and forth with a partner. Basic Catch and Throw: Simple throw and catch exercises with a soft ball. Guided Relaxation: 5 minutes of guided relaxation techniques, including deep breathing and visualization. 4. Cool Down (5 minutes) Gentle Stretching: Stretching major muscle groups, holding each stretch for 20-30 second"
219593565|NCT03021863|BEHAVIORAL|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
219593566|NCT03021863|BEHAVIORAL|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
218853256|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
218853257|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
218853258|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
218853259|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
218853260|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
219465449|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
219465450|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
218853261|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
218853262|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
218853263|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
219465451|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
219465452|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
219465453|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
219593567|NCT03021863|BEHAVIORAL|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
219593568|NCT01352416|DRUG|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
219593569|NCT01352416|DRUG|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
219593570|NCT00807716|OTHER|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
219593571|NCT00807716|OTHER|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
219593572|NCT02943135|DRUG|lidocaine in-situ gel|lidocaine in-situ gel
219593573|NCT02943135|DRUG|placebo in-situ gel|placebo in-situ gel
219593574|NCT02597127|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
218853264|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
219465454|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
219465455|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
218853265|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
219465456|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219465457|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219465458|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219465459|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219465460|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
219465461|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
219465462|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
219465463|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
219465464|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
219593575|NCT02597127|DRUG|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
219593576|NCT03231566|BEHAVIORAL|Pain Neuroscience Education|See arm/group description
219593577|NCT03097848|PROCEDURE|RFA|for eligible cases, radiofrequency ablation will be given only.
219465465|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
219465466|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
219593578|NCT03097848|DRUG|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
219593579|NCT00823810|OTHER|PET/CT|18F-FDG PET/CT
219593580|NCT03938623|OTHER|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
219593581|NCT00645632|DRUG|cisplatin|
219593582|NCT00645632|DRUG|doxorubicin hydrochloride|
219593583|NCT00645632|DRUG|ifosfamide|
219465467|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
219465468|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
219465469|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
219593584|NCT00645632|DRUG|methotrexate|
219593585|NCT00645632|PROCEDURE|adjuvant therapy|
219593586|NCT00645632|PROCEDURE|neoadjuvant therapy|
219593587|NCT00645632|PROCEDURE|therapeutic conventional surgery|
219593588|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
219593589|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
219593590|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
218853266|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
218853267|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
219198735|NCT06867029|PROCEDURE|Onlay Mesh|to compare between two techniques of mesh placement in uncomplicated ventral hernias, onlay (mesh on external oblique) versus sublay (mesh in the retromuscular space).
219198736|NCT06867146|DRUG|Three-drug chemotherapy group|Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.
219593591|NCT00658047|DRUG|CH-1504|Comparison of different doses of CH-1504
219593592|NCT00658047|DRUG|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
219593593|NCT05456230|DRUG|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
219593594|NCT02679638|OTHER|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
218853268|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
218853269|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
218853270|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
218853271|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
218853272|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
218853273|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
218853274|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
218853275|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
218853276|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
218853277|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
218853278|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
218853279|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
219465470|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
219465471|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
219465472|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
219465473|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
219465474|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
219465475|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
219198737|NCT06867146|DRUG|two-drug chemotherapy group|two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)
218853280|NCT04669938|OTHER|host immune factors|analysis of host immune factors
218853281|NCT04669938|OTHER|viral sequence|analysis of viral sequence
218853282|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
219198738|NCT06867549|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
219198739|NCT06867549|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
219465476|NCT05278663|DRUG|E6742|E6742 tablet.
219465477|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
219465478|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
219593595|NCT02679638|OTHER|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
219593596|NCT05062213|OTHER|Moisturizer Body Lotion|Moisturizer Body Lotion
219593597|NCT03829787|DEVICE|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
219593598|NCT00994578|BEHAVIORAL|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
219198740|NCT06867549|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Trained staff will provide evaluation and up to 3 follow up appointments of BBTI for all participants. These will be done remotely to assess behavioral approaches to improve overall sleep habits.
219465479|NCT01252992|GENETIC|Genetic analysis|"1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
219465480|NCT01252992|RADIATION|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
219465481|NCT01252992|OTHER|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
219465482|NCT01252992|OTHER|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
218853283|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
219465483|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
219465484|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
219465485|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
219465486|NCT00083616|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
219593599|NCT00994578|BEHAVIORAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
219593600|NCT00994578|BEHAVIORAL|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
218853284|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
219198741|NCT06866392|DIAGNOSTIC_TEST|photoelectric detection|Methylation test and colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test and colposcopic biopsy and OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results.
219198742|NCT06866327|BEHAVIORAL|Piano lessons|The program consists of 12-weekly piano lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn note reading, finger positioning, and song playing. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with a keyboard and bench provided.
219198743|NCT06866327|BEHAVIORAL|Music Lessons|The program consists of 12-weekly music lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn various instruments, engage in group playing during group lessons, and engage in music appreciation activities. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with instruments provided.
218853285|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
219198744|NCT06619093|OTHER|blood sampling|3 additional citrate tubes (2.7mL)
219198745|NCT06866587|OTHER|exercise therapy|Priorities of the treatment included care and interventions to avoid inappropriate neck positions and to provide a regular exercise program for neck muscles and ergonomics training (ergonomic arrangements for desk setup, reading position, computer and mobile phone use, handcrafts, television watching, and pillow height). Of note, patients were advised to avoid cold exposure, particularly in the neck area (air-conditioned environments, wet hair, and holding the hair dryer too close to the scalp). Patients that did not show improvement after training and regular exercise were initiated on medical treatment after the second week and were given myorelaxant gel and oral tablets (diclofenac sodium) for the neck area.
219198746|NCT05112900|BEHAVIORAL|Text Messaging (TM)|\[see arm/group descriptions\]
219198747|NCT05112900|BEHAVIORAL|Text Messaging + Health Navigation (TM+HN)|\[see arm/group descriptions\]
219198748|NCT05849610|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
219198749|NCT05849610|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
219198750|NCT05849610|DRUG|Lenalidomide|Lenalidomide will be administered by oral route.
219198751|NCT05849610|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
219198752|NCT05849610|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
219198753|NCT04745962|DEVICE|Slimscope|Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
219198754|NCT03350516|DIETARY_SUPPLEMENT|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
219465487|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
219465488|NCT00597129|BIOLOGICAL|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
218853286|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
218853287|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
218853288|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
218853289|NCT01588314|DRUG|placebo|compounded placebo capsules
218853290|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
219465489|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
219465490|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
219465491|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
219465492|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
219465493|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
219465494|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
219465495|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
219465496|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
219465497|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
219465498|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
218853291|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
218853292|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
218853293|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
219198755|NCT03350516|DIETARY_SUPPLEMENT|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
219465499|NCT02264132|DRUG|Pramipexole ER tablet|
219465500|NCT02264132|DRUG|Pramipexole IR tablet|
219465501|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
219465502|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
219465503|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
219465504|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
219465505|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
219465506|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
219465507|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
219465508|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
219465509|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
219593601|NCT00220831|DRUG|Natural source Vitamin E 400IU/day|
219593602|NCT02008435|BEHAVIORAL|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
219593603|NCT02008435|BEHAVIORAL|Standard GLB|This arm is the standard Group Lifestyle Balance program
219593604|NCT05914688|DRUG|LY3209590 (Formulation 1)|Administered SC.
219593605|NCT05914688|DRUG|LY3209590 (Formulation 2)|Administered SC.
219593606|NCT04045483|OTHER|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
219593607|NCT03687411|PROCEDURE|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
219593608|NCT02922738|OTHER|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
219593609|NCT01010113|OTHER|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
219593610|NCT01010113|OTHER|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
219593611|NCT00385008|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
219593612|NCT00385008|DRUG|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
219593613|NCT00811928|DRUG|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
218853294|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
219465510|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
219198756|NCT06854068|DEVICE|laser treatment|In the laser treatment groups, the Fotona LightWalker® Erbium laser (2,940 nm) will be used, with each session lasting five minutes. During treatment, the energy density will be set to 20 J/cm², and the laser tip will be held perpendicular to the target area, applied in continuous and contact modes.
219465511|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
219465512|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
219465513|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
219465514|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
219465515|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
219465516|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
219465517|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
219465518|NCT00091039|DRUG|carboplatin|
219465519|NCT00091039|DRUG|paclitaxel|
219465520|NCT00091039|RADIATION|radiation therapy|
219198757|NCT06854068|DEVICE|application of desensitizing agent|"Mix the product for 15 s. Apply in a thin layer on treatment area(s) with aid of a microbrush, with no rinsing or removal"
219198758|NCT06854068|OTHER|Placebo|"Simulation of a single layer application (15s) , with the aid of a microbrush, on the surface of the tooth and with no rinsing or removal."
219198759|NCT06225232|DRUG|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
219465521|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
219465522|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
219465523|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
219465524|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
219465525|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
219593614|NCT00811928|DRUG|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
219593615|NCT03353883|DRUG|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
219593616|NCT06548997|DRUG|GZR18|5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
219593617|NCT06548997|OTHER|Placebo|administered the same volume as GZR18
219593618|NCT00641069|DEVICE|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
218853295|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
219198760|NCT03581071|DRUG|TS-143|
219198761|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C1|Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
219465526|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
219593619|NCT05537350|DIETARY_SUPPLEMENT|Lumenato|Supplementation of 12 weeks
219465527|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
219465528|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
219465529|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
219465530|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
219465531|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
219465532|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
219465533|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
219465534|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
219465535|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
219465536|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
219465537|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
219465538|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
219465539|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
219465540|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
219465541|NCT06424756|DIETARY_SUPPLEMENT|MitoQ|MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
219465542|NCT06424756|DIETARY_SUPPLEMENT|Placebo|MitoQ matched Placebo
219465543|NCT06424756|DRUG|MitoTempo|During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
219465544|NCT06424756|DRUG|Tempol|During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
219465545|NCT06424756|DRUG|L-NAME|During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
219465546|NCT06424756|DRUG|SNP - Sodium Nitroprusside|At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
219593620|NCT03431545|BEHAVIORAL|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
219198762|NCT05447338|PROCEDURE|Maitland C2|Maitland central posterior-anterior passive joint mobilization at C2: The patient will lie prone, the therapist behind the patient's head, with both thumbs will apply a central force on the spinous process of C2. The duration of the application will be up to five applications of 10 to 30 seconds in duration, depending on clinical judgment.
219465547|NCT01853397|DEVICE|Liposonix System (Model 2)|
219465548|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
219465549|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
219465550|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
219465551|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
219465552|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
219465553|NCT02132312|DRUG|OMS302|
219465554|NCT02132312|DRUG|Phenylephrine HCl|
219465555|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
219465556|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
219465557|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
219465558|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
219465559|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
219465560|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
219465561|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
219465562|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
219465563|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
219465564|NCT02242305|DRUG|Placebo|
219465565|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
219593621|NCT03431545|BEHAVIORAL|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
219593622|NCT03431545|BEHAVIORAL|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
218853296|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
218853297|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
219465566|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
219465567|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
219593623|NCT05231005|BIOLOGICAL|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
219593624|NCT00171951|DRUG|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
219593625|NCT05593419|DEVICE|TIIC signature|Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
218853298|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
218853299|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
219465568|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
219465569|NCT06268288|DEVICE|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
219465570|NCT06268288|OTHER|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
218853300|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219465571|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
219593626|NCT02234219|PROCEDURE|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
219593627|NCT02234219|PROCEDURE|Soave anastomosis|traditional approach for Hirschsprung disease
219593628|NCT00396812|DRUG|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
219593629|NCT04839484|DEVICE|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
218853301|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
218853302|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
218853303|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
218853304|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
218853305|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
218853306|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
218853307|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
218853308|NCT03434431|OTHER|Reverse dieting|
218853309|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
218853310|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
218853311|NCT03469830|OTHER|SSCP|Insert
218853312|NCT03469830|OTHER|SPMS|Pressure therapy
219465572|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
219465573|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
219465574|NCT00769821|OTHER|questionnaire administration|
219465575|NCT00769821|PROCEDURE|assessment of therapy complications|
219465576|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
219465577|NCT00769821|PROCEDURE|quality-of-life assessment|
219465578|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
219593630|NCT04839484|DEVICE|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
218853313|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
218853314|NCT02174523|DRUG|40mg lurasidone|
218853315|NCT02174523|DRUG|placebo|
219465579|NCT04052711|DRUG|FMX-101|
219465580|NCT06112249|BEHAVIORAL|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
219593631|NCT02695784|DIETARY_SUPPLEMENT|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
219198763|NCT05447338|PROCEDURE|SNAG C1|Sustained natural apophyseal slippage (SNAG) will be applied e.g. in the case of wanting to improve the left rotation. The therapist performs a sustained anterior glide to the C1 transverse process on the left. The participant will be seated, simultaneously rotating their head to the left while holding the SNAG. The glide of C1 will be maintained by the therapist until the participant's head returns to the neutral starting position. The same will be done, but in the opposite direction to improve the right rotation.
219465581|NCT06520046|OTHER|Experimental Group|Propioceptive exercises
219465582|NCT06520046|OTHER|Control Group|Usual exercises
219465583|NCT03451630|BEHAVIORAL|High-Touch|Intensive, in-person and/or telephonic support.
219465584|NCT03451630|BEHAVIORAL|High-Tech|Remote care management and self-directed digital tools.
219465585|NCT03451630|BEHAVIORAL|Optimal Discharge Planning|Transition to other Health Plan disease management programs and/or community resources.
219465586|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
219465587|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
219465588|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
219465589|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
219465590|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
219465591|NCT06334237|OTHER|personalized treatment|According to the condition of each individuals, the study continues their routine clinical care. The study does not offer anything more than a routine clinical care. It is named personalized treatment because the condition of each individual varies, so the doctor may prescribe or offer clinical advice accordingly. .
219593632|NCT04873973|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
219593633|NCT04935684|DRUG|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
219593634|NCT06301906|DRUG|LipoCol Forte Capsule 600mg bid|LipoCol Forte Capsule 600mg bid for 12 months
219593635|NCT00534456|DRUG|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
219465592|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
219465593|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
219465594|NCT02146911|DRUG|Bupropion|
219465595|NCT02146911|DRUG|Varenicline|
219465596|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
219465597|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
219465598|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
218853316|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
218853317|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
218853318|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
218853319|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
219465599|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
219465600|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
219465601|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
219198764|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C2|The therapist rotates the head to the right side until the final sensation of the movement is noted, either due to pain or muscular tension. From this position, the therapist asks the patient to rotate the head to the left side while offering resistance with both hands in the opposite direction, in such a way as to generate an isometric contraction of the rotator muscles of the head to the left. The therapist then asks the patient to hold the position for 6 seconds. Subsequently, the therapist with the finger in the transverse process of C1, pushes it in the postero-anterior direction and simultaneously (with the contratome hand) rotates the patient's head to the right. The technique is repeated until the ROM improves, always taking into account the patient's tolerance.
219361499|NCT03623724|BEHAVIORAL|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
219593636|NCT00534456|DRUG|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
219593637|NCT03153033|BEHAVIORAL|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
219593638|NCT05577195|DEVICE|Impella|To provide active left ventricular unloading in the experimental arm
219593639|NCT05577195|DEVICE|VA-ECMO|To provide circulatory support in both arms
219465602|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
218853320|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
219465603|NCT00000131|PROCEDURE|Photocoagulation Therapy|
219465604|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
219465605|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
219593640|NCT03008317|DEVICE|PEEK|a metallic denture base
218853321|NCT01839240|DRUG|azacitidine|Given IV or SC
218853322|NCT01839240|DRUG|cytarabine|Given IV
218853323|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
218853324|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
218853325|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
218853326|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
219593641|NCT03783325|BEHAVIORAL|UV Counseling|This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.
218853327|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
218853328|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
218853329|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
218853330|NCT00410319|BEHAVIORAL|Fear-reducing Information|
218853331|NCT00410319|BEHAVIORAL|Symptom-based exercise|
219593642|NCT03783325|OTHER|UV Photo|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
219593643|NCT03783325|OTHER|Biological Sample|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
219593644|NCT04601571|DEVICE|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
219593645|NCT03998397|BIOLOGICAL|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
219593646|NCT05178342|DRUG|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
219593647|NCT00131599|DRUG|5FU/LV|5FU/LV
219593648|NCT04590105|DEVICE|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
219593649|NCT04590105|OTHER|Written Instruction|Written Instruction
219361500|NCT03623724|OTHER|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
219361501|NCT00001398|DRUG|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
219361502|NCT05836649|BEHAVIORAL|Oculus Go headset without active intervention|VR software with non-interactive content.
219361503|NCT05836649|BEHAVIORAL|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
219361504|NCT00546364|DRUG|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
219361505|NCT00546364|DRUG|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
219361506|NCT00546364|DRUG|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
219361507|NCT04793399|DRUG|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
219361508|NCT04793399|DRUG|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
219363047|NCT04925895|OTHER|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
218853332|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
219465606|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
219465607|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
219465608|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
219465609|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
219465610|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
219465611|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
219465612|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
219465613|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
219465614|NCT03570476|DRUG|Olaparib|Given orally
219465615|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
219465616|NCT02041533|BIOLOGICAL|Nivolumab|
219593650|NCT06968468|BEHAVIORAL|Resilient Together ALS|This intervention will teach resiliency and coping skills (mindfulness, meaning making, etc) to dyads soon after ALS diagnosis in order to manage distress associated with an ALS diagnosis. These sessions will take place over Zoom with both the person diagnosed with ALS and their primary informal caregiver.
219593651|NCT06079320|DRUG|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
219593652|NCT06079320|DRUG|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
218853333|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
219465617|NCT02041533|DRUG|Gemcitabine|
219465618|NCT02041533|DRUG|Cisplatin|
219465619|NCT02041533|DRUG|Carboplatin|
219465620|NCT02041533|DRUG|Paclitaxel|
219465621|NCT02041533|DRUG|Pemetrexed|
219465622|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
219465623|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
219465624|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
219465625|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
219465626|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
219465627|NCT04177186|OTHER|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
219465628|NCT04177186|COMBINATION_PRODUCT|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
219465629|NCT00641979|DRUG|budesonide|Current product
219465630|NCT00641979|DEVICE|Budesonide|New type device
219465631|NCT00641979|DRUG|Placebo|
219465632|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
219465633|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
219465634|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
219465635|NCT03138798|DEVICE|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
219465636|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
219465637|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
219593653|NCT03218124|OTHER|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
219593654|NCT00233402|DRUG|Hexvix|Single Instillation, Transurethral Resection of the Bladder
219593655|NCT00233402|PROCEDURE|Standard white light cystoscopy|
218853334|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
219465638|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
219465639|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
219465640|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
219465641|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
219465642|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
219465643|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
219593656|NCT00259233|DRUG|peripheral Peptide YY administration|
219465644|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
219465645|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
219593657|NCT04084457|DIETARY_SUPPLEMENT|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
218853335|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
218853336|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
218853337|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
218853338|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
218853339|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
219465646|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
218853340|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
219465647|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
218853341|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
218853342|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
218853343|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
218853344|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
218853345|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
219593658|NCT04084457|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
219593659|NCT06975501|BEHAVIORAL|Exercise Intervention|Participants will receive twice-weekly aerobic and balance training sessions, with medication compliance education.
219593660|NCT06975501|BEHAVIORAL|Cognitive Intervention|Participants will participate in twice-weekly structured cognitive training sessions, with medication compliance education.
218853346|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
218853347|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
218853348|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
218853349|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
218853350|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
218853351|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
218853352|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
218853353|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
219465648|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
219465649|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
219465650|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
219593661|NCT04034563|PROCEDURE|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
219593662|NCT01963286|DEVICE|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
219593663|NCT03663634|OTHER|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
218853354|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
218853355|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
218853356|NCT01391572|DRUG|cisplatin|
218853357|NCT01391572|DRUG|fluorouracil|
218853358|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
218853359|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
218853360|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
218853361|NCT00416156|BEHAVIORAL|Lifestyle modification|
219465651|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
219593664|NCT06007066|DRUG|HSK16149 capsule|Subjects will be given 40mg or 60mg of HSK16149 orally.
219593665|NCT06007066|DRUG|Placebo|Subjects will be given HSK16149 placebo orally.
218853362|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
218853363|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
218853364|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
218853365|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
218853366|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
218853367|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
218853368|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
218853369|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
218853370|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
218853371|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
219465652|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
219465653|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
219465654|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
219465655|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
219465656|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
219465657|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
219465658|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
219465659|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
219465660|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
219465661|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
219465662|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
219465663|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
219465664|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
219465665|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
219465666|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
219465667|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
219465668|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
219593666|NCT04091711|DEVICE|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
219465669|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
218853372|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
219465670|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
219465671|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
219465672|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
219593667|NCT04016220|DRUG|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
219593668|NCT04016220|DRUG|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
218853373|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
218853374|NCT03581695|OTHER|Blood test|Blood test
218853375|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
218853376|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
218853377|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
218853378|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
219465673|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
219465674|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
219465675|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
219465676|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
219465677|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
219465678|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
219465679|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
219593669|NCT04278950|DRUG|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
219593670|NCT04278950|DRUG|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
218853379|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
218853380|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
219465680|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
219465681|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
219465682|NCT05047601|DRUG|PF-07321332|PF-07321332
219465683|NCT05047601|DRUG|Placebo for PF-07321332|Placebo
219465684|NCT05047601|DRUG|Placebo for Ritonavir|Placebo
218853381|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
218853382|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
218853383|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
219465685|NCT05047601|DRUG|Ritonavir|Ritonavir
219465686|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
218853384|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
218853385|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
218853386|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
218853387|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
218853388|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
219465687|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
219465688|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
219465689|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
219465690|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
219465691|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
219465692|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
219465693|NCT00208572|DRUG|Citalopram|
219593671|NCT02581722|DEVICE|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
219593672|NCT06182761|DRUG|Sunvozertinib combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
218853389|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
218853390|NCT05611229|DRUG|Nivolumab|Nivolumab
219198765|NCT05447338|PROCEDURE|Myofascial inductions; Suboccipital induction|The therapist places his hands under the patient's head in such a way that he can palpate the spinous processes of the cervical vertebrae with his fingers. Next, slowly bring your fingers up until they contact the occipital condyles. At this time he should gently move his fingers downward, thus finding the space between the condyles and the spinous process of the axis. Next, flexing the metacarpophalangeal joints to 90°, slowly elevate the skull. The therapist's hands should remain together and the base of the skull should rest on their palms. The therapist should apply pressure with the index, middle and ring fingers of each hand. This pressure should be maintained for a few minutes until a release of the fascia is noted. In the last phase of the technique, the therapist, without releasing the pressure, opens his hands and slowly brings his head back.
219465694|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
219465695|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
219465696|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
219465697|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
219465698|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
219465699|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
219465700|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
219465701|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
219465702|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
219465703|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
219465704|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
219465705|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
219465706|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
219465707|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
219465708|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
219465709|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
219465710|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
219465711|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
219593673|NCT04032249|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
219593674|NCT04032249|BEHAVIORAL|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
219593675|NCT04810949|DIETARY_SUPPLEMENT|Vitamine D3 supplementation|1\. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
219593676|NCT04810949|DIETARY_SUPPLEMENT|Diet and sun exposure|"2\. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
219593677|NCT06407986|DIAGNOSTIC_TEST|pulmonary function test|Whether the estimated value of FEV1 and FVC is greater than 80%.
219465712|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
218853391|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
218853392|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
218853393|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
218853394|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
218853395|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
218853396|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
218853397|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
218853398|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
218853399|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
218853400|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
219465713|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
219465714|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
219465715|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
219465716|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
219465717|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
219465718|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
219465719|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
219465720|NCT04084275|BEHAVIORAL|breastfeeding education|
219465721|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
219465722|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
219465723|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
219465724|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
219465725|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
219465726|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
219465727|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
218853401|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
218853402|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
219465728|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
219593678|NCT06484725|GENETIC|Oncotype DX assay|Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
219593679|NCT04181723|DRUG|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
219593680|NCT04181723|OTHER|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
219593681|NCT05509816|DRUG|Midazolam|Administered orally.
219593682|NCT05509816|DRUG|Imlunestrant|Administered orally.
219593683|NCT05161247|OTHER|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
219593684|NCT05161247|OTHER|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
219593685|NCT05161247|OTHER|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
218853403|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
218853404|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
218853405|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
218853406|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
218853407|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
218853408|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
218853409|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
218853410|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
218853411|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
218853412|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
218853413|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
218853414|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
218853415|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
219465729|NCT02471625|DEVICE|ClearView Scanning|
219465730|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
219465731|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
219465732|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
219465733|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
219465734|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
219465735|NCT00997906|DRUG|carboplatin,|Given IV
219465736|NCT00997906|DRUG|cisplatin|Given IV
219465737|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
219465738|NCT00997906|DRUG|paclitaxel|Given IV
219465739|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
219593686|NCT02087189|DEVICE|First ICD/CRT-D implantation or upgrade from pacemaker|
219465740|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
219465741|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
219465742|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
219465743|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
219465744|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
219465745|NCT02909920|OTHER|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
219465746|NCT02909920|OTHER|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
219465747|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
219593687|NCT05375877|DEVICE|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
218853416|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
218853417|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
218853418|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
218853419|NCT06587334|PROCEDURE|SRP|SRP alone
218853420|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
218853421|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
218853422|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
218853423|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
219465748|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
219465749|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
219465750|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
219465751|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
219465752|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
219465753|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
219593688|NCT04570462|OTHER|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
219593689|NCT03203564|DRUG|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
219593690|NCT02377050|OTHER|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
219593691|NCT06199063|OTHER|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
219465754|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
219465755|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
219465756|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
219465757|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
219465758|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
219465759|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
219465760|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
219465761|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
219465762|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70\_R84-064)
219465763|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
219465764|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
219465765|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
219593692|NCT06199063|OTHER|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
219593693|NCT06199063|OTHER|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
219593694|NCT04429438|BIOLOGICAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
219593695|NCT00500136|PROCEDURE|mortality salience|
218853424|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
218853425|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
218853426|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
219593696|NCT04810637|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
218853427|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
218853428|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
218853429|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
218853430|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
219593697|NCT05129007|DEVICE|Oura ring|Photopletysmography based noninvasive device
219593698|NCT05434429|OTHER|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
219593699|NCT04869215|OTHER|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
219593700|NCT04869215|OTHER|Control bread|Bread baked with normal Bakers flour
219593701|NCT05865730|OTHER|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
219593702|NCT01189487|DRUG|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
219593703|NCT01879748|DRUG|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
219593704|NCT01879748|DRUG|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
219593705|NCT04386486|OTHER|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
219593706|NCT04386486|OTHER|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
219593707|NCT06112392|DIAGNOSTIC_TEST|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
218853431|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
218853432|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
218853433|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
218853434|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
218853435|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
218853436|NCT06730698|OTHER|No intervention|No intervention
218853437|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
218853438|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
218853439|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
219465766|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
218853440|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
219465767|NCT00001126|DRUG|Cidofovir|
219465768|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
219465769|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
219465770|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
219465771|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
219465772|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
219465773|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
219593708|NCT06112392|DIAGNOSTIC_TEST|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
219593709|NCT04630158|OTHER|SAF312 Placebo|Topical ocular, suspension eye drops
219593710|NCT04630158|DRUG|SAF312|Topical ocular, suspension eye drops
219593711|NCT05886387|OTHER|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
219593712|NCT05886387|OTHER|Standard PEEP. Low positive end-expriatory pressure|Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
219593713|NCT03363386|PROCEDURE|Proprioceptive Exercises|Patients trained for proprioceptive exercises
219593714|NCT03363386|PROCEDURE|Resistive Exercises|Patients trained for resistive exercises
219593715|NCT03363386|PROCEDURE|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
219465774|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
219465775|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
219465776|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
219465777|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
219465778|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
219465779|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
219465780|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219465781|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
219465782|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
219593716|NCT05269979|BEHAVIORAL|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
219593717|NCT05162014|DRUG|empagliflozin|empagliflozin
219593718|NCT05162014|DRUG|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
219593719|NCT00120679|DRUG|darbepoetin alfa|
218853441|NCT03985410|DRUG|ETX2514|intravenous infusion
218853442|NCT03985410|DRUG|Placebo|intravenous infusion
218853443|NCT03985410|DRUG|moxifloxacin|oral tablet
218853444|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
219593720|NCT00120679|DRUG|recombinant human erythropoietin (rHuEPO)|
219593721|NCT02074618|OTHER|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
218853445|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
218853446|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
218853447|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
218853448|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
218853449|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
218853450|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
218853451|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
218853452|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
218853453|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
218853454|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
219465783|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
219465784|NCT03459976|DIAGNOSTIC_TEST|evaluate serum level HE4 in endometrial cancer|"1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer"
219465785|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
219465786|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
219465787|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
219465788|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
219465789|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
219465790|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
219465791|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
219465792|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
219593722|NCT00912925|BIOLOGICAL|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
219593723|NCT00912925|BIOLOGICAL|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
219465793|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
219465794|NCT02465541|OTHER|questionnaire administration|Ancillary studies
219465795|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
219465796|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
219593724|NCT04594317|DEVICE|low level laser therapy|buccal application of diode laser on non-contact mode
219593725|NCT03103139|PROCEDURE|Transpapillary Stent|ERCP with placement of short stent
219465797|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
219593726|NCT03103139|PROCEDURE|Stent across bile leak|ERCP with long stent
219593727|NCT00390559|DRUG|nicotine transdermal system|21 mg nicotine transdermal system
219593728|NCT00390559|DRUG|Nicotine transdermal system|Placebo nicotine patch
219593729|NCT00390559|OTHER|Nicotine containing cigarette|Nicotine containing cigarette
219465798|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
219465799|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
219465800|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
219465801|NCT03824756|OTHER|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
219593730|NCT00390559|OTHER|Placebo cigarette|Non nicotine containing cigarette
219593731|NCT04152187|OTHER|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
219593732|NCT03136965|BIOLOGICAL|PRP|Injection of autologous platelet rich plasma (PRP)
219593733|NCT03136965|PROCEDURE|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
219593734|NCT03136965|PROCEDURE|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
219593735|NCT04868968|DRUG|DFV890|100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
219593736|NCT01527812|PROCEDURE|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
219593737|NCT00767624|DRUG|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
219593738|NCT00767624|BEHAVIORAL|Desensitization Therapy for Insomnia|
218853455|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
218853456|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
218853457|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
218853458|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
219465802|NCT03824756|OTHER|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
219465803|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
219465804|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
219593739|NCT00767624|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
219593740|NCT01410643|OTHER|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
219593741|NCT01349777|DRUG|Pregrel®|Pregrel® 75mg daily for 12 months
219593742|NCT01349777|DRUG|Plavix®|Plavix® 75mg daily for 12 months
219198766|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 1|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought
219593743|NCT02563392|PROCEDURE|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
219593744|NCT02563392|PROCEDURE|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
219593745|NCT04269681|DEVICE|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
219593746|NCT04269681|OTHER|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
219593747|NCT00499421|PROCEDURE|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
219593748|NCT06060379|OTHER|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
219593749|NCT02612259|DIETARY_SUPPLEMENT|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
219593750|NCT02612259|OTHER|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
219593751|NCT04292652|PROCEDURE|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
219593752|NCT04962152|DRUG|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
219593753|NCT06532851|OTHER|Progressive Resistance Exercise (PRE)|A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
218853459|NCT06660992|DRUG|Placebo|the placebo comparator of study
218853460|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
218853461|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
219593754|NCT06532851|OTHER|Aerobic Exercise|An exercise program focusing on cardiovascular conditioning using a stationary bike.
219593755|NCT06532851|OTHER|Control|A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
219465805|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
219465806|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
219465807|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
219465808|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
219465809|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
219465810|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
219465811|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
218853462|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
218853463|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
218853464|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
218853465|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
218853466|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
218853467|NCT05131971|DRUG|GSK3888130B|GSK3888130B will be administered.
219465812|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
219465813|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
219465814|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
219465815|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
219593756|NCT06462560|OTHER|Vivo Online Exercise Program|Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
219593757|NCT06462560|OTHER|Medbridge Home program|At home exercise program accessed through exercise descriptions and short vidoes
219593758|NCT03357653|DRUG|Losartan group|Losartan 50 mg daily
218853468|NCT05131971|DRUG|Placebo|Placebo will be administered.
218853469|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
219465816|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
219593759|NCT03357653|DRUG|Placebo group|Placebo 1 pill daily
219593760|NCT00763061|DRUG|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo \& 9 PM
218853470|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
219198767|NCT05447338|PROCEDURE|Myofascial inductions; Horizontal induction of the TMJ.|The therapist places the middle fingers of both hands on the lingual aspect of the lower molar teeth and then gently presses towards the table. This pressure must be maintained for a minimum of 90 to 120 seconds. Afterwards, the therapist, very attentive to the changes in the direction of the fascial restriction, follows the release movement.
219593761|NCT00763061|DRUG|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM \& 9 PM
219465817|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
219465818|NCT02992054|OTHER|stimulating activities|
219465819|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
219465820|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
219465821|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
219465822|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
219465823|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
219465824|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
219465825|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
219465826|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
219465827|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
219465828|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
219465829|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
219465830|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
219465831|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
219465832|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
219465833|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
219465834|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
219465835|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
219465836|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
219465837|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
219593762|NCT03661697|DEVICE|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
219465838|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
219593763|NCT03661697|OTHER|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
219593764|NCT03661697|OTHER|Lytera|cosmeceutical serum applied to face daily for 12 weeks
219593765|NCT04590638|OTHER|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
219593766|NCT04590638|OTHER|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
219465839|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
219465840|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
219465841|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
219465842|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
219465843|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
219465844|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
219465845|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
219465846|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
219465847|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
219465848|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
219465849|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
219465850|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
219465851|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
219593767|NCT05179538|BEHAVIORAL|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
219593768|NCT03638414|OTHER|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
219465852|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
219465853|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
219465854|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
219465855|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
219465856|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
219465857|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
219465858|NCT06724185|DIETARY_SUPPLEMENT|LP28 capsule|LP28 capsule : 5.0×10\^9 CFU/capsule
219465859|NCT06724185|DIETARY_SUPPLEMENT|Placebo Capsule|Maltodextrin
219465860|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
219465861|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
219465862|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
219465863|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
219465864|NCT02557815|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
219465865|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
219465866|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
219465867|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
219465868|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
219593769|NCT01740050|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
219465869|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
219465870|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
219465871|NCT02510976|DRUG|prucalopride|
219465872|NCT02510976|DRUG|placebo|
219465873|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
219465874|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
219465875|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
218853471|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
219465876|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
219465877|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
219465878|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
219465879|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
219465880|NCT03377985|PROCEDURE|brachial plexus block|
219465881|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
219465882|NCT03461705|DEVICE|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
219465883|NCT03461705|DEVICE|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
219465884|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
219465885|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
219465886|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
219593770|NCT01740050|PROCEDURE|RYGB|
219593771|NCT01740050|PROCEDURE|LAGB|
219593772|NCT05233111|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
219593773|NCT05233111|BEHAVIORAL|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
219593774|NCT00343356|DRUG|Trement|
219465887|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
219465888|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
219465889|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
219465890|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
219465891|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
219465892|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
219465893|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
219465894|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
219465895|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
219465896|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
219465897|NCT00982800|DRUG|Placebo Sugar Pill|
219593775|NCT03460392|DRUG|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
219593776|NCT06633055|DRUG|JH013 injection|JH013 injection is a BAFF-R inhibitor monoclonal antibody
219593777|NCT06633055|DRUG|Placebo|JH013 injections placebo
219593778|NCT00843635|DRUG|Tadalafil|Given orally
219593779|NCT00843635|OTHER|Placebo|Given orally
219593780|NCT00776750|BIOLOGICAL|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
219593781|NCT06310304|DRUG|Ruxolitinib IR|Tablet
219593782|NCT06310304|DRUG|Ruxolitinib XR|Tablet
219465898|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
219465899|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
219465900|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
219465901|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
219465902|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
219465903|NCT03044730|DRUG|Capecitabine|Given PO
219465904|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
219593783|NCT00140348|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
218853472|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
218853473|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
218853474|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
219465905|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
219465906|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
219465907|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
219465908|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
219465909|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
218853475|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
218853476|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
219465910|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
218853477|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
219465911|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
219465912|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
219593784|NCT04523935|OTHER|Placebo|Fructose powder identical with the drugs was used
219465913|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
219465914|NCT05486715|DRUG|Vit D|Vit D
219465915|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
219465916|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
219465917|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
219465918|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
219465919|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
219465920|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
219465921|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
218853478|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
218853479|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
218853480|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
218853481|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
218853482|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
219465922|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
219465923|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
219465924|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
219465925|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219465926|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219465927|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
219465928|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
219465929|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
219465930|NCT01304576|OTHER|MRI|Cerebral MRI
219465931|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
219465932|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
219465933|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
219465934|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
219465935|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
219465936|NCT02496715|DRUG|Placebo|Placebo inhaler
219465937|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
219465938|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
219465939|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
219465940|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
219465941|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
219465942|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
219465943|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
219465944|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
219465945|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
219465946|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
219465947|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
219465948|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
219465949|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
219465950|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
219465951|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
219465952|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
219465953|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
219465954|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
219465955|NCT00977600|DRUG|Ammonul|
219465956|NCT00977600|DRUG|Buphenyl|
219465957|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
219465958|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
219465959|NCT02335359|DRUG|Placebo|Saline
218853483|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
218853484|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
218853485|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
218853486|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
218853487|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
218853488|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
218853489|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
218853490|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
218853491|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
218853492|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
218853493|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
219465960|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
219465961|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
218853494|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
218853495|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
218853496|NCT03243578|OTHER|None as this is an observational study|
218853497|NCT02403635|DRUG|Midazolam|
218853498|NCT02403635|DRUG|ASP2151|
218853499|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
218853500|NCT00195520|DRUG|Totelle®|
218853501|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
218853502|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
218853503|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
218853504|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
218853505|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
218853506|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
219465962|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
219465963|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
219465964|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
219465965|NCT01786707|OTHER|Hyperbaric oxygen therapy|
219465966|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
219465967|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
219465968|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
219465969|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
218853507|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
219465970|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
219465971|NCT01953380|BEHAVIORAL|extended information|
219465972|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
219465973|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
219593785|NCT04523935|DRUG|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
218853508|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
218853509|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
218853510|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
218853511|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
218853512|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
218853513|NCT01919047|DRUG|Betanis|Oral
218853514|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
218853515|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
218853516|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
218853517|NCT02080039|DEVICE|Electrical Stimulation|
218853518|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
218853519|NCT00937144|DRUG|placebo|
219465974|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
219465975|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
219465976|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
219465977|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
219465978|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
219465979|NCT02641691|RADIATION|Radiation|
219465980|NCT02641691|DRUG|Oxaliplatin|
219465981|NCT02641691|DRUG|Leucovorin|
219465982|NCT02641691|DRUG|Fluorouracil|
219465983|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
219465984|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
219465985|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
219593786|NCT02457663|PROCEDURE|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
219593787|NCT03013855|DEVICE|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
219593788|NCT03013855|DEVICE|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
219593789|NCT02803424|OTHER|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
219593790|NCT02803424|OTHER|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
219593791|NCT02143921|BEHAVIORAL|Training intervention|Intervention group service providers received intervention training
219465986|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
219465987|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
218853520|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
219465988|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
219593792|NCT03496610|DRUG|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
219593793|NCT03496610|PROCEDURE|QL Block|Patient will receive ultrasound guided QL Block
219593794|NCT03360084|PROCEDURE|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
218853521|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
218853522|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
219593795|NCT02714426|BEHAVIORAL|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
218853523|NCT02869698|DEVICE|Hybride electrode|
218853524|NCT02869698|DEVICE|Macro electrode|
218853525|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
218853526|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
218853527|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
218853528|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
218853529|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
219465989|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
219593796|NCT02714426|OTHER|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
219593797|NCT04435184|DRUG|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
218853530|NCT00357617|DRUG|celecoxib|
219593798|NCT04435184|OTHER|0.9% saline|0.9% saline 100 ml IV once.
218853531|NCT00357617|GENETIC|microarray analysis|
218853532|NCT00357617|GENETIC|protein expression analysis|
218853533|NCT00357617|OTHER|immunoenzyme technique|
218853534|NCT00357617|OTHER|immunohistochemistry staining method|
219198768|NCT05447338|PROCEDURE|Myofascial inductions; Posterior elongation of the cervical fascia in the supine position|Position of the patient, lying on the stretcher in the supine position. Therapist position: Sitting at the head of the table. Technique: With one of his hands, the therapist supports the patient's head on the occipital area and slowly brings it to flexo-elevation. With the other hand, he contacts the mass of the paravertebral muscles, placing the thumb on one side of the spine and the proximal interphalangeal joint of the index finger in flexion on the other. While one hand holds the head position, the other performs a downward vertical slide. The maneuver is repeated between 3 and 7 times in a slow and progressive manner.
219593799|NCT05046743|OTHER|Colonic gas load|Colonic infusion of gas via an anal cannula
219593800|NCT05046743|OTHER|Sham load|Sham infusion of gas via an anal cannula
219465990|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
219465991|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
219593801|NCT01727726|DRUG|Brexpiprazole|tablet/capsule
219593802|NCT01727726|DRUG|Seroquel XR|tablet/capsule
219593803|NCT01727726|DRUG|Placebo|tablet/capsule
219593804|NCT04333030|OTHER|questionnaire|Tobacco Use and Risk Questionnaire
219593805|NCT05318430|DEVICE|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
219593806|NCT03939715|BIOLOGICAL|DermaPure®|Surgical intervention using DermaPure®
219593807|NCT03939715|PROCEDURE|native tissue|Surgical intervention using native tissue
219593808|NCT02985216|DRUG|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
219593809|NCT02985216|DRUG|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
219593810|NCT01131468|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
219593811|NCT04760496|DRUG|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
219593812|NCT04760496|DRUG|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
219593813|NCT00258700|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
219593814|NCT04627987|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
218853535|NCT00357617|OTHER|laboratory biomarker analysis|
218853536|NCT00357617|PROCEDURE|biopsy|
218853537|NCT00357617|PROCEDURE|conventional surgery|
218853538|NCT00357617|PROCEDURE|neoadjuvant therapy|
218853539|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
218853540|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
218853541|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
218853542|NCT04656795|DRUG|MT-7117|MT-7117
218853543|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
218853544|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
218853545|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
218853546|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
219593815|NCT04627987|DIAGNOSTIC_TEST|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
219198769|NCT05447338|PROCEDURE|Myofascial induction; Angle of the scapula|Position of the patient, supine position, with the arm resting along the trunk. Position of the therapist, standing or sitting at the head of the table. The therapist places one of his hands under the shoulder blade, embracing the lower angle with the fingertips and bringing it slightly cranially. This maneuver frees access to the superior angle of the scapula, which makes it easier for the index and middle fingers of the other hand to contact the insertion of the angle. More sustained pressure is applied to this point, while the hand placed on the scapula moves in the direction of release.
219361559|NCT01646099|BEHAVIORAL|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
219593816|NCT04627987|PROCEDURE|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
219593817|NCT04627987|DIAGNOSTIC_TEST|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
219593818|NCT04627987|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
219361560|NCT02415712|DRUG|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
219593819|NCT01476332|DRUG|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
219593820|NCT01476332|DRUG|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
219593821|NCT01476332|DRUG|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
219593822|NCT03259412|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil Capsule
219361561|NCT01668654|DRUG|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
219593823|NCT03259412|DIETARY_SUPPLEMENT|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
219593824|NCT03810326|DEVICE|CTR device (tradename named Xtend)|Non invasive active splint
219593825|NCT03306446|DRUG|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
219593826|NCT01405014|BEHAVIORAL|Hold Me Tight|Relationship enhancement group
219593827|NCT01882972|BEHAVIORAL|Exercise|
219593828|NCT01882972|BEHAVIORAL|Meditation|
219593829|NCT05769257|DRUG|IS-001|Intravenous injection of IS-001 investigational drug
219593830|NCT00770081|DRUG|vildagliptin|50mg qd
219361562|NCT01526668|BEHAVIORAL|Follow-up strategy|Comparison of different follow-up strategies
219361563|NCT01526668|BEHAVIORAL|No contact after discharge|
219361564|NCT03335085|DRUG|Oxytocin|
219361565|NCT03335085|OTHER|Placebo|
219361566|NCT04557384|DRUG|Ramucirumab|Administered SC
219361567|NCT05590598|COMBINATION_PRODUCT|Azelastine + Mometazone, nasal spray|140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
219361568|NCT05590598|COMBINATION_PRODUCT|Momat Rhino Advance|140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
219361569|NCT06098859|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia was started preoperatively and rest posoperative 48 hours
219361570|NCT06098859|PROCEDURE|Erector spinae plane block|Erector spinae plane block was applied preoperatively using local anesthetic
219361571|NCT02397473|DRUG|Galcanezumab|Administered SC
219361572|NCT02397473|DRUG|Placebo|Administered SC
219361573|NCT02137408|DIETARY_SUPPLEMENT|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
219593831|NCT00770081|DRUG|sitagliptin|25mg qd
219593832|NCT01869855|PROCEDURE|Subdural Drainage|
219593833|NCT01869855|PROCEDURE|Subperiosteal Drainage|
219593834|NCT00323466|PROCEDURE|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
219593835|NCT00006348|DRUG|ondansetron|
219593836|NCT00006348|OTHER|placebo|
219593837|NCT00010530|PROCEDURE|Meditation|
219593838|NCT03813953|PROCEDURE|Liver resection|Resection of diseased liver
219593839|NCT03357718|DRUG|Precedex|2 µg/kg oral
219593840|NCT03357718|DRUG|Midazolam|0.5 mg/kg
219593841|NCT00048737|DRUG|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
219593842|NCT00048737|DRUG|Rituximab|250 mg/m\^2 on day 1 and day 8
219593843|NCT00048737|DRUG|Fludarabine|30 mg/m\^2/day for 3 days
219593844|NCT00048737|DRUG|Cyclophosphamide|750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
219593845|NCT00048737|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
219593846|NCT04496284|OTHER|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
219593847|NCT00776087|DEVICE|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
219593848|NCT00776087|DEVICE|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
219593849|NCT06015763|PROCEDURE|Endoscopy|Endoscopic biopsy
219465992|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
219465993|NCT02426359|DRUG|Q301 Cream|
219465994|NCT02426359|DRUG|Placebo|
219465995|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
218853547|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
219593850|NCT03190902|BEHAVIORAL|Attention Processing Training program (APT)|
219593851|NCT03190902|BEHAVIORAL|nonspecific computer training (n-ST)|
218853548|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
218853549|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
218853550|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
218853551|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
218853552|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
219465996|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
219465997|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
219593852|NCT01019668|DRUG|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
219465998|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
219465999|NCT05417373|OTHER|calculated radscore|The development cohort is case\_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
219466000|NCT01958944|DRUG|Nitric oxide|
219593853|NCT01019668|DRUG|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
219593854|NCT06550466|OTHER|Breakfast only|Participants will attend a breakfast-only arm without the exercise protocol.
219593855|NCT06550466|OTHER|FAST|Participants will be exercised for 90 minutes following a 12-hour overnight fast
219593856|NCT06550466|OTHER|FED|Participants will be exercised 90 minutes after a breakfast
219593857|NCT05011045|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219593858|NCT05011045|OTHER|Neurocognitive Assessment|Undergo neurocognitive function assessment
219593859|NCT05011045|OTHER|Quality-of-Life Assessment|Complete questionnaires
219593860|NCT05011045|OTHER|Questionnaire Administration|Complete questionnaires
219593861|NCT06974357|DIAGNOSTIC_TEST|Genetic testing|blood draws for genetic testing
219593862|NCT04546880|OTHER|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
219466001|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
219466002|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
219466003|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
219466004|NCT05794204|DRUG|RMP-A03 - Dose 1|Patients will randomized to low dose of RMP-A03
219466005|NCT05794204|DRUG|RMP-A03 - Dose 2|Patients will be randomized to high dose of RMP-A03
219466006|NCT05794204|DRUG|RMP-A03 Placebo|Patients will be randomized to RMP-A03 Placebo
219466007|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
219466008|NCT02977741|DRUG|Olanzapine|
219466009|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
219466010|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
219466011|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
219466012|NCT06323655|DRUG|Tasimelteon|oral capsule
219466013|NCT06323655|DRUG|Active Control Placebo|oral capsule
219466014|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
219466015|NCT06323655|DRUG|Active Control|oral capsule
219466016|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
219466017|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
219466018|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
219466019|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
218853553|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
218853554|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
219466020|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
219466021|NCT02064491|DRUG|Erlotinib|
218853555|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
218853556|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
218853557|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
218853558|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
218853559|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
219466022|NCT02064491|DRUG|Chemotherapy|
219466023|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
219466024|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
219466025|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
219466026|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
219466027|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
219466028|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
219466029|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
218853560|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
218853561|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
219466030|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
218853562|NCT02029183|DEVICE|bi-level positive airway pressure|
218853563|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
218853564|NCT03294096|OTHER|Routine care|Routine post-op care
218853565|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
218853566|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
218853567|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
219361574|NCT02137408|DRUG|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
219361575|NCT02487186|DRUG|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
219361576|NCT02487186|PROCEDURE|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
219361577|NCT05340205|DRUG|Tranexamic acid|Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
219361578|NCT05340205|DRUG|Misoprostol|"Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~."
219361579|NCT05340205|DRUG|Oxytocin|Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
219361580|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
219361581|NCT02274285|BIOLOGICAL|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
219361582|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
219361583|NCT06342869|PROCEDURE|Anesthesia|application of different anesthesia techniques
219361584|NCT03932994|BEHAVIORAL|ACT on Health|This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
219361585|NCT01337973|BEHAVIORAL|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
219361586|NCT01337973|BEHAVIORAL|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
219361587|NCT01337973|BEHAVIORAL|E-TAU|Enhanced Treatment as Usual
219361588|NCT04456452|BIOLOGICAL|Ampion|Ampion, administered by intravenous infusion
219361589|NCT04456452|OTHER|Standard of Care|Standard of Care
219361590|NCT00248703|DRUG|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
219361591|NCT05422872|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to expert consensus.
219361592|NCT01990157|DRUG|TAB08|Weekly intravenous administration in escalating doses.
219361593|NCT02529579|OTHER|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
219361594|NCT02529579|DRUG|Gemcitabine|standard Gemcitabine therapy
219361595|NCT01448395|DRUG|[14C]NXL104|500mg/100mL intravenous solution
219361596|NCT00055380|PROCEDURE|Oral cytobrushing|
219361597|NCT03256045|DRUG|Carfilzomib|Given IV
219361598|NCT03256045|OTHER|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
219361599|NCT03256045|DRUG|Dexamethasone|Given PO
219361600|NCT03256045|OTHER|Laboratory Biomarker Analysis|Correlative studies
219361601|NCT03256045|DRUG|Panobinostat|Given PO
219361602|NCT01244256|DRUG|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
219361603|NCT01244256|DRUG|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
219361604|NCT02765282|DEVICE|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
219361605|NCT01255774|DRUG|ranibizumab|An open-label, study of intravitreally administered ranibizumab
219361606|NCT00254566|OTHER|Moxifloxacin Placebo|1 capsule once daily for 5 days
219361607|NCT00254566|DRUG|Moxifloxacin|1 X 400mg capsule once daily for 5 days
219361608|NCT00254566|OTHER|Azithromycin SR Placebo|single dose, oral.
219361609|NCT00254566|DRUG|Azithromycin SR|single dose 2.0 g oral
218853568|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
218853569|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
218853570|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
218853571|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
218853572|NCT00617071|OTHER|medical chart review|
218853573|NCT00617071|OTHER|survey administration|
218853574|NCT00617071|PROCEDURE|fecal occult blood test|
218853575|NCT00617071|PROCEDURE|screening colonoscopy|
218853576|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
218853577|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
219361610|NCT03762304|OTHER|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
219593863|NCT04546880|OTHER|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
219593864|NCT04711616|BEHAVIORAL|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
218853578|NCT04525924|DEVICE|bright light therapy|please see arm description
218853579|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
218853580|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
218853581|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
218853582|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
218853583|NCT00091338|BIOLOGICAL|MART-1 antigen|
218853584|NCT00091338|BIOLOGICAL|gp100 antigen|
219593865|NCT05360940|DIAGNOSTIC_TEST|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
218853585|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
218853586|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
218853587|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
219593866|NCT00720252|DEVICE|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
218853588|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
218853589|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
219361611|NCT01786317|DEVICE|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
219361612|NCT05207228|BEHAVIORAL|CBT4CBT|Cognitive behavioral treatment through the web CBT4CBT
219593867|NCT04762277|DRUG|Spesolimab - solution for infusion|Solution for infusion
219593868|NCT04762277|DRUG|Placebo matching spesolimab - solution for infusion|Solution for infusion
219593869|NCT04762277|DRUG|Spesolimab- solution for injection|Solution for injection
219361613|NCT06097897|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
219361614|NCT03345186|OTHER|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
219361615|NCT01571115|BEHAVIORAL|Physical Exercise|
219593870|NCT04762277|DRUG|Placebo matching to spesolimab- solution for injection|Solution for injection
218853590|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
219466031|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
219466032|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
219466033|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
219466034|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
219466035|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
219466036|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
219466037|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
218853591|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
218853592|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
219466038|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
219466039|NCT06690086|PROCEDURE|Lesion biopsy|Lesions enrolled in the study are biopsied to confirm histopathology
219466040|NCT06690086|DEVICE|DermaSensor Device Use|Users are blinded to the DermaSensor Device result
219466041|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
219466042|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
219466043|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
219466044|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
219466045|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
219593871|NCT01860677|DEVICE|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
218853593|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
218853594|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
218853595|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
218853596|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
219019956|NCT06795906|DRUG|AZD8630|AZD8630 will be administered via dry powder inhalation (DPI).
219019957|NCT06795906|OTHER|Placebo|Placebo will be administered via DPI.
219019958|NCT06795906|DEVICE|Saphira device|AZD8630 or placebo will be administered to participants via Saphira device.
219466046|NCT00000459|BEHAVIORAL|diet, fat-restricted|
219466047|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
219466048|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
219466049|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
219466050|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
219466051|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
219466052|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
219466053|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
219466054|NCT02158949|BEHAVIORAL|mROAD|
219593872|NCT06975631|DEVICE|TrHCROSS®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked.
219593873|NCT06975631|DEVICE|Hyalone®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked
219593874|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
219198770|NCT05447338|PROCEDURE|Myofascial induction sternocleidomastoid muscles|Objective, release the myofascial restrictions of the fascia of the SCM muscle. Position of the patient, supine position with the head near the upper edge of the stretcher. Therapist position. sitting at the head of the stretcher. Technique: The therapist, with one hand placed on the occipital region, gently rotates the patient's head. The other hand places it on the mass of the SCM muscle with the thumb at the point of insertion on the mastoid process. While one hand applies the rotational movement and a slight extension of the head, the other performs a transverse slide over the zone of restriction in the SCM muscle. A longitudinal sliding movement of the SCM muscle can be made between the thumb and forefinger of the executing hand.
219198771|NCT05447338|PROCEDURE|Myofascial induction of pectoralis major and minor|Objective, release the fascia of the pectoralis major and minor muscle. Position of the patient, supine position, with the arm abducted to about 120 degrees. Position of the therapist, standing next to the patient, at head height. Technique: with his cranial hand, the therapist holds the patient's arm, and with the caudal hand, placed in a prone position, contacts the space between pectoralis major and ribs. This contact is made with the fingertips. The pressure should be maintained for about 5 minutes. As the release occurs, both of the therapist's hands must adjust to the direction of the changes. When detecting the restriction in the pectoralis minor, the penetration should be deepened with the hand, sliding it over the ribs. Contact and restraints with the pectoralis minor and major are often particularly painful, forcing the therapist to apply controlled force.
219593875|NCT06654687|DEVICE|Transthoracic Echocardiography|Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.
219361616|NCT01526109|BEHAVIORAL|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
219593876|NCT06654687|DRUG|Ringer lactate 1000 ml|Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.
219593877|NCT06654687|DRUG|Albumin|Patients will receive 250 mL of human albumin 5% over 10 minutes
219593878|NCT06654687|DRUG|Ringer lactate 750 ml|Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.
219593879|NCT06978010|OTHER|Platelet-Rich Plasma (PRP) intraoperatively|Patients receive platelet-rich plasma (PRP) intraoperatively during cesarean section (5 ml before hysterography, 5 ml subcutaneously before skin closure).
218853597|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
218853598|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
218853599|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
219361617|NCT01526109|BEHAVIORAL|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
219361618|NCT01526109|BEHAVIORAL|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
219361619|NCT01491256|DRUG|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
219361620|NCT01491256|DRUG|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
219361621|NCT01131195|BIOLOGICAL|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
219361622|NCT01131195|BIOLOGICAL|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
219361623|NCT00929071|DEVICE|Evolence|Injectable collagen
219361624|NCT00929071|DEVICE|Lidocaine|admix anesthetic
219361625|NCT00929071|DRUG|topical anesthetic|
219361626|NCT03856255|DEVICE|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
219361627|NCT02995304|DRUG|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
219361628|NCT02995304|DRUG|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
219361629|NCT02995304|DRUG|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
219593880|NCT06979427|DIAGNOSTIC_TEST|NIFFR|Fractional flow reserve derived from CT angiography from lesion between 50-70%
219593881|NCT06041217|DRUG|Semaglutide|Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
219593882|NCT06041217|DRUG|Placebo|Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
219593883|NCT06983691|BEHAVIORAL|Patient Navigation Program|The patient navigation program will integrate 1) education to enhance understanding of the treatment regimen, follow-up care, and the importance of adherence, 2) symptom management and adherence strategies, and 3) skills and resources to enhance women's symptom coping and self-management abilities.
219593884|NCT06982248|DRUG|NSP and chitosan nanoparticles gel loaded by quercetin|NSP and chitosan nanoparticles gel loaded by quercetin
219593885|NCT06982248|DRUG|NSP and chitosan nanoparticles gel|NSP and chitosan nanoparticles gel
219593886|NCT06982248|PROCEDURE|scaling and root planning|NSPT
219593887|NCT06982703|DIETARY_SUPPLEMENT|Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc,|In this prospective pilot study, we plan to evaluate the effects of a Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc, on the variation of intestinal microbiota and prevention of antibiotic-induced diarrhea, in individuals who have been prescribed antibiotic therapy.
219593888|NCT06982703|DIETARY_SUPPLEMENT|Placebo|The intervention with Placebo involves the intake of a product free of bityrate, zinc and vitD
219593889|NCT06982950|OTHER|Manipulation of Sleep Duration|After a baseline assessment of sleep, participants will undergo either 2 nights of restricted sleep (4 hour time in bed) followed by a recovery sleep, OR 3 nights of an extended sleep opportunity (10 hour time in bed)
218853600|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
218853601|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
218853602|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
218853603|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
218853604|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
218853605|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
218853606|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
218853607|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
218853608|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
219361630|NCT03130790|DRUG|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219361631|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219361632|NCT03130790|DRUG|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219361633|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219361634|NCT04206878|DIAGNOSTIC_TEST|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
219361635|NCT01793415|DRUG|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
219361636|NCT01793415|OTHER|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
219361637|NCT01325103|PROCEDURE|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
219361638|NCT03616431|DIAGNOSTIC_TEST|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
219361639|NCT04845412|DIAGNOSTIC_TEST|Hearing screening tests|"Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device."
219361640|NCT03008395|BEHAVIORAL|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
219361641|NCT03008395|OTHER|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
219361642|NCT01851408|DRUG|sorafenib tosylate|Given orally
219361643|NCT01851408|DRUG|temsirolimus|Given IV
219361644|NCT01521273|OTHER|Bean varieties|10 x 50 g/ arm
219361645|NCT04835285|DIAGNOSTIC_TEST|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
219593890|NCT06982638|DEVICE|TMS+ Gait training|"Participants in this single-arm study will receive a personalized, accelerated course of continuous theta burst stimulation (cTBS) over a functionally defined subregion of the supplementary motor area (SMA), which is individually targeted using resting-state functional MRI. The stimulation will be delivered using a MagPro Cool-B65 A/P figure-of-eight coil at 110% of resting motor threshold.~Each participant will undergo 6 treatment visits over 2 weeks , receiving 8 rTMS sessions per day (600 pulses/session), totaling 28,800 pulses across the study. TMS sessions will be interleaved with dual-task gait training involving cognitive walking exercises. Gait training will be conducted for 30 minutes per visit, immediately following stimulation blocks. Safety, tolerability, adherence, gait performance, and neuroplasticity will be evaluated pre- and post-intervention using clinical scales, motor evoked potentials (MEPs), and functional MRI."
218853609|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
218853610|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
218853611|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
218853612|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
219466055|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
219466056|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
219466057|NCT06564961|DRUG|Placebo|1 tab once daily
219466058|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
219466059|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
219466060|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
218853613|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
218853614|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
218853615|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
218853616|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
218853617|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
218853618|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
219019961|NCT06632444|DRUG|Survodutide|Subcutaneous injection
219019962|NCT06632444|DRUG|Placebo|Subcutaneous injection
219466061|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
219466062|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
219466063|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
219466064|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
219466065|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
219466066|NCT05349214|OTHER|Placebo|placebo s.c.
218853619|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
218853620|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
218853621|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
218853622|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
218853623|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
218853624|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
218853625|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
218853626|NCT00898924|GENETIC|molecular diagnostic method|
218853627|NCT00898924|GENETIC|mutation analysis|
218853628|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
218853629|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
218853630|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
218853631|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
218853632|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
219466067|NCT05549804|DRUG|KL340399 Intratumoral|KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
219466068|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
218853633|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
218853634|NCT00825058|DRUG|paroxetine|oral 20 mg/day
218853635|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
218853636|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
218853637|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
218853638|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
218853639|NCT00906451|DRUG|Simvastatin|Simvastatin
218853640|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
218853641|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
218853642|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
218853643|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
218853644|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
218853645|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
219466069|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
219593891|NCT05604456|PROCEDURE|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
219593892|NCT00896480|BIOLOGICAL|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
218853646|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
219593893|NCT03580486|OTHER|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
218853647|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
218853648|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
218853649|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
218853650|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
218853651|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
218853652|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
218853653|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
219466070|NCT06101381|BIOLOGICAL|CART-19|The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
219466071|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
219466072|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219466073|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
219466074|NCT06796712|DIETARY_SUPPLEMENT|Prebiotic fibre fortified bread roll|Subjects will consume a prebiotic fibre-fortified bread roll (10g of added prebiotic fibre/day).
219593894|NCT01069874|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
219593895|NCT01069874|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
218853654|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
218853655|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
218853656|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
219593896|NCT02012348|OTHER|Antibacterial soap with triclocarban|
219593897|NCT02012348|OTHER|Antibacterial soap + benzalkonium chloride|
219593898|NCT02012348|OTHER|Control soap|
218853657|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
218853658|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
218853659|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
219019968|NCT07083583|DRUG|IV Iron (standard of care)|Participants will receive IV iron therapy as part of standard management for iron deficiency
219019971|NCT07122739|BEHAVIORAL|Active Real-time fMRI Neurofeedback|Active neurofeedback to target a functional connection associated with increased memory control ability
219019972|NCT07122739|BEHAVIORAL|Sham Real-time fMRI neurofeedback|Sham neurofeedback
219019973|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately before meal
219019974|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately after meal
219019975|NCT07078344|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|The oil-based supplements will include the Ultra Omega-3 product that delivers 683 mg EPA and 252 mg DHA (as ethyl esters) per capsule. A daily dose will provide 2.8 g of EPA+DHA (as ethyl esters). This product is part of the Nature Made line manufactured by Pharmavite (see Letter of Support). Three capsules will be self-administered orally by study participants, preferably at a single mealtime.
219019976|NCT07078344|OTHER|Placebo|Safflower oil (placebo) that delivers 70-80% oleic acid and 10-14% LA. The placebo is identical in appearance and shape to the active study agent. Three capsules will be self-administered orally by study participants, preferably at mealtimes.
219019979|NCT07079306|BEHAVIORAL|BeFree+Bot|Text messaging program called BeFree and access to BBot, ChatGPT chatbot
219593899|NCT02760745|OTHER|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
218853660|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
218853661|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
218853662|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
218853663|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
218853664|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
218853665|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
218853666|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
218853667|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
218853668|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
218853669|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
218853670|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
218853671|NCT00106600|DRUG|Pixantrone IV infusion|
218853672|NCT00892203|DRUG|BGG492|
218853673|NCT00892203|DRUG|Sumatriptan|
218853674|NCT00892203|DRUG|Placebo|
218853675|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
218853676|NCT00000729|DRUG|Foscarnet sodium|
218853677|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
218853678|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
218853679|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
218853680|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
218853681|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
218853682|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
218853683|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
218853684|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
218853685|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
218853686|NCT01024491|DRUG|placebo|active daily treatment with placebo
218853687|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
218853688|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
218853689|NCT02130336|BEHAVIORAL|Aerobic interval training|
218853690|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
218853691|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
218853692|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
218853693|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219019980|NCT07079306|BEHAVIORAL|BeFree|Text messaging program called BeFree
219361646|NCT00883675|DRUG|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
219361647|NCT06548763|DRUG|Topotecan|1.4mg/㎡, orally administered, d1-5
219361648|NCT06548763|DRUG|Toripalimab|240mg, intravenous drip, d1, q3w
219361649|NCT04743557|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
219361650|NCT03884400|PROCEDURE|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
219361651|NCT00364689|DRUG|Rifaximin|
219361652|NCT00364689|DRUG|Lactulose|
219361653|NCT00364689|OTHER|Placebo|
219361654|NCT00984750|DRUG|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
219593900|NCT06982170|DEVICE|A physical activity and reminiscence therapy|There were two parts in this study, one was co-design (participants co-designed the device) and the other was a pilot intervention. The two parts were iterative. In the interventional part, participants were asked to cycling the co-design rehabilitation bike and also did reminiscence or any cognitive therapy at the same time. The intervention session lasted at least 15 minutes, twice a week for 12 weeks.
219593901|NCT06695572|DRUG|CKD-383|QD, PO
219198772|NCT05447338|PROCEDURE|Myofascial induction; upper trapezius|Objective, release the myofascial restrictions of the upper trapezius. Position of the patient, supine, with the elbow flexed and the hand resting on the abdomen, and the arm in a slight abduction. Therapist position, sitting at the head of the table. Technique: The therapist places his hand on the patient's shoulder so that he can grasp the fibers of the upper trapezius between the index, middle, and ring fingers above and the thumb below. Subsequently, he exerts gentle and sustained pressure overcoming three restraining barriers.
219198773|NCT05447338|PROCEDURE|Myofascial induction, of the fascia of the subscapularis muscle|Position of the patient, supine, with the arm raised about 90-160 degrees, depending on the degree of movement restriction. Therapist position, standing at the head of the table. Phase A With his cranial hand, the therapist holds the patient's arm and performs very gentle traction. The palm of the caudal hand, thumb up, is placed on the outer edge of the scapula, as close as possible to the glenohumeral joint. A slight traction is performed with both hands in opposite directions, subsequently following the direction of release. Phase B, The thumb of the caudal hand slightly invades the space between the inner aspect of the scapula and the thorax. The rest of the application is performed as in phase A. Phase C, the therapist places his caudal hand in a prone position and slowly penetrates the aforementioned space with the tips of the fingers. sustained for a time ranging between 90 seconds and 5 minutes, following the release stages.
219198774|NCT05447338|PROCEDURE|Intraoral myofascial induction of the masseter|Position of the patient, supine position, on the stretcher without the pillow. Position of the therapist, sitting at the head of the table. Technique: The therapist, with the index of his hand, contacts the masseter just below the zygomatic arch and inside the mouth. To ensure proper contact on the masseter, the patient is asked to attempt to close the mouth. Once the muscle is correctly located, the patient should immediately relax the masseter. Next, the therapist compresses the masseter between his index finger and thumb. You have to wait long enough for the release to occur. Sometimes both hands are used by placing the forefinger of the other hand on the outer surface.
218853694|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
218853695|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
218853696|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
218853697|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
218853698|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
218853699|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
218853700|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
218853701|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
219361655|NCT00984750|DRUG|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
219361656|NCT00841737|OTHER|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
218853702|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
219361657|NCT00841737|OTHER|Control Group|In the control group the depression is treated as usual with the conventional treatment.
219361658|NCT04545905|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
218853703|NCT06294938|OTHER|Dextrose|Dextrose beverage
218853704|NCT00403533|DRUG|20 mg of atorvastatin daily|
218853705|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
218853706|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
218853707|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
218853708|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
219361659|NCT04553211|BEHAVIORAL|EPT|Expedited Partner Therapy (EPT) involves provision of empiric oral antibiotic therapy to the recent sexual partners of an individual diagnosed with gonorrhea and/or chlamydia infection.
219361660|NCT05611957|DRUG|LY3437943|Administered SC.
219361661|NCT04095169|DIAGNOSTIC_TEST|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
219361662|NCT00003160|DRUG|paclitaxel|
219361663|NCT02441504|OTHER|Low intensity Exercise|aerobic exercise training using walking and running
219361664|NCT03650998|DRUG|Ropivacaine|See arm description
218853709|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
219361665|NCT03650998|DRUG|Saline|See arm description
219361666|NCT05565963|OTHER|Virtual reality exercise intervention|The experimental group received VR exercise sessions for 75-90 minutes, twice a week for a duration of 12 weeks.
219361667|NCT00592475|DRUG|conivaptan|IV
219361668|NCT00592475|DRUG|Placebo|IV
219361669|NCT06240910|OTHER|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise.
219361670|NCT06240910|OTHER|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
219361671|NCT01114529|DRUG|Everolimus|Early CNI to everolimus conversion
218853710|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
218853711|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
218853712|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
219466075|NCT06796712|DIETARY_SUPPLEMENT|Regular bread roll|Subjects will consume a regular bread roll (0g of added prebiotic fibre blend/day).
219466076|NCT06829602|DIAGNOSTIC_TEST|Rapid Syphilis/HIV point-of-care test|The INSTI Multiplex HIV/Syphilis Duo Antibody Test is a rapid immunoassay that can detect HIV and syphilis antibodies in the blood using finger-prick blood samples. The test is Health Canada-approved.
218853713|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
218853714|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
218853715|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
219019992|NCT06930664|BIOLOGICAL|Sotatercept|Subcutaneous Injection
219019993|NCT06930664|BIOLOGICAL|Sotatercept Autoinjector|Subcutaneous Auto Injection
219019998|NCT06905470|PROCEDURE|Eccentric (KREHA) training|20 eccentric resistance training sessions will be performed on a symmetric arm-crank ergometer in a supine position.
219361672|NCT01114529|DRUG|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
219361673|NCT00449514|DRUG|tamoxifen|
219361674|NCT00449514|DRUG|clomiphene citrate|
219361675|NCT06205108|DEVICE|taVNS stimulation|Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
219361676|NCT06205108|DEVICE|sham stimulation|Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
219361677|NCT00356031|DRUG|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
219361678|NCT00356031|RADIATION|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
219361679|NCT00356031|PROCEDURE|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
219361680|NCT05361629|PROCEDURE|Intralesional steroid administration|Treatment by administering steroids into the lesion
219361681|NCT05361629|PROCEDURE|Intraoperative cavity steroid administration|Treatment by administering steroids into the surgical cavity
219361682|NCT05637554|PROCEDURE|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
219361683|NCT05637554|PROCEDURE|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
219361684|NCT06520189|DEVICE|F-18 FDGPET/CT|F-18 FDGPET/CT oncology protocol for lung cancer patients
219361685|NCT04507984|DIAGNOSTIC_TEST|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
219361686|NCT04507984|DIAGNOSTIC_TEST|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
219361687|NCT04615637|DEVICE|MEG recordings|"1. Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~2. MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
219361688|NCT06193941|DIAGNOSTIC_TEST|RT-qPCR|RT-qPCR
219361689|NCT00813397|DEVICE|Sepraspray|Max. 10g of Sepraspray
219361690|NCT06001944|OTHER|Blood flow restriction|The BFR training group will be given detailed information about the technique and discussed possible side effects.The American Association of Sports Physicians (ACSM) recommends that at least 65% of 1 maximum repetition, similar to high-intensity exercise, 8-12 repetitions of resistant weight lifting strength training, can be used with low loads such as 20% to 30% of the maximum 1 repetition in therapy to caste hypertrophy and strength.
218853716|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
219466077|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
219466078|NCT01162031|DRUG|Velcade|IV
219466079|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
219466080|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
219466081|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
219466082|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
219466083|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
219466084|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
219466085|NCT06412289|DIAGNOSTIC_TEST|US-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The ultrasound investigation will be conducted using the ultrasound machine supplied to the Center involved in the trial and usually used in eTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
219466086|NCT06412289|DIAGNOSTIC_TEST|CT-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The CT scan will be performed using the CT machinery equipped by the Center involved in the trial and usually used for the tTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
219466087|NCT03252808|BIOLOGICAL|TBI-1401(HF10)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
218853717|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
218853718|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
218853719|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
218853720|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
218853721|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
218853722|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
218853723|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
218853724|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
218853725|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
218853726|NCT02454439|OTHER|CRT implantation|
218853727|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
218853728|NCT00397852|PROCEDURE|Kirschner-wires or not|
218853729|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
218853730|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
218853731|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
218853732|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
218853733|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
218853734|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
218853735|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
219466088|NCT03252808|DRUG|Gemcitabine|1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
218853736|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
218853737|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
218853738|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
218853739|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
218853740|NCT00666588|DRUG|idarubicin|Given IV
218853741|NCT00666588|DRUG|cytarabine|Given IV or IT
218853742|NCT00666588|DRUG|bortezomib|Given IV
218853743|NCT00666588|DRUG|etoposide|Given IV
218853744|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
219466089|NCT03252808|DRUG|Nab-paclitaxel|125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
219466090|NCT03252808|DRUG|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
219466091|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
219466092|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
219466093|NCT00772031|DRUG|placebo|an inactive substance
219466094|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
219593902|NCT04703582|DIAGNOSTIC_TEST|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
219593903|NCT03862066|OTHER|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
219593904|NCT03862066|OTHER|Tissue collection|Left over tissue will be collected at the time of surgery
219593905|NCT03911518|PROCEDURE|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
219593906|NCT03911518|PROCEDURE|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
218853745|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
218853746|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
218853747|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
218853748|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
218853749|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
218853750|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
218853751|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
218853752|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
218853753|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
218853754|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
218853755|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
218853756|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
218853757|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
219019999|NCT06905470|PROCEDURE|Standard clinical routine strength (STAN) training|The regular strength training intervention consists of a total of 20 training sessions at the gym of the study center, performed following clinical routine procedures.
219466095|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
218853758|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
219466096|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
218853759|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
218853760|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
219466097|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
219466098|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
219466099|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
219466100|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
219466101|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
219466102|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
218853761|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
219466103|NCT00752518|DRUG|bortezomib|
219466104|NCT00656136|DRUG|placebo|Patients receive placebo once daily
219466105|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
218853762|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
218853763|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
218853764|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
218853765|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
218853766|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
218853767|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
218853768|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
218853769|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
218853770|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
219198775|NCT05447338|PROCEDURE|Deep myofascial induction of the external pterygoid|"Objective, release the myofascial restrictions and recover the functional coordination of the external pterygoid muscles.~Position of the patient, supine position, on the stretcher without the pillow. Therapist position, sitting at the head of the table. Technique: The therapist palpates the temporomandibular joint with the index or middle finger of one hand. With the index finger of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs."
218853771|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
218853772|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
219466106|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
219466107|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
219466108|NCT01490385|DEVICE|LED Phototherapy|
219466109|NCT02505945|DRUG|Omeprazole|
219466110|NCT02505945|DEVICE|LINX Reflux Management System|
219466111|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
219466112|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
219466113|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
219466114|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
219466115|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
218853773|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
218853774|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
218853775|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
218853776|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
218853777|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
219466116|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
219466117|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
219466118|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
219466119|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
219466120|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
219466121|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
219466122|NCT01097057|DRUG|Carboplatin|Given IV
219466123|NCT01097057|DRUG|Etoposide|Given IV
219466124|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
219466125|NCT01097057|DRUG|Ifosfamide|Given IV
219466126|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
219466127|NCT01097057|DRUG|Plerixafor|Given SC
219466128|NCT01097057|BIOLOGICAL|Rituximab|Given IV
219466129|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
219466130|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
219466131|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
219466132|NCT00005990|DRUG|tipifarnib|
219466133|NCT00005990|DRUG|topotecan hydrochloride|
219466134|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
219593907|NCT06367491|OTHER|Registration in a database|All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
219466135|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
219466136|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
219593908|NCT00792363|DRUG|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
219593909|NCT00792363|DRUG|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
218853778|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
218853779|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
218853780|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
218853781|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
218853782|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
219466137|NCT02063802|BEHAVIORAL|Healthy habits program|
218853783|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
218853784|NCT04126889|OTHER|questionnaire survey|questionnaire survey
218853785|NCT02060994|OTHER|No intervention|No intervention
219020003|NCT03973268|DEVICE|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
219466138|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
219466139|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
219466140|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
219466141|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
219466142|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
219466143|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
219466144|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
219466145|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
219466146|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
219466147|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
219466148|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
219466149|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
219466150|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
219466151|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
219466152|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
219466153|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
219466154|NCT02738073|DRUG|Control: Saline|
218853786|NCT05731908|DRUG|BI 690517|BI 690517
218853787|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
218853788|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
218853789|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
218853790|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
218853791|NCT05933356|OTHER|scheduled activities|scheduled activities
218853792|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
218853793|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
219020004|NCT03973268|OTHER|Arm 2 Interventions|Placebo
219020005|NCT03973268|DRUG|Arm 1, 2, 3 drug Interventions|Ketamine
219020006|NCT03973268|DRUG|Arm 1 and 2 Interventions|Perampanel
219466155|NCT02738073|DRUG|Tranexamic Acid|
219466156|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
219466157|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
219466158|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
219466159|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
219466160|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
219466161|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
219466162|NCT06088017|DRUG|CKD-391(2)|QD, PO
219466163|NCT06088017|DRUG|CKD-331, D337|QD, PO
219466164|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
218853794|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
218853795|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
218853796|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
218853797|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
218853798|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
218853799|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
218853800|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
218853801|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
218853802|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
219466165|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
219466166|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
219466167|NCT01102439|DRUG|Aspirin|81 mg daily
219466168|NCT01102439|DRUG|Aspirin|325 mg daily
219466169|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
219466170|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
219466171|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
219466172|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
219466173|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
219466174|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219466175|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
219466176|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
219466177|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
219466178|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
218853803|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
218853804|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
218853805|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
218853806|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
218853807|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
219466179|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
219466180|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
219466181|NCT02701374|DRUG|TRK-700|
219466182|NCT02701374|DRUG|Placebo|
219466183|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
219466184|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
219466185|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
219466186|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
219466187|NCT00124865|BIOLOGICAL|rFla-MBP|
219466188|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
219466189|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
219466190|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
219466191|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
219466192|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
219466193|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
219466194|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
219466195|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
219466196|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
219466197|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
219466198|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
219466199|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
219466200|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
219466201|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219466202|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
219466203|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
219466204|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
219466205|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
219466206|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
219466207|NCT03143465|DRUG|Sildenafil|
219020011|NCT06828848|DRUG|Meropenem plus vaborbactam|Meropenem plus vaborbactam fixed dose combination adjusted by body weight up to 2g/2g
219466208|NCT03143465|DRUG|Placebo|
219466209|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
219466210|NCT02263976|DRUG|BEA 2180 BR|
219466211|NCT02263976|DRUG|Placebo|
219466212|NCT02263976|DEVICE|Respimat® A 4|
219466213|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
219466214|NCT02263976|DRUG|Spiriva|
219466215|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
219466216|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
219466217|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
219466218|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
219466219|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
219466220|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
219466221|NCT01973920|DRUG|Oshadi Icp|
219466222|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
219466223|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
219466224|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
219466225|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
219593910|NCT00658021|DRUG|Placebo|Subcutaneous injection, twice a day
219593911|NCT00658021|DRUG|Exenatide|Subcutaneous injection, 5 µg, twice a day
219593912|NCT00658021|DRUG|Exenatide|Subcutaneous injection,10 µg, twice a day
219593913|NCT04121754|DEVICE|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
218853808|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
218853809|NCT00012129|DRUG|liposomal annamycin|
218853810|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
218853811|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
218853812|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
218853813|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
218853814|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
218853815|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
218853816|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
218853817|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
219466226|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
219466227|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
219466228|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
219593914|NCT04121754|OTHER|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
219593915|NCT04544501|BEHAVIORAL|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
219466229|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
219593916|NCT04544501|OTHER|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
219593917|NCT01196676|DRUG|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
218853818|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
218853819|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
218853820|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
218853821|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
218853822|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
218853823|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
218853824|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
218853825|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
218853826|NCT03587025|DRUG|Placebo|Placebo
218853827|NCT00460278|DRUG|XL418|
218853828|NCT00149994|DRUG|Cyclosporine A|
218853829|NCT00149994|DRUG|Tacrolimus|
218853830|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
218853831|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
218853832|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
219466230|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
219466231|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
219466232|NCT02406586|DRUG|Placebo|One tablet
219466233|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
219466234|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
219466235|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
219466236|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
219466237|NCT00987558|DRUG|Eslicarbazepine acetate|
219466238|NCT00987558|DRUG|Simvastatin|
219466239|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
218853833|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
218853834|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
218853835|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
218853836|NCT02280824|DEVICE|Amplatzer Duct Occluder|
218853837|NCT04394273|OTHER|Exercise|stabilization exercise
218853838|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
218853839|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
218853840|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
219466240|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
219466241|NCT01384513|DRUG|Fludarabine|Given IV
218853841|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
219466242|NCT01384513|DRUG|Busulfan|Given IV
219466243|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
219466244|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
219466245|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
219466246|NCT01384513|DRUG|Tacrolimus|Given IV or PO
219466247|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
219466248|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
218853842|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
218853843|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
218853844|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
218853845|NCT00297102|DRUG|Placebo|once daily
218853846|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
218853847|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
218853848|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
218853849|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
218853850|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
218853851|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
218853852|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
218853853|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
218853854|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
218853855|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
218853856|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
218853857|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
218853858|NCT02681796|DRUG|Bupivacaine|
218853859|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
218853860|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
219466249|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
219466250|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
219466251|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
219466252|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
219466253|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
219466254|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
219466255|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
219466256|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
219593918|NCT01196676|DRUG|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
219593919|NCT01550627|OTHER|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
219466257|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
219466258|NCT05411705|DRUG|Control|Non-rhTPO treatment
219466259|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
219466260|NCT00755976|DRUG|epirubicin hydrochloride|
219466261|NCT00755976|DRUG|sulindac|
219466262|NCT00755976|OTHER|immunologic technique|
219466263|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
219466264|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~\- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
219466265|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~\- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
219466266|NCT02649673|DRUG|LCL161|
219466267|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
219466268|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
219466269|NCT05710848|DRUG|STM-416|STM-416 monotherapy
219466270|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
219466271|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
219466272|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
219466273|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
219466274|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
219466275|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
219466276|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
219466277|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
219466278|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
218853861|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
218853862|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
218853863|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
218853864|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
218853865|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
219466279|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
218853866|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
218853867|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
218853868|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
218853869|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
218853870|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
218853871|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
218853872|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
218853873|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
218853874|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
218853875|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
218853876|NCT02748434|OTHER|Lipohypertrophy|
219466280|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
219466281|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
219466282|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
219466283|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
219466284|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
219466285|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
219466286|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
219466287|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
219466288|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
219466289|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
218853877|NCT02748434|OTHER|Normal Subcutaneous Tissue|
218853878|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
218853879|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
219020017|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
219020018|NCT06029673|DRUG|Placebo|Placebo
219466290|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
218853880|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
218853881|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
218853882|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
218853883|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
219466291|NCT02204722|DRUG|600mg/day of Imatinib|
219466292|NCT02204722|DRUG|400mg/day of Imatinib|
219466293|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
219466294|NCT00218439|DRUG|Placebo|
219466295|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
219466296|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
219466297|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
219466298|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
219466299|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
218853884|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
219466300|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
219466301|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
219466302|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
219466303|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
219466304|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
219466305|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
219466306|NCT00145080|BEHAVIORAL|Disease Management Assessment|
219466307|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
219466308|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
219466309|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
218853885|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
218853886|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
218853887|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
218853888|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
218853889|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
218853890|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
218853891|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
218853892|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
218853893|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
218853894|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
218853895|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
218853896|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
218853897|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
218853898|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
218853899|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
218853900|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
218853901|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
218853902|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
218853903|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
218853904|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
218853905|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
218853906|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
218853907|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
218853908|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
218853909|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
218853910|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
218853911|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
218853912|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
218853913|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
218853914|NCT00897403|OTHER|biologic sample preservation procedure|
218853915|NCT00897403|PROCEDURE|diagnostic colonoscopy|
218853916|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
218853917|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
218853918|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
218853919|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
218853920|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
218853921|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
218853922|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
218853923|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
218853924|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
218853925|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
218853926|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
218853927|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
218853928|NCT01517165|DRUG|Pioglitazone|
218853929|NCT01517165|DRUG|Placebo|
218853930|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
218853931|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
218853932|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
218853933|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
218853934|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
218853935|NCT02060630|PROCEDURE|Open surgical revascularization|
218853936|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
218853937|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
218853938|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
218853939|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
218853940|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
218853941|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
218853942|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
218853943|NCT00004552|DRUG|acamprosate (Campral)|
218853944|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
218853945|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219198776|NCT05447338|PROCEDURE|Intraoral mifascial induction of the internal pterygoid|Objective, release the restrictions of the internal pterygoid fascia. Position of the patient, supine position on the stretcher. Therapist position, sitting laterally at the head of the stretcher and looking at the patient. Technique: Therapist palpates the TMJ with the index or middle finger of one hand. With the index of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs. You have to wait three consecutive releases.
219466310|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
219466311|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
219466312|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
219593920|NCT01550627|OTHER|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
219593921|NCT02490267|OTHER|Quality of Life questionnaire|
218853946|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
218853947|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
219593922|NCT00238706|DEVICE|Radiofrequency ablation|
218853948|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
218853949|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
218853950|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
218853951|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
218853952|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
218853953|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
218853954|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
218853955|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
218853956|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
218853957|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
218853958|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
218853959|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
219466313|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
219466314|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
219466315|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
219466316|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
219466317|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
219466318|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
219466319|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
219466320|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
219466321|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
219466322|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
218853960|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
218853961|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
219466323|NCT00079079|DRUG|carboplatin|
219466324|NCT00079079|DRUG|cisplatin|
219466325|NCT00079079|DRUG|gemcitabine hydrochloride|
219466326|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
219466327|NCT02136927|DRUG|SPARC1210|
219466328|NCT02136927|DRUG|Reference1210|
219466329|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
219466330|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
219466331|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
219466332|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
219466333|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
219466334|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
218853962|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
218853963|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
218853964|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
218853965|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
219466335|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
219466336|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
219466337|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
219466338|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
219593923|NCT04808466|DRUG|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
219593924|NCT04808466|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
219466339|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
219466340|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
219466341|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
219466342|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
219466343|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
218853966|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
218853967|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
218853968|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
218853969|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
218853970|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
218853971|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
218853972|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
218853973|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
218853974|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
219593925|NCT06405282|OTHER|Manual Lymphatic Drainage|MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
219593926|NCT06405282|DEVICE|Near infrared spectroscopy|Oxygen saturation measurement
219593927|NCT06405282|DEVICE|Temperature|Thermal imaging
219593928|NCT06405282|DEVICE|Tissue Dialectic Constant|TDC captured by lymphatic fluid scanning device
219593929|NCT06050473|PROCEDURE|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
218853975|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
218853976|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
218853977|NCT03122353|DRUG|Placebo|vehicle used as placebo
218853978|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
219593930|NCT06050473|PROCEDURE|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
219593931|NCT06884852|DRUG|Erector spinae plane block (ESPB)|"Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%.~We will inject 15ml at the level of T2 and 15ml at the level of T5."
219198777|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 2|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought.
219198778|NCT01601808|DRUG|Placebo|Orally once a day, continuously throughout the study
219198779|NCT01601808|DRUG|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
219198780|NCT04031209|DEVICE|G7 Acetabular System|All patients will receive G7 Acetabular System
219198781|NCT06869395|OTHER|Questionnaire|"The responses obtained will be recorded as follows:~\- Referred to a dentist~\- Referred to a physician~\- Prescribed an over the counter (OTC) preparation~\- Prescribed an OTC preparation and referred to a dentist or a physician~\- Wanted to see the patient~\- Other answers: ……….."
219198782|NCT06001125|DRUG|Methotrexate|Methotrexate 20 mg PO weekly
218853979|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
218853980|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~\- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
218853981|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|\- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
218853982|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
218853983|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
218853984|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
218853985|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
218853986|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
219466344|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
218853987|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
218853988|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
218853989|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
219593932|NCT06884852|DRUG|Thoracic epidural block|Thoracic epidural block at level of T5 -T6 using 10 ml of bupivacaine 0.25% as a bolus followed by 5 ml bupivacaine 0.25% every 1-2 hours depending on the duration of surgery and the response of the patient.
218853990|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
218853991|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
219198783|NCT06677970|DRUG|BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
219198784|NCT06677970|DRUG|BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate BP raising (20% increase in SBP, maximum of 180 from baseline SBP) are administered.
219198785|NCT06873711|BIOLOGICAL|vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
219466345|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
219466346|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
219466347|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
219466348|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
219466349|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
219593933|NCT02573090|PROCEDURE|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
219466350|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
219593934|NCT02573090|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
219466351|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
219466352|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
219466353|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
219466354|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
219466355|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
219466356|NCT02631434|PROCEDURE|sit-to-stand test|
219466357|NCT02631434|PROCEDURE|six-minutes walking test|
219466358|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
219466359|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
219466360|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
219466361|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
219466362|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
219466363|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
219466364|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
219466365|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
219466366|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
219466367|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
219466368|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
219466369|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
219466370|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
219466371|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
219466372|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
218853992|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
218853993|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
218853994|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
218853995|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
218853996|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
218853997|NCT04165473|BEHAVIORAL|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
218853998|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
219466373|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
219466374|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
219593935|NCT01830491|DRUG|Clopidogrel|
219593936|NCT01830491|DRUG|aspirin 100mg|
218853999|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
218854000|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
219466375|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
219466376|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
219466377|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
219466378|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
219466379|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
219466380|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
219466381|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
219466382|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
219466383|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
219466384|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
219466385|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
219466386|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
219466387|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
218854001|NCT05602675|DRUG|LY3871801|Administered orally.
219198786|NCT06867562|DRUG|Paclitaxel Lipid Suspension|The formulation consists of uniformly sized (\< 100 nm) particles of Paclitaxel suspended in a lipid-based formulation. The advantage of such a Lipid-Based formulation of Paclitaxel is an improvement of the safety profile by eliminating excipients, Cremophor and ethanol which are present in conventional Paclitaxel formulations (Taxol®).
218854002|NCT05602675|DRUG|Methotrexate|Administered orally.
219466388|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
219466389|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
219466390|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
219198787|NCT06867562|DRUG|Conventional paclitaxel or Taxol|Conventional formulation with detergent Cremophor and alcohol
219198788|NCT06868862|OTHER|Exercise|Two Exercise Modalities: HIIE and MICE
219466391|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
218854003|NCT05602675|DRUG|Warfarin|Administered orally.
219466392|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
219466393|NCT01781130|PROCEDURE|Steroid injection|
219593937|NCT04358289|OTHER|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
218854004|NCT05602675|DRUG|Dextromethorphan|Administered orally.
218854005|NCT05602675|DRUG|Midazolam|Administered orally.
218854006|NCT05602675|DRUG|Repaglinide|Administered orally.
219466394|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
219466395|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
219466396|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
219466397|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
219466398|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
218854007|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
218854008|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
219466399|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
219466400|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
219466401|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
219466402|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
218854009|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
218854010|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
218854011|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
218854012|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
219466403|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
219466404|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
219466405|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
219466406|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
219466407|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
219466408|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
219466409|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
219466410|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
219466411|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
219466412|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
219466413|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
219466414|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
219466415|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
219466416|NCT02358707|OTHER|Ibuprofen phonophoresis|
219466417|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
219466418|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
219466419|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
219466420|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
219466421|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
219466422|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
219466423|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
219466424|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
219593938|NCT04358289|OTHER|Participatory action research group in commune health center and community|"* Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
219593939|NCT04358289|OTHER|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
219593940|NCT04358289|OTHER|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
219198789|NCT06871137|OTHER|Welfare Benefits Advice (WBA)|Appointment offered to receive financial advice from a Welfare Benefits Advisor (WBA) co-located with routine 6-8 week newborn health checks
219198790|NCT06871137|OTHER|Usual care|No intervention, existing London Borough of Tower Hamlets 'service as usual'
219593941|NCT00151112|PROCEDURE|Positioning and plexus anesthesia|positioning during plexus anesthesia
219593942|NCT00678197|OTHER|Access Intervention|
219593943|NCT00678197|OTHER|Bonus/Pay-for-Performance Intervention|
219593944|NCT04102280|DEVICE|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
219593945|NCT00000535|BEHAVIORAL|diet, reducing|
219593946|NCT00000535|BEHAVIORAL|diet, sodium-restricted|
218854013|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
218854014|NCT01825395|DRUG|3, 4-Diaminopyridine|
218854015|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
218854016|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
218854017|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
218854018|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
218854019|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
218854020|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
218854021|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
218854022|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
218854023|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
218854024|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
218854025|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
218854026|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
218854027|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
219466425|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
219466426|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
219466427|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
219466428|NCT00118885|BEHAVIORAL|Tai Chi Chih|
219466429|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
219466430|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
219466431|NCT02450656|DRUG|Afatinib|Tablet
219466432|NCT02450656|DRUG|Selumetinib|Capsule
218854028|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
218854029|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
218854030|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
218854031|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
219466433|NCT02450656|DRUG|Docetaxel|
219466434|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
219466435|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
219466436|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
219466437|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
219466438|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
219466439|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
219466440|NCT04591782|OTHER|Water|Drink 8 oz water
219466441|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
219593947|NCT01835054|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
218854032|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
219466442|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
218854033|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
219466443|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
219466444|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
219466445|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
219466446|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
219466447|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
219466448|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
219466449|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
219466450|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
219466451|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
219466452|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
218854034|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
218854035|NCT05494736|DRUG|MK-8527|MK-8527 capsule taken by mouth.
219020024|NCT05157620|OTHER|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
219020025|NCT05157620|OTHER|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
219466453|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
219466454|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
219466455|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
219466456|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
219466457|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219466458|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
219593948|NCT01835054|GENETIC|DNA collection|Observational Study using Imaging and Biomarkers
219593949|NCT01835054|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
219593950|NCT01835054|OTHER|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
219593951|NCT01835054|OTHER|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
219593952|NCT01835054|OTHER|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
218854036|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
218854037|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
218854038|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
218854039|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
218854040|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
218854041|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
218854042|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
218854043|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
218854044|NCT00192660|DRUG|Lamivudine|
218854045|NCT00192660|DRUG|Stavudine|
218854046|NCT00192660|DRUG|Didanosine|
218854047|NCT00192660|DRUG|Zidovudine|
218854048|NCT00192660|DRUG|Tenofovir|
219466459|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
219466460|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
219466461|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
219466462|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
218854049|NCT00192660|DRUG|Abacavir|
218854050|NCT00192660|DRUG|Efavirenz (EFV)|
218854051|NCT00192660|DRUG|Nevirapine|
219466463|NCT01196754|OTHER|sevoflurane|
219466464|NCT01395420|DRUG|CAZ104|IV Infusion
219466465|NCT01395420|DRUG|CAZ104|IV Infusion
218854052|NCT00192660|DRUG|Indinavir|
219466466|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
219466467|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
219466468|NCT00405925|DRUG|Trizivir|
218854053|NCT00192660|DRUG|Saquinavir|
218854054|NCT00192660|DRUG|Amprenavir|
218854055|NCT00192660|DRUG|Ritonavir|
218854056|NCT00192660|DRUG|Nelfinavir|
218854057|NCT00192660|DRUG|Tipranavir|
218854058|NCT00192660|DRUG|enfuvirtide (T20)|
218854059|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
218854060|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
218854061|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
218854062|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
218854063|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
218854064|NCT04410666|OTHER|Placebo Mouthwash|distilled water
218854065|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
218854066|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
218854067|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
218854068|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
218854069|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
218854070|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
218854071|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
218854072|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
219466469|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
219466470|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
219466471|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
219466472|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
219593953|NCT01835054|OTHER|Holter ECG|Observational Study using Imaging and Biomarkers
218854073|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
219466473|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
219466474|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
219466475|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
219466476|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
219466477|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
219466478|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
219466479|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
219466480|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
219466481|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
219466482|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
219466483|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
219466484|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
219466485|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
219466486|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
219466487|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
219466488|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
219466489|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
219466490|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
219466491|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
219466492|NCT01111058|OTHER|Placebo|
219466493|NCT01917396|DRUG|Fleet enema|
219198791|NCT06871657|PROCEDURE|Sinus lift using osseodensification technique|Osseodensification dislocates existing bone into trabeculated space by using a bur that turns in anti-clockwise direction. The procedure itself is not part of the research, but is the intervention of interest to the study.
219198792|NCT06871657|PROCEDURE|Sinus lift using the osseocondensation technique|This procedure is performed by using osteotome hand instruments. The procedure itself is not part of the research, but is the intervention of interest to the study.
219198793|NCT06873100|DRUG|Upadacitinib|Upadacitinib is an oral Janus kinase (JAK) inhibitor used in this study to treat patients with relapsing polychondritis. The drug is administered at a dose of 15 mg once daily for a duration of 24 weeks.
219198794|NCT06873100|DRUG|corticosteroids and immunosuppressants|Corticosteroids combined with immunosuppressants is a conventional treatment for relapsing polychondritis. In this study, it serves as the control arm against Upadacitinib for the treatment of relapsing polychondritis. Dosing is tailored to the individual patient's condition, with the selection of different types of corticosteroids and immunosuppressive agents based on the specific needs of the patient's clinical profile.
218854074|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
219198795|NCT06681870|DRUG|ASP1893|Intravenous infusion
219198796|NCT01438853|BIOLOGICAL|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
219198797|NCT01438853|DRUG|Placebo|Single intravenous dose of saline control
219466494|NCT05024721|DRUG|HIP2101|Test drug
219466495|NCT05024721|DRUG|RLD2101|Reference drug
219466496|NCT05024721|DRUG|HPP2101|Placebo drug
219466497|NCT05024721|DRUG|HPP2102|Placebo drug
219466498|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
219466499|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
219466500|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
218854075|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
218854076|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
218854077|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
219466501|NCT01751490|OTHER|physiotherapy|physiotherapy
219466502|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
218854078|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
218854079|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
219466503|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
219466504|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
219466505|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
219466506|NCT03939429|DRUG|QPX2015|antibiotic
219593954|NCT01062867|DRUG|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
218854080|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
218854081|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
218854082|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
218854083|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
218854084|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
218854085|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
218854086|NCT06495840|OTHER|no intervention|no intervention
218854087|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
219466507|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
219020028|NCT06748092|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP) in sitting and supine position
219466508|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
219466509|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
219466510|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
219466511|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
219466512|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
219466513|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
219466514|NCT04963517|BEHAVIORAL|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
219466515|NCT04963517|OTHER|Information|"* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations."
219466516|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
219593955|NCT05423795|OTHER|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
219593956|NCT05423795|OTHER|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
219593957|NCT05068453|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
219593958|NCT05068453|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
219593959|NCT05068453|RADIATION|RT|3 times radiation，totally 24-30 Gy for each lession.
219020029|NCT06748092|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP) in sitting and supine position
219020030|NCT06748092|DEVICE|GAT|Measurement of Intraocular Pressure (IOP) in sitting position
219020031|NCT06748092|DEVICE|Perkins|Measurement of Intraocular Pressure (IOP) in supine position
219020032|NCT06763796|OTHER|Postural Decryption Technique|"Assessment:~PDT begins with visual inspection and palpation to check postural alignment and identify joint or muscle imbalances. Evaluations proceed distal to proximal, examining the spine and shoulder complex in coronal, sagittal, and transverse planes to assess symmetry and neutral positioning.~Treatment Process:~PDT applies the 4R Technique:~1. Reposition - Correct joint alignment.~2. Restore - Release muscle tension and adhesions.~3. Reinforce - Strengthen stabilizing muscles.~4. Retrain - Improve movement patterns and posture.~Key Techniques:~1. Spinal and Shoulder Adjustments: Manual traction, mobilizations, and stretches.~2. Joint Mobilization: Multi-directional gliding within pain-free ranges.~3. Trigger Point Therapy: 5-10 seconds of pressure to relieve localized pain.~4. Proprioception Training: Balance challenges to improve stability and control."
219466517|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
219466518|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
219466519|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
219466520|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
219466521|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
219466522|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
219466523|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
219466524|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
219198798|NCT06625658|DEVICE|Direct printed clear aligners|chang aligner every 10 days
218854088|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
219198799|NCT04807777|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
219198800|NCT04743973|DEVICE|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
219198801|NCT06624527|OTHER|Psychoeducation based on Cognitive Behavioral Therapy|A psycho-educational application based on Cognitive Behavior Therapy consisting of a total of 8 sessions prepared by the researcher.
219198802|NCT03279978|DRUG|BI 730357|BI 730357 film-coated tablet
219198803|NCT03279978|DRUG|Placebo|Placebo
219198804|NCT03279978|DRUG|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
219198805|NCT06872853|OTHER|diagnosis, surgery, drugs for rare neoplasms|diagnostic and surgical procedures, drugs (pharmacological active substance, dose, regimen)
219198806|NCT06874036|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is a procedure to see the ascending, transverse, decending, sigmoid, rectum of colon parts
219198807|NCT06873893|PROCEDURE|Midpoint transverse process block|This group will receive a volume of 20ml of bupivacaine 0.5% at midpoint of the line between the posterior border of the transverse process of T4 and the pleura ( injection will be deep to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligament )
219198808|NCT06873893|PROCEDURE|Pectoral Nerve Block|This group will receive a volume of 10ml of bupivacaine 0.5% will be injected between the pectoralis major and pectoralis minor muscle then another 10ml bupivacaine will be injected between pectoralis minor and serratus anterior muscle
219466525|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
219466526|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
218854089|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
218854090|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
219466527|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
219466528|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
219466529|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
218854091|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
219466530|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
219466531|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
218854092|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
218854093|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
219466532|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
219466533|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
219466534|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
219466535|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
218854094|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
218854095|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
218854096|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
218854097|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
219466536|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
219466537|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
219593960|NCT03958253|OTHER|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines"
218854098|NCT01712997|DRUG|Iloprost|
218854099|NCT01712997|DRUG|Bosentan|
218854100|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
218854101|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
218854102|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
218854103|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
218854104|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
219466538|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
219466539|NCT03153436|BIOLOGICAL|Myoinositol|
219466540|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
219466541|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
219466542|NCT00752427|DRUG|Paliperidone ER OROS®|
219593961|NCT06167863|DIAGNOSTIC_TEST|radiomics|extracted image features from CT or MRI
219593962|NCT01246063|DRUG|carfilzomib|
219593963|NCT01246063|DRUG|pegylated liposomal doxorubicin (PLD)|
219593964|NCT01246063|DRUG|Dexamethasone|
218854105|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
219466543|NCT00131027|DRUG|Cyclophosphamide|
219466544|NCT00131027|DRUG|Daunorubicin|
219466545|NCT00131027|DRUG|Vincristine|
219466546|NCT00131027|DRUG|Prednisolone|
219466547|NCT00131027|DRUG|L-asparaginase|
219466548|NCT00131027|DRUG|Cytarabine|
219198809|NCT06873971|DRUG|Topical estrogen therapy based on estriol (E3)|Patients will use low-dose isolated topical estrogen therapy in the form of estriol 1mg/g vaginal cream (Generic), with disposable, individualized vaginal applicators pre-set at the recommended dosage of 5g/dose each. Initially, they will use it for 14 consecutive nights, and then use it 2 times a week, always during the night, on Mondays and Thursdays, for 16 consecutive weeks from the start of the research. The treatment will be provided in fractions for each 30-day period and will always be delivered after each laser session, along with a leaflet containing usage, storage, and application instructions for the vaginal cream. The patients will be monitored through a messaging app, reinforcing the instructions and the days of application correctly.
219198810|NCT06873971|RADIATION|Laser Er:YAG On|All participants in the group will undergo 3 applications of the Er:YAG laser with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03-fractional tip: the internal stage (vaginal canal) and the external stage (region of the vestibule and introitus).
219198811|NCT06873971|RADIATION|Laser Er:YAG Off|All participants in the group will undergo 3 applications of the Er:YAG laser with the device turned off, with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03 fractional tip: the internal stage (vaginal canal) and the external stage (vestibule and introitus region).
219466549|NCT00131027|DRUG|Etoposide|
219466550|NCT00131027|DRUG|Dexamethasone|
219593965|NCT03694600|DIAGNOSTIC_TEST|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
218854106|NCT03006458|DEVICE|comfilcon A|toric contact lens
218854107|NCT03006458|DEVICE|omafilcon B|toric contact lens
218854108|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
218854109|NCT03011970|DRUG|Oxytocin|
219020033|NCT06763796|OTHER|Traditional Chinese Medicine (TCM) Massage Therapy|"Definition:~A manual therapy based on Traditional Chinese Medicine (TCM) principles, using techniques like kneading, pressing, rolling, and stretching to relieve pain, improve circulation, and enhance mobility.~Key Features:~1. Techniques: Soft tissue manipulation, joint mobilization, and acupressure.~2. Focus: Pain relief, joint function recovery, and muscle relaxation.~Treatment Plan:~4 weeks, 5 sessions per week, 40 minutes per session."
219466551|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
219466552|NCT00131027|DRUG|Mercaptopurine|
219593966|NCT02332954|DRUG|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
219593967|NCT03364868|DRUG|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
219020036|NCT06878118|DEVICE|Single-vision contact lens|Standard single vision contact lens
219020037|NCT06878118|DEVICE|A.R.R.E.S.T.® contact lens|Contact lens with edge pattern
219466553|NCT00131027|DRUG|Doxorubicin|
219593968|NCT03364868|OTHER|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
219466554|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
219466555|NCT02213627|DRUG|Corifollitropin alfa|
219466556|NCT02213627|DRUG|Recombinant FSH|
218854110|NCT03011970|DRUG|Placebo|
219466557|NCT02213627|DRUG|HP-hMG|
219466558|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
219466559|NCT04784676|OTHER|restoration|indirect restoration
219466560|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
218854111|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
218854112|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
218854113|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
218854114|NCT01316757|BIOLOGICAL|cetuximab|Given IV
219466561|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
219466562|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
219466563|NCT03007680|OTHER|Core muscle activation|
219466564|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
219466565|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
219466566|NCT01065662|DRUG|cediranib|Taken orally daily
219466567|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
218854115|NCT01316757|DRUG|paclitaxel|Given IV
218854116|NCT01316757|DRUG|carboplatin|Given IV
218854117|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
218854118|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
219466568|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
219466569|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
219466570|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
219466571|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
219466572|NCT03380091|DRUG|Metformin|Oral medication daily
219466573|NCT03380091|DRUG|Vitamin D|Oral medication daily
219466574|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
219466575|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
219466576|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
219466577|NCT05602818|DRUG|Soticlestat 300 mg|Administered orally.
219466578|NCT05602818|DRUG|Soticlestat 600 mg|Administered orally.
219466579|NCT05602818|DRUG|Soticlestat 900 mg|Administered orally.
219466580|NCT05602818|DRUG|Alprazolam|Administered orally.
218854119|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
218854120|NCT02381717|DRUG|bupivacaine|
218854121|NCT02381717|DRUG|morphine|
219466581|NCT05602818|DRUG|Placebo|Administered orally.
218854122|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
218854123|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
219466582|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
219466583|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
219466584|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
219466585|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
219466586|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
219466587|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
218854124|NCT00144248|DRUG|nevirapine|
218854125|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
218854126|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
218854127|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
219198812|NCT06693518|DRUG|Treatment B|Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
219198813|NCT06693518|DRUG|Treatment A|Dabigatran Etexilate 150 mg
219198814|NCT04330040|DRUG|Olaparib|Tablet
219198815|NCT03386513|DRUG|IMGN632|CD123-targeted ADC
219198816|NCT06460467|DEVICE|scintigraphy of 177Lu-DOTATATE|The medical device under study is a hybrid wide-field CZT solid-state camera, the VERITON-CT ™ camera.
218854128|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
219466588|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
219466589|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
219466590|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
219466591|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
219466592|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
219466593|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
219466594|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
219466595|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
219466596|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
219466597|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
219466598|NCT00538434|BIOLOGICAL|Reslizumab|
219466599|NCT00538434|OTHER|Saline|
219466600|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
219466601|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
219466602|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
219466603|NCT02164058|DEVICE|TandemHeart System|
219466604|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
219466605|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
219466606|NCT03054493|BEHAVIORAL|no intervention|no intervention
219466607|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
219466608|NCT00078689|DRUG|Daclizumab|
219466609|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
219593969|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of parenchymal lung change cause|Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
219466610|NCT00136344|DRUG|Cefuroxime|
219466611|NCT00136344|DRUG|Levofloxacin|
219466612|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
219593970|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
219593971|NCT00483483|BEHAVIORAL|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
219593972|NCT00483483|BEHAVIORAL|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
219593973|NCT00187382|DRUG|Multiple vs. single courses of antenatalcorticosteroids|
218854129|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
218854130|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
219466613|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
219466614|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
219466615|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
219466616|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
219466617|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
219466618|NCT02353234|OTHER|Bread|In each arm subjects consume bread
219466619|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
219466620|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
219466621|NCT00001422|DRUG|fludarabine|
219466622|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
219466623|NCT00509275|DRUG|W0027|capsule
219466624|NCT00509275|DRUG|Placebo|Placebo
219466625|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
219466626|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
219466627|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
219466628|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
219466629|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
219466630|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
219466631|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
219466632|NCT03605277|DRUG|Asciminib|40 mg single dose
219466633|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
219466634|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
219466635|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
219593974|NCT06906081|DRUG|Kerendia (Finerenone, BAY94-8862)|"Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Finerenone is administered orally as immediate release tablets."
219593975|NCT06906081|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
219593976|NCT06135051|DEVICE|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
219466636|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
219466637|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
219466638|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
219466639|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
219466640|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
219466641|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
219466642|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
219466643|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
219466644|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
219466645|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
219466646|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
218854131|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
219466647|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
219466648|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
219466649|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
219466650|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
219466651|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
219466652|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
219466653|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
219466654|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
219466655|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
219466656|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219466657|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219466658|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
218854132|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
218854133|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
218854134|NCT00422149|DRUG|Placebo treatment|Placebo treatment
219198817|NCT02639754|BEHAVIORAL|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
219466659|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
219198818|NCT02639754|BEHAVIORAL|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
219466660|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
219466661|NCT02711085|OTHER|No intervention|No intervention - observational study
219466662|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
219466663|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
219466664|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
219466665|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
219466666|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
219466667|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
219466668|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
219466669|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
219466670|NCT00697255|DRUG|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
219466671|NCT00697255|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
219466672|NCT00697255|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
219466673|NCT00697255|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
219466674|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
219466675|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
219466676|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
219198819|NCT06396689|DIETARY_SUPPLEMENT|Synbiotic|The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
219466677|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
219466678|NCT02184312|DRUG|Nevirapine XR low dose|
219198820|NCT06396689|DIETARY_SUPPLEMENT|Placebo|The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
219466679|NCT02184312|DRUG|Nevirapine XR medium dose|
219466680|NCT02184312|DRUG|Nevirapine XR high dose|
219198821|NCT05906199|DRUG|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
219466681|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
219466682|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
219466683|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
219593977|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
219466684|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
219466685|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
219198822|NCT05906199|DRUG|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
219466686|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
219466687|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
219466688|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
219466689|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
219466690|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
219466691|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
219466692|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
218854135|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
218854136|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
219466693|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
219466694|NCT00336986|DRUG|recombinant interleukin-21|
218854137|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
218854138|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
218854139|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
218854140|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
218854141|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
218854142|NCT00096148|DRUG|idarubicin|Given IV
218854143|NCT00096148|DRUG|cytarabine|Given IV
219593978|NCT03441282|DRUG|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
219593979|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - None|Participants will view smokeless tobacco ads with no modified risk claim (control)
218854144|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
218854145|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
218854146|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
219466695|NCT06443138|OTHER|Personalized pre-habilitation program|"Each patient will undergo 4 weeks of individualized pre-habilitation before surgery.~Each session (1 session per day) will be carried out autonomously by the patient at home, via a dedicated application (Activiti Pro) installed on their tablet or smartphone."
219466696|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
219466697|NCT01960036|BEHAVIORAL|Womens Health Education|
219466698|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
218854147|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
218854148|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
219198823|NCT05418140|OTHER|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
219466699|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
219466700|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
219466701|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
219466702|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
219466703|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
218854149|NCT01115894|DRUG|Placebo|Placebo
218854150|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
218854151|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
219198824|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
219198825|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
219198826|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
219466704|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
219466705|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
219466706|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
219466707|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
219466708|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
219466709|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
219466710|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
219593980|NCT06927700|BEHAVIORAL|Product Brand - General Snus|Participants will views ads for the smokeless tobacco brand General Snus
219593981|NCT06927700|BEHAVIORAL|Product Brand - Copenhagen|Participants will views ads for the smokeless tobacco brand Copenhagen
218854152|NCT00634712|DRUG|Candesartan|
218854153|NCT00634712|DRUG|Placebo|
218854154|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
218854155|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
218854156|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
218854157|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
218854158|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
218854159|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
218854160|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
219466711|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
219466712|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
218854161|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
218854162|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
218854163|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
218854164|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
218854165|NCT00503412|DRUG|AZD2171|oral 14C
218854166|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
218854167|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
218854168|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
218854169|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
218854170|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
218854171|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
218854172|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
219466713|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
219466714|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
219466715|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
219466716|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
219466717|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
219466718|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
219466719|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
219466720|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
219466721|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
218854173|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
218854174|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
219466722|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
219466723|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
219466724|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
219593982|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Multiple Diseases|Participants will view smokeless tobacco ads with a claim about lower risks for multiple diseases
219593983|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Lung Cancer|Participants will either view smokeless tobacco ads with a modified risk claim about lower risks for lung cancer only
219593984|NCT06934889|DRUG|ERAS-801|will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.
218854175|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
218854176|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
219593985|NCT06934889|DRUG|ABBV-637|will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.
219593986|NCT06934889|DRUG|ABBV-155|will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.
219593987|NCT06934889|DRUG|Temozolomide|Temozolomide will be continued for 6 cycles after radiation.
219466725|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
219466726|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
219466727|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
219466728|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
218854177|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
218854178|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
218854179|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
218854180|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
218854181|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
219020043|NCT07091422|DEVICE|Etch-Free Adhesive|A self-adhesive orthodontic bonding material applied directly to enamel without prior phosphoric acid etching or primer application. Brackets are bonded following the manufacturer's instructions.
219020044|NCT07091422|DEVICE|Conventional Etch-and-Bond Adhesive|A standard orthodontic bonding protocol using 35-37% phosphoric acid etching, primer application, and a conventional light-cure adhesive. Brackets are bonded following the manufacturer's recommended procedure.
219020046|NCT05821972|DRUG|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
219020047|NCT05821972|DRUG|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
219020048|NCT06909214|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
219020049|NCT06902818|DRUG|AD-115A, AD-1151|AD-115A , AD-1151 Oral Tablet
219020050|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
219020051|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
219020052|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
219466729|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
219466730|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
219466731|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
219466732|NCT01778673|PROCEDURE|Cast immobilization|
219466733|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
218854182|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
218854183|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
218854184|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
219466734|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
219466735|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
219466736|NCT03176979|OTHER|Contrast Agent|Given IV
219466737|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
219466738|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
219466739|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
219466740|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
219466741|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
219466742|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
219466743|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
219466744|NCT00184730|DRUG|somatropin|
219466745|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
219466746|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
219593988|NCT06934889|RADIATION|Radiotherapy|will be given as per standard of care radiation for GBM
219593989|NCT06941181|OTHER|neurocognitive tasks|"1. risk-processing: Participants choose between two choices across 72 trials of a forced choice decision-making neurocognitive task (Holt and Laury, 2002). Each trial included a high and low monetary outcome with an associated probability of occurring. Each choice option is shown as a pie with ten slices represented probabilities, in which each piece corresponded to ten percent.~2. cognitive control: A multi-source interference task (MSIT; Bush et al., 2003) is used in which participants are presented with three digits and asked to identify the digit different from the others. In the neutral condition, the target's identity is congruent with its relative position. In the interference condition, the target's identity does not match its relative position. There are a total of 96 neutral trials and 96 interference trials."
218854185|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
218854186|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
219466747|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
219466748|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
219466749|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
219466750|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
219466751|NCT00318032|DRUG|multi-factorial intervention|
219466752|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
219466753|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
218854187|NCT03919968|BEHAVIORAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
219466754|NCT01074320|OTHER|Other|Observational study
219466755|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
219466756|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
219466757|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
218854188|NCT03919968|BEHAVIORAL|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
218854189|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
218854190|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
219466758|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
219466759|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
219466760|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
219593990|NCT05978141|OTHER|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
219593991|NCT06372496|DRUG|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate|Participants will receive FF/UMEC/VI
219593992|NCT06372496|DRUG|Inhaled corticosteroids/long-acting beta-2 agonists|Participants will receive ICS/LABA
219593993|NCT06229262|DIETARY_SUPPLEMENT|Mango group|Participants will consume 1.5 cups of mangos per day for 12 weeks.
219593994|NCT05846230|DRUG|BI 1291583|Tablet
219593995|NCT05846230|DRUG|Placebo matching BI 1291583|Tablet
219593996|NCT06236139|BIOLOGICAL|Anti-STEAP1 CAR T-cells|Given IV
219593997|NCT06236139|PROCEDURE|Biopsy|Undergo tumor biopsy
219593998|NCT06236139|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218854191|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
218854192|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
218854193|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
218854194|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
218854195|NCT02141698|DRUG|TAK-438|TAK-438 tablets
218854196|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
219466761|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
219466762|NCT00491595|DRUG|High Dose Soy isoflavones|
219466763|NCT00057642|DRUG|Sertraline|
219466764|NCT00057642|DRUG|Venlafaxine Extended Release|
219466765|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
219466766|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
219466767|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
219466768|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
219466769|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
219466770|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
219466771|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
219593999|NCT06236139|PROCEDURE|Bone Scan|Undergo NM bone scan
219594000|NCT06236139|PROCEDURE|Computed Tomography|Undergo CT scan
219594001|NCT06236139|DRUG|Cyclophosphamide|Given IV
218854197|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
218854198|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
218854199|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
219594002|NCT06236139|PROCEDURE|Echocardiography|Undergo ECHO
219594003|NCT06236139|DRUG|Enzalutamide|Given PO
219594004|NCT06236139|DRUG|Fludarabine|Given IV
219594005|NCT06236139|PROCEDURE|Leukapheresis|Undergo leukapheresis
219594006|NCT06236139|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219594007|NCT06236139|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219594008|NCT06236139|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219594009|NCT06832410|BIOLOGICAL|Biological/Vaccine|Infused into the hepatic portal vein.
219594010|NCT03646058|DRUG|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
219594011|NCT03646058|DRUG|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
218854200|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
218854201|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
218854202|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
218854203|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
219466772|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
218854204|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
218854205|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
218854206|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
218854207|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
218854208|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
218854209|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
218854210|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
218854211|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
218854212|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
218854213|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
218854214|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
218854215|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
218854216|NCT06660641|DEVICE|0.9 % saline|placebo
219466773|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
219466774|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
219466775|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
218854217|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
219466776|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
219594012|NCT04876092|DRUG|JNJ-67856633|Participants will receive JNJ-67856633 orally.
219594013|NCT04876092|DRUG|Ibrutinib|Participants will receive Ibrutinib orally.
218854218|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
218854219|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
218854220|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
218854221|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
218854222|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
218854223|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
218854224|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
218854225|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
218854226|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
218854227|NCT05050617|DIAGNOSTIC_TEST|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
218854228|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
218854229|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
218854230|NCT00223405|DEVICE|crown placement|
218854231|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
218854232|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
218854233|NCT03200977|OTHER|Non-Interventional|Non-Interventional
219466777|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
219466778|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
219466779|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
219466780|NCT00001426|DRUG|Cyclophosphamide|
219020061|NCT05704049|DRUG|Isatuximab|Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
219020062|NCT05704049|DRUG|Carfilzomib|Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
219020063|NCT05704049|DRUG|Dexamethasone|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
219020064|NCT05704049|DRUG|Dexamethasone IV|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
219466781|NCT00001426|DRUG|Paclitaxel|
219466782|NCT00001426|DRUG|Cisplatin|
219466783|NCT00001426|DRUG|G-CSF|
219466784|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
219466785|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
219466786|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
219020065|NCT05704049|DRUG|Montelukast|Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
219020066|NCT05704049|DRUG|Acetaminophen|Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
218854234|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
218854235|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
218854236|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
218854237|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
218854238|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
218854239|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
218854240|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
218854241|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
219466787|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
219466788|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
219466789|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
219466790|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466791|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
218854242|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
218854243|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
219020067|NCT05704049|DRUG|Diphenhydramine|Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
219020068|NCT05704049|DRUG|Methylprednisolone|Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
219466792|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466793|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466794|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466795|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466796|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466797|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
219466798|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
219466799|NCT00003701|DRUG|carboplatin|
219466800|NCT00003701|DRUG|cisplatin|
219466801|NCT00003701|DRUG|doxorubicin hydrochloride|
219466802|NCT00003701|DRUG|methotrexate|
219466803|NCT00003701|DRUG|paclitaxel|
219466804|NCT00003701|DRUG|vinblastine sulfate|
219466805|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
219466806|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
219466807|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
219466808|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
219466809|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
219466810|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
219466811|NCT01014104|DRUG|Control|Normal salin injection
219466812|NCT00005068|DRUG|fluorouracil|
219466813|NCT00005068|DRUG|irinotecan hydrochloride|
219466814|NCT00005068|DRUG|leucovorin calcium|
219466815|NCT00005068|DRUG|oxaliplatin|
219466816|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
219466817|NCT00077896|PROCEDURE|Direct Current Polarization|
219466818|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
219466819|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
219466820|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
219466821|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
219466822|NCT03914456|OTHER|rehabilitation treatment|
219466823|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
219466824|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
219466825|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
219466826|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
219466827|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
219466828|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
219466829|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
219466830|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
219466831|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
219466832|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
219466833|NCT02849873|DRUG|IDP-123 Lotion|Lotion
219466834|NCT02849873|DRUG|Tazorac Cream|Cream
219466835|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
219466836|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
219594014|NCT05219474|DIAGNOSTIC_TEST|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
219594015|NCT05307731|DRUG|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
219594016|NCT05307731|DRUG|guideline-based treatment for DM|guideline-based treatment for DM
219020077|NCT05095116|DRUG|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
218854244|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
218854245|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
218854246|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
218854247|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
218854248|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
218854249|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
218854250|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
218854251|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
218854252|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
218854253|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
218854254|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
218854255|NCT00499330|PROCEDURE|lobectomy|
218854256|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
218854257|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
219466837|NCT00456586|DRUG|KW-6002 (istradefylline)|
219466838|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
218854258|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
218854259|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
219466839|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
219466840|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
219466841|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
219466842|NCT05915455|OTHER|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
219466843|NCT05915455|OTHER|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
218854260|NCT06589050|OTHER|"Toe flexor device experimental group"|This intervention group will perform toe flexion using a toe flexor (TF) device, which facilitates the shortening and stretching of the TF muscle-tendon units (MTUs) against resistance bands. While seated, participants will push a pedal down with their toes over two counts and release it over two counts.
218854261|NCT06589050|OTHER|"Inclined Heel Rise experimental group"|This intervention group will perform single-leg heel rises on an inclined platform. Participants will place their hands against a barre for balance support, lift their heels over two counts, and lower them over two counts.
218854262|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
218854263|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
218854264|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
218854265|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
219466844|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
219466845|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
218854266|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
218854267|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
218854268|NCT06819995|PROCEDURE|Static guided implant placement with a 3D printed guide|3D-printed guides (E-Guide resin, EnvisionTEC®, Germany) (D4K Pro printer, EnvisionTEC®, Germany) performed by acommercial manufacturing center (Archimedes, Spain). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
218854269|NCT06819995|PROCEDURE|Static guided implant placement with a milled guide|Milled guides (anaxCAM PMMA Clear blanks, Anaxdent, Germany) (CORiTEC 150i PRO miller, Imes-icore®, Germany). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
218854270|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
218854271|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
218854272|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
218854273|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
218854274|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
218854275|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
218854276|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
219466846|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
219466847|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
219466848|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
219466849|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
219466850|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
219466851|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
219466852|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
219466853|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
219466854|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
219594017|NCT06195072|DRUG|Amlitelimab|"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"
218854277|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
218854278|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
218854279|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
218854280|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
218854281|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
219020078|NCT00597012|PROCEDURE|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
219020079|NCT00597012|OTHER|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
219020080|NCT00597012|OTHER|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
219020085|NCT07090785|DRUG|LY4088044|Administered IV
219020086|NCT07090785|DRUG|LY4088044|Administered SC
218854282|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
218854283|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
218854284|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
218854285|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
219466855|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
219466856|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
219466857|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
218854286|NCT06657859|DRUG|GLM101|GLM101 IV infusion
218854287|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
219020087|NCT07090785|DRUG|Placebo|Administered IV
219020088|NCT07090785|DRUG|Placebo|Administered SC
219198827|NCT06696300|OTHER|Classical Physiotherapy Group|"Classical physiotherapy group (CF) will be treated face to face for 30 sessions in total, 3 days a week, 10 weeks. Hotpack, Ultrasound, TENS and Basic Exercises will be applied to the CF group. Hotpack will be applied superficially to the lumbar region for 15 minutes. Ultrasound 1MHz- 1.5 Wt/cm2 will be applied to the lumbar region. TENS 50 Hz will be applied for 15 minutes, leaving the painful area in the middle. Basic exercises will be applied as 8-12 repetitions, 2 sets. The number of repetitions and sets will be increased as the tolerance of the patients increases.~Pelvic tilt exercises Supine hip flexor stretch Supine lumbar extensor stretch Crunches Cat-Camel Exercises"
219466858|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
219466859|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
219466860|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
219466861|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
219466862|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
219466863|NCT00665366|DRUG|Lithium|Participant's ongoing dose
219466864|NCT00665366|DRUG|Valproate|Participant's ongoing dose
219466865|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
219466866|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
219466867|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
219466868|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
219466869|NCT01229865|DRUG|VB-111|
219466870|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
219466871|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
218854288|NCT06669546|OTHER|Phase-locked auditory stimulation (PLAS)|"Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation."
219198828|NCT06696300|OTHER|Foundation Inspiratory Muscle Training in Addition to Classical Physiotherapy|In addition to Classical Physiotherapy, Foundation Inspiratory Muscle Training (IKE) will be treated face to face for 30 sessions, 3 days a week, 10 weeks. On other days, IKE will be applied at home for 15 minutes in the morning and evening for a total of 30 minutes and will be followed up with a diary. IKE will be applied with a device that can load with threshold pressure. The IKE group will continue the exercise program for 10 weeks. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be asked. As tolerance increases, the consecutive respiratory cycle will be increased. The intensity will be adjusted by taking weekly MIP measurements. Daily monitoring forms will be created for each participant to ensure exercise follow-up.
219198829|NCT06696300|OTHER|Functional Inspiratory Muscle Training Group in Addition to Classical Physiotherapy|Functional Inspiratory Muscle Training Group will receive functional inspiratory muscle training in addition to classical physiotherapy, 3 days a week, 10 weeks, 30 sessions in total, face-to-face treatment. On other days, foundation-ICE will be applied at home for 15 minutes in the morning and evening, for a total of 30 minutes, and will be followed with a diary. The same protocol will be applied with the foundation IKE group for teaching the respiratory cycle in the first 4 weeks, and resisted breathing will be worked simultaneously with the exercises in Table 2 in the last 6 weeks. The exercise program will be continued for a total of 10 weeks, including F-ICE, foundation IKE for the first 4 weeks, and F-ICE for 6 weeks thereafter. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be requested. As tolerance increases, the number of consecutive respiratory cycles will be increase
219198830|NCT06696794|DRUG|Mitomycin C (MMC)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (mitomycin) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
219020091|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
219198831|NCT06696794|DRUG|Normal Saline (Placebo)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
219198832|NCT03116061|OTHER|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
218854289|NCT06669546|OTHER|Sham Phase-Locked Auditory Stimulation|Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.
218854290|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
218854291|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
218854292|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
218854293|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
219466872|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
219466873|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
219466874|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
219466875|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
219466876|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
219466877|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
219466878|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
219466879|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
219466880|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
218854294|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
218854295|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
218854296|NCT04926831|DRUG|capmatinib|150 mg and 200 mg tablets for oral administration
219020092|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
219466881|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
219466882|NCT02928198|DEVICE|ABSORB BVS|
219594018|NCT06195072|DRUG|BI 1015550 (Nerandomilast)|Study participants will take the active investigational product BI 1015550 (Nerandomilast) or matching placebo provided as film-coated tablets, administered orally BID.
219594019|NCT06195072|DRUG|Placebo|see Experimental Arm intervention description
218854297|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
218854298|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
219466883|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
219466884|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
218854299|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
219466885|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
219466886|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
219466887|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
219466888|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
219466889|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
219466890|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
219466891|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
219466892|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
219466893|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
219466894|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219466895|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
219594020|NCT05291260|PROCEDURE|Cast immobilization|A cast to immobilize the MCP, in 10-30 degrees (slight) flexion (neutral position), and the CMC joint, in 30-40 degrees palmar abduction, is applied (IP joint is free).
219594021|NCT05291260|PROCEDURE|Surgical treatment|"In general, two surgical techniques are described in literature and used in daily clinical practice:~* If the UCL is ruptured in the middle of the ligament, sutures are used to reattach the ligament remnants together.~* When no viable UCL ligaments are present, the UCL is reattached directly to the bone using suture anchors."
219594022|NCT06529757|OTHER|Whole body cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
218854300|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
218854301|NCT06607068|OTHER|None (Observational study)|None (Observational study)
219466896|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
219466897|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
219466898|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
219466899|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
219466900|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
219466901|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
219466902|NCT00406939|GENETIC|IL-12 gene|
219466903|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
219466904|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
219466905|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
219466906|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
219466907|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
219466908|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
219466909|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
219466910|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
219466911|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
219466912|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
219466913|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
219466914|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
219466915|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
219466916|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
219466917|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
219020103|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
219020104|NCT06127043|DRUG|Placebo|Administered via SC
219466918|NCT04979325|OTHER||
219466919|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
219466920|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
219466921|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
219466922|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
219466923|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
219594023|NCT06529757|OTHER|Non-cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
219594024|NCT01707264|DRUG|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
219594025|NCT02420912|DRUG|Ibrutinib|Given PO
219594026|NCT02420912|OTHER|Laboratory Biomarker Analysis|Correlative studies
219594027|NCT02420912|BIOLOGICAL|Nivolumab|Given IV
219594028|NCT02291640|DEVICE|MIL|direct laryngoscopy
219594029|NCT02291640|DEVICE|CoPilot|video laryngoscopy
219466924|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
219466925|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
219466926|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
219466927|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
218854302|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
218854303|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
218854304|NCT05118984|DRUG|Placebo|A treatment that has no active properties
218854305|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
218854306|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
218854307|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
219466928|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
219466929|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
219466930|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
219466931|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
219466932|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
219594030|NCT05790603|DEVICE|Intervention group with PHD-Band|The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.
219594031|NCT05790603|DEVICE|Control group with TR-Band|TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
219594032|NCT04533997|DRUG|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
218854308|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
218854309|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
218854310|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
218854311|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
218854312|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
219466933|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
219466934|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
219466935|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
219466936|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
219466937|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
219466938|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
219466939|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
219466940|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
219466941|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
219466942|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
219466943|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
219466944|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
219466945|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
219466946|NCT00474994|DRUG|sunitinib malate|
219466947|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
219466948|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
219466949|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
219466950|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
218854313|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
218854314|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
218854315|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
219020106|NCT07092527|DRUG|Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
219466951|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
219466952|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
219466953|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
219466954|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
219466955|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
219466956|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
219466957|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
219466958|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
219466959|NCT06344858|DRUG|Ketamine|One bolus of ketammine
219466960|NCT00350935|PROCEDURE|fMRI|One 30 minute session
219466961|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
219466962|NCT00030849|DRUG|bexarotene|
219466963|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
219466964|NCT00721513|BIOLOGICAL|cetuximab|
219466965|NCT00721513|DRUG|cisplatin|
219466966|NCT00721513|DRUG|docetaxel|
219466967|NCT00721513|DRUG|fluorouracil|
219198833|NCT06699199|DRUG|Silver diamine Fluoride 38%|"Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~\- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%."
219466968|NCT00721513|PROCEDURE|computed tomography|
219594033|NCT04533997|DRUG|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg"
219594034|NCT02218554|GENETIC|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
219198834|NCT06699199|DRUG|Silver diamine fluoride- potassium iodide|"Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~\- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)"
219198835|NCT06701357|DRUG|CR-CHOP+PD1 inhibitor|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1
219198836|NCT06701357|DRUG|CR-CHOP + Orelabrutinib|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21
219198837|NCT06701357|DRUG|CR-CHOP + decitabine|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1
219198838|NCT03745716|DRUG|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
219198839|NCT03745716|DRUG|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
219466969|NCT00721513|PROCEDURE|positron emission tomography|
219466970|NCT00721513|PROCEDURE|quality-of-life assessment|
219466971|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
219466972|NCT00721513|RADIATION|intensity-modulated radiation therapy|
219466973|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
219466974|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
219466975|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
219466976|NCT01700907|DRUG|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
219466977|NCT01700907|DRUG|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
219466978|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
219466979|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
219466980|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
219466981|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
219466982|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
219466983|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
219466984|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
219466985|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
219466986|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
219466987|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
219466988|NCT03231423|OTHER|Drainage|Using drain after operation
219466989|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
219466990|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
219466991|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
219466992|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
219466993|NCT00326339|DRUG|Placebo|Placebo PO bid
219466994|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
219594035|NCT05188677|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
219594036|NCT05188677|BIOLOGICAL|Comirnaty Vaccine|intramuscular injection
219594037|NCT05188677|BIOLOGICAL|Vaxzevria Vaccine|intramuscular injection
219594038|NCT05188677|BIOLOGICAL|CoronaVac Vaccine|intramuscular injection
219594039|NCT05982002|DEVICE|shock wave|ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
219198840|NCT06700733|DEVICE|PEEK prosthesis|For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.
219198841|NCT06700733|DEVICE|Titanium prosthesis|For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
219198842|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
219198843|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
219198844|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
219198845|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
219594040|NCT05982002|OTHER|Moderate intensity aerobic exercise|Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
219594041|NCT05982002|OTHER|Energy-restricted diet|energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
219466995|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
219594042|NCT01547702|BEHAVIORAL|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
219594043|NCT00839397|DRUG|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
219594044|NCT04394039|OTHER|Public space exposure|landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
219594045|NCT01860625|DRUG|Donepezil patch|
219594046|NCT01860625|DRUG|placebo|
219594047|NCT00270855|PROCEDURE|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
219594048|NCT00270855|PROCEDURE|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
219466996|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
219466997|NCT04857879|OTHER|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
219466998|NCT06216600|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Participants will undergo ACT in combination with exercise and social support.
219466999|NCT06216600|BEHAVIORAL|Body weight circuit training|Participants will learn and undergo body weight circuit training in combination with ACT and social support.
219467000|NCT06216600|BEHAVIORAL|Empathetic social support|Study participants will participate in empathetic social support
219467001|NCT06216600|OTHER|Control - list of resources|A local list of resources to access exercise, therapy and social support will be provided.
219467002|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
219594049|NCT01794455|DRUG|Sertraline|50mg - 200mg daily
219594050|NCT01794455|DRUG|Candesartan|4mg - 32mg daily
219198846|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
219198847|NCT06632613|DRUG|ENN0403 capsules, low dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
219467003|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
219467004|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
219467005|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
219198848|NCT06632613|DRUG|ENN0403 capsules, high dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
219198849|NCT06632613|DRUG|Placebo|Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
219467006|NCT04792684|DIAGNOSTIC_TEST|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
219467007|NCT06175000|PROCEDURE|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
218854316|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
218854317|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
219467008|NCT06175000|BIOLOGICAL|Obinutuzumab|Given IV
219467009|NCT06175000|OTHER|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
219467010|NCT04726787|RADIATION|Bridging Radiotherapy|Bridging Radiotherapy will start immediately after leukapheresis and before Tisagenlecleucel treatment
219467011|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
219467012|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
219467013|NCT06765642|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The use of this approach aims to potentially maximize motor recovery in chronic stroke by harnessing corticospinal plasticity and modulating motor learning behavior.
219467014|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
219467015|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
219467016|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
219467017|NCT00794131|BIOLOGICAL|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
219594051|NCT04292041|OTHER|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
219594052|NCT05531110|DEVICE|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
218854318|NCT06897397|OTHER|Case Study|Students will be provided with information about the education plan flow chart, education plan content, and environment. 40 students assigned to the intervention group will be provided with information about EFM training based on the case method. Before the application, all groups will be provided with 4 hours of theoretical information about EFM interpretation via a power point presentation.
219467018|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
219467019|NCT06311045|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Participants will take two NAC 600mg capsules daily for four weeks.
219467020|NCT06311045|DIETARY_SUPPLEMENT|Placebo|Participants will take two placebo 600mg capsules daily for four weeks.
219467021|NCT06311045|PROCEDURE|Positive Airway Pressure (PAP) Therapy|All participants will receive PAP therapy per standard of care for OSA.
219467022|NCT01860456|DRUG|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
219467023|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
219467024|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
219467025|NCT05934422|OTHER|Intervention (Study Nutritional Drink)|Study nutritional drink containing a mix of enriched micronutrients, probiotics and myo-inositol.
219594053|NCT05531110|DEVICE|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
219467026|NCT05934422|OTHER|Control (Standard Nutritional Drink)|Control nutritional drink containing a standard mix of micronutrients
219467027|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
219467028|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
219467029|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
219467030|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
219467031|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
219467032|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
219467033|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
219198850|NCT04159519|DRUG|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
219467034|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
219467035|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
219467036|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
219467037|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
218854319|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
218854320|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
218854321|NCT06753071|DRUG|Pyridostigmine oral tablet|Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
218854322|NCT06753071|DRUG|Placebo|Placebo oral tablet, twice daily, for 3 months
218854323|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
218854324|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
218854325|NCT06411912|DRUG|Placebo|Placebo oral tablets
219198851|NCT04159519|DRUG|Fasenra®|Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
219198852|NCT04159519|DRUG|Ventolin®|Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
219467038|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
219467039|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
219198853|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
219198854|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
219363048|NCT04925895|OTHER|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
219467040|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
219467041|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
219467042|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
219467043|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
218854326|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
218854327|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
218854328|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
218854329|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
218854330|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
218854331|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
219199513|NCT04700774|BEHAVIORAL|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
219467044|NCT06018389|BEHAVIORAL|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
219467045|NCT06018389|BEHAVIORAL|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
219594054|NCT05424679|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
219594055|NCT05424679|BEHAVIORAL|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
219594056|NCT00292890|DEVICE|insulin needle|
219594057|NCT00719875|DRUG|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
219594058|NCT02027532|DRUG|Cefazolin|
219594059|NCT02027532|DRUG|Vancomycin|
218854332|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
218854333|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
218854334|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
218854335|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
218854336|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
218854337|NCT02851407|DRUG|Defibrotide|
218854338|NCT02851407|OTHER|Best Supportive Care|
218854339|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
218854340|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
218854341|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
218854342|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
218854343|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
218854344|NCT00075725|DRUG|Cyclophosphamide|Given IV
218854345|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
218854346|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
218854347|NCT00075725|DRUG|Dexamethasone|Given PO or IV
218854348|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
218854349|NCT00075725|DRUG|Leucovorin Calcium|Given IV
218854350|NCT00075725|DRUG|Mercaptopurine|Given PO
218854351|NCT00075725|DRUG|Methotrexate|Given IT or IV
219467046|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
219467047|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
219467048|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
219467049|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
219467050|NCT06243679|DRUG|Immunotherapy|Monotherapy with PD-1 inhibitors, up to 1 year.
219467051|NCT05935137|DIAGNOSTIC_TEST|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
219467052|NCT03476681|DRUG|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
219467053|NCT00000740|DRUG|Sitamaquine|
219594060|NCT06582030|BEHAVIORAL|Assessment|Ancillary studies
218854352|NCT00075725|DRUG|Pegaspargase|Given IM
218854353|NCT00075725|DRUG|Prednisone|Given PO or IV
218854354|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
218854355|NCT00075725|DRUG|Thioguanine|Given PO
218854356|NCT00075725|DRUG|Vincristine Sulfate|Given IV
218854357|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
219199514|NCT06860269|DRUG|Randomization + Blinatumomab + chemotherapy|Rando 1 : BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 4 cycles (first cycle starts with 9 µg/day for 7 days)
219199515|NCT06860269|OTHER|Randomization + Standard frontline T-ALL chemotherapy backbone|Rando 3 : standard of care
219199516|NCT06860269|DRUG|Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone|Rando 3 : ISA will be given at 10 mg/kg IV for a maximum of 28 infusions starting at induction up to maintenance phase.
218854358|NCT00027365|BIOLOGICAL|NefTat|
218854359|NCT00027365|DRUG|AS02A Adjuvant|
218854360|NCT00027365|BIOLOGICAL|gp120W61D|
218854361|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
218854362|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
219363049|NCT04925895|OTHER|Cryotherapy|application of cold pack on knee joint for 10 minutes
219363050|NCT04925895|OTHER|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
219363051|NCT01657578|DRUG|Omeprazole|administration of Omeprazole
219363052|NCT03664375|OTHER|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
219363053|NCT03664375|OTHER|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
219363054|NCT06148038|DRUG|CBD Oral|CBD Oral 350mg twice daily for 28 days
219363055|NCT06148038|OTHER|Control|Placebo Control
219363056|NCT06023732|BEHAVIORAL|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
219363057|NCT01462266|DRUG|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
219363058|NCT01462266|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
219363059|NCT01462266|BIOLOGICAL|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
219363060|NCT01462266|DRUG|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
219363061|NCT03391947|PROCEDURE|semilunar coronally positioned flap|The description of this intervention has been already given before
219363062|NCT03391947|PROCEDURE|coronally advanced flap|The description of this intervention has been already given before
219363063|NCT01106846|DRUG|Group A: Saline Group|Saline continuous infusion
219363064|NCT01106846|DRUG|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
219363065|NCT03396094|DEVICE|High-flow nasal cannulae (HFNC) oxygenation|Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher \& Paykel Healthcare, Auckland, New Zealand)
218854363|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
218854364|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
218854365|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
219467054|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
219467055|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
219467056|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
219467057|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
219467058|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
219467059|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
219467060|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
219467061|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
219467062|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
219467063|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
219467064|NCT00495963|PROCEDURE|bronchoaleolar lavage|
219594061|NCT06582030|OTHER|Educational Activity|View the chronically relapsing brain disease vignette
219594062|NCT06582030|OTHER|Educational Activity|View the brain disease vignette
219594063|NCT06582030|OTHER|Educational Activity|View the disease vignette
219594064|NCT06582030|OTHER|Educational Activity|View the illness vignette
219594065|NCT06582030|OTHER|Educational Activity|View the disorder vignette
219594066|NCT06582030|OTHER|Educational Activity|View the problem vignette
219594067|NCT06582030|OTHER|Training|Attend a SAS workshop
218854366|NCT00869804|BEHAVIORAL|Attention control|
218854367|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
218854368|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
218854369|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
218854370|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
218854371|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
218854372|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
218854373|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
218854374|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
218854375|NCT04579302|DRUG|Bupivacaine|bupivacaine
218854376|NCT02387801|DRUG|Ixekizumab|Administered SC
218854377|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
218854378|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
218854379|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
218854380|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
219467065|NCT00495963|PROCEDURE|Bronchoscopy|
219467066|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
219467067|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
219467068|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
219467069|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
219467070|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
219467071|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
219467072|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
219467073|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
219467074|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
218854381|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
219198855|NCT06874686|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|"Pediatric patients diagnosed with Hirschsprung's Disease from 2017-2023 at the National Children's Hospital underwent two minimally invasive procedures: conventional laparoscopic pull-through (CLP) and single-incision laparoscopic pull-through (SILPS).~CLP involves three to five small incisions for trocars, allowing laparoscopic visualization and instrument access. Pneumoperitoneum is established, and the aganglionic colon segment is identified and mobilized using laparoscopic energy devices. The rectum is dissected circumferentially to preserve mesenteric blood supply, and a transanal approach is used to excise the diseased segment, followed by coloanal anastomosis with absorbable sutures.~SILPS follows the same principles but is performed through a single umbilical incision using a multi-port device for all instruments. This technique offers benefits like reduced scarring and less postoperative pain but requires advanced laparoscopic skills due to instrument crowding."
219467075|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
219467076|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
219198856|NCT06874101|DEVICE|Activated ROAM System with User Feedback|The activated ROAM device will provide the user with daily information about their oxygen therapy usage and pulse oximetry.
219198857|NCT06874101|DEVICE|Sham Comparator|The sham comparator is a ROAM device that monitors oxygen usage, but keeps the usage details blind to the user.
219198858|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
219198859|NCT05430230|DRUG|Placebo|lactose NF
219198860|NCT06693635|DIAGNOSTIC_TEST|Implant planning|The implant planning will be carried out using various software programs. The AI assistance provided by each software will be evaluated.
219467077|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
219467078|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
219467079|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
219467080|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
219467081|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
219467082|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
219467083|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
219467084|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
219467085|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
219467086|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
219198861|NCT06413355|DRUG|[F-18]-FAPI-74|A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
219198862|NCT06871540|OTHER|Probiotic Agent|Patients in the test group were instructed to take one tablet immediately after tooth brushing (before bedtime) once daily for 30 consecutive days. Probiotic was administered in tablets containing 1x109 cfu/g S. salivarius K12.
219198863|NCT06871540|OTHER|Non-Surgical Intervention|Patients in the control group received non-surgical periodontal treatment only.
219198864|NCT06871761|DRUG|HR17031 injection|HR17031 injection
219198865|NCT06871761|DRUG|insulin glargine|insulin glargine
219467087|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
219467088|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
219467089|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
219467090|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
219467091|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
219467092|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
219467093|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
219467094|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
219467095|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
219467096|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
219467097|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
219467098|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
219467099|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
219467100|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
219467101|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
219467102|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
219467103|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
219467104|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
218854382|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
218854383|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
218854384|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
218854385|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
218854386|NCT00106574|DRUG|Placebo|iv every 4 weeks
219467105|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
218854387|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
218854388|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
219467106|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
219467107|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
219467108|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
219467109|NCT00719706|DRUG|Placebo|Placebo
219467110|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
218854389|NCT03020017|OTHER|Pharmacological Study|Correlative studies
218854390|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
218854391|NCT00164957|DEVICE|continuous pump feeding|
218854392|NCT00164957|OTHER|intermittent bolus feeding|
218854393|NCT05770024|OTHER|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
218854394|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
218854395|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
218854396|NCT05632588|OTHER|Observational study|Observational surveillance study
218854397|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
218854398|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
219467111|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
219467112|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
219467113|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
219467114|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
219467115|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
219467116|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
219467117|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
219467118|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
219467119|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
218854399|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
218854400|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
218854401|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
218854402|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
218854403|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
218854404|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
219467120|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
219467121|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
219467122|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
219467123|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
219467124|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
219467125|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
219467126|NCT01493791|DRUG|CDB-2914|
219467127|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
219467128|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
219467129|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
219467130|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
219467131|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
219467132|NCT00002715|DRUG|Stanford V regimen|
219467133|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
218854405|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
218854406|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
218854407|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
218854408|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
219467134|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
219467135|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
219467136|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
219467137|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
219467138|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
219467139|NCT00197691|PROCEDURE|blood draws, etc.|
219467140|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
219467141|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
218854409|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
219467142|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
218854410|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
218854411|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
218854412|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
218854413|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
218854414|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
218854415|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
218854416|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
218854417|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
218854418|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
218854419|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
219020109|NCT07096310|DRUG|Meropenem I.V. 2g as a 3 hour infusion every 8 hours|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
219020110|NCT07096310|DRUG|Tazocin (pipercillin/tazobactam)|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
219198866|NCT04539808|DRUG|Capecitabine|Given PO
219198867|NCT04539808|DRUG|Fluorouracil|Given IV
219198868|NCT04539808|DRUG|Irinotecan Hydrochloride|Given IV
219198869|NCT04539808|DRUG|Leucovorin Calcium|Given IV
219198870|NCT04539808|DRUG|Losartan Potassium|Given PO
219198871|NCT04539808|DRUG|Oxaliplatin|Given IV
219198872|NCT04539808|RADIATION|Radiation Therapy|Undergo short-course or long-course RT
219198873|NCT04539808|PROCEDURE|Resection|Undergo surgical resection
219198874|NCT04539808|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
219198875|NCT04539808|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219198876|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
219198877|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
219198878|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
219198879|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
218854420|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
218854421|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
218854422|NCT01376375|PROCEDURE|Acupuncture|
219363066|NCT03396094|DEVICE|Non-rebreather mask and standard nasal cannula|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
219467143|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
218854423|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
218854424|NCT01103063|DRUG|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
219467144|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
219467145|NCT02425774|PROCEDURE|Vagus stimulation|
219467146|NCT02425774|PROCEDURE|Sham stimulation|
219467147|NCT02425774|DRUG|Prucalopride|
219467148|NCT02425774|DRUG|Placebo|
219594068|NCT04862910|OTHER|Kinect Based Virtual Reality Training|The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.
218854425|NCT01103063|DRUG|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
218854426|NCT02045693|DRUG|Methadone|
218854427|NCT02045693|DRUG|DCV 3DAA FDC|
218854428|NCT02045693|DRUG|BMS-791325|
219467149|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
219467150|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
219467151|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
219467152|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
219467153|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
219467154|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
219467155|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
219467156|NCT00242645|BEHAVIORAL|Health Information|
219467157|NCT00242645|BEHAVIORAL|Preventive Services|
219467158|NCT00242645|BEHAVIORAL|Computer tailored information|
219467159|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
219467160|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
219467161|NCT02007798|DRUG|normal saline|100 ml per bag
219594069|NCT04862910|OTHER|Control Group|"* They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication"
218854429|NCT02045693|DRUG|Buprenorphine|
218854430|NCT02045693|DRUG|Naloxone|
218854431|NCT03376685|BEHAVIORAL|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
218854432|NCT03376685|BEHAVIORAL|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
218854433|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
218854434|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
218854435|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
218854436|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
218854437|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
218854438|NCT05786339|DRUG|Tested Irbesartan Tablet|T
218854439|NCT05786339|DRUG|Reference Irbesartan Tablet|R
218854440|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
219467162|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
218854441|NCT02340182|DRUG|Vancomycin|250mg 3dd2
218854442|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
219467163|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
218854443|NCT02340182|DRUG|Metronidazole|500mg 3dd1
219467164|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
219467165|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
219467166|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
219467167|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
219594070|NCT06582823|OTHER|Health belief model-based community educational program|"The 5-week intervention includes two weekly 60-minute face-to-face sessions for 8-10 participants, two weekly telephone follow-ups, and a booster session.~Week 1: Focuses on increasing knowledge about atrial fibrillation (AF), its risks, complications, and treatment benefits. The principal investigator (PI) provides education using interactive methods and colored visuals.~Week 2: Emphasizes skill building for pulse palpation to detect irregular pulses. Participants learn through demonstrations and practice using a simulated arm.~Weeks 3-4:Telephone follow-ups monitor adherence to pulse checking and address barriers. Support and advice are provided by the PI.~Week 5: A booster session reinforces knowledge and skills with scenario-based practice and use of a simulated arm."
218854444|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
218854445|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
218854446|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
218854447|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
218854448|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
218854449|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
218854450|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
218854451|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
218854452|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
218854453|NCT00004564|DRUG|Clopidogrel|
218854454|NCT00004564|DRUG|Atorvastatin|
218854455|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
219020111|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
219020112|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
219020113|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
218854456|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
219594071|NCT06582823|OTHER|Control|The control group will receive an information leaflet presenting information about AF, health risks and complications associated with AF, common methods to screen for AF, and follow-up actions if positive screening results are suspected.
218854457|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
218854458|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
218854459|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
218854460|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
218854461|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
218854462|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
218854463|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
218854464|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
218854465|NCT01649544|DRUG|Amiodarone|
218854466|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
218854467|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
218854468|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
218854469|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
218854470|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
218854471|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
218854472|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
219594072|NCT01396512|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
219594073|NCT01396512|BIOLOGICAL|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
219594074|NCT04653025|DEVICE|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
219594075|NCT02755649|DRUG|Dupilumab|
219594076|NCT02755649|DRUG|Matching Placebo|
219594077|NCT00098605|DRUG|lapatinib ditosylate|Given orally
219594078|NCT00098605|OTHER|laboratory biomarker analysis|Correlative studies
219594079|NCT00098605|PROCEDURE|quality-of-life assessment|Ancillary studies
219594080|NCT00098605|OTHER|questionnaire administration|Ancillary studies
219594081|NCT03420911|DRUG|dexketoprofen trometamol|
219594082|NCT03420911|DRUG|Midazolam|
219594083|NCT06435689|OTHER|Sampling|Blood and surgical specimen sampling the day of surgery
219594084|NCT00142389|BIOLOGICAL|pneumococcal polysaccharide and protein conjugate vaccines|
218854473|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
219467168|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
219467169|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
219467170|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
219467171|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
219467172|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
219198880|NCT06877806|OTHER|Core exercise|The experimental treatment had a total of 18 introductory courses lasting 30 minutes each. The treatment included exercises to increase the mobility and strength of the neck, shoulders, pelvis and hips, and anti-flexion, anti-extension and rotation exercises were used to stabilize the spine. McGill curl-up was performed during each treatment for all 6 weeks. In the first two weeks, the subjects did general and introductory exercises (all positioned planks, plank walking, forearm cranes, plank pad forearms, etc.). Week 3 and 4 with additional movements and rotations (alternating hand and foot board holding, superman posture, faceplate switches, etc.). During the fifth and sixth weeks, the exercises were performed on unstable surfaces (one-handed board, ball stirring pot, feet raised sideboard, etc.). The intensity of those training courses was individual, but each one started at submaximal.
219198881|NCT06877507|DEVICE|Gastroscopy|Gastroscopy for all included patients
219594085|NCT03365557|PROCEDURE|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
219594086|NCT01822106|OTHER|Placebo|
219594087|NCT01739049|DRUG|Liraglutide|liraglutide
219594088|NCT01739049|BEHAVIORAL|Diet and Exercise|diet and exercise
219594089|NCT02152605|DRUG|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
218854474|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
218854475|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
219594090|NCT02152605|DRUG|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
219594091|NCT05864989|PROCEDURE|Non-incised papila surgical approach only|Reconstructive periodontal surgery
219198882|NCT06877507|DIAGNOSTIC_TEST|Gas Chromatography - Mass Spectrometry|Using a patient's exhaled breath test with Gas Chromatography - Mass Spectrometry
219467173|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
219467174|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
219467175|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
219467176|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
219467177|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
219594092|NCT05864989|PROCEDURE|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
219594093|NCT05366140|OTHER|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
219594094|NCT02271347|DRUG|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
218854476|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
218854477|NCT01960088|DRUG|HPV vaccine|
218854478|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
218854479|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
218854480|NCT01181024|DRUG|RO5303253|Single dose
218854481|NCT01181024|DRUG|RO5303253|Multiple doses
219467178|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
219467179|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
219467180|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
219467181|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
219467182|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
219467183|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
219467184|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
219467185|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
219467186|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
219467187|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
219467188|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
219467189|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
219594095|NCT04419753|BEHAVIORAL|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
218854482|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
218854483|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
219467190|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
218854484|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
218854485|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
219594096|NCT03647085|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
218854486|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
219467191|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
219467192|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
219467193|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
218854487|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
218854488|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
218854489|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
218854490|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
218854491|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
218854492|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
218854493|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
218854494|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
219467194|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
219467195|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
219467196|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
219467197|NCT03907072|DRUG|Placebo|Buffered saline solution
219467198|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
219467199|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
219467200|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
219467201|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
219467202|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
219467203|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
219467204|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
219467205|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
219467206|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
219467207|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
219467208|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
219467209|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
219467210|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
219594097|NCT04458285|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
218854495|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
218854496|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
218854497|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
218854498|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
218854499|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
219467211|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
219467212|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
219467213|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
219467214|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
219467215|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
219467216|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
219467217|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
219594098|NCT04458285|DRUG|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
219594099|NCT04524208|DRUG|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
219594100|NCT02692443|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
219594101|NCT02692443|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
218854500|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
219467218|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
218854501|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
218854502|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
218854503|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
218854504|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
218854505|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
218854506|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
218854507|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
218854508|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
219467219|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
219467220|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
219467221|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
219467222|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
219467223|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
219467224|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
219467225|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
219467226|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
218854509|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
218854510|NCT01978249|PROCEDURE|Systemic chemotherapy|
218854511|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
218854512|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
218854513|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
218854514|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
218854515|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
218854516|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
218854517|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
218854518|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
218854519|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
218854520|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
218854521|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
219467227|NCT05216302|BEHAVIORAL|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
219467228|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
219467229|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
219594102|NCT03063411|OTHER|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
219198883|NCT06695767|BEHAVIORAL|Neurobehavioral therapy|Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
219594103|NCT03063411|OTHER|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
219594104|NCT03301649|DRUG|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
219594105|NCT03301649|DRUG|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
219594106|NCT03301649|DRUG|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
219594107|NCT00646334|DEVICE|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
219594108|NCT00646334|DEVICE|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
218854522|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
218854523|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
218854524|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
218854525|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
219020133|NCT07104370|PROCEDURE|Bone augmentation using an autologous bone block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the control group, an autologous bone block graft is harvested from the retromolar donor area using rotary instruments and piezoelectric surgery.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In the case of an amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
219199517|NCT06860269|DRUG|Randomization + Blinatumomab + Ponatinib + chemotherapy|"Rando 2 :~* PONA will be given at 45 mg/day PO during 2 cycles, 30 mg/day during 2 additional cycles, and 15 mg/day during maintenance phase or after alloHSCT~* BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 5 cycles (first cycle starts with 9 µg/day for 7 days). Patients allografted will receive two courses before transplant."
218854526|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
218854527|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
218854528|NCT01872039|DRUG|Perdipine injection|IV
218854529|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
218854530|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
219467230|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
218854531|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
218854532|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
218854533|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
218854534|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
218854535|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
218854536|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
218854537|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
219594109|NCT03275116|DRUG|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
219198884|NCT03998488|DRUG|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
219198885|NCT03998488|DIETARY_SUPPLEMENT|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
219199518|NCT06860269|OTHER|Randomization 1 + Allo HSCT|Rando 1 : standard of care - Allogeneic Hematopoietic Stem Cell Transplantation
219199519|NCT06860269|OTHER|Randomization 2 + Allo HSCT|Rando 2 : standard of care
219594110|NCT03275116|DRUG|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
218854538|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
219199520|NCT06269809|PROCEDURE|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
219594111|NCT01551108|BEHAVIORAL|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
218854539|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
218854540|NCT01741142|DRUG|Placebo|Subject receiving placebo
218854541|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
218854542|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
218854543|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
218854544|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
218854545|NCT03828422|DIAGNOSTIC_TEST|imaging|
219467231|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
219467232|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
219467233|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
219467234|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
219467235|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
219467236|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
219467237|NCT02860676|DRUG|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
219467238|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
219467239|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
219467240|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
219467241|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
219467242|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
219467243|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
219467244|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219467245|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219467246|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
219467247|NCT06547502|DRUG|GZR4|single dose
219467248|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
219467249|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
219467250|NCT03319160|DEVICE|Wearable Cardioverter Defibrillator|A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
219467251|NCT03473691|DRUG|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
219594112|NCT01551108|BEHAVIORAL|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
219594113|NCT04149106|DRUG|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
219594114|NCT04149106|DRUG|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
219594115|NCT00837473|DEVICE|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
219467252|NCT06416462|PROCEDURE|antimicrobial photodynamic therapy|When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
219467253|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
219467254|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
219594116|NCT05030558|BEHAVIORAL|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
219594117|NCT05030558|BEHAVIORAL|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
219594118|NCT04285593|OTHER|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
219594119|NCT01952210|BEHAVIORAL|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
218854546|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
218854547|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
218854548|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
219467255|NCT03846310|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
219467256|NCT03846310|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
219467257|NCT03846310|DRUG|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
219467258|NCT03846310|DRUG|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
219467259|NCT03846310|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
219467260|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
218854549|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
218854550|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
218854551|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
218854552|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
218854553|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
219020134|NCT07104370|PROCEDURE|Bone augmentation using freeze-dried allograft block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the test group, a freeze-dried allograft bone block is prepared to the required size using rotary instruments.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In case of amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
219020135|NCT07104370|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|• Preoperatively, a CBCT scan is performed to assess inflammatory and other pathological changes and anatomical variations in the dentomaxillofacial region.
219020136|NCT07104370|DIAGNOSTIC_TEST|post-operative cone beam computed tomography (CBCT)|Postoperatively, a CBCT scan is performed to assess bone quantity and quality before implantation.
219020137|NCT07104370|PROCEDURE|Dental implant placement|Following the 3-month-long healing period following bone augmentation, dental implants are placed non-submerged in the augmented bone under local anaesthesia.
219020138|NCT07104370|DIAGNOSTIC_TEST|Bone core biopsy|At the time of dental implant placement, a rotary instrument is used to harvest a bone core biopsy sample from the augmented bone. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
219020139|NCT07104370|PROCEDURE|Fixed dental prosthesis (FDP) fabrication|After 3 months of dental implant placement, fixed dental prosthesis are delivered on the dental implants.
219020140|NCT07104370|DEVICE|Bone grafting|Freeze-dried bone allograft block
218854554|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
218854555|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
219467261|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
219467262|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
219467263|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
219467264|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
219467265|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
219467266|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
219467267|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
218854556|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
218854557|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
218854558|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
218854559|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
218854560|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
218854561|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
218854562|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
218854563|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
219199521|NCT06269809|PROCEDURE|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
219467268|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
219467269|NCT03001726|DRUG|S1|S1 40mg/m2
219467270|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
219594120|NCT01952210|BEHAVIORAL|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
218854564|NCT01880749|DRUG|RAD001|
218854565|NCT00252694|DRUG|candesartan|32 mg oral tablet
218854566|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
218854567|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
218854568|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
218854569|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
218854570|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
218854571|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
218854572|NCT00434083|DRUG|sumatriptan|
218854573|NCT00434083|DRUG|naproxen sodium|
218854574|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
218854575|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
218854576|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
218854577|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
218854578|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
218854579|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
219594121|NCT01724489|DRUG|Growth hormone|
219594122|NCT01724489|DRUG|Placebo|
219594123|NCT04576923|DIAGNOSTIC_TEST|Velacur by Sonic Incytes|liver stiffness measurement
219594124|NCT00128271|DRUG|Bavituximab|
219594125|NCT04732624|DRUG|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
219594126|NCT04732624|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
218854580|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
218854581|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5\. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
218854582|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
218854583|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
218854584|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
218854585|NCT02542891|OTHER|Blended CBT|
219467271|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
218854586|NCT02542891|OTHER|Treatment as Usual (TAU)|
218854587|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
219198886|NCT06871878|OTHER|PRACTISE Physiotherapy Intervention|The PRACTISE programme is a 16-week personalised physiotherapy programme, incorporating tele-rehabilitation, which aims to support individuals to achieve optimal dose of exercise to improve motor and functional outcomes after stroke. There are three core components to the intervention: goal setting, exercise and a supported self-management approach. PRACTISE comprises of nine therapist supported sessions: five in person, home-based rehabilitation sessions (weeks 1-4, two visits in week 1) and four telephone or video consultations (Near Me) (weeks 6, 8, 12 and 16), a simple self-management workbook (with space to record personal goals, action plans and progress) to develop skills for self-management, and a personalised online exercise programme delivered through the Giraffe platform five times per week.
219467272|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
219467273|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
219467274|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
219594127|NCT00620100|DRUG|Docetaxel|
219198887|NCT06885892|PROCEDURE|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps|Posterior tibial artery perforator-pedicled propeller flaps are feasible, safe, and effective procedure in the reconstruction of the defects in the lower leg.
219198888|NCT06885892|PROCEDURE|Perforator-Pedicled Propeller Flaps|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps
219198889|NCT06882330|BEHAVIORAL|Dialectical behavior therapy|A complex psychotherapy program for patients with borderline personality disorder.
219198890|NCT06726850|DRUG|Placebo|In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
219467275|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
219467276|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
219594128|NCT04485832|DEVICE|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
219594129|NCT04485832|DIAGNOSTIC_TEST|Weekly CAT measurement|
219594130|NCT02940132|DRUG|SC10914|SC10914 will be administered orally.
219594131|NCT00800007|DRUG|ANZ-521|3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
219594132|NCT00800007|DRUG|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
219594133|NCT04865393|DRUG|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
218854588|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
218854589|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
218854590|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
219467277|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
219467278|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
219467279|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
219467280|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
219467281|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
219467282|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
219467283|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
219467284|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
219467285|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
219467286|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
219467287|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
219467288|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
219467289|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
218854591|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
218854592|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
219467290|NCT02367196|DRUG|CC-90002|
219467291|NCT02367196|DRUG|Rituximab|
219467292|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
219467293|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
219467294|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
219467295|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
219467296|NCT00004219|DRUG|granisetron hydrochloride|
219467297|NCT00004219|DRUG|lerisetron|
219467298|NCT00004219|RADIATION|radiation therapy|
219467299|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
219467300|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
219467301|NCT00100711|DRUG|Motexafin Gadolinium|
219467302|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
219467303|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
219594134|NCT00923273|DRUG|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
219594135|NCT00923273|DRUG|Pemetrexed|
218854593|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
218854594|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
219467304|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
219467305|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
219467306|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
219467307|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
219467308|NCT01713907|DEVICE|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
219467309|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
219467310|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
219467311|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
219467312|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
219467313|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
219467314|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
219467315|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
219467316|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
219467317|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
219467318|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
219467319|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
219467320|NCT00422955|DRUG|rosiglitazone|
218854595|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
218854596|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
218854597|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
218854598|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
219467321|NCT01353976|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
219467322|NCT01353976|OTHER|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
219467323|NCT00397527|DRUG|lactoserum|
219467324|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
219467325|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
219198891|NCT06726850|DRUG|GS1-144|In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
219198892|NCT06735976|DEVICE|PAVM Embolization|This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.
219198893|NCT06735976|DEVICE|PAVM Embolization with a LOBO™ device|Participants will undergo PAVM embolization with the LOBO™ device per standard of care.
219198894|NCT06738030|DEVICE|Transcranial current stimulation|The transcranial alternating current stimulation is delivered during the speech stimulus and the current matches the envelope of the target speech
219198895|NCT06738030|BEHAVIORAL|Auditory training|An at-home auditory training program that adaptively and interactively trains the listener in degraded speech, cognitive skills, and communication strategies
219467326|NCT00004911|PROCEDURE|bowel obstruction management|
219467327|NCT00004911|PROCEDURE|quality-of-life assessment|
219467328|NCT01450566|DRUG|Lidocaine|Use of lidocaine
219467329|NCT01450566|DRUG|Saline|Saline
219467330|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
219467331|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
218854599|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
219467332|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
219467333|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
219467334|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
219467335|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
219467336|NCT06371560|OTHER|Questionnaire|online based questionnaire
219467337|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
219467338|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
219467339|NCT00307073|DEVICE|Implantable Pulse Generator|
219467340|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
219467341|NCT02918136|DRUG|Cortisone Injectable|
219467342|NCT06376201|DRUG|Amphotericin B cholesterol-sulfate complex for injection|"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
219467343|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
219467344|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
219467345|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
219467346|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
219594136|NCT00923273|DRUG|Sirolimus|
219594137|NCT00923273|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
218854600|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
218854601|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
218854602|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
218854603|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
219467347|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
219467348|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
219467349|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
219467350|NCT04657406|DRUG|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
219467351|NCT03602209|PROCEDURE|Removal of infected implant|
219467352|NCT03602209|DRUG|Antibiotic durations|
219467353|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
219467354|NCT05512273|PROCEDURE|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
219467355|NCT05512273|PROCEDURE|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
219467356|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
219467357|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
219467358|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
219467359|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
219467360|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
219594138|NCT00923273|DIETARY_SUPPLEMENT|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
219594139|NCT00923273|DRUG|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
219594140|NCT05082792|DIAGNOSTIC_TEST|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
219594141|NCT00224419|BEHAVIORAL|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
219594142|NCT00224419|BEHAVIORAL|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
219594143|NCT00224419|DRUG|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
219198896|NCT06738589|DEVICE|non-invasive ventilation|Non-invasive ventilation adds positive pressure to the upper airway via a mask on the face.
219199522|NCT00760630|DEVICE|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
219199523|NCT06445465|DRUG|[18F]MNI-1216|\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
219467361|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
219467362|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
219467363|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
219467364|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
219467365|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
219467366|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
219467367|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
219467368|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
219467369|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
219467370|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
219467371|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
219467372|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
219467373|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
219199524|NCT06363747|OTHER|Very Low Calorie Diet|Optifast is a medically supervised very low-calorie diet (VLCD) diet that safely induces caloric restriction
219467374|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
219594144|NCT05574608|BIOLOGICAL|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
219467375|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
219467376|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
219467377|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
219594145|NCT03795766|PROCEDURE|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
219594146|NCT03275714|DEVICE|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
219594147|NCT05682651|PROCEDURE|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
219594148|NCT04437459|OTHER|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
219467378|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
219467379|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
219467380|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
219467381|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
219467382|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
219467383|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
219467384|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
219467385|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
219594149|NCT04437459|OTHER|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
219467386|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
219467387|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
219467388|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
219467389|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
219467390|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
219467391|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
219467392|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
219467393|NCT01636076|DRUG|QMF149|delivered via Concept1 device
219467394|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
219467395|NCT00002276|DRUG|Ibuprofen|
219467396|NCT00002276|DRUG|Zidovudine|
219467397|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
219467398|NCT02949544|OTHER|water immersion|warm water immersion
219363067|NCT01119456|BIOLOGICAL|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
219363068|NCT01119456|BIOLOGICAL|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
219363069|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
219363070|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
218854604|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
218854605|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
219363071|NCT01119456|BIOLOGICAL|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
219363072|NCT01119456|BIOLOGICAL|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
219363073|NCT01119456|BIOLOGICAL|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
219363074|NCT01119456|BIOLOGICAL|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
219363075|NCT05325320|BEHAVIORAL|SMI/SIA Stigma Reduction Intervention|Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.
219363076|NCT05325320|OTHER|Disaster Preparedness Course|Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
219363077|NCT05982587|OTHER|Survivorship passport (SurPass) delivery|"The Survivorship Passport (SurPass) is a digital tool developed thanks to several EU projects to help Childhood Cancer Survivors (CCS), their families and health care providers (HCPs) in the follow-up process after completion of anticancer treatment. It comprises two main components: Treatment Summary including demographic, diagnosis and treatment data and personalized Survivorship Care Plan providing individual follow-up care recommendations The SurPass assists both CCS and HCPs to improve Long-Term Follow-Up care, in a partnership, supporting CCS empowerment and satisfaction with care, as well as shared decision-making by CCS and HCPs.~The aim of the PCSP implementation study is to evaluate feasibility and outcomes (personal and economic) of implementing the SurPass v2.0 in six clinics located in Austria, Belgium, Germany, Italy, Lithuania and Spain by using interoperability procedures according to Health Level 7- Fast Healthcare Interoperability Resource (HL7-FHIR) standards."
219467399|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
219467400|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
219467401|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
219467402|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
219467403|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
219467404|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
219467405|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
219467406|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
219467407|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
219594150|NCT04855578|OTHER|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
219467408|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
219467409|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
219467410|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
219467411|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
219467412|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
219467413|NCT00507312|DEVICE|HD medical device (ViScope)|Device
219467414|NCT00507312|DEVICE|CSIRO device|device
219467415|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
219467416|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
219467417|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
219467418|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
219467419|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
219467420|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
219467421|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
219467422|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
219467423|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
219467424|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
219467425|NCT00277862|DRUG|Ribavirin|
219467426|NCT02173158|DRUG|lomitapide|
219594151|NCT04855578|OTHER|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
219594152|NCT06353542|DIAGNOSTIC_TEST|Software analysis|The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
219594153|NCT06353542|DIAGNOSTIC_TEST|Ophthalmologist examination|The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
219467427|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
219467428|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
219467429|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
219467430|NCT01817218|DRUG|Platelet Rich Plasma|
219467431|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
219467432|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
219467433|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
219467434|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
219467435|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
219467436|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
219467437|NCT00402662|DRUG|everolimus|
219467438|NCT00402662|DRUG|Imatinib|
219467439|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
218854606|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
219467440|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
219467441|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
219467442|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
219467443|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
219467444|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
219467445|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
219467446|NCT04619043|DEVICE|Ankle Orthotic|
219467447|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
219467448|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
219467449|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
219467450|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
219467451|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
219467452|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
219467453|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
219467454|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
218854607|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
218854608|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
218854609|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
219467455|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
218854610|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
218854611|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
219467456|NCT00702637|DRUG|Modafinil|
219467457|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
218854612|NCT00226408|DRUG|Interferon-alpha-2b|
218854613|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
218854614|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
218854615|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
219467458|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
219467459|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
219467460|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
219467461|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
219467462|NCT01832753|DRUG|Levothyroxine|
219467463|NCT06717217|PROCEDURE|NURSING EDUCATION GIVEN BEFORE TYMPANOPLASTY SURGERY|EAR CARE TRAINING
218854616|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
218854617|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
219467464|NCT06715761|OTHER|Myofascial release|The sequence of myofascial release is as follows: 30 seconds of contact between the therapist's hands and the entire region of the participant's spine, sliding with medium pressure in a caudocranial direction; palpation of the erector spinae, quadratus lumborum, gluteus and piriformis muscles bilaterally, to identify trigger points, marking each point of tension with a dermographic pencil for subsequent manipulation; 3 cycles of bilateral paravertebral release, by sustained pressure with crossed hands, until the restrictive tissue barrier is found, for 60 seconds; 90 seconds of the vertical rolling technique (superficial elevation of the skin and mobilisation of the tissue with the tips of all the fingers) on the bilateral paravertebrals and, at the end, sliding along the entire length of the bilateral multifidus, with the fingers flexed, using the bony prominence between the proximal and middle phalanges as contact with the skin, in a caudocranial direction and returning craniocaudal.
218854618|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
218854619|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
218854620|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
218854621|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
218854622|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
219467465|NCT06715761|OTHER|Cupping therapy|The acrylic cups (DongBang®) will be placed on the meridional points, as Traditional Chinese Medicine calls them, 1 cup in the central region of each popliteal fossa, the so-called B40 or Wei Zhong point, 6 cups in the region of the quadratus lumborum muscles, more specifically on the BL23 or Shenshu points (approximately 5 centimetres lateral to the edge of the L2 spinous process), BL24 or Qihaishu (approximately 5 centimetres lateral to the edge of the spinous process of L3) and BL25 or Dachangshu (approximately 5 centimetres lateral to the edge of the spinous process of L4) bilaterally, as well as a cup on a single point of the participant's choice, where they report the most lower back pain (ashi point). The cups will be attached to the skin using a gun, applying two suction pressures, and the participant will be asked to signal whether the pressure is strong or weak. The cups will remain attached for 12 minutes on the B40 meridian and 15 minutes on the other meridians. If a cup lo
219467466|NCT00006358|DRUG|temozolomide|
219467467|NCT00006358|DRUG|thalidomide|
219467468|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
219467469|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
219467470|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
219467471|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
219467472|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
219467473|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
219467474|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
219467475|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
219467476|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
219467477|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
219467478|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
219467479|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
219467480|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
219467481|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
219467482|NCT05391113|DIAGNOSTIC_TEST|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
219467483|NCT05391113|DIAGNOSTIC_TEST|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
219467484|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
219467485|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
219467486|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
219467487|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
219467488|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
219467489|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
219467490|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
219467491|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
219467492|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
219467493|NCT00935961|DRUG|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
219198897|NCT06811142|DRUG|Botulinum Toxin Type A (BoNT-A)|This intervention involves the early administration of botulinum toxin type A (BoNT-A) within the first 12 weeks after a cerebrovascular event. The injections target muscles affected by spasticity, aiming to reduce abnormal tone, prevent contractures, and improve functional mobility. BoNT-A works by blocking acetylcholine release at the neuromuscular junction, resulting in muscle relaxation. Ultrasound guidance or anatomical landmarks will be used for accurate injection. This early intervention capitalizes on the neuroplastic window and is combined with standard rehabilitation to enhance motor recovery and prevent long-term complications.
219198898|NCT06954545|BEHAVIORAL|Healthy Kids Programme|Our intervention was prepared by adopting an interactive curriculum shaped on role-play with visual materials and toy models of foods appropriate for the age of the children
219594154|NCT02376400|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.
219594155|NCT02376400|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.
218854623|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
219198899|NCT06954298|BEHAVIORAL|supervised lifestyle modification|Supervised lifestyle intervention will consist of regular exercise (3x a week), nutritional counselling (weekly), cognitive bahavioural therapy (monthly).
219198900|NCT05182463|DRUG|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
219198901|NCT05182463|DRUG|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
219198902|NCT06151236|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
219198903|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|All enrolled participants who attended the laboratory visit underwent stress-inducing tasks (psychological stress) using validated research tools. Participants performed a 5-minute computer Stroop Color Test and a 5-minute verbal Mental Arithmetic Task. The research assistant asked the participant to work as quickly and accurately as possible for both tasks.
219198904|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
219467494|NCT03651011|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
219467495|NCT03651011|PROCEDURE|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
219467496|NCT06143449|OTHER|Observational study - registry|Observational study - registry
219467497|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
219467498|NCT00323479|DRUG|Anastrozole|1mg/Day oral
219467499|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
219594156|NCT02376400|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
219594157|NCT06362863|DIETARY_SUPPLEMENT|enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
219594158|NCT01551030|DRUG|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
219594159|NCT01917214|OTHER|Sutent: Observational Study|Sutent oral therapy
219467500|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
219467501|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
219467502|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
219594160|NCT03914092|DRUG|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
219467503|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
219198905|NCT06385106|DEVICE|Real repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session.
219467504|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
219467505|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
219467506|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
219467507|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
219467508|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
219467509|NCT06323863|RADIATION|ultra high resolution CT|imaging study
219594161|NCT03914092|BEHAVIORAL|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
219467510|NCT01362062|DRUG|Tocilizumab|
219467511|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
219467512|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
219594162|NCT04918589|DRUG|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
219594163|NCT04918589|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
219594164|NCT03332810|BEHAVIORAL|SME family based physical activity|"* One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
219594165|NCT03332810|BEHAVIORAL|Gathering activity|\- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
219594166|NCT06280521|OTHER|fGQ-ASC|French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)
219594167|NCT02256423|DRUG|REFERENCE 1: Nurofen® 200 mg tablet|
219594168|NCT02256423|DRUG|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
219594169|NCT02256423|DRUG|ibuprofen 200 mg soft gel capsule|
219594170|NCT03600987|BEHAVIORAL|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
219594171|NCT03600987|BEHAVIORAL|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
219594172|NCT03600987|BEHAVIORAL|Control|control condition using reading materials without music.
219594173|NCT04511260|DEVICE|NuEra Tight VRF Handpiece|"The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue."
219594174|NCT00578266|DRUG|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
219594175|NCT04762472|DRUG|Montelukast Oral Tablet|i) Montelukast 10mg daily (tablet) orally x 26 weeks
218854624|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
219467513|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
219467514|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
219467515|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
219467516|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
219467517|NCT01733394|DRUG|lamotrigine|
219467518|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
219467519|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
219467520|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
219467521|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
219467522|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
219467523|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
218854625|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
218854626|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
219198906|NCT06385106|DEVICE|Sham repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session. The patients were applied with the coil angled away from the head to reproduce the noise of the stimulation as well as some local sensation
219198907|NCT02246127|DRUG|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
218854627|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
218854628|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
219198908|NCT02246127|DRUG|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops."
219198909|NCT05257772|DEVICE|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
219467524|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
219467525|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
219467526|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
219467527|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
219467528|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
219467529|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
219467530|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
219467531|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
219467532|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
219467533|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
219467534|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
219467535|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
219467536|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
219198910|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
219198911|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
219198912|NCT06952829|OTHER|evaluation of intravenous access of patients with Adult-Difficult IntraVenous Access (A-DIVA) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
219198913|NCT06952829|OTHER|evaluation of intravenous access of patients with modified Adult-Difficult IntraVenous access(A-DIVA modified) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA-m score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
219467537|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
219198914|NCT04998305|DRUG|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
219198915|NCT04998305|DRUG|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
219198916|NCT05357768|OTHER|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
218854629|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
218854630|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
218854631|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
218854632|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
218854633|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
218854634|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
218854635|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
218854636|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
218854637|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
218854638|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
218854639|NCT03648489|DRUG|TAK228|Please refer to arm/group description
218854640|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
219467538|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
219198917|NCT00488072|DRUG|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
219198918|NCT00488072|DRUG|Placebo|One placebo tablet by mouth daily.
219198919|NCT06469034|DEVICE|conventional ultrasound|The operators in the control group will perform the procedure by visualizing the conventional ultrasound images displayed directly on the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. To standardize the approach, the ultrasound machine will be placed just to the right of the patient and operators will be asked to stand at the head of the patient and perform the procedure on the patient's internal jugular vein. Each operator could determine the height of the surgical table, and the posture during the procedure that will be most familiar to him/her to increase the success rate. Every procedure will be recorded by focusing on the participant's hands and faces.
219467539|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
219467540|NCT00451776|DRUG|etomidate|patients who received etomidate
219467541|NCT00451776|DRUG|propofol|patients who received propofol
219467542|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
219467543|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
219467544|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
219594176|NCT04762472|DRUG|Montelukast Placebo Oral Tablet|i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
218854641|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
218854642|NCT06895083|OTHER|self ligating brackets|selfligating are new brackets
218854643|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
218854644|NCT02240849|DEVICE|Placebo general pillow|
218854645|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
218854646|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
218854647|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219467545|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~\- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
219467546|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~\- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
219467547|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
219467548|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
219467549|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
219467550|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
219467551|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
219467552|NCT02926833|DRUG|Fludarabine|Administered intravenously
218854648|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
218854649|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
218854650|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
218854651|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
218854652|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
218854653|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
219467553|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
219467554|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
219467555|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
219467556|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
219467557|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
219467558|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
218854654|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
218854655|NCT03298984|DRUG|Cytarabine|continuous infusion
218854656|NCT03298984|DRUG|Daunorubicin|IV bolus
218854657|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
218854658|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
218854659|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
218854660|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
218854661|NCT00005631|BIOLOGICAL|filgrastim|
218854662|NCT00005631|BIOLOGICAL|rituximab|
218854663|NCT00005631|DRUG|carboplatin|
218854664|NCT00005631|DRUG|etoposide|
218854665|NCT00005631|DRUG|ifosfamide|
218854666|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
218854667|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
218854668|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
219467559|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
219467560|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
218854669|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
219198920|NCT06469034|DEVICE|Head-mounted display ultrasound|In the HMD group, the ultrasound machine will be located behind the operator to remove the distraction, and the operator will not be allowed to see the ultrasound screen during the procedure. Images from the MR ultrasound machine will be transmitted to HMD via a novel connection developed specifically for this purpose. The operator will wear a pair of HMD and perform the procedure by visualizing the ultrasound images displayed on their HMD screen instead of the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. Every procedure will be recorded by focusing on the participant's hands and faces.
219467561|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
219467562|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
219467563|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
219467564|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
219467565|NCT02776631|DEVICE|Pinloc|Internal fixation device
219467566|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
219467567|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
219467568|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
219467569|NCT01277757|OTHER|Pharmacological Study|Correlative studies
219467570|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
219467571|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
219467572|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
219467573|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
219467574|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
219467575|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
218854670|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
218854671|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
218854672|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
218854673|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
218854674|NCT00701298|DRUG|decitabine|Given IV
218854675|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
218854676|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
218854677|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
219467576|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
219467577|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
219594177|NCT05630417|OTHER|Feet and Back Massage|"Foot massage: Feet are the most neglected organs of people and therefore cause many complaints. Foot massage is a massage applied to the back of the foot, toes, soles of the feet, the muscles between the thumb and little fingers, and the heel, where the muscles between the metatarsal bones are located.~Back massage: Back massage is a non-invasive nursing intervention that can be easily applied by nurses. In back massage application; A 10-minute back massage program applied by Çınar and Eşer (2012) will be applied."
219594178|NCT05177718|DRUG|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
219594179|NCT00117910|DRUG|pegfilgrastim|
219594180|NCT04737096|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
218854678|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
218854679|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
219594181|NCT04737096|DRUG|Placebo|placebo
219198921|NCT05942339|DEVICE|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
219198922|NCT06965166|PROCEDURE|PCD-CT|Participants undergo PCD-CT scan on study
219198923|NCT06751394|DRUG|PD-1 antibody (Toripalimab)|PD-1 antibody: (Toripalimab): 240mg q3w
219198924|NCT06751394|DRUG|Capecitabine|Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
219198925|NCT06751394|DRUG|Oxaliplatin|130 mg/m² q3w
218854680|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
219594182|NCT04737096|DEVICE|tDCS|tDCS
219198926|NCT06751394|DRUG|Irinotecan|200 mg/m² q3w
219594183|NCT01326650|DRUG|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
218854681|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
219198927|NCT06751394|RADIATION|Radiation|45-50Gy/25Fx or 30Gy/15Fx
219198928|NCT06751394|PROCEDURE|surgery|The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.
218854682|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
218854683|NCT00075387|DRUG|Carboplatin|Given IA
219198929|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
219198930|NCT05623189|DRUG|Placebo|Placebo, BID
219198931|NCT06239259|OTHER|Questionare As described in Secondary Outcomes|All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
219198932|NCT02107105|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
218854684|NCT00075387|DRUG|Cyclophosphamide|Given IV
218854685|NCT00075387|DRUG|Etoposide Phosphate|Given IV
218854686|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
218854687|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
219198933|NCT02107105|OTHER|Questionnaire Administration|Complete quality of life questionnaire
219198934|NCT03525639|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
219198935|NCT06841380|OTHER|sesame-based oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
219198936|NCT06841380|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
219198937|NCT04802876|DRUG|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
219198938|NCT04802876|DRUG|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
219198939|NCT02095691|DEVICE|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
219198940|NCT06756191|DRUG|Combination therapy group|Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
219198941|NCT06756191|DRUG|Liposomal Amphotericin B|Liposomal amphotericin B (AmBisome®) alone
219198942|NCT03476369|DRUG|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
219198943|NCT03476369|DRUG|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
219198944|NCT06040840|PROCEDURE|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
219198945|NCT06040840|PROCEDURE|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
219198946|NCT06040840|DRUG|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
219594184|NCT01326650|DRUG|placebo|daily oral placebo supplement for three years
219594185|NCT06112496|DEVICE|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
219594186|NCT06240195|OTHER|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
219594187|NCT05187130|OTHER|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
219594188|NCT06382610|DIETARY_SUPPLEMENT|Melatonin|Melatonin will be administered in three different forms
219594189|NCT04680858|OTHER|DECT|Use of a digital enhanced telecommunication headset for team communication
219594190|NCT03879434|DEVICE|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
219594191|NCT01053000|DRUG|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
218854688|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
218854689|NCT01057225|DRUG|carfilzomib|Given IV
218854690|NCT01057225|DRUG|cyclophosphamide|Given orally
219467578|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
218854691|NCT01057225|DRUG|thalidomide|Given orally
218854692|NCT01057225|DRUG|dexamethasone|Given orally
218854693|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
218854694|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
218854695|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
218854696|NCT02229214|DRUG|Qsymia|
218854697|NCT02229214|DRUG|Placebo|
218854698|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
218854699|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
219467579|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
219467580|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
219594192|NCT04962386|DRUG|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
219198947|NCT06040840|PROCEDURE|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
219198948|NCT06040840|DRUG|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
219467581|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
218854700|NCT00000344|DRUG|Buprenorphine/naloxone|
218854701|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
218854702|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
218854703|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
218854704|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
218854705|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
218854706|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
219467582|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
219467583|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
219467584|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
219198949|NCT02724540|DEVICE|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
219198950|NCT02724540|COMBINATION_PRODUCT|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
219198951|NCT02724540|COMBINATION_PRODUCT|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
219594193|NCT00299286|DRUG|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
219198952|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
219467585|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
218854707|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
218854708|NCT01953549|PROCEDURE|physical fitness training|
218854709|NCT01953549|PROCEDURE|relaxation|
218854710|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
218854711|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
218854712|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
218854713|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
219467586|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
219467587|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
219467588|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
218854714|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
218854715|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
218854716|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
218854717|NCT03937648|DRUG|Placebo|Placebo
219198953|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
219198954|NCT06050915|DRUG|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
219198955|NCT06050915|DRUG|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
219198956|NCT06602141|PROCEDURE|Muscle Biopsy|This procedure is used to sample muscle cells from the leg Vastus Lateralis (thigh) muscle.
219467589|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
219467590|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
219467591|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
219594194|NCT00299286|DRUG|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
219594195|NCT00126282|BEHAVIORAL|behavior therapy|
219594196|NCT00126282|DRUG|D-Cycloserine|
219198957|NCT06602141|PROCEDURE|Adipose Biopsy|This procedure is used to sample fat tissue from the abdomen (belly).
219198958|NCT06602141|OTHER|Glucose Clamp|In this test, we will measure the effect of insulin by giving you insulin and glucose (sugar) intravenously through an IV line in your arm.
219467592|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
218854718|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
218854719|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
218854720|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
218854721|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
218854722|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
219467593|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
219467594|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
219467595|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
219467596|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
219467597|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
219467598|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
219467599|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
219467600|NCT02919709|BIOLOGICAL|blood taking|
219467601|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
219467602|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
219467603|NCT06665009|DEVICE|Manually Opened and Device-Opened Ampoules|this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
219467604|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
219467605|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
219467606|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
219467607|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
219467608|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
219467609|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
219467610|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
219467611|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
219467612|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
219467613|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
219467614|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
219467615|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
219467616|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
219467617|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
219467618|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
219467619|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
219467620|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
219467621|NCT00223158|DRUG|Liothyronine|
219467622|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
218854723|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
219467623|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
219467624|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
219467625|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
219467626|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
219467627|NCT01674010|DRUG|ELND005|
219467628|NCT01674010|DRUG|Lamotrigine|
219467629|NCT01674010|DRUG|Valproic acid|
219467630|NCT01674010|DRUG|Placebo|
219467631|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
219467632|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
219467633|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
219467634|NCT03159455|DRUG|BI 1467335|Duration - 28 days
219467635|NCT03159455|DRUG|Placebo|Duration - 28 days
219467636|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
219467637|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
219467638|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
219467639|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
219467640|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
219467641|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
219467642|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
219467643|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
219467644|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
219467645|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
219467646|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
218854724|NCT02154620|DEVICE|Synthes TCP volar plate|
218854725|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
219467647|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
219467648|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
219467649|NCT02319018|DRUG|Alisertib|Given PO
219467650|NCT02319018|DRUG|Fluorouracil|Given IV
219467651|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
219467652|NCT02319018|DRUG|Leucovorin Calcium|Given IV
219467653|NCT02319018|DRUG|Oxaliplatin|Given IV
219467654|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
219467655|NCT02617602|OTHER|Control|
218854726|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
218854727|NCT06065059|DRUG|Olaparib|PARP inhibitor
218854728|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
219467656|NCT04037579|OTHER|Survey|Non-randomised survey
218854729|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
219467657|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
219467658|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
219467659|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
219467660|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
219467661|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
219467662|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
219467663|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
219467664|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
218854730|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
219467665|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
218854731|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
218854732|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
218854733|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
218854734|NCT06232148|DEVICE|Type of surgery|
218854735|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
218854736|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
218854737|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
218854738|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
218854739|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
218854740|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
218854741|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
218854742|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
218854743|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
218854744|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
218854745|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
219467666|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
218854746|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
219467667|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
218854747|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
218854748|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
218854749|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
218854750|NCT00427531|OTHER|physiologic testing|
219467668|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
219467669|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
219467670|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
219467671|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
219467672|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
219467673|NCT03096899|OTHER|Observational|Best Supportive Care
219467674|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
219467675|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
218854751|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
219467676|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
218854752|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
218854753|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
218854754|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
218854755|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
218854756|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
218854757|NCT03535662|DRUG|Orvepitant|Single oral dose
218854758|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
218854759|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
218854760|NCT02323204|OTHER|So you've been in an accident|Educational materials
219020203|NCT05327010|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
218854761|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
218854762|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
219467677|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
219467678|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
219467679|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
219467680|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
219467681|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
219467682|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
219467683|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
219467684|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
219467685|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
219467686|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
219467687|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
219467688|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
219467689|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
219467690|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
219467691|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
219467692|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
218854763|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
218854764|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
219020204|NCT05327010|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219020205|NCT05327010|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219020206|NCT05327010|PROCEDURE|Diagnostic Imaging Testing|Undergo diagnostic imaging
219020207|NCT05327010|DRUG|Talazoparib|Given PO
219467693|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
219467694|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
219467695|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
219467696|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
219467697|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
219467698|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
219467699|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
219467700|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
219467701|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
219467702|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
219467703|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
218854765|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
219467704|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
218854766|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
219198959|NCT06602141|OTHER|Accelerometer|The tri-axial accelerometer measure activity and uses those values to estimate the number of calories burned based on your height, weight, age, and gender. The monitor also evaluates physical effort and the body's response to different activities.
219198960|NCT06602141|OTHER|Endurance Exercise|Visit the study site 3 times a week to engage in endurance exercise training for approximately 12 weeks. Each session will last approximately 75 minutes, and exercise group can choose to use either a stationary bike or a treadmill to complete the training.
219198961|NCT06602141|OTHER|Physical activity/ dietary habits|Visit the study site bi-weekly to get weight measurements and speak to the study team about weight maintenance and participant physical activity/dietary habits.
219198962|NCT06602141|OTHER|Heavy Water Labeling Period|Participants in both control groups will be required to drink heavy water, which is ordinary water that is enriched with deuterium (stable, non-radioactive isotope) and called deuterium-labeled water, for 12 weeks.
219198963|NCT06587516|BEHAVIORAL|Neuromuscular Warmup Program|This intervention consists of a structured warm-up routine specifically designed to enhance neuromuscular function and balance. The program includes exercises such as two way forward lunge, single-leg balance, multidirectional lunges, single-leg hops forward and backward, and single-leg calf raises. Each exercise is aimed at improving proprioception, dynamic stability, and lower limb strength.
218854767|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
219198964|NCT06587516|BEHAVIORAL|Traditional Warmup Program|This intervention involves a conventional warm-up program. It includes general stretching exercises and light jogging intended to prepare the body for physical activity.
219020219|NCT02048033|DEVICE|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
219198965|NCT06668792|DRUG|BCD-248|subcutaneously
219198966|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
219198967|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
219198968|NCT04468672|BEHAVIORAL|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
219198969|NCT05819502|DRUG|Restylane line of injectables|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
219198970|NCT05147584|DEVICE|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
219198971|NCT06571812|DEVICE|TSX|Treatment of tooth loss with TSX dental implants
219198972|NCT05460871|DRUG|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
219198973|NCT03967379|BEHAVIORAL|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
218854768|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
218854769|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
218854770|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
218854771|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
218854772|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
218854773|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
218854774|NCT01317537|OTHER|Electronic personal health record|
218854775|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
218854776|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
218854777|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
218854778|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
218854779|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
219467705|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
219467706|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
219467707|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
219467708|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
219467709|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
219467710|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1\) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
219467711|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
219467712|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
218854780|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
218854781|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
219020220|NCT02048033|DIAGNOSTIC_TEST|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
219467713|NCT00039429|DRUG|atrasentan hydrochloride|
219467714|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
219467715|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
219467716|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
219467717|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
219467718|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
219467719|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
219467720|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
219467721|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
219467722|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
219467723|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
219467724|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
219467725|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
219467726|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
219467727|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
219467728|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
219467729|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
219467730|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
219467731|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
219467732|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
219198974|NCT03967379|OTHER|Enhanced Standard Care|Standard of care administered by the institution
219467733|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
219467734|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
219467735|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
219467736|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
219198975|NCT03329937|DRUG|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
219594197|NCT03880786|DEVICE|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
219594198|NCT00089024|DRUG|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
219020230|NCT06425159|DRUG|BHV-7000|BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily
219020231|NCT06425159|DRUG|Placebo|Matching placebo taken once daily
219198976|NCT04664959|DRUG|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
219467737|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
219594199|NCT00089024|DRUG|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
218854782|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
219467738|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
219467739|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
219467740|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
219198977|NCT04664959|DRUG|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
219198978|NCT04782752|RADIATION|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
219467741|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
219467742|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
219198979|NCT05269888|OTHER|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
219198980|NCT05269888|OTHER|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
219198981|NCT01223352|DRUG|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
219198982|NCT06291207|DRUG|AD-224A|PO, Once daily, 8weeks
219198983|NCT06291207|DRUG|AD-224B|PO, Once daily, 8weeks
219467743|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
218854783|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
218854784|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
218854785|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
218854786|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
218854787|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
218854788|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
218854789|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
218854790|NCT00000627|DRUG|Fluconazole|
219467744|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
219467745|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
219467746|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
219467747|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
219467748|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
219467749|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
219467750|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
219467751|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
219467752|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
219594200|NCT00089024|DRUG|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
219594201|NCT00089024|DRUG|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
219198984|NCT06291207|DRUG|AD-224C|PO, Once daily, 8weeks
219198985|NCT06291207|DRUG|Placebo of AD-224A|PO, Once daily, 8weeks
219198986|NCT06291207|DRUG|Placebo of AD-224B|PO, Once daily, 8weeks
219198987|NCT06291207|DRUG|Placebo of AD-224C|PO, Once daily, 8weeks
219198988|NCT05840237|OTHER|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
219198989|NCT05840237|OTHER|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
219198990|NCT04632433|DRUG|Cemiplimab|350 mg every 3 weeks
219467753|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
219467754|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
219467755|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
219467756|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
219467757|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
219467758|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
219467759|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
219467760|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
219467761|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
219198991|NCT04965766|DRUG|U3-1402|U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
218854791|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
218854792|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
218854793|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
219198992|NCT04217603|DEVICE|Continuous positive airway pressure (CPAP) device|Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
218854794|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
219198993|NCT04217603|DEVICE|Sham-continuous positive airway pressure (CPAP) device|An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
219198994|NCT03754465|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
219198995|NCT03754465|PROCEDURE|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
219198996|NCT04623775|BIOLOGICAL|Nivolumab|Specified dose on specified days
219467762|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
218854795|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
218854796|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
218854797|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
218854798|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
219467763|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
219467764|NCT04214483|OTHER|No intervention|There is no intervention for this study.
218854799|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
218854800|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
219467765|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
219467766|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
219467767|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
219467768|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
219467769|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
219467770|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
219467771|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
219467772|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
219467773|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
219467774|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
219467775|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
219467776|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
219467777|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
219020238|NCT01568671|OTHER|Room temperatures|Room temperature of metabolic chamber set between 16C and 31C
219467778|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
219594202|NCT00089024|PROCEDURE|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
218854801|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
218854802|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
218854803|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
218854804|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
218854805|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
218854806|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
218854807|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
219020251|NCT07110532|BIOLOGICAL|A/Arkansas/08/2020 (pH1N1)|GMP-grade, cell-based influenza A (pH1N1) virus (Lot #24-005), derived via reverse genetics for use in controlled human infection studies.
219020252|NCT07110532|OTHER|Sham/Diluent (1X SPG+Arg+Gel)|Sterile diluent containing 1X Sucrose Phosphate Glutamate (SPG), 1% arginine, and 1% hydrolyzed gelatin, used as a sham comparator in the human challenge trial.
219020265|NCT06911632|DEVICE|ECG-based AI Device - Results Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.
219020266|NCT06911632|PROCEDURE|Echocardiogram and Right Heart Catheterization|Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart
219020267|NCT06911632|DEVICE|ECG-based AI Device - Results Not Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.
219467779|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
219467780|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
219467781|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
219467782|NCT00351611|DRUG|placebo|Twice a day, oral administration
219467783|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219467784|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
219467785|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
218854808|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
219467786|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
218854809|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
219467787|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
219467788|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
219467789|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
219594203|NCT00089024|PROCEDURE|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
219594204|NCT00089024|PROCEDURE|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
219594205|NCT00089024|RADIATION|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
219594206|NCT00714896|BEHAVIORAL|Stepped-Care|"* stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
219198997|NCT04623775|BIOLOGICAL|Relatlimab|Specified dose on specified days
219198998|NCT04623775|DRUG|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219198999|NCT04623775|DRUG|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219199000|NCT04623775|DRUG|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
218854810|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
218854811|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
219199001|NCT04623775|DRUG|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219594207|NCT00714896|BEHAVIORAL|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
218854812|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
219594208|NCT03924518|DRUG|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
218854813|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
218854814|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
218854815|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
218854816|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
218854817|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
218854818|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
219199002|NCT04623775|DRUG|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219199003|NCT06808139|PROCEDURE|Plasma-Rich Platelet Graft|The clot was extracted from the tube, separated from red blood cells, and gently compressed between two surgical swabs to obtain a soft and resistant membrane. The Snodgrass technique was carried out for all patients, with a suitable size catheter (8-12-Fr), repair was carried out by a continuous layer of polyglycolic suture (Vicryl) size 6/0, covered by an interrupted second layer. In group A, after finishing the Snodgrass TIPU, a PRP sheet coverage was applied over urethroplasty and secured by Vicryl 7/0, and finally the skin sutured directly without any covering layers
219199004|NCT06808139|PROCEDURE|Dartos Flap|preputial dartos flap will be used
219594209|NCT03924518|DRUG|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
219363078|NCT05154292|BEHAVIORAL|Serious Game: Emotional Health Island (SAEM)|This intervention aims to aim to develop competencies for emotional regulation through exposure and acceptance strategies. This intervention is applied through a serious game developed for this purpose. the adolescent will complete a series of missions aimed at developing skills related to psychological flexibility, namely, greater psychological acceptance, mindfulness in the present moment, and committed actions in the direction of personal values. This serious game is guided by a therapist.
219363079|NCT03088865|DIAGNOSTIC_TEST|aspirating first blood volume into a regular blood collection tube|order of blood drawing
219363080|NCT02833246|OTHER|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
219363081|NCT02833246|OTHER|usual care|
219363082|NCT01967290|DEVICE|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
219594210|NCT01539018|DRUG|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
218854819|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
218854820|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
218854821|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
219363083|NCT01967290|DEVICE|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
219363084|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|100 000 U drops is given once
219363085|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|500 U drops given once
219363086|NCT06264115|PROCEDURE|Laparoscopic Cholecystectomy|Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
219363087|NCT02843620|DIETARY_SUPPLEMENT|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
218854822|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
218854823|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
218854824|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
218854825|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
218854826|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
219020279|NCT07105891|OTHER|Thawing protocol|Standard thwaing
219020280|NCT07105891|OTHER|thawing protocol|Fast thawing
219020281|NCT07105891|OTHER|thawing protocol|Ultrafast thawing
219020282|NCT07113093|OTHER|Augmented Reality|Gait training will be conducted using the AR applications Stepping Stones, Reactive Stones, Obstacles, Speed Adjustment, Slalom, Tandem, and Monster Game for 45 minutes.
219020283|NCT07113093|OTHER|Virtual Reality|Gait training will be conducted using the VR applications Nature Island, Italian Apps, and Soccer for 45 minutes.
219020284|NCT07113093|OTHER|Self Directed Exercises|"Patients will be taught exercises including walking on a flat surface, walking with varying step lengths, walking over obstacles, and walking at different speeds. They will be instructed to perform these exercises for 45 minutes per day."
219020285|NCT07113093|OTHER|Others|The treatment duration is 60 minutes. Based on the patient's needs, the following exercises will be performed: scapular and thoracolumbar mobilization; upper and lower extremity exercises (range of motion, stretching, and strengthening); bed mobility and transitional movements such as rolling, coming to a sitting position, and standing up; core activation exercises such as bridging and functional reaching; weight shifting and balance training; gait training (e.g., walking between parallel bars, walking in different directions, and walking over obstacles); and cycling on a bicycle ergometer.
219020286|NCT07103278|DRUG|AD-116|AD-116 Oral Tablet
219020287|NCT07103278|DRUG|AD-1161|AD-1161 Oral Capsule
219020288|NCT07108439|OTHER|Administration of intra-osseous local anesthesia before the extraction of a first permanent molar under general anesthesia|Intra osseous administration of articain 4% 1/100 000 during general anesthesia for the extraction of a first permanent molar. The administration will be done with Quicksleeper 5.
219020289|NCT06919744|DRUG|Best medical care|Acetazolamide will be introduced at the time of papilledema discovery. Weight loss will be recommended.
219467790|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
219467791|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
219467792|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
219467793|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
219467794|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
219467795|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
219467796|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
219467797|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
219467798|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
219467799|NCT00000912|DRUG|Indinavir sulfate|
219467800|NCT00000912|DRUG|Abacavir sulfate|
219467801|NCT00000912|DRUG|Amprenavir|
219467802|NCT00000912|DRUG|Nelfinavir mesylate|
219467803|NCT00000912|DRUG|Efavirenz|
219467804|NCT00000912|DRUG|Levocarnitine|
219467805|NCT00000912|DRUG|Adefovir dipivoxil|
219467806|NCT00000912|DRUG|Saquinavir|
219467807|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
219467808|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
219467809|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
219467810|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
219467811|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
219467812|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
219467813|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
219467814|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
219467815|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
219467816|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
219467817|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
219467818|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
219467819|NCT02243306|DRUG|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
219467820|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
219467821|NCT03080675|DIETARY_SUPPLEMENT|Control|
219363088|NCT02843620|OTHER|Placebo|Excipients only
219363089|NCT03575715|DEVICE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
219363090|NCT02793037|DEVICE|Zirconia resin bonded bridge|
219363091|NCT05060757|DIAGNOSTIC_TEST|biotax|patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample
219363092|NCT05673941|OTHER|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
219363093|NCT02286531|DRUG|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
219363094|NCT04405960|DRUG|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
219363095|NCT04405960|DRUG|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
219363096|NCT06176937|DRUG|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
219363097|NCT06176937|OTHER|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
219363098|NCT05860348|DEVICE|Barostim™ System|Implantation of the Barostim™ System
219363099|NCT00738478|DEVICE|nasogastric tube|insertion of nasogastric tube for 2 days after operation
219363100|NCT00738478|DEVICE|without nasogastric tube|without nasogastric tube after operation
219363101|NCT00396175|DRUG|MK0906, finasteride / Duration of Treatment : 48 Weeks|
219363102|NCT00396175|DRUG|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
219363103|NCT03652142|OTHER|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
219363104|NCT03652142|DRUG|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
219363105|NCT01382693|BEHAVIORAL|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
219363106|NCT01382693|BEHAVIORAL|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
219363107|NCT00883532|DRUG|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated
219363108|NCT00883532|DRUG|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
219363109|NCT03885128|DEVICE|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
219363110|NCT03885128|DEVICE|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
219363111|NCT03344003|DRUG|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
219363112|NCT01493336|DRUG|capecitabine RTD|single oral dose
219363113|NCT01493336|DRUG|capecitabine [Xeloda]|single oral dose
219363114|NCT01493336|DRUG|capecitabine [Xeloda]|standard treatment
219363115|NCT04686630|OTHER|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
218854827|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
218854828|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
219467822|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
219467823|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
219467824|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
219467825|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
219467826|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
219467827|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
219467828|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
219594211|NCT01539018|DRUG|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
219594212|NCT03887793|OTHER|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
219594213|NCT02191761|DRUG|SM04755|Escalating Doses
219467829|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
219467830|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
219467831|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
219594214|NCT01422629|DEVICE|Ultrasonic ablation device|High Intensity focused ultrasound treatment
219594215|NCT04472676|DRUG|LY3473329|Administered orally.
219594216|NCT04472676|DRUG|Placebo|Administered orally.
219594217|NCT05853744|DRUG|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
219594218|NCT05853744|DRUG|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
219594219|NCT05853744|DRUG|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
219594220|NCT00103220|DRUG|SJG-136|Given IV
218854829|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
218854830|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
219467832|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
219467833|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
219467834|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
219467835|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
219467836|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
219467837|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
219467838|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
219467839|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
219467840|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
219467841|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
219467842|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
218854831|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
218854832|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
218854833|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
218854834|NCT00147862|DRUG|Tranexamic Acid|
219020290|NCT06919744|DEVICE|Intervention (stenting)|Transverse venous sinus will be stented by neuro-radiological intervention
219467843|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
219467844|NCT06464081|OTHER|Sleep quality assessment|1\. Pediatric Sleep Questionnaire.
219467845|NCT06464081|OTHER|Anthropometry|2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
219467846|NCT06464081|OTHER|Tongue strength assessment|3\. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
219467847|NCT06464081|OTHER|Tongue endurance assessment|6\. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
219467848|NCT06464081|OTHER|Orofacial praxis assessment|8\. Motricité Bucco-Linguo-Faciale (MBLF) test.
219467849|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
219467850|NCT06234501|OTHER|Placebo|Placebo tablet once daily
219467851|NCT01288911|DRUG|enzalutamide|capsules
219467852|NCT01288911|DRUG|bicalutamide|tablets
219467853|NCT05963555|DEVICE|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
219467854|NCT05963555|DEVICE|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
219467855|NCT05963555|DEVICE|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
219467856|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
219467857|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
219467858|NCT02189239|DRUG|Placebo|
219467859|NCT02189239|OTHER|No Treatment|
219467860|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
219467861|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
219467862|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
219594221|NCT03513055|OTHER|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
218854835|NCT00025428|DRUG|carboplatin|
218854836|NCT00025428|DRUG|cyclophosphamide|
218854837|NCT00025428|DRUG|doxorubicin hydrochloride|
218854838|NCT00025428|DRUG|etoposide|
218854839|NCT00025428|DRUG|vincristine sulfate|
219467863|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
219467864|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
219467865|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
219467866|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
219467867|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
219467868|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
219467869|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
218854840|NCT00025428|PROCEDURE|adjuvant therapy|
219467870|NCT05300256|DEVICE|Sham|Sham
219467871|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
219467872|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
219467873|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
219467874|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
219467875|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
218854841|NCT00025428|PROCEDURE|conventional surgery|
218854842|NCT00025428|PROCEDURE|neoadjuvant therapy|
219467876|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
219467877|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
219467878|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
219467879|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
219467880|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
219594222|NCT00905710|PROCEDURE|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
219594223|NCT02485119|DRUG|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
218854843|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
218854844|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
218854845|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
219594224|NCT02552303|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
219594225|NCT02552303|DRUG|Armodafinil|Active medication
219594226|NCT02552303|DRUG|Placebo|Placebo for Nuvigil (armodafinil)
219594227|NCT01377987|DRUG|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
219594228|NCT01377987|DRUG|Placebo|4 mg/kg, once daily before bed, for 7 days
218854846|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
218854847|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
218854848|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
218854849|NCT02692040|DRUG|G3215|Gut hormone analogue
218854850|NCT02692040|DRUG|Placebo|0.9% saline
218854851|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
218854852|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
219594229|NCT02814890|PROCEDURE|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
219363116|NCT04431830|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
219363117|NCT05455047|DIAGNOSTIC_TEST|PET-CT at 18F-FDG|PET-CT at 18f6FDG in nuclear medicine departement of Nancy's hospital
219363118|NCT00030342|BIOLOGICAL|recombinant interferon alfa|
219363119|NCT00030342|BIOLOGICAL|sargramostim|
219594230|NCT02814890|PROCEDURE|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
219594231|NCT05635032|OTHER|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
219594232|NCT06149806|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
219594233|NCT04093375|PROCEDURE|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
219594234|NCT04093375|OTHER|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
219594235|NCT05853042|DIAGNOSTIC_TEST|high-sensitivity cardiac troponin testing|Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
219594236|NCT02529215|BEHAVIORAL|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
218854853|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
219363120|NCT00030342|BIOLOGICAL|therapeutic autologous lymphocytes|
219363121|NCT00030342|DRUG|fluorouracil|
219363122|NCT02456428|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363123|NCT02456428|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363124|NCT02456428|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
219363125|NCT02456428|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363126|NCT02456428|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363127|NCT02456428|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363128|NCT02456428|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219363129|NCT02456428|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
219363130|NCT01678183|BEHAVIORAL|Monthly Financial Incentive|A cash payment.
219363131|NCT01678183|BEHAVIORAL|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
219363134|NCT06183268|RADIATION|Spot Delete|"The treatments plans will utilize the scripted spot delete method to remove spots from the skin rind. To ensure all relevant skin spots are removed, the SkinSpots structure will be a 0.5 cm rind extending inward from the skin contour within 5 cm of the CTV. Spots will be removed from this structure and optimization will continue. Optimization objectives will be utilized to spare the skin rind structure during treatment planning, in addition to deleting spots."
218854854|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
218854855|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
219199005|NCT06810986|BEHAVIORAL|16-week digital intervention|"Participants will be enrolled in a 16-week programme with the aim to manage T2DM through lifestyle adjustments. Participants will be given online support by their personal health coach with additional support from a dietitian or clinician in the study if required.~Each participant will receive personalised recommendations for blood glucose monitoring schedule, diet and physical activity. Participants are required to log their blood glucose, diet and physical activity in the BruHealth application. Participants will review their progress with their health coach via video consultation on a regular basis. Additionally, participants will also participate in a structured diabetes self-management education course."
219467881|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
219467882|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
219467883|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
219467884|NCT02543918|DRUG|Boostrix®|Administered by IM injection
219467885|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
219467886|NCT02826005|DEVICE|MRI|
219467887|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
219467888|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
219467889|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
219467890|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
219467891|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
219467892|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
219467893|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
219467894|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
219467895|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
219467896|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
219467897|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
219467898|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
219467899|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
219467900|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
219467901|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
219467902|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
219467903|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
219467904|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
219594237|NCT06427707|DRUG|Intravenous Infusion of propofol, lidocaine, Magnesium sulfate|intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
219594238|NCT06427707|DRUG|Intravenous infusion of ketamine, lidocaine, Magnesium sulfate|Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
219467905|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
219467906|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
218854856|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
218854857|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
218854858|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
218854859|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
218854860|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
219467907|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
219467908|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
219467909|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
219467910|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
218854861|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
218854862|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
219467911|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
219467912|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
219467913|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219467914|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219467915|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219467916|NCT05949528|OTHER|no intervention|no intervention
219467917|NCT04193228|DEVICE|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
219467918|NCT04193228|BEHAVIORAL|Exercise|Ankle muscle strength training
219467919|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
219467920|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
219467921|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
219467922|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
219467923|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
219467924|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
219467925|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
218854863|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
218854864|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
218854865|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
218854866|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
218854867|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
218854868|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
218854869|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
218854870|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
218854871|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
219467926|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
219467927|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
219467928|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
219467929|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
219467930|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
219467931|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
219467932|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
218854872|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
218854873|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
218854874|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
219199006|NCT03419260|OTHER|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
219199007|NCT06065280|DRUG|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
219199008|NCT06065280|DRUG|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
218854875|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
218854876|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
219363135|NCT02065453|DEVICE|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
219363136|NCT02065453|DEVICE|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
219363137|NCT02490293|DRUG|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
219363138|NCT02490293|DRUG|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
219363139|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using closing system|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the SDD group prior to the procedure, the femoral access will be closed with a closure system. Ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
218854877|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
218854878|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
218854879|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
219363140|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using figure-of-eight stitch|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the ONS group prior to the procedure, the femoral access will be closed with a figure-of-eight suture. The ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
219363141|NCT04899297|OTHER|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
219363142|NCT05876052|DEVICE|Hypothermic oxygenated Perfusion - HOPE|HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
219467933|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
218854880|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
219467934|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
219467935|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
219467936|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
219467937|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
219467938|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
219467939|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
219467940|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
219467941|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
219467942|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
219467943|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
219467944|NCT01985152|DRUG|Placebo|
219467945|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
219467946|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
219467947|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
218854881|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
218854882|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
218854883|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
218854884|NCT00252226|DRUG|Quetiapine|
218854885|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
218854886|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
219020295|NCT06915454|DEVICE|Intra-op PET/CT Specimen Scanner|Once the tumor or cancer is resected, it will then be imaged with the XEOS Aura 10 PET/CT Imaging Device. Imaging will be obtained utilizing a XEOS AURA 10 scanner in real time while in the operating room with the surgery team still present.
219467948|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
219467949|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
219467950|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
218854887|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
218854888|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
219467951|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
219594239|NCT06427707|DRUG|Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate|Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
219199009|NCT06656325|DEVICE|Erchonia® FX405|"Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit."
219594240|NCT01247883|DRUG|PF-04634817|single dose, 20mg, tablet
219594241|NCT01247883|DRUG|PF-04634817|single dose, 20mg, solution
219594242|NCT05708989|PROCEDURE|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
219020304|NCT07111598|BIOLOGICAL|Blood test at D0|Six extra blood collection tubes (28 mL) will be drawn during the visit (D0), in addition to the routine blood samples, at the blood collection center
219020305|NCT07111598|BIOLOGICAL|Blood test at D+3 months|six extra blood collection tubes (28 mL) will be drawn during the visit (D+3 months) for group 3 patients, in addition to the routine blood samples, at the blood collection center
219594243|NCT05708989|PROCEDURE|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
219594244|NCT05708989|DRUG|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
219594245|NCT05708989|DRUG|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
219594246|NCT02600689|BEHAVIORAL|Physical exercise training|
218854889|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
218854890|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
218854891|NCT01693874|BEHAVIORAL|control (health education)|health education
219020314|NCT05870787|DIAGNOSTIC_TEST|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
219467952|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
219467953|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
219467954|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
219467955|NCT01294319|DRUG|Mifepristone|
219467956|NCT01294319|DRUG|Placebo|
219467957|NCT01294319|DRUG|Spironolactone|
219467958|NCT01294319|DRUG|Combined|
219467959|NCT01294319|DRUG|Dexamethasone|
219467960|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
219594247|NCT02600689|BEHAVIORAL|Cognitive exercise training|
219594248|NCT04603157|BEHAVIORAL|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
219594249|NCT00461201|PROCEDURE|Nurse practitioner care of patients|
219594250|NCT02046486|DRUG|Ticagrelor 180mg whole tablets|
219594251|NCT02046486|DRUG|Ticagrelor 180mg crushed and dispersed|
219594252|NCT04799938|BEHAVIORAL|Exercise|180 minutes of moderate-intensity exercise per week
219594253|NCT06091670|OTHER|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
219594254|NCT01016470|DIETARY_SUPPLEMENT|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
219594255|NCT01016470|DIETARY_SUPPLEMENT|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
218854892|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
219199010|NCT06656325|DEVICE|Placebo Laser|"Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit."
219594256|NCT06174597|PROCEDURE|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
219363143|NCT06706661|OTHER|Nutritional treatment|At the day of discharge the intervention group (IG) receives a package containing foods and drinks covering dietary requirements for the next 24 h. Further, a goodie-bag containing samples of protein-rich milk-based drinks is provided. At day 4 after discharge, the IG receives dietetic counselling including a recommendation of daily exercise, and an individual nutrition plan. Information regarding recommendations of nutritional therapy after discharge is systematically and electronically communicated to the municipality. The dietician performes telephone follow-ups on day 30 and a home visit at 12 weeks
218854893|NCT03749096|DRUG|Placebos|Normal Saline
218854894|NCT00150358|DRUG|Sildenafil Citrate|
219363144|NCT06467773|RADIATION|Radiation: PET-MRI with [18F]-DPA-714|Radiation: PET-MRI with \[18F\]-DPA-714
219363145|NCT01020864|DRUG|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
218854895|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
218854896|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
218854897|NCT00977938|DRUG|Placebo & Aspirin|
218854898|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
218854899|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
219363146|NCT01020864|DRUG|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
219363147|NCT01020864|DRUG|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
219363148|NCT06883981|BEHAVIORAL|Free and Cued Recall Memory. Temporal Sequence and Spatial Memory|Memory for real-world episodic experiences will be tested in the laboratory first with free recall (spoken narration of their recollections from each environment) and then with cued recall, in which participants will be cued with an event image from the CAPTURE app, a map location, or a relative time and asked to recall the other two non-cued pieces of episodic information (event, place, or time). Because we will know the 'ground truth', the cued recall test will allow us to measure how accurately the participant is able to remember key details of each episode. We will also assess temporal order memory by asking participants to arrange 1st person images in the order in which they occurred, and we will assess spatial memory by asking them to place each image on a schematic map of the venue.
219363149|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (40:1)|Myo-inositol and D-chiro-inositol (40:1 ratio), 2 grams (twice a day) for three months
218854900|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
218854901|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
219363150|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (3.6:1)|Myo-inositol and D-chiro-inositol (3.6:1 ratio), 1.4 grams (once daily) for three months
219363151|NCT06733532|DIETARY_SUPPLEMENT|Berry Propel Fitness Water|Subject will consume 1 Liter of commercially available Berry Propel Fitness Water at a rate of 250 milliliters per 7.5 minutes
219363152|NCT06733532|DIETARY_SUPPLEMENT|Essentia Hydroboost Raspberry Pomegranate|Subject will consume 1 Liter of commercially available Essentia Hydroboost Raspberry Pomegranate at a rate of 250 milliliters per 7.5 minutes
219363153|NCT06733532|DIETARY_SUPPLEMENT|Smart Water|Subject will consume 1 Liter of commercially available Smart Water at a rate of 250 milliliters per 7.5 minutes.
219363154|NCT06893679|OTHER|Qigong sensory training|Participants will be received 15 mints massage therapy 2 times in a day and 5 days a week for 8 weeks. Before and after 8 week of intervention, Assessment of sensory modulation scale (ASMS) will be used to check the sensory modulation level and strength and difficulties questionnaire (SDQ) will be used to check the behavior. Data will be collected from Nishtar Hospital Multan. The pre and post intervention assessments will be done.
219363155|NCT06916988|BEHAVIORAL|Sports Stars Brazil|Modified sports interventions promote physical activity participation in individuals with ASD by addressing intrinsic factors, however they do not address contextual barriers, such as environmental and interpersonal factors, which also influence participation. Factors like bullying, parents' perceptions often prioritizing therapy intervention, and challenges faced in community programs (as the lack of adaptations in existing programs to meet their needs) are some of these obstacles, which reduce adherence to physical activities (Jachyra et al., 2021). Therefore, it may be necessary to combine interventions targeting intrinsic factors, such as Sports Stars, with those that address the extrinsic contextual factors impacting the participation of adolescents with ASD in their community.
219363156|NCT06916988|BEHAVIORAL|context-centered therapy|"The complimentary approach of combining intrinsic (Sports Stars) and extrinsic (PREP) interventions aligns with the relationships between the person, their environment, and the quantity and quality of their participation proposed in the family of participation related constructs (Imms et al., 2017). By recognizing that participation depends on both the individual's abilities and the contexts and conditions in which it occurs, professionals can adopt a more holistic and tailored approach to individual needs (Imms et al., 2015)."
219363157|NCT02805205|DRUG|PEG-rhG-CSF|
219363158|NCT05738122|OTHER|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
219199011|NCT06807476|OTHER|Validity and reliability|"The scale consists of 40 items and four sub-dimensions, and is scored according to a 5-point Likert rating scale (ranging from Strongly Disagree (Score = 1 point) to Strongly Agree (Score = 5 points)). The scale evaluates the healthy/patient individual's readiness attitude level towards acupuncture, personal beliefs, preferences and experiences. The score received per sub-dimension varies between a minimum of 10 and a maximum of 50 points. The average cut-off score per sub-dimension is 25. The higher the score (above the average cut-off score), the more open the healthy/patient individual is to acupuncture. Sub-dimensions:~Sub-Dimension 1 (Items 1-10): Willingness to Try Acupuncture Sub-Dimension 2 (Items 11-20): Belief in the Effectiveness of Acupuncture Sub-Dimension 3 (Items 21-30): Comfort in the Acupuncture Sub-Dimension 4 (Items 31-40): Concerns and Preferences"
219199012|NCT06656026|DRUG|ZSP1273 granules|Oral
218854902|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
218854903|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
219467961|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
219467962|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
219467963|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
219594257|NCT01807247|PROCEDURE|Intensive lower limbs muscles strengthening|
219594258|NCT02506283|DEVICE|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
219594259|NCT04837924|PROCEDURE|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
219594260|NCT04837924|DRUG|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
219594261|NCT04837924|DRUG|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
219199013|NCT06368050|BEHAVIORAL|practice structure intervention|practice structure intervention
219199014|NCT03498521|DRUG|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219199015|NCT03498521|DRUG|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219199016|NCT03498521|DRUG|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219467964|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
219467965|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
218854904|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
218854905|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
218854906|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
219467966|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
219467967|NCT00741624|OTHER|Bandage|one application for one week
219467968|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
219467969|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
219594262|NCT04837924|PROCEDURE|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
219594263|NCT04718948|DEVICE|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
219594264|NCT04718948|DIAGNOSTIC_TEST|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
219594265|NCT04718948|PROCEDURE|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
218854907|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
218854908|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
218854909|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
219199017|NCT03498521|DRUG|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219594266|NCT02156167|DEVICE|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
219594267|NCT05248165|DEVICE|PCI|Percutaneous coronary intervention
218854910|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
218854911|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
218854912|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
218854913|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
218854914|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
219363159|NCT05027932|OTHER|IN Placebo|The placebo is normal saline in two syringes administered IN.
219594268|NCT05719792|PROCEDURE|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
219363160|NCT05027932|OTHER|IM Placebo|The placebo is normal saline in a syringe administered IM.
219363161|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It is administered either IM or IN depending on the assigned treatment group.
219363162|NCT06910930|DEVICE|DidgeriTU|the study device that immitate the principle of didgeridoo for expiratory muscle exercise
219363163|NCT06910930|DEVICE|Sham device|a device that look alike DidgeriTU but without resistance plate
219594269|NCT05719792|PROCEDURE|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
219594270|NCT03763357|DEVICE|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
218854915|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
218854916|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
218854917|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
218854918|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
218854919|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
218854920|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
219020317|NCT07118241|DRUG|Recombinant Human Proteoglycan 4|rhPRG4 450ug/ml
219020318|NCT07118241|DRUG|Vehicle Control|PBS based Vehicle Conrtol
219020319|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
219020321|NCT06923839|BIOLOGICAL|Test bacterial peptide: RUCILP|The naturally occuring gut peptide RUCILP synthesized by the commensal gut bacterium Ruminococcus torques
219020322|NCT06923839|OTHER|Placebo|Placebo is identical to the active intervention except for the absence of the RUCILP molecule.
219020323|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
219020324|NCT06919835|DRUG|Cilostazol 100 mg|Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.
218854921|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
219467970|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
219199018|NCT03498521|DRUG|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219467971|NCT03240666|OTHER|non applicable|non applicable
219467972|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
219467973|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
219467974|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
219467975|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
219594271|NCT00741286|DRUG|Aspirin|Asprin (100mg) plus placebo
218854922|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
219199019|NCT03498521|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219199020|NCT03498521|DRUG|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219199021|NCT03498521|DRUG|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219199022|NCT03498521|DRUG|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219199023|NCT03498521|DRUG|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
219199024|NCT03498521|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219199025|NCT03498521|DRUG|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
219199026|NCT03498521|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
219199027|NCT03498521|DRUG|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
219199028|NCT03498521|DRUG|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
219199029|NCT03498521|DRUG|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
219199030|NCT03498521|DRUG|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
219467976|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
219467977|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
219467978|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
219467979|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
219467980|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
219467981|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
219467982|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
219467983|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
219467984|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
219467985|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
219594272|NCT00741286|DRUG|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
218854923|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
218854924|NCT06276452|BEHAVIORAL|Psychoeducation|Psychoeducation is the therapeutic management of illness through the increase of related knowledge, skills, and motivation.
218854925|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
219199031|NCT03498521|DRUG|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
218854926|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
219467986|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
219467987|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
219467988|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
218854927|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
218854928|NCT03158623|BIOLOGICAL|Cellerate|
218854929|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
219020327|NCT07127809|BEHAVIORAL|Mindfulness Practice|Participants in this group will engage in a structured mindfulness practice program delivered via a custom-developed mobile app. The intervention includes guided mindfulness exercises such as meditation, breathing techniques, and body awareness, designed to be practiced daily alongside routine nursing duties. The program aims to enhance psychological capital and reduce job burnout symptoms over a 40-day intervention period, with follow-up assessments at 2 and 4 months post-intervention.
219020332|NCT07140016|DRUG|gilteritinib|Oral
219199032|NCT06061575|DRUG|Acetaminophen|fever will be managed with acetaminophen
219199033|NCT06061575|DRUG|Ibuprofen|fever will be managed with ibuprofen
219199034|NCT06876688|DRUG|Relma-cel Followed by Tislelizumab|Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by treatment with Tislelizumab (200mg, IV, q4w, for 12 months) starting at 35 days post-infusion. BTK inhibitors will be used in combination as needed.
219467989|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
219467990|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
219467991|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
219467992|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
219467993|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
219467994|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
219467995|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
219467996|NCT00002075|DRUG|Flucytosine|
218854930|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
219020334|NCT06507657|DRUG|empagliflozin|"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
219020335|NCT06507657|DRUG|Placebo tablet|"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
218854931|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
218854932|NCT02030080|BEHAVIORAL|Financial incentives|
218854933|NCT02030080|BEHAVIORAL|Teams|
218854934|NCT02030080|BEHAVIORAL|Framing of feedback|
218854935|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
218854936|NCT01760330|DRUG|IV acetaminophen|
218854937|NCT01760330|DRUG|Placebo|
219020346|NCT05633966|DRUG|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
219020351|NCT07142577|OTHER|Mandala coloring|Mandala coloring activities will be carried out by the certified researcher 3 days a week for 8 weeks.
219020352|NCT05184764|BIOLOGICAL|AP-SA02|Bacteriophage administered via intravenous bolus infusion
219020353|NCT05184764|OTHER|Placebo|Inactive Placebo administered via intravenous bolus infusion
219467997|NCT00002075|DRUG|Fluconazole|
219467998|NCT00002075|DRUG|Amphotericin B|
218854938|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
218854939|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
218854940|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
218854941|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
218854942|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
218854943|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
219467999|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
219468000|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
219468001|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
219468002|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
219468003|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
219468004|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
219468005|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
219468006|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
219468007|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
219468008|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
219594273|NCT05689957|DRUG|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
219468009|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
219468010|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
219594274|NCT00391963|DEVICE|Bispectral index, Entropy|
218854944|NCT03717792|OTHER|no intervention|no intervention
218854945|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
218854946|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
218854947|NCT02839226|DRUG|AR/101|
219020361|NCT06935500|PROCEDURE|endoscopic ureteric lithotripsy|2 different sizes of ureteroscopes, 4.5/65f and 7.5/9.5f, will be used in the study.
219020364|NCT06938412|DEVICE|Physical Activity Intervention Using FitBit Wearable Device|The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device.
218854948|NCT02839226|DRUG|Placebo|
219468011|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
219468012|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
219468013|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
219594275|NCT06467110|DEVICE|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
218854949|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
218854950|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
219199036|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
219199037|NCT06810401|PROCEDURE|Debridement of implant surface with titanium curettes and irrigation with sterile saline solution|All patients in both groups received non-surgical treatment of peri-implantitis involving the debridement of hard- and soft accumulations on implant surfaces using titanium curettes (Titanium Implant Scaler 204SD, Hu-Friedy) for 15 minutes, followed by irrigation with sterile saline solution
219199038|NCT03188692|BIOLOGICAL|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
219199039|NCT06589635|DRUG|ADC-189 and Itraconazole|"Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals."
219199040|NCT05830799|DRUG|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
219199041|NCT06817434|DRUG|Revascularization/Conservative management|Revascularization/Conservative management
219199042|NCT06820255|DRUG|Platinum + Gemcitabine|Eligible patients will be treated with platinum-based chemotherapy (i.e. cisplatin + gemcitabine or carboplatin + gemcitabine).
219199043|NCT06820255|DRUG|Avelumab first-line maintenance|Patients with stable disease or tumor response after treatment with platinum-based chemotherapy will start treatment with avelumab 800 mg fat dose Q2 weeks until progression of disease or unacceptable toxicity
219468014|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
219468015|NCT05776511|PROCEDURE|eVOG|video digital oculography
219468016|NCT04613076|BEHAVIORAL|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
219468017|NCT04613076|BEHAVIORAL|Enhanced Usual Treatment|Enhanced Usual Treatment
219468018|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
219594276|NCT01831258|DEVICE|SensAwake On|
219594277|NCT01831258|DEVICE|SensAwake Off|
219594278|NCT05115487|DIAGNOSTIC_TEST|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
218854951|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
218854952|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
218854953|NCT01887821|DRUG|Chloroquine|
218854954|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
218854955|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
218854956|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
218854957|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
218854958|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
219468019|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
219468020|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
219468021|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
219468022|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
219468023|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
219468024|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
219468025|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
219468026|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
219468027|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
219468028|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
219468029|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
219468030|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
219468031|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
219468032|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
219468033|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
219468034|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
218854959|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
219468035|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
218854960|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
218854961|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
218854962|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
218854963|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
218854964|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
219468036|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
219468037|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
219468038|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
219468039|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
219468040|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
219468041|NCT00545974|DRUG|memantine|memantine 10mg BID
218854965|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
218854966|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
218854967|NCT00717522|DRUG|Pomalidomide|
218854968|NCT02182908|OTHER|PET-Scan|PET-Scan
219468042|NCT00545974|DRUG|Placebo pill|Placebo pill BID
219468043|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
219468044|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
219468045|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
219468046|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
219468047|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
219468048|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
219199044|NCT06820255|DIAGNOSTIC_TEST|NGS test for DDR alterations|All patients will be tested for DDR alterations on tumor tissue.
219199045|NCT06821165|OTHER|Dr. Goniometer Application|The Dr. Goniometer application is a digital tool used for measuring elbow flexion range of motion (ROM). In this study, participants' elbow flexion ROM will be assessed using both the Dr. Goniometer application and a manual goniometer. Measurements will be taken twice by two different raters to evaluate the validity and reliability of the digital application compared to the manual goniometer.
219199046|NCT06820762|DRUG|irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity|"Drug: ivonescimab 20mg/kg, IV, D1, Q3W~Other Names:~AK112 Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W"
219199047|NCT06820294|OTHER|No intervention|As per widely adopted clinical research practice for case reviews of de-identified, anonymised data, no explicit consent of participants (or their legal guardians) would be required for this study other than the consent they provided at biopsy (from which the whole genome sequencing data is derived) for researchers to access their notes (as documented on hospital consent form).
219199048|NCT06815991|DRUG|MIB-725|MIB-725 is a modified precursor of the NAD+ biosynthetic pathway.
219199049|NCT06816134|DRUG|TmBU conditioning Regimen|TmBU conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT) : Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
219199050|NCT06816134|DRUG|mBUCY conditioning regimen|mBUCY conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT): Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
219468049|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
218854969|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
218854970|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
218854971|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
219199051|NCT06817096|DRUG|Nitazoxanide 600Mg Oral Tablet / placebo oral tablet|1 tablet every 12 hours
219199052|NCT06817369|OTHER|Exercises given with internal focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
219199053|NCT06817369|OTHER|Exercises given with external focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
219199054|NCT06813599|OTHER|Neurodevelopmental Technique on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group A received a designed NDT program, attending three sessions per week for two consecutive months. The internationally recognized neurodevelopmental therapy (NDT) intervention will be used, consisting chiefly of three components:~1\. Exercise training: the therapist is goal-oriented and works with the child to make a family exercise plan. The plan is developed based on specific activities of the children in the family. The plan is designed step by step, and all tasks allow the child to reach a functional goal. Having set an exercise target, the child is able to achieve the goal as his/her exercise ability increases. Subsequently, the difficulty level of the task is increased or the environment altered, so the infant continues to face challenges to exercise ability. In the process of implementing the training plan, the therapist should pay attention to the degree of completion and quality of child movements, making corrections and offering guidance twice weekly."
219468050|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
218854972|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
218854973|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
218854974|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
218854975|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
219199055|NCT06813599|OTHER|Motor Planning Exercises on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group B will receive a designed motor planning program, attending three sessions per week for two consecutive months. Practicing skills will help children with poor motor planning ability become more confident. There are many things we can do to help children improve their motor planning. Using simple language, Thinking about all the different steps to complete a sequence of steps can be difficult for children with motor planning difficulties so we should keep language simple to help them better understand what they need to do to complete a task.~Breaking new skills down into smaller steps, Guiding the child through a task by providing one instruction at a time. This will help them to better follow instructions and reduce anxiety over learning a new skill. Starting with the simplest movement first, Practice the individual movements that make up a task, gradually increasing the degree of difficulty as your child gains confidence in the simpler movements."
219199056|NCT06818188|OTHER|Turning based specific training with rhythmic auditory stimulation (RAS)|"The study involved an experimental group that underwent a 6-week turning-based training with rhythmic auditory stimulation (TBST-RAS), performed three times a week on alternate days. The purpose was to improve motor control and walking abilities through rhythmic auditory cues, specifically adjusting the metronome's beat to the patient's cadence.~Week 1: Patients performed turning exercises around a cone and walking with visual cues at 5% rhythmic auditory cue intensity, with rest periods.~Weeks 2-3: The intensity of rhythmic auditory cues increased to 10%, and patients engaged in cone turning, figure-of-eight walking, and walking with visual cues, with rest breaks in between.~Weeks 4-5: Rhythmic auditory cue intensity increased to 15%. Exercises included cone turning, figure-of-eight walking, walking with visual cues, multidirectional stepping, and rest periods.~Week 6: The final week involved exercises with a further increase in rhythmic auditory cue intensity to 20%. The exercise"
219199057|NCT06818188|OTHER|Turning based specific training without rhythmic auditory stimulation (RAS)|"The control group underwent 6 weeks of turning-based specific training without rhythmic auditory stimulation (TBST), performed three times a week on alternate days. The training followed this pattern:~Week 1: Patients began with cone turning for 5 minutes, followed by 2 minutes of rest. Then, they walked with visual cues for 5 minutes, also without rhythmic auditory stimulation.~Weeks 2-3: The exercises continued with cone turning and figure-of-eight walking for 5 minutes each, with 2-minute rest periods in between. Patients also walked with visual cues for 5 minutes without RAS.~Weeks 4-5: The exercises included cone turning, figure-of-eight walking, walking with visual cues, and multidirectional stepping (forward, backward, laterally), all for 5 minutes each, with rest periods between exercises.~Week 6: In the final week, the duration of cone turning and figure-of-eight walking was reduced to 3 minutes, but the exercises still had 2-minute rest periods in between. Patients also p"
219199058|NCT06817798|OTHER|Specific foot mobility|Specific mobility of the foot, performed bilaterally.
219199059|NCT03818178|DIETARY_SUPPLEMENT|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
219199060|NCT03818178|DIETARY_SUPPLEMENT|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
219199061|NCT03818178|OTHER|Saline|All participants will serve as their own controls with a saline infusion study day.
219468051|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
219468052|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
219468053|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
219468054|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
219468055|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
219468056|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
219468057|NCT00302731|DRUG|Estradiol , estriol , progesterone|
219468058|NCT00302731|DRUG|estradiol, progesterone|
219468059|NCT00302731|DRUG|estriol, progesterone|
219468060|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
219468061|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
219468062|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
219468063|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
219468064|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
219468065|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
219468066|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
219468067|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
219468068|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
219199062|NCT06592443|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
219468069|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
219468070|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
219468071|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
218854976|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
219468072|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
219468073|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
218854977|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
218854978|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
218854979|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
218854980|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
219468074|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
219468075|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
219468076|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
219468077|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
219468078|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
219468079|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
219468080|NCT02780869|DEVICE|HEMOBLAST Bellows|
219468081|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
219468082|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
219468083|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
219468084|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
219468085|NCT03284931|DRUG|SAGE-217 high dose|high dose
219468086|NCT03284931|DRUG|Placebo|placebo
219468087|NCT03284931|DRUG|SAGE-217 low dose|low dose
219468088|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
219468089|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
218854981|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
218854982|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Tilting|Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.
218854983|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure|The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.
218854984|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
218854985|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
218854986|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
218854987|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
218854988|NCT00314717|BEHAVIORAL|Control diet|
218854989|NCT00314717|BEHAVIORAL|Low GI diet|
219199063|NCT06592443|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
219199064|NCT06592443|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
218854990|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
218854991|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
219468090|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
218854992|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
218854993|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
218854994|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
218854995|NCT05341895|OTHER|Kinesiotape|Taping
218854996|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
218854997|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
218854998|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
218854999|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
218855000|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
219199065|NCT06365684|DRUG|Sodium zirconium cyclosilicate|In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
219468091|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
218855001|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
218855002|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
218855003|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
218855004|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
218855005|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
218855006|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
218855007|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
218855008|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
218855009|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
218855010|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
218855011|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
219468092|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
219468093|NCT02861521|DEVICE|Sham|Sham shoe modification
219468094|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
219468095|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
219468096|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
219468097|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
219468098|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
219468099|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
219468100|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
218855012|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
218855013|NCT04836416|OTHER|Observational|Observational
218855014|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
218855015|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
218855016|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
219468101|NCT02815670|DRUG|Idarucizumab|
219468102|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
218855017|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
218855018|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
219468103|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
219468104|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
218855019|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
218855020|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
218855021|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
218855022|NCT00460759|DRUG|Moxifloxacin|
219468105|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
219468106|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
219468107|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
219468108|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
219468109|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
219468110|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
218855023|NCT00460759|DRUG|Rifapentine|
218855024|NCT01371253|OTHER|Nintendo wii balance training|
218855025|NCT01371253|OTHER|EVA-soles|
218855026|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
218855027|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
218855028|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
218855029|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
219468111|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
219468112|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
219468113|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
219468114|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
219468115|NCT00658918|DRUG|Placebo|placebo
219468116|NCT02791906|DRUG|ISMN|
219468117|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
219468118|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
219468119|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
219468120|NCT03918356|OTHER|healthy control group|healthy control
219468121|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
219468122|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
219468123|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
219468124|NCT02114346|DRUG|Atorvastatin|
218855030|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
218855031|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
219468125|NCT02114346|DRUG|Placebo|
219468126|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
219468127|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
219468128|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
219468129|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
219468130|NCT00004844|PROCEDURE|tissue implantation|
219468131|NCT01157585|DRUG|paliperidone ER|8 week prospective study
219468132|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
218855032|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
218855033|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
218855034|NCT01498627|OTHER|Data collection|PGRx information system
219020367|NCT06941363|RADIATION|SBRT|Eligible patients are those with (1) persistently detectable PSA post-operatively or (2) developing biochemical recurrence after prostatectomy with initially undetectable PSA, without evidence of macroscopic local relapse and/or regional and distant metastases at restaging, proposed for receiving up to 15 Gy in a single session to the prostate bed.
219020375|NCT06943521|DRUG|MT-4561|i.v.
219468133|NCT05801016|BEHAVIORAL|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
219468134|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
218855035|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
218855036|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
218855037|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
219468135|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
219468136|NCT00003736|DRUG|motexafin gadolinium|
219468137|NCT00003736|PROCEDURE|biopsy|
219468138|NCT00003736|PROCEDURE|breast imaging study|
219468139|NCT00003736|PROCEDURE|comparison of screening methods|
219468140|NCT00003736|PROCEDURE|magnetic resonance imaging|
219468141|NCT00003736|PROCEDURE|study of high risk factors|
219468142|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
219468143|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
219468144|NCT03874208|OTHER|MRI|MRI exam
219468145|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
219468146|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
219468147|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
219468148|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
219468149|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
219468150|NCT00143728|DRUG|Lamivudine|See Detailed Description.
218855038|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
218855039|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
218855040|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
219468151|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
219468152|NCT00045006|DRUG|vorinostat|
219468153|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
219468154|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
219468155|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
219468156|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
219468157|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
218855041|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
218855042|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
219468158|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
219468159|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
219468160|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
219468161|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
219468162|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
219468163|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
219468164|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
219468165|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
219468166|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
219468167|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
219468168|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
219468169|NCT02438111|GENETIC|metagenome|metagenome
219468170|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
219468171|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
219468172|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
219468173|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
219468174|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
219468175|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
219468176|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
218855043|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
218855044|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
218855045|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
218855046|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
219468177|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
219468178|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
219468179|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
219468180|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
218855047|NCT02157792|DRUG|M6620|
218855048|NCT02157792|DRUG|Gemcitabine|
218855049|NCT02157792|DRUG|Cisplatin|
218855050|NCT02157792|DRUG|Etoposide|
218855051|NCT02157792|DRUG|Carboplatin|
218855052|NCT02157792|DRUG|Irinotecan|
218855053|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
218855054|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
218855055|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
219468181|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
219468182|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
219468183|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
219468184|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
219468185|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
219468186|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
219468187|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
219468188|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
219468189|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
219468190|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
219468191|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
219468192|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
219468193|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
219468194|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
219468195|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
219468196|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
219468197|NCT05405738|OTHER|normal group|control normal group
219468198|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
219468199|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
218855056|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
219468200|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
219468201|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
219468202|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
219468203|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
219468204|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
219468205|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
219468206|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
219468207|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
219468208|NCT02939326|DRUG|EB-001 injection|
219468209|NCT02939326|DRUG|Placebo injection|
219468210|NCT04247724|BEHAVIORAL|Recreational handball|
219468211|NCT04247724|BEHAVIORAL|Control|
219468212|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
219468213|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
219468214|NCT02565303|PROCEDURE|Intervertebral space|
218855057|NCT00545220|BEHAVIORAL|problem-solving training|
218855058|NCT00545220|BEHAVIORAL|sham intervention|
218855059|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
218855060|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
218855061|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
219468215|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
219468216|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
219468217|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
219468218|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
219468219|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
219468220|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
219468221|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
219468222|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
219199066|NCT06656507|PROCEDURE|Quadro Iliac Plane Block (QIPB)|The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.
219468223|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
219468224|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
219468225|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
219468226|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
219468227|NCT01209299|GENETIC|DNA methylation analysis|
219468228|NCT01209299|GENETIC|gene expression analysis|
219468229|NCT01209299|OTHER|laboratory biomarker analysis|
219468230|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
219468231|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
219468232|NCT03092141|OTHER|Physical training|
219468233|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
219468234|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
219468235|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
219468236|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
219468237|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
219468238|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
219468239|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
219468240|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
219594279|NCT05110820|DIAGNOSTIC_TEST|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
219594280|NCT00253448|RADIATION|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
219594281|NCT00253448|RADIATION|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
219594282|NCT04626648|BEHAVIORAL|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
219594283|NCT04683016|OTHER|Questionnaires|"Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
219594284|NCT02318303|DRUG|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
219594285|NCT02318303|DRUG|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
219594286|NCT02318303|DRUG|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
219594287|NCT02318303|DRUG|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
219594288|NCT02318303|DRUG|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
219594289|NCT02318303|DRUG|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
219594290|NCT02318303|DRUG|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
219594291|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
218855062|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
218855063|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
219468241|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
219468242|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
219468243|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
219468244|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
219468245|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
219468246|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
219468247|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
219468248|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
219468249|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
219468250|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
219468251|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
219468252|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
219468253|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
219468254|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
219468255|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
219468256|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
218855064|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
218855065|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
218855066|NCT05330858|DRUG|Rabeprazole|Oral Tablet
218855067|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
218855068|NCT01289223|DRUG|Bendamustine IV|
218855069|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
218855070|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
218855071|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
219468257|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
219468258|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
219468259|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
219468260|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
219468261|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
219468262|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
219468263|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
219468264|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219468265|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219468266|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219468267|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
219468268|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
219468269|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
219468270|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
219468271|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
219468272|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
219468273|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
219468274|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
219468275|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
219468276|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
219468277|NCT00000291|DRUG|Labetalol|
219468278|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
219468279|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
219468280|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
219468281|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
219468282|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
219468283|NCT02983968|OTHER|Description of the cirrhosis management|
219468284|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
219468285|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
219468286|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
219468287|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
219594292|NCT01090518|DRUG|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
219199067|NCT06656507|PROCEDURE|Erector Spinae Plane Block (ESP)|The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
219594293|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
219594294|NCT06551376|OTHER|Ovarian Stimulation Start|To compare ovarian response accordin to ovarian stimualtion start
219199068|NCT06656377|BEHAVIORAL|exercise intervention|A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
219199069|NCT06657729|OTHER|Succiometry|Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
219468288|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
219468289|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
219468290|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
219468291|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (\_\_\_mg/m2 iv weekly x 4 weeks)
219468292|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
219468293|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
219594295|NCT06256107|DEVICE|Virtual Reality Headset|Virtual Reality Headset
219594296|NCT01638585|DRUG|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
219468294|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
219468295|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
219468296|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
218855072|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
218855073|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
219199070|NCT06812598|DRUG|Letermovir (0-24w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 24 weeks post-transplant (approximately 170 days).
219199071|NCT06812598|DRUG|Letermovir (0-14w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 14 weeks post-transplant (approximately 100 days).
219199072|NCT06988215|OTHER|Kinesiology Taping with Exercise|Real kinesiology taping is applied to the suprahyoid region in three directions (from the hyoid bone to the clavicle, to the sternum, and horizontally). Taping is renewed every three days. Participants also perform effortful swallowing and oromotor exercises daily (5 sets of 10 repetitions) for 6 weeks.
219199073|NCT06988215|OTHER|Placebo Taping with Exercise|Non-therapeutic kinesiology taping with no tension is applied to the suprahyoid region to mimic the appearance of the therapeutic tape. Participants perform the same daily swallowing and oromotor exercises as the intervention group for 6 weeks
219468297|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
219199074|NCT06857721|DEVICE|Intraoral Scanners|Intraoral scanners for pediatric patients
219468298|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
219468299|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
219468300|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
219468301|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
219468302|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
218855074|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
219468303|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
219468304|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
219468305|NCT04927858|DRUG|Empagliflozin|Empagliflozin
219468306|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
219468307|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
219468308|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
219468309|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
219468310|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
219468311|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
219199525|NCT06684080|OTHER|A care bundle|"1. Risk evaluation for PPH and Reserve plan;~2. Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape;~3. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered: 1） Lack of uterine contractions 2） Persistent bleeding 3）Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④~   * Maintain uterus tone (Administration of Oxytocin and second-line medications to promote uterine contraction)~     * Intravenous infusion ③ Administered tranexamic acid ④ Multi-methods and Multi-disciplinary"
219468312|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
218855075|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
218855076|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
219468313|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
219468314|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
219468315|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
219468316|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
219468317|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
219468318|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
219468319|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
219468320|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
218855077|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
218855078|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
218855079|NCT00137696|PROCEDURE|Collection of serum|
218855080|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
218855081|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
218855082|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
218855083|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
218855084|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
219468321|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
219468322|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
219468323|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
219468324|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
219468325|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
219468326|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
219468327|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
219594297|NCT06626295|OTHER|exercise-snack group|Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
218855085|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
218855086|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
218855087|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
218855088|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
218855089|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
218855090|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
218855091|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
218855092|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
218855093|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
218855094|NCT00093886|DRUG|clevidipine|
218855095|NCT00093886|DRUG|nitroglycerin|
218855096|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
218855097|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
218855098|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
218855099|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
219468328|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
219468329|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
219468330|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
218855100|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
219468331|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
219468332|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
219594298|NCT01320384|OTHER|O2 conventional|standard low flow therapy
219594299|NCT01320384|DEVICE|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
219594300|NCT01320384|DEVICE|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
219594301|NCT02248883|DRUG|TPV low|
219594302|NCT02248883|DRUG|Placebo|
219594303|NCT02248883|DRUG|Moxifloxacin|
219594304|NCT02248883|DRUG|TPV high|
219594305|NCT02248883|DRUG|RTV|
219594306|NCT04218734|DRUG|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
219594307|NCT04218734|DRUG|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
219594308|NCT04218734|DRUG|placepo|placebo:100 mg, once daily for 24 weeks.
219594309|NCT00100308|DRUG|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
219594310|NCT00100308|DRUG|saline|Saline placebo
219594311|NCT04032717|DRUG|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
219594312|NCT04032717|OTHER|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
219468333|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
219468334|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
219468335|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
219468336|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
219468337|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
219468338|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
219468339|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
219468340|NCT06924619|RADIATION|neoadjuvant radiotherapy|Target the primary tumor region with 40-50 Gy in 20-25 fractions.
219468341|NCT06924619|DRUG|cisplatin|The cisplatin will be given concurrently with radiotherapy (25 mg/m² , D1, QW) for 4-5 cycles.
219468342|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
219468343|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
219468344|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
219468345|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
219468346|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
219468347|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
219468348|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
219468349|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
219468350|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
219468351|NCT00103831|DRUG|Oral Taxane|
219468352|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
219468353|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
219594313|NCT04327323|DEVICE|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
219594314|NCT00314951|DRUG|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
219594315|NCT00314951|DRUG|Vancomycin|125 mg capsules q6hr (4 times a day)
219594316|NCT00314951|DRUG|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
219594317|NCT05063032|OTHER|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
218855101|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
219594318|NCT03495921|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
219199075|NCT06855901|DEVICE|Ultra-longterm EEG monitoring at home by means of a scubscalp electrode implant.|"Subjects with uncontrolled seizures previously investigated in outpatients epilepsy clinics and for whom an admission to the Epilepsy Monitoring Unit is indicated by clinical practice, will be screened for eligibility.~Implantation of subcutaneous EEG electrodes will be done at each Research Unit by a neurosurgeon/surgeon. The implantation procedure will consist of placing subcutaneously the electrode contacts over the site of the suspected seizure focus as defined by a previous Video-EEG and neuroimaging evaluations. Surgical procedures will be performed under local anesthesia. If the device is well-tolerated, all the subjects will proceed to the extended home monitoring study, which is the core of the study protocol. The aim of the extended study is to assess sensitivity of seizure detection of sqEEG in comparison to subject's home diary, and the tolerability and safety of sqEEG in a period of 6 months."
219468354|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
219468355|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
219468356|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
219468357|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
219468358|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
219468359|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
219199076|NCT06856980|PROCEDURE|Suture button fixation|Patients undergoing suture button fixation of syndesmosis injury.
219468360|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
219468361|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
219199077|NCT06856980|PROCEDURE|Syndesmotic screw fixation|Patients undergoing syndesmotic screw fixation of syndesmosis injury.
219199078|NCT06818578|PROCEDURE|Lesion Sterilization and Tissue Repair Therapy|LSTR treatment is a minimally invasive, cost-effective, and easy-to-apply procedure for necrotic primary teeth, with a focus on disinfection with an antibiotic mixture without the need for root canal instrumentation.
219199079|NCT06818578|DRUG|Different Antibiotic Combinations|Clinical and Radiographic Success of Different Antibiotic Combinations (evaluating whether the alternative 3Mix-MP combination of clindamycin instead of minocycline is as effective as the standard 3Mix-MP formulation) in Lesion Sterilization and Tissue Repair Therapy
219199080|NCT06816888|OTHER|No Prompt|Presence and type of message included in the prompt will be randomized
219199081|NCT06816888|OTHER|Prompt 1|Presence and type of message included in the prompt will be randomized
219468362|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
219468363|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
219468364|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
219468365|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
219468366|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
219468367|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
219468368|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
219468369|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
219468370|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
219468371|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
219468372|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
219468373|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
219468374|NCT02059473|PROCEDURE|Physiotherapy|
219468375|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
219468376|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
219468377|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
219468378|NCT02479594|OTHER|control|control group without competence-feedback
219468379|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
219468380|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
219468381|NCT00014066|DRUG|hematoporphyrin derivative|
219468382|NCT00014066|RADIATION|brachytherapy|
219468383|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
219468384|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
219468385|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
219468386|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
219468387|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
219468388|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
219468389|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
219468390|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
219594319|NCT03495921|DRUG|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
219594320|NCT03495921|DRUG|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
219594321|NCT05320887|OTHER|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
219594322|NCT05320887|OTHER|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
219594323|NCT05320887|OTHER|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
219594324|NCT05320887|OTHER|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
219594325|NCT06457893|OTHER|The health belief model-based exercise training program and health belief model-based education|The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
219594326|NCT06125730|OTHER|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
218855102|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
219594327|NCT02590965|DRUG|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
219594328|NCT02590965|DRUG|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
219594329|NCT06381557|DRUG|Zhengyuan Capsules|Zhengyuan capsules, 4 capsules at a time, 3 times per day;
219594330|NCT06381557|DRUG|Placebo contains 5%-10% Zhengyuan Capsule total mixed powder|Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
218855103|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
219199082|NCT06816888|OTHER|Prompt 2|Presence and type of message included in the prompt will be randomized
219468391|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
219468392|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
219468393|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
219468394|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
219468395|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
219199083|NCT06818890|DEVICE|Definitive abutment base|Definite abutment base, this is a two-piece definitive abutment where the base is connected to the implant as soon as it is placed.This abutment will allow the tissues around the implant to heal undisturbed, thus, establishing a good and healthy periimplant soft and hard tissue with long-term stability.
219199084|NCT06818890|DEVICE|Conventional Healing Abutment|A healing abutment of different diameters (4.3, 5, 6 mm) and heights (1.5, 3 mm) is placed on the day of the surgery, and the flaps are sutured around them to allow for tissue healing around the abutment to create an optimum emergence profile and tissue cuff around the implant and definitive abutment.
219199085|NCT06855615|DRUG|Mixtard® 30 TDS|The clinical use of TDS premixed human insulin (PHI) is unclear. In contrast, biphasic insulin analogue given thrice daily is a well-proven, safe and suitable alternative to an intensified insulin regimen.
219199086|NCT06855615|DRUG|Insulatard® once daily and thrice daily prandial Actrapid®|Basal bolus regimen is considered a physiological form of treatment and the standard of care in clinical practice but the multiple daily injections often lead to poor compliance.
219199087|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
219199088|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
219199089|NCT06659861|OTHER|RV3278B-OS0386|Cosmetic product to be applied twice a day on the face during the whole study
219199090|NCT06659861|OTHER|RV4632A-RY1845|Cosmetic product to be applied in the event of facial skin discomfort only
219199091|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
219199092|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
219199093|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
219199094|NCT06662682|OTHER|Control Condition|Non-intervention control condition
219594331|NCT05717465|OTHER|Anatomy diagrams|"The visual aids used included:~* An anatomical diagram illustrating how a lumbar puncture is carried out~* Paling palette, diagram illustrating the number of individuals affected by a particular condition~* Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks"
219594332|NCT05717465|OTHER|Standard informed consent|Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
219594333|NCT00904657|DRUG|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
219199095|NCT06663813|BEHAVIORAL|Educational Intervention|Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
219594334|NCT03446807|DRUG|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
219594335|NCT03446807|DRUG|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
219468396|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
219468397|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
219468398|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
219468399|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
219199096|NCT06662019|DRUG|N-IP-00001 inhalation solution|Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
219199097|NCT06662019|DRUG|0.9% NaCl isotonic saline solution|Nebulized treatment consisting of 0.9% saline solution.
219199098|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
219199099|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
219199100|NCT06777745|OTHER|Model-assisted breast examination application|Designed for the development of self-examination skills, this model is in the shape of a female upper body with medium-sized breasts. Thanks to its ergonomic design, it can be worn easily and offers a comfortable use. Made of high quality, dermatologically tested and tactile silicone material. This model, which reflects all the details of the skin realistically, has a structure suitable for standing and lying examination. For educational use, there are 2 benign tumours, 4 malignant tumours and 2 typical anomalies. This model allows for practical explanation of all stages of breast examination such as determining the area to be examined, manual examination of the area, examination method, nipple examination and detection of malignant formations in the breast.
219199101|NCT04214834|DRUG|Morphine|The dose interval for morphine will be either every 3 or 4 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
219199102|NCT04214834|DRUG|Methadone|The dose interval for methadone will be every 8 or 12 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
219199103|NCT03349801|OTHER|No intervention|According to clinical practice.
218855104|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
218855105|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
218855106|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
218855107|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
219199104|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
219199105|NCT06498388|OTHER|Stiffness measurement by visco-elastography|Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
219199106|NCT05464251|OTHER|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
219199107|NCT03901534|DEVICE|Continuous positive airway pressure (CPAP) therapy|Standard, clinically used CPAP therapy. CPAP will be prescribed by the participants' clinician provider and not by the study investigators.
219199108|NCT03901534|DEVICE|Nox A1 Recorder|Non-invasive, body-worn, sleep recording device for nocturnal polysomnography.
219199109|NCT05161819|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
219199110|NCT05161819|DEVICE|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
219468400|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
219468401|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
219468402|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
219468403|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
219468404|NCT01334502|BIOLOGICAL|rituximab|PO
219468405|NCT01334502|DRUG|cyclophosphamide|IV
219468406|NCT01334502|DRUG|doxorubicin hydrochloride|IV
219468407|NCT01334502|DRUG|everolimus|PO
219468408|NCT01334502|DRUG|prednisone|PO
219468409|NCT01334502|DRUG|vincristine sulfate|IV
218855108|NCT04092907|DRUG|placebo|Ophthalmic Solution
218855109|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
218855110|NCT01161550|DRUG|Cladribine|
219468410|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
219468411|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
219468412|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
219594336|NCT03247179|OTHER|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
219594337|NCT03281759|DEVICE|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
219594338|NCT03281759|DEVICE|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
219594339|NCT00599053|DRUG|Azithromycin|10 mg/kg IV per dose given for 10 days
219594340|NCT00381433|DRUG|AVI-4065 Injection|
219594341|NCT02734407|PROCEDURE|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
219199111|NCT03327714|BEHAVIORAL|Mindfulness and compassion|
219199112|NCT06814769|DEVICE|hyaluronic acid|intra-articular administration
219199113|NCT06407739|OTHER|Three-Phase Physical Therapy Intervention|Phase 1: It include subtalar and talocrural joint mobilization in the supine position along with stretching and home education Stage 2: It include subtalar and talocrural joint mobilization in the supine position along with Kinesiotaping and functional exercises Phase 3: this phase include balance and propioceptive training aling with along with strengthening exercises of peroneal and tibialis anterior
219199114|NCT05659147|DIAGNOSTIC_TEST|Research MRI without administration of intravenous secretin|Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
219199115|NCT05659147|DIAGNOSTIC_TEST|Research MRI with administration of intravenous secretin|Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
219594342|NCT02734407|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
219594343|NCT05309018|OTHER|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
219594344|NCT00271401|OTHER|Angioplasty|
219594345|NCT00271401|OTHER|Intracoronary Stent|
219594346|NCT00271401|DRUG|Abxicimab|
219594347|NCT00271401|DRUG|Heparin|
219594348|NCT00271401|DRUG|Placebo|
219594349|NCT05567510|DRUG|BMS-986369|Specified dose on specified days
219594350|NCT02015065|DRUG|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
219594351|NCT00014352|DRUG|docetaxel|
219594352|NCT00014352|DRUG|doxorubicin hydrochloride|
219594353|NCT00014352|DRUG|estramustine phosphate sodium|
218855111|NCT01161550|DRUG|Cytarabine|
219594354|NCT00014352|DRUG|ketoconazole|
219594355|NCT00014352|DRUG|warfarin|
219594356|NCT01120704|DRUG|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes \>10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
219594357|NCT01120704|DRUG|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes \>10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
219594358|NCT01120704|BEHAVIORAL|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
218855112|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
219468413|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
218855113|NCT01161550|DRUG|Midostaurin|
218855114|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
218855115|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
218855116|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
218855117|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
218855118|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
218855119|NCT01617135|DRUG|CVT-301|
219468414|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
219468415|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
218855120|NCT01617135|DRUG|Placebo|
218855121|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
218855122|NCT01617135|DRUG|CVT-301|
218855123|NCT02466074|DRUG|Acetazolamide|see arm description
218855124|NCT02466074|DRUG|Placebo|Placebo arm
218855125|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
218855126|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
218855127|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
218855128|NCT00325676|DRUG|Pantoprazole|
218855129|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
218855130|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
219468416|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
219468417|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
219468418|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
219594359|NCT01120704|BEHAVIORAL|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
219594360|NCT01120704|BEHAVIORAL|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
218855131|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
218855132|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
218855133|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
218855134|NCT00299780|DRUG|Stem cell mobilization|
218855135|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
218855136|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
218855137|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
219468419|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
219468420|NCT00004808|DRUG|fluconazole|
218855138|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
219468421|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
219468422|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
219468423|NCT01520038|RADIATION|Proton therapy|
219468424|NCT01520038|RADIATION|IMRT|
218855139|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
218855140|NCT02087813|DRUG|Alpha1-antitrypsin|
219199116|NCT05659147|GENETIC|Genetic Sequencing|Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
218855141|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
218855142|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
218855143|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
218855144|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
218855145|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
218855146|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
218855147|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
218855148|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
218855149|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
219199117|NCT05659147|DIAGNOSTIC_TEST|Blood Tests|Research blood draw (for markers of pancreatic endocrine insufficiency)
219199118|NCT05659147|DIAGNOSTIC_TEST|Stool Tests|Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
219199119|NCT05659147|OTHER|Survey Completion|Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
219199120|NCT05659147|DIAGNOSTIC_TEST|Endoscopic pancreatic function tests (ePFTs)|At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
219468425|NCT04924608|DRUG|Selumetinib|Selumetinib oral capsules (10 mg and 25 mg)
219468426|NCT04924608|OTHER|Placebo|Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
219468427|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
219468428|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
219468429|NCT03389633|OTHER|rehabilitation|
219468430|NCT00021554|DRUG|Enfuvirtide|
219468431|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
219468432|NCT01890876|OTHER|Walking uphill|ascending about 500 m
219468433|NCT01890876|OTHER|Walking downhill|descending about 500 m
219468434|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
219468435|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
219468436|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
219468437|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
219468438|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
219199121|NCT05659147|DRUG|Secretin|"Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study."
219199122|NCT06258707|DEVICE|LuxBoost IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
219468439|NCT00043134|DRUG|decitabine|
219468440|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
218855150|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
218855151|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
218855152|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
218855153|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
218855154|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
218855155|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
219199123|NCT06258707|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
219468441|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
219468442|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
219468443|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
219468444|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
219468445|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
219468446|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
219468447|NCT00002110|DRUG|Cysteamine|
219468448|NCT00002110|DRUG|Zidovudine|
219468449|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
219468450|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
219468451|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
219468452|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
219468453|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
219468454|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
219468455|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
219468456|NCT00346775|DRUG|Flunisolide|Flunisolide
219468457|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
219468458|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
218855156|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
219199124|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
219199125|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
219199126|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
219468459|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
219468460|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
219468461|NCT00811499|DRUG|Placebo; oral|matching placebo
219468462|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
219468463|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
219468464|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
219468465|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
219468466|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
219199127|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
219199128|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
219199129|NCT06823154|DRUG|Amoxicillin|Prospective cohort study of patients presenting to the ED with a reported BLA. (1) Allergy history and risk assessment, (2) Oral provocation challenge (if eligible), and (3) Post-discharge follow-up (if received OPC or referred to allergy).
219199130|NCT06823154|OTHER|Study questionnaire|"In the first component of the study, research staff will survey patients for history pertinent to their BLA label. This includes questions regarding any prior evaluations, patients' perception of their allergy label, and clinical details of allergy history. The latter involves an allergy history risk assessment, which will screen patient for high-risk features (eg, new maculopapular rash within 2 hours of administering antibiotic). Presence of any high-risk features will disqualify the patient from subsequent study components.~Finally, the questionnaire will screen for presence of any clinical confounders that would preclude administration of the OPC (eg, use of antihistamines within prior 72 hours)."
219199131|NCT06819267|OTHER|Horizontal Plyometric Group|"Group A~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Horizontal ankle jumps\| Long jumps \| Diagonal obstacle jumps~* Intensity: Moderate to high."
219199132|NCT06819267|OTHER|Vertical Plyometric Group|"Group B~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Vertical ankle jumps~* Counter movement jump~* Front obstacle jumps"
219199133|NCT06826040|DRUG|SKB445 for injection|SKB445 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
219468467|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
219468468|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
219468469|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
219468470|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
219468471|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
219468472|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
219199134|NCT06825767|DEVICE|Conventional Treatment|Conventional treatment including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg for 4 weeks, 3 days a week for 4 weeks in 24 patients
219199135|NCT06825767|DEVICE|conventional treatment and high-intensity laser therapy(HILT)|Conventional treatment and HILT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and HILT for 4 weeks, 3 days a week for 4 weeks in 24 patients .
219199136|NCT06825767|DEVICE|conventional treatment and low-intensity laser therapy (LLLT)|Conventional treatment and LLLT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and LLLT for 4 weeks, 3 days a week for 4 weeks in 24 patients.
219199137|NCT06825104|DEVICE|Volta AF-Xplorer|Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms
219199138|NCT06825104|PROCEDURE|Dispersion ablation + PVI|TAILORED-AF index procedure: Dispersion ablation + PVI
219199139|NCT06825104|PROCEDURE|PVI|TAILORED-AF index procedure: PVI only
219199140|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 50%-60% of maximal oxygen uptake (VO2max).
219468473|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
219468474|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
219468475|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
219468476|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
219468477|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
219468478|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
219468479|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
219468480|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
219594361|NCT01120704|BEHAVIORAL|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23."
219468481|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
219468482|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
219468483|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
219594362|NCT05810584|DEVICE|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
219594363|NCT02675569|PROCEDURE|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
219199141|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 70 - 80% of maximal oxygen uptake (VO2max).
219199526|NCT06684288|PROCEDURE|Access flap surgery|Granulation tissue attached to the alveolar bone was excised to ensure complete access and optimal visibility of the root surfaces. In addition, instrumentation was performed using a combination of ultrasonic and hand instruments, and no alveolar bone modification was undertaken during the flap procedure. Subsequently, the mucoperiosteal flap was repositioned and primarily closed with proximal simple sutures employing monofilament suture material (5/0 Propilen, Dogsan, Türkiye). Patients were given post-operative recommendations; however, no medication was prescribed.
219468484|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
219468485|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
219468486|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
219468487|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
219468488|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
219468489|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
219468490|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
219468491|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
219468492|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
219468493|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
219468494|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
219468495|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
219468496|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
219468497|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
218855157|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
219468498|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
219468499|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
219468500|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
219468501|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
219468502|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
219468503|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
219468504|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
219468505|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
219468506|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
219468507|NCT03157804|DRUG|Plerixafor|Given SC
219468508|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
219468509|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
219468510|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
219468511|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
219468512|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
219468513|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
219468514|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
219468515|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
218855158|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
218855159|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
218855160|NCT04627675|DRUG|IL-12 plasmid|cytokine
218855161|NCT04627675|DEVICE|Cliniporator|electroporation system
219468516|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
219468517|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
219468518|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
219468519|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
219468520|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
219468521|NCT04717310|DRUG|Vehicle|Twice a day (BID)
218855162|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
218855163|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
219468522|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
219468523|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
219468524|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
219468525|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
218855164|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
218855165|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
218855166|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
218855167|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
218855168|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
218855169|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
218855170|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
219199527|NCT02781883|DRUG|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
219468526|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
219468527|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
219468528|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
219468529|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
219468530|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
219468531|NCT05725642|OTHER|Polysomnography|Polysomnography
219468532|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
219468533|NCT02501642|OTHER|Treatment as usual|Treatment as usual
219468534|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
219468535|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
219468536|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
219468537|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
219468538|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
218855171|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
218855172|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
218855173|NCT02796885|OTHER|no intervention - observational study|
218855174|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
218855175|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
218855176|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
218855177|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
218855178|NCT01696344|PROCEDURE|PVAI|
219199528|NCT02781883|DRUG|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
219468539|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
219468540|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
219468541|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
219468542|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
219468543|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
218855179|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
218855180|NCT00042068|DRUG|Meloxicam|
218855181|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
218855182|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
218855183|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
218855184|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
218855185|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
218855186|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
218855187|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
219468544|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
219468545|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
219468546|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
219468547|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
219468548|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
219468549|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
219468550|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
219468551|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
219468552|NCT02027766|OTHER|Calf muscle stretching|
219468553|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
219468554|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
218855188|NCT02662153|OTHER|Observation only|No intervention.
218855189|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
218855190|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
218855191|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
218855192|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
218855193|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
219199529|NCT06681987|BEHAVIORAL|simulation training|One group of students will practice computer-based simulation for pre-eclampsia and eclampsia case management skills using a high-fidelity simulator (n = 15) (subgroups n=3), while the other group will practice with a low-fidelity model (n = 15; subgroups n=3). In the first stage, the case will be written for the high-fidelity simulator and will be submitted to the opinions of experts in the field. After the necessary arrangements are made, the groups will be randomized and allocated. In the second stage, the experimental group will be presented with a virtual reality simulator, and the control group will be presented with a case example of preeclampsia and eclampsia with a low-level simulator. In order to evaluate and increase the teamwork skills of the students in the experimental and control groups, the students will be divided into subgroups of three.
218855194|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
219468555|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
219468556|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
219468557|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
219468558|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
219468559|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
219468560|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
219468561|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
219468562|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
219468563|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
219468564|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
219468565|NCT03580746|PROCEDURE|Taping and posteromedial release|
219468566|NCT03580746|PROCEDURE|Ponseti|
219468567|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
219468568|NCT01358266|DRUG|DE-109 44 ug|Low dose
219468569|NCT01358266|DRUG|DE-109 440 ug|Medium dose
219468570|NCT01358266|DRUG|DE-109 880 ug|High dose
218855195|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
218855196|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
219468571|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
219468572|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
219468573|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
219468574|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
218855197|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
218855198|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
218855199|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
219468575|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
219468576|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
219468577|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
218855200|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
218855201|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
218855202|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
218855203|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
219199142|NCT06662435|BEHAVIORAL|GYNCOG|"Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours."
219468578|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
219199143|NCT06663072|DRUG|Fulvestrant|"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."
219199144|NCT06663072|DRUG|177Lu-DOTATATE|"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."
219199145|NCT06824324|DRUG|intramuscular Botulinum Toxin|A thirty units of Botulinum toxin A was injected intramuscularly in Triger zone of patient with myofascial pain syndrome
219199146|NCT06825949|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
219199147|NCT06825936|OTHER|Diet intervention|For participants assigned to the intervention arm, the dietary intervention consists of: a) pre-cooked Asian-Mediterranean meals: participants will receive free meals, two meals a day, five days a week, and b) pre-packed nuts, 30g a day, five days a week, during the intervention period. Additionally, participants will receive a dietary consultation session at baseline and every four weeks.
219199148|NCT06825936|OTHER|Control|For participants assigned to the control arm, they will receive a leaflet with dietary advice based on national guidelines at baseline.
219199149|NCT06825819|BIOLOGICAL|Subjects with and without Long COVID|To collect biospecimens (matched stool \& blood) samples from 400 people with and without long COVID (200 participants/group) to understand how COVID-induced dysbiosis impacts symptom severity, immune suppression, and gut barrier dysfunction both ex vivo and in vitro.
219468579|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
219468580|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
219468581|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
219468582|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
219594364|NCT02675569|PROCEDURE|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
219594365|NCT05141617|PROCEDURE|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
219594366|NCT05141617|PROCEDURE|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
219594367|NCT01061268|DRUG|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
219594368|NCT01061268|DRUG|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
219594369|NCT00755443|DEVICE|Drug eluting stent|Drug eluting stent implantation
219594370|NCT00755443|DEVICE|Bare metal stent|
219594371|NCT00109408|DRUG|Methotrexate|7.5-20mg po weekly
219594372|NCT00109408|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
219594373|NCT06012461|OTHER|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
219594374|NCT06012461|OTHER|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
219594375|NCT06012461|OTHER|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
219594376|NCT06012461|OTHER|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
219594377|NCT03485365|DRUG|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
218855204|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
218855205|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
219594378|NCT03485365|DRUG|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
219594379|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
219594380|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
219594381|NCT02361242|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
219594382|NCT00486941|BEHAVIORAL|Exercise and diet - based on DPS and DPP|
219594383|NCT04159870|DRUG|Rifaximin|Rifaximin pills 400 mg x 3/day
219594384|NCT04159870|DRUG|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
219594385|NCT06043687|DRUG|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
219594386|NCT00339092|BEHAVIORAL|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
219468583|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
219468584|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
219468585|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
219468586|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
219468587|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
219468588|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
219468589|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
219468590|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
219468591|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
219199150|NCT06825858|DRUG|KH658|KH658: AAV vector containing a coding sequence for an anti-VEGF protein
219199151|NCT06824779|DRUG|Flu Vaccine|Vaccination against FLU by one of FLU vaccines in the french market
219199152|NCT06824779|BIOLOGICAL|Biological samples|"Before and after the FLU vaccination, according the french recommendations, the following samples will be collected :~Nasal fluid sampling Saliva sampling Blood samples Nasal cell sampling"
219199153|NCT06823999|DRUG|Ascorbic acid (Vitamin C)|In the study, acute ischemic stroke patients will receiving vitamin C 4 gram perday for 4 days.
219199154|NCT06823999|OTHER|Normal Saline (Placebo)|Particiapnts receiving normal saline 20 ml perday for 4 days
219199155|NCT06665724|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Patients will receive 5-Aminolevulinic acid hydrochloride via oral administration (20 mg/kg) 6-8 hours before CV01 treatment.
219199156|NCT06665724|DEVICE|CV01|Ultrasound will be delivered 6-8 hours after administration of 5-aminolevulinic acid hydrochloride. A total of 12 fields will be treated (10 treatment sites across the hemisphere with 2 additional treatments over areas of increased enhancement).
219199157|NCT06664827|DEVICE|Delfi PTS Blood Flow Restriction Tourniquet System|In Houston Methodist rehabilitation clinics these devices are used as standard of care for BFR therapy in many post-operative treatments. General guidelines suggest using ranges between 30% - 80% of limb occlusion pressure (LOP). In our previous research efforts involving BFR the investigators have adhered to these guidelines and experienced no adverse events while observing these ranges to be well tolerated by subjects.
219468592|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
219199158|NCT05189236|PROCEDURE|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
219468593|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
219468594|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
219594387|NCT00339092|BEHAVIORAL|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
218855206|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
219468595|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
219468596|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
219468597|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
219468598|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
219468599|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
219468600|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
219468601|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
219468602|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
219468603|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
219468604|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
219468605|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
219468606|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
219468607|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
218855207|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
218855208|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
219199159|NCT05189236|PROCEDURE|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
219199530|NCT06684028|DRUG|68Ga-FAPI-JNU|Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
219468608|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
219468609|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
219468610|NCT02151565|DEVICE|HTEMS|
219468611|NCT02151565|DEVICE|TENS|
219468612|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
219468613|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
219468614|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
219468615|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
219468616|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
219468617|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
219468618|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
219468619|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
219468620|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
219468621|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
219468622|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
219468623|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
219468624|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
219468625|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
219468626|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
219199160|NCT06824636|OTHER|a personalized diet plan was prepared according to the calculated requirements of each patient by two expert dietitians|Oral enteral nutrition products were added to the diet if the daily calorie and/or protein requirements could not be met by the diet. All of the patients underwent follow-up visits (4th and 8th weeks) after the initial assessment on admission. Each visit (0, 4th and 8th weeks) included screening of the nutritional status and food consumption, and measurements of body mass index (BMI), muscle mass, muscle strength, gait speed, serum albumin and serum C-reactive protein (CRP). Anthropometric measurements, muscle strength, physical performance, and the physical exercise plan were assessed.
219199161|NCT06665737|DRUG|Early receiving G-CSF group|Early receiving G-CSF group will be given within 72 hours post chemotherapy
219199162|NCT06665737|DRUG|Late receiving G-CSF group|Late receiving G-CSF group will be given after 72 hours post chemotherapy
218855209|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
218855210|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
218855211|NCT06193408|DRUG|VR-AD-1005|oral capsule
218855212|NCT06193408|DRUG|Placebo|oral capsule
218855213|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
219468627|NCT03276858|DRUG|CRN00808|Investigational drug
219468628|NCT03276858|DRUG|Placebo Oral Solution|Placebo
219468629|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
219199163|NCT06826183|DEVICE|REVEAL Linq device|Implantable loop recorder
219199164|NCT06825611|DEVICE|Momentum Application|A mobile application to scan and predict spinal curvature. The application monitors curvature and track changes over time.
219199165|NCT06825728|DRUG|Different doses of Metoprolol.|The control group received 23.75mg/d of metoprolol, and the experimental group received the maximum tolerable dose of metoprolol.
219199166|NCT06824298|OTHER|TENS|"Before surgery: The socio-demographic data of the patients will be recorded. During surgery: After patients are taken to the operating room and anesthesia is induced, TENS electrodes will be attached to the paravertebral muscles at the level of Lumbar vertebrae 2, 3 and Sacral Vertebrae 2, 3. After the surgery is completed, TENS will be activated before the patient is woken up.~TENS settings: In modulation type, medium intensity contractions will be given at a frequency ranging from 60-80 Hertz to 1-5 Hertz, with a current rate ranging from 50-100 microseconds to 150-200 microseconds.~After surgery: TENS will continue to be applied to patients in the recovery room for 30 minutes after the surgery. Patients will be evaluated by researchers in terms of pain and comfort associated with bladder tenesmus at 0, 15 and 30 minutes in the recovery room and at 6, 12 and 24 hours in the postoperative ward."
219199167|NCT05008172|PROCEDURE|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
218855214|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219199168|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
219468630|NCT03276858|DRUG|Placebo oral capsule|Placebo
219468631|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
219468632|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
219468633|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
219468634|NCT01756586|DRUG|Dexamethasone|
219468635|NCT01756586|DRUG|Bupivacaine|Control
219468636|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
219468637|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
219468638|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
219468639|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
219468640|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
219468641|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
219468642|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
219468643|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
219468644|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
219468645|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
219468646|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
219468647|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
219199169|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group B: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15)+Carboplatin (AUC=5, d 1 )+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
219199170|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group C： Albumin-bound paclitaxe (260 mg/m²,d 1, 6 cycles)+Carboplatin (AUC=5,d 1, 6 cycles)+Camrelizumab (200 mg, , d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
219199171|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group D: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15,6 cycles)+Carboplatin (AUC=5, d 1, 6 cycles)+Camrelizumab (200 mg, d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
219199172|NCT06818942|OTHER|Observations on preoperative and intraoperative factors influencing the difficulty of surgery|Age, body mass index, gender, inflammatory indicators, previous history of abdominal surgery, underlying disease
219199173|NCT06267716|PROCEDURE|PENG block|preoperative ultrasound-guided pericapsular nerve group block
219199174|NCT06267716|PROCEDURE|IPB|preoperative ultrasound-guided iliopsoas plane block
219468648|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
219468649|NCT05116410|DRUG|HS-20094|Administrated SC
219468650|NCT05116410|DRUG|Placebo|Administrated SC
219468651|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
219199175|NCT06818500|OTHER|high-fat meal|Participants will report fasted and consume two Jimmy Dean breakfast bowls (sausage).
219199176|NCT06818500|OTHER|Stress|Participants will report fasted and undergo a mental stress task.
219199177|NCT03370913|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
219468652|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
219468653|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
219468654|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
219468655|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
219468656|NCT02477319|OTHER|Observational|
219468657|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
219468658|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
219468659|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
219468660|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
219468661|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
219468662|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
219468663|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
219468664|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
219468665|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
219468666|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
219468667|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
219468668|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
219468669|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
219468670|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
219468671|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
219468672|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
219468673|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
219468674|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
219468675|NCT01710007|DRUG|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
219468676|NCT01710007|DRUG|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
219468677|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
219468678|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
219468679|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
219468680|NCT01153971|DRUG|rituximab|1
219199178|NCT04616924|DRUG|RHB-204|RHB-204
219199179|NCT04616924|DRUG|Placebo|Matching placebo to RHB-204
219199180|NCT06825962|OTHER|Water intake|Water ingested to fully replace sweat losses during exercise.
219199181|NCT06825962|OTHER|Water restriction|Water restriction to induce hypohydration of \~3% body mass through sweat losses during exercise.
218855215|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
218855216|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
219468681|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
219468682|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
219468683|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
219468684|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
219468685|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
219468686|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
219468687|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
219468688|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
219468689|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
219468690|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
219468691|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219468692|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
219468693|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
219468694|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
219468695|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
219468696|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
219468697|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
219468698|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
219468699|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
219468700|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
219468701|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
219468702|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
219468703|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
219468704|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
218855217|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
218855218|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
218855219|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
218855220|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
218855221|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
218855222|NCT00624780|DRUG|Placebo|Placebo
218855223|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
218855224|NCT05960305|OTHER|P1213416|Tobacco Flavor
218855225|NCT05960305|OTHER|P1213422|Tobacco Flavor
218855226|NCT05960305|OTHER|P1213716|Tobacco Flavor
218855227|NCT05960305|OTHER|P1213722|Tobacco Flavor
218855228|NCT05960305|OTHER|P1211216|Menthol Flavor
218855229|NCT05960305|OTHER|P1211222|Menthol Flavor
218855230|NCT05960305|OTHER|P1213616|Menthol Flavor
219468705|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
219468706|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
219468707|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
219468708|NCT00953576|DRUG|ketoconazole|
219468709|NCT00953576|DRUG|hydrocortisone|
219468710|NCT00953576|DRUG|dutasteride|
219468711|NCT00953576|DRUG|lapatinib|
219468712|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
219468713|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
219468714|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
219468715|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
219468716|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
219468717|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
219468718|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
219594388|NCT05147324|BEHAVIORAL|"MyPlan - Individualized Planned Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
219594389|NCT03975231|DRUG|Dabrafenib|Given PO
219594390|NCT03975231|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219594391|NCT03975231|DRUG|Trametinib|Given PO
219594392|NCT04204473|DRUG|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
219594393|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|Online rehabilitation program.
219594394|NCT06050343|DRUG|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
219594395|NCT06050343|DRUG|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
219594396|NCT01547130|DRUG|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
219468719|NCT02822729|DRUG|DE-117 ophthalmic solution|
219468720|NCT02822729|DRUG|Timolol ophthalmic solution|
219468721|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
219594397|NCT01547130|DRUG|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
219594398|NCT01324505|DRUG|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
219594399|NCT01324505|DRUG|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
219594400|NCT01324505|DRUG|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
219594401|NCT05369312|DRUG|BPI-442096|Subjects will receive BPI-442096 until disease progression
219594402|NCT02965586|DRUG|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
219468722|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
219468723|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
219468724|NCT02122874|OTHER|1200 Kcal diet|
219468725|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
219468726|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
219468727|NCT04149366|DEVICE|Retainer|Orthodontic retainer
219468728|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
219468729|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
219468730|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
219468731|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
219468732|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
219468733|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
219468734|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
219468735|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
219468736|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
219468737|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
219468738|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
219594403|NCT05924607|OTHER|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
219594404|NCT05924607|OTHER|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
218855231|NCT05960305|OTHER|P1213622|Menthol Flavor
219468739|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
219468740|NCT02681991|DRUG|Renamezin capsule|
219468741|NCT02557191|OTHER|Observational study|
219594405|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
219594406|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
218855232|NCT05960305|OTHER|P1213816|NTNM Flavor
218855233|NCT05960305|OTHER|P1213822|NTNM Flavor
218855234|NCT05960305|OTHER|P1211916|NTNM Flavor
218855235|NCT05960305|OTHER|P1211922|NTNM Flavor
218855236|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
218855237|NCT02124512|OTHER|Placebo|80 mg placebo once daily
219468742|NCT05665257|DEVICE|Inspiratory muscle training|
219468743|NCT05665257|DEVICE|Mini-PEP|
219468744|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
219468745|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
219468746|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
219468747|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
219468748|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
219468749|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
219468750|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
219468751|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
219468752|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
219468753|NCT00475839|DEVICE|Tension-free Vaginal Tape|
219468754|NCT00475839|DEVICE|Monarc sub-fascial hammock|
219468755|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
219468756|NCT00594334|DRUG|Risedronate|Weekly Risedronate
219594407|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
219594408|NCT05738044|OTHER|No intervention|No intervention
219594409|NCT03486366|OTHER|non interventional trial|other
219594410|NCT02508129|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
218855238|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
218855239|NCT01735669|DRUG|Remifentanil|
218855240|NCT01735669|DRUG|Nitrous Oxide|
218855241|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
218855242|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
218855243|NCT00792662|DRUG|Placebo|Standard inactive pill.
218855244|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
218855245|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
219468757|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
219468758|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
219468759|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
219468760|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
219468761|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
219468762|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
219468763|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
218855246|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
218855247|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
218855248|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
218855249|NCT00097162|PROCEDURE|Anodal stimulation|
218855250|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
218855251|NCT02361424|DRUG|placebo|
218855252|NCT01760538|BEHAVIORAL|Exercise training|exercise training
218855253|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
218855254|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
218855255|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
218855256|NCT00152711|DEVICE|nCPAP|
218855257|NCT00464061|DRUG|Volinanserin|oral administration
218855258|NCT00464061|DRUG|Placebo|oral administration
218855259|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
218855260|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
218855261|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
219199182|NCT06825676|BEHAVIORAL|CKD Patient Management Based on Guidelines|"1. Lifestyle Education: smoking cessation, physical activity, healthy eating, and weight management.~2. Pharmacological Treatment: Implement targeted and guideline-based pharmacological treatment plans for patients with different comorbidities, such as the use of RAAS inhibitors (RASi), SGLT2 inhibitors, statins, and other medications.~3. Risk Factor Management: Effectively manage risk factors such as hypertension, diabetes, and dyslipidemia, and regularly reassess these factors.~4. Risk Assessment: Perform risk assessments for CKD patients based on eGFR and UACR, and implement graded management according to the results.~4、Referral Management: Refer patients with eGFR \< 30 ml/min/1.73m² or severe proteinuria.~5、CKD Patient Management Checklist: Community doctors should complete the CKD patient management checklist in a standardized manner, including records of risk factors, dynamic kidney function, and follow-up plans."
219468764|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
219468765|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
219468766|NCT05620186|OTHER|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
219468767|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
219468768|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
219468769|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
219468770|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
219468771|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
219468772|NCT02062541|OTHER|usual assessment+fast rehabilitation|
219468773|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
219468774|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
219468775|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
219468776|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
219468777|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
219468778|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
219468779|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
219468780|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
219468781|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
219468782|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
219468783|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
219468784|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
218855262|NCT04202224|DRUG|Glucose|Placebo.
218855263|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
218855264|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
218855265|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
218855266|NCT02362516|DRUG|BI 425809|
218855267|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
219468785|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
219468786|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
219468787|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
219468788|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
219468789|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
219468790|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
219468791|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
219468792|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
219594411|NCT02508129|BEHAVIORAL|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
219594412|NCT02508129|BEHAVIORAL|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
219594413|NCT02018575|DIETARY_SUPPLEMENT|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
218855268|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
218855269|NCT04811443|DRUG|Empegfilgrastim|Extimia®
218855270|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
218855271|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
218855272|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
218855273|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
218855274|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
218855275|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
218855276|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
218855277|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
219199183|NCT05521477|DIETARY_SUPPLEMENT|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
219468793|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
219468794|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
219468795|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
219468796|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
219468797|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
219468798|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
219468799|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
219594414|NCT02018575|DIETARY_SUPPLEMENT|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
218855278|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
219594415|NCT06126341|OTHER|Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM|Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
219594416|NCT06126341|BEHAVIORAL|Hospital Anxiety and Depression Scale|Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
218855279|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
218855280|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
218855281|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
219468800|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
219468801|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
219468802|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
219468803|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
219468804|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
219594417|NCT06126341|BEHAVIORAL|Duke-UNC Functional Social Support Questionnaire|A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
219594418|NCT06126341|BEHAVIORAL|Distress Thermometer|The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
219594419|NCT06126341|BEHAVIORAL|FACT-BMT|The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
219594420|NCT06126341|BEHAVIORAL|Psychosocial Assessments of Candidates for Transplantation|The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
218855282|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
218855283|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
218855284|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
218855285|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
218855286|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
218855287|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
218855288|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
219468805|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
219468806|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
219468807|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
219468808|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
219594421|NCT04384653|DRUG|Furosemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution for subcutaneous administration (80 mg)
219594422|NCT04384653|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
219594423|NCT04384653|DEVICE|Medfusion 3500 (v6) precision infusion pump|Furosemide Injection Solution for subcutaneous administration (80 mg)
219594424|NCT06977867|DEVICE|Stress Ball|All hemodialysis patients who meet the inclusion criteria will be asked to squeeze a stress ball during their dialysis sessions (3 times a week for 1 month, totaling 12 sessions). Anxiety, comfort, and patient satisfaction levels will be assessed using three measurements: a pre-test before the intervention, a mid-test at the end of the 6th session (2nd week), and a post-test after the 12th session. Patients will be instructed to use the stress ball throughout their dialysis session. They will be asked to squeeze the ball for at least 10-15 minutes during each session.
219020383|NCT06940830|DRUG|Efanesoctocog alfa|Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.
219468809|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
219468810|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
219468811|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
219594425|NCT06977867|OTHER|standard care|The hemodialysis patients in the control group will not use the stress ball and will receive standard care throughout the study period. Similar to the intervention group, levels of anxiety, comfort, and patient satisfaction will be assessed at three time points: prior to the intervention (pre-test), at the end of the second week (after the 6th session), and at the end of the fourth week (post-test, after the 12th session).
219594426|NCT06983444|PROCEDURE|TURP|Using bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH.
219468812|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
219468813|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
219468814|NCT03418025|OTHER|Survey Administration|Ancillary studies
219468815|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
219468816|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
219468817|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
219468818|NCT00207025|DRUG|BMS-275183|
219468819|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
219468820|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
219468821|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
219468822|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
219468823|NCT02726516|OTHER|Placebo|1 sachet per day
219468824|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
219468825|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
219468826|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
219468827|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
219468828|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
219468829|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
219468830|NCT03333564|OTHER|Control|No intervention was given
219468831|NCT00211575|BEHAVIORAL|Disease Management Assessment|
219468832|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
219468833|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
219468834|NCT02231606|OTHER|Free Glasses|Provide free glasses
219468835|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
219468836|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
219468837|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
219468838|NCT03964896|OTHER|Survey|Complete survey
219468839|NCT03964896|OTHER|Survey Administration|Ancillary studies
219468840|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
219468841|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
219468842|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
219468843|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
219468844|NCT02550418|DRUG|Budesonide|
219468845|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
219468846|NCT04964076|OTHER|No intervention|No intervention
219468847|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
219468848|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
219468849|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
219468850|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
219468851|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
219468852|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
219468853|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
219468854|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
219468855|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
219468856|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
219468857|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
219594427|NCT06983444|PROCEDURE|TUEP|Using bipolar enucleation loop diathermy via cystoscopy, to anatomically enucleate prostate.
219594428|NCT06983457|COMBINATION_PRODUCT|Therapeutic ultrasound|Participants in Group A will receive therapeutic ultrasound (TUS) as the primary intervention for managing chronic heel spur pain. The TUS treatment will be administered using a frequency of 1 MHz, which is effective for targeting deeper tissues. The intensity will range from 0.8 to 2.0 W/cm², depending on patient tolerance, and will be applied in a continuous mode to maximize thermal effects. Each treatment session will last for 4 minutes, and Treatment sessions will be conducted daily Monday through Friday for a period of 2 weeks in a series of ten treatments. The TUS application will focus on the medial calcaneal tubercle and the surrounding inflamed soft tissues to reduce pain and promote tissue healing.
219594429|NCT06983457|COMBINATION_PRODUCT|Shockwave Therapy|Group B (Shockwave therapy) Participants in Group B will receive extracorporeal shockwave therapy to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used, i.e., BTL-5000 SWT POWER + HIGH INTENSITY LASER 12 - to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used. Before starting the procedure, each patient was informed about the principles of the shock wave action and the possibility of side effects. Each of the project participants underwent a series of 5 treatments at 7-day intervals.
219594430|NCT06982781|DEVICE|Flow Re-Direction Endoluminal Device System(FRED)|Flow Diverter (FD) devices are developed based on reconstructing the parent artery's lumen. FDs are designed with a denser mesh compared to conventional intracranial stents. By covering the aneurysm neck, these stents redirect blood flow away from the aneurysm, promoting intra-aneurysmal flow stagnation and subsequent thrombosis formation. Currently, FDs are primarily used for the treatment of wide-neck aneurysms.
219594431|NCT04492826|PROCEDURE|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
219594432|NCT03457935|OTHER|blood samples|Blood samples
219468858|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
219468859|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
219468860|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
219468861|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
219468862|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
219468863|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
219468864|NCT03632837|DEVICE|Hemoadsorption|see arm description
219468865|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
219468866|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
219594433|NCT01478386|OTHER|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
219594434|NCT01478386|DEVICE|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
219468867|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
219468868|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
219468869|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
219468870|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
219468871|NCT02454413|OTHER|denture brushing with water and soap|denture brushing with water and soap
219468872|NCT02454413|OTHER|ultrasonic denture cleaning|ultrasonic denture cleaning
219468873|NCT02454413|OTHER|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
219468874|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
219468875|NCT02751372|DRUG|BAY 987517|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
219468876|NCT02751372|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
219468877|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
219468878|NCT06452290|DEVICE|brain 18F-FDG PET-CT|PET scanner, Philips VEREOS PET/CT scanner. Three Philips VEREOS digital PET/CT scanners are installed in the nuclear medicine department.
219468879|NCT05154994|DRUG|Belinostat|Given IV
219468880|NCT05154994|BIOLOGICAL|Durvalumab|Given IV
219468881|NCT05548582|DRUG|OxyCODONE 5 mg Oral Tablet|No opioid prescription after laparoscopic hysterectomy
219468882|NCT05548582|DRUG|Acetaminophen 500 mg Tab|Standard prescription
219468883|NCT05548582|DRUG|Ibuprofen 600 mg|Standard prescription
219468884|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
219468885|NCT04812678|PROCEDURE|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
219594435|NCT01478386|DEVICE|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
219594436|NCT04220424|DIAGNOSTIC_TEST|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
219594437|NCT05183386|PROCEDURE|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
218855289|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
218855290|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
218855291|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
219468886|NCT04812678|PROCEDURE|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
219468887|NCT05675579|DRUG|Sacituzumab Govitecan|Given by IV (vein)
219468888|NCT05675579|DRUG|Pembrolizumab|Given by IV (vein)
219468889|NCT03757585|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
219468890|NCT03757585|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
219468891|NCT06785194|DEVICE|REVIVE samfilcon B custom toric contact lenses|REVIVE samfilcon B custom toric contact lenses
219468892|NCT03472586|BIOLOGICAL|Ipilimumab|Given IV
219468893|NCT03472586|BIOLOGICAL|Nivolumab|Given IV
219468894|NCT03472586|DRUG|Embolization Therapy|Undergo immunoembolization
219468895|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
219468896|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
219468897|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
219468898|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
219468899|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
219468900|NCT02461173|DEVICE|shepherd catheter|
219468901|NCT04148222|OTHER|No intervention|There is no intervention for this study
219468902|NCT06119269|DIAGNOSTIC_TEST|Therapeutic drug monitoring|At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)
219468903|NCT06119269|DIAGNOSTIC_TEST|Molecular Response|BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib
219468904|NCT01291420|BIOLOGICAL|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10\*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
219468908|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
219468909|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
219468910|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
219468911|NCT02528331|DEVICE|Transcranial magnetic stimulation|
219468912|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
219468913|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
219468914|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
219468915|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read positive messages
219468916|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about positive experiences
219468917|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about neutral topics
219468918|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read neutral messages
219468919|NCT04776941|OTHER|Quality-of-Life Assessment|Ancillary studies
219468920|NCT04776941|OTHER|Questionnaire Administration|Complete questionnaires
219468921|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
219468922|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
219468923|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
219594438|NCT03887312|BEHAVIORAL|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
218855292|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
219468924|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
219468925|NCT03650218|DEVICE|THIODERM STRONG|Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
219468926|NCT06050928|DRUG|Oral EP262|Once daily
219468927|NCT06008938|GENETIC|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
219468928|NCT06008938|BIOLOGICAL|Factor IX (FIX)|FIX prophylaxis therapy
219468929|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
219468930|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
219468931|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
219468932|NCT06522074|DIAGNOSTIC_TEST|Coronary angiography with OCT|Intravascular imaging with Optical Coherence Tomography (OCT) in patients with chronic coronary syndrome who have been indicated for coronary angiographic will be used at the operator's discretion, for diagnostic purposes and/or to guide possible coronary artery disease treatment.
218855293|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
219468933|NCT01793610|DRUG|Comparator Dose (40mg) MDMA HCl|An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg).
219468934|NCT01793610|DRUG|Active Dose 2 (100 mg) MDMA HCl|An initial dose of full-dose 100 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg).
219468935|NCT01793610|DRUG|Active Dose 1 (125 mg) MDMA HCl|An initial dose of full-dose 125 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg).
219468936|NCT01793610|BEHAVIORAL|Psychotherapy|Non-directive manualized therapy
219468937|NCT06793410|BIOLOGICAL|Early start post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.
219468938|NCT06793410|BIOLOGICAL|Late post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.
219468939|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
219468940|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
219468941|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
219468942|NCT04791449|OTHER|Structured exercise program|Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
219468943|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
219468944|NCT05854719|BEHAVIORAL|Speechreading training with an application|The Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
219468945|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
219468946|NCT02176148|DRUG|fluocinonide 0.05% cream|
219468947|NCT05981443|DEVICE|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
219468948|NCT05981443|OTHER|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
219468949|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
219468950|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
219468951|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
219468952|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
219468953|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
219468954|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
219468955|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
218855294|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
219468956|NCT06193343|BEHAVIORAL|Adaptive Daily Step Promotion|"Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps."
219468957|NCT06045026|OTHER|Stannous fluoride|Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
219468958|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
218855295|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
218855296|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
218855297|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
218855298|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
218855299|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
219468959|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
219468960|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
219468961|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
218855300|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
218855301|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
219468962|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
219468963|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
219468964|NCT03398759|DRUG|Butorphanol|IV injection during induction
219468965|NCT03398759|DRUG|Placebos|IV injection during induction
219468966|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
219468967|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
219468968|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
219468969|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
219468970|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
219594439|NCT03887312|BEHAVIORAL|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
219594440|NCT00818987|OTHER|Open reduction internal fixation; reduction and immobilization|
219594441|NCT03915509|DEVICE|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
219594442|NCT06982001|BEHAVIORAL|Brachial line guided hemodynamic management|Anesthesiologists in charge of the patients will guide their hemodynamic management based on the monitoring of brachial/humeral arterial line, instead of the most frequently used radial line.
219594443|NCT06982001|BEHAVIORAL|Radial line guided hemodynamic management|The anesthesiologist will guide their hemodynamic management on the classically used radial arterial line.
219594444|NCT06982001|DEVICE|Radial line catheterization|An arterial line will be inserted in the radial artery of the patient.
219594445|NCT06982001|DEVICE|Brachial line catheterization|An arterial line will be inserted in the brachial artery of the patient.
218855302|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
218855303|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
218855304|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
218855305|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
218855306|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
219468971|NCT06566157|DIETARY_SUPPLEMENT|Prebiotic|WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
218855307|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
219468972|NCT06566157|DIETARY_SUPPLEMENT|Maltodextrin (Corn)|Placebo
219468973|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
219468974|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
219468975|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
218855308|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
219468976|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
219468977|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
219468978|NCT00497822|PROCEDURE|Aerobic exercise training|
219468979|NCT02190994|DRUG|Hydrocortisone|used intravenously
219468980|NCT02190994|DRUG|Prednisone|used as tablet form
219468981|NCT00231322|DRUG|praziquantel|
219468982|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
219199184|NCT06824220|DEVICE|High-Flow Tracheal Oxygen|High-Flow Tracheal Oxygen is the use of high oxygen flows in tracheostomized patients. Unlike conventional oxygen therapy which is performed through siliconized nasal prongs, this is done through a connector directly on the tracheostomy tube.
219468983|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
219468984|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
219468985|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
219468986|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
219468987|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
219468988|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
219468989|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
219594446|NCT06983067|DEVICE|Cornerstone C1000 Robotic Surgery System|Minimally invasive surgical instruments are controlled by the physician using a master-slave operating system for urologic laparoscopic surgical operations.
218855309|NCT01054937|DRUG|4SC-203|i.v. administration
218855310|NCT01054937|DRUG|Placebo|i.v. administration
218855311|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
219468990|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
219468991|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
219468992|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219468993|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
219468994|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
219468995|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
219468996|NCT01399619|DRUG|BI201335|BI201335 for 12w
219468997|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
219468998|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
219468999|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
219469000|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
219469001|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
219469002|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
219469003|NCT06383715|BEHAVIORAL|Cognitive-Behavioral Therapy Workshop for Content Moderators|"This 4-session group workshop is based on the principles of Cognitive Behavioral Therapy. It consists of four sessions:~1. Presentation. Scientific evidence of psychological consequences on content moderatos. Psicoeducation on the effects of vicarious trauma exposure.~2. Presentation of the cognitive model. Identification/operationalization of thoughts. Discussion of possible irrational thoughts.~3. Psychoeducation of emotions and their adaptive function. Behavioral strategies of emotions: exposure therapies and behavioral activation.~4. The role of social support. Strategies for appropriate work and sleep hygiene. Strategies for maintaining gains. Farewell."
219594447|NCT06587217|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
219594448|NCT06587217|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
219469004|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
219469005|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
219469006|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
219469007|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
219469008|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
219469009|NCT00742404|DRUG|bortezomib|
219469010|NCT00742404|DRUG|dexamethasone|
219469011|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
219469012|NCT00742404|GENETIC|protein analysis|
219469013|NCT00742404|OTHER|immunologic technique|
219469014|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
219469015|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
219469016|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
219469017|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
219469018|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
219469019|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
218855312|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
219199185|NCT06826339|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219199186|NCT06826339|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219199187|NCT06826339|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219469020|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
219469021|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
219469022|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
219469023|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
219469024|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
219469025|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
219469026|NCT00291109|DRUG|letrozole 2.5 mg|
219469027|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
219469028|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
219469029|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
219469030|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
219469031|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
219469032|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
219469033|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
219469034|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
219469035|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
219469036|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
219469037|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
219469038|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
219469039|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
219199188|NCT06825286|DRUG|Bupivacaine|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block wilh (20 ml bupivacaine 0.25%).
219469040|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
219469041|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
219469042|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
219469043|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
219469044|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
219469045|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
219469046|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
219594449|NCT00860392|DRUG|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
219594450|NCT03553576|DRUG|Low volume bolus|Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
218855313|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
219469047|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
219469048|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
219469049|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
219469050|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
219469051|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
219469052|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
219469053|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
219199189|NCT06825286|DRUG|Bupivacaine and Dexmedetomidinc) group|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block with (20ml Bupivacaine 0.25%) + (Dexmedetomidine Imic/kg)
219469054|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
219469055|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
219469056|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
219469057|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
219469058|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
219469059|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
219469060|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
219469061|NCT00399542|DRUG|Lubiprostone|
219469062|NCT00399542|DRUG|Placebo|
219469063|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
219469064|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
219469065|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
219594451|NCT03553576|DRUG|High volume bolus|Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
219594452|NCT06981871|OTHER|Evaluation of the gingival phenotype of the incisors in the upper and lower jaws|Assessment of gingival thickness (Kan et al 2015) and keratinised tissue height of the incisors with UNC-15 peridontal probe (Hu-Freidy, USA) and clinical photography.
219594453|NCT06983093|OTHER|Rain Stick|The rain stick to be used in the study is a toy made of wood, ranging in length from 20 to 120 cm. It is also a very entertaining musical instrument that imitates the sound of real rain. It is suitable for use by children aged 4 to 6. It has spiral shapes and colorful beads inside. When the rain stick is turned up and down, it produces a perfect rain sound that drizzles and patters. It is also known as a rain sound stick. The visual and auditory nature of the rain stick can distract the child during the blood collection process.
219469066|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
219469067|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
219469068|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
218855314|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
218855315|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
219469069|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
219469070|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
219469071|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
219469072|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
219469073|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
219594454|NCT06983093|OTHER|Musical Egg|The musical egg to be used in the study is a toy made of wood, approximately 6.5-7 cm in size. These wooden shaker eggs are a fun and interesting musical instrument. It is suitable for use by children aged 4-6. It is filled with iron sand and when shaken, it makes a clear sound and adds a unique rhythm to the music. This egg imitates the sound of maracas when shaken. Maracas are a musical instrument that makes a sound when shaken thanks to the parts in its hollow body. It is also known as musical eggs, egg shakers, musical egg maracas, Easter egg percussion instruments. The visual and auditory nature of the musical egg can distract the child during the blood collection process.
219469074|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
219594455|NCT06982209|DEVICE|Analgesia/Nociception Index (ANI)|ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group
219594456|NCT03799328|OTHER|multi-OIT|low dose OIT to multiple foods
219594457|NCT05498779|PROCEDURE|Ablation therapy|Radiofrequency or microwave ablation
219594458|NCT02985190|DRUG|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
219594459|NCT01413490|DRUG|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
219594460|NCT03535389|DIAGNOSTIC_TEST|Knee 4DCT|Dynamic knee 4DCT
219469075|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
219594461|NCT02379572|DEVICE|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
219594462|NCT02379572|DRUG|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
219594463|NCT00345657|DRUG|Niacin Extended Release/Lovastatin|
219594464|NCT00401986|DEVICE|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
219594465|NCT03741699|DRUG|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
219594466|NCT06616844|DEVICE|InnovaMatrix® AC|SOC plus weekly application of the study device
218855316|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
218855317|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
218855318|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
218855319|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
218855320|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
219594467|NCT05419609|PROCEDURE|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
219594468|NCT05419609|PROCEDURE|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
219594469|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
219594470|NCT05419609|OTHER|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
218855321|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
218855322|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
219469076|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
219469077|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
219594471|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
219594472|NCT05419609|OTHER|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
219594473|NCT02623985|DEVICE|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
219594474|NCT02623985|DEVICE|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
219594475|NCT02623985|DEVICE|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
219594476|NCT01867983|BEHAVIORAL|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
219594477|NCT01867983|BEHAVIORAL|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
219594478|NCT05697016|DRUG|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
219594479|NCT05697016|DRUG|The Placebo|Excipients used for the sivelestat sodium
219594480|NCT05038800|BIOLOGICAL|MK-0482|IV infusion
219594481|NCT00017823|PROCEDURE|Acupressure|
219594482|NCT05185401|OTHER|Observational study|Retrospective data-analysis
219594483|NCT01104792|DRUG|Cariprazine|Cariprazine was supplied in capsules.
219594484|NCT01432379|BIOLOGICAL|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
219594485|NCT00937482|DRUG|cediranib maleate|Given orally
219594486|NCT00937482|RADIATION|whole-brain radiation therapy|Undergo whole-brain radiotherapy
219594487|NCT05710939|OTHER|exercises|
219594488|NCT03866720|OTHER|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
219594489|NCT03866720|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
219594490|NCT02116959|DRUG|Melphalan|
219594491|NCT02116959|DRUG|Carboplatin|
219594492|NCT02116959|DRUG|Etoposide|
219594493|NCT02116959|DRUG|Vincristine|
219594494|NCT02831647|DIETARY_SUPPLEMENT|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
219594495|NCT01190943|OTHER|Laboratory Biomarker Analysis|Correlative studies
219594496|NCT03559166|DRUG|BLD-2660|Randomized to active product or placebo
219594497|NCT01175031|OTHER|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
219594498|NCT06240520|DRUG|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
219594499|NCT06240520|DRUG|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
219594500|NCT06240520|DRUG|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
219594501|NCT01212354|RADIATION|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
219594502|NCT00555360|BEHAVIORAL|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
219594503|NCT00555360|BEHAVIORAL|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
219469078|NCT03885817|BEHAVIORAL|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
219469079|NCT03885817|OTHER|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
219469083|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
219469084|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
219469085|NCT00000610|DRUG|magnesium|
219469086|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
219469087|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
219469088|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
219469089|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
219469090|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
219469091|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
219469092|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
219469093|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
219469094|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
219469095|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
219469096|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
219469097|NCT02806804|BIOLOGICAL|one dose test vaccine|
219469098|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
219469099|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
219469100|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
219469101|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
219469102|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
219469103|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
219469104|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
219469105|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
219469106|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
218855323|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
219469107|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
219469108|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
218855324|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
219469109|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
219469110|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
219469111|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
219469112|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
219469113|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
219469114|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
219469115|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
219469116|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
219469117|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
219469118|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
219594504|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
218855325|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
218855326|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
219469119|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
219469120|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
219469121|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
219469122|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
219469123|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
219469124|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
219469125|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
218855327|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
218855328|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
218855329|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
219469126|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
219469127|NCT04039282|DEVICE|myfood24|online website for dietary analysis
219469128|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
219469129|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
219469130|NCT00381017|DRUG|Peg interferon alpha-2b|
219469131|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
219469132|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
219469133|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
219469134|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
219469135|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
219469136|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
219469137|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
219469138|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
219469139|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
219469140|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
219469141|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
219594505|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
219469142|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
219469143|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
219469144|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
219469145|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
219469146|NCT00334893|DRUG|eribulin mesylate|Given IV
219469147|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
219469148|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
219469149|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
219594506|NCT03301623|OTHER|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
219594507|NCT03301623|OTHER|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
218855330|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
218855331|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
218855332|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
218855333|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
218855334|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
219469150|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
219469151|NCT02078557|DRUG|MK-8892|
219469152|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
219469153|NCT00117520|DRUG|Caffeine|
219469154|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
219469155|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
219469156|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
219469157|NCT01830621|DRUG|BBI608|
219469158|NCT01830621|DRUG|Placebo|
219469159|NCT01830621|OTHER|Best Supportive Care|
219469160|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219469161|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219594508|NCT01866059|DEVICE|Calcium silicate cement|Calcium silicate cement
219594509|NCT01866059|DEVICE|Glass Ionomer Cement|Glass Ionomer Cement
219594510|NCT01866059|DEVICE|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
219594511|NCT05352347|DRUG|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
219594512|NCT05352347|DRUG|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
219594513|NCT05352347|DRUG|Placebo|Normal saline (NS) 100mL bid
219594514|NCT03258073|OTHER|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
219594515|NCT01058460|PROCEDURE|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
219594516|NCT00003920|BIOLOGICAL|filgrastim|
219594517|NCT00003920|DRUG|cyclosporine|
219594518|NCT00003920|PROCEDURE|peripheral blood stem cell transplantation|
218855335|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
219594519|NCT00003920|RADIATION|indium In 111 monoclonal antibody m170|
219594520|NCT00003920|RADIATION|yttrium Y 90 monoclonal antibody m170|
219594521|NCT02304627|DRUG|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
219594522|NCT04197427|DEVICE|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
219594523|NCT04197427|DEVICE|Placebo|Placebo formulation without the active ingredients
219594524|NCT00309894|BIOLOGICAL|sargramostim|
219594525|NCT00309894|DRUG|ketoconazole|
219594526|NCT00309894|DRUG|therapeutic hydrocortisone|
219594527|NCT00393965|DRUG|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
219594528|NCT03449927|OTHER|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
219594529|NCT03449927|OTHER|Standard of care menu|-Standard registered dietitian support
219594530|NCT03449927|OTHER|Self report dietary intake worksheet|-Self report nausea and diarrhea
219594531|NCT03449927|OTHER|Post study questionnaire|-Completed upon count recovery and prior to discharge
219594532|NCT05896930|DRUG|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
219594533|NCT05896930|DRUG|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
219594534|NCT05896930|DRUG|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
218855336|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
219199190|NCT06825117|DIETARY_SUPPLEMENT|OMNi-BiOTiC® 41167|The probiotic OMNi-BiOTiC® 41167 consists of 3g of 3 x 10\^9 CFU total L. gasseri W15, L. plantarum W1, L. plantarum W21, B. lactis W51, L. acidophilus W70 and L. reuteri W192 per sachet of which two are to be taken each day. Additional non-probiotic components are cranberry-extract (0.01g), D-mannose (0,4 g), vitamin D (2,25µg), maize starch and hydrolyzed rice protein. All the strains in OMNi-BiOTiC® 41167 are specifically tested and selected for their inhibition potential against the known most common uropathogens like the uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Proteus mirabilis and Entercoccus faecalis.
219469162|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219469163|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
219469164|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
219594535|NCT05896930|DRUG|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
219594536|NCT05896930|DRUG|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
219594537|NCT05896930|DRUG|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
219594538|NCT05896930|DRUG|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
219594539|NCT05896930|DRUG|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
219594540|NCT05896930|DRUG|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
219594541|NCT05896930|DRUG|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
219594542|NCT06490614|DRUG|Dexmedetomidine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
219594543|NCT06490614|DRUG|Nalbuphine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
219594544|NCT01176708|DRUG|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
219594545|NCT01176708|OTHER|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
219594546|NCT01176708|OTHER|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
218855337|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
218855338|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
218855339|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
219199191|NCT06825117|DIETARY_SUPPLEMENT|Placebo|The placebo consists of all components of OMNi-BiOTiC® 41167, except the probiotic bacteria, cranberry-extract, D-mannose and vitamin D. It has the same smell, taste and texture as the OMNi-BiOTiC® 41167.
218855340|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
218855341|NCT02202213|DRUG|Placebo|
218855342|NCT02202213|DRUG|Lu AF11167|
219469165|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
219469166|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
219469167|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
219469168|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
219469169|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
219469170|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
219469171|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
218855343|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
218855344|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
219199192|NCT06824441|BEHAVIORAL|Age- and Role-Specific Questionnaire Administration|"Participants will be assigned a sequence number upon eligibility confirmation. The intervention consists of completing a series of questionnaires, as follows:~Child/AYA/Caregiver Group:~Pre-clinic Visit: 3 questionnaires (approximately 15-20 minutes total). Post-clinic Visit: 2 questionnaires (approximately 5-10 minutes total).~Clinician Group:~Post-clinic Visit: 2 questionnaires (approximately 5 minutes total)."
219469172|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
219469173|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
219469174|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
219594547|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
219199193|NCT06826300|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
219594548|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
219199194|NCT06826300|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
219199195|NCT06823284|DRUG|Esflurbiprofen Topical System|The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)
219469175|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
219469176|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
219469177|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
219469178|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
219469179|NCT02965027|DRUG|Prazosin|
219469180|NCT02965027|DRUG|Placebo|
219469181|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
219469182|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
219469183|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
219469184|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
219469185|NCT05865002|DRUG|AUR107|Once daily
219469186|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
219594549|NCT04141475|DIETARY_SUPPLEMENT|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
219594550|NCT04141475|DIETARY_SUPPLEMENT|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
219594551|NCT05922475|DIETARY_SUPPLEMENT|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
218855345|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
218855346|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
218855347|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
218855348|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
218855349|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
218855350|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
219199196|NCT06823284|DRUG|Flurbiprofen tablet|3 tablets per day for 4 days
219469187|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
219469188|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
219469189|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
219469190|NCT02081352|OTHER|Standard care|
219469191|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
219469192|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
219469193|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
219469194|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
219469195|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
219469196|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
219469197|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
219594552|NCT05922475|OTHER|Placebo|Resistance exercise training only group did not consume supplemental protein.
219594553|NCT03681327|OTHER|Sensory stimulation during sleep|Sensory stimulation during sleep
219594554|NCT04885465|BEHAVIORAL|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
219469198|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
219469199|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
219469200|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
219469201|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
219469202|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
219469203|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
219594555|NCT02015429|DIETARY_SUPPLEMENT|Pasta meal with added fractions or control with no fractions|
219594556|NCT06311162|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
219594557|NCT06311162|OTHER|Sham Comparator|The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
219594558|NCT03577548|OTHER|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
219594559|NCT01205386|DEVICE|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
219594560|NCT02954263|DRUG|TD-1439|
219594561|NCT02954263|DRUG|Placebo|
219594562|NCT05944380|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the PENG block
219594563|NCT05944380|DRUG|0,9% normal saline|20 mL 0.9% normal saline will be injected for the PENG block
219469204|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
219469205|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
219469206|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
219469207|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
219469208|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
219469209|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
219469210|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
219469211|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
219469212|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
219469213|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
219469214|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
219469215|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
219469216|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
219469217|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
219469218|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
219469219|NCT06073782|OTHER|Education Group|"The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit."
219469220|NCT06073782|OTHER|Text Message Group|. Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
219469221|NCT05950269|DEVICE|Walking aid|A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).
219469222|NCT05950269|OTHER|Telemonitoring|Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.
219469223|NCT05950269|OTHER|Guidance on safe walking and risk of falling|Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
219469224|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
219594564|NCT01498731|BEHAVIORAL|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
219594565|NCT02067273|DEVICE|Transcranial Magnetic Stimulation (TMS)|
219469225|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
219594566|NCT04211727|DIAGNOSTIC_TEST|Capillary finger prick blood sample|Patients will have a blood finger prick sample
219594567|NCT02092467|DRUG|tofacitinib|Oral tablet, 5 mg BID
219594568|NCT02092467|DRUG|tofacitinib|Oral tablet, 10 mg BID
219594569|NCT02092467|BIOLOGICAL|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
219199197|NCT04298450|BEHAVIORAL|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
219199198|NCT04298450|BEHAVIORAL|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
219199199|NCT04633538|DEVICE|6MWT smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
219199200|NCT01027728|DRUG|CCX 354-C|"* Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
219469226|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
219469227|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
219469228|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
219469229|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
219469230|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
219469231|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
219469232|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
219469233|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
219469234|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
219469235|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
219469236|NCT03646916|OTHER|No dexamethasone|Nothing
219469237|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
219469238|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
219469239|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
219199201|NCT05061017|DRUG|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
219199202|NCT05061017|DRUG|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
219469240|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
219469241|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
219594570|NCT02092467|BIOLOGICAL|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
219594571|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
219594572|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
219594573|NCT01104467|OTHER|Placebo|1 bolus injection of placebo IV
219594574|NCT01595386|DRUG|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
218855351|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
219469242|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
219469243|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
219469244|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
219469245|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
219469246|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
219469247|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
219469248|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
219469249|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
219469250|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
219469251|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
219469252|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
219469253|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
219469254|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
219469255|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
219469256|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
219469257|NCT03737812|DRUG|elezanumab|solution for infusion
219199203|NCT05061017|DRUG|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
219469258|NCT03737812|DRUG|placebo|solution for infusion
219469259|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
219469260|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
219469261|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
219594575|NCT01595386|DRUG|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
219594576|NCT05778487|DIETARY_SUPPLEMENT|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
219594577|NCT01831401|PROCEDURE|Operating table position 0° head down (Horizontal)|
219594578|NCT01831401|PROCEDURE|Operating table position 7° head down.|
219594579|NCT01831401|PROCEDURE|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
219594580|NCT01831401|DEVICE|Standard straight acetabular component introducer without alignment guide.|
219594581|NCT01831401|DEVICE|Modified 35° acetabular component introducer.|
219594582|NCT01831401|DEVICE|Inclinometer-assisted acetabular component introducer.|
219594583|NCT01119794|DRUG|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
219594584|NCT05182320|DEVICE|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
219594585|NCT05182320|DEVICE|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
219594586|NCT04180631|DIAGNOSTIC_TEST|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
219469262|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
219469263|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
219469264|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
219594587|NCT02167373|OTHER|Cogito Companion Intervention|
219594588|NCT02167373|DEVICE|mobile phone application|
219594589|NCT05819216|DEVICE|Treadmill|Gait training on treadmill training
219594590|NCT01147263|OTHER|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
219594591|NCT03869086|OTHER|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
219594592|NCT03869086|OTHER|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
219594593|NCT03330210|PROCEDURE|3D printing|Manufacturing and use of a model printed in 3D
219594594|NCT05600790|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
218855352|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
218855353|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
219594595|NCT02418481|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
219594596|NCT02418481|BIOLOGICAL|γδ T Cell|γδ T cells will be used against breast tumor.
219594597|NCT02418481|BIOLOGICAL|Combination|γδ T/DC-CIK cells will be used against breast tumor.
219594598|NCT05259995|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
219594599|NCT05201196|OTHER|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
219594600|NCT05201196|OTHER|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
218855354|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
218855355|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
218855356|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
218855357|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
219469265|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
219469266|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
219469267|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
219469268|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
219469269|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
219469270|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
219469271|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
219469272|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
219469273|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
219469274|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
219469275|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
219469276|NCT03644862|DEVICE|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
219469277|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
219469278|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
219469279|NCT00019565|PROCEDURE|magnetic resonance imaging|
219469280|NCT00019565|PROCEDURE|positron emission tomography|
219469281|NCT00019565|RADIATION|fludeoxyglucose F 18|
219469282|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
219469283|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
219469284|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
219469285|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
219469286|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
219469287|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
219469288|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
219469289|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
219469290|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
219469291|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
219469292|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
219469293|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
219469294|NCT03927209|DRUG|BI 1467335|tablet
219469295|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
219469296|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
219469297|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
219469298|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
219469299|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
219469300|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
219469301|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
219469302|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
219469303|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
219469304|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
219594601|NCT04013984|OTHER|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
219594602|NCT06632314|DIETARY_SUPPLEMENT|Enteral feeding|Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
218855358|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
218855359|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
218855360|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
219594603|NCT00005614|DRUG|Gemcitabine hydrochloride|Gemcitabine via IV
219469305|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
219469306|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
219469307|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
219469308|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
219469309|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
219594604|NCT02906566|DRUG|Retinol|Retinol in the form of vitamin A lotion
219594605|NCT02906566|DRUG|Placebo|Placebo of Retinol
219594606|NCT04320121|DIETARY_SUPPLEMENT|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
219594607|NCT04320121|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
218855361|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
218855362|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
218855363|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
218855364|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
218855365|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
218855366|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
219594608|NCT00006458|RADIATION|indium In 111 monoclonal antibody MN-14|
219594609|NCT00006458|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
218855367|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
219469310|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
219469311|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
219469312|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
219469313|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
219469314|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
219469315|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
219469316|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
219469317|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
219469318|NCT00138281|BIOLOGICAL|FluMist|
219469319|NCT00138281|BIOLOGICAL|Fluzone|
219469320|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
219594610|NCT02297698|BIOLOGICAL|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
219594611|NCT02297698|DRUG|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
219594612|NCT02297698|DRUG|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
219594613|NCT02761005|DRUG|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
219594614|NCT02952898|DRUG|GDC 695|GDC 695 is a topical gel.
219594615|NCT02952898|DRUG|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
218855368|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
218855369|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
218855370|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
219469321|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
219469322|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
219469323|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
219469324|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
219469325|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
219469326|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
219594616|NCT02952898|DRUG|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
219594617|NCT02868645|BIOLOGICAL|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
218855371|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
218855372|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
218855373|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
218855374|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
218855375|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
218855376|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
218855377|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
218855378|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
218855379|NCT06661317|OTHER|no intervention|no intervention
218855380|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
218855381|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
218855382|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
218855383|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
218855384|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
219469327|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
218855385|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
218855386|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
219594618|NCT03252912|BIOLOGICAL|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
219594619|NCT00255710|BIOLOGICAL|filgrastim|
218855387|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
219469328|NCT06401798|DRUG|placebo gel|Methylcellulose gel was applied topically to the pocket
219469329|NCT06401798|DRUG|CWP gel|Methylcellulose gel combined with CWP was applied topically to the pocket
219594620|NCT00255710|DRUG|cyclophosphamide|
219594621|NCT00255710|DRUG|fludarabine phosphate|
219594622|NCT00255710|DRUG|mycophenolate mofetil|
219594623|NCT00255710|DRUG|tacrolimus|
219594624|NCT00255710|PROCEDURE|allogeneic bone marrow transplantation|
219594625|NCT00255710|PROCEDURE|peripheral blood stem cell transplantation|
219594626|NCT00255710|RADIATION|radiation therapy|
219469330|NCT06401798|DRUG|NCWP gel|Methylcellulose gel combined with NCWP was applied topically to the pocket
219469331|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
219469332|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
219469333|NCT03025295|DRUG|Saline|It is safe Placebo.
219469334|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
219469335|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
219469336|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
219469337|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
219469338|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
219469339|NCT01813162|DRUG|Tenofovir 1% gel|
219469340|NCT01813162|DRUG|Vaginal product|
219594627|NCT02864810|DRUG|[18F]GP1|\[18F\]GP1 PET/CT imaging for detecting thromboembolism
219594628|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
219594629|NCT04844762|BEHAVIORAL|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
219469341|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
219469342|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
219469343|NCT03911401|DRUG|1% OPA-15406|Twice daily
219469344|NCT03911401|DRUG|Placebos|Twice daily
219594630|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
219594631|NCT00399880|BEHAVIORAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
219594632|NCT00007527|DRUG|naloxone|
219594633|NCT00007527|DRUG|buprenorphine|
219594634|NCT02188173|DRUG|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
219594635|NCT04129073|OTHER|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
219594636|NCT04067986|DRUG|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
219594637|NCT04067986|DRUG|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
219594638|NCT01399879|OTHER|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
219594639|NCT01696851|OTHER|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
219594640|NCT02829151|DRUG|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
219594641|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
218855388|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
218855389|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
218855390|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
218855391|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
218855392|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
219363164|NCT06912243|OTHER|Educational animation about the process of ear tube surgery|A nurse will explain the process of ear tube surgery to children in an educational video. This educational video scenario includes information about a child's fears before surgery, the structure of the ear, what they are most curious about, what an ear tube is, what happens during and after surgery. The educational video will be made by a person specialized in computer technologies. Artificial intelligence will be used in the vocalization of the educational video. Expert opinion will be taken for the instructional video. The duration of the educational video is planned to be in the range of 3-4 minutes in total.
219469345|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
219469346|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
219469347|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
219469348|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
219469349|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
219469350|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
219469351|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
219469352|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
219594642|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
219594643|NCT04257045|OTHER|Interview|Participate in semi-structure, in-depth qualitative interviews
219594644|NCT04257045|OTHER|Questionnaire Administration|Complete questionnaires
219594645|NCT04257045|OTHER|Survey Administration|Complete survey
219594646|NCT04400682|DRUG|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
219594647|NCT04400682|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
219469353|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
219469354|NCT00462501|BIOLOGICAL|bevacizumab|
219469355|NCT00462501|DRUG|fluorouracil|
219469356|NCT00462501|DRUG|leucovorin calcium|
219469357|NCT00462501|DRUG|oxaliplatin|
219469358|NCT00462501|PROCEDURE|conventional surgery|
219469359|NCT00462501|RADIATION|radiation therapy|
219469360|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
219469361|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
219469362|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
219469363|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
219469364|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
219469365|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
219469366|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
219469367|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
219469368|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
219469369|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
219594648|NCT01333891|DRUG|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
218855393|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
219469370|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
219469371|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
219469372|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
219469373|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
219469374|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
219469375|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA\_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
219469376|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
219594649|NCT01333891|DRUG|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
219469377|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
219469378|NCT00998166|DRUG|Cisplatin|4\. Cisplatin 75mg/m2 IV over 60-120 minutes
219469379|NCT00998166|DRUG|Bevacizumab|5\. Bevacizumab 15mg/kg IV over 90 minutes
219469380|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
219469381|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
219469382|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
219469383|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
219469384|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
219469385|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
219469386|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
219469387|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
219469388|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
219594650|NCT01333891|DEVICE|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
219594651|NCT01333891|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
218855394|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
219469389|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
219469390|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
219469391|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
219469392|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
219469393|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
218855395|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
218855396|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
218855397|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
218855398|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
218855399|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
218855400|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
218855401|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
218855402|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
218855403|NCT01513603|DRUG|CLAG-M|IV times 5 days
218855404|NCT01513603|DRUG|CLAG-M|Chemotherapy
218855405|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
218855406|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
218855407|NCT06607393|DRUG|Pembrolizumab|
218855408|NCT06607393|DRUG|Pemetrexed|
218855409|NCT06607393|DRUG|Cisplatin|
218855410|NCT06607393|DRUG|Carboplatin|
218855411|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
218855412|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
218855413|NCT06454890|BIOLOGICAL|Anti-Trop2 CAR-NK cell|chemotherapy followed by Trop2 CAR-NK infusion
218855414|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
218855415|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
218855416|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
218855417|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
219363165|NCT06912243|OTHER|Control-Standard Care|The standard information given to all children who had ear tube surgery in the relevant ward will be given to the children in the control group.
219363166|NCT06917612|PROCEDURE|Normal diagnostic laparoscopy|The appendix is left in situ e.g., not resected and no other surgical resection is needed to treat other diseases
219363167|NCT06917612|PROCEDURE|Negative appendectomy|The appendix is resected but is without histopathological-confirmed inflammation and no other surgical resection is needed to treat other diseases
219363168|NCT06917261|DIAGNOSTIC_TEST|nasopharyngeal swab.|The only additional procedure related to the study is a nasopharyngeal swab.
219363169|NCT06915428|BEHAVIORAL|Care coordination|"Research team members will serve as research assistants and will also function as perinatal care coordinators.~In the care coordination role, team members will provide emotional support, liaise with clinical staff, and execute regularly scheduled check-ins with each study participant. Team members also assist with helping participants with logistics, obtaining and remembering to take prescribed medications, and other similar related activities. Participants receive access to contact the research assistant / care coordinator by text, email, phone, or through the electronic medical record participant portal.~\- Per protocol, the research staff will meet in person with participants at least twice (visit 1, visit 2) during pregnancy and once postpartum (0-10 weeks after delivery, for most participants).~Research staff may also meet in person with participants prior to visit 1 for recruitment/enrollment purposes."
219363170|NCT06915428|BEHAVIORAL|Electronic massage|"Participant is given the option to receive a 15-minute electronic massage / relaxation session in clinic via (a) a specialized massage chair or (b) a massage pad that is placed on top of a standard recliner chair.~* the electronic massages provide gentle massages and are safe for most people to use throughout pregnancy.~* participants are always be in control of the massage experience and will be given instructions on how to stop the massage at any time.~* participants are advised to consult the primary obstetric provider before using the massage chair regarding any specific concerns or questions~* during the session, participants may view relaxation videos (from free, publicly available sites online).~  * participants may choose to sign up for massage(s) at any obstetric visit in the clinic between visit 1 and delivery."
219363171|NCT06915428|BEHAVIORAL|support gift #1|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 14+0 and 23+6 weeks gestation at time of routine prenatal appointment"
219363172|NCT06915428|BEHAVIORAL|Support gift #2|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 18+0 and 27+6 weeks gestation at time of routine prenatal appointment"
219469394|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
219469395|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
219469396|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
219469397|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
219469398|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
219469399|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
219469400|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
218855418|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
218855419|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
219469401|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
219469402|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
219469403|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
219469404|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
219469405|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
218855420|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
218855421|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
218855422|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
218855423|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
218855424|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
219199204|NCT06745466|DRUG|ganirelix acetate|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.
219199205|NCT05057468|DRUG|Cyclosporine|2.5-5 mg orally for 3 months
219199206|NCT05057468|DRUG|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
219199207|NCT06219668|PROCEDURE|Omentopexy group|Omentopexy and Clips on staple line during LSG
219469406|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
219469407|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
219469408|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
219469409|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
219469410|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
219469411|NCT06008015|DRUG|BR1015|One tablet administered alone
219469412|NCT06008015|DRUG|BR1015-1|One tablet administered alone
219469413|NCT06008015|DRUG|BR1015-2|One tablet administered alone
219469414|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
219469415|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
219469416|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
219469417|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
219469418|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
218855425|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
218855426|NCT01549808|OTHER|mobilization|sitting, standing and walking
218855427|NCT00091130|BIOLOGICAL|HspE7|Given SC
218855428|NCT00091130|OTHER|placebo|Given SC
218855429|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
218855430|NCT02966964|DRUG|DWPUR001|
218855431|NCT02966964|DRUG|Placebo|
218855432|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
218855433|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
218855434|NCT00349323|BEHAVIORAL|Community directed treatment|
218855435|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
218855436|NCT00521430|DRUG|busulfan|
218855437|NCT00521430|DRUG|cyclosporine|
218855438|NCT00521430|DRUG|fludarabine phosphate|
218855439|NCT00521430|DRUG|methotrexate|
218855440|NCT00521430|DRUG|methylprednisolone|
218855441|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218855442|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
218855443|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
218855444|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
218855445|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
218855446|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
219199208|NCT04992299|BEHAVIORAL|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
219199209|NCT04992299|BEHAVIORAL|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
218855447|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
218855448|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
218855449|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
218855450|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
218855451|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
218855452|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
218855453|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
218855454|NCT05884112|DEVICE|sham control|sham control
218855455|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
219199210|NCT04992299|BEHAVIORAL|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
219199211|NCT04101916|DEVICE|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
219199212|NCT04101916|DEVICE|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
219363173|NCT06915428|BEHAVIORAL|Support gift #3|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 22+0 and 29+6 weeks gestation at time of routine prenatal appointment"
218855456|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
218855457|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
219469419|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
219469420|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
219469421|NCT04433858|DRUG|Psilocybin|open-label
219469422|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
219469423|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
219469424|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
219469425|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
219469426|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
219469427|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
219469428|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
219469429|NCT06513494|BEHAVIORAL|Active Students Education plus Teacher Training|The teacher undergoes 30 hours of self-instructional training on vaccination through an online platform tailored for the relevant age group. Additionally, students receive active vaccinations and health education over two months
219469430|NCT06513494|BEHAVIORAL|Active Students Education|Students receive active vaccinations and health education over two months.
219469431|NCT06513494|BEHAVIORAL|Basic Health Unit Active Orientation|Nurses from basic health units will conduct an active orientation session at schools about vaccination for students.
219469432|NCT06513494|OTHER|Usual care|No project interventions will be carried out.
219469433|NCT06567314|DRUG|Ivonescimab|Given by PO
219469434|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"\- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill\_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
219469435|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
219469436|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
218855458|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
218855459|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
218855460|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
218855461|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
218855462|NCT01824823|DRUG|afatinib|Given PO
218855463|NCT01824823|OTHER|placebo|Given PO
218855464|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
219469437|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
219469438|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
219469439|NCT04825639|OTHER|No intervention|no intervention
219469440|NCT05065840|BEHAVIORAL|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
219469441|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
219469442|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
218855465|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
218855466|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
218855467|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
219469443|NCT06339268|BEHAVIORAL|Cognitive training, CogniFit App|A patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.
219469444|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
219469445|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
219469446|NCT04450173|DRUG|Ibrutinib|Given PO
219469447|NCT04450173|BIOLOGICAL|Obinutuzumab|Given IV
219469448|NCT04450173|DRUG|Venetoclax|Given PO
219469449|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
219469450|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
219469451|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
219469452|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
219469453|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
219469454|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
219469455|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
219469456|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
219469457|NCT05017116|DRUG|RBD1016|subcutaneous injection
219469458|NCT05017116|DRUG|Placebo|subcutaneous injection
219469459|NCT05017116|DRUG|Entecavir|Take orally.
219469460|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
219469461|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
218855468|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
218855469|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
218855470|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
218855471|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
218855472|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
218855473|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
218855474|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
218855475|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
219469462|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
219469463|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
219469464|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
219469465|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
219469466|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
219469467|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
219469468|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
219469469|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
219469470|NCT04190199|OTHER|Observational|Cross-sectional only
219469471|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
219469472|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
219469473|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
219469474|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
219469475|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
219469476|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
219469477|NCT05638594|DRUG|Pyrotinib|320mg, qd
219469478|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
219469479|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
219469480|NCT05638594|DRUG|Letrozole|2.5mg，qd
219469481|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
219469482|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
219469483|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
219469484|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
219469485|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
219469486|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
218855476|NCT00420615|DRUG|Patupilone and Omeprazole|
218855477|NCT00420615|DRUG|Patupilone + Midalzolam|
218855478|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
218855479|NCT00033709|DRUG|temozolomide|
218855480|NCT00033709|DRUG|thalidomide|
218855481|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
219469487|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
219469488|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
219469489|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
218855482|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
218855483|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
219199213|NCT05500040|BEHAVIORAL|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
219469490|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
219469491|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
218855484|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
218855485|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
219469492|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
219469493|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
219469494|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
219469495|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
219469496|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
219199214|NCT04831086|DRUG|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
219469497|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
219469498|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
219469499|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
219469500|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
219469501|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
219469502|NCT01889342|BEHAVIORAL|Metacognitive therapy|
219469503|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
219469504|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
219469505|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
219469506|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
219469507|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
219469508|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
219469509|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
219469510|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
219469511|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
219469512|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
219469513|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
219469514|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
219594652|NCT01333891|DEVICE|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
219594653|NCT04128020|DRUG|Nivolumab|Nivolumab
219594654|NCT04128020|DRUG|Azacitidine|Azacitidine
219594655|NCT05083130|BEHAVIORAL|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
219594656|NCT03664492|OTHER|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
219594657|NCT04824157|OTHER|Non|Follow up
219594658|NCT03812744|DRUG|Whole coffee cherry extract (WCCE)|100mg WCCE
219199215|NCT04831086|DRUG|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
219469515|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
219469516|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
219469517|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
219469518|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
219469519|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
218855486|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
218855487|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
219469520|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
219469521|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
219469522|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
218855488|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
218855489|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
218855490|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
219469523|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
218855491|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
218855492|NCT05385081|OTHER|genomic profiling|next generation sequencing
218855493|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
218855494|NCT03134365|OTHER|Combined meal|Combined meal.
218855495|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
219594659|NCT03812744|DRUG|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
218855496|NCT02196116|OTHER|MRI|
218855497|NCT02196116|OTHER|neuropsychological tests|
218855498|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
218855499|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
218855500|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
218855501|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
218855502|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
219199216|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1\. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2\. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
219469524|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
219469525|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
219469526|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
219469527|NCT02405182|OTHER|Magnetic Resonance Imaging|
219469528|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
219594660|NCT03393663|OTHER|CKD-related outcomes|the study is observational
219594661|NCT02293863|DRUG|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
219594662|NCT02293863|DRUG|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
219594663|NCT02293863|DRUG|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
219594664|NCT02865421|DRUG|stem cells|adipose tissue derived stromal vascular fraction
218855503|NCT05967546|OTHER|Observational|No interventions will be given to patients.
218855504|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
219594665|NCT02865421|DRUG|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
219594666|NCT00566566|OTHER|sample without DNA|family history, anthropometric measurements and blood sampling
219594667|NCT00927797|DRUG|Cyclophosphamide, Pentostatin, Rituximab|
219594668|NCT01975727|DRUG|Placebo|Injection of placebo (saline 0.9%)
219469529|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
219469530|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
219469531|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
219469532|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
219469533|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
219469534|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
219469535|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
219469536|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
219469537|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
219594669|NCT01975727|DRUG|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
219594670|NCT01975727|DRUG|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
219594671|NCT01975727|DRUG|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
218855505|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
219469538|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
219469539|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
219469540|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
219469541|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
219469542|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
219469543|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
219469544|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
219469545|NCT04419558|DRUG|Placebo|Sterile solution for injection
219469546|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
219594672|NCT00901992|BEHAVIORAL|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
219594673|NCT00901992|BEHAVIORAL|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
219594674|NCT06017076|OTHER|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
219594675|NCT06017076|DEVICE|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
219594676|NCT02097680|DRUG|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
219594677|NCT02097680|DRUG|Placebo|One placebo capsule every two days during four months
218855506|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
219594678|NCT00361062|BEHAVIORAL|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
219594679|NCT03761563|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
219594680|NCT03165838|BEHAVIORAL|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
219594681|NCT03165838|BEHAVIORAL|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
218855507|NCT02802241|DRUG|placebo|
218855508|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
218855509|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
218855510|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
218855511|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
218855512|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
219469547|NCT02672475|DRUG|Galunisertib|Given PO
219469548|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
219469549|NCT02672475|DRUG|Paclitaxel|Given IV
219469550|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
219469551|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
219594682|NCT04277143|DRUG|Daptomycin|"Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours."
218855513|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
218855514|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
218855515|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
219469552|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
219594683|NCT00477633|DRUG|Norethindrone/ethinyl estradiol|1 tablet per day
219594684|NCT02553447|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219594685|NCT02553447|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219594686|NCT03323047|DRUG|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
219594687|NCT03323047|DRUG|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
219594688|NCT03323047|DRUG|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
219594689|NCT03323047|DRUG|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
219594690|NCT03583684|BEHAVIORAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
219594691|NCT05888194|DEVICE|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
219594692|NCT00963560|DEVICE|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
219594693|NCT00963560|DEVICE|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
219594694|NCT00963560|DEVICE|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
219594695|NCT03509805|DIAGNOSTIC_TEST|polysomnography|
219594696|NCT00095797|DRUG|R(+)XK469|Given IV
219594697|NCT00095797|OTHER|pharmacological study|Correlative studies
219594698|NCT00095797|OTHER|laboratory biomarker analysis|Optional correlative studies
218855516|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
218855517|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
218855518|NCT00969761|DRUG|BI 6727|low to high dose
219594699|NCT04494984|DRUG|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
219594700|NCT04494984|DRUG|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
219594701|NCT00815360|DRUG|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
219594702|NCT00815360|PROCEDURE|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
218855519|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
218855520|NCT05293444|OTHER|overnight fasting|no intervention
218855521|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
218855522|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
218855523|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
219594703|NCT00815360|DRUG|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
219594704|NCT00815360|PROCEDURE|macular laser|macular laser to areas of retinal thickening or leakage
219594705|NCT05050110|OTHER|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
219594706|NCT02996214|DRUG|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
218855524|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
218855525|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
218855526|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
218855527|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
218855528|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
218855529|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
219594707|NCT02996214|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
219594708|NCT02996214|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
219594709|NCT04676659|DRUG|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
219594710|NCT02242032|DRUG|P-321 Ophthalmic Solution|
219594711|NCT02242032|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
218855530|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
219469553|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
219469554|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
219469555|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
219469556|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
219469557|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
219469558|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
219469559|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
219469560|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
219469561|NCT00967889|GENETIC|gene expression analysis|
219469562|NCT00967889|GENETIC|protein analysis|
219469563|NCT00967889|OTHER|biologic sample preservation procedure|
219469564|NCT00967889|OTHER|laboratory biomarker analysis|
219469565|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
219469566|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
219469567|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
219469568|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
218855531|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
218855532|NCT02351687|DRUG|Albendazole|
219469569|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
219469570|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
219469571|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
219469572|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
218855533|NCT02351687|DRUG|Zinc|
218855534|NCT02351687|OTHER|Insecticide-treated bednet|
219469573|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
219594712|NCT01852500|OTHER|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
219594713|NCT01852500|OTHER|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
219594714|NCT02340052|DRUG|Pain treatment|Registration af actual analgesic treatment and outcomes
219594715|NCT04123561|DRUG|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
218855535|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
218855536|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
218855537|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
218855538|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
218855539|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
218855540|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
218855541|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
218855542|NCT00270088|DRUG|epoetin alfa|
218855543|NCT01774253|DRUG|Vismodegib|
218855544|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
218855545|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
218855546|NCT06163183|DEVICE|Edi catheter|
219469574|NCT00084188|BEHAVIORAL|Behavior Therapy|
219594716|NCT04123561|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
219594717|NCT04123561|OTHER|Normal Saline|0.9% normal saline
218855547|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
219469575|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
218855548|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
218855549|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
219469576|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
218855550|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
219199217|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
219469577|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
219469578|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
219469579|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
219469580|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
219469581|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
219469582|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
219469583|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
218855551|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
219199218|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
219469584|NCT05146999|BIOLOGICAL|Placebo|Placebo
219469585|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
219469586|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
219469587|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
219469588|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
219594718|NCT00522561|OTHER|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
219594719|NCT05404945|DRUG|Pembrolizumab|Pembrolizumab 400 mg IV
219594720|NCT05404945|DRUG|Doxorubicin|Doxorubicin 25mg/m2 IV
219594721|NCT05404945|DRUG|Vinblastine|Vinblastine 6mg/m2 IV
219594722|NCT05404945|DRUG|Dacarbazine|Dacarbazine 375mg/m2 IV
219594723|NCT05404945|DRUG|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
219594724|NCT05236283|DIAGNOSTIC_TEST|Blood Culture|Blood Culture
219594725|NCT02454127|BEHAVIORAL|Atkins Diet|Dietary counseling for 1 year
219594726|NCT02454127|BEHAVIORAL|Zone Diet|Dietary counseling for 1 year
219594727|NCT02454127|BEHAVIORAL|Weight Watchers Diet|Dietary counseling for 1 year
219594728|NCT02454127|BEHAVIORAL|Ornish Diet|Dietary counseling for 1 year
219594729|NCT02777073|DRUG|Victoza|Single dose of Liraglutide
219594730|NCT02777073|DRUG|Placebo|Single dose of generic placebo
219594731|NCT02777073|DRUG|Dapagliflozin 10mg Tab|single dose of 10 mg dapagliflozin
219594732|NCT04328961|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
219594733|NCT04328961|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
219594734|NCT02388360|DRUG|topical prostaglandin analogs|
219594735|NCT01296282|DEVICE|Medronics CRT Optivol Impedance Measurement|Pacemaker
219594736|NCT01296282|DEVICE|External Thoracic Impedance Measurement|
219594737|NCT04229927|DRUG|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
218855552|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
218855553|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
218855554|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
219469589|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
219469590|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
219469591|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
219469592|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
219469593|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
219469594|NCT04668157|DRUG|TAK-536|TAK-536 granule formulation
219469595|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
219469596|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
219594738|NCT05614427|DIAGNOSTIC_TEST|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
219594739|NCT05734612|DRUG|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
218855555|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
218855556|NCT00343369|DRUG|asparaginase|
218855557|NCT00343369|DRUG|cyclophosphamide|
219594740|NCT05734612|DRUG|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
219594741|NCT03132779|DRUG|Intralipid|Adose of intralipid given and rechecking NKcells activity
218855558|NCT00343369|DRUG|cytarabine|
218855559|NCT00343369|DRUG|daunorubicin hydrochloride|
218855560|NCT00343369|DRUG|dexamethasone|
218855561|NCT00343369|DRUG|doxorubicin hydrochloride|
218855562|NCT00343369|DRUG|mercaptopurine|
218855563|NCT00343369|DRUG|methotrexate|
218855564|NCT00343369|DRUG|pegaspargase|
218855565|NCT00343369|DRUG|prednisolone|
218855566|NCT00343369|DRUG|teniposide|
218855567|NCT00343369|DRUG|thioguanine|
218855568|NCT00343369|DRUG|vincristine sulfate|
218855569|NCT00343369|RADIATION|radiation therapy|
218855570|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
218855571|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
218855572|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
218855573|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
218855574|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
218855575|NCT00992381|DRUG|Naprosyn|500mg Naproxen
218855576|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
218855577|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
218855578|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
218855579|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
219469597|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
219469598|NCT04100863|OTHER|No Intervention|There is no intervention for this study.
219469599|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
219594742|NCT04286451|BEHAVIORAL|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
219469600|NCT01074060|DRUG|plerixafor|Given IV
219469601|NCT01074060|BIOLOGICAL|filgrastim|Given SC
219199219|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
219594743|NCT04286451|BEHAVIORAL|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
219594744|NCT01178528|DRUG|ivabradine|7.5 mg bd
219594745|NCT01178528|DRUG|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
219594746|NCT01178528|DRUG|Carvedilol|25 mg bd
219594747|NCT05150847|OTHER|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
219594748|NCT01374269|OTHER|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
219199220|NCT06253234|BIOLOGICAL|personalized dendritic cell injection ZSNeo-DC1.1|Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles
219199221|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
219469602|NCT01074060|DRUG|cyclophosphamide|Given IV
219469603|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
219469604|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
219469605|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
219469606|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
219469607|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
219469608|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
219469609|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
219469610|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
219594749|NCT01374269|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
219594750|NCT03961659|DRUG|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219594751|NCT03961659|DRUG|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219594752|NCT03961659|DRUG|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
219594753|NCT05154461|OTHER|Alginate|BHB covered in alginate will be realised in stomach-duodenum
219594754|NCT05154461|OTHER|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
219469611|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
219469612|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
219469613|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
219594755|NCT03854682|PROCEDURE|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
219469614|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
219469615|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
219469616|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
219469617|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
219469618|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
219469619|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
219469620|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
219469621|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
219469622|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
219469623|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
219469624|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
219469625|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
219469626|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
219469627|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
219469628|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
219469629|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
219469630|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
219469631|NCT05729516|BEHAVIORAL|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
219469632|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
219469633|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
219469634|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
219594756|NCT03854682|BEHAVIORAL|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
219594757|NCT04553874|OTHER||observational study without intervention
219469635|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
219469636|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
219469637|NCT05856916|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
219469638|NCT05856916|DIETARY_SUPPLEMENT|Placebo|Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
219469639|NCT05705310|BEHAVIORAL|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
219469640|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
219469641|NCT05587933|DRUG|Antispasmodic|Antispasmodic
219469642|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
219469643|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
219469644|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
219469645|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
218855580|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
218855581|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
218855582|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
218855583|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
218855584|NCT00199316|DRUG|spinal morphine|
219469646|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
218855585|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
218855586|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
218855587|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
218855588|NCT02101684|DRUG|Orteronel 300mg BID|
218855589|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
218855590|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
219469647|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
219469648|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
219594758|NCT02602444|DRUG|ticagrelor|180 mg loading dose
219469649|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
219469650|NCT05593523|DRUG|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
219469651|NCT05593523|DEVICE|Clinical Fluorescence Imaging Device|OnLume Clinical Imaging System or Commercially-available FDA approved clinical fluorescence imaging device (SPY Elite fluorescence imaging system, SPY-PHI portable handheld imaging system, or EleVision IR platform (also known as VS3-IR system)
219469652|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
219469653|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
219469654|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
219469655|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
219469656|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
219469657|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
219469658|NCT02221882|DRUG|LY3164530|Administered IV.
219469659|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
219469660|NCT00796367|DRUG|Placebo|placebo
219469661|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
219469662|NCT02395445|DEVICE|orotracheal intubation|
219469663|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
219469664|NCT00122395|BEHAVIORAL|Screening via pen and paper|
219199222|NCT06608173|BEHAVIORAL|radKIDS2.0 Safety and Empowerment Education Program|radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
219594759|NCT04228016|DEVICE|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
219594760|NCT05439083|BIOLOGICAL|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
219594761|NCT05602883|BEHAVIORAL|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
219594762|NCT02944305|PROCEDURE|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
219469665|NCT00122395|BEHAVIORAL|Screening via audiotape|
219594763|NCT06732895|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
218855591|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
218855592|NCT01230515|OTHER|interview, focus group and structured survey|
218855593|NCT01230515|OTHER|interview, focus group and structured survey|
219469666|NCT05295810|DRUG|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
219469667|NCT00307775|DRUG|oestradiol|
219469668|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
219469669|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
219469670|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
219469671|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
219469672|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
219469673|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
219469674|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
219469675|NCT05968157|DIAGNOSTIC_TEST|Breast MRI|Supplemental MRI (in addition to standard of care MRI).
219469676|NCT05968157|DEVICE|MIRAI|Artificial intelligence software
219469677|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
219469678|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
219469679|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
219469680|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
219594764|NCT06732895|DRUG|Placebo for navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
219594765|NCT06129305|OTHER|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography
219594766|NCT05017597|OTHER|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during \& after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms \& any identified barriers or supports. Weeks 1, 3, 5, \& 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, \& 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal \& action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
219594767|NCT05607654|DEVICE|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
219594768|NCT05607654|DEVICE|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219469681|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
219469682|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
219469683|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
219469684|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
219469685|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
219469686|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
219469687|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
219469688|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
219469689|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
219594769|NCT03705130|DEVICE|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
219594770|NCT03705130|DEVICE|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
218855594|NCT01230515|OTHER|interview, focus group and structured survey|
218855595|NCT00096499|DRUG|ispinesib|Given IV
218855596|NCT00096499|OTHER|pharmacological study|Correlative studies
218855597|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
219199223|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
219469690|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
219594771|NCT03705130|DEVICE|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
219594772|NCT03276065|DEVICE|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
219594773|NCT03276065|OTHER|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
219594774|NCT04669847|OTHER|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
219199224|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
218855598|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
219469691|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
219469692|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
219469693|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
219469694|NCT01263652|DRUG|Tramadol|IM/PO tramadol
219469695|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
219469696|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
219469697|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
219469698|NCT00052403|PROCEDURE|anti-cytokine therapy|
218855599|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
218855600|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
219469699|NCT00052403|PROCEDURE|antiangiogenesis therapy|
219469700|NCT00052403|PROCEDURE|antibody therapy|
219469701|NCT00052403|PROCEDURE|biological response modifier therapy|
218855601|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
218855602|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
219469702|NCT00052403|PROCEDURE|growth factor antagonist therapy|
219469703|NCT00052403|PROCEDURE|monoclonal antibody therapy|
219469704|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
219469705|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
219469706|NCT04920786|DRUG|TB006|TB006
219469707|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
219469708|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
219469709|NCT06427577|DRUG|ZhenQi FuZheng granules (ShiDaiYangGuang)|1 bag at a time, twice a day. Oral orally for 4 weeks.
219469710|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
219469711|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
219469712|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
219469713|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
219469714|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
219469715|NCT00019331|BIOLOGICAL|aldesleukin|
219469716|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
219469717|NCT00019331|BIOLOGICAL|sargramostim|
219469718|NCT00019331|DRUG|DetoxPC|
219469719|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
219469720|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
219469721|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
219469722|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
219469723|NCT02020681|DEVICE|Fluoride|Single application on day D90
219469724|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
219469725|NCT01467531|DRUG|Dolutegravir|50mg q 24h
219469726|NCT01467531|DRUG|Rlipivirine|25mg q24h
219469727|NCT01467531|DRUG|GSK1265744|30mg q24h
219469728|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
219469729|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
219594775|NCT04669847|OTHER|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
219594776|NCT00278889|DRUG|AZD2171|oral tablet
219594777|NCT00278889|DRUG|5-fluorouracil|intravenous infusion
219594778|NCT00278889|DRUG|Leucovorin|intravenous infusion
219469730|NCT00516945|DRUG|Lamivudine|
219469731|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
219469732|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
219469733|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
219469734|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
219469735|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
219469736|NCT04236986|DRUG|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
219469737|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
219469738|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
219469739|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
219469740|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
219594779|NCT00278889|DRUG|Oxaliplatin|intravenous infusion
219594780|NCT00278889|DRUG|Bevacizumab|intravenous infusion
219594781|NCT06871722|BEHAVIORAL|Plant based diet|"The plant-based diet in this study is defined as a predominantly vegetarian dietary pattern, consisting of two vegetarian meals per day and one meal that includes animal-derived protein. The diet is based on whole foods while avoiding ultra-processed foods.~Macronutrient Composition Caloric Intake: 30-35 kcal per kilogram of body weight per day Protein Intake: 0.8-1 g per kilogram of body weight per day Fat Sources Animal-derived fats are to be avoided. Plant-based oils are recommended as the primary source of dietary fats. Protein Sources Emphasis is placed on plant-based protein sources, including nuts, beans, edamame, tofu, and tempeh.~Dairy consumption is permitted, but cow's milk is discouraged. Instead, plant-based alternatives such as almond milk and soy-based milk (e.g., tofu milk) are recommended.~Egg consumption is allowed but limited to no more than one egg per day"
219594782|NCT05006391|OTHER|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
218855603|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
218855604|NCT01904916|PROCEDURE|Histological biopsy procedure|
218855605|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
218855606|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
218855607|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
218855608|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
218855609|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
219469741|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
219469742|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
219469743|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
219469744|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
219469745|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
219469746|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
219469747|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
219469748|NCT04224662|OTHER|No intervention|There is no intervention for this study
219469749|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
219469750|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
219469751|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
219469752|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
219469753|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
219469754|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
219469755|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
219469756|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
219469757|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
218855610|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
219469758|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
219469759|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
219469760|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
218855611|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
218855612|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
218855613|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
218855614|NCT00002211|DRUG|Nelfinavir mesylate|
218855615|NCT00002211|DRUG|Delavirdine mesylate|
218855616|NCT00002211|DRUG|Stavudine|
218855617|NCT00002211|DRUG|Didanosine|
218855618|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
218855619|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
218855620|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
218855621|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
218855622|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
218855623|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
218855624|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
218855625|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
218855626|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
219199225|NCT03409718|DEVICE|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
219469761|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
219469762|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
219469763|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
218855627|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
218855628|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
218855629|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
219199226|NCT06587841|DEVICE|Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)|The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
219594783|NCT06821633|PROCEDURE|Targeted laser photocoagulation guided by OCTA (Optical Coherence Tomography Angiography)|The patient's eyes were first scanned using the Topcon OCTA (five-field montage) with a 24×20mm and a 6×6mm scan range. After enrollment, the patient underwent treatment on the same day in the retinal laser room. The laser treatment was performed by the same ophthalmologist. After obtaining baseline fundus images, the treating ophthalmologist overlaid the OCTA images onto the fundus images using retinal vessel alignment to guide targeted photocoagulation of the retinal non-perfusion (NP) areas under OCTA guidance. The specific photocoagulation method involved applying a grid pattern of spot laser (3×3) to the NP area once, with the treatment area extending beyond the NP boundary by one laser spot diameter. The total procedure duration was 10-20 minutes.
219469764|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
219469765|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
219469766|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
219469767|NCT00497744|DRUG|Intraperitoneal Cefepime|
219469768|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
219469769|NCT02249377|DRUG|Corticosteroid|Corticosteroid
219469770|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
219594784|NCT06347705|BIOLOGICAL|2141-V11 Antibody|2141-V11 Antibody: Intratumor injection
219469771|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
219469772|NCT01326481|DRUG|TRC105|IV
219469773|NCT01326481|DRUG|Capecitabine|oral
219469774|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
219469775|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
219469776|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
219469777|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
219469778|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
219469779|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
219469780|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
219469781|NCT01729806|BIOLOGICAL|Rituximab|Given IV
219469782|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
219469783|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
219469784|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
219469785|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
219469786|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
219469787|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
219469788|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
219469789|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
219469790|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
219469791|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
219594785|NCT06831552|BEHAVIORAL|RISE Intervention|Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
219594786|NCT06115044|PROCEDURE|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
218855630|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
218855631|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
218855632|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
218855633|NCT02125916|OTHER|oxygen therapy|
218855634|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
219469792|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
219469793|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
219469794|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
219469795|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
219469796|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
219469797|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
219469798|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
219469799|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
219469800|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
219469801|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
219594787|NCT06115044|PROCEDURE|Continuous|Calculated daily nutritional requirement given over 24 hours
218855635|NCT00017589|BIOLOGICAL|oblimersen sodium|
218855636|NCT00017589|DRUG|gemtuzumab ozogamicin|
219594788|NCT04157127|BIOLOGICAL|Autologous DC Therapy|Autologous DC Therapy
219594789|NCT03462459|DRUG|Vancomycin|Vancomycin capsule, 125 mg
219594790|NCT03462459|DRUG|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
218855637|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
218855638|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
219199227|NCT06824038|BEHAVIORAL|nutritional counseling|"Nutritional counseling based on the nutritional assessment of each patient. Each patient will receive a package of:~i. A booklet that contains the whole instructions and dietary records to help in remembering information and record their application of the plan.~ii. A tailored diet menu adjusted according to the required calories of the patient calculated by the Harris Benedict equation, considering the patient preferences, individualized requirements and with choices suitable for different economic classes."
219469802|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
219469803|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
219469804|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
219469805|NCT00278213|BIOLOGICAL|alemtuzumab|
219469806|NCT00278213|DRUG|cyclophosphamide|
219469807|NCT00278213|DRUG|fludarabine phosphate|
219469808|NCT00278213|DRUG|mitoxantrone hydrochloride|
219469809|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
219469810|NCT00039936|BEHAVIORAL|Self Help|
219469811|NCT00039936|BEHAVIORAL|Partial Self Help|
219469812|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
219469813|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
219469814|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
219469815|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
219469816|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
219469817|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
219594791|NCT01449097|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
219594792|NCT01449097|PROCEDURE|The femoral nerve block|US-guided femoral nerve block with ropivacaine
219594793|NCT01449097|PROCEDURE|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
219594794|NCT06659718|DRUG|Oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
219594795|NCT06659718|DRUG|Sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
219469818|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
219469819|NCT02348931|PROCEDURE|corrective surgery|
219469820|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
219469821|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
219469822|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219469823|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219469824|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
219469825|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
219469826|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
219469827|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
219469828|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
219469829|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
219469830|NCT04873609|BEHAVIORAL|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
218855639|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
218855640|NCT01753219|PROCEDURE|Onstep|
218855641|NCT01753219|PROCEDURE|Lichtenstein|
219469831|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
219469832|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
219469833|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
219469834|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
219469835|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
219469836|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
219469837|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
219469838|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
218855642|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
218855643|NCT02887053|DEVICE|MRI|
218855644|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
218855645|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
218855646|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
218855647|NCT06413420|OTHER|No treatment|No treatment
218855648|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
219199228|NCT06591728|DIETARY_SUPPLEMENT|Oral PCA|Administration of 1,000 mg BID of oral PCA in individuals with knee prosthetic joint infection prior to revision surgery
219199229|NCT06842446|DIAGNOSTIC_TEST|POC D-dimer|POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model
219199230|NCT06842446|DIAGNOSTIC_TEST|POC ultrasound|Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician.
219199231|NCT06842446|DIAGNOSTIC_TEST|Machine learning model|The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
219199232|NCT05997979|DRUG|Capsaicin 8% patch|Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
219199233|NCT05997979|DEVICE|Hydrocolloid dressing|Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
219469839|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
219469840|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
219469841|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
219469842|NCT04781946|PROCEDURE|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
219594796|NCT06865131|DEVICE|StrataXRT|StrataXRT being a silicone-based cream forming a film, it is very flexible and can be applied easily to the prone position and to the contours of the large breast unlike some other barrier film skin interventions
219199234|NCT06609538|OTHER|Control Group|Receives standard preoperative instructions and propofol or ketamine infusion.
219199235|NCT06609538|OTHER|Suggestion Group|Receives positive preoperative suggestions and propofol or ketamine infusion.
219199236|NCT06611007|DRUG|embolization therapy|Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
219199237|NCT06855069|DRUG|HS-20089|HS-20089 dose 1
219199238|NCT06855069|DRUG|Paclitaxel|Paclitaxel dose 2
219199239|NCT06855069|DRUG|Doxorubicin|Doxorubicin dose 3
219199240|NCT06855069|DRUG|Topotecan|Topotecan dose 4
219199241|NCT04602611|OTHER|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
219199242|NCT06858072|OTHER|Instrument assissted soft tissue mobilization(IASTM)|IASTM (Instrument-Assisted Soft Tissue Mobilization) in four specific body areas. The quadratus lumborum, posterior fascia, sacrum, hip lateral rotators, and hamstring bilaterally were these areas. The subjects were asked to kneel directly on the bed to stimulate the lumbar posterior muscles erector spinae (iliocostalis, longissimus), lumborum, and multifidus. At the same time, the IASTM treatment was applied to the rear fascia. The same treatment was applied to the sacrum while the subject kneeled on the bed. For hip lateral rotators, the IASTM treatment was applied to the gluteus maximus and gluteus medius while kneeling in a prone position with knee and hip flexion. Similarly, for the hamstring bilaterally, the IASTM treatment was applied to the biceps femoris, semitendinosus, and semimembranosus while in a prone position. The instrument was used for about 20 seconds in a direction parallel to the muscle fibers being treated and then for an additional 20 sec perpendicular to fibres
219363174|NCT06915428|BEHAVIORAL|Support gift #4|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 26+0 and 33+6 weeks gestation at time of routine prenatal appointment"
219363175|NCT06915428|BEHAVIORAL|Additional PTBCARE+ support|"Additional benefits / support items and support elements are provided to some participants on an as needed basis, per study protocol.~* Information / details intentionally withheld and not made public in order to preserve the scientific validity of the study and protect the rights of the research participants~* participant eligibility for additional resources as a part of the PTBCARE+ program will be determined by the research staff on the day of Visit 1 after initial set of surveys are completed, and is per protocol"
219363176|NCT06915428|BEHAVIORAL|Stress reduction toolkit - Visit 1 (V1)|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include:~Tote bag with the following stress reduction items or similar:~* eye mask~* set of pocket index cards, printed back and front, on a variety of topics that influence pregnancy health, ranging from physical to emotional/mental~* water bottles~* small notebook~* pill minder case~* magnet and business card for Health Resources and Services Administration (HRSA) national maternal mental health hotline~* log in codes for electronic resources~* initial handouts with self care plan, introduction to stress reduction toolkit, etc."
219469843|NCT04781946|PROCEDURE|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
219594797|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
219594798|NCT06498869|DRUG|Ketamine Hcl 50Mg/Ml Inj|This group will be administered ketamine (0.25-0.50 mg/kg)
219594799|NCT04666805|DRUG|Tamoxifen|20 mg/d, oral administration
219594800|NCT04666805|DRUG|Toremifene|60 mg/d, oral administration
219594801|NCT04666805|DRUG|Anastrozole|1 tablet (1 mg) per day, oral administration
219594802|NCT04666805|DRUG|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
219469844|NCT04781946|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
219469845|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
219469846|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
219469847|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
219469848|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
219469849|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
219469850|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
219469851|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
219469852|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
219469853|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
219469854|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
219469855|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
219469856|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
219469857|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
219469858|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
219469859|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
219469860|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
219594803|NCT04666805|DRUG|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
219594804|NCT06758661|DRUG|D352|1 tablet
219594805|NCT06758661|DRUG|D794|4 capsule
219594806|NCT06907537|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take four capsules per day in the morning.
219594807|NCT06907537|DIETARY_SUPPLEMENT|Food without plasmalogen|Take four capsules per day in the morning.
219594808|NCT04042376|DRUG|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
219594809|NCT04465552|OTHER|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
219469861|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
219469862|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
219469863|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219594810|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
219594811|NCT00254852|PROCEDURE|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
219594812|NCT00254852|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
219594813|NCT00254852|PROCEDURE|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
219469864|NCT02442284|DRUG|Ribavirin|Tablet
219469865|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
219469866|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
219469867|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
219469868|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
219469869|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
219469870|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
219469871|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
219469872|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
219594814|NCT00254852|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
219594815|NCT00254852|PROCEDURE|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
219594816|NCT06915857|DEVICE|Topical Betamethasone|Betamethasone a TC, reduces RD by promoting the synthesis of anti-inflammatory proteins while also preventing other inflammatory proteins from being synthesized
219594817|NCT04215991|DRUG|Cefiderocol|Administered intravenously over 3 hours
219594818|NCT04215991|DRUG|Standard of Care|Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
219594819|NCT06938867|BIOLOGICAL|SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli|SNIPR001 is a live biotherapeutic product
219594820|NCT06938867|OTHER|Placebo 10 mL|Placebo 10 mL matching to SNIPR001 will be administered.
219469873|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
219469874|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
219469875|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
219469876|NCT00324519|DEVICE|Foley bulb|
219469877|NCT00324519|DRUG|misoprostol|
219469878|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
219469879|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
219469880|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
219469881|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
219469882|NCT06679920|DEVICE|Optical coherence tomography|Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
219469883|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
219594821|NCT06943222|OTHER|Traditional Play|"The intervention for the traditional play group included activities such as Shtapu and skipping rope. Both traditional play activities were scheduled 3 times per week (3 Session/week) over the 6-month period.~Both activities took place outdoors and in the institutional gymnasium, depending on the prevailing weather conditions. Each session lasted 35 minutes and took place in the morning hours (8-11 a.m.). Prior to each type of activity, a specific warm-up was conducted, following methodological guidelines for preschoolers' physical education."
218855649|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
218855650|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
218855651|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
219469884|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
219469885|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
219469886|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
219469887|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
219469888|NCT01966406|DEVICE|Nasogastric tube|
219469889|NCT01966406|OTHER|No nasogastric tube|
219469890|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
219469891|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
219469892|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
219469893|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
219469894|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
219469895|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
219594822|NCT06952361|PROCEDURE|Red blood cell transfusion|Standard red blood cell transfusion performed as part of routine clinical care. All participants received one or more units of RBCs based on a restrictive hemoglobin threshold. The transfusion protocol was not altered for the purpose of the study.
218855652|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
218855653|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
219469896|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
219469897|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
219469898|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
219469899|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
219469900|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
219469901|NCT00459680|DEVICE|Laser acupoint treatment|Laser
219594823|NCT06954532|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy, relative to their objective accuracy.
219594824|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
219594825|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
219594826|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
219594827|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
219594828|NCT05927363|OTHER|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
219594829|NCT05927363|OTHER|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
219594830|NCT05927363|OTHER|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
219594831|NCT05927363|OTHER|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
219594832|NCT05927363|OTHER|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
219594833|NCT05927363|DIAGNOSTIC_TEST|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
219469902|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
219469903|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
219469904|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
219469905|NCT06376942|OTHER|Saline|0.9% saline 2 ml
219469906|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
219469907|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
219469908|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
219469909|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
219469910|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
219469911|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
219469912|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
219469913|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
219469914|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
219469915|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
219469916|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
219469917|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
219469918|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
219469919|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
219469920|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
219469921|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
219469922|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
219469923|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
219469924|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
219469925|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
219469926|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
219469927|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
219469928|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
219469929|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
219469930|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
219469931|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
219469932|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
219469933|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
219469934|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
219469935|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
219469936|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
219469937|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
219469938|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
219469939|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
219594834|NCT05927363|DIAGNOSTIC_TEST|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
219469940|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
219469941|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
219594835|NCT05927363|DEVICE|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
219594836|NCT05927363|OTHER|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
218855654|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
218855655|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
218855656|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
219469942|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
219469943|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
219469944|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
219469945|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
219469946|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
219594837|NCT06953973|OTHER|Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. Participants in the experimental group included in the Tecar therapy application will be applied to the muscle groups in the neck region at a fixed frequency of 0.448 Mhz for 10 minutes.
219594838|NCT06953973|OTHER|Sham Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. The patient will be positioned as in the Tecar group, but the heating feature of the device will not be activated.
219594839|NCT06953973|OTHER|Standard Physiotherapy Program|This study will include routinely applied conventional physiotherapy, heat modalities, electrotherapy (transcutaneous electrical nerve stimulation (TENS) and ultrasound therapy), and exercises. In this study, hot pack will be used to induce vasodilation and reduce muscle spasm. Hot pack will be used for 15 minutes to relax muscle spasms and increase soft tissue flexibility. TENS is a simple noninvasive modality and is widely used in both acute and chronic neck pain. In our study, 50 Hz conventional TENS with a pulse duration of \<150 microseconds will be used. TENS will be applied to the painful area of the neck for 20 minutes. Ultrasound therapy used to warm deep tissues is one of the most frequently used physical therapy methods. An ultrasound device (Chattanooga, USA) will be used in the study. Ultrasound gel will be applied circularly with a thickness of 2-3 mm. Ultrasound will be applied with a 4 cm2 probe for 5 minutes with a frequency of 1 MHz and 1.5 Wt/cm2. Within the scope o
219594840|NCT04759105|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
219594841|NCT04759105|OTHER|Sham Procedure|anaesthesia, no disc injection, no placebo injection
219594842|NCT06809114|DRUG|AT03-65|Treatment will continue until disease progression, unacceptable toxicity, subject withdrawal of consent or death.
219594843|NCT03464721|DEVICE|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
219594844|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
219594845|NCT04343157|RADIATION|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
219594846|NCT03914625|DRUG|Asparaginase Erwinia chrysanthemi|Given IV or IM
218855657|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
218855658|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
218855659|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
218855660|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
219594847|NCT03914625|BIOLOGICAL|Blinatumomab|Given IV
219469947|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
219594848|NCT03914625|DRUG|Cyclophosphamide|Given IV
219594849|NCT03914625|DRUG|Cytarabine|Given IT or IV
219469948|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
219469949|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
219469950|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
219469951|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
219469952|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
219469953|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
219469954|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
219469955|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
219469956|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
219469957|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
219469958|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
219469959|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
219469960|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
219469961|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
219469962|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
219469963|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
219469964|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
219469965|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
219469966|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
219469967|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
219469968|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
219469969|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
219469970|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
219594850|NCT03914625|DRUG|Dexamethasone|Given PO or IV
219594851|NCT03914625|DRUG|Doxorubicin Hydrochloride|Given IV
219594852|NCT03914625|DRUG|Leucovorin Calcium|Given PO or IV
219594853|NCT03914625|DRUG|Mercaptopurine|Given PO
219594854|NCT03914625|DRUG|Mercaptopurine Oral Suspension|Given PO
219594855|NCT03914625|DRUG|Methotrexate|Given IT or IV
219594856|NCT03914625|DRUG|Pegaspargase|Given IV or IM
219594857|NCT03914625|DRUG|Prednisolone|Given PO or IV
219594858|NCT03914625|DRUG|Prednisone|Given PO or IV
219594859|NCT03914625|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
219594860|NCT03914625|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
219594861|NCT03914625|DRUG|Thioguanine|Given PO
219594862|NCT03914625|DRUG|Vincristine Sulfate|Given IV
219469971|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
218855661|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
218855662|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
218855663|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
218855664|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
219469972|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
219469973|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
219469974|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
219469975|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
219469976|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
219469977|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
219469978|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
219469979|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
219469980|NCT00004024|BIOLOGICAL|aldesleukin|
219469981|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
219469982|NCT00004024|BIOLOGICAL|muromonab-CD3|
219469983|NCT00004024|BIOLOGICAL|sargramostim|
219469984|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
219469985|NCT00004024|PROCEDURE|surgical procedure|
219594863|NCT05870579|DRUG|[68Ga]Ga-NeoB|"\[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose."
219594864|NCT05870579|DRUG|[177Lu]Lu-NeoB|Study participants will receive \[177Lu\]Lu-NeoB once every cycle
219469986|NCT00004024|RADIATION|radiation therapy|
219469987|NCT02744963|OTHER|Free and convenient medicine access|
219469988|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
219469989|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
219469990|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
219469991|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
219469992|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
219469993|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
219594865|NCT05870579|DRUG|Ribociclib|600 mg once daily (OD) days 1 to 21 every 28 days
219594866|NCT05870579|DRUG|Fulvestrant|500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
219594867|NCT05870579|OTHER|Goserelin|For pre/peri-menopausal women and men only.
219594868|NCT06057571|DRUG|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
219594869|NCT02633163|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
219469994|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
219469995|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
219469996|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
219469997|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
219469998|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
219469999|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
219470000|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
219470001|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
219594870|NCT02633163|DRUG|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.
219594871|NCT02633163|DRUG|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
219594872|NCT05459935|DEVICE|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
219594873|NCT05459935|DEVICE|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
219594874|NCT06084117|OTHER|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
219594875|NCT06084117|OTHER|NIV|Respiratory support with Non-invasive ventilation, standard of care
218855665|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
219470002|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
219470003|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
219470004|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
219594876|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
219594877|NCT06408298|DRUG|Placebo|Inactive tablet
219594878|NCT03385655|DRUG|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
219594879|NCT03385655|DRUG|Savolitinib|600mg once daily, orally.
219594880|NCT03385655|DRUG|Darolutamide|600mg twice daily, orally.
219594881|NCT03385655|DRUG|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
219594882|NCT03385655|DRUG|Ipatasertib|400mg daily 3 weeks on, 1 week off
219594883|NCT03385655|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
219594884|NCT03385655|DRUG|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
219594886|NCT06850753|PROCEDURE|Liver transplantation after en bloc resection of the liver and pancreas|Exenteration of the upper right part of the abdomen, including the liver and pancreas en bloc in locally advanced hilar cholangiocarcinoma, followed by liver transplantation
219594887|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
219594888|NCT06425926|DRUG|GIM-531|GIM-531 administered orally daily
219594889|NCT06425926|DRUG|Anti-PD-1 monoclonal antibody|Continued treatment with anti-PD-1 therapy
219594890|NCT05873686|DRUG|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
219594891|NCT03648814|PROCEDURE|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
219594892|NCT03648814|PROCEDURE|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
219470005|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
219470006|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
219470007|NCT06400420|OTHER|Exercise|classic futsal training program
219470008|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
219470009|NCT00381602|OTHER|Placebo|
219594893|NCT06457256|BEHAVIORAL|CLS-A-FUERTE|CLS-A-FUERTE Intervention Description: The CLS-A-FUERTE program is a school clinician training and psychosocial intervention program designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). Participating school clinicians are supported by a clinical research team of trainers who co-leads weekly training/consultation meetings and observes each intervention component (i.e., 6 weekly parent and student skills groups, as well as classroom management in the form of a Daily Report Card) in-vivo via videoconferencing.
219594894|NCT05557591|DRUG|BNT116|BNT116 is administered by IV injection.
219470010|NCT03742895|DRUG|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
218855666|NCT06896123|BEHAVIORAL|Dance Well: an artistic, multisensory dance intervention based on art and music|DW is specifically designed for people with early to mild severe PD and aims to de-liver multiple stimuli, including rhythmical auditory cues, proprioceptive and sensorimo-tor stimulation, balance training, and aerobic exercise, using carefully selected music to cue movement and promote relaxation. The components of DW are relatively simple and easy to be learned and performed for people with compromised mobility. The intervention is also enjoyable and engaging, as reported for other genres of dance
219470011|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
219470012|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
219470013|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
219199243|NCT06858072|OTHER|Transverse friction massage|patient was lying prone while the therapist administered a transverse friction massage to the affected area. Before the massage, the therapist cleansed and dried the place to be treated, ensuring it was free of dirt or debris. The therapist used their palpation skills to locate the site of pain and apply the massage technique accordingly. The therapist performed the transverse friction massage using their thumb to apply pressure across the muscle fiber, with each repetition lasting for two minutes
219470014|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
219470015|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
219470016|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
219470017|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
219470018|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
218855667|NCT06896123|BEHAVIORAL|Conventional motor therapy group|Conventional Motor Therapy consisted on 60-minute conventional physiotherapy, twice a week, for four weeks
218855668|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
218855669|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
219199244|NCT06858748|OTHER|Observational|This is a 24-month observational study in adults in three disease domains, consisting of screening visit, baseline visit, quarterly telemonitoring visit and end of monitoring period
219470019|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
219470020|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
219470021|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
219470022|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
219594895|NCT05557591|DRUG|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
219594896|NCT02185690|DRUG|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
218855670|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219470023|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
219470024|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
219470025|NCT00482976|DRUG|Ruboxistaurin|
219470026|NCT00482976|DRUG|Placebo|
219470027|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
219470028|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
219594897|NCT02185690|DRUG|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
219594898|NCT02185690|DRUG|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
219594899|NCT06671457|DEVICE|Active transcranial direct current stimulation|"The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some"
218855671|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
218855672|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
218855673|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
219199245|NCT06859060|BEHAVIORAL|BRIDGES Healthcare Manager Intervention|A culturally adapted, multilevel intervention consisting of monthly 60-minute sessions over a 12-month period. Sessions will be conducted by graduate clinical psychology students acting as healthcare managers. The intervention focuses on care coordination, patient activation, and reducing provider stigma to improve access to preventive primary care services.
219470029|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
219470030|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
219470031|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
219470032|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
219470033|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
219470034|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
219470035|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
219470036|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
219470037|NCT02250157|DRUG|Oratecan|
219470038|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
219470039|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
219470040|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
219470041|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
219470042|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
219470043|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
219470044|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
219470045|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
219470046|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
219470047|NCT00798161|DRUG|matching placebo|matching placebo
219594900|NCT06671457|DEVICE|Sham transcranial direct current stimulation|In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
219594901|NCT04201964|DRUG|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
219594902|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
219594903|NCT02438904|BIOLOGICAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
219594904|NCT02438904|DEVICE|Miltenyi device|Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
219594905|NCT00072787|DRUG|S-1|
219594906|NCT00072787|DRUG|cisplatin|
219594907|NCT02302989|DRUG|Ranibizumab 0.5mg|
219594908|NCT00478244|DRUG|busulfan|Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
218855674|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
218855675|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
218855676|NCT03783741|BEHAVIORAL|Questionnaire|Interview
218855677|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
218855678|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
219363199|NCT06092294|BEHAVIORAL|Tactical training in numerical superiority and numerical inferiority|"In the present study, the SSGs training sessions will be carried out in the following areas:~2c1: length 11.5m and width 9m (total: 103.5m2), equivalent to 34.5m2 for each player.~3c2: length 14m and width 12m (total: 168m2), equivalent to 33.6m2 for each player.~4c3: length 17m and width 14m (total: 238m2), equivalent to 34m2 per each player."
219594909|NCT00478244|DRUG|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
219594910|NCT00478244|DRUG|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
218855679|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
218855680|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
219594911|NCT00478244|PROCEDURE|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
219594912|NCT05968417|OTHER|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
219594913|NCT01870440|DRUG|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
219594914|NCT00154518|PROCEDURE|Orthodontic treatment|
219594915|NCT04618640|BIOLOGICAL|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
219594916|NCT01675466|PROCEDURE|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
219594917|NCT01675466|PROCEDURE|General anaesthesia|
219199246|NCT06859060|OTHER|Enhanced Treatment as Usual (ETAU)|Participants will continue to receive standard psychiatric care, including routine visits with their mental health providers at the designated clinical sites. They will also receive a booklet with information on how best to link with primary care providers. This ensures that participants are aware of available resources and basic health care recommendations, but does not include any active follow-up or intervention components.
219363200|NCT06092294|BEHAVIORAL|Conventional training in numerical equality|Coach who will run the CG training program will be different from the coach who will run the GE training program. As with the GE, a coach will also be assigned to the CG to record, quantify and monitor the training stimuli of this comparison group, who will record it on forms designed for this purpose.
219363201|NCT02856750|DRUG|Gabapentin|Gabapentin 300 mg three times daily x30 days
219594918|NCT01675466|DEVICE|Laparoscopic instruments|
219594919|NCT03106389|DRUG|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
219594920|NCT03106389|DEVICE|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
219594921|NCT01658501|DRUG|50 mg PB1023|
219594922|NCT01658501|DRUG|70 mg PB1023|
219594923|NCT01658501|DRUG|100 mg PB1023|
219594924|NCT01658501|DRUG|Placebo (0.9% Sodium Chloride)|
219363202|NCT03017560|BEHAVIORAL|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
219594925|NCT01658501|DRUG|Victoza®|
219594926|NCT01658501|OTHER|Diet and Exercise|
219594927|NCT01658501|DRUG|Metformin|
219594928|NCT01658501|DRUG|Sulfonylurea|
219594929|NCT01658501|DRUG|Metformin and Sulfonylurea|
219363203|NCT04762628|DIETARY_SUPPLEMENT|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
219363204|NCT04762628|DIETARY_SUPPLEMENT|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
219363205|NCT04762628|OTHER|Standard of care|Standard of care
219363206|NCT01757717|RADIATION|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
219363207|NCT03612687|DEVICE|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
219363208|NCT05301075|DRUG|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
219363209|NCT05254028|PROCEDURE|filiform needle|Manual acupuncture using filiform needles
219363210|NCT05410782|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
219363211|NCT03061266|BEHAVIORAL|E-health Education|E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.
219363212|NCT03061266|OTHER|Routine care|Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
219363213|NCT02685917|PROCEDURE|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
219363214|NCT02685917|PROCEDURE|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
219363215|NCT00670410|PROCEDURE|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
219363216|NCT00670410|PROCEDURE|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
218855681|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
218855682|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
218855683|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
219594930|NCT00373633|PROCEDURE|Thoracic Epidural|Gold standard for post thoracotomy pain
219594931|NCT00373633|PROCEDURE|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
219594932|NCT06142318|DRUG|Pirfenidone|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
218855684|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
218855685|NCT00413920|DRUG|Prednisone|Oral tablets
219363217|NCT00670410|DRUG|Busulfan|Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients \> 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration \> 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
218855686|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
219363218|NCT00670410|DRUG|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
219363219|NCT00670410|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
219363220|NCT00518479|DRUG|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
219363221|NCT00518479|DRUG|Valsartan 160mg OD; Moxonidine 400mcg OD|
219363222|NCT04426695|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
219363223|NCT04426695|DRUG|Placebo|Placebo IV Single Dose
219363224|NCT05389488|DEVICE|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
219363225|NCT05389488|DEVICE|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
219363226|NCT02590484|PROCEDURE|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
219363227|NCT03618745|DEVICE|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
219363228|NCT04703569|PROCEDURE|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
219363229|NCT04703569|PROCEDURE|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
219363230|NCT00559273|DRUG|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
219363231|NCT00559273|DRUG|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
219363232|NCT04803760|OTHER|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
219363233|NCT01717131|PROCEDURE|Surgery for standard axillary node dissection|
219363234|NCT01717131|OTHER|No axillary lymph node dissection|No surgery on axillary lymph node
219363235|NCT01648257|DRUG|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
219363236|NCT01648257|DRUG|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
219363237|NCT01648257|DRUG|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
219363238|NCT05398614|BIOLOGICAL|SENL101|Patients will be treated with CD7 CAR-T cells
219363239|NCT02663739|DEVICE|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
219363240|NCT06547983|OTHER|Personalized nutritional advice|Participants in the intervention group received personalized nutrition advice based on their dietary habits, weight, anthropometric data and physical activity.
219363241|NCT06547983|OTHER|Personalized nutritional advice and food boxes|Participants in the intervention plus group received the personalized nutrition advice while also receiving food boxes which are composed based on the personalized nutritional advice.
219363242|NCT00732745|DRUG|docetaxel|Given IV
219363243|NCT00732745|DRUG|oxaliplatin|Given IV
219363244|NCT00732745|DRUG|vandetanib|Given orally
219363245|NCT00732745|OTHER|placebo|Given orally
219363246|NCT02798926|DEVICE|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
219363247|NCT04401033|BEHAVIORAL|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
219363248|NCT04401033|PROCEDURE|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
218855687|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
218855688|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
218855689|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
218855690|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
218855691|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
218855692|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
219470048|NCT03334942|BEHAVIORAL|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
219470049|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
219470050|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
219470051|NCT00761761|DRUG|Sensoril|
219470052|NCT00761761|OTHER|Placebo|
219470053|NCT06326203|BIOLOGICAL|CELULAS TRONCO|Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
219594933|NCT06142318|DRUG|Placebo|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
219594934|NCT03778684|DIAGNOSTIC_TEST|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
219594935|NCT03778684|DIAGNOSTIC_TEST|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
218855693|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
218855694|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
218855695|NCT03730961|DRUG|BMS-986231|Intravenous administration
218855696|NCT03730961|DRUG|Furosemide|Intravenous administration
218855697|NCT03730961|DRUG|Placebo|Intravenous administration
218855698|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
218855699|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
219363249|NCT04401033|PROCEDURE|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
219363250|NCT03387787|DEVICE|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
219594936|NCT02929056|BIOLOGICAL|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
219594937|NCT02929056|PROCEDURE|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
218855700|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
218855701|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
219363251|NCT03387787|DRUG|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
218855702|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
219470054|NCT06326203|DEVICE|CONVENTIONAL DRESSING|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
219470055|NCT03342911|DRUG|Paclitaxel|Given IV
219470056|NCT03342911|DRUG|Carboplatin|Given IV
219470057|NCT03342911|BIOLOGICAL|Nivolumab|Given IV
219470058|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
219594938|NCT02647385|DRUG|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
219594939|NCT03132155|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
219594940|NCT05860855|PROCEDURE|Augmentative craniotomy|Expansion of the skull
218855703|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
218855704|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
218855705|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
218855706|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
219199531|NCT05625646|OTHER|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
219470059|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
219470060|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
219470061|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
219470062|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
219594941|NCT05860855|PROCEDURE|Decompressive craniotomy|Standard hemicraniectomy
219594942|NCT04584762|DEVICE|Automated Variable Pressure Insufflation|Acute migraine treatment
219470063|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
219470064|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
219470065|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
219470066|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
219470067|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
219594943|NCT01654016|DRUG|Detralex|Detralex 500 mg twice daily for three month prior to surgery
219594944|NCT00538369|OTHER|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
219594945|NCT00538369|DEVICE|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
219594946|NCT05089669|OTHER|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
219594947|NCT05089669|OTHER|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
218855707|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
218855708|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
219594948|NCT04638101|BEHAVIORAL|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
219199532|NCT02624050|DRUG|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
219470068|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
219470069|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
219470070|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
219470071|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
219470072|NCT01390376|DRUG|placebo|starch pill
219594949|NCT00109226|DRUG|Avastin (Bevacizumab)|
219594950|NCT03763305|DRUG|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
219594951|NCT03763305|DRUG|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
219594952|NCT03763305|DRUG|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
219594953|NCT03763305|DRUG|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
219594954|NCT03763305|DRUG|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
219594955|NCT03763305|DRUG|Fentanyl|Fentanyl intravenous injection for anesthetic induction
219594956|NCT01650584|DRUG|ISTA Tears|sterile ophthalmic solution
219594957|NCT01650584|DRUG|Systane|Sterile ophthalmic solution
219594958|NCT06226181|PROCEDURE|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
219594959|NCT06226181|PROCEDURE|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
218855709|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
218855710|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
219594960|NCT03655314|OTHER|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
219594961|NCT03655314|OTHER|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
219594962|NCT04320823|DEVICE|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
219594963|NCT04320823|DEVICE|Current Plasma Collection Approach|Plasma collection using the current collection approach.
219594964|NCT04365192|DEVICE|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
219594965|NCT04365192|DEVICE|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
218855711|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
218855712|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
218855713|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
218855714|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
219470073|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
219470074|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
219470075|NCT02434666|DRUG|CPC-201|
219470076|NCT05178290|BEHAVIORAL|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
219470077|NCT05178290|BEHAVIORAL|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
219594966|NCT03451357|DIAGNOSTIC_TEST|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
219594967|NCT02521272|OTHER|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
219594968|NCT02521272|DEVICE|air pocket|Zero air pocket or one-liter air pocket in the snow.
218855715|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
218855716|NCT00274560|DRUG|Tiotropium|
218855717|NCT00274560|DRUG|Salmeterol|
218855718|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
218855719|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
218855720|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
218855721|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
218855722|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
218855723|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
218855724|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
218855725|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
218855726|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
218855727|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
218855728|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
218855729|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
218855730|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
219199533|NCT02624050|DRUG|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
218855731|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
219470078|NCT05178290|BEHAVIORAL|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
219470079|NCT00006292|DRUG|Infliximab|
219470080|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
219470081|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
219470082|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
219470083|NCT02319265|DRUG|Melatonin|Oral liquid
219470084|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
219470085|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
219470086|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
219470087|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
219470088|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
219594969|NCT03685812|DIAGNOSTIC_TEST|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
219594970|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
219594971|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
219199247|NCT06860126|BEHAVIORAL|Intergenerational Activity Program: This indicates a program that involves activities designed for interaction between older adults and younger participants|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a controlled indoor environment.~* Spend the first 45 minutes actively interacting with a younger participant in pairs, collaborating on activities of interest to the senior.~* Participate in group activities such as book reading, puzzles, joke-telling, and sharing experiences for the remaining 45 minutes.~* Attend 36 sessions held on odd days in the main hall of the Neshat Center.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
219470089|NCT04969653|OTHER|Exposure of venous thromboembolism|Composite of pulmonary embolism and deep vein thrombosis
219470090|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
218855732|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
219470091|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
219470092|NCT05078658|OTHER|Low-carbohydrate diet|The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
219470093|NCT05078658|OTHER|Recommended-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.
219470094|NCT04985916|BIOLOGICAL|Vehicle|topical liniment without investigational product
219470095|NCT04985916|BIOLOGICAL|botulinum toxin, Type A|ET-01 topical liniment
219594972|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
219594973|NCT00251511|DRUG|Arsenic Trioxide|
219594974|NCT02925403|BIOLOGICAL|R21/Matrix-M1|
219594975|NCT02925403|OTHER|Saline|
218855733|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
218855734|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
218855735|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
218855736|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
219199534|NCT06492642|OTHER|Patient Education for Chronic Low Back Pain|"Patient education on chronic low back pain (LBP), including:~Day 5: Basic LBP education, types of LBP, red flags; Day 8: LBP guideline recommendations re: imaging; Day 11: LBP guideline recommendations re: use of rehabilitation services, sitting and standing desks; Day 14: LBP guideline recommendations re:pharmacologic management; Day 17: LBP guideline recommendations re: injections and surgery."
219470096|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
219470097|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
219470098|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
219470099|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
219470100|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
219470101|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
219470102|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
219470103|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
219470104|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
219470105|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
219594976|NCT02879903|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
219594977|NCT02879903|PROCEDURE|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
219594978|NCT02879903|PROCEDURE|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
219594979|NCT02488954|OTHER|Probiotics in the form of cheese portion|
219594980|NCT00199147|DRUG|Cytarabine|
219470106|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
219470107|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
219470108|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
219594981|NCT00199147|DRUG|Etoposide|
219594982|NCT00199147|DRUG|Idarubicin|
219594983|NCT00199147|DRUG|G-CSF|
219594984|NCT00199147|DRUG|Fludarabine|
219594985|NCT00199147|PROCEDURE|Stem cell apheresis|
219594986|NCT00199147|PROCEDURE|Stem cell transplantation|
219470109|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
218855737|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
219470110|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
219470111|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
219470112|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
219594987|NCT06505798|PROCEDURE|Catheter Ablation|Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
219594988|NCT04173325|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
219594989|NCT04173325|DRUG|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
219470113|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
219470114|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
219470115|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
219470116|NCT02918968|DRUG|Enzalutamide|Oral Capsule
219470117|NCT02918968|DRUG|Flutamide|Oral tablet
219470118|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
219594990|NCT05625074|PROCEDURE|Conventional surgery for great saphenous vein insufficiency|Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
219594991|NCT01184443|DRUG|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
219594992|NCT00459043|DRUG|ZD6474|Taken orally once every morning
219594993|NCT00459043|DRUG|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
219594994|NCT02499484|DRUG|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
219594995|NCT02499484|OTHER|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
219594996|NCT02499484|OTHER|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
219594997|NCT00167284|BEHAVIORAL|physician and patient education; physician practice redesign|
219594998|NCT03127111|GENETIC|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
219470119|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
219470120|NCT00266617|DRUG|epoetin alfa|
219594999|NCT03127111|GENETIC|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
219595000|NCT03127111|GENETIC|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
219595001|NCT03127111|GENETIC|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
218855738|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
218855739|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
218855740|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
219199535|NCT03685110|DEVICE|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
219470121|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
219470122|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
219470123|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
219470124|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
219470125|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
219470126|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
219470127|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
219595002|NCT03127111|GENETIC|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
219595003|NCT02521805|OTHER|Animal protein|
219595004|NCT02521805|OTHER|Vegetable protein|
219595005|NCT02521805|OTHER|Dietary fiber (cereal food matrice)|
219470128|NCT01388946|DRUG|Ropivacaine 0.75|
219470129|NCT01388946|DRUG|Normal saline|
219595006|NCT02521805|OTHER|Dietary fiber (meat food matrice)|
219595007|NCT02521805|OTHER|Dietary fiber (vegetable food matrice)|
219595008|NCT01842997|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
218855741|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
218855742|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
218855743|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
218855744|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
218855745|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
218855746|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
219470130|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
219470131|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
218855747|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
219470132|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
218855748|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
218855749|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
218855750|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
218855751|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
218855752|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
218855753|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
219470133|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
219470134|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
219470135|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
219470136|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
219595009|NCT00004186|DRUG|carboplatin|
219595010|NCT00004186|DRUG|etoposide|
219595011|NCT00004186|DRUG|ifosfamide|
219595012|NCT00004186|DRUG|topotecan hydrochloride|
219595013|NCT00004186|RADIATION|radiation therapy|
219595014|NCT02618525|OTHER|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
219595015|NCT02618525|OTHER|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
219595016|NCT04683224|BIOLOGICAL|UB-612|100 µg \[microgram\] of an experimental study vaccine
219595017|NCT04683224|OTHER|Placebo|Placebo is a 0.9% sodium chloride (normal saline) injection
219199536|NCT06060535|BEHAVIORAL|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
219470137|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
219470138|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
219470139|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
219470140|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
219470141|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219470142|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219470143|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
219470144|NCT00295256|BEHAVIORAL|nurse case manager|
219470145|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
219470146|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
219470147|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
219470148|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
219470149|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
219595018|NCT06387524|PROCEDURE|McConnell Taping|Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
219595019|NCT06387524|PROCEDURE|ECCENTRIC EXERCISES:|"Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch"
219595020|NCT01477723|OTHER|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
219595021|NCT06334224|DEVICE|Low load resistance training with blood flow restriction|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
219020396|NCT07105280|DEVICE|Conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with the patient's original conventional DBS (cDBS) settings.
219020397|NCT07105280|DEVICE|Optimized conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with a previously optimized version of the patient's original conventional DBS (O-cDBS) settings.
219199537|NCT06690983|DIAGNOSTIC_TEST|18F-S16/T807|Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
219470150|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
219470151|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
219470152|NCT05375942|DRUG|Inflectra|1\. To describe the characteristics of patients newly initiated on Inflectra.
219470153|NCT05375942|DRUG|Inflectra|2\. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
219470154|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
219470155|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
219470156|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
219470157|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
219470158|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
219470159|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
219470160|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
219470161|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
219470162|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
218855754|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
218855755|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
218855756|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
218855757|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
218855758|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
218855759|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
218855760|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
218855761|NCT03332719|BIOLOGICAL|Etanercept|
219470163|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
219470164|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
219470165|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
219470166|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
219470167|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
219470168|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
219470169|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
219470170|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
219470171|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
219470172|NCT03454191|PROCEDURE|No injection|No injection
219470173|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
218855762|NCT03332719|DRUG|Methotrexate|
219470174|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
219470175|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
219470176|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
219470177|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
219470178|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
219470179|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
219470180|NCT03562676|OTHER|weightlessness|parabolic flight
219470181|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
219470182|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
219470183|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
219595022|NCT06334224|OTHER|Low load resistance training|Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
219595023|NCT03414216|PROCEDURE|Group 1 early offloading surgery|As above.
218855763|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
218855764|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
218855765|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
218855766|NCT03054597|PROCEDURE|Exercise|
218855767|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
218855768|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
219470184|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
219470185|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
219470186|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
219470187|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
218855769|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
218855770|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
218855771|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
218855772|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
218855773|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
218855774|NCT03576755|DRUG|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
218855775|NCT03576755|DRUG|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
218855776|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
219020398|NCT07105280|DEVICE|Optimized adaptive DBS|Treatment for a minimum of 2 to a maximum of 7 days with previously optimized adaptive DBS (O-aDBS) settings.
219470188|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
219595024|NCT03414216|PROCEDURE|Group 2 - off-loading in fiberglass cast|As above.
219595025|NCT04190758|OTHER|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
219595026|NCT00330317|DRUG|letrozole|2.5mg letrozole once-daily
219595027|NCT03794050|OTHER|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
219595028|NCT03794050|OTHER|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
219595029|NCT03523455|DIETARY_SUPPLEMENT|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
219595030|NCT03523455|OTHER|Sugar Pill|Taken orally in capsule form
219470189|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
219470190|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
218855777|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
218855778|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
218855779|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
218855780|NCT05244460|DRUG|Diphenhydramine|Treatment
218855781|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
218855782|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
218855783|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
218855784|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
218855785|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
218855786|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
218855787|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
218855788|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
218855789|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
218855790|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
218855791|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
219470191|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
219470192|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
219470193|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
219470194|NCT01256866|DRUG|Dexmedetomidine|
219470195|NCT01256866|DRUG|Midazolam|
219470196|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
219470197|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
219470198|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
218855792|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
219199538|NCT06686147|DIAGNOSTIC_TEST|Assessment of Joint Range of Motion|Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.
219199539|NCT06622590|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
219199540|NCT06622590|BIOLOGICAL|QIV control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
219199541|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of Ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
219470199|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
219470200|NCT00139269|DRUG|Docetaxel|
219470201|NCT00139269|DRUG|Cisplatin|
219470202|NCT00139269|DRUG|5-Fluorouracil|
219470203|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
219470204|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
219470205|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
218855793|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
218855794|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
218855795|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
218855796|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
218855797|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
218855798|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
218855799|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
218855800|NCT00129870|DRUG|oxaliplatin|
219470206|NCT00161148|DRUG|Probiotics|
218855801|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
218855802|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
218855803|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219199542|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
219470207|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
219470208|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
219470209|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
219470210|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
219470211|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
219470212|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
219470213|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
219470214|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
219470215|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
219595031|NCT02899195|DRUG|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
219595032|NCT00351403|DRUG|Ribavirin|Rebetol 200 mg: applied as hard capsule
219595033|NCT00351403|DRUG|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
219595034|NCT00010764|PROCEDURE|Acupuncture|
219595035|NCT04153903|OTHER|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
219595036|NCT00192803|DRUG|candesartan|
218855804|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
218855805|NCT03933410|DRUG|KB195|KB195 is a novel glycan
218855806|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
218855807|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
219199543|NCT06623331|OTHER|AI-enhanced endoscopy training|Endoscopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.
218855808|NCT01151735|DRUG|placebo|placebo
218855809|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
218855810|NCT03444766|DRUG|Nivolumab|specified dose on specified days
218855811|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
218855812|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
219470216|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
219470217|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
219470218|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
219470219|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
219595037|NCT03838900|DEVICE|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
219595038|NCT04561271|OTHER|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
219595039|NCT04561271|OTHER|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
219595040|NCT03758716|DRUG|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
219595041|NCT02206360|PROCEDURE|Endoscopic Ultrasound|
219595042|NCT02206360|PROCEDURE|Magnetic Resonance Imaging (MRI)|
219595043|NCT01998763|DIETARY_SUPPLEMENT|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
219595044|NCT01998763|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU per day
219595045|NCT04520126|DIETARY_SUPPLEMENT|Olivomed (capsules containing hydroxytyrosol)|patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.
218855813|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
218855814|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
218855815|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
218855816|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
218855817|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
218855818|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
218855819|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
219199544|NCT06623331|OTHER|Conventional endoscopy training|Endoscopists trained conventionally
219595046|NCT04520126|DIETARY_SUPPLEMENT|OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).|patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
219020401|NCT06946485|BIOLOGICAL|Universal anti-CD70 CAR-T (CHT101)|Universal anti-CD70 CAR-T (CHT101) cell therpy
219020402|NCT06948786|DRUG|Pirtobrutinib|Given PO
219020403|NCT06948786|BIOLOGICAL|Mosunetuzumab|Given IV
219020404|NCT06948786|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral swab and/or rectal swab collection
219020405|NCT06948786|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219595047|NCT03156504|DRUG|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
218855820|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
218855821|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
218855822|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
218855823|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
219595048|NCT04342455|OTHER|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
219595049|NCT00450801|DRUG|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
219595050|NCT00450801|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
219595051|NCT00450801|DRUG|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
219595052|NCT00450801|DRUG|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
219595053|NCT00450801|DRUG|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
219595054|NCT00450801|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
219595055|NCT00450801|DRUG|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
219595056|NCT00450801|DRUG|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
219595057|NCT00450801|DRUG|Thalidomide|Maintenance therapy.
219595058|NCT00450801|DRUG|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
219595059|NCT00450801|DRUG|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
218855824|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
219470220|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
219470221|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
219470222|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
219595060|NCT00450801|DRUG|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
219595061|NCT00450801|DRUG|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
219595062|NCT00450801|DRUG|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
219595063|NCT04677101|DIAGNOSTIC_TEST|Liver Biopsy|Fine-needle liver biopsy
219595064|NCT01423123|DRUG|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
218855825|NCT00196586|DRUG|Interleukin 2|
219470223|NCT00381680|DRUG|vincristine sulfate|Given IV
219595065|NCT01423123|BIOLOGICAL|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
219470224|NCT00381680|DRUG|prednisone|Given PO
218855826|NCT00196586|DRUG|pegylated interferon alpha 2a|
218855827|NCT00196586|DRUG|ribavirin|
218855828|NCT02737644|OTHER|observation|This is an observational study
219020406|NCT06948786|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
219020407|NCT06948786|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219020408|NCT06948786|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219470225|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
219595066|NCT01423123|DRUG|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
219595067|NCT03452137|DRUG|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
219020409|NCT06948786|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219020410|NCT06948786|OTHER|Questionnaire Administration|Ancillary studies
219470226|NCT00381680|DRUG|pegaspargase|Given IM
219470227|NCT00381680|DRUG|cytarabine|Given IT or IV
219470228|NCT00381680|DRUG|methotrexate|Given IT or IV
219470229|NCT00381680|DRUG|dexamethasone|Given PO
219470230|NCT00381680|DRUG|etoposide|Given IV
219470231|NCT00381680|DRUG|cyclophosphamide|Given IV
219470232|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
219470233|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
219470234|NCT00381680|DRUG|asparaginase|Given IM
219595068|NCT03452137|DRUG|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
219595069|NCT05963815|OTHER|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
219595070|NCT00004126|DRUG|oxaliplatin|
219595071|NCT00004126|DRUG|paclitaxel|
219595072|NCT02372279|OTHER|Embryo observation|In EO group, conventional observations will be made.
219595073|NCT05186649|OTHER|WARFARIN|5 mg of daily dosage
219595074|NCT05081986|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
219595075|NCT05081986|DRUG|Cycloserine|Cycloserine 100mg
219595076|NCT05081986|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
219470235|NCT00381680|DRUG|mercaptopurine|Given PO
219470236|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
218855829|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
218855830|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
218855831|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
219199545|NCT06179953|OTHER|NAO intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
219470237|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
219470238|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
219470239|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
219470240|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
219470241|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
219470242|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
219470243|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
219470244|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
219470245|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
219470246|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
219470247|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
219470248|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
219595077|NCT04205058|DIETARY_SUPPLEMENT|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
219595078|NCT04205058|DIETARY_SUPPLEMENT|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
219470249|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
219595079|NCT04205058|DIETARY_SUPPLEMENT|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
219595080|NCT02373449|OTHER|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
219595081|NCT02373449|DRUG|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
219595082|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
219595083|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
218855832|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
218855833|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
218855834|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
218855835|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
219470250|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
219470251|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
219470252|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
219470253|NCT04211454|OTHER|No intervention|There is no intervention for this study.
219470254|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
219470255|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
219470256|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
219470257|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
219470258|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
219470259|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
219470260|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
219595084|NCT04175288|OTHER|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
219595085|NCT03541928|DRUG|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
219595086|NCT03541928|DRUG|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
218855836|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
218855837|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
218855838|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
218855839|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
218855840|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
218855841|NCT01701479|DRUG|ch14.18/CHO|
218855842|NCT01701479|DRUG|Aldesleukin|
218855843|NCT01701479|DRUG|Isotretinoin|
218855844|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
218855845|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
218855846|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
218855847|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
219470261|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
218855848|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
218855849|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
218855850|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
218855851|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
218855852|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
218855853|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
219363252|NCT00395967|DRUG|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
219363253|NCT01016873|DEVICE|IRay|Low voltage stereotactic radiotherapy system
219363254|NCT03073746|OTHER|Health Search|
219363255|NCT03073746|OTHER|Standard Search|
219363256|NCT00506857|DRUG|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
219363257|NCT00506857|DRUG|Fludarabine|30 mg/m\^2 by vein daily x 4 days.
219363258|NCT03118947|DRUG|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
219363259|NCT04765605|DEVICE|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
219363260|NCT01109940|BIOLOGICAL|AIN457A|
219363261|NCT05429567|DRUG|Fentanyl|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
219363262|NCT03653390|BEHAVIORAL|EnhanceWellness for Disability (EW-D)|Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
219363263|NCT03653390|BEHAVIORAL|Wellness Education|Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
219363264|NCT02953145|DRUG|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
219363265|NCT05479292|OTHER|Sars-CoV-2 outbreak|Sars-CoV-2 pandemic's impact on provision of healthcare for cancer patients
219363266|NCT01261819|DEVICE|cystoscopy|
219363267|NCT03031600|DIAGNOSTIC_TEST|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
219363268|NCT03031600|DIAGNOSTIC_TEST|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
219363269|NCT00344097|PROCEDURE|Soy protein|
219470262|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
219470263|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
219470264|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
219470265|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
219470266|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
219470267|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
219470268|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
219470269|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
219470270|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
219470271|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
219470272|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
219470273|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
219470274|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
219470275|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
219470276|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
219470277|NCT00359866|RADIATION|IMRT with tomotherapy|
219470278|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
219470279|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
219470280|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
219470281|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
219470282|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
219470283|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
219470284|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
219470285|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
219470286|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
219470287|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
219470288|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
219470289|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
219470290|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
219470291|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
219470292|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
219470293|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
219470294|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
219470295|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
219470296|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
219470297|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
219470298|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
219470299|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
219470300|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
219470301|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
219470302|NCT00734318|DRUG|Flutiform 250/10 micrograms|
219470303|NCT00734318|DRUG|Flutiform 50/5 micrograms|
219470304|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
219470305|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
219470306|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
219470307|NCT02419443|DRUG|Placebo|Control group
219470308|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
219470309|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
218855854|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
219470310|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
218855855|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
219470311|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
218855856|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
219470312|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219470313|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
219470314|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
219470315|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
219470316|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
219470317|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219470318|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219470319|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
219470320|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
219470321|NCT06129851|DRUG|Relugolix|Given PO
219470322|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
219470323|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
219470324|NCT05851924|DRUG|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle"
219470325|NCT05851924|COMBINATION_PRODUCT|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
219470326|NCT05212246|DRUG|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
218855857|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
218855858|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
218855859|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
218855860|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
218855861|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
218855862|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
218855863|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
219020411|NCT07147764|OTHER|Physiotherapy|Physiotherapy treatment programs include therapeutic ultrasound, muscle relaxation techniques, range of motion exercises, and joint and soft tissue mobilization.
219020412|NCT07147764|BEHAVIORAL|Pain Neuroscience Education|"PNE sessions will be conducted in addition to physiotherapy programs for intervention groups. PNE sessions will occupy half of each session during the first two weeks. Physiotherapists trained in PNE will deliver sessions using a combination of metaphors, animated videos, and scientifically accurate descriptions. The same physiotherapist will lead both sessions with the same patient.~Active learning techniques will include:~Connecting new information with prior knowledge. Operationalizing key pain concepts into individual contexts. Facilitated problem-solving and critical reflection."
219470327|NCT05212246|DRUG|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
219470328|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
219470329|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
219470330|NCT05718895|DRUG|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
219470331|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
219470332|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
218855864|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
218855865|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
218855866|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
218855867|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
218855868|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
218855869|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
218855870|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
218855871|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
218855872|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
218855873|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
219470333|NCT04626947|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab infusion
219470334|NCT00439920|DRUG|High-dose anthracycline|
219470335|NCT02630615|OTHER|Blood draw|Whole blood will be collected using standard phlebotomy procedures
219470336|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
219470337|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
219470338|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
219470339|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
219470340|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
219470341|NCT05577689|OTHER|Tissue|Tissue will be derived from patients during a standard of care procedure
218855874|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
218855875|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
218855876|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
218855877|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
218855878|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
218855879|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
218855880|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
218855881|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
218855882|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
218855883|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
218855884|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
219470342|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
219595087|NCT03541928|DRUG|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
219470343|NCT06080308|OTHER|No intervention|No intervention
219470344|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
219470345|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
219470346|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
219470347|NCT02967393|DRUG|ccIIV4|
219470348|NCT02967393|DRUG|IIV4|
219470349|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
219470350|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
219470351|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
219470352|NCT02183948|DRUG|Oxytocin|
219470353|NCT02183948|DRUG|Placebo|
219595088|NCT03541928|DRUG|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
219595089|NCT03541928|RADIATION|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
219595090|NCT03541928|PROCEDURE|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
219595091|NCT02323828|DIETARY_SUPPLEMENT|High RS cookies|High RS cookies ingestion in healthy young adults
219595092|NCT02323828|DIETARY_SUPPLEMENT|Placebo|Placebo cookies ingestion in healthy young adults
219595093|NCT02625597|DEVICE|Cotton Pellet|
219595094|NCT02625597|DEVICE|Polytetrafluoroethylene Tape|
219595095|NCT02625597|DEVICE|Synthetic Foam|
219595096|NCT02625597|DEVICE|Polyvinylsiloxane|
218855885|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
218855886|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
218855887|NCT02540330|DRUG|Fulvestrant|
218855888|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
219470354|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
219470355|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
219470356|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
219470357|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
219470358|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
219470359|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
219470360|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
219470361|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
219470362|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
219470363|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
219470364|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
219470365|NCT05489432|BEHAVIORAL|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
219470366|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
219595097|NCT02089659|DRUG|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
219595098|NCT00470392|DRUG|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
218855889|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
219020414|NCT07149038|DEVICE|Cerogrin|Participants in this arm will receive transcutaneous auricular vagus nerve stimulation using the Cerogrin device. This device non-invasively delivers electrical stimulation to the vagus nerve located on the outer ear, aiming to improve cognitive function.
219363270|NCT05261854|DEVICE|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
219363271|NCT05261854|OTHER|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
219363272|NCT05901467|DRUG|kisspeptin 112-121|One IV bolus of kisspeptin 112-121
219363273|NCT05901467|DRUG|GnRH|One IV bolus of gonadotropin-releasing hormone
219363274|NCT03983395|BIOLOGICAL|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
219363275|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
219363276|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
219363277|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
219363278|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
219363279|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
219363280|NCT03983395|BIOLOGICAL|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
219363281|NCT03983395|BIOLOGICAL|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
219363282|NCT04428801|BIOLOGICAL|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
219363283|NCT04735276|DEVICE|HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.
219363284|NCT02516670|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
219363285|NCT02516670|DRUG|Docetaxel|Given IV
219363286|NCT02516670|OTHER|Laboratory Biomarker Analysis|Correlative studies
219363287|NCT02516670|OTHER|Pharmacological Study|Correlative studies
219363288|NCT02516670|OTHER|Placebo|Given IV
219363289|NCT02516670|OTHER|Quality-of-Life Assessment|Ancillary studies
219363290|NCT02276859|DRUG|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
219363291|NCT02276859|DRUG|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
219363292|NCT02276859|DRUG|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
219363293|NCT01385735|DRUG|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
219363294|NCT01385735|DRUG|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
219363295|NCT04619394|OTHER|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
219363296|NCT04619394|OTHER|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
219363297|NCT01262976|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 2 doses
219363298|NCT01262976|BIOLOGICAL|Physiological saline|Intramuscular, 2 doses
219363299|NCT05574179|DRUG|Dexmedetomidine injection|Inj precedex 200mcg in 1ml given in stat doses
219363300|NCT05574179|DRUG|Midazolam|Inj.midazolam 5mg/5ml given in stat doses
218855890|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
219470367|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
219470368|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
219470369|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
219595099|NCT00470392|DRUG|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
219595100|NCT05012189|DRUG|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
219595101|NCT05012189|DRUG|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
219595102|NCT02657928|OTHER|Laboratory Biomarker Analysis|Correlative studies
219595103|NCT02657928|DRUG|Letrozole|Given PO
219595104|NCT02657928|DRUG|Ribociclib|Given PO
218855891|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
218855892|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
219470370|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
219470371|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
219470372|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
219470373|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
219595105|NCT02753361|PROCEDURE|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
219595106|NCT04864028|OTHER|physical activity|15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
219470374|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
219470375|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
219595107|NCT01644383|BEHAVIORAL|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
219595108|NCT02881697|OTHER|Adipose tissue sampling|
219595109|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block|
218855893|NCT04053400|DRUG|Ketamine|
219595110|NCT03228797|PROCEDURE|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
219595111|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
219595112|NCT04786847|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
219595113|NCT05099250|DRUG|Bupivacain|local anesthetic agent
218855894|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
218855895|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
219470376|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
219470377|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
219470378|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
219470379|NCT02528149|OTHER|blood sample|
219470380|NCT00483782|BIOLOGICAL|bevacizumab|
219470381|NCT00483782|DRUG|carboplatin|
219470382|NCT00483782|DRUG|paclitaxel|
219470383|NCT00483782|OTHER|questionnaire administration|
219470384|NCT00483782|OTHER|study of socioeconomic and demographic variables|
219470385|NCT00483782|PROCEDURE|quality-of-life assessment|
219595114|NCT05099250|DRUG|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
218855896|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
218855897|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
219020415|NCT07149038|DEVICE|Sham Device|Participants in this arm will use a sham device. This device is identical in appearance to the active Cerogrin device but delivers no electrical stimulation or therapeutic effect. The sham device serves as a control to compare outcomes with the active treatment group.
219595115|NCT05099250|OTHER|saline|medical solution
219595116|NCT05602324|DIETARY_SUPPLEMENT|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
218855898|NCT02374814|DRUG|Placebo|Placebo
218855899|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
218855900|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
219363301|NCT03686566|DRUG|13C-glucose|Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
219363302|NCT03686566|OTHER|No glucose infusion|Only includes standard pre-operation nursing care
219363303|NCT03227367|OTHER|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
219363304|NCT03624322|DRUG|Zyprexa IM|5mg
219363305|NCT03624322|DRUG|Zydis|10mg orally disintegrating wafer
219363306|NCT03624322|DRUG|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
219363307|NCT03624322|DEVICE|I231 POD® Device|Precision Olfactory Delivery (POD) device
219363308|NCT02690194|DEVICE|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
219363309|NCT02690194|DEVICE|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
219363310|NCT01552681|BIOLOGICAL|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
219363311|NCT01552681|OTHER|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
219363312|NCT02769728|DEVICE|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
219363313|NCT05360667|OTHER|Standard care plus plus Exergame-based multicomponent training program|"The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)"
219363314|NCT05360667|OTHER|Standard care|The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
219363315|NCT03129074|DRUG|Varlitinib|everyday
219363316|NCT03129074|DRUG|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
219363317|NCT03671057|DEVICE|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
219363318|NCT03671057|DRUG|Midazolam|current practice in Jessa
219363319|NCT05463809|DRUG|Continuous Gastrocnemius plane block with ropivacaine|After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.
219363320|NCT05463809|DRUG|oxycodone|The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
219595117|NCT00590616|PROCEDURE|transthoracic examination|observational transthoracic examination
219470386|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
218855901|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
218855902|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
218855903|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
218855904|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
218855905|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
218855906|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
218855907|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
218855908|NCT02270762|OTHER|Rest in bed|
219470387|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
219470388|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
219470389|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
219470390|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
219470391|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
219470392|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
219470393|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
219470394|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
219595118|NCT01782014|PROCEDURE|colonoscopy|colonoscopy using different methods of insufflation
219595119|NCT02094417|DRUG|AMG531|Subcutaneous, weekly injection
219595120|NCT01937078|DRUG|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
219595121|NCT03886298|PROCEDURE|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
219595122|NCT03886298|PROCEDURE|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
219595123|NCT00411411|DRUG|Januvia|200 mg t.i.d
218855909|NCT02270762|OTHER|Passive verticalization|
218855910|NCT02270762|OTHER|Rest in bed|
219595124|NCT00411411|DRUG|Placebo|Placebo
219595125|NCT00748761|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
219595126|NCT00748761|BEHAVIORAL|Waitlist|Contact waitlist weekly for 12 weeks
218855911|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
218855912|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
219470395|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
219470396|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
219470397|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
219470398|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
219470399|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
219470400|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
219470401|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
219470402|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
219470403|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
219470404|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
219470405|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
219595127|NCT04913558|OTHER|Aerobic exercise|"The exercise will be performed by using the treadmill as the following:~\- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~\- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~\- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour."
219595128|NCT04913558|OTHER|Traditional Treatment|"1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing"
219595129|NCT03317418|OTHER|ATR-FTIR Spectrophotometry|Spectrometry imaging
219595130|NCT02159313|DRUG|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
219595131|NCT00762918|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
219595132|NCT03564158|DRUG|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
218855913|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
219470406|NCT00015912|DRUG|thalidomide|Given orally
219595133|NCT03564158|DRUG|Placebo|Placebo
218855914|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
218855915|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
218855916|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
218855917|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
218855918|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
219470407|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
219595134|NCT03564158|DRUG|Moxifloxacin|Active Comparator
219595135|NCT02816606|PROCEDURE|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
219595136|NCT02816606|PROCEDURE|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
219595137|NCT01564537|DRUG|Ixazomib|Ixazomib capsules
219595138|NCT01564537|DRUG|Lenalidomide|Lenalidomide capsules
219470408|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
219470409|NCT01274104|OTHER|Placebo|Placebo
219470410|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
219595139|NCT01564537|DRUG|Dexamethasone|Dexamethasone tablets
219595140|NCT01564537|DRUG|Placebo|Ixazomib placebo-matching capsules
218855919|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
218855920|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
218855921|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
218855922|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
219595141|NCT05076357|BEHAVIORAL|Caloric Restriction|-30% of participants total energy requirements
219595142|NCT05076357|OTHER|Cold intervention|Sessions of 90min each every 2nd day involving cold exposure
219595143|NCT01909856|DRUG|Palonosetron|Palonosetron 0.25mg d1,d3
219595144|NCT01909856|DRUG|Granisetron|Granisetron 3mg d1-3
219595145|NCT01909856|DRUG|Dexamethasone|Dexamethasone 10mg d1-3
219595146|NCT01909856|DRUG|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
219595147|NCT02525900|PROCEDURE|Wound Infiltration|Wound Infiltration with 0.25% Bupivacine
219595148|NCT02525900|PROCEDURE|TAP Blocks|bilateral TAP block with 0.25% Bupivacaine
218855923|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
218855924|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
218855925|NCT00346489|DRUG|5-fluorouracil|
218855926|NCT00346489|DRUG|Mitomycin C|
218855927|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
219470411|NCT05869188|DRUG|Isotretinoin|"* Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients ."
219470412|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
219470413|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
219470414|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
219470415|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
219470416|NCT02852876|DRUG|ASP2151|Oral
219470417|NCT02852876|DRUG|Placebo|Oral
219470418|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
219470419|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
218855928|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
219470420|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
219595149|NCT02525900|PROCEDURE|TAP Catheters|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
218855929|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
218855930|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
218855931|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
218855932|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
218855933|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
218855934|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
218855935|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
218855936|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
218855937|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
218855938|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
219199248|NCT06860126|BEHAVIORAL|Yoga and Mindfulness Sessions|"Participate in 90-minute intergenerational yoga sessions, three times a week for three months, in a gym setting.~* Perform modified yoga exercises suitable for seniors, including:~* 20 minutes of warm-up with stretching and joint rotations.~* 50 minutes of main exercises (asanas and pranayama).~* 20 minutes of relaxation and meditation (Shavasana).~* Attend sessions on odd days at 9 AM in the Neshat Center yoga hall.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
219470421|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
219470422|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
219470423|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
219470424|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
219470425|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
219470426|NCT00230711|BEHAVIORAL|Physical activity counseling|
219470427|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
219470428|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
219470429|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
219595150|NCT04405843|DRUG|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
219595151|NCT04405843|DRUG|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
219595152|NCT01286935|DRUG|Safinamide|
219470430|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
219470431|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
219470432|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
219470433|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
219470434|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
219470435|NCT04648943|PROCEDURE|Trabeculectomy|
219470436|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
219470437|NCT03556202|DRUG|Mirikizumab|Administered SC
219470438|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
219470439|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
219470440|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
219470441|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
219470442|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
219470443|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
218855939|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
219470444|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
219470445|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
218855940|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
218855941|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
218855942|NCT02436668|DRUG|Ibrutinib|
218855943|NCT02436668|DRUG|Gemcitabine|
218855944|NCT02436668|DRUG|Nab-paclitaxel|
218855945|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
218855946|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
219470446|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
219470447|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
219470448|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
219470449|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
219470450|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
219470451|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
219470452|NCT00981565|OTHER|Night-cast|individual night time splinting
219470453|NCT02253849|DRUG|Carbamazepine|
219470454|NCT02253849|DRUG|Tipranavir|
219470455|NCT02253849|DRUG|Ritonavir|
219470456|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
219470457|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
219595153|NCT01286935|DRUG|Safinamide|
218855947|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
218855948|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
219595154|NCT01286935|DRUG|Placebo|
219470458|NCT05156749|DEVICE|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
219470459|NCT05156749|DEVICE|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
219470460|NCT06094075|OTHER|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
219470461|NCT06094075|OTHER|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
219470462|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
219470463|NCT03158532|DRUG|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
219470464|NCT03158532|DRUG|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
219470465|NCT03158532|DRUG|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
219470466|NCT03158532|DRUG|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
219470467|NCT04885036|BEHAVIORAL|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
219470468|NCT04885036|BEHAVIORAL|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
219470469|NCT04479358|DRUG|Tocilizumab|Tocilizumab 40mg
219470470|NCT04479358|DRUG|Tocilizumab|Tocilizumab 120mg
219470471|NCT04479358|OTHER|Standard of Care|Tocilizumab-Free Standard of Care
219595155|NCT01635218|DRUG|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
219595156|NCT01635218|DRUG|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
219595157|NCT01635218|DRUG|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
219595158|NCT03559400|DRUG|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
219595159|NCT03559400|DRUG|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
218855949|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
219470472|NCT04479358|OTHER|Standard of Care|Tocilizumab 400mg or 8mg/kg
219595160|NCT04707976|DEVICE|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
219595161|NCT04707976|OTHER|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
219595162|NCT03401125|OTHER|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
219595163|NCT03262038|DRUG|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
218855950|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
219470473|NCT06279000|DRUG|Colchicine|"Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion."
219470474|NCT06279000|DRUG|Placebo|"Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion."
219470475|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
219470476|NCT06068790|DEVICE|28 French sized rigid sheath|The 28Fr is the standard of care sheath size used at this site.
219470477|NCT06068790|DEVICE|22 French sized rigid sheath|The 22Fr is the smaller, investigational sheath size to be used in this study.
219470478|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
219470479|NCT03260322|DRUG|ASP8374|intravenous
219470480|NCT03260322|DRUG|Pembrolizumab|intravenous
219470481|NCT06363461|DRUG|TDM-180935 topical ointment 1.0%|TDM-180935 topical ointment 1.0%
219470482|NCT06363461|DRUG|TDM-180935 topical ointment 2.0%|TDM-180935 topical ointment 2.0%
219470483|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 1|TDM-180935 topical vehicle ointment 1
219470484|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 2|TDM-180935 topical vehicle ointment 2
219470485|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
219470486|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
219470487|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
219470488|NCT00764465|DRUG|Maraviroc|300 mg BID
219470489|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
219470490|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
219470491|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
219470492|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
219470493|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
218855951|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
218855952|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
218855953|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
219470494|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
218855954|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
218855955|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
219470495|NCT06047886|DRUG|Infusion of CD34 selected hematopoietic stem cells|CD34 stem cell isolation and infusion to reduce alloreactive complication of stem cell infusion
219470496|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
219470497|NCT00674440|RADIATION|PET scan|
219470498|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
219470499|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
219470500|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
219470501|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
219470502|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
219470503|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
219470504|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
219470505|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
219470506|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
219470507|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
218855956|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
218855957|NCT04899440|OTHER|Control|No Oral Irrigator Control
219363321|NCT01822808|DRUG|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
218855958|NCT02230761|DRUG|XOPH5 Ointment|
218855959|NCT02230761|DRUG|Placebo|
218855960|NCT05617053|DEVICE|DAART|
218855961|NCT05617053|DEVICE|ATP/Supera stenting|
218855962|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
218855963|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
218855964|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
218855965|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
218855966|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
218855967|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
219363322|NCT01822808|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
219363323|NCT00627237|BEHAVIORAL|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
219363324|NCT00627237|BEHAVIORAL|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
219363325|NCT00570102|DIETARY_SUPPLEMENT|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
219363326|NCT00570102|DIETARY_SUPPLEMENT|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
219363327|NCT04417829|DEVICE|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
219363328|NCT02373761|DEVICE|Stryker Triathlon Tritanium primary knee|
219363329|NCT00000690|DRUG|Dextran sulfate|
219363330|NCT04203485|BIOLOGICAL|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
219363331|NCT04203485|DRUG|Apatinib Mesylate 250mg|Apatinib Mesylate 250mg po qd
219363332|NCT04203485|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium for injection 500 mg/m2 q3w
219363333|NCT04203485|DRUG|Paclitaxel injection|Paclitaxel injection 175 mg/m2 q3w
219363334|NCT04203485|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min q3w
219363335|NCT05048160|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
219363336|NCT04853628|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
219363337|NCT04853628|BEHAVIORAL|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
219363338|NCT02946801|DRUG|Essential oils|
219363339|NCT02946801|DRUG|Essential oils without alcohol|
219363340|NCT02946801|DRUG|Sterile water|
218855968|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
218855969|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
218855970|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
218855971|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
218855972|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
219363341|NCT05675007|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
218855973|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1\) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2\) Oxaliplatin via IV, predetermined dosage per protocol~* 3\) Leucovorin via IV, predetermined dosage per protocol~* 4\) 5-Fluorouracil via IV, predetermined dosage per protocol"
218855974|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
218855975|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
218855976|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
218855977|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
218855978|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
218855979|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
218855980|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
218855981|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
219363342|NCT05675007|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
219363343|NCT03817372|DEVICE|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
219363344|NCT03817372|DEVICE|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
219363345|NCT04047901|OTHER|exercise training|Patients undergo 16 weeks of physical training
219363346|NCT01629407|OTHER|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
219363347|NCT05752929|DRUG|Insulin|correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme
219363348|NCT05752929|DRUG|insulin|correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
219363349|NCT00918151|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study
219363350|NCT05152940|DRUG|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
219363351|NCT05152940|DRUG|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
219363352|NCT02377895|DRUG|Nasapaque Nasal Solution|
219363353|NCT02377895|DRUG|Placebo Saline Nasal Solution|
219363354|NCT00778973|DRUG|sertraline 100 mg tablets|
219363355|NCT03932552|OTHER|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
219363356|NCT03932552|OTHER|nutritional therapy|individualised nutritional intervention
218855982|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
219470508|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
218855983|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
219470509|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
219470510|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
219470511|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
219595164|NCT03262038|DRUG|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
219595165|NCT04933968|BIOLOGICAL|ALVR106|Infusion, visually identical to placebo
219595166|NCT04933968|BIOLOGICAL|Placebo|Infusion, visually identical to ALVR106
219595167|NCT03621501|DEVICE|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
219595168|NCT06369597|PROCEDURE|Robotic telesurgery|Telesurgery by domestic surgical robot
218855984|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
218855985|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
218855986|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
218855987|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
219470512|NCT00281931|BIOLOGICAL|rituximab|
219470513|NCT00281931|DRUG|cyclophosphamide|
219470514|NCT00281931|DRUG|fludarabine phosphate|
219470515|NCT03332225|DRUG|Anakinra|Treatment with anakinra
219470516|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
219470517|NCT03332225|DRUG|Placebo|Treatment with Placebo
219595169|NCT06369597|PROCEDURE|Laparoscopic surgery|Local laparoscopic surgery
219595170|NCT04327739|OTHER|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
218855988|NCT00127283|DRUG|eptacog alfa (activated)|
218855989|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
218855990|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
219470518|NCT00212082|DRUG|doxorubicin, docetaxel|
219470519|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
219470520|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
219470521|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
218855991|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
218855992|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
218855993|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
218855994|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
218855995|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
218855996|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
218855997|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
218855998|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
218855999|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
218856000|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
218856001|NCT00257595|DRUG|Cetirizine Dry Syrup|
218856002|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
218856003|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
218856004|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
218856005|NCT00003787|BEHAVIORAL|educational/counseling intervention|
218856006|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
218856007|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
219470522|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
219470523|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
219470524|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
219470525|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
219470526|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
219470527|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
219470528|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
219470529|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
219470530|NCT05733208|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
218856008|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
218856009|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
218856010|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
218856011|NCT00717587|DRUG|motexafin gadolinium|
218856012|NCT00717587|DRUG|sunitinib malate|
218856013|NCT00717587|GENETIC|comparative genomic hybridization|
218856014|NCT00717587|GENETIC|gene expression analysis|
218856015|NCT00717587|GENETIC|mutation analysis|
218856016|NCT00717587|GENETIC|polymorphism analysis|
218856017|NCT00717587|OTHER|immunohistochemistry staining method|
218856018|NCT00717587|OTHER|iodine I-124 girentuximab|
218856019|NCT00717587|OTHER|laboratory biomarker analysis|
218856020|NCT00717587|OTHER|pharmacological study|
218856021|NCT00717587|PROCEDURE|adjuvant therapy|
218856022|NCT00717587|PROCEDURE|neoadjuvant therapy|
218856023|NCT00717587|PROCEDURE|therapeutic conventional surgery|
218856024|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
218856025|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
219470531|NCT05733208|PROCEDURE|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
218856026|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
218856027|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
218856028|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
219470532|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
219470533|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
219470534|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
219470535|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
219470536|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
219470537|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
219470538|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
219470539|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
219470540|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
219470541|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
219470542|NCT05466994|OTHER|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
219470543|NCT05466994|OTHER|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
219595171|NCT04327739|OTHER|Intervention 2 Exercise and INIT|"* Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
218856029|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
218856030|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
218856031|NCT00287937|DRUG|vorinostat|Given orally
218856032|NCT00287937|DRUG|paclitaxel|Given IV
218856033|NCT00287937|DRUG|carboplatin|Given IV
218856034|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
218856035|NCT00287937|OTHER|pharmacological study|Correlative studies
218856036|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
218856037|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
218856038|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
218856039|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
218856040|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
218856041|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
218856042|NCT00000630|BIOLOGICAL|HIVAC-1e|
218856043|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
218856044|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
218856045|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
219470544|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
219470545|NCT05718323|DRUG|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
219470546|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
219470547|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
219470548|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
219470549|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
219470550|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
218856046|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
219470551|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219470552|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
219470553|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
219470554|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
219470555|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
219595172|NCT04327739|OTHER|Intervention 3 Exercise and SMT|"* Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
219595173|NCT04327739|OTHER|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
218856047|NCT02156544|DRUG|CKD-519|
218856048|NCT02156544|DRUG|placebo|
218856049|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
219470556|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
218856050|NCT00003825|DRUG|pentosan polysulfate sodium|
219595174|NCT03751618|PROCEDURE|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
219595175|NCT02679235|DRUG|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
219595176|NCT01567475|DRUG|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
218856051|NCT00003825|PROCEDURE|quality-of-life assessment|
218856052|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
218856053|NCT02342379|DRUG|Bevacizumab|10mg/kg
218856054|NCT02342379|DRUG|TH-302|670mg/m2
219363357|NCT03882424|BIOLOGICAL|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
219363358|NCT03882424|BIOLOGICAL|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
219363359|NCT03882424|BIOLOGICAL|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
219363360|NCT00236080|DRUG|PROVIGIL 200 mg|PROVIGIL 200 mg/day
219363361|NCT00236080|DRUG|Armodafinil 250 mg|Armodafinil 250 mg/day
219363362|NCT00236080|DRUG|Armodafinil 200 mg|Armodafinil 200 mg/day
219363363|NCT00236080|DRUG|Armodafinil 150 mg|Armodafinil 150 mg/day
219363364|NCT00236080|DRUG|Placebo|Matching placebo tablets
219363365|NCT05709808|OTHER|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
219363366|NCT05709808|OTHER|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
219363367|NCT05709808|OTHER|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
219363368|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
219363369|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
219363370|NCT00602355|DRUG|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
219363371|NCT00602355|DRUG|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
219363372|NCT00602355|BEHAVIORAL|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
219363373|NCT00602355|BEHAVIORAL|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
219363374|NCT00602355|BEHAVIORAL|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
219363375|NCT04255667|PROCEDURE|Eyelid margin crush|after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
219363376|NCT05316714|PROCEDURE|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
219363377|NCT04536220|DIAGNOSTIC_TEST|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
219363378|NCT05213988|DIETARY_SUPPLEMENT|Intermittent Fasting|Intermittent fasting meal pattern
219363379|NCT05213988|DRUG|Fibrates|Bezafibrate 400 mg/day
219363380|NCT05213988|DIETARY_SUPPLEMENT|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
219363381|NCT02159027|DRUG|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
219363382|NCT02159027|DRUG|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
219363383|NCT01868984|DRUG|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
219363384|NCT01868984|PROCEDURE|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
219363385|NCT03244007|PROCEDURE|Vitrectomy|
219363386|NCT02538484|DRUG|Letrozole|Aromatase inhibitor
219363387|NCT02538484|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 free fatty acid
218856055|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
219363388|NCT05491785|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
219363389|NCT05491785|DRUG|Cebranopadol 800 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
219595177|NCT04559737|OTHER|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
219595178|NCT03040700|OTHER|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
219595179|NCT03040700|OTHER|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
219595180|NCT00094861|DRUG|Palifermin|
219595181|NCT00094861|DRUG|Placebo|
219595182|NCT00094861|RADIATION|Radiotherapy|
219595183|NCT00094861|DRUG|Paclitaxel|
219595184|NCT00094861|DRUG|Carboplatin|
219595185|NCT03214393|DIAGNOSTIC_TEST|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
219595186|NCT03214393|DIAGNOSTIC_TEST|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
219595187|NCT03679182|DRUG|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
219363390|NCT05491785|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
219363391|NCT05491785|DRUG|Oxycodone 30 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
219363392|NCT05491785|DRUG|Oxycodone 60 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
219363393|NCT05491785|DRUG|Placebo|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
219363394|NCT02859155|PROCEDURE|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
219363395|NCT01961544|DRUG|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
219363396|NCT05679362|BEHAVIORAL|online brief CBT intervention|Cognitive behavioral therapy
219363397|NCT00269529|PROCEDURE|femoral nerve block|
219363398|NCT00269529|PROCEDURE|knee infiltration and injection via catheter|
219363399|NCT00892554|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
219363400|NCT00892554|DIETARY_SUPPLEMENT|Corn/soy oil|Capsules taken once daily
219363401|NCT03498274|DEVICE|Fitting System|End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.
219363402|NCT03498274|DEVICE|Traditional Fitting System|The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
219470557|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
219470558|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
219470559|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
219470560|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
219470561|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
219470562|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
219470563|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
219470564|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
219470565|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
219470566|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
219470567|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
219470568|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
219470569|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
219470570|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
219470571|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
219470572|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
219470573|NCT02377258|OTHER|Non Interventional|
219470574|NCT03145584|DRUG|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
219470575|NCT03145584|OTHER|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
219470576|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
219470577|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
219470578|NCT04227665|OTHER|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
219470579|NCT04227665|OTHER|Altitude|Altitude exposure / altitude exposure Iron metabolism
219470580|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
219470581|NCT05677373|DRUG|Trametinib|Given PO
219470582|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
219470583|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
219470584|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
219470585|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
219470586|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
219470587|NCT02691845|BEHAVIORAL|BA (brief advice)|
219470588|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
219470589|NCT02691845|BEHAVIORAL|HE (health education)|
219470590|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
219470591|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
219470592|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
219470593|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
219470594|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
219470595|NCT01728194|DRUG|Escitalopram|20 mg target dose for 12 weeks
219470596|NCT01728194|OTHER|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
219470597|NCT04493229|DRUG|Oxytocin|IM Oxytocin
219470598|NCT04493229|DRUG|Placebo|Placebo IM
219595188|NCT03339167|DIETARY_SUPPLEMENT|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
219595189|NCT03902730|OTHER|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
219595190|NCT03902730|OTHER|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
219020426|NCT07150845|DRUG|EVO756|Dose 1
219020427|NCT07150845|DRUG|EVO756|Dose 2
219020428|NCT07150845|DRUG|EVO756|Dose 3
219020429|NCT07150845|DRUG|Placebo control|Placebo control
219020430|NCT07142811|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
219020431|NCT07142811|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
219020432|NCT07142811|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
219470599|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
219470600|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
219470601|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
219470602|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
219470603|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
219470604|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
219470605|NCT00114257|DRUG|decitabine|
219470606|NCT00114257|DRUG|romidepsin|
219470607|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
219470608|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
219470609|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
218856056|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
219470610|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
219470611|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
219470612|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
219470613|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
219470614|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
219470615|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
219470616|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
219470617|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
219470618|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
219470619|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
219470620|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
219470621|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
219470622|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
219470623|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
219470624|NCT01078974|DRUG|pomalidomide|Taken orally once a day
218856057|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
218856058|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
219595191|NCT03902730|OTHER|Box Squat|Participants will complete box squat in this four treatment crossover design.
219595192|NCT03902730|OTHER|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
219020438|NCT05611931|DRUG|Selinexor|Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
219020439|NCT05611931|DRUG|Matching Placebo for selinexor|Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
219470625|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
219470626|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
219470627|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
219470628|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
219470629|NCT00553319|DRUG|Placebo|Placebo group
219470630|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
219470631|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
219470632|NCT00508118|DRUG|Nicardipine|on bypass
219470633|NCT00508118|DRUG|0.9% saline|on bypass
219470634|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
219470635|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
219470636|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
219470637|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
219470638|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
219470639|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
219470640|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
218856059|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
218856060|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
218856061|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
218856062|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
218856063|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
218856064|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
219595193|NCT05856630|DRUG|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
219199249|NCT06860126|BEHAVIORAL|Physical Exercise and Storytelling|"Engage in 60-minute light aerobic exercises, three times a week for three months, in a park setting.~* Follow warm-up and aerobic exercises led by a senior fitness instructor.~* Spend 30 minutes in a friendly group discussion, sharing experiences and memories with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
219595194|NCT05856630|DRUG|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
219595195|NCT01865240|DEVICE|Renal Denervation|Renal Denervation Catheter
219595196|NCT06224465|OTHER|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
218856065|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
218856066|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
218856067|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
219363403|NCT02300454|DEVICE|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
219363404|NCT02300454|DEVICE|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
219363405|NCT02327091|DRUG|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
219363406|NCT05509478|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
219363407|NCT05509478|DRUG|PD-1 inhibitors|Regular dose intravenously every 3 weeks
219363408|NCT01656902|DRUG|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
219363409|NCT01656902|PROCEDURE|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
219363410|NCT02733874|DRUG|Compound Clobetasol Propionate Ointment|
219363411|NCT02733874|DRUG|Calcipotriol Betamethasone Ointment|
219363412|NCT03665285|DRUG|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
219363413|NCT02047669|BEHAVIORAL|Biopsychosocial|
219363414|NCT02047669|BEHAVIORAL|Reference|
219363415|NCT04598542|DRUG|Lorecivivint (LOR)|0.07 mg
219363416|NCT04598542|DRUG|Triamcinolone acetonide (TA)|40 mg
219363417|NCT03106532|DRUG|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
219363418|NCT03106532|DRUG|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
219363419|NCT03106532|DRUG|Placebo ophthalmic solution|3 drops daily, 28 days
219363420|NCT01766947|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
219363421|NCT00354601|DRUG|capecitabine|oral capecitabine twice daily on days 1-21
219363422|NCT00354601|DRUG|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
219363423|NCT00378170|DEVICE|intubation of patients undergoing elective surgery|
219363424|NCT01135732|PROCEDURE|brush cytology|brush cytology during ERCP
219363425|NCT04082260|DRUG|Alemtuzumab Injection [Lemtrada]|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
219363426|NCT01554930|DRUG|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
218856068|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
218856069|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
218856070|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
218856071|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
218856072|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
219470641|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
219470642|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
219470643|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
219470644|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
219470645|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
219470646|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
219470647|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
219470648|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
219470649|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
219595197|NCT01250886|DRUG|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
218856073|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
218856074|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
219020442|NCT07157696|DEVICE|High-Flow Nasal Cannula (HFNC) Oxygen Therapy|"Type: Device / Procedure~Description: Humidified high-flow nasal cannula oxygen therapy delivered via a home device. Provides warmed (37°C), humidified air and supplemental oxygen at ≥30 L/min, titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use the device for ≥8 hours per day, preferably overnight.~Special Features: Integrated remote monitoring system that automatically records flow, FiO₂, SpO₂, heart rate, and usage time, transmitting data to a secure cloud platform for clinical follow-up."
219470650|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
219470651|NCT00976521|OTHER|No local infusion|Intervention without local infusion
219470652|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
219470653|NCT01979003|DRUG|Fluorescein|
219470654|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
219470655|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
219470656|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
219470657|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
219470658|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
219470659|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
219470660|NCT02220608|BIOLOGICAL|Bortezomib|
219470661|NCT02220608|DRUG|G-CSF|
219470662|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
219470663|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
219470664|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
219470665|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
219470666|NCT02768428|OTHER|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
219470667|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
219595198|NCT01250886|DRUG|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
218856075|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
218856076|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
218856077|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
218856078|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
218856079|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
218856080|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
218856081|NCT03584191|OTHER|No treatment given|Completion of a survey
218856082|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
218856083|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
219020443|NCT07157696|DEVICE|Oxygen therapy|"Type: Device / Procedure~Description: Standard long-term oxygen therapy delivered through conventional low-flow systems (e.g., nasal cannula or mask). Oxygen is titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use oxygen for ≥8 hours per day, preferably overnight.~Special Features: No humidification, high-flow delivery, or remote monitoring capabilities."
219470668|NCT05768360|DRUG|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
219020448|NCT07153276|DEVICE|Fractional CO2 laser (vaginal)|Vaginal fractional CO2 laser applications will be performed once a month for three consecutive months.
219020449|NCT07153276|DRUG|Promestriene Vaginal|Patients in the group treated with promestriene will apply a 10 mg vaginal capsule at night for fifteen consecutive days and, after this period, one application every three days, until completing six months of treatment.
219470669|NCT05768360|DRUG|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
219470670|NCT05768360|DRUG|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
219470671|NCT05768360|DRUG|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
219470672|NCT05768360|DRUG|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
219470673|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
219470674|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
219470675|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
219470676|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
219470677|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
219595199|NCT01250886|DRUG|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
218856084|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
218856085|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
219595200|NCT00509366|DRUG|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
219595201|NCT00509366|DRUG|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
218856086|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
218856087|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
219595202|NCT00509366|DRUG|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
218856088|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
218856089|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
219595203|NCT00509366|DRUG|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
219595204|NCT03936426|DRUG|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
219595205|NCT06380881|DRUG|SHR-2017|SHR-2017
218856090|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
218856091|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
218856092|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
219363427|NCT01554930|DRUG|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
219363428|NCT05935254|DEVICE|Plaque removal efficacy of children's electric toothbrush (Oral-B D100 Vitality; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with an electric toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
219363429|NCT05935254|DEVICE|Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
219363430|NCT04732754|DIETARY_SUPPLEMENT|Aerobic exercise + Theobroma cocoa (AETC)|Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
219595206|NCT03253055|RADIATION|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.
219470678|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
219595207|NCT03253055|RADIATION|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
219470679|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
219470680|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
219470681|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
219470682|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
219470683|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
219595208|NCT03253055|OTHER|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
219595209|NCT03253055|OTHER|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
219595210|NCT03253055|OTHER|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
219595211|NCT03253055|BIOLOGICAL|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
219595212|NCT03253055|OTHER|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
219595213|NCT01120509|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
219595214|NCT01995305|GENETIC|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
219595215|NCT01995305|GENETIC|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
219595216|NCT04270318|OTHER|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
219595217|NCT04270318|OTHER|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
219595218|NCT04270318|OTHER|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
219595219|NCT04270318|OTHER|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
219595220|NCT06403124|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation by reconstruction plate and screws
219595221|NCT02172235|DRUG|Pioglitazone|
219595222|NCT02172235|DRUG|Pioglitazone - low dose|
219595223|NCT02172235|DRUG|BI 10773 - low dose|
219595224|NCT02172235|DRUG|BI 10773 - medium dose|
219595225|NCT02172235|DRUG|BI 10773 - high dose|
219595226|NCT03269318|DRUG|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
219595227|NCT02132858|OTHER|cytology specimen collection procedure|Correlative studies
219595228|NCT02132858|OTHER|laboratory biomarker analysis|Correlative studies
219595229|NCT02119819|DRUG|LY2944876|Administered SC
219595230|NCT02119819|DRUG|Exenatide extended-release|Administered SC
219595231|NCT02119819|DRUG|Placebo|Administered SC
219595232|NCT02119819|DRUG|Metformin|Oral
219595233|NCT02699684|DEVICE|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
219595234|NCT02699684|DEVICE|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
219595235|NCT02699684|DEVICE|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
219470684|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
219470685|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
219470686|NCT03405324|DEVICE|sham tDCS|sham tDCS
219470687|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
219470688|NCT01791088|DRUG|sirolimus|Given PO
219470689|NCT01791088|OTHER|pharmacological study|Correlative studies
219470690|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
219470691|NCT01183299|OTHER|Dietary salt intake|
219470692|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
219470693|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
219470694|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
219470695|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
218856093|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
218856094|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
218856095|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
219470696|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
219470697|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
219470698|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
219470699|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
219470700|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
219470701|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
219470702|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
219470703|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
219363431|NCT04732754|DIETARY_SUPPLEMENT|Control Group (CG)|Daily consumption of placebo capsules for 8 weeks
219363432|NCT04732754|DIETARY_SUPPLEMENT|Aerobic Exercise (AE)|Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
219363433|NCT04732754|DIETARY_SUPPLEMENT|Theobroma Cocoa (TC)|Daily consumption of 500mg cocoa in capsules for 8 weeks.
219363434|NCT00022087|DIETARY_SUPPLEMENT|calcium salts|1000 mg PO per day
219363435|NCT00022087|DIETARY_SUPPLEMENT|cholecalciferol|400 IU PO per day
219363436|NCT00022087|DRUG|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
219363437|NCT02371265|OTHER|Adherence and retention package|"Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~* Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~* Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision."
219363438|NCT06348381|OTHER|No intervention|No intervention
219363439|NCT01175291|DRUG|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).
219363440|NCT01175291|DRUG|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
219363441|NCT00809107|DRUG|HCG|5000IU
219363442|NCT03287258|OTHER|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
219363443|NCT03287258|OTHER|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
218856096|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
218856097|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
218856098|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
218856099|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
218856100|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
218856101|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
218856102|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
218856103|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
218856104|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
218856105|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
218856106|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
218856107|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
218856108|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
218856109|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
218856110|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
219470704|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
219470705|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
219470706|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
219470707|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
219020455|NCT07153796|DRUG|Blinatumomab|Given by IV
219470708|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
219470709|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
218856111|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
219020456|NCT07153796|DRUG|Mini-CVD|Given by IV
219020457|NCT07153796|DRUG|MTX/ARA-C|Given by IV
219470710|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
219470711|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
219470712|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219470713|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
219470714|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
219470715|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
219470716|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
219470717|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
219470718|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
219470719|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
219470720|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
219470721|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
218856112|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
219470722|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
219470723|NCT03244280|DRUG|MOB015B|Topical formulation
219470724|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
219470725|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
219470726|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
219470727|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
219470728|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
219470729|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
219470730|NCT00208702|DRUG|Triiodothyronine|
219470731|NCT00208702|OTHER|Placebo|
219470732|NCT00208702|DRUG|Sertraline|
219470733|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
219595236|NCT02699684|DEVICE|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
219595237|NCT02699684|DEVICE|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
219595238|NCT06028321|DRUG|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
219470734|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
218856113|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
219470735|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
219470736|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
219470737|NCT01884142|OTHER|Aerobic Exercise Training|
219470738|NCT03039699|DRUG|Ergoferon|
219020458|NCT07160439|BEHAVIORAL|Digital Micro-Interventions|Digital Micro-Interventions are brief interventions that target specific behavioral and cognitive mechanisms of mental health, designed for brief periods of engagement.
219020459|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain)
219020460|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)
219470739|NCT03039699|DRUG|Placebo|
219470740|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
219470741|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
219470742|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
219470743|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
219470744|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
219470745|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
219470746|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
219470747|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
219470748|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
219470749|NCT02651038|DRUG|Micafungin|Measurement of PK
219470750|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
219470751|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
219470752|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
219470753|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
219470754|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
219595239|NCT06028321|DRUG|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
219595240|NCT06028321|DRUG|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
219595241|NCT06028321|DRUG|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
219470755|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
219470756|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
219470757|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
219470758|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
219470759|NCT00016068|DRUG|ganciclovir|
219470760|NCT00016068|DRUG|valganciclovir|
219470761|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
219470762|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
219470763|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
219470764|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
219470765|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
219470766|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
219470767|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
219470768|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
219470769|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
219470770|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
219470771|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
219470772|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
219470773|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
219470774|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
219470775|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
219470776|NCT02104232|BEHAVIORAL|THPP-I|
219470777|NCT02104232|BEHAVIORAL|EUC|
219470778|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
219470779|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
219470780|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
219470781|NCT02911285|DRUG|Placebo|Placebo pills bid
219470782|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
219470783|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
219470784|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
219470785|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
219470786|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
219470787|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
219470788|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
219470789|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
219470790|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
219470791|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
219470792|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
219470793|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
219470794|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
219595242|NCT06028321|DRUG|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
219470795|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
219470796|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
219470797|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
219470798|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
219470799|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
219470800|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
219470801|NCT00561262|OTHER|questionnaire administration|
219470802|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
219470803|NCT00561262|PROCEDURE|quality-of-life assessment|
219470804|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
219470805|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
219470806|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
219470807|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
219470808|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
219470809|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
219470810|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
219470811|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
219470812|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
219595243|NCT06028321|DRUG|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
219470813|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
219470814|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
219470815|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
219470816|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
219470817|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
219470818|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
219470819|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
218856114|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
218856115|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
218856116|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
218856117|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
218856118|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
219199250|NCT06860126|BEHAVIORAL|Outdoor Interaction Games|"Participate in 90-minute intergenerational interaction sessions, three times a week for three months, in a park setting.~* Engage in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
219470820|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
219470821|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
219470822|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
219470823|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
219470824|NCT04366869|DEVICE|overdenture|removal of overdenture at night
219470825|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
219470826|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
219470827|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
219470828|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
219470829|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
219470830|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
219470831|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
219470832|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
219470833|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
219470834|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
219470835|NCT05965089|BIOLOGICAL|Placebo|Placebo
218856119|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
219470836|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
219470837|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
218856120|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
219470838|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
219470839|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
219470840|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
219470841|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
219470842|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
219470843|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
219470844|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
219470845|NCT05614544|DRUG|Placebo|Intralipid
219470846|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
219470847|NCT00280839|DRUG|Topiramate|
219470848|NCT00280839|DRUG|Placebo|
219470849|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
219470850|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
219470851|NCT01411124|DRUG|placebo|placebo
219470852|NCT00116610|DRUG|picoplatin|
219470853|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
219470854|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
219470855|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
219470856|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
219470857|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
219470858|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
219470859|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
219470860|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
219595244|NCT06028321|DRUG|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
218856121|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
219199251|NCT06860126|BEHAVIORAL|Social Visits to Nursing Homes|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a nursing home setting.~* Participate in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on odd days at 9 AM in the nursing home.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
219470861|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
219470862|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
219470863|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
219470864|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
219470865|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
219470866|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
219470867|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
219470868|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
219470869|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
219470870|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
219470871|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
219470872|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
218856122|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
218856123|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
218856124|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
219470873|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
219470874|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
218856125|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
219470875|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
219470876|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
219470877|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
219470878|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
219470879|NCT00403962|DRUG|vestipitant/paroxetine|
218856126|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
218856127|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
218856128|NCT05452369|DRUG|Rhomboid intercostal plane block|\- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
219470880|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
219470881|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
219470882|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
219470883|NCT01458535|DRUG|ABT-450|tablets
219470884|NCT01458535|DRUG|ABT-267|tablets
219470885|NCT01458535|DRUG|ribavirin|tablets
219470886|NCT01458535|DRUG|ritonavir|capsules
219595245|NCT06028321|OTHER|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
218856129|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
218856130|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
218856131|NCT01574898|DRUG|V0474 - A mg|Single oral administration
218856132|NCT01574898|DRUG|V0474 - B mg|Single oral administration
218856133|NCT01574898|DRUG|V0474 - C mg|Single oral administration
219595246|NCT06028321|OTHER|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
219595247|NCT06028321|OTHER|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
219595248|NCT06028321|OTHER|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
218856134|NCT01574898|DRUG|V0018 - B mg|Single oral administration
218856135|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
218856136|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
219595249|NCT01160003|DRUG|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
219595250|NCT01160003|DRUG|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
219595251|NCT03256279|DEVICE|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
218856137|NCT00043108|DRUG|carboplatin|
218856138|NCT00043108|DRUG|paclitaxel|
218856139|NCT00043108|PROCEDURE|conventional surgery|
218856140|NCT00043108|RADIATION|radiation therapy|
218856141|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
218856142|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
218856143|NCT02443493|RADIATION|radiotherapy|
219363444|NCT03603652|DEVICE|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
219363445|NCT03228368|DRUG|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
219363446|NCT06035822|OTHER|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
219363447|NCT04431115|OTHER|Interviews|Interviews for stakeholders
219363448|NCT05684640|DRUG|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
219363449|NCT05684640|DRUG|Placebo|Tablets, Oral, 0mg, BID
219363450|NCT00454493|DRUG|Omacor (omega-3-acid ethyl esters)|
219363451|NCT03450083|DRUG|Benralizumab|30mg Benralizumab will be delivered subcutaneously
219363452|NCT03450083|DRUG|Placebo|Subcutaneous placebo injection
219363453|NCT02822456|PROCEDURE|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
219363454|NCT00511680|BEHAVIORAL|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
219363455|NCT03076983|DEVICE|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
219363456|NCT01711827|DRUG|Isavuconazole|oral
219363457|NCT01711827|DRUG|Prednisone|oral
219363458|NCT00943995|DRUG|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
219363459|NCT02195492|DRUG|Synvisc®|
219363460|NCT05546619|DRUG|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
219595252|NCT03256279|DEVICE|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
219595253|NCT04584385|DIAGNOSTIC_TEST|EEG|EEG monitoring
219595254|NCT05875311|DEVICE|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
218856144|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
218856145|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
218856146|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
218856147|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
218856148|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
218856149|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
219470887|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
219470888|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
219470889|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
219470890|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
219470891|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
219470892|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
219470893|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
219470894|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
219470895|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
219470896|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
219470897|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
219470898|NCT02027831|DRUG|Indocyanine Green|
219595255|NCT05875311|OTHER|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
219595256|NCT02897583|PROCEDURE|YAG vitreolysis|
219595257|NCT03850548|OTHER|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
219595258|NCT04541316|DEVICE|ProFlor inguinal hernia device|Inguinal hernia repair
219595259|NCT06255158|BEHAVIORAL|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
219595260|NCT06255158|OTHER|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
219595261|NCT00087620|DRUG|XELODA [capecitabine]|
219470899|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
219470900|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
219470901|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
219470902|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
219470903|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
219470904|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
219470905|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
219470906|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
219470907|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
219470908|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
219470909|NCT00274573|DRUG|Tiotropium bromide|
219470910|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
219470911|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
219470912|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
219470913|NCT02753608|OTHER|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
219470914|NCT01097759|PROCEDURE|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
219470915|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
219470916|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
219470917|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
219470918|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
219470919|NCT02404675|DRUG|icotinib|
219470920|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
219470921|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
219470922|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
219470923|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
219470924|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
219470925|NCT02989259|DRUG|Apatinib|apatinib 500mg p.o. qd
219470926|NCT00544349|BIOLOGICAL|cetuximab|
219470927|NCT00544349|DRUG|fluorouracil|
219470928|NCT00544349|DRUG|leucovorin calcium|
219470929|NCT00544349|DRUG|oxaliplatin|
219470930|NCT02854215|OTHER|Collection of additional data with questionnaires|"* questionnaires for quality of life measurements: QLQC30; QLQ-OV28~* questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
219595262|NCT00955526|DRUG|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
218856150|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
218856151|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
219595263|NCT00955526|DRUG|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
219595264|NCT00955526|DRUG|Placebo|Two placebo tablets once daily for 12 weeks
219595265|NCT05160857|DRUG|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
219595266|NCT02249130|DRUG|Tipranavir (TPV)|
219595267|NCT02249130|DRUG|Ritonavir (RTV)|
219595268|NCT02249130|DRUG|Delavirdine (DLV)|
219595269|NCT02249130|DRUG|Zidovudine (ZDV)|
219595270|NCT02249130|DRUG|Lamivudine (3TC)|
219020473|NCT07166042|BEHAVIORAL|10-15 minute, Audio-Recorded Guided Mediation Practices|"The 5 mindfulness practices, all of which have been validated in prior research.~Body Scan practice will consist of how to direct non-judgmental attention to different regions of the body~The Mindful Breathing practice will consist of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations.~The Mindfulness of Discomfort practice will consist of instruction in how to zoom in to deconstruct discomfort and precisely map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences.~The Savoring practice will consist of instruction in identifying and amplifying pleasant memories.~The Loving-Kindness practice will consist of instruction in cultivating feeling of warmth and compassion toward the self and others."
219595271|NCT02249130|DRUG|Stavudine (d4T)|
219595272|NCT04236323|DRUG|Not used remifentanil infusion|Remifentanil is not used during operation
219595273|NCT03460639|RADIATION|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
219595274|NCT03460639|RADIATION|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
219595275|NCT03460639|DIAGNOSTIC_TEST|Control group|In this group, we will only induce fatigue.
219595276|NCT03239223|DRUG|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
219595277|NCT02283008|BEHAVIORAL|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
219595278|NCT04007653|OTHER|Observation|No intervention
219595279|NCT06582862|OTHER|Exercise|Subjects will do aerobic and anaerobic exercise
219595280|NCT01439009|DRUG|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
219595281|NCT01439009|DRUG|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
219595282|NCT01458691|PROCEDURE|Steroid injection into the glenohumeral joint|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
219595283|NCT01458691|PROCEDURE|Allogeneic PRP injection into the glenohumeral joint|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
219595284|NCT06582992|OTHER|RRBS|Measure of genomic regions with differentially methylated profiles and differentially expressed protein
219595285|NCT00070551|BIOLOGICAL|GTI-2040|Given IV
219595286|NCT00070551|DRUG|cytarabine|Given IV
219595287|NCT00070551|OTHER|pharmacological study|Optional correlative studies
219595288|NCT00070551|OTHER|laboratory biomarker analysis|Optional correlative studies
219595289|NCT05810233|DIETARY_SUPPLEMENT|Ascorbic acid 1000mg|Health supplement
219470931|NCT00460421|DRUG|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
219595290|NCT05810233|OTHER|Placebo|Glucose chewable tablet without any ascorbic acid
219595291|NCT01649401|DEVICE|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
219595292|NCT01649401|DEVICE|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
219595293|NCT04257539|BEHAVIORAL|Intervention to Reduce Sedentary Time|Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
219595294|NCT06142474|DRUG|SGLT2 inhibitor|Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
219470932|NCT00460421|RADIATION|Total Body irradiation|
219470933|NCT00460421|DRUG|Chemotherapy|High dose etoposide, Cyclophosphamide
219470934|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
219470935|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
219595295|NCT05871723|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
219595296|NCT05871723|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
219595297|NCT02656069|DRUG|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
219595298|NCT02656069|DRUG|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
219595299|NCT02666209|DRUG|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
219595300|NCT02666209|DRUG|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
218856152|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
218856153|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
219470936|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
219470937|NCT06104774|BEHAVIORAL|Tai Chi Exercise|The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.
219020482|NCT07168915|BIOLOGICAL|V118E|IM administration
219470938|NCT05136859|PROCEDURE|preserve|preserve the perivascular fat of the target cephalic vein
219020483|NCT07168915|BIOLOGICAL|PREVNAR 20™|IM administration
219470939|NCT05310396|OTHER|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
219470940|NCT05310396|OTHER|Control Formula|Cow's milk-based infant formula with standard nutritional composition
219020484|NCT07168915|BIOLOGICAL|Saline|IM administration
219020485|NCT07169318|OTHER|Placebo for VNT-101|Capsules will be size 00 and filled with microcrystalline cellulose
219470941|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
219470942|NCT06501625|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
219470943|NCT06501625|DRUG|Durvalumab (for the first 8, 21-day, cycles)|1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
219470944|NCT06501625|DRUG|Gemcitabine (for the first 8, 21-day, cycles)|1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
219470945|NCT06501625|DRUG|Cisplatin (for the first 8, 21-day, cycles)|25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
219470946|NCT06501625|DRUG|Durvalumab (starting from cycle 9)|1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
219470947|NCT06501625|DRUG|Ivosidenib Recommended Combination Dose (RCD)|RCD administered orally once daily, taken continuously throughout treatment duration
219470948|NCT04602078|DRUG|Atezolizumab 1200 mg/m2|Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.
219470949|NCT04602078|DRUG|Gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.
219470950|NCT04602078|DRUG|Cisplatin 70 mg/m2|Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.
219470951|NCT03160131|DEVICE|Neuro Vision Technology|Training using Neuro Vision Technology
219470952|NCT04001790|BEHAVIORAL|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
219470953|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
219470954|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
219470955|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
219470956|NCT06954467|DRUG|JS207|10 mg/kg q3W or adjust the dose (e.g. 15 mg/kg) based on accumulated data on the safety and efficacy of JS207 from clinical studies.
219595301|NCT02666209|DRUG|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
219470957|NCT06954467|DRUG|JS007|Dose exploration stage: C1-C4, group 1:3 mg/kg, C1D1 once (single dose); Group 2:3 mg/kg, D1, Q6W; Group 3:1 mg/kg,D1, Q3W; ≥C5, 1 mg/kg, Q6W; Dose expansion stage: according to the group medication confirmed in the dose exploration stage.
219470958|NCT04448028|DRUG|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
219470959|NCT04448028|DRUG|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
219470960|NCT06426680|BIOLOGICAL|ILB-3101|There are eight escalating dose cohorts.
219470961|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
219470962|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
219470963|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
219470964|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
219470965|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
219470966|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
219470967|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
219470968|NCT06135493|DRUG|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
219470969|NCT04464746|OTHER|implementation of a specific program to improve therapeutic adherence|"1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
219470970|NCT06501885|BEHAVIORAL|Ethnodrama Intervention|The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
219470971|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
219470972|NCT04542304|DRUG|Metolazone|Participants receive a single dose of metolazone.
218856154|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
219470973|NCT04542304|DRUG|Placebo|Participants receive a single dose of placebo to match metolazone.
219595302|NCT02666209|DRUG|Dexamethasone|steroid given at physician discretion on a 28 day cycles
219595303|NCT01549405|OTHER|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
219595304|NCT04777149|OTHER|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
219595305|NCT04777149|OTHER|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
218856155|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
219020486|NCT07169318|DRUG|VNT-101|VNT-101 is an orally bioavailable, direct-acting antiviral with a novel mechanism of action - inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.
219020488|NCT07169162|DRUG|ADZENYS XR-ODT|ADZENYS XR-ODT™ (amphetamine) is an extended-release orally disintegrating tablet approved for once-daily oral administration for the treatment of ADHD in patients 6 years and older.
219020489|NCT07169162|DRUG|Placebo Oral Tablet|Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.
219020490|NCT07168564|DEVICE|AVA lenses|Participants are prescribed to receive AVA lenses through the AVA protocol and wear these lenses during 2 weeks.
219470974|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
219470975|NCT04450420|OTHER|Standard training|See arm/group description
219595306|NCT04777149|OTHER|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
219020491|NCT07168564|DEVICE|Standard lenses|Participants are prescribed to receive Standard lenses through the Gold standard protocol and wear these lenses during 2 weeks.
219595307|NCT00290550|DRUG|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
219595308|NCT02837848|PROCEDURE|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
218856156|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
218856157|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
218856158|NCT02781792|DRUG|Temozolomide|-Given standard of care
219470976|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
219470977|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
219470978|NCT06959017|GENETIC|Gene Expression Analysis|Each subject analysed for SERPİNH1 and ROCK1 gene exppression
219470979|NCT05807867|BEHAVIORAL|WMM-based intersectional stigma intervention|"Intervention components consist of:~1. psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~2. cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~3. Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
219470980|NCT05807867|BEHAVIORAL|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
219470981|NCT03921008|DRUG|Paclitaxel|-Commercial supply
219470982|NCT03921008|RADIATION|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
219470983|NCT03921008|PROCEDURE|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
219470984|NCT06327113|DRUG|CeFAZolin Injectable Solution|One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
219470985|NCT05524051|DRUG|TIN816|TIN816
219470986|NCT05524051|OTHER|Placebo|Placebo
219595309|NCT02837848|PROCEDURE|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
219595310|NCT05630690|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
219595311|NCT03215186|OTHER|observational study|
219470987|NCT03983668|DRUG|CMP-001|Immunostimulatory therapeutic agent
219470988|NCT03983668|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy
219470989|NCT06847763|OTHER|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education applied in the form of one-on-one seminar format, focused on pain neurophysiology, and in the form of speaking sessions. Within the scope of these speaking sessions, pictures, diagrams, graphs, examples, metaphors, and homework assignments explaining the neurophysiology of pain are used.
219199252|NCT06860126|OTHER|control group|"Continue with their daily routines without participating in any intergenerational interaction or structured activities.~* No specific interventions or programs are provided.~* Gender Representation:~* 78 participants (39 women and 39 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population."
219595312|NCT03558386|BEHAVIORAL|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
219595313|NCT01192763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219595314|NCT01192763|OTHER|laboratory biomarker analysis|Correlative studies
219595315|NCT01192763|OTHER|pharmacological study|Correlative studies
219595316|NCT01192763|PROCEDURE|neoadjuvant therapy|
218856159|NCT02781792|OTHER|Functional Assessment of Cancer Therapy - Brain|"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
218856160|NCT02781792|OTHER|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
218856161|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
219595317|NCT01192763|PROCEDURE|therapeutic conventional surgery|
218856162|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
219470990|NCT06847763|OTHER|Conventional Program|Conventional physiotherapy includes hot packs (20 minutes), ultrasound (1 mHz frequency, 1,5 watt/cm², 5 minutes left/right lumbar region), TENS (100Hz, 20 minutes), and home exercises.
218856163|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
219470991|NCT06077344|PROCEDURE|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation
219199253|NCT06860048|DEVICE|Arm sleeve|Randomised to wear arm sleeve on left or right
219470992|NCT06077344|PROCEDURE|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment
219470993|NCT06028373|DRUG|ATG-031|ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
219470994|NCT02669173|DRUG|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
219470995|NCT02669173|DRUG|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
219470996|NCT04881799|DRUG|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
219470997|NCT04881799|DRUG|Placebo|Daily injection
219470998|NCT06182358|DRUG|Lotilaner ophthalmic solution, 0.25%|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
219470999|NCT06182358|DRUG|Vehicle control|Vehicle of XDEMVY administered topically twice a day for approximately 43 days
219471000|NCT01513538|DEVICE|TherapyGuide|Use of TherapyGuide function to help programming the device
219471001|NCT06013384|DEVICE|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
219471002|NCT06013384|DEVICE|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
219471003|NCT02471898|DRUG|HTX-011|
219471004|NCT02471898|DRUG|Placebo|Saline
219471005|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
219471006|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
219471007|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
219595318|NCT06414226|DIETARY_SUPPLEMENT|Krill and Fish Oil vs. Placebo|Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
219471008|NCT04123743|OTHER|Placebo|Placebo topical cream
219471009|NCT03050879|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
219471010|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
219471011|NCT06015789|OTHER|Questionnaire|Administration of questionnaires for the evaluation of self-care
219471012|NCT05888740|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
219471013|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
219471014|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
219471015|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
219471016|NCT05866445|DEVICE|Wearable BP device|Wearable study BP device to be worn for 8 hours within study participation.
219595319|NCT00041626|GENETIC|INGN 201|
218856164|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
218856165|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
218856166|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
218856167|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
219199254|NCT06858176|OTHER|No intervention was implemented in this observational study|No intervention was implemented in this observational study
219595320|NCT05127512|OTHER|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
218856168|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
219471017|NCT05866445|DEVICE|24-hour ambulatory blood pressure monitor|24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
219471018|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
219471019|NCT05214898|BEHAVIORAL|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
219471020|NCT05755958|DEVICE|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
219471021|NCT05755958|DEVICE|SHAM HIFU procedure|SHAM HIFU procedure
219471022|NCT04936776|BEHAVIORAL|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
219471023|NCT01913613|DEVICE|IASD|IASD device implantation
219471024|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
219471025|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219471026|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
219471027|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
219471028|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
219471029|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
219471030|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
219471031|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
219471032|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
219471033|NCT00722618|OTHER|Written materials|2 written materials available on public website
219471034|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
219471035|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
219471036|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
219471037|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
219020492|NCT07167225|OTHER|Effectiveness of different recruitment approaches|Subjects will asked which type of recruitment material they've seen when completing the screening survey
219471038|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
219471039|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
219471040|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
219471041|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
219471042|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
219471043|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
219471044|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
219471045|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
219471046|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
219471047|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
219471048|NCT02040415|DRUG|Placebo drug of DW-1030|
219471049|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
219471050|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
219595321|NCT05623618|BEHAVIORAL|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
218856169|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
219471051|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
218856170|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
218856171|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
218856172|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
218856173|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
219471052|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
219471053|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
219471054|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
219471055|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
218856174|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
218856175|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
218856176|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
218856177|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
218856178|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
218856179|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
218856180|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
218856181|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
218856182|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
218856183|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
218856184|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
218856185|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
219471056|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
219595322|NCT01602718|OTHER|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
219471057|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
219471058|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
219471059|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
219471060|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
219595323|NCT06633315|OTHER|low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops
219595324|NCT06633315|OTHER|high dos dexmedetomidine|received dexmedetomidine 3 μ g/kg nasal drops
219595325|NCT06633315|OTHER|dexmedetomidine and esketamine|received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops
219595326|NCT05304247|OTHER|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
218856186|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
218856187|NCT02017145|DRUG|Chloraprep|
219471061|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
218856188|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
219471062|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
219471063|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
219471064|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
219471065|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
219471066|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
219471067|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
219471068|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
219595327|NCT02187692|BEHAVIORAL|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
219471069|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
219471070|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
219471071|NCT06104423|DRUG|Nebivolol 5 mg|1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.
219471072|NCT06104423|DRUG|Ramipril 2.5/5/10 mg|1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.
219471073|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
219471074|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
219471075|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
219471076|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
219595328|NCT02916667|OTHER|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
219595329|NCT01796418|DRUG|Beraprost sodium|
218856189|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
218856190|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
218856191|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
218856192|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
219020493|NCT07167225|OTHER|Choice of study completion locations|subjects will choose location when coordinator calls to schedule appointment
219020494|NCT07167225|OTHER|Cannabis Engagement Assessment|Self reported measure of current cannabis use that contains 30 questions assessing quantity, frequency of use and method of consumption in the past 30 days.
219471077|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
219471078|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
219471079|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
218856193|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
218856194|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
218856195|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
219471080|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
218856196|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
219471081|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
219471082|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
219471083|NCT03950947|DEVICE|Amplatzer vascular plug|See above
219471084|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
219471085|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
219471086|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
219471087|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
219471088|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
218856197|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
218856198|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
218856199|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
218856200|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
218856201|NCT00328653|DRUG|Vehicle|
218856202|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
218856203|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
218856204|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
218856205|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
219020495|NCT07167225|OTHER|E-cigarette dependence Scale|A 22-item questionnaire measuring e-cigarette dependence. Higher scores indicate greater dependence.
219199255|NCT06860191|DRUG|Root Canal Sealants|In this study, different irrigation agitation methods and different root canal sealers will be compared.
219471089|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
219471090|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
219471091|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
219471092|NCT00193076|DRUG|Gemcitabine|Gemcitabine
219471093|NCT00193076|DRUG|Carboplatin|Carboplatin
219471094|NCT00193076|DRUG|Trastuzumab|Trastuzumab
219471095|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
219471096|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
219471097|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
219471098|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471099|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
219471100|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471101|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
219471102|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471103|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
219471104|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471105|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
219471106|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471107|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
219471108|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
219471109|NCT03417245|DRUG|fitusiran|by SC injection
218856206|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
219471110|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
219471111|NCT04491955|BIOLOGICAL|CV301|CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
219471112|NCT04491955|DRUG|MSB0011359C|"Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
219471113|NCT04491955|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
219471114|NCT04491955|DRUG|NHS-IL12|NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
219471115|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
219471116|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
219471117|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
219471118|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
219471119|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
219471120|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
218856207|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
219199256|NCT06859801|DEVICE|Percutaneous Ablation|Percutaneous ablation is a minimally invasive alternative therapy for metastatic bone disease and can be used for destruction of nerves mediating pain signals, tumor destruction, decompression, or inhibition of tumor growth.
219199257|NCT06859801|RADIATION|Radiation Therapy|Radiation therapy (RT) is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients.
219471121|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
219471122|NCT02910895|OTHER|tumor biopsy|biopsy
219471123|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
219471124|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
219471125|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
219471126|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
219471127|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
219471128|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
218856208|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
219471129|NCT02708524|DEVICE|Senofilcon C Contact Lens|
218856209|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
219471130|NCT02708524|DEVICE|Comfilcon A Contact Lens|
219471131|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
219471132|NCT02708524|DEVICE|Samfilcon A Contact Lens|
219471133|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
219471134|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
218856210|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
219471135|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
219471136|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
219471137|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
219471138|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
219471139|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
219471140|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
219471141|NCT06162611|DRUG|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
219471142|NCT06162611|DEVICE|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
219471143|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
219471144|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
219471145|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
219471146|NCT00016211|RADIATION|radiation therapy|
219471147|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
219595330|NCT04809051|OTHER|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
219595331|NCT04809051|OTHER|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
219595332|NCT03430765|BEHAVIORAL|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
218856211|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
218856212|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
218856213|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
219471148|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
219471149|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
219471150|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
219471151|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
218856214|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
218856215|NCT00902993|DRUG|Placebo|Placebo
218856216|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
219471152|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
219471153|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
219471154|NCT05867186|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
219595333|NCT03107221|BEHAVIORAL|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
219595334|NCT01191944|DRUG|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
219471155|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
219471156|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
219471157|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
219471158|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
219471159|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
219471160|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
219471161|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
219471162|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
219471163|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
219471164|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
219471165|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
219471166|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
219471167|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
219471168|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
219471169|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
219471170|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
219471171|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
219199258|NCT06858267|BEHAVIORAL|PeSSKi questionnaire survey|The control group will only receive the questionnaire without meditation. The PeSSKi questionnaire survey will be receive in 4 time point, First questionnaire will sent via email after the appointment for the surgery is scheduled. The second PeSSKi questionnaire survey will share via email at halfway point to the surgery. The third questionnaire survey will be done immediately before the day of surgery in person to assess how anxious the patient is. The final questionnaire survey will be done 1 week postoperatively to assess how much pain the patient is still in after the quantity of analgesic usage logged throughout the week.
219471172|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
219471173|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
219471174|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
219471175|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
219471176|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
219471177|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
219471178|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
219471179|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
219471180|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
219471181|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
219471182|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
219471183|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
219471184|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
219471185|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
219471186|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
219199546|NCT06179953|OTHER|Traditional intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
219471187|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
219471188|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
219471189|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
219471190|NCT02900508|OTHER|Exergaming training|
219471191|NCT02900508|OTHER|Physical therapy intervention|
219471192|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
219471193|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
219471194|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
219471195|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
219471196|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
219471197|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
219471198|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
219471199|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
219471200|NCT03290131|DRUG|Placebo|Placebo comparator
219471201|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
219471202|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
219471203|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
219471204|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
219471205|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
219471206|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
219471207|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
219471208|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
219471209|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
219471210|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
219471211|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
219471212|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
219471213|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
219471214|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
219471215|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
219471216|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
219471217|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
219471218|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
219471219|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
219471220|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
219471221|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
219471222|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
219471223|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
219471224|NCT05110118|DRUG|LY01008|Single intravenous injection
219471225|NCT05110118|DRUG|Avastin|Single intravenous injection
219471226|NCT05875337|OTHER|Acupressure|Before starting the acupressure point application, the area around the area where the pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.
219471227|NCT05875337|OTHER|Placebo acupressure|Before starting the application to the placebo acupressure point, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Light pressure will be applied to the determined points (1.5 cm away from LI4, LI11 and HT7 points) with the thumb, index or middle finger. Each point will be applied for 2 minutes and the application will last 12 minutes.
219471228|NCT04722627|DRUG|AT-752|Parallel Assignment
219471229|NCT04722627|DRUG|Placebo|Parallel Assignment
219471230|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
219471231|NCT00442741|DRUG|Patupilone|
219471232|NCT00442741|DRUG|Patupilone + Omeprazole|
219471233|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
219471234|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
219471235|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
219471236|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
218856217|NCT05705973|DEVICE|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
218856218|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
219471237|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
219471238|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
219471239|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
219471240|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
219471241|NCT00450814|DRUG|Cyclophosphamide|Given IV
219471242|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
219471243|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
219471244|NCT00450814|OTHER|Pharmacological Study|Correlative studies
219471245|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
219471246|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
219471247|NCT02267343|DRUG|ONO-4538|
219471248|NCT02267343|DRUG|Placebo|
219471249|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
218856219|NCT02924714|OTHER|Discontinuation of imatinib|
218856220|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
218856221|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
218856222|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
218856223|NCT00532571|DRUG|CoQ10|
218856224|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
218856225|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
218856226|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
218856227|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
218856228|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
218856229|NCT00445848|BIOLOGICAL|bevacizumab|
218856230|NCT00445848|DRUG|erlotinib hydrochloride|
218856231|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
219471250|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
219471251|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
219471252|NCT04047459|OTHER|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
218856232|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
218856233|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
218856234|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
218856235|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
218856236|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
219471253|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
219471254|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
219471255|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
219471256|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
219471257|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
219471258|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
218856237|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
218856238|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
218856239|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
219471259|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
219471260|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
219471261|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
219471262|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
219471263|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
219595335|NCT01191944|DRUG|pramipexole extended release tablet|0.375mg-4.5mg, once a day
219595336|NCT02709291|BEHAVIORAL|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
218856240|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
218856241|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
218856242|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
218856243|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
218856244|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
218856245|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
218856246|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
218856247|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
218856248|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
218856249|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
219471264|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
219471265|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
219471266|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
219471267|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
219471268|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
219471269|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
219471270|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
219471271|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
219471272|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
219471273|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
219471274|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
219471275|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
219471276|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
219471277|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
219471278|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
219471279|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
219471280|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
219471281|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
219471282|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
219471283|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
219471284|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
219471285|NCT00003758|DRUG|cytarabine|
219471286|NCT00003758|DRUG|idarubicin|
219471287|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
219471288|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
219471289|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
219471290|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
219471291|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
219471292|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
218856250|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
218856251|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
218856252|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
219199547|NCT06874673|DRUG|Pronase|During the colonoscopy procedure on participants in Group A, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses a solution of pronase (200 U/mL) delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
219471293|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
219471294|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
219471295|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
218856253|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
218856254|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
218856255|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
218856256|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
218856257|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
218856258|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
218856259|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
218856260|NCT01044212|DRUG|Docusate|Docusate 100mg BID
219471296|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
219471297|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
219471298|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
219471299|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
219471300|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
219471301|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
219471302|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
219471303|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
219471304|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
219471305|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO\_QOL.
218856261|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
219471306|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
219471307|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
219471308|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
219471309|NCT02780180|DRUG|QGC001|
219471310|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
219471311|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
219471312|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
219471313|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
219471314|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
219471315|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
219471316|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
219471317|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
218856262|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
218856263|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
219471318|NCT02190604|DRUG|Placebo|Capsule- oral dose
219471319|NCT02190604|DRUG|QBW251|Capsule - oral dose
219471320|NCT02888782|OTHER|Pharmacist Consultation|
219471321|NCT00683462|DRUG|Placebo|
219471322|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
219471323|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
219471324|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
219471325|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
219471326|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
219471327|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
218856264|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
218856265|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
218856266|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
218856267|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
218856268|NCT02627547|BEHAVIORAL|De-training|No training
218856269|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
219471328|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
219471329|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
219471330|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
218856270|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
218856271|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
218856272|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
218856273|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
219471331|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
219471332|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
219471333|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
219471334|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
219471335|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
219471336|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
219471337|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
219595337|NCT02709291|BEHAVIORAL|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
219471338|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
219471339|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
219471340|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
219471341|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
219595338|NCT01404130|DRUG|Isotretinoin|0.5-1mg/kg daily for 4-6 months
219595339|NCT00358410|DRUG|GW679769 oral tablets|2x GW679769 60mg tablets
219595340|NCT00358410|DRUG|Placebo|Placebo oral tablets to match experimental intervention
219595341|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to hemodynamic parameters|Patient who will be adjusted according to hemodynamic parameter
219595342|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to NOL monitoring|Patient who will be adjusted according to NOL monitoring
218856274|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
218856275|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
219595343|NCT00018356|PROCEDURE|exercise|
219471342|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
219471343|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
219471344|NCT03894111|OTHER|decesased patients|mortality ratio
219471345|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
219471346|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
219471347|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
219471348|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
219471349|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
219471350|NCT04095039|PROCEDURE|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
219471351|NCT05596409|DRUG|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
219471352|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
219595344|NCT00018356|DRUG|testosterone|
219595345|NCT01226407|DRUG|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
219595346|NCT01797237|DEVICE|PFNA|
219595347|NCT01797237|DEVICE|InterTAN|
218856276|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
218856277|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
218856278|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
219471353|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
219471354|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
219471355|NCT06165471|BEHAVIORAL|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
219471356|NCT06165471|BEHAVIORAL|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
219471357|NCT05206305|DEVICE|GammaSense Stimulation device|Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
219471358|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
219471359|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
219471360|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
219471361|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
219471362|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
219471363|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
219471364|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
219471365|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
219471366|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
219471367|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
219471368|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
219471369|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
219595348|NCT03548701|DIAGNOSTIC_TEST|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
219595349|NCT00000246|DRUG|Flumazenil|
219595350|NCT04185623|PROCEDURE|denudation time lag|The time between ovum pickup and denudation of oocyte
219595351|NCT00603837|DEVICE|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
219595352|NCT00603837|DEVICE|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
219595353|NCT04611529|DRUG|Ibuprofen 400 mg|Ibuprofen 400mg
219595354|NCT04611529|DRUG|Topical diclofenac|Diclofenac 1% gel 4gm
219471370|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
219471371|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
218856279|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
218856280|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
219199259|NCT06858267|BEHAVIORAL|Meditation Video|"The experimental group pediatric patients selected for this study and their parents will be receiving meditation and PeSSKi (Perceived Stress Scale for Kids) questionnaire. The ideal meditation schedule will be 3-5 meditations per week for 5 minutes beginning 3 weeks before surgery. This will provide a dose-response relationship of meditation to anxiety and postoperative pain for data analysis. The Patient and their parents will open the link, enter their assigned number, and follow the guided meditation embedded in the Qualtrics. This will track how many times and for how long the patients are following the regimen.~The questionnaire has eleven questions on a five-point scale ranging from Not at all to A lot. An example of the meditation video questionnaire is linked here:~https://augusta.qualtrics.com/jfe/form/SV\_3DeFFKdJVupMJQq (experimental group) https://augusta.qualtrics.com/jfe/form/SV\_2b2DZ9x16jY9IzQ (PeSSKi questionnaire)"
219471372|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
219471373|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
219471374|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
219471375|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
219471376|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
219471377|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
219471378|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
218856281|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
219471379|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
218856282|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
218856283|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
218856284|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
218856285|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
219471380|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
219471381|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
219471382|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
219471383|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
219471384|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
219471385|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
219471386|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
219471387|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
219471388|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
219471389|NCT00002625|DRUG|topotecan hydrochloride|
219471390|NCT00002625|RADIATION|low-LET electron therapy|
219471391|NCT00002625|RADIATION|low-LET photon therapy|
219595355|NCT04762849|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
219595356|NCT04762849|DEVICE|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
218856286|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
219595357|NCT04879680|PROCEDURE|sentinel node detection|Under general anesthesia 5 ml at 2.5mg/ml of Infracyanine ® (Laboratoire SERB; France) were injected circumferentially around the areola. Two ml of patent blue-V dye (Laboratoire Guerbet, Aulney-Sous-Bois, France) were injected in combination in the cohort of patients undergoing the procedure after primary chemotherapy. This was followed by a breast massage to facilitate absorption into the lymph vessels, then the surgical lights were turned off and image were obtained under near-infrared light using a first generation Near Infra Red (NIR) device \[K\]. Course of subcutaneous lymphatic drainage pathway fluorescence was followed up to where it disappeared to enter to deeper axilla and an incision was performed at that place. Lymphatic duct identification using the NIR camera allowed localization and removal of the sentinel lymph node(s).
219595358|NCT03578549|DEVICE|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
219595359|NCT03905720|PROCEDURE|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
219595360|NCT03905720|BEHAVIORAL|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
219595361|NCT02305160|DRUG|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
219471392|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
219471393|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
219471394|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
219471395|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
219471396|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
219595362|NCT02305160|DRUG|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
218856287|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
219471397|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
219471398|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
219471399|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
219471400|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
218856288|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
218856289|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
218856290|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
218856291|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
219471401|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
219471402|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
219471403|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
219471404|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
219471405|NCT00160147|DRUG|Placebo|Placebo
219471406|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
219471407|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
219471408|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
219471409|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
219471410|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
219471411|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
219471412|NCT01061073|DRUG|Omexel|
219020498|NCT07167238|BEHAVIORAL|Virtual reality exercises|"Program Duration: 8 weeks Implementation: The conventional program plus supervised video game-based training sessions.~Additional Protocol: Video Game-Based Exercises~1. Breathing Labs - Breathing Games (Slovenia) Frequency: 3 days per week, on non-walking days, supervised at the hospital. Structure: 5 mini-games per session, performed sequentially.~   Exercises:~   Balloon: Weeks 1-4: Level 1; Weeks 5-8: Level 2. Focus on sustained controlled exhalation.~   Plane: Weeks 1-4: \~6 sec breath cycle; Weeks 5-8: \~8 sec breath cycle. Wolf: Weeks 1-4: Easy; Weeks 5-8: Medium. Flowers: Weeks 1-4: Sunflower module; Weeks 5-8: Rose module. Pluto: Weeks 1-4: Easy; Weeks 5-8: Medium. Intensity: Target MBS 4-6/10 for dyspnea and fatigue.~2. Nintendo Wii / Wii Fit - Functional Training Duration: \~5 minutes per game, 30-40 minutes total per session.~Games and targets:~Lower limb/aerobic: Basic Run, Basic Step, Obstacle Course, Island Cycling. Upper limb: Boxing, Canoe. Balance: Rhythm Parade."
219471413|NCT01061073|DRUG|spasfon|
219471414|NCT00032058|PROCEDURE|magnetic resonance imaging|
219471415|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
219471416|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
219471417|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
219471418|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
219471419|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
219471420|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
219471421|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
219471422|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
219471423|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
219471424|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
219471425|NCT01038609|DRUG|Acetaminophen|
219471426|NCT01038609|DRUG|Morphine Extended Release|
219471427|NCT01038609|DRUG|Placebo|
219471428|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
219471429|NCT02357524|DRUG|Oritavancin|
219471430|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
219595363|NCT01776931|DIETARY_SUPPLEMENT|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
219595364|NCT03668392|DRUG|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
219595365|NCT03079635|DIETARY_SUPPLEMENT|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
219471431|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
219471432|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
219471433|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
219471434|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
219471435|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
219471436|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
219471437|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
219471438|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
219471439|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
219471440|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
219471441|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
219595366|NCT03079635|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
219595367|NCT00900835|OTHER|educational intervention|
219595368|NCT00900835|OTHER|questionnaire administration|
218856292|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
219471442|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
219471443|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
219471444|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
219471445|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
219595369|NCT00900835|OTHER|study of socioeconomic and demographic variables|
219595370|NCT00900835|PROCEDURE|assessment of therapy complications|
219595371|NCT00900835|PROCEDURE|fatigue assessment and management|
219595372|NCT00900835|PROCEDURE|quality-of-life assessment|
219595373|NCT00900835|PROCEDURE|standard follow-up care|
219595374|NCT02040441|DRUG|Spironolactone|
218856293|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
218856294|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
218856295|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
218856296|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
219199260|NCT06859229|DEVICE|Innovative technology pathway for gait neurorehabilitation|Participants will be assigned to either an advanced or traditional training pathway based on the protocol. The innovative tehcnology pathway for gait rehabilitation will incorporate devices such as exoskeletons, virtual reality systems, and body-weight suspension (BWS) devices to enhance gait rehabilitation. At the end of the training period, participants will undergo follow-up evaluation tests to assess outcomes.
219471446|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
219471447|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
219471448|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
219471449|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
219471450|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
219471451|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
219471452|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
219471453|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
219471454|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
219471455|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
219595375|NCT02040441|DRUG|Placebo|
219595376|NCT02040441|DRUG|Standard care|Standard diabetes care
219595377|NCT03624309|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
219595378|NCT03624309|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
219595379|NCT04380597|DRUG|Calcipotriene and betamethasone dipropionate aerosol foam|Prescribed according to clinical practice and following Product Data Sheet instructions
219595380|NCT01927198|DRUG|Placebo|
219595381|NCT01927198|DRUG|RDEA3170 5 mg|
219595382|NCT01927198|DRUG|RDEA3170 10 mg|
219595383|NCT01927198|DRUG|RDEA3170 12.5 mg|
219595384|NCT02723747|OTHER|myocardial perfusion with magnetic resonance imaging|
219595385|NCT06050304|BEHAVIORAL|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
219595386|NCT06050304|BIOLOGICAL|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
219471456|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
218856297|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
219471457|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
219471458|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
219471459|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
219471460|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
219471461|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
219471462|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
219471463|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
219471464|NCT00039104|DRUG|rebimastat|Given PO
219471465|NCT00039104|DRUG|zoledronic acid|Given IV
219471466|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
219471467|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
219471468|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
219595387|NCT05742035|PROCEDURE|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
219595388|NCT05616637|DIAGNOSTIC_TEST|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
218856298|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
218856299|NCT02984150|DIETARY_SUPPLEMENT|saline|
218856300|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
218856301|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
218856302|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
219471469|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
219471470|NCT04421105|DRUG|Placebo|
219471471|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
218856303|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
218856304|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
219471472|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
219471473|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
219471474|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
219471475|NCT02400281|DRUG|Crenolanib besylate|
219471476|NCT02400281|DRUG|Idarubicin|
219471477|NCT02400281|DRUG|Cytarabine|
219471478|NCT02400281|DRUG|Azacytidine|
219471479|NCT02400281|DRUG|Mitoxantrone|
218856305|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
218856306|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
218856307|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
218856308|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
218856309|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
219471480|NCT02400281|DRUG|Etoposide|
219471481|NCT02400281|DRUG|Fludarabine|
219471482|NCT02400281|DRUG|G-CSF|
219471483|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
219471484|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
219471485|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
219471486|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
219471487|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
219471488|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
219471489|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
219471490|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
218856310|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
218856311|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
218856312|NCT02115750|DRUG|Etanercept|Head-to-head comparison
218856313|NCT02115750|DRUG|CHS-0214|
218856314|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
218856315|NCT03054350|DRUG|Vadadustat|Daily oral dose
218856316|NCT03054350|DRUG|Placebo|Daily oral dose
219471491|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
219471492|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
219471493|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
218856317|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
218856318|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
219471494|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
218856319|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
219199261|NCT06859229|OTHER|Conventional gait rehabilitation strategy|The control group will undergo a traditional rehabilitation program that follows standard clinical protocols for gait recovery. This program will include conventional therapeutic exercises aimed at improving strength, balance, coordination, and functional mobility
219471495|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
219471496|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
219471497|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
219471498|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
219471499|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
219471500|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
219471501|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
219199262|NCT06859580|DRUG|Zoledronic acid 4 mg|Product name/EU MP number: Zoledronic Acid Oresund Pharma 4 mg/100 ml infusionsvätska, lösning/PRD8924813 (Test) Substance (name/ code): ZOLEDRONIC ACID/SUB00176MIG Strength: Zoledronic Acid 0.04mg Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 52486 / SE Modified in relation to MA: No Max Dosage: mg milligram(s) Duration of use: Week
218856320|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
218856321|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
218856322|NCT01858805|PROCEDURE|esophagectomy|
218856323|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
218856324|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
218856325|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
218856326|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
218856327|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
218856328|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
218856329|NCT01133405|DRUG|LY2886721|Oral capsules
218856330|NCT01133405|DRUG|Placebo|Oral capsules
218856331|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
219471502|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
219471503|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
219471504|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
219471505|NCT06083428|DRUG|Control Test|Only spinal anesthesia
219471506|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
219471507|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
219471508|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
219471509|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
219471510|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
219471511|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
219471512|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
219471513|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
219471514|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
219471515|NCT02389868|DRUG|Lovastatin|
219471516|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
219471517|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
219471518|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
219471519|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
219471520|NCT00252798|DRUG|Gefitinib|
219471521|NCT00252798|DRUG|Carboplatin|
219471522|NCT00252798|DRUG|Paclitaxel|
219471523|NCT00252798|PROCEDURE|Radiation|
218856332|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
219471524|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
219471525|NCT03216499|OTHER|Pharmacological Study|Correlative studies
219471526|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
219471527|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
219471528|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
219471529|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
218856333|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
218856334|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
218856335|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
218856336|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
218856337|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
218856338|NCT02673567|DRUG|Placebo|Matching Placebo
218856339|NCT05675267|OTHER|data collection|HEART score calculation
218856340|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
219471530|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
218856341|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
218856342|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
218856343|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
218856344|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
218856345|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
218856346|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
218856347|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
218856348|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
218856349|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
218856350|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
218856351|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
218856352|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
218856353|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
218856354|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
218856355|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
219471531|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
219471532|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
219471533|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
219471534|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
219471535|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
219471536|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
219471537|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
219471538|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
219471539|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
218856356|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
218856357|NCT06463704|OTHER|There is no intervention|There is no intervention
218856358|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
218856359|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
218856360|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
218856361|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
218856362|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
218856363|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
218856364|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
219471540|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
218856365|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
219471541|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
219471542|NCT00208715|DRUG|Provigil|
219471543|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
219471544|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
219471545|NCT02536209|DRUG|MT-8554 low dose|
218856366|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
218856367|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
219471546|NCT02536209|DRUG|MT-8554 high dose|
219471547|NCT02536209|DRUG|Oxycodone hydrochloride|
219471548|NCT02536209|DRUG|Placebo|
218856368|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
219471549|NCT00005627|DRUG|carboplatin|
219471550|NCT00005627|DRUG|docetaxel|
219471551|NCT00005627|DRUG|estramustine phosphate sodium|
219471552|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
219471553|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
219471554|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
219471555|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
219471556|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
219471557|NCT00000758|DRUG|Fluorouracil|
219471558|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
219471559|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
219471560|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
219471561|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
219471562|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
219471563|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
219471564|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
219471565|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
219471566|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
219471567|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
219471568|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
219471569|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
219471570|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
219471571|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
219471572|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
219471573|NCT03804476|DRUG|Placebo|Placebo control for this study.
219471574|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
219471575|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
219471576|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
219471577|NCT04881669|DEVICE|obturator|variable bulbs
219471578|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
219471579|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
219471580|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
219471581|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
219471582|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
219471583|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
219471584|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
219471585|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
218856369|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
218856370|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
218856371|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
219471586|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
219471587|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
219471588|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
219471589|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
219471590|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
219471591|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
219471592|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
219471593|NCT02033486|DEVICE|TOBI + DBT|
219471594|NCT02183220|DRUG|Metamizol|
218856372|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
218856373|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
218856374|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
219471595|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
219471596|NCT02183220|DRUG|Metamizol placebo|
219471597|NCT02183220|DRUG|ASA placebo|
219471598|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
219471599|NCT00166595|DRUG|Risperidone|
218856375|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
218856376|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
219471600|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
219471601|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
219471602|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
219471603|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
219471604|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
218856377|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
218856378|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
218856379|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
218856380|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
218856381|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
218856382|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
219595389|NCT05616637|OTHER|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
218856383|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
218856384|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
218856385|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
218856386|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
218856387|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
218856388|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
218856389|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
218856390|NCT00089986|OTHER|Placebo|
218856391|NCT00522314|DEVICE|NIV and ACBT|
218856392|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
218856393|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
218856394|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
218856395|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
218856396|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
218856397|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
218856398|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
219471605|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
219471606|NCT04824118|DIAGNOSTIC_TEST|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
219471607|NCT04824118|DIAGNOSTIC_TEST|Clotting Studies|"Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen"
218856399|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
218856400|NCT00529126|DRUG|SKY0402|SKY0402
218856401|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
219471608|NCT04824118|DIAGNOSTIC_TEST|Full Blood Count|For platelet count
219471609|NCT04824118|DIAGNOSTIC_TEST|Quantitative hCG|Serum human chorionic gonadotrophin
219471610|NCT04824118|DIAGNOSTIC_TEST|Pregnancy Test|Point of care urinary pregnancy test
219471611|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
219471612|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
219471613|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
219471614|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
218856402|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
218856403|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
218856404|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
218856405|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
218856406|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
218856407|NCT02281474|DRUG|Nilotinib|
218856408|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
218856409|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
218856410|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
218856411|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
218856412|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
218856413|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
218856414|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
218856415|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
218856416|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
218856417|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
218856418|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
218856419|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
218856420|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
219471615|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
219471616|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
219471617|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
218856421|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
218856422|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
218856423|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
218856424|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
218856425|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
218856426|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
218856427|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
218856428|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
219471618|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
219471619|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
219471620|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
219471621|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
218856429|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
218856430|NCT01185418|DRUG|risperidone|
218856431|NCT01185418|DRUG|aripiprazole|
218856432|NCT01185418|DRUG|haloperidol|
218856433|NCT01185418|DRUG|amisulpride|
218856434|NCT01185418|DRUG|lactose|
218856435|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
219471622|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
219471623|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
219471624|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
219471625|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
218856436|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
218856437|NCT06896942|OTHER|Autism Doula|The Autism Doula provides caregiver support, navigation with next steps for their child, connects families to resources and the Black autism community, and coordinates services to help alleviate caregiver stress (e.g., cleaning, cooking, respite care).
218856438|NCT06896942|OTHER|DDBP Family Navigation|A one-time consult with a DDBP family navigator via telehealth to come up with an action plan for next steps for the patient's care.
218856439|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
218856440|NCT00637637|DRUG|indinavir sulfate|
218856441|NCT00637637|DRUG|ritonavir|
218856442|NCT00637637|RADIATION|radiation therapy|
218856443|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
218856444|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
218856445|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
218856446|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
218856447|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
218856448|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
218856449|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
218856450|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
218856451|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
218856452|NCT00379782|OTHER|Navigation|Navigation and escourt
218856453|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
218856454|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
218856455|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
218856456|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
218856457|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
218856458|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
218856459|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
218856460|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
219471626|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
219471627|NCT01207427|DRUG|Placebo|
219471628|NCT01207427|DRUG|ADL5945 0.1 mg|
219471629|NCT01207427|DRUG|ADL5945 0.25 mg|
219471630|NCT01732380|DRUG|Raltitrexed|
219471631|NCT01732380|DRUG|Oxaliplatin|
219471632|NCT01732380|RADIATION|Radiotherapy|
219471633|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
219471634|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
219471635|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
219471636|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
219471637|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
219471638|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
219471639|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
218856461|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
219471640|NCT02986321|DRUG|Budesonide|active control
219471641|NCT02986321|DRUG|Placebo|placebo control
219471642|NCT04301271|DRUG|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
219471643|NCT04301271|DRUG|Placebo oral tablet|12 weeks Placebo add-on
219471644|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
219471645|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
219471646|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
219471647|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
219471648|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
219471649|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
218856462|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
219471650|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
219471651|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
219471652|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
219471653|NCT00821847|OTHER|DEXA scan|DEXA scan
219471654|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
219471655|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
218856463|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
218856464|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
219471656|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
219471657|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
219471658|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
219471659|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
218856465|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
218856466|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
218856467|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
218856468|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
218856469|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
218856470|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
219471660|NCT06722391|OTHER|Resistance Training|Group will receive exercise training.
219471661|NCT06724237|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219471662|NCT06724237|OTHER|Best Practice|Receive standard of care observation
219471663|NCT06724237|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219471664|NCT06724237|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219471665|NCT06724237|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219471666|NCT06724237|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219471667|NCT06724237|DRUG|High Dose Chemotherapy|Receive high dose chemotherapy
219471668|NCT06724237|PROCEDURE|Leukapheresis|Undergo leukapheresis
219471669|NCT06724237|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219471670|NCT06724237|DRUG|Stem Cell Mobilization Therapy|Receive stem cell mobilization therapy
219471671|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
219471672|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
219471673|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
219471674|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
219471675|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
218856471|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
219471676|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
219471677|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
219471678|NCT06722001|BEHAVIORAL|"The Brief insomnia intervention interactive e-book"|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
219471679|NCT06722001|BEHAVIORAL|traditional paper handout|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
219471680|NCT06722729|DRUG|KDT-3594|Oral administration
219471681|NCT06722729|DRUG|Placebo|Oral administration
219595390|NCT05616637|OTHER|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
219471682|NCT06722105|BIOLOGICAL|2 infusions of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 MSC(AT) (2x10\^6 cells/kg) injection at M3
219471683|NCT06722105|BIOLOGICAL|1 infusion of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 placebo injection at M3
219471684|NCT06722105|OTHER|Placebo|Placebo at M0 and M3
218856472|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
219471685|NCT04613687|DEVICE|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
219471686|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
219471687|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
219471688|NCT06704243|BEHAVIORAL|Peer Support|"The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable."
218856473|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
218856474|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
219471689|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
219471690|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
219471691|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
219471692|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
219471693|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
219471694|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
218856475|NCT00537667|DRUG|anakinra|anakinra
218856476|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
218856477|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
219471695|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
219471696|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
219471697|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
219471698|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
219471699|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
219471700|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
219471701|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
219471702|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
219471703|NCT06768138|DRUG|Intra-arterial infusion of Alteplase|Patients enrolled in the experimental arm will receive intra-arterial thrombolysis with Alteplase. The dose of Intra-arterial Alteplase is 0.225 mg/kg body weight with a maximal dose of 20 mg
219471704|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
219471705|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
219471706|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
219471707|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
219471708|NCT02723539|DRUG|MBN-101|Topical application
219471709|NCT02723539|DRUG|Placebo|Topical application
218856478|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
219471710|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
219471711|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
219471712|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
218856479|NCT04005560|OTHER|no interventional study|no interventional study
218856480|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
219471713|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
218856481|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
219471714|NCT06526104|DRUG|Tremelimumab|Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
219471715|NCT06526104|DRUG|Durvalumab|Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
219471716|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
218856482|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
218856483|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
218856484|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
219471717|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
219471718|NCT06597968|DEVICE|AI Based CAD Software (qXR-Ln)|All x-ray images have already been obtained and will then be run through CAD software for secondary nodule detection
219471719|NCT04374461|DRUG|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
219471720|NCT04374461|OTHER|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
219471721|NCT01716221|DRUG|bupropion & Citalopram|
219471722|NCT01716221|DRUG|Bupropion & Placebo|
219471723|NCT01716221|DRUG|Placebo & Citalopram|
219471724|NCT01716221|DRUG|Placebo & Placebo|
219471725|NCT02875743|DRUG|Posaconazole|
219471726|NCT02701907|OTHER|Blood sampling|
219471727|NCT02046551|DRUG|Atomoxetine|
219471728|NCT02046551|DRUG|Placebo|
219471729|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
219471730|NCT02334891|OTHER|Standard|Standard management
219471731|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
219471732|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
219471733|NCT00957827|DRUG|placebo|placebo BID for five days
219471734|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
219471735|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
219471736|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
219471737|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
219471738|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
219471739|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
219471740|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
219471741|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
219471742|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
219471743|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
219471744|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
218856485|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
219471745|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
218856486|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
218856487|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
219471746|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
219471747|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
219471748|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
218856488|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
218856489|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
218856490|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
218856491|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
219471749|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
219471750|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
218856492|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
218856493|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
218856494|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
219471751|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
219471752|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
219471753|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
219471754|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
218856495|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
218856496|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
219471755|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
219471756|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
219471757|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
219471758|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
219471759|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
219471760|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
219471761|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
219471762|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
219471763|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
219471764|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
218856497|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
218856498|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
219471765|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
219471766|NCT00403429|DRUG|capecitabine|
219471767|NCT01301157|DRUG|M518101|Proper quantity twice a day
219471768|NCT01301157|DRUG|placebo|Proper quantity twice a day
219471769|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
219471770|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
219471771|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
219471772|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
219471773|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
219471774|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
219471775|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
219471776|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
219471777|NCT02778477|OTHER|Placebo|Multiple dose of placebo
218856499|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
218856500|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
218856501|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
218856502|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
218856503|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
218856504|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
218856505|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
218856506|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
218856507|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
218856508|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
218856509|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
219471778|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
219471779|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
219471780|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
218856510|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
219471781|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
219471782|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
219471783|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
219471784|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
219471785|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
219471786|NCT00161031|DRUG|Atomoxetine|
219471787|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
219471788|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
219471789|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
219471790|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
219471791|NCT03085940|DRUG|Placebo|Placebo
219471792|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
219471793|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
219471794|NCT04058665|DEVICE|Floseal|Hemostatic agent
219471795|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
219471796|NCT00031616|DRUG|brivudine phosphoramidate|
219471797|NCT00847002|DEVICE|Standard Wound Care|
219471798|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
219471799|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
219471800|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
219471801|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
219471802|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
219471803|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
219471804|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
218856511|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
219595391|NCT05913505|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
219471805|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
219471806|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
219471807|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
219471808|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
219471809|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
219471810|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
219471811|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
219471812|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
218856512|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
218856513|NCT04775927|OTHER|education|premarital education
218856514|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
218856515|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
218856516|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
219471813|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
219471814|NCT05957367|DRUG|Inlexisertib|Oral Tablet Formulation
219471815|NCT05957367|DRUG|Ripretinib|Oral Tablet Formulation
219471816|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
219471817|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
219471818|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
219471819|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
219471820|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
219471821|NCT02279082|DRUG|DFN-02|Active Experimental Drug
219471822|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
219471823|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
219471824|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
219471825|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
219471826|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
219471827|NCT00602082|DRUG|capecitabine|
219471828|NCT00602082|DRUG|cisplatin|
219471829|NCT00602082|DRUG|streptozocin|
218856517|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
218856518|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
218856519|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
218856520|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
218856521|NCT00236418|DRUG|topiramate|
218856522|NCT01068782|DRUG|XL184|given orally as capsules
218856523|NCT01933126|DRUG|HCG injection|
218856524|NCT01933126|DRUG|Placebo|
218856525|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
218856526|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
218856527|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
218856528|NCT04963530|PROCEDURE|No intervention|No intervention.
218856529|NCT00244348|DRUG|Oxaliplatin (via HAI)|
218856530|NCT00244348|DRUG|5 Fluorouracil (systemic)|
219471830|NCT00602082|GENETIC|DNA analysis|
219471831|NCT00602082|GENETIC|RNA analysis|
219471832|NCT00602082|GENETIC|protein analysis|
219471833|NCT00602082|GENETIC|proteomic profiling|
218856531|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
218856532|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
219471834|NCT00602082|OTHER|laboratory biomarker analysis|
219471835|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
218856533|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
218856534|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
218856535|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
219471836|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
219471837|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
219471838|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
219471839|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
219471840|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
219471841|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
219471842|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
219471843|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
219471844|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
219471845|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
219471846|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
219471847|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
218856536|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
219471848|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
218856537|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
218856538|NCT00505037|DRUG|ASP1585|Oral
218856539|NCT00505037|DRUG|Placebo|Oral
218856540|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
218856541|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
218856542|NCT00159731|DRUG|Pregabalin|
218856543|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
219471849|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
219471850|NCT00364338|BEHAVIORAL|gourment cooking workshop|
219471851|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
219471852|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
219471853|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
219471854|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
218856544|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
219471855|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
219471856|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
218856545|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
218856546|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
218856547|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
218856548|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
218856549|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
218856550|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
218856551|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
218856552|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
219471857|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
218856553|NCT02257177|DRUG|Placebo|DPI placebo
218856554|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
219471858|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
219471859|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
219471860|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
219471861|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
218856555|NCT00001155|DRUG|cyclophosphamide|
218856556|NCT00791401|DRUG|ER OROS Paliperidone|
218856557|NCT01396265|DRUG|Afatinib|single dose
218856558|NCT01396265|DRUG|Afatinib|single dose
218856559|NCT01396265|DRUG|Rifampicin|multiple doses
218856560|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
218856561|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
218856562|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
218856563|NCT05976503|DRUG|Placebo|Placebo
218856564|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
218856565|NCT02081638|DRUG|Aspirin|Daily Asprin daily
219471862|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
219471863|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
219471864|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
219471865|NCT00333437|DRUG|Mycophenolate mofetil|
219471866|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
219471867|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
219595392|NCT05913505|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
219595393|NCT03372291|OTHER|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
218856566|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
218856567|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
218856568|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
218856569|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
218856570|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
218856571|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
218856572|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
218856573|NCT00174681|DRUG|Insulin Glargine|
218856574|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
218856575|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
219020499|NCT07167238|BEHAVIORAL|Home exercises|"Program Duration: 8 weeks Implementation: Home-based, instructed face-to-face at baseline by a physiotherapist, supported with video materials, and monitored with regular feedback.~A) Posture + Breathing Exercises Frequency: 3 sessions per day (morning, noon, evening)~Content:~Shoulder girdle mobilization: Scapular elevation-depression, abduction-adduction (3 sets × 3 repetitions).~Stretching exercises: Shoulder, cervical, and trunk muscles; 5-second hold at end range.~Combined with breathing: Inspiration during concentric phase, expiration during eccentric phase.~B) Breathing Exercises Frequency: 3 sessions per day; 10 repetitions of each exercise per session~Content:~Pursed-Lip Breathing, Thoracic Expansion Exercises, Diaphragmatic Breathing, Breathing Control C) Walking Program Frequency: 2 days per week Duration: 30 minutes (5 min warm-up, 20 min walking, 5 min cool-down) Intensity: Self-selected pace targeting Modified Borg Scale (MBS) 4-6/10 for dyspnea."
219471868|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
219471869|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
219471870|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
219471871|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
219471872|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
219471873|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
219471874|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
219471875|NCT03022526|PROCEDURE|CSE|
219471876|NCT03022526|PROCEDURE|Epidural|
219471877|NCT03022526|DRUG|Bupivacaine / fentaNYL|
219471878|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
219471879|NCT03734874|OTHER|control|no supplementation
219595394|NCT03372291|OTHER|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
219471880|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
218856576|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
218856577|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
219471881|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
218856578|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
218856579|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
218856580|NCT03132103|RADIATION|Placebo SSR|
219471882|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
219471883|NCT00591552|DEVICE|Electrocautery|
219471884|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
219595395|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
219595396|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
219595397|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
218856581|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
219471885|NCT05018533|DRUG|TAKC-02|Inhalation Solution
218856582|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
218856583|NCT02275117|BIOLOGICAL|ALD403|
218856584|NCT02275117|BIOLOGICAL|Placebo|
218856585|NCT00297973|PROCEDURE|Blood pressure measurements|
218856586|NCT00297973|PROCEDURE|Blood samples|
218856587|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
218856588|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
218856589|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
219471886|NCT05018533|DRUG|Placebo|Inhalation Solution
219471887|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
219595398|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
219471888|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
219471889|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
219471890|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
219471891|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
219471892|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
219471893|NCT00887562|OTHER|Placebo|Placebo - No idebenone
219471894|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
219471895|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
219471896|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
219471897|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
219471898|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
219471899|NCT00103389|DRUG|PI-88|PI-88+docetaxel
219471900|NCT00103389|DRUG|docetaxel|docetaxel only
219471901|NCT00542165|DRUG|Alfuzosin|
219471902|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
219471903|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
219595399|NCT04141930|DRUG|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
219471904|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
219471905|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
219471906|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
219471907|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
219471908|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
219471909|NCT06397248|OTHER|No intervention|No intervention
219595400|NCT06552013|OTHER|MERV 13 filter|This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
219595401|NCT06552013|OTHER|Sham filter|This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
219595402|NCT02896790|OTHER|Interviews with 2 oncologists and 10 patients|
219595403|NCT02896790|OTHER|Interviews with 15 patients|
219595404|NCT03138590|DEVICE|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
219595405|NCT04981327|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
219595406|NCT06034782|DIAGNOSTIC_TEST|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
219595407|NCT06034782|PROCEDURE|Histologic Examination|Histologic examination of resected salivary tumor
219471910|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
219471911|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
219471912|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
219471913|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
219471914|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
219471915|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
219471916|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
219471917|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
219471918|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
219471919|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
219471920|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
219471921|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
219471922|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
219471923|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
219471924|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
219471925|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
219471926|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
219471927|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
219471928|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
219471929|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
219471930|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
219471931|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
219471932|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
219471933|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
219471934|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
219471935|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
219471936|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
219471937|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
219471938|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
219471939|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
219471940|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
219471941|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
218856590|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
218856591|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
218856592|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
218856593|NCT02240823|OTHER|adipose derived stem cells|
218856594|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
218856595|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
218856596|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
219471942|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
219471943|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
219471944|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
219471945|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
219471946|NCT00270400|DRUG|nesiritide|
219471947|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
219471948|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
219471949|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
218856597|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
218856598|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
218856599|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
218856600|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~\- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
219471950|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
219471951|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
218856601|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
218856602|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
218856603|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
219471952|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
219471953|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
219471954|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
219471955|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
219595408|NCT03803982|PROCEDURE|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
219595409|NCT03803982|DRUG|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
219595410|NCT03918460|DEVICE|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
219595411|NCT03458260|DRUG|Pixantrone|6 cycles - dose = 80mg/m²
219595412|NCT03458260|OTHER|Ifosfamide|6 cycles - 1500 mg/m2
219595413|NCT03458260|OTHER|Etoposide|6 cycles - 150 mg/m2
218856604|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
218856605|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
218856606|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
218856607|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
218856608|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
218856609|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
218856610|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
218856611|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
218856612|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
218856613|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
218856614|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
218856615|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
219020500|NCT07173088|OTHER|Ankle Muscle Power (AMP) program|The AMP program targets various aspects of muscle power development through a program that takes the participant through 3 different stages of training over the course of their rehabilitation. This portion of the program is in addition to receiving standard rehabilitation exercises as well.
219471956|NCT05918952|DIAGNOSTIC_TEST|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
219471957|NCT05918952|OTHER|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
219471958|NCT00873496|DRUG|Hydroxychloroquine|
219471959|NCT04934228|DRUG|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
219471960|NCT04934228|DRUG|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
219471961|NCT04934228|DRUG|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
219471962|NCT02131805|RADIATION|Electronic Skin Surface Brachytherapy|
219471963|NCT02131805|BEHAVIORAL|Quality of life assessment|
219471964|NCT04260698|BIOLOGICAL|omidubicel|hematopoietic stem cell transplant
219471965|NCT04963231|DRUG|Setmelanotide|SC injection
219471966|NCT04963231|DRUG|Placebo|SC injection
219471967|NCT04951544|OTHER|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
219471968|NCT04951544|OTHER|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
218856616|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
219020501|NCT07173088|BEHAVIORAL|Standard of Care|Standard rehabilitation program
219020503|NCT07174492|DRUG|Masitinib 4.5 mg/kg/day|Masitinib (titration to 4.5 mg/kg/day)
219020504|NCT07174492|DRUG|Placebo|treatment per os
219020505|NCT07174492|DRUG|Riluzole (100 mg)|Riluzole 50 mg tablet, treatment per os
219595414|NCT03458260|OTHER|Rituximab|6 cycles - 375 mg/m2
219595415|NCT03458260|PROCEDURE|Transplant|after 2 or 6 cycles
219595416|NCT04363957|OTHER|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
219595417|NCT04363957|OTHER|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
219595418|NCT02564887|DEVICE|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
219595419|NCT00043628|PROCEDURE|Stem Cell Mobilization|
219595420|NCT02227511|DIETARY_SUPPLEMENT|Fruits|Randomization to extra fruit or nuts as snacks
219595421|NCT02227511|DIETARY_SUPPLEMENT|Nuts|
219471969|NCT06084780|PROCEDURE|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
219471970|NCT06084780|DRUG|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
218856617|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
218856618|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
218856619|NCT01716338|DRUG|Glyburide|
218856620|NCT01716338|DRUG|Placebo|
219471971|NCT06084780|DRUG|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
219471972|NCT06084780|DRUG|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
218856621|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
218856622|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
219471973|NCT05442840|COMBINATION_PRODUCT|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
218856623|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
218856624|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
218856625|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
218856626|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
218856627|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
218856628|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
218856629|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
218856630|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
218856631|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
218856632|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
218856633|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
219471974|NCT01982942|DRUG|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
219471975|NCT01982942|DRUG|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
219471976|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
219471977|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
219471978|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
219471979|NCT03373422|DRUG|Placebo|Matching placebo tablets
219471980|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
219595422|NCT01851330|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
219595423|NCT01851330|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219595424|NCT02850731|DEVICE|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
219595425|NCT00348504|DRUG|levosimendan|
219595426|NCT00348504|DRUG|dobutamine|
218856634|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
219471981|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
218856635|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
218856636|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
218856637|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
218856638|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
218856639|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
218856640|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
218856641|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
218856642|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
218856643|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
218856644|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
219471982|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
219471983|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
219471984|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
218856645|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
218856646|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
219471985|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
218856647|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
218856648|NCT00188851|DRUG|therapeutic management strategy|
218856649|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
218856650|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
218856651|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
219471986|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
219471987|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
219471988|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
218856652|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
218856653|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
218856654|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
218856655|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
218856656|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
219595427|NCT04352868|DEVICE|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
218856657|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
219471989|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
219471990|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
219471991|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
219471992|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
219595428|NCT04352868|DEVICE|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
219595429|NCT03238612|DRUG|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
218856658|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
218856659|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
218856660|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
218856661|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
218856662|NCT02954419|OTHER|No intervention|No intervention
219595430|NCT03238612|DRUG|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
218856663|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
218856664|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
218856665|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
218856666|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
218856667|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
218856668|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
219595431|NCT01199016|PROCEDURE|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
218856669|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
219471993|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
219471994|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
219471995|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
219471996|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
218856670|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
218856671|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
219020512|NCT07178444|BEHAVIORAL|"New care pathway"|"Initially, the patient will have an interdisciplinary consultation aimed at identifying personalized goals for the patient and providing educational/preventive care using tools that will be provided to all centers. This consultation will bring together a cardiologist, an advanced practice nurse (APN), a dietitian and a pharmacist. This consultation will take place approximately 4 weeks after the hospitalization for acute coronary syndrome (ACS).~Secondly, the patient will have 3 follow-up consultations with the APN (at 3, 6 and 12 months after discharge from hospitalization for an ACS). During these consultations, the APN will perform a clinical assessment, a personalized educational support, a coaching based on the patient's personalized goals, an adjustment of therapies and, depending on needs, referral to other health professionals."
219020513|NCT07178444|OTHER|"Standard care pathway"|The French National Health Authority recommends two medical visits (at 6 and 12 month) and, if necessary, a third one (between the first and third month post-ACS) for the monitoring of the left ventricular. - The European Society of Cardiology recommends a reassessment of the lipid profile within 4-6 weeks post-ACS.
219471997|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
219471998|NCT04679064|DRUG|Niraparib|PARP-inihibitor
219471999|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
219472000|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
219472001|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
219472002|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
218856672|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
218856673|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
218856674|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
219020514|NCT07178405|OTHER|Meal low in energy density, low in ultra-processed food|Meal low in energy density, low in ultra-processed food
219020515|NCT07178405|OTHER|Meal low in energy density, high in ultra-processed food|Meal low in energy density, high in ultra-processed food
219020516|NCT07178405|OTHER|Meal high in energy density, low in ultra-processed food|Meal high in energy density, low in ultra-processed food
219020517|NCT07178405|OTHER|Meal high in energy density, high in ultra-processed food|Meal high in energy density, high in ultra-processed food
219472003|NCT04679064|DRUG|Topotecan|Chemotherapy drug
219472004|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
219472005|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
219472006|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
219472007|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
219472008|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
219472009|NCT05261906|BEHAVIORAL|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
219472010|NCT01878708|DRUG|PEG-L-asparaginase|
219472011|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
219472012|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
219472013|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
219472014|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
219472015|NCT01811004|DEVICE|miraDry|miraDry
219472016|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
219472017|NCT01811004|DEVICE|Botox®|Botox®
219472018|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
219472019|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
219472020|NCT04009122|OTHER|Placebo|Group B
219472021|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
219472022|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
219472023|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
219472024|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
219472025|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
219472026|NCT00750061|DRUG|Placebo|Matching placebo
219472027|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
219472028|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
219472029|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
219472030|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
219472031|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
219472032|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
219472033|NCT05480046|DRUG|Risperidone ISM|Risperidone ISM is administered every 4 weeks
219472034|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
219472035|NCT03772210|OTHER|Sham|Apparent Stimulation administered
219472036|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
219472037|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
219472038|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
219472039|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
219472040|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
218856675|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
219472041|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
219472042|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
219472043|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
219595432|NCT01199016|PROCEDURE|Nose/throat swab|To be performed at every study visit
219595433|NCT01199016|BIOLOGICAL|Observational|Observational Study Only
218856676|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
218856677|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
218856678|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
218856679|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
219472044|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
218856680|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
218856681|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
218856682|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
218856683|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
218856684|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
219472045|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
219472046|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
218856685|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
218856686|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
218856687|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
218856688|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
218856689|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
218856690|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
218856691|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
218856692|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
218856693|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
218856694|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
218856695|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
218856696|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
218856697|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
218856698|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
218856699|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
218856700|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
218856701|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
218856702|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
218856703|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
219472047|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
219472048|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
219472049|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
219472050|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
219472051|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
219472052|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
219472053|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
219472054|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
219472055|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
219472056|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
219472057|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
218856704|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
218856705|NCT03436641|OTHER|No intervention|No intervention
218856706|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
218856707|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
218856708|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
218856709|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
218856710|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Physical Activity|Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.
218856711|NCT05941000|BEHAVIORAL|Action Planning for Physical Activity|Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.
218856712|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Mood|Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.
218856713|NCT05941000|BEHAVIORAL|Action Planning for Mood|Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.
218856714|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
218856715|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
219472058|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
219472059|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
219472060|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
219472061|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
219472062|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
219472063|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
219472064|NCT03045926|DRUG|Diosmectite (Smecta®)|
218856716|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
218856717|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
218856718|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
219472065|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
219472066|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
218856719|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
219472067|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
219472068|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
219472069|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
219472070|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
219472071|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
219472072|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
219472073|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
219472074|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
219472075|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
219472076|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
219472077|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
219472078|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
219472079|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
219472080|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
219472081|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
219472082|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
219472083|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
219472084|NCT01575158|DRUG|Citalopram|
219472085|NCT01575158|DRUG|Clomipramine|
218856720|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
218856721|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
218856722|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
218856723|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
219472086|NCT01575158|DRUG|placebo|
219472087|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
219472088|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
219472089|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
219472090|NCT01671462|DEVICE|BD HPV assay on Viper LT|
219472091|NCT03219372|DRUG|Pravastatin Pill|statin
219472092|NCT03219372|DRUG|Placebo Oral Tablet|placebo
219472093|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
219472094|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
219472095|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
219472096|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
219472097|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
219595434|NCT06003296|PROCEDURE|Calcaneocuboid arthrodesis|Calcaneocuboid arthrodesis in triple arthrodesis
219472098|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
219472099|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
219472100|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
219472101|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
219472102|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
219472103|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
219472104|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
219472105|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
219472106|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
219595435|NCT03155516|OTHER|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
219595436|NCT03155516|OTHER|Current practice procedure|Current practice clinical procedure for pain management
219472107|NCT02325206|DRUG|dapagliflozin|one administration in the morning
219472108|NCT02325206|DRUG|Placebo|one administration in the morning
219472109|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
219472110|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
219472111|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
219472112|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
219472113|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
219472114|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
219472115|NCT03677973|OTHER|Placebo|Matching Placebo
219472116|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
219472117|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
219472118|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
219472119|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
219472120|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
219472121|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
219472122|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
219472123|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
219595437|NCT06256523|DRUG|GZR18|0.5mg-13mg
219595438|NCT06256523|OTHER|Placebo|administered the same volume as GZR18
219595439|NCT01105624|DRUG|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
219595440|NCT01105624|DRUG|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
219595441|NCT00561418|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
219595442|NCT00561418|OTHER|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
219472124|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
219595443|NCT00309803|DEVICE|FiberNet Embolic Protection Device|
219472125|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
219472126|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
219472127|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
219472128|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
219472129|NCT02797951|DRUG|Galcanezumab|Administered SC
219472130|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
219472131|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
219472132|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
219472133|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
219472134|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
219472135|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
219472136|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
219472137|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
219472138|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
219472139|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
218856724|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
219472140|NCT02694393|DRUG|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
219472141|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
219472142|NCT05113277|BEHAVIORAL|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
219472143|NCT05113277|BEHAVIORAL|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
219472144|NCT05986955|OTHER|Diet|Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
219472145|NCT05288400|COMBINATION_PRODUCT|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
219472146|NCT05288400|DRUG|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
219472147|NCT05288400|DRUG|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
219472148|NCT05288400|DRUG|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
219472149|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
218856725|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
218856726|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
219595444|NCT00437359|DRUG|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
219595445|NCT00437359|DRUG|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
219595446|NCT01616342|DEVICE|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
219595447|NCT01480362|DEVICE|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
218856727|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
218856728|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
218856729|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
218856730|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
219472150|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
219472151|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
219472152|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
219472153|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
218856731|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
218856732|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
218856733|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
218856734|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
219472154|NCT05707494|DEVICE|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
219472155|NCT06133348|BEHAVIORAL|Promoting Resilience in Stress Management Intervention|"PRISM is a manualized, brief, skills-based intervention targeting four resilience resources; PRISM is delivered by trained intervention staff (called coaches within the PRISM program). Session 1, Stress-Management. Session 2, Goal setting. Session 3, Cognitive Restructuring. Session 4, Meaning-Making. Session 5 (optional), Coming Together. Session 6 (optional) involved advance care planning to discuss."
219472156|NCT03800121|BIOLOGICAL|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
219472157|NCT01952821|OTHER|Six-Minute Walk Test|
219472158|NCT01952821|OTHER|10-Meter Walk Test|
219472159|NCT01952821|OTHER|30-Second Chair Stand|
219472160|NCT01952821|OTHER|Linear Analog Scale of Function|
219472161|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
219472162|NCT01952821|OTHER|FACIT-Fatigue|
219472163|NCT03643224|DEVICE|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
219199263|NCT06859580|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|"Product name/EU MP number: Natriumklorid Baxter ClearFlex 9 mg/ml,infusionsvæske, opløsning/PRD456031 (Placebo) Substance (name/ code): SODIUM CHLORIDE/SUB12581MIG Strength: Sodium Chloride 0.9g / 100mL Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 32466 / DK Modified in relation to MA: No Max Dosage: ml millilitre(s) Duration of use: Week"
219472164|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
219595448|NCT01480362|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
219595449|NCT03111771|PROCEDURE|carcinological surgery|carcinological surgery for Group K +
219595450|NCT03111771|PROCEDURE|cervical surgery|cervical surgery for Group K-
219595451|NCT00843895|BIOLOGICAL|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
219595452|NCT02667067|DEVICE|Simplify Disc|Simplify Disc at one level in the cervical spine.
219595453|NCT02667067|DEVICE|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial."
218856735|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
218856736|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
218856737|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
219472165|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
219472166|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
219472167|NCT05588193|BEHAVIORAL|PVO|post-visit outreach
219472168|NCT05588193|BEHAVIORAL|TSH|tele-sexual health visit during the ED visit
219472169|NCT05690230|OTHER|Virtual reality|Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.
219472170|NCT05690230|OTHER|Environmental changes|A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
219472171|NCT04792528|OTHER|Computerized cognitive training.|COGMED RM program (Pearson Inc., UK)
219472172|NCT04792528|OTHER|Generalized brain training / Active control|Solitaire
219472173|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
219472174|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
219472175|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
219472176|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
219472177|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
219472178|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
219472179|NCT02487524|OTHER|QST|Quantitative sensory testing.
218856738|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
218856739|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
218856740|NCT01253265|DRUG|LY2439821|Administered subcutaneously
219472180|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
219472181|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
219472182|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
219472183|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
219472184|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
219472185|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
219472186|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
219472187|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
219472188|NCT00283517|DRUG|antipsychotics|as prescribed
219472189|NCT00883402|PROCEDURE|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
219472190|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
219472191|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
219472192|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
219472193|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
219472194|NCT00010634|DRUG|Adaptogenic herbs|
218856741|NCT01253265|DRUG|Placebo|Administered subcutaneously
219199264|NCT06859086|PROCEDURE|class II restoration|A class II cavity will be prepared after local anesthesia has been given as requierd . Rubber dam isolation will be done. Sectional matricing and wedging will be done. Followed by placement of restorative material according to the randomization sequence.
218856742|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
219472195|NCT00010634|DRUG|glutamine|
219472196|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
219472197|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
219472198|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
219472199|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
219472200|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
219472201|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
219472202|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
219472203|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
219472204|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
219472205|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
219472206|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
219472207|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
219472208|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
219472209|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
219472210|NCT01695707|DRUG|Pioglitazone|see Arm Description
219472211|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
219472212|NCT05705544|DEVICE|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
219472213|NCT05705544|DEVICE|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
219472214|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
219472215|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
219472216|NCT06446453|DIAGNOSTIC_TEST|Echography-guided Surfactant THERapy (ESTHER)|Decision to administer surfactant therapy using a semi-quantitative lung ultrasound score.
219472217|NCT06074341|BEHAVIORAL|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
219472218|NCT06074341|BEHAVIORAL|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
219472219|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
219472220|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
219472221|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
219472222|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
219472223|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
219472224|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
219472225|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
219472226|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
219472227|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
219472228|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
218856743|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
218856744|NCT02159378|OTHER|Fructosamines|
218856745|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
218856746|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
219472229|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
219472230|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
219472231|NCT02043002|PROCEDURE|18F-FDG-PET scan|
219472232|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
219472233|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
219472234|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
219472235|NCT06260995|OTHER|Social Prescribing Link Worker Intermediary Intervention|Social prescribing link workers \[SPLW\] receive referrals from healthcare professionals, community services, or through self-referral. Individuals are referred for social isolation or social needs, frequent healthcare attendance, or to address a pre-existing health issue. SPLW carry out an in-depth assessment of the individual's needs, and then work with the individual over weeks and months to connect them to community services and supports, which can include local physical activities. They use several strategies during this follow-up period, such as instrumental support (doing things for the individual), empowerment and motivation techniques and/or attending activities with the individual. After the SPLW establishes a connection to a local physical activity, the individual enrols and participates in the chosen activity. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi.
219472236|NCT06260995|OTHER|Local Sports Partnership Community Development Officer Intervention|Local sports partnership community development officers \[LSPO\] mainly receive self-referrals, or can receive referrals, to improve physical activity levels of individuals through participation in physical activity groups delivered by the partnership. LSPO do not carry out an in-depth assessment but may carry out screening before explaining/signposting to local physical activities. They use several strategies to connect the individual to local physical activities, such as attending the first session of the group, providing reassurance and practical support, and keeping the person updated and informed as to upcoming groups. After the LSPO establishes a connection to a local physical activity, the individual enrols and participated in the chosen activity. The LSPO continues to support this engagement during the follow-up period. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi amongst others.
219472237|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
218856747|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
218856748|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
218856749|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
218856750|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
218856751|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
218856752|NCT03271047|DRUG|binimetinib|Orally, twice daily.
218856753|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
218856754|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
219199265|NCT06826170|RADIATION|hypofractionated radiosurgery|The total dose will be 25 Gy, delivered in 5 fractions, in 5 consecutive days
219472238|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
219472239|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
218856755|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
219472240|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
219472241|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
219472242|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
219472243|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
219472244|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
219472245|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
219472246|NCT04790630|OTHER|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|computerized experimental brain-training treatment
219472247|NCT04790630|OTHER|Active Control|computerized intervention that follows recommendations for cognitive fitness
219472248|NCT01612949|OTHER|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
219472249|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
219472250|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
219472251|NCT04148339|OTHER|No Intervention|There is no intervention for this study.
218856756|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
219472252|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
219472253|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
219472254|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
219472255|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
219472256|NCT00281736|DRUG|HPPH|Given IV
219472257|NCT03205605|DRUG|oxybutynin|patch
219472258|NCT03205605|DRUG|oxybutynin|gel
219472259|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
219472260|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
219472261|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
219472262|NCT02679300|OTHER|Virtual reality exercise group|
219472263|NCT02679300|OTHER|Conventional exercise group (control group)|
219472264|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
219472265|NCT03054311|BEHAVIORAL|Lifestyle Matters|
219472266|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
218856757|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
218856758|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
218856759|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
218856760|NCT00002522|DRUG|cisplatin|
218856761|NCT00002522|DRUG|cyclophosphamide|
218856762|NCT00002522|DRUG|etoposide|
218856763|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
218856764|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
219472267|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
219472268|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
219472269|NCT06987916|BIOLOGICAL|ssCART-19|autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene
219472270|NCT06984432|DEVICE|XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%)|Injectable implant containing 1.1%, 1.8%, or 2.2% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization to improve skin quality through biorevitalization.
219472271|NCT06984432|DEVICE|Electri (non-cross-linked hyaluronic acid 0.55%)|Injectable implant containing 0.55% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization aimed at improving skin hydration, elasticity, and appearance.
219472272|NCT05946174|OTHER|Intervention Set A|exercise sessions and meals over approximately 12 weeks
219472273|NCT05946174|OTHER|Intervention Set B|exercise sessions and meals over approximately 3 weeks
219472274|NCT05946174|OTHER|Intervention Set C|meals over approximately 3 weeks
219472275|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
219472276|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
219472277|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
219472278|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
219472279|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
219472280|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
219472281|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
219472282|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
219472283|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
219472284|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
218856765|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
218856766|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
218856767|NCT00002522|RADIATION|radiation therapy|
218856768|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
219472285|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
219472286|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
219472287|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
219472288|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
219472289|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
218856769|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
218856770|NCT04531358|DEVICE|nasal spray|application of nasal spray
218856771|NCT04531358|OTHER|no treatment|no treatment
218856772|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
218856773|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
219472290|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
219595454|NCT04628897|BEHAVIORAL|Exposures|"1. Total area of available floor space inside the home (m2)~2. Frequency that child plays outdoors~3. Total number of physical hazards in the home (presence of open stairwells, stove height)~4. Total number of fine-motor activity items available to the child~5. Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~6. Hemoglobin concentration (g/L)."
218856774|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
218856775|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
218856776|NCT01884558|DRUG|isavuconazole|oral
218856777|NCT01884558|DRUG|metformin|oral
218856778|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
218856779|NCT02654288|OTHER|gemcitabine-based chemotherapy|
218856780|NCT00034229|DRUG|Felbamate|
219472291|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
219472292|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
219472293|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
219472294|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
219595455|NCT00832156|BIOLOGICAL|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
219595456|NCT03395457|DRUG|Care as usual|Application of usual pharmacological care for chronic migraine
219595457|NCT03395457|OTHER|Manual Therapy|5 sessions of manual therapy over 12 weeks
219595458|NCT02971098|PROCEDURE|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
219595459|NCT03140371|DIETARY_SUPPLEMENT|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
218856781|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
218856782|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
218856783|NCT00051467|GENETIC|TNFerade|
218856784|NCT00110071|DRUG|fludarabine phosphate|Given IV
218856785|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
218856786|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
218856787|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
218856788|NCT00110071|OTHER|flow cytometry|Correlative studies
218856789|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
218856790|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
219472295|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
218856791|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
219472296|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
219472297|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
219472298|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
219472299|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
219472300|NCT00945815|BIOLOGICAL|epratuzumab|
219472301|NCT00945815|DRUG|clofarabine|
219472302|NCT00945815|DRUG|cytarabine|
219472303|NCT00945815|OTHER|laboratory biomarker analysis|
219472304|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
219472305|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
219472306|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
219472307|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
219472308|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
219472309|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
219472310|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
219472311|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
219472312|NCT00363272|DRUG|ispinesib|Given IV
219472313|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
219472314|NCT00363272|OTHER|pharmacological study|Correlative studies
219472315|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
219472316|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
219595460|NCT03791463|DRUG|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
219595461|NCT02368314|DRUG|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
218856792|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
219472317|NCT00282373|DEVICE|mild hypothermia|
219472318|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
219472319|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
219472320|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
219472321|NCT06623032|OTHER|Medium-Chain Fatty Acid (MCFA)|The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)
219472322|NCT06623032|OTHER|Long-Chain Fatty Acid (LCFA)|The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
219472323|NCT02576106|DEVICE|Cryoablation|
219472324|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
219472325|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
218856793|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
218856794|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
219472326|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
219472327|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
219472328|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
219472329|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
219472330|NCT02987166|DRUG|Pembrolizumab|200 mg
219472331|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
219472332|NCT00086164|DRUG|edifoligide (E2F Decoy)|
219472333|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
219472334|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
219472335|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
219472336|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
219472337|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
219472338|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
219472339|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
219472340|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
219472341|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
219472342|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
219472343|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
219472344|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
219472345|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
219472346|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
219472347|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
219595462|NCT00986050|DRUG|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
219199266|NCT06859255|DIAGNOSTIC_TEST|MRI|The patients will be undergo to a MRI without contrast after 1 month from the procedure/surgery to test the hwmodynamic performance 4d flow in the implanted valve
219199267|NCT06857747|DRUG|Capecitabine|metronomic capecitabine, 500 mg, tid， po
219199268|NCT06857747|DRUG|Vinorelbine|metronomic vinorelbine, 40mg/d, TIW1, po
219199269|NCT06857747|DRUG|Etoposide|metronomic etoposide, 50mg/d, po
219472348|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
219595463|NCT00986050|DEVICE|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
219595464|NCT00986050|DEVICE|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
219472349|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
219472350|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
219472351|NCT01914042|DRUG|Morphine|
219472352|NCT01914042|DRUG|Milnacipran|
219472353|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
219472354|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
219472355|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
219472356|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
219472357|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
219472358|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
219472359|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
219472360|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
219472361|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
219472362|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
219472363|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
219472364|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
219472365|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
219472366|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
219472367|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
219595465|NCT05042895|PROCEDURE|Group A|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
219472368|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
219472369|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
219472370|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
219472371|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
219472372|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
219595466|NCT05042895|PROCEDURE|Group B|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
219595467|NCT05396235|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
219595468|NCT05396235|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
219595469|NCT02352935|DEVICE|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
219595470|NCT02381184|DRUG|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
219595471|NCT02381184|PROCEDURE|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
218856795|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
218856796|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
218856797|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
218856798|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
218856799|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
218856800|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
219472373|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
219472374|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
219595472|NCT00242632|DRUG|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
219595473|NCT04001946|DEVICE|Button Huggie|low profile, external securement device for G-buttons
218856801|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
218856802|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
219472375|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
219472376|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
219595474|NCT01902225|DRUG|Istodax|
219595475|NCT01902225|DRUG|Doxil|
219472377|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
219472378|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
219472379|NCT00004166|DRUG|amifostine trihydrate|
219472380|NCT00004166|PROCEDURE|quality-of-life assessment|
219472381|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
219472382|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
219472383|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
219595476|NCT02565212|DRUG|Montelukast,mometazon froat|
219595477|NCT01992718|PROCEDURE|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
218856803|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
218856804|NCT00002652|DRUG|suramin|
218856805|NCT00302016|DRUG|AMN107|
218856806|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
218856807|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
218856808|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
218856809|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
219472384|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
218856810|NCT00002824|BIOLOGICAL|gene therapy|
218856811|NCT00002824|DRUG|chemotherapy|
218856812|NCT00002824|DRUG|ganciclovir|
218856813|NCT00002824|PROCEDURE|conventional surgery|
218856814|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
218856815|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
218856816|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
218856817|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
218856818|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
218856819|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
219472385|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
219472386|NCT04852809|OTHER|No intervention|This is an observational study
219472387|NCT00002362|DRUG|Abacavir sulfate|
219472388|NCT00002362|DRUG|Efavirenz|
219472389|NCT00002362|DRUG|Emtricitabine|
219472390|NCT00002362|DRUG|Stavudine|
218856820|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
218856821|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
219472391|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
219595478|NCT01992718|PROCEDURE|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
219595479|NCT01739699|DRUG|Acetaminophen|
218856822|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
218856823|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
218856824|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
218856825|NCT02436408|DRUG|Vismodegib|
218856826|NCT04424030|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography exam performed as part of clinical management.
218856827|NCT04424030|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
218856828|NCT04424030|DIAGNOSTIC_TEST|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
218856829|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
219595480|NCT01739699|DRUG|Placebo|
219595481|NCT05972330|DIETARY_SUPPLEMENT|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
219472392|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
219472393|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
219472394|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
219472395|NCT06205459|PROCEDURE|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
218856830|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
218856831|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
219472396|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
219472397|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
218856832|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
218856833|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
218856834|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
218856835|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
218856836|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
218856837|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
218856838|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
218856839|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
219595482|NCT01767038|PROCEDURE|OCT Spectralis|
219595483|NCT01767038|PROCEDURE|microperimetry|
219595484|NCT01390532|DEVICE|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
219595485|NCT06206798|BEHAVIORAL|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
219595486|NCT02468856|DRUG|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
219595487|NCT02468856|DRUG|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
218856840|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
219472398|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
219472399|NCT01297621|OTHER|control|follow up, questionnaire responses
219472400|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
219472401|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
219595488|NCT05432661|DEVICE|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
219595489|NCT01663883|OTHER|Isometric exercise|use of a handgrip for 3x2 minutes
219595490|NCT05453097|DIAGNOSTIC_TEST|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
219595491|NCT05503511|DRUG|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
219472402|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
219472403|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
219472404|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
219472405|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
219472406|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
219472407|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
219472408|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
219472409|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
219472410|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
218856841|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
218856842|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
218856843|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
218856844|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
218856845|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
218856846|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
218856847|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
218856848|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
218856849|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
218856850|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
218856851|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
218856852|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
218856853|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
218856854|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
218856855|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
219472411|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
219472412|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
219472413|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
219595492|NCT05938504|OTHER|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS\_320275) orally daily at any time of day.
219595493|NCT05938504|OTHER|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS\_211567) orally daily at any time of day.
218856856|NCT01156168|GENETIC|DNA analysis|
218856857|NCT01156168|GENETIC|gene expression analysis|
218856858|NCT01156168|GENETIC|polymorphism analysis|
218856859|NCT01156168|GENETIC|protein expression analysis|
218856860|NCT01156168|OTHER|immunohistochemistry staining method|
219595494|NCT02842073|DRUG|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
219595495|NCT02842073|DRUG|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
219472414|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
219472415|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
219472416|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
219472417|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
218856861|NCT01156168|OTHER|laboratory biomarker analysis|
218856862|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
218856863|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
218856864|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
219472418|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
218856865|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
218856866|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
218856867|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
219472419|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
219472420|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
218856868|NCT04103463|OTHER|Home exercise|Home exercise
218856869|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
219472421|NCT02661789|DRUG|Placebo|Injection of saline
219472422|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
219472423|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
219472424|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
219595496|NCT00195338|DRUG|etanercept|
219595497|NCT03523338|DRUG|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
219472425|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
219472426|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
219472427|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
219595498|NCT03523338|DRUG|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
219595499|NCT04302038|DIETARY_SUPPLEMENT|Protein|Additional daily protein provided by potato protein.
219595500|NCT04302038|DIETARY_SUPPLEMENT|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
219595501|NCT02437435|OTHER|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
218856870|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
218856871|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
218856872|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
218856873|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
218856874|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
218856875|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
218856876|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
218856877|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
218856878|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
219472428|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
219472429|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
219472430|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
219472431|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
219472432|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
219472433|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
219472434|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
219472435|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
219472436|NCT02473029|RADIATION|Vascular tomodensitometry|
219472437|NCT02473029|OTHER|Magnetic resonance angiography|
219595502|NCT02437435|OTHER|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
219472438|NCT02473029|OTHER|Vascular ultrasonography|
219472439|NCT02473029|OTHER|Retinal angiography|
219472440|NCT02473029|OTHER|Retinal optical coherence tomography|
219595503|NCT03981913|BEHAVIORAL|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
218856879|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
218856880|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
218856881|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
218856882|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
218856883|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
219472441|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
219472442|NCT02609529|OTHER|Placebo|
219472443|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
218856884|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
218856885|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
218856886|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
218856887|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
218856888|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
218856889|NCT02652416|DRUG|BI 1026706|oral administration
218856890|NCT02652416|DRUG|Placebo|placebo
218856891|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
218856892|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
219472444|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
219472445|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
219472446|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
219472447|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
218856893|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
218856894|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
218856895|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
218856896|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
218856897|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
218856898|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
218856899|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
218856900|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
218856901|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
219472448|NCT01632007|DRUG|SYR-472|
219472449|NCT01632007|DRUG|Alogliptin 25 mg|
219472450|NCT01632007|DRUG|Placebo|
219472451|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
219472452|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
219472453|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
219472454|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
219472455|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
219472456|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
218856902|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
218856903|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
219472457|NCT00283673|BEHAVIORAL|Exercise|
219472458|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
219595504|NCT06632535|OTHER|Chiropractic care|Chiropractic treatment will involve a personalized treatment plan within the context of a general care protocol administered by a chiropractor at the Osher Clinical Center for Integrative Health. The treatment plan will be customized to the patient's clinical needs following the current evidence and clinical practice guidelines.
219595505|NCT06632535|OTHER|Group medical visits|Participants will simultaneously enroll in virtual group medical visits with group discussion, practice based learning, and curricular themes pertaining to chronic pain management, healthy aging, and pillars of lifestyle medicine.
219595506|NCT05354921|DEVICE|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
219595507|NCT05354921|DEVICE|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
219595508|NCT01192607|DEVICE|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
219595509|NCT01228578|DIETARY_SUPPLEMENT|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
219595510|NCT00183911|DRUG|floxuridine, 5-Fluorouracil, leucovorin|
219595511|NCT00183911|PROCEDURE|External Beam Radiotherapy|
219595512|NCT00183911|PROCEDURE|Surgery|
219595513|NCT05538078|DRUG|Ozone gel|application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket
219595514|NCT00002678|DRUG|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
219595515|NCT00002678|DRUG|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
219595516|NCT00002678|DRUG|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
219595517|NCT03900897|DEVICE|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
219595518|NCT03900897|OTHER|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
219595519|NCT03244683|DIETARY_SUPPLEMENT|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
219595520|NCT03244683|OTHER|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
218856904|NCT01357135|DRUG|Metformin|
218856905|NCT01357135|DRUG|Sitagliptin|
218856906|NCT01357135|DRUG|Sulfonylurea|
219472459|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
219472460|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
219472461|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
219472462|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
219595521|NCT03244683|OTHER|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
219595522|NCT01150812|DRUG|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
219595523|NCT03742947|DIAGNOSTIC_TEST|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
219595524|NCT05311579|COMBINATION_PRODUCT|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
219595525|NCT00717379|DRUG|Tacrolimus|oral
218856907|NCT01357135|DRUG|Antihyperglycemic Medication|
218856908|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
218856909|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
218856910|NCT01656343|DRUG|Belatacept|No Intervention
219020520|NCT07181694|DRUG|Adalimumab (BCD-057) 100 mg/mL|Single subcutaneous injection
219595526|NCT00717379|DRUG|Mycophenolate Mofetil|oral
219595527|NCT00717379|DRUG|Methylprednisolone or equivalent|oral
219595528|NCT00717379|DRUG|Prednisone|oral
218856911|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
219472463|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
219472464|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
219472465|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
219472466|NCT06724822|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
219472467|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
219472468|NCT06721988|DRUG|oxycodone and parecoxib sodium combinations|Participants will receive 0.1ml/kg oxycodone (1mg/ml) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Oxycodone is administered 5 minutes after parecoxib sodium administration.
219472469|NCT06721988|DRUG|Placebo and parecoxib sodium combinations|Participants will receive 0.1ml/kg placebo (0.9% saline) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Placebo is administered 5 minutes after parecoxib sodium administration.
219472470|NCT06722885|RADIATION|Standard radiotherapy treatment|"* 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases"
219472471|NCT06724289|DRUG|Psilocybin 25 mg|25 mg psilocybin administered to each participant in single arm, open-label trial
219472472|NCT06724627|DIAGNOSTIC_TEST|Dermatology/Skin - Other|Belle AI for skin image assessment.
219595529|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
219595530|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
218856912|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
218856913|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
218856914|NCT01500369|OTHER|standard of care|Placebo Comparator
218856915|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
218856916|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
218856917|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
218856918|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
218856919|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
219472473|NCT06724874|OTHER|Web-Based Deep Relaxation Exercise|Web-based deep relaxation exercise videos have been prepared online. Each video lasts approximately 20-25 minutes. The 4-week applications will be sent to pregnant women one video each week and they will be asked to continue the exercises at home 4 times a week.
219472474|NCT06722300|DEVICE|Ultrasonic teeth cleaning plus Tinidazole microneedle patches applying|After gargling with compound chlorhexidine rinse or 3% hydrogen peroxide rinse for 1 minute, ultrasonic teeth cleaning was performed. After teeth cleaning, the wound was rinsed with 3% hydrogen peroxide and bleeding was stopped. After ultrasonic teeth cleaning, two metronidazole oral composite microneedle patches were immediately applied to the upper and lower gums near the inner side of the first molar, especially where the teeth were lost or damaged. The mouth was kept closed for 15 minutes. After the microneedles were fully degraded, the patient could leave the clinic.
219472475|NCT06906900|DEVICE|TTF-200M and TTF-200A systems|Participants will receive one cycle and treatment will continue as long as the doctor thinks it is in the participant's best interest.
219472476|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
219472477|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
219472478|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
219595531|NCT01333397|DRUG|Placebo|I.M. on day 1 (single treatment cycle)
219595532|NCT03840187|DIAGNOSTIC_TEST|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
218856920|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
218856921|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
218856922|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
218856923|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
218856924|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
218856925|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
218856926|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
218856927|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
218856928|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
218856929|NCT04201366|OTHER|No intervention|No intervention
218856930|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
218856931|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
219472479|NCT06735755|DRUG|BEAM-301: Single dose of BEAM-301 administered by IV|BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
219472480|NCT06917027|OTHER|education|clean intermittent catheterization education
219472481|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
219472482|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
219472483|NCT00121251|DRUG|Capecitabine|Given PO
219472484|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
219595533|NCT02068703|BEHAVIORAL|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
219595534|NCT02068703|BEHAVIORAL|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
219595535|NCT03266939|DRUG|Lorcaserin|10 mg acute administration of lorcasein
218856932|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
218856933|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
219595536|NCT03266939|DRUG|Placebo Oral Tablet|Placebo
219595537|NCT02939625|DEVICE|muscle training|
219595538|NCT02939625|DEVICE|Continue Positive Airway Pressure|
219595539|NCT02939625|DEVICE|bilevel positive airway pressure|
219595540|NCT00004757|DRUG|acyclovir|
218856934|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
218856935|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
218856936|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
218856937|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
218856938|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
218856939|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
218856940|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
218856941|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
218856942|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
219595541|NCT00796055|DRUG|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
219595542|NCT01085357|PROCEDURE|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
219595543|NCT01085357|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
219595544|NCT00435812|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
218856943|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
218856944|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
219020521|NCT07181694|DRUG|Adalimumab (BCD-057) 50 mg/mL|Single subcutaneous injection
218856945|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
218856946|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
218856947|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
218856948|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
218856949|NCT02349607|DRUG|Placebo|Placeco
218856950|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
218856951|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
219472485|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
219472486|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
219472487|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
219595545|NCT00435812|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
219472488|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
219472489|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
219595546|NCT01439412|PROCEDURE|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
219595547|NCT01439412|OTHER|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
219595548|NCT04637555|DRUG|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
219595549|NCT03100123|DRUG|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
219595550|NCT03100123|DRUG|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
218856952|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
218856953|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
218856954|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
218856955|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
218856956|NCT02435680|DRUG|MCS110|taken by I.V
218856957|NCT02435680|DRUG|carboplatin|taken by I.V
218856958|NCT02435680|DRUG|gemcitabine|taken by I.V
218856959|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
218856960|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
218856961|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
218856962|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
218856963|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
218856964|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
219020522|NCT07181694|DRUG|Adalimumab (Humira) 100 mg/mL|Single subcutaneous injection
219472490|NCT02899884|OTHER|No Intervention|
219472491|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
219472492|NCT06931197|BEHAVIORAL|Contingency management|"If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. great job!). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
219472493|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
219472494|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
218856965|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
218856966|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
218856967|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
218856968|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
218856969|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
218856970|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
218856971|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
218856972|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
218856973|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
218856974|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
219595551|NCT03957850|BEHAVIORAL|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
219595552|NCT03957850|BEHAVIORAL|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
219595553|NCT00003643|BIOLOGICAL|bleomycin sulfate|
219595554|NCT00003643|BIOLOGICAL|filgrastim|
218856975|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
218856976|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
218856977|NCT01671501|BEHAVIORAL|Motivational Interviewing|
218856978|NCT01671501|BEHAVIORAL|Email Feedback|
218856979|NCT01671501|OTHER|Usual Care|
219363480|NCT02532855|DRUG|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
219595555|NCT00003643|DRUG|cisplatin|
219595556|NCT00003643|DRUG|etoposide|
219363481|NCT02532855|DRUG|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
219363482|NCT04981275|OTHER|No intervention study|This observational study will only collect data, not provide any intervention to participants.
219363483|NCT02668367|DRUG|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
219363484|NCT02668367|DRUG|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
219363485|NCT00434044|DRUG|Enbrel (etanercept)|
219595557|NCT00003643|DRUG|paclitaxel|
219595558|NCT00034138|DRUG|oregovomab|
219595559|NCT00378495|DRUG|Miltefosine: initially 2.5 mg/kg/day for 28 days|
219363486|NCT04846361|OTHER|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
219595560|NCT04082338|BEHAVIORAL|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
218856980|NCT00206882|DRUG|corticosteroids|
218856981|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
219472495|NCT06934421|DEVICE|Ultrasound-Guided Genicular Nerve Radiofrequency Ablation|This intervention involves a single-session ultrasound-guided thermal radiofrequency ablation of the superomedial, superolateral, and inferomedial genicular nerves in patients with moderate to severe knee osteoarthritis. Target points follow anatomical references described by Fonkoue et al. and validated in cadaveric studies, differing from classical approaches. Under ultrasound guidance, monopolar RF cannulas are placed, with sensory and motor stimulation confirming accurate positioning. Local anesthesia (2% lidocaine) is applied. Lesions are performed at 85°C for 90 seconds per site. The radiofrequency generator used is CE-marked for pain procedures. The study evaluates a novel targeting protocol, not the safety or effectiveness of the device itself. No fluoroscopy is used. The procedure is performed once. Participants are followed for two years to assess outcomes.
219472496|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
219472497|NCT06942091|OTHER|Traumatic Brain Injury (TBI)|Presence of TBI identified by intracerebral hemorrhage on brain computed tomography (CT) at emergency department; not actively assigned by investigators but used to stratify comparison groups.
219472498|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral, fasting
219472499|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal
219472500|NCT06942299|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal or fasting
218856982|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
218856983|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
219020523|NCT07183800|OTHER|Water|Participants will undergo a standardized 10-minute high-intensity trampoline jumping protocol designed to elicit mechanical loading on the pelvic floor. Prior to the jumping session, bladder volume will be assessed via transabdominal ultrasound. If a participant's bladder contains less than 100 mL of urine, they will be asked to drink water and wait until a target range of 100-200 mL is reached to ensure consistent pre-jump bladder filling across participants. This approach minimizes variability in bladder volume, which could influence pelvic floor measurements.
219472501|NCT06935643|OTHER|Birth Ball|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, the pregnant woman will have a birth ball application for 10 minutes. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
219472502|NCT06935643|OTHER|Perineal Massage|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out. When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, 10 minutes of perineal massage will be applied to the pregnant woman. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
219595561|NCT04082338|BEHAVIORAL|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
219595562|NCT06463522|PROCEDURE|Autologous Tumor-infiltrating Lymphocytes|Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.
219595563|NCT06070558|DEVICE|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
219595564|NCT03776916|OTHER|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
219595565|NCT03776916|OTHER|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
219595566|NCT03776916|OTHER|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration \> 60 min before the procedure.
219595567|NCT03669224|OTHER|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
218856984|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
218856985|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
218856986|NCT00015860|DRUG|daunorubicin hydrochloride|
218856987|NCT00015860|DRUG|imatinib mesylate|
218856988|NCT00015860|DRUG|prednisone|
218856989|NCT00015860|DRUG|vincristine sulfate|
218856990|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
218856991|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
218856992|NCT00336011|DEVICE|Magnetic resonance imaging|
219595568|NCT03669224|OTHER|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
219595569|NCT03669224|OTHER|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
219595570|NCT00039702|DRUG|[123] 5-I-A-85380|
219595571|NCT00469664|DRUG|Guanfacine/Tenex|
219595572|NCT06469502|PROCEDURE|Stretching Exercises|Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
219595573|NCT06469502|PROCEDURE|Strengthening Exercises|Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
219595574|NCT01044121|OTHER|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
219595575|NCT02211443|BIOLOGICAL|Recombinant full human Anti-EGFR Monoclonal Antibody|
219595576|NCT05019443|DEVICE|Wedge Scoring Balloon|Scoring balloon
219595577|NCT05019443|DEVICE|Conventional Balloon|Conventional balloon
219595578|NCT01654003|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
219595579|NCT01654003|OTHER|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
219595580|NCT04537832|OTHER|No Intervention|No Intervention
219472503|NCT06935643|OTHER|Control Group|"Pregnant women in the control group will not receive any intervention. Pregnant women in this group will only receive routine midwifery care.~Written and verbal consent will be obtained by giving information about the study.Pregnancy Diagnosis Form will be filled.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, Visual Analog Scale (VAS) will be completed. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed."
219472504|NCT06937385|DRUG|0.5% Bupivacaine HCl|bilateral cervical injections of 0.5% bupivacaine into the paraspinous muscle at the c6-7 location for headache treatment
219595581|NCT05567770|DRUG|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
219595582|NCT05567770|RADIATION|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
219595583|NCT05567770|DRUG|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
219595584|NCT03579342|BEHAVIORAL|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
219595585|NCT03579342|BEHAVIORAL|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
219595586|NCT02685683|DRUG|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
219020526|NCT07176728|DRUG|BAY 3389934|Solution for intravenous infusion
219472505|NCT06937385|DRUG|standard IV treatment for headache|physicians choice of IV medications in treatment of headache
219472506|NCT06942130|OTHER|Artificial intelligence|Incorporating artificial intelligence as an aid to video-based skill learning
219595587|NCT05961917|OTHER|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
219595588|NCT05961917|OTHER|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
219595589|NCT02072603|OTHER|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
219595590|NCT02072603|OTHER|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
219595591|NCT04223375|BEHAVIORAL|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
219595592|NCT04010552|DRUG|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
219020527|NCT07176728|DRUG|Matching Placebo / Diluent|Solution for intravenous infusion
219472507|NCT06942130|OTHER|Video|Skill learning solely through videos
219472508|NCT06942988|BIOLOGICAL|intracavernous platelet rich plasma therapy|intracavernous platelet-rich plasma therapy for erectile dysfunction
218856993|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
218856994|NCT00393302|PROCEDURE|HIV screening in pregnancy|
219020529|NCT07179601|PROCEDURE|Hemorrhoidal artery embolization|Hemorrhoidal artery embolization (HAE) involves the deliberate blockage of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve symptoms related to internal hemorrhoids, especially bleeding.
219472509|NCT02277418|DEVICE|VAVL|Videolaryngoscope
219472510|NCT02277418|DEVICE|MIL|Direct laryngoscopy
219472511|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
219472512|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
219472513|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
219472514|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
219595593|NCT04387942|DRUG|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
219595594|NCT02658799|DRUG|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
219595595|NCT02658799|DRUG|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
219472515|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
219595596|NCT01382537|DEVICE|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
219595597|NCT01382537|DEVICE|InterX 5000|Placebo treatment
219595598|NCT02052193|DRUG|Dabrafenib|Measurement of toxicity related to UV exposure
218856995|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
218856996|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
218856997|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
218856998|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
218856999|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
218857000|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
218857001|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
218857002|NCT00003103|BIOLOGICAL|oblimersen sodium|
218857003|NCT00003103|DRUG|docetaxel|
218857004|NCT00003234|DRUG|vinorelbine tartrate|
218857005|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
218857006|NCT02509052|DRUG|Leflunomide|Given PO
218857007|NCT02509052|OTHER|Pharmacological Study|Correlative studies
219595599|NCT02052193|DRUG|Vemurafenib|Measurement of toxicity related to UV exposure
219595600|NCT03790371|DRUG|Misoprostol|vaginal misoprostol prior IUD insertion
219595601|NCT03790371|DRUG|Placebos|vaginal placebo tablet prior IUD insertion
219595602|NCT01577771|BIOLOGICAL|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
219595603|NCT02289456|DRUG|nab-Paclitaxel|
219595604|NCT02289456|DRUG|Carboplatin|
219595605|NCT05511311|PROCEDURE|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
219595606|NCT05511311|PROCEDURE|Standard Therapy|Standard therapy for 12 weeks
218857008|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
218857009|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
219472516|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
219472517|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
219472518|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
219472519|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
219472520|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
219595607|NCT02279108|DRUG|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
219595608|NCT02279108|DRUG|isotope|One injection, 20 MBq techntium99, intradermal use
219595609|NCT00920790|BIOLOGICAL|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
219595610|NCT03885115|BEHAVIORAL|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
219472521|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
219472522|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
219472523|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
219472524|NCT04335084|DRUG|Hydroxychloroquine|Prophylaxis treatment for COVID-19
219472525|NCT04335084|DIETARY_SUPPLEMENT|Vitamin C|Prophylaxis treatment for COVID-19
219472526|NCT04335084|DIETARY_SUPPLEMENT|Vitamin D|Prophylaxis treatment for COVID-19
219595611|NCT04410614|PROCEDURE|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
219595612|NCT00377832|DRUG|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
219472527|NCT04335084|DIETARY_SUPPLEMENT|Zinc|Prophylaxis treatment for COVID-19
219472528|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
219472529|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
219472530|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
219472531|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
219472532|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
219472533|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
219472534|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
219472535|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
219472536|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
219595613|NCT05291611|BEHAVIORAL|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
219595614|NCT02108093|PROCEDURE|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
219595615|NCT04969731|DRUG|Immuncell-LC|IV
219595616|NCT04969731|DRUG|Gemcitabine|IV
219595617|NCT04048291|BEHAVIORAL|Brisk walking and balance training|6 months of combined brisk walking and balance training
219595618|NCT04048291|BEHAVIORAL|Upper limb exercise|6 month of hand dexterity training
218857010|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
218857011|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
218857012|NCT00010387|DRUG|cyclophosphamide|
218857013|NCT00010387|DRUG|filgrastim|
218857014|NCT02494089|OTHER|distress analysis|
218857015|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
218857016|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
218857017|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
218857018|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
218857019|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
218857020|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
218857021|NCT00620425|DRUG|Sumatriptan|injection
218857022|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
218857023|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
218857024|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
218857025|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
218857026|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
218857027|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
218857028|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
219472537|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
218857029|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
218857030|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
218857031|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
218857032|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
218857033|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
219472538|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
219472539|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
219472540|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
219472541|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
219472542|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
219472543|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
219472544|NCT06450990|OTHER|PLACEBO|Placebo
219595619|NCT05341830|BEHAVIORAL|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
219595620|NCT03650530|OTHER|The Family Talk Intervention|The family meets two interventionists at six time points.
219595621|NCT03096158|OTHER|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
218857034|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
218857035|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
218857036|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
218857037|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
218857038|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
218857039|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
218857040|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
218857041|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
218857042|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
218857043|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
218857044|NCT00361699|DRUG|Statin|
218857045|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
218857046|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
218857047|NCT05266183|OTHER|Single-Food|1 food served
218857048|NCT05266183|OTHER|Small Portion|Small meal portion size
218857049|NCT05266183|OTHER|Large Portion|Large meal portion size
218857050|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
218857051|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
218857052|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
218857053|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
218857054|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
218857055|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
218857056|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
218857057|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
218857058|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
218857059|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
219472545|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
219472546|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
219595622|NCT03096158|OTHER|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
219595623|NCT03096158|OTHER|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
219595624|NCT01525017|BIOLOGICAL|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
219595625|NCT02166658|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
219595626|NCT02929888|DRUG|Lysine Acetilsalicilate|
219595627|NCT02929888|DRUG|Aspirin|
219595628|NCT01515917|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
218857060|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
218857061|NCT01061047|DRUG|Ertapeneme|
218857062|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
218857063|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
218857064|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
218857065|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
218857066|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
218857067|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
218857068|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
218857069|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
218857070|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
218857071|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
218857072|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
218857073|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
218857074|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
218857075|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
219472547|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
219472548|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
219472549|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
219472550|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
219472551|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
219472552|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
219472553|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
219472554|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
219472555|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
219472556|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
219472557|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
219472558|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
219595629|NCT01515917|DRUG|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
219595630|NCT01515917|OTHER|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
219595631|NCT01515917|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
218857076|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
218857077|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
218857078|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
218857079|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
218857080|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
218857081|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
218857082|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
218857083|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
218857084|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
218857085|NCT03556098|DRUG|Saline Solution|Infusion of Saline
218857086|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
218857087|NCT00823992|DRUG|placebo|sc once weekly
218857088|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
218857089|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
219020531|NCT07176793|OTHER|Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes|Conduct implementation mapping to develop a multilevel health system breastfeeding support strategy for patients with GDM at UC Davis Health in Sacramento, California, a large academic medical center. The study design for this mapping process will include five steps in this 1-year proposal: (1) conduct a needs and assets assessment and identify implementers; (2) identify implementation outcomes and determinants; (3) choose mechanisms of change and design implementation strategies; (4) produce implementation protocols and materials; and prepare for the final step, (5) evaluate implementation outcomes, by selecting outcome measures for a future trial . This disciplined and systematic approach to intervention development will directly inform my future directions: a mixed methods feasibility trial to pilot the implementation strategy developed here, followed by a full-scale randomized trial to test the strategy's effectiveness in reducing diabetes risk.
219472559|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
219472560|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
219472561|NCT06724861|OTHER|Explicit Sensory Retraining for the lower extremities|Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.
219472562|NCT06724861|OTHER|no treatment|Usual care
219472563|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
219472564|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
219472565|NCT01761461|DRUG|TS-1, oxaliplatin|
219472566|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
219472567|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
219472568|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
219472569|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
219472570|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
219595632|NCT02808416|BIOLOGICAL|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
219595633|NCT06164262|OTHER|Individuals with CSVD|This does not entail the application of interventions.
219595634|NCT01035983|DRUG|Frovatriptan 2.5 mg|
219595635|NCT00895414|DRUG|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
219595636|NCT00895414|DRUG|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
219595637|NCT01229163|DEVICE|Automated Contingency Management (ACM) software|
219595638|NCT00252239|DRUG|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
219595639|NCT00252239|DRUG|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
219595640|NCT06442306|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
219595641|NCT06442306|OTHER|General Health Education|General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
219595642|NCT04235361|DIAGNOSTIC_TEST|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
219595643|NCT00478426|DRUG|Sunitinib Malate|Given PO
219595644|NCT01216787|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
219472571|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
219472572|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
219472573|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
219472574|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
219472575|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
219472576|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
219472577|NCT00066573|DRUG|anastrozole|Given orally
219472578|NCT00066573|DRUG|exemestane|Given orally
219595645|NCT01216787|OTHER|pharmacological study|
219595646|NCT01216787|PROCEDURE|therapeutic conventional surgery|
219472579|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
219472580|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
219472581|NCT00165191|DRUG|Doxorubicin|
219595647|NCT01216787|OTHER|laboratory biomarker analysis|Correlative studies
219595648|NCT05572671|BEHAVIORAL|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
218857090|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
219595649|NCT02288156|DRUG|Capsaicin|via nasal spray
219595650|NCT02288156|DRUG|placebo|via nasal spray
219595651|NCT03251235|BEHAVIORAL|Cognitive Behaviour Therapy|
218857091|NCT00174174|DRUG|Modafinil|
218857092|NCT02636244|DRUG|SHAPE Gel|
218857093|NCT00005764|DRUG|Lamivudine/Zidovudine|
218857094|NCT00005764|DRUG|Abacavir sulfate|
218857095|NCT00005764|DRUG|Lamivudine|
218857096|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
219472582|NCT00165191|DRUG|Cisplatin|
219472583|NCT00165191|DRUG|5-fluorouracil|
219472584|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
219472585|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
219472586|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
219472587|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
219472588|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
219472589|NCT02584972|OTHER|no intervention required|no intervention required
219472590|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
219472591|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
219472592|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
219595652|NCT02474875|OTHER|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
219595653|NCT02752087|DRUG|LY900014|Administered SC
219595654|NCT02785952|BIOLOGICAL|Ipilimumab|Given IV
219472593|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
218857097|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
218857098|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
219472594|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
219472595|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
219472596|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
219472597|NCT04260594|OTHER|basic treatment|basic treatment
219472598|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
219472599|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
219472600|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
219472601|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
219472602|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
218857099|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
218857100|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
219472603|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
219472604|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
219472605|NCT00662974|OTHER|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
219472606|NCT00662974|OTHER|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
219472607|NCT02137473|OTHER|Human milk-based fortifier|
219472608|NCT02137473|OTHER|Bovine protein-based fortifier|
219472609|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
219472610|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
219472611|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
219472612|NCT00329225|DRUG|rosiglitazone|
219472613|NCT04662424|OTHER|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
219595655|NCT02785952|OTHER|Laboratory Biomarker Analysis|Correlative studies
219595656|NCT02785952|BIOLOGICAL|Nivolumab|Given IV
219595657|NCT02785952|OTHER|Quality-of-Life Assessment|Ancillary studies
219595658|NCT02785952|OTHER|Questionnaire Administration|Ancillary studies
219595659|NCT01226394|PROCEDURE|laparotomy plus HIPEC|Laparotomy + HIPEC
219595660|NCT06164093|OTHER|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
218857101|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
219472614|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
218857102|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
218857103|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
219199270|NCT06856512|OTHER|Remote ischaemic preconditioning|The dialysis protocol integrates a sequence of five ischaemia/reperfusion blocks applied to the upper limb. Each block consists of a 5-minute period of cuff inflation at a supra-systolic pressure individualized to each patient-20 mmHg above the limb occlusion pressure-followed by a 25-minute period of cuff deflation. This intervention begins 30 minutes after the start of dialysis and is referred to as hemodialysis remote ischaemic preconditioning (HD-rIPC).
219472615|NCT02119858|DRUG|indocyanine green solution|Given transperineally
219595661|NCT06164093|OTHER|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
219199271|NCT06856512|OTHER|Exercise|The exercise protocol consists of five sequential bouts of physical activity, initiated 30 minutes after the start of dialysis. Each bout comprises a 5-minute cycling exercise at moderate intensity, corresponding to a Borg Scale rating of 12-14, followed by a 25-minute passive recovery phase. This structured intervention is referred to as hemodialysis exercise (HD-EX).
219472616|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
219595662|NCT02304133|OTHER|Education|
219595663|NCT02895828|OTHER|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
219595664|NCT02895828|OTHER|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
219595665|NCT05351671|DRUG|RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
219595666|NCT05351671|DRUG|RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
219472617|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
219472618|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
219472619|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
218857104|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
218857105|NCT00975104|DRUG|Placebo|Placebo IV QW
218857106|NCT00793429|DRUG|Prucalopride|
218857107|NCT00793429|OTHER|Placebo|
218857108|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
218857109|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
218857110|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
219472620|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
219472621|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
219472622|NCT00252668|DRUG|Etanercept|
219472623|NCT00252668|DRUG|Methotrexate|
219472624|NCT06446427|OTHER|Acute high altitude exposure|"Thirty minutes after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 1, high altitude at 3450 masl) is performed."
219595667|NCT05351671|DRUG|Placebo (saline dosed every 8 hours for a total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
219595668|NCT05639075|OTHER|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
219595669|NCT06983301|OTHER|Brief Cognitive Behavioural Therapy (CBT) for OCD|A brief 5-session CBT face-to-face intervention (therapist supported, involving workbooks) for adolescent Obsessive Compulsive Disorder (OCD). The brief CBT consists of 5 sessions of 60 to 90-minutes, with the option of 2 additional booster sessions (also 60 to 90 minutes), spanning a total of 24 weeks. The intervention includes home tasks, completion of regular routine outcome measures and participants listening to audio-recordings of the therapy sessions. The intervention sessions are delivered by routine child and adolescent mental health services (CAMHS) practitioners and take place in NHS and NHS-commissioned child and adolescent mental health services.
219595670|NCT05734014|BEHAVIORAL|Connectedness Activities|Indigenous Connectedness: Promoting respect, listening to elders, understanding Crow cultural values.
219595671|NCT02728843|DRUG|Deferiprone|600 mg tablets
219020536|NCT07178912|DRUG|Blinatumomab|Given by Iv
219472625|NCT06446427|OTHER|Acute high altitude exposure, with supplementary oxygen|"4 hours after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 2, high altitude at 3450 masl) is performed, while the participants receive 4 litres / minute of oxygen via nasal route."
219472626|NCT06446427|OTHER|Subacute high altitude exposure, after having spent a night at high altitude|"After having spent a night at the Research Station Jungfraujoch, a simulated scenario of patient care (Intervention 3, high altitude at 3450 masl) is performed."
219472627|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
219472628|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
219472629|NCT05392920|OTHER|assessment study|there is no intervention in this study
219472630|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
219472631|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
219472632|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
219472633|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
219472634|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
219472635|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
219472636|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
219472637|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
219472638|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
219472639|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
219472640|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
219472641|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
219472642|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
219472643|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
219472644|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
219472645|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
219472646|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
219472647|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
219595672|NCT02728843|DRUG|Placebo|Tablets that match the deferiprone tablets in appearance
219595673|NCT01671332|DRUG|Docetaxel|IV over 60 minutes, 75 mg/m2
219595674|NCT01671332|DRUG|Suramin|IV over 30 minutes
219595675|NCT01671332|DRUG|Docetaxel|IV over 60 minutes. 56 mg/m2
219595676|NCT00351533|DRUG|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
219472648|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
219472649|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
219472650|NCT03323034|DRUG|Irinotecan|Given IV
219472651|NCT03323034|DRUG|Pevonedistat|Given IV
219472652|NCT03323034|DRUG|Temozolomide|Given PO
219472653|NCT02646566|DRUG|APD421|
219472654|NCT02646566|DRUG|Placebo|
219472655|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
219472656|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
219472657|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
219472658|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
219472659|NCT01738282|DRUG|Baclofen|
219472660|NCT01738282|DRUG|Placebo (for baclofen)|
219472661|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
219595677|NCT01806506|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
218857111|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
219020537|NCT07178912|DRUG|olverembatinib|Given by PO
219472662|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
219472663|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
219472664|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
219472665|NCT04268394|DRUG|CC-99677|CC-99677
219472666|NCT04268394|DRUG|Methotrexate|Methotrexate
219472667|NCT04268394|DRUG|Sulfasalazine|Sulfasalazine
219472668|NCT04268394|DRUG|Itraconazole|Itraconazole
219472669|NCT04268394|DRUG|Rifampin|Rifampin
219472670|NCT04268394|DRUG|Midazolam|Midazolam
219472671|NCT04268394|DRUG|Digoxin|Digoxin
219472672|NCT04268394|DRUG|Metformin|Metformin
219472673|NCT04268394|DRUG|Rosuvastatin|Rosuvastatin
219472674|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
219472675|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
219595678|NCT01806506|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
219595679|NCT01771471|BIOLOGICAL|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
219020538|NCT03270839|DRUG|Bonine 25Mg Chewable Tablet|Motion sickness drug
219020539|NCT03270839|DRUG|Kwells|Motion sickness drug
219020540|NCT03270839|DRUG|Placebo Oral Tablet|No active substance in the tablet
219472676|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
219472677|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
219472678|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
219472679|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
219472680|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
219472681|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
219595680|NCT01771471|OTHER|Placebo|0.9% w/v Sodium Chloride for Injection, USP
219595681|NCT01305174|DEVICE|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
219595682|NCT01293838|DRUG|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512"
219472682|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
219472683|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
219472684|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
219472685|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
219472686|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
219472687|NCT02660489|DRUG|OC459|
219472688|NCT02660489|DRUG|Placebo|
219472689|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
219595683|NCT04297033|DRUG|Lovastatin|lovastatin 40mg/d 12m
219595684|NCT04297033|DRUG|Placebo|placebo
218857112|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
219472690|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
219472691|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
219472692|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
219472693|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
219472694|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
219472695|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
219472696|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
219472697|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
219472698|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
219472699|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
219595685|NCT00088621|DRUG|Lurasidone 80mg tablet|
219595686|NCT03321838|BEHAVIORAL|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
219595687|NCT00373698|BEHAVIORAL|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
219595688|NCT06494345|BIOLOGICAL|Genolair, solution for subcutaneous administration, 150 mg|Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
219595689|NCT06494345|BIOLOGICAL|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
218857113|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
218857114|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
218857115|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
219472700|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
218857116|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
218857117|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
218857118|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
219199272|NCT06856512|OTHER|standard dialysis|The hemodialysis control condition (HD-CONT) consists of standard hemodialysis treatment without the integration of any additional interventions, such as exercise or ischaemia/reperfusion protocols.
219199273|NCT06858423|DRUG|Budesonide buffered with 0.9% isotonic saline.|120 patients received budesonide buffered with 0.9% isotonic saline.
219472701|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
219595690|NCT06494345|BIOLOGICAL|Xolair®, solution for subcutaneous administration, 150 mg|Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
219472702|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
219595691|NCT05458180|DRUG|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
218857119|NCT05804513|DRUG|Placebo|s/c injection
218857120|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
218857121|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
218857122|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
218857123|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
218857124|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
219472703|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
218857125|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
219472704|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
219595692|NCT02841163|DRUG|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
219595693|NCT02841163|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
218857126|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
218857127|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
219199274|NCT06858423|DRUG|Fluticasone propionate nasal spray.|120 patients received fluticasone propionate nasal spray.
218857128|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
218857129|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
218857130|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
219595694|NCT02841163|PROCEDURE|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218857131|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
218857132|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
219472705|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
219472706|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
219472707|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
219472708|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
219472709|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
219472710|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
219472711|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
219595695|NCT02841163|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219595696|NCT02841163|PROCEDURE|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219472712|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
219472713|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
219472714|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
219472715|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
219472716|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
219472717|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
218857133|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
218857134|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
218857135|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
218857136|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
218857137|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
219472718|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
219472719|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
219472720|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
219472721|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
219595697|NCT03862755|DRUG|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
219595698|NCT00227110|DRUG|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
219472722|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
219472723|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
219595699|NCT00227110|DRUG|Placebo|Placebo is given to match pioglitazone.
219595700|NCT02792608|BEHAVIORAL|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
219595701|NCT00769873|DRUG|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
219595702|NCT05622240|DRUG|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
218857138|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
219472724|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
219595703|NCT05756283|BEHAVIORAL|Multimodal Prehabilitation|"EXERCISE~* Supervised exercise~  * High intensity interval training~ * Strength exercise~* Home-based exercise / promotion of physical activity~  * Low-moderate intensity aerobic training~ * Inspiratory muscle training~ * Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
218857139|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
219199275|NCT06858423|OTHER|0.9% saline for nasal irrigation.|120 patients used 0.9% saline for nasal irrigation.
219472725|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
219472726|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
219472727|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
219472728|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
219472729|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
219472730|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
219472731|NCT04182386|PROCEDURE|Portal vein embolization|Selective preoperative portal vein embolization
219472732|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
219472733|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
219472734|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
219472735|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
219472736|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
219472737|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
219472738|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
219472739|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
219472740|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
219472741|NCT05518058|OTHER|device and exercises|strengthening exercises plus balance training program conducted with type of functional electrical stimulation for muscles
219472742|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
219472743|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
219472744|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
219472745|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
219472746|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
219472747|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
219472748|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
219595704|NCT03962283|DRUG|Rifaximin|Rifaximin 200mcg four times daily
219595705|NCT03962283|DRUG|Placebo oral tablet|Placebo Rifaximin four times daily
219595706|NCT05097794|DRUG|BR1015-1|\- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
219595707|NCT05097794|DRUG|BR1015-2|\- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
219472749|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
219472750|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
219472751|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
219472752|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
219472753|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
219472754|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
219472755|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
219472756|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
219472757|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
219472758|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
219472759|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
219472760|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
219472761|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
219595708|NCT05097794|DRUG|BR1015-1 + BR1015-2|\- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
219595709|NCT06632912|BIOLOGICAL|2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.
218857140|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
218857141|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
218857142|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
218857143|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
219020549|NCT07186192|OTHER|Intervention Arm (Digital health intervention)|Patients and family caregivers that are randomized into the intervetnion arm (Digital health intervention) will receive a 90 day nurse-drive, digital health intervention.
219472762|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
219472763|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
219472764|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
219472765|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
219472766|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
219472767|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
219472768|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
219472769|NCT00249600|BEHAVIORAL|Contingency management|
219472770|NCT06379061|OTHER|Adult and Pediatrics|This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.
219472771|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
219472772|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
219472773|NCT02863874|DEVICE|VicrylPlus®|Suture
219472774|NCT02863874|DEVICE|Vicryl®|Suture
219472775|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
219472776|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
219472777|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
219472778|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
219472779|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
219472780|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
219472781|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
219472782|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
219472783|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
219472784|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
219595710|NCT06632912|BIOLOGICAL|3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.
219472785|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
219595711|NCT00996892|DRUG|Cobimetinib|Repeated oral dosing.
219595712|NCT00996892|DRUG|Pictilisib|Repeated oral dosing.
219472786|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
219472787|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
219472788|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
219595713|NCT01653912|DRUG|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
219595714|NCT01144247|DRUG|alloreactive CTL|cellular immunotherapy with alloCTL
218857144|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
219595715|NCT03309527|BEHAVIORAL|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
218857145|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
218857146|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
218857147|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
219020550|NCT07186192|OTHER|Standard of Care Arm (Enhanced usual care)|Patients and family caregivers that are randomized into the Standard of Care Arm ( Enhanced usual care) will receive standard CAR-T print materials only.
219595716|NCT03309527|BEHAVIORAL|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
219595717|NCT06052280|OTHER|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
218857148|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
219020551|NCT07195045|DIAGNOSTIC_TEST|Thai PainPREDICT Questionnaire and Mobile Application|The Thai PainPREDICT Questionnaire is a culturally adapted and validated version of an internationally recognized neuropathic pain assessment tool. In this study, it is administered via both paper form and a secure mobile application designed for Thai patients with diabetes. The app automates scoring, provides real-time feedback, and securely stores data in REDCap in compliance with Thai Personal Data Protection Act (PDPA). The intervention is used to screen for painful diabetic neuropathy and compare results against clinical diagnosis and neurophysiological testing, including DN4, nerve conduction studies, and quantitative sensory testing.
219595718|NCT06052280|OTHER|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
219595719|NCT03940625|DIAGNOSTIC_TEST|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
218857149|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
218857150|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
218857151|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
219472789|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
218857152|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
218857153|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
219472790|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
219595720|NCT01987479|DRUG|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
219595721|NCT01987479|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
219595722|NCT01987479|DRUG|Methotrexate|Methotrexate will be administered per investigator's discretion.
219472791|NCT00401726|DRUG|Venlafaxine ER|
219472792|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
219472793|NCT00242840|DRUG|No intervention; Observational study|
219472794|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
218857154|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
218857155|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
219472795|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
219472796|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
219472797|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
219472798|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
219472799|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
219472800|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
219472801|NCT00798902|OTHER|Iliac crest autograft|autograft
219472802|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
219472803|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
219595723|NCT02171494|DRUG|IVAX Warfarin|
219595724|NCT02171494|DRUG|BMS Coumadin|
219595725|NCT06246968|DRUG|Pembrolizumab|Participants will receive Pembrolizumab as part of standard of care treatment.
218857156|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
218857157|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
218857158|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
218857159|NCT01118520|DRUG|placebo|one daily
218857160|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
218857161|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
218857162|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
218857163|NCT00000419|DRUG|Premarin and Provera|
218857164|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
218857165|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
218857166|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
218857167|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
219472804|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
219472805|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
219472806|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
219595726|NCT06246968|DEVICE|Cryoablation|Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
219595727|NCT06484621|BEHAVIORAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support calls.
219595728|NCT06484621|BEHAVIORAL|Physical Activity Education Control|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support calls.
219595729|NCT04944979|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
218857168|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
218857169|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
218857170|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
218857171|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
218857172|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
218857173|NCT02008513|BIOLOGICAL|Placebo|
218857174|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
219472807|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
219472808|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
219472809|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
219595730|NCT06490939|DRUG|Efepoetin Alfa|Single-intravenous administration
219595731|NCT05983250|DRUG|TNX-103|oral levosimendan 1 mg
219472810|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
219595732|NCT05983250|DRUG|Placebo|Placebo
219595733|NCT03955978|DRUG|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
218857175|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
219472811|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
219472812|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
219472813|NCT00785252|DEVICE|standard central line|placement of a central line
219472814|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
219472815|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
219472816|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
219472817|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
219472818|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
219472819|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
218857176|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
218857177|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
218857178|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
219472820|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
218857179|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
218857180|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
219472821|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
219472822|NCT05333861|DRUG|hetrombopag|According to prescription
219472823|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
219595734|NCT03955978|RADIATION|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
219595735|NCT03955978|PROCEDURE|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
219595736|NCT03955978|PROCEDURE|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
219595737|NCT00602641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219595738|NCT00602641|DRUG|Lenalidomide|Given PO
219595739|NCT00602641|DRUG|Melphalan|Given PO
219595740|NCT00602641|DRUG|Prednisone|Given PO
219595741|NCT00602641|OTHER|Quality-of-Life Assessment|Ancillary studies
219595742|NCT00602641|DRUG|Thalidomide|Given PO
219595743|NCT06496828|PROCEDURE|Biologically-oriented preparation technique|The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
219595744|NCT06496828|PROCEDURE|Conventional method of preparation|Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
219595745|NCT02181855|PROCEDURE|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
219595746|NCT00586534|BEHAVIORAL|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
219595747|NCT00586534|BEHAVIORAL|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
218857181|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
218857182|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
219472824|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
219472825|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
219472826|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
219472827|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
219472828|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
219472829|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
219472830|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
219472831|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
219472832|NCT03412448|OTHER|observation|Observation,
219472833|NCT05034146|DRUG|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
219472834|NCT05034146|DEVICE|PET/CT|68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
219595748|NCT03722589|BIOLOGICAL|Flublok|0.5 mL intramuscular dose of Flublok
219595749|NCT03722589|BIOLOGICAL|Flucelvax|0.5 mL intramuscular dose of Flucelvax
218857183|NCT00391469|DRUG|Rapid infusion of cold normal saline|
218857184|NCT03073018|DRUG|Fosinopril|oral administration, capsules
218857185|NCT03073018|DRUG|Pravastatin|oral administration, capsules
219595750|NCT03722589|BIOLOGICAL|Fluarix|0.5 mL intramuscular dose of Fluarix
219595751|NCT03722589|BIOLOGICAL|Fluzone|0.5 mL intramuscular dose of Fluzone
219595752|NCT03722589|BIOLOGICAL|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
219595753|NCT00003392|BIOLOGICAL|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
219595754|NCT00003392|DRUG|carboplatin|18 AUC IV, approximately days 21, 42
219595755|NCT00003392|DRUG|cyclophosphamide|4 gm/m2 IV, day 1
219595756|NCT00003392|DRUG|melphalan|140 mg/m2 IV , approximately day 63
219595757|NCT00003392|DRUG|paclitaxel|170 mg/m2 IV day 1
218857186|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
218857187|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
218857188|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
218857189|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
218857190|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
218857191|NCT00491660|BEHAVIORAL|supine positioning|
218857192|NCT00491660|BEHAVIORAL|lateral positioning|
219595758|NCT00003392|PROCEDURE|bone marrow ablation with stem cell support|
219595759|NCT00003392|PROCEDURE|peripheral blood stem cell transplantation|
219595760|NCT06235489|OTHER|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
219595761|NCT02267044|DRUG|Ropivacaine|The drug used for the interscalene blocks
219595762|NCT04488315|DRUG|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
219595763|NCT04488315|DRUG|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
218857193|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
218857194|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
219472835|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
218857195|NCT01725230|DRUG|Fostamatinib|100-mg tablet
218857196|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
218857197|NCT01725230|DRUG|Simvastatin|40-mg tablet
219595764|NCT02145715|DRUG|Velcade|
219595765|NCT02145715|DRUG|Thalidomide|
219595766|NCT02145715|DRUG|Dexamethasone|
219595767|NCT02145715|DRUG|Panobinostat|
218857198|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
219595768|NCT02168192|BEHAVIORAL|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
219595769|NCT02168192|BEHAVIORAL|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
219595770|NCT03301545|PROCEDURE|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
219595771|NCT06582459|DEVICE|HFNC treatment|HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
219595772|NCT06582459|DEVICE|NIV treatment|NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
219595773|NCT06486870|DRUG|Gonadotropin|Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
218857199|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
218857200|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
218857201|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
218857202|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
218857203|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
218857204|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
218857205|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
218857206|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
218857207|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
218857208|NCT00024661|DRUG|LErafAON|
219472836|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
219472837|NCT02244385|OTHER|no intervention|
219472838|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
219472839|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
219472840|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
219472841|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
219472842|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
219472843|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
219472844|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
219472845|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
219472846|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
219472847|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
218857209|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
218857210|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
218857211|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
218857212|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
218857213|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
218857214|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
218857215|NCT03754582|DRUG|Perampanel|Oral tablets.
218857216|NCT03754582|DRUG|Perampanel|Intravenous infusion.
218857217|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
219199276|NCT06857734|DRUG|Vitamin B Complex|group of vit. B will recieve as an oral capsules for 4 days preoperative , and infusion of vitamin B complex 1ml diluted in 100 ml normal saline administered intravenously after anathesia induction .
219472848|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
219472849|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
219595774|NCT06486870|DRUG|Letrozole|5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
219595775|NCT06486870|PROCEDURE|laparoscopic ovarian drilling|"Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure"
219595776|NCT04659642|DRUG|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
219472850|NCT00843739|DEVICE|sham EMST|Four week sham device training program
219472851|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
219472852|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
219472853|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
219472854|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
219595777|NCT04659642|DRUG|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
219595778|NCT04659642|COMBINATION_PRODUCT|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
219595779|NCT01738295|DRUG|Donepezil administration|
219595780|NCT01738295|DRUG|Placebo administration|
219595781|NCT02540005|OTHER|ROTEM analysis|
218857218|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
218857219|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
218857220|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
218857221|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
219472855|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
219472856|NCT03735849|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
219472857|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
219472858|NCT01439776|DRUG|Vit D|800IU/day
219472859|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
219472860|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
219472861|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
219472862|NCT01652482|DRUG|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
219472863|NCT01652482|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
219472864|NCT01652482|DRUG|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
219595782|NCT01861912|DEVICE|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
218857222|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
218857223|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
219472865|NCT01652482|DRUG|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
219595783|NCT01861912|DRUG|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
218857224|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
218857225|NCT01806025|OTHER|no intervention|
219472866|NCT01652482|DRUG|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
219472867|NCT04585906|BEHAVIORAL|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
219472868|NCT00004199|DRUG|cisplatin|
219472869|NCT00004199|DRUG|gemcitabine hydrochloride|
219472870|NCT00004199|DRUG|prinomastat|
219472871|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
219472872|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
219472873|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
219472874|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
219472875|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
219595784|NCT01861912|DRUG|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
219595785|NCT01861912|DRUG|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
218857226|NCT02504112|OTHER|there is no intervention|
218857227|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
218857228|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
218857229|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
218857230|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
219472876|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
219472877|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
219472878|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
219472879|NCT04148378|OTHER|No intervention|There is no intervention for this study.
219472880|NCT06484387|BEHAVIORAL|Social interaction|Participants are required to speak to one another. Participants are given various topics of conversation.
219595786|NCT02836314|OTHER|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
219595787|NCT02836314|OTHER|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
219472881|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
219472882|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
219472883|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
219472884|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
219472885|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
219472886|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
219595788|NCT00750581|DRUG|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
219595789|NCT03252561|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
219595790|NCT03252561|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
219595791|NCT01533012|PROCEDURE|Pressure difference|Peak inspiratory pressures difference between two lungs
219595792|NCT06185881|PROCEDURE|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
219595793|NCT02009592|DRUG|Rifaximin|Both arms receive Rifaximin
219595794|NCT03120325|DEVICE|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
219595795|NCT02401997|BEHAVIORAL|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
219472887|NCT05419765|DIAGNOSTIC_TEST|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
218857231|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
218857232|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
218857233|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
219472888|NCT04986865|DRUG|ATG-101|ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
219472889|NCT06280092|DRUG|AMSCs|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
219472890|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
219472891|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
219472892|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
219472893|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
218857234|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
218857235|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
218857236|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
218857237|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
219020553|NCT07192237|DRUG|Blinatumomab|Given by IV
219020554|NCT07193927|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum Probiotic Mixture|A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.
219472894|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
219472895|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
218857238|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
219020555|NCT07193927|DIETARY_SUPPLEMENT|Placebo comparator containing maltodextrin|Placebo comparator containing maltodextrin
219595796|NCT04431765|OTHER|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
218857239|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
219472896|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
219472897|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
219472898|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
219472899|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
219472900|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
219472901|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
219472902|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
219472903|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
219472904|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
219472905|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
219472906|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
219472907|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
219472908|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
219472909|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
219595797|NCT04431765|BEHAVIORAL|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
218857240|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
218857241|NCT04362371|DEVICE|Ainara|1 g at each administration
219472910|NCT04405115|BEHAVIORAL|Geriatric Assessment|Geriatric Assessment Visit
219472911|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
219472912|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
219472913|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
219472914|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
219595798|NCT01689779|DRUG|100,000 IU cholecalciferol|active drug
219595799|NCT01689779|DRUG|Placebo|comparator drug
218857242|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
218857243|NCT00044681|DRUG|risperidone|
219199277|NCT06857734|DRUG|vitamin C|group of vitamin C will recieve 1000 mg as an oral capsule for 4 days and infusion at dose of 50 mg/kg diluted in 100 ml normal saline administered iv after induction of anathesia .
219199278|NCT06857734|DRUG|Placebo|patients will recieve placebo tablets with identical regimen preoperative and a placebo infusion of 100 ml normal saline after induction of anathesia ,prepared with identical appearance and taste by the pharmacist according to the randomization group.
219472915|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
219472916|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
219472917|NCT06312501|DEVICE|Satelia®Cardio|Use of a remote patient monitoring system by NP Medical.
219472918|NCT06312501|OTHER|Conventional care|No use of RPM solutions for follow-up
219472919|NCT05758701|COMBINATION_PRODUCT|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
219472920|NCT05758701|DEVICE|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
219472921|NCT06105983|DRUG|Sisunatovir|Single Dose
219472922|NCT06105983|DRUG|Rabeprazole 40 mg|Tablets once daily for 7 days
219472923|NCT06105983|DRUG|Sisunatovir suspension|Tablets once daily for 7 days
219472924|NCT06105983|DRUG|Rabeprazole 20 mg|Tablets once daily for 7 days
219472925|NCT01624805|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219472926|NCT01624805|DRUG|Cyclosporine|Given PO
219472927|NCT01624805|BIOLOGICAL|Filgrastim|Given SC
219472928|NCT01624805|DRUG|Methylprednisolone|Given IV or PO
219472929|NCT01624805|BIOLOGICAL|Pegfilgrastim|Given SC
219199279|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
219199280|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
219199281|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be performed during each cardio-oncologic evaluation.
219472930|NCT06016556|DRUG|nirmatrelvir, ritonavir|single cohort
219472931|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
219472932|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
219472933|NCT00629343|DRUG|Azacitidine|Azacitidine will be delivered sub-cutaneously for 5 days
219472934|NCT00629343|DRUG|Temozolomide|Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days
219472935|NCT04160949|OTHER|No Intervention|There is no intervention for this study.
219472936|NCT03729752|DRUG|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
219472937|NCT04054713|DIAGNOSTIC_TEST|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
218857244|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
218857245|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
218857246|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
218857247|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
218857248|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
218857249|NCT00022685|BIOLOGICAL|epratuzumab|
218857250|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
218857251|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
218857252|NCT01663428|OTHER|Sup-ER Splint|
219472938|NCT04054713|DIAGNOSTIC_TEST|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
219472939|NCT04578600|DRUG|Lenalidomide|Given PO
219472940|NCT04578600|BIOLOGICAL|Obinutuzumab|Given IV
219595800|NCT01966250|DEVICE|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
219595801|NCT01966250|DEVICE|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
218857253|NCT01663428|OTHER|Currently accepted treatment|
218857254|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
218857255|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
218857256|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
219472941|NCT04578600|DRUG|Oral Azacitidine|Given PO
219595802|NCT02435732|DRUG|Placebo saline solution|saline solution
218857257|NCT00003772|PROCEDURE|quality-of-life assessment|
218857258|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
218857259|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
218857260|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
218857261|NCT01009346|DRUG|Cetuximab|250mg/m2/week
218857262|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
219472942|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
219472943|NCT05889156|DRUG|NST-1024|400 mg BID
219472944|NCT05889156|OTHER|Placebo|matched placebo to active arm
219595803|NCT02435732|DRUG|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
219595804|NCT02435732|DRUG|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
219595805|NCT00587860|DRUG|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
218857263|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
218857264|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
218857265|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
218857266|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
219472945|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
219472946|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
219472947|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
218857267|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
218857268|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
218857269|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
218857270|NCT00301548|DRUG|perioperative chemotherapy|
218857271|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
219472948|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
219472949|NCT04246593|OTHER|Mobile Market program implementation|"Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component"
219472950|NCT05644080|RADIATION|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
218857272|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
218857273|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
219472951|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
219595806|NCT00587860|DRUG|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
219595807|NCT00109460|BEHAVIORAL|Tobacco Use Disorder|
218857274|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
218857275|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
218857276|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
218857277|NCT00267605|BEHAVIORAL|ADHD Standard Care|
219020556|NCT07197749|DRUG|Vitamin C (Ascorbic Acid)|"All patients enrolled on this trial will receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Patients will be treated with intravenous (IV) or oral (PO) vitamin C depending on the severity of symptoms, ability to tolerate PO intake, and location of treatment (inpatient versus outpatient setting): IV dosing:~50 mg/kg/day divided TID (max 4 grams total/day) PO dosing: 500 mg BID or 1000 mg daily (depending on the prescribed formulation)~Vitamin C will be administered through day 56 from start of vitamin C treatment. Patients initially receiving IV administration may be transitioned to PO formulation once tolerating PO intake; per treating physician discretion."
219472952|NCT01713374|OTHER|no intervention|control visit
219472953|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
219472954|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
219472955|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
219472956|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
219595808|NCT06582394|COMBINATION_PRODUCT|Exp Group|Balance and coordination were targeted through virtual stepping tasks, where participants practiced stepping in various directions to improve postural control and lower limb function. Additionally, they performed virtual balance exercises by standing on simulated platforms of varying stability. For gait and mobility, participants practiced walking in a virtual environment with real-time feedback to correct gait abnormalities. They also encountered virtual obstacles, which required them to adapt their walking patterns and improve mobility. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
218857278|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
218857279|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
218857280|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
219472957|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
219472958|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
219472959|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
219472960|NCT03677102|OTHER|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
219472961|NCT03677102|OTHER|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
219472962|NCT06438549|BEHAVIORAL|HCP-CHW Integration into Prenatal Care for Smoking Cessation|CHWs will be integrated into primary care, and subjects will receive CHW home visits (up to 8) that will provide brief behavioral smoking cessation interventions before, during, and after a quit date. This brief behavioral intervention will include watching a video and reviewing self-help materials.
219472963|NCT06438549|OTHER|Control Arm|Standard of Care which provides referrals to community-based smoking cessation resources.
219472964|NCT06961916|DEVICE|Active rTMS|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
219472965|NCT06961916|BEHAVIORAL|Cognitive Training|For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes.
219472966|NCT03571568|BIOLOGICAL|BI-1206|"BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion"
219472967|NCT03571568|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2, as per SmPC
219472968|NCT03571568|BIOLOGICAL|Acalabrutinib|Acalabrutinib 100 mg orally as per SmPC
219472969|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
219472970|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
219595809|NCT06582394|OTHER|Control group|For gait training, participants practiced walking on flat surfaces, sometimes with the assistance of parallel bars or walking aids, to improve their walking speed, step length, and rhythm. They also performed sit-to-stand exercises to strengthen the lower limbs and improve mobility for daily activities. Additionally, manual therapy techniques, such as joint mobilizations and stretching, were applied to reduce spasticity and increase range of motion in the affected limbs. Both treatment groups progressed based on individual capabilities, with therapists adjusting exercises accordingly throughout the study. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
219595810|NCT04283019|DRUG|CBD|CBD will be orally ingested
219595811|NCT04283019|DRUG|THC|THC will be orally ingested
219595812|NCT00261443|DRUG|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
219595813|NCT00261443|DRUG|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
219472971|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
219472972|NCT03164304|DRUG|Magnesium Sulfate|intravenous
219472973|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
219472974|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
219472975|NCT02369874|DRUG|Standard of Care|Standard of Care
219472976|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
219472977|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
219472978|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
219472979|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
219472980|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
219595814|NCT03536741|PROCEDURE|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
219472981|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
219472982|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
219472983|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
218857281|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
218857282|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
218857283|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
218857284|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
218857285|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
219472984|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
219472985|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
219472986|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
219472987|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
219472988|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
219472989|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
219472990|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
219472991|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
219472992|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
219472993|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
219472994|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
219472995|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
219472996|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
219472997|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
219472998|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
219472999|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
219473000|NCT03374059|OTHER|Exercise program|
219473001|NCT03374059|OTHER|Life modification|
219473002|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
219473003|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
218857286|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
218857287|NCT04429581|OTHER|Anthropometry|
219473004|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
219473005|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
219473006|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
219473007|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
219473008|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
219473009|NCT02058849|OTHER|Placebo|Placebo
219595815|NCT03536741|DRUG|General Intravenous Anesthetic|General Intravenous Anesthetic
219595816|NCT04747145|DEVICE|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
219473010|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
219473011|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
219473012|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
219473013|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
219473014|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
219473015|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
219473016|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
219595817|NCT04747145|DRUG|Concurrent Chemotherapy (Temozolomide)|75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
219595818|NCT04747145|DRUG|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
219595819|NCT01772875|PROCEDURE|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
219595820|NCT00154752|PROCEDURE|CCRT, Pelvic lymphadenoectomy.|
219595821|NCT02711878|BEHAVIORAL|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
219595822|NCT02711878|BEHAVIORAL|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
219595823|NCT02711878|BEHAVIORAL|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
219199282|NCT06664528|DIAGNOSTIC_TEST|ELECTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
219473017|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
219473018|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
219595824|NCT01049178|DRUG|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
219595825|NCT01049178|DRUG|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
219595826|NCT01049178|DRUG|Placebo|
219595827|NCT04370678|BEHAVIORAL|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
219595828|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
219595829|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
219595830|NCT05083897|OTHER|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
219473019|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
219473020|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
219473021|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
219473022|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
219473023|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
219473024|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
219473025|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
219473026|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
219473027|NCT01379911|OTHER|Yogurt|
219473028|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
219473029|NCT05926687|BEHAVIORAL|Social Communication|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
219473030|NCT05926687|BEHAVIORAL|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
219595831|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
218857288|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
218857289|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
218857290|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
219020564|NCT07199647|OTHER|Questionnaire Administration|Participants completed a sociodemographic questionnaire, the Hospital Anxiety and Depression Scale, the Pain Beliefs Questionnaire, the Complementary, Alternative, and Conventional Medicine Attitude Scale, the Complementary and Alternative Medicine Health Belief Scale, and the Three-Factor Spiritual Well-Being Scale.
219473031|NCT05926687|BEHAVIORAL|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour once/week
219473032|NCT05926687|BEHAVIORAL|Social Communication + Add Tools|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
219595832|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
219595833|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
218857291|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
218857292|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
218857293|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
219473033|NCT05926687|BEHAVIORAL|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour every other week
219473034|NCT05926687|BEHAVIORAL|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
219473035|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
218857294|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
219473036|NCT00038428|DRUG|TLK286|
218857295|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
219473037|NCT01694849|DRUG|GFT505 80mg|
219473038|NCT01694849|DRUG|GFT505 120mg|
219473039|NCT01694849|DRUG|Placebo|
219473040|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
219473041|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
219595834|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
219595835|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
218857296|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
218857297|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
218857298|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
219473042|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
219473043|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
219473044|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
219473045|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
219473046|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
219473047|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
219473048|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
219473049|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
219473050|NCT00241566|DEVICE|implantation of stimulator|
219473051|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
219473052|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
219473053|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
219473054|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
219595836|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
218857299|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
218857300|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
218857301|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
219473055|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
219473056|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
218857302|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
219473057|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
219473058|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
219473059|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
219473060|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
219473061|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
219473062|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
219473063|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
219473064|NCT01439308|DRUG|Placebo|SB-705498 placebo
219473065|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
219473066|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
219595837|NCT00923897|RADIATION|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
218857303|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
218857304|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
219020565|NCT07199088|OTHER|Acetazolamide|A carbonic anhydrase inhibitor, 500 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
219020566|NCT07199088|OTHER|Metolazone|A thiazide-like diuretic, 5 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
219473067|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
219473068|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
219473069|NCT04503655|OTHER|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
219473070|NCT00003695|DRUG|chemotherapy|
219473071|NCT00003695|PROCEDURE|surgical procedure|
219473072|NCT02688881|DRUG|sirolimus|Rapamune
219473073|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
219595838|NCT01286753|DRUG|Vemurafenib|Vemurafenib 960 mg orally twice daily.
219595839|NCT01259271|DEVICE|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
219595840|NCT02240615|DEVICE|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
219595841|NCT01609452|BIOLOGICAL|Blisibimod|
219595842|NCT01609452|OTHER|Placebo|
219595843|NCT06323447|DIAGNOSTIC_TEST|PointCheck|Binary classification of severe neutropenia
219595844|NCT01228799|PROCEDURE|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
219595845|NCT01228799|PROCEDURE|Canaloplasty|Canaloplasty with implant of suture
219020567|NCT07199556|DIETARY_SUPPLEMENT|Food supplement|Tenflex® is an authorized food supplement.
219020568|NCT07199387|OTHER|App Users (Structured Implementation)|The structured implementation (intervention) group will follow a structured protocol designed to promote weekly app engagement. This includes regular updates to customized content, reminders to use the app, and feedback on use. Weekly content updates and push notifications will be provided through the app, and the research team will communicate monthly with organizational champions with feedback reports on app utilization to reinforce engagement.
219473074|NCT02219477|DRUG|dasabuvir|tablet
219473075|NCT02219477|DRUG|ribavirin|tablet
219595846|NCT00750685|DEVICE|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
219595847|NCT05703087|BEHAVIORAL|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
219473076|NCT05674461|OTHER|WhatsApp Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
219020569|NCT07199387|OTHER|App Users (Standard Implementation)|The standard implementation (control) group will receive baseline support, allowing firefighters to use the app as they choose. The research team will provide an initial orientation for organizations and peer supporters, but the organizational champion will be responsible for communication and follow-up. The research team will respond to questions and prompt data collection.
219473077|NCT05674461|OTHER|Face-to-face Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
219473078|NCT05674461|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
219473079|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
219473080|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
219473081|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
219595848|NCT06020144|DRUG|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
219595849|NCT06020144|DRUG|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
219595850|NCT00311597|PROCEDURE|Radiosurgery|single fractionated radiation therapy
219595851|NCT04050215|PROCEDURE|Computed Tomography|Undergo PET/CT
219595852|NCT04050215|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
219595853|NCT04050215|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219595854|NCT04050215|OTHER|Questionnaire Administration|Ancillary studies
219595855|NCT03946852|DEVICE|Abdominal Regional Perfusion|Abdominal Regional Perfusion
219595856|NCT05985629|DRUG|IPACK|Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
219595857|NCT05985629|DRUG|PLACEBO|The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
219595858|NCT00005884|DRUG|eflornithine|
219595859|NCT03635476|OTHER|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
219595860|NCT05646459|DRUG|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
219595861|NCT05646459|DEVICE|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
219595862|NCT05646459|DEVICE|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
219595863|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
219595864|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
219595865|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
219595866|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
219595867|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
219595868|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
219595869|NCT01371747|DRUG|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
219473082|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
219473083|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
219473084|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
219473085|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
219473086|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
219473087|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
219473088|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
219473089|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
219473090|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
219473091|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
219473092|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
219473093|NCT02144311|PROCEDURE|PET/CT Scan|
219473094|NCT02144311|PROCEDURE|MRI|
219473095|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
219473096|NCT02489682|OTHER|Long-form written Informed consent information|
219473097|NCT02489682|OTHER|Short-form written Informed consent information|
219473098|NCT02489682|OTHER|Video Informed consent information|
219473099|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
219473100|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
219473101|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
219473102|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
219473103|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
219473104|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
219473105|NCT02223520|DRUG|Placebo ointment and placebo cloths|
219473106|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
219473107|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
219473108|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
219473109|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
219473110|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
219473111|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
219473112|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
219473113|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
219595870|NCT01371747|DRUG|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
219473114|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
219473115|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
219473116|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
219595871|NCT03261505|DEVICE|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
219595872|NCT01868347|OTHER|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
219595873|NCT01868347|OTHER|control|PEEP after pneumoperitoneum and trendelenburg
219595874|NCT05825443|DRUG|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
219595875|NCT06552039|OTHER|Polyherbal Hair Oil|Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical
218857305|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
219473117|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
219473118|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
219473119|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
219473120|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
219473121|NCT00138723|DRUG|SPM 907|
219473122|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
219473123|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
219473124|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
219473125|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
219473126|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
219473127|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
218857306|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
219473128|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
219473129|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
219473130|NCT04338685|DRUG|RO7119929|RO7119929 will be administered orally as a capsule
219473131|NCT04338685|DRUG|Tocilizumab|"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV"
219473132|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
219473133|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
219473134|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
219473135|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
219473136|NCT04213690|OTHER|No Intervention|There is no intervention for this study
219473137|NCT00012350|DRUG|FTI|
219473138|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
219199283|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
219473139|NCT00145795|DRUG|Current Regimen|
219473140|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
219473141|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
219473142|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
219473143|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
219473144|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
219473145|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
219473146|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
219473147|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
219473148|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
219473149|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
219473150|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
219473151|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
219473152|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
219473153|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
218857307|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
218857308|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
218857309|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
219473154|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
219473155|NCT00272194|DEVICE|Ambu Laryngeal Mask|
219473156|NCT00272194|DEVICE|Aintree Exchange Catheter|
219473157|NCT00272194|DEVICE|Laryngeal Mask Airway|
219473158|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
219595876|NCT06552039|OTHER|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|"First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical"
219595877|NCT06552039|OTHER|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
219473159|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
219473160|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
219473161|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
219473162|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
219595878|NCT01744639|BEHAVIORAL|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
219595879|NCT05231434|OTHER|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
219595880|NCT05231434|OTHER|aerobic activity|aerobic activity
219595881|NCT04012788|DIETARY_SUPPLEMENT|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
219595882|NCT04012788|OTHER|Placebo comparator|Placebo powder
218857310|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
218857311|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
218857312|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
218857313|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
218857314|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
219595883|NCT05269095|PROCEDURE|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
218857315|NCT06120595|OTHER|Standard follow-up|Standard follow-up
218857316|NCT01878110|BEHAVIORAL|COMB|
218857317|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
218857318|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
218857319|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
218857320|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
219473163|NCT01487109|DRUG|Placebo|Matching placebo tablet
219473164|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
218857321|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
218857322|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
219473165|NCT05921851|OTHER|no intervention|no intervention
219473166|NCT03133429|DEVICE|MER|carotid artery stenting
219473167|NCT05128656|OTHER|serology|serology at M3 and serology at M6
219473168|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
219473169|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
219595884|NCT05269095|BIOLOGICAL|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
219595885|NCT05269095|BIOLOGICAL|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
218857323|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
219473170|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
219473171|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
219473172|NCT03907111|DEVICE|placebo|traditional gauze
219473173|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
219473174|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
219473175|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
219473176|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
219473177|NCT03529539|DRUG|PSV|
219473178|NCT00752206|DRUG|Saracatinib|Oral Agent
219473179|NCT00752206|DRUG|Placebo|Oral Agent
219473180|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
219473181|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
219473182|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
219473183|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
219473184|NCT00473187|DRUG|somatropin|
218857324|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
218857325|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
218857326|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
218857327|NCT01688843|DEVICE|INGEVITY lead|
218857328|NCT00248430|BIOLOGICAL|aldesleukin|
218857329|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218857330|NCT00248430|DRUG|melphalan|
218857331|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
218857332|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
218857333|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
218857334|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
218857335|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
218857336|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
218857337|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
219199284|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
219473185|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
219473186|NCT00037908|PROCEDURE|Strength training|
219473187|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
219473188|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
219473189|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
219473190|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
219473191|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
219473192|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain…~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)"
219473193|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
219473194|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
219473195|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
219473196|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
219473197|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
219473198|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
219473199|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
219473200|NCT01961765|DRUG|cabozantinib|
219473201|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
218857338|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
218857339|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
219473202|NCT06639477|OTHER|Treatment As Usual|In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
219473203|NCT06639477|BEHAVIORAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
219473204|NCT06639477|BEHAVIORAL|Active Comparator|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
219473205|NCT05416333|DRUG|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
219473206|NCT05416333|OTHER|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
219473207|NCT04218903|BEHAVIORAL|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
219473208|NCT04218903|BEHAVIORAL|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
219473209|NCT06316817|DEVICE|FloPatch|A novel, hands-free ultrasound patch for continuous monitoring of quantitative Doppler in the carotid artery.
219473210|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
219473211|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
219473212|NCT05471791|DEVICE|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
219595886|NCT03507088|DRUG|Fluoroestradiol (18F)|A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
219595887|NCT00725257|OTHER|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
219595888|NCT00725257|OTHER|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
219595889|NCT00269139|BEHAVIORAL|Crisis resolution|
219595890|NCT05161910|OTHER|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
219595891|NCT05088850|OTHER|no intervention|no intervention
219595892|NCT05314803|BEHAVIORAL|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
219595893|NCT05175703|DEVICE|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
219595894|NCT05858918|DRUG|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
219595895|NCT05858918|DRUG|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
218857340|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
219595896|NCT02291575|OTHER|Training|(please see Arm Description)
218857341|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
218857342|NCT00052312|DRUG|cisplatin|
219199285|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
219199286|NCT06659445|OTHER|Sham|Sham injection
219199287|NCT04631016|DRUG|Tozorakimab|Participants will receive SC injection of tozorakimab as stated in arm description.
218857343|NCT00052312|DRUG|doxorubicin hydrochloride|
218857344|NCT00052312|DRUG|paclitaxel|
218857345|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
219473213|NCT06799455|DEVICE|Endotracheal tube|participants either receive the ETT during the procedure
219473214|NCT05405530|DEVICE|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
219473215|NCT05405530|DEVICE|regular nasal cannula|Using nasal cannula for oxygenation.
219473216|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
219473217|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
219473218|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
219473219|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
219473220|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
219473221|NCT06456151|DIAGNOSTIC_TEST|Invasive candidiasis test|The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
219473222|NCT06456151|OTHER|Urine sample collection for future research|Patients will be asked to provide a urine sample for future research (urine biobank).
219473223|NCT05346887|BEHAVIORAL|Home-based Therapy|The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
219473224|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
219473225|NCT04456816|DRUG|Placebo|Matching placebo tablet
219473226|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
219473227|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
219473230|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
219473231|NCT06072586|DRUG|BDTX-1535|BDTX-1535 is an inhibitor of EGFR mutations
219595897|NCT02291575|OTHER|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
219595898|NCT00580788|DRUG|PTHrP (1-36)|IND # 49,175
219595899|NCT02729571|BIOLOGICAL|MTBVAC|Live-attenuated tuberculosis vaccine
219595900|NCT02729571|BIOLOGICAL|BCG|Commercially available live-attenuated tuberculosis vaccine
219595901|NCT00912938|DRUG|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
218857346|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
219473232|NCT06072586|DRUG|BDTX-1535 combined with radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT, followed by adjuvant monotherapy with BDTX-1535 continuously in 28-day cycles after RT.
219473233|NCT06072586|DRUG|BDTX-1535 combined with temozolomide and radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT and TMZ, followed by adjuvant BDTX-1535 combined with standard of care TMZ continuously in 28-day cycles after RT.
218857347|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
218857348|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
218857349|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
219473234|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
219473235|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
219473236|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
219473237|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
219473238|NCT06040905|OTHER|Placebo|Starch, dextrin
219473239|NCT05555745|DEVICE|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
219473240|NCT05555745|DEVICE|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
219473241|NCT05382715|DRUG|Ozanimod|Specified Dose on Specified Days
219595902|NCT05187728|OTHER|No Intervention|No more intervention will be given.
219595903|NCT01761383|OTHER|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
219595904|NCT00293111|DRUG|SDX-101 (R-Etodolac)|
219595905|NCT01443728|DRUG|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
219595906|NCT01443728|DRUG|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
219595907|NCT02861924|OTHER|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
219595908|NCT04971187|DRUG|Bintrafusp Alfa|Given IV
219595909|NCT04971187|DRUG|Pemetrexed|Given IV
219595910|NCT04971187|DRUG|Carboplatin|Given IV
219595911|NCT04971187|DRUG|Cisplatin|Given IV
219595912|NCT00125671|DRUG|Warfarin|
218857350|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
218857351|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
218857352|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
218857353|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
219473242|NCT05956951|DEVICE|Closed-loop auditory stimulation|Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.
219473243|NCT05956951|DEVICE|Sham auditory stimulation|Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
219473244|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
219473245|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
219473246|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
219473247|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
219473248|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
219473249|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
219473250|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
219473251|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
219473252|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
219473253|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
219473254|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
219473255|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
219473256|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
218857354|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
219473257|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
219473258|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
219473259|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
219473260|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
219473261|NCT03335228|DEVICE|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
219473262|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
219473263|NCT02440490|BEHAVIORAL|Computerised cognitive training|
219473264|NCT02440490|BEHAVIORAL|Video watching|
219595913|NCT00229775|DRUG|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
219595914|NCT06361199|DRUG|Proximod|Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
219595915|NCT06361199|DRUG|Placebo|Placebo controlled
219595916|NCT01531660|BEHAVIORAL|step-up jogging program|
218857355|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
218857356|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
218857357|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
219473265|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
219473266|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
219473267|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
219473268|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
219473269|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
219473270|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
219595917|NCT05780060|BEHAVIORAL|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
219595918|NCT05780060|BEHAVIORAL|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
219595919|NCT05937360|OTHER|cross-sectional community based study|Participants (women between the ages of 18 and 45 years) are selected randomly throughout various regions of Trinidad. Every 10th house from the selected regions would be assessed.
218857358|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
219595920|NCT00108134|DRUG|PEP005|
219595921|NCT02382042|BEHAVIORAL|Intensive Referral Intervention|
218857359|NCT02532712|DRUG|Placebo|Placebo with same shape and size
218857360|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
219595922|NCT04653649|BIOLOGICAL|HSP-CAR30|Anti-CD30 CAR T-cells
219595923|NCT00880178|DRUG|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
219595924|NCT00880178|DRUG|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
219595925|NCT05173181|DEVICE|Flexible intramedullary nail|Fixation of distal ulna fracture with flexible intramedullary nail
218857361|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
219473271|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
219473272|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
219473273|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
219473274|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
219473275|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
219473276|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
219473277|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
219473278|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
219473279|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
219473280|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
219473281|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
219473282|NCT05714839|DRUG|Belantamab|Belantamab will be administered.
219473283|NCT05714839|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219473284|NCT05714839|DRUG|Belantamab and belantamab mafodotin|Belantamab and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
219473285|NCT05303428|OTHER|Neuromodulation with low-intensity focused ultrasound|application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
219473286|NCT01243437|DRUG|ciprofloxacin|"* For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
219473287|NCT01243437|DRUG|doxyxcycline|"* For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
219473288|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
219473289|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
219473290|NCT06977646|PROCEDURE|Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction|The proposed intervention is a variation of classical myectomy, but unlike it, the main substrate for resection is not only the hypertrophied interventricular septum, but the abnormal papillary muscles and interpapillary trabeculae in the left ventricular cavity
219473291|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
219473292|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
219473293|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
219473294|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
219473295|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
219595926|NCT03402061|DIETARY_SUPPLEMENT|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
219595927|NCT03318731|OTHER|Sugar Pill|Taken orally in capsule form
219595928|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, Low Dose|Taken orally in capsule form
219595929|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, High Dose|Taken orally in capsule form
219595930|NCT03729817|DEVICE|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
219595931|NCT01229709|BEHAVIORAL|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
219595932|NCT02252991|OTHER|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
219595933|NCT02906358|BEHAVIORAL|Community-based pain self-management|
219595934|NCT02906358|BEHAVIORAL|Clinic-based pain self-management|
219595935|NCT01171118|DRUG|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
219595936|NCT01171118|DRUG|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
219473296|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
219473297|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
219473298|NCT05733013|OTHER|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
219473299|NCT05525559|DRUG|ET0038|ET0038 for oral administration
219473300|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
219473301|NCT00154986|PROCEDURE|immunohistochemical staining, transfection, invasion assay|
219595937|NCT01171118|DRUG|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
219595938|NCT04435535|PROCEDURE|PEP|Positive expiratory pressure 10 cmH2O 15 min
219595939|NCT01145508|DRUG|Docetaxel|Given IV
219473302|NCT01882166|DRUG|fostimon|
219473303|NCT01882166|DRUG|puregon|
219473304|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
219473305|NCT00984958|DEVICE|Bulkamid expectation|expectance
219473306|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
219595940|NCT01145508|OTHER|Laboratory Biomarker Analysis|Correlative studies
218857362|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
218857363|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
218857364|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
218857365|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
218857366|NCT01862835|DRUG|Degarelix|
218857367|NCT01862835|DRUG|Testosterone|
218857368|NCT01862835|DRUG|Anastrozole|
218857369|NCT01862835|DRUG|Estrogen patch|
218857370|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
218857371|NCT02844283|DRUG|Ad-HGF|
219473307|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
219595941|NCT01145508|DRUG|Prednisone|Given PO
218857372|NCT02844283|OTHER|0.9% NaCl|
218857373|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
218857374|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
219473308|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
219473309|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
219595942|NCT01145508|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
219595943|NCT01145508|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
218857375|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
218857376|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
218857377|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
218857378|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
218857379|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
218857380|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
218857381|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
218857382|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
218857383|NCT01110798|OTHER|intraoperative complication management/prevention|
218857384|NCT01110798|PROCEDURE|assessment of therapy complications|
218857385|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
218857386|NCT01110798|PROCEDURE|quality-of-life assessment|
218857387|NCT01110798|PROCEDURE|therapeutic conventional surgery|
218857388|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
219473310|NCT06997133|DIETARY_SUPPLEMENT|sucralose|Encapsulated sucralose po BID
218857389|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
218857390|NCT00334906|DRUG|memantine HCl|
218857391|NCT00711802|DRUG|Daptomycin|
218857392|NCT00711802|DRUG|Standard of Care (SOC)|
218857393|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
218857394|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
218857395|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
218857396|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
219473311|NCT06997133|OTHER|Placebo|Encapsulated lactose po bid
219473312|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
219473313|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
219473314|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
219473315|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
219473316|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
218857397|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
218857398|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
218857399|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
218857400|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
218857401|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
218857402|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
218857403|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
218857404|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
218857405|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
218857406|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
218857407|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
218857408|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
218857409|NCT02305849|DRUG|Peficitinib|oral tablet
218857410|NCT02305849|DRUG|Placebo|oral tablet
218857411|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
218857412|NCT01913665|OTHER|B.lactis|
218857413|NCT01913665|OTHER|Inulin|
218857414|NCT01913665|OTHER|B.Lactis +Inulin|
218857415|NCT01913665|OTHER|Placebo|
219473317|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
219473318|NCT06326164|PROCEDURE|kinesio-taping.|A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
219473319|NCT06326164|PROCEDURE|A designed physiotherapy program.|The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
218857416|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
218857417|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
218857418|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
219473320|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
219473321|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
219473322|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
219473323|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
219473324|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
219473325|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
219473326|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
219473327|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
219473328|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
219473329|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
219473330|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
219473331|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
218857419|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
218857420|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
218857421|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
218857422|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
218857423|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
218857424|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
218857425|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
219473332|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
219473333|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
219473334|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
219473335|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
219473336|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
218857426|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
219473337|NCT01422395|PROCEDURE|Freezing|Vitrification
219473338|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
218857427|NCT05008757|OTHER|no drug|no intervention
218857428|NCT00084019|DRUG|Atazanavir|
218857429|NCT00084019|DRUG|Ritonavir|
219199288|NCT04631016|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
219199289|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
218857430|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
218857431|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
218857432|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
219595944|NCT06633679|BEHAVIORAL|Se Cuida Intervention|The intervention consist in an internet based cognitive behavioural therapy program delivered through a online platform. Intervention consist of 8 weeks with 8 weekly modules assigned to the participants. The program has been translated and adapted to the Brazilian and is based on CBT techniques focused on managing psychological symptoms of anxiety and depression in young people. Out of a total 14 modules adaptaded, 8 will be delivered in the treatment: 5 will be available to all participants and 3 will be tailored according to the initial assessment and interviews. The intervention is self-guided with support on demand, meaning that when participants need support, they could chat directly through the platform text message channel with a psychoteraphist responsible for them. Also, once a week each participants receive feedbacks regarding their work on the program\&#39;s exercises.
219595945|NCT02844400|DEVICE|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
218857433|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
218857434|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
218857435|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
218857436|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
218857437|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
218857438|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
218857439|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
218857440|NCT00136825|DRUG|N-Acetylcysteine|
218857441|NCT00136825|DRUG|Placebo|
218857442|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
218857443|NCT03638869|DRUG|Placebo|
218857444|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
219199290|NCT06670963|DRUG|Iron|Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
219199291|NCT06670963|DRUG|EPO|Epoetin alfa 50 units/kg IV 3 times weekly
219199292|NCT06670963|DRUG|0.9 % NaCl|Volume of 0.9% NaCl identical as volume of medications used in experimental arm
218857445|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
218857446|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
218857447|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
218857448|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
218857449|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
218857450|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
219473339|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
219473340|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
218857451|NCT02818036|DRUG|Naltrexone|
218857452|NCT02818036|DRUG|Placebo|
218857453|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
218857454|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
218857455|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
218857456|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
218857457|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
218857458|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
219473341|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
219473342|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
219595946|NCT02844400|OTHER|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
219595947|NCT06340711|DRUG|OBP-301|2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
219595948|NCT06340711|DRUG|Pembrolizumab|400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
219595949|NCT00062985|BEHAVIORAL|Mail-based weight loss intervention|
219595950|NCT00062985|BEHAVIORAL|Phone-based weight loss intervention|
219595951|NCT02593253|OTHER|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
219595952|NCT02593253|OTHER|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
219595953|NCT02662283|DRUG|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
219595954|NCT02662283|DRUG|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
218857459|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
218857460|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
218857461|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
218857462|NCT03983772|OTHER|Placebo|The placebo is starch.
218857463|NCT00031018|DRUG|Aricept|
218857464|NCT00031018|DRUG|IFN-alpha2A|
218857465|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
218857466|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
218857467|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
218857468|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
219595955|NCT02045147|BEHAVIORAL|Grp 1a Low Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
219595956|NCT02045147|BEHAVIORAL|Grp 2a Low Cognition, High Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
218857469|NCT02223416|DRUG|RGB-10|
218857470|NCT02223416|DRUG|Teriparatide|
218857471|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
218857472|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
219473343|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
219473344|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
219473345|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
219473346|NCT06915259|OTHER|Doula Model of Care|Doula model of care is defined as emotional support, prenatal support, intrapartum support, and postpartum support provided to the birthing individual by a certified doula.
219473347|NCT06912984|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training intervention will consist of moderate-intensity aerobic exercise training program consisting of treadmill walking/running and upright cycling. The training program involves 3 training sessions per week for 12 weeks. Each session will be ≈ 60 minutes in duration.
218857473|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
219473348|NCT06913283|PROCEDURE|Pulp Therapy with Mineral trioxide aggregate (MTA)|MTA allowed to set for twenty four hours
219473349|NCT06913283|PROCEDURE|Pulp Therapy with Biodentine|Biodentine is triturated before use
219473350|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
219473351|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
219473352|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
219473353|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
219473354|NCT01099670|DRUG|Placebo|Placebo
219473355|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
219473356|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
219473357|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
219473358|NCT00394173|DRUG|Placebo|Matching placebo
219473359|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
219473360|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
219473361|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
219473362|NCT06943365|OTHER|Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies|Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray
219473363|NCT06943365|GENETIC|DPP6 risk haplotype|Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies
219595957|NCT02045147|BEHAVIORAL|Grp 3a Normal Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
219595958|NCT02045147|BEHAVIORAL|Grp 4a Normal Cognition, High Activation Intervention|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
219595959|NCT06415877|OTHER|Episio Training|episio repair training
219595960|NCT04987697|BEHAVIORAL|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
218857474|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
218857475|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
218857476|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
218857477|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
218857478|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
218857479|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
218857480|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
219473364|NCT06942065|PROCEDURE|Sham-BFR|The exercise protocol for the operated leg (with sham pressure of 20mmHg) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
219473365|NCT06942065|PROCEDURE|Blood Flow Restriction Training|The exercise protocol for the operated leg (with a BFR pressure of 60% of the LOP) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
219473366|NCT06942390|DEVICE|Micro-Needling Combined with ketofin and metformin|After micro-needling, topical ketotifen is applied to one half of the face and topical metformin to the other half. Between sessions, patients continue daily application of both treatments.
219473367|NCT06942390|DRUG|ketofin and metformin Alone|This arm includes 51 patients receiving daily applications of topical ketotifen on one half of their face and topical metformin on the other half without undergoing micro-needling sessions.
219473368|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
219473369|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
219473370|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
218857481|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
218857482|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
218857483|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
218857484|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
218857485|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
219199293|NCT06228781|PROCEDURE|Autologous haemopoietic stem cell transplantation|"Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant."
219199294|NCT04496752|DEVICE|DCTclock|Cognitive Test
219199295|NCT06134076|OTHER|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
218857486|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
218857487|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
218857488|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
218857489|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
218857490|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
218857491|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
218857492|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
219473371|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
219473372|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
218857493|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
218857494|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
218857495|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
218857496|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
218857497|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
218857498|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
218857499|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
218857500|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
218857501|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
218857502|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
219473373|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
218857503|NCT05995197|OTHER|action observation|cartoon observation
218857504|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
218857505|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
218857506|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
218857507|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
218857508|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
219199296|NCT06134076|OTHER|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
219199297|NCT06310005|DRUG|BI 3006337|BI 3006337
219199298|NCT06310005|DRUG|Placebo|Placebo
219473374|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
218857509|NCT00206284|DRUG|AZD0865|
218857510|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
218857511|NCT04041427|OTHER|High fat content diet|High fat content diet
218857512|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
218857513|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
218857514|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
218857515|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
218857516|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
218857517|NCT02984059|GENETIC|Genomic DNA|blood draw
218857518|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
218857519|NCT02984059|GENETIC|Microbiome|Stool microbiome
219199299|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
219595961|NCT05262998|PROCEDURE|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
218857520|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
219473375|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
219473376|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
219473377|NCT04964739|BEHAVIORAL|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
218857521|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
219473378|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
219473379|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
219473380|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
219473381|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
219473382|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
219473383|NCT03229902|BEHAVIORAL|mantra meditation|see study description
219473384|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
219473385|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
219473386|NCT00106717|PROCEDURE|Narrative medicine|
218857522|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
219473387|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
219473388|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
219473389|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
219473390|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
219473391|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
219473392|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
219473393|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
219473394|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
219473395|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
218857523|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
218857524|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
218857525|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
218857526|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
218857527|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
219473396|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
219473397|NCT00076544|DRUG|Ziconotide|
219473398|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
218857528|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
218857529|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
218857530|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
219473399|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
219473400|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
219473401|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
219473402|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
219473403|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
219473404|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
219473405|NCT00395317|OTHER|Placebo|placebo tablet
219473406|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
219473407|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
219473408|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
219473409|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
219473410|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
219473411|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
219473412|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
219473413|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
219473414|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
219473415|NCT01961778|DEVICE|Radio-Frequency Ablation|
218857531|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
219473416|NCT01961778|DEVICE|Cryotherapy|
218857532|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
218857533|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
219473417|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
218857534|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
218857535|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
219199300|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
219199301|NCT02506673|DEVICE|Zeiss, Cinema ProMED (audiovisual equipment)|
219473418|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
219473419|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
219473420|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
219473421|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
219473422|NCT01406327|DRUG|Ambrisentan|Ambrisentan
219473423|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
219473424|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
219473425|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
219473426|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
219473427|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
219473428|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
219473429|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
219473430|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
219473431|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
218857536|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
219199302|NCT02506673|DRUG|Midazolam|
219473432|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
219473433|NCT00213486|DRUG|irinotecan|
219473434|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
219473435|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
219473436|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
219473437|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
219473438|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
219473439|NCT00856570|DRUG|warfarin|Oral
219473440|NCT00856570|DRUG|YM178|Oral
219473441|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
219473442|NCT00314275|DEVICE|Endeavor|Drug eluting stent
219473443|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
219473444|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
219473445|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
219473446|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
219473447|NCT00093327|PROCEDURE|Acupuncture|
219473448|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
219473449|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
219473450|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
219595962|NCT05262998|PROCEDURE|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
219199303|NCT02506673|DEVICE|Skin Conductance Monitor|
219199304|NCT06613009|DRUG|IBI3009|Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
219199305|NCT04344158|DRUG|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
219199306|NCT04344158|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219199307|NCT04344158|DRUG|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
219473451|NCT03651440|OTHER|PNF|PNF
219473452|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
219595963|NCT04839692|DRUG|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
219595964|NCT04924257|DRUG|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
219473453|NCT03651440|OTHER|Physical Therapy|Physical Therapy
219473454|NCT03651440|OTHER|Control|Control group
219473455|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
219473456|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
219473457|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
219473458|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
219473459|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
219473460|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
219473461|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
219473462|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
219473463|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
218857537|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
218857538|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
218857539|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
218857540|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
218857541|NCT02183129|DRUG|Diclofenac|
218857542|NCT02183129|DRUG|Meloxicam|
218857543|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
219473464|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
218857544|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
218857545|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
218857546|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
218857547|NCT01107119|OTHER|usual care|
218857548|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
218857549|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
218857550|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
218857551|NCT01287221|DRUG|placebo|placebo
218857552|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
219199308|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
219199309|NCT05692011|DEVICE|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
219199310|NCT05692011|DEVICE|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
219199311|NCT04967599|BEHAVIORAL|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
219473465|NCT02191033|BEHAVIORAL|Smoking counseling|
219473466|NCT02191033|BEHAVIORAL|Text messaging|
219473467|NCT02191033|DRUG|Nicotine patch|
219473468|NCT00190476|DRUG|Weekly docetaxel alone|
219473469|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
219473470|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
219473471|NCT02815540|PROCEDURE|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
219473472|NCT02815540|DRUG|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
219473473|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
219595965|NCT04924257|PROCEDURE|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
219595966|NCT04798612|DRUG|Pegasys|45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
219595967|NCT04798612|DRUG|Saline|0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
218857553|NCT00657150|DRUG|Enoxaparin|40 mg once daily
219473474|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
219473475|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
219595968|NCT02556983|RADIATION|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
219595969|NCT03146962|DRUG|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
219595970|NCT00549289|DRUG|cyclosporine A|
219473476|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
219473477|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
219595971|NCT01158092|DEVICE|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
219595972|NCT01158092|OTHER|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
219595973|NCT04135326|OTHER|Quality-of-Life Assessment|Ancillary studies
219595974|NCT04135326|OTHER|Questionnaire Administration|Ancillary studies
219595975|NCT04135326|PROCEDURE|Transcranial Direct Current Stimulation|Undergo tDCS
219595976|NCT05438914|DEVICE|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
218857554|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
218857555|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
218857556|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
218857557|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
218857558|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
218857559|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
219595977|NCT03899441|OTHER|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
219595978|NCT04067453|OTHER|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
219595979|NCT00700830|DRUG|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
219595980|NCT03385850|OTHER|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
219595981|NCT03112642|PROCEDURE|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
219595982|NCT03112642|DEVICE|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
219595983|NCT04261101|OTHER|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
218857560|NCT04194918|OTHER|Text Message|Receive text messages
219199312|NCT04967599|BEHAVIORAL|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
219595984|NCT01062347|BIOLOGICAL|Zinc|
219595985|NCT00264550|DRUG|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
219595986|NCT00264550|DRUG|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
219595987|NCT00264550|DRUG|Methotrexate|Participants will receive methotrexate capsules weekly.
219595988|NCT00264550|DRUG|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
218857561|NCT04194918|OTHER|Handout|Receive handouts via email
218857562|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
218857563|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
218857564|NCT04194918|OTHER|Survey Administration|Ancillary studies
218857565|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
218857566|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
218857567|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
218857568|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
218857569|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
218857570|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
219595989|NCT00264550|DRUG|Placebo capsules|Participants will receive placebo capsules weekly
219473478|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
219473479|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
219473480|NCT03467919|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
219473481|NCT03467919|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
219473482|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
219473483|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
219473484|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
219473485|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
219473486|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
219473487|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
218857571|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
219473488|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
219595990|NCT04497948|DRUG|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
219595991|NCT04455321|PROCEDURE|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
219595992|NCT02740114|DRUG|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
219595993|NCT02740114|DRUG|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
219595994|NCT02740114|DRUG|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
219199313|NCT05666947|OTHER|Home-based exercise|Eight weeks of home-based exercise programs
219199314|NCT03267563|BEHAVIORAL|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
219473489|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
219473490|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
219473491|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
219473492|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
219473493|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
219473494|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
219595995|NCT02740114|BEHAVIORAL|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
219595996|NCT02740114|BEHAVIORAL|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
219595997|NCT02246114|DEVICE|piCO+ Smokerlyzer® monitor|
219595998|NCT02246114|OTHER|Text messages|
219595999|NCT00000542|DRUG|Inhibitors, ACE|
219596000|NCT00000542|DRUG|amlodipine|
219596001|NCT00000542|DRUG|lisinopril|
219596002|NCT00000542|DRUG|doxazosin|
219596003|NCT00000542|DRUG|chlorthalidone|
219596004|NCT00000542|DRUG|pravastatin|
219596005|NCT00000542|BEHAVIORAL|diet, fat-restricted|
219596006|NCT00171665|DRUG|Diclofenac topical sodium gel 1%|
219596007|NCT03416829|BEHAVIORAL|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
219596008|NCT02091024|DIETARY_SUPPLEMENT|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
219596009|NCT02091024|DIETARY_SUPPLEMENT|Placebo|Placebo 200mg, twice a day
219596010|NCT02125864|PROCEDURE|intravitreal injection|collecting blood samples
218857572|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
218857573|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
218857574|NCT00151034|DRUG|Trastuzumab|
218857575|NCT00151034|DRUG|Paclitaxel|
219596011|NCT05516355|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn,1990).~During the retreat, participants will receive intensive training during 3 days (from 4:00pm to 9pm the first day and from 7 am to 10 pm including breaks, the second and third days), including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga. Training is delivered by certified instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
219596012|NCT05516355|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of daily formal and informal practices.~Training will be conducted during 3 days of the retreat (same schedule as the MBSR training). The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering. CCT program is delivered by certified instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
219596013|NCT06581913|OTHER|Behavioral assessment|Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
219596014|NCT03392350|BEHAVIORAL|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
219596015|NCT01403220|PROCEDURE|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
219596016|NCT01403220|PROCEDURE|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
219596017|NCT00696787|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
219596018|NCT00696787|DRUG|Lyrica® (Pregabalin)|
219596019|NCT00696787|DRUG|Placebo|
219596020|NCT05015257|DIETARY_SUPPLEMENT|Standard F100|100 kcal and 3 g protein per 100 ml
219596021|NCT05015257|DIETARY_SUPPLEMENT|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
218857576|NCT00151034|DRUG|Carboplatin|
218857577|NCT00151034|DRUG|Gemcitabine|
218857578|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
218857579|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
218857580|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
218857581|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
218857582|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
218857583|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
219199315|NCT03267563|BEHAVIORAL|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
219596022|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
219596023|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
219473495|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
219473496|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
219473497|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
219473498|NCT05294133|BEHAVIORAL|physical activity|physical activity
219473499|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
219473500|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
219473501|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
219596024|NCT05723939|DIETARY_SUPPLEMENT|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
219596025|NCT05723939|DIETARY_SUPPLEMENT|Controls|Intake of placebo capsules or regular chicken meet for three weeks
219596026|NCT06632886|DIAGNOSTIC_TEST|AI-Assisted Non-Contrast CT for Multi-Cancer Screening|Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
219596027|NCT04578405|PROCEDURE|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
219596028|NCT04578405|PROCEDURE|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
219596029|NCT00129389|DRUG|Fluorouracil|Arm A: FAC Arm B: FAC-wP
219596030|NCT00129389|DRUG|Doxorubicin|Arm A: FAC Arm B: FAC-wP
218857584|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
218857585|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
218857586|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
218857587|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
218857588|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
219596031|NCT00129389|DRUG|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
219596032|NCT00129389|DRUG|Paclitaxel|Arm B: FAC-wP
219596033|NCT02329535|DRUG|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
219596034|NCT03760185|DRUG|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
219596035|NCT00170664|DRUG|Paclitaxel|
219596036|NCT00170664|DRUG|Carboplatin|
219596037|NCT01013558|DRUG|Remifentanil|0.15 microgram/kg/min continuous infusion.
219596038|NCT01013558|DRUG|saline|continuous infusion
219596039|NCT03348735|DRUG|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
219596040|NCT03348735|DRUG|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
219596041|NCT03348735|DRUG|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
218857589|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~\- access to stoma care by specialist nurses"
218857590|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~\- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
218857591|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
218857592|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
218857593|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
218857594|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
218857595|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
219473502|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
218857596|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
219473503|NCT00536991|DRUG|Ketoconazole|Given PO
219473504|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
219596042|NCT01830790|DRUG|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
219596043|NCT03219190|BEHAVIORAL|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
218857597|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
218857598|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
219473505|NCT00536991|OTHER|Pharmacological Study|Correlative studies
218857599|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
219473506|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
219473507|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
219473508|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
219596044|NCT00754715|DRUG|AZD2516|Solution administered once orally
219596045|NCT00754715|DRUG|Placebo|Solution administered only once
219199316|NCT03267563|BEHAVIORAL|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
219473509|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
219473510|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
219596046|NCT00706862|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
219596047|NCT00706862|DRUG|Placebo|Oral, twice per day
219596048|NCT00601562|DRUG|Zidovudine|
219473511|NCT04621227|DRUG|Midazolam|2mg single dose
219473512|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
219473513|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
219473514|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
219596049|NCT04735926|DRUG|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
219596050|NCT04735926|DRUG|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
218857600|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
218857601|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
218857602|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
219473515|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
219473516|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
219473517|NCT04666012|BIOLOGICAL|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
218857603|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
218857604|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
219473518|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
218857605|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
218857606|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
218857607|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
218857608|NCT03561701|DRUG|Placebo|matching placebo capsule
218857609|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
218857610|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
218857611|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
218857612|NCT04575818|DRUG|Placebo|Placebo oral suspension
219473519|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
219473520|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
219596051|NCT04735926|DRUG|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
219596052|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
219596053|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
218857613|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
218857614|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
218857615|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
218857616|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
218857617|NCT00824551|OTHER|Standard care|Patient will undergo standard care
218857618|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
219596054|NCT04130750|COMBINATION_PRODUCT|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
219596055|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using Polypropylene mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
218857619|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
218857620|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
218857621|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
218857622|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
218857623|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
218857624|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
218857625|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
218857626|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
219473521|NCT04926467|DRUG|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
219473522|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
219473523|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
219473524|NCT01974869|DRUG|Anti-tumor necrosis factor alpha agents|Treatment with biologics
219473525|NCT05556031|OTHER|Standard care|Standard clinical care
219473526|NCT00317031|DRUG|Acamprosate or Naltrexone|mg\&d 90 days
219473527|NCT02204449|BEHAVIORAL|Cardiac Rehabilitation Peer Mentorship|
219473528|NCT04861207|DRUG|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
219473529|NCT04766632|DEVICE|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
219596056|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
219596057|NCT00967460|BEHAVIORAL|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
219596058|NCT06486857|DIAGNOSTIC_TEST|a novel gas detection method for dyslipidemia screening|Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection
219596059|NCT01577589|DRUG|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
218857627|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
219473530|NCT06269965|DEVICE|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
219473531|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Resistance Exercise Training|Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
219473532|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Endurance Exercise Training|Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
219596060|NCT01577589|DRUG|Placebo in 50 ml infusion volume|IV infusion
219596061|NCT01577589|DRUG|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
219596062|NCT01577589|DRUG|Placebo in 250 ml infusion volume|IV infusion
219596063|NCT01577589|DRUG|600 mg ceftaroline in 100 ml infusion volume|IV infusion
219596064|NCT01577589|DRUG|Placebo in 100 ml infusion volume|IV infusion
219596065|NCT04867174|BEHAVIORAL|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
219596066|NCT04867174|BEHAVIORAL|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
219596067|NCT04867174|BEHAVIORAL|Race concordant|Randomized to a messenger who is race concordant with the participant
219596068|NCT04867174|BEHAVIORAL|Gender concordant|Randomized to a messenger who is gender concordant with the participant
219596069|NCT02121873|DEVICE|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
219596070|NCT02121873|DEVICE|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
219596071|NCT02121873|DEVICE|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
219596072|NCT04851392|DRUG|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
219596073|NCT04851392|DRUG|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
219596074|NCT04851392|DRUG|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
219596075|NCT02974712|DRUG|Fentanyl|
219596076|NCT02974712|DRUG|Saline|
219596077|NCT03571412|DEVICE|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
219596078|NCT03988686|PROCEDURE|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
219596079|NCT03988686|DRUG|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
219596080|NCT00451048|DRUG|sunitinib malate|Given orally
218857628|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
219020595|NCT07199608|PROCEDURE|subcision|patients will undergo subcision procedure alone using 18 gauge blunt cannula to release fibrous bands under atrophic acne scars.this group will serve as control comparator
219020596|NCT07199608|PROCEDURE|subcision+fractional co2 laser|patients will undergo subcision procedure followed by fractional co2 laser applied to right side of face, the left side will receive subcision alone
219020597|NCT07199608|BIOLOGICAL|subcision+PRP|patients will undergo subcision procedure followed by intradermal injection of autologous PRP prepared from patients blood on right side.left side will receive subcision alone
219199317|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
219473533|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
219473534|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
219473535|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
219473536|NCT03978936|BEHAVIORAL|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
219473537|NCT03978936|BEHAVIORAL|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
219473538|NCT06567275|PROCEDURE|Erector Spinae Plane Block|Ultrasound-guided erector spinae plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
219596081|NCT04795596|PROCEDURE|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
219596082|NCT04795596|DRUG|Chemotherapy|second line chemotherapy according to investigator's choice
219596083|NCT00026299|DRUG|ZD1839|
219596084|NCT00026299|DRUG|oxaliplatin|
219596085|NCT00001605|BIOLOGICAL|Nontypeable Haemophilus influenzae|
219596086|NCT04414345|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
219596087|NCT04414345|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
219596088|NCT05529446|DEVICE|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
219596089|NCT04573114|PROCEDURE|Verticalization|Progressive levels of verticalization
219596090|NCT04149093|DIAGNOSTIC_TEST|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
219596091|NCT04140162|DRUG|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
219473539|NCT06567275|PROCEDURE|Serratus Anterior Plane Block|Ultrasound-guided serratus anterior plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
219473540|NCT05793788|BEHAVIORAL|Outreach Text Messages|"The investigators will send randomized participants an SMS message encouraging them to click provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures. Message content will vary based on randomization arm as noted below."
219473541|NCT05793788|BEHAVIORAL|Specific|The message will inform patients that the care team has identified tests/screenings that they are due for.
219473542|NCT05793788|BEHAVIORAL|General|The message will inform patients that the care team has identified a care gap in their record.
219473543|NCT05793788|BEHAVIORAL|Elevating Intentions|The message will point out that even if patients feel healthy, their doctor recommends them to take care of their health gaps.
219473544|NCT05793788|BEHAVIORAL|Prompting Action|The message will prompt patients to take care of their health gaps right away before they forget.
219473545|NCT06392737|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
219473546|NCT06392737|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
219473547|NCT05617495|OTHER|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
219473548|NCT03687957|DRUG|rhIL-7-hyFc|-Given by intramuscular injection
219473549|NCT03687957|DRUG|Placebo|-Given by intramuscular injection
219473550|NCT03687957|DRUG|Temozolomide|-Standard of care
219473551|NCT03687957|RADIATION|Radiation therapy|-Standard of care
219473552|NCT03687957|PROCEDURE|Blood sample|"* Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression"
219473553|NCT06785064|BEHAVIORAL|Reduced Food Variety (RFV)|Participants engaged in reduced food variety (RFV) will be asked to choose a few high-calorie, low nutrient main meals and snacks to eat regularly. At the beginning of each month, they will choose one main meal (entrée) to eat at least 2 times a week and one snack food to eat at least 4 times a week within the month. They will have the option to keep or change their main meal and snack options from month to month.
218857629|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
219199318|NCT03782818|DRUG|Olaparib|Olaparib up to 300 mg BID for 24 weeks
219473554|NCT06785064|BEHAVIORAL|Home-based Resistance Training (HBRT)|Participants assigned to receive home-based resistance training (also called strength training or lifting weights) will be asked to engage in at-home exercises that strengthen muscles at least 2 days each week (≤45 minutes per home session) and track their progress. They will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first two months of Phase 2 to learn these skills. They will receive exercise plans and equipment (sets of dumbbells, a rack to hold the dumbbells, and an exercise mat) needed to complete exercises.
219596092|NCT04140162|DRUG|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
219596093|NCT04140162|DRUG|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
219596094|NCT04140162|DRUG|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
219596095|NCT04194294|DRUG|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
218857630|NCT01668641|DRUG|GLPG0634|
218857631|NCT01668641|DRUG|Placebo|
218857632|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
219596096|NCT04194294|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
219596097|NCT03926520|DEVICE|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
219596098|NCT04150263|PROCEDURE|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
219596099|NCT04150263|PROCEDURE|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
219473555|NCT06785064|BEHAVIORAL|Buddy Training and Support (BTS)|"Participants assigned to buddy training and support will be asked to identify an eligible friend or family member who is over 18 years old that can be their buddy. Study staff will contact the buddy to be sure they are eligible, willing, and have all the details they need. The participant's buddy will be asked to attend up to 6 training sessions with the study staff, so they can learn the best ways to support the participant during the program. After the buddy completes training, they will be asked to check in with the participant 1-2 times each week about their progress."
219473556|NCT06785064|BEHAVIORAL|Acceptance and Commitment (ACT) Workshops|Participants assigned to receive Acceptance and Commitment (ACT) Workshops will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first three months of Phase 2. These workshops will help them develop skills to handle tough thoughts about weight control, keep their values in mind, and be mindful of their decisions and the impact of their decisions related to weight control. They will also be asked to apply ACT skills regularly during the rest of Phase 2.
219473557|NCT06835127|PROCEDURE|Infrainguinal peripheral endovascular revascularization|Percutaneous endovascular angioplasty and/or stenting of infrainguinal arteries (femoropopliteal and/or infrapopliteal arteries) under local anesthesia and adjunct mild conscious sedation.
219473558|NCT05567601|DRUG|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
219473559|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
219473560|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
219473561|NCT04711655|PROCEDURE|ARMA (antireflux ablation of the cardiac mucosa)|is an endoscopy in which argon gas ablation of the cardiac mucosa
219596100|NCT05184543|OTHER|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
219596101|NCT05184543|OTHER|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
219596102|NCT05184543|OTHER|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
218857633|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
219473562|NCT04711655|PROCEDURE|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
219473563|NCT05216016|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
219473564|NCT06300580|DRUG|ABBV-932|Oral Capsule
219473565|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
219596103|NCT02548390|DRUG|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
218857634|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
218857635|NCT02322294|OTHER|Placebo|
218857636|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
218857637|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
218857638|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
218857639|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
218857640|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
218857641|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
218857642|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
219473566|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
218857643|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
219473567|NCT04148313|OTHER|No Intervention|There is no intervention for this study.
219596104|NCT06633978|DEVICE|MediTrain|Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
219596105|NCT06633978|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
219596106|NCT06633978|DEVICE|Sleep monitor|Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
219596107|NCT02237391|OTHER|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
219596108|NCT02237391|OTHER|Treatment as Usual (TAU)|Control group
219596109|NCT00425373|DRUG|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
219596110|NCT00425373|DRUG|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
219596111|NCT00425373|DRUG|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
219596112|NCT00425373|DRUG|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
219596113|NCT00425373|DRUG|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
218857644|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
219596114|NCT00425373|DRUG|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
219596115|NCT00425373|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
219596116|NCT00425373|DRUG|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
219596117|NCT00425373|DRUG|Placebo|4 tablet and 2 capsule placebos taken once daily
219596118|NCT00436865|BEHAVIORAL|Weight loss|
218857645|NCT03288194|BEHAVIORAL|Time Management|
218857646|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
218857647|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
219473568|NCT04211467|OTHER|No Intervention|There is no intervention for this study
218857648|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
218857649|NCT00468845|DRUG|matched placebo|matched placebo
218857650|NCT02960646|DRUG|Cyclophosphamide|Given IV
218857651|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
218857652|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
218857653|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
218857654|NCT02960646|DRUG|Melphalan|Given IV
218857655|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
218857656|NCT02960646|BIOLOGICAL|Rituximab|Given IV
218857657|NCT02960646|DRUG|Tacrolimus|Given IV or PO
218857658|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
218857659|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
218857660|NCT02388594|DRUG|Cyclophosphamide|
218857661|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
218857662|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
218857663|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
218857664|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
219473569|NCT05216419|DRUG|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
218857665|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
218857666|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
218857667|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
218857668|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
218857669|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
218857670|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
218857671|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
218857672|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
218857673|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
218857674|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
219473570|NCT01342445|DRUG|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
219473571|NCT01342445|DRUG|Placebo|
219473572|NCT06212427|DIETARY_SUPPLEMENT|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
219473573|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
219473574|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
219473575|NCT04208178|DRUG|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
219473576|NCT04208178|DRUG|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
219473577|NCT04208178|DRUG|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
219473578|NCT04208178|DRUG|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
219473579|NCT05933655|BEHAVIORAL|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
219473580|NCT05141266|BEHAVIORAL|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
219473581|NCT05141266|OTHER|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
219473582|NCT06341972|BEHAVIORAL|Cognitive behavioral therapy based self-management for anxiety|Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
219473583|NCT05512533|DEVICE|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
219473584|NCT05881031|OTHER|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
218857675|NCT04218162|DRUG|Placebo|Placebo
219473585|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
219473586|NCT06009523|DEVICE|Transcranial direct current stimulation|1 stimulation per day during 15 days.
219473587|NCT02392078|DEVICE|NeuroBlate System|
219473588|NCT04961645|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.
219473589|NCT04961645|BEHAVIORAL|Computer-based Test|Participants will be seated comfortably in a chair and asked to complete a simple computer-based task where they imagine walking through a room and press a button indicating if they can leave through a door on the left, center, or right wall. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
219473590|NCT04961645|BEHAVIORAL|Behavioral-based Test|Participants will be asked to complete a simple behavioral task that will require them to walk around in a small room and search for hidden objects. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
219473591|NCT02652793|DRUG|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
219473592|NCT02652793|DRUG|Lamivudine|Lamivudine 300 mg once dailly
219473593|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
218857676|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
219473594|NCT02177370|DRUG|Fenoterol MDI|
219473595|NCT02177370|DRUG|DSCG MDI|
218857677|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
219473596|NCT06262867|DIETARY_SUPPLEMENT|Ready. Set. Food! Stage 1 Mix ins|These supplements contain cow's milk, eggs, and peanuts.
219473597|NCT05268367|BEHAVIORAL|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
219473598|NCT06095557|DEVICE|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
219473599|NCT05899166|OTHER|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
219596119|NCT06523660|BEHAVIORAL|CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills|The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
219596120|NCT06523660|BEHAVIORAL|Parent Psychoeducation|Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
219596121|NCT00599963|DRUG|paricalcitol|paricalcitol 1 mg/day
219596122|NCT04588025|DEVICE|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
218857678|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
219473600|NCT05899166|OTHER|Standard diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
219473601|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
219596123|NCT01365312|DRUG|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
219596124|NCT01365312|DRUG|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
219596125|NCT04504123|DRUG|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
219596126|NCT04504123|DRUG|Placebo|Placebo
219596127|NCT01859910|PROCEDURE|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
219596128|NCT01859910|PROCEDURE|routine preparation for cataract|
218857679|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
219473602|NCT06570031|DRUG|ONO-4578|Specified dose on specified days
219473603|NCT06570031|DRUG|letrozole|Specified dose on specified days
219473604|NCT06570031|DRUG|Palbociclib|Specified dose on specified days
219473605|NCT06570031|DRUG|abemaciclib|Specified dose on specified days
219473606|NCT05611892|COMBINATION_PRODUCT|18F-FDS PET/CT|20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
219473607|NCT05903690|DRUG|RAG-17|RAG-17 60mg is used
219473608|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
219473609|NCT04643431|DIAGNOSTIC_TEST|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
219473610|NCT06534580|DEVICE|Virtual Reality|"A range of virtual reality software, delivered through the DR.VR (TM) device."
219473611|NCT03234023|BEHAVIORAL|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
219473612|NCT04800029|OTHER|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
219473613|NCT04800029|OTHER|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
219473614|NCT04800029|OTHER|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
219473615|NCT04148248|OTHER|No intervention|There is no intervention for this study
219473616|NCT03338257|BEHAVIORAL|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
219473617|NCT06445179|PROCEDURE|Total Laparoscopic Hysterectomy|"The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy."
219473618|NCT06445179|DEVICE|Ureterolysis|unilateral or bilateral ureterolysis with or without bilateral adnexectomy
219473619|NCT02866747|RADIATION|Hypofractionated stereotactic radiation therapy|
219473620|NCT02866747|DRUG|Durvalumab|
219473621|NCT04884594|DRUG|AAV8-hCocH|2e12 vg/kg single infusion intravenous
219473622|NCT04884594|DRUG|AAV8-hCocH|6e12 vg/kg single infusion intravenous
219473623|NCT04884594|DRUG|AAV8-hCocH|4e12 vg/kg single infusion intravenous
219473624|NCT03913936|OTHER|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
219473625|NCT05168930|DRUG|Venetoclax|C4-15
219473626|NCT05168930|DRUG|Zanubrutinib|C1-15
219473627|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
218857680|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
219473628|NCT03868410|DEVICE|New Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
219473629|NCT03868410|DEVICE|Conventional Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
219473630|NCT04914975|OTHER|Neuromuscular electrical stimulation|The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
219473631|NCT01059175|DEVICE|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
219473632|NCT01059175|DEVICE|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
219473633|NCT06389214|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
218857681|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
219596129|NCT03624907|RADIATION|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
219596130|NCT03624907|RADIATION|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
219596131|NCT02052011|DRUG|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
219596132|NCT02052011|DRUG|Placebo|
218857682|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
218857683|NCT03764917|OTHER|Time|Different detecting time
218857684|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
218857685|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
218857686|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
218857687|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
218857688|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
219596133|NCT04234971|DRUG|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
219596134|NCT04234971|DRUG|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
219596135|NCT02341898|OTHER|Educational programme for all nurses|
218857689|NCT02668861|OTHER|placebo|placebo for 8 weeks
218857690|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
219473634|NCT06389214|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
219473635|NCT06580145|DRUG|L-leucine|"L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally."
219473636|NCT06580145|DRUG|L-lysine|"L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally"
219473637|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
219473638|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
219473639|NCT04322929|DRUG|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
218857691|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
218857692|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
219473640|NCT06123481|PROCEDURE|Core Decompression|Standard core decompression procedure is performed by drilling into the necrotic bone of the femoral head. A sham bone marrow aspiration involves advancing a needle to the iliac crest (no bone penetration, no bone marrow aspiration) through a small skin incision.
219473641|NCT06123481|PROCEDURE|Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate|This involves bone marrow aspiration, concentrating the bone marrow aspirate, and injecting 6 milliliters of bone marrow aspirate concentrate into the necrotic femoral head through an opening created by the core decompression.
219473642|NCT03372564|PROCEDURE|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
219473643|NCT06198023|BEHAVIORAL|Educational|The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.
219473644|NCT06198023|BEHAVIORAL|Interactive|The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
219473645|NCT06579027|DEVICE|SPEED Training|Children will use ride-on toys controlled using their affected arm to navigate through their environment and complete playful theme-based challenges. Children will use their affected UE during navigation to start and stop the toy, move steadily forward and backward, turn to the right and left, perform 180° and 360° turns to either side, and avoid obstacles. Children will complete object-based UE tasks requiring gross and fine motor control at intermediate stops during navigation. Navigational tasks will be progressed by increasing complexity of paths (straight to slalom paths needing more directional changes), spaces (wide to narrow spaces), and precision (obstacle courses and mazes requiring skillful navigation, motor planning, and route finding). Object-based tasks will be progressed in terms of force requirements (small to large forces), range of motion (near to far reaches), precision (manipulation of large to small objects), and speed of movements (slow to fast).
219596136|NCT02341898|OTHER|Training and structured support for nominated key nurses|
219596137|NCT02341898|OTHER|Facultative train-the-trainer module for key nurses|
218857693|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
218857694|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
218857695|NCT01869361|DRUG|Indomethacin|Study drug
218857696|NCT01869361|DRUG|Placebo|Control drug
218857697|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
218857698|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
218857699|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
218857700|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
219596138|NCT02341898|OTHER|Printed study material|
219596139|NCT02341898|OTHER|Supportive material (poster, mugs etc.)|
219596140|NCT00000620|DRUG|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
219596141|NCT00000620|DRUG|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
219596142|NCT00000620|DRUG|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
219596143|NCT06600269|PROCEDURE|Cycling Training|Cycling combined with priming strategies to enhance motor learning tasks. Each session will last for 15 minutes, conducted three times per week, over a period of two weeks.
218857701|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
218857702|NCT01955434|DRUG|Cyclophosphamide|Given PO
218857703|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
218857704|NCT01955434|OTHER|Pharmacological Study|Correlative studies
218857705|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
219596144|NCT06323148|DRUG|Osimertinib|Adjuvant osimertinib for three years after radical surgery
219596145|NCT06323148|DRUG|No adjuvant therapy|No adjuvant therapy
218857706|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
218857707|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
218857708|NCT04289077|OTHER|Questionnaires|\- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
218857709|NCT00001399|DRUG|Transduced CD34+ Cells|
218857710|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
218857711|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
218857712|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
218857713|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
218857714|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
218857715|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
219473646|NCT06579027|BEHAVIORAL|CRAFT Training|Children will engage in predominantly seated activities based on conventional occupational therapy to promote unimanual and bimanual UE function. Training sessions will be based on playful child-friendly themes (e.g., dinosaurs, space exploration, aquatic theme, etc.) and all training activities will incorporate the session theme. Activities will involve practice of functional gross and fine motor UE movement patterns that children typically use during daily life. Training will emphasize the use of the affected UE in different roles (i.e., stabilizer, mobilizer, and active and passive assist) during warm-up, building, and art-craft activities. The training will be progressed in terms of forces needed, range of motion, precision, and movement speed.
219473647|NCT06477588|BEHAVIORAL|Health Navigation|Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
219596146|NCT02354794|DIETARY_SUPPLEMENT|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
219596147|NCT02354794|DIETARY_SUPPLEMENT|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
219596148|NCT02480348|DEVICE|Polymer-free DES (Drug Eluting Stent)|
219596149|NCT00134667|DRUG|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
219596150|NCT00134667|DRUG|Macugen (pegaptanib sodium)|
219596151|NCT03267901|OTHER|food|45 g of walnut / iso-caloric white bread
219596152|NCT04207463|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
219596153|NCT04207463|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219596154|NCT01210872|OTHER|questionnaire administration|
219596155|NCT01210872|PROCEDURE|quality-of-life assessment|
219596156|NCT01210872|PROCEDURE|standard follow-up care|
219596157|NCT00551668|PROCEDURE|proximal patellar surgery|Initial proximal patellar surgery
219596158|NCT00551668|PROCEDURE|Nonoperative|Nonoperative without surgery
218857716|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
218857717|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
219596159|NCT04554446|PROCEDURE|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
219596160|NCT04554446|PROCEDURE|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
219596161|NCT03529825|DRUG|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
219596162|NCT02648932|BIOLOGICAL|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
219596163|NCT02648932|PROCEDURE|Matched Unrelated Donor Transplant|
219596164|NCT04819763|OTHER|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~1. A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~2. The lower jaw moves to the left and back to the center with little contact to the spatula~3. The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~1. The left palm is placed on the left temple region~2. Right hand forms a fist and is placed on the tip of the right chin~3. Both arms are aligned parallel to the surface of the floor~4. The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~5. With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
218857718|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
218857719|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
218857720|NCT00219037|DRUG|aliskiren|
218857721|NCT00165542|OTHER|A PROTEIN level|
218857722|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
218857723|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
219473648|NCT06477588|BEHAVIORAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
219473649|NCT06232616|PROCEDURE|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
219473650|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
219473651|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
219473652|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
219473653|NCT06419634|DRUG|BMS-986497|Specified dose on specified days
219473654|NCT06419634|DRUG|Azacitidine|Specified dose on specified days
219473655|NCT06419634|DRUG|Venetoclax|Specified dose on specified days
219473656|NCT06190249|BIOLOGICAL|LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-144), followed by IL-2.
219473657|NCT06190249|DRUG|Cyclophosphamide|Given by IV.
219473658|NCT06190249|DRUG|Mesna|Given by IV.
219473659|NCT06190249|DRUG|Fludarabine|Given by IV.
219473660|NCT06190249|BIOLOGICAL|Interleukin-2 (IL-2)|Given by IV.
219473661|NCT06190249|DRUG|Pembrolizumab|Given by IV.
218857724|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
218857725|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
219596165|NCT04819763|OTHER|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
219596166|NCT05412355|PROCEDURE|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
219596167|NCT00124124|DRUG|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
219473662|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
219473663|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
219596168|NCT00124124|DRUG|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
219596169|NCT05840679|DRUG|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
219473664|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
219596170|NCT04963543|OTHER|FID123238|Lubricant applied to the ocular surface
219596171|NCT01596738|DRUG|Tranexamic Acid|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
219596172|NCT01596738|DRUG|Saline|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
219596173|NCT02960490|DRUG|E6011|subcutaneous administration
219596174|NCT02960490|DRUG|Placebo|subcutaneous administration
219596175|NCT06354452|OTHER|Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis."
219596176|NCT00516152|DRUG|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"
219596177|NCT06357806|DRUG|Sintilimab|100mg/10ml/1bottle
219596178|NCT06357806|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
219596179|NCT06357806|DRUG|NAs|tablets
219596180|NCT02603991|PROCEDURE|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
219596181|NCT02603991|DRUG|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
219596182|NCT04079465|DEVICE|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
219596183|NCT03068117|OTHER|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
219596184|NCT02678078|PROCEDURE|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
219596185|NCT03461731|DEVICE|Control|laser beam only
219596186|NCT03461731|DEVICE|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
219596187|NCT03461731|DEVICE|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
219596188|NCT03461731|DEVICE|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
219596189|NCT00002926|DRUG|cytarabine|
219596190|NCT00002926|DRUG|etoposide|
219596191|NCT00002926|DRUG|idarubicin|
219596192|NCT00002926|PROCEDURE|allogeneic bone marrow transplantation|
219596193|NCT00002926|PROCEDURE|peripheral blood stem cell transplantation|
219596194|NCT01753557|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
219596195|NCT01753557|DRUG|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
219596196|NCT01753557|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
219596197|NCT01261923|DRUG|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
219473665|NCT05763667|DRUG|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
219473666|NCT05763667|DRUG|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
219473667|NCT06296628|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
219473668|NCT06296628|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
219473669|NCT04951206|DEVICE|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
219473670|NCT04951206|DRUG|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
219473671|NCT05450198|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
219473672|NCT05450198|BIOLOGICAL|Placebo|Placebo comparator to MK-6194 administered SC
219473673|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
219473674|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
219473675|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
219473676|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
219473677|NCT00185146|DRUG|Pactimibe|
219473678|NCT05173714|BEHAVIORAL|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
219473679|NCT05173714|BEHAVIORAL|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
219473680|NCT05173714|BEHAVIORAL|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
219473681|NCT05173714|DRUG|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
219473682|NCT05173714|DRUG|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
219473683|NCT05843604|OTHER|Functional MRI|Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
219473684|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
219473685|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
219473686|NCT06585670|OTHER|Calm Health - smartphone application|Participants randomized to the intervention arm of the study will be given free access to a mobile phone application called Calm Health, which they will use to engage in guided meditation and mindfulness modules for at least 10 minutes per day for 8 weeks.
219596198|NCT01027338|OTHER|Tai chi exercise|
219473687|NCT06131398|DRUG|AMG 355|Short-term intravenous (IV) infusion
219473688|NCT06131398|DRUG|Pembrolizumab|Short-term IV infusion
219473689|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
219596199|NCT03071939|OTHER|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
219596200|NCT03521843|DEVICE|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
219596201|NCT03521843|DEVICE|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
219596202|NCT05336032|OTHER|Food (rice)|Cooked rice with 75 gm carbohydrate
219596203|NCT04009707|OTHER|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
219596204|NCT04009707|OTHER|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
219473690|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
219473691|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
219473692|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
219596205|NCT01307111|DRUG|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
219596206|NCT01307111|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
219596207|NCT02090166|OTHER|Blood test|a blood test will be taken from each patient
219596208|NCT02265926|DEVICE|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
219596209|NCT05727826|DEVICE|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
219596210|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
219473693|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
219473694|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
219473695|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
219473696|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
219473697|NCT06827678|OTHER|No Intervention: Observational Cohort|No intervention
219473698|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
219596211|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
219596212|NCT00682357|DRUG|Placebo and Lidocaine|Placebo and lidocaine 20 mg
219596213|NCT06137625|BEHAVIORAL|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
219596214|NCT06137625|BEHAVIORAL|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
219596215|NCT04682522|DRUG|Metronidazole Oral|250 mg Three times a day
219596216|NCT06501430|OTHER|Heating Therapy|Heating Therapy will be performed on subjects along with PNF Exercises.
219596217|NCT06501430|OTHER|Manual Soft tissue Release|Manual Soft tissue Release will be performed on subjects along with PNF Exercises.
219473699|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
219473700|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
219596218|NCT04738695|DIAGNOSTIC_TEST|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
218857726|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
219473701|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
218857727|NCT05017818|OTHER|Observational retrospective data|Non-intervention
219473702|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
219473703|NCT00005803|DRUG|Carmustine|Given IV
219473704|NCT00005803|DRUG|Cyclophosphamide|Given IV
219473705|NCT00005803|DRUG|Cyclosporine|Given PO
219473706|NCT00005803|DRUG|Cytarabine|Given IV
219473707|NCT00005803|DRUG|Etoposide|Given IV
219473708|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
219473709|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
219596219|NCT05605899|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
219596220|NCT05605899|DRUG|Cyclophosphamide|Administered intravenously
218857728|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
218857729|NCT04150952|OTHER|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
219473710|NCT00005803|DRUG|Melphalan|Given IV
219473711|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
219473712|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
219473713|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
219473714|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
219473715|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
219473716|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
219473717|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
219473718|NCT04173520|DRUG|DDA|Follow up after SVR
219473719|NCT04100616|OTHER|No intervention|There is no intervention for this study
219473720|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
219473721|NCT00157638|DRUG|optimizing therapeutic treatments|
219473722|NCT00157638|BEHAVIORAL|optimizing processes of care|
219473723|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
219596221|NCT05605899|DRUG|Fludarabine|Administered intravenously
219596222|NCT05605899|DRUG|Etoposide|Administered intravenously
219596223|NCT05605899|DRUG|Rituximab|Administered intravenously
219596224|NCT05605899|DRUG|Doxorubicin|Administered intravenously
219596225|NCT05605899|DRUG|Vincristine|Administered intravenously
219596226|NCT05605899|DRUG|Prednisone|Administered orally
219473724|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
218857730|NCT04150952|OTHER|TRAD training|Traditional endurance training
218857731|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
219473725|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
219473726|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
219473727|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
219596227|NCT02931981|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
219596228|NCT03474458|DRUG|Doxycycline|Doxycycline
219596229|NCT03474458|DRUG|Standard of care therapy|Standard of care therapy
219596230|NCT00588458|PROCEDURE|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
219473728|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
219473729|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
219473730|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
219473731|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
219596231|NCT05461196|BEHAVIORAL|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
219596232|NCT03300843|BIOLOGICAL|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
219596233|NCT00549679|DRUG|GSK256066|PDE4 inhibitor
219596234|NCT00549679|DRUG|Placebo|Placebo
219596235|NCT04577664|PROCEDURE|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
219596236|NCT04577664|PROCEDURE|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
219596237|NCT05516979|DRUG|100 mg AP1189|AP1189 tablets for oral use
219596238|NCT05516979|DRUG|Placebo|Matching placebo for oral use
219596239|NCT04011670|OTHER|200 mg caffeine tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
219596240|NCT04011670|OTHER|Non-active tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
219473732|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
219473733|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
219473734|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
219473735|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
219473736|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
219473737|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
219473738|NCT04337463|DRUG|ATG-008|Tablet
219473739|NCT04337463|DRUG|Toripalimab|IV infusion
219473740|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
219473741|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
219473742|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
219473743|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
219473744|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
219473745|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
219473746|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
219473747|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
219473748|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
219473749|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
219473750|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
219473751|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
219473752|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
219473753|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
219473754|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
219473755|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
219473756|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
219473757|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
219473758|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
219473759|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
219473760|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
219473761|NCT05877508|OTHER|Placebo|Placebo infusion
219473762|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
219596241|NCT05096832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
219473763|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
219473764|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
219473765|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
219473766|NCT04435431|DRUG|Mesdopetam|Oral use
219473767|NCT04435431|DRUG|Placebo|Oral use
219596242|NCT05096832|BIOLOGICAL|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
219596243|NCT04482387|DEVICE|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
219596244|NCT04462887|BEHAVIORAL|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
219473768|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
219473769|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
219596245|NCT03938285|OTHER|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
219596246|NCT03938285|OTHER|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
219596247|NCT04566289|DEVICE|PiCSO|Percutaneous coronary intervention
218857732|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
218857733|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
219473770|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
219473771|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
219473772|NCT02059265|DRUG|Dasatinib|Given PO
219473773|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
219473774|NCT00433368|DRUG|L-Ornithine L-Aspartate|
219473775|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
219473776|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
219473777|NCT00036621|DRUG|BMS-275291|
219473778|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
219473779|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
219473780|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
219473781|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
219473782|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
219473783|NCT01725204|DRUG|Dasatinib + PegIFN|
219596248|NCT01517958|OTHER|Respiratory Distress Group|Diagnostic lung ultrasound.
219596249|NCT01517958|OTHER|Control Group|Lung ultrasound
219596250|NCT04322058|OTHER|The Dads' Club|The core intervention is Core 24/7 workshop attendance
219596251|NCT05652595|DRUG|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
219596252|NCT05652595|DRUG|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
219596253|NCT03000478|BEHAVIORAL|Prolonged Exposure|
219596254|NCT03000478|BEHAVIORAL|Virtual Reality Exposure Therapy|
219596255|NCT01366625|DEVICE|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
219596256|NCT03545893|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
219596257|NCT03545893|DRUG|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
219596258|NCT06239857|PROCEDURE|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
219596259|NCT02964572|DRUG|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
219473784|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
219596260|NCT02964572|DRUG|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
219596261|NCT01535092|DRUG|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
219596262|NCT01535092|DRUG|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
219596263|NCT03458299|BEHAVIORAL|Motivational Interviewing|2 hours of motivational interviewing
219596264|NCT03458299|BEHAVIORAL|Psychoeducation|2 hours of DVD viewing and discussion
218857734|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
218857735|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
218857736|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
218857737|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
218857738|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
218857739|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
218857740|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
218857741|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
218857742|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
218857743|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
218857744|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
218857745|NCT05240521|OTHER|ARM A|30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
218857746|NCT05240521|OTHER|ARM B|30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days
218857747|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
219199319|NCT06814951|PROCEDURE|TAR Method|Patients selected for the intervention group will undergo thoracoabdominal rebalancing management such as abdominal supports and/or in the ileocostal space, inspiratory assistance, release of the shoulder girdle, thoracic balance, release of the pectoralis major and deltoid muscles together with aspiration if necessary.
219596265|NCT02460406|OTHER|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).
218857748|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
219199320|NCT06814951|PROCEDURE|Conventional physiotherapy|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, acceleration of expiratory flow, fractional inspiration in times, diaphragmatic breaths and aspiration when necessary.
219363487|NCT04846361|OTHER|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
219363488|NCT04697329|DRUG|Preincisional infiltration with levobupivacaine|Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
218857749|NCT03497364|DRUG|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
218857750|NCT03497364|DRUG|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
218857751|NCT04631965|BEHAVIORAL|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
218857752|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
218857753|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
219363489|NCT02568358|OTHER|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
219363490|NCT01780792|OTHER|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
219363491|NCT05252793|BEHAVIORAL|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
219363492|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
219363493|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
219363494|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
219596266|NCT02460406|OTHER|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
218857754|NCT06006624|DRUG|Exparel 30 mL|30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
219473785|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
218857755|NCT06006624|DRUG|0.5% bupivacaine|5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
218857756|NCT06006624|DRUG|Dexamethasone|10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
218857757|NCT06006624|DRUG|iPACK block|iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
218857758|NCT01106508|DRUG|LEQ506|
218857759|NCT06331468|DRUG|Cisplatin|A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
218857760|NCT06331468|RADIATION|intensity modulated radiation therapy (IMRT)|given once daily Monday-Thursday, four fractions per week for 2 weeks. The radiation dose is 4.56 Gy x 8 fractions.
218857761|NCT06331468|RADIATION|high-dose-rate (HDR) brachytherapy|administered 2x weekly (allow at least 72-hours window between sessions); weekdays only for 2 weeks. The radiation dose is 7 Gy x 4 fractions.
219596267|NCT01873183|OTHER|Goal directed fluid therapy|
219596268|NCT01285297|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
219596269|NCT03059797|DRUG|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
219596270|NCT03059797|DRUG|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
218857762|NCT06764771|DRUG|BMS-986488|Specified dose on specified days
218857763|NCT06764771|DRUG|Adagrasib|Specified dose on specified days
218857764|NCT06764771|DRUG|Cetuximab|Specified dose on specified days
218857765|NCT06764771|DRUG|Nivolumab|Specified dose on specified days
219596271|NCT05696379|OTHER|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
219596272|NCT02498041|PROCEDURE|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
218857766|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
218857767|NCT05320393|DRUG|OnabotulinumtoxinA|One treatment of 20 units
218857768|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
218857769|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
218857770|NCT06503380|OTHER|No intervenrion.|This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
218857771|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
218857772|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
218857773|NCT05964335|DRUG|NAL ER|Oral tablets
218857774|NCT05964335|DRUG|Placebo|Oral tablets
218857775|NCT05964335|DRUG|NAL ER|Oral Tablets
218857776|NCT05964335|DRUG|NAL ER|Oral tablets
218857777|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
218857778|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
218857779|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
218857780|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
219199321|NCT06827548|DEVICE|vagal nerve stimulation|"Cervical neck electrodes used in this part of the study will include the multi electrode array (MEA). The MEA can be placed on either side of the neck over the area of the vagus nerve to record any electrical activity that might occur during the baseline period.~Two ECG electrodes are placed either one on each arm or on the chest for measurement of the electrocardiogram (ECG).~Three ECG electrodes are placed on the abdomen in a line parallel to the longitudinal axis of the stomach to record the electrogastrogram (EGG).~A onetime baseline recording will be made for 20 minutes after which the subject will be discharged from the study."
219596273|NCT02498041|DEVICE|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
219596274|NCT02498041|DEVICE|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
219596275|NCT02498041|PROCEDURE|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
219596276|NCT03817541|DEVICE|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
219596277|NCT02786225|BEHAVIORAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
219596278|NCT02786225|BEHAVIORAL|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
219363495|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
219363496|NCT00142129|DRUG|Bortezomib (Velcade)|
219363497|NCT05616702|OTHER|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~* prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~* Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~* Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~* Duration: 15 mins~* Frequency: 3 sessions/ week~* Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
219363498|NCT05616702|OTHER|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
219363499|NCT01934569|DRUG|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
219363500|NCT05034900|OTHER|Chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.
219363501|NCT05034900|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) device|Shaker® device will be used.
219363502|NCT01727258|DEVICE|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
219596279|NCT03957525|OTHER|Pre-Operative Preparatory Virtual Reality Program|The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
219596280|NCT05489614|DRUG|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
218857781|NCT02248207|DRUG|Pramipexole|
219363503|NCT01727258|DRUG|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
219363504|NCT01727258|DRUG|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
219363505|NCT02857218|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
219363506|NCT02857218|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
219363507|NCT01409603|DRUG|darexaban|oral
219363508|NCT01409603|DRUG|Naproxen|oral
219363509|NCT02296411|DRUG|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
219363510|NCT02296411|DRUG|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
219473786|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
219473787|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
219596281|NCT05368116|OTHER|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
219596282|NCT05368116|OTHER|Standard of care|Standard of care
219596283|NCT05301595|PROCEDURE|TAP block|Please see description of TAP block group.
219596284|NCT05301595|PROCEDURE|QL Block|Please see description of QL block group.
219596285|NCT02029196|OTHER|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
219596286|NCT02029196|OTHER|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
219596287|NCT02847871|BEHAVIORAL|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~* Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~* Perform a nutritional assessment by a dietician followed by appropriate care management.~* Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~* At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~* Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
219596288|NCT02715570|DRUG|PC945 - single doses|Safety and tolerability of single doses
219596289|NCT02715570|DRUG|Placebo - single doses|Safety and tolerability of single doses
219596290|NCT02715570|DRUG|PC945 - repeat doses|Safety and tolerability of repeat doses
219596291|NCT02715570|DRUG|Placebo - repeat doses|Safety and tolerability of repeat doses
219596292|NCT00451945|PROCEDURE|biopsy|
219473788|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
219596293|NCT00451945|DEVICE|3d-ultrasound and fusion of UL and PET/CT|
219596294|NCT01109147|OTHER|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
219596295|NCT01109147|GENETIC|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
219596296|NCT03518645|DEVICE|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
219596297|NCT03518645|DEVICE|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
219596298|NCT03585920|BEHAVIORAL|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
219596299|NCT01320891|BEHAVIORAL|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
219596300|NCT01320891|BEHAVIORAL|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
219596301|NCT00479960|BEHAVIORAL|commercially available omega-3 fatty acids supplementation|
218857782|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
218857783|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
219473789|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
219596302|NCT04999891|OTHER|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
219596303|NCT05786846|DRUG|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
219596304|NCT02952586|DRUG|Avelumab|Avelumab + SOC Chemoradiation
219596305|NCT02952586|OTHER|Chemoradiation|Cisplatin + Radiation Therapy
219596306|NCT01121081|DRUG|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
219596307|NCT01121081|DRUG|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
219596308|NCT00435760|DRUG|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
219596309|NCT00435760|DRUG|Placebo Tiotropium|1 puff once daily, 1 day treatment
218857784|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
218857785|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
218857786|NCT02857192|BIOLOGICAL|Blood samples|
218857787|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
218857788|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
218857789|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
218857790|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
218857791|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
219473790|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
219473791|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
218857792|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
218857793|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
218857794|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
219473792|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
219473793|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
218857795|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
218857796|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
218857797|NCT01932255|PROCEDURE|prophylactic spinal tap|
218857798|NCT01932255|PROCEDURE|no prophylactic spinal tap|
219473794|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
219473795|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
219473796|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
219473797|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
219473798|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
219596310|NCT00435760|DRUG|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
218857799|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
219473799|NCT06309069|OTHER|None, purely observational study|None, purely observational study
219473800|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
219473801|NCT04753606|DRUG|Obicetrapib|tablets
219473802|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
219473803|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
219473804|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
219473805|NCT00489411|OTHER|placebo|Given orally
218857800|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
219473806|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
219473807|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
219473808|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
219596311|NCT00435760|DRUG|Placebo LAS34273|1 puff, 1 dat treatment
218857801|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
218857802|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
218857803|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
218857804|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
219473809|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
219473810|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
219596312|NCT04936165|PROCEDURE|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
219596313|NCT02490644|PROCEDURE|Blood sampling|Blood sampling 5ml
219596314|NCT04682925|OTHER|skin care arm of where evidence-based practices in the implementation guide|"1. The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~2. A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~3. Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~4. The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
219596315|NCT04682925|DEVICE|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
219596316|NCT04682925|OTHER|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
219596317|NCT01767324|DEVICE|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
219596318|NCT01767324|DEVICE|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
219596319|NCT01767324|DEVICE|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
219596320|NCT04594824|OTHER|No Intervention|no intervention
219596321|NCT02796638|DEVICE|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
219596322|NCT03743155|BIOLOGICAL|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
219596323|NCT00030225|BIOLOGICAL|ELAD|
219596324|NCT00030225|OTHER|Standard of care (Control)|
219596325|NCT02106234|OTHER|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
219596326|NCT03375177|OTHER|Natural history of disease|registry plan
219596327|NCT03915405|DRUG|KHK2455|orally, once daily.
219596328|NCT03915405|DRUG|Avelumab|IV Administration
219596329|NCT02567877|PROCEDURE|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
219596330|NCT02567877|DRUG|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
219596331|NCT00055367|DRUG|natalizumab|
219596332|NCT01661062|OTHER|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
219596333|NCT04411914|DRUG|Clavulanic Acid|Drug will be given in 250mg capsules.
219596334|NCT04411914|OTHER|Placebo|Placebo
219596335|NCT04284059|DRUG|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
219596336|NCT04284059|DIETARY_SUPPLEMENT|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
219596337|NCT04284059|DIETARY_SUPPLEMENT|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
219596338|NCT01375179|DRUG|KRP203|
219596339|NCT01375179|DRUG|Placebo matching KRP203|
219596340|NCT02569918|DEVICE|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
218857805|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
218857806|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
219473811|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
219473812|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
218857807|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
219473813|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
219473814|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
219473815|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
219473816|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
219473817|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
219473818|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
219473819|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
219473820|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
219473821|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
219473822|NCT06566729|OTHER|Peripheral blood sample collection|In this study, peripheral blood samples would be collected before adjuvant chemotherapy, after adjuvant chemotherapy and every 3 months thereafter until 2 years after surgery.
219473823|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
219473824|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
219473825|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
218857808|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
218857809|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
218857810|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
219473826|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
219473827|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
219473828|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
219473829|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
219596341|NCT01581125|BEHAVIORAL|Sleep:wake 1|Sleep and Wake durations for arm 1
219596342|NCT01581125|BEHAVIORAL|Sleep:wake 2|Sleep and Wake durations for arm2
219596343|NCT01778634|DRUG|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
219596344|NCT01778634|DRUG|Placebo|D5W
218857811|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
218857812|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
218857813|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
218857814|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
218857815|NCT01930890|BIOLOGICAL|BIIB023|
218857816|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
218857817|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
218857818|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
218857819|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
218857820|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
218857821|NCT01278407|DRUG|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
218857822|NCT01278407|DRUG|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
218857823|NCT01278407|DRUG|Donepezil matched placebo|
218857824|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
218857825|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
218857826|NCT05883943|DEVICE|Cook® Venous Valve System|The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
218857827|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
219473830|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
219473831|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
219596345|NCT01072617|DEVICE|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
219596346|NCT03168334|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
218857828|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
219473832|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
219473833|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
219473834|NCT01748162|DRUG|Prednisolone IF needed|
219596347|NCT03168334|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
218857829|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
218857830|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
218857831|NCT02241876|DRUG|N-acetylcysteine|
218857832|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
218857833|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
219473835|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
219473836|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
219473837|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
219473838|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
219473839|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
219473840|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
219473841|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
219596348|NCT05456958|OTHER|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
219596349|NCT05456958|OTHER|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
219199322|NCT02044484|BEHAVIORAL|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
219473842|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
219473843|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
219473844|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
219596350|NCT00979641|DRUG|Docetaxel|
219473845|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
219473846|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
219473847|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
219596351|NCT05440318|DEVICE|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
219596352|NCT02876718|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
219596353|NCT05906524|DRUG|KD6001|KD6001 will be administered intravenously.
219596354|NCT05906524|DRUG|Tislelizumab|Tislelizumab will be administered intravenously.
218857834|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
218857835|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
218857836|NCT05394532|OTHER|Education|Common Education
218857837|NCT03633279|DRUG|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
218857838|NCT03633279|DRUG|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
218857839|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
218857840|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
218857841|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
219199323|NCT06862726|DRUG|Anti Xa dosage|VKA: quadriseparable tablet Apixaban: 5 mg twice daily or 2.5 twice daily Rivaroxaban: 20 mg once a day or 15 mg once a day
219199324|NCT06862726|DRUG|Dosage of PT-INR|This arm contain 40 pateints treated by VKA,. PT-INR dosage will be performed.
218857842|NCT04431713|DRUG|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
219199325|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program|Online program (mindful movement, meditation, breathwork)
219199326|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program + Nutritional Counselling|Online program (mindful movement, meditation, breathwork) + nutrition counselling
219199327|NCT06861842|DRUG|Theralite®|Reference
219199328|NCT06861842|DRUG|Actilitio®|Test
219199329|NCT06862414|DEVICE|Smartphone-based deep learning system|The smartphone-based deep learning system was trained using a dataset of over 50,000 white-light macroscopic images collected between 2006 and 2013 to develop the YOLOv7 model. Lesions were categorized into three referral grades: benign (green), potentially malignant (yellow), and malignant (red).
219199330|NCT06862349|DRUG|Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
219473848|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
219473849|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
219473850|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
219473851|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
219473852|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
218857843|NCT02238314|DRUG|Tipranavir low dose|
218857844|NCT02238314|DRUG|Tipranavir high dose|
218857845|NCT02238314|DRUG|Ritonavir|
218857846|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
218857847|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
218857848|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
218857849|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
218857850|NCT02855957|OTHER|Free α-Hb pool analysis|
218857851|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
218857852|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
218857853|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
218857854|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
218857855|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
218857856|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
218857857|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
219473853|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
219473854|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
219473855|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
219473856|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
219473857|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
219473858|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
219473859|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
219596355|NCT05906524|DRUG|Bevacizumab|Bevacizumab will be administered intravenously.
218857858|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
218857859|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
219596356|NCT03944824|OTHER|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
219596357|NCT03944824|DIAGNOSTIC_TEST|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
219596358|NCT01034956|DEVICE|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
219596359|NCT01504997|DEVICE|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
219596360|NCT01495078|PROCEDURE|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
219596361|NCT03296111|OTHER|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~* Questionnaire about the characteristics of ocular neuropathic pain (7 items)~* DEQ-5 (Dry Eye Questionnaire)~* ODI (Ocular Surface Disease Index)~* BPI (Brief Pain Inventory)~* HADS (Hospital Anxiety and Depression Scale)"
219596362|NCT05198180|DRUG|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
219596363|NCT05198180|DRUG|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
219596364|NCT06063057|BIOLOGICAL|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
219596365|NCT06063057|BIOLOGICAL|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
219596366|NCT06063057|BIOLOGICAL|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
219596367|NCT06063057|BIOLOGICAL|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
219596368|NCT06434974|OTHER|Interview|Interviewer administered questionnaire
218857860|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
218857861|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
218857862|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
218857863|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
218857864|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
218857865|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
219199331|NCT06862349|DRUG|Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist.|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
219473860|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
219473861|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
219473862|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
219473863|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
219473864|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
219473865|NCT02433522|DRUG|Placebo|
219473866|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
219473867|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
218857866|NCT05854576|PROCEDURE|vascular acess|AVF
218857867|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
219473868|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
219473869|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
218857868|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
218857869|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
218857870|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
218857871|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
219473870|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
219473871|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
218857872|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
218857873|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
218857874|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
218857875|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
218857876|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
219473872|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
219473873|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
219473874|NCT06250660|DIETARY_SUPPLEMENT|Strawberry Intervention|"This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries."
219473875|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
218857877|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
218857878|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
218857879|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
218857880|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
218857881|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
218857882|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
218857883|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
219473876|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
219473877|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
219473878|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
218857884|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
218857885|NCT00049608|DIETARY_SUPPLEMENT|mistletoe extract|
218857886|NCT00049608|DRUG|gemcitabine hydrochloride|
218857887|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
218857888|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
218857889|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
218857890|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
219473879|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
218857891|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
219473880|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
219473881|NCT04389008|OTHER|no interventions|no interventions
219473882|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
219473883|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
219473884|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
219473885|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
219596369|NCT01917292|PROCEDURE|One-Stage Full-Mouth Disinfection|"1. Basic oral hygiene instructions~2. Dental extractions will be performed (only in cases of teeth that could not be saved)~3. Standard cycle of supragingival ultrasonic scaling and polishing~4. Scaling and root planning after the administration of local anesthesia, four quadrants in one session~5. Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
219596370|NCT01917292|PROCEDURE|Periodontal care|"1. Basic oral hygiene instructions~2. Standard cycle of supragingival ultrasonic scaling and polishing"
218857892|NCT00118352|DRUG|fludarabine phosphate|Given IV
218857893|NCT00118352|DRUG|cyclosporine|Given PO or IV
218857894|NCT00118352|DRUG|mycophenolate mofetil|Given PO
218857895|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
218857896|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
218857897|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
218857898|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
218857899|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
218857900|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
219596371|NCT02304666|PROCEDURE|Colonoscopy for biopsies samples|
218857901|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
218857902|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
219596372|NCT00098423|DRUG|tanespimycin|Given IV
219596373|NCT00098423|DRUG|cytarabine|Given IV
219596374|NCT03138408|DRUG|SC-004|Intravenous
219596375|NCT03138408|DRUG|ABBV-181|Intravenous
218857903|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
218857904|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
218857905|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
218857906|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
218857907|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
218857908|NCT04337736|OTHER|Physical exercise|
218857909|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
219473886|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
218857910|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
218857911|NCT02159222|PROCEDURE|Additional physical therapy|
218857912|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
218857913|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
218857914|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
218857915|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
218857916|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
218857917|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
218857918|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
218857919|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
218857920|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
218857921|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
218857922|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
218857923|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
218857924|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
218857925|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
219473887|NCT03948646|DRUG|Vehicle|Vehicle gel
219473888|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
219473889|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
219473890|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
219473891|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
219473892|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
219473893|NCT06385275|DRUG|Vitamin K1 500 µg|One pill daily for 4 weeks.
219473894|NCT06385275|DRUG|K1 1000 µg|One pill daily for 4 weeks.
219473895|NCT06385275|DRUG|Vitamin K2 (MK-7) 300 µg|One pill daily for 4 weeks.
219473896|NCT06385275|OTHER|Placebo|Placebo pill daily for 4 weeks.
219473897|NCT05355506|DEVICE|Application|Knowledge \& record
219473898|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
219473899|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
219473900|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
219473901|NCT01901393|DRUG|IV ibuprofen|
219473902|NCT01901393|DRUG|Ketorolac|
219473903|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
219473904|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
219473905|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
219473906|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
219473907|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
219473908|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
219596376|NCT06500325|PROCEDURE|retrograde titanium elastic nails for fixation of proximal third tibial shaft fractures in children|Two TENs were used in all cases using the double-C construct in most cases to gain three point of fixation. The starting point for nail insertion is 1.5-2.0 cm proximal to the physis of distal tibia. Both nails are then inserted through the entry holes and advanced to pass the level of the fracture site to achieve fixation. The two incisions for nail entry are closed in a layered fashion, and the wounds are well padded with gauze.
218857926|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
218857927|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
218857928|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
218857929|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
219199332|NCT06860698|OTHER|E-cig use|Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes
219199333|NCT06856109|DIAGNOSTIC_TEST|68Ga-Pentikra PET/CT Scan|68Ga-Pentikra Injection, Intravenous, administered at 0.05 mCi/kg by weight.
219473909|NCT02823782|OTHER|neuropsychological assessment|
219473910|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
219199334|NCT06861166|DRUG|Geranium wilfordii combined with androgen deprivation treatment|Geranium wilfordii 15g decoction (Geranium 15g, decocted by the decocting machine in the decocting room of the pharmacy Department of the hospital) was taken orally, 200mL/ time, once/day, for 3 months + continuous androgen deprivation treatment
219199335|NCT06861166|DRUG|Androgen deprivation treatment|Continuous androgen deprivation therapy
219473911|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
219473912|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
219473913|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
219473914|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
219473915|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
219596377|NCT00693095|BIOLOGICAL|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
219473916|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
219473917|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
219473918|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
219473919|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
219473920|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
219473921|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
219596378|NCT00693095|BIOLOGICAL|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
219596379|NCT02468050|BEHAVIORAL|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
218857930|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
219199336|NCT06861166|PROCEDURE|radical prostatectomy|After completion of treatment, radical prostatectomy was performed 3 weeks later (±7 days).
219473922|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
219473923|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
219473924|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
219473925|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
219596380|NCT02468050|BEHAVIORAL|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
218857931|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
219473926|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
218857932|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
218857933|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
218857934|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
218857935|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
218857936|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
218857937|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
219596381|NCT00711035|BIOLOGICAL|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
219199337|NCT06666361|OTHER|Experimental Group|"The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator.~The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window."
219473927|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
219473928|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
219473929|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
219596382|NCT04236934|OTHER|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
219596383|NCT04233996|DRUG|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
219473930|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
219473931|NCT00596466|DRUG|pregabalin|pregabalin
219473932|NCT02223624|OTHER|walking and light weights|
219473933|NCT02223624|OTHER|eccentric aerobic exercise|
219596384|NCT04233996|DRUG|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
219596385|NCT04233996|DRUG|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
219473934|NCT02223624|OTHER|concentric aerobic exercise|
219596386|NCT04462432|OTHER|no intervention|This is an observation study, with no intervention.
219596387|NCT05873933|OTHER|Hemptress Oil|Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
219596388|NCT04669561|DRUG|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
219199338|NCT06666361|OTHER|control group|The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
219473935|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
219473936|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
219473937|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
219473938|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
219473939|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
219473940|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
219473941|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
219596389|NCT05468801|OTHER|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
219596390|NCT05468801|OTHER|Placebo|Placebo plus Standard Pharmacologic Treatment
219473942|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
219473943|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
219473944|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
219473945|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
219473946|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
219596391|NCT03338725|OTHER|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
219596392|NCT00051935|DRUG|Alglucosidase alfa|20 mg/kg (qow); intravenous
219596393|NCT00626808|DRUG|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
219596394|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
219596395|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
219596396|NCT00047112|DRUG|cisplatin|
219596397|NCT00047112|DRUG|fluorouracil|
219596398|NCT00047112|PROCEDURE|conventional surgery|
219596399|NCT00047112|PROCEDURE|neoadjuvant therapy|
219596400|NCT00047112|RADIATION|radiation therapy|
219473947|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
218857938|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
219199339|NCT06269926|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP consists of skill-based therapy sessions completed weekly for 12 weeks. Participants are oriented to CBT and set individualized goals (sessions #1-3) before focusing on cognitive and behavior skill building including physical activity, pacing, relaxation training, and cognitive restructuring (#4-10) then focusing on maintenance and discharge planning (#11-12). It will be completed in Maryland in an online real-time audio/video virtual group therapy format.
219199340|NCT06670027|OTHER|Family voice|Group A receives the family voice
219473948|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
219473949|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
219473950|NCT00117975|BIOLOGICAL|galiximab|given IV
218857939|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
219199341|NCT06670027|OTHER|Nature sound|Group B receives the nature sound.
219199342|NCT05545449|BEHAVIORAL|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
219199343|NCT05243966|DEVICE|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
219473951|NCT00117975|BIOLOGICAL|rituximab|Given IV
219473952|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
219473953|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
219596401|NCT00643812|OTHER|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
219596402|NCT00643812|OTHER|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
219596403|NCT03203122|OTHER|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
219596404|NCT03203122|OTHER|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
219473954|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
219473955|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
219473956|NCT00353392|DEVICE|Laser Therapy|
219473957|NCT04717466|BIOLOGICAL|Secukinumab|300mg subcutaneous injection
219473958|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
219473959|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
219473960|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
219473961|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
219473962|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
219473963|NCT04616183|DRUG|Abemaciclib|Given PO
219473964|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
219473965|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
219473966|NCT03155061|DRUG|ONO-4578|ONO-4578 specified dose on specified days
219473967|NCT03155061|DRUG|ONO-4538|ONO-4538 specified dose on specified days
219473968|NCT05876923|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219473969|NCT05876923|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
219473970|NCT05876923|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
219473971|NCT05876923|OTHER|Electronic Health Record Review|Ancillary studies
219473972|NCT05876923|OTHER|Exercise Intervention|Undergo aerobic based training program
219473973|NCT05876923|PROCEDURE|Physical Examination|Undergo measurement of height/weight and vital signs
219596405|NCT03555123|DRUG|Simdax|Levosimendan2.5mg/ml
219596406|NCT03226535|DEVICE|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
219473974|NCT05876923|OTHER|Questionnaire Administration|Ancillary studies
219473975|NCT05876923|PROCEDURE|Spirometry|Undergo spirometry
219473976|NCT05876923|OTHER|Physical Performance Testing|Undergo muscular strength and functional endurance measurements
219473977|NCT05876923|OTHER|Best Practice|Receive usual care
219473978|NCT05219110|OTHER|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing \< 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
219473979|NCT05219110|OTHER|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
219473980|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
219473981|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
219473982|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
219473983|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
219473984|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
219473985|NCT00078663|BEHAVIORAL|Oral Care|
219473986|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
219473987|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
219473988|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
219473989|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
219473990|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
219473991|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
219596407|NCT02208830|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
219596408|NCT02208830|OTHER|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
219596409|NCT03396003|DEVICE|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
219596410|NCT03396003|DEVICE|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
219596411|NCT03953326|BEHAVIORAL|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
219596412|NCT03953326|DRUG|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
219596413|NCT03953326|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
219596414|NCT03953326|DRUG|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
219596415|NCT00621270|DRUG|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
219473992|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
219473993|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
219473994|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
219473995|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
219473996|NCT01298323|BEHAVIORAL|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
219473997|NCT01298323|DRUG|Vandetanib|Treatment 300mg vandetanib opel label.
219473998|NCT01333046|BIOLOGICAL|Antigen-Escalation Stage|"Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~* Day 0: PRAME-specific T cells~* Day 28: PRAME- and SSX-specific T cells~Schedule Two:~* Day 0: PRAME- and SSX-specific T cells~* Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~* Day 0: PRAME/SSX/MAGE-specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
219596416|NCT05051514|DIAGNOSTIC_TEST|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
219596417|NCT00820781|PROCEDURE|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
219596418|NCT00820781|PROCEDURE|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
219596419|NCT01586507|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
219596420|NCT01586507|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
219199344|NCT04870359|PROCEDURE|Pre-emptive increase of immunosuppressive treatments|"1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day."
219473999|NCT01333046|BIOLOGICAL|Dose-Escalation Stage|"Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2~DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2~DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2"
219474000|NCT01333046|BIOLOGICAL|azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~1. ANC \>1,000 or Platelets \>50,000 (or any other grade I AE attributable to aza)~   Adjustment: None~2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~   Adjustment: 50% dose reduction~3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion"
219474001|NCT01333046|BIOLOGICAL|Pediatric multiTAA T cells Stage|Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
219474002|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
219474003|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
219474004|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
219474005|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
219474006|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
219474007|NCT04567771|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
219474008|NCT04567771|OTHER|Questionnaire Administration|Complete adverse event assessments
219474009|NCT04567771|RADIATION|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
219199345|NCT04870359|DRUG|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
219474010|NCT05312411|BIOLOGICAL|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
219474011|NCT05312411|DRUG|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
219474012|NCT04875611|DRUG|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
219474013|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
219474014|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
219474015|NCT02184234|DRUG|Antistax film coated tablets|
219474016|NCT06452316|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
219474017|NCT02118467|DRUG|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
218857940|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
218857941|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
219474018|NCT02118467|DRUG|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
219474019|NCT02118467|DRUG|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
219474020|NCT02118467|DRUG|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
219474021|NCT04902378|DEVICE|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
219474022|NCT06321471|DEVICE|AeviceMD|AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
219474023|NCT05847751|DEVICE|Aortic valve replacement|Trans Aortic Valve Replacement (TAVI)
219474024|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
219474025|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
219474026|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
219474027|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
219474028|NCT06815055|OTHER|Quality of life questionnary|Subjects will be call 1 month and 6 months after prostetectomy to evaluate the type of reeducation received and they will be evaluated with the help of QoL questionnaries : KHQ-HR QoL and ICIQ-SF QoL
219474029|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
219474030|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
219596421|NCT02548169|BIOLOGICAL|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
219596422|NCT04349943|OTHER|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
219596423|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 70%|The incubator will be set to an ambient relative humidity (RH) of 70%.
219596424|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 90%|The incubator will be set to an ambient relative humidity (RH) of 90%.
219596425|NCT00345943|OTHER|MRI|Magnetic Resonance Imaging scans
219596426|NCT00345943|BEHAVIORAL|Neuropsychological Testing|Neuropsychological tests
219596427|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
218857942|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
218857943|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
218857944|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
219474031|NCT06661694|DRUG|Treatment A|Single 875 mg dose of mevrometostat standard tablet formulation
219474032|NCT06661694|DRUG|Treatment B|Single 875 mg dose of mevrometostat alternative tablet formulation
219474033|NCT06661694|DRUG|Treatment C|Single 875 mg dose of mevrometostat alternative tablet formulation
219474034|NCT06661694|DRUG|Treatment D|Single 875 mg dose of mevrometostat alternative tablet formulation
219474035|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
219474036|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
219474037|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
219474038|NCT03572153|BEHAVIORAL|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
218857945|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
218857946|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
219474039|NCT03572153|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
219596428|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
218857947|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
218857948|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
218857949|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
218857950|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
218857951|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
218857952|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
218857953|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
218857954|NCT03384823|DRUG|Placebo|placebo to match EDP-938
218857955|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
218857956|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
218857957|NCT00499655|DRUG|celecoxib|Given orally
218857958|NCT00499655|OTHER|placebo|Given orally
218857959|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
218857960|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
218857961|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
218857962|NCT00499655|GENETIC|mutation analysis|Correlative studies
218857963|NCT00499655|GENETIC|protein expression analysis|Correlative studies
218857964|NCT00499655|GENETIC|gene expression analysis|Correlative studies
219596429|NCT03052868|OTHER|Cognitive Assessment|Cognitive testing session
219596430|NCT00789737|DRUG|Welchol|Welchol 625mg tablets
218857965|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
218857966|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
218857967|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
218857968|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
218857969|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
218857970|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
218857971|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
219596431|NCT00789737|DRUG|Placebo|placebo
219596432|NCT00891917|DIETARY_SUPPLEMENT|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
218857972|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
218857973|NCT02372708|DRUG|dinitrophenyl(DNP)|
218857974|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
218857975|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
218857976|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
218857977|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
218857978|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
218857979|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
218857980|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
218857981|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
218857982|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
218857983|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
218857984|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
218857985|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
218857986|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
218857987|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
218857988|NCT00136968|DRUG|Voriconazole|
218857989|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
218857990|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
218857991|NCT00915668|DRUG|JNJ-31001074|
218857992|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
218857993|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
219474040|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
219474041|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
218857994|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
218857995|NCT00003847|DRUG|biricodar dicitrate|
218857996|NCT00003847|DRUG|doxorubicin hydrochloride|
218857997|NCT00003847|DRUG|vincristine sulfate|
218857998|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
218857999|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
218858000|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
218858001|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
218858002|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
219474042|NCT06986109|DRUG|Ketamine|Ketamine (concentration 5mg/ml) will be administered at 0.05-ml/kg over 5-minutes followed by continuous intraoperative ketamine infusion of 0.05-ml/kg /h.
219596433|NCT00891917|DIETARY_SUPPLEMENT|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
218858003|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
218858004|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
218858005|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
218858006|NCT01035346|DRUG|Placebo|Single dose of a placebo
218858007|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
218858008|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
218858009|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
218858010|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
218858011|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
218858012|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
218858013|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
218858014|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
219199346|NCT05809986|OTHER|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
219596434|NCT02950818|BEHAVIORAL|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
219596435|NCT05354635|OTHER|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
219596436|NCT02870218|DRUG|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
218858015|NCT02654431|PROCEDURE|Cancer patients|Samples
219596437|NCT02870218|DRUG|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
219596438|NCT03489109|BEHAVIORAL|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
219596439|NCT03489109|OTHER|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
219596440|NCT04147923|DIETARY_SUPPLEMENT|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
218858016|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
218858017|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
218858018|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
218858019|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
218858020|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
219199347|NCT06488573|BEHAVIORAL|Nutritional intervention|7 individual sessions + 8 small group sessions
219199348|NCT04409795|DRUG|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
219596441|NCT04147923|DIETARY_SUPPLEMENT|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
219596442|NCT06201429|DEVICE|Mechanical Tissue Resuscitation (MTR™)|Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.
218858021|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
218858022|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
218858023|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
218858024|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
218858025|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
218858026|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
218858027|NCT00631150|DRUG|Levetiracetam (Keppra)|
218858028|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
218858029|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
218858030|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
218858031|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
219474043|NCT06986109|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
219474044|NCT06986109|DRUG|Placebo|Normal saline bolus 0.05-ml/kg will be administered over 5-minutes and it will be followed by continuous intraoperative normal saline infusion at 0.05-ml/kg /h.
219474045|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
219474046|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
219474047|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219474048|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
219474049|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
219474050|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
219596443|NCT00384930|DRUG|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
219596444|NCT00384930|DRUG|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
218858032|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
218858033|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
218858034|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
218858035|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
218858036|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
218858037|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
218858038|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
219474051|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
219474052|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
219474053|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
219596445|NCT00384930|DRUG|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
219596446|NCT00384930|DRUG|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
219020632|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
218858039|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
218858040|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
218858041|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
218858042|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
218858043|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
218858044|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
218858045|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
218858046|NCT06980961|PROCEDURE|short-pulse ND: YAG 1064 laser|Nd: YAG 1064 nm short pulse laser (5 nanoseconds), 4 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Smart, a Q-Switch Laser produced by Medical San (Lajeado, RS, Brazil).
218858047|NCT06980961|PROCEDURE|ultra-short-pulse ND: YAG 1064 laser|Nd: YAG1064 nm ultra-short pulse laser (400 picoseconds), 2 to 10 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for 6 visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Premium, a picolaser produced by Medical San (Lajeado, RS, Brazil).
218858048|NCT06980961|DRUG|cold cream|The control vehicle is a cold cream, supplied by HERVA'S manipulation pharmacy. The composition of cold cream will be beeswax, acetyl palmitate, BHA, cetearyl alcohol, propylparaben, and water. This topical agent will be applied to patients daily throughout the treatment period. It is scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days.
218858049|NCT06980792|PROCEDURE|Pancreatectomy and liver resection|Surgery for synchronous liver metastasis from PDAC with or without previous neoadjuvant chemotherapy
218858050|NCT06980792|DRUG|Chemotherapy|Chemotherapy alone in potentially resectable patients with PDAC and synchronous liver metastasis
218858051|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218858052|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
219474054|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
218858053|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218858054|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
218858055|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
218858056|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
218858057|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
218858058|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
219474055|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
219474056|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
219474057|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
219474058|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
219474059|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
219474060|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
219474061|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
219474062|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
219474063|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
219474064|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
219474065|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
219596447|NCT00384930|DRUG|placebo|Placebo tablet taken by mouth one a day for twelve weeks
218858059|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
219474066|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
219474067|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
219474068|NCT06995131|DIAGNOSTIC_TEST|Del 1|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. DEL 1 will be analyzed by ELISA
219474069|NCT06995131|DIAGNOSTIC_TEST|IL 17|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. IL 17 levels will be analyzed by ELISA
219474070|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
219474071|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
219474072|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
219474073|NCT00439010|DRUG|[123I] AV 39|
219474074|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
219474075|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
219474076|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
219474077|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
218858060|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
219474078|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
219474079|NCT03115723|PROCEDURE|Coronary angiography|
219474080|NCT05173025|DRUG|Fimasartan|\- Fimasartan group: fimasartan, 60 mg once a day, oral administration
218858061|NCT03313284|PROCEDURE|Control|No intervention
218858062|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
218858063|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
218858064|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
218858065|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
218858066|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
218858067|NCT02337283|DRUG|BI 425809|Tablets
218858068|NCT02337283|DRUG|Placebo|Tablets
218858069|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
219020633|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
219020634|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
219020635|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
219474081|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
219474082|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
219474083|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
219474084|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
219474085|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
219474086|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
219474087|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
219474088|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
219474089|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
219474090|NCT04235673|DRUG|placebo|orally administered drops
219474091|NCT07000214|DEVICE|Peripheral magnetic stimulation|During the warm-up exercise, 10-Hz rPMS will be applied to the tibialis anterior with an on-time of 4 seconds (40 pulses per train), followed by an off-time (inter-train interval) of 8 seconds, for a total of 25 trains for each leg. During the one-leg stance exercise, 20-Hz rPMS will be applied to the plantar surface of the standing foot for 3 seconds of on-time (60 pulses per train), followed by 12 seconds of off-time, for a total of 20 trains for each foot. Stimulation intensity will be set at 110% of MCT for the warm-up exercise and 120% of MCT for the treatment during the one-leg stance exercise.
219596448|NCT03471000|OTHER|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
218858070|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
218858071|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
218858072|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
218858073|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
218858074|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
218858075|NCT05074888|DRUG|Prospekta|Oral administration.
218858076|NCT05074888|DRUG|Placebo|Oral administration.
218858077|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
218858078|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
218858079|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
218858080|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
218858081|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
219474092|NCT07000214|BEHAVIORAL|Balance training|The warm-up exercise consists of 25 repetitions of 4-second active contractions of the tibialis anterior muscle in each leg while seated. Following the warm-up, participants will stand on the MAGBATA platform and perform 20 cycles of one-leg stance exercises under the supervision of a physiotherapist. Each cycle lasts 20 seconds, consisting of 3 seconds of one-leg stance while the other leg is raised about 10 centimeters above the ground, followed by 12 seconds of rest during which the participant stands on both legs, keeping their arms close to their body and hands free. The same sequence will then be repeated for the other leg. To prevent falling, participants will wear a safety belt around the waist, allowing the physiotherapist to assist if they lose balance. Participants will also be allowed to grab the walker positioned in front of them to prevent falling.
219474093|NCT07000214|OTHER|Sham stimulation|During the warm-up exercise, the stimulation coil will be placed perpendicular to the participants' shin. The same parameter settings will be used, except for the intensity, which will be set at 30% of the maximum stimulator output (MSO). Sham stimulation during the one-leg stance exercise is achieved by disconnecting the coil mounted in MAGBATA and placing an alternate coil, connected to the magnetic stimulator placed behind the participants so they can hear a clicking pattern similar to that of the rPMS-BT arm.
219474094|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
219474095|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
219474096|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
219474097|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
219474098|NCT06999486|OTHER|CAT well-being test|Evaluate the psychometric properties (e.g., reliability, validity) of the Computerized Adaptive Testing (CAT) system for assessing the well-being of caregivers of children with Type 1 Diabetes (T1D).
219474099|NCT06858085|OTHER|Turkish Version of the Late Life Function and Disability Instrument|The Late Life Function and Disability Instrument (LLFDI) was developed to assess significant changes in functional and disability categories
219474100|NCT07005882|DRUG|Elacestrant|Preoperative treatment
219474101|NCT07005882|RADIATION|PULSAR|Preoperative treatment
219474102|NCT07006038|DEVICE|Veinlite PEDI2|The Veinlite PEDI2 used before the catheter insertion.
219474103|NCT07007455|BEHAVIORAL|wrist extensor strength training with BFR.|Wrist extensor strength training without BFR.
219474104|NCT06867367|BEHAVIORAL|Isha Kriya and Naddi Shuddhi|Isha Kriya, a 15-minute guided meditation, and Nadi Shuddhi, a 3-5-minute alternate-nostril breathing practice. Participants in the intervention groups will be instructed to practice ideally twice or at least once daily.
219474105|NCT07005180|DRUG|HBI-002|Oral liquid containing carbon monoxide
219474106|NCT07005180|DRUG|Vehicle (placebo)|Vehicle control (placebo)
218858082|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
218858083|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
218858084|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
218858085|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
218858086|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
218858087|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
218858088|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
218858089|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
218858090|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
218858091|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
219199349|NCT04409795|DRUG|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
219199350|NCT06112340|DRUG|linsitinib|Study medication taken twice daily by mouth
219474107|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1000mg
219199351|NCT06865066|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy with acceptance commitment therapy components
219474108|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1500mg
219474109|NCT07007221|DRUG|Metformin|8 weeks of Metformin
219474110|NCT07007221|OTHER|Placebo|8 weeks placebo drug
219474111|NCT07007221|DRUG|Metformin|12 weeks of Metformin
219474112|NCT07007221|DRUG|Fluoxetine|12 weeks of Fluoxetine
219474113|NCT07007221|DRUG|Metformin+Fluoxetine|12 weeks of Metformin+Fluoxetine
219474114|NCT07007221|OTHER|double placebo|12 weeks of double placebo
219474115|NCT07006337|OTHER|Surgical Operating Room Enrichment Course|The intervention consists of multiple structured training sessions delivered during the gynecology rotation. Sessions include lectures on surgical principles and gynecologic procedures. The course is taught by OBGYN physicians and is designed to enhance students' proficiency in surgical techniques, perioperative care, and management of gynecologic emergencies. Educational materials are based on relevant surgical guidelines and textbooks
218858092|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
218858093|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
219474116|NCT07006337|OTHER|Active Comparator #1|Active Comparator #1
218858094|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
218858095|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
218858096|NCT04371822|OTHER|placebo|No Intervention
218858097|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
218858098|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
218858099|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
218858100|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
218858101|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
218858102|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
218858103|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
218858104|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
218858105|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
219199352|NCT04889066|RADIATION|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
219474117|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
219474118|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
219596449|NCT03471000|OTHER|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
219596450|NCT06111352|DRUG|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
219596451|NCT06111352|DRUG|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
219596452|NCT02181790|DEVICE|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
219596453|NCT02181790|DRUG|Acitretin|17.5mg/d
219596454|NCT01005277|OTHER|Laboratory Biomarker Analysis|Correlative studies
219596455|NCT01942889|DIETARY_SUPPLEMENT|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
219596456|NCT05255796|PROCEDURE|one-piece|Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
218858106|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
218858107|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
218858108|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
218858109|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
218858110|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
218858111|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
219474119|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
219474120|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
219474121|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
219474122|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
219596457|NCT05255796|PROCEDURE|plate-haptic|Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
219596458|NCT00927732|DRUG|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
218858112|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
218858113|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
218858114|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
218858115|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
218858116|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
219474123|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
219474124|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
218858117|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
219474125|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
219474126|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
219474127|NCT04373616|BIOLOGICAL|ACI-24|injections
219474128|NCT04373616|BIOLOGICAL|Placebo|injections
219474129|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
219474130|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
219474131|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
219474132|NCT05818215|OTHER|NO intervention|NO intervention
219474133|NCT02490111|DRUG|DWJ1319|
219474134|NCT02490111|DRUG|Placebo|
219596459|NCT00927732|DRUG|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
219596460|NCT00482807|DRUG|bicalutamide|
219596461|NCT00482807|DRUG|docetaxel|
218858118|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
219474135|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
219596462|NCT00482807|DRUG|goserelin|
219596463|NCT00482807|RADIATION|intensity-modulated radiation therapy|
219596464|NCT02798432|PROCEDURE|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
219596465|NCT02798432|DEVICE|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
219596466|NCT03107247|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
218858119|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
219596467|NCT01819610|DRUG|SPRIX|
218858120|NCT06601933|OTHER|Cognitive Training|"Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions."
218858121|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
218858122|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
218858123|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
218858124|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
218858125|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
218858126|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
218858127|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
218858128|NCT00101764|DRUG|Triamcinolone Acetonide|
218858129|NCT07041944|OTHER|HEMImprove APP|"Experimental Group:~Use HEMImprove 1.0 mobile app at home for 30 minutes/session, 5 days/week, for 4 weeks. Exercises tailored progressively with avatar guidance.~Control Group:~Perform conventional home exercises guided by printed manual with instructions and images, matching frequency and duration of intervention group."
219474136|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
219474137|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
218858130|NCT07041944|OTHER|exercises to upper limb|The patients will do the same exercises than the experimental group, without APP and using the same dosage
218858131|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
219474138|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
219474139|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
219596468|NCT05039138|OTHER|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
218858132|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
218858133|NCT07040540|PROCEDURE|Intradermal methylene blue injection|All eligible patients will receive an intradermal injection of 5 mL of 1% methylene blue into the quadrant of the breast where the tumor is located or into the subareolar region prior to skin incision, as part of the standard sentinel lymph node mapping procedure during elective breast surgery. After injection, the site will be massaged for 10 minutes to facilitate lymphatic uptake. The procedure will be performed under general anesthesia, and all other aspects of perioperative care will follow standard clinical practice.
218858134|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
218858135|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
218858136|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
218858137|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
219596469|NCT05039138|OTHER|traditional training exerises|traditional strength training exercises in group I
219596470|NCT03696238|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
219596471|NCT03696238|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
218858138|NCT02089113|DRUG|Dexamethasone|
218858139|NCT02089113|PROCEDURE|Placebo Vehicle|
219474140|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
219474141|NCT01255449|DRUG|albuterol|400 mcg by inhalation
218858140|NCT00380991|DRUG|lactoserum|
218858141|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
218858142|NCT01817673|DIETARY_SUPPLEMENT|placebo|
218858143|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
219020638|NCT02481245|DRUG|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
219199353|NCT04889066|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
219474142|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
219474143|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
219474144|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
219474145|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
219474146|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
219474147|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
219474148|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
219474149|NCT00106860|DRUG|a benzodiazepine drug|
219474150|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
219474151|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
219474152|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
219474153|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
219474154|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
219596472|NCT02845193|DEVICE|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
219596473|NCT02845193|DEVICE|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
219596474|NCT02845193|DEVICE|CAD/NAM|computer aided design NAM
219596475|NCT01323751|DRUG|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
219596476|NCT02613182|DRUG|NEOD001|NEOD001
219596477|NCT06168630|OTHER|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
219596478|NCT06168630|OTHER|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
219596479|NCT02493192|DRUG|pethidine and haloperidol injection|
218858144|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
219474155|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
219474156|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
219474157|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
219474158|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
219474159|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
219474160|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
219474161|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
219596480|NCT02493192|OTHER|birth ball|
219596481|NCT00194701|BEHAVIORAL|Walking exercise|
219474162|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
218858145|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
219474163|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
219596482|NCT01686230|OTHER|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
219596483|NCT01686230|DRUG|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
219596484|NCT04785755|DRUG|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
219596485|NCT04785755|DRUG|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
219596486|NCT04785755|DRUG|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
219596487|NCT03047434|OTHER||
219596488|NCT05809167|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
219596489|NCT01741883|BEHAVIORAL|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
219199354|NCT06865404|PROCEDURE|PIFPB block|The ultrasound probe will be positioned parallel and 2-3 cm lateral from the midline in the 4th or 5th intercostal space. The needle will be inserted in-plane in a cauda-cranial direction until the tip of the needle reaches the plane of the fascia between the pectoralis major muscle and the external intercostal muscles. A 20 ml volume of bupivacaine 0.25% will be injected on each side.
219474164|NCT01156636|DRUG|Placebo|
219474165|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
219474166|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
219474167|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
219474168|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
219474169|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
219474170|NCT03138707|OTHER|patients who die|
219474171|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
218858146|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218858147|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218858148|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
218858149|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
219474172|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
219474173|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
219474174|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
219474175|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
219474176|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
219474177|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
219596490|NCT01741883|BEHAVIORAL|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
218858150|NCT06216782|OTHER|Non-intervention|Non-intervention
218858151|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
218858152|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
219199355|NCT06865404|PROCEDURE|PIRSB Block|After the PIFPB is performed with the same position and probe, a bilateral posterior rectus sheath block (PRSB) will be conducted. The probe will be placed 2-3 cm next to the xiphoid in the epigastric region and parallel to the costal margin. The needle will be inserted into the plane between the rectus abdominal muscle and its posterior sheath. After verifying needle placement, 10 ml of bupivacaine 0.25% will be injected on each side.
219474178|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
219474179|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
218858153|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
218858154|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
218858155|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
218858156|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
218858157|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
219199548|NCT06874673|DRUG|Saline (NaCl 0,9 %) (placebo)|During the colonoscopy procedure on participants in Group B, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses saline delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
219474180|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
219474181|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
219474182|NCT06723730|PROCEDURE|Upper Quadrant Core Strengthening protocol|"Upper Quadrant Core Strengthening protocol Core strengthening protocol will comprise of following four week protocol.~1. Week one Scapular postural correction and shoulder shrugging exercises~2. Week two External rotation at 0 degree~3. Week three Internal rotation at 0 degree~4. Week four Standing row at 45 and 90 degree , Anterior shoulder stretch and Thoracic exercise in sitting"
219474183|NCT06723730|PROCEDURE|Mobilization with movement|"In addition to upper quadrant core strengthening protocol participants will also perform mobilization with movement.~Mobilization with movement protocol will comprise of following forms.~1. Acromioclavicular joint glides~2. Scapular glides~3. Glenohumeral joint glides ( inferior glides, postero-lateral glides, postero-inferior)"
219474184|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
219474185|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
219474186|NCT06892834|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219474187|NCT06892834|DRUG|Sodium Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219474188|NCT06892834|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219474189|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
219474190|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
219474191|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
219474192|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
219474193|NCT06911957|DIETARY_SUPPLEMENT|Prebiotic blend|10g of prebiotic fibre blend powder
219474194|NCT06911957|DIETARY_SUPPLEMENT|Placebo|10g of matched placebo powder
218858158|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
219199549|NCT06874231|OTHER|Neuroimaging|The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples
218858159|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
218858160|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
218858161|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
218858162|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
218858163|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
219474195|NCT06222138|OTHER|The samples described below will be collected:|"For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure."
218858164|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
218858165|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
218858166|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
219474196|NCT06942273|RADIATION|hyperthermia|hyperthermia over the carpal tunnel area and adjacent areas
219474197|NCT06942273|OTHER|physical exercise|Performing therapeutic physical exercise focused on the flexor muscles of the hand and neural stretching
219474198|NCT06942273|OTHER|splint|imposition of a night splint
218858167|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
219199356|NCT06865404|PROCEDURE|PIEOB block|After the PIFPB is performed with the same position and probe, an external oblique block will be used to place the linear array ultrasound probe between the midclavicular line and the anterior axillary line at the level of the 6th rib, with the direction mark pointing to the cephalad. The probe will be rotated on the slightly medial cranial end, and the caudal end will be lateral to produce a mesial sagittal oblique view and a short-axis view of the ribs. The following structures will be identified from superficial to deep layers: subcutaneous tissue, external oblique muscle, intercostal muscles, pleura, and lung. After determining the thoracic fascial space between the external oblique muscle and the intercostal muscles, bupivacaine 20 mL will be slowly injected into the space with a nerve block needle at the head side of the 6th rib horizontally near the mid axillary line. The block will be repeated in the same way on the other side.
219474199|NCT06943300|OTHER|Aerboic Training|Group A will perform Aerobic training exercises will be conducted 2 times per 12 weeks in which the warm up phase for 10 minutes. 30 minutes of aerobic exercise like walking, jogging, cycling, calisthenics, rhythmic exercises, continuous slow running, sit ups and cool down phase for stretching Phase 1: stretching of upper limb, trunk, lower limb muscles for 10 minutes. Phase 2: Individualized walking, jogging, cycling, rhythmic exercises, continuous slow running, sit ups Phase 3: Cool down exercise for 10 minutes.
219596491|NCT06550752|COMBINATION_PRODUCT|UC-MSCs and PRP|UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
219596492|NCT01617252|DEVICE|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
219596493|NCT03968978|BIOLOGICAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
219199357|NCT06203106|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
218858168|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
219474200|NCT06943300|OTHER|Circuit Training|The training program will consist of 10 types of resistance and aerobic exercise and will be done 2 times per week for 12 weeks. Specifically, the resistance exercise program comprises of push-up, squat, crunches, lunge and superman exercise. An aerobic exercise program comprises of light jumping, running on the spot, foot stamping, stepping and jumping jack. Phase 1: In Warm up period, dynamic stretching for 10 minutes. Phase 2: Resistance and aerobic exercise (push-up, squat, crunches, lunge and superman exercise, light jumping, running on the spot, foot stamping, stepping and jumping jack) Phase 3: In cool down period, static stretching for 10 minutes.
219474201|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
218858169|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
218858170|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
218858171|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
218858172|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
218858173|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
218858174|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
218858175|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
218858176|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
218858177|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
218858178|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
219474202|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
219596494|NCT03968978|BIOLOGICAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
219596495|NCT03832101|BEHAVIORAL|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
219596496|NCT03421795|OTHER|Let's Talk About Pain Training|See arm/group descriptions.
219596497|NCT03421795|OTHER|Family Centered Care Training|See arm/group descriptions.
219596498|NCT03471923|DIAGNOSTIC_TEST|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
219596499|NCT03471923|DIAGNOSTIC_TEST|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
219596500|NCT04655430|OTHER|3-second SDF application|Dosage: 3-second 38% SDF solution application
218858179|NCT02024022|DRUG|Individualized approach|
218858180|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
218858181|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
219199358|NCT06343051|DEVICE|USCOM|Device that measures how much blood is being pumped in and out of the heart.
219199359|NCT06610890|DRUG|Hemay005|One 15mg tablet, four tablets at a time
219474203|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
218858182|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
218858183|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
219474204|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
219474205|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
219474206|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
219474207|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
219474208|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
219474209|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
219474210|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
219474211|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
219596501|NCT04655430|OTHER|5-second SDF application|Dosage: 5-second 38% SDF solution application
218858184|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
219199360|NCT06610890|DRUG|Midazolam maleate|One 15mg tablet, one tablet at a time
219474212|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
219596502|NCT04655430|OTHER|10-second SDF application|Dosage: 10-second 38% SDF solution application
219596503|NCT04655430|OTHER|15-second SDF application|Dosage: 15-second 38% SDF solution application
219596504|NCT04655430|OTHER|30-second SDF application|Dosage: 30-second 38% SDF solution application
219596505|NCT04655430|OTHER|45-second SDF application|Dosage: 45-second 38% SDF solution application
219596506|NCT04655430|OTHER|60-second SDF application|Dosage: 60-second 38% SDF solution application
219199361|NCT03003533|GENETIC|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
219199362|NCT02361658|OTHER|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
219199363|NCT02361658|OTHER|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
219596507|NCT04655430|OTHER|120-second SDF application|Dosage: 120-second 38% SDF solution application
219596508|NCT04655430|OTHER|180-second SDF application|Dosage: 180-second 38% SDF solution application
219596509|NCT02029157|DRUG|ARQ197|
219596510|NCT02029157|DRUG|Placebo|
219596511|NCT06633770|DIAGNOSTIC_TEST|proclcitonin and presepsin|"All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin)."
219596512|NCT03616717|DRUG|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
218858185|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
218858186|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
218858187|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
218858188|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
218858189|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
218858190|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
219474213|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
218858191|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
218858192|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
218858193|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
218858194|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
218858195|NCT00182767|DRUG|ixabepilone|Given IV
218858196|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
218858197|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
218858198|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
219474214|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
219474215|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
219474216|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
219474217|NCT00000172|DRUG|Galantamine|
219474218|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
219474219|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
218858199|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
218858200|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
219474220|NCT00048438|DRUG|paricalcitol|
219474221|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
218858201|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
218858202|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
218858203|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
218858204|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
218858205|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
218858206|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
218858207|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
218858208|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
219474222|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
219474223|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
219474224|NCT06648408|PROCEDURE|Balett Training|The ballet training will happen twice a week for six weeks, with each session lasting 60 minutes, for a total of 12 sessions. These sessions will be held in groups of 10 to 12 children and led by experienced ballet teachers. The classes will follow a beginner-level ballet routine, introducing the kids to ballet techniques in a fun and playful way, making sure they learn the movements step by step. Each lesson will follow the same structure, allowing the children to improve their skills week after week. In addition to the group sessions, the children will be given a 10-minute daily home exercise program. This will include simple ballet exercises they learned in their first class, which they should practice on the five days when they don't have ballet sessions. The children will track their practice in a child-friendly diary designed just for them.
219474225|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
219474226|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
219474227|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
219474228|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
219474229|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
219474230|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
219474231|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
219474232|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
219474233|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
219474234|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
219474235|NCT02670356|DIETARY_SUPPLEMENT|Fish oil|two 750 mg/capsules/day
219474236|NCT02670356|DIETARY_SUPPLEMENT|Krill oil|one 300 mg capsule/day
218858209|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
219474237|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
219474238|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
218858210|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
218858211|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
219474239|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
219474240|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
219474241|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
219474242|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
218858212|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
218858213|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
218858214|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
218858215|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
218858216|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
219474243|NCT01564680|OTHER|placebo|normal saline
219474244|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
219474245|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
219474246|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
219474247|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
219474248|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
218858217|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
218858218|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
218858219|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
218858220|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
218858221|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
218858222|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
218858223|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
218858224|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
218858225|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
218858226|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
218858227|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
218858228|NCT00212199|DRUG|orlistat|
218858229|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
219596513|NCT03616717|DRUG|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
219474249|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
219474250|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
219596514|NCT02722915|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
218858230|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
219474251|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
219596515|NCT02722915|BEHAVIORAL|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
219596516|NCT02722915|OTHER|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
219596517|NCT02722915|OTHER|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
219596518|NCT02722915|OTHER|SF36|questionnaire about life quality after 1 week during a telephone interview
219596519|NCT00908310|DRUG|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
219596520|NCT06981650|BEHAVIORAL|video|use of a video
219596521|NCT06981650|BEHAVIORAL|education|standard talk and paper handout
219596522|NCT06292403|OTHER|Strength Training|training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
219596523|NCT06292403|OTHER|Mirror therapy|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
219596524|NCT01741051|DEVICE|HEPA Filter|
219596525|NCT05700370|DIAGNOSTIC_TEST|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
219596526|NCT00062400|PROCEDURE|psychosocial assessment and care|
219596527|NCT02566356|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
219474252|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
219474253|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
218858231|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
218858232|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
218858233|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
218858234|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
218858235|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
218858236|NCT00069524|DRUG|oyster mushroom|
218858237|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
218858238|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
218858239|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
218858240|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
218858241|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
218858242|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
218858243|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
218858244|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
218858245|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
219474254|NCT01511562|DRUG|carmustine|Given IV
219474255|NCT01511562|DRUG|cytarabine|Given IV
219596528|NCT02566356|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
219596529|NCT05148390|DEVICE|Cutimed® Gelling Fiber|application of dressing
219474256|NCT01511562|DRUG|etoposide|Given IV
219474257|NCT01511562|DRUG|thiotepa|Given IV
219596530|NCT05608980|DRUG|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
219596531|NCT05608980|DRUG|Placebo|once daily eyelid wipes for 2 weeks
219596532|NCT06084897|DRUG|TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
218858246|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
218858247|NCT03454867|DEVICE|Hemofiltration|
218858248|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
218858249|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
219474258|NCT01511562|PROCEDURE|stem cell transplant|
218858250|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
218858251|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
219474259|NCT01511562|DRUG|G-CSF|
219474260|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
219474261|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
218858252|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
218858253|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
218858254|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
218858255|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
218858256|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
218858257|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
219596533|NCT06084897|BIOLOGICAL|PD-1 inhibitor|Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
219596534|NCT06084897|RADIATION|Consolidation Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
218858258|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
218858259|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
218858260|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
218858261|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
218858262|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
218858263|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
218858264|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
218858265|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
218858266|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
218858267|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
219474262|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
219474263|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
219474264|NCT02494882|DRUG|Ruxolitinib|
219474265|NCT02494882|DRUG|Dasatinib|
219474266|NCT02494882|DRUG|Dexamethasone|
219474267|NCT00231530|DRUG|topiramate|
219474268|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
219474269|NCT00201630|DRUG|Uroxatrol (drug)|
219474270|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
219474271|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
219474272|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
219474273|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
219474274|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
219474275|NCT00020995|PROCEDURE|therapeutic dietary intervention|
218858268|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
218858269|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
218858270|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
218858271|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
218858272|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
218858273|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
218858274|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
218858275|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
218858276|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
218858277|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
218858278|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
218858279|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
218858280|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
218858281|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
218858282|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
218858283|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
218858284|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
218858285|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
218858286|NCT02032693|OTHER|Placebo|
218858287|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
219474276|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
219474277|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
219474278|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
219474279|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
219474280|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
219474281|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
219474282|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
219474283|NCT01587807|DRUG|LPS|50 μg
219474284|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
219474285|NCT00718809|DRUG|saracatinib|Given orally
219474286|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
218858288|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
218858289|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
218858290|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
218858291|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
218858292|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
218858293|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
218858294|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
218858295|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
218858296|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
218858297|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
219474287|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
219596535|NCT06084897|RADIATION|Salvage Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
219596536|NCT00892996|DRUG|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
218858298|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
218858299|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
219474288|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
219474289|NCT00870415|PROCEDURE|quality-of-life assessment|
219474290|NCT00870415|PROCEDURE|therapeutic conventional surgery|
219474291|NCT00463385|DRUG|Pomalidomide|
219596537|NCT00892996|DRUG|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
219596538|NCT04468516|DEVICE|KKT|Vibroacoustic sound waves applied focally.
219596539|NCT04468516|DEVICE|sham KKT|sham KKT
219596540|NCT05911880|BEHAVIORAL|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
218858300|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
218858301|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
218858302|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
218858303|NCT00061074|DRUG|Nicotrol|
218858304|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
218858305|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
218858306|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
219474292|NCT00463385|DRUG|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
218858307|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
218858308|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
218858309|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
218858310|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
218858311|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
218858312|NCT01110837|OTHER|Allergen|Allergen nasal challenge
218858313|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
218858314|NCT03670329|DEVICE|URGO2875|Dressing
218858315|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
218858316|NCT03366103|DRUG|Vistusertib|Given PO
218858317|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
218858318|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
218858319|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
219474293|NCT00463385|DRUG|Placebo to pomalidomide|Matching pomalidomide placebo tablets
219474294|NCT00463385|DRUG|Placebo to prednisone|Matching prednisone placebo tablets
219474295|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
219474296|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
219474297|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
219474298|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
219474299|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
219596541|NCT04990427|DRUG|CLBS201|1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
219474300|NCT00449761|DRUG|LBH589|
218858320|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
218858321|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
219474301|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
219474302|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
219474303|NCT03143933|DRUG|Propofol|I.V propofol
218858322|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
218858323|NCT00456976|DRUG|Selegiline|
218858324|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
218858325|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
218858326|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
218858327|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
218858328|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
218858329|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
218858330|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
218858331|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
218858332|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
219199550|NCT06875674|DIETARY_SUPPLEMENT|supplementation with control strawberry|control strawberry supplementation (100 grams/day) for 30 days
219474304|NCT03143933|DRUG|Fentanyl|
219474305|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
219596542|NCT00006630|DRUG|Vaccinia Immune Globulin (Human)|
219474306|NCT04398680|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered
219474307|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
219474308|NCT01969201|DRUG|Urofollitrophin|
219474309|NCT01969201|DRUG|Follitrophin alpha|
219474310|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
219474311|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
219474312|NCT00625768|DRUG|AS1409|Study drug
219474313|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
219474314|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
219474315|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
219474316|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
219474317|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
219474318|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
219474319|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
219474320|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
219474321|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
219596543|NCT02777398|PROCEDURE|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
218858333|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
218858334|NCT00000916|DRUG|Indinavir sulfate|
219199364|NCT02361658|OTHER|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
218858335|NCT00000916|DRUG|Lamivudine/Zidovudine|
219474322|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
218858336|NCT00000916|DRUG|Hydroxyurea|
219199365|NCT05123027|BEHAVIORAL|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
218858337|NCT00000916|DRUG|Lamivudine|
218858338|NCT00000916|DRUG|Stavudine|
218858339|NCT00000916|DRUG|Zidovudine|
218858340|NCT00000916|DRUG|Didanosine|
219474323|NCT01422876|DRUG|high dose FDC|once daily
218858341|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
219474324|NCT01422876|DRUG|BI 10773 high dose|once daily
219474325|NCT01422876|DRUG|high dose FDC placebo|once daily
219474326|NCT01422876|DRUG|low dose FDC placebo|once daily
219474327|NCT01422876|DRUG|high dose FDC placebo|once daily
219474328|NCT01422876|DRUG|high dose FDC placebo|once daily
219199366|NCT05123027|BEHAVIORAL|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
219199367|NCT06678945|PROCEDURE|Bar-Clip attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
219199368|NCT06678945|PROCEDURE|Bar- OT Equator attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
219474329|NCT01422876|DRUG|low dose FDC placebo|once daily
219474330|NCT01422876|DRUG|low dose FDC placebo|once daily
219474331|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
219474332|NCT01422876|DRUG|low dose FDC|once daily
218858342|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
219474333|NCT01422876|DRUG|high dose FDC placebo|once daily
219474334|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
219474335|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
219474336|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
219474337|NCT01422876|DRUG|linagliptin|once daily
218858343|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
218858344|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
218858345|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
218858346|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
218858347|NCT02066506|OTHER|symptomatic group|2 visits with MRI
218858348|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
219474338|NCT01422876|DRUG|low dose FDC placebo|once daily
219474339|NCT01422876|DRUG|linagliptin placebo|once daily
219474340|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
219474341|NCT01422876|DRUG|linagliptin placebo|once daily
219474342|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
219474343|NCT01422876|DRUG|linagliptin placebo|once daily
219474344|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
219474345|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
219474346|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
219474347|NCT01422876|DRUG|linagliptin placebo|once daily
219474348|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
218858349|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
218858350|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
218858351|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
218858352|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
218858353|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
218858354|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
218858355|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
218858356|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
218858357|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
218858358|NCT01922375|DRUG|Naftopidil|
218858359|NCT00298493|PROCEDURE|Sedation management strategy|
218858360|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
218858361|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
218858362|NCT02159677|DEVICE|EIM Measurements|
218858363|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
219474349|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
219474350|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
219474351|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
219474352|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
218858364|NCT03542435|DRUG|SXC-2023|Oral capsule
219474353|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
218858365|NCT03542435|DRUG|Placebo|Placebo
218858366|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
218858367|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
218858368|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
218858369|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
218858370|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
218858371|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
218858372|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
218858373|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
218858374|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
218858375|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
218858376|NCT00002465|DRUG|megestrol acetate|
218858377|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
218858378|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
218858379|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
219474354|NCT01166074|BIOLOGICAL|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
219474355|NCT00374465|DRUG|Verapamil|
219474356|NCT00374465|DRUG|Carvedilol|
219474357|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
219474358|NCT00305331|DRUG|Domperidone (drug)|
218858380|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
219474359|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
218858381|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
218858382|NCT02714270|PROCEDURE|modified partograph|
218858383|NCT02714270|PROCEDURE|paperless partograph|
218858384|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
218858385|NCT02102152|DRUG|Tobramycin|
218858386|NCT00787137|DRUG|PG102|A single intravenous infusion
218858387|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
218858388|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
219474360|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
218858389|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
218858390|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
219474361|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
218858391|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
218858392|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
218858393|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
218858394|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
218858395|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
218858396|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
218858397|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
218858398|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
218858399|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
218858400|NCT02823132|BIOLOGICAL|blood sample|
218858401|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
218858402|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
218858403|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
219476190|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
218858404|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
218858405|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
218858406|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
218858407|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
218858408|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
218858409|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
218858410|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
218858411|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
218858412|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
218858413|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
218858414|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
218858415|NCT04401956|OTHER|bread|Different types of bread
218858416|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
218858417|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
218858418|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
218858419|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
218858420|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
218858421|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
219199551|NCT06875674|DIETARY_SUPPLEMENT|supplementation with biofortified strawberry|selenium biofortified strawberry supplementation (100 grams/day) for 30 days
219199552|NCT06875674|DIETARY_SUPPLEMENT|supplementation with selenium in tablet|selenium supplementation in tablet (100 micrograms/day) for 30 days
218858422|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
218858423|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
218858424|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
219363511|NCT02328066|DEVICE|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
219363512|NCT04166279|OTHER|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
219363513|NCT04166279|OTHER|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
219363514|NCT04856241|OTHER|Coaching|Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.
219363515|NCT04856241|OTHER|Peer support|Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.
219363516|NCT04856241|OTHER|Educational materials|Prep-to-Play program resources are available online for coaches and players to view
219363517|NCT01960855|DRUG|ABT-494|ABT-494 capsule administered orally twice daily (BID).
219363518|NCT01960855|DRUG|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
219363519|NCT06175897|PROCEDURE|Deep Brain Stimulation|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
219363520|NCT06175897|PROCEDURE|non-Deep Brain Stimulation|Patients with PD were given their original drug dose and did not receive DBS.
219474362|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
219474363|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
218858425|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
219474364|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
218858426|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
219474365|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
219474366|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
219474367|NCT00540735|PROCEDURE|photodynamic therapy|
219199369|NCT06678516|DIETARY_SUPPLEMENT|Intermittent fasting|Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
219199370|NCT06323044|OTHER|Best Practice|Receive usual care
219474368|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
218858427|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
218858428|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
218858429|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
218858430|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
219199371|NCT06323044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218858431|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
218858432|NCT00739180|OTHER|Control|Standard care control (no exercise)
219199372|NCT06323044|OTHER|Electronic Health Record Review|Ancillary studies
218858433|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
219474369|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
219474370|NCT00567086|DRUG|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
218858434|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
219474371|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
218858435|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
218858436|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
218858437|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
219474372|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
219474373|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
219474374|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
219474375|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
218858438|NCT00041171|DRUG|Hypericum perforatum|
218858439|NCT00041171|DRUG|docetaxel|
218858440|NCT00041171|OTHER|placebo|
219474376|NCT02423564|OTHER|Placebo|
219474377|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
219474378|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
218858441|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
219020639|NCT07205029|COMBINATION_PRODUCT|Experimental: Nutritional and Virtual reality intervention|Over a 6-month period, the experimental group received nutritional recommendations based on the Mediterranean Diet from the nutritionist. In each session, the participant went through the 4D body modelling machine, which captures the morphological changes of each participant over time. The experimental group observed the changes in their bodies through immersive virtual reality goggles. After visualising their bodies, all participants in the experimental group completed a questionnaire designed to assess their perception of body image. Personal and sociodemographic data, clinical information, general health status, anthropometric, nutritional, and lifestyle data, as well as psychological and neuropsychological variables, were collected at two time points: at the beginning (pre-test measures) and at the end of the intervention (post-test measures).
219020640|NCT07205029|COMBINATION_PRODUCT|Control: Nutritional intervention|Over a 6-month period, the control group received nutritional recommendations based on the Mediterranean Diet from the nutritionist. In each session, the participant went through the 4D modelling machine, which captures the morphological changes of each individual over time. The control group did not visualise these morphological changes through the virtual reality goggles. Personal and sociodemographic data, clinical information, general health status, anthropometric, nutritional, and lifestyle data, as well as psychological and neuropsychological variables, were collected at two time points: at the beginning (pre-test measures) and at the end of the intervention (post-test measures).
219020641|NCT07207252|DIETARY_SUPPLEMENT|Tea Theanine Casein Hydrolysate Pressed Candy|Take 4 candies once a day. It is recommended to consume it one hour before bedtime.
219020642|NCT07207252|DIETARY_SUPPLEMENT|Pressed Candy|Take 4 candies once a day.
219474379|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
219474380|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
219474381|NCT01541410|DEVICE|Vascutek Hybrid Graft|Single Group Assignment
219474382|NCT06491719|OTHER|NCR300（Allogenic Ipsc-derived Natural Killer cells ）|"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."
218858442|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
218858443|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
218858444|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
218858445|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
218858446|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
219199373|NCT06323044|OTHER|Interview|Ancillary studies
219199374|NCT06323044|OTHER|Medical Device Usage and Evaluation|Receive MedSupport intervention
219199375|NCT06323044|OTHER|Medical Device Usage and Evaluation|Use MEMS device
219199376|NCT06323044|OTHER|Survey Administration|Ancillary studies
219474383|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
219199377|NCT05844956|DRUG|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
219474384|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
219474385|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
219474386|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
219474387|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
219476191|NCT03862222|OTHER|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
219476192|NCT03862222|OTHER|Pupillometry|Participants will complete a task studying pupillary response to light
219476193|NCT03862222|OTHER|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
219199378|NCT04959695|BEHAVIORAL|PE Coach|PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
218858447|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
218858448|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
218858449|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
218858450|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
218858451|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
219199379|NCT04959695|BEHAVIORAL|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
219199380|NCT06866860|OTHER|Implant surgical guide with internal irrigation|"* Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted.~* The entry point of the surgical drill into the alveolar bone will be identified.~* An irrigation channel will be added, directed toward the entry point of the drill and adjusted to have the same diameter as the irrigation system tube."
218858452|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
218858453|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
218858454|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
218858455|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
219199381|NCT06866860|OTHER|Conventional implant surgical guide with external irrigation|Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted. Conventional guide will be printed
219199382|NCT06865352|BIOLOGICAL|HSCT donor leukemia-specific cytotoxic T-cells|donor T-cells stimulated with patient leukemia blasts
219199383|NCT05744895|DEVICE|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
219199384|NCT05744895|DEVICE|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
219199385|NCT05744895|DEVICE|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
218858456|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
218858457|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
218858458|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
218858459|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
218858460|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
218858461|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
219474388|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
219474389|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
219474390|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
219474391|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
219474392|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
219474393|NCT05259059|OTHER|No intervention is involved|No intervention is involved
219474394|NCT02952300|PROCEDURE|neolix|single rotation file
219474395|NCT02952300|PROCEDURE|wave one|single reciprocation file
219474396|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
219474397|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
218858462|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
218858463|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
219199386|NCT05744895|DEVICE|FocusMotion app|Will survey patients with PROMS
219199387|NCT06483308|RADIATION|Radiotherapy|Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
219199388|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
218858464|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
218858465|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
218858466|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
218858467|NCT00349258|DRUG|Leuprolide acetate|
219474398|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
219474399|NCT02515175|DRUG|Placebo|0.9% Normal Saline
219474400|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
219474401|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
218858468|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
218858469|NCT04317157|OTHER|Placebo|Placebo pill.
218858470|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
218858471|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
218858472|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
219199389|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
219474402|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
219474403|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
219474404|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
219474405|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
219474406|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
219474407|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
219474408|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
218858473|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
218858474|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
218858475|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
218858476|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
218858477|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
218858478|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
218858479|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
218858480|NCT02698904|OTHER|Documentary Movie|
218858481|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
219474409|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
218858482|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
219474410|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
219474411|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
219474412|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
219474413|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
219474414|NCT02016027|DRUG|Carica folia|
219474415|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
219474416|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
219596544|NCT02777398|PROCEDURE|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
219596545|NCT01229579|DRUG|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
219596546|NCT01229579|OTHER|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
219596547|NCT03904589|DIAGNOSTIC_TEST|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
219596548|NCT01128608|PROCEDURE|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
219596549|NCT01128608|PROCEDURE|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
218858483|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
218858484|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
218858485|NCT04766385|DRUG|KHK7791|oral administration
218858486|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
218858487|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
218858488|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
219199390|NCT05412758|DIETARY_SUPPLEMENT|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
219199391|NCT03771612|DRUG|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
219199392|NCT03771612|DRUG|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
219199393|NCT05727085|OTHER|All pregnant women with a twin pregnancy and the offspring|No intervention
219199394|NCT00001481|DRUG|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
218858489|NCT02252809|DRUG|adalimumab|
218858490|NCT02252809|DRUG|methylprednisolone|
218858491|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
218858492|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
218858493|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
218858494|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
218858495|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
218858496|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
218858497|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
219199395|NCT00001481|OTHER|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
218858498|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
218858499|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
218858500|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
218858501|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
218858502|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
218858503|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
218858504|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
218858505|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
218858506|NCT05732883|DRUG|Normal saline|Placebo
218858507|NCT00183963|DRUG|Tamoxifen|20mg
218858508|NCT00183963|DRUG|Fulvestrant|250mg
218858509|NCT00183963|DRUG|Fulvestrant|500 mg IM
218858510|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
218858511|NCT04671082|DRUG|Placebo|TID
218858512|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
219199396|NCT00001481|DRUG|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
219199397|NCT06681077|PROCEDURE|Community Health Education|Receive I CAN intervention
219199398|NCT06681077|OTHER|Survey Administration|Ancillary studies
219474417|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219474418|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
219474419|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
219474420|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
219474421|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
219474422|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
219474423|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
219474424|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
219474425|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
219474426|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
218858513|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
218858514|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
218858515|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
218858516|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
218858517|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
218858518|NCT00176176|DEVICE|EEG|
218858519|NCT03770494|DRUG|LY3405105|Administered orally.
218858520|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
218858521|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
218858522|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
219474427|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
219474428|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
218858523|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
218858524|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
218858525|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
218858526|NCT02743780|DRUG|MGV354 ophthalmic suspension|
218858527|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
218858528|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
218858529|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
218858530|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
218858531|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
218858532|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
218858533|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
218858534|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
218858535|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
218858536|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
218858537|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
218858538|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
218858539|NCT01811576|DRUG|TV-1106|
218858540|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
218858541|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
219474429|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
219474430|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
219474431|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
219474432|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
219474433|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
219474434|NCT00054639|BIOLOGICAL|rituximab|Given IV
219474435|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
219474436|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
218858542|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
218858543|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
218858544|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
219474437|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
219474438|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
219474439|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
219474440|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
219474441|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
219474442|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
219474443|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
218858545|NCT01983280|OTHER|Healing Touch|
218858546|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
218858547|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
218858548|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
218858549|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
218858550|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
218858551|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
218858552|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
218858553|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
219474444|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
218858554|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
218858555|NCT01400243|DRUG|Placebo Patch|Placebo patch
218858556|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
219474445|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
219474446|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
219596550|NCT00125112|BEHAVIORAL|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
218858557|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
218858558|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
218858559|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
218858560|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
218858561|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
218858562|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
218858563|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
218858564|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
218858565|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
218858566|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
218858567|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
218858568|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
218858569|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
218858570|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
218858571|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
218858572|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
218858573|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
218858574|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
218858575|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
219020643|NCT07207343|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|Haifu Focused Ultrasound tumor therapeutic System is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
219474447|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
219474448|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
219474449|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
219596551|NCT03197181|DEVICE|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
219596552|NCT02125721|DRUG|Tiopronin 1g per day|500mg PO BID x 7 days
219596553|NCT02125721|DRUG|Tiopronin 2g per day|1g PO BID x 7 days
219596554|NCT02125721|DRUG|Tiopronin 3g per day|1.5g PO BID x 7 days
218858576|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
218858577|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
218858578|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
218858579|NCT01223898|DRUG|Tasigna|
219596555|NCT02551484|DEVICE|Measurements using NIRS|
219596556|NCT02551484|DEVICE|TCPO2 measurements|
219596557|NCT02551484|OTHER|2-minute walk test|
219596558|NCT05322109|DIAGNOSTIC_TEST|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
219596559|NCT05537636|OTHER|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
219596560|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
218858580|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
219474450|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
219474451|NCT00238108|DRUG|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
219474452|NCT00238108|DRUG|Placebo|Placebo
218858581|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
218858582|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
218858583|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
218858584|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
218858585|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
219474453|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
219474454|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
218858586|NCT00377546|DRUG|Nepafenac|
218858587|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
218858588|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
218858589|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
218858590|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
219474455|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
219474456|NCT02729350|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
219474457|NCT02729350|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
219474458|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
219474459|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
219474460|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
219474461|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
219596561|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
219596562|NCT05997732|DRUG|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
218858591|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
218858592|NCT01310959|OTHER|Database|Database
218858593|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
218858594|NCT00029757|DRUG|Estrogen|
218858595|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
218858596|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
218858597|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
218858598|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
219020644|NCT07206862|DEVICE|DEBRICHEM®|Single topical application of DEBRICHEM® (desiccant gel for chemical debridement) at inclusion, then standard wound dressings and care.
219020645|NCT07206667|PROCEDURE|T1 GRE GADO MRI sequence|Addition of a T1 gradient echo sequence with gadolinium (T1 TFE GADO) during the two MRI scans performed in routine practice before and after neurosurgery.
219474462|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
219474463|NCT03291249|OTHER|placebo|Placebo oral solution
219474464|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
219474465|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
219474466|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
219474467|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
219474468|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
219474469|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
219474470|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
218858599|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
218858600|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
218858601|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
218858602|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
218858603|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
218858604|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
218858605|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
219474471|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
219474472|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
219474473|NCT03207607|OTHER|Snack skipping|no snack
219474474|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
219474475|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
219596563|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
219596564|NCT05997732|DRUG|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
219596565|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
219596566|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
219596567|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
218858606|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
218858607|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
219596568|NCT00431483|BEHAVIORAL|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
219596569|NCT01062711|DIETARY_SUPPLEMENT|Whey or soy protein|Whey and casein are isolated milk proteins
219596570|NCT04054557|OTHER|Telemedicine|Participate in virtual visits with oncologist
218858608|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
218858609|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
218858610|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
218858611|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
218858612|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
218858613|NCT00758589|DRUG|Placebo|
219020646|NCT07206342|PROCEDURE|embolization therapy|Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
219199399|NCT06681766|DRUG|Nomlabofusp|Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
219474476|NCT02192307|DEVICE|Potassium oxalate|
219474477|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
219474478|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
219474479|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
219474480|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
219474481|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
219474482|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
219474483|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
219474484|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
219474485|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
219474486|NCT06023511|DEVICE|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
219474487|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
219596571|NCT04054557|OTHER|Best Practice|Receive 4 in-office visits with oncologist
219596572|NCT04054557|OTHER|Questionnaire Administration|Ancillary studies
219596573|NCT04054557|OTHER|Quality-of-Life Assessment|Ancillary studies
219596574|NCT04054557|OTHER|Survey Administration|Complete electronic survey
219596575|NCT04054557|BEHAVIORAL|Behavioral Intervention|Use smart pill bottle
219474488|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
219474489|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
219199400|NCT06681766|DRUG|Placebo|The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
219474490|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
219474491|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
219474492|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
219474493|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
219474494|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
219474495|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
219474496|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
219474497|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
219474498|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
219474499|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
219474500|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
219596576|NCT04054557|OTHER|Educational Intervention|Receives time-specific reminders and messages
219596577|NCT05304039|BEHAVIORAL|Questionnaires|Questionnaires about asthma control and quality of life
219020647|NCT07206342|PROCEDURE|embolization followed by aspiration|"Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group Embolization alone but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization."
219474501|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
219474502|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
219474503|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
219474504|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
219474505|NCT01548573|DRUG|Dexamethasone|Given PO
219474506|NCT01548573|PROCEDURE|Tandem autologous stem cell transplant|
219596578|NCT05304039|DEVICE|Spirometry|Spirometry monitoring at home
219596579|NCT05304039|DEVICE|Fractional Exhaled Nitric Oxide (FeNO)|Measuring fractional exhaled nitric oxide at home
219596580|NCT05304039|DEVICE|Corsano watch|Monitoring vital parameters at home
219596581|NCT05304039|DEVICE|e-Nose|Breathprint will be performed using e-Nose
219596582|NCT05304039|PROCEDURE|Nasopharyngeal swabs and nasal lining fluid|Nasopharyngeal swabs and nasal lining fluid will be performed
219596583|NCT05304039|DEVICE|Sputum culture|If patients produce sputum, the sputum will be analysed
219596584|NCT05304039|PROCEDURE|Blood sample|Blood sample for standard care and 10 ml extra will be taken
219596585|NCT06381596|DEVICE|OcuMet Beacon|OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
219474507|NCT01548573|DRUG|Cisplatin|Given IV
219474508|NCT01548573|DRUG|Doxorubicin|Given IV
219474509|NCT01548573|DRUG|Cyclophosphamide|Given IV or PO
219474510|NCT01548573|DRUG|Etoposide|Given IV
219474511|NCT01548573|DRUG|Bortezomib|Given IV
219474512|NCT01548573|DRUG|Thalidomide|Given PO
219474513|NCT01548573|DRUG|Melphalan|Given IV
218858614|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
218858615|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
218858616|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
219474514|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
219474515|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
219474516|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
219474517|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
219474518|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
219474519|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
218858617|NCT00005048|DRUG|estramustine phosphate sodium|
219474520|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
219474521|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
219474522|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
219474523|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
219596586|NCT06137261|DIAGNOSTIC_TEST|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
218858618|NCT00005048|DRUG|paclitaxel|
218858619|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
218858620|NCT02088567|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
218858621|NCT02088567|OTHER|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
218858622|NCT00238368|BIOLOGICAL|filgrastim|
218858623|NCT00238368|BIOLOGICAL|rituximab|
218858624|NCT00238368|DRUG|busulfan|
218858625|NCT00238368|DRUG|cisplatin|
218858626|NCT00238368|DRUG|cyclophosphamide|
218858627|NCT00238368|DRUG|cytarabine|
219474524|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
219474525|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
219474526|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
218858628|NCT00238368|DRUG|doxorubicin hydrochloride|
218858629|NCT00238368|DRUG|etoposide|
218858630|NCT00238368|DRUG|methylprednisolone|
218858631|NCT00238368|DRUG|prednisone|
218858632|NCT00238368|DRUG|vincristine sulfate|
218858633|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
218858634|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
218858635|NCT00238368|PROCEDURE|positron emission tomography|
218858636|NCT00238368|RADIATION|fludeoxyglucose F 18|
218858637|NCT00238368|RADIATION|radiation therapy|
218858638|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
218858639|NCT04759469|BEHAVIORAL|High-intensity interval training|High-intensity interval training is a form of intermittent training using relatively high exercise intensity
218858640|NCT04759469|BEHAVIORAL|Moderate intensity interval training|Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
218858641|NCT01243827|DRUG|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
218858642|NCT01243827|DRUG|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
218858643|NCT00053807|BIOLOGICAL|aldesleukin|
218858644|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
218858645|NCT00053807|DRUG|fluorouracil|
219476194|NCT03862222|DIAGNOSTIC_TEST|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
219476195|NCT03862222|GENETIC|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
219476196|NCT03862222|OTHER|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
219020648|NCT07206277|OTHER|Immunosuppression reduction|In patients with LSM \< 8.4 kPa we will gradually reduce IS by 30% (e.g. if on tacrolimus 6 mg daily, dose will be reduced to 4 mg daily) over three months. In patients with immunosuppression reduction we will perform TE at 4, 7 and 12 months after IS reduction to ensure there is no change in LSM. We will get liver biochemistry every 2 weeks x 4 months to ensure labs remain within normal range. Following this, patients will resume monthly labs.
219020649|NCT07204938|DRUG|navenibart|Navenibart will be administered as a subcutaneous injection.
219476197|NCT03862222|OTHER|Gait Assessment|Gait assessment will be conducted by trained researcher
218858646|NCT00053807|PROCEDURE|adjuvant therapy|
218858647|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
218858648|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
218858649|NCT04379115|DEVICE|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
218858650|NCT04379115|DEVICE|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
218858651|NCT05951959|DRUG|Acalabrutinib|Investigational Product
218858652|NCT05951959|DRUG|Venetoclax|Investigator Product
218858653|NCT05951959|DRUG|Rituximab|Investigator Product
218858654|NCT02525614|DEVICE|Triathlon Standard Keel|Implantation of Knee Prosthesis
218858655|NCT02525614|DEVICE|Triathlon Short Keel|Implantation of Knee Prosthesis
218858656|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
218858657|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
218858658|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
218858659|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
218858660|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
219476198|NCT03862222|OTHER|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
219476199|NCT06216132|COMBINATION_PRODUCT|BIOPIN-6 Active Implant with Naltrexone|An extended release formulation of naltrexone implanted in the subcutaneous space.
219476200|NCT06216132|DEVICE|BIOPIN-6 Placebo Implant|The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
219476201|NCT03449238|DRUG|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
219476202|NCT06418659|DRUG|CD-801|"CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA (CD-801 or CD-GA-102) therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per mRECIST criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
219476203|NCT04050761|BIOLOGICAL|Nivolumab|Specified dose on Specific Days
219476204|NCT04100980|OTHER|No Intervention|There is no intervention for this study
218858661|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
218858662|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
218858663|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
218858664|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
218858665|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
218858666|NCT05216003|BEHAVIORAL|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
218858667|NCT04735198|PROCEDURE|Primary tumor surgery|Large bowel resection.
218858668|NCT04735198|PROCEDURE|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
218858669|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
219474527|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
219474528|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
219474529|NCT00558831|DRUG|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
218858670|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
218858671|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
218858672|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
218858673|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
218858674|NCT02253823|DRUG|EFV|
218858675|NCT02253823|DRUG|TPV/RTV - low dose|
218858676|NCT02253823|DRUG|TPV/RTV - high dose|
219020650|NCT07206758|DRUG|SHR-2173 Injection|SHR-2173 injection treatment
219474530|NCT00558831|DRUG|Moisturizing Lotion|
219474531|NCT02846987|DRUG|Abemaciclib|
219474532|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
219474533|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
218858682|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
218858683|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
218858684|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
218858685|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
218858686|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
219474534|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
218858687|NCT00549185|DRUG|SAR3419|Intravenous infusion
218858688|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
218858689|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
218858690|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
218858691|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
218858692|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
218858693|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
218858694|NCT01151761|DRUG|5FU|200 mg/m2
218858695|NCT01151761|PROCEDURE|Liver transplantation|
218858696|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
218858697|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
218858698|NCT06410521|BEHAVIORAL|Exercise|Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 8-12 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 60 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (Leg extension, unilateral hip extension, and standing calf raise), with a load progression from 50% of 1-estimated one repetition maximum (e-RM) to 80% of 1-eRM.
218858699|NCT06410521|BEHAVIORAL|Usual care|Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.
218858700|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
218858701|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
218858702|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
218858703|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
218858704|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
218858705|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
219476205|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
219476206|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
219476207|NCT04275999|DRUG|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
219474535|NCT02395094|BEHAVIORAL|Child Life|"Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU"
219474536|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
219474537|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
218858706|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
219474538|NCT00447265|DRUG|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
219474539|NCT00447265|DRUG|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
218858707|NCT02127034|DRUG|Mirabegron|oral
218858708|NCT02127034|DRUG|Solifenacin|oral
218858709|NCT02127034|DRUG|Digoxin|oral
218858710|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
218858711|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
218858712|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
219474540|NCT00447265|DRUG|Placebo|
219474541|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
219474542|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
219474543|NCT00910065|DRUG|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
219474544|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
219474545|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
219474546|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
219474547|NCT03724422|RADIATION|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
219596587|NCT06229171|OTHER|adherence support system based on a vocal assistant|"Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre."
218858713|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
218858714|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
218858715|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
218858716|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
218858717|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
218858718|NCT06350747|BEHAVIORAL|Face-to-Face Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
219474548|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
219474549|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
219474550|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
219474551|NCT04121169|DRUG|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
219474552|NCT00503035|DRUG|Celecoxib|400 mg by mouth twice daily x 6 months
218858719|NCT06350747|BEHAVIORAL|Online Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
218858720|NCT06350747|OTHER|control group|Participants in the control group will not receive the laughter yoga intervention. They will continue with their usual daily routines and will only complete pre- and post-test assessments.
218858721|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
219474553|NCT00503035|PROCEDURE|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
219474554|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
219474555|NCT04645342|DEVICE|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
219474556|NCT04645342|DEVICE|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
219474557|NCT02173132|DRUG|Acetyl-L-carnitine|
219474558|NCT02173132|OTHER|Placebo|
218858722|NCT06076291|DRUG|SG1827|PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
219474559|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
219474560|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
219474561|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
219474562|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
219474563|NCT06786091|OTHER|Pelvic floor muscle training rehabilitation|The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week.
219474564|NCT05578586|DRUG|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
219596588|NCT05497180|DEVICE|passive myofunctional appliance|passive myofunctional appliance
218858723|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
218858724|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
219596589|NCT05497180|DEVICE|standard oral appliance|standard oral appliance
219596590|NCT06002204|OTHER|Observational Study|No Treatment or Intervention Provided
219596591|NCT06780176|OTHER|Biospecimen Collection|Blood collection at baseline and time of surgery
219596592|NCT06780176|DIAGNOSTIC_TEST|Surgical Tissue Collection|Tissue collection will be attempted at time of surgery
219596593|NCT06780176|BEHAVIORAL|Survey Collection|Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
219596594|NCT06239077|OTHER|Non Invasive Prenatal Test via blood sample|Maternal - blood draw, Paternal - blood draw/Saliva sample
219596595|NCT01200069|DRUG|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
219596596|NCT01200069|DRUG|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
219596597|NCT01313377|DRUG|gemcitabine hydrochloride|
218858725|NCT01963013|DEVICE|Non-returning catheter valve|
218858726|NCT01963013|DEVICE|Conventional urine bag|
218858727|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
218858728|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
218858729|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
218858730|NCT02285114|DRUG|F/TAF|F/TAF tablets administered orally once daily
218858731|NCT02285114|DRUG|3rd ARV agent|A 3rd antiretroviral (ARV) agent may include one of the following: allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV); Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)
218858732|NCT02285114|DRUG|Boosted PIs|Allowed boosted PIs: LPV, ATV, DRV.
218858733|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
218858734|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
218858735|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
218858736|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
218858737|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
218858738|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
218858739|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
218858740|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
218858741|NCT00241098|DRUG|valsartan|
218858742|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
218858743|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
218858744|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
218858745|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
218858746|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
218858747|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
218858748|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
219020661|NCT07205406|BEHAVIORAL|group based-parenting training|The group received approximately three hours of parenting training once a week for 5 weeks that focused on understanding children with ID in the first week, practical parenting skills in the second week, and how to provide emotional support and regulate parental emotions in the third week. Knowledge and skills were reinforced in the fourth and fifth weeks. The intervention group received training in small groups, each consisting of only 10 participants. The training involved experts in mental health counseling, pediatric nurses, special school teachers, and a motivator.
219020662|NCT07205068|DEVICE|Shockwave M5 IVL Catheter|The Shockwave M5 IVL Catheter is a balloon catheter designed to modify calcified arterial plaque using intravascular lithotripsy prior to vascular access
219020663|NCT07205068|PROCEDURE|Modified Seldinger Technique|Standard of care for femoral access in patients with calcified femoral arteries
219020664|NCT07205068|PROCEDURE|Modified Seldinger Technique|Standard femoral artery access using the modified Seldinger technique without any prior vessel preparation or plaque modification.
219020665|NCT07205601|BIOLOGICAL|RB-ADSC|RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product
219020666|NCT07205601|OTHER|Placebo|0.9% NaCl USP
219020667|NCT07205471|PROCEDURE|Laparoscopic Partial Splenectomy|The laparoscopic partial splenectomy technique involved preserving the short gastric vessels and the splenic suspensory ligament, with resection conducted along the demarcation line.
219020668|NCT07206186|OTHER|Music|Music as per patient choice
219020669|NCT07205965|BEHAVIORAL|Experimental Group|The experimental group will consist of 16 participants and the participants will receive internet-based environment psychoeducation for 6 weeks, each session for 30 minutes.
219020670|NCT07205900|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
219020671|NCT07205900|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
219596598|NCT01313377|DRUG|oxaliplatin|
219596599|NCT01313377|OTHER|clinical observation|
219596600|NCT01313377|PROCEDURE|adjuvant therapy|
219596601|NCT01313377|PROCEDURE|quality-of-life assessment|
219596602|NCT02390947|DRUG|Famitinib|25 mg p.o. qd
218858749|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
219596603|NCT02390947|DRUG|Placebo|25 mg p.o. qd
218858750|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
218858751|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
218858752|NCT01752400|DRUG|AUY922|
218858753|NCT06419179|DRUG|Durvalumab|1500 mg i.v. Q4W
218858754|NCT06419179|DRUG|Olaparib|300 mg BID orally
218858755|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
218858756|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
218858757|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
218858758|NCT04599166|BEHAVIORAL|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
219020672|NCT07205835|BEHAVIORAL|ChatGPT Exercise Group|Participants in the ChatGPT group will follow an exercise program generated by ChatGPT and supervised by a physiotherapist. The program will be delivered twice weekly for 6 weeks, with each 50-minute session including exercises designed to improve posture, flexibility, and musculoskeletal function.
219020673|NCT07205835|BEHAVIORAL|Clinical Pilates Group|Participants in this arm will perform supervised clinical Pilates exercises twice weekly for 6 weeks. Each session will last 50 minutes and include core stabilization, postural correction, and flexibility exercises.
219020674|NCT07207122|DEVICE|Transcranial focused ultrasound modulation administered to a region involved in disease pathology.|Using Sanmai's device to administer tFUS to regions of interest.
219020675|NCT07206264|DRUG|Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody|"Induction phase (cycle 1-6):~Bendamustine (90 mg/m², day 1-2) +anti-CD20 monoclonal antibody (375 mg/m², day 0) from cycles 1-4. Patients who achieve CR and MRD negative continue to receive bendamustine (90 mg/m², day 1-2) + anti-CD20 monoclonal antibody (375 mg/m², day 0) from cycles 5-6; MRD positive patients receive orelabrutinib (150 mg) + anti-CD20 monoclonal antibody (375 mg/m², day 0).~Maintenance phase (cycle 7-24):~Patients who achieve CR and are MRD negative at cycle 4 receive bendamustine (90 mg/m², day 1-2) + anti-CD20 monoclonal antibody (375 mg/m², day 0); MRD-positive patients receive orelabrutinib (150 mg) + anti-CD20 monoclonal antibody (375 mg/m², day 0)."
219596604|NCT01541085|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
219020676|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for intravenous injection, 40 mg/mL
219020677|NCT07206043|BIOLOGICAL|RPH-104 160 mg|solution for intravenous injection, 40 mg/mL
219020678|NCT07206043|BIOLOGICAL|RPH-104 320 mg|solution for intravenous injection, 40 mg/mL
219596605|NCT01541085|DRUG|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
219596606|NCT03408639|DRUG|CinnaPoietin®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
219596607|NCT03408639|DRUG|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
219596608|NCT03408639|DRUG|Nephrovit|Nephrovit tablet is daily administered to all the patients.
219596609|NCT03408639|DRUG|Vitamin B12 Injection|Vitamin B12 is monthly injected to all the patients.
219596610|NCT06179654|BEHAVIORAL|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
219596611|NCT02925481|BEHAVIORAL|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
219596612|NCT02925481|BEHAVIORAL|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
219596613|NCT02925481|BEHAVIORAL|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
219596614|NCT01405482|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
219596615|NCT01405482|OTHER|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
219020679|NCT07206043|BIOLOGICAL|RPH-104 320 mg|solution for subcutaneous injection, 80 mg/mL
219020680|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous injection, 40 mg/mL
219020681|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous injection, 80 mg/mL
219474565|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
218858759|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
219474566|NCT06467916|BEHAVIORAL|Behavioral Treatment|anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
219474567|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
219474568|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
219474569|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
219474570|NCT04161066|DRUG|Psilocybin with facilitated counseling|open-label pilot study
219474571|NCT05205109|DRUG|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
219474572|NCT05205109|DRUG|KEYTRUDA ®( Pembrolizumab)|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1."
219474573|NCT05047237|BEHAVIORAL|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
219474574|NCT04051606|DRUG|Regorafenib|Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.
219474575|NCT00823563|PROCEDURE|30 cc blood draw|
219474576|NCT00823563|PROCEDURE|Intravascular ultrasound (IVUS)|
219474577|NCT00823563|PROCEDURE|Coronary pressure/flow wire testing|
219474578|NCT00823563|PROCEDURE|Coronary pressure/flow testing: Acetycholine challenge|
219596616|NCT05113368|DRUG|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
219596617|NCT05113368|DRUG|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
219596618|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
219596619|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
219596620|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
219596621|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
219596622|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
219596623|NCT04998851|DRUG|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
219596624|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
219596625|NCT00268385|OTHER|Pharmacological Study|Correlative studies
219596626|NCT00268385|DRUG|Temozolomide|Given orally
219596627|NCT00268385|DRUG|Vorinostat|Given orally
219596628|NCT00070499|DRUG|Dasatinib|Given PO
219596629|NCT00070499|DRUG|Imatinib Mesylate|Given PO
219596630|NCT00070499|OTHER|Laboratory Biomarker Analysis|Correlative studies
219596631|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
218858760|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
218858761|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
219020682|NCT07206043|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
219474579|NCT00823563|PROCEDURE|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
219474580|NCT00823563|PROCEDURE|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
219474581|NCT03319901|DRUG|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
219474582|NCT03319901|DRUG|Standard Chemotherapy|Standard treatment of chemotherapy is administered
219596632|NCT05964387|DEVICE|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
219596633|NCT05964387|DEVICE|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
219596634|NCT06795724|OTHER|PENG block|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
219596635|NCT06795724|OTHER|Control|Standard analgesia method will be applied and analgesia will be provided with tramadol hydrochloride and paracetamol.
219596636|NCT02883049|DRUG|Clofarabine|Given IV
218858762|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
218858763|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
218858764|NCT00272324|DRUG|Aspirin|
218858765|NCT00272324|DRUG|Folate|
218858766|NCT06980402|PROCEDURE|Early post-surgical discharge with post-surgical home based monitoring|The SKH@home program, is a post-discharge monitoring program, which allows stable post-surgical patients to be discharged earlier from hospital while providing regular post-discharge monitoring at the patient's own home, either through home visits and patient assessment, or telemonitoring of patients.
218858767|NCT06980402|PROCEDURE|Standard inpatient care until deemed suitable for discharge|Patients will receive standard postoperative management in the acute hospital until they are deemed fit for discharge by their primary surgeon
218858768|NCT06981026|OTHER|Telemedicine-based prehabilitation and postoperative rehabilitation protocol, including physical activity monitoring, respiratory and postural training, and guidance via telehealth tools.|A combination of wearable technology, activity guidelines, educational support, remote monitoring with notifications and consultations with physiotherapists.
218858769|NCT06979817|OTHER|TLS-Informed Machine Learning Prognostic Model|This intervention involves the development and application of a machine learning-based prognostic model that integrates features derived from tertiary lymphoid structures (TLSs) identified in tumor pathology slides, along with clinical and immunological data, to predict overall survival and immune landscape in patients with locally advanced gastric cancer. The model utilizes digital pathology, image analysis, and advanced computational algorithms to quantify TLS-related characteristics and correlate them with patient outcomes. It is designed to stratify patients into risk groups and provide insight into the tumor immune microenvironment, aiming to support personalized treatment planning.
218858770|NCT06984692|OTHER|iRise curriculum|"Intervention group: The intervention group would download the iRise mHealth app (iRise app) via Canvas on the participant's respective smart phones, and based on the participant's own schedules and preferences, would complete different modules of iRise. The iRise app would include emergency management elements as received by the control group, but presented via smart phone-based content delivery (i.e., rather than rather than via the in-person modality utilized for the control group)."
218858771|NCT06984692|OTHER|Control Curriculum|The control group will receive standard training in crisis response and management, which is offered as a course on Emergency Management and Response at AKU, for which study participants from JPMC will also readily access. The course involves introduction to disaster terminology, emergency management cycle and hospital-based patient treatment guidelines. The control curriculum will offer a comprehensive focus on disaster preparedness, addressing important subjects such as emergency management techniques, disasters, and triage. The eight-hour training will be split into two parts, aiming to improve academic and practical understanding. The first part will be a didactic session, where participants will learn fundamental information through lectures and discussions. The second part will consist of hands-on training, allowing attendees to practice and apply learned concepts in simulated emergency scenarios.
218858772|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
218858773|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
218858774|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
218858775|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
218858776|NCT06608836|OTHER|an ice massage|an ice massage
218858777|NCT06608836|OTHER|the cold spray|the cold spray
218858778|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
218858779|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
218858780|NCT06994013|OTHER|High-frequency vibration foam rolling|Athletes will be performed three sets of HFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during HFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During HFVFR, the vibrator booster will be set to a frequency of 67 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
219020683|NCT07206225|DRUG|PF-08052667|PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash
218858781|NCT06994013|OTHER|Low-frequency vibration foam rolling|Athletes will be performed three sets of LFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during LFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During LFVFR, the vibrator booster will be set to a frequency of 35 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
218858782|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
218858783|NCT03761069|DRUG|PTC299|PTC299 will be administered per the treatment arm description
218858784|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
218858785|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
218858786|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
218858787|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
218858788|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
218858789|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
218858790|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
218858791|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
218858792|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
218858793|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
218858794|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
218858795|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
219474583|NCT06190912|DRUG|Bryostatin 1|Eligible participants will be treated with bryostatin over a 26-week period. Doses 1, 2, 8, and 9 of the study drug will be a loading dose 20% higher (i.e., 24 µg) than the assigned fixed dose and will be administered one week apart. Otherwise, the assigned fixed dose is 20 µg. Drug is administered intravenously (IV) by continuous infusion over 45(±5) minutes. Participants are scheduled to receive 14 doses over 26 weeks.
219474584|NCT05028816|DEVICE|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
219474585|NCT05028816|OTHER|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
218858796|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
218858797|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
219474586|NCT05028816|DEVICE|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
219474587|NCT05028816|OTHER|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
218858798|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
218858799|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
218858800|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
219020684|NCT07206225|DRUG|Sasanlimab|Sasanlimab will be administered as subcutaneous (SC) injection
219474588|NCT06964425|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Insertion of a endoscopic fiber-optic Raman probe under fluoroscopic control during endoscopic retrograde cholangiopancreatography to measure Raman spectra of extrahepatic cholangiocarcinoma and healthy bile duct.
219474589|NCT05064436|DRUG|11C-BMS-986196|Specified dose on specified days
219596637|NCT02883049|DRUG|Cyclophosphamide|Given IV
219596638|NCT02883049|DRUG|Cytarabine|Given IT, IV, or SC
218858801|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
218858802|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
218858803|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
219020685|NCT07206225|DRUG|BCG|BCG will be administered intravesical (IVe) instillation
219020686|NCT07206225|DRUG|PF-02921367|PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation
219474590|NCT06008808|DRUG|Ruxolitinib|Ruxolitinib is provided by Incyte Corporation.
219474591|NCT06008808|DRUG|Abatacept|Abatacept is commercially available.
218858804|NCT01442506|OTHER|biopsies|taking biopsies
218858805|NCT01442506|OTHER|biopsy|biopsy
218858806|NCT06699589|BEHAVIORAL|Old SCHOOL Hip-Hop (Dementia Education)|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
218858807|NCT06699589|BEHAVIORAL|My Plate (Nutrition Education)|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
218858808|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
218858809|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
218858810|NCT04639219|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
218858811|NCT07033949|DEVICE|Green light glasses|Exposure to green light for 30 minutes
218858812|NCT07033949|DEVICE|Transparent light exposure|Exposure to transparent light for 30 minutes
219199401|NCT06484400|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.
219199402|NCT06484400|BEHAVIORAL|Ericksonian Hypnotehrapy|Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
219474592|NCT04552769|DRUG|Abemaciclib|200 mg orally
219474593|NCT05011760|RADIATION|Baseline [C-11]NPA PET Scan|Radiotracer
219474594|NCT05011760|DRUG|d-amphetamine|Oral, 0.5 mg/Kg
219474595|NCT05011760|RADIATION|Post-amphetamine [C-11]NPA PET Scan|Radiotracer
219474596|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
219474597|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
219474598|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
219596639|NCT02883049|DRUG|Dasatinib|Given PO
219596640|NCT02883049|DRUG|Daunorubicin Hydrochloride|Given IV
218858813|NCT07033286|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
218858814|NCT07033286|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
219199403|NCT05997082|OTHER|Mindfulness Self-Compassion Course|This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).
218858815|NCT07041957|OTHER|Individualized flow-controlled ventilation strategy|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP) will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. Compliance-guided driving pressure (ΔP) trial: In the FCV group, an additional incremental ΔP trial in 1 cmH2O steps is initiated after the PEEP trial. This trial evaluates if the tidal volume increases (over-)proportional to the dynamic compliance on the previous ΔP level when the ΔP is increased by 1 cmH2O. In the FCV group, participants are ventilated with a ΔP consistent with the highest dynamic compliance ± 1-2 cmH2O. The compliance-guided PEEP and ΔP trials are repeated every 8 hours in order to account for changes in overall lung compliance."
219474599|NCT06367764|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
219474600|NCT06367764|BEHAVIORAL|STAIR Narrative Therapy|STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
219474601|NCT06209060|BEHAVIORAL|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
219596641|NCT02883049|DRUG|Dexamethasone|PO or IV
219596642|NCT02883049|DRUG|Doxorubicin Hydrochloride|Given IV
219596643|NCT02883049|DRUG|Etoposide|Given IV
219596644|NCT02883049|DRUG|Hydrocortisone Sodium Succinate|Given IT
219596645|NCT02883049|OTHER|Laboratory Biomarker Analysis|Correlative studies
218858816|NCT07041957|OTHER|Pressure-controlled ventilation strategy via the application of Biphasic Positive Airway Pressure ventilation|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP)will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. The driving pressure (ΔP) is set to achieve a tidal volume of 6-8 ml/kg predicted body weight.~The compliance-guided PEEP trial is repeated every 8 hours in order to account for changes in overall lung compliance."
218858817|NCT07041866|DIETARY_SUPPLEMENT|Fortified Biscuit with Local Iron-Rich Ingredients|Participants consumed one fortified biscuit per day, five days a week (school days), for a period of three months. The biscuit was formulated using wheat flour, millet, maize, peanut paste, sugar, and was filled with a blend of Moringa oleifera, Hibiscus sabdariffa, Adansonia digitata, and Detarium senegalense-all selected for their high iron and vitamin C content. The iron content was approximately 4 mg per 100 g.
218858818|NCT07041866|DIETARY_SUPPLEMENT|Non-Fortified Biscuit|Participants received a placebo biscuit daily for the same period and frequency as the intervention group. The placebo biscuit was visually and texturally identical to the fortified biscuit but did not contain the micronutrient-rich filling.
218858819|NCT07040852|BEHAVIORAL|Mental Health Literacy Promotion Intervention Program|10 sessions, 90 minutes each, weekly. A face-to-face group treatment for Chronic Pain that focuses on enhancing individuals' understanding of mental health issues, promoting help-seeking behaviors, and reducing stigma associated with mental illness. Intervention includes group discussions, audio-visual material and written material.
218858820|NCT07042009|OTHER|Nutritional resources|The participants will be provided with the nutritional resources only.
218858821|NCT07042009|OTHER|Milk docosahexaenoic acid levels|The participants will be provided with information on the levels of docosahexaenoic acid in their breast milk.
218858822|NCT07040124|PROCEDURE|ti mesh|prebent titamesh on a 3-d virtually augmented model
218858823|NCT07040124|PROCEDURE|3d peek mesh|milled 3d peek mesh
218858824|NCT07032675|DEVICE|Low-temperature radio-frequency reshaping of autologous cartilage nasal and/or auricular cartilage|The device settings will be set per the manufacturer's instructions: temperature = 60° C, power = 4 W, treatment time = 18 seconds, and cooldown = 12 seconds. For curved-to-straight (CTS) samples (natively curved cartilage to be remolded to be flat), the cartilage specimens will be placed on a blue towel on a flat surface with the transmission medium over top and treated. For straight-to-curved (STC) samples (natively flat cartilage to be remolded to be curved), cartilage specimens will be placed along the inner surface of various shallow, plastic, cylindrical objects with the transmission medium over top and treated. Various device settings may be tested for reshaping efficacy.
218858825|NCT07040501|DEVICE|Chat GPT|On the date of appointment, participants will be given up to 30 minutes, to interact with a pre-prompted Chat GPT (Prostate Pathology Guide) using a Cleveland clinic device.
218858826|NCT07040189|OTHER|Gustabor server|AI based web platform providing individual lifestyle tips and recipe recommendations based on the patient's individual data and taste disorder
218858827|NCT07041762|PROCEDURE|Rhomboid Intercostal Block with Sub-Serratus Plane Block|"Ultrasound-guided regional anesthesia combining two injections:~Rhomboid Intercostal Block (20 mL of 0.25% bupivacaine injected between rhomboid major and intercostal space)~Sub-Serratus Plane Block (20 mL of 0.25% bupivacaine injected between serratus anterior and ribs).~Both performed 30-45 minutes before Modified Radical Mastectomy under general anesthesia."
218858828|NCT07041762|PROCEDURE|Erector Spinae Plane Block|"Ultrasound-guided regional block with 30 mL of 0.25% bupivacaine injected into the paraspinal plane at the T4-T5 level, between the erector spinae muscle and the transverse processes.~Performed 30-45 minutes prior to general anesthesia for Modified Radical Mastectomy."
218858829|NCT07040241|PROCEDURE|Confocoal laser endomicroscopy-assisted ultrasound-guided pleural biopsy|Using the probe-based confocal laser endomicroscopy to detect the pleural, and ensure the biopsy location. Then, use the pleural biopsy tool to complete the pleural biopsy. The whole procession will under the ultrasound guidance.
218858830|NCT07040241|PROCEDURE|Ultrasound-guided pleural biopsy|Using ultrasound to detect the biopsy site and perform pleural biopsy.
218858831|NCT07041697|DEVICE|Light-emitting diode photobiomodulation therapy|For the intervention, the isolated arteries were assigned to three experimental groups. The first group (red) was exposed to light at a wavelength of 650 nm for 83 seconds. The second group (infrared) received irradiation at 940 nm for 94 seconds. The third group (mixed) was irradiated with a combination of red (650 nm) and infrared (940 nm) light for 73 seconds.
218858832|NCT07040670|PROCEDURE|Confocal laser endomicroscopy-assisted endobronchial ultrasound-guided transbronchial needle aspiration|First, use the EBUS needle to create a hole in the airway wall. Then, insert the CLE into the lymph node via this hole and detect the lymph node. When the specific pathological finding is detected by CLE, record the location. Finally, using the needle to perform EBUS-TBNA in the area under EBUS guidance.
218858833|NCT07040670|PROCEDURE|Endobronchial ultrsound-guided Mediastinal cryobiopsy|Using the cryoprobe to perform EBUS-TBMC three times per person.
219020687|NCT07206329|DRUG|Polyethylene Glycol plus Ascorbic Acid (PEG-Asc)|Participants receive a split-dose bowel preparation with 1 L polyethylene glycol plus ascorbic acid (PEG-Asc). The first dose is administered at 20:00 the evening before the procedure (500 mL PEG-Asc solution consumed over 1 hour, followed by 500 mL clear liquids). The second identical dose is taken at 06:00 on the day of the capsule procedure.
219199404|NCT05334355|OTHER|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
219474602|NCT06209060|BEHAVIORAL|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
219474603|NCT03396445|DRUG|Boserolimab|IV infusion
219474604|NCT03396445|BIOLOGICAL|Pembrolizumab|IV infusion
219474605|NCT03396445|DRUG|Pemetrexed|IV infusion
219474606|NCT03396445|DRUG|Carboplatin|IV infusion
219474607|NCT03396445|DRUG|Nab-paclitaxel|IV infusion
219474608|NCT01892397|DEVICE|Optune (NovoTTF-100A)|
219596646|NCT02883049|DRUG|Leucovorin Calcium|Given PO or IV
219596647|NCT02883049|DRUG|Mercaptopurine|Given PO
219474609|NCT06583993|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per RECIST v1.1 criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
219474610|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
219474611|NCT05216575|DRUG|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
219474612|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
219474613|NCT02957149|OTHER|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
219474614|NCT02957149|DEVICE|Angel Concentrated Platelet Rich Plasma System|
219474615|NCT04076657|BEHAVIORAL|Brock String Therapy|Oculomotor exercise to improve binocular vision function
219596648|NCT02883049|DRUG|Methotrexate|Given IT and IV
218858834|NCT07040176|PROCEDURE|Upper molar distalization|This study aims to compare upper molar distalization movement achieved with a non-compliance miniscrew implant supported appliance (AMDA®) with distalization of upper molars achieved with clear aligners (Spark®) supported by Class II elastics.
218858835|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
218858836|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
218858837|NCT07040683|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative pressure wound therapy (NPWT) applied over the split-thickness skin graft on the lower leg after tumour excision. A protective silicone interface layer will be used, with continuous negative pressure of -125 mmHg applied until postoperative day 5, unless earlier change is clinically indicated.
218858838|NCT07040683|OTHER|Traditional Dressing|Traditional dressing applied over the split-thickness skin graft on the lower leg after tumour excision. The dressing consists of one or more layers of foam dressing applied on top, which may or may not be fixed with sutures according to surgeon preference, and an elastic bandage applied over the foam to provide gentle, even compression and immobilisation of the graft. The dressing will remain undisturbed until postoperative day 5 unless earlier change is clinically indicated.
219020688|NCT07206329|DRUG|Sodium Picosulfate with Magnesium Citrate (SPMC)|Participants receive sodium picosulfate with magnesium citrate (SPMC) in a split-dose regimen. The first sachet is dissolved in 150 mL water and followed by 1.5-2 L of clear fluids the evening before the procedure, and the second sachet is taken with the same fluid regimen on the morning of the procedure.
219474616|NCT04076657|BEHAVIORAL|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
219474617|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
219474618|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
219474619|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
219474620|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
219474621|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
219596649|NCT02883049|DRUG|Pegaspargase|Given IV
219596650|NCT02883049|DRUG|Prednisone|Given PO or IV
219596651|NCT02883049|RADIATION|Radiation Therapy|Undergo radiation therapy
219596652|NCT02883049|DRUG|Thioguanine|Given PO
219596653|NCT02883049|DRUG|Vincristine Sulfate|Given IV
219596654|NCT05877716|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
219474622|NCT01406548|DRUG|BPS804 20mg/Kg|
219474623|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
219596655|NCT05877716|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
219474624|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
219596656|NCT05877716|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
219596657|NCT05806606|OTHER|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
218858839|NCT00383643|DRUG|zolpidem tartrate|
218858840|NCT00383643|DRUG|sodium oxybate|
219474625|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
219474626|NCT00094146|DRUG|Sandostatin LAR Depot|
219474627|NCT00082134|DRUG|ILX651|
219474628|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
219474629|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
219474630|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
218858841|NCT00383643|DRUG|Matching Placebos|
218858842|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
219474631|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
219474632|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
218858843|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
218858844|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
218858845|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
219474633|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
218858846|NCT01689714|DRUG|Tc 99m EC20|
218858847|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
218858848|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
218858849|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
218858850|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
219474634|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
218858851|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
218858852|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
218858853|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
218858854|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
218858855|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
218858856|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
218858857|NCT01989780|DRUG|Paclitaxel|
218858858|NCT01989780|DRUG|Bevacizumab|
219474635|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
219474636|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
219474637|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
219596658|NCT05806606|OTHER|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
219596659|NCT05041829|OTHER|Dietary sodium|Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
219596660|NCT04769921|DEVICE|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
219596661|NCT06647056|DRUG|Psilocybin|Administration of psilocybin 25 mg
218858859|NCT01989780|DRUG|Letrozole|
218858860|NCT01989780|DRUG|Anastrozole|
218858861|NCT01989780|DRUG|Exemestane|
218858862|NCT01989780|DRUG|Fulvestrant|
218858863|NCT01989780|DRUG|Goserelin|
218858864|NCT01989780|DRUG|leuprorelin|
218858865|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
218858866|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
218858867|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
218858868|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
218858869|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
218858870|NCT02183337|DRUG|BI 1356|
218858871|NCT02183337|DRUG|BI 1356 + Pioglitazone|
218858872|NCT02183337|DRUG|Pioglitazone|
219474638|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
219474639|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
219474640|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
219474641|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
218858873|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
218858874|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
218858875|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
218858876|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
218858877|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
218858878|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
218858879|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
218858880|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
218858881|NCT03397888|DRUG|Betrixaban|80 mg capsule
218858882|NCT02626234|DRUG|INC280|
218858883|NCT02626234|DRUG|digoxin|
218858884|NCT02626234|DRUG|rosuvastatin|
219474642|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
219474643|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
219474644|NCT03324373|DRUG|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
219474645|NCT03324373|DRUG|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
218858885|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
218858886|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
219474646|NCT03324373|PROCEDURE|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
219474647|NCT00267917|DEVICE|Berodual Respimat|
219474648|NCT00267917|DEVICE|Berodual HFA-MDI|
218858887|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
218858888|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
219474649|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
218858889|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
218858890|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
218858891|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
218858892|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
218858893|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
218858894|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
219596662|NCT06647056|OTHER|MRI|Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
219596663|NCT06151626|OTHER|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
218858895|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
219474650|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
219474651|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
219474652|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
219474653|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
219474654|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
219474655|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
219474656|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
219474657|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
219474658|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
219474659|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
219474660|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
219474661|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
219474662|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
219476208|NCT04275999|BEHAVIORAL|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
219476209|NCT04275999|DEVICE|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
219476210|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
219476211|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
219476212|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
219476213|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
219476214|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
218858896|NCT02187523|DRUG|Hydrochlorothiazide|
218858897|NCT02187523|DRUG|Telmisartan|
218858898|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
218858899|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
218858900|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
218858901|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
218858902|NCT03554772|DRUG|Placebo|Oral Solution
218858903|NCT02010736|OTHER|Single treadmill gait training with additional loading|
219596664|NCT06151626|OTHER|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
219596665|NCT06151626|OTHER|strengthening group|Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
219596666|NCT06151626|OTHER|breathing and muscle relaxation exercises|5 minutes of breathing and muscle relaxation exercises
218858904|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
218858905|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
219363521|NCT01305863|DEVICE|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
219363522|NCT01305863|DEVICE|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
219363523|NCT02058147|DRUG|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
219363524|NCT02058147|DRUG|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
219363525|NCT02058147|DRUG|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
219363526|NCT02058147|DRUG|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
219363527|NCT04009993|DEVICE|A-BIRTHPERFORM digital tool|use of A-BIRTHPERFORM digital tool
219363528|NCT05236998|DRUG|SID1903 (FDC)|Single oral administration of SID1903 (FDC) after an overnight fast
219363529|NCT05236998|DRUG|Dapagliflozin and Sitagliptin|Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
219363530|NCT05572463|COMBINATION_PRODUCT|Sintilimab + IBI110|IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
219363531|NCT03640832|OTHER|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
219363532|NCT03640832|OTHER|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
219363533|NCT02642926|PROCEDURE|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
219363534|NCT02642926|PROCEDURE|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
219363535|NCT04801628|DEVICE|Active Tecar|Active Tecar
219363536|NCT04801628|DEVICE|Placebo Tecar|Placebo Tecar
219363537|NCT05334446|BEHAVIORAL|The Effect of the Mobile Application|"This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control."
219363538|NCT05537545|PROCEDURE|Soft tissue grafting|A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
219363539|NCT02170116|DRUG|BIBR 1048 MS dose 1|
219363540|NCT02170116|DRUG|BIBR 1048 MS dose 2|
219363541|NCT02170116|DRUG|BIBR 1048 MS dose 3|
219363542|NCT02170116|DRUG|BIBR 1048 MS dose 4|
218858906|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
219474663|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
218858907|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
218858908|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
218858909|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
218858910|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
218858911|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
218858912|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
219476215|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
218858913|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
218858914|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
218858915|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
218858916|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
219476216|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
219476217|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
219476218|NCT01955824|DRUG|1% lignocaine|
219476219|NCT01955824|DRUG|2% lignocaine|
219476220|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
219476221|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
219476222|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
219476223|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
219476224|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
218858917|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
218858918|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
218858919|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
218858920|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
218858921|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
218858922|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
218858923|NCT01363180|OTHER|No stress condition|
218858924|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
218858925|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
218858926|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
219474664|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
219596667|NCT05064423|BEHAVIORAL|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
219596668|NCT04648696|DRUG|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
219596669|NCT04648696|DRUG|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
219596670|NCT05133934|OTHER|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
219596671|NCT03761940|OTHER|EQ5D questionnaire and a demographic questionnaire|questionnaires
219596672|NCT06303843|OTHER|Transfer with an electric ride-on car|The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
219596673|NCT01589718|DRUG|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
219596674|NCT01589718|DRUG|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
219596675|NCT06160219|DRUG|Hydroxycobalamin|prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
219596676|NCT03597919|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
218858927|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
218858928|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
219474665|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
219596677|NCT06121934|DRUG|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
219596678|NCT06121934|DRUG|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
219596679|NCT00894829|BIOLOGICAL|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
219596680|NCT00894829|BIOLOGICAL|heparin sodium - APP|Heparin sodium APP 5.000 USP
219474666|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
219474667|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
219474668|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
218858929|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
218858930|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
218858931|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
219474669|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
219474670|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
219474671|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
219474672|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
219474673|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
219596681|NCT05096429|BEHAVIORAL|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
219596682|NCT02295540|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated IMRT
219596683|NCT02295540|RADIATION|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
219596684|NCT02295540|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219596685|NCT02295540|OTHER|laboratory biomarker analysis|Correlative studies
219596686|NCT04107792|BEHAVIORAL|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
219596687|NCT03103841|PROCEDURE|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
219596688|NCT05495698|DRUG|single-inhaler triple therapy (Trimbow)|Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
219596689|NCT05495698|DEVICE|E-health application: Curavista app & FindAir e-device|Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
219596690|NCT05495698|DRUG|multi-inhaler triple therapy (Qvar + Bevespi)|Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
218858932|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
218858933|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
218858934|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
219199405|NCT06609421|OTHER|Informative Appointment|The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.
219199406|NCT06669338|OTHER|Music therapy|patients listen to music for 20 minutes with headphones before colonoscopy.
218858935|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
218858936|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
218858937|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
218858938|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
218858939|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
219474674|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
219474675|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
219474676|NCT01987570|DRUG|Allopurinol|
219474677|NCT01987570|DRUG|Placebo|
219474678|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
219474679|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
219474680|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
219474681|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
219474682|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
218858940|NCT03564964|DRUG|SUVN-502|Tablet
218858941|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
219199407|NCT06669338|OTHER|listen to white noise|patients listen to white noise with headphones for 20 minutes before colonoscopy.
219199408|NCT06669338|OTHER|listen to hospital ambient sound|patients listen to recorded ambient sound for 20 minutes with headphones before colonoscopy.
219199409|NCT06157086|OTHER|ofatumumab|There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
219199410|NCT06376474|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
219199411|NCT05104983|DRUG|Sirolimus|The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
219199412|NCT05104983|DRUG|Placebo|Matching placebo
219474683|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
219474684|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
219474685|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
219474686|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
219474687|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
219474688|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
219474689|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
219474690|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
219474691|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
219474692|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
219474693|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
219474694|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
219474695|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
219474696|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
219474697|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
219474698|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
219474699|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
219474700|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
218858942|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
218858943|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
218858944|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
218858945|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
218858946|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
218858947|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
218858948|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
218858949|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
219474701|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
219474702|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
219474703|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
219474704|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
219474705|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
219474706|NCT00308555|DRUG|Cannabis|
219474707|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
219596691|NCT05173441|BIOLOGICAL|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
218858950|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
218858951|NCT04972227|DRUG|CY6463|oral tablets
219474708|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
219199413|NCT05473637|DIAGNOSTIC_TEST|MRI|Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
219199414|NCT05693337|DEVICE|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
219474709|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
219474710|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
219474711|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
219596692|NCT05173441|DRUG|Placebo|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
219199415|NCT06189170|DRUG|KP405|Experimental drug
219199416|NCT06189170|DRUG|Placebo|Placebo
219474712|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
219474713|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
219474714|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
219474715|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
219474716|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
219474717|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
219474718|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
219474719|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
219474720|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
218858952|NCT04972227|DRUG|Placebo|oral tablets
218858953|NCT02202512|DRUG|Placebo|tablets
218858954|NCT02202512|DRUG|Cimetidine|
218858955|NCT02202512|DRUG|Placebo|tablets
218858956|NCT02202512|DRUG|Placebo|tablets
219474721|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
218858957|NCT02202512|DRUG|BI 1060469 high dose|tablets
218858958|NCT02202512|DRUG|BI 1060469 low dose|tablets
218858959|NCT02202512|DRUG|Naproxen|
218858960|NCT02202512|DRUG|BI 1021958|tablets
219474722|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
218858961|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
218858962|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
218858963|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
218858964|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
218858965|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
218858966|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
218858967|NCT00302276|DRUG|Metobes-compound|
218858968|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
218858969|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
218858970|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
218858971|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
218858972|NCT03417596|OTHER|Control|Routine treatment
218858973|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
218858974|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
218858975|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
218858976|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
218858977|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
218858978|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
218858979|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
218858980|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
218858981|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
219363543|NCT02170116|DRUG|BIBR 1048 MS dose 5|
219363544|NCT02170116|DRUG|Placebo to BIBR 1048 MS|
219363545|NCT04972994|PROCEDURE|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
219363546|NCT00784667|DRUG|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
219363547|NCT00784667|DRUG|Erlotinib|100mg orally daily continuously
219363548|NCT03556215|DEVICE|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
219363549|NCT03556215|PROCEDURE|Myringotomy|Myringotomy will be performed using a standard procedure.
219474723|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
219474724|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
218858982|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
218858983|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
218858984|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
218858985|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
218858986|NCT00241631|DRUG|Fluticasone Propionate|500 u
218858987|NCT00241631|DRUG|placebo|
219474725|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
218858988|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
218858989|NCT01188148|DRUG|Memantine|5 mg per day of memantine
218858990|NCT01188148|DRUG|Placebo|
219474726|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
219474727|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
219474728|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
219474729|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
219474730|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
218858991|NCT04059523|DRUG|S6G5T-3|once daily
218858992|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
218858993|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
218858994|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
218858995|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
219199417|NCT04711759|DEVICE|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
219476225|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
218858996|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
218858997|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
218858998|NCT00004664|DRUG|megestrol|
218858999|NCT00004664|BEHAVIORAL|Exercise|
218859000|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
218859001|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
218859002|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
219199418|NCT04711759|DEVICE|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
219199419|NCT04024059|BEHAVIORAL|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
219474731|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
219474732|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if… then…. This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
219596693|NCT05985772|OTHER|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
219596694|NCT05985772|PROCEDURE|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
219596695|NCT01476566|BEHAVIORAL|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
219596696|NCT06416046|DEVICE|Gemini laser|Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis. A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
219596697|NCT06416046|OTHER|Placebo|Examination and follow-up until the lesion heals spontaneously. The laser will not be activated.
219596698|NCT01887171|DRUG|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
219596699|NCT01691235|DEVICE|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
218859003|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
218859004|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
218859005|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
218859006|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
218859007|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
218859008|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
218859009|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
219199420|NCT04024059|BEHAVIORAL|Contingency Management for abstinence|Incentives contingent on opiate abstinence
219199421|NCT03384537|COMBINATION_PRODUCT|Listerine total care zero|reducing intra-oral cariogenic microorganism.
219199422|NCT03384537|COMBINATION_PRODUCT|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
219474733|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
219474734|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
219474735|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
219474736|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
219596700|NCT03456388|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
218859010|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
218859011|NCT00004174|BIOLOGICAL|filgrastim|
218859012|NCT00004174|DRUG|cyclophosphamide|
218859013|NCT00004174|DRUG|paclitaxel|
218859014|NCT00004174|DRUG|thiotepa|
218859015|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
218859016|NCT00004174|RADIATION|radiation therapy|
218859017|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
218859018|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
218859019|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
218859020|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
218859021|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
218859022|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
219020689|NCT07206446|DEVICE|RiSolve|"RiSolve is a Class I device in accordance with Rule 11 of Annex VIII of EU Medical Device Regulation (MDR) 2017/745. The RiSolve App is a smartphone application that users can download following a diagnosis of OAB by a healthcare provider, and following prescription of the RiSolve App. RiSolve consists of an 8-week program including activities to set baselines and assess progress, treatment modules, and modules to enhance engagement.~As part of setting baselines and assessing progress, participants complete a series of clinically validated questionnaires. This data is presented to users to promote self-monitoring of behaviours and a deeper understanding of their symptoms. A patient report is auto-generated at the end of treatment. This is sent to the patient and contains their in-app self-generated data, their questionnaire results and their bladder diary data (see Appendix 1: RiSolve Patient Report). This information is also provided to the prescribing healthcare provider as an object"
218859023|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
218859024|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
218859025|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
218859026|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
219020690|NCT07205172|OTHER|Orthodontic and periodontal analysis|Intraoral digital impression aimed at orthodontic analysis and periodontal evaluation using a dedicated periodontal probe, as part of the routine dental examination.
218859027|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
218859028|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
218859029|NCT00004480|DRUG|botulinum toxin type A|
218859030|NCT00315770|PROCEDURE|weight loss diets for young adults|
218859031|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
218859032|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
218859033|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
218859034|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
219474737|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
219474738|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
219474739|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
219474740|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
219474741|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
219474742|NCT03869905|DRUG|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
218859035|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
218859036|NCT01355263|DRUG|iron and vitamin a|
219474743|NCT03869905|DRUG|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
219474744|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
219474745|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
218859037|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
218859038|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
218859039|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
219474746|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
219020691|NCT07207161|BEHAVIORAL|Infant Massage|A standardized infant massage protocol applied by a physiotherapist, including gentle tactile stimulation to promote growth, relaxation, and neuromuscular development in premature infants.
218859040|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
218859041|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
218859042|NCT02102126|PROCEDURE|Renal denervation|
218859043|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
218859044|NCT00001065|DRUG|Amphotericin B|
218859045|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
219020692|NCT07207161|BEHAVIORAL|Physiotherapy (Moyer-Mileur Protocol)|A single-session physiotherapy intervention consisting of gentle range of motion and flexion-extension exercises following the Moyer-Mileur protocol to stimulate musculoskeletal and neuromotor development in premature infants.
219474747|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
219474748|NCT06357299|BEHAVIORAL|Small Bottle Size|Small sized bottle
219474749|NCT06357299|BEHAVIORAL|Standard Bottle Size|Standard sized bottle
219474750|NCT06357299|BEHAVIORAL|Clear Bottle|Clear bottle
219474751|NCT06357299|BEHAVIORAL|Opaque Bottle|Opaque bottle
219474752|NCT05081531|RADIATION|Adaptive Radiotherapy|All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.
219474753|NCT00480077|DEVICE|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
219474754|NCT05868135|BEHAVIORAL|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
219474755|NCT04214015|OTHER|No intervention|There is no intervention for this study
219474756|NCT06510894|DRUG|Sotagliflozin|Sodium-glucose cotransporter-1/2 inhibitor
219474757|NCT05879614|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
219474758|NCT05356182|OTHER|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
219474759|NCT05969678|BEHAVIORAL|breathing training|receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete
219474760|NCT03104491|DRUG|Inotuzumab Ozogamicin|"Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)"
219474761|NCT05324449|DRUG|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
219474762|NCT04211428|OTHER|No intervention|There is no intervention for this study
219474763|NCT06801054|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|All patients will receive a second dose of tenecteplase.
219474764|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
219474765|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
219474766|NCT04899206|DRUG|With an Antidepressant Drug|Current users of an antidepressant drug.
219474767|NCT04899206|DRUG|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
219474768|NCT03196518|PROCEDURE|PET Imaging|PET/CT study immediately after injection
219020693|NCT07206706|DRUG|Tadalafil 5Mg Tab|PDE5 inhibitor
219474769|NCT03196518|OTHER|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
219020694|NCT07206706|DRUG|Darifenacin 7.5 MG|anti muscarinic
219474770|NCT06279910|DRUG|Calcifediol|Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
219474771|NCT05265975|DRUG|ATG-010|Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
219474772|NCT05265975|DRUG|Lenalidomide|Oral administration,QD, Days 1-21 of each cycle
219474773|NCT05265975|DRUG|Rituximab|Intravenous injection Days 1 of each cycle, Cycles 1-6
219476226|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
219476227|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
219474774|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
219596701|NCT03456388|DRUG|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
219596702|NCT00620685|DRUG|Placebo|Tablet, once daily for 4 weeks
219596703|NCT00620685|DRUG|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
219596704|NCT00620685|DRUG|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
219596705|NCT01810510|PROCEDURE|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
219596706|NCT01810510|PROCEDURE|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
219596707|NCT02245412|BIOLOGICAL|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
219596708|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
219596709|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
218859046|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
219596710|NCT00001526|DRUG|Daclizumab (Zenapax)|
219596711|NCT05009511|BEHAVIORAL|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
219596712|NCT03293316|DEVICE|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
219596713|NCT02593643|DRUG|Ketamine|
219596714|NCT02593643|DRUG|Midazolam|
219596715|NCT02593643|OTHER|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
219596716|NCT03677583|OTHER|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
219596717|NCT03677583|OTHER|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
219596718|NCT05146843|DRUG|Mitoquinone|Mitoquinone pill, 20 mg/day
219474775|NCT05295888|DEVICE|Temporal Interference stimulation|TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
219474776|NCT05295888|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
219474777|NCT04920968|DRUG|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
219474778|NCT04920968|DRUG|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
219474779|NCT03050723|DEVICE|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
219474780|NCT06446765|BEHAVIORAL|mindfulness-based Neurofeedback|Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
219474781|NCT06446765|OTHER|control Neurofeedback|Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
219474782|NCT06308952|DRUG|Atorvastatin 20mg|Eligible subjects screened will enter the pretreatment period (at least 24 hours) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). Additionally, the patient was started on basic dual anti-platelet (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
219474783|NCT03210545|DRUG|Betamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
219596719|NCT05146843|OTHER|Placebo|Placebo pill, 20 mg/day
219020695|NCT07206095|GENETIC|Analysis of genetic modifiers|Genetic modifiers for rare anemia disorders will be analyzed through massive sequencing.
219474784|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
219474785|NCT05363397|DRUG|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
219474786|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
219474787|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
219596720|NCT06013826|OTHER|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
219596721|NCT04320043|PROCEDURE|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
219596722|NCT00490984|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
219596723|NCT05576766|PROCEDURE|Routine care|"1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14)."
219020696|NCT07206095|DIAGNOSTIC_TEST|Disease phenotyping|Peripheral blood samples will be used for conventional phenotyping characterization including among others: RBCs morphology, fragility osmotic test, hemoglobin fraction and quantification, hemoglobin stability test, EMA binding test, RBC enzymes quantification assay, RBC rheological properties through Lorrca Maxsis Osmoscan/Oxygescan (Lorrca®)
219020697|NCT07206797|DEVICE|Functional Electrical Stimulation|Functional electrical stimulation will be applied to the ankle muscles. The resulting torque will be collected, and ultrasound data will be obtained during stimulation.
219474788|NCT05793489|OTHER|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
219474789|NCT05307237|DEVICE|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
219474790|NCT05307237|DEVICE|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
219474791|NCT04099979|OTHER|No Intervention|There is no intervention for this study
219474792|NCT06339203|DEVICE|Irrisept|450ml low concentration (0.05%) Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water
219474793|NCT06339203|DRUG|Normal Saline|450mL
219474794|NCT06017713|BEHAVIORAL|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
219474795|NCT05923203|OTHER|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
219474796|NCT05660070|BEHAVIORAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
219474797|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
219474798|NCT05762276|BIOLOGICAL|Placebo|Normal saline
219474799|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
219474800|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
219474801|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
219474802|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
219474803|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
219474804|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
218859047|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
218859048|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
218859049|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
219020698|NCT07206797|DEVICE|Transcutaneous (Non-Invasive) Spinal Cord Stimulation|Non-invasive spinal cord stimulation will be applied. The resulting torque data will be collected, and ultrasound data will be obtained during stimulation.
219020699|NCT07206797|DEVICE|Ultrasound|Ultrasound data will be collected from the shin muscles during FES and tSCS.
219020700|NCT07205484|BEHAVIORAL|Parent-Mediated Intervention (PMI)|The PMI consisted of weekly, 1-hour intervention sessions via Zoom for 6 months. In total, the intervention consisted of 26 intervention sessions.
219474805|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
219474806|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
219474807|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
219474808|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
219474809|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
219474810|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
219474811|NCT00618046|DRUG|Oxcarbazepine|
219474812|NCT00262119|DEVICE|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
219474813|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
219474814|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
219474815|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
219474816|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
219474817|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
219474818|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
219474819|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
219474820|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
219474821|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
219474822|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
219474823|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
219474824|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
219474825|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
219474826|NCT02116374|OTHER|Physiopathology study|
219596724|NCT05576766|PROCEDURE|ERAS management pathway|"1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
219020701|NCT07205380|PROCEDURE|Endoscopic Retrograde Cholangiopancreaticography|Anaesthesia or sedation during ERCP for common bile duct stones
219474827|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
219474828|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
219474829|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
219474830|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
219474831|NCT04865536|DRUG|TBI-223 1800 mg|3 x 600 mg SR1 tablets
219474832|NCT04865536|DRUG|TBI-223 2400mg|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
219474833|NCT04865536|DRUG|TBI-223 Placebo|Placebo SR and IR tablets for TBI-223
219474834|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
219474835|NCT05551585|DEVICE|Transcranial pulse stimulation|TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,
219474836|NCT05774080|OTHER|Observational|Observational
219474837|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
219020702|NCT07207200|DEVICE|Morning Light Therapy|One hour of morning light therapy each day for four weeks
219020703|NCT07206537|DRUG|Vitamin K 2|Oral vitamin K2 supplementation
219020704|NCT07206693|DIAGNOSTIC_TEST|Prostate specific antigen (PSA)|Prostate specific antigen (PSA) for prostate cancer screening
219020705|NCT07207291|DRUG|JKN2501|Administration: Intravenous (IV) infusion.
219020706|NCT07207291|DRUG|Placebo|0.9% Sodium Chloride Injection as Placebo. Administration: Intravenous (IV) infusion.
219474838|NCT02427620|DRUG|Cyclophosphamide|Given IV
219474839|NCT02427620|DRUG|Cytarabine|Given IV
219474840|NCT02427620|DRUG|Dexamethasone|Given PO or IV
219474841|NCT02427620|DRUG|Doxorubicin|Given IV
219474842|NCT02427620|DRUG|Doxorubicin Hydrochloride|Given IV
219474843|NCT02427620|DRUG|Ibrutinib|Given PO
219474844|NCT02427620|OTHER|Laboratory Biomarker Analysis|Correlative studies
219474845|NCT02427620|DRUG|Methotrexate|Given IV
219474846|NCT02427620|BIOLOGICAL|Rituximab|Given IV
219474847|NCT02427620|DRUG|Vincristine|Given IV
219474848|NCT02427620|DRUG|Vincristine Sulfate|Given IV
219474849|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
219474850|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
219474851|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
219474852|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
219474853|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
219474854|NCT05261126|DRUG|Enclitide Chloride|Enclitide Chloride administered orally
219474855|NCT05261126|DRUG|Placebo|Placebo matching enclitide chloride administered orally
219474856|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
219474857|NCT00005607|DRUG|FOLFIRI regimen|
219474858|NCT00005607|DRUG|fluorouracil|
219474859|NCT00005607|DRUG|irinotecan hydrochloride|
219474860|NCT00005607|DRUG|leucovorin calcium|
218859050|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
218859051|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
219474861|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
219474862|NCT04999969|DRUG|AZD0171|AZD0171
219474863|NCT04999969|DRUG|Durvalumab|Durvalumab
219474864|NCT04999969|DRUG|Gemcitabine|Chemotherapy (Standard-of-Care)
219474865|NCT04999969|DRUG|Nab-paclitaxel|Chemotherapy (Standard-of-Care)
219474866|NCT04647916|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219474867|NCT05060549|DRUG|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
219474868|NCT03901274|BEHAVIORAL|Wellness|The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
219474869|NCT03901274|BEHAVIORAL|Partnership|The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
219474870|NCT05570604|BEHAVIORAL|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
219474871|NCT05570604|BEHAVIORAL|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
219474872|NCT05570604|BEHAVIORAL|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
219474873|NCT05570604|BEHAVIORAL|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
219596725|NCT03003650|DEVICE|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
219596726|NCT00004492|DRUG|clotrimazole|
219596727|NCT00004492|DRUG|hydroxyurea|
219596728|NCT02713009|DIETARY_SUPPLEMENT|Pregnancy multi-vitamin (including 10μg vitamin D3)|
219596729|NCT02713009|DIETARY_SUPPLEMENT|10μg vitamin D3|
219596730|NCT02713009|DIETARY_SUPPLEMENT|0μg vitamin D (placebo)|
218859052|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
218859053|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
219474874|NCT05570604|BEHAVIORAL|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
219474875|NCT05570604|BEHAVIORAL|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
219474876|NCT04774991|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
219474877|NCT05739682|PROCEDURE|Local anaesthetic injection of 4% articaine with 1:100000 epinephrine|Buccal infiltration injection using a side loading aspirating syringe and a 30-gauge needle
218859054|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
219474878|NCT05739682|PROCEDURE|Tooth isolation|Rubber dam application to the affected tooth
218859055|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
218859056|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
219474879|NCT05739682|PROCEDURE|Access cavity preparation|Complete removal of caries, undermined tooth structure, and defective restoration. Access cavity preparation with complete removal of the pulp chamber roof using a sterile bur other than the ones used for caries removal.
219474880|NCT05739682|PROCEDURE|Root canal shaping and cleaning|Working length determination using an electronic apex locator and then canal instrumentation using Hyflex CM rotary files up to size 40.04 with irrigation using 2.5% NaOCl between files.
219474881|NCT05739682|PROCEDURE|Final irrigation with antimicrobial-corticosteroid mixture|1 ml of levofloxacin will be withdrawn in a 3ml plastic syringe followed by 1 ml of fluconazole and 1 ml of dexamethasone sodium phosphate, the whole solution is then passively delivered into the canal using a 30-gauge side vented needle reaching 1 mm shorter than the working length. The solution will be left inside the canal for 5 minutes
219474882|NCT05739682|PROCEDURE|Final irrigation with cold saline|Frozen sterile saline will be brought at room temperature and monitored using a digital liquid thermometer till the temperature reaches 2.5°c. 4ml are then withdrawn in a 5ml plastic syringe and delivered inside the canal in 1 minute. The process is then repeated 5 times so that the canal receives 20 ml of 2.5°c cold saline for 5 minutes.
219474883|NCT05739682|PROCEDURE|Temporary restoration and patient's instructions|The canals are dried using paper points and the access cavity is sealed using a non-eugenol temporary filling.
219474884|NCT05739682|PROCEDURE|Root canal obturation|After the 1st visit by 3 days to 1 week, the patient is scheduled for a second appointment for root canal obturation.
219596731|NCT05644197|OTHER|Multidisciplinary program|"Multidisciplinary program:~* APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~* Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~* Psychological intervention:~  5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
219596732|NCT01050465|OTHER|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
219474885|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
219474886|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
219474887|NCT06354686|DEVICE|TMS Tolerability|The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
219596733|NCT01392963|DRUG|botulinum toxin type A neurotoxin complex|29-40 U injection
219596734|NCT01392963|DRUG|Placebo|29-40 U 0.9% NaCl injection
219020707|NCT07207148|DRUG|GLP-1|Glucagon-like peptide-1 agonist agent is the study agent of interest. This study will not supply the GLP-1 drug but depends on the patient's clinical prescription of this drug.
219020708|NCT07207148|DRUG|Ocrelizumab (US)|All participants will be treated with Ocrelizumab for the indication of MS; however, the study will not provide Ocrelizumab as it will be part of the participant's routine clinical care.
219474888|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
219596735|NCT00369486|PROCEDURE|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
219596736|NCT00369486|DRUG|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
219596737|NCT00369486|DRUG|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
219474889|NCT06210321|OTHER|Prescription of escitalopram using pharmacogenetic testing|Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
219474890|NCT06230393|DEVICE|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
218859057|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
218859058|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
218859059|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
218859060|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
218859061|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
218859062|NCT02386891|OTHER|Thermal Environment|
218859063|NCT00454753|DRUG|Dasatinib|
218859064|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
218859065|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
219474891|NCT04708223|DEVICE|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
219474892|NCT04708223|DEVICE|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
218859066|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
218859067|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
218859068|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
219474893|NCT06548113|DEVICE|TMS|transcranial magnetic brain stimulation
219474894|NCT04691674|PROCEDURE|Endoscopy|Endoscopic removal of the pancreatic stent
219474895|NCT06037603|BEHAVIORAL|Brain & Walk Exercise Every Day (BraW-Day)|The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
219474896|NCT03716349|DIAGNOSTIC_TEST|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
219474897|NCT03716349|OTHER|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
218859069|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
218859070|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
218859071|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
218859072|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
218859073|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
219474898|NCT03716349|DRUG|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
219474899|NCT03716349|DEVICE|rubber dam|The area will be isolated with rubber dam isolation
219474900|NCT03716349|OTHER|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
219474901|NCT03716349|PROCEDURE|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
219474902|NCT03716349|PROCEDURE|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
219474903|NCT03716349|PROCEDURE|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
219474904|NCT03716349|OTHER|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
219474905|NCT03716349|PROCEDURE|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
219474906|NCT03716349|PROCEDURE|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
219474907|NCT03716349|OTHER|Consent|The consent form will be signed, copy will be provided to the patient
219474908|NCT03716349|OTHER|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
219596738|NCT00369486|DRUG|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
219596739|NCT00369486|DRUG|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
219596740|NCT00402116|DRUG|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
219596741|NCT00402116|DRUG|temozolomide|75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
219596742|NCT00402116|RADIATION|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
219596743|NCT05815017|DEVICE|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
219596744|NCT04214197|DRUG|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
219596745|NCT01998945|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
218859074|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
218859075|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
219474909|NCT03716349|RADIATION|xray|When necessary a radiograph (xray) will be obtained
219474910|NCT03716349|OTHER|Release of medical information signed|The release of medical information form will be signed
219474911|NCT03716349|OTHER|Oral Exam|An Oral Exam will be completed
219474912|NCT03716349|OTHER|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
219474913|NCT03716349|OTHER|Clinical Assessment|A clinical assessment will be completed by the evaluators
219474914|NCT03716349|DEVICE|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
219474915|NCT03716349|DEVICE|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
218859076|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
218859077|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
219474916|NCT06324864|BEHAVIORAL|START NOW Adapted|"The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions."
219474917|NCT06053307|BEHAVIORAL|Acceptance commitment therapy|The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
219474918|NCT05434754|OTHER|eHealth Tool|text messaging algorithm
219474919|NCT04527380|DRUG|Ixekizumab|Administered SC
219474920|NCT04527380|DRUG|Adalimumab|Administered SC
219474921|NCT06241768|OTHER|mPATH-CRC Web app|Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening
219474922|NCT05410418|DRUG|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
219474923|NCT05410418|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
219474924|NCT05127837|BEHAVIORAL|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
219474925|NCT06521320|DIAGNOSTIC_TEST|speaking valve combined with airway pressure|All patients were given speaking valves and airway pressure was measured to assess upper airway patency.
219474926|NCT06521320|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
219474927|NCT03978988|DEVICE|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
219474928|NCT03978988|DRUG|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
219474929|NCT03978988|DRUG|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
218859078|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
219474930|NCT03978988|PROCEDURE|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
219474931|NCT05311878|DEVICE|EEG-based perceptual training|Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
219474932|NCT05311878|DEVICE|Behavior based perceptual training|Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
219474933|NCT06137040|DRUG|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg"
218859079|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
218859080|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
218859081|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
218859082|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
218859083|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
219474934|NCT06137040|OTHER|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
219474935|NCT05688943|PROCEDURE|Spinal Anesthesia|Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
219474936|NCT05688943|PROCEDURE|General Anesthesia|General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
218859084|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
219474937|NCT04525755|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
219474938|NCT04525755|DRUG|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
219474939|NCT05241249|DRUG|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
219474940|NCT05241249|DRUG|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
219474941|NCT05241249|DRUG|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
218859085|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
218859086|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
218859087|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
218859088|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
218859089|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
218859090|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
218859091|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
219596746|NCT01998945|BEHAVIORAL|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
218859092|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
218859093|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
218859094|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
218859095|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
218859096|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
218859097|NCT00058149|DRUG|gemcitabine hydrochloride|
218859098|NCT00058149|DRUG|oxaliplatin|
218859099|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
218859100|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
218859101|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
218859102|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
218859103|NCT01983722|DRUG|Stiripentol|
218859104|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
218859105|NCT00481312|DRUG|Midazolam|Continuous Infusion
218859106|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
218859107|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
218859108|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
218859109|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
219020709|NCT07205185|DRUG|QL1706 + Eribulin + Anlotinib + Radiotherapy|"QL1706: 5 mg/kg, intravenous injection (IV) on Day 1, every 3 weeks (Q3W). Eribulin : 1.1 mg/m², intravenous infusion (IV) on Days 1 and 8, Q3W. Anlotinib : Oral administration before breakfast, 12 mg once daily (QD) on Days 1-14, followed by a 1-week drug holiday, Q3W.~Radiotherapy : Hypofractionated radiotherapy, 15-60 Gy delivered in 5-8 fractions.~Eribulin is administered for 6 cycles. Epalizumab and anlotinib are continued until disease progression, intolerable toxicity, initiation of new anti-tumor treatment, loss to follow-up, death, or withdrawal from the study (whichever occurs first)."
219020710|NCT07206849|DRUG|Tovorafenib|Tovorafenib will be given orally once weekly (QW) throughout each cycle.
219020711|NCT07205263|PROCEDURE|AI-assisted robotic-guided endoscopic hematoma evacuation|Surgical removal of hematoma using AI-assisted robotic-guided stereotactic navigation and endoscopic aspiration techniques.
218859110|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
219020712|NCT07205263|PROCEDURE|Conventional craniotomy|Standard open surgical evacuation of hematoma through craniotomy.
219020713|NCT07205263|PROCEDURE|AI-assisted robotic-guided puncture and hematoma evacuation|AI-assisted robotic-guided stereotactic puncture and aspiration of hematoma.
219474942|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
218859111|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
219474943|NCT04081805|PROCEDURE|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
218859112|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
218859113|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
218859114|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
218859115|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
218859116|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
218859117|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
218859118|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
218859119|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
218859120|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
218859121|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
219474944|NCT04081805|PROCEDURE|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
219474945|NCT04081805|DRUG|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
219474946|NCT06127121|BEHAVIORAL|Digital Art Activity|"* complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again"
218859122|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
218859123|NCT01863134|DRUG|Eptifibatide|
219474947|NCT03671746|DRUG|Ketorolac|Participants will receive Ketorolac at 15 mg IV every 6 hours for their first 5 days of hospitalization
219474948|NCT03671746|DRUG|Saline Solution|Participants will receive 1 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
218859124|NCT01863134|DRUG|Placebo|
218859125|NCT00025168|DRUG|gemcitabine hydrochloride|
218859126|NCT00025168|DRUG|irinotecan hydrochloride|
218859127|NCT00025168|RADIATION|radiation therapy|
218859128|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
218859129|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
218859130|NCT04075968|OTHER|Home exercise|Home exercise will be applied
218859131|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
218859132|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
218859133|NCT00002368|DRUG|Nevirapine|
219474949|NCT05065554|DRUG|Acalabrutinib|Dose per protocol, oral twice daily per cycle
219474950|NCT05065554|DRUG|Rituximab|Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
218859134|NCT00002368|DRUG|Lamivudine|
218859135|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
218859136|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
218859137|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
218859138|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
218859139|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
219474951|NCT04996173|DEVICE|Spray cryotherapy|A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
219474952|NCT04996173|DEVICE|Ballon Dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.
219474953|NCT04996173|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
219474954|NCT04100889|OTHER|No Intervention|There is no intervention for this study.
218859140|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
218859141|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
218859142|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
218859143|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
218859144|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
218859145|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
219474955|NCT06500819|DRUG|B7-H3CART Dose (Intravenous)|"Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg"
219020714|NCT07205263|OTHER|Standard medical management|Guideline-based conservative therapy without surgical hematoma evacuation.
219020715|NCT07205263|PROCEDURE|AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage|AI-assisted robotic-guided endoscopic evacuation of ventricular hematoma combined with external ventricular drainage.
219020716|NCT07205263|PROCEDURE|External ventricular drainage (EVD)|Conventional ventricular catheter placement for hematoma drainage.
218859146|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
218859147|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
218859148|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
219199423|NCT05496140|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
219474956|NCT06137742|DRUG|PF-07868489|Experimental Treatment
219474957|NCT06137742|DRUG|Placebo for PF-07868489|Placebo
219474958|NCT05437211|DEVICE|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
218859149|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
218859150|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
218859151|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
218859152|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
218859153|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
218859154|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
218859155|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
218859156|NCT00002239|DRUG|Enfuvirtide|
218859157|NCT00002239|DRUG|Ritonavir|
218859158|NCT00002239|DRUG|Abacavir sulfate|
218859159|NCT00002239|DRUG|Amprenavir|
218859160|NCT00002239|DRUG|Efavirenz|
218859161|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
218859162|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
218859163|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
218859164|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
218859165|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
219474959|NCT05721976|BEHAVIORAL|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
219474960|NCT05866107|DEVICE|"Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention (SWIM trial)"|"Participants receive a digital-behavioral intervention via Huawei Health App and smart scale:~1. Weekly weigh-ins (auto-synced)~2. Dietary logging (≥3x/week) with calorie-deficit targets~3. Biweekly exercise plans (150-300 min/week)~4. Weekly motivational messages~Implementation:~Staggered rollout: Batch 1 (Month 3-6), Batch 2 (Month 5-6). Includes 2-week training. Effectiveness monitored via app metrics and adherence. Routine care maintained."
219474961|NCT02566304|DRUG|Fludarabine|Given IV
219474962|NCT02566304|RADIATION|Total-Body Irradiation|Undergo TBI
218859166|NCT02726191|BEHAVIORAL|Token Task Exercise|
218859167|NCT02726191|BEHAVIORAL|Story Recall Exercise|
218859168|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
219474963|NCT02566304|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
219474964|NCT02566304|DRUG|Cyclophosphamide|Given IV
218859169|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
218859170|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
218859171|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
218859172|NCT02726191|BEHAVIORAL|Memory Match Exercise|
218859173|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
218859174|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
218859175|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
218859176|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
218859177|NCT02358655|OTHER|Retrospective review of OAC prescription|
218859178|NCT02358655|OTHER|Prescription of OAC in ED|
218859179|NCT02358655|OTHER|Community AF clinic|
218859180|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
218859181|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
218859182|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
218859183|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
218859184|NCT00005013|DRUG|Sertraline|
218859185|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
218859186|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
219474965|NCT02566304|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
219474966|NCT02566304|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
219474967|NCT02566304|DRUG|Tacrolimus|Given PO
218859187|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
218859188|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
218859189|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
218859190|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
218859191|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
219474968|NCT02566304|DRUG|Mycophenolate mofetil|Given IV
219474969|NCT02566304|OTHER|Laboratory Biomarker Analysis|Correlative studies
219474970|NCT04715451|OTHER|Novel Swaddle|A novel swaddling method.
219474971|NCT04210817|OTHER|No Intervention|There is no intervention for this study
219596747|NCT04588545|RADIATION|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
219596748|NCT04588545|DRUG|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
219474972|NCT03172195|PROCEDURE|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
218859192|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
218859193|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
218859194|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
218859195|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
218859196|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
218859197|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
218859198|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
219596749|NCT04588545|DRUG|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
219596750|NCT01822626|BEHAVIORAL|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
218859199|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
218859200|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
218859201|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
218859202|NCT00029458|DRUG|Clozapine|
219199424|NCT05541484|DRUG|SGLT2 inhibitor|See above.
219199425|NCT05541484|DEVICE|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
219474973|NCT03172195|BIOLOGICAL|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
219474974|NCT03172195|BIOLOGICAL|blood sample|Blood sample will be collected in more.
219474975|NCT04100005|OTHER|No intervention|There is no intervention for this study.
219474976|NCT05751473|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
219474977|NCT05751473|BEHAVIORAL|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
219474978|NCT04410991|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
219474979|NCT04410991|DRUG|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
218859203|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
218859204|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
218859205|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
218859206|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
218859207|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
218859208|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
218859209|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
218859210|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
219474980|NCT04410991|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
218859211|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
218859212|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
218859213|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
219474981|NCT04410991|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
219474982|NCT05545007|RADIATION|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
219474983|NCT05545007|PROCEDURE|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
219474984|NCT06579079|OTHER|Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy.
219474985|NCT06579079|OTHER|Waitlist Comparison - Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy. Participating schools receiving this treatment will wait one year before developing an implementation strategy for testing.
219596751|NCT04778904|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
219596752|NCT04778904|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
219596753|NCT04778904|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
218859214|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
218859215|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
218859216|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
218859217|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
218859218|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
218859219|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
218859220|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
218859221|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
218859222|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
218859223|NCT00208520|DRUG|Carbamazepine|
218859224|NCT00208520|DRUG|Lamotrigine|
218859225|NCT00208520|DRUG|Levetiracetam|
219474986|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
219474987|NCT06167096|OTHER|Water|Water
219474988|NCT05102929|DEVICE|active intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
219596754|NCT02896712|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
219474989|NCT05102929|DEVICE|sham intermittent Theta Burst Stimulation (iTBS)|"Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons."
218859226|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
218859227|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
219474990|NCT05870202|OTHER|screening tool|The screening tool identifies areas of treatment burden in patients with type 2 diabetes. The tool is in the form of a brief questionnaire that the patient completes prior to a clinical appointment. The patient's responses to the questionnaire are then included in the discussion with the patient's primary care clinician during the clinical visit.
219474991|NCT04256018|DRUG|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
219474992|NCT04256018|RADIATION|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
219474993|NCT06638801|BEHAVIORAL|Coach-led caregiver-implemented early literacy and developmental programming|Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
219474994|NCT06638801|BEHAVIORAL|Reach Out and Read Training|Reach Out and Read parent training
219474995|NCT04208217|BEHAVIORAL|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
219474996|NCT04208217|BEHAVIORAL|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
219474997|NCT06421311|DRUG|nivolumab|According to approved product label (France)
219474998|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
219596755|NCT02896712|BEHAVIORAL|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
219474999|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
219475000|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
219475001|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
219475002|NCT05535738|DRUG|Dupilumab|300mg
219475003|NCT05535738|DRUG|Adalimumab|40mg
219475004|NCT05535738|DRUG|Ustekinumab|45mg
219475005|NCT05535738|DRUG|Guselkumab|100mg
218859228|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
218859229|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
219475006|NCT05535738|DRUG|Canakinumab|150mg
219475007|NCT05535738|DRUG|Sarilumab|200mg
219475008|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
219475009|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
219475010|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
219475011|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
219475012|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
219475013|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
219475014|NCT02265874|DRUG|Habitrol|Patch used daily for 28 weeks
219475015|NCT02265874|DRUG|Placebo to Habitrol|
219475016|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
219475017|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
219475018|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
219475019|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
219475020|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
219475021|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
219475022|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
218859230|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
218859231|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
218859232|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
218859233|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
219475023|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
219475024|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
219596756|NCT02896712|BEHAVIORAL|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
219596757|NCT02896712|DRUG|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
219596758|NCT02896712|DRUG|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
219596759|NCT05048329|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and colorectal clinical team
219596760|NCT05048329|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
219596761|NCT01437930|DIETARY_SUPPLEMENT|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)"
219596762|NCT06297421|PROCEDURE|Fecal Microbiota Transplantation|Oral Fecal Microbiota Transplantation Capsule
219596763|NCT06297421|PROCEDURE|Placebo|Oral Placebo Capsule
219596764|NCT03524521|BEHAVIORAL|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
219596765|NCT03524521|BEHAVIORAL|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
218859234|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
218859235|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
218859236|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
218859237|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
218859238|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
219476228|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
219596766|NCT03057821|OTHER|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
219596767|NCT03772717|DEVICE|Non-invasive vagus nerve stimulation (nVNS)|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
218859239|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
218859240|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
218859241|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
218859242|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
218859243|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
218859244|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
219475025|NCT00911560|BIOLOGICAL|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or \>2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
219475026|NCT00911560|BIOLOGICAL|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
219475027|NCT06150183|BIOLOGICAL|BNT314|Intravenous infusion
219475028|NCT01211405|DRUG|Low dose MDMA-assisted therapy|30 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg 1.5 to 2 hours later
219475029|NCT01211405|DRUG|Medium dose MDMA-assisted therapy|75 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg 1.5 to 2 hours later
219475030|NCT01211405|DRUG|Full dose MDMA-assisted therapy|125 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg 1.5 to 2 hours later
219475031|NCT01211405|BEHAVIORAL|Therapy|Non-directive therapy during each session
218859245|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
218859246|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
218859247|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
218859248|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
218859249|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
218859250|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
218859251|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
219475032|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
219475033|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
219475034|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
219475035|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
219475036|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
219476229|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
218859252|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
218859253|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
218859254|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
218859255|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
218859256|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
218859257|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
218859258|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
218859259|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
218859260|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
218859261|NCT00085254|DRUG|cilengitide|Given IV
218859262|NCT00085254|DRUG|temozolomide|Given orally
218859263|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
218859264|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
218859265|NCT00085254|OTHER|pharmacological study|Correlative studies
218859266|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
218859267|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
218859268|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
218859269|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
218859270|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
218859271|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
218859272|NCT02930408|PROCEDURE|electrocardiogram|
218859273|NCT02930408|PROCEDURE|Echocardiography|
218859274|NCT01460407|DRUG|LY2216684|Administered orally
218859275|NCT01460407|DRUG|Clarithromycin|Administered orally
219476230|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
218859276|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
218859277|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
219476231|NCT01197846|DRUG|Placebo|Placebo
219476232|NCT03222570|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
219476233|NCT03222570|DRUG|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
219476234|NCT03222570|OTHER|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
219476235|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
219476236|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
218859278|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
218859279|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
219475037|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
218859280|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
218859281|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
218859282|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
219475038|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
219475039|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
219475040|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
218859283|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
218859284|NCT02295007|BEHAVIORAL|text message|
218859285|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
219475041|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
219475042|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
219475043|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
219475044|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
218859286|NCT00103519|DRUG|Placebo|Placebo
218859287|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
218859288|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
218859289|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
219475045|NCT00243620|DEVICE|Vacuum therapy (device)|
219475046|NCT00003266|DRUG|methylphenidate hydrochloride|
219475047|NCT00003266|PROCEDURE|quality-of-life assessment|
219475048|NCT04155567|DRUG|TAK-123|TAK-123 infusion
219475049|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
219476237|NCT05932979|OTHER|Placebo|Starch
219476238|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
219476239|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
219476240|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
219476241|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
219476242|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
218859290|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
218859291|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
218859292|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
218859293|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
219596768|NCT03772717|OTHER|Standard of care treatment|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
219596769|NCT04634279|BEHAVIORAL|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
218859294|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
218859295|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
218859296|NCT00378937|DRUG|acetaminophen|
219475050|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
219475051|NCT06221111|DRUG|Rimegepant 75 MG [Nurtec]|placebo controlled trial
219475052|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219596770|NCT02358902|DEVICE|tDCS|tDCS - DC stimulator, Neurocom, Germany
219596771|NCT02358902|PROCEDURE|active intervention of aerobic exercise|different types of aerobic exercise
219475053|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
219475054|NCT02596074|DRUG|Vehicle topical gel|
218859297|NCT00378937|DRUG|codeine phosphate|
218859298|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
219475055|NCT00138866|DRUG|Risedronate|
219475056|NCT01463631|DRUG|LY3007113|Administered orally
219475057|NCT05847023|BEHAVIORAL|LUNA|see description above
219475058|NCT04689334|OTHER|Outcome|The number of surgeries
219475059|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
219475060|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
219475061|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
219596772|NCT02358902|DEVICE|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
218859299|NCT00378937|DRUG|morphine sulfate|
218859300|NCT00378937|DRUG|oxycodone hydrochloride|
218859301|NCT00378937|PROCEDURE|management of therapy complications|
218859302|NCT00378937|PROCEDURE|quality-of-life assessment|
218859303|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
219475062|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
219596773|NCT02358902|PROCEDURE|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
219596774|NCT02856802|DRUG|Sumatriptan 10 mg Nasal Spray|100 μL nasal spray once
219596775|NCT02856802|OTHER|Sumatriptan Placebo Nasal Spray|100 μL nasal spray once
219596776|NCT04138043|DRUG|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
219596777|NCT04138043|DRUG|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
219596778|NCT05787626|OTHER|manipulation|miofascial technique in diaphragmatic region
219596779|NCT06553352|DRUG|Zanubrutinib combined with Obinutuzumab|Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
218859304|NCT00844805|DRUG|Infliximab|
219475063|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
219475064|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
218859305|NCT00844805|DRUG|Placebo|
218859306|NCT00844805|DRUG|Naproxen|
218859307|NCT00567918|DRUG|FK506|Ophthalmic suspension
218859308|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
218859309|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
219475065|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
219475066|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
219475067|NCT06502002|DRUG|Placebo|normal saline infusion
219475068|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
219475069|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
219475070|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
219475071|NCT05354349|DRUG|PRA023 SC|Drug
218859310|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
218859311|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
218859312|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
218859313|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
218859314|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
218859315|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
218859316|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
218859317|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
218859318|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
218859319|NCT00146185|DRUG|ALGRX 3268|
218859320|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
218859321|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
218859322|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
218859323|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
218859324|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
218859325|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
218859326|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
218859327|NCT00020462|BIOLOGICAL|aldesleukin|
218859328|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
218859329|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1\. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
218859330|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
218859331|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
218859332|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
218859333|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
218859334|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
218859335|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
218859336|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
218859337|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
219475072|NCT05354349|DRUG|Placebo IV|Placebo
218859338|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
218859339|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
218859340|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
218859341|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
219475073|NCT05354349|DRUG|Placebo SC|Placebo
219475074|NCT05354349|DRUG|PRA023 IV High Dose|Drug
219475075|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
218859342|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
219475076|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
219475077|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
219475078|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
219475079|NCT06380075|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
219475080|NCT06380075|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
219475081|NCT06380075|DEVICE|Clarus imaging|Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
219475082|NCT05053334|DRUG|Omalizumab Prefilled Syringe|150mg/ml of Omalizumab prefilled syringe
219475083|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
219475084|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
219475085|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
219475086|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
219475087|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
219475088|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
219475089|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
219475090|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
219475091|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
219475092|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
219475093|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
219475094|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
219475095|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
219475096|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
219475097|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
219475098|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
219475099|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
219475100|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
219475101|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
219475102|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
219475103|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
219475104|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
219476243|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
219476244|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
218859343|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
218859344|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
218859345|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
218859346|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
218859347|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
218859348|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
218859349|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
218859350|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
218859351|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
218859352|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
218859353|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
218859354|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
218859355|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
218859356|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
218859357|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
218859358|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
219475105|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
219475106|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
219475107|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
219475108|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
219475109|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
219475110|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
219475111|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
219475112|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
218859359|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
218859360|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
218859361|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
218859362|NCT00168077|DRUG|Prothrombin Complex Concentrate|
218859363|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
218859364|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
218859365|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
218859366|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
218859367|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
218859368|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
218859369|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
218859370|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
218859371|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
218859372|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
218859373|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
219475113|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
219475114|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
219475115|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
219475116|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
219475117|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
219475118|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
219475119|NCT03563729|DRUG|Trametinib|In combination with trametinib
219475120|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
218859374|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
218859375|NCT00057434|DRUG|multivitamin|
218859376|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
219475121|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
219475122|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
219475123|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
219475124|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
219476245|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
219476246|NCT05939440|OTHER|Usual Care|As in Arm description
219476247|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
219476248|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
219476249|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
219476250|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
219476251|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
219476252|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
219476253|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
219476254|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
219476255|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
219476256|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
219476257|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
219476258|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
219476259|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
219476260|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
219476261|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
219476262|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
219476263|NCT04056650|DRUG|L-theanine|up to 250 mg
219476264|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
219476265|NCT04056650|DEVICE|N1 app|N1 App on mobile device
219476266|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
219476267|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
219476268|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
219476269|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
219476270|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219476271|NCT00104858|DRUG|Cyclosporine|Given PO
219476272|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
219476273|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
218859377|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
219475125|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
218859378|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
218859379|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
218859380|NCT02110888|OTHER|SCS Only|
218859381|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
218859382|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
218859383|NCT00174538|DRUG|Codeine (30 mg)|
218859384|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
218859385|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
218859386|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
218859387|NCT01747200|PROCEDURE|Sham rTMS|
218859388|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
218859389|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
218859390|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
218859391|NCT01747200|PROCEDURE|rTMS over TP8|
218859392|NCT01747200|PROCEDURE|rTMS over TP7|
219475126|NCT02500173|RADIATION|Radiation|Radiation therapy
219475127|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
219475128|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
219596780|NCT05114213|RADIATION|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
219596781|NCT05114213|DRUG|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
219596782|NCT03352739|DEVICE|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
219596783|NCT03352739|DEVICE|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
219596784|NCT03352739|DEVICE|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
218859393|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
218859394|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
218859395|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
218859396|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
218859397|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
218859398|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
218859399|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
218859400|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
218859401|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
218859402|NCT00346502|DRUG|20% betulinic acid ointment|
218859403|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
218859404|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
219475129|NCT06615245|BEHAVIORAL|No VR vs. immersive high tech VR|No VR vs. immersive High Tech VR
219475130|NCT06615245|BEHAVIORAL|Plausible control vs immersive High Tech VR|plausible control condition vs. immersive high tech VR
219596785|NCT03352739|DEVICE|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
219596786|NCT02522923|OTHER|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
218859405|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
219475131|NCT00181051|DEVICE|Alaris AEP monitor|
219475132|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
219475133|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
219475134|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
219475135|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
219475136|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
219475137|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
219475138|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
219475139|NCT00608127|DEVICE|LupusorbTM|Single treatment
219475140|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
219475141|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
219475142|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
219475143|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
219475144|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
219476274|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
219476275|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
219476276|NCT00104858|OTHER|Pharmacological Study|Correlative studies
219476277|NCT00104858|BIOLOGICAL|Rituximab|Given IV
219476278|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
218859406|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
219476279|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
219476280|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
219476281|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7\_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7\_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
219476282|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
218859407|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
218859408|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
218859409|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
218859410|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
218859411|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
218859412|NCT02220023|DRUG|INOmax Inhalation|
218859413|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
218859414|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
218859415|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
219475145|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
218859416|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
218859417|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
219475146|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
219475147|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
219475148|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
219596787|NCT02522923|OTHER|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
219596788|NCT04852523|DRUG|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
219596789|NCT04678050|DRUG|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
219596790|NCT04678050|DRUG|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
219596791|NCT03324295|DIAGNOSTIC_TEST|cortical cataract|Blood urea
219596792|NCT06257381|OTHER|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
219596793|NCT06194617|DRUG|Direct oral anticoagulant|Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
218859418|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
218859419|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
219475149|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
219475150|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
219475151|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
218859420|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
219475152|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
219475153|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
219475154|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
219475155|NCT05703009|DRUG|Placebo|Placebo
219475156|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
219475157|NCT02389621|DRUG|Placebo|Tablets for oral administration
219475158|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
219475159|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
219475160|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
219475161|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
219475162|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
219596794|NCT03092219|DEVICE|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
219596795|NCT03209843|PROCEDURE|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
218859421|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
218859422|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
219596796|NCT02666443|DRUG|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
219596797|NCT02666443|DRUG|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
219596798|NCT02666443|DRUG|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
219596799|NCT06306248|OTHER|Total sleep deprivation|non pharmacologic treatment for depression
219596800|NCT05289869|DRUG|High-dose oxytocin|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
218859423|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
218859424|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
218859425|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
218859426|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
219475163|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
219475164|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
219475165|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
219475166|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
219475167|NCT02999646|OTHER|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
219475168|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
219475169|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
219475170|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
219475171|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
218859427|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
218859428|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
218859429|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
218859430|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
219475172|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
219475173|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
219596801|NCT05289869|DRUG|Low-dose oxytocin|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
219596802|NCT05146830|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
219596803|NCT00373763|PROCEDURE|Fetoscopic tracheal balloon occlusion|
219596804|NCT01867463|BIOLOGICAL|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
218859431|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
218859432|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
218859433|NCT00225342|DRUG|Rosiglitazone|
218859434|NCT00225342|DRUG|Gliclazide (Comparison drug)|
218859435|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
218859436|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
218859437|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
218859438|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
218859439|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
218859440|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
218859441|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
218859442|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
218859443|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
218859444|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
218859445|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
218859446|NCT02366767|DEVICE|Control|Threshold suspend
218859447|NCT01806649|DRUG|BKM120|
218859448|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
218859449|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
218859450|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
218859451|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
218859452|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
218859453|NCT01389349|OTHER|Sham Control|Sham control acupuncture
219475174|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
219475175|NCT01002118|DRUG|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
219475176|NCT01002118|DRUG|Placebo|4 capsules each day for 16 weeks
219475177|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
218860133|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
218860134|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
218860135|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
218860136|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
218860137|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
218860138|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
218860139|NCT01904643|DRUG|lenalidomide|Given PO
218860140|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
218860141|NCT01904643|DRUG|etoposide|Given IV
218860142|NCT01904643|DRUG|cytarabine|Given IV
218860143|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
218860144|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
218860145|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
218860146|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
218860147|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
218860148|NCT00693004|DRUG|PRX-03140|
218860149|NCT00693004|DRUG|Donepezil|
218860150|NCT00693004|DRUG|Placebo|
218908150|NCT03743441|OTHER|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
218908151|NCT03743441|OTHER|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
219613496|NCT02286258|DRUG|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
218908152|NCT03743441|OTHER|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
218908153|NCT06215534|DIETARY_SUPPLEMENT|first reference product series 1|dextrose (containing 25 grams of carbohydrates)
219613497|NCT02286258|DRUG|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
219613498|NCT02792920|DEVICE|CoCr-EES|
218860151|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
218860152|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
218860153|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
218860154|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
218860155|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
218860156|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
218860157|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
218860158|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
218860159|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
218860160|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
218860161|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
218860162|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
218860163|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
218860164|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
218860165|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
218860166|NCT01718249|OTHER|Implantable neurostimulation system|
218860167|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
218860168|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
218860169|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
218860170|NCT03508323|DRUG|Teneligliptin|20mg/qd
218860171|NCT03508323|DRUG|Placebo|1T/qd
218860172|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
218860173|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
219613499|NCT05330260|DIAGNOSTIC_TEST|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
218860174|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
218860175|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
218908154|NCT06215534|DIETARY_SUPPLEMENT|second reference product seies 1|dextrose (containing 25 grams of carbohydrates)
218908155|NCT06215534|DIETARY_SUPPLEMENT|third reference product series 1|dextrose (containing 25 grams of carbohydrates)
218908156|NCT06215534|DIETARY_SUPPLEMENT|first concept product series 1|Standard tube feed (containing 25 grams of carbohydrates)
218860176|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
218908157|NCT06215534|DIETARY_SUPPLEMENT|second concept product series 1|Tube feed with added fibers (containing 25 grams of carbohydrates)
219476535|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
219476536|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
219476537|NCT07004309|PROCEDURE|Microfluidic sperm sorting|Sperm selection using the ZyMot Microfluidic Sperm Separation Device. Process involves loading semen into microfluidic channels to isolate motile sperm with low DNA fragmentation.
219476538|NCT07004309|PROCEDURE|Density Gradient Centrifugation|Sperm preparation using a discontinuous density gradient technique with SpermGrad and SpermRinse media. Centrifugation separates motile sperm for use in ICSI.
219476539|NCT06598397|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
219476540|NCT06598397|BEHAVIORAL|Peer Mentoring|Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
219476541|NCT06598397|BEHAVIORAL|Skills-based Text Messaging|NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
219476542|NCT06598397|DRUG|Combination NRT|If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
219476543|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique with PRP as protective layer|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
219476544|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
219476545|NCT07005492|DIAGNOSTIC_TEST|radiological and clinical examination|Standard radiological (periapical radiography) and clinical (inspection, percussion, palpation tests etc.) examinations were performed.
219476546|NCT07005908|OTHER|Physical evaluations of post-COVID-19 individuals|In this study, pain, posture and musculoskeletal disorders were evaluated in post-COVID-19 individuals. The data to be obtained from all these evaluations were collected from the individuals at one time and over a period of approximately 1 hour at the most.
219476547|NCT07007338|BIOLOGICAL|Supplementary blood samples and urines samples|Supplementary blood and urines samples realised during routine visits
219476548|NCT07005323|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
219476549|NCT07005843|DEVICE|The Elana Anastomotic System|The Elana Anastomotic System is a medical device and is intended to create a suture less blood vessel anastomosis in Coronary Artery Bypass Grafting (CABG) procedures on the beating heart, without blo
219476550|NCT07007351|DEVICE|Intradermal injection|The product is the first solution with free hyaluronic acid boosted with silicium the administration mode is same as any other intradermal multi-injection procedure
219476551|NCT07007130|DRUG|Actrapid insulin|0.1 IU/kg of short-acting human insulin diluted in 100 mL of normal saline, instilled intraperitoneally before closure
219476552|NCT07007130|DRUG|Normal saline|100 mL normal saline intraperitoneally
219613500|NCT05338931|DRUG|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
219476553|NCT07005544|DEVICE|RealityCare|Participants utilized a Virtual Reality scenario that simulated a complete handwashing sequence with water and soap, including an instructional display demonstrating the correct hand hygiene technique.
219476554|NCT07006116|OTHER|Synchronous/asynchronous online course|"* Synchronous weekly 90-120-minute-long sessions that will be conducted on a videoconferencing platform (i.e., Zoom). If participants miss a synchronous session.~* Asynchronous online course: available segments of the online course with asynchronous instructional materials delivered 2-4 days in between sessions, and supplemental course materials that will be received by mail."
219476555|NCT07006870|OTHER|Virtual Reality plus Balance Exercise Training|Virtual reality balance training will be completed using the BRU system's preloaded programs for postural training and rehabilitation. Rehabilitation exercises will include tasks performed standing with virtual reality headset on whereby the visual and vestibular systems will be stressed and will be customized according to the participant's needs and ability to tolerate the training stimulus. Postural training exercises will be used to develop limits of stability, with 3 exercises performed requiring participants to move their center of mass to collect rings/blocks through a course within a given amount of time. Each of the 3 postural training exercises contained 15 levels of varying difficulty. Sessions will be tailored to everyone, with progression of increasing the level of difficulty or time of exposure for each exercise. Participants at this group will be also participate in a Balance exercise training program for 40 min/3 times per week for 8 weeks.
218860177|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
218860178|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
218860179|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
218860180|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
218860181|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
218860182|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
218860183|NCT01113489|DRUG|placebo|1 ml b.i.d.
218860184|NCT01735708|BEHAVIORAL|HIVPASS|
218860185|NCT01735708|OTHER|Health Education|
218860186|NCT01971216|BEHAVIORAL|Relaxation|
218860187|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
218860188|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
218860189|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
218860190|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
219476556|NCT07006870|OTHER|Balance Exercise Training|Each session of balance exercises will be composed of three phases, including warm-up, balance training and cool down. The warm-up phase will involve gentle stretching for calf, hamstring, quadriceps, iliopsoas muscles, as well as anterior, posterior and lateral step-ups for 5-10 minutes. The active phase will be performed on a balance training for 20 minutes. It included heel and toe raises, one-legged stance for each extremity, shifting weight anteriorly, posteriorly, laterally and diagonally, step-ups, narrow walking, backward walking, sideward walking, stepping over obstacles, passing balls arranged on the training mat in a circle, and throwing and catching a ball on the training mat. A rest period of 1 minute will be given between each component. The program will be ended with 5-10 minutes of cool down. During the cool-down phase, patients will perform deep breathing exercises and static exercises for back extensors in a recumbent position.
219476557|NCT05896670|DRUG|licaminlimab|ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks.
219476558|NCT05896670|OTHER|vehicle of OCS-02|inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks.
219476559|NCT05896670|OTHER|Artificial tears|Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days.
219476560|NCT04900506|PROCEDURE|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
219476561|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
219476562|NCT06613685|DRUG|GS-1720|Tablets administered orally without regard to food
219476563|NCT06613685|DRUG|GS-4182|Tablets administered orally without regard to food
219476564|NCT06613685|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
219476565|NCT06613685|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
219476566|NCT06613685|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
218860191|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
218860192|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
219476567|NCT06613685|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
218860193|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
218860194|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
218860195|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
219476568|NCT05590624|OTHER|Lower-Carbohydrate Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 45% fats, 35% carbs, 20% protein"
219476569|NCT05590624|OTHER|Low-Fat Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 70% carbs, 20% protein, 10% fat"
219476570|NCT07002632|DRUG|Dexpanthenol 5 % Topical Ointment|Dexpanthenol is a topical agent, a derivative of pantothenic acid (a B-complex vitamin), used for its moisturizing and skin regenerative properties. The formulation studied was a 5% dexpanthenol in a water-in-oil emulsion.
219476571|NCT07006779|BEHAVIORAL|Music intervention|Engaging into conversation during procedure
219476572|NCT07006779|BEHAVIORAL|Conversation|Engaging patients into conversation
219476573|NCT07006402|PROCEDURE|Reverse NAGS(experimental)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Reverse NAGs on hypomobile segments at level T1-T4.~In these type of mobilization, the inferior facet glides up on the superior. The mobilizations are repeated \<6 times and then movements are reassessed. If no change occurs, the process will be repeated upto 10 minutes with resting period."
219476574|NCT07006402|PROCEDURE|Grade III Ventro-Cranial Translatoric Glides(standard protocol)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Grade III Ventro-Cranial Translatoric Glides on hypomobile segments at level T1-T4.~The mobilization will be applied and sustained for 30-40 seconds and will be continued for 10-15 minutes in a cyclic manner.~The grades of mobilization will be tapered as per individual needs."
219476575|NCT07007208|DRUG|a positon emission tomography (PET) exam|TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)
219476576|NCT07007208|OTHER|MRI Contrast|"Data acquisition will include different sequences (anatomical MRI, resting fMRI). The MRI sequences performed will be anatomical imaging (i.e. T1 imaging, FLAIR), a diffusion sequence, a neuromelanin-sensitive sequence and functional imaging at rest (i.e. the resting state, which allows the functional connectivity within the so-called default network to be assessed)."
219476577|NCT07007208|OTHER|oculometry assessment|Pupillometry and oculometry will be conducted using an EyeBrain medical device (class IIa). Several cognitive tasks will be submitted to the participant, during which the same measurements will be taken. Different stimuli will be presented on the computer screen (visual scenes, text, geometric shapes) during the eye tracking measurement, and an instruction (cognitive task, such as semantic categorization, free exploration of the gaze, reading, saccade execution) will be associated with each type of stimulus. The successive stimuli will be spaced more than 7 secondes apart in order to allow the pupillary response to the first stimulus to be recorded and then to return to the basal diameter before presentation of the next stimulus.
219476578|NCT07007208|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through 6 interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare.
219476579|NCT07005804|GENETIC|transcriptomic and metabolomic analysis|Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
219476580|NCT07006506|DRUG|Belumosudil|Belumosudil is an oral selective inhibitor of Rho-GTPase-associated coiled-coil kinase 2 (ROCK2)
219522288|NCT04281706|DRUG|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
219522289|NCT03057262|DEVICE|Repositioning splint|Application of repositioning splint in the study group.
219522290|NCT04431271|PROCEDURE|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
219613501|NCT03506256|DRUG|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
218860196|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
219613502|NCT02422134|OTHER|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
219613503|NCT02498002|DEVICE|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
218860197|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
218860198|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
219476581|NCT07007000|DEVICE|Temporary cardio-neural pacing|After routine ventricular lead implantation, a coronary sinus sheath will be delivered to RA septum, posterior to CS ostium, at the expected location of parasympathetic ganglion plexus. Pace mapping will be performed with a pacing lead at 30Hz, variable amplitude (20, 10, 5V) at 1ms pulse width. An electrophysiology catheter may be used where necessary for pace-mapping the response. At the site where lowest output can generate 30% prolongation of ventricular CL, the lead is fixed for 2-5mm depth. The output is tested again to achieve 50% prolongation of ventricular CL (at 20, 10, 5, 2, 1V). Fluoroscopic image will be collected with contrast injection at the sheath. Repositioning of lead can be performed if the rate suppression cannot be achieved with 3V@0.4ms. Implanted lead will serve as an atrial sensing and pacing lead and will not be removed at the end of procedure. Patient will be connected to a dual to a dual chamber pacemaker with device programming per usual clinical care.
219476582|NCT07006974|OTHER|SMCs|patients with SMCs
219476583|NCT03653052|DRUG|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
219476584|NCT07005895|OTHER|Hydration assessment via mobile app|Open the Gatorade Sports Science Institute (GSSI) branded mobile application and click on 'Complete Hydration Assessment'
219476585|NCT07006259|OTHER|Bobath Therapy|Treatment with bobath therapy
219476586|NCT07006259|OTHER|Bobath therapy plus virtual reality|Treatment with bobath therapy plus virtual reality
219476587|NCT07006259|OTHER|Home exercises|Treatment with home exercises
219476588|NCT07006675|DRUG|600 mg Ibuprofen|Treatment patients will receive oral ibuprofen 600 mg three times a day (tid) for up to six weeks. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs. For patients who have a clinical concern regarding NSAID and prophylactic anticoagulation, the treating physician may consider prescribing misoprostol.
219476589|NCT07006415|DEVICE|Brain-computer interface rehabilitation|10 sessions of motor imagery rehearsal rehabilitation using a brain-computer interface with functional electrical stimulation and a virtual avatar
219476590|NCT07005700|DIAGNOSTIC_TEST|Targeted genomic sequencing|Single 0.5 mL venous or capillary blood sample.
219476591|NCT07005856|OTHER|Soft tissue mobilization|Soft tissue mobilization: mobilization participants' soft tissue by using hands
219204435|NCT06840457|BEHAVIORAL|Mindfulness without Tailored Messages|The study will use an app designed to train the user in mindfulness practices.
219476592|NCT07005856|OTHER|Stretching|Stretching: help patients do the movement that they're limited to stretch their soft tissue
219476593|NCT07005856|OTHER|Hot pack|Add an hot pack on participants' shoulder
219476594|NCT06867666|BEHAVIORAL|In Person CBT-I|6-week CBT-I delivered in-person at the TBI Clinic at NMCSD or via telehealth on a secure, Health Insurance Portability and Accountability Act (HIPAA) compliant platform by a doctoral-level clinician.
219476595|NCT06867666|BEHAVIORAL|CBT-I via COAST|6-week CBT-I delivered remotely via a clinician supervised digital platform by a doctoral-level clinician.
219613504|NCT02498002|OTHER|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
218908158|NCT06215534|DIETARY_SUPPLEMENT|third concept product series 1|Tube feed with extra energy (containing 25 grams of carbohydrates)
219476596|NCT05595499|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219476597|NCT05595499|DRUG|Fisetin|Given PO
219476598|NCT05595499|DRUG|Placebo Administration|Given PO
219476599|NCT05595499|OTHER|Quality-of-Life Assessment|Ancillary studies
219476600|NCT05595499|OTHER|Questionnaire Administration|Ancillary studies
219476601|NCT07011589|BIOLOGICAL|Efgartigimod|Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks
219476602|NCT07006207|OTHER|olfactory stimulation|the patients have a sniff-test
219476603|NCT07006207|OTHER|functional MRI|patients have a an f MRI
219476604|NCT07006545|OTHER|Return to Activity Battery|The main target parameters are muscle mass (sonography), muscle strength (isometric maximum strength measurement), neuromuscular activation (surface EMG), functionality (e.g. 6MWT, chair rising test), knee swelling and subjective assessment of everyday and leisure activities, quality of life (e.g. SF-36) and return to work
219476605|NCT07005661|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet apheresis was initiated immediately after central venous catheterization and completed before systemic heparinization using the XTRA system (LivaNova, UK). Whole blood was collected at \~60 mL/min via central venous access, \~300 mL per cycle, anticoagulated with sodium citrate. After separation, autologous platelet rich plasma and concentrated RBCs were obtained. The process was repeated for 4-6 cycles, collecting plasma equal to \~20-30% of estimated blood volume (Nadler formula). Crystalloids or colloids were infused during the procedure, and RBCs from the prior cycle were reinfused to maintain hemodynamic stability. Platelet rich plasma was stored in collection bags, agitated at room temperature, and reinfused after heparin neutralization .
219476606|NCT07005661|PROCEDURE|Standard Blood Management|Perioperative transfusion is based on intraoperative hemodynamics and internal environment. Routine blood salvage is performed, with tranexamic acid given throughout (30 mg/kg IV loading dose, 16 mg/kg/h IV maintenance, 2 mg/kg for CPB priming). CPB is primed with 1500 ml using an integrated oxygenator, without ultrafiltration emphasis. At surgery's end, heparin-protamine neutralization is guided by a decision-making system, with point-of-care coagulation monitoring to selectively transfuse blood products based on coagulation abnormalities.
219476607|NCT06872151|DEVICE|Gel containing a Propionibacterium extract|Patients will apply 1 ml of gel (equal to one phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
219476608|NCT06872151|DRUG|Hyaluronic acid and silver sulfadiazine|Patients will apply 1ml of gel (equal to a phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
219476609|NCT05078047|DRUG|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
219476610|NCT07013877|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
219613505|NCT02498002|OTHER|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
219476611|NCT06372197|DRUG|Psilocybin|Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
218860199|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
218860200|NCT01386541|DRUG|BYK324677|capsules, administered orally
218860201|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
218860202|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
218860203|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
218860204|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
218860205|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
218860206|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
218860207|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
218860208|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
218860209|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
218860210|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
218860211|NCT00074373|OTHER|No intervention; observational|
218860212|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
218860213|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
218860214|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
218860215|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
218860216|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
218860217|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
218860218|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
218860219|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
218860220|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
218860221|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
219476612|NCT07006363|OTHER|IASTM|IASTM: For the application, the participant is seated on a chair, puts his hands together on the bed in front of him and puts his head on his hands (Figure 4). Vaseline cream is applied to the area to be applied to ensure that the Graston Technique instruments slide more easily in the tissue. The application area is the area between the mastoid processes proximally, the acromial processes laterally, and the T2 vertebra level distally. The researcher who will perform the application stands behind the participant. Application is performed for 10 minutes at a 45o angle with 3 different Graston instruments.
218860222|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
219476613|NCT07007286|DRUG|ETV,TDF,TAF,TMF combination with PEG IFNα-2b|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
219476614|NCT07007286|DRUG|ETV,TDF,TAF or TMF|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
219476615|NCT07007039|OTHER|Datos Health App|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and/or strength bouts completed over 3 month period. Individualized goals will be selected and set with a customized amount by a rehabilitation provider with at least monthly follow up contact to modify goals.
219613506|NCT02498002|PROCEDURE|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
219613507|NCT02498002|PROCEDURE|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
218860223|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
218860224|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
219613508|NCT02498002|DRUG|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
219476616|NCT07007468|OTHER|Abdominal Massage|Abdominal massage is a massage technique performed with soft and rhythmic movements applied to the abdomen. Abdominal massage is an inexpensive, non-invasive, non-harmful, non-invasive method that can be applied by nurses for the treatment of constipation or by teaching the patient and his/her family. During the application of abdominal massage, effleurage (patting), abdominal effleurage , petrissage (kneading), abdominal petrissage maneuvers are applied.
218860225|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
218860226|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
218860227|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
218860228|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
218860229|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
218860230|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
218860231|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
218860232|NCT00537732|DRUG|omeprazole|20 mg daily
218860233|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
218860234|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
218860235|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
218860236|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
218860237|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
218860238|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
218860239|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
218860240|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
218860241|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
218860242|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
219476617|NCT07007169|DIETARY_SUPPLEMENT|The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food.|The intervention group will receive personalized education and guidance from a nutrition therapist.
218860243|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
218860244|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
218860245|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
218860246|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
218860247|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
218860248|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
218860249|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
218860250|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
218860251|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
219476618|NCT07007169|OTHER|Standard Diet|The control group will continue their normal diet, and not receive guidance or participate in group sessions.
219476619|NCT05775718|DRUG|Zoster Vaccine Recombinant|Injection
218860252|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
218860253|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
218860254|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
218860255|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
218860256|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
218860257|NCT04272008|OTHER|Tampon|Annovera with tampon use
218860258|NCT00000357|DRUG|Buprenorphine|
218860259|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
218860260|NCT04366557|OTHER|Education program|education about pelvic floor
218860261|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
218860262|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
218860263|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
218860264|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
218860265|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
218860266|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
218860267|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
218860268|NCT02119039|DEVICE|Genteal HA eye drops|
218860269|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
218860270|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
218860271|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
218860272|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
218860273|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
218860274|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
218860275|NCT02549222|OTHER|Standard of Care|
218860276|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
218860277|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
218860278|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
218860279|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
218860280|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
218860281|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
218860282|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
218860283|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
218860284|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
219020729|NCT07206082|DEVICE|Laser atherectomy|"ELCA procedure will be performed using the Spectranetics CVX300 (Spectranetics, Colorado Spring, CO, USA) and the latest generation Philips Laser System Excimer (Philips, San Diego, CA, USA) System, which is based on pulsed xenon-chlorine laser catheters capable of delivering excimer energy (wavelength 308 nm, pulse length 185 ns) from 30 to 80 mJ/mm2 (fluencies) at pulse repetition rates from 25 to 80 Hz.~The ELCA technique will be performed according to current recommendations (18). The laser probe size will be at the operator´s discretion among the available options (rapid exchange concentric 0.9 mm, 1.4 mm, 1.7mm or 2.0mm). The selection of fluence, and repetition rate will be left to the operator. A saline infusion technique will be recommended, although application of laser with blood or contrast will be recommended in resistant lesions. In the event of unsuccessful initial therapy, additional plaque modification techniques may be employed at the discretion of the operator and wi"
218860285|NCT00957333|OTHER|ketamine|
218860286|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
218860287|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
218860288|NCT00514345|GENETIC|gene expression analysis|
218860289|NCT00514345|GENETIC|polymorphism analysis|
218860290|NCT00514345|PROCEDURE|management of therapy complications|
218860291|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
218860292|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
219476620|NCT05962463|PROCEDURE|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
219476621|NCT05962463|PROCEDURE|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
219476622|NCT05405218|DEVICE|CTR with Ultrasound Guidance using the UltraGuideCTR device|Carpal Tunnel Release with Ultrasound Guidance using UltraGuideCTR device
219476623|NCT05405218|PROCEDURE|mOCTR|Mini Open Carpal Tunnel Release
219476624|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
219476625|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
219476626|NCT06686862|DRUG|ibuprofen|Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.
219476627|NCT07005349|OTHER|Quality improvement program|The intervention comprises two mandatory risk assessments (preoperatively in theatre and postoperatively prior to discharge from the recovery area) which are linked to hospital-specific responses. Assessments for bleeding will occur intraoperatively (through direct vision, haemodynamic changes and/or measurement of blood loss) and postoperatively (with the use of the rapid assessment tool). If bleeding is diagnosed at any point, the THUMB checklist will be used to activate bundled care. On discharge from recovery, high-risk patients will be scheduled to receive a postoperative ward visit within four hours, when a further assessment for bleeding will occur.
219476628|NCT07006246|DRUG|Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)|Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
219476629|NCT07006168|DRUG|Ketorolac 15mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
219476630|NCT07006168|DRUG|Triamcinolone Acetonide 40mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
219476631|NCT07006168|DRUG|Ropivacaine HCL 1% 15ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
219476632|NCT07006168|DRUG|0.9 % Normal Saline 35ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
219476633|NCT07006168|DRUG|Adrenaline 1:1000 0.5ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
219476634|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
219476635|NCT04416451|DRUG|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
219020730|NCT07206485|DEVICE|vibro-acoustic therapy|Vibroacoustic therapy (VAT) is a type of sound therapy that involves passing low frequency sine wave vibrations into the body via a device with embedded speakers
219020731|NCT07206485|DEVICE|Motion Guidance Laser|Motion Guidance Laser is a tool used to improve the curative progression by leading to excessive participation of the subject, helping to facilitate motor skills, postural stability
219020732|NCT07206485|OTHER|selected physical therapy exercises program|"1. Passive Prolonged Stretching and positioning~2. Range of motion exercises for both upeer limb and lower limb~3. Balance exercises static and dynamic"
219522291|NCT04757090|DRUG|89Zr-trastuzumab|"-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure."
219522292|NCT06446180|DRUG|SsK12@Lip@GSH|SsK12@Lip@GSH powder contained 1×10\^9 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
219613509|NCT02498002|OTHER|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
219020733|NCT07206615|OTHER|Endoscopic marker|Study to confirm the safety and performance of the Laborie Spot Ex Endoscopic Marker in accordance with the approved labelling/instructions for use (IFU).
218860293|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
218860294|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
218860295|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
219476636|NCT04416451|DRUG|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
219476637|NCT06316557|DEVICE|iTBS group|iTBS on the contralesional cerebellum, twice a day for seven days
219476638|NCT06316557|DEVICE|control group|shame stimulation on the contralesional cerebellum, twice a day for seven days
219476639|NCT06869330|BEHAVIORAL|psychosocial|Measure changes in mental health indicators like depression, anxiety, and stress levels using validated scales (e.g. DASS 21).
219476640|NCT06870279|DRUG|CGC738|CAR-NKT Cells treatment
219476641|NCT04479241|BIOLOGICAL|lerapolturev|Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
218860296|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
218860297|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
218860298|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
218860299|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
218860300|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
218860301|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
219476642|NCT04479241|BIOLOGICAL|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
219476643|NCT07007481|DEVICE|Purrble|"The intervention takes the form of an interactive plush toy, which was co-designed with children to support in-the-moment soothing. The device is framed as an anxious creature, in need of care and attention when it feels distressed. This distress is indicated by a simulated heartbeat using embedded electronics to produce vibration patterns of i) frantic and anxious, to ii) slow, steady and relaxed. When held, the device emits a frantic heartbeat which can be slowed by stroking movements registered by embedded sensors. Once the device has been soothed for long enough, the heartbeat transitions into a purring vibration indicating a relaxed state. This transition can be achieved in under 1 minute but is dependent on the device-human interaction."
219476644|NCT06690164|DRUG|Atorvastatin 40mg Tablet|once a day for 30 days
218860302|NCT00072891|BEHAVIORAL|telephone counseling|
218860303|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
218860304|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
218860305|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
218860306|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
218860307|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
218860308|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
218860309|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
218860310|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
218860311|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
218860312|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
218860313|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
218860314|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
218860315|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
218860316|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
218860317|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
218860318|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
218860319|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
218860320|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
218860321|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
218860322|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
218860323|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
218860324|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
218908159|NCT06215534|DIETARY_SUPPLEMENT|4th concept product seris 1|Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)
218908160|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 1|Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates
218908161|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 1|Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates
218908162|NCT06215534|DIETARY_SUPPLEMENT|1st reference product series 2|dextrose (containing 25 grams of carbohydrates)
218908163|NCT06215534|DIETARY_SUPPLEMENT|2nd reference product series 2|dextrose (containing 25 grams of carbohydrates)
218860325|NCT05704660|BEHAVIORAL|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
218860326|NCT05704660|BEHAVIORAL|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
218860327|NCT03929926|OTHER|Best Practice|receive usual care
218860328|NCT03929926|BEHAVIORAL|Cancer Educational Materials|Receive educational materials via mail
218860329|NCT03929926|OTHER|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
218860330|NCT03929926|OTHER|Counseling|Undergo decision counseling session
218860331|NCT00131456|DRUG|Venlafaxine|375mg/day
218860332|NCT00131456|DRUG|Placebo|Placebo
218860333|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
218860334|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
218860335|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
218860336|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
218860337|NCT00262847|DRUG|Carboplatin|Given IV
219476645|NCT06690164|DRUG|Omeprazole 20mg Capsule|once a day for 30 days
219476646|NCT05947084|OTHER|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
219596942|NCT05209594|BEHAVIORAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
219596943|NCT05209594|BEHAVIORAL|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
219596944|NCT02954991|DRUG|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
219596945|NCT02954991|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
219596946|NCT02954991|DRUG|Mocetinostat|Mocetinostat is an HDAC inhibitor.
219596947|NCT02954991|DRUG|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
218860338|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
218860339|NCT00262847|DRUG|Paclitaxel|Given IV
218860340|NCT00262847|OTHER|Placebo|Given IV
218860341|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
218860342|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
218860343|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
218860344|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
218860345|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
218860346|NCT00290667|BIOLOGICAL|pegfilgrastim|
218860347|NCT00290667|BIOLOGICAL|rituximab|
218860348|NCT00290667|DRUG|cyclophosphamide|
218860349|NCT00290667|DRUG|doxorubicin hydrochloride|
218860350|NCT00290667|DRUG|prednisone|
218860351|NCT00290667|DRUG|vincristine sulfate|
218860352|NCT00290667|OTHER|pharmacological study|
218860353|NCT00290667|RADIATION|radiation therapy|
219476647|NCT04571658|OTHER|Communication|The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.
219476648|NCT05025800|DRUG|CD47 Antagonist ALX148|Given IV
219596948|NCT06079567|DIAGNOSTIC_TEST|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
219596949|NCT00576316|DRUG|Symbicort Turbuhaler 160/4.5|
219596950|NCT06410235|OTHER|Thoracic manipulation and exercise program|The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
219596951|NCT06410235|OTHER|exercise program|The group received exercise
219596952|NCT05757973|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
218860354|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
218860355|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
218860356|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
218860357|NCT02212769|DRUG|Losartan 50mg|Losartan 50mg once daily for 7 days
218860358|NCT02212769|DRUG|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
218860359|NCT06562582|DRUG|Bisoprolol Oral Tablet|Timing of drug intervention after PCI
218860360|NCT06562582|DRUG|Ramipril Oral Product|Timing of drug intervention after PCI
218860361|NCT06562582|DRUG|Dapagliflozin Oral Product|Timing of drug intervention after PCI
218860362|NCT03880838|BEHAVIORAL|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
218860363|NCT03880838|BEHAVIORAL|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
218860364|NCT03880838|BEHAVIORAL|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
218860365|NCT03880838|BEHAVIORAL|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
218860366|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
218860367|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
219204436|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to deliver cognitive behavioral therapy."
219596953|NCT05576883|BEHAVIORAL|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
219596954|NCT01624701|OTHER|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
218860368|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
218860369|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
218860370|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
218860371|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
218860372|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
218860373|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
218860374|NCT05399004|OTHER|Survey Administration|Complete surveys
219204437|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) without Tailored Messages|The study will use an app designed to deliver cognitive behavioral therapy.
219204438|NCT05144633|DEVICE|Auscultation|This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
219596955|NCT03876262|DRUG|Moxidectin|2mg tablets, encapsulated for blinding
219476649|NCT05025800|DRUG|Lenalidomide|Given PO
219476650|NCT05025800|BIOLOGICAL|Rituximab|Given IV
219476651|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
219476652|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
219476653|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
219476654|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
218860381|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
218860382|NCT03617055|DIAGNOSTIC_TEST|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
218860383|NCT00245648|DRUG|fibrinolytic therapy or combination reduced fibrinolytic therapy|
218860384|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
218860385|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
218860386|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
218860387|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
218860388|NCT04397458|DRUG|Saline|0.9% saline on each side
218860389|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
218860390|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
218860391|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
218860392|NCT03150628|DRUG|Perioperative chemotherapy|Perioperative chemotherapy
218860393|NCT03150628|PROCEDURE|Cytoreduction|Cytoreductive surgery
218860394|NCT03150628|DRUG|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
218860395|NCT02442258|DRUG|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
218860396|NCT02442258|DRUG|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
218860397|NCT04306939|OTHER|venipuncture|Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
218860398|NCT04306939|BEHAVIORAL|Questionnaires|PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
218908164|NCT06215534|DIETARY_SUPPLEMENT|3rd reference product series 2|dextrose (containing 25 grams of carbohydrates)
218908165|NCT06215534|DIETARY_SUPPLEMENT|1st concept product series 2|High energy plant based tube feed (containing 25 grams of carbohydrates)
218908166|NCT06215534|DIETARY_SUPPLEMENT|2nd concept product series 2|High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)
218908167|NCT06215534|DIETARY_SUPPLEMENT|3rd concept product series 2|High protein tube feed (containing 25 grams of carbohydrates)
219204439|NCT02531932|DRUG|Carboplatin|Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
219476655|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
219476656|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
219476657|NCT05692427|DEVICE|Cryopen - Cryotherapy|Cryotherapy with N20
219476658|NCT06597747|DEVICE|Audio processor|MED-EL SONNET 3 (EAS) audio processor
219476659|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
219476660|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
219476661|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
219476662|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
219476663|NCT07031193|PROCEDURE|Foam roller instructions for pain reduction|Foam rolling procedure with pain reduction instructions over hamstring muscle group
219476664|NCT07031193|PROCEDURE|Foam rolling for range of motion improvement|Foam rolling over hamstring muscle group with range of motion improvement instructions.
219596956|NCT03876262|DRUG|Ivermectin|3mg tablets, encapsulated for blinding
218860399|NCT04306939|OTHER|Additional Sample Collections|We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
218860400|NCT05693792|OTHER|Observational|No treatment regimen will be deployed in this follow-up study.
218860401|NCT02847559|BIOLOGICAL|Bevacizumab|Given IV
218860402|NCT02847559|PROCEDURE|Electric Field Therapy|Undergo electric field therapy using Optune device
218860403|NCT02847559|DEVICE|NovoTTF-200A Device|Undergo electric field therapy using Optune device
218860404|NCT02847559|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
218860405|NCT06581133|DEVICE|Alarm system|Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
219476665|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
219476666|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
219476667|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
219476668|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
218860406|NCT05467371|BEHAVIORAL|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
218860407|NCT05467371|BEHAVIORAL|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
219476669|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
219476670|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
219476671|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
219476672|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
219476673|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
219476674|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
219476675|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
219476676|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
219476677|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
218860408|NCT01912690|OTHER|aerobic training|
218860409|NCT01912690|OTHER|aerobic and strength training|
218860410|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
218860411|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
218860412|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
218860413|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
218860414|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
218860415|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
218860416|NCT04949542|BEHAVIORAL|Bolster|Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.
218860417|NCT04949542|BEHAVIORAL|Control|Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
218860418|NCT02303782|DRUG|OTX015|
218860419|NCT02303782|DRUG|Vidaza (azacitidine)|
218860420|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
218860421|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
218860422|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
218860423|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
219476678|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
218860424|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
218860425|NCT02209948|DRUG|Temozolomide|
218860426|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
218860427|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
218860428|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
219476679|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
219476680|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
219476681|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
219476682|NCT02215915|PROCEDURE|DES implantation|
219476683|NCT00028015|DRUG|SarCNU|
219476684|NCT05539378|BEHAVIORAL|Auditory Stimulation|enhancement of sleep slow wave activity through acoustic stimulation
219476685|NCT05539378|BEHAVIORAL|Sham (no stimulation)|Playing no tones during sleep but still recording brain activity
219476686|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
219476687|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
219476688|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
219476689|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
219476690|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
219476691|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
219476692|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
219476693|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
219476694|NCT00000721|DRUG|CD4 Antigens|
219476695|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
218860429|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
218860430|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
218860431|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
218860432|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
219476696|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
219476697|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
219476698|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
219476699|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
218860433|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
218860434|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
219476700|NCT02944604|DRUG|PEG-rhG-CSF|
219476701|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
218860435|NCT06631378|PROCEDURE|Transverse groin incision|The transverse incision is made parallel to the inguinal ligament either superiorly or inferiorly to the skin crease directly over the femoral artery. The subcutaneous tissue is dissected in the transverse direction till Scarpaes fascia after which the dissection is performed in the longitudinal direction along the line of the vessels. The lymphatic vessels are spared as much as possible. Any damaged lymph vessels are closed with surgical clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage. In case of difficulty with proper access to the femoral arteries, the incision can be extended either medially, laterally, or vertically.
219476702|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
219476703|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
219476704|NCT04300556|DRUG|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
219476705|NCT04300556|DRUG|Prednisone|Prednisone administered orally.
219476706|NCT04300556|DRUG|Prednisolone|Prednisolone administered orally.
219476707|NCT04300556|DRUG|Dexamethasone|Dexamethasone administered orally.
219476708|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
219476709|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
218908168|NCT06215534|DIETARY_SUPPLEMENT|4th concept product series 2|High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)
219204440|NCT02531932|DRUG|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
219204441|NCT06485752|BIOLOGICAL|tNIV 1 and Matrix-M Adjuvant|tNIV will be administered as a single 0.5 mL IM injection Day 0
219204442|NCT06746272|PROCEDURE|Serratus Anterior Plane Block|Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department using an ultrasound guided transducer to inject 2mg/kg of 0.5% ropivacaine with an adjuvant. A sterile plaster will be placed on the puncture site after performing the block. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
219476710|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
219476711|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
219476712|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
219476713|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
219476714|NCT06712433|DRUG|2% intranasal mupirocin ointment|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
219476715|NCT06712433|DRUG|4% chlorhexidine gluconate body cleanser|Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.
219204443|NCT00709956|DRUG|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
219476716|NCT06278571|BEHAVIORAL|Educational intervention with App and web site education|This group will only receive intervention with access to the educational website from home, where they will review the different modules focused on diabetes care, nutrition and exercise. in addition to the usual medical care by your treating physician.
219476717|NCT06278571|BEHAVIORAL|Educational interventión with web site education|This group will receive, in addition to nutritional therapy, diabetes education through an educational site, to learn more about the most important aspects of diabetes care. In addition to the usual medical care by your treating physician.
219476718|NCT06278571|OTHER|Control group with nutritional therapy|This group will receive only the usual medical care by your treating physician.
218860436|NCT06631378|PROCEDURE|Longitudinal incision|The longitudinal incision is made directly over the femoral artery from the inguinal ligament. The subcutaneous tissue is dissected along the line of the vessel sparing the lymphatic vessels as much as possible. Any damaged lymph vessels are closed with clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage.
218860437|NCT06037265|DEVICE|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
218860438|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
218860439|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
218860440|NCT05934708|BEHAVIORAL|Eccentric leg extension|Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
218860441|NCT07029425|PROCEDURE|Procedure: craniosacral therapy techniques.|Participants in the experimental group will receive Manual Therapy (MT) designed for this study, which will include craniosacral therapy techniques. The sessions will last 40 minutes and will be conducted twice a week for the first 4 weeks, followed by once a week for the final 4 weeks.
218860442|NCT07029425|PROCEDURE|Placebo Group|The placebo group will receive a dummy treatment with a duration of 40min, twice a week for the firt 4 week, follwed by once a week for the final 4 week.
218860443|NCT07040748|BEHAVIORAL|Immersive VR-Based Multimodal Intervention (Virtual-METS)|This intervention consists of a 12-week, group-based program using immersive virtual reality technology (MK360) without head-mounted displays. Each 60-minute session combines mindfulness practices adapted from the Mindfulness-Based Stress Reduction (MBSR) program, cognitive training targeting attention, processing speed, memory, and executive function through realistic virtual environments (such as parks, markets, or home interiors), and chair-based physical exercises focused on balance, stretching, and muscle strengthening. The intervention is delivered in small groups of five participants, twice per week, for a total of 24 sessions, and is led by a trained neuropsychologist.
218860444|NCT07042230|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques were applied to the cervical region using rhythmic initiation, dynamic reversals, and contract-relax methods. Movements followed diagonal cranio-cervical patterns including flexion/extension with rotational components. Each session lasted 15-30 minutes, delivered three times per week for four weeks. Repetitions and sets were progressively increased based on patient tolerance. The goal was to enhance neuromuscular coordination, improve cervical range of motion, and reduce pain through active facilitation techniques.
218860445|NCT07042230|OTHER|Passive Vertebral Mobilization (PVM)|Passive Vertebral Mobilization (PVM) was administered using Maitland mobilization techniques applied to the cervical spine. Posteroanterior central and unilateral glides were performed with the participant in a prone position. Mobilizations started with Grades I-II during Weeks 1-2 and progressed to Grades III-IV in Weeks 3-4, depending on patient response. Each session lasted 15-20 minutes and was conducted three times weekly over four weeks. This passive manual therapy aimed to improve joint mobility, reduce muscle stiffness, and alleviate mechanical neck pain.
218860446|NCT07042048|DEVICE|EVD placement - image-guidance assisted|During EVD placement, an image-guided noninvasive systems will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of image-guidance system occurs once during initial EVD placement in this trial.
218860447|NCT07042048|DEVICE|EVD placement - AR assisted|During EVD placement, an AR system will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of AR occurs once during initial EVD placement in this trial.
218860448|NCT07041632|OTHER|electro-acupuncture|electro-acupuncture for pain relief in egg collection in IVF
219476719|NCT06875986|DRUG|Brexpiprazole (Rexulti)|In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.
219476720|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
218860449|NCT07041632|OTHER|Conscious sedation|IVf egg collection using conscious sedation as the usual analgesia
218860450|NCT07041437|DRUG|SHR-A2102|ADC
218860451|NCT07041437|DRUG|Adebrelimab|PD-L1 inhibitor
218860452|NCT07041515|OTHER|Mobile app|"This study will be conducted in two stages, recruiting patients scheduled for low anterior resection and those scheduled for ostomy restoration after low anterior resection. The pilot stage study will recruit 20 subjects without randomization to evaluate the feasibility of the management program app, and the second stage study will be a parallel experimental-control study, recruiting approximately 300 research participants, 150 from each group.~Patients scheduled for ostomy repair after low anterior resection and low anterior resection are required to fill out a consent form the day before, and participants are randomly assigned to one of two groups in a 1:1 ratio: the experimental group and the control group. Both groups are randomly assigned to four surveys. The types are three quality of life assessment questionnaires (QOL (EORTC QLQ-C30, CR-29, EQ-5D-L)) and a questionnaire related to bowel symptoms (LARS). However, patients undergoing ostomy repair are excluded from the preoperati"
219476721|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
219476722|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
218860453|NCT07041515|OTHER|standard|Subjects classified as control group will receive educational materials. One month and three months after surgery, a questionnaire related to bowel symptoms (LARS) will be administered by phone. The researcher will call the subjects and administer it according to the period. The results of the questionnaire related to bowel symptoms (LARS) administered by phone will be confirmed by the medical staff during outpatient treatment.
218860454|NCT07041567|OTHER|Inhalational anesthesia|"In Group D, patients undergoing bariatric surgery will receive low-flow inhalational anesthesia (0.5-1 L/min) with sevoflurane. The aim is to evaluate whether the reduced fresh gas flow rate decreases the incidence of postoperative atelectasis, assessed via pulmonary ultrasonography.~In Group N, patients undergoing bariatric surgery will receive standard-flow inhalational anesthesia (2-4 L/min) with sevoflurane. This group serves as the comparator to evaluate the impact of flow rate on postoperative atelectasis incidence."
218860455|NCT07040345|OTHER|Annurca apple oleolite|3 mg twice daily for 28 days
218860456|NCT07040345|OTHER|Placebo|3 mg twice daily for 28 days
218860457|NCT07042191|BEHAVIORAL|Disco (Discussion of Cost) Provider Companion Intervention|A communication intervention for providers to assess financial toxicity in Cancer patients
218860458|NCT07041983|DRUG|anti obesity medication|"Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study.~Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study"
218860459|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
218860460|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
218860461|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
218860462|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
218860463|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
218860464|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
218860465|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
218860466|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
218860467|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
218860468|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
218860469|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
218860470|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
218860471|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
218860472|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
218860473|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
218860474|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
218860475|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
218860476|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
219596957|NCT02220062|PROCEDURE|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
219204444|NCT00709956|DRUG|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
218860477|NCT04355858|DRUG|SHR3162|PARP inhibitor
218860478|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
218860479|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
218860480|NCT04355858|DRUG|SHR1210|PD-1 antibody
218860481|NCT04355858|DRUG|Everolimus|mTOR inhibitor
218860482|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
219204445|NCT06201611|DRUG|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
219596958|NCT02220062|PROCEDURE|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
219613510|NCT02498002|RADIATION|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
218860483|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
218860484|NCT04355858|DRUG|SHR3680|AR inhibitor
218860485|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
218860486|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
218860487|NCT04355858|DRUG|SERD|Fulvestrant
218860488|NCT04355858|DRUG|AI|aromatase inhibitor
218860489|NCT04355858|DRUG|VEGFi|Bevacizumab
218860490|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
218860491|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
218860492|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
218860493|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
218860494|NCT04253899|OTHER|Observation|observation and follow up
218860495|NCT02783378|DRUG|Gaviscon Syrup|
218860496|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
218860497|NCT04589351|DRUG|Placebo|Matching placebo
218860498|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
218860499|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
218860500|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
219476723|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
219476724|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
219476725|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
219476726|NCT07034755|OTHER|autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy|The efficacy of autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy was evaluated in patients with multiple myeloma who either achieved partial response (PR) or better (but not complete response \[CR\]) after four cycles of first-line chemotherapy, or those who achieved CR but had high-risk factors.
218860501|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
218860502|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
218860503|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
219476727|NCT06722495|RADIATION|SBRT|Patient will receive SBRT (8Gy\*3F) in combination with the original regimen of neoadjuvant immunochemotherapy in course 3. Gross tumor target volume (GTV) based on the primary foci clearly identified by clinical and imaging examinations. The GTV was discharged 3 mm to generate a Planning target volume (PTV). the target area (PTV) was dosed accordingly to the PTV.
219476728|NCT06722469|OTHER|WCI|The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
219522293|NCT02716129|DRUG|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
219613511|NCT02498002|OTHER|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
219613512|NCT02498002|OTHER|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
218860504|NCT04634708|OTHER|No intervention|No intervention due to observational design
218860505|NCT03604874|DRUG|Oxytocin|intravenous infusion
218860506|NCT02046174|BIOLOGICAL|RENCA macrobeads|
218860507|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
219613513|NCT02498002|OTHER|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
218860508|NCT05180318|DRUG|0.9% saline|0.9% saline
218860509|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
218860510|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
219613514|NCT02498002|OTHER|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
219613515|NCT06342687|PROCEDURE|High compliance with ERAS protocol|Patients were categorized into two groups based on their adherence to the ERAS protocol: group 1 with a compliance rate below 80% and group 2 with a compliance rate of 80% or above.
219613516|NCT01169350|RADIATION|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
219613517|NCT01169350|OTHER|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
218860511|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
218860512|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
219476729|NCT06723093|BEHAVIORAL|Social Medicine Housing Initiative|"Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies."
219476730|NCT06723223|DIAGNOSTIC_TEST|Traditional Peritoneal Equilibrium Test|The first day started with a traditional PET consisting of a 240-minutes dwell with 2.3% glucose PD solutions. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
219476731|NCT06723223|DIAGNOSTIC_TEST|Combined Peritoneal Equilibrium Test|The PET test on the first day (Day 1) was followed by a short (60 min) combined PET with 4.25% glucose solution. On the second day (Day 2), the combined PET was repeated. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
219476732|NCT06722066|DEVICE|Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves|Device: Edwards SAPIEN 3 valve, Medtronic Evolut valve, Boston Acurate Neo valve, or Abbott Navitor Access route: transfemorak, subclavian, transapical, transcarotid, or transcaval The use of balloon dilation will be left to the discretion of the operator.
219476733|NCT06723067|DEVICE|Wearable wireless breast pump|As above
219476734|NCT06723769|DEVICE|rTMS treatment|Repetitive transcranial magnetic stimulation (rTMS) is a new physiotherapy technique for the treatment of PSD Compared to other strategies, it has the advantages of simple operation, non-invasive, painless, and safe. Studies have comprehensively shown that rTMS can effectively improve depressive symptoms in PSD patients
219476735|NCT06723769|OTHER|conventional treatment|general treatment of stabilizing vital signs (such as antidepressants, stabilizing blood pressure, stabilizing blood sugar, etc. ) and conventional rehabilitation treatment (hemiplegic limb comprehensive training, swallowing speech training, cognitive perception training, etc. ).
218860513|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
218860514|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
218860515|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
218860516|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
218860517|NCT02252601|OTHER|HFDT test|
218860518|NCT02252601|OTHER|Pure tone Audiogram|
219204446|NCT06201611|DRUG|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
219476736|NCT06724653|DRUG|RAS blocker tapering group|RAS blocker tapering out
219476737|NCT06724653|DRUG|Beta blocker tapering out|Beta blocker tapering out group
219476738|NCT06724536|OTHER|non interventional study with the use of biological samples.|"Patients will undergo to the follow evaluations:~Gut microbiome on stool samples by NGS (16S rRNA gene amplicon sequencing); Markers of impaired intestinal permeability \[diaminoxidase (DAO), serum zonulin\], and markers of inflammation of the GI tract (fecal calprotectin); Plasma inflammatory indices, cytokines (by Luminex), markers of autoimmunity, and metabolic profile; Acquired and adaptive immunity by multiparametric flow cytometry on PB samples."
219476739|NCT06724770|OTHER|Resilience training intervention|Training intervention on tools and strategies to strengthen the resilience of work teams in healthcare centres.
219476740|NCT06722287|BEHAVIORAL|Caregiver Mental Health Mobile Application Intervention|The mobile application includes self-care tools, caregiving management tools, and online support groups
219476741|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
219476742|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
219204447|NCT06201611|DRUG|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
218860519|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
218860520|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
218860521|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
218860522|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
218860523|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
218860524|NCT05853315|PROCEDURE|Surgery|Surgical Excision
218860525|NCT01891344|DRUG|Oral rucaparib|600 mg BID
218860526|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
218860527|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
218860528|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
218860529|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
218860530|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
218860531|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
218860532|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
219476743|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
219476744|NCT06893484|DIAGNOSTIC_TEST|Weekly high-sensitivity urine pregnancy tests|Participants will take a high-sensitivity urine pregnancy test at home weekly for up to 4 weeks compared to the taking just one home urine pregnancy test at 4-5 weeks. Participants will also complete short weekly questionnaires on their pregnancy symptoms and follow-up care.
219476745|NCT00157820|DEVICE|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
219476746|NCT00157820|DEVICE|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF \& GemIII AT as DC ICDs (DC true and SC sim arms)
219476747|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219476748|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
219476749|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
219476750|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
219476751|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
219476752|NCT06868589|DRUG|Methadone|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
219476753|NCT06868589|DRUG|ketamine|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
219476754|NCT06868589|DRUG|Hydromorphone|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
219476755|NCT06868589|DRUG|fentanyl|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
218860533|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
218860534|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
218860535|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
218860536|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
218860537|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
218860538|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
218860539|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
218860540|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
218908169|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 2|Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)
218908170|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 2|Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)
218908171|NCT02743585|DEVICE|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in \< 1 - 1.5 hours
219476756|NCT06747338|DRUG|KN026|KN026
219476757|NCT06747338|DRUG|HB1801|HB1801
219476758|NCT06747338|DRUG|Pertuzumab|Pertuzumab
219476759|NCT06747338|DRUG|Trastuzumab|Trastuzumab
219476760|NCT06747338|DRUG|Docetaxel|Docetaxel
218860541|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
218860542|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
218860543|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
218860544|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
218860545|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
218860546|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
218860547|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
218860548|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
218860549|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
218860550|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
218860551|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
218860552|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
218860553|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
218860554|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
218860555|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
219476761|NCT06747338|DRUG|Carboplatin|Carboplatin
218860556|NCT00186537|DRUG|Rosiglitazone|
218860557|NCT00186537|DRUG|Fenofibrate|
218860558|NCT00186537|BEHAVIORAL|Weight Loss|
218860559|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
219476762|NCT05111652|OTHER|observational|observational electromiographic musculature activation
218860560|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
218860561|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
218860562|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
218860563|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
218860564|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
219204448|NCT06117670|COMBINATION_PRODUCT|posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft|Posterior colporrhaphy with application of the gamma-irradiated amniotic membrane graft will be done
219476763|NCT06449326|DEVICE|Active Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
219476764|NCT06449326|DEVICE|Sham Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
219476765|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (5×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Five patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
219613518|NCT01169350|PROCEDURE|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
219613519|NCT01169350|PROCEDURE|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
219613520|NCT01169350|OTHER|laboratory biomarker analysis|Correlative studies
218860565|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
218860566|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
218860567|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
218860568|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
218860569|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
218860570|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
218860571|NCT02590562|OTHER|Routine clinical practice|
218860572|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
218860573|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
218860574|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
218860575|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
218860576|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
218860577|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
218860578|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
218860579|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
218860580|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
218860581|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
218860582|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
218860583|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
218860584|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
218860585|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
218860586|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
219596959|NCT01823601|BEHAVIORAL|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
218860587|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
218860588|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
218860589|NCT02605811|DRUG|temozolomide|
218860590|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
218860591|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
219596960|NCT01823601|BEHAVIORAL|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
219596961|NCT05467696|DRUG|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
218860592|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
218860593|NCT00054691|DRUG|Iressa|250 mg by mouth daily
218860594|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
218860595|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
219476766|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (3.25×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
219476767|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (2×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
219476768|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 2: Expansion Study. ssCART-19 cells combined with FTCs at the optimal biological dosage determined in the Phase 1 study were given to expanded Philadelphia chromosome-positive B-ALL patients with remission. The 5×10\^6 cells/kg of CD19+ FTCs was the optimal biological dose determined in phase I. Therefore, CD19+ FTCs at 5×10\^6 cells/kg were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle, while ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. The Bayesian optimal design was applied to perform the futility assessment at the specified interim analyses. Thirty-four evaluable subjects were recruited, and all the patients received at least two cycles of ssCART-19 consolidation.
219476769|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
219476770|NCT06772597|DRUG|Setmelanotide|Setmelanotide (daily subcutaneous injection)
219476771|NCT06910306|DEVICE|Device :DaRT seeds|The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle
219476772|NCT06768658|DRUG|TAK-951|TAK-951 subcutaneous injection.
219476773|NCT06768658|DRUG|TAK-951 Placebo|TAK-951 placebo-matching subcutaneous injection.
219476774|NCT05469893|DRUG|Teclistamab|Intravenous (IV) dosage and timing per protocol design
219476775|NCT05469893|DRUG|Lenalidomide|Oral, dosage and timing per protocol design
219476776|NCT05469893|DRUG|Dexamethasone|Oral, dosage and timing per protocol design
218860596|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
218860597|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
218860598|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
218860599|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
218860600|NCT00190138|DEVICE|Bi-ventricular pacing|
218860601|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
219476777|NCT05657457|DRUG|Tenecteplase|intra-arterial tenecteplase
219476778|NCT05044039|DRUG|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
219476779|NCT06934200|DRUG|Omalizumab|omalizumab injections
219522294|NCT02716129|DRUG|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
218860602|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
218860603|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
218860604|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
218860605|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
218860606|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
219020734|NCT07206953|BEHAVIORAL|Peer Functional Relationship Enhancement Program|The Peer Functional Relationship Enhancement Program is a 9-week psychoeducational intervention for early adolescents. It consists of weekly group sessions that include cooperative activities, role-play, and creative exercises designed to strengthen peer relationships, improve attitudes toward bullying, enhance self-efficacy, and develop critical thinking skills. This program is structured and standardized to ensure consistent delivery across participants and is distinct from other behavioral or social skills programs targeting similar age groups.
219020735|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
219522295|NCT06028607|DIETARY_SUPPLEMENT|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
218860607|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
218860608|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
218860609|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
218860610|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
218860611|NCT05848700|DRUG|Placebo|Placebo Tablet
219476780|NCT06936982|OTHER|Sports Exercise|The exercise intervention program used a combination of moderate-intensity aerobic exercise and resistance exercise in the form of exercise day time: 9:00 a.m. to 10:30 a.m., in which 10min warm-up exercise after 45min aerobic exercise, each aerobic exercise 10-12min, with a rest in the middle of the rest 3-5min. resistance exercise was placed in the aerobic exercise after the resistance exercise, resistance exercise using 3 movements, 2 groups, each group 10 times. Each movement was performed 10 times, with a 3-min break between each movement in each group and a 5-min break between groups. 15-min stretching exercises were performed after the exercise. The RPE scale was examined during the exercise, and the subjects were asked about the RPE scale level at the end of every 10 min during the exercise.
219476781|NCT06936982|OTHER|control group|No intervention
219476782|NCT06943482|DRUG|Prednisolone|20mg of prednisolone will be prescribed, taken orally, and daily for first month followed by tapering doses of 15mg over one month, then 12.5mg for one month, proceeding to 10mg for one month, subsequently taking 7.5mg for one month, and lastly 5mg for one month.
219476783|NCT06943482|DRUG|Methotrexate|10mg of methotrexate will be prescribed to be taken once a week for one month. The dosage will be increased to 15mg of methotrexate taken once a week on the 1st (T1) month clinical visit and will be further increased to 20mg of methotrexate taken once a week on the 2nd (T2) month clinical visit. There will be no further escalation of dosage after this visit.
219476784|NCT06943482|DRUG|Folic Acid 5 MG|5mg of folic acid is to be taken together with methotrexate once a week.
219476785|NCT06943482|DRUG|Omeprazole 20 mg|Omeprazole will be prescribed at 20mg to protect the stomach lining.
218860612|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
219476786|NCT06942182|DRUG|Isomyosamine 250mg|Isomyosamine 250 mg capsules dosed 4 times daily
219476787|NCT06942182|DRUG|Placebo 250 mg|Placebo 250 mg capsule 4 times daily
219476788|NCT06943703|DRUG|Sclerotherapy with intralesional bleomycin injection|The intervention studied is intralesional Bleomycin injection, which involves the direct injection of Bleomycin, a chemotherapeutic agent, into the lymphangioma lesions. This minimally invasive procedure is aimed at reducing the size of the lymphangioma by disrupting the abnormal growth of lymphatic vessels. The dosage of Bleomycin is tailored based on the patient's body weight, typically ranging from 1 to 3 mg per kg of body weight per injection. The intervention is distinct from other treatments, such as surgical excision or other sclerotherapy agents, as it specifically utilizes Bleomycin's mechanism of action to induce tissue sclerosis and promote lesion regression without the need for invasive surgery. This intervention may require multiple treatment sessions, depending on the size, location of the lymphangioma, and individual's response to therapy, with the goal of achieving long-term effectiveness and improving cosmetic outcomes.
219476789|NCT06943092|DRUG|Piroxicam group|Experimental drug
219476790|NCT06943092|DRUG|Diclofenac group|Active drug
219476791|NCT06942845|OTHER|non-intervention|non-intervention
219476792|NCT06943430|OTHER|laughter yoga|Participants in the intervention group received laughter yoga sessions twice a week for a total of four weeks.
219476793|NCT06203067|BEHAVIORAL|Standard of Care|Quarterly clinic visits with endocrinology provider.
218860613|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
218860614|NCT00792025|DRUG|sunitinib malate|
219476794|NCT06203067|BEHAVIORAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
218860615|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
219476795|NCT06941909|OTHER|Mindfulness-Based Self-Compassion|The intervention consisted of weekly online group training and counseling sessions over an 8-week period. Following each session, participants were provided with a practice guide and audio recordings to support home-based practice.
219476796|NCT06943508|OTHER|Conventional Therapy|Conventional Therapy group: Group A will be control group which will recieve conventional physical therapy program like curl up, lateral step up and sit to stand for 6 weeks( 5 sessions per week)
218860616|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
219476797|NCT06943508|OTHER|Nordic Walk|Nordic Walk group: Group B will recieve Nordic walking for 6 weeks ( 5 sessions per week)
219596962|NCT05321641|BEHAVIORAL|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
219596963|NCT01161134|DRUG|Meloxicam|Meloxicam Tablets 15 mg
219596964|NCT02193334|DRUG|KP-100IT|
219596965|NCT02193334|DRUG|Placebo|
219596966|NCT04831359|DEVICE|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
218860617|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
218860618|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
218860619|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
218860620|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
218860621|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
218860622|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
218860623|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
218860624|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
218860625|NCT05026892|OTHER|no intervention|no intervention, only collection of data
218860626|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
219476798|NCT06943677|DRUG|TQB3019 capsules|TQB3019 capsule is a targeted protein degrader
218860627|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
218860628|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
218860629|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
219204449|NCT06843395|BEHAVIORAL|ACT-based ecological momentary intervention|The intervention is based on Acceptance and Commitment Therapy (ACT) and includes the six core processes (being present, acceptance, defusion, self-as-content, values, and taking action). It is delivered in the form of an ecological momentary intervention (EMI), lasting for 7 days with two sessions per day. The intervention aims to enhance mental health, well-being, and psychological flexibility.
219476799|NCT06942208|DIETARY_SUPPLEMENT|Low-dose iron (ferrous sulfate)|Encapsulated low-dose ferrous sulphate (40mg elemental iron)
219476800|NCT06942208|DIETARY_SUPPLEMENT|Yeast-bound iron (ferrous sulfate)|Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)
219476801|NCT06942208|DIETARY_SUPPLEMENT|High-dose iron (ferrous sulfate)|Encapsulated high-dose ferrous sulphate (150mg elemental iron)
219476802|NCT06943040|OTHER|There will be no intervention on the participants within the scope of this study.|There will be no intervention on the participants within the scope of this study.
219476803|NCT04148235|OTHER|No Intervention|There is no intervention for this study
219476804|NCT06943625|OTHER|tDCS|"Transcranial direct current stimulation protocol involves 20 minutes of anodal stimulation, with the anodal electrode placed over the motor cortex (primary motor area), and cathodal stimulation applied to the contralateral supraorbital area.~The intensity of the current will be set to 1.5 mA, with the current density ranging from approximately 0.03 to 0.06 mA, with the electrode measuring of 5x7cm. To ensure a gradual and comfortable experience for participants, the current will ramp up and down over 30 seconds at the beginning and end of each session. Each stimulation session will last for 20 minutes, with participants undergoing five sessions per week. The entire intervention protocol will be carried out over a period of four weeks"
219476805|NCT06943625|OTHER|Green light|Green light exposure will be administered using light with a wavelength of about 520 nm. The sessions will take place in a dimly lit room to minimize external light interference and enhance the therapeutic effect of the green light. Each exposure session will last for 2 hours, with participants receiving 3 to 5 sessions per week. The light intensity will be set to 100 lux, a level that is both safe and effective for migraine treatment. The entire intervention protocol will span over four weeks to allow for sufficient evaluation of the effects. During each session, participants will be seated comfortably in a chair to ensure they are relaxed and able to tolerate light exposure without discomfort.
219476806|NCT06943625|OTHER|medicine|Advised medicine by the medical doctors will be utilized by the participants of the study
218860630|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
218860631|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
218860632|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
219204450|NCT06843395|OTHER|Mood monitoring|Participants do not receive any intervention. During the intervention period, they only need to complete ecological momentary assessments twice a day.
219476807|NCT06943417|DEVICE|Over the scope clip|over the scope clip group
219596967|NCT06173271|DIETARY_SUPPLEMENT|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
219596968|NCT01105871|DRUG|naloxone|4 mg naloxone in 10 ml saline given iv bolus
218860633|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
218860634|NCT00102297|DRUG|FG-3019|
218860635|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
218860636|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
218860637|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
218860638|NCT00035360|DRUG|PEG-Intron|
218860639|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
218860640|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
219476808|NCT06943248|OTHER|Image-Sand Play Therapy|Over the course of seven sessions, the child initially engaged in chaotic sandbox play, showing difficulty in altering or organizing his scenes. By the fourth session, he began experimenting with different symbols, including familiar TV characters. From the fifth session onward, his play gained structure, evolving into strategic battle scenarios involving animals, loggers, and castles. By the seventh session, hero figures emerged, and the therapist noted improved classroom behavior and cooperation, though social challenges with peers remained.
219476809|NCT06943248|OTHER|Table Top Training Program with Weighted Cuff|"Task include: Stacking cones Lift a cone with one hand and stack it on top of a fixed cone. (The difficulty level was controlled by using resistance bands of varying weights or instructing patients to sit or stand while performing the task.) Task Therapy Program Stacking 3 × 3 cm blocks Pick up blocks one at a time by using one hand and stack them. (The difficulty level was controlled by using resistance bands of varying weights.) Tailwind Use both hands to push the handles of an instrument up and down to the sounds of a metronome.~(The difficulty level was controlled by varying the angle.) Pinch exerciser Take a pinch pin and put it on a rod. (The difficulty level was controlled by varying the resistance of the pinch pin (5 grades) and the diameter of the rod (3 grades).) O'Connor Tweezer Dexterity Test Pick up a pin (2.5 cm long) and put it in a 15 mm hole. (The difficulty level was controlled by using different tweezers.)"
219476810|NCT04971720|DRUG|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
219476811|NCT04971720|DRUG|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
219476812|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
219476813|NCT01302366|DRUG|TBL12|
219476814|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
219476815|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
218860641|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
218860642|NCT01657136|DRUG|Ivabradine|comparison of different drugs
218860643|NCT01657136|DRUG|Beta blocker|comparison of different drugs
218860644|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
218860645|NCT00642148|DRUG|GW856553|Active tablet
218860646|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
218860647|NCT00642148|DRUG|Seretide|Active comparator inhaler
219476816|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
219476817|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
219596969|NCT01105871|DRUG|Placebo|10 ml of normal saline iv bolus
219596970|NCT01935518|DRUG|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
218860648|NCT01960543|DRUG|fentanyl 15 microg|
218860649|NCT01960543|DRUG|Bupivacaine 7 mg|
218860650|NCT01960543|DRUG|Bupivacaine 9 mg|
218860651|NCT01960543|DRUG|Levobupivacaine 7 mg|
219020736|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
219020737|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
218860652|NCT01960543|DRUG|Levobupivacaine 9 mg|
218860653|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
218860654|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
218860655|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
218860656|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
218908172|NCT02743585|DEVICE|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
219476818|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
218860657|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
218860658|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
218860659|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
218860660|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
218860661|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
218860662|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
218860663|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
218860664|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
218860665|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
219365013|NCT01468649|DEVICE|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
219596971|NCT02594865|DIETARY_SUPPLEMENT|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
218860666|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
218860667|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
218860668|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
218860669|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
218860670|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
218860671|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
218860672|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
218860673|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
218860674|NCT00598078|DRUG|Sodium Oxybate|Dose 1
218860675|NCT00598078|DRUG|Sodium Oxybate|Dose 2
218860676|NCT00598078|OTHER|Placebo|Dose 3
219365014|NCT02773329|OTHER|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
219365015|NCT02773329|OTHER|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
219365016|NCT00270894|DRUG|epirubicin|epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
219365017|NCT00270894|DRUG|cyclophosphamide|cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
219365018|NCT00270894|DRUG|docetaxel|docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
219365019|NCT00270894|DRUG|trastuzumab|trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
219365020|NCT03933943|DRUG|LY3361237|Administered SC
219365021|NCT03933943|DRUG|Placebo|Administered SC
219365022|NCT03724448|DRUG|aleozen|treatment with herbal medicine
219365023|NCT03724448|DRUG|Placebo Oral Tablet|No aleozen treatment
219365024|NCT01067820|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
219365025|NCT01067820|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
219365026|NCT05422729|BEHAVIORAL|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
219365027|NCT05422729|BEHAVIORAL|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
219365028|NCT02669693|DIETARY_SUPPLEMENT|bread without olives|
219365029|NCT02669693|DIETARY_SUPPLEMENT|bread with olives|
219365030|NCT02707770|OTHER|Pulmonary Rehabilitation|
219365031|NCT05619965|DRUG|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
219365032|NCT05619965|DEVICE|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
219365033|NCT05619965|DEVICE|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
218860677|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
218860678|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
218860679|NCT01897753|DRUG|growth hormone|36 months
218860680|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
219476819|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
219476820|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
219476821|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
219476822|NCT00467051|DRUG|Carboplatin|Given IV
219476823|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
219476824|NCT00467051|DRUG|Ifosfamide|Given IV
219476825|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219476826|NCT00467051|DRUG|Paclitaxel|Given IV
219476827|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
219476828|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
219476829|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
219596972|NCT02594865|DIETARY_SUPPLEMENT|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
218860681|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
218860682|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
218860683|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
219020738|NCT07205328|DRUG|Placebo|The placebo does not contain any active ingredients.
219020739|NCT07204951|DEVICE|Gurunanda - Water Flosser|"Mode of Usage: Follow the below listed steps for product usage post brushing of teeth.~1. Fill - Add water to the tank of the Flosser~2. Insert - Add the tip to the flosser~3. Select - Choose the level of pressure~4. Floss - Guide the stream between your teeth and along the gumline~5. Clean - After use, insert the tip in the water tank and sanitize Frequency: Use twice a day after brushing. Route of administration: Topical - Oral Storage Condition: Store in a cool, dry place, away from direct sunlight, and do not submerge in water."
219020740|NCT07204951|OTHER|No water Flossing|No water Flossing
219476830|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
219596973|NCT01014793|DRUG|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
219596974|NCT05257226|BEHAVIORAL|frailty|questionaire
219596975|NCT06088030|DRUG|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
219596976|NCT01342757|DRUG|vorinostat|Given orally
218860684|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
218860685|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
218860686|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
218860687|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
219020741|NCT07207057|DRUG|Placebo|An over-encapsulated placebo capsule taken once daily to match the treatment arms following a 5-week titration phase.
219596977|NCT01342757|DRUG|temozolomide|Given orally
218860688|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
218860689|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
219476831|NCT05950529|OTHER|No product|no product
219476832|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
219476833|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
219476834|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
219476835|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
219476836|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
219476837|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
219476838|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
219476839|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
219476840|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
219476841|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
219476842|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
219476843|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
219476844|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
219476845|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
219476846|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
219476847|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
219476848|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
219476849|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
219476850|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
219476851|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
219476852|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
219476853|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
219476854|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
219476855|NCT02277665|BEHAVIORAL|CUD Treatment|
219476856|NCT02277665|BEHAVIORAL|Tobacco Treatment|
219476857|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
219476858|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
219476859|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
218908173|NCT06472284|DEVICE|TetraGraph|etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
218908174|NCT00005567|BEHAVIORAL|Parental knowledge and beliefs about infant sleep position|
219476860|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
218860690|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
219476861|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
219476862|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
219476863|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
219476864|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
219476865|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
218908175|NCT01393834|PROCEDURE|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
218908176|NCT01393834|PROCEDURE|Milking of the cord|Milking of the cord 4 times in 10 seconds
219476866|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
219476867|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
219476868|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
219476869|NCT03309072|DEVICE|tDCS|active tDCS
219476870|NCT03309072|DEVICE|sham tDCS|sham tDCS
218908177|NCT03793751|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
219476871|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
219476872|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
219476873|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
219596978|NCT01342757|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MRI
219596979|NCT01342757|OTHER|survey administration|Ancillary studies
219596980|NCT05378594|DIAGNOSTIC_TEST|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
219596981|NCT04117802|OTHER|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
219596982|NCT04117802|OTHER|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
219596983|NCT04974203|DEVICE|AptameX|DNA aptamer-based test using patient's saliva
219596984|NCT03032679|OTHER|Non interventional study|No intervention
218908178|NCT00301795|BIOLOGICAL|oblimersen sodium|Given IV
218908179|NCT00301795|BIOLOGICAL|rituximab|Given IV
219476874|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
218860691|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
218860692|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
218860693|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
218860694|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
218860695|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
218860696|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
218860697|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
218860698|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
218860699|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
218860700|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
218860701|NCT00378911|DRUG|sunitinib malate|Given orally
218860702|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
218860703|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
218860704|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
219476875|NCT00018343|DRUG|estrogen|
219476876|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
219476877|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
219596985|NCT06171100|DRUG|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
219596986|NCT05350605|BEHAVIORAL|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
219596987|NCT04516993|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
218860705|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
218860706|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
218860707|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
218860708|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
218860709|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
218860710|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
218860711|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
218860712|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
218860713|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
218860714|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
218860715|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
218860716|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
218860717|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
218860718|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
218860719|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
218860720|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
218860721|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
218860722|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
218860723|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
218860724|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
218860725|NCT02177643|DRUG|Placebo|Placebo oral capsules
218860726|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
219476878|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
219476879|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
219476880|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
219476881|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
219476882|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
219476883|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
219476884|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
219476885|NCT02484131|BEHAVIORAL|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
219476886|NCT02484131|BEHAVIORAL|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
219476887|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
218860727|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
218860728|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
218860729|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
218860730|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
218908180|NCT00301795|OTHER|laboratory biomarker analysis|Correlative studies
218908181|NCT06073613|DIAGNOSTIC_TEST|oral health status|"* CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions"
218908182|NCT03779542|PROCEDURE|cataract surgery|phacoemulsification and intraocular lens implantation
218908183|NCT00925834|BEHAVIORAL|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
218860731|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
218860732|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
218860733|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
218860734|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
218860735|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
218860736|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
219476888|NCT00632138|BEHAVIORAL|exercise intervention|
219476889|NCT00632138|OTHER|questionnaire administration|
219476890|NCT00632138|PROCEDURE|biofeedback|
219476891|NCT00632138|PROCEDURE|management of therapy complications|
218860737|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
219476892|NCT00632138|PROCEDURE|psychosocial assessment and care|
219476893|NCT00632138|PROCEDURE|quality-of-life assessment|
219476894|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
219476895|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
219476896|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
219476897|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
219596988|NCT04516993|DRUG|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
219596989|NCT01266031|DRUG|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
219596990|NCT01266031|DRUG|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
218860738|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
218860739|NCT00388284|DEVICE|Arterial Sealing|
218908184|NCT02230735|DRUG|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
218908185|NCT02230735|DRUG|Normal Saline|(placebo for bupivacaine)
219476898|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
219476899|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
219476900|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
219476901|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
219476902|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
219476903|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
219476904|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
219596991|NCT00013091|BEHAVIORAL|Self-management therapy; Psychoeducational group therapy|
219596992|NCT04399486|OTHER|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
219596993|NCT05908292|PROCEDURE|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
219596994|NCT01434810|DEVICE|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
218860740|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
218860741|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
218860742|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
218860743|NCT02593708|DRUG|Neratinib|
218860744|NCT02593708|DRUG|Paclitaxel|
218860745|NCT02593708|DRUG|Pertuzumab|
218860746|NCT02593708|DRUG|Trastuzumab|
218860747|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
218860748|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
218860749|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
218860750|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
218860751|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
218860752|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
218860753|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
218860754|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
219476905|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
219476906|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
219596995|NCT01434810|DEVICE|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
219020742|NCT07207057|DRUG|Telmisartan|"Over-encapsulated telmisartan 40mg per day for 36 months (plus their usual SoC) following a 5-week titration phase.~Titration phase for telmisartan: Week 1-3: one 20 mg capsule per day; Week 4-5: one 40 mg capsule per day"
219476907|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
219476908|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
218860755|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
218860756|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
218860757|NCT01726673|DEVICE|Placebo sham|
218860758|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
218860759|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
218860760|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
218860761|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
218860762|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
218860763|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
218860764|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
218860765|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
218860766|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
218860767|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
218860768|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
219476909|NCT00219024|DRUG|aliskiren|
219476910|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
219596996|NCT01287026|PROCEDURE|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
219596997|NCT04550923|COMBINATION_PRODUCT|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
219596998|NCT04550923|COMBINATION_PRODUCT|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
219596999|NCT04036838|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
219597000|NCT04036838|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
219597001|NCT04036838|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
219597002|NCT04036838|DIAGNOSTIC_TEST|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
219597003|NCT06358235|OTHER|Music Therapy|30-minute music therapy session.
219597004|NCT06358235|OTHER|No Music therapy|The practice where patients are simply fitted with headphones and rest quietly without listening to music.
219597005|NCT04893018|BIOLOGICAL|Efineptakin alfa|Given IM
219597006|NCT05388513|PROCEDURE|Surgical Resection|Surgically treated patients included
218860769|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
218860770|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
218860771|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
218860772|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
218860773|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
218860774|NCT02189408|BIOLOGICAL|Platelet rich plasma|
218860775|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
218860776|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
218860777|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
219476911|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
218860778|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
218860779|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
218860780|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
218860781|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
218860782|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
218860783|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
218860784|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
218860785|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
218860786|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
218860787|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
218860788|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|\- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
218860789|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|\- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
218860790|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|\- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
218860791|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
218860792|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
219476912|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
219476913|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
219476914|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
219476915|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
219597007|NCT04022408|DIAGNOSTIC_TEST|Liquid based cytology|Liquid based cytology
218860793|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
218860794|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
218860795|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
219476916|NCT01019746|DRUG|propofol|propofol administration
219476917|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
219476918|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
219476919|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
219597008|NCT04022408|DIAGNOSTIC_TEST|Conventional cytology|Conventional cytology
219597009|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219597010|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219597011|NCT01886079|DRUG|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
219476920|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
219476921|NCT00396318|DRUG|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
219476922|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
219476923|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
219476924|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
219476925|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
219476926|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
219476927|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
219476928|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
219476929|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
219476930|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
219476931|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
219476932|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
219476933|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
219476934|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
219476935|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
219476936|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
219476937|NCT00000847|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219476938|NCT00000847|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219476939|NCT00000847|BIOLOGICAL|rgp120/HIV-1 SF-2|
219476940|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
219476941|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
219476942|NCT00152594|DRUG|voriconazole|
219476943|NCT01802762|DEVICE|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
219476944|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
219476945|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
219476946|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
219476947|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
219476948|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
219476949|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
219476950|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
219476951|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
219476952|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
219476953|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
219476954|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
219476955|NCT00036556|DRUG|Atrasentan|
219476956|NCT02763007|DRUG|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
219476957|NCT02763007|DRUG|alogliptin|nesina add on metformin
219597012|NCT01886079|DRUG|Saline|0.4 mcg/kg/h, IV
219597013|NCT01350570|OTHER|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
219476958|NCT02763007|DRUG|pioglitazone|actos add on metformin
219476959|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
219476960|NCT00144859|DRUG|SB681323|
219476961|NCT02916056|DRUG|Azeliragon 5mg|
219476962|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
219476963|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
219597014|NCT01350570|OTHER|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
219597015|NCT01350570|OTHER|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
219597016|NCT01350570|DRUG|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
219597017|NCT05575609|OTHER|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
219597018|NCT04030715|DRUG|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
219597019|NCT00003911|RADIATION|stereotactic radiosurgery|
219597020|NCT00627861|DRUG|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
219597021|NCT00627861|DRUG|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
219597022|NCT02645331|BEHAVIORAL|Remind-to-move|
219597023|NCT02645331|BEHAVIORAL|Modified constraint induced movement therapy|
219597024|NCT02645331|BEHAVIORAL|Conventional rehabilitation|
219597025|NCT02122029|BEHAVIORAL|Lifestyle counselling|Behavioral techniques for weight management
219597026|NCT02122029|PROCEDURE|Bariatric Surgery|Vertical Banding Gastroplasty
219597027|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice1|100% Orange Juice
219597028|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
218860796|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
218860797|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
218860798|NCT00002427|DRUG|Hydroxyurea|
218860799|NCT00002427|DRUG|Stavudine|
218860800|NCT00002427|DRUG|Didanosine|
218860801|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
218860802|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
218860803|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
218860804|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
218860805|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
218860806|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
218860807|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
218860808|NCT00700102|DRUG|Chemotherapy|As prescribed
218860809|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
218860810|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
218860811|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
218860812|NCT02525939|DRUG|Placebo|matching placebo tablets
218860813|NCT01028716|DRUG|Cyclophosphamide|Given IV
218860814|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
218860815|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
218860816|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
218860817|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
218860818|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
218860819|NCT01028716|DRUG|Tacrolimus|Given IV or PO
218860820|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
218860821|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
218860822|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
219020743|NCT07207057|DRUG|Terazosin (Hytrin)|"Over-encapsulated terazosin 5mg per day for 36 months (plus their usual SoC) following a 5-week titration phase.~Titration phase for terazosin: Week 1: one 1 mg capsule per day; Week 2: one 2 mg capsule per day; Week 3: one 3 mg capsule per day; Week 4: one 4 mg capsule per day; Week 5: one 5 mg capsule per day"
219476964|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
218860823|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
218860824|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
218860825|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
218860826|NCT03040869|OTHER||
218860827|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
218860828|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
218860829|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
218860830|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
218860831|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
219476965|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
219476966|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
219476967|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
219476968|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
219476969|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
219476970|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
219476971|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
219476972|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
219476973|NCT02536625|OTHER|prospective study|
219476974|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
219476975|NCT01638260|DRUG|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
219476976|NCT01638260|BEHAVIORAL|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
219476977|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
219476978|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
219476979|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
219476980|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
219476981|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
219476982|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
219476983|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
219476984|NCT00611780|RADIATION|tube voltage|standard 120 kV
219476985|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
219476986|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
219476987|NCT02191969|BEHAVIORAL|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
219476988|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
219476989|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
219476990|NCT00626574|DRUG|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
219476991|NCT00626574|DRUG|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
219476992|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
219597029|NCT03685201|DIETARY_SUPPLEMENT|Raw Orange|Raw Orange
219476993|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
219476994|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
219476995|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
219476996|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
219476997|NCT01683331|DRUG|Insulin treatment for hyperglycemia|
219476998|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
219476999|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
219477000|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
219597030|NCT03857269|OTHER|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
219477001|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
219477002|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
219477003|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
219477004|NCT01009073|DRUG|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
219597031|NCT03857269|OTHER|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
218860832|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
218860833|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
218860834|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
218860835|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
219477005|NCT01009073|DRUG|erlotinib|150 mg of erlotinib is taken orally once daily.
219477006|NCT01009073|DRUG|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
219477007|NCT01009073|DRUG|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
219477008|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
218860836|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
218860837|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
218860838|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
219477009|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
219477010|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
219477011|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
219477012|NCT04167839|OTHER|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
219477013|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
219477014|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
219597032|NCT03857269|OTHER|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
218860839|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
218860840|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
218860841|NCT05460598|OTHER|commonly used bedding|commonly used bedding
219477015|NCT00421369|DRUG|sertraline|
219477016|NCT00421369|DRUG|triiodothyronine (T3)|
219477017|NCT00421369|DRUG|reboxetine|
219477018|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
219477019|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
219477020|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
219477021|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
219477022|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
218860842|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
219477023|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
219477024|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
219477025|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
219477026|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
219597033|NCT01644630|PROCEDURE|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~\- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
218860843|NCT00762996|DEVICE|etafilcon A|contact lens
218860844|NCT00762996|DEVICE|omafilcon A|contact lens
218860845|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
218860846|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
218860847|NCT00536874|GENETIC|protein expression analysis|
218860848|NCT00536874|GENETIC|proteomic profiling|
218860849|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
218860850|NCT00536874|PROCEDURE|adjuvant therapy|
218860851|NCT00536874|PROCEDURE|neoadjuvant therapy|
218860852|NCT00536874|PROCEDURE|therapeutic conventional surgery|
219477027|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
219477028|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
219477029|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
219477030|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
219477031|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
219477032|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
219477033|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
218860853|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
218860854|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
218860855|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
218860856|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
219477034|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
219477035|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
219477036|NCT03491800|BEHAVIORAL|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
219477037|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
219477038|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
218860857|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
219477039|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
218860858|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
219477040|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
218860859|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
218860860|NCT02182674|DRUG|Placebo Combivent HFA|
218860861|NCT02182674|DRUG|Combivent HFA|
218860862|NCT02182674|DRUG|Combivent (CFC)|
218860863|NCT02182674|DRUG|Placebo Combivent (CFC)|
218860864|NCT02723890|DEVICE|Tyto Device|
218860865|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
218860866|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
218860867|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
218860868|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
218860869|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
218860870|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
218860871|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
218860872|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
218860873|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
218860874|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
218860875|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
218860876|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
218860877|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
218860878|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
218860879|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
218860880|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
218860881|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
219477041|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
219477042|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
218860882|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
218908186|NCT06527170|PROCEDURE|Sleeve gastrectomy|Each patient undergoes bariatric surgery. Each patient is diagnosed before surgery for erectile dysfunction. Similar tests are done 1 year after
218908187|NCT04498078|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate (20 g per day)
219477043|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
219477044|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
219597034|NCT01644630|PROCEDURE|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
219597035|NCT01703624|DRUG|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
219597036|NCT01171755|DRUG|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
219597037|NCT05232812|RADIATION|3-[11C]-OHB|The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
219597038|NCT00569855|DRUG|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
219597039|NCT06257095|BEHAVIORAL|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
219597040|NCT06257095|BEHAVIORAL|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
219597041|NCT06206135|DRUG|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
219597042|NCT00520819|DRUG|Antioxidant-rich food items|
219597043|NCT06467396|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of blood biomarkers (FABP+NT-proBNP) associated to Large Vessel Occlusion in blood samples used in combination with an APP.
218860883|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
218860884|NCT02275728|OTHER|Eletromyography Biofeedback|
218860885|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
218860886|NCT00784732|DRUG|QAV680|
218860887|NCT00784732|DRUG|QAV680|
218860888|NCT00784732|DRUG|Mometasone Furoate|
218860889|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
218860890|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
218860891|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
218860892|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
218860893|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
218860894|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
218860895|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
218860896|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
218860897|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
218860898|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
218860899|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
218860900|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
218860901|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
218860902|NCT01304329|DRUG|BI 10773|Medium dose oral administration
218860903|NCT01304329|DRUG|simvastatin|Medium dose oral administration
219597044|NCT05368064|OTHER|observational|collection of phenotype data
219597045|NCT05162508|OTHER|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
218860904|NCT01304329|DRUG|simvastatin|Medium dose oral administration
219597046|NCT03883308|BEHAVIORAL|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
218860905|NCT01304329|DRUG|BI 10773|Medium dose oral administration
219597047|NCT03883308|BEHAVIORAL|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
219597048|NCT06474208|DRUG|Formulation 1|Oral suspension of Vericiguat (BAY1021189) in single dose (SD).
218860906|NCT02973568|OTHER|Observational Study|
218860907|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
218860908|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
218860909|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
218860910|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
219597049|NCT06474208|DRUG|Formulation 2|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
219597050|NCT06474208|DRUG|Formulation 3|Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
219597051|NCT06474208|DRUG|Formulation 4|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
218860911|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
218860912|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
218860913|NCT00062608|BEHAVIORAL|Written self-disclosure|
218860914|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
218860915|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
218860916|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
218860917|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
218860918|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
219477045|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
219477046|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
219597052|NCT06474208|DRUG|Formulation 5 (placebo)|Matching placebo of formulation 1 in SD.
219597053|NCT06964113|DRUG|Filgotinib Maleate|Administered as oral tablets.
219597054|NCT03660306|PROCEDURE|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
219597055|NCT03660306|PROCEDURE|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
218860919|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
218860920|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
218860921|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
218860922|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
218860923|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
218860924|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
218860925|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
218908188|NCT04393415|COMBINATION_PRODUCT|stem cells|giving stem cells to patients with covid - 19
218908189|NCT01906333|OTHER|Exercise|
218908190|NCT01906333|OTHER|Glucose|
218908191|NCT01906333|OTHER|Fasted|
219477047|NCT02303977|DRUG|Abraxane|
219477048|NCT02303977|DRUG|Gemcitabine|
219477049|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
219477050|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
219477051|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
219477052|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
219477053|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
219597056|NCT05532709|OTHER|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
219597057|NCT05532709|OTHER|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
219597058|NCT01146756|DRUG|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
219597059|NCT04625491|OTHER|Observational|Observational
219597060|NCT06361121|PROCEDURE|mid-point transverse process to pleura (MTP) block|"the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL\_50, 15\_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL."
218860926|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
218860927|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
218860928|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
218860929|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
218860930|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
218860931|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
218860932|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
218860933|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
218860934|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
219597061|NCT06361121|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
218860935|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
218860936|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
218860937|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
218860938|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
219477054|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
219477055|NCT03001427|BEHAVIORAL|Structured center-based lifestyle intervention|
219477056|NCT03001427|BEHAVIORAL|Standard education and physician advice|
219477057|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
219477058|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
219477059|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
219477060|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
219477061|NCT04341727|DRUG|Azithromycin|Antibiotic
219477062|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
219477063|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
219477064|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
219477065|NCT00088504|DRUG|Merimepodib|
219477066|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
219477067|NCT00088504|DRUG|Ribavirin (Copegus®)|
219477068|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
219477069|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
219477070|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
219477071|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
219477072|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
219597062|NCT00273689|DRUG|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
218860939|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
218860940|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
218860941|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
218860942|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
218860943|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
219477073|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
219477074|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
219477075|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
219477076|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
219477077|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
219477078|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
219477079|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
219477080|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
219597063|NCT00273689|DRUG|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
219597064|NCT00046241|DRUG|Extended-release bupropion hydrochloride|
219597065|NCT05424458|PROCEDURE|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
218860944|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
218860945|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
218860946|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
218860947|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
218908192|NCT01233596|DEVICE|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
219477081|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
219477082|NCT01861730|BIOLOGICAL|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
219477083|NCT01861730|BIOLOGICAL|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
219597066|NCT03731442|RADIATION|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
219597067|NCT03731442|RADIATION|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
219597068|NCT03731442|DRUG|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
219597069|NCT03731442|DRUG|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
219597070|NCT03731442|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
219597071|NCT04311671|DRUG|Moxidectin|2 mg tablets, encapsulated for blinding
219597072|NCT04311671|DRUG|Ivermectin|3 mg tablets, encapsulated for blinding
219597073|NCT04311671|DRUG|Albendazole|400 mg tablets
219597074|NCT03296878|OTHER|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
219597075|NCT03296878|OTHER|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
219597076|NCT03349983|BIOLOGICAL|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
219597077|NCT02655705|DRUG|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
219597078|NCT02655705|DRUG|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
219597079|NCT04664946|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
219477084|NCT06702150|BEHAVIORAL|Changing the nursing care model to the primary nursing model|The nurses received training in primary nursing care before the start of the intervention. The model was tested and implemented in early April 2022. Since then, all patients admitted to the unit have been assigned to a primary nurse within the first 48 hours. This nurse is responsible for developing and monitoring the patient's care plan, assessing care needs, implementing the care plan and evaluating the outcomes. This nurse is also responsible for coordinating care needs and discharge planning with other healthcare professionals. When the primary nurse is not working, another nurse from his or her team continues the care plan that he or she has defined. All patients admitted to the unit who met the selection criteria were informed about the study and, if they agreed to take part, completed a self-care competence questionnaire at admission (baseline), at discharge and one month after discharge. They also completed a questionnaire on satisfaction with nursing care at discharge.
219477085|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
219477086|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
218860948|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
218860949|NCT02525913|DEVICE|RFA Applicator|
218860950|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
218860951|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
219477087|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
219477088|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
219477089|NCT02516917|BEHAVIORAL|Attention Training Technique|
219477090|NCT05604521|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
219477091|NCT05604521|BIOLOGICAL|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
219477092|NCT05604521|OTHER|Normal Saline|0.9% sodium chloride
219597080|NCT06582940|RADIATION|MRI-guided adaptive SRT|MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
219597081|NCT06582940|RADIATION|Conventional SRT|Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
218860952|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
218860953|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
219597082|NCT00022334|BIOLOGICAL|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
218860954|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
219597083|NCT04976413|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
219597084|NCT04976413|BEHAVIORAL|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
218860955|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
218860956|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
218860957|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
218860958|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
218860959|NCT00012090|DRUG|bicalutamide|
218860960|NCT00012090|DRUG|goserelin acetate|
218860961|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
218860962|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
218860963|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
218860964|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
218860965|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
218860966|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
218860967|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
218860968|NCT02784015|DRUG|Cisplatin|
218860969|NCT02784015|DRUG|Etoposide|
218860970|NCT02784015|DRUG|Doxorubicin|
218860971|NCT02784015|DRUG|Cyclophosphamide|
218860972|NCT02784015|DRUG|Ifosfamide|
218860973|NCT02784015|DRUG|Carboplatin|
218860974|NCT02784015|RADIATION|Radiotherapy|
218860975|NCT02784015|DRUG|Thiotepa|
218860976|NCT02784015|DRUG|Melphalan|
218860977|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
218860978|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
218860979|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
219477093|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
219477094|NCT04352907|DEVICE|Continuous Glucose Sensor|Continuous glucose sensor results will be compared with arterial glucose samples
219477095|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
219597085|NCT03031418|DIAGNOSTIC_TEST|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
219597086|NCT02252406|DRUG|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
219597087|NCT02252406|OTHER|Placebo|Matching placebo tablets daily for 24 weeks.
219597088|NCT04034407|PROCEDURE|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
219597089|NCT00187993|DRUG|Growth hormone|
218860980|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
218860981|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
218860982|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
219477096|NCT04669756|PROCEDURE|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
218860983|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
218860984|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
218860985|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
218860986|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
218860987|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
219477097|NCT04669756|PROCEDURE|placebo operation|in arm D sutures are transabdominal only
219477098|NCT03981315|DIAGNOSTIC_TEST|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
219477099|NCT03981315|DIAGNOSTIC_TEST|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
219597090|NCT01117571|DEVICE|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
218860988|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
219477100|NCT03981315|DIAGNOSTIC_TEST|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
218860989|NCT00461994|BEHAVIORAL|diet|
218860990|NCT00461994|BEHAVIORAL|exercise|
218860991|NCT00461994|BEHAVIORAL|diet and exercise|
218860992|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
218860993|NCT05531721|OTHER|Observation|Observation and retrospective data collection
218860994|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
218860995|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
218860996|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
219477101|NCT03981315|DIAGNOSTIC_TEST|Microbiological bile test|Determination of the microbiological composition of the bile
219477102|NCT03877276|DIETARY_SUPPLEMENT|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
219477103|NCT03877276|DIETARY_SUPPLEMENT|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
219477104|NCT03877276|DIETARY_SUPPLEMENT|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
219477105|NCT03877276|DIETARY_SUPPLEMENT|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
219477106|NCT03877276|DIETARY_SUPPLEMENT|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
219477107|NCT03877276|DIETARY_SUPPLEMENT|Sodium oxalate drink|a prepared sodium oxalate drink
219477108|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
219477109|NCT06048198|OTHER|No intervention|No intervention
219477110|NCT00672308|OTHER|Benefiber|
219477111|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
219477112|NCT00672308|OTHER|Benefiber with ORS|
219477113|NCT00672308|OTHER|Benefiber with ORS|
219477114|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
219477115|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
219477116|NCT03350880|OTHER|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
219477117|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
219477118|NCT02599610|OTHER|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
219477119|NCT02599610|DEVICE|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
219477120|NCT04296071|OTHER|Research study|Blood and tracheal aspirates will be collected
219477121|NCT04377516|OTHER|pelvic floor muscle training|pelvic floor muscle training
219477122|NCT04377516|OTHER|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
219477123|NCT04377516|OTHER|education of pelvic girdle|education of pelvic girdle
219477124|NCT04390100|DRUG|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
219477125|NCT04390100|OTHER|Platelet rich fibrin|coverage of the free gingival graft area in the palate
219477126|NCT04390100|OTHER|Gel foam|coverage of the free gingival graft area in the palate
219477127|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
219477128|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
219477129|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
219477130|NCT01491737|DRUG|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
219477131|NCT01491737|DRUG|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
219477132|NCT01491737|DRUG|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
219477133|NCT01491737|DRUG|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
219597091|NCT05549531|DRUG|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
219597092|NCT05549531|DRUG|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
218860997|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
218860998|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
218860999|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
218861000|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
218861001|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
218861002|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
219477134|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
219477135|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
219477136|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
219477137|NCT04500054|OTHER|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
219477138|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
219477139|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
219477140|NCT03212443|PROCEDURE|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
219477141|NCT03212443|PROCEDURE|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
219477142|NCT01976663|DEVICE|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
219597093|NCT05909280|OTHER|Pressure-volume loop measurements|Pressure-volume loop measurements using a conductance catheter
219597094|NCT04264676|DRUG|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
218861003|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
218861004|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
219477143|NCT01976663|DEVICE|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
219597095|NCT04264676|DRUG|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
219477144|NCT06604949|DRUG|LP-003 200mg|Subcutaneous injection of 200 mg LP-003
219477145|NCT06604949|DRUG|Placebo|Subcutaneous injection of placebo
218861005|NCT02590601|DRUG|Bromocriptine|
218861006|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
218861007|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
218861008|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
218861009|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
218861010|NCT02552251|BIOLOGICAL|metabolic balance measurements|
218861011|NCT02552251|BIOLOGICAL|bone balance measurements|
218861012|NCT02552251|BEHAVIORAL|quality of life assessment|
218861013|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
218861014|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
218861015|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
218861016|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
218861017|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
218861018|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
218861019|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
218861020|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
219477146|NCT05383703|DRUG|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
219477147|NCT05868187|BEHAVIORAL|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
219477148|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
219477149|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
219477150|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
219477151|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
219597096|NCT02533180|BIOLOGICAL|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
219597097|NCT00447876|BIOLOGICAL|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
218861021|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
218861022|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
218861023|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
218861024|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
218861025|NCT01281228|DRUG|placebo|saline infusion
219477152|NCT05465330|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min
219477153|NCT05465330|DRUG|Desflurane, Propofol|After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
219597098|NCT00447876|DRUG|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
218861026|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
218861027|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
218861028|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
218861029|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
218861030|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
218861031|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
218861032|NCT01406015|DRUG|Spironolactone|50 mg once daily for 6 weeks.
218861033|NCT01406015|DRUG|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
218861034|NCT05025722|OTHER|Non Interventional|This is an observational study.
218861035|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
218861036|NCT01755650|RADIATION|18F FPM|
218861037|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
218861038|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218861039|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
218861040|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
218861041|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218861042|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
218861043|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
218861044|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
218861045|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
218861046|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
218861047|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
218861048|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
219477154|NCT05443659|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
219477155|NCT04211376|OTHER|No Intervention|There is no intervention for this study
219477156|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
219477157|NCT06020378|DRUG|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
219477158|NCT03110107|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219477159|NCT03110107|BIOLOGICAL|BMS-986218|Specified dose on specified days
219597099|NCT05762692|DEVICE|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
219597100|NCT01970774|OTHER|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
219597101|NCT03753191|DEVICE|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
219597102|NCT02397876|OTHER|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
219597103|NCT04914169|DEVICE|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
218861049|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
218861050|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
218861051|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
218861052|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
218861053|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
219477160|NCT03110107|BIOLOGICAL|Nivolumab|Specified dose on specified days
219477161|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
218861054|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
218861055|NCT00050973|DRUG|bexarotene|
218861056|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
219477162|NCT06839872|DRUG|Pirtobrutinib|Patients will receive pirtobrutinib orally with dosing schedule as prescribed
219597104|NCT05537974|PROCEDURE|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
218861057|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
218861058|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
218861059|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
218861060|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
218861061|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
218861062|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
218861063|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
218861064|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
218861065|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
218861066|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
218861067|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
218861068|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
218861069|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
219597105|NCT03042091|DRUG|Polyethylene Glycol|Given orally
218861070|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
219477163|NCT06839872|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule as prescribed.
219477164|NCT02050945|BEHAVIORAL|Resistance training|
219477165|NCT02050945|BEHAVIORAL|Endurance training|
219477166|NCT06630663|BEHAVIORAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
219597106|NCT03042091|DRUG|Neomycin|Given orally
219597107|NCT03042091|DRUG|Metronidazole Hydrochloride|Given orally
219597108|NCT03042091|PROCEDURE|Therapeutic Conventional Surgery|Undergo colorectal resection
219597109|NCT05705076|DRUG|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
218861071|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
218861072|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
218861073|NCT00006799|DRUG|megestrol acetate|
218861074|NCT00006799|PROCEDURE|quality-of-life assessment|
218861075|NCT01445522|DRUG|ABT-888|
218861076|NCT01445522|DRUG|Cyclophosphamide|
218861077|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
219477167|NCT06630663|BEHAVIORAL|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
219477168|NCT03217422|BIOLOGICAL|VAY736|VAY736
219477169|NCT03217422|OTHER|Placebo|Placebo control with conversion to active VAY736
219477170|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
219477171|NCT06025565|DIAGNOSTIC_TEST|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
219477172|NCT06402435|DRUG|Lvonescimab (AK112)|"8Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion (for patients with axillary lymph node metastasis) or 6Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion and axillary lymph node metastasis (for patients without axillary lymph node metastasis) will be administered at first.~Then the first cycle of chemotherapy + AK112 will be given within 24 hours after the end of SBRT.~The total eight cycles of preoperative chemotherapy combined with immunotherapy will be administered.~Surgical resection will be performed within 4-6 weeks after the completion of the eighth cycle.~The chemotherapy regimen consists of: Four cycles of doxorubicin 50 mg/m² (Q3W) + cyclophosphamide 600 mg/m² (Q3W), followed by Four cycles of albumin-bound paclitaxel 125 mg/m², Day 1 and Day 8 (every 28 days).~The immunotherapy drug used is Ivonescimab (AK112) (20mg/kg) , administered every 3 weeks concurrently with chemotherapy for 8 cycles."
219477173|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
219477174|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
219477175|NCT01700894|BEHAVIORAL|Walking Program|
218861078|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
218861079|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
218861080|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
218861081|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
218861082|NCT02072187|DIETARY_SUPPLEMENT|Active|
218861083|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
218861084|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
219477176|NCT00384072|DRUG|bazedoxifene BZA-20|
219477177|NCT00617175|DEVICE|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
219477178|NCT00617175|DEVICE|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
219477179|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
218861085|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
218861086|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
218861087|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
218861088|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
218861089|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
218861090|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
218861091|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
218861092|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
218861093|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
219477180|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
218861094|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
218861095|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
218861096|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
218861097|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
218861098|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
218861099|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
218861100|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
218861101|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
218861102|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
218861103|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
218861104|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
218861105|NCT00349687|BEHAVIORAL|self-control practice|
218861106|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
218861107|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
218861108|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
218861109|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
218861110|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
218861111|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
218861112|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
218861113|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
218861114|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
218861115|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
218861116|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
219365034|NCT05802030|OTHER|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
219365035|NCT05802030|OTHER|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
218861119|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
218861120|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
218861121|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
218861122|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
218861123|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
219365036|NCT03269981|RADIATION|Whole breast irradiation|Radiotherapy to the whole breast alone.
219365037|NCT03269981|RADIATION|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
219365038|NCT05294731|DRUG|BGB-16673|Orally administered
219365039|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
219365040|NCT00083187|DRUG|hydroxyurea|
218861124|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
218861125|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
218861126|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
218861127|NCT00002177|DRUG|Hydroxyurea|
219477181|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
219477182|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
219477183|NCT01757873|DRUG|Z160|
219477184|NCT01757873|DRUG|Placebo|
219477185|NCT03378531|DRUG|AEB1102|modified human arginase I
218861128|NCT00002177|DRUG|Nelfinavir mesylate|
218861129|NCT00002177|DRUG|Stavudine|
218861130|NCT00002177|DRUG|Didanosine|
218861131|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
218861132|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
218861133|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
218861134|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
218861135|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
218861136|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
218861137|NCT02073032|OTHER|No intervention, only observation|
218861138|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
218861139|NCT01840254|DRUG|dexmedetomidine|
218861140|NCT01840254|DRUG|normal saline|
218861141|NCT00533650|DRUG|MK0429|
218861142|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
218861143|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
218861144|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
218861145|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
218861146|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
218861147|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
218861148|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
218861149|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
218861150|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
219477186|NCT00002634|BIOLOGICAL|filgrastim|
219477187|NCT00002634|BIOLOGICAL|monoclonal antibody 3F8|
219477188|NCT00002634|DRUG|cisplatin|
219477189|NCT00002634|DRUG|cyclophosphamide|
219477190|NCT00002634|DRUG|doxorubicin hydrochloride|
219477191|NCT00002634|DRUG|etoposide|
219477192|NCT00002634|DRUG|mesna|
219477193|NCT00002634|DRUG|perfosfamide|
219477194|NCT00002634|DRUG|vincristine sulfate|
219477195|NCT00002634|PROCEDURE|autologous bone marrow transplantation|
219477196|NCT00002634|PROCEDURE|in vitro-treated bone marrow transplantation|
219477197|NCT00002634|RADIATION|low-LET cobalt-60 gamma ray therapy|
218861151|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
219477198|NCT00002634|RADIATION|low-LET photon therapy|
219477199|NCT00002634|RADIATION|radioisotope therapy|
219477200|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
219477201|NCT06540352|DRUG|Mannitol|Placebo in tablets
219477202|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
219477203|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
219477204|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
219477205|NCT01821131|OTHER|muffin|
219477206|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
219477207|NCT02675660|DRUG|Placebo|placebo capsules once daily
219477208|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
219477209|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
219477210|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
219477211|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
218861152|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
218861153|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
218861154|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
218861155|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
218861156|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
218861157|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
218861158|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
218861159|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
218861160|NCT05840692|DRUG|Placebo|
218861161|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
218861162|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
218908193|NCT05252897|PROCEDURE|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
219597110|NCT00005957|RADIATION|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
219597111|NCT00005957|RADIATION|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
219597112|NCT05012826|OTHER|Osteopathic Manipulative Treatment in addition to Physiotherapy|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
219365041|NCT00083187|DRUG|laromustine|
219365042|NCT02944916|DEVICE|IryPump R Set|
219365043|NCT04682158|DRUG|Carboplatin|Given IV
219365044|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
219365045|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
219365046|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
219365047|NCT04682158|DRUG|Paclitaxel|Given IV
219365048|NCT03798886|OTHER|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
219365049|NCT03798886|OTHER|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
219365050|NCT03798886|OTHER|embryo transfer|we will do transfer when the endometrium is ready
219365051|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
219365052|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
219365053|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
219365054|NCT00793793|DRUG|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
219365055|NCT00793793|DRUG|Placebo|
219365056|NCT00950170|PROCEDURE|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
219477212|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
219477213|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
219477214|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
219477215|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
218861163|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
218861164|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
218861165|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
218861166|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
218861167|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
218861168|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
219597113|NCT05012826|OTHER|Physiotherapy|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
219597114|NCT01510626|DIETARY_SUPPLEMENT|Food proteins|Food proteins
219597115|NCT01510626|DRUG|Omalizumab|Drug
219597116|NCT03171974|DRUG|Dexamethasone|dexamethasone will be injected intracapsular under US
219597117|NCT03171974|DEVICE|US|dexamethasone will be injected intracapsular under US
218861169|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
218861170|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
218861171|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
218861172|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
218861173|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
218861174|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
218861175|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
218861176|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
219477216|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
219477217|NCT05568654|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen, UAT and procalcitonin testing.
219477218|NCT05568654|OTHER|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
219477219|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
219477220|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
219477221|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
219477222|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
219477223|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
219477224|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
218861177|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
218861178|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
218861179|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
218861180|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
219199586|NCT06817564|BEHAVIORAL|AI-PEF|Participants will follow a 12-week walking program with five 30-minute sessions per week, progressively increasing intensity based on heart rate and effort indices. Garmin fitness trackers will monitor adherence and intensity. Remote guidance will support participants via weekly digital health messages on the LINE app, offering personalized feedback, goal reinforcement, and lifestyle recommendations. Participants will also receiThese AI feedback implementations will be tailored to complement the in-person education and will include reminders of the individualized goals set during the remote exercise intervention and consultation . The digital component will also offer a platform for patients to share their progress and seek further guidance during the scheduled in-person consultation. The use of digital AI feedback aligns with the trend of integrating technology into healthcare services, providing a convenient and accessible modality for supporting parents engaging in regular exercise.
219199587|NCT06817564|BEHAVIORAL|Theory-based digital exercise|The theory-based digital exercise group will follow the same in-person clinic visits and walking program as AI-PEF but without AI-driven feedback
219365057|NCT05588323|DRUG|Naldemedine|Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
219365058|NCT02084446|DRUG|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
219597118|NCT05056662|DIAGNOSTIC_TEST|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
219597119|NCT04475172|COMBINATION_PRODUCT|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
219597120|NCT02354625|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
219597121|NCT00292786|BEHAVIORAL|Walking Practice with Functional Electrical Stimulation|
219597122|NCT00292786|BEHAVIORAL|Walking Practice|
218861181|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
218861182|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
218861183|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
218861184|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
218861185|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
219365059|NCT02084446|DRUG|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
219365060|NCT02084446|DRUG|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
219365061|NCT02084446|DRUG|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
219365062|NCT02084446|DRUG|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
219365063|NCT02084446|DRUG|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
219365064|NCT05855733|DEVICE|radiofrequency treatment|patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
219365065|NCT02522767|DRUG|Mesalamine|
219365066|NCT02522767|DRUG|Placebo|
219365067|NCT03913663|OTHER|vestibuloocular training|using vestibulo ocular training program for training neglect patient
219365068|NCT03913663|OTHER|regular exercise training for hemiplegic patients|Traditional gait training program.
219365069|NCT02664116|DRUG|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
219365070|NCT02664116|DRUG|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
219365071|NCT01260155|DRUG|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
219365072|NCT01260155|DRUG|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
219365073|NCT01260155|DRUG|E5501|Treatment C: 40 mg new tablet formulation administered with food
218861186|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
218861187|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
218861188|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
218861189|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
219477225|NCT00423137|DRUG|BIBW 2948 BS|Capsule
219477226|NCT00423137|DRUG|Placebo|Capsule
219477227|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
219477228|NCT05361005|DRUG|Placebo|Intravenous injection
218861190|NCT05397639|DRUG|Masupirdine 50 mg|Tablet, Once Daily
219477229|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
219477230|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
219477231|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
219477232|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
219477233|NCT04943627|DRUG|Topotecan|Chemotherapy
219597123|NCT01609023|DRUG|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
219597124|NCT04478812|DIAGNOSTIC_TEST|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
219597125|NCT06435910|BIOLOGICAL|DC vaccines|Antigen-presenting and immune modifying DCvacs to treat MM
218861191|NCT05397639|DRUG|Masupirdine 100 mg|Tablet, Once Daily
219597126|NCT02047734|DRUG|Ozanimod|Oral capsule, daily for 24 months
219597127|NCT02047734|DRUG|Ozanimod placebo|Oral capsule, daily for 24 months
219597128|NCT02047734|DRUG|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
219597129|NCT02047734|DRUG|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
218861192|NCT05397639|DRUG|Placebo|Matching Placebo Tablet, Once Daily
218861193|NCT02525406|OTHER|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
218861194|NCT06570642|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
218908194|NCT05252897|PROCEDURE|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
218908195|NCT04310111|PROCEDURE|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
218908196|NCT05161897|OTHER|Individualized Nutrition Therapy|Explained in arm/group description.
219477234|NCT04943627|DRUG|Vinorelbine|Chemotherapy
219477235|NCT04943627|DRUG|Gemcitabine|Chemotherapy
219477236|NCT04943627|DRUG|Irinotecan|Chemotherapy
219477237|NCT04943627|DRUG|Pemetrexed|Chemotherapy
219477238|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
219477239|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
219477240|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
219477241|NCT00009750|BIOLOGICAL|filgrastim|
219477242|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
219477243|NCT00009750|DRUG|cyclosporine|
219477244|NCT00009750|DRUG|paclitaxel|
219477245|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
219477246|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
219477247|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
219477248|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
219597130|NCT03904108|DRUG|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
219597131|NCT05798455|DRUG|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
219597132|NCT05158543|OTHER|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
218861195|NCT06570642|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
218861196|NCT06570642|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
218861197|NCT04411420|BEHAVIORAL|Pain modulation with physical pain treatment|Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation
218861198|NCT04411420|BEHAVIORAL|Telephone delivered self-management counseling for increasing physical activity|Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient
218861199|NCT04411420|BEHAVIORAL|Telephone delivered behavioral treatment for participants with high risk for continued disability|Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.
218861200|NCT04411420|BEHAVIORAL|Patient preference treatment protocol|the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol
218861201|NCT04411420|BEHAVIORAL|Nonpharmacological guideline adherent treatment protocol|the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient
218861202|NCT04411420|BEHAVIORAL|Facilitated referrals to existing VA or non-VA pain management resources|the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
218861203|NCT04424927|BIOLOGICAL|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
219477249|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
219477250|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
219477251|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
219597133|NCT05158543|OTHER|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
219597134|NCT05158543|OTHER|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
219597135|NCT05850364|BIOLOGICAL|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
218861204|NCT04424927|OTHER|Placebo|Placebo
218861205|NCT05313529|DRUG|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
218861206|NCT05313529|DRUG|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
218861207|NCT05313529|DRUG|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
218861208|NCT05538988|DRUG|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
218861209|NCT05053841|DRUG|Metformin|
218908197|NCT00866177|OTHER|Laboratory Biomarker Analysis|Correlative studies
218908198|NCT00866177|DRUG|Selumetinib|Given orally
219477252|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
219477253|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
219477254|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
218861211|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
218861212|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
218861213|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
219020744|NCT07206810|DRUG|Bortezomib, Lenalidomide, and Dexamethasone|In this study, transplant-eligible patients underwent autologous hematopoietic stem cell transplantation (auto-HSCT) after four cycles of VRD induction therapy, followed by two cycles of VRD consolidation therapy. Chemotherapy was administered in 28-day cycles as follows: subcutaneous bortezomib 1.3 mg/m² on days 1, 4, 8, and 11; oral lenalidomide 25 mg/day (or a dose-adjusted 10 mg based on renal function) from days 1 to 14; and intravenous dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Standard-risk patients received oral lenalidomide as maintenance therapy until disease progression. High-risk patients, defined as those with t(4;14), t(14;16), or del(17p), received bortezomib plus lenalidomide (V+R) as maintenance therapy until disease progression. Enrolled patients had complete clinical information at the time of initial diagnosis and received at least two cycles of VRD therapy.
219477255|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
219477256|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
219477257|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
219477258|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
219477259|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
219477260|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
219597136|NCT03413579|BIOLOGICAL|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
218861214|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
218861215|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
218861216|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
218861217|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
218861218|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
218861219|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
218861220|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
218908199|NCT05510089|DRUG|Etoposide|D1\~D2: 75mg/m\^2
218908200|NCT05510089|DRUG|Cytarabine|D1\~D2: 300mg/m\^2, q12h
218908201|NCT05510089|DRUG|PEG-rhG-CSF|D6: 6mg
219477261|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
219477262|NCT03023358|DRUG|chidamide|30mg po twice a week
219477263|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
219477264|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
219477265|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
219477266|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
219477267|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
219477268|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
219477269|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
219477270|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
219597137|NCT03413579|OTHER|Placebo|
219597138|NCT03872518|DEVICE|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
219477271|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
219477272|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
219477273|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
219477274|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
218861221|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
218861222|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
218861223|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
218861224|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
218861225|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
219477275|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
219199588|NCT06817564|BEHAVIORAL|Active Control|Participants in the active control group will receive standard TBI care, including Garmin-based self-monitoring and routine clinic visits at baseline (T0), 3 months (T1), and 6 months (T2). These visits will include general health education and recommendations on daily physical activity. No personalized or digital exercise strategies will be provided. Participants completing the 6-month protocol will have the option to access the AI-PEF program after the study.
218861226|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
219199589|NCT05215054|DEVICE|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
219199590|NCT05215054|DEVICE|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
219477276|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
219477277|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
219477278|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
219477279|NCT02352831|DRUG|Tosedostat|
219199591|NCT02272309|PROCEDURE|EEG and EP measurement|
219477280|NCT02352831|DRUG|Capecitabine|
219597139|NCT03639818|OTHER|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
219597140|NCT03362606|BIOLOGICAL|OC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
219597141|NCT01936506|BEHAVIORAL|Cognitive Training A|
219597142|NCT01936506|BEHAVIORAL|Cognitive Training B|
218861227|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
218861228|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
218861229|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
218861230|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
218861231|NCT05662852|BIOLOGICAL|Tdap|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur
218861232|NCT05467592|OTHER|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
218861233|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
218861234|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
219477281|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
219597143|NCT00005052|BIOLOGICAL|GM2-KLH vaccine|
219597144|NCT00005052|BIOLOGICAL|QS21|
219477282|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
218861235|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
218861236|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
218861237|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
218861238|NCT02048410|OTHER|low satured diet|
218861239|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
218861240|NCT03330184|DRUG|Berberine Hydrochloride group|
218861241|NCT03330184|DRUG|Bifidobacterium group|
218861242|NCT03330184|DRUG|Berberine Hydrochloride and Bifidobacterium group|
218861243|NCT03330184|DRUG|placebo|
218861244|NCT04809259|DEVICE|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
218861245|NCT03247127|RADIATION|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
218861246|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
218861247|NCT05991232|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
218861248|NCT03622164|RADIATION|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
219477283|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
218861249|NCT03622164|RADIATION|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
218861250|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
218861251|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
218861252|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
218861253|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
218861254|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
218861255|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
219477284|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
219597145|NCT00005052|PROCEDURE|adjuvant therapy|
218861256|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
219199592|NCT06695494|DIAGNOSTIC_TEST|Gene panel array|Blood sample collection for gene panel testing
219477285|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
219477286|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
219477287|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
219477288|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
219477289|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
219477290|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
219477291|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
219597146|NCT01608061|DEVICE|DBS-f on|deep brain stimulation of the fornix
219597147|NCT01608061|DEVICE|DBS-f off|deep brain stimulation of the fornix turned off
219597148|NCT02933437|DRUG|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
218861257|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
218861258|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
219477292|NCT02719613|DRUG|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
218861259|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
218861260|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
218861261|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
218861262|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
218861263|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
218861264|NCT06613360|DRUG|CLN-978|Specified dose on specified days
218861265|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
218861266|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
218861267|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
219477293|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
219597149|NCT06007833|BEHAVIORAL|Physical Therapy and Rehabilitation Modalities|In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.
219597150|NCT06007833|BEHAVIORAL|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
219597151|NCT06168110|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
219613521|NCT04119362|OTHER|Quality of live questionnaires|EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
219613522|NCT04119362|OTHER|Optional translational project|Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
218861268|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
218861269|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
218861270|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
218861271|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
218861272|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
218861273|NCT06053957|PROCEDURE|early mobilization|early mobilization program
219477294|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
218861274|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
218861275|NCT00289198|DRUG|Placebo|placebo nasal spray
218861276|NCT00031980|DRUG|cyclosporine|
219477295|NCT02719613|DRUG|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
219477296|NCT02719613|DRUG|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
219477297|NCT02719613|DRUG|Pomalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
219613523|NCT04807920|DRUG|OnabotulinumtoxinA 100 UNT|Intravesical injection
218861277|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
218861278|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
218861279|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
218861280|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
218861281|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
219477298|NCT02719613|DRUG|Nivolumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
219477299|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
219477300|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
219477301|NCT05978375|PROCEDURE|TARP|Using TARP technique.
219477302|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
219477303|NCT00000147|DRUG|Methylprednisolone|
219477304|NCT00000147|DRUG|Prednisone|
219477305|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
219477306|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
219477307|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
219477308|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
219597152|NCT03229135|DEVICE|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
219597153|NCT06072573|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219597154|NCT06072573|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
218861282|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
219477309|NCT00488098|DRUG|GSK372475|
219477310|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
219477311|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
219477312|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
219477313|NCT00000518|PROCEDURE|electrophysiology|
219477314|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
218861283|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
218861284|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
219199593|NCT06695494|OTHER|Blood Sample Collection|Blood sample collection for research purposes
219477315|NCT00000518|DRUG|imipramine|
219477316|NCT00000518|DRUG|mexiletine|
219477317|NCT00000518|DRUG|procainamide|
219477318|NCT00000518|DRUG|quinidine|
219477319|NCT00000518|DRUG|sotalol|
219477320|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
219477321|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
219477322|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
218861285|NCT06070090|PROCEDURE|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
218861286|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
218861287|NCT05436977|DIAGNOSTIC_TEST|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
218861288|NCT05436977|DIAGNOSTIC_TEST|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
218861289|NCT06773299|BEHAVIORAL|PAT+HEALTH curriculum - Nigeria|This intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.
219477323|NCT02224495|BEHAVIORAL|Structured exercise training|
219477324|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
219597155|NCT00161863|BIOLOGICAL|FSME-IMMUN NEW 0.25 ml|
219597156|NCT02961088|OTHER|Pasta as part of a low GI/GL diet|
219597157|NCT05331807|DIETARY_SUPPLEMENT|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
219597158|NCT05331807|DIETARY_SUPPLEMENT|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
218861290|NCT04298905|OTHER|CHW mHealth patient intervention for trigger escalation|"The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~1. NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~   1. Triggered, escalating adherence coaching:~  2. Safety monitoring: reports all abnormal laboratory values to provider~2. Appointment keeping (RETAIN):~   a. Triggered, escalating adherence coaching~3. vDOT submissions:~   a. Triggered, escalating adherence coaching~4. Symptom reports:~   1. Triggered, escalating adherence coaching"
218861291|NCT05713695|BEHAVIORAL|Full MISSION|MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
218861292|NCT05713695|BEHAVIORAL|Linkage Only Delivered by a Peer Specialist|Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
218861293|NCT06323967|BEHAVIORAL|Large unconditional cash transfers plus voluntary peer support.|These participants will receive monthly cash transfers of $1,500 ($750 twice per month) via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
218861294|NCT06323967|BEHAVIORAL|Nominal cash transfers|These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
218861295|NCT06323967|BEHAVIORAL|Passive comparison group|These families will receive usual care from shelter staff. They will be followed anonymously in administrative records only.
218861296|NCT05443412|DIAGNOSTIC_TEST|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
218861297|NCT05929586|OTHER|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
218861298|NCT04839341|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
219199594|NCT06691490|DEVICE|Transcranial Magnetic Stimulation Sham|cTBS over SMA and cTBS over precuneus (control site)
219477325|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
219477326|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
219477327|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
219477328|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
219477329|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
219597159|NCT05331807|COMBINATION_PRODUCT|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
219597160|NCT00492778|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
219597161|NCT00492778|DRUG|Cisplatin|Given IV
219597162|NCT00492778|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219597163|NCT00492778|RADIATION|Internal Radiation Therapy|Given intracavitarily or interstitially
219597164|NCT05088811|DIAGNOSTIC_TEST|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
219597165|NCT05654311|OTHER|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
219613524|NCT04807920|OTHER|Injectable saline|Intravesical injection
219613525|NCT03352674|DRUG|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
219613526|NCT03352674|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
219613527|NCT06445998|OTHER|task oriented training|Task-oriented training program: \[For study group\] Rocker board training Wobble board training Sit to stand Walk five steps forward Upstairs and downstairs three steps
219613528|NCT00516659|BIOLOGICAL|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
219613529|NCT00516659|BIOLOGICAL|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
219613530|NCT00007631|DRUG|Tretinoin 0.1% cream or placebo|
219613531|NCT00007631|OTHER|Placebo|Patients receive placebo for same amount of time
219613532|NCT05830786|DEVICE|Immersive virtual reality (IVR)|Using Oculus Quest 2 (Reality Labs, Meta Platforms, United States) headsets the PrecisionOS platform version 3.0 (PrecisionOS Technology, Canada) virtual reality surgical modules will be utilized.
219613533|NCT05830786|OTHER|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
219597166|NCT01128309|BEHAVIORAL|Stress Reduction Intervention|eight week group program, plus daily homework practice
218861299|NCT04907526|BIOLOGICAL|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
218861300|NCT04603417|DIAGNOSTIC_TEST|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
218861301|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
218861302|NCT00504790|DRUG|GSK923295|anti-mitotic compound
218861303|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
218861304|NCT00524589|DRUG|dexamethasone|Oral
218861305|NCT00524589|GENETIC|protein expression analysis|Correlative Study
218861306|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
218861307|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
218861308|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
218861309|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
218861310|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
218861311|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
218861312|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
218861313|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
218861314|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
219477330|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
218861315|NCT00265265|DRUG|Atomoxetine|
218861316|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
218861317|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
218861318|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
218861319|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
218861320|NCT03573700|DRUG|Cyclophosphamide|Given IV
218861321|NCT03573700|DRUG|Fludarabine|Given IV
218861322|NCT03573700|DRUG|Mesna|Given IV
218861323|NCT03573700|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
218861324|NCT03573700|BIOLOGICAL|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
218861325|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
218861326|NCT02757859|OTHER|Lavage|Receive EIPL-S
218861327|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
218861328|NCT02757859|OTHER|Lavage|Receive EIPL-D
218861329|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
218861330|NCT04667897|DRUG|601 1.25mg|Solution for injection (intravitreal use)
219477331|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
218861331|NCT04667897|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
218861332|NCT05834010|BIOLOGICAL|Fecal Microbiome Transplant|Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
218861333|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
218861334|NCT00115999|DRUG|alfimeprase|
218861335|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
219597167|NCT01128309|BEHAVIORAL|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
218861336|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
218861337|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
219597168|NCT00237393|DRUG|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
219597169|NCT00237393|DRUG|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
219597170|NCT03709511|OTHER|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
219597171|NCT04521101|OTHER|VAST Course|Educational course to teach non-technical skills
219597172|NCT02208804|DEVICE|Holmium-166-poly (L-lactic acid) microspheres|
218861338|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
218861339|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
218861340|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
219477332|NCT02704988|PROCEDURE|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
219477333|NCT02704988|PROCEDURE|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
219477334|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
219477335|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
219597173|NCT06633601|DEVICE|MR-Guided Focused Ultrasound Technology|MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
219597174|NCT06633601|DRUG|Definity Suspension for Injection|Microbubble contrast agents for ultrasound
218861341|NCT06614504|OTHER|Varying the nicotine content of cigarettes|Altering the nicotine content of the tobacco research cigarettes
218861342|NCT06614504|OTHER|Varying the nicotine content of e-cigarettes|Altering the nicotine content of the research e-cigarettes
218861343|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
218861344|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
218861345|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
219199595|NCT06688123|DRUG|SHR-3167|Dose level 1.
219199596|NCT06688123|DRUG|SHR-3167|Dose level 2.
219597175|NCT03717012|DRUG|Nintedanib|stable dose
219597176|NCT03717012|OTHER|Pulmonary rehabilitation program|12 weeks
219199597|NCT06688123|DRUG|Insulin glargine|Dose level 3.
219597177|NCT06526624|DRUG|HS-20093|Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
219199598|NCT06688227|OTHER|Isolated Core Stability Program|The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
219199599|NCT06688227|OTHER|Integrated Core Stability Program|"An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint."
219365074|NCT02128126|DRUG|ISA101/ISA101b|Four dose levels ISA101/ISA101b
219365075|NCT04887402|DRUG|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation"
219365076|NCT00078364|PROCEDURE|MRI|
219365077|NCT02446392|OTHER|No intervention.|
219365078|NCT02313740|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
219365079|NCT04997239|BIOLOGICAL|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
219365080|NCT04997239|BIOLOGICAL|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
219365081|NCT03640884|DRUG|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
218861346|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
218861347|NCT00221624|DRUG|Peginterferon alfa-2a|
218861348|NCT00221624|DRUG|ribavirin|
218861349|NCT00221624|DRUG|amantadine|
218861350|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
218861351|NCT00387374|DRUG|paclitaxel|Given IV
218861352|NCT00387374|DRUG|carboplatin|Given IV
218861353|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
218861354|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
218861355|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
218861356|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
218861357|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
218861358|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
219477336|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
218861359|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
218861360|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
218861361|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
219477337|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
219477338|NCT02071472|OTHER|DP medication reconciliation|
219597178|NCT05029219|DEVICE|Arm I (Virtual reality group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program."
219597179|NCT05029219|DEVICE|Arm II (Self study group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom."
218861362|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
218861363|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
218861364|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
218861365|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
218861366|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
218861367|NCT02094742|PROCEDURE|biopsy|
218861368|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
218861369|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
218861370|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
218861371|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
218861372|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
218861373|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
218861374|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
218861375|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
218861376|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
218861377|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
218861378|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
218861379|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
218861380|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
218861381|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
218861382|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
219477339|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
219477340|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
219477341|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
218861383|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
219477342|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
219477343|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
219477344|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
219477345|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
219597180|NCT01335035|DRUG|deferasirox|
219597181|NCT00789035|DRUG|BI 10773|
219199600|NCT06689540|BIOLOGICAL|MTS105|"MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg."
219199601|NCT06686381|PROCEDURE|Maximum TURBT|Total removal of the bladder tumor through TURBT
219199602|NCT06686381|DRUG|Chemotherapy + Immunotherapy Induction|Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)
219199603|NCT06686381|RADIATION|Radiotherapy|Hypofractionated radiotherapy: 20 fractions, 55 Grays
219477346|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
219477347|NCT06281522|OTHER|Operated patients with hydatid cyst of the lung|File screening and blood test results will be evaluated
219477348|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
219477349|NCT01449149|RADIATION|Proton Therapy|
219477350|NCT05680987|PROCEDURE|RFN-Advanced Retrograde Femoral Nailing System|RFN-Advanced Retrograde Femoral Nailing System for patients with a distal femur or femoral shaft fracture requiring surgery
219477351|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
219597182|NCT00789035|DRUG|placebo|
219199604|NCT06686381|DRUG|Immunotherapy Maintenance|Maintenance Avelumab every 2 weeks for 12 months
219477352|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
219477353|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
219477354|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
219477355|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
219597183|NCT00789035|DRUG|metformin|
219597184|NCT02386124|OTHER|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
219597185|NCT01425658|DRUG|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
219597186|NCT01425658|DRUG|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
219597187|NCT01425658|DRUG|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
219597188|NCT06361719|OTHER|Experimental Group (EG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
218861384|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
218861385|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
218861386|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
218861387|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
218861388|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
218861389|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
218861390|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
218861391|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
218861392|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
218861393|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
218861394|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
218861395|NCT01866423|DRUG|orteronel|Given PO
218861396|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
218861397|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
218861398|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
218861399|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
218861400|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
218861401|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
218861402|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
218861403|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
218861404|NCT00497328|DRUG|N-acetylcysteine|
218861405|NCT00497328|DRUG|Sodium Bicarbonate|
218861406|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
218861407|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
218861408|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
218861409|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
218861410|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
218861411|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
218861412|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
218861413|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
219199605|NCT06686381|OTHER|Watchful waiting with supportive care|1 year watch and wait
219199606|NCT05269992|OTHER|Real food products|As per arm/group descriptions.
219199607|NCT06870435|BIOLOGICAL|Blood, nasopharyngeal swab and saliva|Collect blood, nasopharyngeal swab and saliva samples from participants.
219477356|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
218861414|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
218861415|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
218861416|NCT00000120|DRUG|Erythromycin Ointment|
218861417|NCT00000120|DRUG|Silver Nitrate Drops|
218861418|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
218861419|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
218861420|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
218861421|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
218861422|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
218861423|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
218861424|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
218861425|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
218861426|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
218861427|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
218861428|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
218861429|NCT02964832|DEVICE|Grasp method|
218861430|NCT02964832|DEVICE|Armband-in-hand method|
219477357|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
219477358|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
219597189|NCT06361719|OTHER|Control Group (CG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
219613534|NCT03380065|DEVICE|Late deflation of TR band|"1. First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation."
218861431|NCT02964832|DEVICE|Armband-on-arm method|
218861432|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
218861433|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
219020745|NCT07205458|BEHAVIORAL|IMB Model Web-Based Breastfeeding Education Program|A structured, model-based online education program designed to increase fathers' knowledge about breastfeeding through interactive lessons, videos, and resources. Fathers will be informed about breastfeeding during the postpartum period. The breastfeeding knowledge test will be completed two weeks after baseline data collection, and motivational interviews will be planned according to fathers' needs.
219597190|NCT01932918|DRUG|Patient controlled analgesia|"1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
218861434|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
218861435|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
218861436|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
218861437|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
218861438|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
218861439|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
218861440|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
218861441|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
218861442|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
218861443|NCT02501564|DRUG|Placebo|One tablet twice a day
219477359|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
219597191|NCT05640258|DIAGNOSTIC_TEST|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
219597192|NCT00157924|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
218861444|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
218861445|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
218861446|NCT01420627|BIOLOGICAL|Adagen|
218861447|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
218861448|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
218861449|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
218861450|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
218861451|NCT02716701|BEHAVIORAL|Exercise Group|
218861452|NCT02716701|OTHER|Control Group|
218861453|NCT02716701|OTHER|wristband activity tracker|
218861454|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
218861455|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
218861456|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
218861457|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
218861458|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
218861459|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
218861460|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
219199608|NCT06870435|DIAGNOSTIC_TEST|EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA|Detect EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA for all participants.
219199609|NCT06870435|DIAGNOSTIC_TEST|Novel screening biomarkers|Next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, etc..
219477360|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
219477361|NCT02042807|DRUG|Placebo|
219477362|NCT02042807|DRUG|MCS®|
219597193|NCT00157924|DRUG|atorvastatin|atorvastatin 10mg
218861461|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
218861462|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
218861463|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
218861464|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
218861465|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
218861466|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
218861467|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
218861468|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
218861469|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
218861470|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
218861471|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
219477363|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
219477364|NCT04298203|DRUG|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
219477365|NCT04298203|DIETARY_SUPPLEMENT|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
219597194|NCT02640690|BEHAVIORAL|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
219597195|NCT02640690|BEHAVIORAL|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
218861472|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
218861473|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
218861474|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
218861475|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
218861476|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
218861477|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
218861478|NCT02020772|OTHER|coordinating primary health care|
218861479|NCT02020772|OTHER|usual primary health care|
218861480|NCT00788580|DRUG|pazopanib hydrochloride|
218861481|NCT00788580|DRUG|temsirolimus|
218861482|NCT00788580|PROCEDURE|immunoenzyme technique|
218861483|NCT00788580|PROCEDURE|laboratory biomarker analysis|
218861484|NCT00788580|PROCEDURE|pharmacological study|
218861485|NCT04259684|DRUG|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
218861486|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
218861487|NCT01747252|DIETARY_SUPPLEMENT|RGC|
218861488|NCT01747252|DIETARY_SUPPLEMENT|RGC|
218861489|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
218861490|NCT00170196|DRUG|prednisone|
218861491|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
218861492|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
218861493|NCT02488291|DRUG|0.25 sufentanil|with different dosage
218861494|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
219477366|NCT04298203|OTHER|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
219477367|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
219477368|NCT03987555|OTHER|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
219477369|NCT03987555|OTHER|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
219477370|NCT03987555|OTHER|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
219477371|NCT03173625|DRUG|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
219477372|NCT03173625|DRUG|Placebo|Sterile 0.9% w/v sodium chloride solution
219477373|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
219477374|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
219477375|NCT05939388|DEVICE|Auricular Acupressure Pads|Pads containing seeds that are placed on specific sites of the ear that are thought to help with pain.
218861495|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
218861496|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
218861497|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
218861498|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
219477376|NCT05598255|DRUG|Dexamethasone|During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).
218861499|NCT02922166|DRUG|SRX246|oral capsule
218861500|NCT02922166|DRUG|Placebo|oral capsule
218861501|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
218861502|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
218861503|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
218861504|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
219477377|NCT05598255|PROCEDURE|Caudale Blockade with levobupivacaine|Administration of levobupivacaine 0,25%0,5ml/kg through the hiatus sacralis lege artis, before incision.
219477378|NCT05598255|PROCEDURE|Dorsal penile nerve block with levobupivacaine|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.
219477379|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
219477380|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
218861505|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
218861506|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
218861507|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
218861508|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
218861509|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
218861510|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
218861511|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
218861512|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
218861513|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
218861514|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
218861515|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
218861516|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
218861517|NCT02251132|DRUG|TPV low 1|
218861518|NCT02251132|DRUG|TPV low 2|
218861519|NCT02251132|DRUG|TPV medium|
218861520|NCT02251132|DRUG|TPV high 1|
218861521|NCT02251132|DRUG|TPV high 2|
218861522|NCT02251132|DRUG|RTV low|
218861523|NCT02251132|DRUG|Ritonavir high|
219477381|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
219477382|NCT02717156|PROCEDURE|Computed Tomography|Correlative studies
219477383|NCT02717156|OTHER|Laboratory Biomarker Analysis|Correlative studies
219477384|NCT02717156|BIOLOGICAL|Pembrolizumab|Given IV
219477385|NCT02717156|PROCEDURE|Positron Emission Tomography|Correlative studies
219477386|NCT02717156|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219477387|NCT06648434|DRUG|Zunsemetinib|Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.
219477388|NCT06648434|DRUG|mFOLFIRINOX|Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
218861524|NCT02251132|DRUG|Radiolabelled erythromycin|
218861525|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
218861526|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
218861527|NCT00764907|DRUG|asparaginase|Given IV during reinduction
218861528|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
218861529|NCT00764907|DRUG|cytarabine|Given IV during reinduction
218861530|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
218861531|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
218861532|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
218861533|NCT00764907|DRUG|etoposide|Given IV during reinduction
218861534|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
218861535|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
218861536|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
218861537|NCT00764907|DRUG|methotrexate|Given orally during reinduction
218861538|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
218861539|NCT00764907|DRUG|thioguanine|Given orally during reinduction
218861540|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
218861541|NCT00764907|DRUG|vindesine|Given IV during reinduction
219477389|NCT06488300|DRUG|Ribavirin|"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"
218861542|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
218861543|NCT02067325|OTHER|Thai massage|
218861544|NCT02579681|DRUG|dimethyl fumarate|dimethyl fumarate administered as per the arm description
218861545|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
219477390|NCT06488300|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5 days
218861546|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
218861547|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
218861548|NCT05918653|OTHER|Home Healthcare|No intervention in this study
218861549|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
219477391|NCT06488300|DRUG|Favipiravir|Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
218861550|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
218861551|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
218861552|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
218861553|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
218861554|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
218861555|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
218861556|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
218861557|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
218861558|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
218861559|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
218861560|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
218861561|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
218861562|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
218861563|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
219199610|NCT06870435|DIAGNOSTIC_TEST|Endoscopic examinations with or without biopsy|High-risk participants will refer to endoscopic examinations with or without biopsy
219199611|NCT06868394|RADIATION|radiotherapy|The impact of previous radiotherapy exposure was studied on developing second primary malignancies.
218861564|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
218861565|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
218861566|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
218861567|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
218861568|NCT02256267|DRUG|LY2835219|Administered orally
218861569|NCT02256267|DRUG|Rifampin|Administered orally
218861570|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
218861571|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~\+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
218861572|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
218861573|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
218861574|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
218861575|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
218861576|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
218861577|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
218861578|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
219477393|NCT05922761|DRUG|Belumosudil|Kinase inhibitor, tablet taken orally
219477394|NCT05922761|DRUG|Fluticasone|Via inhalation by metered-dose inhaler.
219477395|NCT05922761|DRUG|Azithromycin|Semi-synthetic macrolide antibiotic, taken orally
219477396|NCT05922761|DRUG|Prednisone|Corticosteroid, taken orally
219477397|NCT05922761|DRUG|Montelukast|Leukotriene Receptor Antagonist, taken orally
219477398|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
219597196|NCT04648800|DRUG|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
218861579|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
218861580|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
219477399|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
219477400|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
219597197|NCT04648800|DRUG|0.9% saline|0.9% saline
219597198|NCT01118975|DRUG|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
219597199|NCT01118975|DRUG|Lapatinib|1,250 mg once daily
219597200|NCT00176618|DRUG|sulindac|Sulindac 150 mg po BID
219597201|NCT00176618|DRUG|curcumin|Curcumin 250 mg po BID
219597202|NCT01520870|DRUG|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
219477401|NCT04387487|BEHAVIORAL|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
219477402|NCT05524805|DEVICE|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
218861581|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
218861582|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
218861583|NCT06141837|OTHER|Observation|No intervention: observational study
218861584|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
218861585|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
219477403|NCT05273060|PROCEDURE|3D Nasal Reconstruction Planning|3D molds or models to use in the reconstruction of nasal cartilage
219477405|NCT06209268|DRUG|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
219477406|NCT06209268|DRUG|Placebo|0.9% NaCl 1 ml per day in five consecutive days
218861586|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
218861587|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
218861588|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
218861589|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
219597203|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
219597204|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
218861590|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
218861591|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
218861592|NCT02109523|BEHAVIORAL|Routine discharge counseling|
218861593|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
218861594|NCT00334997|PROCEDURE|endoscopic surgery|
218861595|NCT00334997|PROCEDURE|laser surgery|
218861596|NCT00334997|RADIATION|radiation therapy|
218861597|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
218861598|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
218861599|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
218861600|NCT01969500|BEHAVIORAL|Mobile Application|
218861601|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
218861602|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
218861603|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
218861604|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
219477407|NCT05864326|DEVICE|Warm group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.
219477408|NCT05864326|DEVICE|Room temperature group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
219477409|NCT05603572|DRUG|KAT-101|oral dosage form
219477410|NCT05603572|DRUG|KAT-201|IT dosage form
219477411|NCT04871282|DRUG|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
219477412|NCT04871282|OTHER|Placebo|Placebo to match AL102
219477413|NCT05761574|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
218861605|NCT00283972|DEVICE|LAP-BAND System|
218861606|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
218861607|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
218861608|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
218861609|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
218861610|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
218861611|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
218861612|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
218861613|NCT00000765|DRUG|Zidovudine|
218861614|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
218861615|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
218861616|NCT04573426|DRUG|Placebo|Liquid placebo solution
219477414|NCT05761574|DRUG|Naproxen Sodium|Naproxen Sodium will be administered orally.
219477415|NCT05761574|DRUG|Acetaminophen|Acetaminophen will be administered orally.
219477416|NCT05761574|DRUG|Placebo|Placebo will be administered orally.
219477417|NCT06240117|PROCEDURE|Intraoperative cellular salvage|When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If \>100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
219477418|NCT05105126|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
219477419|NCT05105126|DEVICE|Sham tDCS|Sham tDCS
218861617|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
218861618|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
218861619|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
218861620|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
218861621|NCT00000504|DRUG|encainide|
218861622|NCT00000504|DRUG|moricizine|
218861623|NCT00000504|DRUG|flecainide|
218861624|NCT00000504|DRUG|imipramine|
218861625|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
218861626|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
218861627|NCT02282371|DRUG|Cetuximab|
218861628|NCT02282371|DRUG|BYL719|
219477420|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
218861629|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
218861630|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
218861631|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
218861632|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
219477421|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
219477422|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
218861633|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
218861634|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
218861635|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
218861636|NCT00690287|DRUG|Placebo|Placebo
218861637|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
218861638|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
218861639|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
218861640|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
218861641|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
218861642|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
218861643|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
218861644|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
218861645|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
218861646|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
218861647|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
218861648|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
218861649|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
218861650|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
218861651|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
218861652|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
218861653|NCT00201123|OTHER|Placebo|
218861654|NCT00078065|DRUG|Xcellerated T Cells|
218861655|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
218861656|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
218861657|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
218861658|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
218861659|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
218861660|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
218861661|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
218861662|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
218861663|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
218861664|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
218861665|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
218861666|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
218861667|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
218861668|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
218861669|NCT01873729|DRUG|Naltrexone|Adults with ADHD
218861670|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
218861671|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
218861672|NCT00797238|OTHER||No intervention in this study
218861673|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
218861674|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
218861675|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
218861676|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
218861677|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
218861678|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
218861679|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
218861680|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
218861681|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
219477423|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
218861682|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
219477424|NCT05862246|OTHER|Clinical examination|No intervention, only clinical examination
219477425|NCT02662621|OTHER|blood samples|
219477426|NCT02662621|OTHER|Urine samples|
219477427|NCT00102011|PROCEDURE|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
219477428|NCT00102011|PROCEDURE|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
219477429|NCT00102011|PROCEDURE|screening colonoscopy|Patients undergo baseline screening colonoscopy
219477430|NCT00102011|PROCEDURE|standard follow-up care|Standard care
218861683|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
218861684|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
218861685|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
218861686|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
218861687|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
218861688|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
218861689|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
218861690|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
218861691|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
218861692|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
218861693|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
219477431|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
219477432|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
219477433|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
219477434|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
219597205|NCT05978752|PROCEDURE|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
219597206|NCT00905671|DEVICE|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
218861694|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
218861695|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
218861696|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
219477435|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
219477436|NCT04560088|BEHAVIORAL|Mindfulness|Mindfulness-based mobile health intervention.
218861697|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
218861698|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
218861699|NCT00613080|DRUG|oxaliplatin|
218861700|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
218861701|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
218861702|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
219477437|NCT04560088|BEHAVIORAL|Breathing|Breathing mobile health intervention.
219477438|NCT04402125|BEHAVIORAL|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
219477439|NCT05366842|DRUG|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
218861703|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
218861704|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
218861705|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
218861706|NCT02523768|DRUG|ATG-F|
218861707|NCT02523768|DRUG|Simulect|
218861708|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
218861709|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
218861710|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
218861711|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
219477440|NCT05366842|PROCEDURE|Radical prostatectomy|Standard care (no placement of tissue)
219477441|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
219597207|NCT01679509|PROCEDURE|Single-port laparoscopic adnexal surgery|
218861712|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
219477442|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
219477443|NCT00798122|PROCEDURE|Intravascular ultrasound|intravascular ultrasound
219597208|NCT01679509|PROCEDURE|Three-port laparoscopic adnexal surgery|
219597209|NCT06329609|DEVICE|Airvo 3 with respiratory rate algorithm|Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
218861713|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218861714|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
218861715|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
218861716|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
218861717|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
218861718|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
219597210|NCT02463357|DIETARY_SUPPLEMENT|Quercetin|
219597211|NCT02463357|DRUG|Nifedipine extended release|
219597212|NCT02463357|DRUG|Methazolamide|
219597213|NCT02463357|DRUG|Metformin|
219597214|NCT02463357|DRUG|Placebo|
219597215|NCT02463357|DRUG|Nitrite|
219597216|NCT00019240|DRUG|cidofovir|
218861719|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
218861720|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
218861721|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
218861722|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
218861723|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
218861724|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
218861725|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
218861726|NCT01900977|OTHER|Standard of Care|
218861727|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
218861728|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
218861729|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
219477444|NCT00798122|PROCEDURE|MRI|cardiac MRI
219477445|NCT04100915|OTHER|No Intervention|There is no intervention for this study
219477446|NCT06808802|DRUG|Retatrutide|Administered subcutaneously (SC)
218861730|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
219477447|NCT06808802|DRUG|Metoprolol|Administered orally
219597217|NCT01328522|DRUG|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
218861731|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
219597218|NCT00899522|OTHER|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
219597219|NCT00899522|PROCEDURE|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
219597220|NCT06582186|DRUG|Individualization of first voriconazole maintenance doses|Individualization of first voriconazole maintenance doses
218861732|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
219199612|NCT06868394|OTHER|No intervention|This group received no radiotherapy
219477448|NCT03968055|OTHER|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
219477449|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
219477450|NCT04853914|DEVICE|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
219477451|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
219477452|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
219477453|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
219477454|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
218861733|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
219477455|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
219477456|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
219477457|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
219477458|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
219477459|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
219477460|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
219477461|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
219477462|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
219477463|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
219477464|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
219477465|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
219477466|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
219477467|NCT06520098|DRUG|Venetoclax|VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
218861734|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
218861735|NCT02903758|OTHER|cross sectional|
218861736|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
218861737|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
218861738|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
218861739|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
219477468|NCT06520098|DRUG|Ibrutinib, Acalabrutinib, Zanubrutinib|IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
219477469|NCT05726383|DRUG|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
219597221|NCT01619566|DRUG|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
218861740|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
218861741|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
218861742|NCT02312219|DRUG|Placebo|placebo once weekly
218861743|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
218861744|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
218861745|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
219199613|NCT06224855|DRUG|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
219199614|NCT06872476|OTHER|bed bath|
219477470|NCT05951205|BIOLOGICAL|Exa-cel|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
218861746|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
218861747|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
218861748|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
218861749|NCT01269385|BIOLOGICAL|rituximab|Given IV
218861750|NCT01269385|DRUG|PGG beta-glucan|Given IV
219477471|NCT06811090|OTHER|Tele-rehabilitation|Rehabilitation service provided remotely through information and communication technologies.
219477472|NCT06811090|OTHER|Hospital rehabilitation|Rehabilitation program that will be carried out in person at the North Physical Medicine and Rehabilitation Unit. The program will be carried out by a physiotherapist and the patient will be taught: Information about the disease and self-care, Exercise module (Stretching, strengthening and proprioception), and phased gait re-education.
219597222|NCT00851435|BIOLOGICAL|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
219597223|NCT01399658|PROCEDURE|Image-guided brachytherapy|MRI-guided application of brachytherapy
219597224|NCT01399658|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
218861751|NCT01269385|OTHER|flow cytometry|Correlative studies
218861752|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
218861753|NCT01269385|GENETIC|DNA analysis|Correlative studies
218861754|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
218861755|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
218861756|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
219597225|NCT02460679|DRUG|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
219597226|NCT02890784|DRUG|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
219597227|NCT02620579|DRUG|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
218861757|NCT01269385|GENETIC|mutation analysis|Correlative studies
218861758|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
218861759|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
219597228|NCT02620579|DRUG|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
219597229|NCT02620579|BEHAVIORAL|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
218861760|NCT01375803|OTHER|Placebo|Oral consumption in beverage
218861761|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
218861762|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
218861763|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
218861764|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
218861765|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
219477473|NCT06984419|DEVICE|Cross-linked hyaluronic acid dermal filler|Alexa Volume is a CE-marked, cross-linked hyaluronic acid dermal filler used for aesthetic correction of midface volume loss. It was administered subcutaneously or to the upper periosteum in adult female participants according to standardized procedures.
219477474|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
219477475|NCT06605118|DRUG|Placebo|250 mL of normal saline
219477476|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
219477477|NCT00885677|DEVICE|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
219477478|NCT06821074|DEVICE|Defocus-enhanced spectacles|Vision function training while wearing defocus-enhanced spectacles
219477479|NCT06821074|DEVICE|Single vision spectacles|Vision function training while wearing single vision spectacles
219477480|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
219477481|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
219477482|NCT05984628|PROCEDURE|human umbilical cord mesenchymal stem cells|After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
219477483|NCT05984628|PROCEDURE|blank solvent|After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
219477484|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
219477485|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
219477486|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
219477487|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
219477488|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
219477489|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
219477490|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
219597230|NCT02620579|BEHAVIORAL|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
218861766|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
218861767|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
218861768|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
218861769|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
218861770|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
218861771|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
218861772|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
218861773|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
219199615|NCT06872476|OTHER|bed bath with heat|
219597231|NCT01148615|DRUG|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219597232|NCT01148615|DRUG|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219477491|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
219597233|NCT00796107|DRUG|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
219477492|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
218861774|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
218861775|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
218861776|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
218861777|NCT06455410|DRUG|GP|gemcitabine + cisplatin
219477493|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
219477494|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
219477495|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
219477496|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
218861778|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
219477497|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
219477498|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
219477499|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
219477500|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
219477501|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
219477502|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
219477503|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
219477504|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
219477505|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
219477506|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
218861779|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
218861780|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
218861781|NCT03553498|DRUG|IV placebo|given intravenously
218861782|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
218861783|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
218861784|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
218861785|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
219477507|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
219477508|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
218861786|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
218861787|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
218861788|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
218861789|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
218861790|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
218861791|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
218861792|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
218861793|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
218861794|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
218861795|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
218861796|NCT02741570|BIOLOGICAL|Nivolumab|
219477509|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
218861797|NCT02741570|BIOLOGICAL|Ipilimumab|
218861798|NCT02741570|DRUG|Cetuximab/Erbitux|
219477510|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
219477511|NCT00371748|DEVICE|Express2|Coronary Stent System
219477512|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
219477513|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
219597234|NCT00796107|DRUG|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
219597235|NCT03637387|DRUG|BIIB074|Administered as specified in the treatment arm
218861799|NCT02741570|DRUG|Cisplatin/Platinol|
218861800|NCT02741570|DRUG|Carboplatin/Paraplatin|
218861801|NCT02741570|DRUG|Fluorouracil/Adrucil|
218861802|NCT02316210|DEVICE|electrical stimulation|
218861803|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
218861804|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
219477514|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
219477515|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
219477516|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
219477517|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
219477518|NCT01869959|DRUG|LY2405319|Administered SC
219477519|NCT01869959|DRUG|Placebo|Administered SC
219477520|NCT02984904|OTHER|survey|survey
219477521|NCT00828009|BIOLOGICAL|bevacizumab|IV
219477522|NCT00828009|BIOLOGICAL|Tecemotide|
219477523|NCT00828009|DRUG|carboplatin|IV
219477524|NCT00828009|DRUG|cyclophosphamide|IV
219477525|NCT00828009|DRUG|paclitaxel|IV
219477526|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
219597236|NCT03637387|DRUG|Placebo|Administered as specified in the treatment arm.
219597237|NCT00143871|DRUG|Rituximab|
219597238|NCT03672253|DRUG|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
219597239|NCT01013662|PROCEDURE|glycemic control|exogenous insulin
218861805|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
218861806|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
218861807|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
218861808|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
218861809|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
218861810|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
218861811|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
218861812|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
218861813|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
218861814|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
218861815|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
218861816|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
218861817|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
218861818|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
218861819|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
218861820|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
218861821|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
218861822|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
218861823|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
218861824|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
218861825|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
219477527|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
219477528|NCT06861881|DEVICE|Dexcom G7 Continuous Glucose Monitor|Dexcom G7 continuous glucose monitor will be placed prior to cardiac surgery. It will be worn continuously throughout the perioperative period and during the time admitted to the Cardiovascular Intensive Care Unit.
218861826|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
218861827|NCT00849602|DRUG|Placebo|Placebo bid for three days
219477529|NCT07006012|DRUG|RGL-305|RGL-305 is administered intravenously with a recommended rate of 3-5 mL /min. The interval after the first administration was 3 weeks, and then every 2 weeks was a cycle, each cycle was given d1, and up to 5 cycles of cell transfusion were received.
219597240|NCT02997748|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
219597241|NCT05697523|OTHER|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
218861828|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
218861829|NCT00023686|PROCEDURE|surgery|
218861830|NCT00023686|RADIATION|radiation|
218861831|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
218861832|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
219477530|NCT07005388|BEHAVIORAL|Cognitive behavioral therapy for psychosis|Cognitive behavioral therapy for psychosis is a group protocol design specially for psychotic patients to treat their positive and negative symptoms
219613535|NCT03380065|DEVICE|Early deflation of TR band|"1. First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
218861833|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
218861834|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
218861835|NCT03206632|DRUG|BI 690517|single dose
218861836|NCT03206632|DRUG|Placebo|single dose
218861837|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
218861838|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
218861839|NCT00000262|DRUG|30% Nitrous oxide|
218861840|NCT00000262|DRUG|0.4% Sevoflurane|
218861841|NCT00000262|DRUG|0.2% sevoflurane|
219477531|NCT07005271|BEHAVIORAL|virtual reality|The exercises in this group consist of four different games, including: (1) MasterChef, which involves performing daily living tasks in a virtual kitchen environment such as slicing tomatoes and cheese, adding salt, cracking and adding eggs, and stirring with a fork to prepare an omelet; (2) PinchPeg, where participants use a pinch grip to grasp rods generated in the center of a virtual environment and place them into holes on a pegboard, followed by removing and returning them to their original location; (3) Hold and Put, which requires the use of a standard palmar grasp to pick up virtual cups or cans and place them onto designated shelves; and (4) bPuzzle, a task that integrates cognitive and fine motor exercises by requiring participants to change the color of a puzzle using finger movements and place the pieces into the correct positions using hand gestures.
219477532|NCT07005271|BEHAVIORAL|Conventional treatment|Participants will be asked to complete puzzles consisting of 30 to 50 pieces, with 3 to 4 different puzzles used to eliminate the learning effect. They will perform the Nine-Hole Peg Test, which is similar to the PinchPeg game in the virtual reality group, by picking up pegs one by one from a container and placing them into holes on the board as quickly as possible using only the evaluated hand; this will be used for training purposes. Additionally, participants will be instructed to cut out geometric shapes with dotted outlines using scissors, aiming to follow the lines accurately. Finally, they will sort objects by placing the correct number and color of items into designated locations according to a predetermined pattern, and use a magnetic fishing rod to catch wooden fish, promoting both fine motor skills and task-oriented hand function.
218861842|NCT00000262|OTHER|Placebo|
219477533|NCT07005453|DEVICE|SCALE-EYE (1)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then with SCALE-EYE and lastly by biopsy-forceps assisted measurement.
219477534|NCT07005453|DEVICE|SCALE-EYE (2)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then by biopsy-forceps assisted measurement and lastly with SCALE-EYE.
219597242|NCT00824343|DRUG|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
219597243|NCT04174612|DRUG|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
219597244|NCT04174612|DRUG|Daunorubicin|60 mg/m2/die day 1-3
218861843|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
218861844|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
218861845|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
218861846|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
218861847|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
218861848|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
218861849|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
218861850|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
219477535|NCT07007377|OTHER|Follow-up|Follow-up
219477536|NCT06999590|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
219477537|NCT06999590|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
219597245|NCT04174612|DRUG|Midostaurin|50 mg/bid day 8-21
219597246|NCT04174612|DRUG|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
219597247|NCT03028116|BIOLOGICAL|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
219597248|NCT03028116|BIOLOGICAL|Placebo|water for injection
219597249|NCT03977142|DIAGNOSTIC_TEST|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
218861851|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
218861852|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
219477538|NCT06999590|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
218861853|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
218861854|NCT00088790|DRUG|AZD5438|
218861855|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
218861856|NCT02606227|OTHER|No financial incentive|No financial intervention
218861857|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
219477539|NCT07005557|DRUG|Chemotherapy|Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.
219477540|NCT07005557|DRUG|CDK4/6 Inhibitor|All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)
218861858|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
219477541|NCT07005557|DRUG|Endocrine therapy|Endocrine therapy (letrozole/anastrozole/exemestane)
219477542|NCT07007143|DRUG|Experimental: Aspirin monotherapy|Aspirin monotherapy
219477543|NCT07007143|DRUG|Active Comparator: Aspirin+Clopidogrel|Aspirin+Clopidogrel
219477544|NCT07005076|OTHER|Experimental Group|Participants in the experimental group will participate in a conventional exercise program similar to the control group, but with the addition of a technology-assisted exercise program. The intervention group will receive training with a reaction time measurement set using lights and an exercise set. The reaction time measurement and exercise set will be used, where light pods are placed in different positions, such as on a table, mirror, and floor, and patients will be instructed to extinguish the lit light as quickly as possible. The difficulty level of the sessions will be progressively increased by adjusting factors such as the duration of light activation, colors, the number of illuminated pods, their placement locations, and the distance between them.
219477545|NCT04008108|OTHER|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
219477546|NCT07007065|DRUG|Surabgene Lomparvovec (ABBV-RGX-314)|subretinal injection
219477547|NCT07007065|DRUG|Ranibizumab Control|intravitreal injection
219477548|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
219477549|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
219477550|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
219477551|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
219477552|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
219477553|NCT07043855|DRUG|single dose preoperative antibiotic|Arm A is a single preoperative dose of cefazolin administered immediately before surgery
219477554|NCT07043855|DRUG|Prolonged perioperative antibiotics|Preoperative Single-Dose Cefoxitin followed by Three-Day Cefotaxime and Metronidazole Prophylaxis
219477555|NCT07043920|OTHER|Behavioral Assessment (No therapeutic intervention will be administered)|"Participants will complete two validated questionnaires:~The Fagerström Test for Nicotine Dependence (FTND) - to assess levels of nicotine dependence.~The International Physical Activity Questionnaire - Short Form (IPAQ-SF) - to quantify weekly physical activity levels (walking, moderate, vigorous)."
219477556|NCT06719661|DRUG|Dapagliflozin 10mg|Uncontrolled type 2 diabetic patients receive dapagliflozin 10 mg tablet once daily. They are asked to take it for 3 months, then return for their final assessment after 3 months
219477557|NCT06719661|OTHER|Clinical Pharmacist-led Intervention|Patients with uncontrolled type 2 diabetes will undergo dosage intensification of their dual or triple oral hypoglycemic medicines up to maximum daily doses. Further, they will be advised on specific dietary modification, education on the importance of adherence, strategies to improve adherence, including giving pill boxes, and regular follow-up every month via telephone-based communication.
219597250|NCT04468451|BEHAVIORAL|A 48-hour ROC training program with a standing posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
219613536|NCT02247778|PROCEDURE|conventional plate osteosynthesis|Standard incision
218861859|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
218861860|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
218861861|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
218861862|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
218861863|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
219477558|NCT06719661|OTHER|Standard therapy group|Patients are receiving their standard dual or triple oral hypoglycemic therapy only.
219477559|NCT06878612|BIOLOGICAL|Polyphenol whole tumor cell vaccine|3 patients enrolled in each dose group, and planned dose groups of 5 x 10\*6, 2 x 10\*7, and 5 x 10\*7 cells/dose. The dosing regimen consisted of 5 doses of basal immunization and subsequent individualized treatment. In the basal immunization, the administration times were D0, D14, D28, D42, and D56. After completion of the 5 doses of basal immunization, the subsequent individualized treatment was decided by the investigator based on the subject's tumor assessment, i.e., 1 vaccination per month for a total of 4 doses.
218861864|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
218861865|NCT00000429|DRUG|Calcium carbonate|
219477560|NCT07042880|OTHER|No intervention|No intervention
219477561|NCT06724250|DEVICE|Biofeedback therapy|Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.
219477562|NCT06724250|DRUG|Botulinum Toxin A (Botox )|Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
219477563|NCT06724744|OTHER|Aerobic training|For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.
219477564|NCT06724744|OTHER|Manual Diaphragm Release|The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
219597251|NCT04468451|BEHAVIORAL|A 24-hour ROC training program with a standing posture|The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
218861866|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
218861867|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
219477565|NCT06724367|DEVICE|Transspinal direct current stimulation|Direct current electrical stimulation applied non-invasively to the spinal cord.
219477566|NCT06724367|DEVICE|Sham Comparator|transspinal direct current stimulation simulated
219477567|NCT06722196|DRUG|topical amiodarone|amiodarone soaked patch placed on the left atrial roof at the end of surgery
219477568|NCT06722196|OTHER|saline solution patch|saline solution soaked patch placed on left atrial roof at the end of surgery
219477569|NCT06723977|OTHER|Auditory Hallucination Based Voice Hearing Simulation|"1. st stage: Preparation of the environment, introduction, providing information about the purpose, duration and content of the application, application of data collection tools and distribution of the information brochure were provided.~2. nd stage: Introducing the recording devices and headphones, performing the first task simultaneously while listening to the prepared three-dimensional sound recording (watching a city promotional film and answering verbal questions about this film), performing the second task simultaneously while listening to the prepared three-dimensional voice recording (telling a story). (reading the text and answering the questions about this story text in writing) were applied.~3. rd stage: Information about the next application time of the measurement tools was provided.~Additional stage: Data collection tools were reapplied."
219477570|NCT06722937|OTHER|Observation|Observe the clinical natural changes of eye parameters of the subjects.
219477571|NCT06722820|DRUG|LPH-5|LPH-5
219477572|NCT06722820|DRUG|Placebo|Placebo
219597252|NCT04468451|BEHAVIORAL|A regular therapy program without receiving any ROC training|The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
219597253|NCT00900822|DEVICE|Straumann Bone Ceramic|Granules applied once during surgery
219597254|NCT00900822|DEVICE|BioOss|Granules that are applied once during surgery
219597255|NCT06198166|OTHER|Cuevas Medek|Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes
219020746|NCT07205458|BEHAVIORAL|Motivational interview sessions, Breastfeeding self efficiay,Behavioral Skills|Motivational interview sessions aimed to strengthen fathers' motivation for breastfeeding and improve supportive behaviors. These sessions will begin between postpartum days 13-17 after the information phase is complete. The number of sessions will be based on fathers' needs (minimum of two and up to four). Each session's duration will follow the Turkish Ministry of Health's Postpartum Care Guide (2018). The second session will occur between postpartum days 21-30. After the motivational interviews are completed, fathers will have received information and motivation according to the Information-Motivation-Behavioral Skills (IMB) Model. Education and interview sessions will continue until postpartum day 42, shaped according to fathers' needs. At the end of all trainings, fathers are expected to have developed the skills to support mothers during breastfeeding and to have gained self-efficacy in the breastfeeding process
219477573|NCT06724393|OTHER|Blood flow restrictions in combination with low-intensity resistance training|Blood flow restrictions in combination with low-intensity resistance training to test if an online intervention (telehealth) can improve functional capacity and balance in older adults
219477574|NCT07047768|OTHER|No intervention : data-based study|No intervention : data-based study
219477575|NCT07048444|OTHER|N/A as observational study|N/A as observational study design
219477576|NCT07047729|OTHER|Early oral feeding|Liquid diet will be initiated within 24 hours after surgery and, if well-tolerated without vomiting, will transition to a regular diet over the subsequent 24 hours
219477577|NCT07047729|OTHER|Standard oral feeding|Standard diet (late feeding), including liquid filtrates, will only be introduced after the resolution of the ileus, during which these patients will remain NPO (nothing by mouth).
219477578|NCT07048691|DIAGNOSTIC_TEST|G.E HEALTHCARE ultrasound machine with high-resolution convex probe|After approval from the institutional ethical committee, a total number of patients presenting to the Radiology and Peads Neurosurgery department of Allied Hospital, Faisalabad, that met the inclusion criteria was selected. After obtaining informed consent from each patient and attendant of the patient, transabdominal ultrasound was examined longitudinal, transverse and oblique plans, ultrasound with a high- resolution convex probe was used by the radiologist
219477579|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 2D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 2D imaging colonoscope
219477580|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 3D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 3D imaging colonoscope
219477581|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
219477582|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
219477583|NCT07048600|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|"Monotherapy ACT-i, with no behavioral components, is a brief and low-intensity treatment that has recently been detailed by experts in the field in a session-by-session guideline, intending to help people affected by chronic insomnia. The key components of the sessions are psychoeducation, mindfulness, values and actions derived from chosen values, and defusion.~An adapted, brief and online version of the intervention was developed by the authors of this study. Both interventions were matched in terms of overall duration and delivery format. Each session was tailored to follow a comparable format. Therapeutic alliance, psychoeducation, sleep hygiene, relaxation training and homework was targeted in the first session. In the second session, ACT-i focused on values, acceptance strategies and psychological flexibility. This version will be published online upon request. Each session will last 120 min. They will be delivered once per week, for two consecutive weeks."
219477584|NCT07048600|BEHAVIORAL|Attentional Control Group|The focus of the sessions will be on participants, on general topics. It will not include any active, psychological intervention components, such as cognitive restructuring or ACT processes. No recommendations or psychological guidance will be given. Each session will last 120 minutes. It will be held once per week, for two weeks.
219477585|NCT07046975|DRUG|Torsemide and Spironolactone tablet|Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet
219477586|NCT07046975|DRUG|Torsemide Tablets and Spironolactone Tablets|10 mg Torsemide tablet and 25 mg Spironolactone tablet given together
219477587|NCT07047417|DIAGNOSTIC_TEST|CLE and ROSE|All patients undergo white light bronchoscopy after general anesthesia to rule out abnormalities in the lumen and clear the airways. After locating the target lymph node using convex probe endobronchial ultrasound (CP-EBUS), the target lymph node is routinely explored using the grayscale, blood flow and elastography modes CP-EBUS. Puncture is performed using a puncture needle under the guidance of CP-EBUS, and then the CLE probe is inserted into the target lymph node through the puncture needle. Sodium fluorescein is intravenously injected before CLE imaging. Under the guidance of CP-EBUS, the CLE probe is slowly moved to examine the target lesion. According to the real-time CLE images, the ideal biopsy location is identified. After the CLE examination is completed, cryobiopsy is performed at the ideal biopsy location confirmed by CLE under the guidance of CP-EBUS. After sampling, ROSE of the samples is performed.
219477588|NCT07048119|BEHAVIORAL|Japi 1.0|The intervention has ten sessions, and two sessions of 30 minutes were delivered each week for 5 weeks. Sessions numbers 1 to 5 were focused on emotional recognition and inhibitory control. Sessions numbers 6 to 10 worked on working memory and social competence. Each session had eight activities and five tasks per activity with increasing difficulty levels.
219477589|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
219477590|NCT07046806|DRUG|Deucrictibant XR tablet|Deucrictibant 40 mg XR tablet for prophylaxis
219613537|NCT02247778|PROCEDURE|mini-incision-type osteosynthesis|Mini-incision
218861868|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
218861869|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
218861870|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
218861871|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
218861872|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
218861873|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
218861874|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
218861875|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
218861876|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
218861877|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
218861878|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
219477591|NCT07046806|DRUG|Placebo comparator to XR tablet|Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis
219477592|NCT07046806|DRUG|Deucrictibant 20 mg capsule|Deucrictibant active drug for on-demand treatment of angioedma attacks
219477593|NCT07046806|DRUG|Placebo comparator to 20 mg capsule|Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks
219477594|NCT07048249|DRUG|Romiplostim (AMG-531)|Romiplostim may be started as supportive care, as early as cycle 1 day 1; all patients MUST initiate romiplostim no later than 2 weeks from the start of the 5th cycle of chemotherapy (see exception below for patients with platelet count of 200,000 or greater). If plt count \< 200,000/mm3, patients will start romiplostim based on their weight
219477595|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
219477596|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
219477597|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
219613538|NCT06211309|DRUG|co.mouthwas|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
218861879|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
218861880|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
218861881|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
218861882|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
218861883|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
219477598|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
219477599|NCT07048613|DIAGNOSTIC_TEST|MRI (mpMRI)|: Combines T2-weighted imaging, Diffusion-weighted imaging (DWI), and Dynamic contrast-enhanced MRI (DCE-MRI) to provide detailed anatomical images and assess tissue characteristics.
219477600|NCT07047287|OTHER|global postural reeducation exercise|The global postural reeducation exercise involves a sequence of active, moderate postures as well as exercises that are designed to realign joints, stretch shortened muscles, in addition, strengthen the contraction of the antagonist's muscles to prevent postural asymmetry. There are eight different therapeutic postures in the GPR approach that should be held for 15 to 20 min while lying, sitting, or standing. Only two or three postures have been proposed to encourage treatment standardization+ conventional therapy
219477601|NCT07047287|OTHER|pilates exercises|the patients will receive pilates in the form of single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions
219477602|NCT07047287|OTHER|conventional therapy|the patients will receive conventional physiotherapy treatment which consists of routine physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl up exercises etc along with ultrasound and Transcutaneous electrical nerve stimulation (TENS).
219613539|NCT06211309|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
219477603|NCT07048522|DRUG|Nimodipine|A continuous dose of 4 mg/h (20 ml/h) of nimodipine solution will be administered continuously 1 h prior to start of operation until 1 h after start of the procedure. • The nimodipine dose will be then reduced to 2 mg/h (10 ml/h) until 24 hrs after the end of the procedure.
219477604|NCT07048522|DRUG|Isotonic Saline|A continuous dose of 20 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 1 h after start of the procedure. The normal saline dose will be then reduced to 10 ml/h until 24 h after the end of the procedure.
219477605|NCT07047313|OTHER|jones and mulligan therapy|for jones technique in upper trapezius and suboccipital muscles, the participants supine , the therapist used manual palpation to locate the tender area in the UT and sub-ossipital muscles. Once detected, pressure to the tender area was progressively increased . The participant was then repositioned passively to decrease the stress under palpation, resulting in a 70% subjective decrement in pain. That position was maintained for 90 s. eventually, the participant returned to the neutral position slowly and passively. for mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees) exercises
219477606|NCT07047313|OTHER|mulligan therapy|mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees). The hand, which was touching the spinous process, should be relaxed in order not to squeeze too hard. The source of the power of gliding on the joint surface must come from the opposite hand of the patient-contacting hand. Gliding was applied rhythmically (three times per second) and the width of gliding starts from the middle to the end+ exercises
219477607|NCT07047313|OTHER|exercises program|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
219477608|NCT07047339|DRUG|Probiotics 6600|"As the core commensal bacteria of human body, probiotic 6600 has a unique ability to synthesize adhesins and exopolysaccharides. The intestinal protective effect is mediated by the following mechanisms: (1) regulation of Treg/Th17 balance by producing short-chain fatty acids (SCFAs); (2) activation of TLR2/MyD88 pathway inhibits NF-κB inflammatory cascade; (3) Upregulation of zonula occludens-1 enhances intestinal barrier function. Notably, this strain specifically metabolized arabinoxylan to produce the anti-inflammatory metabolite indole lactate, which has important therapeutic value in the colitis microenvironment.~Probiotic 6600 capsules are enteric capsules (containing probiotic 6600 10\^11 CFU/ capsule), taken orally twice a day (after meals in the morning and evening), one capsule each time, and taken with warm water. The drug was stored at 2-8℃."
219477609|NCT07047339|DRUG|Placebo|The placebo capsules were also enteric-coated capsules, and were taken orally twice a day (morning and evening after meals), one capsule each time, with warm water.
219477610|NCT07047963|DIAGNOSTIC_TEST|ENDI (Neuropsychological Evaluation in Intellectual Disability)|This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
219477611|NCT07048509|OTHER|Control-no treatment|30 minutes of rest
219477612|NCT07048509|OTHER|Exercise|30 minutes of Moderate-Intensity Continuous Exercise
219477613|NCT07048509|OTHER|Exercise|30 minutes of High-Intensity Interval Exercise
219477614|NCT07048704|DRUG|Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics|"Participants will receive a seven-day course of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics. The bacteriophage therapy consists of a pathogen-specific cocktail containing four purified, lytic bacteriophages selected based on pre-treatment sensitivity testing of the participant's bacterial isolate. Each phage cocktail targets one of the following antibiotic-resistant pathogens: Pseudomonas aeruginosa, Klebsiella spp., Stenotrophomonas maltophilia, Escherichia coli, Staphylococcus aureus, or Achromobacter xylosoxidans.~Phage cocktails are administered IV twice daily at a concentration of 1x10⁹ PFU/mL, following antibiotic infusion. The first three doses are observed in clinic; remaining doses are self-administered at home via PICC line. All phages are produced under GMP conditions and screened to be lytic-only, free of known toxin, resistance, or lysogeny genes."
219477615|NCT06722040|OTHER|Implementation of a pediatric triage track|In 2023, a pediatric triage track was implemented at MH1813 to route calls concerning children to specialists in pediatrics, ensuring better expertise.
219477616|NCT06722794|PROCEDURE|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene Suture|This novel technique of fixating the plate of Ahmed glaucoma valve to the sclera using a single flanged prolene suture is an efficient, safe, fast, and reproducible technique that combines the benefits of both fixing the plate providing excellent stability without the complications of free plate techniques and at the same time, minimizing both the risks of conventional old valve plate fixation techniques and the concerns of the relative technical difficulty of suturing due to the difficult access to the posterior globe
219477617|NCT06722144|BEHAVIORAL|Animal-assisted Therapy|By the professor leader makes social interaction, and helping residents with rehabilitation through the Doctor dogs.
219477618|NCT06727266|DIAGNOSTIC_TEST|Shoulder ultrasound|The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.
219613540|NCT06211309|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
219613541|NCT06990711|DRUG|Siltuximab|Interleukin-6 blockade
219613542|NCT06990711|DRUG|Placebo|Siltuximab placebo IV
218861884|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
218861885|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
218861886|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
218861887|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
218861888|NCT01680627|BEHAVIORAL|CASI|
218861889|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
218861890|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
218861891|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
219477619|NCT05436067|DEVICE|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
219477620|NCT05436067|OTHER|Traditional Physical Therapy|Delivery of vestibular rehabilitation through traditional physical therapy.
218861892|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
218861893|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
219477621|NCT07047833|BEHAVIORAL|Plyometric Training with Hamstring Strengthening|This intervention consisted of a six-week training protocol involving both plyometric exercises and targeted hamstring strengthening. Sessions were conducted twice per week, lasting 60 minutes each. Plyometric drills included squat jumps, depth jumps, and lateral jumps, while hamstring exercises included Nordic hamstring curls and machine-based leg curls. All sessions included a standardized 15-minute warm-up and a 5-minute cool-down. The program was designed to enhance lower limb strength, balance, and neuromuscular control for ACL injury prevention in female amateur athletes.
219477622|NCT07047833|BEHAVIORAL|Plyometric Training Only|This intervention involved a six-week plyometric-only training program delivered twice weekly for 40-minute sessions. Exercises included squat jumps, depth jumps, and lateral jumps, performed with progressive intensity and control. Each session included a standardized 15-minute warm-up and a 5-minute cool-down. The program aimed to improve lower limb power, balance, and functional mobility to reduce the risk of ACL injuries in female amateur athletes.
219477623|NCT06722625|OTHER|Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process|Receiving remote care facilitated by a specialized informatic system to support the physician
219477624|NCT06723496|BEHAVIORAL|Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.|is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.
219477625|NCT06723496|BEHAVIORAL|parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer|It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors
219477626|NCT06723496|BEHAVIORAL|Symptom Checklist -90- Revised (SCL-90-R) for parents|It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions
218861894|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
218861895|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
218861896|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
218861897|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
219477627|NCT06723496|BEHAVIORAL|posttraumatic stress disorders by posttraumatic check list -5 (PCL-5) for parents|It is a 20 -item measure that assess the 20 DSM-5 symptoms of PTSD.
219477628|NCT06724458|OTHER|Resistance exercise|All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
219477629|NCT06599684|DRUG|INV-102|0.7% Ophthalmic Solution
219477630|NCT07047352|OTHER|Empirical treatment|Empirical treatment to cover carbapenem-resistant enterobacterales
218861898|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
218861899|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
218861900|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
218861901|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
218861902|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
218861903|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
218861904|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
218861905|NCT00139256|DRUG|Betamethasone|Betamethasone injection
218861906|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
218861907|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
218861908|NCT00162279|DRUG|Abatacept|
218861909|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
218861910|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
219477631|NCT07048353|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
219477632|NCT07047430|DEVICE|Portable air cleaner with HEPA filter|The Winix 9800 is a true HEPA air cleaner that has been AHAM (Association of Home Appliance Manufacturers) Verifide® for rooms that are 500 square feet in size. The air cleaner has a washable fine mesh pre-filter that captures large airborne particles, an activated carbon filter that reduces volatile organic compounds and odors, and a true HEPA filter that captures 99.99% of airborne allergens as small as 0.003 microns in size.
219477633|NCT07047430|DEVICE|Less effective portable air cleaner (no HEPA)|Winix 9800 air cleaner, with data logging energy use monitor is installed in the child's bedroom. In the sham group, the Winix 9800 true HEPA filter and activated carbon filter were removed. This was an internal modification and not visible to the user. The air cleaner still included a washable fine mesh pre-filter that captures large airborne particles.
219477634|NCT04468984|DRUG|Navitoclax|Tablet; Oral
218861911|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
219477635|NCT04468984|DRUG|Ruxolitinib|Tablet; Oral
219477636|NCT04468984|DRUG|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
219597256|NCT06198166|OTHER|Standard kinetic programs|Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
219597257|NCT06346925|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
219597258|NCT00366366|BIOLOGICAL|Infanrix-Hexa|
219597259|NCT05300750|OTHER|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
218861912|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
218861913|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
218861914|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
218861915|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
218861916|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
218861917|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
218861918|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
218861919|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
218861920|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
218861921|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
218861922|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
219477637|NCT07048301|OTHER|BUHOS app|In this study, the BUHOS app initiative will be implemented among participants in the intervention group. BUHOS will be a two-weeks nursing intervention that includes monitoring KAB, employing Education, Guidance and Counseling (education videos), and Surveillance (reminder messages), and assessing the outcomes.
219477638|NCT07048301|OTHER|Control Group|No intervention will be made to the patients in the control group, and the training videos prepared after the study is completed will be shared.
219597260|NCT05300750|OTHER|Chewing gum|Chewed free sugar gum for 15 minutes
219597261|NCT03391414|DRUG|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
219597262|NCT03391414|DRUG|sodium chloride|7% sodium chloride inhaled
219597263|NCT01721317|DRUG|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
218861923|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
218861924|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
218861925|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
219477639|NCT07047950|BEHAVIORAL|Individual Education and Counseling Program|"The educational programme entitled HBM Approach to Prevent CHD was designed by the researcher and delivered as a presentation. The educational sessions were conducted face-to-face at the Cardiology Outpatient Clinic of Van Yüzüncü Yıl University Dursun Odabaş Medical Center and lasted approximately 35-45 minutes. In addition, follow-up telephone calls were made to individuals in the intervention group twice at two-month intervals.~The content of the educational programme was developed based on a comprehensive literature review using resources from the Turkish Society of Cardiology, the WHO, the Ministry of Health, the Turkish Public Health Institution, evidence-based research and previous studies. The programme covered topics such as the definition of CHD, risk factors, treatment, complications, perceived susceptibility and severity of CHD, perceived benefits, barriers and strategies to overcome them, self-efficacy, and rules for engaging in physical activity and maintaining a health"
219477640|NCT07045285|DEVICE|Antibacterial Vicryl Plus 2/0|antibacterial Vicryl Plus 2/0 sutures are multifilament absorbable synthetic sutures that are coated with triclosan, a purified antimicrobial.
219477641|NCT07045285|DEVICE|Standard Vicryl 2/0|Vicryl rapid coated 2/0 sutures are multifilament absorbable synthetic sutures not treated with any antimicrobial.
219477642|NCT07047521|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
219477643|NCT07048171|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using bone graft(DFDBA) and iPRF with collagen membrane in test group and bone graft and iPRF without collagen membrane in control group
218861926|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
218861927|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
219020747|NCT07206888|DIAGNOSTIC_TEST|Imaging|Ultrasound imaging or ultrasound imaging with light (i.e., photoacoustic imaging)
219020748|NCT07205250|DRUG|enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet)|Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.
219020749|NCT07205250|OTHER|a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets|Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.
219020750|NCT07205445|DEVICE|Tensi+|Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
219020751|NCT07205757|DRUG|Lidocaine Hydrochloride|6.5 ml of 2% lidocaine (Lidocaine HCL -Sunny Pharmaceutical)
219020752|NCT07205757|DRUG|Custodiol Solution|cardioplegia solution will be administered as a single dose of 20 mL/kg over 6-8 minutes at a temperature of 5-8 °C. An additional half dose of the same solution will be prepared and infused if the procedure exceeds 180 minutes after the initial dose is completed.
219477644|NCT07048678|COMBINATION_PRODUCT|preoperative respiratory exercises|Participants in Group 1 will receive a combination of preoperative respiratory exercises designed to improve lung function and reduce the risk of postoperative pulmonary complications. The intervention includes:
219477645|NCT07048678|COMBINATION_PRODUCT|Standard Care (Control Group)|Participants in Group 2 will receive standard preoperative care provided by the hospital, which includes routine instructions related to surgery such as fasting guidelines, medication administration, and anesthesia protocols. No preoperative respiratory exercises (incentive spirometry, chest physiotherapy, or deep breathing exercises) will be provided to this group. This group serves as a control to compare the outcomes with the intervention group.
219477646|NCT07043816|BEHAVIORAL|PharmaTE Trial|In addition to standard care, patients in the PharmaTE trial interventional group will receive tele-education led by a clinical pharmacist who has completed a training course and is certified as a diabetes educator. The tele-education program is comprised of five individualized educational sessions, each lasting approximately 20-30minutes and held at two-month intervals. These sessions are conducted via Zoom or telephone based on patient preference. Before the beginning of each session, participants will receive a reminder message along with the Zoom meeting invitation link about the session, covering various educational topics related to diabetes management. Additionally, after each session, patients will receive a brochure summarizing what has been discussed.
219597264|NCT01721317|DRUG|Placebo|Matching placebo will be available
219597265|NCT01117649|DRUG|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
219597266|NCT01117649|DRUG|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
218861928|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
218861929|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
218861930|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
218861931|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
218861932|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
218861933|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
218861934|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
218861935|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
218861936|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
218861937|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
218861938|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
218861939|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
218861940|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
218861941|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
218861942|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
218861943|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
218861944|NCT00276614|DRUG|bortezomib|
218861945|NCT00044824|DRUG|Fexofenadine|
218861946|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
218861947|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
218861948|NCT00229580|OTHER|treatment as usual|
218861949|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
219477647|NCT07048652|DIAGNOSTIC_TEST|High-Resolution Computed Tomography|High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.
218861950|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
218861951|NCT02990195|OTHER|Chyme reinfusion|
218861952|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
218861953|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
218861954|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
218861955|NCT00523497|DEVICE|Non invasive mechanical ventilation|
218861956|NCT03002272|DEVICE|TAVR|subjects that underwent TAVR more than 3 years ago
218861957|NCT03002272|DEVICE|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
218861958|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
218861959|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
218861960|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
218861961|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
218861962|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
218861963|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
218861964|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
218861965|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
218861966|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
218861967|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
218861968|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
218861969|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
218861970|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
218861971|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
218861972|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
218861973|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
218861974|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
219477648|NCT07047092|DEVICE|Non-invasive Ventilation (NIV)|Patients will receive a dedicated training for the use of their NIV in the home setting. The training is the same provided in the usual care of patients established on NIV. They will choose a home care provider for the delivery of NIV as per standard care in France. A telemonitoring of adherence to NIV will be performed.
219477649|NCT07047092|DEVICE|Continous Positive Airway Pressure (CPAP)|Patients will receive a dedicated training the use of their CPAP in the home setting. The training is the same provided in the usual care of patients established on CPAP. They will choose a home care provider for the delivery of CPAP as per standard care in France. Follow-up of CPAP will be performed according to standard care in France and will therefore include a telemonitoring of adherence to CPAP.
219477650|NCT07048275|BEHAVIORAL|Virtual Reality Chest Percussion Teaching Program|Participants will be assessed at two time points: on the day of hospital admission or transfer, and on the fourth day after the teaching intervention.
219477651|NCT06893887|DRUG|FOLFOX4|FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles
219477652|NCT06893887|DRUG|Adebrelimab|Adebrelimab 1200mg, intravenous infusion, every 3 weeks
219477653|NCT06893887|DRUG|Apatinib|Apatinib 250mg, oral, once daily.
219477654|NCT06893887|DRUG|Icaritin|Epimedium extract soft capsules 2.4g, oral, 2 times daily.
219477655|NCT06893887|DRUG|SHR-1701|SHR1701，30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
219477656|NCT06893887|DRUG|QL1706|QL1706，5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
219477657|NCT06893887|DRUG|Bevacizumab|Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.
219477658|NCT06893887|PROCEDURE|HAIC|Hepatic Arterial Infusion Chemotherapy
219477659|NCT06893887|PROCEDURE|Local treatment|Local treatment of oligo-metastases.
219477660|NCT06893887|DRUG|The original treatment regimen|Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.
219477661|NCT04170244|OTHER|AD subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
218861975|NCT01447160|DRUG|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
219477662|NCT04170244|OTHER|PS subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
218861976|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
218861977|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
219020753|NCT07205055|OTHER|video training|No study in the literature has examined the effectiveness of video-based diaper dermatitis education.
219020754|NCT07205094|OTHER|Telerehabilitation exercise program|8-week telerehabilitation program including range of motion, stretching, strengthening, and stabilization exercise
219020755|NCT07205094|OTHER|Conventional physiotherapy program|8-week conventional face-to-face physiotherapy program including range of motion, stretching, strengthening, and stabilization exercises
219477663|NCT04170244|OTHER|Healthy control visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
219597267|NCT01117649|DRUG|balanced electrolyte solution|plasma adapted Ringer's solution
219597268|NCT00006509|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219597269|NCT00006509|BIOLOGICAL|gp160 MN/LAI-2|
219020756|NCT07205926|BIOLOGICAL|IVT Shigella-04|Preventative vaccine for Shigella protection against 4 unique serotypes
219020757|NCT07205926|BIOLOGICAL|Placebo (0.9% saline)|Subjects dosed with 0.9% saline
219477664|NCT07047066|DRUG|Fluzoparib with Temozolomide|"Fluzoparib: 100mg, po.bid. Q4W, d1-28, for a total of 6 cycles~Temozolomide (TMZ): 150-200 mg/m2, po. Q4W, d1-5, for a total of 6 cycles~If unacceptable toxicity occurs and a dose reduction is required, it is recommended to first reduce the dose from 100 mg (2 tablets) to 50 mg (1 tablet) twice a day. If further dose reduction is required, it is recommended to reduce the dose from 50 mg (1 tablet) twice a day to 50 mg (1 tablet) once a day. If it is still intolerable, the patient should withdraw from the clinical study.~The TMZ dose is adjusted by the investigator according to standard chemotherapy requirements. Adjuvant TMZ treatment of less than 6 cycles is allowed depending on the subject's condition (e.g. confirmed disease progression, intolerable toxicity, etc.). Tumor assessment is performed during two cycles of TMZ (q8w±7 days) during the study or when clinically indicated"
219597270|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
218861978|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
218861979|NCT02337166|PROCEDURE|Periodontal flap surgery|
218861980|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
218861981|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
218861982|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
218861983|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
218861984|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
218861985|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
218861986|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
218861987|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
218861988|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
218861989|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
218861990|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
218861991|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
218861992|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
218861993|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
218861994|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
218861995|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
218861996|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
219477665|NCT06267989|PROCEDURE|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
219477666|NCT06267989|PROCEDURE|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
219477667|NCT06895460|DRUG|Budesonide Formoterol|Investigator Selection
219477668|NCT06895460|DRUG|Placebo|Placebo: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
219477669|NCT06895460|DRUG|Immune Modulators (Staphylococcus and Neisseria Tablets)|Staphylococcus and Neisseria Tablets: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
219597271|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
219597272|NCT00706485|DEVICE|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
218861997|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
218861998|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
218861999|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
218862000|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
218862001|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8\_TCID50
218862002|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
218862003|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
218862004|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
218862005|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
218862006|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
218862007|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
218862008|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
218862009|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
218862010|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
218862011|NCT00070681|PROCEDURE|Polysomnography|
219477670|NCT06746623|DIAGNOSTIC_TEST|Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.|"Esocheck (EC)/Esoguard (EG): EC is a encapsulated balloon device available commercially from Lucid Diagnostics (New York, NY). EG assay uses bisulfite sequencing for detection of aberrant methylation in the vimentin and cyclin A1 genomic loci, respectively.~EGD (upper endoscopy): EGD will be performed by gastroenterologists practicing in the Louis Stokes Cleveland VA Medical Center Endoscopy laboratories on the same day when EC/EG is performed."
219477671|NCT05689554|BEHAVIORAL|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
219477672|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
219477673|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
219477674|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
219477675|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
219477676|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
219477677|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
219477678|NCT06822413|OTHER|No Interventions|All blood samples from participating patients were obtained from routine clinical blood tests conducted during hospital admission or other necessary medical evaluations, followed by serum extraction.
219477679|NCT06373432|OTHER|Fingerstick|Fingerstick to check glucose value during labor.
219477680|NCT04810858|OTHER|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
218862012|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
218862013|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
218862014|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
218862015|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
218862016|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
218862017|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
219020758|NCT07206602|DEVICE|AI-assisted Left Bundle Branch Area Pacing|Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure using AI assisted technology
219020759|NCT07206602|PROCEDURE|Left Bundle Branch Area Pacing|Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure
218862018|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
218862019|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
218862020|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
218862021|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
218862022|NCT00002762|PROCEDURE|blood sampling|
218862023|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
219477681|NCT04810858|OTHER|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
219477682|NCT04810858|BEHAVIORAL|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
219477683|NCT06761716|BEHAVIORAL|Ericksonian Hypnotherapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will focus on tailored hypnotic suggestions, subconscious communication techniques, and trauma-focused interventions specifically designed to address PTSD symptoms. Sessions will be conducted by a certified hypnotherapist under clinical supervision.
219477684|NCT06761716|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will utilize cognitive restructuring techniques, exposure exercises, and behavioral interventions aimed at reducing PTSD symptoms. Sessions will be led by a licensed psychotherapist trained in trauma-focused CBT.
219477685|NCT05345392|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
219477686|NCT05345392|BEHAVIORAL|Health and Wellness Intervention (HWI)|The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
219477687|NCT06787742|PROCEDURE|full pulpotomy|access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign
219477688|NCT03422848|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
219477689|NCT03422848|BEHAVIORAL|general life style advice|oral and written advice on diet and physical activity
219477690|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
219477691|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
219477692|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
219477693|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
219477694|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
219477695|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
219477696|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
219477697|NCT01887366|DRUG|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
219477698|NCT01887366|DRUG|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
219477699|NCT01887366|DRUG|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
219477700|NCT00016406|BIOLOGICAL|filgrastim|
219477701|NCT00016406|DRUG|cyclophosphamide|
219477702|NCT00016406|DRUG|doxorubicin|
219477703|NCT00016406|DRUG|paclitaxel|
219477704|NCT00016406|PROCEDURE|surgery|
218862024|NCT00513955|DRUG|bortezomib|
218862025|NCT00513955|DRUG|cyclophosphamide|
218862026|NCT00513955|DRUG|doxorubicin hydrochloride|
218862027|NCT00513955|DRUG|prednisolone|
218862028|NCT00513955|DRUG|vincristine sulfate|
218862029|NCT00513955|OTHER|questionnaire administration|
218862030|NCT00513955|PROCEDURE|quality-of-life assessment|
218862031|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
219477705|NCT01314859|DRUG|Nifedipine|"* Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
219477706|NCT01314859|DRUG|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
219477707|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
219477708|NCT00563706|DRUG|risperidone|
219477709|NCT00563706|OTHER|placebo|
219477710|NCT01502800|DRUG|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
219477711|NCT01502800|DRUG|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
219477712|NCT01502800|DRUG|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
219477713|NCT01502800|DRUG|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
219477714|NCT01827085|DEVICE|Conventional Macintosh laryngoscope|
219477715|NCT01827085|DEVICE|Stortz videolaryngoscope|
219477716|NCT06270537|DEVICE|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
219477717|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
219477718|NCT02472600|DRUG|Colistin|
219477719|NCT02472600|DRUG|Neomycin|
219477720|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
219477721|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
219477722|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
219477723|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
219477724|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
219477725|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
219477726|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
219477727|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
219477728|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
219477729|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
219477730|NCT05454189|DEVICE|Reduced IPD Flush Schedule|IPD flush every 12 weeks
219477731|NCT05454189|DEVICE|Standard IPD Flush Schedule|IPD flush every 4 weeks
219477732|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
219477733|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
218862032|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
218862033|NCT01238978|DRUG|Vildagliptin|
218862034|NCT01238978|DRUG|"Usual Care"|
218862035|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
219020760|NCT07206940|DEVICE|Drainage with Headset Hypno VR|Pleural effusion and pneumothorax will be drained with the patient wearing the virtual reality headset.
219020761|NCT07205848|OTHER|No intervention|No intervention
219020762|NCT07207070|DRUG|JS105|Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.
218862036|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
218862037|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
218862038|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219477734|NCT06170528|DEVICE|AURA_ALZ|AURA\_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA\_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
219477735|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
219477736|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
219477737|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
219477738|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
219597273|NCT02587078|DRUG|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
219477739|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477740|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477741|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477742|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477743|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477744|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477745|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
219477746|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
219477747|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
219477748|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
219597274|NCT02587078|DRUG|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
219597275|NCT03366207|DRUG|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
219597276|NCT01651793|OTHER|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
219597277|NCT01651793|OTHER|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
219597278|NCT01651793|OTHER|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
219597279|NCT01651793|OTHER|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
218862039|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
218862040|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
218862041|NCT04129411|DEVICE|RFA|Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
218862042|NCT05408910|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
218862043|NCT05408910|DRUG|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
218862044|NCT02726061|BEHAVIORAL|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
218862045|NCT03647267|DEVICE|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
218862046|NCT03647267|OTHER|Observation|No intervention; sham injection only
218862047|NCT02432352|BEHAVIORAL|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
219477749|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219477750|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
219477751|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
219477752|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
219477753|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219477754|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
219477755|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
218862048|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
219477756|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
219477757|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
219477758|NCT02665858|OTHER|OCT Imaging|
219477759|NCT01896518|DRUG|Nicotine polacrilex|
219477760|NCT01896518|DRUG|Tobacco lozenge|
219477761|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
219597280|NCT01737073|BEHAVIORAL|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
219597281|NCT01737073|BEHAVIORAL|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
219597282|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tip and usual clinical care
219597283|NCT03907657|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
218862049|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
219477762|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
219477763|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
219477764|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
219477765|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
219477766|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
219477767|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
219613543|NCT04338022|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.
219613544|NCT04338022|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.
219613545|NCT06996795|BEHAVIORAL|music therapy|Music therapy will be applied with drums, maracas, cymbals and orf instruments. It will consist of body rhythms, breathing exercises and rhythm studies.
219613546|NCT06996795|BEHAVIORAL|sensory integration|Sensory integration will include sensory modulation activities, vestibular, proprioceptive, tactile, visual and auditory sensory studies.
219613547|NCT04278456|BEHAVIORAL|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
218862050|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
219477768|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
219477769|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
219477770|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
218862051|NCT03659058|DRUG|Colchicine|Colchicine 0.6
218862052|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
218862053|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
218862054|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
219020763|NCT07207070|DRUG|Dalpiciclib|Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle；
219477771|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
219477772|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
219477773|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
219477774|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
219477775|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
219477776|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
219477777|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
219477778|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
219477779|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
219477780|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
219597284|NCT03907657|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
218862055|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
218862056|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
218862057|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
218862058|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
218862059|NCT01350115|DRUG|Placebo|supplied in capsules
219020764|NCT07207070|DRUG|Fulvestrant 50 Mg/mL Intramuscular Solution|Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.
219020765|NCT07205237|DIETARY_SUPPLEMENT|Diet without Red and Processed Meat|Participants replaced red and processed meat in their daily diet with fish, eggs, or white meat, while keeping the food proportions of their meals unchanged.
219477781|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
219477782|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
219020775|NCT07206524|OTHER|Hemodialysis using dialysate containing citric acid and magnesium at a concentration of 1.0 mmol/L|Change dialysate compositions being used during hemodialysis treatment in each arm.
219477783|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
219477784|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
219477785|NCT01075126|DRUG|Depakote|
219477786|NCT01075126|DRUG|Lithium|
219477787|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
219477788|NCT00003104|RADIATION|radiation therapy|
219477789|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
219597285|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk|Patients in Arm 1, after the surgical procedure, will receive radiotherapy to the at-risk mucosa.
218862060|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
219477790|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
219477791|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
218862061|NCT05079477|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
219477792|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
219477793|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
219477794|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
219477795|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
219477796|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
219477797|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
219477798|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
218862062|NCT05079477|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
218862063|NCT05122299|PROCEDURE|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
218862064|NCT05122299|PROCEDURE|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
218862065|NCT05122299|PROCEDURE|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
218862066|NCT05657873|RADIATION|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
218862067|NCT05657873|BIOLOGICAL|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
219477799|NCT01528839|DRUG|Placebo|
219477800|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
219477801|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
219477802|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
219477803|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
219477804|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
219477805|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
219477806|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
219477807|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
219477808|NCT00008034|DRUG|capecitabine|
219477809|NCT00008034|DRUG|cyclophosphamide|
219477810|NCT00008034|DRUG|epirubicin hydrochloride|
219477811|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
219477812|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
219477813|NCT01800812|BIOLOGICAL|Injections of OM-174|
218862068|NCT05657873|DRUG|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
219477814|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
219477815|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
219477816|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
219597286|NCT06578871|PROCEDURE|Surgical Intervention|These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
219597287|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck|For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node \>3 cm is observed
219477817|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
219477818|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
219597288|NCT02255968|DRUG|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
219597289|NCT02255968|DRUG|Placebo|Matching placebo capsules. All interventions are given as multiple doses
219597290|NCT04077944|DIAGNOSTIC_TEST|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
219597291|NCT02184767|DRUG|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
219597292|NCT02806024|DRUG|Tranexamic Acid|
219597293|NCT02806024|DRUG|Placebo Drug|50 cc Normal Saline IV
218862069|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
218862070|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
218862071|NCT05987488|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
218862072|NCT05987488|OTHER|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
218862073|NCT04948307|DEVICE|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
218862074|NCT04948307|OTHER|Standard of Care|Sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
218862075|NCT05918055|DRUG|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
219020776|NCT07206524|OTHER|Hemodialysis using acetic acid dialysate with magnesium 0.5 mmol/L|Standard dialysate containing acetic acid and magnesium at a concentration of 0.5 mmol/L, used during hemodialysis sessions.
219020777|NCT07206524|OTHER|Hemodialysis using citric acid dialysate with magnesium 0.75 mmol/L|Dialysate containing citric acid and magnesium at a concentration of 0.75 mmol/L, used during hemodialysis sessions.
219597294|NCT03456141|PROCEDURE|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
219597295|NCT02892149|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219597296|NCT02892149|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
219020778|NCT07206173|OTHER|The Londrina Activites of Daily Living Protocol|The Londrina Activites of Daily Living Protocol is a performance-based test protocol that objectively evaluates ADL. The participant was instructed to perform the tasks at the stations at the same speed they would typically do at home. The protocol consists of five stations with different tasks consisting of arranging objects, walking with weights, organizing objects, organizing clothes and walking.
218862076|NCT05918055|DRUG|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
218862077|NCT04758923|PROCEDURE|Cholecystectomy|Under General anaesthesia cholecystectomy and CBD exploration
218862078|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
218862079|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
218862080|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
218862081|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
219020779|NCT07206901|DIETARY_SUPPLEMENT|Maharishi Amrit Kalash|
218862082|NCT01095120|DRUG|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
218862083|NCT05013424|DRUG|Formulation A: OnabotulinumtoxinA|Intramuscular Injection
218862084|NCT05013424|DRUG|Formulation B: OnabotulinumtoxinA|Intramuscular Injection
218862085|NCT05013424|DRUG|Formulation C: OnabotulinumtoxinA|Intramuscular Injection
218862086|NCT06957158|DIAGNOSTIC_TEST|Peripheral venous blood|Peripheral venous blood was collected before and after the surgery to measure the total serum calcium levels.
218862087|NCT06957158|DIAGNOSTIC_TEST|Arterial blood|Arterial blood was collected before anesthesia induction and after removal of the artificial airway to measure ionized calcium levels.
218862088|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
218862089|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
218862090|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
218862091|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
218862092|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
218862093|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
218862094|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
219199616|NCT06868472|PROCEDURE|Prehabilitation|"The waiting time until the operation is about 6 weeks. The intervention is carried out during this time:~The intervention group receives a brochure with an evidence-based exercise program for the shoulder and shoulder girdle. The brochure contains pages in which the patient documents how the exercises are carried out. The exercise program is supplemented by information in the form of a video/Power Point presentation on: Anatomy/function, pain management, hospitalization and subsequent rehabilitation.~After 2 and after 4 weeks, the physiotherapist who has explained the exercise program will contact you by telephone/zoom."
219477819|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
219477820|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
219477821|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
219477822|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
218862095|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
218862096|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
218862097|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
218862098|NCT06303245|OTHER|ABDOMINAL BINDERS|will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided
219199617|NCT06868472|PROCEDURE|Control|The control group receives a leaflet with general information for the period up to the operation (e.g. buy water-resistant plasters, arrange post-op physiotherapy appointments).
219477823|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
219477824|NCT04592666|DRUG|Pemetrexed|standard dose
219477825|NCT04592666|DRUG|Carboplatin|AUC=5
219477826|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
219597297|NCT01994850|DRUG|brentuximab vedotin|Trade name: Adcetris
219597298|NCT05842993|DEVICE|Hydrogen generator|Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
219597299|NCT05842993|DEVICE|Analogue machine|Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
219597300|NCT05235516|DRUG|AK104|q3w iv
219597301|NCT05235516|RADIATION|EBRT|45-50.4Gy
219597302|NCT05235516|RADIATION|BT|≥80Gy
219597303|NCT05235516|DRUG|cisplatin|qw iv
219597304|NCT05235516|DRUG|Placebo|q3w iv
219597305|NCT03629756|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
218862099|NCT06303245|OTHER|TENS|will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
218862100|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
218862101|NCT03925051|DRUG|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
218862102|NCT03925051|DRUG|CMAB807|human monoclonal antibody targeting RANKL.
218862103|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
218862104|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
218862105|NCT03137628|OTHER|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
218862106|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
218862107|NCT01549873|DRUG|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
219477827|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
219477828|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
219477829|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
219477830|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
219477831|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
219477832|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
219477833|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
219477834|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
218862108|NCT01549873|DRUG|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
219020780|NCT07206901|DIETARY_SUPPLEMENT|vitamin C + E|
219020781|NCT07206901|OTHER|Inert Placebo Capsule|placebo is same shape and color as is the active interventions but is inert
219020782|NCT07204990|PROCEDURE|Endotracheal tube removed awake|Patient will have the ETT removed awake and transferred to PACU breathing independently or with a face mask.
219020783|NCT07204990|PROCEDURE|Laryngeal mask airway inserted following deep extubation|Patient will have LMA inserted following deep extubation of endotracheal tube.
219020784|NCT07206836|OTHER|Enhanced Recovery after Surgery Protocol|reduced fasting, no mechanical bowel prep, early feeding, non-opioid analgesia.
219020785|NCT07206836|OTHER|Traditional Care Protocol|Participants receive standard peri-operative management for colostomy reversal. This includes three days of mechanical bowel preparation with oral laxatives and clear fluids, overnight fasting before surgery, routine nasogastric tube placement, opioid-based postoperative pain control, and a nil-per-mouth regimen for at least three days after surgery before gradually resuming oral intake.
219020786|NCT07205081|DRUG|ATTO-3712|ATTO-3712
219020787|NCT07205081|DRUG|Placebo|Placebo preparation to match ATTO-3712 dose
219477835|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
219477836|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
219477837|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
219477838|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
219477839|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
219597306|NCT03629756|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
219597307|NCT00000494|DRUG|indomethacin|
219477840|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
218862109|NCT04097977|OTHER|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
219477841|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
219597308|NCT00000494|PROCEDURE|surgery, cardiovascular|
219597309|NCT02955823|DRUG|Rituximab-Dexamethasone-Lenalidomide|"1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
218862110|NCT05702086|OTHER|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
218862111|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
219597310|NCT01178216|BIOLOGICAL|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
218862112|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
218862113|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
218862114|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
218862115|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
218862116|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
218862117|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
218862118|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
218862119|NCT03710876|BIOLOGICAL|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
218862120|NCT03710876|DRUG|Celecoxib Oral Product|400 mg twice daily
218862121|NCT03710876|DRUG|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
218862122|NCT00480389|DRUG|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
218862123|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
219020788|NCT07207096|COMBINATION_PRODUCT|complementary medicine|Complementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition.
219020789|NCT07205315|BIOLOGICAL|GT801 Injection|GT801 Injection
219020790|NCT07206147|OTHER|FaStEx - Structured strength training|Strength training in group session, 2 times a week for 8 weeks. 150 minutes of physical activity per week that is carried out independently.
219020791|NCT07206147|OTHER|Control group|150 minutes of physical activity per week that is carried out independently.
219477842|NCT02189928|OTHER|Usual care|
219597311|NCT00025259|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
219597312|NCT00025259|DRUG|Cisplatin|Given IV
219597313|NCT00025259|DRUG|Cyclophosphamide|Given IV
219597314|NCT00025259|DRUG|Cytarabine|Given IV
219597315|NCT00025259|DRUG|Dexamethasone|Given IV
219597316|NCT00025259|DRUG|Doxorubicin Hydrochloride|Given IV
219597317|NCT00025259|DRUG|Etoposide|Given IV
219477843|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
219477844|NCT02594254|OTHER|Placebo|Placebo
218862124|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
218862125|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
218862126|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
218862127|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
218862128|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
218862129|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
218862130|NCT05518708|DRUG|BI 3032950|BI 3032950
219477845|NCT06650293|DRUG|Vitamin D|Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
218862131|NCT05518708|DRUG|Placebo|Placebo
218862132|NCT01263145|DRUG|Akt Inhibitor MK2206|Given PO
218862133|NCT01263145|OTHER|Laboratory Biomarker Analysis|Correlative studies
218862134|NCT01263145|DRUG|Paclitaxel|Given IV
218862135|NCT01263145|OTHER|Pharmacological Study|Correlative studies
218862136|NCT04897763|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
218862137|NCT00465140|DRUG|creatine supplementation|
218862138|NCT00465140|BEHAVIORAL|aerobic exercise training|
218862139|NCT01133119|DRUG|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
218862140|NCT01133119|DRUG|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
218862141|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
219020794|NCT07206719|PROCEDURE|Malone Antegrade Continent Enema (MACE) and Mitrofanoff procedures|"* MACE Split appendix procedure: division of appendix into two segments, so making Mitrofanoff procedure by the distal appendicular segment and Malone procedure by proximal appendicular segment.~* MACE Colonic flap Neoappendecosotomy procedure: creating the colonic flap from the ascending colon, tubularization done. The tip of the neo-appendix was spatulated and sutured with the triangular skin flap of umbilicus, then the silicon catheter in place passing through the neo appendix into the colon~* Mitrofanoff procedure: The appendix was mobilized with its mesentery. The tip of the appendix was incised and a 10-12Fr feeding tube was inserted to confirm patency. Then Opening of the urinary bladder was done. The distal end of the appendix was then inserted into the bladder in a submucosal tunnel. The distal opening of the appendix was sutured to the inner bladder wall and mucosa using absorbable sutures."
219020795|NCT07205640|DEVICE|Low-Level Laser Therapy|A 980 nm diode laser will be applied immediately after extraction of the first permanent molar. The laser will be used in continuous mode at 0.5 W, with a total energy of 300 J, applied for 60 seconds at three points around the extraction socket.
219020796|NCT07205640|DRUG|Hyaluronic Acid (HA)|Hyaluronic acid gel will be applied directly into the extraction socket immediately after tooth removal.
219020797|NCT07207226|DEVICE|Laser doppler vibrometry|Non-invasive CARDIS Technology Demonstrator (CTD) device is a 2 x 6 beam laser Doppler vibrometer (LDV) for non-contact measurement of skin vibrations caused by underlying cardiac action. The CTD device is a split device with a master device and a slave device, which are connected to a data acquisition rack, which again is connected to a computer for signal processing, data presentation and data logging.
219477846|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
219477847|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
218862142|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
218862143|NCT06263322|BEHAVIORAL|Actionable remotely generated health data|Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
218862144|NCT06263322|BEHAVIORAL|Non-Actionable remotely generated health data|Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
218862145|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
218862146|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
218862147|NCT06962163|DIAGNOSTIC_TEST|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.
218862148|NCT05740124|BEHAVIORAL|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
218862149|NCT05740124|BEHAVIORAL|alternative balance training|Participants practice standing and walking under varied sensory conditions.
218862150|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
218862151|NCT05996471|BIOLOGICAL|VH3810109|VH3810109 will be administered.
218862152|NCT05996471|DRUG|Cabotegravir|Cabotegravir will be administered.
218862153|NCT05996471|DRUG|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
219477848|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
219477849|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
219477850|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
219477851|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
219477852|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
219477853|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
219477854|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
219477855|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
219477856|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
219477857|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
219477858|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
219477859|NCT00560573|DRUG|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
219477860|NCT00560573|DRUG|Cisplatin|"Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
218862154|NCT05996471|BIOLOGICAL|rHuPH20|rHuPH20 will be administered.
219020798|NCT07206732|DEVICE|Ultrasound-Guided Inferior Vena Cava Assessment|This intervention involves bedside ultrasound measurement of the inferior vena cava (IVC) diameter and calculation of the IVC collapsibility/distensibility index. Assessments will be performed both at initial presentation and after fluid resuscitation in shock patients. The procedure is non-invasive, rapid, and performed according to standardized emergency ultrasound protocols, distinguishing it from invasive monitoring methods.
219477861|NCT00560573|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
218862155|NCT03635164|DRUG|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
218862156|NCT03635164|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
218862157|NCT03635164|PROCEDURE|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
218862158|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
219199618|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures and internal fixation by dynamic hip screws|Open reduction of femoral neck using watson jones or smith peterson approach fractures then fixation of fractures by dynamic hip screws
219477862|NCT00560573|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
219477863|NCT00347776|DRUG|azithromycin|oral antibiotic
219477864|NCT00347776|DRUG|topical tetracycline|
219477865|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
219477866|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
218862159|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
218862160|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
218862161|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
218862162|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
218862163|NCT00889889|BIOLOGICAL|Placebo|Placebo
218862164|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
218862165|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
218862166|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
218862167|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
218862168|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
218862169|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
218862170|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
218862171|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
218862172|NCT01883011|DRUG|Piracetam|
218862173|NCT01883011|OTHER|Placebo|
219477867|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
218862174|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
218862175|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
218862176|NCT01838785|DRUG|18F-DTBZ AV-133|
218862177|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
218862178|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
219477868|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
219477869|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
218862179|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
218862180|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
218862181|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
218862182|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
218862183|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
218862184|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
218862185|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
218862186|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
218862187|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
218862188|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
218862189|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
218862190|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
218862191|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
218862192|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
218862193|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
218862194|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
218862195|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
219477870|NCT00002329|DRUG|Celgosivir hydrochloride|
219477871|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
219477872|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
219477873|NCT06501131|OTHER|full-spectrum light exposure|Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
219477874|NCT06501131|OTHER|specific spectrum absence light exposure|Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
219477875|NCT04220073|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
219477876|NCT04220073|DRUG|placebo|placebo
219597318|NCT00025259|BIOLOGICAL|Filgrastim|Given SC
219477877|NCT02364882|DRUG|Sildenafil|
219477878|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
219477879|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
219477880|NCT00299546|DRUG|Placebo|SC injections
219477881|NCT00299546|BIOLOGICAL|Golimumab 50 mg|SC injections
219477882|NCT00299546|BIOLOGICAL|Golimumab 100 mg|SC injections
219477883|NCT01902992|DRUG|Depiquick Birch (DPG103)|
219477884|NCT01902992|DRUG|Placebo|
219477885|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
219477886|NCT03099265|DRUG|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
219597319|NCT00025259|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
219597320|NCT00025259|DRUG|Prednisone|Given orally
218862196|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
218862197|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
218862198|NCT02335632|DRUG|Placebo|For probiotics
218862199|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
218862200|NCT01013415|DRUG|HAART|
218862201|NCT01013415|BIOLOGICAL|T cells|
219199619|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures using watson jones or smith peterson approachand internal fixation by cannulated screws and medial buttress plate|Open reduction of femoral neck fractures then fixation of fractures by cannulated screws and medial buttress plate
219199620|NCT06872398|OTHER|Blood and saliva sampling|"Physical and biological evaluation at inclusion visit V0 and at follow up visit V1 (after 1 year).~the biological evaluation includes blood and saliva sampling at the 2 visits."
219477887|NCT03099265|DRUG|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
219477888|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
219477889|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
219477890|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
219597321|NCT00025259|DRUG|Vincristine Sulfate Liposome|Given IV
219597322|NCT05043441|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
219597323|NCT05043441|BEHAVIORAL|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
219597324|NCT06226012|DEVICE|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
219613548|NCT02749617|DRUG|apixaban|2.5 mg PO BID
218862202|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
219477891|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
219199621|NCT06698757|BIOLOGICAL|Sintilimab|Subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W)
219477892|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
219477893|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
219477894|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
219477895|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
219477896|NCT06380101|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
219477897|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
219477898|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
219477899|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
219477900|NCT05424939|PROCEDURE|Colectomy|Colon resection
219477901|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
219477902|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
219477903|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
219597325|NCT06226012|DEVICE|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
219597326|NCT00270907|DRUG|CT-2103|135 mg/m\^2 IV on Day 1.
219199622|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®)|ADM (Novomatrix®) will be used alone
219199623|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF|ADM in combination with L-Prf will be applied
219477904|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
219477905|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
219477906|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
219477907|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
219477908|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
219477909|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
219477910|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
219477911|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
219477912|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
219477913|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
219477914|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
219477915|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
219477916|NCT01800500|OTHER|questionnaire administration|Ancillary studies
219477917|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
219477918|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
219477919|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
219477920|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
219477921|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
219597327|NCT00270907|DRUG|Gemcitabine|1000 mg/m\^2 IV on Day 1 and 8.
219597328|NCT01953978|DRUG|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
219597329|NCT01953978|OTHER|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
218862203|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
219477922|NCT01578109|DRUG|Sorafenib|Given PO
219477923|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
219477924|NCT03488537|DEVICE|AeonoseTM|Breath test
219477925|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
219477926|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
219477927|NCT00153751|DRUG|Holopon|holopon
219477928|NCT00153751|OTHER|placebo|placebo
219597330|NCT01953978|DRUG|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
219597331|NCT01953978|DRUG|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
219597332|NCT01953978|DRUG|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
218862204|NCT02559414|DRUG|Aspirin|
218862205|NCT02559414|DRUG|Clopidogrel|
218862206|NCT04786418|OTHER|Standard of care|Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
218862207|NCT04786418|DIETARY_SUPPLEMENT|Low-calorie diet|The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
219477929|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
219477930|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
219597333|NCT01953978|DRUG|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
219597334|NCT00863772|BIOLOGICAL|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
219597335|NCT00863772|BIOLOGICAL|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
218862208|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
218862209|NCT05792527|DRUG|L-carnitine|One 500 mg tablet twice daily after meals
219199624|NCT04998422|DRUG|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
219199625|NCT04918316|OTHER|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
219199626|NCT06876311|DEVICE|Anterior Cervical Interbody Fusion|Standard Anterior Cervical Interbody Fusion with Stand-alone Cervical Cages
219199627|NCT06876311|DEVICE|Anterior lumbar Interbody Fusion|Standard Anterior Lumbar Interbody Fusion with Stand-Alone Lumbar Cages
219199628|NCT06876311|DEVICE|Lateral Lumbar Interbody Fusion|Standard Lateral Lumbar Interbody Fusion with Stand-alone Lumbar cage
219477931|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
219597336|NCT00863772|OTHER|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
219597337|NCT01449370|DRUG|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
219597338|NCT01883349|PROCEDURE|Kidney Transplant|Kidney Transplant Surgery
219597339|NCT01883349|OTHER|No kidney transplant|The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
219597340|NCT06525103|DEVICE|electromagnitic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V"
219597341|NCT06525103|DEVICE|whole body vibration|"Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels."
219597342|NCT03864887|PROCEDURE|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
219597343|NCT03864887|PROCEDURE|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
218862210|NCT04694495|DIAGNOSTIC_TEST|16S rRNA gene sequencing of cervical secretions|"1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
218862211|NCT05632328|DRUG|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
218862212|NCT05632328|DRUG|Botensilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
218862213|NCT05632328|DRUG|Gemcitabine|per standard care
218862214|NCT05632328|DRUG|Nab-paclitaxel|per standard care
218862215|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
218862216|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
218862217|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
219477932|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
219477933|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
218862218|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
218862219|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
219597344|NCT03864887|DEVICE|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
219597345|NCT02335918|DRUG|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
218862220|NCT00002055|DRUG|Pentamidine isethionate|
218862221|NCT05891054|BEHAVIORAL|Active breaks|Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.
218862222|NCT05891054|BEHAVIORAL|Physically active learning|"The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
218862223|NCT05688826|DIETARY_SUPPLEMENT|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
218862224|NCT05880914|PROCEDURE|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
218862225|NCT05880914|DRUG|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
218862226|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 700rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
218862227|NCT06546709|BIOLOGICAL|HDCV Comparator|Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M
218862228|NCT06546709|OTHER|Normal Saline Placebo|Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
218862229|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 1400rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
218862230|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
218862231|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
218862232|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
218862233|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
218862234|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
218862235|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
219477934|NCT00292006|DEVICE|Computerized tomography|
219477935|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
219597346|NCT02254434|DRUG|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
219597347|NCT05189834|DIETARY_SUPPLEMENT|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
219613549|NCT02860546|DRUG|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
219613550|NCT02860546|DRUG|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
218862236|NCT01357876|OTHER|Metformin|withdrawral
218862237|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
218862238|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
219597348|NCT03149757|BEHAVIORAL|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
218862239|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
218862240|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
218862241|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
218862242|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
218862243|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
218862244|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
218862245|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
218862246|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
218862247|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
218862248|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
218862249|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
219477936|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
219477937|NCT00518531|DRUG|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
219477938|NCT00518531|DRUG|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
218862250|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
218862251|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
218862252|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
218862253|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
218862254|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
218862255|NCT04578639|DRUG|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
218862256|NCT04578639|DRUG|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
218862257|NCT05925088|OTHER|Focus group|Participants will take part in a 1 hour focus group.
219477939|NCT00032825|DRUG|Ketaconazole|
219477940|NCT00032825|DRUG|Docetaxel|
218862258|NCT06378463|OTHER|Cognitive remediation + active tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive active brain stimulation."
218862259|NCT06378463|OTHER|Cognitive remediation + sham tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive sham brain stimulation."
218862260|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
219477941|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
219477942|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
219477943|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
219477944|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
219477945|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
219477946|NCT00087763|DRUG|Macugen ™ (pegaptanib sodium injection)|
219477947|NCT04406363|OTHER|non interventional|non interventional
219477948|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
219477949|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
219477950|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
219477951|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
219477952|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
218862261|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
219477953|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
219477954|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
219477955|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
219477956|NCT02351206|RADIATION|x-ray, MRI|
219477957|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
219477958|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
219477959|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
219477960|NCT01326611|DRUG|Clarithromycin|
219477961|NCT01326611|DRUG|Dextrose|
219477962|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
219477963|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
219597349|NCT03149757|BEHAVIORAL|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
219477964|NCT06195358|DEVICE|Mobile Health (Smartphone) Application|The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
219597350|NCT00769938|DEVICE|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
218862262|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
218862263|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
218862264|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
219477965|NCT06195358|OTHER|Printed Caregiving Materials|The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
219477966|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
219477967|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
219477968|NCT00096317|DRUG|ixabepilone|
219477969|NCT00096317|DRUG|ketoconazole|
219477970|NCT00551473|DRUG|Lavoltidine|
219477971|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
219477972|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
219477973|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
219477974|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
219477975|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
219477976|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
219477977|NCT04651582|BEHAVIORAL|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
219477978|NCT04651582|BEHAVIORAL|Cognitive Stimulating Activities|20 hours of traditional computer games
219477979|NCT02414165|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
219477980|NCT02414165|DRUG|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
219597351|NCT02607267|OTHER|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
219597352|NCT06611280|OTHER|No Interventions|No delivered intervention.
219597353|NCT04854889|DRUG|Decitabine|Demethylating agents
219597354|NCT03423186|DRUG|SOBI003|Weekly i.v.infusion
219477981|NCT02414165|DRUG|Lomustine|
219597355|NCT05343546|DEVICE|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
218862265|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
218862266|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
218862267|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
219597356|NCT01888510|PROCEDURE|computed tomography|Undergo conventional free breathing CT
219477982|NCT02414165|DRUG|Temozolomide|
219477983|NCT02414165|BIOLOGICAL|Bevacizumab|
219477984|NCT06098131|OTHER|Neurodynamic|Neurodynamic Slider and Tensioner Technique
219477985|NCT06563492|DEVICE|insole|evaluation of individuals using different insoles
219477986|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
219477987|NCT06698263|DRUG|Isotretinoin|ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
219477988|NCT06698263|DRUG|Control group (placebo)|placebo administration
219477989|NCT03681769|DEVICE|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
219477990|NCT03681769|DEVICE|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219477991|NCT03681769|DEVICE|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
219597357|NCT01888510|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT
219597358|NCT01888510|PROCEDURE|computed tomography|Undergo ABC CT
218862268|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
218862269|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
218862270|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
218862271|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
218862272|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
219477992|NCT03681769|DEVICE|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219477993|NCT02705417|PROCEDURE|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
219477994|NCT02705417|PROCEDURE|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
219477995|NCT02705417|PROCEDURE|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
219477996|NCT02705417|PROCEDURE|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
219477997|NCT02705417|PROCEDURE|arteriovenous graft placement|surgical placement of arteriovenous graft
219477998|NCT04476459|DRUG|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
218862273|NCT01610596|DRUG|Placebo|
219597359|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo ABC CBCT
219597360|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo free breathing CBCT
219597361|NCT00564330|DRUG|Esomeprazole|20mg bid
219597362|NCT00564330|DRUG|Placebo|Placebo bid
219597363|NCT04792424|OTHER|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
219597364|NCT04792424|DRUG|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
219597365|NCT04792424|DRUG|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
219597366|NCT04792424|DEVICE|Dialysis with continuous renal replacement therapy|Prismaflex
219597367|NCT00464789|DRUG|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
219477999|NCT04476459|DRUG|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
218862274|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
219478000|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
219478001|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
219478002|NCT00000254|DRUG|0.2% isoflurane|
219478003|NCT00000254|DRUG|0.4% isoflurane|
219478004|NCT00000254|DRUG|0.6% isoflurane|
219478005|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
219478006|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
219478007|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
219478008|NCT01277107|DRUG|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
219478009|NCT01277107|DRUG|Placebo capsule|Identical placebo capsule
219478010|NCT01637207|OTHER|Palpation|Group A: Palpation Group
219478011|NCT01637207|OTHER|Ultrasound|Group B: Ultrasound Group
219597368|NCT01709929|DRUG|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
219597369|NCT00534404|DRUG|Nicotine patches|Participants will wear nicotine patches.
219597370|NCT00534404|BEHAVIORAL|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
218862275|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
218862276|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
218862277|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
218862278|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
219478012|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
219478013|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
219478014|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
219478015|NCT04861168|PROCEDURE|driving pressure guided ventilation|driving pressure guided ventilation
219478016|NCT04861168|PROCEDURE|Conventional protective lung strategy|Conventional protective lung strategy
219478017|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
219478018|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
219478019|NCT05726110|DRUG|Selinexor|Given PO
219478020|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
219597371|NCT00534404|BEHAVIORAL|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
219597372|NCT01898273|DRUG|I-124-CLR1404|single-dose, intravenous
219597373|NCT05232188|PROCEDURE|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
219597374|NCT06283732|DIETARY_SUPPLEMENT|Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
219613551|NCT01956474|OTHER|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
219613552|NCT04267796|OTHER|Aerobic Exercise|Complete aerobic training
218862279|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
218862280|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
219478021|NCT05726110|DRUG|Daunorubicin|Given per standard of care
219613553|NCT04267796|OTHER|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
218862281|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
218862282|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
218862283|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
218862284|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
218862285|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
218862286|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
219478022|NCT05726110|DRUG|Cytarabine|Given per standard of care
218862287|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
218862288|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
218862289|NCT00799591|OTHER|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
219020801|NCT07205432|DRUG|XTL6001|XTL6001 is a triple-target Glucagon-like peptide-1 receptor （GLP-1R） relevant agonist, intending to manage overweight/obesity and other metabolic diseases
219020802|NCT07205432|DRUG|Placebo|This intervention contains no active ingredients
219478023|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
219478024|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
219478025|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
219597375|NCT05191537|OTHER|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
219597376|NCT05191537|OTHER|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
219597377|NCT01307748|OTHER|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
219597378|NCT02180737|DRUG|Dexmeditomedine|
219597379|NCT05421364|BIOLOGICAL|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
219597380|NCT06982430|OTHER|phone call|"Included patients were evaluated on day 7 after discharge from the ED through a telephone call.~This evaluation aimed to identify a recurrence of RC, defined as a NRS score greater than 3 within the 7 days following inclusion and/or a return visit for the same complaint"
219613554|NCT04267796|OTHER|Quality-of-Life Assessment|Ancillary studies
219613555|NCT04267796|OTHER|Questionnaire Administration|Ancillary studies
219478026|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
219478027|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
219478028|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
219613556|NCT04267796|OTHER|Resistance Training|Complete high-resistance circuit training sessions
219613557|NCT06601764|OTHER|Circuit Training|"1. Warm-up, balance~2. Aerobic, balance~3. Muscle strength Upper Limbs~4. Muscle strength Lower Limbs~5. Stretching both Upper Limb and Lower Limb"
219478029|NCT06214065|DIAGNOSTIC_TEST|fMRI|fMRI will be performed pre- and post-rTMS
219478030|NCT06214065|DEVICE|rTMS|TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
218862290|NCT05982119|DEVICE|ActiMyo/Syde|"The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion."
218862291|NCT03908736|DRUG|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
218862292|NCT06397560|RADIATION|PRDR|Proton pulsed reduced dose rate (PRDR) technique, to a dose of 54 Gy in 30 fractions (treatments) with proton radiotherapy. Treatments will occur once per day on consecutive weekdays.
218862293|NCT03573349|DRUG|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
218862294|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
218862295|NCT04100694|DRUG|MCLA-128|
218862296|NCT05744557|OTHER|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
218862297|NCT06816043|DRUG|MK-8527|Oral Capsule
218862298|NCT06816043|DRUG|FTC/TDF|Oral Tablet
218862299|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
218862300|NCT00315107|DRUG|Alesse|
218862301|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
218862302|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
218862303|NCT00005574|DRUG|Gentamicin|
218862304|NCT04424225|DRUG|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
218862305|NCT04424225|DRUG|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
218862306|NCT06645028|BEHAVIORAL|Intensive treatment programme|"Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client."
218862307|NCT06645028|BEHAVIORAL|Treatment as Usual (TAU)|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
218862308|NCT06980116|DRUG|EXS73565|EXS73565 oral administration
218862309|NCT06980129|OTHER|Rehabilitation in the home|Participants will receive home-based therapy from a MDT team, including physiotherapists, occupational therapists, social workers, dietitians, medical practitioners, psychologists, and pharmacists. Participants will be transferred to RITH once they achieve a level of mobility (+/- assistance) that enables them to manage at home. As per usual care, the disciplines required, frequency of visits, duration of visits, and duration of rehabilitation will be based on the patient's specific needs. There will be weekly MDT conferences to discuss patient progress led by medical staff. Telehealth care may be incorporated into the RITH program, subject to patient preference and provider availability. If the participant deteriorates during the RITH program, the escalation plan mandated by the LHD HITH Department will be followed to ensure appropriate care is provided. As for UCIR, discharge occurs when patients achieve sufficient walking and functional ability with available assistance.
218862310|NCT06980129|OTHER|Usual care inpatient rehabilitation|Participants will receive care in a rehabilitation ward or subacute hospital, including therapy from a MDT team. Discharge occurs when patients achieve sufficient walking and functional ability with available assistance, typically within 1-3 weeks, though this varies.
218862311|NCT06980389|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by standard first-line chemotherapy combined with a PD-1 inhibitor starting 2-5 days after radiotherapy. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
218862312|NCT06980389|COMBINATION_PRODUCT|First-line treatment|Patients will receive standard first-line chemotherapy combined with a PD-1 inhibitor. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
218862313|NCT06980441|BEHAVIORAL|Problem Management Plus with Emotional Processing module|PM+ EP comprises of Problem Management Plus, an evidence-based low intensity psychological intervention developed by the World Health Organization (WHO), with an additional Emotional Processing module specifically to address psychological distress related to trauma exposure. The core of the intervention is designed for adults impaired by distress in communities exposed to conflict and adversity; it consists of CBT techniques that have been adapted for communities that do not have good availability of specialist care. The additional module was developed by researchers treating refugee youth (Alozkan Sever et al, 2021). For this study, PM+ EP will be a six-session individual and guided support program. The original sections of PM+ are available in many languages including Farsi, and the additional EP module will be translated by PoMA's Afghan translator. The sessions cover the topics of managing stress, strengthening social support, staying well and persevering.
219478031|NCT00526162|DEVICE|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
219613558|NCT06601764|OTHER|Progressive Resistance|"1. Muscle habituation exercises~2. Hypertrophic phase 1 exercises~3. Hypertrophic phase 2 exercises"
219478032|NCT05842330|DRUG|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
219478033|NCT05842330|DRUG|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
219478034|NCT04461678|DIAGNOSTIC_TEST|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
219478035|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
218862314|NCT06979661|DIAGNOSTIC_TEST|Haystack™ ctDNA Assay|A personalized, tumor-informed circulating tumor DNA (ctDNA) test that analyzes blood samples to detect minimal residual disease (MRD) and guide postoperative treatment decisions for patients with Stage II-III non-small cell lung cancer (NSCLC) following surgical resection. The test results will help determine whether patients should receive postoperative radiation therapy (PORT) and/or systemic therapy adjustments.
218862315|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
218862316|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
218862317|NCT01563289|DRUG|Ibuprofen|3 times a day
218862318|NCT01563289|DRUG|Placebo|3 times a day
218862319|NCT04646226|DEVICE|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
218862320|NCT04646226|PROCEDURE|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
219478036|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
219478037|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
219478038|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
219478039|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
219478040|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
219478041|NCT03642249|BEHAVIORAL|E-learning|delirium care video
219478042|NCT03777839|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
219478043|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
219478044|NCT05283226|DRUG|NRC-2694-A|300 mg orally once daily
219478045|NCT05283226|DRUG|Paclitaxel|175 mg/m² IV infusion over approximately 3 hours
219478046|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
218862321|NCT05821374|DRUG|Deucravacitinib|6 mg tablet
218862322|NCT00722202|DRUG|ERB-257|
218862323|NCT00722202|OTHER|placebo|
218862324|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
219478047|NCT05727267|BIOLOGICAL|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
218862325|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
218862326|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
218862327|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
218862328|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
218862329|NCT03309293|BIOLOGICAL|blood samples|blood samples
218862330|NCT05859815|BEHAVIORAL|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
218862331|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
218862332|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
218862333|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
218862334|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
218862335|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
218862336|NCT07018089|BEHAVIORAL|iWork.Comp|The iWork.COMP is a short-term and low-time consuming internet delivery CFT-based intervention specifically designed to mitigate the impact of toxic leadership styles through the development of compassionate motivation in the workforce of EU hospitals. The iWork.COMP encompasses 8 individual sessions (20 minutes each; mixed format including text, audio and video presentations), which will be available weekly for participants at the KEEPCARING website (https://keepcaring.eu). Each session has three parts. Part 1 encompasses a brief check-in on the stress level of the participant at that moment and on the source of their stress (if applicable). In Part 2, the theme of the session is developed. Finally, Part 3 encompasses a brief check-in on the stress level of the participant at the end of the session and on the usefulness of the session; an optional open question to provide feedback will also be displayed.
218862337|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
218862338|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Mid
218862339|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-High
218862340|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Low
218862341|NCT07040826|DRUG|Xiidra|Administered on Day 1 to subjects in Group B, and on Day 8 to subjects in Group A as part of a crossover study design.
218862342|NCT07040826|DRUG|Lifitegrast|Administered on Day 1 to subjects in Group A, and on Day 8 to subjects in Group B as part of a crossover study design.
218862343|NCT07040657|PROCEDURE|Sentinel Lymph Node Detection/Cervical Methylene Blue Injection|Sentinel Lymph Node (SLN) detection using cervical methylene blue injection is a surgical technique designed to identify the primary lymph nodes responsible for draining the uterus in patients with endometrial cancer. The procedure involves injecting methylene blue dye into specific locations within the cervical stroma to enable lymphatic uptake. The dye subsequently travels through the lymphatic channels, allowing for intraoperative visual identification of the sentinel nodes. This targeted approach facilitates selective SLN excision for pathological evaluation, providing critical information about lymphatic involvement while minimizing the extent of surgical dissection. The effectiveness of SLN mapping is contingent upon the accuracy of the injection technique and the anatomical distribution of lymphatic drainage.
218862344|NCT07030244|BEHAVIORAL|Moodpep|See arm description
218862345|NCT07041489|DIETARY_SUPPLEMENT|Active Comparator- Xtressé™ Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Intervention group will receive Xtressé™ Supplements and Serum in Part A and Part B of the study.~Participants in the Placebo Group will receive Xtressé™ Supplement and Serum in Part B of the study only."
218862346|NCT07041489|DIETARY_SUPPLEMENT|Placebo Comparator- Placebo Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Placebo Group will receive Placebo Supplement and Serum in Part A of the study only."
218862347|NCT07041424|PROCEDURE|treatment group 1: total etch bonding agent used with rebonding technique|class 1 composite restoration is done using total etch type bonding agent and rebonding technique applied
219478048|NCT05727267|BIOLOGICAL|TherVacB|Administration of the described combinations via the intramuscular route
219478049|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
219613559|NCT06999460|PROCEDURE|Infraspinatus teres minor block group|Patients in this group will receive a unilateral ultrasound-guided Infraspinatus-teres minor (ITM) block with injection of local anesthetics (20 mL of bupivacaine 0.25% (50 mg), 50 mcg dexmedetomidine (0.5 ml) and 8 mg dexamethasone (2 ml)) before induction of general anesthesia
219613560|NCT06999460|PROCEDURE|Control group|Patients in this group will receive general anesthesia
218862348|NCT07041424|PROCEDURE|treatment group 2: self etch bonding agent used with rebonding technique|class 1 composite restoration is done using self etch type bonding agent and rebonding technique applied
219478050|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
219478051|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
219478052|NCT05963217|BIOLOGICAL|TBI-2001|"Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
219478053|NCT05963217|DRUG|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
219478054|NCT05963217|DRUG|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
218862349|NCT07041034|BEHAVIORAL|Active Comparator Group|"The group will receive:~1.Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches. 2.Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~This group will not receive the protocol-based intervention component."
218862350|NCT07041034|BEHAVIORAL|Experimental Group|"The intervention consists of three components:~1. Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches.~2. Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~3. SUNAM Protocol Training: Instruction on a structured, theory-informed protocol aimed at identifying and addressing underlying factors that contribute to BPSD in institutionalized residents."
218862351|NCT07040254|BEHAVIORAL|Father-Inclusive Antenatal Education Program|A structured six-week antenatal education program designed for pregnant women and their spouses. The program included sessions on pregnancy care, labor, breastfeeding, newborn care, and postpartum health. Fathers in the intervention group attended the program alongside their partners and were actively engaged in discussions and learning activities related to breastfeeding support. The goal was to enhance paternal awareness and involvement to improve maternal breastfeeding adaptation and both maternal and paternal breastfeeding self-efficacy. No additional materials were provided beyond the scheduled sessions.
218862352|NCT07041047|DEVICE|APAISANT SERUM - INGROWN NAILS|Topical application of APAISANT SERUM - INGROWN NAILS twice daily for 7 days.
218862353|NCT07041411|PROCEDURE|maxillary sinus elevation through transcrestal approach using OSSIX® Bone|After a careful radiologic analysis, using a surgical guide, maxillary sinus elevation through transcrestal access to sinus mucosa was achieved. The elevation of the maxillary sinus mucosa was performed through micro-elevators and graft material was inserted.
218862354|NCT07040228|DRUG|Regorafenib combined with Toripalimab and Albumin paclitaxel|Regorafenib combined with Toripalimab and Albumin paclitaxel as the third line treatment for patients with advanced pancreatic cancer
218862355|NCT03106415|DRUG|Binimetinib|Given PO
218862356|NCT03106415|OTHER|Laboratory Biomarker Analysis|Correlative studies
218862357|NCT03106415|BIOLOGICAL|Pembrolizumab|Given IV
219039982|NCT04134000|DRUG|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
219478055|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
218862358|NCT07040722|OTHER|Baseline|During the baseline, children will carry out their standard paper-and-pencil exercises for writing difficulties (that their perform during usual rehabilitation).
218862359|NCT07040722|OTHER|Intervention|During the intervention, they will carry out usual exercises and they will use VR 15 minutes during each session
218862360|NCT06892444|DIETARY_SUPPLEMENT|Yellow Sweet Corn|Participants will consume 1.5 cups daily of yellow or white canned sweet corn.
218862361|NCT06892444|DIETARY_SUPPLEMENT|White Sweet Corn|1.5 cups daily of canned yellow sweet corn
219478056|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
218862362|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
218862363|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
218862364|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
218862365|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
218862366|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
218862367|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219478057|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
219478058|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
218862368|NCT06903780|OTHER|Survey using a questionnaire.|A short 23-item survey concerning patients' experiences of their biologic treatments for their severe asthma.
219478059|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
218862369|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
218862370|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
218862371|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
218862372|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
219478060|NCT05028894|OTHER|No intervention|No intervention
219478061|NCT04638439|DRUG|P1101 + Nivolumab + Entecavir|P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks), followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks), with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.
219478062|NCT06505694|DIETARY_SUPPLEMENT|Alcohol Alternative Herbal Tincture (Test Product)|The test product contains organic vegetable glycerin, distilled water, organic elderberries, organic bilberries, organic beetroot juice powder, organic California poppy (whole plant), organic tart cherry, organic hawthorn berries, organic blue vervain (aerial parts), organic ceylon cinnamon bark, organic black pepper fruit, and L-theanine.
219478063|NCT06505694|DIETARY_SUPPLEMENT|Placebo|The placebo is designed to match the test product in appearance and taste but does not contain the active herbal ingredients. Participants will take 2 ml of the placebo directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks. The placebo contains organic vegetable glycerin, distilled water, organic beet juice powder, organic tart cherries, organic ceylon cinnamon chips, and natural green food coloring (derived from spirulina and turmeric).
219597381|NCT06982404|DIAGNOSTIC_TEST|Time Zero Donor Heart Biopsy for Molecular Analysis|"This intervention involves obtaining a right ventricular myocardial biopsy from the donor heart at the time of organ procurement (Time Zero), prior to transplantation. The biopsy is divided into two parts: one for routine histopathological evaluation and the other preserved in RNAlater® for molecular analysis using microarray technology. This molecular profiling is designed to detect early tissue injury and gene expression patterns associated with graft viability and transplant outcomes. The intervention is performed only once per donor and does not alter the standard clinical care of the recipient."
219478064|NCT05614128|OTHER|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
219478065|NCT05087888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219478066|NCT05087888|PROCEDURE|Magnetic Resonance Imaging|Undergo functional MRI
219478067|NCT05087888|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
219478068|NCT05087888|OTHER|Questionnaire Administration|Complete questionnaires
219478069|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
218862373|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
219199629|NCT06878651|DEVICE|The Whole Body Vibration|Whole Body Vibration device may positively affect balance, dual-tasking and gait parameters by increasing the sensory input received under the sole in individuals diagnosed with diabetic foot. In individuals diagnosed with diabetic foot, the sensory/vibration perception threshold of individuals decreases due to the disease, so the balance of individuals is impaired. This may cause these individuals to experience gait disturbances in daily life. There are almost no studies in the literature on the use of whole body vibration for this patient group. This study will discuss the applicability of whole body vibration in the clinic for individuals diagnosed with diabetic foot and that it can be an additional adjunct to treatment.
219199630|NCT06879353|DRUG|Tranexamic Acid (TXA)|A single intravenous dose of tranexamic acid (15 mg/kg) was administered before surgery to assess its efficacy in reducing perioperative blood loss and the need for transfusion.
219478070|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
219478071|NCT06551467|BEHAVIORAL|Online Ayurveda Program for Detox and Lifestyle|The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
219478072|NCT03007615|OTHER|Intimate Lubricant Gel|
218862374|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
218862375|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
218862376|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
218862377|NCT02608580|OTHER|Survey|
218862378|NCT00520013|DRUG|bevacizumab|
218862379|NCT00520013|DRUG|erlotinib|
218862380|NCT00520013|DRUG|paclitaxel|
218862381|NCT00520013|DRUG|carboplatin|
218862382|NCT02227823|DRUG|Pyridostigmine Bromide|
218862383|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
218862384|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
218862385|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
218862386|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
218862387|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
218862388|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
218862389|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
218862390|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
219199631|NCT06879353|DRUG|Placebo|An equal volume of intravenous normal saline was administered as a placebo before surgery to compare outcomes with the tranexamic acid group.
219478073|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
219478074|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
219478075|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
219478076|NCT03699995|OTHER|Confocal Microscopy|Undergo confocal microscopy
219478077|NCT03699995|OTHER|Dermoscopy|Undergo digital dermoscopy
218862391|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
218862392|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
219478078|NCT03699995|PROCEDURE|Imaging Procedure|Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
219478079|NCT03699995|DRUG|Lidocaine|Given SC
219478080|NCT03699995|PROCEDURE|Punch Biopsy|Undergo punch biopsy
219478081|NCT03699995|PROCEDURE|Shave Biopsy|Undergo shave biopsy
218862393|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
218862394|NCT06909461|OTHER|Pain neuroscience education|The pain neuroscience education group will be receive a 70-min pain neuroscience education.
218862395|NCT06909461|OTHER|Red-flags education|The control group will be receive a 70-min red-flags education.
218862396|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
218862397|NCT06905054|DRUG|Fenofibrate (drug)|Once daily fenofibrate for 36 months
219478082|NCT05165277|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
219020803|NCT07205939|DEVICE|Mobile Application usage|"Articipants complete a brief symptom questionnaire and upload a standardized photo of the cesarean incision on postpartum days 3, 7, and 15 (±1 day) via the study mobile platform. Patients will be reminded remotely on these mandatory days. They will be informed that if they have concerns about the wound outside of these mandatory days, they can use the app and share their survey and image data.~The surveys and images uploaded to the app will be evaluated by the researcher and reviewed by a clinician. Retakes will be requested for photos that are not of sufficient quality for evaluation. Clinical recommendations after review will be based on the patient's reported symptoms, and the wound images will provide additional information on this topic. One month after the cesarean section, all participants will be contacted by the researcher. They will be asked about the current status of their wounds and a patient satisfaction survey will be administered."
219478083|NCT05713916|OTHER|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
219478084|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
219597382|NCT06983587|RADIATION|Bone densitometry scan|"Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).~In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.~The total duration of the patient's participation in this research will be approximately 2 hours."
219597383|NCT06983535|DEVICE|cervical balloon catheter|Patients will be randomized to inpatient or outpatient setting while having the cervical ripening balloon catheter
218862398|NCT06905054|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Serum assessments will be performed every 3 months during the study period
218862399|NCT06905054|DIAGNOSTIC_TEST|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.
219597384|NCT06982898|PROCEDURE|Fixed prosthesis with bimanual CR and intraoral scan|"Tooth-supported fixed prostheses were fabricated using centric relation records obtained by two different methods:~1. Bimanual manipulation technique, with jaw relation records captured using an intraoral scanner.~2. Neuromuscular deprogramming technique, with jaw relation records obtained using a jaw movement tracking and analysis device."
218862400|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
218862401|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
218862402|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
218862403|NCT05124587|OTHER|No intervention group|No intervention group
218862404|NCT02677844|DRUG|Abemaciclib|Administered orally
218862405|NCT02677844|DRUG|Placebo|Administered orally
218862406|NCT02677844|DRUG|Loperamide|Administered orally
218862407|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
219478085|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
219478086|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
219478087|NCT02989623|RADIATION|Copper Cu 64 TP3805|Given Intravenously
219597385|NCT01363024|DRUG|MFGR1877S|Intravenous escalating dose
218862408|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
219478088|NCT02989623|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo copper Cu 64 TP3805 PET/CT scan
219597386|NCT04688905|DIAGNOSTIC_TEST|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
218862409|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
219020805|NCT07205549|RADIATION|MSK Ultrasound with Doppler on joints, muscles & tendons|Musculoskeletal Ultrasound (MSK-US) is a non-invasive, real-time, and sensitive imaging modality that can detect synovial hypertrophy, joint effusion, enthesitis, tenosynovitis, bursitis, and power Doppler (PD) signal indicative of active inflammation. Unlike standard clinical assessment, which may miss subclinical inflammation.
219478089|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
219478090|NCT01727804|OTHER|Laser in caries prevention|
219478091|NCT06594588|BEHAVIORAL|Aerobic exercise|Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
219478092|NCT04199312|DEVICE|Magnetic Muscle Stimulation (MMS) device|The MMS device will be used to perform the treatments.
219478093|NCT06575062|PROCEDURE|Direct Pulp Capping with ProRoot MTA|In this intervention, following the removal of carious dentin, the pulp tissue is directly exposed. ProRoot MTA is carefully applied over the exposed pulp to create a protective barrier. The material is mixed according to the manufacturer's instructions and placed directly onto the pulp exposure site. A light pressure is applied to ensure a good adaptation of the material. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
219597387|NCT06633185|DRUG|phenytoin cream|application of the cream after internal anal sphincterotomy versus non application.
219597388|NCT06633185|DRUG|no phenytoin cream|Non application of the phenytoin cream
218862410|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
218862411|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
218862412|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
218862413|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
218862414|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
218862415|NCT04291794|DRUG|Propofol|2mg/kg single bolus
218862416|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
219020806|NCT07205783|PROCEDURE|open radical prostatectomy|open surgery to remove prostate gland and the tumor
219478094|NCT06575062|PROCEDURE|Pulpotomy with ProRoot MTA|In this procedure, after the removal of the coronal pulp tissue, ProRoot MTA is applied over the exposed root canal orifices. The MTA is mixed according to the manufacturer's instructions and placed in the pulp chamber to cover the root canal entrances. The material is carefully adapted to create a seal that prevents bacterial contamination and promotes tissue healing. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
218862417|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
219478095|NCT04099368|BEHAVIORAL|Musical pitch training|Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
219478096|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
219478097|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
219478098|NCT03066011|DRUG|Posaconazole|Oral and intravenous
219478099|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
219478100|NCT00478933|DEVICE|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
219478101|NCT00478933|PROCEDURE|Blood sampling|Blood sampling
219478102|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
219478103|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
218862418|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
218862419|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
219478104|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
219478105|NCT02444676|OTHER|Stratification and outcomes|No necessary
219478106|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
219478107|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
219597389|NCT01141855|DRUG|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
219597390|NCT01141855|BEHAVIORAL|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
219597391|NCT02793505|DRUG|metformin|This is not an intervention but an observed exposure.
218862420|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
218862421|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
218862422|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
218862423|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
219478108|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
218862424|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
219478109|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
219478110|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
219478111|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
219478112|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
219478113|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
219478114|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
219478115|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
219478116|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
219478117|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
219478118|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
219478119|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
219478120|NCT03401502|DRUG|Placebos|Oral, b.i.d
219478121|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
219597392|NCT02793505|DRUG|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
219597393|NCT01026311|DRUG|Coenzyme q 10|200 mg of Coenzyme q 10
219597394|NCT01026311|DRUG|placebo|1 placebo q d during treatment period
219597395|NCT04917471|DIETARY_SUPPLEMENT|Beet root juice|70 ml bid
219597396|NCT04917471|DIETARY_SUPPLEMENT|Placebo juice|70 ml bid
219597397|NCT02520297|DRUG|TRV130|Drug
219597398|NCT00111553|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
219597399|NCT05671016|PROCEDURE|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
219597400|NCT05795647|DRUG|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
218862425|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
218862426|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
218862427|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
218862428|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
219597401|NCT01321463|DRUG|PH-797804|6 mg oral tablet once daily for 12 weeks
219478122|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
219478123|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
219478124|NCT02432027|DRUG|Daivonex cream|comparator
219478125|NCT02432027|DRUG|Diprosis gel|comparator
219478126|NCT01298362|DRUG|Aromatase Inhibitors|
219478127|NCT01298362|DRUG|Chemotherapy|
219478128|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
219478129|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
219478130|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
219478131|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
219597402|NCT01321463|DRUG|Placebo|Placebo oral tablet once daily for 12 weeks
218862429|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
218862430|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
218862431|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
219478132|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
219478133|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
218862432|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
218862433|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
218862434|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
218862435|NCT01004016|DRUG|KPS-0373|
218862436|NCT01004016|DRUG|Placebo|
218862437|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
218862438|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
219478134|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
219478135|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
219597403|NCT03564418|PROCEDURE|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
219613561|NCT07001735|BEHAVIORAL|Talking for Change Group Psychotherapy|Talking for Change (TFC) is a secondary prevention program that targets dynamic risk factors for child sexual abuse, including (1) atypical sexual interests and sexual self-regulation problems; (2) problems in relationships; (3) offense-supportive attitudes; and (4) general self-regulation deficits and related traits (e.g., impulsivity, emotion regulation deficits). Participants will complete 20 weekly, 120-minute sessions delivered via WebEx.
219478136|NCT04804319|OTHER|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
219478137|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
219478138|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
219478139|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
219478140|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
219478141|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
218862439|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
218862440|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
218862441|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
218862442|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
218862443|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
218862444|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
218862445|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
218862446|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
218862447|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
218862448|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
218862449|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
218862450|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
219478142|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1\) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
219478143|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
218862451|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
218862452|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
218862453|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
218862454|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
218862455|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
218862456|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
218862457|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
219478144|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
219478145|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
218862458|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
218862459|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
218862460|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
218862461|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
218862462|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
219478146|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
219478147|NCT04128059|OTHER|placebo|placebo
219613562|NCT07001735|BEHAVIORAL|Healthier Me: Managing Risk and Stress in Everyday Life|The active therapeutic control is a non-directive supportive psychotherapy that targets general mental health concerns. It consists of psychoeducation about human sexuality and common mental health concerns, as well as instruction and practice in applied relaxation and stress management, and group discussions that will facilitate sharing and problem-solving current stressors. This active control intervention is equivalent in length to Talking for Change (TFC), consisting of 120-minute long occurring weekly over the course of 20 weeks.
219613563|NCT02466321|PROCEDURE|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
218862463|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
218862464|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
219478148|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
218862465|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
218862466|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
218862467|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
218862468|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
218862469|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
219478149|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
218862470|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
218862471|NCT00003136|BIOLOGICAL|filgrastim|
218862472|NCT00003136|DRUG|amifostine trihydrate|
218862473|NCT00003136|DRUG|carboplatin|
218862474|NCT00003136|DRUG|cyclophosphamide|
218862475|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
218862476|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
218862477|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
218862478|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
218862479|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
218862480|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
218862481|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
218862482|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
218862483|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
218862484|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
218862485|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
218862486|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
218862487|NCT01053013|BIOLOGICAL|RENCA macrobeads|
219199632|NCT06725212|DEVICE|Water Vapor Thermal Ablation|The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
218862492|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
218862493|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
218862494|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
218862495|NCT01873053|DRUG|Placebo|
218862496|NCT02073838|DRUG|Ribavirin|
218862497|NCT02073838|DRUG|Vismodegib|
218862498|NCT02073838|DRUG|Decitabine|
218862499|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
218862500|NCT00232388|PROCEDURE|Blood draw|
219478150|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
219478151|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
219478152|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
219478153|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
219478154|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
218862501|NCT00241514|DRUG|Esomeprazole|
218862502|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
219478155|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
219478156|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
219478157|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
219478158|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
219478159|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
219478160|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
219478161|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
219478162|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
218862503|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
218862504|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
218862505|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
218862506|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
218862507|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
219478163|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
219478164|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
219478165|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
219478166|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
219478167|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
219478168|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
219478169|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
219478170|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
218862508|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
218862509|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
218862510|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
218862511|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
218862512|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
218862513|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
218862514|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
218862515|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
218862516|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
218862517|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
218862518|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
218862519|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
218862520|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
218862521|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
219478171|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
219478172|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
219020807|NCT07207304|PROCEDURE|Anesthesia|Patients diagnosed with hepatocellular carcinoma will be randomly assigned to one of four groups. They will receive standard anesthesia with maintenance based on either sevoflurane or propofol. Two of the groups will additionally receive intravenous lidocaine, administered from induction until the end of surgery. Blood samples will be collected preoperatively and six hours postoperatively to measure citrullinated histone H3 (H3Cit), a reliable biomarker of NETosis. Additional inflammatory markers will also be analyzed. All patients will be followed for a period of one year
219478173|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
218862522|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
218862523|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
218862524|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
218862525|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
219478174|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
218862526|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
218862527|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
218862528|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
218862529|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
218862530|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219478175|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
219478176|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
219597404|NCT03564418|PROCEDURE|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
219597405|NCT01656538|DRUG|Paclitaxel|
219597406|NCT01656538|DRUG|Reolysin|
219597407|NCT05644600|DRUG|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
219597408|NCT05644600|DRUG|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
219597409|NCT00315731|BIOLOGICAL|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
218862531|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
218862532|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
218862533|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
218862534|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
218862535|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
218862536|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
219020808|NCT07207304|PROCEDURE|Anesthesia induction with TCI|During induction, patients will receive fentanyl (2-3 µg/kg), propofol (1-1.5 mg/kg) as a bolus or via TCI, and rocuronium (0.5-0.6 mg/kg) to facilitate anesthesia induction and ensure adequate neuromuscular relaxation for endotracheal intubation. Anesthesia will be maintained using TIVA with 1% propofol administered via TCI, guided by the Schneider pharmacokinetic model. The initial target effect-site concentration will be 4 µg/mL and will be titrated intraoperatively to maintain a BIS value between 40 and 59.
219478177|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
219478178|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
219478179|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
219478180|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
219478181|NCT04141085|OTHER|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
219478182|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
219597410|NCT06457165|DEVICE|Difficult Intubation|Noted for each patient.
219597411|NCT06457165|DEVICE|Not Difficult Intubation|Noted for each patient.
219597412|NCT04614246|DRUG|BAY1817080|Tablet, oral administration
218862537|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
218862538|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
218862539|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
219478183|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
219478184|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
219597413|NCT04614246|DRUG|Elagolix|Tablet, oral administration
219597414|NCT04614246|DRUG|Placebo|Tablet, oral administration
219597415|NCT01851200|DRUG|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
219597416|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
219597417|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
219597418|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
219478185|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
219478186|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
219478187|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
218862540|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
218862541|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
219478188|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
219478189|NCT00762073|DRUG|budesonide|oral suspension
219478190|NCT00762073|DRUG|placebo|oral suspension matching budesonide
219478191|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
219478192|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
219478193|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
219478194|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
219478195|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
219597419|NCT01680497|DEVICE|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
219597420|NCT00725205|BIOLOGICAL|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
218862542|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
218862543|NCT04564248|OTHER|Website access|website access will be provide to families
218862544|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
218862545|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
219478196|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
219478197|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
219478198|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
219478199|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
219478200|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
219478201|NCT04622540|PROCEDURE|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
219478202|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
219478203|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
219478204|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
219478205|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
219478206|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
219478207|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
219478208|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
219478209|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
219478210|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
219478211|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
219478212|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
219478213|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
219478214|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
219478215|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
219478216|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
219478217|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
219478218|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
219478219|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
219478220|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
218862546|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
219478221|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
219478222|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
219478223|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
219478224|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
218862547|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
219478225|NCT04954625|PROCEDURE|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
219478226|NCT04954625|PROCEDURE|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
219478227|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
219478228|NCT02001038|OTHER|Survey|
219478229|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
219478230|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
219478231|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
219478232|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
219478233|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
219478234|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
219478235|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
219478236|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
219478237|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
219478238|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
218862548|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
218862549|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
218862550|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
218862551|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
218862552|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
218862553|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
218862554|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
219199633|NCT06725212|DEVICE|Cystoscopy|Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
219478239|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
218862555|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
218862556|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
218862557|NCT00278330|DRUG|alvocidib|Given by infusion
218862558|NCT00278330|DRUG|vorinostat|Given orally
218862559|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
218862560|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
218862561|NCT00921310|DRUG|Pemetrexed|
218862562|NCT00921310|DRUG|Temsirolimus|
218862563|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
218862564|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
219478240|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
218862565|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
218862566|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
218862567|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
218862568|NCT06907797|BEHAVIORAL|TRIAL Web-Based Application|A web-based application that provides disease and trial education and access to resources provided by the Leukemia and Lymphoma Society (LLS). iPads will be provided to participants for 14 days.
218862569|NCT00001307|DRUG|Oxygen-15 Water|
218862570|NCT00001307|DRUG|Capsaicin|
218862571|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
218862572|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
218862573|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
218862574|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
219199634|NCT01756300|DEVICE|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
218862575|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
218862576|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
218862577|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
218862578|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
218862579|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
218862580|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
218862581|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
218862582|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
218862583|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
218862584|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
218862585|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
218862586|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
218862587|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
218862588|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
218862589|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
218862590|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
219020809|NCT07207304|PROCEDURE|sevoflurane anesthesia|"During induction, patients will receive fentanyl (2-3 µg/kg), propofol (1-1.5 mg/kg), and rocuronium (0.5-0.6 mg/kg) to facilitate anesthesia induction and ensure adequate neuromuscular relaxation for endotracheal intubation.~For patients in the inhalation anesthesia group, maintenance will be performed using sevoflurane. The end-tidal concentration of sevoflurane (EtSevo) will be maintained between 1.0 and 1.5 MAC, with adjustments in increments or decrements of 0.25-0.5 MAC, depending on the BIS value, which will be maintained between 40 and 59."
219020810|NCT07207304|DRUG|Lidocaine Infusion|During induction, a 1.5 mg/kg intravenous bolus of 1% lidocaine will also be administered. In the maintenance phase of anesthesia, a continuous infusion of 1% lidocaine at 2 mg/kg/hour-up to a maximum of 200 mg/hour-will be administered, starting after endotracheal intubation and continued until emergence from anesthesia.
219478241|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
219199635|NCT03247309|BIOLOGICAL|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
219478242|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
219478243|NCT06568627|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
219478244|NCT06568627|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
219478245|NCT06165679|DRUG|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
219478246|NCT06165679|DRUG|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
219478247|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
219478248|NCT02195271|DRUG|Melatonin|
219478249|NCT05803941|DRUG|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.
219478250|NCT03660059|DRUG|Peficitinib|Oral
219478251|NCT03660059|DRUG|Plaebo|Oral
219478252|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
219478253|NCT02331680|DRUG|OPC-41061|
219478254|NCT02331680|DRUG|OPC-41061|
218862591|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
218862592|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
219478255|NCT02331680|DRUG|Placebo|
219478256|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
219478257|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
219478258|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
219478259|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
219478260|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
219478261|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
219478262|NCT06273904|DEVICE|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
219478263|NCT06273904|DEVICE|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
219478264|NCT04477343|DRUG|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
219478265|NCT04477343|DRUG|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
219478266|NCT01068041|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
219478267|NCT00602667|DRUG|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
219478268|NCT00602667|DRUG|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
219478269|NCT00602667|DRUG|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
219478270|NCT00602667|DRUG|Intermediate-Risk Therapy|"Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan."
219478271|NCT06566768|DRUG|Deucravacitinib|Specified dose on specified days
219478272|NCT01569321|DEVICE|MRI|
219478273|NCT01569321|DEVICE|PET-CT scan|
219478274|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
219478275|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
219478276|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
218862593|NCT00040508|DRUG|Sirolimus|
218862594|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
218862595|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
218862596|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
218862597|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
218862598|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
218862599|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
218862600|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
219478277|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
219478278|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
219478279|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
218862601|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
219478280|NCT05038228|DRUG|Apixaban|Anticoagulant
219478281|NCT05038228|DRUG|Rivaroxaban|Anticoagulant
219478282|NCT05038228|DRUG|Dabigatran|Anticoagulant
219478283|NCT05038228|DRUG|Vitamin K antagonist (VKA)|Anticoagulant
219478284|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
219478285|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
219597421|NCT00725205|DRUG|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
219597422|NCT02743429|DRUG|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
219597423|NCT03659929|DRUG|Amphetamine Sulfate|active experimental AR19
219597424|NCT03659929|DRUG|Placebo|Matching placebo
219597425|NCT02764346|BEHAVIORAL|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
219597426|NCT02764346|BEHAVIORAL|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
218862602|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
218862603|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
218862604|NCT00767234|PROCEDURE|Observation|Standard of Care
218862605|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
218862606|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
218862607|NCT02227836|DEVICE|Allergy Patch Testing|
218862608|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
219478286|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
219478287|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
219478288|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
219478289|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
219478290|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
219478291|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
219478292|NCT04103645|DRUG|Vactosertib|50 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
218862609|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
218862610|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
218862611|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
219478293|NCT04103645|DRUG|Vactosertib|100 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
219478294|NCT04103645|DRUG|Vactosertib|150 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
219478295|NCT04103645|DRUG|Vactosertib|200 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
219478296|NCT04103645|DRUG|Vactosertib|The lowest dose level of vactosertib for which no DLT was observed in Tier 1 AND The lowest dose level for which at least one of the 12 subjects enrolled on Tier 1 met Criteria for Clinical Benefit. Or, if a single dose level does not fulfil both Criterion 1 and Criterion 2, the starting dose level for Tier 2 will lowest dose from Tier 1 for which no DLT was identified.
219478297|NCT05198323|DRUG|LT3001 Drug Product|LT3001 Drug Product administered once by intravenous infusion
219478298|NCT05198323|DRUG|Placebo|Placebo administered once by intravenous infusion
219478299|NCT06975605|DRUG|Radiprodil + co-administered drugs|"Study drug radiprodil will be administered asbelow in a sequential manner.~\- Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.~Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg."
219478300|NCT02159742|OTHER|Data Collection|
219478301|NCT04410978|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
219478302|NCT04410978|DRUG|Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
219478303|NCT04410978|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
218862612|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
218862613|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
219478304|NCT04410978|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
218862614|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
219020811|NCT07207304|DRUG|Intraoperative analgesia|Intraoperative analgesia will be ensured by administering fentanyl 0.5-1 µg/kg as needed, based on clinical signs of inadequate analgesia (e.g., an increase in blood pressure or heart rate exceeding 20% of baseline, mydriasis, lacrimation, or diaphoresis)
219478305|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
218862615|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
218862616|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
218862617|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
218862618|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
218862619|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
219478306|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
219478307|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
218862620|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
218862621|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
218862622|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
219020812|NCT07207304|DRUG|Non-opioid analgesics|Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities, surgical particularities, extent of resection, and residual liver volume.
219020813|NCT07207304|DRUG|Morphine (+)|Postoperative analgesia will be provided with morphine at a dose of 0.1-0.2 mg/kg, administered 30 minutes before emergence from anesthesia. The administration will be performed intravenously, with the dose adjusted based on patient weight and clinical condition. Additional bolus doses may be given in the post-anesthesia care unit (PACU), guided by the patient's reported pain intensity using the Visual Analog Scale (VAS). In the PACU, morphine will be titrated starting with 2-5 mg IV given slowly over 4-5 minutes, with repeated doses every 5-10 minutes if needed, while closely monitoring respiratory rate, level of consciousness, and hemodynamic stability. For ongoing pain management, intermittent IV bolus dosing (typically 0.05-0.1 mg/kg every 4 hours as required) may be used, taking into account factors such as patient comorbidities, type of surgery, and residual hepatic function.
219020814|NCT07207304|DEVICE|Bispectral Index (BIS)|Bispectral index (BIS) monitoring will be used to guide the depth of anesthesia. The target BIS value will be maintained between 40 and 59 throughout the procedure to ensure adequate hypnosis while avoiding excessive anesthetic depth. BIS values will be continuously recorded and adjustments to anesthetic agents will be made accordingly.
219478308|NCT04820179|DRUG|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
219199636|NCT03247309|DIAGNOSTIC_TEST|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
219478309|NCT06212011|OTHER|Functional Neuromuscular Electrical Stimulation|The functional NMES technique involves the application of electrical stimulation during functional activity. In our study, in the functional neuromuscular electrical simulation group, neuromuscular electrical stimulation will be applied to the lumbar multifidus muscle while individuals perform the activity of standing up from sitting.
219478310|NCT06212011|OTHER|Conventional Neuromuscular Electrical Stimulation|The conventional neuromuscular electrical simulation technique, electrical stimulation is applied without the individual performing voluntary contractions. In our study, conventional NMES will be applied to the lumbar multifidus muscle with the individual lying in the prone position and the individual will not elicit any voluntary contractions during the simulation.
219478311|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
219597427|NCT03281018|BEHAVIORAL|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
219597428|NCT03310749|DRUG|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
219597429|NCT03310749|DRUG|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
218862623|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
218862624|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
218862625|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
219478312|NCT04813484|BEHAVIORAL|Kickin it with the Gulz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
219478313|NCT05396950|DEVICE|CPAP|CPAP in conjunction with radiotherapy
219478314|NCT05221762|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) at 3 Tesla
219478315|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
219478316|NCT04133675|DEVICE|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
218862626|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
218862627|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
218862628|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
218862629|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
218862630|NCT00003231|DRUG|cisplatin|
218862631|NCT00003231|DRUG|docetaxel|
218862632|NCT00003231|PROCEDURE|surgical procedure|
218862633|NCT00003231|RADIATION|radiation therapy|
218862634|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
218862635|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
218862636|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
218862637|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
218862638|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
219478317|NCT04133675|DEVICE|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
219478318|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
219478319|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
218862639|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
218862640|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
218862641|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
218862642|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
218862643|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
218862644|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
218862645|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
218862646|NCT00099229|DRUG|Licarbazepine|
218862647|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
218862648|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
219478320|NCT05653388|OTHER|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
219478321|NCT06308263|DRUG|Tuvusertib [14C]Tuvusertib microtracer|Participants will receive single oral dose of Tuvusertib containing a \[14C\] Tuvusertib microtracer solution on Day 1 of period 1 under fasted conditions.
219478322|NCT06308263|DRUG|Tuvusertib|Participants will also receive a single oral dose of Tuvusertib on Day 1 of Period 1 or Period 1a, and daily single oral dose of Tuvusertib for 2 weeks in 21 days cycle of Period 2.
219478323|NCT06308263|DRUG|Tuvusertib + [14C]Tuvusertib microdose bolus injection|In Period 1a, participants will receive on Day 1 of Period 1 a single oral dose of tuvusertib and an intravenous (IV) (14C) tuvusertib microdose as bolus injection.
218862649|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
218862650|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
218862651|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
219478324|NCT05182476|DRUG|Placebo|Oral tablets
219478325|NCT05182476|DRUG|Luvadaxistat|Oral tablets
219478326|NCT04099446|OTHER|Non-interventional|There is no intervention for this study
218862652|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
219478327|NCT02202811|BEHAVIORAL|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
219478328|NCT00900471|OTHER|biologic sample preservation procedure|
219478329|NCT00900471|OTHER|medical chart review|
219597430|NCT03310749|DRUG|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
219597431|NCT03667638|COMBINATION_PRODUCT|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
219597432|NCT04530955|DEVICE|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
219597433|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
219597434|NCT02340481|DRUG|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
219597435|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
219597436|NCT02340481|DRUG|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
218862653|NCT02973191|DRUG|JCAR015|
218862654|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
218862655|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218862656|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218862657|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218862658|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218862659|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218862660|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
218862661|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
218862662|NCT02191839|DRUG|Alpha 1-Antitrypsin|
218862663|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
218862664|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
218862665|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
219478330|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
219597437|NCT04187755|DRUG|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
219478331|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
219597438|NCT04187755|DRUG|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
219597439|NCT00408525|DRUG|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
219597440|NCT02115490|DRUG|Bisphosphonates|
219597441|NCT04981717|DRUG|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
219597442|NCT04981717|DRUG|Matching Placebo|SC for a total of 5 administrations
219597443|NCT04686955|DRUG|Xiao-Xian-Gui-Fu-Tang|The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
218862666|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
218862667|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
219478332|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
218862668|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
218862669|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
218862670|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
218862671|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~\- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~\- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
218862672|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
218862673|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
218862674|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
218862675|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
219478333|NCT06653777|DRUG|Pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
218862676|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
218862677|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
218862678|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
218862679|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
219020815|NCT07207304|PROCEDURE|Intraoperative mechanical ventilation|Intraoperative mechanical ventilation will be performed using a lung-protective strategy. Patients will be ventilated with a volume-controlled mode, using a tidal volume of 6-8 mL/kg of predicted body weight, a respiratory rate adjusted to maintain end-tidal CO₂ (EtCO₂) between 35-45 mmHg, and a positive end-expiratory pressure (PEEP) of minimum 6 cmH₂O. Fraction of inspired oxygen (FiO₂) will be set to maintain peripheral oxygen saturation (SpO₂) above 94%. Recruitment maneuvers may be applied periodically or as clinically indicated.
219478334|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
219478335|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
219478336|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
219478337|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
219478338|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
219478339|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
219478340|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
218862680|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
218862681|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
219478341|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
219478342|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
219597444|NCT01519310|OTHER|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
219597445|NCT02207634|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219597446|NCT02207634|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219597447|NCT02207634|DRUG|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
219597448|NCT05050812|DEVICE|grounding mat|Participants will sleep on an Earthing Elite sleep mat produced and sold by Earthing.com
219597449|NCT03275142|DEVICE|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
218862682|NCT03990805|DRUG|saline|saline, 1 time injection
218862683|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
218862684|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
219478343|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
219478344|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
219478345|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
219478346|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
219478347|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
219478348|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
219478349|NCT06253195|DRUG|BGB-43395|Administered orally.
219478350|NCT06253195|DRUG|Fulvestrant|Administered via intramuscular injection.
219478351|NCT06253195|DRUG|Letrozole|Administered orally.
219478352|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
219478353|NCT06978062|DRUG|Bemarituzumab|• Bemarituzumab will be given as a IV infusion
219478354|NCT06978062|DRUG|FLOT|FLOT will be given as a IV infusion
219597450|NCT00038025|DRUG|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
219597451|NCT00563329|PROCEDURE|Reduction Intervention + Adherence Intervention|
219597452|NCT00563329|BEHAVIORAL|Reduction Intervention|
219597453|NCT00563329|PROCEDURE|control|
219597454|NCT03691766|OTHER|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
219597455|NCT03691766|OTHER|Placebo|Device with sham light source
219597456|NCT01368653|BEHAVIORAL|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
219478355|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
218862685|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
218862686|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
218862687|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
218862688|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
218862689|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
218862690|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
218862691|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
218862692|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
218862693|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
218862694|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
218862695|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
218862696|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
218862697|NCT00306644|DRUG|Rosiglitazone|study drug
218862698|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
218862699|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
219478356|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
218862700|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
218862701|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
218862702|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
218862703|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
218862704|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
218862705|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
218862706|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
218862707|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
219478357|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
219478358|NCT06106633|DEVICE|TriNaV|Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
219478359|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
219478360|NCT04071769|DRUG|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
218862708|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
218862709|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
218862710|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
218862711|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
218862712|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
218862713|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
218862714|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
218862715|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
218862716|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
218862717|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
218862718|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
218862719|NCT00190047|DRUG|DP-b99|
218862720|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
218862721|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
218862722|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
219478361|NCT06537583|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
219478362|NCT06537583|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
219478363|NCT03277638|DRUG|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
219478364|NCT03277638|DRUG|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
219478365|NCT03277638|DRUG|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
219478366|NCT03277638|PROCEDURE|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
218862723|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
219478367|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
219478368|NCT06588725|BEHAVIORAL|Play Nicely|Multimedia tool and handbook designed to educate parents about healthy discipline strategies.
219478369|NCT06588725|BEHAVIORAL|Cavity Prevention Handout|Two page handout with information about how to prevent cavities.
218862724|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
219478370|NCT06589908|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
219478371|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
219478372|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
219478373|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
219478374|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
219478375|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
219478376|NCT03884556|DRUG|TTX-030|Variable dose and schedule
219478377|NCT03884556|DRUG|Pembrolizumab|Dose and schedule per standard of care
219478378|NCT03884556|DRUG|Gemcitabine|Dose and schedule per standard of care
219478379|NCT03884556|DRUG|nab paclitaxel|Dose and schedule per standard of care
219478380|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
219478381|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
219478382|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
219478383|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
219478384|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
219478385|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
219478386|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
219478387|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
219478388|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
218862725|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
218862726|NCT02146677|OTHER|Osteopathic manipulative treatment|
218862727|NCT02146677|OTHER|Sham therapy|
218862728|NCT02146677|OTHER|Usual care|
218862729|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
218862730|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
218862731|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
218862732|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
218862733|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
218862734|NCT02893826|DRUG|Enteral Nimodipine|
218862735|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
218862736|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
218862737|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
218862738|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
218862739|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
218862740|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
218862741|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
218862742|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
218862743|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
218862744|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
219478389|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
219478390|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
219597457|NCT01368653|BEHAVIORAL|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
218862745|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
218862746|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
218862747|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
218862748|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
218862749|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
218862750|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
218862751|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
218862752|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
218862753|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
219478391|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
219478392|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
219478393|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
219478394|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
219597458|NCT01368653|DRUG|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
219597459|NCT02101125|DRUG|BMS-986020|
219597460|NCT02101125|DRUG|Rosuvastatin|
219597461|NCT03054701|OTHER|Hip specific resistance exercise|Hip specific resistance exercise
219597462|NCT03054701|OTHER|Knee specific resistance exercise|Knee specific resistance exercise
218862754|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
218862755|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
218862756|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
218862757|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
218862758|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
219478395|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
219478396|NCT05687266|DRUG|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
219478397|NCT05687266|DRUG|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
218862759|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
218862760|NCT01898104|DRUG|Valproic Acid|
218862761|NCT01898104|DRUG|Capecitabine|
218862762|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
219478398|NCT05687266|DRUG|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
219478399|NCT05687266|DRUG|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
219478400|NCT05687266|DRUG|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
219478401|NCT05687266|DRUG|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219478402|NCT05687266|DRUG|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
219478403|NCT02008396|DRUG|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
219478404|NCT02008396|DRUG|Midomafetamine HCl|Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
219478405|NCT02008396|BEHAVIORAL|Therapy|Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
219478406|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
219478407|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
219478408|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
219478409|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
219478410|NCT00179101|PROCEDURE|Deep Brain Stimulation|
219597463|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
219597464|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
219597465|NCT00591773|DRUG|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
219597466|NCT00264173|DRUG|Valproate sodium|
219597467|NCT00459355|BEHAVIORAL|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
219199637|NCT06722092|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
218862763|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
218862764|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
218862765|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
218862766|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
218862767|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
218862768|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
218862769|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
218862770|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
218862771|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
218862772|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
218862773|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
218862774|NCT04064346|DRUG|Placebo|Matching placebo
218862775|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
218862776|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
219199638|NCT06722092|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and prerecorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
218862777|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
218862778|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
218862779|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
218862780|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
218862781|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
219478411|NCT06854406|DRUG|Varenicline|Initial, 0.5 mg orally once daily for 3 days, then 0.5 mg every 12 hours on days 4 through 7, and then 1 mg in morning of day 8. Medication is taken after eating and with a full glass of water.
219478412|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
219478413|NCT07005232|DEVICE|defibrillation lead|This is a device registry for the OmniaSecure™ defibrillation lead. The OmniaSecure lead is a steroid eluting, integrated bipolar, nonretractable screw-in, catheter delivered, transvenous ventricular lead with a Right Ventricular (RV) defibrillation coil electrode. The lead is designed for pacing, sensing, cardioversion, and defibrillation therapies, and has application for patients whom transvenous ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated.
219478414|NCT07006766|OTHER|Microsurgical Training Models|"Four models will be compared: Japanese shirataki konjac noodle, Dragon skin silicone vessel, standard silicone vessel from Microsurgery and Regenerative Medicine (MSRM) lab, and the blue-blood chicken thigh model."
219478415|NCT07005596|DEVICE|Passy-Muir Speaking Valve|This intervention group receives early speaking valve intervention during ventilator weaning.
219478416|NCT07005596|BEHAVIORAL|Standard Non-Verbal Communication Methods|This control group continues using conventional non-verbal communication methods such as gestures and lip-reading.
218862782|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
218862783|NCT03689244|DRUG|Placebo|Oral tablets without active compound
218862784|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
218862785|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
218862786|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
218862787|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
218862788|NCT00053547|DRUG|paricalcitol injection|
218862789|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
218862790|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
218862791|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862792|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862793|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862794|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862795|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862796|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
218862797|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
218862798|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
218862799|NCT03738007|DEVICE|Perlane|Treatment with Perlane
218862800|NCT00227513|DRUG|bortezomib|Given IV
218862801|NCT00227513|DRUG|vorinostat|Given orally
218862802|NCT00199667|DRUG|Mycophenolate Mofetil|
218862803|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
218862804|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
218862805|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
218862806|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
218862807|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
218862808|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
218862809|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
218862810|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
219597468|NCT01849965|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
218862811|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
219478417|NCT07005531|PROCEDURE|Ultrasound-Guided Microbubble Clearance During Circuit Priming|CRRT circuits will be primed under real-time ultrasound monitoring. A portable ultrasound probe will be used to scan key points in the circuit and filter to detect and guide the removal of residual microbubbles before treatment. The process is considered complete when three consecutive scans (at 2-minute intervals) show no detectable microbubbles.
219478418|NCT07005193|DEVICE|Using rang hood during cooking|Cooking ventilation facilities
219478419|NCT07005193|BEHAVIORAL|Using liquefied gas for cooking|Using liquefied gas instead of solid fuels for cooking
219478420|NCT07007078|DRUG|dihydroartemisinin|DHA 40mg tid for 90 days
218862812|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
218862813|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
218862814|NCT03394690|OTHER|control|2 capsuls
218862815|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
218862816|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
218862817|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
218862818|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
218862819|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
218862820|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
219478421|NCT07011563|BEHAVIORAL|Intervention|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, b) individualized information about HIV risk reduction including PrEP, and c) use of motivational interviewing strategies to discuss barriers to PrEP.~Parents: brief (\~20-30 min) web-based, interactive learning module (module) designed to provide information about sexual health communication (SHC) best practices, HIV prevention strategies (e.g., condoms, STI testing, PrEP), as well as build practical skills around SHC using evidence-based behavior change methods (e.g., building confidence, aligning values with actions)."
219478422|NCT07011563|BEHAVIORAL|Control|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, and b) didactic information about condom use, STI testing (including HIV), and PrEP (but not motivational interviewing or individualized information on HIV risk reduction).~Parent: brief written information on a digital platform (i.e., website) with advice about talking to youth about sexual health with web-links to resources about STI/HIV prevention and PrEP. This information will not be interactive or use behavior change methods."
219597469|NCT01849965|DRUG|placebo vehicle gel|
219597470|NCT01849965|DRUG|Standard of Care gel, Aquasite|
219597471|NCT03579108|OTHER|Retrospective Chart Review|Chart review
219597472|NCT05439681|DEVICE|Theranova 400|medium cut off (MCO) membrane
219597473|NCT05439681|DEVICE|FX 10|low-flux membrane
218862821|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
218862822|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
219039983|NCT04134000|DRUG|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
219039984|NCT02997033|OTHER|No intervention|No intervention
219039985|NCT05180136|DIETARY_SUPPLEMENT|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
219597474|NCT05439681|DEVICE|FX CorDiax 800|high-flux membrane
219597475|NCT05439681|DEVICE|HDF|hemodiafiltration
219597476|NCT02998697|DRUG|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
219597477|NCT02998697|DRUG|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
219597478|NCT01068145|DRUG|SCH 527123|Very low dose SCH 527123, once daily for 7 days
219597479|NCT01068145|DRUG|SCH 527123|Low dose SCH 527123, once daily for 7 days
219597480|NCT01068145|DRUG|SCH 527123|Medium dose SCH 527123, once daily for 7 days
219597481|NCT01068145|DRUG|SCH 527123|High dose SCH 527123, once daily for 7 days
219597482|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
219597483|NCT01068145|DRUG|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
219597484|NCT01068145|DRUG|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
219597485|NCT01068145|DRUG|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
219597486|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
218862823|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
218862824|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
218862825|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
219478423|NCT06125483|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
219478424|NCT07005089|PROCEDURE|Laparotomy or laparoscopic ovarian cystectomy|to evaluate diagnostic accuracy of ultrasound and tumors markers in diagnosis of complex ovarian cysts in adolescent with histopathological correlation.
219478425|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
218862826|NCT00040807|DRUG|docetaxel|
218862827|NCT00040807|DRUG|irinotecan hydrochloride|
218862828|NCT06002516|OTHER|RELIEF-pathway|"The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory."
218862829|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
218862830|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
218862831|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
218862832|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
218862833|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
218862834|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
218862835|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
218862836|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
218862837|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
218862838|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
219039986|NCT05180136|DIETARY_SUPPLEMENT|Control group|Placebo 1,000 mg/day for 8 weeks
219039987|NCT04582851|OTHER|some risk factors correlated with TMD|exposure factors causing TMD
219597487|NCT01358214|BEHAVIORAL|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
219597488|NCT02135614|DRUG|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
219597489|NCT02135614|DRUG|Presatovir placebo|Presatovir placebo tablets administered orally
219597490|NCT05768581|OTHER|Concurrent Training|Participants should perform strength training and aerobic exercises
219597491|NCT05768581|OTHER|Strength Training|Participants should perform strength exercises
218862839|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
218862840|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
218862841|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
218862842|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
218862843|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
218862844|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
219478426|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
219478427|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
218862845|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
218862846|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
218862847|NCT05225259|DRUG|LOXO-260|Oral
218862848|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
218862849|NCT04429399|OTHER|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
218862850|NCT04429399|OTHER|mechanical features assessment|evaluation of the mechanical features of respiratory system
219478428|NCT07019688|OTHER|Standard Information|Participants will receive only the standard written information routinely provided prior to dental procedures. This version does not include any additional content related to frequently asked questions.
219478429|NCT07019688|OTHER|Clinician Information|Participants will receive written information prepared by clinicians, which includes responses to the most frequently asked questions collected from patients undergoing same procedures.
219478430|NCT07019688|OTHER|AI Info|Participants will receive written information generated by ChatGPT, based on the identified frequently asked questions and formulated specifically for this study.
219478431|NCT07023484|DIAGNOSTIC_TEST|KELIM|(i) Patients with KELIM =\>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery
219478432|NCT07023484|DRUG|Carboplatin plus Paclitaxel|Neoadjuvant chemotherapy
219478433|NCT07023484|PROCEDURE|Interval debulking surgery|Interval debulking surgery
219478434|NCT06871306|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|taVNS was performed using the Vagustim device (Vagustim Health Technologies, Teknokent, Istanbul, Türkiye) at the tragus and concha regions for 30 minutes, with a frequency of 25 Hz and a pulse width of 300 µs in both groups. The difference in stimulation between the groups depends only on to which ear it was applied. Electrical stimulation was increased in 0.1 mA steps until the detection threshold was reached.
218862851|NCT04429399|OTHER|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
218862852|NCT02032407|DRUG|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
218862853|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
218862854|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
218862855|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
219020816|NCT07207304|PROCEDURE|Blood sampling|A total of 10 mL of peripheral venous blood will be collected from each patient at two time points: preoperatively (baseline) and 6 hours after surgery. These samples will be used to quantify the concentration of neutrophil extracellular trap (NET)-associated biomarkers, including myeloperoxidase-DNA complexes (MPO-DNA) and cell-free DNA (cfDNA), which are closely associated with NET formation. Following collection, samples will be centrifuged at 1000 rpm, and the resulting plasma will be aliquoted and stored at -80 °C for later analysis. In parallel, additional inflammatory and metabolic markers will be measured, including C-reactive protein (CRP), total leukocyte count, blood glucose, procalcitonin, and interleukin levels (IL-6, IL-8, IL-10, and IL-17) in selected patients. All participants will be monitored for a period of one year to assess the incidence of postoperative complications and cancer recurrence, including metastasis.
219020817|NCT07206394|OTHER|ScarWork therapy|ScarWork is a manual therapy technique involving gentle, hands-on massage of scar tissue. It is designed to improve the mobility and integration of scar tissue, reduce discomfort, and support tissue healing. The approach is tailored to each individual, based on the characteristics of their scar and sensitivity of the surrounding tissue. It is commonly used with people recovering from surgery or radiotherapy to help address symptoms such as pain, tightness, numbness, or altered sensation. In this study, participants in the intervention group will receive up to five ScarWork sessions delivered by a trained therapist, in addition to standard care.
218862856|NCT05406609|OTHER|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
218862857|NCT05406609|OTHER|Time|Time of using operating room
219039988|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
218862858|NCT03737877|OTHER|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners."
219478435|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
218862859|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
219478436|NCT00069654|PROCEDURE|Forearm blood flow study|
219478437|NCT00069654|PROCEDURE|Brachial artery reactivity study|
219478438|NCT00069654|PROCEDURE|Treadmill exercise test|
219478439|NCT02576951|DRUG|Galcanezumab|Administered SC
219478440|NCT02576951|DRUG|Placebo|Administered SC
219478441|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
219478442|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
219478443|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
219478444|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
219478445|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
219478446|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
219478447|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
219478448|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
219478449|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
219478450|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
219478451|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
219478452|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
218862860|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
218862861|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
218862862|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
218862863|NCT02379468|DRUG|Pedyphar Ointment|
218862864|NCT02379468|DRUG|Panthenol|Ointment
219478453|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
219478454|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
219478455|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
219478456|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
219597492|NCT05768581|OTHER|Aerobic training|Participants should perform aerobic exercises
219597493|NCT03675061|OTHER|Current care|Tocolysis and a complete corticosteroid treatment.
218862865|NCT02248363|OTHER|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
219478457|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
219478458|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
219478459|NCT02218619|DRUG|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
219478460|NCT02218619|DRUG|Sugar Pill (placebo)|Placebo
219478461|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
219478462|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
219478463|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
219478464|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
219478465|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
219478466|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
219478467|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
219478468|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
219478469|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
219478470|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
219478471|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
219478472|NCT01352923|OTHER|blood test|preparation of blood platelets
219478473|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
219478474|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
219478475|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
219478476|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
219597494|NCT03675061|DEVICE|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
219597495|NCT03675061|DEVICE|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
219597496|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
219478477|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
219478478|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
219478479|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
219478480|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
219478481|NCT02827747|OTHER|Placebo|Placebo pill
219478482|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
219478483|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
219478484|NCT06709612|DRUG|AMT-143 hydrogel containing containing ropivacaine|AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine HCl equivalence basis). AMT-143 hydrogel will be provided as pre-filled syringes for administration via instillation into the surgical site after surgery and prior to suture.
219478485|NCT06709612|DRUG|Ropivacaine|5 mL Ropivacaine 10 mg/mL (1%) solution
219478486|NCT06709612|OTHER|Placebo|Saline Placebo
219597497|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
218862866|NCT06104098|DEVICE|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
218862867|NCT05067751|DEVICE|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
219478487|NCT06716008|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
219478488|NCT06716008|OTHER|Manual Diaphragm Release|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
219478489|NCT06724211|OTHER|Treatment bundle of care|The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
219478490|NCT06724211|OTHER|Control Group|Routine clinical care for kidney transplant patients
219478491|NCT06724263|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
219478492|NCT06723847|PROCEDURE|Robotic pancreaticoduodenectomy|All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
219478493|NCT06724042|DRUG|ISM5939|ISM5939 tablets will be administered orally once daily (QD).
219199639|NCT06872736|DEVICE|WeFun-wearable activated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the experimental group will have the wearable's experimental movement functions activated.
218862868|NCT04787055|DEVICE|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
218862869|NCT05874622|DRUG|VC005 tablets|VC005 groups repeat administration for 4 weeks
218862870|NCT05874622|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
219478494|NCT06724042|DRUG|Cisplatin|Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
219478495|NCT06724042|DRUG|Docetaxel|Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
219478496|NCT06724042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
219478497|NCT06722456|DIAGNOSTIC_TEST|Analysis of protein signatures in stool samples|Stool protein signatures are to be established in parallel to standard clinical evaluation of the intestinal inflammatory activity.
218862871|NCT05828667|OTHER|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
218862872|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
218862873|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
219597498|NCT05409586|PROCEDURE|segmental mastectomy|The preferred method in the treatment of some patients diagnosed with IGM
219597499|NCT05415163|PROCEDURE|vascular photobiomodulation|application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
219597500|NCT02147041|DRUG|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
219597501|NCT02147041|DRUG|Placebo|
219597502|NCT00033007|BEHAVIORAL|Behavior Therapy|
219597503|NCT01507311|DRUG|liraglutide|A single dose injected subcutaneously (under the skin)
219597504|NCT01507311|DRUG|placebo|A single dose injected subcutaneously (under the skin)
219597505|NCT01726829|DEVICE|MD-Logic Artificial Pancreas (MDLAP) system|
219597506|NCT01726829|PROCEDURE|sensor augmented pump therapy|
219597507|NCT02655731|DEVICE|PVI with HeartLight|Catheter ablation
219597508|NCT01542801|DRUG|Norfloxacin|Norfloxacin 400 mg per day
219597509|NCT01542801|DRUG|ciprofloxacin|Ciprofloxacin 750 mg per week
219597510|NCT02495259|DEVICE|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
219597511|NCT02495259|DEVICE|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
218862874|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
218862875|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
218862876|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
218862877|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
218862878|NCT00783081|DRUG|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
218862879|NCT00783081|DRUG|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
218862880|NCT00783081|DRUG|Placebo|Placebo BID for 26 weeks.
218862881|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
218862882|NCT00373945|DRUG|Observational Study|
218862883|NCT03769987|OTHER|observation|observe patients every 6 months
218862884|NCT05648019|BIOLOGICAL|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
218862885|NCT06065891|PROCEDURE|PALN resection|Resection of paraaortic lymph nodes in pancreatic cancer
218862886|NCT01545427|DRUG|Imatinib mesylate|200 mg bid for 6 months
218862887|NCT01545427|OTHER|Placebo|Placebo coated to match appearance of Gleevec identically.
219478498|NCT06724107|RADIATION|UVC|It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
219478499|NCT06724497|PROCEDURE|face scanning pre and post orthognathic surgery|patient will be scanned pre operative using both scanners and then undergo orthognathic surgery then will be rescanned again 6 montsh later
219478500|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
219478501|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
219478502|NCT06724835|DRUG|XKDCT293|Autologous targeted Nectin4 chimeric antigen receptor T cell injection
219478503|NCT06724835|OTHER|CAR-T cell|Nectin-4-CAR-T
219597512|NCT02495259|DEVICE|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
219597513|NCT02495259|DEVICE|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
218862888|NCT00960479|DRUG|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
218862889|NCT00960479|DRUG|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
218862890|NCT06587685|DRUG|PG-011Gel|Twice daily for 52 weeks or 44 weeks
218862891|NCT06587685|DRUG|Vehicle|Vehicle Gel twice daily for 8 weeks
218862892|NCT03519295|DRUG|MPDL3280A|MPDL3280A administered every 2 weeks at 800 mg for 12 months.
218862893|NCT03519295|DRUG|mDCF|8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
218862894|NCT02384434|DEVICE|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
218862895|NCT06416722|OTHER|Cognitive-Motor Dual Task Activities|Patients included in this group will be given additional cognitive tasks (e.g. counting months, subtracting 5 from 100) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
218862896|NCT06416722|OTHER|Motor-Motor Dual Task Activities|Patients included in this group will be given additional motor tasks (e.g. passing the ball from the right hand to the left hand while standing on a soft surface, clapping) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
218862897|NCT06416722|OTHER|Cognitive-Motor & Motor-Motor Dual Task Activities|Simultaneously with balance and large amplitude functional activities (such as stepping forwards-sideways-backwards, sitting and standing), patients included in this group will be given additional cognitive (e.g. counting while standing with feet closed) and motor (e.g. passing the ball from the right hand to the left hand while standing on a soft surface) tasks in accordance with the physiotherapist's commands.
218862898|NCT04715646|DRUG|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
218862899|NCT06030180|DEVICE|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
219597514|NCT02495259|DEVICE|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
219597515|NCT05097365|DIETARY_SUPPLEMENT|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
219597516|NCT05097365|DIETARY_SUPPLEMENT|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
219597517|NCT03718650|DRUG|Pimonidazole|Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
218862900|NCT06481566|RADIATION|stereotactic ablative body radiotherapy|The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
218862901|NCT06059716|BEHAVIORAL|Gluten detection technology|Portable technology to sense gluten after ingestion
218862902|NCT06059716|BEHAVIORAL|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
218862903|NCT06240728|DRUG|NPX887|NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
218862904|NCT04886986|DRUG|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
218862905|NCT04886986|DRUG|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
218862906|NCT04886986|DRUG|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
219478504|NCT07047261|PROCEDURE|Adjunctive use of Xanthan-Chlorexidine based gel|"The chlorhexidine and xanthan-based gel contains 0.5% chlorhexidine digluconate, 1% chlorhexidine dihydrochloride, and 0.5% xanthan gel. Xanthan is a polymer that creates a three-dimensional, pseudo-plastic network with water, forming a stable gel that allows a slow and prolonged release of chlorhexidine, allowing effectiveness for about 30 days. Chlorhexidine digluconate is released immediately upon application, whereas Chlorhexidine dihydrochloride is gradually delivered the following days, providing bacteriostatic and bactericidal effects for up to two weeks, helping the prevention of recolonization of treated site.~The clinician cleaned and dried the implant site using compressed air and applied the XanCHX gel on the implant sites assigned to the test group, positioning the blunt needle at the bottom of the pocket and gently extruding the product while moving it out of the site. Finally, the patient was instructed not to drink or rinse for the following hour."
218862907|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
219597518|NCT03718650|PROCEDURE|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
219597519|NCT02153463|BEHAVIORAL|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
218862908|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
218862909|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
218862910|NCT00240110|DRUG|Placebo|Control arm
218862911|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
219478505|NCT06887062|DRUG|Bosentan|6 weeks of treatment with Bosentan, a dual endothelin receptor antagonist, administered to the large vessel vasculitis patient group
219478506|NCT07047495|OTHER|prostate patient|patients with prostate cancer treated with RT at IEO
219478507|NCT07047495|OTHER|breast patients|patients with breast cancer treated with RT at IEO
219478508|NCT06722742|DRUG|Ketamine only|Inj: Ketamine given to group K following spinal anesthesia
219597520|NCT03074786|DRUG|Dapivirine|Silicone elastomer vaginal matrix ring
219597521|NCT03074786|DRUG|Truvada|Tablets to be taken orally daily
219597522|NCT01708967|PROCEDURE|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
219597523|NCT00789243|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
219478509|NCT06722742|DRUG|Tramadol|Inj Tramadol given to group T following spinal anesthesia
219597524|NCT04417413|DEVICE|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
219597525|NCT01275729|DRUG|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
219597526|NCT00131495|DRUG|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
218862912|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
218862913|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
218862914|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
218862915|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
218862916|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
218862917|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
218862918|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
218862919|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
218862920|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
218862921|NCT00005875|DRUG|rubitecan|
218862922|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
218862923|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
219478510|NCT07046962|OTHER|Intervention Type Device: Manual pump expressing breast milk|"Since this study aimed to examine the macronutrient content of milks expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, hand pumping and electric pumping.~Hand expressing: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
219597527|NCT00131495|DRUG|Placebo patch|placebo patch changed twice a week for one year
219597528|NCT04860609|OTHER|Conventional Physiotherapy|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
218862924|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
218862925|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
218862926|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
218862927|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
218862928|NCT00806143|DEVICE|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
218862929|NCT00806143|DEVICE|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
218862930|NCT00649831|DRUG|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
218862931|NCT00649831|DRUG|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
219199640|NCT06872736|DEVICE|WeFun-wearable desactivated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the control group will not have experimental functions in their wearables.
218862933|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
218862934|NCT02737150|DEVICE|CoreValve Evolut R|
218862935|NCT02737150|DEVICE|Edwards Sapien 3|
218862936|NCT02737150|PROCEDURE|Local anesthesia with conscious sedation|
218862937|NCT02737150|PROCEDURE|General anesthesia|
218862938|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
218862939|NCT04032301|DRUG|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
218862940|NCT04032301|OTHER|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
219199641|NCT06732713|OTHER|Swiss Ball|Swiss ball exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes , 3 to 4 sessions per week for 8 weeks
219478511|NCT07046962|OTHER|Intervention Type Device: Hand pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Manual pump expressing: Milk was expressed with a manual pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
218862941|NCT05490186|PROCEDURE|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
218862942|NCT04638127|BEHAVIORAL|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
218862943|NCT04638127|BEHAVIORAL|Attention Control|usual care and welcome videos
218862944|NCT02696993|PROCEDURE|Cognitive Assessment|Ancillary studies
218862945|NCT02696993|BIOLOGICAL|Ipilimumab|Given IV
219478512|NCT07046962|OTHER|Intervention Type Device: Electric pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Electric pump expressing: Milk was expressed with an electric pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
219478513|NCT07048821|DIETARY_SUPPLEMENT|Dietary modification|3-month dietary plan
219478514|NCT06719947|DEVICE|Active HD-tDCS|10 sessions of anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) with a defined electrical current intensity over the cortical representation zone of the left diaphragmatic motor cortex
219478515|NCT06719947|DEVICE|Simulated HD-tDCS|10 sessions of sham anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) over the cortical representation zone of the left diaphragmatic motor cortex. The device will provide a 30-second ramp and then maintain a minimal, non-effective continuous current
219478516|NCT06329921|OTHER|PTT protocol|Patients will be monitored using the nurse-managed PTT protocol.
219478517|NCT06329921|OTHER|anti-Xa protocol|Patients will be monitored using the pharmacy-managed anti-Xa protocol.
219478518|NCT06760481|DRUG|Tiragolumab|Given by IV
219478519|NCT06760481|DRUG|Atezolizumab|Given by IV
219478520|NCT06760481|RADIATION|Radiation Therapy|Given by IV
218862946|NCT02696993|OTHER|Laboratory Biomarker Analysis|Correlative studies
218862947|NCT02696993|BIOLOGICAL|Nivolumab|Given IV
218862948|NCT02696993|RADIATION|Stereotactic Radiosurgery|Undergo SRS
218862949|NCT02696993|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219478521|NCT06742502|DRUG|Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)|First strategy of targeted immunotherapy followed by chemotherapy for PMBL. Participants will first receive sintilimab(200mg) plus rituximab(375mg/m2) for 2 cycles. If patients achieve CR or CMR, they will continue to receive 2 courses of sintilimab plus rituximab, followed by 4 cycles of R-CHOP. Patients will receive 6 courses of R-CHOP if they do not achieve CR or CMR after 2 cycles of sintilimab plus rituximab. Patients will undergo PET-CT assessment and will receive 6 cycles of maintenance treatment with nintedanib if CR/CMR/PR is achieved and will be withdrawn from the study if SD/PD occurs. Total treatment cycles will not exceed 14 cycles.
219478522|NCT06900881|COMBINATION_PRODUCT|Kefir Mouth Wash|A kefir-based mouthwash was developed with active bacterial and yeast cultures, including Lactococcus lactis, Lactococcus cremoris, Lactococcus diacetylactis, Lactobacillus acidophilus, Saccharomyces cerevisiae, and Kluyveromyces lactis, along with maltodextrin and 3% fat milk. The recipe also calls for milk from Pegah, Iran. The milk is initially heated to boiling point and then allowed to cool to room temperature (25°C). After cooling, the kefir powder will be dissolved in the cooled milk and mixed well. For every 1 liter of milk, 3g of kefir starter yogurt (Yogourmet, France) will be added. The inoculated milk will then be transferred into a clean, airtight container, and the lid will be sealed. The container will be left at room temperature for approximately 24 hours until the kefir curd forms. After 24 hours, the kefir will be refrigerated for about 8 hours to halt the fermentation process.
219478523|NCT06900881|DRUG|Chlorhexidine 0,12%Biofresh Mouthwash|Chlorhexidine mouthwash is used as a standard treatment (Scitra Co for Biofresh LIC, P.O. Box 87218, Dubai, U.A.E.). It contains 0.12% Chlorhexidine Digluconate, purified water, sodium saccharin, cremophor, flavor, and glycerin.
219478524|NCT06887972|DRUG|Suzetrigine|Tablets for oral administration.
219478525|NCT03384836|OTHER|Laboratory Biomarker Analysis|Correlative studies
219478526|NCT03384836|BIOLOGICAL|Pembrolizumab|Given IV
219478527|NCT03384836|DRUG|Propranolol Hydrochloride|Given PO
219478528|NCT05844176|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international and local guidelines
219478529|NCT01721369|DIAGNOSTIC_TEST|Transient Loss of Consciousness (T-LOC)|
219597529|NCT04860609|OTHER|Lumber Spinal Decompression|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
218862950|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
218862951|NCT02247180|BEHAVIORAL|standardized cognitive training|
218862952|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
218862953|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
218862954|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
218862955|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
218862956|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
218862957|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
219478530|NCT06941935|OTHER|Etiological Classification and Digital Intervention|Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medication initiation, participants will continue to monitor their blood pressure through home diaries. Monthly evaluations will be conducted, and if blood pressure fails to reach the target value, medication adjustments will be made based on the blood pressure diary until target levels are achieved. This regimen will be maintained long-term.
219478531|NCT06943053|DEVICE|Isolate waterproof dressing (Opsite)|Application of standard Opsite® waterproof dressing directly over the surgical incision following primary total knee arthroplasty. No additional drape or coverage was applied. The dressing remained in place until removal.
219478532|NCT06943053|DEVICE|Ioban coverage group|Application of Ioban® iodine-impregnated antimicrobial incise drape over the standard waterproof dressing following primary total knee arthroplasty. The Ioban drape extends 2 cm beyond all edges of the dressing and remains in place until removal.
219478533|NCT06942533|DEVICE|EMST with SpiroGym app|"Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States). Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app.~The SpiroGym app video feedback: During a correct performance of the expiratory manoeuvre with the expiratory handheld device, the exhalation valve opens, and the air flow increases the sound level detected by the microphone. Simultaneously, the application gives visual feedback on the mobile phone screen in real time using a curve depicting the current sound level, and the task of the patient is to keep the curve in the training zone depicted by two lines corresponding to the low and high level, respectively."
219478534|NCT06942533|DEVICE|EMST without SpiroGym app|Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States) without video feedback . Participants will be instructed to perform five sets of five forceful expirations.
218862958|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
218862959|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
218862960|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
218862961|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
219478535|NCT06060314|PROCEDURE|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
219478536|NCT06060314|PROCEDURE|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
219478537|NCT05610813|DRUG|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
219478538|NCT05610813|DRUG|Opioid therapy|The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
219597530|NCT04813783|OTHER|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
218862962|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
219597531|NCT00040131|DRUG|IL-10|
218862963|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
218862964|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
218862965|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
218862966|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
218862967|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
218862968|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
218862969|NCT05917132|OTHER|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
218862970|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
219478539|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
219478540|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
219478541|NCT02871466|DRUG|stem cells infusion|
219478542|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
219478543|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
218862971|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
219478544|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
219478545|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
219478546|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
219478547|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
219478548|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
219478549|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
219199642|NCT06732713|OTHER|Frenkel exercise|Frenkel exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes, 3 to 4 sessions per week for 8 weeks
219199643|NCT06740136|OTHER|Exercise|Muscle induced-damage eccentric exercise
219199644|NCT06739174|DEVICE|Confidence Be 1-Piece Closed Bag|Active Chamber Filter - Circle Shape
219478550|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
219478551|NCT05647733|PROCEDURE|Low splanchnic blood volume restrictive fluid management strategy|Hemodynamic goal-directed restrictive fluid management strategy.
219478552|NCT05647733|PROCEDURE|Optimized cardiac output liberal fluid management strategy|Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
219478553|NCT05647733|PROCEDURE|Phlebotomy|Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
219478554|NCT01243645|BEHAVIORAL|biofeedback training|
219478555|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
219478556|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
219478557|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
219478558|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
219478559|NCT02337543|DRUG|Placebo|Placebo
219478560|NCT00202254|BEHAVIORAL|Physiotherapy|
219478561|NCT00202254|BEHAVIORAL|Occupational therapy|
219478562|NCT00202254|BEHAVIORAL|Speech pathology|
219478563|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
219478564|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
219199645|NCT06739174|DEVICE|Confidence Natural 1-Piece Closed Bag|Protective Filter - Circle Shape
219478565|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
219199646|NCT06739174|DEVICE|Confidence Be go 1-Piece Closed Bag|Active Chamber Filter - Hexagon Shape
219478566|NCT03315780|DRUG|Dulaglutide|Administered SC
219478567|NCT03315780|DRUG|Placebo|Administered SC
219478568|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
219478569|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
219478570|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
219478571|NCT00003582|DRUG|amifostine trihydrate|
219478572|NCT00003582|DRUG|cisplatin|
219597532|NCT04355065|BEHAVIORAL|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
219597533|NCT04355065|BEHAVIORAL|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
219597534|NCT04355065|DRUG|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
219597535|NCT02432157|DRUG|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
219597536|NCT02432157|DRUG|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
219597537|NCT02524457|OTHER|This is an observational study. There are no interventions|
219597538|NCT01038362|OTHER|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
219597539|NCT01038362|OTHER|No Almonds|NCEP Step 1 diet without almonds
219199647|NCT06870604|PROCEDURE|do open surgery|Open surgery was performed in patients undergoing gastric perforation
219597540|NCT04283968|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
219597541|NCT04283968|BIOLOGICAL|placebo fecal transplantation|placebo fecal transplantation
219597542|NCT05734248|PROCEDURE|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
219597543|NCT04400422|DIETARY_SUPPLEMENT|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
219199648|NCT06870604|PROCEDURE|do laparoscopic surgery|Laparoscopic surgery was performed in patients undergoing gastric perforation
219199649|NCT06734299|OTHER|Sunscreen A|Sunscreen A will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
219199650|NCT06734299|OTHER|Sunscreen B|Sunscreen B will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
219478573|NCT00003582|DRUG|fluorouracil|
219478574|NCT00003582|DRUG|paclitaxel|
219478575|NCT00003582|PROCEDURE|quality-of-life assessment|
219478576|NCT00003582|RADIATION|radiation therapy|
219478577|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
219478578|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
219478579|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
219478580|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
219478581|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
219478582|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
219478583|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
219478584|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
219478585|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
219478586|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
219478587|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
219478588|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
219478589|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
219478590|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
219478591|NCT00473928|DRUG|POT-4|Single intravitreal injection.
219478592|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
219478593|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
219597544|NCT02352012|OTHER|Autologous blood|Autologous blood was perfused to the target pulmonary segment
219597545|NCT02352012|DEVICE|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
219478594|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
219478595|NCT06439186|DRUG|Lidocain|Local anesthesia
219478596|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
219478597|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
219478598|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
219478599|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
219478600|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
219199651|NCT06734299|OTHER|Sunscreen C|Sunscreen C will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
219478601|NCT01947010|BIOLOGICAL|Prevenar 13|
219478602|NCT01947010|BIOLOGICAL|Pneumovax|
219478603|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
219478604|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
219478605|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
219478606|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
219478607|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
219478608|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
219478609|NCT01716442|DRUG|Placebo|
219478610|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
219478611|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
219478612|NCT01636011|OTHER|Light Touch sham|Light Touch sham
219478613|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
219478614|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
219478615|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
219478616|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
219478617|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY\_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY\_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
219478618|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY\_1) or in phase 2 of the study (subjects randomized to study arm ACWY\_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
219478619|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
219478620|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
219478621|NCT01863394|OTHER|Screening by mothers|
219478622|NCT01863394|OTHER|Active comparator: Screening by community health workers|
219478623|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
219478624|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
219478625|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
219478626|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
219478627|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
219478628|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
219478629|NCT02491086|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT
219478630|NCT02491086|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling
219478631|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
219478632|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
219478633|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
218862972|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
218862973|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
218862974|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
218862975|NCT04458831|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
218862976|NCT04458831|DRUG|Pomalidomide|Pharmaceutical form: oral
218862977|NCT04458831|DRUG|Dexamethasone|Pharmaceutical form: oral
218862978|NCT04458831|DRUG|Carfilzomib|Pharmaceutical form: solution for infusion
218862979|NCT04066348|BIOLOGICAL|Etanercept|To treat blast or noise induced tinnitus
218862980|NCT04066348|OTHER|Saline|Placebo
218862981|NCT06394869|DIAGNOSTIC_TEST|Cxbladder Triage Plus|Cxbladder Triage Plus is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
218862982|NCT01829568|DRUG|Ibrutinib|Given PO
218862983|NCT01829568|DRUG|Lenalidomide|Given PO
218862984|NCT01829568|BIOLOGICAL|Rituximab|Given IV
219478634|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
219478635|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
219478636|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
219478637|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
219478638|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
219478639|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
219478640|NCT00594568|DRUG|LY450139|Administered orally once daily
218862985|NCT04521686|DRUG|LY3410738|Oral LY3410738
218862986|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
218862987|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
218862988|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
218862989|NCT05339984|PROCEDURE|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
218862990|NCT05339984|PROCEDURE|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
218862991|NCT05339984|PROCEDURE|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
218862992|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
218862993|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
218862994|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
218862995|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
219478641|NCT00594568|DRUG|Placebo|Administered orally once daily
219478642|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
219478643|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
218862996|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
218862997|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
218862998|NCT01940536|DRUG|Tranexamic Acid|antifibrinolytic
218862999|NCT01940536|DRUG|Placebo|Placebo
218863000|NCT00490776|DRUG|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
218863001|NCT06583408|OTHER|Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
218863002|NCT06583408|OTHER|REVEAL Questionnaire|Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
218863003|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
218863004|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
218863005|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
218863006|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
218863007|NCT06583421|BEHAVIORAL|4-week MVPA intervention|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
218863008|NCT06583772|DIAGNOSTIC_TEST|VR-based 9-hole peg test|The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
218863009|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
219478644|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
219478645|NCT06566807|DRUG|Orelabrutinib, obinutuzumab|orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
218863010|NCT02180841|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
219478646|NCT01888978|DRUG|Gem-OX|
218863011|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
218863012|NCT05525598|BEHAVIORAL|"One step at a time"|\[see 'arms' section for full description\]
218863013|NCT05525598|BEHAVIORAL|"Get started"|\[see 'arms' section for full description\]
218863014|NCT05542914|BEHAVIORAL|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
218863015|NCT05542914|BEHAVIORAL|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
219478647|NCT01888978|DRUG|Gem-5FU|
219478648|NCT01888978|DRUG|Gem-Tax|
219478649|NCT01888978|DRUG|Modified FOLFOX-6|
219478650|NCT01888978|DRUG|Ox-Tax|
219478651|NCT01888978|DRUG|FOLFIRI|
219478652|NCT01888978|DRUG|Tax-Iri|
219478653|NCT05341583|DRUG|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
219478654|NCT05341583|DRUG|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
219478655|NCT04311411|DRUG|Tirzepatide|Administered SC.
219478656|NCT04311411|DRUG|Placebo|Administered SC.
219478657|NCT04311411|DRUG|Liraglutide|Administered SC.
219478658|NCT00003769|DRUG|perillyl alcohol|
219478659|NCT00003769|PROCEDURE|surgical procedure|
219478660|NCT02305329|DRUG|BIA 9-1067|
219478661|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
219478662|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
219478663|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
219478664|NCT06701448|DIAGNOSTIC_TEST|robotic bronchosopy|robotic bronchoscopy
218863016|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
218863017|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
218863018|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
218863019|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
219478665|NCT06701448|DIAGNOSTIC_TEST|Electromagnetic Navigation Bronchoscopy|Electromagnetic Navigation Bronchoscopy
219478666|NCT06701448|DIAGNOSTIC_TEST|Fluoroscopy bronchoscopy|Fluoroscopy bronchoscopy
219478667|NCT05674864|DRUG|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
219478668|NCT03722849|DRUG|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
219478669|NCT03722849|DRUG|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
219478670|NCT03722849|OTHER|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
219478671|NCT03962218|PROCEDURE|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
219478672|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
219478673|NCT01955031|OTHER|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
219478674|NCT01955031|OTHER|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
219478675|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
219478676|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
219478677|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
219478678|NCT05785299|DIAGNOSTIC_TEST|Cow's milk|clinical introduction of cow's milk
219478679|NCT05785299|DIAGNOSTIC_TEST|Placebo|clinical introduction of placebo
219478680|NCT05785299|DIAGNOSTIC_TEST|Home introduction|home introduction of cow's milk
219478681|NCT02365818|BIOLOGICAL|CG0070|
219478682|NCT04764825|DRUG|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
219478683|NCT04764825|DRUG|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
219478684|NCT06827626|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive-Behavioural Therapy for Insomnia (CBT-I) includes behavioral methods, cognitive methods, and sleep hygiene counselling.
219478685|NCT06827626|BEHAVIORAL|Sleep hygiene counselling|Sleep hygiene counselling includes common instructions to improve sleep.
219597546|NCT00852722|OTHER|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
218863020|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
218863021|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
218863022|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
218863023|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
218863024|NCT05155501|PROCEDURE|Robot-assisted radical prostatectomy (RP)|The conventional approach to prostate cancer surgery
218863025|NCT05155501|PROCEDURE|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate.
219478686|NCT05077774|DEVICE|Harmony TPV System|Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
219478687|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
219478688|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
219478689|NCT03009175|DEVICE|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
219597547|NCT00616512|PROCEDURE|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
219597548|NCT05107596|DRUG|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
219597549|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
218863026|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
218863027|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
219597550|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
219597551|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
219597552|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
218863028|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
218863029|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
218863030|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
219199652|NCT06735846|DEVICE|Guide wire|Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
219597553|NCT04302714|PROCEDURE|Hysteroscopic injection|Hysteroscopic injection
219597554|NCT04302714|PROCEDURE|Cervical injection|Cervical injection
219597555|NCT00093275|DRUG|HP184|
219597556|NCT01915745|OTHER|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
219597557|NCT05204498|BEHAVIORAL|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
219597558|NCT00799825|BIOLOGICAL|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
219597559|NCT05603403|DRUG|Probiatop|1 sachet orally, 2 times a day, for 42 days
219597560|NCT05603403|OTHER|Placebo|1 sachet orally, 2 times a day, for 42 days
219597561|NCT02439970|DRUG|Brincidofovir|
219597562|NCT02439970|DRUG|Valganciclovir|
218863031|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
218863032|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
218863033|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
218863034|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
218863035|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
218863036|NCT03924921|OTHER|autogenic training|autogenic training
218863037|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
218863038|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
218863039|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
218863040|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
219478690|NCT05791942|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
219478691|NCT05791942|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
219478692|NCT05791942|BEHAVIORAL|Behavioral: Action prompt|The message will prompt people to take care of the health gap right away before it slips their mind.
219478693|NCT05644756|BEHAVIORAL|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
219478694|NCT04634877|BIOLOGICAL|Pembrolizumab|IV infusion
219478695|NCT04634877|DRUG|Carboplatin|IV infusion
219597563|NCT01492920|DIETARY_SUPPLEMENT|Acetyl-L-Carnitine Hydrochloride|Given orally
219597564|NCT01492920|OTHER|Placebo|Given orally
219597565|NCT01492920|OTHER|Questionnaire Administration|Ancillary studies
219597566|NCT01492920|OTHER|Quality-of-Life Assessment|Ancillary studies
219478696|NCT04634877|DRUG|Paclitaxel|IV infusion
219478697|NCT04634877|DRUG|Placebo for pembrolizumab|IV infusion
219478698|NCT04634877|DRUG|Docetaxel|IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
219597567|NCT03766607|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
219597568|NCT03766607|DRUG|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
219478699|NCT04634877|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
219478700|NCT04634877|RADIATION|External Beam Radiotherapy (EBRT)|≥4500 cGY given according to local practice, at the discretion of the investigator
219597569|NCT03766607|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
219597570|NCT04218578|DIAGNOSTIC_TEST|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
219597571|NCT00008307|BIOLOGICAL|anti-thymocyte globulin|
219597572|NCT00008307|DRUG|cyclosporine|
219597573|NCT00008307|DRUG|fludarabine phosphate|
219597574|NCT00008307|DRUG|melphalan|
219597575|NCT00008307|DRUG|methylprednisolone|
219597576|NCT00008307|DRUG|mycophenolate mofetil|
219597577|NCT00008307|PROCEDURE|allogeneic bone marrow transplantation|
219597578|NCT00008307|PROCEDURE|peripheral blood stem cell transplantation|
219597579|NCT00008307|PROCEDURE|syngeneic bone marrow transplantation|
218863041|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
218863042|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
218863043|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
218863044|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
218863045|NCT02994368|OTHER|Observation|
218863046|NCT01560455|DEVICE|single stent|single stent
218863047|NCT01560455|DEVICE|two stent|culotte
218863048|NCT01207349|BEHAVIORAL|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
218863049|NCT01207349|BEHAVIORAL|standard follow up|
218863050|NCT01113580|BIOLOGICAL|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
219478701|NCT04634877|DRUG|Cisplatin (as radiosensitizer)|If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
219478702|NCT04634877|RADIATION|Brachytherapy|Given according to local practice, at the discretion of the investigator
219478703|NCT05219643|DEVICE|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
219478704|NCT05219643|DEVICE|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
219478705|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
219478706|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
219478707|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles
219478708|NCT06537505|DRUG|Adebrelimab|Q3W,IV
218863051|NCT00695552|BEHAVIORAL|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
219478709|NCT06537505|DRUG|Apatinib|QoD
219478710|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
218863052|NCT00695552|BEHAVIORAL|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
218863053|NCT03113695|DRUG|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
218863054|NCT03113695|DRUG|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
218863055|NCT03113695|DRUG|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
219478711|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
219478712|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
219478713|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I\_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
218863056|NCT05149560|DRUG|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
218863057|NCT04587154|OTHER|low-fat vegan diet with 1/2 cup soybeans daily|Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
219478714|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
219478715|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
219478716|NCT00261352|DRUG|Tesaglitazar|
219478717|NCT00261352|DRUG|Metformin|
219478718|NCT00261352|DRUG|Fenofibrate|
219478719|NCT00544570|BIOLOGICAL|filgrastim|
219478720|NCT00544570|DRUG|carmustine|
219478721|NCT00544570|DRUG|cyclophosphamide|
219478722|NCT00544570|DRUG|etoposide|
219478723|NCT00544570|DRUG|melphalan|
219478724|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
219478725|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
219478726|NCT00544570|RADIATION|radiation therapy|
219478727|NCT00544570|RADIATION|total-body irradiation|
219478728|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
219478729|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
219478730|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
219478731|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
219478732|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
218863058|NCT04873037|DEVICE|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
218863059|NCT04873037|DEVICE|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
218863060|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
218863061|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
218863062|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
218863063|NCT03238118|OTHER|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
218863064|NCT03238118|OTHER|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
219478733|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
219478734|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
219478735|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
219478736|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
219478737|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
219478738|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
219478739|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
218863065|NCT03238118|OTHER|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
219597580|NCT02498028|PROCEDURE|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
219597581|NCT02498028|PROCEDURE|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
219597582|NCT04743687|DRUG|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
219597583|NCT03254498|DEVICE|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
218863066|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
219597584|NCT03254498|DEVICE|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
218863067|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
219597585|NCT04520009|BEHAVIORAL|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
218863068|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
218863069|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
219478740|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
219478741|NCT03478982|DRUG|Placebos|single dose for inhalation
219478742|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
219478743|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
219478744|NCT03698825|DRUG|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
219478745|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
219478746|NCT00000658|DRUG|Bleomycin sulfate|
219478747|NCT00000658|DRUG|Vincristine sulfate|
218863070|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
218863071|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
218863072|NCT02189278|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
219478748|NCT00000658|DRUG|Doxorubicin hydrochloride|
219478749|NCT00000658|DRUG|Cyclophosphamide|
219478750|NCT00000658|DRUG|Allopurinol|
219478751|NCT00000658|DRUG|Methotrexate|
219478752|NCT00000658|DRUG|Cytarabine|
219478753|NCT00000658|DRUG|Leucovorin calcium|
218863073|NCT00002254|DRUG|Alovudine|
218863074|NCT06965192|BEHAVIORAL|Visual|Physician participants will view the visual decision support before entering the patient's room during the intervention period, with the option to share with the patient.
218863075|NCT06965192|OTHER|No intervention|No intervention
219478754|NCT00000658|DRUG|Sargramostim|
219478755|NCT00000658|DRUG|Dexamethasone|
219478756|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
219478757|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
219478758|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
219478759|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
219478760|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
219478761|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
219478762|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
219478763|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
219478764|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
219478765|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
219478766|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
219478767|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
219597586|NCT04520009|BEHAVIORAL|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
219597587|NCT04575311|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
219597588|NCT04575311|OTHER|Placebo|Matching Placebo
219597589|NCT03300583|BEHAVIORAL|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
219597590|NCT03300583|BEHAVIORAL|Semi-structured interviews|1:1 semi-structured interviews led by the PI
219597591|NCT02910011|DRUG|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
219478768|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
219478769|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
219478770|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
219478771|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
219478772|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
219478773|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
219597592|NCT06319040|OTHER|Muscle strength measurement|Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
219597593|NCT06319040|OTHER|Knee joint proprioception|Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)
219597594|NCT06319040|OTHER|Balance|The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
219597595|NCT06319040|OTHER|Fall risk test|Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
219597596|NCT06319040|OTHER|Tegner Activity Level|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
219597597|NCT06319040|OTHER|Lysholm Knee Scoring Scale|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
218863076|NCT05639751|DRUG|PRT3789|PRT3789 will be administered by intravenous infusion
219478774|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
219478775|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
219478776|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
219478777|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
219478778|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
218863077|NCT05639751|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion
219199653|NCT06735638|PROCEDURE|OTC MIE Esophagectomy|"Consenting patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic-assisted technique. The procedure will follow the exact standard steps of traditional VATS/RATS esophagectomy, except the thoracic ports will be placed in the subcostal plane. The number of ports (1-4) will be determined based on the patient and case characteristics.~The Da Vinci Xi® surgical system will be used to perform the thoracic portion of the esophagectomy through subcostal ports using the standard technique. Once the procedure is completed, the robotic arms and ports will be removed from the chest, and figure-of-8 stitches with non-absorbable sutures will be placed to close the diaphragm at the port sites. A 24 Fr soft chest tube will be left in place, as per standard VATS/RATS esophagectomy protocols. Incisions will be closed in the standard manner."
219478779|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
219597598|NCT03742791|DRUG|TS-134|5 mg to 80 mg oral solution
219597599|NCT03742791|DRUG|Placebo|Matched Placebo oral solution
219597600|NCT04844060|OTHER|Lumbar punction|Lumbar punction
219597601|NCT04944186|OTHER|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
219597602|NCT04944186|OTHER|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
219597603|NCT00181558|DRUG|Atrasentan|
219597604|NCT00181558|DRUG|Zoledronic Acid (Zometa)|
219597605|NCT00356655|BEHAVIORAL|Psychoeducation|
219597606|NCT00641225|DRUG|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
219597607|NCT04230902|BIOLOGICAL|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
219597608|NCT04230902|DRUG|Corticosteroid injection|intra-articular knee injection of corticosteroid
219597609|NCT06551870|OTHER|Physical activity|The complexity of the games will increase as the levels of the sports games advance, which leads to faster movements with greater demands to progress in the sequence of the games, which allows reaching increases in intensity.
218863078|NCT05082259|DRUG|ASTX660|ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
219478780|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
219478781|NCT04034875|OTHER|Questionnaire|questionnaire
219478782|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
219478783|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
219478784|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
219478785|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
219478786|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
218863079|NCT05082259|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
218863080|NCT05153070|DRUG|Cyclosporin|• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60
218863081|NCT05153070|DRUG|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
219478787|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
219478788|NCT06193044|DRUG|Amlodipine/Valsartan|Amlodipine 10 mg \&valsartan 160 mg
219478789|NCT06193044|DRUG|Amlodipine 10 mg &valsartan 160 mg (Exforge)|Amlodipine 10 mg \&valsartan 160 mg
219478790|NCT01975129|DRUG|Vagitocin|
219478791|NCT05054621|BIOLOGICAL|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
219478792|NCT05054621|BIOLOGICAL|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
219478793|NCT00104962|DRUG|lenalidomide|Given orally
219478794|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
219478795|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
219478796|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
219478797|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
219478798|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
219478799|NCT06567665|DIETARY_SUPPLEMENT|Leucine|Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
219478800|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
219478801|NCT00326625|DRUG|Placebo|
219478802|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
219597610|NCT01277159|DRUG|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
219597611|NCT01277159|DRUG|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
218863082|NCT05153070|DRUG|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
218863083|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
218863084|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
218863085|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
218863086|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
218863087|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
218863088|NCT02300519|OTHER|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
218863089|NCT03808337|RADIATION|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
218863090|NCT03808337|DRUG|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
218863091|NCT05921188|BEHAVIORAL|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
218863092|NCT03093493|DIAGNOSTIC_TEST|Genotyping|Genotyping by next generation sequencing
218863093|NCT04152499|DRUG|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
218863094|NCT06013137|OTHER|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
219478803|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
219597612|NCT01277159|DRUG|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
219597613|NCT01277159|DRUG|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
219597614|NCT01277159|DRUG|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
219597615|NCT05518188|BIOLOGICAL|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
219597616|NCT02871323|BIOLOGICAL|Durvalumab|Given IV
219597617|NCT02871323|OTHER|Laboratory Biomarker Analysis|Correlative studies
219597618|NCT01516918|DRUG|VX-222|tablet, 400-mg twice daily
219597619|NCT01516918|DRUG|telaprevir|tablet, 1125-mg twice daily
219597620|NCT01516918|DRUG|ribavirin|tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
219597621|NCT01516918|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
219597622|NCT03872687|DEVICE|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
218863095|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
219597623|NCT03872687|DEVICE|interdental brushes|Subjects in this group will only receive interdental brushes
219597624|NCT03149796|OTHER|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
219597625|NCT01491191|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
219597626|NCT01491191|DIETARY_SUPPLEMENT|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
219597627|NCT01044108|DRUG|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
219597628|NCT01044108|DRUG|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
219597629|NCT01044108|DRUG|placebo|Placebo will be administered as a comparator at each dose level.
219597630|NCT00999817|DRUG|reference [dextromethorphan]|single 30 mg oral dose
219597631|NCT00999817|DRUG|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
219597632|NCT02203409|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
219597633|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
219597634|NCT04022876|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
218863096|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
218863097|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
218863098|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
218863099|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
218863100|NCT06504524|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219478804|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
219478805|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
219478806|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
219478807|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
219478808|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
219478809|NCT01894542|DIETARY_SUPPLEMENT|Control|
219478810|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
219478811|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
219478812|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
219478813|NCT02122744|DEVICE|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
218863101|NCT06504524|DRUG|Standard of Care|control arm
219597635|NCT04022876|DRUG|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
219478814|NCT02122744|DEVICE|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
219478815|NCT02277548|DRUG|Lyrica 300 mg|Lyrica 300 mg per day
219597636|NCT04022876|DRUG|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
219020821|NCT07205822|DRUG|Dato-DXd|All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Continued treatment with the same study drug post-progression may be allowed, based on prior discussion with sponsor/sponsor representative/study physician on a case-by-case basis following written investigator's confirmation of continuing clinical benefit to the patient post progression. The study is anticipated to enrol for an 18-month period, and DCO is expected to occur approximately 6 months after the last participant has been dosed.
219478816|NCT02277548|DRUG|Placebo|
219478817|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
219478818|NCT01708694|DIETARY_SUPPLEMENT|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
219478819|NCT01708694|DIETARY_SUPPLEMENT|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
219597637|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
219597638|NCT04022876|DRUG|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
219597639|NCT00215280|DRUG|ivermectin and albendazole|
219597640|NCT05523466|OTHER|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
219597641|NCT05523466|OTHER|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
218863102|NCT06975358|PROCEDURE|Alveolar decortication plus CGF injection|Experimental sides will receive CGF injection (70 units) disto-buccal and disto-palatal to the maxillary canine after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
219478820|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
219478821|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
219478822|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
219478823|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
219478824|NCT01843439|DIETARY_SUPPLEMENT|Magnesium|
219478825|NCT01843439|BEHAVIORAL|Education for asthma action plan|
219478826|NCT01843439|BEHAVIORAL|hot-lines for acute exacerbation of asthma|
219478827|NCT01843439|BEHAVIORAL|Inhaler technique training|
219478828|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
218863103|NCT06975358|PROCEDURE|canine retraction without acceleration|in the control side, the maxillary canine will be retracted without any acceleration procedure
218863104|NCT01969877|DRUG|cetuximab|
218863105|NCT01969877|DRUG|cisplatin|
218863106|NCT03035253|DRUG|OMP-305B83|
218863107|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
218863108|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
219020822|NCT07207213|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) is world-renowned for providing evidence-based social skills treatment to adolescents with autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and other socio-emotional problems.
219478829|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
219478830|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
219478831|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
219478832|NCT00455923|DRUG|Seretide|Seretide
219478833|NCT00455923|DRUG|Flixotide|Flixotide
219478834|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
219478835|NCT02234427|DRUG|Aspirin|2-week aspirin therapy (81mg/day)
219478836|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
219478837|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
219478838|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
219478839|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
219478840|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
219478841|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
219478842|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
219478843|NCT02364414|DEVICE|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
219478844|NCT01265875|DRUG|Human Secretin|Dose Escalation
219478845|NCT05275673|DRUG|sapanisertib|capsules for oral administration
219597642|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
218863109|NCT06981013|OTHER|balance based torso weighting|The intervention in this study is the Balance-Based-Torso-Weighting (BBTW) which will be applied on individuals with MS and healthy controls. It involves the strategic placement of weights based on the assessment of the loss of balance in three dimensions: anterior-posterior, lateral, rotational to counteract the balance loss.4 The BBTW Evaluation Tool Kit will be used to determine the location of the weights. It consists of an adjustable testing vest; rigid orthotic; five pounds worth of weights divided into 1/16, 1/8, 1/4, 1/2 lb. increments; and exam evaluation forms (www.motiontherapeutics.com).
218863110|NCT06980324|OTHER|integrated neuromuscular inhibition technique|"integrated neuromuscular inhibition technique consists of:~* ischemic compression~* Positional release~* Muscle energy technique"
218863111|NCT06980324|OTHER|conventional physical therapy treatment|"Conventional physical therapy treatment:~* Ultrasound~* Hotpacks~* Iliotibial band stretching~* Static quadriceps and hamstring exercises"
218863112|NCT06980597|BIOLOGICAL|OL-108|OL-108 will be given through IV bolus with ascending dose levels to determine the maximum tolerated dose (MTD)
218863113|NCT05681195|DRUG|Pemetrexed|Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
218863114|NCT05681195|DRUG|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
218863115|NCT05681195|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
218863116|NCT05681195|RADIATION|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
218863117|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218863118|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218863119|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218863120|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218863121|NCT04319627|DRUG|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
218863122|NCT04319627|DRUG|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
218863123|NCT06980701|BEHAVIORAL|AI OHI group|The participants will receive personalized OHI such as toothbrush and interdental cleaning to specific areas provided by AI. An mHealth system will be used to detect intraoral photograph of anterior teeth and analysis of the photograph and label the gum condition as Healthy (green)/questionable (yellow)/diseased (red) within 2 minutes by AI. Then specific OHI to each particular site would be provided by AI according to tested results on the photograph
218863124|NCT06980701|BEHAVIORAL|Dental professionals OHI group|ll participants will receive personalized OHI by dental professionals. This instruction includes brushing and interdental cleaning in each particular dental site. If they have any personal concern or unclear points regarding oral hygiene practice, they can ask.
218863125|NCT06979843|OTHER|A psychosocial model|"The first aim is to evaluate if participating in the psychosocial model (including Team Young and PRISM) maintains or improves psychological resilience, psychological wellbeing, quality of life and hope among AYAs at a six-month follow-up, compared to time of diagnosis. The second aim is to evaluate how participants in the model of psychosocial support (including Team Young and PRISM) experience it with regard to acceptability, relevance and benefit.~The design is a longitudinal cohort study."
218863126|NCT02603445|DRUG|BCL201|
218863127|NCT02603445|DRUG|Idelalisib|
219478846|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
219478847|NCT03659617|DEVICE|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
219478848|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
218863128|NCT05837767|RADIATION|Stereotactic body radiotherapy|The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
218863129|NCT05837767|RADIATION|Lattice Radiation Therapy|A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
218863130|NCT06981000|BEHAVIORAL|Locally adapted nature-based health intervention|"The locally adapted NBHIs are organized according to the following structure:~* Duration of the program: Minimum 10 weeks, once a week, 1.5-2.5 hours per session~* Group composition: Across conditions: mild to moderate anxiety, depression, and/or stress~* Group size: 8-12 participants in a closed group~In the locally adapted programs, activities in nature are based on three main mechanisms of change (nature interaction and sensory experiences, social communities, and physical activity and movement)."
218863131|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
218863132|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors
218863133|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
218863134|NCT06174116|DRUG|Lumateperone|Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
218863135|NCT06174116|DRUG|Placebo|Subject will take placebo for 12 weeks, in addition to their regular medications.
218863136|NCT06981572|PROCEDURE|Modified Enhanced Recovery After Surgery Protocol|This study is to determine the comparison of the effectiveness of the ERAS modification protocol with the standard protocol in reducing length of stay and improving postoperative outcomes for pediatric patients at RSCM who underwent major gastrointestinal surgery using the ERAS modification method. This study is a single-blind clinical trial. Research subjects will be randomly divided into two groups, namely the group who underwent surgery with the ERAS modification protocol and the group who underwent surgery without the ERAS modification protocol. Modified ERAS protocol will be applied during perioperative
218863137|NCT03887559|BEHAVIORAL|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
218863138|NCT03887559|OTHER|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
218863139|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
218863140|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
218863141|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
218863142|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
219478849|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
219478850|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
218863143|NCT07018583|BEHAVIORAL|Pharmacist's Counseling and Self-Management Application Program|This interventional study is structured around established counseling principles and self-management theory, consisting of six sequential stages: Initial Disclosure, Problem Assessment, Commitment to Action, Skill Enhancement, Monitoring, and Follow-up and Evaluation. These stages are delivered through both in-person pharmacist counseling and a dedicated mobile application. The intervention follows a repeated-measures design, with assessments conducted at 3 and 6 months after enrollment.
218863144|NCT07018583|BEHAVIORAL|Usual Care|Usual care or Standard pharmacy practices such as medication reviews, patient education during the initial visit or when medication changes occur, and counseling upon patient request. No additional structured counseling or self-management tools are provided.
218863145|NCT07016152|BIOLOGICAL|Glyconjugate Klebsiella pneumoniae bivalent vaccine|CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.
218863146|NCT07015229|PROCEDURE|septorhinoplasty|To provide scientific contribution to more effective and timely pain management strategies in the postoperative period by evaluating the time-dependent course of pain scores and the effect of analgesic intervention timing on clinical outcomes in patients who underwent septorhinoplasty and who are followed in the postanesthetic care unit.
218863147|NCT06868836|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
218863148|NCT06868836|DRUG|Pemetrexed|Pemetrexed (500 mg/m², IV, d1)
218863149|NCT06868836|DRUG|Carboplatin or cisplatin|Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles
218863150|NCT04786587|DIAGNOSTIC_TEST|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
218863151|NCT04786587|OTHER|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
219478851|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
218863152|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
218863153|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
218863154|NCT07032090|BEHAVIORAL|Health education|Participants will receive face-to-face health education, followed by 12 sessions of laughter yoga.
218863155|NCT07032090|BEHAVIORAL|Laughter Yoga|The intervention groups will receive a total of 12 sessions of laughter yoga, delivered by the researcher over 6 weeks, twice a week, each lasting 40-45 minutes.
218863156|NCT07032454|OTHER|High Caffeine Consumption|Individuals consuming 300 mg or more of caffeine daily, meeting DSM-5/ICD-10 criteria for caffeine dependence.
219478852|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
218863157|NCT07032454|OTHER|Low Caffeine Consumption|Individuals consuming caffeine within recommended levels (20-200 mg/day).
218863158|NCT07041892|OTHER|Prebiotic Supplement + Synbiotic Supplement + Topical Lotion + Unscented Soap|"The intervention includes 4 products:~1. An oral prebiotic dietary supplement~2. An oral synbiotic dietary supplement~3. A topical lotion~4. An unscented bar of soap"
219478853|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
219478854|NCT04614402|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
218863159|NCT07041996|DIAGNOSTIC_TEST|Mobile-based SARC-F screening application|SARC-F mobile application as a digital health intervention for sarcopenia risk assessment.
218863160|NCT07041463|OTHER|Psychoeducation program coordinated by an APRN|"Individual and group psycho-education programs. Each investigating center will be trained in the same tools, in order to harmonize practices:~* BREF: This is a 3-session psycho-educational program in which each family is received individually by a pair of caregivers who are not involved in the patient's care.~* PEPs Caregiver: This is a group psycho-education program in 5 2-hour sessions developed in the coordinating center."
218863161|NCT07041463|OTHER|Usual Care|"The caregiver will benefit from the interventions and referrals provided for caregivers as usual at each center."
218863162|NCT07040553|BEHAVIORAL|Motivational Interviewing and WhatsApp Support|This intervention consists of weekly face-to-face motivational interviews and supportive WhatsApp messages, delivered over 8 weeks. It is based on the principles of Motivational Interviewing (Miller \& Rollnick, 2012) and aims to support symptom management and emotion regulation in participants with moderate to severe premenstrual syndrome.
218863163|NCT07040293|DEVICE|Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g absorbable bone wax subsequently applied to the osteotomy surface."
218863164|NCT07040293|DEVICE|Traditional bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft fusion, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g traditional bone wax subsequently applied to the osteotomy surface."
218863165|NCT07040865|DRUG|Gadobutrol (Gadovist/Gadavist)|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadobutrol contrast injection.
218863166|NCT07040865|DRUG|Gadopiclenol|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadopiclenol contrast injection.
218863167|NCT07040618|PROCEDURE|Ultrasound-guided Rhomboid Intercostal Block|This intervention involves an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the fascial plane between the rhomboid major and intercostal muscles. The patient is positioned laterally, and the block is performed at the T5-T6 level using a high-frequency linear ultrasound probe. The goal is to anesthetize the lateral cutaneous branches of the intercostal nerves to provide postoperative thoracic analgesia.
218863168|NCT07040618|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|This intervention consists of an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the plane deep to the erector spinae muscle at the T4-T5 transverse process level. The patient is positioned sitting or in lateral decubitus, and the procedure uses a curved or linear ultrasound probe. This block targets the dorsal and ventral rami of thoracic spinal nerves to manage postoperative pain after thoracotomy.
219478855|NCT04614402|DEVICE|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
219478856|NCT01958593|DRUG|Placebo|Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
219478857|NCT01958593|DRUG|Midomafetamine HCl|Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
218863169|NCT07040813|DRUG|CGRP mAbs and onabotulinumtoxin A|CGRP mAbs given subcutanously every 4th week and onabotulinumtoxin A 155 given once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study intervention.
218863170|NCT07040813|DRUG|CGRP mAbs and placebo|CGRP mAbs given subcutanously every 4th week and placebo once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study
218863171|NCT06887296|OTHER|women answer a questionnaire|Sexual Function and Distress Assessment in Women with Polycystic Ovary Syndrome (PCOS) Using Standardized Questionnaires
218863172|NCT07040631|DEVICE|Endotra Gel|Endotra Gel is a hyaluronic acid-based, water-soluble wound dressing gel approved by the Korean Ministry of Food and Drug Safety. In this study, it is applied to the cuff of the endotracheal tube before intubation to evaluate its effect on reducing postoperative sore throat and hoarseness.
218863173|NCT06721299|DRUG|Clenbuterol|Beta-Agonist
219020823|NCT07207213|BEHAVIORAL|Control|This group will also consist of children diagnosed with high-functioning ASD. However, these children will not receive PEERS therapy. Instead, they will continue their usual treatments in their local settings without participating in the PEERS therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of PEERS therapy.
219478858|NCT01958593|BEHAVIORAL|Psychotherapy|Psychotherapy before and after experimental sessions.
219478859|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
219597643|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
219597644|NCT04860674|DRUG|PD-1 inhibitor +ICE|PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
219597645|NCT02130622|DRUG|Promethazine|
219597646|NCT02130622|DRUG|Sugar pill|
219597647|NCT00751192|DEVICE|HIV-testing motivational videos|
219597648|NCT00751192|DEVICE|Standard public health text|
219478860|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
219478861|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
219478862|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
219478863|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
219478864|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
219478865|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
219478866|NCT06829719|BIOLOGICAL|TTV DNAemia|Every 3 months, one sample added at the same time (7mL) of a routine laboratory analysis for TTV DNAemia
219478867|NCT06829719|OTHER|EQ-5D-5L questionnaire|Completed every 6 months and each time a complication of interest occurs
219478868|NCT06829719|BIOLOGICAL|Biological tests|Biological tests as routine care procedure (creatinine, CNI pre-dose trough level) will be performed every 6 months
219478869|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
219478870|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
219478871|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
219478872|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
219478873|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
218863174|NCT07041970|OTHER|Exergame|The training program will focus on strength and functional movements. It requires a Nintendo Switch console, a Ring-Con (a Pilates ring that the user holds or ring holder), wireless Joy-Con controllers (the right Joy-Con, connected to the Ring-Con; and the left Joy-Con, attached to the strap around the player's thigh) and a screen. In adventure mode, women will move through the game by performing physical activities such as jogging or doing squats. To minimize risk, knee-assist mode will be used, which makes the game more accessible. Activating knee assist mode provides support when women perform exercises that require walking, kneeling or squatting, making these activities easier for pregnant women, increasing the fitness benefits of the game. In battle mode women will perform aerobic activities, strength training and yoga exercises that involve the whole body to advance in the game.
219478874|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
219478875|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
219478876|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
219597649|NCT06241625|DIAGNOSTIC_TEST|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
219597650|NCT04413110|DEVICE|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
219597651|NCT02444910|DRUG|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
219199654|NCT06734676|DEVICE|Intermittent theta burst stimulation (iTBS)|iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
219478877|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
219478878|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
219478879|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
219597652|NCT03740581|DRUG|Insulin|Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
219597653|NCT02455895|DEVICE|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
219597654|NCT05382234|DIAGNOSTIC_TEST|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
219597655|NCT01837134|DEVICE|telemedical (TM) group|telemedical devices (weighing machine and step counter)
219597656|NCT01837134|BEHAVIORAL|telemedical coaching (TMC) group|care calls once per week for 12 weeks
219597657|NCT03399708|DRUG|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
218863175|NCT07041255|PROCEDURE|Cold endoscopic mucosal resection|3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard polypectomy loop available to the operator (depending on the randomization result). The formation is removed by mechanical cutting without using electric current.
219478880|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
219478881|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
219020824|NCT07207278|DRUG|Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line|Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line therapy. Clinical response will be assessed via RECIST v1.1 criteria using serial CT imaging (baseline, 8 weeks, and every 12 weeks thereafter). Correlative analyses will evaluate TKI efficacy in relation to TIME subtype, ALK fusion variant, and multi-omic signatures.
219478882|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
219199655|NCT06734871|DRUG|CAR T cells|chimeric antigen receptor T cells
219478883|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
219478884|NCT06091826|DRUG|NFL-101|Subcutaneous injections
219478885|NCT06091826|DRUG|Placebo|Subcutaneous injections
219478886|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
219478887|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
219478888|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
219478889|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
219478890|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
219478891|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
219478892|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
219478893|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
219478894|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
219478895|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
219478896|NCT02231502|OTHER|Vegetable-based convenience food|
219478897|NCT02231502|OTHER|Vegetable meal|
219478898|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
219478899|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
219478900|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
219478901|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
219478902|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
219478903|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
219478904|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
219478905|NCT01405989|DRUG|darexaban|oral
218863176|NCT07041255|PROCEDURE|Hot endoscopic mucosal resection|"3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard diathermic polypectomy loop available to the operator (depending on the randomization result). The formation is removed using electric current in the Endocat mode (or its analogue, providing alternating cutting and coagulation under the control of a processor built into the electrical unit).~After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then an examination with magnification. The examination results are recorded in the scientific protocol separately, and are assessed as a whole. The criteria for visual removal of the formation within healthy tissues are the absence of visible fragments of the formation. The time of complete cessation of capillary bleeding is recorded."
219478906|NCT01405989|DRUG|ketoconazole|oral
219478907|NCT00210366|DRUG|Idarubicin|
219020825|NCT07206745|DRUG|Fei Re Qing Granules|"Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.).~Routine standard treatments：Routine standard treatments according to clinical guidelines."
219478908|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
219478909|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
219478910|NCT02553291|BEHAVIORAL|SystemCHANGE|
219478911|NCT02553291|BEHAVIORAL|Control|
219478912|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
219597658|NCT02393352|OTHER|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
219597659|NCT02393352|OTHER|Electrical Stimulation Therapy|
219020826|NCT07206745|DRUG|Placebo of Feireqing Granules|"Placebo of Feireqing Granules：The placebo granules are prepared using 5% of the active drug combined with pharmaceutical excipients, including starch, dextrin, microcrystalline cellulose, and food-grade coloring and flavoring agents, to ensure consistency in appearance, weight, color, and odor with the Fei Re Qing Granules.~Routine standard treatments：Routine standard treatments according to clinical guidelines."
219478913|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
219597660|NCT03713632|DRUG|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
219597661|NCT03713632|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
219597662|NCT03744299|OTHER|Questionnaire|Patients and caregivers are asked to complete a questionnaire
219597663|NCT03543215|OTHER|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
219597664|NCT01469078|DRUG|Monofer®|Single Bolus Injections
219597665|NCT02751671|PROCEDURE|POCUS|The use of Point-of-care ultrasound before urine sample procedure
219597666|NCT02751671|PROCEDURE|Standard|Urine sampling procedure without prior ultrasound
219478914|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
219478915|NCT01048710|OTHER|No intervention|
219478916|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
219478917|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
219478918|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
219478919|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
219478920|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
219597667|NCT00141089|DRUG|Tegaserod|
219597668|NCT01602393|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
219597669|NCT01602393|DRUG|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
219478921|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
219478922|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
219478923|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
219597670|NCT01602393|DRUG|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
219478924|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
218863177|NCT07041229|PROCEDURE|EMR|"3-4 ml of high-osmolar solution or saline solution stained with indigo carmine are introduced into the submucosal layer under the formation. The formation and the surrounding mucous membrane (at least 5 mm from the edge of the formation) are removed using a standard diathermic polypectomy loop available to the operator. The formation is removed using electric current in the EndocatQ mode. After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then examined with magnification. If residual tissue of the formation is detected, it is removed using the same technique. If the removal of residual tissue of the formation was performed by another method, indicate which one and why.~The removed formation is extracted using a snare loop; if it is removed in parts, then all fragments, if possible, are extracted through the aspiration channel of the endoscope; for large fragments, a snare loop is used."
218863178|NCT07041229|PROCEDURE|ESD|After assessing the boundaries of the formation, a mark is made at least 5 mm from the edge, then a circular or semicircular incision of the mucosa is made, after which the formation is removed by dissection of the submucosal layer using a scarecrow knife, a knife with a ceramic head at the end in EndocutQ mode, spray-coag swift-coag. The EDPS technique - a tunnel method, will also be used where feasible. The essence of the technique is a semilunar incision of the mucous membrane, retreating from the marks, and creating a tunnel under the formation to the proximal edge of the marks, with subsequent cutting off of the formation along the edges. The removed neoplasm is extracted and stretched on a plate. After removal, the edges and bottom of the wound are assessed, if necessary, prophylactic coagulation of visible vessels and clipping are performed.
219478925|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
219478926|NCT02147015|DRUG|Glucocorticoids|
219478927|NCT02147015|DRUG|Antibiotics|
219478928|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
219478929|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
219478930|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
219478931|NCT02147015|OTHER|Physical treatments|
219478932|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
219478933|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
219478934|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
219478935|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
219478936|NCT02335411|DRUG|cisplatin|IV infusion
219478937|NCT02335411|DRUG|5-FU|IV infusion
219478938|NCT02335411|DRUG|capecitabine|oral tablets
219478939|NCT02101957|DRUG|RP103|
219478940|NCT02101957|DRUG|Placebo|
219478941|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
219478942|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
219478943|NCT06116799|DEVICE|Orthotic|Arch support orthotic
219478944|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
219478945|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
219478946|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
219478947|NCT05735119|DEVICE|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
219478948|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
219478949|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
219478950|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
219478951|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
219478952|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
218863179|NCT06893107|PROCEDURE|Intentional Replantation|The intervention involves intentional replantation (IR) of periodontally compromised single-rooted teeth. Patients are selected based on criteria ensuring no vertical root fractures and potential for restoration. Preoperative preparation includes radiographic evaluation (CBCT/periapical), scaling, and root planing, along with antibiotic prophylaxis. The tooth is extracted non-traumatically using periotomes to preserve the periodontal ligament (PDL). After extraction, the tooth is stored in a sterile medium and granulation tissue is excised. Optional modifications (apical resection, retrograde filling, or surface treatment) may be performed. The tooth is then replanted into the socket, secured with a non-rigid splint, and occlusal adjustment is made. Postoperative care includes analgesics, antibiotics, and chlorhexidine rinse. Follow-ups are scheduled at 1 week, 4 weeks, and 9 months for evaluation of healing, survival, and patient-reported outcomes.
218863180|NCT06736093|DRUG|Vitamin D3|Vitamin D3 60,000 IU given once weekly Pre Liver Transplant atleast for 6 weeks
218863181|NCT06736093|DRUG|Placebo|Placebo capsules once weekly for atleast 6 weeks pre liver transplant
218863182|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
218863183|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
219478953|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
218863184|NCT06609928|BIOLOGICAL|FOLR1 CAR T-cells|Given IV
218863185|NCT06609928|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
218863186|NCT06609928|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218863187|NCT06609928|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218863188|NCT06609928|DRUG|Cyclophosphamide|Given IV
218863189|NCT06609928|PROCEDURE|Echocardiography|Undergo ECHO
219478954|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
219478955|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
219597671|NCT05063851|DRUG|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
219597672|NCT05063851|DRUG|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
219478956|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
219478957|NCT04519294|DEVICE|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
219478958|NCT04519294|DEVICE|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
219478959|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
219597673|NCT01730924|PROCEDURE|Pulmonary vein isolation using contact force sensing catheter|
218863190|NCT06609928|DRUG|Fludarabine|Given IV
218863191|NCT06609928|PROCEDURE|Pheresis|Undergo apheresis
219478960|NCT00040209|DRUG|JP 1730|
219478961|NCT00040209|DRUG|IV Levodopa|
219478962|NCT00040209|DRUG|IV Apomorphine|
219478963|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
219478964|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
219478965|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
219478966|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
219597674|NCT01098474|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
219597675|NCT01098474|BIOLOGICAL|Tritanrix™ HB+Hib|Intramuscular, 3 doses
219597676|NCT01098474|BIOLOGICAL|Prevnar™|Intramuscular, 3 doses
219597677|NCT01098474|BIOLOGICAL|Polio Sabin™|Oral, 3 doses
219478967|NCT06650605|DRUG|123I-ATT001|123I-ATT001
218863192|NCT06609928|PROCEDURE|Positron Emission Tomography|Undergo PET
219478968|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
218863193|NCT06226805|DRUG|BB-031|Solution for injection
218863194|NCT06226805|DRUG|Placebo|0.9% sodium chloride for injection
219478969|NCT04041063|DEVICE|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
218863195|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
218863196|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
218863197|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
218863198|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
218863199|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
218863200|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
218863201|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
219478970|NCT04041063|PROCEDURE|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
219478971|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
219478972|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
219478973|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
219478974|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
219478975|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
219478976|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
219597678|NCT01098474|BIOLOGICAL|Menjugate™|Intramuscular, 3 doses
219597679|NCT05847829|DEVICE|T-REEX algorithm|Phase locked transcranial stimulation.
218863202|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
219020827|NCT07206680|DEVICE|Shockwave therapy|The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
218863203|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
219597680|NCT01139229|OTHER|hybrid everted esophagogastric anastomosis|
219597681|NCT01139229|OTHER|the conventional hand-sewn anastomosis|
219597682|NCT01139229|OTHER|a stapled anastomosis|
219597683|NCT04128189|BIOLOGICAL|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
219597684|NCT05560386|BEHAVIORAL|Text messaging|text messaging content to support diabetes prevention.
218863204|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
219597685|NCT05560386|BEHAVIORAL|Virtual workshop|virtual workshop content to support diabetes prevention.
218863205|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
218863206|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
218863207|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
219020828|NCT07206680|DRUG|Medical treatment|Patients in both groups will receive medical treatment in the form of emollients \& corticosteroids for one month.
219478977|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
219478978|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
219478979|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
219478980|NCT03906565|DRUG|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
219478981|NCT06505902|OTHER|Exercise|Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.
219478982|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
219478983|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
219597686|NCT03498495|BEHAVIORAL|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
219597687|NCT00032786|DRUG|natalizumab|
219597688|NCT02352688|PROCEDURE|Enhanced Colorectal Geriatric Care|
219597689|NCT00595309|BIOLOGICAL|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
219597690|NCT00652561|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
219597691|NCT00101283|DRUG|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
219597692|NCT00101283|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
219597693|NCT00101283|DRUG|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
219597694|NCT00626561|DRUG|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
219597695|NCT00626561|DRUG|Paclitaxel|60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
219597696|NCT04736745|BIOLOGICAL|IPN59011|Powder and solvent for solution for injection
219597697|NCT04736745|BIOLOGICAL|Azzalure|Powder for solution for injection
219478984|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
219478985|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
219597698|NCT04736745|DRUG|Placebo|Powder for solution for injection
219597699|NCT02451761|BIOLOGICAL|Blood sampling|
219597700|NCT03266601|DRUG|Recombinant Human Interferon α-2b Spray|Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
219597701|NCT03266601|DRUG|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
219478986|NCT06043830|DRUG|Acetazolamide|Acetazolamide 250 mg 2 capsules by mouth nightly
219478987|NCT06043830|OTHER|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly
219478988|NCT05967533|DRUG|Fermented Wheat Germ Extract|Given orally (PO)
219478989|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
219478990|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
218863208|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
218863209|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
218863210|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
218863211|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
219478991|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
218863212|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
218863213|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
218863214|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
218863215|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
218863216|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
219478992|NCT04373330|BEHAVIORAL|Intensive Lifestyle Intervention|There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
219597702|NCT03260725|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
219597703|NCT03260725|BEHAVIORAL|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
219597704|NCT04663971|PROCEDURE|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
219597705|NCT04663971|PROCEDURE|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
219597706|NCT05291338|DRUG|Doxorubicin|no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
219039989|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
219597707|NCT05291338|DRUG|Lipiodol|Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
219597708|NCT03638388|PROCEDURE|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
219597709|NCT03638388|PROCEDURE|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
219597710|NCT02335697|BEHAVIORAL|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
218863217|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
218863218|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
218863219|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
218863220|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
218863221|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
218863222|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
218863223|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
218863224|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
218863225|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
218863226|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
219478993|NCT05922033|DRUG|Patient-led Insulin (intervention group)|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
219478994|NCT05922033|DRUG|Provider-led Insulin (standard care)|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
219478995|NCT06490874|DEVICE|CGM device - Metformin group|Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
219478996|NCT06490874|DEVICE|CGM device - Insulin group|Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
219478997|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
219478998|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
219478999|NCT01355653|DEVICE|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
219597711|NCT02335697|OTHER|No intervention|
219597712|NCT01078870|DRUG|Lexapro|10mg/cap 1\~2# QD
219597713|NCT01078870|DRUG|Cymbalta|30mg/cap 30\~60mg/QD
219597714|NCT01078870|DRUG|Placebo|1\~2#/cap QD
219597715|NCT02010645|DRUG|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
218863227|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
218863228|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
218863229|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
218863230|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
218863231|NCT02111135|BIOLOGICAL|b-OPV|
218863232|NCT02111135|BIOLOGICAL|m-OPV2|
218863233|NCT02111135|BIOLOGICAL|m-IPV HD|
218863234|NCT02111135|BIOLOGICAL|t-IPV|
218863235|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
219597716|NCT02010645|DRUG|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
218863236|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
218863237|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
218863238|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
218863239|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
218863240|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
218863241|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
218863242|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
218863243|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
218863244|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
218863245|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
218863246|NCT00002514|BIOLOGICAL|sargramostim|
218863247|NCT00002514|DRUG|asparaginase|
218863248|NCT00002514|DRUG|cyclophosphamide|
218863249|NCT00002514|DRUG|cytarabine|
218863250|NCT00002514|DRUG|daunorubicin hydrochloride|
218863251|NCT00002514|DRUG|dexamethasone|
218863252|NCT00002514|DRUG|etoposide|
218863253|NCT00002514|DRUG|imatinib mesylate|
218863254|NCT00002514|DRUG|leucovorin calcium|
218863255|NCT00002514|DRUG|mercaptopurine|
218863256|NCT00002514|DRUG|methotrexate|
218863257|NCT00002514|DRUG|prednisone|
218863258|NCT00002514|DRUG|thioguanine|
218863259|NCT00002514|DRUG|vincristine sulfate|
218863260|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
219479000|NCT01355653|DEVICE|ThermaCare heatwrap|heatwrap, topical, one time application, 8 hour duration
219522296|NCT03947515|PROCEDURE|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
219597717|NCT01654315|DEVICE|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
218863261|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
218863262|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
218863263|NCT00002514|RADIATION|radiation therapy|
218863264|NCT02404922|DRUG|CTP-730|
219039990|NCT04943731|DEVICE|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
218863265|NCT02404922|DRUG|Placebo for CTP-730|
218863266|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
218863267|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
218863268|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
218863269|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
218863270|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
218863271|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
218863272|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
218863273|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
218863274|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
218863275|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
218863276|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
218863277|NCT00459693|DRUG|[11C]PBR28|
218863278|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
218863279|NCT02949388|DRUG|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
218863280|NCT02949388|DRUG|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
218863281|NCT02949388|DRUG|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
218863282|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
218863283|NCT02642146|DRUG|Calcium Channel Blockers|
218863284|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
218863285|NCT02642146|DRUG|Endothelin receptor blocker|
218863286|NCT02642146|DRUG|Prostanoids|
218863287|NCT02642146|DRUG|Other vasodilator|
218863288|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
218863289|NCT02002468|OTHER|Test result sent by letter|
218863290|NCT02002468|OTHER|Test result conveyed by general practitioners|
218863291|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
219039991|NCT05992506|DIAGNOSTIC_TEST|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
219039992|NCT02462967|DRUG|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
219039993|NCT02462967|DRUG|Placebo|Placebo for GR-MD-02
219479001|NCT06431308|BEHAVIORAL|nutritional intervention|A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent . If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received.
219479002|NCT05662111|DRUG|Etidronate|The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.
219479003|NCT05662111|DRUG|Placebo|Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
219479004|NCT05631847|PROCEDURE|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
219479005|NCT05631847|DRUG|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
219479006|NCT00400985|DEVICE|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
219479007|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
219479008|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
219479009|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
219479010|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
219479011|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
219479012|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
219479013|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
219479014|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
219479015|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
219597718|NCT01654315|BEHAVIORAL|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
219597719|NCT00398866|DRUG|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
219597720|NCT00398866|DRUG|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
218863292|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
218863293|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
218863294|NCT00494377|DRUG|duloxetine|
219597721|NCT00398866|DRUG|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
219597722|NCT05550506|DRUG|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
218863295|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
218863296|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
218863297|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
218863298|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
219597723|NCT00247312|RADIATION|Pd-103|
219597724|NCT05084924|DEVICE|Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
219597725|NCT00078117|DRUG|Buprenorphine|
219597726|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
219597727|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
219597728|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
218863299|NCT03270267|OTHER|Questionnaires|
218863300|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
219479016|NCT05397847|BEHAVIORAL|Education|"Rational Drug Use in Elderly Individuals~1. Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~2. Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training."
219479017|NCT05397847|OTHER|Rational Drug Use Guide|At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
219479018|NCT05397847|OTHER|Medicine Box|Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
219479019|NCT05397847|BEHAVIORAL|Counseling|After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.
219479020|NCT03142919|BIOLOGICAL|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
219479021|NCT03142919|BIOLOGICAL|Placebo|Saline solution
219479022|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
219479023|NCT03792633|BIOLOGICAL|huCART19|IV injection
219479024|NCT05382637|DRUG|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
219479025|NCT04973007|DRUG|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
219479026|NCT04973007|DRUG|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
219479027|NCT05054725|DRUG|RMC-4630|RMC-4630 administered orally as a capsule
219479028|NCT05054725|DRUG|Sotorasib|Sotorasib administered orally as a tablet
219479029|NCT06131723|BEHAVIORAL|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
219479030|NCT05522816|DRUG|KX01 0.01% (0.1 mg/g)|Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
219479031|NCT05522816|DRUG|Placebo|Contains same excipients with KX01 but do not contain Tirbanibulin
219479032|NCT05522816|DRUG|KX01 0.1% (1.0 mg/g)|Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
219479033|NCT05522816|DRUG|KX01 1% (10 mg/g) for 5 days|Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
219479034|NCT05522816|DRUG|KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles|Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
219479035|NCT03093688|BIOLOGICAL|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
219479036|NCT06256484|DRUG|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
219479037|NCT05128955|DEVICE|Splenic artery embolization with vascular embolic coils or plugs|Splenic artery embolization with vascular embolic coils or plugs
219479038|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
219479039|NCT02565537|PROCEDURE|LASIK|WFG vs. WFO LASIK
218863301|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
218863302|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
218863303|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
219479040|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
219479041|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
219479042|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
219479043|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
219479044|NCT04636437|DRUG|Doravirine 100 Mg|Participants received a 100 mg tablet by mouth daily with or without food.
218863304|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
218863305|NCT01826266|DRUG|PER977, Placebo|
218863306|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
218863307|NCT02266875|DRUG|hypertonic saline|
218863308|NCT02266875|DRUG|standard saline|
218863309|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
218863310|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
219479045|NCT04636437|DRUG|Integrase strand transfer inhibitors|INSTIs were acquired through the standard of care locally.
219479046|NCT04636437|DRUG|Tenofovir alafenamide/emtricitabine|NRTIs (TAF/FTC) were acquired through the standard of care locally.
219479047|NCT04636437|DRUG|tenofovir disproxil fumarate/emtricitabine|NRTIs (TDF/FTC) were acquired through the standard of care locally.
219479048|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
219479049|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
219597729|NCT01111955|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
219597730|NCT01111955|DRUG|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
219597731|NCT04254341|OTHER|patients with OSA|Sleep study
219597732|NCT04102917|DIAGNOSTIC_TEST|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
219597733|NCT04891003|DIAGNOSTIC_TEST|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
219597734|NCT03893084|OTHER|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
218863311|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
218863312|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
218863313|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
218863314|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
218863315|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
219479050|NCT00065169|DRUG|Celecoxib|
219479051|NCT01074853|DRUG|propranolol|10mg twice daily escalated to 80mg once daily
219479052|NCT01074853|DRUG|placebo|Matched placebo
218863316|NCT04132635|OTHER|growth factor|growth factor
218863317|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
218863318|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
218863319|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
218863320|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
218863321|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
218863322|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
219479053|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
219479054|NCT05493683|DRUG|Tislelizumab|400mg，q6w
219479055|NCT06575244|OTHER|Community-based sailing|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
219597735|NCT00386984|DRUG|Somatostatin (octreotide)|
219597736|NCT05709379|BEHAVIORAL|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
219597737|NCT03774407|DRUG|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
219597738|NCT02417987|OTHER|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
219479056|NCT06575244|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
219479057|NCT06277921|PROCEDURE|Elective Surgery for gastric cancer|Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
218863323|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
218863324|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
218863325|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
219479058|NCT06525623|OTHER|Recommendation: No Further Resuscitation|Treatment teams are encouraged not to administer any additional fluids
219597739|NCT02417987|DRUG|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
219597740|NCT02417987|BIOLOGICAL|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
219597741|NCT04841577|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
219597742|NCT04841577|BIOLOGICAL|FLU-QIV|FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
218863326|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
219479059|NCT06525623|OTHER|Recommendation: Resuscitation with Crystalloid|Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
219479060|NCT06525623|OTHER|Recommendation: Resuscitation with Colloid|Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
219479061|NCT06525623|OTHER|Recommendation: Standard of Care IV Albumin|Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
218863327|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
218863328|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
218863329|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
218863330|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
218863331|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
218863332|NCT00236392|DRUG|rabeprazole|
219479062|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
219479063|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
219479064|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
219479065|NCT04928677|DRUG|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
218863333|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
218863334|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
218863335|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
218863336|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
218863337|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
218863338|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
219479066|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
219479067|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
219479068|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
218863339|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
218863340|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
218863341|NCT00457444|DRUG|Pollen|
218863342|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
218863343|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
219479069|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
219479070|NCT02401724|OTHER|Transcranial direct current stimulation|
218863344|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
218863345|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
218863346|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
218863347|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
219199656|NCT06736626|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.
219479071|NCT02401724|OTHER|Action Training|
219479072|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
219479073|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
219479074|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
219479075|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
219479076|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
219479077|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
219479078|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
219479079|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
218863348|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
218863349|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
218863350|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
219199657|NCT06742463|DRUG|Venetoclax|BCL-2 inhibitor
219199658|NCT06742463|DRUG|homoharringtonine|alkaloid
219199659|NCT06742463|DRUG|Cytarabine (Ara-C)|Metabolic antagonist.
219199660|NCT06742463|DRUG|G-CSF|Granulocyte colony-stimulating factor
218863351|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
218863352|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
218863353|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
218863354|NCT00199225|DRUG|Rupatadine|
218863355|NCT00199225|DRUG|moxifloxacin|
218863356|NCT00199225|PROCEDURE|Continous electrocardiographic register|
218863357|NCT00199225|PROCEDURE|Pharmacokinetic profile|
218863358|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
218863359|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
218863360|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
218863361|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
218863362|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
218863363|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
218863364|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
219597743|NCT06209840|OTHER|Control Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of classical physiotherapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
219597744|NCT06209840|OTHER|Study (Music) Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of music therapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
219597745|NCT00001725|DRUG|Dextromethorphan|
219597746|NCT06170216|DRUG|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
219597747|NCT01134302|PROCEDURE|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
218863365|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
219597748|NCT01134302|PROCEDURE|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
219597749|NCT05102552|DRUG|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
219597750|NCT05102552|DRUG|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
219597751|NCT05102552|DRUG|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
219597752|NCT00943748|DRUG|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
218863366|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
218863367|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
218863368|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
218863369|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
218863370|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
218863371|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
218863372|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
218863373|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
219039994|NCT02455310|BEHAVIORAL|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
219039995|NCT02844296|BEHAVIORAL|Video about exercise|Video about short-bout exercise will be played for the participants.
219039996|NCT02844296|BEHAVIORAL|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
218863374|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
218863375|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
219479080|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
219479081|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
219479082|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
219479083|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
219479084|NCT04209673|OTHER|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
219479085|NCT04209673|OTHER|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
219479086|NCT06293963|BEHAVIORAL|Guideline Daily Amounts label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
219479087|NCT06293963|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
219479088|NCT06293963|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
219479089|NCT06293963|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
219597753|NCT00943748|DRUG|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
219479090|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
219479091|NCT05477147|DEVICE|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
219479092|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
219597754|NCT06198244|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS)|Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
218863376|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
218863377|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
218863378|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
218863379|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
218863380|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
218863381|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
218863382|NCT00570934|DRUG|Placebo|Placebo
218863383|NCT01706042|OTHER|legume meal|
219479093|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
219479094|NCT03287154|DEVICE|Active tDCS stimulations|20 min, 2mA
219479095|NCT03287154|DEVICE|Sham tDCS|20 min, Sham
219479096|NCT06588972|DIETARY_SUPPLEMENT|Medium Chain Triglyceride solution|Placebo
219479097|NCT06588972|OTHER|Cannabis Sativa|Group 2: Cannabis sativa extract with CBD (45mg/day).
219479098|NCT06588296|DRUG|Ixekizumab|Administered SC
219479099|NCT06588296|DRUG|Tirzepatide|Administered SC
219479100|NCT05146726|OTHER|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
219479101|NCT05146726|OTHER|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
219479102|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
219479103|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
219479104|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
219479105|NCT05774756|DRUG|Setmelanotide|Solution for daily subcutaneous injection
218863384|NCT01706042|OTHER|white bread|
219479106|NCT05774756|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
219479107|NCT06603948|DEVICE|Spectral Focused Imaging|Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy
219479108|NCT06603948|DEVICE|White Light Imaging|Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
219479109|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
219479110|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
219479111|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
219479112|NCT06311851|DRUG|Bevacizumab|Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
219479113|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
219479114|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
219479115|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
219479116|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
219479117|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
219479118|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
219479119|NCT05534958|DEVICE|Accexible|Speech Analysis
219479120|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
219479121|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
219479122|NCT04162756|DRUG|Fludarabine|Administered per package insert
219479123|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
219479124|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
219039997|NCT02844296|BEHAVIORAL|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
219479125|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
219479126|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
219479127|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
219479128|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
218863385|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
218863386|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
218863387|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
218863388|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
218863389|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
218863390|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
218863391|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
219479129|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
218863392|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
219479130|NCT06991673|BEHAVIORAL|Behavioral Treatment|"Positive Activity Interventions within Ane-Roadmap App~Positive Piggy Bank - Capture happy moments by mentally savoring them, recording details, and depositing them into a piggy bank. Open it when you need a boost.~Gratitude Diary - Write two unique things daily for which you're grateful. Smile as you record them to enhance gratitude.~Savoring - Each day, spend 2-3 minutes fully enjoying two positive experiences. Log them for reflection.~Pleasant Activity Scheduling - Plan and engage in enjoyable activities at least twice weekly. Treat them as important appointments.~Random Acts of Kindness - Perform five intentional kind acts in a day, four for others and one for yourself.~Signature Strengths - Use a personal strength in a new way daily and reflect on its impact.~Love Letter - Express deep appreciation to a loved one in a heartfelt letter and share it with them.~Engaging with Beauty - Keep a log of beautiful moments in nature, art, or human kindness."
219479131|NCT04959019|BEHAVIORAL|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
219522297|NCT03947515|OTHER|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
218863393|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
218863394|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
218863395|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
219039998|NCT02844296|BEHAVIORAL|Video about diet|Video about healthy diet will be played for the participants.
219522298|NCT03947515|OTHER|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
219522299|NCT02498964|OTHER|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
219522300|NCT00605930|DIETARY_SUPPLEMENT|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
219522301|NCT00605930|DIETARY_SUPPLEMENT|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
219522302|NCT03043378|BEHAVIORAL|Questionnaires|Participants complete three questionnaires at consultation visit.
219039999|NCT02844296|BEHAVIORAL|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
218863396|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
218863397|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
218863398|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
219040000|NCT02844296|BEHAVIORAL|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
219040001|NCT03640026|DRUG|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
218863399|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
219479132|NCT04959019|BEHAVIORAL|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
219479133|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
219479134|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
219479135|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
219479136|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
219479137|NCT01058707|DRUG|MLN0128|MLN0128 capsules
219479138|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
219479139|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
219479140|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
219479141|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
219479142|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
218863400|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
218863401|NCT05440136|DRUG|Placebo (SC)|Administered SC.
218863402|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
219479143|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
219479144|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
219479145|NCT03860038|DRUG|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
219479146|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
219479147|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
219479148|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
219479149|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
219479150|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
218863403|NCT05440136|DRUG|Placebo (IV)|Administered IV.
218863404|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
218863405|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
218863406|NCT02568449|DRUG|Nintedanib|Given PO
219199661|NCT02934867|OTHER|Protocol phone advice|Protocol phone advice
219199662|NCT02934867|OTHER|Usual phone advice|Usual phone advice
219479151|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
219479152|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
219479153|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
219479154|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
219479155|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
219479156|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
219479157|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
219479158|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
219479159|NCT06670261|OTHER|Data collection|Retrospective pseudo-anonymized clinical and scannographic data from the routine management of patients in rhino-sinusology consultations.
219479160|NCT00308230|PROCEDURE|Six minute walk test|
219479161|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
219479162|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
219479163|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
219479164|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
219479165|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
219479166|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
219479167|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
219479168|NCT06864533|DRUG|Docetaxel|Chemotherapy will start 4-8 weeks after the completion of radiotherapy. The chemotherapy regimen will consist of docetaxel 75 mg/m² administered intravenously on Day 1, repeated every 21 days for a total of 4-6 cycles. In cases of significant neuroendocrine differentiation and if well-tolerated, a combination of docetaxel and carboplatin (docetaxel 75 mg/m² and carboplatin AUC 4-6) will be used. Pre-treatment with dexamethasone will be administered to reduce potential side effects.
219479169|NCT06995352|DRUG|Popliteal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
219479170|NCT06995352|DRUG|Adductor canal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
218863407|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
218863408|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
218863409|NCT00610441|DRUG|MK-8777|
218863410|NCT00610441|DRUG|Placebo|
218863411|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
218863412|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
218863413|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
218863414|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
219479171|NCT06995352|DRUG|Continuous popliteal nerve block with normal saline|A perineurial infusion of normal saline (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
219479172|NCT06995352|DRUG|Popliteal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
219479173|NCT06995352|DRUG|Adductor canal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
219479174|NCT06995352|DRUG|Continuous popliteal nerve block with unencapsulated bupivacaine|A perineurial infusion of unencapsulated bupivacaine 0.125% (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
219479175|NCT06995742|DEVICE|Device Array Use|Study participants assigned to the intervention study arm will wear a wireless Bluetooth capable vital sign detection array, with one device externally worn on each of their chest, one finger, and one arm, with healthcare providers using an additional oral temperature probe.
219479176|NCT06995742|DEVICE|Routine Vital Sign Measurement|Study participants randomized to the control arm will have their vital signs obtained by routine means, without use of the wireless vital sign device array.
219479177|NCT06674629|DEVICE|High flow oxygen therapy|Application of high flow oxygen therapy through asymmetric cannula at 40 and 60 L/m
219479178|NCT07000409|OTHER|Medical management regimen|Patients will receive the standard medical regimen alone.
218863415|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
219479179|NCT07000409|OTHER|Erector spinae plane (ESP) block|Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.
218863416|NCT02680210|OTHER|Questionnaires and cognitive measures|
218863417|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
219479180|NCT06999707|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
219479181|NCT06999707|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
218863418|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
218863419|NCT02606760|DRUG|P-3073|
218863420|NCT02606760|DRUG|Vehicle of P-3073|
218863421|NCT03109691|DRUG|bupivacaine|group 1
218863422|NCT03109691|DRUG|Dexamethasone|group 2
219479182|NCT06999707|DRUG|Durvalumab|Treatment Duration Guidelines: \* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years. \* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years. \* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.
219479183|NCT06999109|BEHAVIORAL|TEAM-LEADS|TEAM-LEADS will be an online, self-administered intervention for stress reduction and cardiovascular health behavior promotion in adolescents and young adults with juvenile-onset systemic lupus erythematosus and dermatomyositis
219479184|NCT07002489|DIETARY_SUPPLEMENT|Nuotelande Shuhuajun Study Product|Participants in this arm need to take in the assigned product - Nuotelande Shuhuajun Study Product, 1 capsule per day, for 14 consecutive days. Don't take in similar products in the following 7 days (regression phase).
219479185|NCT06669585|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
218863423|NCT03109691|DEVICE|ultrasound|in all groups
219479186|NCT07000604|OTHER|Mouth Care Training|Patients will be educated on how to care for their mouths after using inhaled medication.
219479187|NCT07000656|DEVICE|Micturition Desire-Relaxation Training Device|The device was developed by Shanghai Children's Medical Center in collaboration with Shanghai University of Engineering Science. It plays relaxation videos through a VR device and monitors the subjects' brain waves in real time using electroencephalography to evaluate their relaxation levels. The relaxation material is adjusted accordingly, and urination is recorded after training. Urine is collected and analyzed with a flow meter, generating a diagnostic report.
219479188|NCT07000656|DEVICE|Sham device|Participants diagnosed with nocturnal enuresis, daytime urinary incontinence, and urinary frequency will be screened at Shanghai Children's Medical Center, and eligible patients will be recruited. Participants will be randomly assigned to the sham training group, in which they will wear the device without powering it on for 10 minutes each session, 5-10 times a day, for 4 weeks.
219479189|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
219479190|NCT06672159|DEVICE|Two defibrillators|DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.
218863424|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
218863425|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
219479191|NCT06672159|DEVICE|One defibrillator|Standard OHCA treatment according to existing guidelines.
219597755|NCT06198244|OTHER|Baseline Treatment|In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
219597756|NCT00700362|PROCEDURE|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
219597757|NCT00700362|PROCEDURE|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
219597758|NCT00182325|BEHAVIORAL|personalized web prenatal information|
219597759|NCT00182325|BEHAVIORAL|general web prenatal information|
219597760|NCT03617783|DRUG|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
219597761|NCT03617783|DRUG|Placebo|placebo-OEI
219597762|NCT01992185|DRUG|Photocil for Vitiligo|Photocil for Vitiligo
219597763|NCT01992185|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
219597764|NCT02419781|PROCEDURE|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
218863426|NCT03909451|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
218863427|NCT03909451|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
218863428|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
218863429|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
218863430|NCT00025116|DRUG|gefitinib|
218863431|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
218863432|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
218863433|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
218863434|NCT00554099|OTHER|Dietary Advice|Dietary advice
218863435|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
218863436|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
218863437|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
218863438|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
219479192|NCT07006740|PROCEDURE|MR-guided Focused Ultrasound Thalamotomy|This intervention involves a unilateral magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy targeting the ventral intermediate nucleus (VIM) of the thalamus. The procedure is non-invasive and uses MRI guidance to deliver focused ultrasound energy to ablate the target area. It is performed without surgical incisions or implanted devices. The intervention is intended for patients with medication-refractory essential tremor. Participants receiving this intervention will be followed for 12 months to assess efficacy and safety.
219479193|NCT07005167|PROCEDURE|endocrowns|endocrowns made of HC hard blocks or cerasmart blocks to restore endo treated molars
219479194|NCT07005167|PROCEDURE|endocrowns|endocrowns made of Cerasmart blocks to restore endo treated molars
219479195|NCT07005609|DIETARY_SUPPLEMENT|Snakehead fish meal|Subjects in the treatment group received snakehead fish meal daily for about 3 months until delivery. The meal contained carbohydrate, protein, vegetables and fruits. Snakehead fish was given +- 100 g per serving.
219479196|NCT07006051|OTHER|Exposed group|All subjects are tested pre-season for their sport. They are then prospectively followed for orthopaedic and/or concussive injury. If injuries occur, then repeat testing is performed.
219479197|NCT07005830|BEHAVIORAL|Twin Hearts Meditation|Twin Hearts Meditation (THM) is a 21-minute guided meditation practice developed by Master Choa Kok Sui as part of Pranic Healing \& Arhatic Yoga (Sui, 2005).
219479198|NCT07006935|BEHAVIORAL|Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness|The Clubhouse Model (CM) is a strengths-focused, evidence-based, and comprehensive approach to psychosocial rehabilitation for serious mental illness. The CM uses an intentional community of support to create a safe and holistic setting to practice real-world functioning. The core of the CM is the 'work-ordered day', a concept where members, as opposed to patients, are integral to and needed for the successful daily operation of the Clubhouse. Members choose a 'work unit' each day of attendance. Most clubhouses have four work units, such as (1) Administration (e.g., database management); (2) Hospitality (e.g., Clubhouse cafe); (3) Membership (e.g., employment programs); and (4) Communications (e.g., newsletter). Other unique aspects include its voluntary and humanistic nature, prioritization of member choice, unrestricted and flexible membership, and the elimination of provider-patient hierarchy. The CM has a sophisticated accreditation process based on 37 international standards.
219479199|NCT07006935|BEHAVIORAL|Usual Community-Based Mental Health Care|Usual care includes services typically available in the community at mental health agencies, including case management, including Assertive Community Treatment, counseling, peer support services, psychoeducational support groups, family support groups, supported education/employment, permanent supportive housing, and medication management.
219479200|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab|Short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
219479201|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy|Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
219479202|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
219479203|NCT07005622|OTHER|O2 Trainer|The O2 Trainer uses varying caps to limit airflow during inspiration.
219479204|NCT07005622|OTHER|Deep breathing|Comparator/placebo for the control group
219479205|NCT07006194|DIETARY_SUPPLEMENT|Nicotinamide Tablet|One nicotinamide tablet per day during the month preceding surgery
219597765|NCT02419781|PROCEDURE|No endovascular therapy|
218863439|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
219597766|NCT03222310|DRUG|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
219597767|NCT03222310|DRUG|Itraconazole|Itraconazole 100 mg capsules orally once daily.
218863440|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
218863441|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
218863442|NCT00139763|PROCEDURE|Educational Materials|
218863443|NCT00771121|DRUG|urea/lactic acid|new emulsion type
218863444|NCT00771121|DRUG|Placebo|only emulsion base
219040002|NCT06353490|DEVICE|Infrared Forehead Thermometer (GE-TF03)|Infrared Forehead Thermometer (GE-TF03) is an investigational device intended to measure body temperature on the forehead. GE-TF03 took three measurements for each subject.
219040003|NCT06353490|DEVICE|Infrared Ear Thermometer (GE-TE06)|Infrared Ear Thermometer (GE-TE06) is an investigational device intended to measure body temperature in the ear canal. GE-TF06 took three measurements for each subject.
219597768|NCT00985244|DRUG|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
219597769|NCT00985244|DRUG|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
219479206|NCT07006285|OTHER|Measure of T2 biomarkers|"T2 Biomarkers are estimated via induced sputum:~Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution.~Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge"
219479207|NCT06303713|DRUG|Carboplatin|Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.
219479208|NCT06303713|DRUG|177Lu-PSMA-617|Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
219479209|NCT04880850|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
218863445|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
218863446|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
218863447|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
218863448|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
218863449|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
218863450|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
218863451|NCT01011933|DRUG|Selumetinib|Given PO
218863452|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
218863453|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
218863454|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
219479210|NCT04880850|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
219479211|NCT04880850|DRUG|Insulin aspart|Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
219479212|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
219479213|NCT03189706|DRUG|Irinotecan|50mg/m\^2/day IV will be administered from day 1-5
219479214|NCT03189706|DRUG|temozolomide|(given concurrently with Irinotecan) 150mg/m\^2/day orally
219479215|NCT03189706|BIOLOGICAL|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
219479216|NCT03189706|DRUG|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
219479217|NCT07006428|DEVICE|Clareon PanOptix or PanOptix Toric IOLs|Bilateral implantation of the Clareon PanOptix or PanOptix Toric IOLs.
219479218|NCT07006428|DEVICE|Comparable multifocal IOL|Bilateral implantation of a comparable multifocal IOL
219479219|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.
219479220|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.
218863455|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
218863456|NCT01439074|DEVICE|Mepilex Ag|Dressing
218863457|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
219479221|NCT03405155|BIOLOGICAL|Nivolumab|Given IV
219479222|NCT07006610|DEVICE|Kinesio Tex® Gold Taping|Elastic kinesio tape applied postoperatively to the facial region and left in place for 5 days.
219597770|NCT02513225|BEHAVIORAL|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
219597771|NCT02513225|OTHER|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
219597772|NCT00237978|DRUG|Adapalen|
219597773|NCT00237978|RADIATION|VIS and wIRA|
218863458|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
218863459|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
219479223|NCT07006610|DEVICE|Hilotherm® Facial Cooling System|A polyurethane facial mask delivering continuous +17°C water cooling for 48 hours post-surgery.
219479224|NCT06365424|DRUG|Fenofibrate|Fenofibrate (200 mg/day)
218863460|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
218863461|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
218863462|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
218863463|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
218863464|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
218863465|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
219479225|NCT06365424|DRUG|UDCA|Ursodeoxycholic acid (13-15 mg/kg/day)
219479226|NCT06697028|OTHER|Usability and Comparison|PACER will be used to assess cardiorespiratory fitness in individuals with rheumatic diseases. The results will be compared with those of healthy individuals, and the relationship between body composition and VO2 max will be examined.
219479227|NCT07022535|DIAGNOSTIC_TEST|KELIM|"(i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable.~(ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery"
219479228|NCT07022535|DRUG|Carboplatin plus Paclitaxel|Chemotherapy as neaodjuvant chemotherapy
219597774|NCT06467708|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
218863466|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
218863467|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
218863468|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
218863469|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
218863470|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
218863471|NCT00002742|DRUG|amphotericin B deoxycholate|
219479229|NCT07022535|PROCEDURE|Interval debulking surgery|Interval debulking surgery
219479230|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #25/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #25/0.4 rotary file. After mechanical preparation, passive ultrasonic irrigation (PUI) was performed using a VDW Ultra device with an IRRI S 21/25 ultrasonic tip. Irrigation was activated with 3% sodium hypochlorite (NaOCl) in three 20-second cycles, using 1 ml per cycle. The ultrasonic tip was placed 2 mm short of the working length without contacting canal walls.
219479231|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #35/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #35/0.4 rotary file. The same passive ultrasonic irrigation protocol was applied as in Arm 1, using 3% NaOCl in three 20-second cycles with 1 ml per cycle. The ultrasonic tip was positioned 2 mm short of the working length without contacting the canal walls.
218863472|NCT00002742|DRUG|nystatin|
219040004|NCT06353490|DEVICE|Electronic Thermometer (MT-B321FB)|Electronic Thermometer (MT-B321FB) is an investigational device intended to measure body temperature on the temporal artery. MT-B321FB took three measurements for each subject.
219040005|NCT06353490|DEVICE|Electronic Thermometer (MT-B231)|Electronic Thermometer (MT-B231) is a reference device that measured axillary temperature one time for each subject.
219479232|NCT07028983|BEHAVIORAL|Active Music Group (AMG)|Active music group is a music therapy intervention where participants actively make/play music in groups. The sessions will be conducted by an appropriately qualified music therapist.
219597775|NCT02782806|DEVICE|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
219597776|NCT00438217|DRUG|Triptorelin (GnRH agonists)|
219597777|NCT00438217|DRUG|Leuprolide (GnRH agonists)|
218863473|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
218863474|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
219479233|NCT07028983|BEHAVIORAL|Music Listening Group (MLG)|Music listening group is a music therapy intervention where participants partake in music listening in groups. The sessions will be conducted by an appropriately qualified music therapist.
219479234|NCT07028983|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as provided locally, which may include pharmacological and/or non-pharmacological interventions (e.g. mindfulness-based intervention, structured physical activity).
219479235|NCT06699394|DRUG|Teclistamab (Tec)|Teclistamab is administered subcutaneously with higher step-up doses (SUDs). Patients receive teclistamab with SUDs: 0.2 and 0.7 mg/kg and 1.5 mg/kg in Cycle 1 (2-4 days between doses). 3 mg/kg every 4 weeks will be used in subsequent cycles.
219597778|NCT02895100|DRUG|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
219597779|NCT02895100|DRUG|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
218863475|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
219479236|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
219597780|NCT04319783|DRUG|Darolutamide|Darolutamide alone
218863476|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
218863477|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
218863478|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
218863479|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
218863480|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
218863481|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
218863482|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
218863483|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
218863484|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
218863485|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
219040006|NCT01564303|DRUG|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
219040007|NCT03844126|OTHER|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
219479237|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
219479238|NCT07028463|BEHAVIORAL|ALERT-ED|Patient receives link to the Livi Chatbot in After Visit Summary
219479239|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
219479240|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
219479241|NCT00034476|DRUG|sPLA2 Inhibitor|
219479242|NCT06702228|DIAGNOSTIC_TEST|Six minute walk test (6MWT)|Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
219479243|NCT06702228|DIAGNOSTIC_TEST|Computer-tomography of the thorax (CT Thorax)|Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
219479244|NCT06702228|OTHER|Quality of life questionnaires.|Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
219479245|NCT06702228|DIAGNOSTIC_TEST|Genetic Testing|10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
219479246|NCT06702228|DIAGNOSTIC_TEST|Spirometry|We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
219597781|NCT04319783|RADIATION|Radiotherapy|Darolutamide + Consolidation Radiotherapy
219597782|NCT05119153|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo designed to mimic coffee color.
219597783|NCT05119153|DIETARY_SUPPLEMENT|Light Roasted Coffee|12 oz light roast coffee
219597784|NCT05119153|DIETARY_SUPPLEMENT|Medium Roasted Coffee|12 oz medium roast coffee
219597785|NCT05119153|DIETARY_SUPPLEMENT|Dark Roasted Coffee|12 oz dark roast coffee
219597786|NCT06040775|DEVICE|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
219597787|NCT06040775|DEVICE|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
219479247|NCT06702228|DIAGNOSTIC_TEST|Serology|Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
218863486|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
218863487|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
218863488|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
219479248|NCT06702228|OTHER|Other Quality of Life Questionnaires|Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months
219479249|NCT06702228|OTHER|PatientMPower Home Monitoring App|Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
219479250|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
219479251|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
219479252|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
219479253|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
219479254|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
219479255|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
219479256|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
219479257|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
219479258|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
219479259|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
219479260|NCT00208858|DRUG|Topiramate|
219479261|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
219479262|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
219479263|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
219479264|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
219479265|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
219479266|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
219479267|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
219479268|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
219479269|NCT07034352|BEHAVIORAL|Health Impact 360|Participants will be assigned to a team and teams will meet 1-2 times per week for sessions at a local community organization. Sessions will be up to 2 hours long and will include two parts: (1) 30-60 minutes of activities related to physical, mental, social, financial, and community health, and (2) 60-75 minutes of group physical activity (walking), including stretches to warm up and cool down.
219479270|NCT07034352|OTHER|Usual care - Wait list control|Participants will be on this for approximately 16 weeks and be asked to complete data collection information at baseline and 16 weeks.
219479271|NCT07036484|BEHAVIORAL|Online program|We tested the feasibility of the introductory modules of an online couple-based program (STORK), designed to be grounded in empirically established risk and protective factors associated with couples' perinatal sexual well-being. STORK is a web-based program including psychoeducation and behavioral tasks to be completed by couples
219479272|NCT06429800|DRUG|ATA3219|ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
219479273|NCT07038551|DRUG|Naldemedine|over-encapsulated capsule of either 0.2 mg of naldemedine
219479274|NCT07038551|DRUG|Placebo|over-encapsulated capsule of placebo
219479275|NCT06717958|DRUG|Ivosidenib 250 MG (milligram)|oral
219479276|NCT06708416|DRUG|ONO-1110|ONO-1110 tablets once a day
219479277|NCT06708416|DRUG|Placebo|Placebo tablets once daily
219479278|NCT07040696|DEVICE|Venous excess ultrasound score (VEXUS)|Doppler examination of inferior vena cave, portal vein, hepatic vein, and intrarenal vein will be conducted by an experienced operator
218863489|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
218863490|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
218863491|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
218863492|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
219479279|NCT06716710|BEHAVIORAL|Art therapy group|In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, a mandala coloring session will be held 3 days a week, 2 times a week under the supervision of the researcher. In order to ensure standardization in the pregnant women included in the study group, each pregnant woman will be given the same mandala work box (36 colored coloring pencils, file, eraser, pencil sharpener and the same mandala prints for all pregnant women). The selection of mandala patterns will be determined by the researchers. In the second week of the training, the researcher will evaluate the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of birth scale. At the end of the four-week activity, the researcher will evaluate again.
219479280|NCT06716710|OTHER|Control group|In addition to the medical treatments that the pregnant women in the control group will receive in the clinic for 4 weeks, no other application will be made. After two weeks, the researcher will evaluate them using the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of childbirth scale. At the end of the fourth week, the researcher will evaluate them again.
219479281|NCT07040969|DRUG|Spray of spirulina derivatives|An oral spray formulated with purified spirulina-derived exosomes.
219479282|NCT07040969|DRUG|Spray of placebo|The placebo oral spray will be formulated with inactive ingredients matched in appearance and flavor profile to the active spirulina-derived product.
219479283|NCT07040969|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
219597788|NCT00593151|OTHER|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
219597789|NCT00593151|BIOLOGICAL|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
219597790|NCT00004378|PROCEDURE|Stem Cell Transplantation|
219597791|NCT02695810|DRUG|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
219597792|NCT02695810|DRUG|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
219597793|NCT02695810|BEHAVIORAL|Exercise|Interval training, 5 times per week, 30 min per session
219597794|NCT00339144|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
219597795|NCT00339144|DRUG|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
219597796|NCT00339144|DRUG|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
219597797|NCT06393517|DRUG|PF-06954522 IR (Formulation 1)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
219597798|NCT06393517|DRUG|PF-06954522 MR (Formulation 2)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
219597799|NCT06393517|DRUG|PF-06954522 MR (Formulation 3)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
219597800|NCT00912613|OTHER|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
219479284|NCT06713746|DIAGNOSTIC_TEST|growth differentiation factor 15|rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
219479285|NCT03577418|BEHAVIORAL|Templated, clinician-facilitated intervention to align everyday living preferences assessment|"In step 1, persons living with dementia or cognitive impairment (PLWD/CI) will complete the PELI (hereafter, assessment PELI-CI for Cognitive Impairment) to articulate their preferences. In step 2, care partners will consider the preferences of PLWD/CI; care partners will complete concurrent but separate proxy PELI assessments from the perspective of the PLWD/CI (i.e., as if acting as surrogate decision-makers; hereafter assessment PELI-CP for Care Partner). In the Intervention (step 3), the study clinician will ask the PLWD/CI to identify up to 3 social engagement preferences that matter most to them. Second, in discussion with the PLWD/CI and care partner, the study clinician will review areas where there is a difference in ratings between the PELI-CI and PELI-CP. The study clinician will then ask the PLWD/CI to identify up to 3 items of disagreement that are most important for the care partner to know about. A 1-page Preferences Priorities document will then be created."
219479286|NCT06722703|PROCEDURE|shock wave lithotripsy|Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.
219479287|NCT06722703|PROCEDURE|Flexible ureteroscope lithotripsy|All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
219479288|NCT06724146|DEVICE|Sofwave and Pure Impact|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated."
219479289|NCT06724952|DRUG|MTX S.C or IM and Silymarin 140 mg tab|IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
219479290|NCT06724952|DRUG|MTX S.C or IM|IM or SC Methotrexate plus placebo tablet once daily for 3 months.
219597801|NCT00555841|DRUG|ALC and Placebo|ALC and Placebo
219597802|NCT05354739|DEVICE|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
219597803|NCT06398119|OTHER|Traditional Treatment Program|Traditional Treatment Program for improving hand function
219597804|NCT06398119|OTHER|Virtual Reality Program|Virtual Reality Program for improving hand function
219597805|NCT04900519|BIOLOGICAL|STI-6643|Anti-CD47 human monoclonal antibody
219597806|NCT05011318|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
219597807|NCT05011318|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
219597808|NCT02365116|BEHAVIORAL|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
219597809|NCT02365116|BEHAVIORAL|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
219597810|NCT01890434|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
219597811|NCT02072343|DEVICE|No-DCCM|
219597812|NCT02072343|DEVICE|DCCM|
219597813|NCT02072343|OTHER|Water 5ml in tracheal tube|
219597814|NCT02072343|OTHER|Water 10ml in tracheal tube|
219199663|NCT06738693|PROCEDURE|External Fixation|External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.
218863493|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
218863494|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
218863495|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
218863496|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
219479291|NCT06723002|DRUG|Atherolive 500mg/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
218863497|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
218863498|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
218863499|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
218863500|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
218863501|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
218863502|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
218863503|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
218863504|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
218863505|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
218863506|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
218863507|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
218863508|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
218863509|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
218863510|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
218863511|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
218863512|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
219479292|NCT06723002|DRUG|Atherolive 1000/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
219479293|NCT06723002|DRUG|Placbo_Atherolive|"Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
219479294|NCT06723990|DRUG|Neoadjuvant standard treatment for HER2+|NEOADJUVANT SETTING
219479295|NCT06723990|DRUG|Adjuvant standard treatment for HER2+|ADJUVANT SETTING
219479296|NCT06185335|GENETIC|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
219479297|NCT06185335|GENETIC|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
219479298|NCT06185335|GENETIC|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
219479299|NCT07044115|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
219479300|NCT07044115|DRUG|placebo|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
219479301|NCT07043608|DRUG|Zanzalintinib|Given orally (PO)
219479302|NCT07043608|DRUG|Investigator Choice of Bone Strengthening Agents (BSA)|One BSA will be chosen, at the discretion of the investigator and given intravenously (IV)
219479303|NCT07043608|RADIATION|Non-Investigational Radiation Therapy (RT)|Non-investigational RT is permitted for symptomatic bone metastases.
219479304|NCT07043608|PROCEDURE|Bone Scan|Undergo Bone Scan
219479305|NCT07043608|PROCEDURE|Computerized tomography (CT) Scan|Undergo Imaging
219479306|NCT06724783|DEVICE|Collagen membrane|Implant placement with simultaneous GBR covered with a collagen membrane
218863513|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
218863514|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
218863515|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
218863516|NCT02008357|DRUG|Placebo|Administered IV
218863517|NCT02008357|DRUG|Solanezumab|Administered IV
218863518|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
218863519|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
218863520|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
218863521|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
218863522|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
218863523|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
218863524|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
218863525|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
219479307|NCT06723249|DIETARY_SUPPLEMENT|stingless bee honey|Participants under intervention group will receive 20g of stingless bee honey in a packet form but participants under control group will not receive any stingless bee honey
219479308|NCT06710626|DEVICE|Assistive Robotic Arm|The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.
219479309|NCT04954027|BEHAVIORAL|Questionnaires|"5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator"
219597815|NCT01751737|PROCEDURE|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
218863526|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
218863527|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
218863528|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
218863529|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
218863530|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
218863531|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
219522303|NCT02419690|BEHAVIORAL|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
219522304|NCT01247948|PROCEDURE|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
219522305|NCT01247948|PROCEDURE|traditional spine surgery|traditional spine surgery without navigation assist
219597816|NCT00055042|DRUG|Vitamin E|
219597817|NCT00766779|PROCEDURE|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
219597818|NCT00766779|DRUG|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
218863532|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
218863533|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
218863534|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
219479310|NCT07048080|BEHAVIORAL|(P)rehabilitation Progresive Resistance Exercise Training|The (p)rehabilitation intervention program will be based on supervised whole-body RET performed 3 times/week before (2-week) and up to 12 weeks after surgery, with one day in-between sessions. Training will consist of a 10-min warm-up, followed by one warm-up and 4 sets on leg press, leg-extension and leg abductor machines. Upper body exercises (chest press, lat pulldown and horizontal row will be performed with 2 sets of each exercise. During the 2-week training before surgery, the workload will be increased from 70% (week 1) to 80% (week 2) of 1RM (10 repetitions in each set). After surgery, the workload will be increasing from 50% of 1RM to 80% from the last 6 weeks. All the participants included in the per-protocol analysis must complete at least 80% of the training sessions. We will take into consideration the mobility precautions so as not to dislocate the prosthesis (avoid hip flexion of 90 degrees and more; do not perform adduction exercises and hip rotations).
218863535|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
218863536|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
218863537|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
218863538|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
218863539|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
218863540|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
218863541|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
218863542|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
219479311|NCT07048080|BIOLOGICAL|Prehabilitation Group Deuterated Water|In a sub-study, the first 10 participants of the (P)rehabilitation group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of prehabilitation.
219479312|NCT07048080|BIOLOGICAL|Usual Care Group Deuterated Water|In a sub-study, the first 10 participants of the Usual Care group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of usual care.
218863543|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
218863544|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
218863545|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
218863546|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
218863547|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
218863548|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
219479313|NCT07048080|OTHER|Usual Care|Participants assigned to the usual care group will receive the usual therapy, medical monitoring, and educational lectures after surgery. No intervention is planned before total hip replacement surgery. The patient is hospitalized for surgery. At hospital discharge, the usual care group will start with standard rehabilitation (sessions: 1st month, 2-3x/week, 2nd month 1-2x/week and 3rd month 1x/month) based on mobility and strength exercises without using progressive RET with machines until 3 months after surgery.
219479314|NCT07046780|DRUG|Observation arm|To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world
219522306|NCT01513070|DRUG|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
219522307|NCT01513070|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
219522308|NCT01513070|DRUG|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
219522309|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
219522310|NCT01513070|DRUG|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
218863549|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
218863550|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
218863551|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
218863552|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
219479315|NCT07048665|DIAGNOSTIC_TEST|CT Imagesa in HCCT|Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter
219479316|NCT07048782|OTHER|Observational assessment of clinical outcomes|This is a non-interventional observational study. No treatment or behavioral intervention is administered.
219479317|NCT07046832|DEVICE|Augmented Reality Guided Biopsy|Augmented Reality system in adjunct to standard of care guidance for needle guidance during a percutaneous biopsy
219597819|NCT01154361|DRUG|Icatibant (subcutaneous) and plazebo (intravenous)|
218863553|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
218863554|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
218863555|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
218863556|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
218863557|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
218863558|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
219597820|NCT01154361|DRUG|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
219597821|NCT04149652|DIAGNOSTIC_TEST|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
218863559|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
218863560|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
219479318|NCT07046832|DEVICE|Ultrasound Guided Biopsy|Ultrasound guided biopsy as a part of standard of care.
219479319|NCT06722339|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|"Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects."
219522311|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
219522312|NCT05134792|DRUG|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
219522313|NCT01223612|DRUG|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
219522314|NCT01223612|PROCEDURE|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
219522315|NCT04785937|DIAGNOSTIC_TEST|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
219522316|NCT07020728|BEHAVIORAL|Solo: Unmasked Speech Stimuli|Speech stimuli recorded using non-moving speakers and mics. No masking sources present. No BSS applied to multi-channel recordings. Very high output QoS values.
219522317|NCT07020728|BEHAVIORAL|Raw: Fully masked speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. No speech separation or extraction methods applied to multi-channel recordings. Very low output QoS values.
219522318|NCT07020728|BEHAVIORAL|StatScrub: Extracted Speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Very high output QoS values.
219522319|NCT07020728|BEHAVIORAL|SlideSpch: Scrubbed Speech emitted from linearly moving speaker stimuli|Speech stimuli recorded using linearly moving speech source and stationary masking sources and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Moderately high output QoS values.
219522320|NCT07020728|BEHAVIORAL|SlideNoise: Speech Scrubbed from linearly moving and stationary noise stimuli|Mixed speech and noise sources recorded using a stationary speech source, a stationary noise source, and a linearly moving noise source. A valid source hypothesis of the speech source is used to extract the speech source. High output QoS values.
219522321|NCT07020728|BEHAVIORAL|SlideMic: Stationary sources scrubbed from a linearly moving mic stimuli|Mixed speech and noise sources recorded using all stationary sources, and a linearly moving microphone (mic 1). Joint ACES scrubbing of both noise sources is used to reduce the response of Mic 1 to a residue of speech. Low output QoS values.
219479320|NCT06884917|OTHER|Sleep Hygiene Training|Written consent will be obtained from the women, and a Personal Information Form will be applied. The General Comfort Scale (GCS) will be applied to the women. The Pittsburgh Sleep Quality Index (PSQI) will be applied to the women. Each level will include the physical, socio-cultural, psycho-spiritual, and environmental dimensions where the requirements to ensure comfort arise.
218863561|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
218863562|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
218863563|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
218863564|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
218863565|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
218863566|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
218863567|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
218863568|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
218863569|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
218863570|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
218863571|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
218863572|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
218863573|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
218863574|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
218863575|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
218863576|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
218863577|NCT00514020|GENETIC|gene expression analysis|Blood collection
218863578|NCT00514020|GENETIC|polymorphism analysis|Blood collection
218863579|NCT00514020|GENETIC|protein expression analysis|Blood collection
219479321|NCT07044934|OTHER|No Intervention: Observational Cohort|This observational cohort includes female patients undergoing non-cardiac surgery. No intervention was administered as part of the study protocol. Preoperative serum uric acid levels were measured, and patients were followed for the development of postoperative acute kidney injury. Data were analyzed retrospectively to assess the association between uric acid levels and acute kidney injury, with subgroup analyses based on menopausal status (premenopausal vs. postmenopausal women).
219479322|NCT06732882|DRUG|AZD4604|Participants will receive AZD4604 via Genuair/Turbuhaler device.
219479323|NCT06732882|OTHER|Placebo|Participants will receive placebo via Genuair/Turbuhaler device.
219479324|NCT06732882|DEVICE|Genuair|Participants will either receive AZD4604 or placebo via Genuair device.
219479325|NCT06732882|DEVICE|Turbuhaler|Participants will receive either AZD4604 or placebo via Turbuhaler device.
219479326|NCT04595422|OTHER|Educational Intervention|Undergo training consisting of a 60-minute educational session
219479327|NCT04595422|OTHER|Educational Intervention|Receive lung cancer screening educational materials
219479328|NCT04595422|OTHER|Questionnaire Administration|Complete questionnaire
219597822|NCT02768831|OTHER|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
219479329|NCT04595422|OTHER|Survey Administration|Ancillary studies
219479330|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
219479331|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
219479332|NCT07048548|BEHAVIORAL|Thyroid Function Monitoring|This study will include healthcare professionals from the radiology and nuclear medicine departments at INMOL Cancer Hospital with at least one year of radiation exposure. A total of 44 participants will be selected through purposive sampling. Data will be collected using a structured questionnaire and blood tests for thyroid hormones (TSH, T3, T4) to assess thyroid function. Blood analysis will be conducted using CLIA or ELISA methods. The aim is to detect any association between low-dose radiation exposure and thyroid dysfunction.
218863580|NCT00514020|OTHER|pharmacological study|Blood collection
218863581|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
218863582|NCT01688921|DEVICE|Needle-Syringe|
218863583|NCT01688921|DEVICE|Stratis needle-free injection device|
218863584|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
218863585|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
218863586|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
218863587|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
218863588|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
218863589|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
219479333|NCT07047222|BEHAVIORAL|Behavioral change communication (BCC) module|The behavior change communication (BCC) module was designed to enhance awareness and promote effective management of menstrual disorders through structured lifestyle and behavioral guidance. It consisted of three 1-hour sessions: (1) education on menstrual disorders and related risk factors; (2) healthy dietary practices; and (3) physical activity (including yoga) and other lifestyle improvements. Sessions were held from May 20 to June 30, 2023, at three public universities in Bangladesh and were delivered by trained female educators. All session dates were approved by university authorities. Activities included interactive presentations, yoga demonstrations, pamphlet distribution, quizzes, and gift giveaways. To reinforce and support behavior change, follow-up visits were conducted every two months from July 15, 2023, to January 15, 2024.
219479334|NCT07048054|DRUG|TrophiPatch: allogeneic adipose-derived stromal cell patch|Topical application of an allogeneic adipose-derived stromal cell patch
219479335|NCT06736548|BEHAVIORAL|The Sleep Treatment Education Program Together (STEP-Together)|STEP-Together is delivered in a single videoconference group session delivered live by a presenter. During the session, the participants are able to see and hear the presenter, view the presentation slides, and ask questions. The presentation includes educational information on the problem of insomnia after cancer and specific suggestions for improving sleep. Suggestions are presented in four sections addressing lifestyle issues, sleep environment, sleep timing, and managing expectations and challenges. During the course of the session, participants are asked to use these suggestions to develop an individual sleep action plan they will use to improve their sleep.
219479336|NCT06736548|BEHAVIORAL|Coaching Session|Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
219479337|NCT07048730|OTHER|Questionnaire|"A standardized questionnaire was specifically developed for the study to explore:~* Women's socio-demographic data~* Data about their hematological disease (type of leukemia, conditioning protocol, relapses, graft-versus-host disease etc.)~* Information received by patients prior to transplantation concerning gynecological complications~* Symptoms, screening, diagnosis and treatment of the main gynecological complications~* Patients fertility (spontaneous or after assisted reproductive treatments)"
219522322|NCT02393040|OTHER|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
219522323|NCT07013682|BIOLOGICAL|PRF as adjunct to non-surgical mechanical debridement|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, the PRF will be inserted in all pockets of the allocated side of the jaw in all pockets ≥ 5 mm.
219522324|NCT07013682|BIOLOGICAL|Control, non-surgical mechanical debridement alone|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, an empty sy will be inserted in all pockets of the allocated control side of the jaw in all pockets ≥ 5 mm.
218863590|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
218863591|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
218863592|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
218863593|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
218863594|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
218863595|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
218863596|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
218863597|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
218863598|NCT00314301|DEVICE|loaded sit-to-stand training|
218863599|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
218863600|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
218863601|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
218863602|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
218863603|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
218863604|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
218863605|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
218863606|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
218863607|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
219479338|NCT07047846|OTHER|Dynamic soft tissue mobilization|Begin with gentle heat application or light massage to warm up the tissue for 5 minutes. Assess the range of motion and identify specific areas of tightness and pain. - Use hands or specialized tools to apply sustained pressure to the fascia and underlying muscles, concentrating on the scapular, pectoral, deltoidal, and rotator cuff muscles. Apply specific DSTM techniques to the identified muscles, gradually increasing the intensity as tolerated by the patient. Follow up with gentle stretching and strengthening exercises to maintain the gained ROM and improve muscle function.For subscapular are release Gentle circular movements over the subscapularis region to decrease the tension and increase the freedom of this muscle.For Supraspinatus and Infraspinatus Work Specific exercise over these muscles to help relieve pain and improve the shoulder joint.
219479339|NCT07047846|OTHER|Bowen Technique and 3 moves|As the client sits, take a position across from the shoulder that needs attention. Hold the side you are working on by its forearm. Arrange the forearm so that it is horizontal at about chest level, keeping the elbow at a 90˚ angle and the shoulder apart from the trunk. Move 1: This is an anterior move that involves placing the fingers of the other hand over the midpoint of the triceps and posterior deltoid tendon, which is situated deeper. The ideal way to execute the exercise is to adduct the shoulder joint to its maximum ROM while placing the thumb of the same hand on the humeral head.Move 2: After the shoulder has fully adducted to the other side, strike the humeral head percussionally in the neck's direction. Move 3: Put the arm back in the beginning position and work the anterior deltoid at its midpoint with a supero-lateral move. Then take a pause for 2 minutes and repeat the moves. Complete 3 sets of all these moves in 35 minutes including 2 minutes pause after these 3 moves.
219479340|NCT07047469|PROCEDURE|Group (1): spinal anesthesia with median approach|patients undergoing orthopedic surgery will receive spinal anesthesia with median approach under ultrasound guided techniques
219479341|NCT07047469|PROCEDURE|Group (2): spinal anesthesia with paramedian approach|patients undergoing orthopedic surgery will receive spinal anesthesia with paramedian approach under ultrasound guided techniques
218863608|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
218863609|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
219479342|NCT07046884|BEHAVIORAL|Integrated Oncological Decision-making Model|In the IODM-based practice, the following three information components should be incorporated when forming a personalized treatment plan: 1. State-of-the-art oncological treatment options with advantages and disadvantages; 2. General health status based on physical, psychosocial, and emotional functioning; 3. Goals and preferences of the patient, both in treatment and daily life. Together with the professionals, optimal tools and strategies to integrate these components within the care path will be discussed.
219479343|NCT07048145|DEVICE|Vaginal Kegel Exercise Ball|A 90-gram medical-grade silicone device with internal jiggle balls used intravaginally for 30 minutes daily in the first 3 weeks and 1 hour daily in the final 3 weeks.
219479344|NCT07048145|BEHAVIORAL|Pelvic Floor Muscle Training|Participants will perform daily Kegel exercises for 6 weeks, starting with 5 sets per day and increasing to 10 sets per day in the final 3 weeks. Each set consists of 10 fast and 10 slow contractions.
219479345|NCT07047898|DRUG|The group receiving dexmedetomidine infusion|Dexmedetomidine will be administered intravenously at an infusion dose of 0.2-0.7 µg/kg/hour during the maintenance phase of anesthesia.
219479346|NCT07047898|DRUG|The group not receiving dexmedetomidine infusion|Infusion will not be given.
219479347|NCT06212544|BEHAVIORAL|Immediate Intervention|Enhanced microeconomic intervention
219479348|NCT06212544|BEHAVIORAL|Delayed Intervention|Usual care and then access to enhanced microeconomic intervention
219597823|NCT02768831|OTHER|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
218863610|NCT03327168|DRUG|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
218863611|NCT03327168|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
218863612|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
218863613|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
218863614|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
218863615|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
218863616|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
218863617|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
218863618|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
219479349|NCT05131828|DRUG|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
219479350|NCT05131828|DRUG|Placebo|Placebo tablets to match both metformin and clemastine tablets.
219479351|NCT06896565|DRUG|nano hydroxy apatite varnish|Intervention (1)
219479352|NCT06896565|DRUG|Potassium Nitrate Gel|Intervention (2)
219479353|NCT06896565|DRUG|Varnishes, Fluoride|Control
219479354|NCT06748690|PROCEDURE|mucosal cutting biopsy|"Under intravenous anesthesia, the patient inserted a gastroscopy (Olympus GIF-260J) through the mouth and used a disposable high-frequency cutting knife to cut open the surface mucosa of the tumor. Biopsy forceps were used to extract tissue that could be fully evaluated for pathological examination. Use a disposable hemostatic clip to suture the mucosal incision, and after thorough observation of the hemostasis, withdraw from the endoscope.~("
219479355|NCT06748690|PROCEDURE|endoscopic ultrasound-guided-fine needle aspiration|2\) EUS-FNA group: Standard (Endoscopic Ultrasonography-Guided Fine-Needle Aspiration) EUS-FNA technology was used, and electronic linear array ultrasound endoscopy (GF-UCT-260, Olympus, Japan) was used to scan and locate the lesion. Puncture needle (Boston Scientific, USA) was used for aspiration biopsy. The thickness of the puncture needle depends on the size, hardness, and location of the tumor.
219479356|NCT06896968|BEHAVIORAL|Earthquake Preparedness and Awareness Training|Earthquake Preparedness and Awareness Training + standard education
219479357|NCT03222856|DRUG|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
219479358|NCT03222856|DRUG|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
218863619|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
218863620|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
219040008|NCT05155384|OTHER|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
219479359|NCT05925322|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
219479360|NCT05925322|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
219479361|NCT06898255|DRUG|GFS202A injection|Participants will receive GFS202A intravenously every 3 weeks (Q3W) in a 21-day cycle. The treatment duration was 12 weeks.
219479362|NCT03934372|DRUG|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
219479363|NCT04587687|DRUG|Bendamustine Hydrochloride|Given IV
219479364|NCT04587687|DRUG|Brentuximab Vedotin|Given IV
219479365|NCT02346747|BIOLOGICAL|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
219479366|NCT02346747|OTHER|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
219479367|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
219479368|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
219479369|NCT06828380|RADIATION|Particle beam radiation therapy|The prescribed dose and fractionation for proton therapy to the PTV will be determined by the physician, taking into account the dose-volume constraints of normal tissues such as the liver and bowel.
219479370|NCT06861452|DRUG|RR001|RR001, a cell-based gene therapy administered following administration of chemotherapy (Nab-PTX 125 mg/mq and GEM 1000 mg/mq)
219522325|NCT07024654|DRUG|Doxycycline Injection|Injection of doxycycline as a sclerosing agent into the genicular artery region under ultrasound guidance for the purpose of evaluating its effectiveness in reducing knee pain.
219522326|NCT07027553|BEHAVIORAL|Mobile health exercise programme|8 week personalised exercise intervention. Delivered and monitored via mobile health technology
218863621|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
218863622|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
218863623|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
218863624|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
218863625|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
218863626|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
218863627|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
218863628|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
218863629|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
218863630|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
218863631|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
219479371|NCT06805877|OTHER|Predictive Analytics and Clinical Decision Support|The intervention will include automated EHR notifications to clinicians at 16 OCHIN community health centers about patients who are likely to benefit from PrEP. These patients will be identified by an HIV prediction model that was developed and validated during the pilot phase of this study using historical OCHIN EHR data. For patients above a preselected threshold of predicted HIV risk, clinicians will be notified at the point of care that the patient may benefit from PrEP and will be provided with EHR-based tools to support discussions and prescribing. The intervention will also include coaching on PrEP and the decision support tool, as well as project team support during the trial period.
219479372|NCT04299646|RADIATION|Steretactic radiotherapy|Steretactic radiotherapy
219479373|NCT03923907|BEHAVIORAL|EIM intervention group|As in arm description
218863632|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
218863633|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
219479374|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
218863634|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
218863635|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
219020829|NCT07205354|OTHER|ADAPTATION|"For each patient (set of at least 35 patients), the assessor will ask the patient:~* Have you ever eaten this food? YES or NO~* Does the photo match the description? YES or NO~* 20 photos of foods per category are provided (10 + 10)~* If the foods tested are recognised (YES answer to both questions) by more than 80% of the study population, they will be retained.~* The 16 foods (8+8) with the highest recognition rates will be retained.~* If fewer than 16 foods (8+8) per category are recognised, the list will be modified by retaining the recognised foods and adding new foods to obtain the 'modified list'.~  2- If the criteria are not validated, a modified list is resubmitted to a new sample of 35 patients until the objectives are validated and a suitable questionnaire is obtained.~Obtaining an ADAPTED DYSPHAGING PREFERENCES QUESTIONNAIRE is a prerequisite for moving on to the test-retest reliability phase"
219479375|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
219479376|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
219522327|NCT07027553|OTHER|Lifestyle maintenance|Continue current lifestyle
219522328|NCT07027319|OTHER|Parenting Education|The intervention group will receive 8 sessions of Triple P (positive parenting training).
218863636|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
218863637|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
218863638|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
218863639|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
218863640|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
218863641|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
218863642|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
218863643|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
218863644|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
218863645|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
218863646|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
218863647|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
218863648|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
218863649|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
218863650|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
218863651|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
218863652|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
218863653|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
218863654|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
218863655|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
218863656|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
218863657|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
218863658|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
218863659|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
218863660|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
218863661|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
218863662|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
218863663|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
218863664|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
218863665|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
218863666|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
218863667|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
218863668|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
218863669|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
218863670|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
218863671|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
218863672|NCT03159104|DRUG|Placebo|Tablet for oral use.
218863673|NCT06542991|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
218863674|NCT00242307|DRUG|Roflumilast|
218863675|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
218863676|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
218863677|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
218863678|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
218863679|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
218863680|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
218863681|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
218863682|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
218863683|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
218863684|NCT05987436|OTHER|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
218863685|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
218863686|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
218863687|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
218863688|NCT00478309|OTHER|counseling intervention|
218863689|NCT00478309|OTHER|educational intervention|
218863690|NCT04722757|PROCEDURE|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
218863691|NCT04722757|PROCEDURE|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
218863692|NCT04958746|DRUG|Ciprofol|intravenous bolus
218863693|NCT04958746|DRUG|Propofol|intravenous bolus
218863694|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
218863695|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
219479377|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
218863696|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
219020830|NCT07205354|OTHER|test-retest reliability|"For each patient (new set of 35 patients)~* the DYSPHAGING preferences questionnaire (including previously adapted pictures) will be assessed and preference indexes will be determined.~* Within 3-7 days, each patient will be asked for the forced choice in the second step of phase 2. A new preference index will be determined using the first recognition and the second forced choices answers.~* Test-retest reliability will be assessed by determination of an intra-class correlation coefficient between the two indexes obtained for each patient tested. (Good test-retest reliability will be considered with an intra-class correlation coefficient upper than 0,75 in each category and will be expected in at least 4 of the 6 tested categories to perform the cross-sectional study (phase 3)"
219479378|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
219479379|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
219479380|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
219479381|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
219479382|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
218863697|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
219020831|NCT07205354|OTHER|Cross-sectional study|"For each patient (new set of 174 patients)~* the DYSPHAGING preferences questionnaire (including previously adapted pictures) will be assessed and preference indexes will be determined.~* In addition, for each patient, collection of geriatric covariates obtained in routine care will be performed for analyses ( demographic characteristics (age, sex, functionality according to the activity of daily living (ADL)8 and instrumental ADL6 scores), local and factors affecting taste, mastication or dietary patterns (dental condition/dental apparatus, alcoholism, smoking, food allergies, comorbidities, treatments), nutritional status (ideal and current weight/height/BMI, albumin, pre-albumin, Vitamins B12, B9, D), comedications (as described as according to the galenic form and drug class prescribed) and swallowing disorders (EAT-10 score with cut-off of 3)"
218863698|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
219020832|NCT07206368|OTHER|Fall prevention exercise|Participants will attend a virtual exercise-based group fall prevention class that focuses on movement and obstacle negotiation 3 times per week for 3 months.
219479383|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
219479384|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
218863699|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
218863700|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
218863701|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
219479385|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
218863702|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
218863703|NCT03098225|RADIATION|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
218863704|NCT03098225|DRUG|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
218863705|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
218863706|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
218863707|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
218863708|NCT01086176|DEVICE|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
218863709|NCT00235911|DRUG|budesonide/formoterol Turbuhaler|
218863710|NCT03053869|DRUG|Benzodiazepine - limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
219479386|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
219479387|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
219479388|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
219479389|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
219479390|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
218863711|NCT03053869|DRUG|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
218863712|NCT06387836|DRUG|Isoflurane 0.8 MAC|Patients in this group will be anesthetized using isoflurane with the depth of 0.8\~1.0MAC during the operation.
219479391|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
219479392|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
219479393|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
219479394|NCT02246244|DRUG|Escitalopram|
219479395|NCT02246244|OTHER|Placebo|
219479396|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
219479397|NCT03542864|OTHER|Control|Progress registration of body composition values
219479398|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
218863713|NCT06387836|DRUG|Desflurane 0.8MAC|Patients in this group will be anesthetized using desflurane with the depth of 0.8\~1.0MAC during the operation.
218863714|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
218863715|NCT00434356|DRUG|sunitinib|Oral repeating dose
218863716|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
218863717|NCT00006268|BIOLOGICAL|cintredekin besudotox|
218863718|NCT00006268|DRUG|isolated perfusion|
218863719|NCT00006268|PROCEDURE|conventional surgery|
219040009|NCT05155384|OTHER|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
219479399|NCT00013910|DRUG|NNC 90-1170|
219479400|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
219479401|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
219479402|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
218863720|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
218863721|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
218863722|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
218863723|NCT06829641|PROCEDURE|Tislelizumab Combined with Chemotherapy,|Tislelizumab Combined with Chemotherapy as Induction Therapy
218863724|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
218863725|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
218863726|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
218863727|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
218863728|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
218863729|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
218863730|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
218863731|NCT02315482|PROCEDURE|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
218863732|NCT05714137|BEHAVIORAL|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
218863733|NCT00151372|BEHAVIORAL|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
218863734|NCT00151372|BEHAVIORAL|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
218863735|NCT03219411|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
218863736|NCT03219411|OTHER|placebo|Placebo administered orally as capsules three times a day over 12 weeks
218863737|NCT03301116|BEHAVIORAL|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
218863738|NCT03301116|BEHAVIORAL|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
218863739|NCT06208345|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
218863740|NCT03348995|DEVICE|Bridge-Enhanced ACL Restoration (BEAR)|In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
218863741|NCT06360341|BEHAVIORAL|Emergency Department Digital Pain Self-Management Intervention (EDPSI)|The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
218863742|NCT06360341|OTHER|Routine Discharge Care|Routine Discharge Care
219020833|NCT07206368|OTHER|Health promotion education|Participants will attend a virtual group health promotion education class that focuses on reasons to maintain a healthy lifestyle and local resources to support them in this. The sessions will take place 1 time per week for 3 months.
219040010|NCT05155384|OTHER|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
218863743|NCT05276310|BIOLOGICAL|IMC-002|Part 1: Dose escalation IMC-002 5, 10, 20, and 30 mg/kg over 3 hours (±30 minutes) intravenous (IV) infusion every 2 weeks Part 2: Expansion cohort IMC-002 20 mg/kg over 3 hours (±30 minutes) IV infusion at the first cycle, if the first infusion is tolerated, then over 1 to 1.5 hours (±10 minutes) IV infusion at all following cycles every 3 weeks In hepatocellular (HCC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In triple negative breast cancer (TNBC) Cohort, Paclitaxel 175 mg/m2 IV infusion on Day 1 of each cycle, or Gemcitabine 1,000 mg/m2 followed by Carboplatin AUC 2 IV infusion on Day 1 and Day 8 of each cycle In biliary tract cancer (BTC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In B-cell lymphoma Cohort, Rituximab 375 mg/m2 IV infusion on Day 1 of each cycle
218863744|NCT05845671|DRUG|Amivantamab 1050mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
219020834|NCT07205016|BEHAVIORAL|Dual task exercise|The intervention group will conduct the same multicomponent intervention than the control group, but adding the dual cognitive task while performing the therapeutic physical activity, which may include counting numbers backwards, in 2s, mentioning names of animals, food, countries and others. The objective of this additional condition is to stimulate cognitive and functional capacity simultaneously, increasing the complexity of the activity and the transfer to daily life activities.
219020835|NCT07205016|BEHAVIORAL|Otago exercise|The proposed intervention is a multicomponent program designed to address frailty in community-dwelling older adults. It integrates three evidence-based domains: therapeutic physical activity, cognitive psychological intervention, and nutritional support.
219020836|NCT07206199|BEHAVIORAL|exposure therapy in virtual reality|Participants complete five 30-40-minute sessions of exposure therapy administered via a virtual reality headset once a week. The exposure involves exposure to various symptom-provoking scenarios in the virtual house environment. Scenarios can be adjusted to distinct OCD dimensions: contamination/cleaning, fear-of-harm/checking symmetry/ordering, and also to symptoms of hoarding. Stimuli can be also freely combined across different dimensions, so that the scenarios fit the individual needs.
219020837|NCT07206199|OTHER|Wait list|The patients are assigned to a waitlist period for 5 weeks. During this period they are not allowed to change any treatment (phramacotherapy and/or psychoterapy as usual) started prior to the trial.
219479403|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
219479404|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
219597824|NCT03280381|OTHER|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
219597825|NCT03280381|OTHER|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
219597826|NCT01772485|BEHAVIORAL|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
219479405|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
218863745|NCT05845671|DRUG|Amivantamab 1400mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
218863746|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
219040011|NCT05155384|OTHER|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
219040012|NCT05155384|DEVICE|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
219479406|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
219479407|NCT00823680|DRUG|Placebo|po bid for 4 weeks
219479408|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
219479409|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
219479410|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
219479411|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
219479412|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
219040013|NCT02393963|DRUG|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
219479413|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
219479414|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
219479415|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
219522329|NCT07027670|DRUG|5-Aminolevulinic Acid hydrochloride (5-ALA)|5-ALA: supplied for oral administration as a dark green, opaque, size 0, hypromellose (HPMC) capsule containing drug alone at a dosage strength of 75mg (58.7mg as 5-ALA). There are no excipients.
219522330|NCT07027670|OTHER|Placebo|Supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing 125mg lactose. The capsule shells are of non-animal origin, and are comprised of HPMC, titanium dioxide, and a copper complex of chlorophyllins.
219522331|NCT07027670|DRUG|Sodium ferrous citrate (SFC)|SFC: supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing drug alone at a dosage strength 118mg (12.5mg as Fe). There are no excipients.
219522332|NCT01924130|OTHER|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
219522333|NCT01924130|BEHAVIORAL|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
218863747|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
218863748|NCT05084014|OTHER|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
218863749|NCT05084014|OTHER|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
218863750|NCT05432388|DRUG|remibrutinib|oral tablets
219020838|NCT07206563|DRUG|Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer|"Intervention: Penfluridol, an oral antipsychotic drug, is used as monotherapy. It targets DRD2, inhibits glycolysis, and induces apoptosis.~Dosing Schedule:~Phase Ib: 3+3 dose-escalation design. Initial dose 20 mg weekly, escalating to 40 mg, then 60 mg until recommended Phase II dose (RP2D) is determined based on 21-day DLT assessment.~Phase II: Expansion cohort at RP2D to further evaluate safety and estimate ORR. Duration: Treatment continues until progression, unacceptable toxicity, withdrawal, or investigator decision.~Monitoring: Regular AE/SAE monitoring using NCI-CTCAE v5.0. Assessments include weekly vital signs, biweekly blood tests, and ECGs every 2 weeks. Tumor response evaluated by RECIST 1.1 criteria with imaging every 2-3 cycles.~Dose Modification: Adjustments made for EPS, QTc prolongation, and proteinuria. Rationale for Single-Arm Design: Chosen due to the ultra-rare patient population and lack of established comparators. Efficient for determining RP2D and ORR."
219479416|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
219479417|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
219479418|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
219479419|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
219479420|NCT04928625|DRUG|SHR-A1904|SHR-A1904
219479421|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
219479422|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
219479423|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
219479424|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
219479425|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
218863751|NCT05432388|DRUG|placebo|oral tablets
218863752|NCT05306288|OTHER|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.
218863753|NCT04687033|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
219479426|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
219479427|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
219479428|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
219479429|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
218863754|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
218863755|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
218863756|NCT06546072|OTHER|MRI|
218863757|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
218863758|NCT02920723|OTHER|Training|
218863759|NCT02920723|OTHER|Control|
219479430|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
219479431|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
219479432|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
219479433|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
219479434|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
219479435|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
219479436|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
219479437|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
219597827|NCT01772485|BEHAVIORAL|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
218863760|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
219479438|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
219479439|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
219597828|NCT01141205|BIOLOGICAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
218863761|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
218863762|NCT04300036|DIETARY_SUPPLEMENT|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
218863763|NCT04300036|DIETARY_SUPPLEMENT|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
219597829|NCT01141205|DRUG|Saline|1.2 ml saline intramuscularly
219597830|NCT05810428|PROCEDURE|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
218863764|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
218863765|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
218863766|NCT04831099|DRUG|Placebo|The route of administration is transdermal
218863767|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
218863768|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
218863769|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
219479440|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
218863770|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
219479441|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
218863771|NCT00003252|DRUG|amifostine trihydrate|
218863772|NCT05691374|PROCEDURE|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes \| no), Signs of anchor displacement and location (lateral\|medial row), Location of defect (at the foot print\|medial cuff failure), Status of long biceps tendon (intact\|in continuity\|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
218863773|NCT05691374|PROCEDURE|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
218863774|NCT02743455|DRUG|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
218863775|NCT02743455|BIOLOGICAL|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
218863776|NCT02743455|BIOLOGICAL|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
218863777|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
219479442|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
219479443|NCT03653637|BEHAVIORAL|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
219479444|NCT03653637|BEHAVIORAL|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
219479445|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
219479446|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
219479447|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
219479448|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
219597831|NCT05810428|PROCEDURE|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
219597832|NCT04538482|BEHAVIORAL|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
219597833|NCT04538482|BEHAVIORAL|standard American diet|Participants will receive foods following the standard American diet for 28 days.
219597834|NCT03799432|OTHER|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
219479449|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
219613564|NCT07010562|DEVICE|Data collection|A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization. No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital. A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.
218863778|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
219479450|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
218863779|NCT02743455|BIOLOGICAL|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
218863780|NCT05264116|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
218863781|NCT02772588|DRUG|ARN-509|
218863782|NCT02772588|DRUG|Abiraterone|
218863783|NCT02772588|DRUG|Leuprolide|
218863784|NCT02772588|RADIATION|stereotactic, ultra-fractionated radiotherapy|
219479451|NCT01231880|DRUG|Monthly IPT using DP|Given every month
219479452|NCT01231880|DRUG|Placebo given every month|No active ingredient
219479453|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
219479454|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
219479455|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
219479456|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
219479457|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
219479458|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
219479459|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
219479460|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
219479461|NCT01741259|DRUG|Meperidine|
219479462|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
219479463|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
219479464|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
219479465|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
219479466|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
219479467|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
218863785|NCT04603001|DRUG|LY3410738|Oral LY3410738
218863786|NCT04603001|DRUG|Venetoclax|Oral venetoclax
218863787|NCT04603001|DRUG|Azacitidine|Subcutaneous or intravenous azacitidine
218863788|NCT06419166|DRUG|GC012F injection|"Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells"
218863789|NCT01073475|OTHER|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
218863790|NCT05756608|DIAGNOSTIC_TEST|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
218863791|NCT03357874|DRUG|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
218863792|NCT03357874|DRUG|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
218863793|NCT02808910|BEHAVIORAL|Nudged to eat less added salt and more other seasonings|
218863794|NCT02808910|BEHAVIORAL|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
218863795|NCT02808910|BEHAVIORAL|Nudged to eat more vegetables|
218863796|NCT02808910|BEHAVIORAL|Nudged to eat smaller portions|
218863797|NCT02808910|BEHAVIORAL|Nudged to eat less calorie-dense food|
218863798|NCT02220426|DRUG|Xenon|Inhalation of hyperpolarized xenon gas
218863799|NCT06034652|DEVICE|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
218863800|NCT05627219|BEHAVIORAL|Training and Education|Undergo training and education
218863801|NCT05627219|OTHER|Educational Intervention|Receive educational booklet
218863802|NCT05627219|PROCEDURE|Discussion|Attend discussion with peer genetic coach
218863803|NCT06196125|OTHER|Four body positions|Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
218863804|NCT05351216|OTHER||No intervention
218863805|NCT06392776|OTHER|Early diagnosis and treatment|Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
218863806|NCT06570382|OTHER|Videos: Taste messaging focused|Participants in this intervention will watch the taste focused videos.
218863807|NCT06570382|OTHER|Videos: Health messaging focused|Participants in this intervention will watch the health focused videos.
218863808|NCT06569953|DRUG|Liposomal bupivacaine|Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
218863809|NCT06569953|DRUG|Bupivacaine Hydrochloride|Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
218863810|NCT02965885|DRUG|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
218863811|NCT05796973|BEHAVIORAL|Guided physical exercise|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
218863812|NCT05796973|DRUG|Atorvastatin|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
219479468|NCT05984329|OTHER|Retrospective analysis of patients' choice|Retrospective analysis of patients' choice of tonic or Burst DR(TM) waves for their analgesic effect.
219479469|NCT00027573|BIOLOGICAL|filgrastim|
219479470|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219479471|NCT00027573|DRUG|cyclophosphamide|
219479472|NCT00027573|DRUG|fludarabine phosphate|
219479473|NCT00027573|DRUG|methotrexate|
219479474|NCT00027573|DRUG|tacrolimus|
219479475|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
219479476|NCT06537531|OTHER|Compare VCI scale|Compare VCI scale
219479477|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
219479478|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
219479479|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
219479480|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1\) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
219597835|NCT03799432|OTHER|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
219597836|NCT04052334|DRUG|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
218863813|NCT05796973|OTHER|Independent exercise|The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
218863814|NCT04901741|DRUG|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
218863815|NCT04901741|DRUG|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
218863816|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
218863817|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
218863818|NCT02448589|DRUG|TAS-119|
219479481|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
219479482|NCT03165630|BEHAVIORAL|Transportation incentives|Free transportation only for the first 3 months post-discharge.
219479483|NCT03165630|BEHAVIORAL|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
219479484|NCT01262274|DRUG|Anastrozole|ANA is given 1mg daily for 24 weeks.
219479485|NCT01262274|DRUG|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
219479486|NCT02342574|DRUG|F901318|Administration of active compound
219479487|NCT02342574|DRUG|Placebo|Administration of placebo
219479488|NCT00216073|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
219479489|NCT00216073|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
219479490|NCT00216073|DRUG|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
219479491|NCT03818867|PROCEDURE|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
219199664|NCT06738693|PROCEDURE|Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate|ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
219479492|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
219479493|NCT06514586|DRUG|Oxytocin|Oxytocin gel 600 IU . 1mg/g
219479494|NCT06514586|OTHER|Hydroxypropyl methylcellulose|Placebo
219479495|NCT04485624|OTHER|No intervention|Observational study
219479496|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
219479497|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
219479498|NCT06613412|DIAGNOSTIC_TEST|Remote Robotic Bronchoscopy system|Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
219597837|NCT04052334|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
219597838|NCT04052334|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
219597839|NCT04052334|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
219597840|NCT04664933|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
219597841|NCT05937828|OTHER|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
218863819|NCT03737721|COMBINATION_PRODUCT|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
218863820|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
218863821|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
218863822|NCT06508983|DRUG|SG301 Injection|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
218863823|NCT06508983|DRUG|SG301 placebo|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
219199665|NCT06737003|DEVICE|Nasal high frequency oscillatory ventilation|NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
219597842|NCT03651882|DRUG|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
219597843|NCT03651882|DRUG|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
219597844|NCT03430388|BIOLOGICAL|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
219479499|NCT03109613|DEVICE|Positive end-expiratory pressure (PEEP)|level changes as per arm description
218863824|NCT06508983|DRUG|pomalidomide|Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
219479500|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
219479501|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
219479502|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
219479503|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
219479504|NCT00976859|BEHAVIORAL|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
219479505|NCT00976859|BEHAVIORAL|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
219479506|NCT05388032|BEHAVIORAL|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to \<2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
219479507|NCT02384837|DEVICE|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
219479508|NCT03173807|BEHAVIORAL|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
218863825|NCT06508983|DRUG|dexamethasone|Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
218863826|NCT02651480|DIETARY_SUPPLEMENT|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
218863827|NCT02651480|DIETARY_SUPPLEMENT|Control Group|Unrestricted diet with no instruction.
218863828|NCT05544136|DIAGNOSTIC_TEST|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
219479509|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
219479510|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
219479511|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
219522334|NCT01924130|BEHAVIORAL|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
219522335|NCT01924130|BEHAVIORAL|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
219522336|NCT03953170|DRUG|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
218863829|NCT05544136|RADIATION|Chemoradiation therapy|"* 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
218863830|NCT05544136|DRUG|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
218863831|NCT06579690|DRUG|8.4% sodium bicarbonate solution|Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
219522337|NCT03953170|DRUG|Placebo|Placebo
218863832|NCT06579690|OTHER|0.9% Normal Saline|The comparision group will receive 50 mls of 0.9% Normal Saline
219040014|NCT02393963|OTHER|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
219522338|NCT07029308|PROCEDURE|Modified poco-poco exercise program as the home-based therapy (Intervention)|Patient will do the exercise at home 5 days/week and supervised via zoom application. Supervised via Zoom will be conducted every week. The instructor will monitor the exercise movement of the participants, if there is any mistake the instructor will pause the session and correct it immediately. The monitoring will also be done by researcher assistant to collect attendance, help ensure correct movement and operational problem. The intensity of the exercise will be evaluated and adjusted every 4 weeks.
219522339|NCT07028840|OTHER|Physiotherapy|10 sessions over 2 weeks, including TENS, cold therapy, ultrasound, and exercise therapy, 5 sessions per week.
219522340|NCT07028840|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|4 sessions total, applied 2 times per week for 2 weeks.
219040015|NCT00235872|BIOLOGICAL|adalimumab|40 mg eow, sc
219040016|NCT00004066|BIOLOGICAL|filgrastim|
219040017|NCT00004066|DRUG|docetaxel|
219040018|NCT00004066|DRUG|gemcitabine hydrochloride|
219522341|NCT07028840|DEVICE|High-Intensity Laser Therapy (HILT)|4 sessions total, applied 2 times per week for 2 weeks.
219522342|NCT06625307|DRUG|NNC0537-1482|Administered via subcutaneous route
219522343|NCT06625307|DRUG|Placebo|Administered via subcutaneous route
219522344|NCT07025915|DRUG|[14C]SSS17|single oral dose
219522345|NCT03328793|BEHAVIORAL|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
219522346|NCT03328793|BEHAVIORAL|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
219479512|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
219479513|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
219479514|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
218863833|NCT06579846|DRUG|Cytisinicline and exercise|"Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes."
218863834|NCT06579846|DRUG|Cytisinicline|Same intervention as the experimental group without directed exercise prescription
218863835|NCT05773963|DEVICE|Irilens; Iridina; Afomill Lubricating Eye Drops|"* Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
218863836|NCT06528288|PROCEDURE|Erector Spinae Plane Block|The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.
218863837|NCT06528288|PROCEDURE|Subcutaneous Anesthesia|Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
218863838|NCT05725018|BIOLOGICAL|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"
218863839|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
218863840|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
218863841|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
218863842|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
218863843|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
218863844|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
219020839|NCT07206823|DRUG|Romiplostim N01|"Romiplostim N01 will be administered via subcutaneous injection once weekly for a total treatment duration of 12 weeks. The starting dose is set at 3 μg/kg. Weekly dose adjustments will be guided by platelet counts measured immediately prior to administration, as follows:~For a platelet count below 50 × 10⁹/L, the dose will be increased by 1 μg/kg.~For a platelet count between 50 and 200 × 10⁹/L, the current dose will be maintained as the minimum therapeutic dose for bleeding risk reduction.~For a platelet count between 200 and 400 × 10⁹/L, the dose will be decreased by 1 μg/kg.~For a platelet count exceeding 400 × 10⁹/L, the administration will be withheld. It is stipulated that dosing will resume at a reduction of 1 μg/kg from the previous dose once the platelet count returns to 200 × 10⁹/L or below.~Under no circumstances shall the dose exceed the maximum allowable limit of 10 μg/kg per week."
219479515|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
219020840|NCT07206823|DRUG|Rituximab|Rituximab will be administered in accordance with the Chinese guidelines for the diagnosis and management of adult primary immune thrombocytopenia (2020 edition). The dosage will be 375 mg/m² per infusion, administered via intravenous infusion once weekly for a total of four weeks.
219199666|NCT06737003|DEVICE|Vapotherm Group|The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
219479516|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
219479517|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
219479518|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
219479519|NCT01644461|OTHER|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
219479520|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
218863845|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
218863846|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
218863847|NCT00109356|DRUG|AQ4N (Chemotherapy)|
219479521|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
219479522|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
219479523|NCT05905874|OTHER|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
218863848|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
218863849|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
219479524|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
219479525|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
218863850|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
218863851|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
219479526|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
219479527|NCT02354352|DRUG|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
219479528|NCT02354352|DRUG|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
219479529|NCT05657964|DEVICE|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
219479530|NCT02885259|DRUG|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
219479531|NCT05211037|DIAGNOSTIC_TEST|Kidney function assessment|kidney clearance measured by scintigraphy
219597845|NCT02257385|DRUG|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
218863852|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
219479532|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
219479533|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
219479534|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
219479535|NCT03354143|OTHER|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
219479536|NCT03354143|OTHER|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
219479537|NCT03891732|DIAGNOSTIC_TEST|MRI prostate|plain biparametric MRI prostate
219479538|NCT00160771|BEHAVIORAL|Joint Motion Analysis|Joint motion will be recorded for analysis.
219479539|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
219479540|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
219597846|NCT02257385|DRUG|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
219479541|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
218863853|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
218863854|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
218863855|NCT00007267|BEHAVIORAL|Disease/health education|
218863856|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
218863857|NCT02792023|OTHER|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
218863858|NCT02792023|DEVICE|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
218863859|NCT02792023|DEVICE|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
218863860|NCT03908918|OTHER|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
218863861|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
218863862|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
218863863|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
218863864|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
218863865|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
218863866|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
218863867|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
218863868|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
218863869|NCT03242356|OTHER|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~* oral intake of clear fluid during the labor~* oral intake of solid meal during the labor~* fasting duration for solid and liquids~* instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~* discomfort related to thirst during labor~* discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
218863870|NCT02853435|DRUG|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
218863871|NCT02853435|DRUG|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
219199667|NCT06737003|DEVICE|Nasal CPAP Group|CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
219479542|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
219479543|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
219040019|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
219040020|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
219040021|NCT02150668|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|
219040022|NCT02150668|BEHAVIORAL|Homework Support Intervention (HSI)|
219040023|NCT02126969|RADIATION|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
219040024|NCT02126969|DRUG|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
219040025|NCT01164449|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
219479544|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
219597847|NCT02257385|DRUG|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
219597848|NCT02257385|DRUG|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
219597849|NCT02257385|DRUG|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
219597850|NCT02257385|DRUG|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
218863872|NCT02853435|DRUG|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
218863873|NCT03747120|DRUG|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
218863874|NCT03747120|DRUG|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
218863875|NCT03747120|DRUG|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
218863876|NCT03747120|DRUG|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
218863877|NCT04467671|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
218863878|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
218863879|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
218863880|NCT02194322|DRUG|Placebo|
218863881|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
218863882|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
218863883|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
218863884|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
218863885|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
218863886|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
218863887|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
218863888|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
218863889|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
218863890|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
218863891|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
218863892|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
218863893|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
218863894|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
218863895|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
218863896|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
218863897|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
218863898|NCT02804750|DRUG|CORT125134|
218863899|NCT01073917|OTHER|Spontaneous Breathing|
219479545|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
219479546|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
218863900|NCT01073917|OTHER|Pressure Controlled Ventilation|
218863901|NCT01073917|OTHER|Pressure Support Ventilation|
218863902|NCT04144959|DEVICE|Indigo Aspiration System|Indigo Aspiration System
218863903|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
218863904|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
218863905|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
218863906|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
218863907|NCT05674799|BEHAVIORAL|NDPP-NextGen|"NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance."
218863908|NCT05031065|RADIATION|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
218863909|NCT05627583|OTHER|Rehabilitation|Hospitalized patients with AN under treatment for rehabilitation
218863910|NCT05048433|BEHAVIORAL|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
218863911|NCT05048433|BEHAVIORAL|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
218863912|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
218863913|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
218863914|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
218863915|NCT03591172|DRUG|Propolis|Using propolis as a final irrigation in revascularization
218863916|NCT03591172|DRUG|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
218863917|NCT03591172|DRUG|saline|Using saline as a final irrigation in revasculariztion
218863918|NCT02886871|BEHAVIORAL|Step Goal Delivery by Smartphone|
218863919|NCT02975726|DEVICE|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
218863920|NCT02975726|PROCEDURE|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
218863921|NCT02975726|BIOLOGICAL|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
218863922|NCT02975726|PROCEDURE|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
218863923|NCT04964596|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
218863924|NCT04964596|DIAGNOSTIC_TEST|FIT test|faecal immunochemical test
218863925|NCT04964596|DIAGNOSTIC_TEST|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
218863926|NCT06583785|OTHER|Black rice (Intervention)|210 g of cooked black rice
218863927|NCT06583785|OTHER|Brown rice (Control)|210 g of cooked brown rice
219199668|NCT06741059|OTHER|Transkutanöz Elektriksel Sinir Stimülasyonu - TENS|Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option
219479547|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
218863928|NCT06583811|DRUG|Remifentanil|to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
218863929|NCT06584123|DIAGNOSTIC_TEST|18F-Fluoro-ethyl-tyrosine (FET) PET|18F-Fluoro-ethyl-tyrosine PET study of the pituitary
218863930|NCT06584019|OTHER|Range Of Motion applied group|Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
218863931|NCT00308165|PROCEDURE|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
218863932|NCT00308165|DRUG|Topotecan|chemotherapeutic drug for the treatment of brain tumors
218863933|NCT05871996|OTHER|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
218863934|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
218863935|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
218863936|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
219479548|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
218863937|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
218863938|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
219479549|NCT00373282|DRUG|Triamcinolone acetonide|
218863939|NCT04248894|OTHER|Untraining|Sedentary
218863940|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
218863941|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
218863942|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
218863943|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
218863944|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
218863945|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
218863946|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
218863947|NCT00002506|BIOLOGICAL|recombinant interferon alfa|
218863948|NCT00002506|DRUG|isotretinoin|
219479550|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
218863949|NCT04271475|DRUG|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
219199669|NCT06735105|DIAGNOSTIC_TEST|Scanning parameter|Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.
219199670|NCT06743412|OTHER|Regular music listening|Regular listening of self-selected music sung in Italian language during the hospital stay and after discharge till the follow-up visit after 3 months.
219199671|NCT06739434|GENETIC|GCB-002|GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.
219479551|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
219199672|NCT06754618|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
219479552|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
219479553|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
219479554|NCT01510704|DRUG|APD421|IV
219199673|NCT06740318|OTHER|Motivational enhancement therapy|The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
219479555|NCT01510704|DRUG|Placebo|IV
219479556|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
219479557|NCT02208518|DEVICE|EUS-elastography|
219479558|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
219479559|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
219479560|NCT02763410|OTHER|PRBC transfusion|
218863950|NCT04271475|DRUG|Placebo|Participant will receive matching placebo tablets orally od.
218863951|NCT06585709|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
218863952|NCT06585709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
218863953|NCT06585709|DIAGNOSTIC_TEST|High Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define high ventral striatal reactivity as having \>mean voxels in the ventral striatum activate
218863954|NCT06585709|DIAGNOSTIC_TEST|Low Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define low ventral striatal reactivity as having \<mean voxels in the ventral striatum activate
218863955|NCT06454149|OTHER|MALT lymphoma|New diagnosis with gastric MALT lymphoma
219479561|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
219479562|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
219479563|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
219479564|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
219479565|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
219479566|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
219479567|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
219479568|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
218863956|NCT06979908|DRUG|Fruquintinib+Sintilimab+Chidamide|"Fruquintinib: 5 mg orally once daily on days 1-14 of each 21-day cycle (Q3W).~Sintilimab (anti-PD-1): 200 mg intravenously on day 1 of each cycle (first infusion over 60 minutes, subsequent infusions over 30-60 minutes, Q3W).~Chidamide: 30 mg orally twice weekly (BIW; e.g., Monday \& Thursday or Tuesday \& Friday, with ≥3 days between doses), taken 30 minutes after meals."
218863957|NCT06980142|BIOLOGICAL|CM512|Administered SC
218863958|NCT06980142|DRUG|Placebo|Administered SC
218863959|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
218863960|NCT06102811|OTHER|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.075% (50 mL)
218863961|NCT06102811|OTHER|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.25% (50 mL)
218863962|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
218863963|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
218863964|NCT05982444|PROCEDURE|water vapor thermal therapy (Rezum) for prostate|all patients underwent rezum therapy for bph are evaluated for its effectiveness for long period
218863965|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
219479569|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
219479570|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
219479571|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
219479572|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
219479573|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
219479574|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
219479575|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
219479576|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
218863966|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
218863967|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
218863968|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.
218863969|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)
218863970|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.
218863971|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
218863972|NCT06053398|DRUG|Phenylephrine|Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) \> 65 mm Hg.
218863973|NCT06053398|DRUG|Norepinephrine|Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
218863974|NCT07041788|DRUG|Iparomlimab and Tuvonralimab Injection|"Induction Therapy:~Spatially Fractionated Radiotherapy: Administer 10-20 Gy in a single fraction to the tumor.~Chemotherapy + Immunotherapy:~Docetaxel 75 mg/m² IV on Day 1. Cisplatin 25 mg/m² IV on Days 1-3. Iparomlimab and Tuvonralimab Injection 5 mg/kg IV on Day 1. Cycles: Every 3 weeks (Q3W) for 3 cycles.~Maintenance Therapy:~Begin 4-6 weeks after radiotherapy completion.~Iparomlimab and Tuvonralimab:~Dose: 5 mg/kg diluted in 100 mL 0.9% NaCl or 5% glucose. Administration: IV infusion over ≥20 minutes (total duration including flushing ≤60 minutes).~Cycles: Q3W for 14 cycles (maximum 1 year).~Iparomlimab and Tuvonralimab Injection:~Continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of consent, or investigator decision to discontinue.~Maximum treatment duration: 1 year."
218863975|NCT07041710|OTHER|experimental in day hospital|multidisciplinary day hospital
219479577|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
219199674|NCT03441971|DEVICE|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
219479578|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
219479579|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
219479580|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
218863976|NCT07041710|OTHER|taste and smell disorders questionnaire|Answer to the home-made questionnaire at inclusion and at 6 months
218863977|NCT07041645|DIETARY_SUPPLEMENT|Vitamin K|each participant will recive one dose of each of the four vitamin K vitamers but in different orders (4 different orders).
218863978|NCT07040982|DRUG|Asciminib|Given PO
218863979|NCT07040982|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218863980|NCT07040982|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218863981|NCT07040982|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218863982|NCT07040982|PROCEDURE|Echocardiography Test|Undergo echocardiography
218863983|NCT07040982|OTHER|Survey Administration|Ancillary studies
218863984|NCT07040280|DRUG|Sulforaphane (broccoli sprout extract)|Sulforaphane - Three tablets of Avmacol® Extra Strength \[Nutramax\] by mouth, once daily, for 12 months.
218863985|NCT07040280|DRUG|Placebo|Three tablets by mouth, once daily, for 12 months
218863986|NCT07040280|DEVICE|Derma-AI|Photographs of lesions as part of the clinical exam at baseline, three (3) months, and twelve (12) months. These photographs will be submitted for assessment by a software called Derma-AI, which tracks moles over time for changes in size, number, and appearance
219479581|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
219479582|NCT02743182|DRUG|Pegylated interferon alfa-2a|
219479583|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
219479584|NCT06537336|DEVICE|lung function|lung function tests using spirometry
219479585|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
219479586|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
219479587|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
219479588|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
219479589|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
219479590|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
219479591|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
219479592|NCT02269800|DRUG|Normal saline|Tid, 7 days
218863987|NCT07041138|BEHAVIORAL|cognitive behavioural programme with physical training|Participants will receive 7 sessions of cognitive behavioural programme over 8 weeks and have physical training at home for 8 weeks.
218863988|NCT07041138|BEHAVIORAL|health education with physical training|Participants will receive 7 sessions of health education over 8 weeks and have physical training at home for 8 weeks.
218863989|NCT07041138|BEHAVIORAL|Usual Care|Participants will maintain their usual life and activities for 8 weeks.
218863990|NCT07041476|OTHER|Exercise|Tele-rehabilitation methods can provide an important advantage for patients who cannot receive hospital services due to pain, mobility limitations, and distance to the hospital
219479593|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
219479594|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
219479595|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
219479596|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
219479597|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
219479598|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
219479599|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
218863991|NCT07041476|OTHER|telemedicine|Tele-rehabilitation will be achieved through a video conference (VC) via the internet platform Zoom at the time and day 29 decided upon with the therapist
219199675|NCT06812936|DRUG|Acetaminophen|"This intervention involves the administration of acetaminophen 500mg tablets, taken up to three times within the first 24 hours following archwire insertion to manage pain associated with orthodontic treatment. Acetaminophen is a centrally acting analgesic that reduces pain without significantly affecting tooth movement, making it a preferred choice for pain relief in orthodontic patients. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over a five-day period post-bonding to assess the effectiveness of this treatment."
219479600|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
219479601|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
219479602|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
219479603|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
219479604|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
219479605|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
219479606|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
219479607|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
219479608|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
219479609|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
218863992|NCT07040891|BEHAVIORAL|Just ASK training|"Just ASK™ is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training framework aims to increase clinical trial discussions with all cancer patients."
219479610|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
219479611|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
219597851|NCT02257385|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
219597852|NCT03259438|BEHAVIORAL|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
219597853|NCT03259438|BEHAVIORAL|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
219479612|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
219479613|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
219479614|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
219479615|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
219479616|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
219479617|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
219479618|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
219479619|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
218863993|NCT07040384|DEVICE|Knee Extensors Activation (KEA) Device|A portable, non-electric device consisting of an inflatable cushion, pressure gauge, and digital counter. It provides objective feedback during isometric quadriceps exercises after ACL reconstruction. The device encourages full contraction by only counting repetitions that exceed a preset pressure threshold and return to baseline.
218863994|NCT07040384|OTHER|Conventional Towel-Based Exercise|Standard rehabilitation method using a rolled towel under the knee during quadriceps setting exercises. Patients perform isometric contractions without feedback or objective measurement. Repetitions are manually counted by the physiotherapist.
218863995|NCT07041502|OTHER|Aut-CARE|There is no intervention
218863996|NCT07040579|DEVICE|transcatheter closure of outlet VSDs with bioabsorbable occluders|Transcatheter closure of outlet ventricular septal defects using a bioabsorbable occluder (Shape Memory Alloy Ltd, Shanghai, China). Implantation is performed via femoral/transthoracic approach under echocardiographic guidance following standard interventional protocols.
218863997|NCT07040410|PROCEDURE|Aromatherapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, aromatherapy will be administered via inhalation. Five drops of 100% pure organic lavender oil
218863998|NCT07040410|PROCEDURE|Music Therapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, music chosen by the child or parent will be played. Pain and vital signs will be assessed as in the control group.
218863999|NCT07040410|PROCEDURE|Control|"Peritoneal dialysis treatment will be started with discharge first, and then the amount of dialysate fluid determined by the physician's request will be filled. In the clinical routine, nonpharmacological pain treatment method is not applied during excretion and filling. Nonpharmacological pain treatment method will not be applied to the control group. The Wong-Baker Facial Expressions Rating Scale and Life Signs Evaluation Form will be filled in by the researcher at the 0th and 1st minutes of the first discharge and at the 0th and 1st minutes of the first filling."
219479620|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
219479621|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
219479622|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
219479623|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
219479624|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
219479625|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
219597854|NCT05228938|PROCEDURE|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
219597855|NCT05228938|PROCEDURE|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
219597856|NCT03017703|DRUG|Eplerenone|
219597857|NCT01242722|DEVICE|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
219597858|NCT01822366|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy|
219597859|NCT06393946|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
219597860|NCT02875964|DEVICE|electroencephalogram|Implanting electrode to measure brain activity
219597861|NCT02875964|DEVICE|magnetoencephalogram|Implanting electrode to measure brain activity
219597862|NCT03147755|OTHER|No intervention|No intervention
219597863|NCT01990482|DIETARY_SUPPLEMENT|caffe|
219597864|NCT01990482|DIETARY_SUPPLEMENT|Water|
218864000|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with piezotome extraction kit, and subsequent immediate implant placement|piezotome extraction kit,
218864001|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with periotome, and subsequent immediate implant placment|periotome
218864002|NCT06726863|DRUG|Vamifeport IRF|Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.
218864003|NCT06726863|DRUG|Vamifeport PR1|Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.
218864004|NCT06726863|DRUG|Vamifeport PR2|Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
219597865|NCT03414086|OTHER|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
218864005|NCT07040371|OTHER|Health Promotion Behavior Intervention Program|The intervention program is structured around a three-step framework: ① building motivation and providing opportunities; ② reinforcing motivation, enhancing capabilities, and providing opportunities; and ③ sustaining motivation, strengthening capabilities, and providing opportunities. The process involves assessing the current state of health-promoting behaviors among elderly migrants, implementing interventions to promote these behaviors, and evaluating the effectiveness of the interventions. The program spans 12 weeks and is carried out by a team of researchers and nursing students. Key intervention components include: ① helping elderly migrants recognize their health issues, analyzing the impact of migration on health-promoting behaviors, and emphasizing the importance of such behaviors through comparisons of negative and positive case studies; ② conducting thematic training on health habits, dietary nutrition, exercise safety, oral hygiene, and other topics through health lectures,
218864006|NCT07040371|OTHER|receiving routine community care and management only|It primarily included distributing health manuals, conducting regular health education sessions, and performing follow-ups. Researchers and community nurses collected and addressed health-related inquiries raised by the elderly migrants. Additionally, to ensure scientific rigor and equity in the study, compensatory interventions (such as providing equivalent intervention opportunities or distributing relevant intervention materials) were offered to participants based on their actual needs upon completion of the research project.
218864007|NCT07041671|DEVICE|ColdZyme|"ColdZyme is a medical device classified as a Class III device, certified according to the European Medical Devices Regulation (2017/745/EU) (MDR). It has been CE-marked since 2013.~ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The viscous barrier catches the virus and thereby the contact between the virus and the epithelial cells are reduced and avoided, thus the barrier disables the viruses' ability to spread and multiply."
218864008|NCT06823297|OTHER|Total mesorectal excision|Direct surgery without receiving neoadjuvant chemoradiotherapy
218864009|NCT06823297|OTHER|Neoadjuvant Chemotherapy followed by total mesorectal excision|Neoadjuvant chemoradiotherapy treatment regimens (including conventional chemoradiotherapy/radiotherapy/chemotherapy regimens or total neoadjuvant chemoradiotherapy regimens) before surgery
219479626|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
218864010|NCT03756311|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
218864011|NCT06736132|DEVICE|High-flow nasal oxygen|In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.
218864012|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
218864013|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
219597866|NCT03414086|OTHER|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
219597867|NCT05833698|DIAGNOSTIC_TEST|Elevation of NLR|Blood test
219597868|NCT00620087|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
219597869|NCT00620087|PROCEDURE|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
218864014|NCT06727552|BIOLOGICAL|Barzolvolimab|Subcutaneous Administration
219479627|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
219479628|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
219479629|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
219479630|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
219479631|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
218864015|NCT06727552|DRUG|Matching placebo|Subcutaneous Administration
218864016|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
218864017|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
218864018|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
218864019|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
218864020|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
218864021|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
218864022|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
218864023|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
218864024|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
218864025|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
219479632|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
219479633|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
219479634|NCT01761123|BIOLOGICAL|VXA-A1.1|
219479635|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
219479636|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
219479637|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
219479638|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
219479639|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
219479640|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
219479641|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
219479642|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
219479643|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
219479644|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
219479645|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
219479646|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
219479647|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
219479648|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
219479649|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
219479650|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
219522347|NCT03328793|BEHAVIORAL|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
219522348|NCT03328793|OTHER|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
219522349|NCT03328793|OTHER|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
219522350|NCT03328793|OTHER|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
219522351|NCT06709599|OTHER|Three-Week Strength and Conditioning Program|Athletes train six days a week for three weeks, totaling approximately 15 hours of training per week. Training includes circuit training, weightlifting, technique drills, and sparring, designed to mimic typical MMA preparation.
219522352|NCT06707896|DRUG|TCR1020-CD8 T cells|TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.
219597870|NCT00575887|DRUG|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
219597871|NCT03276078|DRUG|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
219597872|NCT03476733|OTHER|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
219199676|NCT06812936|PROCEDURE|Acupressure|This intervention involves the application of acupressure to two specific acupressure points: Jaw Chariot (St 6) and Facial Beauty (St 36). Participants will be trained to apply firm pressure to these points up to five times within the first 24 hours after archwire insertion to alleviate orthodontic pain. Acupressure is a non-invasive therapy based on traditional Chinese medicine that aims to stimulate the body's natural healing processes and promote pain relief by balancing energy flow. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over the first five days post-bonding to assess its effectiveness.
219479651|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
218864026|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
218864027|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
218864028|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
219479652|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
219199677|NCT06811779|DRUG|Sodium Hypochlorite|Sodium hypochlorite used in 5% concentration for disinfection
219479653|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
219479654|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
219479655|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
219597873|NCT05151354|OTHER|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
219597874|NCT00418002|DRUG|AQW051|
219597875|NCT02552732|DEVICE|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
219597876|NCT02686138|DRUG|Tenapanor|
218864029|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
219479656|NCT02966366|DEVICE|Cochlear implant|
219597877|NCT02686138|DRUG|Placebo|
218864030|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
218864031|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
218864032|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
218864033|NCT02508740|DRUG|bevenopran|Single oral dose
218864034|NCT01292083|DRUG|azacitidine|Given IV
218864035|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
218864036|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
218864037|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
218864038|NCT01292083|GENETIC|western blotting|Correlative studies
219199678|NCT06811779|DRUG|Chlorhexidine|Chlorhexidine 0.2% concentration for disinfection
219199679|NCT06826092|DRUG|Metformin Pill|Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy
219597878|NCT04988087|DRUG|MHV370|MHV370 for 24 weeks
219597879|NCT04988087|DRUG|Placebo|Placebo for 24 weeks
219597880|NCT04134338|OTHER|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
219597881|NCT00827437|OTHER|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
219597882|NCT02458287|BIOLOGICAL|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
219597883|NCT02458287|BIOLOGICAL|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
219597884|NCT02458287|BIOLOGICAL|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
219479657|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
219479658|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
219479659|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
219479660|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
219479661|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
219479662|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
219479663|NCT00399204|DRUG|Pioglitazone vs Metformin|
218864039|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
218864040|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
218864041|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
218864042|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
218864043|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
218864044|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
218864045|NCT03165214|DEVICE|coil|microcoils
219479664|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
219479665|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
219479666|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
219479667|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
219479668|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
219479669|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
219479670|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
219479671|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
219479672|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
218864046|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
218864047|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
218864048|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
218864049|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
218864050|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
218864051|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
218864052|NCT00002039|DRUG|Foscarnet sodium|
218864053|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
218864054|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
218864055|NCT00931801|DRUG|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
218864056|NCT02506686|DRUG|Meropenem|Meropenem i.v.
218864057|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74\_R84-086)
218864058|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
218864059|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
218864060|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
218864061|NCT05857449|DRUG|LPM3480392|Intravenous infusion
218864062|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
218864063|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
219479673|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
219479674|NCT02615652|OTHER|no intervention|no intervention, observational study
219479675|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
219479676|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
219597885|NCT02458287|BIOLOGICAL|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
218864064|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
218864065|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
218864066|NCT03755232|OTHER|Control|water or dextrose or white bread
218864067|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
218864068|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
218864069|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
218864070|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
218864071|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
218864072|NCT01995552|DEVICE|External Loop Recorder|
218864073|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
218864074|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
218864075|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
219479677|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
219479678|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
219479679|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
219479680|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
219597886|NCT00087282|DRUG|alvocidib|
219597887|NCT00087282|DRUG|irinotecan hydrochloride|
219597888|NCT06629831|OTHER|group with complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
219597889|NCT06629831|OTHER|group without complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
219597890|NCT05382585|OTHER|Next generation Sequencing|Next generation sequencing for 161 genes
219597891|NCT06423807|DRUG|Ondansetron lozenge|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
218864076|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
218864077|NCT01968057|DRUG|Baricitinib|Administered orally
218864078|NCT01968057|DRUG|Ciclosporin|Administered orally
218864079|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
218864080|NCT02819960|DRUG|Placebo|Maltodextrin
219479681|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
219597892|NCT02600533|PROCEDURE|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
219597893|NCT00655343|DRUG|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
219597894|NCT02290223|BEHAVIORAL|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
219597895|NCT02495623|DRUG|SYN-010 21 mg|
218864081|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
218864082|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
218864083|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
219479682|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
219479683|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
219479684|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
219479685|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
219597896|NCT02495623|DRUG|SYN-010 42 mg|
219597897|NCT02495623|DRUG|Placebo|
219597898|NCT02800642|DRUG|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
219597899|NCT04004585|BEHAVIORAL|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
218864084|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
218864085|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
218864086|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
218864087|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
219479686|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
219479687|NCT01977703|OTHER|Ultra Conservative ICD Programming|
219479688|NCT01977703|OTHER|Traditional ICD Programming|
218864088|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
218864089|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
218864090|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
218864091|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
218864092|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
218864093|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
218864094|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
218864095|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
219479689|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
219479690|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
219479691|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
219479692|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
219479693|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
219479694|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
219479695|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
219597900|NCT05589506|DEVICE|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
218864096|NCT02322190|PROCEDURE|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
218864097|NCT02322190|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
218864098|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
218864099|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
218864100|NCT00990145|DRUG|EDP-322|
219479696|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
219479697|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
218864101|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
218864102|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
218864103|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
218864104|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
219479698|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
219613565|NCT05743257|BEHAVIORAL|Questionnaire|Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.
219199680|NCT06826092|DRUG|FOLFIRI plus target therapy only|FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy
219199681|NCT06877117|BEHAVIORAL|Pictorial Framing|Visual aids illustrating collimation benefits
219199682|NCT06877117|BEHAVIORAL|Traffic Light Color Coding Framing|Decision cues using color-based risk indicators
219199683|NCT06855628|OTHER|[6,6-²H₂]-Glucose|\[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI).
219199684|NCT06818084|COMBINATION_PRODUCT|TAVR+GDMT|"The patient will undergo transcatheter aortic valve replacement on the basis of guideline-directed medical therapy with The VitaFlow™ system.~The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve."
219479699|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
219479700|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
219597901|NCT03368456|BEHAVIORAL|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
219597902|NCT03368456|BEHAVIORAL|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
218864105|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
218864106|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
219199685|NCT06818084|COMBINATION_PRODUCT|SAVR+GDMT|The patient will undergo conventional surgical aortic valve replacement on the basis of guideline-directed medical therapy.
219199686|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
219199687|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
219199688|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
219199689|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
219479701|NCT01923207|DRUG|DX-2930|
219479702|NCT01923207|DRUG|Placebo|placebo, subcutaneous administration
219597903|NCT06223776|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
219597904|NCT04800679|DRUG|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
219597905|NCT04800679|DRUG|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
219597906|NCT04800679|DRUG|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
219597907|NCT07135128|DRUG|225Ac-FAPI-XT|Patients will receive \[225Ac\]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose.
219479703|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
219479704|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
219479705|NCT03529045|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
219479706|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
219479707|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
219479708|NCT01649999|DRUG|peficitinib|oral
219479709|NCT01649999|DRUG|Placebo|oral
219479710|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
218864107|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
219479711|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
219479712|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
219479713|NCT03176953|DRUG|topiramate|active medication
219479714|NCT03176953|BEHAVIORAL|prolonged exposure|psychotherapy
219479715|NCT03176953|DRUG|placebo|non-active medication
219479716|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
219479717|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
219479718|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
219479719|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
219479720|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
219479721|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
219479722|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
219597908|NCT07133698|DEVICE|High Flow nasal Cannula|"Eligible subjects successfully passing a SBT will be extubated and immediately randomized (1:1:1) to receive one of the following post-extubation respiratory supports for ≥24 hours:~HVNI Arm: High-Velocity Nasal Insufflation (Flow: 40-60 L/min, FiO₂ titrated to SpO₂ ≥92%)."
219597909|NCT07133698|DEVICE|High velocity nasal insufflation|HFNC Arm: High-Flow Nasal Cannula (Flow: 50-60 L/min, FiO₂ titrated to SpO₂ ≥92%).
219479723|NCT04067856|DRUG|Bevacizumab Injection|Intravitreal injection
218864108|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
218864109|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
218864110|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
219479724|NCT00286936|DRUG|Zolpidem|
218864111|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
218864112|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
219479725|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
219479726|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
219479727|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
218864113|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
219020841|NCT07207083|BEHAVIORAL|Immersive Virtual Reality-based Exercise (FitXR, Meta Quest 3s)|"participants assigned to the intervention group will perform a 15-minute immersive virtual reality (VR) exercise program using the FitXR application on the Meta Quest 3s headset.~This program provides interactive, visually immersive exercise tasks designed to engage participants in physical activity while reducing fear of movement and enhancing functional recovery."
219479728|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
219597910|NCT07133698|DEVICE|Noninvasive ventilation|NIV Arm: Non-Invasive Ventilation (Mode: \[e.g., PSV\], IPAP: \[e.g., 8-12 cmH₂O\], EPAP: \[e.g., 4-6 cmH₂O\], FiO₂ titrated to SpO₂ ≥92%) delivered via \[e.g., oronasal mask\] for ≥16 hours/day initially, with weaning per protocol.
219597911|NCT07115069|DRUG|GLP-1 receptor agonist|Any FDA-approved GLP-1 receptor agonist
219479729|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
219597912|NCT07115069|PROCEDURE|Gastric Bypass Surgery (laparoscopic)|Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
219597913|NCT07115069|PROCEDURE|Gastric Bypass Surgery (robotic)|Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
219597914|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
219597915|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
219479730|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
219597916|NCT07133555|OTHER|Healthcare counseling service|Using peer health navigators to support linkage to HIV prevention and treatment resources among Black MSM in online spaces following mobile testing.
218864114|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
218864115|NCT02675335|DRUG|Sitagliptin|
218864116|NCT02675335|DRUG|Placebo|
218864117|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
218864118|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
218864119|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
218864120|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
219020842|NCT07207083|BEHAVIORAL|Conventional Exercise Program (Matched Exercise, without VR)|"Participants assigned to this arm will perform the same 15-minute exercise program without virtual reality equipment.~This allows comparison between immersive VR-based exercise and conventional exercise of equivalent intensity and duration."
219479731|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
219479732|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
219479733|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
219479734|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
219479735|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
219479736|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
219479737|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
219479738|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
219597917|NCT07133802|BIOLOGICAL|Placebo Group|Each human dose: 0.2 mL
219597918|NCT07133802|BIOLOGICAL|Test Group|Each human dose is 0.2 mL
219597919|NCT07134595|OTHER|C-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
219597920|NCT07134595|OTHER|M-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
219597921|NCT07133282|BEHAVIORAL|Group exercise programme|12-week group exercise programme
219597922|NCT07134634|DEVICE|tremor device|tremor ball on versus tremor ball off
219597923|NCT07133815|DRUG|SHR-1918|SHR-1918
219597924|NCT07133542|BEHAVIORAL|Dynamic Matrix Management for Weight Control (DMM-WC)|Precision weight management using a two-dimensional grid model. Participants undergo bi-weekly positioning on a waist risk-body fat matrix (9 grids), receiving tiered interventions (e.g., high-intensity exercise + dietary control for high-risk grids; maintenance plans for low-risk grids). Real-time progress feedback via visual spatial migration maps promotes adherence. Comparator group receives standardized aerobic prescription without dynamic adjustments.
218864121|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
218864122|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
218864123|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
219479739|NCT03125564|PROCEDURE|Sham|Infusion of sham
218864124|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
219479740|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
219597925|NCT07133542|BEHAVIORAL|Standard Aerobic Prescription|Personalized progressive aerobic exercise program. Participants receive baseline-adjusted intensity prescriptions (40-90% heart rate reserve), with adherence monitored via wearable devices. NO dynamic adjustments, tiered strategies, or visual feedback are provided throughout the 8-week intervention.
219597926|NCT07133659|DRUG|Avatrombopag 20 mg Oral Tablet|Description: Patients will start on avatrombopag 20 mg every other day for a week then the dose will be readjusted according to the platelet count.
218864125|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
218864126|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
219597927|NCT05973292|OTHER|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
219597928|NCT05973292|OTHER|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
219597929|NCT04288479|BEHAVIORAL|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
219597930|NCT05967871|BIOLOGICAL|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
219597931|NCT06983886|DRUG|Tranexamic Acid|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of tranexamic acid (50 mg/ml), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after completion of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before the surgical incision was made.
219597932|NCT06983886|DRUG|Normal Saline Solution (NSS)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
219597933|NCT06983886|DRUG|Lidocaine (drug)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS) or 5 ml of tranexamic acid (50 mg/ml) depends on allocated group, resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
219597934|NCT04070235|DRUG|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
219597935|NCT04070235|DRUG|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
219597936|NCT04961463|BEHAVIORAL|psychoeducation|
219597937|NCT02602600|DRUG|Liraglutide|"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"
218864127|NCT00189943|BIOLOGICAL|MVA-BN|
219020843|NCT07205705|DIETARY_SUPPLEMENT|Millet|Wheat + Barnyard millet/ Wheat +Barley/ wheat+ Bengal gram flour
219020844|NCT07206589|OTHER|Cancer Screening|Undergo BE-SOS test
219020845|NCT07206589|OTHER|Computer-Assisted Intervention|Undergo BE risk assessment using AI powered BE Risk Tool
219020846|NCT07206589|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
219020847|NCT07206589|BEHAVIORAL|Health Risk Assessment|Undergo manual BE risk assessment
219479741|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
219479742|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
219020848|NCT07206589|OTHER|Navigation|Receive RN navigation
219020849|NCT07206589|OTHER|Questionnaire Administration|Ancillary studies
219479743|NCT02766959|OTHER|Observational study|
219597938|NCT01004003|DRUG|Sorafenib|
219597939|NCT01004003|DRUG|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
219479744|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
218864128|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
219479745|NCT02217397|DEVICE|OA, CPAP, combination therapy|
219479746|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
218864129|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
218864130|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
218864131|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
218864132|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
219199690|NCT06543667|BIOLOGICAL|Limbal Stem Cell Derived Exosomes Eye Drop|Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
219199691|NCT04338581|BIOLOGICAL|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
219199692|NCT04338581|BIOLOGICAL|Placebo|Placebo for AMG 714
219199693|NCT04338581|PROCEDURE|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
219479747|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
219479748|NCT00557700|DRUG|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
219479749|NCT00557700|DRUG|Administration of placebo|Administration of placebo
219479750|NCT05244109|OTHER|Blood sample|Blood samples (2 times; 21mL per visit)
219479751|NCT05244109|DRUG|anti-TNF antibody administration|Anti-TNF antibody administration, according to current recommendations and randomization results
219479752|NCT05244109|DRUG|anti-IL-17 antibody administration|Anti-IL-17 antibody administration, according to current recommendations and randomization results
219597940|NCT05079581|OTHER|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
219597941|NCT00351975|DRUG|Belinostat|Given IV
219597942|NCT00351975|DRUG|Azacitidine|Given SC
219479753|NCT00021476|BEHAVIORAL|Behavioral treatments|
219479754|NCT00021476|BEHAVIORAL|Physical therapy|
219479755|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
219479756|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
219479757|NCT00004646|DRUG|prednisone|
219479758|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
219479759|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
219479760|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
219479761|NCT03813160|DRUG|Lenabasum 20 mg|oral capsule
219479762|NCT03813160|DRUG|Lenabasum 5 mg|oral capsule
219479763|NCT03813160|DRUG|Placebo|oral capsule
219479764|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
219479765|NCT02374008|DRUG|Ropivacaine|
219479766|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
219479767|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
219597943|NCT00351975|OTHER|Laboratory Biomarker Analysis|Correlative studies
219597944|NCT01188278|DRUG|Imatinib|Drug being observed but not provided
219597945|NCT00517556|DRUG|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
219597946|NCT00517556|DRUG|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
219479768|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
218864133|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
219479769|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
218864134|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
219479770|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
219479771|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
219479772|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
219479773|NCT03733301|DRUG|Baricitinib|Administered orally.
219479774|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
219479775|NCT03733301|DRUG|Placebo|Administered orally.
219479776|NCT04369885|DEVICE|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
219479777|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
219479778|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
219479779|NCT00566397|DRUG|Placebo|Placebo
218864135|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
218864136|NCT00084175|BEHAVIORAL|Behavior Therapy|
218864137|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
218864138|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
218864139|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
219479780|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
219479781|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
219479782|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
219479783|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
219479784|NCT06453707|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
219479785|NCT00005009|BIOLOGICAL|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
219479786|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
219479787|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
219479788|NCT03542500|BEHAVIORAL|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
219479789|NCT03542500|BEHAVIORAL|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
219479790|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
219479791|NCT00568464|DRUG|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
219479792|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
219479793|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
219479794|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
219479795|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
219479796|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
219479797|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
219479798|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1\. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
219479799|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
219479800|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
219479801|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
219597947|NCT03108053|PROCEDURE|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
218864140|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
218864141|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
219597948|NCT03108053|DEVICE|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
219597949|NCT02064985|DRUG|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
218864142|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
218864143|NCT01950585|DRUG|Hydroxyurea|
218864144|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
218864145|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
219597950|NCT04142112|DEVICE|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
218864146|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
218864147|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
218864148|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
219479802|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
218864149|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
218864150|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
218864151|NCT02145871|OTHER|standard fluid management|
218864152|NCT02145871|OTHER|fluid management guided by the EV1000|
218864153|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
218864154|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
218864155|NCT00239954|DRUG|Escitalopram|
218864156|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
218864157|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
218864158|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
218864159|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
218864160|NCT00321997|DRUG|Pegaptanib sodium|
218864161|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
218864162|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
218864163|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
219479803|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
219479804|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
219479805|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
219479806|NCT03689595|OTHER|Sample of Blood|Collection of blood sample from participants
219479807|NCT01912547|PROCEDURE|Blood draw for TEG analysis|Blood drawn for TEG analysis
218864164|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
218864165|NCT03026478|DRUG|Betamethasone Dipropionate|
218864166|NCT03026478|DRUG|Clobetasol Propionate|
218864167|NCT00900185|GENETIC|mutation analysis|
218864168|NCT00900185|GENETIC|polymerase chain reaction|
218864169|NCT00900185|GENETIC|polymorphism analysis|
218864170|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
218864171|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
219479808|NCT02288650|OTHER|early refeeding|
219479809|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
219479810|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
219479811|NCT04593277|OTHER|Internet Mobile Technology|Use INSPIRE mobile application
218864172|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
218864173|NCT00004705|DRUG|amiloride|
218864174|NCT00004705|DRUG|uridine|
219020850|NCT07206134|PROCEDURE|Modified Omega bone plate for fixation of mandibular fractures in mental foramen region|Reflection of vestibular flap without dissection around mental bundle and fracture reduction and fixation with 3D Modified Omega bone plate
219020851|NCT07206134|PROCEDURE|Conventional miniplates for fixation of mandibular fractures|Reflection of vestibular flap with dissection around mental bundle and fracture reduction and fixation with 2 miniplates
219479812|NCT04593277|OTHER|Internet-Based Intervention|Access to a study-specific control website
219479813|NCT04593277|OTHER|Questionnaire Administration|Ancillary studies
219479814|NCT04593277|PROCEDURE|Supportive Care|Receive telehealth stepped care
219479815|NCT04593277|OTHER|Informational Intervention|Receive printed SCP materials
219479816|NCT06477354|DIETARY_SUPPLEMENT|ACEMg|Softgel capsules
219479817|NCT04199741|DRUG|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
219479818|NCT04199741|DRUG|SC16.56, Phase I, Cohort 2|7.5mg
219479819|NCT04199741|DRUG|SC16.56, Phase I, Cohort 3|22.5mg
219479820|NCT04199741|DRUG|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
219479821|NCT06222879|DRUG|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
219479822|NCT06222879|DRUG|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
219479823|NCT06222879|DRUG|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
219479824|NCT06577714|DIAGNOSTIC_TEST|Electromechanical wave imaging (EWI)|EWI is a high-frame rate ultrasound technique that images the electromechanical wave corresponding to the propagation of the onset of myocardial contraction in response to electrical activation, namely electromechanical coupling.
219479825|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
218864175|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
218864176|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
218864177|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
218864178|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
218864179|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
218864180|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
219020852|NCT07207018|BEHAVIORAL|CFTSI (Child and Family Traumatic Stress Intervention)|CFTSI is a family-centered intervention lasting five to eight sessions, aiming to strengthen parental support for the child by facilitating the identification of the child's typical responses to traumatics events, improving communication between the child and the parent, and teaching coping strategies and behavioral interventions to both parents and children to reduce acute post-traumatic reactions.
219199694|NCT06317038|DEVICE|Total 30 Contact Lens|Patients will be give a contact lens for 1 month
219479826|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
219479827|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
219479828|NCT05963022|DRUG|Tirzepatide|Administered SC
219479829|NCT05963022|DRUG|Placebo|Administered SC
219479830|NCT05014672|DRUG|Setanaxib|Oral tablets, 400mg per tablet
219479831|NCT05014672|DRUG|Placebo|Oral tablets
219479832|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
219479833|NCT04455620|BIOLOGICAL|BNT151|intravenous (IV)
218864181|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
218864182|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
218864183|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
218864184|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
218864185|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
218864186|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
218864187|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
218864188|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
218864189|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
218864190|NCT02419170|PROCEDURE|Standard of care surgery|
218864191|NCT02419170|PROCEDURE|Apheresis|
218864192|NCT02419170|DRUG|Cyclophosphamide|
218864193|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
218864194|NCT01059383|DRUG|VECAM 40/300|1 capsule, orally, once daily at bedtime.
218864195|NCT01059383|DRUG|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
218864196|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
218864197|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
218864198|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
219479834|NCT05492188|BEHAVIORAL|Operant Conditioning of Cutaneous Reflexes|This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
219479835|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
218864199|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
219479836|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
219479837|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
219597951|NCT04142112|DEVICE|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
219597952|NCT02394704|OTHER|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
219597953|NCT05450601|DRUG|HCP2102-1|Take once daily for 2 weeks orally
218864200|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
219597954|NCT05450601|DRUG|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
219597955|NCT05450601|DRUG|HCP2102-2|Take once daily for 6 weeks orally
219597956|NCT05450601|DRUG|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
219597957|NCT05450601|DRUG|RLD2106-1|Take once daily for 2 weeks orally
219597958|NCT05450601|DRUG|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
218864201|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
219020853|NCT07207018|BEHAVIORAL|non-specific psychological support therapy|non-specific psychological support therapy, focused on the child rather than the family, and aimed at supporting the child and strengthening their daily adaptation. This support therapy is already integrated into the standard practice of the CRPOCC, but will be conducted by psychotherapists from the Montpellier University Hospital who are not trained in CFTSI, to ensure a consistent format that facilitates comparisons between the two groups. The number of sessions may be increased to a total of eight sessions if the clinician determines that additional aspects need to be addressed during the sessions.
219199695|NCT06953739|DRUG|P-GEMD|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (12 mg/m2) on day 1, every 3 weeks; Drug: Pegaspargase Pegaspargase(3750 IU) on day 2, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1, every 3 weeks; Drug: Etoposide Etoposide (65 mg/m2) on day 2-4, every 3 weeks. Drug: Dexamethasone Dexamethasone (40 mg/d) will be taken orally from day 1-4, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
219479838|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
219479839|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
219597959|NCT05450601|DRUG|RLD2106-2|Take once daily for 6 weeks orally
219597960|NCT05450601|DRUG|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
219597961|NCT05857852|DEVICE|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
219597962|NCT05857852|DEVICE|Sham LIFU device|Sham LIFU device administered in one of two sessions
219597963|NCT05123183|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
218864202|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
218864203|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
218864204|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
219479840|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
219479841|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
219479842|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
218864205|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
219479843|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
219479844|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
219479845|NCT01883141|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
218864206|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
218864207|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
218864208|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
219479846|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
219479847|NCT06339632|OTHER|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|"The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session."
219479848|NCT06339632|OTHER|Transcutaneous electrical diaphragm stimulation (TEDS)|The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
219479849|NCT06852612|DIETARY_SUPPLEMENT|Fructose|40g fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
219479850|NCT06852612|DIETARY_SUPPLEMENT|Fructose and galactose|10g galactose (mostly from lactose) plus 40g of fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
219479851|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
219479852|NCT04486859|DEVICE|IPC|mechanical prevention
219479853|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
219479854|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
219479855|NCT00306124|DRUG|Levodopa|
219479856|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
219479857|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
219199696|NCT06953739|DRUG|P-Gemox|Drug: Pegaspargase Pegaspargase(2000-2500 IU/m2) on day 1, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1 and day 8, every 3 weeks; Drug: Oxaliplatin Oxaliplatin (130mg/m2) on day 1, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
219479858|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
219597964|NCT05123183|OTHER|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
219597965|NCT05123183|OTHER|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
219597966|NCT01326923|DRUG|Cetuximab|Single arm phase II study of chemotherapy
219597967|NCT01130597|DRUG|patiromer|Active investigational drug
219597968|NCT01130597|DRUG|spironolactone|
219597969|NCT05052476|DIETARY_SUPPLEMENT|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
219597970|NCT00822978|DRUG|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
219479859|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
219479860|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
219479861|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
219597971|NCT02693860|DRUG|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
219597972|NCT02693860|DRUG|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
219597973|NCT03039114|DRUG|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
219597974|NCT03039114|DRUG|Hexal|Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.
219597975|NCT03039114|DRUG|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
219597976|NCT06820190|OTHER|Multiple Mid-Transverse Process to Pleura (MTP) Block|Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.
219597977|NCT06820190|DRUG|Morphine|Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.
218864209|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
219199697|NCT04756076|DIAGNOSTIC_TEST|Metal level measurements|Measure multiple metal levels
219479862|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
219479863|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
219479864|NCT00116246|PROCEDURE|McRobert's manoeuvre|
219479865|NCT00066417|DRUG|cyclophosphamide|
219479866|NCT00066417|DRUG|cyclosporine|
219479867|NCT00066417|DRUG|fludarabine phosphate|
219479868|NCT00066417|DRUG|methylprednisolone|
218864210|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
218864211|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
218864212|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
218864213|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
218864214|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
218864215|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
219479869|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
219479870|NCT00066417|DRUG|thiotepa|
218864216|NCT01650714|OTHER|Full thickness gastric biopsy|
218864217|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
218864218|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
219479871|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
218864219|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
218864220|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
219479872|NCT00066417|PROCEDURE|biological therapy|
219479873|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
219479874|NCT00066417|PROCEDURE|bone marrow transplantation|
219479875|NCT00066417|PROCEDURE|chemotherapy|
219479876|NCT00066417|PROCEDURE|leukocyte therapy|
219479877|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
219479878|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
219479879|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
219479880|NCT00066417|PROCEDURE|radiation therapy|
219479881|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
219479882|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
219479883|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
219479884|NCT01994369|DRUG|EC17|
219479885|NCT03486015|DRUG|Sterile water|2 ml of sterile water
219479886|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
219479887|NCT05499481|DRUG|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~\- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~\- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
219479888|NCT03010163|OTHER|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
219479889|NCT03010163|OTHER|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
218864221|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
219479890|NCT03010163|OTHER|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
219479891|NCT03010163|OTHER|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
219479892|NCT04678440|DRUG|[18F]F-AraG Imaging|Total body PET imaging using \[18F\]F-AraG
219479893|NCT05487625|BEHAVIORAL|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219479894|NCT05487625|BEHAVIORAL|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219479895|NCT05487625|BEHAVIORAL|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219479896|NCT05487625|BEHAVIORAL|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219479897|NCT05487625|BEHAVIORAL|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219479898|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
219479899|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
219479900|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
219479901|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
219479902|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
219479903|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
219479904|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
219479905|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
219479906|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
219479907|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
219479908|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
219479909|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
218864222|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
218864223|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
219479910|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
219479911|NCT02743598|DRUG|Liraglutide|
219479912|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
218864224|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
218864225|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
218864226|NCT00973102|DRUG|Placebo|One time dose of placebo.
219199698|NCT05770375|DRUG|MDMA 40mg|MDMA 40mg
219199699|NCT05770375|DRUG|MDMA 80mg|MDMA 80mg
219199700|NCT05770375|DRUG|MDMA 120mg|MDMA 120mg
219479913|NCT02030509|OTHER|Quick diagnosis program|
219479914|NCT06405087|DRUG|Vedolizumab SC|Vedolizumab subcutaneous injection.
219199701|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
219199702|NCT04149600|PROCEDURE|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
219020854|NCT07206459|OTHER|Healthy Patients|"RESEARCH DESIGN AND METHODS This will be a physiological observational study~Study design. Participants will breathe on CPAP with a ventilator. The investigators will deliver the PNS at PEEP levels of zero cmH2O (baseline EELV), zero cmH2O + an abdominal binder (to reduce lung volume), five cmH2O and ten cmH2O. The abdominal binder will be used to achieve an EELV lower than at baseline. At the end of the protocol another PNS at zero cmH2O (baseline EELV) will be performed. Healthy participants will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed.~At every PEEP level, relative changes in EELV (∆z) will be measured with Electrical Impedance Tomography (EIT) to record relative changes in EELV and the electrical activity of the costal diaphragm will be measured using surface electromyography"
219479915|NCT06405087|OTHER|No Intervention|As this is an observational cohort, no intervention will be administered.
219479916|NCT06167083|DIAGNOSTIC_TEST|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
219479917|NCT04913285|DRUG|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
219479918|NCT04913285|DRUG|KIN-2787 and binimetinib|Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles
219597978|NCT06824857|OTHER|Abdominal Massage Application|As part of the abdominal massage application, patient follow-up forms and checklists were prepared. Before starting the study, the abdominal massage practitioner participated in a certification program on this topic and received a competency certificate. Patients will be followed up for the first 3 days postoperatively using the prepared patient follow-up forms. Abdominal massage will be applied to each patient for 15 minutes according to a certain standard as stated in the literature
219597979|NCT00200044|DEVICE|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
219597980|NCT06990256|DIETARY_SUPPLEMENT|Fisetin intervention|Participants assigned to this intervention take capsules containing a fixed dose of Fisetin daily after breakfast.
219597981|NCT06990256|DIETARY_SUPPLEMENT|Placebo|Participants assigned to this intervention take a capsule containing 500 mg of corn starch daily after breakfast.
219479919|NCT04620590|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
219020855|NCT07206459|OTHER|Critically Care Patients|"RESEARCH DESIGN AND METHODS This will be a physiological observational study~Study design. For patients. The investigators will perform PNS at the patients own mode of ventilation at their clinical level of PEEP (baseline EELV), PEEP of zero cmH2O (if acceptable for 5 minutes), clinical PEEP ± 2 - 4 cmH2O. At the end of the protocol, another stimulation at the clinical level of PEEP (baseline EELV) will be performed. Patients will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed."
219199703|NCT01663831|OTHER|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
219199704|NCT06295263|OTHER|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
219199705|NCT05299346|OTHER|Follow up|Comprehensive follow up in dedicated follow up unit
219199706|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
219199707|NCT05438862|PROCEDURE|State of art aortic valve surgery|Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
219199708|NCT05370352|BEHAVIORAL|Standard smoking cessation treatment|Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
219479920|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
219479921|NCT06013371|DRUG|Placebo Ointment|matching placebo
219479922|NCT05919043|OTHER|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
219479923|NCT05919043|OTHER|Lower limb-based movement priming (LL-priming)|Repetitive lower limb movements administered to the beat of a metronome.
218864227|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
218864228|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
218864229|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
218864230|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
218864231|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
218864232|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
218864233|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
218864234|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
218864235|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
219479924|NCT05919043|OTHER|Sham priming|Auditory stimulation.
219479925|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
219479926|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
219479927|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
219479928|NCT03885401|BEHAVIORAL|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
219479929|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
219479930|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
219479931|NCT05456607|BEHAVIORAL|Mood Monitoring|The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
219479932|NCT04581473|DRUG|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
219479933|NCT04581473|DRUG|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
219479934|NCT06228534|PROCEDURE|Root coverage with tunneling technique|THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
219020856|NCT07205614|OTHER|pain consultation, biopsychosocial pain education + usual care|"Participants will receive a link to a digital pain education program. The program will include standard information about endometriosis, but will also introduce a biopsychosocial understanding of pain including influence of psychological factors such as excessive worry, stress, sleep disturbance and emotional distress. Self-management strategies including physical activity, relaxation and breathing techniques, cognitive techniques, psychosocial support and appropriate use of pain medication and supplemental treatment (e.g. physical therapy, TENS, heat), will be introduced.~Participants will then attend a single good pain consultation, a patient-centered consultation with a clinician associated with the project, in which content from the educational package will be reinforced. The consultation will provide the opportunity to address the biopsychosocial factors including anxiety, previous trauma, emotional distress etc. Shared decision-making regarding preferred self-management strat"
218864236|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
219479935|NCT06374732|BEHAVIORAL|High-intensity interval training|The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.
219479936|NCT06374732|BEHAVIORAL|Control group|The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
219479937|NCT04961437|OTHER|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~\- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
219479938|NCT05980260|OTHER|Symptom-based Dosing Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.
219479939|NCT05980260|OTHER|Scheduled Opioid Taper Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
219479940|NCT03539952|DRUG|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
219597982|NCT06990256|DIETARY_SUPPLEMENT|Urolithin A intervention|Participants assigned to this intervention take capsules containing a fixed dose of Urolithin A daily after breakfast.
219597983|NCT03371459|DRUG|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
218864237|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
218864238|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
218864239|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
218864240|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
218864241|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
218864242|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
219020857|NCT07205614|OTHER|Usual Care|Usual follow up at the department of gynecology
219479941|NCT03539952|DRUG|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
219479942|NCT03539952|DRUG|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
219479943|NCT03539952|DRUG|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-\<W108)
219479944|NCT02702375|OTHER|Fructose-containing Sugars|
219479945|NCT06975189|DEVICE|Lung ultrasound group|Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.
219597984|NCT03371459|DRUG|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
219597985|NCT05761665|OTHER|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
219597986|NCT05645705|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
219597987|NCT05645705|OTHER|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
219597988|NCT05645705|OTHER|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
219597989|NCT05645705|OTHER|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
218864243|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
218864244|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
218864245|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
218864246|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
218864247|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
218864248|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
218864249|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
218864250|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
219020858|NCT07205198|DRUG|SIBP-A10|"SIBP-A10 injection. Strength: 0.5, 1.5, 3, 5, 7, 10 and 15 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage,0.5 mg/kg group was subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If unacceptable toxic reactions occurred, the traditional 3+3 dose escalation method was immediately switched. If unacceptable toxic reactions do not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
219020859|NCT07204964|BIOLOGICAL|Flu mRNA (Formulation B1)|One dose of Flu mRNA (Formulation B1) received intramuscularly.
219479946|NCT06975189|DIAGNOSTIC_TEST|Standard Care|Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.
219479947|NCT06978114|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219479948|NCT06978114|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
219020860|NCT07204964|BIOLOGICAL|Flu mRNA (Formulation B3)|One dose of Flu mRNA (Formulation B3) received intramuscularly.
219479949|NCT00390676|DRUG|ADH -1 and carboplatin|
219479950|NCT00390676|DRUG|ADH -1 and docetaxel|
219479951|NCT00390676|DRUG|ADH -1 and capecitabine|
219479952|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
218864251|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
219020861|NCT07204964|BIOLOGICAL|Flu mRNA(Formulation A)|One dose of Flu mRNA (Formulation A) received intramuscularly.
219479953|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
219479954|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
218864252|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
218864253|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
218864254|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
218864255|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
218864256|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
218864257|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
218864258|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
218864259|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
218864260|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
219020862|NCT07204964|COMBINATION_PRODUCT|Comparator 1|One dose of Comparator 1 received intramuscularly.
219020863|NCT07204964|COMBINATION_PRODUCT|Comparator 2|One dose of Comparator 2 received intramuscularly.
219020864|NCT07204964|COMBINATION_PRODUCT|Comparator 3|One dose of Comparator 3 received intramuscularly.
219020867|NCT07205913|OTHER|25 ml blood sample|A 25-ml blood sample
219020868|NCT07205913|OTHER|Urine sample|A 10-ml urine sample
219020869|NCT07205913|OTHER|Stools|10-g stools
219020870|NCT07205913|OTHER|40 ml blood sample|A 40-ml blood sample
219020871|NCT07206108|PROCEDURE|modified endocrown|Combining the advantages of post-core crown and endocrown, an modified endocrown was designed
219479955|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
219479956|NCT00000362|BEHAVIORAL|Chin-down position|
219479957|NCT00000362|BEHAVIORAL|Thickened liquid administration|
218864261|NCT06915636|OTHER|DPL|Half of the face was randomly treated with DPL, with an energy of 6-8 J/cm2, at an interval of 10 days, for a total of 8 treatments.One randomly assigned half of the face was treated with a large-spot, low-energy 1064nm laser at an energy of 0.8-1 J/cm², administered at 10-day intervals, for a total of 8 treatment sessions.
219479958|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
218864262|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
218864263|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
219479959|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
219479960|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
219479961|NCT06670482|DEVICE|Non-invasive ventilation (NIV)|Delivery of positive airway pressure to the lungs via an interface, such as a mask.
218864264|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
218864265|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
218864266|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
218864267|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
218864268|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
218864269|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
218864270|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
218864271|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
218864272|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
218864273|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
218864274|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
218864275|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
218864276|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
218864277|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
218864278|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
218864279|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
218864280|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
218864281|NCT02460341|DRUG|placebo|placebo pill
218864282|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
218864283|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
218864284|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
219479962|NCT00012766|BEHAVIORAL|Integrated team care|
219479963|NCT06993662|COMBINATION_PRODUCT|Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.
218864285|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
219020872|NCT07205224|OTHER|Anesthesia Type|Patients receive either spinal or general anesthesia according to routine clinical decision-making. No investigational drug or device is administered.
218864286|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
218864287|NCT01887119|DRUG|Eplerenone|
218864288|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
218864289|NCT00200538|DRUG|memantine|
218864290|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
218864291|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
218864292|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
218864293|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
219020873|NCT07205276|DIAGNOSTIC_TEST|Non-contrast multiparametric breast MRI with AI-based radiomics analysis|Participants will receive standardized non-contrast multiparametric breast MRI scans (T2WI, DWI, ADC). Imaging features will be extracted and analyzed using artificial intelligence-based radiomics and deep learning algorithms to improve early detection and diagnosis of breast cancer.
219020874|NCT07205276|DIAGNOSTIC_TEST|Standard radiologist reading of non-contrast multiparametric breast MRI|Imaging data interpreted by trained radiologists following routine clinical practice, without AI assistance.
219020875|NCT07205120|DEVICE|Heart Failure Management Intervention|Participants will receive access to their weight and fluid levels on the Cardiac Scale and through the Bodyport Patient Portal. The provider will receive access to the Congestion Index, alerts, and Clinical Dashboard to support the remote management of the participant. The provider will receive a notice when an alert is generated and twice weekly reminders until the Congestion Index returns below an alert threshold. When an alert is generated, providers will attempt to contact the participant and will be encouraged to follow the recommendations contained within the ARG. Providers will also be encouraged to provide feedback and suggest improvements to the ARG throughout the study. Any changes to medical therapy resulting from an alert will be documented in the Bodyport Clinical Dashboard.
218864294|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
218864295|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
218864296|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
218864297|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
218864298|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
218864299|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
219020876|NCT07205289|BIOLOGICAL|Gamma-PN|Killed whole-cell pneumococcal vaccine
218864300|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
218864301|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
219020877|NCT07205575|DIAGNOSTIC_TEST|Proteomic Biomarker Panel|A blood-based ELISA test measuring circulating ICAM1, CFHR5, and GRN. Index test performance will be evaluated against microbiological gold standards and adjudication.
219020878|NCT07205367|DEVICE|Zio Monitor|The Zio monitor is a long-term continuous ambulatory patch ECG monitor which adheres to the patient's left pectoral region.
219020879|NCT07205510|OTHER|nothing|This is an observational study.
219020880|NCT07205133|OTHER|Whole Body Vibration Training|Information already included in arm/group descriptions.
219020881|NCT07205133|OTHER|Otago Exercise|Usual Care
218864302|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
219020882|NCT07206017|OTHER|prebiotic dried chicory root (WholeFiber)|Supplementing with WholeFiber for 6 weeks two times a day (10 g per portion).
219020883|NCT07206238|DIAGNOSTIC_TEST|Positron Emission Tomography / Magnetic Resonance Imaging|FDG PET/MRI with Black Blood sequences of the head and neck area.
219020884|NCT07205159|DRUG|FB102|Route of administration- Intravenous (IV)
219020885|NCT07205159|DRUG|Placebo|Route of administration- Intravenous (IV)
219020886|NCT07205419|DEVICE|Eye-Tracking Interaction System|The eye-tracking interactive interface designed based on evidence-based and co-design principles is installed on tablets or computers equipped with cameras, forming the eye-tracking interactive system.
219020887|NCT07205770|OTHER|PNF|Applying to the extensor muscles for 30 seconds
218864303|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
219479964|NCT06993662|COMBINATION_PRODUCT|Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD
219479965|NCT06993662|COMBINATION_PRODUCT|Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.|The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
219479966|NCT06993662|COMBINATION_PRODUCT|Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.
219479967|NCT06993662|COMBINATION_PRODUCT|Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders|The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.
219479968|NCT06993662|COMBINATION_PRODUCT|Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics) and individual cognitive behavioral psychotherapy by personality disorders.
219479969|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
219479970|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
219479971|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
219479972|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
219479973|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
219479974|NCT02461407|DRUG|Anlotinib|Anlotinib p.o. qd
219479975|NCT02461407|DRUG|Placebo|Placebo p.o. qd
219020888|NCT07205770|OTHER|Passive Stretching|Applying to the extensor muscles for 30 seconds
219020889|NCT07205991|BEHAVIORAL|Phone calls|Participants will receive standard app notifications and be contacted for adherence via two phone calls, a week apart, if they fail to engage with the intervention for more than three consecutive days. The purpose of these calls will be to assess whether participants are experiencing any difficulties using the app or completing the sessions.
219020890|NCT07205991|BEHAVIORAL|Text messages|Participants will receive the standard app notifications and receive a maximum of 2 text messages (SMS) a week apart, if they fail to engage with the intervention for more than three consecutive days.
219020891|NCT07205991|BEHAVIORAL|App notifications|Participants will receive the standard app notifications .
219479976|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
219479977|NCT05071235|DEVICE|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
218864304|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
218864305|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
218864306|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
219479978|NCT05071235|DEVICE|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
219479979|NCT05071235|DEVICE|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
219020892|NCT07205731|DRUG|Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1|It is the first study which evaluate efficacy and safety of anti PD-1 immune checkpoint inhibitor alone in the first-line treatment of elderly esophageal squamous-cell carcinoma patients who no fit to received chemotherapy with platine
219020893|NCT07205497|DRUG|QL1706+TC|Participants will take eparbrutinib (QL1706) alongside cisplatin and albumin-bound paclitaxel (TC) every three weeks for three cycles. If the lesion was reduced to less than or equal to 2cm, conectomy was performed; if the pathological results indicated no high-risk factors, total hysterectomy was performed, and QL1706+TC was treated after surgery. If the lesion is larger than 2cm, a type III hysterectomy is performed and adjuvant treatment is determined according to sedlis criteria after surgery.
219479980|NCT05071235|DEVICE|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
219479981|NCT05071235|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
219479982|NCT06994871|OTHER|Aerobic exercise|"Intensity of exercise：Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR).~Time of aerobic exercise：from 30 to 45 minutes each day, five days a week."
219479983|NCT06994871|OTHER|Resistance exercise|"The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 3 times a week.~Intensity of equipment trainings: 70% 1-RM. Exercise volume: 15-20 repetitions for a set, from 2 sets to 4 sets gradually.~Body weight trainings: 15-30 repetitions for a set, from 2 sets to 4 sets gradually."
219479984|NCT06994871|OTHER|combined exercise|"Subjects conduct both aerobic and resistance trainings. Details of aerobic training session: Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR) from 50-55 minutes each day, 3-4 days a week.~Details of resistance training session: The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 2 times a week."
219479985|NCT05368428|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
219479986|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
219479987|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
219479988|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
218864307|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
218864308|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
218864309|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
219479989|NCT01977482|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
219479990|NCT01977482|DRUG|Placebo|Matching placebo tablet for GSK1278863
219479991|NCT01977482|DRUG|rhEPO|rhEPO will be procured from local market
219479992|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
218864310|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
218864311|NCT05158985|OTHER|phonophoresis|treatment
218864312|NCT05158985|OTHER|exercises|treatment
218864313|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
218864314|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
218864315|NCT02144155|DRUG|Placebo|placebo drug
219479993|NCT06099509|OTHER|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
219479994|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
219479995|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
219479996|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
219479997|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
219020896|NCT07206290|DRUG|Survodutide (BI 456906)|0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c. weekly
219020897|NCT07206290|DRUG|Placebo|Placebo matching survodutide
219479998|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
219479999|NCT00805857|DRUG|Tipranavir|
219480000|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
219480001|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
218864316|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
219480002|NCT05230342|DIETARY_SUPPLEMENT|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
218864317|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
218864318|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
218864319|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
218864320|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
218864321|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
218864322|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
218864323|NCT02718014|OTHER|scaling and root planing (srp)|
218864324|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
218864325|NCT03964753|PROCEDURE|surgery|surgery
218864326|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
218864327|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
218864328|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
218864329|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
218864330|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
218864331|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
218864332|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
218864333|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
219480003|NCT05230342|OTHER|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
219480004|NCT06673966|OTHER|Regular follow-up assessments without intervention.|Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.
219480005|NCT06673966|OTHER|Cross-sectional assessment|Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
218864334|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
218864335|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
218864336|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
218864337|NCT00024310|DRUG|lometrexol|
218864338|NCT00024310|DRUG|paclitaxel|
219020898|NCT07205302|DEVICE|flow diverter|the treatment of intracranial non-saccular aneurysms with flow diverter
218864339|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
218864340|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
218864341|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
218864342|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
218864343|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
218864344|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
218864345|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
218864346|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
218864347|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
218864348|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
219480006|NCT00024271|BIOLOGICAL|recombinant interferon gamma|
219480007|NCT00024271|DRUG|cisplatin|
219480008|NCT00024271|DRUG|doxorubicin hydrochloride|
218864349|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
218864350|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
218864351|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
218864352|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
219199709|NCT05370352|BEHAVIORAL|Personalised chat messaging|Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).
219480009|NCT00024271|DRUG|gemcitabine hydrochloride|
218864353|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
218864354|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
219480010|NCT00024271|DRUG|mitomycin C|
219480011|NCT00024271|PROCEDURE|conventional surgery|
219480012|NCT00024271|PROCEDURE|hyperthermia treatment|
219480013|NCT00024271|RADIATION|radiation therapy|
219480014|NCT03826771|BEHAVIORAL|Power training|high-intensity lower extremity resistance training
219480015|NCT03826771|BEHAVIORAL|Stretching|upper and lower body range of motion exercises
219480016|NCT06999174|DIAGNOSTIC_TEST|Multiparametric MRI|Diagnostic multiparametric liver MRI, performed at three time points: before (≤14 days), 24 hours after, and 4-6 weeks after TACE or 3 months after SIRT.
219480017|NCT06865144|DRUG|Netarsudil ophthalmic solution 0.02%|Apply one drop in each eye every evening
219480018|NCT06865144|DRUG|Artificial tears|Apply one drop in each eye every evening
219480019|NCT02500147|DRUG|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
219480020|NCT02500147|DRUG|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
219480021|NCT05460832|DRUG|MBS2320 5 mg|Oral capsule
219480022|NCT05460832|DRUG|MBS2320 20 mg|Oral capsule
218864355|NCT00114023|DRUG|Imiquimod 5% cream|
218864356|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
219480023|NCT05460832|DRUG|MBS2320 40 mg|Oral capsule
219480024|NCT05460832|DRUG|Placebo|Oral capsule
219480025|NCT05554471|DEVICE|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
219597990|NCT05645705|OTHER|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
219597991|NCT03870165|BEHAVIORAL|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
219597992|NCT03870165|OTHER|Salmon|Participants will ingest salmon immediately after resistance exercise
219597993|NCT03870165|DIETARY_SUPPLEMENT|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
219597994|NCT02824471|OTHER|SCD Group|No Intervention. Use of discard blood/tissue
219597995|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
219480026|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
219480027|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
219480028|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
219480029|NCT03313297|DRUG|Placebo|Matching placebo
219480030|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
219480031|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
219480032|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
219480033|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
219480034|NCT07005635|OTHER|Listening Music|Music group students listen Beethoven Moonlight Sonata during scrubing hands
219480035|NCT07005635|OTHER|Alarm|Alarm group students listen alarm sound at the end of the (2 min) during scrubing hands
219480036|NCT07005310|DEVICE|Powerglide pro™|A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.
219597996|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
218864357|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
218864358|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
219597997|NCT06633523|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.
218864359|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
218864360|NCT02001896|DRUG|erlotinib|
219199710|NCT05370352|BEHAVIORAL|SMS text messaging|SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
219199711|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
219480037|NCT07005310|DEVICE|Introcan safety deep access|The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.
219480038|NCT07006155|DEVICE|Images|PET/CT images
219480039|NCT07006688|DRUG|Ivosidenib Oral Tablet|500mg Ivosidenib taken orally once daily for continuous 28-day cycles
219597998|NCT03633201|DEVICE|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
219597999|NCT03633201|DEVICE|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
219598000|NCT07001319|DRUG|GS-3242|Administered orally
218864361|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
218864362|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
218864363|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
218864364|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
218864365|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
218864366|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
218864367|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
218864368|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
218864369|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
218864370|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
218864371|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
219199712|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
219199713|NCT02632175|BIOLOGICAL|Adalimumab|every other week or weekly subcutaneous injection
219199714|NCT05284097|DRUG|Ad26.ZEBOV, MVA-BN-Filo|"Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus"
219199715|NCT04726293|DIETARY_SUPPLEMENT|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
219199716|NCT04726293|DIETARY_SUPPLEMENT|Control|control beverage 1 cup, twice a day for 4 weeks
219199717|NCT03417531|DIETARY_SUPPLEMENT|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
219598001|NCT07001319|DRUG|BVY|Administered orally
219598002|NCT07001319|DRUG|Standard of Care|Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
219598003|NCT07134530|DEVICE|HPI-driven intraoperative hemodynamic management strategy|Hemodynamic management protocol based on information detected by Edwards HemoSphere monitor equipped with the Acumen Hypotension Prediction Index software (HPI)
219598004|NCT07134530|DEVICE|GDT strategy|Current clinical hemodynamic care
219598005|NCT06867523|OTHER|Eye Mask|Participants in this group will wear an eye mask between 11:00 PM and 07:00 AM for three consecutive nights to assess its effects on delirium and pain levels in pediatric intensive care unit patients
219598006|NCT06867523|OTHER|Earplugs|Participants in this group will use earplugs between 11:00 PM and 07:00 AM for three consecutive nights to evaluate their effects on delirium incidence and pain levels.
219598007|NCT05737784|DRUG|PRAX-222 - Initial Dose|PRAX-222
219598008|NCT05737784|DRUG|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
218864372|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
218864373|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
218864374|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
218864375|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
219199718|NCT03417531|DIETARY_SUPPLEMENT|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
219199719|NCT03417531|PROCEDURE|Active Exercise|Program includes five strength exercises that can be easily performed at home
219199720|NCT03417531|PROCEDURE|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
219598009|NCT05737784|DRUG|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
218864376|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
219598010|NCT05737784|DRUG|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
219598011|NCT05737784|PROCEDURE|Placebo|Placebo procedure
219598012|NCT06874751|OTHER|No treatment given|No treatment given
219598013|NCT06874751|OTHER|No treatment given|No treatment given
219598014|NCT02988635|OTHER|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
218864377|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
218864378|NCT02645617|DRUG|Varnish|Topical application to the teeth
218864379|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
218864380|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
218864381|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
218864382|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
218864383|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
218864384|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
218864385|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
218864386|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
219480040|NCT07007507|BEHAVIORAL|Aerobic Exercise|Aerobic exercise is performed by repeating sequences of light to moderate intensity activities for extended periods of time.(12) The American Heart Association recommends that for stroke survivors, exercise intensity should be 40%-70% of VO2 reserve or heart rate (HR) reserve; 55%-80% HR max; RPE 11-14 Borg rating of perceived exertion (RPE) scale 6-20 scale, 3-5 days/week, 30-60 min/session (or multiple 10 min sessions)
219480041|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
219480042|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
219480043|NCT07035249|DRUG|Low Dose DCSZ11|Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).
219480044|NCT07035249|DRUG|Medium Dose DCSZ11|Patients will receive DCSZ11 at 800 mg Q3W.
218864387|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
218864388|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
218864389|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
218864390|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
219199721|NCT04158024|OTHER|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
219199722|NCT01144455|DRUG|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
219480045|NCT07035249|DRUG|High Dose DCSZ11|Patients will receive DCSZ11 at 1200 mg Q3W.
219480046|NCT07035249|DRUG|Standard Treatment|The available standard treatment for head and neck cancer patients.
219480047|NCT07037043|DRUG|hydrocortisone plus fludrocortisone|"* Hydrocortisone 200 mg/day for 5 days or until ICU discharge, starting at the initiation of cardiopulmonary bypass (CPB), administered intravenously via syringe pump in a double-blind manner~* Fludrocortisone 50 µg/day in the morning for 5 days or until ICU discharge, administered orally or via nasogastric tube (if the patient is sedated), diluted in a glass of water, in a double-blind manner"
219598015|NCT01864395|PROCEDURE|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
219598016|NCT01864395|PROCEDURE|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
219598017|NCT01864395|PROCEDURE|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
219598018|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
218864391|NCT06942598|BEHAVIORAL|Produce prescription|Participants randomized to this arm will receive $10 worth of fruits and vegetables from Help Our People Eat (H.O.P.E) of Winston Salem each week. H.O.P.E is a local non-profit that distributes nutritious meals and fruits and vegetables to neighborhoods throughout Forsyth County to help families with FI. H.O.P.E also collaborates with local farmers to provide a Neighborhood Produce Market that provides low-cost produce. Participants will have the produce delivered to their home each week for 3 months.
218864392|NCT06942598|BEHAVIORAL|Medically tailored meals|Medically-tailored meals will be provided by Second Harvest Food Bank of Northwest NC. During the 3 months, participants will receive 10 medically-tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly. All meals are planned by a registered dietitian. Meals have minimal preparation time, can be heated by stove, oven, or microwave. Because the meals are medically-tailored, participants are asked not to share them.
218864393|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
218864394|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
218864395|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
218864396|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
218864397|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
218864398|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
218864399|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
218864400|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
218864401|NCT00581451|DRUG|bifeprunox|oral tablet once daily
218864402|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
218864403|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
218864404|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
218864405|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
218864406|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
218864407|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
218864408|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
218864409|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
218864410|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
218864411|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
218864412|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
218864413|NCT02303899|DRUG|Gemcitabine|infusion drug
218864414|NCT02303899|DRUG|Imatinib mesylate|oral drug
218864415|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
218864416|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
218864417|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
218864418|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
218864419|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
218864420|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
218864421|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
218864422|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
219480048|NCT07037043|DRUG|placebo of hydrocortisone plus fludrocortisone|"* Placebo for hydrocortisone (0.9% NaCl) administered following the same protocol as fludrocortisone in the intervention group~* Placebo for fludrocortisone (capsule containing microcrystalline cellulose diluted in a glass of water) administered following the same protocol as fludrocortisone in the intervention group"
219480049|NCT05583838|DRUG|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
219480050|NCT05583838|DRUG|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
219480051|NCT06709976|DEVICE|Vaginal microbiome swab|All swabs were collected using FLOQSwabs™ (Copan Italia SpA, Brescia, Italy). The patients were instructed to spread the labia with one hand, insert the swab 3-5 cm beyond the vaginal orifice with the other hand, and rotate the swab along the vaginal wall for 10-15 seconds.
219480052|NCT06709976|DEVICE|Menstrual Blood Collection via Menstrual Cup|Self-collect menstrual blood during 24 hours in 2 blocks of 12 hours
219480053|NCT06723756|DRUG|Treatment A: BGF MDI HFO|Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.
219480054|NCT06723756|DRUG|Treatment B: BGF MDI HFA|Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
219480055|NCT06722859|PROCEDURE|Open surgical decompression in degenerative lumbar canal stenosis|Open surgical decompression in degenerative lumbar canal stenosis
219480056|NCT06722859|PROCEDURE|Microsurgical decompression|Microsurgical decompression of degenerative lumbar canal stenosis
218864423|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
219480057|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
218864424|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
218864425|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
218864426|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
218864427|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
218864428|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
219480058|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
219480059|NCT07048470|DIETARY_SUPPLEMENT|Synbiotic|The patients received synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
218864429|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
218864430|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
218864431|NCT03472690|OTHER|Placebo|Subcutaneous injection
219598019|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
219598020|NCT01909063|DIETARY_SUPPLEMENT|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
219598021|NCT06230406|PROCEDURE|surgery for artherial and/or venous diseases|collection of vascular samples from surgery and blood samples
219598022|NCT05365724|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine according to the immunization schedule of 0, 21-28 days
219598023|NCT01589497|DRUG|Rifampicin|Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
219598024|NCT01589497|DRUG|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
219480060|NCT07048470|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
219480061|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
219480062|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
219480063|NCT06821204|OTHER|Health education group|Participants will be given one session (40 minutes) of training on the definition and importance of hygiene, the rules and importance of hand washing, the importance of cleaning make-up materials, which method, material and how often they should be cleaned, and the health risks that may occur if they are not cleaned.
218864432|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
218864433|NCT02728531|DRUG|Bendamustine|
218864434|NCT02728531|DRUG|Rituximab|
219480064|NCT06821204|OTHER|control group|No intervention will be applied to participants in this group.
219480065|NCT06928831|OTHER|Experimental|Course materials were shared with the students in the flipped group one week before the theoretical lesson. Google Classroom platform was used so that students could easily access these materials and repeat them at any time and frequency they wanted. A link and QR code were shared with the students to log in to the system. The frequency of downloading and watching the course materials was monitored by the researcher. Next week, the theoretical course was taught in line with the flipped learning model.
219480066|NCT06928831|OTHER|Experimental|The link to the mobile application developed for mobile learning was shared with the students in this group. Students were given 2 weeks to use the application, and students had the opportunity to read and watch the content in the application at any time and frequency they wanted.
218864435|NCT02728531|DRUG|Cytarabine|
218864436|NCT02728531|DRUG|Pegfilgrastim|
219480067|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
219480068|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
219199723|NCT01144455|DRUG|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
219480069|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
219480070|NCT06053203|OTHER|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
218864437|NCT02728531|PROCEDURE|Leukapheresis|
218864438|NCT02728531|DRUG|Filgrastim|
219199724|NCT01144455|DRUG|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
219480071|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
219480072|NCT06902610|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and combines a musical and cognitive training program and written language training program.
219480073|NCT06898281|PROCEDURE|intracardiac echocardiography (ICE)-guided catheter ablation|Intracardiac echocardiography (ICE)-guided catheter ablation.
219480074|NCT06898281|PROCEDURE|Pressure-sensing catheter ablation alone|Pressure-sensing catheter ablation alone
219480075|NCT06904300|DRUG|AK112 + paclitaxel|AK112 (20 mg/kg IV, D1/D15) + paclitaxel (80 mg/m² IV, D1/D8/D15), Q4W
219480076|NCT06904300|DRUG|Paclitaxel ± ramucirumab|Paclitaxel (80 mg/m² IV, D1/D8/D15) ± ramucirumab (8 mg/kg IV, D1/D15), Q4W
219480077|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
218864439|NCT02728531|PROCEDURE|Autologous stem cell transplant|
218864440|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
218864441|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
218864442|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
218864443|NCT06377709|OTHER|ProACTive|ProACTive intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
218864444|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
218864445|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
218864446|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
218864447|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
218864448|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
218864449|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
219199725|NCT06772090|BIOLOGICAL|Lactobacillus and Bifidobacterium|"Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61\>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62\>)."
219199726|NCT06772090|OTHER|Placebo|Placebo capsule manufactured in same facility as experimental capsule.
219199727|NCT06136936|DEVICE|CT-156-C-001|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
219199728|NCT05657639|DRUG|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
219199729|NCT05657639|DRUG|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
219199730|NCT00147056|DEVICE|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
219199731|NCT03775161|DEVICE|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
219199732|NCT06964932|DIETARY_SUPPLEMENT|Probiotc|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
219480078|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
219480079|NCT06853626|DIAGNOSTIC_TEST|QuidelOrthos TriageTrue hs-cTnI whole-blood assay|Already described
219480080|NCT04213703|OTHER|No intervention|There is no intervention for this study
218864450|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
218864451|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
219480081|NCT05412290|DRUG|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
218864452|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
219020910|NCT07205809|PROCEDURE|bioceramic coated gutta percha|"Experimental Arm (Bioceramic-coated GP + Bioceramic Sealer):~Specimens will be obturated using bioceramic-coated gutta-percha cones in combination with bioceramic sealer after canal preparation with ProTaper NEXT files up to size F3."
219020911|NCT07205809|PROCEDURE|conventional(non-coated) gutta percha|"Active Comparator Arm (Conventional GP + Bioceramic Sealer):~Specimens will be obturated using conventional (non-coated) gutta-percha cones in combination with the same bioceramic sealer after canal preparation with ProTaper NEXT files up to size F3."
219020912|NCT07206550|BEHAVIORAL|Framing|The participants will receive different messages using different terms and behavioral framings, encouraging them to review their EHRs and report any potential errors. These wording variations are expected to induce variance in subjects' behaviors with regard to the likelihood of reviewing EHRs, as well as discovering and reporting potential errors in them.
219020913|NCT07206381|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Group Therapy|Sessions conducted in groups with one therapist and one co-therapist; each session follows the EMDR standard protocol.
219020917|NCT07206004|DIAGNOSTIC_TEST|Fibroscan|Fibroscan will be perfomed while the patient receives their usual parenteral support
219199733|NCT06964932|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
219480082|NCT06902285|DRUG|Magnesium Threonate|Participants will receive a daily 145 mg pill by mouth 30 minutes before going to sleep
218864453|NCT02170909|DRUG|BIBR 1048 MS low dose|
218864454|NCT02170909|DRUG|BIBR 1048 MS medium dose|
218864455|NCT02170909|DRUG|BIBR 1048 MS high dose|
218864456|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
218864457|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
218864458|NCT04608734|DRUG|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
219480083|NCT06902285|OTHER|Control|Participants will receive two sugar pills daily by mouth 30 minutes before going to sleep
219480084|NCT06905691|OTHER|Conventional Training|Patients will execute the concentric and eccentric phases unilaterally, maintaining consistent load levels, with each phase lasting 2 seconds.
219480085|NCT06905691|OTHER|Eccentric Training|The concentric phase will be performed bilaterally in approximately 1 second, followed by the unilateral eccentric phase lasting approximately 3 seconds.
219480086|NCT04960280|DEVICE|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
219598025|NCT01589497|DRUG|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
219598026|NCT01589497|DRUG|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
219598027|NCT01589497|DRUG|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
219598028|NCT04771975|BEHAVIORAL|Exercise Counselling|Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.
219598029|NCT04771975|BEHAVIORAL|Partner Matching|"Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics."
218864459|NCT04608734|DRUG|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
218864460|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
219598030|NCT04771975|BEHAVIORAL|Resistance training sessions led by a QEP|Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
219598031|NCT05645952|OTHER|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
218864461|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
218864462|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
218864463|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
218864464|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
218864465|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
218864466|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
218864467|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
218864468|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
218864469|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
218864470|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
218864471|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
218864472|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
218864473|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
218864474|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
218864475|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
218864476|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
218864477|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
218864478|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
218864479|NCT03716752|PROCEDURE|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
218864480|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
218864481|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
219480087|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
219480088|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
219480089|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
219480090|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
219598032|NCT02648100|OTHER|biomarker study|
219598033|NCT03783429|DRUG|Digoxin|Digoxin tablets will be given orally
219598034|NCT03783429|DRUG|Placebos|Placebo tablets will be given orally
219598035|NCT03683771|DIAGNOSTIC_TEST|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
219598036|NCT00002070|DRUG|Sargramostim|
219598037|NCT00002070|DRUG|Ganciclovir|
219480091|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
219480092|NCT06440005|DRUG|AGX101|Antibody Drug Conjugate
218864482|NCT00337584|PROCEDURE|Pre-surgical screening|
218864483|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
218864484|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
218864485|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
218864486|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
218864487|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
218864488|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
219480093|NCT06076889|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
219480094|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
219480095|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
219480096|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure and videos containing information about mental health problems.
219598038|NCT07134179|OTHER|Experience of pain during caesarean delivery|We wish to investigate how women experience insufficient regional anesthesia during cesarean sections, in cases where the regional anesthesia was not converted to general anesthesia. The focus is on exploring the factors that contribute positively and negatively to the woman's experience in this situation
219598039|NCT04440670|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
218864489|NCT01133015|DEVICE|IVUS|intravascular ultrasound
218864490|NCT00342706|PROCEDURE|Community based intervention|
218864491|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
219598040|NCT04440670|BIOLOGICAL|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
219598041|NCT01833819|DRUG|Dexmedetomidine and lidocaine|
219598042|NCT01833819|DRUG|Remifentanil|
219598043|NCT04262180|OTHER|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
219598044|NCT04262180|OTHER|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
219598045|NCT04262180|OTHER|Online Gym|Non-responders to base intervention will be randomized to online gym.
219598046|NCT06619626|DEVICE|alveolar recruitment strategy applied group|the effect of alveolar recruitment strategy on the mechanical parameters of the patients
219598047|NCT06619626|DRUG|group without alveolar recruitment strategy|effect on mechanical parameters of patients without alveolar recruitment strategy
219598048|NCT06803927|DEVICE|Barrett's Esophagus Test (LDT)|Barrett's Esophagus Test (LDT) will be performed on esophageal cells collected using the EndoSign Cell Collection Device (510(k) cleared) and compared to the results of standard of care EGD plus biopsies (if applicable)
219598049|NCT04252898|BEHAVIORAL|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
219598050|NCT01179698|PROCEDURE|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
218864492|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
218864493|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
218864494|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
219598051|NCT01179698|PROCEDURE|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
219598052|NCT04450576|DIAGNOSTIC_TEST|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
218864495|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
218864496|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
218864497|NCT00156169|DRUG|Dunaliella|
218864498|NCT00418054|DRUG|Nitazoxanide plus peginterferon alfa-2b|
218864499|NCT00418054|DRUG|Peginterferon alfa-2b|
219598053|NCT03038594|DRUG|Somatropin|
219598054|NCT03038594|DRUG|0.09% Saline Solution|
219598055|NCT02906241|BEHAVIORAL|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
219598056|NCT02906241|BEHAVIORAL|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
219598057|NCT05157906|BEHAVIORAL|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
219598058|NCT05157906|BEHAVIORAL|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
219598059|NCT03790150|OTHER|Evidence-based practices|Implementation of evidence-based practices
218864500|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
218864501|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
218864502|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
218864503|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
218864504|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
218864505|NCT06229054|DRUG|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
218864506|NCT06229054|DRUG|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
218864507|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
219598060|NCT03492827|DRUG|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
219598061|NCT01045213|OTHER|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
219598062|NCT00732576|DIETARY_SUPPLEMENT|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
219480097|NCT06894446|DIETARY_SUPPLEMENT|Numeta G13%E|Dose selected and dosing schedule are as deemed appropriate by the ordering attending physician in conjunction with the Investigator.
218864508|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
218864509|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
218864510|NCT01326832|DEVICE|Primoris|Total hip arthroplasty with the new Primoris femoral component
218864511|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
218864512|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
218864513|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
218864514|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
218864515|NCT02757612|RADIATION|laser diode|laser diode
219480098|NCT06894446|DIETARY_SUPPLEMENT|Compounded Parenteral Nutrition (cPN) solution|Will be administered as institutional SOC procedure for the hospital.
219480099|NCT06909539|DEVICE|Home Pelvic Floor Trainer|"The intervention utilizes a perineometer device with biofeedback features.~This device employs external electrodes to measure pelvic floor muscle strength. It then provides real-time feedback through a smartphone application during exercise sessions. The application uses gamification to engage users and track progress. Patients can choose between two games: a bird game or a space-themed game. In the bird game, patients activate their pelvic floor muscles to make the bird fly upward. In the space game, pelvic floor contractions fire a laser or activate a shield. A visual bar displays the strength of pelvic floor contractions. Games are designed to be played for 5 minutes daily, 7 days a week, with increasing difficulty as the user progresses through levels."
219480100|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen)|"Combination of two procedures Preoxygenation prior to intubation with NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen).~During intubation, NIV is stopped and apneic oxygenation is maintained with HFNO"
219598063|NCT00732576|DIETARY_SUPPLEMENT|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
219598064|NCT00732576|DIETARY_SUPPLEMENT|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
219598065|NCT01203020|DRUG|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
219598066|NCT01203020|DRUG|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
219598067|NCT05393843|DIETARY_SUPPLEMENT|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
219598068|NCT05393843|BEHAVIORAL|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
218864516|NCT01024192|DRUG|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
218864517|NCT01685021|DRUG|MOR00208 (formerly Xmab5574)|
218864518|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
218864519|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
218864520|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
218864521|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
219480101|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation)|Single procedure Preoxygenation prior to intubation with NIV (Non Invasive Ventilation).
219480102|NCT06830174|DEVICE|Starstim system|Transcranial direct current stimulation (tDCS)
219480103|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
219480104|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
219598069|NCT05393843|OTHER|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
219598070|NCT02368951|DRUG|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
219598071|NCT02976987|DRUG|Cidofovir|
218864522|NCT06398925|DRUG|Placebo|Placebo capsule
218864523|NCT06484361|DRUG|68Ga-PSMA|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
218864524|NCT06484361|DRUG|68Ga-RM2|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
218864525|NCT02198235|DRUG|Dexamethasone|
218864526|NCT02198235|DRUG|Buprenorphine|
218864527|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
218864528|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
219598072|NCT02317289|DEVICE|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
219598073|NCT00929279|DRUG|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
219598074|NCT00929279|DRUG|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
218864529|NCT02264548|RADIATION|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
218864530|NCT04619277|DEVICE|drug-coated balloon|drug-coated balloon
218864531|NCT03350906|DRUG|n3-PUFA|The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
218864532|NCT03350906|DRUG|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
218864533|NCT03350906|PROCEDURE|Biopsy|Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
218864534|NCT03350906|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
218864535|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
218864536|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
218864537|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
218864538|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
218864539|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
219480105|NCT06910605|DRUG|"drug holidays (D)"|Participants omit three consecutive daily doses of ADHD-medication (stimulant).
219480106|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
219480107|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
219480108|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
219480109|NCT06876597|DEVICE|Motor-cognitive interactive robot|Motor-cognitive interactive robot-assisted training integrates motor and cognitive rehabilitation using an upper limb rehabilitation robot. If patients cannot actively lift the robotic arm, an eye-tracking mode detects movement intention and guides the arm along predefined trajectories, adjusting motor and cognitive loads dynamically. As motor function improves, training shifts to an active mode with increased resistance. Patients complete cognitive tasks before moving the robotic arm, while the system monitors movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load progresses by increasing robotic arm speed or resistance, while cognitive load advances based on task accuracy, ensuring personalized and adaptive rehabilitation.
219522353|NCT07029048|OTHER|Standard Post-COVID Rehabilitation Program|This standardized rehabilitation intervention includes a 14-day inpatient course comprising physiotherapy, therapeutic exercises, massage, and respiratory gymnastics. The program is delivered equally to all participants regardless of cognitive status and is intended to promote post-viral recovery in patients recently discharged following COVID-19 pneumonia. No specific cognitive therapy or pharmacological treatment is administered during the rehabilitation period. The intervention is used as background care, not as an experimental variable.
219522354|NCT07028320|DRUG|SAL056 (56.5μg)|Administered by subcutaneous injection once a week during treatment phase
219598075|NCT00798876|DIETARY_SUPPLEMENT|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
218864540|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
218864541|NCT02991469|DRUG|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
218864542|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
218864543|NCT05845463|DEVICE|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
218864544|NCT01076413|BEHAVIORAL|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
219480110|NCT06876597|DEVICE|Motor-focused robot|Motor-focused robot-assisted training primarily emphasizes motor rehabilitation through the use of an upper limb rehabilitation robot. When patients are unable to actively lift the robotic arm, an eye-tracking mode is employed to guide movements, with adjustments made solely to the motor load. As motor function improves, the training transitions to an active mode, progressively increasing resistance while maintaining a constant, minimal level of cognitive difficulty. Patients are required to complete cognitive tasks before initiating movement of the robotic arm, while the system monitors key movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load is progressively increased by adjusting the speed or resistance of the robotic arm, while cognitive load remains consistently at the lowest level throughout the training.
219480111|NCT06876597|BEHAVIORAL|Conventional rehabilitation training|Conventional rehabilitation training adheres to internationally established guidelines and employs task-oriented approaches tailored to activities of daily living (ADLs). The therapeutic regimen incorporates fundamental motor skill exercises, including but not limited to grasp-and-release maneuvers, targeted reaching, fine motor skill development (e.g., button manipulation, zipper operation), and bilateral coordination tasks (e.g., garment folding, towel wringing). The intervention protocol emphasizes progressive task difficulty and functional task integration, with each session lasting 60 minutes. The treatment schedule consists of daily sessions, five times per week, over a four-week duration.
219598076|NCT00798876|DIETARY_SUPPLEMENT|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
219598077|NCT00798876|DIETARY_SUPPLEMENT|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
219598078|NCT00798876|DIETARY_SUPPLEMENT|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
218864545|NCT01076413|BEHAVIORAL|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
218864546|NCT03972878|OTHER|control snack|dry fruit snack (200 kcal) + 250 ml water
218864547|NCT03972878|OTHER|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
218864548|NCT03972878|OTHER|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
218864549|NCT03972878|OTHER|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
218864550|NCT03972878|OTHER|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
219598079|NCT00798876|OTHER|Medical Examination|Subjects will have a routine medical exam.
219598080|NCT00798876|OTHER|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
219598081|NCT00798876|OTHER|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
219598082|NCT00798876|PROCEDURE|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
218864551|NCT03972878|OTHER|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
218864552|NCT03972878|OTHER|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
218864553|NCT05863208|DEVICE|Artificial intelligence|ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
218864554|NCT05863208|DEVICE|Endocuff vision|Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
218864555|NCT05863208|DEVICE|High-definition endoscope|High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
218864556|NCT05696093|DRUG|cotrimoxazole|Use of cotrimoxazole therapy for enterobacterial VAP
218864557|NCT05696093|DRUG|standard antibiotic therapy|Use of standard antibiotic therapy for enterobacterial VAP
218864558|NCT04973696|BEHAVIORAL|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
218864559|NCT04973696|OTHER|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
218864560|NCT02582281|DEVICE|intrauterine device TCu 380A|
219598083|NCT02445976|DRUG|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
218864561|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
218864562|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
218864563|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
218864564|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
218864565|NCT04118790|PROCEDURE|MRI scan|1\. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
219480112|NCT06929988|OTHER|Creanz Lotion|"Mode of Usage: Apply sufficient quantity of Creanz Nourishing Body lotion to face and body for smooth and moisturised skin.~Frequency: Twice a Day Route of Administration: Topical"
219480113|NCT06933225|OTHER|WOW fusion Microneedling Device, 1.00 mm|One treatment session on the whole face, on D0 and second treatment on D30.
218864566|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
218864567|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
218864568|NCT04332614|BEHAVIORAL|Less-is-better|Email
218864569|NCT04332614|BEHAVIORAL|Social proof|Email
218864570|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
218864571|NCT04332614|BEHAVIORAL|Standard email|Email
218864572|NCT05533372|DRUG|IA-14069|IA-14069 for oral administration.
218864573|NCT05533372|DRUG|Placebo|Placebo for oral administration.
218864574|NCT05533372|DRUG|Methotrexate|Methotrexate for oral or SC administration.
218864575|NCT05533372|DRUG|Methotrexate|Methotrexate for oral administration.
218864576|NCT06339515|BEHAVIORAL|Universal Design Model|Universal design-based learning is based on the application of universal design approach principles to education. Universal design-based learning considers three broad networks of the brain to enable learning. These are recognition networks, strategic networks and affective networks. Universal design-based learning is a student-centered approach and curricula are designed to appeal to all students. Curricula consist of objectives, teaching methods, teaching materials and assessment and evaluation elements. Students' interests, needs and abilities are taken into consideration when designing curricula. Students' learning disabilities are identified and alternative practices are planned to eliminate these disabilities. All students are given equal opportunity to learn
218864577|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
218864578|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
218864579|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube|
219480114|NCT06935747|COMBINATION_PRODUCT|Medical device: beta-tricalcium phosphate|The description of the intervention for BTCP in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. BTCP is indicated for the treatment of segmental and cavitary bone loss, aesthetic repairs, and bone augmentations (such as inlay or onlay grafts); for filling dental alveolar bone; for dental implant placement; and for the stabilization of osteotomies and prostheses in dentistry.
218864580|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes|
218864581|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
218864582|NCT04401878|DRUG|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
218864583|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
218864584|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
218864585|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
218864586|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
219522355|NCT07028320|DRUG|Alendronate|70 mg tablet taken once a week during treatment phase
219522356|NCT07036029|DRUG|NAL ER|Oral tablets
219522357|NCT07036029|DRUG|Placebo|Oral tablets
219522358|NCT07035262|OTHER|serum metabolites|serum metabolites before and after colorectal cancer surgery
219522359|NCT07036172|DRUG|HDM1702|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
219522360|NCT07036172|DRUG|Wegovy ®|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
219522361|NCT07037576|PROCEDURE|Breast Reconstruction Surgery|Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy
219522362|NCT07037355|COMBINATION_PRODUCT|Handgrip Strength and Hand-Eye Coordination Assessment|Children underwent standardized testing to assess functional recovery post-healing of distal radius greenstick fractures.
218864587|NCT06583291|DRUG|Allogeneic dopaminergic neural precursor cell(iDAP)|Bilateral implantation
218864588|NCT04007770|OTHER|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
218864589|NCT04007770|OTHER|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
219480115|NCT06935747|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
219480116|NCT06935877|DRUG|Hyaluronic acid injection|traditional rehabilitation programs
219480117|NCT06935877|DRUG|Triamcinolone Acetonide injection|traditional rehabilitation programs
219598084|NCT00563576|DRUG|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
218864590|NCT04007770|OTHER|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
218864591|NCT02535533|DRUG|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
218864592|NCT02535533|DRUG|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
219480118|NCT06939322|OTHER|Use of the Log-AFTER software|The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients
219598085|NCT00563576|DRUG|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
219598086|NCT05934240|OTHER|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
219598087|NCT05934240|OTHER|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
218864593|NCT02535533|DRUG|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
218864594|NCT02535533|DRUG|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
218864595|NCT02535533|DRUG|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
218864596|NCT05178381|DEVICE|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates \[x,y,z\] = \[35,50,15\] for frontal pole and \[x,y,z\] = \[56,16,22\] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
219480119|NCT06937242|DEVICE|Ottobock C-Leg 4 Microprocessor Knee|Subjects in the intervention group who can walk more than 0.83m/s in the 2-minute walk test (2MWT) will receive the Ottobock C-Leg 4, a stance-and-swing microprocessor knee.
219480120|NCT06937242|DEVICE|Ottobock Kenevo|Subjects in the intervention group who can walk up to 0.83m/s (3km/hr) in the 2-minute walk test (2MWT) will receive the Kenevo, a stance-only microprocessor knee.
218864597|NCT06402396|DRUG|bDMARDS|Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
219480121|NCT06943131|OTHER|YWTL EXERCISES|YWTL exercises are shoulder and upper back exercises to improve posture, strengthen upper back. Each letter represents different arm position that copies shape of letter.
219480122|NCT06943131|OTHER|Closed kinetic chain exercises|Closed kinetic chain exercises include corner stretch hold, sleeper stretch hold - lawn mover and robbery maneuver, Scapula clock exercises, wall wash. Low row exercise maneuver, Scapular stabilization of Black burn exercises, press up, push up.
219480123|NCT06942416|DRUG|Paclitaxel and Cisplatin/ Carboplatin|Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Carboplatin 0.3-0.4g/m², intravenous infusion, Day 1, Q3W .Duration: 4-6 cycles.
219598088|NCT00521040|DRUG|Levocetirizine dihydrochloride|
219598089|NCT01525264|BEHAVIORAL|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
218864598|NCT05036707|DEVICE|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
218864599|NCT05036707|PROCEDURE|skin biopsy|2-3 mm skin punch biopsies will be performed.
218864600|NCT05036707|PROCEDURE|blood draw|Peripheral blood draws will be performed.
218864601|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
219480124|NCT06942416|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab 5mg/kg, intravenous infusion, Day 1, Q3W. Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
218864602|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
218864603|NCT05365048|OTHER|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
218864604|NCT05365048|OTHER|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
219480125|NCT06942416|RADIATION|Radiotherapy|Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases. Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases. Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 4-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions. echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy.
219480126|NCT06943235|DRUG|Probiotics|Subjects received probiotics before radiotherapy
219480127|NCT06943235|RADIATION|concurrent Hyperfractionated Radiotherapy|Increase radiation dose on the basis of conventional radiotherapy
219480128|NCT06936579|DEVICE|proprioceptive stimulation|"Condition without proprioceptive stimulation: Participants will not receive the stimulus, and MEP activity will be recorded under the same motor cortex stimulation conditions.~Condition with proprioceptive stimulation 1: Participants will receive proprioceptive stimulation through the output plunger, applied continuously for 15 seconds, with 20-second rest intervals, over a total duration of 5 minutes. MEP activity will then be recorded via motor cortex stimulation.~Condition with proprioceptive stimulation 2: Participants will receive proprioceptive stimulation continuously during the application of TMS pulses while MEP activity is recorded."
219480129|NCT06940804|BIOLOGICAL|CLDN6 CAR-T|Intravenous (IV) infusion
218864605|NCT05755815|PROCEDURE|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
219480130|NCT06940804|BIOLOGICAL|CLDN6 RNA-LPX|IV injection
219480131|NCT06942442|DRUG|Physician's Choice|Patients who are HLA-A\*02:01-negative and ineligible to receive tebentafusp will be prospectively enrolled onto a separate study arm and treated with physicians' choice of treatment. They will also be radiographically assessed at the same schedule as patients treated with tebentafusp, if feasible, and kept on this treatment arm until progression of disease or unacceptable toxicity on the physicians' choice regimen.
218864606|NCT05755815|PROCEDURE|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
219480132|NCT06942442|DRUG|Tebentafusp|Patients who screen positive for HLA-A\*02:01 and meet the eligibility requirements will be treated with weekly tebentafusp
219480133|NCT06942559|DEVICE|EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation.~500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5 ms inter-pulse interval will be applied at an average inter-burst interval of 2 s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
219480134|NCT06942559|DEVICE|Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot.~High-frequency rTMS consisting of 50 trains at 20 Hz (2 s on, 18 s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
219480135|NCT06943079|DEVICE|Effect of Hold Relax technique with Blood Flow Restriction technique on functional outcome|Participants are randomly allocated to group A through computerised generated method. The both combine intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
219480136|NCT06943079|OTHER|Effect of Hold Relax technique without Blood Flow Restriction technique on functional outcomes|Participants are randomly allocated to group B through computerised generated method. The intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
219480137|NCT06942728|DEVICE|nLIFE EyeFitness|A software called nLIFE EyeFitness, certified as a Class I Medical device, allows to carry out individualized rehabilitation exercises at home, using own PC or tablet, with monitoring by the Center's operators.
219480138|NCT06943261|OTHER|task oriented training|The 8-week intervention program targets fine motor and functional play skills in children through progressive weekly activities. Week 1 focuses on eye-hand coordination (e.g., stacking blocks, bead stringing), followed by grasp and release control in Week 2 (e.g., object transfer tasks). Week 3 enhances reaching and precision (e.g., targeting and catching), while Week 4 develops bilateral coordination (e.g., buttoning, tearing paper). Week 5 works on visual-motor planning (e.g., drawing, tracing), and Week 6 encourages daily functional play (e.g., pouring, pretend cooking). Week 7 combines skills (e.g., dressing a doll, coin placement), and Week 8 consolidates learning through review and practice of previous tasks.
219598090|NCT01525264|BEHAVIORAL|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
219598091|NCT06633731|OTHER|Biocellulose Mask|Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
219598092|NCT06633731|OTHER|Post Procedure Cream|Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
219598093|NCT06633731|OTHER|Gentle Cleanser|Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
219598094|NCT06633731|OTHER|Facial Moisturizer|Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
219598095|NCT06633731|OTHER|sunscreen|Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
218864607|NCT05433415|BEHAVIORAL|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
218864608|NCT06083584|OTHER|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
218864609|NCT04460859|OTHER|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
218864610|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
218864611|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
219480139|NCT06943261|OTHER|conventional therapy|The control group will receive standard physical therapy consisting of general exercises aimed at improving overall strength, flexibility, and gross motor skills, without specifically targeting visual-motor integration or fine motor skills. Sessions will also include non-specific recreational activities such as free play or unstructured tasks. The intervention will be conducted three times per week, with each session lasting 45-60 minutes, over a total duration of 8 weeks.
219480140|NCT06942338|DEVICE|Corsano CardioWatch 287-2|Temperature readings from wearable Cardiowatch BT sensor, wearable Radius-T BT sensor, tympanic temperature and rectal temperature will be collected. Each participant will remain in the study as long as the rectal temperature is measured with a maximum of 24 hours. Other than the wearable Cardiowatch, the Radius-T sensors, and the rectal thermometer no additional interventions will take place due to the study. Temperature monitoring of patients will be performed according to hospitals routine care and will not be affected by the study. Patients may receive additional treatment to ensure best care.
219480141|NCT06942169|BEHAVIORAL|Mindfulness-Based Self-Compassion Training|Mindfulness-Based Self-Compassion Training is a very comprehensive approach that addresses the awareness and acceptance of individuals towards their bodies, as well as encouraging them to live a conscious life. Studies found that self-compassion increases well-being during menopause (Brown, 2015; Arab et al., 2020). Psychiatric nursing is a special field that works to evaluate, diagnose, and enhance mental health in every area where people are present.
219598096|NCT01945073|BEHAVIORAL|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
219598097|NCT01945073|OTHER|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
219598098|NCT04769063|OTHER|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
219598099|NCT00147602|DRUG|atorvastatin|
219598100|NCT03735069|PROCEDURE|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
219598101|NCT03735069|PROCEDURE|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
218864612|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
218864613|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
218864614|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
218864615|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
218864616|NCT03566017|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
219598102|NCT03735069|PROCEDURE|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
219598103|NCT01170013|BEHAVIORAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
219598104|NCT01170013|BEHAVIORAL|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
218864617|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
218864618|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
218864619|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
218864620|NCT05924477|PROCEDURE|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
219480142|NCT06943274|OTHER|Standardized Walking Course Activities|"A randomized controlled trial investigate the effect of a standard walking obstacle course on balance, gait and endurance in children with ASD. Activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces.~* Balance activities~* Gait activities~* Endurance activities Start with easier task and end with difficulties. SWOC activities performs 2 to 3 times a week for 4weeks."
219480143|NCT06943274|OTHER|Common Physical Activities|Either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running, climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy.
219598105|NCT03320421|RADIATION|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
219598106|NCT05819203|DEVICE|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
219598107|NCT05819203|DEVICE|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
218864621|NCT05924477|PROCEDURE|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
218864622|NCT05780918|OTHER|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
219040026|NCT04729166|BEHAVIORAL|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
219480144|NCT06942975|OTHER|Patients with turberculosis|The study plans to collect data from patients with microbiological confirmation of tuberculosis, notified to the SS Hospital Infection Surveillance and Control Antimicrobial Stewardship, in the period between 2019 and 2023, taken in charge by the SC Infectious Diseases of the A.O. SS Antonio e Biagio and Cesare Arrigo of Alessandria (Piedmont Region, Italy).
219480145|NCT06941883|DRUG|Botulinum toxin injection under anatomical landmark|Patients received botulinum toxin injections under the anatomical landmark.
219598108|NCT03033966|DEVICE|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
219598109|NCT06010849|DIAGNOSTIC_TEST|Trunk control|Trunk control
219598110|NCT00527306|DIETARY_SUPPLEMENT|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
219598111|NCT01064752|DRUG|Minocycline|100 mg po bid for 8 weeks
219598112|NCT03058432|RADIATION|Radiotherapy alone|
218864623|NCT06269705|DRUG|ZILRETTA|IA injection of 32 mg ZILRETTA
219598113|NCT03058432|RADIATION|Concurrent chemoradiotherapy|
219598114|NCT03232632|DRUG|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
219598115|NCT02748967|DRUG|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
219598116|NCT02748967|DRUG|Placebo|Participant will receive single dose of Placebo on Day 1.
219598117|NCT00094406|PROCEDURE|Bronchoscopy|
219598118|NCT00094406|PROCEDURE|Bronchoalveolar lavage|
218864624|NCT06269705|DRUG|TCA-IR|IA injection of 40 mg TCA-IR
219480146|NCT06941883|DRUG|Ultrasound-guided botulinum toxin injection|Patients received ultrasound-guided botulinum toxin injection
219480147|NCT06941896|DEVICE|Use of the Atalante Exoskeleton|"Assisted verticalization (sit-to-stand transition)~Orthostatic stabilization (unsupported standing posture)~Assisted locomotion (stabilized walking)"
219480148|NCT06942156|DRUG|Everolimus|Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit
219480149|NCT06942156|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1.5g BID(total 3g daily), PO
219480150|NCT06941805|DIAGNOSTIC_TEST|Physical Fitness|Physical fitness levels of blue- and white-collar university workers were measured and compared.
219480151|NCT06941805|DIAGNOSTIC_TEST|Physical activity|Weekly physical activity levels of blue- and white-collar university workers were measured and compared.
218864625|NCT06269705|OTHER|Placebo|IA injection of placebo (normal saline)
218864626|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
218864627|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
218864628|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
218864629|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
218864630|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
218864631|NCT02506660|DRUG|Bupivacaine|
218864632|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
218864633|NCT02506660|DRUG|Intravenous dexamethasone|
218864634|NCT02506660|DRUG|Intravenous saline|
218864635|NCT02506660|DRUG|Perineural saline|Saline in nerve block
218864636|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
218864637|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
219480152|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
218864638|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
218864639|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
218864640|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
218864641|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
218864642|NCT02187315|DEVICE|Routine intravenous drip|
218864643|NCT02187315|DRUG|induction chemotherapy|
219480153|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
219480154|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
219480155|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
219598119|NCT00094406|DRUG|Endotoxin|
219598120|NCT00094406|DRUG|Carbon Monoxide|
219598121|NCT04475783|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
219598122|NCT03993730|DEVICE|ICD|Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
219598123|NCT03993730|DEVICE|ILR|Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
218864644|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
218864645|NCT02187315|RADIATION|intensity-modulated radiation therapy|
218864646|NCT02187315|DRUG|cisplatin routine-chemotherapy|
218864647|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
218864648|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
218864649|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
218864650|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
218864651|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
218864652|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
218864653|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
218864654|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
218864655|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
218864656|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
218864657|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
219480156|NCT06943391|DEVICE|laser|patients subjected to a tooth extraction and immediately given an intraoral PBM session with an EPIC X Biolase diode laser (BIOLASE, Inc. USA), with a voltage of 100-240 V, 1.5 A, a power of 0.5 W, and an application of an energy of 15J per cm², for 10-30 seconds at 1 mm of the tissue with an sterile surgical tip. It was applied at three points in the area: buccal, pala-tal/lingual, and occlusal to stimulate the tissue.
219480157|NCT06938698|OTHER|PROM collection|PROM collection using a digital health web application. PROMs will be based on the HF Standard Set created by the International Consortium of Health Outcomes Measurements (ICHOM), adapted to the patient follow-up protocol already in use by GEstIC. Half the participants will complete the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and the other half will complete the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
219480158|NCT06943352|OTHER|Sensory Bins|The sensory bin is a basket filled with different objects of different shapes, sizes, and textures.
219480159|NCT06943352|OTHER|Drawing and Painting|Colored pencils and watercolors will be used.
219480160|NCT06943313|DIAGNOSTIC_TEST|68Ga-pAKTi PET/CT probe|A total of 20 patients with breast cancer will be enrolled. Screening will be conducted within 14 days prior to administration of 68Ga-pAKTi (from Day -14 to Day -1). Subjects who meet all inclusion criteria and none of the exclusion criteria will receive an intravenous injection of 68Ga-pAKTi on Day 0, followed by PET/CT imaging.
219480161|NCT06941636|DRUG|5U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 2 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 5 U/0.1 mL. Each patient will receive a total dose of 50 U, administered bilaterally into the masseter and temporalis muscles.
219480162|NCT06941636|DRUG|10U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 1 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 10 U/0.1 mL. Each patient will receive a total dose of 100 U, administered bilaterally into the masseter and temporalis muscles.
219480163|NCT06942663|OTHER|Surveillance|Close monitoring for disease recurrence.
219480164|NCT06942663|DRUG|Adjuvant Chemotherapy|The adjuvant chemotherapy regimen will be standardized based on current clinical guidelines and may include combinations of agents such as fluoropyrimidines and oxaliplatin with or without docetaxel. Treatment until the progression of the process is detected or the maximum effect of therapy is achieved (the maximum duration of treatment is 3 months).
219480165|NCT06943651|DEVICE|HealthyW8 Digital Twin of healthy lifestyle recommendations|The applied intervention with the developed healthy lifestyle recommender system will be unique and is not used in any other clinical study. However, a large number of intervention studies on young adults' obesity, considering nudging (e.g. 60 in www.clinical.trials.gov), were found. Among the registered clinical trials in the referred database, 3 considered young adults obesity and saliva salivary analysis, but with a different purpose. Moreover, the type of digital solution that will be tested will put together different aspects that are not usually to see together in the same application. These different lifestyle aspects will be used for personalized recommendations.
219480166|NCT06941948|OTHER|PSQI|PSQI
219480167|NCT06943586|GENETIC|CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)|CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
219480168|NCT06942013|DEVICE|Computer-Guided Autogenous Cortical Shell Technique (Study Group)|"This study utilizes two patient-specific 3D-printed surgical guides to enhance precision in bone harvesting and fixation for horizontal ridge augmentation in the anterior mandible.~Chin Harvesting Guide~This tooth-supported guide is placed on the exposed mandibular symphysis to ensure accurate osteotomy cuts for harvesting a cortical bone shell.~It directs piezo drill cuts (superior, inferior, and vertical) to minimize errors and prevent damage to vital structures.~Bone Block Fixation Guide~After harvesting, this guide helps in precise fixation of the cortical shell onto the recipient site.~It includes pre-planned screw holes to ensure stable positioning of the graft and improve surgical accuracy.~These guides enhance precision, reduce surgical time, and improve graft stability, making the computer-guided technique superior to the traditional free-hand method."
219598124|NCT06027385|DIAGNOSTIC_TEST|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
219598125|NCT06400277|OTHER|Edentulous maxilla final impression for complete denture|Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
219598126|NCT02185053|DRUG|CPC-201|
219598127|NCT04688892|DEVICE|Cupping|dynamic cupping
219598128|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
218864658|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
218864659|NCT05455502|DRUG|VX-548|Tablet for oral administration.
218864660|NCT04788056|PROCEDURE|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
218864661|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
218864662|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
218864663|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
218864664|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
218864665|NCT02667756|OTHER|Non-interventional|
218864666|NCT01331928|DRUG|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
218864667|NCT04803955|DRUG|16mg，KB|16mg,Q8h±3min,Day1-Day7
218864668|NCT04803955|DRUG|Placebos|16mg,Q8h±3min,Day1-Day7
219480169|NCT06942013|PROCEDURE|Free-Hand Autogenous Cortical Shell Technique (Control group)|In this group, horizontal ridge augmentation of the anterior mandible is performed using a free-hand technique without computer-guided assistance. Autogenous cortical bone is harvested from the mandibular symphysis using a conventional osteotomy performed manually. The harvested cortical shell is adapted and fixated at the recipient site using titanium mini screws, based on the surgeon's clinical judgment and intraoperative assessment. Bone particulate grafting using a 1:1 ratio of autogenous bone and xenograft material is packed into the defect to enhance volume stability. This approach may result in increased variability in graft positioning, longer surgical time, and higher dependence on surgeon experience.
219480170|NCT06943118|PROCEDURE|Chemical Peels|Chemical peel is a dermatological procedure in which chemical solution is applied to the skin to remove the top layer
218864669|NCT01984450|PROCEDURE|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
218864670|NCT01984450|PROCEDURE|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
218864671|NCT01984450|DEVICE|implant with a collagen + fibrin gel mixture|
219480171|NCT06941649|PROCEDURE|Expansive open-door laminoplasty via intermuscular space approach|The cervical laminoplasty via intermuscular space approach will apply bilateral blunt dissection to create the operative space between capital semispinalis muscle and cervical semispinalis muscle
219480172|NCT06941649|PROCEDURE|cervical single-door laminoplasty via the conventional approach|The cervical laminoplasty via the conventional approach will apply median dissection of the cervical spinous ligament and seperate muscles to expose the whole lamina of cervical vertebrae.
219480173|NCT06942468|DRUG|Topical nano preparation of Phenytoin|Topical nano preparation of Phenytoin will be used to treat atrophic post-acne scars. It will be in form of spanlastics.
218864672|NCT06441474|BEHAVIORAL|Presentation of personal breast cancer risk estimate|All participants will be presented with their personal breast cancer risk estimate, calculated using the Gail Model
219480174|NCT06942468|DEVICE|Fractional CO2 laser|Fractional CO2 laser will be used alone for treatment of atrophic post acne scars.
219480175|NCT06941870|DRUG|Efanesoctocog alfa|Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous
219480176|NCT06955936|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoadsorption. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The therapy will be performed once no later than 4 hours after the diagnosis of cardiogenic shock.~The duration of hemoadsorption is from 4 to 12 hours. The rate of hemoadsorption is from 80 to 150 ml/min. Anticoagulation is systemic (heparin or sodium citrate)."
219480177|NCT00519948|DRUG|new MPS, opti-free express no rub MPS|
219480178|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
219480179|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
218864673|NCT03584243|PROCEDURE|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
218864674|NCT01660620|DRUG|Betaxolol|
218864675|NCT01660620|DRUG|topical betaxolol|given topically
218864676|NCT04180566|OTHER|Ultrasound Examination|Includes a regular growth ultrasound examination.
219598129|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
219598130|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
219598131|NCT01462812|DRUG|Sumatriptan|Sumatriptan 20mg
218864677|NCT04180566|OTHER|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
219480180|NCT05442190|DRUG|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
219480181|NCT05442190|DRUG|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
219480182|NCT04633824|OTHER|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
219480183|NCT04224506|OTHER|No intervention|There is no intervention for this study.
219480184|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
219480185|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
219480186|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
219598132|NCT01462812|DRUG|Placebo|Matching placebo
219598133|NCT00471952|DRUG|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
219598134|NCT00471952|DRUG|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
219598135|NCT00471952|DRUG|Placebo + Placebo|One migraine attack will be treated with double placebo
218864678|NCT02101489|OTHER|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
218864679|NCT02961946|DRUG|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
218864680|NCT01659099|DRUG|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
218864681|NCT01659099|DRUG|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
218864682|NCT01659099|DRUG|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
218864683|NCT01659099|DRUG|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
218864684|NCT01659099|DRUG|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
218864685|NCT01659099|DRUG|Bleomycin|in ACBVP 10 mg from D1 to D5
218864686|NCT01659099|DRUG|Vindesin|in ACBVP 2 mg/m² from D1 to D5
218864687|NCT01659099|DRUG|Vincristine|in CHOP 1,4 mg/m² on D1
218864688|NCT05218525|OTHER|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
218864689|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
218864690|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
218864691|NCT00114088|PROCEDURE|hysterectomy|
218864692|NCT00114088|PROCEDURE|endometrial ablation|
218864693|NCT04555837|DRUG|Alisertib|Given PO
218864694|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
218864695|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
218864696|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
218864697|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
218864698|NCT05632783|OTHER|Placebo|Placebo tablets
218864699|NCT05773976|DEVICE|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil"
219480187|NCT05987163|DEVICE|GP0116|GP0116 is an injectable, sterile, transparent product.
219480188|NCT05987163|DEVICE|Active Comparator: FDA approved dermal filler device (RHA 3)|FDA approved dermal filler device (RHA 3)
219480189|NCT05643651|DRUG|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
219480190|NCT05643651|DRUG|Aspirin or Clopidogrel|Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[1.0 mg/kg; once daily\]
219480191|NCT05643651|DRUG|Warfarin|Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
219480192|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
219480193|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
219480194|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
219480195|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
219480196|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
219480197|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
219480198|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
219480199|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
219480200|NCT00246675|DRUG|Frusemide|
219480201|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
219480202|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
219480203|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
219040027|NCT06113952|DEVICE|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
219480204|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
219480205|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
219480206|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
219480207|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
219480208|NCT02881866|DRUG|Furosemide|
219480209|NCT02881866|DRUG|Saline|
219480210|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
219480211|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
219480212|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
219480213|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
219480214|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
219480215|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
219480216|NCT02524366|DEVICE|Artificial Urinary Sphincter|
219480217|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
219040028|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
219040029|NCT00555984|DRUG|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
219480218|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
219480219|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
219480220|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
218864700|NCT03542279|PROCEDURE|Plasma exchange (PE)|PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
218864701|NCT03542279|DRUG|intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)|IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
218864702|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
218864703|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
218864704|NCT05838573|DRUG|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
218864705|NCT05838573|DRUG|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
218864706|NCT05838573|OTHER|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
219040030|NCT00555984|DRUG|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
219480221|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
219480222|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
219480223|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
219480224|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
219480225|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
219480226|NCT01807780|BIOLOGICAL|biological monitoring|
219480227|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
219480228|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
219480229|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
219480230|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
219480231|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
219480232|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
219480233|NCT02157181|DRUG|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
219480234|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
219040031|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
219480235|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
219480236|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
219480237|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
219480238|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
219480239|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
219480240|NCT00243672|DRUG|Atorvastatin|
219480241|NCT00243672|DRUG|Gemfibrozil|
219480242|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
219480243|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
218864707|NCT05838573|OTHER|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
219480244|NCT03361332|OTHER|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
219480245|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
219480246|NCT05557968|OTHER|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
219480247|NCT05557968|OTHER|Action Observation Therapy (AO)|"The video consists of :~1. Ascending and descending the step box.~2. Ascending and descending the stairs in the treatment room.~3. Holding the handrails to climb and descend the stairs inside and outside the building.~4. Climbing and descending the stairs inside and outside the building without holding the handle.~5. Climbing and descending the sidewalk block"
218864708|NCT05785182|PROCEDURE|Open Fracture|Patients 18 years of age or older with open fracture. Provision of informed consent.
218864709|NCT05785182|PROCEDURE|Infected Fracture|Patients 18 years of age or older with infected fracture. Provision of informed consent.
218864710|NCT03493607|DRUG|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
218864711|NCT04163367|BEHAVIORAL|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
218864712|NCT04163367|OTHER|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
218864713|NCT02936284|BEHAVIORAL|Music Enhancement|
218864714|NCT02936284|BEHAVIORAL|Play Date|
218864715|NCT05369832|DRUG|Ozanimod|Specified dose on specified days
218864716|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
218864717|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
218864718|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
218864719|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
218864720|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
218864721|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
218864722|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
218864723|NCT04877236|DEVICE|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
218864724|NCT00606983|DRUG|Tamsulosin|oral administration of Tamsulosin
218864725|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
219480248|NCT06346080|OTHER|Survey|Discrete choice survey
219480249|NCT04029766|DRUG|HSK3486|
219480250|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
218864726|NCT06292104|DIAGNOSTIC_TEST|multimodal diagnostic testing|Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
218864727|NCT05825235|DRUG|Pramipexole|6 months of treatment with add-on Pramipexole
218864728|NCT06562595|BEHAVIORAL|Education Intervention|Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
218864729|NCT05011877|DEVICE|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
218864730|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
218864731|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
218864732|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
218864733|NCT01549119|BIOLOGICAL|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
218864734|NCT01549119|BIOLOGICAL|Placebo|Comparison with experimental vaccine
218864735|NCT06080100|DRUG|Xenon|inhalation of xenon in a sub-narcotic dosage
218864736|NCT06080100|OTHER|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
218864737|NCT06779669|OTHER|Questionnaire CAM|Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.
219480251|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
219480252|NCT02070367|OTHER|Somatosensory rehabilitation|
219480253|NCT02070367|OTHER|Usual treatment: physiotherapy|
219480254|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
219480255|NCT00685763|RADIATION|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
219480256|NCT06701916|BEHAVIORAL|Intervention group.|The intervention will be carried out by a multidisciplinary team composed of nurses, doctors, social workers, and psychologists from each hospital. Through this intervention, a narrative from the patients will be obtained regarding their goals, desires, capabilities, and resources related to their health situation. A health plan will be jointly created, reflecting both short- and long-term objectives, identifying the resources available to the person and within their immediate environment, and outlining how they want and expect to receive support from healthcare professionals.
219480257|NCT06701916|BEHAVIORAL|Usual care|Usual care for the outpatient management of Chronic Heart Failure.
219480258|NCT04602208|PROCEDURE|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
219480259|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
219613566|NCT05743257|BEHAVIORAL|Food diary supply|Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.
219480260|NCT02306018|DEVICE|EV1000™/volumeView™|
219480261|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
219480262|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
219480263|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
219480264|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
219480265|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
219480266|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
219613567|NCT05743257|BEHAVIORAL|Interviews (semi-structured)|Sample of participants was interviewed about their food provisioning practice and living conditions.
218864738|NCT01068249|DRUG|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
218864739|NCT01068249|DRUG|RAD001 (Everolimus)|10 mg by mouth daily
218864740|NCT05139797|OTHER|EchoNet-LVH screening for cardiac amyloidosis|An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
218864741|NCT05572398|BEHAVIORAL|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
218864742|NCT06797895|BEHAVIORAL|VR assisted mobility|Commercially-based VR experience used to help move upper extremities to music, similar to dancing or Tai-Chi.
218864743|NCT04023227|DRUG|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
218864744|NCT04023227|DRUG|Enalapril|5 mg and 10 mg will be available for dose adjustments.
218864745|NCT06098534|BEHAVIORAL|Hospi'Senior|The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.
218864746|NCT06098534|BEHAVIORAL|Conventional room|"The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair."
218864747|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
219480267|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
219480268|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
219480269|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
219480270|NCT01853969|OTHER|Typing assessment|
219480271|NCT05286580|BEHAVIORAL|Morbidity and mortality conference toolkit|"* Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form"
219480272|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
218864748|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
218864749|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
218864750|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
218864751|NCT06981273|PROCEDURE|Robotic pancreatoduodenectomy|A Robotic approach pancreatoduodenectomy is performed on patients
218864752|NCT06981273|PROCEDURE|open pancreatoduodenectomy|An open approach for pancreatoduodenectomy is performed
218864753|NCT06980844|OTHER|No intervention: no treatment|translationnal study: Only blood sampling and imaging will be performed on two groups of ILD patients.
218864754|NCT06980103|BEHAVIORAL|Decision Aid|The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.
218864755|NCT06980103|BEHAVIORAL|Usual Care|Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.
218864756|NCT06815003|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
219480273|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
219480274|NCT01205373|DRUG|BI 671800|High dose oral drinking solution
219480275|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
219480276|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
219480277|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
219522363|NCT07037095|DIAGNOSTIC_TEST|Ankle plantar flexion test:|Ankle plantarflexion is valid test used to assess for gastrocnemius muscle strain . Patient is asked to actively plantarflex the foot against resistance while examiner Observe ,this action activates the gastrocnemius muscle .The reliability for ankle plantar flexion is 0.81 to 0.99. If the patient reports pain in the region of gastrocnemius, the test is positive. If there is no pain , weakness or difficulty performing plantarflexion then suggest that test is negative.
219522364|NCT07037290|DIAGNOSTIC_TEST|Ankle proprioceptive neuromuscualar facilitation technique|Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic technique that uses sensory input to enhance muscle function and improve flexibility. For the ankle, PNF techniques can be used to increase range of motion, improve balance and stability, and reduce pain associated with ankle injuries.
219522365|NCT07037290|DIAGNOSTIC_TEST|Foot core exercises along with conventional physiotherapy|This Group will be given foot core exercises which includes heel raise, toe curls, foot doming, toe spreading, balancing board, and tennis ball roll under foot along with conventional therapy which includes ultrasound, plantar fascia stretching and Achilles stretching.
219522366|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with lymphatic taping|Participants will receive a supervised, moderate-to-vigorous intensity resistance training program designed specifically for pregnant women, The resistance training will involve the use of light barbells (1-10 lbs) and weight plates (2.5-10 lbs), targeting all major muscle groups through 50-80 repetitions per muscle group over 3-5 minutes, with short rest intervals. Exercises will be performed at a self-rated intensity level considered moderate to vigorous, following the Borg scale for perceived exertion. The training program is based on the BodyPump format but modified to suit pregnancy-related safety considerations.
218864757|NCT06815003|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218864758|NCT06815003|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218864759|NCT06815003|PROCEDURE|Computed Tomography|Undergo CT
219199734|NCT06262347|BEHAVIORAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
219199735|NCT06262347|BEHAVIORAL|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
219480278|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
218864760|NCT06815003|DRUG|Cyclophosphamide|Given IV
218864761|NCT06815003|PROCEDURE|Echocardiography|Undergo ECHO
218864762|NCT06815003|DRUG|Fludarabine|Given IV
218864763|NCT06815003|DRUG|Melphalan|Given IV
219480279|NCT02074982|DRUG|AIN457 300 mg|
219480280|NCT02074982|DRUG|ustekinumab 45/90 mg|
219480281|NCT02074982|DRUG|placebo secukinumab|Placebo
219480282|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
218864764|NCT06815003|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218864765|NCT06815003|OTHER|Questionnaire Administration|Ancillary studies
218864766|NCT06815003|DRUG|Tacrolimus|Given IV or PO
218864767|NCT06815003|BIOLOGICAL|Vedolizumab|Given IV
218864768|NCT06602063|PROCEDURE|surgery/chemotherapy|secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy
218864769|NCT06602063|DRUG|Iparomlimab/Tuvonralimab|Iparomlimab/tuvonralimab will be administered at a dose of 5 mg per kilogram IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
218864770|NCT06981312|BEHAVIORAL|Acceptance and Commitment Therapy|Participants receive a 9-week internet-delivered intervention: 2 weeks of Pain Neuroscience Education (PNE) based on the PSE curriculum, followed by 7 weeks of Acceptance and Commitment Therapy (ACT) targeting psychological flexibility. In addition to value-oriented behavioral activation, the ACT content includes classical exposure. The treatment is mainly text-based, supported by multimedia content, and delivered on a secure digital platform. Communication with a clinician occurs at least weekly. Parents receive a parallel program based on PSE, ACT, and behavioral principles to support flexible and effective parenting.
218864771|NCT06981312|BEHAVIORAL|Pain Science Education|Participants receive 9 weeks of internet-delivered Pain Science Education (PSE), based on the PSE curriculum but with more detailed content, including extended examples, reflection exercises, and behavioral experiments. The aim is to reduce the threat value of pain by promoting a reconceptualization of pain. Parents receive a parallel program with tailored content. The intervention is text-based with multimedia components and delivered via a secure platform. Clinician support is provided asynchronously at least once weekly.
218864772|NCT06981286|OTHER|A dataset comprising participants withT2D will be used to evaluate the classification performance of various machine learning techniques.|A dataset comprising participants with T2D will be used to evaluate the classification performance of various machine-learning techniques.
218864773|NCT06980467|OTHER|Large Language Model|An artificial intelligence system generating clinical recommendations using prompts, designed to simulate clinical advisory outputs. The protocol focuses on structured medical language generation.
218864774|NCT06980714|BEHAVIORAL|Powered|The intervention involves the use of the Oral-B iO6 powered toothbrush, which provides oscillating-rotating brushing action with personalized feedback via its smart pressure sensor and app integration. Participants in this group are instructed to brush for at least two minutes twice daily. The toothbrush is designed to ensure consistent brushing performance, with real-time feedback on brushing technique and duration, allowing for improved oral hygiene habits. The intervention aims to standardize brushing duration and technique, eliminating potential variations found with manual brushing.
219480283|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
219480284|NCT02094573|DRUG|Brigatinib|Brigatinib tablets
219480285|NCT00566969|DRUG|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
219480286|NCT00566969|DRUG|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
219598136|NCT06536959|DRUG|PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine|"For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors)."
219598137|NCT04332887|BEHAVIORAL|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
218864775|NCT06980714|BEHAVIORAL|Manual|The intervention involves the use of the TePe Select Soft manual toothbrush, which features soft bristles for gentle yet effective plaque removal. Participants in this group are instructed to brush for at least two minutes twice daily, with guidance on proper brushing technique. To ensure compliance with the brushing duration, participants are required to use a smartphone app that tracks and records their brushing sessions. The manual toothbrush allows for participant control over brushing pressure and technique, with no additional oral hygiene aids allowed during the study period.
218864776|NCT06981117|OTHER|12 hr Respite Service|12 hours of respite service within 3 months will be provided by volunteers. Volunteers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
218864777|NCT06981117|OTHER|36 hr Respite Service|36 hours of respite service within 3 months will be provided by substitute caregivers. Substitute caregivers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
218864778|NCT06825910|DEVICE|LMA igel|adults allocated to the LMA igel group, an LMA igel device will be inserted intraoperatively
218864779|NCT06825910|DEVICE|LMA protector|adults allocated to the LMA protector group, an LMA protector device will be inserted intraoperatively
218864780|NCT06997887|OTHER|CH2 vaginal gel|12-week intervention with CH2 vaginal gel
219480287|NCT00566969|DRUG|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
219480288|NCT02495974|DRUG|enzalutamide|oral
219480289|NCT02437526|OTHER|Analytic treatment interruption|
219480290|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
219480291|NCT04328311|OTHER|Watermelon Juice|500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
219480292|NCT04328311|OTHER|Water|500 mL low nitrate water
219480293|NCT04973644|DEVICE|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
219480294|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
219480295|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
219480296|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
219480297|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
219480298|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
219480299|NCT03296059|OTHER|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
219480300|NCT03296059|OTHER|conventional treatment|neonates is treated with conventional treatment.
219480301|NCT00544778|BIOLOGICAL|filgrastim|
219480302|NCT00544778|DRUG|dexrazoxane hydrochloride|
219480303|NCT00544778|DRUG|doxorubicin hydrochloride|
219480304|NCT00544778|DRUG|ifosfamide|
219480305|NCT00544778|DRUG|irinotecan hydrochloride|
219480306|NCT00544778|GENETIC|protein expression analysis|
219480307|NCT00544778|OTHER|immunoenzyme technique|
219480308|NCT00544778|PROCEDURE|adjuvant therapy|
219480309|NCT00544778|PROCEDURE|conventional surgery|
219480310|NCT00544778|PROCEDURE|neoadjuvant therapy|
219480311|NCT00544778|RADIATION|radiation therapy|
219480312|NCT06101251|BEHAVIORAL|Driving Tips|Each week participants will receive a safe driving tip for one of the four behaviors via text message.
219480313|NCT06101251|BEHAVIORAL|Standard Feedback|Each week participants will receive a text message showing their overall driving score (out of 100) and subscores for distraction, hard braking, fast acceleration, and speeding (all running averages). The scoreboard will indicate whether their scores have gone up, down, or stayed the same. The message will include a link to a dashboard.
219598138|NCT00198237|DRUG|docetaxel & capecitabine|
219480314|NCT06101251|BEHAVIORAL|Assigned Focus Area Feedback|Each week feedback will focus the participant's attention on the driving behavior with the greatest opportunity for improvement based on their baseline driving behavior. Participants will be assigned a goal for the week of a score 5 points (3 points in the case of Driver Focus) better than their baseline for that area. If they meet the goal, they will be given a new goal 5 points higher; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be assigned a new behavior to focus on.
219480315|NCT06101251|BEHAVIORAL|Study Dashboard (Standard)|By clicking the link in the feedback text, they will be able to view a weekly dashboard that provides detailed information about their baseline, best, last, and average scores for each of the four behaviors, plus descriptions of the four behaviors.
219480316|NCT06101251|BEHAVIORAL|Study Dashboard (focused)|Same as standard study dashboard, except participants will see at the top of the dashboard how well they are doing relative to their weekly goals.
219598139|NCT05603377|DIAGNOSTIC_TEST|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
219598140|NCT02521376|DRUG|Entospletinib|Entospletinib 100 mg tablet administered orally
219598141|NCT00006460|DRUG|hyperbaric oxygen|
219598142|NCT00006460|RADIATION|radiation therapy|
218864781|NCT06997887|OTHER|vaginal rehabilitation exercises|12-week intervention with vaginal rehabilitation exercises
218864782|NCT02092402|OTHER|Fecal transplantation|
219480317|NCT06101251|BEHAVIORAL|UBI-like Behavioral Incentive|At the end of the 12-week intervention period, their overall driving score will be translated into a $0-$100 reward amount. For example, a participant with an overall driving score of 84 at the end of the intervention period would receive $84 in compensation.
218864783|NCT07007364|DRUG|Adebrelimab Combined With Albumin Paclitaxel|Eligible patients received neoadjuvant low-dose radiotherapy combined with Adebrelimab and monotherapy with albumin paclitaxel for two cycles. Radical surgical resection is planned to be carried out 3 to 4 weeks after neoadjuvant therapy. Patients who obtain PCR after evaluation by the researchers after the operation will be maintained for 6 cycles of immunomonotherapy
218864784|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
218864785|NCT06687824|OTHER|Black Tea Extract|Sterile gauze is impregnated into 5ml of black tea-extract solution with tannin concentration 18.67mg/ml
218864786|NCT06687824|OTHER|0.5% Povidone Iodine Impregnated Sterile Gauze|Diluted povidone-iodine act as negative control is added into sterile gauze to color blind the involved subject and the operator
218864787|NCT06396221|DRUG|Estetrol 15 mg/Drospirenone 3 mg (24/4)|Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
218864788|NCT06396221|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
218864789|NCT02596191|OTHER|Clinical evaluation|
218864790|NCT02596191|OTHER|electrophysiological record|
218864791|NCT02596191|OTHER|Muscle MRI|
218864792|NCT02596191|OTHER|blood samples analysis|
218864793|NCT07032623|PROCEDURE|Spinal Manipulation|The spinal manipulation will target the sacroiliac joint using the global pelvic manipulation technique. Participants will be positioned in lateral decubitus with the ACL-reconstructed limb placed uppermost. The therapist will apply progressive rotation and flexion at the hip and knee joints to increase tissue tension. To establish contact, the therapist's knee will be placed against the participant's flexed knee. A high-velocity, low-amplitude thrust will then be delivered to optimize joint motion, with cavitation being monitored throughout the procedure.
218864794|NCT07033026|DRUG|NGM120 Q4W|NGM120 given subcutaneously every 4 weeks
218864795|NCT07033026|DRUG|NGM120 Q8W|NGM120 given subcutaneously every 8 weeks
218864796|NCT07033026|DRUG|Placebo given|Placebo given subcutaneously every 4 weeks
218864797|NCT07033351|PROCEDURE|Dental implant placement without PRF|Standard dental implant placement procedure with flap elevation and suturing, without the application of any PRF membrane over the implant site.
218864798|NCT07033351|BIOLOGICAL|Single-layer PRF membrane application|PRF membrane prepared via centrifugation is applied as a single layer over the implant site following implant placement before flap closure.
218864799|NCT07033351|BIOLOGICAL|Triple-layer PRF membrane application|Three autologous PRF membranes prepared via centrifugation are stacked and applied as a 3-layer membrane over the implant site before flap closure.
218864800|NCT07036068|DEVICE|IceMagic™ CryoAblation Catheter|IceMagic™ CryoAblation Catheter is available in two diameters: 23 mm and 28 mm. Each diameter has two types of balloon outer surfaces: with or without multi-channel tissue temperature measurement function. The catheter length is 140 cm, and the tube diameter is 10.5 F. Doctors can choose according to the size of the target pulmonary vein.
218864801|NCT07039032|DEVICE|FireMagic™ Magbot Ablation Catheter 、FireMagic™ TrueForce™ Ablation Catheter|"1. The pressure-sensing catheter primarily consists of electrodes, a catheter body, and a control handle. The catheter body comprises a high-torque body and a flexible tip, divided into an adjustable bending segment and a main segment. By pushing or pulling the handle at the proximal end of the catheter, the internal traction wire at the catheter tip can be activated to control the bending of the tip. The adjustable bending segment is fixed with four electrodes at regular intervals, including one tip electrode and three ring electrodes.~2. The disposable star-shaped magnetoelectric positioning catheter is specifically designed for cardiac electrophysiological mapping. The distal end of the catheter has multiple 3F branches, each with multiple platinum-iridium electrodes for collecting cardiac electrophysiological signals. The distal end of the catheter features an adjustable bend design; pushing the button on the catheter forward will cause the distal end of the catheter to bend."
218864802|NCT07040137|DRUG|KPS-0373|Oral administration
218864803|NCT07040137|DRUG|Placebo|Oral administration
218864804|NCT00293436|DRUG|celecoxib|
218864805|NCT00293436|DRUG|erlotinib hydrochloride|
218864806|NCT00293436|PROCEDURE|adjuvant therapy|
218864807|NCT07041749|DRUG|Bleomycin|);will be treated with combination of microneedling and topical bleomycin .
218864808|NCT07041749|DEVICE|Microneedling alone|' Microneedling will be performed on each wart using dermapen supplied with 12 needles arranged in rows. Topical anesthetic cream will be applied for 60 min before the procedures. Microneedling will be performed on each wart using dermapen. The penetration depth will be adjusted at 2-mm, endpoint is pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the warts.
218864809|NCT07041749|DRUG|5 fluorouracil|);will be treated with combination of microneedling and topical 5-flurouracil .
219480318|NCT06101251|BEHAVIORAL|Sef-Chosen Focus Area Feedback|Participants will be asked to select which driving behavior they want to focus on improving, and to set a goal for the week that is above their baseline score. If they meet the goal, they will be asked to set a new, higher goal; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be asked if they want to focus on a new behavior.
219480319|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
219480320|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
218864810|NCT07040449|BEHAVIORAL|Montreal Imaging Stress Task|Psychosocial stress procedure consisting of completing sections of mental arithmetic that are 5.5 minutes in length, during which the individual receives neutral and negative evaluative feedback about their performance relative to their peers.
218864811|NCT07040449|BEHAVIORAL|Trier Social Stress Test for Children|Psychosocial stress procedure in which the individual tells a story for 5 minutes in front of two neutral judges and performs mental arithmetic in front of the judges for 5 minutes.
218864812|NCT07042113|DRUG|new formulations of 611|Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1
218864813|NCT07042113|DRUG|existing formulations of 611|Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1
218864814|NCT07040163|DRUG|ketamine|This is the experimental intervention to be used as an alternative sedation method to the other comparator intervention (fentanyl).
218864815|NCT07040163|DRUG|fentanyl|This is the traditional (comparator) intervention used in interventional radiology procedure sedation.
218864816|NCT07040163|DRUG|Midazolam|Adjuvant administered in combination with either fentanyl (comparator) or ketamine (experimental).
218864818|NCT07040215|DEVICE|Freewalk lower limb Robotic Assistive Gait Training|"Participants in this group will receive robotic-assisted gait training three times per week (every other day) for 30 minutes per session, using the FREE Walk exoskeleton device (FREE Bionics, Taiwan). The device assists with walking, standing, and sitting. A physical therapist will help the participant wear the exoskeleton and supervise the training, adjusting the level of robotic support and intensity based on the participant's ability. In addition to RAGT, participants will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) on the remaining weekdays (2 days/week), 30 minutes per session.~Intervention Duration: 4 weeks."
218864819|NCT07040215|OTHER|Physiotherapy|Participants in this group will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) 5 days/week, 30 minutes per session. Intervention Duration: 4 weeks.
218864820|NCT07038980|OTHER|Observational Assessment|"Participants in both groups undergo a one-time diagnostic evaluation consisting of:~Smartphone Addiction Scale - Short Form (SAS-SF)~Neck Disability Index (NDI)~MyotonPRO measurement of cervical muscle tone, stiffness, and elasticity~Pressure pain threshold measurement using a handheld algometer~Social Media Addiction Scale (SMAS)~No therapeutic or behavioral intervention is applied. All procedures are non-invasive and conducted for observational purposes only."
218864821|NCT07040995|OTHER|Swift follow-up|Swift and structured follow-up on-demand for 6 months at a disease-specific outpatient clinic following hospitalization for heart failure among older adults
218864822|NCT07042204|PROCEDURE|Group I (extended platelet-rich fibrin)|mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
218864823|NCT07042204|PROCEDURE|Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)|bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
218864824|NCT07042204|PROCEDURE|Group III (bioactive glass nanoparticles and covered by a collagen membrane)|bioactive glass nanoparticles and covered by a collagen membrane
218864825|NCT07041060|DIETARY_SUPPLEMENT|EOLO|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts
218864826|NCT07041060|DRUG|PPI (proton pump inhibitor)|Received a half-dose of PPIs for 24 weeks
218864827|NCT07041060|DIETARY_SUPPLEMENT|Group C: Eolo|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts for 24 weeks
219598143|NCT04105127|DEVICE|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
218864828|NCT07041346|OTHER|Education|"1. Objectives of the Training Program To increase students' knowledge and awareness of gender concepts, gender roles, and gender inequality.~   To help students develop more conscious and critical thinking skills regarding social norms and gender-based discrimination.~   To promote the development of gender-sensitive attitudes and contribute to positive attitude changes following the training.~2. Duration and Structure of the Training Total Duration: 2 weeks~   Weekly Duration: 2 hours~   Training Format: In-person~   Training Methods: Presentations, group discussions, surveys, brainstorming, Q\&A sessions, debates~3. Training Content and Modules Week 1 Topic 1: Fundamental Concepts, Gender Roles, and Inequality~Introduction and Training Objectives~Gender and Social Norms: Definition of gender norms and their impact on individuals"
219480321|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
219480322|NCT00471237|DRUG|Teriparatide|PTH (1-34)
219480323|NCT00471237|DRUG|Alendronate|Bisphosphonate
219480324|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
219480325|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
219480326|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
219480327|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
219480328|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
219480329|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
219480330|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
218864829|NCT07041112|DRUG|Biologic therapy for psoriasis|Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.
219480331|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
218864830|NCT07035405|DRUG|Colchicine 0.5 mg|Oral colchicine will be initiated with a dose of 0.5 mg per day.
218864831|NCT07035405|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.
219480332|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
219480333|NCT00802295|DRUG|Low dosis Gonadotrophin|
219480334|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
218864832|NCT07042061|DEVICE|Mobile external automated defibrillator|A single-use, hand-held, chocolate bar sized portable AED
218864833|NCT06887387|DEVICE|Wearable device|This is an observational study that does not impact routine clinical care for participants
218864834|NCT07042126|DRUG|611|Double blind treatment period : 611 600 mg/450 mg at day 1，then 300 mg subcutaneous injection Q2W thereafter until week 16 Maintenance treatment period : 611 300 mg subcutaneous injection Q2W/Q3W until week 52.（The subjects in the placebo group during the double-blind treatment period need to be given a loading dose at week 16.）
218864835|NCT07042126|DRUG|Matching placebo|Double blind treatment period : placebo subcutaneous injection Q2W until week 16.
218864836|NCT07040462|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|CPP is a structured, evidence-based dyadic therapy designed for children aged 0-6 exposed to trauma and their caregivers. The intervention involves weekly joint sessions emphasizing safety, emotional expression, and caregiver reflective functioning. Delivered by trained psychologists either online or in person.
219480335|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
219480336|NCT01387958|DRUG|LCQ908|
218864837|NCT07040436|DRUG|OPM-101|"OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.~Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision."
218864838|NCT07040709|OTHER|Opioid Analgesic (tramadol hydrochloride)|For postoperative pain management, a patient-controlled analgesia (PCA) pump will be routinely applied to the patient in our clinic. An infusion of an opioid (tramadol hydrochloride) at an appropriate dose will be administered via intravenous route through the pump, and the patient will be provided with detailed information about its use. Instead of continuous infusion, the device will deliver intermittent bolus doses when the patient's numeric rating scale (NRS) score is 4 or higher.
218864839|NCT07040709|OTHER|Prophylactic analgesia (intravenous paracetamol)|All patients will receive routine prophylactic analgesia with 1 gram of intravenous paracetamol every 6 hours (which may be skipped if the patient's pain score is 2 or below and they do not request pain relief).
218864840|NCT07040709|OTHER|Rescue analgesia (intramuscular diclofenac sodium)|If the pain persists despite the administered analgesics and the patient's pain score remains 4 or above, rescue analgesia with intramuscular diclofenac sodium, which is routinely used in our clinic, will be administered.
218864841|NCT06924177|OTHER|Telehealth with dietician|9 weeks of telehealth visit with dietician using the DPP diet modules
219480337|NCT01387958|DRUG|Placebo|
219480338|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
219480339|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
219480340|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
219480341|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
219480342|NCT00051766|BEHAVIORAL|Computer-based Intervention|
219480343|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
219480344|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
219480345|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
219480346|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
219480347|NCT01826006|DEVICE|Excimer laser|
219480348|NCT01826006|DEVICE|Manual Thrombus Aspiration|
219480349|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
219480350|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
219480351|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
219480352|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
219480353|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
219480354|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
219480355|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
219480356|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
219480357|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
219480358|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
219480359|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
219480360|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
219480361|NCT00283621|DRUG|Adriamycin|
219480362|NCT00283621|DRUG|Ifosfamide|
219598144|NCT04105127|DEVICE|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
219598145|NCT02391129|PROCEDURE|Operation for Periprosthetic fractures of the hip with stem loosening|
218864842|NCT06732453|OTHER|Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)|Two one-hour chair-based yoga sessions that will include gentle movements, breathing practices, and meditation, along with home practice.
219480363|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
219598146|NCT03193073|DIAGNOSTIC_TEST|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
219598147|NCT03193073|DIAGNOSTIC_TEST|serum fibroblast growth factor-23|serum levels of FGF-23
219598148|NCT03193073|DIAGNOSTIC_TEST|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
219598149|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
219598150|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
219598151|NCT00729573|DRUG|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
218864843|NCT06733558|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy (ECT) is a medical treatment that uses controlled electrical stimulation to induce a brief, generalized seizure in the brain. This intervention is performed under general anesthesia with muscle relaxants to ensure patient comfort and safety. ECT is typically used to treat severe depression, bipolar disorder, and other mental health conditions when other treatments, such as medication and psychotherapy, have not been effective.
218864844|NCT06718140|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound to one of the 4 brain locations
218864845|NCT07041372|DIAGNOSTIC_TEST|FDG-PET|The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.
219598152|NCT00729573|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
219598153|NCT00277173|BEHAVIORAL|Adoption of Crew Resource Management approach|
219598154|NCT01197144|DRUG|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
218864846|NCT07041801|DRUG|hUC-MSCs treatment (low dose)|patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.
218864847|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (medium dose)|patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.
218864848|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (high dose)|patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.
218864849|NCT07041801|DRUG|Placebo|patients will receive conventional therapy plus Placebo
219598155|NCT01197144|DRUG|Placebo|Subcutaneous, every other week for 4 weeks
219480364|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
218864850|NCT07041801|BIOLOGICAL|hUC-MSCs treatment （Double dose）|Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.
218864851|NCT07040904|BEHAVIORAL|mindfulness|MBSR: Mindfulness Program A novel and culturally-adapted version of the well-validated mindfulness-based stress reduction (MBSR) course will be used for the intervention. The adapted program curriculum embeds core MBSR principles and practices within a culturally responsive didactic framework developed directly from community focus-group feedback. The course will be delivered via a group meeting across 8 weeks, with weekly classes held at a local community center. All classes will be held in hybrid format, with most participants attending in person, but with a live-stream option offered via Zoom.
218864852|NCT06893978|DRUG|Placenta organoids treatment|Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin
218864853|NCT06747455|DRUG|BCG for Therapeutic Use|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
218864854|NCT06747455|DRUG|BCG for Therapeutic Use ( BI SAI JI )|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
219480365|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
219480366|NCT03204006|DRUG|sterile saline|normal saline preinduction
219480367|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
219480368|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
219480369|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
218864855|NCT06756256|DEVICE|Customized insole|Participants will wear the produced customized insoles during daily activities and interventions for six weeks under the guidance of physical therapists working at Miso Hospital in Iksan City. As their continuation of their rehabilitation program, they will receive a conservative physiotherapy treatment five times a week for six weeks.
218864856|NCT06748703|DEVICE|CPAP Treatment|CPAP therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
218864857|NCT05888662|PROCEDURE|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
218864858|NCT05888662|PROCEDURE|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
219480370|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
219480371|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
218864859|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
219480372|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
219480373|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
219480374|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
219480375|NCT03384576|OTHER|No music|No music played in emergency waiting room
219480376|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
219480377|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
219480378|NCT00563927|PROCEDURE|Conventional RT|
219480379|NCT00563927|DRUG|Cisplatin|
219480380|NCT00563927|DRUG|5-fluorouracil|
219480381|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
219480382|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
219480383|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
218864860|NCT00623168|DRUG|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
219480384|NCT04938869|OTHER|Survey Administration|Ancillary studies
218864861|NCT03921554|DRUG|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
218864862|NCT06900543|DRUG|NRT6003 Injection|Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.
218864863|NCT06900543|DRUG|cTACE|Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.
218864864|NCT04505267|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
218864865|NCT04505267|RADIATION|Radiation Therapy|Undergo RT
218864866|NCT06664866|DIAGNOSTIC_TEST|EchoNet-LVH Assessment|The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.
218864867|NCT06930677|DEVICE|embolization therapy|MSK embolization
218864868|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
218864869|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
218864870|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
218864871|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
218864872|NCT06903286|DRUG|SPG302|Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.
218864873|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
219480385|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
219480386|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
219480387|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
219480388|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
219480389|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
218864874|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
219480390|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
219480391|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
218864875|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
218864876|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
218864877|NCT06194955|DRUG|GIP(1-42)|Infusion
218864878|NCT06194955|DRUG|GLP-1|Infusion
218864879|NCT06194955|DRUG|GLP-2|Infusion
218864880|NCT06194955|OTHER|Placebo|Saline
219480392|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
219480393|NCT01283659|OTHER|Standard Imaging|
218864881|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
218864882|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
218864883|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
218864884|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
218864885|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
219480394|NCT01283659|OTHER|Advanced Imaging|
219480395|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
219480396|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
219480397|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
219480398|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
219480399|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
219480400|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
219480401|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
219480402|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
219480403|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
219598156|NCT03844386|BIOLOGICAL|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
219598157|NCT03844386|BIOLOGICAL|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
219598158|NCT03844386|OTHER|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
219480404|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
219480405|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219598159|NCT03766412|OTHER|High School start time|The time that the school starts
219598160|NCT00151346|DRUG|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
219598161|NCT00151346|DRUG|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
218864886|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
219480406|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219480407|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
219480408|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
219480409|NCT02190162|DRUG|Tantum Verde® mouthwash|
219480410|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
219480411|NCT04707612|OTHER|No intervention.|No intervention.
219480412|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
219480413|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
219480414|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
219598162|NCT05228535|DIETARY_SUPPLEMENT|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
219598163|NCT01796938|DRUG|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
219480415|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
219522367|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with compression Bandage|Participants in will receive progressive resistance exercise same as Group B and also receive thecompression bandaging as the primary intervention for the management of lower-limb oedema during pregnancy. The compression bandage will be applied in a multi-layered manner, beginning from the base of the toes and extending proximally to below the knee, ensuring graded pressure with higher compression distally and gradually reducing proximally to support venous and lymphatic return. Prior to each application, participants will be asked to lie in a supine position with their legs elevated for 15-20 minutes to reduce pre-existing swelling.
219598164|NCT03597464|DRUG|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
219598165|NCT03597464|DRUG|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
219598166|NCT04960033|BEHAVIORAL|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
219598167|NCT02128061|DRUG|Lenalidomide|
219598168|NCT02128061|DRUG|Rituximab|
219598169|NCT01371383|DIETARY_SUPPLEMENT|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
219598170|NCT01371383|DIETARY_SUPPLEMENT|placebo|Soybean oil
219598171|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
219598172|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
219598173|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
219598174|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
218864887|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
219480416|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
219480417|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
219480418|NCT01946295|DRUG|Placebo|
219480419|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
219480420|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
219480421|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
219480422|NCT00421746|DRUG|Piboserod|
219480423|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
219480424|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
219480425|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
219480426|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
219480427|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
219480428|NCT00552422|DRUG|domperidone|10mg orally four times per day
218864888|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
219480429|NCT03484858|OTHER|High glycaemic index meal and exercise|
219480430|NCT03484858|OTHER|High glycaemic index meal and rest|
219480431|NCT03484858|OTHER|Low glycaemic index meal and exercise|
219480432|NCT03484858|OTHER|Low glycaemic index meal and rest|
219480433|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
219480434|NCT01650142|OTHER|No intervention|No intervention
219480435|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
219480436|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
219480437|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
219480438|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
219480439|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
219480440|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
219480441|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
219480442|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
219480443|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
219480444|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
219522368|NCT07036341|OTHER|Protein-enriched diet|A protein intake of 1.5 g/kg bodyweight/day. This will be obtained by consuming protein-rich and protein-enriched foods.
219522369|NCT07036341|OTHER|Progressive resistance exercise|The intervention group will perform resistance training during three non-consecutive days with a minimum of 48 hours between the sessions. Subjects will continue the resistance training after discharge for 2 times a week, also with a minimum of 48 hours between sessions until the study period of 3 months is completed. All sessions will be supervised by physiotherapists.
218864889|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
218864890|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
218864891|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
218864892|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
218864893|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
219480445|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
219480446|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
219480447|NCT02237768|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
218864894|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
218864895|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
218864896|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
218864897|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
218864898|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
218864899|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
219480448|NCT02237768|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
219480449|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
219480450|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
219480451|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
219480452|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
219480453|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
219480454|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
219480455|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
218864900|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
218864901|NCT04104685|OTHER|Vehicle Foam|Placebo
218864902|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
218864903|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
218864904|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
218864905|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
218864906|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
219480456|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
219480457|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
219480458|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
219480459|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
219480460|NCT00138658|DRUG|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
218864907|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
218864908|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
219480461|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
219480462|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
219480463|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
219480464|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
219480465|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
219480466|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
219480467|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
219480468|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
219480469|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
219480470|NCT04269746|DIAGNOSTIC_TEST|CCAT1|Long Non coding RNA
219480471|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
219480472|NCT00297063|DRUG|Rosiglitazone|
218864909|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
219480473|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
219480474|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
219480475|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
219480476|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
219480477|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
219480478|NCT04836832|DRUG|Acalabrutinib|Given PO
219480479|NCT04836832|DRUG|Duvelisib|Given PO
219480480|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
219480481|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
219480482|NCT00771654|DRUG|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
219480483|NCT00771654|OTHER|Placebo|daily for one year
219480484|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
218864910|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
219480485|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
219480486|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin|
218864911|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
219480487|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
219480488|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
219480489|NCT02758509|DRUG|Ledipasvir/Sofosbuvir|
219480490|NCT02758509|DRUG|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
219480491|NCT02758509|DRUG|Daclatasvir+Sofosbuvir|
219480492|NCT02758509|DRUG|Simeprevir+Sofosbuvir|
219480493|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
219480494|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
219480495|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
219480496|NCT05193435|OTHER|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
219480497|NCT05193435|OTHER|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
219480498|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
218864912|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
218864913|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
218864914|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
219480499|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
219480500|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
218864915|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
218864916|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
218864917|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
219598175|NCT05852561|OTHER|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
219598176|NCT05852561|OTHER|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
219598177|NCT04243083|DRUG|TLL018 tablet, placebo|Oral QD
219598178|NCT04502420|DIAGNOSTIC_TEST|Lung function before and after surgery|A diagnostic test
219598179|NCT02143076|BEHAVIORAL|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
218864918|NCT01604655|PROCEDURE|Stress Test|Stress Test
218864919|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
218864920|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
218864921|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
219480501|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
219480502|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
219480503|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
219480504|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
219480505|NCT01856296|PROCEDURE|Biopsy|
219480506|NCT03415139|DRUG|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
219480507|NCT03415139|DRUG|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
219480508|NCT03415139|DRUG|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
219480509|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
219480510|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
219480511|NCT05950828|BEHAVIORAL|SkillTalk|A subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
219480512|NCT00142961|DRUG|Atomoxetine|atomoxetine
219480513|NCT00142961|OTHER|placebo|
219480514|NCT05619484|DEVICE|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
219480515|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
219480516|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
219480517|NCT00262483|DRUG|VX-950|
219480518|NCT00262483|DRUG|ribavirin|
219480519|NCT00262483|DRUG|peginterferon alfa-2a|
219480520|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
219480521|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
219480522|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
219480523|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
219480524|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
219480525|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
219480526|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
219480527|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
219480528|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
219480529|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
219480530|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
219480531|NCT00577031|DRUG|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
219480532|NCT00577031|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
219480533|NCT00577031|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
219480534|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
219480535|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
219480536|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
219480537|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
219480538|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
219480539|NCT05518565|OTHER|No intervention|No intervention
219480540|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
219480541|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
219480542|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
218864922|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
218864923|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
219480543|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
219480544|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
219480545|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
219480546|NCT03005262|DRUG|MLN8237|
219480547|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
219480548|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
219480549|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
219480550|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
219480551|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
219480552|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
219480553|NCT05923333|DIETARY_SUPPLEMENT|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
219480554|NCT05923333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219480555|NCT00138801|DRUG|Ceftriaxone|
219480556|NCT00138801|DRUG|Doxycycline|
219480557|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
219480558|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
219480559|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
218864924|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
218864925|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
218864926|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
218864927|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
218864928|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
218864929|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
219480560|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
219480561|NCT04469322|DIAGNOSTIC_TEST|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
219480562|NCT04469322|DIAGNOSTIC_TEST|Sham Test|"Names of 53 medications listed with use as directed"
219480563|NCT00109278|BIOLOGICAL|V205C, measles, mumps, and rubella virus vaccine live|
219480564|NCT00109278|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
219480565|NCT01470352|DRUG|Doluxetine|30 mg/d
219480566|NCT01470352|DRUG|Placebo|suger pill 30mg/d
219480567|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
219480568|NCT03323021|OTHER|Standard of Care|Standard of Care
219480569|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
219480570|NCT03490331|OTHER|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
219480571|NCT06568718|DRUG|bovhyaluronidase azoximer|Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
219480572|NCT06568718|DRUG|tamsulosin|Tamsulosin 0.4mg per os every day
219480573|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
219480574|NCT06067191|DRUG|RV299|Oral Suspension
218864930|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
219480575|NCT06067191|DRUG|Placebo|matching placebo
218864931|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
218864932|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
218864933|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
218864934|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
219480576|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
219480577|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
219480578|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
219480579|NCT05527301|DRUG|Placebo|Placebo
219480580|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
219480581|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
219480582|NCT02018601|PROCEDURE|BRILMA|
219480583|NCT02018601|PROCEDURE|paravertebral block|
219480584|NCT02018601|DRUG|dexketoprofen|
219480585|NCT02018601|DRUG|paracetamol|
219480586|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
219480587|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
219480588|NCT03868176|OTHER|short message service|short message service
219480589|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
219480590|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
219480591|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
219480592|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
219480593|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
219480594|NCT01010724|DRUG|bIAP|
219480595|NCT01010724|DRUG|Placebo|
219480596|NCT00544713|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
219480597|NCT00544713|DRUG|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
219480598|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
219480599|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
219480600|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
219480601|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
219480602|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
219480603|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
219480604|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
219598180|NCT02143076|BEHAVIORAL|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
219598181|NCT02143076|BEHAVIORAL|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
219598182|NCT05996562|PROCEDURE|Pulmonary Artery Denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
219598183|NCT04334694|DEVICE|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
219598184|NCT00115427|DRUG|Liatermin (r-metHuGDNF)|
219598185|NCT00397774|BEHAVIORAL|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
219598186|NCT00397774|OTHER|best supportive care|
219480605|NCT00062075|DRUG|romidepsin|Given IV
219480606|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
219480607|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
219480608|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
219480609|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
219480610|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
218864935|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
218864936|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
218864937|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
218864938|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
218864939|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
218864940|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
218864941|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
218864942|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
219480611|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
219480612|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
219480613|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
219480614|NCT01759056|DRUG|AVX 470|active comparator
219480615|NCT01759056|DRUG|Placebo|
219480616|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
219480617|NCT03992261|DRUG|Halobetasol Topical Foam|Foam
219480618|NCT03278639|BEHAVIORAL|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
219480619|NCT03278639|BEHAVIORAL|Kinesiology|Training will be directed to ameliorate gait and balance
219480620|NCT01365741|OTHER|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
219480621|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
219480622|NCT02208934|DRUG|PBF-999|5, 10, 20 and 40 mg of PBF-999
219480623|NCT02208934|DRUG|Placebo|Placebo for all dosis of PBF-999
219480624|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
219480625|NCT05702827|DRUG|Bupivacaine-Meloxicam|All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
219480626|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
219480627|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
219480628|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
219480629|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
219480630|NCT02187406|PROCEDURE|Modified ankle athletic taping|
219480631|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
219480632|NCT03365869|DRUG|Sirolimus|Sirolimus or placebo were added to patients every day
219480633|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
219480634|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
219480635|NCT00103155|PROCEDURE|conventional surgery|
219480636|NCT00103155|PROCEDURE|radiofrequency ablation|
219480637|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
218864943|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
218864944|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
218864945|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
218864946|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
218864947|NCT01790555|DRUG|Namisol|
219480638|NCT03943199|DIAGNOSTIC_TEST|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
219480639|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
219480640|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
219480641|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
219480642|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
219480643|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
218864948|NCT01790555|DRUG|Diazepam/placebo|
218864949|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
218864950|NCT02663141|DRUG|Losartan|
219040032|NCT03800719|BEHAVIORAL|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
219480644|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
219480645|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
219480646|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
219480647|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
219480648|NCT06039007|DIETARY_SUPPLEMENT|7-day Fasting-Mimicking Diet (7-DAY FMD)|This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
218864951|NCT02663141|DRUG|Intravitreal bevacizumab|
218864952|NCT02663141|DRUG|Placebo|
218864953|NCT05810714|OTHER|Best Practice|Receive usual care
218864954|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
218864955|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
218864956|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
218864957|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
218864958|NCT05810714|OTHER|Survey Administration|Ancillary studies
218864959|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
219480649|NCT05505851|OTHER|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
219480650|NCT05505851|OTHER|Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
219480651|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
218864960|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
218864961|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
218864962|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
218864963|NCT06194500|DRUG|LY3549492|Administered orally.
218864964|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
218864965|NCT02177019|OTHER|Personalized health plan|
218864966|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
218864967|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
219480652|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
219480653|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
219480654|NCT04237779|BIOLOGICAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
219480655|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
219480656|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
218864968|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
218864969|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
219598187|NCT01279720|BIOLOGICAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
219598188|NCT00000474|BEHAVIORAL|behavior therapy|
218864970|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
218864971|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
218864972|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
218864973|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
218864974|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
218864975|NCT00940784|DRUG|Aspirin|81-100 mg qd
218864976|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
218864977|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
218864978|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
218864979|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
218864980|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
219040033|NCT03800719|BEHAVIORAL|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
218864981|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
219040034|NCT03800719|BEHAVIORAL|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
219480657|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
219480658|NCT03724292|DRUG|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
219480659|NCT03724292|DRUG|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
219480660|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
219480661|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
219480662|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
219480663|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
219480664|NCT00557830|DRUG|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
219480665|NCT00557830|DRUG|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
219598189|NCT05600465|BEHAVIORAL|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
219598190|NCT05600465|BEHAVIORAL|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
219598191|NCT00708773|DRUG|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
219480666|NCT01035112|PROCEDURE|MRI|
219480667|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
219480668|NCT00001972|DRUG|15 O Water|
219480669|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
219480670|NCT00210925|DRUG|topiramate|
219480671|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
219480672|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
219480673|NCT03009591|OTHER|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver."
219480674|NCT05718505|DEVICE|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
219480675|NCT05718505|DEVICE|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
219480676|NCT03889405|DEVICE|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
218864982|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
219598192|NCT05856643|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
218864983|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
219480677|NCT03889405|DEVICE|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
219598193|NCT03159338|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
219598194|NCT03159338|BIOLOGICAL|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
219598195|NCT02542605|DRUG|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
219480678|NCT03889405|DEVICE|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
219480679|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
219480680|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
218864984|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
218864985|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
218864986|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
218864987|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
218864988|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
218864989|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
218864990|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
218864991|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
219480681|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
219480682|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
219598196|NCT02542605|DRUG|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
219598197|NCT02542605|DRUG|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
219598198|NCT02682927|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
219598199|NCT02682927|DRUG|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
219598200|NCT00676780|DRUG|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
219598201|NCT00005827|DIETARY_SUPPLEMENT|genistein|
219598202|NCT01566227|OTHER|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
219598203|NCT04605874|OTHER|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
218864992|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
219480683|NCT03829020|DRUG|Bortezomib|Given SC
219598204|NCT04473066|PROCEDURE|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
218864993|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
218864994|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
218864995|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
218864996|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
218864997|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
218864998|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
219480684|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
219480685|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
218864999|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
218865000|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
218865001|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
218865002|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
218865003|NCT00110487|DRUG|ERB-041|
219480686|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
219480687|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
219598205|NCT01621477|DRUG|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
219598206|NCT01621477|DRUG|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
218865004|NCT00506194|DRUG|Insulin|
218865005|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
218865006|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
219480688|NCT01388101|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
219480689|NCT02981667|OTHER|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
219480690|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
219480691|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
219480692|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
219480693|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
219598207|NCT01621477|DRUG|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
219598208|NCT01621477|DRUG|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
219598209|NCT01621477|DRUG|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
219598210|NCT01621477|DRUG|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
219480694|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
219480695|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
219480696|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
219480697|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
219480698|NCT06345183|COMBINATION_PRODUCT|Nivolumab + Ipilimumab combination therapy|As per product label
219480699|NCT06345183|COMBINATION_PRODUCT|Pembrolizumab + Lenvatinib combination therapy|As per product label
219480700|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
219480701|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
219480702|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
219480703|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
219480704|NCT05013827|BEHAVIORAL|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
219480705|NCT03823859|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
219480706|NCT03823859|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
219480707|NCT03823859|DIAGNOSTIC_TEST|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
219480708|NCT02264509|PROCEDURE|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
219480709|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
219480710|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
219480711|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
219480712|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
219480713|NCT03933709|OTHER|recommended diet|WHO Diet
219480714|NCT02168205|DRUG|Pomalidomide|Capsules
219480715|NCT02168205|OTHER|Caffeine|Capsules
219480716|NCT02168205|OTHER|Tobacco|Cigarettes
219480717|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
219480718|NCT04356196|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
219480719|NCT04356196|DRUG|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
219480720|NCT04356196|DRUG|Placebo oral tablet|Placebo oral tablet
219480721|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
219480722|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
219480723|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
219480724|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
219480725|NCT03562923|DRUG|Placebo|Placebo Product
219480726|NCT06244095|OTHER|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
219480727|NCT06244095|OTHER|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
219480728|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
219480729|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
219480730|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
219480731|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
219480732|NCT01766141|OTHER|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
219480733|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
219480734|NCT00127192|DRUG|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
219598211|NCT01621477|BIOLOGICAL|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
219598212|NCT01621477|DRUG|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
219598213|NCT01621477|DRUG|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
219598214|NCT03878771|BIOLOGICAL|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
219598215|NCT03878771|DRUG|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
219598216|NCT00203593|BEHAVIORAL|Exercise|
219598217|NCT00203593|DEVICE|Blood volume|
219598218|NCT00203593|PROCEDURE|VO2max test|
219598219|NCT00203593|PROCEDURE|Lower body negative pressure|
219598220|NCT00203593|BEHAVIORAL|Heart Rate|
219598221|NCT00203593|PROCEDURE|Blood Pressure|
219598222|NCT00203593|BEHAVIORAL|Total Peripheral Resistance|
219598223|NCT07134192|PROCEDURE|Fluorescent-guided Surgery|Surgical treatment of the patient group will include the administration of a fluorescent dye and intraoperatively the resection will be aided and guided by the fluorescent signal. The wound bed will be inspected, areas with fluorescent signal will be excised and obtained separately for histopathology. Patients will receive the current post-operative standard of care for sarcoma patients
219598224|NCT07133620|DEVICE|Transcutaneous electrical acupoint stimulation|"Before the operation, the patient received transcutaneous electrical acupoint stimulation (TEAS) at bilateral Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupoints with sterilized electrode patches. The stimulation intensity and current intensity that gave the patient an effective pricking sensation (Qi arrival) were maintained for 30 minutes. The stimulation method in the post-anesthesia care unit (PACU) was consistent with that before the operation."
219598225|NCT07133620|DEVICE|Sham transcutaneous Electrical Acupoint Stimulation|Before the operation, disinfection patches with electrodes were applied to Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupointst, but no electrical stimulation was conducted. The stimulation method in the post-anesthesia care unit (PACU) was the same as that before the operation.
219598226|NCT07134452|DIAGNOSTIC_TEST|Baseline Assessments|Evaluation of isokinetic muscle strength, grip strength, upper extremity weight-bearing capacity, proprioceptive sense, reaction time, and functional performance in both groups
219480735|NCT00127192|DRUG|Comparator: placebo (unspecified)|placebo QD 12-weeks
218865007|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
219480736|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
219480737|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
219480738|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
219480739|NCT01870921|DRUG|Ticagrelor|90mg/tablet, 1 tablet bid
219480740|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
219480741|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
219480742|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
219480743|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
219480744|NCT05790200|DRUG|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
219480745|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
219480746|NCT03659032|PROCEDURE|Educational Physical Therapy|
219598227|NCT06904846|DEVICE|iCan o3 CGM Continuous Glucose Monitoring System|"A continuous Glucose Monitoring System (CGM System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes for adult persons (age 18 and older). It is intended to replace finger prick blood glucose testing for diabetes treatment decisions. The CGM System also shows trends and tracks patterns, and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the CGM System results should be based on the glucose trends and several sequential readings over time.~The CGM System can be used in conjunction with smart devices with corresponding applications (apps) where the user manually controls actions for therapy decisions. During this study, Self-Monitoring Blood Glucose (SMBG) assessed by an iCan o3 CGM System blinded to the patient for 15 days as the baseline and unblinded observation period using an iCan o3 CGM System for 45 days occurs."
218865008|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
219480747|NCT01590537|DRUG|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
219480748|NCT01590537|DEVICE|Copper IUD|Copper device, inserted intrauterine
219598228|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
219598229|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
219598230|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
219598231|NCT04679701|DEVICE|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
219598232|NCT04734405|DRUG|Prof-001|Prof-001 cream
219480749|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
219480750|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
219480751|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
219480752|NCT04688502|OTHER|High intensity interval training|High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
219480753|NCT04688502|OTHER|Continuous exercise training|5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
219598233|NCT04734405|DRUG|Fluconazole 150 mg|Fluconazole capsule
219480754|NCT04127994|OTHER|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
219480755|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
219480756|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
219480757|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
219480758|NCT05519527|DRUG|Part 1 (STI-6129)|Given by vein (IV)
219480759|NCT05519527|DRUG|Part 2 (STI-6129)|Given by vein (IV)
218865009|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
219480760|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
219480761|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
219480762|NCT02257411|DEVICE|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
219480763|NCT06416527|DEVICE|Photobiomodulation (Experimental)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each).
219480764|NCT06416527|PROCEDURE|Pompage Technique (manual therapy)|To perform cervical Pompage the patient lies comfortably on their back or sits upright. The therapist locates the target area on the cervical spine. Using gentle pressure, the therapist applies traction to the cervical spine, stretching the muscles and fascia. The traction is held for 20 seconds. The therapist then releases the traction, allowing the cervical spine to return to its neutral position. This process will be repeated 3 times, with adjustments made based on the patient's response and comfort level.
219480765|NCT06416527|DEVICE|Photobiomodulation (Placebo)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each) with the device turned off (inactive), simulating the time with a recorded beep sound.
219480766|NCT04706520|DIETARY_SUPPLEMENT|Study Beverage Consumption|All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
219480767|NCT06568666|OTHER|Lumbar spinal manipulation|Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
219480768|NCT06568666|OTHER|Sacroiliac joint manipulation|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
219480769|NCT03640442|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
219598234|NCT04734405|DRUG|Placebo cream|ointment base to mimic Prof-001
218865010|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
219480770|NCT03640442|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
219480771|NCT04171089|BEHAVIORAL|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
219480772|NCT05620706|BIOLOGICAL|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
219480773|NCT00693056|DRUG|Placebo|Placebo (w/o API)
219480774|NCT00693056|DRUG|RX-10100 5mg|5 mg/dose of RX-10100
219480775|NCT00693056|DRUG|RX-10100 10mg|10 mg/dose of RX-10100
219598235|NCT04734405|DRUG|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
218865011|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
218865012|NCT03625752|DEVICE|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
218865013|NCT03625752|DEVICE|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
218865014|NCT02717130|DRUG|Aripiprazole|
218865015|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
218865016|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
218865017|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
218865018|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
218865019|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218865020|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218865021|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
219480776|NCT00693056|DRUG|RX-10100 15mg|15 mg/dose of RX-10100
219480777|NCT05148286|DRUG|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
219480778|NCT05148286|DRUG|Placebo|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
219480779|NCT05581199|DRUG|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219480780|NCT05581199|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219480781|NCT05581199|DRUG|Placebo|Matching placebo SC
219480782|NCT06544954|DIETARY_SUPPLEMENT|Freeze-dried grape powder|48 grams powder
219480783|NCT06544954|OTHER|Placebo powder|48 grams powder
219480784|NCT06224413|OTHER|No Intervention|This is non-interventional study.
219480785|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
219480786|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
219480787|NCT05160675|OTHER||No intervention
218865022|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
218865023|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
218865024|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
218865025|NCT00073463|GENETIC|tgAAVCF|
218865026|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
218865027|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
219480788|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
219480789|NCT06185140|OTHER|TELEA platform|TELEA platform
219480790|NCT05159739|GENETIC|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
219480791|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
219480792|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
219480793|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
219480794|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
219480795|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
219480796|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
219480797|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
219480798|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
219480799|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
219480800|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
219480801|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
218865028|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
218865029|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
218865030|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
218865031|NCT02184832|OTHER|Low tryptophan diet|
218865032|NCT02184832|OTHER|High tryptophan diet|
218865033|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
218865034|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
218865035|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
218865036|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
218865037|NCT00530920|DRUG|tipranavir|
218865038|NCT00530920|DRUG|ritonavir|
219480802|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
218865039|NCT02122809|DRUG|Chiauranib|Take orally
218865040|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
218865041|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
219480803|NCT01454037|PROCEDURE|Radiation|Radiate prostate
219480804|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
219598236|NCT03533023|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
218865042|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
218865043|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
218865044|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
218865045|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
218865046|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
218865047|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
218865048|NCT00487448|DRUG|Fludarabine|
218865049|NCT00487448|DRUG|Cytarabine|
218865050|NCT00487448|DRUG|G-CSF|
218865051|NCT00487448|DRUG|Idarubicin|
218865052|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
218865053|NCT00487448|PROCEDURE|Bone marrow transplantation|
219598237|NCT03533023|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
218865054|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
218865055|NCT01901965|BEHAVIORAL|eccentric training|
218865056|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
218865057|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
218865058|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
218865059|NCT00707746|DRUG|mipomersen|
218865060|NCT00707746|DRUG|placebo|
218865061|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
218865062|NCT00495378|DRUG|epoetin alfa|
218865063|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
219020974|NCT07205146|OTHER|menometrorrhagia|rate of menometrorrhagia at 2 months after treatment
219480805|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
219480806|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
219480807|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
219480808|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
219480809|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
218865064|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
218865065|NCT05006209|OTHER|One visit root canal treatment|
218865066|NCT05006209|OTHER|Two visit root canal treatment|
218865067|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
218865068|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
218865069|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
218865070|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
218865071|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
218865072|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
218865073|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
218865074|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
219480810|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
219598238|NCT05314816|DIAGNOSTIC_TEST|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
218865075|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
218865076|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
218865077|NCT04218071|DRUG|9-ING-41|9-
219480811|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
219480812|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
219480813|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
218865078|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
219480814|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
219598239|NCT07133672|OTHER|Exercise|Exercise sessions will begin with flexibility exercises targeting the shoulder and neck regions. This will be followed by breathing exercises utilizing fundamental respiratory techniques. Extremity exercises will include movements focused on the upper extremities and trunk, with progression applied according to a pre-established plan. Each session will conclude with cool-down exercises. Additionally, patients will be encouraged to engage in regular walking on a weekly basis.
218865079|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
218865080|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
219598240|NCT07133672|OTHER|Standard care|Patients will receive education regarding the critical aspects to consider after hospital discharge. Standard postoperative care protocols will be implemented.
218865081|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
218865082|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
218865083|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
218865084|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
219480815|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
219480816|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
218865085|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
219480817|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
219480818|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
219480819|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
219480820|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
219480821|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
218865086|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
218865087|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
218865088|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
219480822|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
219480823|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
219480824|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
219480825|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
218865089|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
219480826|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
219480827|NCT00150137|DRUG|Methimazole|
218865090|NCT00612625|DRUG|Saline|continuous infusion of saline
218865091|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
218865092|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
219480828|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
218865093|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
218865094|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
218865095|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
218865096|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
218865097|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
218865098|NCT02642965|DRUG|Cytarabine|Given IT or IV
218865099|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
218865100|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
218865101|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
218865102|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
218865103|NCT02642965|OTHER|Pharmacological Study|Correlative studies
218865104|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
218865105|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
218865106|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
218865107|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
218865108|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
219480829|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
219480830|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
219480831|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
219480832|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
219480833|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
219480834|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
219480835|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
219480836|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
219480837|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
219480838|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
219480839|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
219480840|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
219480841|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
219480842|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
218865109|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
218865110|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
219020992|NCT07205744|DEVICE|Restylane SkinBoosters Vital|"Restylane® Skinboosters™ Vital (HASBV) is manufactured by Galderma Laboratories. It is a sterile non-animal hyaluronic acid (20mg/mL) based gel that is supplied in a 1mL glass syringe. The syringed is packed with a 29G TW (thin-walled) needle.~For this study, commercial products will be used. The study products are for single use only."
219480843|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
219480844|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
219480845|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
219480846|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
219480847|NCT04150107|OTHER|Placebo|Fish oil capsule
219480848|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
219480849|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
219480850|NCT06135129|DEVICE|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
219480851|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
219480852|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
219480853|NCT01754805|DRUG|peficitinib|oral
219480854|NCT01754805|DRUG|methotrexate|oral
218865111|NCT02880813|OTHER|Infusion|infusion of nutrients
218865112|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
218865113|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
219480855|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
219480856|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
219480857|NCT00346970|DRUG|Placebo|Placebo tablets
219480858|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
219480859|NCT02894541|DRUG|CKD-519 100mg|
219480860|NCT02894541|DRUG|CKD-519 200mg|
219480861|NCT02894541|DRUG|CKD-519 100mg|
219480862|NCT02894541|DRUG|CKD-519 200mg|
219480863|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
219480864|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
219480865|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
219480866|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
219480867|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
219480868|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
219480869|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
219480870|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
219480871|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
219480872|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
219480873|NCT04190056|DRUG|Tamoxifen|Given PO
219480874|NCT04190056|DRUG|Vorinostat|Given PO
219480875|NCT03107442|BEHAVIORAL|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
219480876|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
219480877|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
219480878|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
219480879|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
219480880|NCT05510739|BEHAVIORAL|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
219480881|NCT05510739|BEHAVIORAL|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
219480882|NCT02738866|DRUG|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
219480883|NCT02738866|DRUG|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
219480884|NCT00139243|DRUG|Taxotere|
219480885|NCT00139243|DRUG|Cisplatin|
219480886|NCT00139243|DRUG|5-Fluorouracil|
219480887|NCT00139243|DRUG|Leucovorin|
219480888|NCT03929601|DRUG|Rituximab-pvvr|All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart.
219480889|NCT03929601|DRUG|Abatacept|Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL).
219480890|NCT03929601|DRUG|Sterile Sodium Chloride|Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to \<50 kg receive 0.7 mL and \> 50 kg receive 1.0 mL.
219480891|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
219480892|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
219480893|NCT02775383|OTHER|Therapeutic|Observational Study
219480894|NCT05764733|DRUG|Bisphosphonate|Medicine used to treat bone problems, called osteopenia or osteoporosis.
219480895|NCT05764733|BEHAVIORAL|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
219480896|NCT05764733|OTHER|Placebo|Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
218865114|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
218865115|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
218865116|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
218865117|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
218865118|NCT00220493|DRUG|Ritalin|
218865119|NCT02635334|DRUG|Montelukast 10 mg orally|
219480897|NCT04616768|OTHER|PRO questionnaire|These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
219480898|NCT04616768|OTHER|Step monitoring|A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
219480899|NCT04616768|OTHER|Active nudge text feedback|"Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.)."
219480900|NCT04616768|OTHER|PROStep Dashboard (clinicians)|"The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~1. Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~2. Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~3. A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~4. Whether the patient has had an outpatient palliative care visit~5. Whether the patient has had a documented Serious Illness Conversation"
219480901|NCT00295919|DRUG|fenretinide lipid matrix|
219480902|NCT00295919|DRUG|ketoconazole|
219480903|NCT00295919|OTHER|laboratory biomarker analysis|
219480904|NCT00295919|OTHER|pharmacological study|
218865120|NCT02635334|OTHER|Placebo|
218865121|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
218865122|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
218865123|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
218865124|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
218865125|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
218865126|NCT00023751|DRUG|fluorouracil|
219480905|NCT06228456|DRUG|Ticagrelor 60mg|Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
219480906|NCT06228456|DRUG|Clopidogrel|Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
218865127|NCT00023751|DRUG|leucovorin calcium|
218865128|NCT00023751|PROCEDURE|conventional surgery|
218865129|NCT00023751|RADIATION|radiation therapy|
218865130|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
218865131|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
219480907|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
218865132|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
218865133|NCT01175200|DRUG|Prasugrel|antiplatelet agent
218865134|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
219480908|NCT05349734|OTHER|upper body blanket|applying upper body blanket with forced-air blower set to 43℃
219480909|NCT05349734|OTHER|full underbody blanket|applying full underbody blanket with forced-air blower set to 43℃
219480910|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
219480911|NCT00031902|BIOLOGICAL|bleomycin sulfate|
219480912|NCT00031902|BIOLOGICAL|rituximab|
219480913|NCT00031902|DRUG|prednisolone|
219480914|NCT00031902|DRUG|vincristine sulfate|
219480915|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
218865135|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
218865136|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
219480916|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
219480917|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
219480918|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
219480919|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
218865137|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
218865138|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
218865139|NCT01829282|BEHAVIORAL|Risk Reduction|
218865140|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
219480920|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
219480921|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
218865141|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
218865142|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
218865143|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
218865144|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
218865145|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
218865146|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
218865147|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
219480922|NCT02463058|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
219480923|NCT06591455|DRUG|Fenofibrate|Fenofibrate 200mg/day
219480924|NCT06591455|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 13-15mg/kg/day
219480925|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
219480926|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
219480927|NCT06610760|DRUG|Ursodeoxycholic Acid|Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
219480928|NCT06610760|DRUG|Placebo|Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
218865148|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
219480929|NCT06604884|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
218865149|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
218865150|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
218865151|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
218865152|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
219480930|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
219480931|NCT00774722|DRUG|Metronidazole|10% ointment, three times daily for 14 days
219480932|NCT06610266|DRUG|Weifuchun|Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
219598241|NCT07133581|OTHER|FEXO (Fun Exercise for Older Adults)|A 14-week supervised multicomponent playful exercise program for institutionalized older adults. It consists of 3 sessions per week (55-60 minutes), including aerobic, strength, balance, flexibility, and gait exercises in a group-based, game-like setting. The structure includes 2 weeks of familiarization followed by 3 progressive 4-week levels. The intervention aims to improve intrinsic capacity, reduce frailty, and enhance physical and cognitive function.
219598242|NCT07134712|BIOLOGICAL|Cord Blood Nucleated cells|MiSaver will be administered via peripheral intravenous injection. Based on dosage, the experimental group will be divided into two subgroups: 0.5 × 10⁷ or 1.6 × 10⁷ nucleated cells per kilogram of patient body weight.
218865153|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
218865154|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
218865155|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
219480933|NCT06610266|DRUG|Folic Acid|Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
219480934|NCT00912756|DRUG|cilostazol|200 mg/day BID
219480935|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
219480936|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
219480937|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
219480938|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
219598243|NCT07134062|OTHER|Bridge technique MWM|Patient in supine, head resting on a pillow, cervical spine relaxed in a neutral position, physiotherapist sitting or standing at the head of the table. Hands support both sides of the head through the thenar eminence on each side, fingers in contact with the C7, T1or T2 articular pillar bilaterally.
219598244|NCT07134062|OTHER|Dry Needling|Participants in this group received two sessions per week of D.N. treatment for the trapezius muscle.
219598245|NCT07133490|DRUG|intraperitoneal chemotherapy|Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy
218865156|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
218865157|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
218865158|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
218865159|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
218865160|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
218865161|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
218865162|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
219480939|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
219480940|NCT05534646|DRUG|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
219480941|NCT05534646|DRUG|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
219480942|NCT06995703|BEHAVIORAL|Pre-Visit Patient Text Message|Patients will be sent a text message reminder 1 day prior to their scheduled primary care visit. This message will remind them of their upcoming appointment, highlight that they may be overdue for their mammogram, and encourage them to speak with their provider or schedule now by using the provided online scheduling link or phone number. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
219480943|NCT06995703|BEHAVIORAL|Post-Visit Patient Text Messages|Patients will be sent text message reminders 4 days and 14 days after their completed primary care visit if they have not yet scheduled or completed their screening mammogram. The message delivered at 4 days post-visit will remind the patient to schedule and that appointments are available for them. The message delivered at 14-days post-visit will again encourage the patient to schedule their mammogram, if one has not already been scheduled or completed. Both messages will include a scheduling phone number and link to self-schedule online. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
219480944|NCT06995703|BEHAVIORAL|Smart Data Element (SDE)|The clinician-facing Smart Data Element (SDE) in the EHR will be visible to the provider and care team during the visit encounter. The SDE will display as a section in pre-charting, check-in, and rooming and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding scheduling an overdue mammogram and including results from prior work that show that patients are more likely to complete their screening if they receive an order and recommendation from their provider.
218865163|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
218865164|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
218865165|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
219480945|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
218865166|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
218865167|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
218865168|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
218865169|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
218865170|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
218865171|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
218865172|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
219020993|NCT07205744|DRUG|Sculptra Aesthetic|"Sculptra® Aesthetic (PLLA-SCA) is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%).~For this study, commercial products will be used. The study products are for single use only."
219480946|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
219480947|NCT00209560|DRUG|fospropofol disodium|
219480948|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
219480949|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
219480950|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
219480951|NCT03336918|DRUG|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
219480952|NCT06615986|DIETARY_SUPPLEMENT|Cardiosyn|Two sachets by mouth daily. Each dose (sachet) is 8.1 grams. For 2 doses it will be 16.2 grams per person per day.
219480953|NCT05470777|COMBINATION_PRODUCT|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5\*10\^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Modified BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
219480954|NCT07005869|PROCEDURE|brachial plexus tumors excision|excision of brachial plexus tumors
219480955|NCT07005440|OTHER|Functional Training|Each training session includes a preparation phase (warm-up, neuromuscular activation, dynamic stretching, and core activation), followed by two main modules: motor skill development (walking, jumping, crawling, throwing, pushing, catching) and physical fitness (balance, agility, endurance). Sessions conclude with motor skill consolidation and static stretching. Training spans 12 weeks: once weekly during weeks 1-8, and twice weekly during weeks 9-12
218865173|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
218865174|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
218865175|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
218865176|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
218865177|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
218865178|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
218865179|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
218865180|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
218865181|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
219480956|NCT07005440|OTHER|Dynamic Play Exercise|This includes warm-up (for 3-5 mins), rhythmic exercise (5-10 mins), games (7-10 mins) and free play exercises (10-15 mins). This group will receive the lesson once a week during week 1-8 and twice a week during 9-12 weeks
219480957|NCT07005583|DRUG|QL1706 Plus Olaparib|QL1706: 5 mg/kg administered via intravenous (IV) infusion every 3 weeks (Q3W). Olaparib: 300 mg (two 150 mg tablets) taken orally twice daily (BID). Treatment will continue until protocol-defined discontinuation criteria are met, including disease progression, unacceptable toxicity, withdrawal of consent, or death.
219480958|NCT07007156|OTHER|NECPAL positive|This group has a positive result for NECPAL scale
219480959|NCT07006805|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide
219480960|NCT07007026|OTHER|Immersive Virtual Reality|The intervention program was implemented over a period of eight weeks, with three ses-sions per week, each lasting 35 minutes.
219480961|NCT07007026|OTHER|Traditional Home-based Exercises|The participants were instructed to adhere to the exercise program thrice weekly for a period of eight weeks.
218865182|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
218865183|NCT01228994|DRUG|placebo pill|placebo pill
218865184|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
218865185|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
218865186|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
218865187|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
218865188|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
218865189|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
218865190|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
218865191|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
218865192|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
218865193|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
218865194|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
218865195|NCT01703065|DRUG|Cabozantinib|Given orally once a day
219480962|NCT07007325|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor PET-CT
218865196|NCT02916459|DEVICE|21G EBUS-TBNA needle|
218865197|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
218865198|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
219480963|NCT04624828|PROCEDURE|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
219480964|NCT04624828|DRUG|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
219480965|NCT04624828|BIOLOGICAL|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
219480966|NCT07008391|DIAGNOSTIC_TEST|high sensitivity Troponin I|Study participants in the intervention group will have the high-sensitivity Troponin I blood test analyzed during emergency medical service (EMS) care using the point-of-care Siemens Atellica® VTLi system. The test result will be documented in the EMS electronic medical record (FRAPP), transmitted along with the ECG, and communicated verbally to the receiving hospital during handover.
219480967|NCT05017831|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
219480968|NCT05017831|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
219480969|NCT07005336|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles
219480970|NCT07005336|DRUG|Sintilimab|Intravenous infusion at a recommended dose of 200 mg once every 3 weeks，at most 35 cycles
219480971|NCT07005336|DRUG|Pemetrexed|Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses.
219480972|NCT07005336|DRUG|Gemcitabine|1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles
219480973|NCT07005336|DRUG|Cisplatin Or Carboplatin|"Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles~Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles"
219480974|NCT07006857|OTHER|Exercise|Exercise without music
219480975|NCT07006857|OTHER|Low Frequency|396 Hertz (Hz), 417 Hz, 528 Hz, 639 Hz
219480976|NCT07006857|OTHER|High Frequency Music|741 Hz, 852 Hz, 963 Hz
219480977|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
219480978|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
219480979|NCT07005778|OTHER|Traditional pain education|Participants in the control group received a 70-minute lecture based on the biomedical model of pain. Educational content included anatomical pathways for pain process (receptors, Aδ and C fibers, spinal cord, and ascending tracts), mechanisms of action potential generation, and the Gate Control Theory. The role of the brain was briefly addressed in the context of descending inhibition. While the Neuromatrix Theory was mentioned, the presentation lacked metaphorical or narrative-based content. Case examples centered on inflammation and tissue injury.
218865199|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
218865200|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
218865201|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
218865202|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
218865203|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
218865204|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
218865205|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
219199736|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
219480980|NCT07005778|OTHER|PNE-based education|"Students in the intervention group received a 70-minute lecture grounded in the biopsychosocial model of pain. The session emphasized that pain is not a direct result of tissue damage, but rather a complex and context-dependent output of the brain. The lecture explored how pain emerges from the brain's interpretation of various inputs, including sensory signals, prior experiences, beliefs, emotions, and environmental factors.~Instructional strategies included the use of clinically relevant metaphors and storytelling to promote reconceptualization of pain. Examples such as the alarm system were used to illustrate peripheral and central sensitization, while real-life anecdotes (a player unaware of injury during a game or a nail-in-foot case with no significant damage) highlighted the dissociation between nociception and pain experience."
219480981|NCT07006753|PROCEDURE|Transvaginal Diverticulum Wall Filling and Coverage Technique|This surgical intervention is a modified transvaginal technique for the treatment of circumferential female urethral diverticulum (UD). Instead of performing a complete diverticulectomy, the procedure utilizes the patient's own demucosalized diverticular wall to fill the diverticular cavity and reinforce closure of the ostium. The technique aims to preserve the integrity of the dorsal urethra, reduce the risk of fistula, minimize dead space, and improve functional outcomes such as continence and sexual function. This approach is specifically designed for circumferential UD, which poses unique anatomical and surgical challenges.
219480982|NCT07011602|BEHAVIORAL|8-week Physical Activity and Nutrition Program|Participants will be enrolled in an 8-week (Monday-Friday) daily physical activity program where treatment group participants will receive daily physical activity via organized games and daily lutein (6mg/d) snacks.
219480983|NCT06627322|DRUG|Dual-combination therapy|Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
219480984|NCT06627322|DRUG|Triple-combination therapy|Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
219480985|NCT06627322|DEVICE|Dexcom G7, Pasta|Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
219480986|NCT02051673|BIOLOGICAL|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
219480987|NCT07029490|OTHER|Chatbot|The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.
219480988|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
219480989|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
219480990|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
219480991|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
219480992|NCT03899545|OTHER|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
219480993|NCT03899545|OTHER|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
219480994|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
219480995|NCT05205824|OTHER|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
218865206|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
218865207|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
218865208|NCT03715192|DRUG|Placebo|Administered IV
218865209|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
218865210|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
218865211|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
218865212|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
218865213|NCT03033953|DIETARY_SUPPLEMENT|Milk|
218865214|NCT03033953|OTHER|Strength training|
218865215|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
218865216|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
218865217|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
218865218|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
218865219|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
218865220|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
219480996|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
219480997|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
219480998|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
219480999|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
219481000|NCT01970423|DEVICE|conventional right ventricular stimulation|
219481001|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
219481002|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
219481003|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
219481004|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
219481005|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
219481006|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
219481007|NCT00003876|PROCEDURE|surgical procedure|
219598246|NCT07133854|DIAGNOSTIC_TEST|Imaging PET/MRI|"MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed.~\[11C\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \[18F\]-FTHA: oral administration of 75 MBq followed by TEP imaging."
218865221|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
218865222|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
218865223|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
218865224|NCT06135363|DRUG|SC1011|SC1011 tablet
218865225|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
218865226|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
218865227|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
219481008|NCT00003876|RADIATION|iodine I 125|
219481009|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
219481010|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
219481011|NCT03014427|OTHER|Biological Database|Biological Database
219481012|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
219481013|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
219481014|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
219598247|NCT07133854|DIAGNOSTIC_TEST|Stable isotope infusions|"\[6,6 D2\]-glucose infusion (0.22 µmol/kg/min, preceded by a bolus of 22 µmol/kg) will start from -180 until time + 360.~\[1,1,2,3,3-2H\]-glycerol (0.05 µmol/kg/min.) and of \[7,7,8,8-2H\] palmitate (0.01 µmol/kg/min) will start from time -60 until time +360."
218865228|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
218865229|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
218865230|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
218865231|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
219481015|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
218865232|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
218865233|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
218865234|NCT00005053|DRUG|glufosfamide|
218865235|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
219481016|NCT01836094|DRUG|Placebo|oral, one time
219481017|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
219481018|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
219481019|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
219481020|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
219481021|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
219481022|NCT00006014|DRUG|semaxanib|
219481023|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
219481024|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
219481025|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
219481026|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
219481027|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
219481028|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
219481029|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
219481030|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
219481031|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
219481032|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
219481033|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
219481034|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
219481035|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
219481036|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
219481037|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
219481038|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
219481039|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
219481040|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
219481041|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
219481042|NCT05992285|DEVICE|transcranial magnetic stimulation|the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
219481043|NCT02396238|DEVICE|Celution Device|ADRCs prepared using the investigational Celution Device
219481044|NCT02396238|OTHER|Placebo|Placebo
219481045|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
218865236|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
218865237|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
218865238|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
218865239|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
219481046|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
218865240|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
219020995|NCT07206212|BEHAVIORAL|A group-based lifestyle intervention for individuals with OCD|Participants will take part in 12 weekly group sessions, consisting of both education on lifestyle habits and physical exercise. Each educational session will focus on a specific topic/lifestyle habit, alternating more informative sessions with sessions discussing how the information can be applied, taking into account specific hinders due to Obsessive-Compulsive Disorder. Between-sessions homework will include, for example, daily registration of physical activity and implementing changes in the lifestyle habits discussed during each session. All homework assignments will be registered in a digital platform. After the 13 weeks of lifestyle intervention, participants will get access to a booster module in the digital platform to help them maintain their behavioral changes.
219481047|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
219481048|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
218865241|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
218865242|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
218865243|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
218865244|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
218865245|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
218865246|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
218865247|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
218865248|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
218865249|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
219020996|NCT07206212|BEHAVIORAL|Medical advice|One individual session with a clinical psychologist on week 1 of about 1 hour of duration. During this session, participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk.
219481049|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
219481050|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
219481051|NCT02504060|DRUG|Starch Placebo|
219481052|NCT02504060|DRUG|N-acetyl-D-glucosamine|
219481053|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
219481054|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
219481055|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
219481056|NCT01570127|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
219598248|NCT07133854|DIAGNOSTIC_TEST|meal test|A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\[13C\]-glucose and 9 μmol/kg lean mass of \[U-13C\]-palmitate.
219598249|NCT07133854|DIAGNOSTIC_TEST|Indirect calorimetry|Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.
218865250|NCT03504566|DRUG|Linagliptin|Linagliptin
218865251|NCT03504566|DRUG|Empagliflozin|Empagliflozin
218865252|NCT03504566|DRUG|Telmisartan|Telmisartan
218865253|NCT03504566|DRUG|Sulodexide|Sulodexide
218865254|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
219481057|NCT01570127|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
219481058|NCT01570127|PROCEDURE|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
219481059|NCT01570127|OTHER|Waiting|No interventions were applied to the patients in this group.
218865255|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
219481060|NCT03540446|DEVICE|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
219481061|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
219481062|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
218865256|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
219481063|NCT04132102|DRUG|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
219481064|NCT03348319|OTHER|radiation|Scanning cadaver organs
219481065|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
219481066|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
219481067|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
219481068|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
219481069|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
219481070|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
219481071|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
219481072|NCT03847532|GENETIC|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
219481073|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
219481074|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
219481075|NCT00798707|DRUG|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
219481076|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
219598250|NCT07134894|BEHAVIORAL|Intensive Bimanual Therapy plus Conventional Physical Therapy|A combined rehabilitation program delivered over 8 weeks, three sessions per week. Each 60-minute session includes 30 minutes of Conventional Physical Therapy (CPT) to improve range of motion, muscle strength, balance, and gross motor function, and 30 minutes of Intensive Bimanual Therapy (IBT) to enhance bilateral hand coordination and functional independence. IBT tasks progress from basic grasping and object transfer to complex daily activities such as buttoning, puzzle assembly, water pouring, and feeding with utensils. Two sessions are supervised by a physiotherapist and one is completed at home under caregiver guidance.
219598251|NCT07134894|BEHAVIORAL|Conventional Physical Therapy|A standard physiotherapy program delivered over 8 weeks, three sessions per week, each lasting 40 minutes. Sessions focus on upper limb range of motion, strengthening, postural control, and functional mobility without targeted bimanual training. Exercises include assisted stretches, squats, heel raises, step-ups, knee lifts, yoga-based poses, animal walks, single-leg stance, and stair climbing to promote flexibility, balance, and gross motor performance. Two sessions are supervised by a physiotherapist and one is performed at home with caregiver supervision.
219598252|NCT07134036|DEVICE|Navigation system|Patients underwent total hip arthroplasty via the direct anterior approach using a computer navigation system to assist in intraoperative limb length measurement.
219598253|NCT07134036|PROCEDURE|Conventional total hip arthroplasty|Patients underwent total hip arthroplasty via the direct anterior approach conventionally.
219598254|NCT07133425|DRUG|SAR445877|Given by IV
219598255|NCT07135193|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
219598256|NCT07135193|DIETARY_SUPPLEMENT|Blank control|Blank control
219598257|NCT00588068|OTHER|Tumor and Marrow Markers|Tumor and Marrow Markers
219598258|NCT06484491|RADIATION|Dose-escalated intensity-modulated proton therapy (IMPT-74)|Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).
218865257|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
219481077|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
219481078|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
218865258|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
218865259|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
218865260|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
219481079|NCT03473145|BEHAVIORAL|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.
218865261|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
218865262|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
219481080|NCT03473145|DEVICE|activPAL inclinometer|Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
219481081|NCT03473145|OTHER|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
219481082|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
219481083|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
219481084|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
219481085|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
219481086|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
219481087|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
219481088|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
219481089|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
219481090|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
219481091|NCT04904978|OTHER|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
218865263|NCT00430001|DRUG|docetaxel|
218865264|NCT00430001|DRUG|vinorelbine|
218865265|NCT00430001|DRUG|trastuzumab|
218865266|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
218865267|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
218865268|NCT02225912|OTHER|PrevinC|
218865269|NCT02225912|DRUG|placebo|
219481092|NCT04904978|OTHER|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
219481093|NCT01876628|DRUG|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
219481094|NCT01876628|DRUG|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
218865270|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
218865271|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
218865272|NCT01007422|BEHAVIORAL|telephone-based intervention|
218865273|NCT01007422|OTHER|communication intervention|
218865274|NCT01007422|OTHER|intervention by caregiver|
218865275|NCT01007422|OTHER|medical chart review|
219020997|NCT07206212|OTHER|Treatment as usual (TAU)|Written educational information in a digital platform, on healthy lifestyle habits based on national Swedish guidelines issued by the National Board of Health and Welfare. The recommendations include engaging in regular physical activity, dietary guidelines based on Nordic Nutrition Recommendations, and advice to reduce alcohol consumption and quit tobacco use.
219199737|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
219481095|NCT01876628|DRUG|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
219481096|NCT03213769|DRUG|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
219481097|NCT03213769|DRUG|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
219481098|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
218865276|NCT01007422|OTHER|survey administration|
218865277|NCT01007422|PROCEDURE|end-of-life treatment/management|
219481099|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219481100|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219481101|NCT06700902|BEHAVIORAL|Taking Action|Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
219481102|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
219481103|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
219481104|NCT05052827|DIETARY_SUPPLEMENT|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
218865278|NCT01007422|PROCEDURE|pain therapy|
218865279|NCT01007422|PROCEDURE|psychosocial assessment and care|
218865280|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
218865281|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
218865282|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
218865283|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
219481105|NCT05052827|DIETARY_SUPPLEMENT|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
219481106|NCT05052827|DIETARY_SUPPLEMENT|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
219481107|NCT05883527|OTHER|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
219481108|NCT05883527|OTHER|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
219481109|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
219481110|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
219481111|NCT01889927|OTHER|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
219598259|NCT06484491|DRUG|Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy|"Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days."
219598260|NCT06484491|DRUG|Immunotherapy: adjuvant durvalumab|"Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total."
219598261|NCT06170944|DEVICE|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
219598262|NCT06570369|DRUG|SP-624|Oral dose, once daily for 2 weeks
219598263|NCT06570369|DRUG|Placebo|Oral dose, once daily for 2 weeks
219598264|NCT05207891|DEVICE|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
218865284|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
218865285|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
219481112|NCT00929201|DRUG|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
219481113|NCT00929201|DRUG|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
219481114|NCT00929201|DRUG|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
219481115|NCT04640701|OTHER||
219481116|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
219481117|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
219481118|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
219598265|NCT06478706|DRUG|ETD001|Twice daily doses
219598266|NCT06478706|DRUG|Placebo|Twice daily doses
219598267|NCT04936737|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
219598268|NCT04936737|OTHER|High intensity interval exercise|The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
219598269|NCT03383523|DRUG|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
219598270|NCT03358706|DRUG|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
219598271|NCT03358706|DRUG|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
218865286|NCT00138112|DRUG|Empirical Vancomycin|
218865287|NCT00138112|DRUG|Prophylactic Vancomycin|
219598272|NCT03358706|DRUG|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
219199738|NCT05184114|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
219199739|NCT03364127|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
219199740|NCT03364127|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
218865288|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
218865289|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
219481119|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
219481120|NCT01626794|BIOLOGICAL|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
219481121|NCT01626794|BIOLOGICAL|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
218865290|NCT02337699|PROCEDURE|QST Testing|
218865291|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
218865292|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
219598273|NCT03358706|DRUG|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
219481122|NCT01626794|BIOLOGICAL|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
219481123|NCT00018174|DRUG|Fluoxetine|
219481124|NCT00018174|BEHAVIORAL|Behavioral group smoking cessation treatment|
219481125|NCT00018174|DRUG|Placebo|
219481126|NCT06111131|DEVICE|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
219481127|NCT02049580|DRUG|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
219481128|NCT02049580|DRUG|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
219481129|NCT02049580|DRUG|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
219481130|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
219481131|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
219481132|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
219481133|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
219481134|NCT02384239|DRUG|Palbociclib|Given orally (PO)
219481135|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
219481136|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
219481137|NCT05940467|OTHER|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
219481138|NCT01299272|DRUG|LY2216684|
219481139|NCT01299272|DRUG|Placebo|
219481140|NCT01299272|DRUG|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
219481141|NCT00633295|DRUG|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
219481142|NCT02501655|DEVICE|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
219598274|NCT03358706|DRUG|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
219598275|NCT03358706|DRUG|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
218865293|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
218865294|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
218865295|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
218865296|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
218865297|NCT02840786|DEVICE|plaque excision system|
218865298|NCT02840786|DEVICE|balloon and Stent|
218865299|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
218865300|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
218865301|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
218865302|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
219598276|NCT03358706|DRUG|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
219598277|NCT03358706|DRUG|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
219598278|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
219598279|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
219598280|NCT01193179|DRUG|OPC-262|Oral administration of tablets for 52 weeks
219598281|NCT01810302|DRUG|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
218865303|NCT01536483|DRUG|Butyrate enemas|"Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
219481143|NCT02501655|DEVICE|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
219481144|NCT04095546|OTHER|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
219481145|NCT01054469|PROCEDURE|TAP block placement with placebo|20 ml of normal saline (placebo)
219481146|NCT01054469|PROCEDURE|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
219598282|NCT01810302|DRUG|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
219598283|NCT03584087|DRUG|Normal Saline|TG 0 (0Hr)
219598284|NCT03584087|DRUG|Terlipressin|Duration of Terlipressin after EVL
219598285|NCT02126826|DRUG|BI 1026706|Multiple Rising Doses (oral solution, tablet)
219481147|NCT03308123|OTHER|Observational study, not interventional|Not an intervention study
219598286|NCT02126826|DRUG|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
219598287|NCT03251170|DRUG|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
219598288|NCT03251170|DRUG|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
219598289|NCT03251170|DRUG|Midazolam|Patients will receive 0.05 mg/Kg midazolam
219598290|NCT04622241|OTHER|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
219598291|NCT04622241|OTHER|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
219598292|NCT04622241|OTHER|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
218865304|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
218865305|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
218865306|NCT05126628|DRUG|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
218865307|NCT05126628|DRUG|Placebo|Placebo 3 tablets q.d. for 14 days
218865308|NCT03024138|RADIATION|Repeat CT scan|
218865309|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
218865310|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
219481148|NCT06356038|PROCEDURE|intra-operative phrenic nerve infiltration|patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
219481149|NCT05226013|DRUG|Polyglycol lated urate oxidase for injection|Single dose escalation
219481150|NCT05226013|DRUG|Placebo|Placebo
219481151|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
218865311|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
219481152|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
219481153|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
219481154|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
219481155|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
219481156|NCT00090337|PROCEDURE|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
219481157|NCT00090337|PROCEDURE|standard follow-up care|Patients undergo standard care
219481158|NCT00308100|DRUG|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
219481159|NCT00308100|DRUG|5% Albumin|5% albumin, administered intra- and perioperatively
219481160|NCT03606109|DRUG|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
219481161|NCT00619671|DRUG|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
218865312|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
218865313|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
219481162|NCT04839133|DEVICE|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
218865314|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
218865315|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
218865316|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
218865317|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
218865318|NCT02038660|DEVICE|Balloon angioplasty|
218865319|NCT02242981|DRUG|LY2623091|Administered orally
218865320|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
219481163|NCT02995928|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
219481164|NCT02995928|PROCEDURE|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
219481165|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
219481166|NCT02650609|DRUG|Methylprednisolone|
219481167|NCT02650609|DRUG|Placebo|
219598293|NCT04622241|OTHER|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
218865321|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
218865322|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
218865323|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
218865324|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
219598294|NCT03888066|DRUG|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
218865325|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
218865326|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
219598295|NCT03888066|DRUG|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
219598296|NCT06115525|OTHER|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
218865327|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
218865328|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
218865329|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
219481168|NCT00820183|OTHER|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
219481169|NCT00006397|DRUG|Indinavir sulfate|
219481170|NCT00006397|DRUG|Ritonavir|
219481171|NCT00006397|DRUG|Stavudine|
219481172|NCT00006397|DRUG|Didanosine|
219481173|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
219481174|NCT00718978|PROCEDURE|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
218865330|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
218865331|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
218865332|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
218865333|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
218865334|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
218865335|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
218865336|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
218865337|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
218865338|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
219481175|NCT06116994|OTHER|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
218865339|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
218865340|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
219021004|NCT07205627|OTHER|Rehabilitation program|"Participants will complete an 8-week structured pulmonary rehabilitation program, delivered in 2-3 supervised sessions per week at the Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde. Each session will last 60-90 minutes and include the following components:~Aerobic Training: Walking or cycling at 60-80% of maximum workload, progressively adjusted based on tolerance.~Strength Training: Resistance exercises for major muscle groups (upper and lower limbs), 2-3 sets of 10-15 repetitions, individualized according to baseline strength.~Breathing Techniques: Diaphragmatic and pursed-lip breathing, plus thoracic expansion exercises.~Inspiratory Muscle Conditioning: Threshold device training at 30% of maximal inspiratory pressure (MIP), with progressive increments.~Education Sessions: Information on disease self-management, energy conservation, medication adherence, and lifestyle recommendations."
219481176|NCT06116994|OTHER|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
219481177|NCT00630994|DRUG|Dacogen|
219481178|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
219481179|NCT06567457|BIOLOGICAL|SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
219481180|NCT06567457|BIOLOGICAL|SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
219481181|NCT00159367|DEVICE|Repetitive magnetic stimulation to the quadriceps|
219598297|NCT06115525|OTHER|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
219598298|NCT03278626|DRUG|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
219598299|NCT02428439|DRUG|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
219598300|NCT01613768|DRUG|eribulin mesylate|Given IV
219598301|NCT00168935|DRUG|Fresubin protein energy Drink (CAVE! nutritional intervention)|
219598302|NCT01824381|PROCEDURE|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
219598303|NCT01824381|PROCEDURE|Obtaining and Cryopreservation of amniotic membrane|
219598304|NCT01824381|DRUG|amniotic membrane|
219598305|NCT05013008|DRUG|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
219598306|NCT05013008|DRUG|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
219598307|NCT01094015|DRUG|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
218865341|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
218865342|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
218865343|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
218865344|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
218865345|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
218865346|NCT02437786|DRUG|GRAZAX|GRAZAX
218865347|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
218865348|NCT04720768|DRUG|Binimetinib|MEK inhibitor
218865349|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
218865350|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
219481182|NCT03669640|DRUG|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
219481183|NCT03669640|DRUG|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
219481184|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
219481185|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
219481186|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
219481187|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
219481188|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
219481189|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
219481190|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
219481191|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
219481192|NCT00664417|BIOLOGICAL|Physiological saline|0.5 mL, IM, 2 injections
219481193|NCT03464786|DEVICE|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
219481194|NCT03464786|DEVICE|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
219481195|NCT03035981|OTHER|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481196|NCT03035981|OTHER|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481197|NCT03035981|OTHER|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481198|NCT03035981|OTHER|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481199|NCT03035981|OTHER|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481200|NCT03035981|OTHER|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219598308|NCT01094015|OTHER|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
219598309|NCT04109092|DRUG|E7766|E7766, solution, intravesically.
219481201|NCT03035981|OTHER|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
219481202|NCT03130855|DRUG|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
219481203|NCT03130855|DRUG|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
219481204|NCT01224418|DRUG|Tacrolimus|oral
219481205|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
219481206|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
219481207|NCT04583384|DIAGNOSTIC_TEST|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
219481208|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
219481209|NCT04185207|OTHER|no intervention|There is no intervention.
219481210|NCT06568445|DRUG|Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）|one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
219598310|NCT02351661|OTHER|There was no intervention|observational study, no intervention
219598311|NCT05327153|BEHAVIORAL|Acceptance and Commitment Therapy|The theoretical foundation of ACT is Relational Frame Theory (RFT) based on the functional contextualism philosophy, which suggests that the main psychological problem derived verbal and cognitive interaction with environment, leading to behaviors contrary to long-term values and psychological inflexibility. The psychopathological model of ACT includes six core parts: experiential avoidance, cognitive fusion, attachment to the conceptualized self, conceptualized past and feared future, lack of value clarity, inaction.
218865351|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
218865352|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
218865353|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
218865354|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
218865355|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
218865356|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
218865357|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
218865358|NCT00123773|PROCEDURE|Positron Emission Tomography|
218865359|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
218865360|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
218865361|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
218865362|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
218865363|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
219481211|NCT06568445|DRUG|as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）|as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
219481212|NCT02118818|GENETIC|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
219481213|NCT03533608|BEHAVIORAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
218865364|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
219481214|NCT00122148|BEHAVIORAL|Feedback on provision of care|
219481215|NCT06700382|DRUG|capecitabine|different methods of treatment for capecitabine
219481216|NCT04872127|DEVICE|proximal embolism protection device|a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
218865365|NCT01730404|DRUG|CHF6001 DPI|
218865366|NCT01730404|DRUG|Roflumilast|
219481217|NCT04872127|DEVICE|distal embolism protection device|a distal SpiderFX will be used as the embolism protection device during CAS
219481218|NCT03541668|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
219481219|NCT03541668|DRUG|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
219481220|NCT03286426|DIAGNOSTIC_TEST|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
219481221|NCT05241626|DIAGNOSTIC_TEST|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
218865367|NCT01730404|DRUG|Placebo|
218865368|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
219481222|NCT01953731|DRUG|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
219481223|NCT01953731|DRUG|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
219481224|NCT02255773|BEHAVIORAL|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
219481225|NCT02255773|BEHAVIORAL|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
219481226|NCT00871104|DRUG|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
219598312|NCT00956423|BEHAVIORAL|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
219598313|NCT00956423|BEHAVIORAL|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
219598314|NCT06582797|OTHER|discontinuation of ART|patient will discontinue their standard of care HIV treatment with ART while being closely monitored
219598315|NCT01194167|DRUG|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
219598316|NCT02478229|DRUG|Sofosbuvir (SOF) and Ledipasvir (LDV)|
218865369|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
218865370|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
218865371|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
218865372|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
218865373|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
218865374|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
218865375|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
218865376|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
218865377|NCT00354666|DRUG|GSK159797|
218865378|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
219481227|NCT00871104|DRUG|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
219481228|NCT03196739|DEVICE|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
219481229|NCT06073041|OTHER|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then receive an in-depth standardized onboard training.
219481230|NCT03514121|BIOLOGICAL|FPA150|A monoclonal antibody against B7-H4
219481231|NCT03514121|BIOLOGICAL|Pembrolizumab|An anti-PD1 antibody
219481232|NCT05553600|DEVICE|Tampon BR|Modified Regular Absorbency Tampons
219481233|NCT05553600|DEVICE|Tampon CR|Reference Regular Absorbency Tampons
219481234|NCT05553600|DEVICE|Tampon BS|Modified Super Absorbency Tampons
219481235|NCT05553600|DEVICE|Tampon CS|Reference Super Absorbency Tampons
219481236|NCT01493063|OTHER|Physiopathology|Samples of breastmilk and infant serum and questionnaires.
219598317|NCT05629715|DEVICE|ROSA Knee System|The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
219598318|NCT05629715|DEVICE|KneeAlign Computer Assisted Navigation System|The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
219598319|NCT03884361|DIAGNOSTIC_TEST|Vaginal Microbiome as result of aminocentesis|we will take a blood samples and a vaginale samples after and before the aminicentesis and check if the sample that we took after is different and contain microrganisms , if we find a different o we can say that as result of the Elective Amniocentesis
219598320|NCT06109155|DRUG|Tranexamic acid|tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
219598321|NCT03134248|DEVICE|Dailies Aquacomfort Plus Toric|daily disposable contact lens
218865379|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
218865380|NCT01651091|OTHER|Treatment as usual|
218865381|NCT00126984|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
218865382|NCT00126984|BIOLOGICAL|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
218865383|NCT00126984|BIOLOGICAL|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
219481237|NCT04714684|DEVICE|Fitostimoline proctogel|Medical device for topical use for the treatment of fissures
219598322|NCT03134248|DEVICE|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
219598323|NCT03134248|DEVICE|MyDay Toric|daily disposable contact lens
218865384|NCT00126984|BIOLOGICAL|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
218865385|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
218865386|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
218865387|NCT01858753|BIOLOGICAL|placebo sterile saline|
219598324|NCT02836522|BEHAVIORAL|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
218865388|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
218865389|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
219481238|NCT04714684|DEVICE|Fitostimoline proctogel + muscle relaxant|medical device for topical use for the treatment of fissures
219481239|NCT00949052|GENETIC|DNA analysis|
219481240|NCT00949052|GENETIC|polymorphism analysis|
219481241|NCT00949052|OTHER|laboratory biomarker analysis|
219481242|NCT00949052|OTHER|medical chart review|
219481243|NCT00949052|OTHER|questionnaire administration|
219481244|NCT00949052|PROCEDURE|assessment of therapy complications|
219481245|NCT00949052|PROCEDURE|evaluation of cancer risk factors|
219481246|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
219481247|NCT02980029|OTHER|Placebo|Placebo
219481248|NCT01319747|PROCEDURE|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
219598325|NCT03015987|OTHER|diode laser activated irrigation|diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
218865390|NCT02631265|OTHER|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
219199741|NCT05015868|DIAGNOSTIC_TEST|Standard of care|"Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing"
219199742|NCT05015868|DIAGNOSTIC_TEST|Functional magnetic resonance imaging-Electroencephalogram combined analysis|"A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities."
219199743|NCT05015868|DIAGNOSTIC_TEST|High density- electroencephalogram or 7 Tesla magnetic resonance imaging|"In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
219481249|NCT01319747|PROCEDURE|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
219481250|NCT01922973|OTHER|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
219481251|NCT06329076|DRUG|Losartan|Administration of losartan tablets (50 mg)
219481252|NCT06329076|DRUG|Placebo|Administration of placebo tablets
219481253|NCT01900392|BEHAVIORAL|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
219481254|NCT04861831|OTHER|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
219481255|NCT00457431|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
219481256|NCT00861731|DRUG|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
219481257|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
219481258|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
219481259|NCT06562439|BEHAVIORAL|Sickle Cell Collaboration for Child Development|The Sickle Cell Collaboration for Child Development (SCCCD) combines the Parents as Teachers curriculum with experienced occupational therapy to help families and children meet their learning and developmental goals.
219481260|NCT01063439|DRUG|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
219481261|NCT03585868|OTHER|Placebo|Beverage with no flavonoids
219481262|NCT03585868|OTHER|Flavonoids|Flavonoids-enriched cacao beverage
219481263|NCT03585868|DIETARY_SUPPLEMENT|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
219481264|NCT06539143|DRUG|Lidocaine|The Paracervical Block with lidocaine for manual vacuum aspiration
219481265|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
219481266|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
219481267|NCT04676386|DIAGNOSTIC_TEST|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
219481268|NCT01200316|PROCEDURE|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
219481269|NCT01200316|PROCEDURE|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
219481270|NCT01200316|BEHAVIORAL|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
219481271|NCT03667586|BEHAVIORAL|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
219481272|NCT05001763|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
219481273|NCT05001763|DRUG|Placebo|Glucose, 2mg, tablet.
219481274|NCT00368914|DRUG|sirolimus|
219481275|NCT00368914|OTHER|laboratory biomarker analysis|
219481276|NCT00368914|OTHER|pharmacological study|
219481277|NCT00368914|PROCEDURE|biopsy|
219481278|NCT03422081|DIAGNOSTIC_TEST|arterial doppler ultrasound|doppler ultrasound
218865391|NCT02631265|OTHER|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
218865392|NCT02631265|OTHER|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
219199744|NCT00527410|DRUG|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
219481279|NCT06563050|PROCEDURE|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
219481280|NCT06563050|PROCEDURE|Lidocaine spray|Subjects in group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
219481281|NCT06563050|PROCEDURE|Combination of nebulized lidocaine and lidocaine spray|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
219481282|NCT04707066|BEHAVIORAL|Treatment As Usual (TAU)|Treatment As Usual
219481283|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
219481284|NCT04707066|BEHAVIORAL|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
219481285|NCT04707066|BEHAVIORAL|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
219481286|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
219481287|NCT03172390|DEVICE|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
219481288|NCT01466959|OTHER|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
219481289|NCT01466959|OTHER|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
219481290|NCT03286400|DEVICE|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
219481291|NCT02260752|PROCEDURE|hysterectomy|surgical removal of the uterus
219481292|NCT02260752|PROCEDURE|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
219481293|NCT02260752|PROCEDURE|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
219481294|NCT02260752|DRUG|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
219481295|NCT02260752|PROCEDURE|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
219481296|NCT02260752|PROCEDURE|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
219481297|NCT02260752|PROCEDURE|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
219481298|NCT05500235|BEHAVIORAL|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
219598326|NCT01153100|DRUG|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
219598327|NCT02116270|BIOLOGICAL|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
219598328|NCT03928483|BEHAVIORAL|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
219598329|NCT03675230|DEVICE|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
219598330|NCT03675230|DEVICE|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
219598331|NCT03011138|PROCEDURE|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
219598332|NCT04237337|OTHER|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
219598333|NCT05642845|DRUG|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
218865393|NCT00083486|DRUG|epoetin alfa|
219481299|NCT05500235|BEHAVIORAL|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
219481300|NCT05179980|OTHER|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
219481301|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
218865394|NCT06339970|OTHER|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
218865395|NCT06339970|OTHER|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
218865396|NCT00474617|DRUG|Sugammadex|
219481302|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
218865397|NCT00474617|DRUG|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
218865398|NCT04162522|DRUG|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
219481303|NCT06359964|PROCEDURE|Transperineal Biopsy without antibiotics prophylaxis|Transperineal Biopsy without antibiotics prophylaxis
219481304|NCT06359964|PROCEDURE|Transperineal Biopsy with antibiotics prophylaxis|Transperineal Biopsy with antibiotics prophylaxis
219481305|NCT05447559|DRUG|Cefazolin|Intravenous administration of 2 g cefazolin
219481306|NCT05447559|DRUG|Water for injection|Intravenous administration of 10mL sterile water for injection
219481307|NCT06236152|DRUG|Ferrous sulfate|Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.
219481308|NCT06236152|DRUG|Deltacortril|Deltacortil 10mg was given orally once daily for 4 to 6 weeks
218865399|NCT04162522|DRUG|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
218865400|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
218865401|NCT05231798|DRUG|[18F]-FEOBV Radiotracer|Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
218865402|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
219481309|NCT06340087|OTHER|10% Sucrose|10% sucrose corresponding to a regular soft drink
219481310|NCT06340087|DRUG|Sucrose+ Hesperetin|Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
219481311|NCT06340087|OTHER|7% Sucrose|7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
219481312|NCT00171756|DRUG|valsartan/atenolol|
219481313|NCT04219800|BEHAVIORAL|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
219481314|NCT04219800|BEHAVIORAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
219481315|NCT02802137|DRUG|tafluprost|
219481316|NCT02802137|DRUG|tafluprost and dorzolamide/timolol|
219481317|NCT03852407|DRUG|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
219481318|NCT03852407|DRUG|Melphalan|100mg/m² on day -2
219481319|NCT03852407|DRUG|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
219481320|NCT03852407|DRUG|Cyclophosphamid|50 mg/kg on days +3 and +4.
219481321|NCT01861600|OTHER|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
219481322|NCT01861600|OTHER|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
219598334|NCT05642845|DRUG|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
219598335|NCT03734939|OTHER|None intervention is planned.|None intervention is planned, just a survey.
218865403|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
218865404|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
219481323|NCT01861600|OTHER|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
219481324|NCT01861600|OTHER|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
219481325|NCT01861600|OTHER|Human Milk|Human Milk
218865405|NCT02870530|PROCEDURE|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
218865406|NCT03102060|OTHER|Dietary Intervention|Undergo gluten free diet
219481326|NCT03102788|BEHAVIORAL|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
219481327|NCT03102788|BEHAVIORAL|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
219481328|NCT06143683|PROCEDURE|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
219481329|NCT06143683|PROCEDURE|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
219481330|NCT00826176|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
219481331|NCT02543229|DRUG|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
219481332|NCT02543229|DRUG|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
219481333|NCT02406365|DEVICE|Diagnostic imaging aid for one-visit management of cervical lesions|
219481334|NCT01921725|DEVICE|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
219481335|NCT03593239|OTHER|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
219481336|NCT03593239|OTHER|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
219481337|NCT03593239|OTHER|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
219481338|NCT03593239|OTHER|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
219481339|NCT03593239|OTHER|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
219598336|NCT00237965|BEHAVIORAL|Mole Mapping Diagram|
219598337|NCT05228431|DRUG|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
219481340|NCT03593239|OTHER|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
219598338|NCT05228431|DRUG|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
219598339|NCT05228431|RADIATION|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
218865407|NCT03102060|OTHER|Laboratory Biomarker Analysis|Correlative studies
218865408|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
218865409|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
218865410|NCT05082727|DIETARY_SUPPLEMENT|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
218865411|NCT05082727|DIETARY_SUPPLEMENT|Placebo oral softgel|Placebo
218865412|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
218865413|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
219481341|NCT03593239|OTHER|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
219481342|NCT03593239|OTHER|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
219481343|NCT03593239|OTHER|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
219481344|NCT03593239|OTHER|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
219481345|NCT00317967|DRUG|Atorvastatin|80 mg pills daily
219481346|NCT00317967|DRUG|Placebo|80 mg pills daily
219481347|NCT05296369|DRUG|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
219481348|NCT00752401|DRUG|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
219481349|NCT00752401|DRUG|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
219481350|NCT06079801|DEVICE|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
219481351|NCT06079801|DRUG|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
219021005|NCT07207239|DEVICE|repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol|Theta-burst rTMS treatment stimulates the left Dorsolateral Prefrontal Cortex (DLPFC). The TBS parameters the investigators adopted follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. The investigators plan to deliver 1800 stimuli to the left DLPFC daily in 9.5-minute blocks for four weeks.
218865414|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
218865415|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
218865416|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
219481352|NCT04430101|PROCEDURE|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
219481353|NCT04430101|PROCEDURE|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
219481354|NCT03823339|DRUG|Insulin degludec/liraglutide|Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
219481355|NCT01502917|DRUG|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
219481356|NCT01502917|RADIATION|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
219481357|NCT06566508|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide Intracanal medication
218865417|NCT05855655|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
218865418|NCT04441008|DEVICE|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
218865419|NCT04441008|DEVICE|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
218865420|NCT03261206|OTHER|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
218865421|NCT05160766|BIOLOGICAL|Comirnaty (BTN162b2)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
219021006|NCT07205887|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
219021007|NCT07205887|DRUG|Aflibercept 2.0 mg|Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose EYE103.
219481358|NCT06566508|DRUG|Leddermix Intracanal medication|Leddermix Intracanal medication
219481359|NCT06566508|DRUG|Asiaticoside Intracanal medication|Asiaticoside Intracanal medication
219481360|NCT06057233|DIAGNOSTIC_TEST|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
218865422|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
218865423|NCT02292004|DEVICE|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
219481361|NCT02881970|DRUG|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
218865424|NCT02292004|PROCEDURE|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
219481362|NCT01687400|DRUG|decitabine|
219481363|NCT00002628|BIOLOGICAL|filgrastim|
218865425|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
219481364|NCT00002628|DRUG|carboplatin|
219598340|NCT05009017|DRUG|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
219598341|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention + IVR booster calls|1\) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
219598342|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
219598343|NCT01125371|BEHAVIORAL|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
218865426|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
218865427|NCT00044187|DRUG|Sibutramine|
218865428|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
218865429|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
218865430|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
218865431|NCT06176768|DRUG|LY3972406|Administered orally
218865432|NCT06176768|DRUG|Placebo|Administered orally
218865433|NCT04175769|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
219481365|NCT00002628|DRUG|cyclophosphamide|
219481366|NCT00002628|DRUG|mesna|
219481367|NCT00002628|DRUG|paclitaxel|
219481368|NCT00002628|PROCEDURE|peripheral blood stem cell transplantation|
219481369|NCT03932747|OTHER|pre- Hydratión skin|Measurement of hydration of the skin.
219481370|NCT03932747|OTHER|post- Hydratión skin|Measurement of hydration of the skin.
219481371|NCT04475068|PROCEDURE|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
219481372|NCT06145880|DIAGNOSTIC_TEST|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
219481373|NCT02995265|DEVICE|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
219598344|NCT00029029|PROCEDURE|pain therapy|
219598345|NCT00029029|PROCEDURE|radiofrequency ablation|
219598346|NCT05938608|DRUG|Regimen 1 (Oral primaquine)|Primaquine 15 mg base orally once
219598347|NCT05938608|DRUG|Regimen 2 (IV primaquine phosphate)|Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
219598348|NCT05938608|DRUG|Regimen 3 (IV carboxyprimaquine)|Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
219598349|NCT00316095|DRUG|telmisartan|
219598350|NCT00316095|DRUG|simvastatin|
219598351|NCT05823324|BEHAVIORAL|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
219598352|NCT02111603|DRUG|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
219598353|NCT01713452|PROCEDURE|Purse string closure|"1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken."
219598354|NCT01713452|PROCEDURE|Primary closure|"1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken."
219598355|NCT06548178|DRUG|T-DXd|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
218865434|NCT04175769|OTHER|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
218865435|NCT04461418|DRUG|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
219481374|NCT02995265|OTHER|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
219481375|NCT00665704|BEHAVIORAL|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
219481376|NCT00437710|PROCEDURE|cell therapy, bone marrow derived stem cell|
219481377|NCT05033379|BEHAVIORAL|Control|Importance of sleep
219481378|NCT05033379|BEHAVIORAL|Resilience coaching|Arena Strive
219481379|NCT03016104|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219481380|NCT03016104|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
219481381|NCT03016104|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
219481382|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
219481383|NCT05255354|DEVICE|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
219481384|NCT04920162|OTHER|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
219481385|NCT03032575|BEHAVIORAL|SEARCH010/RV254|
219481386|NCT05301452|RADIATION|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
219481387|NCT05301452|RADIATION|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
219481388|NCT05301452|PROCEDURE|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
219481389|NCT00436397|RADIATION|radiation therapy|
219481390|NCT01408056|DRUG|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
219481391|NCT01408056|DRUG|Mupirocin 2% Ointment|Topical application twice per day for 60 days
219481392|NCT04798430|DRUG|lerodalcibep|PCSK9 inhibitor
219481393|NCT03953768|DEVICE|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
219481394|NCT05957913|DRUG|Truvada (tenofovir/emtricitabine)|Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
219481395|NCT04800822|DRUG|PF-07284892|PF-07284892
219481396|NCT04800822|DRUG|lorlatinib|lorlatinib
219481397|NCT04800822|DRUG|binimetinib|binimetinib
219481398|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
219481399|NCT04800822|DRUG|encorafenib|encorafenib
219481400|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
219481401|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
219481402|NCT04846920|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
219481403|NCT02902757|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
218865436|NCT05696782|DRUG|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
219481404|NCT02902757|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
219481405|NCT02902757|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219481406|NCT04943913|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219481407|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
219481408|NCT05854745|BEHAVIORAL|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
218865437|NCT05696782|OTHER|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
218865438|NCT05696782|DIAGNOSTIC_TEST|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
219481409|NCT05854745|BEHAVIORAL|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
219481410|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
219481411|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219481412|NCT01970280|DRUG|Enoxaparin|
219481413|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
219481414|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
218865439|NCT05696782|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
218865440|NCT06975137|BEHAVIORAL|Zithandani Stepping Stones and Creating Futures|Delivered to heterosexual couples. 14 group based sessions, with each session lasting approximately 3 hours. Sessions are delivered by two trained facilitators. Intervention focused on transforming gender norms, strengthening communication, reducing symptoms of poor mental health and improving relationship dynamics. Mixture of couples focused, same-gender discussions, and whole group discussions.
218865441|NCT06017258|BIOLOGICAL|CD371-specific/YSNVz/I-18 CAR T cells|Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
218865442|NCT05965401|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
218865443|NCT05965401|OTHER|GLAD-PC guided dosing|SSRI dosing based on GLAD-PC clinical practice guidelines
218865444|NCT06979739|BEHAVIORAL|reiki|6 week reiki
218865445|NCT06979739|BEHAVIORAL|refleksologia|6 week refleksologia
218865446|NCT06979739|BEHAVIORAL|reiki and refleksologia|6 week reiki and refleksologia
218865447|NCT06979934|BEHAVIORAL|3D printing splint group|Wear 3D printing design splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Wear 3D printed design hand splint and change objects according to the ability of grasp, such as hold a cup, handle, eraser, pen, etc.
219481415|NCT02530320|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
219481416|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
219481417|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
218865448|NCT06979934|BEHAVIORAL|functional splint group|Wear functional splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Grasp the holder according the grasp ability, such as hold a cup, handle, eraser, pen, etc.
219481418|NCT00297882|DRUG|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
219481419|NCT00297882|DRUG|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
219481420|NCT03534635|DRUG|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
219481421|NCT03534635|DRUG|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
219481422|NCT03665246|BEHAVIORAL|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
219481423|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
219481424|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
219481425|NCT05873959|BIOLOGICAL|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
219481426|NCT06405152|OTHER|Chart review|Retrospective Chart Review
218865449|NCT06981130|DEVICE|FebriDx Point of Care Test|Patients self-referring to their GP practice with symptoms of acute respiratory infection (ARI) will receive the FebriDx point-of-care test during their clinical consultation.
218865450|NCT06981182|OTHER|Faith-placed intervention to promote breast, cervical, bowel, and AAA screening uptake in Black communities.|The intervention includes a two-hour workshop, delivered in person to the entire congregation, that aims to promote the uptake of breast, cervical, bowel, and AAA screening among Black communities in the North East of England, Leeds and Scotland. However, we will only include effectiveness data (i.e., surveys and screening uptake) from those who meet the study eligibility criteria. The intervention will be a peer-led, multidimensional community workshop. It will incorporate multiple components that tackle barriers to screening and that are present in the existing IMCAN and PROCAN-B interventions, if the PICE group believe these are helpful, such as health education about breast, cervical, bowel and AAA screening delivered by a healthcare provider with an opportunity to ask questions, personal testimonials through survivors' stories, as well as members of the community discussing experiences of screening, and utilising community and peer support and religious leaders.
218865451|NCT06980493|DRUG|Amphotericine in liposome (Ambisome®)|The aim of the study will be to evaluate the efficacy and safety of topical amphotericin B solution in treatment of non-inflammatory type of tinea capitis after resistant response to oral systemic treatment
218865452|NCT06657378|OTHER|No Intervention|This is a non-interventional study.
218865453|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
218865454|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
218865455|NCT06980363|DRUG|traditional inferior alveolar nerve block by articaine|use articaine for inferior alveolar nerve block with buccal infiltration to anesthetized lower molar teeth
218865456|NCT06980363|DRUG|hyaluronidase plus articain buccal infilteration|use of articain plus hyaluronidase enzyme buccal infiltration to anesthetized lower molar teeth
218865457|NCT07042087|BEHAVIORAL|Mindfulness Yoga|A structured 9-month program integrating physical yoga postures (asanas), breathing techniques, sound, and meditation. Sessions are conducted twice weekly (90 minutes each) and focus on enhancing physical health, stress regulation, and cognitive performance. Delivered by certified instructors.
218865458|NCT07042087|BEHAVIORAL|Time-Restricted Eating with nutritional counseling promoting a flexitarian dietary pattern|Participants follow a 16:8 time-restricted eating schedule (16 hours fasting / 8 hours eating window) for 9 months, with nutritional counseling promoting a flexitarian dietary pattern. The intervention is designed to support metabolic health and reduce risk factors for neurodegeneration.
218865459|NCT07042087|BEHAVIORAL|Cognitive Training|A 9-month structured program of twice-weekly cognitive training sessions (90 minutes each), targeting memory, attention, executive function, and social cognition using both paper-based and computer-based tasks. Supervised by trained therapists.
219481427|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
219481428|NCT03290976|OTHER|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
219481429|NCT03290976|OTHER|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
219481430|NCT06488469|BEHAVIORAL|Psychological Interventions for children and adolescents|"Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets"
219481431|NCT04484987|OTHER|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
219481432|NCT04484987|OTHER|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
218865460|NCT07042087|BEHAVIORAL|Stretching|A twice-weekly stretching routine performed over 9 months (90-minute sessions), led by physiotherapists. This intervention provides low-intensity physical activity to control for physical engagement across study arms.
218865461|NCT07041086|PROCEDURE|Extracorporeal membrane oxygenation (ECMO)|In extracorporeal membrane oxygenation (ECMO), blood is pumped outside of the body to a heart-lung machine. The machine removes carbon dioxide and sends oxygen-rich blood back to the body. Blood flows from the right side of the heart to the heart-lung machine. It's then rewarmed and sent back to the body.
219481433|NCT03944798|OTHER|Frequency: Every 3 Months|every 3 months
219481434|NCT03944798|OTHER|Frequency: Every 6 Months|every 6 months
219481435|NCT03944798|OTHER|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
219481436|NCT03944798|OTHER|Imaging Modality: Chest CT|Chest computed tomography (CT)
219481437|NCT04242264|OTHER|Placebo|0.9% Sterile Normal Saline, USP
219481438|NCT04242264|BIOLOGICAL|Shigella sonnei strain 53G|1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
218865462|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
218865463|NCT07042074|BEHAVIORAL|Augmented Reality (AR) / Virtual reality (VR) Exposure Therapy + Cognitive Behavioral Therapy (CBT) Exposure Therapy|AR/VR (Apple Vision Pro or Meta Quest 3) will be used together with Cognitive Behavioral Therapy (CBT) Exposure Therapy
218865464|NCT07042074|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Exposure Therapy|Participant will experience the traditional CBT exposure therapy only
218865465|NCT07040878|BEHAVIORAL|Antigravity Treadmill Training|Antigravity treadmill training uses air pressure to reduce effective body weight during walking, minimizing joint load while preserving gait mechanics. The 6-week intervention includes five sessions per week within a 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks. Unloading is progressively reduced: 60% support in weeks 1-2, 40% in weeks 3-4, and 20% in weeks 5-6, allowing gradual adaptation to full weight-bearing.
218865466|NCT07040878|BEHAVIORAL|Body Weight-Supported Treadmill Training|Body weight-supported treadmill training uses a harness-based system to partially offload body weight, promoting safe ambulation and gait normalization in early postoperative rehabilitation. The 6-week intervention includes five sessions per week within the 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks, depending on tolerance. The unloading level remains constant and is individually adjusted to ensure safety.
218865467|NCT07040878|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilitation follows standard postoperative protocols after hip or knee arthroplasty. The 6-week program includes five weekly sessions. Gait training is conducted in hospital corridors under physiotherapist supervision, using assistive devices as needed (crutches, walkers). Daily therapy includes 120 minutes of kinesiotherapy (general exercises and gait training), 30 minutes of ergotherapy to improve functional independence, and three individualized physical therapy procedures (laser therapy, magnetic therapy, or electrotherapy) tailored to patient needs.
219021008|NCT07206927|OTHER|Qualitative Study: Semi-structured interview for patients|A semi-structured interview, lasting 20 to 30 minutes, will be conducted by the sociologist and anthropologist. They will use questionnaires (semi-structured interview grids), administered to patients face-to-face or by telephone. Patients will be interviewed only once. The interview grid includes the following sections: personal characteristics such as age, family and professional situation, municipality of residence, and knowledge of clinical research.
219021009|NCT07206927|OTHER|Quantitative Study : Healthcare professionals questionnaires|Questionnaires will be administered by email, in a single session, to healthcare professionals who have agreed to participate in the study.
219481439|NCT04242264|BIOLOGICAL|WRSs2|10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
219481440|NCT01016925|PROCEDURE|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
219481441|NCT02141373|DEVICE|Glubran 2|
219481442|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
219481443|NCT06370039|DRUG|INV-102|INV-102 Ophthalmic Solution
219481444|NCT06370039|DRUG|Vehicle|Vehicle Ophthalmic Solution
219481445|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
219481446|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
219481447|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
219598356|NCT06548178|DRUG|THP|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
219598357|NCT02931929|DRUG|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
219481448|NCT05948917|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
219481449|NCT02384200|DRUG|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
219481450|NCT02384200|DRUG|ampicillin|IV (2 g)
219598358|NCT06551766|DEVICE|Photosensitive hydrogel|In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
219598359|NCT06551766|DEVICE|6-0 absorbable stitches|In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
219598360|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
218865468|NCT07041593|OTHER|Inspiratory Muscle Training and Traditional Physiotherapy|Participants in this group will undergo inspiratory muscle training (IMT). The resistance to be applied at the start of IMT has been set at 30% of the maximum inspiratory pressure (MIP) value. The MIP value will be remeasured every week, and the training load will be updated according to 30% of the new value obtained. IMT will be carried out twice a week with a physiotherapist and on the remaining days as a home programme, for a total of eight weeks, five days a week, 15 minutes a day. Participants in the experimental group will receive traditional physical therapy treatments for cerebral palsy in the same manner as the control group. In this context, traditional physical therapy methods based on neurodevelopmental principles will be applied and designed according to the individual's needs.
218865469|NCT07041593|OTHER|Traditional Physiotherapy|Participants in the control group will undergo a neurodevelopmental-based traditional physiotherapy programme for 8 weeks, with two 40-minute sessions per week under the supervision of a physiotherapist; on other days, they will be asked to continue the exercises taught to their families at home.
218865470|NCT07041073|DEVICE|Active swLORETA Z-score Neurofeedback|Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
218865471|NCT07041073|DEVICE|Yoked-sham swLORETA Z-score Neurofeedback|"Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group (yoked design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding."
218865472|NCT07041827|DIAGNOSTIC_TEST|Cardiovascular assessment|A cardiovascular assessment will be performed to screen for (sub)clinical cardiovascular diseases and to compare the prevalences in survivors of non-Hodgkin lymphoma and a control group.
218865473|NCT07041190|DRUG|Abrysvo|Maternal RSV Vaccine (MV). RSV bivalent recombinant vaccine with subgroup A and B stabilised prefusion F antigens, single intramuscular injection of 0.5 mL, administered once, in pregnancy.
218865474|NCT07041190|DRUG|Nirsevimab|Infant RSV monoclonal antibody (mAb). For infants \<5kg: 50mg (0.5mL in pre-filled syringe), for infants ≥5kg: 100mg (1mL in pre-filled syringe), administered as a single intramuscular injection.
218865475|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
218865476|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
218865477|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
218865478|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
218865479|NCT00970450|DRUG|Placebo|Saline
218865480|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
219481451|NCT02384200|DRUG|gentamicin|IV (5 mg/kg)
219481452|NCT02384200|DRUG|vancomycin|IV (1 g)
219481453|NCT02384200|DRUG|ceftriaxone|IV (2 g)
219481454|NCT05097066|PROCEDURE|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
219598361|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
219598362|NCT03179423|DRUG|GNbAC1|Monthly IV repeated dose
219598363|NCT03179423|DRUG|Placebo|Monthly IV repeated dose
219598364|NCT00775125|DRUG|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
219598365|NCT03106987|DRUG|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
218865481|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
218865482|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
218865483|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
218865484|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219481455|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
219481456|NCT06219499|OTHER|Placebo|Placebo
219481457|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
219481458|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
219598366|NCT03106987|DRUG|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
219598367|NCT04368351|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
218865485|NCT06876896|DEVICE|Accuryn Foley catheter device|Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation
219481459|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
219481460|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
219481461|NCT02014428|DRUG|Placebo|
219481462|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
219481463|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
219481464|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
219481465|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
219481466|NCT02116309|DRUG|Rectal Indomethacin|
219598368|NCT04368351|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
218865486|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
218865487|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
218865488|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
218865489|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
218865490|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
218865491|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
218865492|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
218865493|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
218865494|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
218865495|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
218865496|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
218865497|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
218865498|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
219481467|NCT02116309|DRUG|Epinephrine|
219481468|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
219481469|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
219021012|NCT07207109|OTHER|Test: Follow-on formula with synbiotics|Intervention description: both products are nutritionally complete follow-on formulas
219021013|NCT07207109|OTHER|Control: Regular follow-on formula|Intervention description: both products are nutritionally complete follow-on formulas
219021014|NCT07206472|DRUG|Combination of bempedoic acid and ezetimibe|No drug was administered in this observational study.
219481470|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
219481471|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
219481472|NCT02185820|DRUG|Carfilzomib|
219481473|NCT02185820|DRUG|Pomalidomide|
219481474|NCT02185820|DRUG|Dexamethasone|
219598369|NCT04368351|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
219598370|NCT05931653|OTHER|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
219481475|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
219481476|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
219481477|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
219481478|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
219481479|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
219481480|NCT02206100|DRUG|enoxaparin|
219481481|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
219481482|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
219481483|NCT00848965|DRUG|Placebo|Placebo comparator
219481484|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
219481485|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
219481486|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
219481487|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
219481488|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
219481489|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
219481490|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
219481491|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
219481492|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
219481493|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
219481494|NCT03005717|DRUG|LIPO-202|
219481495|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
219481496|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
219481497|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
219481498|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
219481499|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
219481500|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
219481501|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
219481502|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
219481503|NCT00578448|DRUG|Belatacept|IV infusion
219481504|NCT02129257|DRUG|AFLIBERCEPT|
219481505|NCT02129257|DRUG|Irinotecan|
219481506|NCT02129257|DRUG|5-Fluorouracil|
219481507|NCT02129257|DRUG|Folinic Acid|
219481508|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
219481509|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
219481510|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
219481511|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
219481512|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
219481513|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
219481514|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
219481515|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
219481516|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
219481517|NCT02041182|BEHAVIORAL|Pre-Visit Questionnaire|
219481518|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
219481519|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
219481520|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
219481521|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
219481522|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
219481523|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
218865499|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
218865500|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
218865501|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
219021015|NCT07202026|BEHAVIORAL|Patient-centered Decision Aid to support long-term opioid therapy tapering|Earlier aims of this study developed a patient-centered Decision Aid (DA) that uses stories of people who benefited from discontinuing and clear explanations of evidence for key choices to decrease stigma; empower patients; increase engagement and productive interaction with providers in decision making; and reduce fear, anger and anxiety about tapering. The DA will be designed to support conversations that providers often find challenging and help providers maintain patient trust and satisfaction. Participants in the pilot test will be asked to: 1) complete a pre-DA survey, 2) review the DA, 3) have a guided conversation with a trained study interventionist with a behavioral health background who is trained on how to use the DA, and 4) complete a post-DA survey.
219021016|NCT07207317|PROCEDURE|Laparoscopic ileocecal-reconstruction right hemicolectomy (LIRRH)|The ileocolic vessels are divided at their roots, and lymph nodes of stations 203, 202, and 201 are dissected. The right colic and middle colic vessels are also divided at their roots, and the surrounding lymphatic and adipose tissue (stations 211/212/213 and 221/222/223) is cleared. The transverse colon is transected 10 cm distal to the tumor, and the ileum is divided 10 cm proximal to the ileocecal region. After tailoring the ileal mesentery, an end-to-end ileo-transverse colonic anastomosis is performed. Using a seromuscular suture, the ileum and its tailored mesentery are invaginated into the wall of the transverse colon 2 cm proximal to the anastomosis, thereby reconstructing the ileocecal valve complex.
219021017|NCT07207317|PROCEDURE|traditional laparoscopic right hemicolectomy (TRH)|The ileocolic vessels are divided at their roots, and lymph nodes of stations 203, 202, and 201 are dissected. The right colic and middle colic vessels are likewise divided at their roots, and the surrounding lymphatic and adipose tissue (stations 211/212/213 and 221/222/223) is cleared. The transverse colon is transected 10 cm distal to the tumor, and the ileum is divided 10 cm proximal to the ileocecal junction. An end-to-side or side-to-side ileo-transverse colonic anastomosis is then performed.
219481524|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
219481525|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
219481526|NCT06542445|DRUG|Oral CBD oil enriched with terpenes|"Stage I dosing, increasing titration:~days 1-2: 2.5 mg/kg BW/day; days 3-4: 5 mg/kg BW/day; day 5-7: 7.5 mg/kg BW/day; days 8-35: 10 mg/kg BW/day.~Stage II dosing, increasing titration:~days 36-37: 2.5 mg/kg BW/day; days 38-39: 5 mg/kg BW/day; day 40-42: 7.5 mg/kg BW/day; days 43-70:10 mg/kg BW/day."
219481527|NCT06542445|DRUG|Oral Placebo|Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
219481528|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
219613568|NCT05743257|BEHAVIORAL|air and noise|Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
218865502|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
218865503|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
218865504|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
219481529|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
218865505|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
219481530|NCT06043219|OTHER|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
219481531|NCT06043219|OTHER|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
218865506|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
219598371|NCT05931653|OTHER|Proprioceptive training along with and Multimodal Physical therapy|"* Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2\. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
219021019|NCT07206576|DEVICE|a percussion massage gun|"Participants assigned to the intervention group will receive a single session of percussion massage therapy (PMT) using the Compex® Fixx™ 2.0 handheld device. The treatment will be applied bilaterally to three major muscle groups: gluteus maximus, quadriceps femoris, and gastrocnemius.~The device will operate at a high intensity setting (Level 4) with a frequency of 41.7 Hz.~A wedge-shaped applicator head will be used to ensure consistent pressure across the treatment area.~Each muscle group will be treated for 3 minutes, following a standardized linear stroke pattern from proximal to distal and back.~The total duration of the intervention will be approximately 18 minutes.~The intervention will be performed once, immediately before the post-test evaluations, and aims to assess acute effects on neuromuscular performance."
219481532|NCT06043219|OTHER|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
219481533|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
219481534|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
219481535|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
219481536|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
219481537|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
219481538|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
219481539|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
219481540|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
219481541|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
219481542|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
219481543|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
219481544|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
219481545|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
219481546|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
219481547|NCT01550354|DRUG|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
219481548|NCT01550354|DRUG|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
219021020|NCT07206251|BEHAVIORAL|Foiled Windowed room (foil added)|Foiled Windowed room (foil added)
219481549|NCT01550354|DRUG|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
219481550|NCT01335620|DRUG|Raltegravir|400 mg twice daily
219481551|NCT01335620|DRUG|Tenofovir|245 mg once daily
219481552|NCT01335620|DRUG|Emtricitabine|200mg once daily
219481553|NCT02951182|DRUG|TEZ|
219481554|NCT02951182|DRUG|IVA|
219481555|NCT02951182|DRUG|VX-440|
219481556|NCT02951182|DRUG|Matched Placebo|
219481557|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
219481558|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
219481559|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
218865507|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
218865508|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
218865509|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
218865510|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
219481560|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
219481561|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
219481562|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
219481563|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
219481564|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
219481565|NCT04257773|BEHAVIORAL|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
219598372|NCT06633094|OTHER|Educational videos|Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
219598373|NCT00275574|PROCEDURE|acupuncture|acupuncture
219598374|NCT04495335|DEVICE|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
218865511|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
219598375|NCT02827695|BEHAVIORAL|SMASK|Medication adherence and BP monitoring
218865512|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
218865513|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
218865514|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
218865515|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
218865516|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
218865517|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
218865518|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
219598376|NCT02827695|BEHAVIORAL|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
219598377|NCT00437918|DRUG|nateglinide|
218865519|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
219481566|NCT00236730|DRUG|topiramate|
219481567|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
219481568|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
219598378|NCT00437918|DRUG|acarbose|
219598379|NCT02392949|BEHAVIORAL|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
219598380|NCT02392949|OTHER|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
219598381|NCT04272749|BEHAVIORAL|Assess opinons on the milk beverages|Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
219598382|NCT01867203|OTHER|Genotyping|DNA extraction from blood
219481569|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
219481570|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
219598383|NCT00979199|OTHER|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
219598384|NCT02268578|DEVICE|Transcranial Direct Current Stimulation|2mA tDCS
218865520|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
218865521|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
219481571|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
219598385|NCT02268578|PROCEDURE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
219598386|NCT03566615|DEVICE|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
219598387|NCT03566615|DEVICE|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
219598388|NCT03566615|OTHER|water|using water instead of traditional air insufflation to help insertion
218865522|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
218865523|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
218865524|NCT00343863|DRUG|cyclophosphamide|Given orally
219021023|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients with vascular dementia|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
219199745|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
219481572|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
219598389|NCT02114385|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
219598390|NCT02114385|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
219598391|NCT05296863|COMBINATION_PRODUCT|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
219598392|NCT05296863|COMBINATION_PRODUCT|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
219598393|NCT05296863|COMBINATION_PRODUCT|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
219598394|NCT04204057|DRUG|Tenalisib|Tenalisib 800 mg BID, Orally
218865525|NCT00343863|DRUG|dexamethasone|Given orally or IV
218865526|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
218865527|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
218865528|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
218865529|NCT00343863|PROCEDURE|management of therapy complications|Given IV
218865530|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
218865531|NCT00343863|OTHER|survey administration|Ancillary studies
219481573|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
218865532|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
218865533|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
218865534|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
218865535|NCT04790487|DRUG|Placebo|Saline
218865536|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
218865537|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
218865538|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
219481574|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219481575|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
219481576|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
219481577|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
219481578|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
219481579|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
219481580|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
219481581|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
219481582|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
219481583|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
219481584|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
219481585|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
218865539|NCT00005056|DRUG|bryostatin 1|
219199746|NCT06494098|PROCEDURE|Nasoalveolar Molding|presurgical orthopedics
219199747|NCT06494098|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch and nose
219199748|NCT06656169|DRUG|Subcutaneous polyvidone collagen|Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
219481586|NCT02992808|DRUG|recombinant gonadotropins|
219481587|NCT02992808|DRUG|HP-HMG|
219481588|NCT01995656|DRUG|Placebo - Capsule|Administered orally
219481589|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
219481590|NCT01995656|DRUG|Placebo - Solution|Administered orally
219481591|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
219481592|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
219481593|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
219481594|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
219481595|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
219481596|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
219481597|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
219598395|NCT01325844|PROCEDURE|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
219598396|NCT02229474|BEHAVIORAL|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
219598397|NCT02315274|OTHER|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
219598398|NCT01045330|BEHAVIORAL|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
219598399|NCT00972296|DEVICE|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
219598400|NCT05263310|BEHAVIORAL|Prepare for Your Diabetes Care|Educational video and Action Plan handout
219598401|NCT05263310|BEHAVIORAL|Usual Care|Control arm patients will continue with usual care
219598402|NCT01174043|DRUG|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
219598403|NCT00261781|BEHAVIORAL|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
219481598|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
219481599|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
219481600|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
219481601|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
219481602|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
219598404|NCT02049970|DRUG|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
219598405|NCT02049970|DRUG|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
218865540|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
219021024|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients with Alzheimer's disease|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
219199749|NCT06656169|OTHER|saline solution|administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
219481603|NCT06263543|DRUG|Sacituzumab govitecan|IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
219481604|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
219481605|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
219481606|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
219481607|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
219598406|NCT02470845|DRUG|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
219598407|NCT02470845|DRUG|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
219598408|NCT00053183|PROCEDURE|conventional surgery|
219598409|NCT00053183|RADIATION|brachytherapy|
219598410|NCT00053183|RADIATION|radiation therapy|
219598411|NCT00302445|DRUG|Efalizumab|
219598412|NCT00302445|DEVICE|Narrow Band Phototherapy|
219598413|NCT02646761|DEVICE|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
219598414|NCT02646761|OTHER|Standard of Care Physical Therapy|Physical therapy rehabilitation program
219481608|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
218865541|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
218865542|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
218865543|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
218865544|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
218865545|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
218865546|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
219199750|NCT06838572|PROCEDURE|Skin cooling to 20°C|According to the group, copper parts at a constant temperature of 20°C were placed on the superficial skin of the brachial plexus for 15 minutes.
219481609|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
219481610|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
219481611|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
219481612|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
219481613|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
219481614|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
219481615|NCT02416505|BEHAVIORAL|Verbal+Video|
219481616|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
219481617|NCT03253601|BEHAVIORAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
219481618|NCT03862469|PROCEDURE|Individualized laboratory test|Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
219199751|NCT06838572|PROCEDURE|Skin cooling to 15°C|According to the group, copper parts at a constant temperature of 15°C were placed on the superficial skin of the brachial plexus for 15 minutes.
219481619|NCT00775827|DRUG|fenofibrate 160 mg tablets|
219481620|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
219481621|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
219598415|NCT00448383|BIOLOGICAL|adalimumab|40mg every other week
218865547|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
218865548|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
218865549|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
218865550|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
218865551|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
218865552|NCT00313547|DRUG|Quinapril 40 mg|
219199752|NCT06838572|PROCEDURE|Skin cooling to 8°C|According to the group, copper parts at a constant temperature of 8°C were placed on the superficial skin of the brachial plexus for 15 minutes.
219481622|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
219481623|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
219598416|NCT00593905|DRUG|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
219598417|NCT00593905|DRUG|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
218865553|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
218865554|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
218865555|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
219199753|NCT06838572|PROCEDURE|No skin cooling|According to the group, copper parts at room temperature (23°C) were placed on the superficial skin of the brachial plexus for 15 minutes.
219199754|NCT06811558|BIOLOGICAL|Ixekizumab|injected with ixekizumab
219199755|NCT06811558|BIOLOGICAL|Secukizumab|injected with secukizumab
219481624|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
219481625|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
219481626|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
219481627|NCT04918095|DEVICE|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
219481628|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
219481629|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
219481630|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
219481631|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
219598418|NCT06501677|BEHAVIORAL|WBI|"The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness."
219598419|NCT03527953|OTHER|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
219199756|NCT06769568|DRUG|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
219199757|NCT06161584|DRUG|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
219199758|NCT05590455|DRUG|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
219199759|NCT04979455|OTHER|Core temperature monitoring|Core temperature will be monitored on the day of exercise
219199760|NCT04979455|BEHAVIORAL|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
219199761|NCT04979455|OTHER|Heart rate monitoring|Heart rate will be monitored on the day of exercise
218865556|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
218865557|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
218865558|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
218865559|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
218865560|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
218865561|NCT00096018|DRUG|fludarabine phosphate|Given IV
219481632|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
219481633|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
219481634|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
218865562|NCT00096018|DRUG|thalidomide|Orally
219481635|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
218865563|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
219199762|NCT04979455|OTHER|Urine collection|Urine samples will be collected at baseline and on the day of exercise
219199763|NCT04979455|OTHER|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
219481636|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
219481637|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
219481638|NCT01588678|DRUG|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
219481639|NCT02550509|DEVICE|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
219481640|NCT02550509|DEVICE|elastography|elastography to patient with stoke
219481641|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
219598420|NCT03527953|OTHER|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
218865564|NCT00252772|DRUG|Tesaglitazar|
218865565|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
218865566|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
218865567|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
218865568|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
218865569|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~\+ calcium 500 mg/cholecalciferol 400 IU x2/d"
218865570|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
218865571|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
219199764|NCT04979455|OTHER|Blood collection|Blood samples will be completed at baseline
219199765|NCT04979455|OTHER|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
219481642|NCT04138173|BEHAVIORAL|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
218865572|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
218865573|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
218865574|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
218865575|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
218865576|NCT03689712|DRUG|Placebo|60 minute IV infusion
218865577|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
218865578|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
219481643|NCT00039572|DRUG|boronophenylalanine-fructose complex|
219481644|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
219481645|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
219481646|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
219481647|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
219481648|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
219481649|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
219481650|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
219199766|NCT04979455|OTHER|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
219481651|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
219481652|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
219481653|NCT00939965|DRUG|isotretinoin|
219481654|NCT00939965|GENETIC|DNA analysis|
218865579|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
218865580|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
218865581|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
218865582|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
218865583|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
218865584|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
218865585|NCT00386555|DRUG|docetaxel|
219199767|NCT04979455|OTHER|Stool collection|Stool samples will be collected at baseline and on the day of exercise
219481655|NCT00939965|GENETIC|polymerase chain reaction|
218865586|NCT00386555|DRUG|CP-868,596 + docetaxel|
219481656|NCT00939965|OTHER|laboratory biomarker analysis|
219481657|NCT00939965|OTHER|pharmacological study|
219481658|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
219481659|NCT01188759|DRUG|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
219481660|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
219481661|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
219481662|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
219598421|NCT03527953|OTHER|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
219598422|NCT05547841|DEVICE|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
219598423|NCT02441660|DRUG|Capsaicin 8% Patch|Applied topically for 1 hour
219598424|NCT02441660|DRUG|Low Dose Capsaicin 0.025% Well Patch|
219598425|NCT03148665|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
219598426|NCT03486665|OTHER|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
219598427|NCT03486665|OTHER|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
219598428|NCT03002701|BEHAVIORAL|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
219199768|NCT06816225|OTHER|Actigraphy|Actigraphy is a validated complementary means of diagnosis, the gold standard for the assessment of circadian rhythm.
219481663|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
219481664|NCT05919069|DRUG|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
219481665|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
219481666|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
218865587|NCT00386555|DRUG|AG-013736 + docetaxel|
218865588|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
218865589|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
219199769|NCT06816225|OTHER|Schedule of Growing Skills II|Assessment scale for skills in child development from 0 to 6 years.
219481667|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
219481668|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
219481669|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
219481670|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
219481671|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
219481672|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
219481673|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
219481674|NCT02241200|DRUG|DA3880|
219481675|NCT02241200|DRUG|Aranesp|
219481676|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
218865590|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
218865591|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
219199770|NCT06816225|OTHER|Questionnaire Children Sleep habits|Questionnaire for assessing sleep habits, validated for the Portuguese population (4) which allows us to understand the sleep hygiene habits of the child
219481677|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
219481678|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
219481679|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
219481680|NCT04172727|DRUG|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
219481681|NCT04172727|DRUG|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
219481682|NCT04764669|DRUG|E2027|Oral hypromellose capsules.
218865592|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
219481683|NCT05875116|BEHAVIORAL|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
219481684|NCT05875116|BEHAVIORAL|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
219481685|NCT05875116|BEHAVIORAL|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
218865593|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
219481686|NCT01816334|DRUG|methylprednisolone|
218865594|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
218865595|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
219021025|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients not presenting dementia.|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
219199771|NCT06816225|OTHER|Melatonin evaluation|Melatonin will be measured in the first-morning urine and it is considered to be a good marker of plasma MLT level since its concentration is highly correlated with nocturnal plasma melatonin.
219199772|NCT06816511|PROCEDURE|magnetic resonance-guided focused ultrasound surgery, MRgFUS|Magnetic Resonance-Guided Focused Ultrasound Surgery The clinical symptoms, brain imaging, and cognitive function status were followed up for 2 years before and after surgery.
219199773|NCT06657690|DRUG|Irinotecan liposome|Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
219199774|NCT06657690|DRUG|S-1|S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
219481687|NCT01816334|DRUG|Ketoprofen|
219481688|NCT01816334|DRUG|Sodium Chloride|
219481689|NCT04776135|DRUG|MT-1186|Suspension
219481690|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
219481691|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
219481692|NCT02972086|BEHAVIORAL|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
219481693|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
219481694|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
219481695|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
219481696|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
219481697|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
219481698|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
219481699|NCT05355194|OTHER|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
219481700|NCT05355194|OTHER|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
219481701|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
219481702|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
219481703|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
219481704|NCT05914987|OTHER|Targeted Therapy|Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.
219481705|NCT02969473|DRUG|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
219481706|NCT02969473|DRUG|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
219481707|NCT04762771|DRUG|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
219481708|NCT01696227|DRUG|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
219481709|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
219481710|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
219481711|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
219481712|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
219481713|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
219481714|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
219598429|NCT03438292|DIETARY_SUPPLEMENT|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
219199775|NCT06657105|DRUG|EE/LNG|EE/LNG tablet will be administered orally.
219199776|NCT06657105|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
219481715|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
219481716|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
218865596|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
218865597|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
219481717|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
219481718|NCT00227591|DRUG|lenalidomide|Given orally (PO)
219481719|NCT00227591|DRUG|prednisone|Given PO
219481720|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
219481721|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
219481722|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
219598430|NCT03438292|DIETARY_SUPPLEMENT|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
219598431|NCT03438292|DIETARY_SUPPLEMENT|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
219481723|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
219598432|NCT04283422|DIAGNOSTIC_TEST|Biofire filmarray|"Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray"
218865598|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
218865599|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
218865600|NCT03793491|OTHER|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
219021026|NCT07205042|BEHAVIORAL|Supervised Walking Program|A structured walking program consisting of 30 minutes per session, 5 sessions per week, for 12 weeks at 55-65% of age-predicted maximum heart rate. Sessions will be supervised by an exercise physiologist, with adherence monitored by heart rate tracking and attendance logs. Participants will continue their standard levothyroxine treatment but will not begin any new structured exercise programs.
219481724|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
219481725|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
219199777|NCT06286800|DEVICE|Transcranial direct current stimulation (tDCS) with OT|Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.
219481726|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
219598433|NCT03685422|OTHER|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
219598434|NCT03399825|DEVICE|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
218865601|NCT03793491|OTHER|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
218865602|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
218865603|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
218865604|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
219481727|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
219481728|NCT02905695|DRUG|Chirocaine|
219481729|NCT02905695|OTHER|Placebo|
219481730|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
219481731|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
219481732|NCT04372810|PROCEDURE|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
219481733|NCT04372810|PROCEDURE|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
219481734|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
219481735|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
219481736|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
219481737|NCT01603927|DEVICE|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
218865605|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
219481738|NCT06021054|DRUG|Veligrotug (VRDN-001)|Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor
219481739|NCT06021054|DRUG|Placebo|5 IV infusions of placebo
219481740|NCT06662422|DEVICE|Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System|The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
219481741|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
218865606|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
218865607|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
218865608|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
218865609|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
218865610|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
218865611|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
218865612|NCT06905444|COMBINATION_PRODUCT|Myofascial Release Technique|"GROUP A (Multimodal Therapy) Group A was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Postural education like correct posture and forward head posture exercises like chin tuck in. Patient was sitting on chair. Therapist was standing on side of patient treated part. Strengthening exercises for the deep cervical flexors, shoulder blade stabilizers, and core muscles with 3 Sets of 3 repetitions with hold for 5 seconds of each exercise. Then breathing exercises for 1 minute. Then grade A (pain free range) cervical spine mobilization 1 Set of 3 repetition. During entire treatment session, the therapist kept close eye on patient's discomfort."
218865613|NCT06905444|COMBINATION_PRODUCT|Multimodal Therapy|Group B (Myofascial Release Technique) Group B was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Palpate the muscles and fascia to identify areas of restriction. Apply gentle, sustained pressure to the restricted area using the fingertips or knuckles for Fascial Unwinding. Hold the pressure for 3-5 minutes to allow the fascia to release. Encourage the patient to breathe deeply and slowly to promote relaxation. The stretching of tight muscles 1 set of 3 repetitions. Apply gentle, sustained pressure to release tension of these tight muscles, Suboccipital, Scalene, Pectoralis Major, Trapezius, Levator Scapulae
218865614|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
219481742|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
219481743|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
219481744|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
219481745|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
219481746|NCT05376293|BEHAVIORAL|Behavioral Internet program|The 12-week behavioral Internet program is designed to increase physical activity to recommended levels. Participants will be asked to plan and report aerobic exercise weekly, watch weekly video lessons, and complete brief weekly homework assignments.
219481747|NCT05376293|BEHAVIORAL|Informational newsletter condition|Newsletters will focus on the health benefits of regular physical activity, exercise safety, and will provide information on national exercise guidelines.
219481748|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
219481749|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
219481750|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
219481751|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
219481752|NCT06859359|OTHER|Hypertension Disorders of Pregnancy (HDP) Implementation Bundle|The HDP Implementation Bundle will consist of 4 main blocks namely; patient education, home BP monitoring, a contextualized follow-up protocol and provision of free anti-hypertensives if need. Collectively, these will lead to design and development of a contextualized home BP monitoring program.
219481753|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
219481754|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
218865615|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
218865616|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
218865617|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
218865618|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
218865619|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
218865620|NCT00005976|DRUG|carboplatin|
218865621|NCT00005976|DRUG|pyrazoloacridine|
218865622|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
218865623|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
218865624|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
218865625|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
218865626|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
218865627|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
218865628|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
218865629|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
218865630|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
219199778|NCT06286800|DEVICE|Sham tDCS with OT|Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.
219481755|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
219481756|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
219481757|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
219481758|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
219481759|NCT02908191|DRUG|ABI-H0731|
219481760|NCT02908191|DRUG|Placebo for ABI-H0731|
219481761|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
219481762|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
219481763|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
219481764|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
219481765|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
218865631|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
218865632|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
218865633|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
218865634|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
219598435|NCT05086263|DEVICE|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
219481766|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
218865635|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
218865636|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
218865637|NCT05203159|OTHER|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
218865638|NCT05203159|OTHER|Routine|No sound will be played before, during and after the ROP examination.
218865639|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
218865640|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
218865641|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
218865642|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
218865643|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
219481767|NCT01826929|OTHER|Therapeutic education|
219481768|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
219481769|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
219481770|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
219481771|NCT02183168|DRUG|Meloxicam suppository|
219481772|NCT02183168|DRUG|Meloxicam tablet|
219598436|NCT04600258|DIETARY_SUPPLEMENT|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
219598437|NCT05489666|DIETARY_SUPPLEMENT|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
218865644|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
218865645|NCT00004864|DRUG|GEM 231|
218865646|NCT00004864|DRUG|docetaxel|
218865647|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
218865648|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
218865649|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
218865650|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
218865651|NCT06243055|OTHER|questionnare|laval questionnare
218865652|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
218865653|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
218865654|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
218865655|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
219199779|NCT04966637|OTHER|COPD cohort|as this a retrospective descriptive study no intervention will be administered to study participants
219481773|NCT02183168|DRUG|Indomethacin|
219481774|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
219481775|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
219481776|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
219481777|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
219481778|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
219481779|NCT05838755|DRUG|GSK3858279|GSK3858279 will be administered
219481780|NCT05838755|DRUG|Placebo|Placebo will be administered
219598438|NCT05489666|DIETARY_SUPPLEMENT|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
219481781|NCT06722950|DRUG|CAPEOX|CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
218865656|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
218865657|NCT02674425|DEVICE|Dark Adaptometer|
218865658|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
218865659|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
219481782|NCT06722950|DRUG|Placebo|Placebo：3 times a day (daily), taken with boiled water.
219481783|NCT06722950|DRUG|AC591|AC591 : 3 times a day (daily), taken with boiled water.
219481784|NCT06722911|DRUG|Nimotuzumab|Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
219481785|NCT06722911|DRUG|AG|Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
219481786|NCT06723964|DRUG|AP505|AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
219481787|NCT06723548|DRUG|Telitacicept|Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
219481788|NCT06925646|PROCEDURE|Finger hyperperfusion via adenosine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be increased by brachial artery infusions of adenosine administered at 6.25 mcg/100ml tissue per minute for 30 minutes into the brachial artery to increase blood flow by 5 to 10-fold."
219481789|NCT06925646|PROCEDURE|Finger hypoperfusion via by norepinephrine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be decreased to \~25% of baseline, by infusing norepinephrine at 4 ng/100ml of tissue per minute for 30 minutes."
219481790|NCT06925646|PROCEDURE|Baseline hypoxic test|Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.
219481791|NCT07047443|DRUG|SHR- A1811|HER2 ADC
219481792|NCT07047924|DEVICE|MCOK-01|The investigational device is a Rigid Gas Permeable contact lenses for orthokeratology. MCOK-01 applied the reverse geometry design and adopted the lens material which possesses the highest oxygen permeability among all the materials for orthokeratology lens.
219598439|NCT00582010|DRUG|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
219598440|NCT00582010|DRUG|nitrogen gas|inhaled
219598441|NCT03596138|OTHER|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
219598442|NCT00792350|DRUG|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
219598443|NCT05579002|OTHER|Questionnaires and tests|"Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1\) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
218865660|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
218865661|NCT00088283|DRUG|pegaptanib sodium|
218865662|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
218865663|NCT02124954|DRUG|TA-8995|
219481793|NCT07047742|DIETARY_SUPPLEMENT|lemon juice|in this study for the first arm fresh lemon juice two times daily is advised
219481794|NCT07047742|DIETARY_SUPPLEMENT|Roselle|for the second arm Roselle tea is advised tow times per day
219481795|NCT07047742|OTHER|Education on urolithiasis management|all the arms except control group receive education about urolithiasis management
219481796|NCT07047625|BEHAVIORAL|control group (Routine nursing)|the implementation of routine treatment and nursing measures, including (1) Monitoring vital signs: according to the condition of vital signs change detection, found abnormal, timely notify the doctor, comply with medical treatment, observe the curative effect. (2) Relieve pain: tell patients the method of distraction, follow the doctor's advice, and observe the curative effect. (3) Improve disease awareness: Inform patients or family members of disease-related knowledge, examination, diagnosis and treatment, surgery and other purposes, significance and precautions. (4) Ensure patient safety: strengthen safety education, strict three check seven pairs, bed placed a variety of safety warning signs. (5) Avoid the occurrence of unexpected risks: guide patients and their families to prevent burns, trauma, etc. (6) Prevention of infection: strict implementation of disinfection and isolation system, the implementation of hand hygiene norms, reduce visits. (7) Raise the affected limb, early f
219481797|NCT07047625|BEHAVIORAL|Experimental group （Health education path）|On the basis of the control group, the health education path nursing program was adopted. The specific intervention measures were as follows: ① A program implementation team was set up, including 2 urologists, 2 nurses and 1 psychological counselor. All members have received relevant professional training; ②Two nurses were the main liaisons for the intervention and were responsible for monitoring the treatment and nursing of patients throughout the course. The workflow was as follows: starting from the patient's discomfort experience, the patient was managed according to the nursing procedure steps. By assessing the patient's existing discomfort symptoms, interventional cognitive intervention and psychological intervention, and based on the intervention plan proposed in this study, a health education path nursing plan was developed for patients from the aspects of diet, liquid intake, position adjustment, and symptomatic intervention (see Table 1). In the process of intervention, feedb
219481798|NCT07046988|DRUG|Terbinafine Tablets|"Oral administration once daily:~For patients weighing \<20 kg: 62.5 mg qd; For patients weighing 20-40 kg: 125 mg qd; For patients weighing \>40 kg: 250 mg qd; Total 8 weeks."
219481799|NCT06724354|OTHER|The Surgical Site Infections Precaution Package Form includes the parameters that should be applied to patients before, during and after surgery.|Surgical site infections are a preventable cause of morbidity following surgical procedures. Strategies to reduce SSI rates should address preoperative, perioperative and postoperative factors, and multiple interventions can be combined into 'bundles'. Adoption of these measures may reduce SSIs, but this is dependent on a high level of package compliance. The aim of this study was to evaluate the change in SSI rates after the implementation of the SSI prevention package after neurosurgical operations. It is thought that if the results of our study are positive, the package form created will be pioneered for use in other patient groups. In addition, reducing SSI rates will shorten the postoperative recovery time of patients and reduce hospital costs.
219481800|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
219481801|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
219481802|NCT06903975|DRUG|prabotulinumtoxinA-xvfs|Each participant will receive 60 units (U) of prabotulinumtoxinA-xvfs into each SCM for a total of 120 U. Participants will return in 2 weeks to determine if any touch-up injection is needed.
219598444|NCT03955003|BEHAVIORAL|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
218865664|NCT02124954|DRUG|Midazolam|
218865665|NCT02124954|DRUG|Digoxin|
218865666|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
218865667|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
218865668|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
218865669|NCT00140699|BEHAVIORAL|Balance|
218865670|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
218865671|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
218865672|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
218865673|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
218865674|NCT02196480|BIOLOGICAL|anti-TNF|Anti-tumor necrosis factor therapy
218865675|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
218865676|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
218865677|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
218865678|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
218865679|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
219481803|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
219481804|NCT06942546|DEVICE|Wrist orthosis|The wrist orthosis referred in this study is two different prefabricated (of the shelf) types; a semi-rigid orthosis in elastic fabric with a volar splint or a short elastic wrist orthosis without a splint. Both ment to be worn when the person use the hand in everyday occupation.
219481805|NCT06941623|DIAGNOSTIC_TEST|Ultrasonography of gastric residual volume|Gastric ultrasound will be performed by the radiologist on each participant before the study and at 0, 10, 20, 30, 60, 90, 120 minutes after drinking in the position of head upright 45 degree with left lateral decubitus to evaluate the gastric residual volume and time to empty gastric antrum. If time to empty gastric antrum is extended, ultrasound will be serial performed at 150 and 180 minutes.
219481806|NCT06941623|DIAGNOSTIC_TEST|Point-of-care testing of glucose|We will perform the point-of-care test of glucose before the study and at 60, and 120 minutes after drinking.
219481807|NCT06941623|OTHER|Hunger numeric rating scale|Hunger will be measured by a numeric rating scale(NRS) before drinking, 60 and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of hunger levels, defined by numbers from 0 to 10, where 0 represents the lowest level of hunger and 10 represents the highest.
219481808|NCT06941623|OTHER|Thirst numeric rating scale|Thirst will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of thirst levels, defined by numbers from 0 to 10, where 0 represents the lowest level of thirst and 10 represents the highest.
218865680|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
219481809|NCT06941623|OTHER|Nausea numeric rating scale|Nausea will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of nausea levels, defined by numbers from 0 to 10, where 0 represents the lowest level of nausea and 10 represents the highest.
219481810|NCT06942403|OTHER|Associated product 1 : RV2666C|Applied twice a day minimum during 7 days (from Day 1 to Day 7)
219481811|NCT06942403|OTHER|Associated product 2 MORNING : RV5000A|"Applied in the mornings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
219481812|NCT06942403|OTHER|Test product : RV4983A|"Applied once a day, at the evening. Avoid contact with eyes. If sensations of discomfort appear, allow more time between applications.~* From Day 8 to Day 95 (87 days) for post LASER and post peeling subjects~* From Day 8 to Day 176 (169 days) for post-injections subjects"
219481813|NCT06942403|OTHER|Associated product 2 EVENING: RV5000A|"Applied in the evenings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
219481814|NCT06941779|DEVICE|Cueing|Inertial sensors (via a smartphone worn on the lower back) will capture and analyze validated gait-related characteristics (via a gold-standard inertial system worn on both feet). Personalised auditory cues (via smartphone) will be examined for their ability to correct variable gait. To reduce burden on participants (i.e., minimal number of wearable sensors) and to streamline data capture and deliver auditory cues, a single smartphone and a gold standard reference (2 inertial wearables on each foot) will only be used. All devices attached over clothes via belt attachments.
219481815|NCT06942715|OTHER|Electric Induction Cookstoves|The intervention consists of high-quality, locally available electric induction cookstoves with one or two burners, each equipped with cloud-connected data loggers, and includes compatible cookware.
219481816|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
218865681|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
218865682|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
219199780|NCT06817109|DEVICE|interactive technological intervention for improvement of mental health symptoms in Primary Care users Health|Intervention based on cognitive and behavioral techniques, such as psychoeducation on anxiety, depression and insomnia; muscle relaxation and breathing techniques; sleep hygiene techniques, behavioral activation and mindfulness techniques
219598445|NCT03955003|OTHER|Attention Control|This is intended to control for time, place, and group affect.
219481817|NCT04846049|OTHER|Comprehensive Care|"1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration"
219481818|NCT04846049|OTHER|Standard Care|No intervention or treatment will be provided.
219481819|NCT05060913|DRUG|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
219481820|NCT05060913|DRUG|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
219481821|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
219481822|NCT00739206|DRUG|SAR97276A|Dose based on body weight
219481823|NCT02287142|PROCEDURE|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
219481824|NCT01826032|DEVICE|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
219481825|NCT01826032|OTHER|Standard care for OSA|sleep higiene and dietary counseling
219481826|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
219481827|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
218865683|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
218865684|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
218865685|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
218865686|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
218865687|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
219481828|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
219481829|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
219481830|NCT03939728|RADIATION|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
219481831|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
219481832|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
219481833|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
219481834|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
219481835|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
219481836|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
219481837|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
219481838|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
219481839|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
219481840|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
218865688|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
219481841|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
219481842|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
219481843|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
219481844|NCT02087865|DRUG|donepezil HCL|
218865689|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
219481845|NCT02087865|DRUG|Placebo|
219481846|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
219481847|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
219481848|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
219481849|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
219481850|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
219481851|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
219481852|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
219481853|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
219481854|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
219481855|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
219481856|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
219481857|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
219481858|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
219481859|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
218865690|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
218865691|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
218865692|NCT05329870|OTHER|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
218865693|NCT06505486|DRUG|Gemcitabine-Oxaliplatin Regimen|Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
218865694|NCT04861428|OTHER|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
218865695|NCT04861428|OTHER|Smoking as Usual|Cigarette smoking
218865696|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
219481860|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
219481861|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
219481862|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
219481863|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
219481864|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
219481865|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
219481866|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
219481867|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
219481868|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
219481869|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
219598446|NCT05382403|DEVICE|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
219598447|NCT05382403|OTHER|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
219598448|NCT00601575|DRUG|Lithium|
218865697|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
218865698|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
218865699|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
219481870|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
219481871|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
219481872|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
219481873|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
219481874|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
219598449|NCT04049136|DIAGNOSTIC_TEST|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
219598450|NCT00086593|DRUG|lamotrigine|
219598451|NCT04679493|DRUG|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
219598452|NCT04679493|DRUG|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
219598453|NCT04679493|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
218865700|NCT05418595|OTHER||
218865701|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
218865702|NCT01479582|DRUG|Access to unlicensed cord blood units|
219199781|NCT06857201|PROCEDURE|Left Bundle Branch Area Pacing|LBBAP is performed during permanent pacemaker implantation post-TAVR.
219199782|NCT06857201|PROCEDURE|Right Ventricular Pacing|RVP is performed during permanent pacemaker implantation post-TAVR.
219598454|NCT04679493|DRUG|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
219598455|NCT04679493|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
218865703|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
218865704|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
219481875|NCT04028570|RADIATION|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
219481876|NCT03829527|BEHAVIORAL|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
219481877|NCT05058027|DEVICE|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
219481878|NCT05058027|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
219481879|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
219481880|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
219481881|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
219598456|NCT04316793|OTHER|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
219598457|NCT04316793|OTHER|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
219598458|NCT03903211|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
219598459|NCT01159561|BIOLOGICAL|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
219598460|NCT00333151|DRUG|liraglutide|
219598461|NCT00333151|DRUG|rosiglitazone|
219598462|NCT00333151|DRUG|metformin|
219598463|NCT05035277|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
219481882|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
218865705|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
218865706|NCT02787590|DRUG|Simvastatin|
218865707|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
218865708|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
218865709|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
218865710|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
218865711|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
218865712|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
218865713|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
218865714|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
218865715|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
218865716|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
218865717|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
219481883|NCT01392469|DRUG|Sildenafil|Oral Administration
219481884|NCT01392469|DRUG|Bosentan|Oral Administration
218865718|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
218865719|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
218865720|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
218865721|NCT00316888|BIOLOGICAL|cetuximab|Given IV
218865722|NCT00316888|DRUG|cisplatin|Given IV
219481885|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
219481886|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
219481887|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
219481888|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
219481889|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
219481890|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
219481891|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
218865723|NCT00316888|DRUG|fluorouracil|Given IV
218865724|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
219481892|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
219481893|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
219481894|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
219481895|NCT03255226|DRUG|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
219481896|NCT05104268|DEVICE|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
219481897|NCT04686968|PROCEDURE|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
219598464|NCT05035277|DRUG|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
219598465|NCT05035277|DRUG|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
219481898|NCT04686968|PROCEDURE|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
219481899|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
219481900|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
219481901|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
219481902|NCT00511329|DRUG|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
219481903|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
219481904|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
219481905|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
219481906|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
219481907|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
219481908|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
219481909|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
219481910|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
219481911|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
219481912|NCT00003652|DRUG|cisplatin|
219481913|NCT00003652|DRUG|fluorouracil|
219481914|NCT00003652|PROCEDURE|neoadjuvant therapy|
219481915|NCT00003652|RADIATION|radiation therapy|
219481916|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
219481917|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
219481918|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
219481919|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
219481920|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
219481921|NCT05511805|OTHER|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
219481922|NCT05511805|OTHER|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
219598466|NCT05035277|DRUG|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
219598467|NCT02104115|OTHER|MRI scanners|
219598468|NCT02104115|OTHER|VAS Symptom scores|
219481923|NCT05511805|OTHER|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
219598469|NCT00486031|DRUG|Balsalazide Disodium|
219598470|NCT03092973|DIAGNOSTIC_TEST|Ultrasound|
219481924|NCT05511805|DEVICE|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
219481925|NCT05511805|DEVICE|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
219481926|NCT05511805|DEVICE|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
219481927|NCT05511805|DEVICE|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
219481928|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
219481929|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
219481930|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
219481931|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
219481932|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
219481933|NCT01261650|DEVICE|transcranial direct current stimulation|
219481934|NCT01261650|DEVICE|sham treatment|
219481935|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
219481936|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
219481937|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
219481938|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
219481939|NCT05645263|OTHER|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
219481940|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
218865725|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
218865726|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
218865727|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
218865728|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
219481941|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
219481942|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
219481943|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
219481944|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
219481945|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC\_ASC)
219481946|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
219481947|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
219481948|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
219481949|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
219481950|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
219481951|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
219481952|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
219481953|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
219481954|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
219481955|NCT02492152|DEVICE|Study group|Dianatal
219481956|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
218865729|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
218865730|NCT01972685|PROCEDURE|Transbronchial Biopsy|
218865731|NCT01972685|PROCEDURE|VATS biopsy|
218865732|NCT02177409|DRUG|Telmisartan|
218865733|NCT02177409|DEVICE|Amlodipine|
218865734|NCT02177409|DRUG|Placebo|
218865735|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
218865736|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
218865737|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
218865738|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
218865739|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
218865740|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
218865741|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
218865742|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
218865743|NCT03254277|DRUG|Placebo|Placebo
218865744|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
219481957|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
219481958|NCT03476837|BEHAVIORAL|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
219481959|NCT03476837|BEHAVIORAL|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
219481960|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
219481961|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
219598471|NCT03763474|COMBINATION_PRODUCT|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
219598472|NCT06498167|DRUG|Upadacitinib|Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
219598473|NCT02806115|PROCEDURE|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
219598474|NCT02806115|DRUG|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
218865745|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
218865746|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
218865747|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
219481962|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
219598475|NCT02806115|DEVICE|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
219598476|NCT01161485|BEHAVIORAL|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
218865748|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
219481963|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
219481964|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
219481965|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
219481966|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
219481967|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
219481968|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
219481969|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
219481970|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
219481971|NCT03015207|DRUG|NNC0194-0499|
219481972|NCT03015207|DRUG|Placebo|
219481973|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
219481974|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
219481975|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
219481976|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
218865749|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
218865750|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
219481977|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
219481978|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
219481979|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
219481980|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
219481981|NCT04625907|RADIATION|radiotherapy|Ionising radiation
218865751|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
219481982|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
219481983|NCT03862807|DRUG|Patisiran|Patisiran was administered via IV infusion.
219481984|NCT03144115|DRUG|Oxytocin|
219481985|NCT03144115|DRUG|Placebos|
219481986|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
219481987|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
218865752|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
218865753|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
218865754|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
218865755|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
218865756|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
218865757|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
219481988|NCT00003861|OTHER|laboratory biomarker analysis|
219481989|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219481990|NCT04362761|DRUG|IVA|Tablet for oral administration.
219481991|NCT05595161|BEHAVIORAL|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
219481992|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
219481993|NCT04729504|BEHAVIORAL|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
219481994|NCT01771627|DRUG|varenicline|Given PO
219481995|NCT01771627|DRUG|nicotine patch|
219481996|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
219481997|NCT03486327|DRUG|BR55|A novel targeted ultrasound contrast agent
219481998|NCT02755727|PROCEDURE|Platelet Rich Plasma Injection|See Arms
219481999|NCT02755727|PROCEDURE|Open Surgical Release|See arms
219482000|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
219482001|NCT03126682|DRUG|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
219482002|NCT03770182|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
219482003|NCT05801094|DRUG|QL1604|QL1604 3 mg/kg Q3W
218865758|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
218865759|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
218865760|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
218865761|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
219482004|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
218865762|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
219482005|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
219482006|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
219482007|NCT03347929|DRUG|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
219482008|NCT03347929|DRUG|Placebo|10 days treatment with Placebo1 tablet twice daily
219482009|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
219482010|NCT00096473|DRUG|Donepezil hydrochloride|
219482011|NCT01534429|PROCEDURE|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
219482012|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
219482013|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
219482014|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
219482015|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
219482016|NCT02046239|PROCEDURE|Suture Group|
219598477|NCT01161485|BEHAVIORAL|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
218865763|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
218865764|NCT00185874|BIOLOGICAL|autologous dendritic cells|
218865765|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
218865766|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
218865767|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
218865768|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
218865769|NCT06917690|DRUG|Oleogel-S10|Topical gel
218865770|NCT02710942|BEHAVIORAL|SPHERE|
218865771|NCT02710942|BEHAVIORAL|PRISM|
219482017|NCT02046239|BIOLOGICAL|Staple Group (control)|
219482018|NCT02350439|DRUG|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
219482019|NCT03425773|BIOLOGICAL|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
219482020|NCT02817269|OTHER|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
219482021|NCT02817269|OTHER|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
219482022|NCT03065517|DEVICE|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
219482023|NCT03065517|DEVICE|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
219482024|NCT06247579|OTHER|Dietary polystyrene microplastics from disposable plastic tableware|Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
219482025|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
218865772|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
219482026|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
219482027|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
219482028|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
219482029|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
219482030|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
218865773|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
219482031|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
219482032|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
219482033|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
219482034|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
219598478|NCT01161485|BEHAVIORAL|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
219482035|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
219482036|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
219482037|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
219482038|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
219482039|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
219482040|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
219482041|NCT00836238|BEHAVIORAL|Interview|Physical Function and Symptom Assessment Interviews
219482042|NCT00836238|OTHER|Physical Function Tests|3 physical function tests.
219482043|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
219482044|NCT06079437|PROCEDURE|Cheer|Maximum isometric contraction was performed with cheering.
219482045|NCT06079437|PROCEDURE|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
219482046|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
219482047|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
219482048|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
219482049|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
219482050|NCT00107809|DRUG|Modafinil|
219482051|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
219482052|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
219482053|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
219598479|NCT03509857|DEVICE|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
219598480|NCT03509857|OTHER|No Intervention|No intervention
219598481|NCT05082740|OTHER|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
219482054|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
219482055|NCT05174273|BIOLOGICAL|Fecal Microbiota Transplantation|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
219482056|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
219482057|NCT01937546|PROCEDURE|Primary delivery of anterior shoulder|
218865774|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
218865775|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
219482058|NCT01937546|PROCEDURE|Primary delivery posterior shoulder|
219482059|NCT00249327|BEHAVIORAL|education|
219482060|NCT02525627|DEVICE|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
219482061|NCT02525627|DEVICE|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
219482062|NCT02525627|DEVICE|Symax stem|Orthopaedic implant
219482063|NCT02525627|DEVICE|Accolade TMZF stem|Orthopaedic implant
219482064|NCT01382680|DEVICE|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
219482065|NCT02416167|DRUG|FYU-981|
219598482|NCT01537939|BEHAVIORAL|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
219598483|NCT01098630|OTHER|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
219598484|NCT01098630|OTHER|Questionnaire Administration|Ancillary studies
219598485|NCT01371539|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
219598486|NCT01371539|DEVICE|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
219598487|NCT01009502|DRUG|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
219482066|NCT02416167|DRUG|Placebo|
219482067|NCT03746080|DRUG|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
219482068|NCT03746080|DRUG|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
219482069|NCT03746080|RADIATION|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
219482070|NCT03746080|RADIATION|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
219482071|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
219482072|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
219482073|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
219482074|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
219482075|NCT01473589|DRUG|Teriparatide|Administered by SC injection
219482076|NCT01473589|DRUG|Placebo|Administered by SC injection
218865776|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
218865777|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
218865778|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
219482077|NCT01473589|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
219482078|NCT01473589|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
219482079|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
219482080|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
219482081|NCT03178474|OTHER|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
219482082|NCT03178474|OTHER|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
219482083|NCT03178474|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
219482084|NCT04196439|PROCEDURE|continuous epidural analgesia|injection of local anaesthetic into epidural space
219482085|NCT04196439|PROCEDURE|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
219482086|NCT04440631|OTHER|no intervention, observational only|no intervention, observational only
219482087|NCT05752344|OTHER|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
218865779|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
218865780|NCT04518163|DRUG|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
218865781|NCT04518163|DRUG|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
218865782|NCT04518163|DEVICE|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
219482088|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
219482089|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
219482090|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
219482091|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
219482092|NCT03666819|DEVICE|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
219482093|NCT03666819|OTHER|Questionnaire Administration|Ancillary studies
219482094|NCT05354141|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219482095|NCT05354141|OTHER|Intravenous normal saline|Placebo
219482096|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
219482097|NCT06080503|RADIATION|LT-SABR|42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
219482098|NCT06080503|RADIATION|IMRT|63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
219482099|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
219482100|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
219482101|NCT00000423|BEHAVIORAL|Social support group|
219482102|NCT00000423|BEHAVIORAL|Social support and education group|
219482103|NCT03140527|DRUG|PTI-801|Active
219482104|NCT03140527|DRUG|Placebo|Placebo
219482105|NCT03140527|DRUG|PTI-808|Active
219482106|NCT03140527|DRUG|Placebo|Placebo
219482107|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
219482108|NCT03356431|OTHER|Supervised group exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
218865783|NCT04353700|BEHAVIORAL|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
219482109|NCT03356431|OTHER|Home-based exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
219482110|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
219482111|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
219598488|NCT02006602|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
219598489|NCT02006602|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
219598490|NCT06251089|DRUG|CPC mouthwash|0.07% CPC mouthwash
219598491|NCT06251089|DRUG|Placebo|placebo of the CPC mouthwash
219598492|NCT00294580|DRUG|Maloprim|
218865784|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
218865785|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
219598493|NCT03242525|DIAGNOSTIC_TEST|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
219598494|NCT04902014|BEHAVIORAL|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
219598495|NCT04902014|BEHAVIORAL|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
219598496|NCT04902014|BEHAVIORAL|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
219598497|NCT04902014|BEHAVIORAL|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
219598498|NCT00551512|DRUG|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
218865786|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
218865787|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
218865788|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
219482112|NCT01441401|DRUG|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
219482113|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
219482114|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
219482115|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
219482116|NCT04907994|OTHER|Cohort|Nothing. Only implementation of a cohort with data collection via the SNDS.
219482117|NCT00002074|DRUG|Fluconazole|
219482118|NCT00002074|DRUG|Amphotericin B|
219482119|NCT00339066|DRUG|Sertraline|
219598499|NCT01783912|BEHAVIORAL|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
219598500|NCT01783912|BEHAVIORAL|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
218865789|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
218865790|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
218865791|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
218865792|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
218865793|NCT02576860|DRUG|Vehicle|Vehicle gel
218865794|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
218865795|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
218865796|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
218865797|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
218865798|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
218865799|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
218865800|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
218865801|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
218865802|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
218865803|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
218865804|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
218865805|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
218865806|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
218865807|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
218865808|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
218865809|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
218865810|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
218865811|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
218865812|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
218865813|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
218865814|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
218865815|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
218865816|NCT00659503|DRUG|Placebo|placebo
218865817|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
218865818|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
218865819|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
219482120|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
218865820|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
218865821|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
218865822|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
218865823|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
218865824|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
218865825|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
219482121|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
219482122|NCT06319573|OTHER|Counseling Supported by Univfy® Report|The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
219482123|NCT06319573|OTHER|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
218865826|NCT04965961|DRUG|EPO|Please refer to the arm description
218865827|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
218865828|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
218865829|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
218865830|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
218865831|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
218865832|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
218865833|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
218865834|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
218865835|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
218865836|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
218865837|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
219482124|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
219482125|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
218865838|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
218865839|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
218865840|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
218865841|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
219482126|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
219482127|NCT01732666|DRUG|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
219482128|NCT01732666|DRUG|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
219482129|NCT01732666|DRUG|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
219482130|NCT03256526|DRUG|Placebo|0 mg
219482131|NCT03256526|DRUG|PF-06835919 Low Dose|75 mg once daily
219482132|NCT03256526|DRUG|PF-06835919 High Dose|300 mg once daily
219482133|NCT04177173|DRUG|Simvastatin 20 mg|improvement of disease activity
219598501|NCT01783912|DRUG|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
218865842|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
218865843|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
218865844|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
218865845|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
218865846|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
218865847|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
218865848|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
218865849|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
218865850|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
218865851|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
218865852|NCT00525824|DRUG|Ezetimibe|10 mg
219482134|NCT04177173|DRUG|Methotrexate 10 mg|improvement of disease activity
218865853|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
218865854|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
218865855|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
218865856|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
218865857|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
218865858|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
218865859|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
219482135|NCT04049448|DRUG|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
219482136|NCT03877848|DEVICE|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
219482137|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
219482138|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
219482139|NCT02985567|OTHER|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
219482140|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
219482141|NCT03328468|OTHER|Breathing Exercise|Breathing exercise for stroke patients
219482142|NCT03113201|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
219482143|NCT03113201|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
219482144|NCT05902767|OTHER|Nuts|"* A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines"
219482145|NCT05902767|OTHER|Control|\- Dietary counselling on how to follow the Australian Dietary Guidelines
219482146|NCT03469440|OTHER|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
219482147|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
219482148|NCT06704139|DRUG|Morphine - .25 mg|Fifty patients will receive intrathecal morphine
219482149|NCT06704139|DRUG|fentanyl + morphine|Fifty patients will receive intrathecal morphine and fentanyl
219482150|NCT06704139|DRUG|Ondansetron + Dexamethasone|All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
219482151|NCT01506986|DRUG|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
219482152|NCT01506986|DRUG|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
219482153|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil + boswellic acid supplement|This supplement contains frankincense essential oil and boswellic acid as its active ingredients.
219482154|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil supplement|This supplement contains frankincense essential oil as its active ingredient.
219482155|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
219482156|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
219482157|NCT04682210|DRUG|Sintilimab|Sintilimab 200mg IV Q3W
219482158|NCT04682210|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
219482159|NCT05533112|OTHER|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
219482160|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
219482161|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
219482162|NCT04950413|OTHER|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
219482163|NCT04950413|OTHER|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
219482164|NCT04950413|DEVICE|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
219598502|NCT01783912|BEHAVIORAL|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
219482165|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
219482166|NCT03080402|DEVICE|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
219598503|NCT02681510|DRUG|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
218865860|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
219482167|NCT00896038|DRUG|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
218865861|NCT03699137|OTHER|No interventions|No interventions
218865862|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
218865863|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
219482168|NCT00896038|DRUG|Placebo|Non-active placebo
219482169|NCT05138900|RADIATION|SBRT|SBRT for central non small cell lung cancer
219482170|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
218865864|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
219482171|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
219482172|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
219482173|NCT00390507|PROCEDURE|Post-tetanic count frequency|
219482174|NCT00185107|DRUG|Colesevelam Hydrochloride|
219482175|NCT00185107|DRUG|Ezetimibe|
219482176|NCT00185107|DRUG|Simvastatin|
219482177|NCT03032237|OTHER|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
219482178|NCT03032237|OTHER|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
219482179|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
219598504|NCT02681510|DRUG|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
219598505|NCT02681510|DRUG|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
218865865|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
218865866|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
218865867|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
218865868|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
218865869|NCT01694719|BEHAVIORAL|Cognitive Control Training|
218865870|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
218865871|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
218865872|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
218865873|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
218865874|NCT04728594|BEHAVIORAL|Social Proof|Email
218865875|NCT04728594|BEHAVIORAL|Reframing|Email
218865876|NCT04728594|BEHAVIORAL|Scarcity Message|Email
218865877|NCT00180167|DRUG|randomization between two established Chemotherapies|
218865878|NCT04665115|DRUG|Ibrutinib|Given PO
218865879|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
218865880|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
219482180|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
218865881|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
219482181|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
218865882|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
218865883|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
218865884|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
218865885|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
218865886|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
218865887|NCT00049777|DRUG|Unfractionated heparin|
218865888|NCT00049777|DRUG|Low molecular weight heparin|
218865889|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
219482182|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
218865890|NCT03817294|OTHER|Comparison of exercise training modalities|As above
218865891|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
218865892|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
218865893|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
218865894|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
218865895|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
219482183|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
219482184|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
219598506|NCT00079950|DRUG|Pegamotecan|
218865896|NCT00196768|DRUG|Arsenic trioxide|
218865897|NCT00196768|DRUG|Trisenox|
218865898|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
218865899|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
218865900|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
218865901|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
218865902|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
218865903|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
218865904|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
218865905|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
219482185|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
219482186|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
219482187|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
219482188|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
219482189|NCT03858920|DEVICE|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
219482190|NCT03858920|PROCEDURE|Low-dose non-contrast CT|CT scan as part of routine research care
219482191|NCT04965896|OTHER|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
219482192|NCT04965896|OTHER|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
219598507|NCT03991676|BEHAVIORAL|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
219598508|NCT03005665|DRUG|Acetazolamide|
219598509|NCT03005665|DRUG|Normal Saline|
219598510|NCT06501326|DRUG|Liraglutide|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
219598511|NCT06501326|DRUG|Orlistat|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
219598512|NCT01284010|GENETIC|DNA analysis|
219598513|NCT01284010|GENETIC|fluorescence in situ hybridization|
219598514|NCT01284010|GENETIC|gene expression analysis|
218865906|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
218865907|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
219482193|NCT06703827|BEHAVIORAL|The metacognitive training group|The MCT will consist of spending 90 minutes a week in a small online group setting working through a series of workshops. Participants will also be asked to complete homework each week and they will be supported with this. Interviews and questionnaires regarding symptoms and thinking errors will be used before and immediately after the intervention. The participants who attended the group and improved in their symptoms and thinking errors will be invited to an interview asking them what worked for them and how they found the group.
219482194|NCT00000227|DRUG|Buprenorphine|
219482195|NCT03088280|DRUG|Thymoglobulin|reduced dose (3mg/Kg)
219482196|NCT00001001|DRUG|Zidovudine|
219482197|NCT03925116|OTHER|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
219482198|NCT06648317|OTHER|FDG-PET|All study participants will undergo 18F-FDG PET/CT scan within 1 week
219482199|NCT06451679|OTHER|Observational|Observational prospective study
219482200|NCT00571909|PROCEDURE|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
219482201|NCT03112707|DRUG|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
219482202|NCT03112707|DRUG|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
218865908|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
218865909|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
219482203|NCT03303807|DEVICE|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
219482204|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
219482205|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
219482206|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
219482207|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
219482208|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
219482209|NCT03494673|DIAGNOSTIC_TEST|BOLD MRI|"1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
219482210|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
219482211|NCT06567717|DRUG|Zinc|Zinc has not previously been investigated in the treatment of IPF.
219482212|NCT06567717|OTHER|Placebos for zinc and nicotinamide riboside|These will be identical in appearance to the active substances
219482213|NCT06567717|DRUG|Nicotinamide riboside|Nicotinamide riboside has not previously been investigated in the treatment of IPF.
218865910|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
218865911|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
218865912|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
218865913|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
218865914|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
219482214|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
219482215|NCT00002879|DRUG|cladribine|
219482216|NCT01022177|PROCEDURE|acupuncture|acupuncture of the eye in traditional chinese schematics
219598515|NCT01284010|GENETIC|microarray analysis|
219598516|NCT01284010|GENETIC|mutation analysis|
219598517|NCT01284010|GENETIC|polymerase chain reaction|
219598518|NCT01284010|OTHER|laboratory biomarker analysis|
219598519|NCT00741338|BIOLOGICAL|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
219598520|NCT00741338|DRUG|Cyclosporine A (CsA)|Orally three times daily.
218865915|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
218865916|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
218865917|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
218865918|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
218865919|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
218865920|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
218865921|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
218865922|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
218865923|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
218865924|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
219482217|NCT00379925|BEHAVIORAL|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
219482218|NCT04960774|OTHER|Observational study, no intervention|Observational study, no intervention
218865925|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
219482219|NCT02191930|DRUG|B-CAP|
219482220|NCT02191930|DRUG|Brentuximab Vedotin|
219482221|NCT05332080|PROCEDURE|Telerehabilitation via application on cell phone|Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
219482222|NCT05643027|BEHAVIORAL|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
219482223|NCT05229562|DRUG|BIIB122|Administered as specified in the treatment arm.
219482224|NCT04464382|PROCEDURE|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
218865926|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
218865927|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
218865928|NCT00135252|PROCEDURE|nasal cannula oxygen delivery|
218865929|NCT00135252|PROCEDURE|supplemental oxygen delivery by hood|
218865930|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
218865931|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
218865932|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
218865933|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
218865934|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
218865935|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
218865936|NCT00424268|DRUG|Placebo|once daily
218865937|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
219482225|NCT04464382|PROCEDURE|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
219482226|NCT05359640|OTHER|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
219482227|NCT06558630|PROCEDURE|Endotracheal intubation|Over the course of several years as many as possible ED centres in the Netherlands will be included in the collection of all data involving airway management. Airway management is defined as the process of planning, preparation and execution of endotracheal intubation.
219482228|NCT01064830|DRUG|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
218865938|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
218865939|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
219482229|NCT01064830|DRUG|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
219482230|NCT06125886|DIAGNOSTIC_TEST|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
219482231|NCT03956901|OTHER|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
219482232|NCT05130086|DRUG|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
219482233|NCT05368714|BEHAVIORAL|Economic Empowerment (EE)|EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.
219482234|NCT05368714|BEHAVIORAL|Multiple Family Group based Family Strengthening (MFG-based FS)|MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.
219482235|NCT05368714|BEHAVIORAL|EE plus MFG-based FS|EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
219482236|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
219482237|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
219482238|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
219482239|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
219482240|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
218865940|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
218865941|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
218865942|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
218865943|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
218865944|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
219482241|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
219482242|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
219482243|NCT03637270|DIETARY_SUPPLEMENT|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
219482244|NCT03637270|OTHER|Exercise training|Including aerobic cycling training and progressive resisted exercise
219482245|NCT00380575|DRUG|YM087|
219482246|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
219482247|NCT05078632|OTHER|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
219482248|NCT05399407|OTHER|Health e-coaching|Management of overweight / obesity
219482249|NCT06573697|OTHER|low-frequency continuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
219482250|NCT06573697|OTHER|discontinuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
219482251|NCT06573697|OTHER|dilatational wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
219482252|NCT06542068|BEHAVIORAL|Line Bot Assistance|"The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.)."
219482253|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
219598521|NCT00741338|DRUG|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
219598522|NCT01764399|BEHAVIORAL|Care4U|
219598523|NCT02234076|BEHAVIORAL|VRET|
219598524|NCT02234076|BEHAVIORAL|TAU|Treatment as usual offered by the participating mental health care organisations
219598525|NCT05220644|PROCEDURE|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
219598526|NCT06304246|OTHER|Measurement Pain Threshold|Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
218865945|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
218865946|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
218865947|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
218865948|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
218865949|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
218865950|NCT01378429|DRUG|Placebo|Placebo
218865951|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
219482254|NCT06019286|DIAGNOSTIC_TEST|SCINEXA score|\- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
219482255|NCT00609063|DRUG|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
219482256|NCT00609063|DRUG|Placebo|Placebo capsules taken daily for 6 months
219598527|NCT06304246|OTHER|Measurement of Serum Asprosin|Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
218865952|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
218865953|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
218865954|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
218865955|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
218865956|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
218865957|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
218865958|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
218865959|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
218865960|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
218865961|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
218865962|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
218865963|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
218865964|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
218865965|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
219482257|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
219482258|NCT04149769|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
219482259|NCT04930536|DRUG|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
219482260|NCT04329013|OTHER|Left lateral Position during intervention|Left lateral position during EGD
219482261|NCT04329013|OTHER|Prone Position during intervention|Prone position during EGD
219598528|NCT04832022|OTHER|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
218865966|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~\- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
218865967|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
218865968|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
218865969|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
218865970|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
218865971|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
218865972|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
218865973|NCT04243395|OTHER|Pork|1 oz lean pork
219482262|NCT01855321|DRUG|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
219482263|NCT01855321|DRUG|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
219482264|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
219482265|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
219482266|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
219482267|NCT04425642|DRUG|Glucose/Amino acids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
218865974|NCT04243395|OTHER|Egg|1 large whole egg
219482268|NCT04425642|DRUG|Glucose/Amino acids/Lipids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
219482269|NCT06537206|OTHER|Application Footbath|The foot bath application for the experimental group will be applied with water at 38-40 degrees Celsius for an average of 10 minutes under thermometer control. Immediately afterward, the second physiological parameters will be measured.
219482270|NCT04835207|OTHER|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
218865975|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
218865976|NCT04243395|OTHER|Almonds|0.5 oz almonds
219482271|NCT02437981|DRUG|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
218865977|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
218865978|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
218865979|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
218865980|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
218865981|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
218865982|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
218865983|NCT02450968|DRUG|Dexamethasone|
218865984|NCT02450968|DRUG|Placebo|
218865985|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
218865986|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
218865987|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
218865988|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
219482272|NCT05712915|OTHER|RRT operation|"A retrospective observational study was conducted at a 990-bed tertiary care referral teaching hospital from April 2014 to December 2020. The RRT implemented in April 2017 as a part-time RRT operating 8 hours on weekdays. In March 2018, operation time was extended to 15 hours on weekdays and finally, extended to 24 hours a day, 7 days a week in February 2019.~Impact of RRT operation on CPR incidence was retrospective analyzed without any prospective intervention."
219482273|NCT01542879|PROCEDURE|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
219482274|NCT01542879|PROCEDURE|18-F-FDG PET scan|
219482275|NCT01542879|DRUG|Ferumoxytol|
219482276|NCT01542879|PROCEDURE|18-F-FDG PET/MR scan|
219482277|NCT04931147|DRUG|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
218865989|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
218865990|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
218865991|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
218865992|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
218865993|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
218865994|NCT03979599|PROCEDURE|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
218865995|NCT03979599|DRUG|magnesium sulphate& levobupivacaine|magnesium sulphate\& levobupivacaine
218865996|NCT03979599|DRUG|Levobupivacaine|levobupivacaine
219482278|NCT04931147|DRUG|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
219482279|NCT06649591|BEHAVIORAL|Survey|The intervention is an email based survey as described in the study description.
218865997|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
219482280|NCT06703268|DRUG|HSK7653 10 mg|HSK7653 10 mg Q2W
219482281|NCT06703268|DRUG|Daily DPP-4 inhibitor|Daily DPP-4 inhibitor
219482282|NCT00514709|BIOLOGICAL|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
219482283|NCT00514709|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, IM
219482284|NCT00514709|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine.
219482285|NCT01340703|PROCEDURE|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
219482286|NCT00387231|PROCEDURE|Percutaneous coronary angioplasty/intervention (PCI)|
219482287|NCT00387231|DRUG|Anti-ischemic drug therapy|
219482288|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
219482289|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
218865998|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
219482290|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
219482291|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
219482292|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
219482293|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
218865999|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
218866000|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
218866001|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
218866002|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
218866003|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
218866004|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
218866005|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
218866006|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
218866007|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
219482294|NCT01067729|DEVICE|AWBAT Wound Dressing|
219482295|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
219482296|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
219482297|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
218866008|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
219482298|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
219482299|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219482300|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
219598529|NCT00067743|DRUG|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
218866009|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
218866010|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
218866011|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
218866012|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
218866013|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
218866014|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
218866015|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
218866016|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
218866017|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
218866018|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
218866019|NCT02899923|OTHER|Data collection|
218866020|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
218866021|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
218866022|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
218866023|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
218866024|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
219482301|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
219482302|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
219482303|NCT01177865|OTHER|informational intervention|
219482304|NCT01177865|OTHER|questionnaire administration|
219482305|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
219482306|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
219482307|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
219482308|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
219482309|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
219482310|NCT01292291|OTHER|biologic sample preservation procedure|
219482311|NCT01292291|OTHER|laboratory biomarker analysis|
219482312|NCT01292291|OTHER|study of socioeconomic and demographic variables|
219482313|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
219482314|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219482315|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
219482316|NCT01292291|PROCEDURE|quality-of-life assessment|
219482317|NCT01292291|PROCEDURE|transperineal prostate biopsy|
219482318|NCT01292291|PROCEDURE|transrectal prostate biopsy|
219482319|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
219482320|NCT00433771|DEVICE|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
219482321|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
218866025|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
218866026|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
219482322|NCT01145872|BEHAVIORAL|Health Enhancement Program|
219482323|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
219482324|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
219482325|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
219482326|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
219482327|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
219482328|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
219482329|NCT04208165|OTHER|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
219482330|NCT04208165|OTHER|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
219482331|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
219482332|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
219482333|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
219482334|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
219482335|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
219482336|NCT06126770|BEHAVIORAL|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
219482337|NCT04509440|DRUG|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
218866027|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
218866028|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
218866029|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
218866030|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
219482338|NCT04509440|DRUG|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
219482339|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
219482340|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
218866031|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
218866032|NCT00408590|OTHER|laboratory biomarker analysis|
218866033|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
219021059|NCT07206498|DRUG|Osimertinib (Tagrisso®)|"Drug: Osimertinib Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: Osimertinib Given PO, 80mg, once daily"
219021060|NCT07206498|DRUG|WSD0922-FU|"Drug: WSD0922-FU Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
219482341|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
219482342|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
219482343|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
219482344|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
219482345|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
219482346|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
219482347|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
219482348|NCT02585375|DRUG|Preserved latanoprost 0.005%|
219482349|NCT02353572|DRUG|Melphalan|Given IV
219482350|NCT02353572|DRUG|Bortezomib|Given IV
219482351|NCT02353572|DRUG|Dexamethasone|Given IV
219482352|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
218866034|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
218866035|NCT02671565|DRUG|Hyaluronic Acid injections|
218866036|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
218866037|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
218866038|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
218866039|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
218866040|NCT05607329|DRUG|Chemotherapy|chemotherapy
218866041|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
218866042|NCT01440881|DRUG|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
218866043|NCT01440881|DRUG|Placebo|infuses at 0.01MCG/KG/min for 48 hours
218866044|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
218866045|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
218866046|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
218866047|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
218866048|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
218866049|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
218866050|NCT02774655|DEVICE|Pai APP|prescribed 100 PAI weekly
219482353|NCT01783860|DRUG|Azithromycin|
219482354|NCT01783860|DRUG|Doxycycline|
219482355|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
219482356|NCT01742390|DRUG|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
219482357|NCT01742390|DRUG|risperidone or paliperidone|
218866051|NCT02774655|DEVICE|FitBit APP|prescribed 10000 steps daily
219482358|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
219482359|NCT05418517|PROCEDURE|Tracheostomy|temporary tracheostomy insertion
219482360|NCT05418517|PROCEDURE|Overnight intubation|Patient who had overnight intubation
219482361|NCT05879796|DRUG|cis-platinum|chemotherapeutics
219482362|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
219482363|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
219482364|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
219482365|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
219482366|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
219482367|NCT02623530|OTHER|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
219482368|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
219482369|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
219482370|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
219482371|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
219598530|NCT00309686|DRUG|Paliperidone ER|
218866052|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
218866053|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
218866054|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
218866055|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
218866056|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
219482372|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
218866057|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
219482373|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
219482374|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
219482375|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
219482376|NCT00256217|DRUG|Anastrozole|1 mg. oral every day for 2 - 4 weeks
219482377|NCT00024557|DRUG|IL13-PE38QQR|
219482378|NCT00024557|PROCEDURE|targeted fusion protein therapy|
219482379|NCT00024557|PROCEDURE|surgery|
219482380|NCT00832286|DRUG|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
219482381|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
219482382|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
219482383|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219482384|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
219482385|NCT04962958|DRUG|Donafenib|administration of Donafenib
219482386|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
219598531|NCT05810103|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
219598532|NCT03423719|DIETARY_SUPPLEMENT|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
219598533|NCT03423719|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
218866058|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
218866059|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
218866060|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
219482387|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
219482388|NCT00000549|DRUG|estrogen replacement therapy|
219482389|NCT00000549|DRUG|hormone replacement therapy|
219482390|NCT00000549|DRUG|estrogens|
219482391|NCT00000549|DRUG|progestins|
219482392|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
219482393|NCT03184402|DRUG|DWJ1252|tablet
219482394|NCT03184402|DRUG|Gasmotin|tablet
219482395|NCT03184402|DRUG|Placebo of Gasmotin|tablet
219482396|NCT03184402|DRUG|Placebo of DWJ1252|tablet
219482397|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
219482398|NCT02792400|DRUG|LY2403021 placebo|
219482399|NCT02792400|PROCEDURE|Standardised liquid meal|
219482400|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
219482401|NCT02792400|DRUG|Linagliptin placebo|
219482402|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
219482403|NCT02792400|DRUG|Empagliflozin placebo|
219482404|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
219482405|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
219482406|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
218866061|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
218866062|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
218866063|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
218866064|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
218866065|NCT02920957|DEVICE|comfilcon A|contact lens
218866066|NCT02920957|DEVICE|senofilcon C|contact lens
218866067|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
219482407|NCT04911075|DRUG|85% TCA Solution|"* TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
219482408|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
219482409|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
219482410|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
219482411|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
219482412|NCT03861533|OTHER|survey|Cross-Reference
219482413|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
219482414|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
219482415|NCT02230332|DRUG|Alendronate|
219482416|NCT02230332|DRUG|Placebo|
219482417|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
219482418|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
219482419|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
219482420|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
219482421|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
219482422|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
219482423|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
218866068|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
218866069|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
218866070|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
218866071|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
218866072|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
218866073|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
219482424|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
219482425|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
219482426|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
219482427|NCT00552812|DEVICE|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
219598534|NCT05854524|PROCEDURE|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
219598535|NCT03861624|PROCEDURE|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
218866074|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
218866075|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
218866076|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
218866077|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
218866078|NCT03713541|OTHER|No intervention|Survey during normal supply.
218866079|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
218866080|NCT02139904|OTHER|Active Symptom Control|
219482428|NCT04120701|DRUG|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
219482429|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
219482430|NCT00080925|BIOLOGICAL|filgrastim|
219482431|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
219482432|NCT00080925|BIOLOGICAL|rituximab|
219482433|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219482434|NCT00080925|DRUG|cyclophosphamide|
219482435|NCT00080925|DRUG|cyclosporine|
219482436|NCT00080925|DRUG|cytarabine|
219482437|NCT00080925|DRUG|doxorubicin hydrochloride|
219482438|NCT00080925|DRUG|etoposide|
219482439|NCT00080925|DRUG|fludarabine phosphate|
219482440|NCT00080925|DRUG|prednisone|
219482441|NCT00080925|DRUG|vincristine sulfate|
219482442|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
219482443|NCT05242146|DRUG|GB5121|Capsule containing GB5121
219482444|NCT01556646|DRUG|Tolvaptan|15 to 30mg qd titrated to sodium concentration
219482445|NCT06700486|PROCEDURE|SOCKET SHIELD|in implant dentistry
219482446|NCT06700486|PROCEDURE|Immediate implant and sticky bone|in implant dentistry
219482447|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
219482448|NCT00002373|DRUG|Maribavir|
219598536|NCT03861624|PROCEDURE|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
219482449|NCT03474952|PROCEDURE|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
219598537|NCT03632018|BEHAVIORAL|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
218866081|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
219482450|NCT03474952|PROCEDURE|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
219598538|NCT03632018|BEHAVIORAL|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
219482451|NCT01179256|DIETARY_SUPPLEMENT|CURCUMIN|oral supplementation of curcumin 2000mg
219482452|NCT01179256|OTHER|no intervention other than stopping study|no intervention other than stopping study
219598539|NCT06168487|DRUG|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
219598540|NCT06168487|OTHER|Standard of Care Regimen|Standard of Care Regimen
218866082|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
219482453|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
219482454|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
219482455|NCT05269615|DRUG|Valsartan 80 mg|The well-established angiotensin II receptor blocker (ARB) valsartan will be used in the present study to selectively block AT1 receptors. Valsartan is a generic medication widely used in hypertensive patients since 1996 as well as safely applied in physiological studies comprising healthy individuals.1-3 A minimal valsartan dose of 80 mg known to acutely reduce circulating EPO levels in healthy individuals will be provided 4 hours before starting Study 1 to optimize AT1 blockade according to valsartan's half-life.1-3 The same dose of valsartan (80 mg) will be provided 4 hours before each ET session in Study 2. The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
219482456|NCT05269615|DRUG|Placebo|The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
219482457|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
219482458|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
219598541|NCT05870618|BIOLOGICAL|vaccinate with DTap|vaccinate with DTap
219598542|NCT05870618|BIOLOGICAL|vaccinate with DT|vaccinate with DT
219598543|NCT05671536|BEHAVIORAL|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
219598544|NCT02995408|BEHAVIORAL|Relaxation Response Resiliency Program for Parents of Children with ASD|
219598545|NCT01630070|DEVICE|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
219598546|NCT06622642|PROCEDURE|Transoral technique for mandibular angle fracture reduction|In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.
218866083|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
218866084|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
218866085|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
219598547|NCT06622642|PROCEDURE|Transbuccal technique for mandibular angle fracture reduction|In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
219598548|NCT03511599|DRUG|Cycloserine|Cycloserine 100mg
218866086|NCT01071616|DRUG|Cannabis Cigarette|
218866087|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
218866088|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
218866089|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
218866090|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
218866091|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
219482459|NCT01776060|OTHER|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
219482460|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
219598549|NCT03511599|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
219482461|NCT01830257|OTHER|sending message|Sending the suggestive short message
219482462|NCT01139801|DRUG|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
219482463|NCT01139801|DRUG|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
218866092|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
219482464|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
219482465|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
219482466|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of low-fat milk (fat <1.5%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
219598550|NCT03511599|DRUG|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
219598551|NCT02688660|OTHER|MRI Scans|
219598552|NCT00313989|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants
219598553|NCT00425763|DRUG|AQAS|AQAS dosed by body weight, on days 0, 1, 2
219598554|NCT03389516|OTHER|Polymem|wound care dressings
219598555|NCT03389516|OTHER|Lanolin|wound care oinment
219598556|NCT05932043|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
219482467|NCT04482101|OTHER|Root canal obturation|Root canal filling
219482468|NCT03759301|DRUG|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
219482469|NCT03759301|DRUG|Placebo saline solution|same volume as growth hormone ampule used
219482470|NCT06536868|DRUG|Tislelizumab|Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
219482471|NCT06536868|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
219482472|NCT06536868|DRUG|Carboplatin or Cisplatin|Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
219482473|NCT06536868|RADIATION|Thoracic radiotherapy|IMRT 30-45Gy/10-15f
218866093|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
218866094|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
218866095|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
218866096|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
218866097|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
218866098|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
218866099|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
218866100|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
218866101|NCT03449433|DRUG|LY900014|Administered SC
218866102|NCT03449433|DRUG|Insulin Lispro|Administered SC
219482474|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
219598557|NCT06416514|OTHER|Personalized intervention|Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
218866103|NCT03449433|DRUG|Insulin Aspart|Administered SC
219482475|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
219598558|NCT01271218|OTHER|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
219598559|NCT01271218|OTHER|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
219598560|NCT04450758|PROCEDURE|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
219482476|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
219482477|NCT04907916|OTHER|SIRTUIN1|The NAD dependent deacetylase activity of Sirtuin1
219482478|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
218866104|NCT03449433|DRUG|Insulin Aspart|Administered SC
218866105|NCT00099281|DRUG|YMB 1002|
218866106|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
218866107|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
218866108|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
218866109|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
219482479|NCT05869019|OTHER|education|Premature baby care training will be provided.
219482480|NCT00858611|DRUG|VRC-FLUDNA047-00-VP|
219482481|NCT00858611|DRUG|Flulaval (Registered) Seasonal Influenza Vaccine|
219482482|NCT00417820|DRUG|BCT194|
219482483|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
219482484|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
219482485|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
219482486|NCT05095896|OTHER|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
219482487|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
219482488|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
219482489|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
218866110|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
219482490|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
219482491|NCT01135901|BEHAVIORAL|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
219482492|NCT02233465|PROCEDURE|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
219522370|NCT07037485|OTHER|Renal resistive index|"It will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or inter-lobar artery will be localized, and three successive Doppler measurements at different positions in the kidney (high, middle, and low) will be performed. The average value for each kidney will be taken.~The renal resistive index will be calculated as follows:~(systolic peak flow velocity - diastolic minimum flow velocity)/systolic peak flow velocity"
219598561|NCT00242424|BIOLOGICAL|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
219598562|NCT00098618|DRUG|sorafenib tosylate|Given orally
219598563|NCT00098618|BIOLOGICAL|recombinant interferon alfa|Given orally
219598564|NCT00098618|OTHER|laboratory biomarker analysis|Correlative studies
219598565|NCT01238107|DRUG|MT-102|BETA BLOCKER
219598566|NCT00295061|DRUG|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
219598567|NCT00295061|DRUG|alpha-1 proteinase inhibitor (human)|Prolastin
219598568|NCT00002528|DRUG|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
219598569|NCT00002528|PROCEDURE|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
219598570|NCT00002528|RADIATION|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
219598571|NCT00002528|PROCEDURE|Axillary clearance|Axillary node dissection.
218866111|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
218866112|NCT01958892|PROCEDURE|TURP, TUERP|
218866113|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
218866114|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
218866115|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
218866116|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
218866117|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
218866118|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
218866119|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
218866120|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
218866121|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
218866122|NCT04254120|BEHAVIORAL|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
218866123|NCT04254120|BEHAVIORAL|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
218866124|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
219040035|NCT03800719|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
219482493|NCT03387267|DEVICE|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
219482494|NCT01576731|DRUG|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
219482495|NCT01576731|DRUG|Tenofovir, Emtricitabine, Raltegravir|Combination drug
219482496|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
219482497|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
219482498|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
219482499|NCT00244881|DRUG|cediranib maleate|Given orally
219482500|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
219482501|NCT02179385|BEHAVIORAL|Health Coaching|
219482502|NCT01213004|PROCEDURE|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
219482503|NCT01213004|PROCEDURE|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
219482504|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
219482505|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
218866125|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
218866126|NCT01345682|DRUG|Afatinib|Once daily
218866127|NCT01345682|DRUG|Methotrexate|Weekly
219482506|NCT03664024|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
218866128|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
219482507|NCT03664024|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
219482508|NCT03664024|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
219482509|NCT03664024|DRUG|Cisplatin|Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
218866129|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
218866130|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
218866131|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
219482510|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
219482511|NCT01984931|DRUG|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
219482512|NCT01984931|DRUG|Metoclopramide hydrochloride monohydrate|
219482513|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
218866132|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
218866133|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
219482514|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
219482515|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
219482516|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
219482517|NCT05346939|DEVICE|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
219482518|NCT02292407|DEVICE|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
219482519|NCT05343793|OTHER|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
219482520|NCT05343793|OTHER|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
219482521|NCT05343793|OTHER|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
219482522|NCT05343793|OTHER|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
218866134|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
218866135|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
218866136|NCT00795288|DRUG|placebo|Control group
218866137|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
218866138|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
218866139|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
218866140|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
219482523|NCT04180371|DRUG|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
219482524|NCT04180371|DRUG|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
218866141|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
218866142|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
219482525|NCT06701175|PROCEDURE|Nerve Block|anterolateral geniculate nerve block
219482526|NCT06701175|PROCEDURE|Portal Anesthesia|portal anesthesia
219482527|NCT00638118|DRUG|Fexofenadine|
219482528|NCT06697483|DRUG|Daratumumab|Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.
219482529|NCT06697483|DRUG|Lenalidomide|"Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance."
219482530|NCT03159611|DRUG|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
219482531|NCT03159611|DRUG|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
219482532|NCT03394794|DEVICE|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
219482533|NCT01291069|DRUG|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
219482534|NCT01291069|DRUG|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
219482535|NCT02120482|DEVICE|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
219482536|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
219482537|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
219482538|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
219482539|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
219482540|NCT01779466|DRUG|Desmopressin|
218866143|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
218866144|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
218866145|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
218866146|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
218866147|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
218866148|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
218866149|NCT04166539|BEHAVIORAL|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
218866150|NCT04166539|BEHAVIORAL|Interviews|Behavioral and Memory interviews will take place with the patient.
219040036|NCT03800719|BEHAVIORAL|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
219482541|NCT01779466|DRUG|Placebo (not active)|
219482542|NCT03865550|DRUG|Isotonic saline|Placebo
219482543|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
219482544|NCT02651246|OTHER|data collection|
219482545|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
219482546|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
218866151|NCT04166539|OTHER|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
218866152|NCT04166539|RADIATION|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
219482547|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
219482548|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
219482549|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
219482550|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
219598572|NCT01598194|DEVICE|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
218866153|NCT04166539|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
218866154|NCT03442660|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
218866155|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
218866156|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
218866157|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
219482551|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
219482552|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
219482553|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
219482554|NCT02391194|DRUG|AVB-620|
219482555|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
219482556|NCT01572610|DRUG|RTA 402|once a day, oral administration
219482557|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
219482558|NCT06439511|DEVICE|Darwin smartphone app|The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
219482559|NCT06439511|DEVICE|Pulse oxymetry|Heart rate will be measured with pulsoe oximetry (gold standard)
219482560|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
219482561|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
219482562|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
219482563|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
219482564|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
219598573|NCT02910804|DRUG|68Ga-BBN-IRDye800CW|
218866158|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
218866159|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
219040037|NCT03800719|BEHAVIORAL|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
219040038|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
219040039|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
219040040|NCT00423891|DRUG|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
219482565|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
219482566|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
219482567|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
219482568|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
219482569|NCT00036868|BIOLOGICAL|trastuzumab|
219482570|NCT00036868|DRUG|CMF regimen|
219482571|NCT00036868|DRUG|cyclophosphamide|
219482572|NCT00036868|DRUG|fluorouracil|
219482573|NCT00036868|DRUG|methotrexate|
219482574|NCT02618096|DRUG|Oxytocin|
219482575|NCT02618096|DRUG|Dinoprostone|
219598574|NCT02910804|DEVICE|PET/NIRF|
219598575|NCT02910804|PROCEDURE|PET/NIR fluorescent imaging-guided surgery|
219482576|NCT02618096|PROCEDURE|Membrane sweeping|
218866160|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
219482577|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
219482578|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
219482579|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
219482580|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
219482581|NCT06874855|DRUG|Lemborexant|Lemborexant tablet administered orally once daily
219482582|NCT06874855|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily
219482583|NCT07040267|DIAGNOSTIC_TEST|Thumb evaluations|"There is no therapeutic or experimental intervention in this study. All procedures will be limited to diagnostic evaluations. The study will include non-invasive biomechanical and sensory assessments to compare the thumb muscle characteristics and sensory discrimination between smartphone-addicted and non-addicted university students.~Specifically, muscle tone, stiffness, and elasticity will be measured using the MyotonPro™ device, and thumb sensory sensitivity will be evaluated using a Baseline Aesthesiometer with a two-point discrimination test. These assessments will be conducted during a single laboratory visit and will not involve any treatment, medication, or behavioral intervention.~This is a purely observational study aimed at identifying potential associations between smartphone usage patterns and thumb neuromuscular or sensory changes."
219598576|NCT05972369|OTHER|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
219598577|NCT01804972|OTHER|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
219598578|NCT01804972|OTHER|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
218866161|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
218866162|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
219482584|NCT06720948|DEVICE|ION 3D Facet Screw System|Observational study of subjects previously implanted with ION 3D Facet Screw System.
219482585|NCT06722963|DRUG|fentanyl|Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
219482586|NCT06722963|DRUG|Nalbuphine|Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
219598579|NCT05034016|DEVICE|High Myopic Posterior Scleral Fixation System|Implant HM into the eye through posterior scleral reinforcement
218866163|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
218866164|NCT02666794|DRUG|Epidural sufentanil|20 mcg
218866165|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
218866166|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
218866167|NCT02666794|DRUG|Intrathecal morphine|60 mcg
218866168|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
218866169|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
218866170|NCT01075984|DRUG|Posaconazole|
219482587|NCT07048067|PROCEDURE|Carotid endarterectomy (CEA)|carotid endarterectomy (CEA) with the use of Baxter VASCU-GUARD vascular patches
219482588|NCT07048626|COMBINATION_PRODUCT|PRP treatment|PRP treatment involves drawing a blood sample, processing it to concentrate platelets, and then injecting that concentrated plasma back into the body, typically at the site of an injury or area needing regeneration. The procedure aims to utilize the growth factors within the platelets to accelerate healing and tissue repair.
219482589|NCT07048626|COMBINATION_PRODUCT|low level laser therapy post prp treatment|will receive low-level laser therapy post prp treatment upto 12 weeks .Low-level laser therapy (LLLT) is a non-invasive treatment for hair loss that uses low-intensity laser light to stimulate hair follicles and improve blood circulation. It's often used on its own or combined with other therapies like PRP.
219482590|NCT07048561|OTHER|observation alone|No interventions will be conducted during the one-year observation period, maintaining participants' normal daily living conditions.
219482591|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 150mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 150mg.
219482592|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 300mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 300mg.
219482593|NCT07047105|DIETARY_SUPPLEMENT|Placebo|Microcristalline Cellulose MCC
219482594|NCT07047105|DIETARY_SUPPLEMENT|Caffeine 75mg|Caffeine anhydrous Pulver, 75mg
219482595|NCT07046871|BEHAVIORAL|1. Intervention Name (Arm 1) Name: Adapted Basketball Program with Video Support Type: Behavioral Description: A 7-week basketball intervention for adolescents with obesity, combining pedagogically a|A 7-week basketball intervention for adolescents with obesity, combining pedagogically adapted activities with pre-session video instruction delivered via a private Facebook group.
218866171|NCT01075984|DRUG|Dextrose 5% in water|
219482596|NCT07046871|BEHAVIORAL|ADAPT Adapted Basketball Program|A 7-week adapted basketball intervention including non-competitive, inclusive drills tailored to adolescents with obesity, without any video supplementation.
218866172|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- Cefuroxime in 100ml saline~2. \- Metronidazole in 500ml saline"
218866173|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- 2x amoxicillin in 100ml saline~2. \- Fluconazole in 500ml saline"
218866174|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 100ml saline solution~2. \- 500ml saline solution"
219482597|NCT07047807|BEHAVIORAL|PDAC-PATHWAYS|A digital app for patients initiating neoadjuvant therapy for PDAC
219482598|NCT07047807|OTHER|Usual Care|Routine treatment
219482599|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 5|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 5.
219482600|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 6|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 6.
218866175|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 2x 100ml saline solution~2. \- 500ml saline solution"
219598580|NCT02514902|DEVICE|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
218866176|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
219482601|NCT07047911|OTHER|Observational only - surgical management not assigned by study|Observational only - surgical management not assigned by study
219482602|NCT06723119|OTHER|Resveratrol (VRES) 500 mg oral once daily.|Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
218866177|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
218866178|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
218866179|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
218866180|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
218866181|NCT05644093|DRUG|SPL026 IV|IV dosing
218866182|NCT05644093|DRUG|SPL026 IM|IM dosing
218866183|NCT01286571|DRUG|BI 135585|one oral single dose per subject
218866184|NCT01286571|DRUG|BI 135585|one oral single dose per subject
218866185|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
218866186|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
218866187|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
218866188|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
219482603|NCT06723119|OTHER|Placebo 500 mg oral once daily.|Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
218866189|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
218866190|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
218866191|NCT00052156|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
218866192|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
218866193|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
219482604|NCT07047560|DRUG|fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev)|"Liposomal irinotecan (II): 30 mg/m² IV on D1 and D3, Q2W; Fluorouracil (5-FU): Q2W;~* 400 mg/m² IV bolus on D1~* Followed by 2400 mg/m² continuous IV infusion over 46-48 hours Leucovorin (LV): 400 mg/m² IV infusion on D1 Bevacizumab: 5 mg/kg IV infusion on D1, Q2W."
219482605|NCT07047248|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
219482606|NCT07047248|OTHER|Placebo PBM|A placebo whole body red light will be carried out during 20 minutes
219482607|NCT07048327|OTHER|No intervention (observational study)|No intervention (observational study)
219482608|NCT07047755|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan
219482609|NCT07047755|DRUG|Pertuzumab|Pertuzumab
219482610|NCT07048457|PROCEDURE|Radical cystectomy|The intervention in this clinical trial consists of definitive surgical management through radical cystectomy with bilateral pelvic lymph node dissection (PLND), urinary diversion, and metastasectomy of surgically resectable or previously radiated metastatic disease. Surgical approach may be either open or robotic, based on surgeon discretion and patient-specific factors. The PLND will be performed in a standard oncologic fashion, including dissection of the common iliac, external iliac, internal iliac, and obturator nodal basins bilaterally. In cases where metastatic lymph nodes are identified beyond these regions, the lymph node dissection may be extended to achieve gross resection of involved nodal disease within the abdomen or retroperitoneum.
219598581|NCT04812808|DRUG|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
218866194|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
218866195|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
218866196|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
218866197|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
218866198|NCT02174744|OTHER|numeric pain rating scale|
218866199|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
218866200|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
218866201|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
218866202|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
219482611|NCT07048431|DIAGNOSTIC_TEST|Shear Wave Elastography Measurement|It is a non-invasive imaging technique used to evaluate tissue stiffness. This method involves the use of ultrasound-based shear wave elastography to assess bilateral tibial nerve, by measuring the speed of shear wave propagation through the tissue. Stiffness values are expressed in kilopascals (kPa).
219482612|NCT07047079|OTHER|Preoperative rehabilitation exercises + Usual care|"1. Preoperative rehabilitation exercises~   1. Intervention methods: At the time of admission, the investigator demonstrated the content of preoperative rehabilitation exercises and provided a guidebook. Participants exercise on their own for approximately 3-7 days from the day of admission to the day of surgery as directed by the investigator and the manual.~  2. Exercise content:~      * Pulmonary function exercises: including abdominal breathing exercises and effective cough learning.~     * Muscle strength exercises: including straight leg raises and lateral leg raises.~     * Knee range of motion exercises: including knee flexion exercises and knee extension exercises.~     * ankle pump exercise~2. Usual care: Provided by a ward nurse."
218866203|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
218866204|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
218866205|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
218866206|NCT02410577|DEVICE|PET/CT Scan|
218866207|NCT02410577|DEVICE|MRI|
218866208|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
218866209|NCT04573881|DEVICE|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
219482613|NCT07047079|OTHER|The navigator guides the whole process of preoperative rehabilitation exercise + Usual care|"1. The navigator guides the whole process of preoperative rehabilitation exercise~   1. On the day of admission, the same intervention as in the preoperative rehabilitation autonomous exercise group was added:~      * Exercise Verification: Subjects demonstrate prescribed exercises to ensure correct execution.~     * Education \& Rapport:The navigator establishes therapeutic rapport and provides essential disease education.~  2. During the preoperative period (admission to surgery), the navigator implements:~      * Daily Supervised Exercise: Two 20-minute face-to-face rehabilitation sessions in the patient's room daily.~     * Standardized Reminders:Daily exercise adherence reminders via We Chat at 19:00-20:00.~     * Comprehensive Support: assessing needs and connecting to resources,,offering psychosocial/emotional support ,verbal interpretation, addressing exercise barriers and developing self-management skills~2. Usual care: Provided by a ward nurse."
219482614|NCT06742788|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is an emerging, non-invasive adjunctive therapy.~The taVNS protocol is configured with a pulse width of 500 µs, a frequency of 25 Hz, and a current intensity titrated to each patient's pain tolerance threshold (range: 0.5-2.0 mA). The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.~The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks."
219598582|NCT04187170|OTHER|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
219598583|NCT05224609|DRUG|Lorlatinib|Single 100mg oral dose anti-cancer agent
219021088|NCT07207135|OTHER|Isometric Exercise at 15° and 90° Knee Angles|Participants performed quadriceps and hamstring isometric contractions at 15° and 90° of knee flexion. Each contraction lasted 10 seconds against resistance, three times per week for eight weeks, with progressive repetitions. Hip and ankle strengthening was also included.
219021089|NCT07207135|OTHER|Isometric Exercise at 30° and 105° Knee Angles|Same protocol as Group 1, but at 30° and 105° of knee flexion.
218866210|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
218866211|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
218866212|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
218866213|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
218866214|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
218866215|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
219021090|NCT07207135|OTHER|Isometric Exercise at 45° and 120° Knee Angles|Same protocol as Group 1, but at 45° and 120° of knee flexion.
219021091|NCT07207135|OTHER|Isometric Exercise at 60° and 135° Knee Angles|Same protocol as Group 1, but at 60° and 135° of knee flexion.
219482615|NCT06742788|DEVICE|sham transcutaneous auricular vagus nerve stimulation (staVNS)|The sham transcutaneous auricular vagus nerve stimulation (staVNS) serves as a sub-threshold therapeutic stimulus functions as a sham stimulus. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 0.1 mA. The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime. The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
219482616|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office|2.00x10⁸ HB-adMSCs IV at the doctor's office.
219482617|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR|100 million stem cells (1.00x10⁸ HB-adMSCs) in the corpora cavernosa of the penis suspended in a 4 cc of sterile saline. 50 million stem cells (5.0x 10⁷ HB-adMSCs) along the right neurovascular bundle and 50 million cell (5.0x 10⁷ HB-adMSCs) along the left neurovascular bundle of the penis suspended in a 4 cc of sterile saline during the surgery
219482618|NCT07048314|DRUG|Placebo in the OR|4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis during the surgery .
219482619|NCT07048314|DRUG|Placebo in clinic|30 mL syringe of the product should be mixed into a 250cc bag of sodium chloride solution 0.9% for infusion. should be administered intravenously, with a dosing rate of 4-5mL/min.
219482620|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
219482621|NCT01525407|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
219482622|NCT01525407|DRUG|Atorvastatin Calcium|Given PO
219482623|NCT01525407|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
219482624|NCT01209000|PROCEDURE|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
219482625|NCT03220282|OTHER|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
219482626|NCT03220282|OTHER|Preterm infant formula|Preterm formula determined by clinical practice
219482627|NCT06928610|BEHAVIORAL|HeartMath Resilience Program|Resiliency-based intervention designed to reduce stress, build resilience, and maintain energy levels.
219482628|NCT05227053|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter|Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
219482629|NCT06901713|OTHER|cognitive behaviour thearpy|Participants will access the CBT text materials through a dedicated platform
219482630|NCT06901713|OTHER|mindfulness|Participants will access the mindfulness audio via a compatible device
218866216|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
218866217|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
219482631|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
219482632|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
219482633|NCT06910267|BEHAVIORAL|APS Treatment as Usual|APS agencies conduct in-home investigations of alleged abuse and neglect against disabled and older adults. Investigations result in short-term stop-gap measures, primarily brief case-management centering on referral linkage to community-based services and provision of resource allocation. No direct psychological services or treatments are provided by APS, however referral to other services is also standard.
219482634|NCT06910267|BEHAVIORAL|Intervention-Behavioral Activation (BA)|Participants will be will be guided through 8 one-hour sessions via home telehealth by the study community health worker. Each weekly \< 60 minute BA session will include modules focusing on 1) Psychoeducation for depression and techniques for self-management, including pharmacologic and psychosocial treatment options; 2) Introduction of BA and guided problem-solving techniques to enhance self efficacy for managing depression and other chronic illnesses; 3) BA and problem-solving techniques to support medication management and adherence strategies; 4) BA to develop strategies and techniques for communicating with health providers and/or support resources to foster positive mood and self management; and 5) Developing a relapse prevention plan, which includes identifying triggers for lower functioning, support resources, and practice of BA techniques.
218866218|NCT02411786|BIOLOGICAL|gm-csf|Given ID
218866219|NCT03400813|BEHAVIORAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
219040041|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
219482635|NCT06936306|PROCEDURE|GBT|GBT Protocol
219482636|NCT06936306|DEVICE|Master|Use master piezon
219482637|NCT06936306|PROCEDURE|scalling|scalling
218866220|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
218866221|NCT00317408|DRUG|busulfan|
218866222|NCT00317408|DRUG|carboplatin|
218866223|NCT00317408|DRUG|carmustine|
218866224|NCT00317408|DRUG|cyclosporine|
218866225|NCT00317408|DRUG|cytarabine|
218866226|NCT00317408|DRUG|dexamethasone|
218866227|NCT00317408|DRUG|etoposide phosphate|
218866228|NCT00317408|DRUG|idarubicin|
218866229|NCT00317408|DRUG|ifosfamide|
218866230|NCT00317408|DRUG|leucovorin calcium|
219482638|NCT06935149|DRUG|18-PSMA|Intravenous push 4 MBq/kg per patient (for a 70 kg patient, 280 MBq of \[18F\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \[18F\]FPSMA, intravenous flushing was performed with 20 ml of normal saline.
219482639|NCT06942117|OTHER|Experimental|Approximately 280 grams of caffeine containing coffee will be given
219482640|NCT06942117|OTHER|Placebo|Decaffeinated coffee will be given.
219482641|NCT06942364|OTHER|Action Observation Therapy|"The AOT video comprised four specific tasks designed to improve lower extremity function, balance, and gait (Figure 1):~1. Sitting Balance: Movements to enhance balance while seated (Figure 2).~2. Sit-to-Stand Transition: Exercises to facilitate the transition from sitting to standing.~3. Walking and Balance: Gait and balance training on a parallel bar or flat surface.~4. Single-Leg Balance: Activities focused on improving balance on one leg. For each task, children observed the movement for 1 minute, then practiced the action for 5 minutes. A 1-minute rest period was allowed between tasks, with a total AOT session lasting 30 minutes. All sessions were conducted by the same physiotherapist."
218866231|NCT00317408|DRUG|lomustine|
218866232|NCT00317408|DRUG|melphalan|
218866233|NCT00317408|DRUG|methotrexate|
219021105|NCT07206316|OTHER|Individual Placement and Support Model|"The Individual Placement and Support (IPS) model is an employment support program specifically designed for people with severe mental illness (Bond, Drake, \& Becker, 2012). The core philosophy of IPS is that anyone can obtain competitive employment in the open labor market, provided it is the right job combined with appropriate support.~IPS support is delivered by a job coach, specifically trained in this model, who devotes their entire working time to assisting patients in their vocational integration."
219021106|NCT07206316|OTHER|Standard Method|In psychiatric wards, patients who wish to do so are usually offered support to initiate the process of returning to competitive employment in the open labor market. This assistance is provided by the social workers (such as social workers or educators) within the care unit.
219482642|NCT06942364|OTHER|conventional physiotherapy|Conventional physiotherapy is a widely used therapeutic approach that focuses on improving physical function, mobility, and overall quality of life through evidence-based techniques. It typically includes exercises for strength, flexibility, balance, and coordination, along with manual therapy, postural training, and education about movement and body mechanics. This traditional method is commonly applied in the rehabilitation of patients with neurological, orthopedic, and musculoskeletal conditions. In pediatric populations, such as children with cerebral palsy, conventional physiotherapy plays a vital role in promoting motor development, enhancing functional independence, and preventing secondary complications.
219482643|NCT06941675|OTHER|Hybrid Closed-Loop Artificial Pancreas System|Hybrid Closed-Loop Artificial Pancreas System Group: Uses an open-source system with Novo Nordisk ultra-rapid-acting insulin (approval: J20050097, 3 mL: 300 U). Daily insulin dose calculated at 0.3-0.6 U/(kg\*d) based on weight; system auto-adjusts basal rate. Physicians prescribe bolus doses, entered by nurses via AAPS software. Glucose correction uses CGM + 4 daily capillary tests (fasting, 2h post-meal). AAPS features hypoglycemia prediction suspend (pauses basal if glucose ≤4.4 mmol/L, resumes upon recovery) and alarms (\<3.9 mmol/L, ensures nighttime alert).
219482644|NCT06942195|OTHER|Ca-1000|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 1000 mg, stimulates gut hormones and motility, will be 'higher dose' in this condition.
219482645|NCT06942195|OTHER|Ca-500|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 500 mg, stimulates gut function. In this condition, it will be considered 'lower dose.'
219482646|NCT06942195|OTHER|Control|Saline (an isotonic solution containing 2.8 g of sodium chloride (NaCl), dissolved in 225 mL of distilled water).
219482647|NCT06943742|DIAGNOSTIC_TEST|Magnetoencephalography plus Computed Tomography/Magnetic Resonance Imaging|Use Magnetoencephalography and Computed Tomography/Magnetic Resonance Imaging in the preoperative assessment of pediatric brain tumors.
219482648|NCT06943326|OTHER|nutrition monitoring|There is no investigator intervention in the study. Patients' nutrition is recorded for one week from the beginning of the study.
219482649|NCT06942884|DRUG|Dexmedetomidine and dexamethasone in addition to bupivacaine in rectus sheath block|addition of dexmedetomidine to dexamethasone in rectus sheath block
218866234|NCT00317408|DRUG|mitoxantrone hydrochloride|
218866235|NCT00317408|DRUG|prednisolone|
218866236|NCT00317408|DRUG|thiotepa|
218866237|NCT00317408|DRUG|vinblastine sulfate|
218866238|NCT00317408|DRUG|vindesine|
218866239|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218866240|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
218866241|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
218866242|NCT00317408|RADIATION|total-body irradiation|
218866243|NCT05380323|DRUG|LY3541105|Administered SC.
218866244|NCT05380323|DRUG|Placebo|Administered SC.
219482650|NCT06942884|DRUG|dexamethsone in addition to bupivacaine in rectus sheath block|addition of dexamethasone in rectus sheath block
219482651|NCT06939309|PROCEDURE|Acupuncture|In this study, both the acupuncture SC group and the acupuncture CS group will receive two acupuncture treatments in one session. The SC group will first receive acupuncture at the standardized acupoint followed by the controlled acupoint, while the CS group will first receive acupuncture at the controlled acupoint followed by the standardized acupoint.
218866245|NCT05008198|OTHER|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
219482652|NCT06939309|PROCEDURE|Rehabilitation|Participants will complete a 30-minute rehabilitation session, which includes electrotherapy and thermotherapy applied to the shoulder.
219482653|NCT06941688|DRUG|Decitabine with GemOx|Each treatment cycle consists of 3 weeks, and a total of 6 cycles will be administered. The drugs will be administered sequentially in the following order: decitabine, gemcitabine, and oxaliplatin. Decitabine will be administered at a dose of 7.5 mg/m² on days 1 to 5; gemcitabine at 1000 mg/m² on days 1 and 8; and oxaliplatin at 100 mg/m² on day 1 of each cycle.
219482654|NCT06941688|DRUG|GemOx|Each treatment cycle spans 3 weeks, with a total of 6 cycles planned. Gemcitabine will be administered at a dose of 1000 mg/m² on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1 of each cycle.
219482655|NCT06942000|DRUG|dexmedetomidine 3mcg group|3mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
219482656|NCT06942000|DRUG|dexmedetomidine 5mcg|5mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
219482657|NCT06942000|DRUG|preservative-free 0.9% saline.|(0.5 ml) preservative-free 0.9% saline
219482658|NCT06942026|DRUG|Control 1|Researchers will perform oral care with ozonated water and hypochlorous acid solution to restore oral mucous membrane integrity.
219482659|NCT06941662|DIAGNOSTIC_TEST|computer vision, remote monitoring, blood, urine, wrist bands, mobile-app|This is a low burden study that relies on a combination of cutting edge remote monitoring methods to deliver individualized evaluations to participants in their homes.
219482660|NCT06942520|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
219482661|NCT06942520|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
219482662|NCT06942520|BIOLOGICAL|Aflibercept (2.0 mg)|Commercially available Active Comparator
219482663|NCT06941584|DIAGNOSTIC_TEST|Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay|To evaluate the prevalence of specific autoantibodies (AQP4, AChR, LGI1, and CASPR2) in the population of patients carrying AIRE mutations (second cohort)
218866246|NCT02564978|DRUG|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
219482664|NCT06941584|GENETIC|AIRE single gene sequencing|To assess the prevalence of AIRE gene mutations in patients with NMOSD associated with AQP4 autoantibodies, myasthenia gravis (MG) associated with AChR autoantibodies, acquired neuromyotonia, and autoimmune encephalitis associated with CASPR2 and LGI1 autoantibodies (first cohort)
219482665|NCT06941584|GENETIC|Molecular typing of HLA class I and II alleles|To assess the HLA haplotypes of class I and II by comparing patients with and without AIRE mutations, as well as those with and without autoimmune neurological diseases
219598584|NCT05434169|BIOLOGICAL|Arterial Blood Gas|The procedure of arterial blood collection will be conducted in a seated position for all three groups. The patient is in a supine position, with the forearm comfortably placed on a small table. The needle used for blood collection is a 25 gauge needle without local anesthetic. This method of sampling is identical to the one used in daily practice in the Emergency department of Fribourg
218866247|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
218866248|NCT03684694|DRUG|Ibrutinib|Oral capsule.
219522371|NCT07037485|OTHER|Renal Artery Pulsatility Index|"It will be measured using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney, the interlobular artery will be located using color Doppler mode, and the velocity of the interlobular arteries will be assessed in one or two kidneys.~The Renal Artery Pulsatility Index (RAPI) will be calculated as follows:~RAPI = \[(peak systolic velocity) - (end diastolic velocity)\] /average velocity"
219522372|NCT07037485|OTHER|Urinary oxygen tension (PUO2)|Urinary oxygen tension (PUO2) will be measured preoperatively (baseline), postoperatively just after intensive care unit admission, 12 hours after surgery, and then once daily for 7 days.
219598585|NCT05273346|BEHAVIORAL|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
218866249|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
219482666|NCT06943560|BEHAVIORAL|Emotion Regulation Selection Flexibility Training|7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on days without sessions. Psychoeducation includes information on selection of appropriate strategy according to the regulatory selection flexibility rule (i.e., distraction for high intensity vs reappraisal in low intensity). In the computerized task participants are exposed to emotional words and are asked to select a regulatory strategy in a flexible matter according to the regulatory selection flexibility rule, and receive feedback on whether they chose flexibly or not. Following , they are instructed to implement the chosen strategy. Homework includes choosing two daily events one of high intensity and a second one of low intensity, and describe which strategy they selected and how they implemented their chosen strategy according to the flexibility rule.
219482667|NCT06943560|BEHAVIORAL|Emotion Regulation Active control Training|"All the interventional sections are similar to the experimental group except that in the control group we omit the regulatory selection rule that defines which strategy is compatible with which emotional situation.~7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on the days without sessions. Psychoeducation explicitly included information on regulatory strategies (without the regulatory selection flexibility rule). In the computerized task participants are exposed to the same emotional words and are asked to choose freely a regulatory strategy (without the regulatory selection flexibility rule or feedback), and implement it. Homework includes choosing two daily events and selecting and implementing a regulatory strategy (without the regulatory selection flexibility rule)."
219482668|NCT06943339|OTHER|Standard enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the standard enteral nutrition group for standard product (1kkal/1ml) intake. No intervention will be made by the researchers during the treatment process of the patients.
219482669|NCT06943339|OTHER|High energy and protein enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the high energy and protein enteral nutrition group for the intake of high energy and protein containing product (1.5kkal/1ml + protein content increased). No intervention will be made by the researchers during the treatment process of the patients.
219482670|NCT06949748|DRUG|Flecainide (monotherapy)|"• Medication: Flecainide acetate, administered orally.~* Initial Dosing and Titration:~* Patients were started on an appropriate dose based on body weight and renal function.~* The typical starting dose was 100-150 mg per day, split into two doses.~* Dosing was titrated as needed, depending on patient response and tolerability, under close ECG and clinical monitoring.~* Monitoring Protocol:~* Continuous ECG monitoring during drug initiation (especially in-hospital or via Holter).~* Regular outpatient follow-up visits, including:~* 12-lead ECGs~* Holter monitoring~* Echocardiography (to monitor LVEF and assess for reverse remodeling)~* ECG parameters (QRS width, QTc interval) were closely monitored for proarrhythmic changes."
219482671|NCT06531512|DRUG|Xianglei Tangzu Gao|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
219482672|NCT06531512|OTHER|Vehicle Cream|Cream base of Xianglei Tangzu Gao
219482673|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
219482674|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
219482675|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
219482676|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
218866250|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
218866251|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
218866252|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
219040042|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
219040043|NCT03031288|DEVICE|A|standard bottle
219040044|NCT03031288|DEVICE|B|vented base bottle
219040045|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
219040046|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
218866253|NCT01825941|DRUG|metoclopramide|10 milligrams, administered intravenously over 15 minutes
218866254|NCT01825941|DRUG|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
218866255|NCT01825941|DRUG|placebo|
218866256|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
218866257|NCT03076723|OTHER|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
219482677|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
219482678|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
219482679|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
219482680|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
219482681|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
219482682|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
219482683|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
219482684|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
218866258|NCT03076723|OTHER|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
218866259|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
218866260|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
218866261|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
218866262|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
218866263|NCT02406729|OTHER|Placebo|Route:subcutaneous
218866264|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
218866265|NCT00528996|DRUG|BEA 2180 BR|Solution
218866266|NCT00528996|DRUG|Tiotropium Bromide|Solution
218866267|NCT00528996|DRUG|Placebo|Solution
218866268|NCT00048113|DRUG|Alicaforsen|
219482685|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
219482686|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
219482687|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482688|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482689|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482690|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482691|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219598586|NCT05273346|BEHAVIORAL|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
218866269|NCT04291768|OTHER|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
218866270|NCT04291768|OTHER|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
218866271|NCT01307462|DRUG|fluticasone propionate|Given inhaled PO
219482692|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482693|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482694|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482695|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
219482696|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
219482697|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
219482698|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
219482699|NCT04530227|DRUG|Pemetrexed|chemotherapy
219482700|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
218866272|NCT01307462|DRUG|montelukast sodium|Given PO
218866273|NCT01307462|DRUG|azithromycin|Given PO
218866274|NCT03341455|BEHAVIORAL|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
218866275|NCT01232855|GENETIC|protein expression analysis|
218866276|NCT01232855|GENETIC|western blotting|
218866277|NCT01232855|OTHER|flow cytometry|
218866278|NCT01232855|OTHER|laboratory biomarker analysis|
218866279|NCT06502808|OTHER|Hyperbaric oxygen therapy|Series of 30 HBOT sessions of 60 minutes at 2 ATA in the hyperbaric chamber for five consecutive days per week.
219482701|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
218866280|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
218866281|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
219482702|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
218866282|NCT02349685|PROCEDURE|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
219482703|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
219482704|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
219482705|NCT02182726|DRUG|MOBEC|
219482706|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
219482707|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
219482708|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
219482709|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
219482710|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
219482711|NCT00370929|BEHAVIORAL|Meditation|
219482712|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
219482713|NCT00003401|DRUG|carmustine|
219482714|NCT00003401|DRUG|cisplatin|
219482715|NCT00003401|DRUG|cyclophosphamide|
219482716|NCT00003401|DRUG|dexamethasone|
219482717|NCT00003401|DRUG|etoposide|
219482718|NCT00003401|DRUG|gemcitabine hydrochloride|
219482719|NCT00003401|DRUG|melphalan|
218866283|NCT02349685|DRUG|14 day PBMT group|Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
219482720|NCT00003401|DRUG|paclitaxel|
219482721|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
219482722|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
219482723|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
219482724|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
219482725|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
219482726|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
219482727|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
219482728|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
219482729|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
219482730|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
219482731|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
219598587|NCT05273346|BEHAVIORAL|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
219482732|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
219482733|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
219482734|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
219482735|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
219598588|NCT05273346|OTHER|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
219598589|NCT05273346|BEHAVIORAL|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
218866284|NCT02349685|DRUG|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
218866285|NCT03875664|DRUG|Liposomal bupivacaine|Extended-release local anesthetic
219482736|NCT01927159|OTHER|Placebo|
219482737|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
219482738|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
219482739|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
219482740|NCT03223506|DRUG|Paracetamol|
219482741|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
219482742|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
219482743|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
218866286|NCT03875664|DRUG|Placebo - injection|Injectable normal saline solution
219482744|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
219482745|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
218866287|NCT03394352|OTHER|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
219482746|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
219482747|NCT01872832|DRUG|RDEA3170 and Placebo|
219482748|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
219482749|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
219482750|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
219482751|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
219482752|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
219522373|NCT07036393|OTHER|Acupuncture|"Cholecystectomy involves a procedure where patients' spines are kept in position and skin around the acupoints is disinfected with 75% alcohol. Acupuncture treatment is given when patients return to units within 2 hours after surgery. The needles are inserted using disposable sterile needles and manipulated to induce a sense of De qi (soreness, numbness, distension, or heaviness). Gastrectomy involves daily acupuncture sessions for 5 consecutive days, starting on postoperative day 1. The needles are inserted perpendicular to the acupoints in the extremities to a depth of approximately 20 mm from the skin surface."
218866288|NCT03394352|OTHER|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
218866289|NCT02927821|BEHAVIORAL|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
218866290|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
218866291|NCT06258590|DEVICE|Transcutaneous auricular vagus nerve stimulation|Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
218866292|NCT05226078|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
218866293|NCT05065190|DRUG|Nintedanib|Soft gelatin capsule
218866294|NCT05065190|DRUG|Placebo|Soft gelatin capsule
218866295|NCT01797523|DRUG|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
219482753|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
218866296|NCT01797523|DRUG|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
218866297|NCT01797523|DRUG|Everolimus|10 mg by mouth once daily in a 28 day cycle.
218866298|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
218866299|NCT05669872|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
218866300|NCT05669872|DRUG|RBC|pack RBC transfusion
218866301|NCT02108314|BEHAVIORAL|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
218866302|NCT05971446|DEVICE|Visual Evoked Potential (VEP)|Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.
218866303|NCT05971446|DEVICE|Electroretinogram (ERG)|Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
219482754|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
218866304|NCT05039892|DRUG|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
218866305|NCT05736419|DRUG|Fludarabine|PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
218866306|NCT05736419|DRUG|Cyclophosphamide|Cyclophosphamide will be administered Post-Transplant
218866307|NCT05736419|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day +5
218866308|NCT05736419|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
218866309|NCT05736419|BIOLOGICAL|Rabbit ATG|The dose and schedule of ATG will be determined according to the nomogram in Appendix A
218866310|NCT05736419|DRUG|Dexamethasone|Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
218866311|NCT05736419|DRUG|Bortezomib|Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
218866312|NCT05736419|DRUG|Rituximab|Rituximab on days -71, -58, -43, and -30.
218866313|NCT05767827|DRUG|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
218866314|NCT05767827|DRUG|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
218866315|NCT06434233|DRUG|Acetaminophen|"All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter."
218866316|NCT06434233|DRUG|Ibuprofen|"All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter."
218866317|NCT06434233|DRUG|Oxycodone|"Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1"
219482755|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
219482756|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
219482757|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
219482758|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
218866318|NCT05691010|RADIATION|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
218866319|NCT05691010|DRUG|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
218866320|NCT05691010|DRUG|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
218866321|NCT00988949|DRUG|PF-04455242|Single oral 18 mg dose of PF-04455242.
218866322|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
219040047|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
219040048|NCT04999631|DRUG|Ethanol Solution|Control
219482759|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
219482760|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
218866323|NCT00988949|OTHER|Placebo|Oral placebo.
218866324|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
218866325|NCT00988949|DRUG|PF-04455242|Single 30 mg oral dose of PF-04455242.
218866326|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
218866327|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
218866328|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
218866329|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
218866330|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
219482761|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
219482762|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
219482763|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
219482764|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
219482765|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
219482766|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
219482767|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
218866331|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
218866332|NCT05565937|DEVICE|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
218866333|NCT05565937|DEVICE|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
219482768|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
219482769|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
219482770|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
219482771|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
219482772|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
219482773|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
219482774|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
219482775|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
218866334|NCT06276998|DRUG|LNK01001|Capsule; Oral
218866335|NCT06276998|DRUG|Placebo|Capsule; Oral
218866336|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
218866337|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
218866338|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
218866339|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
218866340|NCT01099436|DRUG|cyclophosphamide|
218866341|NCT01099436|DRUG|docetaxel|
219482776|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
218866342|NCT01099436|DRUG|doxorubicin hydrochloride|
218866343|NCT01099436|DRUG|zoledronic acid|
218866344|NCT01099436|PROCEDURE|neoadjuvant therapy|
218866345|NCT01022424|DRUG|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
218866346|NCT04934644|PROCEDURE|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
218866347|NCT02706197|DEVICE|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
219482777|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
219482778|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
218866348|NCT06479694|BEHAVIORAL|Real-life Dual-Task Training|The intervention is Real-life Dual-Task Training (Real-DTT) which uses instrumental activities of daily living training with explicit focus on the cognitive and motor elements and when to focus attention to one vs. the other to reduce fall risk. The Real-DTT sessions will be delivered once a week for 10 weeks during their occupational therapy sessions, delivered by a licensed occupational therapist. Real-DTT is a modified version of occupational therapy, with a protocol tailored to the participants.
218866349|NCT05415137|DRUG|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
218866350|NCT05415137|DRUG|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
218866351|NCT05415137|DRUG|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
219482779|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
219482780|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
219482781|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
219482782|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
219482783|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
219482784|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
219482785|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
219482786|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
219482787|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
219482788|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
219482789|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
219482790|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
219482791|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
218866352|NCT02783170|BIOLOGICAL|Tetanus, Diphtheria, and Pertussis Vaccine|
218866353|NCT02783170|BIOLOGICAL|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
218866354|NCT02783170|BIOLOGICAL|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
218866355|NCT06794372|DRUG|[68Ga]Ga-FAPI-46 PET/CT|\[68Ga\]Ga-FAPI-46 PET/CT
218866356|NCT06797037|OTHER|Decentralised Pathway Coordinated by the Advanced Practice Nurse|"For each patient enrolled in the study: a decentralised treatment delivery route will be organised. To achieve this, two visits will be planned by the investigating centre's Advanced Practice Nurse (APN) and carried out at the patient's home by a service-providing nurse. During these visits, the APN will take the patient's vital signs before handing over the treatment.~In addition, for the purposes of the study, during the 2nd visit the patient will be asked to complete a satisfaction questionnaire."
219482792|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
219482793|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
219482794|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
219482795|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
219482796|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
219482797|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
219482798|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
219482799|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
219522374|NCT07036393|OTHER|Transcutaneous electrical nerve stimulation|Patients will receive a transcutaneous electrical nerve stimulation unit (ENNRAF) for up to 48 hours post-surgery, with instructions to self-titrate intensity for pain relief. Postoperative stimulation will be 20-40 milliampere and pulse width 5
218866357|NCT04253587|DEVICE|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
218866358|NCT04253587|DEVICE|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
219482800|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
219482801|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
219482802|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
219482803|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
219482804|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
219482805|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
219482806|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
219482807|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
219482808|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
219482809|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
219482810|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
219482811|NCT02060227|PROCEDURE|Open Latarjet procedure|
219482812|NCT02060227|PROCEDURE|Arthroscopic Bankart repair|
219482813|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
219598590|NCT05273346|BEHAVIORAL|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
218866359|NCT04253587|DEVICE|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
218866360|NCT04253587|DEVICE|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
218866361|NCT05006833|BEHAVIORAL|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
219021145|NCT07207005|DEVICE|ECIMA CORIN|Mobile cup (Corin) made of highly cross-linked PE doped with vitamin E (ECIMA, Corin).
219021146|NCT07207005|DEVICE|CORIN|Mobile cupule (Corin) is made of conventional PE
219040049|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
219482814|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
219482815|NCT06567171|PROCEDURE|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures.|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures. Parental use of pain relief strategies (PURPS) and parental postoperative pain management (PPPM) tools were used to collect data on the adequacy of knowledge of the use of different pain relief strategies and the skill of parental pain assessment, respectively. We used Spearman's rank correlation coefficient was used to determine the relationships between pain score given by parents and nurses. The statistical tests were performed at a 95% confidence interval and a 5% significance level.
219482816|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
219482817|NCT05351437|DRUG|Placebo|0.9% saline
219522375|NCT07036393|OTHER|drugs|analgesics and nonsteroidal anti-inflammatory drugs
219522376|NCT07035847|PROCEDURE|Echocardiography guided TAVR|Echocardiography guided TAVR
219522377|NCT07036978|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
219522378|NCT07036432|DEVICE|Endosign|"The intervention involves the EndoSign® Cell collection device (Cyted Ltd), a non-endoscopic method for esophageal sampling.~Patients swallow a gelatine/HPMC capsule containing a sponge attached to a string. After \~7 minutes in the stomach for dissolution and sponge expansion, a trained nurse withdraws the sponge via the string, collecting cells. Optional throat anesthetic is offered.~It can be performed without sedation in an outpatient clinic setting by a nurse. Samples undergo central analysis for TFF3, atypia, and p53, differing from standard biopsy histopathology. This study specifically evaluates its feasibility, acceptability, and nurse-led implementation in Swedish hospitals for Barrett's surveillance."
218866362|NCT05006833|BEHAVIORAL|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
218866363|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
218866364|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
219482818|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
219482819|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
219482820|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
219482821|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
219482822|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
219482823|NCT00274807|BIOLOGICAL|filgrastim|
219598591|NCT05273346|BEHAVIORAL|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
219598592|NCT05273346|OTHER|Oral painkillers|NSAID drugs, if necessary.
219598593|NCT05547217|DEVICE|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
219598594|NCT05387343|DIAGNOSTIC_TEST|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
219598595|NCT00704132|DRUG|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
218866365|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
219482824|NCT00274807|DRUG|cytarabine|
219482825|NCT00274807|DRUG|etoposide|
219482826|NCT00274807|DRUG|mitoxantrone hydrochloride|
219482827|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
219482828|NCT03026842|DRUG|Decitabine|20 mg/m2/day for 5 days
219482829|NCT03026842|DRUG|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
219482830|NCT03026842|DRUG|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
219482831|NCT03026842|DRUG|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
219598596|NCT00704132|DRUG|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
219598597|NCT01618565|PROCEDURE|Hands-On Training|one-time, 30 minute hands-on training
219598598|NCT01618565|PROCEDURE|Demonstration|30 minutes passive training
219598599|NCT03610230|DRUG|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
219598600|NCT03610230|DRUG|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
219598601|NCT00442962|DRUG|Efavirenz|600-mg tablet taken orally daily
219598602|NCT00442962|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
219598603|NCT06025240|DIAGNOSTIC_TEST|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
219482832|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
219482833|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
219482834|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
219482835|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
219482836|NCT05303844|DRUG|H101|H101 intratumorally injection starts at day 0.
219482837|NCT05303844|DRUG|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219482838|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
218866371|NCT03320330|OTHER|Laboratory Biomarker Analysis|Correlative studies
219482839|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
219482840|NCT05517746|DRUG|BAY2395840 tablet|tablets, oral administration
219482841|NCT05517746|DRUG|BAY2395840 oral solution|solution, oral administration
219482842|NCT05517746|DRUG|Placebo oral solution|Placebo matching BAY2395840, oral administration
219482843|NCT05517746|DRUG|Placebo tablet|Placebo matching BAY2395840, oral administration
219482844|NCT02222168|DRUG|BI 409306|film-coated tablet
219482845|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
219482846|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
219482847|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
219482848|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
219482849|NCT06196970|OTHER|Pilate exercises|After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
219482850|NCT06196970|OTHER|Burpees exercises|"After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set."
219482851|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
218866372|NCT03320330|BIOLOGICAL|Pepinemab|Given IV
218866373|NCT03320330|OTHER|Pharmacological Study|Correlative studies
219482852|NCT00530621|DRUG|placebo|oral, daily
218866374|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
218866375|NCT04835168|DRUG|BT-11 low|Oral
218866376|NCT04835168|DRUG|BT-11 high|Oral
219482853|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
219482854|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
219482855|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
218866377|NCT04835168|DRUG|Placebo|Oral
218866378|NCT01806064|DRUG|TRC105 and Axitinib|
218866379|NCT01806064|DRUG|Axitinib|
218866380|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
219482856|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
219482857|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
219482858|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
219482859|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
219482860|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
219482861|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
219482862|NCT00518011|DRUG|Erlotinib|150 mg po daily
219482863|NCT00518011|DRUG|Gemcitabine|As prescribed
219482864|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
219482865|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
219482866|NCT05676164|DEVICE|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
219482867|NCT05676164|DEVICE|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
219482868|NCT02959398|DEVICE|Standard mammography|Standard mammography
219482869|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
219482870|NCT02998645|DRUG|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
219482871|NCT02998645|DRUG|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained"
219482872|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
219482873|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
219482874|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
219482875|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
219598604|NCT06025240|DIAGNOSTIC_TEST|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
219598605|NCT06025240|OTHER|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
219598606|NCT01144429|BIOLOGICAL|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
219598607|NCT00323050|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
219598608|NCT02228850|DRUG|Alprostadil|
219482876|NCT02139969|DEVICE|GreenLight XPS Laser System|
219482877|NCT05270512|DEVICE|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
219482878|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
219598609|NCT02228850|OTHER|Placebo|
219598610|NCT05175040|PROCEDURE|Prophylactic manual rotation|Prophylactic manual rotation, performed in the experimental arm, involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation, performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
219021149|NCT07206121|DEVICE|Radiofrequency ablation alone|Demonstrate the accuracy of the device to produce 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation deep shave margins.
219482879|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
219021150|NCT07206121|DEVICE|Radiofrequency ablation Electrosurgical Device|SIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.
219482880|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
219482881|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
219482882|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
219482883|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
219482884|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
219482885|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
219482886|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
219482887|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
219482888|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
219482889|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
219482890|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
219482891|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
219482892|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
219482893|NCT00006092|DRUG|Arsenic Trioxide|
219482894|NCT06566222|PROCEDURE|chemoradiotherapy after surgery|chemoradiotherapy after surgery vs preoperative chemoradiotherapy
219482895|NCT06566222|OTHER|High-risk Factors|High-risk Factors vs low-risk Factors
219482896|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
219482897|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
219598611|NCT05175040|PROCEDURE|Sham rotation|Sham rotation, performed in the comparator arm, involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation. Duration of the vaginal exam for sham rotation will be consistent with that used for prophylactic manual rotation and will be performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
219598612|NCT03633825|BEHAVIORAL|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
219482898|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
219482899|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
219040050|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
219482900|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
219482901|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
219482902|NCT04611152|DRUG|KSI-301|Intravitreal Injection
219482903|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
218866381|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
218866382|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
218866383|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
218866384|NCT01417364|DRUG|Testosterone enanthate|100 mg. IM weekly throughout study
218866385|NCT01417364|DRUG|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
218866386|NCT01417364|DRUG|Placebo|Injected IM weekly throughout study
218866387|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
218866388|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
218866389|NCT03046225|DEVICE|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
218866390|NCT03046225|DEVICE|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
218866391|NCT03046225|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
218866392|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
218866393|NCT05287217|OTHER|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
219482904|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
219482905|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
219482906|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
219482907|NCT00029159|OTHER|placebo|an inactive substance
219482908|NCT01248000|PROCEDURE|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
218866394|NCT04720846|OTHER|Matrix-based physical therapy|Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
218866395|NCT04720846|OTHER|Standard-of-care physical therapy|Physical therapy that is being conducted as standard-of-care
218866396|NCT05859074|BIOLOGICAL|MQ719|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
218866397|NCT05859074|DRUG|Pembrolizumab|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
218866398|NCT04617522|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
218866399|NCT04438291|OTHER|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
218866400|NCT04438291|OTHER|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
218866401|NCT01051401|DRUG|rosuvastatin|Given PO
218866402|NCT01051401|OTHER|placebo|Given PO
218866403|NCT01051401|OTHER|survey administration|Correlative study
218866404|NCT01051401|PROCEDURE|management of therapy complications|
218866405|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
218866406|NCT04753021|OTHER|Exercise|Progressively increasing training load
219482909|NCT05343247|DIAGNOSTIC_TEST|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
219598613|NCT05973968|DRUG|Surufatinib|Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
219040051|NCT03073278|RADIATION|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
218866407|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
218866408|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
218866409|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
218866410|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
218866411|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
218866412|NCT00258466|RADIATION|radiation therapy|
218866413|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
218866414|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
219482910|NCT05343247|DIAGNOSTIC_TEST|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
218866415|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
218866416|NCT06264856|PROCEDURE|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
219482911|NCT02263677|DRUG|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
219482912|NCT04045405|DRUG|CDR132L|i.v. administration
219482913|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
219482914|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
219482915|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
219482916|NCT03258515|DRUG|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
219482917|NCT03258515|OTHER|Placebo|AZD6094 matching placebo without any pharmacological activity.
219482918|NCT03258515|DRUG|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
219482919|NCT00580931|DRUG|Nicotinamide|1500 mg twice a day for 6 months
219482920|NCT00580931|DRUG|Enduramide placebo|1 tab twice a day
219482921|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
219482922|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
219482923|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
219482924|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
219482925|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
219482926|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
218866417|NCT06264856|PROCEDURE|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
218866418|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
218866419|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
218866420|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
219040052|NCT03348696|DRUG|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
219040053|NCT03348696|DRUG|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
219482927|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
219482928|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
218866421|NCT01308229|DEVICE|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
219040054|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
218866422|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
218866423|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
218866424|NCT05776212|RADIATION|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
219482929|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
219482930|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
219482931|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
219482932|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
219482933|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
219482934|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
219482935|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
219040055|NCT01790464|DRUG|placebo|
219040056|NCT00197379|DRUG|roxithromycin|
219482936|NCT03166969|PROCEDURE|Holter 21 days|
219482937|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
219482938|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
219482939|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
219482940|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
219482941|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
219482942|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
219482943|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
219482944|NCT00956813|OTHER|placebo|Given orally
219598614|NCT01938495|DEVICE|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
219598615|NCT03335514|DIAGNOSTIC_TEST|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
219598616|NCT00186524|BEHAVIORAL|Breast Cancer Support Group|
219482945|NCT00134472|PROCEDURE|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
219482946|NCT04797637|DEVICE|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
218866425|NCT06777303|DRUG|curcurmin loaded on chitosan nano-particles|the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
218866426|NCT06777303|DRUG|hyaluronic acid loaded on chitosan nano-particles|the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
218866427|NCT06777303|PROCEDURE|scaling and root planning|the -ve control group in the study
218866428|NCT06777303|DRUG|chitosan nano-particles|the +ve control group in the study
219482947|NCT02944682|OTHER|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
219482948|NCT00120380|DRUG|Aerosolized iloprost|
219482949|NCT00120380|DRUG|Placebo|
218866429|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
218866430|NCT06010173|DRUG|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
219482950|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
219482951|NCT00240786|DRUG|acetaminophen extended release|
219482952|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219482953|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
218866431|NCT06010173|DRUG|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
218866432|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
218866433|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
219021155|NCT07205718|DRUG|TAK-188|TAK-188 IV infusion
219482954|NCT00170898|DRUG|Lumiracoxib|
219482955|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
219482956|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
219482957|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
219482958|NCT04736316|BEHAVIORAL|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
219482959|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
218866434|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
218866435|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
218866436|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
218866437|NCT01943006|DRUG|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
218866438|NCT01943006|DRUG|Placebo cream without active substance|
219482960|NCT00117013|DRUG|Topotecan|
219482961|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
219482962|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
218866439|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
218866440|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
219482963|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
219482964|NCT05421715|OTHER|TELEDUC-DIAB|"* Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
218866441|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
218866442|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
218866443|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
218866444|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
218866445|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
218866446|NCT00004445|PROCEDURE|Surgery|
218866447|NCT00004445|DEVICE|IRS-8|
218866448|NCT04692077|DRUG|Cabotegravir (CAB) tablet|30 mg tablets
219482965|NCT05043220|DEVICE|PPG and PROM|description will follow
219482966|NCT04897334|DEVICE|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
219482967|NCT04897334|DEVICE|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
219482968|NCT04897334|BEHAVIORAL|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
219482969|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e4|
219482970|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e5|
219482971|NCT02076139|OTHER|Distilled water|
219482972|NCT06542887|DRUG|Atomoxetine|Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
219482973|NCT06542887|DRUG|Black Seed Oil Cap/Tab|Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
219482974|NCT00301639|DRUG|OROS methylphenidate hydrochloride|
219482975|NCT00301639|DRUG|methylphenidate hydrochloride|
219482976|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
219482977|NCT04440761|OTHER|Observation only|Observation only
218866449|NCT04692077|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
218866450|NCT04692077|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet|300 mg/200 mg fixed-dose combination tablets
218866451|NCT06343532|DRUG|SXC-2023|200 mg capsules
218866452|NCT06343532|DRUG|SXC-2023 Placebo|200 mg capsules
218866453|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
218866454|NCT03157765|PROCEDURE|endometrial biopsy|endometrial biopsy
219482978|NCT06621173|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, after enrollment, the investigator will determine the HNF4α srRNA dose, whether to combine it with immunotherapy, and the dose and schedule of the combination, based on the patient's treatment history and the safety/efficacy data of HNF4α srRNA administered via peripheral vein for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or colorectal cancer. Participants initially on HNF4α srRNA monotherapy who are considered for combination with immunotherapy must complete at least two treatment cycles and the post - treatment safety assessment."
218866455|NCT06583681|OTHER|The measuring of the sagittal curvatures of the spine|Research tool was Baseline Bubble inclinometer.
218866456|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
219598617|NCT01964079|DRUG|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
219040057|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
219482979|NCT05117294|DRUG|Bocidelpar|Oral
219482980|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
219482981|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
219482982|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
219482983|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
219482984|NCT01023022|OTHER|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
219482985|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
219482986|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
219482987|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
218866457|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
218866458|NCT04243330|BEHAVIORAL|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
218866459|NCT04243330|BEHAVIORAL|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
218866460|NCT06664502|DRUG|EYE201|EYE201 solution for intravitreal administration
218866461|NCT05915442|DRUG|Quemliclustat|100mg IV once every two weeks
218866462|NCT05915442|DRUG|Etrumadenant|150 mg orally (PO) once a day (QD)
218866463|NCT05915442|DRUG|Zimberelimab|240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
219482988|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
219482989|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
219482990|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
219482991|NCT01919853|BEHAVIORAL|Mindfulness-Based Stress Reduction|
219482992|NCT01919853|BEHAVIORAL|Attention Control|
219199783|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
218866464|NCT05915442|RADIATION|Stereotactic Body Radiation Therapy|Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
219199784|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
219199785|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).
219199786|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).
219482993|NCT04686500|DEVICE|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
219598618|NCT01964079|DRUG|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
219482994|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
219482995|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
219482996|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
219482997|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
219598619|NCT03188224|OTHER|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
219598620|NCT03692832|PROCEDURE|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
219598621|NCT03692832|PROCEDURE|VH|Vaginal hysterectomy following Heaney technique
219598622|NCT05630911|OTHER|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
219598623|NCT00182546|PROCEDURE|Two diagnostic management strategies|
219598624|NCT01420965|DRUG|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
219598625|NCT01420965|OTHER|Sipuleucel-T (Provenge)|Vaccine
219598626|NCT01420965|DRUG|Cyclophosphamide|Low dose- Immune Enhancer
219598627|NCT01816659|DRUG|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
219598628|NCT01322867|DRUG|alprazolam tablet|0,25 mg oral tablets given once
219598629|NCT01322867|DRUG|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
218866465|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
218866466|NCT02753127|DRUG|Fluorouracil|
218866467|NCT02753127|DRUG|Leucovorin|
218866468|NCT02753127|DRUG|Irinotecan|
218866469|NCT02753127|DRUG|Bevacizumab|
219482998|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
219482999|NCT00088400|DRUG|TransMID|
219483000|NCT02614352|DRUG|Atorvastatin + Candesartan|
219483001|NCT02614352|DRUG|AG1502|
219483002|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
219483003|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
219483004|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
219483005|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
219483006|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
219483007|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
219483008|NCT02919033|OTHER|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
219483009|NCT02919033|DEVICE|Self-management|"* Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App."
219483010|NCT02919033|OTHER|PCTM intervention|"* Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website."
219483011|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
219483012|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
219483013|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
219483014|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
219483015|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
219483016|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
219483017|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
219483018|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
219598630|NCT02547090|PROCEDURE|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
219598631|NCT06236841|DRUG|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
219598632|NCT06236841|DRUG|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
219598633|NCT06159491|DRUG|Pacritinib|Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
219598634|NCT06159491|DRUG|Azacitidine|Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
219598635|NCT06250036|DRUG|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
219598636|NCT06250036|DRUG|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
219598637|NCT05326412|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
219598638|NCT02928185|BEHAVIORAL|semi-structured interviews|
219040058|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
219598639|NCT06298513|OTHER|Cardiac rehabilitation|Six weeks of cardiac rehabilitation with physical training
219598640|NCT06037694|PROCEDURE|Conventional Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.
218866470|NCT04043598|DRUG|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
219483019|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
218866471|NCT04043598|DRUG|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
218866472|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
218866473|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
219483020|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
219483021|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
219483022|NCT05428267|OTHER|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
218866474|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
219483023|NCT05428267|OTHER|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
219040059|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
219598641|NCT06037694|PROCEDURE|'Mesh Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
219598642|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
219598643|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
218866475|NCT03826342|BEHAVIORAL|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
219040060|NCT05379296|BEHAVIORAL|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
219040061|NCT05379296|BEHAVIORAL|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
219040062|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
219040063|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
219483024|NCT06184646|DIETARY_SUPPLEMENT|Prune|30 g of prune/day
219598644|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
219598645|NCT05405660|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
219598646|NCT05405660|DRUG|Matching Placebo|Subcutaneous Administration
219483025|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
219483026|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
219483027|NCT06211075|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia with Motivational Interviewing|This intervention implements elements of Cognitive Behavioural Therapy for Insomnia with motivational interview techniques incorporated into the intervention, aiming to build long-lasting motivation, better rapport with the patients and self-efficacy to increase engagement rate despite its remotely delivered format. The whole intervention is delivered online.
219483028|NCT06441266|DRUG|KeraStat cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions. The intervention is a topical cream applied at least twice daily starting at start of radiation therapy until 1-month from the end of radiation therapy completion
219598647|NCT06470295|OTHER|Saline|Normal saline will be infused during insulin-induced hypoglycemia
219598648|NCT06470295|BIOLOGICAL|C-peptide|C-peptide will be infused during insulin-induced hypoglycemia
219598649|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
219598650|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
219598651|NCT04714983|BIOLOGICAL|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
219483029|NCT06441266|DEVICE|M-PART Assessments via MyCap|The M-PART approach harnesses the remote data collection capabilities of MyCap to facilitate remote collection or data including but not limited to toxicity assessments, quality of life surveys, and patient-provided photographs of the skin in the treated area
219483030|NCT06441266|OTHER|Clinical Assessments|Participants will undergo assessments at baseline (prior to radiation therapy start), weekly during and after radiation therapy until 1-month post-radiation therapy. Medical history will be collected at baseline including primary cancer site, HPV status (if oropharyngeal cancer primary), laterality, TNM classification, stage, surgical resection prior to radiation therapy, weight, body mass index and patient self-reported Fitzpatrick skin phototype.
218866476|NCT03826342|BEHAVIORAL|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
219040064|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
219040065|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
218866477|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
218866478|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
219199787|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
219199788|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
219199789|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
219483031|NCT06441266|OTHER|Feedback phone interview|Participant satisfaction, perceptions and preferences with using M-PART will be discussed.
219483032|NCT05018286|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
219483033|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
219483034|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
219199790|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
219522379|NCT07035483|PROCEDURE|bariatric surgery|This is a prospective observational study evaluating the metabolic and tissue-level effects of bariatric surgery in obese individuals. The intervention includes either laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB), performed according to standard clinical guidelines. No experimental procedures are added beyond routine care. Skeletal muscle quality and visceral fat distribution are assessed using MRI and clinical biomarkers at multiple postoperative time points (baseline, 3 months, 12 months, and annually up to 5 years). A healthy control group undergoes baseline evaluation only, without surgical intervention.
219522380|NCT07035509|BIOLOGICAL|Pharmaceutical fresh frozen plasma|OCTAPLAS LG® has been registered with INVIMA in Colombia for five years and is used as a plasma replacement in cardiac surgery, hematologic diseases, or intensive care settings where blood bank plasma is unavailable
219522381|NCT07035509|DRUG|Normal Saline|Bolus dose of 10 mL/kg normal saline (NS) (max. 500 mL) administered over \<15 minutes.
219522382|NCT07035509|DRUG|Ringer lactate (RL)|Bolus dose of 10 mL/kg Ringer's lactate (max. 500 mL) administered over \<15 minutes.
219522383|NCT07037407|PROCEDURE|IOS|Intra oral scanning
219522384|NCT07037407|PROCEDURE|WTI|window technique Impression
219522385|NCT07037472|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventioanl US imaging
219522386|NCT07037472|DRUG|Drug treatment|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventional US imaging. The histopathological biopsy results before and after treatment are combined as indicators for evaluating therapeutic efficacy and predicting treatment outcomes.
219522387|NCT07036263|OTHER|Oculomotor therapy|"Oculomotor therapy will follow and adapt the protocol for treating convergence insufficiency (CI). Procedures will be organized progressively, from easiest to most difficult. Gross convergence techniques: (1) Brock String: A 1.5-2 m cord with colored beads; the patient focuses on each bead to train binocular fusion, observing the X shape of the cord. (2) Barillé Chart: A card with paired images for each eye; the patient merges the images into one using convergence and sensory fusion. Accommodative techniques: (1) Eccentric Circles: Printed circles with eccentric marks; viewed through filters to train motor and sensory fusion by aligning them into a single 3D image. (2) Opaque Lifesaver Cards: Cards with figures on an opaque background, used with red-green filters to stimulate convergence and fixation by reducing peripheral stimuli and enhancing visual attention."
219522388|NCT07036263|OTHER|No Treatment Added|Participants in the control group will not receive any type of treatment for a period of five weeks. After this period, they will be re-evaluated
219522389|NCT07036276|BEHAVIORAL|Co-adapted intervention|An existing co-created intervention will be adapted by researchers and 7th and 8th grade pupils and teachers during 3 to 5 design sessions in both co-adaptation intervention schools.
219598652|NCT03236415|DEVICE|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
219199791|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
219199792|NCT06777771|OTHER|Reformer pilates exercises|The reformer pilates exercises session will start with 5 minutes of warm-up exercises, continue with resistance exercises for 20 minutes, and end with 5 minutes of cool-down exercises. The springs of the reformer pilates device will be adjusted to create mild fatigue in the first week and will be gradually increased to create moderate fatigue in the following weeks. Reformer pilates sessions will consist of 15-20 different exercises with 12-15 repetitions, including all major muscle groups. These sessions will also include exercises that strengthen the pelvic floor muscles. Reformer pilates sessions will be applied twice a week for 6 weeks, a total of 12 sessions. Apart from this, they will be asked to walk for at least 30 minutes a day, at least 3 days a week.
219483035|NCT01306968|DRUG|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
219483036|NCT01306968|OTHER|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
219483037|NCT06230692|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
219483038|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
219483039|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
219483040|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
219483041|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
219483042|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
219483043|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
219483044|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
219483045|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
219483046|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
219483047|NCT02058264|DRUG|BBI-4000|
219483048|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
219483049|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
219483050|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
219598653|NCT03236415|DEVICE|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
219598654|NCT03652558|DEVICE|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
219598655|NCT00858481|DRUG|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
219598656|NCT00858481|DRUG|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
219598657|NCT00858481|DRUG|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
219199793|NCT02163694|DRUG|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
219483051|NCT03252015|DRUG|Probe Drug Cocktail|Administered orally
219483052|NCT03252015|DRUG|Lasmiditan|Administered orally
219483053|NCT03252015|DRUG|Placebo|Administered orally
219483054|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
219483055|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
219483056|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
219483057|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
219483058|NCT05163925|DEVICE|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
219483059|NCT03886402|DEVICE|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
219483060|NCT00307138|DRUG|hetastarch|
219483061|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
219483062|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
219483063|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
219483064|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
219483065|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
219483066|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
219483067|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
219483068|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
219483069|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
219483070|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
219483071|NCT00002738|DRUG|leucovorin calcium|
219483072|NCT00002738|DRUG|trimetrexate glucuronate|
219483073|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
219483074|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
219483075|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
219483076|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
219199794|NCT02163694|DRUG|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
219483077|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
219483078|NCT01159652|DRUG|zaleplon|10 mg
219483079|NCT01159652|DRUG|zolpidem extended release|12.5 mg
219483080|NCT01159652|DRUG|bedtime placebo|placebo
219483081|NCT01159652|DRUG|middle of the night placebo|placebo
219483082|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
219483083|NCT02604849|DRUG|Neomycin|
219483084|NCT02604849|DRUG|Streptomycin|
219483085|NCT02604849|DRUG|Gentamicins|
219483086|NCT03628872|PROCEDURE|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
219199795|NCT02163694|DRUG|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
219199796|NCT02163694|DRUG|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
219199797|NCT06825572|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
219199798|NCT06306898|OTHER|Endotracheal Intubation|Ventilation with an endotracheal tube
219199799|NCT06306898|OTHER|Laryngeal tube|Ventilation with an laryngeal tube
219199800|NCT06306898|OTHER|Laryngeal mask|Ventilation with an laryngeal mask
219483087|NCT03628872|DEVICE|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
219483088|NCT03628872|DEVICE|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
219483089|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
219483090|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
219598658|NCT00858481|DRUG|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
219598659|NCT01267994|DRUG|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
219598660|NCT04791514|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
219598661|NCT03052296|DEVICE|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
219598662|NCT01316302|DRUG|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
219598663|NCT01316302|DRUG|Placebo|Matching placebo, taken QD for 12 weeks.
219598664|NCT04730037|DRUG|Edoxaban|\- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
219598665|NCT04730037|DRUG|Warfarin Potassium|\- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
219199801|NCT06306898|OTHER|I-Gel-Laryngeal Mask|Ventilation with an I-Gel-laryngeal mask
219483091|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
219483092|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
219483093|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
219483094|NCT01998659|DRUG|Placebo|Oral drinking solution
219483095|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
219483096|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
219483097|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
219483098|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
219483099|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
219483100|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
219483101|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
219483102|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
219598666|NCT04730037|DRUG|Warfarin Potassium placebo|\- Warfarin K 1 mg placebo tablets once daily
218866479|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
219483103|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
219598667|NCT04730037|DRUG|Edoxaban placebo|\- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
218866480|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
218866481|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
218866482|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
218866483|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
218866484|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
218866485|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
218866486|NCT04648514|PROCEDURE|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
218866487|NCT04648514|BEHAVIORAL|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
219598668|NCT03850925|PROCEDURE|Laser therapy|4 consecutive sessions of laser therapy
219598669|NCT00818688|PROCEDURE|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
219598670|NCT05127915|DEVICE|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
219598671|NCT05127915|DEVICE|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
219598672|NCT03388489|BEHAVIORAL|Mind-Body Walking|walking, breathing, and mindfulness
219598673|NCT06522633|DRUG|The intervention involves the discontinuation of the opioid.|Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
219598674|NCT00424918|BEHAVIORAL|Physical Activity, reduced sedentary behavior|
219598675|NCT05199090|DRUG|MBL949|subcutaneous injections administered for 14 weeks
218866488|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
218866489|NCT03527524|OTHER|exercise with ball|exercise with ball
218866490|NCT03527524|OTHER|exercise without ball|exercise without ball
218866491|NCT02738424|OTHER|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
219483104|NCT00061568|DRUG|Sirolimus|Sirolimus
219483105|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
219483106|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
219598676|NCT05199090|DRUG|Placebo|Placebo Comparator to MLB949
219598677|NCT06237439|BEHAVIORAL|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
219483107|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
219199802|NCT06666179|BIOLOGICAL|low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
219199803|NCT06666179|BIOLOGICAL|adjuvanted low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
219199804|NCT06666179|BIOLOGICAL|high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
219199805|NCT06666179|BIOLOGICAL|adjuvanted high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
219199806|NCT06666179|OTHER|Placebo|0.9% NaCl saline placebo
219199807|NCT02405221|BIOLOGICAL|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
218866492|NCT06960629|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 3 months.
218866493|NCT06960629|DRUG|Placebo|Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 3 months.
218866494|NCT05327127|DRUG|K-877-ER|K-877-ER tablet
218866495|NCT05327127|DRUG|CSG452|CSG452 tablet
218866496|NCT05327127|DRUG|Placebo|Placebo tablet
218866497|NCT06433999|DRUG|Brepocitinib|Oral Brepocitinib PO QD
218866498|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
218866499|NCT03691350|DRUG|Cigarette|Smoke usual brand
218866500|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
218866501|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
218866502|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
219522390|NCT07036276|BEHAVIORAL|Standard intervention|The existing co-created intervention will be implemented in the standard intervention schools. So, adolescents and school staff from the standard intervention schools will not be involved in adapting the intervention.
219522391|NCT07035444|DIETARY_SUPPLEMENT|L-Carnitine 4g|500ml enteral nutrition solution containing 4g of L-carnitine
219522392|NCT07035444|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition was given 500 ml per day for a total of 84 days.
218866503|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
219522393|NCT06126393|DIAGNOSTIC_TEST|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
219522394|NCT06719375|DEVICE|Gait Analysis Using IMU Sensor|Inertial Measurement Unit (IMU) sensor-based 3D gait analysis to assess spasticity and gait impairment. This intervention aims to provide quantitative data on gait parameters in DCM patients before and after surgery.
219522395|NCT07036809|DIAGNOSTIC_TEST|Antithrombin III|quantitative measurement(%)
219522396|NCT07036809|DIAGNOSTIC_TEST|Protein C|quantitative measurement(%)
219522397|NCT07036809|DIAGNOSTIC_TEST|Protein S|quantitative measurement(%)
219522398|NCT07036809|DIAGNOSTIC_TEST|D-dimer|quantitative measurement( ug/ml)
219522399|NCT07036809|DIAGNOSTIC_TEST|Flow cytometry immunophenotyping|Flow cytometry immunophenotyping
218866504|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
218866505|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
218866506|NCT05501743|DRUG|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
219522400|NCT07037186|DEVICE|Electroencephalogram|All patients will receive intraoperative electroencephalography monitorization during general anesthesia.
219522401|NCT07036861|DRUG|Ibuprofen 2%|Reformulated Ibuprofen 2% oral suspension (Berlin-Chemie AG)
219522402|NCT07036861|DRUG|Ibuprofen 4%|Reformulated Ibuprofen 4% oral suspension (Berlin-Chemie AG)
219522403|NCT07036861|DRUG|Ibuprofen 4%|Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension (Polish brand name)
219522404|NCT02158936|DRUG|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
219522405|NCT02158936|DRUG|Azacitidine|Subcutaneous Injection (IV if local standard)
219522406|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets
219522407|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets will be supplied
218866507|NCT05501743|PROCEDURE|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
218866508|NCT02846649|BEHAVIORAL|PIER|Daily text message queries with tailored support
218866509|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
218866510|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
218866511|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
218866512|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
218866513|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
218866514|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
218866515|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
218866516|NCT04531514|OTHER|Sensitivity to phonological rules & referents OR: Toddlers|Assess whether the inclusion of a semantic reference decreases OR phonological rule learning
218866517|NCT04531514|OTHER|Sensitivity to phonological rules & referents FR: Toddlers|Assess whether the inclusion of a semantic reference increases FR phonological rule learning
218866518|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
218866519|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
219483108|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
219483109|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
219598678|NCT01857843|DEVICE|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
219598679|NCT01857843|DEVICE|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
218866520|NCT05661903|DRUG|Positron Emission Tomography / Magnetic Resonance Imaging|Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
218866521|NCT06316752|OTHER|Observational study|It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
218866522|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
218866523|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
218866524|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
218866525|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
218866526|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
218866527|NCT01818284|DRUG|Filgrastim|5 µg/kg in the morning daily for 4 days.
219598680|NCT01857843|DRUG|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
218866528|NCT01818284|DRUG|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
218866529|NCT01818284|PROCEDURE|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
218866530|NCT06822439|DEVICE|Fetal ECG monitoring|Patients will wear a fetal ECG monitor which they will place on their abdomen
219483110|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
219483111|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
219199808|NCT02405221|BIOLOGICAL|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
219483112|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
219483113|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
219483114|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
219483115|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
219483116|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
219598681|NCT01857843|DRUG|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
219598682|NCT06359288|OTHER|Group receiving QR code supported training|During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
219598683|NCT06625632|DRUG|Antiemetic Drug|All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.
218866531|NCT06970184|PROCEDURE|tooth extraction with alveolar ridge preservation|alveolar ridge preservation performed after tooth extraction
218866532|NCT06970184|PROCEDURE|Implant placement|Implant placement
219598684|NCT06625632|DIETARY_SUPPLEMENT|Vitamin B6|All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.
218866533|NCT03440190|DRUG|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
219483117|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
219483118|NCT03444909|DEVICE|cardiotocograph|Monitoring of 20 min with the cardiotocograph
219483119|NCT03444909|DEVICE|Toconaute|Monitoring of 20 min withToconaute
219598685|NCT06625632|OTHER|Home care advice|All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.
218866534|NCT03681678|DEVICE|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
218866535|NCT05717062|DRUG|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
218866536|NCT05717062|DRUG|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
219483120|NCT03444909|DEVICE|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
218866537|NCT05717062|DRUG|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
218866538|NCT05717062|DRUG|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
219483121|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
219483122|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
219483123|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
219483124|NCT01238523|PROCEDURE|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
219483125|NCT01238523|PROCEDURE|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
219483126|NCT05553028|PROCEDURE|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
219483127|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
219483128|NCT03803514|DRUG|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
219483129|NCT04376073|DRUG|Niraparib|Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
219483130|NCT04376073|DRUG|Anlotinib|Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
219483131|NCT03190707|BEHAVIORAL|Intervention|"1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed."
219483132|NCT00005886|DRUG|arzoxifene hydrochloride|
219483133|NCT00005886|DRUG|tamoxifen citrate|
219483134|NCT04995510|OTHER|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
219483135|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
219483136|NCT02653469|OTHER|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
219483137|NCT02653469|OTHER|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
219598686|NCT06625632|OTHER|Kinesiotaping|It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.
219598687|NCT04635293|PROCEDURE|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
219598688|NCT04635293|PROCEDURE|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
219483138|NCT02496442|DEVICE|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
219483139|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
219483140|NCT04450316|DRUG|Placebo|1 tab nightly
219483141|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
219483142|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
218866539|NCT06522243|BEHAVIORAL|8-week mindful parenting program|The current study adopts the Mindful Parenting program developed by Prof Susan Bögels (Bögels \& Restifo, 2013), which is an application of mindfulness-based intervention which aims to improve parenting by reducing parents' own stress levels, decreasing parental automatic reactivity, increasing open and unbiased attitudes towards children, and decreasing inter-generational dysfunctional parenting (Bögels et al., 2014). The program consists of eight consecutive weeks of parent groups and one follow-up session two months after the last session. Each parent group will include 15-20 participants. The original Mindful Parenting Program will last for around 3 hours for each session, with the longest practice of 40 minutes. Considering parents recruited in the study may have a higher risk of psychiatric conditions than the general population, each session of mindful parenting group will be reduced to 2 to 2.5 hours with the longest mindfulness practice of 30 minutes (Baer et al., 2019).
218866540|NCT06973811|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
219483143|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
219483144|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
219483145|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
218866541|NCT06973811|DRUG|Rituximab (R)|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
218866542|NCT06973811|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
218866543|NCT06973811|DRUG|Methotrexate (MTX)|Methotrexate 3.5g/m2 intravenous infusion d1, every 21 days for cycle 5 and 6 only.
218866544|NCT06966791|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery and other breast cancer treatments.
218866545|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from honey chlorella|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
218866546|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from faba bean meat analogue|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
218866547|NCT03714503|DEVICE|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
218866548|NCT04979910|DRUG|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
219483146|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
219483147|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
219483148|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
219483149|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
219483150|NCT01396499|DRUG|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
219483151|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
219483152|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
219483153|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
219483154|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
219483155|NCT02725840|RADIATION|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
218866549|NCT05729009|DIAGNOSTIC_TEST|skin microvascular reactivity|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
218866550|NCT06366230|DRUG|Urea in the dialysate|Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
218866551|NCT03469011|DRUG|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
218866552|NCT05991934|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
219483156|NCT02725840|RADIATION|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
219483157|NCT02725840|PROCEDURE|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
218866553|NCT05394064|GENETIC|SBT101|SBT101 Treatment
218866554|NCT05394064|PROCEDURE|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
218866555|NCT05487885|DEVICE|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
218866556|NCT05487885|BEHAVIORAL|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
219483158|NCT02725840|PROCEDURE|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
219483159|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
219483160|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219483161|NCT00903409|DRUG|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
219483162|NCT04526379|BEHAVIORAL|Questionnaires|Evaluation of behavioral disorders of children with PWS by questionnaires
219483163|NCT04526379|DEVICE|t-VNS|Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
219483164|NCT00461396|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
218866557|NCT05487885|DRUG|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
218866558|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
219483165|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
219483166|NCT00797316|DRUG|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
219598689|NCT00925366|OTHER|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
218866559|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
218866560|NCT06450106|DRUG|STM-416p|STM-416p monotherapy
219483167|NCT00797316|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
219483168|NCT01555242|DRUG|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
219483169|NCT01516684|DRUG|placebo administration|Given topically
219598690|NCT03096912|DRUG|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
219598691|NCT04939194|BEHAVIORAL|Fast Track Protocol|We will apply 22 items of ERAS society
218866561|NCT06082830|BEHAVIORAL|Intervention|"The intervention arm includes five components:~1. Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~2. Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~3. Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~4. Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~5. Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week)."
218866562|NCT06277245|DRUG|LNK01001|Capsule; Oral
218866563|NCT06277245|DRUG|Placebo|Capsule; Oral
218866564|NCT06980727|DRUG|Salbutamol 2,5 mg|In this study group, patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml IV normal saline as placebo, and 5mg salbutamol in 5ml nebulisation during 10min.
219483170|NCT01516684|DRUG|EMLA|Given topically
219483171|NCT01516684|DRUG|propofol|Given IV
219483172|NCT01516684|DRUG|fentanyl citrate|Given IV
219483173|NCT00227734|DRUG|capecitabine and oxaliplatin + cetuximab|cetuximab
219483174|NCT00227734|DRUG|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
219598692|NCT01767948|DRUG|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
219598693|NCT06634238|OTHER|Incremental shuttle walk test|Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
219598694|NCT00387556|DRUG|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
219598695|NCT03391726|OTHER|CART-19 cells|CART-19 cells treat
218866565|NCT06980727|DRUG|Dexamethasone|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
218866566|NCT06980727|DRUG|Placebo|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
218866567|NCT06979479|BEHAVIORAL|school-based intervention|AFL is a four-day program aimed at combating the stigma associated with mental health conditions and reducing suicidal ideation among youth. The program focuses on improving knowledge about depression and mental illness, enhancing self-efficacy skills for coping and seeking help, and increasing receptiveness to receiving assistance. Facilitated by mental health experts, the educational curriculum equips youth with the necessary tools to address feelings of hopelessness.
218866568|NCT06980545|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) will be given in complete six cycles
218866569|NCT06980571|DEVICE|radiofrequency ablation|FDA approved intervention being compared with gold standard (most common intervention)
219483175|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
218866570|NCT06980818|OTHER|No intervention|No intervention will take place.
218866571|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
219483176|NCT05787496|DRUG|NC525|Monoclonal antibody specific for LAIR-1
219598696|NCT00487968|DRUG|eltrombopag|
219598697|NCT04942743|DIAGNOSTIC_TEST|MRI|MRI OF TMJ
219598698|NCT06552156|DIETARY_SUPPLEMENT|Dietary Emulsifier|Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
219598699|NCT03912545|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219598700|NCT03277924|DRUG|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219483177|NCT06584708|OTHER|Low-volume high intensity interval training|"Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes"
219483178|NCT06584708|OTHER|Moderate intensity continuous exercise|"Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes"
219483179|NCT06154772|OTHER|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
219483180|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
219483181|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
219598701|NCT03277924|DRUG|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598702|NCT03277924|DRUG|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598703|NCT03277924|DRUG|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219483182|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
218866572|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
218866573|NCT06979999|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|Application of 10 cmH₂O PEEP during mechanical ventilation after pneumoperitoneum creation in patients undergoing laparoscopic cholecystectomy.
219483183|NCT02070718|DRUG|Standard Dose Kappa Agonist|
219483184|NCT02070718|DRUG|Half Dose Kappa Agonist|
219483185|NCT02070718|OTHER|Placebo|
219483186|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
218866574|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
219483187|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483188|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483189|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483190|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483191|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219598704|NCT03277924|DRUG|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598705|NCT03277924|DRUG|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598706|NCT03277924|DRUG|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598707|NCT03277924|DRUG|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219598708|NCT00933647|DIETARY_SUPPLEMENT|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
219598709|NCT00933647|DIETARY_SUPPLEMENT|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
218866575|NCT06983769|DEVICE|MAD|"Mandibular Advancement Device. It is a custom-fitted oral appliance used primarily to treat obstructive sleep apnea (OSA) and snoring. The device works by gently advancing the lower jaw (mandible) forward, which helps keep the airway open during sleep by preventing the tongue and soft tissues from collapsing and blocking the airway.~MADs are a non-invasive alternative to CPAP therapy and are especially suitable for patients with mild to moderate OSA or those who are intolerant to CPAP"
219483192|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483193|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
219483194|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
219483195|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
219483196|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
219483197|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
219483198|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
219483199|NCT00482664|DRUG|Placebo|Tablets for oral administration
219483200|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
219483201|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
219483202|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
219483203|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
219483204|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
219483205|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
219483206|NCT01934777|DRUG|placebo pearls|placebo
219483207|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
219483208|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
219483209|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
219483210|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
219483211|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
219483212|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
219483213|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
219483214|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
219483215|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
219483216|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
219483217|NCT05141045|DIETARY_SUPPLEMENT|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
219598710|NCT00933647|DIETARY_SUPPLEMENT|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
219598711|NCT02122692|DRUG|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
219598712|NCT02122692|DRUG|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
218866576|NCT06983769|DEVICE|CPAP|"CPAP stands for Continuous Positive Airway Pressure. It is the standard treatment for obstructive sleep apnea (OSA). A CPAP machine delivers a constant stream of air through a mask worn over the nose or nose and mouth during sleep. This air pressure keeps the airway open, preventing pauses in breathing caused by airway collapse.~CPAP is highly effective, especially for moderate to severe OSA, but some patients may find it uncomfortable or difficult to tolerate."
218866577|NCT06855641|PROCEDURE|Opioid based Anesthesia|in this group, patient will receive standard of care at UCLA including fentanyl administration during surgery
218866578|NCT06855641|PROCEDURE|opioid free anesthesia|In this group, patients will not receive any opioids intraoperatively
219483218|NCT05141045|DIETARY_SUPPLEMENT|placebo|placebo
219483219|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219483220|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
219483221|NCT05227807|BEHAVIORAL|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
219483222|NCT05227807|BEHAVIORAL|Usual care|routine care including written mouth exercise instructions
219483223|NCT01031342|PROCEDURE|Early colonoscopy|Colonoscopy within 12 hours of presentation
219483224|NCT01031342|PROCEDURE|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
219598713|NCT02122692|DRUG|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
219598714|NCT02175901|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
219598715|NCT02175901|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
219598716|NCT02175901|DRUG|Amoxicillin|antibiotic of each quadruple therapy
219598717|NCT02175901|DRUG|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
219598718|NCT02175901|DRUG|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
218866579|NCT06981221|DEVICE|Masimo Radical-7 Pulse Oximeter|"PVI is continuously monitored using the Masimo Radical-7 pulse oximetry device to evaluate respiratory variation in the plethysmographic waveform amplitude during laparoscopic-assisted vaginal hysterectomy (LAVH). No fluid intervention is applied; device use is for observational measurement of fluid responsiveness."
218866580|NCT06980311|OTHER|Aerobic Exercise|"Traditional Aerobic Exercise group will undergo treadmill-based aerobic exercise training under the supervision of a physiotherapist twice a week for a total of 8 weeks. For participant safety, they will be instructed to hold onto the handrails while walking, and proper use of the safety key will be ensured during each session.~Using the ULTIMA DC-5000 treadmill, participants will follow an exercise protocol based on the guidelines of the American College of Sports Medicine (ACSM), consisting of: a 10-minute warm-up, a 20-30-minute loading phase at 40-60% of heart rate reserve (moderate-to-vigorous intensity), and a 10-minute cool-down, all performed at 0% incline.~Throughout the sessions, participants' heart rate and oxygen saturation levels will be monitored via a fingertip pulse oximeter. Fatigue and dyspnea levels will also be assessed and recorded using the Modified Borg Scale."
219483225|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
219483226|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04\_0 Page 45-46)"
219483227|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
219483228|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
219483229|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
219598719|NCT03223701|COMBINATION_PRODUCT|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
219598720|NCT05835908|OTHER|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
219598721|NCT06443723|DIAGNOSTIC_TEST|USG, blood tests, waist, hip, height and blood pressure measurements|"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
219598722|NCT01616355|OTHER|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
219598723|NCT01858272|DRUG|H5.020CMV.PDGF-b and limb compression bandage|
219598724|NCT04759768|DRUG|Nalmefene Hydrochloride|3mg nasal spray
219598725|NCT04759768|DRUG|Nalmefene|1mg intramuscular injection
219598726|NCT06469203|DRUG|Oxytocin|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
219483230|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
219483231|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
219483232|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
219483233|NCT06185764|DRUG|VX-670|Solution for intravenous administration.
219483234|NCT06185764|DRUG|Placebo|Solution for intravenous administration.
219483235|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
219483236|NCT04933708|BEHAVIORAL|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
219483237|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
219483238|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
219483239|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
219483240|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
219483241|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
219483242|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
219483243|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
219483244|NCT02127788|DRUG|Micafungin|intravenous
219598727|NCT06469203|DRUG|Sodium Chloride 0.9% Inj|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
219598728|NCT04898530|OTHER|NO INTERVENTION|There is no intervention for this study.
219598729|NCT00812448|DIETARY_SUPPLEMENT|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
219598730|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
219199809|NCT06824597|BEHAVIORAL|Baby-friendly hospital initiative training program|"The Baby-Friendly Hospital Training Program is a critical intervention to improve maternal and infant health outcomes by promoting and supporting breastfeeding worldwide. It empowers the maternity nurses in this study to create an environment that prioritizes the needs of mothers and babies, ensuring the best possible start to life. It will be conducted for eight sessions (theoretical and practical), each session for about 20-30 minutes. It will include the importance of early initiation of breastfeeding, skin-to-skin contact immediately after birth, the importance of exclusive and continued breastfeeding, positions of breastfeeding, the importance of avoiding pre-lacteal feeds and unnecessary supplementation, advantages of rooming-in, and how to manage common breast and nipple conditions.~The researcher will design an Arabic booklet and distribute it to the nurses at the first session as a guide to reinforce the teaching"
219199810|NCT06819150|OTHER|Newborn bathing|The babies in the experimental group will have a bathtub bath before starting phototherapy treatment.
219598731|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
219483245|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
219483246|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
219483247|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
219483248|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
219483249|NCT01526707|DRUG|inhaled steroid|inhaled budesonide for 7 days
219483250|NCT01860690|DRUG|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
218866581|NCT06980311|OTHER|Aerobic exercise with music therapy|Music Therapy-Based Aerobic Exercise Training group will follow the same treadmill exercise program as the Traditional Aerobic Exercise group. However, during the exercise sessions, music therapy will be applied according to the beats per minute (BPM) ranges specified below: Warm-up (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo music Loading Phase (20-30 minutes, BPM: 120-140): Moderate-to-high intensity walking accompanied by rhythmic, motivational music Cool-down (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo sedative music Music will be used throughout the exercise sessions to regulate participants' heart rate and blood pressure, reduce perceived fatigue, enhance motivation, and support rhythmic movement patterns. During training, participants' heart rate and oxygen saturation will be monitored using a fingertip pulse oximeter.
218866582|NCT06592222|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
218866583|NCT06592222|DRUG|Standard of care|Standard of care
218866584|NCT06610552|BEHAVIORAL|Powerly|Powerly is a mental well-being mobile app, in which pregnant women can track their mood and level of stress, and receive personalized psychological modules to increase their mental health and well-being. By integrating evidence-based content and cognitive behavioral techniques with insights from pregnant and postpartum individuals and health professionals, Powerly offers a comprehensive psychological support including reappraisal, mental imagery, gratitude, mindfulness, self-efficacy and behavioral activation exercises.
218866585|NCT05698745|PROCEDURE|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
218866586|NCT06993480|DRUG|AHB-137|AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).
218866587|NCT06600308|OTHER|Walk tests|"Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).~At the end of each walking test, measurement of the difficulty of exertion using the Borg scale."
218866588|NCT06600308|OTHER|ecological (real-life) assessment of walking ability|Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days
219483251|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
219483252|NCT02143479|DRUG|Tacrolimus|oral
219483253|NCT03952962|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
219483254|NCT05310578|PROCEDURE|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
218866589|NCT06993584|OTHER|Adult patients in cardiogenic shock|evaluate the elimination clearance of levosimendan (LVSMD) in the group without extracorporeal membrane oxygenation (ECMO) and in the group with ECMO.
218866590|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (active)|non-invasive active repetitive stimulation applied to the scalp surface
219483255|NCT04141761|DIETARY_SUPPLEMENT|Visbiome|This group will receive Visbiome probiotic in powder form.
219483256|NCT04141761|OTHER|Placebo|This group will receive a placebo in powder form.
219483257|NCT05309993|DEVICE|PTNS|See arm description
219483258|NCT05309993|DEVICE|TENS|See arm description
219483259|NCT06281184|DRUG|Methotrexate|Methotrexate 5-25 mg x 1 per week, combined with folic acid 1mg daily.
219483260|NCT06281184|OTHER|Treatment as usual|No specific treatment after MERINO-trial
219483261|NCT05968300|BEHAVIORAL|INFORMED-Living Well|1\) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging
219483262|NCT05968300|BEHAVIORAL|Text Messaging Only|A 6-week automated SMS text messaging
219483263|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
219483264|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
219598732|NCT02027428|DRUG|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
219598733|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
219598734|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
218866591|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (sham)|non-invasive active repetitive stimulation applied to the scalp surface
219598735|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
218866592|NCT06856668|BEHAVIORAL|Behavioral Activation (Action Brings Change Project 10-Minute Version)|"A behavioral activation SSI where users learn about negative thought spirals, give advice to an imagined peer, then create an action plan of helpful activities to do in the near future. This is a shorter version of the original 15-minute Action Brings Change SSI."
219483265|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
218866593|NCT06856668|BEHAVIORAL|Mindful Acceptance|A clinical psychologist explains a few ways to use mindful acceptance to deal with difficult thoughts and feelings.
218866594|NCT06856668|BEHAVIORAL|Moral Elevation|Users learn about moral elevation, then watch a touching video where a man does good deeds for people in his community (originally a Thai life insurance advertisement). Finally, they plan a positive action they can take to help others in their own life.
219483266|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
219483267|NCT06810180|BEHAVIORAL|Go/No-Go Task|A computerized test in which participants are presented with red and green spaceship stimuli. They are told to press the spacebar in response to green spaceships (80% of trials) and withhold their response to red spaceships (20% of trials).
219483268|NCT06810180|BEHAVIORAL|Delay discounting task|Participants make decisions between smaller, immediate rewards and larger, delayed rewards. The amount of the immediate reward and delay time are manipulated to identify individual delay discounting curves, or how the reward value decreases as a function of delay.
219483269|NCT06810180|BEHAVIORAL|Mirror Tracing Persistence Task|A computerized test in which participants trace a star line drawing with a computer cursor using a trackpad with reversed directional controls. There are increasing levels of difficulty with participants being told they could quit the task during the very hard third star that they try to trace.
219483270|NCT06810180|BEHAVIORAL|Spatial Span|Participants are instructed to attend to a computer screen to keep track of the order in which a happy face stimuli appears in a sequence of boxes positioned on the screen. They are presented with 2 trials at each level of difficulty, increasing from 2 stimuli by 1 additional stimuli per trial until they respond incorrectly for both trials within a level. There are two task conditions, forward and backward span, with the participant responding in the reverse order that the stimuli were presented for backward span.
219483271|NCT06810180|BEHAVIORAL|Stop Signal Task|A computerized test in which participants are presented with a right or left facing arrow and are instructed to press a response button indicating the direction of the arrow. On 25% of the trials, an auditory beep is presented (i.e., stop signal) following the onset of the arrow (i.e., go signal) and participants are instructed to withhold their response when they hear the stop signal.
219483272|NCT06810180|BEHAVIORAL|Flanker task|A computerized test in which a group of arrows are presented on the screen with the central arrow (target) pointing in the same/opposite direction as the 4 surrounding arrows (flankers). Participants are instructed to respond as quickly and accurately as possible to the central target arrow.
219598736|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
219598737|NCT04965077|DRUG|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
219598738|NCT00747032|DRUG|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
218866595|NCT06856668|BEHAVIORAL|Mindful Attention Skills|A series of videos teach mindfulness skills: how to release thoughts and re-evaluate negative interpretations.
218866596|NCT06856668|BEHAVIORAL|5 Habits to Beat Depression|A clinical psychologist and science communicator describes his top 5 one-minute habits to beat depression.
218866597|NCT06856668|BEHAVIORAL|Interactive Cognitive Reappraisal|An interactive SSI where participants learn how to reframe negative thoughts
218866598|NCT06856668|BEHAVIORAL|Expressive Writing (AI-supported)|Participants describe a negative thought they struggle with and an LLM helps them to consider a story in which a peer overcomes that thought.
218866599|NCT06856668|BEHAVIORAL|Inner Child Healing Walk|An interactive journey to reconnect and heal one's inner child through breathing exercises, positive affirmations, and supportive animal companions.
218866600|NCT06856668|BEHAVIORAL|Savoring Strategies|An SSI introducing savoring strategies to improve mood.
218866601|NCT06856668|BEHAVIORAL|Personalized Intervention Recommender|Identifies the kinds of depression one struggles most with and offers a personalized recommendation for future depression support options
218866602|NCT06856668|BEHAVIORAL|Dialectical Behavioral Therapy Skills|Presents videos from dialectical behavioral therapy on various ways to control negative emotions.
219483273|NCT06649799|DEVICE|LenSx|The patients in Group 1 conduct FLACS under LenSx
218866603|NCT06856668|BEHAVIORAL|All about Trout|An 8-10 minute educational program with information and interactive exercises about trout fish. Intended to capture one's attention and require some effort, while minimizing influence on depressive symptoms.
219483274|NCT06649799|DEVICE|Z8|The patients in Group 1 conducted FLACS using Z8
219483275|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
219483276|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
219483277|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
219483278|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
219483279|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
219483280|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
218866604|NCT06856668|BEHAVIORAL|Reframing Negative Thoughts|An audio-only program in which users are guided to reflect on how they might challenge negative automatic thoughts and beliefs they struggle with.
219040066|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
219483281|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
219483282|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
219483283|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
219598739|NCT00747032|DRUG|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
218866605|NCT01603316|BEHAVIORAL|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
219483284|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
219483285|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
219483286|NCT05385783|DRUG|Placebo|Placebo
219483287|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
219598740|NCT05509075|DIETARY_SUPPLEMENT|nutraceuticals|antioxidants
219598741|NCT07134166|OTHER|data collection|data collection
219598742|NCT07135050|GENETIC|MZ-1866|AAV-9 gene therapy delivered by intracerebroventricular injection
219598743|NCT07134647|BEHAVIORAL|video animation-supported inhaler medication training|"The training is presented not verbally but with the prepared Video Animation Support"
219598744|NCT07133750|DRUG|PM8002|IV infusion
219598745|NCT07133750|DRUG|Chemotherapy Regimen 1|IV infusion
219598746|NCT07133750|DRUG|Chemotherapy Regimen 2|Oral administration and IV infusion
218866606|NCT01603316|BEHAVIORAL|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
219483288|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
219483289|NCT02061293|DRUG|Psilocybin|
219483290|NCT02061293|DRUG|Diphenhydramine|
218866607|NCT06675331|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
218866608|NCT06534424|OTHER|Best Practice|Receive standard care
218866609|NCT06534424|PROCEDURE|Biospecimen Collection|Undergo collection of blood or mouthwash sample
218866610|NCT06534424|OTHER|Counseling|Receive tailored counseling
218866611|NCT06534424|PROCEDURE|Discussion|Participate in phone discussion
218866612|NCT06534424|PROCEDURE|Genotyping|Undergo genotyping
218866613|NCT06534424|PROCEDURE|Molecular Risk Assessment|Undergo enhanced risk assessment
218866614|NCT06534424|OTHER|Questionnaire Administration|Ancillary studies
218866615|NCT03007745|DEVICE|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
218866616|NCT05649514|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
219483291|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
219483292|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
218866617|NCT05649514|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
218866618|NCT05649514|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
218866619|NCT05649514|PROCEDURE|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
218866620|NCT05649514|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
218866621|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
218866622|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
218866623|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
218866624|NCT06860880|OTHER|Exercise|Each patient will receive an individualized exercise prescription that will encompass both aerobic and resistance training, with modifications as necessary to accommodate each patient's needs, abilities, and medical condition. For those not participating in any formal exercise at baseline, the exercise prescription will consist of a basic conditioning program targeting 150 minutes of moderate physical activity weekly with the assistance of a physical therapist if deemed appropriate.
218866625|NCT06860880|OTHER|Diet|Participants will undergo nutritional consultations with a registered dietitian who specializes in oncology. The dietitian will provide tailored dietary recommendations using evidence-based nutrition guidelines. Participants will also be screened ffor ormal nutrition based on American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines as indicated.
219040067|NCT02103829|BEHAVIORAL|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
219483293|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
219483294|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
219040068|NCT02103829|BEHAVIORAL|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
219483295|NCT01866605|DEVICE|Bair Hugger|Forced air warming
219483296|NCT02866201|OTHER|Rectal swab|
219483297|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
219598747|NCT07133334|OTHER|Selenium disulfide|1% SeS2
218866626|NCT06794255|DIETARY_SUPPLEMENT|Vitamin C|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
218866627|NCT06794255|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
218866628|NCT07042178|OTHER|Meditation video at the beach|A virtual reality video consisting of a 5 minute meditation video at te beach.
218866629|NCT07042178|OTHER|Rollercoaster video|A virtual reality video consisting of a five minute rollercoaster ride.
218866630|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 1000 mg of rituximab\* in 500 ml of NaCl 0.9% \* Mabthera® and all registered biosimilars are likely to be used in this trial
218866631|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 500 ml of NaCl 0.9%
218866632|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
219598748|NCT07133334|OTHER|Piroctone olamine|0.5% piroctone olamine
218866633|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
219483298|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
219483299|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
219483300|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
218866634|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
218866635|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
218866636|NCT06902662|DIETARY_SUPPLEMENT|SS-MN4|Participants in the SS-MN4 group will take 2 capsules daily containing a total of 1000 mg/day of Sanghuangporus sanghuang mycelia extract for 42 consecutive days. The capsules are identical in appearance to the placebo.
218866637|NCT06902662|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take 2 capsules daily of an inert substance designed to match the SS-MN4 capsules in color, taste, and appearance. The placebo contains no active ingredients and will be taken for 42 consecutive days.
218866638|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
218866639|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
218866640|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
218866641|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
218866642|NCT00114920|DRUG|Resiquimod|
218866643|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
219483301|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
219483302|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
219483303|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
219483304|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
218866644|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
218866645|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
218866646|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
218866647|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
218866648|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
218866649|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
219483305|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
219483306|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
218866650|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
219483307|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
219483308|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
219483309|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
219483310|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
219483311|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
219483312|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
219483313|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
219483314|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
219483315|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
219483316|NCT05303727|DRUG|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
219483317|NCT05303727|DRUG|Fludarabine|30 mg/m2/day for 5 days
219483318|NCT05303727|DRUG|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
219483319|NCT05303727|DRUG|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
219483320|NCT05303727|DRUG|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
219483321|NCT05303727|DRUG|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
219483322|NCT05303727|DRUG|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
219483323|NCT05303727|DRUG|Cyclosporine|2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
218866651|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
219483324|NCT05303727|DRUG|Tacrolimus|0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
219483325|NCT05303727|DRUG|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
219483326|NCT05303727|DRUG|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
219483327|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
219483328|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
219483329|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
219483330|NCT00014300|DRUG|glufosfamide|
218866652|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
218866653|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
218866654|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
218866655|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
218866656|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
218866657|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
218866658|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
218866659|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
218866660|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
218866661|NCT04494724|DRUG|Clazakizumab|Infusion
218866662|NCT04494724|DRUG|Placebo|Infusion
218866663|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
218866664|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
219483331|NCT03378999|DIETARY_SUPPLEMENT|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
219483332|NCT03378999|DIETARY_SUPPLEMENT|Control|Capsules containing microcrystalline cellulose
219483333|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
219483334|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
219483335|NCT03203746|DRUG|Lycopene + SRP|
219483336|NCT03203746|PROCEDURE|SRP only|
219483337|NCT03542253|PROCEDURE|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
219483338|NCT03494816|DRUG|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
219483339|NCT04297254|DRUG|Lenvatinib|Lenvatinib capsules.
219483340|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
219483341|NCT06604299|BEHAVIORAL|Meditation-enhanced Cognitive Behavioral Therapy|Self-guided online intervention
219483342|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
219483343|NCT03782688|DIAGNOSTIC_TEST|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
219598749|NCT07133256|BEHAVIORAL|Resistance Exercise|Structured machine-based resistance exercise protocol performed under supervision, targeting osteogenic loading to improve bone mineral density and alter bone metabolism markers in CKD stage 3-4 patients.
218866665|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
218866666|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
218866667|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
218866668|NCT00958737|DRUG|CAPOX|4 or 8 cycles
218866669|NCT02475616|DRUG|PCO371|
218866670|NCT02475616|DRUG|Placebo|
218866671|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
219598750|NCT07133256|BEHAVIORAL|Aerobic Training|"Participants in this arm performed supervised aerobic exercise (treadmill walking) three times per week for six months. Each session included:~5-minute warm-up~30-minute treadmill walking at 60%-80% of age-predicted maximum heart rate (HRmax = 220 - age)~10-minute cool-down Exercise sessions were supervised by trained exercise professionals and tailored to maintain target heart rate zones."
219598751|NCT07134465|DRUG|HSK31858 Tablets and Itraconazole Capsules|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Itraconazole capsules After a 10-day washout period, Take Itraconazole capsules 200mg in the morning and 200mg in the evening on D11 . A single dose of Itraconazole capsules 200 mg will be administered every morning from Day 12 to Day 14. On the morning of Day 15, take a single dose of itraconazole capsules 200mg, followed by a single dose of HSK31858 tablets 40 mg 1 hour later,"
218866672|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
218866673|NCT01724424|DRUG|Melatonin|20 mg oral single dose
218866674|NCT01724424|DRUG|Melatonin|30 mg oral single dose
218866675|NCT01724424|DRUG|Melatonin|50mg oral single dose
218866676|NCT01724424|DRUG|Melatonin|100mg oral single dose
218866677|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
218866678|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
218866679|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
219365082|NCT05202626|DIAGNOSTIC_TEST|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
219365083|NCT00214461|BIOLOGICAL|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
219365084|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
219365085|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
219365086|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
218866680|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
218866681|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
218866682|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
218866683|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
218866684|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
218866685|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
218866686|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
218866687|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
218866688|NCT00265018|DRUG|Adriamycin|
218866689|NCT00265018|DRUG|Bleomycin|
218866690|NCT00265018|DRUG|Vinblastine|
218866691|NCT00265018|DRUG|DTIC|
218866692|NCT00265018|RADIATION|30 Gy IF-RT|
218866693|NCT00265018|RADIATION|20 Gy IF-RT|
218866694|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
219483344|NCT02660775|BEHAVIORAL|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)"
219483345|NCT02660775|BEHAVIORAL|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
218866695|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
219483346|NCT02660775|BEHAVIORAL|Healthy controls|only social cognitive measures
219483347|NCT06656390|DRUG|ALK201|Administered intravenously, once every 3 weeks
219483348|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
219483349|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
219598752|NCT07134413|DRUG|QL1706 plus bevacizumab with or without chemotherapy|"QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Bevacizumab is a monoclonal antibody medication used to treat various cancers and a specific eye disease. It works by blocking a protein called VEGF, which helps tumors form new blood vessels, thus starving the tumor of nutrients and oxygen.~Chemotherapy (nab-paclitaxel, pemetrexed, or docetaxel) Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers. It's a form of paclitaxel that's bound to albumin nanoparticles, which improves its solubility and delivery to cance"
219598753|NCT07134699|OTHER|Participants are not assigned an intervention|For observational studies, participants are not assigned an intervention as part of the study.
219598754|NCT06828224|DEVICE|KOS® L|Delivery of medical device as injection
219598755|NCT06983080|DRUG|Trazodone 25 mg|Trazodone 25 mg at bedtime, which can be increased to 50 mg after 14 days of treatment.
218866696|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
218866697|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
218866698|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
218866699|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
218866700|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
218866701|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
218866702|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
218866703|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
218866704|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
218866705|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
218866706|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
218866707|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
218866708|NCT01533922|DEVICE|Respimat|Respimat inhaler
218866709|NCT00799539|DRUG|bortezomib|From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
218866710|NCT00799539|DRUG|bortezomib|From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
218866711|NCT00799539|DRUG|melphalan|9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
218866712|NCT00799539|DRUG|prednisone|60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
218866713|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
218866714|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
218866715|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
218866716|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
218866717|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
218866718|NCT00151788|DRUG|Pactimibe sulfate|
218866719|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
218866720|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
218866721|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
218866722|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
218866723|NCT02679820|DEVICE|Copper T intrauterine device|
218866724|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
218866725|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
218866726|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
218866727|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
219483350|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
219483351|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
219598756|NCT06982456|OTHER|Manual Therapy on the Upper Trapezius with or without Passive Stretching|The intervention consists of manual therapy techniques applied to the upper fibers of the trapezius muscle, including superficial massage, deep massage, and pressure release technique. In one of the experimental groups, this treatment is followed by passive stretching. The control group receives no intervention. Algometric measurements (pressure pain threshold) are taken before and after the intervention, and at one-week and two-week follow-up points to assess the effectiveness and persistence of the treatment.
219598757|NCT00000591|PROCEDURE|lymphocyte depletion|
218866728|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
218866729|NCT00311116|DRUG|Vitamin E|
218866730|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
218866731|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
218866732|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
218866733|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
218866734|NCT00154362|DRUG|Oxcarbazepine|
218866735|NCT01839136|PROCEDURE|Intrauterine transfer of gametes|
219483352|NCT02622607|DRUG|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
219483353|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
219483354|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
219483355|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
218866736|NCT01839136|PROCEDURE|Intrauterine transfer of embryos|
218866737|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
218866738|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
219483356|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
219483357|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
219483358|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
219598758|NCT04798131|OTHER|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
219598759|NCT04798131|OTHER|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
219598760|NCT05245318|OTHER|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
219598761|NCT05245318|DEVICE|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
219598762|NCT00000116|DIETARY_SUPPLEMENT|Vitamin A|15000 IU/d as retinyl palmitate
219598763|NCT00000116|DIETARY_SUPPLEMENT|Docosahexaenoic acid|1200 mg/d
219598764|NCT00000116|DIETARY_SUPPLEMENT|Control fatty acid|
219598765|NCT04085055|DIAGNOSTIC_TEST|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
218866739|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
218866740|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
218866741|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
218866742|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
219483359|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
219483360|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
219483361|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
219483362|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
219483363|NCT05044143|OTHER|Monitoring the length of the uterine cervix using transvaginal ultrasound|Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
219483364|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
219483365|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
219483366|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
219483367|NCT06650397|OTHER|Placebo|Traditional maize
219483368|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
219483369|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
219483370|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
219598766|NCT00743418|DEVICE|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
219040069|NCT02103829|BEHAVIORAL|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
219483371|NCT01101269|DRUG|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
219483372|NCT01101269|DRUG|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
219483373|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
219483374|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
219483375|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
219483376|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
219483377|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
219483378|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
219483379|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
219483380|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
219483381|NCT02046655|DRUG|Corifollitropin alfa|
219483382|NCT02046655|DRUG|rFSH|
219483383|NCT00004454|GENETIC|lymphocyte gene therapy|
219483384|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
219483385|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
219483386|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
219483387|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
219483388|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
219483389|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
219483390|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
219483391|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
219483392|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
219483393|NCT06669117|DRUG|VERT-002|Route of Administration: Intravenous
219483394|NCT06995118|PROCEDURE|HUAXI hole 1|A small incision of 2mm is made at the junction of the upper outer edge of the areola and the skin, through which the scalpel is placed to assist in the resection of breast glands in reverse-sequence nipple-sparing mastectomy and direct-to-implant breast reconstruction.
219483395|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
219483396|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
219483397|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
218866743|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
218866744|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
218866745|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
218866746|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
219483398|NCT06995729|DRUG|Zavegepant|Zavegepant 5 mg or 10 mg (dose is weight-dependent)
219483399|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
219483400|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
219483401|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
219483402|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
219483403|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
219483404|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
219483405|NCT01126359|DRUG|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
219483406|NCT01126359|DRUG|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
219483407|NCT03141346|BEHAVIORAL|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
219483408|NCT03141346|BEHAVIORAL|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
219483409|NCT03141346|OTHER|Home water delivery|Home delivery of bottled water administered over 24 months
219483410|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
219483411|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
219483412|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
219483413|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
219483414|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
219483415|NCT04116359|DRUG|Cisplatin|Given IV
219483416|NCT04116359|DRUG|Etoposide|Given IV
219483417|NCT04116359|DRUG|Etoposide Phosphate|Given IV
219483418|NCT04116359|DRUG|Molibresib|Given PO
218866747|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
218866748|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
218866749|NCT00016965|DRUG|ixabepilone|
218866750|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
219483419|NCT04116359|DRUG|Molibresib Besylate|Given PO
219483420|NCT05419635|DRUG|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
219483421|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
219483422|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
219483423|NCT00902486|DRUG|INCB028050|4 mg capsules QD
219483424|NCT00902486|DRUG|INCB028050|7 mg capsules QD
219483425|NCT00902486|DRUG|INCB028050|10 mg capsule QD
219483426|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
219483427|NCT04078893|OTHER|telephone recruitment|using telephone to recruit inactive donors on two different methods
219483428|NCT00364416|OTHER|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
219483429|NCT03328286|BEHAVIORAL|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
219483430|NCT00488007|DEVICE|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
219483431|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
219483432|NCT03906773|OTHER|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
219483433|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
219483434|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
219483435|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
219598767|NCT05104190|OTHER|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
219598768|NCT01026987|DRUG|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
219598769|NCT01026987|DRUG|AMD3100|
219483436|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
219483437|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
219483438|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
219483439|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
219483440|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
219483441|NCT07047573|BIOLOGICAL|PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer|Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.
218866751|NCT02276547|DEVICE|Mitral valve replacement|Transcatheter mitral valve replacement
218866752|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
219483442|NCT06736743|DIAGNOSTIC_TEST|SMART Tool for Feeding Skill Assessment|Infant Oral Feeding Skill Assessment (FSA) done using SMART Tool
219483443|NCT07047989|BIOLOGICAL|NWRD09 injection|NWRD09 administered by intramuscular injection
219598770|NCT01026987|PROCEDURE|Leukapheresis|
219598771|NCT01026987|PROCEDURE|Stem Cell Infusion|
219598772|NCT00392912|DRUG|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
218866753|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
219598773|NCT06216678|OTHER|Healthy Dietary Pattern with Cottonseed Oil|Cottonseed Oil
219598774|NCT06216678|OTHER|Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils|Plant oil blend fatty acid matched
219598775|NCT06216678|OTHER|Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil|Plant oil with matched PUFA to SFA ratio
219598776|NCT01507766|DRUG|early enteral nutrition|The enteral nutrition was started within 48h after admission
219598777|NCT01507766|DRUG|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
219598778|NCT00117832|DRUG|Azelastine nasal spray|
218866754|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
218866755|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
218866756|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
218866757|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
218866758|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
219040070|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
219483444|NCT06761469|OTHER|Implementing active-case finding strategies|Implementation of a multifactorial active-case finding strategy, including: (1) raising awareness among the population about leprosy; (2) theoretical and practical educational training for healthcare workers; (3) georeferencing of historical and existing cases in the municipality (from 2012 to 2023) and of new cases diagnosed throughout the study (dynamic changes); (4) screening tools for signs/symptoms of the disease (application of Leprosy Suspicion Questionnaire); and (5) serological profile (rapid test) of patients with reported signs/symptoms (positive answers Leprosy Suspicion Questionnaire).
219483445|NCT05014074|OTHER|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
219483446|NCT06828887|DRUG|LV232 40mg|LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
219483447|NCT06828887|DRUG|LV232 60mg|LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
219483448|NCT06828887|DRUG|Escitalopram|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
219483449|NCT06828887|DRUG|Placebo|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
219483450|NCT06926426|BEHAVIORAL|oral function training|A 12-week program including oral muscle strengthening, pronunciation drills, and swallowing-related exercises designed to improve oral function in older adults.
219483451|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
219483452|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
219483453|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
219598779|NCT05931978|OTHER|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
219483454|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
219483456|NCT00381667|DRUG|GW642444M|M salt
218866759|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
218866760|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
218866761|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
218866762|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
218866763|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
219040071|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
219040072|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
219040073|NCT01127750|DRUG|FTY720|
219040074|NCT01232296|DRUG|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
219040075|NCT01232296|DRUG|sorafenib|400 mg p.o. b.i.d.
219483457|NCT00381667|DRUG|GW642444H|H salt
219483458|NCT00381667|OTHER|placebo|placebo
219483459|NCT06446973|OTHER|35 patients with meniscus tear|Have meniscus pathologies in one or both knees confirmed by MRI.
219598780|NCT03816943|BEHAVIORAL|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
219598781|NCT03816943|BEHAVIORAL|Call|a telephone call will be made after bond up to provide encoring words
219598782|NCT04646876|DRUG|Magnesium Sulfate|Prospective , comparative , double blind study
219598783|NCT04646876|DRUG|Placebo|Prospective , comparative , double blind study
218866764|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
218866765|NCT00450736|DRUG|celecoxib|
218866766|NCT00450736|PROCEDURE|adjuvant therapy|
219483460|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
219483461|NCT06936540|OTHER|Virtual Tour|The intervention group will be trained by the researcher with a virtual tour material about surgical environments via a tablet computer.
219483462|NCT06936540|OTHER|No Interventions|The control group will not receive any intervention other than verbal training in the routine of the organization.
219483463|NCT06932588|DIAGNOSTIC_TEST|Biomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT|"The i-STAT TBI cartridge is a point-of-care, whole-blood, biomarker-based assay that measures the level of biomarkers associated with brain injury in the bloodstream 24 hours after injury. Blood samples (5-10cc of whole blood) will be collected upon admission during a routine blood draw in the ED. These samples will be tested using the iSTAT system for mild TBI biomarkers.~In a subset of admitted patients, serial blood draws and iSTAT testing will be performed at 4, 8, 16, and 24 hours, depending on the patient's length of stay."
219483464|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
219483465|NCT06942624|BIOLOGICAL|Phage Therapy|Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).
219483466|NCT06942325|DEVICE|OTC self-fitting hearing aid|OTC hearing aid to be compared to prescription hearing aid
219483467|NCT06942325|DEVICE|Prescription hearing aid|Prescription hearing aid used as active comparator to the OTC self-fitting hearing aid
219483468|NCT06943170|OTHER|Aerobic Exercise and Low Calorie Diet|Group A: Aerobic Exercise with Low calorie diet Group B: Aerobic Exercise without Low Calorie Diet
219483469|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
219483470|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
219483471|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
219483472|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
219483473|NCT01017731|DRUG|Moxifloxacin|Administered orally
219483474|NCT01017731|DRUG|Diphenhydramine|Administered IV
218866767|NCT00450736|RADIATION|radiation therapy|
218866768|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
218866769|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
218866770|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
218866771|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
218866772|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
218866773|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
219483475|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
219483476|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
219483477|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
219483478|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
219483479|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
219483480|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
219598784|NCT06470178|COMBINATION_PRODUCT|corhot1: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
219598785|NCT06470178|COMBINATION_PRODUCT|corhot2: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
219598786|NCT04529954|DRUG|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
219598787|NCT03921593|PROCEDURE|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
219598788|NCT06824259|PROCEDURE|Follow up if MRI is negative|Enter the follow-up cohort without systematic biopsy when prostate cancer is clinically suspected and no PIRADS v2.1 score ≥3 lesions are detected on initial examination. MR plus regional saturation biopsy was performed when MRI progressed.
219598789|NCT06824259|PROCEDURE|Systematic biopsy if MRI is negative|Systematic biopsy was performed if there was clinical suspicion of prostate cancer and no PIRADS v2.1 score ≥3 lesions were detected on initial examination. If the biopsy was negative enter the follow-up cohort.
218866774|NCT01657708|OTHER|Shared Decision Making|
218866775|NCT02042313|OTHER|continuous epidural infusion|
218866776|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
218866777|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
218866778|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
218866779|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
218866780|NCT05041348|DIAGNOSTIC_TEST|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
219483481|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
219483482|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
219598790|NCT06858007|DEVICE|KOS® M|Delivery of medical device as injection
218866781|NCT03313336|DRUG|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
218866782|NCT03313336|DRUG|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
218866783|NCT03313336|DRUG|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
218866784|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
218866785|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
218866786|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
218866787|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
218866788|NCT00003358|DRUG|chemotherapy|
218866789|NCT00003358|DRUG|cisplatin|
218866790|NCT00003358|DRUG|gemcitabine hydrochloride|
218866791|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
219483483|NCT02238639|PROCEDURE|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
219483484|NCT00330772|DRUG|Aspirin|
219483485|NCT00330772|DRUG|Clopidogrel|
219483486|NCT03902249|DRUG|Dexamethasone|
219483487|NCT06694974|BEHAVIORAL|APP calculation for FIB-4|the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
219483488|NCT06694974|BEHAVIORAL|Standard Care (in control arm)|The standard group proceeds as regular practice
219483489|NCT05276869|OTHER|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
218866792|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
219483490|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
218866793|NCT01369186|DRUG|Morphine|i.v. bolus injection
218866794|NCT01369186|DRUG|Placebo|i.v. bolus injection
218866795|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
218866796|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
218866797|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
219483491|NCT00242567|DRUG|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
219483492|NCT00242567|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
219483493|NCT06653686|OTHER|Hyperthermia combined with oral febuxostat.|Extracorporeal high-frequency hyperthermia combined with oral febuxostat
219483494|NCT06653686|DRUG|Febuxostat|The control group subjects were administered oral febuxostat.
219598791|NCT05520125|BIOLOGICAL|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
219598792|NCT05520125|OTHER|Standard treatment of bone defects|Standard surgical treatment of bone defects
219598793|NCT01956305|DRUG|DS-7309|DS-7309 powder in bottle
219598794|NCT01956305|DRUG|placebo|placebo to match DS-7309 powder in bottle
219598795|NCT01956305|DRUG|Metformin|Metformin 500mg tablet for Cohort F
219598796|NCT04704570|OTHER|Exercise|Spinal stabilization exercise
219613569|NCT07017140|DEVICE|Immersive Functional Virtual Reality Intervention using a Head-Mounted Display System for Spatial Neglect Rehabilitation|Participants receive 12 sessions (30 minutes each, 3 per week over 4 weeks) of immersive functional virtual reality (IFVR) using the KINESIX system, a CE-certified Class I head-mounted display device. The intervention targets visuospatial attention and upper limb function through progressively challenging, gamified exercises. All sessions are supervised by a physiotherapist or occupational therapist and delivered in a safe, controlled rehabilitation setting. Participants continue receiving usual care.
218866798|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
218866799|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
218866800|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
219483495|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
218866801|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
218866802|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
218866803|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
219483496|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
218866804|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
218866805|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
219483497|NCT04338646|OTHER|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
218866806|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
218866807|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
218866808|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
218866809|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
218866810|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
218866811|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
219483498|NCT06693336|DRUG|SMS001|One time administration
219483499|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
219483500|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
219483501|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
219483502|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
219483503|NCT00140101|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
218866812|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
218866813|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
218866814|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
218866815|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
218866816|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
219483504|NCT00140101|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219483505|NCT04862052|PROCEDURE|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
219483506|NCT02561728|DEVICE|Hangar Helmet|Child will be fitted with the Hangar Helmet
219483507|NCT02561728|DEVICE|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
219483508|NCT02729545|OTHER|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
219483509|NCT02729545|DRUG|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
219598797|NCT04704570|OTHER|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
218866817|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
218866818|NCT03778320|DRUG|CTP-692|Single oral dose
218866819|NCT03778320|DRUG|D-Serine|Single oral dose
218866820|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
218866821|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
219598798|NCT05794503|DRUG|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
218866822|NCT02106247|DRUG|BI 1181181 high dose|two tablet
219483510|NCT02243059|DRUG|Gadofosveset trisodium (Ablavar™ )|
218866823|NCT02106247|DRUG|BI 1181181 low dose|one tablet
218866824|NCT02106247|DRUG|Placebo|tablet
218866825|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
218866826|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
219483511|NCT02243059|DEVICE|MRI|
218866827|NCT01989702|OTHER|Fermented blueberry drink|
218866828|NCT01989702|OTHER|Placebo drink|
218866829|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
218866830|NCT01989702|OTHER|Sachets with placebo powder|
218866831|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
218866832|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
219483512|NCT04794452|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
219598799|NCT05794503|DRUG|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
218866833|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
218866834|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
218866835|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
218866836|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
218866837|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
218866838|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
218866839|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
218866840|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
218866841|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
219483513|NCT04794452|DEVICE|Manual toothbrush|Device on plaque removal efficacy
219483514|NCT04372888|BEHAVIORAL|choice decision frame|active choice for genetic testing
219483515|NCT04372888|BEHAVIORAL|opt-in decision frame|"gain frame for genetic testing"
219483516|NCT04372888|BEHAVIORAL|opt-out decision frame|"loss frame for genetic testing"
219483517|NCT04372888|BEHAVIORAL|enhanced choice (context) decision frame|consequences of genetic testing
219483518|NCT04372888|BEHAVIORAL|enhanced choice (norms) decision frame|social norms for genetic testing
219483519|NCT04372888|BEHAVIORAL|enhanced choice (affect) decision frame|commitments for genetic testing
219483520|NCT00768105|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
219483521|NCT00768105|DRUG|Placebo|Dosing to match AZD1656
219483522|NCT03072329|PROCEDURE|Pudendal nerve block|
219483523|NCT03072329|DRUG|Bupivacaine|
219598800|NCT02567630|BEHAVIORAL|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
219598801|NCT01051947|DRUG|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
218866842|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
218866843|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
218866844|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
218866845|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
218866846|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
218866847|NCT04229836|DRUG|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
218866848|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
218866849|NCT03801746|DRUG|Rifampin|IV Rifampin
218866850|NCT03801746|DRUG|Probenecid|Oral Probenecid
218866851|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
218866852|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
218866853|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
218866854|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
218866855|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
218866856|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
219483524|NCT05084807|OTHER|Endoscopy|"* A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
219483525|NCT01387672|DRUG|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
219598802|NCT01051947|DRUG|Metoprolol|dosage prescribed prior to starting on study
219598803|NCT00497861|PROCEDURE|Activator Methods Chiropractic Technique|
219598804|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
219598805|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
218866857|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
218866858|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
218866859|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
218866860|NCT01496911|DRUG|Levocetirizine|a single oral dose of 5 mg
218866861|NCT01496911|DRUG|Hydroxyzine|a single oral dose of 50 mg
218866862|NCT01496911|DRUG|Placebo|a single oral dose
218866863|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
218866864|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
218866865|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
218866866|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
218866867|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
218866868|NCT02378207|BIOLOGICAL|BCG|
218866869|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
218866870|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
219483526|NCT01387672|OTHER|Placebo|Placebo ointment
219483527|NCT01093040|DRUG|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
219483528|NCT01093040|DRUG|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
219483529|NCT01093040|DRUG|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
219483530|NCT01211496|BEHAVIORAL|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
219598806|NCT05758857|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
219598807|NCT07133789|OTHER|blood sampling of all patients and their parents|blood sampling of all patients and their parents
218866871|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
218866872|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
219483531|NCT01211496|BEHAVIORAL|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
219483532|NCT01150409|DRUG|hydrocortisone|1\) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
218866873|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
218866874|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
219483533|NCT01150409|DRUG|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
219483534|NCT00441207|DRUG|Ascorbic Acid|Delivered via IV Infusion.
219483535|NCT06567080|BIOLOGICAL|JWCAR201|JWCAR201 is a autologous CAR-T targeting CD19/CD20
219483536|NCT06004401|DRUG|Vonopazan +Amoxicillin|Vonopazan 20mg 2//day+Amoxicillin
219483537|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
219483538|NCT06004401|DRUG|Vonopazan +Minocycline|Vonopazan 20mg 2/day+Minocycline 100mg 2/day
219483539|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
219483540|NCT06113263|PROCEDURE|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
219483541|NCT06113263|PROCEDURE|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
219483542|NCT04108884|DEVICE|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
219483543|NCT04108884|DEVICE|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
219483544|NCT03079869|DRUG|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
219483545|NCT02411110|COMBINATION_PRODUCT|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
219483546|NCT02411110|COMBINATION_PRODUCT|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
219483547|NCT01863095|BEHAVIORAL|Personalized Feedback and Exercise|
219483548|NCT03806478|DRUG|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
218866875|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
218866876|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
219483549|NCT03806478|OTHER|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
219483550|NCT00295308|DRUG|Clonidine|clonidine up to 0.3 mg/day oral
219483551|NCT00295308|DRUG|Placebo|oral capsules daily
219483552|NCT03596060|DRUG|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
219483553|NCT03596060|DRUG|Propofol|Propofol will be used for introduction in general anesthesia.
219483554|NCT03596060|DRUG|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
219483555|NCT03596060|DRUG|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
219483556|NCT03596060|DRUG|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
219483557|NCT04934891|DRUG|ION547|ION547 will be administered by SC injection.
219483558|NCT04934891|DRUG|Placebo|ION547-matching placebo will be administered by SC injection.
219483559|NCT01731574|DRUG|dapivirine|
219483560|NCT01731574|DRUG|miconazole|
219483561|NCT01908998|OTHER|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
219598808|NCT07134803|DEVICE|Bonding of the orthodontic brackets with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm|Bonding of the orthodontic brackets on patients' teeth with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm. Then the scanned for STL file and be superimposed with the gold standard created for the patient individually.
219613570|NCT07018128|OTHER|Study 2: deep breathing|Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months.
219483562|NCT04259801|DRUG|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
219483563|NCT04259801|DRUG|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
219483564|NCT04259801|DRUG|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
218866877|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
218866878|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
219483565|NCT04259801|DRUG|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
219483566|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
219483567|NCT03246321|COMBINATION_PRODUCT|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
219483568|NCT04580511|DEVICE|CELLIS (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in abdominal reconstruction
219483569|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
219483570|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
219483571|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
219483572|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
219483573|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
219483574|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
219483575|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
219483576|NCT06288490|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
219483577|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
219483578|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
219483579|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
219483580|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
219483581|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
219483582|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
219483583|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
219483584|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
219483585|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
219483586|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
219483587|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
219483588|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
219483589|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
219483590|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
219598809|NCT07133503|OTHER|radiological evaluation|Using a line drawn through the midpoints of the teeth, parallel to their long axes, the anterior crest morphology was assessed. For maxillary central, lateral, and canine teeth, alveolar crest width and height, buccal bone thickness, and tooth-crest angle were measured separately. To determine buccal bone thickness, measurements were taken from the buccal crest apex, the midpoint of the root, and the apex of the tooth. The height of the alveolar crest was defined as the length of a line drawn parallel to the crest's long axis between the nasal fossa floor and the alveolar crest. The width of the alveolar crest was calculated by averaging measurements taken from the midpoints of three equal sections of the alveolar crest. The buccal undercut was determined as the point where the crest came closest to the root in the sagittal plane. Additionally, the angle between the tooth roots and the alveolar crest was measured to determine the root position in the radial plane
219598810|NCT07133529|BEHAVIORAL|Perceived food uncertainty|Participants remain unaware of both the scheduled time and the length of the next meal.
219598811|NCT07133529|BEHAVIORAL|Perceived food certainty|Participants are aware of both the scheduled time and the length of the next meal.
219483591|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
218866879|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
219483592|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
219483593|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
219483594|NCT04492488|DRUG|MRG002|Administrated intravenously
219483595|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
219483596|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
219483597|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
219598812|NCT07133438|DRUG|Anti-VEGF drug|conventional anti-VEGF therapy (intravitreal injections of conbercept 0.5 mg initially once a month for 3 months, followed by on-demand therapy which based on recurrence criteria)
219598813|NCT07133438|DRUG|Mecobalamin 5 MG|oral mecobalamin capsules 0.5 mg three times daily for 6 months
219598814|NCT07133438|DRUG|Placebo|placebo capsule with a similar appearance and odor to the mecobalamin capsules three times daily for 6 months
219598815|NCT06866444|DRUG|Observational|In a cohort of patients treated with duloxetine for fibromyalgia, participants vitals signs (blood pressure, heart rate, oxygen saturation level, temperature) will be taken as well as height and weight. Participants will fill out a questionnaire regarding their fibromyalgia diagnosis and symptoms. Lastly, participants will complete two sets of blood samples. One blood sample will evaluate genetic variants for duloxetine metabolizing capacity. The other sample will be used to analyze the level of concentration of duloxetine.
219598816|NCT07135180|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
219598817|NCT07135180|DIETARY_SUPPLEMENT|Blank control|Blank control
219598818|NCT07134764|DEVICE|Virtual reality session|Patients included in the intervention group (VR group) participated in a comprehensive virtual reality program designed to reduce perioperative anxiety and pain. Prior to their surgery, they attended an introductory VR session aimed at familiarizing them with the technology and providing a calming, immersive environment to help alleviate preoperative stress. Throughout their surgical journey, these patients continued to receive the usual standard care, which included thorough preoperative consultations with healthcare providers, detailed information about the planned surgical procedure, and the provision of standard postoperative care to support recovery. Additionally, during the surgery itself, patients underwent a VR session delivered via a headset, offering real-time immersive distraction and relaxation to minimize intraoperative anxiety and pain perception.
219598819|NCT07003529|OTHER|Unenhanced brain MRI|Unenhanced brain MRI in five sequences: 1) T1-weighted anatomical sequences 2) Resting-state functional sequences 3) Task-based functional sequence 4) Structural sequence using Diffusion Tensor Imaging (DTI) 5) Routine magnetic resonance spectroscopy sequence
219598820|NCT07134296|RADIATION|MR-Guided Irradiation|MR-Guided Irradiation
219598821|NCT07134075|DRUG|intracochlear triamcinolone acetonide injection|intracochlear triamcinolone acetonide injection of through the round window membrane
219598822|NCT07134075|DRUG|intracochlear injection of dexamethasone through the round window membrane|intracochlear injection of dexamethasone sodium phosphate through the round window membrane
219598823|NCT07134075|DRUG|intracochlear dexamethasone injection and intratympanic dexamethasone injection|intracochlear dexamethasone sodium phosphate injection of through the round window membrane, intratympanic dexamethasone sodium phosphate injection through the tympanic membrane
218866880|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
218866881|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
218866882|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
218866883|NCT01184417|DRUG|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
218866884|NCT01184417|DRUG|placebo|100 m l saline
218866885|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
219598824|NCT07134075|DRUG|intratympanic dexamethasone injection|intratympanic dexamethasone sodium phosphate injection (10mg/ml) through tympanic membrane，once every other day, for a total of 4 injections.
219613571|NCT07018128|OTHER|Study 2: 4-7-8 breathing|Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out daily for a duration of 3 months.
219483598|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
219483599|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
218866886|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
218866887|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
218866888|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
218866889|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
218866890|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
218866891|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
218866892|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
218866893|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
219483600|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
219483601|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
219483602|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
219483603|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
219483604|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
219613572|NCT07018128|OTHER|Study 2: slow breathing with device|Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.
219483605|NCT04909879|DRUG|Placebo|Excipient solution
219483606|NCT00226447|DRUG|Pegylated Interferon|
219483607|NCT00226447|DRUG|Lamivudine|
219483608|NCT00026156|DRUG|docetaxel|
219483609|NCT00026156|DRUG|vinorelbine tartrate|
219483610|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
219483611|NCT04040738|PROCEDURE|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
219483612|NCT04040738|PROCEDURE|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
219483613|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
218866894|NCT01943019|DRUG|Linagliptin|
218866895|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
218866896|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
218866897|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
218866898|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
218866899|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
218866900|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
218866901|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
218866902|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
218866903|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
218866904|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
218866905|NCT02580513|BEHAVIORAL|Circadian Misalignment|
218866906|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
218866907|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
219199811|NCT06824922|BEHAVIORAL|"Be yourself, educational intervention with chatbot to promote self-determined motivation and prevent adolescent pregnancy: pilot trial protocol"|"The Be Yourself educational intervention stands out for its focus on self-determined motivation and teen pregnancy prevention. Unlike traditional interventions, which focus on transmitting information, this intervention promotes adolescent autonomy in making responsible sexual decisions. It uses interactive technology such as a web page and a chatbot, which provide personalized follow-up and reinforcement activities between sessions, encouraging active participation. It also employs competency-based learning, which strengthens practical and emotional skills, such as effective communication and problem solving. Sessions include role-plays and practical activities to apply what has been learned. This comprehensive approach and the use of digital platforms distinguish Be Yourself from other interventions, offering continuous and personalized accompaniment to reinforce learning throughout the process."
219483614|NCT04551027|BEHAVIORAL|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
219483615|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
219483616|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
219483617|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
219483618|NCT02930538|OTHER|Survey|Completing a survey on RedCap
219483619|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
219598825|NCT07021053|BEHAVIORAL|Alcohol Change Course Enhanced|The Alcohol Change Course Enhanced is an adaptation of the Alcohol Change Course, originally developed and evaluated in Switzerland. The Course is a six-lesson ICBT intervention delivered over eight weeks to individuals who self-report alcohol misuse. Due to therapist registration and availability, eligible clients residing in Saskatchewan will be offered the option of receiving therapist assistance (or not) alongside the Course, while clients from other Canadian provinces will not receive therapist support. In addition to the monitoring of weekly measures available to all clients, those receiving therapist support will receive weekly secure messaging from their assigned therapist for eight weeks. Therapists will spend approximately 15 minutes per week/per client receiving therapist support. Phone calls will be used in the event that there is a significant clinical issue requiring therapist attention that cannot be addressed over messaging (e.g., sudden increase in symptoms).
219598826|NCT01382654|DRUG|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
219598827|NCT01382654|DRUG|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
219598828|NCT01382654|DRUG|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
219598829|NCT01382654|DRUG|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
219598830|NCT01382654|DRUG|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
219598831|NCT03303209|OTHER|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
219598832|NCT06435156|DRUG|Sotagliflozin|Sodium-glucose Co-transporter inhibitor
219598833|NCT06435156|DRUG|Placebo|Matched placebo
219483620|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
219483621|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
219483622|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
219483623|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
218866908|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
218866909|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
218866910|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
218866911|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
219483624|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
219483625|NCT02263222|DRUG|MDT-10013|
219483626|NCT00795379|BEHAVIORAL|Interoceptive Exposure|Exposure to internal stimuli.
218866912|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
219483627|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
219483628|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
219483629|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
219483630|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
219483631|NCT03916692|DIETARY_SUPPLEMENT|Carbohydrate drink|Meal replacement drink containing 200 kcal
219483632|NCT03916692|DIETARY_SUPPLEMENT|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
219598834|NCT06697626|DIETARY_SUPPLEMENT|Inulin, B-vitamins and vitamin D|"Intervention twice daily with:~10g chicory inulin 100µg folic acid 5µg vitamin B12 5mg vitamin B6 2.5mg riboflavin 5µg vitamin D"
218866913|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
218866914|NCT02621398|DRUG|Carboplatin|Given IV
218866915|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
219483633|NCT03916692|DIETARY_SUPPLEMENT|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
219483634|NCT02286284|DEVICE|Apheresis for extracorporal removal of sFlt-1|
219483635|NCT04934969|DIETARY_SUPPLEMENT|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
219483636|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
219483637|NCT06107127|PROCEDURE|STOP|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
219483638|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
219598835|NCT06697626|DIETARY_SUPPLEMENT|Placebo group|A twice daily placebo drink with similar energy content but without the additional nutrient provision
219598836|NCT03072979|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy
219598837|NCT05503810|BEHAVIORAL|Social support|Contact ones a week with Informal caregiver or peer support
219598838|NCT05535153|OTHER|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
219598839|NCT06102083|DRUG|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
219598840|NCT01840865|DEVICE|brain stimulation|oscillating direct current brain stimulation
218866916|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
218866917|NCT02621398|DRUG|Paclitaxel|Given IV
218866918|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
218866919|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
218866920|NCT01314560|OTHER|Blood sample|Blood sample
218866921|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
218866922|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
218866923|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
218866924|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
218866925|NCT05551975|OTHER|Control Product|Fed from Study Day 1
219199812|NCT06824922|OTHER|Conventional Sex Education|For the CG, two theoretical sessions are planned. In the first, an orientation on adolescent sexual health will be provided through a one-hour PowerPoint presentation. Topics of anatomy, physiology, biological changes in adolescence and contraceptive methods will be addressed, highlighting their proper use and the prevention of adolescent pregnancy. The second session, also lasting one hour, will develop sexual health self-care skills, discussing the importance of self-care, self-respect and informed decision making. There will be a question and answer session to address concerns and reflect on how self-care contributes to a healthy and safe sexual life.
219483639|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
219483640|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
219483641|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
219483642|NCT04012008|OTHER|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
219483643|NCT04012008|OTHER|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
218866926|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
218866927|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
219199813|NCT06823011|DIAGNOSTIC_TEST|blood collection|Blood was collected from the study group and the control group at 10 am in the morning on an empty stomach.
219199814|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
219483644|NCT00132600|DRUG|bacitracin (allergen)|
218866928|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
218866929|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
219483645|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
219483646|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
219483647|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
219483648|NCT03911882|DIETARY_SUPPLEMENT|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
218866930|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
218866931|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
218866932|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
218866933|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
218866934|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
218866935|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
218866936|NCT00351182|DRUG|Telithromycin|
218866937|NCT00351182|DRUG|Doxycycline|
218866938|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
218866939|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
219483649|NCT00759668|DEVICE|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
219483650|NCT00759668|DEVICE|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
219483651|NCT00410839|PROCEDURE|ALA rich diet|
219483652|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
219483653|NCT03890835|PROCEDURE|MTA Pulpotomy.|Pulpotomy using MTA.
219483654|NCT03890835|PROCEDURE|Biodentine Pulpotomy|Pulpotomy using Biodentine
219483655|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483656|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483657|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483658|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483659|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219598841|NCT01840865|DEVICE|no stimulation|sham Stimulation
219598842|NCT02365194|BEHAVIORAL|Prehabilitation|information included in arm description
218866940|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
218866941|NCT01264770|DRUG|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
219483660|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
218866942|NCT01264770|DRUG|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
219483661|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483662|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219483663|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
219483664|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
219483665|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
219483666|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
219483667|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
219483668|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
219483669|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
219483670|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
219483671|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
219483672|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
219483673|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
218866943|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
219199815|NCT06598345|BEHAVIORAL|Routine Pet Fish Care|Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.
219483674|NCT02091388|DRUG|LY03004|
219483675|NCT02091388|DRUG|Risperdal® Consta®|
219483676|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
219483677|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
219483678|NCT01410565|DRUG|Apaziquone|Apaziquone 4 mg in 40 mL diluent
219483679|NCT01410565|DRUG|Placebo|Placebo for Double Blind Phase
219483680|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
218866944|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
218866945|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
219483681|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
219483682|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
219483683|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
219483684|NCT06388265|OTHER|Trifold information|Additional detailed and written information about the procedure will be given to the participants
219483685|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
219483686|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
219483687|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
219598843|NCT02365194|BEHAVIORAL|Standard counseling|information included in arm description
219598844|NCT03865368|OTHER|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
219598845|NCT00070200|BIOLOGICAL|filgrastim|
219598846|NCT00070200|DRUG|cisplatin|
219598847|NCT00070200|DRUG|cyclophosphamide|
219598848|NCT00070200|DRUG|doxorubicin hydrochloride|
219598849|NCT00070200|DRUG|etoposide|
219598850|NCT00070200|DRUG|isotretinoin|
219598851|NCT00070200|DRUG|melphalan|
218866946|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
218866947|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
219483688|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
219483689|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
219483690|NCT02394379|DEVICE|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
219483691|NCT03121664|DRUG|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
219483692|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
219483693|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
219483694|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
219483695|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
219483696|NCT04060979|DRUG|Nitric Oxide|Nitric Oxide given intermittently via inhalation
219483697|NCT04060979|OTHER|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
219483698|NCT00270179|DRUG|epoetin alfa|
219483699|NCT02446496|DRUG|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
219598852|NCT00070200|DRUG|topotecan hydrochloride|
219598853|NCT00070200|DRUG|vincristine sulfate|
218866948|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
218866949|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
219483700|NCT02446496|DRUG|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
219483701|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
219483702|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
218866950|NCT02699372|DRUG|Placebo|
219598854|NCT00070200|PROCEDURE|conventional surgery|
219598855|NCT00070200|PROCEDURE|peripheral blood stem cell transplantation|
219598856|NCT00070200|RADIATION|radiation therapy|
219598857|NCT04784533|DRUG|CTP-543|Oral dosing
219598858|NCT04784533|DRUG|Placebo|Oral dosing
218866951|NCT02699372|DRUG|RO6889450|
218866952|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
218866953|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
219483703|NCT00631709|OTHER|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
219483704|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
219483705|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
219483706|NCT00369798|PROCEDURE|PET scan|
219483707|NCT00369798|DRUG|Rolipram|
219483708|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
219598859|NCT04339283|DIETARY_SUPPLEMENT|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
219598860|NCT02632461|BEHAVIORAL|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
219598861|NCT02632461|BEHAVIORAL|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
219598862|NCT02632461|BEHAVIORAL|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
219598863|NCT07047781|OTHER|Assessment|Individuals between the ages of 7 and 14 who are receiving primary education and meet the inclusion criteria will be included in this study planned to evaluate the relationship between smartphone addiction and thoracic hyperkyphosis in children with thoracic hyperkyphosis.
219598864|NCT05189444|DRUG|Vonoprazan|20mg bid
219598865|NCT05189444|DRUG|Amoxicillin|0.75g tid
219598866|NCT05189444|DRUG|Esomeprazole|20mg bid
219598867|NCT05189444|DRUG|Amoxicillin|1.0g bid
219598868|NCT05189444|DRUG|Clarithromycin|0.5g bid
218866954|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
218866955|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
218866956|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
219483709|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
219483710|NCT03300882|OTHER|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
219483711|NCT01618903|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
219483712|NCT01618903|DRUG|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
219483713|NCT03853980|DEVICE|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
219483714|NCT02122939|DRUG|Escitalopram|
219483715|NCT06393816|DRUG|Durvalumab with etoposide and Carboplatin/Cisplatin|"Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months"
219483716|NCT02023723|DIETARY_SUPPLEMENT|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
219483717|NCT02023723|DIETARY_SUPPLEMENT|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
219483718|NCT01131208|GENETIC|gene expression analysis|
219483719|NCT01131208|OTHER|laboratory biomarker analysis|
219483720|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
219483721|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
219483722|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
219483723|NCT00983255|DRUG|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
219483724|NCT00983255|DRUG|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
219483725|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
219483726|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
219483727|NCT00124579|DRUG|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
219483728|NCT00124579|DRUG|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
219598869|NCT05189444|DRUG|Bismuth potassium citrate|0.22g bid
219598870|NCT05567263|PROCEDURE|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
219598871|NCT05567263|PROCEDURE|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
219598872|NCT05312320|OTHER|Information film|"* Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe"
219613573|NCT07017218|DIETARY_SUPPLEMENT|IMPACT|immune enhanced formula enriched in arginine, n-3 PUFA and nucleotide
219199816|NCT06598345|BEHAVIORAL|Collaborative Communication|Parents and participants in the Collaborative Communication group will be given recommendations for how to conduct weekly meetings in a collaborative approach based on a modified version of the Minute Meeting protocol.
219199817|NCT06841497|OTHER|Dolabi|herbal remedy for DM II
219483729|NCT00124579|DRUG|thalidomide|100 mg/d PO days 1-21 every 21 days
219483730|NCT00874042|DRUG|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
219483731|NCT04747678|DRUG|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
219483732|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
219483733|NCT05131893|DRUG|Tamoxifen|endocrine therapy
219483734|NCT05131893|DRUG|Goserelin|endocrine therapy
219483735|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
219483736|NCT05131893|DRUG|Epirubicin|chemotherapy
219483737|NCT05131893|DRUG|cyclophosphamide|chemotherapy
219613574|NCT07017894|COMBINATION_PRODUCT|Experimental: breast mask containing cabbage leaves extract group|apply breast mask to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days
218866957|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
218866958|NCT02660892|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
218866959|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
218866960|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
218866961|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
219483738|NCT05131893|DRUG|Docetaxel|chemotherapy
218866962|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
218866963|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
218866964|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
218866965|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
218866966|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
219483739|NCT05131893|DRUG|paclitaxel|chemotherapy
218866967|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
218866968|NCT00563823|DRUG|vatalanib|
218866969|NCT00048750|DRUG|Micafungin|IV
218866970|NCT00048750|DRUG|Placebo|IV
218866971|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
218866972|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
218866973|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
219483740|NCT05131893|DRUG|trastuzumab|biological treatment
219483741|NCT05131893|DRUG|pertuzumab|biological treatment
219483742|NCT05131893|DRUG|Capecitabine|chemotherapy
219483743|NCT01080911|DRUG|Morphine|spinal morphine 0.05 mg
219483744|NCT01080911|DRUG|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
218866974|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
218866975|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
218866976|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
218866977|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
218866978|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
218866979|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
218866980|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
218866981|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
218866982|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
219483745|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
219483746|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
219483747|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
219483748|NCT05912153|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT of the foot and ankle
219483749|NCT05912153|DIAGNOSTIC_TEST|MRI|MRI of the foot and ankle
219483750|NCT00535873|DRUG|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
219483751|NCT00915980|PROCEDURE|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
219483752|NCT05778227|DRUG|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
219483753|NCT05778227|DRUG|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
219483754|NCT05778227|DRUG|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
218866983|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
218866984|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
219483755|NCT05778227|DRUG|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
219483756|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
219483757|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
219483758|NCT03724591|PROCEDURE|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
219598873|NCT03269227|RADIATION|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
219598874|NCT05962762|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
218866985|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
219483759|NCT03724591|PROCEDURE|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
219483760|NCT00632476|OTHER|Placebo|Placebo capsule once a day
219483761|NCT00632476|DIETARY_SUPPLEMENT|Vitamin C|A 500-mg vitamin C capsule once a day
219483762|NCT05922592|PROCEDURE|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
219483763|NCT05922592|PROCEDURE|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
219598875|NCT04290273|DIAGNOSTIC_TEST|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
218866986|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
218866987|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
218866988|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
218866989|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
219199818|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (250 mg/kg)|250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
219199819|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (500 mg/kg)|500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
219483764|NCT06150001|DRUG|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
219483765|NCT06150001|DRUG|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
219483766|NCT06150001|DRUG|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
219483767|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
219483768|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
219483769|NCT00143416|DRUG|Pegvisomant|
219483770|NCT06567132|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
219483771|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
219483772|NCT01735864|DRUG|Indirubin 200μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
218866990|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
218866991|NCT00261703|DRUG|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
218866992|NCT00261703|DRUG|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
218866993|NCT00261703|OTHER|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
218866994|NCT02241187|DRUG|PEGPH20|
218866995|NCT02241187|DRUG|Cetuximab|
219483773|NCT01735864|DRUG|Indirubin 100 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
219483774|NCT01735864|DRUG|Indirubin 50 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
219483775|NCT01735864|DRUG|Indirubin 10 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
219483776|NCT01596049|DEVICE|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
219483777|NCT02310815|DEVICE|ReSure Sealant|
219483778|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
219483779|NCT00722007|DEVICE|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
219483780|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
219483781|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
219483782|NCT00513578|BIOLOGICAL|sargramostim|
218866996|NCT02241187|DEVICE|DW & DCE-MRI|
218866997|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
218866998|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
218866999|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
219483783|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
219483784|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
219483785|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
219483786|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
219483787|NCT05982158|BEHAVIORAL|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
219483788|NCT05982158|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
218867000|NCT00539929|DRUG|E6201 0.005%|
218867001|NCT00539929|DRUG|E6201 0.01%|
218867002|NCT00539929|DRUG|E6201 0.03%|
218867003|NCT00539929|DRUG|Placebo|
218867004|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
218867005|NCT00002342|DRUG|Tecogalan sodium|
218867006|NCT00076518|DRUG|Fenofibrate|
218867007|NCT00076518|DRUG|Fish Oil|
218867008|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
218867009|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
218867010|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
219199820|NCT05888532|DRUG|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
219483789|NCT01244516|DEVICE|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
219483790|NCT01244516|DEVICE|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
219483791|NCT01244516|DEVICE|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
219483792|NCT02215434|DRUG|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
219483793|NCT02215434|DRUG|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
219483794|NCT04256135|OTHER|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
219483795|NCT04256135|OTHER|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
218867011|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
219483796|NCT01700335|DRUG|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
219483797|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
219483798|NCT01950338|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
219483799|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
219483800|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
219483801|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483802|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483803|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483804|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483805|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483806|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
219598876|NCT04290273|DEVICE|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
219598877|NCT00307437|DRUG|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
218867012|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
218867013|NCT01020903|DRUG|Placebo|Orally, pre-op
218867014|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
219199821|NCT05888532|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
218867015|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
218867016|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
219598878|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
219598879|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
219483807|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
219483808|NCT05907044|BIOLOGICAL|RQ3013|0.15mL/dose containing mRNA 30μg
219483809|NCT05907044|BIOLOGICAL|RQ3025|0.15mL/dose containing mRNA 30μg
219483810|NCT05907044|BIOLOGICAL|RQ3027|0.15mL/dose containing mRNA 30μg
219483811|NCT04432129|BEHAVIORAL|IBBIS II|"The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support."
219483812|NCT04432129|BEHAVIORAL|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
219483813|NCT06080191|DRUG|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR\_Lenti\_ALLO~A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0"
219598880|NCT00797537|PROCEDURE|Echography|Echography
219483814|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
219483815|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
219483816|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
219483817|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
219483818|NCT05302414|BEHAVIORAL|Board game-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a board game-based teaching approach.
219483819|NCT05302414|BEHAVIORAL|Simulation-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a simulation-based teaching approach.
219483820|NCT05302414|BEHAVIORAL|Lecture-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through an interactive lecture-based approach.
219483821|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
219598881|NCT06427837|OTHER|Same 2nd course|The same snack food will be served in the second course
219598882|NCT06427837|OTHER|Different 2nd course|A different snack food will be served in the second course
219598883|NCT03835676|DRUG|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
219613575|NCT07017894|COMBINATION_PRODUCT|Sham Comparator|Apply a breast mask without cabbage leaves extract to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days.
219613576|NCT07018648|DEVICE|Medical device|Adding Kardi Ai medical device for detection of heart rythm disorders
218867017|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
219598884|NCT01609712|PROCEDURE|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
219483822|NCT04537052|PROCEDURE|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
219483823|NCT03262519|DIAGNOSTIC_TEST|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
219483824|NCT05474794|DIAGNOSTIC_TEST|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
219483825|NCT05474794|DIAGNOSTIC_TEST|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
219483826|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
219483827|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
219483828|NCT05672394|DRUG|Bupivacaine|bupivacaine
219483829|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
219483830|NCT06061601|DEVICE|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
219598885|NCT05895955|BIOLOGICAL|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
218867018|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
218867019|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
218867020|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
218867021|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
219483831|NCT02657746|OTHER|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
218867022|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
218867023|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
218867024|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
218867025|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
218867026|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
218867027|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
218867028|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
218867029|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
218867030|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
219483832|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
219483833|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
219483834|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
219483835|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
219483836|NCT01102972|DRUG|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
219483837|NCT01102972|DRUG|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
219483838|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
218867031|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
218867032|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
218867033|NCT03258060|PROCEDURE|Temporary pacing study|
219483839|NCT02024386|DRUG|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
219483840|NCT03487614|BEHAVIORAL|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
219483841|NCT06439316|BEHAVIORAL|Sedentary behavior|Total sedentary time was assessed by self-reported daily hours of sitting
218867034|NCT03258060|RADIATION|Body Surface Mapping|
218867035|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
218867036|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
218867037|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
218867038|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
218867039|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
218867040|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
219483842|NCT06439316|BEHAVIORAL|Depressive symptoms|depressive symptoms were assessed by Patient Health Questionnaire 9 scale
219483843|NCT06564155|DEVICE|carotid duplex|measure Carotid intima media thickness
219483844|NCT00002680|BIOLOGICAL|filgrastim|
219483845|NCT00002680|DRUG|cyclophosphamide|
219483846|NCT00002680|DRUG|megestrol acetate|
219483847|NCT00002680|DRUG|melphalan|
218867041|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
218867042|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
218867043|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
218867044|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
218867045|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
218867046|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
219021201|NCT07207044|BEHAVIORAL|Exercise - Strength + Cardio|Supervised strength training 2x/week + self-administered cardio training 2x/week.
219021202|NCT07207044|BEHAVIORAL|Time-restricted feeding|Time-restricted feeding in a 16/8 regimen - 16 hours of fast and 8 hours of eating per day.
219021203|NCT07207044|BEHAVIORAL|Time-restricted feeding + Exercise|Strength and cardio exercise 2x/week each combined with time-restricted feeding in a 16/8 regimen.
219483848|NCT00002680|DRUG|tamoxifen citrate|
219483849|NCT00002680|DRUG|thiotepa|
219483850|NCT00002680|PROCEDURE|conventional surgery|
219483851|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
219483852|NCT00002680|RADIATION|radiation therapy|
219483853|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
219483854|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
219483855|NCT04935931|DRUG|Naltrexone|naltrexone 50 mg PO x 1
219483856|NCT06393673|DRUG|HS-10384 tablet Dose 1|Administered orally QD
219483857|NCT06393673|DRUG|HS-10384 tablet Dose 2|Administered orally QD
219483858|NCT06393673|DRUG|HS-10384-matched placebo tablets|Administered orally QD
219483859|NCT04083274|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219613577|NCT07018206|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day
219613578|NCT07017868|DIAGNOSTIC_TEST|interleukin- 17|focused on the importance of IL-17 in SLE, and its relation to different disease activity
218867047|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
219483860|NCT04083274|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
219483861|NCT04344782|DRUG|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
219598886|NCT05895955|BIOLOGICAL|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
219598887|NCT05920512|DRUG|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
219598888|NCT02505308|OTHER|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
219483862|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
219483863|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
219598889|NCT04104802|DEVICE|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1\) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
219021210|NCT07206992|DRUG|24 hours antibiotics|Antibiotic therapy will start 24 hours before urological surgery
219021211|NCT07206992|DRUG|48 hours antibiotics|Antibiotic therapy will start 48 hours before urological surgery
219040076|NCT05357872|DEVICE|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
219040077|NCT05357872|DEVICE|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
219040078|NCT03633981|OTHER|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~* right and left pupillometry (3 times)~* BIS values~* right and left NIRS values~* right and left transcranial Doppler~* neurological clinical examination"
219040079|NCT03633981|OTHER|neurological assessment when a neurological event occurs|"next neurological event:~* seizures~* pupillary asymmetry~* myoclonias~* brain stem reflex abnormalities~* osteotendinous reflex abnormalities"
219040080|NCT03633981|OTHER|mortality assessment|to 28 days
219040081|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
219040082|NCT02078804|PROCEDURE|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
219040083|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
219040084|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
219598890|NCT01581866|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
218867048|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
218867049|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
219483864|NCT03287141|DIAGNOSTIC_TEST|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
219483865|NCT03287141|DEVICE|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
219483866|NCT03287141|DEVICE|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
219483867|NCT00868816|DRUG|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
219483868|NCT00868816|DRUG|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
219483869|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
218867050|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
218867051|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
219483870|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
219483871|NCT00424632|DRUG|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
219483872|NCT06567951|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
219483873|NCT04393831|PROCEDURE|Retzius sparing|Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
219483874|NCT06144931|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
219483875|NCT04457531|DRUG|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
219483876|NCT04457531|OTHER|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
218867052|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
218867053|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
218867054|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
218867055|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
218867056|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
219040085|NCT00404352|DRUG|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
219040086|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
219483877|NCT06420427|DIAGNOSTIC_TEST|Assess the risk of recurrence and the efficacy of medication|Evaluation of recurrence risk and medication efficacy through liquid biopsy
219483878|NCT00345826|DRUG|dasatinib|
219483879|NCT04451109|DEVICE|Dilapan-S|Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
219483880|NCT00713765|DRUG|AZD3480|18 total doses of 40 mg, on days 1-18
219483881|NCT00713765|DRUG|Donepezil|One single dose of mg on day 5
219483882|NCT05813665|DRUG|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
218867057|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
218867058|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
218867059|NCT02059954|PROCEDURE|Hysterectomy|
218867060|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
219483883|NCT05813665|DRUG|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
219483884|NCT00686231|DRUG|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
219483885|NCT00686231|DRUG|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
219483886|NCT00686231|DRUG|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
219483887|NCT00686231|DRUG|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
219483888|NCT00686231|DRUG|Placebo|Topical skin moisturizing cream with same appearance as active agent
219483889|NCT00445458|DRUG|HKI-272|
219483890|NCT00445458|DRUG|Paclitaxel|
219483891|NCT01527942|DRUG|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
219483892|NCT01527942|DRUG|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
219483893|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
219483894|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
219483895|NCT05339542|OTHER|platelet rich plasma|derived from patient own blood
219483896|NCT05339542|DRUG|MethylPREDNISolone 40 MG|active comparative intervention
219483897|NCT03634007|BIOLOGICAL|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
219483898|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
219483899|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
218867061|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
218867062|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
218867063|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
218867064|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
218867065|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
218867066|NCT03158181|OTHER|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
218867067|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
218867068|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
218867069|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
219483900|NCT02367807|DRUG|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
219483901|NCT03987737|PROCEDURE|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
219483902|NCT03833856|PROCEDURE|colonoscopy perforation|The development of perforation after colonoscopy
219483903|NCT06652230|OTHER|Smile Arc Marginal Ridge Approach (SAMRA)|Smile Arc Marginal Ridge Approach (SAMRA) is a new orthodontic bonding technique proposed by Dr. Dalia El Bokle where she stated that it provides more accurate orthodontic results and less time and effort needed during finished. No randomized clinical trials are done on this new approach yet so our study is the first one to test it. 0.018-inch MBT brackets will be used in our study.
218867070|NCT06194461|BIOLOGICAL|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
218867071|NCT06194461|BIOLOGICAL|AZD0754|Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
218867072|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
218867073|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
218867074|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
218867075|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
219483904|NCT06652230|OTHER|MBT Chart Method|For our comparator group MBT Chart Method will be used. Using charts during orthodontic bonding procedures is considered the gold standard. 0.018-inch brackets will be used.
219483905|NCT03539939|PROCEDURE|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
219483906|NCT03049371|OTHER|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
219483907|NCT03003728|DRUG|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
219483908|NCT03003728|DRUG|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
219483909|NCT03003728|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
218867076|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
218867077|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
218867078|NCT01919736|BEHAVIORAL|Gait Retraining|
218867079|NCT01713556|DRUG|Propranolol|
218867080|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
218867081|NCT01713556|DRUG|placebo|
218867082|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
218867083|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
218867084|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
218867085|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
218867086|NCT00037674|DRUG|Topiramate|
218867087|NCT06019806|OTHER|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
219040087|NCT00852709|DRUG|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
219040088|NCT00852709|DRUG|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
219483910|NCT03003728|BIOLOGICAL|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
219483911|NCT03003728|DRUG|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
219483912|NCT00116207|DRUG|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
219483913|NCT02513693|DRUG|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
219483914|NCT02513693|DRUG|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
219483915|NCT00728988|DRUG|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
219483916|NCT00728988|DRUG|Atorvastatin|40mg daily after PCI for 30 days.
219483917|NCT05188807|DIAGNOSTIC_TEST|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
219483918|NCT00029042|DRUG|Infliximab|
219483919|NCT01247753|BEHAVIORAL|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
219483920|NCT03412994|DRUG|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
219483921|NCT03412994|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
219483922|NCT02238886|DIETARY_SUPPLEMENT|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
219483923|NCT00764816|OTHER|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
219483924|NCT00764816|OTHER|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
219483925|NCT00710060|BEHAVIORAL|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
219483926|NCT00710060|BEHAVIORAL|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
219598891|NCT03578666|OTHER|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
219598892|NCT03578666|OTHER|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
219598893|NCT03006302|DRUG|Epacadostat|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
219483927|NCT01984229|DRUG|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
219483928|NCT01984229|DRUG|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
219483929|NCT04620863|OTHER|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
219483930|NCT04620863|OTHER|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
219483931|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
219483932|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
219483933|NCT00937859|DRUG|SER120|SER120
219483934|NCT00937859|DRUG|Placebo|Placebo
219483935|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
219483936|NCT05157529|DEVICE|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
218867088|NCT06019806|OTHER|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
218867089|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
218867090|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
218867091|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
218867092|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
219483937|NCT05157529|DEVICE|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
219483938|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
219483939|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
219483940|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
218867093|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
218867094|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
218867095|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
218867096|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
219040089|NCT05026684|OTHER|Personalized cost handout|Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
219040090|NCT01044082|PROCEDURE|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
219040091|NCT01044082|PROCEDURE|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
219483941|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
219483942|NCT04992897|DEVICE|Remote Electrical Neuromodulation (REN)|Acute migraine treament
219483943|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
219483944|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
219483945|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
219483946|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
219483947|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
219483948|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
219483949|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
219483950|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
219483951|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
219483952|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
219483953|NCT01166126|DRUG|temsirolimus|Given IV
219483954|NCT01166126|DRUG|selumetinib|Given orally
219483955|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
219483956|NCT00394862|DRUG|multivitamin|
219598894|NCT03006302|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
219598895|NCT03006302|BIOLOGICAL|CRS-207|CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
219598896|NCT03006302|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
219598897|NCT03006302|BIOLOGICAL|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
219598898|NCT03450252|DEVICE|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
219598899|NCT03450252|DEVICE|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
219598900|NCT05200000|BIOLOGICAL|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
219598901|NCT04364659|BEHAVIORAL|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
219483957|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
219483958|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
219598902|NCT01754337|OTHER|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
219598903|NCT01844232|DRUG|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
219598904|NCT06633354|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
219598905|NCT02598947|OTHER|Manual therapy|Exercise, behaviour change interventions and manual therapy
219598906|NCT02655783|OTHER|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
219598907|NCT02655783|OTHER|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
219598908|NCT05238454|BIOLOGICAL|SCTV01C|intramuscular injection
219598909|NCT05238454|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
219598910|NCT05238454|BIOLOGICAL|Comirnaty|intramuscular injection
219598911|NCT00788944|PROCEDURE|blood draw|Test Article was not provided to subjects for this study.
219598912|NCT03131544|DEVICE|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
219598913|NCT05637164|DRUG|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
219598914|NCT03909269|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
219598915|NCT03909269|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
219598916|NCT03909269|RADIATION|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
219598917|NCT03909269|DEVICE|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
219598918|NCT01593943|BEHAVIORAL|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
219598919|NCT05607979|DRUG|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
219483959|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
219483960|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
219483961|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
219483962|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
219483963|NCT02549391|DRUG|KHK7580|Oral administration
219483964|NCT02549391|DRUG|KRN1493|Oral administration
219483965|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
219483966|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
219483967|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
219598920|NCT05607979|DRUG|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
219598921|NCT00338728|DRUG|Imatinib Mesylate|Given PO
219598922|NCT00338728|DRUG|Letrozole|Given PO
219598923|NCT02111928|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
219598924|NCT02796794|DIETARY_SUPPLEMENT|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
219598925|NCT02796794|OTHER|enteral nutrition only|These are the patients receiving enteral nutrition
219598926|NCT05705765|OTHER|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
219598927|NCT05705765|OTHER|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
219598928|NCT04940559|DRUG|Danicopan - Tablet|Oral tablet.
219598929|NCT04940559|DRUG|Danicopan - Softgel|Oral softgel capsule.
219598930|NCT04940559|DRUG|Danicopan - LFC|Oral LFC.
219598931|NCT01559883|OTHER|no intervention is being made|This is a Non-Interventional Study (NIS)
219598932|NCT00143247|DRUG|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
219598933|NCT01562561|DRUG|repaglinide|2 mg at each main meal
219483968|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
219483969|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
219483970|NCT00327080|PROCEDURE|MRI|
219483971|NCT00327080|DRUG|L-NMMA|
219483972|NCT00327080|DRUG|Acetylcholine|
219483973|NCT04469868|BEHAVIORAL|No opioids at discharge|"Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues."
219483974|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
219483975|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
219483976|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
219483977|NCT00700037|DRUG|high-dose atorvastatin|20mg/day
219483978|NCT00700037|DRUG|low-dose atorvastatin|5mg/day
219598934|NCT01562561|DRUG|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
219598935|NCT04820205|DRUG|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
219598936|NCT04820205|DRUG|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
219598937|NCT06548945|DRUG|GZR18|5 mg-maximum tolerated dose (MTD), single dose
219598938|NCT06548945|OTHER|Placebo|administered the same volume as GZR18
219598939|NCT00003445|DRUG|docetaxel|
219598940|NCT01952314|DRUG|Naftopidil 75mg|naftopidil 75mg 1T qd hs
219598941|NCT01952314|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
219598942|NCT01952314|DRUG|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
219598943|NCT00591981|BEHAVIORAL|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
219598944|NCT00627510|OTHER|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
219598945|NCT01613313|DRUG|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
219598946|NCT00340678|DRUG|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
219598947|NCT00340678|DRUG|Placebo|Treatment with placebo corresponding to each dose of losartan.
219598948|NCT02766283|DRUG|iodinated contrast agents|Intravascular application
219598949|NCT00096837|DRUG|Motexafin Gadolinium Injection|
219598950|NCT01795911|BIOLOGICAL|Pegylated Interferon Lambda|
219598951|NCT01795911|DRUG|Ribasphere|
219598952|NCT01795911|DRUG|Daclatasvir|
219483979|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
219483980|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
219483981|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
219483982|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
219483983|NCT05450900|OTHER|Microcellulose filler|supplement, oral
219483984|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
219483985|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
219483986|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
219483987|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
219483988|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
219483989|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
219483990|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
219483991|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
219483992|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
219021224|NCT07205536|DRUG|Mecapegfilgrastim injection|After enrollment, a single subcutaneous dose of mecapegfilgrastim should be administered 24 hours following completion of each chemotherapy cycle. The recommended dose is a fixed 6 mg, or an individualized 100 μg/kg based on the patient's body weight. If neutrophil counts remain below 0.5 × 10⁹/L for more than 24 hours after mecapegfilgrastim administration, short-acting G-CSF may be used as rescue therapy at the investigator's discretion until neutrophil levels return to normal.
219483993|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
219483994|NCT00390091|DRUG|abetimus sodium (LJP 394)|
219483995|NCT01615900|OTHER|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
219598953|NCT04244383|DIAGNOSTIC_TEST|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
219598954|NCT01790477|PROCEDURE|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
219040092|NCT03504358|PROCEDURE|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
219040093|NCT02838212|DRUG|adverse drug reaction|drug-related death
219040094|NCT05539482|BEHAVIORAL|Community-based Health Education based on core intervention package|"Community-based Health Education will potentially include the following three components:~1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.~2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.~3. Knowledge of vaccines and their benefits and resources for vaccination.~Collaborators should design and implement health programs based on the core intervention package."
219598955|NCT03917927|DEVICE|Eztetic dental implant|narrow diameter dental implant
218867097|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
218867098|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
218867099|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
218867100|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
219483996|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
219483997|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
219598956|NCT04670276|PROCEDURE|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
219598957|NCT03295682|DEVICE|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
219598958|NCT00212680|DRUG|ONO-1101|
219598959|NCT03532373|OTHER|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
219598960|NCT00467324|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
219598961|NCT00338312|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
219598962|NCT00338312|DRUG|Placebo patch|placebo patch changed twice a week for one year
218867101|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
218867102|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
218867103|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
218867104|NCT00220207|BEHAVIORAL|Internet co-management module|
218867105|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
218867106|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
218867107|NCT03918707|DIAGNOSTIC_TEST|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
218867108|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
218867109|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
218867110|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
219040095|NCT05539482|BEHAVIORAL|Health Information Sharing Group|Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.
219598963|NCT00049179|DRUG|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
219598964|NCT00049179|DRUG|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
219598965|NCT03925259|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
219598966|NCT02987452|OTHER|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
219598967|NCT02987452|OTHER|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
219598968|NCT02987452|OTHER|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
219598969|NCT06089200|PROCEDURE|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
219598970|NCT06089200|PROCEDURE|Spinal Morphine|100 µg was administered intrathecally preoperatively
219598971|NCT00886405|DRUG|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
218867111|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
218867112|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
218867113|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
218867114|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
219483998|NCT02362243|OTHER|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
219483999|NCT02362243|OTHER|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
219484000|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
219484001|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
219199822|NCT06668116|DRUG|Ropivacaine 0,1%|"The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness."
219199823|NCT06668116|OTHER|NaCl (placebo)|0.9 % NaCl solution (saline) injection
219484002|NCT02380248|OTHER|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
219484003|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
218867115|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
218867116|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
218867117|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
219040096|NCT03341988|DRUG|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
219199824|NCT06611098|DEVICE|Viscosupplements|intra-articular injection
219040097|NCT05296603|DRUG|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
219040098|NCT03088176|DRUG|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
219040099|NCT03088176|DRUG|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
219040100|NCT03088176|DRUG|Dabrafenib|150mg PO qday
219484004|NCT02687763|BIOLOGICAL|ProQuad|"2\) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."
219484005|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
219484006|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
219484007|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
219484008|NCT06014359|DRUG|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
219484009|NCT06014359|DRUG|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
219484010|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
218867118|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
218867119|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
219484011|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
219484012|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
219484013|NCT04551859|OTHER|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
219484014|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
219484015|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
219484016|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
219484017|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
218867120|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
218867121|NCT03172130|DEVICE|Straight CPAP|
219484018|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
219484019|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~\--------------------------------------------------------------------------------"
219484020|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
219484021|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
219484022|NCT06701162|PROCEDURE|Ultrasoud-guided TAP block|the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.
219484023|NCT06701162|PROCEDURE|Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block|the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
219484024|NCT00900276|OTHER|immunologic technique|
219484025|NCT00900276|OTHER|laboratory biomarker analysis|
219484026|NCT00900276|OTHER|mass spectrometry|
219484027|NCT02204839|DRUG|Basal insulin dose|
219484028|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
219484029|NCT00605839|DEVICE|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
219484030|NCT00605839|DEVICE|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
219484031|NCT00605839|OTHER|Usual Care|This intervention was usual care, without either device.
219484032|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
219484033|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
219484034|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
219484035|NCT00590785|DRUG|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
219484036|NCT00590785|DRUG|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
219484037|NCT00590785|DRUG|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
219484038|NCT00590785|DRUG|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
219484039|NCT00590785|DRUG|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
219598972|NCT03629197|BEHAVIORAL|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
219598973|NCT03629197|OTHER|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
219598974|NCT06432374|BEHAVIORAL|WET|"The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions."
218867122|NCT03172130|DEVICE|Sham CPAP|
218867123|NCT03709394|PROCEDURE|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
218867124|NCT03709394|PROCEDURE|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
218867125|NCT03709394|PROCEDURE|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
219484040|NCT02864953|DRUG|BIIB093|Administered as specified in the treatment arm.
219484041|NCT02864953|DRUG|Placebo|Administered as specified in the treatment arm.
219484042|NCT06343142|OTHER|Nuts|Isocaloric meal with nuts
219484043|NCT06343142|OTHER|Nut-free meal|Isocaloric meal without nuts
219484044|NCT06277466|DRUG|Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs|Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
219484045|NCT06277466|DRUG|Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs|"The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing."
219484046|NCT05090085|OTHER|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
219484047|NCT05090085|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
219598975|NCT05886868|DRUG|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
218867126|NCT03295396|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
218867127|NCT05445895|DRUG|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
218867128|NCT05445895|DRUG|Plavix 75mg|Plavix 75mg will be added to Aspirin 100mg
218867129|NCT02218593|DEVICE|WREX orthosis|Upper extremity exoskleton used to assist movement
219484048|NCT05090085|OTHER|3m ESPE etch|32% phosphoric acid
219484049|NCT05090085|OTHER|OT Primer|Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
219040101|NCT03088176|DRUG|Trametinib|2mg PO qday
219484050|NCT06073873|DRUG|Ozanimod|According to local product label
219484051|NCT02487407|DRUG|ODM-109|ODM-109 1 mg capsule for oral administration.
219484052|NCT02487407|DRUG|Placebo for ODM-109|Placebo capsule for oral administration.
219484053|NCT00394992|DRUG|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
219484054|NCT00394992|DRUG|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
219484055|NCT00181974|DRUG|Tisseel Fibrin Sealant|
219484056|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
218867130|NCT03878901|COMBINATION_PRODUCT|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
218867131|NCT03878901|COMBINATION_PRODUCT|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
218867132|NCT03878901|COMBINATION_PRODUCT|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
219199825|NCT06611228|OTHER|Multidomain Interventions|Multidomain Interventions The intervention group will receive a personalized MDI approach from a multidisciplinary team, including a digital coach, physiotherapist, clinical nutrition expert, neuropsychologist, geriatrician, and nurse. This approach will encompass physical activity program, nutritional interventions, cognitive training and stimulation, medication reconciliation, coaching on the use of technological supports, and group activities. Environmental modifications at home will also be proposed
219484057|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
219484058|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
219484059|NCT01059552|DRUG|vorinostat|vorinostat once daily for 12 weeks of therapy
219484060|NCT01119352|DRUG|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
219484061|NCT01119352|DRUG|Placebo|Oral suspension, once daily. Totally 8 doses
219484062|NCT04959708|OTHER|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
219484063|NCT06330545|RADIATION|Radiation therapy|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
219598976|NCT02963233|PROCEDURE|Closed reduction and percutaneous pinning and immobilization|
219598977|NCT02963233|PROCEDURE|Non-operative reduction and immobilization|
219598978|NCT06076460|OTHER|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
218867133|NCT03878901|OTHER|passive warming|cotton blanket warming through operation
218867134|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
218867135|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
218867136|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
218867137|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
218867138|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
218867139|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
218867140|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
218867141|NCT03317119|OTHER|Laboratory Biomarker Analysis|Correlative studies
218867142|NCT03317119|DRUG|Trametinib|Given PO
218867143|NCT03317119|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219040102|NCT02308735|OTHER|N/A - No intervention|
219040103|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
219040104|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
219040105|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
219040106|NCT02838264|DRUG|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
219040107|NCT02838264|DRUG|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
219040108|NCT02250196|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
219040109|NCT02250196|DRUG|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
219040110|NCT03087656|DRUG|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
219040111|NCT03087656|DRUG|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
219040112|NCT04619706|DRUG|FSD201|Tablets for oral administration.
219040113|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
219040114|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
219484064|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
219484065|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
219484066|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
219484067|NCT06262490|DEVICE|Traditional ultrasound therapy|Ultrasound therapy for 2 session per week for until completing 12 treatment sessions (six weeks) with frequencies up to 3 MHz are used clinically to promote healing
219484068|NCT06262490|OTHER|Pelvic floor rehabilitation|Pelvic floor rehabilitation for 3 sessions per week for (six weeks) until completing 18 sessions with sessions lasting between 30-45 minutes
219484069|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
218867144|NCT05196555|PROCEDURE|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
218867145|NCT04580095|OTHER|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
218867146|NCT00952887|BIOLOGICAL|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
218867147|NCT00952887|BIOLOGICAL|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
218867148|NCT03419065|BEHAVIORAL|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
218867149|NCT02913768|DRUG|Ondansetron|
219199826|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
219598979|NCT06076460|OTHER|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
219598980|NCT06632548|DEVICE|telescopic overdenture|two implant retained mandibular overdenture with telescopic attachment
219598981|NCT02944773|PROCEDURE|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
219598982|NCT03245827|DRUG|Clomiphene|clomiphene capsule 25mg twice a week
218867150|NCT02913768|DRUG|Normal saline|
219199827|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
219199828|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
219484070|NCT05351606|DRUG|Bupropion|Given orally
219484071|NCT05351606|DRUG|Nicotine patch|Given transdermally
219199829|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
219199830|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption|Participants eat a defined portion of guava.
219484072|NCT05351606|DRUG|Nicotine lozenge|Given orally
219484073|NCT01096862|DRUG|peficitinib|oral
219484074|NCT01096862|DRUG|Placebo|oral
219484075|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
219484076|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
219484077|NCT04065386|DEVICE|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
219598983|NCT03245827|DRUG|Placebo|placebo capsule 25mg twice a week
219598984|NCT04246827|BEHAVIORAL|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
218867151|NCT03087292|OTHER|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
218867152|NCT03708666|OTHER|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
218867153|NCT02831933|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
218867154|NCT02831933|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
218867155|NCT02831933|RADIATION|SBRT|Low-dose SBRT
218867156|NCT02831933|DRUG|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
218867157|NCT01089790|DRUG|Dutogliptin|400 mg tablet, once daily
218867158|NCT01089790|DRUG|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
218867159|NCT02687100|DRUG|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
219484078|NCT04065386|DEVICE|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
218867160|NCT02687100|DRUG|Placebo|patients will receive 8 mL of saline without any drug
218867161|NCT05943210|RADIATION|Short Course Radiation Therapy (scRT)|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
218867162|NCT05943210|PROCEDURE|Total Mesenteric Excision (TME)|Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
218867163|NCT05280600|OTHER|Not applicable - non-interventional study|Not applicable - non-interventional study
218867164|NCT04913662|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
218867165|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
218867166|NCT00463554|DEVICE|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
218867167|NCT04784624|BEHAVIORAL|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
218867168|NCT03568669|OTHER|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
218867169|NCT05455931|DRUG|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
218867170|NCT05698524|DRUG|PCI 24781|Participants will take PCI-24781/Abexinostat on days 1 - 4, 8 - 11, and 15 - 18 of each 28-day cycle.
218867171|NCT05698524|DRUG|Temozolomide|Participants will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
218867172|NCT05042284|DRUG|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
218867173|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521).|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
218867174|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
218867175|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
219199831|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption|Participants consumed fresh-cut pineapple purchased from street vendors. Health outcomes, including potential microbial contamination and GI symptoms, were assessed for five days after consumption.
219199832|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption|Fresh-Cut Watermelon Consumption Description: Participants consumed fresh-cut watermelon obtained from street vendors. GI symptoms and microbial contamination effects were monitored for five days following consumption.
219199833|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption (With Gastric Acidity)|Same as intervention 2, but in participants with acidity
219199834|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption (With Gastric Acidity)|Same as intervention 3, but in participants with acidity.
218867176|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
219199835|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption (With Gastric Acidity)|Same as intervention 4, but in participants with acidity.
219484079|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
218867177|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
218867178|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
219598985|NCT05865548|DRUG|Aspirin 150 mg|Aspirin 150 mg PO daily
219598986|NCT05865548|PROCEDURE|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
218867179|NCT04584242|DRUG|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
218867180|NCT04584242|DRUG|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
218867181|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
218867182|NCT06957444|PROCEDURE|Sylke Adhesive Dressing|Topical wound closure device, made from silk fibroin woven mesh coated with a pressure-sensitive acrylic adhesive.
218867183|NCT06957444|PROCEDURE|Exofin Skin Glue|2-octil cyanoacrylate formulation, applied using a soft and flexible applicator.
218867184|NCT06957444|PROCEDURE|Suture Strip Plus|Flexible wound closure strip designed for primary wound closure made up of macroporous non-woven polyamide with a pressure sensitive adhesive.
218867185|NCT06450886|DRUG|Ulviprubart (ABC008)|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
218867186|NCT04601896|OTHER|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
218867187|NCT03623009|BEHAVIORAL|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
218867188|NCT03623009|BEHAVIORAL|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
218867189|NCT02636686|DRUG|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
218867190|NCT02204488|PROCEDURE|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
218867191|NCT02204488|PROCEDURE|Trapeziectomy|Trapeziectomy
219598987|NCT05615831|BEHAVIORAL|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
219598988|NCT03928067|BEHAVIORAL|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
218867192|NCT03665584|DEVICE|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
218867193|NCT03665584|DEVICE|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
218867194|NCT01882868|DRUG|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
218867195|NCT01882868|DRUG|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
218867196|NCT01882868|DRUG|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
218867197|NCT01882868|DRUG|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
218867198|NCT06206655|DIAGNOSTIC_TEST|rapid ACTH stimulation test|Take 2ml blood/saliva sample at baseline. Then, we will inject synacthen 250mcg IV to patients and collect 2ml blood/saliva after 30minutes and 60 minutes.
218867199|NCT00102284|DRUG|levodopa|
218867200|NCT00102284|DRUG|rivastigmine|
218867201|NCT00102284|DRUG|pergolid|
218867202|NCT00102284|DRUG|modafinil|
218867203|NCT04544683|DRUG|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
218867204|NCT04135014|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
218867205|NCT04135014|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
219598989|NCT04011163|DEVICE|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
219598990|NCT04011163|DRUG|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
218867206|NCT04135014|DRUG|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
218867207|NCT01992211|DRUG|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
218867208|NCT01992211|DRUG|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
218867209|NCT01992211|DRUG|BCWP_C003|Participant will be administered a single oral dose of BCWP\_C003 under Fasting condition or Fed condition according to sequence.
218867210|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
218867211|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
218867212|NCT06081894|DRUG|Aficamten|Oral Tablet
218867213|NCT06081894|DRUG|Placebo|Oral Tablet
219484080|NCT06436469|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) Program|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
219484081|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
219484082|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
219484083|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
219484084|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
219484085|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
219484086|NCT04184882|DRUG|Bocidelpar|Oral
218867214|NCT02870738|PROCEDURE|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
218867215|NCT02870738|DRUG|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
219484087|NCT04184882|DRUG|Placebo|Oral
219484088|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
219484089|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
219484090|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
219484091|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
219484092|NCT02305069|DRUG|Pioglitazone|Described elsewhere
219484093|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
219484094|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
219484095|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
219484096|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
218867216|NCT04677127|BEHAVIORAL|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
218867217|NCT05595733|DEVICE|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
218867218|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
218867219|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
218867220|NCT04538313|DRUG|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
218867221|NCT05501795|DEVICE|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
218867222|NCT02297555|DEVICE|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
218867223|NCT05755568|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
218867224|NCT03024190|OTHER|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
218867225|NCT03024190|OTHER|stretching exercise|15- min stretching exercise for upper extremity twice daily
218867226|NCT03024190|OTHER|OT rehabilitation program|regular rehabilitation program for 3 weeks
218867227|NCT04927663|PROCEDURE|Computed Tomography|Undergo CT imaging
218867228|NCT04927663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218867229|NCT04927663|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
218867230|NCT04927663|DRUG|11C-YJH08|Given IV
218867231|NCT04927663|PROCEDURE|Optional Tumor Biopsy|Optional procedure to obtain tumor tissue
218867232|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
218867233|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
218867234|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
218867235|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
218867236|NCT06234215|OTHER|functional task training|functional exercise
218867237|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
218867238|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
218867239|NCT04924153|OTHER|No Intervention|Administered as specified in the treatment arm.
218867240|NCT05605340|BEHAVIORAL|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
218867241|NCT05207046|OTHER|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
218867242|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
218867243|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
218867244|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
218867245|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
218867246|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
218867247|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
218867248|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
218867249|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
218867250|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
218867251|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
218867252|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
218867253|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5\) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
218867254|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
219021225|NCT07205536|DRUG|Oral or short-acting granulocyte-stimulating agents|In the first cycle after enrollment, patients will be followed for changes in neutrophil counts. Should the neutrophil level fall below 1.5 × 10⁹/L, the investigator may, based on clinical judgment, decide whether to intervene with leucogen tablets or other granulocyte-boosting agents. If the count remains below 1.0 × 10⁹/L, short-acting G-CSF may be administered as a rescue therapy.
219484097|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
219598991|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
219598992|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
219598993|NCT04269473|PROCEDURE|Telehealth Gait Retraining|Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.
219598994|NCT04269473|PROCEDURE|Standard Physical Therapy Treatment|Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.
219598995|NCT04269473|PROCEDURE|Return to Running Protocol|The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.
219484098|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
219598996|NCT04269473|PROCEDURE|At Home Exercise Program|The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
219598997|NCT02414776|DRUG|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
218867255|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
218867256|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
219484099|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
219484100|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
219484101|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
219484102|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
219484103|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
219484104|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
219598998|NCT06764225|OTHER|low-sodium substitute salt|This study specifically customized sodium reducing substitute salts with a sodium chloride content not exceeding 62% and without the addition of potassium chloride.
218867257|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
218867258|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
218867259|NCT02060032|DRUG|Placebo local drug delivery|
218867260|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
218867261|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
218867262|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
218867263|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
218867264|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
218867265|NCT01727011|RADIATION|IPAS|
218867266|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
218867267|NCT02504307|DEVICE|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
218867268|NCT02504307|DEVICE|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
219598999|NCT04007991|DRUG|Ecopipam|Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
219599000|NCT04007991|DRUG|Placebo|Matching Placebo
218867269|NCT03418558|DRUG|Trastuzumab emtansine|
218867270|NCT06200883|DRUG|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
219484105|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
219484106|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
219484107|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
219484108|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
219484109|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
219484110|NCT03029559|OTHER|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
219484111|NCT03029559|OTHER|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
219484112|NCT03029559|OTHER|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
219484113|NCT00381134|DRUG|losartan 100 mg orally once daily|
219484114|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
219484115|NCT00381134|DRUG|placebo once orally once daily|
219484116|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
219484117|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
218867271|NCT06200883|DRUG|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
218867272|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
218867273|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
218867274|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
218867275|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
219484118|NCT00232245|DRUG|Fish oil|
219484119|NCT02792088|DRUG|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
219484120|NCT02792088|DRUG|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
219484121|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
219484122|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
219599001|NCT03654599|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
218867276|NCT02764684|DRUG|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
218867277|NCT01075503|PROCEDURE|brachial plexus block|0.5% Ropivacaine 40ml
218867278|NCT05251753|DEVICE|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
218867279|NCT00890682|DRUG|SKY0402|Local infiltration of 8cc SKY0402
219484123|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
219484124|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
219484125|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
219484126|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
219484127|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
219484128|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
218867280|NCT00890682|DRUG|Placebo|Local infiltration of 8cc Placebo
218867281|NCT01761695|OTHER|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
219484129|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
219484130|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
219484131|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
219599002|NCT03654599|BEHAVIORAL|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
218867282|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
218867283|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
218867284|NCT05588245|BEHAVIORAL|Standard of Care|Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
218867285|NCT05588245|BEHAVIORAL|Community-based prenatal/perinatal/postpartum patient navigator|Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
218867286|NCT05730348|BEHAVIORAL|Post mealtime activity|Therapist lead movement post meals
218867287|NCT05727722|BIOLOGICAL|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
218867288|NCT06012110|DEVICE|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
218867289|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
218867290|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
218867291|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
218867292|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
218867293|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
218867294|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
218867295|NCT02593656|BEHAVIORAL|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
218867296|NCT02593656|BEHAVIORAL|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
218867297|NCT06256926|DRUG|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
218867298|NCT06256926|DRUG|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
218867299|NCT04213378|DEVICE|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
218867300|NCT04213378|DEVICE|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
218867301|NCT06667713|BEHAVIORAL|ENTRUST - substance use and HIV counseling and goal setting with economic empowerment and photovoice training|The ENTRUST intervention consists of an adapted counseling intervention based on motivational interviewing techniques and goal setting (SBIRT-T); Economic skill building using a tailored app (WorthIt for ENTRUST); and, Photovoice Activities with an optional photo exhibit
219599003|NCT03654599|BEHAVIORAL|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
218867302|NCT06667713|BEHAVIORAL|SBIRT-T only|An adapted screening brief intervention and referral to treatment intervention to link transgender women to substance use and HIV services
218867303|NCT04436068|DEVICE|Hyperfine MRI scan|Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
218867304|NCT05100836|DEVICE|Impella 5.5|Impella 5.5 mechanical circulatory support
218867305|NCT04619004|DRUG|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
218867306|NCT04619004|DRUG|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
218867307|NCT05803252|BEHAVIORAL|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~1. Awareness: Able to experience the present moment, able to take perspective on self~2. Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~3. Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
218867308|NCT05803252|OTHER|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
219484132|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
219484133|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
219484134|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
219484135|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
219484136|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
219484137|NCT00763126|BEHAVIORAL|stress level|Stress levels
219484138|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
219484139|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
219484140|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
219484141|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
219484142|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
219484143|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
219484144|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
219484145|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
219484146|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
219484147|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
219484148|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
219484149|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
219484150|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
219484151|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
219484152|NCT02949219|OTHER|Laboratory Biomarker Analysis|Correlative studies
219484153|NCT02949219|BIOLOGICAL|Pembrolizumab|Given IV
219484154|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
219484155|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
219484156|NCT01379365|DEVICE|Cryo-Touch III|Percutaneous treatment with the device
219484157|NCT01679418|DEVICE|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
219484158|NCT01679418|OTHER|No-drain after surgery|After surgery, no drain was put
219484159|NCT03932474|COMBINATION_PRODUCT|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
219484160|NCT03932474|OTHER|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
219484161|NCT04819282|DIAGNOSTIC_TEST|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
219040115|NCT05243095|OTHER|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
219040116|NCT00112242|BIOLOGICAL|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
219040117|NCT00112242|BIOLOGICAL|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
219040118|NCT00112242|BIOLOGICAL|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
219040119|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
219040120|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
219040121|NCT04213456|DIETARY_SUPPLEMENT|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
219040122|NCT04213456|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
219040123|NCT01358227|DRUG|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
219040124|NCT06470659|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW
219040125|NCT02381912|OTHER|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
219040126|NCT05008991|DEVICE|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
219040127|NCT00606892|DRUG|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
219040128|NCT00606892|DRUG|Placebo|Sugar Pill
219484162|NCT02316743|DRUG|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
219484163|NCT02606864|DRUG|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
219484164|NCT04037683|DRUG|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
219484165|NCT04037683|DRUG|Oxytocin|Oxytocin infusion
219484166|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
219484167|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
219484168|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
219484169|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
219484170|NCT06652594|BEHAVIORAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to theirchild's myopia progression at baseline, 1 month, 3 months, 6 months.
219484171|NCT06652594|BEHAVIORAL|Control|Parents in the control group will not receive eye health education informationfrom doctors and nurses.
219484172|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
219484173|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
219484174|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
219484175|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
219484176|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
219484177|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
219484178|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
219040129|NCT00606892|DRUG|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
219040130|NCT06456281|DIAGNOSTIC_TEST|A noninvasive cfDNA multi-omics assay|Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).
218867309|NCT05332275|BEHAVIORAL|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
219484179|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
219484180|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
219484181|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
219040131|NCT02144740|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
219040132|NCT02144740|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
219484182|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
219484183|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
219484184|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
218867310|NCT05332275|BEHAVIORAL|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
218867311|NCT06108830|DRUG|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
218867312|NCT06108830|DRUG|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
218867313|NCT06108830|DRUG|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
218867314|NCT06108830|DRUG|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
218867315|NCT06026163|DRUG|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
218867316|NCT06026163|OTHER|Placebo|Equivalent volume of saline
218867317|NCT05644041|DRUG|gemcitabine + docetaxel|The study drugs, Gemcitabine and Docetaxel, will be administered intravesically at 1000 mg and 40 mg, respectively.
218867318|NCT04030962|DRUG|AGN-242428|Ophthalmic solution administered as a topical eye drop
218867319|NCT04030962|DRUG|AGN-231868|Ophthalmic solution administered as a topical eye drop
218867320|NCT04030962|OTHER|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
218867321|NCT04030962|OTHER|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
219484185|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
219484186|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
219484187|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
219599004|NCT06840314|DEVICE|Pelvic floor therapy|Once randomized to either the vibrating pelvic floor massage arm or the traditional vaginal dilator arm, they will receive instructions on frequency of device use and will use manufacturer's instructions for specifics of device use. We will not dictate more specific instructions on use, nor is this standard of care, as every patient is unique and will need to retain autonomy in terms of how quickly they progress in the use of the product. They will then complete a survey at 4 weeks which includes measures of sexual function and pelvic pain, as well of global impressions of improvement in their symptoms.
219599005|NCT07135011|DEVICE|Primary gluteal enhancement|120 participants will undergo primary buttock enhancement procedures utilizing the Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, Motiva® Reusable Channel Dissector, and Motiva® GEM Channel Separator devices.
219599006|NCT07135141|DRUG|Sleeve gastrectomy plus early mazdutide initiation|After sleeve gastrectomy is preformed, mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg (4.0 mg → 6.0 mg)weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
218867322|NCT04030962|DRUG|Lifitegrast 5% Ophthalmic Solution|Ophthalmic solution administered as a topical eye drop
218867323|NCT06976255|BEHAVIORAL|Cinnamon sugar|In the 2nd and 3rd month of the study, the participants were asked to eat 1 g of cinnamon candies 3 times a day for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
218867324|NCT06976255|BEHAVIORAL|Dark chocolate|In the 2nd and 3rd month of the study, they were asked to eat 40 mg of 60% cocoa dark chocolate daily for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
219484188|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
219484189|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
218867325|NCT05235061|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.
218867326|NCT05235061|BEHAVIORAL|HOBSCOTCH-PTE for Caregivers|Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
218867327|NCT06574139|BEHAVIORAL|Unstained|Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
218867328|NCT06574139|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
218867329|NCT00306475|DRUG|Divalproex Sodium Extended-Release Tablets|divalproex sodium extended-release (ER) 1000 mg
218867330|NCT00306475|DRUG|placebo|placebo identical in appearance to active comparator
218867331|NCT06638710|DRUG|oral administration of midazolam or placebo|If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
218867332|NCT02159755|DRUG|Ibrutinib|Given PO
218867333|NCT02159755|OTHER|Laboratory Biomarker Analysis|Correlative studies
218867334|NCT02159755|DRUG|Palbociclib|Given PO
218867335|NCT02159755|OTHER|Pharmacological Study|Correlative studies
218867336|NCT05879276|DRUG|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
218867337|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
219040133|NCT01632202|DEVICE|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
219484190|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
219484191|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
219484192|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
219484193|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
219484194|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
219484195|NCT02042573|DEVICE|rTMS|
218867338|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
218867339|NCT06433180|DRUG|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
219040134|NCT01632202|DEVICE|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
219040135|NCT03522766|OTHER|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
219484196|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
219484197|NCT02042573|OTHER|Genetic samples|
219040136|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
219040137|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
218867340|NCT06433180|DRUG|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
219484198|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
219484199|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
219484200|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
219484201|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
219484202|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
219484203|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
219484204|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
219484205|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
219599007|NCT07135141|DRUG|Sleeve gastrectomy followed with early mazdutide placebo initation|After sleeve gastrectomy is preformed, mazdutide placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg placebo, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg placebo(4.0 mg → 6.0 mg) weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
218867341|NCT05601102|BEHAVIORAL|danceSing Care|\- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
218867342|NCT04648202|DRUG|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
218867343|NCT05765175|DEVICE|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
218867344|NCT05765175|PROCEDURE|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
219040138|NCT00633191|DRUG|Anti-pseudomonas IgY gargle|Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
219484206|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
219484207|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
219484208|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
219484209|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
219484210|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
219484211|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
219484212|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
219484213|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
219484214|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
219484215|NCT06127862|OTHER|No training was given|No training was given
219484216|NCT00000856|DRUG|Foscarnet sodium|
219484217|NCT00000856|DRUG|Ganciclovir|
219484218|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
219484219|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
219484220|NCT01704482|DRUG|placebo|
219484221|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
219484222|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
219484223|NCT00083226|DRUG|doxorubicin|Given IV
219484224|NCT00083226|DRUG|bortezomib|Given IV
219484225|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
218867345|NCT05759793|DRUG|CAR-GPRC5D|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
218867346|NCT06321055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Retrospective analysis.
218867347|NCT03460210|DRUG|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
219484226|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
219484227|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
218867348|NCT06653010|BIOLOGICAL|Universal CAR-T cells injection for treating mCRC|A novel universal CAR-T platform to treat cancer patients
218867349|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
218867350|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
218867351|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
219484228|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
219484229|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
219484230|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
219484231|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
218867352|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
218867353|NCT02106611|OTHER|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
218867354|NCT02106611|PROCEDURE|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
219599008|NCT07134517|OTHER|Pilates exercise|The principles of centering, concentration, breathing, control, flow, and precision in the Pilates method will be explained to participants. Pelvic floor activity and lateral breathing will be taught and practiced, along with neutral spine alignment. The first and last 5 minutes of each session will consist of stretching exercises. Stretching exercises will begin with 3-5 repetitions, while strengthening and stabilization exercises will start with 6-8 repetitions, with the number of repetitions increasing each week based on participants' tolerance. Springs are attached according to the purpose and difficulty level of the exercises. Stretching exercises are performed with lighter resistance springs, while strengthening and stabilization exercises are performed with higher resistance springs. All movements will be demonstrated and explained to ensure the exercises are performed correctly. Verbal cues will be given for breath control and centering.
218867355|NCT02106611|PROCEDURE|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
218867356|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 80 mg|1 tablet per day
218867357|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 160 mg|2 tablets per day
218867358|NCT05288166|DRUG|Abemaciclib|Administered orally.
218867359|NCT05288166|DRUG|Abiraterone|Administered orally.
218867360|NCT05288166|DRUG|Prednisone or Prednisolone|Administered orally.
218867361|NCT05288166|DRUG|Placebo for Abemaciclib|Administered orally.
219484232|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
219484233|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219599009|NCT07133841|DIAGNOSTIC_TEST|Pre-Season Assessments|Pre-Season Assessments including performance based tests and thermal imaging.
218867362|NCT06980974|BEHAVIORAL|ACT-for-chemsex|16 weeks of acceptance and commitment therapy, delivered online weekly, 45-55 minute sessions
218867363|NCT06980974|OTHER|Treatment as Usual (TAU)|Participants in TAU will receive health/mental health interventions as needed
219484234|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
219484235|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
218867364|NCT06979765|BIOLOGICAL|blood sampling|3 blood tubes will be taken during a standard check-up
218867365|NCT06979765|OTHER|self-administrated questionaires|4 self administrated questionaires and scales at the inclusion
218867366|NCT06980831|PROCEDURE|ECT group|VR-ECT group, nursing students will practice via virtual reality for taking care of patients with ECT.
218867367|NCT06981039|DEVICE|Patella Anatomical Locking Plate|Patients in the patella anatomical locking plate group will undergo internal fixation with an anterior locking plate and screw construct using the 2.7mm variable angle (VA) locking patella plating system (DePuy Synthes, Zuchwil, Switzerland)
218867368|NCT06981039|DEVICE|Tension Band Wiring|Patients in the tension band wiring group will undergo open anatomical reduction and internal fixation with a tension band wire construct.
219484236|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
219484237|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
218867369|NCT06979830|BEHAVIORAL|yoga exercises|"The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4).~Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught.~Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study.~Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was"
218867370|NCT06980779|OTHER|ultrasonographic examination|ultrasonographic examination
218867371|NCT06980155|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
218867372|NCT06980155|BIOLOGICAL|PD-1 inhibitor|Toripalimab
219204451|NCT06882109|OTHER|Five-in-two ankle block|"The FIT block is a new approach for regional anesthetic block of the ankle. We use an optimized ultrasound guided approach for the FIT Block, based on optimal nerve anatomical locations. A one puncture proximal approach for the fibular nerves is used, while maintaining the benefit of preserved extrinsic motricity. Another one puncture approaches the sural nerve laterally, after the block of the tibial nerve during the same puncture and then the subcutaneous infiltration of the saphenous nerve. An anatomical proof of concept study has been done before the exploratory clinical study.~These approaches permit a surgical anesthetic block for foot surgery using 2 punctures (instead of 5) with a single patient's body position, compatible with sedation."
218867373|NCT06980558|OTHER|Progressive relaxation exercises|"Sit or lie down comfortably and close your eyes.~* Feel the rhythm of your breathing.~* Breathe in through your nose and out through your mouth throughout the process.~* Relax as much as you can.~* Get rid of negative thoughts in your mind.~* Stretch your hands by hanging your arms down to your sides, tighten your fists as much as you can and then open them and let them relax."
218867374|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.4 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.4 mg/kg, administered 30 minutes before the induction of general anesthesia.
219484238|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
219599011|NCT06934564|BEHAVIORAL|Active de-Implementation|During active de-implementation (3 months), the local team will distribute the strategy components (i.e., clinician education, decision support, evaluation, consensus building around perioperative testing pathways, facility-specific feedback, and a pay-for-performance incentive) at the local site.
218867375|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.2 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.2 mg/kg, administered 30 minutes before the induction of general anesthesia.
218867376|NCT06981260|PROCEDURE|Group A Deactivated TENS with beeping sound (15-second interval)|Deactivated TENS with beeping sound (15-second interval)
218867377|NCT06981260|PROCEDURE|Group B|Deactivated TENS without sound
218867378|NCT06981091|OTHER|XH-S004 20 mg|Administered once per day for 24 weeks.
218867379|NCT06981091|OTHER|XH-S004 40 mg|Administered once per day for 24 weeks.
218867380|NCT06981091|OTHER|Placebo|Administered once per day for 24 weeks.
218867381|NCT06981494|DRUG|Dexmedetomidine|"Loading Dose:~Dexmedetomidine is usually administered as a loading dose of 0.25 mcg/kg slowly.~Maintenance Dose:~After the loading dose, the maintenance infusion rate is typically 0.2 to 0.7 mcg/kg/hour in syringe pump . The exact rate can be adjusted based on the hemodynamics of the patient (blood pressure and heart rate) and the patient's response."
218867382|NCT06981494|DRUG|Dexmedetomidine and ketamine ( Ketodex )|"Ketodex Group (Combination of Ketamine and Dexmedetomidine) (K):~Ketamine Component:~Loading Dose:~Ketamine is typically given at a dose of 0.5 mg/kg as a bolus injection.~Maintenance Dose:~A maintenance infusion of 0.2 to 0.5 mg/kg/hour is common to maintain anesthesia in syringe pump.~Dexmedetomidine Component:~Loading Dose:~As with the dexmedetomidine group, a loading dose of 0.25 mcg/kg slowly is administered.~Maintenance Dose:~The maintenance infusion rate for dexmedetomidine remains 0.2 to 0.7 µg/kg/hour in syringe pump."
218867383|NCT06979960|BEHAVIORAL|cancer screening education|It will be carried out to examine the effect of the educational intervention given using the cancer screening training booklet on women's knowledge, attitude and shyness levels.
218867384|NCT06979648|DIETARY_SUPPLEMENT|Qualia Magnesium+®|Qualia Magnesium+® manufactured by Qualia Life Sciences
218867385|NCT06979648|DIETARY_SUPPLEMENT|Placebo|Rice Flour
219484239|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
219484240|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
219484241|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
219599012|NCT04399044|PROCEDURE|Prophylactic muscle flap|"A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection."
218867386|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 1|The first interventional product for this study is a low-sodium beverage containing Dose 1 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
218867387|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 2|The second interventional product for this study is a low-sodium beverage containing dose 2 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
218867388|NCT06981468|OTHER|Control (placebo) group|Water
218867389|NCT06187987|DEVICE|Mechanical thrombectomy|Aspirational mechanical thrombectomy
218867390|NCT06187987|DRUG|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
218867391|NCT06980753|DEVICE|Participants will use the biossensor for 48 h|Participants will use the biossensor for 48 h
218867392|NCT04908280|DRUG|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
218867393|NCT06980532|DRUG|Glumetinib Combined with Fruquintinib|"Fruquintinib: 3mg, po.qd, d1-14，q3w;~Guemitinib:~Grade 1:200mg, po, qd, q3w; Grade 2:250mg, po, qd, q3w; Phase I: The dose of Glumetinib (200 mg → 250 mg) is dynamically adjusted using the 3+3 dose-escalation rule to determine the optimal dose of Fruquintinib.~Phase II: The RP2D (Recommended Phase II Dose) of Glumetinib identified in Phase I is continued in combination with Fruquintinib."
219599013|NCT01288144|OTHER|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
218867394|NCT06675630|BEHAVIORAL|Education|Consumers will receive monthly targeted educational materials on fibre
218867395|NCT06675630|BEHAVIORAL|Control|Consumers will receive educational materials on healthy eating at two timepoints
218867396|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
218867397|NCT06675513|BIOLOGICAL|An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:|"Autologous WD-01 CAR-T therapy with Wondercel's Warrior armor strategy will be explored for its advantage over other armor platforms."
218867398|NCT06621407|PROCEDURE|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
219484242|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
219484243|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
219484244|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
219484245|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
219484246|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
219484247|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
219484248|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
219484249|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
219484250|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
219484251|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
219484252|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
219484253|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
219484254|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
219484255|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
219484256|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
219484257|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
219484258|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
219484259|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
219599014|NCT06937593|DRUG|VIS954|A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
219599015|NCT06937593|DRUG|Placebo|VIS954 Placebo
219599016|NCT05529667|DRUG|INCB054828, Paclitaxel|"phase 1\>~\- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
219599017|NCT06953154|DIAGNOSTIC_TEST|monocyte distribution width|We compare the measured value with the MDW threshold value already established in the literature and its correlation with the SOFA score, qSOFA, lactate, and PVI in terms of sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV).
219599018|NCT06514742|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
219599019|NCT06514742|OTHER|Placebo|Placebo tablet will be administered orally.
219484260|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
218867399|NCT06621407|PROCEDURE|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
219484261|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
219484262|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
219484263|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
219484264|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
219599020|NCT03424122|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
219599021|NCT03424122|DRUG|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
219599022|NCT03424122|DRUG|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
218867400|NCT06600867|DIAGNOSTIC_TEST|Tooth mobility assessment|The examiner, holding the instruments (two clinical mirror handles), will apply labial/lingual or labial/palatal displacement movements using the subjective technique, just as routinely done. Using the endodontic spacer and the stop, the deflection will be measured in millimeters. Subsequently, the examiner, with the instruments in hand (tensiometer and dynamometer), will apply labial/lingual and labial/palatal displacement movements, determining the force required to achieve the same displacement previously established by the subjective method (reference/limit of displacement).
218867401|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
219484265|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
219484266|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
219484267|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
218867402|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
218867403|NCT07033247|DEVICE|EDDY Sonic Activation System|EDDY is a sonic irrigation activation system operating at 6,000 Hz frequency with a flexible polyamide tip (25/04). In endodontic procedures, the EDDY tip is inserted 2 mm short of the working length into the root canal and activated for 20 seconds in three consecutive cycles. The sonic activation enhances irrigant agitation through cavitation and acoustic streaming, improving cleaning efficacy within the root canal system, especially in curved canals. The device does not contact dentin walls, reducing the risk of iatrogenic damage. In this study, EDDY was used to activate sodium hypochlorite solutions of either 2.5% or 5.25% concentration depending on the assigned group.
218867404|NCT07033247|DEVICE|Passive Ultrasonic Irrigation (PUI)|Passive Ultrasonic Irrigation (PUI) involves the use of an ultrasonically activated file or tip inserted into the root canal 2 mm short of the working length, without contacting the dentinal walls. The ultrasonic tip is operated in a non-cutting, passive manner to generate acoustic streaming and cavitation within the irrigant. In this study, after initial irrigation with 2 mL of sodium hypochlorite (either 2.5% or 5.25%, depending on the group), ultrasonic activation was performed for 20 seconds in three consecutive cycles. Each activation was followed by 1 mL NaOCl irrigation. This method is designed to enhance the penetration and effectiveness of irrigants, especially in anatomically complex areas of the root canal system.
218867405|NCT07036822|DEVICE|Skeletal Anchored Maxillary Expander (MARPE)|Mini implant assisted rapid maxillary expander (MARPE) used for skeletal maxillary expansion in adolescent and adult patients
218867406|NCT06847867|DRUG|Momelotinib|Momelotinib will be administered.
218867407|NCT06545656|DRUG|Doxycycline|Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.
218867408|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
218867409|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
218867410|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
219484268|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
219484269|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
219484270|NCT00034593|DRUG|ALIMTA|
219484271|NCT00034593|DRUG|gemcitabine|
219484272|NCT04607265|DIAGNOSTIC_TEST|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
219484273|NCT02048059|DRUG|ANG1005|
219484274|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
219484275|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
219484276|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
218867411|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
219484277|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
218867412|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
218867413|NCT00612859|DRUG|levetiracetam|
219484278|NCT02831686|DRUG|Selinexor|
218867414|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
218867415|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
218867416|NCT00247442|BEHAVIORAL|Decision aid|
219484279|NCT02831686|DRUG|Ixazomib|
219599023|NCT03424122|DRUG|Ibrutinib|Ibrutinib administered orally once daily.
218867417|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
218867418|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
218867419|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
219204452|NCT06747325|DRUG|Fei Re Qing Granules|Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.)
219204453|NCT06747325|OTHER|Routine standard treatments|Routine standard treatments
219484280|NCT02831686|DRUG|Dexamethasone|
219484281|NCT06943690|PROCEDURE|Single-port robotic surgery|In this group, patients will be operated using a single-port surgical robot system. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen. The surgical procedure followed the principle of total mesorectal excision.
219484282|NCT06943690|PROCEDURE|Multi-port robotic surgery|In this group, patients will be operated using a multi-port surgical robot system. Surgical instruments enter the abdominal cavity through 4 separate trocars. The surgical procedure followed the principle of total mesorectal excision.
219484283|NCT06942312|DIAGNOSTIC_TEST|Ketoisocaproic acid breath test|13C-alpha-ketoisocaproic acid breath test to estimate hepatic mitochondrial reductive stress (1 mg/kg body weight; oral dose; study duration 390 min)
219484284|NCT06942312|DIAGNOSTIC_TEST|Ammonium Chloride|15N-ammonium chloride stable isotope test to estimate ureagenesis (20 mg/kg body weight; oral dose; study duration 390 min)
219484285|NCT06942312|DIAGNOSTIC_TEST|Bicarbonate de sodium|13C-bicarbonate breath test to estimate body bicarbonate pool size and gastric emptying (0.5 mg/kg body weight; oral dose; study duration 390 min)
219484286|NCT06942312|DIAGNOSTIC_TEST|Deuterated Water|Deuterated water stable isotope test to estimate hepatic de novo lipogenesis and gluconeogenesis (3 g/kg body water; oral dose; duration: overnight)
219484287|NCT06942312|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|A standard 2-hour 75-gram oral glucose tolerance test to assess glucose tolerance and whole body metabolism
219484288|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
219599024|NCT04951700|OTHER|Other|This is not an intervention study
219599025|NCT01876225|BEHAVIORAL|Forced coughing during cervical punch biopsy|
219599026|NCT01659125|BEHAVIORAL|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
219599027|NCT01913886|PROCEDURE|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
219599028|NCT04392895|PROCEDURE|Para Aortic Lymphadenectomy (PAL) by laparoscopy|Para Aortic Lymphadenectomy (PAL) by laparoscopy
219599029|NCT02972190|PROCEDURE|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
219599030|NCT02972190|PROCEDURE|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
219599031|NCT02972190|DEVICE|Pedicle screw and interbody cage|Pedicle screw and interbody cage
218867420|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
218867421|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
218867422|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
219484289|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
218867423|NCT00003842|DRUG|isolated perfusion|
218867424|NCT00003842|PROCEDURE|surgical procedure|
218867425|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
218867426|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
218867427|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
218867428|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
218867429|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
218867430|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
218867431|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
218867432|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
218867433|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
218867434|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
218867435|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
218867436|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
218867437|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
219484290|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
219484291|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
218867438|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
218867439|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
218867440|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
218867441|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
218867442|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
218867443|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
218867444|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
218867445|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
218867446|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
218867447|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
219484292|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
219599032|NCT04211116|DEVICE|Central venous line insertion|Pediatric patients indicated to central venous line insertion
219599033|NCT01860235|DRUG|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
219599034|NCT01860235|DRUG|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
219599035|NCT01860235|DRUG|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
219599036|NCT01860235|DRUG|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
219599037|NCT02712723|DRUG|Letrozole|Nonsteroidal aromatase inhibitor
219599038|NCT02712723|DRUG|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
218867448|NCT05413122|DRUG|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
218867449|NCT05413122|DRUG|Nicotine patch|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
218867450|NCT05413122|DRUG|Nicotine gum|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
218867451|NCT05413122|BEHAVIORAL|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
219484293|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
219484294|NCT03300804|DRUG|Placebo|Placebo herb formulation
219484295|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
219484296|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
219484297|NCT05378269|OTHER|Placebo|Placebo vaginal insert
219484298|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
219484299|NCT04285736|DRUG|Conventional Treatment|
219484300|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
219484301|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
219484302|NCT01495104|DRUG|RO4917838|Multiple doses
219484303|NCT01495104|DRUG|valproate|Multiple doses
219599039|NCT02712723|DRUG|Placebo|Placebo for ribociclib
219599040|NCT04965805|DEVICE|cold plasmaJet kINPen Med|experimental, non-inferiority
219599041|NCT04965805|DEVICE|Best practice wound dressings|comparative,
218867452|NCT05413122|BEHAVIORAL|Peer Counselling|Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
218867453|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
218867454|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
218867455|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
219484304|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
219484305|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
219484306|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
219484307|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
219484308|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
219484309|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
219484310|NCT00182273|PROCEDURE|Canalith repositioning maneuver (CRM)|
219484311|NCT06557473|DRUG|Lidocaine IV|1.5mg/kg IV for induction of GA
219484312|NCT06557473|DRUG|Fentanyl|Fentanyl IV 2 µg/kg for GA induction
219484313|NCT01721200|OTHER|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
219599042|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
219599043|NCT01762800|DRUG|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
219599044|NCT01762800|DRUG|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
219599045|NCT01762800|DRUG|tiotropium bromide placebo|Placebo, Once daily(morning)
219599046|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
218867456|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
218867457|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
218867458|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
218867459|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
218867460|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
218867461|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
218867462|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
219040139|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
219204454|NCT06747325|DRUG|Placebo granules|The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules
219484314|NCT01721200|OTHER|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
219484315|NCT05500456|DEVICE|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
219484316|NCT05500456|DEVICE|Fixed appliances|Conventional wires and brackets will be used.
219484317|NCT03926728|BIOLOGICAL|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
219484318|NCT03926728|BIOLOGICAL|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
219484319|NCT03926728|BIOLOGICAL|CTH522 ID|24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
218867463|NCT01123473|DRUG|capecitabine|
218867464|NCT01123473|DRUG|cisplatin|
218867465|NCT01123473|DRUG|epirubicin hydrochloride|
218867466|NCT01123473|DRUG|fluorouracil|
218867467|NCT01123473|DRUG|lapatinib ditosylate|
218867468|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
218867469|NCT02334488|DRUG|Everolimus|Active Comparator
218867470|NCT02334488|DRUG|Tacrolimus|Active Comparator
218867471|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
218867472|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
218867473|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
218867474|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
218867475|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
219484320|NCT03926728|BIOLOGICAL|CTH522 TO|24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
219484321|NCT03926728|BIOLOGICAL|Placebo (Saline)|Placebo only given as IM, ID and TO.
219484322|NCT01900353|OTHER|brushing methods|
219484323|NCT02791581|DIAGNOSTIC_TEST|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
219484324|NCT04313686|BEHAVIORAL|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
219484325|NCT04313686|BEHAVIORAL|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
219484326|NCT00118196|DRUG|arsenic trioxide|
219484327|NCT00118196|DRUG|azacitidine|
219484328|NCT00739687|DRUG|ALT-711|200 mg tablet BID for 9 months.
219484329|NCT00739687|DRUG|Placebo|200 mg tablet BID for 9 months.
219484330|NCT05635773|DEVICE|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
219484331|NCT05385276|PROCEDURE|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
219484332|NCT05385276|PROCEDURE|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
218867476|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
218867477|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
218867478|NCT00120055|DRUG|Atorvastatin (Lipitor)|
218867479|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
218867480|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
219484333|NCT03647280|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
219484334|NCT03647280|DRUG|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
219484335|NCT02629380|BIOLOGICAL|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
219484336|NCT02629380|PROCEDURE|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
219484337|NCT05486663|OTHER|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
219484338|NCT04832984|BEHAVIORAL|Mobile health|Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
219484339|NCT04832984|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
218867481|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
218867482|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
218867483|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
218867484|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
219484340|NCT00534521|DEVICE|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
218867485|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
219484341|NCT00534521|DEVICE|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
219484342|NCT02267759|DEVICE|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
219484343|NCT02267759|DEVICE|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
219484344|NCT06539780|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
219484345|NCT05526924|RADIATION|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
219484346|NCT05526924|DRUG|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
219484347|NCT05526924|DRUG|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
219484348|NCT05526924|DRUG|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
219484349|NCT05526924|DRUG|Tislelizumab|An anti-cancer drug.
219484350|NCT01956123|DRUG|Follitropin Delta (FE 999049)|
218867486|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
219484351|NCT01956123|DRUG|Follitropin Alfa (GONAL-F)|
219484352|NCT03582059|PROCEDURE|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
219484353|NCT03582059|PROCEDURE|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
219484354|NCT00398632|DRUG|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
218867487|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
218867488|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
219484355|NCT04449640|PROCEDURE|Hysteroscopic septum resection.|Resection of a uterine septum by hysteroscopic surgery.
219484356|NCT02816554|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
219484357|NCT02816554|BIOLOGICAL|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
218867489|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
218867490|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
218867491|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
218867492|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
218867493|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
219484358|NCT02816554|BIOLOGICAL|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
219484359|NCT02816554|BIOLOGICAL|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
219484360|NCT06204536|OTHER|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
219484361|NCT03596086|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
218867494|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
218867495|NCT02784600|DEVICE|Bioinductive implant|
218867496|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
218867497|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
219484362|NCT02397174|OTHER|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
219040140|NCT02101502|OTHER|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
219484363|NCT02397174|OTHER|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
219484364|NCT04794582|DEVICE|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
219484365|NCT03574194|DIETARY_SUPPLEMENT|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
219484366|NCT01467401|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
219484367|NCT01467401|DRUG|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
219484368|NCT04242368|DRUG|Isotonic saline|Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
218867498|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
219484369|NCT04242368|DRUG|Hypertonic Nasal Wash|Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
218867499|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
218867500|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
218867501|NCT02942654|DRUG|Insulin Lispro|Administered SC
218867502|NCT01557959|DRUG|cisplatin|Given IV
218867503|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
218867504|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
218867505|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
218867506|NCT01557959|GENETIC|polymorphism analysis|Correlative study
218867507|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
219484370|NCT04242368|DRUG|Fluticasone Propionate|Fluticasone nasal spray administered two sprays to each nare twice a day
219484371|NCT00736060|OTHER|Observational|Summary of clinical and laboratory data
219484372|NCT06459076|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)|Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1.
219484373|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 14 days|
219484374|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 28 days|
219484375|NCT02102529|PROCEDURE|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
219484376|NCT04443673|DIETARY_SUPPLEMENT|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
219484377|NCT00154830|BEHAVIORAL|cerebral palsy|
219484378|NCT00154830|BEHAVIORAL|crouch gait|
219484379|NCT01926301|PROCEDURE|continuous veno-venous hemodialysis|
219484380|NCT03795064|PROCEDURE|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
219484381|NCT03795064|PROCEDURE|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
218867508|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
218867509|NCT01557959|DRUG|docetaxel|Given IV
218867510|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
218867511|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
218867512|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
218867513|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
218867514|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
218867515|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
218867516|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
218867517|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
218867518|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
218867519|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
218867520|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
218867521|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
218867522|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
218867523|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
219484382|NCT03649607|OTHER|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
218867524|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
218867525|NCT01360177|DRUG|Na134I|25 to 150 mCi
219484383|NCT04442178|DRUG|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
218867526|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
219484384|NCT04442178|DRUG|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
219484385|NCT05515627|DRUG|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
219484386|NCT01909817|PROCEDURE|Routine coronary angiogram|
218867527|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
218867528|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
218867529|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
218867530|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
218867531|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
218867532|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
218867533|NCT01496105|DRUG|Lidocaine|
218867534|NCT01496105|DRUG|saline|
218867535|NCT05432167|DRUG|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
218867536|NCT05432167|DRUG|Placebo|Patients will take placebo tablets by mouth once daily.
218867537|NCT04476875|OTHER|Open Outpatient Clinic Programme|
218867538|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
218867539|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
218867540|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
219204455|NCT06741774|DEVICE|Trabecular Meshwork Microstent Drainage System|The device is implanted on the functional trabecular meshwork with head in schlemm canal and tail in anterior chamber. There is a hollow tube connecting schlemm canal and anterior chamber. The device can promote external drainage of aqueous humor to reduce intraocular pressure.
218867541|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
218867542|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
219204456|NCT06741774|PROCEDURE|phacoemulsification|Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
219484387|NCT04691739|OTHER|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
219484388|NCT04740801|DEVICE|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
219484389|NCT01325701|DRUG|ibrutinib|ibrutinib is an inhibitor of BTK
219484390|NCT00997672|DRUG|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
219484391|NCT00997672|DRUG|Placebo|
219484392|NCT02812368|DRUG|Clonidine|
219484393|NCT02812368|DRUG|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
219484394|NCT04924946|OTHER|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"* Time to monitor blood pressure values in target targets~* Need for administration of another antihypertensive drug~* Disappearance of organ failure attributable to hypertension~* Weaning from an extra-renal purification~* Weaning from mechanical ventilation~* Improved kidney function~* Iatrogenic hypotension~* Need for suspension of treatment~* Other side effect"
219484395|NCT04650516|DEVICE|Virtual reality|20 minutes treatment in virtual reality
219484396|NCT04650516|DEVICE|Digital control|20 minutes digital control movie on tablet without virtual reality
219484397|NCT06515717|DIETARY_SUPPLEMENT|ketone ester|oral supplement
219484398|NCT06515717|DIETARY_SUPPLEMENT|dextrose (placebo)|oral supplement calorie and taste matched to ketone supplement
218867543|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
218867544|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
218867545|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
218867546|NCT04750980|OTHER|food allergy|food allergy
218867547|NCT04750980|OTHER|respiratory allergy|respiratory allergy
218867548|NCT04750980|OTHER|healthy controls|healthy controls
218867549|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
218867550|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
219484399|NCT01898858|DEVICE|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
219484400|NCT01898858|DEVICE|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
219484401|NCT01898858|DEVICE|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
219484402|NCT06349434|DEVICE|MyoMo|To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).
219484403|NCT06349434|OTHER|conventional therapy|To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
219484404|NCT06217835|OTHER|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
219484405|NCT06217835|OTHER|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
219484406|NCT02255734|DRUG|Acyclovir|
219484407|NCT04616079|DRUG|REGN6490|Single dose of REGN6490
219484408|NCT04616079|DRUG|Placebo|Placebo matching single dose of REGN6490
219484409|NCT04511884|DIAGNOSTIC_TEST|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
219484410|NCT04918810|DRUG|Docetaxel intermittent|After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
219484411|NCT01483612|BEHAVIORAL|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
219484412|NCT04957914|DRUG|Insulin Glargine|Administered SC
219484413|NCT04957914|DRUG|LY3209590|Administered SC
218867551|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
219484414|NCT00500695|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
219484415|NCT00500695|BEHAVIORAL|Psychoeducation|Psychoeducation
219484416|NCT05124990|DIAGNOSTIC_TEST|thermal imaging|no risk infrared thermal image would be used to capture pictures of the patients joints that are reported to be painful during a rheumatoid arthritis flare along iwth labs such as esr and crp. these will then be fed to a machine learning algorithm that will learn to predict the DAS 28 score for the RA patient and their flare.
219484417|NCT06023303|DEVICE|Potenza|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
219484418|NCT06023303|DEVICE|Morpheus|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
219484419|NCT00864409|DRUG|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
219484420|NCT00864409|DRUG|saline.9%|Wound infiltration with 170 mL sterile saline
218867552|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
218867553|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
219484421|NCT03540407|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
219484422|NCT03540407|DIETARY_SUPPLEMENT|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
219484423|NCT00561093|DRUG|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
219484424|NCT00561093|DIETARY_SUPPLEMENT|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
219484425|NCT00561093|DIETARY_SUPPLEMENT|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
218867554|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
218867555|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
219484426|NCT00561093|DRUG|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
219484427|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
219484428|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
219484429|NCT02470078|DEVICE|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
219484430|NCT02470078|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
218867556|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
218867557|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
218867558|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
218867559|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
218867560|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
218867561|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
219484431|NCT06513988|DEVICE|MI-BCI combined with tDCS treatment|The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
219484432|NCT01053078|DRUG|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
219484433|NCT01053078|OTHER|Placebo|1 month treatment; placebo tablet once daily for 28 days
218867562|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
218867563|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
218867564|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
218867565|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
218867566|NCT00261508|DRUG|risperidone|
218867567|NCT02451891|BIOLOGICAL|MVA-EBO Z|
218867568|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
218867569|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
219484434|NCT01642693|RADIATION|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
219484435|NCT01642693|OTHER|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
219484436|NCT06540183|PROCEDURE|Percutaneous intramyocardial septal radiofrequency ablation|Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) is an innovative minimally invasive ablation treatment. Under the real-time transthoracic echocardiography guidance, a radiofrequency electrode needle is introduced into the hypertrophied interventricular septum via the percutaneous intramyocardial approach. Then the needle tip is pushed to the target region of the interventricular septal (IVS) basal segment 8 to 10 mm from the subaortic valve. The main objective of PIMSRA is to reduce ventricular septal hypertrophy and left ventricular outflow tract obstruction by means of thermal ablation.
219484437|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
219484438|NCT05725577|OTHER|care via the telemedicine system|Care via the telemedicine system
219484439|NCT05725577|OTHER|Routine care|Routine care
219484440|NCT03232554|DRUG|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
219484441|NCT03232554|DRUG|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
219484442|NCT03232554|DRUG|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
219484443|NCT06568653|PROCEDURE|exosome|human placenta mesenchymal stem cell-derived exosome
219484444|NCT06568653|PROCEDURE|routine conventional fistulotomy|routine conventional fistulotomy
219484445|NCT04404530|DRUG|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
218867570|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
219199836|NCT06858371|BEHAVIORAL|AI Depression Literacy and Support Training|"The intervention consists of two AI-based chatbots designed to enhance depression literacy, reduce stigma, and improve confidence in supporting others with depression.~AI Depression Education Teacher - This chatbot provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others. Participants engage in a structured conversation to enhance their understanding and receive real-time feedback.~AI Depression Patient Simulation (Beibei) - Participants interact with a simulated individual experiencing depression to practice empathetic communication and support strategies. Through guided conversations, they learn to recognize depressive symptoms, offer emotional support, and encourage help-seeking.~This two-phase intervention provides both knowledge and practical experience in a safe, interactive environment. Participants will engage with both chatbots sequentially within a one-hour session."
219484446|NCT01033201|OTHER|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
219484447|NCT04061057|DRUG|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
219484448|NCT04061057|DRUG|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
219484449|NCT00388674|DRUG|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
219484450|NCT00388674|DRUG|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
218867571|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
218867572|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
218867573|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
218867574|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
218867575|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
218867576|NCT01836081|OTHER|Volume expansion|
218867577|NCT00242333|DRUG|AD 237|
218867578|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
218867579|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
218867580|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
218867581|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
218867582|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
218867583|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
218867584|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
218867585|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
218867586|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
218867587|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
218867588|NCT00922805|DIETARY_SUPPLEMENT|guar gum|guar gum (20 g/l of formula) for one week
219199837|NCT06858371|BEHAVIORAL|AI Depression Literacy Education|This intervention consists of interaction with an AI chatbot, i.e., AI Depression Education Teacher, which provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others.
219484451|NCT01728363|DRUG|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
219484452|NCT00002902|DRUG|irinotecan hydrochloride|
219484453|NCT00002902|DRUG|raltitrexed|
219484454|NCT00504842|DRUG|MRX-801|
219484455|NCT00504842|DRUG|Placebo|
219484456|NCT00219752|DRUG|Imatinib mesylate 400 mg|
218867589|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
218867590|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
218867591|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
218867592|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
218867593|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
218867594|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
218867595|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
218867596|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
218867597|NCT01420822|DRUG|Fluticasone|Collection of safety data
218867598|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
218867599|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
218867600|NCT02690649|OTHER|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
218867601|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
219484457|NCT04058600|BEHAVIORAL|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
218867602|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
218867603|NCT00399399|DRUG|azathioprine|
218867604|NCT00399399|DRUG|cyclophosphamide|
218867605|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
219484458|NCT01474148|DEVICE|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
219484459|NCT05292079|DEVICE|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
219484460|NCT04219956|OTHER|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
219484461|NCT03568929|DRUG|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
218867606|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
218867607|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
218867608|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
218867609|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
218867610|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
218867611|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
218867612|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
218867613|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
218867614|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
219484462|NCT06385665|BEHAVIORAL|Graded companionship|Accompanying levels are divided into beginner, intermediate and advanced
219484463|NCT00265863|DRUG|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
219484464|NCT00776269|PROCEDURE|argon laser and radiofrequency|
219484465|NCT05355987|OTHER|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
219484466|NCT05355987|OTHER|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
219484467|NCT04955873|DEVICE|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
219484468|NCT04955873|DEVICE|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
218867615|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
218867616|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
218867617|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
218867618|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
218867619|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
219484469|NCT04628143|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
219484470|NCT06567288|PROCEDURE|spencer mscle energy technique|The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
219484471|NCT01777607|DEVICE|IMPELLA® RP|
219484472|NCT04243005|PROCEDURE|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
218867620|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
218867621|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
218867622|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
218867623|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
218867624|NCT02238340|DRUG|Extended- release Oxycodone|
218867625|NCT02238340|DRUG|ketoprofen|
218867626|NCT02238340|DRUG|dipirone|
218867627|NCT02238340|DRUG|dexametasone|
218867628|NCT02238340|DRUG|Morphine IV (rescue)|
218867629|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
218867630|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
218867631|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
218867632|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
218867633|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
218867634|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
218867635|NCT02554214|DEVICE|Glafkos drainage device|
218867636|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
218867637|NCT01824706|PROCEDURE|craniectomy|craniectomy
218867638|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
219484473|NCT04243005|PROCEDURE|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
218867639|NCT00660985|DRUG|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
218867640|NCT00660985|DRUG|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
218867641|NCT03695822|DRUG|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
218867642|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
218867643|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
218867644|NCT02126007|BEHAVIORAL|Sleep and Rhythm Intervention|
218867645|NCT02126007|BEHAVIORAL|Dietary Modifications|
218867646|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
218867647|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
218867648|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
218867649|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
218867650|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
218867651|NCT00803972|DRUG|Insulin Human Injection|injection
218867652|NCT00803972|DRUG|Insulin Lispro Injection|injection
218867653|NCT02068417|DEVICE|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
218867654|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
218867655|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
218867656|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
218867657|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
218867658|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
218867659|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
219484474|NCT06701227|OTHER|In Situ Simulation|"The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker."
218867660|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
218867661|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
218867662|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
219040141|NCT02202447|DRUG|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
219484475|NCT02426827|DEVICE|Spinal Cord Stimulation|
219484476|NCT00355680|DEVICE|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
219484477|NCT00355680|DEVICE|Green Laser (Iridex)|Already available green laser
219484478|NCT04441801|OTHER|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
219484479|NCT00568776|DRUG|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
219484480|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
219484481|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
219484482|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
219484483|NCT00379366|DEVICE|External ionizing radiations|14 Gy in one time
219599047|NCT05204706|OTHER|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
219484484|NCT01385670|DEVICE|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
219484485|NCT01130701|OTHER|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
219484486|NCT01862718|PROCEDURE|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
219484487|NCT01862718|PROCEDURE|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
219484488|NCT00704990|DIETARY_SUPPLEMENT|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
219484489|NCT04305184|DRUG|ASP0598|ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
219484490|NCT04305184|OTHER|Placebo|Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
219484491|NCT06201598|DEVICE|Group 1 - Intervention 1|Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
219484492|NCT03401762|BEHAVIORAL|MCI|EMG-controlled game
219484493|NCT03401762|BEHAVIORAL|Sham MCI|Sham control game
219484494|NCT03425786|BEHAVIORAL|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
219484495|NCT03425786|BEHAVIORAL|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
219484496|NCT03506646|DIETARY_SUPPLEMENT|Placebo|Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
219599048|NCT02640482|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
219484497|NCT03506646|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
219484498|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
219484499|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
219484500|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
219484501|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
219484502|NCT04793815|PROCEDURE|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
219484503|NCT04793815|DRUG|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
219040142|NCT02202447|OTHER|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
219484504|NCT05804240|DIAGNOSTIC_TEST|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
219484505|NCT02118896|DRUG|FK506E|oral
219484506|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
219599049|NCT02640482|DRUG|Placebo for ABT-493/ABT-530|tablet
219599050|NCT00478062|BIOLOGICAL|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
219599051|NCT00478062|PROCEDURE|adjuvant therapy|
218867663|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
218867664|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
218867665|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
218867666|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
218867667|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
218867668|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
218867669|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
218867670|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
218867671|NCT06244836|OTHER|Implementation of a bundle of care|
219484507|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
219484508|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
219484509|NCT00011999|DRUG|cisplatin|
219484510|NCT00011999|DRUG|paclitaxel|
218867672|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
219484511|NCT00011999|PROCEDURE|conventional surgery|
219484512|NCT00011999|RADIATION|radiation therapy|
219484513|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
219484514|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
219484515|NCT06522828|DRUG|carboplatin|chemotherapy
218867673|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
218867674|NCT03084042|DEVICE|fMRI|
218867675|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
218867676|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
219484516|NCT06522828|DRUG|paclitaxel|chemotherapy
219484517|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
219484518|NCT01722058|DRUG|Peptide application|
219484519|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
218867677|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
218867678|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
218867679|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
218867680|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
219484520|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
219484521|NCT03901352|DRUG|Placebo|Matching placebo tablets for oral administration
219484522|NCT03901352|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
219484523|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
218867681|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
218867682|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
218867683|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
218867684|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
218867685|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
219484524|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
219484525|NCT02448212|DRUG|TS-121|Oral
219484526|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
219484527|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
219484528|NCT04426019|BEHAVIORAL|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
219484529|NCT04426019|BEHAVIORAL|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
219484530|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
219484531|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
219484532|NCT03684473|BEHAVIORAL|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
219484533|NCT01845181|DRUG|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
219484534|NCT01845181|DRUG|Placebo|1 or 2 or 3 capsules of placebo.
219484535|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
219484536|NCT01965431|DRUG|BI 207127|Medium dose oral administration
218867686|NCT06299722|OTHER|STEEL|Relatively heavy strength training
218867687|NCT06299722|OTHER|Circuit training|Circuit training
218867688|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
218867689|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
219484537|NCT01965431|DRUG|BI 207127 placebo|
219484538|NCT01965431|DRUG|Faldaprevir placebo|
219484539|NCT01965431|DRUG|Faldaprevir|Medium dose oral administration
219484540|NCT01965431|DRUG|Moxifloxacin (Avalox®)|
219484541|NCT04635631|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
218867690|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
218867691|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
218867692|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
218867693|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
218867694|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
219484542|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
218867695|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
218867696|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
218867697|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
219484543|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
218867698|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
218867699|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
218867700|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
218867701|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
218867702|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
219484544|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
219484545|NCT00811031|DRUG|Taxotere|75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
219484546|NCT00811031|DRUG|Prednisone|5 mg twice a day by mouth.
219484547|NCT02050373|RADIATION|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
219484548|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
219484549|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
219484550|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
218867703|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
219484551|NCT02341872|OTHER|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
218867704|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
218867705|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
218867706|NCT02804308|BEHAVIORAL|Combined Training|
218867707|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
218867708|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
218867709|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
218867710|NCT02385916|OTHER|Placebo|Placebo
218867711|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
218867712|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
218867713|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
218867714|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
218867715|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
218867716|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
218867717|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
218867718|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
218867719|NCT01023386|DRUG|YM155|I.V.
218867720|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
218867721|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
219484552|NCT02341872|OTHER|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
219484553|NCT06274697|DEVICE|Evaluation by magnetic sensor|Evaluation by magnetic sensor on arm and leg
219484554|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219484555|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
218867722|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
218867723|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
218867724|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
218867725|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
218867726|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
219484556|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
219484557|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
219484558|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
219484559|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
219599052|NCT04675099|BEHAVIORAL|pCARE|"Mothering from the Inside Out is an evidence-based intervention delivered in substance use treatment settings that helps mothers with substance use disorders foster parent-child attachment, cope with stressful parenting situations, and promote their child's healthy development. This 3 month counseling intervention both improves parent-child attachment and decreases rates of drug relapse among mothers. The proposed mechanism of action targeted by the intervention is a change in parental reflective functioning, defined as the capacity to recognize and make sense of mental states (especially emotional states) and understand how they influence behavior and relationships."
218867727|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
219484560|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
219484561|NCT03046966|PROCEDURE|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds"
219484562|NCT03046966|OTHER|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
219484563|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
219484564|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
219484565|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
219484566|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
219484567|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
219484568|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
219484569|NCT02560207|DRUG|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
218867728|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
218867729|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
218867730|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
218867731|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
218867732|NCT00538993|BEHAVIORAL|Stage based counseling|
218867733|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
218867734|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
218867735|NCT03470363|DRUG|Bupivacaine / SUFentanil|
218867736|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
219484570|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
219484571|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
219484572|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
219484573|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
219484574|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
219484575|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
218867737|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
218867738|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
219484576|NCT04537130|BIOLOGICAL|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
218867739|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
219484577|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
219484578|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
219484579|NCT02148835|OTHER|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
219484580|NCT02148835|OTHER|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
219484581|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
219484582|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
219484583|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
219484584|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
219599053|NCT04675099|OTHER|Standard Early Intervention services|The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
219599054|NCT05690932|DRUG|PBI-200 Tablet|Single dose of PBI-200 tablet
218867740|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
218867741|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
219199838|NCT06858371|BEHAVIORAL|Psychoeducation Material Group|"The intervention contains standard psychoeducation materials about depression. Participants will be directed to:~A depression-related article - Provides general information about depression, including its symptoms, causes, and treatment options.~A video describing the lived experience of a depression patient - Shares a personal story to help participants understand the real-life impact of depression."
219484585|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
219484586|NCT01104935|DRUG|trastuzumab monotherapy|
219484587|NCT01104935|DRUG|trastuzumab and chemotherapy|
219599055|NCT05690932|DRUG|PBI-200 Capsule|Single dose of PBI-200 capsule
219599056|NCT05690932|DRUG|PBI-200 Suspension|Single dose of PBI-200 suspension
219599057|NCT02968602|DRUG|Minocycline|Minocycline capsules taken twice daily for two weeks.
219599058|NCT02968602|OTHER|Placebo|Placebo capsules taken twice daily for two weeks.
219599059|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
219599060|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
219599061|NCT02013817|DRUG|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
219599062|NCT02013817|DRUG|fludarabine|Every 4 weeks, 6 cycles
219599063|NCT02013817|DRUG|cyclophosphamide|Every 4 weeks, 3 cycles
219599064|NCT05504837|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
219599065|NCT06057948|BIOLOGICAL|OPT-821 (QS-21)|Comprised of the immunological adjuvant OPT-821 (QS-21)
219599066|NCT06057948|DIETARY_SUPPLEMENT|oral β-glucan|Participants will be randomized to receive this agent in two different schedules
219599067|NCT04447313|OTHER|Survey Administration|Ancillary studies
219599068|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive ACT telephone coaching
219599069|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive SBT telephone coaching
219599070|NCT04158388|OTHER|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
218867742|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
218867743|NCT01956045|OTHER|Patient's capacity|
218867744|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
218867745|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
218867746|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
218867747|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
218867748|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
218867749|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
218867750|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
218867751|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
219484588|NCT03843307|DEVICE|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
219484589|NCT04038307|DRUG|paracetamol|1gm
219484590|NCT04038307|DRUG|Saline Solution|100ml
219484591|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
219484592|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
219484593|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
219599071|NCT04158388|OTHER|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
219599072|NCT04158388|OTHER|Manual therapy|That group received moderate pressure digital manual therapy.
218867752|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
218867753|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
218867754|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
218867755|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
218867756|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
218867757|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
218867758|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
218867759|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
218867760|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
218867761|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
218867762|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
219599073|NCT04158388|OTHER|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
218867763|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
218867764|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
218867765|NCT00477269|DRUG|Imatinib mesylate|
218867766|NCT00477269|DRUG|Placebo|
218867767|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
218867768|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
218867769|NCT00897624|GENETIC|gene expression analysis|
218867770|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
218867771|NCT00897624|OTHER|laboratory biomarker analysis|
219484594|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
219484595|NCT04051840|DRUG|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
219484596|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
218867772|NCT01792518|DRUG|Placebo|
218867773|NCT01792518|DRUG|Linagliptin 5mg|
218867774|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
218867775|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
218867776|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
218867777|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
218867778|NCT04808193|OTHER|Survey|Participants will fill in the survey
218867779|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
218867780|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
218867781|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
218867782|NCT03010020|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
218867783|NCT03010020|BEHAVIORAL|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
218867784|NCT06933706|DRUG|losartan 25 mg|Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatment for diseases ranging from rheumatoid arthritis, osteoarthritis, chronic kidney disease, Marfan syndrome, and fatty liver. TGF-β plays an active role in fibrosis leading to the formation of adhesions and scar tissue. By limiting the formation of adhesions and scar tissue, losartan may reduce pain, myofibroblast activity, synovitis, fibrosis, and cartilage degeneration.
218867785|NCT06933706|OTHER|Placebo capsule|The placebo capsule will look identical to the active study drug, but will not have any active ingredient and will be filled with corn starch
219021278|NCT07197047|OTHER|Neck static stretching|"The static stretching intervention targeted the right posterolateral region of the neck. The stretching protocol consisted of four sets of 45 seconds each, separated by 45-second rest intervals, for a total intervention time of 3 minutes. Seated in a chair, participants performed the stretch by gently flexing their head forward and to the left in an anterolateral direction, using their contralateral (left) hand to assist the movement and ensure selective stretching of the right posterolateral region of the neck. Participants were asked to achieve a subjective discomfort intensity of at least 8 out of 10 on the Numerical Rating Scale (NRS), where 0 represents no pain and 10 indicates the strongest pain imaginable"
218867786|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
218867787|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
218867788|NCT02107872|DRUG|REGN1500|
218867789|NCT02107872|DRUG|placebo|
218867790|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
219484597|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
219484598|NCT00331604|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
219484599|NCT00331604|DRUG|insulin detemir|Injection s.c., 50% of daily dose.
219484600|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
219484601|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
219484602|NCT04406129|BIOLOGICAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool.
219484603|NCT04406129|OTHER|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug.
219484604|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
219484605|NCT00649155|DRUG|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
219484606|NCT00649155|DRUG|Cipro® XR Tablets (500 mg|500mg, single dose fasting
219484607|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
219484608|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
218867791|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
218867792|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
218867793|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
218867794|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
218867795|NCT02894450|OTHER|blood test|bioassay xaban
219484609|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
218867796|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
218867797|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
218867798|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
218867799|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
218867800|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
219484610|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
219484611|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
219484612|NCT00457418|DRUG|PEG-Intron|
219484613|NCT01459679|DEVICE|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
219484614|NCT01459679|DEVICE|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
219484615|NCT01459679|DEVICE|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
219484616|NCT01459679|DRUG|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
219484617|NCT00595127|DRUG|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
219484618|NCT00595127|DRUG|Fludarabine|Fludarabine (30mg/m\^2/day x 5 days)
219484619|NCT00595127|RADIATION|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
219484620|NCT05859893|BEHAVIORAL|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
219484621|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
219484622|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
219599074|NCT02462291|OTHER|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
218867801|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
218867802|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
218867803|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
219484623|NCT03259646|BEHAVIORAL|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
219484624|NCT01327989|DEVICE|Solitaire™ FR device|Mechanical Thrombectomy
219484625|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
219484626|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
219484627|NCT05398731|OTHER|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
219484628|NCT02086968|DRUG|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
219484629|NCT02086968|DRUG|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
219484630|NCT03858660|OTHER|No intervention|No intervention
219599075|NCT02366429|BEHAVIORAL|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
219599076|NCT02366429|OTHER|TAU|Treatment as usual provided at antenatal clinics and other health care instances
219599077|NCT06140446|DEVICE|FeverApp|The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
219599078|NCT06140446|DEVICE|DMT App|The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
219484631|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH\_DETINBACK Tangerine Mix)
219484632|NCT03915041|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
219484633|NCT03915041|DEVICE|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
219484634|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
219599079|NCT04209283|BEHAVIORAL|Visuospatial interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
219484635|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
218867804|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
218867805|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
218867806|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
218867807|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
218867808|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
218867809|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
218867810|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
218867811|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
218867812|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
218867813|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
219484636|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
219484637|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
219599080|NCT03327259|BEHAVIORAL|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
219599081|NCT03327259|BEHAVIORAL|Therapist Guided Activity Practice|The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
219599082|NCT02075307|DIETARY_SUPPLEMENT|Blueberry Powder|
219599083|NCT02075307|DIETARY_SUPPLEMENT|Placebo|
219484638|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
218867814|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
218867815|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
219484639|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
219484640|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
219484641|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
219484642|NCT03480165|DRUG|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
219484643|NCT03480165|DRUG|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
219484644|NCT06283069|BEHAVIORAL|compilation of a questionnaire about LifeStyle|compilation of a questionnaire about LifeStyle
219484645|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
219484646|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
219484647|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
219484648|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
219484649|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
219484650|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
219484651|NCT02591602|OTHER|Teleradiology Service|Teleradiology Service at home or in nursing homes
219484652|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
219484653|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
218867816|NCT00002460|DRUG|goserelin acetate|
218867817|NCT00002460|DRUG|tamoxifen citrate|
218867818|NCT00002460|PROCEDURE|ablative endocrine surgery|
219484654|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
219484655|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
219484656|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
219599084|NCT06192056|BEHAVIORAL|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
218867819|NCT00002460|PROCEDURE|oophorectomy|
218867820|NCT00357383|DRUG|Azithromycin (T1225)|
218867821|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
218867822|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
218867823|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
218867824|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
218867825|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
218867826|NCT03335254|DRUG|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
219484657|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
219484658|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
219484659|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
219599085|NCT03336528|DRUG|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
218867827|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
218867828|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
218867829|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
218867830|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
218867831|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
218867832|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
218867833|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
218867834|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
218867835|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
218867836|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
218867837|NCT04588181|BEHAVIORAL|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
218867838|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
218867839|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
219484660|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
219484661|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
219484662|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
218867840|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
218867841|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
218867842|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
219599086|NCT03336528|DRUG|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
218867843|NCT00351273|DRUG|Placebo|Methylcellulose
218867844|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
219484663|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
219599087|NCT03336528|DRUG|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
218867845|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
218867846|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
218867847|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
218867848|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
218867849|NCT01926769|DRUG|Metformin|
218867850|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
218867851|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
219484664|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
219484665|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
219484666|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
219484667|NCT01146886|DRUG|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
219484668|NCT01146886|DRUG|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
219484669|NCT03267316|BIOLOGICAL|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
219484670|NCT03267316|DRUG|Cisplatin|Standard of care treatment
219484671|NCT03267316|DRUG|Gemcitabine|Standard of care treatment
219484672|NCT03267316|DRUG|Nab-paclitaxel|Standard of care treatment
219484673|NCT03267316|DRUG|Carboplatin|Standard of care treatment
219484674|NCT03267316|DRUG|Pemetrexed|Standard of care treatment
219484675|NCT04061655|DRUG|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
218867852|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
218867853|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
218867854|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
218867855|NCT03204669|OTHER|Trace elements replacement|
218867856|NCT03740568|DRUG|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
219484676|NCT04061655|OTHER|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
219484677|NCT05260658|DRUG|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
219484678|NCT05260658|DRUG|Placebo|CFTX-1554 matching placebo
219484679|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
219484680|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
219484681|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
219484682|NCT01915485|RADIATION|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
219484683|NCT05455593|BEHAVIORAL|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
218867857|NCT03740568|DRUG|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
218867858|NCT01387724|GENETIC|RNA analysis|
218867859|NCT01387724|GENETIC|polymerase chain reaction|
218867860|NCT01387724|GENETIC|protein expression analysis|
218867861|NCT01387724|GENETIC|proteomic profiling|
218867862|NCT01387724|GENETIC|western blotting|
218867863|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
218867864|NCT01387724|OTHER|immunohistochemistry staining method|
218867865|NCT01387724|OTHER|laboratory biomarker analysis|
218867866|NCT01387724|OTHER|liquid chromatography|
218867867|NCT01387724|OTHER|mass spectrometry|
219484684|NCT05455593|BEHAVIORAL|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
219484685|NCT05455593|BEHAVIORAL|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
219484686|NCT01048411|DRUG|Naja-comp.|homeopathic remedy
219484687|NCT01048411|DRUG|Placebo|s.c. injection of NaCl-solution three times a week
219484688|NCT02231671|DRUG|ALS-008176|
219484689|NCT02231671|DRUG|ALS-008112|
219484690|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
219484691|NCT03753893|OTHER|No intervention used|no intervention used
219484692|NCT06565520|DEVICE|transcranial direct current stimulator|"The total amount of participation time per qualified subject will be approximately 150 minutes over two sessions. The participant screening session will take approximately 30 minutes, which is an appropriate amount of time to complete all screening tasks. The tDCS and sham sessions will take approximately a total of 120 minutes over two sessions.~The first session will include a screening (30 minutes) to ensure they qualify for the study, followed by a treatment session (60 minutes): including non-invasive brain stimulation combined with hip strengthening exercises and functional movement testing at UNLV Maryland Campus. Subjects will return for a second treatment session (60 minutes) 2 weeks after the first."
219484693|NCT03123120|DRUG|Spesolimab|12 weeks treatment
219484694|NCT03123120|DRUG|Placebo|12 weeks treatment
219484695|NCT01977560|BEHAVIORAL|Intensive Lifestyle Intervention|Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
218867868|NCT03999086|PROCEDURE|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
218867869|NCT03999086|OTHER|Control Group|Laboratory analysis to guide transfusion
218867870|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
218867871|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
218867872|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
218867873|NCT03055390|DRUG|placebo|2ml of saline intravenous
218867874|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
218867875|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
218867876|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
218867877|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
218867878|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
218867879|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
218867880|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
218867881|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
218867882|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
218867883|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
218867884|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
218867885|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
219484696|NCT01977560|BEHAVIORAL|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
218867886|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
218867887|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
218867888|NCT05538390|OTHER||
218867889|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
218867890|NCT00005079|PROCEDURE|conventional surgery|
218867891|NCT04052776|DRUG|Buspirone|40mg
218867892|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
218867893|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
218867894|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
218867895|NCT00327990|DRUG|Ibandronate|
218867896|NCT00327990|DRUG|Alendronate|
219040143|NCT03618264|DRUG|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219484697|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
219484698|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
219484699|NCT02989467|DRUG|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
219484700|NCT02989467|DRUG|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
219484701|NCT00137462|DRUG|torcetrapib/atorvastatin|
218867897|NCT02383433|DRUG|Regorafenib|Given PO
218867898|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
218867899|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
218867900|NCT02535416|DRUG|ARC-520|
218867901|NCT02535416|DRUG|cetirizine|
218867902|NCT02535416|DRUG|diphenhydramine|
218867903|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
218867904|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
218867905|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
218867906|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
218867907|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
218867908|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
218867909|NCT01977690|DEVICE|Clavicle Brace|
218867910|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
218867911|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
218867912|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
218867913|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
218867914|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
218867915|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
218867916|NCT02401204|OTHER|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
218867917|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
218867918|NCT01055483|DRUG|panobinostat/LBH589B|
219484702|NCT00137462|DRUG|atorvastatin|
219484703|NCT00203892|BIOLOGICAL|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
219484704|NCT00203892|BIOLOGICAL|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
219484705|NCT00203892|BIOLOGICAL|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
219484706|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
219599088|NCT04366687|BEHAVIORAL|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
219599089|NCT04366687|BEHAVIORAL|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
219599090|NCT03886883|OTHER|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
219599091|NCT03886883|OTHER|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
218867919|NCT02472236|DRUG|PEX168|200µg,injected subcutaneously,once a week.
218867920|NCT02472236|DRUG|Digoxin|0.5mg,oral,two times.
218867921|NCT04044976|DRUG|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
218867922|NCT00447122|DRUG|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
218867923|NCT00447122|DRUG|Lapatinib 1000mg/d|1000mg/d
218867924|NCT00447122|DRUG|Lapatinib 1500mg/d|1500mg/d
218867925|NCT00447122|DRUG|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
218867926|NCT00447122|DRUG|Oxaliplatin 100mg/m2|100mg/m2
218867927|NCT03083145|DIETARY_SUPPLEMENT|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
218867928|NCT03083145|DIETARY_SUPPLEMENT|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
218867929|NCT03083145|BEHAVIORAL|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
218867930|NCT01149902|BIOLOGICAL|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
218867931|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
218867932|NCT03907033|DRUG|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
219484707|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
219484708|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
219484709|NCT03080272|OTHER|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
219484710|NCT00806416|DRUG|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
219484711|NCT00806416|DRUG|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
219599092|NCT03886883|OTHER|Rest|The participants rested in a seated position for 10 minutes
219599093|NCT03886883|OTHER|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
219599094|NCT03581591|BIOLOGICAL|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
219484712|NCT00806416|DIETARY_SUPPLEMENT|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
219484713|NCT05598619|DIETARY_SUPPLEMENT|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
219484714|NCT05598619|OTHER|placebo|Colon delivered placebo once a day for 12 weeks
219484715|NCT02871336|OTHER|Data collection|
219484716|NCT02709759|BEHAVIORAL|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
219484717|NCT02709759|BEHAVIORAL|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
219484718|NCT02709759|BEHAVIORAL|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
219484719|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
219484720|NCT01654211|DRUG|danoprevir|single iv infusion
219484721|NCT01654211|DRUG|danoprevir|single oral dose
219484722|NCT01654211|DRUG|placebo|single iv infusion
219484723|NCT01654211|DRUG|ritonavir|oral doses
219484724|NCT00081978|DRUG|TMC125|
219484725|NCT01596088|DRUG|Dexrazoxane|
219484726|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
219484727|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
219484728|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
218867933|NCT03907033|DRUG|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
218867934|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
218867935|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
219484729|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
219484730|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
218867936|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
218867937|NCT01174173|DRUG|Ranolazine|ranolazine 1000 mg PO BID for 3 months
218867938|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
218867939|NCT02648672|DRUG|Placebo|
218867940|NCT05491434|DIETARY_SUPPLEMENT|Protein supplement|One líquid brick every day during 3 weeks
218867941|NCT05981183|DEVICE|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
219484731|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
219484732|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
219484733|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
219484734|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
219484735|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
219484736|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
219484737|NCT01291186|DRUG|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
219484738|NCT01291186|DRUG|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
219484739|NCT01291186|DRUG|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
219484740|NCT01291186|DRUG|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
219484741|NCT01291186|DRUG|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
219484742|NCT01291186|DRUG|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
219484743|NCT01291186|DRUG|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
219484744|NCT01291186|DRUG|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
219484745|NCT01291186|DRUG|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
219484746|NCT01291186|DRUG|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
219484747|NCT01291186|DRUG|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
219484748|NCT01291186|DRUG|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
219484749|NCT03490539|DRUG|Mycophenolate Mofetil|oral tablets
219484750|NCT03490539|DRUG|Azathioprine|oral tablet
218867942|NCT05549557|DRUG|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
218867943|NCT05365126|BEHAVIORAL|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
218867944|NCT02402413|PROCEDURE|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
218867945|NCT02402413|PROCEDURE|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
218867946|NCT02402413|DEVICE|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
218867947|NCT01699568|DEVICE|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
218867948|NCT00320463|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
218867949|NCT04868149|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
218867950|NCT01456312|DRUG|Peginterferon alfa-2a|Duration and combination
218867951|NCT01456312|DRUG|Entecavir|combination
218867952|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
218867953|NCT02317978|PROCEDURE|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
218867954|NCT00218699|BEHAVIORAL|Cognitive-Behavioral Intervention|
218867955|NCT01816867|DEVICE|Intramesh T1 implantation|
218867956|NCT01688115|PROCEDURE|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
219484751|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
218867957|NCT01688115|OTHER|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
219484752|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
219484753|NCT05105035|DRUG|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
219484754|NCT05105035|DRUG|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
219599095|NCT02842138|BIOLOGICAL|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
218867958|NCT04073485|PROCEDURE|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
218867959|NCT05496556|OTHER|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
218867960|NCT04751188|DRUG|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
218867961|NCT04751188|DRUG|Placebo|Placebo one tablet every 12 hours for six months.
218867962|NCT04751188|DRUG|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
218867963|NCT00168454|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
218867964|NCT00168454|DRUG|Placebo|Placebo (normal saline) injected into detrusor on Day 1
219484755|NCT05105035|DRUG|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
219484756|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
219599096|NCT04063150|BIOLOGICAL|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
218867965|NCT03938324|BEHAVIORAL|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
218867966|NCT03938324|BEHAVIORAL|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
219484757|NCT01402193|DRUG|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
219484758|NCT01402193|DRUG|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
219484759|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
219599097|NCT04063150|BIOLOGICAL|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
218867967|NCT03401385|DRUG|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
219484760|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
218867968|NCT03401385|DRUG|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
218867969|NCT03401385|OTHER|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
218867970|NCT02769962|DRUG|EP0057|"EP0057 (formerly CRLX101) intravenous (IV) every (Q) 2weeks Day 1 and Day 15, administered in 28-day cycles, until disease progression or development of intolerable side effects.~Plus olaparib (by mouth (PO) days 3-13\* and days 17-26\*) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
218867971|NCT02769962|DRUG|olaparib|"Olaparib (by mouth (PO) days 3-13\* and days 17-26\* administered in 28-day cycles, until disease progression or development of intolerable side effects Plus EP0057 (formerly CRLX101) (intravenous (IV) every (Q) 2 weeks, Day 1 and Day 15) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)."
218867972|NCT02769962|DIAGNOSTIC_TEST|CT scan|Screening and baseline.
218867973|NCT02769962|DIAGNOSTIC_TEST|CT chest, abdomen, and pelvis|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
218867974|NCT02769962|DIAGNOSTIC_TEST|Bone scan|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
219484761|NCT05372211|OTHER|not use of any intervention|not use of any intervention
219484762|NCT03837340|OTHER|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
219484763|NCT03837340|OTHER|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
219484764|NCT00023426|DRUG|rifapentine|
219599098|NCT04063150|BIOLOGICAL|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
219599099|NCT04063150|BIOLOGICAL|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
219599100|NCT00482781|BIOLOGICAL|Infanrix|
219599101|NCT00482781|BIOLOGICAL|Pediatrix|
219599102|NCT05676814|DRUG|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
218867975|NCT02769962|DIAGNOSTIC_TEST|ECG|Screening, baseline, Day 1, Day 15 and cycle 2, Day 1.
218867976|NCT02769962|DIAGNOSTIC_TEST|Echocardiogram|At screening.
218867977|NCT02769962|PROCEDURE|Biopsy|Baseline Day 4 and end of treatment/disease progression.
219484765|NCT03910101|PROCEDURE|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
219484766|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
219484767|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
219484768|NCT06547814|BEHAVIORAL|Standard implementation webinar and online training|The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, vaccine eligibility, mechanisms of action, and outcomes. The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.
219484769|NCT06547814|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and at least 8, 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
219599103|NCT05676814|DRUG|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
219599104|NCT01960023|DRUG|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
218867978|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
219484770|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
219484771|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
219484772|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
218867979|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
219484773|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
219484774|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
219484775|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
219484776|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
219484777|NCT06109402|DRUG|TQB2450|Specified dose on specified days
219484778|NCT06109402|DRUG|Carboplatin|Specified dose on specified days
218867980|NCT00837759|DRUG|Insulin|
218867981|NCT00837759|DRUG|Lansoprazole|
218867982|NCT00837759|DRUG|Sitagliptin|
218867983|NCT00837759|BIOLOGICAL|Diamyd|
218867984|NCT00837759|DRUG|GAD65 (Diamyd)|
219484779|NCT06109402|DRUG|Pemetrexed|Specified dose on specified days
218867985|NCT01073930|DRUG|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
219484780|NCT06109402|DRUG|Nab-paclitaxel|Specified dose on specified days
219484781|NCT06109402|PROCEDURE|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
219484782|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
219599105|NCT01960023|DRUG|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
219599106|NCT02735538|PROCEDURE|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
219599107|NCT02735538|PROCEDURE|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
219599108|NCT00529139|DEVICE|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
219599109|NCT00529139|DEVICE|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
219599110|NCT05597150|DIETARY_SUPPLEMENT|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
219599111|NCT00039338|PROCEDURE|conventional surgery|Radial hysterectomy
219599112|NCT00039338|PROCEDURE|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
219484783|NCT00335985|DRUG|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
219599113|NCT00039338|RADIATION|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
219599114|NCT00039338|RADIATION|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
219599115|NCT00039338|DRUG|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
219599116|NCT02295917|DEVICE|Transvaginal sonography|Transvaginal sonography
219599117|NCT00002638|BIOLOGICAL|filgrastim|
219599118|NCT00002638|BIOLOGICAL|sargramostim|
219599119|NCT00002638|DRUG|carmustine|
219599120|NCT00002638|DRUG|cyclophosphamide|
219599121|NCT00002638|DRUG|cytarabine|
219599122|NCT00002638|DRUG|etoposide|
219599123|NCT00002638|PROCEDURE|peripheral blood stem cell transplantation|
218867986|NCT01073930|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
218867987|NCT01073930|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
219484784|NCT00335985|DRUG|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
219484785|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
219599124|NCT00002638|RADIATION|radiation therapy|
219599125|NCT04271917|DRUG|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
219599126|NCT04271917|DRUG|placebo|Inactive placebo oil to imitate CBD oil
219599127|NCT04271917|DRUG|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
219040144|NCT03618264|DRUG|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219484786|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
219599128|NCT00946517|OTHER|Questionnaires|Parenting and behavioral questionnaires
219599129|NCT06172634|DRUG|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
219599130|NCT03834142|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
219599131|NCT05526755|DRUG|Osimertinib 80 mg/40 mg|Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
219599132|NCT02202707|DRUG|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
219599133|NCT06349941|DEVICE|Movn app|Participants will have 12-week home-based exercise program delivered via a commercially available home-based cardiac rehabilitation platform called Movn. The plan includes an accelerometer, blood pressure scale, and mobile application.
219599134|NCT06349941|DEVICE|Accelerometer|Participants will receive a FitBit for monitoring of physical function.
219599135|NCT02458209|BIOLOGICAL|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
219484787|NCT02875431|PROCEDURE|Patients undergo ACDF or cervical vertebral body replacement|
219599136|NCT02458209|BIOLOGICAL|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
219599137|NCT02458209|BIOLOGICAL|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
218867988|NCT04660396|DEVICE|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
218867989|NCT00555737|DEVICE|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
218867990|NCT00959127|DRUG|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
219484788|NCT05503160|BEHAVIORAL|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
219484789|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
218867991|NCT04708860|BEHAVIORAL|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
218867992|NCT04708860|BEHAVIORAL|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
218867993|NCT02555176|DIETARY_SUPPLEMENT|Dietary intervention|Follow a low-carbohydrate diet
218867994|NCT04043468|OTHER|Audit and feedback|Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
218867995|NCT02081599|DRUG|Teneli (Teneligliptin)|
218867996|NCT02081599|DRUG|Placebo|
218867997|NCT02081599|DRUG|Insulin|
219484790|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
219484791|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
219484792|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
219484793|NCT03750916|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
218867998|NCT01266590|DRUG|LY2216684|Administered orally
218867999|NCT01266590|DRUG|Digoxin|Administered orally
218868000|NCT04274335|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
218868001|NCT04274335|DRUG|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
219599138|NCT04733261|OTHER|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
218868002|NCT04274335|DRUG|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
218868003|NCT04500886|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
218868004|NCT04500886|DRUG|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
218868005|NCT03795727|DEVICE|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
218868006|NCT03795727|DEVICE|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
218868007|NCT02595294|PROCEDURE|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
218868008|NCT04483336|OTHER|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
218868009|NCT04483336|OTHER|TV Screen Distraction|A cartoon video was played on a regular TV screen.
219484794|NCT01610284|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
219484795|NCT01610284|DRUG|BKM120|BKM120 100 mg once daily
218868010|NCT01372176|OTHER|Early Goal-Directed Nutrition|"1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
218868011|NCT01372176|OTHER|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
218868012|NCT06202040|PROCEDURE|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
219484796|NCT01610284|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
219484797|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
219484798|NCT05596552|DRUG|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
219484799|NCT05596552|DRUG|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
219484800|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
219484801|NCT03327532|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
219484802|NCT03327532|PROCEDURE|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
219484803|NCT03327532|BIOLOGICAL|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
219599139|NCT04733261|OTHER|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
219599140|NCT01753297|DRUG|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
218868013|NCT06202040|PROCEDURE|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
218868014|NCT04558359|OTHER|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
219484804|NCT03327532|OTHER|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
219484805|NCT03327532|BIOLOGICAL|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
219484806|NCT03327532|PROCEDURE|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
219484807|NCT02405494|DIETARY_SUPPLEMENT|Beverage 1|
219484808|NCT02405494|DIETARY_SUPPLEMENT|Beverage 2|
219484809|NCT02405494|DIETARY_SUPPLEMENT|Beverage 3|
219484810|NCT02405494|DIETARY_SUPPLEMENT|Beverage 4|
219484811|NCT02405494|DIETARY_SUPPLEMENT|Beverage 5|
219484812|NCT02405494|DIETARY_SUPPLEMENT|Beverage 6|
219484813|NCT02405494|DIETARY_SUPPLEMENT|Beverage 7|
219484814|NCT02405494|DIETARY_SUPPLEMENT|Beverage 8|
219599141|NCT00230178|DRUG|Rasburicase (SR29142)|30-min IV infusion
219599142|NCT00230178|DRUG|Allopurinol|Oral administration
219599143|NCT04687683|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
219484815|NCT02405494|DIETARY_SUPPLEMENT|Beverage 9|
219484816|NCT06700694|OTHER|Technology-assisted, family-engaged in-bed activities|Technology-assisted, family-engaged in-bed activities include handgrip interactive games, virtual reality butterfly catching, virtual reality magic cube games, and immersive in-bed cycling, performed 20 minutes per session, twice daily, five days a week, primarily assisted by family members.
218868015|NCT04558359|DRUG|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
218868016|NCT06244680|DEVICE|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
218868017|NCT02364934|DRUG|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
219484817|NCT06700694|OTHER|Protocol-oriented early mobilization program|The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
218868018|NCT02364934|DRUG|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
219484818|NCT04035694|OTHER|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
219599144|NCT04687683|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
219599145|NCT04687683|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
219484819|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
219484820|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
219484821|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
219484822|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
219484823|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
219599146|NCT06423092|OTHER|Music therapy songwriting|"Session 1: The goal of the first music therapy session is to know the parents musically and to provide information about song creation. This is achieved by exploring their favorite songs. Options for creating a song (original song or song parody) are presented and possibilities for creating lyrics are discussed.~Sessions 2-7: The structure of the song will be created and discussed with the parents. Parents will also be invited to include written messages from other family members in the lyrics if they wish. In each session, the developing welcome song is sung together with the parents, accompanied by the music therapist, who provides vocal or instrumental support.~The final sessions (Sessions 8-9) are dedicated to singing the final version of the song with the parents and their infant. Should the parents desire, a final recording of the song will also be made and the digital songbook will be created."
219599147|NCT01346787|DRUG|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
219484824|NCT02395601|DRUG|CPI-1205|Small molecule inhibitor of the enzyme EZH2
219484825|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
219484826|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
218868019|NCT05984485|PROCEDURE|neoadjuvant chemotherapy plus total mesorectal excision|Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
218868020|NCT05984485|PROCEDURE|total mesorectal excision|Standard total mesorectal excision
218868021|NCT02905669|DEVICE|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
219484827|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
219484828|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
219599148|NCT00878176|PROCEDURE|First stage tined lead procedure|bilateral first stage tined lead placement
218868022|NCT05270798|DRUG|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
218868023|NCT06034249|BEHAVIORAL|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
218868024|NCT06034249|BEHAVIORAL|Audio|The mindfulness-based audio files for six weeks.
218868025|NCT02404428|DIETARY_SUPPLEMENT|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
218868026|NCT02404428|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
219484829|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
219484830|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
219484831|NCT06543095|OTHER|Pain level|Post-operative pain levels of the patients with detected using VAS score.
219484832|NCT04924738|BEHAVIORAL|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
219484833|NCT01508923|DRUG|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
219484834|NCT01508923|DRUG|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
219484835|NCT01184781|DEVICE|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
219484836|NCT02854722|DRUG|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
219484837|NCT02854722|DRUG|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
218868027|NCT03970369|BEHAVIORAL|Usual care|Personalized goals and an activity prescription.
218868028|NCT03970369|BEHAVIORAL|Monitor|Participants wear a step counter to track activity goals.
218868029|NCT02446080|DIETARY_SUPPLEMENT|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
218868030|NCT02446080|DIETARY_SUPPLEMENT|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
219599149|NCT00611260|BEHAVIORAL|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
219599150|NCT00611260|OTHER|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
219599151|NCT00840489|DRUG|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
218868031|NCT00720343|DRUG|Choline|Oral Choline 20 grams before surgery
218868032|NCT00720343|DRUG|Placebo|Gelatin Capsule
218868033|NCT03305978|DEVICE|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
218868034|NCT03305978|DEVICE|Low dose chest CT|standard diagnostic low dose chest CT
218868035|NCT06964620|DRUG|Sanggua tablets|Patients will continue their background medications and receive Sang Gua tablets, twice daily (bid).
219599152|NCT00840489|DRUG|Colchicine|Colchicine 0.5 mg bd for 24 weeks
219599153|NCT03577301|BEHAVIORAL|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
218868036|NCT06964620|DRUG|Placebo|Patients will continue their background medications and receive placebo, twice daily (bid).
218868037|NCT05862649|OTHER|NeuraLight|NeuraLight software-based platform
218868038|NCT06494085|OTHER|Measuring Respiratory Mechanics|"First, for each patient enrolled we will perform inspiratory and expiratory occlusions - routinely performed diagnostic maneuvers to measure patient's breathing effort - at the clinically set level of breathing assistance by the mechanical ventilator. Importantly, we will measure pressure-muscle-index (PMI).~Second, we will set the level of assistance (i.e. pressure support, PS) in order to make PMI=0. The PS level at which PMI=0 (PS PMI=0) will be used as reference for the study protocol. After 5 minutes at PS PMI=0 we will perform inspiratory and expiratory occlusions."
218868039|NCT06494085|OTHER|Randomized Pressure Support|3 steps of PS above (+2, +4, +6 cmH2O) and 3 below (-2, -4, -6 cmH2O) PSPMI=0 done in a randomized order (sequence in envelopes opened blindly by the investigators). Each step will last ≤5 minutes if poorly tolerated (see tolerance rule in description). At the end of each step we will perform 1 inspiratory occlusion and 3 expiratory occlusions. Each of the expiratory occlusion will be separated by 30 seconds in order to restore the patient's breathing pattern. We will resume a 3-minutes clinical PS in between each step to minimize changes in PaCO2. If not yet comprised by the study steps each patient will undergo an adjunctive 5 minutes step at PS 0 (zero) cmH2O.
218868040|NCT05315726|OTHER|Dynamometer|Measurement of elbow/wrist spasticity
219484838|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
219484839|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
219484840|NCT00448110|DRUG|placebo|placebo
219484841|NCT05760638|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
219484842|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
219484843|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
219484844|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
219484845|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
219484846|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
219484847|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
219484848|NCT01614158|DEVICE|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
219484849|NCT01614158|OTHER|D-BCVA|D-BCVA using EDTRS chart
219484850|NCT01614158|OTHER|RAPD|RAPD using swinging flashlight test
219484851|NCT01614158|DEVICE|IOP|IOP using applanation tonometer
219484852|NCT01614158|DEVICE|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
219484853|NCT01614158|OTHER|Fundus photography|Optic disk morphology will be documented by fundus photography
219484854|NCT04434235|OTHER|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
219599154|NCT03577301|BEHAVIORAL|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
219199839|NCT06855758|DRUG|terlipressin|Terlipressin was given prior to the opening of the graft circulation (with the possibility of reperfusion hypotension) when the blood pressure is suboptimal and does not respond well to dobutamine or fluid volume resuscitation. 1 mg terlipressin + 100 ml of sodium chloride injections was given for intravenous infusion.
219484855|NCT03112096|DRUG|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
219484856|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
219484857|NCT01125358|DRUG|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
219484858|NCT01125358|DRUG|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
219484859|NCT04332835|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
219484860|NCT04332835|DRUG|Standard Therapy|Standard therapy defined by institutional protocol.
219484861|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
219484862|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
219484863|NCT01157065|DRUG|AL-78898A|Investigational treatment
219484864|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
219484865|NCT01764776|DRUG|LDE225|LDE225
219484866|NCT00318409|DRUG|Bupropion|
219484867|NCT00318409|DRUG|Placebo|
219484868|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
219599155|NCT03577301|BEHAVIORAL|Multi-modal Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
218868041|NCT05315726|OTHER|Muscle vibrations|1 session of 10 minutes
219199840|NCT06855914|PROCEDURE|surgerical repair|surgical repair of AVF aneurysm
219484869|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
219484870|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
219484871|NCT01304017|OTHER|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
219484872|NCT01304017|OTHER|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
219484873|NCT01591902|DRUG|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
219484874|NCT01591902|DRUG|Placebo-Control|3.0 mL vials
219484875|NCT01060007|RADIATION|External beam radiation|
219484876|NCT01060007|DRUG|Oxaliplatin|
219484877|NCT01060007|DRUG|Leucovorin|
218868042|NCT05315726|OTHER|Muscle vibrations|3 times/week for 6 weeks
218868043|NCT05315726|OTHER|Placebo muscle vibration|3 times/week for 6 weeks
218868044|NCT05293626|DRUG|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
218868045|NCT05293626|DEVICE|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
218868046|NCT06060028|DEVICE|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
219484878|NCT01060007|DRUG|5-FU|
219484879|NCT01060007|DRUG|Capecitabine|
219484880|NCT04995302|PROCEDURE|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
219484881|NCT04995302|PROCEDURE|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
219484882|NCT04022759|BEHAVIORAL|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
219484883|NCT04022759|BEHAVIORAL|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
219484884|NCT05428059|OTHER|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
219484885|NCT06132100|DEVICE|digitalized incentive spirometry|digitalized incentive spirometry
219484886|NCT06132100|DEVICE|traditional incentive spirometry|traditional incentive spirometry
219484887|NCT06251154|DEVICE|Lens 1|Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
218868047|NCT06060028|DEVICE|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
218868048|NCT06371417|DRUG|RAY121|Injection
219199841|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
219484888|NCT06251154|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
219484889|NCT06567184|BEHAVIORAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
219484890|NCT00742859|DRUG|betrixaban|orally, once daily for at least 3 months
219484891|NCT00742859|DRUG|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
219484892|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
219484893|NCT00956709|DRUG|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
219484894|NCT00956709|DRUG|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
218868049|NCT05722743|BEHAVIORAL|Harmony at HOME|The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
218868050|NCT05722743|BEHAVIORAL|National Institute on Aging Program|"Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage."
218868051|NCT05266339|OTHER|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
218868052|NCT05266339|OTHER|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
218868053|NCT05646862|DRUG|Inavolisib|Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
219484895|NCT03501407|DIAGNOSTIC_TEST|Blood samples|1 or 2 blood samples will be collected from the patient.
218868054|NCT05646862|DRUG|Fulvestrant|Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
219484896|NCT03501407|DIAGNOSTIC_TEST|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
219484897|NCT04064931|DIAGNOSTIC_TEST|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
219599156|NCT02897518|DEVICE|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
218868055|NCT05646862|DRUG|Alpelisib|Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
218868056|NCT05710432|OTHER|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
219599157|NCT02897518|DEVICE|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
219599158|NCT02765763|DRUG|2-Minute Reveal Masque|
219599159|NCT02765763|DRUG|24/7 Barrier Repair Cream|
219599160|NCT02765763|DRUG|8-in-1 BioSerum|
219599161|NCT02765763|DRUG|Null Formula 2-Minute Reveal Masque|
219599162|NCT02765763|DRUG|Null Formula 24/7 Barrier Repair Cream|
219599163|NCT02765763|DRUG|Null Formula 8-in-1 BioSerum|
218868057|NCT05710432|OTHER|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
218868058|NCT06441617|DEVICE|Online Program for Fatigue|An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
218868059|NCT06231966|DRUG|Combination therapy of high-intensity dose rosuvastatin and ezetimibe|Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
218868060|NCT06231966|DRUG|Rosuvastatin monotherapy for treat-to-target|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
218868061|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
218868062|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
218868063|NCT06523985|BEHAVIORAL|Push messages (standard)|Push messages will be developed based on best practice recruitment principles in cooperation with an external marketing team and then reviewed and finalized by the study team. Messages will be different each month and sent across 12 months. The monthly time frame was selected based on our need to balance contact with responders and research or expert opinions on push messaging saturation.
218868064|NCT06523985|BEHAVIORAL|Push messages (customized)|These messages are similar to content in the standard push messages but are customized to address common misperceptions about opioid overdose and naloxone.
218868065|NCT02933554|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
218868066|NCT04624763|PROCEDURE|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met:~   1. Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~  2. If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~  3. LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is \< 10ms;~  4. A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
218868067|NCT04624763|PROCEDURE|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
218868068|NCT04667910|DRUG|601 1.25mg|Solution for injection (intravitreal use)
218868069|NCT04667910|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
218868070|NCT05293496|BIOLOGICAL|vobramitamab duocarmazine|Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
218868071|NCT05293496|BIOLOGICAL|lorigerlimab|Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
219484898|NCT04978194|OTHER|University-based intervention to promote better management of emotions and learning|It included 9 video capsules (that take place over 9 weeks), with the following themes: stress information, learning information, emotion and stress regulation strategies, cognitive and metacognitive learning strategies, motivation for learning, physical activity, diet, sleep, and managing worry and uncertainty. It is based on previous online student mental health intervention studies. It presents two innovative aspects: elements and examples specific to the COVID-19 pandemic and the addition of modules focused on learning strategies. The different modules were designed by 5 associate professors, 2 Master students in clinical psychology and 2 undergraduate students in psychology. For the control group, the videos will be posted every week on a You Tube channel and broadcast on a private discord group. For the hybrid group, student will have to attend 10 lessons of 2 hours. These courses include the viewing of videos and a time for discussion between students and the teacher.
219484899|NCT05171920|DRUG|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
219484900|NCT05171920|DRUG|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
219484901|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
218868072|NCT01773304|OTHER|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
218868073|NCT02008773|DRUG|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
218868074|NCT02008773|DRUG|placebo|placebo capsules 6/day oral for 16 weeks
218868075|NCT02759081|DEVICE|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
218868076|NCT02759081|PROCEDURE|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
218868077|NCT06232785|DRUG|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
219484902|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
219484903|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
219484904|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
219484905|NCT04522310|OTHER|MR-Pro-ADM|Dosage of MR-pro-ADM
219484906|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
219484907|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
219484908|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
219484909|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
219484910|NCT02097966|DRUG|Daclatasvir|
219484911|NCT02097966|DRUG|Sofosbuvir|
219484912|NCT02097966|DRUG|Ribavirin|
219484913|NCT02960724|OTHER|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
219484914|NCT03864367|DEVICE|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
219599164|NCT03776149|DIETARY_SUPPLEMENT|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
219599165|NCT03776149|DIETARY_SUPPLEMENT|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
218868078|NCT06232785|DRUG|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
218868079|NCT04179253|DIAGNOSTIC_TEST|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
218868080|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
219484915|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
219599166|NCT01114607|DRUG|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
218868081|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
218868082|NCT00081133|DRUG|arsenic trioxide|
219199842|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (20 grams)|20 grams of whey protein
219484916|NCT01288417|DRUG|boceprevir|10 days of boceprevir 800mg TID
219484917|NCT01288417|DRUG|raltegravir|raltegravir 400mg single dose
219484918|NCT05589649|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block
219484919|NCT05589649|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block
219484920|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
219484921|NCT04527549|DRUG|Hydroxychloroquine|Given PO
218868083|NCT00081133|DRUG|imatinib mesylate|
218868084|NCT04159792|OTHER|no intervention|No intervention
218868085|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
218868086|NCT03137498|DRUG|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
218868087|NCT03137498|DRUG|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
218868088|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
219199843|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (60 grams)|60 grams of whey protein.
219484922|NCT04527549|DRUG|Placebo Administration|Given PO
219484923|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
219484924|NCT00486642|DRUG|Bicalutamide|Given PO
219484925|NCT00486642|OTHER|Laboratory Biomarker Analysis|Correlative studies
219484926|NCT00486642|DRUG|Pazopanib Hydrochloride|Given PO
219484927|NCT00486642|OTHER|Pharmacological Study|Correlative studies
219484928|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
219484929|NCT02284152|BEHAVIORAL|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
219484930|NCT03706209|DRUG|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
219599167|NCT01114607|DRUG|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
218868089|NCT00710463|DEVICE|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
219484931|NCT03706209|DRUG|Placebo|hard gelatin capsules containing no active ingredient
219484932|NCT04681807|BEHAVIORAL|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
219484933|NCT04681807|BEHAVIORAL|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
219484934|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
219484935|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
219484936|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
219484937|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
219484938|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
219484939|NCT05634629|PROCEDURE|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
218868090|NCT05164614|COMBINATION_PRODUCT|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
218868091|NCT05164614|DRUG|Forteo|A commercial formulation of PTH for SC control (20 µg)
218868092|NCT05164614|COMBINATION_PRODUCT|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
218868093|NCT03631134|DRUG|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
219484940|NCT05634629|PROCEDURE|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
219484941|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
219484942|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
219484943|NCT02437929|PROCEDURE|Mobilization|
219484944|NCT02437929|PROCEDURE|Positioning|
218868094|NCT02156778|BEHAVIORAL|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
219484945|NCT02437929|PROCEDURE|Personal Hygiene Care|
219484946|NCT02437929|PROCEDURE|Bladder catheterization|
219484947|NCT02437929|PROCEDURE|Wound care|
219484948|NCT02437929|PROCEDURE|Subcutaneous drugs administration|
219484949|NCT04125160|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
219484950|NCT04125160|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
219599168|NCT01114607|DRUG|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
219599169|NCT01114607|DRUG|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
219599170|NCT01114607|DRUG|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
219599171|NCT04774497|OTHER|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
219599172|NCT04774497|OTHER|Control group|The control group was not given oxygen inhalation.
219599173|NCT05114278|DRUG|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
219599174|NCT05114278|DRUG|oral iron|All patients will receive an oral iron supplementation (100mg/day).
219599175|NCT01562860|PROCEDURE|Pronator Teres Release|Surgical release of median nerve compression
219599176|NCT01562860|PROCEDURE|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
219599177|NCT01562860|PROCEDURE|dual compression release|both procedures will be done on the same day
219599178|NCT01562860|PROCEDURE|median nerve release only|only the carpal tunnel compression is released
219484951|NCT02815189|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
219484952|NCT02815189|DRUG|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
218868095|NCT02156778|BEHAVIORAL|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
219199844|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
219484953|NCT06701292|DEVICE|PVS-PVI targeted ablation|"Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI."
219484954|NCT06701292|DEVICE|Wide area circumferential ablation (WACA)|After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
219484955|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
219484956|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
219484957|NCT06694168|PROCEDURE|Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery|The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
219484958|NCT06694168|PROCEDURE|REGEND001 Autologous Therapy Product|L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.
219484959|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
219484960|NCT03972709|DRUG|Sham Control|Sham control
219484961|NCT00852072|PROCEDURE|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
219484962|NCT00852072|PROCEDURE|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
219484963|NCT05192954|DEVICE|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
219484964|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
219484965|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
219599179|NCT05668546|DEVICE|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT\_E) and concentric flexion (PT\_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT\_E, 60 PT\_F, 180 PT\_E, and 180 PT\_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
219484966|NCT05225116|DRUG|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
219484967|NCT05225116|DRUG|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
219484968|NCT05225116|RADIATION|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
219484969|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
219599180|NCT00659958|DRUG|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
219599181|NCT00137761|DRUG|ZD 1839|Taken orally once daily
219599182|NCT00137761|DRUG|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
219599183|NCT06395805|DIAGNOSTIC_TEST|BREF, ADL, AIS.|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
219599184|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
219599185|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
219599186|NCT05065255|DEVICE|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
219599187|NCT04350450|DRUG|Hydroxychloroquine|400 mg tablet
219599188|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
219599189|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
219599190|NCT03484650|OTHER|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
219599191|NCT01918202|DRUG|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
219599192|NCT01918202|DRUG|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
219599193|NCT01918202|DRUG|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
219599194|NCT01384903|DRUG|KW-3357|Intravenous infusion once a day
218868096|NCT04083950|BIOLOGICAL|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
219599195|NCT01384903|DRUG|Plasma-derived antithrombin|Intravenous infusion once a day
219599196|NCT06632574|DRUG|paclitaxel cationic liposomes|Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
219599197|NCT04131348|PROCEDURE|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
219599198|NCT00328848|BEHAVIORAL|Behavioral|Group Treatment(patient education, self management support, caregiver support)
219599199|NCT00328848|BEHAVIORAL|behavioral|patient education, self management support, caregiver support
219599200|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
219599201|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
219599202|NCT01499446|DRUG|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
219599203|NCT01499446|DRUG|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
218868097|NCT04083950|DRUG|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
218868098|NCT05360069|DEVICE|Linear stapler|Linear stapler is adopted in esophagojejunostomy
218868099|NCT05360069|DEVICE|Circular stapler|Circular stapler is adopted in esophagojejunostomy
218868100|NCT01918332|DRUG|Valsartan 160mg|
218868101|NCT01918332|DRUG|Rosuvastatin 20mg|
218868102|NCT01918332|DRUG|Valsartan 160mg placebo|
218868103|NCT01918332|DRUG|Rosuvastatin 20mg placebo|
219199845|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
219484970|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
219484971|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
219484972|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
219484973|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
219484974|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
219484975|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
219484976|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
219484977|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
219484978|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
219484979|NCT00139802|DEVICE|Coronary Stent Implantation|
219599204|NCT04335539|DRUG|Cefiderocol|Administered intravenously over 3 hours
219599205|NCT04335539|DRUG|Standard of Care|Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
219599206|NCT06488339|DIETARY_SUPPLEMENT|Protein and oil supplement|Take 1 sachet/day replaced dinner
219599207|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
219599208|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
219484980|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
219484981|NCT05641246|DRUG|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
219484982|NCT05641246|DRUG|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
219484983|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
219484984|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
218868104|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
218868105|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
218868106|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
218868107|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
218868108|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
218868109|NCT04670393|OTHER|Placebo|400 mcg folic acid
219484985|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
219484986|NCT04503031|DEVICE|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
219484987|NCT04503031|DEVICE|cylindrical endotracheal tube|endotracheal tube is intubated
219484988|NCT01935882|DRUG|Artemether-lumefantrine combination|
219484989|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
219484990|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
219484991|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
219484992|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
219599209|NCT02609438|BEHAVIORAL|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
218868110|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
218868111|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
219484993|NCT00061646|DRUG|ABT-510/Thrombospondin-1 mimetic|
218868112|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
218868113|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
218868114|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
219484994|NCT00061646|DRUG|Carboplatin/Taxol|
219484995|NCT05647200|DRUG|Treatment: additional albumin during cardiopulmonary bypass|Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
219484996|NCT05647200|DRUG|control: additional ringers during cardiopulmonary bypass|Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
219484997|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
219484998|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
219484999|NCT04807231|BIOLOGICAL|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
218868115|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
218868116|NCT04872517|DEVICE|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
218868117|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
218868118|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
219485000|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
219485001|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
219485002|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219485003|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
219599210|NCT02609438|BEHAVIORAL|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
219599211|NCT00515918|DIETARY_SUPPLEMENT|iron|
219599212|NCT03209817|DIETARY_SUPPLEMENT|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
219599213|NCT03209817|DIETARY_SUPPLEMENT|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
219599214|NCT05821335|OTHER|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
219599215|NCT05821335|OTHER|Traditional program|Hand Therapy by physiotherapist via traditional methods
219599216|NCT01402635|DEVICE|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
219599217|NCT01931878|DRUG|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
219599218|NCT01931878|DRUG|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
219599219|NCT01157988|DRUG|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
218868119|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
218868120|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
219485004|NCT00345969|DRUG|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
219485005|NCT00345969|BEHAVIORAL|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
219485006|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
219485007|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
219485008|NCT06700603|DRUG|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
219485009|NCT05121779|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
219599220|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
219599221|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
219599222|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
219599223|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
218868121|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
218868122|NCT00701805|DRUG|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
219485010|NCT05121779|DRUG|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
219485011|NCT06646991|DEVICE|Nasal canula - up to 6 liters per minute|"Oxygen will be administered via nasal cannula up to 6 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
219485012|NCT06646991|DEVICE|Nasal canula - up to 15 liters per minute|"Oxygen will be administered via nasal cannula up to 15 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
219485013|NCT06646991|DEVICE|Open oxygen mask|"Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
219485014|NCT06646991|DEVICE|Simple oxygen face mask|"Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
219485015|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
219485016|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
219485017|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
219485018|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
219485019|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
219485020|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
219485021|NCT02850783|PROCEDURE|89Zr-nanocoll and Indocyanine Green|
219485022|NCT02873195|DRUG|Atezolizumab|Given IV
219485023|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
219485024|NCT02873195|DRUG|Capecitabine|Given PO
219485025|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
219485026|NCT02873195|OTHER|Placebo|Given IV
219485027|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
219485028|NCT02174549|DRUG|Tirapazamine|Intra-arterial injection into the tumor feeding artery
219485029|NCT02174549|PROCEDURE|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
219485030|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
219599224|NCT06551818|OTHER|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
219599225|NCT06551818|OTHER|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
219599226|NCT06579235|DIAGNOSTIC_TEST|Proteomics|All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
219599227|NCT04974749|BIOLOGICAL|REPLAGAL|REPLAGAL IV infusion.
219599228|NCT04775303|DRUG|Cyclosporine 0.1% (Ikervis®) eye drop|One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
219599229|NCT01134432|DRUG|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
219599230|NCT01134432|DRUG|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
219599231|NCT05044559|OTHER|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
219485031|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
219485032|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
219485033|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
219485034|NCT02329496|DEVICE|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
219485035|NCT03935451|DRUG|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
219485036|NCT03935451|DRUG|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
218868123|NCT03865485|BEHAVIORAL|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
219485037|NCT04278872|DRUG|SJX-653|administered orally once daily
219485038|NCT04278872|DRUG|Placebo|administered orally once daily
219599232|NCT05044559|OTHER|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
219599233|NCT00052637|DRUG|hexaminolevulinate|
219599234|NCT00052637|PROCEDURE|biopsy|
219599235|NCT00052637|PROCEDURE|cystoscopy|
219599236|NCT01645787|DRUG|4-aminopyridine|10 mg/twice daily
219485039|NCT00435240|BEHAVIORAL|Paleolithic diet|
219485040|NCT05437718|OTHER|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
219485041|NCT04900415|DRUG|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
219485042|NCT04900415|DEVICE|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
219485043|NCT06658275|OTHER|Constraint-induced movement therapy|During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
219599237|NCT01645787|DRUG|Placebo|Crossover study involving one trial with sugar pill (placebo)
218868124|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
219485044|NCT06658275|OTHER|Hand Arm Bimanual Intensive Training -HABIT|For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
219599238|NCT02473198|DRUG|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
218868125|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
219599239|NCT02473198|DRUG|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
219599240|NCT02473198|DRUG|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
218868126|NCT00468988|DRUG|Travatan® Z|
218868127|NCT00468988|DRUG|Xalatan®|
218868128|NCT00877370|DRUG|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
218868129|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
219485045|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
218868130|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
218868131|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
218868132|NCT03350555|DEVICE|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
218868133|NCT01705093|DIETARY_SUPPLEMENT|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
218868134|NCT01705093|DIETARY_SUPPLEMENT|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
218868135|NCT02252965|DRUG|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
219485046|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
219485047|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
219485048|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
219485049|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
219485050|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
219485051|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
219485052|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
219485053|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
219485054|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
219485055|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
219485056|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
219485057|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
219485058|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
219485059|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
219485060|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
219485061|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
218868136|NCT02252965|DRUG|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
218868137|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
218868138|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
219485062|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
219485063|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
218868139|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
218868140|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
219485064|NCT00608075|DRUG|Lithium|600 - 1800 mg
219599241|NCT02473198|DRUG|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
219599242|NCT04637802|BEHAVIORAL|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
219599243|NCT04637802|BEHAVIORAL|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
218868141|NCT00867555|DIETARY_SUPPLEMENT|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
218868142|NCT04228601|DRUG|Fluzoparib|PARP
218868143|NCT04228601|DRUG|Fluzoparib placebo|Placebo
218868144|NCT04228601|DRUG|mFOLFIRINOX|mFOLFIRINOX
219485065|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
219599244|NCT01493921|DRUG|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
218868145|NCT00633828|BEHAVIORAL|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
219485066|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
219485067|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
219485068|NCT01701180|DRUG|Placebo|
219485069|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
219485070|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
219485071|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
219485072|NCT02392377|DRUG|Oxaliplatin|Given IV
219485073|NCT02392377|DRUG|Leucovorin Calcium|Given IV
219485074|NCT02392377|DRUG|Fluorouracil|Given IV
219485075|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
219485076|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
219485077|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
219485078|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
219485079|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
218868146|NCT05433597|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
219485080|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
219485081|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
219485082|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
219485083|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
219485084|NCT00985127|DRUG|placebo|administered daily for 21 days
219485085|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
219485086|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
219485087|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
219485088|NCT00757198|DRUG|remifentanil|remifentanil infusion
219485089|NCT00757198|DRUG|remifentanil|remifentanil infusion
219485090|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
219485091|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
219485092|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
219599245|NCT01493921|DRUG|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
219599246|NCT03893019|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
219599247|NCT01545518|DRUG|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
219599248|NCT04315506|BEHAVIORAL|#EnufSnuff.TXT Intervention|The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
219599249|NCT04315506|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
219599250|NCT03545542|DIAGNOSTIC_TEST|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
219599251|NCT03545542|DIAGNOSTIC_TEST|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
219599252|NCT03545542|DIAGNOSTIC_TEST|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
218868147|NCT05433597|DRUG|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
218868148|NCT05433597|RADIATION|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
218868149|NCT05433597|DRUG|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
218868150|NCT05433597|DRUG|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
218868151|NCT06254859|PROCEDURE|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
218868152|NCT06338202|DRUG|Mavacamten|As detailed in the product label
219485093|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
219199846|NCT06663969|OTHER|Temporal Interference|Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
219485094|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
219485095|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
219485096|NCT00730067|DRUG|sildenafil|Sildenafil 50 mg three times daily
219485097|NCT00730067|DRUG|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
219485098|NCT02472431|OTHER|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
219485099|NCT02472431|PROCEDURE|Liposuction|
219485100|NCT02472431|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
219485101|NCT06167798|OTHER|biopsy|two 2 mm gingival biopsies were obtained.
219485102|NCT02242331|DRUG|Micardis®|
219485103|NCT00288782|DRUG|Mirtazapine|
219485104|NCT00003276|DRUG|irinotecan hydrochloride|
219485105|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
219485106|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
219485107|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
219485108|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
219485109|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
219485110|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
219485111|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
219485112|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
219485113|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
219485114|NCT07006129|PROCEDURE|Perineorrhaphy|Concomitant perineorrhaphy
219485115|NCT07006129|PROCEDURE|No perineorrhaphy|No concomitant perineorrhaphy
219485116|NCT06723483|PROCEDURE|Distraction Plate|This technique deals with comminuted distal radius fracture using a distraction plate. The plate was inserted by minimally invasive skin incisions, fixed from the 2end metacarpal distally to the 2end extensor compartment at intact radius proximally Spaning the comminution, Restoring the Radial Length, Radial Inclination, Volar Tilt
219485117|NCT06723600|OTHER|Information|Nurse-led family member information
219485118|NCT07042542|OTHER|Mulligan Spinal Mobilization with Arm Movement|In the neurodynamic SNAGs technique, participants sat on a chair. The therapist placed the medial border of the distal phalanx of one thumb under the facet joints of the C5, C6, and C7 levels, respectively. Then, the therapist placed the tip of the other thumb on the lateral side of the first thumb. In neurodynamic spinal mobilization combined with arm movement, the therapist provided manual contact to the affected spinous process level by supporting the medial aspect of one thumb with the index finger of the other hand. The therapist applied a transverse shift from the affected side to the unaffected side, but only in the transverse plane. While the glide was in progress, the patient was asked to perform neurodynamic movements for the median nerve, including scapular depression, shoulder abduction, elbow extension, forearm supination, and wrist and finger extension, all without crossing the pain limit for the affected side.
219485119|NCT07042542|OTHER|Conventional Neurodynamic Mobilization|A neurodynamic mobilization technique involving a specific sequence of movements along the median nerve line was applied. For the right side, the procedure was performed as follows: The individual was placed supine on a stretcher. The therapist stood on the right side of the stretcher, facing the participant, with their right leg in front of their left leg. The individual's arm rested on the therapist's right thigh, and the therapist held the individual's right hand with his left hand. During the procedure, the therapist placed one hand on the individual's shoulder to depress the shoulder girdle by pressing the scapula downward. The individual's shoulder was abducted 90° and laterally rotated, and the forearm was supinated. The wrist, thumb, and fingers were extended. In this position, the therapist dynamically alternated between simultaneous elbow flexion/wrist extension and simultaneous elbow extension/wrist flexion.
219599253|NCT03545542|DIAGNOSTIC_TEST|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
219485120|NCT07042542|BEHAVIORAL|Tendon Gliding and Hand Strengthening Exercises|Tendon glide exercises were performed in five consecutive positions. Each position was practiced for seven seconds, with three sets of five repetitions and one minute of rest between sets. Participants were asked to perform the exercises three times during the day. Hand muscle strengthening exercises were performed by placing a tire on the fingertips, abducting the fingers, and stretching the tire to strengthen the intrinsic muscles and fingers. Resistance could be increased by thickening the tire or adding a second one. Participants were given a grip strength exercise. The hand grip exercise strengthened the extrinsic muscles. Finger flexion and extension exercises strengthened the hand and finger muscles. Participants were asked to perform 10 repetitions of each exercise in each session and to perform the strengthening exercises three times during the day.
219485121|NCT07047534|DEVICE|Real-time EEG-triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulation target: left dorsolateral prefrontal cortex (DLPFC; F3 electrode position, 10-20 EEG system); Frequency: 10 Hz; Intensity: 110% of resting motor threshold (RMT); Pulse number: 2000 pulses/session (20 trains of 100 pulses, 30-second inter-train interval); EEG triggering: Stimulation pulses synchronized to the peak of the participant's ongoing θ-wave (4-7 Hz) activity. Duration: 20 sessions over 4 weeks.
219485122|NCT07047534|BEHAVIORAL|Group Therapy|Semi-closed group therapy; 10 participants/group, 2 sessions/week, 90 minutes/session for 4 weeks (total 8 sessions). Content included: Sessions 1-2: Emotional recognition and expression training; Sessions 3-4: Cognitive restructuring; Sessions 5-6: Impulse control training; Sessions 7-8: Self-esteem building and future planning.
219485123|NCT07048639|DIAGNOSTIC_TEST|4D-CT (Four-Dimensional Computed Tomography)|To assess tumor and organ motion during breathing
219485124|NCT06724120|OTHER|No interventions|No interventions
219485125|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
219485126|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
219485127|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
219599254|NCT03545542|DIAGNOSTIC_TEST|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
219599255|NCT03545542|DIAGNOSTIC_TEST|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
219599256|NCT03545542|DIAGNOSTIC_TEST|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
219599257|NCT03545542|DIAGNOSTIC_TEST|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
219599258|NCT03545542|DIAGNOSTIC_TEST|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
219485128|NCT06937281|RADIATION|SABR|Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)
219599259|NCT03196245|OTHER|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
219485129|NCT06236373|OTHER|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
219485130|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
219485131|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
219485132|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
219485133|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
219485134|NCT05171712|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
219485135|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
219485136|NCT01258452|DRUG|CHF 5074|Drug is administered to subject in a fasting state
219485137|NCT01258452|DRUG|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
219485138|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
219485139|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
219485140|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
219485141|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
219485142|NCT01462188|PROCEDURE|Immediate stenting|Primary coronary stenting
219485143|NCT01462188|PROCEDURE|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
219485144|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
219599260|NCT06550960|DEVICE|Evaluation of two biopsy systems|Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
219599261|NCT05125965|OTHER|additional time for the MRI|3 additional minutes to perform the MRI
219599262|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
219485145|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
219485146|NCT02626273|RADIATION|weight loss|
219485147|NCT03840031|OTHER|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
219599263|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
219599264|NCT00919126|DRUG|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
219599265|NCT02559180|DRUG|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
219485148|NCT03840031|OTHER|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
219485149|NCT00584831|DEVICE|senofilcon A|toric contact lens
219485150|NCT00584831|DEVICE|balafilcon A|toric contact lens
219485151|NCT00584831|DEVICE|omafilcon A|toric contact lens
219485152|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
219485153|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
219485154|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
219485155|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
219485156|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
219485157|NCT00465322|DRUG|fluvastatin|
219485158|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
219485159|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
219199847|NCT06669182|DEVICE|Intermittent Theta-Burst Transcranial Magnetic Stimulation|50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.
219485160|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
219199848|NCT06670716|OTHER|Examination by a speech therapist|MASTcz test
219485161|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
219485162|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
219485163|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
219199849|NCT06670716|DIAGNOSTIC_TEST|Cognitive examination|ALBA test, PICNIR test
219199850|NCT06670716|OTHER|Examination of delirium|CAM-ICU and ICDSC questionnaire
219199851|NCT06670716|OTHER|History taking|The first page includes several sections: personal information, pre-stroke history, time-related data, neurological deficit data, radiological evaluation, pre-admission and admission treatment, and a medical examination focused on motor and speech impairments. The third page will document the physician's delirium examination and the speech therapy assessment. A questionnaire will be given to the relatives or close persons of the patients to fill out in order to collect systematic personal and pre-stroke anamnestic data and to assess the presence of dementia signs before the stroke using the Blessed Dementia Scale (BDS) questionnaire. All pages of the record form and the Questionnaire for Relatives are included in the appendices.
219199852|NCT06669104|DEVICE|Medtronic Hugo™ surgical robotic system|undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
219199853|NCT06010836|BEHAVIORAL|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
219199854|NCT05505942|BEHAVIORAL|LPA Sessions|"A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website."
219485164|NCT02468167|DRUG|Lauromacrogol|
219485165|NCT03363724|OTHER|HaGuide version 1.0 software module|
219485166|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
219485167|NCT02163746|PROCEDURE|Surgical Deroofing|
219599266|NCT00637494|DRUG|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
219199855|NCT05505942|OTHER|Fitbit Only|Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
219199856|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
219199857|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
219199858|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
219199859|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
219199860|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
219199861|NCT06988384|OTHER|Bike fitting|Participants underwent bike fitting using the idmatch system, which utilizes three-dimensional motion capture to optimize rider position.
219485168|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
219485169|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
219485170|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
219485171|NCT05853237|DEVICE|laser therapy for wound management|comparison between laser effect on post median sternotomy incision compared to traditional wound care
219485172|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
219485173|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
219485174|NCT00359073|DRUG|montelukast|10 mg everyday
219485175|NCT00359073|DRUG|placebo|like placebo
219485176|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
219485177|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
219485178|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
219485179|NCT03907709|BEHAVIORAL|In-Home Addiction Treatment Program|"* Treatment was delivered per treatment protocol~* Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~* Urine drug screens administered randomly~* Appointments were scheduled per protocol for 52 weeks~* Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
219485180|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
218868153|NCT06293976|OTHER|Changes in the ventilator respiratory rate and tidal volume|"With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,"
218868154|NCT05294081|BEHAVIORAL|Exposure therapy|10 sessions based on an individualized pain hierarchy
219485181|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
218868155|NCT05294081|BEHAVIORAL|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
219485182|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
219485183|NCT01371006|DRUG|normal dose|efavirenz once daily
219485184|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
219485185|NCT03356366|OTHER|MRI 3T|Magnetic Resonance Imaging 3 Tesla
219485186|NCT03356366|OTHER|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
219485187|NCT03356366|OTHER|MRI 7T|Magnetic Resonance Imaging 7 Tesla
219485188|NCT03530007|DRUG|Normal saline|normal saline used for prevention of spinal shivering
219485189|NCT03530007|DRUG|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
219485190|NCT03530007|DRUG|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
219485191|NCT02973178|DEVICE|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
219485192|NCT01935557|DRUG|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
219485193|NCT01935557|DRUG|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
219485194|NCT00101140|DRUG|anti-thymocyte globulin|
218868156|NCT03599245|DRUG|Ocrelizumab|Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
218868157|NCT05819892|DRUG|Paclitaxel|Given by IV (vein)
219485195|NCT00101140|DRUG|fludarabine phosphate|
219485196|NCT00101140|DRUG|thiotepa|
218868158|NCT05819892|DRUG|Carboplatin|Given by IV (vein)
218868159|NCT05819892|DRUG|Dostarlimab|Given by IV (vein)
218868160|NCT05819892|DRUG|Cisplatin|Given by IV (vein)
218868161|NCT04969341|OTHER|Survey Administration|Complete survey
218868162|NCT04969341|OTHER|Electronic Health Record Review|Review of medical records
218868163|NCT05503225|DRUG|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
218868164|NCT06960655|BEHAVIORAL|Referral to Pharmacist-Driven Medication Management Program|Medication initiations and titrations are based on an established drug-treatment algorithm that utilizes a statutory-defined Collaborative Drug Therapy Management Agreement (CDTM) approved by the BWH Pharmacy and Therapeutic Committee to initiate and titrate lipid-lowering medications. Scenarios outside the prescribed medication algorithm are routed to the supervising physician, and changes are signed off by a pharmacist and communicated to the patient and care team by a patient navigator under the supervision of physicians. After each change in medication, re-assessment and lab monitoring are collected in an iterative process until targets are achieved. Details of the programs can be found in the references.
219199862|NCT05834673|OTHER|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
219485197|NCT00101140|PROCEDURE|biological therapy|
219485198|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
219485199|NCT00101140|PROCEDURE|chemotherapy|
219485200|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
219485201|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
219485202|NCT00101140|PROCEDURE|radiation therapy|
219485203|NCT00880867|DRUG|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
219485204|NCT03642886|BEHAVIORAL|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
219485205|NCT05784363|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
219485206|NCT05784363|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
219485207|NCT01317069|DRUG|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
219485208|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
219485209|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
219599267|NCT00637494|DRUG|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
219485210|NCT04444362|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
219485211|NCT06063291|DRUG|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
218868165|NCT06960655|BEHAVIORAL|Best-Practice Alert|This strategy will employ automated, asynchronous, best-practice alerts (BPAs). Provider notifications via electronic health records (EHRs) are clinical tools designed to improve adherence to evidence-based guidelines by providing real-time alerts that have been widely implemented across healthcare systems to enhance patient safety, reduce clinical inertia, and standardize care delivery. However, their effectiveness depends on factors such as alert fatigue, provider engagement, and integration into existing workflows. BPAs are one of the most common types of automated EHR-based provider notifications.
218868166|NCT05766839|DRUG|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
218868167|NCT03790631|OTHER|The study is observational.|The study is observational.
218868168|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
218868169|NCT05816395|DRUG|RHH646|RHH646 capsule for oral use
218868170|NCT05816395|DRUG|Placebo|RHH646 placebo capsule for oral use
218868171|NCT06578234|DRUG|Adenosine|Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
218868172|NCT03995706|DRUG|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
218868173|NCT06004336|DRUG|Pembrolizumab|Given by vein (IV)
218868174|NCT06004336|RADIATION|Radiation therapy|Given by vein (IV)
218868175|NCT02740361|BEHAVIORAL|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
218868176|NCT03748459|OTHER|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
218868177|NCT03748459|OTHER|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
218868178|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
218868179|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
218868180|NCT01785823|OTHER|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
218868181|NCT01785823|OTHER|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
219599268|NCT04291625|PROCEDURE|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
219599269|NCT02904863|BIOLOGICAL|Extra blood draw samples|
218868182|NCT01785823|OTHER|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
218868183|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
218868184|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
218868185|NCT06030284|DEVICE|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
219485212|NCT06063291|DRUG|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
219485213|NCT02682173|OTHER|MR Abdomen|
219485214|NCT05088382|DEVICE|LH Urine Test|Test for the qualitative measurement of LH in urine
218868186|NCT06030284|DEVICE|BurstDR-SCS|BurstDR-SCS system turned off.
218868187|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
219485215|NCT00897039|OTHER|flow cytometry|
219599270|NCT03539263|DIETARY_SUPPLEMENT|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum"
218868188|NCT03239015|DRUG|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
218868189|NCT03239015|DRUG|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
218868190|NCT03239015|DRUG|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
218868191|NCT03239015|DRUG|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
218868192|NCT03239015|DRUG|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
218868193|NCT03239015|DRUG|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
219599271|NCT03539263|OTHER|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
219599272|NCT01485822|PROCEDURE|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
219599273|NCT01485822|DRUG|Travoprost 0.004% ophthalmic solution|
218868194|NCT03239015|DRUG|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
218868195|NCT03239015|DRUG|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
218868196|NCT03239015|DRUG|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
218868197|NCT03239015|DRUG|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
218868198|NCT03239015|DRUG|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
218868199|NCT03239015|DRUG|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
218868200|NCT04773236|DRUG|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
218868201|NCT04773236|DRUG|2%lidocaine with 1:80.000 epinphrine|injection
218868202|NCT04773236|DEVICE|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
219199863|NCT05834673|OTHER|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
219199864|NCT05834673|OTHER|GP Education|Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy
218868203|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
218868204|NCT00820404|DRUG|BLI-489|
218868205|NCT00820404|DRUG|Placebo|
218868206|NCT03133221|DRUG|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
218868207|NCT02797184|DRUG|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
218868208|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
218868209|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
218868210|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
218868211|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
218868212|NCT04121286|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
219199865|NCT06984367|OTHER|socio-technical intervention|A daily cognitive stimulation at home with specific software (Brainer) and 1 group session per week. Furthermore, each participant will receive the NAO robot at home.
219485216|NCT00897039|OTHER|immunohistochemistry staining method|
219485217|NCT05681104|DIAGNOSTIC_TEST|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
219485218|NCT05681104|DIAGNOSTIC_TEST|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
219485219|NCT05681104|DIAGNOSTIC_TEST|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
219599274|NCT06432855|OTHER|Blood collection|20 ml-blood sample
219599275|NCT06432855|OTHER|saliva collection|saliva sample
219599276|NCT00237523|DRUG|IoGen (molecular iodine)|
219599277|NCT05088135|DEVICE|Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
219485220|NCT03586986|DIAGNOSTIC_TEST|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
219485221|NCT00178763|DEVICE|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
219485222|NCT00178763|OTHER|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
219485223|NCT00178763|OTHER|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
219485224|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
219485225|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
219485226|NCT05005000|BIOLOGICAL|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
219599278|NCT05088135|DEVICE|Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
219599279|NCT05088135|DEVICE|Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
219599280|NCT00150956|PROCEDURE|Daily home hemodialysis|
219599281|NCT00852007|BIOLOGICAL|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
219599282|NCT03035578|DRUG|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
218868213|NCT04642053|BEHAVIORAL|Dynamic Temporal and Tactile Cuing|Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
218868214|NCT01878344|DRUG|NAC|
219599283|NCT03035578|DRUG|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
219599284|NCT00958893|DRUG|25 mg Proellex|one 25 mg capsules
219599285|NCT02032680|BEHAVIORAL|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
219599286|NCT02032680|BEHAVIORAL|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
218868215|NCT01878344|DRUG|Saline|
219485227|NCT05005000|DRUG|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
219599287|NCT02032680|OTHER|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
219599288|NCT03594760|DIAGNOSTIC_TEST|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
219599289|NCT03619265|DIETARY_SUPPLEMENT|Prickly pear juice|3 ounces daily for 8 weeks.
219599290|NCT03619265|DIETARY_SUPPLEMENT|Pear-flavored juice|3 ounces daily for 8 weeks.
219599291|NCT02404116|OTHER|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
219599292|NCT02404116|OTHER|Wait List|Individuals are on a waiting list
219599293|NCT03086486|DRUG|Pretomanid|200mg tablets
219599294|NCT03086486|DRUG|Linezolid|Scored 600mg tablets
219599295|NCT03086486|DRUG|Bedaquiline|100mg tablets
219599296|NCT03086486|DRUG|Placebo Linezolid|Scored 600 mg tablets
219599297|NCT02207712|DEVICE|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
219599298|NCT02207712|DRUG|Ranibizumab|Standard ranibizumab treatment only
219485228|NCT05660837|BEHAVIORAL|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session"
219485229|NCT05660837|BEHAVIORAL|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp"
219485230|NCT03121560|DEVICE|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
219485231|NCT03121560|DEVICE|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
219485232|NCT03955718|BEHAVIORAL|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
219485233|NCT03955718|BEHAVIORAL|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
219485234|NCT00034359|DRUG|ACH-126,443|
219485235|NCT00034359|DRUG|Lamivudine|
219485236|NCT00034359|DRUG|Placebo|
219485237|NCT03509688|DRUG|entecavir+resveratrol|entecavir+resveratrol
219485238|NCT03509688|DRUG|Entecavir|Entecavir
219485239|NCT03509688|DRUG|entecavir+thymosin α1|entecavir+thymosin α1
219485240|NCT00830271|DEVICE|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
219485241|NCT00830271|DEVICE|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
219599299|NCT04736225|OTHER|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
219599300|NCT03593395|OTHER|Peer Mentoring [PM]|Virtual Peer Mentoring
219599301|NCT03593395|OTHER|Structured Education Based Transition Program STE|Education-based program
219599302|NCT05501535|DEVICE|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
219599303|NCT04957238|OTHER|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
219599304|NCT04979936|PROCEDURE|laparoscopic cholecystectomy|
219599305|NCT04979936|PROCEDURE|percutaneous cholecystostomy|
219599306|NCT01059578|DRUG|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
219599307|NCT01059578|DRUG|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
218868216|NCT05149313|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
218868217|NCT05149313|DRUG|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
219599308|NCT01059578|RADIATION|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
219599309|NCT03802071|DRUG|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
219485242|NCT00583128|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
219485243|NCT00583128|DRUG|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
219485244|NCT05231161|DIAGNOSTIC_TEST|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
219485245|NCT06583148|OTHER|Best Practice|Receive usual care
219485246|NCT06583148|BEHAVIORAL|Smoking Cessation Intervention|Receive the smoke-free home program
219485247|NCT06583148|OTHER|Survey Administration|Ancillary studies
219485248|NCT00915473|DRUG|bupivicaine|2.5 mL 0.5% bupivicaine
219485249|NCT00915473|DRUG|normal saline|2.75 mL normal saline
219485250|NCT00915473|DRUG|methylprednisolone|0.5 mL 20 mg methylprednisolone
219485251|NCT00915473|DRUG|lidocaine|0.25 mL 1% lidocaine
219485252|NCT00242450|DRUG|Metoclopramide|
218868218|NCT04831424|BEHAVIORAL|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
218868219|NCT05800275|DRUG|Tucatinib Oral Tablet|300 mg, twice daily
218868220|NCT05800275|DRUG|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
219599310|NCT03959111|OTHER|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
219599311|NCT03959111|OTHER|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
218868221|NCT05800275|DRUG|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
218868222|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
218868223|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
218868224|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
218868225|NCT03095820|BEHAVIORAL|Supportive therapy|
218868226|NCT03095820|BEHAVIORAL|Multidomain intervention|
218868227|NCT01731067|DRUG|Cocktail probe drugs|
218868228|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
218868229|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
218868230|NCT02248402|BIOLOGICAL|Vax-DC/MM|
219199866|NCT06984367|OTHER|Usual care|The subjects will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises, as they would do outside the framework of the experiment. In any case, they will be free to read and do the proposed exercises.
219485253|NCT06200688|OTHER|PEANUT BALL|"Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring."
219485254|NCT03515837|BIOLOGICAL|pembrolizumab|IV infusion
219485255|NCT03515837|DRUG|pemetrexed|IV infusion
219485256|NCT03515837|DRUG|carboplatin|IV infusion
219485257|NCT03515837|DRUG|cisplatin|IV infusion
219485258|NCT03515837|DRUG|saline solution|IV infusion
219485259|NCT00665509|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
219485260|NCT02319954|PROCEDURE|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
219485261|NCT01964898|BEHAVIORAL|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
219485262|NCT01964898|BEHAVIORAL|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
219485263|NCT01964898|DRUG|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
219485264|NCT01964898|OTHER|Printed Self-help materials for Smoking Cessation|
219485265|NCT00276965|DRUG|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
219485266|NCT00276965|DRUG|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
219485267|NCT06540573|DIAGNOSTIC_TEST|Laboratory tests (examination)|Laboratory tests (examination) to be performed include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function tests and kidney function tests; rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and C-C Motif Chemokine Ligand 21 (CCL21).
219485268|NCT06540573|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) This questionnaire is used to assess the health status of osteoarthritis patients introduced in 1988 (13). It is consisted of 33 items which evaluates the health and function of the patient from various aspects including: clinical symptoms (5 questions), severity of joint stiffness (2 questions), degree of pain (9 questions), and activity of daily living (17 questions).The test questions are scored on a scale of 0-4, which correspond to: None(0),Mild (1),Moderate (2),Severe(3),and Extreme (4).The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores.Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
219485269|NCT06540573|DIAGNOSTIC_TEST|The Disease Activity Score28 (DAS28)|The Disease Activity Score (DAS) was created as a numerical tool for quantifying and assessing disease activity in rheumatoid arthritis (RA).The DAS28 (Disease Activity Score using 28 joint counts) was developed from the original DAS (Disease Activity Score).The DAS28 evaluates the disease activity by assessing the number of tender and swollen joints in a patient. Specifically, it considers 28 joints. The DAS28 also takes into account a blood marker of inflammation, typically the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level.A patient with a DAS28 score of less than 2.6 is in remission; a score greater than or equal to 2.6 and less than 3.1 indicates low activity; a score greater than or equal to 3.1 and \<5.1 indicates moderate activity and a score 5.1 or more indicates high activity
218868231|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
219485270|NCT06540573|DIAGNOSTIC_TEST|Patient global assessment (PGA)|Patient global assessment (PGA) of disease activity will be reported by patients. PGA was developed in the late 1970s and was initially designed for the measurement of self-assessed pain in RA \[8\], although it has since been used to evaluate RA more globally. It is interesting to note that the way PGA is used in clinical practice covers, in fact, two very different concepts, one related to global health and the other to overall disease activity. They are both usually used under the heading of PGA without further specification for which is being assessed.
218868232|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
218868233|NCT02923076|OTHER|CCR5 delta32/delta32 cord blood transplantation|
218868234|NCT01867086|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
218868235|NCT01867086|DRUG|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
218868236|NCT01867086|DRUG|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
218868237|NCT06584253|OTHER|Musculoskeletal System Health Questionnaire Scale|It is a 14-item scale that evaluates pain intensity, physical function, sleep, fatigue, emotional state, physical activity level, impact on work and social life, independence, self-management ability and general impact.
218868238|NCT06584253|OTHER|International Physical Activity Questionnaire (short form)|"International Physical Activity Questionnaire (short form) -~The IPAQ assesses a range of physical activities, including leisure-time physical activities, indoor and outdoor activities, work-related physical activities, and transportation-related physical activities."
218868239|NCT06584253|OTHER|Pittsburgh Sleep Quality Index|It is a questionnaire that evaluates sleep quality with questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, use of sleep aids and daytime functions.
218868240|NCT06584253|OTHER|Cognitive Failures Questionnaire|The questionnaire aims to measure daily cognitive errors. It assesses simple errors made over the last 6 weeks, as well as perception (e.g., are there times when you can't see something you need at the supermarket even though it's there?), memory (e.g., have you ever forgotten people's names?) and motor functioning (e.g., have you ever bumped into anyone?).
218868241|NCT06584253|OTHER|Jamar hand dynamometer|Jamar hand dynamometer - students will perform grip strength assessments with their dominant hand while seated. As recommended by the American Association of Hand Therapists protocol, students will sit in a comfortable chair with their shoulders neutrally rotated and adducted, elbow flexed to 90°, and wrist and forearm in neutral positions.
219485271|NCT06540573|DIAGNOSTIC_TEST|Physician global assessment (PhGA)|Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
219599312|NCT01524978|DRUG|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
219599313|NCT01524978|DRUG|vemurafenib|Escalating doses given orally twice a day starting on Day 2
219599314|NCT01524978|DRUG|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
219599315|NCT03536611|DRUG|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
219599316|NCT03536611|DRUG|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
218868242|NCT06584253|OTHER|Depression Anxiety Stress Scale - 21 Short Form|DASÖ-21 consists of 3 subcategories (depression, anxiety and stress). Each category consists of 7 separate questions and a total of 21 questions.
218868243|NCT06584253|OTHER|Body Awareness Questionnaire|The questionnaire aims to determine the level of body composition sensitivity.
218868244|NCT06584253|OTHER|SF-12|This questionnaire consists of two general components related to physical and mental function, consisting of 12 questions and 8 scales measuring physical function (2 questions), bodily pain (1 question), role limitations due to physical problems (2 questions), general health (1 question) vitality (40).
218868245|NCT01786395|DRUG|UF-021|
218868246|NCT01786395|DRUG|Placebo|
218868247|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
218868248|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
219485272|NCT06540573|DIAGNOSTIC_TEST|Health Assessment Questionnaire (HAQ)|Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
219485273|NCT06540573|DIAGNOSTIC_TEST|Clinical disease activity index (CDAI)|Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76
219485274|NCT06540573|DIAGNOSTIC_TEST|The Simplified Disease Activity Index (SDAI)|The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as \>26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17
219485275|NCT06540573|DIAGNOSTIC_TEST|Knee Radiography|Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity
219485276|NCT05883020|OTHER|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
219485277|NCT05883020|OTHER|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
219485278|NCT01609127|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
219485279|NCT01609127|DRUG|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
219485280|NCT01609127|DRUG|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
218868249|NCT05314933|OTHER|Placebo|Intranasal administration
218868250|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
218868251|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
218868252|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
218868253|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
218868254|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
218868255|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
218868256|NCT01012921|DEVICE|MembraGel|Device application at surgery
218868257|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
218868258|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
218868259|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
218868260|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
218868261|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
218868262|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
218868263|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
219485281|NCT00429091|DRUG|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
219485282|NCT00429091|DRUG|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
219485283|NCT00429091|DRUG|placebo|Subjects will take BID for up to four weeks
218868264|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
218868265|NCT00958932|BEHAVIORAL|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
218868266|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
218868267|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
218868268|NCT00875342|DRUG|DCS|1\. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
219485284|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
219485285|NCT01444469|DRUG|Placebo|Lactose powder
219485286|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
219485287|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
219485288|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
219599317|NCT04808973|DRUG|Dolutegravir plus lamivudine in a FDC|All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
219599318|NCT05344131|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
219599319|NCT00687830|DRUG|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
219485289|NCT04309760|OTHER|MRI|Subjects will receive structural and functional (resting state) MRI
219485290|NCT06318091|BIOLOGICAL|platelet poor plasma gel|injection of platelet poor plasma gel in the dark circles around the eye to rejuvenate and improve pigmentation
219485291|NCT06318091|BIOLOGICAL|nanofat|injection of nanofat in the dark circles around the eye to rejuvenate and improve pigmentation
219599320|NCT00687830|DRUG|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
219599321|NCT03146104|DRUG|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
219599322|NCT03146104|DRUG|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
219485292|NCT04881331|OTHER|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
219485293|NCT02703974|BEHAVIORAL|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
219485294|NCT02703974|BEHAVIORAL|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
219485295|NCT02703974|BEHAVIORAL|Nudge|"A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
219599323|NCT00426101|DRUG|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
218868269|NCT00875342|OTHER|Placebo|2\. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
218868270|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
218868271|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
218868272|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
218868273|NCT05194527|OTHER|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
219485296|NCT02703974|BEHAVIORAL|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
219485297|NCT01281631|DRUG|NP001|Low dose of NP001
219485298|NCT01281631|DRUG|NP001|High dose of NP001
219485299|NCT01281631|DRUG|Placebo|normal saline
219485300|NCT04245930|PROCEDURE|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
219485301|NCT04245930|PROCEDURE|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
219485302|NCT00413465|DRUG|Escherichia Coli Endotoxin|
219485303|NCT02056431|BEHAVIORAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
219485304|NCT05496101|PROCEDURE|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
219485305|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
219485306|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
219485307|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
219485308|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
219485309|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
219485310|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
219485311|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
219485312|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
219485313|NCT03526679|DRUG|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
219485314|NCT03526679|DRUG|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
219485315|NCT01738490|DEVICE|Bone anchored hearing implant|
219599324|NCT00426101|DRUG|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
219599325|NCT00426101|DRUG|Cyclosporin|"WK 1-8:~\- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~\- Aim for around 200 microgram/L. Monitor GFR."
218868274|NCT01878994|BEHAVIORAL|Counselling group|
218868275|NCT01878994|BEHAVIORAL|Nereu group|
219485316|NCT06675695|DRUG|New use of osimertinib|New use of osimertinib described in electronic health records is used as the exposure.
218868276|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
218868277|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
219485317|NCT06675695|DRUG|New use of erlotinib or gefitinib|"New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference."
219485318|NCT01072318|DRUG|Letrozole|Letrozole 2.5mg
219485319|NCT03944538|BEHAVIORAL|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
219599326|NCT00426101|PROCEDURE|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg."
219599327|NCT00426101|PROCEDURE|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
219599328|NCT05858112|DIAGNOSTIC_TEST|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
219599329|NCT02447601|DRUG|PEX168|200µg,injected subcutaneously,once a week.
219599330|NCT02447601|DRUG|Simvastatin|40mg,oral,two times
219199867|NCT06612047|PROCEDURE|Prostate biopsy|All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
219485320|NCT03944538|BEHAVIORAL|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
219485321|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
219485322|NCT05831787|OTHER|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
219599331|NCT03349346|DRUG|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
219485323|NCT03257137|OTHER|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
219599332|NCT03349346|DRUG|Rituximab|375 mg/m\^2 administered intravenously
219599333|NCT03349346|DRUG|Ifosfamide|3 mg/m\^2 administered intravenously
219599334|NCT03349346|DRUG|Carboplatin|635 mg/m\^2 administered intravenously
219599335|NCT03349346|DRUG|Etoposide|100 mg/m\^2 administered intravenously
218868278|NCT06915376|DEVICE|CPES Monitoring|Noninvasive blood pressure data will be collected using a combined pulse oximeter and ECG signal system (CPES) during elective non-cardiac surgery under general anesthesia. This system is used for observational purposes and does not alter the standard of care. The goal is to compare CPES-derived blood pressure values with invasive arterial blood pressure measurements.
218868279|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
218868280|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
218868281|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
218868282|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
218868283|NCT00110461|DRUG|placebo|Placebo tablet
218868284|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
218868285|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
219485324|NCT05764837|OTHER|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
219485325|NCT06202807|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219485326|NCT06202807|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219485327|NCT06202807|BEHAVIORAL|comprehensive rehabilitation therapy|"Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219485328|NCT00310700|BIOLOGICAL|Meningococcal C conjugate vaccine|
219485329|NCT02855788|DRUG|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
219485330|NCT00418509|DRUG|Mometasone furoate|
219485331|NCT00418509|DRUG|Formoterol fumarate|
219485332|NCT05789511|DEVICE|High Resolution Electrogastography|a new generation 64- channel high-resolution electrogastrography recording technology by Alimetry Limited that is able to record and analyze body surface gastric mapping/ HR-EGG
219599336|NCT05383755|BEHAVIORAL|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
219599337|NCT01427530|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
219599338|NCT04812522|BEHAVIORAL|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
219599339|NCT03252730|OTHER|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
218868286|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
218868287|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
218868288|NCT02616393|DRUG|Tesevatinib|
218868289|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
218868290|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
218868291|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
218868292|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
219485333|NCT05831267|OTHER|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
219485334|NCT05831267|OTHER|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
219485335|NCT05831267|OTHER|Negative control|this group will not receive any material.
219485336|NCT03208218|DRUG|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
219485337|NCT03208218|DRUG|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
219485338|NCT03443973|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
219485339|NCT03443973|DRUG|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
219485340|NCT03282617|BIOLOGICAL|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
219485341|NCT05388136|PROCEDURE|Conventional follow up schedule with imaging|Frequent of follow up visit and imaging
219485342|NCT05388136|PROCEDURE|Deintensified follow up schedule without imaging|Less intense follow up visit without imaging
219485343|NCT01585064|OTHER|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
219485344|NCT01585064|OTHER|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
219485345|NCT01585064|OTHER|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
219485346|NCT00264082|DRUG|Zometa(drug)|
219599340|NCT02888730|DRUG|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
219599341|NCT02888730|DRUG|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
219599342|NCT00687024|PROCEDURE|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
219599343|NCT00687024|PROCEDURE|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
219599344|NCT00687024|PROCEDURE|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
218868293|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
218868294|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
218868295|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
218868296|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
218868297|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
218868298|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
218868299|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
218868300|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
218868301|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
219485347|NCT06701695|PROCEDURE|Periarticular Injection (PAI)|Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
219485348|NCT06701695|PROCEDURE|Control (Standard treatment)|The control group received the conventional treatment protocol.
219485349|NCT00189696|DRUG|YM060|
219485350|NCT01386619|BIOLOGICAL|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
219485351|NCT02268019|PROCEDURE|tourniquet application|
219485352|NCT02268019|DRUG|epinephrine injection|
218868302|NCT02314364|RADIATION|SBRT with protons or photons|
218868303|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
218868304|NCT01041443|DRUG|tetrahydrouridine|Given IV
218868305|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
218868306|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
218868307|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
218868308|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
218868309|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
219199868|NCT04524689|DRUG|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
219485353|NCT00704717|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
219485354|NCT00704717|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
219485355|NCT01245595|DRUG|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
219485356|NCT01245595|DRUG|Placebo|Normal Saline
219485357|NCT01476345|DRUG|LY2963016|Administered subcutaneously
219485358|NCT01476345|DRUG|Lantus|Administered subcutaneously
219485359|NCT02209454|DRUG|Enantyum® oral solution|One dose of 25 mg DKP oral solution
219485360|NCT02209454|DRUG|Keral® tablet|One dose of 25 mg DKP tablet
219485361|NCT01945554|PROCEDURE|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
218868310|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
218868311|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
218868312|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
219199869|NCT04524689|DRUG|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
219485362|NCT01945554|PROCEDURE|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
219485363|NCT01945554|DRUG|Mephamesone|
219485364|NCT01945554|DRUG|0.5% bupivacaine (Bupivacain®)|
219485365|NCT01945554|DRUG|Kenacort®|
219485366|NCT00207974|DRUG|Marine active|
219599345|NCT04944524|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
219485367|NCT02139085|DEVICE|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
219485368|NCT02139085|DEVICE|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
219599346|NCT04944524|DRUG|Methotrexate|"1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
218868313|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
218868314|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
219485369|NCT03403920|OTHER|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
218868315|NCT02916147|DRUG|Sevoflurane|
219199870|NCT04524689|DRUG|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
219485370|NCT01520766|DEVICE|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
219199871|NCT04524689|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
219199872|NCT04524689|DRUG|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
219199873|NCT05868577|DRUG|Corticosteroid injection (CSI) with local anesthetic (LA)|The PI will then administer the injection using an infracalcaneal needle peppering
219199874|NCT05868577|DRUG|Local anesthetic (LA) with Saline injection|The PI will then administer the injection using an infracalcaneal needle peppering
219485371|NCT01520766|DEVICE|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
219485372|NCT05644938|PROCEDURE|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
219485373|NCT05644938|PROCEDURE|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
219485374|NCT04906473|DRUG|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
219485375|NCT03151967|DRUG|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
219485376|NCT03151967|DRUG|Placebo|vaginal applicator with medium containing no drug
219485377|NCT00197184|BIOLOGICAL|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
219485378|NCT00197184|BIOLOGICAL|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
219599347|NCT03697824|DRUG|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
219599348|NCT03697824|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
219599349|NCT03697824|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
219599350|NCT03697824|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
218868316|NCT02916147|DRUG|Propofol|
218868317|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
219485379|NCT05200507|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
218868318|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
218868319|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
218868320|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
219485380|NCT00366678|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
219485381|NCT00366678|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
219485382|NCT00366678|DRUG|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
219485383|NCT04292171|DRUG|Gabapentin|Preoperative treatment with Gabapentin
219485384|NCT04292171|DRUG|Placebos|Preoperative treatment with Placebo
219485385|NCT00317083|PROCEDURE|Cough reflex test|
219485386|NCT04296461|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
219199875|NCT05943821|DRUG|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
218868321|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
219485387|NCT04622488|DRUG|Diclofenac Potassium|\- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
219485388|NCT02337426|DRUG|Dimethyl Fumarate|Given PO
219485389|NCT02337426|DRUG|Temozolomide|Given PO
219485390|NCT02337426|RADIATION|Radiation Therapy|Undergo radiation therapy
219485391|NCT01308073|DEVICE|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
219485392|NCT04720573|DRUG|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
219485393|NCT04720573|DRUG|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
219485394|NCT01658982|OTHER|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
219485395|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
219485396|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
218868322|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
219485397|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
219485398|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
219485399|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
219485400|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
219485401|NCT01777191|DRUG|Ixekizumab Auto-Injector|Administered SC by auto-injector
219485402|NCT01777191|DRUG|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
218868323|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
218868324|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
218868325|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
218868326|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
218868327|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
218868328|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
218868329|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
218868330|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
218868331|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
218868332|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
218868333|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
218868334|NCT00997399|DRUG|panobinostat (LBH589)|
218868335|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
218868336|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
218868337|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
218868338|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
218868339|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
218868340|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
218868341|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
218868342|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
218868343|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
219485403|NCT04946474|DRUG|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
219485404|NCT00591526|DRUG|Arac|Ommit ARAC in the chemotherapy
219485405|NCT04350073|DEVICE|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
219485406|NCT04350073|DEVICE|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
219599351|NCT04631536|DRUG|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
219599352|NCT04631536|DRUG|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
219599353|NCT02501018|BIOLOGICAL|CLBS12|Intramuscular transfusion of CLBS12.
219485407|NCT04350073|DEVICE|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
219599354|NCT02501018|DRUG|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
219599355|NCT02813941|OTHER|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
219599356|NCT02813941|OTHER|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
219599357|NCT02813941|OTHER|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
219599358|NCT01749202|DIETARY_SUPPLEMENT|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
219599359|NCT01749202|DIETARY_SUPPLEMENT|EPA softgels|3 x 500 mg softgel capsules/day
219599360|NCT01749202|OTHER|Sunflower Oil Food|3 servings/day
219599361|NCT01749202|OTHER|SDA soybean Oil Food|3 servings/day
218868344|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
218868345|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
218868346|NCT00493519|PROCEDURE|chocolate cake|
218868347|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
218868348|NCT02152514|DEVICE|PCA|
218868349|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
218868350|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
219485408|NCT00696631|DRUG|Dronedarone (SR33589)|oral administration
219485409|NCT00696631|DRUG|Placebo|oral administration
219485410|NCT01581073|DRUG|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
219599362|NCT01065402|DIETARY_SUPPLEMENT|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
218868351|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
218868352|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
218868353|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
218868354|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
219485411|NCT03165331|OTHER|Ung Face IT|Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
219485412|NCT04829422|DRUG|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
219485413|NCT06410573|BEHAVIORAL|Breast Self-Examination and Practice|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
219485414|NCT01932801|DRUG|XR-NTX|
219485415|NCT01932801|OTHER|Placebo|
219485416|NCT01932801|BEHAVIORAL|HRC|
219485417|NCT00174486|DRUG|UK0369,003|
219485418|NCT00174486|DRUG|Cialis (Tadalafil)|
219485419|NCT04465916|DRUG|EYP001a|Oral tablets
219485420|NCT04465916|DRUG|Placebo|Oral tablets
218868355|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
219485421|NCT04465916|DRUG|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
219485422|NCT02015286|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
219485423|NCT00732784|DRUG|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
219485424|NCT00732784|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
219485425|NCT04711512|BEHAVIORAL|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
219599363|NCT01065402|DIETARY_SUPPLEMENT|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
219599364|NCT02234102|DEVICE|Endoscopically guided laser ablation HeartLight system|
219599365|NCT04931121|DRUG|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
219599366|NCT01181570|DRUG|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
219599367|NCT01181570|DRUG|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
219599368|NCT02352870|BEHAVIORAL|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
218868356|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
219485426|NCT04711512|BEHAVIORAL|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
219485427|NCT00334269|BEHAVIORAL|Health messaging at weekly home visits by health counsellor|
219485428|NCT00334269|BEHAVIORAL|Weekly home delivery of bottled spring water|
219485429|NCT00334269|BEHAVIORAL|Weekly afterschool physical activity program for 5-18y.o.|
219599369|NCT02352870|BEHAVIORAL|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
219599370|NCT02708771|DRUG|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
219599371|NCT02708771|DRUG|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
219599372|NCT03305367|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
219599373|NCT04649944|DIAGNOSTIC_TEST|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
219599374|NCT02165735|BEHAVIORAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
218868357|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
218868358|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
219204457|NCT06728761|BEHAVIORAL|Standardised test meal|"Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant."
219485430|NCT00334269|BEHAVIORAL|Cooking classes and grocery store tours with dietician|
218868359|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
218868360|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
219485431|NCT00334269|BEHAVIORAL|Pedometers to track/increase weekly physical activity|
219485432|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
219485433|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
219485434|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy SHAM|"Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application."
219599375|NCT02165735|OTHER|Usual care|Usual HIV care
219599376|NCT03066258|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
219599377|NCT03892018|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
219599378|NCT02784795|DRUG|LY3039478|Administered orally
219599379|NCT02784795|DRUG|Taladegib|Administered orally
218868361|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
218868362|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
218868363|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
218868364|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
218868365|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
218868366|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
218868367|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
218868368|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
218868369|NCT00148447|DRUG|escitalopram|
219599380|NCT02784795|DRUG|Abemaciclib|Administered orally
219599381|NCT02784795|DRUG|Cisplatin|Administered IV
218868370|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
218868371|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
219599382|NCT02784795|DRUG|Gemcitabine|Administered IV
219599383|NCT02784795|DRUG|Carboplatin|Administered IV
219599384|NCT02784795|DRUG|LY3023414|Administered orally
218868372|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
218868373|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
218868374|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
219599385|NCT04189601|DIAGNOSTIC_TEST|Complement measurements|Blood and urine tests to assess the complement activation state
219599386|NCT04947917|PROCEDURE|SpotTM Tattoo Ink|Ink injection
218868375|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
219599387|NCT06124417|DRUG|Sertraline|The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
219599388|NCT02995863|DEVICE|Rigid Rocker Sole Footwear|
218868376|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
218868377|NCT04519060|DEVICE|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
218868378|NCT00034879|DRUG|ZD1839 (Gefitinib)|
218868379|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
218868380|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
219599389|NCT02995863|DEVICE|Therapeutic Footwear|
219599390|NCT04197778|DRUG|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
219599391|NCT05467787|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
219599392|NCT05467787|BEHAVIORAL|Video-chat Psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
218868381|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
218868382|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
218868383|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
218868384|NCT06491290|OTHER|No intervention administered|NA (not applicable)
218868385|NCT01889134|DRUG|Sedron (alendronate)|
218868386|NCT01889134|PROCEDURE|Parathyroidectomy|
218868387|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
218868388|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
219204458|NCT06728761|BEHAVIORAL|Ingestion of test drink|Ingestion of 2,5 cl Calvados 40° at the 70th min of the meal (before cheese and dessert)
219204459|NCT06728761|BEHAVIORAL|Ingestion of Control drink|Ingestion of 2,5 cl water at the 70th min of the meal (before cheese and dessert)
219204460|NCT06728761|DIAGNOSTIC_TEST|Ultrasound measurement of the antral area|Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
219485435|NCT03025659|OTHER|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
219485436|NCT06533891|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
219485437|NCT06533891|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
219485438|NCT06533891|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
219485439|NCT01776619|DRUG|PF-06305591|14 day repeated 20mg BID doses
219485440|NCT01776619|DRUG|Placebo|14 day repeated BID doses
219485441|NCT01776619|DRUG|PF-06305591|14 day repeated 80mg BID doses
219485442|NCT01776619|DRUG|Placebo|14 day repeated BID doses
219485443|NCT01776619|DRUG|PF-06305591|14 day repeated 40mg BID doses
219485444|NCT01776619|DRUG|Placebo|14 day repeated BID doses
219485445|NCT01776619|DRUG|PF-06305591|14 day repeated BID doses
219485446|NCT01776619|DRUG|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
219485447|NCT06292910|DIAGNOSTIC_TEST|arterial and central venous blood gas analysis, lactate|blood gas analysis
219485448|NCT02814669|DRUG|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
219485449|NCT02814669|DRUG|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
219485450|NCT02897453|DEVICE|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
219485451|NCT03300232|BEHAVIORAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
219485452|NCT01823237|DEVICE|Transcranial Magnetic Stimulation|
219485453|NCT04591600|DRUG|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
219485454|NCT04591600|DRUG|Standard of care|"Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
219485455|NCT05697107|DRUG|Ripretinib Oral Tablet|Oral kinase inhibitor
219485456|NCT00315328|DRUG|Atropine|Atropine 1% each weekend day in the sound eye
219485457|NCT00315328|DEVICE|Patching|Patching 2 hours per day
219485458|NCT00315328|PROCEDURE|Near activities|near visual activities for at least one hour per day
219485459|NCT00753909|DRUG|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
219485460|NCT00753909|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
219485461|NCT00753909|DRUG|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
219485462|NCT03313154|OTHER|Neuropsychiatric screening|"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
219485463|NCT03603405|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
219485464|NCT04504097|BEHAVIORAL|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
219485465|NCT04504097|DIAGNOSTIC_TEST|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
219485466|NCT00795483|DRUG|Zoledronic acid|Zoledronic Acid 5mg/year
219485467|NCT00795483|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications
219485468|NCT00795483|DRUG|Zoledronic acid|Zoledronic acid (5mg/2years)
218868389|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
219204461|NCT06728761|DIAGNOSTIC_TEST|Breathalyser for measurement of the level of exhaled ethanol|Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
219204462|NCT06728761|BEHAVIORAL|Discomfort|discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
219485469|NCT03478345|BEHAVIORAL|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
219485470|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
219485471|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
219485472|NCT02494947|BEHAVIORAL|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
219485473|NCT02494947|OTHER|Usual care|
219485474|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
219485475|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
219485476|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
219485477|NCT00817869|OTHER|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
219485478|NCT01635127|DRUG|Canakinumab|150mg s.c.
219599393|NCT05991869|BEHAVIORAL|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
219485479|NCT01635127|DRUG|Placebo|Constituent of canakinumab
219485480|NCT03519360|OTHER|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
219485481|NCT03519360|OTHER|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
219485482|NCT05088980|DEVICE|VOLBELLA with Lidocaine|Facial Injection
219485483|NCT00387868|DRUG|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33
219485484|NCT00387868|PROCEDURE|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
219485485|NCT00387868|RADIATION|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
219599394|NCT01666769|DRUG|Micafungin|4 mg/kg/day
219599395|NCT01666769|DRUG|Micafungin|8 mg/kg/day
219204463|NCT06728761|BEHAVIORAL|Appetite|Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
219485486|NCT03576469|BIOLOGICAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
219485487|NCT00484120|DRUG|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
219485488|NCT00484120|DRUG|Placebo cream|Placebo cream
219485489|NCT00115466|PROCEDURE|Non-surgical autologous implant of ASCs|
219485490|NCT02838329|OTHER|warming of ropivacaine for BT|
219485491|NCT02838329|DRUG|Ropivicaine|
219485492|NCT01906580|DRUG|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
219485493|NCT01906580|DRUG|Entecavir|0.5mg,oral administration every day
219485494|NCT00448630|OTHER|No intervention|Non-interventional study
219599396|NCT01666769|DRUG|Micafungin|Standard of care Dosing
218868390|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
218868391|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
218868392|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
219485495|NCT03991065|DIAGNOSTIC_TEST|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
219485496|NCT00800722|DRUG|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
219485497|NCT02107963|BIOLOGICAL|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
218868393|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
219485498|NCT02107963|DRUG|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
219485499|NCT02107963|DRUG|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
219485500|NCT04372563|OTHER|aortic prosthetics|aortic prosthetics
219485501|NCT06514924|OTHER|height and weight measurement|Height and weight measurements and socioeconomic status survey
219485502|NCT01950195|PROCEDURE|Stereotactic Radiosurgery (SRS)|
219485503|NCT01950195|BIOLOGICAL|Ipilimumab|
219485504|NCT00468312|DRUG|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
219485505|NCT00468312|DRUG|Placebo|Two sprays in each nostril in the morning
219485506|NCT06072755|DEVICE|Finger pulse oximetry probe|This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
219485507|NCT06072755|DEVICE|Transreflectance oximetry probe|This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
219485508|NCT00713713|PROCEDURE|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
219485509|NCT04201418|DRUG|Patisiran|Patisiran-lipid complex injection, for intravenous use
219485510|NCT01052038|DRUG|Placebo administration|Placebo administration
219599397|NCT06651606|BEHAVIORAL|Progressive Ratio Training (PRT)|"Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc."
219599398|NCT06651606|BEHAVIORAL|Differential Reinforcement of Alternative (DRA) Behavior with Extinction|In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
219485511|NCT01052038|DRUG|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
219485512|NCT01052038|DRUG|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
219485513|NCT06346600|GENETIC|SKG0106|Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
219485514|NCT01277406|DRUG|4SC-201(Resminostat)|oral administration
219599399|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
219599400|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
219599401|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
218868394|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
218868395|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
218868396|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
218868397|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
218868398|NCT06436586|OTHER|No intervention|No intervention
218868399|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
219485515|NCT01277406|DRUG|FOLFIRI|i.v. administration
219485516|NCT04098159|DEVICE|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
219485517|NCT06541236|PROCEDURE|Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix|Incorporation of various bone grafting materials for alveolar ridge preservation
219485518|NCT02587000|DRUG|Ulipristal acetate|
219485519|NCT02587000|DRUG|Placebo|
219485520|NCT05567588|COMBINATION_PRODUCT|Drug: Pembrolizumab|200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
219485521|NCT02594137|PROCEDURE|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
219599402|NCT05294250|DRUG|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
218868400|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
218868401|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
218868402|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
218868403|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
218868404|NCT04246814|DEVICE|CC|Application of placebo LASER.
218868405|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
218868406|NCT05077007|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
218868407|NCT05077007|PROCEDURE|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
218868408|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
218868409|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
218868410|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
219485522|NCT00153868|BIOLOGICAL|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
219199876|NCT05943821|DRUG|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
219485523|NCT05719844|DIAGNOSTIC_TEST|Neuropsychological tests|"List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)"
219485524|NCT03962660|OTHER|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
219485525|NCT03962660|OTHER|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
219599403|NCT00801502|DIETARY_SUPPLEMENT|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
219485526|NCT03976076|DRUG|JBPOS0101|JBPOS0101 (investigational product)
219485527|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
219485528|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
219599404|NCT00801502|OTHER|Control|No change to habitual diet from week 20 of pregnancy until giving birth
219599405|NCT05546437|DEVICE|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
218868411|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
218868412|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
218868413|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
219599406|NCT02605915|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
219599407|NCT02605915|DRUG|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
219599408|NCT02605915|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
218868414|NCT06228690|OTHER|Gold Fish exercises|Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
218868415|NCT06228690|OTHER|Cervico-thoracic postural correction training|"Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening."
218868416|NCT06228690|OTHER|Conventional PT treatment|"Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO."
218868417|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
218868418|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
219485529|NCT01095029|DEVICE|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
219485530|NCT01594580|OTHER|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
219485531|NCT01594580|OTHER|Non-impregnated scrubs|
219485532|NCT02378467|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
219485533|NCT02378467|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
219485534|NCT02228369|DRUG|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
219485535|NCT02228369|DRUG|AZD9291|AZD9291 160mg once daily
219485536|NCT05673369|DRUG|CKD-387|1 Tablet
219485537|NCT05673369|DRUG|D484|1 Tablet
219485538|NCT03628001|PROCEDURE|ERCP|Pts will be randomized with or without sphinterectomy.
219485539|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
219485540|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
219485541|NCT05587517|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
219485542|NCT05587517|OTHER|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
219485543|NCT00734617|DRUG|Nicotine Patch|"Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
219485544|NCT00717158|BEHAVIORAL|Usual medical care|
219485545|NCT00717158|BEHAVIORAL|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
219599409|NCT02605915|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
218868419|NCT05848765|DRUG|Rituximab|Monoclonal antibody
218868420|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
219485546|NCT02125617|DRUG|Abiraterone|1000 mg/day
219485547|NCT02125617|DRUG|Prednisolone|10 mg/day
219485548|NCT05399186|OTHER|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
219485549|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
219485550|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
219485551|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
219599410|NCT02605915|DRUG|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
218868421|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
219485552|NCT01304563|BIOLOGICAL|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
218868422|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
218868423|NCT05848765|DRUG|Doxorubicin|Anthracycline
218868424|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
218868425|NCT05848765|DRUG|Prednisone|Corticosteroid
218868426|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
218868427|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
218868428|NCT01943552|DRUG|placebo|normal saline
218868429|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
218868430|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
218868431|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
218868432|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
219485553|NCT03906786|BEHAVIORAL|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
219485554|NCT00869141|DRUG|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
219485555|NCT01954784|DRUG|fludarabine phosphate|
219485556|NCT01954784|RADIATION|total-body irradiation|Undergo TBI
219485557|NCT01954784|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
219485558|NCT01954784|DRUG|cyclosporine|Given PO
219485559|NCT01954784|DRUG|mycophenolate mofetil|Given PO
219485560|NCT01954784|DRUG|bortezomib|Given SC
219485561|NCT01954784|DRUG|lenalidomide|Given PO
219485562|NCT01954784|OTHER|laboratory biomarker analysis|Correlative studies
219485563|NCT06540755|GENETIC|genetic polymorphism analysis|Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
219485564|NCT02803190|BEHAVIORAL|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
219485565|NCT02803190|BEHAVIORAL|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
219485566|NCT02686710|DRUG|Sevoflurane|
219485567|NCT02686710|DRUG|Propofol|
219485568|NCT00881595|DRUG|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
219485569|NCT00881595|RADIATION|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
219485570|NCT00881595|PROCEDURE|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
219485571|NCT02515981|BEHAVIORAL|NH Medicaid Incentives Program|
219599411|NCT02605915|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
218868433|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
218868434|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
218868435|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
219485572|NCT00212810|DRUG|Topiramate|
219485573|NCT00976313|PROCEDURE|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
219485574|NCT00976313|OTHER|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
219485575|NCT01614808|OTHER|laboratory biomarker analysis|Correlative studies
219485576|NCT04896723|DIAGNOSTIC_TEST|Sexual function questionnaire|Sexual function questionnaire and cognitive screening assessments
219485577|NCT02029313|DRUG|Montelukast|
219599412|NCT02605915|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
219485578|NCT02029313|DRUG|Montelukast sodium|
219485579|NCT01570218|BEHAVIORAL|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
219485580|NCT01398449|RADIATION|Elective nodal irradiation (ENI)|
219485581|NCT01398449|OTHER|Adjuvant chemotherapy only|
219599413|NCT02605915|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
219599414|NCT05980845|BEHAVIORAL|Nature sounds|Nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over.
219599415|NCT03333265|DRUG|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
219599416|NCT03333265|DRUG|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
219599417|NCT03333265|DRUG|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
219599418|NCT04552860|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
219599419|NCT03657186|DIETARY_SUPPLEMENT|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
219599420|NCT03657186|OTHER|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
219599421|NCT05491486|BEHAVIORAL|Mindfulness-based Group Therapy|see above
219599422|NCT03631316|DRUG|Generic Valganciclovir|900 mg daily during 4 days
219599423|NCT03631316|DRUG|Innovative Valganciclovir|900 mg daily during 4 days
219599424|NCT02396719|DEVICE|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
219599425|NCT05167799|DEVICE|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
219599426|NCT03094637|DRUG|Azacitidine|Given IV
219599427|NCT03094637|BIOLOGICAL|Pembrolizumab|Given IV
219599428|NCT00606632|DRUG|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
219599429|NCT00606632|PROCEDURE|CT|contrast enhanced CT scan
219599430|NCT06316011|DEVICE|Magnetocardiography|Magnetocardiography
219599431|NCT05725551|DEVICE|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
219485582|NCT01778452|PROCEDURE|endometrial biopsy|endometrial biopsy
219485583|NCT02469675|DEVICE|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
219485584|NCT02469675|DEVICE|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
219485585|NCT02469675|DEVICE|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
219485586|NCT03390452|BEHAVIORAL|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
219485587|NCT01715259|DRUG|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
219485588|NCT01715259|DRUG|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
219485589|NCT05947799|OTHER|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
219485590|NCT05947799|OTHER|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
219599432|NCT05725551|OTHER|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
219599433|NCT05725551|OTHER|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
219599434|NCT06037005|OTHER|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
219599435|NCT03885687|BEHAVIORAL|Exercise with Music|The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
219599436|NCT03885687|BEHAVIORAL|Exercise|The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
219599437|NCT02268877|OTHER|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
219599438|NCT02268877|DEVICE|Ultrasound|An ultrasound will be performed by a radiology department technician
219599439|NCT02481869|BIOLOGICAL|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
219599440|NCT02481869|DRUG|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
218868436|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
218868437|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
219485591|NCT00053599|DRUG|Simvastatin|
218868438|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
219199877|NCT06149273|BEHAVIORAL|Sleep School|Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
219485592|NCT05202600|PROCEDURE|Appendectomy|Surgical removal of the vermiform appendix.
219485593|NCT05349032|DIETARY_SUPPLEMENT|Curcumin|Oral supplement
218868439|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
219485594|NCT04253756|DEVICE|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
218868440|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
218868441|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
218868442|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
219485595|NCT03816956|DRUG|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
219485596|NCT03816956|OTHER|Placebo|Placebo comparator
218868443|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
218868444|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
219199878|NCT06149273|BEHAVIORAL|Treatment as usual|Oral and written information about improving sleep habits given by an educated nurse.
219199879|NCT06299150|OTHER|IPS e.max CAD|CAD CAM Restoration
219204464|NCT06728761|DIAGNOSTIC_TEST|Pregnancy urine test carried out during the intake visit on the day of the protocol|Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
219485597|NCT00254488|DRUG|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
219599441|NCT00711880|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219599442|NCT00711880|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
219599443|NCT00699426|DRUG|nexium|40 mg once daily is tested together with Yoghurt
219599444|NCT00699426|DRUG|nexium|nexium and placebo are tested
219599445|NCT00699426|DIETARY_SUPPLEMENT|Yoghurt|Yoghurt
219485598|NCT00254488|DRUG|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
218868445|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
219485599|NCT05776732|OTHER|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
219485600|NCT02491307|OTHER|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
219485601|NCT05066607|DRUG|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
219485602|NCT03319693|GENETIC|Somatic Genetic|NGS analysis
219485603|NCT04861415|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
219485604|NCT04861415|RADIATION|Conventionally Fractionated Radiation|External beam radiation therapy treatment
219485605|NCT00471588|DRUG|Pramipexole, Amisulpride|Study Drug
219485606|NCT01910597|DRUG|SBG|
219485607|NCT06541483|PROCEDURE|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
219485608|NCT06541483|PROCEDURE|conventional general anesthesia (CGA)|(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
219485609|NCT02312531|DRUG|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
219485610|NCT02367729|DEVICE|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
219485611|NCT02367729|DEVICE|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
219599446|NCT00699426|DRUG|placebo+placebo|placebo and placebo are tested.
219599447|NCT00953966|OTHER|Genetically modified potatoes|Starch from genetically modified potatoes
219599448|NCT02779166|DRUG|Celecoxib|Received 400mg celecoxib prior to surgery
219599449|NCT02779166|DRUG|placebo|
219599450|NCT00560820|DRUG|Deferasirox|30 mg/kg/day
219599451|NCT01883466|OTHER|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
218868446|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
218868447|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
218868448|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
219485612|NCT02454322|DRUG|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
219485613|NCT02726672|DEVICE|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
219485614|NCT02561013|DEVICE|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
219485615|NCT02561013|DEVICE|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
219485616|NCT01208168|DRUG|NAB001|nail lacquer, once daily, 52 weeks
219485617|NCT01208168|DRUG|Vehicle alone|nail lacquer, once daily, 52 weeks
219485618|NCT00438932|DRUG|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
219485619|NCT00438932|DIETARY_SUPPLEMENT|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
219485620|NCT00438932|DIETARY_SUPPLEMENT|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
219485621|NCT00438932|DRUG|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
219485622|NCT03686137|OTHER|Data collection|Colelction of pre-operative, surgical and post-surgical data
219485623|NCT05366153|DIAGNOSTIC_TEST|Coronary CT|Screening/Management Plan
218868449|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
218868450|NCT05830877|OTHER|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
219199880|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
219485624|NCT06672198|PROCEDURE|ERAC protocol|our study aimed to evaluate pre-peri-post operative practices in women who underwent elective cesarean section (CS) according to the ERAC protocol. In this context, this study aimed to describe the implementation status of the recommendations regarding the ERAC protocol in CS operations, to identify the missing aspects of the ERAC protocol and to raise awareness about its benefits.
219485625|NCT03435822|OTHER|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
219485626|NCT03435822|OTHER|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
219485627|NCT01068795|DRUG|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
219485628|NCT06542549|DRUG|AK104|The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
219485629|NCT05430282|OTHER|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
219485630|NCT05430282|OTHER|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
219599452|NCT05439967|OTHER|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
219599453|NCT05439967|OTHER|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
219599454|NCT04341324|OTHER|It is an observational study.|
219599455|NCT03180281|DRUG|DPP4|sitagliptin phosphate 100mg qd
219599456|NCT03180281|DRUG|Insulin|Insulin Glargine or detemir 0.2U/kg qd
219599457|NCT03180281|DRUG|SU|Glimepiride 1-2mg qd
219599458|NCT06581458|DRUG|tDCS|The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
219599459|NCT05351931|DIETARY_SUPPLEMENT|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
219599460|NCT06582420|DRUG|Fibrinogen concentrate|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
219599461|NCT06582420|DRUG|Standard trauma care|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
219599462|NCT00226291|OTHER|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
219599463|NCT04238650|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
218868451|NCT05830877|OTHER|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
218868452|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
218868453|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
218868454|NCT00139217|DRUG|iNO|
218868455|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
218868456|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
218868457|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
218868458|NCT04250597|DRUG|GNX102|Dose Escalation
219204465|NCT06735573|OTHER|the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes|"Primary Objective The primary objective is to measure the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes, in older female participants with clinically diagnosed COPD.~Secondary Objectives The secondary objective is to investigate whether the level of inflammation (plasma CRP) is associated with the intake of total, plant-based and animal-based protein, with the prevalence of sarcopenic obesity, and with lung function outcomes."
219485631|NCT02726373|OTHER|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
219485632|NCT02077660|DIETARY_SUPPLEMENT|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
219485633|NCT02077660|OTHER|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
219599464|NCT04238650|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
219485634|NCT04760574|DIAGNOSTIC_TEST|Testosterone|Serum total testosterone and free testosterone level
219485635|NCT00400426|PROCEDURE|Radiotherapy|20 Gy in 4 fx
219599465|NCT02289872|DEVICE|Macintosh Laryngoscope|Direct-Laryngoscopy
218868459|NCT04250597|DRUG|GNX102|Expansion Phase
218868460|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
218868461|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
219485636|NCT00354731|DRUG|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
219485637|NCT00354731|DRUG|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
219485638|NCT04254731|DRUG|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
219599466|NCT02289872|DEVICE|TruView PCD Video laryngoscope|Video-Laryngoscopy
219599467|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
219599468|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
219599469|NCT03277066|DRUG|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
219599470|NCT03390855|OTHER|Broccoli sprouts|
219599471|NCT01657435|DEVICE|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
219599472|NCT06581718|DEVICE|Eye Gaze Control|Eye Gaze Control - UGI and LGI endoscopy
219599473|NCT05392218|BEHAVIORAL|motivational interviewing|consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
218868462|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
218868463|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
218868464|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
218868465|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
218868466|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
218868467|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
219485639|NCT02585973|DRUG|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
218868468|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
218868469|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
218868470|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
218868471|NCT04467125|DRUG|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
219199881|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
219204466|NCT06885411|OTHER|metal-on-metal hip arthroplasty|Cobalt and chromium release from metal-on-metal hip arthroplasties.
219204467|NCT06741163|DIETARY_SUPPLEMENT|Pre-activity shot|Water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).
219485640|NCT02585973|DRUG|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
219485641|NCT02585973|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
219485642|NCT01284231|DRUG|MEDI-565|MEDI-565 will be administered by IV infusion
219485643|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
219485644|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
219485645|NCT01284231|DRUG|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
219485646|NCT00759174|DRUG|No intervention|No intervention occurs in this observational study.
219485647|NCT05582200|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
219485648|NCT01890109|BIOLOGICAL|Erenumab|Administered via subcutaneous injection.
219485649|NCT01890109|DRUG|Placebo|Administered via subcutaneous injection
218868472|NCT04467125|DRUG|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
218868473|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
219485650|NCT01225237|DRUG|Ramosetron|oral
219485651|NCT01225237|DRUG|Placebo|oral
219599474|NCT05392218|BEHAVIORAL|general health education|rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
219599475|NCT02289703|DRUG|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
219485652|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
219485653|NCT00540007|DRUG|Lenalidomide|
219485654|NCT02028156|OTHER|Partially Hydrolyzed Infant Formula|Commercially available infant formula
219485655|NCT01643928|BIOLOGICAL|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
219485656|NCT01643928|BIOLOGICAL|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
219485657|NCT01643928|BIOLOGICAL|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
219485658|NCT03745573|BEHAVIORAL|Empateach|Empateach is a behavioural intervention for teachers.
219485659|NCT00053027|BIOLOGICAL|rituximab|
219485660|NCT00053027|DRUG|cladribine|
219485661|NCT05257174|DIETARY_SUPPLEMENT|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
219485662|NCT05257174|DIETARY_SUPPLEMENT|Placebo|intake Placebo twice daily for three months
219485663|NCT05808894|PROCEDURE|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
219485664|NCT04261322|RADIATION|x ray exposure|exposure of whole body to x ray
219485665|NCT04976387|DRUG|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
219204468|NCT06741163|DIETARY_SUPPLEMENT|Placebo|Water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
219485666|NCT04976387|DRUG|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
219485667|NCT04976387|DRUG|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
219485668|NCT04715737|DRUG|Vasopressin|Administration of vasopressin (20IU) intranasally
219485669|NCT04715737|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
219485670|NCT04715737|DRUG|Placebo|Administration of placebo intranasally
219485671|NCT03455647|BEHAVIORAL|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
219485672|NCT02080065|PROCEDURE|living donor liver transplantation|
219485673|NCT06003491|DEVICE|Intra-articular Cages|Using reduction using posterior intra-articular distraction and fusion technique with cages.
219485674|NCT03105882|DEVICE|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
219485675|NCT04552080|DRUG|Amoxicillin|Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
219485676|NCT04552080|OTHER|Placebo|Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
219485677|NCT02453867|OTHER|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels \> 5ng/ml) Stop mycophenolate at month 6
219485678|NCT02453867|DRUG|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
219485679|NCT02453867|DRUG|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
219485680|NCT02453867|DRUG|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
219485681|NCT01058044|OTHER|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
219485682|NCT06377969|DEVICE|ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation|The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
219599476|NCT02423421|OTHER|Faecal microbiota transplantation|Human Stool.
219599477|NCT01010243|DRUG|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
219599478|NCT02756208|BIOLOGICAL|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
219599479|NCT02756208|BIOLOGICAL|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
218868474|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
219485683|NCT02331069|DRUG|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
219485684|NCT02331069|OTHER|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
219485685|NCT05383976|OTHER|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
219485686|NCT00712660|DRUG|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
219199882|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
219485687|NCT00712660|OTHER|no intervention|Treatment as usual
219485688|NCT05335473|DRUG|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
219485689|NCT02532140|DRUG|WCK 5107 250 mg to 2000 mg|
219485690|NCT02532140|DRUG|Cefepime 2000 mg|
219485691|NCT02532140|DRUG|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
219485692|NCT02532140|DRUG|Placebo|
219485693|NCT00488839|DRUG|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
219485694|NCT00488839|DRUG|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
219485695|NCT00488839|DRUG|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
219485696|NCT00488839|DRUG|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
219485697|NCT00488839|DRUG|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
219485698|NCT00488839|DRUG|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
219485699|NCT00488839|DRUG|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
219485700|NCT00488839|DRUG|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
219485701|NCT00488839|DRUG|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
219485702|NCT02700074|OTHER|No Intervention|Intervention is not a part of this study.
219485703|NCT03701490|DRUG|Progesterone subcutaneous|25 mg/twice a day.
219485704|NCT03701490|DRUG|Progesterone Vaginal Product|200 mg three times a day.
219485705|NCT04118855|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
219485706|NCT04118855|DRUG|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
218868475|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
218868476|NCT01873690|DRUG|Placebo|5% Dextrose in water
218868477|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
218868478|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
218868479|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
218868480|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
218868481|NCT00473408|DEVICE|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
218868482|NCT00473408|PROCEDURE|Blood sample|See protocol.
218868483|NCT00473408|PROCEDURE|Tumor sample|See protocol.
218868484|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
218868485|NCT04408911|DRUG|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
218868486|NCT05318820|DRUG|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
218868487|NCT06425432|DEVICE|OVITZ xwave aberrometer|wavefront aberrometer
219599480|NCT02756208|BIOLOGICAL|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
218868488|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
219485707|NCT01097850|DRUG|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
219485708|NCT04434638|OTHER|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
219485709|NCT04434638|OTHER|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
219599481|NCT02756208|BIOLOGICAL|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
219599482|NCT05894837|DRUG|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
219599483|NCT05894837|DRUG|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
219599484|NCT06106347|DEVICE|mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)|physiological macular function
218868489|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
218868490|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
218868491|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
218868492|NCT00329615|DRUG|Insulatard, flexpen|
218868493|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
219199883|NCT05567978|PROCEDURE|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
219199884|NCT00194298|PROCEDURE|FDG-PET Imaging|
219599485|NCT03646994|DRUG|Crizotinib|Crizotinib Cap 250 mg po bid
219599486|NCT03438994|DIAGNOSTIC_TEST|Play.Care|iPad based game to assess movement as the player interacts with the screen
219599487|NCT04258176|OTHER|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
219599488|NCT01102101|DRUG|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
219599489|NCT04495569|BIOLOGICAL|recombinant anti-rabies human monoclonal antibody injection (SYN023)|The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.
219599490|NCT04495569|BIOLOGICAL|Rabies Vaccine|The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
218868494|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
218868495|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
218868496|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
218868497|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
219599491|NCT01990586|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
219599492|NCT02370238|DRUG|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
219599493|NCT02370238|DRUG|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
219599494|NCT02370238|DRUG|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
218868498|NCT06365983|PROCEDURE|Connective Tissue with Free Gingival Graft|The de-epithelialized free gingival grafting will begin with two horizontal incisions, 1.0 to 1.5 mm apical to the margin of the soft tissue of the adjacent teeth and two vertical incisions to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone surface, and once an adequate thickness of soft tissue is obtained, it will be rotated to become almost parallel to the external surface of the palate. The graft thickness will be maintained uniform and the wound will be protected with absorbable collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) and maintained with compressive sutures with non-absorbable 5-0 monofilament thread (Microsuture, São Paulo), anchored to the soft tissue apical to the area of the palatal wound. Immediately after suture completion, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
218868499|NCT06365983|PROCEDURE|Connective Tissue with Linear Incision|The linear technique (Lorenzana ER, Allen EP 2000) will begin with a horizontal incision 2 mm apical to the gingival margin, perpendicular to the palate, which is deepened to the bone crest. Next, a second incision is made to divide the flap and expose the connective tissue bed. The thickness of the outer portion of the flap should be at least 1 mm, with uniformity throughout its extension to reduce the risk of epithelial tissue necrosis. Subsequently, internal lateral incisions (mesial and distal) and the base incision will be made, connecting the vertical incisions to delineate horizontal and vertical boundaries. Immediately after graft removal, an absorbable hemostatic collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) will be placed and sutured using non-absorbable 5-0 monofilament thread (Microsuture, São Paulo).Immediately after suturing is completed, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
218868500|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
218868501|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
218868502|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
218868503|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
219485710|NCT01674959|RADIATION|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
219599495|NCT04867343|DRUG|HR020602 injection|HR020602 injection
219599496|NCT04867343|DRUG|fentanyl injection ； remifentanil injection|fentanyl injection + remifentanil injection
219599497|NCT02819284|DRUG|KPI-121 0.25% Ophthalmic Suspension|
219599498|NCT02819284|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
219599499|NCT04641052|OTHER|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
219599500|NCT05639582|OTHER|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
219599501|NCT01130662|DRUG|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
219599502|NCT06291194|DRUG|AJU-S56 5%|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
219599503|NCT06291194|DRUG|Placebo Group(Vehicle)|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
219599504|NCT04284072|DEVICE|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
219599505|NCT01972399|PROCEDURE|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
219599506|NCT01972399|PROCEDURE|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
219199885|NCT05210374|DRUG|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day"
219485711|NCT01318200|PROCEDURE|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
219599507|NCT05094661|PROCEDURE|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
219599508|NCT05094661|PROCEDURE|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
219599509|NCT03338530|BEHAVIORAL|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
219485712|NCT01318200|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
219485713|NCT00415142|DRUG|saredutant (SR48968)|oral administration (capsules)
219199886|NCT05210374|DRUG|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
219199887|NCT05210374|DRUG|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
219199888|NCT03971955|OTHER|Mixed Meal Test|a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
219199889|NCT03971955|OTHER|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
219485714|NCT00415142|DRUG|placebo|oral administration (capsules)
219485715|NCT00415142|DRUG|escitalopram|oral administration (capsules)
219485716|NCT05741775|OTHER|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
219485717|NCT05741775|OTHER|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
219485718|NCT03801759|DRUG|Vadadustat|Oral dose 600 mg
219199890|NCT03971955|PROCEDURE|Adipose Tissue Biopsy|The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
219485719|NCT03801759|DRUG|Furosemide|Oral Furosemide
219485720|NCT03801759|DRUG|Adefovir|Oral Adefovir
219485721|NCT03801759|DRUG|Digoxin|Oral Digoxin
219485722|NCT06058507|DIAGNOSTIC_TEST|CT angiography|No intervention was made
219599510|NCT02566681|BIOLOGICAL|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
218868504|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
218868505|NCT02108665|RADIATION|Radiographic hysterosalpingography|
218868506|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
218868507|NCT01722435|DRUG|Opiate Substitution Treatment|
219199891|NCT05636085|DEVICE|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
219485723|NCT00092651|DRUG|MK0653A, ezetimibe (+) simvastatin|
219485724|NCT00092651|DRUG|Comparators: simvastatin and ezetimibe|
219485725|NCT00850005|BIOLOGICAL|Intravenous immunoglobulin|2 g/kg divided over five days
219485726|NCT00850005|BIOLOGICAL|Normal Saline|Same volume as experimental arm
219485727|NCT01576627|DIETARY_SUPPLEMENT|zinc citrate|10 mg of zinc as either zinc citrate
219485728|NCT01576627|DIETARY_SUPPLEMENT|Zinc Gluconate|10 mg of zinc as either zinc gluconate
219485729|NCT01576627|DIETARY_SUPPLEMENT|Zinc oxide|10 mg of zinc as either zinc oxide
219485730|NCT04160676|DRUG|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
219485731|NCT04160676|DRUG|Normal saline|Normal saline
219485732|NCT03692078|OTHER|OTDN product 1|Oral tobacco-derived nicotine product
218868508|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
218868509|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
218868510|NCT00273156|BEHAVIORAL|Telephone quitline|
218868511|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
218868512|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
219485733|NCT03692078|OTHER|OTDN product 2|Oral tobacco-derived nicotine product
219485734|NCT03692078|OTHER|Tobacco Cessation|Tobacco Cessation
219485735|NCT02036827|DRUG|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
219485736|NCT03620773|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
219485737|NCT03620773|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
219485738|NCT03620773|PROCEDURE|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
219485739|NCT03620773|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
219485740|NCT01365676|DRUG|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
219485741|NCT01365676|DRUG|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
218868513|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
219485742|NCT02111382|OTHER|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
219485743|NCT02111382|OTHER|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
219485744|NCT06539494|DRUG|Omeprazole 40 MG|Proton pump inhibitor twice a day for 4 weeks
219485745|NCT04783844|DIAGNOSTIC_TEST|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
219485746|NCT01005680|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
219485747|NCT01005680|DRUG|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
219485748|NCT01005680|DRUG|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
219485749|NCT03576131|BIOLOGICAL|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
219485750|NCT03548324|DEVICE|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
219599511|NCT03632213|DRUG|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
219599512|NCT03632213|DRUG|Placebo|Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
218868514|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
218868515|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
219485751|NCT03548324|DEVICE|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
219599513|NCT05175235|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
219599514|NCT05175235|DRUG|Nivolumab, Pembrolizumab|Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
219599515|NCT01867892|DRUG|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
219599516|NCT01867892|DRUG|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
218868516|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
219599517|NCT02850692|OTHER|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
218868517|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
218868518|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
218868519|NCT05883618|OTHER|Exposure|Human Development Index of Country
218868520|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
218868521|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
218868522|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
218868523|NCT01290900|DRUG|NXL104|IV Solution
218868524|NCT01290900|DRUG|Ceftaroline|IV Solution
218868525|NCT01290900|DRUG|Placebo Infusion|IV Saline
218868526|NCT01290900|DRUG|Ceftazidime|IV Solution
218868527|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
218868528|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
218868529|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
219485752|NCT01339858|DRUG|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
219485753|NCT01339858|OTHER|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
219485754|NCT00002338|DRUG|Raluridine|
219485755|NCT06538103|PROCEDURE|Eye soft surgery|Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
219485756|NCT06538103|OTHER|Physical Rehabilitation|Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
219485757|NCT05074602|DRUG|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
219485758|NCT05074602|DRUG|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
219485759|NCT00145652|DRUG|Neo-Recormon and Venofer|
219485760|NCT05512286|RADIATION|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
219599518|NCT02850692|BIOLOGICAL|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
219599519|NCT02850692|OTHER|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
219599520|NCT02850692|DIAGNOSTIC_TEST|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
219599521|NCT03956940|DEVICE|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
219599522|NCT02220517|DEVICE|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
219599523|NCT02220517|DEVICE|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
219599524|NCT06579625|OTHER|Cancer education|Participants in the experimental group will receive cancer education.
219485761|NCT05512286|RADIATION|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
219485762|NCT01456000|DEVICE|EAS-AC (HeartLight)|Pulmonary vien isolation
219485763|NCT01456000|PROCEDURE|Control Arm Ablation|Treatment with standard ablation.
219485764|NCT06539637|COMBINATION_PRODUCT|OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}|10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery
219485765|NCT06539637|OTHER|Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop|Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
219485766|NCT00996632|PROCEDURE|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
219485767|NCT00996632|PROCEDURE|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
219485768|NCT04391400|DIAGNOSTIC_TEST|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
219599525|NCT03417778|DRUG|Filgotinib|100 mg tablet administered orally
219599526|NCT01295320|PROCEDURE|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
219599527|NCT00652340|DRUG|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
219599528|NCT00652340|DRUG|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
219485769|NCT04391400|DIAGNOSTIC_TEST|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~* At least 2mL to 5mL of peripheral blood.~* Collected in EDTA tubes.~* Shipped to ambient LabPMM, LLC within 2 days.~* Specimen Collections:~* Collected at the same time as the NP specimen sent for COVID-19 testing.~* Collected two to three weeks post the original patient's COVID-19 testing."
219485770|NCT03975088|PROCEDURE|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
219485771|NCT02952937|DRUG|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
219485772|NCT02952937|DRUG|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
219485773|NCT02049554|OTHER|Preconception Care Screener|
219485774|NCT00334828|DRUG|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
219485775|NCT00334828|DRUG|Placebo|Matching placebo; intravenous infusion.
219485776|NCT03823677|PROCEDURE|Hypoxia|hypoxia
219485777|NCT01372254|BEHAVIORAL|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
219485778|NCT01372254|BEHAVIORAL|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
219485779|NCT01372254|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
219485780|NCT03409497|OTHER|Concord Grape Juice|Concord Grape Juice
219485781|NCT03409497|OTHER|Low flavonoid low essence beverage|Low flavonoid low essence beverage
219485782|NCT03409497|OTHER|Low flavonoid beverage|Low flavonoid beverage
219485783|NCT04590898|DEVICE|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
219485784|NCT02600273|OTHER|Usual brand cigarettes|Usual brand cigarettes
219485785|NCT02600273|OTHER|Lower nicotine content cigarettes|SPECTRUM research cigarettes
219485786|NCT02600273|OTHER|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
219485787|NCT02600273|OTHER|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
219199892|NCT06786962|DEVICE|Virtual reality Hypnosis|"The experimental group of 22 participants consists of a hypnosis intervention using a virtual reality device (HypnoVR®).~Participants are seated in a quiet area of the unit:~They choose a visual scenario from among 3 proposals, guaranteeing the conditions of a restorative environment. During each session, the same script (support mode) is spoken and the same music (serenity program with soothing tones) is associated with the script. Each participant is fitted with a virtual reality mask and a headset with active noise reduction."
219485788|NCT04166877|DRUG|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
219485789|NCT04166877|DRUG|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
219485790|NCT05501002|DEVICE|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
219485791|NCT05769322|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
219485792|NCT05489380|DEVICE|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
219485793|NCT05358392|OTHER|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
219485794|NCT03004963|DEVICE|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
219485795|NCT03004963|DEVICE|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
219485796|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
219485797|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
219485798|NCT05623449|OTHER|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
219485799|NCT05623449|OTHER|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
218868530|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
218868531|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
219485800|NCT05623449|PROCEDURE|pain scale|Measurement of pain intensity
219599529|NCT04932421|BEHAVIORAL|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
219599530|NCT04932421|OTHER|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
219599531|NCT03682107|BIOLOGICAL|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
219485801|NCT05623449|PROCEDURE|hypnosis consultation|5 hypnosis consultation
219485802|NCT05623449|PROCEDURE|Maintenance|Qualitative assessment
219485803|NCT05623449|OTHER|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
219485804|NCT05098444|BEHAVIORAL|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
219485805|NCT05098444|OTHER|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
219485806|NCT05880485|RADIATION|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
219485807|NCT04018937|DRUG|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
219599532|NCT03682107|OTHER|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
219599533|NCT03021681|OTHER|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
219485808|NCT04018937|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
219485809|NCT04018937|DRUG|Melphalan|Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
219485810|NCT06095362|DRUG|Bevacizumab-IRDye800CW|All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
219599534|NCT04342819|DRUG|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
219599535|NCT00491712|PROCEDURE|Glaucoma drainage implant with/without triamcinolone|
218868532|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
218868533|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
218868534|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
218868535|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
218868536|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
219485811|NCT01598740|DRUG|CLP|Oral administration
219485812|NCT01598740|DRUG|Spironolactone|oral administration
219485813|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
219599536|NCT01004809|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219485814|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
219599537|NCT00214383|BEHAVIORAL|CHESS Internet telehealth|CHESS Internet telehealth
219599538|NCT01569295|DRUG|Idelalisib|Idelalisib 150 mg administered orally twice daily
218868537|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
219199893|NCT06786962|OTHER|Control arm (SEQ):|"Restoration time~Participants are seated in a quiet area of the unit. The control group of 21 participants consists of a break with the following instructions and suggestions:~Take advantage of this break, this time just for you, to recharge your batteries. Sit in this armchair and I suggest you think of something pleasant and comfortable."
219485815|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
219485816|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
219485817|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
219485818|NCT00812045|DRUG|Placebo|
219485819|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
219485820|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
219485821|NCT05830123|DRUG|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219485822|NCT02963909|BIOLOGICAL|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
219485823|NCT02963909|OTHER|Placebo|0.9% Sodium Chloride 5 mcg
219485824|NCT02963909|BIOLOGICAL|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
219485825|NCT02963909|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
219485826|NCT03069365|DRUG|Glecaprevir/pibrentasvir|Film-coated tablet
219485827|NCT01910701|BEHAVIORAL|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
219485828|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
219485829|NCT06471738|DRUG|Zanubrutinib|BTK inhibitor
219485830|NCT06471738|BIOLOGICAL|Rituximab|Monoclonal antibody to CD20
219485831|NCT06471738|DRUG|Venetoclax|BCL-2 inhibitor
219485832|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
219485833|NCT04668131|DRUG|Sodium hyaluronate eye drops|eye drops, three times a day
219485834|NCT04668131|OTHER|acupuncture|three times a week
219485835|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
219485836|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
219485837|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
219485838|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
219485839|NCT01856348|DRUG|Vitamin D|
219485840|NCT02393066|DRUG|Propofol|Sedation
219485841|NCT02393066|DRUG|Dexmedetomidine|Sedation
219485842|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
219599539|NCT01569295|DRUG|Rituximab|Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
219599540|NCT01569295|DRUG|Bendamustine|Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
219599541|NCT01569295|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
219599542|NCT04898686|BIOLOGICAL|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
219599543|NCT04898686|BIOLOGICAL|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
218868538|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
219485843|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
219485844|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
219485845|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
219485846|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
219485847|NCT04342130|DRUG|Morphine|30 mg oral tablet
219485848|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
219485849|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
219485850|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
219485851|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
219485852|NCT02886494|DRUG|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
219485853|NCT02886494|DRUG|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
219485854|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
219485855|NCT02867748|PROCEDURE|TVT-Abbrevo|
219485856|NCT02867748|PROCEDURE|Serasis|
219485857|NCT06232135|OTHER|CBCT scan|analysis of the CBCT scan to assign a calcification stage to the subject's lower left third molar and accordingly calculate the estimated age of each subject
219485858|NCT02084329|DEVICE|Weighted Compression Vest|
219485859|NCT06124534|DEVICE|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
219485860|NCT01436942|BEHAVIORAL|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
219485861|NCT00363428|BEHAVIORAL|exercise intervention|life style
219485862|NCT00363428|BEHAVIORAL|smoking cessation intervention|Life style
218868539|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
218868540|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
218868541|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
218868542|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
218868543|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
219485863|NCT00363428|OTHER|counseling intervention|life style
219485864|NCT00363428|OTHER|educational intervention|life style
219485865|NCT00363428|PROCEDURE|conventional surgery|life style
219485866|NCT00363428|PROCEDURE|pulmonary complications management/prevention|life style
219485867|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
219485868|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
219485869|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
219485870|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
219485871|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
219485872|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
219599544|NCT05778812|BEHAVIORAL|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
219599545|NCT05778812|BEHAVIORAL|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
219199894|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
219599546|NCT02366169|DEVICE|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
219599547|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.M., single or multiple-dose
218868544|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
218868545|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
218868546|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
218868547|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
219199895|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
219599548|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.N., single or multiple-dose
219599549|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.H., single or multiple-dose
219599550|NCT05638581|BIOLOGICAL|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
219599551|NCT05638581|BIOLOGICAL|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
218868548|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
218868549|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
218868550|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
218868551|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
218868552|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
218868553|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
218868554|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
219199896|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
218868555|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
218868556|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
219485873|NCT04112615|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
219485874|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
219485875|NCT05137639|PROCEDURE|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
219599552|NCT00862732|BEHAVIORAL|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
219599553|NCT00862732|OTHER|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
218868557|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
218868558|NCT02282904|RADIATION|Total body 200cGy|Day -1
218868559|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
218868560|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
219485876|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
219485877|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
219485878|NCT01793285|DRUG|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
219485879|NCT05109416|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
219485880|NCT05109416|DRUG|Saline 0.9%|Isotonic crystaloid
219485881|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
219485882|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
219485883|NCT02417207|DRUG|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
219485884|NCT02417207|DRUG|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
219485885|NCT02672488|DRUG|Sorafenib|Standard treatment for advanced HCC
219485886|NCT02672488|DRUG|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
219485887|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
218868561|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
218868562|NCT04139278|OTHER|Observational|Observational retrospective study
218868563|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
218868564|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
218868565|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
218868566|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
218868567|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
218868568|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
218868569|NCT00226863|BEHAVIORAL|meditation plus education|
218868570|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
218868571|NCT00226863|BEHAVIORAL|education|
219485888|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
219485889|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
219485890|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
219485891|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
218868572|NCT06312241|BEHAVIORAL|Metacognitive Training-Silver BeWell|Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
218868573|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
218868574|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
218868575|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
218868576|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
219199897|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
219485892|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
219485893|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
219485894|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
219485895|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
219485896|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
219485897|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
219485898|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
219485899|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
219485900|NCT01976637|OTHER|no compression|no compression stockings worn during the study
219485901|NCT01976637|DEVICE|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
219485902|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
219485903|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
219485904|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
219485905|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
219485906|NCT01387360|DEVICE|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
219599554|NCT03157479|DRUG|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
219599555|NCT03157479|DRUG|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
219485907|NCT01347983|DRUG|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
219485908|NCT00960687|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
219485909|NCT00960687|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
219599556|NCT03157479|DIAGNOSTIC_TEST|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
219599557|NCT03157479|DIAGNOSTIC_TEST|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
219599558|NCT00879411|DRUG|Micardis|
219599559|NCT05786560|BEHAVIORAL|BABE (Body Appreciation and Better Eating)|The participants will be randomized into either a treatment or control group. For the treatment arm, girls will participate in the Body Project for 30 minutes, then will be given a 30-minute self-compassion-based nutrition education lesson. Nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The control group will receive the same 30-minute Body Project class and the same 30-minute nutrition education class; however, there will be no incorporation of self-compassion.
219599560|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
219599561|NCT03607487|DRUG|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
219599562|NCT03607487|DRUG|Placebo|Placebo tablet administered orally once daily.
219599563|NCT05853575|DRUG|Adagrasib|KRAS G12C inhibitor
219599564|NCT02244814|BEHAVIORAL|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
219599565|NCT02244814|BEHAVIORAL|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
219599566|NCT01884337|DRUG|Apixaban|
219485910|NCT04493099|DRUG|Alvocidib Hydrochloride|Given IV
219599567|NCT02021513|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
219599568|NCT02021513|DIETARY_SUPPLEMENT|Olive Oil|Placebo group
219599569|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
219599570|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
219599571|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
219599572|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
219599573|NCT01038297|DRUG|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
219599574|NCT01038297|DRUG|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
219199898|NCT01286766|DRUG|DCS (docetaxel with cisplatin with TS-1)|"1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
219485911|NCT04493099|DRUG|Decitabine|Given IV
219485912|NCT04493099|DRUG|Venetoclax|Given PO
219485913|NCT06652048|DRUG|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
219485914|NCT06652048|DRUG|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
219485915|NCT06652048|DRUG|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
219599575|NCT02382861|DEVICE|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
219599576|NCT02382861|DEVICE|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
219599577|NCT00737152|OTHER|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
219599578|NCT01973595|DIETARY_SUPPLEMENT|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
219599579|NCT01973595|OTHER|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
219599580|NCT03203681|DRUG|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
219599581|NCT00003577|DRUG|CMF regimen|
219599582|NCT00003577|DRUG|cyclophosphamide|
219599583|NCT00003577|DRUG|epirubicin hydrochloride|
219599584|NCT00003577|DRUG|fluorouracil|
219599585|NCT00003577|DRUG|methotrexate|
219599586|NCT00003577|PROCEDURE|adjuvant therapy|
219599587|NCT00003577|RADIATION|radiation therapy|
219485916|NCT00143546|DRUG|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
219485917|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
219485918|NCT00530452|DRUG|CG100649|Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
219485919|NCT00530452|DRUG|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
219485920|NCT02704130|DEVICE|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
219485921|NCT02704130|PROCEDURE|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
219485922|NCT06521138|BEHAVIORAL|Motivational interviewing group|The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
219485923|NCT06521138|OTHER|Control group|Participants in the control group will receive routine care at the center.
219485924|NCT06701708|OTHER|Participants are not assigned to interventions based on a protocol.|Participants are not assigned to interventions based on a protocol.
219485925|NCT04807634|DRUG|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
219485926|NCT01770639|PROCEDURE|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
219485927|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
219485928|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
219485929|NCT00509340|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
219485930|NCT04120714|DEVICE|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
219485931|NCT04120714|DEVICE|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
219485932|NCT04120714|OTHER|Questionnaires|"* visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale"
219485933|NCT05529641|OTHER|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
219485934|NCT05529641|OTHER|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
219485935|NCT06280794|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
219485936|NCT06280794|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
219485937|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
219485938|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
219485939|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
219485940|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
219485941|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
219485942|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
219485943|NCT05744219|DRUG|Placebo|Placebo
219485944|NCT04318041|DRUG|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
219599588|NCT04581330|DEVICE|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
219599589|NCT02859753|OTHER|Percutaneous Radiofrequency Ablation|
219599590|NCT02859753|OTHER|Percutaneous Microwave Ablation|
219485945|NCT04318041|DRUG|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
219599591|NCT03259386|DEVICE|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
219599592|NCT01408602|DRUG|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
219599593|NCT01408602|DRUG|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
219599594|NCT01408602|DRUG|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
219599595|NCT04871672|OTHER|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
219599596|NCT04871672|OTHER|Home Exercise program|home exercise
219599597|NCT01776255|BEHAVIORAL|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
219599598|NCT01776255|BEHAVIORAL|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
219599599|NCT05085444|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
219599600|NCT04852029|OTHER|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
219599601|NCT06254612|DRUG|SP-624|Once daily oral administration of two capsules totaling 20 mg/day
219485946|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
219485947|NCT05495425|DRUG|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
219485948|NCT05495425|DRUG|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
219485949|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
219599602|NCT06254612|DRUG|Placebo|Once daily oral administration of two matching placebo capsules
219599603|NCT06299839|DRUG|PAS-004 Capsules|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
219485950|NCT05217901|DRUG|14C-labeled ASP0367|Oral
219599604|NCT06299839|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
219599605|NCT01898221|DRUG|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
219599606|NCT01898221|PROCEDURE|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
219599607|NCT02984163|BEHAVIORAL|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
219599608|NCT06648967|DIETARY_SUPPLEMENT|Supplementation with a multi-ingredient whey supplement|Malabsorption of two different fructose boluses at baseline and after 3 and 5 weeks of multi-ingredient whey supplementation.
219599609|NCT05101369|DRUG|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
219599610|NCT00004180|DRUG|rosiglitazone maleate|
219599611|NCT03837743|DRUG|DUR-928 Topical Solution|Topical solution containing active drug
219599612|NCT03837743|DRUG|Vehicle Topical Solution|Topical solution containing no active drug
219485951|NCT06076538|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging|PET/MR scan utilizing FDG Radiopharmaceutical
219485952|NCT05558189|DEVICE|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
219485953|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
219485954|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
219485955|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
219485956|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
219485957|NCT01103375|DRUG|isotretinoin|Given PO
219485958|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
219485959|NCT01103375|GENETIC|protein expression analysis|Correlative study
219485960|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
219485961|NCT00903942|RADIATION|radiation therapy|1\) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
219485962|NCT00903942|DRUG|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
219485963|NCT06623526|DRUG|YHR2402|Test Drug: YHR2402
219485964|NCT06623526|DRUG|YHR2402+YHR2403|Test Drug: YHR2402+YHR2403
219485965|NCT01527786|DRUG|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
219485966|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
219485967|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
219599613|NCT04547842|DRUG|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
219599614|NCT04547842|DRUG|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
218868577|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
219485968|NCT00050050|DRUG|Drug therapy|
219485969|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
219599615|NCT01210612|DEVICE|Unilateral CAI|five-toed socks usage
219599616|NCT05129605|DIAGNOSTIC_TEST|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
219599617|NCT01275430|DEVICE|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
219599618|NCT01275430|OTHER|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
219599619|NCT01920022|DRUG|Mifepristone|Day one of medical abortion
219599620|NCT01920022|DRUG|etonorgestrel|
219599621|NCT02558439|DRUG|CNTX-4975|
219599622|NCT02558439|OTHER|Placebo|
219485970|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
219485971|NCT00127296|DEVICE|FlexPen®|
219485972|NCT00127296|DEVICE|vial and syringe|
219485973|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
219485974|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
219485975|NCT01711814|DRUG|peficitinib|oral
219485976|NCT05004181|BIOLOGICAL|BNT162b2|Intramuscular (IM)
219485977|NCT05004181|BIOLOGICAL|Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
219485978|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.7)|Intramuscular (IM)
219485979|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.617.2)|Intramuscular (IM)
219485980|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
219485981|NCT05004181|OTHER|Observational|No vaccination within 3 months after Visit 1.
219485982|NCT03470896|PROCEDURE|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
219599623|NCT03287843|PROCEDURE|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
219599624|NCT03287843|PROCEDURE|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
219599625|NCT02847988|DEVICE|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
218868578|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
219485983|NCT03470896|PROCEDURE|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
219485984|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
219485985|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
219485986|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
219485987|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
219485988|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
219485989|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
219485990|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
219485991|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
219485992|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
219485993|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
219485994|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
219599626|NCT02847988|DEVICE|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
219599627|NCT00086281|DRUG|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
219599628|NCT00086281|DRUG|Zolpidem (Z)|Zolpidem 10 mg oral tablets
219599629|NCT00086281|DRUG|Modafinil (M)|Modafinil Oral Tablets
219599630|NCT00086281|DRUG|Placebo (P)|Placebo Oral Solution
218868579|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
219485995|NCT06330207|BEHAVIORAL|Clinical decision support tool|The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
219522408|NCT06887530|OTHER|Hand-10 questionnaire and ABILHAND-kids questionnaire|"Children and their parents included in the study will be informed about the purpose of the study and the evaluations to be made and will be asked to sign a written consent form. The questions in the data collection form will be asked to individuals in a face-to-face interview. The manual skills classification system, Hand-10 questionnaire and ABILHAND-kids questionnaire will be used.~While validating the Hand10 questionnaire in children with cerebral palsy, it was planned to use the ABILHAND-kids scale, which has been previously validated for reliability and validity in cerebral palsy. It was also planned to use the hand function classification system in the evaluations. The Hand-10 questionnaire will be filled out by the child himself. The ABILHAND-kids questionnaire will be filled out by the parent. An expert will record the manuel ability system according to the hand skills."
219522409|NCT00135395|DRUG|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
219522410|NCT00135395|DRUG|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
218868580|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
218868581|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
218868582|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
219522411|NCT01432171|DRUG|Lacosamide|Given PO
219522412|NCT01432171|OTHER|Placebo|Given PO
219522413|NCT06739083|OTHER|e-mentoring program|The e-mentoring program is planned to last four weeks to facilitate the adaptation process of newly recruited nurses in intensive care units via the e-mentoring website.
219599631|NCT04543890|RADIATION|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
219599632|NCT04543890|RADIATION|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
219599633|NCT04543890|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
219599634|NCT04543890|DRUG|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
219599635|NCT04069338|PROCEDURE|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
219599636|NCT03145389|PROCEDURE|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
219599637|NCT02996487|DRUG|Vancomycin|
219599638|NCT02996487|OTHER|Placebo|
219599639|NCT04492592|BEHAVIORAL|Workshop|Workshop
219485996|NCT02428959|DRUG|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
219485997|NCT01929837|DEVICE|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
219485998|NCT01929837|DEVICE|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
219485999|NCT01929837|DEVICE|sham E-field navigated rTMS|
219486000|NCT01929837|DEVICE|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
219486001|NCT03993288|DRUG|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
219486002|NCT03993288|DRUG|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
219486003|NCT00547209|DRUG|air|60% air combined with 40% oxygen for ventilation
219599640|NCT04492592|BEHAVIORAL|SMS/Texting|SMS/Texting
219599641|NCT04082156|DEVICE|electrical stimulation|electrical stimulation
219486004|NCT00547209|DRUG|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
219486005|NCT05036447|OTHER|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
219486006|NCT03291847|DEVICE|fetal monitoring|Maternal fetal monitoring
219486007|NCT03291847|DRUG|Buprenorphine Naloxone|Treatment for opioid use disorder
219486008|NCT01987843|DRUG|MT-1303-Low|
219486009|NCT01987843|DRUG|MT-1303-Middle|
219599642|NCT04082156|DEVICE|Sham|no stimulation
219486010|NCT01987843|DRUG|MT-1303-High|
219486011|NCT01987843|DRUG|Placebo|
219486012|NCT06159439|DIAGNOSTIC_TEST|Contrast enhanced ultrasound scan|Contrast enhanced ultrasound using Sonovue microbubble contrast
219486013|NCT06159439|DIAGNOSTIC_TEST|MRI scan|Arterial-spin labelling magnetic resonance imaging
219486014|NCT02488473|DRUG|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
219486015|NCT02488473|DRUG|Ropivacaine|20 ml Ropivacaine 5mg/ml
219486016|NCT02488473|DRUG|Isotonic Saline|Placebo
219486017|NCT06383143|OTHER|no intervention|no intervention
219486018|NCT02733601|OTHER|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
219486019|NCT00479739|DRUG|Salmeterol/fluticasone propionate or formoterol/budesonide|
219486020|NCT04871724|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 1 and 14
219486021|NCT04871724|DRUG|Fluconazole|Subjects will receive fluconazole once daily on Days 5 to 18
219486022|NCT03650179|OTHER|Observational study : No intervention|Observational study : No intervention. Only exporting data
219486023|NCT00791284|DRUG|Intermediate release (IR) Paliperidone|
219486024|NCT06123975|OTHER|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
219486025|NCT03500887|DEVICE|intragastric bag|
219486026|NCT04656171|RADIATION|MRI of the hand and forearm,|MRI of the hand and forearm,
219486027|NCT04731909|DRUG|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
219486028|NCT04731909|DRUG|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
219599643|NCT04220970|OTHER|BIA-ALCL|Observational : no intervention
219599644|NCT03212248|DIAGNOSTIC_TEST|Thoracic Ultrasound (TUS)|
219599645|NCT01403857|OTHER|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
219599646|NCT01403857|OTHER|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
219599647|NCT01669603|DIETARY_SUPPLEMENT|Bifidobacterium lactis Bl-04|The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
219599648|NCT01669603|DIETARY_SUPPLEMENT|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
219599649|NCT01669603|BIOLOGICAL|Rhinovirus|rhinovirus for experimental challenge
219599650|NCT04274712|DIAGNOSTIC_TEST|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
219599651|NCT00030472|DRUG|pegylated liposomal doxorubicin hydrochloride|
219599652|NCT02234492|DRUG|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
219599653|NCT06327152|DRUG|Caffeine|"Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
218868583|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
219486029|NCT04731909|DRUG|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
219486030|NCT04731909|DRUG|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
219486031|NCT04979078|DEVICE|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
219486032|NCT01426828|BIOLOGICAL|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
219486033|NCT02133911|DRUG|Ranolazine|
219486034|NCT02446197|OTHER|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
219486035|NCT04143997|DIAGNOSTIC_TEST|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
219486036|NCT01222182|DRUG|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
219486037|NCT01247974|DEVICE|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
219486038|NCT04215653|DRUG|Anaprazole Sodium|administered orally once every 30-60 minutes before breakfast for 4 weeks
219486039|NCT04215653|DRUG|Rabeprazole|administered orally once every 30-60 minutes before breakfast for 4 weeks
219486040|NCT04215653|DRUG|Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
219486041|NCT04215653|DRUG|Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
219486042|NCT03358342|OTHER|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
219599654|NCT06327152|OTHER|Sterile Water Placebo|"Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.~The placebo will be administered for a maximum of 4 weeks. The placebo will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The placebo will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
219599655|NCT02425566|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
219599656|NCT02425566|DRUG|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
219486043|NCT01979588|OTHER|What's Going Around tool|Provider has access to the What's Going Around tool
219486044|NCT01979588|OTHER|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
218868584|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
218868585|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
218868586|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
219486045|NCT05038410|DRUG|Wobenzym®|Wobenzym®
219486046|NCT05038410|OTHER|Placebo|Microcrystalline cellulose
219486047|NCT06492018|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
219486048|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
219486049|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
219486050|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
219486051|NCT02235415|DRUG|Motens® (lacidipine)|
219486052|NCT04404816|DRUG|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
219486053|NCT05116761|BIOLOGICAL|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
219486054|NCT05116761|OTHER|Saline|Placebo Saline
219486055|NCT02106793|DRUG|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
219486056|NCT02106793|DRUG|Identical placebo solution|Identical placebo solution
219486057|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
219486058|NCT00131573|DEVICE|bion|battery powered bion microstimulator
219486059|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
219486060|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
219486061|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
219486062|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
219486063|NCT03978897|DEVICE|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
219486064|NCT03978897|OTHER|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
219486065|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
219486066|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
219486067|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
219486068|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
219486069|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
219486070|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
219486071|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
219486072|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
219486073|NCT02708940|OTHER|Participatory technology development|Creating mobile support tools by patients and their therapists
219486074|NCT02708940|OTHER|Usual Care|Usual care as part of the UCLA PHP and IOP programs
219486075|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
219486076|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
218868587|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
218868588|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
218868589|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
218868590|NCT00560495|OTHER|immunoenzyme technique|
219486077|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
218868591|NCT00560495|OTHER|laboratory biomarker analysis|
218868592|NCT00560495|RADIATION|Tc 99m sestamibi|
219486078|NCT05415618|OTHER|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
219486079|NCT05415618|DEVICE|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
219486080|NCT05415618|OTHER|Nerve gliding|Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
219486081|NCT00576849|DRUG|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
219486082|NCT00576849|DRUG|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
219486083|NCT00576849|DRUG|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
219486084|NCT02712736|OTHER|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
219486085|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
219486086|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
219486087|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
219486088|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
219486089|NCT04222218|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
219486090|NCT03896373|OTHER|Blood samples|Blood samples
219486091|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
219486092|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
219486093|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
219599657|NCT01550029|BEHAVIORAL|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
219599658|NCT01550029|BEHAVIORAL|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
219486094|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
219486095|NCT01179191|DRUG|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
218868593|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
218868594|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
219486096|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
219599659|NCT00802932|DEVICE|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
219599660|NCT00802932|DEVICE|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
218868595|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
219199899|NCT01286766|DRUG|DCF (docetaxel with cisplatin with 5-FU)|"1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles"
219199900|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
219486097|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
219486098|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
219486099|NCT05349760|DRUG|Placebo|Saline/D5W
219486100|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
219486101|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
219486102|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
219486103|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
219599661|NCT05662839|DEVICE|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
219599662|NCT07134049|OTHER|sensory integration therapy|"Sensory Integration Therapy (SIT) is a client-centered rehabilitation approach aimed at improving adaptive and functional responses to sensory stimuli in changing environments. It is based on structured, individualized activities conducted in enriched sensory environments. These environments are designed to be engaging and motivating for children through the use of interactive and playful tasks that match their sensory processing profiles.~Sensory integration plays a key role in motor planning, postural control, attention, and emotional regulation. Deficits in sensory integration-particularly in vestibular, tactile, and proprioceptive systems-may result in poor muscle tone, difficulty with balance and coordination, and impaired motor planning. These issues can negatively impact the development of gross motor, fine motor, language, and academic skills. For this reason, sensory-based interventions that support neural organization and promote adaptive responses are commonly recommended i"
219599663|NCT07134842|BIOLOGICAL|Ipilimumab (3 mg/kg)|All participants will be treated with ipilimumab (3mg/kg) for up to 2 cycles. Each cycle will last 21 days with participants receiving ipilimumab on the 1st day of the cycle.
219599664|NCT07133997|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
219599665|NCT07133997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219599666|NCT07133997|BIOLOGICAL|Blinatumomab|Given CIV
219599667|NCT07133997|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219599668|NCT07133997|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219486104|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
219486105|NCT06346756|OTHER|Treatment of dental caries.|The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
219486106|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
219599669|NCT07133997|DRUG|Cyclophosphamide|Given cyclophosphamide
219599670|NCT07133997|PROCEDURE|Echocardiography Test|Undergo ECHO
219486107|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
219599671|NCT07133997|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218868596|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
218868597|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
219486108|NCT03297801|DIETARY_SUPPLEMENT|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
219486109|NCT02741609|DEVICE|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
219486110|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
219486111|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
219486112|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
219486113|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
219486114|NCT02001285|DRUG|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
219486115|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
218868598|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
218868599|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
219486116|NCT02801838|DRUG|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
219486117|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
219486118|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
219486119|NCT01177735|DRUG|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
218868600|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
218868601|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
218868602|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
218868603|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
219486120|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
219486121|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
219486122|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
219486123|NCT03367949|OTHER|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
219486124|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
219486125|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
219486126|NCT04749121|DEVICE|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
219486127|NCT04749121|DRUG|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
219599672|NCT07133997|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219599673|NCT07133997|DRUG|Venetoclax|Given PO
219599674|NCT07133997|DRUG|Vincristine|Given vincristine
219599675|NCT07134205|DRUG|JMT101|JMT101, 6 mg/kg, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
219599676|NCT07134205|DRUG|Irinotecan|Irinotecan, 180mg/m\^2, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
218868604|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
218868605|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
218868606|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
219486128|NCT04749121|DEVICE|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
219486129|NCT04749121|DEVICE|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
218868607|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
219486130|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
218868608|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
218868609|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
218868610|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
219486131|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
219599677|NCT07134205|DRUG|Regorafenib|Regorafenib, 160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
219599678|NCT07134283|PROCEDURE|Preoperative and Postoperative Cold Therapy with Gel Cold Pack|Cold therapy was applied using a conventional gel cold pack , pre-cooled at -17°C for at least 2 hours. In the intervention group, cold application was performed three times before surgery (20 minutes per session with 40-minute intervals), and continued postoperatively for 24 hours with the same frequency. This protocol aimed to reduce pain, swelling, bleeding, and improve functional outcomes after total knee arthroplasty.
219599679|NCT07134283|PROCEDURE|Postoperative Cold Therapy with Gel Cold Pack|Cold therapy applied only in the postoperative period, for 24 hours, using the same method as the intervention group (20-minute applications with 40-minute breaks.
219599680|NCT07133945|PROCEDURE|Silicone plaster or Steristrip or Vaseline|Prophylatic treatment of the skin before breakage of the skin in dupuytrens disease
219599681|NCT07133724|OTHER|AI-Based Smart Assessment and Rehabilitation Training|Through the integration of wireless inertial sensors and smartphone imaging, the system can monitor pelvic and lumbar movements in real time, generate a digital twin model, and deliver instant feedback to guide patients in performing correct exercises.
219199901|NCT04905914|DRUG|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
219486132|NCT03224741|BEHAVIORAL|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
219486133|NCT03224741|BEHAVIORAL|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
219486134|NCT03224741|BEHAVIORAL|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
219486135|NCT02432521|OTHER|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
219599682|NCT07135167|COMBINATION_PRODUCT|Epi-ON corneal cross-linking (CXL)|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light for 20 minutes."
218868611|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
219199902|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
219486136|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
219486137|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
219486138|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
219486139|NCT00960232|DRUG|placebo|placebo
219486140|NCT04450979|DIETARY_SUPPLEMENT|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
219486141|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
219486142|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
219599683|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
219599684|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
219599685|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
219599686|NCT07134088|DRUG|Blinatumomab|Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).
219599687|NCT06599216|DRUG|Adebrelimab+Dalpciclib+Standard Endocrine Therapy|Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
219599688|NCT04489719|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219599689|NCT04489719|OTHER|Questionnaire Administration|Ancillary studies
219599690|NCT04489719|DRUG|Radium Ra 223 Dichloride|Given IV
219599691|NCT03563651|PROCEDURE|Biopsy|Undergo biopsy
218868612|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
219599692|NCT03563651|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and stool
219599693|NCT03563651|OTHER|Laboratory Biomarker Analysis|Correlative studies
219599694|NCT03563651|OTHER|Questionnaire Administration|Ancillary studies
219599695|NCT02376673|OTHER|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
219599696|NCT02376673|OTHER|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
219599697|NCT06446128|BIOLOGICAL|CD19/CD20/BCMA CAR T cells|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection"
218868613|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
218868614|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
218868615|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
218868616|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
218868617|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
219599698|NCT04873934|DRUG|Inclisiran|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
219599699|NCT02567240|OTHER|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
219599700|NCT01739660|DRUG|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
219599701|NCT07133971|OTHER|skin care product（Cerave Neuroceramide Moisturizing Repair Body Lotion）|All study participants will use Cerave Neuroceramide Moisturizing Body Lotion during the trial period, applying it every night to dry skin areas. If topical medications are used, they should be applied first to dry skin areas, followed by the product.
219599702|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
219599703|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
219599704|NCT00400842|DRUG|Placebo|Placebo
219599705|NCT00315237|DRUG|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
218868618|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
219486143|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
219486144|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
218868619|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
218868620|NCT01675362|DRUG|Placebo|They will receive placebo
218868621|NCT05233345|BEHAVIORAL|Occupational Therapy|online occupational therapy sessions are based on the activity training
218868622|NCT00003447|DRUG|gemcitabine hydrochloride|
218868623|NCT00003447|DRUG|vinorelbine tartrate|
218868624|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
218868625|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
218868626|NCT03168100|DRUG|Lenalidomide|taken by mouth
218868627|NCT03168100|DRUG|Dexamethasone|taken by mouth
218868628|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
218868629|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
218868630|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
218868631|NCT04464824|OTHER|no intervention|no intervention
218868632|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
218868633|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
218868634|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
218868635|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
218868636|NCT00112177|DRUG|Itopride Hydrochloride|
218868637|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
218868638|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
219486145|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
218868639|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
219486146|NCT02742818|DEVICE|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
219486147|NCT02742818|DEVICE|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
219486148|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
219486149|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
219486150|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
218868640|NCT01065831|BEHAVIORAL|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
218868641|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
218868642|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
218868643|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
218868644|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
218868645|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
219486151|NCT02249065|DRUG|Brimonidine|
219486152|NCT01260194|DRUG|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
219486153|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
219486154|NCT06264271|BEHAVIORAL|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
219486155|NCT01068093|DRUG|Ezetimibe|10mg daily
219486156|NCT03740828|DEVICE|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
219486157|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
219486158|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
219486159|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
219486160|NCT01785472|DRUG|LCZ696|LCZ696 200 mg tablet
219486161|NCT01785472|DRUG|Olmesartan|Olmesartan 20 mg capsule
219599706|NCT04591951|BEHAVIORAL|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
219599707|NCT04591951|OTHER|Usual care|Care as usual
219599708|NCT07010887|OTHER|Short Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 24 hours.
219599709|NCT07010887|OTHER|Long Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 72 hours.
219599710|NCT03431142|DRUG|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
219599711|NCT03431142|DRUG|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
219486162|NCT01785472|DRUG|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
219486163|NCT01785472|DRUG|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
219486164|NCT02776215|DRUG|tasimelteon|Melatonin receptor agonist
219486165|NCT02405351|BEHAVIORAL|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
219486166|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
219486167|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
219486168|NCT00969267|OTHER|ear-acupuncture A|with needle stimulation
219486169|NCT00969267|OTHER|stimulation B|with bread stimulation on ear acupuncture point
219486170|NCT00969267|OTHER|stimulation C|without needle stimulation
219599712|NCT03946553|OTHER||No intervention
219599713|NCT02266537|DRUG|Tamsulosin|
219599714|NCT02266537|DRUG|Alfuzosin|
219486171|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
219486172|NCT03840473|BEHAVIORAL|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
219599715|NCT02266537|DRUG|Doxazosin|
219599716|NCT02266537|DRUG|Placebo|
219599717|NCT05500950|OTHER|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
219599718|NCT07133321|BEHAVIORAL|Husband Group Health education.|The community-based husband group health education will target expectant fathers with pregnant partners. It will focus on reshaping gender-related attitudes and beliefs, promoting caregiving best practices, preventing violence against women, and improving men's involvement in maternal health. The intervention will comprise group sessions with 20 participants each, conducted over three sessions lasting 2.5 hours each, with a 15-day interval between sessions. The sessions will cover key topics, including recognizing obstetric danger signs, preparing for childbirth, fostering men's engagement in maternal health, advocating nonviolence and shared responsibility, and encouraging joint decision-making.
218868646|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
219486173|NCT03840473|BEHAVIORAL|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
219486174|NCT03840473|BEHAVIORAL|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
219486175|NCT04859647|OTHER|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
219486176|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
219486177|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
219486178|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
219486179|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
219486180|NCT04074122|DIAGNOSTIC_TEST|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
219486181|NCT05611710|DRUG|Placebo|"Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
219486182|NCT05611710|DRUG|Anakinra|"Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
219486183|NCT00118222|DRUG|porfimer sodium|All patients receive porfimer sodium IV.
219486184|NCT00118222|PROCEDURE|adjuvant therapy|All patients receive porfimer sodium IV.
219486185|NCT00118222|PROCEDURE|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
219486186|NCT06469476|BEHAVIORAL|depression post partum|visit post partum
219486187|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
219486188|NCT02878239|OTHER|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
219486189|NCT02878239|OTHER|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
218868647|NCT01822613|DRUG|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
219486190|NCT01366365|DRUG|methylnaltrexone|
219486191|NCT01366365|DRUG|placebo|
219486192|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
219486193|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
219486194|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
219486195|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
219486196|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
219486197|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
219486198|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
219486199|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
219486200|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
219199903|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
219486201|NCT05263869|DRUG|MRG002|Administrated intravenously
219486202|NCT06041269|DRUG|Rosnilimab|PD-1 agonist antibody
219486203|NCT06041269|DRUG|Placebo|Placebo
219486204|NCT06114017|BEHAVIORAL|Social Media Abstention|People will stop or reduce their social media use for one week.
219486205|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
219486206|NCT01294709|DRUG|telcagepant|
219486207|NCT01294709|DRUG|Placebo to telcagepant|
219486208|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
219486209|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
219599719|NCT07133321|BEHAVIORAL|Helping Mothers Survive + RMC|"The Helping Mothers Survive training is designed by Jhpiego, an affiliate of Johns Hopkins University, in collaboration with global health partners, including the World Health Organization (WHO), Laerdal Global Health, and the International Confederation of Midwives (ICM) for healthcare professionals involved in childbirth care focusing on saving lives at birth in low-resource settings. This on-site training will use realistic simulations to enhance skills in identifying and managing key causes of maternal mortality, such as postpartum hemorrhage and preeclampsia, starting with essential labor care. The program employs the MamaNatalie birthing simulator, a low-tech realistic tool for hands-on practice developed by Laerdal Global Health. MamaNatalie features a model uterus with a neonate, placenta, and umbilical cord, enabling simulations of postpartum hemorrhage, breech delivery, vacuum-assisted birth, and normal labor."
219486210|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
219486211|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
219486212|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
218868648|NCT01822613|DRUG|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
218868649|NCT01822613|DRUG|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
219486213|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
219486214|NCT06521281|BEHAVIORAL|Chan-Chuang qigong|Twice daily, every 15 minutes Chan-Chuang qigong
218868650|NCT01822613|DRUG|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
219486215|NCT05322421|OTHER|Topical Olive Oil|Olive oil will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
219599720|NCT02942641|PROCEDURE|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
218868651|NCT01822613|DRUG|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
218868652|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
218868653|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
218868654|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
218868655|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
218868656|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
218868657|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
218868658|NCT01055678|DRUG|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
218868659|NCT01055678|PROCEDURE|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
218868660|NCT05578378|DRUG|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
219486216|NCT05322421|OTHER|Sodium bicarbonate 5% solution|Sodium bicarbonate 5% solution will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
219486217|NCT02514031|DRUG|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
219486218|NCT02514031|DRUG|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
219486219|NCT02514031|DRUG|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
219486220|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
219486221|NCT02502084|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
219486222|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
219486223|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
219486224|NCT00171899|DRUG|imatinib mesylate|
219486225|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
219486226|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
219486227|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
219486228|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
219486229|NCT00259311|DRUG|LY2422347|
219486230|NCT00259311|DRUG|placebo|
219486231|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
219486232|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
219486233|NCT06565871|DRUG|Placebo Injection|SC
219486234|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
218868661|NCT05578378|DRUG|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
219199904|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia with AI chatbot|digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and patient-centered conversational agents
218868662|NCT01504204|DRUG|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
218868663|NCT01504204|DRUG|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
218868664|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
218868665|NCT00903331|DRUG|Placebo|matching placebo, once daily
218868666|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
219199905|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia without AI chatbot|digital cognitive behavioral therapy for insomnia without two-way interactive, intelligent, and patient-centered conversational agents
219486235|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
219486236|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
219486237|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
219486238|NCT01940276|DRUG|Abiraterone acetate|
219486239|NCT01940276|DRUG|Prednisone|
219486240|NCT06566053|OTHER|Observation|Observation
219486241|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
219486242|NCT02822612|DEVICE|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
219486243|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
219486244|NCT05761522|OTHER|transthoracic echocardiography|"* Concerning the main judgment criterion and the secondary judgment criteria:~  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~ * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~ * Tricuspid Annular Systolic Excursion (TAPSE) (mm)~ * S wave at the tricuspid ring (cm/s)~* Other parameters collected systematically:~  * Surface of the left ventricle (end-systolic and end-diastolic),~ * Global strain of the left ventricle~ * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~ * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~ * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
219486245|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
219486246|NCT03284515|BIOLOGICAL|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
219486247|NCT06538571|DIAGNOSTIC_TEST|Near infrared spectroscopy|Noninvasive monitor for venous saturation
219486248|NCT00163527|DRUG|Roflumilast|
219486249|NCT04473339|PROCEDURE|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
219486250|NCT04473339|PROCEDURE|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
219486251|NCT00232778|DEVICE|GAMMA-Iridium-192 catheter|
219486252|NCT05648097|DEVICE|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
219486253|NCT05311215|DRUG|SL-1002|SL-1002 injectable solution
219486254|NCT05311215|DRUG|Placebo|Matching placebo injectable solution
219486255|NCT00954694|DEVICE|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
219599721|NCT02942641|PROCEDURE|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
219199906|NCT06599190|OTHER|pelvic floor exercises, nutritional instructions|They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
219599722|NCT02942641|DEVICE|Foley|
219599723|NCT02516553|DRUG|BI 894999|film-coated tablets
219599724|NCT01914627|DRUG|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
219599725|NCT01914627|DRUG|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
219599726|NCT00313339|DRUG|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
219599727|NCT00707382|GENETIC|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
219599728|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
219599729|NCT00707382|OTHER|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
219199907|NCT06599190|OTHER|abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions|consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.
219199908|NCT06593457|DRUG|IP|NX-5948 oral
219199909|NCT06593457|DRUG|Matching Placebo|Fluconazole
218868667|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
218868668|NCT06421922|DIETARY_SUPPLEMENT|Group 1 received a regular constipation diet|Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
218868669|NCT06421922|DIETARY_SUPPLEMENT|Group 2 received a constipation diet rich in soluble fiber|Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
218868670|NCT06421922|DIETARY_SUPPLEMENT|Group 3 received a constipation diet supplemented with probiotic yogurt.|"Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks."
218868671|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
218868672|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
218868673|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
218868674|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
218868675|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
218868676|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
218868677|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
218868678|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
218868679|NCT01205477|DRUG|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
218868680|NCT01205477|DRUG|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
219486256|NCT04365829|DEVICE|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
219486257|NCT04727580|DRUG|HSK7653 10mg Q2W|HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
219486258|NCT04727580|DRUG|HSK7653 25mg Q2W|HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
219486259|NCT04727580|DRUG|Placebo|Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
219599730|NCT03052127|DRUG|Light-activated AU-011|Study treatment
219599731|NCT03052127|DEVICE|Laser Activation|Study treatment
219599732|NCT06550973|PROCEDURE|pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
219486260|NCT01612780|DEVICE|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
219486261|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
219599733|NCT02494180|DRUG|fentanyl|arm A receiving iv fentanyl
218868681|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
218868682|NCT04334564|DRUG|Placebos|Placebos were controls.
219486262|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
218868683|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
218868684|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
218868685|NCT02259985|DRUG|Itasetron tablet|
219486263|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486264|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486265|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486266|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486267|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486268|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486269|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
219486270|NCT05005130|OTHER|TASKPEN|"TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)"
219486271|NCT04395040|OTHER|Semi-structured interview|Semi-structured interview
219486272|NCT06402890|DIETARY_SUPPLEMENT|Resistance training with collagen supplementation|"Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week."
219486273|NCT00012194|DRUG|7-hydroxystaurosporine|Given IV
219486274|NCT00012194|DRUG|cisplatin|Given IV
219486275|NCT00012194|OTHER|laboratory biomarker analysis|Correlative studies
219599734|NCT02494180|DRUG|pethidine|arm B receiving iv pethidine
219599735|NCT02494180|DRUG|Diazepam|arm B receiving iv diazepam
219599736|NCT02494180|DRUG|Midazolam|arm A receiving iv midazolam
218868686|NCT02259985|DRUG|Itasetron infusion|
218868687|NCT02259985|OTHER|high fat breakfast|
218868688|NCT05521321|BEHAVIORAL|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
218868689|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
218868690|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
219486276|NCT03016988|DRUG|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
219599737|NCT05451992|DIETARY_SUPPLEMENT|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
219599738|NCT05451992|DIETARY_SUPPLEMENT|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
218868691|NCT05234203|DIETARY_SUPPLEMENT|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
218868692|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
218868693|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
219486277|NCT03016988|DRUG|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
219486278|NCT03016988|DRUG|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
219486279|NCT06422832|OTHER|HeartLogic or TriageHF Algorithms for implantable devices|Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
219486280|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
219486281|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
219486282|NCT05736809|OTHER|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
219486283|NCT05736809|OTHER|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
219486284|NCT05736809|OTHER|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
219486285|NCT00568516|DRUG|ASP3550|subcutaneous administration
219486286|NCT01129518|BIOLOGICAL|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
218868694|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
218868695|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
218868696|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
218868697|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
218868698|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
218868699|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
218868700|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
218868701|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
219486287|NCT01129518|BIOLOGICAL|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
219486288|NCT03310606|OTHER|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
219486289|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
219486290|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
219486291|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
219599739|NCT01118286|DRUG|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
219599740|NCT02312908|DRUG|Clonazepam|For experimental treatment of RBD
219599741|NCT02312908|DRUG|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
218868702|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
218868703|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
219199910|NCT06862427|BEHAVIORAL|Healthy Lifestyle Application (Traditional Chinese Version)|A firefighter-oriented Healthy Lifestyle Application (Traditional Chinese Version)
218868704|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
218868705|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
218868706|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
218868707|NCT00257660|DRUG|Placebo|500 units
218868708|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
218868709|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
219486292|NCT05550025|DRUG|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
219486293|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
219486294|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
219486295|NCT02784002|DRUG|Ridinilazole|
219486296|NCT02784002|DRUG|Fidaxomicin|
219486297|NCT05298215|BIOLOGICAL|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
219486298|NCT05298215|OTHER|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
219486299|NCT02297607|DIETARY_SUPPLEMENT|Tube Feeding|
219486300|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy|"Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;"
219486301|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based.
218868710|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
219486302|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy|"Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller."
219599742|NCT04549103|OTHER|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
219599743|NCT04815655|PROCEDURE|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
219599744|NCT01396915|DIETARY_SUPPLEMENT|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
218868711|NCT04932291|DRUG|vafidemstat|1.2mg capsule
218868712|NCT04932291|DRUG|Placebo|placebo capsule
218868713|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
218868714|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
218868715|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
219486303|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based
219486304|NCT00163371|DRUG|Ciclesonide|
219486305|NCT05494580|DRUG|Pamiparib|Oral
219486306|NCT05494580|DRUG|Surufatinib|Oral
219486307|NCT05282810|OTHER|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
219486308|NCT05268523|BEHAVIORAL|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
219486309|NCT05268523|BEHAVIORAL|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
219486310|NCT04007406|DRUG|dexfadrostat phosphate|DP13 systemic administration
219486311|NCT04074798|BEHAVIORAL|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
219486312|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
219486313|NCT01071083|DRUG|natalizumab|300 mg intravenous every 4 weeks
219486314|NCT01071083|DRUG|interferon beta 1-a|30 ug intramuscular once per week
219486315|NCT01071083|DRUG|methylprednisolone|1000 mg intravenous every 4 weeks
219486316|NCT01071083|OTHER|IV placebo|placebo intravenous every 4 weeks
219486317|NCT01071083|DRUG|glatiramer acetate|20 mg subcutaneous once daily
219486318|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
219486319|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
219486320|NCT00263393|DRUG|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
219486321|NCT00263393|BEHAVIORAL|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
219486322|NCT06414265|DEVICE|Transcatheter mitral valve replacement|The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
219486323|NCT02143401|OTHER|Laboratory Biomarker Analysis|Correlative studies
219599745|NCT03694327|DEVICE|CT-101-M|Mobile Application
219599746|NCT03694327|DEVICE|QuitGuide|Mobile Application
219599747|NCT01166165|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
219599748|NCT01166165|DRUG|Placebo|3 placebo tablets daily for 20 weeks
219486324|NCT02143401|BIOLOGICAL|Navitoclax|Given PO
219486325|NCT02143401|OTHER|Pharmacological Study|Correlative studies
219486326|NCT02143401|DRUG|Sorafenib|Given PO
219486327|NCT02143401|DRUG|Sorafenib Tosylate|Given PO
219486328|NCT01825499|OTHER|Registry|
219486329|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
219486330|NCT05894668|OTHER|ECIRS|Endoscopic Combined Intrarenal Surgery
219599749|NCT03354767|PROCEDURE|Aortic and aortic valve surgery|
219599750|NCT00611481|BEHAVIORAL|Tai Chi|a set of pre-designed Tai Chi Movements
219199911|NCT06588907|DRUG|Bupivacaine Hydrochloride|After preparing the infraclavicular block site, a 22-gauge needle, guided by ultrasound, will be placed in the 6-7 o'clock position in the same plane as the ultrasound probe. Subsequently, lateral, medial, and posterior cords described as hypoechoic nerve fascicles within hyperechoic structures will be identified. Initially, 2 mL of saline will be administered to confirm proper spread. Once confirmed, 20 mL of 0.25% bupivacaine (prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline) will be injected in fractional doses with intermittent negative aspiration. Fifteen minutes after this procedure, anesthesia depth will be assessed using a cold-hot test, followed by reduction and application of the cast.
219486331|NCT06701604|DIETARY_SUPPLEMENT|Single Strain Probiotic + Milk Protein|• Both conditions matched flavor, color, and serving size
219486332|NCT06701604|DIETARY_SUPPLEMENT|Placebo + Milk Protein|• Both conditions matched flavor, color, and serving size
219486333|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
219599751|NCT00611481|BEHAVIORAL|Strength training|Lower-extremity strength training exercises
219599752|NCT00611481|BEHAVIORAL|Low-Impact Exercise Control|a set of chair-based low-impact exercises
219486334|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
219199912|NCT06588907|DRUG|Ketamine|Until the recovery period, patients will be closely monitored by an experienced doctor or nurse during sedation. Emergency equipment will be readily available in case of any complications. The following protocol will be used for procedural sedation-analgesia (PSA): Ketamine will be administered intravenously at a dose of 0.5-1 mg/kg. Patients with Numeric Rating Scale (NRS) scores above 5 may receive additional doses of 0.25-1 mg/kg, repeated every 5 to 10 minutes as needed.
219486335|NCT00045396|DRUG|tipifarnib|Given orally
219486336|NCT05552235|DEVICE|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
219486337|NCT05552235|OTHER|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
219486338|NCT04885816|DEVICE|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
219486339|NCT04885816|DEVICE|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
219486340|NCT04454619|DRUG|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
219486341|NCT02360059|DRUG|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
219486342|NCT02360059|OTHER|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
219486343|NCT02360059|BEHAVIORAL|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
219486344|NCT02360059|OTHER|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
219486345|NCT05189145|DRUG|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
219486346|NCT05189145|OTHER|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
219486347|NCT05189145|DIAGNOSTIC_TEST|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
219486348|NCT05189145|DRUG|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
219486349|NCT05189145|OTHER|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily
219486350|NCT05189145|DRUG|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
219486351|NCT04557982|PROCEDURE|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
219486352|NCT01136044|OTHER|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
218868716|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
219486353|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
219486354|NCT05161559|PROCEDURE|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
219486355|NCT05161559|PROCEDURE|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
219486356|NCT05161559|PROCEDURE|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
219486357|NCT01339000|DRUG|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
218868717|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
218868718|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
218868719|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
218868720|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
219486358|NCT01339000|BIOLOGICAL|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
219486359|NCT01339000|BIOLOGICAL|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
219486360|NCT01339000|BIOLOGICAL|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
219486361|NCT01339000|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
219486362|NCT01339000|BIOLOGICAL|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
219486363|NCT05151796|DRUG|Aspirin|Daily aspirin intake for cardiovascular prevention
219486364|NCT03001869|DRUG|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
219486365|NCT03712046|DIAGNOSTIC_TEST|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
219486366|NCT05785416|OTHER|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
219486367|NCT05785416|OTHER|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
218868721|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
219486368|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
219486369|NCT00601276|DRUG|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
219486370|NCT00601276|DRUG|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
219486371|NCT02659826|DEVICE|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
219486372|NCT02659826|DEVICE|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
219486373|NCT02659826|DEVICE|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
219486374|NCT02659826|DEVICE|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
218868722|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
219486375|NCT02659826|DEVICE|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
218868723|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
219486376|NCT02659826|DEVICE|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
219486377|NCT02659826|DEVICE|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
219486378|NCT02072174|DRUG|Anaferon for Children|Anaferon for children: For oral use.
219486379|NCT03446716|BEHAVIORAL|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
219486380|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
219486381|NCT06417723|PROCEDURE|Maxillary nerve block|It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
219486382|NCT04272255|DRUG|scopolamine HBr|Nasal Gel
219486383|NCT04272255|DRUG|Transdermal Scopolamine|Patch
219486384|NCT05531838|DEVICE|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
219486385|NCT05674721|DRUG|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
219486386|NCT05674721|DRUG|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
219486387|NCT02582359|DRUG|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
219486388|NCT02582359|DRUG|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
219486389|NCT02582359|DRUG|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
219486390|NCT01831518|DEVICE|CRT Implant|
219486391|NCT01831518|DEVICE|Body Surface ECG Mapping|
218868724|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
218868725|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
218868726|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
218868727|NCT04093336|BIOLOGICAL|Placebo|Placebo
218868728|NCT04093336|OTHER|standardized treatment|standardized treatment
218868729|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
218868730|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
218868731|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
218868732|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
219486392|NCT02256059|PROCEDURE|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
219486393|NCT02067585|DIETARY_SUPPLEMENT|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
219599753|NCT02202863|DIETARY_SUPPLEMENT|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
219599754|NCT00357084|DRUG|methotrexate|
219599755|NCT00357084|DRUG|methylprednisolone|
219599756|NCT00357084|DRUG|prednisone|
219599757|NCT00421980|DRUG|Etanercept|
219486394|NCT01895088|DEVICE|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
219486395|NCT02388607|OTHER|measurements|performance measurements
219486396|NCT04466956|DEVICE|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
219486397|NCT00197470|PROCEDURE|IL-1, TNF-alpha, Il-10|
219599758|NCT00097396|BIOLOGICAL|rF1V vaccine|
218868733|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
218868734|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
218868735|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
218868736|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
218868737|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
218868738|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
218868739|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
218868740|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
219486398|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
219486399|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
219486400|NCT01506570|BIOLOGICAL|Placebo|One SC injection at Day 0 and Day 180 of placebo
219486401|NCT05538039|OTHER|Distract with play dough|Distract with play dough
219486402|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
219486403|NCT05538039|OTHER|Control group|Routine nursing care
219486404|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
219599759|NCT02576912|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
219599760|NCT02576912|DRUG|Active Pregnenolone|A dose given sublingually.
219486405|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
219486406|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
219486407|NCT02689726|DRUG|GTL001+|
219599761|NCT02576912|DRUG|Placebo|A placebo dose given sublingually.
219599762|NCT02576912|DRUG|Placebo|Placebo dose given intravenously.
218868741|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
218868742|NCT02317952|OTHER|Active Comparator Formula|
218868743|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
218868744|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
218868745|NCT00381875|BIOLOGICAL|sargramostim|
218868746|NCT00381875|OTHER|immunoenzyme technique|
218868747|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
218868748|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
218868749|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
219486408|NCT02689726|DRUG|Aldara|5% imiquimod cream
219486409|NCT00255476|DRUG|gefitinib|
219486410|NCT00255476|DRUG|cisplatin|
219486411|NCT00255476|DRUG|5-flourouracil|
219486412|NCT03814213|OTHER|CGA|Multi-level Health assessment
219486413|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
219486414|NCT02962869|DRUG|BAY987517|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
219486415|NCT02962869|OTHER|Untreated skin|One site is patched without treatment as control
219486416|NCT01883531|DRUG|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
219599763|NCT04966273|DEVICE|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
219599764|NCT01464931|DRUG|Denosumab|Adminstered by subcutaneous injection
219599765|NCT06186180|OTHER|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
219599766|NCT02936180|BIOLOGICAL|HD-TIV|
219486417|NCT01883531|DRUG|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
219486418|NCT04474288|DIAGNOSTIC_TEST|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
219486419|NCT01885507|OTHER|Pass recommendations on ventilation factors and extubation|"* the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
219486420|NCT03433807|DRUG|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
218868750|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
219486421|NCT00533585|DRUG|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
219486422|NCT00533585|DRUG|Paclitaxel|200 mg/m\^2 By Vein Over 3 Hours on Day 1.
218868751|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
219486423|NCT00533585|DRUG|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
219486424|NCT00533585|DRUG|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
219486425|NCT05409807|DEVICE|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
219486426|NCT05409807|DEVICE|Ultrasound guided|Ultrasound guided interscalene nerve block
219486427|NCT03544606|DRUG|isosorbide mononitrate|40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
219486428|NCT03544606|DRUG|Placebos|In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
219486429|NCT00446771|DRUG|Mannitol|
219486430|NCT01093716|DEVICE|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
219486431|NCT03501017|OTHER|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
219486432|NCT03501017|OTHER|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
219486433|NCT02269501|OTHER|Exercise treatment|
219486434|NCT00091507|DRUG|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
219486435|NCT00091507|DRUG|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
219486436|NCT04437407|DEVICE|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
219486437|NCT04437407|DEVICE|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
219486438|NCT04437407|DEVICE|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
219486439|NCT04437407|DEVICE|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
218868752|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
218868753|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
218868754|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
218868755|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
219486440|NCT04437407|DEVICE|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
219486441|NCT04437407|DEVICE|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
219599767|NCT02936180|BIOLOGICAL|SD-QIV|
219486442|NCT04437407|DEVICE|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
219486443|NCT01879709|BEHAVIORAL|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
219486444|NCT01879709|BEHAVIORAL|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
219486445|NCT01879709|OTHER|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
219486446|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
219486447|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
219486448|NCT04918927|DRUG|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
219486449|NCT04918927|DRUG|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
219486450|NCT04918927|OTHER|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
219486451|NCT06568965|OTHER|De-stress & happy gut powder-U001|Take one sachet daily, 30 minutes before breakfast, for 60 days
219486452|NCT06568965|OTHER|De-Stress & Happy Gut powder-I001|Take one sachet daily, 30 minutes before breakfast, for 60 days
219599768|NCT01982812|DRUG|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
219599769|NCT01982812|DRUG|Standard AED|Active comparitor, Standard AED
219599770|NCT00076076|DRUG|Roflumilast|
219599771|NCT05992766|OTHER|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
219599772|NCT05992766|OTHER|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
219599773|NCT05992766|OTHER|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
219199913|NCT06860672|GENETIC|Dual vector DNA base editor|The base editor is delivered using a dual vector adeno-associated virus (AAV) system and introduced into the child via intrathecal injection to correct the mutated CHD3 gene. The vital signs of the child will be closely monitored during treatment to assess possible acute adverse effects. The child will be followed up regularly after treatment to monitor the success of gene editing and the neurodevelopmental improvement of the child. Possible long-term adverse events will be closely monitored to assess the safety of the treatment.
219486453|NCT06568965|OTHER|Placebo Powder 001|Take one sachet daily, 30 minutes before breakfast, for 60 days
219486454|NCT03933982|DRUG|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
219486455|NCT01057160|DRUG|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
219486456|NCT05672160|DIAGNOSTIC_TEST|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
219486457|NCT01579292|BEHAVIORAL|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
219486458|NCT01579292|BEHAVIORAL|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
219486459|NCT00935415|DRUG|Montelukast|Montelukast 5 mg
219486460|NCT00935415|DRUG|Placebo|capsules of matching placebo
219486461|NCT01947257|OTHER|the measure TRVMAX|by transthoracic echocardiography
219486462|NCT01947257|OTHER|the measure of the pulmonary artery|by transesophageal ultrasound
219486463|NCT01947257|OTHER|the direct measure of the pulmonary pressures|by right catheterization
219486464|NCT00893230|DIETARY_SUPPLEMENT|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
219486465|NCT00893230|DIETARY_SUPPLEMENT|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
218868756|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
219486466|NCT01872858|DRUG|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
219486467|NCT01872858|DRUG|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
218868757|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
218868758|NCT03995355|DEVICE|9618X investigational lipid eye drops|Test Eye Drops
218868759|NCT03995355|DEVICE|Blink® Tears|Control Eye Drops
218868760|NCT00027911|BIOLOGICAL|NY-ESO-1 peptide vaccine|
218868761|NCT00027911|BIOLOGICAL|sargramostim|
218868762|NCT00544284|DRUG|bortezomib|
218868763|NCT00544284|DRUG|temozolomide|
218868764|NCT00544284|OTHER|pharmacological study|
218868765|NCT02505360|OTHER|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
218868766|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
218868767|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
218868768|NCT01467388|PROCEDURE|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
218868769|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
218868770|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
219486468|NCT06538909|DEVICE|VR|Virtual reality that simulates obstacles on the road during walking
219486469|NCT03622086|OTHER|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
219599774|NCT04928079|PROCEDURE|deep brain stimulation|performing deep brain stimulation if needed
219599775|NCT04928079|DRUG|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
219599776|NCT00525798|DRUG|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
219599777|NCT00525798|DRUG|SMC021 Placebo|SMC021 - Placebo, once daily
219204469|NCT06887985|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo chimeric antigen receptor T-Cell (CAR-T cell) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
219204470|NCT06748339|OTHER|no intervention|no intervention
219599778|NCT05812443|OTHER|Shabad Kriya Meditation|The Shabad Krya meditation technique, used in Kundalini Yoga, will be performed by the participants of this intervention group for 8 consecutive weeks, for 30 minutes, before going to sleep. This group will be trained by a Kundalini Yoga teacher with extensive experience in Shabad Krya meditation. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
219599779|NCT05812443|OTHER|Relaxing reading|Relaxing reading will be performed by the participants of this control group for 8 consecutive weeks, for 30 minutes, before going to sleep. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
218868771|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
219599780|NCT00444379|DRUG|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
218868772|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
218868773|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
218868774|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
218868775|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
218868776|NCT04764110|OTHER|Placebo|Maltodextrin
218868777|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
218868778|NCT05733728|OTHER|any therapy suitable|any therapy suitable
218868779|NCT00099294|DRUG|Glufosfamide|
218868780|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
218868781|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
218868782|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
218868783|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
218868784|NCT01694979|OTHER|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
218868785|NCT01694979|OTHER|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
218868786|NCT01694979|OTHER|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
218868787|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
219204471|NCT06893354|DRUG|lorlatinib|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total), and then underwent surgery.
219486470|NCT05254093|OTHER|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
219486471|NCT05254093|OTHER|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
219486472|NCT05357209|DEVICE|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
219486473|NCT06123494|DRUG|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
219486474|NCT06123494|DRUG|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
219486475|NCT03392415|PROCEDURE|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
219486476|NCT01073059|DRUG|Valproic acid and Ertapenem|
219486477|NCT00200590|DRUG|acetaminophen and nalbuphine|
219486478|NCT00200590|DRUG|acetaminophen and morphine|
219486479|NCT00200590|DRUG|acetaminophen and reduced dosage of prostaglandin|
219486480|NCT00877214|DRUG|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
218868788|NCT04584593|BIOLOGICAL|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
218868789|NCT00551603|DRUG|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
218868790|NCT00551603|DRUG|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
218868791|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
218868792|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
218868793|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
218868794|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
218868795|NCT02916251|DRUG|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
219599781|NCT06434623|OTHER|patient record|using patient record to construct AI models
219599782|NCT01531543|DEVICE|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
219599783|NCT04234659|DEVICE|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
218868796|NCT02916251|DRUG|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
218868797|NCT00169507|BIOLOGICAL|Pneumococcal (vaccine)|
218868798|NCT05663671|DIAGNOSTIC_TEST|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC\&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
218868799|NCT00002112|DRUG|Nystatin|
218868800|NCT00002112|DRUG|Fluconazole|
218868801|NCT04105868|OTHER|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
219204472|NCT06893354|DRUG|lorlatinib plus chemotherapy|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total) plus chemotherapy, and then underwent surgery.
219486481|NCT00877214|DRUG|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
219486482|NCT04200781|DRUG|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
219486483|NCT04200781|DRUG|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
219486484|NCT05013749|PROCEDURE|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
219486485|NCT05013749|PROCEDURE|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
219486486|NCT00246441|DRUG|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
219486487|NCT00246441|DRUG|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
219486488|NCT00003119|BIOLOGICAL|filgrastim|
219486489|NCT00003119|BIOLOGICAL|sargramostim|
219486490|NCT00003119|DRUG|carboplatin|
219486491|NCT00003119|DRUG|cyclophosphamide|
219486492|NCT00003119|DRUG|doxorubicin hydrochloride|
219486493|NCT00003119|DRUG|etoposide|
219486494|NCT00003119|PROCEDURE|adjuvant therapy|
219486495|NCT00003119|PROCEDURE|conventional surgery|
219486496|NCT00003119|RADIATION|radiation therapy|
219486497|NCT02806635|BEHAVIORAL|OurRelationship|
219486498|NCT02806635|BEHAVIORAL|PREP Online|
219486499|NCT02017535|DRUG|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
219486500|NCT02017535|BEHAVIORAL|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
219486501|NCT02421770|OTHER|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
219486502|NCT02421770|OTHER|placebo|
219486503|NCT06435598|OTHER|video-based health education|The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
219486504|NCT06169020|DEVICE|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
219486505|NCT06169020|DEVICE|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
219486506|NCT05785026|OTHER|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
219486507|NCT05785026|OTHER|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
219486508|NCT05613920|BEHAVIORAL|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
219486509|NCT01393626|DRUG|Placebo|oral tablets twice daily
219486510|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
219486511|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
219486512|NCT02935946|OTHER|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
219204473|NCT06893952|DEVICE|TREO Endograft|Post Market collection data in use of TREO modular endografts
219599784|NCT03526783|PROCEDURE|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
219599785|NCT03526783|PROCEDURE|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
219599786|NCT06111261|DRUG|Albumin solution|200ml of 20% Human Serum Albumin
219599787|NCT06111261|DRUG|Balanced crystalloid solution|Balanced crystalloid solution
219599788|NCT04803305|DRUG|PF-06946860|subcutaneous injection
219599789|NCT04803305|DRUG|Placebo for PF-06946860|subcutaneous injection
218868802|NCT00418977|BEHAVIORAL|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
219486513|NCT01578343|DRUG|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation"
219486514|NCT01179139|OTHER|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
218868803|NCT00418977|BEHAVIORAL|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
218868804|NCT03926988|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
218868805|NCT02795325|DRUG|DCR-PH1|IV infusion of DCR-PH1
218868806|NCT02795325|OTHER|Placebo|
218868807|NCT03610009|DEVICE|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
218868808|NCT03610009|DEVICE|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
219486515|NCT01902524|DRUG|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
219486516|NCT05941299|DEVICE|REGENERA breast implant implantation|"Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up"
219486517|NCT04959006|DIETARY_SUPPLEMENT|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
219486518|NCT04959006|DIETARY_SUPPLEMENT|Placebo|Placebo
219486519|NCT03820999|OTHER|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
218868809|NCT05688488|DRUG|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
218868810|NCT05688488|DRUG|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
218868811|NCT03719989|DRUG|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
218868812|NCT04816318|OTHER|Social and public health measures against COVID-19|"1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
219486520|NCT05214599|DRUG|Budesonide Gel|Twice daily regimen
219486521|NCT01898117|DRUG|Carbo/cyclo|
218868813|NCT04816318|OTHER|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
218868814|NCT03079219|DRUG|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
218868815|NCT03079219|DRUG|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
218868816|NCT03079219|DRUG|Experimental drug: Dexamethasone|Day 1: 12mg QD
219486522|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
219486523|NCT01898117|DRUG|Paclitaxel|
219599790|NCT05289297|PROCEDURE|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
219599791|NCT05289297|PROCEDURE|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
218868817|NCT03079219|DRUG|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
218868818|NCT03079219|DRUG|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
218868819|NCT03079219|DRUG|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
218868820|NCT03079219|DRUG|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
218868821|NCT02263443|PROCEDURE|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
218868822|NCT02263443|PROCEDURE|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
218868823|NCT02263443|PROCEDURE|No enema|Patients NPO groups will NPO and no bowel preparation.
218868824|NCT06142617|DRUG|Pembrolizumab, pemetrexed, platinum|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
219486524|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
219486525|NCT04871178|BEHAVIORAL|Mindfulness-based intervention|"Eight, 2-hour instructor-led MBI group sessions once a week for 8 weeks, combined with formal meditative training at home for 20 minutes per day, 6 days a week.~Course material consists of facts booklet, weekly training manuals, audio recordings on a CD, with the five formal guided meditative exercises (body scan, breathing anchor, breathing space, mindful movements, sitting meditation).~The weekly home-work also included informal training of being present in daily life activities.~The program is provided according to the standard MBI protocol. Compared to MBSR and MBCT durations of formal meditative practices are shorter and no 'all-day in silence' session is included. Because of participants' physical limitations and safety, the 'mindful movements' sequence, is adapted and performed in a sitting position.~Adherence to the MBI was followed by self-reported weekly training in manuals asked to be submitted at group sessions."
219486526|NCT02602561|DIETARY_SUPPLEMENT|HMB|
219486527|NCT02602561|DIETARY_SUPPLEMENT|Placebo|
219486528|NCT04717232|OTHER|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
219486529|NCT04717232|OTHER|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
219486530|NCT06537245|OTHER|Massage|Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
219599792|NCT05449860|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
219599793|NCT00877162|BEHAVIORAL|Controlled crying and routines|Behavioural (teaching and support)
218868825|NCT06142617|DRUG|Osimertinib|Osimertinib will be the sequential treatment strategy at progression until resistance develops.
218868826|NCT06848023|PROCEDURE|Reverse Total Shoulder Arthroplasty|standard of care treatment reverse total shoulder arthroplasty delivered
218868827|NCT06848023|PROCEDURE|Rotator Cuff Repair|standard of care treatment rotator cuff repair delivered
218868828|NCT05063539|DRUG|LY3372689|given orally
219599794|NCT01017627|OTHER|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
219599795|NCT01017627|OTHER|No change from normal routine|Normal unit policy for labs and anemia treatment
219599796|NCT01666392|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
219599797|NCT01666392|DIETARY_SUPPLEMENT|Placebo|Placebo
219599798|NCT05102227|DEVICE|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
219599799|NCT00753662|DEVICE|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
219599800|NCT00753662|DEVICE|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
219599801|NCT00753662|DEVICE|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
219599802|NCT01270191|DRUG|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
218868829|NCT05063539|DRUG|LY3372689|given orally
218868830|NCT05063539|DRUG|Placebo|given orally
218868831|NCT05791240|BEHAVIORAL|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
218868832|NCT04795050|BEHAVIORAL|Project POWER|Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
218868833|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
218868834|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
218868835|NCT06038383|DEVICE|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
218868836|NCT06038383|DEVICE|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
218868837|NCT06038383|DEVICE|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
218868838|NCT06038383|DEVICE|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
218868839|NCT05268042|OTHER|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
219486531|NCT06003673|COMBINATION_PRODUCT|neoadjuvant therapy|The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.
218868840|NCT05268042|OTHER|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
219486532|NCT02902107|DEVICE|CivaSheet|
219486533|NCT02902107|RADIATION|Brachytherapy|
219486534|NCT02902107|PROCEDURE|surgical resection|
219486535|NCT02858076|DRUG|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
219486536|NCT02858076|PROCEDURE|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
219486537|NCT05760482|DIAGNOSTIC_TEST|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
219486538|NCT05760482|BEHAVIORAL|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
219486539|NCT00478634|DRUG|RAD001, Cetuximab, Irinotecan|
219486540|NCT05818163|DEVICE|electroencephalography spectral analysis|"Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device.~The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis."
219486541|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
219486542|NCT05166473|OTHER|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
219486543|NCT05166473|OTHER|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
219486544|NCT06692166|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
219486545|NCT06692166|DRUG|Chemotherapy|1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
219486546|NCT05402865|DRUG|Denosumab|Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
219486547|NCT01804530|DRUG|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
219486548|NCT03506425|DRUG|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
219599803|NCT01270191|DRUG|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
219599804|NCT05780476|BEHAVIORAL|Psychoeducation|6 sessions of 2 hours over 6 weeks
219486549|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
218868841|NCT06078956|DEVICE|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
218868842|NCT03505320|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
219486550|NCT04789811|OTHER|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
219486551|NCT04789811|OTHER|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
219486552|NCT00209495|DRUG|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
219486553|NCT01141049|DRUG|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
219486554|NCT01141049|OTHER|Placebo|Placebo, TID
219486555|NCT02284295|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
219599805|NCT05780476|BEHAVIORAL|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
219599806|NCT01352780|BEHAVIORAL|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
219599807|NCT00754546|DRUG|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
219599808|NCT00754546|DRUG|Placebo: Normal Saline|Normal saline was nebulized.
219599809|NCT00754546|OTHER|Treadmill Exercise|
218868843|NCT03505320|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
218868844|NCT03505320|DRUG|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
219599810|NCT00754546|OTHER|Cycle Exercise|
218868845|NCT03505320|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
219599811|NCT00208273|DRUG|Letrozole - Concomitant|
219599812|NCT00208273|DRUG|Letrozole - Sequential|
218868846|NCT03505320|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
218868847|NCT03505320|DRUG|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
218868848|NCT03505320|DRUG|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
218868849|NCT03505320|DRUG|Docetaxel|Docetaxel will be administered as a 1-hour IV infusion.
218868850|NCT06261359|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
219486556|NCT02284295|OTHER|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
219486557|NCT06030479|DRUG|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
219486558|NCT06030479|DRUG|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
219486559|NCT03839784|COMBINATION_PRODUCT|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
219486560|NCT04526249|DEVICE|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
219486561|NCT01925378|DRUG|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
219486562|NCT00405210|DRUG|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
219486563|NCT02484235|OTHER|HIIT|Group training with HIIT 3 times per week during 10 sessions
219486564|NCT02484235|OTHER|Strength|Group training with strength exercises 3 times per week during 10 sessions
219486565|NCT03952663|PROCEDURE|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
219486566|NCT03952663|PROCEDURE|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
219486567|NCT02677675|BEHAVIORAL|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
219486568|NCT03468374|DEVICE|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
219486569|NCT03468374|DEVICE|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
219486570|NCT02643394|DRUG|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
219486571|NCT02643394|DRUG|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
219486572|NCT04427956|PROCEDURE|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
219486573|NCT04427956|DRUG|Isotonic riboflavin|CXL protocol with isotonic riboflavin
219486574|NCT04427956|DRUG|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
219486575|NCT04427956|PROCEDURE|Iontophoresis|CXL protocol with iontophoresis and ricrolin
219486576|NCT04471558|OTHER|Music|A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
219486577|NCT04539158|DEVICE|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
219486578|NCT04088734|DRUG|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
219486579|NCT01222559|DRUG|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
219486580|NCT01222559|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
219599813|NCT04948892|OTHER|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
219486581|NCT01345890|PROCEDURE|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
219486582|NCT00096200|DRUG|Carboplatin|Given IV
219486583|NCT00096200|DRUG|Paclitaxel|Given IV
219599814|NCT02349867|DRUG|Gemcitabine|Given IV
219599815|NCT02349867|DRUG|Sorafenib|Given PO
219599816|NCT02349867|DRUG|Vorinostat|Given PO
219599817|NCT02349867|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
219599818|NCT02349867|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219599819|NCT02349867|OTHER|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
219599820|NCT02349867|OTHER|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
218868851|NCT06261359|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
218868852|NCT06261359|DRUG|Nab paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
218868853|NCT04256512|DEVICE|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
218868854|NCT04256512|OTHER|Questionnaire Administration|Ancillary studies
218868855|NCT03913689|DEVICE|StimRouter Neuromodulation System|An implantable neuromodulation device that treats chronic peripheral nerve pain.
218868856|NCT01733771|OTHER|Reflexology|Reflexology intervention involved a 15-minute treatment in the induction room, provided by three reflexologists from the hospital staff. The reflexology protocol was developed through a Delphi method.
218868857|NCT01733771|OTHER|Sham reflexology|Sham reflexology intervention were given by two complementary medicine practitioners with knowledge in touch therapy (shiatsu) and included 15 minutes of gentle, nonspecific foot massage. Similarly to the true reflexology protocol, the protocol for this treatment was also determined in a consensus-reaching process among a group of four experienced reflexologists.
219486584|NCT00096200|DRUG|Sorafenib Tosylate|Given orally
219486585|NCT03506854|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
219486586|NCT06472375|DIAGNOSTIC_TEST|holter|ambulant heart rate monitor (holter) for 24 hour.
219486587|NCT01850901|PROCEDURE|Renal sympathetic denervation|
219486588|NCT06283745|OTHER|Platelet-rich Plasma (PRP)|Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.
219486589|NCT06283745|OTHER|Saline|Saline intranasal injection (sham injection)
219486590|NCT03438474|PROCEDURE|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
219486591|NCT03438474|PROCEDURE|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
219486592|NCT04193033|OTHER|FLOW intervention|The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
219599821|NCT03183167|OTHER|No intervention|
219599822|NCT01249573|OTHER|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
219599823|NCT00000812|DRUG|Thalidomide|
219599824|NCT05772247|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
219486593|NCT04843501|BEHAVIORAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
219486594|NCT04843501|BEHAVIORAL|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
219486595|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
219486596|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
219486597|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
219486598|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
219486599|NCT03648385|DRUG|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
219486600|NCT03648385|OTHER|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
219486601|NCT06254963|OTHER|sand jump training|A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
219486602|NCT06254963|OTHER|land jump training|A series of progressive jumping activities on land increasing in difficulty over the 6 week period
219486603|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
219486604|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
219486605|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
219486606|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
219486607|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
219486608|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
219486609|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
219486610|NCT02121405|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
219486611|NCT02121405|RADIATION|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
219486612|NCT02121405|DRUG|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
219486613|NCT02121405|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
219486614|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
219486615|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
219486616|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
219486617|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
219486618|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
219486619|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
219486620|NCT00053911|DRUG|anastrozole|
219486621|NCT00053911|DRUG|cyclophosphamide|
219486622|NCT00053911|DRUG|docetaxel|
218868858|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
218868859|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
218868860|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
218868861|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
218868862|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
218868863|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
218868864|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
219486623|NCT00053911|DRUG|epirubicin hydrochloride|
219486624|NCT00053911|DRUG|fluorouracil|
219486625|NCT00053911|DRUG|goserelin acetate|
219486626|NCT00053911|DRUG|tamoxifen citrate|
219486627|NCT00053911|PROCEDURE|adjuvant therapy|
219486628|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
219486629|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
219486630|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
219599825|NCT03316547|OTHER|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
219486631|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
219486632|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
219486633|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
219486634|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
219486635|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
219486636|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
219486637|NCT00077870|DRUG|ocrelizumab|
219486638|NCT00118209|BIOLOGICAL|rituximab|IV
219486639|NCT00118209|DRUG|cyclophosphamide|IV
219486640|NCT00118209|DRUG|doxorubicin|IV or CIVI
219486641|NCT00118209|DRUG|vincristine|IV or CIVI
219486642|NCT00118209|DRUG|prednisone|oral
219486643|NCT00118209|DRUG|etoposide|CIVI
219486644|NCT00118209|DRUG|filgrastim|IV
219486645|NCT00118209|DRUG|pegfilgrastim|IV
219486646|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
219486647|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
219486648|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
219486649|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
219486650|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
219486651|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
219486652|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
219486653|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
219486654|NCT04059900|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
219599826|NCT04874805|OTHER|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
219486655|NCT04059900|DRUG|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
219486656|NCT05286931|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
219486657|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
219486658|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
219486659|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
219486660|NCT01924572|PROCEDURE|cord milking|
219486661|NCT01842516|DRUG|LCB01-0371 800mg|LCB0-0371 800mg
219486662|NCT01842516|DRUG|LCB01-0371 1200mg|LCB01-0371 1200mg
219486663|NCT01842516|DRUG|Placebo|Placebo
219486664|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
219486665|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
219486666|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
219486667|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
219486668|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
219486669|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
219486670|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
219486671|NCT01764594|OTHER|Placebo|Placebo comparator
219599827|NCT02939053|DEVICE|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
219599828|NCT00355953|DRUG|Genistein|
219486672|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
219486673|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
219486674|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
219486675|NCT02765958|DEVICE|portable ECG devise|
219486676|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
219599829|NCT03857282|OTHER|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
219599830|NCT03857282|OTHER|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
219599831|NCT00721227|PROCEDURE|Reduction Gastroplasty|"* Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications."
219599832|NCT05650840|PROCEDURE|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
219486677|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
219486678|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
219486679|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
219486680|NCT01743664|BEHAVIORAL|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
219486681|NCT01743664|BEHAVIORAL|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
219486682|NCT01591499|DEVICE|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
219486683|NCT01591499|DEVICE|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
219613579|NCT07018596|DEVICE|CellFX nsPFA Endocardial Ablation Catheter System|The CellFX nsPFA Endocardial Ablation Catheter System includes the nsPFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures to treat arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nanosecond pulses of electrical energy. nsPFA is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the cell's and internal organelles' ability to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
219599833|NCT05650840|PROCEDURE|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
219599834|NCT00553735|DRUG|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
218868865|NCT02396394|BEHAVIORAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
218868866|NCT01799434|OTHER|treadmill run|
218868867|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
218868868|NCT02333890|DRUG|Placebo|
219486684|NCT06700642|OTHER|Educational intervention|"In this study, 3 intervention tools were developed by the researchers. The first of these, 'Rational Drug Use Trainer Guide', was used for trainer training and standardisation of the education given to patients. The sample rational drug use presentations prepared by the Ministry of Health, Turkiye Medicines and Medical Devices Agency, Department of Rational Drug Use were combined in terms of content, enriched with information obtained from the literature and developed for the use of family physicians working in primary health care institutions in their clinical practices.~'Rational Drug Use Individual Education Presentation' was prepared by the researchers in line with the 'Rational Drug Use Trainer Guide'. It has been prepared in a format suitable for individual education presentation with the most concise and understandable content suitable for use during primary healthcare service delivery.~'Rational Drug Use Patient Brochure' was prepared by the researchers in a similar content."
219486685|NCT01135316|DRUG|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
219486686|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
219486687|NCT00973531|DEVICE|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
219486688|NCT00973531|DEVICE|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
219486689|NCT02801201|DRUG|Midazolam|
219486690|NCT02801201|DRUG|Bupivacaine|
219486691|NCT06426186|PROCEDURE|Right-stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia
219486692|NCT00003892|DRUG|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
219486693|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
219486694|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
219486695|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
218868869|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
218868870|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
218868871|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
218868872|NCT03737331|BEHAVIORAL|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
219486696|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
219486697|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
219486698|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
219486699|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
219486700|NCT04361552|OTHER|Best Practice|Receive standard of care
219599835|NCT00553735|DRUG|Arificial Tear|Artificial Tear - three times a day for 18 months.
219599836|NCT06828198|DEVICE|KOS® XL|Delivery of medical device as injection
219599837|NCT06901115|PROCEDURE|Nesbit technique|it is composed of development of trough at the right prostatic lobe (at 10 o'clock) from the bladder neck proximally down to a level just above the external urethral sphincter distally, then deepening the trough until the prostatic capsule, performing haemostasias then resection of lateral lobes in halves, upper right, lower right, upper left and at last lower left respectively with haemostasias in-between. Then resection of the median lobe if present. Final haemostasias then ensues before insertion of the triple way catheter with normal saline irrigation.
218868873|NCT03737331|BEHAVIORAL|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
219486701|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
219486702|NCT00358670|BIOLOGICAL|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
218868874|NCT03737331|BEHAVIORAL|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
218868875|NCT05318196|BIOLOGICAL|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
218868876|NCT05216029|OTHER|Best Practice|Receive standard of care
218868877|NCT05216029|OTHER|Informational Intervention|View oncology dashboard
218868878|NCT05216029|OTHER|Questionnaire Administration|Ancillary studies
218868879|NCT05770037|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
218868880|NCT06426849|OTHER|Liuzijue Exercise|"LiuzijueExercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. It is performed by delivering 6 distinct sounds, (xū,hē, hū sī, chuī, and xī) through termination along with comparing body activities.~The following are 6-8 vital parts of body movements:~1. Swaying and twisting~2. Hip rotations~3. Arm movements~4. Knee bends~5. Foot pivots~6. Spine elongation~7. Hand gestures~8. Breath synchronization Frequency: 1 session per day for a week Intensity:In first week 1 set of Luizijue exercise will be performed then progressively increase to 4 sets till 6th week .~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Luizijue Exercise."
218868881|NCT06426849|OTHER|Tai Chi Chuan Exercise|"Tai Chi Chuan Exercise combines deep diaphragmatic breathing and relaxation with many fundamental postures.~Names of the 10 Movements in Sequence~1. Commencing Form~2. Repulsing the Monkey~3. Brush Knee~4. Parting the Horse's Mane~5. Cloud Hands~6. Golden Cockerel Standing on the Left, then the Right~7. Kick Out Right, Kick Out Left~8. Grasping the Bird's Tail~9. Cross Hands or Embrace the Tiger~10. Closing Form Frequency: 3 sessions / week Intensity: Initially each posture will be performed 3 times then progressively leads to 6 or 10 reps according to patient tolorance.~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Tai Chi Chuan Exercise."
218868882|NCT06203223|OTHER|Ova-max|use Ova-max 3 months prior to treatment initiation
218868883|NCT06203223|OTHER|placebo|use placebo 3 months prior to treatment initiation
218868884|NCT04304014|DIETARY_SUPPLEMENT|L. reuteri|(10\^8 CFU) once a day
218868885|NCT04304014|DIETARY_SUPPLEMENT|B. longum and P. Pentosaceus|(10\^9 CFU) once a day
218868886|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
218868887|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
218868888|NCT06267066|DRUG|Vaseline Topical Product|Emollient
218868889|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
218868890|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
219486703|NCT00358670|BIOLOGICAL|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
219599838|NCT06901115|PROCEDURE|Corkscrew technique|the Corkscrew technique was performed by resection starting at 3 o'clock and carried on in a clockwise manner till 3 o'clock again. Prostate was resected from bladder neck downwards to the verumontanum after dividing the gland, imaginary, into 3 zones or thirds, proximal, middle and distal zone. The gland was resected zone by zone in this corkscrew manner. Once the proximal third is resected and hemostasis done, the middle third resection is done in the same manner, The process is repeated for the distal third. Hemostasis was performed instantly.
219599839|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
219599840|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
219599841|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
219599842|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
218868891|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
219486704|NCT06274385|DIETARY_SUPPLEMENT|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
219599843|NCT07134140|DIETARY_SUPPLEMENT|Omega-3|Participants will take three capsules per day (a total of 1,500 mg EPA and 750 mg DHA). They will take 1 g with each main meal (breakfast, lunch, and dinner).
219599844|NCT07134140|DIETARY_SUPPLEMENT|Placebo comparator|Participants will take 3 g of olive oil. They will take 1 g with each main meal (breakfast, lunch, and dinner).
219599845|NCT07134868|DIAGNOSTIC_TEST|Thiol- Disulfide Blood Sample Measurement|Measurement of thiol-disulfide homeostasis parameters and inflammatory markers from serum samples.
219599846|NCT07133776|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.|This study involves a four-drug combination regimen consisting of a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for the treatment of EBV Infectious diseases, aiming to inhibit viral replication and restore immune function through multiple mechanisms. The intervention includes not only pharmacological treatment but also pre-treatment assessments (such as EBV-DNA load, immune status, cardiac and renal function), efficacy monitoring during treatment (e.g., ORR, changes in EBV-DNA), and post-treatment follow-up for safety and survival outcomes (including OS, PFS, and adverse events), in order to comprehensively evaluate the clinical value and feasibility of this combination therapy.
218868892|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
219599847|NCT07134491|BIOLOGICAL|Piece of kidney removal|removal for a piece of kidney for research purposes during biopsy or graft removal performed as part of routine care
219599848|NCT07134491|BIOLOGICAL|Stool collection|Stool collection for research purposes
219599849|NCT07134491|BIOLOGICAL|Blood collection|Additional blood volume for research purposes during a routine blood collection
219599850|NCT07133269|OTHER|Care Coach-led Palliative Surgical Oncology (PSO)|"* Patients will receive the current standard of care based on their surgeon's usual clinical practice.~* Additionally, patients will receive the Care Coach-led Palliative Surgical Oncology (PSO) intervention. The PSO intervention will be delivered during all phases of an advanced cancer patient's surgical journey.~  * Pre-surgery: After pre-surgery consultations, care coaches will conduct Serious Illness Conversations (SIC) and focus on exploration of patients' hopes and worries, critical functions, social setup, and identification of a healthcare proxy.~ * The Care coach will also screen for psychological and emotional needs using the Distress Thermometer pre-surgery upon recruitment, and at 1, 3, 6, 9 \&12 months post-surgery. This will help to identify areas requiring palliative interventions such as symptom management or psychosocial support and for follow-up actions to be taken."
219599851|NCT07133269|OTHER|Rehabilitation|"• Patients will receive services from a dedicated rehabilitation service comprising of a Rehabilitation Physician, Physiotherapist, and Dietician.~* Pre-surgery: Patients will be triaged based on their frailty \[Clinical Frailty Scale (CFS)\], malnutrition risk \[Malnutrition Universal Screening Tool (MUST)\], and physical function \[5-sit-to-stand (5-STS)\] and will receive preventive rehabilitation interventions tailored to their functional needs.~* During surgical admission: The rehabilitation physician will review the progress of patients and refer them to a dietitian if needed. Patients may be followed-up by a rehabilitation physician one-month post-discharge and referred to a physiotherapist if required.~* Post-surgery: Patients will be screened by care coaches for functional needs using the CFS and 5-STS at months 3, 6, 9 \& 12 post-surgery who will make referrals to rehabilitation professionals as needed."
219599852|NCT07133412|DEVICE|TetraGraph|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
218868893|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
218868894|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
218868895|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
218868896|NCT03305315|OTHER|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
218868897|NCT03305315|OTHER|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
218868898|NCT02472704|DIETARY_SUPPLEMENT|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
218868899|NCT02472704|DIETARY_SUPPLEMENT|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
219486705|NCT06274385|OTHER|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
218868900|NCT06456073|BIOLOGICAL|E-CEL UVEC cells (AB-207)|Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
219599853|NCT07134023|OTHER|Supportive Care|"Initial Educational Assessment In addition to standard care, patients will meet the coordinating nurse for an initial educational assessment to evaluate their needs and present the multidisciplinary workshop program and individual support options. The nurse will register the patient for the first session, provide program materials, schedule the first follow-up call (1 month post-inclusion), and collect study questionnaires and demographics. If needed, the assessment may be scheduled within 15 days of inclusion.~Educational Workshops Patients may attend workshops on topics like endometriosis, diet, sexuality, pain, fatigue, emotions, Pilates, non-drug symptom management, hypnoanalgesia, and fertility. At least three workshops are required, offered over two days.~Telephone Follow-up Monthly calls for 6 months, then at 9 and 12 months, will monitor symptoms and refer patients to support services as needed."
219599854|NCT07134907|DRUG|Silodosin|Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
219599855|NCT07134907|DRUG|Tamsolusin|Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
219599856|NCT07134322|BEHAVIORAL|The aim of this research is to record how many families go to court for the breakdown of parent-child relationships and to understand how many of these families, one year after the judge's ruling, hav|"This is the first qualitative and quantitative study on conflict-ridden families who go to court and involve social and psychological support services.~Furthermore, the survey will provide precise data on the extent of the phenomenon being investigated."
219613580|NCT00716391|OTHER|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
218868901|NCT04736628|DRUG|Avenciguat|Avenciguat
218868902|NCT04736628|DRUG|Placebo|Placebo
218868903|NCT04279613|DRUG|NNC0361-0041|Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
218868904|NCT04279613|OTHER|Placebo|Placebo
218868905|NCT06597695|DRUG|Ketamine-assisted psychotherapy|Ketamine-assisted psychotherapy delivered in a group format
218868906|NCT06422338|OTHER|IMCI-enhanced by suPAR levels (SoC + suPAR POC)|IMCI-guidelines (standard of care) + Point-Of-Care (POC) based on suPAR quantification
218868907|NCT06548932|DRUG|GZR33 Injection|A single dose
218868908|NCT06548932|DRUG|GZR101 Injection|A single dose
218868909|NCT06548932|DRUG|Placebo|A single dose
218868910|NCT04428151|DRUG|Lenvatinib|20 mg once daily, taken as oral capsules
218868911|NCT04428151|BIOLOGICAL|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
218868912|NCT04428151|DRUG|Docetaxel|75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle
218868913|NCT04428151|DRUG|Capecitabine|1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
218868914|NCT04428151|DRUG|Paclitaxel|80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
218868915|NCT04428151|DRUG|Cetuximab|400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
218868916|NCT04428151|DRUG|Lenvatinib|24 mg once daily, taken as oral capsules
218868917|NCT04878952|OTHER|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
218868918|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
218868919|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
219599857|NCT07133763|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.|This study investigates a novel multi-targeted regimen combining a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for relapsed/refractory EBV-associated lymphoproliferative disorders (LPDs). Unlike conventional therapies focused on antivirals or chemotherapy alone, this approach integrates antiviral suppression, epigenetic reactivation, immune modulation, and checkpoint blockade to achieve synergistic antitumor and antiviral effects. Preliminary data show effective EBV inhibition and tumor regression. This strategy offers a promising and distinct therapeutic option for EBV-driven lymphoid malignancies resistant to standard treatment.
219599858|NCT07134556|DRUG|Zimberelimab (AB122)|Patients will receive zimberelimab as an IV at a dose of 360 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
219599859|NCT07134556|DRUG|Domvanalimab (DOM)|Patients will receive domvanalimab as an IV at a dose of 1200 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
219599860|NCT07134556|DRUG|Sacituzumab Govitecan (SG)|Patients will receive sacituzumab govitecan as an IV at a dose of 10 mg/kg on D1 and D8 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
219613581|NCT00716391|OTHER|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
219613582|NCT01622829|PROCEDURE|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
218868920|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
218868921|NCT03632603|RADIATION|No intervention|No intervention during study period.
219486706|NCT04653701|COMBINATION_PRODUCT|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
219486707|NCT06541925|DEVICE|Injection with the needle-free (NF) system|Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
219486708|NCT06541925|DEVICE|Injection with the traditional method (TM)|The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
219486709|NCT06520722|DIAGNOSTIC_TEST|Prolapse scoring system|"A FIXED APCD classification system :~A: Associated symptoms:~FIXED:~F: frequency I: infection X: sex problems E: everted mass(external protrusion of mass from the valva as PV lump sensation ,heaviness,itching and ulceration) D: digitation(patient need to digitate to complete the act of micturation or defecation)~APCD:~A: Dependent point on anterior wall. P: Dependent point on posterior wall. C: Cuff point either cervix or vault. Distance to hymen in centimeters (minus above or plus below) after pushing the opposite wall during maximal straining D: Dimensions; base diameter of vestibule/ perineal length.~The staging system will be interpreted as follows:~Normal:~A-3 P-3 C-8 D 2/2~Stages:~0: No prolapse.~A/P-2 OR C-7 to C-2 A,P or C-1 to +1 A,P or C ˃ +1~X component: (alone or with any stage):~Dimension disruption: ˃2 or \<2"
219486710|NCT01721824|BEHAVIORAL|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
219486711|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
219486712|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
219486713|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
219486714|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
219486715|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
219486716|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
219486717|NCT03940742|DRUG|Tirzepatide|Administered SC
219486718|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
219486719|NCT06313697|BIOLOGICAL|placebo|single dose
219486720|NCT02032823|DRUG|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
219486721|NCT02032823|DRUG|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
219486722|NCT02183701|DRUG|Telmisartan|
219486723|NCT02183701|DRUG|Losartan + Hydrochlorothiazide|
219486724|NCT02183701|DRUG|Placebo|
219486725|NCT06070701|PROCEDURE|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
219486726|NCT06070701|PROCEDURE|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
219486727|NCT06070701|DRUG|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
219486728|NCT06070701|DRUG|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
219486729|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
219486730|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
219486731|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
219486732|NCT03428217|DRUG|CB-839|Oral glutaminase inhibitor
219486733|NCT03428217|DRUG|Cabozantinib|Oral receptor tyrosine kinase inhibitor
219486734|NCT03428217|DRUG|Placebo|Placebo tablets
219486735|NCT06065475|BEHAVIORAL|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, injecting 2.5ml of 2% lidocaine on the surface of the thyroid cartilage each side.
219486736|NCT03889197|DRUG|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
218868922|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
218868923|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
218868924|NCT01310478|DRUG|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
219486737|NCT05899218|BEHAVIORAL|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
219486738|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
219486739|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
219486740|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
219486741|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
219486742|NCT05049460|DEVICE|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
219486743|NCT05049460|DEVICE|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
219486744|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
219486745|NCT04066192|DRUG|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
219486746|NCT04066192|DRUG|Placebo|A medically inert placebo medication will be used as described in the study arms.
218868925|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
218868926|NCT00759525|DRUG|Glycyrrhetic Acid|130 mg daily for fourteen days
218868927|NCT00759525|DRUG|Placebo|Placebo daily for fourteen days
218868928|NCT03543943|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
219486747|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
219486748|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
219486749|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
219486750|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
219486751|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
219599861|NCT07133919|BEHAVIORAL|AI-Assisted Child-Friendly Communication|"AI-assisted communication tailored to the developmental stage, age, and gender of children aged 7-12 will be used. Using ChatGPT, voice recordings explaining the local anesthesia process in a child-friendly and reassuring way-avoiding anxiety-provoking terms such as pain and needle-will be prepared. Additionally, a one-minute calming and distracting story will be generated to be played during anesthesia to reduce anxiety and improve cooperation. Children will listen to the AI-generated explanation before the procedure and the story during anesthesia."
219599862|NCT07133919|BEHAVIORAL|Traditional Behavior Management Techniques|"Before local anesthesia, traditional behavior management techniques will be applied by the pediatric dentist based on clinical experience. These include a modified Tell-Show-Do approach (avoiding direct exposure to anxiety-provoking items like dental syringes), voice control, and positive reinforcement. The anesthesia procedure will be explained verbally in an age-appropriate and reassuring manner, for example by describing the use of a magic sleepy spray to numb the tooth. Following this, topical anesthesia and then local anesthesia will be administered. The total procedure will not exceed 5 minutes."
219599863|NCT04159103|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
218868929|NCT03543943|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
219599864|NCT02834676|DRUG|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
219599865|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
218868930|NCT03543943|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
218868931|NCT05769049|BIOLOGICAL|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
218868932|NCT05769049|BIOLOGICAL|Shingrix|Shingrix
218868933|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
219486752|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
219486753|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
218868934|NCT02337634|DRUG|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
218868935|NCT02337634|DRUG|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
218868936|NCT05797662|DRUG|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
218868937|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
219486754|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
219486755|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
219486756|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
219486757|NCT06136676|BEHAVIORAL|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
218868938|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
218868939|NCT05841498|DEVICE|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
219486758|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
219486759|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
219486760|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
219486761|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
219486762|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
219486763|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
219486764|NCT00208000|DRUG|Marine active|
219486765|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
219486766|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
219486767|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
219486768|NCT06426992|PROCEDURE|Microwave ablation|Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.
219486769|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
219486770|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
219486771|NCT04117958|DRUG|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
219486772|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
219486773|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
219486774|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
219486775|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
219599866|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
218868940|NCT05841498|DEVICE|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
218868941|NCT04068610|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
219486776|NCT03050528|BEHAVIORAL|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
219486777|NCT03050528|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
219486778|NCT02612649|DRUG|Ramosetron|Oral
219486779|NCT05872451|DRUG|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
218868942|NCT04068610|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
218868943|NCT04068610|DRUG|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
218868944|NCT04068610|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
218868945|NCT06292039|OTHER|Human-Centered Injury Thrivorship Pathway|Enrollment in the human-centered injury thrivorship pathway.
218868946|NCT06832579|DEVICE|Wearable|semi-continuous heart rhythm monitoring with Wearable
218868947|NCT02428205|DRUG|Propranolol|Participant will receive Propranolol prior to each EIBI session
218868948|NCT02428205|DRUG|Placebo|Participant will receive placebo prior to each EIBI session
219486780|NCT05872451|DIAGNOSTIC_TEST|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
219486781|NCT00391118|DRUG|enzastaurin|
219599867|NCT06935760|OTHER|Fire and forget|Evidence informed prescription of BP lowering drugs based on the average observed blood pressure (BP) reduction and risk of treatment discontinuation due to adverse effects in double-blind placebo-controlled randomised clinical trials. Clinicians will prescribe BP treatment regimen using generic, established BP lowering medications that will be expected to achieve at least 80% of future systolic BP values under 130 mmHg. Treatment will be delivered remotely through telehealth consultation. Participants will be asked to avoid routine BP measurements after treatment is commenced to avoid misleading chance fluctuations in BP before 12 weeks. Adverse events will be monitored remotely, and treatments can be adjusted according to adverse events but not according to BP measurements
219599868|NCT06935760|OTHER|Usual care with more intensive BP monitoring|"Participants will follow-up with their usual general practitioner, who will treat participants BP according to local practice guidelines. General practitioners will have access to the same BP lowering medications as the fire and forget treatment group. Participants will continue to monitor their BP throughout the 12 week period through home BP monitoring with optional 24 hour ambulatory BP monitoring. Participants will maintain a BP diary and present their BP results to their treating physician."
219599869|NCT03623347|OTHER|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
219599870|NCT01243775|DRUG|Belotaxel|60 mg/m2 3 weekly (day 1)
218868949|NCT01174394|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
218868950|NCT01174394|PROCEDURE|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
219199914|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
219486782|NCT00391118|DRUG|carboplatin|
218868951|NCT01174394|PROCEDURE|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
219486783|NCT00391118|DRUG|paclitaxel|
219486784|NCT00391118|DRUG|placebo|
219486785|NCT02591017|DRUG|Morphine|
219486786|NCT02591017|DRUG|Ketamine|
219486787|NCT02591017|DRUG|Placebo|
219486788|NCT02591017|DRUG|Chitosan|
219486789|NCT03054168|DRUG|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
219486790|NCT03054168|DRUG|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
219486791|NCT03054168|OTHER|Placebo|
219486792|NCT02034500|BIOLOGICAL|S. sonnei 1790GAHB|
219486793|NCT02034500|BIOLOGICAL|Placebo|
219486794|NCT02208388|DEVICE|computed tomography perfusion guided treatment|
219599871|NCT01243775|DRUG|Belloxa|70 mg/m2 3 weekly (day 2)
219599872|NCT06829563|DRUG|RZ-629|Administered orally
219486795|NCT02208388|DEVICE|Fractional flow reserve guided treatment|
219486796|NCT00486577|PROCEDURE|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
219486797|NCT00486577|PROCEDURE|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
219486798|NCT01445873|DRUG|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
219599873|NCT06829563|DRUG|Placebo|Administered orally
219486799|NCT03989037|DRUG|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
219486800|NCT03989037|DRUG|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
219486801|NCT03989037|DRUG|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
219599874|NCT06829563|OTHER|Fasted|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
219599875|NCT06829563|OTHER|Fed|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
219599876|NCT05919160|DEVICE|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
219486802|NCT03989037|DRUG|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
219599877|NCT05825573|DRUG|Vitamin K antagonist|VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
219486803|NCT03078192|DRUG|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
219486804|NCT03078192|DEVICE|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
219486805|NCT00000754|DRUG|Interferon alfa-2a|
219486806|NCT00000754|DRUG|Zidovudine|
219486807|NCT00000754|DRUG|Zalcitabine|
219486808|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
219486809|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.
219486810|NCT00745459|DRUG|NPO-11|20 mL NPO-11
219486811|NCT00171080|DRUG|valsartan|
219486812|NCT00171080|DRUG|irbesartan|
219486813|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
219486814|NCT02427425|DEVICE|TENS|
219486815|NCT05800327|DRUG|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
219486816|NCT01015456|DRUG|mycophenolate sodium|per oral, twice daily, for 12 months
219486817|NCT01015456|DRUG|cyclophosphamide|intravenous, monthly, for 6 months
219486818|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
219486819|NCT00002560|BIOLOGICAL|monoclonal antibody 3F8|
219486820|NCT00002560|BIOLOGICAL|sargramostim|
219486821|NCT05471063|DRUG|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
219486822|NCT05471063|DRUG|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
219486823|NCT05471063|DRUG|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
219486824|NCT03538314|DRUG|UV1|UV1 (300 microgram)
219486825|NCT03538314|DRUG|GM-CSF|GM-CSF (37,5 or 75 microgram)
219486826|NCT06082609|PROCEDURE|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
219486827|NCT06271941|PROCEDURE|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
219486828|NCT06271941|PROCEDURE|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
219486829|NCT03920527|DRUG|Itraconazole 400 mg|Duration of itraconazole
219486830|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
219486831|NCT05073276|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
219486832|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
219486833|NCT01186744|DRUG|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
219486834|NCT01186744|DRUG|CP-690,550|10 mg oral BID
219486835|NCT01186744|DRUG|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
219486836|NCT01186744|DRUG|CP-690,550|5 mg oral BID
219486837|NCT05572424|OTHER|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
219486838|NCT04542902|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
219486839|NCT04542902|PROCEDURE|Blood sampling|An amount of a person's blood taken from their body for use in medical.
219486840|NCT04542902|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
219486841|NCT02547779|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
219486842|NCT02547779|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
219599878|NCT05825573|DRUG|Direct oral anticoagulant|DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
218868952|NCT01174394|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
218868953|NCT05663957|DRUG|Evusheld|EVUSHELD users
219486843|NCT00996008|DRUG|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
219599879|NCT05133726|OTHER|Text4Support|Daily supportive text messages
219599880|NCT05133726|OTHER|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
219599881|NCT02989909|DEVICE|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
218868954|NCT06524479|PROCEDURE|SEEG recordings and SPES|This study will utilize stereoelectroencephalography (SEEG) recordings combined with single-pulse electrical stimulation (SPES) to investigate functional brain connectivity and cortical excitability patterns in patients with epilepsy during both wakefulness and sleep states. The SEEG recordings will provide high-resolution intracranial electrophysiological data, while SPES will be employed to actively probe and quantify cortico-cortical connections. This combined approach will enable characterization of state-dependent neural network dynamics.
218868955|NCT06668389|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
218868956|NCT00412594|DRUG|Cladribine|Given IV
219486844|NCT00996008|DRUG|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
219486845|NCT04275232|BIOLOGICAL|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
219599882|NCT02989909|DEVICE|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
219599883|NCT02864576|BEHAVIORAL|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
219599884|NCT02864576|BEHAVIORAL|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
219599885|NCT05014282|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
219599886|NCT05014282|BEHAVIORAL|Counseling|Phone counseling with the state tobacco quitline.
219599887|NCT05014282|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
219599888|NCT05014282|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
219599889|NCT06236061|DRUG|LCZ|LCZ 200 mg
219599890|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
219599891|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
219599892|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
219599893|NCT06236061|OTHER|Placebo|Matching placebo of Amlodipine.
219599894|NCT04687176|DRUG|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10\^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
218868957|NCT00412594|OTHER|Laboratory Biomarker Analysis|Correlative studies
218868958|NCT00412594|BIOLOGICAL|Rituximab|Given IV
219486846|NCT01020773|BEHAVIORAL|spontaneous breathing trial|
219486847|NCT00769782|PROCEDURE|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
219486848|NCT03576430|DEVICE|active stress handling|biofeed back stress handling
219486849|NCT05292430|OTHER|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
219486850|NCT01280565|DRUG|Masitinib|Masitinib 7.5 mg/kg/day
219486851|NCT01280565|DRUG|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
219486852|NCT05812222|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
219486853|NCT00831467|BIOLOGICAL|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
219486854|NCT01389024|DRUG|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
219486855|NCT01389024|DRUG|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
219486856|NCT00263796|DRUG|Oxytocin|10 international units = 1 cc, IV over 4 hours
219486857|NCT00263796|DRUG|Placebo|Normal Saline, IV over 4 hours
219486858|NCT05743686|DEVICE|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
219486859|NCT01409018|DRUG|Itraconazole|pharmacokinetics
219486860|NCT01900379|PROCEDURE|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
219599895|NCT03663452|BEHAVIORAL|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
218868959|NCT06426914|OTHER|Clinical Pilates|"Warmup: 5-10 minutes Pilates Clinical (Introductory program) The Hundred modified The Roll-up modified The roll-over modified Spine twist modified Single-leg circle modified Rolling like a ball Shoulder Bridge modified~For every Step emphasizing:~FOCUS: On muscle involved REPETITIONS: 3-5 VISUALIZATION: Imagination process (Different for each step) Cool down: 5 minutes Total Time: 30 minutes"
219486861|NCT01900379|OTHER|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
218868960|NCT06426914|OTHER|Cardiac Rehabilitation|"Chest Physical therapy (Chest percussions and active huffs as per need) Breathing strategies (Diaphragmatic and purse lip 1-3 sets \* 5 Reps/Day)~Functional mobility (walk /cycling as per patient tolerance)~Patient education and Wound care Sternal Precaution guidance"
219486862|NCT00887107|DRUG|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
218868961|NCT06971757|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray and clinical visit at 3 months and 1 year after surgery.
218868962|NCT06971757|OTHER|Check-Up on Demand (COD)|Follow-up care with scheduled X-ray and clinical visit at 3 months and only at 1 year if requested.
219486863|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
219486864|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
219486865|NCT01491373|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
218868963|NCT06545643|DEVICE|Dreem headband|The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
218868964|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
219599896|NCT03663452|BEHAVIORAL|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
218868965|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
218868966|NCT05958199|DRUG|NPX267|NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal
218868967|NCT00068094|DRUG|Probiotic-containing powder|
218868968|NCT04373629|BEHAVIORAL|attentional modulation|Attentional instructions when viewing faces will be given
218868969|NCT04373629|OTHER|perceptual modulation|Faces will be presented of varying durations
218868970|NCT04373629|OTHER|naturalistic viewing|Faces will be viewed without specific instructions
218868971|NCT06979973|DRUG|Midazolam|midazolam syrup
219599897|NCT05179928|PROCEDURE|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
218868972|NCT06979973|DRUG|Rosuvastatin|Rosuvastatin
218868973|NCT06979973|DRUG|CKD-508 Tablet|CKD-508
219486866|NCT01491373|DEVICE|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
219486867|NCT04192786|OTHER|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
219486868|NCT04192786|OTHER|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
219486869|NCT04192786|OTHER|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
219486870|NCT03909373|OTHER|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
219486871|NCT00367679|DRUG|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
219486872|NCT01283711|DEVICE|apollo device|RF treatments for wrinkles and rhytides reduction
219486873|NCT03185247|BEHAVIORAL|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
219486874|NCT03715673|DIAGNOSTIC_TEST|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
219486875|NCT02805582|DRUG|10ml ropivacain 0.5%|Ultrasound guided nerve block
219486876|NCT02675426|DRUG|Placebo|Tablet; Oral
219486877|NCT02675426|DRUG|Upadacitinib|Tablet; Oral
219599898|NCT05179928|PROCEDURE|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
219599899|NCT06496542|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
219599900|NCT06496542|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
219599901|NCT04657224|DRUG|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
218868974|NCT06980610|PROCEDURE|digestive stoma closures|"Both surgical techniques (Collatamp interposition and directed healing) are routinely used in the CVMC and Digestive Cancer Surgery departments for stoma closure or restoration of digestive continuity. The choice of technique is at the surgeon\&#39;s discretion.~Specific procedures related to the research:~Procedures that differ from standard management are randomization and patient completion of a questionnaire."
219486878|NCT05467865|OTHER|ZELIAKIDE|"The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process."
218868975|NCT06980935|DEVICE|NervioX-2400|To design the individualized tTIS, each participant completed a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data were used to determine the tTIS montage and stimulation settings via computational modeling.
218868976|NCT03553186|DRUG|Tranexamic Acid 100 MG/ML|TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
218868977|NCT03553186|DRUG|Placebo|Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
218868978|NCT06980857|OTHER|Control Group|In our study, this group will be placed in hyperextension position and immobilized on postoperative day 0. Postop 1-2. Foot pumping exercises, isometric quadriceps exercises, passive knee extension, straight leg raising, 0-40 degree passive knee flexion, partial/full weight ambulation, respiratory exercises and cold application will be performed daily. On postoperative days 3-6 (depending on discharge time), stretching in passive knee extension, active/assisted quadriceps exercises, isometric-isotonic exercise for leg and hip muscles, 90-0 knee extension, 0-90 degree passive knee flexion exercises will be performed.
218868979|NCT06980857|OTHER|ERAS Group|In our study, this group of patients were informed about the surgical procedure to be performed by the orthopedist; detailed information about the postoperative rehabilitation process, prevention of possible complications, preoperative nutrition, smoking and alcohol cessation time will be given. The patient will stop eating solid food 6 hours before the operation and stop drinking fluids 2 hours before the operation. Necessary consultations will be completed before surgery. Preoperative preparation of the patient will be organized according to the ERAS protocol. The patient will be mobilized early, either in bed or in the room, within 6-7 hours after surgery. The exercises of the first group will be continued from the first postoperative day.
218868980|NCT06980857|OTHER|Multimodal physiotherapy group combined with ERAS protocol|In our study, this group of patients who were informed about the surgery by the orthopedist will be examined by the anesthesiologist 1 week before surgery. Patients whose anesthesia preparation is completed will participate in a training program about pain, prevention of postoperative complications, auxiliary devices/equipment and exercises to be used, accompanied by a physiotherapist and a nurse. At the end of the program, patients will be given a 1-week home exercise program prepared by the physiotherapist. NMES device will be connected to the quadriceps muscles for 20 minutes half an hour before surgery, immediately after surgery and every day during hospitalization. Postoperatively, the patient will be mobilized early within 6-7 hours and the knee will be placed in hyperextension position. From the 1st day onwards, the exercises of the first group will be continued.
218868981|NCT06980194|DIAGNOSTIC_TEST|99mTc-4BOH SPECT myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using the investigational radiotracer 99mTc-4BOH with SPECT. Imaging is performed according to a standardized protocol. Each participant receives both this SPECT imaging and a PET imaging procedure using 13N-ammonia, in a randomized sequence, within a 7-day interval.
219486879|NCT01826968|PROCEDURE|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
219486880|NCT02726217|BEHAVIORAL|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
219486881|NCT02726217|BEHAVIORAL|Standard of Care Reminders and Self Assessments|
219486882|NCT04518319|DRUG|Omega-3 polyunsaturated fatty acids|Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
219486883|NCT04518319|BEHAVIORAL|Xbox aerobic exercise|Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
219486884|NCT04518319|DEVICE|transcranial direct current stimulation,tDCS|Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
219486885|NCT04518319|DRUG|Olanzapine|Patients will take only olanzapine pills.
219486886|NCT02143089|DEVICE|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
219486887|NCT04121299|DRUG|Carvedilol|Carvedilol 40mg Extended Release Once Daily
219486888|NCT04121299|DRUG|Amlodipine|Amlodipine 10mg Once Daily
219486889|NCT05274399|OTHER|surveys and questionnaires|The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
218868982|NCT06980194|DIAGNOSTIC_TEST|13N-ammonia PET myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using 13N-ammonia with PET as the active comparator. This procedure is performed according to standard clinical protocols. Each participant also receives 99mTc-4BOH SPECT imaging in a randomized sequence, with both tests completed within a 7-day window.
218868983|NCT06979713|OTHER|yoga, pain education, yoga nidra|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with either yoga nidra with pain acceptance intention. Interventions are completed at home 2x/week for 6 weeks.
218868984|NCT06979713|OTHER|yoga, pain education, relaxing music|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with relaxing music depending on group assignment. Interventions are completed at home 2x/week for 6 weeks.
218868985|NCT06981416|BEHAVIORAL|Digital education group|Digital training for home accidents and first aid based on the Theory of Planned Behavior (PBT) and the pre-test, post-test and follow-up results will be evaluated.
218868986|NCT06981416|BEHAVIORAL|classical education group|"The training content prepared according to the Planned Behavior Theory will be given as classical training in the form of a flow chart."
218868987|NCT06981403|BEHAVIORAL|virtual escape room game-based pediatric medication management education|3 period aplied virtual escape room game-based pediatric medication management education
218868988|NCT06980415|DEVICE|Kay Pictures iSight|Tablet-based visual acuity measurement
218868989|NCT06981247|BEHAVIORAL|m-LIfE: mobile based lifestyle intervention for employees to increase their physical activity and promote healthy diet.|"The m-LIfE will primarily deliver healthy lifestyle educational content, provide customized strategies for PA, and offer participants the option to enter their daily intake of fruits and vegetables through Food Log feature. m-LIfE will track PA and diet, send tailored reminders, and provide motivational messages. Participants will receive two text messages daily: a goal reminder in the morning and feedback or reflection on their progress in the evening. Additionally, they will receive one motivational message at the end of each week to sustain their motivation. Personalized feedback will also be provided through the application, featuring graphs to illustrate daily, weekly, and monthly progress.~To support participants further, the application will enable two-way communication, allowing users to seek assistance and ask questions from the research team. A dedicated contact number will be made available within the app to facilitate direct communication."
219486890|NCT02614937|DRUG|ranibizumab|0.5 mg IVT ranibizumab
219599902|NCT04657224|DRUG|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
218868990|NCT06981247|OTHER|Routine care arm|Participants in the routine care arm will receive educational material in the form of paper-based pamphlets to ensure they still benefit from basic health information on CVD risk prevention. They will continue their usual work routines without access to the app, but their PA and dietary habits will be assessed at baseline, post-intervention and at follow-up for comparative purposes.
218868991|NCT06575400|DRUG|BI 3804379|BI 3804379
219599903|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
219599904|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
219599905|NCT05235126|DEVICE|Decoria intense|All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
218868992|NCT06575400|DRUG|Placebo matching BI 3804379|Placebo matching BI 3804379
218868993|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepared random tables. Participants in the SLND group will receive Endoscopic Submucosal Dissection with systematically mediastinal lymph node dissection
219486891|NCT02614937|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
219486892|NCT03719729|DRUG|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
219599906|NCT01503632|BEHAVIORAL|Behavioral Intervention|Receive intervention program
219599907|NCT01503632|BEHAVIORAL|Compliance Monitoring|Correlative studies
219599908|NCT01503632|OTHER|Laboratory Biomarker Analysis|Correlative studies
219599909|NCT01503632|DRUG|Mercaptopurine|Given orally
219599910|NCT01503632|OTHER|Questionnaire Administration|Ancillary studies
219599911|NCT01503632|PROCEDURE|Standard Follow-Up Care|Receive usual standard of care
219599912|NCT03765788|DRUG|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
219599913|NCT03765788|DRUG|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
219599914|NCT03765788|DRUG|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
219599915|NCT01534169|DRUG|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
218868994|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection without SLND|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepare random tables. Participants in the non-SLND group will just receive Endoscopic Submucosal Dissection treatment, not undergo Systematically mediastinal Lymph Node Dissection.
219486893|NCT06334978|OTHER|Osteopathic intervention|The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
219486894|NCT02131337|OTHER|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
219486895|NCT01286337|PROCEDURE|bipolar vessel sealing|
219486896|NCT01286337|PROCEDURE|control|
219486897|NCT03618082|DRUG|Anesthesic agent guided by ANI (Interventional Group)|Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
219486898|NCT03618082|DRUG|Administration of the lowest effective concentration of desflurane (Interventional Group)|Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
219486899|NCT04768829|DRUG|Moringa oleifera leaf 10mg/100ml|ear drops
219486900|NCT04768829|DRUG|Ear Drop|plain ear drop formulation without moringa
219486901|NCT04921046|DRUG|lignocaine|After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
219486902|NCT04921046|DRUG|Midazolam 1 milligram Prefilled Syringe|after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
219486903|NCT02321215|OTHER|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
219486904|NCT01990079|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
219486905|NCT01990079|DRUG|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
219486906|NCT01990079|OTHER|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
219486907|NCT01990079|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
219486908|NCT01990079|OTHER|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
219486909|NCT03759418|DEVICE|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
219486910|NCT00233376|PROCEDURE|Access to an antibiotic decision support system|
219486911|NCT00233376|BEHAVIORAL|Distribution of local antibiotic guidelines|
219486912|NCT00953927|BIOLOGICAL|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
219486913|NCT00953927|BIOLOGICAL|Candida Skin Test Antigen|1 test, administered once as a placebo control.
219486914|NCT04231994|DEVICE|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
219486915|NCT06413589|OTHER|SMOF lipid 20%|Drug: SMOF lipid 20% SMOF 20%, a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
219599916|NCT02147964|DRUG|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months \[all subjects\]
219599917|NCT02147964|DRUG|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
219599918|NCT02147964|DRUG|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
219599919|NCT02147964|DRUG|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
219599920|NCT02147964|DRUG|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
219599921|NCT02147964|DRUG|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
219599922|NCT02147964|DRUG|placebo ketoconazole|placebo ketoconazole daily for 4 months
219599923|NCT00391560|DRUG|perifosine|Identical intervention in both arms.
219599924|NCT03381170|BIOLOGICAL|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
219599925|NCT03196063|OTHER|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
218868995|NCT06980662|OTHER|laughter yoga|Laughter yoga is a type of complementary therapy that also includes some other components, including light physical exercises. This type of therapy combines unconditional laughter with yoga breathing exercises and yoga stretching positions, enabling patients to laugh in a different way from jokes or humour programmes. Laughter yoga steps; Warm-up exercises (5-10 minutes), Deep breathing exercises (10 minutes), Childish games (10 minutes), Laughter exercises (15 minutes). During laughter yoga, laughter is achieved without any jokes, comedy or humour and supports the realisation of a sincere laughter that does not involve cognitive thinking in individuals. Laughter yoga sessions should be done at home in a quiet and calm environment by making eye contact. Laughter yoga is applied in sessions that include warm-up, breathing and laughing exercises accompanied by applause and songs. The sessions take place in groups and last 45 minutes.
219486916|NCT06413589|OTHER|standard treatment for clozapine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg) \[29\].~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
219486917|NCT02953262|BEHAVIORAL|My HealtheVet Brochure|Participants will receive a mailed brochure with basic My HealtheVet content.
219486918|NCT02953262|BEHAVIORAL|My HealtheVet Training Guide for Veterans Living with Diabetes|Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
219486919|NCT02953262|BEHAVIORAL|My HealtheVet Group Training|Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
219486920|NCT02953262|BEHAVIORAL|My HealtheVet Individual Training|Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
219486921|NCT01652573|DRUG|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
219486922|NCT01652573|DRUG|Saline Nasal Spray Placebo|
219599926|NCT03196063|OTHER|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
219599927|NCT05473494|OTHER|training group|Trainings on diabetic foot care consisting of min 20 max 40 minutes will be given in 5 sessions for nine weeks. Training will be given face to face online.
219599928|NCT05473494|OTHER|control group|Group not to be trained.
219599929|NCT01808547|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed BID
219599930|NCT01808547|OTHER|DuraSite Vehicle|DuraSite vehicle dosed BID
219486923|NCT02797626|PROCEDURE|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
219486924|NCT01747239|DRUG|Cabazitaxel|25 mg/m2 IV every three weeks
219486925|NCT03614065|DRUG|endostar|endostatin
219486926|NCT03614065|DRUG|Placebos|saline solution
219486927|NCT03614065|RADIATION|radiotherapy|radiotherapy
219486928|NCT02148731|OTHER|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
219486929|NCT00934622|DEVICE|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
219486930|NCT01453101|DRUG|Fludarabine monophosphate, melphalan, Bortezomib|"* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
219599931|NCT06230445|OTHER|UHealth digital therapeutic|UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.
219599932|NCT05823688|DEVICE|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
219599933|NCT06531278|DRUG|Irinotecan liposome|"* Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle"
219599934|NCT06531278|DRUG|Adebrelimab|"* Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle"
219599935|NCT06531278|DRUG|Oxaliplatin|"* Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle"
219599936|NCT06531278|DRUG|Fluorouracil|"* Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle"
219599937|NCT06531278|DRUG|Calcium folinate|"* Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle"
219599938|NCT03080025|BEHAVIORAL|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches \& techniques, which contains a resource- \& solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
219599939|NCT00550511|RADIATION|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
218868996|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218868997|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
218868998|NCT06981442|BEHAVIORAL|Community-based environmental management|This intervention will be performed by the local community, who will have been previously informed and trained on the appropriate environmental management methods for the control of the Aedes mosquito. It will be based on the following elements: i) identification and removal of all artificial sources of reproduction of the Aedes mosquito inside and around the house (i.e. covering abandoned containers and/or storage containers to avoid water accumulation); ii) regular collection and disposal of household waste; iii) identification and resolution of all artificial sources of reproduction of the Aedes vector in or around the house (i.e. natural cavities such as tree holes will be filled to prevent water accumulation). This intervention will be carried out as a single intervention in Arm 1, in combination with a larvicidal intervention in Arm 2 and in combination with the intervention against the adult stage of the Aedes mosquito in Arm 3.
218868999|NCT06981442|OTHER|Vector control against immature stages of Aedes|Larvicidal control will be carried out through pyriproxifen-based autodissemination stations combined with Beauveria bassiana, implemented according to the manufacturer's recommended procedures.
219486931|NCT05780944|BEHAVIORAL|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
219486932|NCT02449967|PROCEDURE|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
219486933|NCT02060240|BEHAVIORAL|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
219599940|NCT00517881|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
219599941|NCT00113763|OTHER|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
219599942|NCT00113763|DRUG|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
219599943|NCT04933383|DRUG|AQ001S 0.125 mg/ml|administered by nebulization once daily
219599944|NCT04933383|DRUG|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
218869000|NCT06981442|OTHER|Vector control against the mature stages of Aedes|The control of the adult Aedes mosquitoes will be carried out through mass trapping using BG-GAT traps implemented according to the manufacturer's recommended procedures. In each household, three traps will be deployed.
218869001|NCT06979622|OTHER|ultrasound combined with electromagnetic positioning guidance|TIPS procedure under ultrasound combined with electromagnetic positioning guidance
219486934|NCT01506063|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
219599945|NCT02743624|PROCEDURE|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
219599946|NCT03827889|PROCEDURE|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
219599947|NCT03827889|PROCEDURE|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
219599948|NCT03827889|BEHAVIORAL|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
219599949|NCT05032781|DRUG|Intra-arterial cold saline, minocycline, and magnesium|See study design
218869002|NCT06981169|DIAGNOSTIC_TEST|FeNO|FeNO measured with a NIOX VERO device before the respiratory test
218869003|NCT06981169|DIAGNOSTIC_TEST|blood sample|Blood sample for measuring the blood eosinophil count
219599950|NCT01383707|DRUG|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
219599951|NCT01383707|DRUG|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
219599952|NCT01383707|DRUG|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
219599953|NCT01383707|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
218869004|NCT06980246|OTHER|Plyometric Exercise|The Plyo-Ex program was conducted for 45 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
219486935|NCT04662086|DRUG|Acebilustat|100 mg capsule administered orally once daily
219486936|NCT04662086|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
219486937|NCT02177864|DIETARY_SUPPLEMENT|Fiber|
219486938|NCT02177864|OTHER|Placebo (low fiber bar)|
219486939|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
218869005|NCT06980246|OTHER|Standard exercise program|The standard exercise program lasted for 45 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, coordination exercise, and functional training.
219486940|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
219486941|NCT01856686|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
219486942|NCT01856686|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
219486943|NCT00079963|DIETARY_SUPPLEMENT|Vitamin C|1000 mg/day
219486944|NCT00079963|DIETARY_SUPPLEMENT|Vitamin E|800 IU/day
219486945|NCT00079963|DIETARY_SUPPLEMENT|Placebo|
219486946|NCT03284424|BIOLOGICAL|Pembrolizumab|IV infusion
219486947|NCT01838863|BIOLOGICAL|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
219486948|NCT01838863|DRUG|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
219486949|NCT04647279|DIAGNOSTIC_TEST|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
218869006|NCT06980870|DRUG|Anti-inflammatory drug (ibuprofen)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
218869007|NCT06980870|DRUG|Anti-inflammatory drug (dexamethsaone)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
218869008|NCT06979570|DEVICE|AttentivU|"A device for continuous brain and physiology monitoring. It includes up to 8 EEG sensors as well as EOG and accelerometry which can be monitored in real-time for changes in attention, sleepiness, alertness, cognitive load, stress, and related psychological traits. The EEG data is analyzed in real-time to identify these states and this information can then be used to modulate countermeasures to the state--to either increase or decrease alertness or help counteract cognitive load sleepiness or stress conditions."
219486950|NCT02706041|PROCEDURE|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
219486951|NCT02706041|PROCEDURE|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
219486952|NCT00602979|DEVICE|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
218869009|NCT00527319|DRUG|VT-122 low dose|VT-122 low dose, dose escalated
218869010|NCT00527319|DRUG|VT-122 high dose|VT-122 high dose, dose escalated
218869011|NCT06981377|DIAGNOSTIC_TEST|Analysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)|"Plasma and buffy coat samples are shipped from the recruiting clinical sites to the lab of Professor Francesca Demichelis at the University of Trento (UniTN).~At UniTN, samples are stored in dedicated freezers with restricted access and subsequently used as follows:~* the plasma is used for the isolation of cell free DNA and extracellular vesicles (EVs);~* the buffy coat is used for the extraction of genomic DNA.~Nucleic acids sequencing library preparations and all downstream omics analyses are performed by Prof. Demichelis team."
218869012|NCT06979947|BEHAVIORAL|Structured Menopause Education Program|The structured education program was developed by midwifery researchers and delivered face-to-face by a certified midwife over four weekly sessions. Each session lasted approximately 20-25 minutes and covered topics such as menopausal symptoms, lifestyle changes, and coping strategies. Educational materials were individualized based on participants' MENQOL pre-test scores.
219486953|NCT00602979|DEVICE|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
219486954|NCT00602979|DEVICE|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
219486955|NCT00602979|DEVICE|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
219486956|NCT00602979|DEVICE|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
219486957|NCT00729703|DEVICE|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
219486958|NCT00729703|DEVICE|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
219486959|NCT04252690|DEVICE|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
219486960|NCT05633095|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
219486961|NCT04304846|OTHER|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
219486962|NCT01424618|DRUG|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
219486963|NCT01424618|DRUG|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
219486964|NCT00431236|DRUG|Oral Casopitant (GW679769)|
219486965|NCT00431236|DRUG|IV Casopitant (GW679769)|
219486966|NCT00431236|DRUG|IV ondansetron hydrochloride|
219486967|NCT00431236|DRUG|Oral dexamethasone|
219486968|NCT04950803|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
219486969|NCT04950803|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
219486970|NCT05112679|DEVICE|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
219486971|NCT05112679|DEVICE|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
219486972|NCT00004288|DRUG|olsalazine|
219486973|NCT02534207|DRUG|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
219486974|NCT05805956|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
219486975|NCT05747261|GENETIC|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
219486976|NCT05747261|GENETIC|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
219486977|NCT05747261|GENETIC|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
219486978|NCT02040207|DRUG|AM-101|AM-101 gel for intratympanic injection
219486979|NCT03203005|DRUG|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
219486980|NCT03541798|PROCEDURE|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
219486981|NCT03541798|PROCEDURE|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
219486982|NCT02263586|BEHAVIORAL|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
219599954|NCT05794893|BEHAVIORAL|Good Behavior Game|Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
219599955|NCT03194828|BEHAVIORAL|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
219599956|NCT03194828|BEHAVIORAL|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
219486983|NCT06541977|BEHAVIORAL|Behavioral to reduce sedentary behvaior|This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
219486984|NCT06541977|BEHAVIORAL|Physical activity|This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
219613583|NCT01622829|OTHER|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
219486985|NCT06541977|PROCEDURE|Bariatric Surgery|In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
219486986|NCT03349437|DEVICE|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
219486987|NCT03349437|OTHER|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
219486988|NCT04033627|PROCEDURE|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
218869013|NCT06983522|DEVICE|Toilet training booklet|Education on the subject of motherhood, the concept of motherhood and the role of motherhood. Education on parental attitudes, types of attitudes. Education on education in school, the age of starting education, the duration of education, signs of readiness for child toilet training, Brazelton's child-focused approach and characteristics of toilet training, the effects of parents' attitudes on toilet training and education on problems that may be encountered during toilet training. It covers the topics.
218869014|NCT06980883|OTHER|Dry Needling|dry needles Administered to patients in Group 1 as part of their treatment regimen( 2 days per week).
218869015|NCT06980883|OTHER|myofascial release|"Myofascial Release: Provided to patients in Group 2 along with traditional treatment( 2 days per week).~Evaluation of fascial restriction was assessed using the therapists elbow. Any restrictions felt were assessed and given treatment.Myofascial chain release- Position of the patient- Supine lying, prone lying and side lying Position of the therapist- Side of the patient limb to be treated~\- Technique-Using the therapist elbow a vertical release proximal to the attachment of the muscle belly or fascia was applied. Once an end-feel was reached a slow stroke down the length of the target tissue was performed along with monitoring the indirect feedback and tissue tension to identify any additional restrictions. The long stroke was repeated in a line parallel to the first stroke. It was continued until an end-feel is reached throughout the entire muscle belly or fascia on the most restricted/ painful points."
219486989|NCT03525327|OTHER|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
219486990|NCT00504127|DRUG|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
218869016|NCT06980883|OTHER|(traditional exercises)|comprising straight leg raising and isometric quadriceps exercises (2 days per week).
218869017|NCT06663046|BIOLOGICAL|Single dose injection of certain dose of UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
218869018|NCT06658496|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
218869019|NCT05445518|BEHAVIORAL|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
218869020|NCT05445518|BEHAVIORAL|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
219486991|NCT00504127|DRUG|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
218869021|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength VitaJoy (ES/VJ)|Extra Strength VitaJoy Capsule, 2 capsules in the morning
218869022|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength Vita Calm (ES/VC)|Extra Strength Vita Calm Capsule, 2 capsules in the evening
218869023|NCT06579183|DIETARY_SUPPLEMENT|Placebo|Placebo Capsule, 4 capsules in the morning and evening respectively
218869024|NCT06981104|DRUG|0.05% cyclosporine eyedrops|0.05% cyclosporine, one drop each time, twice a day
218869025|NCT06981104|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, one drop each time, three times a day
218869026|NCT06993974|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
219486992|NCT00504127|DRUG|Naproxen 500 mg bid|Naproxen 500 mg bid
219486993|NCT00504127|DRUG|placebo|placebo
219486994|NCT04156282|PROCEDURE|knot burial technique|surgical suturing intervention
219486995|NCT04156282|PROCEDURE|classical closure|surgical suturing intervention
219486996|NCT03154931|OTHER|CBT-SG|To support the group.
219486997|NCT03154931|OTHER|CFT-G|Teach compassionate skills.
219486998|NCT05796531|BEHAVIORAL|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
219486999|NCT05796531|BEHAVIORAL|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
219522414|NCT06036511|DRUG|Ketamine Hydrochloride|"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."
219487000|NCT05436301|OTHER|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
219487001|NCT01385501|OTHER|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
219487002|NCT05137301|DEVICE|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
219487003|NCT05005676|DIAGNOSTIC_TEST|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
219487004|NCT01461369|DRUG|Diclofenac|35 mg bid Capsules
219487005|NCT01461369|DRUG|Diclofenac|35 mg tid Capsules
219487006|NCT01461369|DRUG|Placebo|Capsules
219487007|NCT04889794|OTHER|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
219487008|NCT02738489|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
219487009|NCT04209244|DIETARY_SUPPLEMENT|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
219487010|NCT04209244|DIETARY_SUPPLEMENT|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
219487011|NCT00364273|DRUG|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
219487012|NCT00364273|DRUG|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
219487013|NCT00364273|DRUG|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
219487014|NCT04144231|BEHAVIORAL|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
219487015|NCT04144231|BEHAVIORAL|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
219487016|NCT03569566|OTHER|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
219487017|NCT01031225|DRUG|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
219487018|NCT02764073|DEVICE|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
219487019|NCT02764073|DEVICE|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
219487020|NCT02764073|DEVICE|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
219487021|NCT03006822|OTHER|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
219487022|NCT03006822|OTHER|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
219487023|NCT03006822|OTHER|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
219487024|NCT01103401|DRUG|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
219487025|NCT01103401|DRUG|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
219487026|NCT02214004|DRUG|Trastuzumab|"\- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
219487027|NCT02214004|DRUG|Letrozole|\- Daily letrozole 2.5 mg/day for 24 weeks
219487028|NCT00695604|DRUG|Placebo|Placebo via MDI.
219487029|NCT00695604|DRUG|Fluticasone|Fluticasone MDI.
219487030|NCT06700564|OTHER|PET scan of FDG|The enrolled patients will undergo PET examination, and the radiation dose generated during the examination will not cause physiological damage to the patients
219487031|NCT04604496|DRUG|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
219599957|NCT05693259|DEVICE|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
219599958|NCT00129883|BEHAVIORAL|Professional education|
219599959|NCT00129883|BEHAVIORAL|Implementation of a Critical Care Pathway|
219487032|NCT02962739|DRUG|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
219487033|NCT06257186|OTHER|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
219487034|NCT01293318|OTHER|No intervention|No intervention
219487035|NCT03849079|OTHER|Hyponut|Prick tests with hyponut
219487036|NCT02406742|DRUG|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
219487037|NCT02406742|DRUG|Ibrutinib|
219599960|NCT00129883|BEHAVIORAL|Professional audit and feedback|
219599961|NCT00129883|BEHAVIORAL|Process analysis and redesign|
219599962|NCT03849911|DIAGNOSTIC_TEST|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
219599963|NCT03849911|DIAGNOSTIC_TEST|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
219599964|NCT05211518|OTHER|Tasty&Healthy|exclude pro-inflammatory dietary components
219599965|NCT05211518|OTHER|Habitual diet|subjects will continue their habitual diet.
219599966|NCT04410419|DIETARY_SUPPLEMENT|Pre-operative carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
219599967|NCT05015426|BIOLOGICAL|Gamma Delta T-Cell Infusion|Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
219599968|NCT06286696|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Point of care ultrasonography of the optic nerve sheath diameter
219599969|NCT05543408|BEHAVIORAL|EXERCISE|individualized, progressive, exercise program
219599970|NCT03719651|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
219599971|NCT03719651|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
219599972|NCT03719651|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
219599973|NCT03719651|BEHAVIORAL|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
218869027|NCT06993974|DRUG|Nitazoxanide|Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.
218869028|NCT06673407|BEHAVIORAL|Group Exposure for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears.
218869029|NCT06673407|BEHAVIORAL|Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion.
219599974|NCT00005553|PROCEDURE|Catheter Ablation|
219599975|NCT03624920|DRUG|THN102 Dosage A|THN102 Dosages A: placebo
219487038|NCT02406742|DRUG|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
219487039|NCT03797573|DEVICE|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
219487040|NCT03797573|DEVICE|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
219599976|NCT03624920|DRUG|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
219599977|NCT03624920|DRUG|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
219599978|NCT01860274|DEVICE|External Mesh for vein grafts|
219599979|NCT04905628|DEVICE|Dexcom CGM System|Dexcom CGM System
219599980|NCT00641628|PROCEDURE|mastectomy|
219599981|NCT03600389|BEHAVIORAL|Patient Priorities Care|
219599982|NCT04233294|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
219599983|NCT04233294|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
219599984|NCT04233294|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
219599985|NCT02352467|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
219487041|NCT06371547|OTHER|Stretching Exercise|Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.
219487042|NCT02301962|DRUG|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
219487043|NCT01638637|DEVICE|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
219487044|NCT03336645|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
219487045|NCT00532454|DRUG|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
219487046|NCT00999245|OTHER|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
219487047|NCT00999245|OTHER|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
219487048|NCT01608776|DEVICE|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
219487049|NCT01608776|OTHER|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
219487050|NCT05652894|DRUG|HX008|Drug: HX008 200 mg ,Q3W
219487051|NCT05652894|DRUG|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI."
219487052|NCT02410031|DRUG|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
219487053|NCT05829473|OTHER|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
219487054|NCT05829473|OTHER|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
219522415|NCT06802315|RADIATION|Intensity modulated total marrow irradiation|"See Treatment Regimen"
219522416|NCT06802315|DRUG|Cyclophosphamide (CTX)|This study will determine the safety of the combination of Total Marrow Irradiation (TMI) and Post-Transplant Cyclophosphamide using a myeloablative fludarabine and iv targeted busulfan (Flu/Bu4) conditioning regimen.
219522417|NCT06802315|DRUG|Fludarabine (Fludara)|chemotherapy conditioning
219522418|NCT06802315|DRUG|Busulfan (conditioning for ALLO Transplant)|chemotherapy conditioning
219522419|NCT02426957|BEHAVIORAL|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
219522420|NCT05768269|OTHER|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
219522421|NCT03248063|DRUG|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
219522422|NCT03248063|DRUG|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
219522423|NCT05423210|COMBINATION_PRODUCT|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
219522424|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
219599986|NCT02654028|PROCEDURE|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
219487055|NCT02837263|RADIATION|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
219487056|NCT02837263|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
219487057|NCT01188005|DEVICE|n-CPAP|administration of continuous positive airway pressure through a nasal device
219487058|NCT01188005|DEVICE|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
219487059|NCT01188005|DRUG|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
219487060|NCT02039817|DRUG|IDN-6556|
219487061|NCT00197509|BEHAVIORAL|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
219487062|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
219487063|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
219599987|NCT02654028|OTHER|Control group|These group of patients will not receive autotransfusion before liver resection.
219599988|NCT05435261|PROCEDURE|BKA|"Below Knee Amputation:~* Under spinal anesthesia~* BKA~* closure in layers (terminal closure) with suction drain."
219599989|NCT05435261|PROCEDURE|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~* Under spinal anesthesia~* wound debridement and wash.~* external fixation."
219599990|NCT04831814|DIAGNOSTIC_TEST|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
219599991|NCT04831814|DIAGNOSTIC_TEST|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
218869030|NCT06673407|BEHAVIORAL|Peer-Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
219487064|NCT04645732|BEHAVIORAL|Personalized exercise therapy and self-management support program|See description under Arms
219487065|NCT04645732|OTHER|Usual care|See description under Arms
219487066|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
219487067|NCT06102824|DRUG|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
219487068|NCT06102824|DRUG|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
219487069|NCT06102824|DRUG|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
219487070|NCT06102824|DRUG|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
219599992|NCT03055624|DEVICE|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
219599993|NCT00000814|DRUG|Nevirapine|
219487071|NCT06102824|DRUG|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
219487072|NCT06102824|DRUG|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
219599994|NCT00000814|DRUG|Zidovudine|
219599995|NCT00000814|DRUG|Didanosine|
219599996|NCT02880670|DRUG|BMS-986142|
219599997|NCT03842319|OTHER|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
219599998|NCT03842319|OTHER|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
219599999|NCT03842319|OTHER|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
219600000|NCT03842319|OTHER|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
219600001|NCT03842319|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
219600002|NCT03842319|OTHER|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
219600003|NCT03842319|OTHER|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (\>40 g/d) for cooking and dressing dishes; b) consumption of \>2 daily servings of vegetables; c) \>2-3 daily serving of fresh fruits; d) \>3 weekly servings of legumes; e) \>3 weekly servings of fish or seafood; f) \>1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
219600004|NCT03573154|OTHER|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
219613584|NCT01622829|OTHER|usual physiotherapy|physiotherapy, treatment as usual
219487073|NCT06102824|DRUG|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
219487074|NCT06102824|DRUG|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
219487075|NCT06102824|DRUG|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
219487076|NCT06102824|DRUG|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
219487077|NCT06102824|DRUG|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
219487078|NCT04458428|OTHER|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
219487079|NCT06568848|COMBINATION_PRODUCT|EKKO therapy|In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
219487080|NCT06568848|DIAGNOSTIC_TEST|Conservative Treatment|In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
219487081|NCT02636166|OTHER|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
219487082|NCT02636166|OTHER|Professional pregnancy test|Alere Professional use pregnancy test
219487083|NCT02636166|OTHER|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
219487084|NCT05365594|DEVICE|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
219487085|NCT05365594|DEVICE|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
219487086|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.
219487087|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
219600005|NCT03573154|OTHER|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
219487088|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
219487089|NCT01563029|DRUG|Fluticasone Furoate|current asthma medicine
219487090|NCT01563029|DRUG|Fluticasone Propionate|Fluticasone propionate
219487091|NCT01563029|DRUG|Placebo|placebo
219487092|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
219600006|NCT03054233|PROCEDURE|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
219487093|NCT05165173|DIETARY_SUPPLEMENT|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
219600007|NCT05224128|DRUG|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
219600008|NCT05224128|DRUG|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
219600009|NCT02352818|OTHER|no study intervention|
219600010|NCT06632223|OTHER|Sensory motor training|Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
219600011|NCT06632223|OTHER|Traditional physical therapy|traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
219600012|NCT01118065|DRUG|everolimus|
219600013|NCT03494101|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
219487094|NCT05165173|DIETARY_SUPPLEMENT|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
219487095|NCT04375735|DRUG|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
219487096|NCT05550259|PROCEDURE|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
219487097|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
219487098|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
219487099|NCT04683874|DEVICE|3D printed tray|3D printed tray
219487100|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
219487101|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
219487102|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
219600014|NCT03494101|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
218869031|NCT06673407|BEHAVIORAL|Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
218869032|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
218869033|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
218869034|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
219487103|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
219487104|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
219487105|NCT01615822|DRUG|Placebo|
219487106|NCT06470841|DRUG|CHG Combined With Venetoclax and Azacytidine|"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."
219487107|NCT06566248|DRUG|TQA3810 tablets+NUC|TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
219487108|NCT06566248|DRUG|Placebo+NUC|"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."
219487109|NCT04317547|BEHAVIORAL|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
219487110|NCT04317547|BEHAVIORAL|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
219600015|NCT03494101|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
218869035|NCT03772054|DRUG|Sevoflurane|Inhalation anesthetic agent
218869036|NCT03772054|DRUG|Propofol|Intravenous anesthetic agent
218869037|NCT03029507|BEHAVIORAL|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
219199915|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
219487111|NCT05315986|DIETARY_SUPPLEMENT|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
219487112|NCT05315986|BEHAVIORAL|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
219487113|NCT05315986|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
219487114|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
219487115|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
219487116|NCT01487018|PROCEDURE|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
219487117|NCT01487018|PROCEDURE|Traditional Surgery|To compare with the experamental group.
219487118|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
219487119|NCT06393907|DEVICE|Hemostatic Forceps|The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.
219487120|NCT06393907|DEVICE|Bipolar Electrocautery Probes|The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.
219600016|NCT03364946|OTHER|No intervention|No intervention, observational study
219600017|NCT03449004|OTHER|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
219487121|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
219487122|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
219487123|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
219487124|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
219487125|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
219487126|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
219487127|NCT04917029|DRUG|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
219487128|NCT04917029|DRUG|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
219487129|NCT04917029|DRUG|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
219487130|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
219487131|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
219487132|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
219487133|NCT02102022|DRUG|ADI-PEG 20 plus modified FOLFOX6|
219487134|NCT05348018|DEVICE|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
219487135|NCT01544816|OTHER|Snack Product|control food product
219487136|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 1
219487137|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 2
219487138|NCT02285452|DRUG|Zingiberis Rhizoma plv.|
219487139|NCT02285452|DRUG|Sinapis nigrea semen|
219487140|NCT02285452|DRUG|Placebo|
219487141|NCT03891875|COMBINATION_PRODUCT|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
219487142|NCT03891875|COMBINATION_PRODUCT|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
218869038|NCT03029507|BEHAVIORAL|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
219487143|NCT00872365|BEHAVIORAL|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
219487144|NCT00872365|DIETARY_SUPPLEMENT|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
219487145|NCT00872365|OTHER|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
218869039|NCT06872749|OTHER|Placebo gel|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
219487146|NCT03449420|DIAGNOSTIC_TEST|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
219487147|NCT00203931|DRUG|Cetuximab|
219487148|NCT00203931|DRUG|Pemetrexed|
219487149|NCT00351078|DRUG|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
219487150|NCT02421107|OTHER|Glysure CGM|
219487151|NCT02421107|OTHER|iStat intermittent testing|
219487152|NCT05353426|PROCEDURE|Paragastric autonomic neural blockade|Paragastric autonomic neural blockade with Bupivacaine
219487153|NCT02426125|DRUG|Ramucirumab|Administered IV
219487154|NCT02426125|DRUG|Docetaxel|Administered IV
219487155|NCT02426125|DRUG|Placebo|Administered IV
219487156|NCT04345887|DRUG|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
219487157|NCT04345887|DRUG|Placebo oral tablet|2 x1 placebo tablet
219487158|NCT00004232|BIOLOGICAL|filgrastim|
219487159|NCT00004232|DRUG|cyclosporine|
219487160|NCT00004232|DRUG|methylprednisolone|
219487161|NCT00004232|DRUG|prednisone|
219487162|NCT00004232|PROCEDURE|allogeneic bone marrow transplantation|
219487163|NCT00004232|PROCEDURE|peripheral blood stem cell transplantation|
219487164|NCT00410592|DRUG|Esomeprazole 40mg|
219487165|NCT00410592|DRUG|Pantoprazole 40mg|
219487166|NCT00410592|DRUG|Lansoprazole 30mg|
219487167|NCT06060639|DIAGNOSTIC_TEST|transthoracic echocardiography|E wave, A wave, e' and vdi measurement
219600018|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
219600019|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
218869040|NCT06872749|OTHER|KF2 (Potassium nitrate gel)|will receive application of potassium nitrate gel on hypersensitive dental surfaces, in an active way, for 10 minutes.
219487168|NCT02899442|OTHER|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
219487169|NCT00892424|DRUG|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
218869041|NCT06872749|OTHER|experimental Copaiba gel|will receive the application of the experimental desensitizing gel on the vestibular surfaces of the hypersensitive teeth in an active manner, for 10 minutes.
218869042|NCT05327972|DRUG|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
219487170|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
219487171|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
219487172|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
219600020|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
219600021|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
218869043|NCT05327972|OTHER|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
218869044|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
218869045|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
218869046|NCT05063201|DRUG|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
219600022|NCT01331850|DRUG|RO5024048|1000 mg oral doses twice a day for 24 weeks
219600023|NCT01331850|DRUG|danoprevir|100 mg oral doses twice a day for 24 weeks
219600024|NCT01331850|DRUG|ritonavir|100 mg oral doses twice a day for 24 weeks
219600025|NCT01149408|DRUG|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
219600026|NCT05249673|OTHER|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
219600027|NCT05249673|OTHER|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
218869047|NCT05063201|DRUG|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
218869048|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting of the socket with Autogenous tooth graft mixed with simvastatin immediately after tooth extraction
219600028|NCT00936247|DRUG|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
219600029|NCT00936247|DRUG|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
218869049|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting the socket with Autogenous tooth graft immediately after tooth extraction
218869050|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
218869051|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
218869052|NCT01650272|DRUG|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
219487173|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
218869053|NCT01650272|DRUG|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
218869054|NCT06886542|OTHER|Dual task training|Dual task training is based on the simultaneous maintenance of motor-motor or cognitive-motor performance. The exercises given in single task training will be applied by combining them with cognitive and motor cognitive tasks.
218869055|NCT06886542|OTHER|Single task training|Single task training is a training approach that aims to improve the performance of individuals by focusing on only one task at a time.
219487174|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
219487175|NCT04011111|PROCEDURE|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
219600030|NCT00181714|DRUG|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
219600031|NCT04352725|PROCEDURE|End-expiratory lung volume measurement and incremental PEEP titration|"* End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
219600032|NCT03437031|DEVICE|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
219600033|NCT02686736|BEHAVIORAL|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
219600034|NCT02794870|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
219600035|NCT02794870|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
219600036|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
219600037|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
219600038|NCT02140385|DEVICE|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
219600039|NCT02140385|DEVICE|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
218869056|NCT06886542|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises, isometric exercise, Before the treatment, a Hotpack will be applied to warm up the muscles, increase flexibility and improve performance. After exercise, transcutaneous electrical stimulation (TENS) will be used to relieve pain, reduce muscle tension and provide faster recovery.
218869057|NCT05757167|DIAGNOSTIC_TEST|Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)|"Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%"
218869058|NCT05757167|DRUG|Artemether-lumefantrine (AL)|oral tablets: 6 doses of 80/480 mg over 3 days
218869059|NCT06074458|OTHER|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
219487176|NCT04486807|DIAGNOSTIC_TEST|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
219600040|NCT02140385|DEVICE|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
219600041|NCT05545124|DRUG|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
219600042|NCT02856438|DRUG|Elotuzumab|Specified dose on specified days
219600043|NCT02856438|DRUG|Lenalidomide|Specified dose on specified days
219600044|NCT02856438|DRUG|Dexamethasone|Specified dose on specified days
219613585|NCT04152967|DEVICE|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
219613586|NCT04152967|DEVICE|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
219613587|NCT06071754|DEVICE|Masimo INVSENSOR00057|Masimo INVSENSOR00057 will be used to collect electrocardiogram measurements.
219487177|NCT00478673|DEVICE|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
219600045|NCT02437903|DEVICE|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
218869060|NCT06074458|BEHAVIORAL|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
218869061|NCT03922087|OTHER|No intervention|No intervention
218869062|NCT06929676|PROCEDURE|Periodontal Treatment|Non-surgical periodontal treatment with scaling and root planing and dental splinting
218869063|NCT06929676|OTHER|assessment of tooth mobility before and after periodontal treatment|Evaluation of dental mobility with a customized device before and after non-surgical periodontal therapy and after stabilization by periodontal splints
218869064|NCT06929676|OTHER|Evaluation of Clinical Parameters|Periodontal: probing depth, bone loss, CAL (clinical attachment level) Clinical: occlusal prematurities and collection of gingival crevicular fluid Questionnaire: quality of life (OHIP-14)
218869065|NCT06653023|BIOLOGICAL|Universal CAR-T cells injection for treating HCC and NSCLC|A novel universal CAR-T platform to treat cancer patients
218869066|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
218869067|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
218869068|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
218869069|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
218869070|NCT07088250|DRUG|Atorvastatin Treatment|Atorvastatin 20 mg once daily for 21 days.
218869071|NCT07088250|OTHER|Best Medical Treatment|Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.
218869072|NCT07087431|BEHAVIORAL|Immediate disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result as soon as it is available after genotyping.
218869073|NCT07087431|BEHAVIORAL|Deferred Disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result after completion of the 12 month follow up period.
219487178|NCT00478673|DEVICE|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
219487179|NCT03701516|DEVICE|etafilcon A with novel molding process|TEST Lens
218869074|NCT07088770|BEHAVIORAL|Community Coalition CLS Workgroup/Network of Providers|Community Coalition/Network of Providers TechMPower forms the foundation of community engagement in this approach, with membership including PLWH and SUD, sheriffs, within-jail staff, community service providers or other partners who are able to advance the adoption of EBPs within jail and service settings. All coalitions are trained and prepared to drive a planning process at the local level for efficient identification and allocation of resources needed to link people from CLS to a network of community providers for HIV and SUD care and retention. Community coalitions integrate evidence-based (ERIC) strategies: Build coalition; Promote network weaving; Identify/train champions; Conduct consensus discussions that support needed services.
219487180|NCT03701516|DEVICE|etafilcon A with current molding process|CONTROL Lens
219487181|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
218869075|NCT07088770|BEHAVIORAL|Tech-mediated Training and Service Delivery|Researchers will train all staff, healthcare providers and peer navigators to recognize and reduce stigma in CLS and healthcare settings using a training program informed by MPI Frye and colleagues in the CHHANGE (MH102182-01) intervention, which developed an anti-intersectional stigma training program for CBOs and offers comprehensive training to healthcare and social service organizations. Additionally, researchers will train staff and support protocol enhancements as needed to utilize tech mediated service delivery for NCM in-reach and services coordination in the community. These integrate 5 evidence-based (ERIC) implementation strategies: promote consultation; provide clinical/technical supervision; centralize technical assistance; change physical structure and equipment.
219199916|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
219487182|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
219600046|NCT02652611|PROCEDURE|SI Screw Removal Surgery|
219600047|NCT02652611|PROCEDURE|Non-screw removal treatment (non-operative management)|
219600048|NCT02237092|PROCEDURE|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
219600049|NCT00002225|DRUG|Efavirenz|
219199917|NCT06665477|DEVICE|Restylane Volyme|Subjects in Restylane Volyme treatment group will receive treatment on Day 1 and optiponal treatment 1 month later.
219487183|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
219487184|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
219600050|NCT00002225|DRUG|Stavudine|
219600051|NCT00002225|DRUG|Didanosine|
219487185|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
219487186|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
219487187|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
219487188|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
219487189|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
219487190|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
219487191|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
219487192|NCT00245258|DRUG|Sildenafil Citrate|
219487193|NCT03230695|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
219487194|NCT03230695|DEVICE|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
219487195|NCT03230695|DEVICE|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
219487196|NCT02903095|DRUG|TD-1439|
219487197|NCT02903095|DRUG|Placebo|
219487198|NCT02125734|DRUG|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
219487199|NCT02125734|DRUG|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
219487200|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
219487201|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
219487202|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
219487203|NCT04203758|OTHER|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
219487204|NCT04203758|OTHER|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
219487205|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
219487206|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
219487207|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
219487208|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
219487209|NCT05597514|OTHER|3D printed educational model|Slide-based presention plus 3D printed airway suction model
219600052|NCT06582498|BEHAVIORAL|Active intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
219613588|NCT07018271|DRUG|sulpegfilgrastim|On Day 1 of each oncological treatment cycle, after administration of the CD38 monoclonal antibody, a subcutaneous injection of Sulfubrolipoyl G-CSF will be given. The recommended fixed dose of Sulfubrolipoyl G-CSF is 6 mg per injection.
219487210|NCT05597514|OTHER|Tranditional model education|Slide-based presention plus tranditional model
219487211|NCT00191256|DRUG|Gemcitabine|
219487212|NCT00191256|DRUG|Carboplatin|
219487213|NCT00191256|DRUG|Paclitaxel|
219487214|NCT00928785|BIOLOGICAL|REPEVAX|1 dose of 0.5 mL at Day 0
219487215|NCT00928785|BIOLOGICAL|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
219487216|NCT05917314|OTHER|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~* Limosilactobacillus fermentum K7-Lb1~* Limosilactobacillus fermentum K8-Lb1~* Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
219487217|NCT05917314|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
219487218|NCT00000282|DRUG|Pemoline|
219487219|NCT05083559|DEVICE|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
219487220|NCT05083559|DEVICE|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
219487221|NCT03907540|DRUG|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
218869076|NCT07088770|BEHAVIORAL|Multidisciplinary Implementation Team with Champion|The multidisciplinary Implementation Team will be comprised of a correctional health nurse, social worker and discharge planner or counselor and corrections officer from the jail. A representative from the community coalition and peer and case manager from NCM will join the team using a tech-mediated platform for conducting the training and for on-going weekly case conferencing addressing system and client level barriers and service planning. The role of the champion from the correctional setting will be to convene meetings focused on fidelity to the intervention components, engagement in shared problem-solving and mediation of administrative issues that may inhibit effective implementation of TechMPower. The champion and implementation team may request technical assistance (TA) or implementation facilitation at any point during implementation. This TA may be provided by the investigative team or outside providers from federal programs.
219487222|NCT03907540|DRUG|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
219487223|NCT03907540|DRUG|[14C]-KD025 200 mg capsule|test investigational medicinal product
219487224|NCT03039517|DEVICE|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
219487225|NCT03039517|DEVICE|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
219487226|NCT00303134|DRUG|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
219487227|NCT04008082|DRUG|Lenvatinib|Lenvatinib capsule.
219487228|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
219487229|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
219487230|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
219487231|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
219487232|NCT04461431|PROCEDURE|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
219487233|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
219600053|NCT06582498|BEHAVIORAL|Low-intensity intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
219487234|NCT06185556|PROCEDURE|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
219487235|NCT06185556|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
219487236|NCT05246111|DRUG|[14C]Berzosertib|Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
219487237|NCT05246111|DRUG|Berzosertib|Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
219600054|NCT04414618|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
219600055|NCT04414618|DRUG|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
219600056|NCT05935202|DRUG|Mitapivat sulfate|Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
219600057|NCT00360984|DRUG|insulin glargine|
219600058|NCT00360984|DEVICE|continuous subcutaneous insulin infusion|
218869077|NCT07088770|BEHAVIORAL|Tech-mediated Peer Navigation Enhanced Case management (NCM)|Navigation-Enhanced Case Management (NCM) uses Project START, a CDC best evidence intervention as its HIV risk reduction framework. Prior to release, a case manager and peer navigator via telehealth and in-person provide discharge planning and patient education and serves as a liaison to the courts. After release, patient navigators facilitate reentry into community care and provide referrals to HIV medical and SUD care as appropriate (e.g., ART, PrEP, MOUD) and assistance with food, housing, transportation, employment, substance dependence, mental health treatment, and legal issues. TechMPower planned to enhance tracking of linkage during NCM services by integrating reporting along with a web-based platform that tracks assignment of providers and peers and follows for 6 months to capture PRISM linkage and retention in MOUD, HIV and ancillary care.
218869078|NCT07087899|OTHER|music|listening music
218869079|NCT07087405|DEVICE|Striae Distensae Treatment Device|One time deep skin treatment
218869080|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
218869081|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
218869082|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
218869083|NCT06853314|BEHAVIORAL|PrEP for WINGS|The PrEP for WINGS intervention involves three sessions of a self-paced and self-directed intervention delivered via a mobile health platform. Session 1 will focus on HIV risk reduction and provide the PrEP Decision Aid, where participants will learn information about PrEP to help them decide if it is appropriate for them. Sessions 2-3 will involve integrated Screening, Brief Intervention, Referral to Treatment (SBIRT) modules focused on IPV and alcohol reduction. The PrEP for WINGS intervention will also involve peer navigation sessions with Community Health Advocates to help intervention participants trouble shoot any barriers to achieving goals they set during the self-paced sessions. The PrEP for WINGS intervention will take place over a 30 day period and Sessions 2-3, and the peer navigation sessions may be delivered using smart phones or using tablets available at study data collection sites.
218869084|NCT06853314|BEHAVIORAL|PrEP Decision Aid|The PrEP Decision Aid will be delivered to participants in the control condition, and focus on helping study participants decide if they should initiate PrEP. This single session will focus on HIV risk reduction, and then launch the patient-centered PrEP Decision Aid. This individual session will be identical to the first session of the PrEP for WINGS three session intervention, and will also be delivered through an online survey platform. In addition, study participants in the control condition will also have one peer navigation session with a Community Health Advocate at the end of the self-paced session to help facilitate linkage to care.
218869085|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
219600059|NCT01857479|DRUG|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
219613589|NCT04648267|OTHER|Cast and bolster placement duration|The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
218869086|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
218869087|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
218869088|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
218869089|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
219487238|NCT05246111|DRUG|Topotecan|Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
219487239|NCT05131282|DIAGNOSTIC_TEST|Blood test of PE risk|A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE
219487240|NCT05131282|DIAGNOSTIC_TEST|Blood test of Preterm PE risk|A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE
219487241|NCT05565872|BEHAVIORAL|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
219487242|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
219487243|NCT03151226|DEVICE|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
219613590|NCT04648267|OTHER|Standard of care|This will be standard of care - the patient will have his cast and bolster on for 5-7 days
219487244|NCT03620760|DRUG|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
219487245|NCT03620760|DRUG|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
219487246|NCT03620760|DRUG|Aspirin|Aspirin 100 mg once daily dose
219487247|NCT03086980|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
219487248|NCT03086980|OTHER|Treatment as Usual|Usual Care will be provided.
219487249|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
219487250|NCT00138827|DRUG|Biotene (mouth care)|
219487251|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
219487252|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
219487253|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
219487254|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
219487255|NCT01016431|OTHER|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
219487256|NCT01016431|OTHER|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
219487257|NCT05844644|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
219487258|NCT04479488|OTHER|Hospital admission|Usual care.
219487259|NCT04479488|OTHER|Non-hospitalization procedures|Usual care.
219487260|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
219487261|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
219487262|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
219487263|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
219487264|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
219487265|NCT00006001|DRUG|semaxanib|
219487266|NCT06123897|OTHER|Regular follow-up assessments without intervention.|Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.
219487267|NCT06123897|OTHER|Cross-sectional assessment|Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
219487268|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
219487269|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
219600060|NCT01857479|DRUG|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
219600061|NCT06139302|DRUG|BI 1015550|BI 1015550
218869090|NCT01988545|OTHER|saline|
218869091|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
219487270|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
219487271|NCT00002037|DRUG|Trifluridine|
219487272|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
219487273|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
219487274|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
219487275|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
219487276|NCT03549143|OTHER|IBS|No intervention, description of routine practice only
219487277|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
219487278|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
219487279|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
219487280|NCT00000705|DRUG|Zidovudine|
219487281|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
219487282|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
219487283|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
219487284|NCT04062643|DIAGNOSTIC_TEST|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
219487285|NCT02508649|DRUG|selepressin|
219487286|NCT02508649|DRUG|placebo|
219487287|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
219487288|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
219487289|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
218869092|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
219487290|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
219600062|NCT00658879|DRUG|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
219600063|NCT02214537|OTHER|MACS|
219600064|NCT05876637|OTHER|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
219600065|NCT05876637|OTHER|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
219487291|NCT02392975|PROCEDURE|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
219487292|NCT02392975|PROCEDURE|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
218869093|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
218869094|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
218869095|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
218869096|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
218869097|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
218869098|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
218869099|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
218869100|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
218869101|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
218869102|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
218869103|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
218869104|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
218869105|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
218869106|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
218869107|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
219487293|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
219487294|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
219487295|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
218869108|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
219487296|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
219487297|NCT04461626|DEVICE|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
219487298|NCT03026868|PROCEDURE|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
218869109|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
218869110|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
218869111|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
218869112|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
218869113|NCT05354193|OTHER|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
218869114|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
218869115|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
218869116|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
219487299|NCT02360124|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
219487300|NCT02360124|OTHER|Water as placebo|topical application of water as a placebo in the control arm
219487301|NCT02360124|OTHER|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
219487302|NCT01305135|DRUG|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
219487303|NCT06505213|OTHER|no intervention|no intervention
219487304|NCT01888159|PROCEDURE|Bilateral Salpingectomy|
219487305|NCT01888159|PROCEDURE|Tubal sterilization with bipolar energy|
219487306|NCT00417859|DEVICE|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
219487307|NCT03739684|DRUG|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
218869117|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
219487308|NCT03739684|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
218869118|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
218869119|NCT07088237|BEHAVIORAL|Stress Feedback|The stress feedback draws on a skills-based model of emotion regulation that emphasizes the ability to identify and label emotions, followed by either actively modifying negative emotions or accepting negative emotions when necessary. Participants will receive a prompt to identify their current emotion, followed by questions regarding their current context.
218869120|NCT07088237|BEHAVIORAL|Music Listening|For the music recommendation component, our system suggests music that is tailored to the individual and the specific context. Because we will use machine learning to predict optimal music features based on physiological, contextual, and musical data, the music items will be naturally suggested based on current emotion and level of intensity as well as the current context and problem type. The music recommendation component is an adaptive playlist that is updated as changes in the user's stress level are detected. To provide personalized music recommendations, we use a supervised learning approach to design an algorithm, referred to as music feature prediction, which predicts optimal values of music features (e.g., energy, valence, instrumentalness, acousticness) that are hypothesized to result in reducing stress. These feature values, referred to as effective music features, are then used to generate a personalized music playlist.
218869121|NCT07089394|PROCEDURE|flexible urs|treating pediatric renal stones with flexible urs+holmium laser fragmentation
219487309|NCT04556500|OTHER|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
219487310|NCT01115699|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
219487311|NCT06375954|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
219487312|NCT06375954|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
219487313|NCT06375954|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
219600066|NCT05707793|OTHER|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
219600067|NCT02614105|PROCEDURE|Pelvic floor muscle training|16 weeks of group-based exercise
219600068|NCT02614105|PROCEDURE|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
219600069|NCT02614105|OTHER|Control|Brief information only
218869122|NCT02591459|OTHER|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
219487314|NCT03563235|DRUG|Xulin Jiangu granules|Xulin Jiangu granules tablets
219487315|NCT03563235|DRUG|Calcitriol capsules|Calcitriol capsules tablets
219487316|NCT05431348|DEVICE|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
219487317|NCT05431348|DIAGNOSTIC_TEST|Serum Cortisol|Level of cortisol in serum will be determined
219487318|NCT05431348|OTHER|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
219487319|NCT03755856|OTHER|Questionnaire|Health-related quality of life
219487320|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
219600070|NCT05998876|DEVICE|Remote Medication Monitor (RMM) - Prototype|Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
219600071|NCT05998876|DRUG|Daily Methadone Dose|patient takes their prescribed daily dose of methadone
219600072|NCT04667286|PROCEDURE|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
219600073|NCT05322122|DEVICE|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
219600074|NCT06161779|OTHER|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
218869123|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
219487321|NCT04331392|BEHAVIORAL|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
219487322|NCT04331392|BEHAVIORAL|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
218869124|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
218869125|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
219487323|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
219487324|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
219487325|NCT04914559|OTHER|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
219487326|NCT04914559|OTHER|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
219487327|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
219487328|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
219487329|NCT05924672|DRUG|Radium-223|Given IV
219487330|NCT05924672|PROCEDURE|PSMA Positron Emission Tomography (PET) Scan|Undergo PSMA PET/CT
219487331|NCT05924672|DRUG|Technetium Tc 99M Medronate|Undergo MDP
219487332|NCT02160054|DRUG|Graceptor®|oral
219487333|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
218869126|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
218869127|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
219487334|NCT04308382|BEHAVIORAL|Health Risk Assessment|"Heath Risk Assessment consists of:~* Survey to include questions about physical activity, stress, hope, household hunger and demographics.~* Lipid panel and HbA1c~* Height and Weight, blood pressure and resting pulse"
219487335|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
219487336|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
219487337|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
219487338|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
219487339|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
219487340|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
218869128|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
218869129|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
219487341|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
219613591|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
219613592|NCT01171729|BIOLOGICAL|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
218869130|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
219487342|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
219487343|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
219487344|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
219487345|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
219487346|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
219487347|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
219487348|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
219487349|NCT03594175|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
219487350|NCT03594175|DRUG|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
219487351|NCT03594175|DRUG|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
219487352|NCT06489847|DIAGNOSTIC_TEST|SPPB++ Application|Participants will have video data collected as they perform the SPPB test one time.
219487353|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
219487354|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
219487355|NCT05416125|DRUG|Lisdexamfetamine Dimesylate|Vyvanse treatment
219487356|NCT05416125|BEHAVIORAL|Lifestyle therapy|Lifestyle treatment
219600075|NCT02798588|RADIATION|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
219600076|NCT02130115|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
219600077|NCT04573894|DIAGNOSTIC_TEST|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
219600078|NCT00616421|BIOLOGICAL|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
219487357|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
219487358|NCT04719728|DIAGNOSTIC_TEST|Aided pure tone audiometry|aided response, speech, evoked potential
219487359|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
219487360|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
219487361|NCT06406894|OTHER|Conventional physical therapy|"lower limb muscle stretching ( pelvic bridging, Knee to chest,cat and camel stretch) (30 seconds hold and 3 sets of 5 repetitions with 1 min rest interval in between each set, per session on daily basis for only one week for immediate results and for long term effect on alternate 3 days in remaining 2nd ,3rd week).~Treatment protocol will be given on daily basis to check immediate effect and for long term effect treatment will be given in alternating 3 days for remaining 2 weeks. Total 12 session were given (3 weeks)."
219613593|NCT00295425|DRUG|Cyclosporine A versus mycophenolate mofetil for psoriasis|
219613594|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin|Tetracycline combined with levofloxacin quadruple therapy
219613595|NCT05850117|DRUG|esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole|standard tincture quadruple therapy
219613596|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin|amoxicillin combined with levofloxacin quadruple therapy
219613597|NCT05137392|OTHER|oral hygiene instruction|The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
219613598|NCT06721871|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
219613599|NCT06721871|DRUG|Placebo Powder for Oral Solution|Matching Placebo Powder for Oral Solution
219613600|NCT02665156|PROCEDURE|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
219613601|NCT04631354|DRUG|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
219613602|NCT04631354|DEVICE|S-770108 Inhaler A1|Dry powder inhaler
219613603|NCT00729937|DRUG|Cephalexin|500 mg, four times per day.
219613604|NCT00729937|DRUG|Clindamycin|300 mg, four times per day.
219613605|NCT00729937|OTHER|Placebo|Placebo tablet administered orally.
219613606|NCT00729937|DRUG|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
219487362|NCT06406894|OTHER|Superficial back line relaxation (SMIT & CCFE)|Experimental group was given superficial back line relaxation includes SMIT \& CCFE along with conventional therapy includes lower limb muscle stretching. SMIT For short term effect 10-12 repetitions per session, on daily basis for 1st week. For long term effect 10-12 repetitions per session, for 3 alternate days in remaining 2nd\&3rd week. CCFE For short term effect 3 sets of 10 reps , 10 sec hold , 1 min rest after each set, on daily basis for 1st week. For long term effect 3 sets of 10 reps, 10 sec hold , 1 min rest after each set, for 3 alternate days , remaining 2nd \& 3rd week. Conventional therapy lower limb muscle stretching ( For short term effect 30 seconds hold , 3 sets of 5 repetitions , 1 min rest after each set, per session on daily basis for 1st week , for long term effect on alternate 3 days in remaining 2nd ,3rd week). Total 12 sessions were given (3 weeks).
218869131|NCT05808517|BEHAVIORAL|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
219487363|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
219487364|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
219487365|NCT04983095|RADIATION|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
219487366|NCT04983095|COMBINATION_PRODUCT|androgen deprivation therapy|Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
218869132|NCT05808517|OTHER|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
218869133|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
218869134|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
218869135|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
218869136|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
218869137|NCT02747511|DRUG|Haloperidol|
218869138|NCT02747511|DRUG|Placebo|
218869139|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
218869140|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
219487367|NCT04983095|RADIATION|Radiotherapy|RT to the prostate for de novo patients
219487368|NCT06147856|DRUG|mRNA-3210|IV infusion
219487369|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
219487370|NCT02159651|DRUG|tacrolimus|oral
219487371|NCT05027425|DRUG|Durvalumab|1500 mg IV, Q4W
219487372|NCT05027425|DRUG|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
219487373|NCT05027425|PROCEDURE|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
219487374|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
219487375|NCT04233788|DEVICE|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
219487376|NCT06173713|DEVICE|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
219487377|NCT04824560|BEHAVIORAL|Blood pressure education|One page teaching protocol performed by pharmacy students; phone follow-up
219487378|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
219600079|NCT00616421|BIOLOGICAL|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
219600080|NCT00616421|BIOLOGICAL|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
219487379|NCT05631652|DEVICE|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
219487380|NCT06348823|DIAGNOSTIC_TEST|volume survey|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
218869141|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
218869142|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
218869143|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
218869144|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
218869145|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
218869146|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
218869147|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
218869148|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
218869149|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
218869150|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
219487381|NCT05362955|DRUG|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
219487382|NCT04873830|BIOLOGICAL|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
219487383|NCT04873830|PROCEDURE|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
219600081|NCT04660279|DIAGNOSTIC_TEST|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
219600082|NCT02490280|BEHAVIORAL|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
219600083|NCT03798925|OTHER|None Intervention|It is observational study
218869151|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
218869152|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
219600084|NCT03417635|BEHAVIORAL|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
219600085|NCT03417635|BEHAVIORAL|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
218869153|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
218869154|NCT03395561|OTHER|control|2 capsuls
218869155|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
218869156|NCT03474198|DRUG|Rifampicin|10mg/kg
218869157|NCT03474198|DRUG|Isoniazid|5mg/kg
218869158|NCT03474198|DRUG|Pyrazinamide|25mg/kg
218869159|NCT03474198|DRUG|Ethambutol|15mg/kg
218869160|NCT03474198|DRUG|Linezolid|600mg
218869161|NCT03474198|DRUG|Clofazimine|200mg
218869162|NCT03474198|DRUG|Rifapentine|1200mg
218869163|NCT03474198|DRUG|Levofloxacin|1000mg
218869164|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
218869165|NCT03474198|DRUG|Rifampicin|35mg/kg
219487384|NCT06146517|OTHER|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
219487385|NCT06146517|OTHER|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
219487386|NCT06146517|OTHER|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
219487387|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
219487388|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
219487389|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
219487390|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
218869166|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
218869167|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
218869168|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
218869169|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
218869170|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
219487391|NCT00334477|DRUG|tadalafil|
219487392|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
219487393|NCT05187507|OTHER|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
219487394|NCT05187507|OTHER|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
219487395|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
219487396|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
219487397|NCT00351156|PROCEDURE|Blood sample|
219487398|NCT01205542|BEHAVIORAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
219487399|NCT01205542|BEHAVIORAL|Reference|Health check and advice to continue ordinary physical activity
218869171|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
219487400|NCT06232538|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
218869172|NCT01160432|DRUG|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
218869173|NCT02694497|OTHER|Chlamydia care as usual|
218869174|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
218869175|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
219487401|NCT00191620|DRUG|Gemcitabine|
219487402|NCT00191620|DRUG|cisplatin|
218869176|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
218869177|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
218869178|NCT03403309|DRUG|1) Inosine 5'-monophosphate|1\) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
218869179|NCT03403309|DRUG|Placebo|2\) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
218869180|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
219487403|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
219487404|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
219613607|NCT04215237|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg oral once a day
219613608|NCT02287155|BEHAVIORAL|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
219613609|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
219613610|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
219613611|NCT04614753|OTHER|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
218869181|NCT00517569|GENETIC|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
219487405|NCT06607692|DRUG|Olaparib; 177Lu-DOTATATE|7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
219487406|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
219487407|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
219487408|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
219487409|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
219487410|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
219487411|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
219487412|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
219600086|NCT02661217|DRUG|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
219600087|NCT02758639|BEHAVIORAL|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
219600088|NCT03046641|OTHER|Continuous training|Study group I (42 participants) received the continuous training.
218869182|NCT00517569|DRUG|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
218869183|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
218869184|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
218869185|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
218869186|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
218869187|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
218869188|NCT02776592|OTHER|Cow's milk-based formula|
218869189|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
218869190|NCT01033318|DRUG|MK1809|single oral doses of MK1809
219600089|NCT03046641|OTHER|The interval training|Study group II (40 participants) received the interval training.
219600090|NCT01666665|DRUG|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
219600091|NCT01666665|DRUG|Sugar pill|Sugar pill up to 3 times per day for 12 months
219600092|NCT02879344|OTHER|Blood draw|
218869191|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
218869192|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
218869193|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
218869194|NCT00550901|DRUG|cisplatin|
218869195|NCT00550901|DRUG|dexrazoxane hydrochloride|
218869196|NCT00550901|OTHER|high performance liquid chromatography|
218869197|NCT00550901|OTHER|laboratory biomarker analysis|
218869198|NCT00550901|OTHER|mass spectrometry|
218869199|NCT00550901|OTHER|pharmacological study|
218869200|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
218869201|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
218869202|NCT03465553|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
218869203|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
219487413|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
219487414|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
219487415|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
219487416|NCT01827072|DRUG|NPB-01|
219487417|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
219487418|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
219487419|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
219487420|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
218869204|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
219487421|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
219487422|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
219600093|NCT02538822|DEVICE|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
219600094|NCT02538822|DEVICE|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
219600095|NCT02982291|PROCEDURE|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
219600096|NCT02982291|PROCEDURE|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
219600097|NCT04742374|BIOLOGICAL|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
218869205|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
219199918|NCT06860854|PROCEDURE|Epidural Analgesia|"The eligible patients will have their vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery measured directly before the administration of ELA. They will be also asked to rate their level of pain on the visual analogue scale (VAS).~The specific method and drug regimen for ELA will be determined by the attending anesthesiologist. The mode of administration (continuous infusion, intermittent bolus, or patient-controlled epidural analgesia) will be recorded along with the anesthetic agents used for future subgroup analysis.~The vital signs, the Doppler velocities and VAS score will be recorded after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor."
219487423|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
219600098|NCT03806010|PROCEDURE|Quantitative sensory testing|Quantitative sensory testing
219600099|NCT00185588|DRUG|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
219600100|NCT00185588|DRUG|Gemcitabine|850 mg/m2
219487424|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
219487425|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
219487426|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
219487427|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
219487428|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
219487429|NCT01916759|DRUG|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
219600101|NCT02604407|DRUG|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
219600102|NCT02604407|OTHER|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
219600103|NCT02604407|DRUG|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
219600104|NCT01914692|DRUG|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
219600105|NCT02067962|BIOLOGICAL|Blood sample|Blood sample
219600106|NCT03778138|DRUG|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
218869206|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
219487430|NCT04252040|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
219600107|NCT01822717|BEHAVIORAL|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
219600108|NCT01822717|BEHAVIORAL|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
219600109|NCT00734058|DEVICE|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
219600110|NCT06452134|DRUG|Coenzyme Q10 100 MG Oral Tablet|Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
219600111|NCT06452134|DRUG|Placebo|Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
219613612|NCT04614753|OTHER|Control Beverage|300ml of Sugar Water and Acid Content
219613613|NCT05333731|DRUG|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
218869207|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
218869208|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
218869209|NCT00116363|GENETIC|investigational drug INGN 241|
219487431|NCT00058045|BIOLOGICAL|aldesleukin|
218869210|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
218869211|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
218869212|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
219487432|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
219487433|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
219487434|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
219487435|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
219487436|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
219487437|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
219487438|NCT03441373|DRUG|Placebo|once daily during 5 days.
219487439|NCT00788008|DRUG|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
219487440|NCT00213629|OTHER|transcriptome analysis|transcriptome analysis from muscle biopsy
219613614|NCT05227963|OTHER|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
218869213|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
218869214|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
218869215|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
218869216|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
218869217|NCT06924658|OTHER|placebo|Placebo will have the same look of metformin
219487441|NCT00213629|OTHER|T cell repertoire analysis|blood T cell repertoire analysis
218869218|NCT06924658|DRUG|Metformin|Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
218869219|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 7 days
218869220|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 5 days
218869221|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 7 days
218869222|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 5 days
218869223|NCT06929962|DRUG|Vonoprazan and Amoxicillin for 14 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 14 days
218869224|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
218869225|NCT02768753|PROCEDURE|The Axillary Bilateral-breast Approach|
218869226|NCT02768753|PROCEDURE|The bilateral Axillo-breast Approach|
219487442|NCT06538714|OTHER|MIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling."
219487443|NCT06538714|OTHER|MIIT + HIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling."
219487444|NCT06538714|OTHER|Control group|"Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling."
219487445|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
219487446|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
219487447|NCT06056323|DRUG|HB0045 Drug Product|Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
219487448|NCT01038531|OTHER|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
219487449|NCT01038531|OTHER|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
219487450|NCT00005879|DRUG|arzoxifene|one tablet daily
219487451|NCT00005879|DRUG|Placebo|matched tablet dialy
219487452|NCT05207176|DRUG|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
219487453|NCT00363935|DRUG|Dexmedetomidine|
219487454|NCT02352207|OTHER|identification of a pulmonary malformation in the fetus|
219487455|NCT03138135|BEHAVIORAL|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
218869227|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
218869228|NCT05107466|DIAGNOSTIC_TEST|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
218869229|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
218869230|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
219487456|NCT03138135|BEHAVIORAL|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
219487457|NCT06430307|DRUG|Saussurea Involucrata Liquid Tonic|This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
219487458|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
219487459|NCT02790619|DEVICE|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
219487460|NCT02790619|DEVICE|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
219487461|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
219487462|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
219487463|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
219487464|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
219487465|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
219487466|NCT03676673|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219487467|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
219600112|NCT03908437|DRUG|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
219600113|NCT05445492|DEVICE|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
218869231|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
219600114|NCT00191191|DRUG|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
219600115|NCT00191191|DRUG|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
218869232|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
218869233|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
218869234|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
218869235|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
218869236|NCT02857101|OTHER|dosage of calprotectin|
218869237|NCT01875718|DRUG|UC1010|
219600116|NCT02704169|OTHER|Spatially registered endoscopy|
219600117|NCT03348163|DRUG|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
219600118|NCT03348163|DRUG|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
218869238|NCT01875718|DRUG|Placebo|
218869239|NCT01771614|BEHAVIORAL|Exercise|
218869240|NCT01771614|PROCEDURE|Hyperglycemia|
218869241|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
218869242|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
218869243|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
219487468|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
219487469|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
219487470|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
219487471|NCT00230217|DRUG|Rasburicase (SR29142)|
219487472|NCT06395584|DEVICE|White Light LED|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
218869244|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
218869245|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
218869246|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
218869247|NCT04971941|DEVICE|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
218869248|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
218869249|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
218869250|NCT01567995|DRUG|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
218869251|NCT01567995|DRUG|Vehicle (base cream)|Vehicle (base cream)
218869252|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
218869253|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
218869254|NCT06938308|DEVICE|LMA Igel|adults allocated to the LMA Igel group, an LMA Igel device will be inserted intraoperatively
218869255|NCT06938308|DEVICE|LMA Protector|adults allocated to the LMA Protector group, an LMA Protector device will be inserted intraoperatively
218869256|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
218869257|NCT03898128|DRUG|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
218869258|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
218869259|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
218869260|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
218869261|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
218869262|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
218869263|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy plus CME|
218869264|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy|
218869265|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
218869266|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
219487473|NCT06395584|DEVICE|Green Light LED|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
219487474|NCT05832242|OTHER|Ultrasound|Point-of-care ultrasound in the emergency department
218869267|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
218869268|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
218869269|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
218869270|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
218869271|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
218869272|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
218869273|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
218869274|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
218869275|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
218869276|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
218869277|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
219600119|NCT03347825|PROCEDURE|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
219487475|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
219487476|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
219487477|NCT03980561|DRUG|Varenicline|Active medication
219487478|NCT03980561|DRUG|Placebo|Inactive medication
219487479|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
219487480|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
219487481|NCT06360679|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted and retrieved once treatment is completed
219487482|NCT05406596|DEVICE|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
219487483|NCT03162120|DRUG|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
219487484|NCT03162120|DRUG|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
219487485|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
219487486|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
219487487|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
219487488|NCT05549986|OTHER|Observational|Observational
219600120|NCT03347825|PROCEDURE|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
219600121|NCT03347825|PROCEDURE|Open lobectomy|Open lobectomy
219600122|NCT00390208|DRUG|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
219600123|NCT00390208|DRUG|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
219600124|NCT01749423|BIOLOGICAL|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
219600125|NCT02054338|DRUG|Vinflunine+Gemcitabine|Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
219600126|NCT02054338|DRUG|Paclitaxel+Gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
219487489|NCT00228878|PROCEDURE|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
219600127|NCT03225001|DEVICE|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
219600128|NCT00790725|OTHER|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
219600129|NCT00790725|OTHER|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
219487490|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
219487491|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
218869278|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
218869279|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
218869280|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
218869281|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
218869282|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
218869283|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
218869284|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
219487492|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
219487493|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
219487494|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
219600130|NCT04080466|RADIATION|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
218869285|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
218869286|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
218869287|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
218869288|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
219487495|NCT04591327|PROCEDURE|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
219522425|NCT06929429|PROCEDURE|Bilateral Sphenopalatine Ganglion Block|A bilateral sphenopalatine ganglion block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine. The local anesthetic will be applied intranasally with a cotton-tipped applicator placed parallel to the zygomatic arch and advanced to the posterior nasal cavity. The applicator will remain in place for 15 minutes.
219522426|NCT06929429|PROCEDURE|Bilateral Infraorbital Nerve Block|A bilateral infraorbital nerve block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine per side. The block will be guided by linear ultrasound to identify the infraorbital foramen and administered with a 22G needle around the nerve. A 15-minute absorption period will be allowed before the surgical procedure begins.
218869289|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
218869290|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail|
218869291|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
218869292|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
218869293|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
218869294|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
219487496|NCT02334839|OTHER|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
219487497|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
219487498|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
219487499|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
219487500|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
219487501|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
219487502|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
219487503|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
219487504|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
218869295|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
218869296|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
218869297|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
219199919|NCT03893903|DRUG|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
219487505|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
219487506|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
219487507|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
219487508|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
219487509|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
219487510|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
219487511|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
219487512|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
219487513|NCT02041000|OTHER|Adipose Derived Stem Cells|
219487514|NCT02805673|PROCEDURE|Osteopathy|
219487515|NCT00901420|PROCEDURE|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
219487516|NCT00901420|BEHAVIORAL|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
219487517|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
219487518|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
219487519|NCT00187174|DRUG|Everolimus|The drug is given orally in 28 day courses.
219487520|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
219487521|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
219487522|NCT05475535|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
219487523|NCT05475535|BEHAVIORAL|Self-Compassion|Self-Compassion focused exercises
218869298|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
218869299|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
218869300|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
218869301|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
218869302|NCT01561963|DRUG|Apremilast|Tablets for oral administration
218869303|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
218869304|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
218869305|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
219487524|NCT05475535|BEHAVIORAL|Active Control|Engagement in a mobile application (Cooperation skills)
219487525|NCT03943407|DRUG|Zyclara 3.75 % Topical Cream|The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
219487526|NCT03943407|DRUG|Prudoxin|The anti-histamine cream Prudoxin, containing 5% doxepin hydrochloride (1 g contains 50 mg of doxepin) (Healthpoint, San Antonio, TX) will be applied on the volar forearm. Two adhesive patches 4×4 cm (1mm thick, 3M foam adhesive tape, 3M, St. Paul, MN) each with a 3.5×3.5 cm center cut out (to deposit 1.2 grams of cream) will be each placed 3 cm distal and 3 cm proximal to the center of the volar aspect of each arm. Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1 h and 30 minutes.
219487527|NCT03943407|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction. . A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
219487528|NCT03943407|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip. The active substance delivered (mucunain) has been calculated to be in the nanogram range. The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
219487529|NCT03943407|OTHER|L-menthol|L-menthol (≥99.9%, TRPM8 agonist; (Sigma Aldrich, Broendby, Denmark) is dissolved in 96% ethanol at concentrations of 40%(w/v) L-menthol. A 1 mL aliquot is dispensed onto a 3 × 3 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape. In between the cotton pad and the medical tape, a layer of parafilm will be added to avoid evaporation. This configuration was subsequently applied for 1 h.
219487530|NCT03943407|OTHER|Trans-cinnamaldehyde (CA)|CA will be obtained from Sigma Aldrich (Brøndby, Denmark) and dissolved in 90% ethanol at a concentration of 10% (vol/vol) CA. One ml aliquot of CA is dispensed onto a 3x3 cm cotton pad and placed on a 5x5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic film will be added to inhibit the evaporation of the solutions. This configuration will be applied for 1 h.
219487531|NCT06317870|PROCEDURE|Intrathecal morphine|"Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding."
219487532|NCT06317870|PROCEDURE|Pericapsular nerve group block (PENG)|"Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected."
219487533|NCT05021120|DRUG|AK127|Subjects will receive AK127 by intravenous administration
219487534|NCT05021120|DRUG|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
219487535|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
219487536|NCT02108366|DRUG|Celecoxib|Celecoxib 200mg daily
219487537|NCT02108366|DRUG|Oseltamivir|Oseltamivir 75mg bid
219487538|NCT02108366|DRUG|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
219487539|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
219600131|NCT04080466|OTHER|Blood/Urine Collection|"Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study."
218869306|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
219199920|NCT03893903|DRUG|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
218869307|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
218869308|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
219487540|NCT04499391|OTHER|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
219487541|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
219487542|NCT03313401|DRUG|Aflibercept|Intravitreal aflibercept injection
219487543|NCT03313401|DEVICE|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
219487544|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
219487545|NCT06702475|DIAGNOSTIC_TEST|Home Sleep Test with Watch PAT-one|Each participant will have a Watch-PAT one home sleep test, recording pulse oximetry, pulse tonometry, wrist actigraphy, snoring (by microphone), and chest motion by accelerometer.
219487546|NCT06723353|OTHER|Visceral Manipulation Therapy|Visceral Manipulation (VM) is a manual therapy consisting of gentle, specifically placed manipulations that encourage normal mobility, tone, and inherent tissue motion of the viscera and their connective tissues. These manipulations can potentially improve the structural integrity of the abdominal cavity and enhance the physiological functioning of the organs. VM will be administered by certified therapists trained in this specialized technique, focusing on reducing the Inter-Recti Distance (IRD) and associated symptoms of DRA.
219600132|NCT04080466|OTHER|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
219600133|NCT04080466|RADIATION|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
219600134|NCT04080466|RADIATION|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
219600135|NCT04080466|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
218869309|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
218869310|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
218869311|NCT04345094|OTHER|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
218869312|NCT04345094|OTHER|Hydroquinone|Emulsions containing hydroquinone as an active
219487547|NCT06723353|OTHER|Abdominal Kinesio Taping|Kinesio Taping (KT) involves the application of a thin, stretchable tape over and around muscles to enhance function, reduce inflammation, and support muscles in movement on a 24hr/day basis. It is non-restrictive, allowing for full range of motion. In this study, KT will be applied in a crisscross pattern across the abdomen to support the abdominal muscles affected by DRA, potentially aiding in muscle function and reducing pain and discomfort.
219600136|NCT04080466|RADIATION|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
219600137|NCT01850134|OTHER|Experimental Study Product|
219600138|NCT01850134|OTHER|Control Study Product|
219600139|NCT05465837|PROCEDURE|Tracheostomy|Early and Late Tracheostomy (\</= 10 days: Early and \>10 days: Late)
218869313|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
218869314|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
218869315|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
218869316|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
218869317|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
218869318|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
219487548|NCT06723353|OTHER|Combined Visceral Manipulation and Kinesio Taping|This intervention combines Visceral Manipulation and Kinesio Taping to leverage the benefits of both modalities. The combination aims to enhance the functional and structural support of the abdominal region by improving organ function through VM and providing muscular support through KT. This dual approach is hypothesized to offer a synergistic benefit, potentially providing a more effective treatment for reducing IRD and improving overall abdominal function.
219487549|NCT06723353|OTHER|Postpartum Core Strengthening Program|The Core Strengthening Program is designed to strengthen the deep core muscles, including the transverse abdominis, multifidus, and the pelvic floor muscles. Exercises will be tailored to accommodate postpartum women and will be progressively adjusted to match improvements in strength and endurance. The program includes supervised training sessions focusing on enhancing core stability, which is crucial for postpartum recovery and long-term spinal and pelvic health.
219487550|NCT05366725|DRUG|Avelumab|As provided in real world practice
218869319|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
218869320|NCT00162240|DRUG|Muraglitazar|
218869321|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
218869322|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
218869323|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
218869324|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
218869325|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
218869326|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
218869327|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
219487551|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
219487552|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
219487553|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
219487554|NCT00228332|DRUG|Administration of zinkgluconaat or placebo|
219487555|NCT00872573|DEVICE|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
219487556|NCT03725267|DRUG|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
219487557|NCT03725267|DRUG|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
218869328|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
218869329|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
218869330|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
218869331|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
219487558|NCT04619472|DEVICE|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
219487559|NCT05543863|DIAGNOSTIC_TEST|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
219487560|NCT01788163|GENETIC|EGFR mutation test|EGFR mutation being tested in tissue and blood
219487561|NCT00545441|DEVICE|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
219487562|NCT00545441|DEVICE|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
219487563|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
219487564|NCT00650637|DRUG|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
219487565|NCT00650637|DRUG|nelfinavir|1250 mg twice a day
218869332|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
219487566|NCT00650637|DRUG|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
219487567|NCT00650637|DRUG|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
219487568|NCT00650637|OTHER|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
219487569|NCT00650637|DRUG|nelfinavir|nelfinavir 1250 mg twice a day
219487570|NCT00650637|DRUG|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
219487571|NCT00265239|DRUG|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
219487572|NCT02773641|DRUG|Botulinum Toxin Type A|
219487573|NCT02773641|DRUG|Sterile Saline Solution|
219487574|NCT04704817|OTHER|obsevation|prospective data collection for colonic or rectal surgery
219487575|NCT03596879|BEHAVIORAL|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
219487576|NCT03596879|BEHAVIORAL|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
219487577|NCT06211803|DIAGNOSTIC_TEST|Positron-Emission Tomography Imaging|Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
219487578|NCT02298595|DRUG|cisplatin|75 mg/m2 IV day 1 of each cycle
219487579|NCT02298595|DRUG|Cetuximab|XXXX day 1, 8, and 15 of each cycle
219487580|NCT02298595|DRUG|BYL719|200, 250, 300, or 350 mg/day by mouth every day
219487581|NCT06701110|DRUG|[U-14C] WX-081|A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
219487582|NCT03610646|DRUG|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
219487583|NCT03610646|DRUG|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
218869333|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
218869334|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
218869335|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
218869336|NCT02204852|DRUG|Iloprost+eptifibatide|
219487584|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
219487585|NCT02532023|DIETARY_SUPPLEMENT|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
219487586|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
219487587|NCT02532023|DIETARY_SUPPLEMENT|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
219487588|NCT04460521|DRUG|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
219487589|NCT04460521|DEVICE|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
219487590|NCT05877235|DIETARY_SUPPLEMENT|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
219487591|NCT05877235|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 60 days
219487592|NCT00467038|BEHAVIORAL|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
219487593|NCT02803138|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
219487594|NCT02803138|DRUG|Dasabuvir|Tablet
219487595|NCT02803138|DRUG|Ribavirin|Tablet
219487596|NCT02803138|BEHAVIORAL|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
219487597|NCT06576375|DRUG|Dapagliflozin|oral Dapagliflozin
219487598|NCT06576375|DRUG|Metformin|oral metformin
219487599|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
219487600|NCT00792675|OTHER|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
219487601|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
219487602|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
219487603|NCT02719015|DRUG|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
219487604|NCT02719015|DRUG|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
219487605|NCT06537908|DRUG|Anti-PD-1/PD-L1 antibodies|Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
219487606|NCT06537908|DRUG|Anti-VEGF|Anti-VEGF Intravenous injection for at least 6 months
219487607|NCT01133444|DRUG|Finasteride|Finasteride tablets 1 mg
219487608|NCT03402165|DRUG|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir|Response to DAAD's and developing HCC
219487609|NCT02095626|DRUG|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
218869337|NCT02204852|DRUG|Placebo|
219487610|NCT02095626|DRUG|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
219487611|NCT01283373|DRUG|DSTP3086S|DSTP3086S administered intravenously
219487612|NCT01283373|DRUG|DSTP3086S|Escalating intravenous dose
219487613|NCT00013182|BEHAVIORAL|social activity|
219487614|NCT06084273|OTHER|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
219487615|NCT06084273|OTHER|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
219487616|NCT04071366|DRUG|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
219600140|NCT04811937|DIAGNOSTIC_TEST|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
219600141|NCT03583307|DRUG|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
219600142|NCT03026491|OTHER|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
218869338|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
219487617|NCT04071366|DRUG|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
219487618|NCT04071366|DRUG|Placebo|Participants will receive placebo twice daily.
219487619|NCT04071366|BIOLOGICAL|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
219600143|NCT02467140|DEVICE|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
219600144|NCT02467140|DEVICE|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
219600145|NCT02947360|OTHER|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
219600146|NCT04562610|DRUG|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
219600147|NCT04562610|DRUG|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
218869339|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
218869340|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
218869341|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
218869342|NCT01576185|DRUG|quizartinib|Via gavage
218869343|NCT01576185|DRUG|sorafenib tosylate|Via gavage
218869344|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
219487620|NCT00816517|BIOLOGICAL|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
219487621|NCT04023318|BEHAVIORAL|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
218869345|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
218869346|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
218869347|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
218869348|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
219487622|NCT00291512|BEHAVIORAL|Theory-based counseling program|
219487623|NCT04366778|DIAGNOSTIC_TEST|TEM-tPA|325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
219600148|NCT04151680|DRUG|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
218869349|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
218869350|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
218869351|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
218869352|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
218869353|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
219600149|NCT04151680|DRUG|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
218869354|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
218869355|NCT03597282|OTHER|Adjuvant|immune adjuvant
218869356|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
218869357|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
218869358|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
218869359|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
218869360|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
218869361|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
219487624|NCT00021229|DRUG|imatinib mesylate|"* Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
219600150|NCT00578474|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219600151|NCT00578474|DRUG|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
218869362|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
218869363|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
218869364|NCT02231385|DRUG|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
218869365|NCT05897697|OTHER|Interview|Structured interview
218869366|NCT01416623|DRUG|henatinib|Henatinib Maleate Tablets
218869367|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
218869368|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
218869369|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
218869370|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
218869371|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
218869372|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
218869373|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
219487625|NCT00021229|RADIATION|local irradiation therapy|"* Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
219600152|NCT00578474|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
219600153|NCT00714116|DRUG|SBI-087|Single IV or SC dose of SBI-087
219600154|NCT01863914|DRUG|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
219600155|NCT02905058|DRUG|Ketoprofen|oral non-steroidal antiinflammatory drug
218869374|NCT05487183|BEHAVIORAL|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
218869375|NCT05487183|BEHAVIORAL|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
218869376|NCT05487183|BEHAVIORAL|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
219487626|NCT04386668|OTHER|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
219487627|NCT04386668|OTHER|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
219600156|NCT02905058|DRUG|placebo|
218869377|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
218869378|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
218869379|NCT02800590|DRUG|ABP-700|
218869380|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
218869381|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
219487628|NCT02278731|OTHER|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
219487629|NCT03774173|DRUG|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
219487630|NCT02156466|DRUG|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
219487631|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
218869382|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
218869383|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
218869384|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
218869385|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
218869386|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
218869387|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
218869388|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
219487632|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
219487633|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
219487634|NCT02156466|DRUG|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
219487635|NCT05226468|DRUG|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
219600157|NCT02263287|OTHER|LeSCoD scale|LeSCoD is a clinical scale
219600158|NCT01101815|DRUG|Oral Naltrexone|50 mg/day-oral
219600159|NCT01101815|DRUG|Naltrexone Implant|monthly-implant
219600160|NCT01101815|BEHAVIORAL|Group Drug Counseling Manual Driven|Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
219600161|NCT01187056|BEHAVIORAL|Training programme|2 x 2 hours of training (workshops)
219600162|NCT04307888|DEVICE|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
219600163|NCT00017095|BIOLOGICAL|filgrastim|
219600164|NCT00017095|DRUG|cyclophosphamide|
219600165|NCT00017095|DRUG|docetaxel|
219600166|NCT00017095|DRUG|epirubicin hydrochloride|
219600167|NCT00017095|DRUG|fluorouracil|
219600168|NCT00017095|GENETIC|microarray analysis|
219600169|NCT00017095|OTHER|immunohistochemistry staining method|
218869389|NCT01012323|BIOLOGICAL|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
218869390|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
218869391|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
219487636|NCT02237118|DEVICE|Mepitel One|
219487637|NCT02237118|DEVICE|UrgoTul|
219487638|NCT01303588|BEHAVIORAL|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
219487639|NCT01303588|BEHAVIORAL|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
219487640|NCT01001715|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
219487641|NCT01001715|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
219487642|NCT03582007|DRUG|Murepavadin|Murepavadin + ertapenem
219487643|NCT03582007|DRUG|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
219487644|NCT06520228|BEHAVIORAL|Active video games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
219487645|NCT06520228|BEHAVIORAL|Traditional sports games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
219487646|NCT03225066|DEVICE|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
219487647|NCT00694031|PROCEDURE|Hemodialysis|3 times per week
219487648|NCT00694031|PROCEDURE|On-line hemodiafiltration|3 times per week
219487649|NCT06293573|DEVICE|Whole-body vibration|GROUP A : will receive whole body vibration exercises combined with resistance exercises
219600170|NCT00017095|OTHER|laboratory biomarker analysis|
218869392|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
218869393|NCT02201836|OTHER|One time music therapy|
218869394|NCT02201836|OTHER|Group music therapy|
218869395|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
218869396|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
218869397|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
218869398|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
218869399|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
218869400|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
218869401|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
219600171|NCT00017095|PROCEDURE|biopsy|
218869402|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
219600172|NCT00017095|PROCEDURE|conventional surgery|
219600173|NCT00017095|PROCEDURE|neoadjuvant therapy|
219600174|NCT00017095|RADIATION|radiation therapy|
218869403|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
219487650|NCT06293573|OTHER|aerobic exercises|Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.
219600175|NCT02738710|PROCEDURE|transumbilical incision|incision within umbilicus
219600176|NCT02738710|PROCEDURE|Infra umbilical incision|incision about 1 cm below umbilicus
219600177|NCT03908450|DEVICE|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
219600178|NCT03908450|DEVICE|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
219600179|NCT03597295|DRUG|Retifanlimab|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
219600180|NCT01728129|DEVICE|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
219600181|NCT01728129|OTHER|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
219600182|NCT00428116|DRUG|HAART|Combination first line antiretrovirals as previously described.
219487651|NCT06293573|OTHER|resistance exercises|Group c: will receive progressive resistance exercises with diet modification life style.
219487652|NCT04006691|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
219487653|NCT03999229|DRUG|SNO|S-nitrosylating agent (SNO) Inhalation
219487654|NCT03999229|DRUG|Normal Saline|Normal Saline transfusion
219487655|NCT03999229|DRUG|Red Blood Cell|Blood transfusion (RBCs)
219487656|NCT00774202|DRUG|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
219487657|NCT00774202|DRUG|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
219487658|NCT00150475|PROCEDURE|Powered Air purifying respirator|
219487659|NCT01268683|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
219487660|NCT04738552|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
219487661|NCT03888131|DRUG|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
219487662|NCT03888131|DRUG|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
219487663|NCT02216214|DRUG|Mirabegron|oral tablet
219487664|NCT02216214|DRUG|Placebo|oral tablet
219600183|NCT02455518|DRUG|Oxycodone/acetaminophen|
219600184|NCT02455518|DRUG|Hydrocodone/acetaminophen|
219600185|NCT02455518|DRUG|Codeine/acetaminophen|
219600186|NCT02455518|DRUG|Ibuprofen/acetaminophen|
219600187|NCT03852537|DRUG|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
219600188|NCT03852537|OTHER|Usual Care|Usual care as determined by the patients treatment team.
219600189|NCT05342779|PROCEDURE|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
219487665|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
219487666|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
219487667|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
219487668|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
219487669|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
219487670|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
219487671|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
219487672|NCT06234124|DEVICE|Variable Friction Shoe Training|The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
219487673|NCT06234124|DEVICE|Ankle Foot Orthosis (AFO) Training|The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
219487674|NCT02645266|DRUG|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
219487675|NCT03430037|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
219487676|NCT03430037|DRUG|Placebo oral capsule|Placebo
219487677|NCT04137770|OTHER|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
219487678|NCT06520267|DRUG|Antibiotic therapy|Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
219487679|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
219487680|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
219487681|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
219487682|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
219487683|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
219487684|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
219487685|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219487686|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219487687|NCT00713830|DEVICE|Pen auto-injector|
219487688|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
219487689|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
219600190|NCT05896735|PROCEDURE|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
219600191|NCT02508935|DRUG|XARTEMIS XR|XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
219600192|NCT02125877|DRUG|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
219600193|NCT02125877|DRUG|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
219600194|NCT03901092|DRUG|flortaucipir F 18|No study drug will be administered.
219600195|NCT01513278|DRUG|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
219600196|NCT01513278|DRUG|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
219487690|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
219487691|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
219487692|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
219487693|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
219487694|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
219487695|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
219487696|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
219487697|NCT00174473|DRUG|Voriconazole|
219487698|NCT00357708|DRUG|decitabine|Given IV
219487699|NCT00357708|DRUG|vorinostat|Given orally
219487700|NCT00357708|OTHER|laboratory biomarker analysis|Correlative studies
219487701|NCT00357708|OTHER|pharmacological study|Correlative studies
219487702|NCT00552682|DRUG|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
219487703|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
219487704|NCT00256841|DRUG|Chemotherapy|
219487705|NCT00256841|PROCEDURE|Radiation Therapy|
219487706|NCT04650984|DRUG|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
219487707|NCT04650984|DRUG|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
219487708|NCT05150340|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
219487709|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
219487710|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
219487711|NCT03981614|DRUG|Binimetinib|Given PO
219600197|NCT02293889|DIETARY_SUPPLEMENT|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.
219487712|NCT03981614|DRUG|Palbociclib|Given PO
219600198|NCT02293889|BEHAVIORAL|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
219600199|NCT02293889|OTHER|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
219600200|NCT05698225|OTHER|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
219600201|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
219487713|NCT03981614|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219487714|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
219487715|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
219487716|NCT00182208|DEVICE|Veno-device (Venowave)|
219487717|NCT02404272|OTHER|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
219487718|NCT02836704|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
219600202|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
219600203|NCT00710866|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
219487719|NCT02836704|DRUG|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
219487720|NCT02836704|DRUG|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
219487721|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
219487722|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
219487723|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
219487724|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
219487725|NCT03716804|DRUG|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
219487726|NCT03716804|DRUG|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
219487727|NCT03654365|OTHER|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
219487728|NCT03654365|OTHER|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
219487729|NCT01062100|DEVICE|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
219522427|NCT06648252|BEHAVIORAL|Healing Minds Biofeedback and Breathing Practices Intervention|The study participant will attend ten weekly Healing Minds sessions at the Hoskinson Health and Wellness Clinic. The parent (s) or guardian will accompany the study participant and follow along with the cues during the weekly session. Each session will be approximately 60 minutes. The principal investigator/pediatrician or trained and certified health care or research staff member will deliver the intervention. Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
219600204|NCT04928768|OTHER|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
219600205|NCT03311750|DRUG|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
219600206|NCT06179563|OTHER|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
219600207|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
219600208|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
219600209|NCT04036110|OTHER|Placebo|1 tablet taken orally with one meal daily
219600210|NCT05210010|DEVICE|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
219600211|NCT05056623|BEHAVIORAL|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
219600212|NCT05056623|OTHER|Usual care and pain management pamphlet|Usual care and pain management pamphlet
219600213|NCT01471730|DRUG|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
219600214|NCT01471730|DRUG|Saline solution|Normal saline will be administered to control patients.
219600215|NCT01471730|DRUG|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
219600216|NCT03946280|PROCEDURE|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
219600217|NCT03946280|PROCEDURE|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
219600218|NCT00898573|DRUG|lapatinib ditosylate|
218869404|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
218869405|NCT01150643|GENETIC|gene expression analysis|
218869406|NCT01150643|GENETIC|microarray analysis|
218869407|NCT01150643|GENETIC|polymerase chain reaction|
218869408|NCT01150643|GENETIC|polymorphism analysis|
218869409|NCT01150643|OTHER|immunohistochemistry staining method|
218869410|NCT01150643|OTHER|laboratory biomarker analysis|
218869411|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
218869412|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
219487730|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
219487731|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
219487732|NCT00499252|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
219487733|NCT04629300|BEHAVIORAL|Supportive Care Mobile Application|Tablet computer with application providing modules on skills for managing symptoms and coping.
219487734|NCT04629300|OTHER|Usual Care|Standard oncology care with monitoring of supportive care services usage
218869413|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
218869414|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
218869415|NCT02064608|DRUG|AZD2014|mTOR inhibitor
218869416|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
218869417|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
218869418|NCT02477553|BEHAVIORAL|DA - Quantitative|
218869419|NCT02477553|BEHAVIORAL|DA - Verbal|
218869420|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869421|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869422|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869423|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869424|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869425|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
218869426|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
218869427|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
219487735|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
219487736|NCT01687777|BIOLOGICAL|OrthADAPT|
219487737|NCT03667742|DIAGNOSTIC_TEST|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
219487738|NCT00397072|DRUG|ZK 219477|
219487739|NCT00566631|DRUG|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
219600219|NCT00898573|GENETIC|fluorescence in situ hybridization|
219600220|NCT00898573|GENETIC|gene expression analysis|
219600221|NCT00898573|GENETIC|mutation analysis|
219600222|NCT00898573|GENETIC|polymerase chain reaction|
219600223|NCT00898573|GENETIC|reverse transcriptase-polymerase chain reaction|
219600224|NCT00898573|OTHER|cell sorting|
219487740|NCT02964052|OTHER|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
218869428|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
219487741|NCT03801018|OTHER|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
219487742|NCT00003786|DRUG|irofulven|
219487743|NCT04335565|OTHER|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
219487744|NCT02076230|DRUG|[14C] TH-302 (Label 1)|\[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
219487745|NCT02076230|DRUG|[14C] TH-302 (Label 2)|\[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
219487746|NCT02076230|DRUG|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
219600225|NCT00898573|OTHER|immunohistochemistry staining method|
219600226|NCT00898573|OTHER|laboratory biomarker analysis|
219487747|NCT02968641|DRUG|Lonafarnib|antiviral farnesyltransferase inhibitor
219600227|NCT04252092|OTHER|Sensory training|15 session,20 minutes sensory training program
219600228|NCT04252092|OTHER|Electrical stimulation|15 session,20 minutes electrical stimulation program
219600229|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
219600230|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
219600231|NCT04775615|DRUG|DDO-3055 tablets；Placebo|High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
219600232|NCT02077361|GENETIC|rAAV2.REP1 vector|No additional details needed.
219600233|NCT03382587|DRUG|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
219600234|NCT05937737|BEHAVIORAL|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
219600235|NCT00613652|DRUG|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
219600236|NCT02892552|RADIATION|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
219600237|NCT02892552|RADIATION|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
219600238|NCT00420732|BIOLOGICAL|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
218869429|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
219199921|NCT06858059|OTHER|psychological intervention|All participants of the lighthouse parenting programme will engage in the full program over a period of five weeks, divided into ten sessions. The 5 group interventions will occur once a week for 1.5 hours. During this time, the psychotherapist will disseminate psychological knowledge and skills pertinent to parenting, after which the group members will engage in practice exercises and discourse. Subsequently, one individual session will be conducted each week for one hour.
219487748|NCT02968641|DRUG|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
219487749|NCT05954338|DRUG|DWC202307|DWC202307
219487750|NCT05954338|DRUG|DWJ1543|DWJ1543
219487751|NCT05954338|DRUG|DWC202216|DWC202216
219600239|NCT05532033|DEVICE|High flow nasal cannula|A device able to delivery high flow oxygen therapy
219600240|NCT05532033|DEVICE|Facial mask|standard oxygen therapy
219600241|NCT00282451|DRUG|biphasic insulin aspart|
219600242|NCT00282451|DRUG|insulin aspart|
219600243|NCT03500380|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
219600244|NCT03500380|DRUG|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
219600245|NCT03500380|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
219600246|NCT01267487|DRUG|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
219487752|NCT04718727|DRUG|Placebo|oral Placebo tablets one-hour preoperatively
218869430|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
218869431|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
218869432|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
218869433|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
218869434|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
218869435|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
218869436|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
218869437|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
218869438|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
219487753|NCT04718727|DRUG|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
219487754|NCT04718727|DRUG|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
219487755|NCT03387735|OTHER|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
219600247|NCT01267487|DRUG|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
219600248|NCT01267487|DRUG|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
218869439|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
218869440|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
218869441|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
218869442|NCT02597088|OTHER|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
218869443|NCT01410708|DRUG|Dasatinib|
218869444|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
218869445|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
218869446|NCT05823272|OTHER|ONS|oral nutritional supplement
218869447|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
218869448|NCT04023682|DRUG|Provodine Hand Sanitizer|Intervention with Provodine
218869449|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
218869450|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
218869451|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
218869452|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
218869453|NCT00077844|DRUG|Enoxaparin sodium|
218869454|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
218869455|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
218869456|NCT03495791|OTHER|YouTube Video|Educational Video
219487756|NCT03387735|BEHAVIORAL|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
219487757|NCT05204849|DEVICE|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
219487758|NCT05204849|PROCEDURE|Standard ventriculostomy|Standard passive external ventricular drainage
219487759|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
219487760|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
219487761|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
219487762|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
219487763|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219487764|NCT00986609|OTHER|flow cytometry|Correlative studies
219487765|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
219487766|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
219487767|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
219487768|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
219487769|NCT00537056|DRUG|Sunitinib|50 mg/day po
219487770|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
219487771|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
219600249|NCT06281444|DEVICE|ESWT|"All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week."
219600250|NCT06281444|DEVICE|Sham-ESWT|Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
219600251|NCT03394157|OTHER|metabolic surgery|operation to cure type2 diabetes
219600252|NCT00537511|DRUG|Pomalidomide|
219600253|NCT00537511|DRUG|Cisplatin|
219600254|NCT00537511|DRUG|Etoposide|
219600255|NCT06257251|OTHER|Histological slides digitization|Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
219600256|NCT00396565|DRUG|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
219600257|NCT00396565|DRUG|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
219600258|NCT00396565|DRUG|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
219600259|NCT00103714|DRUG|denufosol tetrasodium (INS37217)|
219600260|NCT06141343|DIETARY_SUPPLEMENT|Veillonella atypica FB0054|Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.
219600261|NCT06141343|OTHER|Placebo|Placebo will be given as the non-active study control
219600262|NCT05507736|OTHER|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
219600263|NCT00004338|DRUG|zinc acetate|
219600264|NCT02192398|DRUG|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
219600265|NCT02192398|DRUG|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
219600266|NCT01252277|DRUG|Lovaza™|4 capsules daily for 6 months
219600267|NCT05610423|OTHER|no intervention|No intervention. Observational study only
219487772|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
219487773|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
219487774|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
219600268|NCT04196647|OTHER|Home titration|Patients have their initial dosage titration of duodopa done in their own home, supported by one visit from nursing staff, and one video consultation a day
219600269|NCT00457483|DRUG|hydrochlorothiazide|12.5 mg once-a-day
219600270|NCT00457483|DRUG|valsartan, 80 mg once-a-day|80 mg once-a-day
219600271|NCT04940637|DRUG|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
219600272|NCT02771470|DRUG|Probiotics|Microbial composition using probiotic
219600273|NCT02771470|DRUG|placebo|Microbiota modulation using placebo
219600274|NCT04535687|DRUG|Fluzoparib|Fluzoparib
219600275|NCT03140787|DRUG|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
219600276|NCT03140787|DRUG|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
218869457|NCT00237263|DRUG|Entacapone|
218869458|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
218869459|NCT05288140|OTHER|use of diary|a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
218869460|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
218869461|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
218869462|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
218869463|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
218869464|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
218869465|NCT01107782|DRUG|placebo|50mg tid
218869466|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
218869467|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
218869468|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
218869469|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
218869470|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
218869471|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
219487775|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
219487776|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
219487777|NCT05145647|RADIATION|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.
219487778|NCT05145647|DEVICE|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
219600277|NCT02802904|OTHER|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
218869472|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
219487779|NCT02953418|DEVICE|Radiofrequency ablation|RFA
219487780|NCT03020966|DRUG|Acetaminophen|Oral acetaminophen, intravenous placebo
219487781|NCT03020966|DRUG|Acetaminophen|Intravenous acetaminophen, oral placebo
219600278|NCT02802904|OTHER|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
219600279|NCT02802904|OTHER|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
218869473|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
218869474|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
218869475|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
219487782|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
219487783|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
219487784|NCT00527527|PROCEDURE|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
219487785|NCT00527527|OTHER|placebo control|Placebo for comparison with flexion distraction treatment
219600280|NCT04317092|DRUG|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
219487786|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
219487787|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
219487788|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
219487789|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
219487790|NCT02628418|OTHER|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
219600281|NCT06581367|DRUG|Tailoring the course duration to the patient's needs.|Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.
218869476|NCT01761812|OTHER|MRI with gadofosveset and MR elastography|
218869477|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
218869478|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
218869479|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
218869480|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
218869481|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
218869482|NCT00383396|DRUG|Topical Cyclosporine|
218869483|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
218869484|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
218869485|NCT04726059|DEVICE|Transcutaneous Spinal Cord Stimulation|Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
218869486|NCT04726059|DEVICE|SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation|Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
218869487|NCT04726059|DEVICE|Activity-Based Therapy|"Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics."
218869488|NCT00809653|DEVICE|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
218869489|NCT00809653|DEVICE|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
219600282|NCT06581367|DRUG|Complete a 7-day course|The antibiotic course must be completed (7 days at least).
218869490|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
219600283|NCT01632657|DRUG|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
219600284|NCT01632657|OTHER|Placebo|Single injection saline 0.5ml subcutaneously in recovery
219600285|NCT03687840|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
219600286|NCT02447146|OTHER|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
219600287|NCT02447146|OTHER|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
219522428|NCT04655248|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
219522429|NCT06909357|OTHER|Quitline Treatment (QT)|Tobacco Free Florida Quitline. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
219522430|NCT06909357|OTHER|App-based Treatment (mHealth)|Fully automated digitally-delivered smoking cessation intervention targeted to cancer patients. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
219522431|NCT02754622|OTHER|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
219522432|NCT05928845|DIAGNOSTIC_TEST|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
219487791|NCT02628418|DEVICE|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
219487792|NCT02628418|OTHER|Specific hand rehabilitation performed by physiotherapist|"The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
219487793|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
219487794|NCT04130594|OTHER|placebo|placebo
219487795|NCT04512391|PROCEDURE|Ultrasound guided Erector Spinae Plane Block (ESPB)|Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
219487796|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
219487797|NCT02502565|OTHER|Uric acid level|
219487798|NCT01215955|DRUG|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
219487799|NCT01215955|DRUG|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
219487800|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
219487801|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
219487802|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
219487803|NCT04196699|BEHAVIORAL|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
219487804|NCT02507271|OTHER|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
219487805|NCT02507271|OTHER|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
219487806|NCT04011904|OTHER|Cross-over study|Traditional Inuit Diet vs Westernized Diet
219487807|NCT05485571|DEVICE|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
219487808|NCT03406611|DRUG|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
219487809|NCT03406611|DRUG|Placebo|Normal saline for subcutaneous injection
219487810|NCT06700577|DIAGNOSTIC_TEST|Gene expert|Gene expert and XDR to detect multidrug resistance between tb patient
219487811|NCT06700577|GENETIC|Ultra xpert and xdr xpert|Detect resistance between tyberculous patient
219487812|NCT05309031|OTHER|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
219487813|NCT02517346|OTHER|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
219487814|NCT02517346|OTHER|Telemonitoring|Follow up by telemonitoring system during 3 months
219487815|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
218869491|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
218869492|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
218869493|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
218869494|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
218869495|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
219487816|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
219487817|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
219487818|NCT00093067|DRUG|daptomycin|
219487819|NCT05425823|OTHER|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
219487820|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
219487821|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
219487822|NCT01805258|DRUG|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
219487823|NCT01805258|DRUG|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
219487824|NCT00486213|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
219487825|NCT00486213|OTHER|Placebo|
219487826|NCT05314413|PROCEDURE|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
219487827|NCT05996549|DRUG|Quadrivalent Influenza Vaccine|All high-risk groups have been getting one dose of seasonal influenza vaccination (Inactivated Influenza Vaccine ), except children aged six months to 8 years, who will receive two doses four weeks apart. All vaccines are in the southern hemisphere, as Bangladesh's influenza season matches the southern hemisphere areas.
219487828|NCT02912884|DRUG|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
219487829|NCT06229379|DEVICE|"Digital twin patient"|"Digital twin patient can serve as patients with specific diseases for medical students to acquire disease history and thus practice clinical questioning skills."
219487830|NCT06229379|BEHAVIORAL|Interaction with real patients|As in traditional medical education, medical students need to interact with real patients to practice history collection skills.
219487831|NCT06568900|OTHER|cigarette smoking|continue smoking usual brand of cigarette
219487832|NCT06568900|OTHER|tobacco flavored and unflavored pouch|provide tobacco flavored and unflavored options of nicotine pouch
219487833|NCT06568900|OTHER|unrestricted flavor options pouch|provide unrestricted flavor options of nicotine pouch
218869496|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
219487834|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
219487835|NCT05455411|BEHAVIORAL|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
219600288|NCT04603326|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
219600289|NCT01668914|PROCEDURE|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
218869497|NCT03668834|PROCEDURE|Dermabrasion with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
219199922|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain Placebo|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of placebo orally per a day during the entire period of antibiotic therapy."
219487836|NCT05455411|BEHAVIORAL|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
219487837|NCT01447628|DRUG|Saline|intravenous, no active drug
219487838|NCT01447628|DRUG|Ferinject or CosmoFer|Intravenous, 1000 mg iron
219487839|NCT02258399|BEHAVIORAL|Exercise|Moderate intensity exercise
219487840|NCT02258399|DIETARY_SUPPLEMENT|Breakfast|Breakfast consumption
219487841|NCT00698607|DEVICE|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
219487842|NCT00698607|DEVICE|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
219600290|NCT01668914|RADIATION|99mTc-SC|Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
219600291|NCT01668914|DEVICE|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
219600292|NCT01668914|DEVICE|LSG|lymphoscintigraphy was performed 0.5\~1.0 hour before surgery
219600293|NCT01668914|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
219600294|NCT04566055|DEVICE|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
219600295|NCT05154838|PROCEDURE|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
219600296|NCT04324021|BIOLOGICAL|Emapalumab|I.v. infusion every third day
219600297|NCT04324021|BIOLOGICAL|Anakinra|Daily i.v. infusion
219600298|NCT05902338|OTHER|Music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music)."
219600299|NCT02454855|DRUG|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
219199923|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain LP299v|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of LP299v orally per a day during the entire period of antibiotic therapy."
219487843|NCT00698607|DRUG|6-month clopidogrel therapy|Use clopidogrel for 6 months
219487844|NCT00698607|DRUG|12-month clopidogrel therapy|Use clopidogrel for 12 months
219487845|NCT02341794|DRUG|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
219600300|NCT02454855|DRUG|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
219600301|NCT03097991|BEHAVIORAL|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
219600302|NCT00604682|DRUG|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
219600303|NCT05107648|BEHAVIORAL|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
219487846|NCT00185731|DRUG|Atorvastatin|80 mg orally once daily
219487847|NCT03087773|DRUG|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
219487848|NCT03087773|DRUG|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
219487849|NCT03613194|PROCEDURE|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
219487850|NCT04656782|OTHER|Imaging survey|Participation as expert panelist in the imaging survey.
219487851|NCT04656782|OTHER|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
219487852|NCT00571220|PROCEDURE|gastric bypass surgery|weight loss bariatric surgery
219487853|NCT00571220|OTHER|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
219600304|NCT00002704|BIOLOGICAL|filgrastim|
219600305|NCT00002704|DRUG|asparaginase|
219600306|NCT00002704|DRUG|cyclophosphamide|
219600307|NCT00002704|DRUG|daunorubicin hydrochloride|
219600308|NCT00002704|DRUG|dexamethasone|
219600309|NCT00002704|DRUG|etoposide|
219600310|NCT00002704|DRUG|leucovorin calcium|
219487854|NCT00764244|PROCEDURE|Vitrectomy|Vitrectomy
219487855|NCT00764244|DRUG|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
219487856|NCT00764244|PROCEDURE|Laser photocoagulation|Laser photocoagulation
218869498|NCT03668834|PROCEDURE|Dermaroller with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
219487857|NCT05875064|COMBINATION_PRODUCT|Restoration with resin composite and polyvinyl crown|Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
219487858|NCT05875064|PROCEDURE|Restoration with conventional resin composite|Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
219487859|NCT06376773|PROCEDURE|combination chemotherapy with Apatinib or Camrelizumab|Apatinib, chemotherapy alone, Camrelizumab
219487860|NCT01339468|DRUG|Advagraf|oral
219487861|NCT01339468|DRUG|Prograf|oral
219487862|NCT01339468|DRUG|Prograf|intravenous
219487863|NCT01040546|BEHAVIORAL|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
219487864|NCT01040546|BEHAVIORAL|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
219487865|NCT00396981|DEVICE|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
219487866|NCT00396981|DEVICE|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
219487867|NCT06540924|OTHER|single nucleotide polymorphisms|The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
219487868|NCT02624817|DRUG|Sulfonylurea|See Arm description.
219487869|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
219487870|NCT01931501|DRUG|Torrent's Montelukast Sodium Chewable Tablets 5mg|
219487871|NCT01931501|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
219487872|NCT03347474|PROCEDURE|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
219487873|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
219600311|NCT00002704|DRUG|liposomal cytarabine|
219600312|NCT00002704|DRUG|mercaptopurine|
219600313|NCT00002704|DRUG|mesna|
219600314|NCT00002704|DRUG|methotrexate|
219600315|NCT00002704|DRUG|therapeutic hydrocortisone|
219600316|NCT00002704|DRUG|thiotepa|
219600317|NCT00002704|DRUG|vincristine sulfate|
219600318|NCT00002704|RADIATION|low-LET electron therapy|
219600319|NCT00002704|RADIATION|low-LET photon therapy|
219600320|NCT06147648|DRUG|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
219600321|NCT00246324|DRUG|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
219600322|NCT05578599|DEVICE|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
219600323|NCT06181149|BEHAVIORAL|Delaying speech initiation|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
219600324|NCT06181149|BEHAVIORAL|Auditory errors and pre-speech auditory modulation|This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
219600325|NCT06181149|BEHAVIORAL|Contributions of the speech premotor cortex to pre-speech auditory modulation|This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
219487874|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
218869499|NCT03668834|PROCEDURE|Liquid nitrogen induced blister with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
219199924|NCT06862817|DRUG|Aloe vera gel|Aloe vera mouthgel not only as a potent agent for prevention mucositis, but also as a prevention of candidiasis in patients undergoing radiotherapy of head and neck with its antifungal and immunomodulation properties
219487875|NCT06566287|OTHER|Immediate implant|Immediate Implant with Socket Shield Group
219487876|NCT06566287|OTHER|Delayed implant|Delayed Implant with Socket preserved with socket Shield and dentin graft Group
219487877|NCT01749618|BEHAVIORAL|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
219487878|NCT06565832|PROCEDURE|One-Minute Sit-to-Stand Test|This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
219487879|NCT06565832|PROCEDURE|Chester Step Test|This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
219199925|NCT06862817|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|. Benzydamine's mechanisms of action are rooted in its anti-inflammatory, anesthetic, and analgesic properties. It has been shown to reduce the synthesis of TNF-α, IL-1β and prostaglandins while also acting as an antioxidant by scavenging reactive oxygen species (ROS) benzydamine inhibits leukocyte-endothelial interactions, thereby decreasing neutrophil degranulation, and helps mitigate histamine-induced vasodilation and vascular permeability.
219487880|NCT03008252|OTHER|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
219600326|NCT06181149|BEHAVIORAL|Delaying auditory feedback|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
219600327|NCT01284452|DRUG|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
219600328|NCT01284452|DRUG|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
219487881|NCT03008252|OTHER|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
219487882|NCT03210142|PROCEDURE|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
219487883|NCT01059942|OTHER|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
219487884|NCT01059942|OTHER|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
219487885|NCT03666299|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
219487886|NCT03666299|DRUG|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
219600329|NCT04267432|DIETARY_SUPPLEMENT|Placebo|Blank
219600330|NCT04267432|DIETARY_SUPPLEMENT|TCI633|Probiotics
219600331|NCT04267432|DRUG|Type 2 collagen|Positive control group
219487887|NCT00934778|PROCEDURE|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
219487888|NCT02993016|PROCEDURE|patient-specific instruments|
219487889|NCT02993016|DEVICE|The Signature™ Vanguard|
219487890|NCT02993016|PROCEDURE|conventional instruments|
219487891|NCT02993016|DEVICE|Vanguard PS(posterior stabilized)|
219487892|NCT00639158|DRUG|ABT-335|135 mg capsule, daily, 12 weeks
219600332|NCT02505737|BEHAVIORAL|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
219600333|NCT02505737|OTHER|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
219600334|NCT02547688|DEVICE|Nasal High Flow|
219600335|NCT00321178|DRUG|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
219487893|NCT00639158|DRUG|placebo|placebo capsule, daily, 12 weeks
219600336|NCT04936711|DEVICE|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
219600337|NCT04936711|DRUG|Marcaine|Marcaine spray at incision site after closure
219600338|NCT02006732|DRUG|olodaterol|fixed dose combination
219600339|NCT02006732|DRUG|tiotropium|fixed dose combination
219600340|NCT02006732|DRUG|placebo|
219487894|NCT00639158|DRUG|atorvastatin|40 mg, tablet, daily, 12 weeks
219487895|NCT00639158|DRUG|ezetimibe|10 mg capsule, daily, 12 weeks
219487896|NCT00116129|DRUG|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
219487897|NCT03403712|DRUG|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
219487898|NCT03403712|DRUG|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
219487899|NCT03403712|DRUG|dexamethasone|Oral dexamethasone (12 mg)
219487900|NCT00164086|DRUG|atorvastatin|
219487901|NCT04264988|PROCEDURE|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
219600341|NCT00690066|DRUG|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
219600342|NCT00690066|DRUG|Placebo|Intravenous infusion of excipients of PROCHYMAL®
219600343|NCT02649569|DEVICE|Monitoring Device|Wear activity monitor
219600344|NCT02649569|OTHER|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
219600345|NCT00299130|DRUG|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
219600346|NCT00299130|DRUG|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
219600347|NCT00299130|DRUG|Methylprednisolone|Intravenous infusion
219600348|NCT00299130|DRUG|Placebo|Placebo to rituximab intravenous infusion
219600349|NCT00299130|DRUG|Rituximab|Intravenous infusion
219600350|NCT01198132|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
219600351|NCT01198132|DIETARY_SUPPLEMENT|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
219600352|NCT01198132|DRUG|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
219600353|NCT03732430|DRUG|IBI308|A humanized anti-PD-1 monoclonal antibody
219600354|NCT04133987|BIOLOGICAL|Tetravalent live attenuated dengue vaccine admixture TV005|The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
219199926|NCT06862817|DRUG|bioadhesive gel|bioadhesive These polymers increase viscosity through a liquid-to-semi-solid phase transition, improving retention at the administration site and providing a sustained release profile ,Mucoadhesive Dosage Forms These dosage forms are typically employed to administer medications to epithelial surfaces, including the buccal cavity, sublingual area, oral cavity, eyes, nasal passages, vagina, and lungs
219199927|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
219199928|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
219199929|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219487902|NCT05221476|OTHER|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
219487903|NCT05728918|DIETARY_SUPPLEMENT|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
219487904|NCT05728918|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
219487905|NCT00001729|DRUG|Ribavirin|
219487906|NCT03789058|DRUG|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
219487907|NCT03455114|DEVICE|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
219600355|NCT04133987|BIOLOGICAL|Placebo|PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
219600356|NCT02358512|OTHER|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
219600357|NCT05755971|OTHER|Combination taping|Elastic and rigid tapes applied together for six weeks
219600358|NCT02274831|OTHER|Email Reminder of need to follow up with primary physician|
219600359|NCT03516513|BEHAVIORAL|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
219600360|NCT03516513|BEHAVIORAL|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
219600361|NCT07134998|DRUG|HRS-6093|HRS-6093
219600362|NCT07134790|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
219600363|NCT07134790|DRUG|Placebo|Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)
219600364|NCT07134790|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
219600365|NCT07134309|OTHER|Exercise Training|Reformer, mat pilates, and general posture exercise training were performed twice a weekly for 12 weeks. Before starting pilates training, the key elements of pilates were taught to patients for one session. In evaluation, Visual Analog Scale (VAS) was used for pain intensity, Oswestry Low Back Pain Questionnaire for disability, Short Form - 36 Questionnaire (SF-36) for quality of life, Sit-lie test for flexibility, McGill extension test for trunk extension endurance. Demographic information of individuals was recorded.
219600366|NCT07134218|DRUG|serplulimab、bevacizumab|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 2 cycles of FOLFOX + serplulimab + bevacizumab → 2 cycles of FOLFOX + serplulimab.
219199930|NCT06858956|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
219487908|NCT03147521|OTHER|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
219487909|NCT04331418|DRUG|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
219487910|NCT04331418|PROCEDURE|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
219487911|NCT01563393|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
219487912|NCT01563393|OTHER|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
219487913|NCT04341207|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
219487914|NCT04341207|DRUG|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
219487915|NCT04608656|OTHER|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
219487916|NCT04608656|OTHER|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
219487917|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
219487918|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
219487919|NCT03405701|PROCEDURE|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
219487920|NCT03405701|PROCEDURE|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
219522433|NCT03732846|DRUG|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
219522434|NCT04281563|OTHER|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
219522435|NCT05192330|DEVICE|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
219522436|NCT05192330|BEHAVIORAL|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
219522437|NCT03155048|DRUG|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
219522438|NCT03155048|DRUG|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
219522439|NCT00002725|DRUG|bryostatin 1|
218869500|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
218869501|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
218869502|NCT04672421|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
218869503|NCT04672421|DEVICE|Placebo|No device after laparoscopic surgery
218869504|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
219522440|NCT00002725|DRUG|chemotherapy|
219522441|NCT05008822|OTHER|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
219600367|NCT07134218|OTHER|neoadjuvant chemoradiation therapy|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 4 cycles of FOLFOX alone.
219487921|NCT04222556|BEHAVIORAL|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
219487922|NCT04222556|BEHAVIORAL|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
219487923|NCT03821688|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass
219487924|NCT03821688|PROCEDURE|OAGB|one anastomosis gastric bypass
219487925|NCT03821688|PROCEDURE|LSG|laproscopic sleeve gastrectomy
218869505|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
218869506|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
219487926|NCT01825915|PROCEDURE|Laparoscopic Hysterectomy|
219487927|NCT01825915|PROCEDURE|Laparoscopic Supracervical Hysterectomy|
219487928|NCT01787188|DRUG|Meloxicam Test Capsules|
219487929|NCT01787188|DRUG|Meloxicam Test Capsules|
219487930|NCT01787188|DRUG|Placebo Capsules|
219522442|NCT05008822|OTHER|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
219522443|NCT00465881|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
219522444|NCT01861210|BEHAVIORAL|Couples Voluntary HIV Counseling and Testing|
219522445|NCT01861210|BEHAVIORAL|Individual Counseling and Testing|
219522446|NCT03106610|DRUG|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
219522447|NCT03106610|BEHAVIORAL|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
219522448|NCT03805438|DRUG|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
219522449|NCT01174134|OTHER|Nutritional beverage|
219522450|NCT00366899|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
219522451|NCT00366899|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
219522452|NCT02812849|DRUG|Cu-64 DOTATATE|
219522453|NCT03163875|OTHER|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
219522454|NCT01619800|DEVICE|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
219522455|NCT01619800|DEVICE|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
219522456|NCT02665013|BEHAVIORAL|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
219522457|NCT02665013|BEHAVIORAL|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
219522458|NCT02927509|DRUG|TNF alpha blockers|
219522459|NCT02429271|DRUG|Ticagrelor|
219522460|NCT02429271|DRUG|Clopidogrel|
219522461|NCT02429271|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
219522462|NCT02429271|PROCEDURE|Coronary Angiography|
219522463|NCT01255878|DEVICE|occlusal stabilization splint|
219522464|NCT01255878|DRUG|Gabapentine|100 mg(1 capsule)three times per day for two months
219487931|NCT03884907|PROCEDURE|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
219487932|NCT06568770|DRUG|USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK|"With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected"
219487933|NCT06568770|DRUG|PERICAPSULAR NERVE BLOCK|"an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected."
219487934|NCT02515461|DEVICE|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
219487935|NCT00004086|BIOLOGICAL|filgrastim|
219487936|NCT00004086|DRUG|cisplatin|
219487937|NCT00004086|DRUG|cytarabine|
219487938|NCT00004086|DRUG|etoposide|
219487939|NCT00004086|DRUG|ifosfamide|
219487940|NCT00004086|PROCEDURE|autologous bone marrow transplantation|
219487941|NCT00004086|PROCEDURE|peripheral blood stem cell transplantation|
219487942|NCT00004086|RADIATION|indium In 111 LL2 IgG|
219487943|NCT00004086|RADIATION|yttrium Y 90 epratuzumab|
219487944|NCT00921765|DRUG|Saline|Saline single bolus dose followed by saline single bolus dose iv
219487945|NCT00921765|DRUG|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
219487946|NCT00921765|DRUG|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
219487947|NCT00921765|DRUG|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
219487948|NCT02192541|DRUG|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
219487949|NCT02192541|DRUG|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
219487950|NCT05467709|DRUG|Midazolam|2 mg Day 1 and Day 16
219487951|NCT05467709|DRUG|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
219487952|NCT02127229|PROCEDURE|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
219487953|NCT01519895|BEHAVIORAL|Telephone intervention|counseling and education support
219487954|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
219487955|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
219487956|NCT04752085|DIAGNOSTIC_TEST|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
219487957|NCT02460133|DRUG|Paritaprevir|
219487958|NCT02460133|DRUG|Ritonavir|
219487959|NCT02460133|DRUG|Dasabuvir|
219487960|NCT02460133|DRUG|Ombitasvir|
219487961|NCT02460133|DRUG|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
219487962|NCT00196573|PROCEDURE|Shoulder bursectomy alone|
219487963|NCT06563973|OTHER|Milk odor|One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
219487964|NCT06563973|OTHER|Pacifier|To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
219487965|NCT04143477|DRUG|peficitinib|Oral
219487966|NCT00425282|DRUG|RWJ-333369|
219487967|NCT01272739|DIETARY_SUPPLEMENT|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
219487968|NCT01272739|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
219487969|NCT06701981|OTHER|Filter comparison|Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device
219487970|NCT06290258|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
219487971|NCT00003981|DRUG|indisulam|
219487972|NCT02357407|DRUG|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
219487973|NCT02357407|DRUG|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
218869507|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
218869508|NCT02032654|DRUG|Flucloxacillin|
218869509|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
218869510|NCT00930007|OTHER|Blood sampling|Blood sampling for later hormone measurements
218869511|NCT03652675|BEHAVIORAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
218869512|NCT03246659|DRUG|111In-CP04|Radiopharmaceutical preparation
218869513|NCT03246659|DRUG|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
218869514|NCT04060966|BEHAVIORAL|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
218869515|NCT04060966|BEHAVIORAL|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.
218869516|NCT04060966|DEVICE|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
218869517|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
219487974|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
219487975|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
219487976|NCT05349188|OTHER|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
219487977|NCT00005893|DRUG|anti-thymocyte globulin|
219487978|NCT00005893|DRUG|busulfan|
219487979|NCT00005893|DRUG|cyclophosphamide|
219487980|NCT00005893|PROCEDURE|Bone marrow transplantation|
219487981|NCT01456871|PROCEDURE|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
218869518|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
218869519|NCT02539511|DRUG|CI-581a|
219487982|NCT01456871|PROCEDURE|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
219487983|NCT02079428|OTHER|No interventions|
219487984|NCT02756078|DEVICE|TEST Contact Lens|
219487985|NCT02756078|DEVICE|CONTROL Contact Lens|
219487986|NCT01370434|DRUG|PAD combination|"* Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11"
219487987|NCT05605457|DEVICE|PRG barrier coat + nanohybrid composite|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
219487988|NCT05605457|DEVICE|resin modified glass ionomer|RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction
219487989|NCT05860608|DEVICE|Us2.ai (AI-enabled report) handheld echocardiogram|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
219487990|NCT06066866|OTHER|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
218869520|NCT02539511|DRUG|CI-581b|
218869521|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
218869522|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
218869523|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
218869524|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
218869525|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
218869526|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
218869527|NCT01744314|DRUG|Indomethacin and Pantoprazole|
218869528|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
218869529|NCT01649024|DRUG|Tremelimumab|Given IV
218869530|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
218869531|NCT01181674|DRUG|insulin glargine|sc injection
218869532|NCT01181674|DRUG|metformin|oral administration
218869533|NCT01181674|DRUG|acarbose|oral administration
218869534|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
218869535|NCT01181674|DRUG|insulin glargine|sc injection
218869536|NCT01181674|DRUG|metformin|oral administration
218869537|NCT01181674|DRUG|acarbose|oral administration
218869538|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
218869539|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
218869540|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
218869541|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
219487991|NCT02233881|DRUG|Atrovent® - inhalets|
219487992|NCT04098471|PROCEDURE|transanal local excision following radiotherapy|transanal local excision following radiotherapy
219487993|NCT00943384|DEVICE|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
219487994|NCT00574379|DRUG|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
219487995|NCT00574379|DRUG|Placebo|Placebo tablets twice daily for 14 days
219487996|NCT05341076|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
219487997|NCT05341076|DRUG|Oxytocin|oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
219487998|NCT05341076|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
219487999|NCT06566066|OTHER|no intervention|register study without intervention
219488000|NCT04641754|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
219488001|NCT00553033|PROCEDURE|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
219488002|NCT03821831|DEVICE|Continuous Positive Airway Pressure|CPAP machine
219488003|NCT03821831|DEVICE|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
219488004|NCT05324709|BEHAVIORAL|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
219488005|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
219488006|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
219488007|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
219488008|NCT00438685|BEHAVIORAL|Outpatient MST/OPTION-A|
219488009|NCT00438685|BEHAVIORAL|Usual Services|
219488010|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM)|
219488011|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).|
219488012|NCT00213031|DRUG|Carraguard (PC-515)|
219488013|NCT01890018|BEHAVIORAL|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
219488014|NCT01890018|BEHAVIORAL|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
219488015|NCT01890018|BEHAVIORAL|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
219488016|NCT06439615|DRUG|Baricitinib 4 MG|Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
219488017|NCT06439615|OTHER|Standard treatment|Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
219488018|NCT04532489|DRUG|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
219488019|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
219488020|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
219488021|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
219488022|NCT02275039|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
219488023|NCT02275039|DRUG|gemcitabine hydrochloride|Given IV
219488024|NCT02275039|OTHER|laboratory biomarker analysis|Correlative studies
219488025|NCT03259867|DRUG|Nivolumab Injectable Product|a PD-1 immune check inhibitor
219488026|NCT03259867|COMBINATION_PRODUCT|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
219488027|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
219488028|NCT03304990|OTHER|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
219488029|NCT03023007|PROCEDURE|Loco-regional anaesthesia|Loco-regional anaesthesia
219600368|NCT04521803|DRUG|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
219600369|NCT06854757|BEHAVIORAL|RIVER|RIVER is a peer grief support process intervention developed by Peer Support Community Partners.
219488030|NCT04036786|BEHAVIORAL|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
219488031|NCT04036786|BEHAVIORAL|standard care|standard pregnancy follow up
219600370|NCT06854757|BEHAVIORAL|Enhanced care as usual|The enhanced care as usual condition involves a psychoeducational booklet developed by What's Your Grief, as well as a list of local grief resources.
219600371|NCT06655857|OTHER|Usual Care|Participants are provided care as usual. Clinicians (CKD, HD, KTx) will educate participants on the kidney transplant process. Clinician will receive the education intervention to provide participants at study end.
219600372|NCT06655857|OTHER|Community Health Worker Assistance|Community health worker will address unmet social needs and participant symptoms through evaluations and intake to clinical and community services
219600373|NCT06655857|OTHER|Intervention Providers|Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
218869542|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
219488032|NCT05117073|DIAGNOSTIC_TEST|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
219488033|NCT00835068|OTHER|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
219488034|NCT05008419|BEHAVIORAL|Narrative discourse treatment|The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
219488035|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
218869543|NCT00311909|DEVICE|Thalamic deep brain stimulation|
218869544|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
218869545|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
219488036|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
219488037|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
219488038|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
219600374|NCT06983639|DIAGNOSTIC_TEST|Fecal occult blood testing|Fecal testing for blood as surveillance efter polyp removal
219488039|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
219488040|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
219488041|NCT01914289|PROCEDURE|Resection|
219600375|NCT06983639|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy after polyp removal according to guidelines
219488042|NCT01914289|RADIATION|Radiotherapy|
219488043|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
218869546|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
219488044|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
219488045|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
219488046|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
219488047|NCT02575807|DRUG|Epacadostat|PO BID
219488048|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
219488049|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
219488050|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
219488051|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
219488052|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
219488053|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
219488054|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
219488055|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
219488056|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
219488057|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
219488058|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
219600376|NCT06981598|BEHAVIORAL|Cognitive Behavioral Coaching Training|Behavioral technicians will engage in a structured, deliberate-practice-based training program designed to enhance competence in evidence-based interventions (EBIs) over a 10-week period. The program begins with an initial seminar that provides an overview of the training framework, key research supporting deliberate practice, and specific intervention techniques. Each participant is assigned a coach-either a clinical psychologist or a licensed MSW with expertise in the EBI Toolkit-who will provide individualized guidance throughout the training. During the weekly coaching sessions, participants will review session notes, engage in structured practice exercises, and work toward mastering the skills and competencies necessary for effective intervention delivery. Weekly homework assignments will allow participants to practice each tool as though they were working with an SM client, followed by self-reflections that will be discussed in coaching sessions.
219600377|NCT06981611|BEHAVIORAL|Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia|The intervention is based around physiological and psychosocial components working with goal-directed behavioral change. Includes both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are approximately 60 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions.
219600378|NCT04603547|DEVICE|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
218869547|NCT00119964|BEHAVIORAL|internet based weight management tools|
218869548|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
219488059|NCT00116545|DRUG|troglitazone|
219488060|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
219488061|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
219488062|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
218869549|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
218869550|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
218869551|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
218869552|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
218869553|NCT01895309|DRUG|Enbrel (etanercept)|
218869554|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
218869555|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
219488063|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
219488064|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
218869556|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
218869557|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
219600379|NCT06066957|DRUG|Letermovir 480 MG [Prevymis]|"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."
219600380|NCT06856213|DRUG|Cetuximab|Cetuximab 250 mg/m2 will be administered as an intravenous infusion over 60 minutes. Cetuximab loading dose is 400 mg/m2 infusion and will be administered over 120 minutes. During maintenance, cetuximab at 500 mg/m2 will be administered as an intravenous infusion over 120 minutes.
219600381|NCT06856213|DRUG|Paclitaxel|Paclitaxel at a dose of 80 mg/m² will be administered after cetuximab as an intravenous infusion over 60 minutes weekly.
218869558|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
218869559|NCT00794066|PROCEDURE|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
219600382|NCT02881840|DRUG|14C-APD421|
219600383|NCT00093119|DRUG|ABI-007|
219600384|NCT00967655|BIOLOGICAL|panitumumab|
219600385|NCT00967655|DRUG|capecitabine|
219600386|NCT00967655|DRUG|irinotecan hydrochloride|
219600387|NCT00967655|PROCEDURE|neoadjuvant therapy|
218869560|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
218869561|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
218869562|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
218869563|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
218869564|NCT02062203|DRUG|Placebo|Single oral dose of placebo
218869565|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
218869566|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
219488065|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
219488066|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
219488067|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
219488068|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
219488069|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
219488070|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
219600388|NCT00967655|PROCEDURE|therapeutic conventional surgery|
219600389|NCT00967655|RADIATION|radiation therapy|
219600390|NCT01098487|DRUG|Eltrombopag olamine|Thrombopoietin receptor agonist
219600391|NCT05223140|BEHAVIORAL|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
219600392|NCT05223140|BEHAVIORAL|Premature cord clamping|Umbilical cord clamping \<1 minute following birth
219600393|NCT00345631|OTHER|Manual Compression|Manual compression
219600394|NCT00345631|DEVICE|Vascular Closure Device|Investigational vascular closure device
219600395|NCT05866185|BEHAVIORAL|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
218869567|NCT01667874|DRUG|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
219488071|NCT03973086|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
219488072|NCT01955473|DRUG|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
219488073|NCT01138852|DRUG|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
219488074|NCT01138852|DRUG|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
219488075|NCT04473729|OTHER|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
219488076|NCT01413152|BIOLOGICAL|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
219488077|NCT02619370|BEHAVIORAL|Conversation card game|
219488078|NCT02619370|BEHAVIORAL|Active Control|
219488079|NCT03311828|BIOLOGICAL|Daratumumab|Given IV
219488080|NCT03311828|DRUG|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
219488081|NCT03311828|PROCEDURE|Positron Emission Tomography|Undergo PET
219488082|NCT03311828|OTHER|Pharmacological Study|Correlative studies
219600396|NCT05866185|BEHAVIORAL|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
219600397|NCT03294720|PROCEDURE|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
219488083|NCT04356092|DIAGNOSTIC_TEST|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
219488084|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
219600398|NCT03294720|DEVICE|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
219600399|NCT00751556|DRUG|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
219600400|NCT00751556|DRUG|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
218869568|NCT00221494|DRUG|citalopram + tiodothyronine, or + pindolol, or + placebo|
219488085|NCT02978729|OTHER|Telephone remote genetic counseling|
219488086|NCT06539286|DEVICE|Laser Irradiation|three different laser wavelengths will be used
219600401|NCT01716975|DRUG|EVP-6124|Arms 1, 2
218869569|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
218869570|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
218869571|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
218869572|NCT00359723|DRUG|methylphenidate|
218869573|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
218869574|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
218869575|NCT04147546|DIAGNOSTIC_TEST|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
218869576|NCT04147546|DRUG|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
218869577|NCT04147546|OTHER|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
219488087|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
219488088|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
219488089|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
219488090|NCT05186727|OTHER|Family History education|The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
219488091|NCT05186727|OTHER|Patient Ambassador|The support of a Patient Ambassador in addition to the education is also tested.
219488092|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
219488093|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
219600402|NCT01716975|DRUG|Placebo|Arm 3
219600403|NCT06321679|PROCEDURE|Imaging evaluation|each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
219600404|NCT01301729|DRUG|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
218869578|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
219488094|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
219488095|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
219488096|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
219488097|NCT04431622|DEVICE|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
219488098|NCT03332212|DRUG|Empagliflozin|12 weeks
219488099|NCT03332212|DRUG|Placebo|12 Weeks
219488100|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
219488101|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
219488102|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
219488103|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
219488104|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
219488105|NCT03273010|PROCEDURE|Free gingival graft|Free gingival graft was harvested from palatal donor site
219488106|NCT03273010|PROCEDURE|Cyanoacrylate application|Periacyrl was applied on palatal wounds
219488107|NCT04381468|DRUG|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
219488108|NCT04381468|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
219488109|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
219488110|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
219488111|NCT05564494|PROCEDURE|Bankart Repair|Patients Randomized to Bankart Repair Group
219488112|NCT05564494|PROCEDURE|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
219488113|NCT04383769|OTHER|questionnaires survey|data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
219488114|NCT00607906|DRUG|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
219488115|NCT00607906|DRUG|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
219488116|NCT00607906|DRUG|Placebo|Subjects will also receive placebo capsules.
219488117|NCT04141670|DRUG|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
218869579|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
218869580|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
219488118|NCT02357173|OTHER|electronic cigarette|
219488119|NCT02357173|OTHER|cigarette group|
218869581|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
218869582|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
218869583|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
218869584|NCT05077332|DRUG|Famotidine|80 mg tablet, QID for 14 days
219040145|NCT04736238|PROCEDURE|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
219488120|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
219488121|NCT03447054|BEHAVIORAL|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
219488122|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
219488123|NCT03447054|BEHAVIORAL|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
219522465|NCT02707978|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219522466|NCT01186588|DRUG|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
219600405|NCT01301729|DRUG|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
219522467|NCT02352298|DEVICE|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
219522468|NCT02352298|DEVICE|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
219600406|NCT01301729|DRUG|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
219600407|NCT03071276|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
219600408|NCT03071276|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
218869585|NCT05077332|DRUG|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
218869586|NCT05077332|OTHER|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
218869587|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
218869588|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
218869589|NCT00595816|OTHER|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
218869590|NCT01908439|OTHER|whole-body vibration|High amplitude whole-body vibration
218869591|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
218869592|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
218869593|NCT01829022|PROCEDURE|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
218869594|NCT02807870|DRUG|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
218869595|NCT02807870|BEHAVIORAL|Parental training|Weekly parental training conducted by behavioral psychologists.
218869596|NCT02807870|OTHER|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
218869597|NCT02807870|DRUG|Placebo pill|Placebo pill during 8 weeks.
218869598|NCT02166268|DRUG|AVANZ Phleum pratense 15,000 SQ+|
218869599|NCT02166268|DRUG|Placebo|
218869600|NCT00255528|DRUG|metoprolol succinate|
219600409|NCT03071276|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
218869601|NCT01834079|BIOLOGICAL|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
218869602|NCT05976347|DRUG|Fluoxetine 20 MG|Fluoxetine 20 mg once daily
218869603|NCT05976347|DRUG|Duloxetine 30 MG|Duloxetine 30 mg once daily
219488124|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
219488125|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
219488126|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
219488127|NCT06025487|BIOLOGICAL|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
219488128|NCT06390423|DIAGNOSTIC_TEST|Passive leg raise, SVI via bioreactance, Echo based VTI|No interventions other than fluid challenge
219488129|NCT06565377|BEHAVIORAL|Multimodal biopsychosocial teleprehabilitation|"Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet."
219488130|NCT06565377|OTHER|Best-evidence prehabilitation advice|Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
219522469|NCT01110447|DRUG|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
219522470|NCT01110447|OTHER|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
218869604|NCT05976347|OTHER|Observation|Referral to behavioral health and resources for addressing depressive symptoms
218869605|NCT06041698|OTHER|Planned Notification|Receive text notification
218869606|NCT06041698|OTHER|Survey Administration|Complete surveys
218869607|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in TXT-Chatbot
218869608|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
218869609|NCT06041698|OTHER|Interview|Ancillary studies
218869610|NCT06041698|OTHER|Survey Administration|Complete surveys
218869611|NCT06041698|OTHER|Planned Notification|Receive email notification
218869612|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in MyChart/Patient Portal
218869613|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
218869614|NCT06041698|OTHER|Interview|Ancillary studies
219522471|NCT03416777|BEHAVIORAL|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
219522472|NCT03416777|DIETARY_SUPPLEMENT|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
219522473|NCT03416777|BEHAVIORAL|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
219522474|NCT04175548|OTHER|Data extraction from medical files|Data extraction from medical files
219522475|NCT05121233|DRUG|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
219522476|NCT05121233|DRUG|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
219522477|NCT06148090|DIAGNOSTIC_TEST|clobetasol decreasing measurement|"At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month"
218869615|NCT05873855|BEHAVIORAL|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
219488131|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
219488132|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
219488133|NCT06568913|DIAGNOSTIC_TEST|CBC|Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
219488134|NCT05473247|BEHAVIORAL|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
219488135|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
219488136|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
219488137|NCT05243134|OTHER|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
219488138|NCT03533335|OTHER|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
218869616|NCT05873855|BEHAVIORAL|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
218869617|NCT04236791|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
218869618|NCT04236791|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
219488139|NCT02392559|DRUG|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
219488140|NCT02392559|DRUG|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
219488141|NCT04574037|OTHER|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
218869619|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
218869620|NCT00331188|DRUG|Sanvar® (vapreotide)|
218869621|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
219488142|NCT06232707|DRUG|Alnuctamab|Specified dose on specified days
219488143|NCT06232707|DRUG|Pomalidomide|Specified dose on specified days
219488144|NCT06232707|DRUG|Daratumumab|Specified dose on specified days
219488145|NCT06232707|DRUG|Elotuzumab|Specified dose on specified days
219488146|NCT06232707|DRUG|Carfilzomib|Specified dose on specified days
219488147|NCT06232707|DRUG|Dexamethasone|Specified dose on specified days
219488148|NCT00392717|DRUG|Atorvastatin|
219488149|NCT00392717|DRUG|Fish oils|
219488150|NCT01946087|PROCEDURE|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
219488151|NCT01946087|PROCEDURE|Control group|keeping the cuff deflated
219488152|NCT04770194|DRUG|SP-8008 Prototype Capsule A|Oral
219488153|NCT04770194|DRUG|SP-8008 Prototype Capsule B|Oral
219488154|NCT04770194|DRUG|Placebo|Oral
219488155|NCT03434808|OTHER|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
219600410|NCT03071276|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
219600411|NCT05638061|OTHER|Soy protein|Soy foods or isolated soy protein
219600412|NCT06998966|BEHAVIORAL|Algorithmic Defaulting (Indication-Based Default)|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether modifying defaulted prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
218869622|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
218869623|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
218869624|NCT00299117|BEHAVIORAL|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
218869625|NCT05265897|OTHER|CAQ|Informational document
218869626|NCT00278616|BIOLOGICAL|Stem Cell Transplantation|Autologous Stem Cell Transplantation
218869627|NCT03105349|DRUG|elbasvir/grazoprevir|16 weeks treatment
218869628|NCT03105349|DRUG|Sofosbuvir|16 weeks treatment
218869629|NCT03105349|DRUG|Ribavirin|16 weeks treatment
218869630|NCT06011369|PROCEDURE|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
218869631|NCT02908789|RADIATION|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
218869632|NCT02908789|OTHER|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
219488156|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
219488157|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
219488158|NCT03370627|BIOLOGICAL|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
219488159|NCT06543251|OTHER|High-intensity interval training group (HIIT)|The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
219488160|NCT06543251|OTHER|Moderate continuous training group (MCT)|Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
219488161|NCT06543251|OTHER|Sedentary control group (CON)|The control group had normal daily life.
219488162|NCT01874015|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
219488163|NCT01874015|BIOLOGICAL|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
219488164|NCT06541171|OTHER|Magnetic resonance imaging as fpr clinical practice|An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.
219488165|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
219488166|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
219488167|NCT00402779|DRUG|Erlotinib|150 mg by mouth daily
219488168|NCT00402779|DRUG|Placebo|Tablet by mouth daily
219488169|NCT04661163|OTHER|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
219488170|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
219488171|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
219600413|NCT06998966|BEHAVIORAL|Active Physician Choice|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether requiring providers to actively select prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
219600414|NCT00567905|DIETARY_SUPPLEMENT|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
219600415|NCT01281605|BEHAVIORAL|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
219600416|NCT01281605|BEHAVIORAL|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
218869633|NCT01286077|DRUG|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
218869634|NCT00136552|DRUG|rituximab|
218869635|NCT02331498|DRUG|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
218869636|NCT02237638|BIOLOGICAL|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
218869637|NCT00015951|BIOLOGICAL|bevacizumab|
218869638|NCT00015951|DRUG|cytarabine|
218869639|NCT00015951|DRUG|mitoxantrone hydrochloride|
218869640|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
219488172|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
219488173|NCT04014556|DRUG|Aflibercept|Aflibercept
219488174|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
219488175|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
218869641|NCT01841255|DEVICE|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
218869642|NCT01841255|DEVICE|facemask|
219488176|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
219488177|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
219488178|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
219488179|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
219488180|NCT05967767|DEVICE|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
219488181|NCT05967767|DEVICE|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
219600417|NCT07133477|DIETARY_SUPPLEMENT|Omega 3-9-11|Fish oil capsules containing a fish oil concentrate from North Atlantic fish species containing EPA / DHA / cetoleic acid and gondoic in controlled amounts.
219600418|NCT07133477|DIETARY_SUPPLEMENT|Placebo|Corn oil capsules
219600419|NCT07133893|BEHAVIORAL|Attention bias assessment and modification|Attention bias assessment and modification involve two versions of the dot-probe task. These tasks are based on the premise that repeated attention shifts can retrain attentional biases, with the expectation that reducing attentional bias toward threats will alleviate sub-clinical anxiety symptoms.
219488182|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
219488183|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
219488184|NCT00094900|DRUG|IL-1 Trap|
219488185|NCT04708626|OTHER|Description and analysis|Collection of clinical, laboratory and radiological data from medical records.
219488186|NCT04708626|OTHER|Description and analysis|Collection of laboratory data.
219488187|NCT00408135|DRUG|telithromycin (HMR3647)|
219488188|NCT04982718|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
219488189|NCT04982718|DIAGNOSTIC_TEST|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
219488190|NCT05775536|DRUG|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
219600420|NCT07133893|DEVICE|Transcranial photobiomodulation|Participants will receive near-infrared light at 1064 nanometers to the right side of the forehead for 8 minutes. The investigators have introduced this form of transcranial photobiomodulation (tPBM) as a means of human cognitive enhancement, and as an adjunct for attention bias modification for the reduction of symptoms of depression. In the present study, the investigators wish to extend these findings to the use of attention bias modification for the reduction of sub-clinical anxiety.
219600421|NCT07134478|DRUG|HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg will be administered every morning from Day 6 to Day 14. On the morning of Day 15, rifampicin capsules 600 mg and HSK31858 tablets 40 mg will be co-administered."
219600422|NCT03591497|OTHER|Virtual Reality|As described in Experimental arm description.
219600423|NCT05186675|PROCEDURE|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
219600424|NCT06689748|OTHER|Delphi procedure|The study involves generating consensus statements by experts on the training requirements for physicians involved with airway management in critically ill patients using a Delphi process.
219600425|NCT07033598|DRUG|Pacritinib|100-mg capsules
219600426|NCT07033598|DRUG|Hydroxyurea|capsules or tablets
219488191|NCT05775536|DIETARY_SUPPLEMENT|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
219488192|NCT03775382|OTHER|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
219488193|NCT03775382|OTHER|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
218869643|NCT06453291|DRUG|NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):|"Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence."
219488194|NCT02149199|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
219488195|NCT02149199|DRUG|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
219488196|NCT02149199|DRUG|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
219488197|NCT05840601|DEVICE|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
219600427|NCT07036679|DIETARY_SUPPLEMENT|Energy Active Product|Participants will use their Energy Active Product as directed for a period of 6 weeks.
219600428|NCT07036679|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
219600429|NCT05890534|DRUG|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
219488198|NCT05840601|DEVICE|Comparator|Unmodified commercially available prosthetic hand.
218869644|NCT06453291|PROCEDURE|Standard Physical Therapy|"Objective: To improve mobility, strength, and reduce pain.~Techniques:~Stretching exercises. Strengthening exercises for core and back muscles. Manual therapy techniques. Postural training. Frequency: Twice a week sessions. Duration: 45-60 minutes per session. Monitoring: Progress will be assessed during each session and adjusted as necessary"
218869645|NCT06453291|PROCEDURE|Neuromodulation via Dorsal Root Ganglion (DRG):|"Objective: To modulate excitatory pathways and reduce pain through targeted stimulation.~Procedure:~Placement of electrodes near the DRG. Application of pulsed radiofrequency (RF) at 42°C for 3-20 minutes.~Frequency:~Initial treatment: Once a week for the first month. Maintenance: Monthly sessions if needed. Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels and functional improvement will be assessed before and after each session."
219488199|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
219488200|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
219488201|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
219488202|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
219488203|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
219488204|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
219488205|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
219488206|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
219488207|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
219488208|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
219488209|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
219488210|NCT05397288|BEHAVIORAL|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
219488211|NCT05397288|BEHAVIORAL|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
219488212|NCT05397288|BEHAVIORAL|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~* 1st month: group talk (1 time/week), individual consultation (2 times/week)~* 2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~* 3rd month: group talk (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
219488213|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
219488214|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
219488215|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
219488216|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
219488217|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
219488218|NCT04580472|DRUG|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
219488219|NCT04580472|OTHER|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
219488220|NCT06470737|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
219488221|NCT06470737|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
219488222|NCT06470737|OTHER|Cowhage|This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
219488223|NCT06470737|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
219488224|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
219488225|NCT06653478|OTHER|No Intervention|No Intervention
219488226|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
219488227|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
219488228|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
219488229|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
219488230|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
219488231|NCT03793309|DRUG|Vitamin D|Oral vitamin D
219488232|NCT01806259|DRUG|Ketorolac 30 mg IV|Active drug
219488233|NCT01806259|DRUG|Placebos|Placebo looking like the Active drug
219488234|NCT01995058|DRUG|cabozantinib|Tablets taken orally
218869646|NCT06453291|PROCEDURE|Platelet-Rich-Plasma Therapy|"Objective: To promote healing and reduce inflammation through the application of concentrated platelets.~Procedure:~Blood draw from the patient. Centrifugation to separate platelets. Injection of PRP into the affected area of the lower back.~Frequency:~Initial treatment: Once a week for the first three weeks. Follow-up: Additional injections may be given based on patient response and clinical judgment.~Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels, inflammation markers, and functional improvement will be assessed before and after each injection."
218869647|NCT06558877|BEHAVIORAL|pharmacist-led multifaceted intervention|"Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol.~Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring."
218869648|NCT06558877|BEHAVIORAL|conventional health education|The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
219488235|NCT01995058|DRUG|abiraterone|Tablets taken orally daily
218869649|NCT06222034|DRUG|Filgotinib|Film-coated mini-tablets administered orally once daily
218869650|NCT06222034|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally once daily
218869651|NCT05771675|DRUG|Simvastatin|40Mg Oral Tablet
218869652|NCT05771675|DRUG|Placebo|Matching Simvastatin Placebo tablet
219488236|NCT01995058|DRUG|prednisone|Tablets taken orally twice daily
219488237|NCT03271541|DRUG|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
219488238|NCT04631185|DRUG|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
219488239|NCT04631185|DRUG|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
219488240|NCT03001856|PROCEDURE|Oblique Intradermal Suture|
219488241|NCT03001856|PROCEDURE|Intradermal Suture|
219488242|NCT06515496|DIETARY_SUPPLEMENT|Scale HLV Clinical Formula Hair Vitamins|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
219488243|NCT06515496|OTHER|Placebo|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
219488244|NCT01991184|DRUG|GDC-0853|Multiple escalating doses
219488245|NCT02957461|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
219488246|NCT02800278|OTHER|observational|describe bone status and outcome of odontoid fracture
219488247|NCT02781688|BEHAVIORAL|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
218869653|NCT05623683|OTHER|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
218869654|NCT05623683|OTHER|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
219488248|NCT04643054|DIETARY_SUPPLEMENT|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
219488249|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
219488250|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
219488251|NCT01500434|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
219488252|NCT01500434|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
219488253|NCT01500434|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
219488254|NCT03309631|DIAGNOSTIC_TEST|In vitro Diagnostic|
219488255|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
219488256|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
219488257|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
219600430|NCT05890534|DRUG|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
219600431|NCT03390426|DRUG|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
219600432|NCT03390426|PROCEDURE|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
218869655|NCT04137250|PROCEDURE|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
219488258|NCT06594094|GENETIC|HG302|Once intravenous injection; The duration of the study is about 32 weeks for each subject, including a 6 weeks screening period, enrollment visit, treatment visit, and 26 weeks follow-up period.
219488259|NCT01407107|DRUG|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
219488260|NCT01407107|DRUG|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
219600433|NCT03390426|DRUG|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
219600434|NCT02593682|DRUG|suvorexant|
219600435|NCT02593682|DRUG|placebo|
219600436|NCT01568138|DEVICE|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
219600437|NCT05736627|OTHER|Online|Online research course delivered live digitally at a distance.
219600438|NCT01325181|DRUG|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
219600439|NCT01325181|DRUG|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
219600440|NCT02874209|OTHER|sodium MRI|
219600441|NCT03673527|DRUG|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
219600442|NCT02335736|DRUG|Gonadotropins releasing hormone antagonist|
219600443|NCT01781000|BEHAVIORAL|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
219488261|NCT01407107|DRUG|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
219488262|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
219488263|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
219488264|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
219488265|NCT05764434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
219488266|NCT01307488|DRUG|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
219488267|NCT01307488|DRUG|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
219488268|NCT06596382|DIETARY_SUPPLEMENT|Tocotrienol rich-vitamin E|Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome
219488269|NCT06596382|DIETARY_SUPPLEMENT|Placebo|Replicate for tocotrienol rich-vitamin E without any active ingredients
219488270|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
219488271|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
219488272|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
219488273|NCT01966107|DRUG|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
219488274|NCT01966107|DRUG|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
219488275|NCT00538707|BEHAVIORAL|2-minute Bondet test|2-minute Bondet test
219488276|NCT00532779|DRUG|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
219488277|NCT00532779|DRUG|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
219488278|NCT00532779|DRUG|Placebo|
219488279|NCT00532779|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
219488280|NCT01465074|DRUG|Nicotine polacrilex|4 mg
219488281|NCT01465074|DRUG|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
219488282|NCT00958698|OTHER|Communication Intervention|Ancillary studies
219488283|NCT00958698|OTHER|Educational Intervention|Ancillary studies
219488284|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
219488285|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
219488286|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
219488287|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
219488288|NCT02246231|DEVICE|MR imaging|
219488289|NCT02662556|DRUG|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
219488290|NCT04382560|OTHER|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
219600444|NCT01781000|BEHAVIORAL|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
219600445|NCT01781000|BEHAVIORAL|Treatment as usual|standard treatment protocol of schizophrenia ward
218869656|NCT04137250|PROCEDURE|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
219488291|NCT04382560|OTHER|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
219488292|NCT00689273|DRUG|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
219600446|NCT03540771|OTHER|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~1. Patient/caregiver understanding of diagnosis, illness and prognosis~2. Symptom assessment and management~3. Psychosocial assessment and management~4. Distress screening and management~5. Discussion of goals of care~6. Advanced directives"
219600447|NCT01584453|DRUG|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
219600448|NCT01584453|DRUG|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
219600449|NCT02716727|DEVICE|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
219600450|NCT02716727|DEVICE|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
219600451|NCT02516527|DRUG|Ipilimumab|
219600452|NCT03830827|DRUG|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
219600453|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
218869657|NCT06567704|BEHAVIORAL|Interviews|Interviews
218869658|NCT06601192|DRUG|zelicapavir (therapeutic dose)|Subjects will receive zelicapavir (TD) once per treatment period.
218869659|NCT06601192|DRUG|zelicapavir (supratherapeutic dose)|Subjects will receive zelicapavir (SD) once per treatment period.
218869660|NCT06601192|DRUG|Placebo|Subjects will receive zelicapavir matching placebo once per treatment period.
219488293|NCT00689273|DRUG|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
219600454|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
219600455|NCT02924727|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
218869661|NCT06601192|DRUG|moxifloxacin|Subjects will receive moxifloxin once per treatment period.
218869662|NCT06663722|BIOLOGICAL|Axatilimab|Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.
218869663|NCT06663722|PROCEDURE|Extracorporeal Photopheresis|"Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7.~Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7.~After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months."
219488294|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
219488295|NCT01556165|DRUG|rasagiline|1 mg/day, tablets, once daily, orally
219488296|NCT01556165|DRUG|placebo|tablets, once daily, orally
219488297|NCT01238172|OTHER|dietary education and counseling|
219488298|NCT01238172|OTHER|prostate cancer foundation booklet|
219600456|NCT02924727|DRUG|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
219600457|NCT02924727|DRUG|Placebo of LCZ696|Matching placebo of LCZ696 tablets
219600458|NCT02924727|DRUG|Placebo of ramipril|Matching placebo of ramipril capsule
219600459|NCT02924727|DRUG|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
219600460|NCT02924727|DRUG|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
219600461|NCT00682682|OTHER|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
219600462|NCT00682682|OTHER|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
219600463|NCT06206382|PROCEDURE|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
219600464|NCT02636543|OTHER|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
219488299|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
219488300|NCT02639195|OTHER|Treatment|Retrospective chart review of patients treated with manual therapy.
219488301|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
219488302|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
219488303|NCT02531698|BIOLOGICAL|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
219488304|NCT02531698|BIOLOGICAL|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
219488305|NCT02531698|OTHER|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
219488306|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
219488307|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
219600465|NCT02636543|OTHER|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
219600466|NCT03791047|OTHER|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
219600467|NCT01404715|DRUG|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
219600468|NCT01404715|DRUG|Imatinib|A single oral dose of 600 mg of imatinib
218869664|NCT06587230|BEHAVIORAL|Teachers Leading the Frontlines|"1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention.~2. The teachers select students whom they believe have the highest mental health needs to receive care.~3. Teachers analyze chosen students' symptoms.~4. Teachers analyze students' behavior with the AABC Chart.~5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior.~6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home."
218869665|NCT06587230|BEHAVIORAL|Responding to Students' Emotions Through Education|"All processes for RE-SEED are the same as in Tealeaf except...~1. Teachers receive only 1 day of training~2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision~This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students."
218869666|NCT06980675|DEVICE|Activated Ozonized Olive Oil Gel|It is a natural oil which has been ozonized to improve the antimicrobial activity against periodontopathogenic bacterias
218869667|NCT06980675|OTHER|Placebo gel|Placebo gel with same texture, color, way of administration and taste of Activated Ozonized Olive Oil Gel
219488308|NCT04225416|OTHER|Questionnaire/Structured Interview|No intervention
219488309|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
219600469|NCT03778827|BEHAVIORAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
219488310|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
219488311|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
219488312|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
219488313|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
219488314|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
219488315|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
219600470|NCT01879865|OTHER|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
219600471|NCT01879865|OTHER|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
219600472|NCT02767154|DEVICE|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
219600473|NCT02767154|DEVICE|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
219600474|NCT06122376|DEVICE|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
219600475|NCT06122376|DEVICE|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
219600476|NCT03781284|DIAGNOSTIC_TEST|[18F]-FDG PET/MRI|
219600477|NCT03781284|DIAGNOSTIC_TEST|Colonoscopy|
218869668|NCT06980064|DIAGNOSTIC_TEST|Smartwatch + GP|Participants in the intervention group will be required to wear a smartwatch continuously for 24 hours. After this period, the collected data will be processed using a pre-trained foundational model for disease diagnosis, generating preliminary diagnostic suggestions. GPs will then integrate these smartwatch-derived findings with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
218869669|NCT06980064|DIAGNOSTIC_TEST|GP only|GPs will make diagnosis with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
219488316|NCT05268965|BEHAVIORAL|Experimental: group comparison|"* Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality"
219488317|NCT04282733|BEHAVIORAL|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
219488318|NCT00701558|DRUG|Erlotinib|150 mg po daily
219488319|NCT00701558|DRUG|Gemcitabine|1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
219488320|NCT05481554|BIOLOGICAL|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
219488321|NCT00116376|DRUG|AEE788|
219488322|NCT00395200|PROCEDURE|MSC Treatment|Intravenous administration of up to 2x10\^6 autologous MSCs per kg
219488323|NCT00131937|DRUG|sorafenib tosylate|Given orally
219488324|NCT05531591|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
219488325|NCT05531591|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
219488326|NCT05531591|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
219488327|NCT05531591|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
219488328|NCT05531591|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
219488329|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
219488330|NCT06418074|DIETARY_SUPPLEMENT|Ketone Monoester (KE4)|Each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4) 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
219488331|NCT06418074|OTHER|Placebo|Each subject will receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
219488332|NCT06700681|DRUG|Propofol|TIVA induction and maintain with Propofol.
218869670|NCT06981364|DIETARY_SUPPLEMENT|Fish Oil|Upon completion of baseline testing both groups will be instructed not to alter their normal diet and activity levels throughout the study period. Zach Townsend, an individual who will not be directly involved with the data analysis, will create a spread sheet containing the weight of the subjects and separate identifier generated via algorithm. The spread sheet will be provided to the principle and co-investigators who will partition the supplements out into 42 separate sealable bags per subject. The bags will be dispersed by Mr. Townsend to maintain the double-blind standard. Subjects will either consume 4 g/day GNC Triple Strength Fish Oil Mini, General Nutrition Corporation, Pittsburgh, PA, or placebo (dextrin) of equal volume for six weeks. They will be instructed to consume fish oil or the placebo with a glass of water at the same time every day. These protocols are similar to ones used in previous investigations1-7.
218869671|NCT06086483|DRUG|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
219488333|NCT06700681|DRUG|Remimazolam|TIVA induction and maintain with Remimazolam.
219488334|NCT06700681|DEVICE|With intubation and controlled ventilation to maintain airway|Patient receives intubation and controlled ventilation to maintain airway.
219488335|NCT06700681|DEVICE|Maintain spontaneous ventilation without intubation|Patient maintains spontaneous ventilation without intubation.
219488336|NCT06701084|GENETIC|Genomic Sequencing|Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.
219488337|NCT06702267|DEVICE|arterial blood samplers with needles PICO70 and safePICO syringes.|"PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation.~safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle."
219488338|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
219488339|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
219488340|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
218869672|NCT06086483|DRUG|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
218869673|NCT06825546|DRUG|Icaritin|"Icaritin soft capsules, 600 mg, taken twice daily, should be swallowed with warm water within 30 minutes after breakfast and dinner. If a patient misses a dose and cannot take it within 2 hours after a meal, they should continue with the next scheduled dose without needing to make up for the missed dose.~Gemcitabine, 1000 mg/m², is administered on days 1 and 8, followed by a 14-day pause, constituting a 21-day treatment cycle. Nab-paclitaxel, 125 mg/m², is also administered on days 1 and 8, with a 14-day pause, making up a 21-day treatment cycle."
218869674|NCT06825546|DRUG|AG chemotherapy|"Gemcitabine (1000 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush.~Nab-paclitaxel (125 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush"
218869675|NCT06980207|DRUG|LY03017|administered orally
218869676|NCT06980207|DRUG|LY03017-Placebo|administered orally
218869677|NCT07002645|OTHER|Web-based conflict resolution training program|"Researchers developed the content of the web-based conflict resolution training program. First, ten experts were consulted to check the program's clarity and suitability. Second, the program was revised and finalized according to the experts' feedback.~A web page was obtained from the World Wide Web (www) by using hosting and domain services. Technical support and consultancy were received from a professional web design company during the implementation of the website. The content of the training program, for which expert opinions were obtained, was transferred to the web page. Web-based conflict resolution training program will be applied to the intervention group for 2 week."
218869678|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
218869679|NCT06870526|BEHAVIORAL|Food box delivery|"* Time Needed: 12 weeks (duration of intervention)~* Description: Participants will receive grocery boxes containing a selection of food items tailored to their cultural and nutritional needs. They will be asked to utilize the groceries provided and provide feedback on the quality and quantity of items received. The pilot study will partner with Instacart, utilizing Instacart Care Carts for the medically tailored grocery delivery in which researchers order and deliver groceries on behalf of participants. Although families are not able to modify the order, they select when and where they want the grocery box delivered."
218869680|NCT05660213|DRUG|Targeted drugs combined with anti-PD-1/PD-L1 antibodies|Targeted drugs combined with anti-PD-1/PD-L1 antibodies
218869681|NCT05660213|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|TACE (transarterial chemoembolization) combined with targeted/immunotherapy
218869682|NCT05660213|DRUG|Lenvatinib monotherapy|For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.
218869683|NCT05660213|DRUG|Huaier granules combined with any of the above Cohorts for treatment|Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.
218869684|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
218869685|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
218869686|NCT06123754|DRUG|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
218869687|NCT06123754|DRUG|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
218869688|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
219199931|NCT06861556|PROCEDURE|Ultrasound guided Transversus Abdominis Plane block with 0.2ml/kg bupivacaine 0.25%|The operator applied a linear ultrasound probe transversally to the mid-axillary line between the costal margin and iliac crest. Landmarks were then identified as three muscles layers beneath the subcutaneous tissue; from external to internal lay respectively the external oblique muscle (EO), the internal oblique muscle (IO) and the transversus abdominis (TA). The needle was inserted in plane from the iliac crest level on the midaxillary line advancing towards the midline to the fascia laying between the IO and the TA muscles until pop detection. A clear aspiration ruled out vascular effraction. Finally, the space between the two muscle planes was hydrodissected with the bupivacaine.The end goal was visualizing the IO moving upward leaving room to a hypoechoic lens-shaped local anesthetic distribution.
219488341|NCT06713954|BEHAVIORAL|Dietary assessment|Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
219488342|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
219488343|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
219488344|NCT06703086|DIETARY_SUPPLEMENT|Berberine Hydrochloride group|The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.
219488345|NCT06703086|BEHAVIORAL|nutritional plan|nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months
219488346|NCT06703086|BEHAVIORAL|controlled moderate aerobic exercise|controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.
219488347|NCT06703515|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
219488348|NCT06703515|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
219488349|NCT06702514|OTHER|Exercise|After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
219488350|NCT06702514|OTHER|Paraffin|It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
219488351|NCT06702514|OTHER|Balneotherapy|The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
219488352|NCT06703294|PROCEDURE|Crow's feet injection filling|Patients with crow's feet of different degree were randomly divided into two groups, which were injected with bovine collagen and humanized collagen respectively
219488353|NCT06703294|PROCEDURE|Humanized collagen filling crow's feet|Bovine collagen filling crow's feet
219522478|NCT04840251|OTHER|Well-being review and rehabiliation|"For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~* how they are~* what they can do for themselves~* what it is challenging for them to do~* how active they are~* if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes."
218869689|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)
218869690|NCT06876740|BEHAVIORAL|Project Safe Guard - Trauma|Project Safe Guard-Trauma (PSG-T) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals with posttraumatic stress disorder (PTSD). PSG-T is designed to promote secure firearm storage practices by (1) using motivational interviewing techniques and (2) addressing the functional link between PTSD symptoms and unsafe firearm storage practices. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy. PSG-T combines PSG-proven motivational interviewing techniques with PTSD- and firearm-specific psychoeducation.
219522479|NCT04840251|OTHER|Qualitative Interviews|Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
218869691|NCT06876740|BEHAVIORAL|Project Safe Guard|Project Safe Guard-Trauma (PSG) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals. PSG-T is designed to promote secure firearm storage practices by using motivational interviewing techniques. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy.
219488354|NCT06713967|PROCEDURE|Metformin (Glucophage)|In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
219488355|NCT06713967|PROCEDURE|Standard Care (Diet and Exercise Only)|In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
219488356|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
219488357|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash without erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash without erythritol.
219488358|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash with erythritol.
219488359|NCT06723054|OTHER|high fluoride 500 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a high fluoride 500 ppm F mouthwash with erythritol.
219488360|NCT06722573|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219488361|NCT06723782|BIOLOGICAL|AMTRIX-D|Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
219522480|NCT03119480|DEVICE|electronic alerts|electronic alerts for AKI
219522481|NCT02857270|DRUG|LY3214996|Administered orally
219522482|NCT02857270|DRUG|Midazolam|Administered orally
219522483|NCT02857270|DRUG|Abemaciclib|Administered orally
219522484|NCT02857270|DRUG|Nab-paclitaxel|Administered IV
219522485|NCT02857270|DRUG|Gemcitabine|Administered IV
218869692|NCT07037381|OTHER|KN95 mask|AIR+ KN95 mask
218869693|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
218869694|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
219522486|NCT02857270|DRUG|Encorafenib|Administered orally
219522487|NCT02857270|DRUG|Cetuximab|Administered IV
219522488|NCT04220151|GENETIC|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
219522489|NCT04271826|PROCEDURE|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
219522490|NCT00414466|DRUG|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
219522491|NCT01218165|DIETARY_SUPPLEMENT|Probiotic drink|This group receives a probiotic drink daily for 6 week.
219522492|NCT01218165|OTHER|Control Group|without intervention
219522493|NCT02446626|PROCEDURE|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
219522494|NCT02446626|PROCEDURE|Blood draw|Peripheral blood draws will be performed.
219522495|NCT02446626|DEVICE|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
219522496|NCT05007795|DIAGNOSTIC_TEST|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
219522497|NCT05031884|DEVICE|MGIR3-US|MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
219522498|NCT02804737|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
219522499|NCT01975207|BEHAVIORAL|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
218869695|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
219600478|NCT01894594|DRUG|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
219600479|NCT03122080|DEVICE|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
219600480|NCT03122080|DEVICE|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
218869696|NCT05092373|BIOLOGICAL|Atezolizumab|Given IV
218869697|NCT05092373|DRUG|Cabozantinib S-malate|Given PO
219488362|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
219488363|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
219488364|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
218869698|NCT05092373|DRUG|Nab-paclitaxel|Given IV
218869699|NCT05092373|PROCEDURE|Tumor Treating Fields Therapy|Receive TTF
218869700|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
218869701|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
218869702|NCT06747871|BEHAVIORAL|Very Low Nicotine Cigarettes (VLNC)|Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.
219488365|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
218869703|NCT06747871|BEHAVIORAL|Normal Nicotine Cigarettes (NNC)|Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.
219488366|NCT04796142|OTHER|medication reconciliation|medication reconciliation
219488367|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
219488368|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
219488369|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
219488370|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
219488371|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
219522500|NCT01975207|BEHAVIORAL|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
218869704|NCT06175156|PROCEDURE|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
218869705|NCT06175156|PROCEDURE|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
219488372|NCT05302700|BEHAVIORAL|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
219488373|NCT06317337|OTHER|focused ultrasound cavitation augmented with aerobic exercises|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
219488374|NCT05673915|DEVICE|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
219488375|NCT05673915|DEVICE|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
219488376|NCT02026882|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
219488377|NCT05983029|DIAGNOSTIC_TEST|Intergluteal Cleft|Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line
219488378|NCT05983029|DIAGNOSTIC_TEST|Neuraxial Midline|Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line
219488379|NCT05983029|DIAGNOSTIC_TEST|Horizontal Distance between Vertical Markings|The horizontal distance between these two vertical marks will be measured at the level of the intercristal line
219488380|NCT04445129|DEVICE|Portable EEG Device|Portable EEG device is lightweight and designed for nighttime wear.
219488381|NCT04445129|DEVICE|Portable ECG Device|Portable ECG device is waterproof and will be adhered to the chest of the participant.
219488382|NCT04445129|DEVICE|Accelerometry|Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
219488383|NCT01120522|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
219488384|NCT03957317|OTHER|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
219488385|NCT01393717|DRUG|brentuximab vedotin|Given IV
219488386|NCT01660490|PROCEDURE|ORIF|Open reduction internal fixation of the proximal femur
219488387|NCT02406703|DRUG|Chloroprocaine|
219488388|NCT02406703|DRUG|Mepivacaine|
219488389|NCT00731510|DIETARY_SUPPLEMENT|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
219488390|NCT00731510|DIETARY_SUPPLEMENT|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
219488391|NCT04252508|OTHER|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
218869706|NCT06745583|DRUG|EI-1071 tablet, oral|Dose: 448.2 mg BID for 28 days
219488392|NCT05000918|DIETARY_SUPPLEMENT|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
219488393|NCT03149965|OTHER|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
219488394|NCT04794400|OTHER|oxygen mask|All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
219488395|NCT05761132|DRUG|Pembrolizumab|neoadjuvant immunotherapy
219488396|NCT04739852|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
219488397|NCT01664000|DRUG|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
219488398|NCT04461652|PROCEDURE|prophylactic air-extraction catheter drainage|This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
219488399|NCT05066100|OTHER|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
219488400|NCT04876859|PROCEDURE|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
219600481|NCT03122080|OTHER|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
219600482|NCT01925300|DRUG|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
219600483|NCT01925300|DRUG|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
219600484|NCT01925300|DRUG|Concor 5mg 2T and Crestor 20 mg 1Tab|
218869707|NCT05215730|DEVICE|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
218869708|NCT06856330|PROCEDURE|furlow with buccal myomucosal flap|patients were treated with furlow with buccal myomucosal flap
219488401|NCT04876859|PROCEDURE|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
218869709|NCT06856330|PROCEDURE|two flap palatoplasty|patients were treated with two flap palatoplasty
218869710|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
219488402|NCT03046537|DIAGNOSTIC_TEST|Breath test|Collecting breath test from participants
219488403|NCT01741909|BEHAVIORAL|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
219488404|NCT03963856|OTHER|parbolic flight|weightlessness during parabolic flight
218869711|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
219488405|NCT04408300|PROCEDURE|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
219488406|NCT02269007|BIOLOGICAL|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
219488407|NCT01739088|OTHER|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
218869712|NCT07088939|BEHAVIORAL|dialectical behavior therapy|This internet-delivered dialectical behavior therapy (iDBT) intervention consists of an e-learning course with 4 modules based on the 4 areas of skills training in dialectical behavior therapy: mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Participants can work through the modules at a self-guided pace to learn more than 30 specific skills using psychoeducational materials. The intervention incorporates psychoeducational elements of skills training with introductory videos, interactive quizzes, practice and homework suggestions, as well as quotes and videos from individuals with lived experience. In preliminary testing, it was estimated to take approximately 8-10 hours to complete all material.
218869713|NCT07087444|BEHAVIORAL|Health education intervention to improve knowledge and uptake of personal protective equipment and visibility materials among commercial motorcycle riders and passengers|This intervention consists of a structured health education program targeting commercial motorcycle riders and passengers in the Limbe Health District. It includes interactive group sessions focused on the importance, benefits, and correct use of personal protective equipment (helmets, reflective jackets) and visibility materials (reflective strips, lights). Educational materials such as leaflets and posters are distributed to reinforce learning. Additionally, participants receive follow-up SMS reminders to encourage consistent and proper use of protective gear. The goal is to increase awareness and uptake of safety measures to reduce road traffic injuries. This intervention is community-based and tailored to the local context in Cameroon.
219488408|NCT01739088|OTHER|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
219488409|NCT05318807|OTHER|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~1. Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~2. Patient Activation Measure - to measure patient activation~3. Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~4. Patient Generated Subjective Global Assessment - to identify malnutrition risk~5. Emotions thermometer - to detect emotional disorders and identify risk"
219600485|NCT00201409|DRUG|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
219600486|NCT00201409|DRUG|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
219600487|NCT02094911|BEHAVIORAL|Combined lifestyle intervention|"10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change"
218869714|NCT07089004|DIAGNOSTIC_TEST|No intervention (observational study)|Observational - Biochemical, Hematological and Clinical Scoring Assessments
218869715|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
218869716|NCT07089680|DRUG|Nirmatrelvir/Ritonavir|Participants aged 60 years or older residing in long-term care hospitals (LTCHs) in Korea who were diagnosed with COVID-19 and received Paxlovid (Nirmatrelvir/Ritonavir) as part of their clinical care. This group will be assessed for multiple outcomes including mortality, progression to severe disease, worsening of activities of daily living (ADL), and frailty.
219600488|NCT02094911|OTHER|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
219488410|NCT05318807|OTHER|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~* Review the initial questionnaires to inform the personalised plan and goal setting~* Complete a further four questionnaires related to quality of life, diet and exercise~* Measure handgrip strength~* Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
219600489|NCT00509795|BIOLOGICAL|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
218869717|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
218869718|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
219600490|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
218869719|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
218869720|NCT04886258|DRUG|DFV890|DFV890
218869721|NCT04886258|DRUG|Placebo|Placebo
219488411|NCT05318807|OTHER|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
219600491|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219600492|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
219600493|NCT02391480|DRUG|ABBV-075|ABBV-075 Oral tablets
219600494|NCT02391480|DRUG|Venetoclax|Venetoclax tablets, film-coated
219600495|NCT01897038|DRUG|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
219600496|NCT01897038|DRUG|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
219600497|NCT04102189|DRUG|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
219600498|NCT04102189|OTHER|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
218869722|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
218869723|NCT03860363|DEVICE|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
218869724|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
218869725|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
218869726|NCT00676910|DRUG|JNJ-26854165|
218869727|NCT02214745|OTHER|Questionnaire|Questionnaire developed for this purpose by the investigators
218869728|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
219488412|NCT01286688|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
219488413|NCT02038959|OTHER|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
219488414|NCT00005578|BIOLOGICAL|bleomycin sulfate|
219488415|NCT00005578|BIOLOGICAL|filgrastim|
219488416|NCT00005578|DRUG|cyclophosphamide|
219600499|NCT00409448|BEHAVIORAL|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
219600500|NCT00409448|BEHAVIORAL|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
219488417|NCT00005578|DRUG|dexrazoxane hydrochloride|
219488418|NCT00005578|DRUG|doxorubicin hydrochloride|
219488419|NCT00005578|DRUG|etoposide|
219488420|NCT00005578|DRUG|prednisone|
219488421|NCT00005578|DRUG|vincristine sulfate|
219488422|NCT00005578|RADIATION|radiation therapy|
219488423|NCT04738188|PROCEDURE|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
219488424|NCT04738188|PROCEDURE|cTACE|Transcatheter arterial chemoembolization
219600501|NCT05289973|DEVICE|TruNatomy Files|Newly introduced endodontic file with high flexibility.
219600502|NCT05289973|DEVICE|HyFlex EDM Files|Endodontic files
218869729|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
218869730|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
218869731|NCT07088432|DRUG|Dexamethasone|Single intravenous injection of 8 mg dexamethasone (2 mL) administered 5 minutes before spinal anesthesia. This intervention was tested for its effect on prolonging the duration of sensory and motor blocks induced by hyperbaric bupivacaine combined with sufentanil. The drug was administered under sterile conditions by an anesthesiologist blinded to group allocation.
218869732|NCT07088432|DRUG|Placebo|Single intravenous injection of 2 mL isotonic saline (0.9% NaCl) administered 5 minutes before spinal anesthesia. This placebo was used to mimic the dexamethasone injection in the control group. The preparation, volume, and timing were identical to the intervention group to maintain blinding. The saline was administered under sterile conditions by an anesthesiologist blinded to group allocation.
219488425|NCT04738188|DEVICE|Drug-eluting Beads|Drug-eluting beads
219488426|NCT04738188|DRUG|Epirubicin|Chemotherapy drug for intra-arterial infusion
219600503|NCT03889080|DIAGNOSTIC_TEST|functional MRI|functional MRI scan of the brain
219600504|NCT04275986|PROCEDURE|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
219600505|NCT04275986|DRUG|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
218869733|NCT05511350|DRUG|TJ210001|
218869734|NCT02580786|BEHAVIORAL|Breastfeeding peer support|
218869735|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
218869736|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
218869737|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
218869738|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
218869739|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
219600506|NCT01178710|DRUG|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
219600507|NCT01747746|DRUG|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
219600508|NCT01747746|DRUG|Warfarin and Enoxaparin|Historical Control
219600509|NCT00656266|DRUG|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
219600510|NCT00656266|OTHER|placebo medication|medication that looks like mycophenolate mofetil
219488427|NCT00534209|BIOLOGICAL|Allogeneic B7.1/HLA-A1|Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
219488428|NCT00534209|OTHER|Placebo|Given intradermally
219488429|NCT00646256|BEHAVIORAL|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
219488430|NCT03233737|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
219488431|NCT03233737|DEVICE|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
219488432|NCT03233737|DEVICE|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
219488433|NCT02083588|DEVICE|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
219488434|NCT04901871|DRUG|0.02 mg/kg, age<65|Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
219488435|NCT04901871|DRUG|0.07 mg/kg, age<65|Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
219488436|NCT04901871|DRUG|0.12 mg/kg, age<65|Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
219488437|NCT04901871|DRUG|0.17 mg/kg, age<65|Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
219488438|NCT04901871|DRUG|0.22 mg/kg, age<65|Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
219488439|NCT04901871|DRUG|0.27 mg/kg, age<65|Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
219600511|NCT03020537|BIOLOGICAL|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
218869740|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
218869741|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
218869742|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
218869743|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
218869744|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
218869745|NCT03826199|DRUG|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
219488440|NCT04901871|DRUG|0.02 mg/kg, age≥65|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
219488441|NCT04901871|DRUG|0.07 mg/kg, age≥65|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
219488442|NCT04901871|DRUG|0.12 mg/kg, age≥65|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
219488443|NCT04901871|DRUG|0.17 mg/kg, age≥65|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
219488444|NCT04901871|DRUG|0.22 mg/kg, age≥65|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
219488445|NCT04901871|DRUG|0.27 mg/kg, age≥65|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
219488446|NCT02080533|OTHER|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
219600512|NCT04293900|OTHER|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600513|NCT04293900|OTHER|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219488447|NCT03117777|BEHAVIORAL|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
219488448|NCT01638754|PROCEDURE|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
219488449|NCT01638754|PROCEDURE|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
219600514|NCT04293900|OTHER|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600515|NCT04293900|OTHER|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600516|NCT04293900|OTHER|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600517|NCT04293900|OTHER|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219488450|NCT01136005|OTHER|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
218869746|NCT03826199|BEHAVIORAL|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
218869747|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
218869748|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
218869749|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
218869750|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
218869751|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
218869752|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
219488451|NCT01136005|OTHER|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
219488452|NCT01561586|DRUG|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
219488453|NCT01561586|DRUG|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
219488454|NCT00245427|DRUG|all macrolide antibiotics|Varies based on antibiotic
219488455|NCT00245427|DRUG|all beta-lactam antibiotics|Varies based on antibiotic
219488456|NCT02759627|OTHER|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training."
219488457|NCT03533920|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
219488458|NCT04395131|DEVICE|Clearum HF Hemodialyzer|the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
219488459|NCT02757131|OTHER|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
219488460|NCT06282068|DIAGNOSTIC_TEST|AI computer-aided detection software|non-invasive
219488461|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
219488462|NCT06700434|OTHER|Bleaching treatment|"After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session."
219488463|NCT04095819|PROCEDURE|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
219488464|NCT04095819|PROCEDURE|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
219488465|NCT00424515|DRUG|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
219488466|NCT05204628|DRUG|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
219488467|NCT05204628|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
219488468|NCT06408454|DIAGNOSTIC_TEST|Gingival crevicular fluid collection|Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
219600518|NCT04293900|OTHER|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600519|NCT04293900|OTHER|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
219600520|NCT02849483|DRUG|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
219600521|NCT02849483|DRUG|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
219488469|NCT06408454|DIAGNOSTIC_TEST|periodontal test|A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
219488470|NCT00111774|DRUG|ABX-EGF|
219488471|NCT04256057|DRUG|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
219488472|NCT00267020|DRUG|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
219488473|NCT00267020|DRUG|gemcitabine|1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
219488474|NCT00276731|DRUG|carboplatin|
219488475|NCT00276731|DRUG|cisplatin|
219488476|NCT00276731|DRUG|cyclophosphamide|
219488477|NCT00276731|DRUG|etoposide|
219488478|NCT00276731|DRUG|vincristine sulfate|
219488479|NCT00276731|PROCEDURE|conventional surgery|
219488480|NCT00276731|PROCEDURE|neoadjuvant therapy|
219488481|NCT00276731|RADIATION|radiation therapy|
219488482|NCT01094873|BIOLOGICAL|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
219488483|NCT01094873|BIOLOGICAL|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
219600522|NCT05006547|OTHER|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
219600523|NCT05706883|PROCEDURE|Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes|Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
219488484|NCT03851731|DRUG|Naltrexone|Intranasal spray
219488485|NCT03851731|DRUG|Naloxone|Intranasal spray
219488486|NCT03851731|DRUG|Naltrexol|Intranasal spray
219488487|NCT02832882|PROCEDURE|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
219488488|NCT02832882|PROCEDURE|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
219488489|NCT04264663|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
219488490|NCT04264663|DRUG|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
219488491|NCT02808663|BIOLOGICAL|fecal calprotectin concentration|
219488492|NCT02808663|BIOLOGICAL|blood collection|
219488493|NCT05675384|DEVICE|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
219488494|NCT05675384|DEVICE|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
219488495|NCT02941237|DEVICE|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
219488496|NCT04498156|OTHER|No intervention|No intervention, observational study
219488497|NCT00926653|DRUG|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
219488498|NCT02306473|DRUG|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
219488499|NCT06004076|OTHER|Release of upper track of deep front fascial line|I will work on upper track of deep front fascial line, I will make release to diaphragm,mediastinum,scalene muscles, scalene fascia,Fascia endothoracic, transversus thoracis,Infrahyoid muscles, fascia pretracheal and Suprahyoid muscles.
219488500|NCT06004076|OTHER|Corrective exercises for upper crossed syndrome|strength for scapular muscles and deep neck flexor
219488501|NCT04858074|DRUG|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
219488502|NCT02007369|BEHAVIORAL|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
219488503|NCT02007369|BEHAVIORAL|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
219488504|NCT01380860|PROCEDURE|Colostomy with mesh implantation|Colostomy with mesh implantation
219488505|NCT01380860|PROCEDURE|Simple colostomy|Colostomy with no mesh implantation.
219488506|NCT01573494|OTHER|Sampling of blood|7,5 ml of blood
219488507|NCT03569020|OTHER|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
219488508|NCT05472857|BIOLOGICAL|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
219488509|NCT06310473|DRUG|Cadonilimab|10mg/kg intravenous (IV) every 3 weeks ;
219488510|NCT06310473|DRUG|Oxaliplatin|130mg/m², iv drip for 2h, d1, q3w;
219488511|NCT06310473|DRUG|Capecitabine|1000mg/m² po, Bid, d1-14, q3w ;
219488512|NCT02428231|DRUG|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
219488513|NCT04911673|BEHAVIORAL|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
219488514|NCT04911673|DIETARY_SUPPLEMENT|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
219488515|NCT02830230|DRUG|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
219488516|NCT02277639|DEVICE|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
219488517|NCT04052074|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
219488518|NCT04052074|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
219488519|NCT05538169|DEVICE|low-level laser diode (Pioon Laser)|"Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session."
219488520|NCT00470119|BEHAVIORAL|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
219488521|NCT00470119|BEHAVIORAL|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
219488522|NCT01784419|DRUG|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
219488523|NCT01784419|DRUG|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
219488524|NCT06539455|DRUG|standard anti-TB treatment|standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
219488525|NCT06286410|OTHER|Bespoke glasses prescription worn during amblyopia treatment.|The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
219488526|NCT04090684|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
219488527|NCT00944008|DRUG|DepoCyte|
219600524|NCT05706883|PROCEDURE|Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes|Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
219600525|NCT05327673|OTHER|questionnaire|"* quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire"
219600526|NCT00482586|OTHER|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
219600527|NCT00482586|OTHER|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
219600528|NCT00482586|PROCEDURE|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
219600529|NCT02933255|BIOLOGICAL|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
219600530|NCT02933255|DRUG|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
219199932|NCT06861556|PROCEDURE|Ultrasound-guided Quadratus Lumborum block with 0.2ml/kg bupivacaine 0.25%|The patient was laid in a lateral decubitus position. The operator applied the probe transversally on the iliac crest directing the indicator to display the back muscles encompassed by the thoracolumbar fascia (TLF).The intended image was spotted by the emergence of the transverse process L4, delimiting the stem of a shamrock-like shape. Quadratus lumborum (QL) muscle represented the upper leaf of the shamrock, and psoas major (PM) and erector spinae (ES) stood respectively for the anterior and posterior leaves. The needle was inserted in plane from the postero-median lumbar wall directed antero-laterally with tip aiming at the posterior border of the QL muscle adjacent to the ES muscles. Pop detection indicated the middle TLF where the local anesthetic would spread, homogenous and resistance-free
219488528|NCT05134259|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
219488529|NCT01462552|DRUG|Lapatanib|Prescription of lapatinib (Tykerb)
219488530|NCT00624975|BIOLOGICAL|Peru-15 Vaccine|up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
219488531|NCT00624975|BIOLOGICAL|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
219488532|NCT00637052|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
219488533|NCT05539599|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
219488534|NCT02010970|DRUG|Group 1 AZD3293|AZD3293 oral solution
219488535|NCT02010970|DRUG|Group 2 AZD3293|AZD3293 oral solution
219488536|NCT02010970|DRUG|Group 3 AZD3293|AZD3293 oral solution
219488537|NCT02010970|DRUG|Group 1 Itraconazole|itraconazole capsule
219488538|NCT02010970|DRUG|Group 2 Diltiazem|Diltiazem ER tablet
219488539|NCT02010970|DRUG|Group 3 Midazolam|midazolam syrup
219488540|NCT01598415|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
219488541|NCT01598415|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
219488542|NCT01794156|BEHAVIORAL|Cognitive behavior therapy|
219488543|NCT01794156|BEHAVIORAL|Mindfulness-based stress reduction|
219488544|NCT01794156|BEHAVIORAL|Inference-based therapy|
219488545|NCT01298154|OTHER|Dietary intervention|Dietary treatments with beverages
219488546|NCT02253654|DRUG|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
219488547|NCT02751086|PROCEDURE|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
219488548|NCT02751086|PROCEDURE|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
219199933|NCT04490109|BIOLOGICAL|B244|B244 suspension
219199934|NCT04490109|BIOLOGICAL|Vehicle|Vehicle suspension
219199935|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
219488549|NCT01249391|DEVICE|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
219488550|NCT02486471|PROCEDURE|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
219488551|NCT02486471|OTHER|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
219488552|NCT00975273|BEHAVIORAL|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
219488553|NCT00975273|BEHAVIORAL|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
219488554|NCT00552227|DRUG|ruboxistaurin|oral 32 mg daily
219488555|NCT00552227|OTHER|placebo|placebo
219488556|NCT04693182|OTHER|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
219488557|NCT00069160|DRUG|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
219488558|NCT00069160|DRUG|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
219488559|NCT00069160|OTHER|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
219488560|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
219488561|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
219488562|NCT02962531|DRUG|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
219488563|NCT05351073|DRUG|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
219488564|NCT02615873|DRUG|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
219488565|NCT00149552|DIETARY_SUPPLEMENT|zinc|supplementation with zinc gluconate
219488566|NCT01767545|DRUG|Dexamethasone implant|
219488567|NCT01767545|DRUG|Bevacizumab|
218869753|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
219488568|NCT04507529|OTHER|Peer-mentoring|Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
219488569|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|600 IU daily oral supplementation
219488570|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU supplementation bi-monthly
219488571|NCT01392586|PROCEDURE|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
219488572|NCT01392586|OTHER|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
219488573|NCT01470586|PROCEDURE|Surgery for colorectal cancer|Surgical resection of colorectal cancer
219488574|NCT02034227|DRUG|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
219488575|NCT03371680|DRUG|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
219488576|NCT06362616|RADIATION|Preoperative accelerated partial breast irradiation|Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
219488577|NCT06362616|PROCEDURE|Breast conserving surgery|Patients will be treated with breast conserving surgery.
219488578|NCT06362616|PROCEDURE|Sentinel node procedure|Patients will undergo a (repeat) sentinel node procedure.
219488579|NCT06362616|PROCEDURE|Biopsy track removal|The biopsy track will be surgically removed.
219488580|NCT00709475|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219488581|NCT06527846|DRUG|JARDIANCE®|JARDIANCE®
219488582|NCT05210998|OTHER|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
218869754|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
219488583|NCT05210998|OTHER|Gradual Aerobic exercise training|Aerobic exercise Group
219488584|NCT04127682|OTHER|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
219488585|NCT05949931|DRUG|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
219488586|NCT05949931|DRUG|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
219488587|NCT02691312|DEVICE|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
219488588|NCT00871065|DRUG|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
219488589|NCT00480363|PROCEDURE|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
219488590|NCT00854386|DRUG|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
219488591|NCT00854386|DRUG|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
219488592|NCT05451134|OTHER|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
218869755|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
218869756|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
218869757|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
218869758|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
219199936|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
219488593|NCT06537024|PROCEDURE|RTSA|
219488594|NCT01835808|DEVICE|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
219488595|NCT00765999|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
219488596|NCT01226615|DRUG|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
219488597|NCT01226615|DRUG|Placebo|Two placebo capsules taken once a day for four months.
219488598|NCT01738009|OTHER|Induction of flow limitation|
219488599|NCT06515340|OTHER|Allulose Dose 1|5 gram consumed orally
219488600|NCT06515340|OTHER|Allulose Dose 2|10 gram consumed orally
219488601|NCT06515340|OTHER|Allulose Dose 3|20 gram consumed orally
218869759|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
218869760|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
218869761|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
218869762|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
218869763|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
218869764|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
218869765|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
218869766|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
218869767|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
218869768|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
219488602|NCT05492019|DRUG|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
219488603|NCT05492019|DRUG|Placebo|Oral placebo identical to Doxycycline
219488604|NCT03945760|DRUG|Baricitinib|Baricitinib 2 mg
219488605|NCT03945760|DRUG|Placebo|Placebo
219488606|NCT05027373|DRUG|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
218869769|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
218869770|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
218869771|NCT00601913|DRUG|erlotinib hydrochloride|
218869772|NCT00601913|GENETIC|protein analysis|
218869773|NCT00601913|GENETIC|western blotting|
218869774|NCT00601913|OTHER|immunohistochemistry staining method|
218869775|NCT00601913|OTHER|laboratory biomarker analysis|
218869776|NCT00601913|OTHER|liquid chromatography|
218869777|NCT00601913|OTHER|mass spectrometry|
219488607|NCT05027373|DRUG|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
219488608|NCT00148473|DRUG|Misoprostol|
219488609|NCT01480882|PROCEDURE|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
219488610|NCT01480882|DEVICE|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
219488611|NCT01048268|DRUG|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
219488612|NCT01048268|DRUG|Placebo|copy GIP infusion rates
219488613|NCT00923494|DRUG|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
219488614|NCT00923494|DRUG|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
219488615|NCT00923494|DRUG|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
219600531|NCT02933255|PROCEDURE|Prostatectomy|Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
219600532|NCT02933255|PROCEDURE|Biopsy|A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
219600533|NCT02933255|DRUG|Tylenol|Participants who experience aches or fever after vaccination may take Tylenol as directed.
219600534|NCT05251610|DRUG|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
219600535|NCT05251610|DRUG|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
219600536|NCT00368017|DRUG|pioglitazone|30 mg once a day for 12 weeks
219600537|NCT00368017|DRUG|placebo|1 pill once a day for 12 weeks
219600538|NCT03005912|DEVICE|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
219600539|NCT03005912|DEVICE|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
219600540|NCT03005912|DEVICE|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
219600541|NCT03005912|DEVICE|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
219488616|NCT06156631|BEHAVIORAL|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
218869778|NCT00601913|PROCEDURE|neoadjuvant therapy|
218869779|NCT00601913|PROCEDURE|therapeutic conventional surgery|
218869780|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
219488617|NCT01410747|DRUG|Tacrolimus|oral
219488618|NCT04938063|OTHER|Assessing the correlation between Functional Impairment and Parenting Stress|Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
219488619|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
219600542|NCT01824043|DRUG|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
219600543|NCT00758966|DRUG|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
218869781|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
218869782|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
218869783|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
218869784|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
218869785|NCT02514005|OTHER|Manual therapy|\- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
218869786|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
218869787|NCT02955459|DRUG|VNRX-5133|
218869788|NCT02955459|DRUG|Placebo|
218869789|NCT04028466|DRUG|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
218869790|NCT04028466|DRUG|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
218869791|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
218869792|NCT02668029|DRUG|medical air|Placebo
219600544|NCT00758966|DRUG|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
219600545|NCT00758966|DRUG|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
219600546|NCT00481403|BEHAVIORAL|Microarray analysis|Microarray analysis
219600547|NCT00481403|BEHAVIORAL|Microarray|Microarray
219600548|NCT03387566|DRUG|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
219600549|NCT04875936|BEHAVIORAL|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
219600550|NCT04875936|BEHAVIORAL|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
218869793|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
218869794|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
219488620|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
219488621|NCT00490399|DRUG|gemcitabine|
219488622|NCT00490399|DRUG|cisplatin|
219488623|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
219488624|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
219488625|NCT03323359|DEVICE|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
219488626|NCT03323359|PROCEDURE|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
219488627|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
219488628|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
219488629|NCT06540820|DIAGNOSTIC_TEST|Dexa or Biompedance analysis with clinical and biochemical evaluations|All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
219488630|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
219488631|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
219488632|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
219488633|NCT05559242|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
219488634|NCT04701658|DRUG|Bamlanivimab|Administered intravenously.
219488635|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
219488636|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
219488637|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
219488638|NCT02099331|DRUG|Melatonin|
219488639|NCT02099331|DRUG|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
219488640|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
219488641|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
219488642|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
219488643|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
219488644|NCT02379650|DRUG|Hydroxychloroquine (HCQ)|
219488645|NCT02379650|DRUG|Placebo|
219488646|NCT06701253|DIAGNOSTIC_TEST|point of care ultrasound|Point of care ultrasound for upper airway evaluation.
218869795|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
218869796|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
218869797|NCT03247959|BEHAVIORAL|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
218869798|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
218869799|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
218869800|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
219600551|NCT03513133|BEHAVIORAL|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
219488647|NCT06336174|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
219488648|NCT06336174|PROCEDURE|Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
219488649|NCT03127943|DRUG|Lidocaine|Efficacy for mandibular molar and canine anesthesia
219488650|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
219488651|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
219488652|NCT02368119|BIOLOGICAL|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
219488653|NCT02368119|OTHER|Placebo|IM injection injection of Phosphate Buffered Saline
219488654|NCT06562335|OTHER|Booster|See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
219488655|NCT02280915|OTHER|Savoury food product|
219488656|NCT02977494|DRUG|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
219488657|NCT02977494|DRUG|Bortezomib|
219488658|NCT02977494|DRUG|Dexamethasone|
219488659|NCT02519582|DRUG|Niclosamide|2 g per day orally
219488660|NCT00295529|BEHAVIORAL|Multifaceted educational intervention|Educational materials available at end of study
219488661|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
219488662|NCT02494583|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
219488663|NCT02494583|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
219488664|NCT02494583|DRUG|5-FU|5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
219488665|NCT02494583|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
219488666|NCT02494583|DRUG|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
219488667|NCT04916067|DEVICE|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
219488668|NCT00898742|GENETIC|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
219600552|NCT03166137|DEVICE|Carbon dioxide laser|Radiation by carbon dioxide laser
219600553|NCT03166137|DEVICE|Cryotherapy|Device using cooling effect
219600554|NCT02862561|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
218869801|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
218869802|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
218869803|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
218869804|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
218869805|NCT01471210|DRUG|Urelumab (BMS-663513)|
218869806|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
218869807|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
218869808|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
219488669|NCT00898742|GENETIC|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
219488670|NCT00898742|OTHER|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
219488671|NCT01844869|DRUG|omacetaxine mepesuccinate|
219488672|NCT02802007|DEVICE|Elipse Intragastric Balloon|
219488673|NCT05443009|DRUG|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
219488674|NCT05443009|DRUG|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
219488675|NCT05988411|DEVICE|Renal Denervation|Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
218869809|NCT03316950|DEVICE|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
218869810|NCT03316950|DEVICE|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
218869811|NCT03316950|DEVICE|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
218869812|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
218869813|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
219199937|NCT06614205|DIAGNOSTIC_TEST|tumoral dosimetry by scintigraphy|The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
219199938|NCT04791579|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic
219199939|NCT04791579|DRUG|Placebo|Placebo pill
219199940|NCT06779825|COMBINATION_PRODUCT|fMRI Neurofeedback attention task|Neurofeedback is an attentive task where participants are shown their real-time brain signals while in the scanner with the use of a representation, such as a rocket moving towards a portal. Participants are able to increase this brain signal by more purposefully engaging certain brain regions, and this is reflected in the representation that they see. Ultimately, this study is interested in whether neurofeedback can replicate the effects of stimulant medication in ADHD.
219199941|NCT04323397|DEVICE|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
219199942|NCT05440084|PROCEDURE|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
219488676|NCT05988411|DEVICE|Catheter Ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
219488677|NCT02232685|DEVICE|18F-Choline PET/CT|18F-Choline PET/CT
219488678|NCT04832178|DIETARY_SUPPLEMENT|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~* S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~* Betaine hydrochloride 250 mg~* Vitamin C 80 mg~* Vitamin B1 1.1 mg~* Vitamin B2 1.4 mg~* Vitamin B6 1.4 mg~* Vitamin B12 2,5 µg~* Folic Acid 200 µg~* Selenium 37 µg"
219488679|NCT04832178|OTHER|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
219488680|NCT02528630|OTHER|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
219488681|NCT02528630|OTHER|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
219488682|NCT03386071|DRUG|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
219488683|NCT05807347|DRUG|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
219488684|NCT01920074|DRUG|Nitroglycerin Ointment 0.4%|
219600555|NCT02862561|BIOLOGICAL|Precision Cells|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
219600556|NCT03645707|BEHAVIORAL|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
219600557|NCT01410656|BEHAVIORAL|Telephone Implementation Intention|Telephone implementation intention counseling
219600558|NCT01410656|BEHAVIORAL|Self-completed implementation intention|Self-administered implementation intention intervention
219600559|NCT05753878|DRUG|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
219600560|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
219488685|NCT01210885|BIOLOGICAL|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
219488686|NCT04004273|BEHAVIORAL|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
219488687|NCT05409599|OTHER|Exercises|Exercises
219600561|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
219600562|NCT05753878|DRUG|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
219600563|NCT05753878|OTHER|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
219600564|NCT00683345|DRUG|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
219600565|NCT00683345|DRUG|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
219600566|NCT00015873|DRUG|asparaginase|
219600567|NCT00015873|DRUG|cytarabine|
219488688|NCT01419873|DRUG|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
219488689|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
219600568|NCT00015873|DRUG|mercaptopurine|
219600569|NCT00015873|DRUG|methotrexate|
219600570|NCT00015873|DRUG|prednisolone|
219600571|NCT00015873|DRUG|vincristine sulfate|
219600572|NCT04570787|PROCEDURE|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
219600573|NCT05258383|OTHER|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
219600574|NCT00589927|DRUG|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
219600575|NCT00589927|DRUG|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
219613615|NCT05227963|OTHER|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
219613616|NCT00243412|DRUG|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
219488690|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
219488691|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
219488692|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
219488693|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
219488694|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
219488695|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
219488696|NCT01280305|DRUG|placebo|Placebo bid
219488697|NCT00101374|DRUG|Leflunomide|
219488698|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
219488699|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
219600576|NCT04841005|OTHER|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
219600577|NCT04841005|OTHER|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
219600578|NCT03608527|BEHAVIORAL|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
219600579|NCT03608527|BEHAVIORAL|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
219600580|NCT01827865|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
219600581|NCT01827865|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
219600582|NCT05528601|BEHAVIORAL|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
219600583|NCT04479644|DRUG|BRII-198|BRII-198 given intravenously
219600584|NCT04479644|DRUG|Placebo|Placebo given intravenously
219600585|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3|50,000 IU VD3 / week for 8 weeks
218869814|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
218869815|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
218869816|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
218869817|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
218869818|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
219488700|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
219488701|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
219488702|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
219488703|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
219488704|NCT02180659|DRUG|sublingual buprenorphine tablets|
219488705|NCT02180659|DRUG|Buprenorphine implant|
219488706|NCT02180659|DRUG|placebo implants|
219488707|NCT02180659|DRUG|sublingual placebo tablets|
219488708|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
219488709|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
219488710|NCT04265209|DRUG|SPECT|\[123I\]-FP-CIT SPECT imaging procedure
219488711|NCT04265209|DRUG|PET|\[18F\] LBT-999 PET imaging procedure
219488712|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
219488713|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
219488714|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
219488715|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
219488716|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
219488717|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
219488718|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
219488719|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
219488720|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
219488721|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
219488722|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
219488723|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
219488724|NCT05972954|DRUG|OMT-28|once daily
219488725|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
219488726|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
219488727|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
218869819|NCT02133976|BEHAVIORAL|cognitive therapy|
219488728|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
219488729|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
219488730|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
219488731|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
219488732|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
219488733|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
219488734|NCT05153590|DRUG|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
219488735|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
219488736|NCT02959554|DRUG|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
219488737|NCT02959554|DRUG|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
219600586|NCT04005612|DIETARY_SUPPLEMENT|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
219600587|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
219600588|NCT04005612|OTHER|control|no intervention
219600589|NCT01159080|DRUG|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
219600590|NCT01159080|DRUG|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
219600591|NCT02759692|DEVICE|TEST Contact Lens|
219600592|NCT02759692|DEVICE|CONTROL Contact Lens|
219600593|NCT06570187|DRUG|Dexmedetomidine|Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
219600594|NCT06570187|DRUG|Propofol|Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
219600595|NCT02217254|PROCEDURE|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
219600596|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
219600597|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
219600598|NCT04169945|OTHER|Ultrasonic instrumentation|Full mouth root surface debridement
219600599|NCT04169945|OTHER|Air polishing with erythritol powder|Air flow PLUS
219600600|NCT06093230|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
219600601|NCT05871034|PROCEDURE|phacoemulsification|cataract extraction
219600602|NCT05185765|OTHER|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
219600603|NCT00679133|DRUG|MGCD265|Oral daily administration; 7 days on / 7 days off
219600604|NCT03763006|PROCEDURE|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
219600605|NCT00451178|DRUG|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
219600606|NCT00451178|DRUG|rituximab|375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
218869820|NCT02133976|BEHAVIORAL|mindfulness training|
218869821|NCT02133976|BEHAVIORAL|behavioral therapy|
218869822|NCT02133976|OTHER|treatment as usual|
218869823|NCT02087722|DRUG|KI1001|
218869824|NCT02087722|DRUG|Placebo|
218869825|NCT04545463|DIETARY_SUPPLEMENT|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
218869826|NCT04545463|DIETARY_SUPPLEMENT|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
218869827|NCT04545463|DIETARY_SUPPLEMENT|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
219488738|NCT02959554|DRUG|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
219488739|NCT01158976|DIETARY_SUPPLEMENT|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
219488740|NCT01158976|OTHER|Placebo|soybean oils with strawberry flavoring
219488741|NCT03147001|OTHER|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
219488742|NCT03147001|OTHER|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
219488743|NCT00769431|OTHER|educational intervention|
219488744|NCT00769431|OTHER|study of socioeconomic and demographic variables|
219488745|NCT03422796|DRUG|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219488746|NCT03422796|DRUG|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219488747|NCT03422796|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219488748|NCT02611531|BEHAVIORAL|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
219488749|NCT02611531|BEHAVIORAL|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
218869828|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
219199943|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
219199944|NCT06350539|OTHER|Biological Sample Collection|Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
219488750|NCT00481871|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
219488751|NCT00481871|DRUG|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
219488752|NCT00481871|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
219488753|NCT00481871|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
219488754|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
219488755|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
219488756|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
219488757|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
219488758|NCT01411475|OTHER|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
219488759|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
219600607|NCT00451178|DRUG|cyclophosphamide|750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
219600608|NCT00451178|DRUG|doxorubicin|50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
219600609|NCT00451178|DRUG|vincristine|1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
219600610|NCT00451178|DRUG|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
219600611|NCT00732485|DRUG|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
219600612|NCT00732485|DRUG|placebo|Placebo, sugar pill, from admission to 6 months post burn
218869829|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
218869830|NCT00678834|DIETARY_SUPPLEMENT|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
219600613|NCT00050245|DRUG|Rituximab|
219613617|NCT00243412|DRUG|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
219613618|NCT00243412|DRUG|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
219488760|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
219488761|NCT04292756|PROCEDURE|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
219488762|NCT04292756|PROCEDURE|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
219488763|NCT04292756|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
219488764|NCT04292756|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
219488765|NCT04292756|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
219488766|NCT04292756|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
219488767|NCT04292756|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
219488768|NCT04292756|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
219488769|NCT04292756|DIAGNOSTIC_TEST|IOP|Ophthalmic examination
219488770|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
219488771|NCT01395693|DEVICE|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
219488772|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
218869831|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
219488773|NCT03311386|DRUG|Actilyse|thrombolytic therapy
219488774|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
219488775|NCT06017856|OTHER|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
219488776|NCT01807910|DRUG|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
219488777|NCT06565910|DRUG|Liposomal bupivacaine plus bupivacaine|Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.
219488778|NCT06565910|DRUG|Ropivacaine|Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.
219488779|NCT01267968|DRUG|GSK2251052|1500 mg (dosing detailed in Arm description)
219488780|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
219488781|NCT01898624|DRUG|mirabegron|oral
218869832|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
219199945|NCT06478173|BEHAVIORAL|Exercise training|Exercise training will be performed as supervised small sided soccer games (3v3 to 7v7) 3 times a week for 14 weeks. Each session will last \~1 hour. Patients allocated to soccer training will undergo a ramp-up phase consisting of walking soccer training during weeks 1 and 2, after which normal soccer training will be applied from weeks 3 to 14.
219199946|NCT06865365|DRUG|Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions|Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
219199947|NCT06865365|BEHAVIORAL|Dietologic measures and lifestyle optimization for weight loss|all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
219488782|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
219600614|NCT07059585|BEHAVIORAL|CGA|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive delirium assessment questionnaires twice daily in the hospital for a duration of up to 7 days after surgery and, up to two sensory aids if required, one pair of eyeglasses as well as frequent orientation of physical and occupational therapy. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
219600615|NCT07059585|OTHER|control|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive assessment questionnaires regarding perioperative delirium, twice daily in the hospital for a duration of up to 7 days after surgery. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
219600616|NCT05792579|PROCEDURE|stoma closure|early closure of stoma in trauma patients
218869833|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
218869834|NCT06464965|BIOLOGICAL|CB CAR-NK182|To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer
219488783|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
219488784|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
219488785|NCT01875419|DEVICE|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
219488786|NCT01875419|BEHAVIORAL|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
219488787|NCT00924573|DRUG|Metformin|oral administration
219488788|NCT00924573|DRUG|placebo|oral administration
219488789|NCT00924573|DRUG|Glimepiride (HOE490)|oral administration
219488790|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
219488791|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
219488792|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
219488793|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
219488794|NCT00991146|DRUG|canakinumab|canakinumab
219488795|NCT00403923|DIETARY_SUPPLEMENT|Lactose in water|
219488796|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
219600617|NCT02653833|DRUG|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
219600618|NCT02653833|OTHER|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
219600619|NCT03764618|DRUG|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
219600620|NCT03764618|DRUG|Placebo|Placebo
218869835|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
219600621|NCT07063238|DRUG|MK-8527|Oral administration
219600622|NCT07063238|DRUG|Moxifloxacin|Oral administration
219600623|NCT07063238|DRUG|Placebo|Oral administration
219600624|NCT07069517|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
219600625|NCT07069517|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
219600626|NCT07069517|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
219600627|NCT07069517|BEHAVIORAL|Sleep Hygiene|Involves reviewing sleep diary data, sleep education, and reviewing and discussing sleep hygiene practices.
219600628|NCT07133932|DEVICE|Transcutaneous electrical phrenic nerve stimulation|Non-invasive transcutaneous electrical phrenic nerve stimulation which can cause explicit contraction of the diaphragm, and the stimulation current may be set to 5-30mA depending on the participant's condition.
218869836|NCT04382417|OTHER|Observational study|Not required
218869837|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
218869838|NCT04890015|PROCEDURE|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
218869839|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
218869840|NCT03665116|DIETARY_SUPPLEMENT|L-arginine|L-arginine capsule
219488797|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
219488798|NCT02504463|DRUG|Samidorphan IV|Single IV administration
219488799|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
219488800|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
219488801|NCT06499935|OTHER|Rigid Taping|It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
219488802|NCT06499935|OTHER|Kinesio-Taping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
219488803|NCT06499935|OTHER|Sham Taping|Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
219488804|NCT05665712|PROCEDURE|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
219488805|NCT05031286|OTHER|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
219488806|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
219488807|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
219488808|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
219488809|NCT06701799|PROCEDURE|CAF+ L-PRF 1 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
219522501|NCT01975207|BEHAVIORAL|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
219522502|NCT01308593|DEVICE|Juvederm XC|Filler
219522503|NCT01308593|DRUG|Botox|26 units dosed one time
219522504|NCT01781637|DRUG|Omalizumab|subcutaneous injection
219600629|NCT07133932|DEVICE|Sham (No Treatment)|The stimulation current is set to 0.
219600630|NCT07133347|DEVICE|Brain computer interface controlled functional electrical stimulation therapy integrated with social media|The investigators created an app interface (FlickTok) to have brain computer interface (g.tech gel 16 channel EEG headset) controlled functional electrical stimulation (NeuroTrac Electrical Stimulator) integrated with social media (Instagram reels or YouTube Shorts)
219600631|NCT07133984|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI, also known as cardiac magnetic resonance imaging, is a non-invasive imaging technique that uses strong magnetic fields and radio waves to produce detailed pictures of the heart and its surrounding structures
219600632|NCT07134270|PROCEDURE|MDRO Rectal Screening|Repeated rectal swab collection for screening digestive colonization with multidrug-resistant organisms (MDRO), performed at admission (or within 14 days prior), on day 7, weekly during hospitalization, and at discharge.
219600633|NCT07134270|OTHER|30-Day Telephone Follow-Up|Structured phone interview conducted 30 days post-discharge, using a standardized questionnaire assessing new infections, rehospitalizations, antibiotic use, and self-rated health status.
219488810|NCT06701799|PROCEDURE|CAF+ L-PRF 2 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
219488811|NCT06650241|OTHER|Behavioral therapy|
219488812|NCT06650241|OTHER|Lip Bumper Therapy|
219488813|NCT06650241|OTHER|Modified Twin-Block Therapy|
219488814|NCT01923961|PROCEDURE|HDF NaCl|
219488815|NCT01923961|PROCEDURE|Hemodialysis|
219488816|NCT01923961|PROCEDURE|Standard Predilution Hemodiafiltration|
219488817|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
219488818|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
219488819|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
219488820|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
219488821|NCT06117566|DRUG|WX390|WX390 tablet, once a day
219488822|NCT06117566|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
219488823|NCT02362646|BIOLOGICAL|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
219488824|NCT02362646|DRUG|Control Solution|
219488825|NCT00668369|PROCEDURE|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
219488826|NCT00865306|BEHAVIORAL|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
219488827|NCT05395702|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
219488828|NCT06701214|OTHER|Blood collection|Blood will be taken from participants already undergoing blood collection
219488829|NCT06701214|OTHER|Saliva collection|Undergo saliva collection
219488830|NCT06701214|OTHER|Bone marrow collection|Bone marrow will be taken from participants already undergoing bone marrow collection
219488831|NCT00141479|DRUG|Bifeprunox|
218869841|NCT06398717|PROCEDURE|adductor canal block|"group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound"
218869842|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
218869843|NCT06245538|BEHAVIORAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
218869844|NCT06245538|BEHAVIORAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
218869845|NCT06245538|BEHAVIORAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
218869846|NCT03782441|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
218869847|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
218869848|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
218869849|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
218869850|NCT02335424|BIOLOGICAL|pembrolizumab|IV infusion
219488832|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
219488833|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
219488834|NCT00397904|BIOLOGICAL|cetuximab|
219488835|NCT00397904|DRUG|cisplatin|
219488836|NCT00397904|DRUG|irinotecan hydrochloride|
219488837|NCT00397904|OTHER|immunohistochemistry staining method|
219488838|NCT00397904|OTHER|laboratory biomarker analysis|
218869851|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
219488839|NCT00397904|PROCEDURE|biopsy|
219488840|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
219488841|NCT02058368|DRUG|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
219600634|NCT07134582|OTHER|Hippotherapy 1x/week|This group will perform hippotherapy once per week for 12 weeks
219600635|NCT07134582|OTHER|Hippotherapy 2x/week|This group will perform hippotherapy twice per week for 12 weeks
219600636|NCT07133594|OTHER|RTEQ (RadioTherapy Experience Questionnaire) in French|Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
219600637|NCT07133594|OTHER|EORTC PATSAT-C33 questionnaire|Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
219600638|NCT07078630|DIETARY_SUPPLEMENT|Placebo|Participants instructed to intake the placebo capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
219600639|NCT07078630|DIETARY_SUPPLEMENT|HydroCurc®|Participants instructed to intake the HydroCurc® capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
219600640|NCT07078630|DIETARY_SUPPLEMENT|Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron|Participants instructed to intake the ferrous sulphate tablet along with the HydroCurc® or the placebo together, preferably and separated from food, tea or coffee, at the same time of the day.
219600641|NCT06898593|BEHAVIORAL|Collaborative care model with clinical decision support system|A new patient-level clinical decision support system (CDSS) will include enhancing the existing pre-visit questionnaire to capture patient-reported goals and concerns, and displaying pre-visit questionnaire responses and clinical information within a patient-level dashboard in the electronic health record (EHR) for use by clinicians and patients.
219600642|NCT06898593|BEHAVIORAL|Collaborative care model|Collaborative care model of integrated behavioral health and primary care.
219600643|NCT07081022|DRUG|JS203 in combination with gemcitabine and oxaliplatin|Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
219600644|NCT07081022|DRUG|JS203 in combination with ifosfamide, carboplatin and etoposide|Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
219600645|NCT07081022|DRUG|JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
218869852|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
218869853|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
219488842|NCT02058368|DRUG|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
219488843|NCT02058368|DRUG|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
219488844|NCT02058368|DRUG|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
219488845|NCT02591316|OTHER|no intervention|
219600646|NCT07081022|DRUG|JS203 combined with lenalidomide|lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
219613619|NCT00243412|DRUG|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
218869854|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
219488846|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
219488847|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
219488848|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
219488849|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
219488850|NCT02656875|DRUG|TRV130|
219488851|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
219488852|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
219488853|NCT02292732|DRUG|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
219488854|NCT02292732|DRUG|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
219488855|NCT02292732|DRUG|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
219488856|NCT02292732|DRUG|Placebo|Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
219488857|NCT06354959|BEHAVIORAL|Prehabilitation|8-week community based prehab program
219488858|NCT05945147|DRUG|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
219488859|NCT05945147|DRUG|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
219488860|NCT05945147|DRUG|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
219488861|NCT06564467|DRUG|JMT202|subcutaneous injection
219488862|NCT06564467|DRUG|Placrbo|subcutaneous injection
219488863|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
219488864|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
218869855|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
218869856|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
218869857|NCT04322825|DEVICE|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
219488865|NCT02181842|DRUG|Pioglitazone|Pioglitazone tablets
219488866|NCT01217567|PROCEDURE|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
219488867|NCT01217567|PROCEDURE|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
219488868|NCT05719129|BEHAVIORAL|Date With Destiny (DWD) Seminar|6 days of immersive seminar
219488869|NCT00559975|BIOLOGICAL|Subunit influenza vaccine|0.5 mL single dose vaccine
219488870|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
219488871|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
219488872|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
219488873|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
219488874|NCT05072145|OTHER|Telemedicine|Receiving care in a tele-ED hospital
219488875|NCT03681275|DRUG|Tofacitinib 10 MG [Xeljanz]|administered twice daily for two days
218869858|NCT01779635|DEVICE|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
219488876|NCT03681275|DRUG|Placebo to match Tofacitinib|administered twice daily for two days
219488877|NCT04824300|PROCEDURE|erector spinae block|Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
219488878|NCT01652872|BIOLOGICAL|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
219488879|NCT01652872|OTHER|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
219488880|NCT02184169|DEVICE|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
219488881|NCT02184169|DEVICE|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
219488882|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
219488883|NCT00719758|DRUG|TRK-100STP (BERASUS LA)|oral
219488884|NCT00719758|DRUG|AST-120 (Kremezin®)|oral
219488885|NCT02790372|OTHER|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
219488886|NCT06702358|OTHER|Potential Therapeutic Implications of laser Acupoints on Visceral Fat and Hormonal Changes in Post-menopausal Women|Application of laser acupuncture ( E M E ) on 10 acupuncture procedure for each woman which will be detected by therapist according to Acupuncture points Will stimulate St 25 (Tianshu), St 36 (Zusanli), Liv 3 (Taichong); P 6 (Neiguan), H 7 (Shenmen) for the psychical aspect of the therapy and Auriculothera- py: 55 (Shenmen) and 87 (Stomach) Each point stimulating will be Stimulation time, 30 s/point
219488887|NCT04681495|BEHAVIORAL|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
219522505|NCT01781637|DRUG|placebo|subcutaneous injection
219522506|NCT06083337|DEVICE|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
219522507|NCT00458848|DRUG|asparaginase|
219522508|NCT00458848|DRUG|daunorubicin hydrochloride|
218869859|NCT01779635|DEVICE|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
219522509|NCT00458848|DRUG|etoposide|
219522510|NCT00458848|DRUG|idarubicin|
219522511|NCT00458848|DRUG|imatinib mesylate|
219522512|NCT00458848|DRUG|mercaptopurine|
219522513|NCT00458848|DRUG|methotrexate|
219522514|NCT00458848|DRUG|methylprednisolone|
219488888|NCT03173521|BIOLOGICAL|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
219488889|NCT04160416|DRUG|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
219488890|NCT03056716|PROCEDURE|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
219488891|NCT04179123|DEVICE|Customised PAP interfaces|Customised PAP interfaces
219488892|NCT06567990|DIAGNOSTIC_TEST|Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.|"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"
219488893|NCT00713622|DRUG|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
219488894|NCT00713622|DRUG|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
219600647|NCT07081152|OTHER|Ferrous sulfate|All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1
219600648|NCT06817278|BEHAVIORAL|Adaptable IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support. The adapted IERITA intervention is tailored to the participant and can thus entail different adaptions for different participants. Adaptions can entail changes in therapist contact, what material to focus on, and how to work with the treatment. The adapted IERITA intervention is offered between week four and 12.
219600649|NCT06817278|BEHAVIORAL|Standard IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support.
219600650|NCT06817278|OTHER|Treatment as usual|Participants are free to any receive regular care (i.e., psychosocial treatment, medications, or a combination of both) as needed during the trial.
219600651|NCT07082244|PROCEDURE|Dental implant placement|Participants will have a dental implant placed at a toothless site
219600652|NCT07082244|PROCEDURE|Guided bone regeneration with collagen membrane|Participants will receive guided bone regeneration at a toothless site with bone substitute and a collagen membrane.
218869860|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
219600653|NCT07082244|PROCEDURE|Guided bone regeneration with acellular dermal matrix.|Participants will receive guided bone regeneration at a toothless site with bone substitute and an acellular dermal matrix.
219600654|NCT07080229|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
219600655|NCT07080229|DRUG|Intranasal normal saline|Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
219488895|NCT03857139|DRUG|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
218869861|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
218869862|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
219488896|NCT02542722|BEHAVIORAL|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
219488897|NCT02542722|BEHAVIORAL|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
219488898|NCT06567522|DRUG|Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%|Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
219488899|NCT01216319|DEVICE|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
219488900|NCT04529096|DRUG|LY3016859|Administered IV
219488901|NCT04529096|DRUG|Placebo|Administered IV
219488902|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
219488903|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
219488904|NCT04663711|BEHAVIORAL|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
219488905|NCT01695837|BEHAVIORAL|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
219488906|NCT04769908|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
219600656|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
219488907|NCT04769908|DRUG|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
219488908|NCT04769908|DRUG|Sintilimab|Sintilimab, IV, 200mg, q3w
219488909|NCT05663216|OTHER|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
219488910|NCT06541106|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma."
219488911|NCT00388115|PROCEDURE|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
219488912|NCT00388115|PROCEDURE|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
219488913|NCT00388115|PROCEDURE|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
219488914|NCT03087929|OTHER|Follow up|
219488915|NCT05593783|PROCEDURE|lithotripsy|lithotripsy
219488916|NCT06568978|OTHER|Assessments of respiratory parameters|respiratory muscle strength, respiratory function test
219488917|NCT05766761|BEHAVIORAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
219488918|NCT00929864|DRUG|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
219488919|NCT00929864|DRUG|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
219488920|NCT01403428|OTHER|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
219488921|NCT04234373|OTHER|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
218869863|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
218869864|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
219488922|NCT05692739|DRUG|Insulin|see arm description
219488923|NCT05692739|DRUG|Cyclosporins|see arm description
219488924|NCT05692739|DRUG|Artificial tears|see arm description
219488925|NCT01858129|DRUG|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
219488926|NCT01858129|DRUG|placebo|
219600657|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
219522515|NCT00458848|DRUG|mitoxantrone hydrochloride|
219522516|NCT00458848|DRUG|prednisone|
219522517|NCT00458848|DRUG|vincristine sulfate|
219522518|NCT00458848|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219522519|NCT00458848|PROCEDURE|autologous hematopoietic stem cell transplantation|
219522520|NCT00458848|PROCEDURE|peripheral blood stem cell transplantation|
219522521|NCT00458848|RADIATION|radiation therapy|
219522522|NCT00917657|PROCEDURE|Photorefractive keratectomy|
219522523|NCT00277381|BEHAVIORAL|Automated feedback regarding drug adherence|
219522524|NCT01483352|DEVICE|Accu-Chek DiaPort|
219522525|NCT00416481|BEHAVIORAL|quality of life questionnaires|
219522526|NCT04205942|DEVICE|Argon Plasma Jet|Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
219488927|NCT04507789|OTHER|exercise intervention|Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
218869865|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
219488928|NCT04507789|OTHER|routine radiotherapy protokol|This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
219488929|NCT02624349|DRUG|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
219488930|NCT02684669|DRUG|Naloxone|active drug infusion
219488931|NCT02684669|DRUG|Normal saline|placebo comparator
219488932|NCT05069428|DRUG|Ramelteon 8mg|administered crushed, orally at 20:30
219488933|NCT03039205|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
218869866|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
218869867|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
218869868|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
219488934|NCT03039205|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
219488935|NCT04737811|OTHER|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
219488936|NCT03178019|OTHER|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
219488937|NCT02199834|BEHAVIORAL|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
219488938|NCT02199834|BEHAVIORAL|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
219488939|NCT06373419|DEVICE|TFL|Participant undergoing bladder tumour resection that has been randomized to this arm.
219488940|NCT06373419|DEVICE|MOSES holmium laser|Participant undergoing bladder tumour resection that has been randomized to this arm.
219488941|NCT06525155|DRUG|Triptorelin Embonate|Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
219488942|NCT06525155|DRUG|Triptorelin Embonate|Treatment 2: 3.75 mg once after surgery at week-12
219488943|NCT04754919|OTHER|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
219488944|NCT04754919|OTHER|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
219488945|NCT02674074|DEVICE|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
219488946|NCT06545526|DRUG|celecoxib monotherapy|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
219488947|NCT06545526|DRUG|celecoxib and metformin combination|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
219488948|NCT06272448|OTHER|Telerehabilitation|The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation…), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
219488949|NCT03974516|DRUG|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
219613620|NCT00243412|DRUG|Rituximab|500 mg or 1000 mg IV\*2.
218869869|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
219488950|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
219488951|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
219600658|NCT05052047|OTHER|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
219600659|NCT05052047|OTHER|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
219600660|NCT02713269|PROCEDURE|Computed Tomography|Undergo CT scan
219488952|NCT06290739|PROCEDURE|lymph nodes dissection|Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
219488953|NCT03474640|BIOLOGICAL|Part A|Part A: 80, 240, and 480 mg IV every 14 days.
219600661|NCT02713269|OTHER|Quality-of-Life Assessment|Ancillary studies
219600662|NCT02713269|OTHER|Questionnaire Administration|Ancillary studies
219600663|NCT02713269|RADIATION|Stereotactic Radiosurgery|Undergo CT-guided SSRS
219600664|NCT02713269|PROCEDURE|Thermal Ablation Therapy|Undergo thermal ablation therapy
219600665|NCT06930755|DRUG|NMS-03305293|Route of administration: Oral
219488954|NCT03474640|BIOLOGICAL|Part B|Part B: 240 mg IV every 3 weeks
219600666|NCT06930755|DRUG|Topotecan|Route of administration: Intravenous
219600667|NCT05002998|DRUG|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
219600668|NCT05002998|DRUG|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
218869870|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
218869871|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
219488955|NCT06389968|DEVICE|Light stimulation|see arm description
219488956|NCT06389968|DEVICE|Sham light stimulation|see arm description
219600669|NCT06071169|OTHER|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
219600670|NCT00256399|DRUG|Alfuzosin 10 mg|
219600671|NCT01807286|DRUG|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
219600672|NCT01807286|DRUG|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
219600673|NCT01807286|DRUG|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
218869872|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
218869873|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
219488957|NCT03454672|DEVICE|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
219488958|NCT03454672|DEVICE|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
218869874|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
218869875|NCT02712424|BIOLOGICAL|DAR-901|
218869876|NCT02712424|BIOLOGICAL|Sterile saline placebo|
218869877|NCT02355951|OTHER|blood draw|
219488959|NCT06110338|DRUG|placebo|placebo iv. once.
219488960|NCT06110338|DRUG|IBI355|IBI355 iv. once.
219488961|NCT05198349|DRUG|M1069|Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
219600674|NCT01807286|BEHAVIORAL|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
218869878|NCT04033874|OTHER|kangaroo care|kangaroo care
219488962|NCT06569680|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"
219488963|NCT04175691|GENETIC|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
219488964|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
219488965|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
219488966|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
219488967|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
219488968|NCT02647632|DRUG|Grazoprevir/Elbasvir|
219488969|NCT02647632|DRUG|Sofosbuvir|
219488970|NCT02647632|DRUG|Ribavirin|
219488971|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
219488972|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
219488973|NCT00367601|DRUG|Erlotinib|Erlotinib 150 mg qd days 1-21
219488974|NCT00367601|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
219488975|NCT06542354|BEHAVIORAL|Physical exercise|Physical exercises personally scheduled consisting of daily aerobic exercise(30mins) of fast walking(≥5km) and resisitance training.
219488976|NCT06542354|DIETARY_SUPPLEMENT|Nutrition supplement|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Oral nutrition supplement (ENSURE) is provided daily seperated in 2 doses
219488977|NCT06542354|BEHAVIORAL|Mental support|Relaxation exercise and psychological counselling delivered by weekly telephone follow-up
219488978|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
219488979|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
219488980|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
219488981|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
218869879|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
219488982|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
219488983|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
218869880|NCT04033874|OTHER|white noise listening|white noise listening
218869881|NCT04033874|OTHER|ambient sound listening|ambient sound listening
219488984|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
219488985|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
219488986|NCT03004417|DRUG|CHF 6001 Dose1|CHF 6001 plus placebo
219488987|NCT03004417|DRUG|CHF 6001 Dose2|CHF 6001 only (high dose)
219488988|NCT03004417|OTHER|Placebo|Placebo only
219488989|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
219488990|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
219488991|NCT04483570|PROCEDURE|Redo-tethering operation|
218869882|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
218869883|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
218869884|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
218869885|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
219488992|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
219488993|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
219488994|NCT00458016|DRUG|MB07803|Daily oral administration
218869886|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
219488995|NCT00458016|DRUG|Placebo|Daily oral administration
219488996|NCT05179434|PROCEDURE|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
219488997|NCT05179434|PROCEDURE|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
219488998|NCT05410769|BEHAVIORAL|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
219488999|NCT02804191|DRUG|LO2A|eye drop solution.
219489000|NCT02804191|DRUG|Saline|Placebo
219489001|NCT00629668|GENETIC|TNF-alpha and HBV genotype|
219489002|NCT00629668|OTHER|TNF-alpha and HBV genotypes|
219489003|NCT05496595|DRUG|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
219489004|NCT06567158|OTHER|Moderate carbohydrate diet|During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.
219489005|NCT06567158|OTHER|Traditional diet|During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
219489006|NCT03757741|DIAGNOSTIC_TEST|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
219489007|NCT03757741|DIAGNOSTIC_TEST|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
219489008|NCT01058876|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
219489009|NCT03735238|OTHER|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
219489010|NCT03890861|BEHAVIORAL|Physical activity|Promotion of physical activity to the current federal physical activity guidelines.
219489011|NCT03890861|BEHAVIORAL|Successful Aging|Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
218869887|NCT02713867|BIOLOGICAL|Nivolumab|
218869888|NCT01647334|RADIATION|Adaptive radiotherapy|
218869889|NCT05729984|BEHAVIORAL|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
218869890|NCT05729984|BEHAVIORAL|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
219489012|NCT04730973|DRUG|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
219489013|NCT04730973|OTHER|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
219489014|NCT02810496|GENETIC|blood collection for mutation characterization|
219489015|NCT03393312|DEVICE|Transcranial direct current stimulation (tDCS)|Electric current
219489016|NCT05923541|DRUG|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
219489017|NCT04288323|DRUG|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
219489018|NCT02988310|OTHER|No intervention|
219489019|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
218869891|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
218869892|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
219199948|NCT06865378|PROCEDURE|Carbon dioxide (CO2) gas insufflation|Artificial pneumoperitoneum created by the Trendelenburg position and carbon dioxide (CO2) insufflation, which is widely used in laparoscopic procedures, frequently leads to physiological changes such as postoperative nausea and vomiting (PONV) and pain. Therefore, the currently limited usable parameters PI and PVI will be evaluated in correlation with end tidal CO2 in continuous monitoring.
219489020|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
219489021|NCT00390572|BEHAVIORAL|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
219489022|NCT05405478|DRUG|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
219489023|NCT05405478|DIAGNOSTIC_TEST|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
219489024|NCT03534830|DIAGNOSTIC_TEST|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
219489025|NCT00711165|DRUG|Placebo|2 puffs, qd
219489026|NCT00711165|DRUG|Mometasone Furoate|400 mcg, qd for 8 weeks
219489027|NCT05359341|DRUG|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
219489028|NCT05359341|DRUG|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
219489029|NCT05359341|DRUG|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
219489030|NCT05359341|DRUG|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
219489031|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
219489032|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
219600675|NCT06389682|DRUG|68Ga-NYM005 injection|he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
219600676|NCT07134816|OTHER|Cognitive and behavioral therapy for auditory hallucinations|Consists of 16 one-hour individual sessions (one session per week over a 16-week period) of cognitive behavioral therapy, divided into three types of interventions (modules) that have been independently proven to be effective in the management of auditory hallucinations.
219600677|NCT07134816|OTHER|Usual treatment|Consists of an antipsychotic medication treatment (including dosage changes and molecule changes.), regular consultation with a psychiatrist (once a month on average), and if necessary, one-off psychological support or family interventions not including specific CBT for positive symptoms
219600678|NCT07134985|OTHER|No intervention|No intervention
219600679|NCT07134569|BEHAVIORAL|VR-based motor training|Six weeks, twice per week.
219489033|NCT05576285|DIAGNOSTIC_TEST|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
219489034|NCT01242332|DRUG|Pregabalin|75 mg po 2 hrs before surgery
219489035|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
219489036|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
219489037|NCT02704299|BIOLOGICAL|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
218869893|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
219489038|NCT02383537|OTHER|Diabetes|the trial is observational with no intervention
219489039|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
219489040|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
219489041|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
219489042|NCT00823875|DRUG|control group|routine treatment
219489043|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
219489044|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
219489045|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
219489046|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
219489047|NCT00000891|DRUG|Ritonavir|
219489048|NCT00000891|DRUG|Saquinavir|
219489049|NCT00000891|DRUG|Delavirdine mesylate|
219489050|NCT00000891|DRUG|Lamivudine|
218869894|NCT03652467|DRUG|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
219489051|NCT00000891|DRUG|Stavudine|
219489052|NCT00000891|DRUG|Zidovudine|
219489053|NCT00000891|DRUG|Didanosine|
219489054|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
219489055|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
219489056|NCT02317094|OTHER|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
218869895|NCT03652467|DRUG|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
218869896|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
218869897|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
218869898|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
219199949|NCT06865261|DIETARY_SUPPLEMENT|Bioarginina C|Bioarginine®C oral vials is a dietary supplement based on L-arginine and liposomal Vitamin C that is useful for making an integrative share of L-arginine and Vitamin C. Liposomal Vitamin C is a particular type of Vitamin C produced through an innovative technology that optimizes and amplifies its absorption.
219489057|NCT02317094|DRUG|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
219489058|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
219489059|NCT02604238|DRUG|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
219489060|NCT03791515|DRUG|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
219522527|NCT04205942|DEVICE|Placebo|Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
219522528|NCT00304447|DRUG|Mylotarg|
219489061|NCT03791515|DRUG|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
218869899|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
219489062|NCT06386471|OTHER|Whole grain rye bread|Single consumption of 4.3 oz of whole grain rye bread
219489063|NCT06386471|OTHER|Refined grain rye bread|Single consumption of 4.3 oz of refined grain rye bread
219489064|NCT06381401|DRUG|bupivacaine 0.25%|superficial cervical plexus block using 10 ml of bupivacaine 0.25%
219489065|NCT06381401|DRUG|bupivacaine 0.125%|superficial cervical plexus block using 10 ml of bupivacaine 0.125%
219489066|NCT04229758|DRUG|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
219489067|NCT01556464|DEVICE|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
219489068|NCT03376984|COMBINATION_PRODUCT|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
219489069|NCT03376984|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
219489070|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
219489071|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
219489072|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
219489073|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
218869900|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
219489074|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
219489075|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
219489076|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
219489077|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
219199950|NCT06865261|DIETARY_SUPPLEMENT|Placebo|Vials containing placebo were made to be indistinguishable in appearance from active treatment
219489078|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
219489079|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
219489080|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
219489081|NCT05860049|OTHER|Conventional physiotherapy|All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.
219489082|NCT05860049|OTHER|Core stability|All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.
219489083|NCT05860049|DEVICE|Instrument assisted soft tissue mobilization|Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
219489084|NCT05161546|DEVICE|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
219522529|NCT01909557|DRUG|Acetyl-L-carnitine|
219522530|NCT01909557|DRUG|placebo|
219522531|NCT02092922|DRUG|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
219522532|NCT02092922|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
219522533|NCT01085045|DRUG|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
219522534|NCT01085045|DRUG|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
219522535|NCT01085045|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
218869901|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
218869902|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
218869903|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
218869904|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
218869905|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
219489085|NCT05161546|DEVICE|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
219489086|NCT05161546|BEHAVIORAL|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
219489087|NCT05161546|DEVICE|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
219489088|NCT06565754|OTHER|BFR|"Blood flow restriction training is an accessory to a variety of different exercise modes (e.g., resistance exercise, walking, cycling) has recently become a popular research topic. It involves the application of pressurized cuffs to the proximal portion of each lower extremity or upper extremity. It enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet or cuff.~The 3rd Generation SmartCuffs® pump (SmartCuffs® 3.0 PRO) is Personalized Pressure feature which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it is calculate arterial occlusion pressure and set the optimal pressure for patient's body. There is no need for an external doppler probe or hand pump. This unit will do everything for patient. Smart Cuffs 3rd generation is FDA Approved Listed Class 1 device.~The automatized tourniquet (Smart Tools) contains a ring-shaped single- chamber"
219489089|NCT06565754|OTHER|strengthening exercise|Quadriceps strengthening exercises are part of the treatment of PFPS, but the heavy resistance exercises may aggravate knee pain. Blood flow restriction training (BFRT) provides a low-load quadriceps strengthening method to treat PFPS (Giles et al., 2017).
219489090|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
219489091|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
219489092|NCT04975113|OTHER|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
219489093|NCT04975113|OTHER|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
219489094|NCT01345058|DRUG|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day."
219489095|NCT01345058|DRUG|levetiracetam|Low dose ≤1500 mg/day, High dose \>1500 mg/day
219489096|NCT04181697|DEVICE|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
219600680|NCT02072304|BEHAVIORAL|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
218869906|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
218869907|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
218869908|NCT06386679|BIOLOGICAL|allogenic amniotic fluid mesenchymal stem cell|Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
218869909|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
218869910|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
218869911|NCT02001584|DRUG|Baclofen|
218869912|NCT02001584|DRUG|Memantine|
218869913|NCT02001584|DRUG|Placebo|
218869914|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
218869915|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
218869916|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
218869917|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
219489097|NCT04181697|DEVICE|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
219489098|NCT03176511|BEHAVIORAL|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
219489099|NCT03176511|BEHAVIORAL|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
218869918|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
218869919|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
218869920|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
218869921|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
218869922|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
218869923|NCT06110000|OTHER|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization.~5. Pectoralis minor stretch~6. Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
218869924|NCT06110000|OTHER|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
218869925|NCT03583736|BEHAVIORAL|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
218869926|NCT03583736|BEHAVIORAL|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
218869927|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
218869928|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
218869929|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
218869930|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
219199951|NCT06864377|OTHER|Quality of life questionnair|The questionnaire used is the Abdominal Hernia Q, which is specific to ventral hernias. Patients will receive the questionnaire at baseline and at 1, 3, 6, and 12 months after ventral hernia repair. If treated conservatively, the questionnaire will be administered at 1, 3, 6, and 12 months after completing the baseline questionnaire.
219199952|NCT06857110|PROCEDURE|ultrasound-guided supracondylar block of the radial nerve|75 mg of intramuscular diclofenac will be administered, or 1 gram of oral acetaminophen in case of contraindications for the administration of Non-Steroidal Anti-inflammatory Drugs
219489100|NCT05920707|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
219489101|NCT05920707|DRUG|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
219489102|NCT05920707|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
219489103|NCT05775237|DIETARY_SUPPLEMENT|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
219489104|NCT05775237|DIETARY_SUPPLEMENT|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
219489105|NCT05775237|DIETARY_SUPPLEMENT|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
219522536|NCT01085045|DRUG|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
219522537|NCT01085045|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
219600681|NCT02072304|BEHAVIORAL|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
219600682|NCT07104461|OTHER|Oat porridge|"Oat flakes, 81g (equivalent to 9 g of protein), were presented to participants in the form of porridge, prepared with 500 mL coconut milk (equivalent to 0.5 g of protein) and 10 g of zero calorie sugar free syrup.~The total energy content was equivalent to 400 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
219600683|NCT07104461|DIETARY_SUPPLEMENT|Whey protein isolate|"Whey protein isolate, 38g (equivalent to 34.2 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the whey protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content was equivalent to 401.74 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study"
219600684|NCT07104461|DIETARY_SUPPLEMENT|Potato protein isolate|"Potato protein isolate, 38g (equivalent to 34.39 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the potato protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content equiv. 401.36 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
218869931|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
218869932|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
218869933|NCT02372422|OTHER|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
218869934|NCT02372422|OTHER|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
218869935|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
218869936|NCT03133923|BIOLOGICAL|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
219489106|NCT03850262|RADIATION|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
218869937|NCT03133923|BIOLOGICAL|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
219489107|NCT02820324|DRUG|Oliceridine|
219489108|NCT02820324|DRUG|Placebo|
219489109|NCT02820324|DRUG|Morphine|
219489110|NCT04425369|PROCEDURE|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
218869938|NCT03133923|BIOLOGICAL|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
219489111|NCT04980417|PROCEDURE|concomitant cholecystectomy|delayed cholecystectomy
219489112|NCT00291356|DRUG|GSK189075 oral tablets|
219489113|NCT00291356|DRUG|GW869682 oral tablets|
219489114|NCT05359380|OTHER|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
218869939|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
218869940|NCT00301288|PROCEDURE|Autologous stem cell transplant|
218869941|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
218869942|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
218869943|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
218869944|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
218869945|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
218869946|NCT02350738|OTHER|Period I MCET (8 wks)|MCET\_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock\_MCET group: mock-therapy (3 sessions/wk)
218869947|NCT02350738|OTHER|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
218869948|NCT02350738|OTHER|Period II MCET (8 wks)|MCET\_Mock group: mock therapy (MCET) (3 sessions/wk) Mock\_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
219489115|NCT01892020|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
219489116|NCT01892020|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
219489117|NCT06164431|DRUG|ZSP1273 tablet|Participants receive ZSP1273 tablet orally.
219489118|NCT06164431|DRUG|zsp1273 granules|Participants receive ZSP1273 granules orally.
219489119|NCT05093192|OTHER|Exercise trial|Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
219489120|NCT02251431|DRUG|BYDUREON|Exenatide-extended release, Cohorts A and B
219489121|NCT02251431|DRUG|Placebo|Cohort A only
219489122|NCT04398888|OTHER|Banxie Xiexin Decoction (BXD)|A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
219489123|NCT02752451|OTHER|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
219489124|NCT02752451|OTHER|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
219489125|NCT02752451|OTHER|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
219489126|NCT02493088|OTHER|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
219489127|NCT01841398|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
219489128|NCT01841398|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
219489129|NCT00981864|RADIATION|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
219489130|NCT01838278|BEHAVIORAL|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
219489131|NCT05133843|PROCEDURE|Assession of complete coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
219489132|NCT03764592|OTHER|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
219489133|NCT06427954|BEHAVIORAL|Digital Health App|access to a digital health app
219489134|NCT06476171|DIAGNOSTIC_TEST|Determination of the level of the studied biomarkers|Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
219489135|NCT04925453|COMBINATION_PRODUCT|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
219600685|NCT07104461|DIETARY_SUPPLEMENT|Meal replacement shake|"A meal replacement, 90 g (equivalent to 40 g of total protein), was presented to participants in the form of a shake.~Other ingredients in the meal replacement shake:~\- Water 500 mL~The total energy was equivalent to 400 Kcal~Participants were instructed to consume the entire meal replacement shake presented to them in 15 minutes on an empty stomach when attending the study."
219600686|NCT05565079|BIOLOGICAL|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
219522538|NCT01085045|DRUG|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
219522539|NCT00714103|DRUG|8-Chloro-Adenosine|45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
219522540|NCT00202982|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
219522541|NCT00202982|DRUG|glatiramer acetate 40 mg|glatiramer acetate 40 mg
219522542|NCT02188641|OTHER|Diet|
219522543|NCT02188641|OTHER|Exercise|
219522544|NCT02188641|OTHER|Diet and Exercise|
219600687|NCT05565079|BIOLOGICAL|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
219522545|NCT02188641|OTHER|Healthy Lifestyle (Control) Group|
219522546|NCT04462926|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
219600688|NCT03554434|BIOLOGICAL|AM0010|AM0010
218869949|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
218869950|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
218869951|NCT02557984|DRUG|Placebo|Placebo Pill
218869952|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
218869953|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
218869954|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
218869955|NCT03031119|DRUG|Placebo|Tablets administered once or twice daily, with food, in Part A.
218869956|NCT03031119|DRUG|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
218869957|NCT03031119|DRUG|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
218869958|NCT00003719|DRUG|irinotecan hydrochloride|
218869959|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
219489136|NCT04925453|COMBINATION_PRODUCT|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
219489137|NCT06210516|DEVICE|PowerBreathe|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
218869960|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
218869961|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
218869962|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
218869963|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
218869964|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
218869965|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
219489138|NCT06210516|OTHER|Conventional Physiotherapy|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
219489139|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
218869966|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
218869967|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
218869968|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
218869969|NCT04790292|DRUG|group M|10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
218869970|NCT04790292|DRUG|group MD|10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
218869971|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
218869972|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
218869973|NCT03536026|PROCEDURE|Biopsy|-Standard of care
218869974|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
218869975|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
218869976|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
218869977|NCT03797092|OTHER|Control group|No treatment
218869978|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
218869979|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
218869980|NCT04405245|DRUG|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
218869981|NCT04405245|DRUG|AKB-9778 4%|Razuprotafib opthalmic solution
218869982|NCT04405245|DRUG|Placebo|placebo for razuprotafib opthalmic solution
218869983|NCT06331689|OTHER|Mortality ratio|Mortality rates at 30-day, 90-day and 1-year intervals
218869984|NCT01789216|DRUG|NSAID|
218869985|NCT01789216|DRUG|Gabapentinoids|
218869986|NCT01789216|DRUG|placebo|
218869987|NCT05993962|DIETARY_SUPPLEMENT|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
218869988|NCT05993962|OTHER|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
218869989|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
218869990|NCT01380704|DRUG|ABT-436|QD Days 1-7
219199953|NCT06857110|PROCEDURE|hematoma block|The orthopedic surgeon will perform a hematoma block before closed reduction. Intramuscular diclofenac (75 mg) or oral acetaminophen (1 g) will be administered if NSAIDs are contraindicated. With the patient in a supine position, the fracture site will be identified through palpation. After antisepsis with 2% chlorhexidine gluconate, a 10 cc syringe with a 21-gauge needle will be inserted to aspirate and confirm placement over the fracture hematoma. Then, 1% lidocaine (2 mg/kg) without epinephrine will be infiltrated. A 10-minute waiting period will be observed before performing closed reduction maneuvers.
219489140|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
219489141|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
219489142|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
219489143|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
219489144|NCT05925309|DRUG|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
219489145|NCT05925309|DRUG|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
219489146|NCT02452775|BIOLOGICAL|OC-L|
219489147|NCT02452775|OTHER|Montanide|
219489148|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
219489149|NCT03485508|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
219489150|NCT06701123|DEVICE|uMAT-R mobile app with coaching component|uMAT-R recovery mobile app with coaching component
219489151|NCT06722690|BEHAVIORAL|eTSF|eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
219489152|NCT06722690|BEHAVIORAL|Educational materials|Educational materials on drinking problems and a list of local/online AA meetings.
219489153|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
219600689|NCT06085573|DRUG|Dexmedetomidine Hydrochloride|"\<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
219600690|NCT00274118|DRUG|telmisartan|
219600691|NCT00274118|DRUG|enalapril|
219600692|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
219600693|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
219600694|NCT05792696|BEHAVIORAL|PPI guided strategies|For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.
219600695|NCT05792696|BEHAVIORAL|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
219600696|NCT06828237|DEVICE|KOS® S|Delivery of medical device as injection
218869991|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
218869992|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
218869993|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
219522547|NCT01638988|DRUG|Metformin|"1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
218869994|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
218869995|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
218869996|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
218869997|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
219613621|NCT03207386|BEHAVIORAL|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
219613622|NCT03939663|DRUG|misoprostol|misoprostol 2 tablets
219613623|NCT03939663|DRUG|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
219613624|NCT05970666|DRUG|TACE with adebrelimab and bevacizumab|TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
219613625|NCT05349552|RADIATION|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
219613626|NCT06745063|DRUG|Empagliflozin|12 week treatment with 10mg empagliflozin daily
219613627|NCT06745063|DRUG|Placebo|12 week treatment with 10mg placebo daily
219613628|NCT06724718|OTHER|smartwatch|Patients in the smartwatch group will undergo rhythm monitoring with a smartwatch
219613629|NCT06724718|OTHER|ECG|Detected POAF episodes will be confirmed via a 12-lead ECG
219199954|NCT06857110|DRUG|5 mg of intramuscular diclofenac|the orthopedic surgeon on duty will perform the hematoma block prior to closed reduction in the procedure room as follows: 75 mg of intramuscular diclofenac will be administered
219199955|NCT06856369|PROCEDURE|Platelet rich fibrin|sub-gingival administration of platelet rich fibrin following open flap surgery
219522548|NCT01638988|DRUG|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
219522549|NCT00234078|DRUG|0.5% OPC-12759|
219522550|NCT00234078|DRUG|1% OPC-12759|
219522551|NCT00234078|DRUG|2% OPC-12759|
219522552|NCT00234078|DRUG|placebo|
219522553|NCT05620225|DEVICE|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
219522554|NCT05620225|DEVICE|Sham and CMM|Sham and CMM
219522555|NCT03212222|OTHER|Peek Acuity|Cell phone application for visual acuity screening
219522556|NCT03212222|OTHER|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
219522557|NCT05859386|BEHAVIORAL|Mindfulness maintenance program|"1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
219522558|NCT01556308|PROCEDURE|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
219522559|NCT00936169|PROCEDURE|IVUS optimised DES implantation|Ivus optimised stent implantation
219522560|NCT00936169|PROCEDURE|angiographically guided DES implantation|angiographically guided DES implantation
219522561|NCT02127281|DEVICE|Prevena|Device will be applied at end of procedure over closed incision.
219522562|NCT04177290|DRUG|Sintilimab (M1b)|Intravenous infusion
219522563|NCT04177290|DRUG|Sintilimab (approved)|Intravenous infusion
219522564|NCT04793347|DEVICE|shock master (shock waves device)|device produces shock waves
219522565|NCT00076947|BIOLOGICAL|EnvPro|
219522566|NCT01533298|DRUG|CombiflexOmega peri|intravenously over 3 days infusion
219522567|NCT01533298|DRUG|SmofKabiven peripheral|intravenously over 3 days infusion
219522568|NCT02757248|DRUG|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
219522569|NCT02757248|DRUG|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
219522570|NCT03048526|DEVICE|NovaTears®|Topical eye drops for lubrication of the ocular surface
219522571|NCT03048526|DEVICE|Hydrabak®|Eye drops
219600697|NCT06827951|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|"Participants will undergo the standard PCIT program, which consists of two phases: Child-Directed Interaction (CDI) and Parent-Directed Interaction (PDI).~* CDI Phase: Parents will learn and practice techniques that focus on strengthening the parent-child relationship through play and positive reinforcement.~* PDI Phase: Parents will be coached in effective discipline strategies to manage their child's behavioral problems."
219600698|NCT00633347|DRUG|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
218869998|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
218869999|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
218870000|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
218870001|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
218870002|NCT01771445|DRUG|IL-1Ra|100mg, s.c, once only
218870003|NCT01771445|DRUG|Placebo|100mg, s.c., once only
218870004|NCT00439881|DRUG|SB-681323|
219489154|NCT06722131|OTHER|Sampling|"Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)"
219489155|NCT06722404|DIETARY_SUPPLEMENT|Standard therapeutic foods|All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days
219489156|NCT06722404|COMBINATION_PRODUCT|Therapeutic foods plus Synbiotics|the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
219489157|NCT03216798|OTHER|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
219489158|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
219600699|NCT00633347|DRUG|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
219600700|NCT06196814|DRUG|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
219600701|NCT07113236|BEHAVIORAL|Instructions, advices|A first moment: informed conversation and exploration of myths and realities with the aim of exploring the perceptions and attitudes of participating children and adolescents towards the vaccine against HPV-associated cancers through an open and reflective dialogue; a second moment with the presentation of a testimonial video and reflection with the aim of learning from the experiences of others, finding inspiration and motivation in their stories, and feeling connected with other people; and a third moment of 360° feedback with the aim of receiving final information about HPV, HPV-associated cancers, and the importance of vaccination.
219600702|NCT07113236|OTHER|No instructions|No instructions for vaccination
218870005|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
218870006|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
218870007|NCT03775564|OTHER|TAU|Treatment as usual
218870008|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
218870009|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
218870010|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
218870011|NCT01348555|DRUG|Bronchodilatator|
218870012|NCT01348555|DRUG|Bronchodilatator|
218870013|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
218870014|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
218870015|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
218870016|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
219489159|NCT05340842|OTHER|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
219489160|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
219489161|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
219489162|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
219489163|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
219489164|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
219489165|NCT01630265|OTHER|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
219489166|NCT01630265|OTHER|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
219600703|NCT06919952|BEHAVIORAL|Resilience|The Resilience program focuses on drawing on resilience assets and resources, both internal and external. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies for improving well-being. Behavior change strategies used are meant to increase intervention adherence and improve well-being and resilience.
219600704|NCT06919952|BEHAVIORAL|Physical Activity|The Physical Activity program focuses on supporting physical activity health habits. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies of evidence-based strategies for physical activity goals. Behavior change strategies used are meant to help establish, improve or maintain healthy physical activity habits.
219199956|NCT06856369|DRUG|Metformin hydrochloride powder|subgingival administration of 1% Metformin Hydrochloride gel with platelet rich fibrin following open flap surgery
219489167|NCT03329586|OTHER|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
219489168|NCT01066273|DEVICE|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
219489169|NCT04675073|PROCEDURE|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
219489170|NCT01566669|DRUG|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
219600705|NCT07115394|OTHER|EEG recording|EEG will be recorded at high sampling rate
219600706|NCT07117669|DRUG|ENP-501|"* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose"
219600707|NCT07117669|DRUG|Placebo|"* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose"
219600708|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301 will be dosed IV, in initial 28 day cycles. First cycle dosing is every week. Second through fifth cycles are dosed every 2 weeks. Sixth cycle and beyond are 21 day cycles, and are dosed once every 3 weeks.
218870017|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
218870018|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
218870019|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
218870020|NCT02940483|DRUG|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
218870021|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
218870022|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
218870023|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
218870024|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
218870025|NCT00784537|DRUG|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
219489171|NCT01566669|DRUG|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
219489172|NCT03091894|DRUG|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
219489173|NCT03091894|DRUG|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
219489174|NCT02023320|DIETARY_SUPPLEMENT|Low dose of blueberry dry powder|
219489175|NCT02023320|DIETARY_SUPPLEMENT|High dose of blueberry dry powder|
219489176|NCT03456726|DRUG|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
219489177|NCT04470622|DRUG|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
219489178|NCT04470622|DRUG|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
219489179|NCT03171610|DRUG|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
219489180|NCT03171610|DRUG|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
219489181|NCT00002269|DRUG|Ampligen|
219489182|NCT00002269|DRUG|Zidovudine|
219489183|NCT00399490|DRUG|RN624 (PF-04383119)|50 mcg/kg
219489184|NCT00464256|DRUG|rimonabant|
219489185|NCT00268554|DRUG|dipyridamole|
219489186|NCT00268554|DRUG|caffeine|
219489187|NCT02576054|BIOLOGICAL|V501|Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
218870026|NCT00784537|DRUG|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
219489188|NCT01190098|DRUG|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
219489189|NCT01190098|DRUG|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
219489190|NCT02281071|PROCEDURE|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
219489191|NCT02957682|DRUG|Praluent (Alirocumab)|
219489192|NCT02957682|DRUG|Placebo|
219489193|NCT04622865|DRUG|Masitinib|Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.
219489194|NCT04622865|DRUG|Isoquercetin|Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.
219489195|NCT04622865|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
219489196|NCT04500691|OTHER|pain intensity reporting|pain intensity reporting
219489197|NCT02100527|DRUG|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
219489198|NCT02100527|DRUG|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
219600709|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
219600710|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
219600711|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
218870027|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
218870028|NCT05340803|DRUG|midazolam|midazolam
219489199|NCT06542276|DEVICE|Thermal Vectored Pulsation|The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
219489200|NCT05801640|OTHER|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
219489201|NCT05801640|OTHER|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
219489202|NCT05617573|PROCEDURE|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
219489203|NCT02828748|OTHER|no intervention in patients treatment, only biopsy taken|
218870029|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
219489204|NCT05423301|PROCEDURE|Experimental|Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
219600712|NCT07128056|BEHAVIORAL|Mobile phone video game distraction|Children in the intervention group will play age-appropriate, non-violent mobile phone video games for approximately 20 minutes before induction of anesthesia. This is intended as a distraction technique to reduce preoperative anxiety and improve postoperative pain outcomes. Participants will also receive standard perioperative care.
219600713|NCT07128056|OTHER|Standard peri operative care|Standard preoperative and postoperative care according to institutional protocol, without mobile phone video game distraction.
219600714|NCT07128238|BEHAVIORAL|lifestyle intervention|This study implemented lifestyle interventions including dietary and exercise interventions. Based on the assessment of the physical condition of the volunteers, a personalized training plan is formulated and a standardized diet is provided. The entire intervention process lasts for 8 weeks.
219600715|NCT07133711|DEVICE|Noninvasive ventilation|Weaning from noninvasive ventilation for patients with acute exacerbation of COPD
219600716|NCT06937788|DRUG|Upadacitinib|30 mg tablet daily
219600717|NCT06937788|BIOLOGICAL|Dupilumab|300 mg injection every other week
218870030|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
218870031|NCT02219503|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
218870032|NCT02219503|DRUG|Dasabuvir|Tablet
218870033|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
218870034|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
218870035|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
218870036|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
218870037|NCT00211952|DRUG|celecoxib|
219199957|NCT06856369|DRUG|alendronate sodium powder|subgingival administration of 1% Alendronate gel with platelet rich fibrin following open flap surgery
219600718|NCT00550030|RADIATION|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
219600719|NCT00550030|OTHER|No treatment|no UV exposure
219600720|NCT02447744|BEHAVIORAL|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
218870038|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
218870039|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
218870040|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
218870041|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
218870042|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
218870043|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
218870044|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
218870045|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
218870046|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
218870047|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
218870048|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
218870049|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
218870050|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
218870051|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
219489205|NCT05423301|PROCEDURE|Control|The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
219489206|NCT06538363|BEHAVIORAL|Education|Personalized training advice
219489207|NCT06538363|BEHAVIORAL|Generic Education|Generic training advice
219489208|NCT02490527|DIETARY_SUPPLEMENT|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
219489209|NCT02490527|DRUG|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
219489210|NCT02490527|OTHER|Placebo|A substance that has no therapeutic effect and will act as a control.
218870052|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
218870053|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
218870054|NCT00473525|DRUG|Placebo|Placebo QD
218870055|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
218870056|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
218870057|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
218870058|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
218870059|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
218870060|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
218870061|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
219489211|NCT02525146|OTHER|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
219489212|NCT05135143|COMBINATION_PRODUCT|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
219489213|NCT02065973|BIOLOGICAL|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
219489214|NCT04190966|BEHAVIORAL|Integrated Behavioural therapy|Integrated smoking cessation behavioural therapy
219489215|NCT04190966|DRUG|Integrated Pharmacotherapy|Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
219489216|NCT04190966|DEVICE|Integrated Web-based application|Integrated smoking cessation web-based application
219489217|NCT00003673|DRUG|chemotherapy|
219489218|NCT00003673|DRUG|gemtuzumab ozogamicin|
219489219|NCT02404779|DRUG|cisatracurium besilate|
219489220|NCT02404779|OTHER|Placebo|
219489221|NCT04296799|DRUG|SMP-100|SAD/MAD
219489222|NCT04296799|DRUG|Placebo|Placebo
219489223|NCT04856579|PROCEDURE|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
219489224|NCT02387788|DRUG|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
219489225|NCT02775227|DRUG|Hydrocortisone|
219489226|NCT02775227|DRUG|Pasireotide|
219489227|NCT05640882|OTHER|VRET|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
219489228|NCT05640882|OTHER|VRET OLFACTION|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
219489229|NCT03778359|DRUG|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
219600721|NCT00912912|DRUG|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
219600722|NCT01123967|OTHER|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
219600723|NCT01123967|OTHER|telephone counseling (TC)|free telephone counseling
219600724|NCT01123967|OTHER|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
219600725|NCT01123967|OTHER|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
219489230|NCT03778359|DEVICE|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
219489231|NCT03778359|DRUG|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
219489232|NCT03778359|DRUG|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
219489233|NCT05190900|OTHER|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
219489234|NCT05786053|PROCEDURE|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
219489235|NCT03724669|BEHAVIORAL|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
219489236|NCT03724669|BEHAVIORAL|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
219489237|NCT05741268|BEHAVIORAL|Dialectical behavior therapy|14\) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
219489238|NCT00149669|BEHAVIORAL|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
219489239|NCT02903927|DEVICE|Implantation of CT LUCIA IOL|
219489240|NCT02903927|DEVICE|Implantation of Acrysof IQ SN60WF IOL|
219489241|NCT03793595|DEVICE|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
219489242|NCT03793595|DEVICE|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
219489243|NCT02458365|BEHAVIORAL|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
219489244|NCT02458365|BEHAVIORAL|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
219489245|NCT00166374|PROCEDURE|balloon kyphoplasty|
219489246|NCT03395574|DRUG|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
219489247|NCT03395574|DRUG|Normal saline|drug will be given after 30 minutes as placebo in control group
219489248|NCT03565666|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
219489249|NCT03565666|DRUG|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
218870062|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
218870063|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
218870064|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
218870065|NCT05580068|DEVICE|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
218870066|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
218870067|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
219489250|NCT03565666|OTHER|Usual care|Usual care
219489251|NCT02282007|BEHAVIORAL|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
219489252|NCT01035593|PROCEDURE|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
219489253|NCT01035593|DRUG|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
219489254|NCT05991778|DEVICE|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
219489255|NCT05991778|DIAGNOSTIC_TEST|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
219489256|NCT05991778|DIAGNOSTIC_TEST|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
219489257|NCT05988593|DIETARY_SUPPLEMENT|placebo|consume one bottle (30 mL) per day
219489258|NCT05988593|DIETARY_SUPPLEMENT|MelaGene+|consume one bottle (30 mL) per day
219489259|NCT01472315|DRUG|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
219489260|NCT01472315|DRUG|Placebo|Placebo pills were taken in same way as active comparator
219600726|NCT03207867|DRUG|NIR178|"NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days."
219600727|NCT03207867|DRUG|PDR001|PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
219489261|NCT02703454|PROCEDURE|FIRM-guided RF ablation|
219489262|NCT02703454|PROCEDURE|Conventional RF ablation|
219489263|NCT01226654|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
219489264|NCT00984828|DRUG|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
219489265|NCT01019278|RADIATION|proton beam radiation therapy|Undergo external proton beam radiation
219489266|NCT01019278|RADIATION|radiation therapy treatment planning/simulation|
219489267|NCT01019278|DRUG|cisplatin|Given IV
219489268|NCT00791154|DRUG|AMG 479|AMG 479 is administered to subjects
219489269|NCT00791154|DRUG|Etoposide|Etoposide is administered to subjects
219489270|NCT00791154|DRUG|Placebo|Placebo is administered with Carboplatin and Etoposide
219489271|NCT00791154|DRUG|AMG 102|AMG 102 is administered to subjects
219489272|NCT00791154|DRUG|Carboplatin|Carboplatin is administered to some subjects in combination
219600728|NCT05327192|OTHER|No intervention, only sampling|No intervention
219600729|NCT00306995|BIOLOGICAL|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
218870068|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
218870069|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
218870070|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
218870071|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
219489273|NCT00791154|DRUG|Cisplatin|Cisplatin is administered to some subjects in combination
219489274|NCT04960254|BEHAVIORAL|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy \& Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
218870072|NCT04764344|DRUG|Ondansetron|Ondansetron
219489275|NCT02913651|DEVICE|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
219489276|NCT03549845|BEHAVIORAL|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
219489277|NCT02284373|OTHER|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
219489278|NCT02284373|OTHER|Routine wound care for venous ulcers and lymphedema|wound care /dressings
219489279|NCT02284373|DEVICE|Flexitouch pneumonic compression|pneumonic compression only
219489280|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
219489281|NCT05476276|DRUG|ISA specific|ISA specific interventions will be listed in their protocols.
219489282|NCT04428060|OTHER|PERSEUS CPR|Resuscitation based on patient physiology
219489283|NCT04428060|OTHER|Standard CPR|Resuscitation based on current guidelines
219489284|NCT00447291|DRUG|Supplement: Omega-3 Fish Oil|
219489285|NCT00447291|BEHAVIORAL|Multi-Disciplinary Nutrition & Exercise program|
219489286|NCT06568926|DIAGNOSTIC_TEST|Serum Ferritin level|follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
219489287|NCT06056531|OTHER|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
219489288|NCT06056531|OTHER|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
219489289|NCT00122031|DEVICE|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
219489290|NCT06190873|BEHAVIORAL|post-discharge rehabilitation training|Telephone training will be provided for post-discharge rehabilitation
219489291|NCT01206946|DRUG|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
219489292|NCT01206946|OTHER|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
219489293|NCT02665026|PROCEDURE|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
219489294|NCT00685048|BEHAVIORAL|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
218870073|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
218870074|NCT04547361|DRUG|E2511|E2511 tablets.
218870075|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
219489295|NCT00685048|BEHAVIORAL|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
219489296|NCT00685048|BEHAVIORAL|four 50-minute individual therapy sessions of MET & CBT|MET \& CBT
219489297|NCT04161118|DRUG|CTL019|IV Infusion
219600730|NCT00306995|BIOLOGICAL|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
219600731|NCT00306995|BIOLOGICAL|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
219600732|NCT00306995|BIOLOGICAL|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
219600733|NCT00306995|BIOLOGICAL|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
219600734|NCT00306995|BIOLOGICAL|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
219600735|NCT00306995|BIOLOGICAL|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
219600736|NCT06379724|DRUG|Tranexamic acid|100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
218870076|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
218870077|NCT00868036|PROCEDURE|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
218870078|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
218870079|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
218870080|NCT04507971|BIOLOGICAL|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
218870081|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
218870082|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
218870083|NCT00924404|DRUG|Saline|saline for sinus rinse
218870084|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
218870085|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
219489298|NCT01681979|DRUG|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
219489299|NCT02499406|BEHAVIORAL|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
219489300|NCT03179956|DRUG|Ribociclib|Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
219489301|NCT02399488|DEVICE|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
219600737|NCT06379724|DRUG|Thrombin JMI|The wound base is then sprayed with a film of Thrombin-JMI
219600738|NCT06379724|PROCEDURE|skin graft|Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
219600739|NCT05422625|DEVICE|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
219600740|NCT05422625|DEVICE|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
218870086|NCT06000605|OTHER|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
218870087|NCT06000605|OTHER|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
218870088|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
218870089|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
218870090|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
219600741|NCT03205527|OTHER|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
218870091|NCT00145691|DRUG|Oxcarbazepine|
218870092|NCT01932775|DEVICE|GlucoTab System|
219489302|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
219489303|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
219489304|NCT03560115|DIAGNOSTIC_TEST|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
219489305|NCT02757261|DEVICE|Laser|Low-level laser therapy administrated to acupoints
219489306|NCT02757261|DEVICE|Occlusal splint|Occlusal splint with expander
219489307|NCT02757261|DEVICE|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
219489308|NCT02632227|PROCEDURE|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
219489309|NCT01372527|OTHER|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
218870093|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
218870094|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
218870095|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
218870096|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
218870097|NCT01843270|DEVICE|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
218870098|NCT01843270|DEVICE|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
219600742|NCT06010628|DRUG|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
219600743|NCT05083416|BEHAVIORAL|Prolonged Nightly Fasting|Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
219489310|NCT05380882|DRUG|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
219489311|NCT02476760|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219489312|NCT02476760|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
219600744|NCT05083416|BEHAVIORAL|Regular Eating pattern|Food intake not limited to a specific time during day/night.
219600745|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
218870099|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
218870100|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
218870101|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
218870102|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
218870103|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
218870104|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
218870105|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
219489313|NCT02476760|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
219489314|NCT02476760|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219600747|NCT06421532|DRUG|XYWAV|Daily before bedtime for 3 months
218870106|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
219600748|NCT06421532|DEVICE|gammaCore Sapphire|Twice daily for 3 months
219600749|NCT03325101|PROCEDURE|Cryosurgery|Undergo cryosurgery
219489315|NCT02476760|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219489316|NCT02476760|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219489317|NCT02476760|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
219600750|NCT03325101|BIOLOGICAL|Pembrolizumab|IV
218870107|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
219600751|NCT03325101|PROCEDURE|Pheresis|apheresis
218870108|NCT00343382|OTHER|placebo|Given orally
218870109|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
218870110|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
218870111|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
219600752|NCT03325101|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Intra-tumoral injection
218870112|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
219600753|NCT05338528|BEHAVIORAL|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
218870113|NCT00933894|DRUG|Telaprevir; Escitalopram|
219489318|NCT02476760|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
219489319|NCT04586569|OTHER|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
219600754|NCT05792020|DEVICE|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
219600755|NCT02721459|DRUG|XL888|"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."
218870114|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
218870115|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
218870116|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
218870117|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
218870118|NCT01167868|DRUG|FosD|oral tablet
218870119|NCT01167868|DRUG|Placebo|oral tablet
218870120|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
218870121|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
218870122|NCT02973776|DRUG|LEO 90100 aerosol foam|
218870123|NCT02973776|DRUG|Dermoval®/Dermovate®|
218870124|NCT02973776|DRUG|Diprosone|
218870125|NCT02973776|DRUG|Elocon|
218870126|NCT02973776|DRUG|Locoid|
218870127|NCT02973776|OTHER|LEO 90100 foam vehicle|
219489320|NCT01551394|DRUG|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
219489321|NCT01551394|DRUG|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
219489322|NCT05070689|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
219489323|NCT02833558|DEVICE|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
219600756|NCT02721459|DRUG|Vemurafenib|Vemurafenib 720 mg by mouth twice a day (BID)
218870128|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
218870129|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
218870130|NCT00186277|DRUG|Taxotere|Calculated per patient
218870131|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
218870132|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
218870133|NCT00718341|DRUG|AF056|
218870134|NCT00718341|DRUG|Placebo|
218870135|NCT00945932|DRUG|GW870086X|Investigational product
218870136|NCT00945932|DRUG|Placebo|Placebo control
218870137|NCT01073007|DRUG|Simvastatin|Simvastatin 40 mgrs daily for three months.
219489324|NCT02833558|PROCEDURE|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
219489325|NCT05151822|OTHER|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
219489326|NCT05151822|OTHER|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
219489327|NCT05151822|OTHER|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
219489328|NCT05151822|OTHER|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
219489329|NCT01506817|PROCEDURE|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
219600757|NCT02721459|DRUG|Cobimetinib|Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
219600758|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
219600759|NCT05541887|OTHER|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
218870138|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
218870139|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
218870140|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
218870141|NCT00710385|DRUG|Heroin|Heroin (25 mg)
218870142|NCT00710385|DRUG|Naloxone|.4 mg
218870143|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
218870144|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
218870145|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
218870146|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
218870147|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
218870148|NCT05687513|DRUG|Yisui granule|Yisui granule
218870149|NCT05687513|DRUG|Placebo|placebo
218870150|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
218870151|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
218870152|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
218870153|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
218870154|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
218870155|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
219600760|NCT05541887|OTHER|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
219600761|NCT05904132|DEVICE|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
219600762|NCT05291676|BIOLOGICAL|Fluzone|Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
218870156|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
218870157|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
219489330|NCT04759716|OTHER|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
219489331|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
219489332|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
219600763|NCT05291676|BIOLOGICAL|Fluad|Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
219600764|NCT05540327|DRUG|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
219600765|NCT05540327|DRUG|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
219600766|NCT05540327|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
219600767|NCT05540327|DRUG|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
219600768|NCT05921643|DEVICE|verre bioactif 45S5 GlassBONE|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
219600769|NCT05921643|DEVICE|verre bioactif S53P4 Bonalive|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
219600770|NCT06206408|DRUG|Fezolinetant|oral
219600771|NCT06206408|DRUG|Placebo|oral
219600772|NCT04069884|RADIATION|regional nodal irradiation|external-beam radiotherapy (XRT)
219600773|NCT04069884|RADIATION|WBI|Whole Breast Irradiation
219600774|NCT04069884|RADIATION|chestwall XRT|chestwall irradiation
219600775|NCT06489899|BEHAVIORAL|PEGISUS|PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
219600776|NCT06424938|PROCEDURE|Patients who underwent epidural block|The researchers administered an epidural block to prevent post-operative pain to the epidural block group undergoing midline incision surgery for major gynecologic cancer.
218870158|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
218870159|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
219489333|NCT04973839|BEHAVIORAL|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
219489334|NCT04973839|BEHAVIORAL|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
219600777|NCT06424938|PROCEDURE|Patients who underwent erector spina plane block|Researchers applied a erector spina plane block to prevent postoperative pain to the erector spina plane block group undergoing midline incision surgery for major gynecological cancer.
219600778|NCT03842982|DRUG|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
219600779|NCT05573763|DEVICE|F&P Toffee|Nasal pillows mask
219600780|NCT04324073|DRUG|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
218870160|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
218870161|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
218870162|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
218870163|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
218870164|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
218870165|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
219489335|NCT01382134|DRUG|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
219489336|NCT01382134|DRUG|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
219489337|NCT02677402|OTHER|immersion|
219489338|NCT02751255|DRUG|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
219489339|NCT03372395|OTHER|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
219489340|NCT00438295|PROCEDURE|temperature control|
219489341|NCT04651218|BEHAVIORAL|exericse|participants perform aerobic exercise until they expend 500 kcal
219489342|NCT00188279|PROCEDURE|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
219489343|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
219489344|NCT06536699|RADIATION|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
219489345|NCT06536699|RADIATION|Radiotherapy - Conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
219489346|NCT04365842|BEHAVIORAL|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
219489347|NCT04365842|OTHER|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
219489348|NCT00951717|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
218870166|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
218870167|NCT05611814|OTHER|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
218870168|NCT05611814|OTHER|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
218870169|NCT02237482|DEVICE|Trilogy cup|
218870170|NCT02237482|DEVICE|Trabecular metal cup (TM)|
218870171|NCT02237482|DEVICE|ZCA cup|
218870172|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
218870173|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
218870174|NCT02198690|OTHER|Mammography decision aid|
218870175|NCT02198690|OTHER|Home safety pamphlet|
219613630|NCT06418516|DEVICE|Capsule-sponge|The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
219489349|NCT05761015|DRUG|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
219489350|NCT00875537|OTHER|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
218870176|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
219489351|NCT00875537|OTHER|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
219489352|NCT00003607|RADIATION|radiation therapy|
219489353|NCT00414011|DRUG|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
219489354|NCT00414011|DRUG|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
218870177|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
219489355|NCT00668109|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
219489356|NCT00668109|DRUG|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
218870178|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
218870179|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
218870180|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
218870181|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
218870182|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
218870183|NCT00043927|DRUG|topotecan/cisplatin|
218870184|NCT00043927|DRUG|etoposide/cisplatin|
219489357|NCT01532011|DRUG|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
219489358|NCT01532011|DRUG|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
219489359|NCT02476851|DEVICE|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
219489360|NCT02476851|DEVICE|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
219489361|NCT04075045|BEHAVIORAL|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
219489362|NCT04075045|BEHAVIORAL|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
219489363|NCT04075045|BEHAVIORAL|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
219489364|NCT01399125|DRUG|Rivastigmine Patch|Once-daily target patch size 10 cm²
219489365|NCT01399125|DRUG|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
219489366|NCT01399125|DRUG|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
219600781|NCT06795815|OTHER|Go Wish Game|"The Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important.~This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks."
219489367|NCT01399125|DRUG|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
219489368|NCT00040625|DRUG|Pemetrexed|
219489369|NCT00040625|DRUG|Cisplatin|
219489370|NCT04249063|DRUG|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
219489371|NCT04249063|DRUG|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
219489372|NCT03638102|BEHAVIORAL|Sleep extension|Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching
219489373|NCT03638102|BEHAVIORAL|Healthy living|Participants will receive weekly health education
219489374|NCT05384327|OTHER|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
219489375|NCT05384327|OTHER|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
219489376|NCT04215120|DRUG|Desidustat Oral Tablet|Desidustat tablet
219600782|NCT06797362|DRUG|NVL-520|Oral tablet
219600783|NCT05520567|DRUG|Gilteritinib|Oral
219489377|NCT04215120|DRUG|Epoetin Alfa|Epoetin Injection
219489378|NCT00296829|BIOLOGICAL|Inactivated, split-virion influenza vaccine|
219489379|NCT06045429|DRUG|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
219489380|NCT06045429|DRUG|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
219600784|NCT05520567|DRUG|Venetoclax|Oral
219489381|NCT05628766|OTHER|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
219489382|NCT01027026|OTHER|Early discharge|The patients are discharged the same day as coronary angiography.
219489383|NCT01027026|OTHER|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
219489384|NCT05709626|DRUG|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
219489385|NCT05709626|DRUG|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
219600785|NCT05520567|DRUG|Azacitidine|Subcutaneous injection or intravenous infusion
219600786|NCT06790004|PROCEDURE|Laparotomy|Open Surgery
219600787|NCT06790004|PROCEDURE|Laparoscopy|Minimally invasive surgery
219600788|NCT05714657|RADIATION|Shortened Course Adjuvant Radiotherapy Following TORS|Shortened Course Adjuvant Radiotherapy Following TORS
219600789|NCT06795945|DIETARY_SUPPLEMENT|TPG1|"* Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\])~* Placebo (6 tablets, 2x/day; total 12 tablets per day)"
219600790|NCT06795945|DIETARY_SUPPLEMENT|TPG2|"* Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\])~* Placebo (3 tablets, 2x/day; total 6 tablets per day)"
219600791|NCT06795945|DIETARY_SUPPLEMENT|TPG3|Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])
218870185|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
218870186|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
218870187|NCT06939660|DEVICE|BCI-SCS-EXS|"Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes:~1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent.~2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation.~3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance.~4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS.~5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention.~This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance."
218870188|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
219489386|NCT00647426|DRUG|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
219489387|NCT02374931|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
219489388|NCT02374931|PROCEDURE|Positron Emission Tomography|Undergo 18F-FES PET/CT
219489389|NCT02374931|PROCEDURE|Computed Tomography|Undergo 18F-FES PET/CT
219489390|NCT02374931|OTHER|Laboratory Biomarker Analysis|Correlative studies
219489391|NCT03996382|DIAGNOSTIC_TEST|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
219489392|NCT03235973|DRUG|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
219489393|NCT05748522|OTHER|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
219489394|NCT05748522|PROCEDURE|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
219489395|NCT01410695|DRUG|masitinib 3 mg|
219489396|NCT01410695|DRUG|masitinib 6.0 mg|
218870189|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
219489397|NCT01410695|DRUG|methotrexate|
219489398|NCT01410695|DRUG|Placebo (methotrexate)|
219489399|NCT01410695|DRUG|Placebo (masitinib)|
219489400|NCT00804349|DEVICE|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
219489401|NCT02252484|OTHER|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
219489402|NCT02252484|OTHER|Standard of Care|Standard of Care for this patient population.
219489403|NCT01131702|DRUG|Ranitidine|Ranitidine Tablets, 300 mg
219489404|NCT01635686|DRUG|DWP422 25mg|
219489405|NCT01635686|DRUG|ENBREL 25MG PFS INJ.|
219489406|NCT01891786|BEHAVIORAL|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
219489407|NCT01891786|BEHAVIORAL|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
219489408|NCT02093650|DRUG|black cohosh extract|Black cohosh extract 80 mg
219489409|NCT02093650|DRUG|Placebo|Soy bean oil
219489410|NCT06514118|RADIATION|residual tumor irradiation|lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
219600792|NCT06795945|DIETARY_SUPPLEMENT|Placebo|Placebo (8 tablets, 2x/day; total 16 tablets per day)
219600793|NCT06958328|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
219600794|NCT06958328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219600795|NCT06958328|DRUG|Capecitabine|Given capecitabine
219600796|NCT06958328|PROCEDURE|Computed Tomography|Undergo CT
219600797|NCT06958328|RADIATION|Dose-escalated Radiation Therapy|Undergo dose-escalated radiation using intensity-modulated radiation therapy treatment planning
219600798|NCT06958328|DRUG|Fluorouracil|Given fluorouracil
218870190|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
219489411|NCT06087302|BEHAVIORAL|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
219489412|NCT05267184|PROCEDURE|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
219489413|NCT05267184|PROCEDURE|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
219489414|NCT00116259|DRUG|Aripiprazole|
219489415|NCT04934332|PROCEDURE|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
219489416|NCT04934332|PROCEDURE|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
219489417|NCT04934332|PROCEDURE|Clinical examination|Weekly clinical examination from week-2 to week-5.
219489418|NCT04300907|DEVICE|Provant Infinity Therapy System|Treatment with the Provant Infinity Therapy System, PEMF device
219489419|NCT05394428|OTHER|No intervention|No intervention
219489420|NCT02172183|DRUG|Psychopharmacological treatment|methylphenidate or atomoxetine
219489421|NCT02172183|BEHAVIORAL|CBT group|
219489422|NCT06438354|BIOLOGICAL|subgingival instrumentation plus Perisolv / hyaDent BG|Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.
219489423|NCT06438354|PROCEDURE|subgingival instrumentation|Group B: sites requiring re-treatment are subjected to subgingival scaling
219489424|NCT06540157|OTHER|Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)|Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
219489425|NCT06540157|OTHER|Sham group|Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
219489426|NCT02498899|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
219489427|NCT02498899|BEHAVIORAL|Video|Participants watch a video lasting about 4 minutes.
219489428|NCT03578276|DRUG|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
219489429|NCT03578276|DRUG|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
219489430|NCT03578276|DRUG|Gatifloxacin Ophthalmic|Antibiotic
219489431|NCT03578276|DRUG|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
219489432|NCT00037973|BEHAVIORAL|ventilation feedback|
219600799|NCT06958328|DRUG|Gemcitabine|Given gemcitabine
219489433|NCT00037973|BEHAVIORAL|exercise|
219489434|NCT05774873|DRUG|IBI334 D|Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219489435|NCT05774873|DRUG|IBI334 C|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219489436|NCT05774873|DRUG|IBI334 A|Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219489437|NCT05774873|DRUG|IBI334 B|Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219489438|NCT05774873|DRUG|IBI334 F|Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219489439|NCT05774873|DRUG|IBI334 E|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
219600800|NCT06958328|DRUG|Irinotecan Hydrochloride|Given irinotecan hydrochloride
219600801|NCT06958328|DRUG|Irinotecan Sucrosofate|Given liposomal irinotecan
219600802|NCT06958328|DRUG|Leucovorin Calcium|Given leucovorin calcium
219600803|NCT06958328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219600804|NCT06958328|DRUG|Nab-paclitaxel|Given nab-paclitaxel
219489440|NCT06521034|DRUG|FHND-9041|"In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled."
219489441|NCT04904432|GENETIC|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
219489442|NCT01986400|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
219489443|NCT06147609|DEVICE|lower lingual holding arch space maintainer|lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar
219600805|NCT06958328|OTHER|Observation Activity|Undergo observation
219600806|NCT06958328|DRUG|Oxaliplatin|Given oxaliplatin
219600807|NCT06958328|OTHER|Questionnaire Administration|Ancillary studies
218870191|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
218870192|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
218870193|NCT02068560|DRUG|dDAVP infusion|
218870194|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
218870195|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
219489444|NCT06147609|DEVICE|Removable partial denture space maintainer|Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
219489445|NCT05715788|DRUG|Nitric oxide|Nitric oxide inhalation at 20 ppm
219489446|NCT05715788|BEHAVIORAL|prone positioning|vatilation in prone position
219489447|NCT00981409|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
219489448|NCT00981409|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
219489449|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery without mesh|retrospective study
219489450|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery with mesh|
219489451|NCT03153059|OTHER|Stool frequency|This study is just observational study.
219489452|NCT00390949|BEHAVIORAL|Peer education among commercial sex workers and clients|
219489453|NCT00390949|BEHAVIORAL|Condom distribution and promotion|
219489454|NCT00390949|PROCEDURE|Syndromic treatment of sexually transmitted infections|
219489455|NCT00390949|PROCEDURE|Systemic counselling for STI patients|
219489456|NCT04765254|OTHER|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
219489457|NCT02556931|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
219489458|NCT02556931|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
219489459|NCT02556931|RADIATION|Total body irradiation|Day -1: 200 cGy in a single fraction
219489460|NCT02556931|DRUG|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
219489461|NCT02556931|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
218870196|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
219489462|NCT06127004|OTHER|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
219489463|NCT06127004|OTHER|Supportive Counselling|Se arm/group descriptions
219489464|NCT02987504|DRUG|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
219489465|NCT03150134|DRUG|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
219600808|NCT06958328|RADIATION|Radiation Therapy|Undergo standard radiation therapy
219600809|NCT06795529|OTHER|"Palliative Care Intervention, TARGET-PC"|Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.
219600810|NCT06795529|OTHER|Enhanced Usual Care|Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.
219600811|NCT06010719|DRUG|Azithromycin|oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
218870197|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
218870198|NCT04102722|DEVICE|MUST device|Imaging with MUST device
218870199|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
218870200|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
218870201|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
219489466|NCT03150134|DRUG|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
219489467|NCT03361917|DEVICE|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
219489468|NCT00323635|DRUG|tolterodine|tablet, 4 mg, daily, 1 month
219489469|NCT01558869|DRUG|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
219489470|NCT01558869|DRUG|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
219489471|NCT01558869|DRUG|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
219489472|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
219489473|NCT06260319|GENETIC|Whole genome sequencing and Genome-Epigenome-Phenome Associations|"* Whole genome sequencing (WGS) and bioinformatics analysis~* Functional validation~* Genome-Epigenome-Phenome Associations"
219489474|NCT01653223|DRUG|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
219489475|NCT05330143|DRUG|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
219489476|NCT05330143|DRUG|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
219489477|NCT05330143|DRUG|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
219489478|NCT05330143|DRUG|Placebo|0.9% saline vials administered subcutaneously once 4 week.
219489479|NCT05695079|OTHER|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
218870202|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
218870203|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
218870204|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
219489480|NCT05695079|OTHER|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
219489481|NCT05695079|OTHER|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
219489482|NCT05200806|OTHER|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
219489483|NCT03903952|DIETARY_SUPPLEMENT|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
219489484|NCT00646100|PROCEDURE|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
219489485|NCT00654888|PROCEDURE|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
219489486|NCT00654888|DRUG|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
219489487|NCT06170840|DRUG|QY101Placebo/QY101 ointment|External use for BID
219489488|NCT04114526|OTHER|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
219489489|NCT05880420|DEVICE|Caregiver operations with medication accessories|After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
219199958|NCT06860061|PROCEDURE|Laser refractive surgery|"This prospective comparative interventional study will enroll patients with low and moderate myopia who seek laser vision correction at Sohag Center for LASIK and Corneal Surgeries, Sohag, Egypt. Eyes included will be divided into 3 groups according to the type of refractive surgery used (conventional LASIK, Femto-LASIK and PRK) and each group will be subdivided into 2 groups according to the degree of myopia (low and moderate).~All patients will be subjected to routine comprehensive preoperative examinations including manifest uncorrected distant visual acuity (UCDVA), best corrected distant visual acuity (BCDVA), slit-lamp examination, intraocular pressure, and fundus examination.~Corneal topography and corneal aberrometry will be performed on all patients using Sirius's Scheimpflug-Placido topography (CSO, Florence, Italy). The CSO topography system analyzes a total of 6144 corneal points of a corneal area within a circular annulus outlined by an inner radius of 0.33 mm and an outer"
219489490|NCT05880420|DEVICE|Nurse operations with medication accessories|Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
219489491|NCT02860273|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
219489492|NCT02860273|DEVICE|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
219489493|NCT00381446|DEVICE|Marketed contact lens care products|
219489494|NCT00078312|DRUG|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
219489495|NCT05555186|DEVICE|BWL classrooms (Experimental)|Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.
219489496|NCT05555186|DEVICE|DWL classrooms (Comparison)|Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
219489497|NCT02069886|DRUG|deferasirox|125, 250, 500 mg dispersable tablets
219489498|NCT03460119|DEVICE|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
219489499|NCT05262933|OTHER|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
219489500|NCT05262933|OTHER|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
219489501|NCT06266975|DEVICE|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
219489502|NCT05294770|OTHER|Optisource® Plus: Very Low Calorie Diet treatment|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
219489503|NCT05294770|OTHER|Hypocaloric Mediterranean Diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
219489504|NCT02296788|BEHAVIORAL|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
219489505|NCT01968837|OTHER|Cervical cancer screening|
219489506|NCT06224478|OTHER|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
219199959|NCT05520060|OTHER|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
219600812|NCT06010719|DRUG|Amoxicillin|Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
219600813|NCT06010719|OTHER|Placebo|A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
219600814|NCT04329247|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
219600815|NCT05833139|DRUG|Zongertinib|Zongertinib
219199960|NCT05520060|OTHER|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
219600816|NCT05833139|DRUG|Itraconazole|Itraconazole
219600817|NCT06160973|OTHER|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
219600818|NCT06160973|OTHER|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
219489507|NCT02039583|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
219489508|NCT01096407|OTHER|laboratory biomarker analysis|Collection of urine samples
219489509|NCT01096407|OTHER|questionnaire administration|Completion of questionnaires
219489510|NCT01096407|PROCEDURE|assessment of therapy complications|An assessment will be completed.
219489511|NCT03424694|RADIATION|HDR brachytherapy as monotherapy|
219489512|NCT05160727|DRUG|Tislelizumab|200mg ivgtt d1 q3w
219489513|NCT05160727|DRUG|Irinotecan|"Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w."
219489514|NCT05160727|RADIATION|radiotherapy|radiotherapy
219489515|NCT05784727|DEVICE|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
219489516|NCT02400827|OTHER|malignant cells|
219489517|NCT05718882|DRUG|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
219600819|NCT06160973|OTHER|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
219600820|NCT06160973|OTHER|Commercial Shipper|Meals will be delivered by a commercial shipping organization
219600821|NCT06847152|DIAGNOSTIC_TEST|spatial memory test|"The assessment of spatial memory corresponds in our study to a navigation task, i.e. learning a route through the hospital. The route encoding phase is first carried out. The participant follows the experimenter, with the instruction to pay close attention to the route in order to be able to do it again alone. For directions, it is said this way or that way and not left or right. The route includes 18 intersections.~The participant immediately does the route again alone. The number of correct answers (BR), i.e. correct directions taken at each intersection, is counted as well as the time to complete the route (TR). Direction errors are corrected. This is recall 1.~The participant is then asked to do the route a second time. The correct answers and the times to complete the route are recorded. Errors are corrected (feedback). This is recall 2.~If the participant makes a mistake on recall 1 or 2, a third attempt is made. This is recall 3.~After an interval of 1 hour, the partic"
219600822|NCT04819464|DRUG|Cenerimod|A single oral dose of 0.5 mg.
218870205|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
218870206|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
219199961|NCT05520060|OTHER|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
219199962|NCT05520060|OTHER|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
219489518|NCT03429374|DEVICE|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
219489519|NCT03429374|DEVICE|Absorbable tack|Absorbable tack
219489520|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
219600823|NCT06847399|DRUG|Tirzepatide|Tirzepatide
219600824|NCT06847399|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine dimesylate
219600825|NCT06847399|BEHAVIORAL|Guided self-help cognitive behavioral therapy|Guided self-help cognitive behavioral therapy
219600826|NCT06847399|DRUG|Placebo (oral)|Placebo (oral)
219600827|NCT06847399|DRUG|Placebo (injection)|Placebo (injection)
219600828|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
219600829|NCT05621616|DRUG|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
219489521|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
219489522|NCT04840901|DRUG|Lebrikizumab|Administered SC.
218870207|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
218870208|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
218870209|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
219489523|NCT05446376|DRUG|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
218870210|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
219489524|NCT05864235|BEHAVIORAL|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
219489525|NCT05864235|BEHAVIORAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
219489526|NCT05864235|BEHAVIORAL|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
219489527|NCT05354206|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
219489528|NCT05354206|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
219489529|NCT05354206|OTHER|Training with some stimulation|Motor task combined with real or sham stimulation
219489530|NCT06320080|DRUG|TQB2223 injection|TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
219600830|NCT06166186|OTHER|music|A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.
219600831|NCT06166186|OTHER|no music|Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
218870211|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
218870212|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
218870213|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
218870214|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
219489531|NCT06320080|DRUG|Penpulimab Injection|Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
219489532|NCT00085826|DRUG|Exisulind|
218870215|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
218870216|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
218870217|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
219489533|NCT00826865|DRUG|Levetiracetam|750 mg tablet
219489534|NCT01984619|DEVICE|Cryotherapy for the utilization of wrinkle reduction (iovera)|
219489535|NCT06025500|DIAGNOSTIC_TEST|31P-Magnetic Resonance Spectroscopy (31P-MRS)|31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
219489536|NCT06036901|DIAGNOSTIC_TEST|Coronary CT|Coronary CT evaluation
219600832|NCT06087159|BEHAVIORAL|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
219600833|NCT04255277|DRUG|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
219489537|NCT04045600|BEHAVIORAL|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
219489538|NCT04045600|BEHAVIORAL|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
219489539|NCT04045600|BEHAVIORAL|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
219489540|NCT06702202|DRUG|Mixture of local anesthetics|Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
219489541|NCT06702202|DRUG|0.5% hyperbaric bupivacaine|Given in Subarachnoid block group (Group S)
219489542|NCT04744064|DIETARY_SUPPLEMENT|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
219489543|NCT05380830|OTHER|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
219489544|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
219600834|NCT04255277|DRUG|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
219600835|NCT04255277|DRUG|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
219600836|NCT04255277|DRUG|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
219600837|NCT04255277|OTHER|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
219489545|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
219600838|NCT04255277|DRUG|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
219600839|NCT06311838|BEHAVIORAL|Motivational Interviewing/Community Reinforcement Approach (MI/CRA)|MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.
219600840|NCT06311838|BEHAVIORAL|Strengths-Based Outreach and Advocacy (SBOA )|The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.
219600841|NCT06311838|BEHAVIORAL|Services as Usual (SAU)|Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.
219600842|NCT03922529|BEHAVIORAL|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
219600843|NCT03922529|OTHER|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
219600844|NCT06572683|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
219600845|NCT06105645|DEVICE|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
219489546|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
219489547|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
219489548|NCT03848000|OTHER|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
219489549|NCT03848000|BEHAVIORAL|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
219489550|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
219489551|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
219600846|NCT06105645|DEVICE|Standard electrodes|Standard electrodes used usually during the SEEG
219600847|NCT04294160|DRUG|Dabrafenib|Capsule for oral use
219600848|NCT04294160|DRUG|LTT462|Capsule for oral use
219600849|NCT04294160|DRUG|Trametinib|Tablet for oral use
219600850|NCT04294160|DRUG|LXH254|Tablet for oral use
219600851|NCT04294160|DRUG|TNO155|Capsule for oral use
218870218|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
219489552|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
218870219|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
219489553|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
219489554|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
219489555|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
219489556|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
218870220|NCT06943404|DRUG|BXCL501 (dexmedetomidine HCl)|BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
219489557|NCT04911660|DRUG|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
219489558|NCT04911660|OTHER|Placebo|1 placebo capsule per day for 14 days
219489559|NCT03121989|DRUG|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
219489560|NCT03121989|OTHER|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
219489561|NCT03121989|DRUG|NAC|Participants will be receiving NAC as part of their clinical treatment.
218870221|NCT06943404|DRUG|Placebo|Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
218870222|NCT00225784|DRUG|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
218870223|NCT00225784|PROCEDURE|Radiotherapy|Daily radiotherapy for 28 days
218870224|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
218870225|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
218870226|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
218870227|NCT03869333|OTHER|Placebo|Saline
218870228|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
218870229|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
218870230|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
218870231|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
218870232|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
218870233|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
218870234|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
218870235|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
218870236|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
219600852|NCT04294160|BIOLOGICAL|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
219600853|NCT04294160|BIOLOGICAL|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
219600854|NCT06145633|PROCEDURE|Biopsy Procedure|Undergo biopsy
219600855|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219600856|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
219600857|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, SPECT/CT
219600858|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
219600859|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
218870237|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
218870238|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
218870239|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
218870240|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
219489562|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
219600860|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
219600861|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
219600862|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219600863|NCT06145633|DRUG|Vorinostat|Given IV
219600864|NCT06141018|DEVICE|Cross-linked intra-articular hyaluronic acid|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
219600865|NCT06141018|OTHER|Placebo|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
219600866|NCT05562388|DEVICE|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
219600867|NCT02017015|DRUG|nab-paclitaxel|nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
219600868|NCT02017015|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
218870241|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
218870242|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
219489563|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
219489564|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
219489565|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
219489566|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
219489567|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
219489568|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
219600869|NCT03917251|DIAGNOSTIC_TEST|Coronary flow and pressure measurement in patients with ventricular pacing|Coronary flow and pressure measurement in patients with ventricular pacing
219600870|NCT02076087|PROCEDURE|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
219600871|NCT01184495|DRUG|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
219600872|NCT01184495|DRUG|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
219613631|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
218870243|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
218870244|NCT00024375|DRUG|DHA-paclitaxel|
218870245|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
218870246|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
218870247|NCT01781351|OTHER|Taping the ankle|
218870248|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
218870249|NCT02598128|DEVICE|Placebo|Sham device
218870250|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
218870251|NCT02054793|DRUG|Orteronel|300 mg
218870252|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
218870253|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
219600873|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
218870254|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
218870255|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
218870256|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
218870257|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
218870258|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
218870259|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
218870260|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
218870261|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
218870262|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
218870263|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
218870264|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
218870265|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
218870266|NCT01459913|DRUG|Telaprevir|Tablet
219489569|NCT05601193|OTHER|autologous platelet-rich plasma|autologous PRP preparation was done by segregation of PRP following the centrifugation
219489570|NCT02209272|DRUG|bacteriostatic saline|
219489571|NCT02209272|DRUG|buffered lidocaine|
219489572|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
219489573|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
219613632|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
218870267|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
218870268|NCT01459913|DRUG|Ribavirin|Tablet
218870269|NCT00319241|BEHAVIORAL|Parenting Intervention|
218870270|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
218870271|NCT02794389|DRUG|N-acetyl cysteine|
218870272|NCT02794389|DRUG|Placebo|
218870273|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
219489574|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
219489575|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
218870274|NCT01915823|DRUG|Dymista vehicle|
218870275|NCT00137189|PROCEDURE|Resource-oriented music therapy|
218870276|NCT00137189|PROCEDURE|Standard care|
218870277|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
219489576|NCT06417203|PROCEDURE|spinal anesthesia with hyberbaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
219489577|NCT06417203|PROCEDURE|spinal anesthesia with hypobaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
219489578|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
219489579|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
218870278|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
218870279|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
218870280|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
218870281|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
218870282|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
218870283|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
218870284|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
218870285|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
218870286|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
218870287|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
218870288|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
218870289|NCT04316156|OTHER|Brochure|Brochure
218870290|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
219489580|NCT02296671|DRUG|Pemetrexed|
219489581|NCT02296671|DRUG|Oxaliplatin|
219489582|NCT02296671|DRUG|Leucovorin|
219489583|NCT02296671|DRUG|Fluorouracil|
218870291|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
218870292|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
218870293|NCT01064687|DRUG|LY2189265|
218870294|NCT01064687|DRUG|Exenatide|
218870295|NCT01064687|DRUG|Placebo|
218870296|NCT01064687|DRUG|Metformin|
218870297|NCT01064687|DRUG|Pioglitazone|
218870298|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
218870299|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
218870300|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
218870301|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
218870302|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
218870303|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
218870304|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
218870305|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
218870306|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
218870307|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
218870308|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
218870309|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
219489584|NCT02296671|GENETIC|Germline genotyping analyses for TSER|
219489585|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
219489586|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
219600874|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
218870310|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
218870311|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
218870312|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
218870313|NCT01472211|DEVICE|placebo filter|filter purifies water
218870314|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
218870315|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
218870316|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
218870317|NCT02351284|OTHER|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
218870318|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
218870319|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
218870320|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
218870321|NCT02887547|PROCEDURE|micro-osteoperforation|
219489587|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
219489588|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
218870322|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
218870323|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
218870324|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
219489589|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
219489590|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
219489591|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
219600875|NCT02303795|DRUG|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
219600876|NCT02303795|DRUG|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 \> years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
218870325|NCT02223481|DRUG|Terbogrel low dose|
218870326|NCT02223481|DRUG|Terbogrel high dose|
219600877|NCT00080145|DRUG|Risperidone|
218870327|NCT02223481|DRUG|Placebo|
219600878|NCT00080145|BEHAVIORAL|Behavior Therapy|
218870328|NCT02925169|DEVICE|CT Scan|CT imaging
218870329|NCT05808010|BIOLOGICAL|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
218870330|NCT05808010|DRUG|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
219489592|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
219489593|NCT04210700|PROCEDURE|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
219489594|NCT04210700|PROCEDURE|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
219600879|NCT01432067|OTHER|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
219600880|NCT01432067|OTHER|Classic physical activities|Daily physical activities based on a standard guide
219489595|NCT02275182|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
219600881|NCT03102606|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
218870331|NCT01362387|OTHER|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
218870332|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
219489596|NCT02275182|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
219489597|NCT03818542|DRUG|ABBV-181|intravenous infusion
219600882|NCT03102606|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
219600883|NCT03102606|OTHER|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
219600884|NCT03102606|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
218870333|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
218870334|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
218870335|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
218870336|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
218870337|NCT00120328|DRUG|SPP301|
218870338|NCT01969721|DRUG|fluticasone propionate|low dose
218870339|NCT01969721|DRUG|salmeterol|
219600885|NCT05326204|OTHER|Home blood glucose monitoring|Self monitoring of capillary blood glucose
219600886|NCT03707405|BEHAVIORAL|Ride-On Cars Training with Different Postures|All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
219600887|NCT01277601|DRUG|TDF|TDF 300 mg tablets administered orally once daily
219600888|NCT01277601|DRUG|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
219600889|NCT00151931|DRUG|Lanthanum carbonate|
219600890|NCT03120182|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
219600891|NCT03120182|DRUG|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
219600892|NCT06163235|OTHER|Obemar platform|Online platform for education and follow-up
219600893|NCT04158245|DRUG|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
218870340|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
218870341|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
218870342|NCT01969721|DRUG|tiotropium|tiotropium high dose
218870343|NCT01969721|DRUG|olodaterol|
218870344|NCT01969721|DRUG|olodaterol|
218870345|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
218870346|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
218870347|NCT01969721|DRUG|tiotropium|tiotropium low dose
219489598|NCT03818542|DRUG|ABBV-368|intravenous infusion
219489599|NCT03818542|DRUG|ABBV-927|intravenous infusion
219489600|NCT03818542|DRUG|ABBV-927|intratumoral injection
219489601|NCT00326300|DRUG|methylphenidate hydrochloride extended-release tablets|
219600894|NCT05292326|DEVICE|PacePress|an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly
219600895|NCT05292326|DEVICE|standard compression band|standard used compression band/sand bag
219600896|NCT05620238|DRUG|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
219613633|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
218870348|NCT01969721|DRUG|fluticasone propionate|low dose
218870349|NCT01969721|DRUG|salmeterol|
218870350|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
219613634|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
218870351|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
218870352|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
218870353|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
218870354|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
218870355|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
218870356|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
218870357|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
218870358|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
218870359|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
218870360|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
218870361|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
218870362|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
218870363|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
218870364|NCT01063088|BIOLOGICAL|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
219489602|NCT00003166|DRUG|bryostatin 1|Given IV
219489603|NCT00003166|DRUG|vincristine sulfate|Given IV
219489604|NCT00003166|OTHER|laboratory biomarker analysis|Correlative studies
219489605|NCT03250507|DRUG|Bupivacaine|0.25% bupivacaine for TAP block
219489606|NCT03250507|DRUG|Liposomal bupivacaine|Exparel for TAP block
219489607|NCT03250507|DRUG|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
219489608|NCT04449588|DRUG|BDB-001 Injection|BDB-001 Injection+Conventional treatment
219489609|NCT04449588|OTHER|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
219489610|NCT05213507|DRUG|aerosol inhaled Amikacin Sulfate Injection|0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
219489611|NCT05213507|OTHER|conventional therapy|According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
219489612|NCT01839565|DEVICE|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
218870365|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
219489613|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
219489614|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
219489615|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
219489616|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
219489617|NCT05388201|OTHER|N95|3M N95 Respirator
218870366|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
218870367|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
219489618|NCT05388201|OTHER|KN95|KN95 Mask (with and without clip)
219489619|NCT05388201|OTHER|KF94|KF94 Mask (with and without clip)
219489620|NCT05388201|OTHER|Surgical|Surgical Mask (with and without clip)
219489621|NCT02902666|DRUG|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
219489622|NCT02902666|DRUG|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
219489623|NCT04295109|DRUG|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
219489624|NCT01817335|PROCEDURE|psychosocial assessment and care|Participate in psycho-educational program
219489625|NCT01817335|OTHER|educational intervention|Participate in psycho-educational program
219489626|NCT01817335|OTHER|communication skills training|Participate in psycho-educational program
219600897|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
218870368|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
219489627|NCT01817335|OTHER|questionnaire administration|Ancillary studies
219489628|NCT01771419|DEVICE|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
219489629|NCT01771419|DEVICE|Cannulotome CT-25mm Cook Medical|
219489630|NCT03289637|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
219489631|NCT05829382|DIETARY_SUPPLEMENT|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
219489632|NCT05829382|DIETARY_SUPPLEMENT|Placebo|Capsule containing placebo administered daily by the participant during the trial period
219489633|NCT02493023|DEVICE|navigated bronchoscopy|
219489634|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
219489635|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
219489636|NCT04816500|DEVICE|Automatic ischemic conditioning treatment instrument|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
219489637|NCT04816500|DRUG|Regular treatment|Antiplatelet agents and statins administration, vascular risk factors control.
219600898|NCT05848115|DEVICE|Bi-level Positive Airway Pressure|An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
218870369|NCT00449449|DRUG|Pertubation with Lidocain Solution|
218870370|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
218870371|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
219489638|NCT02718976|PROCEDURE|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
219489639|NCT02718976|PROCEDURE|Ultrasound guided lumbar plexus block (Shamrock)|
219489640|NCT02718976|DRUG|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
219489641|NCT00103259|DRUG|bortezomib|Given IV
219489642|NCT00103259|DRUG|irinotecan hydrochloride|Given IV
219613635|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
218870372|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
219489643|NCT00103259|OTHER|laboratory biomarker analysis|Optional correlative studies
219489644|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
219489645|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
219489646|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
219489647|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
219489648|NCT01631370|PROCEDURE|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
219489649|NCT03845855|OTHER|virtual reality|Virtual reality with a game
219489650|NCT03845855|OTHER|robotic gait|robotic gait therapy
219489651|NCT04729634|OTHER|Mobilization|Mobilization and breathing exercises according to clinical care
219522572|NCT04786080|BEHAVIORAL|Parent Positive|"Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~1. structured advice, support and tips for parents~2. facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~3. access to carefully selected high-quality, evidence-based online parenting resources."
219522573|NCT04088422|PROCEDURE|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
219522574|NCT02042365|PROCEDURE|ERAS (Enhanced recovery after surgery)|
219522575|NCT03753425|PROCEDURE|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
218870373|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
218870374|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
219522576|NCT01295372|DRUG|Zicronapine|7.5 mg/day; orally
219522577|NCT01295372|DRUG|Risperidone|5 mg/day; orally
218870375|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
218870376|NCT02950376|OTHER|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
218870377|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
218870378|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
218870379|NCT01975610|DRUG|Placebo|Twice daily for 28 days
219489652|NCT04416295|DEVICE|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
219489653|NCT03292965|DRUG|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
219489654|NCT03292965|DRUG|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
219489655|NCT01572428|PROCEDURE|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
219489656|NCT01572428|PROCEDURE|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
219489657|NCT00853931|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
219489658|NCT05233371|OTHER|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
219489659|NCT05233371|OTHER|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~* Frequency and duration of rehabilitation sessions by type of health professionals,~* Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
219489660|NCT05233371|OTHER|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
219489661|NCT01537575|BIOLOGICAL|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
219489662|NCT01537575|BIOLOGICAL|Saline solution|Placebo
219489663|NCT00946465|DRUG|Ramipril 10 Capsule (Sandoz)|
218870380|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
218870381|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
218870382|NCT05571774|OTHER|collection data|collection data
218870383|NCT00004874|RADIATION|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
218870384|NCT04464096|OTHER|non|non
218870385|NCT00093821|DRUG|tanespimycin|Given IV
218870386|NCT00093821|OTHER|pharmacological study|Correlative studies
218870387|NCT00093821|OTHER|laboratory biomarker analysis|Correlative studies
218870388|NCT02254395|DEVICE|Deep Brain Stimulation|
218870389|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
218870390|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
219489664|NCT00946465|DRUG|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
218870391|NCT03299712|DEVICE|ArteFill|soft tissue filler
218870392|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
219489665|NCT01884870|PROCEDURE|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
219489666|NCT02667496|DRUG|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
219489667|NCT02667496|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
219489668|NCT02667496|DRUG|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
219489669|NCT03330028|DRUG|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
219489670|NCT03330028|DRUG|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
219489671|NCT03330028|DRUG|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
219489672|NCT03330028|DRUG|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
219489673|NCT03330028|DRUG|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
219489674|NCT03330028|DRUG|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
219489675|NCT01906801|DRUG|Glucosamine sulfate|
219600899|NCT05848115|DEVICE|Sham Bi-level Positive Airway Pressure|The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
219600900|NCT03785600|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
219489676|NCT01906801|DRUG|Diacerein|
219489677|NCT01906801|DRUG|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
219489678|NCT00501696|DRUG|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
219489679|NCT00501696|DRUG|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
219489680|NCT05512715|PROCEDURE|radioactive iodine|radioactive iodine 15mci
219489681|NCT03880864|RADIATION|Ultrasound|Lung ultrasound
219489682|NCT04230954|DRUG|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
219489683|NCT04230954|DRUG|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
219489684|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
219489685|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
219489686|NCT02866695|DRUG|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
219489687|NCT03224234|DEVICE|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
219489688|NCT03224234|DEVICE|Insulclock without feedback|Not feedback on insulin administration.
219489689|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
219489690|NCT02235961|DRUG|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
219489691|NCT02235961|DRUG|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
219489692|NCT02235961|DRUG|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
219489693|NCT02629237|OTHER|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
219489694|NCT05016765|DEVICE|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
219489695|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
219489696|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
219489697|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
219489698|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
219489699|NCT04311359|DRUG|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
219600901|NCT03785600|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
218870393|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
218870394|NCT06497296|DRUG|Lidocaine|Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
218870395|NCT01403116|DRUG|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
218870396|NCT01403116|DRUG|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
218870397|NCT01954563|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
218870398|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
218870399|NCT04369625|BEHAVIORAL|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
218870400|NCT04369625|BEHAVIORAL|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
218870401|NCT04369625|BEHAVIORAL|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
218870402|NCT04369625|BEHAVIORAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
218870403|NCT03299283|DIAGNOSTIC_TEST|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
218870404|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
219489700|NCT06423937|DRUG|combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab|"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
219489701|NCT00792142|DRUG|bortezomib|Given IV
219489702|NCT00792142|DRUG|dexamethasone|Given orally
218870405|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
219489703|NCT00792142|DRUG|melphalan|Given IV
219489704|NCT00792142|DRUG|thalidomide|Given orally
219489705|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
219489706|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
219489707|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
219489708|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
219489709|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
219489710|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
219489711|NCT00850382|DRUG|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
219489712|NCT00850382|DRUG|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
219489713|NCT00850382|DRUG|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
219489714|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
218870406|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
219489715|NCT00828581|DRUG|lorcaserin|
219489716|NCT03843034|GENETIC|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
219489717|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
219489718|NCT00274664|DEVICE|6 hours occlusion by patching|
218870407|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
218870408|NCT04778800|DRUG|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
218870409|NCT04778800|DRUG|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
218870410|NCT04778800|DRUG|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
218870411|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
218870412|NCT00006056|DRUG|anti-thymocyte globulin|
219489719|NCT00274664|DEVICE|12 hours occlusion by patching|
219489720|NCT04101721|DRUG|aflibercept|Administered IVT
218870413|NCT00006056|DRUG|busulfan|
219489721|NCT04101721|PROCEDURE|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
219489722|NCT05420818|PROCEDURE|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
219600902|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
219600903|NCT03842228|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218870414|NCT00006056|DRUG|cyclophosphamide|
218870415|NCT00006056|DRUG|cyclosporine|
218870416|NCT00006056|DRUG|etoposide|
218870417|NCT00006056|DRUG|filgrastim|
218870418|NCT00006056|DRUG|methotrexate|
219489723|NCT02564952|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
219489724|NCT02564952|DRUG|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
219489725|NCT02924337|DRUG|Placebo|
219489726|NCT02924337|DRUG|Imeglimin|
219489727|NCT02924337|DRUG|Moxifloxacin|
219489728|NCT03986918|DEVICE|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
219489729|NCT00756652|DEVICE|Mentor Silicone Gel-Filled Breast Implants|
219489730|NCT00756652|DEVICE|Saline Breast Implants|
219489731|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
219489732|NCT01972607|OTHER|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
219489733|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
219600904|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219600905|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
219600906|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
219600907|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
219600908|NCT03842228|PROCEDURE|Echocardiography Test|Undergo ECHO
219600909|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219600910|NCT03842228|DRUG|Olaparib|Given PO
219600911|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
219613636|NCT05256719|BIOLOGICAL|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
218870419|NCT00006056|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218870420|NCT04707248|DRUG|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
218870421|NCT04707248|DRUG|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
218870422|NCT00707954|DRUG|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
218870423|NCT00707954|DRUG|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
218870424|NCT01306656|DRUG|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
218870425|NCT01306656|OTHER|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
218870426|NCT01306656|DIETARY_SUPPLEMENT|Vitamin D|Daily multivitamin with 400 IU vitamin D.
218870427|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
218870428|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
218870429|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
218870430|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
218870431|NCT00017290|BIOLOGICAL|sargramostim|
218870432|NCT00017290|DRUG|cyclophosphamide|
218870433|NCT00017290|DRUG|prednisone|
218870434|NCT00017290|DRUG|vincristine sulfate|
219199963|NCT06860581|DIETARY_SUPPLEMENT|Intervention (Sanprobi®Stress)|The composition of lyophilized strains of Bifidobacterium longum Rosell®-175 and Lactobacillus helveticus Rosell®-52 (trade name: Sanprobi®Stress; manufacturer: Sanprobi sp. z o.o. sp. k., Szczecin, Poland) was placed in capsules, the shell of which consisted of hydroxypropylmethylcellulose. The total bacterial content per capsule was 3x109 CFU. Filling substances were potato starch and magnesium stearate. The weight of the capsule was 420 mg. Dosage: 1 capsule/day for 12 weeks.
219489734|NCT05723861|DEVICE|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
219600912|NCT03336736|DIAGNOSTIC_TEST|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
219600913|NCT02580110|OTHER|Sucrose|
219600914|NCT02580110|OTHER|Stevia glycosides|
219600915|NCT02580110|OTHER|saccharin|
219600916|NCT00305474|DRUG|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
219600917|NCT04643977|DEVICE|mARG-01-17 (mesohyal AGRIBENONE)|Dermal Filler
218870435|NCT03846609|DEVICE|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
218870436|NCT03846609|DEVICE|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
218870437|NCT00711789|DRUG|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
218870438|NCT00711789|DRUG|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
218870439|NCT01321957|DRUG|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
218870440|NCT01321957|DRUG|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
218870441|NCT04654078|DRUG|IN-C004 with water|One time dose of IN-C004 taken with water
218870442|NCT04654078|DRUG|IN-C004 without water|One time dose of IN-C004 taken without water
218870443|NCT04654078|DRUG|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
218870444|NCT00005949|BIOLOGICAL|aldesleukin|Given SC
218870445|NCT00005949|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|Given SC
218870446|NCT00005949|OTHER|laboratory biomarker analysis|Correlative studies
218870447|NCT05310812|DIAGNOSTIC_TEST|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
218870448|NCT05014997|OTHER|no intervention|this study was designed as retrospective observational study
219600918|NCT01478412|OTHER|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
218870449|NCT02353195|OTHER|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
218870450|NCT01052506|DRUG|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
218870451|NCT01052506|DRUG|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
218870452|NCT00172341|DRUG|Staloral TM|
218870453|NCT05476523|OTHER|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
218870454|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
218870455|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
219489735|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
219489736|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
219489737|NCT03813394|DRUG|pembrolizumab|-Pembrolizumab in Solution for Injection
219489738|NCT03813394|DRUG|bevacizumab|"* Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution"
219489739|NCT05596227|DRUG|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
219489740|NCT05596227|DRUG|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
219489741|NCT05596227|DRUG|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
219489742|NCT05596227|DRUG|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
218870456|NCT00056446|DRUG|Vatalanib|
218870457|NCT00421135|DRUG|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
218870458|NCT01365858|OTHER|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
218870459|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
218870460|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
218870461|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
218870462|NCT01854268|DRUG|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
219489743|NCT05596227|OTHER|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
219522578|NCT05531422|DRUG|Inhaled fentanyl aerosol|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
219600919|NCT02291510|DRUG|Met DR|metformin delayed-release tablets
219600920|NCT02291510|DRUG|Met XR|metformin extended-release tablets
219600921|NCT02291510|DRUG|Met IR|metformin immediate-release tablets
219600922|NCT04210219|DRUG|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
219600923|NCT06358001|DEVICE|EchoTip AcuCore|Using endoscopic ultrasound guided needle to collect biopsies
219600924|NCT02567435|DRUG|Cyclophosphamide|Given IV and PO
219199964|NCT06860581|OTHER|Placebo|Filling substances were only potato starch and magnesium stearate.
219600925|NCT02567435|BIOLOGICAL|Dactinomycin|Given IV
219600926|NCT02567435|DRUG|Irinotecan Hydrochloride|Given IV
219600927|NCT02567435|OTHER|Laboratory Biomarker Analysis|Correlative studies
219600928|NCT02567435|OTHER|Questionnaire Administration|Ancillary studies
219600929|NCT02567435|RADIATION|Radiation Therapy|Undergo RT
219600930|NCT02567435|DRUG|Temsirolimus|Given IV
219489744|NCT05596227|OTHER|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
219489745|NCT06138678|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
219489746|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
219489747|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
219489748|NCT03257774|OTHER|Adhesive strip A|Strip consisting of a newly developed adhesive
219489749|NCT03257774|OTHER|Adhesive strip B|Strip consisting of a newly developed adhesive
219489750|NCT03257774|OTHER|Adhesive strip C|Strip consisting of a newly developed adhesive
219489751|NCT06096181|DRUG|Remifentanil TIVA|Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.
219489752|NCT06096181|DRUG|Dexmedetomidine TIVA|Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.
219489753|NCT06096181|DRUG|Propofol TIVA|Propofol is an anesthetic drug that causes sleep during surgery.
219489754|NCT04886232|DEVICE|VP1 Lido US|Hyaluronic acid dermal filler containing lidocaine
218870463|NCT03147443|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
219489755|NCT04886232|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid dermal filler containing lidocaine
219489756|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
219489757|NCT06523309|OTHER|Electroacupuncture treatment|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
219489758|NCT06133907|GENETIC|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
219489759|NCT05905809|DEVICE|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
219489760|NCT05905809|DEVICE|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
219489761|NCT00038467|DRUG|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
219489762|NCT00038467|DRUG|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
219489763|NCT05531799|PROCEDURE|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~\- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
219489764|NCT01988493|DRUG|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
218870464|NCT03147443|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
219489765|NCT01988493|DRUG|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
219600931|NCT02567435|DRUG|Vincristine Sulfate|Given IV
219600932|NCT02567435|DRUG|Vinorelbine|Given IV
219600933|NCT06390826|PROCEDURE|Biopsy Procedure|Undergo biopsy
219600934|NCT06390826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219600935|NCT06390826|PROCEDURE|Computed Tomography|Undergo CT scan
219600936|NCT06390826|PROCEDURE|Echocardiography Test|Undergo ECHO
219600937|NCT06390826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219600938|NCT06390826|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
219600939|NCT06390826|DRUG|Sunitinib|Given PO
219600940|NCT06772623|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219600941|NCT06772623|DRUG|Budigalimab|IV Infusion
219600942|NCT06772623|DRUG|Pembrolizumab|IV Injection
219600943|NCT06772623|DRUG|Pembrolizumab|IV Infusion
219600944|NCT06772623|DRUG|Carboplatin|IV Infusion
219600945|NCT06772623|DRUG|Pemetrexed|IV Infusion
219600946|NCT06772623|DRUG|Cisplatin|IV Infusion
219600947|NCT02196181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219600948|NCT02196181|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219600949|NCT02196181|DRUG|Dabrafenib Mesylate|Given PO
218870465|NCT03147443|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
219489766|NCT01988493|DRUG|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
219489767|NCT01988493|DRUG|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
219489768|NCT01988493|DRUG|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
219489769|NCT00945971|OTHER|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
219600950|NCT02196181|PROCEDURE|Echocardiography Test|Undergo ECHO
219600951|NCT02196181|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219600952|NCT02196181|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219600953|NCT02196181|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
218870466|NCT06581172|DIAGNOSTIC_TEST|D_dimer|DIC score including FDPs,D\_dimer
218870467|NCT01646242|PROCEDURE|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
218870468|NCT01646242|PROCEDURE|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
218870469|NCT02563938|DRUG|AK001|Given parenterally.
219489770|NCT01544374|OTHER|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
219489771|NCT05548543|DRUG|HCP2202|Take it once per period.
219489772|NCT05548543|DRUG|RLD2202|Take it once per period.
219489773|NCT05548543|DRUG|RLD2203|Take it once per period.
219489774|NCT05892965|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
219489775|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
219600954|NCT02091791|PROCEDURE|Traction sessions|
219600955|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
219600956|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
219600957|NCT06390839|PROCEDURE|Biopsy Procedure|Undergo biopsy
219600958|NCT06390839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218870470|NCT02563938|DRUG|Placebo|
218870471|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
218870472|NCT03517969|DRUG|Berzosertib|Given IV
218870473|NCT03517969|DRUG|Carboplatin|Given IV
218870474|NCT03517969|DRUG|Docetaxel|Given IV
218870475|NCT03517969|OTHER|Laboratory Biomarker Analysis|Correlative studies
218870476|NCT00358969|DRUG|guanfacine (Tenex)|
218870477|NCT03060954|DEVICE|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
219600959|NCT06390839|PROCEDURE|Computed Tomography|Undergo CT scan
219600960|NCT06390839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219600961|NCT06390839|DRUG|Palbociclib|Given PO
219600962|NCT04119739|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
219600963|NCT04119739|DRUG|Ibuprofen Arginine|Oral tablets
219600964|NCT04942093|DIETARY_SUPPLEMENT|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
219600965|NCT04942093|DIETARY_SUPPLEMENT|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
219600966|NCT00122759|DRUG|ketamine|
219600967|NCT06550713|DRUG|TQB3455 tablet+Azacitidine for Injection|TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
219600968|NCT01940991|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
219600969|NCT01940991|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
219600970|NCT04269525|BIOLOGICAL|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
219600971|NCT00610246|DRUG|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
219600972|NCT04151043|BEHAVIORAL|Suggestions|Verbal suggestions or no suggestions about treatment outcome
219600973|NCT04151043|DEVICE|Deep brain stimulation|Regulation of deep brain stimulation intensity
219600974|NCT01236443|DRUG|HPPH|3 mg/m2 IV
219489776|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
219489777|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
219489778|NCT00130663|DEVICE|PDA blood pressure screening program and chart reminder|
219489779|NCT04425954|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
219489780|NCT00146133|BEHAVIORAL|diet, exercise|
219489781|NCT06701487|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of Pavlovian-to-instrumental transfer (PIT) effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
219489782|NCT06701487|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
219489783|NCT06701487|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
219489784|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Quantity Frequency: Alcohol, Cannabis, (Meth-) Amphetamine, Cocaine)~* SCID: AUD and SUD (Cannabis, Methamphetamine, Amphetamine, Cocaine) criteria and last year \& depressive symptoms \& symptoms for Mania and psychotic disorder (acute and lifetime) MiniDIPS psychotic disorders"
219489785|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T and STAI-S)~* Adult ADHD Self-Report Scale (ASRS)~* Alcohol Use Disorders Identification Test (AUDIT)~* CAS -A (Alkohol)~* Cannabis Use Disorders Identification Test (CUDIT)~* Fragebogen zu Gedanken und Gefühle 14 Items (FGG-14)~* Fragebogen zur Sozialen Unterstützung (F-SozU-K14)~* Trierer Inventar zum chronischen Stress (TICS)~* Oslo 3-Items-Social-Support Scale (Oslo-3)~* Social Readjustment Rating Scale (SRRS)~* International Trauma Questionnaire (ITQ)~* Positive and Negative Affect Schedule (PANAS)"
219489786|NCT06701487|BEHAVIORAL|Neuropsychological tests|"* Digit-Symbol-Test (DST)~* Digit Span Task~* Value-based decision-making task (VBDM)"
219489787|NCT04221217|DRUG|Icosapent|Icosapent (MND-2119) capsules.
219600975|NCT05021432|OTHER|Virtual reality training group|This group will receive video based games
219600976|NCT05021432|OTHER|Circuit Training group|They will receive Task-oriented Circuit training exercise program
219600977|NCT00963066|DEVICE|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
219600978|NCT00963066|DEVICE|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
219600979|NCT00963066|DEVICE|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
219600980|NCT04587726|BEHAVIORAL|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
219600981|NCT04587726|OTHER|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
219600982|NCT00347386|DRUG|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
218870478|NCT03060954|DEVICE|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
219600983|NCT00347386|DRUG|Placebo|Placebo tablet, once daily
219600984|NCT03203850|DRUG|Deferasirox FCT|Taken orally once per day (QD) as a film coated tablet (FCT)
218870479|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
218870480|NCT01091818|DRUG|dexmedetomidine|Dexemedethomidine is given as major sedative drug
219489788|NCT00221052|DRUG|Diclofenac|
219489789|NCT01270607|PROCEDURE|Acupuncture|Treatment given twice per week for 4 weeks
219600985|NCT03203850|PROCEDURE|Phlebotomy|according to investigator's decision
219600986|NCT01711515|DRUG|Cisplatin|Given IV
219600987|NCT01711515|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219600988|NCT01711515|RADIATION|Internal Radiation Therapy|Undergo intracavitary brachytherapy
219600989|NCT01711515|BIOLOGICAL|Ipilimumab|Given IV
219600990|NCT01711515|OTHER|Laboratory Biomarker Analysis|Correlative studies
218870481|NCT01091818|DRUG|Midazolam|Midazolam is given as major sedative drug
219489790|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.
218870482|NCT04336852|PROCEDURE|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
219489791|NCT06700655|PROCEDURE|Corneal transplantation|The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.
219489792|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation combined corneal stromal stem cell group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
219489793|NCT03537222|DIAGNOSTIC_TEST|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
219489794|NCT04040907|DRUG|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
219489795|NCT04040907|DRUG|Placebo|Placebo and active drug will have the same appearance
219489796|NCT04415177|DEVICE|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
219489797|NCT04415177|DEVICE|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
219489798|NCT03821142|DEVICE|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
219489799|NCT02618252|DEVICE|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
219489800|NCT02618252|DEVICE|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
218870483|NCT04336852|PROCEDURE|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
218870484|NCT04336852|PROCEDURE|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
218870485|NCT04318327|BIOLOGICAL|PHE885|Infusion
219489801|NCT03649256|DIAGNOSTIC_TEST|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
219489802|NCT03411122|DRUG|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
219489803|NCT03411122|DRUG|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
219489804|NCT00627458|BIOLOGICAL|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
219489805|NCT00913861|BEHAVIORAL|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
219489806|NCT00913861|DRUG|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
219489807|NCT00913861|BEHAVIORAL|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
218870486|NCT01474070|DEVICE|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
219489808|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
219489809|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
219489810|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
219489811|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
219489812|NCT00168740|DRUG|rituximab|
218870487|NCT00687102|DRUG|tamoxifen|oral tamoxifen plus placebo daily for 5 years
218870488|NCT00687102|DRUG|raloxifene|oral raloxifene plus placebo daily for 5 years
219489813|NCT01535391|DRUG|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
218870489|NCT02227394|DRUG|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
218870490|NCT02227394|DRUG|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
218870491|NCT03071289|RADIATION|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
218870492|NCT03071289|DRUG|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
218870493|NCT03071289|RADIATION|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
218870494|NCT05443724|DRUG|CVL-231 30 mg|Oral tablets
218870495|NCT06972095|PROCEDURE|EVAR|endovascular repair of the AAA with the endurant stent graft
219489814|NCT02311543|DRUG|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
219489815|NCT00159081|DRUG|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
219613637|NCT05256719|BIOLOGICAL|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
219613638|NCT05256719|BIOLOGICAL|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
218870496|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
218870497|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
218870498|NCT05848297|DEVICE|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
218870499|NCT04051827|DRUG|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
218870500|NCT04051827|DRUG|TAK-788|TAK-788 Oral Capsules.
218870501|NCT06493240|RADIATION|radiation|45 Gy radiation dose in 25 fractions to the pelvis
218870502|NCT06493240|DRUG|PD-1 Monoclonal Antibody|200mg Sintilimab after radiation (3 times, 2-week interval)
219489816|NCT03778190|PROCEDURE|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
218870503|NCT06493240|PROCEDURE|TME surgery|TME surgery for 6\~8 weeks after radiation
219489817|NCT05523310|OTHER|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
218870504|NCT02573753|BEHAVIORAL|Sleep restriction|
218870505|NCT02573753|DIETARY_SUPPLEMENT|Weight gain|
218870506|NCT06979518|DRUG|GSK3862995B|GSK3862995B will be administered.
218870507|NCT06979518|DRUG|Placebo|Matching placebo will be administered.
219489818|NCT01979302|OTHER|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
219489819|NCT01979302|OTHER|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
219489820|NCT00155259|DRUG|Docetaxel , Cisplatin , Capecitabine|
219489821|NCT05174078|OTHER|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
219489822|NCT05174078|OTHER|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
219489823|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min|when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
218870508|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
218870509|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
219489824|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min|the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
219489825|NCT04671160|DIAGNOSTIC_TEST|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
219600991|NCT01080560|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
219600992|NCT01155973|BEHAVIORAL|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
218870510|NCT06922097|DRUG|Giving atropine at heart rates below 60 beats per minute|In patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
218870511|NCT06922097|DRUG|Giving atropine at heart rates below 30 beats per minute|In patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
218870512|NCT05138549|DRUG|Astaxanthin|12 mg oral astaxanthin supplement
218870513|NCT05138549|OTHER|Placebo|Oral placebo identical to astaxanthin supplement
218870514|NCT07011043|DRUG|Budoprutug|Single IV dose of study product on Day 1 of study
218870515|NCT06680440|DRUG|ASC30|Tablet, QD
219489826|NCT06124326|DIETARY_SUPPLEMENT|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
219489827|NCT06404281|BIOLOGICAL|γδ T-PD-1 Ab cells|Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
218870516|NCT06680440|OTHER|Placebo|Tablets, QD
218870517|NCT06713616|DRUG|Racemic ketamine|Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
218870518|NCT06713616|DRUG|Spravato (Esketamine)|Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
218870519|NCT06584448|OTHER|Deuterium Metabolic Imaging with deuterated acetate tracer|Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
218870520|NCT06892639|BIOLOGICAL|D-Fi|D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
218870521|NCT07080944|PROCEDURE|SLN identification using technetium-99m|SLN Biopsy after pre-surgery positive SLN visualization.
219489828|NCT03573115|DRUG|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
218870522|NCT07080944|PROCEDURE|SLN intra-operatory identification with radioguided surgery|SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.
218870523|NCT07080944|PROCEDURE|Axillary Limph Node Dissection (ALND)|Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.
218870524|NCT07079982|OTHER|Freeze-dried whole grape powder|Studying the effects of freeze-dried whole grape powder on immune profiles in healthy aging adults
218870525|NCT07079982|OTHER|Control grape-free powder|Studying effects of a control grape-free powder on immune profiles in healthy aging
219489829|NCT06565689|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
219489830|NCT01447979|DEVICE|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
219600993|NCT01155973|OTHER|Control group|SCORE oral information and counseling as standard practice care
219600994|NCT00429429|PROCEDURE|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
219600995|NCT03956394|DIAGNOSTIC_TEST|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
219600996|NCT01272037|DRUG|Anastrozole|Given PO
219600997|NCT01272037|DRUG|Exemestane|Given PO
219600998|NCT01272037|OTHER|Laboratory Biomarker Analysis|Correlative studies
219600999|NCT01272037|DRUG|Letrozole|Given PO
219601000|NCT01272037|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
219601001|NCT01272037|DRUG|Systemic Chemotherapy|Given IV
219601002|NCT01272037|DRUG|Tamoxifen Citrate|Given PO
219601003|NCT04856930|BIOLOGICAL|Imsidolimab|Humanized Monoclonal Antibody
219601004|NCT04856930|BIOLOGICAL|Placebo|Placebo
219601005|NCT00916643|DEVICE|HELP Secura (apheresis treatment)|Process is described in Arm (above).
218870526|NCT06900920|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
218870527|NCT06900920|DRUG|TQB3473 Placebo|Placebo contains no active substance.
219489831|NCT05234242|PROCEDURE|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
219489832|NCT01538589|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
219489833|NCT03224117|DRUG|DWJ211|inject the Drug into submental fat via subcutaneous
218870528|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
218870529|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
218870530|NCT07081256|DRUG|QLM2010 for injection；dexamethasone|QLM2010 for injection；Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
218870531|NCT07081256|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
219489834|NCT03224117|DRUG|Normal saline|inject the Drug into submental fat via subcutaneous
219489835|NCT04538768|PROCEDURE|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
219489836|NCT04538768|PROCEDURE|Direct suture|direct fascia suture
219489837|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
219489838|NCT02765542|OTHER|Automated disease assessment & self-care support phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
219489839|NCT05109273|PROCEDURE|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
219601006|NCT03632915|DRUG|Levetiracetam|Standard of care
218870532|NCT07088263|DRUG|Gemcitabine, Vinorelbine, Eribulin, or Utidelone|Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
218870533|NCT07087522|BEHAVIORAL|Stress Ball Use|Participants will perform hand exercises using a rubber stress ball for 5 minutes, 3 times daily, for 3 days prior to radial angiography.
219489840|NCT00741117|PROCEDURE|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
218870534|NCT07088289|BEHAVIORAL|TRIPP|In this study, participants will use TRIPP with a VR headset at home, engaging in short mindfulness sessions 3+ times per week for 4-12 weeks.
218870535|NCT07089030|PROCEDURE|Standard endoscopic evaluation|Examinations of the gastrointestinal (GI) tract (including the stomach, small intestine, and colon) will be performed to identify the source of bleeding. These examinations may be repeated based on the treating physician's assessment. Iron supplementation (ferrous sulfate) will be administered either orally (per os) or intravenously (IV), and blood transfusions will be provided if necessary.
219601007|NCT03632915|DRUG|Lacosamide|Standard of care
219601008|NCT03632915|DRUG|Phenytoin|Standard of care
219601009|NCT03632915|DRUG|Phenobarbital|Standard of care
219601010|NCT03632915|DRUG|Ketamine|Standard of care
219601011|NCT03632915|DRUG|Valproic Acid|Standard of care
219601012|NCT01843296|DRUG|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
219021451|NCT05988892|BEHAVIORAL|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.
219021452|NCT06440967|DRUG|Fezolinetant|oral
219021453|NCT06440967|DRUG|Placebo|oral
219021454|NCT06440967|DRUG|Tamoxifen|oral
219021455|NCT06440967|DRUG|Aromatase inhibitor|oral
219021456|NCT04640142|BIOLOGICAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion.
219021457|NCT05948566|BIOLOGICAL|TS23|Monoclonal antibody
219489841|NCT00741117|PROCEDURE|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
219489842|NCT00741117|PROCEDURE|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
219601013|NCT01843296|PROCEDURE|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
219601014|NCT01843296|DRUG|Bupivacaine|
219601015|NCT01843296|DRUG|Fentanyl|
219601016|NCT00678210|DRUG|CP-690,550|tablets, 2 mg BID for 12 weeks
219601017|NCT00678210|DRUG|CP-690,550|tablets, 5 mg BID for 12 weeks
219601018|NCT00678210|DRUG|CP-690,550|tablets, 15 mg BID for 12 weeks
219601019|NCT00678210|DRUG|Placebo|tablets, BID for 12 weeks
219613639|NCT05256719|BIOLOGICAL|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
219613640|NCT05256719|BIOLOGICAL|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
219613641|NCT03787134|BEHAVIORAL|working memory and attention|Behavioral tests of working memory and attention
219613642|NCT01082497|BEHAVIORAL|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
218870536|NCT07089030|PROCEDURE|Conservative Medical Management|The investigational intervention involves a conservative treatment approach guided by a decision-making algorithm based on iron deficiency anemia values. This algorithm, developed from guidelines by the British Society of Gastroenterology and the American Gastroenterological Association, determines whether patients receive oral or IV ferrous sulfate or a blood transfusion. Laboratory parameters (hemoglobin, ferritin) will be monitored at weeks 4, 12, 38, and 64. After iron therapy, hemoglobin response will be assessed at 4 weeks, and treatment will continue for \~3 months post-normalization to ensure iron store repletion. Blood tests will be repeated every 6 months to detect recurrence.
218870537|NCT07087457|BEHAVIORAL|The digital stimulus command|"The digital stimulus command: Providing information on the harms of inactivity and sedentary lifestyle on online, digital platforms. The individual will take the HRV measurement in a sitting position for 5 minutes every morning (before consuming tobacco products for smokers) as taught and will send the screenshot of the data to the researcher via WhatsApp. Ensuring that the digital stimulus commands that will remind the activity in line with TTM are followed by reminders sent to the computer screen or mobile phones. Taking a break from sitting when the command It's time for activity comes (taking a total of 6 breaks in the working hours of 08:30 - 17:30, 1 every 60 minutes recording the activity as completed in the digital diary and survey form) \*Activities of office workers other than the time they spend sitting; Recording the number of steps and activities in the office, its surroundings and in daily life in a digital diary."
218870538|NCT07087457|BEHAVIORAL|5 day 30-minute walking program|5 day 30-minute walking program. This group was also defined as the human stimulus group because, in addition to the digital stimulus command, they will be invited by the researcher and will participate in the walking program with the researcher. This group will first receive the activity program and simultaneously will also receive the digital stimulus command interventions.
218870539|NCT07089251|DRUG|low-dose epinephrine and tranexamic acid|low-dose epinephrine and tranexamic acid
218870540|NCT07089251|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid
218870541|NCT06904235|DRUG|IV NEPA (fosnetupitant/palonosetron)|"In NEPA-22-01, different body weight-based dosages of IV NEPA will be applied to patients below and over 3 months of age:~Formulation A (for patients ≥3 months of age; 235 mg fosnetupitant/1.5 mg palonosetron per vial) or Formulation B (for patients \<3 months of age; 235 mg fosnetupitant/2.5 mg palonosetron per vial)."
218870542|NCT06904235|DRUG|Reference Treatment: IV ondansetron infusion|"IV Ondansetron Dosing Regimen~* Day 1 (before start of chemotherapy): One 30-min infusion of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)~* Day 1 at 4 h and 8 h after the end of first administration: Two 30-min infusions of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)"
218870543|NCT06904235|DRUG|Reference Treatment: IV fosaprepitant infusion|"Fosaprepitant IV Dosing Regimen~* Patients aged 12 years to \<18 years: a single dose of IV fosaprepitant 150 mg~* Patients aged 2 years to \<12 years: a single dose of IV fosaprepitant 4 mg/kg (maximum dose: 150 mg)~* Patients aged 6 months to \<2 years: a single dose of IV fosaprepitant 5 mg/kg (maximum dose: 150 mg)"
218870544|NCT07088523|DRUG|Xintong Oral Liquid (Sequential Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 10 mL tid po from week 5 to 52.
218870545|NCT07088523|DRUG|Xintong Oral Liquid (Intensive Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 20 mL tid po for 4 weeks.
218870546|NCT07088523|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
218870547|NCT07088523|DRUG|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
219021458|NCT04742101|DRUG|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
219021459|NCT02150655|BIOLOGICAL|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
219021460|NCT02150655|BIOLOGICAL|Placebo|
219021461|NCT01811927|DEVICE|PRO-Kinetic Energy Stent|Bare-metal stent
219021462|NCT05023226|PROCEDURE|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
219021463|NCT05023226|PROCEDURE|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
219021464|NCT02504567|DEVICE|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
219021465|NCT02504567|DEVICE|RF ablation|Pulmonary vein isolation using the RF ablation catheter
219021466|NCT04996849|OTHER|Data Capture|Data collected
219021467|NCT04996849|OTHER|Questionnaire Administration|Ancillary studies
219021468|NCT03474887|OTHER|Physical Consultation|Regular physician consultation at the primary care clinic.
219021469|NCT03474887|OTHER|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
219021470|NCT05174910|DEVICE|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
219021471|NCT02893072|BEHAVIORAL|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
219021472|NCT01892930|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219021473|NCT01892930|PROCEDURE|therapeutic conventional surgery|Undergo partial or radical nephrectomy
219021474|NCT01892930|OTHER|laboratory biomarker analysis|Correlative studies
218870548|NCT07087613|DEVICE|Eko CORE 500 Digital Stethoscope|The FDA-cleared Eko CORE 500 digital stethoscope is used to collect phonocardiogram (PCG) and three-lead ECG recordings from participants. This observational study uses these recordings to develop and validate artificial intelligence algorithms to detect pulmonary hypertension and low left ventricular ejection fraction. No modifications to the device or device functionality are being tested.
218870549|NCT07089602|OTHER|Standard of Care DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219021475|NCT03411473|BIOLOGICAL|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
219021476|NCT04095507|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
219021477|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
219021478|NCT05316662|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
219021479|NCT05564936|DEVICE|ME&MG mobile application|ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
219021480|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
219489843|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
219489844|NCT01734213|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
219489845|NCT01734213|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
219489846|NCT03252574|OTHER|A|AIR+ Smart Mask Only
219489847|NCT03252574|OTHER|B|AIR+ Smart Mask with micro-ventilator
219489848|NCT01909388|RADIATION|MRI-TRUS fusion guided real time HDR|
219489849|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
219489850|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
219489851|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
219489852|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
219489853|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
219601020|NCT04825912|BEHAVIORAL|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
219601021|NCT01981902|DEVICE|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
219601022|NCT06048952|BEHAVIORAL|Music Therapy|Huseyni maqam, Pentatonic music
218870550|NCT07089602|OTHER|Tri-Membrane Wrap™ DFU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870551|NCT07089602|OTHER|Membrane Wrap™ DFU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870552|NCT07089602|OTHER|Membrane Wrap-Lite™ DFU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219489854|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
218870553|NCT07089602|OTHER|Membrane Wrap-Hydro™ DFU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219489855|NCT00989365|OTHER|Aerobic training|Treadmill training
219489856|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
219489857|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
219489858|NCT00514501|DRUG|Iodofiltic acid I 123|
219489859|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
219489860|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
219489861|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
219489862|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
218870554|NCT07089602|OTHER|Standard of Care VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870555|NCT07089602|OTHER|Tri-Membrane Wrap™ VLU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870556|NCT07089602|OTHER|Membrane Wrap™ VLU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870557|NCT07089602|OTHER|Membrane Wrap-Lite™ VLU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219489863|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
219489864|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
219489865|NCT02603536|OTHER|WelTel|An evidence-based, text messaging solution for improving patient adherence.
219489866|NCT02788955|BEHAVIORAL|Dietary counselling|
219489867|NCT02788955|OTHER|Dietary Protein|
219489868|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
218870558|NCT07089602|OTHER|Membrane Wrap-Hydro™ VLU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218870559|NCT07089121|DRUG|Descartes-08|In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting.
219489869|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
219489870|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
219489871|NCT01246297|OTHER|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
219489872|NCT01246297|OTHER|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
219489873|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
219489874|NCT06566560|OTHER|redispensing oral anticancer drugs|"Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy."
219601023|NCT02394470|OTHER|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
219601024|NCT02394470|OTHER|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
219601025|NCT02394470|OTHER|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
218870560|NCT07088302|DRUG|lactase administration|1 drop for each 10 ml of formula milk for 14 days
218870561|NCT07088302|OTHER|placebo|10 ml milk without lactase
218870562|NCT07088835|DEVICE|SeizEAR|The in-ear electrode is a two-electrode device that fits snugly into the ear canal of the user. The device electrodes consist of a Ag/AgCl layer over a substrate. In one iteration, the substrate is a silicone rubber. In another iteration, the substrate is copper. The copper iteration consists of a Ag/AgCl ink that is manually applied to the copper, whereas the other iteration is purchased in a finished state with the Ag/Agel already adhered to the silicone. The electrodes are attached to a foam earpiece during the molding process. The foam earbud is made in-house and can be designed to be more firm or less firm.
219021481|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
219021482|NCT02958839|PROCEDURE|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
219489875|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
219489876|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
219489877|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
219489878|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
219489879|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
219021483|NCT04551846|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
219199965|NCT06861725|OTHER|Silver Diamine Fluoride (SDF)|"Silver Diamine Fluoride has been used extensively around the globe for decades. Advantage Arrest silver diamine fluoride 38% will change how you offer your patients the protection they deserve.~Advantage Arrest:~Provides immediate relief from dentinal hypersensitivity Kills pathogenic organisms Hardens softened dentin making it more acid and abrasion resistant Does not stain sound dentin or enamel Can provide important clinical feedback due to its potential to stain visible or hidden lesions Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity."
218870563|NCT07088822|BIOLOGICAL|V4020|The V4020 vaccine was prepared using an iDNA® infectious clone that encodes the full-length rearranged genomic RNA downstream from the optimized CMV promoter. Compared to the wild type VEEV, V4020 contains genetic rearrangement within the genomic RNA, with the capsid gene placed downstream from the glycoprotein genes. V4020 also includes attenuating mutations from the VEE TC83 vaccine, nucleotide A at position 3 in the untranslated region and E2-120Arg in the E2 glycoprotein. Notably, the E2-120Arg attenuating mutation was genetically engineered in V4020 to prevent reversion mutations. The E2-120Arg was encoded in V4020 by a CGA codon instead of AGA in the TC83 virus. Therefore, in the V4020 vaccine, at least two mutations would be needed to revert to the wildtype ACA (E2-120Thr). In contrast, in the TC83 vaccine, an AGA codon encodes the attenuating mutation E2-120Arg, and a single point mutation would be sufficient to revert to the 213 VEEV wild type ACA (E2-120Thr).
219021484|NCT04551846|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
219199966|NCT06861725|OTHER|VOCO Fissurit|Transparent Light-cured pits and fissure sealant, with high stability and good adhesion to enamel
219199967|NCT06862193|BEHAVIORAL|HealthyMoms4MentalHealth|The intervention is a mobile application targeting women during the perinatal period, aiming to promote mental wellbeing.
219199968|NCT06864741|BEHAVIORAL|Virtual reality guided motor rehabilitation|Custom rehabilitation exercises running on a Meta Quest 2/3S/3 head mounted virtual reality display.
219489880|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
219021485|NCT01024296|DEVICE|Port Close|Device for applying loop suture to close surgical site
219021486|NCT05096416|DEVICE|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
219021487|NCT04992572|DRUG|Propofol Injection|25mg Propofol administered by injection
219021488|NCT04992572|DRUG|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
219021489|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
219021490|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
219021491|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
219021492|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
219021493|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
219021494|NCT06710145|BEHAVIORAL|Combat Attention Training|The Combat Attention App is a response-time based mechanized preventive intervention designed to train combat soldiers' attention toward threats before combat exposure in order to reduce the risk for combat-related post-trauma symptoms. In light of the results of controlled studies that proved the efficacy of this preventive intervention, the Israel Defense Forces (IDF) decided at the beginning of the Iron Swords War (October 7th, 2023) to implement an internet-based App of the intervention, and soldiers and combat reservists were invited to train on the Combat Attention App.
219021495|NCT03492255|DRUG|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
219199969|NCT02853500|DEVICE|TriNav|TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
219199970|NCT02853500|DEVICE|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
219199971|NCT02853500|DRUG|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
219199972|NCT03817983|DIAGNOSTIC_TEST|MRE review for evidence of axSpA in SIJs|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease
219199973|NCT03817983|DIAGNOSTIC_TEST|Clinical assessment and dedicated MRI of the spine and pelvis|Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA
219199974|NCT03744676|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
219199975|NCT05394857|DRUG|SHR-1314|SHR-1314 subcutaneously
219199976|NCT06674811|OTHER|Wearing Smartwatch|Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.
219489881|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
219489882|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
219489883|NCT02617446|DRUG|Placebo|IV of matching saline solution
219489884|NCT02617446|DRUG|Istaroxime|IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
219489885|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
218870564|NCT07087873|DEVICE|Neuroelectrical modulation group|Participants received transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device.
218870565|NCT07087873|DEVICE|Pseudo-neuromodulation group|Pseudo-stimulation is performed using the same equipment and procedures as in the neuromodulation group.
218870566|NCT02209974|DRUG|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
219489886|NCT03779282|DRUG|Dexmedetomidine|see descriptions
218870567|NCT02209974|DRUG|Inhaled Placebo|
218870568|NCT02707796|PROCEDURE|Hemicolectomy|
219489887|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
219489888|NCT01904084|DEVICE|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
219489889|NCT01904084|DEVICE|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
218870569|NCT00562562|OTHER|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
218870570|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
218870571|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
218870572|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
218870573|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
218870574|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
218870575|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
218870576|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
218870577|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
218870578|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
218870579|NCT02482402|DRUG|Placebo|inhalation solution placebo
218870580|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
218870581|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
218870582|NCT04221191|OTHER|PSP|PSPs is to support patient care.
218870583|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
218870584|NCT00131651|DRUG|ATN-161|
218870585|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
218870586|NCT03883334|DRUG|Metisoprinol|Immunodulator
218870587|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
218870588|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
219601026|NCT04442399|BEHAVIORAL|Family Connections|Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
219601027|NCT02077140|DRUG|MDT-10013|
219601028|NCT02077140|DRUG|Standard of care for pain|
219601029|NCT04750889|DEVICE|RFID tags|Installation of the RFID tag device wire localization)
218870589|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
218870590|NCT03675516|OTHER|No specific intervention|Usual care
218870591|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
219489890|NCT00301925|BIOLOGICAL|pegfilgrastim|
219489891|NCT00301925|DRUG|capecitabine|
219489892|NCT00301925|DRUG|cyclophosphamide|
219489893|NCT00301925|DRUG|epirubicin hydrochloride|
219489894|NCT00301925|DRUG|fluorouracil|
219489895|NCT00301925|DRUG|methotrexate|
219489896|NCT00301925|PROCEDURE|adjuvant therapy|
219489897|NCT05015803|COMBINATION_PRODUCT|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
219601030|NCT04750889|DEVICE|Wire localization|Installation of the wire localization device
219601031|NCT00251329|DRUG|neoadjuvant chemotherapy|
218870592|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
218870593|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
218870594|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
218870595|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
218870596|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
219489898|NCT05015803|BEHAVIORAL|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
218870597|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
218870598|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
218870599|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
218870600|NCT00004751|PROCEDURE|Surgery|
219199977|NCT06674811|OTHER|Patient Report Outcomes|To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.
219489899|NCT05015803|BEHAVIORAL|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
219489900|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
219489901|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
219489902|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
219489903|NCT01132170|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
218870601|NCT00004751|PROCEDURE|Physical therapy|
218870602|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
218870603|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
218870604|NCT03696901|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
218870605|NCT00248716|DRUG|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
218870606|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
218870607|NCT05504551|PROCEDURE|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
218870608|NCT00036101|DRUG|aripiprazole|
218870609|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
218870610|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
218870611|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
218870612|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
219489904|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
219489905|NCT02578043|DRUG|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
219489906|NCT02578043|DRUG|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
219489907|NCT02578043|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
219489908|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
218870613|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
219021496|NCT03492255|DRUG|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
219021497|NCT03492255|DRUG|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
219021498|NCT03492255|DRUG|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
219021499|NCT04454372|OTHER|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
219199978|NCT06674811|OTHER|Blood Draw|When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
219199979|NCT06674811|OTHER|Clinical Data Review|Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
219489909|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
219489910|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
219489911|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
219489912|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
219489913|NCT05910450|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
219489914|NCT05910450|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
219489915|NCT00530088|DRUG|porfimer sodium|IV
219489916|NCT00530088|DRUG|Photdynamic Therapy (PDT)|
218870614|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
219199980|NCT05827965|BEHAVIORAL|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
219489917|NCT00902278|BIOLOGICAL|Flulaval|one 0.5-mL dose via intramuscular injection
218870615|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
219021500|NCT03055000|BIOLOGICAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
219199981|NCT04599569|DEVICE|indirect calorimetry|indirect calorimetry with and without renal replacement therapy
219489918|NCT00902278|BIOLOGICAL|Fluvirin|one 0.5-mL dose via intramuscular injection
219489919|NCT00902278|BIOLOGICAL|Fluzone|one 0.5-mL dose via intramuscular injection
219489920|NCT00902278|BIOLOGICAL|Fluarix|one 0.5-mL dose via intramuscular injection
219489921|NCT00902278|BIOLOGICAL|Afluria|one 0.5-mL dose via intramuscular injection
219522579|NCT05531422|DRUG|Placebo|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
219522580|NCT02874300|OTHER|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
219522581|NCT02874300|OTHER|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
219522582|NCT00840138|PROCEDURE|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
219522583|NCT05290311|BEHAVIORAL|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
219522584|NCT02683083|BIOLOGICAL|[131I]-SGMIB Anti-HER2 VHH1|
218870616|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
219021501|NCT03055000|BIOLOGICAL|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
219489922|NCT01741428|BEHAVIORAL|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
219489923|NCT05954611|BIOLOGICAL|GR2002 injection|one single dose of GR2002 injection
219489924|NCT05954611|BIOLOGICAL|Placebo|one single dose of placebo
219489925|NCT06312761|DRUG|Relugolix 120Mg Tab|Relugolix 120 mg single dose - All subjects
219489926|NCT06312761|DIETARY_SUPPLEMENT|Curcumin|Curcumin 630 mg single dose
219489927|NCT06312761|DRUG|Testosterone Undecanoate 237 MG Oral Capsule|Testosterone Undecanoate 237 MG Oral Capsule
219489928|NCT01691261|BIOLOGICAL|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
219489929|NCT05810961|BIOLOGICAL|efgartigimod IV|infusion of efgartigimod
219489930|NCT05810961|OTHER|placebo|infusion of placebo
218870617|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
218870618|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
218870619|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
219489931|NCT06496711|OTHER|Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients|The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
219489932|NCT02343497|DIETARY_SUPPLEMENT|Astaxanthin|
219489933|NCT02343497|DIETARY_SUPPLEMENT|Placebo|
219021502|NCT03055000|OTHER|Placebo|WFI (0.5mL) on Day 0 and Day 21
219021503|NCT03566667|DRUG|Metoprolol|Betablocker
219021504|NCT03566667|DRUG|Standard care|Standard care
219021505|NCT01829750|GENETIC|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
219021506|NCT05325879|OTHER|VAGUS-NDT|Neurodynamic test for vagus nerve
219021507|NCT00211445|PROCEDURE|Photodynamic Therapy with Verteporfin|
219021508|NCT00211445|DRUG|verteporfin|
219021509|NCT01477060|DRUG|Lapatinib|1250 mg/ die, os
219021510|NCT01477060|DRUG|Metformin|1500 mg/die, os
219021511|NCT00485407|DRUG|Atomoxetine Hydrochloride|
219021512|NCT00555750|DRUG|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
219489934|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
219489935|NCT04419428|DEVICE|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
219522585|NCT05810753|BEHAVIORAL|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
219522586|NCT02950207|GENETIC|miRNA|miRNA extraction
219489936|NCT05290805|DIAGNOSTIC_TEST|ECMO flow rate reduction|ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
219489937|NCT00197561|DIETARY_SUPPLEMENT|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
219489938|NCT00197561|DIETARY_SUPPLEMENT|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
219489939|NCT04534387|OTHER|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
219489940|NCT04534387|OTHER|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
219489941|NCT04439097|OTHER|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
219489942|NCT04439097|OTHER|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
219489943|NCT02681627|OTHER|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
219489944|NCT02681627|OTHER|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
219489945|NCT02424799|DRUG|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
219489946|NCT02424799|DRUG|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
218870620|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
218870621|NCT03594812|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
218870622|NCT03594812|DEVICE|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
218870623|NCT03594812|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
218870624|NCT06256471|OTHER|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
218870625|NCT04122131|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
218870626|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
218870627|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
218870628|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
218870629|NCT00071448|DRUG|insulin human|
219489947|NCT02424799|DRUG|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
219489948|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
219489949|NCT02941822|DRUG|Ambroxol|Details outlines in the intervention description.
219489950|NCT00831038|PROCEDURE|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
219489951|NCT06702488|DRUG|dexmedetomidine|20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
218870630|NCT00071448|DRUG|insulin lispro|
218870631|NCT00071448|DRUG|insulin aspart|
219489952|NCT06702982|BEHAVIORAL|tele-nursing educational program|The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
219489953|NCT06703047|DRUG|ATRA+pd-1+chemo|All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
219489954|NCT06703047|DRUG|placebo+PD-1+chemo|Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
219489955|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
219489956|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
219601032|NCT03550911|OTHER|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
219601033|NCT01469728|PROCEDURE|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
219601034|NCT01469728|PROCEDURE|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
219601035|NCT00477048|DRUG|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
218870632|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
218870633|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
218870634|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
218870635|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
218870636|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
218870637|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
218870638|NCT01862367|DRUG|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
219489957|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
219489958|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
219489959|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
219489960|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
219489961|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
219489962|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
219601036|NCT00974922|DRUG|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
219601037|NCT00974922|DIETARY_SUPPLEMENT|Cholecalciferol|3000 I.U. once daily for 6 weeks
219601038|NCT00974922|DIETARY_SUPPLEMENT|Placebo|Placebo for two weeks
219601039|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal)|Sealing deep pits and fissures
218870639|NCT00324441|DEVICE|Iratherm® 1000|
218870640|NCT00313859|DRUG|simvastatin|
218870641|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
218870642|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
218870643|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
218870644|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
218870645|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
218870646|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
218870647|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
219489963|NCT02959372|OTHER|lung ultrasound|
219489964|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
219601040|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting|Sandblasting before Sealing deep pits and fissures
219601041|NCT04929327|PROCEDURE|Total etch resin based sealant ultraseal xt|Sealing deep pits and fissures
219601042|NCT03808480|DRUG|CA and Nivolumab|Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1\~4, 1cycle=21days) Nivolumab 360 mg/IV C2\~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
219021513|NCT00555750|DRUG|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
219021514|NCT04407000|DRUG|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
219021515|NCT04407000|DRUG|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
219021516|NCT06178328|BEHAVIORAL|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
219489965|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
219489966|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
219489967|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
219489968|NCT02937285|DRUG|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
219489969|NCT02937285|DRUG|Mitoxantrone|10 mg / m² monthly infusion for 6 months
219489970|NCT04338256|BEHAVIORAL|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
219489971|NCT00572468|DRUG|Simvastatin|40 mg of simvastatin
219489972|NCT00572468|OTHER|Placebo|placebo
219489973|NCT05900739|BEHAVIORAL|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
219489974|NCT00736138|PROCEDURE|training and pellots|training and pellots
219489975|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
219489976|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
219489977|NCT03969979|DIAGNOSTIC_TEST|Shear wave elastography|shear wave elastogrophy will be performed
219489978|NCT03427788|DRUG|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
219489979|NCT03427788|DRUG|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
219489980|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
219522587|NCT01464970|PROCEDURE|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
219522588|NCT01464970|PROCEDURE|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
219522589|NCT01464970|PROCEDURE|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
219522590|NCT01464970|PROCEDURE|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
219522591|NCT00416520|DRUG|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
219522592|NCT00416520|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
219522593|NCT00416520|DRUG|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
218870648|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
218870649|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
218870650|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
218870651|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
218870652|NCT02882100|BIOLOGICAL|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
219489981|NCT05183230|BEHAVIORAL|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
219489982|NCT05183230|BEHAVIORAL|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
218870653|NCT02882100|BIOLOGICAL|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
219489983|NCT03877484|DEVICE|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
219489984|NCT02815930|OTHER|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
219489985|NCT05975463|PROCEDURE|HAIC|hepatic artery infusion for 3-4 times.
219489986|NCT05975463|DRUG|Adebrelimab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
219489987|NCT05975463|DRUG|Bevacizumab|hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
219489988|NCT03186963|PROCEDURE|No immobilization|Conventional wrist dressing
218870654|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
218870655|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
219489989|NCT03186963|PROCEDURE|Volar splint|Volar plaster splint
219489990|NCT02902380|DRUG|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
219489991|NCT02902380|DRUG|control group|0.9% saline infusion
219489992|NCT00357474|PROCEDURE|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
219489993|NCT00357474|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
219489994|NCT00006044|DRUG|therapeutic testosterone|
219489995|NCT02162901|BEHAVIORAL|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
219489996|NCT02162901|BEHAVIORAL|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
219489997|NCT02162901|BEHAVIORAL|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
219489998|NCT02162901|BEHAVIORAL|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
219489999|NCT02162901|BEHAVIORAL|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
219490000|NCT02602964|OTHER|Deep neuromsucular block|Deep or standard neuromuscular block
219490001|NCT04282044|BIOLOGICAL|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
219490002|NCT04282044|COMBINATION_PRODUCT|Fludarabine|25mg/m IV (five doses given from Day -7 until Day -3)
219490003|NCT04282044|COMBINATION_PRODUCT|Cyclophosphamide|60mg/kg intravenous (IV) (two doses given on Day -7 and -6)
219490004|NCT05570968|PROCEDURE|C-arm device|Percutaneous Transluminal Angioplasty
219490005|NCT00858234|DRUG|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
219490006|NCT00858234|DRUG|Bortezomib|Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
219490007|NCT04715386|DRUG|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
219490008|NCT06317363|OTHER|Base Line + ACEPELLA|Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
218870656|NCT05664802|BEHAVIORAL|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
219021517|NCT05111886|BEHAVIORAL|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
219490009|NCT06317363|OTHER|Base Line + Manual Chest Physiotherapy|The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
219021518|NCT05111886|BEHAVIORAL|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
219021519|NCT05111886|BEHAVIORAL|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
219021520|NCT05111886|BEHAVIORAL|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
219490010|NCT01678924|DRUG|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
218870657|NCT00028886|BIOLOGICAL|filgrastim|
218870658|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
218870659|NCT00028886|DRUG|cyclophosphamide|
218870660|NCT00028886|DRUG|dexamethasone|
218870661|NCT00028886|DRUG|doxorubicin hydrochloride|
219021521|NCT05111886|DIAGNOSTIC_TEST|Survey of Experience|Satisfaction with referral process
219021522|NCT01799499|DEVICE|TC-3 hydrogel|
219021523|NCT01799499|DEVICE|TC-3 hydrogel|
219490011|NCT01678924|DRUG|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
219490012|NCT01629134|DEVICE|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
219490013|NCT01733186|BIOLOGICAL|CARTISTEM®|
218870662|NCT00028886|DRUG|melphalan|
218870663|NCT00028886|DRUG|thalidomide|
218870664|NCT00028886|DRUG|vincristine sulfate|
218870665|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
218870666|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
218870667|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
219490014|NCT00757263|GENETIC|polymorphism analysis|
219490015|NCT00757263|OTHER|laboratory biomarker analysis|
219490016|NCT00757263|OTHER|questionnaire administration|
219490017|NCT01207063|OTHER|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
219490018|NCT01379079|DRUG|Acetylsalicylic acid|aspirin intake at bedtime
218870668|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
218870669|NCT05308771|DEVICE|VPC syringe|Use of the visual pressure control syringe for epidural space detection
219021524|NCT01799499|DEVICE|TC-3 hydrogel|
219021525|NCT01927406|DRUG|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
219021526|NCT01927406|DRUG|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
219490019|NCT01379079|DRUG|Acetylsalicylic acid lysinate|aspirin intake on awakening
219522594|NCT04921462|PROCEDURE|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
219522595|NCT03401996|DEVICE|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
219522596|NCT01798732|PROCEDURE|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
219522597|NCT04441970|PROCEDURE|Neutral position|The cuff pressure will be recorded at the neutral head position.
218870670|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
218870671|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
218870672|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
219490020|NCT03711669|BEHAVIORAL|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
219490021|NCT01523769|PROCEDURE|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
219490022|NCT00640614|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
219490023|NCT05110950|PROCEDURE|No suction EBUS-TBNA|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
218870673|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
219601043|NCT04820738|OTHER|Sensorimotor training exercises|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking
219601044|NCT04820738|OTHER|Without Sensorimotor training exercises|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
219601045|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
218870674|NCT02759224|DRUG|BRI-1501|
218870675|NCT02759224|DRUG|Lafutidine|
218870676|NCT02759224|DRUG|Irsogladine maleate|
218870677|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
219490024|NCT05110950|PROCEDURE|Passive suction through dedicated EBUS-TBNA syringe|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
219601046|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
219601047|NCT03965689|DRUG|Carboplatin|Given IV
219601048|NCT03965689|DRUG|Paclitaxel|Given IV
219601049|NCT03965689|DRUG|Pevonedistat|Given IV
219601050|NCT06139822|OTHER|Experimental Group|Hamstring stretching is the main intervention which is being used along with convention protocol for plantar fasciitis.
219601051|NCT06139822|OTHER|Control Group|Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia .
219601052|NCT03022084|DEVICE|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
219601053|NCT03022084|OTHER|Cognitive Behavioral Therapy|Standard of Care
219601054|NCT04667000|OTHER|Forced Air Warming|We will use Forced Air Warming for cesarean patient
218870678|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
218870679|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
218870680|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
218870681|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
218870682|NCT05095857|DRUG|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
218870683|NCT05095857|OTHER|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
219490025|NCT05110950|PROCEDURE|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.."
219490026|NCT00669136|DRUG|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
219490027|NCT00529802|DRUG|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
219490028|NCT03446079|OTHER|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
219490029|NCT06540300|OTHER|rTMS stimulation of right IPL|The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
219490030|NCT02692352|OTHER|Goal Management Training|Goal Management training, 8 sessions of 2 hours
219490031|NCT02692352|OTHER|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
219490032|NCT05736952|DRUG|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
219601055|NCT05005052|DRUG|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
219601056|NCT05005052|DRUG|Placebo|Placebo and no compression or venopharmaceutical regimen
219601057|NCT02735759|DEVICE|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
219601058|NCT02579473|DRUG|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
219601059|NCT01173120|DEVICE|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
219490033|NCT01997099|DEVICE|CADD®-Solis VIP Pump|
219490034|NCT01997099|DEVICE|CADD™ Solis Medication Safety Software Administrator|
219490035|NCT01973842|DRUG|0.1 mg triptorelin|
218870684|NCT06143033|OTHER|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
219490036|NCT01973842|DRUG|0.2 mg triptorelin|
219490037|NCT01973842|DRUG|0.4 mg triptorelin|
219490038|NCT03711942|PROCEDURE|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
219490039|NCT03711942|PROCEDURE|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
219490040|NCT03711942|PROCEDURE|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
219490041|NCT03373409|DRUG|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
219613643|NCT03281876|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
219613644|NCT03281876|BIOLOGICAL|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
219613645|NCT05295576|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
219613646|NCT01510782|DRUG|Placebo to BI 655064|intravenous infusion of escalating doses
218870685|NCT03639142|OTHER|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
218870686|NCT03639142|DRUG|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
218870687|NCT00084149|DRUG|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
218870688|NCT00084149|DRUG|Lopinavir/Ritonavir|antiretroviral therapy
219490042|NCT03373409|DRUG|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
218870689|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
218870690|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
218870691|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
218870692|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
218870693|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
218870694|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
218870695|NCT00389675|DRUG|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
218870696|NCT00389675|DRUG|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
219490043|NCT03373409|DRUG|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
219490044|NCT02409537|DIETARY_SUPPLEMENT|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
219490045|NCT02409537|DIETARY_SUPPLEMENT|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
219601060|NCT03474666|PROCEDURE|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
219613647|NCT01510782|DRUG|Placebo to BI 655064|subcutaneous injection of escalating doses
218870697|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
218870698|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
218870699|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
219490046|NCT02409537|OTHER|placebo|the individuals were given placebo for 1 month
219490047|NCT05048771|OTHER|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
219490048|NCT06542783|BEHAVIORAL|referring to the results of AI model output|determining the ANA pattern type with or without referring to the results of AI model output.
219490049|NCT00003583|DRUG|amifostine trihydrate|
219490050|NCT00003583|DRUG|cisplatin|
219490051|NCT00003583|DRUG|etoposide|
219490052|NCT00003583|RADIATION|radiation therapy|
219490053|NCT06348654|BEHAVIORAL|introduction of digital listening may improve the quality of life of patients withe breast cancer|Introduction of a digital listening and communication pathway aimed at improving the quality of life of patients with advanced HER2-negative breast cancer
219490054|NCT02185235|DEVICE|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
218870700|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
218870701|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
218870702|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
218870703|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
218870704|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
218870705|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
218870706|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
219601061|NCT03474666|PROCEDURE|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
219601062|NCT02380326|PROCEDURE|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
219601063|NCT01207583|OTHER|Non-interventional observational study|Non-interventional observational study
218870707|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
218870708|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
218870709|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
218870710|NCT00908037|DRUG|eltrombopag|thrombopoietin receptor agonist
218870711|NCT00908037|DRUG|Placebo|placebo for comparison
219021527|NCT06349070|BEHAVIORAL|Low Touch - Text Messaging Implementation Strategy|The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.
219021528|NCT06349070|BEHAVIORAL|High Touch - Community Health Worker (CHW) Implementation Strategy|The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
219021529|NCT00988507|DRUG|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
219601064|NCT03757351|DRUG|DNL747|Repeating oral dose
219601065|NCT03757351|DRUG|Placebo|Repeating oral dose
219601066|NCT01899339|OTHER|submassive PA treatment with Ekosonic endo device|Ultra Sound energy along with tPA to treat submassive pulmonary embolism
219601067|NCT03309761|OTHER|Blood test|6ml blood sample taken
219601068|NCT04862221|DRUG|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
219601069|NCT04862221|DRUG|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
219601070|NCT04862221|DRUG|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
219613648|NCT01510782|DRUG|BI 655064|intravenous infusion of escalating doses
218870712|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
218870713|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
218870714|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
218870715|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
218870716|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
219490055|NCT02185235|DEVICE|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
219490056|NCT02185235|OTHER|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
219490057|NCT04093726|OTHER|lollipop|chewing lollipop for 20min
219490058|NCT01014026|OTHER|Screening test|Two Vaginal self sampling devices and HPV test
219490059|NCT01336608|DRUG|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
219490060|NCT01336608|DRUG|Vilanterol|Inhaled long acting beta-agonist
219490061|NCT01336608|DRUG|Placebo|Placebo
219490062|NCT00080288|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
219490063|NCT00080288|DRUG|Placebo|Matching placebo tablets once daily
219490064|NCT03044431|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
218870717|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
218870718|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
218870719|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
218870720|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
218870721|NCT02099201|DRUG|ACT-389949 40 mg|
218870722|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
218870723|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
219490065|NCT00211666|BEHAVIORAL|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
219490066|NCT01325857|PROCEDURE|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
219490067|NCT01325857|PROCEDURE|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
219490068|NCT01325857|PROCEDURE|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
219490069|NCT05744531|OTHER|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
219490070|NCT02169531|DRUG|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
219490071|NCT03970668|DRUG|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
219490072|NCT03970668|DRUG|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
219490073|NCT05443217|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
219490074|NCT02913508|DRUG|Vedolizumab intravenous injection|Vedolizumab intravenous injection
219490075|NCT02913508|DRUG|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
219490076|NCT01938521|DIETARY_SUPPLEMENT|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
219490077|NCT01938521|DIETARY_SUPPLEMENT|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
219522598|NCT04441970|PROCEDURE|Head extension position|The cuff pressure will be recorded at the head extension position.
218870724|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
218870725|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
218870726|NCT02099201|DRUG|Placebo|
219522599|NCT04441970|PROCEDURE|Head flexion position|The cuff pressure will be recorded at the head flexion position.
219522600|NCT04441970|PROCEDURE|Head rotation position|The cuff pressure will be recorded at the head rotation position.
218870727|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
218870728|NCT02565810|DRUG|Adalimumab PFS and Pen|
218870729|NCT00635089|DRUG|reslizumab|
218870730|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
218870731|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
219490078|NCT01440023|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
219490079|NCT01440023|BEHAVIORAL|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
219490080|NCT01440023|BEHAVIORAL|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
219490081|NCT02924103|DEVICE|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
219490082|NCT00525564|DRUG|Placebo|Placebo diskus inhalation powder
219490083|NCT00525564|DRUG|Salmeterol diskus inhalation powder|50 micrograms twice a day
219490084|NCT02874638|DIETARY_SUPPLEMENT|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
219490085|NCT02874638|DIETARY_SUPPLEMENT|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
219490086|NCT02874638|DIETARY_SUPPLEMENT|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
219490087|NCT02874638|DIETARY_SUPPLEMENT|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
219490088|NCT00941252|DRUG|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
219490089|NCT01757236|DRUG|VANCOMYCIN|
219490090|NCT01757236|DRUG|CEFTRIAXONE|
219601071|NCT04862221|DRUG|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
218870732|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~\- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
218870733|NCT00869401|DRUG|dasatinib|Given orally
218870734|NCT00869401|DRUG|temozolomide|Given orally
218870735|NCT00869401|OTHER|placebo|Given orally
218870736|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
218870737|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
218870738|NCT02310997|DRUG|Cyclophosphamide|
218870739|NCT02310997|RADIATION|Total body irradiation|
218870740|NCT02310997|DRUG|Busulfan|
219021530|NCT00988507|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
219021531|NCT00988507|DRUG|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
219490091|NCT01757236|DRUG|CLINDAMYCIN|
219490092|NCT01757236|DRUG|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
219490093|NCT01757236|DRUG|FLUOROQUINOLONE|
219490094|NCT01757236|DRUG|LINEZOLID|
219490095|NCT01757236|DRUG|RIFAMPIN|
218870741|NCT02310997|DRUG|Melphalan|
218870742|NCT02310997|DRUG|Fludarabine|
218870743|NCT01992562|DRUG|Ziconotide|
218870744|NCT01992562|DRUG|placebo|
218870745|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
218870746|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
219490096|NCT00188071|DRUG|paracetamol|
218870747|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
218870748|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
219021532|NCT02093598|DRUG|Temsirolimus|
219021533|NCT03099044|OTHER|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
219490097|NCT00188071|DRUG|ketoprofen|
219490098|NCT00188071|DRUG|ketoprofen + paracetamol|
219490099|NCT03948737|DRUG|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
219490100|NCT03948737|DRUG|Placebo oral tablet|
219490101|NCT03654911|DIAGNOSTIC_TEST|EEG|EEG
219490102|NCT03654911|GENETIC|ApoE|ApoE
219490103|NCT00752154|DRUG|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
219613649|NCT01510782|DRUG|BI 655064|subcutaneous injection of escalating doses
219613650|NCT00002031|DRUG|Dinitrochlorobenzene|
218870749|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
218870750|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
219021534|NCT03099044|OTHER|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
219021535|NCT03099044|OTHER|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
219021536|NCT00002304|DRUG|Ketoconazole|
219490104|NCT02328547|DRUG|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
219490105|NCT02328547|DRUG|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
219490106|NCT00659854|DIETARY_SUPPLEMENT|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
219490107|NCT00659854|DIETARY_SUPPLEMENT|milk based formula|Babies will be given a milk based formula for 12 weeks
219490108|NCT00044005|DRUG|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
219490109|NCT00044005|DRUG|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
218870751|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
218870752|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
219021537|NCT00002304|DRUG|Fluconazole|
219021538|NCT04267003|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
219021539|NCT04568590|BEHAVIORAL|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
219021540|NCT03631901|DRUG|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
219021541|NCT03631901|DRUG|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
219021542|NCT02050282|OTHER|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
219021543|NCT00253474|BIOLOGICAL|PEG-interferon alfa-2a|
219490110|NCT00044005|DRUG|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
219490111|NCT00344305|BIOLOGICAL|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
219490112|NCT01732198|BIOLOGICAL|NU300|
219490113|NCT01732198|BIOLOGICAL|ActHIB|
219490114|NCT01732198|BIOLOGICAL|Prevnar 13|
219490115|NCT01952639|DIETARY_SUPPLEMENT|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
219490116|NCT00079144|BIOLOGICAL|NY-ESO-1 peptide vaccine|
219490117|NCT00079144|BIOLOGICAL|aldesleukin|
219490118|NCT00079144|BIOLOGICAL|filgrastim|
219490119|NCT00079144|BIOLOGICAL|incomplete Freund's adjuvant|
219490120|NCT00079144|BIOLOGICAL|therapeutic autologous lymphocytes|
219490121|NCT00079144|DRUG|cyclophosphamide|
219490122|NCT00079144|DRUG|fludarabine phosphate|
218870753|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
219021544|NCT02540460|DRUG|LCB01-0371 800mg|LCB01-0371 800mg
219021545|NCT02540460|DRUG|LCB01-0371 800mg BID|LCB01-0371 800mg BID
219021546|NCT02540460|DRUG|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
219021547|NCT02540460|DRUG|Placebo|Placebo
219021548|NCT06488482|DRUG|nivolumab or pembrolizumab|See above
219021549|NCT02599155|DRUG|Crystalloid|normal saline administration for volume expansion in hypovolemic status
219490123|NCT03347227|PROCEDURE|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
219490124|NCT03799094|DRUG|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
219490125|NCT03799094|DRUG|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
219490126|NCT00176501|BIOLOGICAL|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
219490127|NCT01139892|PROCEDURE|Surgical management|
219490128|NCT01139892|PROCEDURE|Endovascular management|
219490129|NCT01274273|DRUG|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
219490130|NCT01274273|DRUG|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
219490131|NCT01274273|DRUG|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
218870754|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
219490132|NCT01204073|DRUG|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
219490133|NCT04024280|OTHER|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
219021550|NCT02599155|DRUG|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
219021551|NCT00533533|DRUG|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
219490134|NCT00209430|DRUG|Iodixanol 320 mgI/mL|
219490135|NCT00003273|BIOLOGICAL|filgrastim|
219490136|NCT00003273|DRUG|carboplatin|
219490137|NCT00003273|DRUG|cisplatin|
219490138|NCT00003273|DRUG|cyclophosphamide|
219490139|NCT00003273|DRUG|etoposide|
219490140|NCT00003273|DRUG|leucovorin calcium|
219490141|NCT00003273|DRUG|methotrexate|
219490142|NCT00003273|DRUG|temozolomide|
219490143|NCT00003273|DRUG|thiotepa|
219021552|NCT04930679|DRUG|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
219490144|NCT00003273|DRUG|vincristine sulfate|
219490145|NCT00003273|PROCEDURE|autologous bone marrow transplantation|
219490146|NCT00003273|PROCEDURE|peripheral blood stem cell transplantation|
219490147|NCT00003273|RADIATION|radiation therapy|
219490148|NCT01336218|DRUG|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
219490149|NCT01336218|DRUG|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
219021553|NCT04272528|OTHER|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
219021554|NCT04272528|OTHER|conventional care|Nurses carry out the routine care procedures.
219021555|NCT01769040|DRUG|Rifaximin|550 mg two times daily for 28 days
219021556|NCT01769040|DRUG|placebo|
219490150|NCT03612713|DRUG|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
218870755|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
219490151|NCT03612713|DRUG|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
219490152|NCT01018342|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
219490153|NCT01018342|DRUG|Macrobid® Capsules 100 mg|
219490154|NCT05437484|BEHAVIORAL|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
219490155|NCT00606879|DRUG|SGX523 Capsules|This is a dose escalation study
219490156|NCT00830388|DRUG|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
219490157|NCT04256005|OTHER|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
219490158|NCT03783845|COMBINATION_PRODUCT|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
219490159|NCT06456398|OTHER|Virtual reality|"Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans."
218870756|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
218870757|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
218870758|NCT05768815|BEHAVIORAL|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
218870759|NCT05768815|BEHAVIORAL|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
218870760|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
218870761|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
218870762|NCT01756859|PROCEDURE|MRI Scan|
218870763|NCT01691976|DRUG|Oestrogen Patches|
218870764|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
219490160|NCT02698631|PROCEDURE|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
219522601|NCT01633047|OTHER|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
219522602|NCT01633047|OTHER|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
219522603|NCT03499847|BEHAVIORAL|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
219522604|NCT03499847|BEHAVIORAL|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
219522605|NCT02620670|BEHAVIORAL|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
219522606|NCT01029470|DRUG|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
219522607|NCT02735122|DRUG|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
219522608|NCT02735122|DRUG|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
219522609|NCT02735122|DRUG|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
219522610|NCT02735122|DRUG|Placebo Tablet|2 placebo tablets
219522611|NCT02735122|DRUG|Placebo Caplet|2 placebo caplets
219522612|NCT02735122|DRUG|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
219522613|NCT04608253|DIAGNOSTIC_TEST|11C-choline PET/CT|11C-choline PET/CT
219522614|NCT03348423|DRUG|DEX-IN|IN Dexmedetomidine + IV placebo
219522615|NCT03348423|DRUG|Fentanyl|IN Placebo + IV Fentanyl
219522616|NCT03348423|DRUG|Placebo|IN Placebo + IV Placebo
219522617|NCT05636241|OTHER|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
219522618|NCT05636241|OTHER|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
219522619|NCT01917838|BEHAVIORAL|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
218870765|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
218870766|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
218870767|NCT03888118|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
218870768|NCT01848847|PROCEDURE|Hysteroscopy|
218870769|NCT02024126|OTHER|Exercise therapy|Exercise therapy
218870770|NCT00580762|PROCEDURE|Roux-en-y gastric bypass (RYGB)|
218870771|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
218870772|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
218870773|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
218870774|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
218870775|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
219490161|NCT02698631|PROCEDURE|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~* Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~* In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
219490162|NCT03745027|DIAGNOSTIC_TEST|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
219490163|NCT00507182|PROCEDURE|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
219490164|NCT03152227|OTHER|ACGG|50 high-producing chicks to households along with provision of technical input on production
219490165|NCT03152227|BEHAVIORAL|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
219490166|NCT00131430|DRUG|taranabant|
219490167|NCT05014425|PROCEDURE|pancreaticoduodenectomy|
219490168|NCT05089240|DEVICE|Ophthalmic lens with extra power|
219490169|NCT01143272|DRUG|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
219490170|NCT01143272|DRUG|Placebo|Placebo
219490171|NCT01726335|DRUG|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
219490172|NCT04393155|OTHER|COVID-19+ observational|This is observational -- there is no intervention
219490173|NCT00545181|DRUG|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
218870776|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
218870777|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
218870778|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
218870779|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
218870780|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
218870781|NCT02832336|DRUG|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
218870782|NCT02832336|DRUG|Fiber|Fiber will be used as placebo.
218870783|NCT00025155|DRUG|ixabepilone|Given IV
218870784|NCT04485260|DRUG|KRT-232|administered by mouth
218870785|NCT04485260|DRUG|Ruxolitinib|administered by mouth
218870786|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
218870787|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
218870788|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
218870789|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
218870790|NCT06107660|DRUG|Liposomal bupivacaine|Patients will receive either liposomal bupivacaine as part of the ESPB .
218870791|NCT06107660|DRUG|Bupivacaine|This is the control group comparator as this is standard of care at the investigator's institution.
219490174|NCT00545181|DRUG|Metronidazole control|oral metronidazole therapy alone
219490175|NCT06541717|OTHER|Video-Based Fertility Awareness Training|Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
219490176|NCT04605523|PROCEDURE|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
219490177|NCT01456702|PROCEDURE|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
219490178|NCT01875133|OTHER|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
219490179|NCT01411670|DRUG|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
219490180|NCT01411670|DRUG|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
219490181|NCT01411670|DRUG|Placebo comparator|Standard treatment
218870792|NCT03989323|OTHER|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
218870793|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
218870794|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
218870795|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
218870796|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
218870797|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
218870798|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
219021557|NCT01299623|BEHAVIORAL|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
219021558|NCT00484237|DRUG|etanercept|
219021559|NCT06065761|OTHER|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
219021560|NCT03250546|PROCEDURE|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
219490182|NCT01543607|DEVICE|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
218870799|NCT06175013|DEVICE|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
218870800|NCT06175013|DEVICE|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
218870801|NCT03974672|PROCEDURE|Re-laparotomy|
218870802|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
218870803|NCT04809350|DIETARY_SUPPLEMENT|Adjustable Human Milk Fortification|"BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.~Liquid protein will be added based on serum urea."
219021561|NCT03250546|PROCEDURE|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
219021562|NCT00817167|DEVICE|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
219021563|NCT00817167|DEVICE|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
219021564|NCT01908569|OTHER|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
219490183|NCT02868307|BEHAVIORAL|Answering questionnaire|
219490184|NCT01917578|DEVICE|Ultrasound|"1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards."
219601072|NCT04862221|DRUG|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
219601073|NCT04862221|DRUG|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
219490185|NCT01917578|PROCEDURE|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
219490186|NCT01917578|PROCEDURE|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
218870804|NCT04809350|DIETARY_SUPPLEMENT|Targeted Human Milk Fortification|"Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.~Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes."
219490187|NCT01917578|DEVICE|Pathologic Large Tissue Selected Table|"1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~2. Each piece of breast tissues by cutting with the table has 3mm thickness."
219490188|NCT01917578|DEVICE|Leica TP1020|"Procedure:~1. Alcohol 70 % 1h~2. Alcohol 80 % 1h~3. Alcohol 85 % 1h~4. Alcohol 90 % 1h~5. Alcohol 95 % 1h~6. Alcohol Ⅰ 100 % 1h~7. Alcohol Ⅱ 100 % 1h~8. Xylene Ⅰ 2h~9. Xylene Ⅱ 2h~10. Xylene Ⅲ 2h~11. Paraffin 6h~12. Paraffin 6h"
218870805|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
219601074|NCT04862221|DRUG|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
219601075|NCT04812470|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion
219601076|NCT04812470|DRUG|Melphalan|Melphalan will be administered once as an intravenous infusion.
219601077|NCT04812470|DRUG|Interleukin-2|After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
219601078|NCT06315075|BEHAVIORAL|Dialectical behavior therapy for adolescents (DBT-A)|A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.
219601079|NCT04541537|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
219601080|NCT04541537|DIAGNOSTIC_TEST|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
218870806|NCT04881747|DRUG|Lasmiditan|Administered orally.
218870807|NCT00046553|DRUG|RU-486 (Mifepristone)|
219490189|NCT01917578|DEVICE|Pathologic Large Tissue Embedded Table|"1. The table is made of brass .It is applying for a chinese patent.~2. The table can simultaneously embed 8 piece of breast tissues."
219490190|NCT01917578|DEVICE|Leica SM2000 R|Each of paraffin section has 4 um thickness.
219601081|NCT03104400|DRUG|Adalimumab|Administered by subcutaneous injection
219601082|NCT03104400|DRUG|Upadacitinib|Oral tablet
219601083|NCT03104400|DRUG|Placebo to Upadacitinib|Oral tablet
219601084|NCT03104400|DRUG|Placebo to Adalimumab|Administered by subcutaneous injection
218870808|NCT01573156|DRUG|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
218870809|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
218870810|NCT00556413|BIOLOGICAL|cetuximab|
218870811|NCT00556413|DRUG|fluorouracil|
219601085|NCT05551715|DEVICE|Software development for individualized refractive surgery|Software development for individualized refractive surgery
219601086|NCT04725396|DEVICE|Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).|PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
219601087|NCT04725396|DEVICE|Conventional Mandibular Reconstruction (MR without PVP)|Conventional Mandibular Reconstruction
219601088|NCT05677919|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, stool, and saliva samples
219601089|NCT05677919|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219601090|NCT05677919|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218870812|NCT00556413|DRUG|irinotecan hydrochloride|
218870813|NCT00556413|DRUG|leucovorin calcium|
218870814|NCT00556413|DRUG|oxaliplatin|
218870815|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
218870816|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
219601091|NCT05677919|PROCEDURE|Computed Tomography|Undergo CT scan
219601092|NCT05677919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219601093|NCT05677919|DRUG|Pirtobrutinib|Given PO
219601094|NCT05677919|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219601095|NCT05677919|DRUG|Venetoclax|Given PO
219601096|NCT05677919|PROCEDURE|Echocardiography|Undergo ECHO
219601097|NCT05677919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219601098|NCT05677919|PROCEDURE|Biopsy|Undergo tissue biopsy
219601099|NCT05827614|DRUG|BBI-355|Oral CHK1 inhibitor
219601100|NCT05827614|DRUG|Erlotinib|EGFR Inhibitor
218870817|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
218870818|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
218870819|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
218870820|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
218870821|NCT00756951|DRUG|Placebo|Placebo
218870822|NCT00756951|DRUG|SCV-07|0.02 mg/kg
218870823|NCT00756951|DRUG|SCV-07|0.10 mg/kg
218870824|NCT00214929|BEHAVIORAL|treatment at home|
219490191|NCT01917578|PROCEDURE|HE Stain|"Procedure:~1. Xylene Ⅰ 60℃ 15-20 minutes~2. Xylene Ⅱ 60℃ 15-20 minutes~3. Alcohol 100% Ⅰ 3-5 minutes~4. Alcohol 100% Ⅱ 3-5 minutes~5. Alcohol 95% Ⅱ 3-5 minutes~6. Alcohol 90% Ⅱ 3-5 minutes~7. Wash in running tap water for 3 minutes~8. Hematoxylin 5-10 minutes~9. Wash in running tap water for 3 minutes~10. Differentiate in 1% acid alcohol for 30 seconds~11. Wash in running tap water for 1 minute~12. Bluing in 0.2% ammonia water for 30-60 seconds~13. Wash in running tap water for 3 minutes~14. Counterstain in eosin Y solution for 30-60 seconds~15. Wash in running tap water for 1 minute~16. Alcohol 90% Ⅱ 2-3 minutes~17. Alcohol 95% Ⅱ 2-3 minutes~18. Alcohol 100% Ⅱ 3-5 minutes~19. Alcohol 100% Ⅱ 3-5 minutes~20. Xylene Ⅲ 5-10 minutes~21. Xylene Ⅳ 5-10 minutes~22. Mounting with neutral resin"
219490192|NCT01917578|DEVICE|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
219490193|NCT01917578|DEVICE|Epson V600|"1. Each slice that has been microscopically outlined is scanned by Epson V600.~2. Every image by scanning should be saved as JPG."
218870825|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
218870826|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
218870827|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
218870828|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
218870829|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
218870830|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
218870831|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
218870832|NCT01878669|DRUG|N-acetyl cysteine|
218870833|NCT01878669|DRUG|Saline|
218870834|NCT06941571|OTHER|Irrigation Solution|In this group, the effects of washing burn wounds with different irrigation solutions will be investigated.
218870835|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
218870836|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
218870837|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
218870838|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
218870839|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
218870840|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
218870841|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
218870842|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
218870843|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
218870844|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
219490194|NCT01917578|DEVICE|MRI|"1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.~3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
219601101|NCT05827614|DRUG|Futibatinib|FGFR1-4 Inhibitor
219601102|NCT05827614|DRUG|BBI-825|Oral RNR Inhibitor
218870845|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
218870846|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
218870847|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
218870848|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
218870849|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
218870850|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
218870851|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
218870852|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
219490195|NCT01917578|PROCEDURE|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~3. Observe the shrinkage modes in three-dimensional space.~4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
219490196|NCT01917578|DEVICE|Mammography|"1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size and calcification extent refers to WHO standards.~3. Calcification extent is not only measured in mammography image but also under microscope."
219490197|NCT01917578|DRUG|TAC,TC,TA,CAF,CEF|"1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
219490198|NCT01917578|DRUG|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
219490199|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
219490200|NCT02184507|DIETARY_SUPPLEMENT|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
219490201|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
219490202|NCT02184507|DRUG|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
219490203|NCT02872337|BEHAVIORAL|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
219490204|NCT02872337|BEHAVIORAL|Group Preoperative Education Session (per the standard of care)|
219490205|NCT01528878|RADIATION|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
218870853|NCT00346645|DRUG|Bortezomid (VELCADE®)|
218870854|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
218870855|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
218870856|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
218870857|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
218870858|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
218870859|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
218870860|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
218870861|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
218870862|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
218870863|NCT00000480|PROCEDURE|electrophysiology|
218870864|NCT00000480|DRUG|anti-arrhythmia agents|
218870865|NCT00000480|DEVICE|defibrillators, implantable|
219021565|NCT01908569|OTHER|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
219021566|NCT02126540|DEVICE|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
218870866|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
218870867|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
218870868|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
219490206|NCT01335178|BEHAVIORAL|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project \[parents.org.il\];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
219490207|NCT00778271|DRUG|Gabapentin 400mg capsules|
219490208|NCT02458898|BEHAVIORAL|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
219490209|NCT01000545|DRUG|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
219490210|NCT01000545|DRUG|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
219490211|NCT01433198|OTHER|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
219490212|NCT01953627|PROCEDURE|Surgical procedure with the system Kymerax|
219490213|NCT01953627|DEVICE|The system Kymerax|
219490214|NCT01796860|OTHER|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
219490215|NCT00634582|DRUG|paricalcitol|
219490216|NCT00634582|OTHER|immunoenzyme technique|
219490217|NCT00634582|OTHER|laboratory biomarker analysis|
218870869|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
218870870|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
218870871|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
218870872|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
219490218|NCT00634582|PROCEDURE|dual x-ray absorptometry|
219490219|NCT00634582|PROCEDURE|quality-of-life assessment|
219490220|NCT04252326|OTHER|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
219490221|NCT03078803|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
219490222|NCT03078803|BIOLOGICAL|Placebo|Transfer of water only
219490223|NCT06703463|DRUG|MK-1167|Administered via oral capsule per dosing regimen.
219490224|NCT06703463|DRUG|Diltiazem|Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
219490225|NCT02626182|DRUG|sildenafil|active sildenafil
219490226|NCT02626182|DRUG|placebo|sugar pill that looks like sildenafil tablets
219490227|NCT04316598|DRUG|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
219490228|NCT04316598|DRUG|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
219490229|NCT01508325|DRUG|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
218870873|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
218870874|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
218870875|NCT03214731|DRUG|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
218870876|NCT03214731|OTHER|placebo|placebo was produced by pharmaceutical factory for research specifically
218870877|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
218870878|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
218870879|NCT03323866|DRUG|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
218870880|NCT03323866|DRUG|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
218870881|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
218870882|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
218870883|NCT02182765|DRUG|Nevirapine|
218870884|NCT02182765|DRUG|Amprenavir|
219490230|NCT01508325|DRUG|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
219490231|NCT02343822|OTHER|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
219490232|NCT02343822|OTHER|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
219490233|NCT05504369|OTHER|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
219490234|NCT05504369|OTHER|Placebo tape|Tape without nano particles applied to the skin
219490235|NCT05777369|DRUG|Rituximab|375 mg/m2, d0
219490236|NCT05777369|DRUG|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
219490237|NCT05777369|DRUG|Cyclophosphamide|750 mg/m2, d1
219490238|NCT05777369|DRUG|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
219490239|NCT05777369|DRUG|Prednisone|60 mg/m2, d1\~d5
219490240|NCT01818414|DRUG|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
219490241|NCT01818414|DRUG|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D\&E
219490242|NCT04144387|PROCEDURE|Myelogram|Two additional myelograms will be performed comparing to standard of care.
219490243|NCT03870737|DEVICE|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
219601103|NCT06068491|OTHER|Vet-CALD|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
218870885|NCT02182765|DRUG|Abacavir|
218870886|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
219490244|NCT00921219|DRUG|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
219490245|NCT02696018|DEVICE|Ultrasonography|Ultrasonographic assessment of the diaphragm function
219490246|NCT05958459|OTHER|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
219490247|NCT05958459|OTHER|no intervention|no intervention
219490248|NCT06122571|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
219490249|NCT01329705|DEVICE|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
219490250|NCT01329705|OTHER|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized"
219601104|NCT05132244|PROCEDURE|Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)|Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
218870887|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
218870888|NCT00499746|DRUG|tramadol|oral dose, once per day
218870889|NCT00499746|DRUG|placebo|oral dose, once per day
218870890|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
218870891|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
219490251|NCT02535247|DRUG|MK-3475|
219490252|NCT02535247|DRUG|Copanlisib|
219490253|NCT05684497|BEHAVIORAL|LBPSP in Pregnancy|LBPSP is a 50-minute interactive presentation as face to face program according to Pender's Health Promotion Model Parameters.
219490254|NCT01376180|DRUG|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
219490255|NCT02543164|OTHER|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
219601105|NCT05132244|OTHER|Standard Care|Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
219490256|NCT02543164|OTHER|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
219490257|NCT02732886|DEVICE|Medifoam®|Foam Dressing
219490258|NCT02732886|DEVICE|Betafoam®|Foam dressing including Betadine iodine
219490259|NCT05815186|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
219490260|NCT05815186|DRUG|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
219490261|NCT05282355|DIETARY_SUPPLEMENT|Astaxanthin|Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.
219490262|NCT05282355|DIETARY_SUPPLEMENT|Placebo|To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
219490263|NCT03543046|DEVICE|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
218870892|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
219490264|NCT04477317|DRUG|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
219490265|NCT04477317|DRUG|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
219490266|NCT00938418|RADIATION|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
219490267|NCT04083066|DRUG|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
219490268|NCT03869684|DRUG|MT-0814|Randomly assigned dose
219601106|NCT05869903|DRUG|Orforglipron|Administered orally.
219601107|NCT05869903|DRUG|Placebo|Administered orally.
218870893|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
219490269|NCT03869684|DRUG|Placebo|Placebo manufactured to mimic MT-0814
219490270|NCT00419900|PROCEDURE|diagnosis of breast cancer by x-ray diffraction of hair|
219490271|NCT05084937|OTHER|CeliCAT form|Systematic summary to support transition
219490272|NCT01770678|OTHER|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
219490273|NCT03895307|OTHER|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
219490274|NCT03895307|OTHER|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
219490275|NCT03895307|OTHER|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
219490276|NCT01227954|RADIATION|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
219490277|NCT06538545|BEHAVIORAL|Sitting position is used in Experimental Arms 1-2|sitting position Comparison of sitting position and lithotomy position in labor
219490278|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
219490279|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
219490280|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
219490281|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
219490282|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
219490283|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
219490284|NCT01396473|BEHAVIORAL|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
219490285|NCT02231307|DRUG|SUBLIVAC FIX Birch|
219490286|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
219601108|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
219601109|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
218870894|NCT02858557|BEHAVIORAL|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
218870895|NCT02858557|BEHAVIORAL|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
218870896|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
218870897|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
218870898|NCT01102894|DEVICE|SmartPill|SmartPill
218870899|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
218870900|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
218870901|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
218870902|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
218870903|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
218870904|NCT02264080|DRUG|WAL2014|
218870905|NCT02264080|DRUG|Placebo|
218870906|NCT02745535|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|
219490287|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
219021567|NCT06225089|DRUG|pericapsuler nerve block|-Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
219021568|NCT06081868|BEHAVIORAL|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
219021569|NCT06081868|BEHAVIORAL|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
219021570|NCT04216342|BIOLOGICAL|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
219021571|NCT06153771|OTHER|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
219490288|NCT02787785|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
219490289|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
219490290|NCT06180174|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
219490291|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
219490292|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
219490293|NCT05764200|DIETARY_SUPPLEMENT|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
219490294|NCT05764200|DIETARY_SUPPLEMENT|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
219490295|NCT06566105|GENETIC|precision medicine approach|precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
219490296|NCT00848666|DRUG|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
219490297|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
219490298|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
219490299|NCT00857493|BIOLOGICAL|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
219490300|NCT00857493|BIOLOGICAL|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
219490301|NCT00741520|DEVICE|CPAP|Control - no treatment
219490302|NCT00741520|DEVICE|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
219490303|NCT01281579|DRUG|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
219490304|NCT01281579|DRUG|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
219490305|NCT01281579|DRUG|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
219490306|NCT04188860|DRUG|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
219490307|NCT05851976|DRUG|Naproxen|Naproxen 500mg twice daily for 16 days
219490308|NCT05851976|DRUG|Duloxetine|Duloxetine 60mg daily for 14 days
218870907|NCT00003709|DRUG|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
219490309|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
219490310|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
219490311|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
219490312|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
219490313|NCT00886873|DRUG|Mifepristone|
219490314|NCT04736576|DEVICE|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
219490315|NCT02426294|DRUG|Pioglitazone|
219490316|NCT02426294|DRUG|Glimepiride|
219490317|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
219490318|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
219490319|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
219490320|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
219490321|NCT06702280|DIETARY_SUPPLEMENT|IgY supplement|Ingesting the immune supplement over the experimental period
219490322|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
219490323|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
219490324|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
219490325|NCT00993629|DRUG|pregnenolone|"Administered adjunctively to treatment as usual"
219490326|NCT00993629|DRUG|placebo|adjunctive placebo
219490327|NCT05537246|PROCEDURE|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
219490328|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
219490329|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
218870908|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
219490330|NCT06213389|DEVICE|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
219490331|NCT06213389|DEVICE|Macintosh Blade|Patient will be intubated with Macintosh Blade
219490332|NCT06540040|DEVICE|Aquacel Ag|Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.
218870909|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
219490333|NCT06540040|DEVICE|OPSITE|OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.
219490334|NCT06540040|DEVICE|MEPILEX POST OP BORDER|MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
219490335|NCT06540040|DEVICE|Traditional Dressing|Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
219490336|NCT02107768|OTHER|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1\. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
219490337|NCT06536725|OTHER|Building Organoid-on-chips models|This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
219490338|NCT01850108|DRUG|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT"
219490339|NCT01850108|DRUG|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
219490340|NCT01850108|DRUG|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
219490341|NCT01850108|DRUG|Mesna|Days 3 \& 4 after BMT: 40 mg/kg IV
219490342|NCT01850108|DRUG|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
219490343|NCT01850108|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
219490344|NCT01850108|PROCEDURE|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
219490345|NCT01850108|RADIATION|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
219490346|NCT05584839|OTHER|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
219490347|NCT01155258|DRUG|temsirolimus|Given IV
219490348|NCT01155258|DRUG|vinorelbine ditartrate|Given IV
219490349|NCT05760924|DEVICE|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
219601110|NCT03263650|DRUG|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
219601111|NCT03263650|DRUG|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
219601112|NCT03263650|DRUG|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
219601113|NCT03263650|DRUG|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
219601114|NCT04948333|DRUG|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
219601115|NCT04948333|DRUG|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
219601116|NCT04948333|DRUG|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
219601117|NCT05927571|DRUG|Cevostamab|Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
219601118|NCT05927571|DRUG|Elranatamab|Elranatamab solution for injection will be administered SC as specified in each treatment arm.
219601119|NCT05927571|DRUG|Tocilizumab|Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
219601120|NCT05854381|BIOLOGICAL|VIR-1388|VIR-1388 is given by subcutaneous injection
219601121|NCT05854381|BIOLOGICAL|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
219601122|NCT05674097|OTHER|no intervention|no intervention
219601123|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
219601124|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
219601125|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
219601126|NCT05546463|BEHAVIORAL|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
219601127|NCT03004339|DRUG|SOR007 Ointment 2.0%|
219601128|NCT03004339|DRUG|SOR007 Ointment 1.0%|
219601129|NCT03004339|DRUG|SOR007 Ointment 0.3%|
219601130|NCT03004339|DRUG|SOR007 Ointment 0.15%|
219601131|NCT03004339|DRUG|SOR007 Ointment Placebo|
219601132|NCT03004339|DRUG|Taclonex® Ointment|
219601133|NCT05151289|BIOLOGICAL|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
219601134|NCT05151289|BIOLOGICAL|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
219601135|NCT05151289|DIAGNOSTIC_TEST|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
219601136|NCT01133457|DRUG|Finasteride|Finasteride tablets 1 mg
219601137|NCT02129608|DEVICE|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
219601138|NCT02129608|DRUG|Lorcaserin|10 mg pills twice daily for 12 weeks.
219601139|NCT02678208|DRUG|Tranexamic Acid|
219601140|NCT02678208|DRUG|5% glucose|
218870910|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
218870911|NCT02584920|DRUG|HLX01|
218870912|NCT02584920|DRUG|Rituximab|
218870913|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
218870914|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
218870915|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
218870916|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
219021572|NCT06153771|OTHER|echocardiography|on day 2, day 4 and day 7 of life
219601141|NCT03613233|PROCEDURE|Glaucoma surgery|phacoemulsification
219613651|NCT02208089|PROCEDURE|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
218870917|NCT02116998|BIOLOGICAL|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
218870918|NCT02116998|BIOLOGICAL|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
218870919|NCT02116998|BIOLOGICAL|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
218870920|NCT01238965|DRUG|panobinostat|Given orally
218870921|NCT01238965|DRUG|fluorouracil|Given IV
219021573|NCT03443440|OTHER|Neurocognitive Testing|neurocognitive testing, computerized
218870922|NCT01238965|DRUG|leucovorin calcium|Given IV
219490350|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
219490351|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
219490352|NCT01418534|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
219490353|NCT05302037|BIOLOGICAL|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
219490354|NCT02958774|RADIATION|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
218870923|NCT01238965|PROCEDURE|biopsy|Correlative studies
218870924|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
218870925|NCT01238965|GENETIC|western blotting|Correlative studies
218870926|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
218870927|NCT01238965|GENETIC|gene expression analysis|Correlative studies
219490355|NCT06635577|BEHAVIORAL|Verbal Interference Task|"During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace."
219490356|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
219613652|NCT02208089|PROCEDURE|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
218870928|NCT01238965|GENETIC|RNA analysis|Correlative studies
218870929|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
218870930|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
218870931|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
218870932|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
219021574|NCT01829516|DRUG|Oxytocin|Intranasal oxytocin
218870933|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
218870934|NCT05403229|DRUG|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
218870935|NCT05403229|DRUG|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
218870936|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
218870937|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
218870938|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
219021575|NCT01829516|DRUG|Placebo|Intranasal placebo
219021576|NCT01053364|DEVICE|NL-Prow interspinous spacer implant|Interspinous spacer implant
218870939|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
218870940|NCT06156501|PROCEDURE|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
219601142|NCT05747105|BEHAVIORAL|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (\~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (\<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, \~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
218870941|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
218870942|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
218870943|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
218870944|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
219601143|NCT05628831|PROCEDURE|vNOTES suspension with autologous tissue|Autologous tissue will be fixated on solid points in pelvis using vNOTES.
219601144|NCT05628831|PROCEDURE|Vaginal surgery|Vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Uterosacral and cardinal ligaments will be repositioned and attached to the vaginal vault after hysterectomy at the time of vault closure. A modified McCall culdoplasty will be done in this group to prevent enterocele and further apical prolapse
219601145|NCT05431894|BEHAVIORAL|Laguna Coach Intervention Group|Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
219601146|NCT00451204|DRUG|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
219601147|NCT00451204|DRUG|Placebo|Placebo capsule, once a day, treatment duration is 2 years
219601148|NCT00451204|DRUG|Copaxone|Injection, once a day, all subjects
219601149|NCT00282529|DEVICE|High Risk Lymphedema Education and Device Intervention|
219601150|NCT01257178|DRUG|LY2624803|Administered orally
219601151|NCT05131555|DRUG|Placebo: Placebo + exercise training.|Oral placebo Exercise training: Interval-based cycling exercise
219601152|NCT05131555|DRUG|H1 blockade: H1 receptor antagonist + exercise training|H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
219601153|NCT05131555|DRUG|H2 Blockade: H2 receptor antagonist + exercise training|H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
219601154|NCT05022264|DIAGNOSTIC_TEST|RIA-VS|Measuring vital signs with a new contactless camera technique
219601155|NCT04702243|DIAGNOSTIC_TEST|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
219601156|NCT04702243|OTHER|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
219601157|NCT01582152|DRUG|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
219601158|NCT01582152|DRUG|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
219601159|NCT06066294|BIOLOGICAL|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
219601160|NCT06066294|BIOLOGICAL|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
218870945|NCT01563172|OTHER|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
218870946|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
218870947|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
219021577|NCT00202644|DRUG|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
219021578|NCT00202644|DRUG|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
219601161|NCT02103504|DEVICE|DePuy Attune posterior stabilized fixed bearing total knee replacement|
219601162|NCT02753920|OTHER|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
219601163|NCT02753920|DEVICE|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
218870948|NCT02986815|OTHER|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
218870949|NCT01949519|DRUG|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
218870950|NCT01105377|DRUG|entinostat|Given orally
218870951|NCT01105377|DRUG|azacitidine|Given SC
218870952|NCT01105377|OTHER|laboratory biomarker analysis|Correlative studies
218870953|NCT04198675|BEHAVIORAL|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
218870954|NCT04198675|BEHAVIORAL|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
218870955|NCT04198675|BEHAVIORAL|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
218870956|NCT02495454|DRUG|Ga101|
218870957|NCT00696969|DRUG|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
218870958|NCT00696969|DRUG|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
218870959|NCT00696969|DRUG|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
218870960|NCT00696969|DRUG|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
218870961|NCT02966470|DEVICE|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
218870962|NCT04107441|DRUG|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
218870963|NCT04107441|DRUG|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
218870964|NCT00226070|PROCEDURE|interview and advising|
218870965|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
218870966|NCT00226070|PROCEDURE|interview SF-36 self rated health|
219490357|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
218870967|NCT02532985|OTHER|Negative Control|No added fiber beverage
218870968|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
218870969|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
218870970|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
218870971|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
218870972|NCT01531751|DEVICE|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
218870973|NCT01531751|DRUG|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
218870974|NCT05945303|PROCEDURE|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
218870975|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
218870976|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
218870977|NCT06393881|DRUG|UI059|take UI059 once a day for 7 days
218870978|NCT06393881|DRUG|UIC202201|take UIC202201 once a day for 7 days
219021579|NCT00712829|DRUG|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
219021580|NCT00712829|DRUG|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
219021581|NCT00602576|DRUG|sorafenib tosylate|Given orally
218870979|NCT03950310|DEVICE|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
218870980|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
218870981|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
219199982|NCT06857786|DRUG|Drug: CT041 autologous CAR T-cell injection|The planned dose of satri-cel in this trial was 2.5 × 108 cells, single infusion. The trial will start with a safety run-in phase, which is defined from the day of infusion to the 28th day after infusion for the first 6 participants. The type, grade, incidence rate, and outcome of adverse events during the safety run-in phase will be summarized and assessed by the investigator and collaborator (CARsgen Therapeutics Co., Ltd). The investigator and collaborator could discuss and assess whether the lower or higher doses should be explored based on the based on the safety and tolerability, cellular metabolic characteristics, and benefit-risk profile. If no dose adjustment is required, satri-cel dose will continue to be 2.5 × 108 cells for the rest of the participants.
219490358|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
219490359|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
219490360|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
219490361|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
218870982|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
218870983|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
218870984|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
219490362|NCT00716027|BEHAVIORAL|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
218870985|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
218870986|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
218870987|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
219021582|NCT00602576|DRUG|temozolomide|Given orally
219021583|NCT04171687|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg tablet
219490363|NCT00716027|BEHAVIORAL|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
219021584|NCT04171687|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
219021585|NCT04171687|DRUG|RAPA113|RAPA113 tablet
219021586|NCT05364723|OTHER||no intervention
219021587|NCT05283187|BEHAVIORAL|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
219021588|NCT04611750|DRUG|AD036|AD036 will be given for 14 days
219021589|NCT04611750|DRUG|Placebo|Placebo will be given for 14 days
219021590|NCT03642392|OTHER|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
219021591|NCT01629368|DRUG|Carbamazepine|Multiple doses of carbamazepine
219021592|NCT01629368|DRUG|RO4917523|Single dose of RO4917523
219021593|NCT00829543|PROCEDURE|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
219021594|NCT03662984|DRUG|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
219021595|NCT03662984|DRUG|Placebo Oral Tablet|To compare ciprofibrate
218870988|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
218870989|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
219490364|NCT06459401|DEVICE|Propulsion Neuroprosthesis|A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
219490365|NCT00535301|DEVICE|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
219490366|NCT00535301|PROCEDURE|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
219490367|NCT01087801|DRUG|ChiRhoStim|Human Secretin for Injection
219490368|NCT01087801|DRUG|Placebo|Saline for Injection
219490369|NCT05961319|DEVICE|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
219490370|NCT00542958|DRUG|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
219490371|NCT05960708|DRUG|YH35324|Subcutaneous injection of YH35324
219490372|NCT05960708|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
219490373|NCT05960708|DRUG|Placebo|Subcutaneous injection of None of active ingredient
219490374|NCT03146507|RADIATION|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
219490375|NCT03146507|RADIATION|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
219490376|NCT03146507|RADIATION|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
219490377|NCT04330482|BEHAVIORAL|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
219490378|NCT04330482|BEHAVIORAL|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
219490379|NCT06523465|DRUG|Simvastatin combined with Amlodipine besylate|6-month treatment of Simvastatin combined with Amlodipine besylate
219490380|NCT06523465|DRUG|Simvastatin combined with Spironolactone and Amlodipine besylate.|6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
219490381|NCT06523465|DRUG|Amlodipine besylate combined Spironolactone|6-month treatment of Amlodipine besylate combined with Spironolactone
219490382|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
219490383|NCT00679094|OTHER|placebo|Given orally
219490384|NCT00679094|OTHER|pharmacological study|Correlative studies
219490385|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
219490386|NCT04671329|DEVICE|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
219490387|NCT02079389|DEVICE|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
219490388|NCT04592731|DRUG|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
219490389|NCT04592731|DRUG|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
219490390|NCT05070169|PROCEDURE|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
219490391|NCT00792818|DRUG|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
219490392|NCT00792818|DRUG|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
219490393|NCT05822024|BEHAVIORAL|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
219490394|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
219490395|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
219490396|NCT01906034|BEHAVIORAL|Exercise with supervision|
218870990|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
218870991|NCT02622646|DRUG|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
218870992|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
218870993|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
219490397|NCT01906034|BEHAVIORAL|Home-based without supervision|
219490398|NCT05349890|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
219490399|NCT05349890|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
219490400|NCT05349890|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
219490401|NCT02223598|DRUG|CB-5083|
219490402|NCT02223598|DRUG|Dexamethasone|
219490403|NCT06234605|DRUG|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
219490404|NCT06234605|DRUG|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
219490405|NCT04556877|PROCEDURE|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
219490406|NCT05144477|BEHAVIORAL|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
219490407|NCT03875300|BEHAVIORAL|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
219490408|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
219490409|NCT04903717|BEHAVIORAL|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
219490410|NCT04632563|OTHER|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
219490411|NCT01325896|DRUG|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
219490412|NCT02670993|BEHAVIORAL|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
219490413|NCT02670993|BEHAVIORAL|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
219490414|NCT04700215|DEVICE|BiPAP|To give bilevel positive airway pressure to the lungs
219490415|NCT04700215|DEVICE|Incentive spirometry|IS for 15 minutes after every 4 hours
219490416|NCT03883789|DIAGNOSTIC_TEST|FibroScan|FibroScan will be used to assess liver stiffness
219490417|NCT05145660|RADIATION|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
219490418|NCT05145660|DRUG|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
219490419|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
219490420|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
219490421|NCT05148455|OTHER|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
219490422|NCT05148455|DIAGNOSTIC_TEST|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
219490423|NCT05148455|OTHER|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
219490424|NCT03273712|RADIATION|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
219490425|NCT03273712|DIAGNOSTIC_TEST|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
219490426|NCT03273712|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
219490427|NCT05092802|DRUG|HLX208|450mg bid po
219490428|NCT06700421|DRUG|Adebrelimab + Apatinib|Adebrelimab combined with apatinib
219601164|NCT02011477|OTHER|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
219601165|NCT02011477|OTHER|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
219601166|NCT00266539|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
219601167|NCT06619106|OTHER|Cognitive test|Cognitive test based on building blocks
219601168|NCT04172597|DRUG|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
219601169|NCT04172597|DRUG|Loperamide|Loperamide as prescribed by the physician.
219601170|NCT01542151|OTHER|Time of labor induction|Assigned time of labor induction - morning or evening
219601171|NCT00794339|DRUG|64Cu-ATSM|
219601172|NCT00794339|DRUG|FDG|
219601173|NCT01611857|DRUG|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
219601174|NCT01611857|DRUG|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
219601175|NCT06399575|OTHER|Apnea Following Isocapnic Hypoxia|Decreasing end-tidal partial pressure of oxygen to 50 mmHg for five minutes, targeting 80-85% peripheral oxygen saturation. The end-tidal partial pressure of carbon dioxide will remain +1 mmHg above baseline levels. After five minutes of hypoxia, participants will complete an apnea.
219601176|NCT03523299|PROCEDURE|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
219601177|NCT01573299|OTHER|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
219601178|NCT02759393|DRUG|Dexlansoprazole|receiving 8-week PPI
219601179|NCT02759393|DRUG|Lansoprazole|receiving 8-week PPI
219601180|NCT02934191|DRUG|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
219601181|NCT02934191|OTHER|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
218870994|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
218870995|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
218870996|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219021596|NCT00302042|BEHAVIORAL|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
219490429|NCT04138602|DEVICE|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
218870997|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
219490430|NCT04138602|DEVICE|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
219490431|NCT04333199|BEHAVIORAL|Timely|Email
219490432|NCT04333199|BEHAVIORAL|Transparency|Email
219490433|NCT04333199|BEHAVIORAL|Foot-in-the-door|Email
219490434|NCT03695042|OTHER|Blood Flow Restriction Training with Exercise|The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
219490435|NCT03111407|PROCEDURE|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
219490436|NCT06102707|DRUG|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
219490437|NCT05350358|DEVICE|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
219490438|NCT06652555|OTHER|Group 1|without Intervention
219490439|NCT03287102|PROCEDURE|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
219490440|NCT01341158|DRUG|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
219490441|NCT03022019|DEVICE|ReNovaCell|
219490442|NCT06267118|DRUG|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
218870998|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
218870999|NCT01462890|BIOLOGICAL|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
219021597|NCT00302042|BEHAVIORAL|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
219021598|NCT06482476|DIAGNOSTIC_TEST|Measurement of Lp(a) levels|Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
219490443|NCT06267118|DRUG|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
219490444|NCT00179218|DRUG|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
219490445|NCT00179218|BEHAVIORAL|exercise|leg press exercise; every other day, 3 days per week, for 6 months
219490446|NCT05308576|BIOLOGICAL|SCTV01E|D0; intramuscular injection
219490447|NCT05308576|BIOLOGICAL|Placebo|D0; intramuscular injection
219490448|NCT03299218|DIETARY_SUPPLEMENT|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
219490449|NCT03299218|BEHAVIORAL|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
219490450|NCT03299218|OTHER|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
218871000|NCT01462890|DRUG|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
218871001|NCT01462890|DRUG|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
219490451|NCT00181831|DEVICE|Proton Magnetic Resonance Spectroscopy|
219522620|NCT06485999|PROCEDURE|Biologically Oriented Preparation Technique|It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
218871002|NCT01462890|OTHER|specialized pathology review (Germany only)|before randomization
218871003|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
218871004|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
218871005|NCT06004570|DIETARY_SUPPLEMENT|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
218871006|NCT06004570|DIETARY_SUPPLEMENT|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
219021599|NCT06069973|OTHER|No intervention, observational study|No intervention
219021600|NCT04283162|DRUG|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
219021601|NCT04283162|OTHER|conventional treatment|maintain lifestyle habits and the usual treatment
219490452|NCT04831931|OTHER|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
219490453|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
219490454|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
219490455|NCT04072744|DEVICE|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
219490456|NCT04072744|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
219490457|NCT02198755|DEVICE|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
219490458|NCT02198755|DEVICE|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
219490459|NCT04085263|PROCEDURE|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
219490460|NCT04085263|PROCEDURE|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
219490461|NCT06440486|DIETARY_SUPPLEMENT|Probiotics|Serum and fecal samples were collected at the beginning and end of the study to evaluate the effects of probiotic consumption on immune markers, metabolites, and gut microbiota before and after administration.
219490462|NCT02203188|PROCEDURE|Lid debridgement scaling|
218871007|NCT06004570|OTHER|Placebo|Single oral dose - 2 capsules
219021602|NCT05028179|DIAGNOSTIC_TEST|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
219021603|NCT04345575|DEVICE|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
219021604|NCT04345575|OTHER|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
219021605|NCT00115856|PROCEDURE|Intravascular MRI|Arterial imaging of atherosclerosis
219021606|NCT06164470|BEHAVIORAL|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
219021607|NCT03454074|BEHAVIORAL|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
219021608|NCT03454074|BEHAVIORAL|Education|Education about healthy brain aging behaviors provided.
219490463|NCT04840628|OTHER|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
219490464|NCT01093365|DRUG|Varenicline|"* 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days"
219490465|NCT01938742|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
219601182|NCT02934191|DRUG|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
218871008|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
218871009|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
218871010|NCT02383771|DRUG|Control|No Anti-platelet Therapy
218871011|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
218871012|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
218871013|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
218871014|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
218871015|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
219490466|NCT01938742|DRUG|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
219490467|NCT01468974|DEVICE|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
219490468|NCT00002126|DRUG|Filgrastim|
219490469|NCT03441958|BIOLOGICAL|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
219490470|NCT06566794|DRUG|Caffeine Tablet|0,5 x 100 mg tablet (50 mg caffeine).
219490471|NCT06566794|DRUG|Bupropion Hydrochloride Capsels|1 x 20 mg tablet.
219490472|NCT06566794|DRUG|Repaglinide Capsels|1 x 0,05 mg tablet.
219490473|NCT06566794|DRUG|Flurbiprofen Capsels|1 x 10 mg tablet.
219601183|NCT02934191|DRUG|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
218871016|NCT00381030|DRUG|carvedilol plus nurse management|
218871017|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
218871018|NCT01893736|OTHER|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
218871019|NCT01893736|OTHER|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
218871020|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
218871021|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
219021609|NCT05665790|RADIATION|radiotherapy|radiotherapy
219021610|NCT05665790|PROCEDURE|palliative surgery|palliative surgery
219021611|NCT00539578|DRUG|MK0777|Duration of Treatment: 4 weeks
219490474|NCT06566794|DRUG|Omeprazole 10 MG|1 x 10 mg tablet.
219490475|NCT06566794|DRUG|Dextromethorphan Oral Solution|5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
219490476|NCT06566794|DRUG|Midazolam oral solution|0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
219490477|NCT06566794|DRUG|Simvastatin tablets|1 x 10 mg tablet.
219490478|NCT06566794|DRUG|Placebo|2 x placebo tablets in the Placebo Phase/Arm
218871022|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
218871023|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
218871024|NCT05727800|DRUG|VX-668|Suspension for oral administration.
218871025|NCT05727800|DRUG|Placebo|Suspension for oral administration.
219021612|NCT00539578|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
219021613|NCT00745992|OTHER|Blood drawn (lab data)|"1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
219490479|NCT06566794|DRUG|Carvedilol|2 x 25 mg tablets
219490480|NCT06566794|DRUG|Diclofenac|1 x 50 mg tablet (three times daily for three days)
219490481|NCT03843268|DEVICE|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
219490482|NCT03843268|DEVICE|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
219601184|NCT05083065|BIOLOGICAL|Covid-19 vaccine|"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"
219601185|NCT01777230|PROCEDURE|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
218871026|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
219021614|NCT04976842|DEVICE|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
219490483|NCT03295968|OTHER|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
219490484|NCT00789568|DRUG|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
219490485|NCT00789568|DRUG|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
219490486|NCT00789568|DRUG|Moxifloxacin placebo|Moxifloxacin placebo tablet
219490487|NCT06520995|OTHER|Educational video program|Diabetes education video contents are as follows; Type 2 diabetes definition, symptoms and the effect of diabetes on cognitive functions, Medical nutrition therapy and healthy nutrition recommendations in Type 2 diabetes, The importance of diabetes and exercise, Oral antidiabetic treatments, Insulin treatment, Hypoglycemia symptoms, findings and treatment, Macrovascular complications in diabetes, Microvascular complications in diabetes, Foot Protection and care recommendations, Diabetes self-care skills and problem-solving strategies, Diabetes and stress management.
219601186|NCT01777230|PROCEDURE|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
219601187|NCT01777230|PROCEDURE|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
219490488|NCT06520995|OTHER|A mobile application|This mobile application is a science-based application that patients can access via their smartphone or tablet. It consists of verbal, numerical, visual, logical, memory and attention categories and contains 24 different gamified mind exercises
219490489|NCT02139579|DRUG|Bevacizumab|7.5 mg/kg every 3 weeks
219490490|NCT06301256|DRUG|TIRZEPATIDE|Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
219601188|NCT05795322|OTHER|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
219601189|NCT04060186|PROCEDURE|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
218871027|NCT04706000|GENETIC|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
218871028|NCT00651365|DRUG|JNJ-38877605|
218871029|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
218871030|NCT00752726|DRUG|Orlistat|Weight loss treatment
219490491|NCT00998582|DRUG|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
219490492|NCT04000373|DEVICE|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
219490493|NCT03751527|DEVICE|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
219490494|NCT00000160|PROCEDURE|Xenon Photocoagulation|
219490495|NCT00000160|PROCEDURE|Argon Photocoagulation|
219601190|NCT02292095|PROCEDURE|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
218871031|NCT00752726|DRUG|Placebo|Inactive
218871032|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
218871033|NCT00805064|DRUG|triamcinolone and bevacizumab|
218871034|NCT03504748|DEVICE|deep rTMS|
218871035|NCT03504748|DEVICE|placebo deep rTMS|
218871036|NCT02189681|PROCEDURE|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
218871037|NCT02189681|PROCEDURE|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
218871038|NCT02189681|DEVICE|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
219490496|NCT00000160|PROCEDURE|Photocoagulation|
219490497|NCT02711579|DRUG|Celecoxib|
219490498|NCT02711579|DRUG|Placebo|
219490499|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
219601191|NCT02292095|PROCEDURE|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
218871039|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
218871040|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
218871041|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
218871042|NCT02797496|OTHER|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
218871043|NCT02797496|OTHER|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
218871044|NCT03946085|DIETARY_SUPPLEMENT|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
218871045|NCT03946085|DIETARY_SUPPLEMENT|AREDS2|A commercially-available multivitamin soft gel formula.
218871046|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
219490500|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
219490501|NCT01032330|DEVICE|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
219490502|NCT03250013|DRUG|ADHD medications|
219601192|NCT03237507|DRUG|S-1|40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
219601193|NCT03237507|DRUG|oxaliplatin|100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
219601194|NCT03237507|DEVICE|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
218871047|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
218871048|NCT00435084|DRUG|APO866|
218871049|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
218871050|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
218871051|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
218871052|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
218871053|NCT00006455|DRUG|cyclophosphamide|
218871054|NCT00006455|DRUG|cytarabine|
218871055|NCT00006455|DRUG|dexamethasone|
218871056|NCT00006455|DRUG|doxorubicin hydrochloride|
218871057|NCT00006455|DRUG|etoposide|
218871058|NCT00006455|DRUG|ifosfamide|
218871059|NCT00006455|DRUG|leucovorin calcium|
218871060|NCT00006455|DRUG|methotrexate|
218871061|NCT00006455|DRUG|therapeutic hydrocortisone|
218871062|NCT00006455|DRUG|vinblastine sulfate|
219601195|NCT03237507|DRUG|Paclitaxel|intraperitoneal perfusion
219601196|NCT03533309|PROCEDURE|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
219601197|NCT03533309|PROCEDURE|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
219601198|NCT03751007|BIOLOGICAL|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
219601199|NCT03751007|DRUG|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
218871063|NCT05124171|BIOLOGICAL|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older"
218871064|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older"
218871065|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older"
218871066|NCT03649009|OTHER|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
218871067|NCT03649009|DRUG|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
218871068|NCT03649009|DRUG|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
218871069|NCT03649009|OTHER|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
218871070|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
219021615|NCT04976842|DRUG|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
219021616|NCT02052232|OTHER|Experimental protein powder sachet|mixed with 8 oz. water
219490503|NCT02434796|BEHAVIORAL|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
219490504|NCT02434796|BEHAVIORAL|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
219490505|NCT01995006|DRUG|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
218871071|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
219021617|NCT02052232|OTHER|Control protein powder sachet|mixed with 8 oz. water
219021618|NCT00112658|DRUG|fluorouracil|
219021619|NCT00112658|DRUG|gemcitabine hydrochloride|
219021620|NCT00112658|DRUG|irinotecan hydrochloride|
219021621|NCT00112658|DRUG|leucovorin calcium|
219021622|NCT00112658|DRUG|oxaliplatin|
219021623|NCT01734330|BEHAVIORAL|Cognitive behavioral therapy in group|
219021624|NCT01734330|DRUG|Nicotine replacement|
219490506|NCT01995006|DRUG|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
219490507|NCT06542744|DEVICE|Training with the Emagina device at home until birth|The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
219490508|NCT06542744|OTHER|No intervention|The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
219490509|NCT04230785|GENETIC|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
219490510|NCT03547596|OTHER|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
219490511|NCT01677403|DRUG|Tobramycin|Nebulised 80mg twice daily
219490512|NCT01677403|DRUG|Saline|Nebulised 5mls 0.9% Saline twice daily
219490513|NCT01117714|PROCEDURE|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
219490514|NCT02690584|BEHAVIORAL|Metacognitive therapy|
219490515|NCT00335790|PROCEDURE|Hyperbaric Therapy|
219490516|NCT02192216|BEHAVIORAL|Exercise|
219522621|NCT03626649|DEVICE|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~* DiamondTemp Ablation Catheter~  o Unidirectional and Bidirectional models~* DiamondTemp Catheter-to RFG Cable~* DiamondTemp GenConnect Cable~* DiamondTemp FASTR Generator with Footswitch~* DiamondTemp Irrigation Pump~* DiamondTemp Irrigation Tubing Set"
219522622|NCT06344624|BEHAVIORAL|CBT group|Brief cognitive behavioral therapy
218871072|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
218871073|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
218871074|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
218871075|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
218871076|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
218871077|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
218871078|NCT03853564|BEHAVIORAL|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
218871079|NCT03853564|OTHER|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
218871080|NCT01555125|DRUG|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
218871081|NCT01555125|DRUG|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
218871082|NCT01555125|DRUG|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
218871083|NCT01067365|DRUG|Androxal|12.5 mg once daily
218871084|NCT01067365|DRUG|Androxal|25 mg once daily
218871085|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
218871086|NCT02651220|DRUG|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
218871087|NCT02651220|DRUG|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
218871088|NCT02651220|DRUG|placebo gel|vehicle used as placebo
218871089|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
218871090|NCT06228859|PROCEDURE|overdentures with different attachments|different types of overdenture attachments in relation to retention, bite force, and periimplant tissue health.
218871091|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
218871092|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
218871093|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
218871094|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
218871095|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
218871096|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
219522623|NCT06344624|BEHAVIORAL|Laughter group|Laughter yoga therapy
219522624|NCT01559324|DEVICE|ECT|Bifrontal ECT, low dosage
219522625|NCT01559324|DEVICE|ECT|Right unilateral electrode position, high dosage
219601200|NCT03751007|DRUG|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
219601201|NCT03751007|DRUG|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
218871097|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
218871098|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
218871099|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
218871100|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
218871101|NCT00158951|DEVICE|CONTAK RENEWAL 2/4/4HE CRT-D|
218871102|NCT00158951|DEVICE|EASYTRAK 2 Lead|
218871103|NCT04374058|OTHER|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
218871104|NCT00896441|DRUG|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
219021625|NCT01950533|PROCEDURE|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
219021626|NCT01571206|BIOLOGICAL|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
219021627|NCT00138944|DRUG|placebo|od
218871105|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
218871106|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
219021628|NCT00138944|DRUG|eplerenone|50mg od
219021629|NCT01851720|DRUG|Low dose fentanyl PCA|
219021630|NCT01851720|DRUG|Standard IV fentanyl bolus|
219490517|NCT05094986|BEHAVIORAL|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
219490518|NCT05094986|OTHER|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
219490519|NCT01186952|BEHAVIORAL|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
219601202|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
219601203|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
218871107|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
218871108|NCT01304589|DRUG|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
218871109|NCT00244634|DRUG|candsartan cilexetil|
218871110|NCT01769820|DRUG|Dexamethasone|studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
218871111|NCT01769820|DRUG|placebo|
218871112|NCT03189836|BIOLOGICAL|ACTR707|autologous T cell product
218871113|NCT03189836|BIOLOGICAL|rituximab|CD20-directed cytolytic antibody
219021631|NCT03927612|DEVICE|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
219021632|NCT03927612|DEVICE|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
219021633|NCT00679185|BEHAVIORAL|expressive writing|four non-emotional writing assignments
219021634|NCT05868070|DEVICE|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
218871114|NCT04858282|OTHER|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
218871115|NCT03000036|DRUG|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
219490520|NCT01186952|BEHAVIORAL|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
219490521|NCT02791711|OTHER|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
219490522|NCT03351127|RADIATION|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
219490523|NCT04307537|PROCEDURE|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
219490524|NCT04685941|DRUG|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
219490525|NCT04685941|OTHER|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
219490526|NCT00821522|PROCEDURE|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
219490527|NCT06500299|DRUG|HDM1002 100 mg QD|HDM1002 tablets 100mg daily, 12weeks
218871116|NCT03000036|DEVICE|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
218871117|NCT03000036|DRUG|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
218871118|NCT01976143|DRUG|NKTR-102|
218871119|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
218871120|NCT01922843|DRUG|DP001 softgel capsules|
218871121|NCT01922843|DRUG|Placebo|
218871122|NCT01257022|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
218871123|NCT04256252|DRUG|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
218871124|NCT02545244|DIETARY_SUPPLEMENT|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
218871125|NCT02545244|DIETARY_SUPPLEMENT|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
218871126|NCT02545244|DRUG|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
218871127|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
218871128|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
218871129|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
218871130|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
218871131|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
218871132|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
218871133|NCT00371982|DRUG|Fish oil (Maxepa)|
218871134|NCT01132586|DRUG|Lenalidomide|Given PO
218871135|NCT01132586|DRUG|Cytarabine|Given IV
218871136|NCT01132586|DRUG|Idarubicin|Given IV
219490528|NCT06500299|DRUG|HDM1002 200 mg QD 12weeks|HDM1002 tablets 200mg daily, 12weeks
219490529|NCT06500299|DRUG|HDM1002 400 mg QD 12weeks|HDM1002 tablets 400mg daily, 12weeks
218871137|NCT01132586|OTHER|Pharmacological Study|Correlative studies
218871138|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
219490530|NCT06500299|DRUG|Placebo|Matching placebo will be provided
219490531|NCT05795517|DRUG|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
219601204|NCT02089607|DEVICE|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
219601205|NCT02089607|DEVICE|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
219601206|NCT00841828|DRUG|Epirubicin|
219601207|NCT00841828|DRUG|Cyclophosphamide|
219601208|NCT00841828|DRUG|Docetaxel|
218871139|NCT06147583|OTHER|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
218871140|NCT02243891|PROCEDURE|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
218871141|NCT02243891|PROCEDURE|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
218871142|NCT02733965|OTHER|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
218871143|NCT02733965|OTHER|No Pharmaceutical Consultations|
219490532|NCT05795517|DRUG|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
219490533|NCT05795517|DRUG|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
219601209|NCT00841828|DRUG|Lapatinib|
218871144|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
218871145|NCT02048371|DRUG|Placebo|21 days on and 7 days off
218871146|NCT05464264|DRUG|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
218871147|NCT00076349|DRUG|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
218871148|NCT06136130|DEVICE|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
218871149|NCT03416075|DEVICE|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
218871150|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
219490534|NCT05795517|DRUG|Placebo|placebo ，QD，oral，Day1 to week 12
219490535|NCT05795517|DRUG|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
219490536|NCT04775368|OTHER|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
219490537|NCT02856451|BIOLOGICAL|Nivolumab|Specified dose on specified days
219490538|NCT03497988|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
219490539|NCT03497988|DRUG|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
219490540|NCT02617173|DEVICE|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
219490541|NCT00481273|DRUG|Azacitidine|Physician's discretion
219490542|NCT02268045|BIOLOGICAL|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
219601210|NCT00841828|DRUG|Trastuzumab|
219490543|NCT02268045|BIOLOGICAL|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
219490544|NCT01766310|DRUG|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
219490545|NCT01766310|DRUG|placebo|sugar tablet manufactured to mimic folic acid tablet
219490546|NCT03584035|BEHAVIORAL|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
219021635|NCT01870583|DRUG|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
219021636|NCT01870583|DRUG|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
219490547|NCT03584035|BEHAVIORAL|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
219490548|NCT03797339|OTHER|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
219490549|NCT03797339|OTHER|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
219490550|NCT03797339|OTHER|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
219490551|NCT03797339|OTHER|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
219490552|NCT01154673|DRUG|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
219490553|NCT01154673|DRUG|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
219490554|NCT01154673|DRUG|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
219490555|NCT01154673|DRUG|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
219490556|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
219490557|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
219490558|NCT03768388|DRUG|levoketoconazole|food effect
219490559|NCT03456973|BEHAVIORAL|Nurse AMIE|Supportive care software platform
218871151|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
218871152|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
218871153|NCT03135977|DRUG|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
218871154|NCT04518033|DEVICE|Various commercially available face coverings|Various commercially available face coverings
218871155|NCT03337464|OTHER|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
218871156|NCT02628548|BEHAVIORAL|Cognitive training program|8 week cognitive training program
218871157|NCT03196531|DRUG|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
218871158|NCT03196531|DRUG|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
218871159|NCT00370838|DRUG|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
218871160|NCT00370838|DRUG|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
219490560|NCT05199207|BEHAVIORAL|Physical activity programm|adapted physical activity during 3 month
219490561|NCT05951231|PROCEDURE|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
219490562|NCT01461148|BIOLOGICAL|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
218871161|NCT06171646|BEHAVIORAL|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
218871162|NCT04046250|DRUG|TK-112690|TK112690 treatment pre-methotrexate treatment
219490563|NCT04215107|OTHER|Standard breakfast meal|"The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting."
219490564|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
219490565|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
219490566|NCT02677337|OTHER|Educational Program|
219601211|NCT05308628|DIAGNOSTIC_TEST|Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)|Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)
218871163|NCT04046250|DRUG|Placebo TK-112690|Placebo
218871164|NCT00334711|DRUG|Sulfonylurea|
218871165|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
218871166|NCT02166827|DEVICE|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
218871167|NCT02166827|DEVICE|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
218871168|NCT00922714|DRUG|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
218871169|NCT00922714|DRUG|saline (placebo)|NaCl 0.9 g/L
218871170|NCT03417934|PROCEDURE|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
219490567|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
219490568|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
219490569|NCT00329758|DRUG|Placebo|
219490570|NCT04672824|BIOLOGICAL|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
218871171|NCT04576897|DIAGNOSTIC_TEST|Velacur|Ultrasound elasticity imaging
218871172|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
219490571|NCT04672824|OTHER|Saline|0.5ml saline placebo
219490572|NCT03159000|DRUG|Saline|1ml of 1/3 saline
219490573|NCT03159000|COMBINATION_PRODUCT|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
219490574|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
219490575|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
219601212|NCT01231204|PROCEDURE|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
219490576|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
219490577|NCT04518475|DRUG|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
219490578|NCT04518475|DRUG|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
219490579|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
219490580|NCT04420000|OTHER|Control|Treatment as usual
219490581|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
219490582|NCT00216424|DRUG|Capecitabine (Xeloda)|
219490583|NCT02996461|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
219490584|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
219490585|NCT05121688|OTHER|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
219490586|NCT02618772|DRUG|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
219490587|NCT02618772|DRUG|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
219490588|NCT04348292|DRUG|Durvalumab|Given IV
219490589|NCT04348292|DRUG|Sirolimus|Given PO
219490590|NCT00000510|DRUG|aspirin|
219490591|NCT00000510|DRUG|dipyridamole|
219490592|NCT00000510|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219490593|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490594|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490595|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490596|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
219490597|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490598|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490599|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490600|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219601213|NCT01231204|PROCEDURE|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
219601214|NCT04705272|OTHER|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
219601215|NCT00362336|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
219601216|NCT00362336|BIOLOGICAL|CombAct-HIB®|0.5 mL, IM
219490601|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490602|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490603|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490604|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490605|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
219490606|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490607|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490608|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490609|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490610|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490611|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490612|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490613|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
219490614|NCT01289990|DRUG|Sitagliptin 100mg|Sitagliptin once daily
219490615|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
219490616|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490617|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490618|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490619|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490620|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
219490621|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219601217|NCT00362336|BIOLOGICAL|Engerix B® Pediatric|0.5 mL, IM
219601218|NCT01392235|DRUG|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219601219|NCT05159024|DIAGNOSTIC_TEST|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
219601220|NCT02681835|DEVICE|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
219601221|NCT02681835|DEVICE|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
218871173|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
219490622|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
219490623|NCT04113564|DRUG|Remimazolam|
219490624|NCT05174559|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
218871174|NCT00934908|DIETARY_SUPPLEMENT|Green Tea|Green tea capsules taken twice a day.
218871175|NCT00934908|OTHER|Placebo|"Non-active sugar pill."
218871176|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
218871177|NCT00371904|DRUG|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
219490625|NCT03023098|DEVICE|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
219490626|NCT03023098|DEVICE|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
219490627|NCT01854801|OTHER|Individual medical Care|Individual medical care in occupational and environmental diseases centers
219490628|NCT01854801|OTHER|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
219490629|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
219490630|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
219490631|NCT00567346|DRUG|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
219490632|NCT00567346|DRUG|grass pollen extract|Patients will receive matching placebo sublingually
219490633|NCT04639739|BIOLOGICAL|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
219490634|NCT04289467|DRUG|Fenfluramine|Open-label
219490635|NCT04265456|DRUG|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
219490636|NCT04265456|DRUG|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
219490637|NCT02494310|DEVICE|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
219490638|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
219490639|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
219490640|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
219490641|NCT05085197|DRUG|Placebo|Intravenous injection
219490642|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
219490643|NCT05085197|DRUG|Placebo|Intravenous injection
219490644|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
219490645|NCT05085197|DRUG|Placebo|Intravenous injection
219490646|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
219490647|NCT05085197|DRUG|Placebo|Intravenous injection
219490648|NCT04089163|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
219490649|NCT04089163|DRUG|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
219490650|NCT02253407|BIOLOGICAL|MMR vaccine|
219490651|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
219490652|NCT05633901|OTHER|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
218871178|NCT00371904|DRUG|Standard Care|Standard care
218871179|NCT00552604|DRUG|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
219490653|NCT05633901|OTHER|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
219490654|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
219601222|NCT05430217|DRUG|Buspirone|1 tablet (15 mg) once per day for 28 days
219601223|NCT05430217|DRUG|Placebo|1 placebo tablet once per day for 28 days
219601224|NCT05328219|OTHER|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
219601225|NCT05328219|OTHER|Standard of care|Standard of care
219601226|NCT04290143|OTHER|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
218871180|NCT00552604|DRUG|Placebo|Matching placebo capsules, twice daily
218871181|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
218871182|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
219490655|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
219490656|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
219490657|NCT03417674|COMBINATION_PRODUCT|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
219601227|NCT04290143|OTHER|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
219601228|NCT00612664|DRUG|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
219601229|NCT06551779|PROCEDURE|inyección perineural con solución de dextrosa tamponada|Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
219601230|NCT03647670|DRUG|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
219601231|NCT03647670|DRUG|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
219601232|NCT01727037|PROCEDURE|Bronchoscopic intrabullous autologous blood instillation|
219601233|NCT05620537|OTHER|observation|There are no interventions.
219601234|NCT03011593|OTHER|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
219601235|NCT05100160|DRUG|Gabapentin|Given by PO
219601236|NCT05100160|OTHER|Placebo|Given by PO
218871183|NCT03693781|DRUG|Placebo Oral Tablet|Corresponding tablets for 30 weeks
218871184|NCT01961648|DEVICE|Rebreathing bag|
218871185|NCT01961648|DEVICE|Sham rebreathing|
218871186|NCT01961648|DEVICE|Mask|
218871187|NCT06431230|BEHAVIORAL|standard high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.
219021637|NCT01870583|DRUG|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
219601237|NCT00524966|PROCEDURE|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
219601238|NCT04317079|DIETARY_SUPPLEMENT|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
219601239|NCT04317079|OTHER|Diet|Consultation by a dietitian was offered to all participants
219601240|NCT01474200|DEVICE|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
219601241|NCT01474200|DRUG|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
219601242|NCT05624398|DEVICE|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
219601243|NCT01121562|DRUG|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
219601244|NCT04196881|OTHER|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
218871188|NCT06431230|BEHAVIORAL|plyometric high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
219601245|NCT05316610|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
219490658|NCT06566755|DRUG|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
219490659|NCT01666067|DRUG|placebo|
219490660|NCT01666067|DRUG|vytorin|
219601246|NCT03404739|DRUG|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
219601247|NCT03404739|DRUG|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
219601248|NCT01495702|DRUG|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
219601249|NCT01495702|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
219601250|NCT01495702|DRUG|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
219601251|NCT00742118|PROCEDURE|Colic biopsies|colic biopsies and analysis
219601252|NCT04152863|BIOLOGICAL|Gebasaxturev IV|Administered as an IV infusion of 1 X 10\^9 TCID50
219601253|NCT04152863|BIOLOGICAL|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10\^8 TCID50
219601254|NCT04152863|DRUG|Pembrolizumab|Administered as an IV infusion of 200 mg
219601255|NCT04913142|OTHER|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
219490661|NCT01666067|DRUG|simvastatin|
219490662|NCT01278446|OTHER|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
219490663|NCT01278446|OTHER|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
219490664|NCT05052879|DRUG|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
219490665|NCT05052879|DRUG|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
219490666|NCT05052879|OTHER|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
219490667|NCT05052879|OTHER|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
219490668|NCT06113783|DEVICE|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
219601256|NCT06200506|DEVICE|Transabdominal radiofrecuency application|"A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks"
219601257|NCT06200506|DEVICE|Intracavitary radiofrequency application|"An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks."
219601258|NCT06042582|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
219601259|NCT00196326|DRUG|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
219601260|NCT00808314|DRUG|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
218871189|NCT03389178|DIAGNOSTIC_TEST|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
219490669|NCT04923906|DRUG|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
219490670|NCT04923906|DRUG|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
219490671|NCT05510856|OTHER|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
219490672|NCT05510856|OTHER|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
219490673|NCT05510856|OTHER|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
219490674|NCT04946071|BEHAVIORAL|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
219490675|NCT00881049|DRUG|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
219490676|NCT01488071|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
219490677|NCT01488071|DRUG|Agomelatine|encapsulated tablets, daily, orally
219490678|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
219490679|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
219490680|NCT05317000|DRUG|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
219490681|NCT05317000|DRUG|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
219490682|NCT05317000|DRUG|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
219490683|NCT02587325|DRUG|nab-sirolimus|nab-sirolimus is an mTOR inhibitor
219601261|NCT00808314|DRUG|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
219490684|NCT01273584|DRUG|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
219490685|NCT01273584|DRUG|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
219490686|NCT03478774|DRUG|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher\&Paykel.
219490687|NCT03478774|DRUG|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
219490688|NCT03478774|DRUG|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
219601262|NCT02540083|DEVICE|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
219601263|NCT02797171|BIOLOGICAL|VRC01|Administered by intravenous (IV) infusion
219601264|NCT02797171|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
219490689|NCT03478774|PROCEDURE|Jaw thrust|Continuous
219490690|NCT03478774|PROCEDURE|Videolaryngoscopy|Continuous
219490691|NCT03478774|DRUG|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
219490692|NCT02390466|BIOLOGICAL|VAC-3S|Administered via intra-muscular injection in the arm
219490693|NCT06543004|COMBINATION_PRODUCT|AH plus sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
219490694|NCT06543004|COMBINATION_PRODUCT|Bioceramic sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
219021638|NCT06845774|BEHAVIORAL|CDC PrEP with active referral|The single session SOC utilizes structured risk assessments and educational materials recommended by the CDC, based on the CDC PrEP 101 information, and delivered one-on-one by trained study staff in about 15 minutes. This will be followed by active referral to a local provider; local providers have been identified to receive study referrals in each community. This session will occur the same day or within one week of study enrollment.
218871190|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
219021639|NCT06845774|BEHAVIORAL|TelePrEP|The TelePrEP intervention includes an initial one-on-one in person intervention session with trained study staff that: 1) engages in provides basic education on PrEP care tailored for PWID; 2) encourages participation in a telehealth clinical evaluation for PrEP; and, 3) offers the opportunity to participate in point of care baseline testing for PrEP. At the conclusion of session 1, for those who express readiness to link with PrEP care, study staff will immediately facilitate access to the telehealth platform onsite. Four telehealth visits will be offered to access initial and follow-up clinical care for PrEP.
219021640|NCT05011864|BEHAVIORAL|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
219021641|NCT05011864|BEHAVIORAL|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
219021642|NCT05011864|OTHER|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
219490695|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
219490696|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
219490697|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
219490698|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
219490699|NCT03305783|PROCEDURE|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
219490700|NCT03089931|PROCEDURE|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
219490701|NCT04568642|DEVICE|Activate FiO2 controller|Closed-loop FiO2 controller will be activated in the experimental arm
219601265|NCT01527409|BEHAVIORAL|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
218871191|NCT02085330|DEVICE|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
218871192|NCT01896245|DRUG|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
218871193|NCT01896245|DRUG|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
219490702|NCT04568642|DEVICE|Deactivate FiO2 controller|Closed-loop FiO2 controller will be deactivated in the experimental arm
219490703|NCT03951181|BEHAVIORAL|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
219490704|NCT04599673|DRUG|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
219490705|NCT04599673|OTHER|normal saline|10 ml normal saline
219490706|NCT04099082|OTHER|samples|blood sample nasal swab
219490707|NCT00004328|DRUG|enalapril|
219490708|NCT00004328|DRUG|polystyrene sulfonate|
219601266|NCT01527409|BEHAVIORAL|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
219601267|NCT01606774|OTHER|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
218871194|NCT01896245|DRUG|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
219490709|NCT01831596|DEVICE|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
219490710|NCT06328543|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
219490711|NCT06328543|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
219490712|NCT00682097|DRUG|RO4998452|Escalating oral doses
219490713|NCT00682097|DRUG|placebo|Oral doses
219490714|NCT00444665|DRUG|Travatan-Z|
219601268|NCT00676260|DRUG|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
219601269|NCT00676260|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
219601270|NCT02088801|DEVICE|Airtraq, blade without channel for tracheal tube intubation|Intubation
219601271|NCT02088801|DEVICE|KingVision , blade without channel for tracheal tube intubation|
219601272|NCT02088801|DEVICE|A.P. Advance, blade without channel for tracheal tube intubation|
219601273|NCT02088801|DEVICE|Macintosh|
219601274|NCT03545204|OTHER|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
219490715|NCT02737072|DRUG|LY2510924|Administered SQ
219490716|NCT02737072|DRUG|Durvalumab|Administered IV
219601275|NCT03545204|OTHER|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
219490717|NCT02827188|OTHER|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
219490718|NCT06567236|OTHER|3D software|Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
219601276|NCT05237492|DRUG|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
219601277|NCT02509169|DRUG|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
219601278|NCT02509169|OTHER|TAE|Trans-catheter embolization
219601279|NCT03394469|OTHER|collection|Blood, urinary and faecal samples
219601280|NCT06621446|OTHER|Comprehensive intervention model|A dry eye intervention strategy: including health education, the use of eye drops, and regular review.
219601281|NCT04592146|DEVICE|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
218871195|NCT03878303|DRUG|AC0058TA|25 mg capsules
218871196|NCT03878303|DRUG|Placebo AC0058TA|equivalent dose of investigational product
218871197|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
219601282|NCT04592146|OTHER|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
219490719|NCT06568354|OTHER|Yoga|The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
219490720|NCT06568354|OTHER|Motor control exercises|Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
219522626|NCT05621941|BEHAVIORAL|Game-Supported Goal Management Training|The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
219601283|NCT00134901|DRUG|Memantine|Memantine
219601284|NCT00134901|DRUG|placebo|placebo
219601285|NCT04098510|DIETARY_SUPPLEMENT|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
219601286|NCT05044195|BIOLOGICAL|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
219601287|NCT05044195|BIOLOGICAL|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
219601288|NCT00659243|DRUG|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
219601289|NCT00659243|DRUG|Placebo|One week treatment
219601290|NCT03685214|DRUG|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
219601291|NCT03685214|DRUG|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
219601292|NCT04134195|DEVICE|Transcranial direct current stimulation|2mA stimulation for 20 minutes
218871198|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
218871199|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
218871200|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
218871201|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
219021643|NCT02508493|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
219021644|NCT02508493|OTHER|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool"
219490721|NCT03930056|DEVICE|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
219490722|NCT03930056|DEVICE|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
219601293|NCT06158919|DRUG|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
219601294|NCT01554319|DRUG|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
219601295|NCT01554319|DRUG|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
219601296|NCT06223802|BEHAVIORAL|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
219601297|NCT01933477|OTHER|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
219021645|NCT03061110|BIOLOGICAL|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
219601298|NCT03863548|OTHER|complication|collection of post-operative bleeding complications
219601299|NCT03503695|DEVICE|Sterile acupuncture semi-permanent (ASP) gold needles|
219601300|NCT03135002|OTHER|Other|
219021646|NCT03061110|OTHER|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
218871202|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
218871203|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
218871204|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
218871205|NCT02666105|DRUG|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
218871206|NCT01078168|DRUG|Acitretin|30mg per day from Day 1 to Day 28
218871207|NCT01078168|DRUG|Placebo|Placebo
218871208|NCT02138357|DRUG|buprenorphine transdermal delivery system (BTDS)|
218871209|NCT02138357|DRUG|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
218871210|NCT02868658|BIOLOGICAL|Blood sampling|
218871211|NCT02868658|OTHER|Nasal swab|
219021647|NCT04937296|BEHAVIORAL|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
219021648|NCT04937296|OTHER|Usual care|Usual care.
219021649|NCT00225160|DRUG|acetyl L-carnitine|
219021650|NCT03963791|OTHER|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
219021651|NCT03963791|OTHER|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
219490723|NCT00937599|DIETARY_SUPPLEMENT|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
219490724|NCT02170142|DEVICE|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
219490725|NCT05898009|GENETIC|blood sample for BRCA2 mutation detection|blood sample
219490726|NCT03784612|BEHAVIORAL|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
219601301|NCT05531656|DRUG|CT1812|Study Drug
219601302|NCT05531656|DRUG|Placebo|Non-active study drug
219601303|NCT06263192|PROCEDURE|Intrauterine insemination|Intrauterine insemination with sperm donors
219601304|NCT05933044|DRUG|Durvalumab|Chemoradiotherapy plus durvalumab
219601305|NCT04837144|DEVICE|Physical Rehabilitation with MAK exoskeleton|The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.
219601306|NCT06372574|DRUG|RO7617991|RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
218871212|NCT00302757|DRUG|Radioimmunotherapy|
218871213|NCT00302757|PROCEDURE|allogeneic hematopoietic cell transplantation|
218871214|NCT00867906|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
218871215|NCT00867906|BIOLOGICAL|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
218871216|NCT04216355|DRUG|Azacitidine|Low-dose AZA
218871217|NCT04216355|DRUG|CAG Protocol|Short term CAG derived regimen
218871218|NCT02147769|DEVICE|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
218871219|NCT02635997|DRUG|antiresorptive therapy|
218871220|NCT01392612|DRUG|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
218871221|NCT01681524|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
218871222|NCT02012049|DRUG|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
219490727|NCT05461248|PROCEDURE|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
219490728|NCT05461248|PROCEDURE|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
219490729|NCT05439291|PROCEDURE|Regular Epilation Regimen|Epilation using laser device
219490730|NCT05439291|PROCEDURE|Surgical excision|Excision of pilonidal pit with trephine
219601307|NCT06372574|DRUG|Tocilizumab|Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
219601308|NCT04148573|DRUG|NFX88 - 1|3 times a day
218871223|NCT02012049|DRUG|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
218871224|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
218871225|NCT01735942|DRUG|Ingenol mebutate|
218871226|NCT01735942|PROCEDURE|cryotherapy|
218871227|NCT01962870|DRUG|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
218871228|NCT01962870|DRUG|Placebo|
218871229|NCT03869307|OTHER|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
218871230|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
218871231|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
218871232|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
218871233|NCT05230485|OTHER|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
218871234|NCT02789592|DRUG|Melatonin PR|For experimental treatment of RBD
218871235|NCT02789592|DRUG|Clonazepam|For experimental treatment of RBD
218871236|NCT02789592|DRUG|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
218871237|NCT02789592|DRUG|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
218871238|NCT03753139|DEVICE|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
219490731|NCT00323687|DRUG|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
219601309|NCT04148573|DRUG|NFX88 - 2|3 times a day
219601310|NCT04148573|DRUG|NFX88 - 3|3 times a day
219601311|NCT04148573|DRUG|PLACEBO - 4|3 times a day
218871239|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
218871240|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
218871241|NCT03994198|DIETARY_SUPPLEMENT|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
218871242|NCT03994198|DIETARY_SUPPLEMENT|Collagen peptides|Collagen peptides from bovine sources
219021652|NCT05429190|RADIATION|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
219021653|NCT05429190|RADIATION|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
219021654|NCT00379626|DRUG|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
219021655|NCT00301444|DEVICE|mirror-box treatment|
219021656|NCT00301444|BEHAVIORAL|Mental visualization|
219021657|NCT04518514|DEVICE|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
219601312|NCT03296501|BIOLOGICAL|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
219601313|NCT05472246|DEVICE|Wearing a virtual reality headset|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
219601314|NCT00727012|DEVICE|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
218871243|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
219490732|NCT05887518|DEVICE|Socks Developed with Wearable Technology|This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
219490733|NCT06381375|OTHER|Anti Tuberculosis Drug|"1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)."
219490734|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
219490735|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
219490736|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
219490737|NCT05924555|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
219490738|NCT05924555|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
219490739|NCT05924555|OTHER|Echography of upper leg|Determine upper leg muscle size
218871244|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
218871245|NCT04675996|DRUG|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
219490740|NCT05924555|OTHER|Hand grip strength with hand dynamometer|Determine muscle strength
219601315|NCT04289363|BEHAVIORAL|Clinical program implementation|Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
218871246|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
218871247|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
219021658|NCT05038527|DEVICE|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
219021659|NCT02834104|DEVICE|RMI|
219021660|NCT02834104|OTHER|myocardial biopsy|
219021661|NCT02834104|BIOLOGICAL|blood sample|
219490741|NCT05924555|OTHER|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
219490742|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
219490743|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
219490744|NCT02524665|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
219490745|NCT02524665|OTHER|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
219601316|NCT06128486|DEVICE|Soft Contact Lens|Vision Correction
219490746|NCT02524665|OTHER|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
219490747|NCT02524665|OTHER|Skin Perfecting Lotion|Available over the counter.
219490748|NCT05940688|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
219490749|NCT05940688|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
219490750|NCT05940688|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
219490751|NCT04181216|DEVICE|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
218871248|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
218871249|NCT04889482|OTHER|No intervention|No intervention
218871250|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
218871251|NCT05889078|BEHAVIORAL|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
218871252|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
218871253|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
219021662|NCT00245206|DRUG|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
219021663|NCT00245206|DRUG|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
219021664|NCT00245206|DRUG|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
219021665|NCT04248608|PROCEDURE|serratus plane block|ultrasound guided block
219490752|NCT05297149|BEHAVIORAL|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
218871254|NCT01280695|DRUG|Placebo|Placebo Capsules
218871255|NCT01280695|DRUG|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
218871256|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
219021666|NCT04248608|PROCEDURE|erector spinae block|ultrasound guided block
219021667|NCT04248608|DRUG|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
219021668|NCT02430675|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
219021669|NCT02430675|DEVICE|NanoKnife|
219490753|NCT05297149|BEHAVIORAL|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
219490754|NCT06594289|PROCEDURE|In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake|"The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake)."
219490755|NCT04395885|OTHER|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
219490756|NCT02642991|DEVICE|Phenacite|contact lens
219490757|NCT02642991|DEVICE|comfilcon A|contact lens
219490758|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
219490759|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
219021670|NCT04094922|BEHAVIORAL|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
219021671|NCT06115811|BEHAVIORAL|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
219021672|NCT02763852|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
219021673|NCT02763852|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
219490760|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
218871257|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
218871258|NCT01280695|DRUG|Pioglitazone|Pioglitazone 45 mg Capsules
218871259|NCT05456971|DEVICE|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
218871260|NCT05456971|DEVICE|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
218871261|NCT05231239|DEVICE|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
219490761|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
219490762|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
219490763|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
219490764|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
219601317|NCT00900419|OTHER|immunohistochemistry staining method|Laboratory test
219601318|NCT00900419|OTHER|laboratory biomarker analysis|Laboratory Test
219601319|NCT00900419|OTHER|sputum cytology|Laboratory Test
219601320|NCT00900419|PROCEDURE|biopsy|Laboratory Test
219601321|NCT05881434|OTHER|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
219601322|NCT01457937|DRUG|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
219601323|NCT02585778|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
219601324|NCT02585778|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
218871262|NCT00246701|DRUG|Simvastatin|Simvastatin
218871263|NCT00246701|DRUG|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
219490765|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
219601325|NCT02585778|DRUG|Lipid-Modifying Therapy (LMT)|Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.
219601326|NCT02585778|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
219601327|NCT05731193|OTHER|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
219601328|NCT00504751|DRUG|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
219601329|NCT00504751|DRUG|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
219601330|NCT03188744|OTHER|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
218871264|NCT01662323|BEHAVIORAL|GP's treating HF according the dutch guidelines|
218871265|NCT02476786|BEHAVIORAL|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
219490766|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
219490767|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
219601331|NCT03188744|OTHER|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
219490768|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
219490769|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
219601332|NCT01051362|DRUG|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
219490770|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
219601333|NCT00445432|BIOLOGICAL|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
219601334|NCT00445432|OTHER|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
219601335|NCT00273988|DRUG|nevirapine|
219601336|NCT04456088|COMBINATION_PRODUCT|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
219601337|NCT04456088|COMBINATION_PRODUCT|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
219601338|NCT06067165|BEHAVIORAL|POET feeling|"POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions."
219601339|NCT06067165|BEHAVIORAL|Supportive treatment|The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.
219601340|NCT04470648|DIAGNOSTIC_TEST|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
219601341|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
219601342|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
219601343|NCT00000846|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
219601344|NCT00000846|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
218871266|NCT02476786|DRUG|Goserelin|
218871267|NCT02476786|DRUG|Anastrozole|
219490771|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
219490772|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
219601345|NCT00534950|RADIATION|5 vs 6 weekly fraction of RT|Chemotherapy
219601346|NCT05866965|OTHER|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
218871268|NCT02476786|DRUG|Exemestane|
218871269|NCT02476786|DRUG|Fulvestrant|
218871270|NCT02476786|DRUG|Tamoxifen|
218871271|NCT02476786|OTHER|Archived tissue collection|
218871272|NCT01390922|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
218871273|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
218871274|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
219601347|NCT05866965|OTHER|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
219601348|NCT03810716|DEVICE|Interactive Platform|The participants will see the interactive platform.
219601349|NCT01288716|DRUG|Arbaclofen|
219601350|NCT00366743|PROCEDURE|Conventional LASIK|
219601351|NCT00366743|PROCEDURE|Wavefront-guided LASIK|
219601352|NCT06383455|PROCEDURE|Non-surgical periodontal therapy|An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
219601353|NCT02827955|DEVICE|Gamma Knife® radiosurgery bilateral|
219490773|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
219490774|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
219490775|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
219490776|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
219490777|NCT01999322|DRUG|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
219490778|NCT01999322|DRUG|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
218871275|NCT03545074|BEHAVIORAL|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
219490779|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
219490780|NCT02272972|OTHER|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
219490781|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
219490782|NCT02200614|DRUG|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
219490783|NCT02200614|DRUG|Placebo|Matching placebo 2 tablets twice daily with food.
219490784|NCT02006355|DRUG|Ropivacaine|
218871276|NCT03545074|BEHAVIORAL|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
219522627|NCT05621941|BEHAVIORAL|Information Group|In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
219522628|NCT02325141|PROCEDURE|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
219522629|NCT01564511|DEVICE|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
219522630|NCT01564511|OTHER|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
219522631|NCT03288883|DEVICE|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
219522632|NCT03288883|DEVICE|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
219522633|NCT03422211|OTHER|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
219522634|NCT00003528|DRUG|raltitrexed|Given IV
219522635|NCT05523271|DIAGNOSTIC_TEST|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
219522636|NCT00496548|PROCEDURE|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
219522637|NCT00496548|PROCEDURE|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
218871277|NCT05549791|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
218871278|NCT02146794|DEVICE|Renal denervation|Renal denervation
218871279|NCT06170918|DRUG|Remimazolam|remimazolam is given intravenously
218871280|NCT02416596|PROCEDURE|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
218871281|NCT02416596|DEVICE|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
218871282|NCT00079092|DRUG|procarbazine hydrochloride|
219522638|NCT05054348|BIOLOGICAL|IO-108|IO-108 given as monotherapy
218871283|NCT00079092|DRUG|thalidomide|
218871284|NCT01233063|BEHAVIORAL|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
218871285|NCT02391181|DRUG|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
218871286|NCT02391181|DRUG|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
218871287|NCT04457063|PROCEDURE|PKP|"1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
218871288|NCT05440214|BEHAVIORAL|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
219490785|NCT04379102|OTHER|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
219490786|NCT04503707|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
219490787|NCT03137758|DRUG|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
219490788|NCT00013273|PROCEDURE|Physical Conditioning|
219601354|NCT01482312|DEVICE|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
219601355|NCT01482312|DEVICE|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
218871289|NCT03576859|OTHER|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
219021674|NCT02763852|DRUG|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
219490789|NCT01592227|DRUG|Marketed paracetamol|Marketed paracetamol
219490790|NCT01592227|DRUG|Experimental paracetamol formulation|Experimental paracetamol formulation
219601356|NCT01482312|OTHER|Glasses|Glasses per habitual prescription
219601357|NCT06281015|DIAGNOSTIC_TEST|Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis|Cancer patients referred to fast whole-body bone for detection or follow-up of bone metastasis were retrospectively included in this study.
219021675|NCT00746993|OTHER|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
219021676|NCT03758144|DRUG|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
219021677|NCT00758082|DEVICE|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
219021678|NCT00758082|DEVICE|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
219490791|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
219490792|NCT02432456|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
219490793|NCT02432456|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
219601358|NCT01818115|DEVICE|Hydrus Implant|
219601359|NCT01818115|PROCEDURE|IOL placement|
219601360|NCT01699815|DRUG|Acetaminophen|
219601361|NCT02779244|PROCEDURE|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
219601362|NCT02779244|PROCEDURE|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
219601363|NCT04168892|DRUG|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
219601364|NCT04168892|DRUG|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
219601365|NCT03353701|BEHAVIORAL|Contingency Management (CM)|A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
218871290|NCT04055779|OTHER|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
219490794|NCT02432456|PROCEDURE|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
218871291|NCT04055779|OTHER|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
218871292|NCT03130036|OTHER|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
218871293|NCT04361240|RADIATION|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
218871294|NCT01445197|BIOLOGICAL|Biostate|200 IU/kg administered daily
218871295|NCT02720692|DRUG|N1539|
218871296|NCT02720692|DRUG|Intravenous Placebo|
218871297|NCT05011513|DRUG|PF-07321332|PF-07321332 (tablet)
218871298|NCT05011513|DRUG|Ritonavir|Ritonavir (capsule)
219490795|NCT02432456|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
219490796|NCT02432456|DRUG|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
219490797|NCT02432456|DRUG|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
219490798|NCT02432456|DRUG|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
218871299|NCT05011513|DRUG|Placebo|Placebo (tablet)
218871300|NCT05011513|DRUG|Placebo|Placebo (capsule)
218871301|NCT00582777|BEHAVIORAL|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
218871302|NCT00582777|BEHAVIORAL|HS DOSING|Take your usual BP meds at bed time
218871303|NCT00582777|DRUG|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
218871304|NCT02636023|DEVICE|SPhENo-Cardiograph|SPhENo-Cardiograph
219490799|NCT02432456|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
219490800|NCT05677984|PROCEDURE|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
219490801|NCT02618707|OTHER|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
218871305|NCT01455896|DRUG|ITCA 650|ITCA 650
218871306|NCT01455896|OTHER|ITCA placebo|ITCA placebo
218871307|NCT02412046|PROCEDURE|Muscle biopsy|
218871308|NCT01989247|BEHAVIORAL|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
218871309|NCT03878758|DEVICE|BD Nano™ PRO|Insulin Pen needle
218871310|NCT03878758|DEVICE|33G Artsana Insupen Extr3me|Insulin Pen Needle
218871311|NCT03878758|DEVICE|34G Artsana Insupen Extr3me|Insulin Pen Needle
218871312|NCT03878758|DEVICE|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
218871313|NCT02138968|OTHER|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
218871314|NCT01996124|DRUG|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
218871315|NCT01996124|DRUG|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
218871316|NCT03841435|RADIATION|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
218871317|NCT02315560|DEVICE|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
218871318|NCT06480149|OTHER|SMALC|Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
218871319|NCT06480149|OTHER|no application|In the control group, there was no massage application and only pain and sleep quality were evaluated.
219021679|NCT02547467|OTHER|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
218871320|NCT06238206|OTHER|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
219021680|NCT01122706|OTHER|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
219021681|NCT03394092|DIAGNOSTIC_TEST|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
219021682|NCT04208204|OTHER|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
219021683|NCT05766644|OTHER|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q\&A session. Topics are on general disease information, nutrition, and exercise.
219021684|NCT02988271|OTHER|Interview|Participate in interview
219021685|NCT02988271|PROCEDURE|Meditation Therapy|Complete meditation therapy
219021686|NCT02988271|PROCEDURE|Quality-of-Life Assessment|Complete questionnaires
219021687|NCT02988271|PROCEDURE|Supportive Care|Receive supportive care
219021688|NCT01358591|DIETARY_SUPPLEMENT|High calcium milk|High calcium milk (9 mg/kgBM)
219021689|NCT01358591|DIETARY_SUPPLEMENT|Control|Regular Milk
219021690|NCT05291247|DEVICE|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
219021691|NCT05616156|DEVICE|Cre8™ BTK|Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease
219021692|NCT01577147|OTHER|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
219021693|NCT06054230|DEVICE|Genomic Sequencer|Genomic Sequencing Device
219021694|NCT04246294|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
219021695|NCT00937157|DRUG|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
219021696|NCT01404845|DIETARY_SUPPLEMENT|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
219021697|NCT01404845|DIETARY_SUPPLEMENT|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
219021698|NCT03562104|OTHER|videofluoroscopy|Swallowing description in Minimally consciousness Patient
219490802|NCT03970252|DRUG|Fluorouracil|Given IV
219601366|NCT04453540|DIAGNOSTIC_TEST|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
219601367|NCT00356525|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
219601368|NCT00356525|DRUG|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
219021699|NCT03562104|OTHER|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
219021700|NCT00838058|DRUG|CE-224,535|one 250mg tablet, once in the morning in fasted state
219490803|NCT03970252|DRUG|Irinotecan|Given IV
219490804|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
219490805|NCT03970252|DRUG|Leucovorin|Given IV
219490806|NCT03970252|DRUG|Leucovorin Calcium|Given IV
219490807|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
219490808|NCT03970252|DRUG|Oxaliplatin|Given IV
219490809|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219522639|NCT05054348|BIOLOGICAL|IO-108 + pembrolizumab combination therapy|IO-108 and fixed dose pembrolizumab combination therapy
219522640|NCT05054348|BIOLOGICAL|IO-108 + cemiplimab combination therapy|IO-108 and fixed dose cemiplimab combination therapy
219522641|NCT02125370|OTHER|Qualitative and survey|
219522642|NCT03423849|DRUG|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
219522643|NCT03423849|DRUG|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
219522644|NCT03423849|DRUG|Cisplatin|25mg/m2,day 1,every 3 weeks
219522645|NCT03423849|DRUG|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
219522646|NCT04298177|DEVICE|Atrial fibrillation ablation using the QDOT® catheter|Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.
219522647|NCT04298177|PROCEDURE|Standard atrial fibrillation ablation|Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.
219522648|NCT00060749|DRUG|Docosahexaenoic Acid (DHA) Dietary Supplement|
219522649|NCT00164892|DRUG|Oral Vioxx (Rofecoxib)|
218871321|NCT03090555|PROCEDURE|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
218871322|NCT03090555|PROCEDURE|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
218871323|NCT02506023|DRUG|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
218871324|NCT02253485|DRUG|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
218871325|NCT03615339|DIETARY_SUPPLEMENT|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
218871326|NCT06434467|DRUG|Nelarabine injection|Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
218871327|NCT04416906|DRUG|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
219021701|NCT00838058|DRUG|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
219021702|NCT00838058|DRUG|CE-224,535|4x250mg tablets, once in the morning, in fasted state
219490810|NCT04567160|DRUG|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
219490811|NCT04567160|DRUG|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
219490812|NCT04497571|PROCEDURE|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
219490813|NCT04497571|PROCEDURE|Conventional drilling|Implants placed using drilling technique
219490814|NCT00517257|DRUG|Atorvastatin|80 mg orally once daily for 24 weeks
219490815|NCT00517257|DRUG|Placebo|Placebo tablet orally once daily for 24 weeks
219490816|NCT05862714|DRUG|Fluconazole|400 mg stat. Follow up at 4 weeks
219490817|NCT05862714|DRUG|Itraconazole|1000 mg stat. Follow up at 4 weeks
218871328|NCT01105273|BIOLOGICAL|anti-thymocyte globulin|On days -3 to -1
219490818|NCT01713478|OTHER|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
219490819|NCT06346197|DRUG|Balstilimab|Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
219490820|NCT06346197|DRUG|Botensilimab|Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
219601369|NCT00356525|DRUG|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
219601370|NCT00356525|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
219601371|NCT03717181|DRUG|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
219601372|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
218871329|NCT01105273|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
219021703|NCT00838058|DRUG|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
219021704|NCT00838058|DRUG|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
219601373|NCT04097145|DRUG|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
219601374|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
219601375|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
219601376|NCT06279572|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219021705|NCT00838058|DRUG|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
219021706|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
218871330|NCT01105273|DRUG|Fludarabine|30mg/M2 once daily IV on days -6 to -2
218871331|NCT01105273|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
218871332|NCT01105273|PROCEDURE|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
218871333|NCT01831674|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
218871334|NCT01831674|DRUG|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
218871335|NCT00853138|BEHAVIORAL|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
218871336|NCT01969435|DRUG|Carmustine|
218871337|NCT01969435|DRUG|Etoposide phosphate|
218871338|NCT01969435|DRUG|Cytarabine|
219490821|NCT06346197|DRUG|Folfox Protocol|oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
219490822|NCT06346197|DRUG|XELOX|Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
219490823|NCT06346197|DRUG|Nivolumab|240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
219490824|NCT06702397|DEVICE|Microscope|The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.
218871339|NCT01969435|DRUG|Melphalan HCl (propylene glycol-free)|
218871340|NCT04139850|DRUG|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
218871341|NCT02610946|BEHAVIORAL|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
218871342|NCT02610946|BEHAVIORAL|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
218871343|NCT04616222|DRUG|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
218871344|NCT04616222|DRUG|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
219490825|NCT06702397|DEVICE|Surgical loupes|Surgical loupes offer magnification of 3.5-5x.
218871345|NCT03620084|DEVICE|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
218871346|NCT04243733|OTHER|CEM and MTA|Pulpotomy agent
218871347|NCT04243733|OTHER|MTA and CEM|Pulpotomy agent
218871348|NCT00358436|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
218871349|NCT00358436|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
218871350|NCT02369419|OTHER|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
219490826|NCT06702566|DRUG|PD-1 and PD-L1 inhibitor|"PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab."
219490827|NCT06702566|DRUG|Targeted drugs|Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
219490828|NCT06702566|DRUG|chemotherapy drugs|Chemotherapy drugs are determined based on the investigator's decision.
219490829|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
219490830|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
219490831|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
218871351|NCT00416325|DIETARY_SUPPLEMENT|lycopene|
218871352|NCT00416325|OTHER|laboratory biomarker analysis|
218871353|NCT04039737|DRUG|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
218871354|NCT05101798|DRUG|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
218871355|NCT06156748|PROCEDURE|postoperative adjuvant transarterial chemoembolization|HCC patients received hepatectomy and PA-TACE.
219490832|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
218871356|NCT05147298|OTHER|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
218871357|NCT05147298|OTHER|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
218871358|NCT04906746|DRUG|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
218871359|NCT05614037|DRUG|Felodipine sustained release tablets (trade name: plendil®)|Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
219490833|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
219490834|NCT04032522|OTHER|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
219490835|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
219490836|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
219490837|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
219490838|NCT00206037|DEVICE|COLLOSS E|
219490839|NCT00206037|DEVICE|TomoFix Plate|
219490840|NCT02908607|DEVICE|Thermal imaging|Examination of the cervix by thermal imaging camera
218871360|NCT05614037|DRUG|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
218871361|NCT03893162|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
218871362|NCT03893162|OTHER|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
218871363|NCT02100969|DRUG|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
218871364|NCT01318148|DRUG|caspofungin|Intermittent intravenous application of caspofungin
218871365|NCT01629953|OTHER|Group vocational intervention|Group based manualized vocational rehabilitation
219021707|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
219021708|NCT02943720|DRUG|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
219490841|NCT02549885|OTHER|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
219490842|NCT02549885|OTHER|Static stretching|Static stretching of neck muscles.
219490843|NCT00834288|DRUG|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
219490844|NCT00834288|DRUG|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
219021709|NCT02943720|DRUG|placebo|placebo
219021710|NCT05040854|GENETIC|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
219490845|NCT03061773|OTHER|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
219490846|NCT03061773|BEHAVIORAL|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
219490847|NCT03526796|PROCEDURE|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
219490848|NCT03302299|DRUG|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
219490849|NCT03302299|DRUG|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
219601377|NCT06279572|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
218871366|NCT01629953|OTHER|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
218871367|NCT05936528|DRUG|Lactoferrin|antioxidant, immunomodulatory, anti-inflammatory, antimicrobial effect
219490850|NCT00850837|DRUG|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
219601378|NCT06279572|OTHER|Electronic Health Record Review|Medical records are reviewed
219601379|NCT05992415|OTHER|Virtual Automated Navigator Intervention with Health Education|Consented participants referred for follow-up to in-office appointments from the 10 developments randomized to the Virtual Automated Navigator Intervention with Health Education Arm will receive text messaging support via REDCAP with all aspects of follow-up appointments at either Columbia University Irving Medical Center or Harlem Hospital, specifically appointment scheduling and education about hypertension and/or glaucoma/suspect over a 1 year period.
219601380|NCT05992415|OTHER|Usual Care|Consented participants referred for follow-up to in-office appointments from the 4 developments randomized to the Usual Care Arm will only be scheduled for their initial appointments at either Columbia University Irving Medical Center or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1 year period.
218871368|NCT05936528|DRUG|Antioxidant therapies|Acetyl cysteine 600 mg / 12 hr
218871369|NCT05936528|DRUG|Dexamethasone|dexamethasone I.V 8 mg / day
218871370|NCT05936528|DRUG|Antibacterial therapies|Antibacterial drugs in their approved doses
218871371|NCT02189512|OTHER|blood sampling|cases - blood sampling controles - blood sampling
218871372|NCT03034330|OTHER|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
218871373|NCT03034330|OTHER|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
218871374|NCT01012544|DRUG|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
218871375|NCT06359080|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
218871376|NCT04508153|DEVICE|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
218871377|NCT04508153|OTHER|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
219021711|NCT03892590|BIOLOGICAL|Gut microbiota|Status of microbiota
219021712|NCT05766475|BEHAVIORAL|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
219490851|NCT00850837|DRUG|HEC gel|5 g application of hydroxyethylcellulose gel
219490852|NCT05802342|DRUG|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
219490853|NCT04153201|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg
219490854|NCT00485368|DRUG|Coversyl (perindopril)|
219490855|NCT04466696|BEHAVIORAL|ERAS protocol|items of ERAS protocol applied
219490856|NCT04318535|DRUG|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
219490857|NCT04318535|DRUG|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
219490858|NCT04318535|DRUG|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
219490859|NCT04923269|DRUG|LY3532226|Administered SC.
219490860|NCT04923269|DRUG|Placebo|Administered SC.
219490861|NCT01480908|PROCEDURE|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
219490862|NCT01480908|PROCEDURE|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
219490863|NCT01480908|PROCEDURE|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
219490864|NCT01480908|PROCEDURE|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
219490865|NCT04559217|BIOLOGICAL|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
219490866|NCT04113538|DRUG|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
218871378|NCT04467034|BEHAVIORAL|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
219021713|NCT05766475|BEHAVIORAL|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
219490867|NCT01004900|PROCEDURE|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
219490868|NCT01004900|DRUG|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
219490869|NCT01901146|DRUG|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
219021714|NCT00469092|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
219490870|NCT01901146|DRUG|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
219490871|NCT01901146|DRUG|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
219490872|NCT01901146|PROCEDURE|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
219490873|NCT04238468|PROCEDURE|Intradermal stromal vascular fraction injection|After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
219490874|NCT04567173|DRUG|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
219490875|NCT01586117|DRUG|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
219490876|NCT00002196|DRUG|CI-1012|
219490877|NCT04313023|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
219490878|NCT04313023|DRUG|Placebo|Sterile saline for inhalation
219490879|NCT04953208|DEVICE|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
219490880|NCT04953208|DEVICE|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
219490881|NCT04953208|BEHAVIORAL|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
219490882|NCT04953208|BEHAVIORAL|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
219490883|NCT05202613|DRUG|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
219490884|NCT03338049|DEVICE|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
219490885|NCT01496690|DRUG|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
219490886|NCT01496690|DRUG|Pregabalin Placebo Capsules|Parallel to Active Comparator
219490887|NCT02479932|OTHER|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
219490888|NCT02479932|OTHER|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
219490889|NCT04146454|OTHER|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
218871379|NCT03558490|DEVICE|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
219490890|NCT02314273|DRUG|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
219490891|NCT05976217|DRUG|Venetoclax|100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
219490892|NCT02807324|OTHER|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
219490893|NCT04778176|COMBINATION_PRODUCT|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
219490894|NCT00629629|BEHAVIORAL|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
219490895|NCT03888092|DRUG|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
219601381|NCT06294392|BEHAVIORAL|KEEP-CK|The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
219601382|NCT03749057|DRUG|Rivaroxaban|Rivaroxaban 15-20 mg daily
218871380|NCT03558490|DRUG|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
219021715|NCT00469092|DRUG|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
219021716|NCT00469092|DRUG|metformin|Tablets, 2550 mcg. Administered once daily.
219021717|NCT00469092|DRUG|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
219021718|NCT00002546|DRUG|cisplatin|
219021719|NCT00002546|DRUG|ifosfamide|
219021720|NCT00002546|PROCEDURE|adjuvant therapy|
219021721|NCT00002546|RADIATION|radiation therapy|
219490896|NCT06146543|OTHER|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
219490897|NCT05810974|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
219490898|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
219490899|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
219490900|NCT02996448|DRUG|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
219490901|NCT02308865|OTHER|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
219490902|NCT06354439|DRUG|Letrozole tablets|10 mg of letrozole PO for 7 days
219490903|NCT06354439|DRUG|Methotrexate Sodium|100 mg of methotrexate IM, single dose
219490904|NCT05163431|DEVICE|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
219490905|NCT02766686|RADIATION|Radiotherapy with protons|
218871381|NCT02591485|BEHAVIORAL|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
219021722|NCT05888246|DIAGNOSTIC_TEST|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
219021723|NCT06219447|DEVICE|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
219021724|NCT00344227|DRUG|Lucentis (Ranibizumab)|
219021725|NCT02237859|DRUG|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
219490906|NCT02766686|RADIATION|Radiotherapy with photons|
219021726|NCT02237859|DIETARY_SUPPLEMENT|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
219021727|NCT02116400|OTHER|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
219021728|NCT02116400|OTHER|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
219021729|NCT02116400|BIOLOGICAL|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
219021730|NCT02024867|DRUG|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
219021731|NCT06037720|DEVICE|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
219021732|NCT00047840|DRUG|ZD6474|
219490907|NCT06146504|DIETARY_SUPPLEMENT|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
219490908|NCT06146504|OTHER|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
219490909|NCT06361316|DRUG|Irinotecan liposome injection|Postoperative adjuvant therapy
219490910|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
219021733|NCT00047840|DRUG|Placebo|
219021734|NCT00047840|DRUG|Docetaxel|
219021735|NCT05331287|OTHER|Head position|Influence of different head position on nasal endotracheal intubation
219021736|NCT01571258|BEHAVIORAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
219021737|NCT03592147|OTHER|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
219021738|NCT03592147|OTHER|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
219021739|NCT03592147|OTHER|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
219021740|NCT03592147|OTHER|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
219021741|NCT03592147|OTHER|Music and Relaxation Light|The music and relaxation lighting were combined.
219021742|NCT03592147|OTHER|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
219021743|NCT02621242|PROCEDURE|Upper endoscopy|Upper endoscopy with biopsies
219021744|NCT02621242|PROCEDURE|Anoscopy|Anoscopy with biopsies
219490911|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
219490912|NCT00088023|DRUG|PT-523 for Injection|
219021745|NCT02621242|DRUG|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
219021746|NCT04535960|DRUG|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
219021747|NCT04535960|DRUG|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
219490913|NCT04624750|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
219021748|NCT01225575|DRUG|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
219490914|NCT03891979|DRUG|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
219490915|NCT03891979|DRUG|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
219490916|NCT03891979|DRUG|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
219490917|NCT02083770|BEHAVIORAL|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
219490918|NCT00171119|DRUG|valsartan|
219490919|NCT05285332|PROCEDURE|surgical treatment 1|Mastectomy OR Breast conserving surgery
219490920|NCT05285332|PROCEDURE|surgical treatment 2|Resection of metastasis
219490921|NCT05285332|DRUG|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
219490922|NCT01780688|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
219490923|NCT01780688|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
219490924|NCT04657237|PROCEDURE|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
219490925|NCT05131997|DRUG|AD-221|PO, Once daily(QD), 8 weeks
219601383|NCT00609999|DRUG|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
219601384|NCT01044264|DRUG|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
219601385|NCT01044264|DRUG|Placebo|Placebo
219601386|NCT02542956|DRUG|Exparel|receive Exparel by injection
219021749|NCT01998633|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
219021750|NCT00825747|DEVICE|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
219490926|NCT05131997|DRUG|AD-221A|PO, Once daily(QD), 8 weeks
219490927|NCT05131997|DRUG|AD-221B|PO, Once daily(QD), 8 weeks
219490928|NCT05131997|DRUG|AD-221C|PO, Once daily(QD), 8 weeks
219522650|NCT03733197|BEHAVIORAL|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
219601387|NCT02542956|DRUG|Marcaine|receive Marcaine in a pain pump
219601388|NCT02542956|DRUG|Marcaine|receive Marcaine by injection
219601389|NCT05298345|OTHER|Family Champions Project Primary Services|"Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula.~Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs."
219522651|NCT03733197|BEHAVIORAL|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
219601390|NCT04821193|DRUG|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
219601391|NCT04821193|DRUG|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
219601392|NCT02233439|DIETARY_SUPPLEMENT|Herbal galactagogue|
219601393|NCT02233439|DIETARY_SUPPLEMENT|Placebo|
219021751|NCT00413192|DRUG|E7389|1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
219021752|NCT03988192|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
219490929|NCT00688610|OTHER|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
219490930|NCT00897273|GENETIC|comparative genomic hybridization|
219490931|NCT00897273|GENETIC|gene expression analysis|
219021753|NCT01769833|DRUG|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
219021754|NCT01769833|DRUG|Nucleosides|
219021755|NCT03755986|DEVICE|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
219490932|NCT00897273|OTHER|study of socioeconomic and demographic variables|
219490933|NCT00897273|PROCEDURE|evaluation of cancer risk factors|
219490934|NCT00897273|PROCEDURE|study of high risk factors|
219490935|NCT00795782|PROCEDURE|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
219490936|NCT00606801|DRUG|Galantamine|Galantamine 8 mg/day
219490937|NCT00606801|DRUG|placebo|sugar pill
219021756|NCT02589782|DRUG|Bedaquiline|
219021757|NCT02589782|DRUG|Pretomanid|
219021758|NCT02589782|DRUG|Moxifloxacin|
219021759|NCT02589782|DRUG|Linezolid|
219490938|NCT02465580|DRUG|hrIL-2 active|active group: placebo group =1:1
219490939|NCT02465580|DRUG|hrIL-2 placebo|active group: placebo group =1:1
219490940|NCT05303831|OTHER|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
219490941|NCT00552526|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet is a very strict high fat diet
219490942|NCT00552526|DRUG|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
219021760|NCT02589782|DRUG|Clofazimine|
219021761|NCT02589782|DRUG|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
219490943|NCT02515357|BEHAVIORAL|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
219490944|NCT02515357|BEHAVIORAL|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
219490945|NCT02515357|BEHAVIORAL|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
219490946|NCT00038129|PROCEDURE|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
219490947|NCT00982774|BIOLOGICAL|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
219021762|NCT01860755|OTHER|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
219021763|NCT01860755|OTHER|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
219021764|NCT04999150|PROCEDURE|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
219021765|NCT04999150|PROCEDURE|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
219021766|NCT05673044|PROCEDURE|modified Studer ileal neobladder|orthotopic ileal neobladders
219490948|NCT02232139|DRUG|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
219490949|NCT05459545|DEVICE|Use of Eko CORE and Eko CORE 500 electronic stethoscope|Auscultation of heart sounds using electronic stethoscopes
219490950|NCT02104401|DEVICE|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
219490951|NCT01586767|RADIATION|Proton radiation therapy|Daily proton radiation therapy
219490952|NCT01586767|RADIATION|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
219490953|NCT03413969|BEHAVIORAL|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
219490954|NCT04891367|OTHER|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
219490955|NCT01284244|DEVICE|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
219522652|NCT03149653|DRUG|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
219522653|NCT03149653|DRUG|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
219522654|NCT03149653|DRUG|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
218871382|NCT05162313|DEVICE|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
219021767|NCT01001507|PROCEDURE|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
219021768|NCT01077947|PROCEDURE|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
219021769|NCT01077947|PROCEDURE|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
219490956|NCT01284244|DEVICE|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
219490957|NCT01533272|DRUG|Tenofovir, emtricitabine, maraviroc|experimental drug
219490958|NCT01533272|DRUG|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
219490959|NCT02323139|DRUG|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
219490960|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
219490961|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
219021770|NCT06135233|OTHER|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
219490962|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219490963|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219490964|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219522655|NCT03149653|DRUG|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
219021771|NCT04098107|DEVICE|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
219021772|NCT00755157|DRUG|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
219021773|NCT00755157|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
219522656|NCT03149653|DRUG|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
219522657|NCT03149653|DRUG|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
219522658|NCT00384917|DRUG|Ketoconazole|
219522659|NCT02108119|DIETARY_SUPPLEMENT|Probiotics|
218871383|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for PCV|In pressure control ventilation (PCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
218871384|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for VCV|In volume control ventilation (VCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
218871385|NCT03654066|DRUG|Botulinum toxin type A|Botox injection in the LES
218871386|NCT03654066|DEVICE|Endoscope balloon dilator|Distal esophageal dilation
219490965|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
218871387|NCT03654066|OTHER|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
218871388|NCT03654066|DIAGNOSTIC_TEST|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
219021774|NCT01415063|PROCEDURE|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
219021775|NCT01415063|PROCEDURE|TACE-RFA|TACE first, then RFA within 2 weeks
219021776|NCT03013439|DRUG|Iron Isomaltoside|The trial is a dose escalating trial.
219490966|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219490967|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219490968|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219522660|NCT02108119|DIETARY_SUPPLEMENT|Control placebo|
218871389|NCT06584435|DRUG|Tremelimumab|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
218871390|NCT04976361|OTHER|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
218871391|NCT00304655|DRUG|Aripiprazole|
218871392|NCT00306527|BIOLOGICAL|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
218871393|NCT00306527|BIOLOGICAL|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
218871394|NCT01267942|DRUG|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
218871395|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
218871396|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
218871397|NCT05409066|DRUG|Epcoritamab|Subcutaneous Injection
218871398|NCT05409066|DRUG|Rituximab|Intravenous Infusion
218871399|NCT05409066|DRUG|Lenalidomide|Oral Capsules
218871400|NCT05858710|DRUG|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
218871401|NCT05858710|DRUG|Dexrazoxane|For cardioprotection of participants.
218871402|NCT02462161|DRUG|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
218871403|NCT02462161|DRUG|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
218871404|NCT04584255|DRUG|Niraparib|Predetermined dosage PO Daily
219021777|NCT00159250|DRUG|AVI-4658 (PMO)|morpholino antisense oligonucleotide
219490969|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
219490970|NCT00822263|DRUG|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
219490971|NCT00822263|DRUG|Placebo|Control for study
219490972|NCT02063386|DRUG|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
218871405|NCT04584255|DRUG|Dostarlimab|Predetermined Dosage, IV,q3 weeks
219490973|NCT01318941|DRUG|Ranibizumab|
219490974|NCT01318941|OTHER|Ranibizumab|
219490975|NCT01159119|DRUG|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
219490976|NCT01159119|DRUG|Zenpep|Capsules taken for daily for 28 days during treatment period 2
219490977|NCT01159119|DRUG|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
219490978|NCT01614613|DEVICE|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219490979|NCT01614613|DEVICE|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219490980|NCT01614613|DEVICE|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
218871406|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
219490981|NCT01614613|DEVICE|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219490982|NCT01614613|DEVICE|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219490983|NCT01614613|DEVICE|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219490984|NCT05580549|DIAGNOSTIC_TEST|Alcohol biomarker Phosphatidylethanol (PEth)|The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
219490985|NCT03541213|PROCEDURE|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
219490986|NCT03541213|PROCEDURE|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
219490987|NCT03541213|BIOLOGICAL|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
219490988|NCT00309413|DRUG|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
219490989|NCT00309413|DRUG|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
219490990|NCT00046384|DRUG|aripiprazole|
219490991|NCT00440375|DRUG|Rosiglitazone|
219490992|NCT01557452|DRUG|Givinostat|ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
219490993|NCT04765852|OTHER|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
219490994|NCT04765852|OTHER|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
219021778|NCT04344314|DEVICE|Peripheral Intravenous Catheter|Randomised controlled
219490995|NCT04765852|OTHER|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
219490996|NCT00124475|DRUG|alitretinoin|
219490997|NCT03828656|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
219490998|NCT03251209|OTHER|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
219490999|NCT03251209|OTHER|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
219491000|NCT03251209|OTHER|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
219491001|NCT01134588|OTHER|Paper questionnaire|
219491002|NCT01134588|OTHER|Touch screen questionnaire|
219491003|NCT05839093|DEVICE|Inferior Alveolar Nerve Block Group|A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
218871407|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
218871408|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
219491004|NCT05839093|DEVICE|Intraligamentary Injection Group|An infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. Then, an intraligamentary injection was performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle. The needle was placed alongside the tooth and inserted at a 30 angle relative to the longitudinal axis of the crown with the needle between the teeth and the bone. Then, in the mesiobuccal, distobuccal, mesiolingual and distolingual portions of teeth, 0.18 mL of the solution was injected. Five minutes later, the teeth were isolated and the endodontic procedure was started.
219601394|NCT00655772|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
219601395|NCT00365092|PROCEDURE|Insertion of tympanostomy tubes|
219601396|NCT01350583|DRUG|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
219601397|NCT04405830|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
219491005|NCT02036528|DRUG|Gentamicin Topical Gel|
219491006|NCT02036528|DRUG|Ciprofloxacin|
219491007|NCT02036528|DRUG|Doxycycline|
219491008|NCT04168047|PROCEDURE|Barostat procedure|Pressure threshold will be measured during the barostat procedure
219601398|NCT03510962|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
218871409|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
218871410|NCT04037254|BIOLOGICAL|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
218871411|NCT04037254|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
219040146|NCT04736238|PROCEDURE|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
219040147|NCT05372692|DRUG|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
219491009|NCT04168047|OTHER|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
219491010|NCT04168047|OTHER|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
219491011|NCT02777853|DIETARY_SUPPLEMENT|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
219491012|NCT02777853|DIETARY_SUPPLEMENT|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
219491013|NCT00503854|BEHAVIORAL|Questionnaire|Ancillary studies
219601399|NCT03510962|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219601400|NCT03510962|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219601401|NCT03510962|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
218871412|NCT04037254|DRUG|Niraparib|tablet
218871413|NCT05390658|OTHER|Not application|Not application
218871414|NCT01910467|DEVICE|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
218871415|NCT01910467|DEVICE|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
218871416|NCT00477152|DRUG|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
218871417|NCT00020878|DRUG|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
218871418|NCT05348239|DRUG|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
219040148|NCT04964453|DRUG|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
219040149|NCT04964453|DRUG|BI 474121|Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
219491014|NCT04624061|BEHAVIORAL|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
219491015|NCT01160198|DRUG|ferrous ascorbate|100 mg elemental iron
218871419|NCT05014685|DRUG|Rabeprazole|20mg bid
219491016|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
219491017|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
219491018|NCT00448682|DRUG|Docetaxel|
219491019|NCT00448682|DRUG|Floxuridine|
219491020|NCT00448682|DRUG|Leucovorin|
219491021|NCT00448682|DRUG|Oxaliplatin|
219491022|NCT04496882|DRUG|Vemlidy|25mg Tenofovir Alafenamide
219491023|NCT00451269|DEVICE|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
219491024|NCT06542094|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
219491025|NCT01944189|DIETARY_SUPPLEMENT|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
219601402|NCT03510962|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
218871420|NCT05014685|DRUG|Bismuth potassium citrate|0.6g bid
218871421|NCT05014685|DRUG|Metronidazole|0.4g tid
218871422|NCT05014685|DRUG|Amoxicillin|1g tid
218871423|NCT04241471|PROCEDURE|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
219040150|NCT02254707|DRUG|BILB 1941 ZW|
219040151|NCT02254707|DRUG|Placebo|
219491026|NCT01869712|OTHER|Cupping therapy|
219491027|NCT01869712|OTHER|Acupuncture|
219491028|NCT04681274|DEVICE|Image features extraction and clustering|"The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures."
219491029|NCT04681274|DEVICE|Phenotype signature database building|Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
219491030|NCT00159666|DRUG|pregabalin|
219601403|NCT03510962|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
219601404|NCT00182247|PROCEDURE|venogram|
219491031|NCT01425931|PROCEDURE|Heart Lung machine|measurement of microcirculation with O2C device
219491032|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
219491033|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
219491034|NCT02163031|DEVICE|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
219491035|NCT06543186|OTHER|Oral health education lecture|Conventional oral health education will be given by trained and calibrated dentists.
219491036|NCT06543186|OTHER|Oral health education via mHealth on WhatsaApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material
219491037|NCT06543186|OTHER|Oral health education via Metaverse platform on Meta-OHE|For oral health education intervention via Meta-OHE, it will be done via computer.
219491038|NCT00710086|DRUG|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
219491039|NCT00710086|DRUG|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
219491040|NCT00817258|DRUG|cisplatin|Cisplatin 40mg/m2,weekly
219491041|NCT00817258|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
219491042|NCT02413879|DEVICE|CleanCision|Wound protection during colorectal surgery.
219491043|NCT02016755|BIOLOGICAL|HGF Plasmid|Intramuscular injection in the affected limb.
219491044|NCT01881217|DRUG|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
219491045|NCT00128518|DRUG|Indapamide (T2)|1.5 mg/day during 4 weeks
219491046|NCT00128518|DRUG|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
219491047|NCT00128518|DRUG|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
219491048|NCT00128518|DRUG|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
219491049|NCT06120179|DEVICE|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
219491050|NCT05658107|DRUG|BI 765423|BI 765423
219491051|NCT05658107|DRUG|Placebo|Placebo
219491052|NCT05779488|DIETARY_SUPPLEMENT|maca|2.25 g of Maca extract, twice per day for 12 weeks
219491053|NCT05779488|DIETARY_SUPPLEMENT|placebo|2.25 g of starch, twice per day for 12 weeks
219491054|NCT01485588|DRUG|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
219491055|NCT01485588|DRUG|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
219491056|NCT01485588|DRUG|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
219491057|NCT01582828|PROCEDURE|Epicardial (surgical) ablation|"* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure"
219491058|NCT01582828|PROCEDURE|Hybrid|"Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
219491059|NCT05020197|DIAGNOSTIC_TEST|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
219491060|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
219491061|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
219491062|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
219491063|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
219491064|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
219491065|NCT01493609|BEHAVIORAL|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
219491066|NCT00549107|DRUG|Levosimendan|
219491067|NCT00549107|DRUG|Milrinone|
219491068|NCT02085005|DRUG|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
218871424|NCT04241471|DEVICE|traditional incision and drainage (I&D)|traditional incision and drainage (I\&D)
218871425|NCT02787915|BIOLOGICAL|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
219491069|NCT02085005|DRUG|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
219491070|NCT02085005|DRUG|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
219491071|NCT05171127|PROCEDURE|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
219491072|NCT06566495|DEVICE|collection of microbiological material from reusable tourniquets|"Microbiological analysis~The material was collected in each group in the same way."
219491073|NCT00179374|BEHAVIORAL|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
219491074|NCT00179374|BEHAVIORAL|Print educational intervention|diabetes educational materials by mail
219491075|NCT00843063|DRUG|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
219491076|NCT01803035|DRUG|LTX-109 1 %|
219601405|NCT05454670|PROCEDURE|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
219601406|NCT01685840|OTHER|Usual Care|Usual Care
219601407|NCT01685840|DEVICE|Biomarker-guided care NT-proBNP|Device: NT-proBNP
219601408|NCT01406444|DRUG|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
219601409|NCT01406444|DRUG|Risedronate|Risedronate 35mg PO one time weekly
219601410|NCT01406444|DRUG|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
219601411|NCT01119573|GENETIC|RNA analysis|
218871426|NCT02504580|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
218871427|NCT02504580|DRUG|Placebo|Saline placebo by injection.
218871428|NCT02504580|DRUG|HTX-002|HTX-002, by injection or instillation (pooled).
218871429|NCT02504580|DRUG|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
218871430|NCT02504580|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
218871431|NCT02504580|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
218871432|NCT02504580|DRUG|HTX-009|HTX-009 by injection and instillation (combination).
218871433|NCT00448747|DRUG|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
218871434|NCT00448747|DRUG|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
218871435|NCT03670368|BEHAVIORAL|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
218871436|NCT03670368|BEHAVIORAL|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
219491077|NCT01803035|DRUG|LTX-109 2 %|
219491078|NCT01803035|DRUG|Placebo gel|
219491079|NCT01106118|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
219491080|NCT06155149|OTHER|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
219491081|NCT06155149|OTHER|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
219601412|NCT01119573|GENETIC|microarray analysis|
219601413|NCT01119573|GENETIC|reverse transcriptase-polymerase chain reaction|
219601414|NCT01119573|OTHER|laboratory biomarker analysis|
219601415|NCT05056038|PROCEDURE|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
219601416|NCT05056038|PROCEDURE|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
219601417|NCT01357148|DRUG|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
219601418|NCT03935438|OTHER|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
218871437|NCT00742729|BEHAVIORAL|Arm 1|Educational small group session with free FOBT kit
218871438|NCT00742729|BEHAVIORAL|Arm 2|Educational small group session with no FOBT kit
218871439|NCT00742729|BEHAVIORAL|Arm 3|Educational small group session, exercise
218871440|NCT01575314|DEVICE|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
218871441|NCT04423081|OTHER|EXIT scale|completion of EXIT scale translated in french
218871442|NCT05541445|DRUG|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
218871443|NCT03944408|PROCEDURE|stent implantation|stent implantation
218871444|NCT06271395|DRUG|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
218871445|NCT01737853|DRUG|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
218871446|NCT01737853|DRUG|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
218871447|NCT06514313|DRUG|Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
218871448|NCT06514313|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 4 cycles
218871449|NCT03592485|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
218871450|NCT03592485|PROCEDURE|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
218871451|NCT03592485|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
218871452|NCT03592485|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
218871453|NCT03592485|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
218871454|NCT03155438|DIAGNOSTIC_TEST|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
218871455|NCT03155438|DIAGNOSTIC_TEST|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
218871456|NCT02905006|DRUG|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
219491082|NCT03663959|PROCEDURE|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
219601419|NCT04556786|BEHAVIORAL|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
219601420|NCT00598572|DRUG|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
218871457|NCT02905006|OTHER|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
218871458|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
218871459|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
218871460|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
218871461|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
218871462|NCT01387464|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed QD
218871463|NCT01387464|DRUG|Bromday™|0.09% bromfenac dosed QD
218871464|NCT05513794|DEVICE|MRI Imaging|Neuromelanin sequence imaging
218871465|NCT04091048|DEVICE|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
218871466|NCT03088943|OTHER|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
218871467|NCT03088943|OTHER|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
218871468|NCT03088943|OTHER|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
219199983|NCT06857071|BEHAVIORAL|Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention|"The E-SNRHT intervention will recruit people newly diagnosed with HIV as seeds, briefly remind them of HIV transmission risks and how HIV spreads through networks, and ask them to recruit people in their expanded social networks (i.e., anyone they know) who they think might benefit from being tested for HIV, regardless of whether or not they have engaged in any HIV risk behaviors together. By including expanded social networks, E-SNRHT aims to broaden the reach of HIV testing to people who are reluctant to participate in risk partner recruitment and/or to seek clinic testing. Network members recruited by a seed will also be asked to recruit additional people they know using the same education and recruitment instructions provided to seeds. All network members will be tested for HIV and provided with pre- and post-test counseling, all participants diagnosed with HIV will be referred to care, and all participants who test negative will be referred to 3-month follow-up HIV testing."
219199984|NCT06859034|DRUG|injection of dextrose 10% in retrodiscal tissues|group 1 will recieve 10% dextrose in retrodiscal tissues
219199985|NCT06859034|DRUG|injection of dextrose 25% in retrodiscal tissues|group 2 will recieve 25% dextrose
219199986|NCT06475339|OTHER|30/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
219199987|NCT06475339|OTHER|30/20 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.
219199988|NCT06475339|OTHER|40/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
219601421|NCT03981692|OTHER|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
219601422|NCT03981692|OTHER|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
219601423|NCT02925104|DRUG|INC280|
219601424|NCT00315796|DEVICE|Biophilic Nature Scene and Sound|
219601425|NCT03612349|BEHAVIORAL|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
219601426|NCT00934687|DRUG|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
219601427|NCT00934687|OTHER|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
219601428|NCT01322230|OTHER|Control|Multimedia Control
218871469|NCT00763841|DEVICE|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
218871470|NCT00763841|DEVICE|Sham|
218871471|NCT05586776|DRUG|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
218871472|NCT05586776|DRUG|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
218871473|NCT05586776|DRUG|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
218871474|NCT05586776|DRUG|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
218871475|NCT01932502|DRUG|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
218871476|NCT01932502|DRUG|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
218871477|NCT01932502|DRUG|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
218871478|NCT01932502|DRUG|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
218871479|NCT01932502|DRUG|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
218871480|NCT04494295|DEVICE|Aurora Surgiscope System|MIS evacuation of hematoma using the Aurora Surgiscope System
218871481|NCT02429791|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
218871482|NCT02429791|DRUG|RPV 25 mg|Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
218871483|NCT02429791|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
218871484|NCT05814640|DRUG|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
218871485|NCT05814640|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
218871486|NCT05814640|DRUG|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
218871487|NCT05814640|DRUG|Duloxetine|Commonly used oral antipsychotics intervention therapy.
218871488|NCT05814640|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
218871489|NCT05814640|DRUG|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
218871490|NCT05814640|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
219021779|NCT05972499|OTHER|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
219021780|NCT00217139|DRUG|Celgosivir|
219021781|NCT04727229|DRUG|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
219021782|NCT04727229|DRUG|Normal Saline|Injection of Normal Saline near the stellate ganglion
219021783|NCT02982850|DRUG|Dabigatran|
219021784|NCT02982850|DRUG|Acetylsalicylic acid|
219491083|NCT03663959|PROCEDURE|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
219491084|NCT03555500|OTHER|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
219491085|NCT04876807|DRUG|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
219491086|NCT04876807|DRUG|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
219601429|NCT01322230|OTHER|WISEMD Original|Current WISEMD
219601430|NCT01322230|OTHER|Social Networking|Social networking feature
219021785|NCT02982850|DRUG|Warfarin|
219021786|NCT00751647|OTHER|Physical Therapy|Treatment
219021787|NCT04657614|OTHER|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
219021788|NCT04657614|OTHER|Anterior Alignment|Alignment that is anterior displaced pylon.
219021789|NCT04657614|OTHER|Posterior Alignment|Alignment that is posteriorly displaced pylon.
219021790|NCT02444260|DRUG|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
219021791|NCT02444260|DRUG|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
219021792|NCT02444260|DRUG|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
219601431|NCT01322230|OTHER|Social Networking plus Emotional Design|social networking features plus user interface enhancements
219601432|NCT04428450|DEVICE|Deprexis|CBT-based, integrative online self-help program
219601433|NCT03239847|OTHER|EndoPhys Sheath and Radial Arterial Line|
219601434|NCT03239847|OTHER|EndoPhys Sheath|
218871491|NCT05814640|BEHAVIORAL|GCBT|Commonly used intervention therapy of psychotherapy.
218871492|NCT05529654|DEVICE|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
218871493|NCT03976180|DEVICE|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
218871494|NCT03976180|DEVICE|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
219021793|NCT02444260|DRUG|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
218871495|NCT03976180|DEVICE|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
218871496|NCT03976180|DEVICE|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
218871497|NCT06437470|OTHER|blood flow restriction technique|"All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff."
218871498|NCT03033251|DEVICE|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
218871499|NCT03033251|DEVICE|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
219601435|NCT03364842|DRUG|Furosemide|Administering furosemide
219601436|NCT03437070|DRUG|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
218871500|NCT03033251|DEVICE|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
218871501|NCT04864847|DIAGNOSTIC_TEST|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
218871502|NCT05851430|DEVICE|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
218871503|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.
219021794|NCT03495830|PROCEDURE|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
219021795|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
219021796|NCT02661542|DRUG|FF-10502-01|
219491087|NCT00306137|DRUG|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach"
219491088|NCT00306137|DRUG|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
219491089|NCT06301737|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
219491090|NCT06301737|PROCEDURE|Injection|the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219491091|NCT06301737|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219601437|NCT03437070|DRUG|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
219601438|NCT03437070|DRUG|Olaratumab|Administered intravenously per protocol
218871504|NCT04201093|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
218871505|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.
218871506|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
218871507|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
218871508|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
218871509|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
218871510|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
218871511|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
218871512|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
218871513|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
218871514|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
219021797|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
219021798|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
219021799|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
219199989|NCT06475339|OTHER|20/12 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
219491092|NCT06036537|DIAGNOSTIC_TEST|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
219491093|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
219491094|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
219491095|NCT06416007|RADIATION|Lattice therapy (LRT)|5 Fractions LRT
219491096|NCT02533505|DRUG|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
219491097|NCT02533505|DRUG|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
219491098|NCT00513565|DRUG|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
219491099|NCT03306602|DEVICE|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
219601439|NCT03190811|BIOLOGICAL|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
219601440|NCT03190811|BIOLOGICAL|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
219601441|NCT02195661|DIETARY_SUPPLEMENT|Melatonin|
219491100|NCT03306602|DEVICE|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
219491101|NCT05745064|DRUG|TL-925|TL-925 is an eye drop.
219491102|NCT05745064|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
219491103|NCT05799365|OTHER|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
219491104|NCT04949984|DEVICE|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
219491105|NCT04015479|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
219491106|NCT04015479|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
219491107|NCT02377687|OTHER|observational study|
219491108|NCT00822679|DRUG|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
219491109|NCT00822679|OTHER|Placebo|Subjects are given placebo for 3 consecutive nights
219601442|NCT02195661|DRUG|Chloral Hydrate|
219601443|NCT04272424|PROCEDURE|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
219601444|NCT02884570|OTHER|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
219601445|NCT01464632|DEVICE|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
219601446|NCT03323242|DEVICE|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
219601447|NCT03323242|DEVICE|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
219601448|NCT06006429|OTHER|Numerical dental impression by intraoral scanner|Intervention consists in an 3D intra oral representation of the oral cavity
219601449|NCT03637426|OTHER|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
219601450|NCT03637426|OTHER|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
219601451|NCT03637426|OTHER|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
219491110|NCT04189406|OTHER|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
219491111|NCT02741752|PROCEDURE|Decortication|cortical bone perforation
219491112|NCT04498299|DIAGNOSTIC_TEST|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
219491113|NCT00306852|PROCEDURE|Baerveldt implant|Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
219491114|NCT00306852|PROCEDURE|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
219491115|NCT02046499|DRUG|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
219491116|NCT02046499|DRUG|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
219491117|NCT04954209|OTHER|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
219491118|NCT04954209|OTHER|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
219491119|NCT04766593|OTHER|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living."
219491120|NCT02583607|DEVICE|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
219491121|NCT02307188|DEVICE|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
219491122|NCT06358807|PROCEDURE|Arthroscopic microfracture with intraoperative local PRP gel injection|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
219491123|NCT06358807|PROCEDURE|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
219491124|NCT06337968|PROCEDURE|Circum-psoas Block|Ultrasound-guided circum-psoas block with 40 mL of treatment drug (Ropivacaine 0.2% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
219491125|NCT06337968|PROCEDURE|Sham block|Perform ultrasound scanning without puncture.
219491126|NCT03343054|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
219491127|NCT01467570|DIETARY_SUPPLEMENT|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
219491128|NCT01467570|DIETARY_SUPPLEMENT|ESPGHAN ORS|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
219491129|NCT02156349|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
219491130|NCT02156349|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
219491131|NCT04262869|DRUG|Carboplatin|Given IV
219491132|NCT04262869|BIOLOGICAL|Durvalumab|Given IV
219491133|NCT04262869|DRUG|Paclitaxel|Given IV
219491134|NCT04262869|DRUG|Pemetrexed|Given IV
219491135|NCT00123331|DRUG|Cyclosporine discontinuation|
219491136|NCT00123331|DRUG|Rapamycin medication|
219491137|NCT00325429|DRUG|Vildagliptin|
218871515|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
218871516|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
219491138|NCT01098734|DRUG|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
219491139|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
219491140|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
219601452|NCT03637426|OTHER|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
219613653|NCT02494167|BIOLOGICAL|MultiTAA-specific T cells|"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
218871517|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
218871518|NCT01276223|DRUG|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
218871519|NCT01276223|OTHER|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
218871520|NCT02516319|DRUG|ICG Dye|
218871521|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
218871522|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
218871523|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
218871524|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
218871525|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
218871526|NCT03094065|OTHER|News items with spin|Interpretation of news items with spin
218871527|NCT03094065|OTHER|News items without spin|Interpretation of news items without spin
218871528|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
218871529|NCT06210555|PROCEDURE|Renal transplantation|Operative procedure - receipt of a kidney
219021800|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
219021801|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
219021802|NCT06238635|DRUG|Dostarlimab|Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
219021803|NCT06238635|DRUG|Cobolimab|Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
219021804|NCT06411691|DRUG|KRAS Vaccine with Poly-ICLC adjuvant|"SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
219491141|NCT05131490|BEHAVIORAL|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~1. Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~2. Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~3. Module 3: Current developments on gynecological cancers will be included.~4. Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~5. Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
219491142|NCT01450579|BIOLOGICAL|ASP7373|Intermuscular administration
219491143|NCT01450579|BIOLOGICAL|Placebo|Intramuscular administration
219491144|NCT04221087|DRUG|Placebos|Sugar water based on same ml dosing of intervention arm drug
219601453|NCT05017961|DEVICE|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
219601454|NCT05017961|DEVICE|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
219021805|NCT06411691|DRUG|Balstilimab|"240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 240 mg IV"
219021806|NCT06411691|DRUG|Botensilimab|"75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 15 in the Boost Phase.~Drug: 75 mg IV"
219021807|NCT06540209|DRUG|Bacillus clausii|Children will be give Bacillus clausii for 5 days
219021808|NCT06540209|DRUG|Saccharomyces boulardii|Children will be give Saccharomyces boulardii for 5 days
219021809|NCT06540209|DRUG|Zinc|Zinc will be given to all children for 5 days
219021810|NCT06540209|DRUG|ORS|ORS will be given to all children for 5 days
219021811|NCT06067542|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
219021812|NCT03222596|BEHAVIORAL|Exercise training|Exercise programme includes breathing and upper limbs exercises.
219491145|NCT04221087|DRUG|Dexamethasone Oral|0.6mg/kg/dose - single oral dose administration to intervention arm
219491146|NCT01092299|DRUG|AZD1446|ER Fast, 90mg, p.o. capsule
219491147|NCT01092299|DRUG|AZD1446|ER Moderate, 90mg, p.o. capsule
219491148|NCT01092299|DRUG|AZD1446|ER Slow, 90mg, p.o. capsule
219491149|NCT01092299|DRUG|AZD1446|MR
219491150|NCT01092299|DRUG|AZD1446|IR, 90 mg p.o. capsule
219491151|NCT01092299|DRUG|Placebo|IR
219491152|NCT01092299|DRUG|Placebo|ER/MR
219613654|NCT05298761|DRUG|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
219613655|NCT06581991|DIETARY_SUPPLEMENT|Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)|Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
219491153|NCT05824299|PROCEDURE|General Anesthesia|Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.
219491154|NCT05824299|PROCEDURE|Spinal Anesthesia|Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
219491155|NCT05064488|DRUG|Evobrutinib|Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
219601455|NCT05017961|DEVICE|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
219601456|NCT03899246|DRUG|Eight Percent Topical Capsaicin|See arm description
219613656|NCT05329662|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
218871530|NCT06210555|PROCEDURE|Living kidney donation|Operative procedure - donation of a kidney
218871531|NCT02136147|DRUG|methylphenidate medication|
218871532|NCT02136147|DRUG|atomoxetine medication|
218871533|NCT02136147|DRUG|lisdexamphetamine medication|
218871534|NCT02136147|DRUG|guanfacine medication|
218871535|NCT04772508|PROCEDURE|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
218871536|NCT04772508|BIOLOGICAL|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
218871537|NCT04772508|DRUG|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
218871538|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
218871539|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
218871540|NCT04480255|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
218871541|NCT04480255|OTHER|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
218871542|NCT05325476|OTHER|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
218871543|NCT05325476|OTHER|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
218871544|NCT05856227|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
218871545|NCT02984540|OTHER|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
218871546|NCT02984540|OTHER|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
219491156|NCT05064488|DRUG|Digoxin|Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
219491157|NCT05064488|DRUG|Metformin|Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
219491158|NCT05064488|DRUG|Rosuvastatin|Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
219491159|NCT05064488|DRUG|Sumatriptan|Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
219491160|NCT02766088|PROCEDURE|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
219491161|NCT01222715|BIOLOGICAL|Bevacizumab|Given IV
219491162|NCT01222715|DRUG|Cyclophosphamide|Given IV
219491163|NCT01222715|OTHER|Laboratory Biomarker Analysis|Correlative studies
219491164|NCT01222715|DRUG|Temsirolimus|Given IV
219491165|NCT01222715|DRUG|Vinorelbine Tartrate|Given IV
219491166|NCT03552354|DRUG|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
219491167|NCT05415982|OTHER|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
219491168|NCT04692220|OTHER|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
219491169|NCT01331083|DRUG|PX-866|PX-866: 8mg orally taken daily
219601457|NCT01436630|OTHER|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
219601458|NCT05416242|DEVICE|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
219601459|NCT05416242|DEVICE|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
219601460|NCT05416242|PROCEDURE|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
219601461|NCT03166098|DIAGNOSTIC_TEST|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
219601462|NCT05794698|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
219601463|NCT03936803|BEHAVIORAL|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
219601464|NCT03936803|DEVICE|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
219491170|NCT02425865|DRUG|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
219491171|NCT01381822|DRUG|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
219491172|NCT03272867|DIETARY_SUPPLEMENT|ProManna|
218871547|NCT05849376|BEHAVIORAL|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments. A maximum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 15-20 min to conduct. Novel probe trials will be embedded throughout all sessions to continuously assess for the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
218871548|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 160 mmHg.
219491173|NCT06058468|PROCEDURE|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration \>30% is achieved or if radiofrequency time exceeds 120 seconds.
219491174|NCT06058468|PROCEDURE|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
219491175|NCT01207401|DRUG|Lidocaine|1% Lidocaine
219491176|NCT02917616|OTHER|Alkaline drinking-water|
219491177|NCT02917616|OTHER|Neutral drinking-water|
219491178|NCT05880563|DRUG|[18F]-RoSMA-18-d6|\[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
219491179|NCT04078919|DIETARY_SUPPLEMENT|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
219491180|NCT04078919|OTHER|Low calorie diet|Low calorie diet
218871549|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 180 mmHg.
218871550|NCT06634134|BEHAVIORAL|Adjusting training advice|Based on discomfort related to the menstrual cycle the female cyclist can choose to adjust the suggested training.
218871551|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
218871552|NCT04281979|DRUG|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
218871553|NCT04281979|DRUG|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
218871554|NCT02870088|BEHAVIORAL|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
218871555|NCT02870088|BEHAVIORAL|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
218871556|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
218871557|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
219021813|NCT01086540|BIOLOGICAL|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
219021814|NCT01086540|OTHER|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
219021815|NCT01086540|DIAGNOSTIC_TEST|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
219021816|NCT01086540|DRUG|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
219491181|NCT01498419|DRUG|Moxifloxacin (M)|
219491182|NCT01498419|DRUG|Pretomid (Pa)|
219491183|NCT01498419|DRUG|Pyrazinamide (Z)|
219491184|NCT01498419|DRUG|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
219491185|NCT03555890|DRUG|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
219491186|NCT03555890|DRUG|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
219491187|NCT05397600|DRUG|Bimatoprost Ophthalmic|Eyedrops
219601465|NCT03893643|OTHER|no intervention|no intervention in an observational study
219601466|NCT05497791|DEVICE|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
219613657|NCT01431365|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
219601467|NCT05497791|OTHER|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
218871558|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
219021817|NCT01086540|DRUG|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
219021818|NCT01086540|DRUG|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
219491188|NCT03183271|RADIATION|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
219491189|NCT00439751|DRUG|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
219491190|NCT03372369|OTHER|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
219491191|NCT03372369|OTHER|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
219491192|NCT05739227|OTHER|allogenic CD19-CAR-NK cells|The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10\^6/kg, 5x10\^6/kg, 2x10\^7/kg) after FCE chemotherapy
219491193|NCT02239601|OTHER|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
219491194|NCT00172094|DRUG|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
219491195|NCT00172094|DRUG|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
219491196|NCT00172094|DRUG|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
219491197|NCT02218931|BEHAVIORAL|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
219491198|NCT02218931|OTHER|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
219491199|NCT06544473|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 14 days
219491200|NCT06544473|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 14 days
219491201|NCT00200473|DRUG|Nebivolol|
219601468|NCT01180426|DRUG|CHR-2797|120mg once daily oral for 48 weeks
219601469|NCT03448497|OTHER|Non-interventional|Non-interventional
219601470|NCT06259188|DEVICE|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
219601471|NCT06259188|DEVICE|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
219601472|NCT04302012|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
219601473|NCT04302012|DRUG|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
219601474|NCT03161340|DRUG|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
219601475|NCT02350816|DRUG|HGT-1410|HGT-1410 administered according to Patient Group assignment.
219601476|NCT06604091|OTHER|Treatment protocol|Treatment options for ovarian stimulation include long-acting and antagonist regimens and other ovulation induction regimens. Options for frozen embryo transfer include natural protocols, mild ovarian stimulation regimens, hormone replacement therapy (HRT) regimens, and down-regulated combined HRT regimens. The treatment regimen is refined in the above protocol. The treatment of patients follows the principles of real-world clinical practice.
219601477|NCT06692686|DEVICE|Pre-fabricated (PF) ankle-foot orthosis (AFO)|These pre-manufactured orthoses are customized to fit each patient. These devices can help to distribute weight evenly along the foot, but do not offer much opportunity for adjustment to a patient's specific needs. These AFOs achieve ankle motion through material deflection and lack a single point of articulation.
219601478|NCT06692686|DEVICE|Carbon-strut (CS) ankle-foot orthosis (AFO)|These AFO designs are built from a custom mold of the patient's affected limb for a more individualized fit. It includes a solid ankle design and achieves ankle motion through material deflection and lacks a single point of articulation.
219613658|NCT01431365|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
219491202|NCT00006225|BIOLOGICAL|filgrastim|
219021819|NCT01086540|DRUG|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
219491203|NCT00006225|BIOLOGICAL|recombinant flt3 ligand|
219491204|NCT00006225|BIOLOGICAL|recombinant human thrombopoietin|
219491205|NCT00006225|BIOLOGICAL|recombinant interleukin-3|
219491206|NCT00006225|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219491207|NCT06155825|BEHAVIORAL|no intervention|Group 4 will receive no intervention
219491208|NCT06155825|DRUG|nonnutritive suckling|Group 1 will receive nonnutritive suckling
219491209|NCT06155825|DRUG|oral glucose 25%|Group 2 will receive oral glucose 25%
219491210|NCT06155825|BEHAVIORAL|facilitated tuckling|Group 3 will undergo facilitated tuckling
219491211|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
219491212|NCT04682639|DRUG|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
219491213|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
219491214|NCT01743768|DRUG|SB010|Treatment group (n=19), receiving the active drug substance.
219491215|NCT01743768|DRUG|Placebo|Treatment group (n=19), receiving placebo.
219021820|NCT02201186|OTHER|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
219021821|NCT01068119|PROCEDURE|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
219021822|NCT00746642|DEVICE|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
219491216|NCT00883740|DRUG|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
219491217|NCT00883740|DRUG|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
219491218|NCT00769158|DRUG|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
219491219|NCT00769158|OTHER|Placebo|Placebo Comparator
219491220|NCT02946502|PROCEDURE|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
219491221|NCT01392170|DRUG|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
219491222|NCT00523887|DRUG|Fentanyl transdermal therapeutic system|
219491223|NCT04299737|OTHER|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
219491224|NCT02632383|DEVICE|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder"
219491225|NCT05870826|OTHER|Multiwave locked system laser therapy|High intensity laser therapy
219491226|NCT05870826|OTHER|Sham laser therapy|Sham laser therapy
219613659|NCT05467631|OTHER|Topical oil application|Topical Comparison
219613660|NCT00683657|DRUG|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
219613661|NCT00683657|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
219613662|NCT02473926|BEHAVIORAL|Physical Activity|Physical Activity Program Intervention
219613663|NCT02473926|BEHAVIORAL|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
219613664|NCT02757326|DRUG|Opaganib|Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
219613665|NCT00202930|DRUG|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
219613666|NCT01756430|DRUG|Carvedilol SR 32mg, QD|"* Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
219613667|NCT01756430|DRUG|Carvedilol SR 64mg, QD|"* Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
219613668|NCT01756430|DRUG|Carvedilol IR 25mg, QD|"* Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
219613669|NCT01756430|DRUG|Carvedilol IR 25mg, BID|"* Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks."
219613670|NCT03077139|DEVICE|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
219613671|NCT00194779|DRUG|doxorubicin hydrochloride|Given IV
219613672|NCT00194779|DRUG|cyclophosphamide|Given PO
219613673|NCT00194779|DRUG|paclitaxel|Given IV
219613674|NCT00194779|BIOLOGICAL|filgrastim|Given SC
219613675|NCT00194779|DRUG|capecitabine|Given PO
219613676|NCT00194779|DRUG|methotrexate|Given IV
219613677|NCT00194779|DRUG|vinorelbine tartrate|Given IV
219613678|NCT00194779|PROCEDURE|needle biopsy|Correlative studies
219613679|NCT00194779|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
219613680|NCT00194779|OTHER|immunohistochemistry staining method|Correlative studies
219613681|NCT00194779|BIOLOGICAL|trastuzumab|Given IV
219613682|NCT00194779|DRUG|tamoxifen citrate|Given PO
219613683|NCT00194779|DRUG|letrozole|Given PO
219021823|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
219021824|NCT04679792|DIAGNOSTIC_TEST|Dynamic posturography|Balance evaluation
219491227|NCT04152252|OTHER|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
219491228|NCT04152252|BEHAVIORAL|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
219491229|NCT05171699|OTHER|electroacupuncture|The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
219491230|NCT05171699|OTHER|shame electroacupuncture|The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
219491231|NCT00802776|PROCEDURE|Femtosecond laser assisted keratoplasty|
219491232|NCT00802776|PROCEDURE|PKP|
219491233|NCT00732394|OTHER|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
219491234|NCT00101894|DRUG|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
219491235|NCT00101894|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
219601479|NCT06692686|DEVICE|Multifunctional articulating (MA) ankle-foot orthosis (AFO)|These AFO designs are also built from a custom mold of the patient's affected limb, but these orthoses have a true articulation at the ankle to provide controlled ankle movement in a range determined appropriate by the orthotist through gait analysis.
219601480|NCT01885195|DRUG|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
219601481|NCT01770717|OTHER|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
219601482|NCT04700137|OTHER|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
219601483|NCT04700137|OTHER|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
219601484|NCT03677154|DRUG|Mosunetuzumab Intravenous (IV)|Participants in cohorts A and B will receive IV mosunetuzumab.
219601485|NCT03677154|DRUG|Mosunetuzumab Subcutaneous (SC)|Participants in Cohort C will receive SC mosunetuzumab.
219021825|NCT03164928|DRUG|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
219021826|NCT03164928|OTHER|Placebo|SC Q6M placebo
219601486|NCT03677154|DRUG|Polatuzumab Vedotin|Participants in Cohort C will receive IV polatuzumab vedotin.
219601487|NCT03677154|DRUG|Tocilizumab|Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
219601488|NCT01682616|DRUG|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
219601489|NCT01682616|DRUG|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
219613684|NCT00194779|OTHER|laboratory biomarker analysis|Correlative studies
219021827|NCT05545566|PROCEDURE|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
219021828|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
219613685|NCT01408043|DRUG|plerixafor|Given SC
219613686|NCT01408043|BIOLOGICAL|filgrastim|Given SC
219613687|NCT01408043|DRUG|etoposide|Given IV
219021829|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
218871559|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
218871560|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
218871561|NCT04390724|DEVICE|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
218871562|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
219021830|NCT04260542|BEHAVIORAL|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
219021831|NCT01829555|BEHAVIORAL|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
219021832|NCT00002490|BIOLOGICAL|BCG vaccine|
219021833|NCT00002490|DRUG|mitomycin C|
219021834|NCT00002490|RADIATION|radiation therapy|
219021835|NCT06242249|BIOLOGICAL|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
219021836|NCT00777647|OTHER|Sugar-sweetened soft drink|One litre a day for six months.
219021837|NCT00777647|OTHER|Aspartame-sweetened soft drink|One litre a day for six months.
219021838|NCT00777647|OTHER|Semi-skimmed milk|One litre a day for six months
219491236|NCT00101894|BIOLOGICAL|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
219021839|NCT00777647|OTHER|Water|One litre a day for six months.
219021840|NCT04117425|BIOLOGICAL|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
219021841|NCT00410553|DRUG|Eribulin Mesylate|Given IV
219021842|NCT00410553|DRUG|Gemcitabine Hydrochloride|Given IV
219491237|NCT00101894|DRUG|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
219491238|NCT01547273|PROCEDURE|bone graft inside socket only|bone graft inside socket only
219601490|NCT03692390|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219601491|NCT05808075|OTHER|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
219601492|NCT02836938|OTHER|Collection of exhaled breath volatile organic compounds|
219601493|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
218871563|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
218871564|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
218871565|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
218871566|NCT06447701|DRUG|Tocilizumab|Single dose intravenous application
219021843|NCT03023969|DRUG|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
219021844|NCT00530933|PROCEDURE|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
219021845|NCT00530933|PROCEDURE|Transcutaneous tibial nerve stimulation|30 minutes once weekly
219021846|NCT00530933|PROCEDURE|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
219021847|NCT03975855|DEVICE|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
219021848|NCT01882374|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
219021849|NCT00280956|DRUG|natalizumab|
219021850|NCT04723940|DRUG|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
219021851|NCT04723940|DRUG|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
219021852|NCT04723940|DRUG|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
219601494|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
219613688|NCT01408043|PROCEDURE|leukapheresis|Undergo apheresis
219491239|NCT01547273|PROCEDURE|bone graft inside and outside socket|bone graft inside and outside socket
219491240|NCT01547273|PROCEDURE|no bone graft|no bone graft
219491241|NCT00549120|DRUG|Propranolol|40 mg tablets
219491242|NCT00549120|DRUG|Salbutamol|Metered dose inhaler (600 μg)
219491243|NCT00549120|DRUG|Ipratropium|Metered dose inhaler (40 μg)
219491244|NCT00549120|DRUG|Placebo|Placebo for propranolol tablets
219021853|NCT04723940|DRUG|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
219021854|NCT05643365|RADIATION|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
219021855|NCT03953573|OTHER|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
219491245|NCT01266473|OTHER|Physiotherapy|Physiotherapy for Airway Clearance
219491246|NCT00022126|DRUG|asparaginase|
219491247|NCT00022126|DRUG|cyclophosphamide|
219601495|NCT06197373|PROCEDURE|Laparoscopic cholecystectomy|Doing laparoscopic cholecystectomy after ERCP at different intervals
219601496|NCT03720327|BEHAVIORAL|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
219601497|NCT03720327|BEHAVIORAL|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
219601498|NCT06262230|BEHAVIORAL|Online Inclusive Companionship Intervention|After prior intervention, professionals will conduct a lecture for ordinary children, which includes basic knowledge of ASD and communication skills with ASD children. These ordinary children will be paired with ASD children then. The entire intervention including 12 sessions will last for 3 months. Researchers will prepare a series of themes that the ASD children could choose, and the ordinary children need to ask their paired ASD children what activities they want to choose before each session. Then, they will carry out this entertainment online together through Tencent WeMeet. A researcher will supervise online at the same time and record the communication through instant video. The Researcher will turn off the video and sound throughout the process and will not intervene in the conversation between the ASD children and ordinary children except for special circumstances.
219601499|NCT01461564|PROCEDURE|Colonoscopy|Screening colonoscopy
219601500|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
219601501|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
219601502|NCT00642681|DRUG|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
219601503|NCT02653430|PROCEDURE|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
219601504|NCT00463697|DRUG|GW642444H (100mcg)|H salt
219601505|NCT00463697|DRUG|placebo|placebo
219601506|NCT00463697|DRUG|GW642444M (25, 100 & 400 mcg)|M salt
219613689|NCT02773602|DRUG|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
219021856|NCT05305534|DEVICE|QIAstat-Dx® BCID GN and GPF Plus AMR Panels|The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
219021857|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
219613690|NCT02773602|DRUG|Clonidine|2 μg/kg of clonidine in 1 ml saline
219021858|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
219021859|NCT03495323|DRUG|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
219021860|NCT03495323|DRUG|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
219491248|NCT00022126|DRUG|cyclosporine|
219491249|NCT00022126|DRUG|cytarabine|
219491250|NCT00022126|DRUG|daunorubicin hydrochloride|
219491251|NCT00022126|DRUG|dexamethasone|
219491252|NCT00022126|DRUG|doxorubicin hydrochloride|
219491253|NCT00022126|DRUG|mercaptopurine|
219491254|NCT00022126|DRUG|methotrexate|
219491255|NCT00022126|DRUG|methylprednisolone|
219491256|NCT00022126|DRUG|pegaspargase|
219491257|NCT00022126|DRUG|thioguanine|
219491258|NCT00022126|DRUG|vincristine sulfate|
219491259|NCT00022126|PROCEDURE|allogeneic bone marrow transplantation|
219491260|NCT00022126|RADIATION|radiation therapy|
219491261|NCT05532046|DRUG|BAY2413555 Dose 1|BAY2413555 Dose 1
219491262|NCT05532046|DRUG|BAY2413555 Dose 2|BAY2413555 Dose 2
219491263|NCT05532046|DRUG|Placebo to BAY2413555|Placebo to BAY2413555
219491264|NCT00727896|BEHAVIORAL|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
219491265|NCT00727896|DRUG|Diabetes Treatment|Life style modification and drug therapy
219491266|NCT03966573|RADIATION|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
219491267|NCT03966573|OTHER|Evaluating function|Test function and physical capasity
219491268|NCT03966573|OTHER|Forms|Forms for evaluating quality of life, pain, function
219491269|NCT00675701|DRUG|placebo|capsules
219491270|NCT00675701|DRUG|lixivaptan|capsules
219491271|NCT00675701|DRUG|moxifloxacin|tablets
219491272|NCT04429373|PROCEDURE|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
219491273|NCT04429373|PROCEDURE|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
218871567|NCT06447701|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
218871568|NCT06112938|DRUG|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
218871569|NCT06573242|OTHER|Home-based cardiac rehabilitation for people living with Heart Failure and their caregivers|Intervention DK:REACH-HF is a home-based 12-week CR program for people living with HF and their caregivers.
218871570|NCT01921686|OTHER|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
218871571|NCT01424566|DRUG|Nabiximols|
218871572|NCT01424566|DRUG|Placebo (GA-0034)|
218871573|NCT06035458|DIAGNOSTIC_TEST|Diagnostic radiology|Clinical procedures include bone mineral measurement (bone densitometry, dxa) performed according to clinical practice; venipunctures for laboratory assessments (haematology and blood chemistry; bone turnover biomarkers P1NP and CTX).
219491274|NCT04259879|OTHER|Fasting|Food intake restriction
219491275|NCT04266119|BEHAVIORAL|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
219491276|NCT02821117|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
219491277|NCT02228746|DIETARY_SUPPLEMENT|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
219491278|NCT06700408|DRUG|Dachaihu Decoction combined Erzhiwan with variation|Chinese medicine granules
219491279|NCT06700408|OTHER|Placebo granules|Placebo granules
219491280|NCT05920018|DIETARY_SUPPLEMENT|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
219491281|NCT05920018|DIETARY_SUPPLEMENT|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
219601507|NCT05151783|OTHER|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
219601508|NCT05151783|OTHER|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) \& repeated contractions will be used in all patterns
218871574|NCT04160390|OTHER|Biospecimen Collection-Blood|Undergo collection of blood
218871575|NCT04160390|OTHER|Biospecimen Collection-Stool|Undergo collection of stool
218871576|NCT06679361|BEHAVIORAL|Motor Exercise Program|This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.
219491282|NCT05920018|OTHER|Maltose placebo|Daily application of four sachets for 48 weeks
219491283|NCT05920018|OTHER|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
219491284|NCT00666731|OTHER|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
219491285|NCT00666731|OTHER|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
219491286|NCT00666731|OTHER|study of socioeconomic and demographic variables|Repository
219491287|NCT00666731|PROCEDURE|Excess human biological tissue|Tissue procurement.
219491288|NCT00666731|PROCEDURE|quality-of-life assessment|Cancer care.
219601509|NCT04842292|DRUG|Heparin|Nebulized heparin 25,000 units every 6 hours
219021861|NCT04754737|OTHER|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
219021862|NCT04754737|OTHER|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
219491289|NCT04951973|DIAGNOSTIC_TEST|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
219491290|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
219491291|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
219491292|NCT03386669|DRUG|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
219491293|NCT01495169|DRUG|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
219491294|NCT00884663|DRUG|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
219601510|NCT04842292|DRUG|Placebo|Sodium chloride 0.9% every 6 hours
219601511|NCT00234962|DRUG|Lopinavir/Ritonavir|
219601515|NCT03859765|BEHAVIORAL|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
219021863|NCT04754737|PROCEDURE|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
219601516|NCT05212389|DRUG|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
219491295|NCT00884663|DRUG|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
219491296|NCT00884663|DRUG|placebo|placebo tablets and capsules
219491297|NCT02428634|BEHAVIORAL|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
219491298|NCT02428634|BEHAVIORAL|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
219491299|NCT00690924|DRUG|calcitriol|Oral
219491300|NCT00690924|OTHER|laboratory biomarker analysis|Correlative Study
219491301|NCT00690924|OTHER|pharmacological study|Correlative Study
219491302|NCT03202186|DRUG|Progesterone oral capsule|Oral capsule treatment
219491303|NCT03202186|DRUG|Placebo oral capsule|Oral capsule treatment
219491304|NCT02748616|DRUG|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
219601517|NCT05212389|DRUG|Placebo|Placebo
219601518|NCT01467986|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
219491305|NCT02840214|DEVICE|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
219491306|NCT02840214|DEVICE|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
219491307|NCT03552679|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
219491308|NCT00004375|PROCEDURE|ultraviolet A-1 light treatment|
219491309|NCT01296152|DRUG|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
219491310|NCT02353299|DRUG|Silenor 6 mg|Silenor 6 mg single nighttime dose.
219491311|NCT02353299|DRUG|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
219601519|NCT01467986|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
219601520|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
219601521|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
219601522|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
219601523|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
219491312|NCT02353299|DRUG|Placebo|placebo single nighttime dose-1.5 hours
219491313|NCT02353299|DRUG|Placebo|placebo single nighttime dose-4 hours
219491314|NCT01096706|DRUG|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
219491315|NCT01096706|DRUG|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
219601524|NCT02458859|DEVICE|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
219613691|NCT02773602|DRUG|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
219613692|NCT00470964|PROCEDURE|Titanium Sapphire laser trabeculoplasty|
219613693|NCT02598921|RADIATION|three dimensional ultrasound|
219613694|NCT02598921|DEVICE|Office hysteroscopy|
219613695|NCT02051621|DRUG|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
219613696|NCT02051621|PROCEDURE|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
218871577|NCT06679361|BEHAVIORAL|Sensory Exercise Group|Arm Description: This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.
218871578|NCT06679361|BEHAVIORAL|Combined Motor and Sensory Exercise Group|Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
218871579|NCT06500442|DRUG|NEU-111|Oral Doses
219491316|NCT01096706|DRUG|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
219491317|NCT01096706|DRUG|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
219491318|NCT01096706|DRUG|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
219491319|NCT01268137|PROCEDURE|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
218871580|NCT06500442|DRUG|Placebo|Oral Doses
218871581|NCT06054178|DRUG|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
218871582|NCT06115291|OTHER|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
219491320|NCT01416298|OTHER|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and \> 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching \>10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after \>10% is achieved is acceptable and now will be put into standard clinical practice.
219491321|NCT06336226|PROCEDURE|Brachio basilic arterio venous fistula one stage versus two stage|Comparative study between one stage brachio basilic arterio venous fistula versus two stage
219601525|NCT05393479|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
218871583|NCT05076682|DRUG|Choline|Choline 300mg tid or 500mg bid, p.o
218871584|NCT05076682|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
218871585|NCT05076682|DRUG|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
218871586|NCT05076682|DRUG|Efavirenz|Efavirenz 600mg qd, p.o
218871587|NCT05076682|DRUG|SHR-A1811|4.8mg/kg q3w
218871588|NCT05076682|DRUG|SHR-A2102|6mg/kg q3w
218871589|NCT05076682|DRUG|SHR-1316|1200mg q3w
218871590|NCT05076682|DRUG|Mecapegfilgrastim|Mecapegfilgrastim, 6mg, d3, q3w, s.c.
218871591|NCT05076682|DRUG|AK131|AK131, 40mg/kg i.v., q2w
218871592|NCT06818097|DRUG|TKI|Lenvatinib
218871593|NCT06818097|DRUG|anti PD-1|Sintilimab or Camrelizumab or Tislelizumab
219601526|NCT00685776|DRUG|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
219601527|NCT00685776|DRUG|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
219601528|NCT06516003|DEVICE|Immersive Virtual Reality Goggles|Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.
219601529|NCT06516003|BEHAVIORAL|Standard of Care|Distraction techniques like tablet, phone, television, parent, child life specialist
219601530|NCT05405582|COMBINATION_PRODUCT|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
218871594|NCT06818097|DRUG|XELOX chemotherapy|Capecitabine and Oxaliplatin
218871595|NCT06981351|BEHAVIORAL|Attention to Context (ATC) training|ATC training focuses on learning to attend to and integrate contextual cues present in the environment. Three tasks, Reversal Learning, Divided Visual Field, and Affective Gaze, require ATC functioning and provide individuals with practice noticing changes in contextual information, such as rule changes and using emotion information to modulate behavior.
218871596|NCT06981351|BEHAVIORAL|Affective Cognitive Control (ACC) training|ACC training focuses on providing individuals with practice inhibiting behavior, particularly within motivational or affective contexts. Three tasks, Shapes, Numbers, and Lottery, tap ACC functioning and place demands on the basic employment of cognitive control, such as task switching, as well as on the concurrent engagement of cognitive control and affective processing.
219491322|NCT03081195|BEHAVIORAL|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
219491323|NCT06419803|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
219601531|NCT05405582|OTHER|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
218871597|NCT05943119|RADIATION|Radiotherapy in painting dose on histoscannographic mapping|"The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone)."
218871598|NCT05943119|RADIATION|Standard pan-sinusal Radiotherapy|"The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone)."
218871599|NCT04494113|PROCEDURE|Biopsy Procedure|Undergo biopsy
218871600|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
218871601|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
218871602|NCT04494113|DRUG|Triapine|Given IV
218871603|NCT03441698|DEVICE|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
219021864|NCT04322747|DIAGNOSTIC_TEST|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
219021865|NCT02118012|DRUG|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
219601532|NCT04386616|DRUG|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
219601533|NCT04386616|DRUG|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
219021866|NCT02118012|DRUG|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
219491324|NCT03949283|DIAGNOSTIC_TEST|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
219601534|NCT04386616|DRUG|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
219021867|NCT03130842|DRUG|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
219491325|NCT03949283|DRUG|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
219491326|NCT06180577|DEVICE|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
219491327|NCT06030271|DEVICE|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
219491328|NCT01256346|DEVICE|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
219601535|NCT04386616|DRUG|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
219601536|NCT03848390|BEHAVIORAL|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
219601537|NCT03848390|BEHAVIORAL|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
219601538|NCT03848390|BEHAVIORAL|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
219601539|NCT03848390|BEHAVIORAL|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
219601540|NCT01591343|BIOLOGICAL|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
219601541|NCT00005000|DRUG|Nelfinavir mesylate|
219601542|NCT00005000|DRUG|Efavirenz|
219021868|NCT03130842|DRUG|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
219021869|NCT03899376|RADIATION|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
219021870|NCT03899376|RADIATION|conventional radiotherapy|Radiotherapy focus on pelvis area
219021871|NCT00649623|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
219021872|NCT00649623|DRUG|Benicar® Tablets 40 mg|40mg, single dose fasting
219021873|NCT05958407|DRUG|Tralokinumab|After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks
219021874|NCT05958407|DRUG|Placebo|After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
219021875|NCT05880927|DRUG|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
219601543|NCT00005000|DRUG|Lamivudine|
219601544|NCT00005000|DRUG|Keyhole-Limpet Hemocyanin|
219601545|NCT00005000|DRUG|Stavudine|
219601546|NCT00005000|DRUG|Zidovudine|
219491329|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
219491330|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
219601547|NCT00005000|DRUG|Didanosine|
219601548|NCT05544279|BEHAVIORAL|Education|Education is given about the focused disease and its nursing care management
219601549|NCT01862484|DIETARY_SUPPLEMENT|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
219601550|NCT01862484|DIETARY_SUPPLEMENT|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
219601551|NCT00364000|DRUG|Calcium acetate|Calcium acetate in 240 chronic HD patients
219601552|NCT00364000|DRUG|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
219491331|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
219491332|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
219491333|NCT00149773|BEHAVIORAL|Cognitive Therapy|
219491334|NCT00146003|DRUG|Efalizumab treatment|
219491335|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
219491336|NCT03199846|OTHER|Non-Interventional|Non-Interventional
219491337|NCT05367934|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch for stress
219491338|NCT06540677|OTHER|Musical training|Musical training with Meludia software, an online self-paced music training application
219491339|NCT05340517|PROCEDURE|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
219491340|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
219491341|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
219601553|NCT04423887|OTHER|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
219601554|NCT04423887|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
219491342|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
219491343|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
219491344|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
219491345|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
219491346|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
219491347|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
219491348|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
219601555|NCT04423887|DEVICE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
219601556|NCT04423887|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
219601557|NCT04423887|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
219491349|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
219491350|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
219491351|NCT04057118|DRUG|SKI-O-703|Oral administration, twice per day
219601558|NCT06040151|DEVICE|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
219601559|NCT00782405|DRUG|quetiapine|XR, 150-300mg
219601560|NCT00782405|DRUG|mirtazapine|30-45 mg
219601561|NCT00553176|OTHER|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
219613697|NCT02051621|PROCEDURE|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
219204492|NCT06761391|OTHER|Suboccipital manual therapy|The procedure will be conducted with the patient lying on their back. The practitioner will be seated on a stool at the top of the examination table, their forearm in contact with the surface. After locating the occipital condyles through palpation, the practitioner will position their fingers in the slightly concave region between the occiput and the second cervical vertebra's spinous process. The patient's head will be gently elevated by the practitioner flexing their metacarpophalangeal joints. With the patient's skull base resting in the practitioner's palm, pressure equivalent to the weight of the patient's head will be applied to the rectus capitis posterior and obliquus capitis superior muscles using the practitioner's second, third, and fourth fingers for a duration of 5 minutes. To prevent eye movements from influencing suboccipital muscle tone, patients will be instructed to keep their eyes closed during the procedure.
219491352|NCT04057118|DRUG|Placebo|Oral administration, twice per day
219491353|NCT01315054|BEHAVIORAL|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
219491354|NCT01315054|BEHAVIORAL|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
219491355|NCT01315054|OTHER|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
219491356|NCT01819701|DIETARY_SUPPLEMENT|LC-1000|L-carnitine 1000 mg /d
219491357|NCT01819701|DIETARY_SUPPLEMENT|LC-2000|L-carnitine: 2000 mg/d
219491358|NCT01819701|DIETARY_SUPPLEMENT|Q10-150|Coenzyme Q10: 150 mg/d
219491359|NCT01819701|DIETARY_SUPPLEMENT|Q10-300|Coenzyme Q10: 300 mg/d
219491360|NCT01819701|OTHER|Placebo|
219491361|NCT01651494|DRUG|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
219613698|NCT05662527|DRUG|Pembrolizumab|One dosage of 4mg/kg (maximum of 400mg)
219613699|NCT00494962|DRUG|lecozotan SR|
219613700|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Fumarate|Ferrous Fumarate - 300 mg
219613701|NCT06303531|DIETARY_SUPPLEMENT|Polysaccharide Iron|Polysaccharide Iron - 150 mg
219204493|NCT06771297|OTHER|nursing education|Nursing training will be given before rhinoplasty surgery. As a result, patients' involuntary thoughts and quality of recovery will be questioned.
219491362|NCT01651494|OTHER|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
219491363|NCT06325176|OTHER|Cryotherapy|During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
219491364|NCT06325176|DEVICE|Infrared light therapy|Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
219491365|NCT06390358|OTHER|Tefillin|Wrapping of arm
219491366|NCT01268319|DEVICE|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
219491367|NCT01268319|DEVICE|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
219491368|NCT01268319|DEVICE|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
219491369|NCT06271135|BEHAVIORAL|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
219601562|NCT04094727|DRUG|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
219601563|NCT04094727|OTHER|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
219601564|NCT01632280|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
219613702|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Ascorbate|Ferrous Ascorbate - 100 mg
219613703|NCT02732262|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
219613704|NCT02732262|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
219613705|NCT02732262|DRUG|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
219204494|NCT06735781|DRUG|Nivolumab|As prescribed by the treating clinician
219204495|NCT06745999|DRUG|Ameluz 10% Topical Gel|Paired with device intervention of red light PDT
219204496|NCT06745999|DEVICE|Red Light PDT|Paired with drug intervention of Ameluz 10% topical gel
219204497|NCT06745999|PROCEDURE|Cryotherapy|Liquid Nitrogen
219601565|NCT06055829|DRUG|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
219491370|NCT05928273|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
219491371|NCT01314222|DRUG|BMS-954561|
219491372|NCT01314222|DRUG|Pregabalin|
219021876|NCT04760366|OTHER|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes."
219021877|NCT04760366|OTHER|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes."
219021878|NCT04760366|OTHER|the conventional therapy|the conventional therapy
219021879|NCT04506853|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
219021880|NCT00001437|DRUG|pentoxifylline|
219021881|NCT04621188|DRUG|Lorlatinib|100 mg once daily
219021882|NCT01128257|DRUG|alendronate|As prescribed by physician
219021883|NCT01128257|DRUG|ibandronate [Bonviva/Boniva]|As prescribed by physician
219491373|NCT01314222|DRUG|Placebo matching BMS-954561|
219491374|NCT01314222|DRUG|Placebo matching Pregabalin|
219021884|NCT02268864|DRUG|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
219021885|NCT02268864|DRUG|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
219021886|NCT03849885|DRUG|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
219491375|NCT02253758|DRUG|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
219491376|NCT00190684|DRUG|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
219491377|NCT06540599|DRUG|Analgesic|comparing the effectiveness of analgesics in endometrial biopsy
219491378|NCT04778007|OTHER|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
219491379|NCT06536816|OTHER|Game Profile-based training Group|Game profile-based training is a methodology in sports, including football, where training sessions are designed to simulate the specific conditions and challenges that players face during actual games. Coaches analyze individual and team performance data to identify patterns, positions, and scenarios commonly encountered in matches. The training is then structured to replicate these situations, helping players develop the skills, tactics, and decision-making abilities required in real-game scenarios. This approach aims to make training more targeted and relevant to the dynamics of competitive play.
219491380|NCT06536816|OTHER|Small-sided games Group|"small-sided game in football, often referred to as a SSG, is a practice or training activity where players compete in a reduced playing area with fewer players than a full team."
219601566|NCT02506829|BEHAVIORAL|Smoking cessation counseling (Quitline)|
219601567|NCT02506829|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
219021887|NCT00061698|BEHAVIORAL|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
219491381|NCT06536816|OTHER|Combined training Group with both Game Profile-based training and Small-sided Games|Combined training Group with both Game Profile-based training and Small-sided Games
219601568|NCT02506829|BEHAVIORAL|Financial incentives|
219601569|NCT05972148|OTHER|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
219613706|NCT01526473|BIOLOGICAL|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
219613707|NCT05101668|DEVICE|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
219613708|NCT01998841|DRUG|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
219613709|NCT01998841|DRUG|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
219613710|NCT05706584|OTHER|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
219613711|NCT04539912|DEVICE|angulated screw retained crown|ASC abutment was used in AG;
219613712|NCT04539912|DEVICE|cemented crown|prefabricated Ti abutment was used in CG
219613713|NCT00468364|DRUG|insulin glargine|
219613714|NCT00468364|DRUG|NPH insulin|
219613715|NCT04428814|BIOLOGICAL|CT-P43|45mg single dose
219613716|NCT04428814|BIOLOGICAL|EU-approved Stelara|45mg single dose
219613717|NCT04428814|BIOLOGICAL|US-licensed Stelara|45mg single dose
219491382|NCT02832739|DEVICE|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
219491383|NCT03334526|OTHER|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
219491384|NCT03334526|OTHER|mental training|The task to imagine for the training group will be an abduction of the thumb
219491385|NCT03334526|OTHER|electrical stimulation|electrical stimulation of the muscles
219491386|NCT03304210|DRUG|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
219491387|NCT02872155|OTHER|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
219491388|NCT02872155|DRUG|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
219491389|NCT02872155|DRUG|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
219491390|NCT00136734|DRUG|Methylphenidate|
219491391|NCT00136734|OTHER|placebo|placebo
219491392|NCT03661294|DIAGNOSTIC_TEST|GE Healthcare Metabolic Oxygenator|
219491393|NCT00429468|DRUG|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
219491394|NCT00085722|PROCEDURE|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
219491395|NCT00085722|PROCEDURE|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
219491396|NCT00085722|OTHER|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
219491397|NCT04992481|PROCEDURE|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
219491398|NCT04992481|PROCEDURE|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
219601570|NCT05972148|OTHER|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
219491399|NCT04992481|PROCEDURE|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
219491400|NCT04992481|PROCEDURE|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
219601571|NCT00993421|DRUG|LY377604|Given daily, orally for 24 weeks
219491401|NCT00829439|DRUG|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
219491402|NCT06500039|OTHER|Positive Psychological Intervention Program|An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
219491403|NCT06500039|OTHER|Writing Daily Routines|An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
219491404|NCT06340971|OTHER|Policy|"We will work with stakeholders' policy groups e.g. RCOG, RCM, RCP and policy makers e.g. Department for Health and Social Care, Transport Emissions at the Greater London Authority or Mayor of London's office to disseminate our findings and develop public health messages.~We aim to develop guidance on how pregnant women and their families can reduce their exposure to air pollution by highlighting for example travel routes with less pollution and wear face masks."
219491405|NCT04514328|DEVICE|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
219491406|NCT00418080|DRUG|bicalutamide|
219601572|NCT00993421|DRUG|Sibutramine|given daily, orally for 24 weeks
219601573|NCT00993421|DRUG|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
219601574|NCT00993421|DRUG|Placebo sibutramine|given daily, orally for 24 weeks
219601575|NCT00993421|DRUG|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
219601576|NCT00993421|DRUG|Placebo LY377604|given daily, orally for 24 weeks
219601577|NCT04357080|PROCEDURE|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
218871604|NCT03441698|DEVICE|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
218871605|NCT03441698|OTHER|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
219021888|NCT00061698|BEHAVIORAL|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
219021889|NCT00003147|BIOLOGICAL|Ad5CMV-p53 gene|
219491407|NCT02221583|DRUG|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
219491408|NCT02221583|DRUG|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
219491409|NCT02221583|DRUG|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
219491410|NCT06514209|DRUG|cisatracurium|The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
219491411|NCT04250519|DRUG|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
219491412|NCT01155284|DRUG|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
219491413|NCT01155284|DRUG|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
219491414|NCT06528860|DEVICE|MiSight® 1 day soft contact lenses|Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.
219491415|NCT06528860|DEVICE|Proclear® 1 day soft contact lenses|Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
219491416|NCT02412696|DEVICE|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
219491417|NCT02412696|OTHER|Nasal Dilator Strips|Nasal dilator strips
219491418|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation|Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
219491419|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation|Healing Progression: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
219491420|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
219491421|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
219491422|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
219491423|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
219601578|NCT00716794|DRUG|HE3235|HE3235 will be administered orally in 28 day cycles.
219601579|NCT03101176|DRUG|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
219601580|NCT06633120|OTHER|IVM|Immature oocytes will be retrieved from small ovarian follicles and matured overnight in the laboratory prior to undergoing fertilization and embryo culture.
219613718|NCT00972595|DRUG|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
219613719|NCT00972595|DRUG|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
219613720|NCT02552121|DRUG|Tisotumab vedotin (HuMax-TF-ADC)|
219613721|NCT00462150|BEHAVIORAL|home-based emotional disclosure|
218871606|NCT05251038|DRUG|Sotorasib|Intervention instruction outlined in protocol
218871607|NCT05251038|DRUG|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
219021890|NCT04072211|BIOLOGICAL|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
219021891|NCT02499250|DEVICE|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
219021892|NCT02499250|DRUG|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
219021893|NCT05952024|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule of X.
219491424|NCT03180983|BEHAVIORAL|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
219491425|NCT03030638|DRUG|Olodaterol|Drug
219491426|NCT03030638|DRUG|Indacaterol|Drug
219491427|NCT02441959|PROCEDURE|Lumbar discectomy Open|Open Discectomy
219491428|NCT02441959|PROCEDURE|Lumbar discectomy Endoscopic|Endoscopic Discectomy
218871608|NCT05251038|DRUG|5 Fluorouracil (5FU)|Per standard of care
218871609|NCT05251038|DRUG|Leucovorin (LV)|Per standard of care
219491429|NCT06047249|BEHAVIORAL|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
219491430|NCT06047249|BEHAVIORAL|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
219613722|NCT00462150|BEHAVIORAL|time management control condition|
218871610|NCT05251038|DRUG|Gemcitabine (GEM)|Per standard of care
218871611|NCT05251038|DRUG|Nab paclitaxel|Per standard of care
218871612|NCT03445559|BEHAVIORAL|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
218871613|NCT03445559|BEHAVIORAL|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
218871614|NCT03445559|BEHAVIORAL|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
219021894|NCT05952024|BIOLOGICAL|Rituximab|Patients will receive rituximab via IV infusion on Cycle 1 Day 15 and via SC injection on Day 1 of Cycle 2 through Cycle 8.
219021895|NCT00003573|BIOLOGICAL|filgrastim|
219021896|NCT00003573|DRUG|cisplatin|
219021897|NCT00003573|DRUG|cyclophosphamide|
219021898|NCT00003573|DRUG|etoposide|
219021899|NCT00003573|DRUG|vincristine sulfate|
219021900|NCT00003573|RADIATION|radiation therapy|
219021901|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
219491431|NCT06222398|DEVICE|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
219491432|NCT05535842|OTHER|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
219491433|NCT03785652|DRUG|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
219491434|NCT03785652|DRUG|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
219491435|NCT03785652|DRUG|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
219491436|NCT03785652|DRUG|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
219491437|NCT03785652|DRUG|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
219491438|NCT02606370|OTHER|Unstable shoe|Wearing Unstable shoes during 1 month
219601581|NCT01561261|OTHER|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
219491439|NCT03466788|OTHER|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
219491440|NCT06704061|BEHAVIORAL|Yoga|A 12-week online yoga course designed to treat pain.
219491441|NCT06704061|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A 12-week behavioral therapy course designed to treat pain.
219491442|NCT02553005|PROCEDURE|Acupuncture|
219601582|NCT06745323|DRUG|Tarlatamab|Tarlatamab will be administered by IV infusion.
219601583|NCT01428154|DRUG|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
219601584|NCT03997773|BEHAVIORAL|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
219601585|NCT02215967|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
219601586|NCT02215967|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
219601587|NCT02215967|BIOLOGICAL|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
219601588|NCT06741865|BEHAVIORAL|Lifestyle Intervention|This arm involves interventions like health coaching, dietary changes, exercise programs, and other lifestyle modifications.
219601589|NCT06741865|OTHER|Standard Health Education|Participants in the Standard of Care Arm will receive basic educational materials focused on general cognitive and physical health maintenance.
219601590|NCT05695066|PROCEDURE|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
219601591|NCT06769412|DRUG|aflibercept 2 mg|No study-specific investigations for this descriptive observational study
219601592|NCT02762461|PROCEDURE|IVF or ICSI|
219601593|NCT06764160|DRUG|Eculizumab|Participants will receive Eculizumab via intravenous (IV) infusion.
219601594|NCT05528471|OTHER|Dietary intervention|To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
219601595|NCT05491213|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
219601596|NCT07135037|DRUG|Sildenafil 25 MG|Sildenafil is a vasodilator drug which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
219601597|NCT07135037|DRUG|L-Arginine, 1000 Mg Oral Tablet|Aminoacid with vasodilator property which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
219601598|NCT07134426|OTHER|D10-phenanthrene|All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].
219601599|NCT07077850|DRUG|Dexamethasone (IV)|Intravenous administration of 8 mg dexamethasone sodium phosphate given as a single dose before surgery under spinal anesthesia. This corticosteroid is being evaluated for its potential to prevent postoperative urinary retention (POUR) by reducing inflammation and other perioperative effects.
218871615|NCT06587165|OTHER|N15-thymidine|50mg/kg (oral administration)
219491443|NCT02328404|DRUG|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
219491444|NCT02328404|DRUG|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
219491445|NCT03192566|DRUG|Tylenol|Dosing of Tylenol for post operative pain control
218871616|NCT05432024|DEVICE|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
218871617|NCT06085664|DRUG|REGN5678|Given by IV (vein)
218871618|NCT06085664|DRUG|Piflufolastat F18|Given by IV (vein)
219491446|NCT01417208|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
219491447|NCT06212375|BEHAVIORAL|Vegetable variety|Either children are offered a variety of three vegetables or a single vegetable.
219491448|NCT06212375|BEHAVIORAL|Vegetable offering strategy|Either children can decide when to eat their vegetables or parents initiate a moment.
219491449|NCT03771768|RADIATION|Diode laser 980nm&100 mWatt|Diode laser 980 nm \&100 milli Watt.
219491450|NCT03771768|DRUG|Triamcinolone Acetonide|0.1 \&5gm paste 4 times/day
219491451|NCT04093479|OTHER|blood samples|blood samples will be taken repeatedly
219491452|NCT06543134|PROCEDURE|surgery|ENT surgery lasting more than half an hour
219491453|NCT06543134|PROCEDURE|sedation scale|Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
219491454|NCT00266461|DRUG|Daikenchuto Extract Granules (TU-100)|
218871619|NCT06609590|PROCEDURE|Glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block|Ultrasound guided anterior glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
219021902|NCT06084546|DEVICE|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
219021903|NCT03371628|DEVICE|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
219491455|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
219491456|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
219491457|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
219491458|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
219491459|NCT00684216|DRUG|capecitabine|200 mg, BID, PO, QD until progression of disease
219491460|NCT00684216|DRUG|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
219601600|NCT07077850|DRUG|Normal Saline (0.9% NaCl)|Intravenous administration of 0.9% normal saline (placebo) given as a single dose before surgery under spinal anesthesia. This inert solution is used to compare against the active drug dexamethasone to determine its effect on postoperative urinary retention (POUR).
219601601|NCT06930729|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at weeks 12, 16, 20, and 24 post-randomization.
219601602|NCT06930729|BEHAVIORAL|Telehealth Delivered Behavioral Activation|8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
219601603|NCT07095582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The Wellbeing Course was developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behavioural intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins per week/per client.
218871620|NCT06609590|PROCEDURE|Interscalene brachial plexus block|Ultrasound guided interscalene brachial plexus block
218871621|NCT06610825|DRUG|Enhertu|This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.
218871622|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
218871623|NCT00424697|DRUG|placebo|
219491461|NCT02296047|DRUG|Placebo|physiological saline
219491462|NCT02296047|DRUG|ipratropium bromide|80 µg inhalation once
219491463|NCT02296047|DRUG|salbutamol|400 µg inhalation once
219491464|NCT04234152|OTHER|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
218871624|NCT00424697|DRUG|lorazepam|
218871625|NCT00424697|DRUG|GW876008|
218871626|NCT06993350|OTHER|experimental group|eight weeks of targeted weight bearing program
218871627|NCT06409052|BEHAVIORAL|Qualitative interviews|Interviews will be conducted for approximately 45-60 minutes
218871628|NCT06597799|DRUG|MRT-6160|Orally administered tablets or capsules of MRT-6160
218871629|NCT06597799|DRUG|Placebo|Orally administered tablets or capsules of placebo
218871630|NCT07000734|BEHAVIORAL|Risk managment|Behavioral lifestyle changes including an exercise program, healthy eating recommendations, reviewing medical management for cardiometabolic risk conditions, deprescribing review for brain toxic meds, online cognitive training, as well as recommendations to improve sleep quality, or smoking cessation as needed
218871631|NCT07000734|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
218871632|NCT07000734|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|e intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
218871633|NCT07000734|DRUG|Vortioxetine|Participants will be prescribed vortioxetine to take daily, in combination with online cognitive training
218871634|NCT07087886|BEHAVIORAL|Combined Resilience Intervention|"A two-phase behavioral intervention aimed at improving psychological resilience among socioeconomically disadvantaged adolescents. The intervention includes:~1. a 5-day structured summer camp led by trained university student volunteers, featuring psychoeducational group sessions, emotional expression activities, and life skills training, based on SEL, CBT, and positive psychology frameworks; and~2. a 10-month pen-pal letter-writing component, where each child is matched with a trained university volunteer to receive monthly supportive letters. This stage reinforces the gains from the summer camp through sustained emotional support, skill reminders, and positive guidance.~The intervention is designed to be low-cost, scalable, and ethically safe, and has been standardized through manuals and training protocols."
218871635|NCT05453513|BEHAVIORAL|MRI Study|fMRI Tasks
218871636|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
219491465|NCT04234152|OTHER|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
219491466|NCT04529499|DRUG|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
219491467|NCT04529499|DRUG|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
219491468|NCT04359420|OTHER|BC-Predict|BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
219491469|NCT04359420|OTHER|NHS Breast Screening Programme|usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
219491470|NCT04068155|DEVICE|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
219491471|NCT03406832|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
219491472|NCT03406832|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
219491473|NCT03406832|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
218871637|NCT05719714|DRUG|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
218871638|NCT06624540|BEHAVIORAL|This is a pre- and post- quasi-experimental study.|We will use new equipment and implement EBP (VAP management) for patients by trained nurses (Phase 2) and check the outcome of the patients. We will compare our phase 1 findings for this study as historical data.
218871639|NCT06624540|BEHAVIORAL|Education with EBP|"Phase 2: Nurse's EBP training ( VAP management), 2 hours lecture and 3 hours skill training for total 4 times in 1 month.~Phase 3: Introduce new equipment necessary for EBP implementation for VAP management, and EBP-trained nurses implementation for VAP management."
218871640|NCT06624904|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg), encapsulated identically to placebo.
218871641|NCT06624904|OTHER|Placebo|Single tablet encapsulated identically to placebo.
218871642|NCT07012122|OTHER|visual spatial memory task|The child will be asked to put numbers in an imagined matrices and memorize the position very well then will be asked to remember the position of these numbers.
218871643|NCT07012122|OTHER|nonspatial verbal memory task|The child is presented with a series of sentences that are similar in structure and content, with only slight variations in elements such as the verb, subject, or object. The child's task is to remember and accurately recall these sentences. For example: The dog is running in the park, The cat is running in the park, The dog is playing in the park, The dog is running in the yard.
218871644|NCT07012122|OTHER|visuomotor tracking task|Then the rest will be introduced in the form of computer screen in front of the child with a dot moving under the control of a computer mouse and asking the child to track the dot while maintaining his balance as much as he can.
218871645|NCT05952960|OTHER|Placebo|Open Label Placebo + Rationale
218871646|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
218871647|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
219491474|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
219491475|NCT03109860|BEHAVIORAL|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
219491476|NCT00758706|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
219491477|NCT00758706|DRUG|Placebo|Dosing to match AZD1236
219491478|NCT02507115|BEHAVIORAL|TMAP|Text messages for Alcohol Risk Reduction
219491479|NCT02507115|BEHAVIORAL|Mojo Texts|Motivational texts not alcohol related
219491480|NCT03874533|DEVICE|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
219491481|NCT04339361|DRUG|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
219601604|NCT07095582|BEHAVIORAL|Additional Loneliness Content|The additional Loneliness Content was developed at the Online Therapy Unit, University of Regina, Canada. Relevant sections of the resource will be included at the end of each lesson within the Wellbeing Course. The Loneliness Content provides psychoeducation and skills for loneliness using a cognitive behavioral framework. Consistent with the Wellbeing Course content, the Loneliness Content will target 1) identification of loneliness; 2) loneliness thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling for loneliness; 4) behaviours (conversation skills); and 5) relapse prevention.
219491482|NCT04339361|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
219491483|NCT04339361|DRUG|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
219491484|NCT04828629|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
219491485|NCT01460121|DEVICE|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
219491486|NCT01460121|DEVICE|Placebo|
219491487|NCT01494649|DRUG|Test Toothpaste|0.454% stannous fluoride toothpaste
219491488|NCT01494649|DRUG|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
219491489|NCT03467971|DRUG|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
219491490|NCT01855100|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
219491491|NCT06542211|BEHAVIORAL|Intervention plan for improving ankle dorsiflexion limitation group (experimental group)|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
219491492|NCT06542211|BEHAVIORAL|Plantar fasciitis routine rehabilitation group|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
219491493|NCT00247130|DRUG|Omeprazole|
219491494|NCT00247130|DRUG|Ranitidine|
219491495|NCT03791619|DEVICE|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
219491496|NCT03791619|DEVICE|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
219491497|NCT05413902|DRUG|Toradol|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491498|NCT05413902|DRUG|Morphine|Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
219491499|NCT05413902|DRUG|Orphenadrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491500|NCT05413902|DRUG|Gabapentin|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491501|NCT05413902|DRUG|Acetaminophen|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491502|NCT05413902|DRUG|Bupivacaine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491503|NCT05413902|DRUG|Epinephrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491504|NCT05413902|DRUG|Xylocaine Injectable Solution|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491505|NCT05413902|DRUG|Methylprednisolone|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
219491506|NCT01966341|BEHAVIORAL|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
219491507|NCT01966341|DRUG|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
219491508|NCT04711122|DRUG|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
219491509|NCT06018246|DIETARY_SUPPLEMENT|Malnutrition five-step treatment model + conventional nutritional intervention|"1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
219601605|NCT04326205|DEVICE|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
219601606|NCT04326205|DEVICE|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
219601607|NCT04326205|OTHER|no stimulation|Both tDCS and FES will not be used in this section.
219491510|NCT06018246|OTHER|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
219491511|NCT01174368|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
219491512|NCT00005609|BIOLOGICAL|rituximab|
218871648|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
218871649|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
218871650|NCT00740623|DRUG|placebo|placebo for 14 weeks
219491513|NCT04717869|DIAGNOSTIC_TEST|Ultrasound|2D ultrasound image collection
218871651|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
219021904|NCT06493396|DRUG|Opioid-free Analgesics|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
219491514|NCT04717869|DIAGNOSTIC_TEST|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
219491515|NCT04717869|OTHER|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
218871652|NCT02484950|BIOLOGICAL|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
219491516|NCT04114578|OTHER|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
219491517|NCT06150872|DEVICE|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
219491518|NCT06033703|DRUG|Netarsudil Ophthalmic|Topical administration of Netarsudil
219491519|NCT05120752|OTHER|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
219491520|NCT04446117|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
219491521|NCT04446117|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
219491522|NCT04446117|DRUG|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
219491523|NCT04446117|DRUG|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
219491524|NCT04446117|DRUG|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
219491525|NCT03203265|OTHER|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
219601608|NCT03252743|BEHAVIORAL|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
219601609|NCT02310256|OTHER|Five plus exercise training|calf raise exercise
219601610|NCT00002200|DRUG|Abacavir sulfate|
218871653|NCT02484950|PROCEDURE|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
219491526|NCT03203265|OTHER|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
219021905|NCT06493396|DRUG|Opioid group|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
219021906|NCT02249533|OTHER|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
219021907|NCT03420651|OTHER|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
219021908|NCT03420651|OTHER|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
219491527|NCT03203265|OTHER|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
219601611|NCT06194942|OTHER|chiropractic manipulation|Chiropractic manipulation is a manual therapy technique commonly used by chiropractors. It involves the application of controlled, sudden force to a specific joint, often with the goal of improving joint function, reducing pain, and promoting overall musculoskeletal health.In the context of thoracic chiropractic manipulation, the chiropractor focuses on the vertebrae and joints in the thoracic spine.
219601612|NCT06194942|OTHER|sham manipulation|"Sham manipulation refers to a simulated or placebo form of a manual therapy intervention, often used in research studies, especially in clinical trials involving chiropractic or physical therapy. the term sham manipulation likely implies a procedure that mimics the physical aspects of a real chiropractic manipulation but does not involve the actual therapeutic forces or movements.~The chiropractic treatment group received thoracic chiropractic manipulations (HVLA) twice a week for a total of six sessions over three weeks, while the control group received sham manipulations."
219601613|NCT00352417|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
219601614|NCT00352417|DRUG|Placebo|oral dosing, 1 time daily for 12 weeks
219601615|NCT07133568|OTHER|Fun Exercise for Older Adults (FEXO)|The FEXO (Fun Exercise for Older Adults) program is a 14-week, multicomponent, recreational exercise intervention designed to enhance intrinsic capacity, motivation, and adherence in community-dwelling older adults. Participants engage in three non-consecutive, supervised group sessions per week (maximum instructor-to-participant ratio 1:15), each lasting approximately 60 minutes. The program begins with a two-week familiarization phase followed by three progressive phases (4 weeks each), with exercise intensity, repetitions, and resistance levels adjusted based on functional performance assessed by the Short Physical Performance Battery (SPPB).
219601616|NCT07133568|OTHER|OTAGO|The OTAGO Exercise Program is a structured, evidence-based intervention developed to improve lower-limb strength and balance and reduce fall risk in older adults. In this study, participants in the control group will complete three non-consecutive, supervised sessions per week for a total duration of 14 weeks. Sessions will be delivered in group settings under the supervision of a licensed physiotherapist. The program includes individualized strength training for the lower extremities, progressive balance exercises, and walking routines. Although originally designed as a home-based program, in this trial it will be implemented in indoor, climate-controlled, non-slip-floor facilities provided by local institutions. The OTAGO protocol does not include recreational, cognitive, or playful components, serving instead as a standard, structured intervention against which the FEXO program will be compared.
219601617|NCT07134608|PROCEDURE|Popliteal Plexus Block with 20 ml|Different position while blocking the popliteal sciatic nerve block
219601618|NCT07134933|PROCEDURE|ESP (erector spinae plane)block|The ESP block was performed unilaterally in the direction of the surgery by the same anesthetist. Blocks were performed using an Esaote ultrasound device (Esaote My Lab 6 US machine, Florence, Italy), a multifrequency convex probe (1-8 MHz), and a 22-gauge, 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany). The block needle was placed at the level of the T4 spinal process using the in-plane approach, approximately 3 cm lateral to the T4 spinous process in the parasagittal plane. After visualizing the transverse process with the in-plane approach, the 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany) was inserted through the skin, and a test dose of 1 ml of 0.9% NaCl was injected between the fascia of the trapezius, rhomboid, and erector spinae muscles and the transverse vertebral process to confirm the location. A total of 20 ml of 0.5% bupivacaine was used as a local anesthetic.
219601619|NCT05314101|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
219021909|NCT05095597|PROCEDURE|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
219021910|NCT05095597|DRUG|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
219021911|NCT05095597|PROCEDURE|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
219021912|NCT05095597|PROCEDURE|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
219491528|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
219491529|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
219491530|NCT06593366|BIOLOGICAL|Fecal Microbiota Transplant|An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
219601620|NCT05314101|DRUG|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
219601621|NCT05314101|DRUG|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
219601622|NCT02117739|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
219601623|NCT02117739|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
219601624|NCT05921253|DEVICE|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
219601625|NCT05921253|DEVICE|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
219601626|NCT01496976|DRUG|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
219601627|NCT01496976|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
219601628|NCT01496976|DRUG|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
219601629|NCT06071702|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
218871654|NCT05147662|BIOLOGICAL|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
218871655|NCT07020780|RADIATION|Adjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed|Experimental arm (arm 1-five fractions WBI) patients will be treated to a total dose (TD) of 26 Gy in 5 fractions to whole breast, and a simultaneous integrated boost (SIB) to a TD of 30 Gy to the tumor bed, while arm 2-fifteen-fractions WBI patients with 40 Gy/15 fractions to PTV, and 48 Gy SIB to the tumor bed.
218871656|NCT03626285|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
218871657|NCT03626285|DEVICE|CliniMACS CD34 Reagent System|CD34 selection ex vivo
218871658|NCT03626285|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
218871659|NCT05096949|OTHER|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
219021913|NCT06406621|PROCEDURE|Laser hair depilation|"Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments."
219021914|NCT00857220|DRUG|eszopiclone|One 2 mg tablet per day for 12 months
219491531|NCT06593366|DRUG|Placebo|Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
219021915|NCT00857220|DRUG|eszopiclone|one 3mg tablet per day for 12 months
219491532|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1\. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
219491533|NCT03278483|DRUG|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
219491534|NCT03278483|DRUG|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
218871660|NCT04394715|OTHER|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
219491535|NCT04744077|BEHAVIORAL|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
219491536|NCT04744077|BEHAVIORAL|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
219491537|NCT03953911|BIOLOGICAL|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
219491538|NCT03953911|BEHAVIORAL|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
219491539|NCT06472050|DRUG|Romosozumab|osteoporosis treatment
219491540|NCT06472050|DRUG|Denosumab|osteoporosis treatment
219491541|NCT04449354|DEVICE|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
219491542|NCT01361698|BEHAVIORAL|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
219491543|NCT05224297|RADIATION|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
218871661|NCT02075892|DIETARY_SUPPLEMENT|Mushroom Blend|Scivation
218871662|NCT02075892|DIETARY_SUPPLEMENT|Placebo|
218871663|NCT06695533|BEHAVIORAL|Diabetes self management workbook|The diabetes self-management workbook section used in this pilot study will focus on diet management, specifically carbohydrates, following ADA guidelines. It will include exercises based on the ADA diabetes plate method, aimed at helping subjects understand meal planning, food categories, portion sizes, goal setting, and the impact of foods on blood glucose levels. Activities will include word searches, crosswords, and goal-setting exercises. Subjects will begin the first section during a clinic visit. They can complete the workbook at home over three months, with input from subjects and Certified Diabetes Care and Education Specialists to refine the content.
218871664|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
219021916|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
219021917|NCT03698994|OTHER|Pharmacokinetic Study|Ancillary studies
219021918|NCT03698994|DRUG|Ulixertinib|Given PO
219491544|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
219491545|NCT05789420|OTHER|P1R stick|Regular flavor tobacco stick
219491546|NCT05789420|OTHER|P1M stick|Mentholated flavor tobacco stick
219491547|NCT05789420|OTHER|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
219491548|NCT04699721|DRUG|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
219491549|NCT06235125|DRUG|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
219491550|NCT01029080|OTHER|no interventions|No interventions
218871665|NCT06872515|BEHAVIORAL|Exercise and Nutrition|"The exercise and nutrition intervention will last up to 8 weeks and will include:~* 3-5 times per week of resistance training and 3-5 times per week of aerobic training. The prescribed exercise will be personalized based on the participant's baseline functionality.~* IMPACT Advanced Recovery nutrition supplement drinks: 2 per day for 5 consecutive days leading up to surgery."
219021919|NCT04290689|DRUG|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
219021920|NCT04290689|PROCEDURE|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
219021921|NCT00003443|DRUG|bryostatin 1|
219491551|NCT01220128|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
219491552|NCT01220128|DRUG|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
219491553|NCT01220128|DRUG|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
218871666|NCT06872515|BEHAVIORAL|Usual Care Group|The CONT group will not receive any intervention during study participation and undergo usual medical treatment and surveillance during the duration of the study.
218871667|NCT05968755|DEVICE|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
218871668|NCT05968755|OTHER|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
218871669|NCT06701578|OTHER|Safe and Sound Protocol|Listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli for up to five hours.
218871670|NCT06701578|OTHER|Control|Listening to music that is not filtered and modulated for up to five hours.
219021922|NCT03084874|BEHAVIORAL|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
219021923|NCT05592782|BEHAVIORAL|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
219021924|NCT05542264|DRUG|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
219491554|NCT01220128|DRUG|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219491555|NCT01220128|DRUG|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
219021925|NCT05542264|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
219021926|NCT03646682|PROCEDURE|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
219021927|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
219021928|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
219491556|NCT01220128|DRUG|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219491557|NCT01220128|DRUG|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219491558|NCT01220128|DRUG|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
218871671|NCT02394717|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
218871672|NCT06200051|DIAGNOSTIC_TEST|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
218871673|NCT06710262|DIAGNOSTIC_TEST|T-TAS PL Assay|The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function
219491559|NCT01220128|DRUG|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219491560|NCT01220128|DRUG|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219601630|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
219601631|NCT03597399|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
219601632|NCT03755804|DRUG|bendamustine|Given intravenously (IV)
219601633|NCT03755804|DRUG|Etoposide|Given intravenously (IV)
219601634|NCT03755804|DRUG|Doxorubicin|Given intravenously (IV)
219021929|NCT05206227|BEHAVIORAL|Aerobic Exercise|Subjects will complete a single bout of aerobic exercise.
219021930|NCT05206227|DRUG|alpha-FMH|Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.
219021931|NCT05206227|BEHAVIORAL|Resistance and Aerobic Exercise|Subjects will complete bouts of resistance and aerobic exercise.
219021932|NCT05206227|DRUG|Antihistamine|Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.
219021933|NCT02067299|DRUG|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
219021934|NCT02067299|OTHER|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
219601635|NCT03755804|DRUG|Bleomycin|Given intravenously (IV)
219601636|NCT03755804|DRUG|Vincristine|Given intravenously (IV)
219601637|NCT03755804|DRUG|Vinblastine|Given intravenously (IV)
219601638|NCT03755804|DRUG|Prednisone|Given orally (PO)
219601639|NCT03755804|DRUG|Filgrastim|Given subcutaneously (SQ) or IV
219601640|NCT03755804|DRUG|Brentuximab Vedotin|Given intravenously (IV)
219601641|NCT03755804|DRUG|Cyclophosphamide|Given intravenously (IV)
219601642|NCT03755804|DRUG|DTIC|Given intravenously (IV)
219601643|NCT03755804|OTHER|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
219601644|NCT03755804|RADIATION|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
219601645|NCT05177211|DRUG|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
219601646|NCT05414357|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)"
219601647|NCT06443021|DEVICE|PD cycler|"After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP."
218871674|NCT07038278|DRUG|5-ALA|5-ALA), also known by its brand name Gleolan, is an intermediate in the heme synthesis pathway that has been studied in tumor resections, especially in intracranial tumor resections. One advantage of intraoperative visualization with 5-ALA is the ability to directly visualize fluorescent tumor in the surgical field using a headset-mounted devices with fluorescence in the visual wavelength in real-time.
218871675|NCT06725810|DRUG|Enarodustat|Patients are administered with enarodustat with dosage adjusted according to hemoglobin levels to achieve and maintain hemoglobin target over 96 weeks.
219491561|NCT01220128|DRUG|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
219491562|NCT06090500|PROCEDURE|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
219491563|NCT06090500|PROCEDURE|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
219491564|NCT06090500|PROCEDURE|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
219491565|NCT04931758|OTHER|Pain Questionnaire|Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
219491566|NCT00826722|DRUG|Levetiracetam|1000 mg tablet
219491567|NCT01236053|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
219491568|NCT03286595|OTHER|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
219491569|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
219491570|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
219491571|NCT02460315|PROCEDURE|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
219491572|NCT02460315|PROCEDURE|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
219491573|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
219491574|NCT06569004|DEVICE|randomised study, two group (experimental and control)|Use of IR beam before peripheral intravenous catheter application
219491575|NCT04803773|DEVICE|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
219491576|NCT01734421|OTHER|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
219491577|NCT01734421|DEVICE|Cell phone Aplication for Smarth Phone|
219491578|NCT06568887|COMBINATION_PRODUCT|Dextrose Water|Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
219491579|NCT06568887|COMBINATION_PRODUCT|Corticosteroid Injection|Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
219491580|NCT06568991|DIETARY_SUPPLEMENT|Low Protein Rice MATSUBUMAI|"Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group."
219491581|NCT01016158|DRUG|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
219491582|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
219491583|NCT01111994|DRUG|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
219491584|NCT05685693|PROCEDURE|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
219491585|NCT05685693|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
219491586|NCT00000135|DRUG|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
219491587|NCT00000135|OTHER|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
219491588|NCT05288374|DRUG|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
219491589|NCT05288374|DRUG|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
219491590|NCT02865473|DRUG|Pilocarpine|topical instillation into the study eye
219491591|NCT06503523|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL
219491592|NCT06503523|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
219491593|NCT06503523|OTHER|Cowhage|This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
219491594|NCT06503523|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
219491595|NCT01550068|DIAGNOSTIC_TEST|Echocardiography|
219491596|NCT02340078|DEVICE|HA IDF II plus|
219491597|NCT02340078|DEVICE|HA IDF II|
219491598|NCT05096026|BEHAVIORAL|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
219491599|NCT05096026|BEHAVIORAL|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
219491600|NCT00935896|PROCEDURE|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
219491601|NCT00935896|PROCEDURE|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
219491602|NCT00935896|OTHER|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
219491603|NCT05619809|DIETARY_SUPPLEMENT|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
218871676|NCT07043959|PROCEDURE|Isometrics Exercise|"Shoulder Squeeze:~The therapist instructed the patient to lift their arms to shoulder height while keeping the elbows bent, then move the arms backward until the shoulder blades come together.~Arm Lift to Front and Side:~The therapist instructed the patient to raise their arm forward and upward while applying gentle resistance for 2-3 seconds to facilitate front arm elevation. Then, the patient was guided to lift the arm sideways, with slight resistance applied for 2-3 seconds to assist in side-arm elevation."
219491604|NCT05619809|DIETARY_SUPPLEMENT|Protein supplement|Daily ingestion of protein supplement.
219491605|NCT05619809|DIETARY_SUPPLEMENT|Placebo supplement|Daily ingestion of a placebo dietary supplement.
219491606|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
219491607|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
219491608|NCT01311505|DRUG|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
219491609|NCT01311505|DRUG|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
219491610|NCT04285892|DEVICE|CAPA-IVM|"CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house."
219491611|NCT04657458|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219491612|NCT00002066|DRUG|Thymopentin|
219491613|NCT00567996|DRUG|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
219491614|NCT00567996|DRUG|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
219601648|NCT00371033|DRUG|Pregabalin|Pregabalin 150 mg/d (50 mg orally 3 times daily) for 2 weeks, then 300 mg/d (100 mg orally 3 times daily) for 2 weeks, and then 600 mg/d (200 mg orally 3 times daily) for 2 weeks.
219491615|NCT00567996|DRUG|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
219601649|NCT00371033|DRUG|Placebo|Placebo at same frequency as pregabablin
219601650|NCT04110327|DEVICE|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Peripheral Vascular Stent System
218871677|NCT07043959|PROCEDURE|Range of Motion Exercises|"Wall Climb for Flexion: The therapist instructed the patient to move their fingers upward along the wall until they reach their limit, then repeat the movement.~Arm across Chest for Adduction and Internal Rotation: The therapist instructed the patient to move the affected arm toward the unaffected arm and shoulder.~Wand Exercise for Flexion and Abduction: The patient was instructed to hold a wand with both hands and move it forward and sideways toward the affected side"
218871678|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
219491616|NCT00567996|DRUG|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
219491617|NCT03430557|PROCEDURE|PRP|platelet rich plasma
219491618|NCT03430557|PROCEDURE|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
219491619|NCT04562298|BIOLOGICAL|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
219491620|NCT04245397|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
219491621|NCT04245397|DRUG|Decitabine|Decitabine is a hypomethylating agent.
219491622|NCT05357742|BEHAVIORAL|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
219491623|NCT05357742|BEHAVIORAL|Enhanced usual care|During each session participants will receive DKD education only.
219491624|NCT06582888|DRUG|Varenicline Tartrate|varenicline (target dose 1mg twice daily)
219491625|NCT06582888|DRUG|Placebo|matched placebo
219491626|NCT06567964|PROCEDURE|Erector Spinae Plane Block(ESPB)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
219491627|NCT06567964|PROCEDURE|Wound infiltration|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
219491628|NCT04196270|DRUG|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
219491629|NCT00157729|DRUG|pyridoxal-5'-phosphate with and without ACE inhibitor|
219491630|NCT03128073|DEVICE|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
219491631|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
219491632|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
219491633|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
219491634|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
219491635|NCT01301378|PROCEDURE|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
219491636|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
219491637|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
219491638|NCT05503914|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
219491639|NCT01898884|DRUG|VP 20629|
219491640|NCT01898884|DRUG|Placebo|
219491641|NCT00759759|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
219491642|NCT00759759|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
218871679|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
219491643|NCT04443231|DEVICE|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
219491644|NCT04923607|DRUG|TQC2731|TQC2731 injection
219491645|NCT04923607|DRUG|Placebo|Matching placebo with no active ingredients
219491646|NCT01508572|DRUG|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
219491647|NCT06309121|DIETARY_SUPPLEMENT|Postbiotic ABB C3|A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
219491648|NCT06309121|DIETARY_SUPPLEMENT|Placebo|A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
219491649|NCT06309121|DIETARY_SUPPLEMENT|Follow-up Postbiotic ABB C3 (Optional)|Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
219491650|NCT05166369|BEHAVIORAL|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
219491651|NCT05166369|BEHAVIORAL|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
219491652|NCT03101215|DIETARY_SUPPLEMENT|phosphorus|adding of phosphorus to high carbohydrate meal
219491653|NCT01456494|OTHER|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
219491654|NCT01456494|OTHER|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
219491655|NCT02543515|PROCEDURE|office hysteroscopy|diagnostic procedure
219491656|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
219491657|NCT02130895|OTHER|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with \>=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
219491658|NCT00770354|DRUG|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
219491659|NCT00770354|DRUG|Letrozole|Daily 2.5 mg oral letrozole tablet
219491660|NCT06602037|DIAGNOSTIC_TEST|[89Zr]Zr-DFO-SHR1920|Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
219491661|NCT06602037|DIAGNOSTIC_TEST|[18F]F-RESCA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.
219491662|NCT06602037|DIAGNOSTIC_TEST|[68Ga]Ga-NOTA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.
219491663|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
219601651|NCT05473195|DRUG|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
219601652|NCT05473195|DRUG|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
218871680|NCT06720714|DRUG|Rozanolixizumab|Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
218871681|NCT06727578|DEVICE|of intrapleural saline irrigation with CLR irrigator|patients will have a CLRTM port and CLRTM irrigator (CLR Medical, Calverton, MD, USA) added to their chest tube and atrium circuit to facilitate pleural irrigation.
218871682|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
218871683|NCT07040839|DRUG|Amoxicillin 1 g|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
218871684|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
218871685|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
218871686|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
218871687|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
218871688|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
219491664|NCT06701097|BEHAVIORAL|Emotion regulation training|Man is a social being and therefore interacts with his environment. In the process of interaction, they can transfer their feelings, thoughts, and information. However, the interaction process may not always continue smoothly. People's inability to express their emotions appropriately today negatively affects communication. The reason why people cannot express their emotions may be the high level of alexithymia. The concept of alexithymia means having difficulty in recognizing, expressing, and naming emotions. High levels of alexithymia in students, who are future healthcare professionals, can negatively affect themselves, other healthcare professionals and the patients they care for; it can cause burnout in healthcare professionals, decrease the quality of care they provide and cause them to experience interpersonal communication conflicts.
219491665|NCT06703788|DRUG|A fiixed combination of Chinese herbal medicine|a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
218871689|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
218871690|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
218871691|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
218871692|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
218871693|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
218871694|NCT06727136|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets
218871695|NCT07044635|RADIATION|Radiation Therapy|Reduced dose and Hypofractionated radiation therapy
218871696|NCT06729918|OTHER|Virtual reality|Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
218871697|NCT06729918|OTHER|simulated patient|Thoracic lung physical examination will be studied using a simulated patient.
219491666|NCT06703788|DEVICE|Laser acupuncture|Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
219491667|NCT06703866|OTHER|Non Small Cell Lung Cancer (NSCLC)|"Application of value based medicine predictive model"
219491668|NCT06702917|DEVICE|GSI Cardiac Scan|"The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan."
219491669|NCT06702917|OTHER|Standard of Care CCTA|The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
218871698|NCT07041775|OTHER|myoelectric interface for neurorehabilitation (MINT) conditioning|Myoelectric interface for neurorehabilitation (MINT) conditioning involves training to reduce abnormal co-activation of limb muscles to improve movement.
218871699|NCT07041775|OTHER|One muscle myoelectric feedback|Training to control muscle activity in one muscle only.
218871700|NCT06885229|DEVICE|FloMask - reuseable face mask|Reuseable, elastomeric face mask with replaceable filters
218871701|NCT06454877|DEVICE|active heating|"Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°."
218871702|NCT06454877|BEHAVIORAL|pasive heating|"In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets."
218871703|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
218871704|NCT04528056|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
218871705|NCT04528056|DRUG|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
218871706|NCT04528056|DRUG|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
219021935|NCT05020340|PROCEDURE|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
218871707|NCT04528056|DRUG|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
218871708|NCT06809517|DRUG|AK112|Intrathecal injection of PD-1/VEGF bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
219021936|NCT03987061|DEVICE|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
219021937|NCT01271920|DRUG|AUY922|
218871709|NCT06809517|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
219021938|NCT01271920|DRUG|Trastuzumab|
219021939|NCT02548520|OTHER|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
219491670|NCT06702917|OTHER|Research CCTA|The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
219491671|NCT06702605|DRUG|XNW5004 tablets|XNW5004 will be administered orally as tablets.
219491672|NCT06702709|OTHER|Instrument Assisted Soft Tissue Mobilization|The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds
219491673|NCT06702709|OTHER|Neurodevelopmental Therapy|The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
219601653|NCT05473195|DRUG|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
219601654|NCT05473195|DRUG|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
219601655|NCT05875714|DRUG|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
219601656|NCT06015438|BEHAVIORAL|Home Exercise Program|Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.
219601657|NCT06015438|BEHAVIORAL|Short Exercise Program|Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
219601658|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
219601659|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
219601660|NCT05200208|DIETARY_SUPPLEMENT|Citicoline supplement|Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
219601661|NCT05200208|OTHER|Placebo|Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
219601662|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
219601663|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
219601664|NCT02506153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219601665|NCT02506153|PROCEDURE|Computed Tomography|Undergo CT scan
219601666|NCT02506153|BIOLOGICAL|Ipilimumab|Given IV
218871710|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
218871711|NCT07081425|DEVICE|VRG Group|Care was taken to ensure that patients did not receive analgesia for at least 4 hours before the procedure. Before drain removal, the patient's NRPS level was assessed, and the STAI-I questionnaire was filled out. The experimental group was given a video to watch before the procedure began, and the use of glasses was explained. VRG was put on the patient, and the drain was removed in the 3rd minute while the video was being watched. After the procedure, the patients' pain perception during the procedure was assessed with the NRPS form. The STAI-I questionnaire was filled out again.
219491674|NCT06703775|OTHER|Low level laser therapy (LLLT)|The first experimental will receive LLLT using the Fisioline Lumix 2 (Italy). Participants will be placed in a comfortable, supported sitting position and will wear protective eyeglasses to prevent retinal damage. The LLLT (GaAs type, 1-10 mW, 904 nm) will be applied to the most painful points on the deltoid and/or upper trapezius muscles. Treatment will target a minimum of two and a maximum of four painful points, with each point irradiated for 3-4 minutes, for a total session duration of up to 15 minutes.
219601667|NCT02506153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219601668|NCT02506153|BIOLOGICAL|Pembrolizumab|Given IV
219491675|NCT06703775|OTHER|Neural mobilization techniques|The second experimental will receive Neural Mobilization Therapy (NMT). The procedure will begin by positioning the patient in a sitting position. The initial positioning will involve placing the patient's arm at their side with the elbow bent at 90 degrees. The therapist will gently extend the patient's shoulder (moving the arm backward) while keeping the elbow bent, creating tension on the axillary nerve. This tension will be held for a few seconds, ensuring it remains within the patient's tolerance and does not cause discomfort or pain. The shoulder will then be slowly returned to the initial position, releasing the tension on the nerve. This sequence of tension and release will be repeated, gradually increasing the range of motion as tolerated. The treatment will consist of three sets of 10 repetitions, with a one-minute rest between sets, performed three times per week for a total of 12 sessions over four weeks.
219491676|NCT06703775|OTHER|Conventional physical therapy program|The following exercises will be performed by the patients of three groups. Pendulum exercise, Isometric Scapular Retraction, Rotator cuff exercise, Wall creeping exercise, Active assisted ROM exercises, Codman exercises. Each exercise will be performed for all movements namely flexion extension and abduction-adduction, one sets of each 10-15 repetitions within pain-free range and instructed to carry out their activities of daily living.
218871712|NCT07081347|DEVICE|MINT Minimally Invasive Nasal Trabeculostomy|The MINT® system is a powered surgical device for ab-interno nasal trabeculostomy. It creates \~100-micron trabeculostomy openings from the anterior chamber into Schlemm's canal by removing trabecular meshwork (TM) segments. The system includes a sterile stainless-steel Surgical Device with a micro trephine, driven by a motorized Activation Device that controls rotation and movement. The procedure facilitates aqueous outflow to lower IOP, with minimal collateral tissue damage.
218871713|NCT07082257|OTHER|Functional Assessment|Undergo chair-to-table assessment
219491677|NCT06702813|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
219491678|NCT06703528|DEVICE|cryoablation|The therapeutic cryoablation agent used in this trial was liquid nitrogen with an evaporation temperature of -196°C, which was transported to the ablation pen through a vacuum line to exchange energy at the heart site to perform cryoablation.
219491679|NCT06519266|DEVICE|PHP|Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
219491680|NCT06519266|DRUG|IPI1/NIVO3|Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
218871714|NCT07082257|BEHAVIORAL|Timed Get Up and Go Test|"Undergo Get Up and Go assessment"
219491681|NCT06519266|DRUG|IPI3/NIVO1|Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
219491682|NCT02548117|DRUG|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
219601669|NCT02506153|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219601670|NCT02506153|OTHER|Quality-of-Life Assessment|Ancillary studies
219601671|NCT02506153|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
219601672|NCT05456191|DRUG|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
219601673|NCT05456191|DRUG|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
219601674|NCT06572228|DRUG|dupilumab|Administered by subcutaneous (SC) injection
219601675|NCT06572228|DRUG|Matching Placebo|Administered by SC injection
218871715|NCT07083024|BEHAVIORAL|infection control education|This intervention includes a lecture, hands on practice and identifying IPAC practices in videos
218871716|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
218871717|NCT04320888|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
218871718|NCT04320888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
219601676|NCT06572228|DRUG|ICS/LABA|Administered at a blinded dose
219601677|NCT02723734|OTHER|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
219491683|NCT04479943|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
219491684|NCT04479943|OTHER|Surveys and Focus groups|Nurses will answer surveys about nurse behavior, changes in self-efficacy, frequency and distance of patient ambulation, documentation of ambulation, qualitative data collected to determine barriers to implementation
219491685|NCT01098058|OTHER|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
219491686|NCT01098058|OTHER|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
219491687|NCT05720793|COMBINATION_PRODUCT|FMT Capsule + SIMBA Capsule|Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
219491688|NCT06463756|OTHER|AI|"Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis."
219491689|NCT06495268|OTHER|Individualised data-driven hearing rehabilitation|"HA fittings will be conducted with the Real-Ear Measurements (REM) method that is recommended by the latest ISO-standard (21388:2020) and by the preliminary results of the BREM study at KUH. After the fitting of the HAs, participants' auditory-related outcomes will be immediately assessed using DigiKuulo and re-fitting is performed if needed based on the following criteria:~1. The absolute improvement in the DIN test is less than 1,5dB (SNR), OR~2. The absolute result of the DIN test is more than -8,5 dB (SNR) OR~3. The participant is unsatisfied with the HA fitting~Participants are invited to intervention-related monitoring appointments at 3, 6 and 12 months after the primary HA fitting. At these visits, auditory outcomes of the rehabilitation are assessed via DigiKuulo and re-fittings are performed as needed."
219491690|NCT06495268|OTHER|Standard care hearing rehabilitation|HA will be fitted with automatic algorithms by HA manufacturers and REM-fitting is only applied in complex cases based on the hearing rehabilitator's clinical judgement. Three months after the HA fitting, participants will be contacted via phone call to inquire about the status of the rehabilitation. Additional monitoring visits may be offered based on the participant's feedback. After the 3-month monitoring phone call participants will be advised to further contact the study team if they are dissatisfied with the amplification or for any other problem with their device.
219491691|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
219491692|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
219491693|NCT04737915|BEHAVIORAL|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
219491694|NCT04737915|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
219491695|NCT04347031|DRUG|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
219491696|NCT04347031|DRUG|Hydroxychloroquine|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
219491697|NCT04347031|COMBINATION_PRODUCT|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
219491698|NCT04347031|COMBINATION_PRODUCT|Hydroxychloroquine + azithromycin + / - tocilizumab|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
219491699|NCT06530160|OTHER|ELISA|Enzyme-linked immunosorbent assay
219491700|NCT01755780|OTHER|Left interscalene block|
219491701|NCT01755780|OTHER|Right interscalene block|
219491702|NCT00391092|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
219491703|NCT00391092|DRUG|Docetaxel|100mg/m2 iv every 3 weeks
219491704|NCT00391092|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
219491705|NCT05404568|PROCEDURE|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
219491706|NCT01665573|DRUG|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
219491707|NCT01665573|DRUG|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
219491708|NCT04682431|DRUG|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
219601678|NCT03128060|OTHER|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
219491709|NCT04682431|DRUG|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
219491710|NCT04682431|DRUG|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
219491711|NCT04682431|DRUG|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
219491712|NCT04682431|DRUG|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
219491713|NCT04682431|DRUG|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
219491714|NCT04682431|DRUG|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
219491715|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
219491716|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
219491717|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
219491718|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
219491719|NCT04682431|DRUG|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
219491720|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219491721|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219491722|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219601679|NCT03128060|OTHER|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
219601680|NCT06267846|DRUG|NBI-1070770|Suspension for oral administration
219601681|NCT06267846|DRUG|Placebo|Suspension for oral administration
219601682|NCT05832177|BEHAVIORAL|Cancer CientoUno (101) program|The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.
219491723|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219491724|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219491725|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
219491726|NCT01445431|OTHER|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
219491727|NCT01445431|OTHER|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
219491728|NCT03679312|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
219491729|NCT03679312|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
219491730|NCT03232749|PROCEDURE|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
219491731|NCT03232749|DRUG|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
219491732|NCT03232749|DEVICE|Ultrasound|ultrasound-guided IACSI
219491733|NCT06254521|DRUG|Tislelizumab combined with chemotherapy|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic"
219491734|NCT05224479|OTHER|Traditional workflow triage|Workflow triage is based on order location, STAT designation, and first-in-first-out status.
219491735|NCT05224479|OTHER|Machine learning workflow triage|Workflow triage is based on the machine learning model's confidence of abnormality.
219491736|NCT05224479|OTHER|Random workflow triage|Workflow triage is based on random order.
219491737|NCT03362242|DRUG|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
219601683|NCT05832177|BEHAVIORAL|Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)|This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.
219601684|NCT05832177|BEHAVIORAL|¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)|This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator \[CHE\], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.
219601685|NCT05832177|BEHAVIORAL|Community/Researcher Forum: El Puente (Translation in English: The Bridge).|The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.
219601686|NCT05832177|BEHAVIORAL|Lunch and Learn Updated Recommendations Series.|This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
219491738|NCT03362242|OTHER|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219491739|NCT03967106|OTHER|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
219491740|NCT03967106|OTHER|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
219491741|NCT03232905|DRUG|PF-06651600|PF-06651600 will be administered as tablet
219491742|NCT03232905|DRUG|Placebo|Matching placebo will be administered as tablet
219491743|NCT06476873|BEHAVIORAL|Online self-questionnaire.|"Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French.~An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available.~The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press."
219491744|NCT05164848|DRUG|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
219491745|NCT05164848|DRUG|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
219491746|NCT01047904|DEVICE|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
219491747|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
218871719|NCT04320888|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
218871720|NCT04320888|PROCEDURE|Radionuclide Imaging|Undergo scintigraphy
219491748|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
219491749|NCT01614925|DEVICE|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
218871721|NCT04320888|DRUG|Selpercatinib|Given PO
218871722|NCT04320888|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
218871723|NCT07089329|DRUG|Striatin|Daily administration of Striatin extract will be carried out for 14 days. The dose is 1 sachet/day (5 g of Striatin) which dissolved in 10 mll of syrup.
218871724|NCT07089329|DRUG|Placebo|Daily administration of 1 sachet of placebo will be carried out for 14 days.
219491750|NCT01614925|PROCEDURE|Periodontal surgery|Periodontal surgery alone
219491751|NCT02966522|DRUG|Thalidomide|
219491752|NCT02966522|DRUG|Dexamethasone|
219491753|NCT06522230|OTHER|Fascial Stretch Therapy|Fascial Stretch Protocol uses a combination of circumduction, traction, proprioceptive neuromuscular facilitation (PNF) and specific FST maneuvers. Stretch is applied in both active \& passive methods taking into consideration: (1) Oscillatory - slow passive joint oscillations (back and forth movement in a regular rhythm). Small controlled oscillations help with proprioceptors around the joints, acilitates blood flow, gently stretches the ligaments, tendons, nerves, \& muscles and slows the nervous system down; (2) Traction - allows for assessment of the joint capsule movement and to decompress the joint. (3) Movement - designed to enhance the reflexes and are intentionally gentle to maximize benefits; (4) PNF - helps improve flexibility by alternating muscle contractions and relaxations. This stimulates the neuromuscular system, allowing muscles to relax deeper and increase range of motion. (5) Breath - allows the body to increase oxygen consumption to facilitate recovery.
219491754|NCT03519022|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
219491755|NCT03519022|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
219021940|NCT05023746|DIAGNOSTIC_TEST|Genetron lung cancer panel|Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
219021941|NCT00171223|DRUG|STI571|STI571 oral capsules or tablets.
219491756|NCT03519022|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
219491757|NCT00611741|DRUG|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
219491758|NCT04446819|DEVICE|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
219491759|NCT03633019|DRUG|rhTPO|high dose rhTPO ih
219491760|NCT01291719|DEVICE|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
219491761|NCT02359084|BEHAVIORAL|Family Navigation|
219491762|NCT02359084|BEHAVIORAL|Conventional Care Management|
219491763|NCT01980316|DRUG|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
219491764|NCT01980316|DRUG|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
219491765|NCT02437890|BIOLOGICAL|ALX-0061|
219491766|NCT02437890|BIOLOGICAL|Placebo|
219491767|NCT04268784|DRUG|DNL343|Single and repeating oral dose(s)
219491768|NCT04268784|DRUG|Placebo|Single and repeating oral dose(s)
219491769|NCT04554407|DEVICE|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
219491770|NCT02414854|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
219491771|NCT02414854|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
219491772|NCT02414854|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
219491773|NCT02414854|DRUG|Albuterol/Salbutamol|Oral inhalation as needed
219491774|NCT02414854|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed
219491775|NCT00553748|DRUG|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
219491776|NCT00673322|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
219491777|NCT05380622|DIAGNOSTIC_TEST|Coronary CT angiography|"Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab."
219491778|NCT01357031|DRUG|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
219491779|NCT01357031|DRUG|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
219491780|NCT01357031|DRUG|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
219491781|NCT06515444|BEHAVIORAL|10 minutes program|The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
219491782|NCT06515444|BEHAVIORAL|1 hour PD program|The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
219491783|NCT00798824|PROCEDURE|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
219491784|NCT00798824|PROCEDURE|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
219491785|NCT00798824|DEVICE|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
219491786|NCT00798824|DEVICE|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
219491787|NCT02701816|DEVICE|innova stent (Boston scientific)|
219491788|NCT06036173|OTHER|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
219491789|NCT06036173|OTHER|breast cancer surgery|be diagnosed and undergo surgery
219491790|NCT03451227|DRUG|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
219491791|NCT03451227|DRUG|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
219491792|NCT04723173|DEVICE|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
219491793|NCT04723173|DEVICE|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
219491794|NCT04843800|PROCEDURE|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
219491795|NCT01876199|BEHAVIORAL|intense follow up|
219491796|NCT00750009|OTHER|educational intervention|Patients receive a tailored intervention or generic information
219491797|NCT05731388|DIAGNOSTIC_TEST|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
219491798|NCT03614871|OTHER|Epidemiological study|
219491799|NCT01644578|PROCEDURE|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
219491800|NCT01422720|DRUG|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
219491801|NCT03508362|DEVICE|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
218871725|NCT07089095|OTHER|questionnaire|This is a Relation Research. Use the patient decision aids for acute stroke rehabilitation, then data are collected with patients' characteristics, National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Modified Rankin Scale (mRS), and factors and preferences in the patient selection of rehabilitation care questionnaire.
218871726|NCT07089264|OTHER|Physical rehabilitation|Physical Rehabilitation in 36 sessions
219491802|NCT04189289|PROCEDURE|ESP block group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
219491803|NCT04189289|PROCEDURE|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
219491804|NCT01241162|BIOLOGICAL|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
219491805|NCT01559831|BIOLOGICAL|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
218871727|NCT07088575|PROCEDURE|major gastrointestinal or hepatobiliary surgery under general anesthesia|major gastrointestinal or hepatobiliary surgery under general anesthesia
218871728|NCT07088159|DRUG|SPG302|300 mg SPG302 will taken by mouth once daily.
218871729|NCT07088887|OTHER|control group|The control group included patients aged 18-65 who were systemically healthy, had no clinical or self-reported signs of bruxism, and were eligible for implant treatment. Data collected included demographic characteristics (age, gender), systemic and periodontal health status, and clinical examination findings confirming the absence of bruxism. These patients also completed the Fonseca Anamnestic Index (FAI) to assess temporomandibular disorder (TMD) symptoms and the Perceived Stress Scale-14 (PSS-14) to evaluate emotional stress levels. A bruxism awareness questionnaire was also applied to determine baseline knowledge in individuals without bruxism. All assessments were conducted before implant surgery using standardized diagnostic tools.
219491806|NCT01852773|PROCEDURE|Open repair of thoracic aorta injury|open surgical management of aortic injury
219491807|NCT01852773|PROCEDURE|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
219491808|NCT01287780|DEVICE|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
219491809|NCT02068404|DRUG|Nifedipine|
219491810|NCT04812704|DIETARY_SUPPLEMENT|Whey protein|Patient receive protein supplement in liquid form after each exercice session
219491811|NCT02837367|DIETARY_SUPPLEMENT|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
219491812|NCT05294614|BEHAVIORAL|"Sonreír es diveritdo - Smiling is fun"|Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on… what?; a relapse prevention module.
219491813|NCT00773981|PROCEDURE|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
219491814|NCT01375569|DRUG|TRC105|
219491815|NCT01259518|DRUG|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
219491816|NCT01259518|DRUG|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
219491817|NCT03275779|BEHAVIORAL|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
219491818|NCT03275779|BEHAVIORAL|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
218871730|NCT07088354|DIAGNOSTIC_TEST|The high-throughput extraction of large amounts of quantitative image features from medical images|The high-throughput extraction of large amounts of quantitative image features from medical images
219491819|NCT02891564|BEHAVIORAL|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
219491820|NCT02891564|OTHER|Control Mobile 3D video game|expectancy-matched control game
219491821|NCT05368233|OTHER|ERAS protocol|ERAS protocol whch helps to optimise the length of hospital stay.
219491822|NCT03827785|DEVICE|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
219491823|NCT03827785|DEVICE|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
219491824|NCT00490737|DRUG|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
219491825|NCT01074307|DRUG|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
219491826|NCT01074307|DRUG|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
219491827|NCT02067988|DEVICE|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
219491828|NCT02023788|BIOLOGICAL|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
219491829|NCT05661656|PROCEDURE|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
219491830|NCT01293409|OTHER|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
219491831|NCT04422015|OTHER|No intervention|No intervention
218871731|NCT07089537|OTHER|progressive muscle relaxaiton|Participants will undergo approximately 30 minutes of Progressive Muscle Relaxation (PMR). Prior to the session, a brief introduction to the basic concepts of PMR will be provided. Participants will be instructed to close their eyes and focus on the sensations in their muscles. Following verbal instructions, they will sequentially contract and relax 14 major muscle groups from top to bottom. For each muscle group, participants will be asked to contract the muscles as strongly as possible for 7 seconds, followed by a 45-second relaxation period. This process will be repeated twice for each muscle group.
218871732|NCT07089537|OTHER|Rest|Rest in a semi-recumbent position with eyes closed for 30 minutes, without any additional intervention.
218871733|NCT07088133|DRUG|NA(s)+HT-102+FD-001|Nucleos(t)ide analogues will be administrated throughout the entire treatment course; Patients will be injected with HT-102 once in Day1 (Week1), Day8 (Week2), Day15 (Week3), Day22 (Week4); Patients will be injected with FD-001 once in Day29 (Week5), Day57 (Week9), Day85 (Week13), Day113 (Week17), Day141 (Week21), Day169 (Week25) after confirmed reduction of serum HBsAg to below 10 IU/mL.
219491832|NCT02798237|OTHER|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
219491833|NCT02798237|OTHER|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
219491834|NCT03325452|BIOLOGICAL|venous lactate|value of venous lactate
219491835|NCT00460252|PROCEDURE|insulin titration applying a computer algorithm|
219491836|NCT06540378|DRUG|Stiripentol|
219491837|NCT06218888|DRUG|Tislelizumab|Tislelizumab 200mg，D1, Q3W
218871734|NCT07088107|DEVICE|fNIRS-triggered TMS|The firing of TMS will be triggered according to fNIRS signal intensity.
218871735|NCT07089407|DEVICE|Dental implant placement|Implant site prepared through a consecutive drilling procedure in the maxilla or the mandible, implant placed.
218871736|NCT07089849|OTHER|Rapid HIV testing|At the designated sites for RHT, providers will offer RHT to patients as part of their dental routine care.
218871737|NCT07089849|OTHER|Referral for HIV testing|At the designated sites for HIV testing referral, providers will offer an HIV test referral to the affiliated CHC laboratory to patients as part of their dental routine care.
218871738|NCT07088549|DEVICE|Continuous glucose monitoring|Intravenous insulin therapy will be guided by interstitial glucose measurements using DexcomG7 continuous glucose monitor. Confirmatory blood glucose tests will be performed daily. In extreme clinical conditions (post-resuscitation, pH \< 7.20, severe hypoxia, severe haemodynamic compromise), confirmatory blood tests will be performed in 2 hour intervals until clinical improvement.
218871739|NCT07088549|DIAGNOSTIC_TEST|Control Arm - standard of care|Intravenous insulin dosing will be guided according to blood glucose measurements using RadiometerABL800 (standard of care). DexcomG7 continuous glucose monitor will be applied in blinded mode for interstitial glucose monitoring for later CGM metrics and comparison analysis.
219021942|NCT05805787|OTHER|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
219021943|NCT02115711|BEHAVIORAL|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
219021944|NCT03312972|RADIATION|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
219491838|NCT06218888|DRUG|Fruquintinib|Fruquintinib 3mg ,D1-D14, Q3W
219491839|NCT06218888|DRUG|Chidamide|Chidamide 30mg
219491840|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Pre-Workout Supplement|"The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
219491841|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|"The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
219491842|NCT06130709|PROCEDURE|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
219491843|NCT02625207|DRUG|Maraviroc (Part 1)|300 mg twice daily x 5 days
219491844|NCT02625207|DRUG|Maraviroc (Part 2)|150 mg once daily x 10 days
219491845|NCT02625207|DRUG|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
219491846|NCT01480271|DRUG|2 ng GSK2445053|2ng GSK2445053 administered intranasally
219491847|NCT01480271|DRUG|20ng GSK2445053|20ng GSK2445053 administered intranasally
218871740|NCT07089069|DEVICE|3 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 3 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
219491848|NCT01480271|DRUG|100ng GSK2445053|100ng GSK2445053 administered intranasally
219021945|NCT01966965|DRUG|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
219021946|NCT01966965|DRUG|NEDAX|AS SPECIFIED AT THE LEAFLET
219021947|NCT03935633|DRUG|CN128 Tablets|Iron chelator， oral tablets
219021948|NCT03786757|DRUG|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
219491849|NCT01480271|DRUG|200ng GSK2445053|200ng GSK2445053 administered intranasally
219491850|NCT01480271|DRUG|400ng GSK2445053|400ng GSK2445053 administered intranasally
219491851|NCT01480271|DRUG|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
219491852|NCT01480271|DRUG|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
219491853|NCT01480271|DRUG|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
219491854|NCT01480271|DRUG|Placebo|Placebo administered intranasally
219491855|NCT00192088|DRUG|pemetrexed|
219491856|NCT00192088|DRUG|oxaliplatin|
219491857|NCT04365088|DRUG|Deflazacort 30 MG Oral Tablet|After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
219491858|NCT04365088|DRUG|Sugar pill|Sugar pill
219491859|NCT00362856|DRUG|larazotide acetate|capsule
219491860|NCT00362856|DRUG|Placebo|capsule
219491861|NCT02162511|DEVICE|CliniMACS CD34+ cell enrichment and T-cell depletion|
219491862|NCT05640583|DEVICE|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
219491863|NCT01604954|BEHAVIORAL|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
219491864|NCT01604954|BEHAVIORAL|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
219491865|NCT01604954|BEHAVIORAL|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
219491866|NCT06304545|DRUG|Camrelizumab|Camrelizumab IV 200mg
219491867|NCT06304545|DRUG|Chemotherapy|Capecitabine PO oxaliplatin IV
219491868|NCT06304545|RADIATION|Radiotherapy|Radiotherapy 50Gy /45Gy /25 fractions
219491869|NCT00436527|DRUG|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
219491870|NCT06047782|OTHER|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
219491871|NCT00036582|DRUG|Clozapine|
219491872|NCT06306794|OTHER|crochet octopus|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
219491873|NCT02328001|BEHAVIORAL|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
219491874|NCT05474560|DRUG|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
219491875|NCT05474560|DRUG|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
219491876|NCT05474560|BEHAVIORAL|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
219491877|NCT00802529|DRUG|Methylprednisolone|2 transtympanic injections at interval of two weeks.
219491878|NCT00802529|DRUG|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
219491879|NCT01757366|DRUG|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
219491880|NCT01757366|DRUG|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
219491881|NCT01041937|PROCEDURE|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
219491882|NCT01041937|PROCEDURE|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
219491883|NCT06119373|OTHER|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
219491884|NCT06119373|OTHER|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
219491885|NCT00803673|DRUG|100mcg|100mcg '719
219491886|NCT00803673|DRUG|500mcg|500mcg '719
219491887|NCT00803673|DRUG|1000mcg|1000mcg '719
219491888|NCT00803673|DRUG|Placebo|Placebo '719
219491889|NCT05040035|DIAGNOSTIC_TEST|ACT measurement|Measurement of active clotting time (ACT)
219491890|NCT03928613|BEHAVIORAL|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
219491891|NCT03067506|OTHER|No intervention|No intervention
219491892|NCT06132412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
219491893|NCT06132412|OTHER|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
219491894|NCT05218317|DIAGNOSTIC_TEST|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
219491895|NCT04656574|BEHAVIORAL|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
219491896|NCT02733458|DRUG|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
219491897|NCT02733458|RADIATION|Radiotherapy|Radiotherapy: 50-56Gy
219601687|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for U54 Partnership Investigators|This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.
219601688|NCT05832177|BEHAVIORAL|Community Advisory Panels (CAP)|These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.
219021949|NCT03987893|DRUG|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
219021950|NCT03987893|DRUG|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
219491898|NCT00221572|PROCEDURE|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
219491899|NCT00552617|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
218871741|NCT07089069|DEVICE|2 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
218871742|NCT07089069|DEVICE|1 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 1 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
218871743|NCT07089069|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The intervention will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation，but there is not current in between. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
218871744|NCT07088367|BEHAVIORAL|Virtual reality meditation|"This intervention involves immersive virtual reality (VR)-based guided meditation sessions using MediboothVR, the first Turkish-language supported virtual reality meditation application developed in Türkiye. It is distinct from other VR interventions in the following ways:~Cultural and language adaptation: MediboothVR is fully available in Turkish, providing culturally relevant audio-guided content. This makes it more accessible and emotionally resonant for Turkish-speaking participants, unlike many VR applications designed in other languages.~Duration and consistency: The intervention is delivered over three consecutive days, with a different video used each day, each lasting approximately 10 minutes.~Technical delivery: The application is used exclusively via VR headsets, creating a fully immersive experience that eliminates visual and auditory distractions from the hospital environment."
219491900|NCT00552617|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
219491901|NCT00552617|DRUG|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
219491902|NCT00552617|DRUG|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
219491903|NCT03800186|OTHER|Proximal type A|Patients with fracture of proximal type A
219491904|NCT03800186|OTHER|Proximal type B|Patients with fracture of proximal type B
219491905|NCT03800186|OTHER|Proximal type C|Patients with fracture of proximal type C
219491906|NCT03800186|OTHER|femoral shaft|Patients with fracture of femoral shaft
219601689|NCT05832177|BEHAVIORAL|Research Corner|The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
219601690|NCT05832177|BEHAVIORAL|Community-based Training Program (CBTP) for Community Leaders and Stakeholders.|The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
219491907|NCT03800186|OTHER|distal femur|Patients with fracture of distal femur
219491908|NCT06673550|PROCEDURE|Intragastric balloon|Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.
219491909|NCT04688814|PROCEDURE|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
219491910|NCT04688814|DRUG|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
219491911|NCT04323449|DEVICE|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
219491912|NCT01111084|DRUG|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
219491913|NCT03307902|BIOLOGICAL|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
219491914|NCT03307902|BIOLOGICAL|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
219491915|NCT03307902|BIOLOGICAL|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
218871745|NCT07088367|BEHAVIORAL|Virtual Reality Videos|"This intervention involves the use of a virtual reality headset to present immersive 360-degree calming nature videos to participants. It is distinct from other video- or relaxation-based interventions in several key ways:~Delivery via VR headset: Unlike standard video-based relaxation interventions presented on screens or tablets, this method delivers video content in a fully immersive virtual reality environment, which blocks out external visual and auditory stimuli from the unit.~Non-guided and passive exposure: The video group receives no audio-guided instruction or meditation scripting, making it a purely visual and passive exposure intervention.~Cultural relevance and visual neutrality: The nature videos are non-verbal, visually neutral, and free of religious, symbolic, or emotionally provocative imagery, allowing them to be suitable for a diverse patient population."
219491916|NCT04947059|DRUG|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
219491917|NCT04947059|DRUG|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
219491918|NCT02399059|PROCEDURE|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
219491919|NCT02399059|PROCEDURE|Normal saline lavage|Peritoneal irrigation with normal saline
219491920|NCT06232759|DRUG|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
219491921|NCT02120859|DEVICE|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
219491922|NCT02120859|DEVICE|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
219491923|NCT05931952|OTHER|Buteyko breathing technique|"Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
219491924|NCT05931952|OTHER|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
219601691|NCT05832177|BEHAVIORAL|Integrate Cancer 101 into the Stakeholders Programs|This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.
218871746|NCT07089420|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
218871747|NCT07088744|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. All patients scheduled for endoscopic submucosal dissection (ESD) of gastric lesions must undergo probe-based confocal laser endomicroscopy (pCLE) prior to the ESD procedure.
218871748|NCT07088744|DIAGNOSTIC_TEST|Pathological biopsy|A pathological biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from the body for microscopic examination. It is a crucial diagnostic tool used to identify diseases, particularly cancer, infections, inflammatory conditions, and other abnormalities.
219021951|NCT03199300|DRUG|Anthracyclines|Chemotherapy regimen containing anthracyclines.
219021952|NCT03199300|DRUG|Trastuzumab|Systemic treatment including trastuzumab.
219021953|NCT03199300|DRUG|Cisplatin|Chemotherapy including cisplatin.
219491925|NCT02793375|DRUG|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
219491926|NCT02793375|DRUG|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
219491927|NCT05558852|PROCEDURE|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
219021954|NCT03199300|DRUG|Bleomycin|Chemotherapy including bleomycin.
219021955|NCT02258100|OTHER|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
219199990|NCT06856070|OTHER|(Group A: Preformed Bioflx crown)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2\. The tooth will be prepared similarly to stainless steel crowns (SSCs):~* Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done.~  3.All sharp line angles and corners will be smoothed to ensure proper crown fit.~  4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin.~  5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~  6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked,"
219491928|NCT00593099|DRUG|Bupropion|BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
219491929|NCT00593099|DRUG|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
219491930|NCT06045832|DEVICE|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
219491931|NCT06045832|DEVICE|Water|Water
219491932|NCT03220152|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
219491933|NCT02149537|DRUG|hydroxyurea|
219491934|NCT02878811|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
219491935|NCT03719261|DRUG|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
219601692|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for Lay Community Members|A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
219601693|NCT06230224|DRUG|Odronextamab|Administered by intravenous (IV) infusion
219601694|NCT06230224|DRUG|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
219491936|NCT03719261|DRUG|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
219491937|NCT00423228|DRUG|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
219601695|NCT06230224|DRUG|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
219601696|NCT06230224|DRUG|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
219601697|NCT06230224|DRUG|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
219601698|NCT06230224|DRUG|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
219601699|NCT06230224|DRUG|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
219601700|NCT06230224|DRUG|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
219601701|NCT06230224|DRUG|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
219601702|NCT03418844|OTHER|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
219021956|NCT04229004|DRUG|Gemcitabine combined with nab-paclitaxel|"Arm is closed to recruitment.~Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
219491938|NCT00423228|DRUG|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
219491939|NCT06398561|BEHAVIORAL|Active Patient Program|"The Active Patient Program is a peer-leader intervention that consist of training patients with a chronic disease or mental health illness for improve the symptoms of that pathology.~Training is carried out in groups of about 12-15 patients and usually has 2 patient trainers. These patients lead the sessions through the theoretical content they have integrated, motivation, group leadership, exchange of experiences and promotion of communication. In this way they favor problem-solving by the patients who attend the sessions, thus improving their self-management and self-efficacy.~In the group formed by patients who are trainers and patients who benefit from the sessions, a climate of trust is created that favors the expression of emotions on both sides, empathy and assertiveness. In addition to fostering socio-affective bonds between the participants and increasing perceived social and emotional support."
219601703|NCT03418844|DIAGNOSTIC_TEST|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"
219601704|NCT04524000|DRUG|Alpelisib|"\[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
219601705|NCT04524000|DRUG|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
219601706|NCT06400238|PROCEDURE|Biopsy Procedure|Undergo biopsy
219601707|NCT06400238|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219601708|NCT06400238|PROCEDURE|Computed Tomography|Undergo CT scan
219601709|NCT06400238|DRUG|Copanlisib|Given IV
219021957|NCT04229004|DRUG|Dose -mFOLFIRINOX|"Arm is closed to recruitment.~The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
219601710|NCT06400238|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219601711|NCT05861986|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
219601712|NCT06106295|DRUG|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
219601713|NCT04936854|DRUG|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
219601714|NCT04936854|DRUG|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
219491940|NCT03076528|OTHER|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
219491941|NCT03076528|OTHER|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
219491942|NCT02105597|OTHER|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
219491943|NCT05384197|DRUG|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
219491944|NCT05384197|DRUG|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
219491945|NCT05348707|OTHER|epidemiology|To review medical records to describe diagnosis and severity of the disease.
219491946|NCT05348707|OTHER|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
219491947|NCT00554177|DRUG|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
219491948|NCT00554177|DRUG|Placebo|2 doses of 1200mg, administered 2-3 days apart
219601715|NCT04034927|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219601716|NCT04034927|PROCEDURE|Computed Tomography|Undergo CT
219601717|NCT04034927|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219601718|NCT04034927|DRUG|Olaparib|Given PO
219601719|NCT04034927|BIOLOGICAL|Tremelimumab|Given IV
219601720|NCT05660408|BIOLOGICAL|pp65 RNA LP (DP1)|This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)
219601721|NCT05660408|BIOLOGICAL|pp65/tumor mRNA RNA-LP (DP2)|This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.
219601722|NCT05660408|PROCEDURE|Surgical Biopsy/Resection|Eligible participants will be enrolled and undergo sterile collection of tumor material .
219601723|NCT05698563|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
219601724|NCT05698563|DIAGNOSTIC_TEST|Ultrasound|Ultrasound scan of the feet
219491949|NCT05706454|DRUG|Ramatroban|"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."
219491950|NCT05706454|DRUG|Placebo|Matching placebo will be administered orally twice a day
219601725|NCT05698563|DRUG|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
219601726|NCT05698563|OTHER|Clinical foot evaluation|An examination of the feet
219491951|NCT00386854|BEHAVIORAL|physical training|
219491952|NCT02770053|PROCEDURE|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
219491953|NCT04281654|OTHER|Active Social Conversation|Active Social Conversation
219491954|NCT04184154|OTHER|Questionnaires|The self-questionnaire of 104 questions collected personal and socio-demographics data, global and sexual quality of life characteristics (European Organisation for Research and Treatment of Cancer \[EORTC\] quality of life questionnaires: QLQ-C30 and gynecologic and cervical cancer specific-questionnaire QLQ-CX24), vaginal dilatators and moisturizers use, and barriers and facilitators of their use. Clinical data were extracted from the patients' medical files. Vaginal stenosis was evaluated at 6 weeks after the end of brachytherapy and after 1-year follow-up by in-town gynecologists or in our Institute, and censored in case of complete vaginal obliteration
219491955|NCT06141954|DEVICE|Ultrasound waves therapy|Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
219601727|NCT05698563|OTHER|Picture of the feet|To evaluate the presence of V-sign/spreading toes
219601728|NCT06730217|DEVICE|Intervention : mechanical insufflator|Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).
219601729|NCT06730217|OTHER|Control : standard care|Participants randomized to the control group will receive standard care
219601730|NCT03573648|DRUG|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
219491956|NCT06141954|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
219601731|NCT03573648|DRUG|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~\- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
219601732|NCT03573648|DRUG|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
219601733|NCT06531434|COMBINATION_PRODUCT|"Docetaxel, Cisplatin, fluorouracil, Radiation"|Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.
219601734|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
219601735|NCT06432036|PROCEDURE|Angiogram|Undergo angiogram
219601736|NCT06432036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219601737|NCT06432036|PROCEDURE|Computed Tomography|Undergo CT scan
219601738|NCT06432036|RADIATION|Radioembolization|Undergo radioembolization
219601739|NCT06432036|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
219021958|NCT04229004|DRUG|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
219491957|NCT04064528|DIETARY_SUPPLEMENT|Amino Acids|10 g bolus of essential amino acids
219021959|NCT04229004|DRUG|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
219491958|NCT05558605|DIAGNOSTIC_TEST|AI-guided echo|AI-guided echocardiography
219491959|NCT05558605|DIAGNOSTIC_TEST|Standard echo|Standard echocardiography
219491960|NCT06538805|OTHER|Minimal invasive management of dental caries|Minimal invasive management of dental caries among dentists
219491961|NCT01042002|BEHAVIORAL|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
219491962|NCT00788723|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
219491963|NCT01254994|DRUG|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
219601740|NCT06432036|OTHER|Survey Administration|Ancillary study
219601741|NCT06432036|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
219601742|NCT04108156|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
219601743|NCT04108156|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
219601744|NCT04108156|DRUG|Ranibizumab refill exchange|Will be administered as per the schedule described in individual arm.
219601745|NCT05522660|RADIATION|Stereotactic radiosurgery|"Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of \>20 mm or for \>4 brain metastases.~For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation."
219601746|NCT05522660|DRUG|Immune checkpoint inhibitor|"Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of~  * an approved immune-checkpoint inhibition combination therapy (cohort 1a) or~ * an approved immune-checkpoint inhibition monotherapy (cohort 1b).~* For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).~* For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy)."
219601747|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.
219601748|NCT06075745|DRUG|CMV-MVA Triplex|The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
219601749|NCT06075745|DRUG|Placebo for CMV-MVA Triplex|Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
219491964|NCT01254994|DRUG|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
219491965|NCT01289431|DRUG|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
219601750|NCT03823742|OTHER|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
219601751|NCT03823742|OTHER|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
219601752|NCT03996447|DRUG|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
219601753|NCT03996447|DRUG|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
219601754|NCT06148623|DEVICE|Philips FAST SpO2 with Masimo Pulse Oximetry Sensors|Noninvasive pulse oximeter
218871749|NCT07089810|DEVICE|Digital intervention has a high blood pressure in the high-risk population of stroke Study on the effect of stress on self-management behavior of patients|"Intervention group (n = 60) : Interventions were developed for five behavioral problems, as follows:~1. Lack of knowledge about hypertension~   \- Measures: APP push knowledge (risk factors, medication, lifestyle, etc.), blood pressure monitoring teaching, monthly online lectures, regular feedback and encouragement of blood pressure data.~2. Poor medication compliance~   \- Measures: Medication reminders were set by the APP, and repeated and recorded when no medication was taken.~3. Obesity/overweight Targets: BMI 18.5-23.9, waist circumference \<90cm in men and \<85cm in women Interventions: promoting knowledge about the dangers of obesity, daily exercise reminders, setting weight loss goals and encouraging weight loss.~4. A high-sodium diet Target: \<6g salt per day~   \- Measures: Release of low-salt dietary guidelines (graphic and text) and distribution of salt-limiting spoons (1-2 grams).~5. Drinking too much Target: ≤25g alcohol per day for men and ≤15g for women; Weekly male ≤140g, female ≤80"
219491966|NCT01289431|DRUG|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
219491967|NCT04175873|OTHER|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
219491968|NCT03367286|OTHER|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
219491969|NCT03125824|DEVICE|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
219491970|NCT02069834|DRUG|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
219491971|NCT02069834|DRUG|Arm 2 (control)|Continuation of existing HAART at the time of randomization
219491972|NCT03682627|PROCEDURE|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
219601755|NCT04269551|DRUG|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
219601756|NCT00397111|DEVICE|7T Magnetic Resonance Imaging scanner|Non-significant risk device used for brain imaging
218871750|NCT07089381|DIETARY_SUPPLEMENT|Resveratrol 1 gm.|59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.
218871751|NCT07089381|DRUG|Methotrexate|59 patients will receive the standard treatment for management of RA for 3 months
219601757|NCT03814252|DEVICE|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
219601758|NCT04846517|DEVICE|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
219601759|NCT04648449|OTHER|Artificial intelligence on emergency calls|AI listens to all calls to Bergen EMCC, detecting calls regarding possible stroke.
219601760|NCT05664594|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
219601761|NCT05533671|PROCEDURE|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
219601762|NCT05533671|PROCEDURE|Non-operative group|Physical therapy by following a specific regimen.
219601763|NCT06045221|DRUG|Orforglipron|Administered orally
219491973|NCT03682627|PROCEDURE|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
219491974|NCT01432782|DRUG|Placebo|Saline 4 ml
219491975|NCT01432782|DRUG|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
219491976|NCT05244174|DEVICE|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
219491977|NCT03665480|DRUG|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
219601764|NCT06045221|DRUG|Semaglutide|Administered orally
219601765|NCT06585488|DRUG|BGB-53038|Administered orally
219491978|NCT06568640|PROCEDURE|Superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
219601766|NCT06585488|DRUG|Tislelizumab|administered by intravenous infusion
219601767|NCT06585488|DRUG|Cetuximab|administered by intravenous infusion
219601768|NCT05069558|DEVICE|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
219601769|NCT05069558|DEVICE|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
219601770|NCT03933631|DRUG|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
218871752|NCT07089290|BEHAVIORAL|Nurse-led Telehealth Intervention|"Control group: Patients will receive standard care as per Nepal government guidelines. This includes lifestyle counseling (salt reduction, physical activity, avoiding tobacco/alcohol), antihypertensive medications based on BP and risk profile, and follow-up every 1-3 months. BP will be recorded at 3 and 6 months by research nurses.~Intervention group: Nurse-led telehealth care will be delivered over six months using the Intervention Mapping approach. Participants will receive initial orientation, a BP diary, and instructions to check BP at least twice weekly at nearby centers. Nurses will train local staff, and conduct teleconsultations via Viber/WhatsApp every 15 days (months 1-2) and monthly (months 3-6) covering BP review, adherence, and lifestyle advice. If \<75% of BP readings meet target, nurses will consult physicians for medication adjustments. Emergency protocols will be in place. Data will be collected at baseline, 3, and 6 months."
218871753|NCT07087808|BEHAVIORAL|Digital Wellness Nurse - FIT Families|Participants in this arm will receive a digital adaptation of FIT families, an evidenced based treatment for adolescent obesity. The social support condition will add one additional participant to the treatment group (i.e., caregiver, youth, community health worker, and social support person). The social support person's role is to review the daily engagement reports and completion of weekly goals and provide encouragement via peer-to-peer messaging in the DWN app. The social support person does not communicate with the CHW or participate in any treatment sessions. This person is selected by the family at the beginning of the study and provides reinforcement to the family through encouraging messages.
218871754|NCT07089212|BEHAVIORAL|Phased Rehabilitation Training|"Rehabilitation is divided into three postoperative phases:~Early Phase (Weeks 1-2): Focus on edema control, quadriceps activation, and passive/active-assisted range of motion (ROM) exercises.~Intermediate Phase (Weeks 3-6): Progress to strength training, endurance exercises, and early proprioception drills.~Late Phase (Weeks 7-12): Advance to functional training , dynamic proprioception, and full ROM restoration."
218871755|NCT07089212|DEVICE|Cyclic Compression Cryotherapy|"Initiation: Begin within 24 hours postoperatively. Each session lasts 20-30 minutes, administered 2-3 times daily.~Procedure: Apply a cryotherapy wrap circumferentially around the knee using a pneumatic compression device, with precise control of pressure and temperature.~Pressure Settings: Start at Level I-II (low-to-moderate) and adjust incrementally based on patient tolerance.~Temperature Control: Maintain at 10-12°C."
219601771|NCT03933631|DRUG|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
219601772|NCT03933631|DRUG|Ofloxacin|Ofloxacin Drops
219601773|NCT04969978|BEHAVIORAL|Enhanced Academic Detailing|"* Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~* Follow-up booster sessions~* Monthly performance audit and feedback"
219601774|NCT04969978|OTHER|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
219021960|NCT04229004|DRUG|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
219021961|NCT01627821|DEVICE|Jarvik 2000 VAS|Jarvik 2000 LVAD
219021962|NCT01627821|DEVICE|HeartMate II|HeartMate II LVAD
219021963|NCT03625921|BEHAVIORAL|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
219491979|NCT06418360|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
219491980|NCT06418360|DEVICE|conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack|10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
219491981|NCT05194280|PROCEDURE|Robotic surgery|Robotic-assisted donornephrectomy
219601775|NCT04458922|DRUG|Atezolizumab|Given IV
219601776|NCT04458922|PROCEDURE|Biopsy Procedure|Correlative studies
219601777|NCT04458922|PROCEDURE|Biospecimen Collection|Correlative studies
219601778|NCT04458922|PROCEDURE|Computed Tomography|Undergo CT scan
219601779|NCT03852147|PROCEDURE|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
219601780|NCT04838223|OTHER|Hyperosmolar Response|A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.
219491982|NCT00337129|DRUG|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
219021964|NCT03625921|BEHAVIORAL|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
219021965|NCT00006101|DRUG|eflornithine|Take 500mg of DFMO per day for 12 months
219021966|NCT00006101|DRUG|Placebo|Take placebo per day for 12 months
219491983|NCT05232565|PROCEDURE|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
219491984|NCT06332365|COMBINATION_PRODUCT|Acetonide triamcinolone 0.2% +hyaluronicacid 1%|topical application cream form twice a day for 4 weeks
219491985|NCT06332365|DRUG|Corticoid Acetonide triamcinolone 0.2%|topical application cream form twice a day for 4 weeks
219491986|NCT06332365|DRUG|Hyaluronic acid 1%|topical application cream form twice a day for 4 weeks
219491987|NCT03434626|BEHAVIORAL|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
219491988|NCT03434626|OTHER|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
219491989|NCT03141931|DIETARY_SUPPLEMENT|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
219491990|NCT03141931|DIETARY_SUPPLEMENT|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
219491991|NCT02559531|DEVICE|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
219491992|NCT03801395|OTHER|There is no intervention|No intervention
219491993|NCT06191510|PROCEDURE|Bio-Oss Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
218871756|NCT07089212|BEHAVIORAL|Conventional rehabilitation treatment.|The control group underwent a 12-week conventional rehabilitation program, which primarily included muscle strength training, endurance training, proprioception training, and joint range of motion (ROM) exercises. Assessments were conducted at baseline (before treatment), as well as at 2 weeks, 6 weeks, and 12 weeks post-treatment. The evaluated outcomes included knee joint ROM, muscle strength, knee function, pain levels, and activities of daily living (ADL).
218871757|NCT07087327|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 52 weeks
218871758|NCT07087327|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 52 weeks
218871759|NCT07088926|BIOLOGICAL|AZD0292|AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
218871760|NCT07088926|OTHER|Placebo|Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
218871761|NCT07088445|DRUG|Faricimab|Intravitreal injection of 6mg famotizumab into the vitreous cavity of patients with non primary wet age-related macular degeneration
218871762|NCT07088198|PROCEDURE|Joshi's step|Patients will undergo dorsal onlay buccal mucosal graft urethroplasty with Joshi's step
218871763|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
218871764|NCT04676867|OTHER|Placebo|Placebo Tablets
218871765|NCT07087756|PROCEDURE|laparoscopic ovarian suspension|Suspension of the ovary during laparoscopy for endometriosis
218871766|NCT07088952|PROCEDURE|Trigger at smaller folicular size|Trigger indicated at folicular diameter smaller than standard clinical practice, from 13mm to 16.9mm
218871767|NCT07089199|DRUG|neoadjuvant therapy|tislelizumab （200mg，iv, q3w） + Anlotinib （10mg, orally, D1-14, q3w）+nab-paclitaxel（260mg/m2，q3w）3-4cycle
218871768|NCT07089199|PROCEDURE|Surgery|Surgery should be performed 4 to 6 weeks after the last neoadjuvant therapy (at least 4 weeks after the end of anlotinib treatment).
218871769|NCT07089199|DRUG|Adjuvant therapy|Tislelizumab: 200mg, iv, Q3W, 1year at most(including preoperative treatment medication, a total of 17 cycles).
218871770|NCT07088328|DRUG|Pentoxifylline|Intravenous administration for 3 days
219021967|NCT02167607|DIETARY_SUPPLEMENT|Active Comparator|Purple Potato
219021968|NCT02167607|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Comparator
219021969|NCT04949165|DIETARY_SUPPLEMENT|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
219021970|NCT01958775|DRUG|GLP-2|single subcutaneous dose of 1500mcg
219021971|NCT01958775|DRUG|Placebo|
219021972|NCT06007599|PROCEDURE|Skin closure using skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures with skin adhesive
219021973|NCT06007599|PROCEDURE|Skin closure without skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures without skin adhesive
219491994|NCT06191510|PROCEDURE|Mucograft Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
219491995|NCT00802269|PROCEDURE|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
219491996|NCT04809038|OTHER|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
219491997|NCT04809038|OTHER|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor\_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
219601781|NCT04838223|OTHER|Proparacaine Challenge Test|A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).
218871771|NCT07088328|OTHER|placebo distilled water|Intravenous administration for 3 days
219491998|NCT04809038|OTHER|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
219601782|NCT04838223|OTHER|Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers|The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.
219601783|NCT04838223|OTHER|Ocular Pain Assessment Survey (OPAS)|Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain \[18\]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.
218871772|NCT07089472|BEHAVIORAL|Dry Needling Therapy|Dry needling will be applied along the lateral femoral cutaneous nerve (LFCN) pathway, targeting muscles such as piriformis, iliacus, tensor fascia latae, vastus lateralis, and sartorius. Sterile solid filiform needles (0.25x30mm and 0.30x50mm) will be inserted for 90 seconds to 2 minutes using a cone technique and retained in situ for 15 minutes. Sessions will occur twice weekly for 8 weeks, with standard physiotherapy (hot pack, EMS, and guided stretches) administered alongside.
218871773|NCT07089472|BEHAVIORAL|Cyriax Technique|"The Cyriax technique involves deep friction massage and mobilization of the lateral femoral cutaneous nerve (LFCN) near the anterior superior iliac spine (ASIS). Using the pinch and roll and deep pressure technique, therapists will apply sustained pressure along the nerve path in 3-5 repetitions per session, holding each for 10-15 seconds. Sessions will occur twice weekly for 8 weeks, alongside standard physiotherapy modalities and exercises."
218871774|NCT06087263|DRUG|Regorafenib|Given by PO
218871775|NCT07088094|PROCEDURE|bone-patellar tendon-bone or meniscus allograft transplantation techniques|This clinical study follows an interventional design, focusing on the evaluation of bone-patellar tendon-bone and quasi-anatomical meniscus allograft transplantation techniques。
218871776|NCT07088094|PROCEDURE|Quasi-anatomical meniscus allograft transplantation|Quasi-anatomical meniscus allograft transplantation
218871777|NCT05930145|DEVICE|Double stentriever|Double stentriever technique
219021974|NCT04999462|OTHER|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
219021975|NCT04999462|OTHER|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
218871778|NCT05930145|DEVICE|Single stentriever|Single stentriever technique
219021976|NCT04999462|OTHER|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
219021977|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions|CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.
219021978|NCT04245423|BEHAVIORAL|Augmented Usual Care|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.
219021979|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists|This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
219491999|NCT01327638|DRUG|etoricoxib|Patients with SpA/AS who took etoricoxib
219492000|NCT01327638|DRUG|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
219492001|NCT01327638|DRUG|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
219492002|NCT05828433|OTHER|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
219601784|NCT04838223|OTHER|Visual Analogue Questionnaire|Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.
219601785|NCT04763343|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
219601786|NCT04763343|DRUG|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
219492003|NCT05828433|OTHER|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
218871779|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
219492004|NCT02557568|OTHER|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
219492005|NCT03990246|OTHER|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
219601787|NCT04763343|BEHAVIORAL|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
219601788|NCT06120504|DRUG|PF-08046045|Given into the vein (IV; intravenously)
219601789|NCT05102747|RADIATION|Hypofractionated SRT (stereotactic radiotherapy)|3\*10Gy over 1 week
219601790|NCT05102747|RADIATION|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
219601791|NCT06176170|DEVICE|VividWhite Glaucoma Implant (VW-51)|Subconjunctival surgical implantation of the VW-51 implant in the study eye.
219601792|NCT05004116|DRUG|Repotrectinib|TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
219601793|NCT05004116|DRUG|Irinotecan and temozolomide|Irinotecan and temozolomide will be given as per institutional standard.
218871780|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
218871781|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
218871782|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
218871783|NCT07088172|PROCEDURE|free gingival grafts during the second stage of implant surgery|Free gingival graft surgery performed simultaneously with implant stage II, followed by upper restoration 6-8 weeks later.
218871784|NCT07088172|PROCEDURE|free gingival grafts prior to the implantaion|Free gingival graft surgery performed 6-8 weeks before implant placement
218871785|NCT07089589|DRUG|Preoperative Statin Use|Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol.
218871786|NCT07089615|DEVICE|Capsule swallow|Participant will swallow the investigational device
218871787|NCT07088003|BEHAVIORAL|Yoga as Mindful Movement|YMM is an 8-week hybrid (in-person and virtual) school-based mindful yoga program (modified from its original 10-week, in-person design due to complications of COVID-19) informed by the teachings of Radiant Child Yoga. It was designed to teach students about self regulation through the integration of movement, breath, and present-moment awareness. It was delivered in the form of three, 30-minute YMM sessions each week by the same instructor-an individual with training and experience as an occupational therapist and yoga teacher through the Yoga Alliance and Radiant Child Yoga.
218871788|NCT07088003|BEHAVIORAL|Adapted Physical Education|Adapted PE took place daily (Monday-Friday) for one hour and consisted of lessons on movement skills such as catching, throwing, aiming, running, jumping, skating, and dancing through various activities and games.
219021980|NCT05544565|DRUG|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
219601794|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
218871789|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
219021981|NCT05544565|DRUG|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
219021982|NCT05544565|PROCEDURE|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D10 or 17 and D31 or D38), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
219021983|NCT05544565|PROCEDURE|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
219021984|NCT00934739|DRUG|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
219021985|NCT00934739|DRUG|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
219492006|NCT03990246|OTHER|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
219492007|NCT03990246|OTHER|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
219492008|NCT03990246|OTHER|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
219492009|NCT00893867|DRUG|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
219492010|NCT00893867|DRUG|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
219492011|NCT03904667|OTHER|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
219492012|NCT00563524|DRUG|ILV-094|SC and IV administration on days 1, 14, 28, and 42
219492013|NCT03608696|DRUG|Buprenorphine|buprenorphine 0.075 mg/ml solution
219492014|NCT05478486|DRUG|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
219601795|NCT06139497|BEHAVIORAL|Physical activity programme|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. The sessions are supervised by a coach at least once a week during the first 6 months then monthly. The other session of the PA programme is performed at home and the overall weekly PA is reviewed with the coach at the end of the supervised session.
219492015|NCT01866995|DRUG|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
219492016|NCT01866995|OTHER|standard prostatostasis therapy|
219601796|NCT06139497|BEHAVIORAL|Home-based physical activity|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. Participants have to perform the exercise programme at home exclusively. They are called every week by a research assistant to review the activities performed, collect information on their adherence and perception on the programme.
219021986|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
219021987|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
218871790|NCT07088809|PROCEDURE|Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by nanocrystale hydroxyapatite was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
219021988|NCT04309305|OTHER|No Intervention|Testing Only
219021989|NCT06320132|OTHER|Treatment of spontaneous intracranial hemorrhage|Data collection of therapeutic approach, including radiological, medical, surgical therapies.
219021990|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
219021991|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
219021992|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
219021993|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
219021994|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
219492017|NCT01230502|DRUG|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
219492018|NCT01230502|OTHER|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
219492019|NCT01230502|OTHER|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
219492020|NCT05614479|OTHER|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
219492021|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
219492022|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
219492023|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
219492024|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
219492025|NCT04767542|DRUG|Intravenous Infusion|analgesic
219492026|NCT04767542|PROCEDURE|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
219492027|NCT02476500|PROCEDURE|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
219492028|NCT00102388|DRUG|vildagliptin|
219492029|NCT00102388|DRUG|Gliclazide|
219492030|NCT00817778|DRUG|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
219492031|NCT00817778|DRUG|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
219492032|NCT05424107|OTHER|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
219492033|NCT04780659|BIOLOGICAL|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
219492034|NCT06542328|DEVICE|ERI CVX-air portable X-ray system|investigational device
219492035|NCT06542328|DEVICE|Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)|The commercially available comparator equipment used for pulmonology.
219492036|NCT06542328|DEVICE|Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)|The commercially available comparator equipment used for Orthopaedic.
219492037|NCT00253461|PROCEDURE|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
219492038|NCT00253461|PROCEDURE|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
219492039|NCT00253461|RADIATION|11C topotecan|Phase I and II: IV over 10 minutes
219492040|NCT00253461|RADIATION|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
219492041|NCT05842577|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
219492042|NCT05842577|OTHER|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
219492043|NCT01669044|DRUG|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
219492044|NCT01669044|DRUG|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
219492045|NCT03039582|DIAGNOSTIC_TEST|Bidigital palpation|palpation of the anovaginal distance with two fingers
219492046|NCT03039582|DIAGNOSTIC_TEST|Perineal ultrasound|ultrasound measurement of the anovaginal distance
219492047|NCT00619086|DRUG|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
219492048|NCT00619086|DRUG|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
219492049|NCT06079086|DEVICE|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
219492050|NCT02866019|DEVICE|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
219492051|NCT00002484|RADIATION|radiation therapy|
219492052|NCT00823459|DRUG|Everolimus|Given PO
219492053|NCT00823459|OTHER|Archival Tissue Analysis|Correlative studies
219492054|NCT02530632|DRUG|Propofol|General anesthesia maintained with intravenous propofol infusion
219492055|NCT02530632|DRUG|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
219492056|NCT02530632|PROCEDURE|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
219492057|NCT02855632|DRUG|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
219492058|NCT02855632|DRUG|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
219492059|NCT02855632|DRUG|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
219492060|NCT02855632|OTHER|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
219492061|NCT02360397|DRUG|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
219492062|NCT05801354|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
219492063|NCT05801354|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
219601797|NCT04953637|OTHER|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
219601798|NCT06230042|OTHER|Types of catheters|One type of catheters were used for patients
219492064|NCT05344066|OTHER|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
219492065|NCT05344066|OTHER|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
219492066|NCT01499927|OTHER|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
219492067|NCT06141382|OTHER|English Langugae-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
219492068|NCT06141382|OTHER|English Language-Narrative intervention|Narrative intervention with the help of only pictures in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administred thrice a week in 45-minute long session for 6 weeks.
219021995|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
219021996|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
219021997|NCT04625205|BIOLOGICAL|NEO-PTC-01|Administered via intravenous infusion.
219021998|NCT04625205|DRUG|IL-2|Administered via intravenous infusion.
219021999|NCT04625205|DRUG|PD-1 Inhibitors|Administered via intravenous infusion.
219492069|NCT06141382|OTHER|Urdu Langusge-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
219601799|NCT02934399|OTHER|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
219601800|NCT03674736|DIETARY_SUPPLEMENT|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
219601801|NCT05203783|OTHER|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension"
219601802|NCT05203783|OTHER|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
219601803|NCT04756661|DRUG|Carbetocin|100 mcg of Carbetocin intravenous injection
219601804|NCT04756661|DRUG|Oxytocin|10 IU oxytocin IV drip
218871791|NCT07088809|PROCEDURE|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by Nanocrystalline tricalcium was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
218871792|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
218871793|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
218871794|NCT00336635|BIOLOGICAL|cell-culture derived smallpox vaccine|
219022000|NCT04849351|DRUG|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
219492070|NCT06141382|OTHER|Urdu Language-Narrative intervention|Narrative intervention with the help of only pictures in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
219492071|NCT06141382|OTHER|Bilingual-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
219492072|NCT06141382|OTHER|Bilingual-Narrative intervention|Narrative intervention with the help of only pictures in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
219492073|NCT04229316|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
219492074|NCT05415319|BEHAVIORAL|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
219492075|NCT03250910|DRUG|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
219492076|NCT03250910|DRUG|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
219492077|NCT01676584|DRUG|RO6811135|single ascending doses sc
219492078|NCT01676584|DRUG|placebo|single doses sc
219492079|NCT01824459|DRUG|S-1|S-1：40\~60mg bid，d1\~14 q3W
219492080|NCT01824459|DRUG|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
219492081|NCT01824459|DRUG|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
219492082|NCT00130000|DRUG|Eculizumab|
219492083|NCT01537549|DRUG|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
219492084|NCT05806333|DIAGNOSTIC_TEST|FAPI PET|Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
219492085|NCT00192751|BEHAVIORAL|Psychoeducational group sessions|
219492086|NCT04396483|PROCEDURE|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
219492087|NCT04396483|PROCEDURE|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
219492088|NCT06092645|DRUG|surufatinib plus cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
219492089|NCT01063725|DIETARY_SUPPLEMENT|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
219492090|NCT01063725|OTHER|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
219492091|NCT01208922|DRUG|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
219492092|NCT01208922|DRUG|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
219492093|NCT01400672|BIOLOGICAL|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
219492094|NCT01400672|DRUG|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
219492095|NCT01400672|RADIATION|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
219492096|NCT02880163|DEVICE|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
219492097|NCT04519203|DEVICE|SPI|Either standard monitoring alone or added with SPI
219492098|NCT04519203|DEVICE|Standard|Standard monitoring alone
219492099|NCT05526274|DIAGNOSTIC_TEST|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
219492100|NCT00955760|DRUG|Neramexane|Drug-Drug Interaction Study
219492101|NCT01286207|DRUG|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
219492102|NCT01286207|DRUG|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
219492103|NCT01286207|DRUG|Standard Care|Active standard care
219492104|NCT01383954|DRUG|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
219492105|NCT05980351|OTHER|exercise|The children will receive exercise program(stretching exercise,range of motion exercise and isometric exercise)
219492106|NCT00450177|DRUG|Ferrous Sulfate|Iron group
219601805|NCT04756661|DRUG|Misoprostol|400 mcg rectal
219601806|NCT02166255|BIOLOGICAL|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
219492107|NCT00450177|DRUG|Placebo Oral Tablet|Placebo group
219022001|NCT06335810|BEHAVIORAL|Social Network Intervention|Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.
219492108|NCT05974865|BEHAVIORAL|Healthy Babies and Healthy Moms|
219492109|NCT05974865|BEHAVIORAL|Baby Basics Prenatal Guide|
219492110|NCT01185730|PROCEDURE|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
219492111|NCT01752322|DRUG|Lidocaine 5% medicated plaster|
219492112|NCT01752322|DRUG|Placebo plaster|
219492113|NCT00716586|DRUG|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
219492114|NCT02613416|DRUG|Denosumab|monthly subcutaneous injections
219492115|NCT02287506|OTHER|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
219492116|NCT05620459|PROCEDURE|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
219601807|NCT02166255|OTHER|laboratory biomarker analysis|Correlative studies
219601808|NCT03164876|DRUG|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
219601809|NCT03164876|DRUG|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
219601810|NCT01195610|BEHAVIORAL|Dietary intervention|Instruction to diet for 6 month
219601811|NCT04363580|OTHER|Auditory processing disorder screening tool|"Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~* Reference pattern and portrait of the child.~* Auditory history.~* History of speech and language development.~* School history.~The teacher questionnaire has seven sections:~* Portrait of the child.~* Reading and writing.~* Speaking.~* Mathematics.~* Music.~* Memory.~* Listening skills and understanding:~  * Concentration and organization.~ * Environment.~Mini-battery of tests:~* Dichotic Numeric Listening Test.~* Identification test of 15 patterns of frequency-varying sounds at each ear.~* Test of 10 monosyllables in noise per ear.~* Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing)."
219022002|NCT06335810|BEHAVIORAL|Individual Lifestyle Intervention|The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.
219492117|NCT02706600|BEHAVIORAL|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
219492118|NCT02706600|BEHAVIORAL|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
219492119|NCT01173588|OTHER|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
219492120|NCT00303433|DRUG|Namenda|
219492121|NCT03086083|BEHAVIORAL|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
219492122|NCT03086083|BEHAVIORAL|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
219492123|NCT00763269|DRUG|Triclosan, Silicon dioxide, fluoride|Brush twice daily
219492124|NCT00763269|DRUG|Triclosan, fluoride|Brush twice daily
219492125|NCT02279576|DRUG|Pazopanib|Pazopanib 800mg/day continuously administered.
219492126|NCT02279576|DRUG|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
219492127|NCT00133094|DRUG|Simvastin|
219492128|NCT00133094|PROCEDURE|Computer-based decision support technology|
219492129|NCT05932927|BIOLOGICAL|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
219492130|NCT01971229|OTHER|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
219492131|NCT01971229|OTHER|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
219492132|NCT06038266|PROCEDURE|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
219492133|NCT04155957|OTHER|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
219492134|NCT04155957|DEVICE|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
219492135|NCT06701266|DEVICE|Point of Care Test|PoCT as a chairside test, ELISA as a gold standard
219492136|NCT04638725|OTHER|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
219601812|NCT02333058|DRUG|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
219601813|NCT04070261|OTHER|iOS application usability test|user tasks, questionnaires, semi-structured interviews
219601814|NCT04459039|DRUG|1000 mL 0.9% sterile saline|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
219022003|NCT06335810|OTHER|Social Network Member|The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
219022004|NCT03971188|PROCEDURE|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
219022005|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
219022006|NCT01321515|DRUG|famciclovir|500 mg tablet
219022007|NCT02252198|OTHER|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
219022008|NCT03523754|DRUG|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
219022009|NCT03996954|DEVICE|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
219492137|NCT05049304|OTHER|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
219492138|NCT05049304|OTHER|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
219492139|NCT00425516|DRUG|Taxotere|
219492140|NCT00425516|DRUG|5-Fluorouracil|
219492141|NCT00425516|DRUG|Epirubicin|
219492142|NCT00425516|DRUG|Cyclophosphamide|
219492143|NCT06698614|DIAGNOSTIC_TEST|MRI|MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).
219492144|NCT06698614|DIAGNOSTIC_TEST|Blood tests|full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
219492145|NCT06698614|DIAGNOSTIC_TEST|Urine tests|Urine protein, Urine creatinine
218871795|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
218871796|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
218871797|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
218871798|NCT02182271|DRUG|Placebo|
219492146|NCT06698614|DIAGNOSTIC_TEST|Cardiovascular analysis|24 hour blood pressure, arterial stiffness
219492147|NCT03943121|PROCEDURE|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
219022010|NCT03940066|DEVICE|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
219492148|NCT03943121|PROCEDURE|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
219492149|NCT03061279|DEVICE|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
219492150|NCT03061279|DEVICE|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
219492151|NCT02320838|DEVICE|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219492152|NCT02320838|DEVICE|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219492153|NCT02320838|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219492154|NCT02971332|PROCEDURE|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
219492155|NCT00287352|DRUG|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
219022011|NCT03940066|OTHER|No Intervention|No intervention
219022012|NCT05614739|DRUG|LOXO-435|Oral
219022013|NCT05614739|DRUG|Pembrolizumab|IV
219492156|NCT00287352|DRUG|Olanzapine and placebo|Olanzapine continuing as clinically indicated
219492157|NCT06701942|OTHER|Multiple family group intervention therapy|"Overview The intervention will be implemented at designated clinics where adolescents living with HIV/AIDS (ALHIV) and their families currently receive care. These sites will provide the MFG intervention alongside standard care services. All eligible adolescents and their family members who consent to participate will be included in the intervention group.~Program Structure The MFG intervention consists of 16 structured sessions, each running for 90 minutes. Sessions will be scheduled to coincide with clinic days over a 14-week period to maximize accessibility and attendance. Parent peers and community health workers, trained by the research team, will facilitate these group sessions.~Session Format Sessions on the MFGT will begin with introducing participants to one another, the facilitators, and the program curriculum. Subsequent sessions will concentrate on areas such as respectful communication, support, resilience building, problem-solving, conflict resolution, stress management"
219492158|NCT02648399|PROCEDURE|surgery：BCND（bilateral central lymph node dissection）|
219492159|NCT02648399|PROCEDURE|surgery：UCND（unilateral central lymph node dissection）|
219492160|NCT04056299|BIOLOGICAL|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
219492161|NCT04056299|BIOLOGICAL|Placebo powder|Placebo powder provided in capsules
219492162|NCT06538233|DRUG|Buffered articaine|Injecting buffered articaine in maxillary anterior region and evaluate pain response.
219601815|NCT04459039|DRUG|250 mL 0.9% sterile saline|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
219601816|NCT01009814|DRUG|BMS-663068|BMS-663068 will be administered as a tablet formulation
219601817|NCT01009814|DRUG|Ritonavir|Ritonavir will be administered as a capsule.
219601818|NCT00618371|DRUG|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
219601819|NCT01059461|DRUG|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
219601820|NCT00836407|DRUG|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
219022014|NCT05614739|DRUG|enfortumab vedotin|IV
219022015|NCT05414331|OTHER|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
219022016|NCT03706053|DRUG|Midodrine Hydrochloride|Midodrine Hydrochloride, enteral, 10 or 20 mg
219022017|NCT03706053|OTHER|placebo|investigational pharmacy formulated placebo comparator
219022018|NCT02981498|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219601821|NCT00836407|BIOLOGICAL|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
219601822|NCT04328805|DRUG|ibuprofen tablets|oral tablet
219601823|NCT04328805|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
218871799|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
218871800|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
218871801|NCT04334213|DRUG|CKD-501|QD, PO
218871802|NCT04334213|DRUG|D745, D150|QD, PO
218871803|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
218871804|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
218871805|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
218871806|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
218871807|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
218871808|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
218871809|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
218871810|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
218871811|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
218871812|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
218871813|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
218871814|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
218871815|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
218871816|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
218871817|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
219601824|NCT04140500|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
219601825|NCT04285281|DRUG|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
219601826|NCT04285281|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
219601827|NCT01625988|DRUG|LY2951742|
219601828|NCT01625988|DRUG|Placebo|
219601829|NCT02441725|OTHER|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
219601830|NCT00738257|DRUG|Pamidronate|
219601831|NCT01207895|DEVICE|PET imaging with [18F]-FLT|Up to three \[18F\]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
219601832|NCT01207895|DRUG|[18F]-fluorodeoxythymidine|\[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
219601833|NCT00195455|DRUG|Trimegestone|
219601834|NCT00195455|DRUG|17b Estradiol|
219601835|NCT02370524|DRUG|[18F]T807|All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
219601836|NCT01644617|DRUG|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
219601837|NCT01644617|DRUG|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
219601838|NCT01644617|DRUG|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
219492163|NCT06538233|DRUG|Non buffered articaine|Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
219492164|NCT05588375|BEHAVIORAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
219492165|NCT05021588|PROCEDURE|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
219492166|NCT03355807|DRUG|Magnesium|The magnesium group (group Mg, n \_ 40) received an additional infusion of MgSO4
219492167|NCT01089985|DRUG|Autologous serum eyedrops|3 times a day for the duration of the study
219492168|NCT05305378|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
219492169|NCT01219088|DRUG|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
219492170|NCT04141137|DEVICE|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
219492171|NCT01079078|DRUG|Acetaminophen|
219492172|NCT00305071|DRUG|compound cranberry extract tablet|
219492173|NCT05668715|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
219492174|NCT05699811|BIOLOGICAL|MSC-IFNα|MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks
219492175|NCT05699811|DRUG|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
219492176|NCT05699811|DRUG|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
219492177|NCT05699811|DRUG|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
219492178|NCT04325061|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
219492179|NCT03405909|DIAGNOSTIC_TEST|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
219492180|NCT03405909|DIAGNOSTIC_TEST|MRI|CE-MRI following standardized protocol
219492181|NCT03405909|DIAGNOSTIC_TEST|Histology|diagnostic liver biopsy
219492182|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
219492183|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
219492184|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
219492185|NCT05597163|DRUG|low concentration atropine (0.01%)|0.01% atropine eye drop
219492186|NCT05597163|DRUG|low concentration atropine (0.025%)|0.025% atropine eye drop
219492187|NCT05597163|DRUG|low concentration atropine (0.05%)|0.05% atropine eye drop
219492188|NCT05597163|DRUG|Placebo|Placebo eye drop
219492189|NCT01398982|DRUG|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
219022019|NCT02981498|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
219492190|NCT01398982|DRUG|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
219492191|NCT03174925|DEVICE|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
219492192|NCT02235337|DRUG|Riboflavin 400mg daily|
219492193|NCT03840642|BEHAVIORAL|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
218871818|NCT01476631|BEHAVIORAL|Walking|"* 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
219022020|NCT00612924|DEVICE|Anaconda Stent Graft System|Endovascular device
219022021|NCT00612924|DEVICE|Anaconda ONE-LOK Stent Graft System|Endovascular device
219492194|NCT03840642|BEHAVIORAL|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
219492195|NCT04368182|BIOLOGICAL|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
219492196|NCT03380182|OTHER|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
219492197|NCT03380182|OTHER|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
219492198|NCT03964220|DRUG|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
219601839|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
219492199|NCT03964220|DRUG|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
219492200|NCT02414074|BEHAVIORAL|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
219492201|NCT02414074|BEHAVIORAL|Parent Education|Everyday Parenting is a parent training curriculum.
219492202|NCT06111560|OTHER|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
219601840|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
219601841|NCT01960335|OTHER|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
219492203|NCT03940027|PROCEDURE|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
219492204|NCT02034994|BEHAVIORAL|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
219492205|NCT00451594|DRUG|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~1. Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~2. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~3. If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~4. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~5. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
219492206|NCT00451594|DRUG|Prednisolone|"Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
219492207|NCT04247594|DRUG|Voxelotor|synthetic small molecule supplied as 500 mg tablets
219492208|NCT00060489|DRUG|SEROQUEL (quetiapine fumarate) Tablets|
219492209|NCT03082820|DIAGNOSTIC_TEST|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
219492210|NCT03082820|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
219492211|NCT03082820|DIAGNOSTIC_TEST|Nerve conduction studies (NCS)|NCS were performed with patients only.
219492212|NCT05212831|DEVICE|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
219492213|NCT03218631|DRUG|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
219492214|NCT03183973|BIOLOGICAL|PRF|patients who will receive PRF suspension
218871819|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
218871820|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
218871821|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
218871822|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
219022022|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
219022023|NCT05456425|DRUG|CBT-001|CBT-001 eye drop
219022024|NCT05456425|DRUG|Vehicle|Formulation without drug
219492215|NCT03183973|BIOLOGICAL|placebo group|patients who will receive Placebo
219492216|NCT04217031|OTHER|No intervention|No intervention
219022025|NCT04324554|DIAGNOSTIC_TEST|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
219022026|NCT03033511|DRUG|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
219022027|NCT03033511|DRUG|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
219022028|NCT03033511|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
219022029|NCT03033511|DRUG|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
219022030|NCT05608746|OTHER|Physical Exercise|Home-based individualized training, consisting of unsupervised aerobic exercise and resistance exercise, with moderate intensity. The pt. receives an exercise manual and exercise videos online, through an APP.
219022031|NCT05608746|OTHER|Pelvic Floor exercise|Patients will be assessed by a physiotherapist and instructed in a pelvic floor exercise program, accessed through the APP. Furthermore, the pt. is provided with general information about pelvic floor anatomy and muscle function.
219022032|NCT05608746|OTHER|Sexual counseling|Patients will be provided with 1 video-consultation with a clinical sexologist, during the prehabilitation period. The patients will be instructed in strategies to improve postoperative communication regarding, sex, realistic expectations, erectile dysfunction and the use of aids.
219022033|NCT05608746|DIETARY_SUPPLEMENT|Nutritional supplement|Patients are systematically screened for malnutrition to assess the nutritional status. Patients are given recommendations with dietary advice online, through the APP. If the patient is at nutritional risk, the patient is provided with a nutritional supplement.
219492217|NCT05418257|OTHER|(exposure) telemedicine|medical counseling or treatment only using phone
219022034|NCT05608746|OTHER|Stress management|Patients are systematically screened for anxiety and depression. If patients are at risk of anxiety or depression, they are referred to a consultation with a nurse, who will provide information and strategies to handle the uncertainties they may experience.
219492218|NCT00127348|DEVICE|CPAP (Continuous Positive Airway Pressure)|
219492219|NCT02918825|DRUG|Olanzapine|Olanzapine
219492220|NCT02918825|DRUG|Paliperidone|Paliperidone
219492221|NCT06134765|DRUG|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
219492222|NCT00720473|DRUG|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
218871823|NCT01402648|DIETARY_SUPPLEMENT|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
218871824|NCT01402648|DIETARY_SUPPLEMENT|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
218871825|NCT05407961|DRUG|LY3532226|Administered SC.
219022035|NCT05608746|OTHER|Standard pre-surgical preparation and pt. information.|One week preoperatively the usual regime for the presurgical preparation and information will be followed.
219022036|NCT00987077|DEVICE|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
219022037|NCT00730912|DRUG|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
219022038|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
219022039|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
219022040|NCT03999450|BEHAVIORAL|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
219022041|NCT03999450|BEHAVIORAL|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
219022042|NCT01457066|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
219492223|NCT01273922|BIOLOGICAL|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
219492224|NCT04521439|DIAGNOSTIC_TEST|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
219492225|NCT02846740|DEVICE|Alpha-Stim®.|cranial electrical stimulation
219492226|NCT02846740|BEHAVIORAL|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
219492227|NCT01518621|RADIATION|Radiation|Whole brain radiation
219492228|NCT01518621|DRUG|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
218871826|NCT05407961|DRUG|Placebo|Administered SC.
218871827|NCT05407961|DRUG|Dulaglutide|Administered SC.
219492229|NCT02913469|DRUG|Morphine|The patients in group A would be administrated intravenous morphine 5mg
218871828|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
219022043|NCT02409459|DRUG|Injectafer|
219492230|NCT02913469|DRUG|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
219492231|NCT02913469|DRUG|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
219492232|NCT06460246|DEVICE|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
219492233|NCT00814619|BIOLOGICAL|panitumumab|Given IV
219492234|NCT00814619|DRUG|capecitabine|Given orally
219492235|NCT00814619|PROCEDURE|therapeutic conventional surgery|Patients undergo surgical resection
219492236|NCT00814619|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
219492237|NCT06334250|DEVICE|Catheter ablation of atrial fibrillation using Pulsed Field Ablation|Pulsed Field Ablation of atrial fibrillation at the time of left atrial appendage occlusion
218871829|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
219022044|NCT02409459|DRUG|Placebo|Normal saline solution
219022045|NCT01317745|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
219022046|NCT01317745|DRUG|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
219022047|NCT01317745|BIOLOGICAL|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
219022048|NCT06363656|DEVICE|Wears the smartwatch during the sleep time to capture sleep characteristics and answer questionaires|"* Synchronization of smartwatch with smartphone (internet connection) to send sleep characteristics captured by the application~* Weight~* Height~* Body measurements (circumferences)~* Questionnaires about overall health status~* Pittsburgh Sleep Quality Index questionnaire~* Insomnia Severity Index~* Sleep Hygiene Index~* Epworth Sleepiness Scale~* NoSAS score (Neck, Obesity, Snoring, Age, Sex)"
219022049|NCT04053023|DRUG|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
219492238|NCT06334250|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion using the Watchman device
219492239|NCT04878250|DRUG|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
218871830|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
219492240|NCT05137418|BIOLOGICAL|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
218871831|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
218871832|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
218871833|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
218871834|NCT02350504|BEHAVIORAL|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
218871835|NCT02175914|DRUG|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
219492241|NCT02344459|DEVICE|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
219601842|NCT02075515|BIOLOGICAL|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
218871836|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
218871837|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
218871838|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
218871839|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
219492242|NCT04227652|DRUG|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
219601843|NCT01297985|BEHAVIORAL|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
219492243|NCT04071275|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
219492244|NCT04071275|OTHER|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
219492245|NCT02349009|DRUG|C-82 Topical Gel, 1%|active
219492246|NCT02349009|DRUG|C-82 Topical Gel, Placebo|placebo
219492247|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
219601844|NCT05936515|OTHER|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
218871840|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
218871841|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
218871842|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
219492248|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
219601845|NCT02771288|DEVICE|Bioresorbable Vascular Scaffold|
219601846|NCT06454097|DIAGNOSTIC_TEST|Assess the response glioma to radiochemotherapy using radiogenomics-based AI model|Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
219601847|NCT02658942|PROCEDURE|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
219601848|NCT02658942|PROCEDURE|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
219601849|NCT02829476|BIOLOGICAL|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
218871843|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
218871844|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
218871845|NCT00064402|DRUG|Placebo|Placebo BID
218871846|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
218871847|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
218871848|NCT00479479|DRUG|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
218871849|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
218871850|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
219492249|NCT04064437|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
219492250|NCT04064437|DIAGNOSTIC_TEST|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
219492251|NCT04064437|DIAGNOSTIC_TEST|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
218871851|NCT01409369|DRUG|RO4995819|single oral dose
218871852|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
219022050|NCT04053023|DRUG|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
219022051|NCT02972489|DEVICE|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
219022052|NCT02972489|DEVICE|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
219492252|NCT00589693|DRUG|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
219492253|NCT00589693|DRUG|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
219492254|NCT00589693|DRUG|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
219492255|NCT01716507|PROCEDURE|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
219492256|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
219492257|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
219492258|NCT05578885|PROCEDURE|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
219601850|NCT02436226|DRUG|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
219601851|NCT02436226|DRUG|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
219601852|NCT01613430|BEHAVIORAL|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
219601853|NCT01613430|BEHAVIORAL|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
218871853|NCT05946005|DRUG|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
218871854|NCT05946005|DRUG|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
218871855|NCT05946005|DRUG|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
218871856|NCT05946005|OTHER|control groups|no intervention is given
218871857|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
218871858|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
219022053|NCT04718467|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
219022054|NCT04718467|BIOLOGICAL|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
219022055|NCT01019642|DRUG|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
219022056|NCT01019642|DRUG|placebo|no active principles given.
219022057|NCT04144556|OTHER|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
218871859|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
219492259|NCT01330615|DRUG|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
219492260|NCT01330615|DRUG|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
219492261|NCT00047437|BEHAVIORAL|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
219492262|NCT02609178|PROCEDURE|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
219492263|NCT02609178|PROCEDURE|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
219492264|NCT06013761|OTHER|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
219492265|NCT01128153|DRUG|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
219492266|NCT01128153|DRUG|Placebo|tablet once daily for 24 weeks to be taken orally
219492267|NCT04784845|BIOLOGICAL|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
219492268|NCT01251692|PROCEDURE|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
219492269|NCT03746886|OTHER|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
219492270|NCT02933827|DRUG|ELIXCYTE|Adipose-derived stem cells (ADSCs)
219492271|NCT00002227|DRUG|Efavirenz|
219492272|NCT00002227|DRUG|Lamivudine|
219492273|NCT00002227|DRUG|Stavudine|
219492274|NCT05610982|BEHAVIORAL|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
219492275|NCT04188769|DEVICE|constant deep pressure applied by an air splint|inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
219492276|NCT04188769|DEVICE|intermittent deep pressure applied by an air splint|continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
219492277|NCT04188769|DEVICE|uninflated air splint|no deep pressure applied by the air splint
219492278|NCT04188769|OTHER|contralateral movement|non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
219492279|NCT02419469|DRUG|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
219492280|NCT02419469|DRUG|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
219492281|NCT02419469|DRUG|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
219492282|NCT02419469|DRUG|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
219601854|NCT00580892|DEVICE|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
219601855|NCT00378573|DRUG|docetaxel|
218871860|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
219601856|NCT00378573|DRUG|gemcitabine|
219601857|NCT00378573|DRUG|bevacizumab|
219601858|NCT05771948|DEVICE|CCoat|CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
219601859|NCT00533312|DRUG|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
219601860|NCT00533312|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
219601861|NCT00533312|DRUG|Comparator : niacin / Duraton of Treatment: 4 Weeks|
218871861|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
218871862|NCT03392870|OTHER|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
218871863|NCT03392870|OTHER|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
218871864|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
218871865|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
218871866|NCT03704610|DRUG|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
218871867|NCT03704610|DRUG|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
218871868|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
218871869|NCT00444067|OTHER|Standard of Care|Standard of Care
218871870|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
218871871|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
218871872|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
218871873|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
218871874|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
218871875|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
218871876|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
218871877|NCT00025623|DRUG|carboplatin|
218871878|NCT00025623|DRUG|cyclophosphamide|
219492283|NCT02419469|DRUG|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
218871879|NCT00025623|DRUG|doxorubicin hydrochloride|
218871880|NCT00025623|DRUG|etoposide|
218871881|NCT00025623|DRUG|vincristine sulfate|
218871882|NCT00025623|PROCEDURE|conventional surgery|
218871883|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
218871884|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
218871885|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
218871886|NCT00084487|DRUG|becatecarin|Given IV
218871887|NCT00520260|DRUG|bromfenac|0.09%, BID, 6 weeks
219022058|NCT04144556|OTHER|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
219022059|NCT05052385|DRUG|Ruxolitinib|As per treating physician's decision - non interventional study
219022060|NCT05052385|DEVICE|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
218871888|NCT00520260|DRUG|ketorolac|0.4%, BID, 6 weeks
218871889|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
218871890|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
218871891|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
218871892|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
218871893|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
218871894|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
218871895|NCT00262990|DRUG|EPO906 (Patupilone)|
218871896|NCT00262990|DRUG|doxorubicin|
218871897|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
218871898|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
218871899|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
219022061|NCT05052385|DRUG|Ibrutinib|As per treating physician's decision - non interventional study
219022062|NCT00412022|DRUG|tamoxifen|20 mg daily for 5 years
219199991|NCT06856070|OTHER|(Group B: Preformed Zirconia crown)|1\. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.4. Interproximal Reduction: 1 mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330 tapered carbide bur.5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.7. Glass ionomer cement will be used for cementation.
219199992|NCT06856304|PROCEDURE|laparoscopic disconnection of the hernia sac|disconnection of the hernial sac at the level of the internal ring using hook diathermy with sweeping the vas and the vessels away till completely separating them from the edges of the sac, then narrowing of the internal ring by appling a vicryl 3/0 suture between the ilipubic tract and the transverse arch of the transversus abdominus muscle
219199993|NCT06856304|PROCEDURE|Percutaneous internal ring suturing|A single umbilical trocar was placed through a supraumbilical incision, and then the surgeon stood on the same side of the hernia. To choose the location for the needle puncture, the position of the IIR was assessed by pressing the inguinal region from the outside with the tip of a forceps. Under laparoscopic-guided vision, the previously prepared 18-gauge injection needle threaded with the monofilament suture was introduced into the abdominal wall through a skin puncture at the lateral edge of the internal ring. With the movements of the tip of the needle, the thread passed under the peritoneum, over the lateral half of the IIR. The thread was pushed through the barrel of the needle into the abdominal cavity and eventually made a loop. The needle was pulled out, leaving the loop of the thread inside the abdomen by hanging the loop on the endoscope this prevented the extraction of the loop with the needle and thus prevented repeating this step. Next, the thread loop was pulled out of t
218871900|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"\- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
218871901|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219022063|NCT00412022|DRUG|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
219022064|NCT00412022|DRUG|letrozole|2.5 mg daily for 5 years
219022065|NCT00412022|DRUG|zoledronic acid|4 mg every 6 months
219022066|NCT04566614|OTHER|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
219022067|NCT03424265|DIETARY_SUPPLEMENT|EAA mixture|Dietary supplement intervention for 12-weeks
218871902|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
218871903|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
218871904|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
219022068|NCT03424265|DIETARY_SUPPLEMENT|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
219022069|NCT02401594|DRUG|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
218871905|NCT05715515|DIAGNOSTIC_TEST|Panbio™|"The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
218871906|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
219022070|NCT02401594|DRUG|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
219022071|NCT00726804|DRUG|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
219022072|NCT01797601|DRUG|Human Insulin|160 U of insulin
219492284|NCT02419469|DRUG|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
219492285|NCT02419469|DRUG|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
219492286|NCT02419469|DRUG|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
219492287|NCT02419469|DRUG|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
219492288|NCT02419469|DRUG|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
219022073|NCT01797601|DRUG|Placebo|Insulin dilution medium without insulin
219022074|NCT04667767|OTHER|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
219022075|NCT04667767|OTHER|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
219199994|NCT06859840|DEVICE|LIDAR|Using the LIDAR model to assist in image interpretation, patients with positive results are recalled for further examination based on the LIDAR output information and the original image interpretation, to obtain pathological results and long-term follow-up.
219492289|NCT02419469|DRUG|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
219492290|NCT02419469|DRUG|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
219492291|NCT02419469|DRUG|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
219492292|NCT02670512|DEVICE|Telehome Monitoring|
219492293|NCT01682512|DRUG|BI 695500|
219492294|NCT01682512|DRUG|BI 695500|
219492295|NCT01682512|DRUG|Rituxan®|
218871907|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
218871908|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
218871909|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
218871910|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
218871911|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
218871912|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
218871913|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
219022076|NCT03852641|OTHER|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
219022077|NCT04379882|DEVICE|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
219022078|NCT00002433|DRUG|Interferon gamma-1b|
219022079|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
219022080|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
219022081|NCT00894322|OTHER|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
219022082|NCT00753558|DRUG|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
219492296|NCT01682512|DRUG|Rituxan®|
219492297|NCT01682512|DRUG|MabThera®|
219492298|NCT00127257|BEHAVIORAL|Biofeedback|
219492299|NCT00127257|DRUG|Diazepam|
219492300|NCT00127257|BEHAVIORAL|Pelvic floor retraining|
219601862|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
218871914|NCT02438813|DRUG|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
219492301|NCT04132739|BEHAVIORAL|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
219601863|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
219601864|NCT05797844|OTHER|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
219601865|NCT05797844|OTHER|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
219601866|NCT06301191|DRUG|Semaglutide, 1.0 mg/mL|Semaglutide, 1.0 mg/mL
219601867|NCT06301191|DRUG|Dipeptidyl Peptidase 4 inhibitor|Dipeptidyl Peptidase 4 inhibitor
219601868|NCT06004791|DRUG|Herombopag + CsA|Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
218871915|NCT02438813|PROCEDURE|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
219601869|NCT06004791|DRUG|rhTPO combined with Herombopag + CsA|rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
219601870|NCT05435846|DRUG|Capmatinib|Given orally
219601871|NCT05435846|DRUG|Trametinib|Given orally
219601872|NCT05376644|DRUG|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
218871916|NCT02438813|PROCEDURE|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
218871917|NCT02438813|DEVICE|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
218871918|NCT02438813|OTHER|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
219601873|NCT05376644|DRUG|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
219601874|NCT00611546|OTHER|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
219601875|NCT00611546|OTHER|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
219601876|NCT01694225|OTHER|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
219601877|NCT03786458|BEHAVIORAL|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
219601878|NCT01190631|DEVICE|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
219601879|NCT04237272|OTHER|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
219601880|NCT04237272|OTHER|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
219601881|NCT04237272|OTHER|Control|Participants will not receive any e-cigarette
218871919|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
218871920|NCT01357460|DEVICE|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
218871921|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
218871922|NCT01848366|DEVICE|Biowave Treatment|Twelve weekly treatments
218871923|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
218871924|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
218871925|NCT01027260|DRUG|Placebo|Variable dosing
218871926|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
218871927|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
219601882|NCT05726786|DRUG|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
218871928|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
219492302|NCT04132739|BEHAVIORAL|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
219492303|NCT04132739|BEHAVIORAL|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
219492304|NCT03397563|DEVICE|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
219492305|NCT03397563|DEVICE|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
219492306|NCT06478446|OTHER|observation|HD patients were observed and evaluated with three scales.
219492307|NCT05695235|DEVICE|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
219492308|NCT05695235|DEVICE|Oura ring|Wearable sleep tracking device
219492309|NCT05695235|BEHAVIORAL|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
219492310|NCT00229541|PROCEDURE|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
219492311|NCT04057755|DRUG|botulinum toxin A|
219492312|NCT04057755|DRUG|NaCl|
219492313|NCT03720184|PROCEDURE|HAR|"HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk"
219492314|NCT02887612|OTHER|ctDNA test|
219601883|NCT03170063|PROCEDURE|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
219601884|NCT01372748|OTHER|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
218871929|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
218871930|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
218871931|NCT02068872|PROCEDURE|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
219492315|NCT04074213|DRUG|Clozapine|Clozapine treatment
219601885|NCT01372748|OTHER|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
219601886|NCT04110210|DRUG|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
218871932|NCT03040986|OTHER|Laboratory Biomarker Analysis|Correlative studies
218871933|NCT03040986|DRUG|Selumetinib Sulfate|Given by mouth (PO)
218871934|NCT04421209|DRUG|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
218871935|NCT04421209|DRUG|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
219022083|NCT03522974|DIETARY_SUPPLEMENT|Strawberry powder|Freeze dried strawberry powder
219022084|NCT03522974|DIETARY_SUPPLEMENT|Placebo powder|40 g/d placebo powder matched for taste and appearance
219492316|NCT01826318|BEHAVIORAL|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
218871936|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
218871937|NCT00119496|DRUG|rosiglitazone|oral tablet, 4mg bd for 4 weeks
219492317|NCT00416403|DRUG|fluvastatin sodium|Given orally
219492318|NCT00416403|PROCEDURE|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
219601887|NCT04110210|DRUG|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
219601888|NCT02407639|OTHER|CO2|gas
219601889|NCT02407639|OTHER|air|air
219601890|NCT01709539|PROCEDURE|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
219601891|NCT00199524|DEVICE|Navigator Ureteral Access Sheath|ureteral access sheath
219601892|NCT02641158|OTHER|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
218871938|NCT00119496|DRUG|theophylline|Oral theophylline, 200mg bd
218871939|NCT00119496|DRUG|beclomethasone|inhaled beclomethasone, 200mcg bd
218871940|NCT00119496|DRUG|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
218871941|NCT00054028|DRUG|suramin|Given IV
218871942|NCT00054028|DRUG|paclitaxel|Given IV
218871943|NCT00054028|OTHER|pharmacological study|Correlative studies
218871944|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
218871945|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
218871946|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
218871947|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
218871948|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
218871949|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
218871950|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
218871951|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
218871952|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
219492319|NCT03112993|DRUG|sugammadex|once at the end of the surgery
219492320|NCT03112993|DRUG|Neostigmine|once at the end of the surgery
219492321|NCT01131728|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
218871953|NCT00214084|DRUG|Allopurinol|
218871954|NCT02231268|DRUG|Gladem|
218871955|NCT01183468|BIOLOGICAL|Aralast NP 45 mg dose|\- 45 mg/kg/week
218871956|NCT01183468|BIOLOGICAL|Aralast NP 90 mg dose|\- 90 mg/kg/week
218871957|NCT01183468|BIOLOGICAL|Aralast NP 180 mg dose|\- 180 mg/kg/week
219022085|NCT01302587|DRUG|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
219022086|NCT04177342|DRUG|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
219492322|NCT04363411|OTHER|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
218871958|NCT05283590|DIAGNOSTIC_TEST|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
219022087|NCT04177342|DRUG|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
219022088|NCT00681655|OTHER|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
219492323|NCT06374121|DEVICE|PerSorb cartridge (CytoSorbents Europe GmbH, Germany)|This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.
219492324|NCT06374121|DEVICE|PerLife PerKidney|The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
219492325|NCT04400253|BEHAVIORAL|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
219492326|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
219492327|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
219492328|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
218871959|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
219492329|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
219492330|NCT06348173|DRUG|Mepolizumab|Compare the response to mepolizumab and benralizumab before and after treatment
219492331|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
219492332|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
219492333|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
219492334|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
219492335|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
219492336|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
218871960|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
219492337|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
219022089|NCT00681655|OTHER|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
219022090|NCT01170455|DEVICE|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
219022091|NCT01170455|DEVICE|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
219022092|NCT03183375|DRUG|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
219022093|NCT00151099|DRUG|high caloric drink with protein|
219492338|NCT01080209|DRUG|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
219022094|NCT00197041|BIOLOGICAL|RTS,S/AS02A|
218871961|NCT06455748|DRUG|Daratumumab/daratumumab and hyaluronidase-fihj|Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.
218871962|NCT06455748|DRUG|Pomalidomide|Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).
218871963|NCT06455748|DRUG|Dexamethasone|Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
219022095|NCT02369003|PROCEDURE|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
218871964|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
219492339|NCT01080209|OTHER|Sham|Patients who recieved sham in a previous study.
219492340|NCT03986645|DEVICE|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
219492341|NCT03676959|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
219492342|NCT03676959|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
219492343|NCT03676959|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
219492344|NCT00109629|DRUG|VRC-HIVDNA016-00-VP|
219492345|NCT00109629|DRUG|VRC-HIVADV014-00|
219492346|NCT02030834|BIOLOGICAL|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
219492347|NCT00561405|BEHAVIORAL|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
219492348|NCT00561405|BEHAVIORAL|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
219492349|NCT01132235|BIOLOGICAL|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
218871965|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
218871966|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
218871967|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
219492350|NCT06260384|OTHER|electrocardiogram|it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
219492351|NCT05187663|PROCEDURE|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH \& Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
219492352|NCT05187663|PROCEDURE|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
219492353|NCT05474261|PROCEDURE|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
219492354|NCT05765929|OTHER|Non-operative treatment|Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
219492355|NCT00896883|DEVICE|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
219492356|NCT00447707|BEHAVIORAL|Positive Choice|
219492357|NCT05418387|BEHAVIORAL|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
219492358|NCT05418387|BEHAVIORAL|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
218871968|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
218871969|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
218871970|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
218871971|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
218871972|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
218871973|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
218871974|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
218871975|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
218871976|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
218871977|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
218871978|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
218871979|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
218871980|NCT04086992|OTHER|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
218871981|NCT03161574|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
218871982|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
218871983|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
218871984|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
219492359|NCT01125007|DEVICE|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
219022096|NCT06120920|OTHER|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
218871985|NCT02412059|DRUG|Prednisolone acetate|
219022097|NCT06120920|OTHER|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
219492360|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
219492361|NCT06568809|OTHER|Time interval between recovery of body temperature and operation|The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
219492362|NCT02529800|DRUG|HIP1402|Tamsulosin HCl 0.4mg
219492363|NCT02529800|DRUG|HGP0412|Tamsulosin HCl 0.2mg
219492364|NCT02572427|OTHER|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
219492365|NCT02572427|OTHER|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
219492366|NCT04741945|DRUG|Metformin|2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
219601893|NCT02641158|BEHAVIORAL|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
219601894|NCT03744624|PROCEDURE|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
219492367|NCT01839227|OTHER|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
218871986|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
218871987|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
218871988|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
218871989|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
218871990|NCT00300352|DRUG|Folic Acid|
218871991|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
218871992|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
218871993|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
218871994|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
218871995|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
218871996|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
218871997|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
218871998|NCT00558272|DRUG|AZD0530|Daily oral dose
218871999|NCT00558272|DRUG|Zoledronic Acid|
218872000|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
219492368|NCT04911127|DRUG|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
219492369|NCT04911127|DRUG|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
219492370|NCT04911127|DRUG|Placebo capsules|MCT oil capsules as placebo for CBD
219492371|NCT05190640|DIETARY_SUPPLEMENT|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
219492372|NCT01772394|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
219492373|NCT01772394|BEHAVIORAL|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
219492374|NCT05606913|DRUG|dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
219492375|NCT05606913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219492376|NCT01818219|PROCEDURE|Records of EADI derived parameters|
219492377|NCT02539979|DRUG|Paracetamol|
219492378|NCT02539979|DRUG|Placebo - Normal Saline|Normal Saline 100cc
219492379|NCT06299631|PROCEDURE|Ileocolic resection|Ileocolic resection by open or laparoscopic approach
219492380|NCT04734431|BIOLOGICAL|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
219492381|NCT02390973|PROCEDURE|Sleeve Gastrectomy|
219492382|NCT02390973|PROCEDURE|Roux-en-Y Gastric Bypass|
219492383|NCT02390973|PROCEDURE|Biliopancreatic Diversion with Duodenal Switch|
219492384|NCT02390973|OTHER|Medical management|
219492385|NCT01262729|PROCEDURE|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
219492386|NCT01262729|DRUG|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
219492387|NCT06542731|DRUG|ONO-4578|Specified dose on specified days
219492388|NCT06542731|DRUG|ONO-4538|Specified dose on specified days
219492389|NCT06542731|DRUG|Docetaxel|Specified dose on specified days
219492390|NCT06542731|DRUG|Ramucirumab|Specified dose on specified days
218872001|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
218872002|NCT06947642|DRUG|Pectoral nerve block (PECS)|Patients will receive pectoral nerve block (PECS).
218872003|NCT06947642|DRUG|Erector spinae plane block (ESP)|Patients will receive erector spinae plane block (ESP).
218872004|NCT06947642|DRUG|Serratus anterior plane block (SAP)|Patients will receive serratus anterior plane block (SAP).
218872005|NCT05517694|OTHER|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
219492391|NCT05675072|DRUG|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
218872006|NCT05517694|OTHER|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
218872007|NCT02619032|DRUG|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
218872008|NCT02619032|DRUG|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
218872009|NCT01780753|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
218872010|NCT00278811|PROCEDURE|mobile crisis team|
218872011|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
219492392|NCT05675072|DRUG|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
219492393|NCT05020730|DRUG|PTM-001|PTM-001 (400 mg) every day for 12 weeks
219492394|NCT05020730|DRUG|Placebo|Matching placebo every day for 12 weeks
219492395|NCT00142324|DRUG|Donepezil|
219492396|NCT00996918|DRUG|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
219492397|NCT00996918|DRUG|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
219492398|NCT01754480|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
219492399|NCT01754480|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
219492400|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
219492401|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
219492402|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
219492403|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
219492404|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
219492405|NCT00391040|BEHAVIORAL|SGS education|
219492406|NCT00568100|PROCEDURE|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
219492407|NCT04250896|OTHER|Control group|Standard child care in health unit plus exposure to EsIAN
219492408|NCT04250896|BEHAVIORAL|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
219492409|NCT00279149|PROCEDURE|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
219492410|NCT02341209|DRUG|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
219492411|NCT03384407|DEVICE|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
219492412|NCT06520241|OTHER|Pregnant|Data were collected using the Personal Information Form, Depression-Anxiety-Stress Scale (DASS-21), and Oral Health Impact Scale (OHIP-14-TR).
219492413|NCT00187057|DRUG|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
218872012|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
218872013|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
218872014|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
219492414|NCT00187057|DRUG|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
219492415|NCT00187057|DRUG|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
219492416|NCT00187057|DRUG|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
219601895|NCT03744624|DEVICE|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
219601896|NCT05919719|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
218872015|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
218872016|NCT05755802|PROCEDURE|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
219022098|NCT06431854|BEHAVIORAL|ED-MINERVA Program|ED-MINERVA Program aims to improve ED symptoms and related difficulties of the patient and provide tools to enhance the family's management (nutritionally, emotionally, and behaviorally) in their natural environment. The treatment consists of four phases with a gradually decreasing therapeutic intensity, ranging from total hospitalization, family treatment apartment, to home treatment and subsequent linkage with specialized local facilities. The ED-MINERVA program uses various aspects of family-based treatment, cognitive behavioral therapy, dialectical behavioral therapy, and systemic family therapy.
219492417|NCT00187057|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
219492418|NCT04177745|OTHER|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
219492419|NCT04177745|OTHER|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
219492420|NCT01249690|DRUG|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
219492421|NCT01249690|DRUG|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
219492422|NCT02703779|DRUG|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
219492423|NCT02703779|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
219492424|NCT02703779|DRUG|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
219492425|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
219492426|NCT04432818|BEHAVIORAL|Pack Health's digital life coaching (DLC)|Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
219022099|NCT05713045|DIETARY_SUPPLEMENT|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
219022100|NCT04566354|OTHER|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
219492427|NCT05933226|BEHAVIORAL|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
219492428|NCT03169660|DRUG|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
219492429|NCT04440007|DRUG|Abivertinib|Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
219492430|NCT04440007|OTHER|Standard of Care|Standard of Care as determined by the Investigator
219492431|NCT00282425|BIOLOGICAL|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
219601897|NCT06035835|COMBINATION_PRODUCT|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
219492432|NCT04275388|DRUG|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
219492433|NCT04275388|DRUG|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
219492434|NCT01184378|DIETARY_SUPPLEMENT|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
219492435|NCT01466673|DRUG|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
219492436|NCT01466673|DRUG|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
219492437|NCT01518985|DRUG|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
219492438|NCT01518985|DRUG|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
219492439|NCT01518985|OTHER|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
219492440|NCT01248611|DRUG|fentanyl|nasally, dose titrated to effect
219492441|NCT05078801|PROCEDURE|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
219492442|NCT05078801|PROCEDURE|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
219492443|NCT00854607|OTHER|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
219492444|NCT00294931|DRUG|irinotecan|
219492445|NCT00294931|DRUG|carboplatin|
219492446|NCT00294931|DRUG|bevacizumab|
219492447|NCT02424656|PROCEDURE|MRI|EEG-functional MRI, structural MRI, diffusion MRI
219492448|NCT02424656|PROCEDURE|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
219492449|NCT02424656|PROCEDURE|FDG-PET|
219492450|NCT02424656|OTHER|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
219492451|NCT02857296|OTHER|interview and observation|
219492452|NCT03607656|DRUG|Oxaliplatin|Oxaliplatin powder injection
219492453|NCT03607656|DRUG|Capecitabine|Capecitabine tablet
219492454|NCT03607656|OTHER|TCM|TCM decoction orally taken twice a day for at least 3 months
219492455|NCT03607656|DRUG|S-1|S-1 capsule
219492456|NCT03607656|DRUG|Docetaxel|Docetaxel injection
219492457|NCT03607656|DRUG|5-FU|5-FU injection
219492458|NCT02009982|PROCEDURE|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
219601898|NCT06035835|COMBINATION_PRODUCT|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
219492459|NCT02009982|DEVICE|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
219492460|NCT02394353|DEVICE|Transient hepatic elastography|
219492461|NCT04390035|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
219492462|NCT05449158|PROCEDURE|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
219492463|NCT02735226|OTHER|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
219492464|NCT03054935|OTHER|Indirect Calorimetry|Measurement of resting energy expenditure
219492465|NCT04976088|DRUG|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
219492466|NCT04976088|DRUG|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
219492467|NCT04976088|DRUG|Placebo|Placebo: Placebo plaster, topical application once a day.
219492468|NCT06568120|DEVICE|dragon themed nebulizer masks|This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
219492469|NCT02059369|PROCEDURE|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
219492470|NCT02059369|PROCEDURE|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
219492471|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
219492472|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
218872017|NCT05755802|PROCEDURE|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
218872018|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
219492473|NCT03959137|OTHER|None - Common practice|None - Common practice
219492474|NCT04717999|BIOLOGICAL|NKG2D CAR-T|The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.
219492475|NCT03732729|DEVICE|massage chair|Patient should use massage chair, twice per day, for 30minutes
219492476|NCT03311217|BEHAVIORAL|Healthy retail strategies|
219492477|NCT05255783|DEVICE|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
219492478|NCT06498557|OTHER|Peripheral nerve block methods|We apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.
219492479|NCT02720094|DRUG|Cabotegravir Oral Tablet|30 mg tablet
219492480|NCT02720094|DRUG|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
219492481|NCT02720094|DRUG|Placebo for TDF/FTC tablets|
219492482|NCT02720094|DRUG|Placebo for cabotegravir oral tablet|
219492483|NCT02720094|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
219492484|NCT02720094|DRUG|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
219492485|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
219492486|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
219492487|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
219492488|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
219492489|NCT02913261|DRUG|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
219492490|NCT02913261|DRUG|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
219492491|NCT00285350|DRUG|mycophenolate mofetil|
219492492|NCT04164394|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
219492493|NCT04164394|DIETARY_SUPPLEMENT|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
218872019|NCT00031564|BIOLOGICAL|Interleukin-2|
219492494|NCT01702766|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
218872020|NCT00031564|BIOLOGICAL|B7-1|
219022101|NCT03251079|DEVICE|Continuous glucose monitoring system|Implanted continuous glucose monitoring system
219022102|NCT03729856|BEHAVIORAL|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
219492495|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
219492496|NCT00407966|DRUG|alvocidib|Given IV
219492497|NCT00407966|DRUG|cytarabine|Given IV
219492498|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
219492499|NCT06354972|PROCEDURE|Minimally invasive surgical procedure|All the experimental sites underwent a minimally-invasive surgical technique (MIST) procedure under magnification (Cortellini and Tonetti 2007). The full-thickness flap was minimally raised both on the buccal and oral side, avoiding vertical releasing incisions. Granulation tissue was scraped from the bony surfaces of the defect, and the root was debrided using minicurettes/ultrasonic device and chemically treated by EDTA. Regenerative procedure was carried out using a combination of enamel matrix derivatives and bone xenograft. The flaps were then repositioned and sutured in order to obtain passive primary closure.
219492500|NCT04654286|PROCEDURE|Nerve transfer procedure|"1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
219492501|NCT04654286|PROCEDURE|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
219492502|NCT06425419|DRUG|Topotecan|20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
219492503|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
218872021|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
218872022|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
219492504|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
219492505|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
219492506|NCT01810393|DRUG|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
219492507|NCT04379973|DRUG|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
219492508|NCT00443131|BIOLOGICAL|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
219492509|NCT05886673|OTHER|experimental cream|experimental cream
219492510|NCT05886673|OTHER|standard of care|standard of care
219492511|NCT01241812|BEHAVIORAL|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
219492512|NCT00365469|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
219492513|NCT00365469|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
219492514|NCT03853213|BEHAVIORAL|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
219492515|NCT03853213|BEHAVIORAL|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
219492516|NCT02898064|DEVICE|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
219492517|NCT02898064|OTHER|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
219492518|NCT00350337|BIOLOGICAL|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
219492519|NCT00350337|BIOLOGICAL|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
219492520|NCT00350337|BIOLOGICAL|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
219492521|NCT00350337|OTHER|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
219601899|NCT03993379|DRUG|CX-072|CX-072 in combination with ipilimumab
219601900|NCT03993379|DRUG|Ipilimumab|CX-072 in combination with ipilimumab
219601901|NCT01427608|DRUG|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
218872023|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
218872024|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
219492522|NCT04779385|PROCEDURE|PIPAC|"under general anaesthesia, a laparoscopy was performed using an open laparoscopic technique to prevent intestinal wounds, which would contraindicate the procedure. A 12 mmHg pneumoperitoneum was created, and to ensure the safety of the procedure the pressure of the pneumoperitoneum was maintained constant throughout the procedure. Two laparoscopic balloon trocars (of 11 and 12 mm) were used. A thorough exploration of the abdomen, Peritoneal Cancer Index assessment, images, peritoneal biopsies, and ascites cytology (in the case of ascites) were performed prior to administration of the chemotherapy aerosol.~For carcinomas of gastric origin, Doxurubicin at a dose of 1.5 mg/m2 was administered in combination with Cisplatin 7.5 mg/m2 diluted in 40 and 150 mL of 0.9% sodium chloride, respectively. In the case of contraindication, Oxaliplatine at a dose of 92 mg/m2 in a 5% dextrose solution was recommended."
219492523|NCT06568185|DRUG|Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA|BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
219492524|NCT00000478|DRUG|atenolol|
219601902|NCT01427608|DRUG|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
219601903|NCT00325871|PROCEDURE|concurrent chemoradiation|
219601904|NCT04999657|DEVICE|Non-invasive low-frequency tibial nerve stimulator (TNS-01)|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
219601905|NCT04486365|PROCEDURE|Bifocal bone transport.|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
219601906|NCT04486365|PROCEDURE|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments.
219601907|NCT03443531|DRUG|Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
219601908|NCT03443531|DRUG|Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
219601909|NCT03443531|DRUG|Placebo Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
219601910|NCT03443531|DRUG|Placebo Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
218872025|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
219492525|NCT00000478|DRUG|nifedipine|
219492526|NCT00000478|DRUG|diltiazem|
219492527|NCT00000478|DRUG|isosorbide dinitrate|
219492528|NCT00000478|PROCEDURE|coronary artery bypass coronary artery bypass|
219492529|NCT00000478|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219492530|NCT04462133|DIAGNOSTIC_TEST|Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)|Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
219601911|NCT04766112|OTHER|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
219601912|NCT04766112|OTHER|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
219601913|NCT04816071|DRUG|Essential amino acids|Dietary Supplement
219601914|NCT04816071|DIETARY_SUPPLEMENT|Maltodextrin|Control
219601915|NCT02631889|DEVICE|Transcollation technology|The use transcollation technology for dissection during lung surgery
219601916|NCT02631889|DEVICE|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
219601917|NCT01795950|DRUG|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
219601918|NCT02691325|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
219601919|NCT02691325|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
219601920|NCT02691325|DRUG|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
219601921|NCT04958655|BEHAVIORAL|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
219492531|NCT02858518|OTHER|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
219492532|NCT00244660|PROCEDURE|Frequent blood pressure measurements|
219492533|NCT00244660|BEHAVIORAL|Education|
219601922|NCT04958655|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
219601923|NCT01095302|DRUG|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
219601924|NCT01095302|DRUG|cisplatin|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
219601925|NCT01095302|DRUG|docetaxel|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
219601926|NCT04931979|DRUG|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
219601927|NCT04931979|RADIATION|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
219601928|NCT05113784|DRUG|Meplazumab for Injection|humanized antibody target CD147
219601929|NCT05113784|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
219601930|NCT03723356|DIAGNOSTIC_TEST|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
219601931|NCT03723356|DIAGNOSTIC_TEST|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
219601932|NCT03723356|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
219601933|NCT01807065|BIOLOGICAL|sipuleucel-T|Given IV
219601934|NCT01807065|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
219601935|NCT01807065|OTHER|laboratory biomarker analysis|Correlative studies
219601936|NCT01948115|DRUG|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
219601937|NCT03586089|DRUG|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
219601938|NCT03586089|DRUG|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
219601939|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
219492534|NCT02535676|DEVICE|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
219492535|NCT01040676|BEHAVIORAL|Automated Telephone Nutrition Support|See Intervention Group description.
219601940|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
219601941|NCT02325076|DEVICE|Spirodoc|A device to detect the physical condition of the lungs
219601942|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
219601943|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
219492536|NCT02854189|DEVICE|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
219492537|NCT01169831|OTHER|Exercise Training|2 weeks of daily aerobic exercise training
219492538|NCT01169831|OTHER|Exercise Cessation|Stopping all exercise for 2 weeks
219492539|NCT06567366|BIOLOGICAL|CAR T-cell therapy|Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
219601944|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
219601945|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
219601946|NCT01085760|DRUG|Vancomycin|Comparison of different drug doses
219601947|NCT04522726|DRUG|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
219601948|NCT05246670|DRUG|Palmidrol|Given PEA PO
219601949|NCT05246670|DRUG|Placebo Administration|Given PO
218872026|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
218872027|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
218872028|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
218872029|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
218872030|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
218872031|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
218872032|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
218872033|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
218872034|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
218872035|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
218872036|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
218872037|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
218872038|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
218872039|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
219492540|NCT06567366|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."
219492541|NCT06567366|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
219492542|NCT05722340|PROCEDURE|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
218872040|NCT02082106|OTHER|Alpine skiing|
218872041|NCT02082106|OTHER|cross country skiing|
219492543|NCT05722340|PROCEDURE|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
218872042|NCT02082106|OTHER|Indoor training (cycling)|
218872043|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
218872044|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
219492544|NCT04218344|OTHER|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
219492545|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
219492546|NCT00047554|DRUG|Travoprost, 0.004% ophthalmic solution|
219492547|NCT01892605|BEHAVIORAL|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
219492548|NCT04721327|OTHER|remote CI programming|provision of CI programming provided remotely via Zoom in a 2 hour session
219492549|NCT00833976|DRUG|Lovaza|4 grams per day
219022103|NCT03729856|OTHER|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
219601950|NCT05246670|OTHER|Quality-of-Life Assessment|Ancillary studies
218872045|NCT00871962|OTHER|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
218872046|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
218872047|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
218872048|NCT01789606|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
218872049|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
218872050|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
218872051|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
218872052|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
218872053|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a neurological examination is taken~* a saliva sample is taken"
218872054|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a saliva sample is taken"
218872055|NCT01654809|BIOLOGICAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
218872056|NCT01654809|BIOLOGICAL|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
218872057|NCT01654809|BIOLOGICAL|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
218872058|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
219199995|NCT06859489|DEVICE|Active aGeing And Personalised service's Ecosystem (AGAPE)|"The experimental protocol is structured into two phases:~Phase 1 (pre-pilot) - Preliminary assessment of the functionality and usability of the AGAPE platform by older adults and caregivers, divided into:~Living lab: Three sessions to progressively explore and test the platform and its services, including workshop activities.~Testing phase: Use of the platform in the home environment of older adults for one month.~Phase 2 (pilot study) - Evaluation of the platform's impact on the daily lives of older adults, caregivers, and care organizations, with a 12-month involvement for each user."
218872059|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
218872060|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
218872061|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
218872062|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
218872063|NCT02411370|BEHAVIORAL|phonetic tests|
218872064|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
218872065|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
219199996|NCT06861972|PROCEDURE|Caesarean Hysterectomy|Caesarean delivery followed by hysterectomy
219492550|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT active|Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
218872066|NCT05019768|OTHER|accelerated custom-fast CXL|The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
218872067|NCT05019768|OTHER|Standard CXL|The standard CXL procedure has been carried on following the Dresden protocol
218872068|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
219199997|NCT06861972|PROCEDURE|Conservative management|Focal myometrium resection of the area of diseased myometrium after delivery
219199998|NCT06862310|OTHER|yogurt intervention|daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)
219199999|NCT06862024|BEHAVIORAL|Deep Breathing and Cough Exercise Skills|Ability to apply deep breathing and cough exercise skills will be examined.
219200000|NCT06862024|BEHAVIORAL|Satisfaction with the training method|The level of satisfaction with the training provided will be determined with the PechaKucha presentation.
218872069|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
218872070|NCT05408026|DRUG|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
218872071|NCT05408026|DRUG|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
219200001|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
219200002|NCT06679348|OTHER|walking exercise on treadmill|The study included two intervention groups, consisting of participants who met the inclusion criteria and adhered to the experimental procedures. One group will do treadmill walking exercises, while the other will do treadmill walking exercises using virtual reality (VR). Both interventions were conducted in a single session, with each group participating in a 20-minute walking exercise session at a moderate intensity, as identified by other studies.
219200003|NCT06679348|OTHER|Treadmill walking exercise using VR|Walking on the treadmill with the Free Run game on the Nintendo Wii allows users to walk at 5 miles per hour for 20 minutes. The user gets on the Wii Balance Board and starts walking in the virtual environment after running the application. The application detects the user's movements and controls the progress of the virtual character. During this experience, users increase their motivation by encountering various landscapes while tracking their performance and getting information about the calories they spend. This setup provides a fun, game-like atmosphere for a realistic walking experience.
219492551|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
219492552|NCT03911960|BEHAVIORAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
219492553|NCT03911960|BEHAVIORAL|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
219492554|NCT03515889|BEHAVIORAL|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
219492555|NCT03515889|BEHAVIORAL|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
219492556|NCT06700746|PROCEDURE|Prolotherapy|Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions
219492557|NCT06700746|DEVICE|Extracorporeal shock wave therapy (ESWT)|Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
218872072|NCT02934737|OTHER|Progression of diabetes|
218872073|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
218872074|NCT04943120|PROCEDURE|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
218872075|NCT04943120|PROCEDURE|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
219200004|NCT06677996|DRUG|varegacestat|Experimental intervention
219492558|NCT06540482|DIAGNOSTIC_TEST|Reliability test|The test was administered two days apart to evaluate the reliability of the retest test.
219492559|NCT02670980|DEVICE|Intelligent Retinal Implant System|
219492560|NCT01518465|DRUG|dalteparin|Given SC
219492561|NCT01518465|DRUG|lenalidomide|Given PO
219492562|NCT01518465|DRUG|dexamethasone|Given PO
219492563|NCT01518465|OTHER|laboratory biomarker analysis|Correlative studies
219492564|NCT03872622|OTHER|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
219492565|NCT05762120|OTHER|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase"
219200005|NCT06677996|DRUG|Itraconazole (200 mg)|Intervention to evaluate DDI with experimental intervention
219200006|NCT06333223|DIETARY_SUPPLEMENT|Mixture of (Poly)phenols and a probiotic supplement|Mixture of (Poly)phenols and a probiotic supplement
218872076|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
219492566|NCT06256731|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219492567|NCT02239692|DRUG|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
219492568|NCT06539039|PROCEDURE|non surgical periodontal therapy|participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
219492569|NCT02433535|DRUG|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
219492570|NCT02433535|OTHER|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
219492571|NCT05898490|BEHAVIORAL|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
219492572|NCT03461315|OTHER|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
219492573|NCT01788137|DRUG|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
219492574|NCT01788137|DRUG|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
219492575|NCT03414307|PROCEDURE|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
219492576|NCT03414307|DEVICE|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
219492577|NCT00923728|DRUG|AVN944|
219492578|NCT00297492|BEHAVIORAL|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
219492579|NCT00297492|BEHAVIORAL|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
219492580|NCT00297492|BEHAVIORAL|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
219492581|NCT00297492|DRUG|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
219492582|NCT00297492|DRUG|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
219492583|NCT03367273|OTHER|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
218872077|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
218872078|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
219022104|NCT03729856|OTHER|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
218872079|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
218872080|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
218872081|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
218872082|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
219022105|NCT04554329|PROCEDURE|bandage contact lens|bandage contact lens
219022106|NCT00951808|BIOLOGICAL|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
219022107|NCT00951808|BEHAVIORAL|Standard care|Participants will receive standard care for ACS while in the hospital.
219022108|NCT02654483|DRUG|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
219022109|NCT02654483|OTHER|Placebo|Matching tablets to VPD-737 tablets without active drug
219022110|NCT02314650|OTHER|acupoint stimulation|stimulation was given at acupoints
219022111|NCT02314650|OTHER|non-acupoint stimulation|stimulation was given at non-acupoints
219022112|NCT02314650|OTHER|electrodes attached|electrode were attached to skin
219022113|NCT02120729|OTHER|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
219022114|NCT00768807|DEVICE|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
218872083|NCT06304779|DRUG|Lidocaine|"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."
218872084|NCT06304779|DRUG|Placebo|atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
218872085|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
218872086|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
218872087|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
218872088|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
219492584|NCT05891873|DIAGNOSTIC_TEST|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
218872089|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
218872090|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219022115|NCT01643811|PROCEDURE|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
219022116|NCT01643811|PROCEDURE|Endoscopic submucosal dissection|endoscopic submucosal dissection
219022117|NCT03031977|OTHER|visceral mobilization|
219022118|NCT05691296|BEHAVIORAL|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
219022119|NCT05691296|BEHAVIORAL|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
219022120|NCT04940650|DIAGNOSTIC_TEST|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
219200007|NCT06333223|DIETARY_SUPPLEMENT|Placebo comparator|Mixture of (Poly)phenols and a placebo maltodextrin comparator
219200008|NCT05428852|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219492585|NCT05891873|DIAGNOSTIC_TEST|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
219492586|NCT05891873|DIAGNOSTIC_TEST|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
219492587|NCT05891873|DIAGNOSTIC_TEST|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
219492588|NCT05891873|DIAGNOSTIC_TEST|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
219492589|NCT05891873|DIAGNOSTIC_TEST|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
219492590|NCT05891873|DIAGNOSTIC_TEST|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
219601951|NCT02836925|DRUG|Ledipasvir+Sofosbuvir|"Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options"
219022121|NCT04940650|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
219492591|NCT02664766|BEHAVIORAL|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
219492592|NCT05233774|DRUG|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
219492593|NCT05233774|OTHER|Placebo|Placebo
219492594|NCT05833373|DEVICE|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
219492595|NCT05833373|DEVICE|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
219492596|NCT01038882|DRUG|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation
219492597|NCT01038882|OTHER|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
219492598|NCT00968396|PROCEDURE|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
219492599|NCT00968396|PROCEDURE|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
219492600|NCT00968396|DRUG|Melphalan|100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
219492601|NCT02359734|OTHER|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
219492602|NCT00137358|PROCEDURE|Radiation Therapy|
219492603|NCT00137358|DRUG|Cisplatin|
219492604|NCT00137358|DRUG|Amifostine|
219492605|NCT06209424|BEHAVIORAL|Habitual Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).
219492606|NCT06209424|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
219492607|NCT06209424|BEHAVIORAL|Resistance Exercise|Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups
219492608|NCT03365219|DEVICE|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
219492609|NCT03365219|OTHER|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
219492610|NCT03096717|DIAGNOSTIC_TEST|colonoscopy and histology|colonic biopsies for detection of dysplasia
219492611|NCT05578417|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
219492612|NCT01672814|DRUG|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
219492613|NCT01672814|DEVICE|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
219200009|NCT05428852|OTHER|Neurocognitive Assessment|NRG-CC
219492614|NCT01774695|BEHAVIORAL|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
219492615|NCT04372212|DEVICE|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
219492616|NCT03256708|DIETARY_SUPPLEMENT|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
219492617|NCT03256708|DIETARY_SUPPLEMENT|Placebo|Inactive ingredients
219492618|NCT00786019|BEHAVIORAL|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
219492619|NCT00786019|DRUG|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
219492620|NCT00303264|DRUG|dexloxiglumide|
219492621|NCT00303264|DRUG|Nexium (esomeprazole)|
219492622|NCT00005588|RADIATION|radiation therapy|
219492623|NCT05377333|DRUG|LY3457263|Administered SC.
218872091|NCT04691908|BIOLOGICAL|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
218872092|NCT04691908|OTHER|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
218872093|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
218872094|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
218872095|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
218872096|NCT05658380|DRUG|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
218872097|NCT05658380|DRUG|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
219492624|NCT05377333|DRUG|Placebo|Administered SC.
219492625|NCT05377333|DRUG|Dulaglutide|Administered SC.
219492626|NCT01148680|BIOLOGICAL|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
219492627|NCT04821570|BIOLOGICAL|COVID-19 Vaccine|Per recommended dosing schedule
219492628|NCT02033577|PROCEDURE|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
219492629|NCT02033577|PROCEDURE|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
219492630|NCT00388479|DRUG|Alvimopan|
219492631|NCT04349176|DRUG|Dose|Randomized to either 100U or 155U
219492632|NCT00420888|DRUG|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
219492633|NCT00420888|DRUG|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
219492634|NCT01261416|DRUG|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
219492635|NCT04668118|DRUG|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
219492636|NCT00566618|DRUG|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
219492637|NCT00566618|DRUG|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
219492638|NCT04182984|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
218872098|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
218872099|NCT01702506|DRUG|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
218872100|NCT01702506|DRUG|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
218872101|NCT01702506|DRUG|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
218872102|NCT00774982|DRUG|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
218872103|NCT00774982|DRUG|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
218872104|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
218872105|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
218872106|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
218872107|NCT02795091|OTHER|manual cleaning|manual clean the rag and floor towel
218872108|NCT02795091|DEVICE|machine clean|machine clean the rag and floor towel
218872109|NCT05381285|OTHER|No intervention|Non-interventional study
219492639|NCT01542684|DRUG|Azacytidine|Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
219492640|NCT01542684|DRUG|GM-CSF|250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
219492641|NCT02923115|DRUG|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
219492642|NCT02923115|DRUG|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
219492643|NCT02923115|DRUG|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
219492644|NCT04790409|DRUG|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
219492645|NCT02832076|PROCEDURE|Subcutaneous negative suction drain for 10 days|
219492646|NCT02832076|PROCEDURE|No subcutaneous drain|
219601952|NCT02836925|DRUG|Sofosbuvir+Velpatasvir|"Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment"
219492647|NCT06700629|PROCEDURE|Distal Penile Hypospadias (Disorder)|"Three operations which are Tubularized incised plate urethroplasty (TIP), Mathieu and meatal advancement and glanuplasty (MAGPI).~A three experienced operators with number of operations done by each one more than one hundred operation in the last year.~The operators will be fixed for each surgical technique as follows:~1. Doctor (A) for Matheiu. ( 35 operations)~2. Doctor (M) for MAGPI. ( 35 operations)~3. Doctor (S) for TIP ( 35 operations). Tubularized incised plate urethroplasty:(3,6) Indication: for distal penile hypospadias with or without penile curvature with any width of the uretheral plate and also for any type of distal hypospadias associated with curvature.~Key steps for this operation are as follows:~Glans retraction using stay suture 4-0 or 5-0 silk. Uretheral catheter pass through hypospadic meatus to bladder. Parallel longitudenal incision is done 1-2mm proximal to hypospadic meatus. A circumferential incision is made 2-3 mm below coronal sulcus dorsally"
219492648|NCT05017376|PROCEDURE|small incision lenticular extraction|In patients with the same degree of myopia, different optical zones were designed for operation
218872110|NCT02575703|DRUG|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
218872111|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
218872112|NCT01633177|DRUG|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
218872113|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
218872114|NCT01633177|DRUG|Fish oil placebo|Fish oil placebo
219022122|NCT03946904|DEVICE|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
219022123|NCT00140569|PROCEDURE|CHVP + interferon|
219022124|NCT00140569|DRUG|fludarabine|
219022125|NCT00140569|PROCEDURE|CHOP + TBI and autotransplant|
219022126|NCT01114165|OTHER|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
219022127|NCT01114165|OTHER|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
219022128|NCT04955522|DIAGNOSTIC_TEST|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
219492649|NCT05152407|OTHER|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
219492650|NCT06542861|OTHER|High-frequency simulation-based team training|"The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments."
219492651|NCT01514409|DIETARY_SUPPLEMENT|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
219492652|NCT01514409|DIETARY_SUPPLEMENT|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
219492653|NCT05605184|OTHER|Survey|Survey
219492654|NCT00068406|RADIATION|3-Dimensional Conformal Radiation Therapy|
219492655|NCT00068406|DRUG|Cisplatin|Given IV
219492656|NCT00068406|PROCEDURE|Conventional Surgery|
219022129|NCT00494988|DRUG|insulin aspart|
219022130|NCT00494988|DRUG|insulin NPH|
219022131|NCT00004489|DRUG|alendronate sodium|
218872115|NCT00346229|BIOLOGICAL|filgrastim|
219601953|NCT05305066|DRUG|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
218872116|NCT00346229|BIOLOGICAL|pegfilgrastim|
218872117|NCT00346229|DRUG|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
218872118|NCT00346229|PROCEDURE|hyperthermia treatment|
218872119|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
219022132|NCT00004489|DRUG|calcium carbonate|
219022133|NCT00004489|DRUG|cholecalciferol|
219022134|NCT02045576|DEVICE|sleep position trainer|
219022135|NCT02045576|DEVICE|Oral Appliance Therapy|
219022136|NCT00050843|DRUG|thalidomide|
219022137|NCT00222196|PROCEDURE|lifestyle, PTA|
219022138|NCT00999557|DRUG|bimatoprost ophthalmic solution|Applied topically
219022139|NCT00999557|DRUG|placebo|Applied topically
219022140|NCT03258190|DRUG|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
219022141|NCT05381467|PROCEDURE|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
219200010|NCT05428852|OTHER|Questionnaire Administration|Ancillary studies
219200011|NCT05428852|DEVICE|Fitbit|Fitbit Activity Tracking
219200012|NCT05428852|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
218872120|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
218872121|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
218872122|NCT02001337|OTHER|survey administration|baseline
219492657|NCT06279936|OTHER|Neuropsychological battery|COVID-19 patients with persistent complaints of cognitive disabilities (more than 4 weeks post-infection) in daily life are examined with an extensive neuropsychological test battery (see below) at the outpatient clinic of the University Psychiatric Centre in Duffel and at the University Hospital Antwerp. This battery covers a broad range of reliable and valid tests divided into six cognitive domains: attention, memory, visuospatial functions, language, executive functions and psychomotor speed/coordination. The neuropsychological examination lasts an average of 2 hours per participant. The tests are carried out by the same experienced neuropsychologist and also follow a standardized sequence. In addition to the neuropsychological assessment, two self-report scales are filled out by each patient. These scales are used to detect possible complaints of fatigue and possible cognitive problems which are experienced by the patient during daily life activities.
218872123|NCT02001337|OTHER|Specimen collection|baseline
219492658|NCT06279936|OTHER|Surveys and symptom severity questionnaires|Both self-rated surveys and clinician administered questionnaires
219492659|NCT06279936|OTHER|Blood withdrawal|"Blood samples will be collected in a standardized manner by venipuncture. Two blood vials will be collected and processed to perform the following analyses:~* serum collection tube(s) allowing for HERV-W ENV and serological assays~* plasma collection tubes for the assessment of other immune-related biomarkers (including but not limited to CRP, IL-6, IL-1b, TNF-a, IFN-g, tryptophan, kynurenine, 3-OH-kynurenine, quinolinic acid, kynurenic acid, enzymes of the kynurenine pathway)."
219492660|NCT06279936|OTHER|Saliva swabs|Salivary cortisol measures will be used as functional measure of the HPA axis activity, as the unbound cortisol fraction in saliva is highly correlated to plasma cortisol. Baseline diurnal cortisol and CAR levels will be measured using saliva, collected at home with Salivette® (Sarstedt) synthetic swabs. The rationale behind the choice of home sampling, is to maximize normal circumstances and to minimize stress related to the measuring procedure.
219492661|NCT05251415|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity.
219492662|NCT02052037|DIETARY_SUPPLEMENT|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
219492663|NCT02052037|DIETARY_SUPPLEMENT|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
218872124|NCT05286216|BEHAVIORAL|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
219492664|NCT02212561|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
219492665|NCT02212561|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
219492666|NCT02212561|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
219492667|NCT02212561|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
219601954|NCT05305066|DRUG|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
218872125|NCT06089512|PROCEDURE|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
218872126|NCT06089512|PROCEDURE|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
219200013|NCT05698368|BEHAVIORAL|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
219200014|NCT05698368|OTHER|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
218872127|NCT06089512|PROCEDURE|Control group|Only general anesthesia was applied to the patients.
218872128|NCT01870648|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
218872129|NCT01870648|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
218872130|NCT05663840|BEHAVIORAL|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
218872131|NCT05663840|BEHAVIORAL|Standard of care|Subjects will receive SOC therapy only
218872132|NCT05364502|DEVICE|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
218872133|NCT01107223|OTHER|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
218872134|NCT01107223|OTHER|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
218872135|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
218872136|NCT00125021|DRUG|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
218872137|NCT00125021|DRUG|OSI-774|Given once daily
218872138|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
218872139|NCT02078388|DRUG|Doxorubicin|
219022142|NCT05381467|PROCEDURE|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
219022143|NCT00954902|DIETARY_SUPPLEMENT|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
219022144|NCT00954902|BEHAVIORAL|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
219492668|NCT01098383|DRUG|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
219492669|NCT01098383|DRUG|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
219492670|NCT03451331|DRUG|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
219492671|NCT03451331|DRUG|Gemcitabine|1000 mg/m\^2
219492672|NCT03451331|DRUG|Carboplatin|AUC 4.5 (based on the Calvert formula)
219492673|NCT03451331|DRUG|Oxaliplatin|130 mg/m\^2
219492674|NCT02719782|BIOLOGICAL|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
219022145|NCT00954902|OTHER|Placebo antioxidant concentrate|Placebo capsules
219601955|NCT05305066|DRUG|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
219022146|NCT03106220|BEHAVIORAL|exercise|home exercise program
219492675|NCT01875991|DRUG|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
219492676|NCT01875991|DRUG|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
219492677|NCT05265169|DEVICE|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
219601956|NCT02281422|DRUG|BIA 2-093|
218872140|NCT03204422|OTHER|No intervention|no any other intervention
218872141|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
218872142|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
218872143|NCT03502902|DRUG|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
218872144|NCT03502902|DRUG|Placebo|Placebo
219022147|NCT03106220|OTHER|placebo|encourage walking and physical therapy per standard care.
218872145|NCT00417963|DEVICE|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
218872146|NCT03603106|DRUG|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
218872147|NCT03603106|DRUG|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
218872148|NCT05532891|OTHER|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
219022148|NCT00455429|DRUG|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
219022149|NCT00455429|DRUG|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
219492678|NCT06204276|DEVICE|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
219492679|NCT06204276|DEVICE|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
219492680|NCT05114265|DRUG|KUR-101|Single oral dose of KUR-101
219492681|NCT05114265|DRUG|OxyNorm|Single oral dose of OxyNorm
219492682|NCT05114265|DRUG|Placebo|Single oral dose of placebo
219492683|NCT03244397|OTHER|Physical therapy + educational strategy|See arm/group descriptions
219492684|NCT03244397|BEHAVIORAL|Educational strategy|See arm/group descriptions
219492685|NCT02454972|DRUG|lurbinectedin (PM01183)|
219492686|NCT01795703|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
219492687|NCT01795703|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
219492688|NCT05998733|DIAGNOSTIC_TEST|Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring|"* Correlation analysis of sepsis severity with FDP and D-Dimer~* Discussion on the critical value and area under the curve of FDP and D-Dimer in diagnosis of sepsis~* Differences in age and sex of FDP and D-Dimer in diagnosis of sepsis~* Effect of FDP and D-Dimer diagnosis of sepsis on severe conversion rate and all-cause mortality of patients~* The difference of thromboelastogram in patients with sepsis of different severity~* Thromboelastogram items (R time α Correlation between angle, k time, maximum blood clot strength and comprehensive coagulation index) and sepsis"
219492689|NCT01377233|DRUG|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
219022150|NCT00455429|DRUG|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
219022151|NCT00455429|DRUG|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
219022152|NCT00455429|DRUG|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
219022153|NCT00431210|BIOLOGICAL|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
219022154|NCT06072950|OTHER|Usual care|Patients received usual care
219022155|NCT01165554|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
219022156|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
219022157|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
219492690|NCT01377233|DRUG|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
219492691|NCT01377233|DRUG|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
219492692|NCT01377233|DRUG|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
219492693|NCT01377233|DRUG|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
219492694|NCT06059742|OTHER|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
219022158|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
219022159|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
219022160|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
219022161|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
219022162|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
219022163|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
219022164|NCT06069960|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
219022165|NCT04291391|OTHER|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
219492695|NCT06059742|OTHER|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
219492696|NCT01774006|OTHER|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
218872149|NCT04909658|BEHAVIORAL|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
219022166|NCT02951156|BIOLOGICAL|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
219022167|NCT02951156|BIOLOGICAL|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
219492697|NCT01785875|DRUG|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
219492698|NCT04597554|DIETARY_SUPPLEMENT|Cranberry|Cranberry beverage and gummies supplement
219492699|NCT04597554|DIETARY_SUPPLEMENT|Placebo|Placebo beverages and gummies supplement
219492700|NCT04905654|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
219492701|NCT04905654|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
219492702|NCT06171997|OTHER|Swaddling after bath group|"The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale."
219022168|NCT02951156|BIOLOGICAL|Rituximab|CD20-directed cytolytic antibody
219022169|NCT02951156|OTHER|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
219022170|NCT02951156|DRUG|Bendamustine|Alkylating drug
219022171|NCT02951156|DRUG|Gemcitabine|Nucleoside analogue
219022172|NCT02951156|DRUG|Oxaliplatin|Platinum-based drug
219022173|NCT01427894|OTHER|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
219022174|NCT04669392|DRUG|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
219492703|NCT01182714|PROCEDURE|immediate removal of in-dwelling catheter|
219492704|NCT01182714|PROCEDURE|24 hours delayed removal of catheter|
219492705|NCT03310203|DIAGNOSTIC_TEST|Iron|Labelled iron
219492706|NCT00301431|DRUG|DVS-233|
219492707|NCT06527820|BEHAVIORAL|Talk About It (conversation aid)|"Talk About It is a conversation aid aimed to increase awareness of options and prompt discussion."
219022175|NCT04954612|OTHER|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
219022176|NCT01735643|DEVICE|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
219022177|NCT01735643|OTHER|waiting|waiting for 12 weeks
219200015|NCT06870357|DRUG|propofol|Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).
219200016|NCT05323487|DRUG|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
219492708|NCT05245773|OTHER|Automated SMS program to support post-discharge transitions of care|The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
219492709|NCT00489931|DRUG|VRC-AVIDNA036-00-VP|
219492710|NCT00595426|DRUG|YM150|Oral
219492711|NCT00595426|DRUG|Warfarin|Oral
219492712|NCT05785520|DEVICE|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
219492713|NCT01398592|DRUG|Vildagliptin|50mg vildagliptin bid
219492714|NCT01398592|DRUG|Sitagliptin|100mg sitagliptin po qd
219492715|NCT00689663|PROCEDURE|Laparoscopic cholecystectomy|Randomized to three arm.
219492716|NCT03716999|OTHER|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
219492717|NCT04283487|DIETARY_SUPPLEMENT|Fructans|500ml 0.9% normal saline containing 40g fructans
219492718|NCT04283487|DIETARY_SUPPLEMENT|Glucose|500ml 0.9% normal saline containing 40g glucose
219492719|NCT04283487|DIETARY_SUPPLEMENT|Saline|500ml 0.9% normal saline
218872150|NCT04909658|BEHAVIORAL|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
219492720|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
219492721|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
219492722|NCT00695981|PROCEDURE|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
219492723|NCT00695981|PROCEDURE|Conservative treatment|Physiotherapy according to a standardized protocol
219492724|NCT02149862|OTHER|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
219492725|NCT02046785|OTHER|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
218872151|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
218872152|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
219492726|NCT04991311|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
218872153|NCT04706156|BIOLOGICAL|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
218872154|NCT01023672|DRUG|Armodafinil|150-250 mg armodafinil by mouth daily
219492727|NCT06580782|DRUG|Calcium Carbonate 500 MG|Calcium Carbonate 500mg, orally, every 4 hours.
219492728|NCT06580782|DRUG|Standard Dose Synthetic Pitocin|The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
219492729|NCT02915588|OTHER|early isometric loading after rotator cuff surgery|
219492730|NCT02915588|OTHER|passive motion after rotator cuff surgery|
219492731|NCT03794999|DRUG|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
218872155|NCT02319135|DRUG|Azacitadine|
218872156|NCT02319135|DRUG|Fludarabine|
218872157|NCT02319135|DRUG|Cytarabine|
218872158|NCT02319135|DRUG|Lenograstim|
218872159|NCT02319135|DRUG|Filgastrim|
219022178|NCT06192186|DRUG|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
219022179|NCT06192186|DRUG|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
219022180|NCT03571074|OTHER|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
219022181|NCT05635240|OTHER|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
219022182|NCT01066247|DRUG|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
219492732|NCT03794999|DRUG|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
219492733|NCT00129532|DRUG|1.0% C31G SAVVY vaginal gel|
219492734|NCT00755937|OTHER|Data collection post infusion|
218872160|NCT05899972|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.
219492735|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
219492736|NCT00755573|DRUG|placebo|Regime as described for pregabalin
219492737|NCT03545360|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-703 device
219492738|NCT00991042|OTHER|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
219492739|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
219492740|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
219492741|NCT01676311|DRUG|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
219492742|NCT01676311|DRUG|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
219492743|NCT03368547|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219492744|NCT03368547|RADIATION|Gallium Ga 68 Gozetotide|Given IV
219492745|NCT03368547|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219492746|NCT06531265|PROCEDURE|Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy|Bronchoscopic evaluation of endobronchial lesion with biopsy and cryotherapy for recanalisation
219492747|NCT01440595|DRUG|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
219492748|NCT01440595|DRUG|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
219492749|NCT01440595|DRUG|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
219492750|NCT01440595|DRUG|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
219492751|NCT05099783|DIAGNOSTIC_TEST|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
219492752|NCT04912635|OTHER|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
219492753|NCT01347879|DRUG|Visonac PDT|cream application prior to illumination with red light
219492754|NCT01347879|DRUG|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
219492755|NCT04768764|PROCEDURE|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
219601957|NCT05585203|BEHAVIORAL|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
218872161|NCT05899972|OTHER|Suboccipital inhibition technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.
218872162|NCT05899972|OTHER|Frontal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.
218872163|NCT05899972|OTHER|Parietal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.
218872164|NCT05899972|OTHER|IV ventricle technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
219022183|NCT01066247|DRUG|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
219492756|NCT04768764|PROCEDURE|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
219492757|NCT04768764|DRUG|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
219492758|NCT04768764|PROCEDURE|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
219492759|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)|the intervention is conducting electrical posterior box isolation plus rotor modulation ablation
219492760|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation group (BO group)|the intervention is conducting electrical posterior box isolation alone
219492761|NCT04097119|DIETARY_SUPPLEMENT|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
219492762|NCT04208191|BEHAVIORAL|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
219492763|NCT01950806|OTHER|Pecan-containing diet|
219492764|NCT01950806|OTHER|Nut-free diet|
219492765|NCT01062022|BEHAVIORAL|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
219492766|NCT01062022|BEHAVIORAL|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
219492767|NCT01223196|DRUG|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
219601958|NCT05585203|BEHAVIORAL|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
218872165|NCT01966224|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
218872166|NCT02767661|DRUG|Capecitabine|Capecitabine, 500mg, orally three times daily (continuously)
219492768|NCT01223196|DRUG|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
219492769|NCT00323271|BEHAVIORAL|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
219492770|NCT00323271|OTHER|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
219492771|NCT02071381|DRUG|DW330SR 45mg|
219492772|NCT02071381|DRUG|DW1030 75mg|
219492773|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
219492774|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
219492775|NCT03187288|DRUG|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
219492776|NCT03296215|OTHER|Observational|To determine different patterns of admission and their Outcome
219492777|NCT01238822|DRUG|Methylphenidate|18 mg methylphenidate
219492778|NCT01238822|DRUG|placebo|Placebo
219492779|NCT01238822|DRUG|Methylphenidate|36 mg methylphenidate
219492780|NCT01238822|DRUG|Methylphenidate|54 mg methylphenidate
219492781|NCT02591784|DRUG|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
219492782|NCT02591784|RADIATION|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
219492783|NCT04537585|COMBINATION_PRODUCT|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
219492784|NCT04537585|DRUG|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
218872167|NCT02767661|DRUG|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
218872168|NCT05332652|DEVICE|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
218872169|NCT00006773|DRUG|bortezomib|Given IV
219200017|NCT06868550|BEHAVIORAL|Comprehensive Oral Health Promotion Program|The principal investigator will carry out all treatment procedures, and the patients will be randomly assigned to any of them.
219492785|NCT04078087|DRUG|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
219601959|NCT03362814|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
219601960|NCT03362814|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
219601961|NCT03362814|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
219601962|NCT03362814|DRUG|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
219601963|NCT03362814|DRUG|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
218872170|NCT02219373|DRUG|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
219200018|NCT06870708|PROCEDURE|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique
218872171|NCT02219373|DRUG|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
218872172|NCT02219373|OTHER|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
218872173|NCT05050656|DRUG|Duloxetine 60mg|Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
219601964|NCT03362814|DRUG|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
219200019|NCT06870643|OTHER|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks.
219492786|NCT04078087|DRUG|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
219492787|NCT00864487|DRUG|Neratinib|HKI-272
219492788|NCT03598673|DRUG|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
219492789|NCT01261429|DRUG|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
219492790|NCT00289939|BEHAVIORAL|Motivational interviewing to reduce risk for HIV and DV|
219601965|NCT03362814|DRUG|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
219601966|NCT03362814|DRUG|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
218872174|NCT05050656|DRUG|Placebo|placebo tablets identical to duloxetine tablets
219492791|NCT00123110|DRUG|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
219022184|NCT03386942|DRUG|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
219022185|NCT00130416|BEHAVIORAL|E-mail coaching to improve patient communication with doctor|
219022186|NCT04351087|DEVICE|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
219492792|NCT00123110|DRUG|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
219492793|NCT00123110|DRUG|placebo pill|matching pill twice a day for 12 weeks
219492794|NCT00123110|DRUG|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
219601967|NCT03454503|DRUG|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
219601968|NCT01916525|BEHAVIORAL|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
219601969|NCT05298917|DEVICE|silicone hydrogel contact lens|silicone hydrogel contact lens
219601970|NCT00799058|DRUG|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
219601971|NCT00799058|DRUG|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
218872175|NCT06385054|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
218872176|NCT06385054|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
218872177|NCT05937789|DIETARY_SUPPLEMENT|Vitamin D3|Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
218872178|NCT05937789|DIETARY_SUPPLEMENT|Medium Chain Triglycerides (MCT)|Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
219022187|NCT03849833|DIETARY_SUPPLEMENT|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
219022188|NCT02260479|PROCEDURE|Preheated|Skin disinfection solution is preheated in a warming cupboard
219022189|NCT05202509|DRUG|Obicetrapib|10mg obicetrapib tablet
219022190|NCT05202509|DRUG|Placebo|Placebo tablet to resemble obicetrapib
219200020|NCT06869811|DEVICE|LAA Closurse|LAA Closure + DOAC or OAC
219492795|NCT00004009|DRUG|tipifarnib|
219492796|NCT00876109|DRUG|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
219492797|NCT04989231|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
219492798|NCT04989231|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
218872179|NCT06208111|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
218872180|NCT01058629|DEVICE|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
218872181|NCT06043908|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
219022191|NCT05992597|DRUG|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
219022192|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
219022193|NCT02240199|DRUG|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
219022194|NCT02240199|DRUG|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
219492799|NCT02552394|DRUG|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
219492800|NCT03855462|DEVICE|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months."
219492801|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
219492802|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
219492803|NCT05873075|OTHER|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
219492804|NCT02093468|DRUG|MST-188|
219492805|NCT02093468|DRUG|Saline|
219492806|NCT06406231|DEVICE|comparing efficacy of TENS and PEMF in knee osteoarthritis|"Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups."
219492807|NCT04774809|DRUG|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
219492808|NCT04774809|DRUG|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
219492809|NCT04774809|OTHER|Placebo Comparator: Vehicle|Placebo
219492810|NCT05152004|DRUG|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
219492811|NCT05152004|DRUG|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
219492812|NCT05152004|DRUG|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
218872182|NCT06043908|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
218872183|NCT04766008|DRUG|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
219022195|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
219022196|NCT01593423|BEHAVIORAL|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
219022197|NCT01593423|BEHAVIORAL|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
219022198|NCT01593423|BEHAVIORAL|a comparison group|No intervention.
219040152|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
219492813|NCT05152004|DRUG|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
219492814|NCT06433986|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
219492815|NCT06433986|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
219492816|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
219492817|NCT01294605|BIOLOGICAL|Boostrix™ (dTpa)|Intramuscular, 3 doses
219492818|NCT01294605|BIOLOGICAL|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
219492819|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
219492820|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
219492821|NCT05606159|DIETARY_SUPPLEMENT|Bacillus velezensis DSM 33864|1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
219492822|NCT05606159|DIETARY_SUPPLEMENT|Placebo|1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
219492823|NCT00597727|DRUG|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
219492824|NCT00597727|DRUG|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
219492825|NCT02043093|BEHAVIORAL|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
219492826|NCT02725671|DEVICE|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
219492827|NCT02007746|OTHER|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
219601972|NCT00799058|DRUG|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
219601973|NCT06333418|DEVICE|Virtual Reality Glasses Group|Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.
219601974|NCT06333418|DEVICE|Glass waterfall|Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
219492828|NCT02007746|OTHER|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
219492829|NCT02007746|PROCEDURE|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
219492830|NCT00311571|DRUG|Ethidronate|
219601975|NCT01962818|OTHER|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
218872184|NCT03720288|DRUG|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
219492831|NCT00311571|BEHAVIORAL|Physical training|
219492832|NCT00965263|BIOLOGICAL|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
219492833|NCT05965622|BEHAVIORAL|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
219492834|NCT05965622|BEHAVIORAL|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
219492835|NCT02682433|DEVICE|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
219601976|NCT06128408|DRUG|risperidone, olanzapine, aripiprazole|Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
219601977|NCT00000543|BEHAVIORAL|dietary supplements|
218872185|NCT03720288|DRUG|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
219601978|NCT00000543|DRUG|calcium|
218872186|NCT00777361|DRUG|AZD3480|Iv single dose, 4-hour infusion of 25 mg
218872187|NCT00777361|DRUG|AZD3480|Oral solution single dose of 50 mg
218872188|NCT00590343|DRUG|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
218872189|NCT02783092|DRUG|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
219022199|NCT05212714|DEVICE|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
219022200|NCT02014844|DRUG|250 mg/m2 aldoxorubicin|
219022201|NCT02014844|DRUG|350 mg/m2 aldoxorubicin|
219022202|NCT05585151|DRUG|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
219022203|NCT05585151|DRUG|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
219022204|NCT04602182|PROCEDURE|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
219022205|NCT03519347|OTHER|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
219022206|NCT03519347|OTHER|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
219022207|NCT03519347|OTHER|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
218872190|NCT02783092|DRUG|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
219022208|NCT03519347|OTHER|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
219022209|NCT03519347|DIAGNOSTIC_TEST|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
219200021|NCT06871098|OTHER|Hip Hinge Instruction|The participant will be instructed to perform a hip hinge movement based on their current understanding and ability. This initial movement assessment will serve as a baseline measure to analyze the participant's natural hip hinge mechanics before any intervention. The purpose of this assessment is to determine whether the implementation of the Founder Exercise intervention leads to significant changes in the kinematics of the hip hinge movement.
219492836|NCT02682433|DEVICE|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
219492837|NCT00963599|DRUG|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
219492838|NCT00963599|DRUG|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
219492839|NCT00963599|DRUG|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
219492840|NCT00963599|DRUG|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
219492841|NCT00243282|BEHAVIORAL|Relaxation Response (instruction, pocket practice card prov)|
219492842|NCT00243282|BEHAVIORAL|Mindfulness training using model developed from UMass|
218872191|NCT02479815|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
218872192|NCT06098248|DIAGNOSTIC_TEST|cCeLL - Ex vivo|Neoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.
219492843|NCT02135094|DEVICE|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
219492844|NCT02135094|DEVICE|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
219492845|NCT00148694|DRUG|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
219601979|NCT06299787|DEVICE|intermittent theta burst stimulation|Theta-burst stimulation
218872193|NCT04780412|DRUG|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
218872194|NCT04780412|DRUG|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
218872195|NCT00067379|PROCEDURE|interceptive orthodontic treatments|orthodontic procedures
218872196|NCT05604742|DRUG|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
219022210|NCT03519347|DEVICE|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
219022211|NCT02078609|DRUG|LGH447|LGH447 in patients with AML or MDS
219022212|NCT02078609|DRUG|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
219022213|NCT04890366|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
219022214|NCT05517382|OTHER|supportED|suicide prevention videogame
219022215|NCT05517382|OTHER|Control|non-health related videogame
219492846|NCT06529458|OTHER|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
219492847|NCT06529458|OTHER|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
219492848|NCT06529458|OTHER|Control Group|No interference will be made
219492849|NCT02549274|OTHER|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
219492850|NCT02549274|OTHER|physiotherapy|14 physiotherapy sessions (2 by week)
219601980|NCT06299787|DEVICE|Sham stimulation|Stimulation with double-sided B70-type coil
218872197|NCT04573686|DRUG|Erythropoietin|Erythropoietin will be given subcutenous to all patients
218872198|NCT02286635|DRUG|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
218872199|NCT02286635|DRUG|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
218872200|NCT01085435|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
218872201|NCT00133224|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
218872202|NCT00133224|DRUG|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
219022216|NCT01871116|BEHAVIORAL|POWER-remote|Web-based weight loss program.
219022217|NCT01871116|BEHAVIORAL|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
219022218|NCT01641692|DRUG|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
219022219|NCT01641692|PROCEDURE|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
219022220|NCT01641692|DRUG|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
219601981|NCT03766815|DIETARY_SUPPLEMENT|BCAA 200mg/kg/day|BCAA supplement based on 200mg/kg/day for 18 days.
219601982|NCT03766815|DIETARY_SUPPLEMENT|Placebo|Fiber supplement jelly for 18 days.
219601983|NCT03766815|DIETARY_SUPPLEMENT|BCAA 400mg/kg/day|BCAA supplement based on 400mg/kg/day for 18 days.
219601984|NCT03766815|BEHAVIORAL|Muscle damaging exercise|Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
219022221|NCT03164096|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
219022222|NCT00841087|DRUG|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
219022223|NCT00841087|DRUG|insulin detemir|Injection subcutaneously at bedtime
219022224|NCT00841087|DRUG|insulin aspart|Injection subcutaneously immediately before each meal.
219022225|NCT03249311|DRUG|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
219022226|NCT03249311|DRUG|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
218872203|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
218872204|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
218872205|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
219492851|NCT02634567|BEHAVIORAL|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
219492852|NCT05176301|RADIATION|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
219492853|NCT05700110|OTHER|Non-Interventional|Non-interventional
219492854|NCT02022410|OTHER|CAS after primary and revision TKA|CAS and RAPT
219492855|NCT00839007|DRUG|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
219492856|NCT04496778|DEVICE|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
219492857|NCT04496778|OTHER|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
219492858|NCT02034617|BEHAVIORAL|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
219492859|NCT04382690|BEHAVIORAL|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
218872206|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
218872207|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
218872208|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
218872209|NCT05792917|DRUG|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
219492860|NCT05762510|GENETIC|GMCN-508B (LentiRed)|LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
219492861|NCT01002131|DEVICE|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
219492862|NCT06541418|BEHAVIORAL|Transtheoretic Model Based Behavior Change Program|The Behavior Change Program was implemented in 7 sessions of 50 minutes, once a week. Each session in the Behavior Change Program; The warm-up exercise consisted of giving general information about the purpose and the main theme of the session, discussion and feedback on the subject, and the planning of the next week, and a closing process. The Transtheoretic Model Based Behavior Change Program was prepared by the researcher with reference to the behavior change programs in the literature and the elements of the Transtheoretic model.
219492863|NCT01545752|OTHER|teaching by non-interactive CD|teaching book with non-interactive CD
219492864|NCT01545752|OTHER|Interactive CD|Teaching book with interactive CD
219492865|NCT03027973|DRUG|UPA|Experimental drug
219492866|NCT03027973|DRUG|TEA|Active comparator
219492867|NCT03027973|DRUG|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
219601985|NCT06328049|DRUG|Trilaciclib Injection|Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
219492868|NCT03027973|DRUG|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
219492869|NCT00123487|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
219492870|NCT00123487|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
219492871|NCT02345863|DRUG|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
219601986|NCT03639779|DRUG|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
218872210|NCT05792917|DRUG|tafolecimab (a original manufacturing process)|450mg，SC，single dose
219492872|NCT02345863|DRUG|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
219492873|NCT02345863|DRUG|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
218872211|NCT02114255|OTHER|Placebo|Administration of 0.9% NaCl.
219492874|NCT04368325|DIAGNOSTIC_TEST|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
219492875|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
219492876|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
219492877|NCT02533323|DRUG|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
219492878|NCT02533323|DRUG|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
219492879|NCT02533323|DRUG|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
219492880|NCT00764049|DEVICE|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
219492881|NCT00213213|DRUG|Sucrose|
219492882|NCT03835975|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
219492883|NCT03835975|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
219492884|NCT03835975|BIOLOGICAL|20vPnC|Pneumococcal conjugate vaccine
219492885|NCT01788059|OTHER|injection the mesenchymal stem cell in non union site|
219492886|NCT01406275|DRUG|Amoxicillin and clavulanate|
219492887|NCT01904552|DEVICE|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
219492888|NCT05312255|BEHAVIORAL|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
219492889|NCT05312255|DRUG|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
219601987|NCT03639779|OTHER|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
219601988|NCT02088697|DRUG|Placebo|
219601989|NCT02088697|DRUG|ASC-01|
219601990|NCT02368483|OTHER|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
218872212|NCT02114255|BIOLOGICAL|BCG|Vaccination with the live attenuated BCG vaccine.
218872213|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
219492890|NCT05312255|DRUG|Propranolol|Given PO
219492891|NCT05312255|OTHER|Quality-of-Life Assessment|Ancillary studies
219492892|NCT05312255|OTHER|Questionnaire Administration|Ancillary studies
219492893|NCT05312255|OTHER|Resistance Training|Undergo strength training for 6 months
219492894|NCT05312255|OTHER|Short-Term Fasting|Participate in intermittent fasting
219492895|NCT02267252|OTHER|Antibody-sperm binding|
219492896|NCT02197169|DRUG|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
219492897|NCT02197169|DRUG|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
219492898|NCT04608084|BIOLOGICAL|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
219492899|NCT03115060|DRUG|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
219601991|NCT00810511|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel contact lens
219601992|NCT00810511|DEVICE|Comfilcon A contact lens|Silicone hydrogel contact lens
218872214|NCT04840329|BEHAVIORAL|Education|One-time educational session about menstrual health and endometriosis
218872215|NCT05270239|BEHAVIORAL|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
218872216|NCT05270239|BEHAVIORAL|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
218872217|NCT04079712|DRUG|Cabozantinib S-malate|Given PO
218872218|NCT04079712|BIOLOGICAL|Ipilimumab|Given IV
218872219|NCT04079712|BIOLOGICAL|Nivolumab|Given IV
218872220|NCT03034824|PROCEDURE|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
218872221|NCT03034824|PROCEDURE|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
218872222|NCT03034824|PROCEDURE|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
218872223|NCT04724967|DRUG|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
218872224|NCT04724967|DRUG|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
218872225|NCT05607667|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
218872226|NCT01591356|DRUG|EphA2-targeting DOPC-encapsulated siRNA|Given IV
218872227|NCT01591356|OTHER|Laboratory Biomarker Analysis|Correlative studies
218872228|NCT01591356|OTHER|Pharmacological Study|Correlative studies
218872229|NCT03567473|DRUG|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
218872230|NCT03567473|DRUG|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
218872231|NCT03567473|DRUG|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
219022227|NCT03249311|DRUG|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
219492900|NCT04466774|DIAGNOSTIC_TEST|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
219492901|NCT04466774|DEVICE|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
219022228|NCT01685996|DRUG|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
219022229|NCT01685996|DRUG|placebo|
219022230|NCT02254928|DRUG|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
219022231|NCT06144346|RADIATION|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
219022232|NCT06144346|PROCEDURE|Locoregional treatment|mastectomy or BCS for the primary tumor
219022233|NCT06144346|OTHER|Standard of Care|Systemic treatment and palliative treatment
219022234|NCT01761838|OTHER|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
219022235|NCT01761838|OTHER|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
218872232|NCT03567473|DRUG|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
219022236|NCT01761838|OTHER|Low back pain participants without SMT|No treatment
219022237|NCT02913079|BEHAVIORAL|Sit-stand desk|
219022238|NCT02913079|BEHAVIORAL|Sitting desk|
218872233|NCT03567473|DRUG|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
218872234|NCT03567473|DRUG|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
218872235|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
218872236|NCT00097890|DRUG|Replagal|
219022239|NCT03051321|DEVICE|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
219022240|NCT03945487|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
219022241|NCT03945487|OTHER|Comprehensive treatment|"1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
219022242|NCT00000609|DRUG|amiodarone|
219022243|NCT00000609|DEVICE|defibrillators, implantable|
219022244|NCT04023448|PROCEDURE|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
219022245|NCT01897012|DRUG|Alisertib|Given PO
219492902|NCT00966082|PROCEDURE|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
219492903|NCT00966082|PROCEDURE|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
219492904|NCT04212182|DEVICE|HFNC|HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
219492905|NCT04212182|DEVICE|NPPV|NPPV is the standard therapy for ventilatory failure in AECOPD.
219022246|NCT01897012|OTHER|Laboratory Biomarker Analysis|Correlative studies
219022247|NCT01897012|DRUG|Romidepsin|Given IV
219022248|NCT06526637|OTHER|Paper Package|Paper based (as per current practice at Central and North West London (CNWL) NHS Foundation Trust) version of Palliate.
219022249|NCT06526637|OTHER|V1 + Preparation Sheet|Paper based version of Palliate plus a preparation sheet, that provides visual cues as to what equipment is required for the preparation and administration of the medications.
219022250|NCT06526637|OTHER|V2 + Video Training|Hybrid - paper based materials, preparation sheet, and video instructions available via an interactive portable document format (PDF) version of the training materials.
219022251|NCT02775734|DRUG|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
219022252|NCT02775734|DRUG|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
219492906|NCT01935531|DRUG|3% diclofenac in 2.5% hyaluronic acid gel|
219601993|NCT04258592|DRUG|(18F)MFBG|One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)
219492907|NCT01725074|BEHAVIORAL|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening"
219492908|NCT01725074|BEHAVIORAL|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
219492909|NCT03512626|DEVICE|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
219492910|NCT03512626|DEVICE|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
219492911|NCT04039165|BEHAVIORAL|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
219492912|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
219492913|NCT02265640|DRUG|BIIL 284 BS boli|
219492914|NCT02265640|DRUG|BIIL 284 BS tablet C|
219492915|NCT02265640|OTHER|standard breakfast|
219492916|NCT06567535|PROCEDURE|Navigation and endoscopy|The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
219492917|NCT01188642|BEHAVIORAL|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
219022253|NCT05855668|BEHAVIORAL|CBT|12 weeks of group CBT for AUD or CUD
219022254|NCT03021239|PROCEDURE|Echo Guided Testing|
219022255|NCT03021239|PROCEDURE|Hemodynamic-Echo Ramp Testing -|
219022256|NCT04615663|BEHAVIORAL|Score SMI|the investigator will complete the SMI score
219022257|NCT05666258|DIAGNOSTIC_TEST|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
219022258|NCT05943145|OTHER|Group Dance and Movement Training|Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
219022259|NCT01801644|DRUG|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
219492918|NCT05365022|DEVICE|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
219492919|NCT01350531|BEHAVIORAL|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
219492920|NCT01350531|BEHAVIORAL|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
219492921|NCT01785043|DRUG|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
219601994|NCT04258592|DEVICE|PET/CT|Adult patients will undergo a dynamic PET scan for the first 30 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
219022260|NCT02563795|DRUG|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
219022261|NCT02563795|DRUG|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
219022262|NCT00656409|DRUG|Conjugated pneumococcal vaccine (Prevenar)|
219022263|NCT01326767|DRUG|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
219022264|NCT01326767|DRUG|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
219022265|NCT03563417|PROCEDURE|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
219492922|NCT01785043|DRUG|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
219492923|NCT06566625|DIAGNOSTIC_TEST|Cardiac MRI (CMR) examination|"An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)"
219492924|NCT02314949|PROCEDURE|intestinal transplantation|
219492925|NCT06541743|DEVICE|Regular Toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
219022266|NCT03563417|OTHER|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
219022267|NCT00206414|DRUG|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
219022268|NCT00206414|DRUG|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
219492926|NCT06541743|DEVICE|Musical toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
219492927|NCT06541743|DEVICE|Electric toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
219601995|NCT04258592|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, in patients undergoing a dynamic PET scan venous blood samples will be obtained for metabolite analysis and activity measurements at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min and 120 ± 60 min in adult participants; 5 ± 2 min, 10 ± 5 min, 30 ± 15 min, 50 ± 25 min, 90 ± 30 min in minor participants).
219601996|NCT00462904|DRUG|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
219601997|NCT02325492|DRUG|Aramchol|
219601998|NCT02325492|DRUG|Placebo|
219601999|NCT02325492|DEVICE|Ultrasound|
219602000|NCT04177082|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
219602001|NCT01221701|BEHAVIORAL|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
219022269|NCT00199927|DRUG|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
219022270|NCT00199927|DRUG|standard therapy|standard therapy
219022271|NCT05482009|OTHER|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
219602002|NCT01494116|OTHER|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
219602003|NCT00145951|BEHAVIORAL|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
219602004|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
219602005|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
219022272|NCT04321148|PROCEDURE|standard of care PCI|optimal medical care PCI
219022273|NCT04321148|PROCEDURE|Impella-protected PCI|Impella-protected PCI
219022274|NCT04432051|BEHAVIORAL|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
219022275|NCT06447727|DRUG|SIRT with Yttrium-90 Microspheres|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
219022276|NCT06447727|DRUG|FOLFIRI and Bevacizumab|FOLFIRI and Bevacizumab
219022277|NCT04368286|BEHAVIORAL|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
219022278|NCT04948450|BEHAVIORAL|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (6-10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
219022279|NCT04948450|BEHAVIORAL|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (6-10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
219022280|NCT04948450|BEHAVIORAL|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
219022281|NCT04948450|OTHER|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 8 %."
219602006|NCT03106675|DEVICE|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
219602007|NCT03106675|DEVICE|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
219602008|NCT03232593|DRUG|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
219602009|NCT05271656|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
219602010|NCT03815461|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
219602011|NCT06511765|DRUG|Ropivacaine and dexamethasone injection solution|Injection of Ropivacaine and dexamethasone
219602012|NCT06511765|DRUG|Sodium Chloride 0.9% Injection Solution|Injection of sodium chloride 0.9%
219602013|NCT02930044|OTHER|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
219602014|NCT02930044|OTHER|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
218872237|NCT03771950|BEHAVIORAL|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
219022282|NCT00897247|GENETIC|microarray analysis|
218872238|NCT04195555|DRUG|Ivosidenib|Given PO
218872239|NCT02166463|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
219022283|NCT00897247|GENETIC|protein expression analysis|
219022284|NCT00897247|GENETIC|proteomic profiling|
219022285|NCT00897247|OTHER|laboratory biomarker analysis|
219602015|NCT02930044|DRUG|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
219022286|NCT00358566|BIOLOGICAL|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
219602016|NCT06583044|OTHER|Questionnaire|It includes 33 questions measuring awareness and knowledge about bruxism.
219602017|NCT04606160|BEHAVIORAL|Single Session Problem-Solving Intervention|The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
219602018|NCT04076930|DRUG|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
218872240|NCT02166463|DRUG|Brentuximab Vedotin|Given IV
218872241|NCT02166463|DRUG|Cyclophosphamide|Given IV
219022287|NCT00358566|DRUG|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
219492928|NCT03248778|BEHAVIORAL|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
219492929|NCT02339428|DRUG|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
219492930|NCT02339428|DRUG|Placebo|Inactive pill manufactured to mimic diclofenac tablet
219492931|NCT03343145|BIOLOGICAL|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
219492932|NCT03343145|BIOLOGICAL|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
219492933|NCT00995488|DRUG|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
219492934|NCT06611033|BIOLOGICAL|V118C|Intramuscular Administration
219492935|NCT06611033|BIOLOGICAL|V118|Intramuscular Administration
219492936|NCT06611033|BIOLOGICAL|PREVNAR 20™|Intramuscular Administration
219492937|NCT06611033|BIOLOGICAL|Saline|Intramuscular Administration
219492938|NCT04640909|OTHER|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
219492939|NCT04580173|DIAGNOSTIC_TEST|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
219492940|NCT02238470|DRUG|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
219492941|NCT01832688|OTHER|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
219492942|NCT03345953|DRUG|BP 1.4979|Double blind versus placebo
219492943|NCT03345953|DRUG|Placebo|Double blind versus placebo
219492944|NCT00438035|PROCEDURE|ECG spectral|
219492945|NCT00081835|DRUG|NP-016 Vaccine Immune Globulin (IV-VIG)|
219492946|NCT06701396|DRUG|Tasimelteon|Oral capsule
219492947|NCT06701396|DRUG|Placebo|Oral capsule
219492948|NCT03923816|DRUG|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
219492949|NCT04501341|BIOLOGICAL|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
219492950|NCT04501341|BIOLOGICAL|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
219492951|NCT05354336|DRUG|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
219492952|NCT05354336|DRUG|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
219492953|NCT05354336|DRUG|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
219492954|NCT01781689|PROCEDURE|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
219492955|NCT01781689|OTHER|Rehabilitation programs|include occupational therapy and physical therapy
219492956|NCT00061945|DRUG|allopurinol|Given PO
219492957|NCT00061945|DRUG|cyclophosphamide|Given IV
219492958|NCT00061945|DRUG|daunorubicin hydrochloride|Given IV
219492959|NCT00061945|DRUG|vincristine sulfate|Given IV
219492960|NCT00061945|DRUG|dexamethasone|Given PO and as eye drops
219492961|NCT00061945|DRUG|asparaginase|Given SC
219492962|NCT00061945|BIOLOGICAL|filgrastim|Given SC
219492963|NCT00061945|DRUG|imatinib mesylate|Given PO
219492964|NCT00061945|DRUG|methotrexate|Given IT, IV, and PO
219492965|NCT00061945|DRUG|cytarabine|Given IV
219492966|NCT00061945|DRUG|trimethoprim-sulfamethoxazole|Given PO
219492967|NCT00061945|DRUG|mercaptopurine|Given PO
219492968|NCT00061945|DRUG|leucovorin calcium|Given IV and PO
219492969|NCT00061945|BIOLOGICAL|alemtuzumab|Given SC
219492970|NCT00061945|DRUG|acyclovir|Given PO
219492971|NCT00061945|OTHER|laboratory biomarker analysis|Correlative studies
219492972|NCT00061945|OTHER|pharmacological study|Correlative studies
219492973|NCT02493985|OTHER|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
219492974|NCT02493985|OTHER|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
219492975|NCT06479746|BEHAVIORAL|Emotional support|Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
219492976|NCT04326569|OTHER|Blood sample|Blood sample to quantify copeptin
219492977|NCT06338800|BEHAVIORAL|One session exposure with Virtual Reality|Participants will receive one session exposure with virtual reality from their therapists.
219022288|NCT03099876|PROCEDURE|treatment period|7 days treatment or 10 days treatment
219022289|NCT01352988|DRUG|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
218872242|NCT02166463|DRUG|Doxorubicin Hydrochloride|Given IV
218872243|NCT02166463|DRUG|Etoposide|Given IV
219022290|NCT00623064|DRUG|cisplatin|
219022291|NCT00623064|DRUG|gemcitabine hydrochloride|
219022292|NCT00623064|DRUG|lapatinib ditosylate|
219022293|NCT00623064|OTHER|pharmacological study|
219022294|NCT04528745|DIAGNOSTIC_TEST|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
219022295|NCT02478554|OTHER|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
219022296|NCT00657241|DRUG|Carvedilol CR|
219022297|NCT00657241|DRUG|Valsartan|
219022298|NCT03906903|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
219022299|NCT03906903|BEHAVIORAL|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
219022300|NCT04078061|BEHAVIORAL|MABA|Adaptive, modular, behavioral intervention.
219022301|NCT04078061|BEHAVIORAL|EIBI|Early Intensive Behavioral Intervention
218872244|NCT02166463|OTHER|Laboratory Biomarker Analysis|Correlative studies
218872245|NCT02166463|DRUG|Methylprednisolone|Given IV
218872246|NCT02166463|OTHER|Pharmacological Study|Correlative studies
218872247|NCT02166463|DRUG|Prednisone|Given PO
218872248|NCT02166463|OTHER|Quality-of-Life Assessment|Ancillary studies
218872249|NCT02166463|OTHER|Questionnaire Administration|Ancillary studies
218872250|NCT02166463|DRUG|Vincristine Sulfate|Given IV
218872251|NCT05074277|BEHAVIORAL|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
218872252|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
218872253|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
218872254|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
219022302|NCT05982392|DRUG|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
219022303|NCT05982392|DRUG|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
219022304|NCT05982392|DRUG|Placebo|Placebo will be given 60 minutes before start of procedure.
219022305|NCT00050596|DRUG|MDX-010 / MDX-010 + Docetaxel|
219022306|NCT06914375|OTHER|Goya Foods - Canned Chickpeas|Whole-cooked, canned chickpeas supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
219022307|NCT06914375|OTHER|Goya Foods - Canned Lentils|Whole-cooked, canned lentils supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
219022308|NCT06914375|OTHER|Control|Participants in the Control condition (CTL) will be asked to consume their standard diet while avoiding any and all pulse intake.
219022309|NCT07191106|PROCEDURE|adapted physical activity|Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application
219022310|NCT03730948|BIOLOGICAL|DC vaccine|DC vaccine for colorectal cancer
219022311|NCT00330291|DRUG|Xyrem|
219022312|NCT06081543|DIETARY_SUPPLEMENT|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
219022313|NCT06081543|DIETARY_SUPPLEMENT|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
219022314|NCT05283252|DEVICE|3-D printed Guide|Guided Endodontic micro-surgery
219022315|NCT05283252|OTHER|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
219022316|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
219022317|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
219022318|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
219022319|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
219022320|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
218872255|NCT04705766|OTHER|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
219492978|NCT01578252|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
218872256|NCT05006599|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
218872257|NCT05006599|DRUG|Placebo|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
218872258|NCT05006599|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
218872259|NCT05651126|DRUG|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
218872260|NCT05651126|DRUG|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
218872261|NCT05651126|DRUG|Placebo|Inactive placebo
218872262|NCT06465693|DEVICE|Unblinded CGM plus nutrition therapy|"will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.~will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together"
218872263|NCT06465693|BEHAVIORAL|Nutrition therapy only|will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
218872264|NCT05210283|DEVICE|MRD|ctDNA MRD test
218872265|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 25 mg
218872266|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 50 mg
218872267|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 75 mg
218872268|NCT06777901|DEVICE|Auryon Atherectomy System|Auryon Atherectomy System is composed of a laser and catheter
218872269|NCT06777901|DEVICE|Balloon Angioplasty|Balloon Angioplasty alone
218872270|NCT05134948|DRUG|BMS-986213|Specified dose on specified days
218872271|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 10 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
218872272|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
218872273|NCT06583486|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.
218872274|NCT02478164|DRUG|Ponatinib|
218872275|NCT06481735|BIOLOGICAL|TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
218872276|NCT06481735|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
218872277|NCT06481735|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
218872278|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
218872279|NCT04588389|DRUG|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
218872280|NCT04588389|DRUG|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
218872281|NCT04588389|DRUG|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
218872282|NCT00230958|DRUG|Viramidine|
218872283|NCT00230958|DRUG|Ribavirin|
218872284|NCT00230958|DRUG|pegylated interferon alfa-2b|
218872285|NCT05242952|BEHAVIORAL|Gaming in a virtual environment|To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.
218872286|NCT02911142|DRUG|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
218872287|NCT02911142|DRUG|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH). During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
218872288|NCT02911142|DRUG|Prednisone|During cycle 1, Prednisone 60 mg/m\^2 /day by mouth (PO) days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\^2 /day PO days 1-5.
218872289|NCT02911142|DRUG|Etoposide|During cycle 1, Etoposide 50 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m\^2/day continuous intravenous infusion days 1 to 4.
218872290|NCT02911142|DRUG|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m\^2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
218872291|NCT02911142|DRUG|Vincristine|During cycle 1, Vincristine 0.4 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
218872292|NCT02911142|DRUG|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m\^2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\^2 day 5.
218872293|NCT02911142|DIAGNOSTIC_TEST|CT of neck, chest, abdomen and pelvis|Screening
218872294|NCT02911142|DIAGNOSTIC_TEST|18FDG-PET scan|Baseline
218872295|NCT02911142|DIAGNOSTIC_TEST|MRI Brain|Screening
218872296|NCT02911142|PROCEDURE|Bone marrow biopsy|Baseline
218872297|NCT02911142|DIAGNOSTIC_TEST|EKG|Screening
219492979|NCT01578252|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
219492980|NCT00086931|DRUG|capecitabine|oral dose escalating, twice daily.
219492981|NCT00086931|DRUG|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
219492982|NCT00086931|PROCEDURE|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
219492983|NCT00086931|PROCEDURE|neoadjuvant therapy|chemotherapy and radiation prior to surgery
219492984|NCT00086931|RADIATION|radiation therapy|once daily 5 days a week for 5.5 weeks
219204498|NCT06773442|OTHER|Rehabilitation Practices Group|"Evidence-Based Training Program:Develop a structured training program for rehabilitation professionals focusing on evidence-based shoulder rehabilitation practices.~Clinical Mentorship and Supervision:Implement a mentorship program where experienced rehabilitation professionals provide guidance and support to junior staff members.~Standardization of Rehabilitation Protocols:Review and standardize rehabilitation protocols for common shoulder conditions based on current evidence and best practices.~Patient-Centered Care Approach:Adopt a patient-centered approach to shoulder rehabilitation, emphasizing shared decision-making and individualized treatment plans Outcome Monitoring and Quality Improvement:Use standardized outcome measures to evaluate improvements in pain, function, range of motion, and patient satisfaction."
219492985|NCT02604186|OTHER|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
219492986|NCT02604186|OTHER|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
219492987|NCT04698278|DEVICE|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
219492988|NCT03756207|PROCEDURE|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
219492989|NCT00701168|DEVICE|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
219602019|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
218872298|NCT02911142|DIAGNOSTIC_TEST|Echocardiogram|Screening
218872299|NCT02911142|DIAGNOSTIC_TEST|Ultrasound|Day 6
218872300|NCT02911142|DIAGNOSTIC_TEST|Bronchoscopy|Baseline
218872301|NCT02911142|DIAGNOSTIC_TEST|Endoscopy|Baseline
218872302|NCT02911142|DIAGNOSTIC_TEST|CXR: PA/lat/decub|Screening
218872303|NCT06359756|PROCEDURE|Ischemic postconditioning in carotid surgery|After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.
218872304|NCT06359756|PROCEDURE|Eversion Carotid Endarterectomy|Standard Eversion Carotid Endarterectomy
218872305|NCT06038227|PROCEDURE|Robotic Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
218872306|NCT06038227|PROCEDURE|Video Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
218872307|NCT04396158|RADIATION|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
218872308|NCT03680300|OTHER|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
218872309|NCT03680300|OTHER|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
218872310|NCT03680300|OTHER|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
219492990|NCT02865642|DRUG|Serotonin Uptake Inhibitors|
219492991|NCT02865642|DRUG|Placebo|
219492992|NCT04493554|DRUG|Vasopressin|Administration of vasopressin (20 IU) intranasally
219492993|NCT04493554|DRUG|Placebo|Administration of placebo intranasally
219492994|NCT01819389|DRUG|Imatinib and Nilotinib|
219492995|NCT06390111|DRUG|nadofaragene firadenovec|The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
219492996|NCT01039584|DRUG|Butoconazole Nitrate Vaginal Cream|vaginal cream
219492997|NCT01039584|DRUG|Placebo|vaginal cream
219492998|NCT01039584|DRUG|Gynazole 1 vaginal cream|vaginal cream
219492999|NCT03341715|DRUG|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
219493000|NCT03341715|OTHER|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
219602020|NCT01775826|OTHER|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
219602021|NCT02614924|DEVICE|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
219602022|NCT02614924|DEVICE|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
219602023|NCT05736835|BIOLOGICAL|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
218872311|NCT06321965|OTHER|evaluation of muscle function|Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24
219602024|NCT03003195|DRUG|P10s-PADRE|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
219602025|NCT03673917|OTHER|Educational video|The educational video on skin cancer for cosmetologists
219602026|NCT03673917|OTHER|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
219602027|NCT06488534|DIETARY_SUPPLEMENT|Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)|A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.
219602028|NCT01012336|DRUG|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
219602029|NCT02517008|OTHER|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
219602030|NCT05820464|DIAGNOSTIC_TEST|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
219602031|NCT00911300|DRUG|fondaparinux|Comparison of different drugs
219602032|NCT00911300|DRUG|unfractionated heparin|Comparison of different drugs
219602033|NCT00911300|DRUG|Vitamin-K-Antagonist|Comparison of different drugs
219602034|NCT00180999|DRUG|Erythropoiétine|
219602035|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
219602036|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
219602037|NCT05532189|OTHER|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
219602038|NCT06531837|DRUG|Esketamine(Continuous infusion)|Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
219602039|NCT06531837|DRUG|Remifentanil (Target-Controlled Infusion)|The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
219602040|NCT06531837|DRUG|Flurbiprofen (Single intravenous injection)|Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
218872312|NCT06321965|OTHER|First-line cognitive assessment|"Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2.~All tests are evaluated at D0, and M18 :~Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years)~M-CHAT-R (\< 4 years) :~SRS-2 (≥ 2 years)"
218872313|NCT06321965|OTHER|second-line cognitive assessment|"In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center.~* EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile)~* FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF)~* M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ)."
219022321|NCT06450470|DEVICE|Therapeutic lens alone|Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
219493001|NCT02816749|PROCEDURE|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
219493002|NCT02816749|PROCEDURE|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
219493003|NCT03611751|DRUG|BMS-986165|Specified dose on specified days
219493004|NCT03611751|OTHER|Placebo|Specified dose on specified days
219493005|NCT03611751|DRUG|Apremilast|Specified dose on specified days
219493006|NCT02740660|DRUG|Caffeine 100mg / Albuterol 4mg|
219493007|NCT02740660|DRUG|Placebo|
219493008|NCT02740660|BEHAVIORAL|Family weight management counseling|
219493009|NCT04641273|DRUG|BAY1817080|Tablet, intake orally.
219493010|NCT04641273|DRUG|Placebo for BAY1817080|Tablet, intake orally.
219493011|NCT04641273|DRUG|Placebo for Pregabalin|Capsule, intake orally.
219493012|NCT04641273|DRUG|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
219493013|NCT04816162|DRUG|ketofol|prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
219493014|NCT04816162|DRUG|dexmedetomidine|2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
219022322|NCT06450470|COMBINATION_PRODUCT|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
219022323|NCT05260307|OTHER|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
219022324|NCT06701656|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
219022325|NCT06701656|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
219022326|NCT05591027|DRUG|Centella asiatica product|A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
219022327|NCT05591027|DRUG|Placebo|A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
219022328|NCT04736199|DRUG|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
219022329|NCT04736199|DRUG|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
219022330|NCT04736199|OTHER|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
219493015|NCT04816162|OTHER|normal saline|normal saline 0.9% in a syringe pump
218872314|NCT06321965|OTHER|Cardiac evaluation|"All tests are evaluated at D0, M12, and M24 :~Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate.~Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality:~* end-diastolic/end-systolic diameter/left ventricular ejection fraction~* Septal wall thickness / left ventricular posterior wall~* Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours."
218872315|NCT06321965|RADIATION|MRI|"Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences:~* 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition~* axial T2, spin-echo, slice thickness 4 mm~* 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution."
219493016|NCT02876705|OTHER|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
219493017|NCT06267677|DIETARY_SUPPLEMENT|High protein liquid formula|liquid and high amount of protein
219493018|NCT03529318|PROCEDURE|Biopsies from endoscopy|"1\) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
219493019|NCT05224518|BEHAVIORAL|elastic band training|elastic band training include stretching exercises
219022331|NCT06150118|OTHER|CBT+VR (Cognitive behavioral therapy and virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
219022332|NCT06150118|BEHAVIORAL|Control (placebo) group|The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
219022333|NCT06453642|DEVICE|GPX® Embolic Device|Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches
219022334|NCT05635175|OTHER|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
219022335|NCT05635175|OTHER|Standard pelvic floor muscle training|Standard pelvic floor muscle training
219602041|NCT06531837|DEVICE|Spinal Cord Stimulation|Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.
219022336|NCT05635175|OTHER|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
219022337|NCT04318080|DRUG|Tislelizumab|200 milligrams (mg) intravenously every 3 weeks (Q3W)
219022338|NCT05927376|BEHAVIORAL|Mediterranean diet|All foods, meal plans and instructions provided.
219022339|NCT05927376|BEHAVIORAL|Western diet|All foods, meal plans and instructions provided.
219022340|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
219493020|NCT04183218|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
219493021|NCT04183218|DEVICE|Cardiac Event Monitor|Receive cardiac monitor
219493022|NCT04183218|OTHER|Chemoradiotherapy|Undergo CRT
219493023|NCT04183218|RADIATION|Radiation Therapy|Undergo RT
219493024|NCT03408236|DRUG|Botulinum toxin type A|Experimental
219602042|NCT06531837|OTHER|No intervention|Collect resting-state EEG data and NRS scores.
219602043|NCT01055756|DRUG|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
219602044|NCT00948272|BIOLOGICAL|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
218872316|NCT06321965|OTHER|Assessment of activity and muscle fatigue|"Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities.~Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes.~PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations.~Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment."
219602045|NCT00948272|BIOLOGICAL|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
219602046|NCT05916430|DIAGNOSTIC_TEST|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
219602047|NCT05488964|BEHAVIORAL|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
218872317|NCT06321965|OTHER|Assessment of bulbar function|"DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria.~NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing.~TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker.~\- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit."
219022341|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
219022342|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
219040153|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
219040154|NCT04138875|DRUG|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.
219493025|NCT03408236|DRUG|Botulinum toxin type A|Active Comparator
219493026|NCT03672396|BEHAVIORAL|Home-based exercise|The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
219493027|NCT04270552|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
219493028|NCT04270552|DRUG|Placebo|Matched tablets without any active substance.
219602048|NCT04152291|DIETARY_SUPPLEMENT|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.
219602049|NCT03502460|OTHER|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
219602050|NCT05382559|DRUG|ASP3082|Intravenous Infusion
219602051|NCT05382559|DRUG|Cetuximab|Intravenous Infusion
219602052|NCT05382559|DRUG|Leucovorin|Intravenous Infusion
219602053|NCT05382559|DRUG|Oxaplatin|Intravenous Infusion
219602054|NCT05382559|DRUG|Fluorouracil|Intravenous Infusion
219602055|NCT05382559|DRUG|Irinotecan|Intravenous Infusion
219602056|NCT05382559|DRUG|Nanoparticle albumin-bound-paclitaxel|Intravenous Infusion
219602057|NCT05382559|DRUG|Gemcitabine|Intravenous Infusion
219602058|NCT05382559|DRUG|Docetaxel|Intravenous Infusion
219602059|NCT05382559|DRUG|Pembrolizumab|Intravenous Infusion
219602060|NCT05382559|DRUG|Cisplatin|Intravenous Infusion
219602061|NCT05382559|DRUG|Carboplatin|Intravenous Infusion
219602062|NCT05382559|DRUG|Pemetrexed|Intravenous Infusion
219602063|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
218872318|NCT06321965|OTHER|Evaluation of body composition and metabolism|"Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24.~Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract.~Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density.~Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload.~Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation."
219493029|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
219493030|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
218872319|NCT06321965|OTHER|Questionnaires|"SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24.~HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24.~Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24.~Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24.~Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24.~ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs."
218872320|NCT06321965|BIOLOGICAL|Biocollection|"A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24.~Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional)."
218872321|NCT06321965|OTHER|Skinfold measurement|The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24
218872322|NCT05562778|OTHER|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
218872323|NCT06259136|PROCEDURE|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
218872324|NCT05863650|DEVICE|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
219040155|NCT04138875|DRUG|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
219040156|NCT04138875|DRUG|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
219040157|NCT04845607|DRUG|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
219493031|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
219493032|NCT02306434|BEHAVIORAL|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
219493033|NCT02306434|OTHER|Standard care-counselling|Standard care (Counselling by midwives)
219493034|NCT02441179|OTHER|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
219022343|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
218872325|NCT05863650|OTHER|Face to face education|In the face-to-face education group, one case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
219602064|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
219602065|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
219602066|NCT04444921|DRUG|Carboplatin|Given IV
218872326|NCT05779007|DRUG|Pirfenidone|Pirfenidone
218872327|NCT05779007|DRUG|Nintedanib|Nintedanib
218872328|NCT04597437|DRUG|Zanamivir|Intravenous zanamivir
219493035|NCT02441179|OTHER|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
219493036|NCT02441179|OTHER|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
219493037|NCT04239638|DIAGNOSTIC_TEST|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
218872329|NCT04597437|OTHER|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
218872330|NCT05500807|DRUG|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
218872331|NCT02963064|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
218872332|NCT06299891|DRUG|Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]|To assess safety and maximum tolerated dose as well as efficacy on weight loss of Phentermine/Topiramate in individuals with hypothalamic obesity.
218872333|NCT06299891|OTHER|Placebo|To assess safety and maximum tolerated dose as well as efficacy on weight loss of placebo treatment in individuals with hypothalamic obesity.
218872334|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
219022344|NCT04537026|DRUG|Amniotic Fluid Allograft|Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
219022345|NCT04537026|DRUG|Dexamethasone sodium phosphate|Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
219493038|NCT04628221|DEVICE|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
219493039|NCT04902261|DRUG|Tislelizumab|Tislelizumab 200 mg every three weeks
219493040|NCT04902261|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
219493041|NCT04902261|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
218872335|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
218872336|NCT06987890|OTHER|Practical Geriatric Assessment|The Practical Geriatric Assessment (PGA) is an abridged version of the Comprehensive Geriatric Assessment (CGA). This tool can be completed by any provider within 10-25 minutes while still capturing the key domains of the CGA. This screening tool, which is now recommended by American Society of Clinical Oncology (ASCO), the International Society for Geriatric Oncology (SIOG), and the Cancer \& Aging Research Group (CARG), has the potential capacity to delineate relevant baseline features in geriatric populations without creating undue provider burden.
218872337|NCT05081219|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
218872338|NCT05081219|DRUG|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
218872339|NCT05081219|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
219493042|NCT02702271|DEVICE|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
219493043|NCT02462239|OTHER|Whole-body FDG PET-CT|
219493044|NCT06315725|OTHER|Sweet taste perception with/without sweet taste blockade|In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.
219493045|NCT00393770|DRUG|L-acetylcarnitine|250-500 mg/kg/die.
219493046|NCT03744806|DRUG|Bevacizumab Injection|
219602067|NCT04444921|BIOLOGICAL|Nivolumab|Given IV
219602068|NCT04444921|DRUG|Paclitaxel|Given IV
219602069|NCT06965413|DRUG|RO7204239|RO7204239 or matching placebo will be administered as per the schedule specified in the arms.
218872340|NCT05081219|DRUG|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
218872341|NCT05081219|DRUG|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
219022346|NCT05417516|RADIATION|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
219022347|NCT05417516|RADIATION|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
219022348|NCT06458712|DRUG|DSB2455|PARP1 inhibitor
219022349|NCT06611423|BIOLOGICAL|AZD3427|AZD3427 SC injection to be prepared using AZD3427 diluent
219022350|NCT06611423|OTHER|AZD3427 Placebo|AZD3427 Placebo
219022351|NCT06611423|DRUG|Dopamine|Dopamine Hydrochloride 50mg/5mL
219022352|NCT06611423|OTHER|Radiolabelled ligand|Injection of radioligand for PET examinations
219493047|NCT01257828|DRUG|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
219493048|NCT01257828|DRUG|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
219493049|NCT04690387|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
219493050|NCT04690387|OTHER|GM-CSF|GM-CSF as an adjuvant
219493051|NCT00667498|DRUG|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
219493052|NCT00667498|DRUG|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
219493053|NCT06416761|GENETIC|genetic polymorphisms|
219493054|NCT05969028|DEVICE|igel|First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
219602070|NCT06965413|DRUG|RO7204239 Matching Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the arm.
219602071|NCT06965413|DRUG|Tirzepatide|Tirzepatide will be administered as per the schedule specified in the arms.
219602072|NCT06491680|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose."
219602073|NCT00370240|DRUG|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
219602074|NCT00370240|OTHER|placebo|The PCB group received saline solution in equal volume.
219602075|NCT05565482|BEHAVIORAL|Work Chat: An Interactive Virtual Workday|Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
219602076|NCT05124691|COMBINATION_PRODUCT|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
219602077|NCT05124691|DRUG|Albendazole|Albendazole 400mg single dose
218872342|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
218872343|NCT01638546|OTHER|Placebo Administration|Given PO
218872344|NCT01638546|DRUG|Temozolomide|Given PO
219022353|NCT06611423|OTHER|Saline|Saline solution
218872345|NCT01638546|DRUG|Veliparib|Given PO
218872346|NCT07088783|BEHAVIORAL|Mobile App Education|A 24-week self-care education delivered via a mobile application based on Orem's Self-Care Model
218872347|NCT07089433|PROCEDURE|Palatal stent as wound dressing|The palatal wound after graft harvesting will be protected with a flowable composite resin adhesively secured to adjacent teeth
218872348|NCT07089433|PROCEDURE|Conventional suturing|The wound will be covered with a collagen sponge that will be hold in place with sutures
218872349|NCT07087782|OTHER|Fortini formula|Fortini, a commercially available formula providing 30 kcal/oz, is commonly used in older children with failure to thrive or feeding intolerance. It offers the theoretical benefit of providing higher caloric density in a lower volume, which may be advantageous in infants with single ventricle physiology, who often have limited volume tolerance and high metabolic demands.
219022354|NCT05367440|DRUG|AZD5305|Patients will receive an oral dose of AZD5305 once daily
219022355|NCT05367440|DRUG|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
219022356|NCT05367440|DRUG|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
219022357|NCT05367440|DRUG|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
219022358|NCT05367440|DRUG|Apalutamide|Patients will receive an oral dose of Apalutamide once daily
219602078|NCT05847582|BEHAVIORAL|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
219602079|NCT05847582|BEHAVIORAL|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
219602080|NCT05847582|BEHAVIORAL|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
218872350|NCT07087782|OTHER|Standard Nutritional Care|Standard infant formulas (including hydrolyzed formulas) fortification to 24-30 kcal/oz
218872351|NCT07087548|OTHER|Peloid Therapy|Peloid therapy will be applied using medical mud packs at 45°C for 30 minutes per session, 5 sessions per week for 3 consecutive weeks. The therapy will be administered to the lower back region in patients diagnosed with chronic lumbar disc herniation. This intervention aims to reduce pain and improve function through thermomechanical and biochemical effects of natural peloid.
218872352|NCT07087548|OTHER|Hotpack Therapy|The hot pack group applied 20 minutes, 5 days a week, once a day, for 15 sessions on the lumbar region. The boiler temperature of the hot packs used was 90 °C. Two towels were used, with the thickest side of the towels placed on the lumbar area of the individuals. Then, conventional TENS (80 Hz frequency) was applied to the painful area in the lumbar region for 20 minutes
219022359|NCT06814795|OTHER|Medically tailored meals|"The intervention will be 12-weeks in duration, with doses (meal deliveries) of up to 10 healthy, frozen meals per week for household use as needed, plus selected condiments for personalization"
219022360|NCT00410761|DRUG|ZD6474 (Vandetanib)|once daily oral tablet
219022361|NCT06703073|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
219022362|NCT06703073|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
219022363|NCT06703073|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
219022364|NCT06703073|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
219022365|NCT06703073|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
219022366|NCT06703073|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
219022367|NCT06829329|DRUG|AHB-137|AHB-137 will be administered .
219022368|NCT06829329|DRUG|NAs|NAs will be administered.
219022369|NCT06829329|DRUG|Placebo|Placebo will be administered .
219493055|NCT05969028|PROCEDURE|Compression Rate|Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
219493056|NCT00995540|DRUG|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
219493057|NCT00995540|DRUG|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
219493058|NCT00995540|DRUG|Placebo|Placebo tid subcutaneous injection for 12 weeks
219493059|NCT02044965|OTHER|Antibiotic|2 mg/kg per day via oral ingestion.
219602081|NCT06252948|OTHER|Non-interventional study (observational)|Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
219602082|NCT04724941|OTHER|No intervention|No intervention
218872353|NCT07087730|BEHAVIORAL|Virtual Training Program|Therapists randomized to this condition will receive the professional development via an asynchronous virtual training course. The Virtual Training will include written material, videos, interactive learning activities, and a text-based discussion forum where therapists and faculty will be able to interact in relation to the given activities. Clinical scenario and simulation-based interactive learning will allow therapists to explore clinical situations, make decisions, and evaluate consequences of their actions in a safe environment. Therapists will complete 6 study-related therapy sessions with 3 new patients. After therapists receive the Virtual Training and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
219040158|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
219040159|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
219602083|NCT01724450|DRUG|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
219602084|NCT01724450|DRUG|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
219602085|NCT05240209|OTHER|The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.|Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
219602086|NCT05087212|DRUG|plerixafor + G-CSF|subcutaneous (SC) injection
219040160|NCT05824806|BIOLOGICAL|PRP Protocol A|Platelet rich plasma protocol A
219040161|NCT05824806|BIOLOGICAL|PRP Protocol B|Platelet rich plasma protocol B
219040162|NCT05824806|DEVICE|Hyaluronic acid|Hyaluronic acid
219040163|NCT03671902|DEVICE|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
219040164|NCT04201561|DRUG|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
219040165|NCT04201561|DRUG|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
219040166|NCT04201561|DRUG|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
219493060|NCT02044965|DRUG|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
219493061|NCT00958685|DIETARY_SUPPLEMENT|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
219602087|NCT04151667|DRUG|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
219602088|NCT04151667|DRUG|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
219602089|NCT04151667|DRUG|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
219602090|NCT04151667|DRUG|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
219602091|NCT04975555|DRUG|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
219602092|NCT05810870|DRUG|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
219602093|NCT05810870|DRUG|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
219200022|NCT06867133|DEVICE|Electrophysiological rehabilitation|"On the basis of treatment in the control group, postoperative electrophysiological rehabilitation services were started for 30 minutes each time, once a day, for 6 consecutive days as one course of treatment, for a total of one course of treatment. The patch is located at the projection site of the lower abdomen uterus as shown in the figure, simulating bioelectric stimulation parameters: biphasic pulse current, frequency 2Hz, pulse width 3ms.~Simultaneously conducting family health education, including but not limited to:~1. Guidance on postoperative physical recovery after abortion: provide advice on postoperative care, nutrition, activity, and personal hygiene;~2. Introduction to contraceptive methods: Introduce the advantages and disadvantages of various contraceptive methods, and help patients choose the most suitable contraceptive method for themselves;~3. Other related health education: including fertility planning and the best time to conceive again."
219493062|NCT00958685|DIETARY_SUPPLEMENT|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
219493063|NCT04416672|OTHER|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~* the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~* the Hospital Anxiety and Depression Scale (HADS)~* The Patients' Global Impression of Change (PGIC) Scale."
219493064|NCT01359072|OTHER|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
219493065|NCT01003548|DEVICE|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
219493066|NCT01003548|DEVICE|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
219493067|NCT03887819|DIAGNOSTIC_TEST|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
219493068|NCT06567795|DEVICE|Hemotag|Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
219493069|NCT05473858|DRUG|OraVerse Injectable Product|injection of oraverse,
219493070|NCT05473858|DEVICE|diode laser|patient exposed to diode laser
219493071|NCT02780921|PROCEDURE|prehabilitation|
219493072|NCT02780921|OTHER|nutritional support|
219493073|NCT04517981|BEHAVIORAL|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
219493074|NCT04517981|OTHER|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
219493075|NCT03319381|BEHAVIORAL|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
218872354|NCT07087730|BEHAVIORAL|Training as Usual|Therapists randomized to this condition will receive the professional development training via a 3-day synchronous workshop delivered via video conference covering the same didactic content as the virtual training course. The workshop will include lectures, written material, videos, and live role play activities. Therapists will complete 6 study-related sessions with 3 new patients. After therapists receive the professional development through Training as Usual and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
218872355|NCT07087730|BEHAVIORAL|No Training|Therapists randomized to this control condition will provide psychotherapy via the study video conference platform to 3 new enrolled patients in their typical manner except that they and their patients will also complete the assessments necessary for the study. After study completion, the investigators will provide therapists in the control condition with access to virtual training.
218872356|NCT07088848|DEVICE|Gamified Digital Balance Assessment|"The GDBA further enhances the digitalized Brief-BESTest experience by incorporating gamification elements tailored to older adults, including points, avatars, real-time performance graphs, and leaderboards. The system provides automated feedback and maintains engagement through periodic avatar demonstrations when user inactivity is detected. Upon meeting task initiation criteria, a countdown triggers data capture.~The interface is designed for accessibility, featuring a high-contrast color scheme (black background with orange/green highlights), voice prompts, and intuitive controls. Upon completion, users receive a comprehensive report including total score, task-level feedback and training recommendations. A leaderboard feature promotes continued engagement, with gamified training modules under development.~At the end of the assessment, the system displays a summary including total balance score, task-specific feedback, a fall risk rating, and personalized training suggestions. Users"
218872357|NCT07088848|DEVICE|Digitalized Brief-BESTest design|"The digitalized Brief-BESTest was designed to digitize and automate the Brief-BESTest. While the traditional clinician-administered Brief-BESTest relies on subjective scoring, the digitalized Brief-BESTest enables self-guided assessments with automated, objective scoring-improving accessibility in community and home settings.~The system employs OpenPose to capture skeletal data via a standard 2D camera, tracking 17 anatomical landmarks (e.g., nose, neck, shoulders, hips, knees). Ten joint angles relevant to static and dynamic postural tasks (e.g., standing, sitting, single-leg stance, and simulated falls) are computed. The torso is defined as a vector from the neck to the midpoint between the hips, serving as a reference for postural alignment.~To convert pixel-based coordinates into metric units, the system uses the user's self-reported height with adjustments based on ISO anthropometric standards (correction factors: 10.77 cm for males, 10.06 cm for females) to approximate true body"
218872358|NCT07087470|BEHAVIORAL|Simulation-based education and classical education|Simulation-based psychosocial care skills training and classical psychosocial care skills training will be prepared for oncology nurses.
218872359|NCT07087470|BEHAVIORAL|classical education|classical psychosocial care skills training will be prepared for oncology nurses.
218872360|NCT07087977|DEVICE|HoYAG laser|Patients will be randomly assigned (1:1) to HoYAG laser or TFL laser group for miniPCNL surgery according to standard of care.
218872361|NCT07087977|DEVICE|TFL laser platform|Patients will be randomly assigned (1:1) to HoYAG or TFL laser group for MiniPCNL surgery according to standard of care.
218872362|NCT07088965|OTHER|16 / 5.000 survey application|Participants will be administered a self-administered questionnaire containing basic demographic information, questions on job profile and lifestyle practices, as well as the Standardized Nordic Questionnaire (SNA).
218872363|NCT07087678|DEVICE|Prodigy internal pulse generator occipital nerve stimulator|Electrical stimulation of the occipital nerves using an implantable device
218872364|NCT06912360|OTHER|CPAP|Continuous Positive Airway Pressure (CPAP) with Boussignac valve
218872365|NCT07089563|BEHAVIORAL|Calisthenics Exercise Program|The exercises were administered twice a week for eight weeks alongside their regular swimming training, with each session lasting approximately 30 minutes. Calisthenics exercise included crunch, reverse crunch, plank, super plank, superman, sumo squat, and squat jump movements.
218872366|NCT07089563|BEHAVIORAL|Life Kinetik Exercise Program|The exercise program was conducted twice a week for eight weeks alongside regular swimming training, with each session lasting approximately 30 minutes. It included various exercises designed to improve hand-eye coordination, balance, reaction time, and motor control, such as throwing, catching, and dribbling balls with both the right and left hands. Exercises involved catching the ball mid-air or after a bounce, tossing tennis balls simultaneously with both hands, and throwing balls against a wall with different catching techniques and hand usages to provide varied challenges.
219200023|NCT06867172|DIAGNOSTIC_TEST|computerized tomography|Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.
219493076|NCT02620319|DEVICE|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
219493077|NCT02313519|DIETARY_SUPPLEMENT|Probiotics|Probiotics are prepared in capsule form
219493078|NCT02313519|DIETARY_SUPPLEMENT|Placebo|Glucose powder
219493079|NCT00051636|DRUG|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
219493080|NCT00051636|DRUG|Risedronate|Oral risedronate 30 mg capsules.
219493081|NCT00051636|DRUG|Placebo to Risedronate|Oral placebo of risedronate capsules.
219493082|NCT00051636|DRUG|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
218872367|NCT07087418|DIAGNOSTIC_TEST|Kaplan-Meier analysis with log-rank testing|The non-inferiority of the virtual endoscopy group will be verified by comparing the predictive performance for prognostic indicators (e.g., clinical remission rate, recurrence risk) between the two groups during follow-up.
218872368|NCT07089355|DEVICE|Toro 88 Super Bore Aspiration Catheter|The Toro 88 Super Bore Aspiration Catheter is a neurovascular device designed for clot aspiration during mechanical thrombectomy procedures.
218872369|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
218872370|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
218872371|NCT02643732|DRUG|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
218872372|NCT02643732|DRUG|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
218872373|NCT07088055|DEVICE|Chewing device only|This group will be administered the Myo Munchee and be given a protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
219200024|NCT06867172|DIAGNOSTIC_TEST|Endosonography (EUS)|EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.
219200025|NCT06868121|OTHER|OMGYES.com|OMGYES.com is an interactive website that offers information, video tutorials, interviews, tips, and resources to explore female sexual pleasure through groundbreaking research that's told through the real-life experiences of women of all ages and life stages.
219493083|NCT00051636|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
219493084|NCT01426321|OTHER|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
219493085|NCT04495192|GENETIC|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
219493086|NCT00975884|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
219493087|NCT01656967|DEVICE|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
219493088|NCT01656967|DEVICE|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
219493089|NCT02364219|OTHER|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
219493090|NCT02364219|DEVICE|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
219493091|NCT06282666|PROCEDURE|Spinal anesthesia|Before the beginning of surgery, all patients will be anesthetized with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 1.5 - 2.5 mL solution. A pencil point spinal needle will be used.
219493092|NCT06282666|PROCEDURE|lumbar erector spinae plane block|Investigators will perform the lumbar ESPB under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, we will leave a catheter in the ESP. Then, we used 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL.
219493093|NCT06282666|PROCEDURE|Epidural analgesia|After identifying the epidural space and spinal anesthesia (combined technique), a catheter will be placed in the epidural space. Investigators will give an epidural catheter a test dose of 2% lidocaine (2 mL). At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL).
219493094|NCT06282666|PROCEDURE|patient-controlled analgesia|Each participant will receive a pump with oxycodone (1mg/ml) using a patient-controlled analgesia (PCA) technique, a bolus of 1 mL, and a lockout of 5 minutes for the first postoperative day.
219493095|NCT06282666|DIAGNOSTIC_TEST|Timed Up and Go test|Investigators will measure the time the patient took to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while rotating 180 degrees. We will assess the patient before the surgery and 24 and 48 hours after hip replacement.
219493096|NCT06282666|DIAGNOSTIC_TEST|neuropathic pain symptom inventory|The Neuropathic Pain Symptom Inventory (0-100; 0 denotes no pain, 100 the most severe pain) will be evaluated before the surgery and three and six months following the procedure.
219602094|NCT03985852|OTHER|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
219602095|NCT04345913|PROCEDURE|Biopsy Procedure|Undergo biopsy
219602096|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602097|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
218872374|NCT07088055|DEVICE|Myo Munchee and Oral Motor Therapy Treatment|This group will be administered an Oral Motoro Therapy program as well as a Myo Munchee protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
218872375|NCT07088055|OTHER|Oral Motor Therapy Treatment Arm|This group will be administered an Oral Motor Therapy program to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
218872376|NCT02551419|DIETARY_SUPPLEMENT|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
219022370|NCT06244784|BEHAVIORAL|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
219022371|NCT02926924|DEVICE|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
219022372|NCT02926924|OTHER|Standard Dressing|standard dressing with drain tube and bandage
219022373|NCT06701669|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
219022374|NCT06701669|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
219493097|NCT06282666|DIAGNOSTIC_TEST|Lovett test|A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
219493098|NCT06282666|DIAGNOSTIC_TEST|Visual analog scale|Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.
219493099|NCT06282666|DIAGNOSTIC_TEST|Quality of Recovery 40|Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.
219493100|NCT06282666|DIAGNOSTIC_TEST|Ability to sit, stand upright, and walk|A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
219493101|NCT05186922|BIOLOGICAL|CM326|CM326 injection
219493102|NCT05186922|OTHER|Placebo|Placebo
219493103|NCT05417126|BIOLOGICAL|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
219493104|NCT02528422|DRUG|Acyl-Ghrelin|
219493105|NCT04367922|BEHAVIORAL|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
219493106|NCT01669668|PROCEDURE|radiofrequency ablation|Undergo RFA
219493107|NCT01669668|PROCEDURE|laparoscopy|Undergo laparoscopic ultrasound
219493108|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
219493109|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
219493110|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
219493111|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
219493112|NCT00862888|DRUG|PF-00446687|Single 200mg dose as an oral solution
219493113|NCT00862888|DRUG|Placebo|Placebo for oral solution
218872377|NCT02551419|DIETARY_SUPPLEMENT|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
218872378|NCT01970059|DRUG|Extended-Release Carvedilol Sulfate|
218872379|NCT01970059|DRUG|Sustained-release Metoprolol Succinate|
218872380|NCT05204433|OTHER|no intervention|no intervention
219022375|NCT05695248|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous bolus injection.
219493114|NCT00862888|DRUG|Placebo|Placebo for tablet
219602098|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
219602099|NCT04345913|DRUG|Eribulin Mesylate|Given IV
219602100|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602101|NCT05686512|BEHAVIORAL|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
219022376|NCT05544513|DRUG|Ferrous sulfate 3 days week|Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
219022377|NCT05544513|DRUG|Ferrous sulfate daily|Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
219022378|NCT05544513|DRUG|Ferrous sulfate higher concentration|Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
219022379|NCT05907057|DRUG|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
219022380|NCT05907057|DRUG|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
219022381|NCT04624373|OTHER|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
219493115|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
218872381|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
218872382|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
218872383|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
218872384|NCT01628003|DEVICE|Brain MRI|Brain MRI
219493116|NCT00862888|DRUG|PF-00446687|Single 125 mg dose as an oral solution
219493117|NCT00862888|DRUG|PF-00446687|Single 175 mg dose as an oral solution
219493118|NCT00862888|DRUG|PF-00446687|Single 20 mg dose as an oral solution
219493119|NCT00862888|DRUG|Placebo|Placebo for oral solution
219493120|NCT00862888|DRUG|Placebo|Placebo for tablet
219493121|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
219493122|NCT04810507|DRUG|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
219493123|NCT03604601|PROCEDURE|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
219493124|NCT00479765|DRUG|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
219493125|NCT02105831|OTHER|Contrast ultrasound skeletal muscle perfusion imaging|1\. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
219040167|NCT00914030|OTHER|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
219493126|NCT00348569|DEVICE|64 Channel VCT|
219493127|NCT03983746|DEVICE|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
219493128|NCT04536467|DRUG|Goserelin|chemotherapy+goserelin
219493129|NCT04536467|DRUG|Chemotherapy|standard chemotherapy
219602102|NCT05686512|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
218872385|NCT01628003|DEVICE|MRI|Physical examination Neuropsychological testing Questionnaires
218872386|NCT04378231|DRUG|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
219040168|NCT03799484|DRUG|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
219040169|NCT03799484|DRUG|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
219040170|NCT03799484|DEVICE|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
219040171|NCT01667666|DRUG|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
218872387|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
218872388|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
218872389|NCT00549770|DRUG|LCZ696|
218872390|NCT00549770|DRUG|Valsartan|
218872391|NCT00549770|DRUG|AHU377|
219022382|NCT05449054|PROCEDURE|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
219022383|NCT00000533|BEHAVIORAL|social support|
219022384|NCT02742012|OTHER|the study is observational|the study is observational
219022385|NCT02346253|RADIATION|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
219022386|NCT02346253|DRUG|Bicalutamide|Given PO
219022387|NCT02346253|DRUG|Leuprolide Acetate|Given IM or SC
219022388|NCT02346253|DRUG|Goserelin Acetate|Given SC
219022389|NCT02346253|DRUG|Triptorelin Pamoate|Given IM
219022390|NCT02346253|DRUG|Degarelix|Given SC
219022391|NCT02346253|OTHER|Laboratory Biomarker Analysis|Correlative studies
219022392|NCT02346253|OTHER|Quality-of-Life Assessment|Ancillary studies
218872392|NCT00549770|DRUG|Placebo|
219022393|NCT04629287|DRUG|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
219022394|NCT04629287|DRUG|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
219022395|NCT02519920|DRUG|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
219022396|NCT02519920|DRUG|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
219022397|NCT02519920|DRUG|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
219022398|NCT02519920|DRUG|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
219022399|NCT04221685|OTHER|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
219602103|NCT03495427|DRUG|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
219602104|NCT03495427|DIAGNOSTIC_TEST|PSMA PET|PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
218872393|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
218872394|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
218872395|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
218872396|NCT01916850|DRUG|LX4211 400 mg|
218872397|NCT01916850|DRUG|LX4211 800 mg|
218872398|NCT01916850|DRUG|LX4211 Placebo|
218872399|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
218872400|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
218872401|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
218872402|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
218872403|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
218872404|NCT01940393|DRUG|Cetirizine|Drug administration
218872405|NCT01940393|DRUG|Desloratadine|Drug Administration
218872406|NCT01940393|DRUG|Fexofenadine|Drug administration
218872407|NCT01940393|DRUG|Ebastine|Drug administration
219022400|NCT04221685|OTHER|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
219022401|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
219022402|NCT04884711|OTHER|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
219022403|NCT04884711|OTHER|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
219022404|NCT04884711|OTHER|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
218872408|NCT01940393|DRUG|Bilastine|Drug administration
218872409|NCT00652886|DRUG|Oxandrolone|Tablets, 10mg, single-dose
219493130|NCT05525299|BEHAVIORAL|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, \_\_\_\_\_ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
219493131|NCT06221683|DRUG|Homoharringtonine|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
219493132|NCT06221683|DRUG|Cytarabine|100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
218872410|NCT00652886|DRUG|Oxandrin|tablets, 10mg, single-dose
219022405|NCT05300490|DRUG|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
219493133|NCT06221683|DRUG|Etoposide|100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
219493134|NCT06221683|DRUG|Venetoclax|100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
219493135|NCT06221683|DRUG|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
219493136|NCT06221683|DRUG|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
219493137|NCT06221683|DRUG|Idarubicin Hydrochloride|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
219493138|NCT06221683|DRUG|Sorafenib|100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
219493139|NCT06221683|DRUG|Gilteritinib|20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
219493140|NCT06221683|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
219493141|NCT02747251|OTHER|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
219493142|NCT02747251|OTHER|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
219493143|NCT00179153|DIETARY_SUPPLEMENT|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
219493144|NCT05906498|DRUG|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
219493145|NCT05906498|DRUG|Vitamin E|vitamin E possessing an anti-inflammatory action
219493146|NCT05166512|BEHAVIORAL|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
219493147|NCT05166512|BEHAVIORAL|DPP|Standard DPP
218872411|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
218872412|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
219022406|NCT03048396|PROCEDURE|Uterus transplantation|
219040172|NCT00794196|BEHAVIORAL|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
219040173|NCT00310908|DRUG|Tramadol Hcl|Active Comparator
219493148|NCT04974593|OTHER|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
219493149|NCT03145558|DRUG|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
219493150|NCT03145558|DRUG|Doxorubicin|Standard of care for TACE
219493151|NCT05044832|BEHAVIORAL|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
219493152|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
219493153|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
218872413|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
218872414|NCT02207257|DRUG|Edoxaban|
218872415|NCT05207683|OTHER|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
218872416|NCT02700594|OTHER|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
218872417|NCT03001687|DIETARY_SUPPLEMENT|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
218872418|NCT03001687|OTHER|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
218872419|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
218872420|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
218872421|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
219022407|NCT05601310|DEVICE|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
219022408|NCT05132621|DIAGNOSTIC_TEST|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
219022409|NCT01234545|DRUG|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
219022410|NCT04924829|DRUG|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
219022411|NCT04345757|BEHAVIORAL|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
219022412|NCT05064956|BIOLOGICAL|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
219022413|NCT03491618|OTHER|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
219022414|NCT01365780|PROCEDURE|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
219022415|NCT05882110|PROCEDURE|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
219022416|NCT01028508|DRUG|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
219493154|NCT05425277|BEHAVIORAL|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
219493155|NCT05425277|BEHAVIORAL|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
219493156|NCT02416089|DEVICE|Tampostat|
218872422|NCT01705678|DIETARY_SUPPLEMENT|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
218872423|NCT01705678|DIETARY_SUPPLEMENT|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
219022417|NCT01028508|PROCEDURE|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
219022418|NCT02760446|BEHAVIORAL|CAM-ICU.fr|Neuropsychological testing
218872424|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
218872425|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
218872426|NCT03610776|DEVICE|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
219493157|NCT02416089|DEVICE|Condom catheter tamponade|
218872427|NCT03610776|DEVICE|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
219493158|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
218872428|NCT01209221|DRUG|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
218872429|NCT01209221|DRUG|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
219022419|NCT00772772|DRUG|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
219022420|NCT02570906|DEVICE|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
219493159|NCT02450409|PROCEDURE|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
218872430|NCT01209221|DRUG|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
218872431|NCT01209221|DRUG|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
219602105|NCT06622421|DEVICE|Piezoelectric surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
218872432|NCT01656694|DEVICE|DePuy Sigma HP Partial Knee|
218872433|NCT01105156|BEHAVIORAL|VEW Questionnaire|Patient Self reported questionnaire filled in.
218872434|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
218872435|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
218872436|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
218872437|NCT05215158|DRUG|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
218872438|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
218872439|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
219022421|NCT02750592|DRUG|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
219022422|NCT05118451|PROCEDURE|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
219493160|NCT02450409|PROCEDURE|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
219493161|NCT03999346|OTHER|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
219493162|NCT02139306|DRUG|Ataluren (PTC124®)|Oral Ataluren TID
218872440|NCT05954429|DRUG|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
219022423|NCT06112951|PROCEDURE|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
219022424|NCT00302874|BEHAVIORAL|Implementation of a protocol for treatment of hyperglycemia|
219022425|NCT00861146|BEHAVIORAL|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
219493163|NCT02139306|DRUG|Placebo|Oral Placebo TID
219493164|NCT04237259|OTHER|Parent-administered TCM pediatric massage training|"Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects)."
219493165|NCT04237259|OTHER|Progressive Muscle Relaxation Exercise|The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
219493166|NCT03810742|DRUG|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
219493167|NCT05060952|DIAGNOSTIC_TEST|Calprotectin Lateral Flow Test|Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate
219493168|NCT03438305|OTHER|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
219493169|NCT03438305|OTHER|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
219493170|NCT03166306|DIAGNOSTIC_TEST|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
218872441|NCT05954429|DRUG|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
218872442|NCT00358839|DRUG|CGRP|
218872443|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
218872444|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
218872445|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
218872446|NCT00898391|GENETIC|DNA analysis|Correlative studies
218872447|NCT05061628|DRUG|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
218872448|NCT05061628|DRUG|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
218872449|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
218872450|NCT02294734|DRUG|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
219022426|NCT00671307|DRUG|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
219022427|NCT00671307|DRUG|Placebo|Vehicle control given as IV infusion over 1 hour
219022428|NCT02981342|DRUG|Abemaciclib|Administered orally
219022429|NCT02981342|DRUG|LY3023414|Administered orally
219022430|NCT02981342|DRUG|Gemcitabine|Administered IV
219022431|NCT02981342|DRUG|Capecitabine|Administered orally
219022432|NCT02392962|PROCEDURE|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
219022433|NCT02392962|PROCEDURE|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
219493171|NCT01067989|DRUG|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
219493172|NCT03658356|OTHER|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
219493173|NCT01284816|PROCEDURE|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
219493174|NCT00405483|PROCEDURE|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
219493175|NCT00405483|PROCEDURE|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
218872451|NCT02294734|DRUG|Placebo|Dry powder for inhalation via DISKUS 'device'
218872452|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
219022434|NCT02468869|BEHAVIORAL|"Communication skills training empathy skills"|
219022435|NCT02468869|BEHAVIORAL|"Communication skills training information structuring skills"|
219022436|NCT04430777|DRUG|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
219022437|NCT04622839|OTHER|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
219022438|NCT04510779|DEVICE|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
219022439|NCT04258345|OTHER|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
219022440|NCT04877938|BEHAVIORAL|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
219022441|NCT05333900|BEHAVIORAL|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
219022442|NCT05333900|BEHAVIORAL|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
219022443|NCT03561623|OTHER|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
219022444|NCT03561623|OTHER|quantitative muscle force assessment|quantitative assessment of muscle force
219022445|NCT03666923|DRUG|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
219022446|NCT03666923|DRUG|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
219022447|NCT03666923|DRUG|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
219040174|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
219040175|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
219040176|NCT02254538|DRUG|BILR 355 BS|
218872453|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
218872454|NCT04293302|OTHER|No intervention|No intervention
219493176|NCT05576597|DRUG|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
219493177|NCT02418559|DRUG|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
219493178|NCT02418559|DRUG|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
219493179|NCT02418559|DRUG|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
219493180|NCT02418559|DRUG|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
219493181|NCT04078659|DRUG|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
219493182|NCT04078659|DRUG|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
219493183|NCT04078659|DRUG|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
219493184|NCT04078659|DRUG|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
219493185|NCT04078659|DRUG|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
219493186|NCT04078659|DRUG|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
219493187|NCT04078659|PROCEDURE|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
219493188|NCT01175161|DEVICE|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
219493189|NCT02515552|BEHAVIORAL|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
218872455|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
218872456|NCT00002020|DRUG|Zidovudine|
218872457|NCT03936647|PROCEDURE|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
218872458|NCT03936647|DEVICE|WEB embolization device|WEB embolization device
218872459|NCT00548717|DRUG|Sirolimus|
219493190|NCT05627388|OTHER|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
219493191|NCT05139901|DRUG|Dornase Alfa|inhalations twice daily
219493192|NCT05139901|DRUG|Saline|inhalations twice daily
219493193|NCT05863182|BEHAVIORAL|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
219493194|NCT06033183|BIOLOGICAL|Blood sample|Blood sample collection : 2 X 5 ml
219493195|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
219493196|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
219493197|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
219493198|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
219493199|NCT02956005|DRUG|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
219493200|NCT04384926|PROCEDURE|Elective Cancer Surgery|Planned, curative cancer surgery
218872460|NCT00548717|DRUG|Mycophenolate mofetil|
218872461|NCT00548717|DRUG|Bortezomib|
219022448|NCT01763424|DRUG|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
219022449|NCT01763424|DRUG|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
219022450|NCT04148950|OTHER|Kinesio Tape|
219022451|NCT04148950|OTHER|Compression Stockings|
219022452|NCT04148950|OTHER|Exercise Program|
219022453|NCT00817895|DRUG|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
219022454|NCT00817895|DRUG|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
219022455|NCT00817895|PROCEDURE|TACE|All patients will accept TACE one month after tumor was resected.
219022456|NCT04695860|DRUG|Burosumab|Q4w, 1mg/kg Body weight, s.c.
219022457|NCT01893554|BIOLOGICAL|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
219493201|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
219602106|NCT06622421|PROCEDURE|Conventional surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
218872462|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
218872463|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
218872464|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
218872465|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
218872466|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
219022458|NCT01893554|BIOLOGICAL|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
219022459|NCT06129721|PROCEDURE|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
218872467|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
218872468|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
218872469|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
218872470|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
218872471|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
218872472|NCT01407796|DRUG|[18F](+/-)NOS|
218872473|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
218872474|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
219022460|NCT03011255|BIOLOGICAL|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
219022461|NCT04001881|OTHER|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
219022462|NCT04001881|DRUG|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
219022463|NCT04022720|PROCEDURE|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
219022464|NCT01962129|BIOLOGICAL|Sampling of blood|
219022465|NCT01061242|BEHAVIORAL|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
219493202|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
219493203|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
219493204|NCT03022799|DRUG|KM-819|
218872475|NCT00024011|DRUG|bortezomib|Given IV
218872476|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
218872477|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
218872478|NCT00821912|DRUG|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
218872479|NCT00821912|DRUG|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
219493205|NCT03022799|DRUG|Placebo|
219493206|NCT00199095|DRUG|Adriamycin|
219493207|NCT00199095|DRUG|Cyclophosphamide|
219493208|NCT00199095|DRUG|Cytarabine|
219493209|NCT00199095|DRUG|Dexamethasone|
219493210|NCT00199095|DRUG|Idarubicin|
219493211|NCT00199095|DRUG|Ifosfamide|
219493212|NCT00199095|DRUG|Methotrexate|
219493213|NCT00199095|DRUG|Mercaptopurine|
219493214|NCT00199095|DRUG|VM26|
218872480|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
218872481|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
218872482|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
218872483|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
218872484|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
218872485|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
218872486|NCT01793259|DRUG|methotrexate prefilled pen|
218872487|NCT01793259|DRUG|methotrexate prefilled syringe|
218872488|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
218872489|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
218872490|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
218872491|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
218872492|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
218872493|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
218872494|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
218872495|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
218872496|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
218872497|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
218872498|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
218872499|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
218872500|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
218872501|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
219040177|NCT02254538|DRUG|PEG 400|
219493215|NCT00199095|DRUG|Vincristine|
219493216|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
219493217|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
219493218|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
219493219|NCT02341976|OTHER|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
219493220|NCT01185639|RADIATION|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
219493221|NCT00866528|DRUG|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
219493222|NCT00866528|DRUG|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
219493223|NCT05524207|PROCEDURE|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
218872502|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
218872503|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
218872504|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
219022466|NCT01559896|DIETARY_SUPPLEMENT|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
219022467|NCT04052269|DRUG|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
219022468|NCT05777915|OTHER|Usability testing|Usability testing
219022469|NCT03724812|DEVICE|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
219022470|NCT01434238|OTHER|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
219022471|NCT03276689|DRUG|Duloxetine|The patients will take duloxetine for 8 weeks.
219022472|NCT03276689|DRUG|Pregabaline|The patients will take pregabaline for 8 weeks.
219022473|NCT03276689|OTHER|Placebo|The patients will take placebo for 8 weeks.
218872505|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
218872506|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
219022474|NCT03862274|OTHER|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
219022475|NCT03842384|BEHAVIORAL|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
219493224|NCT04814888|OTHER|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
219493225|NCT06537284|BEHAVIORAL|ImRs-DSR|Imagery Rescripting with Memory Reconsolidation Disruption
219493226|NCT06537284|BEHAVIORAL|ImRs|Imagery Rescripting regular
219493227|NCT00739622|DRUG|TMC278|
219493228|NCT04696627|OTHER|Questionnaire|Participants from all 3 groups will be interviewed
219022476|NCT05349149|DRUG|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
219022477|NCT05349149|DRUG|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
219493229|NCT00593931|OTHER|fMRI|Functional Magnetic Resonance Imaging without contrast
219493230|NCT02440074|OTHER|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
219022478|NCT04160364|OTHER|qualitative study|qualitative research via guided interview
219022479|NCT04382131|OTHER|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
219022480|NCT06843590|DRUG|ALKS 2680|Oral tablet containing ALKS 2680 for once daily administration
219022481|NCT06843590|DRUG|Placebo|Oral placebo tablet for once daily administration
219022482|NCT03510156|BEHAVIORAL|Behavior analytic treatment|Function-based treatment
219493231|NCT00927979|DRUG|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
219493232|NCT00927979|DRUG|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
219493233|NCT00927979|DRUG|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
219493234|NCT04886869|DIETARY_SUPPLEMENT|caffeine|oral consumption
219022483|NCT00379496|PROCEDURE|Antidepressants|
219022484|NCT00379496|PROCEDURE|acupuncture|
219022485|NCT05150535|RADIATION|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
219493235|NCT06392321|DRUG|Fentanyl|comparison between bupivacaine, bupivacaine and fentanyl.
219493236|NCT06392321|DRUG|Dexmedetomidine|comparison between bupivacaine, bupivacaine and dexmedetomidine..
218872507|NCT05375214|DEVICE|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
218872508|NCT04357977|DIAGNOSTIC_TEST|RBA-2|Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
218872509|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
218872510|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
218872511|NCT04316364|DRUG|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
218872512|NCT04316364|DRUG|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
218872513|NCT04316364|DRUG|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
218872514|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
218872515|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
218872516|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
218872517|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
218872518|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
218872519|NCT01141478|DRUG|Sorafenib|400 mg po bid
218872520|NCT00563862|PROCEDURE|Conventional RT|
218872521|NCT00563862|PROCEDURE|Accelerated RT|
218872522|NCT00563862|DRUG|Cisplatin|
218872523|NCT00563862|DRUG|5-fluorouracil|
218872524|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
218872525|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
218872526|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
218872527|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
218872528|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
219022486|NCT05150535|RADIATION|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
219493237|NCT01479556|DRUG|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
219493238|NCT01479556|DRUG|Placebo|150mg BID p.o.
218872529|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
218872530|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
219022487|NCT05423821|OTHER|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
219022488|NCT05408416|PROCEDURE|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
219022489|NCT05425056|DRUG|Sirolimus|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
219040178|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
219040179|NCT04046185|DRUG|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
219493239|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
219493240|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
219493241|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
218872531|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
219493242|NCT05774769|PROCEDURE|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
219493243|NCT01861717|DRUG|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
219493244|NCT00975338|OTHER|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
219493245|NCT00975338|OTHER|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
219493246|NCT05128331|DIETARY_SUPPLEMENT|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
219493247|NCT05128331|DIETARY_SUPPLEMENT|Placebo|dietary supplement that is made of cellulose.
218872532|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
218872533|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
218872534|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
218872535|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
218872536|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
218872537|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
218872538|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
218872539|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
218872540|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
218872541|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
218872542|NCT02636712|DEVICE|ImageReady™ MR Conditional Pacing System|
218872543|NCT03930407|PROCEDURE|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
218872544|NCT01088594|DRUG|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
218872545|NCT01088594|DRUG|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
218872546|NCT01088594|DRUG|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
218872547|NCT01088594|DRUG|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
218872548|NCT01088594|DRUG|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
218872549|NCT01088594|DRUG|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
218872550|NCT04916379|DIETARY_SUPPLEMENT|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
218872551|NCT04916379|OTHER|Placebo|Placebo: 2000 mg per day for 12 weeks
219493248|NCT00399919|DRUG|Propionyl-L-Carnitine|2 grams per day for six months
219493249|NCT00399919|DRUG|PLC|2 grams/day for six months
218872552|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
218872553|NCT00938522|DRUG|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
218872554|NCT00938522|DRUG|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
218872555|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
218872556|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
218872557|NCT06061029|BEHAVIORAL|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
218872558|NCT04460846|DIETARY_SUPPLEMENT|Alkaline water|1.5 liters per day
218872559|NCT04460846|DIETARY_SUPPLEMENT|Reverse osmosis water|1.5 liters per day
219040180|NCT04046185|DRUG|progesterone|progesterone
219493250|NCT06039098|DEVICE|DCS|DCS monitoring of brain
219493251|NCT06125873|DRUG|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
219493252|NCT02670200|BEHAVIORAL|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
219493253|NCT03033069|DRUG|Brexpiprazole|Brexpiprazole oral tablets.
219493254|NCT03033069|DRUG|Sertraline|Sertraline oral capsules.
218872560|NCT01427634|BEHAVIORAL|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
219022490|NCT05256121|OTHER|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
219022491|NCT04925349|DIAGNOSTIC_TEST|Blood sample collection|blood sample collection
219022492|NCT05459571|BIOLOGICAL|Axicabtagene Ciloleucel|Administered intravenously
219022493|NCT05459571|DRUG|Cyclophosphamide|Administered intravenously
219022494|NCT05459571|DRUG|Fludarabine|Administered intravenously
219022495|NCT05459571|DRUG|Dexamethasone|Administered orally or intravenously
219022496|NCT06050694|DRUG|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
219022497|NCT05091437|DIAGNOSTIC_TEST|Observational study|Incidental lung nodules identification
219493255|NCT03033069|DRUG|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
218872561|NCT01427634|OTHER|Usual Care|Receive usual care as provided by the VAD clinical team.
218872562|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
218872563|NCT00490620|DRUG|Placebo|placebo BID for 6 months
218872564|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
218872565|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
218872566|NCT03853070|DEVICE|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
218872567|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
218872568|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
218872569|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
218872570|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
218872571|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
218872572|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
218872573|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
218872574|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
218872575|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
218872576|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
218872577|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
218872578|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
218872579|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
219022498|NCT05856695|DRUG|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
219022499|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
219022500|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
219493256|NCT03033069|DRUG|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
219493257|NCT04992169|BEHAVIORAL|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
219493258|NCT00062036|BIOLOGICAL|aldesleukin|
219602107|NCT05789589|DRUG|Azeliragon|"Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)"
219602108|NCT05789589|RADIATION|Stereotactic radiosurgery|Patients will undergo standard of care SRS as per the treating facility's policies.
219602109|NCT05789589|DRUG|Corticosteroid|"Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT)."
219602110|NCT06976060|BEHAVIORAL|High-Intensity Interval Training|High-intensity interval training (HIIT) sessions will occur twice per week, on non-consecutive days. Each training session will last 45-60 minutes and consist of eight functional movement exercises incorporating the entire body (upper body, lower body, core/stability, cycling, and agility). Participants will complete two rounds of the 8-exercise circuit with 2-minutes of rest between rounds. The load/resistance used for each exercise will be self-selected by the participants that equates to 15-18 on the RPE scale. During each round, participants will have 1 minute to complete as many repetitions as possible of a given exercise and then have 1 minute of rest before completing the next exercise - giving the participants a 1:1 exercise-to-rest ratio.
219602111|NCT06972420|BEHAVIORAL|Hypnosis session|Within the two weeks prior to surgery, in addition to the standard preoperative care currently in place, the patient will receive a 30-minute visit from a nurse anesthetist trained in hypnosis. This is an added procedure complementing the anesthesia consultation. The visit is divided into two parts: 10 minutes to review and clarify the explanations given by the anesthesiologist and surgeon, and 20 minutes of a formal hypnosis session. A personalized liaison form will be completed to facilitate communication between the consultation and the operating room.
219493259|NCT00062036|BIOLOGICAL|filgrastim|
219602112|NCT02143466|DRUG|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
219493260|NCT00062036|BIOLOGICAL|incomplete Freund's adjuvant|
219493261|NCT00062036|BIOLOGICAL|interleukin-2 gene|
219493262|NCT00062036|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219493263|NCT00062036|DRUG|cyclophosphamide|
219493264|NCT00062036|DRUG|fludarabine phosphate|
219493265|NCT05048745|PROCEDURE|interval appendectomy|interval appendectomy
219493266|NCT04793165|DEVICE|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
219493267|NCT01987258|BEHAVIORAL|Interval Walking|
219493268|NCT01987258|BEHAVIORAL|Continuous walking|
219493269|NCT02972151|DRUG|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
219493270|NCT02972151|OTHER|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
219493271|NCT00583245|OTHER|Gait Training|Gait training with physical therapist 2/week for 3 months
219493272|NCT04156867|DEVICE|Dynesys|discectomy with Dynesys
219493273|NCT00279799|BEHAVIORAL|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
219493274|NCT00279799|BEHAVIORAL|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
219493275|NCT04675528|DRUG|DHP107(Oral paclitaxel)|DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
219493276|NCT02431481|DRUG|LEE011|400 mg
219493277|NCT04101084|OTHER|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
219493278|NCT06678191|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
219493279|NCT03761121|OTHER|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
219493280|NCT04247646|DIETARY_SUPPLEMENT|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
219493281|NCT04247646|DIETARY_SUPPLEMENT|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
219493282|NCT05900531|DRUG|K-757|administered orally
218872580|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
218872581|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
218872582|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
219022501|NCT05440929|BEHAVIORAL|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
219022502|NCT05402072|PROCEDURE|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
219493283|NCT05900531|DRUG|K-757 and open-label sitagliptin|both administered orally
219493284|NCT05900531|DRUG|Matching placebo to K-757|administered orally
219493285|NCT05900531|DRUG|Matching placebo to K-757 and matching placebo to K-833|both administered orally
219493286|NCT05900531|DRUG|K-757 and K-833|both administered orally
219493287|NCT05900531|DRUG|Matching placebo to K-757, open-label sitagliptin|both administered orally
219493288|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
219602113|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
219602114|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
218872583|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
218872584|NCT00663845|DRUG|Placebo|Matching placebo
218872585|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
218872586|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
218872587|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
218872588|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
218872589|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
218872590|NCT05340166|PROCEDURE|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
219493289|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
219493290|NCT00272623|PROCEDURE|Seldinger technique or venous cut-down for port placement|
219493291|NCT06697756|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
219493292|NCT06697756|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
219493293|NCT06701344|DRUG|Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)|"Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days"
219493294|NCT06701344|DRUG|Golidocitinib|"Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT."
219493295|NCT06700863|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
219493296|NCT06700785|DIETARY_SUPPLEMENT|Lysine butyrate|Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.
219493297|NCT06700785|DIETARY_SUPPLEMENT|Sodium Butyrate|Oral sodium butyrate supplement.
219493298|NCT06700785|DIETARY_SUPPLEMENT|Tributyrin|Oral tributyrin supplement.
219602115|NCT02143466|DRUG|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
219022503|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
219022504|NCT06573658|BEHAVIORAL|Walking exercise (control)|It will be a two-session training with each session lasting for approximately an hour. The same training duration and format will be used as the PBT group, except that no perturbations will be induced during the treadmill walking.
219022505|NCT03573479|OTHER|PICU Liber8 Bundle|Bundle of elements for quality improvement
219022506|NCT01394523|DRUG|Bupivacaine|0.25% or 0.5%
219493299|NCT06701877|BEHAVIORAL|Circle of security Parenting (COS-P)|The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).
219602116|NCT02143466|DRUG|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
219602117|NCT02143466|DRUG|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
219602118|NCT02143466|DRUG|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
219602119|NCT02143466|DRUG|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
218872591|NCT05340166|PROCEDURE|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
218872592|NCT02816463|DEVICE|Ambu AuraGain|
218872593|NCT02816463|DEVICE|LMA Supreme|
218872594|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
218872595|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
218872596|NCT03139617|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
219493300|NCT06701877|BEHAVIORAL|Traitement as usual (TAU)|TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
219493301|NCT02926053|PROCEDURE|Surgical removal of tumor tissue for T cell production|Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
219493302|NCT02926053|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
219022507|NCT05864469|OTHER|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
219022508|NCT01829581|OTHER|no intervention, only descriptive data analysis|
219022509|NCT03525574|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219022510|NCT03525574|DRUG|IVA|Tablet for oral administration.
219022511|NCT06209229|BIOLOGICAL|sodium nucleinate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
219040181|NCT04120610|DIAGNOSTIC_TEST|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
219040182|NCT04120610|DIAGNOSTIC_TEST|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
219040183|NCT04120610|DIAGNOSTIC_TEST|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
219040184|NCT04240145|DEVICE|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
219040185|NCT02129803|DEVICE|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
219040186|NCT02129803|DEVICE|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
219493303|NCT02926053|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
219493304|NCT02926053|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
218872597|NCT03139617|PROCEDURE|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
218872598|NCT01066962|DRUG|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
218872599|NCT01066962|DRUG|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
218872600|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
218872601|NCT00715858|DRUG|doxycycline|capsule, 100 mg, b.i.d., 12 months
218872602|NCT00715858|DRUG|rifampin|capsule, 300 mg, od, 12 months
218872603|NCT00715858|DRUG|placebo|placebo matched to rifampin; placebo matched to doxycycline
218872604|NCT04235712|OTHER|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
218872605|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
219022512|NCT06018714|DRUG|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
219022513|NCT00905554|PROCEDURE|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
218872606|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
219022514|NCT00905554|PROCEDURE|air insufflation|air insufflation during the insertion phase of colonoscopy
219022515|NCT03794557|DRUG|Sterile Water Injection|Inhaled Sterile Water Injection
219022516|NCT03794557|DRUG|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
219493305|NCT02926053|DRUG|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
219493306|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
219493307|NCT01814917|DRUG|CBPB|
219602120|NCT02143466|DRUG|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
219022517|NCT00373867|BEHAVIORAL|Standard physical therapy|Treatment-based classification physical therapy
219022518|NCT00373867|BEHAVIORAL|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
219022519|NCT00373867|OTHER|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
219022520|NCT04741074|DRUG|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
219022521|NCT04741074|DRUG|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
218872607|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
219022522|NCT00364884|DRUG|ketoaminoacid|
219022523|NCT01684631|DEVICE|Total Hip arthroplasty|
218872608|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
218872609|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
219022524|NCT02432846|BIOLOGICAL|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
219022525|NCT02432846|DRUG|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
219040187|NCT05378139|DEVICE|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
219493308|NCT06702670|DRUG|Treatment with Diphenhydramine|Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
219493309|NCT06702670|COMBINATION_PRODUCT|Usual Care|Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.
218872610|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
219493310|NCT06410859|DRUG|"Botulinum Toxin Type A for Injection,also known as HengLi®"|This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
218872611|NCT01953913|DRUG|Afatinib|Patient will receive afatinib once daily
219493311|NCT04942964|DRUG|Bocidelpar|Oral
219493312|NCT00500656|DRUG|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
219493313|NCT00500656|DRUG|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
219602121|NCT02143466|DRUG|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
218872612|NCT01862653|DEVICE|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
218872613|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
218872614|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
218872615|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
218872616|NCT01828411|DEVICE|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
218872617|NCT01828411|DEVICE|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
218872618|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
218872619|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
218872620|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
218872621|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
219493314|NCT00500656|DRUG|Oral Placebo|hard capsule matched to tranexamic acid
219493315|NCT00500656|DRUG|S.C. Placebo|solution for injection, matched to icatibant for injection
219493316|NCT03030482|PROCEDURE|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
218872622|NCT02901652|DEVICE|noninvasive respiratory support devices|
218872623|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
218872624|NCT02983994|DEVICE|TURBUHALER®|
218872625|NCT02983994|DEVICE|SPIROMAX®|
218872626|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
218872627|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
218872628|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
219022526|NCT01770379|BIOLOGICAL|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
219022527|NCT01770379|BIOLOGICAL|Placebo|
218872629|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
219022528|NCT03045887|DRUG|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
219040188|NCT01655017|PROCEDURE|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
219493317|NCT01903213|DRUG|bixalomer|Oral
219493318|NCT03548454|DRUG|Duloxetine|Open label prescription
219493319|NCT03548454|DRUG|Desipramine|Open label prescription
219493320|NCT05458895|OTHER|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493321|NCT05458895|OTHER|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493322|NCT05458895|OTHER|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219022529|NCT03045887|DRUG|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
219493323|NCT05458895|OTHER|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493324|NCT05458895|OTHER|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493325|NCT05458895|OTHER|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493326|NCT05458895|OTHER|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493327|NCT05458895|OTHER|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
219493328|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
219493329|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
218872630|NCT03537196|DRUG|Ribavirin|"In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
219493330|NCT01400373|DEVICE|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
219493331|NCT04590417|DRUG|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
218872631|NCT03537196|DRUG|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
218872632|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
218872633|NCT01577472|DRUG|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
218872634|NCT01577472|DRUG|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
218872635|NCT01577472|DRUG|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
218872636|NCT01577472|DRUG|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
218872637|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
219022530|NCT03045887|DRUG|Placebo|Lactose as powder for inhalation
219493332|NCT04648774|PROCEDURE|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
219493333|NCT04648774|PROCEDURE|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
218872638|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
218872639|NCT00295932|BIOLOGICAL|rituximab|Given IV
218872640|NCT00295932|DRUG|bortezomib|Given IV
218872641|NCT00295932|DRUG|cyclophosphamide|Given IV
218872642|NCT00295932|DRUG|prednisone|Given orally
218872643|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
218872644|NCT06508242|OTHER|Placebo|placebo
219022531|NCT03689998|DEVICE|immediate implant placement|immediate implant placement in freshly extraction socket
218872645|NCT00109577|DRUG|MCN36 (nutritional supplement)|nutritional supplement
218872646|NCT00109577|DRUG|Placebo|nutritional supplement
218872647|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
219022532|NCT03689998|DRUG|Melatonin|topical application of melatonin
219022533|NCT02400879|DRUG|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
219022534|NCT02400879|DRUG|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
219022535|NCT04219982|DRUG|DPI-386 Nasal Gel|Nasal gel
219022536|NCT04219982|DRUG|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
218872648|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
218872649|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
219022537|NCT04219982|DRUG|Transderm Scop®|Transderm Scop®
219022538|NCT05353127|DIAGNOSTIC_TEST|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
219022539|NCT03839511|PROCEDURE|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
219022540|NCT03145025|DEVICE|Retisert|Intravitreal Implant
219022541|NCT03145025|DRUG|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
219022542|NCT05413707|PROCEDURE|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
219022543|NCT05413707|PROCEDURE|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
219022544|NCT05413707|PROCEDURE|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
219022545|NCT04434690|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeons bilateral TKA group
219493334|NCT06236334|BEHAVIORAL|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
219493335|NCT04528992|OTHER|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
219493336|NCT04528992|OTHER|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
219493337|NCT06253754|OTHER|MRI examination|All included subjects will be examined with MRI
219493338|NCT02082262|DRUG|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
218872650|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
219200026|NCT06865690|OTHER|Eductional training program|"Arms and Interventions~Arms:~VAK Learning Model Group:~Description: Participants in this group will receive an educational program based on Fleming's VAK (Visual, Auditory, Kinesthetic) learning model. The program will tailor teaching methods to participants' sensory preferences (visual, auditory, or kinesthetic).~Kolb Learning Cycle Group:~Description: Participants in this group will receive an educational program based on Kolb's Experiential Learning Cycle. The program will emphasize experiential learning through concrete experiences, reflective observation, abstract conceptualization, and active experimentation.~Interventions:~VAK Educational Training Program:~Description: A structured CPR training program designed to align with participants' sensory preferences (visual, auditory, or kinesthetic). The program includes:~Visual components: Demonstrations, diagrams, and videos.~Auditory components: Verbal instructions, discussions, and feedback.~Kinesthetic components: Hands-on"
219493339|NCT05041244|DEVICE|Negative pressure wound therapy delivered through VAC|Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
219493340|NCT05041244|DEVICE|Standard of care|"Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated."
219493341|NCT03239795|OTHER|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
218872651|NCT01150201|DRUG|Aliskiren|For CKD treatment
218872652|NCT01150201|DRUG|Losartan|Control
218872653|NCT00044889|DRUG|clofarabine (IV formulation)|
218872654|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
218872655|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
219022546|NCT04434690|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
219022547|NCT01912287|BEHAVIORAL|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
219022548|NCT01912287|BEHAVIORAL|Stress Education|Active control group (12 sessions)
219022549|NCT01912287|BEHAVIORAL|Yoga|12 sessions, mindfulness components
219022550|NCT02287558|DRUG|Pomalidomide|
219022551|NCT06201117|BEHAVIORAL|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
219022552|NCT06201117|BEHAVIORAL|Usual information|Preoperative information that is given to patients before having cardiac surgery
219022553|NCT03294395|DRUG|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
219022554|NCT03294395|DRUG|Fosfomycin Oral Suspension|single dose 6g oral suspension
219022555|NCT03294395|DRUG|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
219493342|NCT05578755|BEHAVIORAL|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
219493343|NCT05578755|BEHAVIORAL|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
219022556|NCT03294395|DRUG|Ceftriaxone|single dose 500mg intramuscular injection
218872656|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
218872657|NCT02560298|DRUG|Capecitabine|
218872658|NCT02560298|DRUG|Carboplatin|Given IV
218872659|NCT02560298|DRUG|Cisplatin|Given IV
218872660|NCT02560298|DRUG|Fluorouracil|Given IV
218872661|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
218872662|NCT02560298|DRUG|Paclitaxel|Given IV
218872663|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
218872664|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
218872665|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
218872666|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
219022557|NCT04155632|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
219022558|NCT04155632|DEVICE|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
219022559|NCT00000296|DRUG|Cotinine fumarate|
219022560|NCT03914326|DRUG|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
219022561|NCT03914326|DRUG|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
219022562|NCT06117384|GENETIC|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
219022563|NCT02929823|DRUG|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
219022564|NCT02929823|DRUG|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
219022565|NCT02929823|DRUG|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
219022566|NCT04017585|DIETARY_SUPPLEMENT|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
219493344|NCT03744988|DIAGNOSTIC_TEST|serum androgen levels|measurement of serum free and total testosterone
219493345|NCT00003061|DRUG|cytarabine|
219493346|NCT00003061|DRUG|methotrexate|
219493347|NCT00003061|RADIATION|radiation therapy|
219022567|NCT04017585|DIETARY_SUPPLEMENT|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
219022568|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
219022569|NCT05268133|DIETARY_SUPPLEMENT|Aronia|As described in experimental arm
219022570|NCT05268133|DIETARY_SUPPLEMENT|Control|As described in placebo comparator arm
219200027|NCT06865911|OTHER|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infiltration of cold tumescent solution at 4 C for lipoplasty.
218872667|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~\- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
218872668|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
218872669|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
218872670|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
218872671|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
218872672|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
218872673|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
218872674|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
218872675|NCT02337725|DRUG|Placebo|Placebo tablets
218872676|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
219022571|NCT05137743|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
219022572|NCT05137743|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
219022573|NCT03695562|PROCEDURE|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
219022574|NCT06181097|DEVICE|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
219022575|NCT06181097|OTHER|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
219022576|NCT05276570|DRUG|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
219022577|NCT05276570|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
219022578|NCT04482842|DEVICE|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
219022579|NCT04482842|DRUG|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
219493348|NCT02836197|BEHAVIORAL|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
219493349|NCT04543305|DRUG|PRT1419|PRT1419 will be administered orally
219493350|NCT01408576|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
218872677|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
218872678|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
218872679|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
218872680|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
218872681|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
218872682|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
218872683|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
218872684|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
218872685|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
218872686|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
218872687|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
218872688|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
219022580|NCT05855005|DEVICE|DTC Hearing Aids|DTC hearing aid programmed to the individual participant.
219022581|NCT06441175|OTHER|Intubation device order|"D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy."
219022582|NCT06459648|OTHER|Headache record|The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.
219022583|NCT06459648|OTHER|Scales|Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.
219022584|NCT06459648|DRUG|Monoclonal antibody anti-CGRP|Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab
219022585|NCT06427603|BEHAVIORAL|physical activity|workshops and mobile apps: break sedentary behavior by activity breaks
219022586|NCT03226392|DRUG|QAW039|QAW039 once daily
219022587|NCT03226392|DRUG|Placebo|Placebo once daily
219022588|NCT02357901|DRUG|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
219022589|NCT02357901|DRUG|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
219022590|NCT02357901|DRUG|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
219493351|NCT01408576|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
219493352|NCT00444873|DRUG|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
218872689|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
218872690|NCT00002447|DRUG|Ritonavir|
218872691|NCT00002447|DRUG|Efavirenz|
218872692|NCT00002447|DRUG|Saquinavir|
218872693|NCT04545710|DRUG|Abemaciclib|Abemaciclib 150mg BID
218872694|NCT04545710|DRUG|Osimertinib|Osimertinib 80mg daily
219493353|NCT03751319|OTHER|CGA|Comprehensive Geriatric Assessment
219493354|NCT02026102|BEHAVIORAL|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
219493355|NCT03772184|PROCEDURE|Cervical inversion|inverting the cervical lip after delivery
218872695|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
219022591|NCT02963207|OTHER|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
219022592|NCT02963207|OTHER|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
219022593|NCT02834533|DEVICE|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
219022594|NCT02856633|DEVICE|Vitaliti|
219022595|NCT03808051|PROCEDURE|Physiological-based cord clamping|See Arm description.
219022596|NCT03808051|PROCEDURE|Time-based cord clamping|See Arm description.
219022597|NCT04788953|DRUG|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
219493356|NCT00267579|BEHAVIORAL|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
219493357|NCT00783978|OTHER|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
219493358|NCT03530033|DRUG|Lidocaine|Local injection of lidocaine reduces muscle tremor
219493359|NCT00039416|DRUG|imatinib mesylate|Given orally
219493360|NCT00039416|OTHER|laboratory biomarker analysis|Correlative studies
219493361|NCT00505128|PROCEDURE|Endoscopic sphincterotomy|procedure
219493362|NCT03028883|OTHER|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
219493363|NCT03533530|DIAGNOSTIC_TEST|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
219493364|NCT03533530|DIAGNOSTIC_TEST|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
219493365|NCT03533530|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
219493366|NCT06700954|OTHER|legume-rich Planetary Health Diet|legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein
219493367|NCT06700954|OTHER|control diet based on Western Diet low in legumes|diet based on the Western dietary pattern including animal protein sources (= control diet)
219493368|NCT01791127|DEVICE|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
219493369|NCT03012620|DRUG|Pembrolizumab|Treatment
219493370|NCT00520494|DRUG|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
218872696|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
218872697|NCT00328471|BEHAVIORAL|care management|
218872698|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
218872699|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
218872700|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
218872701|NCT05870683|DRUG|Tegoprazan|Included in dual eradication medication.
218872702|NCT05870683|DRUG|Amoxicillin|Included in dual eradication medication.
218872703|NCT05870683|DRUG|Esomeprazole|Included in dual eradication medication.
218872704|NCT06056856|PROCEDURE|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
218872705|NCT06056856|PROCEDURE|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
219493371|NCT00002774|DRUG|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
219493372|NCT00002774|DRUG|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
219493373|NCT00002774|DRUG|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
218872706|NCT00119665|DRUG|MF101|
218872707|NCT06485466|COMBINATION_PRODUCT|TACE plus camrelizumab and apatinib|"TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
218872708|NCT06485466|COMBINATION_PRODUCT|Camrelizumab and apatinib|"Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
218872709|NCT06429189|BEHAVIORAL|Home-based combined exercise program with self-selected intensity|Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
218872710|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
219022598|NCT04788953|DRUG|Placebo|Control subjects will receive placebo tablets for oral use.
219022599|NCT03643094|DIETARY_SUPPLEMENT|Golden Black Seed|1 capsule per day for 8 weeks.
219493374|NCT00002774|RADIATION|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
219493375|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
219493376|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
219493377|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
219493378|NCT01257529|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
219493379|NCT04870931|PROCEDURE|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
219602122|NCT02143466|DRUG|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
218872711|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
218872712|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
218872713|NCT04629027|DRUG|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
218872714|NCT06303895|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
219022600|NCT04063020|BEHAVIORAL|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
219493380|NCT02966574|DEVICE|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
219493381|NCT05218031|BEHAVIORAL|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
219493382|NCT01307631|DRUG|Akt Inhibitor MK2206|Given PO
219493383|NCT01307631|OTHER|Laboratory Biomarker Analysis|Correlative studies
219493384|NCT05182931|DRUG|Dabrafenib 75 MG|Refer arm description
219493385|NCT05182931|DRUG|Trametinib 2 MG|Refer arm description
219493386|NCT03471182|BEHAVIORAL|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
219493387|NCT03471182|DRUG|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
219493388|NCT03471182|RADIATION|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.
219493389|NCT03471182|OTHER|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
219493390|NCT03970382|BIOLOGICAL|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
219493391|NCT03970382|BIOLOGICAL|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
219493392|NCT03970382|BIOLOGICAL|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
219493393|NCT00422773|DRUG|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
219493394|NCT04167280|DRUG|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
219493395|NCT04167280|DRUG|placebo metered dose inhaler|matched MDI to deliver inactive drug
219493396|NCT00161330|DRUG|oral amoxicilline/clavulanic acid|
219493397|NCT00161330|DRUG|iv ceftriaxone|
218872715|NCT06303895|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
218872716|NCT06303895|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
218872717|NCT01571453|DRUG|Vortioxetine (Lu AA21004)|10 mg/day
218872718|NCT01571453|DRUG|Venlafaxine extended release|150 mg/day
218872719|NCT05243303|DEVICE|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
219022601|NCT05266755|OTHER|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
219022602|NCT04699708|DEVICE|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
219022603|NCT05160831|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
219022604|NCT04478747|PROCEDURE|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
219022605|NCT04478747|PROCEDURE|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
219022606|NCT04561206|DRUG|Brentuximab Vedotin|Given IV
219022607|NCT04561206|BIOLOGICAL|Nivolumab|Given IV
219022608|NCT00491387|DRUG|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
219022609|NCT04695899|DEVICE|Dental Implant|"See Section Procedures."
219022610|NCT06581406|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
219022611|NCT06581406|BIOLOGICAL|Ipilimumab|Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
219022612|NCT06581406|BIOLOGICAL|Nivolumab|Nivolumab: Anti-PD-1 Monoclonal antibody
219022613|NCT02276729|OTHER|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
219022614|NCT06228040|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
219022615|NCT06228040|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
219022616|NCT02631850|BEHAVIORAL|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
219602123|NCT06101264|DEVICE|Control|Control patients following spinal fusion for adolescent idiopathic scoliosis that receive no virtual reality sessions.
218872720|NCT05243303|DEVICE|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
219022617|NCT02631850|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
219022618|NCT02631850|BEHAVIORAL|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
219022619|NCT02631850|BEHAVIORAL|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
219022620|NCT03022344|RADIATION|Cardiac CT|
219022621|NCT06133192|DRUG|Uvadex|Uvadex use for ECP
219022622|NCT06133192|DRUG|Steroids|steroids 2 mg/kg/d
219022623|NCT03331146|DRUG|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
219022624|NCT03331146|DRUG|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
219022625|NCT04860791|OTHER|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
219022626|NCT04699409|OTHER|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
219022627|NCT04699409|OTHER|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
219200028|NCT06865911|OTHER|Warm saline|Infiltration of warm tumescent solution at body temperature for lipoplasty.
219200029|NCT06865911|PROCEDURE|Liposuction of the arms|Infiltration of tumescent solution in both arms, VASER fat emulsification then power-assisted liposuction of the arms.
219200030|NCT06866470|BEHAVIORAL|relaxation group|exercise group
219200031|NCT06870266|DRUG|Nafarelin nasal spray|NAFARLIN 200 MCG X2 DAY
219200032|NCT06870266|DRUG|Utrogestan®|UTROGESTAN 200 MG X2 DAY
219022628|NCT03104114|BEHAVIORAL|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
219022629|NCT03104114|BEHAVIORAL|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
218872721|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
218872722|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
219493398|NCT01153022|OTHER|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
218872723|NCT03502174|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
218872724|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
219022630|NCT05757661|OTHER|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
219022631|NCT05757661|OTHER|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
219493399|NCT01692431|DIETARY_SUPPLEMENT|EPA|High fat meal containing EPA
219493400|NCT01692431|DIETARY_SUPPLEMENT|DHA|High fat meal containing DHA
219493401|NCT01692431|DIETARY_SUPPLEMENT|Placebo|High fat meal containing negligible EPA/DHA content
219493402|NCT04977817|DIETARY_SUPPLEMENT|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
219493403|NCT00063596|DRUG|Vitamin A supplementation|
219493404|NCT02820935|DRUG|CC-220|
219493405|NCT02820935|DRUG|Rifampin|
219493406|NCT02820935|DRUG|Itraconazole|
219493407|NCT04440163|BIOLOGICAL|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
219493408|NCT04440163|BIOLOGICAL|Saline|Placebo
219493409|NCT04440163|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
219493410|NCT04440163|BIOLOGICAL|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
219493411|NCT04742816|DIAGNOSTIC_TEST|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
219602124|NCT06101264|DEVICE|Virtual Reality|Patients will undergo a 20 minute virtual reality session prior to each physical therapy session following spinal fusion for adolescent idiopathic scoliosis. Virtual reality sessions will continue until functionally cleared by physical therapy.
219602125|NCT06004804|BEHAVIORAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
219493412|NCT04742816|DRUG|Iohexol|Iohexol clearance measurement
219602126|NCT06004804|BEHAVIORAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
218872725|NCT03468322|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
218872726|NCT03468322|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
218872727|NCT00205816|DRUG|Tigecycline|
218872728|NCT00905203|OTHER|exercise|exercise training
218872729|NCT03098745|DEVICE|Omafilcon A|contact lens
218872730|NCT03098745|DEVICE|Somofilcon A|contact lens
218872731|NCT03098745|DEVICE|Omafilcon A - Proclear (PC)|contact lens
219493413|NCT06232369|DEVICE|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
219493414|NCT06232369|DEVICE|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
218872732|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
219022632|NCT05792631|DEVICE|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
219022633|NCT02556268|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
219022634|NCT02556268|DRUG|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
219493415|NCT02344914|DEVICE|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
219493416|NCT01368679|PROCEDURE|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
219493417|NCT00106379|DRUG|Truvada (tenofovir DF + emtricitabine)|
218872733|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
218872734|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
218872735|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
219022635|NCT02556268|DRUG|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
219022636|NCT02556268|DRUG|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
219022637|NCT02556268|DRUG|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
219493418|NCT00106379|DRUG|Emtriva (emtricitabine)|
219493419|NCT00106379|DRUG|Viread (tenofovir DF)|
219493420|NCT02229487|OTHER|Oral glucose tolerance|
219493421|NCT02018042|DRUG|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
219493422|NCT06237699|OTHER|Digital ICU diary|A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
219493423|NCT02258607|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
219493424|NCT02258607|DRUG|Trametinib|Trametinib tablet administered orally once daily
219493425|NCT03151785|OTHER|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
219493426|NCT03151785|OTHER|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
219602127|NCT06004804|BEHAVIORAL|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
219602128|NCT06456034|BEHAVIORAL|Perinatal palliative care|Intervention group will receive specialized perinatal palliative care support from moment of severe perinatal diagnosis. This intervention is aimed at 5 major care components, namely 1. Support offered by a fixed perinatal palliative care team, 2. that team has received specialized perinatal palliative care training, 3. care is structured within a new perinatal palliative care approach or pathway, including fixed means of communication with team members, 4. psychological support is structurally being offered to parents and healthcare providers, and 5. debriefings after every perinatal death are being organized in the involved team.
219602129|NCT01900951|DRUG|Temozolomide|
219493427|NCT03151785|OTHER|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
219493428|NCT04456985|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
219493429|NCT04456985|DIETARY_SUPPLEMENT|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
219493430|NCT02656615|DRUG|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
219493431|NCT04276285|PROCEDURE|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
219602130|NCT00794508|BIOLOGICAL|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
219602131|NCT06435286|DRUG|Proflavine Hemisulfate|Approximately 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
218872736|NCT03779074|DRUG|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
219022638|NCT02556268|DRUG|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
219022639|NCT03949205|OTHER|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
218872737|NCT03779074|DRUG|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
218872738|NCT03779074|DRUG|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
219022640|NCT02109120|PROCEDURE|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
219022641|NCT05799807|PROCEDURE|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
219022642|NCT05799807|PROCEDURE|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
219022643|NCT03411681|OTHER|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
219022644|NCT01849627|BEHAVIORAL|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
219022645|NCT01849627|BEHAVIORAL|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
219022646|NCT01220947|DRUG|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
219022647|NCT01220947|DRUG|Danoprevir|Danoprevir 50 mg BID
219022648|NCT01220947|DRUG|Danoprevir|Danoprevir 100 mg BID
219493432|NCT04276285|PROCEDURE|US TAP|Subcostal TAP block will be performed after surgery under US guidance
219493433|NCT06102837|BIOLOGICAL|tumor vaccine|tumor vaccine produced by our team
219493434|NCT06102837|RADIATION|Radiotherapy|conventional treatment in clincial
219493435|NCT06102837|DRUG|Chemotherapy|conventional treatment in clinical
219493436|NCT06102837|PROCEDURE|Surgery|conventional treatment in clinical
219493437|NCT04835415|PROCEDURE|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
219493438|NCT04835415|PROCEDURE|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
219493439|NCT03860571|DRUG|Placebo|Oral tablet
219493440|NCT03860571|DRUG|BT-11|Oral tablet
219493441|NCT05107154|BEHAVIORAL|Dialectical Behavioural Therapy|DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
219493442|NCT03412461|OTHER|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
219493443|NCT03412461|OTHER|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
219493444|NCT05741983|PROCEDURE|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
219602132|NCT06435286|DEVICE|Artificial Intelligence Mobile High-Resolution Microendoscope|The AI-mHRME will be inserted through the endoscope biopsy channel and gently placed against the mucosa where proflavine was sprayed. The probe will transmit images to the computer/laptop for the clinician to observe any abnormal tissues and save photos of these tissues.
219022649|NCT01220947|DRUG|Danoprevir|Danoprevir 200 mg BID
219022650|NCT01220947|DRUG|Pegasys|Pegasys 180 microgram sc qw
219022651|NCT01220947|DRUG|Ritonavir|Ritonavir 100 mg
219022652|NCT03964155|BIOLOGICAL|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
219022653|NCT05153031|OTHER|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
219022654|NCT05153031|PROCEDURE|Emergency surgery|Emergency cholecystectomy
219022655|NCT05153031|PROCEDURE|cholecystectomy|cholecystectomy
219022656|NCT04991155|DRUG|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
219022657|NCT06149507|DRUG|Acetaminophen|Prescribe the drug to the child
219602133|NCT03378752|PROCEDURE|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
219602134|NCT06124937|DRUG|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
218872739|NCT04248023|BEHAVIORAL|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
218872740|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
218872741|NCT00141115|DRUG|levetiracetam|Levetiracetam 1500 mg BID
218872742|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
218872743|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
218872744|NCT00500760|DRUG|Panitumumab|Administered intravenously
218872745|NCT05435118|OTHER|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
218872746|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
218872747|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
218872748|NCT01008085|DEVICE|Stentys coronary stent|Self-expanding Nitinol stent
218872749|NCT01008085|DEVICE|Balloon-expandable stent|VISION/Driver
218872750|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
219022658|NCT06149507|DRUG|Ibuprofen|Prescribe the drug to the child
219022659|NCT03296254|BEHAVIORAL|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
219022660|NCT03296254|BEHAVIORAL|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
219602135|NCT06124937|DRUG|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
219602136|NCT04382287|PROCEDURE|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
219602137|NCT03173287|PROCEDURE|Quantification of liver fibrosis|Procedure MRI and liver biopsy
218872751|NCT04839445|PROCEDURE|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
218872752|NCT04839445|PROCEDURE|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
218872753|NCT00269854|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
218872754|NCT00269854|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
218872755|NCT00269854|DRUG|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
218872756|NCT00269854|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
218872757|NCT00037154|DRUG|Saw Palmetto|
219022661|NCT02318511|PROCEDURE|Knee injection|Injection into knee for the treatment of Osteoarthritis
219022662|NCT02318511|OTHER|ReNu amniotic allograft|
219022663|NCT02318511|DEVICE|placebo saline|
219022664|NCT02318511|DEVICE|Hyaluronic Acid|
219022665|NCT03301142|PROCEDURE|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
219022666|NCT03301142|PROCEDURE|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
219022667|NCT03935373|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
218872758|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
218872759|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
218872760|NCT00000802|DRUG|Atovaquone|
218872761|NCT00000802|DRUG|Dapsone|
218872762|NCT03178669|DRUG|cobitolimod|Rectal administration
218872763|NCT03178669|DRUG|Placebo|Solution manufactured to mimic cobitolimod
218872764|NCT05950620|OTHER|Medical obesity management.|Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
218872765|NCT01014468|DRUG|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
218872766|NCT01014468|DRUG|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
218872767|NCT00738218|OTHER|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
218872768|NCT02626390|OTHER|Frequent instructions/feedback and an Internal Focus of Attention|
218872769|NCT02626390|OTHER|Minimal instructions/feedback and an External Focus of Attention|
218872770|NCT01309685|DRUG|Varenicline|
218872771|NCT00448305|DRUG|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
218872772|NCT00448305|DRUG|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
219602138|NCT01720888|OTHER|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
219602139|NCT04210050|DEVICE|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
219602140|NCT04210050|DIAGNOSTIC_TEST|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
219602141|NCT04210050|DIAGNOSTIC_TEST|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
218872773|NCT00448305|DRUG|Paclitaxel|Paclitaxel 90 mg/m² weekly
218872774|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
218872775|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
218872776|NCT04842305|DIAGNOSTIC_TEST|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
219493445|NCT05741983|DEVICE|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
219493446|NCT05525637|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
219493447|NCT05525637|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
219493448|NCT05525637|DRUG|Placebo|Match placebo tablets, once daily in the evening
218872777|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
218872778|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
218872779|NCT03266913|DRUG|Probiotic|Probiotics drop
218872780|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
218872781|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
219493449|NCT06330077|DRUG|Ifenprodil|Treatment administration
219493450|NCT06330077|DRUG|Placebo|Treatment administration
218872782|NCT05492357|OTHER|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
218872783|NCT05492357|OTHER|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
218872784|NCT06782997|DEVICE|Electroretinogram|Electroretinogram (RETevalTM devices, LKC Technologies) performed and interpreted by an advanced practice nurse compared to the gold standard (retinography) interpreted by an ophthalmologist
218872785|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
218872786|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
218872787|NCT03590249|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
218872788|NCT06149377|PROCEDURE|Test cohort|
218872789|NCT00079677|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
218872790|NCT00079677|DRUG|Placebo|Matching placebo tablets once daily
218872791|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
218872792|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
218872793|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
218872794|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
219493451|NCT01954082|DRUG|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
219493452|NCT01954082|DRUG|Placebo|% glucose(dextrose)
218872795|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
218872796|NCT06092775|DEVICE|DEXA scan,X_ray|"DEXA scan detect osteoporosis~,X\_ray show subclinical vertebral fractures"
218872797|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
218872798|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
218872799|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
218872800|NCT03267914|OTHER|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
218872801|NCT03267914|OTHER|Brush|Patients will brush with the fluoride for 2 minutes each day.
218872802|NCT00565136|DEVICE|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
218872803|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
218872804|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
219493453|NCT03804931|PROCEDURE|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
219493454|NCT03804931|PROCEDURE|Infusion of Saline|Infusion of Saline
218872805|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
218872806|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
218872807|NCT06352255|PROCEDURE|Digital block|Frost's H technique
218872808|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
219022668|NCT03935373|DIAGNOSTIC_TEST|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
219022669|NCT03935373|DIAGNOSTIC_TEST|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
219022670|NCT03935373|DIAGNOSTIC_TEST|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
218872809|NCT03973294|DEVICE|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
219493455|NCT03804931|DRUG|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
219493456|NCT01491282|OTHER|Enabling and disabling VNS|No intervention
218872810|NCT01900288|BEHAVIORAL|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
218872811|NCT01900288|BEHAVIORAL|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
218872812|NCT06334874|DRUG|Astaxanthin Oral Capsule|12 mg of astaxanthin oral capsule
218872813|NCT06334874|DRUG|Placebo|starch placebo capsule
218872814|NCT02517372|DRUG|CRD007|
218872815|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
218872816|NCT00003691|BIOLOGICAL|filgrastim|
218872817|NCT00003691|DRUG|cisplatin|
218872818|NCT00003691|DRUG|doxorubicin hydrochloride|
218872819|NCT00003691|DRUG|paclitaxel|
218872820|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
218872821|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
218872822|NCT04891185|DRUG|Indocyanine green|Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
218872823|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
218872824|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
218872825|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
218872826|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
219493457|NCT04405674|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
219493458|NCT04405674|DRUG|Carboplatin|Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
218872827|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
218872828|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
218872829|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
218872830|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
218872831|NCT01008462|DRUG|Carmustine|Given IV
218872832|NCT01008462|DRUG|Cyclophosphamide|Given IV
218872833|NCT01008462|DRUG|Cytarabine|Given IV
218872834|NCT01008462|DRUG|Etoposide|Given IV
218872835|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
218872836|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
218872837|NCT01008462|DRUG|Melphalan|Given IV
218872838|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
218872839|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
219493459|NCT04405674|DRUG|Pemetrexed|Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
219493460|NCT04405674|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
218872840|NCT01008462|DRUG|Tacrolimus|Given IV or PO
218872841|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
218872842|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
218872843|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
218872844|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
218872845|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
218872846|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
218872847|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
218872848|NCT04284774|DRUG|Tipifarnib|Tipifarnib tablets
219022671|NCT03935373|DIAGNOSTIC_TEST|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
219022672|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
219493461|NCT04405674|DRUG|Nab paclitaxel|Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
219493462|NCT04629131|BIOLOGICAL|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
219022673|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
219022674|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
219022675|NCT03935373|DIAGNOSTIC_TEST|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
219022676|NCT03935373|DIAGNOSTIC_TEST|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
219022677|NCT03935373|DIAGNOSTIC_TEST|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
219022678|NCT04275791|OTHER|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
219493463|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 1, given once
219493464|NCT04629131|BIOLOGICAL|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
219493465|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 2, given once
218872849|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
218872850|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
219022679|NCT03419000|GENETIC|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
219022680|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219493466|NCT04629131|BIOLOGICAL|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
219493467|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 3, given once
219493468|NCT04629131|BIOLOGICAL|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
219493469|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 4, given once
219493470|NCT05585268|OTHER|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
219493471|NCT02190344|DEVICE|8-channel paddle coil|MRI Coil
219493472|NCT03213080|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
219493473|NCT03077594|DEVICE|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
219493474|NCT03077594|OTHER|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
218872851|NCT01344720|DRUG|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
219022681|NCT04422054|PROCEDURE|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
219022682|NCT04422054|PROCEDURE|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
219022683|NCT04659967|BEHAVIORAL|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
219022684|NCT05487326|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
219022685|NCT05487326|PROCEDURE|cervical epidural injection|cervical epidural injection by fluoroscopy
219200033|NCT06869525|BEHAVIORAL|Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, Kongji, after obtaining qi, connect the electric needle (continuous wave, The frequency was 2Hz, the current intensity was 1\~5mA, and the current intensity was gradually increased according to patient tolerance), and the treatment was 30min.
218872852|NCT01344720|DRUG|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
218872853|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
219493475|NCT03077594|DEVICE|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
218872854|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
218872855|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
219022686|NCT04216654|DIAGNOSTIC_TEST|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
219022687|NCT01832870|DRUG|sipuleucel-T|
219022688|NCT01832870|DRUG|ipilimumab|
219022689|NCT00117247|DRUG|darbepoetin alfa|
219022690|NCT00157703|DRUG|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
219022691|NCT00487851|PROCEDURE|surgery|hepaticojejunostomy and gastroenterostomy
219022692|NCT00487851|PROCEDURE|endoscopic strategy|Stent insertion
219022693|NCT03019107|DEVICE|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
219022694|NCT03019107|DEVICE|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
219022695|NCT00684476|DRUG|venom immunotherapy|
219022696|NCT05567055|DRUG|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
219022697|NCT03394287|DRUG|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
219022698|NCT03394287|DRUG|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
219022699|NCT00644280|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
219493476|NCT04670029|OTHER|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
219493477|NCT02299674|OTHER|Level overground ambulation|
219493478|NCT03520621|OTHER|No intervention|no intervention
218872856|NCT00493961|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
218872857|NCT01501123|DRUG|Haloperidol|5mg IM
219022700|NCT03185728|OTHER|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
219022701|NCT02173912|DRUG|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
219022702|NCT02173912|DRUG|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
219493479|NCT00077779|DRUG|Adalimumab|
219493480|NCT01145703|DIETARY_SUPPLEMENT|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
218872858|NCT01501123|DRUG|Midazolam|IM midazolam
219022703|NCT03102931|OTHER|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
219493481|NCT01145703|DIETARY_SUPPLEMENT|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
219493482|NCT01145703|OTHER|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
219493483|NCT01145703|OTHER|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
218872859|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
218872860|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
218872861|NCT02879578|DRUG|Valbenazine|
218872862|NCT00288327|BEHAVIORAL|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
218872863|NCT00288327|BEHAVIORAL|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
218872864|NCT03842072|DEVICE|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
219022704|NCT03102931|OTHER|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
219022705|NCT02065960|RADIATION|Stereotactic body radiotherapy (SBRT)|
219022706|NCT00227305|DRUG|quetiapine fumarate|Oral dosing, flexible dosing
219022707|NCT04739631|OTHER|acupuncture|use disposable sterile needles to insert to the acupuncture point
219022708|NCT04739631|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
219022709|NCT00822458|DRUG|vismodegib|Given orally
219493484|NCT02910310|OTHER|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
219493485|NCT02873481|BEHAVIORAL|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
219493486|NCT01787214|DIETARY_SUPPLEMENT|Full dose|20% of daily energy needs supplied by walnuts
219493487|NCT01787214|DIETARY_SUPPLEMENT|Half dose|10% of daily energy needs supplied by walnuts
219493488|NCT01787214|DIETARY_SUPPLEMENT|Control|Walnut free meals
219493489|NCT02552381|OTHER|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
219493490|NCT02346981|BEHAVIORAL|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
219493491|NCT02154113|DEVICE|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
219493492|NCT02154113|DEVICE|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
218872865|NCT04100941|DIAGNOSTIC_TEST|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
219022710|NCT00822458|OTHER|laboratory biomarker analysis|
219022711|NCT00822458|OTHER|pharmacological study|
219022712|NCT06637995|DEVICE|Intraoperative Nerve Monitoring|Observational data collection from Locating, Stimulating, and Monitoring target nerves during a surgical procedure (clinician standard of care)
219022713|NCT00002161|DRUG|Adefovir dipivoxil|
219022714|NCT01028339|DRUG|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
219022715|NCT01028339|DRUG|Mannitol|Mannitol
219022716|NCT06045195|DRUG|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and BrECADD (P-BrECADD). Response to induction therapy will be measured after 1x P (PET-1) and after 1x P + 2x P-BrECADD (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two further cycles of P-BrECADD while participants with a positive PET-3 will receive four further cycles of P-BrECADD. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
219022717|NCT02940288|OTHER|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
219022718|NCT02940288|OTHER|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
219022719|NCT02627430|DRUG|Hsp90 Inhibitor AT13387|Given IV
219022720|NCT02627430|OTHER|Laboratory Biomarker Analysis|Correlative studies
219022721|NCT02627430|OTHER|Pharmacological Study|Correlative studies
219022722|NCT02627430|DRUG|Talazoparib|Given PO
219493493|NCT03165890|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
219493494|NCT03165890|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
218872866|NCT04100941|DIAGNOSTIC_TEST|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
218872867|NCT04100941|DIAGNOSTIC_TEST|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
219602142|NCT04225910|DRUG|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
218872868|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
218872869|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
218872870|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
218872871|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
218872872|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
218872873|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
218872874|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
218872875|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
218872876|NCT05856565|OTHER|Photo|Photography intake
218872877|NCT02299284|OTHER|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
218872878|NCT00265031|DRUG|Cyclophosphamide|
218872879|NCT00265031|DRUG|Adriamycin|
218872880|NCT00265031|DRUG|Etoposide|
218872881|NCT00265031|DRUG|Procarbazine|
218872882|NCT00265031|DRUG|Prednisone|
218872883|NCT00265031|DRUG|Vincristine|
219493495|NCT03189264|PROCEDURE|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
218872884|NCT00265031|DRUG|Bleomycin|
219493496|NCT02408406|OTHER|Communication Intervention|Use PatientCareAnywhere system
219493497|NCT02408406|OTHER|Educational Intervention|Use PatientCareAnywhere system
219602143|NCT06017050|BEHAVIORAL|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
219602144|NCT06017050|BEHAVIORAL|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
218872885|NCT00265031|PROCEDURE|radiation therapy|
218872886|NCT00790478|DRUG|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
218872887|NCT00790478|OTHER|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
218872888|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
218872889|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
218872890|NCT01583816|DRUG|Resiquimod 0.03%|topical application
218872891|NCT01583816|DRUG|Resiquimod 0.01%|topical application
218872892|NCT01583816|DRUG|placebo|topical application
218872893|NCT00233012|DRUG|Topiramate|
218872894|NCT00455208|DRUG|Cura-100|
218872895|NCT02641067|DRUG|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
219493498|NCT02408406|OTHER|Internet-Based Intervention|Use PatientCareAnywhere system
219493499|NCT02408406|OTHER|Quality-of-Life Assessment|Ancillary studies
219493500|NCT02408406|OTHER|Questionnaire Administration|Ancillary studies
218872896|NCT03066167|OTHER|Validation of different dysphagia scores|
218872897|NCT03464149|DIAGNOSTIC_TEST|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
218872898|NCT04454944|BEHAVIORAL|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
218872899|NCT04454944|BEHAVIORAL|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
218872900|NCT06464419|DEVICE|ultrasound|Measurement of optic nerve sheath diameter by ultrasound
219022723|NCT02591355|DEVICE|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
219022724|NCT02591355|DEVICE|Saline solution injection|Placebo is a saline solution
219022725|NCT01867827|OTHER|Neurofeedback and Physical Exercise|
219022726|NCT01867827|OTHER|Physical Exercise|
219022727|NCT05498038|BEHAVIORAL|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
219022728|NCT00099554|DRUG|Etanercept|
219022729|NCT03930043|DIAGNOSTIC_TEST|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
219022730|NCT05892042|DRUG|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
219493501|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
219493502|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
219493503|NCT01843907|BEHAVIORAL|Empowerment|To give patients the necessary resources to take care of their own health
219022731|NCT03832582|DRUG|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
219493504|NCT01843907|OTHER|Conversation with nurse|To find out, if the nurse, using her ....
219493505|NCT03899337|DRUG|Acalabrutinib|100mg capsule, PO, BD
219493506|NCT03899337|DRUG|Cyclophosphamide|750mg/m\^2, IV bolus
219493507|NCT03899337|DRUG|Doxorubicin|50mg/m\^2, IV bolus
219493508|NCT03899337|DRUG|Vincristine|1.4mg/m\^2, IV infusion
219493509|NCT03899337|DRUG|Prednisolone|40mg/m\^2, PO, OD
219493510|NCT03899337|DRUG|Rituximab|375mg/m\^2, IV infusion
219022732|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
219200034|NCT06869525|BEHAVIORAL|Sham Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, hole the most points open 5\~10mm, shallow piercing through the skin, connected with the electric needle but no electricity, treatment 30min.
219493511|NCT01700920|PROCEDURE|bone marrow aspirate|
219493512|NCT00707174|DRUG|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
219602145|NCT05093764|DEVICE|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
219602146|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
219602147|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
219493513|NCT00707174|DRUG|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
219493514|NCT05716191|OTHER|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
219493515|NCT00139386|DRUG|Candesartan|Candesartan Cilexetil (4-12 mg per day)
219493516|NCT02572180|BEHAVIORAL|EMG-based biofeedback training|
219493517|NCT02572180|BEHAVIORAL|NIRS-based neurofeedback training|
219493518|NCT05177237|DRUG|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
218872901|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
219493519|NCT01447316|OTHER|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
218872902|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
218872903|NCT03068208|PROCEDURE|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
218872904|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
218872905|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
218872906|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
218872907|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
218872908|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
218872909|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
218872910|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
218872911|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
218872912|NCT03100110|DEVICE|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
218872913|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
218872914|NCT05350189|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|At discretion of attending physician
218872915|NCT02423980|DRUG|Glucagon|
218872916|NCT00005834|BIOLOGICAL|filgrastim|Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5
218872917|NCT00005834|DRUG|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
218872918|NCT00005834|DRUG|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
218872919|NCT00005834|DRUG|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
218872920|NCT00005834|DRUG|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
218872921|NCT00005834|DRUG|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
218872922|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
218872923|NCT05359601|PROCEDURE|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
218872924|NCT00857974|OTHER|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
218872925|NCT02517320|DRUG|MT-3995 Low|
219022733|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
219022734|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
219022735|NCT00961844|BIOLOGICAL|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
219493520|NCT00572156|DRUG|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
219493521|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
219493522|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
218872926|NCT02517320|DRUG|MT-3995 Middle|
218872927|NCT02517320|DRUG|MT-3995 High|
218872928|NCT02517320|DRUG|Placebo|
218872929|NCT00598325|BIOLOGICAL|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
218872930|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
218872931|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
218872932|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
218872933|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
218872934|NCT01399008|DRUG|Placebo|Placebo
218872935|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
219022736|NCT00961844|DRUG|Temozolomide|
219022737|NCT00070187|BIOLOGICAL|aldesleukin|Given IV
218872936|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
218872937|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
219493523|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
219493524|NCT03008031|PROCEDURE|CESM with a reduced dose of contrast agent|
219493525|NCT02261974|DEVICE|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
218872938|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
219022738|NCT00070187|BIOLOGICAL|filgrastim|Given IV
219022739|NCT00070187|BIOLOGICAL|recombinant interferon gamma|Given IV
219493526|NCT02261974|DEVICE|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
219493527|NCT01453374|DRUG|VIVITROL 380mg|380 mg IM injection given once monthly
219493528|NCT03523013|DEVICE|CPAP|CPAP treatment with different pressure for OSA patients
219493529|NCT01669278|DEVICE|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
219493530|NCT00195585|DRUG|Isovorin|
219493531|NCT00195585|DRUG|UFT|
219493532|NCT01680289|PROCEDURE|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
219493533|NCT01680289|PROCEDURE|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
219493534|NCT02227537|DEVICE|Providence Nighttime Bracing System|Providence Nighttime Bracing System
219493535|NCT02227537|DEVICE|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
219602148|NCT04167592|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
219022740|NCT00070187|DRUG|carmustine|Given IV
219493536|NCT01201954|DRUG|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
219493537|NCT03155828|DEVICE|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
219493538|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
219493539|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
219493540|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
219493541|NCT04657978|PROCEDURE|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
219493542|NCT02248337|DRUG|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
219493543|NCT06543511|OTHER|Genetic Blood Test|Germline genetic testing using skin fibroblasts
219493544|NCT01150513|DRUG|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
219602149|NCT04167592|DRUG|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
219602150|NCT06133127|OTHER|Frailty assessment|Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
218872939|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
218872940|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
218872941|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
218872942|NCT02709876|BIOLOGICAL|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
218872943|NCT04957056|PROCEDURE|Hospitalization|Hospitalization
218872944|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
218872945|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
218872946|NCT06368908|DEVICE|Transcutaneous Functional Magnetic Muscle Stimulation|Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, SLO). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
218872947|NCT02385435|DRUG|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
218872948|NCT02385435|DRUG|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
218872949|NCT02385435|DRUG|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
218872950|NCT02619721|DEVICE|PINS SNS|
218872951|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
218872952|NCT05104970|DRUG|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
218872953|NCT05104970|DIETARY_SUPPLEMENT|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
218872954|NCT05104970|DRUG|Placebo SunnyD insta ampoule|Olive oil
218872955|NCT05104970|DIETARY_SUPPLEMENT|Placebo SunnyD STAT softgel capsule|Olive oil
218872956|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
219493545|NCT01150513|DRUG|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
219493546|NCT03283865|DIAGNOSTIC_TEST|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
219493547|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
219493548|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
219493549|NCT06236126|PROCEDURE|1% Lidocaine Injection|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal) or subcutaneously (Group Subcutaneous).
219602151|NCT06008275|DRUG|Neratinib Oral Tablet|240mg oral daily. Dosing will follow standard dose escalation procedures
219022741|NCT00070187|DRUG|cyclosporine|Given IV
219022742|NCT00070187|DRUG|cytarabine|Given IV
219022743|NCT00070187|DRUG|etoposide|Given IV
219022744|NCT00070187|DRUG|melphalan|Given IV
219602152|NCT06008275|DRUG|Ruxolitinib Oral Tablet|20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
219022745|NCT00070187|PROCEDURE|autologous bone marrow transplantation|
218872957|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
218872958|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
218872959|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
218872960|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
218872961|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
218872962|NCT05327361|DRUG|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
218872963|NCT05327361|OTHER|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
218872964|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
218872965|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
219022746|NCT00070187|PROCEDURE|bone marrow ablation with stem cell support|
219022747|NCT00070187|PROCEDURE|peripheral blood stem cell transplantation|
219022748|NCT00803868|DRUG|varenicline|up to 1mg po bid for 9 weeks
219022749|NCT00803868|DRUG|placebo|placebo matching study drug up to 1mg po bid
219022750|NCT01572506|DRUG|Biotin RBC survival|
219022751|NCT06453044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219022752|NCT06453044|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219022753|NCT06453044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219022754|NCT06453044|BIOLOGICAL|Mosunetuzumab|Given SC
219022755|NCT06453044|DRUG|Polatuzumab Vedotin|Given IV
219022756|NCT06453044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219022757|NCT06453044|OTHER|Questionnaire Administration|Ancillary Studies
219022758|NCT04959968|DEVICE|eye patch and earplug|The use of eye patch and ear plugs in post-operative intensive care in craniotomy cases.
219022759|NCT06368102|DRUG|Ampicillin|Total 2g vs 3g
219022760|NCT04930848|OTHER|Euphorbia hirta (Dudhiya)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
219022761|NCT04930848|OTHER|PBO(Combined powder of Terminalia arjuna and Terminalia bellerica)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
219022762|NCT04743505|DRUG|APL-101|-Provided by Apollomics
219022763|NCT04743505|DRUG|Osimertinib|-Given standard of care
219022764|NCT06287983|DEVICE|Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)|Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.
219022765|NCT06287983|OTHER|The Sample Spondylitis Exercise Program|The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
219022766|NCT05700825|BEHAVIORAL|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
219022767|NCT04540770|DRUG|HuL001|Anti-ENO1 monoclonal antibody
219493550|NCT00075465|DRUG|docetaxel|
219493551|NCT00075465|DRUG|epirubicin hydrochloride|
219493552|NCT03932838|OTHER|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
218872966|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
218872967|NCT00115661|DRUG|Rosiglitazone|
218872968|NCT01776723|DRUG|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
218872969|NCT04672850|DIETARY_SUPPLEMENT|Probiotic|The participants will consume 2 capsules daily for three months
218872970|NCT04672850|DIETARY_SUPPLEMENT|Placebo|The participants will consume 2 capsules daily for three months
218872971|NCT05477914|OTHER|questionnaire|questionnare about nutritional knowledge of pregnant women
218872972|NCT01269502|DEVICE|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
218872973|NCT01269502|OTHER|Inspection|Inspection of feet daily for one year
218872974|NCT04485884|DRUG|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
218872975|NCT04485884|DRUG|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
218872976|NCT04485884|DRUG|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
218872977|NCT04485884|DRUG|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
218872978|NCT04485884|DRUG|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
218872979|NCT04485884|DRUG|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
218872980|NCT01439373|DRUG|GSK2336805|Active Investigational Drug
218872981|NCT01439373|DRUG|Pegylated interferon alfa-2a|Standard of Care drug
219022768|NCT00213837|DEVICE|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
219022769|NCT04878393|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219022770|NCT05230589|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219022771|NCT05090865|DIETARY_SUPPLEMENT|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
218872982|NCT01439373|DRUG|Ribavirin|Standard of Care drug
218872983|NCT01439373|DRUG|GSK2336805 Matching Placebo|Placebo of Investigational Drug
218872984|NCT02086422|DRUG|ivabradine|
218872985|NCT02086422|DRUG|Placebo|
218872986|NCT02086422|OTHER|Exercise|
219022772|NCT05090865|DIETARY_SUPPLEMENT|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
219022773|NCT04232670|PROCEDURE|EUS + SHAM|Endoscopic Ultrasound
219022774|NCT04232670|PROCEDURE|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
218872987|NCT05784298|DEVICE|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
218872988|NCT00366912|DEVICE|non-invasive ventilation|
218872989|NCT02945644|DRUG|Trazodone|take at bedtime for 14 days
218872990|NCT02945644|DRUG|Placebo|take at bedtime for 14 days
218872991|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
218872992|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
218872993|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
218872994|NCT01731093|DRUG|AT-001|
218872995|NCT01731093|DRUG|Placebo|
218872996|NCT00734721|BEHAVIORAL|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
218872997|NCT00491881|BEHAVIORAL|no added salt diet|
218872998|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
218872999|NCT04611802|OTHER|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
218873000|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
218873001|NCT04611802|OTHER|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
218873002|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
219493553|NCT03375996|DRUG|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
218873003|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
218873004|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
218873005|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
218873006|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
218873007|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
218873008|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
218873009|NCT02500446|DRUG|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
218873010|NCT02500446|OTHER|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
218873011|NCT03834220|DRUG|Debio 1347|Debio 1347 oral tablets.
218873012|NCT01521377|DRUG|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
218873013|NCT01521377|DRUG|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
218873014|NCT01521377|DRUG|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
218873015|NCT01521377|DRUG|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
218873016|NCT01521377|DRUG|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
218873017|NCT01521377|DRUG|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
218873018|NCT06262217|DEVICE|Mobile MRI scanner|Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
218873019|NCT02593318|DRUG|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
219022775|NCT03467841|DEVICE|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
219022776|NCT06235788|BEHAVIORAL|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
219022777|NCT06235788|BEHAVIORAL|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
219022778|NCT04656145|DEVICE|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
219493554|NCT03801278|DRUG|FPA144|Bemarituzumab administration every two weeks
219493555|NCT01364246|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
219493556|NCT05134727|DRUG|AZD5055|Healthy participants will receive AZD5055
218873020|NCT02593318|DRUG|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
218873021|NCT02020408|DRUG|[11C]raclopride|1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
219493557|NCT05134727|DRUG|Placebo|Healthy participants will receive placebo
218873022|NCT02020408|DRUG|[11C]DASB|BPND of \[11C\]DASB.
218873023|NCT02020408|DRUG|amphetamine|The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
218873024|NCT03207802|DEVICE|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
218873025|NCT00156871|BEHAVIORAL|exercise|
218873026|NCT03688568|DRUG|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
218873027|NCT05498467|DRUG|Anakinra|100 mg Anakinra injections s.c.
218873028|NCT05498467|DRUG|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
218873029|NCT02343705|DEVICE|Latella Knee Implant System|
218873030|NCT00199823|GENETIC|Intracoronary aotologous stem cell transplantation|
218873031|NCT01311440|OTHER|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
218873032|NCT02055287|DRUG|LY03004|
218873033|NCT02699567|OTHER|No intervention|
218873034|NCT00854815|PROCEDURE|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
218873035|NCT00854815|PROCEDURE|No Irrigation|Suction only using suction/irrigator
219022779|NCT04147455|BEHAVIORAL|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
219022780|NCT04147455|BEHAVIORAL|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
219022781|NCT03311659|BIOLOGICAL|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
219022782|NCT05241522|DIAGNOSTIC_TEST|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
219022783|NCT00503087|PROCEDURE|Saline Injection|
219022784|NCT00503087|DEVICE|Pneumatic Skin Flattening (PSF)|
219022785|NCT02496832|DRUG|18F-Fluoroazomycin arabinoside|
219022786|NCT05163028|DRUG|HBI-2376|SHP2 Inhibitor
219022787|NCT05737940|DRUG|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
218873036|NCT06051903|OTHER|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
218873037|NCT06409247|BEHAVIORAL|iExposure|There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
219022788|NCT05737940|DRUG|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
219022789|NCT05747092|PROCEDURE|gingival graft|"investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
219022790|NCT03604185|BEHAVIORAL|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
219022791|NCT03604185|BEHAVIORAL|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
219022792|NCT05996874|DRUG|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
218873038|NCT06409247|BEHAVIORAL|iExposure plus attention guidance|The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
218873039|NCT06409247|BEHAVIORAL|iExposure plus attention control|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
219493558|NCT04483427|COMBINATION_PRODUCT|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
218873040|NCT05044013|OTHER|Full access to JomPrEP app|All participants will receive the JomPrEP app with access to all of its features which include: customizable page (using avatars and pseudonyms); visual dashboard (track and visualize progress); HIV testing plan (create plan for HIV testing, order self-testing kits, testing site locator); PrEP Care Plan (PrEPxpress, automated reminders for follow-up care, labs, delivery); chat function and discussion forum; tailored messages and reminders; assessment center (weekly assessment on adherence to PrEP, HIV risk, mood); knowledge center (resources on HIV testing and PrEP); Mental health support (screen for P/SUD, counseling feedback, referral to support services); Integration of provider locator (provides users with a GPS enabled map for PrEP and mental health support providers in Malaysia) and Gamification (offers extrinsic motivation by rewarding points/milestones for doing activities within the app). Participants can also contact the RA using the chat function for support.
219022793|NCT03429179|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
219022794|NCT03429179|OTHER|Physiological saline|intravenous infusion of the same volume of 0.9% saline
219022795|NCT00060931|DRUG|carvedilol|
219022796|NCT00060931|DRUG|metoprolol|
219022797|NCT03948256|PROCEDURE|Control intervention|Prompt closure of EVD with subsequent observation period
219493559|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
219493560|NCT02554344|DRUG|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
219493561|NCT05435872|DEVICE|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
218873041|NCT05044013|OTHER|inactivated JomPrEP app|Only information and resources for PrEP services will be available along with access to risk assessment tools.
218873042|NCT01814124|OTHER|Manual therapy plus exercise|
218873043|NCT01814124|OTHER|Advice and home exercise|
218873044|NCT03442218|DRUG|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
218873045|NCT03442218|DRUG|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
218873046|NCT01735981|OTHER|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
218873047|NCT01735981|OTHER|hand-held video game|hand-held video games
218873048|NCT05897892|DIETARY_SUPPLEMENT|Clinical study on the mangrove sword bean food bar effect for older people|The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
218873049|NCT04847765|DEVICE|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
218873050|NCT05645965|DEVICE|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
218873051|NCT03492034|DEVICE|IUD during CS|IUD insertion during CS
218873052|NCT03492034|DEVICE|IUD after puerperium|IUD after puerperium
218873053|NCT05426278|DEVICE|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
218873054|NCT02900768|BEHAVIORAL|Exercise|Combination of resistance and aerobic exercises for 100 days.
218873055|NCT03580980|DRUG|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
218873056|NCT03580980|PROCEDURE|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
218873057|NCT03580980|DRUG|Morphine|patient controlled analgesia by morphine
218873058|NCT02069119|DRUG|OPC-108459|
218873059|NCT02069119|DRUG|Placebo|
218873060|NCT01033916|OTHER|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
218873061|NCT02902393|BIOLOGICAL|Thromboelastography|
218873062|NCT02270112|DEVICE|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
218873063|NCT02458781|DRUG|Metronidazole|Metronidazole 500mg given twice daily for 14 days
218873064|NCT02458781|DRUG|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
218873065|NCT02458781|DRUG|Placebo|Placebo given twice daily for 14 days
218873066|NCT05181124|DRUG|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
218873067|NCT05181124|DRUG|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
219022798|NCT03948256|PROCEDURE|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
219022799|NCT06376110|DRUG|Topical Antioxidant Serum|An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
219022800|NCT06376110|DEVICE|AviClear Laser|The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
218873068|NCT05181124|DRUG|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
218873069|NCT05181124|DRUG|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
218873070|NCT01740401|DRUG|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
218873071|NCT03825211|PROCEDURE|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
218873072|NCT03825211|PROCEDURE|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
218873073|NCT02602158|DIETARY_SUPPLEMENT|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
218873074|NCT02602158|DIETARY_SUPPLEMENT|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
218873075|NCT05966948|DRUG|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
219022801|NCT01899794|PROCEDURE|TVT-O/Oxytrol|
219022802|NCT01899794|DEVICE|TVT-O|
219022803|NCT01899794|DRUG|Oxytrol|
219022804|NCT00071760|DRUG|GW433908|Fosamprenavir suspension bid
219022805|NCT00071760|DRUG|ritonavir|Ritonavir solution bid
219022806|NCT00375739|DRUG|PEP005|
219022807|NCT02386904|DRUG|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
219022808|NCT05568147|DRUG|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
219022809|NCT05568147|DRUG|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
219022810|NCT02614950|OTHER|Treatment interruption|
219022811|NCT03488654|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
219022812|NCT06440538|DEVICE|PCMS + Contralateral Motor Training|PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
219022813|NCT06440538|DEVICE|PCMS + Rest|PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
219022814|NCT06440538|DEVICE|Sham PCMS + Contralateral Motor Training|360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
219022815|NCT06344754|OTHER|Gamified education|Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
219022816|NCT04651634|DRUG|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
219022817|NCT01994629|BIOLOGICAL|MenACWY-CRM|MenACWY-CRM
219022818|NCT01994629|BIOLOGICAL|MenACWY-TT|MenACWY-TT
219022819|NCT03945396|DRUG|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
219022820|NCT03945396|OTHER|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
219022821|NCT03945396|DRUG|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
219022822|NCT04364308|OTHER|Fetal Echography|Fetal ultrasound and its parameters
219022823|NCT06853067|OTHER|Monitoring of body temperature|Body temperature is monitored in the forehead using the Temperature Monitoring Patient Sensors in patients sedated with dexmedetomidine or remimazolam during spinal anesthesia.
219022824|NCT04828785|OTHER|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
218873076|NCT05966948|DRUG|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
218873077|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
218873078|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
219022825|NCT04828785|OTHER|Food Subsidy|$40/month food subsidy
219200035|NCT06869239|DRUG|Etoposide + cisplatin/carboplatin|Four courses of intravenous cisplatin (75 mg/m² of body surface area on day 1 or divided into 3 days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min on day 1 of each cycle) and intravenous etoposide (100 mg/m² of body surface area on days 1-3) every 3 weeks
219200036|NCT06869239|RADIATION|Thoracic radiotherapy|High-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) concurrent with chemotherapy initiated at the beginning of cycles 1-3
219200037|NCT06869239|RADIATION|Prophylactic cranial irradiation (PCI)|PCI (25Gy in 10 fractions, once daily over two weeks) 3-4 weeks post-chemoradiotherapy for patients achieving PR or CR
219200038|NCT06869239|DRUG|PD-L1 inhibitor|Maintenance therapy with PD-L1 inhibitors (Durvalumab 1500 mg Q4W or Atezolizumab 1200 mg Q3W or Sugemalimab 1200 mg Q3W or Adebrelimab 1200 mg Q3W) post-PCI until disease progression, death, or intolerable toxicity, up to 2 years
219200039|NCT06868810|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
219200040|NCT06868810|OTHER|Injection of 5% NaHCO3|Injection of 5% NaHCO3 through central venous catheter
218873079|NCT03667690|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
218873080|NCT03667690|DRUG|Caspofungin|Intravenous antifungal therapy
218873081|NCT03667690|DRUG|Fluconazole|Oral antifungal therapy
218873082|NCT03667690|DRUG|intravenous placebo|Normal saline
218873083|NCT03667690|DRUG|oral placebo|Microcrystalline cellulose
218873084|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
218873085|NCT00184756|DRUG|somatropin|
218873086|NCT05651815|DEVICE|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
218873087|NCT05105217|OTHER|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
218873088|NCT04984382|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
218873089|NCT05325346|DRUG|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
218873090|NCT05325346|DRUG|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
218873091|NCT03051386|BIOLOGICAL|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
219022826|NCT04957719|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
219022827|NCT04957719|COMBINATION_PRODUCT|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
219022828|NCT04601753|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219493562|NCT03348501|OTHER|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
219493563|NCT02783508|DRUG|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
218873092|NCT06442670|DEVICE|Electroencephalography|Phase synchrony during the completion of the semantic memory task
218873093|NCT03495102|DRUG|Dulaglutide|Administered SC
219022829|NCT04080440|PROCEDURE|Extubation readiness clinical score|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \> 9, extubation has to be completed."
219022830|NCT04080440|PROCEDURE|Usual Care|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to usual care."
219022831|NCT05171231|DEVICE|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
219022832|NCT06829953|BEHAVIORAL|GET ActivE|The GET ActivE health coach will review data from the Vira app and send nudges to the participant with insights encouraging them to engage in activities that bring enjoyment or pleasure.
219022833|NCT06829953|BEHAVIORAL|Treatment As Usual|Participants randomized to Treatment As Usual may have access to activity data from an app and receive summary information about activity patterns at the end of their participation.
219022834|NCT01471808|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
219022835|NCT01471808|DRUG|CSII, Metformin, Pioglitazone|CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
219022836|NCT01471808|DRUG|CSII, Sitagliptin|CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
219022837|NCT05193656|DIAGNOSTIC_TEST|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
219022838|NCT05483179|DIAGNOSTIC_TEST|CPET|Cardiopulmonary exercise test
218873094|NCT04802187|OTHER|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
218873095|NCT04802187|OTHER|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
218873096|NCT00258791|DRUG|Ibuprofen|
218873097|NCT02650063|DRUG|DE-117|
218873098|NCT00317304|BEHAVIORAL|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
219493564|NCT02783508|DRUG|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
218873099|NCT02482116|OTHER|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
218873100|NCT03487211|DRUG|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
218873101|NCT03487211|DRUG|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
219602153|NCT05812534|DRUG|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
219602154|NCT06502366|DRUG|BDA MDI HFO 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFO
219602155|NCT06502366|DRUG|BDA MDI HFA 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFA
218873102|NCT01669083|DRUG|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
218873103|NCT01669083|DRUG|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
218873104|NCT01669083|DRUG|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
218873105|NCT01669083|DRUG|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
218873106|NCT05485623|DEVICE|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
218873107|NCT02736916|RADIATION|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
218873108|NCT02736916|RADIATION|Conventional PCI|LD-SCLC patients with conventional PCI
218873109|NCT05952388|OTHER|Behavioral Patient care|chart review
218873110|NCT01161537|DRUG|VX-770|Tablet.
218873111|NCT01161537|DRUG|Placebo|Tablet.
218873112|NCT04164420|BEHAVIORAL|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
218873113|NCT04164420|BEHAVIORAL|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
218873114|NCT05993910|OTHER|Hyperthermie Register|"* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie"
219602156|NCT06502366|DRUG|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
219602157|NCT01128543|DRUG|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
219602158|NCT04642404|DRUG|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
219602159|NCT04642404|DRUG|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
218873115|NCT00520910|DRUG|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
218873116|NCT01629459|BEHAVIORAL|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
218873117|NCT00269555|DRUG|Genistein Combined Polysaccharide (GCP)|
218873118|NCT04764227|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
218873119|NCT04764227|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
218873120|NCT04764227|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
218873121|NCT04967404|DIETARY_SUPPLEMENT|Phosphatidylserine|800 mg per day for 10 days
218873122|NCT00544219|BIOLOGICAL|rituximab|375 mg/m2 i.v. per cycle
218873123|NCT00544219|DRUG|cyclophosphamide|750 mg/m2 i.v. per cycle
218873124|NCT00544219|DRUG|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
218873125|NCT00544219|DRUG|prednisone|100 mg/day p.o. per cycle
218873126|NCT00544219|DRUG|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
218873127|NCT00544219|PROCEDURE|positron emission tomography|PET Scan during treatment
219200041|NCT06870110|DEVICE|Bias Modification Biofeedback|The device uses EEG-based bias modification biofeedback intended to reduce attention to drug-related cues and increase attention to non-drug pleasant scenes. Specifically, the device measures perceptual biases from Event-Related Potential biomarkers related to Substance Use Disorders.
219200042|NCT06869863|BIOLOGICAL|Medicinal product MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparation of solution for injection in patients with severe spermatogenesis disorders|Human mesenchymal stromal cell secretion1 containing vascular endothelial growth factor (VEGF)2 ≥ 5,0 нг
219200043|NCT06869863|OTHER|Clostilbegit (clomiphene) 50 mg 1 tablet x 1 p a day - 3 months, Triovit - 1 tablet x 1 p a day - 3 months, Folic acid - 1 tablet x 1 p a day - 3 months.|Combination treatment recommended by standards
219200044|NCT06870669|BEHAVIORAL|progressive relaxation exercise|We will use progressive relaxation exercises to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
219200045|NCT03022071|OTHER|Cognitive behavior therapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
219200046|NCT03649971|DRUG|Guselkumab|Guselkumab SC will be administered every 4 weeks.
219493565|NCT04820335|BEHAVIORAL|Structured External Memory Aid Treatment (SEMAT)|"During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase."
219493566|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
218873128|NCT06254287|DRUG|Avatrombopag|Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.
218873129|NCT06254287|DRUG|Avatrombopag +rhTPO|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
218873130|NCT01719133|DRUG|placebo|saline solution
218873131|NCT01719133|DRUG|Histamine|positive control
218873132|NCT01719133|DRUG|AllerT1|synthetic peptide T1
218873133|NCT01719133|DRUG|AllerT2|synthetic peptide T2
218873134|NCT01719133|DRUG|AllerT3|synthetic peptide T3
218873135|NCT01719133|DRUG|AllerT4|synthetic peptide T4
218873136|NCT01719133|DRUG|AllerT5|synthetic peptide T5
218873137|NCT01719133|DRUG|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
218873138|NCT01719133|DRUG|mix of AllerT4-T5|mix T4-T5
218873139|NCT05446571|DRUG|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
219200047|NCT03649971|DRUG|Placebo|Placebo SC will be administered every 4 weeks.
218873140|NCT05446571|DRUG|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
218873141|NCT06351254|PROCEDURE|Sine sound waves|Group A 8 participants will be given sine sound waves treatment with the frequency of 80 pulses on C1 vertebrae. Treatment session will be 6 session 3 times a week followed by 6 sessions 2 times a week.
218873142|NCT06351254|PROCEDURE|Kinesthetic exercises|Kinesthetic exercises was conducted for GROUP 2 8 patients for 6 weeks. Before and after assessment was taken to track patient progress. Cervicocephalic kinesthetic sensibility tests were performed. The first test was Head-to-Neutral Head Position(NHP) repositioning test. In the second repositioning test is Head-toTarget repositioning tests.
219200048|NCT05907616|BEHAVIORAL|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
219200049|NCT05708105|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C or 7100 Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
219602160|NCT04414774|DEVICE|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
219602161|NCT00785148|DRUG|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
219602162|NCT05298826|DRUG|recombinant factor VIIa|using recombinant factor VIIa
219602163|NCT03334461|COMBINATION_PRODUCT|Exposure to oral antiseptics or enamel remineralisation agent|
219602164|NCT00166647|PROCEDURE|Blood Sampling|
219602165|NCT00005195|PROCEDURE|Catheter ablation|
218873143|NCT06351254|PROCEDURE|Sine sound waves plus kinesthetic exercises|Group C 8 was given combine treatment of sine sound waves and kinesthetic exercises before and after measurement was taken.
218873144|NCT04993443|DRUG|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
218873145|NCT04993443|OTHER|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
218873146|NCT02215135|DRUG|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
218873147|NCT00321464|BIOLOGICAL|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
218873148|NCT00321464|DRUG|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
218873149|NCT04327024|DRUG|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
218873150|NCT04327024|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
218873151|NCT04327024|DRUG|Placebo for verinurad|Matching Capsule
218873152|NCT04327024|DRUG|Placebo for allopurinol|Matching tablet
218873153|NCT05204030|OTHER|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
219022839|NCT02625155|OTHER|Urine diagnostic testing as SOC, drug regimen changes per SOC|
219022840|NCT02625155|OTHER|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
219022841|NCT04759209|DIAGNOSTIC_TEST|Biopsies|
219022842|NCT02384707|OTHER|allegic food|"Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose"
219022843|NCT02384707|OTHER|Placebo|
219022844|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
219493567|NCT02145000|BIOLOGICAL|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
219493568|NCT02145000|BIOLOGICAL|Placebo|
219493569|NCT03875131|OTHER|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~  * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
219493570|NCT05180630|DEVICE|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
219493571|NCT05180630|DEVICE|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
219022845|NCT01359657|BIOLOGICAL|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
219022846|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
219022847|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
219022848|NCT01359657|BIOLOGICAL|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
219022849|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
219022850|NCT05941507|DRUG|LCB84|TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
219022851|NCT05941507|DRUG|Anti-PD-1 monoclonal antibody|anti-PD-1 Ab
219022852|NCT01558752|DEVICE|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
219022853|NCT01558752|DEVICE|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
219022854|NCT01716598|DEVICE|IPS System|TLD Therapy will be achieved bronchoscopically.
219022855|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
219022856|NCT02160158|DRUG|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
219022857|NCT02160158|DRUG|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
219493572|NCT05180630|DEVICE|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
219022858|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
219022859|NCT02160158|DRUG|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
219022860|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
219022861|NCT02160158|DRUG|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
218873154|NCT05204030|OTHER|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
218873155|NCT06238284|OTHER|no intervention|Since it is a retrospective study, no intervention is needed.
218873156|NCT02825524|DEVICE|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
218873157|NCT03239080|DRUG|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
218873158|NCT03239080|OTHER|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
218873159|NCT06240104|DIAGNOSTIC_TEST|cardiac output index monitor|During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
218873160|NCT00668811|DRUG|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
219022862|NCT02160158|DRUG|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
219022863|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
219022864|NCT02160158|DRUG|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
219022865|NCT04964154|BEHAVIORAL|Protect Your Elders Campaign|This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
219022866|NCT02172742|DRUG|BIA 2-093|BIA 2-093 1200 mg once-daily
218873161|NCT04204044|DRUG|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
218873162|NCT04204044|DRUG|Myo-inositol|Myo inositol used in PCO
218873163|NCT02327988|OTHER|Cryotherapy|
219022867|NCT02172742|DRUG|Placebo|matching placebo
219022868|NCT02172742|DRUG|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
219022869|NCT01471106|DRUG|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
219022870|NCT01927666|DIETARY_SUPPLEMENT|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
218873164|NCT02327988|DEVICE|Laser therapy|
219022871|NCT05077709|DRUG|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
218873165|NCT03842449|DIAGNOSTIC_TEST|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
218873166|NCT03842449|OTHER|Biological samples|"The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment"
218873167|NCT05169606|OTHER|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
218873168|NCT05169606|OTHER|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
219022872|NCT01601782|PROCEDURE|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
219022873|NCT01601782|DEVICE|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
219022874|NCT05841563|DRUG|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
219022875|NCT04339764|DRUG|iPSC-derived RPE/PLGA transplantation|iPSC-derived RPE/PLGA transplantation
219022876|NCT00387439|BEHAVIORAL|standard medical treatment + anoperineal physiotherapy.|
219022877|NCT00387439|BEHAVIORAL|Standard medical treatment|
219022878|NCT00326456|DRUG|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
219022879|NCT00326456|DRUG|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
219022880|NCT00326456|DRUG|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
219022881|NCT02883153|DRUG|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
219022882|NCT06220669|DRUG|LY3541860|Administered IV
219022883|NCT06220669|DRUG|Placebo|Administered IV
219022884|NCT05999994|DRUG|Ramucirumab|Administered IV
218873169|NCT05169606|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
218873170|NCT00582998|PROCEDURE|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
219022885|NCT05999994|DRUG|Cyclophosphamide|Administered orally
219493573|NCT04506346|DIAGNOSTIC_TEST|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
219493574|NCT05482438|DEVICE|Polyethylene|Wear measurement
219493575|NCT04441203|DEVICE|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
218873171|NCT00582998|DEVICE|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
219022886|NCT05999994|DRUG|Vinorelbine|Administered IV
219022887|NCT05999994|DRUG|Gemcitabine|Administered IV
219022888|NCT05999994|DRUG|Docetaxel|Administered IV
219022889|NCT05999994|DRUG|Abemaciclib|Administered orally
219022890|NCT05999994|DRUG|Irinotecan|Administered IV
219022891|NCT05999994|DRUG|Temozolomide|Administered orally
219022892|NCT01132131|OTHER|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
219022893|NCT03337074|OTHER|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
219022894|NCT03337074|OTHER|Questionnaire|Participants are asked to complete a questionnaire.
219022895|NCT03337074|OTHER|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
219022896|NCT05058443|DRUG|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
219022897|NCT05058443|DRUG|Placebo|placebo subcutaneously every 6 months (Q6M)
219200050|NCT05708105|DIAGNOSTIC_TEST|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and \< 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
219022898|NCT03064360|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
219022899|NCT03064360|DEVICE|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
219022900|NCT03064360|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
219022901|NCT00210041|DRUG|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
219022902|NCT00210041|DRUG|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
219022903|NCT06385223|DEVICE|Beam F3 targeted accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
219200051|NCT05708105|DIAGNOSTIC_TEST|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
219493576|NCT05942131|OTHER|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
219493577|NCT02163629|BEHAVIORAL|Stress management|
219022904|NCT06385223|DEVICE|Individualized connectome-guided accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
219022905|NCT03864250|DRUG|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
219022906|NCT03864250|DRUG|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
219493578|NCT02566967|DRUG|tofacitinib|oral tofacitinib will be taken 2 times daily
218873172|NCT06307093|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
218873173|NCT06307093|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
218873174|NCT06096675|BEHAVIORAL|• Cardiac Rehabilitation|Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
218873175|NCT02272374|PROCEDURE|AVF creation|
218873176|NCT02272374|PROCEDURE|TCC placement|
218873177|NCT02272374|PROCEDURE|AVG creation|
218873178|NCT02905630|OTHER|Exercise training|high intensity aerobic interval training
218873179|NCT04849169|DEVICE|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
218873180|NCT00415922|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
218873181|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
218873182|NCT02641470|DIETARY_SUPPLEMENT|DA9301 (Vaccinium uliginosum extract)|
219493579|NCT06702254|BEHAVIORAL|Experimental: Psychological manualized treatment with CBT and ACT|The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.
219493580|NCT06702254|OTHER|Treatment as usual|This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
219493581|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
218873183|NCT02641470|DIETARY_SUPPLEMENT|Placebo|
218873184|NCT02406911|DRUG|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
218873185|NCT03794674|OTHER|No intervention.|No intervention, since this is a validation study
219493582|NCT06424704|DIAGNOSTIC_TEST|Microbiological culture|Samples taken from chronic suppurative otitis media patients in the Medical Microbiology Laboratory of Selçuk University Faculty of Medicine will be planted in 5% sheep blood Columbia agar, eosin methylene blue agar and saboraud dextrose agar, and the media will be incubated at 37oC for 24-48 hours. Growing bacteria and fungi were examined using traditional methods \[Gram staining, catalase test, coagulase test, bacitracin disk, PYR test (L-pyrrolidonyl-β-naphthylamide), oxidase test, IMViC test, lactophenol cotton blue, etc.\] and VITEK 2 (bioMerieux, France).
218873186|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
218873187|NCT02843828|DEVICE|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
219493583|NCT04676607|DRUG|SHR7390|SHR7390
219493584|NCT03922815|DRUG|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
218873188|NCT02843828|OTHER|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
218873189|NCT02849015|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
218873190|NCT02849015|BIOLOGICAL|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
218873191|NCT01196351|OTHER|Dietary Supplement: water with noncalorie sweetener|
218873192|NCT01196351|OTHER|Activity: With noncalorie sweetener or glucose|
218873193|NCT01192568|DRUG|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
218873194|NCT01192568|DRUG|Placebo|Topical gel
218873195|NCT00652951|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
218873196|NCT00652951|BIOLOGICAL|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
219022907|NCT06371118|DEVICE|Directly mailed self-sampling kit to collect a vaginal sample|"The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment."
219493585|NCT03922815|DRUG|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
219493586|NCT02011516|DRUG|Baclofen|
219493587|NCT02011516|BEHAVIORAL|Psychosocial|
219493588|NCT02011516|DRUG|Placebo|
218873197|NCT00652951|BIOLOGICAL|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
218873198|NCT00652951|BIOLOGICAL|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
218873199|NCT02593825|BEHAVIORAL|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
218873200|NCT02593825|BEHAVIORAL|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
219022908|NCT06371118|DEVICE|Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure|"Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1."
219022909|NCT06371118|DIAGNOSTIC_TEST|Standard of care - screening in a clinical setting|Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
219022910|NCT01351844|BEHAVIORAL|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
219022911|NCT01351844|BEHAVIORAL|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
219022912|NCT02467010|DRUG|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
219493589|NCT05645055|OTHER|treat these patients with biologics|treat these patients with biologics
219493590|NCT05614466|OTHER|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
219493591|NCT03715660|DIAGNOSTIC_TEST|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
219493592|NCT00705796|DRUG|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
219493593|NCT00705796|DRUG|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
219493594|NCT06476743|OTHER|Sensory Integration Therapy|This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
219493595|NCT06476743|OTHER|Balance Board Training|This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
219493596|NCT01825616|DIETARY_SUPPLEMENT|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
219493597|NCT01825616|OTHER|Placebo|Mushroom powder without vitamin D2
219493598|NCT00709735|DRUG|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
219493599|NCT00709735|DRUG|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
219493600|NCT02236390|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
219493601|NCT02236390|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
219493602|NCT06567938|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
219200052|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device + PRF|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.
219200053|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device alone (control)|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
219200054|NCT05974358|PROCEDURE|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
219493603|NCT03899506|DRUG|Olanzapine|Patients receiving Olanzapine per the ED protocol
219493604|NCT03899506|DRUG|Midazolam|Patients receiving Midazolam per the ED protocol
219493605|NCT03939403|DRUG|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
219493606|NCT04547478|DIAGNOSTIC_TEST|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
219493607|NCT05066347|DEVICE|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
218873201|NCT00708695|BEHAVIORAL|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
218873202|NCT00003364|DRUG|cisplatin|
218873203|NCT00003364|DRUG|cyclophosphamide|
218873204|NCT00003364|DRUG|doxorubicin hydrochloride|
218873205|NCT00003364|DRUG|etoposide|
218873206|NCT00003364|DRUG|vincristine sulfate|
218873207|NCT00003364|RADIATION|radiation therapy|
218873208|NCT04397562|DRUG|Levilimab|Levilimab 324 mg
218873209|NCT04397562|DRUG|Placebo|Placebo
218873210|NCT01251835|DRUG|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
218873211|NCT01251835|DRUG|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
218873212|NCT01251835|DRUG|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
218873213|NCT01206582|BIOLOGICAL|Hemin|10 iv infusions for 8 weeks
219493608|NCT06422156|RADIATION|Stereotactic body radiation|Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
218873214|NCT01206582|BIOLOGICAL|Albumin|10 iv infusions for 8 weeks
218873215|NCT04519346|OTHER|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
218873216|NCT01054001|DRUG|sildenafil 100mg|sildenafil 100mg per oral twice a week
218873217|NCT01157026|DIETARY_SUPPLEMENT|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
218873218|NCT01157026|OTHER|placebo plus tamoxifen|20mg tamoxifen daily
218873219|NCT01609998|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
218873220|NCT01609998|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
218873221|NCT02522325|DRUG|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
218873222|NCT02522325|DRUG|Cocaine|Intranasal cocaine will be administered during experimental sessions.
218873223|NCT02522325|DRUG|Placebo|Placebo capsules will contain only cornstarch.
218873224|NCT01209078|DRUG|GSK1322322|GSK1322322 1500mg BID
218873225|NCT01209078|DRUG|Linezolid|Linezolid 600mg
218873226|NCT01209078|DRUG|GSK1322322 placebo|Placebo
218873227|NCT01209078|DRUG|Linezolid placebo|placebo
218873228|NCT00924508|DEVICE|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
218873229|NCT00924508|DRUG|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
218873230|NCT01755455|DRUG|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
218873231|NCT01755455|DRUG|Placebo|Matching placebo capsule
218873232|NCT00856726|DRUG|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
219200055|NCT05974358|PROCEDURE|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
218873233|NCT03458650|DRUG|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
218873234|NCT03458650|DRUG|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
218873235|NCT03458650|DRUG|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
218873236|NCT03458650|DRUG|Placebo|matching placebo tablets
218873237|NCT01435629|DRUG|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
218873238|NCT04119596|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
218873239|NCT04119596|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
218873240|NCT04338763|DRUG|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
218873241|NCT04338763|DRUG|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
219200056|NCT06681545|OTHER|one to one interviews and or focus groups|one to one interviews and or focus groups
219200057|NCT06151730|OTHER|Non-Interventional Study|Non-interventional study
218873242|NCT00005085|DRUG|becatecarin|
218873243|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
218873244|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
218873245|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
218873246|NCT00973323|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
219493609|NCT06422156|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
219493610|NCT06422156|DRUG|mono-chemotherapy|Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
219493611|NCT00003692|PROCEDURE|therapeutic thoracoscopy|
219493612|NCT00003692|PROCEDURE|video-assisted surgery|
219493613|NCT00547807|OTHER|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
219493614|NCT00547807|OTHER|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
219493615|NCT02998515|DEVICE|Companion (Liquid oxygen device)|
219493616|NCT02998515|DEVICE|Activox (concentrator)|
219493617|NCT05430009|RADIATION|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
219493618|NCT05430009|DRUG|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
219493619|NCT04324307|DRUG|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
219493620|NCT04324307|COMBINATION_PRODUCT|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
218873247|NCT04916912|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
218873248|NCT02812719|DRUG|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
219022913|NCT02467010|DRUG|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
219022914|NCT02467010|DRUG|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
219022915|NCT03326258|DRUG|Glembatumumab Vedotin|Given IV
219022916|NCT03326258|BIOLOGICAL|Ipilimumab|Given IV
219022917|NCT03326258|OTHER|Laboratory Biomarker Analysis|Correlative studies
219022918|NCT03326258|BIOLOGICAL|Nivolumab|Given IV
219022919|NCT03326258|OTHER|Pharmacological Study|Correlative studies
219022920|NCT01991457|DRUG|Fludarabine|
219022921|NCT01991457|PROCEDURE|Total Body Irradiation|
219022922|NCT01306357|DRUG|Somatropin|4 mg or 10 mg delivered by needle-free device
219022923|NCT05058300|DEVICE|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
219022924|NCT04366076|DIAGNOSTIC_TEST|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
219022925|NCT01655550|OTHER|Withhold oral contrast|The intervention is to withhold oral contrast
219022926|NCT03792867|DRUG|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
219022927|NCT06027853|DRUG|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
219022928|NCT05079295|PROCEDURE|CSDH evacuation|Burr hole for chronic subdural hematomas
219022929|NCT01109654|DRUG|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
219022930|NCT01941641|DRUG|neoadjuvant FOLFOXIRI|
219022931|NCT01941641|DRUG|Capecitabine|
219022932|NCT00035620|DRUG|pegfilgrastim|pegfilgrastim
219022933|NCT00035620|DRUG|filgrastim|filgrastim
219200058|NCT06886516|DRUG|Apixaban|A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.
219493621|NCT04324307|COMBINATION_PRODUCT|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
219493622|NCT05652816|PROCEDURE|Split-thickness skin graft|Transplantation of autologous skin to burn area
219493623|NCT05652816|BIOLOGICAL|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
219493624|NCT05652816|BIOLOGICAL|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
219493625|NCT00666718|DRUG|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
219493626|NCT00666718|DRUG|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
219493627|NCT00666718|DRUG|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
219493628|NCT00233350|DEVICE|use of navigated 3D ultrasound during surgery|
219493629|NCT00654446|DRUG|Rosuvastatin|
219022934|NCT04608851|DRUG|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
219022935|NCT04608851|OTHER|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
219200059|NCT06803498|PROCEDURE|Receipt of significant resuscitation intervention at birth|Receipt of CPAP, PPV, intubation, or CPR at birth in a hospital delivery room
219493630|NCT00654446|DRUG|Simvastatin|
219493631|NCT05467449|DEVICE|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
219493632|NCT00867126|DRUG|pioglitazone hydrochloride|
219493633|NCT00867126|OTHER|laboratory biomarker analysis|
219493634|NCT00867126|OTHER|questionnaire administration|
219493635|NCT00867126|PROCEDURE|quality-of-life assessment|
219493636|NCT03496207|DRUG|Placebo|Placebo
219493637|NCT03496207|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
219493638|NCT03496207|OTHER|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
218873249|NCT02812719|DRUG|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
219493639|NCT04583631|PROCEDURE|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
219493640|NCT00569335|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
219493641|NCT01235858|PROCEDURE|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
219493642|NCT01235858|PROCEDURE|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
219493643|NCT01498900|DRUG|repaglinide|Prescription according to the product labelling at the physicians' discretion
219493644|NCT04626765|DRUG|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
218873250|NCT00511134|DRUG|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
218873251|NCT00511134|DRUG|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
218873252|NCT01949090|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
218873253|NCT01949090|BIOLOGICAL|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
218873254|NCT03373838|OTHER|Census|Survey and interview
218873255|NCT02024139|OTHER|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
218873256|NCT02024139|OTHER|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
218873257|NCT00122408|DIETARY_SUPPLEMENT|Ergyphilus|5 pills a day of Ergyphilus or placebo
218873258|NCT06039748|OTHER|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
218873259|NCT04520854|OTHER|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
218873260|NCT04520854|OTHER|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
218873261|NCT06105268|OTHER|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
218873262|NCT05572359|DEVICE|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
218873263|NCT05479812|DRUG|WTX-124|Investigation Product Monotherapy
218873264|NCT05479812|DRUG|pembrolizumab|Investigation Product in combination with approved therapy
218873265|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
218873266|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
218873267|NCT04244721|OTHER|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
218873268|NCT04244721|OTHER|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
218873269|NCT06797583|DEVICE|Active Transcranial Photobiomodulation (TPBM)|CytonBrite, 1064nm LED
218873270|NCT06797583|DEVICE|Sham Transcranial photobiomodulation (TPBM)|Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.
218873271|NCT06336915|BEHAVIORAL|Physician-Nurse Dyad Rounding|Collaborative Approach to Improve Unit-Level Metrics
218873272|NCT03459365|DEVICE|Euflexxa|Aspirations performed before each injection and at six weeks.
218873273|NCT06583616|DIAGNOSTIC_TEST|Anion Gap|Patient with acute pulmonary embolism who not survive after hospitalization
218873274|NCT05603598|DRUG|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
219022936|NCT01196923|DEVICE|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
219022937|NCT04776499|DRUG|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
218873275|NCT02979223|DRUG|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
218873276|NCT06186258|DEVICE|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
219022938|NCT00737620|PROCEDURE|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
219022939|NCT03773705|PROCEDURE|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
219022940|NCT00231725|DRUG|insulin lispro injection [rDNA origin] Low Mix|
219200060|NCT06786312|DRUG|Apatinib|250mg, P.O, qd, 21 days per cycle;
219493645|NCT04626765|DRUG|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
219493646|NCT04626765|DRUG|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
219493647|NCT04626765|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
219493648|NCT04626765|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
219493649|NCT03923114|RADIATION|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
219493650|NCT06540612|OTHER|Aerobic exercise|Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
219493651|NCT06540612|BEHAVIORAL|Physical activity counseling|Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
219493652|NCT00657917|DRUG|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
219493653|NCT03454100|BEHAVIORAL|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
219493654|NCT00689208|DRUG|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
219493655|NCT00689208|DRUG|Physostigmine|0,12ug/kg/min
219493656|NCT00689208|DRUG|Placebo Sodium|
219493657|NCT02709122|DEVICE|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
219493658|NCT02492295|DRUG|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
219200061|NCT06786312|DRUG|Adebrelimab|20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
219200062|NCT06786312|DRUG|Etoposide Injection|100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
219493659|NCT00810615|OTHER|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
219493660|NCT00810615|OTHER|Sham treatment|
219493661|NCT03015909|DRUG|Somatropin|
219493662|NCT02525562|DEVICE|Triathlon Total Knee System with X3 insert|Total knee replacement
219493663|NCT02525562|DEVICE|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
219493664|NCT02525562|DEVICE|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
219493665|NCT02525562|PROCEDURE|Total Knee Replacement|Total Knee Replacement
219493666|NCT02525562|PROCEDURE|Partial Knee Resurfacing|Partial Knee Resurfacing
219493667|NCT01731860|DEVICE|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
218873277|NCT01356628|DRUG|PD-0332991|PD-0332991, 125mg, 3 cycles
218873278|NCT04949022|DEVICE|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
219022941|NCT04170114|OTHER|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
219022942|NCT03195543|DIAGNOSTIC_TEST|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
219022943|NCT03195543|DIAGNOSTIC_TEST|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
219022944|NCT03195543|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
219200063|NCT06786312|DRUG|Carboplatin Injection|Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
219200064|NCT06361225|DIAGNOSTIC_TEST|evaluation with RUSH protocol|Daily evaluation of the patient via ultrasound using the RUSH protocol
219200065|NCT05940272|BEHAVIORAL|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
219602166|NCT06581887|BEHAVIORAL|Classical conditioning task|To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome.
219602167|NCT04487067|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
218873279|NCT04922138|DRUG|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
218873280|NCT02575170|DRUG|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
218873281|NCT02575170|DRUG|Ringer's lactate solution|200 ml of Ringer's lactate solution
219022945|NCT03195543|DIAGNOSTIC_TEST|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
219493668|NCT02567266|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
219493669|NCT02567266|BEHAVIORAL|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
219493670|NCT02567266|BEHAVIORAL|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
219493671|NCT03235531|DRUG|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
219493672|NCT03235531|DRUG|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
219493673|NCT05036239|OTHER|Eccentric biceps curls|10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
219493674|NCT05181761|OTHER|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
219493675|NCT03179501|DRUG|NP001|NP001
219493676|NCT03179501|DRUG|Placebo|Normal saline
219493677|NCT00343122|PROCEDURE|echocardiography for intrapulmonary vasodilatation|
219493678|NCT00104117|DRUG|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
219602168|NCT04487067|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
219022946|NCT03659591|BEHAVIORAL|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
219602169|NCT06285292|DEVICE|EMY|"Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study"
218873282|NCT04459520|BEHAVIORAL|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
218873283|NCT04459520|BEHAVIORAL|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
218873284|NCT04459520|BEHAVIORAL|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
219022947|NCT03659591|BEHAVIORAL|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
219022948|NCT05863910|DRUG|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
219022949|NCT02945033|DRUG|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
219022950|NCT02945033|DRUG|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
219022951|NCT02945033|PROCEDURE|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
219022952|NCT02945033|BIOLOGICAL|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
219022953|NCT02945033|BIOLOGICAL|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
219022954|NCT05544331|BEHAVIORAL|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
219022955|NCT05544331|BEHAVIORAL|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
219022956|NCT02738450|BIOLOGICAL|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
219022957|NCT02738450|BIOLOGICAL|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
219022958|NCT02738450|BIOLOGICAL|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
219022959|NCT05126784|BIOLOGICAL|AVT03|AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
219022960|NCT05126784|BIOLOGICAL|Prolia|Prolia (denosumab) will be given as single subcutaneous injection
219022961|NCT03043989|DRUG|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
219022962|NCT03043989|DRUG|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
219022963|NCT03043989|DRUG|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
219022964|NCT00706407|DEVICE|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
219022965|NCT03913884|PROCEDURE|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
219022966|NCT03913884|OTHER|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
219022967|NCT00941044|DEVICE|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
219493679|NCT00732342|BEHAVIORAL|Contingency Management|Prizes given for targeted behavior of abstinence
219493680|NCT05037942|OTHER|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
219493681|NCT05037942|OTHER|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
219022968|NCT04734509|DEVICE|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
219022969|NCT02883634|OTHER|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
219022970|NCT02883634|OTHER|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
219022971|NCT03527199|DIAGNOSTIC_TEST|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
219022972|NCT05237479|PROCEDURE|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
219602170|NCT06116630|DIAGNOSTIC_TEST|DCE-MRI|Both groups will undergo DCE-MRIs.
219493682|NCT04501549|PROCEDURE|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
218873285|NCT04342078|DIETARY_SUPPLEMENT|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
219022973|NCT05237479|OTHER|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
218873286|NCT02207491|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
219022974|NCT06181890|OTHER|Motivational Interview|The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
219022975|NCT05705986|OTHER|Blood Draw|Single blood draw
219022976|NCT05711225|BEHAVIORAL|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
219493683|NCT01225315|DRUG|Placebo|Matching placebo administered orally twice daily
219493684|NCT01225315|DRUG|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
218873287|NCT02207491|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
218873288|NCT02207491|OTHER|Placebo|1 drop QD, AM, OU
219493685|NCT00243815|DRUG|ibuprofen|
219493686|NCT03402620|DRUG|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
219493687|NCT03644459|BIOLOGICAL|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
219493688|NCT01255696|BIOLOGICAL|ALV003|
219493689|NCT01255696|BIOLOGICAL|ALV003 placebo|
219493690|NCT02822807|BIOLOGICAL|Blood sampling|
219493691|NCT02813707|OTHER|QoL questionnaire regarding the long term complication|Micronutrients evaluation
219493692|NCT02572973|OTHER|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
219493693|NCT04067024|PROCEDURE|Local anesthesia made by surgeon|infiltration with local anesthetics
219493694|NCT04067024|PROCEDURE|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
219493695|NCT05771116|PROCEDURE|ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:|catheter will be placed for ERECTOR SPINAE PLANE BLOCK
219493696|NCT05771116|PROCEDURE|PARAVERTEBRAL BLOCK:|catheter will be placed for PARAVERTEBRAL BLOCK
219493697|NCT03313479|DRUG|Dexmedetomidine|Dexmedetomidine will be given with GS
219493698|NCT01797952|DRUG|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
219493699|NCT01797952|OTHER|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
219493700|NCT03963999|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
219493701|NCT03963999|DRUG|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
219493702|NCT04024085|OTHER|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
219493703|NCT01418261|DEVICE|Renal denervation (Symplicity Catheter System)|
219493704|NCT01418261|DIAGNOSTIC_TEST|Renal angiogram|
219022977|NCT00990496|DRUG|Fludarabine|30 mg/m2
219022978|NCT00990496|DRUG|Cyclophosphamide|600 mg/m2
219493705|NCT06410040|DRUG|Lorlatinib|lolatinib 100mg qd po
219493706|NCT02343562|DIETARY_SUPPLEMENT|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
218873289|NCT00377208|BEHAVIORAL|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
218873290|NCT03106974|DEVICE|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
218873291|NCT03106974|DEVICE|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
218873292|NCT04776863|DEVICE|optical biometry measurement|The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
218873293|NCT03515356|BEHAVIORAL|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
218873294|NCT03515356|BEHAVIORAL|Physical Activity Education Pamphlet|Physical activity education pamphlet only
218873295|NCT05921838|OTHER||
218873296|NCT04940962|PROCEDURE|Sampling of adipose tissue|Removal of less than 1 cm3 of adipose tissue during visceral surgery
218873297|NCT06251427|DIETARY_SUPPLEMENT|Multiple micronutrient fortified maize with milk|The study product is a multiple micronutrient fortified maize pap with milk
218873298|NCT04738942|DRUG|Vedolizumab|Vedolizumab 300 mg, IV infusion
218873299|NCT04606095|DIAGNOSTIC_TEST|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
218873300|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 1)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
218873301|NCT04606095|DEVICE|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
218873302|NCT04606095|DEVICE|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
218873303|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 3)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then (for participants prior to January 2025) will return to the fMRI scanner for a few additional scans.
218873304|NCT06570161|DEVICE|SEEUS95 Transparent mask|SEEUS95 developed transparent filtering mask
218873305|NCT06570161|DEVICE|CrystalGuard Mask|CrystalGuard transparent mask
219022979|NCT00990496|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
219022980|NCT02444572|DRUG|Enoxaparin 4000 IU|
219200066|NCT05940272|BEHAVIORAL|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
218873306|NCT06570161|DEVICE|N95 face mask|Standard N95 style face mask
218873307|NCT06572124|PROCEDURE|universal adhesive without Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive without acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
218873308|NCT06572124|PROCEDURE|universal adhesive with Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive which contains acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
218873309|NCT06259734|BEHAVIORAL|Transfusion Camp Rwanda education|Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
218873310|NCT05457868|DRUG|Salbutamol|Salbutamol claim is used as the exposure group.
218873311|NCT05457868|DRUG|LAMA|Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
218873312|NCT00550381|DRUG|HKI-357|Single-dose capsule
219022981|NCT01946997|OTHER|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
219022982|NCT03849742|OTHER|Quality-of-Life Assessment|Ancillary studies
219022983|NCT03849742|OTHER|Questionnaire Administration|Ancillary studies
219022984|NCT03849742|PROCEDURE|Supportive Care|Receive Uber rides
219200067|NCT06857773|DRUG|Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy|Floxuridine is administered via the hepatic arterial infusion pump directly to the hepatic artery with a continous flowrate for a period of 2 weeks. Intra arterial infusion of FUDR is combined with systemic therapy (FOLFOX/FOLFIRI) intravenously. Administration of FUDR via the chemopump is every 4 weeks and systemic therapy is administered every 2 weeks.
219493707|NCT02343562|DIETARY_SUPPLEMENT|Placebo|Multivitamin off-the-counter.
219493708|NCT01987024|DEVICE|Actim Partus® test|
219493709|NCT01987024|OTHER|usual procedure|
219493710|NCT04676919|DEVICE|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
219493711|NCT04676919|DEVICE|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
219493712|NCT04676919|DEVICE|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
219022985|NCT04637542|OTHER|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
219022986|NCT00631566|DRUG|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
218873313|NCT06487975|DIETARY_SUPPLEMENT|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
218873314|NCT06487975|OTHER|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
218873315|NCT06761170|PROCEDURE|Spray cryo therapy|normal flow, 5 seconds repeated for 3-5 cycles
219022987|NCT00631566|DRUG|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
219022988|NCT00060476|DRUG|rofecoxib|
219022989|NCT00060476|DRUG|Comparator: placebo (unspecified)|
219022990|NCT06328153|DEVICE|Fu's Subcutaneous Needling|Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
219200068|NCT06857773|DEVICE|Hepatic arterial infusion pump (HAIP)|The HAIP (pump) is implanted during surgery combined with resection of the primary tumor before start of induction treatment with Floxuridine and concomitant systemic therapy
219200069|NCT06857773|DRUG|Systemic therapy (standard of care)|Patient included in the control arm will receive systemic therapy according to standard clinical practice. Induction therapy regimens include: CAPOX (3 weekly) or FOLFOX/FOLFIRI/FOLFOXIRI (2weekly) with optional addition of Bevacizumab (2 weekly)
219493713|NCT03090919|BIOLOGICAL|Platelet transfusion|
219493714|NCT03090919|OTHER|Saline|
218873316|NCT06761170|PROCEDURE|Standard of Care (SOC)|"1. Steroid injection~2. Radial mucosal incision~3. Balloon dilation (to normal airway diameter)"
218873317|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
218873318|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
218873319|NCT04985669|DRUG|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
218873320|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
218873321|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
219022991|NCT06328153|DRUG|Celecoxib|Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
219200070|NCT06856382|DIAGNOSTIC_TEST|gastric cancer|Patients diagnosed with gastric cancer by pathological biopsy.
219493715|NCT02197754|OTHER|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
219493716|NCT03896919|DIAGNOSTIC_TEST|HLA-DQ by luminex technology in kidney transplantation|HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
219493717|NCT05529628|DIAGNOSTIC_TEST|Cytokine levels|Preoperative cytokine levels of the patients
219493718|NCT02883387|OTHER|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
219493719|NCT02883387|OTHER|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
219493720|NCT05589428|DIETARY_SUPPLEMENT|Low sodium bread|Bread low in sodium
219493721|NCT05589428|OTHER|Placebo|Normal bread from bakery
219493722|NCT01077531|DRUG|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
219493723|NCT01077531|DRUG|Matching placebo|Matching placebo for intravenous infusion
219493724|NCT06129331|DRUG|Amyloid-specific treatment|Amyloid-specific treatment
219493725|NCT06129331|OTHER|No amyloid-specific treatment|No amyloid-specific treatment
219493726|NCT00765466|DRUG|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
218873322|NCT01701934|DRUG|Roflumilast|500 mcg, oral, once daily for 6 months
218873323|NCT01701934|DRUG|Placebo|One placebo pill daily, for 6 months
218873324|NCT02229929|DRUG|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
219493727|NCT00921804|DRUG|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
219493728|NCT00921804|DRUG|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
219493729|NCT00921804|DRUG|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
219493730|NCT00921804|DRUG|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
219493731|NCT04832165|OTHER|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
219493732|NCT01448265|PROCEDURE|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
219493733|NCT02164539|DRUG|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
219493734|NCT02164539|DRUG|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
219493735|NCT02164539|DRUG|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
219493736|NCT03113825|DEVICE|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
219493737|NCT03113825|DRUG|AVB-620|AVB-620 will be administered IV before the surgical procedure.
219493738|NCT01255722|DRUG|iobitridol|single IV injection
219493739|NCT01255722|DRUG|iopromide|Single IV injection
219493740|NCT01255722|DRUG|iomeprol|Single IV injection
219493741|NCT01833221|DRUG|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
219493742|NCT02139605|PROCEDURE|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
219493743|NCT05301166|BEHAVIORAL|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
219493744|NCT05301166|OTHER|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
219493745|NCT02643966|DEVICE|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
219493746|NCT01866982|PROCEDURE|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
219493747|NCT01866982|PROCEDURE|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
219493748|NCT02245360|DRUG|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
219493749|NCT02245360|DRUG|placebo|placebo tablet given once daily over 60 days
219493750|NCT01612702|DRUG|Dexamethasone|Dexamethasone 10 mg intravenous administration
219493751|NCT05033015|PROCEDURE|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
219493752|NCT02331030|PROCEDURE|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
219602171|NCT03852732|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
219602172|NCT03905577|BEHAVIORAL|Action Observation|Action Observation training
218873325|NCT02229929|DRUG|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
218873326|NCT02229929|DRUG|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
219493753|NCT02331030|PROCEDURE|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
219493754|NCT02331030|PROCEDURE|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
219493755|NCT02331030|DRUG|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
219493756|NCT02331030|DRUG|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
219022992|NCT03727412|DRUG|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
219022993|NCT03727412|DRUG|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
219022994|NCT05220579|DEVICE|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
219022995|NCT05220579|DEVICE|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
219022996|NCT01631058|DRUG|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
219022997|NCT02325336|DEVICE|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
219022998|NCT05384067|BEHAVIORAL|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
219022999|NCT04356131|OTHER|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
219023000|NCT06477614|BIOLOGICAL|DC cell Vaccine|Deliver DC cell vaccine into patients for anti-ancer therapy.
219023001|NCT04595513|DRUG|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
219023002|NCT05772936|BEHAVIORAL|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
219023003|NCT04428996|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
219023004|NCT06449469|DRUG|Rivaroxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
219023005|NCT06449469|DRUG|Acetylsalicylic acid|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
219023006|NCT06449469|DRUG|Clopidogrel|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
219023007|NCT06449469|DRUG|Edoxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
219493757|NCT04905719|DIAGNOSTIC_TEST|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
219493758|NCT01542736|DRUG|Carboplatin|Administered concurrently with craniospinal radiation.
219493759|NCT01542736|DRUG|Vincristine|Administered concurrently with craniospinal radiation.
219493760|NCT01542736|RADIATION|24 Gy|Craniospinal radiation.
219493761|NCT04102228|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
219493762|NCT04102228|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
219602173|NCT03905577|BEHAVIORAL|Motor imagery|Motor imagery protocol
219602174|NCT03905577|BEHAVIORAL|Placebo Action observation|Placebo Action Observation
218873327|NCT02229929|DRUG|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
218873328|NCT02229929|DRUG|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
218873329|NCT02229929|DRUG|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
218873330|NCT00385749|DEVICE|RV apical vs RV septal defibrillation threshold testing|
218873331|NCT04262076|OTHER|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
218873332|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
218873333|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
218873334|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
218873335|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
218873336|NCT03873935|OTHER|Evaluation of periodontal status|Clinical examination
218873337|NCT00369642|BEHAVIORAL|Cognitive-behavioral therapy|
218873338|NCT06582927|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT)|"MBAT is an evidence-based 8-hour mindfulness program that comprises 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others.~The course content and materials in the present study will entail the foundational MBAT curriculum and other related content delivered virtually over Zoom but will consist of 8, 1-hour sessions delivered across 8 consecutive weeks."
218873339|NCT01474720|DRUG|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
218873340|NCT04267081|DRUG|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
218873341|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Rich Beetroot Juice|subjects will consume 1 bottle of nitrate-rich beetroot juice (\~400mg of nitrate each) 2x a day
218873342|NCT06480695|BEHAVIORAL|High Intensity Exercise|exercise at an intensity midway between the lactate threshold and VO2peak, from the screening test at an RPE of \~ 15-17
218873343|NCT06480695|BEHAVIORAL|Moderate Intensity Exercise|exercise at the RPE at LT associated an \~ RPE of 10-12
218873344|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Depleted Placebo Beetroot Juice|Subjects will consume 1 bottle of nitrate-depleted beetroot juice 2x a day
218873345|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
218873346|NCT00006094|DRUG|oxaliplatin|Given IV
218873347|NCT00006094|DRUG|fluorouracil|Given IV
218873348|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
218873349|NCT00057369|DRUG|dalbavancin|
218873350|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
218873351|NCT05354687|OTHER|Small-group Teaching|The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
218873352|NCT05354687|OTHER|Self-directed Learning|The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
218873353|NCT06386991|OTHER|Using ethylenediaminetetraacetic acid (EDTA), citric acid ((MONO/ANH) and etidronic acid (HEBP) to clean root canals during regenerative endodontic treatments|Regenerative endodontic treatment using different irrigation solutions
218873354|NCT00369499|DEVICE|PFO Closure|
218873355|NCT06835699|DRUG|Psilocybin 25 mgs|All participants will be administered 25 mg psilocybin and undergo TMS
218873356|NCT06835699|DEVICE|TMS|All participants will be administered 25 mg psilocybin and undergo TMS
218873357|NCT05014867|PROCEDURE|Embryo transfer method|"1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer"
218873358|NCT05937581|DRUG|CSL040|IV Administration
218873359|NCT05937581|DRUG|Placebo|0.9% w/v NaCI, IV Administration
218873360|NCT05635357|DRUG|Anastrozole|Anastrozole claim is used as the exposure group.
218873361|NCT05635357|DRUG|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
219493763|NCT04102228|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
219602175|NCT03924687|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
219602176|NCT05746832|PROCEDURE|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
219602177|NCT02211417|DRUG|Oral DS107|
219602178|NCT02211417|DRUG|Placebo|
219602179|NCT06805305|BIOLOGICAL|DOC1021|Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method
219602180|NCT06805305|PROCEDURE|Tumor resection|SOC brain tumor resection
219602181|NCT06805305|DRUG|Temodar (Temozolomide)|SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation
219602182|NCT06805305|RADIATION|SOC cranial radiation|60Gy radiation over 6 weeks in 2Gy fractions
219602183|NCT02271295|DRUG|Enoxaparine|Enoxaparine 4000UI/day during 24 months
219602184|NCT02930759|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
219602185|NCT00346918|DRUG|Sirolimus|Standard plus Sirolimus
219602186|NCT00346918|OTHER|Standard|Standard
219602187|NCT02495662|DRUG|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
219602188|NCT02495662|DRUG|Placebo|0.9% normal saline
219602189|NCT01959061|DRUG|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
219602190|NCT01959061|DRUG|Oxaliplatin|100\~150mg, every 4 weeks, transhepatic arterial infusion
219602191|NCT01959061|DRUG|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
219602192|NCT00437697|DRUG|dalteparin|
219493764|NCT02619331|PROCEDURE|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
219493765|NCT01682473|DRUG|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
219493766|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
219493767|NCT01511900|DRUG|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
219493768|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
219493769|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
219493770|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
219602193|NCT00257621|DRUG|GW640385|
219602194|NCT00257621|DRUG|Ritonavir|
219602195|NCT00727103|DRUG|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
219602196|NCT00727103|DRUG|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
219493771|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
219493772|NCT00251771|PROCEDURE|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
219493773|NCT02400905|DEVICE|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
219602197|NCT01755091|DRUG|Dronabinol|
219493774|NCT05692466|DIAGNOSTIC_TEST|Comprehensive molecular panel test|Lab test
219493775|NCT05692466|OTHER|EORTC QLQ-30|Quality of life questionnaire
219493776|NCT02854566|DEVICE|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
219493777|NCT06254391|DRUG|Low-dose aspirin|Implementation of low-dose aspirin (30 mg)
219493778|NCT00908531|DRUG|letrozole (Femara)|tablet 2.5 mg daily
219493779|NCT04853888|BEHAVIORAL|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
219602198|NCT01755091|DRUG|Placebo (for Dronabinol)|
219602199|NCT04264325|OTHER|diaphragmatic ultrasound measure|patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
219602200|NCT05677035|DRUG|LINO-1713 1 tablet|LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
219602201|NCT05677035|DRUG|LINO-1713 once a day for 24 days|Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
219602202|NCT04342195|PROCEDURE|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
218873362|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
218873363|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
219200071|NCT06668012|DEVICE|Palomacare® vaginal gel is a medical device with CE class IIa.|"The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not."
219200072|NCT03233646|DEVICE|Retinal and Choroidal Imaging|Non-invasive OCT, OCTA, and UWF fundus photography of retina
219200073|NCT04567056|DIAGNOSTIC_TEST|Blood sample|A separate blood sample will be taken for methylation-analyses
218873367|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
219023008|NCT06449469|DRUG|Dabigatran|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
219023009|NCT06449469|DRUG|Apixaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
219023010|NCT06449469|DRUG|Warfarin|If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
219023011|NCT05612581|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
219023012|NCT05612581|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
219023013|NCT05612581|DRUG|TDF|TDF given orally
218873368|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
218873369|NCT04638114|PROCEDURE|Mini-open DAA|Direct anterior approach hip
218873370|NCT04638114|PROCEDURE|Hip arthroscopy|arthroscopic treatment of hip pathology
218873371|NCT06166368|OTHER|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
218873372|NCT00859937|DRUG|Dasatinib|Given PO
219023014|NCT05612581|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
219493780|NCT00677677|BIOLOGICAL|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
219493781|NCT03874585|BEHAVIORAL|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
219493782|NCT03874585|BEHAVIORAL|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
219493783|NCT05303480|DRUG|Chlormethine|Chlormethine gel 0.016%
219493784|NCT03443219|DEVICE|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
219493785|NCT03443219|DEVICE|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
219493786|NCT00099320|DRUG|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
218873373|NCT00859937|OTHER|Laboratory Biomarker Analysis|Correlative studies
218873374|NCT00615030|DRUG|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
218873375|NCT00615030|DRUG|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
218873376|NCT00615030|DRUG|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
218873377|NCT00615030|DRUG|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
219023015|NCT04262232|BEHAVIORAL|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
219023016|NCT01975909|DEVICE|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
219023017|NCT05634551|BEHAVIORAL|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
219023018|NCT05634551|BEHAVIORAL|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
219023019|NCT00457600|PROCEDURE|patient-driven health IT product|
219023020|NCT05048810|RADIATION|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
219023021|NCT05431933|BIOLOGICAL|Eupolio|Inactivated Polio vaccine (Sabin strains)
219023022|NCT05677815|PROCEDURE|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
219023023|NCT04709341|DEVICE|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
219023024|NCT04709341|DEVICE|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
219023025|NCT03534154|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging
219023026|NCT03534154|DIAGNOSTIC_TEST|Blood Sampling|Sampling of serum
219023027|NCT03534154|DIAGNOSTIC_TEST|Microdialysis|Monitoring of cerebral fluid protein levels
219023028|NCT03534154|DIAGNOSTIC_TEST|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
219023029|NCT03534154|DIAGNOSTIC_TEST|MRI (advanced)|Advanced MRI
219023030|NCT04768465|DRUG|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
219023031|NCT04768465|DRUG|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
219023032|NCT06367543|DIAGNOSTIC_TEST|Time in therapeutic range of vital parameters|"Treatment adherence on NICU to the following vital parameters:~1. Temperature (T\<37,5°C) (every 4 hours during the first 96 h after admission to neurocritical care unit)~2. systolic blood pressure ICD-10 (International Statistical Classification of Diseases 10th Revision) (I60, 161 \& 162): 100-140 mmHg ICD-10 (I63): 120-180 mmHg (every 4 hours during the first 96 h after admission to neurocritical care unit)~3. Mean arterial blood pressure (MAP: 60-90 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~4. Arterial oxygen partial pressure (paO2: 75 - 100 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~5. Arterial carbon dioxide partial pressure (paCO2: 35 - 45 mmHg). (every 4 hours during the first 96 h after admission to neurocritical care unit)~6. Blood glucose (BG: 80-180 mg/dL). (every 4 hours during the first 96 h after admission to neurocritical care unit)"
219023033|NCT06869122|DEVICE|Ablation|Bronchoscopy and microwave ablation of the lung tumour prior to surgical resection.
219023034|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Stenoparib at the recommended phase 2 dose +Temozolomide 40mg/day daily will be given in combination x21 days each cycle
219023035|NCT06681220|DRUG|Lurbinectedin|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
219200074|NCT06755866|DIAGNOSTIC_TEST|The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer|Chest MRI scan outside of standard treatment options
219200075|NCT06753487|PROCEDURE|Myofacial Release|"Manual Myofascial Release:~Control group will receive 3- 5 repetitions of Manual Myofascial Release in Piriformis muscle i.e giving ischemic pressure on muscle directly for 90 secs and then release."
218873378|NCT04207437|DEVICE|Vibration therapy|vibration therapy using hand held vibration device
218873379|NCT04117243|DRUG|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
218873380|NCT04117243|DRUG|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
218873381|NCT04117243|DRUG|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
219493787|NCT00099320|DRUG|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
218873382|NCT05123963|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
218873383|NCT05052567|DRUG|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
218873384|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
218873385|NCT06636162|DRUG|DSP-0390|DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
218873386|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
218873387|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
218873388|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
218873392|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
218873393|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
218873394|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
219493788|NCT00297206|DRUG|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
219493789|NCT02593084|BEHAVIORAL|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
219493790|NCT02593084|BEHAVIORAL|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
219493791|NCT00902252|DEVICE|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
219493792|NCT00902252|DEVICE|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
219493793|NCT00902252|DEVICE|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
219493794|NCT03091400|DRUG|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
219493795|NCT03091400|DRUG|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
219493796|NCT04991896|DRUG|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
219493797|NCT02588742|DIETARY_SUPPLEMENT|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
219493798|NCT02588742|DIETARY_SUPPLEMENT|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
219493799|NCT05955235|OTHER|Not Applicable(Observation Study)|Not Applicable(Observation Study)
219493800|NCT00064935|PROCEDURE|Endometrial biopsy|
218873395|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
219493801|NCT04622618|DRUG|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
219493802|NCT04916288|DEVICE|central venous cathterization|central venous catheterization through the right internal jugular vein
219493803|NCT04529161|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
219493804|NCT04529161|DIETARY_SUPPLEMENT|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
219493805|NCT01319305|DEVICE|FinESS Sinus Treatment|balloon sinuplasty
219493806|NCT02015468|OTHER|Early mobilization|Early weightbearing and physiotherapy
219493807|NCT02015468|OTHER|Late mobilization|Late mobilization, none-weightbearing and home exercises
219493808|NCT01890694|DRUG|Tolvaptan|15 mg once daily
219493809|NCT01890694|DRUG|Placebo|15 mg once daily
219493810|NCT01890694|BEHAVIORAL|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
219023036|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Patients will be assigned to one of three doses of Stenoparib (200mg po qd, 200mg po BID, and 200mg in am and 400mg in pm). The initial starting dose will be the 200 mg po QD orally daily for 21 days.
219023037|NCT06870487|DRUG|PF-08046032|PF-08046032 will be administered intravenously (IV) infusion.
219200076|NCT06753487|PROCEDURE|Facilitated positional release technique|"FPRT:~Treatment group will receive 5 repetitions of FACILITATED POSITIONAL RELEASE technique i.e applying pressure over tender area of muscle while maintaining specific postion"
219602203|NCT00490841|DEVICE|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
218873396|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
218873397|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
218873398|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
218873399|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
218873400|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
218873401|NCT05550948|DEVICE|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
218873402|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
219200077|NCT06593691|OTHER|conventional treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise
219200078|NCT06593691|OTHER|Conventional treatment + multi-wave locked system laser treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
219602204|NCT05870059|DRUG|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
219602205|NCT05870059|DRUG|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
219602206|NCT05973799|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
219602207|NCT05973799|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
219602208|NCT06134726|DIAGNOSTIC_TEST|seropositivity of rheumatoid factor|All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies
219602209|NCT02252354|DRUG|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
219602210|NCT02252354|DRUG|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
219602211|NCT02252354|DRUG|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
219602212|NCT05532150|PROCEDURE|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
219602213|NCT05532150|PROCEDURE|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
219602214|NCT02285088|DRUG|GBT440|GBT440 will be administered as oral capsules
219602215|NCT02285088|DRUG|Placebo|Matching placebo will be administered as oral capsules
219602216|NCT04604613|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo standard of care bilateral salpingo-oophorectomy
218873403|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
218873404|NCT05194267|DEVICE|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
218873405|NCT00802893|DRUG|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
218873406|NCT00802893|OTHER|Placebo|placebo given BID for entire length of study
219023038|NCT06870487|DRUG|Sasanlimab|Sasanlimab will be administered as subcutaneous (SC) injection.
219023039|NCT07039526|DRUG|CYTALUX™ (pafolacianine) injection preoperatively|CYTALUX™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye as a solution in vials containing 1.6 mL at 2 mg/mL. Each subject will be administered a single intravenous dose of not less than 1 hours before and not more than 24 hours before initiation of intraoperative NIR fluorescent imaging.
219023040|NCT06697184|DRUG|Sonrotoclax|Administered orally
219023041|NCT06697184|DRUG|Zanubrutinib|Administered orally
219200079|NCT06872762|BEHAVIORAL|Exercise|Exercise for 90 minutes (cycling) while minimizing thermal strain
219200080|NCT06872762|BEHAVIORAL|Heat strain|Exercise for 90 minutes (cycling) while maximizing thermal strain
219200081|NCT06873594|PROCEDURE|three-ports laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with three ports
219602217|NCT04604613|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219602218|NCT04604613|PROCEDURE|Hysterectomy|Undergo standard of care hysterectomy
219602219|NCT04604613|OTHER|Laboratory Biomarker Analysis|Correlative studies
219602220|NCT04604613|PROCEDURE|Lymph Node Mapping|Undergo sentinel lymph node mapping
218873407|NCT02868229|DRUG|COR-001|
218873408|NCT02868229|OTHER|Placebo|
218873409|NCT04606316|DRUG|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
218873410|NCT04606316|DRUG|Nivolumab|Given as intravenous (IV) infusion into a vein.
218873411|NCT04606316|DRUG|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
219023042|NCT06469112|DEVICE|Vibration|The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.
218873412|NCT04606316|DRUG|Ipilimumab|Given as intravenous (IV) infusion into a vein.
219023043|NCT06469112|OTHER|Placebo|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
219023044|NCT06913556|DIAGNOSTIC_TEST|Preoperative dry eyes|In group 1 we access preoperative dry eyes condition and postoperatively we access the condition in 2nd and 4th week with the use of Hylorunic acid lubricant.
219023045|NCT06913556|COMBINATION_PRODUCT|Lipid coated carbomer gel eye drops|In group 2 we prescribe the lipid coated carbomer gel eye drops and access dry eyes condition preoperative and postoperative on 2nd and 4th week and check the curative effect of drop.
219023046|NCT06912737|BEHAVIORAL|Group Emotion Focused Behavioral Intervention (G-EFBI)|Group EFBI (G-EFBI) is aimed at assisting people with T2D to gain knowledge about emotions and improve their ability to regulate and manage their emotions.
219023047|NCT06912737|BEHAVIORAL|Group - With Every Heartbeat is Life (G-WEHL)|G-WEHL is an educational intervention designed to increase awareness and prevention of cardiovascular disease.
219602221|NCT04604613|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
219602222|NCT04158362|DRUG|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
218873413|NCT04606316|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
218873414|NCT06151288|BIOLOGICAL|31 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-31 was administered into the deltoid muscle at Day 1
218873415|NCT06151288|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 was administered into the deltoid muscle at Day 1
218873416|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
218873417|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
218873418|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
218873419|NCT06584084|DEVICE|WPM-SEMG prototype|Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
218873420|NCT06186700|DRUG|Pentoxifylline 400mg plus chemotherapy|The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel.
218873421|NCT06186700|DRUG|Chemotherapy|The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel..
218873422|NCT01443507|OTHER|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
218873423|NCT05240001|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
218873424|NCT05240001|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
218873425|NCT03161535|OTHER|exercise and dietary education|"1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet)."
219023048|NCT06823167|BIOLOGICAL|IM-1021|IM-1021 is an antibody-drug conjugate
219200082|NCT06873594|PROCEDURE|four-port laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with four ports
219602223|NCT04158362|DRUG|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
219602224|NCT04158362|DRUG|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
219602225|NCT04158362|DRUG|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
219023049|NCT06693310|OTHER|de-escalation or discontinuation of therapy|De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.
219023050|NCT06693310|OTHER|continuation of current therapy|continuation of current maintenance medical therapy for ulcerative colitis
219023051|NCT06744543|DEVICE|SIGHT Prompted Provider Message|Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated.
219023052|NCT06570798|DRUG|Inebilizumab|Intravenous (IV) Infusion
219023053|NCT06570798|DRUG|Blinatumomab|SC Injection
219023054|NCT07100938|DRUG|BGB-45035|Administered orally
219023055|NCT07100938|DRUG|Placebo|Administered orally
219023056|NCT07109843|DIETARY_SUPPLEMENT|Boswellia serrata extract|Boswellia Serrata 1x day (600mg)
219023057|NCT07109843|OTHER|Placebo|Placebo 1x/day
219023058|NCT06914791|PROCEDURE|Kegel arm|in this group participants will be followed up for 8 weeks with kegel exercises
219023059|NCT06914791|PROCEDURE|De Gasquet arm|in this group participants will be followed up for 8 weeks with de gasquet exercises
219023060|NCT06864208|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies paired with behavioral strategies for weight management
219023061|NCT06864208|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception through challenging weight-related stereotypes, practicing self-compassion, reducing self-criticism, and coping with weight stigma
219023062|NCT06914817|DEVICE|Brillouin optical scanning system (Intelon Optics) (BOSS)|Brillouin microscopy is a non-invasive optical imaging technique that measures the mechanical properties of tissues, such as stiffness and elasticity, by analyzing light scattering caused by natural acoustic waves within the tissue.
219493811|NCT01890694|BEHAVIORAL|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
218873426|NCT03161535|OTHER|weekly telephone consultations concerning exercise and diet.|For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
218873427|NCT05653817|DRUG|Carrilizumab|Carrilizumab 200mg Q3W d1
218873428|NCT05653817|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
219023063|NCT06913244|BEHAVIORAL|Multidisciplinary Physiotherapy Program (MD Physio)|"A comprehensive program that integrates:~Specific Exercise Therapy: Supervised stretching and strengthening sessions (30-60 minutes/session, 3× per week for 8 weeks) followed by a prescribed home-based maintenance regimen.~Manual Therapy: Targeted soft-tissue mobilization and myofascial release (20-30 minutes/session, twice per week for 4 weeks).~Education Sessions: Three sessions (both in-person and online) covering pain neuroscience and self-management techniques.~Mind-Body Interventions: Weekly 40-minute sessions of yoga or tai chi for 6 weeks."
219023064|NCT06913244|BEHAVIORAL|Standard Physiotherapy Care|Routine care involves standard follow-up with basic physiotherapy advice as currently provided to breast cancer survivors. This serves as the active comparator in the trial.
219023065|NCT07108114|DRUG|SLV-324 intravenous (IV infusion)|SLV-324 will be administered as an IV infusion
218873429|NCT05653817|DRUG|Apatinib|Apatinib mesylate tablets for treatment: 250mg
219023066|NCT06337864|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.
219493812|NCT01890694|BIOLOGICAL|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
218873430|NCT03871257|DRUG|Carboplatin|Given IV
218873431|NCT03871257|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218873432|NCT03871257|OTHER|Quality-of-Life Assessment|Ancillary studies
218873433|NCT03871257|OTHER|Questionnaire Administration|Ancillary studies
218873434|NCT03871257|DRUG|Selumetinib Sulfate|Given PO
218873435|NCT03871257|DRUG|Vincristine Sulfate|Given IV or IV push
219023067|NCT07115212|DIETARY_SUPPLEMENT|Bromelain|1 tablet daily with water, for 9 days-starting 2 days before surgery and continuing for 7 days after. Record each dose in the provided log, along with any other medications taken and the time they were taken.
219493813|NCT01890694|BIOLOGICAL|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
219493814|NCT01890694|PROCEDURE|Ascites Evaluation|Ascites will be assessed at every visit.
219493815|NCT01890694|PROCEDURE|Edema|Edema will be assessed at every visit.
219602226|NCT04158362|DRUG|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
219602227|NCT04158362|DRUG|Abemaciclib|Oral 150 mg BID continuous
218873436|NCT04514133|BEHAVIORAL|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
218873437|NCT06211049|DRUG|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
219023068|NCT07114198|DRUG|Ibuprofen 10 mg/kg|Ibuprofen was administered orally at a dose of 10 mg/kg body weight, 40 minutes before the start of the dental procedure. This intervention was designed to reduce intraoperative pain and pulse elevation associated with reversible pulpitis.
219200083|NCT06871748|OTHER|Low FODMAP Diet|A standardized diet containing low levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), designed to reduce bloating and gastrointestinal symptoms. Meals are pre-prepared, calorie-matched, and visually identical to those in the high FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence monitored through food diaries and photos.
219602228|NCT06385483|DRUG|Afatinib|Given PO
218873438|NCT06211049|DRUG|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
218873439|NCT05756569|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218873440|NCT05756569|PROCEDURE|Computed Tomography|Undergo CT
218873441|NCT05756569|DRUG|Enfortumab Vedotin|Given IV
218873442|NCT05756569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218873443|NCT05756569|BIOLOGICAL|Pembrolizumab|Given IV
218873444|NCT05756569|OTHER|Questionnaire Administration|Ancillary studies
219023069|NCT06913192|BIOLOGICAL|CAR-T|All enrolled patients will receive three cycles of induction therapy using either the DVRd regimen (Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone) or the DKRd regimen (Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone). Following induction, patients will undergo high-dose melphalan conditioning followed by autologous hematopoietic stem cell transplantation. On Day 5 after stem cell reinfusion, patients will receive anti-BCMA CAR-T cell infusion. After CAR-T therapy, patients will enter the maintenance phase with lenalidomide monotherapy or lenalidomide in combination with bortezomib until disease progression or intolerable toxicity occurs.
219023070|NCT06913101|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
219200084|NCT06871748|OTHER|High FODMAP Diet|A standardized diet containing high levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) to assess its impact on bloating and gastrointestinal symptoms. Meals are calorie-matched and visually identical to those in the low FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence tracked through food diaries and photos.
219200085|NCT06873126|COMBINATION_PRODUCT|Counselling sessions|The study provides insights into the use of awareness counselling sessions for physical activity promotion, which may have a significant impact on physical activity education, promotion, practice and policy making and will be more effective to ensure adherence to activity among young adults.
218873445|NCT06815302|BEHAVIORAL|Experimental intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
219200086|NCT01884961|OTHER|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
219200087|NCT06873165|DIETARY_SUPPLEMENT|Probiotics|1 capsule(with three different dosage) per day for 12 weeks
219493816|NCT02580201|BIOLOGICAL|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
218873446|NCT06815302|BEHAVIORAL|Active intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
219200088|NCT06873165|DIETARY_SUPPLEMENT|Placebo|1 capsule per day for 12weeks
219200089|NCT06869369|OTHER|Turkish PNE4Kids|"Participants in the intervention group will receive 'Turkish PNE4Kids Programme'. The PNE4Kids program was developed based on the book Explain pain by Butler and Moseley and includes an explanation and reassurance on the cause of pain, a brief summary of relevant pain mechanisms, and the integral role of psychosocial and physical factors in precipitating and maintaining pain. This programme has been translated and validated in Turkish children."
219200090|NCT02225301|OTHER|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
219200091|NCT06261112|OTHER|kaleidescope|used to kaleideskope
219602229|NCT06385483|PROCEDURE|Biopsy Procedure|Undergo biopsy
219602230|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218873447|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
218873448|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
218873449|NCT00026312|DRUG|Isotretinoin|Given PO
218873450|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
218873451|NCT00026312|OTHER|Pharmacological Study|Correlative studies
218873452|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
218873453|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
218873454|NCT06987383|DRUG|Vibegron|A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study
218873455|NCT06987383|DRUG|Placebo|Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value
218873456|NCT05432804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218873457|NCT05432804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218873458|NCT05432804|DRUG|Selinexor|Given PO
218873459|NCT05432804|DRUG|Temozolomide|Given PO
218873460|NCT03367741|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218873461|NCT03367741|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218873462|NCT03367741|DRUG|Cabozantinib S-malate|Given PO
218873463|NCT03367741|PROCEDURE|Computed Tomography|Undergo CT scan
218873464|NCT03367741|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218873465|NCT03367741|BIOLOGICAL|Nivolumab|Given IV
218873466|NCT06328660|DEVICE|Lens 1|Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
218873467|NCT06328660|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
219023071|NCT06913101|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
219200092|NCT05954546|DRUG|Enco+bini|Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
219602231|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
219602232|NCT06385483|PROCEDURE|Echocardiography Test|Undergo ECHO
219602233|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602234|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
218873468|NCT07013799|OTHER|BasketUp Warm-up|BasketUp is a basketball-specific warm-up program designed to meet the sport's physical and physiological demands. Based on the FIFA 11+ structure, it includes three blocks: mobility, strength and plyometrics, and agility with neurocognitive exercises. The program progresses weekly and can be adapted in duration and volume to fit different training needs.
219023072|NCT06921785|DRUG|Tremelimumab|IV therapy
219023073|NCT06921785|DRUG|Rilvegostomig|IV therapy
219023074|NCT06921785|DRUG|Bevacizumab|IV therapy
219023075|NCT06921785|DRUG|Atezolizumab|IV therapy
219023076|NCT06924827|DRUG|Epidiolex 100 mg/mL Oral Solution|The participant's 'artisanal' CBD and Epidiolex dose should be taken consistently with food or consistently without food throughout the entire study. The participant's dosing with or without food should be consistent with their method of dosing of 'artisanal' CBD prior to screening. Oral administration is recommended. When necessary, Epidiolex can be enterally administered via silicone feeding tubes, such as nasogastric or gastrostomy tubes.
219023077|NCT06922149|OTHER|Group A Funtional massage therapy and eccentric exercise in lower limb|Functional Massage (FM) on lower limb. FM is a therapeutic technique that incorporates joint motion with massage to treat musculotendinous pain and impairments. Eccentric exercises training for lower limb. It can be useful in strengthening the muscles of the lower limbs, and promoting gait performance.
218873469|NCT03194438|BEHAVIORAL|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
218873470|NCT05273554|DRUG|Pembrolizumab|Given by IV
218873471|NCT05273554|DRUG|lenvatinib|Given by PO
218873472|NCT06692738|DRUG|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
218873473|NCT06692738|DRUG|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
218873474|NCT06692738|DRUG|Carboplatin|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
219023078|NCT06922149|OTHER|Group B. Eccentric exercises training|Eccentric exercises training and therapeutic exercise is a type of physical activity used to treat or prevent injuries and improve functional outcomes. Eccentric exercises focuses on movements, or phases of a movement, that lengthen the muscles. Some examples of eccentric exercise include lowering into a squat or lowering into a press-up. In contrast, when a person pushes out of a squat or press-up, this shortens the muscles. This is known as concentric movement
219493817|NCT03757052|DIAGNOSTIC_TEST|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
219493818|NCT02869828|DEVICE|Monitoring by arterial catheter and Spot-on|
218873475|NCT06692738|DRUG|Paclitaxel|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
218873476|NCT06692738|DRUG|Nab-paclitaxel|Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
218873477|NCT00175266|DRUG|alemtuzumab|
219023079|NCT07126483|PROCEDURE|Thoracic paravertebral block|Ultrasound-guided single-injection thoracic paravertebral block using 0.4 mL/kg of 0.25% bupivacaine with epinephrine (1:400,000) before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
219023080|NCT07126483|DRUG|Morphine|Single intrathecal injection of morphine (5 mcg/kg diluted in 3 mL 0.9% saline) at the L3-L4 or L4-L5 interspace before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
219023081|NCT07128888|DRUG|GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets|GZR18 injection: 3 mg-36 mg，16 weeks; Warfarin Sodium Tablets:2.5mg，twice; Rosuvastatin Calcium Tablets：10mg，twice; Digoxin Tablets:0.25mg，twice
219023082|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ (240 mg)|A once-daily capsule containing 240 mg of NT-II™, a marine-derived undenatured type II collagen supplement obtained from enzymatically processed salmon cartilage and bone. Taken orally for 12 weeks.
219023083|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ 480 mg|Two capsules of NT-II™ (each 240 mg), taken orally once daily for a total of 480 mg/day over 12 weeks. Sourced from salmon bone and cartilage to support joint health via oral tolerance.
219023084|NCT07119645|DIETARY_SUPPLEMENT|Glucosamine/Chondroitin|A combined dietary supplement containing 1500 mg glucosamine and 1300 mg chondroitin, taken orally once daily for 12 weeks. This supplement serves as the active comparator and is widely used to support joint structure and function.
219023085|NCT06930391|DRUG|Oxytocin|Oxytocin 10-5M will be added to 3 groups of myometrial strips for 2 hours to induce desensitization.
219023086|NCT06930391|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M
218873478|NCT00175266|PROCEDURE|islet transplant|
218873479|NCT00175266|DRUG|infliximab|
218873480|NCT07024524|OTHER|Rehabilitation training|This study constructed a novel multimodal assessment system to evaluate speech perception, music perception, and spatial hearing in congenital deafness patients , and subsequently generated targeted rehabilitation training plan based on the assessment data.
219493819|NCT02869828|DEVICE|Monitoring by oesophagal probe and Spot-on|
219493820|NCT06146686|DEVICE|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
218873481|NCT05901103|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
219023087|NCT06930391|DRUG|Calcium|Calcium chloride in the following concentrations:1.25mM, 2.5mM and 5.0mM.
219023088|NCT06934057|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
219023089|NCT06934057|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
219493821|NCT06146686|DEVICE|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
218873482|NCT07040423|PROCEDURE|PENG Block|Preoperative ultrasound giuded PENG block (ropivacaine 0,5% 20mL)
218873483|NCT07040423|PROCEDURE|Magnetic resonance imaging|The patient will undergo a pelvic MRI to assess anesthetic diffusion after PENG block
218873484|NCT05382611|DIAGNOSTIC_TEST|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
219023090|NCT06934915|DRUG|Prednisone|Starting dose: 5 mg daily. Maximum dose: 60 mg daily. Dosage forms: 5 mg, 10 mg, and 20 mg capsules.
219200093|NCT06871735|PROCEDURE|Acellular matrix|Wound closure is obtained by use of acellular matrix material placed over the exposed barrier membrane. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
219200094|NCT06871735|PROCEDURE|Surgical closure|Wound from the graft is surgically closed, with no use of the acellular matrix. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
219200095|NCT06870786|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Evaluation of T-PRF membrane structures obtained from the blood of patients before and after vitamin D supplementation.
219200096|NCT06872541|DRUG|Clopidogrel|Clopidogrel 75 mg uma vez ao dia durante 14 dias
219493822|NCT04895228|PROCEDURE|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
219493823|NCT01745484|OTHER|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
219493824|NCT02533388|DEVICE|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
219493825|NCT02533388|DEVICE|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
219493826|NCT04064333|DEVICE|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
219493827|NCT02726737|DRUG|sodium bicarbonate|
219493828|NCT02726737|DRUG|Lidocaine|
219493829|NCT02726737|DRUG|sterile distilled water|
219493830|NCT06157489|OTHER|Kinesio tape|Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
219493831|NCT00431574|PROCEDURE|dosing|
219493832|NCT06564337|DEVICE|Surveyed zirconia crown|Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
219602235|NCT01682395|PROCEDURE|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
219602236|NCT01682395|PROCEDURE|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
219602237|NCT01682395|PROCEDURE|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
219493833|NCT00420849|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
219493834|NCT00420849|DRUG|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
219493835|NCT00709020|DRUG|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
218873485|NCT06728332|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Providers in the study recruitment network will recruit eligible patients through an existing visit. After this referral, the study is conducted entirely electronically.
219493836|NCT00709020|OTHER|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
219602238|NCT05920837|DEVICE|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
219602239|NCT05920837|OTHER|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
219602240|NCT04519073|BIOLOGICAL|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
219602241|NCT07133906|DEVICE|Continuous glucose monitoring|A blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn
219602242|NCT07133906|DEVICE|Cerebral near-infrared spectroscopy|Blinded cerebral near infrared spectroscopy will be assessed
218873486|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218873487|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
218873488|NCT04195399|PROCEDURE|Echocardiography Test|Undergo ECHO
218873489|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218873490|NCT04195399|DRUG|Nirogacestat|Given PO
218873491|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
218873492|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
218873493|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
218873494|NCT06732856|DRUG|zolbetuximab|"1. Neoadjuvant treatment~   : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~   (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks)~2. Surgery~   : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node~3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
218873495|NCT06732856|DRUG|Oxaliplatin|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
218873496|NCT06732856|DRUG|Docetaxel|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
218873497|NCT06732856|DRUG|S-1|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
218873498|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
219493837|NCT00709020|OTHER|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
219493838|NCT00709020|OTHER|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
219602243|NCT06619405|DIAGNOSTIC_TEST|Streetlab VR|Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.
219493839|NCT00709020|OTHER|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
219493840|NCT00709020|OTHER|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
218873499|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
218873500|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
218873501|NCT01295424|OTHER|No intervention|Observational study, no interventions
219493841|NCT00709020|OTHER|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
219493842|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
218873502|NCT07056517|DRUG|M107 and Duvie - Cohort 1|Dosage form - Oral tablets Dosage - Duvie 0.415 mg and M107 ODT 0.4 mg Participants will receive each treatment once under fasted conditions in a randomized two-period crossover design.
219023091|NCT06934915|DRUG|Placebo|Capsules identical in size and appearance to those containing prednisone. Placebo capsules contain inactive ingredients.
219023092|NCT07137208|PROCEDURE|ESP block|In the ESP group, patients will be positioned in the right lateral position. The ultrasound probe will be placed vertically about 3 cm lateral to the spinous process of T9 to visualize the transverse process, trapezius, and erector spinae muscles. A 22-gauge spinal needle will be inserted in-plane in the cranial-to-caudal direction until the needle tip reaches the fascial plane between the erector spinae muscle and transverse process. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected. Likewise, the same block procedure will be performed at the T11 level and on both levels on the other side, 10 mL will be injected at each of the four injection sites.
219493843|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
219493844|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 2.5-minute intervals|Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
219493845|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 5-minute intervals|Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
219493846|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
219493847|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
219493848|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
219040189|NCT04120532|BEHAVIORAL|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
219493849|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
219493850|NCT04280939|PROCEDURE|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
219493851|NCT06566924|OTHER|Control|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'.
219493852|NCT06566924|OTHER|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made availa
219602244|NCT07134829|BEHAVIORAL|Stroboscopic Visual Conditions|Participants will perform walking trials under three visual conditions: high-frequency stroboscopic glasses, low-frequency stroboscopic glasses, and no-glasses control. Each participant will complete three 5-meter walking trials per condition, with the order of conditions randomized. Gait parameters will be recorded using the GAITRite walkway system, and muscle activity will be measured using surface electromyography.
218873503|NCT07056517|DRUG|M107 - Cohort 2|Dosage form - Orally disintegrating tablet Dosage - 0.8 mg Participants will receive M107 once under fasted conditions and once after a high-fat, high-calorie meal in a two-period crossover design.
218873504|NCT07056517|DRUG|M107 - Cohort 3|Dosage form - Orally disintegrating tablet Dosage - 1.2 mg Participants will receive a single oral dose of M107 under fasted conditions.
218873505|NCT06772168|DRUG|CMG190303(Dapagliflozin/Rosuvastatin)|0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
218873506|NCT06772168|DRUG|Comparator 1: Dapagliflozin/Rosuvastatin placebo|0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
218873507|NCT06772168|DRUG|Rosuvastatin/Dapagliflozin placebo|0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
218873508|NCT07077109|DEVICE|Electrophysiological monitoring|electrofysiological CTG monitoring with the Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands). The NFMS consists of a wireless and beltless electrode patch on the maternal abdomen. It monitors fetal heart rate by fetal electrocardiography, maternal heart rate by maternal electrocardiography and the electrical activity of the uterine muscle by electrohysterography.
219023093|NCT07137208|PROCEDURE|TAP Block|In the TAP group, patients will be positioned in the supine position. A posterior approach will be employed, with the ultrasound probe placed transversely on the anterolateral abdominal wall, midway between the costal margin and iliac crest, posterior to the midaxillary line. This will allow visualization of the external oblique, internal oblique, and transversus abdominis muscles. The probe will then be moved posteriorly to identify the tapering of the transversus abdominis muscle toward the quadratus lumborum. A 22-gauge spinal needle will be inserted in-plane from anterior to posterior. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected into the plane between the internal oblique and transversus abdominis muscles. Likewise, the same block procedure will be performed on the other side.
219023094|NCT07137208|DRUG|Bupivacaine injection|A total of 20 mL of 0.25 bupivacaine will be administered at each side.
219023095|NCT07141901|BEHAVIORAL|Decision Tool|"For patients with life expectancy \<10 years: Active (i.e. interruptive) BPA that will fire when the clinician orders colorectal cancer screening. The BPA will advise that screening is not recommended due to \<10 year life expectancy. An active alert is required to prevent the clinician from ordering a potentially inappropriate test. The BPA will contain a box with suggested language with which to express this to the patient.~For patients with life expectancy ≥10 years: Passive alert on the Storyboard indicating that patient could benefit from screening as their predicted life expectancy is ≥10 years. A passive alert does not interfere with workflow and is available whenever it is convenient for the clinician to address it."
219023096|NCT01721330|DRUG|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
219023097|NCT01721330|DRUG|Placebo|Placebo twice a day for 6 weeks
219023098|NCT00296374|DRUG|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
219023099|NCT00296374|DRUG|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
219023100|NCT00296374|DRUG|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
219023101|NCT07184047|OTHER|Adjuvant Chemotherapy (Standard of Care)|"Patients aged 65 years and older with non-metastatic or locally advanced gastrointestinal cancers will receive standard adjuvant chemotherapy regimens as part of routine clinical practice. Regimens may include FOLFOX, CAPEOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, capecitabine, gemcitabine, 5-FU/leucovorin, or oxaliplatin-based combinations, depending on tumor type and physician decision.~No investigational drugs or experimental interventions are administered. The study is observational, and all treatments follow standard of care."
219023102|NCT07180875|BEHAVIORAL|hypoventilation group|"Traditional Aerobic Training Participants will perform supervised aerobic exercise (e.g., cycling or treadmill walking) under controlled intermittent hypoxic conditions.~Hypoxia protocol: alternating cycles of low-oxygen exposure (FiO₂ 12-16%) for 3-5 minutes followed by normoxic recovery for 2-3 minutes, repeated 6-8 times per session.~Frequency: 3 sessions per week for 12 weeks.~Exercise intensity: Moderate (50-70% of heart rate reserve), adjusted individually based on baseline exercise testing"
219023103|NCT07175623|DRUG|Methyl Prednisolone (MP)|"Dose: 1 mg/kg IV~Timing: at the induction of anesthesia"
219023104|NCT07175623|DRUG|Dexamethasone (0.2 mg/kg)|"Dose: 0.2 mg/kg IV (glucocorticoid equivalent to 1 mg/kg methylprednisolone)~Timing: at the induction of anesthesia"
219023105|NCT07175623|DRUG|Saline (0.9% NaCl)|"Dose: 5 ml IV~Timing: at the induction of anesthesia"
219023106|NCT07177326|DRUG|Tadalafil 2.5 mg|patients recived Tadalafil 2.5 mg daily
219023107|NCT07177326|DRUG|Sildenafil 25 mg|patients recived Sildenafil 25 mg daily
219023108|NCT07177326|DRUG|Tadalafil 5 mg|patients recived Tadalafil 5 mg daily
219023109|NCT07184541|BEHAVIORAL|Wake and Weigh|The Wake and Weigh tool includes the patient's dry weight and instructions for daily weight monitoring. Participants in the intervention group will be instructed on the use of the tool. While in the hospital, weight is being managed by the healthcare team, so the goal during hospitalization is to educate the patient on what to do once discharged, and to recognize changes in weight.
219023110|NCT07184541|BEHAVIORAL|Usual care|The usual care group will receive the heart failure handbook that is routinely given to heart failure patients.
219023111|NCT07181473|DRUG|TJ101|TJ101 is a EGFR/B7H3 directed antibody conjugate with a cleavable linker and a noval topoisomerase I inhibitor.
219023112|NCT07182565|RADIATION|hypofractionated radiotherapy|In Phase Ib, hypofractionated radiotherapy (HFRT) will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
219023113|NCT07182565|DRUG|PD-1 inhibitor|Serplulimab will be administered concurrently with chemotherapy at a fixed dose of 300 mg via intravenous infusion on Day 1 of each 3-week cycle.
219602245|NCT07134153|DRUG|T-DXd|Evaluating safety and efficacy of intrathecal or ommaya reservoir administration of T-DXd in patients with HER2-expressing breast cancer with active leptomeningeal and/or brain metastases based on systemic therapy
219602246|NCT04936399|BIOLOGICAL|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
219602247|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
219602248|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
219602249|NCT05957744|PROCEDURE|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
219602250|NCT00447993|COMBINATION_PRODUCT|Low Dose NT-501|Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
219023114|NCT07182565|DRUG|TS-1|The TS regimen includes paclitaxel at a dose of 175 mg/m² administered via intravenous infusion on Day 1, and oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle). The S-1 dose is based on body surface area (BSA): 40 mg twice daily (bid) for BSA ≤ 1.5 m²; 50 mg bid for BSA 1.5-1.6 m²; and 60 mg bid for BSA ≥ 1.6 m².
219023115|NCT07191158|DEVICE|Group 1 conventional|Conventional miniscrew-supported distal jet appliance
219023116|NCT07191158|DEVICE|Group 2 3D printed|New 3D printed miniscrew-supported molar distalizers
219023117|NCT07189403|DRUG|DS9051b|Administered orally
219023118|NCT07189468|DEVICE|Smartwatch and mobile application|Wearing a smartwatch and using a mobile application for one year
219493853|NCT06255730|PROCEDURE|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219493854|NCT06255730|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219493855|NCT00105352|PROCEDURE|Mixed Meal Tolerance Test|
219493856|NCT00105352|PROCEDURE|Glucagon Stimulation Test|
219493857|NCT03998215|BIOLOGICAL|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
219493858|NCT00743119|DRUG|Placebo capsules|Placebo capsules
219493859|NCT00743119|DRUG|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
219493860|NCT00743119|DRUG|Low dose Dronabinol|Dronabinol 10mg
219493861|NCT00743119|DRUG|High dose Dronabinol|Dronabinol 20mg
219493862|NCT00743119|DRUG|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
219493863|NCT00743119|DRUG|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
219493864|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
219493865|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
219493866|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
219493867|NCT02001870|PROCEDURE|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
219493868|NCT02001870|PROCEDURE|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
219493869|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
219493870|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
219493871|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
219493872|NCT04241185|DRUG|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
219493873|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
219493874|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
219493875|NCT04241185|RADIATION|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
219493876|NCT04241185|DRUG|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
219493877|NCT04241185|DRUG|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
219493878|NCT04241185|DRUG|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
219493879|NCT04241185|DRUG|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
219493880|NCT04241185|DRUG|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
219493881|NCT05887674|BEHAVIORAL|Diet intervention|Low inflammatory-index diet
219493882|NCT05887674|BEHAVIORAL|Exercise|Guided muscle strength training and stretching exercises
219493883|NCT05887674|BEHAVIORAL|Cognitive training|Cognitive training will be implemented in person
219493884|NCT06465706|DEVICE|LAmbre investigational device|Randomized 1:1 to either experimental group or control group.
219493885|NCT04106947|OTHER|Questionnaires|Questionnaires
219493886|NCT06153667|DEVICE|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
218873509|NCT07081308|DEVICE|NIRS-BCI-pneumoorthesis|"Patients recieve 10 NIRS-BCI-pneumoorthesis trainings of 16 minutes each over 2 weeks.~NIRS-BCI-pneumoorthesis Components: NIRScout hardware-software complex (16 light sources, 8 detectors); Software for brain activity classification; Korvit system for plantar support load reproduction; 22-inch monitor for task demonstration.~Training Procedure: Patient seated with lower limbs fixed in pneumatic orthoses; Task: kinesthetically imagine walking or relax; Feedback: visual (color change on screen) and tactile (support load through orthosis).~Training structure: 16 blocks alternating walking imagination and relaxation"
218873510|NCT07083063|DRUG|Nitroglycerin (NTG)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group, and 10cc normal saline will be delivered to the major papilla in the standard group.
218873511|NCT07083063|DRUG|Normal Saline (0.9% NaCl)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group.
218873512|NCT07078942|DRUG|Tranexamic Acid|Tranexamic Acid 1 g intravenous preoperation
218873513|NCT07078942|OTHER|Placebo|normal saline 20 ml intravenous preoperation
218873514|NCT07083414|DEVICE|elderly participant will receive digital educational oral health program.|"* Digital 3D Model Video: A custom-designed 3D animated video illustrating proper tooth brushing techniques tailored for elderly individuals, as well as comprehensive guidance on denture care.~* Written Educational Materials: Printed resources including posters and flyers that provide key messages and visual demonstrations related to maintaining good oral hygiene practices.~* PowerPoint Presentations and Educational Videos: Visual and audiovisual materials focusing on the importance of balanced nutrition in maintaining oral and general health, and early detection of oral cancer, including risk factors, signs, and recommended screening practices.~* Hands-on Brushing Technique Training: Practical sessions utilizing dental cast models to demonstrate and allow participants to practice effective brushing techniques under supervision."
219023119|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) with neuromuscular electrical stimulation (NMES)|The NMES was applied during the plantarflexor contraction phase of the PNF stretching (described as below). Two electrodes (4 × 8 cm) were used for stimulation, placed on the triceps surae of the affected side: one positioned 5 cm below the popliteal fossa, and the other placed 5 cm below the first electrode, directly over the triceps surae. The hold-relax technique of proprioceptive neuromuscular facilitation (PNF) will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
219023120|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) only|The hold-relax technique will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
219023121|NCT07190170|BEHAVIORAL|TRE|Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eating window.
219023122|NCT07190170|BEHAVIORAL|Weight-Loss Maintenance Advice|The CON arm participants will receive written baseline advice following randomization assignment that includes determinants associated with long-term weight-loss maintenance success (e.g., physical activity, and strategies to limit calorie intake).
219493887|NCT00103415|BEHAVIORAL|Endurance training|
219493888|NCT00103415|BEHAVIORAL|Weight-lifting training|
219493889|NCT06536582|BIOLOGICAL|Platelet rich growth factor injection (autologous product)|All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
219493890|NCT02970175|DRUG|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
219493891|NCT02970175|PROCEDURE|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
219493892|NCT02970175|PROCEDURE|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
219493893|NCT05151172|DEVICE|endovascular thrombectomy (EVT)|minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
219493894|NCT05151172|OTHER|Standarad medical care|Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
219602251|NCT00447993|COMBINATION_PRODUCT|High Dose NT-501|High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
219602252|NCT07018713|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
219602253|NCT07018713|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
219602254|NCT07021989|DRUG|Pembrolizumab|Given intravenously
219602255|NCT07021989|RADIATION|Non-investigational, involved site radiotherapy (ISRT)|Undergo possible, standard of care, non-investigational radiation therapy
219602256|NCT07021989|DRUG|Gemcitabine|Given IV
219602257|NCT07021989|DRUG|Vinorelbine|Given IV
219602258|NCT07021989|DRUG|Liposomal Doxorubicin|Given IV
219493895|NCT02955992|BEHAVIORAL|Improving communication during the end-of-life process|
218873515|NCT07083414|OTHER|elderly participant will receive the standard oral health education in geriatric institution.|The use of traditional health promotion materials, such as leaflets and posters, remains valuable in community settings. These tools are cost-effective, easy to produce, and continue to serve as effective educational resources for adults, including the elderly. Participants in the control group will receive standard oral health information. No education sessions will be conducted during the 6 months till the final assessment. However, after the final assessment at 6 months, the control group will be offered access to the digital educational program.
218873516|NCT07082959|BEHAVIORAL|Nursing Pillow|Although there are studies investigating the effects of breastfeeding pillow use on breastfeeding success, comfort, and positive outcomes for both mother and baby, no study has been found examining the effect of breastfeeding pillow use on nipple pain and maternal comfort in women who have undergone vaginal delivery. Therefore, the aim of this study is to evaluate the effect of breastfeeding pillow use on nipple pain and comfort during the postpartum period.
218873517|NCT07082894|DRUG|Magnesium|preoperative oral magnesium dose of 120 mg at one hour before surgery will be given.
218873518|NCT07082894|OTHER|Placebo control|preoperative oral lemon juice at one hour before surgery will be given.
218873519|NCT07083349|DRUG|NK510 : allogeneic genetic modified NK|NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.
218873520|NCT07087158|DRUG|IBR854|Every 21 days is one cycle, and IBR854 will be dosed in a route of intravenous infusion on day 1 and day 8 of each cycle with a fixed dose of 9.0×10\^9 cells.
218873521|NCT07087158|DRUG|Pazopanib|Pazopanib will be dosed orally once daily without food (at least 1 hour before or 2 hours after a meal) with a fixed dose of 800mg.
219023123|NCT07189650|DEVICE|MRI|Proton Density Fat Fraction Magnetic Resonance Imaging (MRI-PDFF )
219023124|NCT07189598|PROCEDURE|Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)|"The doses delivered will be:~* the prostate gland, at a dose of 36.25 Gray, in 5 fractions,~* the dominant intraprostatic lesion, up to 50 Gray, in 5 fractions,~* seminal vesicles, at a dose of 25 Gray in 5 fractions,~* pelvic lymph nodes, at 25 Gray in 5 fractions"
219023125|NCT07189598|PROCEDURE|conventional or a moderately hypofractionated|"* Conventional fractionation includes the prescription of a total dose of 78 Gray in 39 fractions to the prostate gland (and seminal vesicles, in case of T3b disease), and a dose de 50Gy in 25 fractions to pelvic nodal areas.~* Moderate hypofractionation includes the prescription of a total dose of 60 Gray to the prostate gland (and seminal vesicles, in case of T3b disease), and 44 Gray to pelvic nodal areas in 20 fractions using a simultaneous integrated boost (SIB)"
219023126|NCT07190820|PROCEDURE|digital impression|complete arch implant impression with intraoral photogrammetry
219023127|NCT07190820|PROCEDURE|conventional impression|conventional open tray splint impression
219023128|NCT07191054|DEVICE|LifeFlow Rapid infuser|Use of rapid infuser to fluid resuscitate
219023129|NCT07191054|DEVICE|Push Pull|Use of Push Pull syringe technique to fluid resuscitate
219023130|NCT07191119|DEVICE|Soterix tVNS device|"Active transcutaneous auricular vagus nerve stimulation (tVNS) using the Soterix device.~Stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold."
219023131|NCT07191119|DEVICE|Soterix tVNS device (sham programmed)|The sham stimulation used the Soterix device, but without active electrical stimulation. The procedure mimics the verum condition in duration and setup. Inactive stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.
219023132|NCT07191119|BEHAVIORAL|Sleep Quality|Receive Pittsburgh Sleep Quality Index (PSQI); Insomnia Severity Index (ISI); Sleep diaries; Actigraphy via Fitbit Charge 5
219023133|NCT07191119|BEHAVIORAL|Neurocognitive and mental health outcomes|Measured using CNS Vital Signs and DASS-21.
219023134|NCT07190482|DRUG|Olanzapine 5 Mg ORAL TABLET|OLANZAPINE ARM
219023135|NCT07190482|DRUG|Placebo Drug|placebo administered for 8 weeks
219023136|NCT07191379|OTHER|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting.|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. To reduce potential bias, patients will function as their own controls by receiving alternating treatments at home and in the outpatient clinic.
219023137|NCT06308822|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219493896|NCT04068571|BEHAVIORAL|I-PUSH|Innovative partnership for universal and sustainable healthcare
219493897|NCT01814995|BEHAVIORAL|Nutrition/Physical Activity Intervention|Please see Arm description.
218873522|NCT00231413|BIOLOGICAL|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
219023138|NCT06308822|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219023139|NCT06308822|PROCEDURE|Computed Tomography|Undergo CT
219023140|NCT06308822|DRUG|Erdafitinib|Given PO
219023141|NCT06308822|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023142|NCT06124378|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
219493898|NCT04816877|DRUG|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
219602259|NCT07021989|DEVICE|Foresight CLARITY™ LDT|Foresight CLARITY LDT, a laboratory-developed test (LDT),by Foresight Diagnostics, is an ultra-sensitive liquid biopsy and tissue platform that detects MRD in patients with B-cell lymphomas
219602260|NCT07021989|DRUG|Pegfilgrastim|Given IV for supportive care
219023143|NCT06124378|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
218873523|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
219023144|NCT06124378|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
218873524|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
218873525|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
218873526|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
218873527|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
219023145|NCT06124378|PROCEDURE|Colectomy|The specific surgical approach is laparoscopic. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
219023146|NCT05693909|DRUG|SP-420|Capsules for oral intake
219023147|NCT05554380|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219023148|NCT05554380|PROCEDURE|Biospecimen Collection|Undergo blood collection
219023149|NCT05554380|PROCEDURE|Computed Tomography|Undergo CT scan
219023150|NCT05554380|DRUG|Ipatasertib|Given PO
219023151|NCT05554380|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023152|NCT05554380|DRUG|Paclitaxel|Given IV
219023153|NCT06787235|DIETARY_SUPPLEMENT|Modified ketogenic diet|The modified Atkins KD is defined as \<20g carbohydrate per day with freely allowed protein consumption. Recommended protein and fat intake will be calculated for each participant based on their energy needs.
219493899|NCT05632757|BEHAVIORAL|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
219493900|NCT03113175|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
219493901|NCT03113175|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
218873528|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
218873529|NCT07087938|DRUG|Cannabichromene|Participants will be assigned (using block randomization) to begin with one of the two study doses of CBC (400mg or 600mg). Participants will be blinded to dose. They will be asked to take half of their dose in the morning and half in the evening. Participants will be administered dose one for eight weeks. After this, participants will have a two-week timeframe where they will be asked not to take any study medication and to continue refraining from cannabis use, thus providing a washout period. Then, at visit three, they will receive dose two and will take it for eight weeks, concluding the study with another two-week washout period. At each clinic visit participants will complete assessments (self-report and physical examination), urine, and blood samples.
218873530|NCT07088588|DRUG|SYN608|Patients will orally receive SYN608
219023154|NCT06787235|OTHER|Individual nutritional consultation|The nutritional consultation will be provided by a dietician to improve individual health
219023155|NCT06745791|DEVICE|BoneMRI|BoneMRI is a quantitative 3D MRI technique,capable of generating CT-like, quantitative radiodensity bone MRI images to visualize cortical and trabecular bone, allowing to assess bone structure and morphology, in addition to regular clinical MRI images.
219023156|NCT03712904|RADIATION|Stereotactic Body Radiation Therapy|Undergo radiation
219602261|NCT07021989|PROCEDURE|Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
219023157|NCT03712904|BIOLOGICAL|Ziv-Aflibercept|Given IV
219023158|NCT03879707|DRUG|Melatonin 5 mg|Melatonin is known to induce sleep
219023159|NCT03879707|DRUG|Placebo Oral Tablet|Placebo
219023160|NCT03879707|DRUG|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
219023161|NCT04674683|DRUG|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
219040190|NCT06142721|OTHER|3D Gait Analysis|3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
219602262|NCT06629493|BEHAVIORAL|Fitbit Versa 3|Fitbit Versa 3 is a commercially available activity tracker
219602263|NCT06629493|BEHAVIORAL|In-patient alcohol use disorder treatment|In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
219023162|NCT04674683|DRUG|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
218873531|NCT07089758|DEVICE|Cerebral open flow microperfusion|"Patients will undergo intra-operative microperfusion using Joanneum Research's cerebral open flow microperfusion (OFM) catheters, push and pull tubing, and MPP102-II pump. This process utilizes a probe (catheter) inserted into the parenchyma to collect analytes of any size and polarity from the microenvironment. The microperfusion pump peristaltically pushes and pulls perfusate with no net fluid-exchange when the pump heads are set at equal flow rates. As perfusate enters the tip of the microperfusion catheter, analytes are exchanged based on a gradient between the interstitial fluid and the perfusate. The sample is then recovered via the pull portion of the peristaltatic microperfusion pump, enabling constant sampling volumes and preventing loss of the perfusate into the tissue.~The duration is 60-80 minutes (dependent on the speed of progress resecting portions of the tumor without catheters)"
218873532|NCT07088627|PROCEDURE|Intervention 1: UG|Participants perform UG targeting SN and C\&J exercises, varying intensity at 80% of 1RM and volume (5 sets of 5, 4, 3, 2, 1 repetitions) over weeks. Rest between sets: 90 seconds.
218873533|NCT07088627|PROCEDURE|Intervention 2: SG|Participants perform SG with SN and C\&J at consistent 80% 1RM intensity, 5 sets of 5 repetitions each session. Rest between sets: 90 seconds.
218873534|NCT07088627|PROCEDURE|Intervention 3: MG|Participants engage in MG training focusing on SN and C\&J at 100% 1RM, 5 sets of 1 repetition, with 180 seconds rest between sets.
218873535|NCT07087496|OTHER|Insulin application training with mobile augmented reality|Intervention Group 2 (MAR group): Before the training, the participants were briefly informed about how the application would be performed, and their written consent was obtained. Before the insulin administration training was started, the MAR program was shown to them on the tablet by the researcher and the process steps containing QR codes prepared for insulin administration were provided on a blue flat surface and information was given about the use of the application, and a pre-test was administered to determine their knowledge levels on insulin administration. Then, the education application program prepared for insulin administration was opened and the patients were allowed to use it. The training application was performed 20-25 times. Then the post-test was administered to the participants immediately after the training. At the post-test, they were administered the Knowledge Test and Scale for Satisfaction with Patient Education.
219023163|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
219023164|NCT00804518|OTHER|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
219023165|NCT03407742|BEHAVIORAL|CAPAS Youth|9-week parenting intervention
219023166|NCT05174182|OTHER|A novel treatment approach|A novel treatment approach, as described before.
219023167|NCT05174182|OTHER|Usual care|Usual care, as described before.
219023168|NCT05027438|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
219023169|NCT05027438|BEHAVIORAL|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
219023170|NCT05485974|DRUG|HBI-2438|KRAS G12C Inhibitor
219023171|NCT06005922|OTHER|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
219023172|NCT06005922|OTHER|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
219023173|NCT06523751|DIAGNOSTIC_TEST|Trabeculopuncture|Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
219023174|NCT03094845|BIOLOGICAL|Placebo solution|15 injections over 7 weeks
219023175|NCT03094845|BIOLOGICAL|hdmASIT+TM|15 injections over 7 weeks
219023176|NCT05830487|BEHAVIORAL|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
219023177|NCT05830487|BEHAVIORAL|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
219023178|NCT04075565|BEHAVIORAL|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
219493902|NCT03984136|BEHAVIORAL|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
219493903|NCT03984136|BEHAVIORAL|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
219493904|NCT02856620|OTHER|Observational only|Observational only
218873536|NCT07087496|OTHER|insulin administration training with brochure|"The Intervention Group 1 (Brochure group): Before the training, the participants were informed about the study, and their written consent was obtained.~Before insulin administration training, a knowledge test was given as a pre-test to determine the participants' knowledge levels on insulin administrations. After the pre-test, a 15-20 minute practical training was given using the brochure prepared for insulin administrations. Immediately after the training, the knowledge test and Scale for Satisfaction with Patient Education were administered as a post-test. After the post-test, the participants were asked to self-administer insulin. The insulin administration skills of the patients were assessed by the researcher using the Insulin Administration Skill Assessment Checklist. After the assessment, the participants were informed about their deficiencies, or incorrect performances."
218873537|NCT07089446|DRUG|Hyaluronic Acid (HA)|Hyaluronic Acid
219023179|NCT04075565|BEHAVIORAL|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
219023180|NCT01984008|DRUG|Picosulfate sodium, magnesium oxide, citric acid|
219023181|NCT04536298|DIETARY_SUPPLEMENT|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
219023182|NCT04536298|DIETARY_SUPPLEMENT|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
219023183|NCT05775341|OTHER|No Intervention|This is purely an observational study.
219023184|NCT03001388|PROCEDURE|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
219023185|NCT06367309|PROCEDURE|Extended totally extraperitoneal repair|The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.
219023186|NCT06367309|PROCEDURE|Intraperitoneal onlay mesh|Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
219023187|NCT05434650|DEVICE|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
219023188|NCT05699603|PROCEDURE|Biopsy|Undergo skin biopsy
219023189|NCT05699603|DRUG|Calcipotriene|Applied topically
219023190|NCT05699603|DRUG|Fluorouracil|Applied topically
219023191|NCT05782751|PROCEDURE|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
219200097|NCT04106830|DRUG|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
219200098|NCT06872385|OTHER|Answering a questionnaire|The subject have to answer an online questionnaire about her perceptions on menopause and opinion on treatments for the condition
219200099|NCT06873607|DEVICE|mobile app|Mobile application content: general information about rheumatoid arthritis (causes, symptoms, treatment), lifestyle changes, coping strategies for symptoms, nutrition and exercise recommendations, and daily life considerations.
219200100|NCT06873607|OTHER|Control (Standard treatment)|Routine medical check-ups and the information provided during these visits
219602264|NCT07026318|DRUG|Tirofiban|After endovascular treatment, tirofiban is infused at a rate of 0.4 μg/kg/min for 30 minutes, followed by a maintenance infusion at 0.1 μg/kg/min until 24 hours postoperatively.
219602265|NCT07026318|DRUG|Placebo|Following endovascular treatment, patients receive normal saline placebo, with the dosage calculated in the same manner as that of tirofiban in the experimental group.
219602266|NCT07018700|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
219602267|NCT07018700|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
218873538|NCT07089446|DRUG|Platelet Rich Plasma|Platelet rich plasma
218873539|NCT07089446|DRUG|Hyaluronic Acid (HA) and Platelet rich plasma|Hyaluronic Acid and Platelet rich plasma
218873540|NCT07087392|PROCEDURE|Inverted-Ω Anastomosis|After meeting the inclusion and exclusion criteria, duodenum-preserving pancreatic head resection or mid-pancreatic resection will be performed, and inverted-Ω anastomosis will be carried out during the operation for the reconstruction of the digestive tract
218873541|NCT07089368|DRUG|Zn(II)-phthalocyanine gel|Topical application of RLP068/Cl 0.3% gel (Zn(II)-phthalocyanine) at a dose of 1 mL per 25 cm² under occlusion for 30 minutes, followed by red light irradiation at 630 nm (60 J/cm²) for 8 minutes. Sessions will be repeated twice weekly until clinical response is achieved.
218873542|NCT07087847|BIOLOGICAL|TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)|Approximately 28 days post-CAR-T therapy, a hematologic assessment will be performed. Eligible patients meeting the inclusion criteria will subsequently undergo TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).Collect peripheral blood stem cells (PBSC) from the haplo-donor.Split the graft into two fractions at a 9:1 ratio, 90% fraction: subject to TCRαβ+ T-cell depletion, 10% fraction: subject to CD45RA+ T-cell depletion. Primary graft (TCRαβ+depleted and partial CD45RA+ depleted): Freshly infused into the recipient. Residual CD45RA-depleted lymphocytes: Cryopreserved for prophylactic donor lymphocyte infusion (DLI) as needed.
218873543|NCT07088224|OTHER|Observational studies without intervention|Observational studies without intervention
218873544|NCT07089576|DEVICE|Arcevo™ LSA Hybrid Stent Graft System|The Arcevo LSA Hybrid Stent Graft System is an implantable aortic stent graft with LSA branch which is preloaded onto a delivery system and implanted during an open surgical procedure, or more specifically a total arch replacement procedure. The device is intended for use with a proximal surgical graft (not supplied). If additional coverage is needed, a protocol specified thoracic endovascular aortic repair (TEVAR) device may be used.
218873545|NCT07087691|DEVICE|OneMark device|"The OneMark device system consists of a tumor marker preloaded in a delivery system, a handheld probe, and a display console.~The OneMark marker is a metal clip with microparticles embedded in gelatin forming a hydrogel pellet. The pellet is implanted with a preloaded injector percutaneously in soft tissues, such as breast or lymph nodes, to mark a biopsy site or tissue intended for surgical removal. It can be used as a fiducial implant post-biopsy for future identification or monitoring of the tissue, and as an intra-operative localization mark. The microparticles of OneMark marker can be detected by Doppler ultrasound, magnetic resonance imaging (MRI), radiography, and OneMark Detector. During surgery, the OneMark marker may be removed with the target tissue. If patients do not require surgery, the OneMark marker can be left in place."
218873546|NCT04318600|DRUG|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
218873547|NCT00547040|OTHER|no intervention|no intervention
218873548|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
218873549|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
218873550|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
218873551|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
218873552|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
218873553|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
218873554|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
218873555|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
218873556|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
218873557|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
218873558|NCT01032824|OTHER|Book Arm|Book only.
218873559|NCT06171074|BIOLOGICAL|CM310|CM310 injection
218873560|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
218873561|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
218873562|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
218873563|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
219493905|NCT06653790|BEHAVIORAL|Psychosocial stimulations|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
219493906|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
218873564|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
218873565|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
218873566|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
218873567|NCT02882386|OTHER|Strength Training|
218873568|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
219602268|NCT06875310|DRUG|Adagrasib|Specified dose on specified days
219602269|NCT06875310|DRUG|Pembrolizumab|Specified dose on specified days
218873569|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
219493907|NCT05103410|DRUG|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
219493908|NCT05103410|DRUG|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
219493909|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
219493910|NCT05480488|DRUG|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
219493911|NCT05480488|DRUG|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
219493912|NCT05480488|DRUG|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
219493913|NCT06541613|DRUG|local anesthetic injection (bupivacaine)|The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
219493914|NCT06541613|OTHER|normal saline injection|the control group will receive 30ml of normal saline bilaterally into the external oblique intercostal plane on both sides
219493915|NCT00727298|BIOLOGICAL|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
219493916|NCT02176642|DRUG|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
219493917|NCT02176642|DEVICE|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
219493918|NCT02176642|DRUG|Placebo|Tablet taken by mouth daily for 6 weeks
218873570|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
218873571|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
218873572|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
218873573|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
218873574|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
218873575|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
218873576|NCT01979939|DRUG|DCV/ASV/BMS-791325|
218873577|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
218873578|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
218873579|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
218873580|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
218873581|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
218873582|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
218873583|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
218873584|NCT02365571|DRUG|LY3154207|Administered orally
219493919|NCT03510013|PROCEDURE|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
218873585|NCT02365571|DRUG|Placebo|Administered orally
218873586|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
219493920|NCT03510013|DRUG|Sevoflurane|Drug used for wash-in protocol
219602270|NCT06875310|DRUG|Carboplatin|Specified dose on specified days
218873587|NCT00000652|DRUG|Zidovudine|
218873588|NCT00000652|DRUG|Didanosine|
218873589|NCT06754098|DRUG|Doxecitine and Doxribtimine|A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
218873590|NCT02488642|DRUG|Isosorbide Dinitrate|
218873591|NCT02488642|DRUG|Misoprostol|
218873592|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
218873593|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
218873594|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
218873595|NCT02643589|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
219023192|NCT05782751|PROCEDURE|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
219023193|NCT00846755|DRUG|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
219023194|NCT03455660|OTHER|no intervention|no intervention
219493921|NCT00653887|OTHER|Biofeedback|4 sessions of biofeedback one session each week
219023195|NCT00000751|DRUG|Anti-HIV Immune Serum Globulin (Human)|
218873596|NCT04268173|OTHER|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
218873597|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
218873598|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
218873599|NCT00442325|DRUG|Atorvastatin (Lipitor)|
218873600|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
218873601|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
218873602|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
218873603|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
218873604|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
218873605|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
218873606|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
218873607|NCT00545103|DRUG|Placebo|Placebo administered Once Daily (QD)
218873608|NCT00427882|DRUG|ALFUZOSIN|
218873609|NCT02418104|DRUG|CHS-1701|
218873610|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
218873611|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
218873612|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
218873613|NCT00861718|DRUG|Placebo|Capsule, Oral BID
218873614|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
218873615|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
218873616|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
219023196|NCT00000751|DRUG|Globulin, Immune|
219023197|NCT00000751|DRUG|Zidovudine|
219023198|NCT04176900|OTHER|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
219493922|NCT00653887|OTHER|Placebo|4 sessions, one each week, of discussion about anorectal disease
219493923|NCT00508235|BEHAVIORAL|Questionnaire|Questionnaire about the patient's relationship with their best friend.
219493924|NCT03717974|OTHER|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
219493925|NCT03717974|OTHER|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
219023199|NCT04176900|OTHER|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
219493926|NCT04419077|BEHAVIORAL|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
219493927|NCT01309828|DRUG|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
219493928|NCT01309828|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
219493929|NCT00295620|DRUG|Anastrozole|1mg tablet daily
219493930|NCT00217971|DRUG|Dronabinol|Dronabinol
219493931|NCT00217971|DRUG|Placebo|placebo
219493932|NCT02809534|DRUG|Anlotinib|Anlotinib p.o. qd
219493933|NCT02989610|DEVICE|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
219493934|NCT02989610|DEVICE|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
218873617|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
218873618|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
218873619|NCT00436592|DEVICE|NeuroFlo™ Catheter|45 minute Treatment
219023200|NCT05759442|DRUG|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
219023201|NCT05759442|DIETARY_SUPPLEMENT|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
219023202|NCT04718220|DIAGNOSTIC_TEST|Antibody testing for SARS-CoV-2 IgG|Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.
219023203|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 RNA|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.
219023204|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 IgM/IgG|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
219023205|NCT06019325|PROCEDURE|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
219023206|NCT00624494|DEVICE|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
219023207|NCT00624494|DEVICE|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
219023208|NCT01433679|BEHAVIORAL|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
219023209|NCT04355325|DEVICE|modified monolithic zirconia crowns|outcomes and complications of implant restoration
219023210|NCT04355325|DEVICE|Metal Ceramic crowns|outcomes and complications of implant restoration
219023211|NCT01852942|DRUG|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
219023212|NCT01852942|DRUG|Placebo|one tablet by mouth daily
219023213|NCT03346499|BIOLOGICAL|NK cells and IL-2|Natural Killer Cells
219023214|NCT05371574|DRUG|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
219023215|NCT01921179|BEHAVIORAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
219023216|NCT01921179|BEHAVIORAL|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
219023217|NCT00874354|DRUG|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
219023218|NCT05279820|PROCEDURE|Partial pulpotomy|Partial pulp tissue amputation
219023219|NCT05279820|PROCEDURE|Full Pulpotomy|Full Pulpotomy
219493935|NCT00068653|DRUG|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
219493936|NCT00068653|DRUG|ZD1839|ZD1839 250 mg po every day, taken with or without food.
219493937|NCT04179474|DRUG|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
219602271|NCT06875310|DRUG|Pemetrexed|Specified dose on specified days
219023220|NCT01640483|OTHER|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
219023221|NCT02053181|DRUG|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
219023222|NCT06787508|DEVICE|TMS|Continuous high-frequency transcranial magnetic stimulation therapy Targeting the left M1 area, continuous high-frequency stimulation was performed at a frequency of 10Hz with 80-100% TEP for 5 minutes each time, twice a day for a total of 5 days
219023223|NCT06787508|DEVICE|TMS|Consistent with the experimental group protocol, the magnetic stimulation probe is a false stimulation probe that only produces sound but does not actually produce stimulation
219023224|NCT05816187|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program.
219023225|NCT05816187|BEHAVIORAL|Habitual|The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
219023226|NCT00049439|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
219023227|NCT00049439|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
219023228|NCT00049439|DRUG|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
219023229|NCT00049439|DRUG|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
219023230|NCT00049439|DRUG|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
219023231|NCT01089088|DRUG|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
219023232|NCT01089088|DRUG|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
219023233|NCT01089088|DRUG|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
219023234|NCT05791734|OTHER|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
219023235|NCT04693507|DRUG|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
219493938|NCT04179474|DRUG|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
219602272|NCT06875310|DRUG|Placebo|Specified dose on specified days
219602273|NCT06875310|DRUG|Cisplatin|Specified dose on specified days
219602274|NCT05458674|DRUG|Tucatinib|taken orally
219602275|NCT05458674|DRUG|Eribulin|taknen intravenously
219493939|NCT04179474|DRUG|Galcanezumab|2 SC injections of galcanezumab 120 mg \[Intervention C\].
219493940|NCT02643810|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
219602276|NCT05458674|DRUG|Trastuzumab|taken intravenously
219602277|NCT02503787|DEVICE|Spinal Cord Stimulation (SCS)|SCS programming options
218873620|NCT04181177|OTHER|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
218873621|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
218873622|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
219493941|NCT01532349|DRUG|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
219493942|NCT04609865|DRUG|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
219493943|NCT04609865|DRUG|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
219493944|NCT02556632|DRUG|Curcumin-based Gel|Applied topically
219493945|NCT02556632|PROCEDURE|Dermatologic Complications Management|Apply HPR Plus topically
218873623|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
218873624|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
218873625|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
218873626|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
218873627|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
218873628|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
218873629|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
218873630|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
218873631|NCT04627935|BEHAVIORAL|The COPD Assessment Test|Used to assess symptoms in COPD patients.
218873632|NCT04627935|DIAGNOSTIC_TEST|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
218873633|NCT04627935|BEHAVIORAL|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
218873634|NCT04627935|BEHAVIORAL|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
218873635|NCT04627935|BEHAVIORAL|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
218873636|NCT00082381|DRUG|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
218873637|NCT00082381|DRUG|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
218873638|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
218873639|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
218873640|NCT03292276|DEVICE|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
218873641|NCT03465930|PROCEDURE|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
218873642|NCT05600582|BIOLOGICAL|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
219493946|NCT02556632|OTHER|Laboratory Biomarker Analysis|Correlative studies
218873643|NCT00154128|DEVICE|occlusal appliance|
219493947|NCT02556632|OTHER|Placebo|Apply placebo gel topically
218873644|NCT04635813|PROCEDURE|Thyroidectomy|Thyroidectomy
218873645|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
218873646|NCT02359227|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
218873647|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
218873648|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
218873649|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
218873650|NCT00683969|DRUG|placebo|po bid for 36 weeks
218873651|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
218873652|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
218873653|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
218873654|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
218873655|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
218873656|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
218873657|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
218873658|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
218873659|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
218873660|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
218873661|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
218873662|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
219493948|NCT02556632|OTHER|Questionnaire Administration|Ancillary studies
219493949|NCT04175652|BEHAVIORAL|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
219493950|NCT01357785|PROCEDURE|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
219493951|NCT02073188|DEVICE|iBGStar|
219493952|NCT02073188|DEVICE|Traditional Glucometer|
219493953|NCT00116285|BIOLOGICAL|Ragweed MATA MPL|
219493954|NCT03934437|BEHAVIORAL|mLTCR|mHealth-enhanced Linkage to Care and Retention
219493955|NCT03934437|BEHAVIORAL|LTCR|Linkage and Retention Services (Standard-of-Care)
219493956|NCT02574260|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection.
219493957|NCT03168269|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
219493958|NCT01066039|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
218873663|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
218873664|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
218873665|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
218873666|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
218873667|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
218873668|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
218873669|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
219023236|NCT04693507|DRUG|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
219023237|NCT04991181|DRUG|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
219023238|NCT04377360|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
219023239|NCT05310045|BEHAVIORAL|Personalised primary prevention intervention|"Personalised primary prevention intervention~1. Consultation 1~   * Assess caregiver's situation regarding their cancer risk factors~  * Explain the causal links between risk factors and cancer~  * Inform about national recommendations to prevent and limit cancer risk~  * Clarify informal caregiver situation with respect to national screening programs~  * Define a personalised primary prevention program~2. Implementation: personalised primary prevention program~   * Carried out by the informal caregiver~  * Supervised by the coordinating nurse~3. Consultation 2~   * Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~  * Identify barriers and facilitators to their implementation whether actions or no actions have been done.~  * Adapt the personalised primary prevention program to informal caregiver needs."
219023240|NCT00486694|DRUG|Sulfadoxine-pyrimethamine + artesunate|
219023241|NCT00486694|DRUG|Chloroquine|
219023242|NCT01002755|DRUG|Lenalidomide|Given PO
219023243|NCT01002755|BIOLOGICAL|Ofatumumab|Given IV
219493959|NCT01083901|BEHAVIORAL|Resistance training|high intensity progressive resistance exercise training
219493960|NCT01397656|PROCEDURE|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
219493961|NCT01397656|PROCEDURE|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
219602278|NCT04787627|DEVICE|Power Knee|Powered microprocessor controlled prosthetic knee
218873670|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
218873671|NCT02029794|DRUG|3-5% acetic acid|
218873672|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
218873673|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
218873674|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
218873675|NCT02819401|OTHER|pediatric formula|high-fiber enteral formula
218873676|NCT00514462|DEVICE|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
218873677|NCT02453555|DRUG|Linagliptin|
218873678|NCT02453555|DRUG|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
218873679|NCT02453555|DRUG|Empagliflozin + linagliptin low dose|tablet
218873680|NCT02453555|DRUG|Linagliptin placebo|Matching placebo linagliptin
218873681|NCT02453555|DRUG|Empagliflozin + linagliptin high dose|tablet
218873682|NCT02453555|DRUG|Empa + lina highdose placebo|
218873683|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
218873684|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
218873685|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
218873686|NCT00129961|DRUG|sirolimus|
218873687|NCT00129961|DRUG|cyclosporine or tacrolimus|
218873688|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
219493962|NCT04508621|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
219493963|NCT04508621|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
219493964|NCT00808015|DRUG|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
218873689|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
218873690|NCT00332553|DRUG|Raloxifene|
218873691|NCT00332553|DRUG|medroxyprogesterone acetate|
218873692|NCT00332553|DRUG|estrogen|
218873693|NCT00332553|DRUG|17 beta estradiol|
218873694|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
218873695|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
218873696|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
218873697|NCT00224341|DEVICE|Pacemaker Vitatron Selection 9000|
218873698|NCT00224341|DEVICE|Pacemaker Vitatron T70|
218873699|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
218873700|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
219200101|NCT06872307|BEHAVIORAL|RAMP-It-Up Initiation, Adherence, and Retention Intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills
219493965|NCT00057785|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
219493966|NCT00057785|DRUG|fluorouracil|1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
219493967|NCT00057785|RADIATION|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
218873701|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
219200102|NCT06871085|DEVICE|Stability Sock|Use of a stability sock
219493968|NCT03567200|BEHAVIORAL|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
219493969|NCT06610279|DRUG|TAK-951|TAK-951 SC injection
219493970|NCT06610279|DRUG|Placebo|TAK-951 matching placebo SC injection
219493971|NCT06081946|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
219602279|NCT07019064|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
219602280|NCT05533827|OTHER|Kaleidoscope|Kaleidoscope
219602281|NCT05533827|OTHER|Music|Music
219602282|NCT05533827|OTHER|Virtual reality glasses|Virtual reality glasses
218873702|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
218873703|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
218873704|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
218873705|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
218873706|NCT00980304|DRUG|Rituximab|
218873707|NCT06946238|RADIATION|Adjuvant single-fraction accelerated partial breast irradiation|Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.
218873708|NCT01608841|DRUG|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
218873709|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
218873710|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
218873711|NCT04231916|DEVICE|Thermal imaging device|
218873712|NCT01873651|DEVICE|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
218873713|NCT00554762|DRUG|GW842166X|Administer
218873714|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
218873715|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
218873716|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
218873717|NCT05345028|DIETARY_SUPPLEMENT|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
219200103|NCT06869356|PROCEDURE|D2 gastrectomy|Under the requirement of the guideline for laparoscopic gastrectomy for gastric cancer (2016 edition), laparoscopic radical gastrectomy is performed in patients.
218873718|NCT05345028|COMBINATION_PRODUCT|Placebo|250 mg for 5 days
218873719|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
219023244|NCT04295421|PROCEDURE|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
219023245|NCT04295421|PROCEDURE|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
219200104|NCT06866483|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
219200105|NCT06866483|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
219493972|NCT06081946|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
219493973|NCT03717298|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
219493974|NCT04212741|DIETARY_SUPPLEMENT|A+ HA(tm)|oral solution of hyaluronic acid mixture
219493975|NCT04212741|DIETARY_SUPPLEMENT|Placebo|oral solution with no-active ingredients
219493976|NCT03528967|DRUG|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
219493977|NCT03528967|DRUG|Aspirin 100 mg Oral Tablet, Enteric Coated|
219493978|NCT06540365|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
219493979|NCT01725737|DRUG|GlyTI-M|
219602283|NCT06714955|DRUG|Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
219602284|NCT06714955|DRUG|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
218873720|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
218873721|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
218873722|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
218873723|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
218873724|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
218873725|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
219023246|NCT03251573|OTHER|cognitive impairment|one are of patients were exposed to cognitive impairment
219023247|NCT03046199|OTHER|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
219023248|NCT03046199|OTHER|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
219023249|NCT06148272|DRUG|LY3971297|Administered SC
219023250|NCT06148272|DRUG|Placebo|Administered SC
219023251|NCT06148272|DRUG|LY3971297 IV|Administered IV
219023252|NCT01388075|DRUG|Rifampicin|oral, 450 mg/day , 7 days
219023253|NCT03348085|OTHER|No intervention|No intervention.
219040191|NCT00816725|BEHAVIORAL|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
219040192|NCT01194947|DEVICE|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
219040193|NCT04152889|DRUG|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
219040194|NCT04152889|DRUG|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
219040195|NCT04152889|DRUG|Docetaxel|Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
219040196|NCT00500422|DRUG|Doxil|Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
219040197|NCT00500422|DRUG|Gemcitabine|500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
219493980|NCT01725737|DRUG|Placebo|Placebo Comparator: starch
219040198|NCT00500422|DRUG|Velcade|Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
219493981|NCT00084617|DRUG|oxaliplatin|Given IV
218873726|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
218873727|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
218873728|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
218873729|NCT02851823|DEVICE|Periodontal curettes|
219023254|NCT00858442|PROCEDURE|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
219200106|NCT06866483|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
219493982|NCT00084617|DRUG|irinotecan hydrochloride|Given IV
219493983|NCT00084617|DRUG|capecitabine|Given orally
219493984|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
219493985|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
219493986|NCT01625286|DRUG|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
219493987|NCT01625286|DRUG|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
219493988|NCT00377715|DRUG|Dimebon|
218873730|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
218873731|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
218873732|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
218873733|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
219023255|NCT02629692|DRUG|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
219023256|NCT06308809|OTHER|PNF training|The subjects underwent rehabilitation training for 8 weeks, three times a week (Monday, Wednesday and Friday, 6:00 PM to 10:00 PM in the Physical Education College of Guangxi Normal University), and the rehabilitation training time was about 40-45 minutes per person. Before each rehabilitation training, the subjects warmed up the ankle and lower leg muscles for 5 minutes, followed by the corresponding rehabilitation training for 30-35 minutes, and relaxed the ankle and lower leg muscles for 5 minutes after the training.
219023257|NCT02710890|DRUG|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
219200107|NCT06866561|OTHER|aerobic exercise|The exercise group participated in a supervised aerobic exercise program consisting of walking on a treadmill for 30 minutes per day, 3 days per week, at an intensity of 40-60% of maximal heart rate for 4 weeks. Additionally, they were shown an exercise program at the initial assessment that included balance, posture, and endurance exercises using body weight and weights to be performed 3 days a week, with 3 sets of 10 repetitions. The control group did not participate in any exercise program.
219200108|NCT06866561|OTHER|cholecalciferol|Participants were prescribed 2000 IU of vitamin D (cholecalciferol) daily for 12 weeks.
219200109|NCT06866561|OTHER|calcium carbonate|Participants were prescribed 1200 mg of calcium carbonate daily for 12 weeks.
219493989|NCT00377715|DRUG|Placebo|
219493990|NCT01033175|PROCEDURE|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
219493991|NCT01033175|PROCEDURE|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
219493992|NCT04718272|PROCEDURE|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
219493993|NCT00928135|DRUG|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
219493994|NCT00928135|DRUG|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
219493995|NCT03199898|DIAGNOSTIC_TEST|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
219493996|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
219493997|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
219493998|NCT03749525|DRUG|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
219493999|NCT03013517|DRUG|Viaskin Peanut 250µg|DBV712 250 µg, once daily
219494000|NCT04364542|PROCEDURE|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
219494001|NCT04364542|PROCEDURE|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
219494002|NCT04364542|PROCEDURE|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
219494003|NCT03338673|DEVICE|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
219494004|NCT03338673|OTHER|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
219494005|NCT05991492|DEVICE|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I|Digital insomnia treatment
219494006|NCT00140738|BIOLOGICAL|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
219494007|NCT04187469|DRUG|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
219494008|NCT04187469|DRUG|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
219494009|NCT00327652|DRUG|CRS-100|Live-attenuated Listeria monocytogenes
219494010|NCT06320093|OTHER|SOUND Intervention|The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
219494011|NCT00402207|DRUG|extrafine HFA-beclomethasone|
219494012|NCT00402207|DRUG|HFA-fluticasone|
219494013|NCT04471792|DRUG|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
219494014|NCT04471792|DIETARY_SUPPLEMENT|Cellulose|Cellulose will be used in combination with muscle stretching.
219494015|NCT04801030|BEHAVIORAL|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
219494016|NCT00434148|DRUG|Pasireotide|
219023258|NCT03801564|DEVICE|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
219200110|NCT06863714|DRUG|peritonsillar bupivacaine injection|Peritonsillar injection was superficially administered to the superior and inferior peritonsillar regions in a volume of 2-5 ml. A 23 Gouge needle syringe was used for injection. A 0.5% Bupivacaine was administered at a dose of 1 mg/kg (maximum dose of 25 mg)
219602285|NCT06714955|DRUG|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.|Drug: Placebo Administered SC
219602286|NCT05332821|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
218873734|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
218873735|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
218873736|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
218873737|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
218873738|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
218873739|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
218873740|NCT04679909|OTHER|Placebo|Administered intranasally
218873741|NCT02127177|DEVICE|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
218873742|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218873743|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218873744|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218873745|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
218873746|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
218873747|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
218873748|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
218873749|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
218873750|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
219023259|NCT03801564|DEVICE|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
219023260|NCT04298996|DIAGNOSTIC_TEST|taking saliva samples to determine oxidative stress markers TAS and TOS|
219023261|NCT03669120|OTHER|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
219023262|NCT03669120|BEHAVIORAL|Telephone-Based Intervention|Receive individualized text based messages
219023263|NCT04092166|OTHER|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
219023264|NCT01150929|DEVICE|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
219200111|NCT06867471|DIETARY_SUPPLEMENT|Ketone Diol, R-1,3-butanediol (Ketone-IQ)|Effect variables will be measured on the last day of treatment with Ketone-IQ
219602287|NCT05332821|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
219602288|NCT01429116|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
219602289|NCT04735861|DRUG|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
219602290|NCT04735861|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
219602291|NCT05214105|OTHER|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
219023265|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
218873751|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
218873752|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
218873753|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
218873754|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
218873755|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
218873756|NCT03254550|OTHER|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
218873757|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
218873758|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
218873759|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
218873760|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
218873761|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
218873762|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
218873763|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
218873764|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
218873765|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
218873766|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
218873767|NCT02925728|OTHER|Without Finger-Food|Without finger-food
218873768|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
218873769|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
219200112|NCT06867471|OTHER|Placebo drink|Effect variables will be measured on the last day of treatment with Placebo
219602292|NCT04487951|OTHER|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
218873770|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
219023266|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
219200113|NCT06661746|DRUG|Multimodal IV analgesia|Multimodal IV analgesia of lidocaine, ketamine and MS
219200114|NCT06661746|DRUG|epidural analgesia|Opioid-based and epidural analgesia
219602293|NCT00174954|PROCEDURE|MRI|Subjects underwent MRI to evaluate tophi.
219602294|NCT00224380|BEHAVIORAL|Using Medications Effectively|
219602295|NCT02258854|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
218873771|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
218873772|NCT01313962|OTHER|Placebo|Nasal spray
218873773|NCT03468894|BEHAVIORAL|Treadmill desk walking|See intervention arm description
218873774|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
218873775|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
218873776|NCT03189901|DRUG|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
218873777|NCT00135109|DRUG|SPM 927|
218873778|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
218873779|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
218873780|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
219200115|NCT06869616|OTHER|Cognitive Remediation|10 patients will undergo a rehabilitative training (Cognitive Remediation), already published and demonstrated to be feasible for patients with schizophrenia. This program includes domain-specific neurocognitive exercises aimed at training specific cognitive areas known to be impaired in schizophrenia. The treatment plan includes 15 45-minutes sessions.
218873781|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
218873782|NCT01042652|DRUG|Raltegravir|Raltegarvir 400mg bid
218873783|NCT01872013|DRUG|ASP7991|oral
218873784|NCT01872013|DRUG|Placebo|oral
218873785|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
219023267|NCT03051542|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
219023268|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
219023269|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
219200116|NCT06868940|DEVICE|wearable multi-channel ECG acquisition devices|If patients do not meet the exclusion criteria, they will wear the wearable multi-channel ECG device for 7 days after enrollment, followed by a myocardial SPECT examination; there is no specific order for these examinations. After enrollment, baseline information of the patients (such as age, gender, height, weight, etc.), comorbidities (such as hypertension, diabetes, hyperlipidemia, chronic kidney disease, etc.), and auxiliary examination data (such as complete blood count, biochemistry, cardiac injury markers, BNP, echocardiography, wearable multi-channel ECG device data, SPECT-related examination data, such as ST-segment, total load score, total rest score, etc.) will be collected. The endpoint of this study is to evaluate the sensitivity, specificity, and accuracy of the wearable multi-channel ECG device in assessing myocardial ischemia in CHD.
219200117|NCT06869538|OTHER|Exercise|For the Pilates exercises, a Pilates instructor created movements (squeeze mini ball, stretch hoop, circle with large ball, back and forth with large ball, and squat) in the gymnasium of the pregnancy school for 8 weeks, 2 days a week. Auxiliary equipment (mini ball, resistance band, Pilates ring) was used. Kegel exercises were performed 4 days a week, 3 sessions a day for 8 weeks.
219200118|NCT06871033|DRUG|TAP block with neostigmine|40 patients will receive postoperative TAP block with 20ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 500 microgram neostigmine for each side.
218873786|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
218873787|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
218873788|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
218873789|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
219023270|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
219023271|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
219023272|NCT01520116|DRUG|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
219023273|NCT01520116|DRUG|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
219023274|NCT01520116|DRUG|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
219023275|NCT01520116|DRUG|Timoptic|0.5%
219023276|NCT00056030|BIOLOGICAL|cetuximab|
219023277|NCT00056030|DRUG|fluorouracil|
219023278|NCT00056030|DRUG|leucovorin calcium|
219023279|NCT00056030|DRUG|oxaliplatin|
219023280|NCT05351346|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
218873790|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
218873791|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
218873792|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
218873793|NCT04303299|DRUG|Oral|Anti virus treatment
219023281|NCT05351346|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219023282|NCT05351346|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219023283|NCT05351346|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
219023284|NCT05351346|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
219023285|NCT05351346|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
219023286|NCT05351346|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
219023287|NCT05351346|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
219494017|NCT01845701|DRUG|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
218873794|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
218873795|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
219494018|NCT01845701|DRUG|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
219494019|NCT01845701|DRUG|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
219494020|NCT03354923|BEHAVIORAL|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
219494021|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
219494022|NCT03747094|DRUG|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
219494023|NCT03747094|DRUG|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
219494024|NCT01005407|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
219494025|NCT01005407|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
219494026|NCT05278949|OTHER|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
219494027|NCT04369079|OTHER|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
219494028|NCT04369079|OTHER|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
218873796|NCT01154751|DEVICE|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
219023288|NCT04968899|DRUG|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
219023289|NCT04968899|DRUG|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
219023290|NCT04875182|DIAGNOSTIC_TEST|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
219023291|NCT03745326|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
219023292|NCT03745326|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.
219023293|NCT03745326|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
219023294|NCT03745326|BIOLOGICAL|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
219200119|NCT06871033|DRUG|TAP block with Ketamine|40 patients will receive postoperative TAP block with 20 ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 0.5 mg/kg ketamine for each side.
219200120|NCT06871371|DEVICE|Sevoflurane (Volatile Anesthetic)|Both groups will be given sevoflurane and one group will be given low current anesthesia and the other group will be given medium flow anesthesia.
219494029|NCT05567094|DRUG|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
219494030|NCT05567094|DRUG|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
218873797|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
218873798|NCT00083928|DRUG|Å6 subcutaneous injection|
218873799|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
218873800|NCT01840098|DIETARY_SUPPLEMENT|low leucine content drink|
218873801|NCT01840098|DIETARY_SUPPLEMENT|high leucine content drink|
219200121|NCT06871371|DEVICE|low- medium flow anesthetic machine|The study aims to compare the effects of low and normal flow sevoflurane anesthesia on the frontal QRS-T angle and cerebral oxygenation in laparoscopic cholecystectomy surgery.
219200122|NCT06871007|DRUG|Nivolumab|Nivolumab 40 mg on Day 2 is added to dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R).Standard guidelines for conducting the DA-EPOCH-R protocol will be used.
218873802|NCT01840098|DIETARY_SUPPLEMENT|low leucine + HMB drink|
218873803|NCT01840098|DIETARY_SUPPLEMENT|Control/carbohydrate|
218873804|NCT01840098|BEHAVIORAL|36 hour fasting|
219494031|NCT04561934|DRUG|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
218873805|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
218873806|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
219494032|NCT04561934|OTHER|resin modified glassionomer cement|resin modified glassionomer cement
219494033|NCT01624155|BEHAVIORAL|Education|EMR referral to teratogen and contraception counseling
219494034|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
219494035|NCT04399850|OTHER|Hypnosis group|Patients who receive hypnosis
219494036|NCT04169425|PROCEDURE|elective diverting ileostomy|
219494037|NCT06420401|DIETARY_SUPPLEMENT|araboxylan|During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219494038|NCT06420401|DIETARY_SUPPLEMENT|inulin|During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219494039|NCT06420401|DIETARY_SUPPLEMENT|inulin and araboxylan|During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219494040|NCT06420401|DIETARY_SUPPLEMENT|placebo control|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219494041|NCT03461029|DEVICE|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
219494042|NCT04709029|DRUG|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
219494043|NCT04709029|DRUG|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
219494044|NCT04185701|OTHER|SiVIEW software|Eye examination by a technician with the SiVIEW software
219494045|NCT04185701|OTHER|Expert|Eye examination by an expert including optimal correction in distance and near vision
219494046|NCT01832545|OTHER|Aquatic Exercise|
219494047|NCT01832545|BEHAVIORAL|Educational Program|Control Group
219494048|NCT00275236|DRUG|Rotigotine|
219494049|NCT02630004|DRUG|Melatonin oral gel 3%|
219494050|NCT02630004|DRUG|Placebo oral gel|
219494051|NCT04501263|BEHAVIORAL|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
219494052|NCT01155635|DRUG|Carvedilol|Use of Carvedilol with any dose
219494053|NCT01155635|DRUG|No Carvedilol|No use of Carvedilol
219494054|NCT06303882|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
218873807|NCT00534833|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
218873808|NCT00534833|BIOLOGICAL|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
219023295|NCT04767074|OTHER|Non-pharmacological Cough control Therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations."
218873809|NCT00534833|BIOLOGICAL|Oral Polio Vaccine|0.5 mL, Oral
219023296|NCT06570681|DIAGNOSTIC_TEST|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
219494055|NCT06303882|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
219494056|NCT06303882|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
219494057|NCT02414490|DRUG|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
219494058|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
219494059|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume."
219494060|NCT06541912|PROCEDURE|conventional implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
218873810|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
218873811|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
218873812|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
218873813|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
218873814|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
218873815|NCT03992092|DEVICE|C-MAC VS|C-MAC Video Stylet
218873816|NCT03992092|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
218873817|NCT01707381|DRUG|BOL-303259-X|Topical ophthalmic solution
218873818|NCT01707381|DRUG|Timolol maleate|Topical ophthalmic solution
218873819|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
219023297|NCT05443334|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
218873820|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
218873821|NCT00955513|DRUG|Placebo|Placebo
218873822|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
218873823|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
218873824|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
218873825|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
218873826|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
219494061|NCT06541912|PROCEDURE|UV implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
219023298|NCT06701682|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
219023299|NCT06701682|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
219023300|NCT03174197|DRUG|Atezolizumab|Given IV
219023301|NCT03174197|RADIATION|Radiation Therapy|Undergo RT
219023302|NCT03174197|DRUG|Temozolomide|Given PO
219023303|NCT05838404|BEHAVIORAL|M-O-M-S on the Bayou|Peer and mentor support and meetings across pregnancy
219023304|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 1|Pharmaceutical form: suspension for injection Route of administration: intramuscular
219023305|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 2|Pharmaceutical form: suspension for injection Route of administration: intramuscular
218873827|NCT00086411|DRUG|placebo bupropion|placebo pills
218873828|NCT03218930|BEHAVIORAL|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
218873829|NCT03218930|BEHAVIORAL|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
218873830|NCT03218930|BEHAVIORAL|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
218873831|NCT03218930|BEHAVIORAL|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
219494062|NCT00731601|DRUG|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
219494063|NCT00731601|DRUG|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
218873832|NCT00661947|OTHER|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
218873833|NCT04901091|OTHER|Not Provided|Not Provided
218873834|NCT03220386|OTHER|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
218873835|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
219023306|NCT05608005|BIOLOGICAL|Unadjuvanted Panblok Dose 3|Pharmaceutical form: liquid for injection Route of administration: intramuscular
219023307|NCT02418923|OTHER|Procedure: Blood specimen collection|Blood specimen collection
219023308|NCT04322253|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
219023309|NCT01918904|DRUG|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
219023310|NCT01918904|DRUG|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
219023311|NCT02989740|PROCEDURE|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
219023312|NCT01859533|DEVICE|Neopuff|"* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
219023313|NCT04708886|DRUG|Romosozumab|Year 1 study drug
219023314|NCT04708886|DRUG|Alendronate|Year 2 study drug
219023315|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
219023316|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
219023317|NCT05351242|OTHER|Thermotherapy/sauna bath|Thermotherapy/sauna bath
218873836|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
219023318|NCT02498457|OTHER|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
219494064|NCT04056091|PROCEDURE|Back rub stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
218873837|NCT02039856|OTHER|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
218873838|NCT02039856|OTHER|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
218873839|NCT02039856|OTHER|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
218873840|NCT02039856|OTHER|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
218873841|NCT02039856|OTHER|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
218873842|NCT02039856|OTHER|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
218873843|NCT06502938|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
218873844|NCT06502938|PROCEDURE|Traditional artificial percutaneous coronary intervention|Doctors perform traditional percutaneous coronary intervention
218873845|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
218873846|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
218873847|NCT04892108|PROCEDURE|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
218873848|NCT04892108|PROCEDURE|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
218873849|NCT03675984|BEHAVIORAL|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
218873850|NCT06342596|DRUG|[14C]-LY3473329|Administered orally
218873851|NCT06342596|DRUG|[14C]-LY3473329|Administered IV
218873852|NCT06342596|DRUG|LY3473329|Administered orally
219023319|NCT00898157|OTHER|laboratory biomarker analysis|
219023320|NCT03238404|PROCEDURE|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
219023321|NCT03238404|PROCEDURE|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
218873853|NCT04839120|DRUG|MDPK67b|Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
219023322|NCT01372501|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
219023323|NCT04608786|DRUG|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
219023324|NCT04608786|DRUG|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
219023325|NCT04020393|PROCEDURE|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
219023326|NCT01466348|DRUG|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
219023327|NCT01466348|DRUG|Paracetamol|Paracetamol 1000 mg
219023328|NCT05966324|DRUG|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
219023329|NCT04139967|RADIATION|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
219200123|NCT06868888|OTHER|Blood collection|Erythrocyte osmotic deformability was evaluated via osmotic gradient ektacytometry.
219494065|NCT04056091|PROCEDURE|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
219494066|NCT02980562|DRUG|Polyethylene Glycols|(Split dose 2L PEG-Asc)
219494067|NCT02980562|DRUG|Bisacodyl|(1L PEG-Asc plus bisacodyl)
219494068|NCT06540274|PROCEDURE|lumbar surgery|Discectomy, lumbar fusion or laminectomy
219494069|NCT06536920|DIAGNOSTIC_TEST|Migraine screening questionnaire|Screening test
218873854|NCT04839120|DRUG|Placebo|Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
219023330|NCT05334901|DEVICE|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
219023331|NCT05362747|BEHAVIORAL|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
219023332|NCT04599374|OTHER|no intervention|This study collected data only without any intervention.
219023333|NCT03989440|DRUG|AXER-204|human NoGo Trap fusion protein
219023334|NCT03989440|DRUG|Placebo|Phosphate buffered saline formulation
219023335|NCT05405192|DRUG|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
219494070|NCT03862937|DIETARY_SUPPLEMENT|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
219494071|NCT03862937|OTHER|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
219494072|NCT00828516|OTHER|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
219494073|NCT05602974|RADIATION|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
219494074|NCT05602974|OTHER|regular follow-up|regular follow-up
218873855|NCT01441466|OTHER|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
218873856|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
218873857|NCT02409342|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
218873858|NCT02409342|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
218873859|NCT02409342|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
218873860|NCT02409342|DRUG|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
218873861|NCT02409342|DRUG|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
218873862|NCT02486250|OTHER|Validation Study|
219023336|NCT04136054|BEHAVIORAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
219023337|NCT04136054|OTHER|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
219023338|NCT03679780|DRUG|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
219494075|NCT02215239|BEHAVIORAL|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
218873863|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
218873864|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
218873865|NCT03908970|DRUG|1% OPA-15406|Twice daily
219602296|NCT06728683|OTHER|ASSIST-MH|The goal of this SBIR is to create Assist-MH, a new interactive digital support system for SMH providers. Assist-MH will offer an innovative suite of diverse MH strategies to help providers address the clinical needs of youth in distress. In Phase I, the focus will be on depression and anxiety for students ages 12 to 17 years. These MH problems are among the most common for youth, and have shown increasing prevalence in recent years among this age group. Investigators will conduct user-centered testing to determine the set of MH strategies most needed by SMH providers, create a sampling of these resources, and test the usability and promise of the proposed Assist-MH product prior to Phase II full development and pilot testing.
218873866|NCT03908970|DRUG|Placebos|Twice daily
218873867|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
218873868|NCT02280317|DRUG|VAL201|VAL201-001 Sub-cutaneous injection.
218873869|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
218873870|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
218873871|NCT04457492|OTHER|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
218873872|NCT01949610|DRUG|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
218873873|NCT03678168|OTHER|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
218873874|NCT03678168|OTHER|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
218873875|NCT02903732|OTHER|observational|registry
218873876|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
218873877|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
218873878|NCT03526510|RADIATION|Conventionally Fractionated versus Hypofractionated Boost|
218873879|NCT01605721|DEVICE|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
218873880|NCT02107157|DEVICE|755nm Laser with Cap Array|
218873881|NCT03262467|PROCEDURE|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
219494076|NCT06542471|DEVICE|Dual intramedullary nailing|\- Elastic nailing for radius under image guidance through distal entry point and physeal sparing technique.
219494077|NCT06542471|DEVICE|Dual plating|\- ORIF for radius done first through volar approach.
219494078|NCT04808960|DIAGNOSTIC_TEST|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine \& Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
219494079|NCT02350322|OTHER|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
219494080|NCT02350322|OTHER|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
219494081|NCT02350322|DIETARY_SUPPLEMENT|Supplement|Omega-3 capsules three times a week for 12 weeks
218873882|NCT03883087|DRUG|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
218873883|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
218873884|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
218873885|NCT05735249|DRUG|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
218873886|NCT05735249|DRUG|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
218873887|NCT00002077|DRUG|Fluconazole|
218873888|NCT03070899|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
218873889|NCT03070899|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
218873890|NCT03070899|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
218873891|NCT03070899|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
218873892|NCT01462617|DRUG|GSK2269557|Study Drug
218873893|NCT01462617|DRUG|GSK2269557 matching placebo|Study Drug
218873894|NCT06438055|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
218873895|NCT01510743|PROCEDURE|Catheterization of subclavian vein|Catheterization of subclavian vein
218873896|NCT01510743|PROCEDURE|Catheterization of internal jugular vein|Catheterization of internal jugular vein
219023339|NCT03679780|DRUG|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
219494082|NCT01051973|BEHAVIORAL|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
219602297|NCT02016703|OTHER|Erythritol drink|
219602298|NCT02016703|OTHER|Placebo drink|
218873897|NCT01152034|BEHAVIORAL|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
218873898|NCT03896945|DRUG|Placebo|oral capsules
218873899|NCT03896945|DRUG|AVP-786|oral capsules
218873900|NCT05727982|DIAGNOSTIC_TEST|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
218873901|NCT06464263|DRUG|Dexmedetomidine|to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
218873902|NCT05728268|DRUG|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
218873903|NCT03394586|DRUG|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
219023340|NCT03679780|DRUG|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
219023341|NCT03679780|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
219023342|NCT03679780|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
219023343|NCT03679780|DRUG|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
219023344|NCT01312090|BIOLOGICAL|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
219023345|NCT01312090|BEHAVIORAL|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
219023346|NCT02974296|DEVICE|transcranial magnetic stimulation|non invasive brain stimulation approach
219023347|NCT05725954|BEHAVIORAL|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
219023348|NCT06536777|OTHER|Plyometric Exercises|This include Plyometric Training for 8 weeks
219023349|NCT06536777|OTHER|Blood Flow Restriction Training|This include Blood Flow Restriction Training for 8 weeks
219023350|NCT02207790|DRUG|E2609|
219023351|NCT02207790|DRUG|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
219023352|NCT03704272|BEHAVIORAL|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
218873904|NCT00495625|DRUG|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
218873905|NCT01335269|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
219023353|NCT03970733|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
219023354|NCT03970733|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
219023355|NCT03693079|PROCEDURE|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
219023356|NCT02341807|BIOLOGICAL|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
219200124|NCT06868888|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary Exercise Testing (CPET) is a non-invasive assessment that evaluates the integrated function of the cardiovascular, pulmonary, and muscular systems during exercise.
219200125|NCT06872801|DEVICE|High-Flow Nasal Cannula|To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.
219200126|NCT06872801|DEVICE|Noninvasive Ventilation|to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD
219494083|NCT01051973|BEHAVIORAL|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
219494084|NCT01531062|DRUG|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
219494085|NCT01531062|DIETARY_SUPPLEMENT|black sticky rice|300 mg capsule bid, 56 days
219494086|NCT02936479|DRUG|C1-INH (Berinert)|
219494087|NCT06289335|DRUG|saline solution|20 mL of saline
219200127|NCT06681194|DRUG|Silver Nitrate|"See Silver nitrate only study arm"
219200128|NCT06681194|DRUG|triamcinolone|"See Triamcinolone only study arm"
219200129|NCT06681194|DRUG|Silver nitrate + triamcinolone|"See Combination group study arm"
218873906|NCT06051344|DRUG|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
218873907|NCT01912339|DEVICE|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
218873908|NCT01912339|PROCEDURE|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
218873909|NCT01900587|DRUG|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
218873910|NCT01900587|DRUG|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
218873911|NCT01609504|PROCEDURE|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
219023357|NCT03322488|PROCEDURE|Fistulodesis|"Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
219023358|NCT04834479|DEVICE|Ankle US and Ankle MRI|Ankle US and Ankle MRI
219023359|NCT00822068|DEVICE|anodal tDCS|anodal transcranial direct current stimulation
219023360|NCT00822068|DEVICE|cathodal tDCS|cathodal transcranial direct current stimulation
219023361|NCT00822068|DEVICE|sham stimulation|sham stimulation
219023362|NCT04850846|DRUG|Metformin XR|Orally by mouth
219023363|NCT04850846|OTHER|Placebo|Orally by mouth
219494088|NCT06536946|BIOLOGICAL|Immunohistochemical staining|Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
219494089|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
219023364|NCT01447524|BEHAVIORAL|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
219494090|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
219494091|NCT00300573|DRUG|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
219494092|NCT03633773|BIOLOGICAL|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
219494093|NCT02118207|OTHER|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
219494094|NCT06541821|OTHER|survey evaluation|assessment of physical activity, fear of movement, and ostomy compliance
219494095|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
219494096|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
219494097|NCT01552629|DRUG|QGE031|
219494098|NCT01552629|DRUG|Placebo|
219494099|NCT01552629|DRUG|Cyclosporine A|
219494100|NCT00046020|DRUG|Venlafaxine ER|
219494101|NCT01353794|DRUG|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
218873912|NCT01609504|PROCEDURE|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
218873913|NCT03870204|DIAGNOSTIC_TEST|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
218873914|NCT06030167|BEHAVIORAL|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
218873915|NCT01771796|BEHAVIORAL|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
218873916|NCT04647097|BEHAVIORAL|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
218873917|NCT04647097|BEHAVIORAL|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
218873918|NCT03666689|PROCEDURE|surgical technique|surgical reconstruction
218873919|NCT01811134|DEVICE|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
218873920|NCT01811134|DEVICE|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
218873921|NCT01623375|DRUG|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
218873922|NCT01623375|DRUG|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
218873923|NCT04934657|OTHER|no intervention|no intervention
218873924|NCT00001954|DRUG|Etanercept|
218873925|NCT01663064|DEVICE|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
218873926|NCT03464019|DRUG|Etripamil|Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
218873927|NCT03464019|DRUG|Placebo|Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
218873928|NCT03464019|DRUG|Etripamil Test Dose|During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
218873929|NCT01754493|DRUG|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
218873930|NCT06403917|OTHER|Evaluation of breast screening|Evaluation of breast screening program at egyptian women health intiaive
218873931|NCT05575193|OTHER|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
218873932|NCT04371939|DRUG|Romiplostim|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
218873933|NCT04371939|DRUG|Eltrombopag|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
218873934|NCT04694027|DRUG|Omega 3 fatty acid|omega 3 1000 mg
218873935|NCT04694027|DRUG|VitaE|vitamin e 400 mg
218873936|NCT05099666|DRUG|Lurbinectedin|Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
218873937|NCT05099666|DRUG|Doxorubicin|Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
218873938|NCT02392455|DRUG|treatment|Docetaxel plus nintedanib until progression or intolerability
218873939|NCT06087198|DIAGNOSTIC_TEST|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
218873940|NCT06799013|BIOLOGICAL|10 ug HDT 321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
218873941|NCT06799013|BIOLOGICAL|25ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
218873942|NCT06799013|BIOLOGICAL|50ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
218873943|NCT06211738|OTHER|no intervention|no intervention
219023365|NCT04259762|OTHER|Aim 8 (INT, Pilot Test): Breast, Colorectal, and Cervical Cancer Screening Cognitive-Behavioral Interventions|Adult men and women will receive age- and gender-specific INTs. Women age 45-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 45-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The cognitive-behavioral INTs on age-gender specific cancers will range from 1-2 hours. The study team will utilize a digital flipchart that will cover each cancer's specific risk/protective factors, incidence, mortality, screening methods, and resources. The study team member delivering the INTs will function as a facilitator linking information with practical skills.
219023366|NCT01203046|DRUG|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
219023367|NCT05719116|BEHAVIORAL|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
219023368|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
219023369|NCT05537402|DRUG|Atezolizumab and bevacizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
219023370|NCT05537402|RADIATION|transarterial chemoembolization (TACE) or transarterial radioembolization (TARE|TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
219023371|NCT02293655|DRUG|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
219023372|NCT02150954|DRUG|pitocin|
219023373|NCT01206647|DRUG|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
219023374|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
219023375|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
219494102|NCT03841903|DIAGNOSTIC_TEST|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
219494103|NCT05801107|DRUG|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
218873944|NCT04927897|DIAGNOSTIC_TEST|Ultrasound|3D endorectal ultrasound.
218873945|NCT04927897|DIAGNOSTIC_TEST|Rectoscopy|Rigid rectoscopy.
219023376|NCT05501184|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
219023377|NCT05501184|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
219023378|NCT03642210|COMBINATION_PRODUCT|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
219200130|NCT06681103|BEHAVIORAL|Personalized Normative Feedback|Those participating in this condition will receive a personalised brief report which summarises the results of their initial assessment. The PONF will comprise the following elements: (1) Details of the main gambling and trading activities performed, including frequency of engagement and amount of money spent; (2) Scores on the criteria of pathological trading and/or PGSI (pathological gambling), together with an interpretation of the results and the level of severity; (3) Summary of the areas (financial, emotional, etc.) that the participant has indicated as being affected by gambling or trading. All results will be accompanied by graphs enabling participants to compare their scores with the average scores of the Spanish population of the same sex and age range. To prevent an increase in behaviour in participants whose frequency or intensity of gambling/trading is below the norm, as recommended by Newall et al. (2023), the normative data will include extreme averages and percentages
219200131|NCT06872281|DEVICE|Fractional bipolar radiofrequency|The treatment group will receive a single treatment of intravaginal fractional bipolar radiofrequency therapy.
219200132|NCT06872281|DEVICE|Sham device|The sham group will receive treatment with a specialized sham device that mimics the treatment group's equipment. There are no differences in the design of the tip device, the auditory signal (beeping), or the pulse count display.
219494104|NCT02095210|OTHER|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
219494105|NCT05065242|BEHAVIORAL|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
219494106|NCT05445037|DEVICE|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
219494107|NCT05445037|DEVICE|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
218873946|NCT04927897|OTHER|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
218873947|NCT03172156|GENETIC|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
218873948|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
218873949|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
218873950|NCT04141449|OTHER|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
218873951|NCT04141449|OTHER|Enhanced care|Provider education and limited patient counseling.
218873952|NCT03291990|DRUG|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
218873953|NCT00769509|OTHER|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
218873954|NCT00769509|OTHER|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
218873955|NCT06583434|BEHAVIORAL|core-lower extremity Pilates Training Group|Participants in this group will engage in a stabilization-based Pilates exercise program focusing on core and lower extremity stabilization. The program consists of twice-weekly sessions, each lasting 50 minutes, over a period of 8 weeks. The primary goal of the intervention is to improve gait patterns and balance in women with flexible pes planus
218873956|NCT06583434|OTHER|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study.
218873957|NCT06095609|OTHER|Early mobilization plus chest physiotherapy|"Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay."
218873958|NCT01543776|DRUG|abiraterone acetate|Given PO
218873959|NCT06530966|DRUG|ICP-332 Tablets|Eligible patients will receive ICP-332 tablets orally as per the protocol
218873960|NCT06530966|DRUG|ICP-332 Placebo Tablets|Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
218873961|NCT02146001|OTHER|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
218873962|NCT02146001|OTHER|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
218873963|NCT04431492|PROCEDURE|CABG|aminoacids and NO levels
219023379|NCT05240560|DRUG|BP1.3656|Histamine H3 receptor antagonist/inverse agonist
218873964|NCT04688788|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
218873965|NCT04688788|DRUG|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
218873966|NCT04688788|DRUG|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
218873967|NCT04688788|DRUG|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
218873968|NCT04688788|DRUG|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
218873969|NCT05508919|DEVICE|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
218873970|NCT05508919|OTHER|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
218873971|NCT00254670|DRUG|Naltrexone|
218873972|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
218873973|NCT00785980|DRUG|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
218873974|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
218873975|NCT02459678|BEHAVIORAL|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
218873976|NCT02459678|OTHER|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
219023380|NCT04892043|BIOLOGICAL|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
219023381|NCT04892043|DRUG|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
219023382|NCT04892043|DRUG|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
218873977|NCT03055013|PROCEDURE|Nephrectomy|Undergo nephrectomy
218873978|NCT03055013|BIOLOGICAL|Nivolumab|Given IV
218873979|NCT03055013|OTHER|Patient Observation|Undergo observation
218873980|NCT03055013|OTHER|Quality-of-Life Assessment|Ancillary studies
218873981|NCT03055013|OTHER|Questionnaire Administration|Ancillary studies
218873982|NCT06066398|PROCEDURE|medical thoracoscope|Medical thoracoscopy will be performed during which pleural brush will be used first followed by forceps biopsy to obtain pleural specimens from suspect areas under visual control and pleural lavage will be performed by injecting 300 mL of normal saline
219023383|NCT04473937|RADIATION|Radiotherapy|Radiotherapy at pre-determined dose and schedule
219023384|NCT05126342|DRUG|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
219023385|NCT05126342|DRUG|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
219023386|NCT02709031|DRUG|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
219023387|NCT02709031|DRUG|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
219023388|NCT06260709|DRUG|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
219023389|NCT00729027|DRUG|25 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
219023390|NCT00729027|DRUG|50 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
219023391|NCT00729027|DRUG|placebo|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
219023392|NCT02248350|BEHAVIORAL|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
219023393|NCT02248350|BEHAVIORAL|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
218873983|NCT06066398|DIAGNOSTIC_TEST|Forceps biopsy and pleural brush histopathology|Forceps biopsy and pleural brush will be obtained for histopathological examination for diagnosis
219023394|NCT05637112|OTHER|None (Observational study)|Not Applicable since Observational Study
219023395|NCT02881242|OTHER|Laboratory Biomarker Analysis|Correlative studies
219023396|NCT02881242|OTHER|Quality-of-Life Assessment|Ancillary studies
219023397|NCT02881242|DRUG|Trametinib|Given PO
219023398|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
219023399|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
219023400|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
219023401|NCT00531024|DRUG|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
219023402|NCT00531024|DRUG|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
219023403|NCT00914355|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
219494108|NCT03881722|DIETARY_SUPPLEMENT|Mg alginate|Mg alginate after feedings
219494109|NCT01658215|DRUG|V0116 transdermal patch (Test treatment )|
219494110|NCT01658215|DRUG|Nicotine transdermal patch (Reference treatment )|
219494111|NCT02379676|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
219494112|NCT02379676|DRUG|Clopidogrel|Clopidogrel 75mg once daily for 30 days
218873984|NCT06066398|DIAGNOSTIC_TEST|pleural lavage cytology|pleural lavage will be obtained for cytological examination for diagnosis
218873985|NCT04036526|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
218873986|NCT04036526|OTHER|Placebo|Placebo
218873987|NCT00528801|BEHAVIORAL|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
218873988|NCT00528801|PROCEDURE|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
218873989|NCT06354088|DRUG|Alpelisib 300 mg|All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.
218873990|NCT06354088|DRUG|Placebo|All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
218873991|NCT06354088|DRUG|[1-13C] sodium acetate|All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
218873992|NCT06354088|DRUG|[6,6-2H2] D-glucose|All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
218873993|NCT06354088|DIETARY_SUPPLEMENT|Nestlé BOOST Plus|All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)
218873994|NCT00344500|BEHAVIORAL|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition"
218873995|NCT04130672|PROCEDURE|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
218873996|NCT04130672|PROCEDURE|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
218873997|NCT01078649|DRUG|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
218873998|NCT03691870|PROCEDURE|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
218873999|NCT03691870|PROCEDURE|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
218874000|NCT05096000|BEHAVIORAL|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
218874001|NCT05096000|OTHER|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
218874002|NCT05705362|PROCEDURE|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
218874003|NCT05705362|PROCEDURE|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
218874004|NCT05973253|DRUG|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
218874005|NCT04361578|DIAGNOSTIC_TEST|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
218874006|NCT04348981|DEVICE|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
219200133|NCT06873243|BEHAVIORAL|Learning Health System Approach|Our intervention will be informed by the framework for designing LHSs developed by The Health Foundation and the updated framework for developing and evaluating complex evaluations commissioned by the UK Medical Research Council and National Institute for Health Research.The updated framework considers not only if an intervention is effective, but also whether the intervention is acceptable, implementable, cost-effective, scalable, and transferrable across contexts. The trial will encompass three of the four key components of complex intervention design: Development of an intervention Assessment of feasibility of the intervention, and Evaluation of the intervention. . We anticipate that a Plan Do Study Act (PDSA) cycle of quality improvement will be most suited to the Thai context as this approach is currently being promoted by the Thai Ministry of Public Health.
218874007|NCT01237236|DRUG|LEE011|
218874008|NCT00126776|BEHAVIORAL|case management|case/self management for COPD vs usual care
218874009|NCT00126776|BEHAVIORAL|usual care|usual care for COPD
218874010|NCT01958983|BEHAVIORAL|Music Therapy Group Session|
218874011|NCT06208995|OTHER|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys\_tools/mos/36-item-short-form/survey-instrument.html
218874012|NCT05977764|OTHER|Ultrasound|Contrast enhanced ultrasound
218874013|NCT05221229|DRUG|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
219023404|NCT06150976|BEHAVIORAL|MAAT-YS|MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
219200134|NCT06873087|DRUG|İsotretinoin|Isotretinoin treatment at a dose of 0.3 mg/kg/day for 3 months
219494113|NCT03368872|OTHER|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
218874014|NCT05286892|OTHER|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
219023405|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
219023406|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
219023407|NCT05962970|DRUG|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
219023408|NCT05962970|DRUG|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
219023409|NCT02278263|DRUG|Tranexamic Acid|Given intravenously or topically
219023410|NCT02278263|DRUG|Normal saline (0.9% NaCl)|Administered in all 3 groups
219023411|NCT06397352|OTHER|ShotBlocker®|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
219023412|NCT06397352|OTHER|Buzzy® Group|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
219023413|NCT04056442|DRUG|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
219023414|NCT04056442|DRUG|Placebo|Olive Oil Solution, 5%
219200135|NCT06871800|OTHER|blood withdrawal|10 ml of blood, two 5 ml tubes suitable for serum isolation. Blood collection will be done at admission in the rehabilitation department (T0), after completing 50% of their rehabilitation program (T1), and at discharge (T2)
219200136|NCT06871852|OTHER|a video-based physiotherapy and exercise program.|Video-Based Intervention Group: Participants in this group will receive videos detailing migraine triggers, precautionary measures, and a physiotherapy and exercise program. Each exercise will be thoroughly explained by a physiotherapist in the videos, enabling participants to perform the exercises correctly by following the verbal and visual instructions.
219494114|NCT03368872|OTHER|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
219494115|NCT03368872|OTHER|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
219494116|NCT00156286|DRUG|Gleevec|
218874015|NCT05286892|OTHER|Enhanced Education|See control group description above
219494117|NCT00393978|DRUG|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
219494118|NCT00393978|DRUG|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
219494119|NCT02437539|DRUG|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
219494120|NCT02437539|DEVICE|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
219494121|NCT06233175|OTHER|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
219494122|NCT06233175|OTHER|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
218874016|NCT00599755|RADIATION|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
218874017|NCT00599755|DRUG|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
218874019|NCT06042699|DIETARY_SUPPLEMENT|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
218874020|NCT06042699|DIETARY_SUPPLEMENT|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
218874021|NCT05148078|OTHER|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
218874022|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
218874023|NCT02893917|DRUG|Cediranib|Given PO
218874024|NCT02893917|DRUG|Olaparib|Given PO
218874025|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
218874026|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
219023415|NCT02227589|BEHAVIORAL|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
219023416|NCT02227589|BEHAVIORAL|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
219494123|NCT05052320|DEVICE|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
218874027|NCT00793169|PROCEDURE|Blood Draw|Serum levels were measured
218874028|NCT04274556|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
218874029|NCT05809063|OTHER|observational|document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
218874030|NCT01324869|BIOLOGICAL|KH902|Intravitreal injection of 0.5mg/eye/time KH902
218874031|NCT02489669|DEVICE|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
218874032|NCT05311267|OTHER|Action observation training|Subject is asked to observe videos with motor contents
218874033|NCT00568126|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
218874034|NCT00568126|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
219023417|NCT02227589|OTHER|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
219023418|NCT05566990|BIOLOGICAL|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
219023419|NCT03043625|OTHER|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
219023420|NCT03043625|OTHER|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
219023421|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
219494124|NCT04581031|DEVICE|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
219494125|NCT04581031|OTHER|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
219494126|NCT03342326|OTHER|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
218874035|NCT06161480|DEVICE|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
218874036|NCT05035836|DRUG|Zanidatamab|Given IV
218874037|NCT05035836|DRUG|Letrozole|Given by PO
218874038|NCT05035836|DRUG|Tamoxifen|Given by PO
218874039|NCT03450382|OTHER|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
218874040|NCT05391022|DRUG|Pelabresib|Pelabresib monohydrate tablets
219023422|NCT04916470|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
219023423|NCT04916470|DRUG|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
219023424|NCT06068933|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
219023425|NCT06068933|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
219494127|NCT03342326|OTHER|Music Experience Questionnaire|questions about the past music training
219494128|NCT03342326|OTHER|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
219494129|NCT03342326|OTHER|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
219494130|NCT03871569|OTHER|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
219602299|NCT00839254|BIOLOGICAL|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
219023426|NCT06960967|OTHER|Chestnut meal|Participants will receive an isocaloric baked meal with chestnut flour.
218874041|NCT01019850|DRUG|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
218874042|NCT01019850|RADIATION|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
218874043|NCT01019850|PROCEDURE|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
218874044|NCT01019850|DRUG|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
218874045|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
219023427|NCT06960967|OTHER|Control meal|Participants will receive an isocaloric baked meal without chestnut flour.
219023428|NCT06838273|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219023429|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
219023430|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
219023431|NCT00598247|DRUG|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
219023432|NCT05328128|BEHAVIORAL|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
219023433|NCT06838208|DRUG|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f；
219023434|NCT04780763|OTHER|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
219023435|NCT01319903|BIOLOGICAL|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
219023436|NCT01463644|DRUG|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
219023437|NCT01463644|DRUG|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
219494131|NCT00226902|PROCEDURE|Changing hemoglobin concentration|
219494132|NCT02280642|BIOLOGICAL|Both 2nd and 3rd doses on time|
219494133|NCT02280642|BIOLOGICAL|2nd dose late and 3rd dose on time|
219494134|NCT02280642|BIOLOGICAL|2nd dose on time and 3rd dose late|
219494135|NCT02280642|BIOLOGICAL|Both doses late|
219494136|NCT05087199|DIAGNOSTIC_TEST|Rt-PCR.|Nasopharyngeal swab for Rt-PCR for COVID-19
219494137|NCT06292806|DRUG|FSH-R|controlled ovarian stimulation for IVF
219494138|NCT04040959|DRUG|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
219494139|NCT03586037|DRUG|AD-2011 10/20 mg|AD-2011 10/20 mg tablet
218874046|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
218874047|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
218874048|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
218874049|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
219494140|NCT03586037|DRUG|AD-2012 80mg|AD-2012 80mg tablet
219494141|NCT03586037|DRUG|AD-2011 10/20 mg + AD-2012 80mg|AD-2011 10/20 mg + AD-2012 80mg tablet
219494142|NCT01758315|OTHER|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
219494143|NCT04946422|PROCEDURE|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
219602300|NCT00839254|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.
218874050|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
218874051|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
218874052|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
218874053|NCT04623229|PROCEDURE|MCS|Manual Cataract Surgery
218874054|NCT04623229|PROCEDURE|ReLACS Early|ReLACS with early administration of anesthesia
218874055|NCT04623229|PROCEDURE|ReLACS Standard|ReLACS with standard time administration of anesthesia
218874056|NCT00680797|DRUG|Testosterone|Testosterone gel
218874057|NCT00680797|DRUG|Estrogen|Estrogen patch
218874058|NCT06130111|PROCEDURE|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
218874059|NCT01021904|BIOLOGICAL|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
218874060|NCT03122782|DRUG|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
218874061|NCT03122782|DRUG|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
218874062|NCT06208774|PROCEDURE|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
218874063|NCT04965662|DRUG|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
218874064|NCT04965662|DRUG|Truvada|Truvada one tablet once daily
218874065|NCT02337192|DRUG|Curcumin|
218874066|NCT02337192|DEVICE|LED|
218874067|NCT02337192|DRUG|Surfactant|
218874068|NCT02337192|DRUG|DMSO + water|
218874069|NCT02337192|DRUG|Chlorhexidine gluconate|
218874070|NCT04680975|DRUG|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
218874071|NCT01743742|DRUG|Vitamin E, Vitamin C|
218874072|NCT03747679|DRUG|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
218874073|NCT03747679|DRUG|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
218874074|NCT03747679|DRUG|Bosutinib Mannitol|Bosutinib mannitol solution
218874075|NCT03747679|DRUG|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
218874076|NCT03747679|DRUG|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
218874077|NCT03747679|DRUG|bosutinib taste low flavour|bosutinib solution low flavour
218874078|NCT03747679|DRUG|bosutinib high flavour|bosutinib solution high flavour
218874079|NCT03747679|DRUG|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
218874080|NCT03747679|DRUG|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
218874081|NCT03747679|DRUG|bosutinib capsules in water|sham comparator, bosutinb in water retest
218874082|NCT03747679|DRUG|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
218874083|NCT03747679|DRUG|bosutinib capsules high sweet|Bosutinib capsules high sweet
218874084|NCT03747679|DRUG|bosutinib capsules low flavour|Bosutinib capsules low flavour
218874085|NCT03747679|DRUG|bosutinib capsules high flavour|bosutinib capsules in high flavour
219494144|NCT02056574|DRUG|NA-1|
219494145|NCT02056574|DRUG|Placebo|
218874086|NCT05218642|DRUG|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
218874087|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
218874088|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
218874089|NCT05218642|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
218874090|NCT03909152|DRUG|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
218874091|NCT03909152|DRUG|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
219494146|NCT05449327|DRUG|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
219494147|NCT06542627|DEVICE|Freestyle Libre|Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
218874092|NCT05111353|BIOLOGICAL|Optimized neoantigen synthetic long peptide vaccine|Neoantigen vaccines will be provided on a patient-specific basis
218874093|NCT05111353|BIOLOGICAL|Poly-ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
219494148|NCT05347082|DRUG|Cholecalciferol|Tablets of 4000 IU
219494149|NCT01253889|DRUG|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
219494150|NCT01253889|OTHER|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
218874094|NCT06307535|BEHAVIORAL|Meaning-Centered Psychotherapy for Caregivers|MCP-C is a stakeholder-informed, innovative, manualized intervention designed to assist caregivers to connect to a sense of meaning and purpose in life, despite the challenges of caregiving.
218874095|NCT06307535|BEHAVIORAL|Supportive Psychotherapy for Caregivers|Standard of care supportive psychotherapy
218874096|NCT01171391|DRUG|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
218874097|NCT01171391|OTHER|Placebo|Placebo on Day 1
219023438|NCT05931302|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
219494151|NCT04154566|OTHER|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
219494152|NCT01528631|OTHER|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
219494153|NCT01528631|OTHER|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
219494154|NCT02585531|DRUG|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
219494155|NCT02585531|DRUG|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
218874098|NCT05522257|DIAGNOSTIC_TEST|[18F]-JK-PSMA-7 PET/CT scan|A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
218874099|NCT06520774|DEVICE|Concave Supra-arch Branched Stent-Graft System|To evaluate the efficacy and safety of Concave Supra-arch Branched Stent-Graft System for endovascular treatment of Aortic Arch Diseases
218874100|NCT00748254|PROCEDURE|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
218874101|NCT00748254|PROCEDURE|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
218874102|NCT06446089|BEHAVIORAL|THP: cognitive behavior therapy and behavioral activation|The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
218874103|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
218874104|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 1|Daplusiran/Tomligisiran dose level 1 will be administered
218874105|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 2|Daplusiran/Tomligisiran dose level 2 will be administered
218874106|NCT06537414|DRUG|Bepirovirsen|Bepirovirsen will be administered
218874107|NCT06537414|DRUG|Placebo|Placebo will be administered
218874108|NCT04857957|DRUG|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
218874109|NCT06343909|OTHER|Hip abductor strengthening exercise|in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
219023439|NCT05813964|DRUG|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
218874110|NCT06343909|OTHER|Intrinsic foot muscle strengthening along with conventional exercises|in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
218874111|NCT02615691|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
218874112|NCT02615691|BIOLOGICAL|ITI|Immune tolerance induction therapy
218874113|NCT06290661|DEVICE|Active electrostimulation|Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
218874114|NCT06290661|DEVICE|Placebo electrostimulation|No actual electrostimulation
218874115|NCT03179774|DEVICE|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
218874116|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
218874117|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
219023440|NCT05813964|DRUG|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
219023441|NCT05521412|DRUG|[ 161 Tb]Tb PSMA I&T|During dose escalation, doses of \[161 Tb\]Tb PSMA I\&T will range between 4.4 GBq to 9.5 GBq. The recommended phase 2 dose of \[161 Tb\]Tb PSMA I\&T will be used during dose expansion. \[161Tb\]Tb-PSMA-I\&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
219023442|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
219023443|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
219023444|NCT04327232|DRUG|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
219023445|NCT04327232|DRUG|Placebo oral tablet|Placebo
219023446|NCT00002631|DRUG|chemotherapy|
219023447|NCT00002631|DRUG|cisplatin|
219023448|NCT00002631|DRUG|fluorouracil|
219023449|NCT00002631|RADIATION|low-LET electron therapy|
219023450|NCT00002631|RADIATION|low-LET photon therapy|
219023451|NCT02596581|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
219023452|NCT03318250|DEVICE|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
218874118|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
218874119|NCT06801236|DRUG|ACE-232 tablets|ACE-232 tablets will be administered orally daily as a continuous regimen together with Dexamethasone and Fludrocortisone. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
219023453|NCT01127412|BEHAVIORAL|Physical activity stimulating program|
219023454|NCT05539391|OTHER|Data patient|Medical History and characteristic of patient
219023455|NCT05539391|OTHER|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
219023456|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
219023457|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
219023458|NCT04390204|OTHER|intervenions|"* Motor control exercises~* A supervised home self-rehabilitation program"
219023459|NCT03880019|PROCEDURE|Computed Tomography|Undergo CT
219023460|NCT03880019|PROCEDURE|Core Biopsy|Undergo tumor biopsy
219023461|NCT03880019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023462|NCT03880019|DRUG|Olaparib|Given PO
219023463|NCT03880019|DRUG|Temozolomide|Given PO
219023464|NCT03752112|DRUG|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
219602301|NCT00839254|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
219602302|NCT05937997|PROCEDURE|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
219602303|NCT05937997|PROCEDURE|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
219602304|NCT05937997|PROCEDURE|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
219602305|NCT04460560|DRUG|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
219023465|NCT03752112|DRUG|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
219023466|NCT03744533|OTHER|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
219023467|NCT03744533|OTHER|guideline-based treatment|guideline-based treatment
219023468|NCT02432534|DRUG|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
219602306|NCT05755776|DRUG|TMF|switch ETV to TMF
219602307|NCT02647827|OTHER|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
218874120|NCT06024590|DEVICE|Irrisept|Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
218874121|NCT06024590|DEVICE|Saline|Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
218874122|NCT06172075|BEHAVIORAL|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
218874123|NCT06172075|BEHAVIORAL|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
218874124|NCT06172075|BEHAVIORAL|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
218874125|NCT06172075|BEHAVIORAL|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
218874126|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
218874127|NCT06152341|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
218874128|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
218874129|NCT02546661|DRUG|MEDI4736|MEDI4736
218874130|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
218874131|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
219023469|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
219023470|NCT04906551|DEVICE|laser Doppler|A direct measure of blood flow
219494156|NCT04150926|OTHER|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
219494157|NCT04150926|OTHER|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
219494158|NCT04150926|OTHER|Quinoa base|The effect of black currant puree will be compared with quinoa base
218874132|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
219494159|NCT03724968|DRUG|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
219494160|NCT03724968|DRUG|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
219494161|NCT03724968|DRUG|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
218874133|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
218874134|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
218874135|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
218874136|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
218874137|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
218874138|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
218874139|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
218874140|NCT00226135|DRUG|lithium or lamotrigine|
218874141|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
218874142|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
218874143|NCT00261573|DRUG|galantamine hydrobromide|
218874144|NCT00390663|PROCEDURE|Nasal Cautery|
218874145|NCT06232577|DRUG|Hydrocodone|Given by PO
218874146|NCT06232577|DRUG|Tramadol|Given by PO
218874147|NCT06232577|DRUG|Oxycodone|Given by PO
218874148|NCT04615884|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
219023471|NCT06114147|DEVICE|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
219023472|NCT06114147|DEVICE|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
219023473|NCT06114147|DEVICE|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
219023474|NCT00326950|DRUG|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
219023475|NCT00957073|DEVICE|Rheos® system|Implant procedure
219023476|NCT02607891|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219023477|NCT02607891|DRUG|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219023478|NCT02002923|PROCEDURE|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
219023479|NCT02002923|DRUG|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
219023480|NCT05185128|BEHAVIORAL|PEERS social skills intervention|The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
219023481|NCT00519818|DRUG|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
219023482|NCT00519818|DRUG|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
219023483|NCT03711487|DRUG|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
219023484|NCT01053819|DRUG|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
218874149|NCT04615884|OTHER|Placebo capsules|Placebo
218874150|NCT02702414|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
218874151|NCT03291392|GENETIC|Gene expression or biomarkers exploration|
218874152|NCT05746156|DIAGNOSTIC_TEST|lymphatic mapping|"1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
218874153|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
218874154|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
218874155|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
218874156|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
218874157|NCT02343718|DRUG|Vinblastine|
218874158|NCT02343718|DRUG|Temsirolimus|
218874159|NCT05767190|BEHAVIORAL|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
218874160|NCT01167660|DEVICE|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
218874161|NCT00376766|DRUG|levetiracetam|
218874162|NCT06014099|BEHAVIORAL|Long peripheral venous catheters for blood collection|used LPC for blood collection
219023485|NCT01165255|DRUG|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
219023486|NCT01165255|DRUG|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
219023487|NCT01165255|DRUG|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
218874163|NCT06014099|BEHAVIORAL|Midline catheter for blood collection|used MCs for blood collection
218874164|NCT06014099|BEHAVIORAL|SPCs for blood collection|used SPCs for blood collection
218874165|NCT00597493|DRUG|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
219200137|NCT06871852|OTHER|brochure-based physiotherapy and exercise program.|"Brochure-Based Intervention Group: Participants in this group will be provided with brochures that include information on migraine triggers, precautionary measures, and rehabilitation exercises accompanied by visual aids. The exercises will be detailed with written instructions and illustrations.~Exercise Program: The exercise program will include self-massage techniques for specific muscle groups, self C1-C2 joint mobilization, cervical region exercises, cognitive exercises, and progressive relaxation exercises for the back and face."
219200138|NCT06871618|OTHER|Retrospective|Retrospective Operative risk in patients undergoing instrumental abortion
219602308|NCT02647827|DEVICE|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
219602309|NCT02647827|DRUG|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
218874166|NCT05150938|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
219602310|NCT02028494|DRUG|Capecitabine|Two dosages comparison
218874167|NCT05150938|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
218874168|NCT05150938|DRUG|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
218874169|NCT05150938|DRUG|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
218874170|NCT02021903|OTHER|V1: HGPO + meal and V2: placebo + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
218874171|NCT02021903|OTHER|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
218874172|NCT00151476|DRUG|Celecoxib|800 mg total daily dosing
218874173|NCT00151476|OTHER|Routine Medical Care|
218874174|NCT06250335|OTHER|Prebiotic Food-Enriched Diet|Given by PO
218874175|NCT06250335|DRUG|Ipilimumab|Given by IV
218874176|NCT06250335|DRUG|Nivolumab|Given by IV
218874177|NCT03446456|DRUG|Arginine vasopressin|Intranasal vasopressin will be administered shortly before the fMRI experiment.
218874178|NCT03446456|OTHER|Saline|Intranasal saline will serve as a placebo for participants in the Saline Arm
219023488|NCT01552252|DIETARY_SUPPLEMENT|apple juice|unaltered(0% POs-Ca) commercially available apple juice
219023489|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
219023490|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
219023491|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
219200139|NCT06873347|DEVICE|Procedure type|"• Patients undergoing one of the following surgeries:~* Supra cervical hysterectomy~* Total hysterectomy~* Breast conserving surgeries: B-plastic + periareolar mastopexy~* Breast conserving surgeries: segmental resection"
218874179|NCT03446456|BEHAVIORAL|Observational learning|During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.
218874180|NCT03446456|OTHER|fMRI data aquisition|All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
218874181|NCT06139289|PROCEDURE|EVD placements in the OR versus the bedside.|Reducing EVD-related complications
218874182|NCT02982876|PROCEDURE|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
219200140|NCT06873347|DEVICE||"• A dataset from procedure types other than the above mentioned to the type unknown is assigned to this type."
219200141|NCT06871605|PROCEDURE|ultrasound-guided transversalis fascia plane block|With the patient in the lateral decubitus position, an 8-12 Hz linear ultrasound (US) probe is placed transversely over the iliac crest. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The TA muscle is then advanced posteriorly until it tapers to the thoracolumbar fascia with its aponeurosis adjacent to the quadratus lumborum (QL) muscle. The 22 gauge block needle is advanced in plane with the US probe. After placing the needle tip in the virtual triangular plane between the posterior edge of the TA muscle, the QL and the underlying transversalis fascia, 4 mL of 0.5% bupivacaine + 2 mL of a total of 8 mg dexamethasone + 4 mL of saline are injected for a total volume of 10 mL.
219200142|NCT06871605|PROCEDURE|ultrasound-guided ilioinguinal and iliohypogastric nerve block group|With the patient in the supine position, an 8-12 Hz linear ultrasound (US) probe is placed medial and cephalal to the anterior superior iliac spine (ASIS), transversely between the ASIS and the umbilicus. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The II-IH nerves are hyperechogenic in the fascial plane between the IO and TA muscles. A 22 gauge block needle is advanced in plane with the US probe. When the needle tip is advanced to the II and IH nerves, 4 mL of 0.5% bupivacaine + 2 mL total 8 mg dexamethasone + 4 mL saline is injected for a total volume of 10 mL.
218874183|NCT02982876|PROCEDURE|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
218874184|NCT02982876|DEVICE|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
218874185|NCT06414278|OTHER|Non-Interventional Study|Non-interventional study
218874186|NCT04545957|DEVICE|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
218874187|NCT04545957|RADIATION|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
218874188|NCT06295783|OTHER|MDASI-HN|Given by Questionnaire
218874189|NCT06295783|OTHER|EORTC QLQ-C30|Given by Questionnaire
219023492|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
218874190|NCT06295783|OTHER|EORTC HN35|Given by Questionnaire
219023493|NCT03718767|DRUG|Nivolumab|IV Nivolumab
218874191|NCT04532931|DRUG|Paracetamol|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
218874192|NCT04532931|DRUG|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
218874193|NCT04532931|DRUG|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
218874194|NCT04532931|DRUG|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
218874195|NCT04532931|DRUG|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
219023494|NCT06698510|DRUG|Arpraziquantel 150mg dispersible tablet|Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
219023495|NCT02255721|BEHAVIORAL|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
219023496|NCT02255721|BEHAVIORAL|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
219023497|NCT03845907|DEVICE|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
219023498|NCT03845907|DEVICE|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
219023499|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
219023500|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
219602311|NCT02765425|DEVICE|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
218874196|NCT02917733|DRUG|LY3039478|Administered orally
218874197|NCT06257173|BEHAVIORAL|Education|The experimental group will receive 2 hours of patient safety training with a peer educator.
218874198|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
218874199|NCT06447506|DRUG|GSK1070806|Participants will receive GSK1070806.
219023501|NCT04824170|OTHER|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
219023502|NCT04824170|OTHER|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
219023503|NCT06216613|BEHAVIORAL|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics (SEA) utilizes the Sensory Profile to individualize lessons based on children's sensory preferences. The program incorporates evidence-based approaches for autistic children, including: 1) visual supports, 2) sensory supports, 3) communication strategies, 4) behavioral strategies, and 5) modeling to maximize skill acquisition. Lessons will be 1:1 with social opportunities at the beginning and end of each lesson. Like standard swim lessons, skills are taught in progression from water orientation (e.g., blowing bubbles, submerging different body parts) to advanced swimming (e.g., swimming 15 or more yards of different swim strokes). All lessons include instruction of water safety skills. Each skill has been task analyzed by therapists so instruction can be graded according to children's ability. A social story is provided to transition children to lessons. SEA curriculum was reviewed by USA Swimming Foundation and is included as a Swim Lesson Network Provider.
219023504|NCT06216613|BEHAVIORAL|Standard Swim Lessons|Standard swim lessons will adhere to USA Swimming Foundation Swim Network Provider requirements ensuring lessons meet or exceed industry best practices. Lessons have up to a 1:5 instructor to child ratio and will focus on stroke development and water-safety with skills advancing from water-orientation to stroke technique and endurance.
219023505|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
219023506|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
219023507|NCT03777007|DEVICE|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
219200143|NCT06872333|DRUG|Alemtuzumab|Alemtuzumab (Campath) will be administered IV over 2 hours on day -8 to day -4.
219602312|NCT00516373|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219602313|NCT05855122|DRUG|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
219602314|NCT02757573|PROCEDURE|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
219602315|NCT04835623|DRUG|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
219602316|NCT00506792|DRUG|QAU145|
219602317|NCT00506792|DRUG|Placebo|
219602318|NCT02424110|PROCEDURE|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
219602319|NCT02424110|PROCEDURE|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
219602320|NCT02424110|DEVICE|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
219602321|NCT02424110|DEVICE|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
219602322|NCT01138982|BEHAVIORAL|Youth Mentoring program|
219602323|NCT01307176|BEHAVIORAL|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
219602324|NCT00177359|BEHAVIORAL|gait intervention|
219602325|NCT02204306|GENETIC|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
219602326|NCT00919854|DRUG|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
219602327|NCT00919854|DRUG|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
219602328|NCT00789997|DRUG|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
219602329|NCT00789997|DRUG|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
219602330|NCT00789997|DRUG|levofloxacin|Levofloxacin 750 mg daily for 10 days.
219602331|NCT01484327|DRUG|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
218874200|NCT04099511|BEHAVIORAL|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
219494162|NCT06540313|OTHER|Stellate Ganglion Block|Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
219602332|NCT02174289|DEVICE|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
219602333|NCT02687529|DEVICE|CST001|
219602334|NCT05868512|DIAGNOSTIC_TEST|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
219200144|NCT06872333|RADIATION|Total Body Irradiation|400 cGy in 2 split fractions will be administered per Department of RadiationOncology SOPs.
219602335|NCT05868512|DIAGNOSTIC_TEST|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
219602336|NCT03703869|DRUG|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
219602337|NCT01522612|DRUG|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
219602338|NCT01522612|DRUG|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
219602339|NCT01522612|DRUG|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
219602340|NCT03709979|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
219602341|NCT05778903|OTHER|Nerve block|Suprazygomatic maxillary nerve block
219602342|NCT02374138|BEHAVIORAL|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
219602343|NCT02374138|OTHER|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
219602344|NCT03174379|PROCEDURE|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
219602345|NCT03174379|PROCEDURE|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
219602346|NCT00464438|DRUG|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
219602347|NCT00464438|DRUG|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
219602348|NCT01970800|DRUG|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
219602349|NCT03536533|OTHER|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
219602350|NCT05358509|DRUG|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
219602351|NCT05358509|DRUG|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
219602352|NCT05358509|DRUG|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
219602353|NCT06217211|DIETARY_SUPPLEMENT|Remolacha|BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
219602354|NCT04228497|DEVICE|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
219602355|NCT04228497|OTHER|the clear fluid intake|the clear fluid intake
219602356|NCT01977274|OTHER|gynecological cancer|blood and tumor samples
219602357|NCT02132793|BEHAVIORAL|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
219602358|NCT02132793|BEHAVIORAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
219023508|NCT05741411|OTHER|RPM-assisted specialist access|Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
219023509|NCT03913637|BEHAVIORAL|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
219200145|NCT06872333|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines
219602359|NCT02237703|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
219602360|NCT00166582|DEVICE|electronic medication monitoring system|
219602361|NCT00166582|BEHAVIORAL|parent-adolescent communication and problem-solving skills|
219602362|NCT01782430|PROCEDURE|- standard oxygenation|
219602363|NCT02296931|OTHER|Saline|Standard IV Saline Fluids
219602364|NCT02296931|DRUG|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
219602365|NCT02226601|DRUG|Aprepitant|3 days perioperative Aprepitant once a day
219602366|NCT02226601|DRUG|Placebo|3 days perioperative Placebot once a day
219602367|NCT03337269|OTHER|Educational video|Approximately 7 minute video on the HPV vaccine
219602368|NCT03337269|OTHER|Educational handout|One page handout on the HPV vaccine
219602369|NCT03337269|OTHER|Control|Control
219602370|NCT00394563|DRUG|RN624 (PF-04383119)|10 mcg/kg
219602371|NCT00394563|DRUG|RN624 (PF-04383119)|25 mcg/kg
219602372|NCT00394563|DRUG|RN624 (PF-04383119)|50 mcg/kg
219602373|NCT00394563|DRUG|RN624 (PF-04383119)|100 mcg/kg
219602374|NCT00394563|DRUG|RN624 (PF-04383119)|200 mcg/kg
219602375|NCT00394563|DRUG|placebo|
219602376|NCT06549855|DRUG|Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)|"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
219602377|NCT05769010|DRUG|SHR-A1811|SHR-A1811: intravenous
219602378|NCT05769010|DRUG|Pyrotinib|Pyrotinib: oral
219602379|NCT05769010|DRUG|Bevacizumab|Bevacizumab: intravenous
219602382|NCT01590277|DRUG|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
219602383|NCT01590277|DRUG|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
219602384|NCT01590277|DRUG|Placebo|Control: no alcohol, administered for a total of 90 minutes.
219494163|NCT03190018|DEVICE|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
219494164|NCT01142466|DRUG|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
219602385|NCT01590277|DRUG|Placebo|Control: no iomazenil, administered for a total of 10 minutes
219023510|NCT03913637|OTHER|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
219602386|NCT06218576|OTHER|None, purely observational study|None, purely observational study
219602387|NCT02159079|OTHER|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
219023511|NCT02863380|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
219023512|NCT02863380|DEVICE|Individualized rTMS (transcranial magnetic stimulation)|
219023513|NCT02863380|DEVICE|Classical rTMS (transcranial magnetic stimulation)|
219602388|NCT04539652|DRUG|Experimental|Experimental group are treated with TenofoBell®
219602389|NCT00805961|RADIATION|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
219023514|NCT02863380|DEVICE|Classical tDCS (transcranial direct current stimulation)|
219023515|NCT05587309|DRUG|BLI5100|Orally via tablet
219023516|NCT05587309|DRUG|PPI Control|Orally via tablet
219023517|NCT02972554|DRUG|Propanolol hydrochloride|One-time dose of 40mg of propranolol
219023518|NCT02972554|OTHER|Placebo|Outside casing matching that of active drug
219023519|NCT06287333|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
219602390|NCT00805961|DRUG|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
219602391|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
219602392|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
219023520|NCT02193373|OTHER|Osteopathic Manual Medicine|Osteopathic Manual Medicine
219602393|NCT00805961|DRUG|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
219602394|NCT05093361|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
219602395|NCT05093361|PROCEDURE|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
219602396|NCT04380961|DRUG|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
219602397|NCT04380961|DRUG|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
219602398|NCT04380961|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
219602399|NCT00562783|DRUG|Vitaliver|
219602400|NCT00562783|DRUG|Placebo|
219602401|NCT00002505|BIOLOGICAL|filgrastim|
219602402|NCT00002505|BIOLOGICAL|recombinant interferon gamma|
219602403|NCT00002505|BIOLOGICAL|tumor cell lysate vaccine therapy|
219602404|NCT06233773|PROCEDURE|Kinesio Taping|Kinesio Taping
219602405|NCT06233773|PROCEDURE|Manual Lymph Drainage|Manual Lymph Drainage Group
219602406|NCT06233773|OTHER|Control Group|Control Group
219602407|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
219602408|NCT06495112|DIAGNOSTIC_TEST|Soft contact lens with cast molding technique|Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
219602409|NCT01186484|DRUG|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
219602410|NCT02908087|DRUG|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
219602411|NCT02908087|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
219602412|NCT06742996|DRUG|Sonrotoclax|Administered orally
219602413|NCT06742996|DRUG|Zanubrutinib|Administered orally
219494165|NCT04084028|BEHAVIORAL|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
219602414|NCT06742996|DRUG|Placebo|Administered orally
219602415|NCT02687347|DRUG|oral methadone|Oral methadone is the study drug
218874201|NCT04099511|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
219494166|NCT04084028|BEHAVIORAL|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
219494167|NCT04084028|BEHAVIORAL|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
219494168|NCT04515511|OTHER|4% gelatin|Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
219023521|NCT02193373|OTHER|Sham|Osteopathic Manual Medicine
219023522|NCT02280772|DIETARY_SUPPLEMENT|Glucomannan|
219023523|NCT02280772|DIETARY_SUPPLEMENT|Maltodextrin|
219494169|NCT05974345|DRUG|Inclisiran sodium|Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
219602416|NCT02687347|DRUG|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
219602417|NCT01296997|DIETARY_SUPPLEMENT|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
219602418|NCT01296997|OTHER|placebo|the subjects consumed a bread without pentacalcium phosphate
219023524|NCT00988754|BEHAVIORAL|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
219023525|NCT02518555|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
219023526|NCT02518555|DRUG|Ibrutinib|Given PO
219494170|NCT05974345|DRUG|Placebo|Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
219602419|NCT03248973|DRUG|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
219602420|NCT05410964|DEVICE|VIO System|To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
219602421|NCT06894875|DIETARY_SUPPLEMENT|Lentil protein hydrolysate|Plant protein hydrolysate
219023527|NCT02518555|OTHER|Laboratory Biomarker Analysis|Correlative studies
219023528|NCT02518555|OTHER|Pharmacological Study|Correlative studies
219494171|NCT05974345|DRUG|Ezetimibe|Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
219602422|NCT06894875|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
219602423|NCT00970827|PROCEDURE|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
219602424|NCT02304029|DEVICE|MRI|
219494172|NCT05974345|DRUG|Evolocumab|Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
219494173|NCT03521544|OTHER|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
219494174|NCT03989180|DEVICE|C-Scan System|"* Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~* The recorder will be secured to their lower back to test its functionality"
219494175|NCT00779844|PROCEDURE|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
219494176|NCT00779844|PROCEDURE|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
219494177|NCT01140620|DRUG|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
219494178|NCT01140620|DRUG|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
219494179|NCT01140620|DRUG|saline|saline infusion. Duration approximately 3 hours
219494180|NCT01140620|DRUG|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
219494181|NCT02380066|DRUG|Anyu Peibo|Placebo
219494182|NCT02768220|DRUG|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
219494183|NCT02768220|DRUG|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
219494184|NCT00569231|DRUG|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
219494185|NCT01914822|DRUG|methylphenidate hydrochloride|
219494186|NCT01914822|DRUG|Sugar pill (placebo)|
219494187|NCT00004739|DRUG|Antiretroviral therapy|
219494188|NCT00002273|DRUG|Ganciclovir|
219494189|NCT02071758|BIOLOGICAL|LEISH-F3 + SLA-SE|
219494190|NCT02071758|BIOLOGICAL|LEISH-F3 + GLA-SE|
219494191|NCT02100241|PROCEDURE|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
219494192|NCT00821041|BEHAVIORAL|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
219494193|NCT04989621|DRUG|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
219494194|NCT04989621|DRUG|Orelabrutinib|Orelabrutinib 150mg po qd
219494195|NCT03974581|OTHER|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
219602425|NCT03736031|BEHAVIORAL|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
219602426|NCT01700231|PROCEDURE|Liver resection|Liver resection of patient with neoplastic hepatic tumors
219602427|NCT00334373|PROCEDURE|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
219602428|NCT03461601|PROCEDURE|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
219602429|NCT03461601|PROCEDURE|IUI|Intrauterine insemination (IUI)
219494196|NCT03974581|OTHER|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
219494197|NCT00700310|DRUG|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
219494198|NCT00700310|DRUG|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
219494199|NCT00700310|DRUG|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
219494200|NCT00700310|DRUG|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
219494201|NCT02739802|DRUG|Coppertone(BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
219494202|NCT04331652|PROCEDURE|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
219494203|NCT05659706|OTHER|cognitive evaluations and non cognitive evaluations|Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
219602430|NCT03461601|PROCEDURE|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
219602431|NCT05147012|OTHER|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
219602432|NCT00649779|DRUG|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
218874202|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
219023529|NCT02518555|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
219023530|NCT02518555|OTHER|Quality-of-Life Assessment|Ancillary studies
219023531|NCT02518555|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
219023532|NCT05926908|BEHAVIORAL|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
219023533|NCT05926908|BEHAVIORAL|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
219023534|NCT05926908|BEHAVIORAL|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
219023535|NCT05926908|BEHAVIORAL|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
219200146|NCT06872333|DRUG|Thymoglobulin|"ATG will be administered IV every 24 hours beginning on day -8 for all patients.~Dosing will be model-based using Bayesian methodology13,14,15. Total doses and total number of doses (1-4 doses) will be determined based on absolute lymphocyte count and weight."
219200147|NCT06872333|DRUG|Fludarabine|Fludarabine will be administered IV over 1 hour every 24 hours on day -5 to day - 2. The daily dose of fludarabine will be determined by model-based dosing utilizing Bayesian methodology with a cumulative area under the curve (cAUC) of 20 mg\*hr/L (range 18-22 mg\*hr/L).
219494204|NCT02076932|BEHAVIORAL|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
219494205|NCT04397354|DRUG|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
219494206|NCT04397354|DRUG|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
219494207|NCT04397354|DRUG|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
219602433|NCT00649779|DRUG|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
219602434|NCT04825340|BIOLOGICAL|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
219602435|NCT06282783|DRUG|Topiramate|Single dose of 400mg
218874203|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
218874204|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
219023536|NCT05926908|BEHAVIORAL|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
219023537|NCT05926908|BEHAVIORAL|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
219023538|NCT03628755|BEHAVIORAL|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
219200148|NCT06872333|DRUG|Busulfan|Busulfan dosing and administration and therapeutic drug monitoring (TDM) per institutional guidelines. Initial busulfan dosing will be determined by model-based dosing utilizing Bayesian methods with a cumulative area under the curve (cAUC) of 75 mg\*hr/L.
219494208|NCT04806477|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
219602436|NCT05286866|PROCEDURE|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
219602437|NCT02254265|DRUG|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
219602438|NCT02254265|DRUG|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
219602439|NCT02254265|DRUG|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
219494209|NCT04806477|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
219494210|NCT05189483|DRUG|Albumin-Bound Paclitaxel|Enrolled patients will receive 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
219494211|NCT05189483|DRUG|Camrelizumab|Enrolled patients will receive the following treatment: 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
218874205|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
219494212|NCT06190782|COMBINATION_PRODUCT|PD-1 inhibitor+/- chemotherapy combined with local therapy|"1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation"
219494213|NCT06190782|DRUG|systemic therapy alone|"1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)"
219494214|NCT01664273|DRUG|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
219494215|NCT01882231|OTHER|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
219494216|NCT06540092|DIAGNOSTIC_TEST|ultrasound|ultrasound measurements during first trimester
219494217|NCT03666546|DRUG|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
219494218|NCT03666546|DRUG|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
219494219|NCT03666546|DRUG|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
219494220|NCT03666546|DRUG|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
219494221|NCT03666546|DRUG|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
219494222|NCT03666546|DRUG|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
219494223|NCT01913873|OTHER|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
219494224|NCT01837420|DRUG|VB-201 80mg|
219494225|NCT01837420|DRUG|VB-201 160mg|
219494226|NCT01837420|DRUG|Placebo|
219494227|NCT00818831|DRUG|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
219494228|NCT01999231|BIOLOGICAL|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
219494229|NCT01572831|OTHER|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and \>4,000).
219494230|NCT05066074|PROCEDURE|Distal Radial Vascular Access|Distal Radial Vascular Access
219494231|NCT06016101|OTHER|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~* Pill counting~* Morisky questionnaire"
219494232|NCT06016101|OTHER|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~* Evaluation of user experience~* Evaluation of the report produced by the application"
219602440|NCT05801588|OTHER|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
219602441|NCT05801588|OTHER|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
219200149|NCT06872333|DRUG|Thiotepa|Thiotepa will be administered at a dose 5 mg/kg IV every 12 hours on day - 7 over 2 hours. Patients will undergo thiotepa skin care per institutional guidelines
219602442|NCT04244578|DEVICE|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
219602443|NCT04244578|DEVICE|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
219602444|NCT03672045|DRUG|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
219602445|NCT01954745|DRUG|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
219602446|NCT01729403|DRUG|aleglitazar|150 mcg orally daily, 16 weeks
219602447|NCT01729403|DRUG|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
219602448|NCT01729403|DRUG|placebo|orally daily, 16 weeks
219602449|NCT06264063|BEHAVIORAL|control group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
219602450|NCT06264063|BEHAVIORAL|experimental group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
219602451|NCT06264063|DIAGNOSTIC_TEST|EEG power in alpha band|partecipants were submitted to registration of electrical activity with EEG to study the EEG power in alpha band
219602452|NCT06736041|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219602453|NCT06736041|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219602454|NCT06736041|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219602455|NCT06736041|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
219602456|NCT06736041|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219602457|NCT06736041|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219602458|NCT06736041|BIOLOGICAL|Hexaxim Vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219602459|NCT02369198|DRUG|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
219602460|NCT07113678|BEHAVIORAL|Body confidence podcast episode and supplementary exercises in a journal|"The 52-minute long podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave).~The podcast episode is accompanied by supplementary exercises in a journal to reinforce the body confidence messages shared during the episode. The 8-page journal (Beauty on Your Own Terms) consists of two primary activities. The first activity (A vision for your future) involves 3 questions, a 3-minute visualisation exercise, and a prompt for written reflection all intended to facilitate accepting your body as it is, rejecting societal and media pressures that define beauty narrowly, and defining beauty on your own terms. The second activity (Beauty-on-your-own-terms challenge) involves 4 exercises intended to help women reflect on what they can change about your routine and habits to start defining beauty on your own terms."
219602461|NCT07113678|BEHAVIORAL|Body confidence podcast episode|"The podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave)."
219602462|NCT07113678|BEHAVIORAL|Non-body image-related podcast episode|"A podcast episode from the same podcast series as the intervention, How to Fail, which contains no body image content and is matched on length and guest similarities. The episode features host Elizabeth Day in conversation with actor and activist Cynthia Nixon (Being brave is feeling scared and doing it anyway), which is 47 minutes in length."
219023539|NCT03628755|BEHAVIORAL|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
219023540|NCT03628755|BEHAVIORAL|combination Group|combination group intervention of DMT + FST
218874206|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
218874207|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
218874208|NCT00581867|DRUG|Placebo|Placebo
218874209|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
218874210|NCT01936415|DEVICE|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
218874211|NCT01936415|DEVICE|Regenerex|
218874212|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
218874213|NCT02618668|DRUG|Propofol|2 mg/kg I.V
218874214|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
218874215|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
218874216|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
218874217|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
218874218|NCT03247725|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
218874219|NCT03247725|OTHER|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
218874220|NCT00320424|DRUG|Fondaparinux|
218874221|NCT01086371|OTHER|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
218874222|NCT01086371|OTHER|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
218874223|NCT05466331|OTHER|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
218874224|NCT05466331|OTHER|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
218874225|NCT03768128|DEVICE|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
218874226|NCT06362928|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
218874227|NCT04802720|OTHER|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~2. coping effectiveness training (Session 2);~3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~4. challenging and restructuring unhelpful cognitions (Session 4);~5. behavioral activation within the limitations of the caregiving context (Session 5);~6. problem-solving (Session 6);~7. communication strategies and assertiveness training (Session 7);~8. consolidating gains, maintenance, and relapse prevention (Session 8)."
218874228|NCT04802720|OTHER|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~2. attention regulation skills training (Sessions 1-2);~3. training in metacognitive skills (Sessions 3-4);~4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
218874229|NCT06015724|DRUG|Daratumumab|anti-CD38 monoclonal antibody (mAb)
218874230|NCT06015724|BIOLOGICAL|KRAS vaccine|Stimulon QS-21 and Targovax TG01
218874231|NCT06015724|DRUG|Nivolumab|anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
218874232|NCT01297725|PROCEDURE|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
218874233|NCT01297725|PROCEDURE|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
218874234|NCT00558298|DRUG|risperidone|
218874235|NCT04228094|OTHER|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
218874236|NCT03539991|OTHER|Internet-Based Intervention|Complete online courses
218874237|NCT03539991|OTHER|Meeting|Participate in virtual meetings
219602463|NCT07133308|DRUG|Deuruxolitinib|Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
218874238|NCT03539991|OTHER|Survey Administration|Ancillary studies
219602464|NCT07133308|DRUG|Placebo|Deuruxolitinib matching placebo will be dosed orally as tablets
219602465|NCT07133360|PROCEDURE|Third molar extraction|Surgical third molar extraction with conventional medication
219602466|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.05%
219602467|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
219602468|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
219602469|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment placebo
218874239|NCT00880594|DRUG|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
218874240|NCT00658814|DRUG|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
218874241|NCT00658814|DRUG|Gemtuzumab Ozogamicin|Given IV
218874242|NCT06401044|DRUG|AMG 732|SC injection
219023541|NCT05298332|DRUG|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
219023542|NCT03071978|DEVICE|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
218874243|NCT06401044|OTHER|Placebo|SC injection
218874244|NCT02916810|DEVICE|Active rTMS stimulation|Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
218874245|NCT02916810|DEVICE|Sham rTMS stimulation|Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
218874246|NCT03263260|DEVICE|implant|coronary stent implantation
218874247|NCT05664880|DRUG|Paricalcitol|2 MCG Oral Capsule
218874248|NCT05664880|DRUG|Placebo|Matching capsule to 2 MCG Paricalcitol Oral Capsule
219023543|NCT00749918|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
219023544|NCT01266460|BIOLOGICAL|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
219023545|NCT01266460|OTHER|Laboratory Biomarker Analysis|Correlative studies
219023546|NCT06104358|DRUG|HU6|HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
219023547|NCT03756688|DEVICE|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
219023548|NCT03756688|DEVICE|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
219023549|NCT01393340|DRUG|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
219023550|NCT01393340|DRUG|Placebo|Placebo
219023551|NCT01902342|DRUG|Oseltamivir 75 mg 1 cap|
219023552|NCT04263207|OTHER|No intervention|No intervention
219023553|NCT04923867|DEVICE|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
219023554|NCT03024307|OTHER|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
219023555|NCT06038279|DRUG|INI-2004|INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
219023556|NCT06038279|DRUG|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
219023557|NCT05436925|DEVICE|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
219023558|NCT00859235|DRUG|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
219023559|NCT00859235|OTHER|Plain water|Mouth wash prior to procedure
219200150|NCT06872333|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered at a dose of 14.5 mg/kg over 2 hours IV daily on days -6 and -5. Cyclophosphamide dosing is calculated based on actual body weight (ABW).~For Arm D - Cyclophosphamide 50 mg/kg IV will be administered over 2 hours on days +3 and~+4. Cyclophosphamide dosing for post-transplant is calculated based on ideal body weight (IBW) unless patient weighs less than IBW, in which case actual body weight (ABW) will be used."
219200151|NCT06872333|DRUG|Sirolimus|Patients on Arm A and Arm D will receive sirolimus; beginning on day -3 and continuing until day +180 for patients on Arm A or beginning on day +5 and continuing until 1 year post transplant for patients on Arm D.
218874249|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
218874250|NCT02540668|DRUG|Lanabecestat|Administered orally
218874251|NCT02540668|DRUG|Warfarin|Administered orally
218874252|NCT03270891|DIAGNOSTIC_TEST|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
218874253|NCT03596684|DIETARY_SUPPLEMENT|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
218874254|NCT03596684|DIETARY_SUPPLEMENT|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
219023560|NCT01132547|DRUG|cyproheptadine hydrochloride|Given orally
219023561|NCT01132547|OTHER|placebo|Given orally
219494233|NCT01804192|OTHER|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
218874255|NCT03596684|PROCEDURE|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
218874256|NCT05589675|OTHER|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
218874257|NCT05589675|OTHER|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
219494234|NCT01127386|DRUG|Lenalidomide|25mg od, dose reduction according to toxicity
219494235|NCT01127386|DRUG|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
219494236|NCT01127386|OTHER|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
219494237|NCT03406039|BEHAVIORAL|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
219494238|NCT02881463|OTHER|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
219494239|NCT03608410|OTHER|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
219494240|NCT01561118|OTHER|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
218874258|NCT05282433|DRUG|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
218874259|NCT05799417|OTHER|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
218874260|NCT02716181|DEVICE|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
218874261|NCT02716181|DEVICE|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
218874262|NCT00407017|DRUG|Gatifloxacin|
218874263|NCT00407017|DRUG|Ketorolac LS|
218874264|NCT00407017|DRUG|Pred Forte|
218874265|NCT00407017|DRUG|Moxifloxacin|
218874266|NCT00407017|DRUG|Nepafenac|
218874267|NCT00407017|DRUG|EconoPred Plus|
218874268|NCT02251938|DRUG|DE-109 440 μg|Medium Dose
218874269|NCT04456192|BEHAVIORAL|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
218874270|NCT05612334|BEHAVIORAL|exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)|the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
218874271|NCT06245252|OTHER|passive stretching for group A|A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).
219494241|NCT00681824|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
219494242|NCT00681824|PROCEDURE|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
219494243|NCT00158795|BIOLOGICAL|Haemophilus Influenza type b vaccine|
219494244|NCT02272881|PROCEDURE|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
219494245|NCT02272881|PROCEDURE|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
219494246|NCT03724916|DRUG|TAK-079|TAK-079 subcutaneous injection.
219494247|NCT03724916|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
219494248|NCT00077402|DRUG|fenretinide|
219494249|NCT04575038|DRUG|Brequinar|Dihydroorotate dehydrogenase inhibitor (DHODHi)
219494250|NCT04575038|DRUG|Placebo|Placebo capsules
219494251|NCT04315831|DRUG|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
219494252|NCT03191019|BEHAVIORAL|Mobile-phone app for smoking cessation|Android App for smoking cessation
219494253|NCT04972136|DEVICE|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
219494254|NCT04972136|DEVICE|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
219494255|NCT03455335|DRUG|20 million hMSCs|
219494256|NCT03455335|DRUG|40 million hMSCs|
219494257|NCT03455335|DRUG|80 million hMSCs|
219494258|NCT01897558|DEVICE|Pacemaker implantation|
219494259|NCT05321121|DRUG|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
219494260|NCT05321121|OTHER|Placebo|The control arm will receive an infusion of normal saline
219494261|NCT02760784|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
219494262|NCT02615379|DEVICE|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
219494263|NCT05934552|DRUG|Lactulose|lactulose and lactobacillus acidophilus on ckd patients
219494264|NCT03728699|DIAGNOSTIC_TEST|Sample Collection Blood|Collected from each patient twice weekly.
219494265|NCT03728699|DIAGNOSTIC_TEST|Stool Sample|Collected from each patient twice weekly.
219494266|NCT00683332|DRUG|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
219494267|NCT05037552|PROCEDURE|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
219023562|NCT03407573|BIOLOGICAL|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
219023563|NCT01897142|BIOLOGICAL|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023564|NCT01897142|DRUG|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023565|NCT01897142|BIOLOGICAL|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023566|NCT01897142|DRUG|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023567|NCT01897142|BIOLOGICAL|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023568|NCT01897142|DRUG|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023569|NCT01897142|BIOLOGICAL|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023570|NCT01897142|DRUG|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023571|NCT01897142|BIOLOGICAL|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023572|NCT01897142|DRUG|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023573|NCT01897142|BIOLOGICAL|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
219023574|NCT01897142|DRUG|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
219023575|NCT05811234|DRUG|CAL/BDP PAD Cream|As provided in real-world clinical practice.
219023576|NCT00259077|DRUG|Omeprazole|
219494268|NCT05037552|PROCEDURE|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
219494269|NCT00631800|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
219494270|NCT01339078|PROCEDURE|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
219494271|NCT01339078|PROCEDURE|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
219494272|NCT02579785|BEHAVIORAL|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
219494273|NCT03054961|DEVICE|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
219494274|NCT00665197|RADIATION|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
219494275|NCT00665197|RADIATION|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
219494276|NCT00176852|DRUG|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
219494277|NCT00176852|DRUG|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
219494278|NCT00176852|DRUG|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
219602470|NCT07162857|DEVICE|non-invasive cardiac output monitoring|Monitoring commenced immediately after enrollment, with baseline parameters recorded after signal stabilization (≤5 minutes), including cardiac output (CO), stroke volume (SV), stroke volume variation (SVV), and systemic vascular resistance (SVR). The system automatically updated these parameters every 30 seconds and displayed them in real-time on the monitor screen. Fluid resuscitation was dynamically adjusted according to these continuous measurements until achieving the predefined therapeutic targets.
218874272|NCT06245252|OTHER|electrical stimulation for group b|reated by 30 minutes electrical stimulation three times per week for 12 weeks
218874273|NCT03270384|DEVICE|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
218874274|NCT06067737|DRUG|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
218874275|NCT06067737|DRUG|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
218874276|NCT06561932|DEVICE|WiSE CRT System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
218874277|NCT03301038|DRUG|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
218874278|NCT05977049|BEHAVIORAL|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
219023577|NCT04310020|DRUG|Atezolizumab|Given IV
219023578|NCT04310020|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219023579|NCT04310020|PROCEDURE|Computed Tomography|Undergo CT scan
219023580|NCT04310020|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219023581|NCT04310020|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023582|NCT02166554|OTHER|Saline|On the day of initial surgery
219023583|NCT02166554|DEVICE|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
219200152|NCT06872333|DRUG|Tacrolimus|Patients on Arm B and Arm C will receive tacrolimus, beginning on day -3 and continuing until day +180. Tacrolimus dosing and monitoring will be per institutional guidelines.
219494279|NCT00176852|RADIATION|Total Body Irradiation|300 cGY Day -1
219023584|NCT01224847|DRUG|Tetracaine|1 gtt
219023585|NCT01224847|DRUG|Cocaine|1 gtt
219023586|NCT01224847|DRUG|Lidocaine|Lidocaine soaked pledget
219200153|NCT06872333|DRUG|Mycophenolate Mofetil|MMF will begin on day -3 (Arm A, B \& C) or day +5 (Arm D). Patients treated on adult service will receive 15 mg/kg (max 1500 mg/dose) given every 12 hours, rounded to nearest 250 mg. Patients on pediatric service will receive 15 mg/kg (max 1000 mg/dose) given every 8 hours. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. MMF will be stopped at day +30 (Arms A, B \& C) or day +35 (Arm D) or 7 days after engraftment, whichever day is later, if no acute GVHD.
219200154|NCT06626308|OTHER|brain functional MRI|visual protocol stimulation during brain functional MRI
219200155|NCT06623630|DRUG|Cyclophosphamide|Standard of care
219200156|NCT06623630|DRUG|Ciltacabtagene Autoleucel|Standard of care
219200157|NCT06623630|RADIATION|Total body irradiation|Radiation doses delivered to the entire body
219494280|NCT00176852|PROCEDURE|Stem cell infusion|Given Day 0
219494281|NCT04322227|DRUG|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
219494282|NCT04322227|DRUG|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
219494283|NCT04322227|DRUG|Placebo (treatment C)|Placebo, BID capsules, orally
219494284|NCT01001676|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
219494285|NCT01001676|DEVICE|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
219602471|NCT07162857|DEVICE|Ultrasonic technology|In the critical care ultrasound group, patients underwent immediate bedside This protocol ensured real-time, comprehensive evaluation of both cardiac function and fluid status to guide resuscitation.Ultrasound reassessment was performed every 1-2 hours to dynamically adjust both the volume and rate of fluid administration until predefined resuscitation targets were achieved.
219602472|NCT07168018|BIOLOGICAL|Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV)|A single visit of coadministration of 5×10\^10 vp ChAdOx2 RabG (2 site IM) and licensed IRV (2 site IM).
218874279|NCT06362187|DEVICE|Gut Directed VR|The VR experiences follow a protocolized gut-directed therapy
218874280|NCT06362187|DEVICE|Sham Control VR|The same Oculus Quest 2 device as the active treatment group but will use distractive therapy
218874281|NCT06969872|DIETARY_SUPPLEMENT|Placebo|Take a capsule of placebo within 30 minutes after breakfast, and once a day.
218874282|NCT06969872|DIETARY_SUPPLEMENT|Probiotics (ABKefir)|Take a capsule of ABKefir within 30 minutes after breakfast, and once a day.
218874283|NCT05958290|OTHER|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
218874284|NCT06278883|BEHAVIORAL|Disease Risk Assessment|Undergo personal and family history-based risk assessment and make recommendations for managing risk.
218874285|NCT05633979|DRUG|Trastuzumab deruxtecan|Given by IV (vein)
218874286|NCT05633979|DRUG|Valemetostat|Given by PO
218874288|NCT04199767|DRUG|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
218874289|NCT04199767|DRUG|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
218874290|NCT06574997|DRUG|OCU400|Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
218874291|NCT05498272|DRUG|Olaparib|300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
218874292|NCT05498272|DRUG|LHRH agonist|Total duration of therapy will be for 180 days with use of agent as per institutional standards
218874293|NCT06524960|DRUG|Denosumab|Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
218874294|NCT06524960|OTHER|Placebo|Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
218874295|NCT05162469|DRUG|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
218874296|NCT02883062|DRUG|Atezolizumab|Given IV
218874297|NCT02883062|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218874298|NCT02883062|DRUG|Carboplatin|Given IV
218874299|NCT02883062|PROCEDURE|Lumpectomy|Undergo lumpectomy
218874300|NCT02883062|PROCEDURE|Mastectomy|Undergo mastectomy
218874301|NCT02883062|DRUG|Paclitaxel|Given IV
218874302|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
218874303|NCT06445361|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine steatosis and fibrosis.
218874304|NCT02888743|BIOLOGICAL|Durvalumab|Given IV
218874305|NCT02888743|RADIATION|Radiation Therapy|Undergo radiation therapy
218874306|NCT02888743|BIOLOGICAL|Tremelimumab|Given IV
219494286|NCT02037373|BIOLOGICAL|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
218874308|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
219494287|NCT02037373|BIOLOGICAL|Plasma|Plasma as prescribed by the treating physician.
219494288|NCT04345731|OTHER|Over the counter drug labels|A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
219023587|NCT01874847|DIETARY_SUPPLEMENT|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
219023588|NCT01874847|DIETARY_SUPPLEMENT|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
219023589|NCT04267991|DRUG|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
219023590|NCT04267991|PROCEDURE|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
219023591|NCT00121420|DRUG|Motexafin gadolinium|
219023592|NCT05875155|DIAGNOSTIC_TEST|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
219023593|NCT05875155|DIAGNOSTIC_TEST|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
219023594|NCT04658537|RADIATION|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
219023595|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
219023596|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
219023597|NCT05481073|DEVICE|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
219023598|NCT00323518|DRUG|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
219023599|NCT00323518|DRUG|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
219023600|NCT05135520|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE
219023601|NCT05135520|PROCEDURE|Transabdominal specimen extraction|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation
219023602|NCT00483379|BIOLOGICAL|alglucosidase alfa|intravenous infusion
219494289|NCT04562025|DRUG|UC-MSCs|3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
219494290|NCT04562025|DRUG|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
219494291|NCT02123069|DEVICE|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
219023603|NCT06801626|COMBINATION_PRODUCT|Famotidine and 4% topical cromolyn sodium|Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.
219494292|NCT02123069|DRUG|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
219494293|NCT02123069|DRUG|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
219494294|NCT02123069|DRUG|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
219023604|NCT06801626|OTHER|Placebo|Treatment with active H1 antihistamine plus administration of placebo famotidine and placebo cromolyn sodium.
219023605|NCT00123864|PROCEDURE|Intensity-modulated radiation therapy|
219023606|NCT06807632|DRUG|Valemetostat|"Dose level -1 100 mg po once daily~Dose level 1 150 mg po once daily~Dose level 2 200 mg po once daily"
219023607|NCT06807632|DRUG|Atezolizumab|1680 mg IV q4weeks
219023608|NCT04663607|BEHAVIORAL|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
219023609|NCT05882565|BEHAVIORAL|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
219023610|NCT05882565|BEHAVIORAL|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
219023611|NCT05821699|BEHAVIORAL|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination"
219023612|NCT05821699|BEHAVIORAL|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
219023613|NCT05640102|DRUG|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
219023614|NCT06501196|DRUG|BH-30236|BH-30236 will be provided as either a 5 mg, 15 mg or 30 mg tablet. Participants will take BH-30236 tablets orally depending on their dose level assignment.
218874309|NCT06225466|DRUG|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
219023615|NCT06501196|DRUG|Venetoclax|Venetoclax will be provided as 10 mg, 50 mg or 100 mg tablets. Participants will take venetoclax orally per label instructions.
219023616|NCT05041842|DRUG|Tucatinib|300 mg orally twice daily
219023617|NCT05041842|DRUG|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
219023618|NCT05041842|DRUG|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
219023619|NCT05041842|DRUG|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
219023620|NCT05041842|DRUG|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
219023621|NCT06273124|DEVICE|SteadiSet Extended Wear Infusion Set|Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.
219494295|NCT02123069|DRUG|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
219494296|NCT01501201|PROCEDURE|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
219494297|NCT01501201|DRUG|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
219494298|NCT02841540|DRUG|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
219494299|NCT01358019|DRUG|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
219494300|NCT06160479|DRUG|Calcium supplement|Different amount of calcium supplement in pregnancy
219494301|NCT03398655|DRUG|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
219494302|NCT03398655|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
219023622|NCT02860364|PROCEDURE|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
219494303|NCT06542510|BEHAVIORAL|working night shift|working night shift
219494304|NCT03171506|OTHER|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
219023623|NCT06561958|DRUG|REKOVELLE|Individualised dosing regiment of REKOVELLE in routine clinical practice.
219023624|NCT04103892|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
219023625|NCT04103892|DRUG|placebo|1 tablet of placebo administered once daily
219494305|NCT03171506|OTHER|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
219494306|NCT04377178|DEVICE|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
219494307|NCT04377178|DEVICE|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
219494308|NCT02270905|DEVICE|dCELL® Meniscus|decellularised porcine xenograft
219494309|NCT00871598|DRUG|BTT1023|intravenous, three infusions over three weeks
219494310|NCT00871598|DRUG|Placebo|intravenous, three infusions over three weeks
219494311|NCT00871598|DRUG|BTT1023|Test challenge
219494312|NCT06352398|PROCEDURE|erector spina plan block|erector spina plan block
219494313|NCT06352398|PROCEDURE|Serratus posterior superior intercostal plan block (SPSIPB)|Serratus posterior superior intercostal plan block (SPSIPB)
219494314|NCT06352398|DRUG|0.25% bupivacaine|Before the operation, 0.25% bupivacaine 30 ml was administered to both groups.
219602473|NCT07168018|BIOLOGICAL|Inactivated Rabies Vaccine (IRV)|A World Health Organization (WHO) prequalified IRV at two anatomical sites (2 site ID) on days 0, 3 and 7.
219602474|NCT07167732|DIAGNOSTIC_TEST|A General Medical and Neurological Assessment|Clinical assessments will consist of gathering demographic data, detailed relevant medical history, and parents' perspectives on treatment priorities, clinical trial interest, and acceptability of risk in future clinical trials. A general medical and neurological examination will be performed by a trained and skilled physician with a valid Good Clinical Practice Certification.
218874310|NCT06225466|DRUG|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
218874311|NCT06225466|OTHER|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
218874312|NCT04909229|DEVICE|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
218874313|NCT04909229|DEVICE|Fitbit|Patients will receive a Fitbit and receive standard of care
218874314|NCT04909229|BEHAVIORAL|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
218874315|NCT06665997|DRUG|Depot medroxyprogesterone acetate (DMPA)|150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension
218874316|NCT05559853|DIAGNOSTIC_TEST|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
219602475|NCT07167732|DIAGNOSTIC_TEST|World Health Organisation (WHO) Motor Milestones|Ages of six WHO Motor milestones achievements - sitting without support, hands and knees crawling, standing with support, walking with support, standing independently, and walking independently - will be assessed. The age of milestone achievement will be compared to normative variations in age as recommended by the WHO (WHO, 2006).
219602476|NCT07167732|DIAGNOSTIC_TEST|Burke-Fahn-Marsden Dystonia Rating Scale|The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS; Burke, Fahn, Marsden et. al, 1985) is a universally applied biomarker for the severity of dystonia in children and adults. The scale consists of a movement and disability subscale (Burke-Fahn-Marsden Movement Scale \[BFMMS\] and Burke-Fahn-Marsden Disability Scale \[BFMDS\], respectively. Only the BFMMS will be assessed. The BFMMS measures dystonia in nine body regions (including the eyes, mouth, speech and swallowing, neck, trunk, arms, and legs) with scores ranging from 0 (minimum) to 120 (maximum).
219602477|NCT07167732|DIAGNOSTIC_TEST|Spastic Paraplegia Rating Scale|The Spastic Paraplegia Rating Scale (SPRS; Schüle et al., 2006) is a 13-item scale used to measure disease severity in spastic paraplegia. The items include walking distance without pause, gait quality, maximum gait speed, climbing stars, arising from chair, spasticity of hip adductor and knee flexion muscles, weakness of hip abduction and foot dorsiflexion, contracture of lower limbs, pain related to spasticity, and bladder and bowel function. Each item has a score ranging from 0 to 4, where 0 represents no dysfunction and 4 represents most severe dysfunction. The score result is calculated by adding single scores of each of the 13 items. The total score varies between 0 (no dysfunction) and 52 (most severe dysfunction).
219602478|NCT07167732|DIAGNOSTIC_TEST|5. CTNNB1-Related Neurodevelopmental Disorder (NEDSDV) Cardiac Health Questionnaire|In a recent study (Sinibaldi et al., 2023), several patients with NEDSDV showed heart abnormalities. To expand on that, investigators developed a parent report questionnaire on the presence of potential heart defects.
219602479|NCT07167732|DIAGNOSTIC_TEST|10m Walk-Run Test|The 10m Walk-Run Test is is a performance measure used to assess walking or gait speed in meters per second over a short distance. It involves measuring the time it takes for a person to walk the distance, with results reported in meters/second (m/s). The patient's ability to walk at both comfortable and fast speeds can be measured, and assistive devices can be used. The test will be performed in ambulant children by an experienced physiotherapist.
219602480|NCT07167732|DIAGNOSTIC_TEST|The Nine Hole Peg Test|The Nine-Hole Peg Test (9-HPT; Kellor et al., 1971) is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the client to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The 9-HPT has been validated for children above the age of 4 years (Poole et al., 2006). The test will be performed in children over 4 years old by a trained investigator.
219200158|NCT05488522|BIOLOGICAL|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
218874320|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
218874321|NCT02885974|DRUG|Celecoxib|Celecoxib (100 mg daily)
218874322|NCT02885974|DRUG|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
218874323|NCT02885974|DRUG|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
218874324|NCT04816721|DRUG|EDP-938|Oral suspension
218874325|NCT04816721|DRUG|Placebo|Placebo oral suspension to match EDP-938
219023626|NCT05442957|BEHAVIORAL|BRIGHT|BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
219023627|NCT05442957|BEHAVIORAL|Attention Control|AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
219023628|NCT01980355|DRUG|Tranexamic Acid|
219023629|NCT01980355|OTHER|Placebo|
219023630|NCT02419053|OTHER|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
219023631|NCT05559359|DRUG|Lebrikizumab|Administered SC
219023632|NCT05559359|DRUG|Placebo|Placebo given SC
219023633|NCT05559359|DRUG|Topical Corticosteroid (TCS)|TCS administered
219200159|NCT06862570|DRUG|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)
218874326|NCT06854458|DIAGNOSTIC_TEST|Quantitative Myocardial Blood Flow Evaluation|The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
218874327|NCT06854458|DIAGNOSTIC_TEST|Qualitative Myocardial Blood Flow Evaluation|The perfusion sequence will not produce additional quantitative perfusion maps.
218874328|NCT06854458|DRUG|Gadavist|Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
219023634|NCT06965751|DRUG|PDI204|PDI204 is a fully human, immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein
219023635|NCT06965751|OTHER|0.9 % saline|0.9% saline used as placebo
218874329|NCT06854458|DRUG|Vasodilator|All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
218874330|NCT06854458|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.
219023636|NCT06967545|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
219023637|NCT06971874|OTHER|No intervention|No intervention
219023638|NCT06969547|DIAGNOSTIC_TEST|dynamic SPECT (two-day rest/stress protocol)|"All nuclear examinations will be performed using a hybrid specialized SPECT/CT Discovery NM/CT570C. At the first stage the passage of the bolus of the radiopharmaceutical through the chambers and the LV myocardium will be recorded at rest. Through a pre-installed intravenous catheter, a bolus of the radiopharmaceutical in a volume of 5 ml (370 MBq) will be injected at a rate of 0,5 ml/sec, after which 30 ml of saline will be injected at a rate of 2 ml/sec. Data acquisition will begin immediately before the introduction of the radiopharmaceutical. Registration of dynamic images will be performed in the List Mode.~At the second day stress test study will be performed (ATP at a dosage of 160 mcg/kg/min over 4 minutes). The bolus volume of the radiopharmaceutical, saline and the rate are equal to the study at rest. The time of data collection at each stage of the study will be 12 minutes. The introduction of the radiopharmaceutical will be performed at 2 minutes of the stress test."
219023639|NCT06969547|DIAGNOSTIC_TEST|gated myocardial perfusion imaging|"Gated MPI will be performed according to a two-day rest-stress protocol. For both stress and rest studies, the acquisition will be performed 60 minutes after the dynamic SPECT. The recording time will be 5 minutes. To correct the attenuation, a low-dose CT scan of the chest, obtained earlier with dynamic recording, will be used. The voltage on the X-ray tube will be 120 kV, the current strength will be 20 mA; tube rotation time 0.8 s; pitch 0.969:1. Radiopharmaceutical administration will be performed only once a day during dynamic SPECT.~Immediately after recording the gMPI at rest, the patient will undergo a series of sequential injections of dobutamine at doses of 5 and 10 µg/kg/min with simultaneous recording. The duration of data collection on each dose of dobutamine will be 5 minutes."
219023640|NCT06969547|OTHER|blood sampling|"Indicators of:~* endothelial dysfunction (specific endothelial cell molecule 1 (endocan, ESM1), endotelin-1)~* severity of inflammatory response (tumor necrosis factor (TNF-α), interleukin-6 (IL-6))~* myocardial fibrosis (matrix metalloproteinase (MMP-9)~* myocardial dysfunction (NT-proBNP)"
219023641|NCT06969547|DIAGNOSTIC_TEST|Low Dose CT-scan|Scanning parameters: tube voltage 120 kV; current 435 mA; tube rotation time 0.4 s; slice thickness 2.5 mm; interslice interval 2.5 mm.
219200160|NCT06862570|DRUG|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)
219200161|NCT05107518|BEHAVIORAL|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
219200162|NCT02785991|PROCEDURE|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
219494315|NCT05530642|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire \& Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
219494316|NCT01318733|DRUG|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
219494317|NCT02621827|OTHER|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
219494318|NCT03038282|DIETARY_SUPPLEMENT|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
219494319|NCT03038282|OTHER|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
218874331|NCT06687434|BEHAVIORAL|accurate carb counting|Participants will use precise carb counting to manage their meals
219200163|NCT06685913|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test
219200164|NCT06685913|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
219602481|NCT07167732|DIAGNOSTIC_TEST|The Gross Motor Function Classification System|The Gross Motor Function Classification System (GMFCS; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
218874332|NCT06687434|BEHAVIORAL|Simplified qualitative meal size estimation|participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
218874333|NCT06743529|PROCEDURE|control group|immediate empiric Antibiotic Therapy (started within 1 hour after randomization) with antibiotic(s) chosen by the bedside physician based on time of ventilator-associated pneumoniaoccurrence, risk of antimicrobial resistance, local ecology, and local protocol. If the respiratory samples are negative, Antibiotic Therapy will be stopped. If ventilator-associated pneumonia is confirmed by positive samples, Antibiotic Therapy active against the recovered bacterial specie(s) will be given for a total of 7 days.
218874334|NCT06743529|PROCEDURE|Conservative strategy|No Antibiotic Therapy until receipt of the respiratory sample culture and/or polymerase chain reaction results. If these results are negative, no Antibiotic Therapy is given. If they are positive (confirmed ventilator-associated pneumonia), Antibiotic Therapy is started as appropriate for the bacterial specie(s) detected by culture and/or polymerase chain reaction, without considering gram-stain results and without waiting for antimicrobial susceptibility testing results, and continued for a total of 7 days of Antibiotic Therapy active against the identified bacterial specie(s).
218874335|NCT06762080|DRUG|Cadonilimab (AK104)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
218874336|NCT06762080|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
218874337|NCT06886997|DIAGNOSTIC_TEST|Pelvic Floor Ultrasound|Pelvic Floor Ultrasound will be carried out by a sonographer expert in the technique and who will be blinded from the data of clinical examination as well as the UDS results. The 3D/4D abdominal ultrasound probe will be used to perform a transperineal scan to capture midsagittal pelvic floor views. The test will be conducted both at resting state and during the maximum Valsalva maneuver.
218874338|NCT06886997|DIAGNOSTIC_TEST|Urodynamic studies|Urodynamic studies (UDS) will be carried out according to the usual protocol and will include: cystometry, Valsalva leak point pressure, urethral pressure profile, and uroflowmetry.
218874339|NCT06760754|DIETARY_SUPPLEMENT|Digital culinary medicine intervention|Participants will receive 30lbs of healthy foods through an on-site hospital-base food pantry
218874340|NCT06430164|OTHER|Gait Training|Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.
218874341|NCT06430164|DEVICE|Functional electrical stimulation (FES)|"Electrical stimulation involving the parameters and settings proposed here is commonly used in clinical practice and research for pain relief and other applications also referred to as neuromuscular or transcutaneous electrical nerve stimulation. The FES will be delivered using the UDel Stimulator, a custom-designed FES system from the University of Delaware FES lab.~Researchers will use a customized, real-time system to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains will be delivered during gait."
218874342|NCT06430164|DEVICE|Peripheral electrical stimulation paired with cortical magnetic stimulation pulses|The paired associative stimulation (PAS) will be conducted in a static posture (seated or standing), to evaluate effects on somatosensory, spinal-reflex, and/or corticospinal neurophysiology delivered with different stimulation parameters. One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds may be completed before and/or after PAS to evaluate gait performance
218874343|NCT04680949|DRUG|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
218874344|NCT04680949|DRUG|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
218874345|NCT07073378|DEVICE|Brain computer interface|"Families will first complete an in-person visit to review available activities, set their first goals, and learn to use BCI independently. A BCI kit will be given to each family, with a headset and the equipment and software required to pursue their identified goals. Following this, families will participate in 12 virtual sessions over 3-6 months. Scheduling will be flexible to accommodate complex family needs. Daily online support will be provided via a messaging application. Participants who choose to continue using BCI beyond 12 sessions will be provided kits and supported."
218874346|NCT06385327|DRUG|ABI-5366|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
218874347|NCT06385327|DRUG|ABI-5366 Placebo|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
218874348|NCT07077226|DIAGNOSTIC_TEST|Polysomnography|Sleep studies (polysomnography and polygraphy) will be performed and reported according to current American Academy of Sleep Medicine guidelines
218874349|NCT07077707|OTHER|Prenatal GENEie Chatbot|Patient Educational Phone Chatbot Application for Prenatal Genetics in English \& Spanish
218874350|NCT07077707|OTHER|In-person genetic counseling|Standard in-person genetic counseling for prenatal genetics education
219200165|NCT02991313|DEVICE|Endocardial Ablation Procedure|
218874351|NCT07078591|DRUG|Venetoclax|Given PO
218874352|NCT07078591|DRUG|Azacitidine (AZA)|Given SC
219023642|NCT06969547|DIAGNOSTIC_TEST|CT-coronary angiography|The study will be performed on a 64-slice GE Discovery NM/CT 570С (GE Healthcare, Milwaukee, WI, USA) from the level of the tracheal bifurcation to the diaphragm during breath holding (6-8 s) in the prospective (for HR≤55) or retrospective (for HR\>55) ECG-synchronized mode. To contrast coronary arteries, it is planned to use an intravenous infusion of 85-90 ml (at a rate of 5 ml/s) of an iodine-containing (370 mg iodine/ml) radiopaque substance.Scan will be performed with the following parameters: current strength 120 kV; voltage 300-600 mA with ECG modulation; tube rotation speed 0.4 s; pitch: 0.18-0.22 (depending on heart rate).
219494320|NCT05436691|OTHER|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
219494321|NCT03584204|DIAGNOSTIC_TEST|imaging|computed tomography, magnetic resosnance imaging, ultrasound
219494322|NCT00813501|BIOLOGICAL|immunosuppressive therapy|
219494323|NCT00813501|OTHER|immunological diagnostic method|
219494324|NCT00813501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218874353|NCT07078591|DRUG|Daunorubicin|Given IV
218874354|NCT07078591|DRUG|Idarubicin（IDA）|Given IV
218874355|NCT07078591|DRUG|Cytarabine (Ara-C)|Given IV
218874356|NCT07078591|BIOLOGICAL|GPBMC infusion|HLA-mismatched donor GPBMC infusion
218874357|NCT07080996|COMBINATION_PRODUCT|Strengthening training with biofeedback|Participants in this group trained their tongue strength with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 10 repetitions at 80% of their maximum.
218874358|NCT07080996|COMBINATION_PRODUCT|Endurance training with biofeedback|Participants in this group trained their tongue endurance with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 20 repetitions at 60% of their maximum.
218874359|NCT07081945|DEVICE|hAM|The hAM stands for human amniotic membrane, which was used to seal inferior retinal breaks after complete vitrectomy.
219023643|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
219023644|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
219023645|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
219023646|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
219023647|NCT01147029|DRUG|angiogenesis inhibitor GSAO|
219023648|NCT01147029|OTHER|laboratory biomarker analysis|
219023649|NCT01147029|OTHER|pharmacological study|
219023650|NCT01147029|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219023651|NCT06073821|DRUG|Sonrotoclax|Administered orally
219023652|NCT06073821|DRUG|Zanubrutinib|Administered orally
219023653|NCT06073821|DRUG|Venetoclax|Administered orally
219023654|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
219023655|NCT04430114|DEVICE|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
219023656|NCT04837157|DEVICE|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
219023657|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
219023658|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
219023659|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
219023660|NCT03079908|OTHER|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
219023661|NCT03079908|OTHER|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
219023662|NCT03079908|OTHER|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
219023663|NCT03051607|DRUG|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
219023664|NCT05467436|DRUG|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
219023665|NCT06221514|OTHER|Core Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
219023666|NCT06221514|OTHER|Shoulder Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
219023667|NCT05160454|DEVICE|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
219023668|NCT05872711|OTHER|Low carbohydrate diet|"In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants."
219200166|NCT06875219|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
219200167|NCT06875492|COMBINATION_PRODUCT|HMME-PDT|Twice HMME-PDT, and the treatment interval is 2 to 3 months.
219602482|NCT07167732|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development-4: Fine Motor, Gross Motor, Language, and Cognitive Scales|Bayley Scales of Infant and Toddler Development-4 (BSID-4; Bayley et al., 2019) is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. It consists of 419 items across 5 scales, each of which can be administered separately - Cognitive Scale (81 items), Language Scale (79 items), Motor Scale (104 items), Social-Emotional Scale (35 items), and Adaptive Behavior Scale (120 items). In our study, Motor, Language and Cognitive scales will be performed by a trained psychologist - if possible, at the patient's home country and in their native language.
218874360|NCT07081191|BEHAVIORAL|Dance|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the intervention arm would involve 2 sessions of CDP, 75 minutes per session each week.
218874361|NCT07081191|BEHAVIORAL|Active Control|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the active control arm would only include 60 minutes of CDP (1 session) per week to assess the effect of CDP on the cognitive and physical health of older adults.
219494325|NCT01292460|DRUG|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
219494326|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
219494327|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
219494328|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
219494329|NCT00796289|DRUG|clomiphene citrate|Oral, 50 mg daily for 5 days
219494330|NCT00796289|DRUG|placebo clomiphene citrate|oral, taken for 5 days
219494331|NCT00796289|DRUG|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
219494332|NCT05875766|OTHER|Osteopathy|4 sessions of osteopathy after DIDT surgery
219494333|NCT05875766|OTHER|Physiotherapy|Physiotherapy after DIDT surgery (reference treatment)
219494334|NCT02574507|BEHAVIORAL|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
219494335|NCT05216328|DRUG|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
219494336|NCT05216328|DRUG|Magnesium hydroxide 724mg|Information already included in arm/group description.
219494337|NCT02088294|BEHAVIORAL|Lifestyle Education (LS)|See arm description
219494338|NCT02088294|BEHAVIORAL|LS + Stress Reduction Guided Imagery|See Arm Description
219494339|NCT02088294|BEHAVIORAL|LS + Activity/Eating Guided Imagery|See arm description
219494340|NCT05552092|DEVICE|Esophageal temperature monitoring according to the depth|"Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured."
219494341|NCT05552092|OTHER|Anatomical landmark|For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
219494342|NCT02795949|DRUG|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
219494343|NCT02795949|DRUG|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
219494344|NCT00488046|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
219602483|NCT07167732|DIAGNOSTIC_TEST|Wechsler Non-Verbal Scale of Ability|Wechsler Nonverbal Scale of Ability (WNV, Wechsler et al., 2006) is a standardized, individually administered test designed to assess general cognitive ability in individuals aged 4 to 21 years, particularly those who may have language, cultural, or communication challenges that make traditional verbal IQ tests less appropriate. It consists of six different subtests that are utilized based on the participant's age. In our study, the test will be performed in children above the age of 4 years by a trained psychologist - if possible, at the patient's home country and in their native language.
219023669|NCT03341533|PROCEDURE|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
219023670|NCT03341533|OTHER|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
218874362|NCT07086053|DEVICE|MyotonPRO|The MyotonPRO is a non-invasive handheld device that assesses the mechanical and viscoelastic properties of soft tissue (e.g., skin stiffness, elasticity, and relaxation time). In this study, it is used in patients with breast cancer-related lymphedema (BCRL). Each participant is evaluated by two blinded raters to determine intra- and inter-rater reliability.
218874363|NCT02708485|OTHER|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
219200168|NCT06875492|DEVICE|PDL|Prior PDL treatment history.
219494345|NCT05001373|BIOLOGICAL|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
219494346|NCT05001373|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
219494347|NCT03095963|OTHER|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
219494348|NCT03095963|DRUG|levothyroxin|replacement therapy for hypothyroidism
219494349|NCT05674266|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
219494350|NCT05674266|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
219494351|NCT00639587|DRUG|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
219494352|NCT00639587|DRUG|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
219494353|NCT02627885|BEHAVIORAL|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
219494354|NCT02627885|OTHER|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
219494355|NCT04216537|DIAGNOSTIC_TEST|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
219494356|NCT00063700|PROCEDURE|reducing exposure to marketing pressures|
218874364|NCT07077915|OTHER|Osseodensification burs|Densah burs are osseodensification burs used to condense bone and prepare dental implant site, unlike conventional technique which cuts and removes the bone
218874365|NCT07077915|OTHER|Conventional burs|Preparation of dental implant site by the Conventional technique using Conventional burs that are subtractive
218874366|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
219494357|NCT03591107|OTHER|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
219494358|NCT03591107|OTHER|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
219494359|NCT00467337|PROCEDURE|Medial-Wedge Insole intervention|
219494360|NCT06538454|BEHAVIORAL|Resistance training|"The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions."
218874367|NCT07088146|DRUG|Dexamethasone|Immediately after sub-arachnoid block 8mg of Dexamethasone will be administered intravenously
218874368|NCT07088146|DRUG|Placebo|2ml of Normal saline will be given intravenously immediately after administration of spinal anesthesia
218874369|NCT07087704|DIETARY_SUPPLEMENT|High-fat diet|The group follows a Chilean diet (adapted from the Mediterranean Diet using Chilean ingredients) supplemented with 30 g/day of Gevuina avellana and providing 40% of total energy value from fat. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month. Each participant is provided once a month with individually packaged Chilean hazelnuts to reach a daily intake of 30 g.
219200169|NCT03812913|BEHAVIORAL|psychological evaluation|"* Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
219200170|NCT06002386|DEVICE|Vsling|Implantable ventricular repair device
219200171|NCT06408727|DRUG|CNM-Au8|CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
219200172|NCT04827251|DIETARY_SUPPLEMENT|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
219200173|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
219494361|NCT03940326|DRUG|Levetiracetam|Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
218874370|NCT07087704|DIETARY_SUPPLEMENT|Low-fat diet|The group maintains a low-fat diet (\<30% of total energy value) based on the Chilean Ministry of Health (MINSAL) technical guidelines for dyslipidemia management. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month.
219023671|NCT04045340|DEVICE|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
219023672|NCT04946539|DIAGNOSTIC_TEST|Ultrasonography|Enthesitis assessment via ultrasonography
219023673|NCT04208594|DRUG|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
219023674|NCT04208594|DRUG|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
219023675|NCT03965533|DRUG|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
219023676|NCT03965533|DRUG|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
219023677|NCT01074957|DEVICE|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
219023678|NCT01074957|DEVICE|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
219023679|NCT01074957|OTHER|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
219023680|NCT02144389|DRUG|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
219023681|NCT02144389|DIETARY_SUPPLEMENT|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
219023682|NCT02144389|DIETARY_SUPPLEMENT|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
219494362|NCT03940326|DRUG|Valproate|Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
218874371|NCT07089017|DEVICE|medstrom仪器|In addition to conventional monitoring methods, such as electrocardiography (ECG), bispectral index (BIS), and train-of-four (TOF) monitoring, Medstrom instruments were utilized to assess and monitor the patient's pain, sedation, and muscle relaxation status.
219023683|NCT03169582|DRUG|Avanafil|Drug administration (Avanafil)
219023684|NCT03169582|DRUG|Sildenafil|Drug administration (Sildenafil)
219023685|NCT02297269|DEVICE|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
219023686|NCT02297269|DEVICE|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
219023687|NCT01865539|DEVICE|Custom Foot Orthotic|Custom foot orthotic with custom design pads
219200174|NCT03126292|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
219200175|NCT03126292|OTHER|Child Safety Handout|Handout regarding early child safety
219023688|NCT01865539|DEVICE|Sham Orthotic|Leather insert without the custom design pads
219023689|NCT03420469|DRUG|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
219023690|NCT04660448|DIAGNOSTIC_TEST|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
219023691|NCT06547008|BEHAVIORAL|Army-SPRING|Army-SPRING includes a package of implementation options to support implementation of ASIST.
219023692|NCT06547008|BEHAVIORAL|Risk Reduction Group (Control)|Risk Reduction Group is a mandated training from National Guard Service members
219023693|NCT01603459|DRUG|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
219200176|NCT06875830|PROCEDURE|collagen membrane|augmentation of the buccal plate of bone with xenograft and collagen membrane
219200177|NCT06875830|PROCEDURE|titanium mesh|augmentation of the buccal plate of bone with xenograft and titanium mesh
219200178|NCT06867510|PROCEDURE|Block for Anterior Cervical Spine Surgery|The patient will be positioned supine with a slight elevation of the head and the head turned away from the blocked side. After sterilizing the skin, the ultrasound probe will be placed over the middle of the posterior border of the sternocleidomastoid muscle. The needle will be inserted in-plane while keeping the probe in a transverse position. The needle tip will be placed under the sternocleidomastoid muscle and below the superficial fascia, and then, a total volume of 15 ml of 0.25% bupivacaine will be injected bilaterally. The spread of the local anesthetic will be visualized using ultrasound guidance. The same steps will be repeated on the other side
219200179|NCT06867510|DRUG|Saline (NaCl 0,9 %) (placebo)|Total volume of 15 ml of saline 0.9% will be injected subcutaneous bilaterally
219200180|NCT06627036|DEVICE|Dermatoscope|For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
218874372|NCT07088614|OTHER|Remote respiratory physiotherapy|"Remote respiratory physiotherapy protocol supervised 3 times a week via digital video conferencing, based on Chilean national guidelines for cystic fibrosis.~Each 1-hour session (3×/week for 6 months) includes:~Evaluation: respiratory assessment, teaching and reinforcement of airway clearance techniques, inhaled medication use, physical activity, and adherence to non-physiotherapy care. Six checklists are used to guide and monitor weekly patient activities.~Respiratory physiotherapy: conducted on-screen by the patient or caregiver, guided remotely. Includes: short-acting bronchodilator (if indicated), 7% hypertonic saline nebulization (10 min), 5-min Flutter/Acapella, ELTGOL or ELPr (2×5 min), and assisted coughing.~Re-evaluation: reassessment with the initial checklist, Q\&A, and scheduling the next session.~Participants continue their usual hospital-based care and receive baseline and post-intervention measurements."
218874373|NCT07087652|OTHER|Onco Move multicomponent face-to-face training program|The Onco Move intervention will include three training sessions per week (each lasting 60 minutes), held in the fitness rooms and the gym at Gdansk University of Physical Education and Sport in Poland for 16 weeks. The intervention will include aerobic and strength exercises but also coordination/balance and flexibility, with warm-up and cool-down elements.
218874374|NCT07089719|DRUG|Bevacizumab Injection|Participants will receive Bevacizumab at a dose of 10mg/kg via intravenous infusion. They will receive a total of 5 injections, administered every two weeks.
218874375|NCT07088341|DIAGNOSTIC_TEST|elisa|enzyme- linked immunesorbent assay ( ELISA ) was used to measure soluble programmed death ligand-1 level
218874376|NCT07088185|OTHER|Routine medical care|Routine medical care
218874377|NCT07088185|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.
218874378|NCT07087483|BEHAVIORAL|The fathers who receive training|We will provide training to fathers on how they can improve and support their fatherhood skills with their newborns, and the control group will only receive the brochure about the basic fatherhood skills.
218874379|NCT07087483|BEHAVIORAL|Fatherhood Skill Training|"FATHERHOOD TRANSITION TRAINING PROGRAM • Explanation of the goals and objectives of the training~* Introduction to the training program~* Newborn's physiological characteristics (weight, height, head circumference, fontanelles, body temperature, sleep, feeding, urination, meconium, genital organs, reflexes, sleeping position, safety, hygiene)~* Infant feeding and burping the baby~* Changing baby's clothes, giving a bath, diapering, and general care of the eyes, ears, mouth, umbilical cord, and skin~* Importance and benefits of breast milk~* Breastfeeding positions and techniques~* Methods of expressing, storing, and increasing breast milk~* Information about vaccinations, hearing and heel-prick screening, developmental hip dysplasia, and jaundice~* General information on gender roles~* Importance of father-infant bonding and its short- and long-term outcomes"
218874380|NCT07087561|DIETARY_SUPPLEMENT|Personalized Oral Nutritional Supplementation|Participants receive individualized oral nutritional supplementation based on energy and protein requirements, calculated using the Harris-Benedict equation and body weight (1.2-1.5 g protein/kg/day). The supplement may include complete nutrition powder, whey protein powder, and compound multivitamins. The intervention is prescribed and monitored by a clinical nutrition team and adjusted every 3 days during the 14-day intervention phase. The goal is to ensure both energy and protein intake targets are met. Supplements are administered in addition to standard meals.
218874381|NCT07087561|DRUG|Personalized Parenteral Nutritional Supplementation|For participants unable to meet nutritional goals through oral intake, parenteral nutrition is administered intravenously. The formulation includes amino acids, glucose, lipids, electrolytes, trace elements, and vitamins. Dosages are aligned with those of the enteral nutrition group, ensuring a consistent intake of energy and protein (1.2-1.5 g/kg/day protein). Formulation and administration follow standardized hospital protocols and are supervised by the nutrition support team.
219023694|NCT01946373|DRUG|Cyclophosphamide|
219023695|NCT01946373|DRUG|Fludarabine|
219023696|NCT01946373|BIOLOGICAL|T cells|
219494363|NCT02330250|OTHER|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
219023697|NCT01946373|BIOLOGICAL|Interleukin-2|
219023698|NCT01946373|BIOLOGICAL|Dendritic cell vaccine|
219023699|NCT06430203|BEHAVIORAL|Peer mentoring|Indigenous young adult peer mentors who will develop and deliver the program based on needs and wants of our participants. The program will be built on their experience and ideas. They will be empowered to guide the program in the direction they see best for their communities.
219023700|NCT00196716|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
219023701|NCT00399360|DRUG|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
219494364|NCT02330250|OTHER|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
219494365|NCT02464527|BEHAVIORAL|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
219494366|NCT02464527|OTHER|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
219602484|NCT07167732|DIAGNOSTIC_TEST|The Vineland Adaptive Behaviour Scales - 3|The Vineland Adaptive Behaviour Scales (VABS-3; Sparrow et al., 2018) is a standardized assessment tool that utilizes semi-structured interview to measure adaptive behaviour and support the diagnosis of intellectual and developmental disabilities, autism, and developmental delays. It is validated for children of all ages and consists of five primary domains (Communication, Daily Living Skills, Socialization, Motor Skills, and Adaptive Behavior Composit).
219602485|NCT07167732|DIAGNOSTIC_TEST|Aberrant Behaviour Checklist -Community|"The Aberrant Behaviour Checklist-Community (ABC-C) is a parent report behavioural rating scale designed to assess problem behaviours in individuals with developmental disabilities. It consists of 58 likert-type items across five domains (Irritability, Social Withdrawal, Stereotypic Behaviour, Hyperactivity, and Inappropriate Speech) with responses ranging from not at all a problem to the problem is severe in degree."
219602486|NCT07167732|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers|The Modified Checklist for Autism in Toddlers (M-CHAT; Robins, Fein, \& Barton, 2009) is a 2-stage parent report screening tool to assess risk for autism spectrum disorder (ASD). It is validated for children 16-30 months old.
218874382|NCT07087561|BEHAVIORAL|Structured Nutrition-Focused Health Education|"Participants receive structured health education focused on nutrition, physical activity, and psychological well-being. The education is delivered over 14 days using a digital Internet Plus platform, featuring weekly videos, interactive Q\&A sessions, and guidance from a multidisciplinary nutrition support team. Educational content covers dietary recommendations, exercise safety, stress management, and post-treatment recovery strategies. Materials are updated weekly, and participants may access them remotely via smartphone or tablet. This intervention aims to improve nutrition knowledge, adherence, and health behavior change."
218874383|NCT07087925|DRUG|Haloperidol|A single dose of haloperidol (1-2 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention was designed to evaluate its effectiveness in preventing postoperative nausea and vomiting (PONV). Both patients and providers were blinded to the assignment.
219494367|NCT04596930|PROCEDURE|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
219494368|NCT06008639|DEVICE|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
219602487|NCT07167732|DIAGNOSTIC_TEST|The Autism Spectrum Quotient Questionnaire -Children's Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 4 - 11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
219602488|NCT07167732|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 12 - 15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
218874384|NCT07087925|DRUG|Ondansetron 4mg|A single dose of ondansetron (4 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention served as the active comparator to haloperidol in evaluating the prevention of postoperative nausea and vomiting (PONV). The study was conducted in a double-blind manner.
218874385|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
219494369|NCT06008639|DEVICE|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
219494370|NCT02113969|DEVICE|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
219494371|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
219494372|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
219494373|NCT06353035|OTHER|Rewilding|Private yards of the intervention study subjects will be modified with vegetation and deadwood.
219494374|NCT01902134|DRUG|Placebo|Placebo single oral dose (first 8 hours)
219494375|NCT01902134|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
219494376|NCT01902134|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
219494377|NCT01902134|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
219494378|NCT01902134|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
219494379|NCT01902134|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
219494380|NCT01902134|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
218874386|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
218874387|NCT06766357|DRUG|Cyclosporine ophthalmic gel|Administer to eyes
219023702|NCT00399360|DRUG|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
219023703|NCT00399360|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
219023704|NCT00233896|DRUG|Oral beclomethasone dipropionate (drug)|
219023705|NCT02442960|DRUG|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
218874388|NCT06766357|DRUG|Cyclosporine ophthalmic gel vehicle|Administer to eyes
218874389|NCT07087821|BEHAVIORAL|UPLIFT|"UPLIFT is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. UPLIFT is focused on self-management of depressive symptoms.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
219200181|NCT06072924|BEHAVIORAL|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
219200182|NCT06072924|BEHAVIORAL|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
219200183|NCT00591175|BEHAVIORAL|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
219494381|NCT05613335|PROCEDURE|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
219494382|NCT05613335|PROCEDURE|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
219494383|NCT00305110|DRUG|2 mg IV hydromorphone|
219494384|NCT03518710|OTHER|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~* Process evaluation:~* Oculomotors: DEM test (5min)~* Visuo-attention: computerized STROOP (15min)~* Visuo-Perceptive: DTVP3 (30min)~* Phonological \& lexical: Exalang (10min)"
219494385|NCT03518710|OTHER|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~\- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
219494386|NCT05693181|BIOLOGICAL|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10\*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
219494387|NCT05693181|OTHER|Control vehicle (sterile saline)|Sterile saline infusion in control patients
219494388|NCT01824069|OTHER|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
219494389|NCT00678379|DRUG|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
219494390|NCT00678379|DRUG|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
219494391|NCT00678379|DRUG|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
219494392|NCT01407575|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
218874390|NCT07087821|BEHAVIORAL|PACES|"PACES is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. PACES focuses on general epilepsy self-management.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
218874391|NCT07087821|BEHAVIORAL|Enhanced Usual Care|Participants receive referrals to local epilepsy support groups.
219023706|NCT06237595|DEVICE|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
219023707|NCT06237595|DRUG|Medical treatment|Medical treatment for fibromyalgia patients
219023708|NCT06237595|COMBINATION_PRODUCT|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
219023709|NCT05321615|DEVICE|Palpator|Palpator for tumor localization
219023710|NCT05321615|DEVICE|Grasper|Atraumatic lung grasper
219023711|NCT05321615|DEVICE|Ultrasound|VATS ultrasound
219023712|NCT05321615|OTHER|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
219023713|NCT06187610|BEHAVIORAL|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
219200184|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
219200185|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
219200186|NCT02296229|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219200187|NCT02296229|OTHER|quality-of-life assessment|Ancillary studies
219494393|NCT01407575|DRUG|Placebo|matched placebo
219023714|NCT04989400|DRUG|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
218874392|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
218874393|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
218874394|NCT00238459|DRUG|multiple licensed drugs not randomized|
218874395|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
218874396|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
218874397|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
218874398|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
218874399|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
218874400|NCT05153213|PROCEDURE|Finger lengths|Vernier caliper was used to measure finger length
218874401|NCT05153213|PROCEDURE|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
218874402|NCT05222555|DRUG|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
219200188|NCT02296229|OTHER|laboratory biomarker analysis|Correlative studies
218874403|NCT05222555|DRUG|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
218874404|NCT03134781|BEHAVIORAL|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
218874405|NCT03134781|BEHAVIORAL|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
219200189|NCT02296229|DRUG|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
218874406|NCT03134781|BEHAVIORAL|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
218874407|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
219200190|NCT04165733|DIAGNOSTIC_TEST|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
218874408|NCT00300365|OTHER|Placebo|Pioglitazone placebo
218874409|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
218874410|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
218874411|NCT04487457|OTHER|Blood samples|Blood samples
219200191|NCT05960786|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
219200192|NCT05960786|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
219023715|NCT04989400|DRUG|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
219023716|NCT00384722|DEVICE|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
219023717|NCT05966168|DEVICE|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
219023718|NCT04123288|DRUG|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
219200193|NCT06694584|BEHAVIORAL|Tea(m)Time|Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
219023719|NCT04123288|DRUG|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
219023720|NCT01166178|DRUG|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
219023721|NCT01166178|DRUG|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
218874412|NCT03067376|DRUG|[14C]-CORT125134|
218874413|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
218874414|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
218874415|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
218874416|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
219494394|NCT02755233|OTHER|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
219494395|NCT04030884|DIETARY_SUPPLEMENT|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
218874417|NCT00910169|OTHER|inpatient treatment|Hospitalisation modalities are described but are naturalistic
218874418|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
218874419|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
218874420|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
218874421|NCT04767152|DIAGNOSTIC_TEST|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
218874422|NCT02238834|DRUG|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
218874423|NCT02238834|DRUG|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
218874424|NCT02238834|DRUG|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
218874425|NCT02238834|DRUG|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
218874426|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
218874427|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
219023722|NCT01166178|DIETARY_SUPPLEMENT|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
219023723|NCT03797833|PROCEDURE|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
219023724|NCT05003453|DRUG|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
219494396|NCT05488652|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
219494397|NCT03712137|DEVICE|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
219494398|NCT03712137|OTHER|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
219602489|NCT07167732|DIAGNOSTIC_TEST|Continuous Movement Monitoring (Actimyo/Syde)|Continuous movement data will be collected using the ActiMyo/Syde® device (Servais et al., 2022), which is attached to the ankles and uses magneto-inertial sensors to quantify movement. At the first study visit, 20 ambulant patients older than 2 years old will be fitted with a Syde device to each ankle and their carers will be provided with training on use and care of the device. It will be worn for 30 days and then repeated in one year.
218874428|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
218874429|NCT04326088|OTHER|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
218874430|NCT04326088|OTHER|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
219494399|NCT04800900|OTHER|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
219494400|NCT05537337|BEHAVIORAL|Multicomponent Intervention|"The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution"
219494401|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
219494402|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
219494403|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
219494404|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
218874431|NCT04161170|DEVICE|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
218874432|NCT06097546|DIAGNOSTIC_TEST|laboratory test (RAI14 and MACC-1 )|Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
218874433|NCT01195493|OTHER|Essential Oils solution|(Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
218874434|NCT01195493|OTHER|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
218874435|NCT01587092|BEHAVIORAL|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
218874436|NCT01587092|BEHAVIORAL|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
218874437|NCT00143377|DRUG|tolterodine SR, overactive bladder|
218874438|NCT00973492|OTHER|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
218874439|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
218874440|NCT00899158|OTHER|immunologic technique|
218874441|NCT00899158|OTHER|laboratory biomarker analysis|
218874442|NCT00899158|PROCEDURE|biopsy|
219023725|NCT05003453|DRUG|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
219023726|NCT02496455|PROCEDURE|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
219494405|NCT01222871|DRUG|Triamcinolone|Triamcinolone soaked nasopore dressing
219494406|NCT01222871|DRUG|Saline soaked sponge|saline soaked sponge
218874443|NCT02161107|BIOLOGICAL|Grass-SPIRE|Intradermal injection
218874444|NCT02161107|BIOLOGICAL|Placebo|Intradermal injection
219023727|NCT02496455|DRUG|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
219494407|NCT01700751|DRUG|brentuximab vedotin|
219602490|NCT07167732|DIAGNOSTIC_TEST|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children (SDSC; Bruni et al., 1996) is a parent report questionnaire used to identify sleep disorders in children. It contains 26 likert-type items with responses ranging from never to always (daily). The items are divided in six categories - disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal/nightmares, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis (nighttime sweating)."
219602491|NCT07167732|DIAGNOSTIC_TEST|Seizure Diary|A 28-day seizure diary is a self-reported tool used to record seizure activity to obtain insight into the patient's seizure triggers and severity, monitor medication side effects, and promote medication adherence. Patients are asked to record their seizure occurrence, duration, and type of seizures.
218874445|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
219023728|NCT00245674|DRUG|amisulpride|
219023729|NCT01967251|DRUG|Udenafil|Udenafil tablets
219023730|NCT01967251|DRUG|Placebo|Udenafil placebo-matching tablets
219023731|NCT01103609|DRUG|Warfarin|Oral tablet od on Day 4
219023732|NCT01103609|DRUG|Placebo|Oral tablet bd, stepwise increased
219023733|NCT01103609|DRUG|AZD1656|Oral tablet bd, stepwise increased
219023734|NCT01730755|DRUG|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
219023735|NCT01178593|OTHER|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
219023736|NCT00471848|DRUG|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
219023737|NCT00264355|DRUG|cyclosporine A|
219023738|NCT03424174|DEVICE|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
219023739|NCT03424174|DEVICE|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
219023740|NCT03036761|PROCEDURE|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
218874446|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
218874447|NCT02641717|OTHER|vaginal swab|
218874448|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
218874449|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
218874450|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
218874451|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
219023741|NCT01556581|PROCEDURE|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
219023742|NCT01556581|PROCEDURE|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
219200194|NCT06695728|OTHER|exercise|It consists of exercises to be done with the exoskeleton. These are; jumping exercise, squat, sit-stand and forward bending exercises.
219200195|NCT06693921|PROCEDURE|AI/guided block graft|The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.
219494408|NCT01472809|DRUG|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
219494409|NCT01472809|DRUG|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
219494410|NCT05250947|DEVICE|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
219494411|NCT05250947|DRUG|Platelet Rich Plasma|6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
219494412|NCT02046473|PROCEDURE|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
219494413|NCT03867227|DEVICE|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
219494414|NCT02086526|DRUG|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
219494415|NCT03312582|DRUG|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
219494416|NCT03312582|PROCEDURE|Placebo|
219494417|NCT00989040|DRUG|usual treatment: Versatis|"* To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~* To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
219494418|NCT02934386|DEVICE|WinMedical WinPack device|
219494419|NCT01907724|DRUG|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
219494420|NCT01907724|DRUG|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
219494421|NCT01907724|DRUG|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
219494422|NCT01907724|DRUG|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
219602492|NCT07167732|DIAGNOSTIC_TEST|30min EEG Recording|Recording will take place in the hospital's EEG department in a quiet room with low-light levels. If children will be unable to lay still, melatonin or dexmedetomidine may be used, as per standard department protocol. An EEG cap with international system 10-20 electrodes, ECG and respiratory electrodes will be placed on the head and chest respectively. Data will be recorded for at least 30 minutes, and an attempt will be made to capture both wakefulness and sleep. Intermittent photic stimulation will be performed as per standard protocol.
219494423|NCT06311539|OTHER|Theraband Strengthening Exercise Program|"Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00)."
219494424|NCT01084603|DRUG|Oral Nicotine|A new l mg oral nicotine product
218874452|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
218874453|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
218874454|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
219023743|NCT04052984|PROCEDURE|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
219023744|NCT00110409|BEHAVIORAL|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
219494425|NCT01084603|DRUG|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
219602493|NCT07167732|DIAGNOSTIC_TEST|PedsQL Family Impact Module|"The PedsQL Family Impact Module is a parent report standardized questionnaire designed to measure the impact of paediatric chronic health conditions on the health-related quality of life (HRQOL) of parents and the functioning of the family as a whole. It consists of 36 likert-like items over 8 domains (Physical Functioning, Emotional Functioning, Social Functioning, Cognitive Functioning, Communication, Worry, Daily Activities, Family Relationships). The items are scored with responses ranging from never a problem to always a problem."
219602494|NCT07167732|DIAGNOSTIC_TEST|PedsQL Core Module|"The PedsQL™ (Pediatric Quality of Life Inventory) Core Module is a health-related quality of life (HRQOL) questionnaire designed for children and adolescents. It assesses physical, emotional, social, and school functioning by using 23 likert-like items across 4 subscales (Physical Functioning, Emotional Functioning, Social Functioning, School Functioning). The items are scored with responses ranging from never a problem to always a problem. Items differ across age groups - toddlers (2-4 years), young children (5-7 years), children (8-12 years), teens (13-18 years), and young adults (18-25 years). In toddlers, the parents serve as proxy, and in young children, a three-point scale with faces is used instead of likert-type responses."
219023745|NCT00110409|BEHAVIORAL|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
218874455|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
219023746|NCT04780854|DRUG|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
219023747|NCT04780854|DRUG|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
219023748|NCT02420054|BEHAVIORAL|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
219023749|NCT02420054|OTHER|Time control|Time control period with no change in eating habits.
219023750|NCT05132959|DIAGNOSTIC_TEST|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
219023751|NCT01276093|PROCEDURE|PVI ablation|Pulmonary Vein Ablation using RF.
219023752|NCT01276093|DRUG|Amiodarone|Amiodarone tablets
219494426|NCT01084603|DRUG|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
219494427|NCT02869295|DRUG|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
219494428|NCT02360410|BEHAVIORAL|Check Yourself App with Feedback|
219494429|NCT04959110|DIAGNOSTIC_TEST|Pharmacokinetic study|"* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter"
219494430|NCT02545010|DRUG|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
218874456|NCT00294255|DRUG|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
218874457|NCT02846012|OTHER|CSCM2|
218874458|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
218874459|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
218874460|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
218874461|NCT01716104|DRUG|Afalaza|Safety and Efficacy
219200196|NCT06693921|PROCEDURE|AI/guided shell graft|The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
219494431|NCT02545010|RADIATION|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
218874462|NCT01716104|DRUG|Placebo|Safety and Efficacy
218874463|NCT06142006|OTHER|Diabetes Staging System (DSS) use among Primary Care Teams|Evaluate the feasibility of using the DSS in PACT clinics to increase SGLT2i and/or GLP-1 agonist use in Veteran DM2 patients with cardiovascular disease
218874464|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
219200197|NCT06695013|DRUG|zanubrutinib|zanubrutinib 160 mg BID orally
219200198|NCT06695013|DRUG|CAR-T|CAR-T Cell therapy
219200199|NCT06695013|RADIATION|Bridging radiotherapy|For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.
219494432|NCT02886481|DEVICE|perioperative monitoring|
219494433|NCT02483481|DIAGNOSTIC_TEST|shear wave ultrasound elastography|shear wave ultrasound elastography
219494434|NCT00803946|DRUG|Ibuprofen Tablets, 800 mg|
219200200|NCT06695013|DRUG|Tislelizumab|200mg IV Q3-4W
219494435|NCT04514146|OTHER|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
219494436|NCT00350519|DRUG|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
219494437|NCT00350519|DRUG|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
219494438|NCT05826106|PROCEDURE|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
218874465|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
218874466|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
218874467|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
218874468|NCT05047146|OTHER|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
218874469|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
218874470|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
218874471|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
218874472|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
218874473|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
219023753|NCT03141281|BEHAVIORAL|BrainHQ|BrainHQ
219023754|NCT03141281|BEHAVIORAL|Rise of Nations|Rise of Nations
219023755|NCT03141281|BEHAVIORAL|IADL Training|IADL Training
219023756|NCT03141281|BEHAVIORAL|Active Control|Puzzle solving
219023757|NCT01813084|DRUG|RV1729 single dose|Safety and tolerability of single escalating doses
219023758|NCT01813084|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
219023759|NCT01813084|DRUG|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
219023760|NCT01813084|DRUG|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
219023761|NCT05762146|DRUG|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
219023762|NCT05762146|DRUG|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
219023763|NCT05762146|DRUG|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
219023764|NCT03280290|BIOLOGICAL|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
219494439|NCT02197221|DRUG|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
219023765|NCT03322254|OTHER|respiratory pathogen panel|lab testing for respiratory pathogens
219023766|NCT00000806|DRUG|Telinavir|
219023767|NCT02270827|DRUG|Aminophylline|intravenous medication
219023768|NCT02270827|DRUG|Hydrocortisone|Intravenous medication
219023769|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
219023770|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
219200201|NCT06691165|OTHER|Low oxygen therapy (LOT)|"Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels."
219200202|NCT06686082|DRUG|Biologics|The ultrasonic changes of synovitis and enthesitis were observed after 12 weeks of treatment with biologic agents
219200203|NCT06688396|DEVICE|Mobile 6L AI-EKG Screening|"Participants (probands) with DCM will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-EKG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment."
219200204|NCT06691659|DIAGNOSTIC_TEST|CT-DACE|Photon Counting CT scan
219200205|NCT01536938|DRUG|LEO 90100|
219200206|NCT01536938|DRUG|Calcipotriol|
218874474|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
219200207|NCT01536938|DRUG|Betamethasone|
219200208|NCT06872580|DRUG|QLS1209|Levels of QLS1209 will be explored in dose escalation, and determine the maximum tolerated dose.
219200209|NCT06872580|DRUG|QLS1209|Every 21 days is one cycle.1-3 dose levels of QLS1209 will be explored in dose optimization, and determine the recommended dose (RD) of QLS1209 and evaluate the preliminary anti-tumor activity of QLS1209.
219200210|NCT06873399|DIAGNOSTIC_TEST|MS-39|The MS-39 (Costruzione Strumenti Oftalmici, Firenze, Italy) is a device for anterior segment analysis of the eye, which combines Placido disc corneal topography and high-resolution SD-OCT. The device provides information on pachymetry, elevation, curvature, and dioptric power of both corneal surfaces. To obtain corneal topography, 22 Placido disc rings are emanated from a laser emitted diode (LED) light source at 635 nanometres (nm). The central 10 millimetres of the anterior corneal surface are covered. Epithelial thickness maps are calculated for different sectors (central, paracentral inferior/superior/nasal/temporal).
219200211|NCT06680271|OTHER|Remote exercise|The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform
219200212|NCT06680271|OTHER|Home exercise|The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist.
219200213|NCT06696677|DIAGNOSTIC_TEST|CT|CT measurment of small bowel
219200214|NCT06696677|PROCEDURE|Measuring the small instestine length using pre-marked laparoscopic graspers|Intra-operatively, the surgeon will assess the length of the small intestine using a 5-cm marked laparoscopic graspers to accurately assess the whole small intestine length.
219200215|NCT06698107|BEHAVIORAL|Childbirth education programme|"The intervention framework is underpinned by a converging of salutogenic and self-efficacy perspectives, aiming to enhance mothers' ability to adapt to new motherhood life despite stressors, and to address the question, How do teenage mothers stay well despite stressful events of transition to motherhood? The intervention consists of six sessions: three of which will be provided in the antenatal period and the other three in the postpartum period. The sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion sessions (each lasting 90-120 minutes), as supported by the existing evidence."
219200216|NCT06698107|OTHER|Usual Care|The control group will receive the usual maternity care.
219200217|NCT06697964|OTHER|HRA|High resolution anoscopy to help evaluate anal conditions such as precancerous lesions
219200218|NCT06632990|DRUG|BMS-984923|oral capsules once or twice daily
219200219|NCT06632990|DRUG|Midazolam|midazolam, oral, 2mg administered before study drug and after study drug
219200220|NCT06632990|DRUG|Caffeine|Caffeine, oral, 100mg administered before study drug and after study drug
219200221|NCT06632990|DRUG|dextromethorphan|dextromethorphan, oral, 30mg administered before study drug and after study drug
219200222|NCT06632418|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
219200223|NCT03533257|DRUG|AMX0035|Combination Therapy of PB and TURSO
219494440|NCT02197221|DRUG|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
219494441|NCT06173895|DRUG|LY3454738|Administered subcutaneously (SC)
219494442|NCT00058617|BIOLOGICAL|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
219494443|NCT05103059|DIAGNOSTIC_TEST|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
219494444|NCT00591487|DRUG|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
219494445|NCT00410215|DRUG|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
219494446|NCT00410215|DRUG|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
219200224|NCT03533257|DRUG|Placebo|Placebo
219200225|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|"Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)"
218874475|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
219494447|NCT00410215|DRUG|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
219494448|NCT05720728|DIAGNOSTIC_TEST|collection of blood samples|For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
218874476|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
218874477|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
218874478|NCT03129360|DRUG|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
218874479|NCT03129360|DRUG|Placebo|Prepared in capsules to appear identical to levetiracetam.
218874480|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
218874481|NCT02209623|BIOLOGICAL|TDAP|
218874482|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
218874483|NCT04928560|DIAGNOSTIC_TEST|SMI|ULTRASOUND
218874484|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
218874485|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
218874486|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
218874487|NCT03006887|DRUG|lenvatinib|lenvatinib capsules
218874488|NCT03006887|DRUG|pembrolizumab|pembrolizumab intravenous infusion
219023771|NCT03658538|DEVICE|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
219023772|NCT03658538|BEHAVIORAL|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
219023773|NCT03658538|DEVICE|Sham Air Cleaner|The Control arm will receive sham air cleaners
219023774|NCT05554289|DEVICE|Depression Auxiliary Intervention Treatment Software (WL-iCBT)|The Depression Auxiliary Intervention Treatment Software (WL-iCBT) is a mobile application for smartphones that delivers cognitive behavioral therapy (CBT) and cognitive bias modification (CBM) through structured interactive multimedia methods, including animations, videos, audio, and interactive exercises.
219023775|NCT05554289|DEVICE|Placebo Control Software (WL-iHE)|The placebo control software (WL-iHE) is a mobile application that mimics the appearance and usage pattern of the active intervention software but lacks the therapeutic cognitive behavioral therapy components. The software has a similar user interface and time requirements, with participants using it once daily for 10-15 minutes, completing a total of 56 sessions over the 8-week treatment period. Unlike the active intervention, the placebo software does not deliver structured cognitive behavioral therapy content or cognitive bias modification training, instead providing general health education information without specific depression treatment techniques.
219023776|NCT04596631|DRUG|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
219023777|NCT04596631|DRUG|Placebo (semaglutide)|Placebo treatment for 52 weeks.
219023778|NCT05615233|BEHAVIORAL|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~1. 2 sub-ethnic specific social media sites;~2. interactive online educational modules;~3. online resources; and~4. a VR component based on A Walk Through Dementia (WTD)"
219023779|NCT05615233|BEHAVIORAL|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
219023780|NCT06975618|DRUG|CYH33|CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.
219023781|NCT06975618|DRUG|Placebo|Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.
219023782|NCT05270707|RADIATION|Stereotactic radiosurgery|HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
219023783|NCT03671889|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
219200226|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
219494449|NCT03836729|DRUG|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
219494450|NCT03836729|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
219494451|NCT03775148|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
218874489|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
219023784|NCT05219435|DRUG|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
218874490|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
218874491|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
218874492|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
218874493|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
219023785|NCT05219435|DRUG|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
219602495|NCT07167732|DIAGNOSTIC_TEST|Blood Sample Collection|"Venepuncture will be performed by a qualified member of the research team on all participants at each visit and 2x 5ml of blood will be collected (\< 0.8 ml/kg) for analysis of DNA methylation and RNA expression, and analysis of serum for neurofilaments, b-catenin, and zinc. All blood samples will be labelled with the study ID and visit number and processed at the laboratory of the UMCL following the protocol CTNNB1."
218874494|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
218874495|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
218874496|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
218874497|NCT02170766|DRUG|BIBR 1048 low1|
218874498|NCT02170766|DRUG|BIBR 1048 low2|
219494452|NCT03906149|COMBINATION_PRODUCT|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
218874499|NCT02170766|DRUG|BIBR 1048 medium|
219023786|NCT05094037|DEVICE|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
219494453|NCT03906149|COMBINATION_PRODUCT|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
219023787|NCT05094037|OTHER|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
219023788|NCT04173416|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
219023789|NCT05519085|DRUG|mezigdomide|Specified dose on specified days
219494454|NCT06176859|OTHER|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
219494455|NCT00482287|DRUG|MTR105|Intravenous administration, dose escalating (4 arms), single dose
219494456|NCT00001633|PROCEDURE|Coronary magnetic resonance angiography imaging|
219494457|NCT03103659|OTHER|personalised care plan|Quality of life assessement in elderly cancer patients
219602496|NCT07167732|DIAGNOSTIC_TEST|Optical Coherence Tomography|To test for FEVR, the participants will be asked to perform Optical Coherence Tomography in their home countries at baseline and before or after every subsequent visit. OCT will only be performed in patients who will be able to cooperate - focus gaze for about 5 seconds.
218874500|NCT02170766|DRUG|BIBR 1048 high|
218874501|NCT02170766|DRUG|Pantoprazole|
219023790|NCT05519085|DRUG|Pomalidomide|Specified dose on specified days
219023791|NCT05519085|DRUG|Bortezomib|Specified dose on specified days
219023792|NCT05519085|DRUG|Dexamethasone|Specified dose on specified days
218874502|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
218874503|NCT05896813|DRUG|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
218874504|NCT05406869|DEVICE|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
218874505|NCT00304005|DRUG|laromustine|
218874506|NCT00100594|DRUG|Efavirenz|
218874507|NCT00100594|DRUG|Lamivudine/zidovudine|
218874508|NCT03841370|PROCEDURE|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
218874509|NCT00136669|PROCEDURE|Acupuncture|
219494458|NCT03447483|OTHER|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
219494459|NCT01918111|PROCEDURE|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
219494460|NCT01918111|DRUG|adenosine infusion treatment|Continue hypertensive medication
219494461|NCT06182007|PROCEDURE|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
219494462|NCT04629183|OTHER|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
219494463|NCT03536247|PROCEDURE|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
218874510|NCT04940884|BEHAVIORAL|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
218874511|NCT04940884|BEHAVIORAL|Aerobic exercise training|All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
218874512|NCT03370562|DRUG|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
218874513|NCT03370562|DRUG|Placebo|Administration of normal saline
218874514|NCT02625714|DRUG|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
218874515|NCT02625714|DRUG|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
219494464|NCT03536247|PROCEDURE|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
218874516|NCT03125460|DEVICE|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
218874517|NCT00494507|DRUG|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
218874518|NCT00494507|DRUG|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
218874519|NCT00494507|DRUG|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
218874520|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
218874521|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
218874522|NCT03615066|DRUG|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
218874523|NCT03615066|DRUG|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
218874524|NCT03615066|DRUG|TAF|Tablet(s) administered orally once daily with food
218874525|NCT03759106|OTHER|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
218874526|NCT03759106|OTHER|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
218874527|NCT03077204|BIOLOGICAL|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
219023793|NCT05924802|DIETARY_SUPPLEMENT|Ketone Ester|Added to water or lemonade 3 times per day.
219023794|NCT05924802|DIETARY_SUPPLEMENT|Placebo|Added to water or lemonade 3 times per day.
219494465|NCT04272177|OTHER|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
219494466|NCT01483222|DEVICE|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
219494467|NCT01483222|DEVICE|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
219602497|NCT07167732|DIAGNOSTIC_TEST|Brain MRI|If a participant has had a brain MRI performed prior to enrolling in our study, pictorial data will be analysed. If the participant will plan to have an MRI performed as a standard procedure in their native country, they will be asked to follow the CTNNB1 MRI protocol: T1 MPRAGE sequence, 3D FLAIR sequence, T2 axial planeartane, SWI, DWI, and DTI with at least 64, but preferably 90 diffusion directions. MRI will not be performed on site.
219602498|NCT07166549|DRUG|Experimental Intervention|"The study intervention includes:~* Lymphapheresis~* Lymphodepleting chemotherapy~* CAR-T infusion~Lymphocytes will be collected from the patients by lymphapheresis to produce a personalized IMP, bispecific anti-CD19, anti-CD20 CAR T cells, which will be manufactured at the GMP facility of the University Hospital Basel.~Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2), before anti-CD19/20 CAR T cells are infused (day 0 = day of infusion).~Participants will undergo lymphapheresis 2-8 weeks prior to CAR T cell infusion."
219602499|NCT07167758|DRUG|TRIV-509|TRIV-509 (Subcutaneous injection)
219494468|NCT05068206|DRUG|AK105 injection|AK105 is programmed death 1（PD-1） monoclonal antibody
218874528|NCT03077204|DEVICE|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
218874529|NCT06508229|DRUG|Adebrelimab|adebrelimab, IV
218874530|NCT06508229|DRUG|albumin paclitaxel|albumin paclitaxel, iv
218874531|NCT06508229|DRUG|Nedaplatin|Nedaplatin，IV
218874532|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
218874533|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
218874534|NCT03649204|BEHAVIORAL|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
218874535|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
218874536|NCT03948919|DRUG|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
218874537|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
218874538|NCT04738630|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
218874539|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
218874540|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
218874541|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
218874542|NCT05246813|OTHER|Blood and bone marrow cell collection|Collection of blood and bone marrow
218874543|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
218874544|NCT03085186|DRUG|Crizotinib|
218874545|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
218874546|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
219494469|NCT05068206|DRUG|Anlotinib hydrochloride capsule|Anlotinib is small molecule multi-target tyrosine kinase inhibitor.
219494470|NCT05068206|DRUG|CapeOX|CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
219602500|NCT07167758|DRUG|Placebo|Drug: Placebo (Matching Placebo subcutaneous injection)
219602501|NCT07178535|DEVICE|Feasibility of Two Types of Real-Time Visual Feedback in an Augmented Reality|"Participants will walk in a corridor (45 m), equipped with Xsens inertial sensors recording their kinematics and an HTC Vive Elite-XR AR headset superimposing virtual feedback onto the real world. Three real-time feedback conditions (3 trials/condition) will be evaluated randomly: (1) an avatar reflecting the participant's movements; (2) visual bars indicating step lengths; (3) control condition without feedback. Participants take part in an evaluation/intervention session."
218874547|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
218874548|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
218874549|NCT03074682|DEVICE|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
218874550|NCT03074682|DEVICE|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
218874551|NCT03074682|DEVICE|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
218874552|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
218874553|NCT00189501|DRUG|Sensipar®|
218874554|NCT00694304|DRUG|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
219494471|NCT05068206|DRUG|Bevacizumab|Bevacizumab is a recombinant human monoclonal antibody.
219494472|NCT00190320|PROCEDURE|Induction of labor vs waiting|
219494473|NCT03862625|DEVICE|a modular adaptive seating system|
219494474|NCT03862625|OTHER|home exercise program for scoliosis|
219494475|NCT01270841|DRUG|Placebo|Placebo capsule 1x daily for 3 months
219602502|NCT07173543|OTHER|Intermittent Hypoxia 1 (IH1)|Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
219602503|NCT07173543|OTHER|Intermittent Hypoxia 2 (IH2)|Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
219602504|NCT07173543|OTHER|SHAM - normoxia|Participants will receive normoxia (no hypoxia) over 50 minutes.
218874555|NCT05401318|PROCEDURE|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
219023795|NCT05363774|DRUG|NNC0519-0130|"SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels."
219023796|NCT05363774|DRUG|Placebo (NNC0519-0130)|"SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels."
219023797|NCT05450692|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
219023798|NCT05450692|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion.
219023799|NCT05450692|DRUG|Docetaxel|Participants will received docetaxel as an intravenous infusion.
219023800|NCT03681054|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
219023801|NCT03681054|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
219023802|NCT03695796|DIAGNOSTIC_TEST|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
219200227|NCT06105164|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
219200228|NCT06105164|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
219200229|NCT05159700|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
219494476|NCT01270841|DRUG|topical testosterone|testosterone gel applied 1x daily for 3 months
218874556|NCT00034736|DRUG|Levofloxacin|
218874557|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
218874558|NCT04004013|DIETARY_SUPPLEMENT|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
218874559|NCT04004013|DIETARY_SUPPLEMENT|Placebo|"Maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
218874560|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
218874561|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
219023803|NCT03297281|OTHER|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
218874562|NCT03645512|BEHAVIORAL|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
218874563|NCT02722265|DRUG|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
218874564|NCT03004755|OTHER|Tissue Harvest|
218874565|NCT00791596|OTHER|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
218874566|NCT05979168|BEHAVIORAL|Phone call and text Messages|The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
218874567|NCT00000466|DRUG|estrogens, conjugated|
218874568|NCT00000466|DRUG|medroxyprogesterone|
218874569|NCT00000466|DRUG|progesterone|
218874570|NCT00000466|DRUG|estrogen replacement therapy|
218874571|NCT02854254|DEVICE|peripherally inserted central catheter|peripherally inserted central catheter
218874572|NCT02854254|DEVICE|peripherally venous access|standard over-the-needle intravenous catheter
218874573|NCT06002568|PROCEDURE|Silent|Apply wave file created in silence.
218874574|NCT06002568|PROCEDURE|Binaural beats|Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
218874575|NCT01671631|OTHER|Measurement of intracoronary pressure|
218874576|NCT06191107|DEVICE|Removable Partial Denture|Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
218874577|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
218874578|NCT05136261|DEVICE|Basic cream|Basic cream
218874579|NCT03537313|PROCEDURE|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
219023804|NCT03297281|OTHER|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
219023805|NCT05877599|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R175H|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
219200230|NCT06457737|DEVICE|IPS Empress Direct|Resin composite will be heated and used to lute a ceramic partial coverage restoration.
219200231|NCT06457737|DEVICE|Bisco Duo-Link Universal|Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
219200232|NCT06702371|BEHAVIORAL|Mindset Intervention|"The EMBody intervention contains seven short documentary-style films and paired reflection activities across three modules.~Module 1: Introducing Mindsets (Film 1: A New normal; Film 2: What is a Mindset?; Film 3: Your Body is Capable; Film 4: How to Choose Your Mindset).~Module 2: Challenges and Setbacks (Film 5: Living with Uncertainty; Film 6: The Long and Winding Road).~Module 3: Looking to the Future (Film 7: Opportunities Emerge)."
219200233|NCT06699940|DEVICE|Transcranial Magnetic Stimulation|Patients between the age of 12-21 received TMS treatment for MDD disorder.
219200234|NCT05399381|DEVICE|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
218874580|NCT03537313|PROCEDURE|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
218874581|NCT02880150|OTHER|Stress test|
218874582|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
218874583|NCT00803062|BIOLOGICAL|Bevacizumab|Given IV
218874584|NCT00803062|DRUG|Cisplatin|Given IV
218874585|NCT00803062|OTHER|Laboratory Biomarker Analysis|Correlative studies
218874586|NCT00803062|DRUG|Paclitaxel|Given IV
218874587|NCT00803062|OTHER|Quality-of-Life Assessment|Ancillary studies
218874588|NCT00803062|OTHER|Questionnaire Administration|Ancillary studies
218874589|NCT00803062|DRUG|Topotecan Hydrochloride|Given IV
218874590|NCT03589755|BEHAVIORAL|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
218874591|NCT00705887|BEHAVIORAL|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
218874592|NCT04650425|BEHAVIORAL|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
218874593|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
218874594|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
218874595|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
218874596|NCT05117177|DRUG|Inupadenant|Oral administration
219494477|NCT01270841|DRUG|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
219494478|NCT06520436|PROCEDURE|Arthroscopic-Assisted Reduction|The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
219494479|NCT02122159|BIOLOGICAL|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
219494480|NCT06541782|BEHAVIORAL|Dyadic CAT-based Intervention|The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.
218874597|NCT05117177|DRUG|Inupadenant|Oral administration
218874598|NCT05117177|DRUG|Inupadenant|Oral administration
218874599|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
218874600|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
218874601|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
218874602|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
218874603|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
218874604|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
218874605|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
218874606|NCT04117698|DRUG|Ethambutol|Ethambutol
218874607|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
218874608|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
218874609|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
218874610|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
218874611|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
218874612|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
218874613|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
218874614|NCT06949969|DEVICE|OSA LLLT treatment device|The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.
218874615|NCT06949969|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
218874616|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
218874617|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
218874618|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
219023806|NCT04122313|OTHER|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
219023807|NCT05012930|OTHER|Baby Foods - Meat|Commercially available baby foods
219023808|NCT05012930|OTHER|Baby Foods - Dairy|Commercially available baby foods
219023809|NCT05012930|OTHER|Baby Foods - Plant|Commercially available baby foods
219023810|NCT05012930|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
219023811|NCT06479876|OTHER|HBCR|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
219023812|NCT04862923|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
219023813|NCT06732804|BIOLOGICAL|AVT80|Single subcutaneous injection of AVT80 (108mg)
219023814|NCT06732804|BIOLOGICAL|Geographical region 1 Entyvio|Single subcutaneous injection of Geographical region 1 Entyvio (108mg)
219023815|NCT06732804|BIOLOGICAL|Geographical region 2 Entyvio|Single subcutaneous injection of Geographical region 2 Entyvio (108mg)
219023816|NCT03813979|DRUG|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
219023817|NCT03842124|OTHER|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
219023818|NCT02446990|DRUG|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
219023819|NCT02446990|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
219023820|NCT03398057|OTHER|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
219023821|NCT03398057|OTHER|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
219023822|NCT06261554|DIETARY_SUPPLEMENT|Dietary Supplement: Low dose OIT|Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
219200235|NCT06880120|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing|This intervention involves the use of Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing, a non-invasive technique that records mechanical vibrations of the chest caused by heart activity using high-precision accelerometers and gyroscopes. Unlike traditional imaging techniques such as coronary artery calcium computed tomography (CAC-CT), coronary computed tomography angiography (CCTA), and invasive coronary angiography (ICA), this method does not require radiation exposure (unlike CAC-CT and CCTA), is completely non-invasive and does not require contrast agents (unlike ICA), and provides real-time cardiac mechanical activity measurements rather than anatomical imaging.
219200236|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
219200237|NCT06879925|BEHAVIORAL|QI-GONG and control|QIGONG
219200238|NCT06877000|OTHER|VITIQOL questionnaire|16 questions questionnaire measure effect of vitiligo on quality of life
219494481|NCT06541782|BEHAVIORAL|Psycho-Educational Parent Counseling|This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
218874619|NCT03203291|DEVICE|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
218874620|NCT01599741|RADIATION|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
218874621|NCT01599741|RADIATION|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
218874622|NCT00003027|BIOLOGICAL|aldesleukin|
218874623|NCT00003027|BIOLOGICAL|filgrastim|
218874624|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
218874625|NCT00003027|DRUG|cisplatin|
218874626|NCT00003027|DRUG|dacarbazine|
218874627|NCT00003027|DRUG|vinblastine|
218874628|NCT05533710|PROCEDURE|erector spinae plane block|Patients will receive ESB. In the lateral decubitus, after skin sterilization, ESP block will be performed at the level of T9
219023823|NCT00215163|DRUG|Cognitive-behavioral therapy and paroxetine-CR|
219023824|NCT01518920|DRUG|PF-04958242|PF-04958242 0.35 mg oral solution
219023825|NCT01518920|DRUG|PF-04958242|PF-04958242 0.27 mg oral solution
219023826|NCT01518920|DRUG|Placebo|Placebo oral solution
219200239|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
219200240|NCT06880718|DRUG|Brixadi (Injectable Buprenorphine)|Brixadi comes in several doses and can be administered on a weekly or monthly basis. For clinical reasons (i.e., each patient will already be on a stable dose of MOUD in a setting without significant illicit opioid use), the monthly injection will be used. The approximately equivalent to the 300mg Sublocade dose is 96mg of Brixadi. The maximum dose is 128mg. Brixadi can be administered in the abdomen, buttocks, or triceps. Participants in the Brixadi treatment arm will be given one or more Brixadi injections each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Brixadi is covered by most Medicaid health insurances in the state of Rhode Island.
219494482|NCT03638752|OTHER|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
218874629|NCT05533710|PROCEDURE|transversus abdominis plane block|patients will receive TAP block in supine position after skin sterilization, TAP block will be performed between internal oblique and transversus abdominis muscles
218874630|NCT05098509|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
218874631|NCT05098509|DRUG|Placebo|Matching Placebo for RAD011
219494483|NCT04637685|DEVICE|Centurion Phacoemulsification System|Infusion Pressure
219494484|NCT02688309|DRUG|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
219494485|NCT02688309|PROCEDURE|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
219602505|NCT07179874|PROCEDURE|Remote Ischemic Preconditioning|"This intervention involves a non-invasive, mechanical stimulus applied to an upper limb with the goal of activating systemic protective pathways against contrast-induced nephropathy in diabetic patients. Unlike pharmacologic or device-based interventions, RIPC:~* Does not involve any drugs, biologics, or implants~* Is performed using a standard blood pressure cuff, inflated to 50 mmHg above systolic pressure, specifically designed to induce repetitive transient limb ischemia~* Consists of four alternating cycles of 5 minutes inflation followed by 5 minutes reperfusion~* Is applied 45 minutes before coronary catheterization, timed to optimize systemic renal protection prior to exposure to contrast media~* Targets activation of the heme oxygenase-1 (HO-1) enzymatic pathway, linking limb ischemia with antioxidant renal defense mechanisms Unlike interventions that rely solely on hydration or pharmacological antioxidants, this approach seeks to prime endogenous protective systems through is"
218874632|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
218874633|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
218874634|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
218874635|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
219023827|NCT03333044|BEHAVIORAL|Community Health Worker (CHW)-Led Health Coaching|CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to manage diabetes.
219023828|NCT03333044|OTHER|EHR-Embedded Alerts|An electronic health record (EHR) intervention for primary care providers (PCPs) utilizing embedded alerts to identify South Asian patients with uncontrolled diabetes.
219602506|NCT07181122|DRUG|Androgen Receptor Pathway Inhibitors (ARPIs)|Men with metastatic hormone-sensitive prostate cancer will receive androgen receptor pathway inhibitors (abiraterone acetate, apalutamide, enzalutamide, or darolutamide) in addition to standard androgen deprivation therapy. The choice of ARPI will be determined by routine clinical practice. The study does not assign treatments; it observes patient outcomes under real-world conditions.
219602507|NCT02690441|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
219023829|NCT06359691|BEHAVIORAL|Patient-focused strategies|"Patient-focused strategies to increase HTN management practices:~1. Hypertension registry: notify patients of their status, target education and resources to patients~2. Home BP monitoring: provide BP monitors, encourage reporting of home BP readings~3. Enhance standardization of home and office BP readings: patients trained by care staff, posters in clinics on how to measure BP correctly~4. Nurse-directed BP medication titration with CHW/Health Educator reinforcement: self-directed referrals to nurse-directed clinics and CHW/health educators~5. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: tailored educational materials offered to patients in clinic, via text and the patient portal.~6. Social needs screening and linkage to community resources: awareness of and self-referrals to community resources~7. Behavioral science intervention messaging: posters in clinic waiting rooms, scripts for RN/PCP, texts to patients"
218874636|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
218874637|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
218874638|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
218874639|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
218874640|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
218874641|NCT04042727|DRUG|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
218874642|NCT04042727|OTHER|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
218874643|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
219023830|NCT06359691|BEHAVIORAL|Provider-focused strategies|"Provider-focused strategies to increase HTN management practices:~1. Hypertension registry: identify patients with uncontrolled BP, notify care team~2. Home BP monitoring: provide home BP monitors, encourage reporting of BP readings~3. Enhance standardization of home/office BP readings: staff training, posters in clinic~4. Simplify treatment protocols using fixed-dose combo meds: education on fixed-dose combo meds~5. Nurse-directed BP med titration w/ CHW/Health Educator support: system for team-based care, referral to nurse-directed clinics \& CHWs/health educators~6. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: Increased availability of tailored materials~7. Social needs screening and linkage to community resources: referral system to resources~8. CHW assigned to patients with complex medical and social needs: referral of complex patients to CHWs~9. Behavioral science messaging: posters in charting rooms, scripts for RNs"
218874644|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
219023831|NCT06359691|BEHAVIORAL|Patient- and provider-focused strategies|A combination of the 7 patient-focused strategies (see patient-focused strategies outlined above) and 9 provider-focused strategies (see provider-focused strategies outlined above) implemented simultaneously.
219023832|NCT04820075|BEHAVIORAL|improvement of preoperative shower|Process about preoperative shower
219023833|NCT06258837|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
219023834|NCT06258837|PROCEDURE|Adenotonsillectomy|Tonsil and/or adenoid removal
219023835|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
219023836|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
219023837|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
219200241|NCT06880718|DRUG|Sublocade|Sublocade is a 100mg or 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. Participants in the Sublocade treatment arm will be given monthly Sublocade injections, as clinically indicated, each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Sublocade is covered by most Medicaid health insurances in the state of Rhode Island. The standard dosing schedule is two months of 300mg followed by monthly 100mg injections. To maximize real-world generalizability, the medication dosing will be determined by clinical indication of the provider who will have the flexibility to provide medication dosing based on their clinical acumen and/or shared decision-making.
218874645|NCT05460156|BEHAVIORAL|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
218874646|NCT03576573|DEVICE|PROCOTYL® C|Hip Arthroplasty
218874647|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
219494486|NCT02688309|PROCEDURE|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
218874648|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
218874649|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
218874650|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
218874651|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
218874652|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
218874653|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
218874654|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
218874655|NCT03570320|OTHER|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
218874656|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
218874657|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
218874658|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
218874659|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
218874660|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
218874661|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
218874662|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
218874663|NCT03033199|DRUG|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
218874664|NCT03033199|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
218874665|NCT00971295|DRUG|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
218874666|NCT00971295|DRUG|Eslicarbazepine acetate|
219494487|NCT04406883|DRUG|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
219494488|NCT02851953|DEVICE|Aqueduct-100|
219494489|NCT04442373|DIAGNOSTIC_TEST|Rotational thromboelastometry|1.8 ml blood sample
219494490|NCT04388527|BIOLOGICAL|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
219494491|NCT03980860|OTHER|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
219494492|NCT06539091|DRUG|Fluzoparib|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
219494493|NCT06539091|DRUG|Apatinib Mesylate|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
219602508|NCT02690441|BEHAVIORAL|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
219602509|NCT02690441|BEHAVIORAL|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
219602510|NCT07176299|PROCEDURE|Unilateral laparoscopic TAP block (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine into the transversus abdominis plane under direct laparoscopic vision.
218874667|NCT04692142|OTHER|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
218874668|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
218874669|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
218874670|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
218874671|NCT00375167|BEHAVIORAL|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
218874672|NCT00375167|BEHAVIORAL|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
218874673|NCT02597140|DRUG|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
218874674|NCT02597140|DRUG|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
218874675|NCT02597140|DRUG|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
218874676|NCT00175448|PROCEDURE|physiotherapy|See Detailed Description.
219023838|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
219023839|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
219602511|NCT07176299|PROCEDURE|Local anesthetic infiltration (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine distributed across trocar insertion sites under laparoscopic guidance.
219023840|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
219023841|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
219023842|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
219494494|NCT02746029|OTHER|Clinical examination|
219494495|NCT03568526|OTHER|Educational Intervention|Attend a therapy session
219494496|NCT03568526|BEHAVIORAL|Exercise Intervention|Complete exercise
219494497|NCT03568526|OTHER|Quality-of-Life Assessment|Ancillary studies
219494498|NCT03568526|OTHER|Questionnaire Administration|Ancillary studies
219494499|NCT03568526|OTHER|Survey Administration|Ancillary studies
219494500|NCT00550420|DRUG|Rosiglitazone XR|experimental drug
219494501|NCT02845973|BIOLOGICAL|gut microbiota|
219494502|NCT01099280|DRUG|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
219494503|NCT01099280|DRUG|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
219494504|NCT02827422|OTHER|not provided|
219494505|NCT01305265|DEVICE|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
219494506|NCT02264301|DRUG|Puerarin injection 400 mg|
219494507|NCT02264301|DRUG|Qingkailing injection 40 ml|
219494508|NCT05764902|BEHAVIORAL|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
219494509|NCT01046721|DRUG|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
219494510|NCT01046721|DRUG|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
219494511|NCT03733184|PROCEDURE|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
219494512|NCT02377284|OTHER|Photograph|Add a photograph to a chef card.
219494513|NCT00858559|DEVICE|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
219494514|NCT00858559|DEVICE|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
218874677|NCT02449590|DIETARY_SUPPLEMENT|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
218874678|NCT02449590|DIETARY_SUPPLEMENT|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
218874679|NCT03327194|DEVICE|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
218874680|NCT01816802|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
219494515|NCT05990647|DIAGNOSTIC_TEST|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
219494516|NCT05990647|DIAGNOSTIC_TEST|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
219494517|NCT05990647|DIAGNOSTIC_TEST|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
219494518|NCT05990647|DIAGNOSTIC_TEST|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
219494519|NCT01613131|DRUG|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
219494520|NCT01613131|DRUG|Estradiol|Topical, .06%, Applied once daily for 50 days.
219494521|NCT01613131|DRUG|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
219494522|NCT01430182|DRUG|Methadone|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
219494523|NCT01430182|DRUG|Morphine|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
219494524|NCT01074021|DRUG|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
219494525|NCT01074021|DRUG|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
219494526|NCT01997528|DEVICE|Change of blood flow or sweep gas flow ( ILA Activve)|
218874681|NCT05060965|DRUG|Nicotine lozenge|Nicotine replacement therapy
218874682|NCT05060965|DRUG|Nicotine gum|Nicotine replacement therapy
218874683|NCT05060965|DRUG|Nicotine patch|Nicotine replacement therapy
218874684|NCT05060965|OTHER|Maryland Quitline|Telephone-based tobacco cessation service
218874685|NCT05060965|OTHER|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
218874686|NCT00122044|DRUG|trihexyphenidyl|
218874687|NCT02402283|DRUG|Metronidazole benzoate oral granules|Single oral dose of 400 mg
218874688|NCT02402283|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
218874689|NCT02727491|DRUG|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
218874690|NCT02727491|DRUG|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
218874691|NCT02518191|DRUG|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
218874692|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
218874693|NCT04407234|DRUG|Tirzepatide|Tirzepatide administered SC.
218874694|NCT04407234|DRUG|Acetaminophen|Acetaminophen administered orally.
219602512|NCT07176299|PROCEDURE|Combined TAP block and local anesthetic infiltration (0.25% bupivacaine)|10 mL of 0.25% bupivacaine given as a TAP block and 10 mL administered as local infiltration at trocar sites.
218874695|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
218874696|NCT04161001|DRUG|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
218874697|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
218874698|NCT03936972|PROCEDURE|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
218874699|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
218874700|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
218874701|NCT01705912|OTHER|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
218874702|NCT01705912|OTHER|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
218874703|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
218874704|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
218874705|NCT02760641|OTHER|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
219494527|NCT00417027|PROCEDURE|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
218874706|NCT02760641|OTHER|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
218874707|NCT03528226|BEHAVIORAL|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
219494528|NCT05694429|OTHER|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
219494529|NCT00272337|DRUG|Aspirin|Dosage
219494530|NCT00939705|DRUG|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
219494531|NCT04314427|PROCEDURE|Roux-en-Y gastric bypass|
219494532|NCT04314427|PROCEDURE|Sleeve gastrectomy|
219494533|NCT01653483|DRUG|GSK573719|Novel Dry-Powder Inhaler
219494534|NCT01653483|DRUG|GSK573719matched-placebo|Novel Dry-Powder Inhaler
219602513|NCT07177131|BEHAVIORAL|Relative Dehydration Protocol|Participants will abstain from water intake for 12 hours prior to the study visit. Food is allowed, but fluid intake is limited to a maximum of 250 ml until 20:00 h on the previous evening. Eye measurements will be performed in the morning (8-10 h).
219602514|NCT07177131|BEHAVIORAL|Hyperhydration Protocol|Participants will consume 2 liters of water within 4 hours prior to the study visit. Eye measurements will be performed in the morning (8-10 h).
219494535|NCT04063566|PROCEDURE|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
219494536|NCT04063566|PROCEDURE|Prostate-specific antigen (PSA) test|Blood test for PSA levels
219494537|NCT01017029|DRUG|Everolimus|
219494538|NCT01017029|DRUG|Mycophenolate mofetil + Everolimus|
219494539|NCT04426526|DEVICE|BTL 799-2|High power magnet system
219494540|NCT04156191|DRUG|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
219602515|NCT07160205|BIOLOGICAL|ULSC (1.5 x 10^8 cells/dose)|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1.5 x 10\^8 ULSC will be added into 250 sterile saline IV bag for infusion (total volume of 260 mL volume).
219602516|NCT07160205|BIOLOGICAL|Placebo (no cells)|The Placebo will be 250 ml sterile saline with vehicle (total volume of 260 mL) IV bag for infusion.
219602517|NCT07178353|OTHER|Bedrest|5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.
219494541|NCT04156191|DRUG|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
219494542|NCT06529224|OTHER|Online questionnaire|An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
218874708|NCT03528226|BEHAVIORAL|Normal life procedure|No supervised exercise training during the 4 month period.
218874709|NCT00583687|DEVICE|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
219023843|NCT07131358|DEVICE|Glass ionomer pit and fissure sealant plus fluoride varnish|Application of glass ionomer pit and fissure sealant plus fluoride varnish
219023844|NCT07131358|DEVICE|Pit and fissure sealant with Giomer® technology|Application of pit and fissure sealant with Giomer® technology
219023845|NCT07131358|DEVICE|Fluoride varnish|Biannual application of fluoride varnish
219023846|NCT06855264|DRUG|varegacestat|Single oral dose of varegacestat
219023847|NCT06855264|DRUG|Placebo|Single oral dose of placebo
219023848|NCT06855264|DRUG|Moxifloxacin 400 mg|Single oral dose of moxifloxacin
219023849|NCT02849496|DRUG|Atezolizumab|Given IV
219023850|NCT02849496|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219023851|NCT02849496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219023852|NCT02849496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218874710|NCT00583687|OTHER|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
218874711|NCT00583687|OTHER|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
218874712|NCT00583687|DEVICE|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
218874713|NCT04063969|OTHER|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
218874714|NCT04063969|OTHER|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
218874715|NCT04063969|OTHER|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
218874716|NCT04063969|OTHER|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
219023853|NCT02849496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219023854|NCT02849496|PROCEDURE|Bone Scan|Undergo a bone scan
219023855|NCT02849496|PROCEDURE|Computed Tomography|Undergo a CT scan
219023856|NCT02849496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023857|NCT02849496|DRUG|Olaparib|Given PO
219023858|NCT02849496|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219023859|NCT02849496|OTHER|Questionnaire Administration|Ancillary studies
219023860|NCT02849496|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219023861|NCT04537637|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219023862|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
219023863|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
219023864|NCT06799364|OTHER|28-days consumption of Product A in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product A twice per day during 28 consecutive days.
219023865|NCT06799364|OTHER|28-days consumption of Product B in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product B twice per day during 28 consecutive days.
219023866|NCT06799364|OTHER|28-days consumption of Control product in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Control product twice per day during 28 consecutive days.
219023867|NCT06149897|DEVICE|tDCS|Non invasive brain stimulation with sham and active comparators
219023868|NCT06349915|BEHAVIORAL|Supporting Wellbeing with Everyday Experiences of Peers (SWEEP)|Each day during a 14-day trial period, participants will receive one narrative featuring lived experience with and recovery from suicidal thoughts and behaviors. These narratives will be presented in audio and text format via a smartphone app. Participants will also complete self-report surveys assessing study outcomes using the same smartphone app five times per day.
219023869|NCT06812780|DRUG|AZD2389|Single oral dose of AZD2389 in participants from all cohorts
219023870|NCT06800313|DRUG|HLD-0915|A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
219023871|NCT06980649|DRUG|BHV-1300|BHV-1300 is delivered subcutaneously (SC)
219023872|NCT03188094|BEHAVIORAL|CHW-Led Health Coaching|The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.
218874717|NCT00696046|PROCEDURE|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical \& steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
218874718|NCT03221686|DIETARY_SUPPLEMENT|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
218874719|NCT03221686|DIETARY_SUPPLEMENT|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
219602518|NCT07177573|OTHER|Virtual Reality|The demographic information of the participants will be collected through face-to-face interviews. Pain and comfort levels will be assessed using the Visual Analog Scale (VAS) prior to the intervention. Additionally, anxiety levels will be measured with the Spielberger State-Trait Anxiety Inventory, and vital signs will be recorded. Patients included in the study will be informed about the use of virtual reality (VR) goggles and introduced to the videos that will be viewed. During the Continuous Passive Motion (CPM) application, patients will be positioned in a semi-Fowler's position with a pillow placed under the head for support. Through virtual reality, patients will watch the video Forest Walk along the Middle Fork Snoqualmie River Trail with Relaxing Sounds and the accompanying sounds will be delivered through headphones integrated into the goggles.
219602519|NCT07177846|BEHAVIORAL|LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Program|LiveWell: Adapted DBT Skills Training for Patients with Metastatic Lung Cancer
219602520|NCT07185581|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry (IOS) is a simple, non-invasive, effort-independent method that uses sound waves to detect airway changes quickly. It only requires the patient to breathe normally to assess lung function by measuring both resistance and reactance of the airways. 6,7 These features of IOS suggest it may be a useful test for assessing patient respiratory function during exacerbation periods when airway resistance, airflow limitation, and respiratory muscle weakness further impair breathing.
218874720|NCT05307042|DIAGNOSTIC_TEST|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
218874721|NCT00464503|DRUG|Rosuvastatin-Crestor|
218874722|NCT00464503|DRUG|Pravastatin-Pravasine|
218874723|NCT06080685|BEHAVIORAL|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
218874724|NCT06376578|BEHAVIORAL|Exercise intervention|Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
218874725|NCT06376578|BEHAVIORAL|Polar A380 wristwatch physical activity tracker|The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
218874726|NCT03052244|DEVICE|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
218874727|NCT03052244|DEVICE|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
218874728|NCT05958680|BEHAVIORAL|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
218874729|NCT05127239|BEHAVIORAL|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
218874730|NCT06543888|BEHAVIORAL|passive exoskeleton- assisted gait training programs|Participants will wear an exoskeleton during the training. Each 30-minute Passive exoskeleton-assisted gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living
218874731|NCT06543888|BEHAVIORAL|Conventional gait training|Each 30-minute conventional gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living.
218874732|NCT01591187|OTHER|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
218874733|NCT01591187|OTHER|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
218874734|NCT01591187|OTHER|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
218874735|NCT00226824|DRUG|galantamine|
218874736|NCT03840707|BEHAVIORAL|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
218874737|NCT00475748|PROCEDURE|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
219023873|NCT03188094|OTHER|EHR Alerts|Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI \>23 kg/m2 and registries to track outcomes.
219023874|NCT06599879|OTHER|Neuropsychological assessments:|"Several neuropsychological assessments were carried out during the study (at inclusion and 2 years after inclusion), consisting of :~* parental questionnaires (standard questionnaires and questionnaires specifically drawn up for the trial). The aim of these questionnaires will be to assess the patient's neurocognitive level at different times (before and after radiotherapy treatment).~* patient cognitive tests (½ day face-to-face consultation/assessment with a neuropsychologist specialising in paediatrics, followed by a 30-minute telephone call).~Only for patients having received their radiotherapy treatment at the IUCT-O: a multimodal MRI specific to the study (without injection of contrast product) may be performed at inclusion and 2 years after inclusion."
219494543|NCT01671384|DRUG|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
219494544|NCT01671384|DRUG|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
219494545|NCT04934514|BIOLOGICAL|IAH0968|IAH0968 is an investigational product.
219494546|NCT04934514|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenous infusion
219494547|NCT04934514|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 intravenous infusion
219494548|NCT01702350|DRUG|GSK2251052|Oral formulation of an an antibacterial
219494549|NCT05934032|OTHER|observational, non-interventional|observational, non-interventional
219494550|NCT01779947|DRUG|Estradiol Vaginal Tablets 10 mcg|
219494551|NCT01779947|DRUG|placebo|
219494552|NCT00718965|DRUG|AVE5530|one tablet in the evening with dinner
219494553|NCT00718965|DRUG|Placebo|one tablet in the evening with dinner
219494554|NCT00618774|DRUG|telmisartan40/amlodipine5|
219494555|NCT00618774|DRUG|telmisartan80/amlodipine5|
219494556|NCT04342403|DIAGNOSTIC_TEST|Quality of Life|Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
219494557|NCT00092079|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
219494558|NCT04116346|OTHER|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
219494559|NCT00446264|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
218874738|NCT02885246|OTHER|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
219023875|NCT06712745|RADIATION|Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)|Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases
219494560|NCT00446264|DRUG|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
219494561|NCT02056275|OTHER|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
219494562|NCT02056275|OTHER|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
219023876|NCT04406727|BIOLOGICAL|UB-421|UB-421 in combination with their ARV
218874739|NCT00752193|OTHER|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
218874740|NCT00752193|OTHER|Placebo|Placebo in combination with antibiotic therapy
218874741|NCT01965730|DRUG|epsilon-aminocaproic acid (EACA)|
218874742|NCT00575965|DRUG|Simvastatin|Oral tablets taken daily
218874743|NCT04294030|DEVICE|Diagnostic Test: NOWDx HSV-2 Test|For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
218874744|NCT00183326|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
218874745|NCT00183326|BEHAVIORAL|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
218874746|NCT04086914|PROCEDURE|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
218874747|NCT02618161|RADIATION|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
218874748|NCT02618161|RADIATION|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
219023877|NCT04406727|OTHER|Antiretroviral (ARV)|Antiretroviral (ARV)
219023878|NCT02921776|OTHER|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
219494563|NCT04801979|DIAGNOSTIC_TEST|Incremental Step Test|"Performance of the incremental step test (number of steps) for the assessment of exercise capacity. The step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
219494564|NCT00398359|BEHAVIORAL|Motivational Interviewing (physicians)|Identifying and referring children with BMI \>93%.
219494565|NCT00398359|BEHAVIORAL|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
219494566|NCT03619499|DEVICE|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
218874749|NCT02771717|DRUG|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
218874750|NCT02771717|DRUG|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
218874751|NCT00932906|OTHER|Different self-training methods|Self training with MiniAnne Training Kit
218874752|NCT00932906|OTHER|Standard training|Instructor-based training meeting ERC directions
218874753|NCT04407741|DRUG|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
218874754|NCT04407741|DRUG|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
218874755|NCT04149561|OTHER|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
218874756|NCT04102995|DRUG|Sepranolone injection low dose|Subcutaneous (SC) administration
218874757|NCT04102995|DRUG|Sepranolone injection high dose|Subcutaneous (SC) administration
218874758|NCT04102995|DRUG|Placebo injection|Subcutaneous (SC) administration
218874759|NCT03268941|DRUG|TAK-906 Maleate|TAK-906 Maleate Capsules
218874760|NCT03268941|DRUG|Metaclopramide|Metaclopramide Tablets
218874761|NCT03268941|DRUG|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
218874762|NCT05639192|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
218874763|NCT05639192|OTHER|Placebo|Placebo will be administered once per week as an i.v. infusion
218874764|NCT04062591|DRUG|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
218874765|NCT04062591|DRUG|Placebo|saline IM in the same dose of piroxicam
218874766|NCT01324791|PROCEDURE|anti-reflux surgery|
218874767|NCT03749772|BEHAVIORAL|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
218874768|NCT04327947|OTHER|Hyaluronic acid - Research product 1|Health care product (intimate gel)
219023879|NCT02921776|OTHER|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
219023880|NCT02921776|DEVICE|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
218874769|NCT04327947|OTHER|Hyaluronic acid - Research product 2|Health care product (intimate gel)
218874770|NCT04327947|OTHER|Hyaluronic acid - Comparator product|Health care product (intimate gel)
219023881|NCT02921776|OTHER|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
218874771|NCT01216683|BIOLOGICAL|rituximab|Given IV
218874772|NCT01216683|DRUG|Bendamustin|Given IV
218874773|NCT01216683|DRUG|bortezomib|Given IV
218874774|NCT01216683|DRUG|lenalidomide|Given orally
218874775|NCT04295239|PROCEDURE|MRI|Pre and Post operative MRI
218874776|NCT03562312|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
218874777|NCT03562312|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
218874778|NCT00223483|GENETIC|Isolation of genomic DNA|One time blood draw
218874779|NCT03244163|DEVICE|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
218874780|NCT03244163|DEVICE|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
219023882|NCT03975829|DRUG|dabrafenib|dabrafenib oral, twice daily
219023883|NCT03975829|DRUG|trametinib|trametinib oral, once daily
219494567|NCT03372499|DIETARY_SUPPLEMENT|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
219494568|NCT02753400|DRUG|emixustat hydrochloride|Tablet for oral administration
219494569|NCT02753400|OTHER|Placebo|Placebo tablets for oral administration contain only inactive ingredients
219494570|NCT01824771|OTHER|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
219494571|NCT02796196|OTHER|Medical Chart Review|Review of medical chart
218874781|NCT03774030|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
218874782|NCT01413139|DEVICE|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
218874783|NCT00191230|DRUG|gemcitabine|
218874784|NCT00191230|DRUG|carboplatin|
218874785|NCT00191230|DRUG|cisplatin|
218874786|NCT01237613|DEVICE|Artelon|Artelon Tissue Reinforcement
218874787|NCT03563196|RADIATION|Chest Radiograph|Chest radiogram will be obtained on day 1
219023884|NCT06982599|DIETARY_SUPPLEMENT|postbiotics|3 capsules/day postbiotics (20 × 10\^9 CFU/day) for 8 weeks
219023885|NCT06982599|DIETARY_SUPPLEMENT|placebo|3 capsules/day placebo for 8 weeks
219023886|NCT06606899|DRUG|Melatonin 3 MG|Oral syrup melatonin 3 mg
219023887|NCT06606899|DRUG|Chloral Hydrate|Oral chloral hydrate (50 mg/kg, maximum 2 g)
219023888|NCT06606899|DRUG|Sevoflurane|Inhalational Sevoflurane
219494572|NCT02796196|DEVICE|Monitoring Device|Wearable physical activity monitoring device
219494573|NCT02796196|PROCEDURE|Physical Therapy|Undergo primarily self-directed physical therapy
219494574|NCT01415921|DRUG|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
219494575|NCT00600288|DRUG|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
219494576|NCT00600288|DRUG|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
219494577|NCT00377728|DRUG|GSK256066|
219494578|NCT04980521|OTHER|The radon app|Participants will be asked to use the radon app.
219494579|NCT04980521|OTHER|Print brochure|Participants will receive print brochures.
218874788|NCT03563196|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be done on day 1
218874789|NCT01526395|DRUG|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
218874790|NCT00837343|DRUG|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
218874791|NCT00214916|DRUG|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
218874792|NCT00214916|DRUG|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
218874793|NCT03123016|DRUG|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
218874794|NCT03123016|PROCEDURE|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
219023889|NCT06589804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219023890|NCT06589804|BIOLOGICAL|Cetuximab|Given IV
219023891|NCT06589804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219494580|NCT03440203|OTHER|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
219494581|NCT02660385|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
219494582|NCT02660385|BEHAVIORAL|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
219494583|NCT02287337|PROCEDURE|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
219494584|NCT02287337|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
219494585|NCT02883309|OTHER|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
219494586|NCT01527825|BIOLOGICAL|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
219494587|NCT01527825|BIOLOGICAL|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
218874795|NCT04712708|DEVICE|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
218874796|NCT04712708|OTHER|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
218874797|NCT03157284|DIETARY_SUPPLEMENT|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
218874798|NCT03157284|DIETARY_SUPPLEMENT|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
219494588|NCT01830920|DRUG|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
219494589|NCT01830920|DRUG|Placebo|A normal saline solution identical in appearance to the active drug solution
219494590|NCT03726086|DIAGNOSTIC_TEST|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
219494591|NCT00896701|OTHER|flow cytometry|
219494592|NCT00896701|OTHER|immunologic technique|
219494593|NCT00896701|OTHER|laboratory biomarker analysis|
219494594|NCT00002084|DRUG|Valacyclovir hydrochloride|
218874799|NCT02041338|DRUG|Paclitaxel and carboplatin|
218874800|NCT02041338|DRUG|Paclitaxel|
219023892|NCT06589804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219023893|NCT06589804|BIOLOGICAL|Pembrolizumab|Given IV
219023894|NCT06589804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219023895|NCT05938361|OTHER|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
219023896|NCT05938361|OTHER|Quality of life evaluation|DLQI questionnaire at each visit
219023897|NCT05938361|OTHER|Satisfaction assessment|Visual analogic scale at W16, W28, W52
219023898|NCT05938361|OTHER|Pruritus evaluation|Visual analogic scale at each visit
218874801|NCT02041338|DRUG|Epirubicin and Paclitaxel|
218874802|NCT03725813|OTHER|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
218874803|NCT05795192|DRUG|SB17170|Taking SB17170 orally once a day
219494595|NCT00002084|DRUG|Acyclovir|
219494596|NCT05331846|BEHAVIORAL|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
219494597|NCT03876873|PROCEDURE|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
218874804|NCT05795192|DRUG|Placebo|Taking Placebo orally once a day
218874805|NCT06457867|PROCEDURE|microfragmented adipose tissue loaded on bovine graft|microfragmented adipose tissue loaded on bovine graft on ridge preservation
218874806|NCT02566590|DEVICE|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
218874807|NCT02566590|DIETARY_SUPPLEMENT|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
218874808|NCT02566590|DIETARY_SUPPLEMENT|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
218874809|NCT02503501|DRUG|Insulin glulisine|
218874810|NCT02503501|DRUG|Placebo|Bacteriostatic 0.9% Sodium Chloride
218874811|NCT06090084|OTHER|Evaluation|Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
218874812|NCT02806960|DRUG|Nasal Glucagon|Administered intranasally.
218874813|NCT00903435|OTHER|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
218874814|NCT06366360|OTHER|Immersive Virtual Reality Intervention|"The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice."
218874815|NCT06366360|OTHER|Conventional rehabilitation|The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
218874816|NCT05729243|DRUG|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
218874817|NCT05729243|OTHER|Placebo|A placebo identical in appearance to cytisine will be used
218874818|NCT00039858|DRUG|Argatroban|
218874819|NCT00742716|DRUG|CTA018 Injection|Comparison of different dosages of drug
218874820|NCT03444935|BEHAVIORAL|Follow-up phone call|Please see arm/group description.
218874821|NCT01185977|DRUG|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
218874822|NCT01185977|DRUG|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
218874823|NCT01115374|PROCEDURE|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
218874824|NCT01115374|DEVICE|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
218874825|NCT05082311|OTHER|Observational study|This is an observational study
218874826|NCT04488016|DRUG|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
218874827|NCT04488016|DRUG|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
218874828|NCT04488016|DRUG|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
218874829|NCT04488016|DRUG|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
218874830|NCT04488016|DRUG|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
218874831|NCT04488016|DRUG|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
218874832|NCT04488016|DRUG|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
218874833|NCT04488016|DRUG|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
218874834|NCT04358965|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
218874835|NCT04358965|DRUG|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
218874836|NCT04358965|DRUG|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
219494598|NCT03876873|DEVICE|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
219494599|NCT01878500|DEVICE|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
219494600|NCT02103634|DEVICE|NaF PET/MRI|
218874837|NCT05665296|OTHER|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
219023899|NCT06609343|DRUG|Bupropion Hydrochloride 150 MG|Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks
219023900|NCT06013176|OTHER|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
219494601|NCT02103634|DEVICE|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
219494602|NCT02103634|DEVICE|FDG PET/CT|
219494603|NCT03402126|OTHER|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
219494604|NCT02442752|DRUG|Dexlansoprazole|Dexlansoprazole capsules
219494605|NCT02117479|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
219494606|NCT02117479|DRUG|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
219494607|NCT02117479|DRUG|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
219494608|NCT03354962|COMBINATION_PRODUCT|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
219494609|NCT03354962|COMBINATION_PRODUCT|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
219494610|NCT03859570|DRUG|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
219494611|NCT03859570|DRUG|Placebos|Placebo
219494612|NCT01333631|DRUG|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
219494613|NCT01485705|OTHER|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
219494614|NCT00390169|BEHAVIORAL|Mindfulness Meditation-Based Stress Reduction|
219494615|NCT00390169|BEHAVIORAL|Supportive-Expressive Group Therapy|
219494616|NCT02846467|OTHER|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
219494617|NCT02846467|OTHER|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
219494618|NCT01959230|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
219494619|NCT01959230|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
219494620|NCT01959230|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
219494621|NCT01959230|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
219494622|NCT00391937|DEVICE|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
219494623|NCT05284474|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
219494624|NCT05547100|DRUG|LYBALVI|5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
219494625|NCT01444274|DEVICE|Obalon Gastric Balloon(s)|One or two balloons administered per patient
219494626|NCT00101205|DRUG|oxaliplatin|Given IV
219494627|NCT00101205|DRUG|etoposide|Given IV
219494628|NCT00146237|DRUG|phenytoin|
219494629|NCT00309127|BEHAVIORAL|Multidisciplinary team care|
219494630|NCT01243866|OTHER|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
219494631|NCT01243866|OTHER|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
218874838|NCT05665296|OTHER|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
219494632|NCT00720304|DRUG|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
219494633|NCT00720304|DRUG|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
219494634|NCT00720304|GENETIC|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
219494635|NCT00720304|GENETIC|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
219494636|NCT00720304|OTHER|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
219494637|NCT00720304|OTHER|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
218874839|NCT03060200|OTHER|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
218874840|NCT03060200|OTHER|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
218874841|NCT05533320|DEVICE|Cold Cap Therapy|Undergo scalp cooling
218874842|NCT05533320|OTHER|Quality-of-Life Assessment|Ancillary studies
218874843|NCT05533320|OTHER|Questionnaire Administration|Ancillary studies
218874844|NCT04153045|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
218874845|NCT06455865|OTHER|TPACK-Based Blended Learning Instruction|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
218874846|NCT01706588|DRUG|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
219494638|NCT00720304|OTHER|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
219494639|NCT00720304|OTHER|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
219494640|NCT00720304|PROCEDURE|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
219494641|NCT00720304|RADIATION|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
219494642|NCT00720304|RADIATION|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
219494643|NCT03660514|BEHAVIORAL|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
219494644|NCT01933412|BIOLOGICAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
219494645|NCT01933412|BIOLOGICAL|Engerix B Hepatitis B Vaccine|
219494646|NCT01822964|DEVICE|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
219494647|NCT01822964|DEVICE|Placebo - current clinical practice, no cooling|
219494648|NCT01333475|DRUG|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
219494649|NCT03695406|BEHAVIORAL|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
218874847|NCT05921175|DEVICE|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
218874848|NCT05921175|DEVICE|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
218874849|NCT02684149|PROCEDURE|relational touch|
218874850|NCT03909308|BEHAVIORAL|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
218874851|NCT02906267|OTHER|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
218874852|NCT00306059|PROCEDURE|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
218874853|NCT05912972|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
218874854|NCT00994006|DIETARY_SUPPLEMENT|Magnesium oxide|520 mg of elemental magnesium q.d.
218874855|NCT00994006|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
218874856|NCT01037686|RADIATION|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
218874857|NCT01037686|BEHAVIORAL|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
218874858|NCT01037686|DEVICE|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
218874859|NCT03764306|PROCEDURE|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
218874860|NCT03764306|PROCEDURE|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
218874861|NCT03680443|OTHER|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
218874862|NCT04427020|DIETARY_SUPPLEMENT|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
218874863|NCT04427020|DIETARY_SUPPLEMENT|Milk protein|Both conditions matched flavor, color, and serving size
219494650|NCT04494282|PROCEDURE|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
218874864|NCT00765063|DRUG|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
218874865|NCT06222528|BEHAVIORAL|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
218874866|NCT06222528|BEHAVIORAL|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
218874867|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
218874868|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
218874869|NCT06222528|BEHAVIORAL|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
218874870|NCT06222528|BEHAVIORAL|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
218874871|NCT06222528|BEHAVIORAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
218874872|NCT06222528|BEHAVIORAL|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
218874873|NCT05553392|DEVICE|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
218874874|NCT05553392|DRUG|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
218874875|NCT03775746|DRUG|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
218874876|NCT03775746|DRUG|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
218874877|NCT03775746|DRUG|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
218874878|NCT05378737|DRUG|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
218874879|NCT04920383|DRUG|ALPN-202|Various doses
218874880|NCT04920383|DRUG|pembrolizumab KEYTRUDA®|Varies
218874881|NCT03986528|DRUG|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
218874882|NCT03986528|DRUG|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
218874883|NCT01041287|DRUG|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks
218874884|NCT01041287|DRUG|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
218874885|NCT01257945|BEHAVIORAL|Aerobic Exercise|
218874886|NCT01257945|BEHAVIORAL|Flexibility and Function exercise program|
218874887|NCT01257945|BEHAVIORAL|Home exercise program|
218874888|NCT03261609|OTHER|preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
218874889|NCT02501499|OTHER|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
218874890|NCT06256263|PROCEDURE|total laryngectomy|pharyngeal repair after total laryngectomy
219494651|NCT00459589|BEHAVIORAL|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
219494652|NCT00459589|BEHAVIORAL|usual nutritional care|usual nutritional care
219494653|NCT03284073|PROCEDURE|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
219494654|NCT02947373|DRUG|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
218874891|NCT05490940|DRUG|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
218874892|NCT00487071|DEVICE|Anal fistula plug|
219023901|NCT06013176|OTHER|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
219023902|NCT04960722|DEVICE|OIF/β-TCP|bone graft implantation
219023903|NCT06326021|DRUG|autologous FL-33 CAR T therapy|Autologous FL-33 CAR T cells are infused intravenously.
219023904|NCT06326021|DRUG|prior-HSCT donor-derived FL-33 CAR T therapy|Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
219023905|NCT06326021|DRUG|Newly matched donor-derived FL-33 CAR T therapy|Newly matched donor-derived FL-33 CAR T cells are infused intravenously
219023906|NCT06992297|OTHER|Questionnaire|a standardised, structured questionnaire, validated by the department's clinicians, to assess the physical, cognitive and psychological after-effects.
219023907|NCT06854042|DRUG|E1018|Specified dose on specified days.
219023908|NCT06854042|DRUG|Placebo|E1018 matching placebo on specified days.
219023909|NCT06672250|PROCEDURE|CTCs/CTMs culture|Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture
219023910|NCT06671613|DIETARY_SUPPLEMENT|FMD|Plant-based diet program
219023911|NCT06671613|COMBINATION_PRODUCT|Regular Diet Plus FMD|Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
219494655|NCT06013020|DRUG|NOAC+DAPT|Century Clot-guided rivaroxaban plus DAPT.
219494656|NCT06013020|DRUG|DAPT|Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
219494657|NCT02677610|DRUG|MSRD-100|MSRD-100 is a topical gel.
219494658|NCT02677610|DRUG|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
219494659|NCT00559884|DRUG|GSK189075 (Modified and immediate release formulations)|
219023912|NCT06862128|DIAGNOSTIC_TEST|OGTT at home using CGM|OGTT at home using CGM
219023913|NCT06862128|DIAGNOSTIC_TEST|OGTT at the clinic|OGTT at the clinic
219494660|NCT03398928|OTHER|Acupuncture|Acupuncture added to usual care
219494661|NCT03720522|PROCEDURE|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
219494662|NCT03720522|PROCEDURE|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
219494663|NCT03720522|PROCEDURE|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
219023914|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
219023915|NCT06994442|DRUG|Acetaminophen|"Intravenous (IV) dose, 15 mg/kg\* (maximum 600 mg) every 6 h for 5 days.~\*Note: For children \<28 days old, dose will be 12.5 mg/kg every 6 hours, as per U.S. Food and Drug Administration (FDA) recommendations. The dosing of acetaminophen for intravenous infusion will follow the current Acetaminophen for injection labeling based on the participant's age and weight."
219023916|NCT06994442|DRUG|Ketorolac|IV dose; 0.5mg/kg (maximum 30 mg) every 6 h for 5 days 4.1.d. \*Note: Ketorolac for intravenous bolus administration is currently labeled for multiple-dose treatment in adults. For patients under 65 years of age, the recommended dose is 30 mg every 6 hours, with a maximum daily dose of 120 mg. For patients 65 years or older, renally impaired patients, and those weighting less than 50 kg, the recommended dose is 15 mg every 6 hours, with a maximum daily dose of 60 mg. In this study, we will be limiting ketorolac to \<15 mg per dose, with a maximum of 60 mg per day.
219023917|NCT06994442|DRUG|Placebo|Placebos will be normal saline solution, i.e., 0.9% NaCl. In order to maintain blinding, the investigational pharmacy will dispense placebo in a volume to match the corresponding study drug.
219494664|NCT03720522|PROCEDURE|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
219494665|NCT00370396|BIOLOGICAL|Synflorix|1 dose injected IM in the right thigh or deltoid.
219494666|NCT00370396|BIOLOGICAL|Prevenar|1 dose injected IM in the right thigh or deltoid.
219494667|NCT00370396|BIOLOGICAL|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
219494668|NCT00615771|PROCEDURE|Day 3 embryo transfer|Standard of care
219494669|NCT00615771|PROCEDURE|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
219494670|NCT03251183|DIAGNOSTIC_TEST|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
219602521|NCT07186231|DEVICE|Low-load resistance training with Blood flow Restriction|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the one-repetition maximum (1RM) for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 30 percent 1RM, following a standardized sequence of three shoulder-targeted exercises (shoulder abduction, external rotation, Dumbbell Overhead Press), totaling 75 repetition per session (30/15/15/15), 30-second rest intervals per sets. Movements were executed at a controlled 4-sec. tempo (2 seconds concentric, 2 seconds eccentric). BFR was applied using pneumatic cuffs, maintained during each exercise, released for 60 seconds between exercises, and reapplied for the next. Participants rated exercise difficulty, including pain, tension, and numbness, using a 0-10 numeric scale, with protocol adjustments or session cancellation if symptoms exceeded 7/10.
218874893|NCT02406170|DRUG|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
218874894|NCT02406170|DRUG|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
218874895|NCT05332132|DEVICE|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
218874896|NCT03158441|DIAGNOSTIC_TEST|Breast MRI|comparison of DTI to dynamic MRI
218874897|NCT04406558|OTHER|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
219200242|NCT06881706|OTHER|medical nutrition therapy|Medical nutrition treatment was planned for all participants with metabolic syndrome. A diet plan was created considering age, gender, blood findings and nutritional habits. Individuals with MetS were given a weight loss diet planned at the basal energy level calculated with the Harris-Benedict equation and applied for 8 weeks. Individuals who applied the weight loss diet were targeted to lose at least 5% of their initial weight at the end of 8 weeks. Individuals who strictly followed the given medical nutrition treatment and achieved the targeted weight loss formed the intervention group, and individuals who did not follow the medical nutrition treatment formed the control group. At the end of the 8 weeks, all parameters, blood pressure and anthropometric measurements of all individuals who participated in the study and retrospective 24-hour food consumption records were recorded again and the study was concluded.
219494671|NCT03251183|DIAGNOSTIC_TEST|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
219023918|NCT04104178|DRUG|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
219023919|NCT04104178|DRUG|Placebo|Placebo
219023920|NCT04537234|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
219494672|NCT03251183|DIAGNOSTIC_TEST|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
219023921|NCT04537234|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
218874909|NCT03887273|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
218874910|NCT02693041|DRUG|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
218874911|NCT02693041|DRUG|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
218874912|NCT04705246|BEHAVIORAL|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
218874913|NCT04729335|DIAGNOSTIC_TEST|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
218874914|NCT06114927|BEHAVIORAL|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
218874915|NCT00133666|BEHAVIORAL|Asthma Communication Education|
218874916|NCT00133666|BEHAVIORAL|Standard Asthma Education|
218874917|NCT01890408|DRUG|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
219023922|NCT06359171|OTHER|Application ARTH-e|"The ARTH-e application must be downloaded via the PlayStore or Applestore platform on phone and/or tablet. Once the application has been downloaded, the patient must scan a QRcode sent by the CHU to anonymize the data.~Participants will have 6 months to use the application at their convenience."
218874918|NCT05411289|PROCEDURE|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
218874919|NCT05411289|PROCEDURE|sham acupressure|Pressures were applied on sham points consecutively
218874920|NCT05228483|DEVICE|CO2 fractional laser|CO2 fraction laser
218874921|NCT05228483|COMBINATION_PRODUCT|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
218874922|NCT05228483|DRUG|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
218874923|NCT04472455|DIAGNOSTIC_TEST|HRME|
218874924|NCT01517464|GENETIC|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
218874925|NCT01478334|BEHAVIORAL|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
218874926|NCT01478334|BEHAVIORAL|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
218874927|NCT06206018|PROCEDURE|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
218874928|NCT02702180|DRUG|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
219023923|NCT06998433|BIOLOGICAL|Platelet-Rich Plasma (PRP) Injections|PRP will be injected into the affected scalp.
219494673|NCT03251183|DIAGNOSTIC_TEST|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
219494674|NCT03251183|DIAGNOSTIC_TEST|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
219494675|NCT05494775|DRUG|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
219494676|NCT02647554|DRUG|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
219494677|NCT02647554|DRUG|Placebo|matching placebo every 8 hours for 10 days
219494678|NCT00665717|DRUG|Pravastatin|40 mg tablet; QD; 4 days
219494679|NCT00665717|DRUG|Raltegravir|400mg tablet; BD 4 days
219494680|NCT00665717|DRUG|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
219494681|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
219494682|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo MR DENSE imaging
219602522|NCT07186231|OTHER|High-load resistance training.|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the 1RM for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 70 percent following a standardized sequence of three shoulder-targeted exercises (shoulder abduction and external rotation, and Dumbbell Overhead Press). Four sets of 8 to 10 repetitions were completed for each exercise, with 2-minutes rest between sets and exercises. Movement speed was moderate (1-second concentric, 2-second eccentric).
218874929|NCT02702180|DRUG|Placebo|Placebo nebulizer solution for inhalation
218874930|NCT02702180|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
218874931|NCT03877302|OTHER|reflexology|foot reflexology
218874932|NCT00567359|DRUG|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
219023924|NCT06998433|DRUG|Saline|Placebo saline solution will be injected into affected scalp.
219023925|NCT03860584|DIETARY_SUPPLEMENT|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
218874933|NCT05041270|DRUG|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
218874934|NCT05041270|DRUG|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
218874935|NCT05041270|DRUG|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
218874936|NCT03646474|DRUG|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
218874937|NCT03646474|DRUG|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
218874938|NCT04885413|DRUG|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
218874939|NCT01974011|PROCEDURE|Performing dorsal penile nerve block (DPNB)|
218874940|NCT02301026|DRUG|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
218874941|NCT02533492|DEVICE|vicryl|wound closure with vicryl suture
218874942|NCT02533492|DEVICE|Vicryl plus|wound closure with vicryl plus suture
218874943|NCT05433922|DRUG|Avatrombopag|cyclosporine in combination with Avatrombopag to treat
218874944|NCT04785924|DRUG|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
218874945|NCT05083312|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
218874946|NCT05083312|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet
218874947|NCT06579911|DEVICE|High-frequency micro-ultrasound target biopsy|"1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate"
218874948|NCT06579911|DEVICE|conventional Multiparametric MRT target biopsy|"1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate"
218874949|NCT03267888|BIOLOGICAL|Pembrolizumab|Given 200 mg IV.
218874950|NCT03267888|RADIATION|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
218874951|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
218874952|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
218874953|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
218874954|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
218874955|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
218874956|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
219602523|NCT07176455|BEHAVIORAL|Anti-frailty dietary behavior intervention|Design intervention measures based on the mechanism of dietary behavior changes related to frailty
218874957|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
218874958|NCT04489082|DEVICE|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
218874959|NCT06346522|DRUG|Gabapentin (Gaptin ®) 400mg oral capsule once|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
218874960|NCT06346522|DRUG|Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
218874961|NCT00756782|DRUG|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
218874962|NCT00756782|DRUG|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
218874963|NCT03829722|DRUG|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
218874964|NCT03829722|DRUG|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
218874965|NCT03829722|DRUG|Paclitaxel|Given IV once per week during radiation therapy (30mg/m\^2)
218874966|NCT03829722|RADIATION|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
219023926|NCT03860584|DIETARY_SUPPLEMENT|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
218874967|NCT04910035|OTHER|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
218874968|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
218874969|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
218874970|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
218874971|NCT03287037|DEVICE|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator\_plus\_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
218874972|NCT06167876|RADIATION|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
219023927|NCT07001462|BEHAVIORAL|Inspiratory Muscle Training / Positive Expiratory Pressure (IMT/PEP) Therapy|IMT/PEP therapy was administered using a dual-function device (BİO Breathe, Korea) designed to provide both inspiratory muscle resistance and positive expiratory pressure. Patients performed the therapy for 15 minutes, twice daily, over a 12-week period, in addition to standard pharmacological treatment. Pressure levels were individually adjusted between 5-40 cmH₂O based on patient capacity.
219023928|NCT06997198|DRUG|Deutetrabenazine Oral Capsule|Open-label twenty-four-week treatment with Deutetrabenazine oral tablets (up to 24 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
219494683|NCT01872468|BEHAVIORAL|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
219494684|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
219494685|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
219494686|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
219602524|NCT07186361|DEVICE|Symptom Assessment and Management Program (SAM-CKD) which is delivered via Smart Kidney mobile app|An intervention program delivered through a mobile app to support symptom assessment and management for adults with CKD. The SAM-CKD program has three components - introduction, symptom tracker and symptom management. A list of 17 common symptoms will be assessed. Users can self-assess symptoms and rate these according to the severity level (overwhelmingly, severely, moderately, slightly, and not at all). The SAM-CKD program will provide symptom management strategies based on symptoms reported by patients. The intervention's duration is 6 weeks.
219602525|NCT07184632|DRUG|NNC0662-0419|NNC0662-0419 will be administered subcutaneously.
219602526|NCT07184632|DRUG|Placebo|Placebo matched to NNC0662-0419 will be administered subcutaneously.
219602527|NCT07186894|DRUG|Antistaphylococcal penicillins|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
219602528|NCT07186894|DRUG|Cefazolin|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
219494687|NCT05128487|DRUG|NDI-101150|NDI-101150 capsules
219494688|NCT05128487|DRUG|Pembrolizumab|Pembrolizumab IV infusion
219494689|NCT02470442|DRUG|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
219494690|NCT02470442|DRUG|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
219494691|NCT05241899|DRUG|Fruquintinib + RC48|Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
219602529|NCT07186127|DRUG|Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond|MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
219602530|NCT07184918|DRUG|Continuing Ramipril|Participants in this group will continue taking Ramipril at their usual dose before, during, and after the coronary angiography. The objective is to evaluate the renal effects of uninterrupted ACE inhibitor therapy during contrast exposure.
218874973|NCT06167876|OTHER|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
219494692|NCT05889026|DEVICE|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
219494693|NCT05889026|PROCEDURE|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
219494694|NCT00177099|DRUG|FK506, GP11046, GP11511|
219494695|NCT01364298|DRUG|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram \[mg\] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
219494696|NCT01364298|DRUG|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
219494697|NCT05106998|DEVICE|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
219494698|NCT04354402|OTHER|No intervention|No intervention
219602531|NCT07184918|DRUG|Withholding Ramipril|Participants in this group will stop taking Ramipril 48 hours before the angiography procedure and resume it 72 hours after. This intervention is used to evaluate whether temporarily withholding ACE inhibitors reduces the risk of contrast-induced nephropathy.
218874974|NCT06551259|DRUG|Dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
218874975|NCT06551259|DRUG|physiological saline|physiological saline
218874976|NCT05714644|OTHER|FIT kit Screening Test|FIT kit mailed to the patient's home
218874977|NCT05714644|OTHER|Cologuard Screening Test|Cologuard test mailed to the patient's home
218874978|NCT06338592|BEHAVIORAL|MyLungHealth|MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
218874979|NCT06338592|BEHAVIORAL|DecisionPrecision+|DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
218874980|NCT03230565|DRUG|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
218874981|NCT03230565|DRUG|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
218874982|NCT04951466|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
218874983|NCT04951466|BEHAVIORAL|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
218874984|NCT04119128|DEVICE|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
218874985|NCT04119128|DEVICE|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
218874986|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
218874987|NCT01452919|DRUG|LY2140023|Administered orally
218874988|NCT01452919|DRUG|Placebo|Administered orally
218874989|NCT03320590|DIAGNOSTIC_TEST|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
218874990|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
218874991|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
218874992|NCT00256516|OTHER|Eco-Atkins diet (high vegetable protein and vegetable fat)|
218874993|NCT00256516|OTHER|NCEP diet|
219494699|NCT03360526|DEVICE|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
218874994|NCT02396368|DRUG|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
218874995|NCT02396368|RADIATION|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
218874996|NCT00386165|DRUG|larazotide acetate|larazotide acetate 4 mg capsules
219023929|NCT03204721|OTHER|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
219023930|NCT07128615|BIOLOGICAL|AZD4117|Intramuscular (IM) injection
219023931|NCT07128615|BIOLOGICAL|AZD5315|IM injection
219023932|NCT07128615|OTHER|Placebo|IM injection
219023933|NCT07005102|DRUG|Standard of Care|Standard of Care
219023934|NCT07005102|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219023935|NCT07005102|DRUG|Osimertinib (Osi)|Oral Tablet
219023936|NCT07129993|DRUG|Dato-DXd|Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B
218874997|NCT03390309|OTHER|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
218874998|NCT03390309|OTHER|Normal Formula|Normal Formula
219023937|NCT07129993|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL
219602532|NCT07184528|DEVICE|Endobronchial Blood Patch|This component of the procedure involves sealing persistent air leak (PAL) defects using autologous blood delivered via a balloon catheter. After identifying the target segment, carefully noting the airway angle and distal carina, a sizing balloon is deployed and inflated to ensure a tight seal. Under anesthesia, 30 mL of fresh blood is prepared and infused into the target airway until either visible extravasation occurs or the full volume is delivered. Following this, up to 10 mL of tranexamic acid (TXA) may be administered, again until extravasation occurs or the volume is fully instilled. The balloon remains inflated for 3-5 minutes after the instillation to allow clot formation and sealing of the defect.
219602533|NCT07184528|DEVICE|Spiration Valve System (SVS) Placement|Once the blood patch component is complete and the balloon is deflated, a Spiration Valve System (SVS) is placed proximally in the airway. The valve acts as a one-way device that decompresses the targeted lung segment while stabilizing the clot created by the blood patch. This supports durable resolution of the air leak, particularly in cases where collateral ventilation might otherwise reduce the efficacy of valve therapy alone.
218874999|NCT02421588|DRUG|Lurbinectedin (PM01183)|
219494700|NCT03360526|PROCEDURE|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
219494701|NCT06129487|BEHAVIORAL|Narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
218875000|NCT02421588|DRUG|Pegylated liposomal doxorubicin (PLD)|
218875001|NCT02421588|DRUG|Topotecan|
218875002|NCT03792568|OTHER|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
218875003|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
219023938|NCT07129993|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m2
219023939|NCT07129993|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m2 on Day 1 and 8 of every 3 week cycle.
219023940|NCT05356741|DRUG|VIR-5818|Administered as IV infusion
219023941|NCT05356741|DRUG|pembrolizumab|Administered as IV infusion
219023942|NCT06870539|OTHER|Non-Interventional Study|Non-Interventional Study
219023943|NCT06876077|OTHER|Auricular acupuncture|Auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
219023944|NCT06876077|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, without a needle. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
219023945|NCT06876077|OTHER|Artificial Tears (AT)|Artificial tear drops were applied 5-6 times per day over the 4-week period
219023946|NCT07007273|DRUG|Pembrolizumab|Outpatient infusion
219023947|NCT07019129|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
219023948|NCT07019129|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-poor beetroot juice
219023949|NCT07025551|DRUG|MK-8527|Oral administration
219494702|NCT06129487|BEHAVIORAL|Non-narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
218875004|NCT04494126|DRUG|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
218875005|NCT04494126|DRUG|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
218875006|NCT06583603|BEHAVIORAL|Barriers to Implementing Sensory Strategies Survey|Survey, see arm description
218875007|NCT06584500|OTHER|Dry needling|"Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop."
218875008|NCT06584500|OTHER|Sham Dry Needling|The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
218875009|NCT06584058|DRUG|HPP737|\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
218875010|NCT06584214|DIAGNOSTIC_TEST|Diagnostic test: Determine™ Syphilis Advanced test|The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.
218875011|NCT04040829|BEHAVIORAL|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
218875012|NCT04040829|BEHAVIORAL|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
218875013|NCT04040829|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
218875014|NCT05462418|PROCEDURE|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
218875015|NCT05462418|PROCEDURE|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
218875016|NCT01145339|DRUG|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
218875017|NCT05310981|BEHAVIORAL|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
218875018|NCT01359943|BIOLOGICAL|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
218875019|NCT01359943|DRUG|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
218875020|NCT00217568|BIOLOGICAL|pegfilgrastim|
218875021|NCT00217568|DRUG|carboplatin|
218875022|NCT00217568|DRUG|docetaxel|
218875023|NCT00006249|BIOLOGICAL|pegylated interferon alfa|
218875024|NCT00006249|PROCEDURE|adjuvant therapy|
218875025|NCT06429774|OTHER|Neurological function|Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
219023950|NCT06368141|DRUG|Serplulimab|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
219494703|NCT02512991|OTHER|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
219494704|NCT00659581|DRUG|Telmisartan|Oral administration
219494705|NCT02946619|BEHAVIORAL|Self-Regulation Condition|
219494706|NCT02946619|BEHAVIORAL|Enhanced self-Regulation Condition|
219494707|NCT05854277|OTHER|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
219494708|NCT01337609|DRUG|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
219494709|NCT01337609|OTHER|Placebo (sugar pill)|1 pill daily for 60 days
219494710|NCT01337609|OTHER|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
219494711|NCT01010321|DEVICE|confocal microscopy|non-invasive imaging
219494712|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
219494713|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
219494714|NCT02754505|OTHER|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
219494715|NCT02754505|OTHER|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
219494716|NCT01963221|RADIATION|fludeoxyglucose(18f)|
219494717|NCT01963221|OTHER|blood sample|
219494718|NCT01963221|OTHER|cardiac and aortic magnetic resonance imaging|
219494719|NCT01963221|OTHER|carotid femoral pulse wave velocity|
219494720|NCT01963221|RADIATION|positron emission tomography|
219494721|NCT01963221|RADIATION|computed tomography|
219494722|NCT03162354|OTHER|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
219494723|NCT04318249|BEHAVIORAL|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
219494724|NCT04318249|BEHAVIORAL|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
219494725|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
219494726|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
219494727|NCT03394274|OTHER|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
219494728|NCT02595541|DRUG|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
219494729|NCT02595541|DRUG|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
219494730|NCT00881452|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
219494731|NCT00881452|DRUG|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
219494732|NCT03125629|DRUG|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
219494733|NCT03125629|DRUG|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
219494734|NCT03125629|DEVICE|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
219494735|NCT03125629|DEVICE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
218875026|NCT06429774|OTHER|Mental State, cognitive function, and life quality assessment|Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).
218875027|NCT06429774|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
218875028|NCT06429774|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
218875029|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
218875030|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
218875031|NCT00652080|DRUG|API 31510|Topical Cream; 3% active; AM \& PM application
219602534|NCT07187167|DRUG|Lenalidomide|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
219602535|NCT07187167|DRUG|Dexamethasone|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
218875032|NCT02408263|PROCEDURE|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
218875033|NCT03487497|PROCEDURE|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
219023951|NCT06368141|DRUG|Capecitabine|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
219023952|NCT06368141|DRUG|Oxaliplatin|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
219023953|NCT07004972|DRUG|Mavacamten|Specified dose on specified days
219023954|NCT06698237|OTHER|immediate cold-water immersion|immediate 10 minute water immersion in 10 degree Celsius
219023955|NCT06698237|OTHER|delayed cold-water immersion|3 hour delayed 10 minute water immersion in 10 degree Celsius
219023956|NCT06698237|OTHER|immediate thermoneutral water immersion|immediate 10 minute water immersion in 35 degree Celsius
219200243|NCT06880913|BIOLOGICAL|Nanobody-Based CD19/CD22 Tandem Dual CAR-T|"Phase I: Patients will receive a single infusion of autologous CD19/CD22 dual CAR-T cells at one of three dose levels (0.3 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine (25-30mg/m2\*3d) and cyclophosphamide (250-300mg/m2\*3d) (FC) lymphodepleting chemotherapy.~Phase II: Patients will receive autologous CD19/CD22 dual CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
219494736|NCT03933839|BEHAVIORAL|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
219494737|NCT03334916|DRUG|YMC026|YMC026 20mL TID
219494738|NCT03334916|DRUG|Placebo|Placebo 20mL TID
219494739|NCT03909971|DRUG|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
219494740|NCT05780515|BIOLOGICAL|ANX009|ANX009 will be administered per schedule specified in the arm description.
219494741|NCT05851612|PROCEDURE|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
219494742|NCT05851612|PROCEDURE|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
219494743|NCT05851612|PROCEDURE|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
219602536|NCT07187141|DRUG|Protollin|For the 0.1, 0.5, and 1.0 mg dose groups, Protollin (450 μL per vial) in an aqueous buffer will be administered in two, 0.1 μL sprays, one per nostril. For the 1.5 mg dose group, Protollin (450 muL per vial) in an aqueous buffer will be administered in three, 0.1 μL sprays, two in one nostril and one in the other nostril.
218875034|NCT00612560|DRUG|Anastrozole|1 mg per day
218875035|NCT00612560|DIETARY_SUPPLEMENT|flaxseed|25 g per day ground
218875036|NCT00612560|DRUG|Placebo|Placebo pill 1 per day
218875037|NCT00759408|DRUG|BQ-123|6-120 µg/min
218875038|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
218875039|NCT05489367|BIOLOGICAL|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
218875040|NCT03123328|DEVICE|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
219200244|NCT06881199|OTHER|Complete denture with a metallic Co-Cr casted palate|Complete denture with a metallic Co-Cr casted palatal material
218875041|NCT06000865|BEHAVIORAL|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
219023957|NCT06880731|BEHAVIORAL|Modeling with Verbal Mediation|Children will watch and listen as a friendly animated character completes shifting task trials while narrating his thoughts and actions, providing a model of verbal mediation.
219023958|NCT06880731|BEHAVIORAL|Modeling Only|Children will watch as a friendly animated character completes shifting task trials.
219023959|NCT07041125|DEVICE|Watchman FLX™ Pro device.|Patients eligible for the main DISRUPT-AF Registry with a planned concomitant LAAC procedure using the Watchman FLX™ Pro device.
219023960|NCT06717698|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219023961|NCT06717698|DRUG|Placebo|Placebo matching NNC0519-0130 will be administered subcutaneously.
219023962|NCT06717698|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
219023963|NCT07038876|DRUG|Placebo|Matched Placebo
219023964|NCT07038876|DRUG|ML-007C-MA BID|ML-007C-MA dosed as 210/3 mg BID
219023965|NCT07038876|DRUG|ML-007C-MA QD|ML-007C-MA dosed as 330/6 mg QD
219494744|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
219494745|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
219494746|NCT04800913|DIAGNOSTIC_TEST|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
219494747|NCT04800913|DIAGNOSTIC_TEST|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
219494748|NCT05927207|OTHER|TRIP|TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
219494749|NCT04542330|BIOLOGICAL|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
219494750|NCT04542330|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
219494751|NCT03564509|DRUG|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
219494752|NCT03564509|DRUG|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
219494753|NCT03564509|DRUG|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
218875042|NCT06000865|BEHAVIORAL|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
218875043|NCT05693506|OTHER|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
219494754|NCT03564509|DRUG|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
219494755|NCT03564509|DRUG|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
218875044|NCT05830071|DRUG|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
218875045|NCT05830071|DRUG|CHF5259|GB 12.5 μg pMDI
218875046|NCT05830071|DRUG|Moxifloxacin 400mg|400 mg Oral Tablets
218875047|NCT05830071|DRUG|CHF5993 Placebo|placebo pMDI
218875048|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
218875049|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
218875050|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
218875051|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
218875052|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
218875053|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
218875054|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
218875055|NCT02578056|DEVICE|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
218875056|NCT02578056|PROCEDURE|Genital prolapse surgery|Surgical correction of genital prolapse
218875057|NCT03954613|COMBINATION_PRODUCT|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
219494756|NCT03564509|OTHER|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
219494757|NCT05938335|GENETIC|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
219494758|NCT05287802|OTHER|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
219494759|NCT05287802|OTHER|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
219494760|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
219494761|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
219494762|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
219494763|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
218875058|NCT06173908|PROCEDURE|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
218875059|NCT06173908|PROCEDURE|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
218875060|NCT00975949|OTHER|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
218875061|NCT03749278|BEHAVIORAL|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
219023966|NCT07037420|DRUG|ALXN2420|ALXN2420 will be administered via subcutaneous (SC) injection
218875062|NCT05854342|OTHER|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
219023967|NCT07037420|DRUG|Placebo|Placebo will be administered via SC injection.
219023968|NCT06723652|DRUG|SHR-1918|six administration
219200245|NCT06881199|OTHER|Complete denture with an acrylic palate|Complete denture with an acrylic palatal material
219494764|NCT05811260|OTHER|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
219494765|NCT05811260|OTHER|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
219494766|NCT06025786|COMBINATION_PRODUCT|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
218875063|NCT02649894|DEVICE|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
218875064|NCT02649894|DEVICE|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
218875065|NCT04189549|DIAGNOSTIC_TEST|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
218875066|NCT01436474|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
218875067|NCT01436474|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
218875068|NCT00381147|DRUG|Clarithromycin|
218875069|NCT06490042|BEHAVIORAL|Questionnaire|A questionnaire about helmet use and attitude towards helmet use.
218875070|NCT00719680|BIOLOGICAL|IgPro20|
218875071|NCT00722956|DRUG|AZD5672|100 mg once daily, 10 days
218875072|NCT00722956|DRUG|atorvastatin|one single dose of 40 mg on day 10
219023969|NCT06723652|DRUG|SHR-1918 placebo|SHR-1918 placebo three administration+SHR-1918 three administration
219023970|NCT06880848|DRUG|Sonidegib Phosphate Capsules|Sonidegib should be taken 1 hour before or 2 hours after a breakfast
219023971|NCT07043400|DRUG|Subcutaneous Tislelizumab|Administered by subcutaneous injection
219023972|NCT07043400|DRUG|Intravenous Tislelizumab|Administered by intravenous infusion
219023973|NCT07043400|DRUG|Cisplatin|Administered by intravenous infusion
219023974|NCT07043400|DRUG|Leucovorin|Administered by intravenous infusion
219023975|NCT07043400|DRUG|5-fluorouracil (5-FU)|Administered by intravenous infusion
219023976|NCT07043400|DRUG|Oxaliplatin|Administered by intravenous infusion
219023977|NCT07043400|DRUG|Capecitabine|Administered orally
219023978|NCT06888453|DRUG|lozenges containing propolis|lozenges containing propolis Participants will be given the test interventions, lozenges containing propolis, and will be asked to chew twice per day and will be instructed to ordinary oral hygiene instruction, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days
219023979|NCT07047885|DRUG|Ropeginterferon alfa-2b|Will be administered via subcutaneous injection once every 2 weeks
219023980|NCT06728254|DEVICE|medication management|"The test system consists of:~* Linked care platform (backend) which provides a new possibility of data exchange for IT systems of caregivers, pharmacies, and GPs~* User interfaces for caregivers as well as for the systems myneva.carecenter and mynevaTOgo~* An extension of the user interface for GPs in their IT system (in the test only for the physician software PCPO by CompoGroup Medical )~* An extension of the user interface for pharmacists in their IT system (in the test only for pharmacies with software from Apothekerverlag)~Functionally, the solution should, coordinate the medication requirements between pharmacies, GPs, and caregivers (subarea medication)."
219200246|NCT06876090|DIAGNOSTIC_TEST|Sarcopenia tests (for muscle mass, muscle function, physical performance)|We are not aware of any other study performing sarcopenia tests in GDM (or in pregnancy in general), with the aim of assessing sarcopenia prevalence in GDM/pregnancy, and related possible adverse pregnancy outcomes.
219023981|NCT06728254|OTHER|Usual Care Group|Usual care.
218875073|NCT04651491|DRUG|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
218875074|NCT00510744|DRUG|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
218875075|NCT06893939|OTHER|Limited Trophic Feeds (1 day of trophic feeds)|Advancing enteral feeds after 1 day of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
218875076|NCT06893939|OTHER|Extended Trophic Feeds (3 days of trophics)|Advancing enteral feeds after 3 days of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day after 3 days of trophic feeds. Advancement will occur until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
218875077|NCT07089498|OTHER|Dietary Intervention (Low Fodmap Gluten Free Diet)|The intervention provides the administration of a Low Fodmap Diet to celiac or non celiac patients with functional gastrointestinal disorders
218875078|NCT07089108|BEHAVIORAL|Arabic NODA Video-Based Diagnostic Assessment|NODA (Naturalistic Observation Diagnostic Assessment) is a telehealth-based diagnostic tool for Autism Spectrum Disorder (ASD) that guides caregivers to record structured home videos of their child's behavior using a smartphone app. In this study, a culturally adapted Arabic version of NODA was used to capture four standardized behavioral scenarios, which were later reviewed by licensed clinicians for diagnostic evaluation.
218875079|NCT07088042|DRUG|Limitless Allzyme|Received Limitless Allzyme Max® Trypsin/Chymotrypsin/Bromelain(15 microkatal/42microkatal/240 GDU)
218875080|NCT07088042|DRUG|Oral tablets of Alphintern®|received (Trypsin/Chymotrypsin 5 micro Katals/14 micro Katals)
218875081|NCT07088042|DRUG|Cataflam® 50 coated tablet|of Cataflam 50 mg as part of their treatment protocol
218875082|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a moderately rough surface (DCC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
218875083|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a hybrid surface (MSC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
218875084|NCT07089160|BEHAVIORAL|Online Survey (Decision Fatigue Scale and Emotional Exhaustion Scale)|Participants will complete an online survey including demographic questions, the Decision Fatigue Scale (DFS), and the Emotional Exhaustion subscale of the Maslach Burnout Inventory.
218875085|NCT05425680|OTHER|Core muscle training|Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
218875086|NCT07088536|OTHER|Occupational Status Survey and Telephone Follow-up and Quality-of-Life Assessment in a subset of patients|Collection of demographic, employment, and clinical data at hospital admission, with additional EQ-5D-5L quality-of-life questionnaire and telephone follow-up for occupationally active patients undergoing major uro-oncological surgeries or urinary tract stone procedures.
218875087|NCT07088029|PROCEDURE|Indirect occlusal veneer (Occlusal veneer of lithium disilicate)|Split-mouth design, (right/left posterior tooth) will be restored with an Indirect occlusal veneer (Occlusal veneer of lithium disilicate). Indirectly fabricated occlusal veneers of lithium disilicate allow better control and design of the occlusal anatomy and proximal contacts, in addition to possessing better mechanical properties and fracture strength when compared to direct occlusal veneers. However, indirect occlusal veneers are lab fabricated, consequently, more clinical visits are required.
218875088|NCT07088029|PROCEDURE|Direct occlusal veneer ( Occlusal Veneer of Composite resin)|Split-mouth design, (right/left posterior tooth) will be restored with an occlusal veneer composite resin (Direct occlusal veneer). Directly fabricated occlusal veneers are a conservative approach, however, it requires a great skill from the operator to assure good margins and occlusal anatomy. Direct veneers are fabricated from composite resin and can be finished in a single visit, but longer chair time is required, in addition to the low wear resistance compared to ceramics. However, direct occlusal veneers have the benefit of resiliency close to that of natural dental tissue.
218875089|NCT07088484|DRUG|ICI-chemotherapy and LIMT|gemcitabine, docetaxel, paclitaxel, cisplatin, platinum, capecitabine, S1; Tislelizumab.
219023982|NCT03423628|RADIATION|Radiation Therapy|35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks)
219023983|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 2 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. Note: the food effect assessment is currently open to recruitment.~Arm A includes the Japan part following the same dosing administration."
219494767|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
219494768|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
219494769|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
219494770|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
219494771|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
219494772|NCT00281827|DRUG|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
218875090|NCT04797871|BEHAVIORAL|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
219494773|NCT00281827|DRUG|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
219602537|NCT07187258|DRUG|tranexamic acid (1 g diluted in 100 mL of 0.9% saline|The pharmacist also prepared indistinguishable infusion bags containing tranexamic acid (1 g diluted in 100 mL of 0.9% saline) . The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
218875091|NCT04797871|BEHAVIORAL|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
218875092|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
218875093|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
218875094|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
218875095|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
218875096|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
218875097|NCT03897842|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
218875098|NCT00733941|BEHAVIORAL|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
218875099|NCT00733941|BEHAVIORAL|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
218875100|NCT01088022|DRUG|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
218875101|NCT01088022|DRUG|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
218875102|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
218875103|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
218875104|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
218875105|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
218875106|NCT04977219|BEHAVIORAL|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
218875107|NCT04956458|PROCEDURE|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
218875108|NCT04956458|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
218875109|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
218875110|NCT00485966|DRUG|CX-3543|360 mg/m2 daily x 5 q 21 days
218875111|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
219023984|NCT03423628|RADIATION|Radiation Therapy|30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).
219023985|NCT03423628|RADIATION|Radiation Therapy|60 Gy of intensity- modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)
219023986|NCT03423628|DRUG|AZD1390|AZD1390 administered in 1 Cycle. AZD1390 administration concomitantly with RT (2 weeks). Cycle 1 also contains an additional 5 days (post completion of RT with AZD1390 administration). Arm is Closed.
219494774|NCT00281827|DRUG|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
219494775|NCT00281827|PROCEDURE|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
219494776|NCT01164137|BEHAVIORAL|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
218875112|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
218875113|NCT02110797|OTHER|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
218875114|NCT00902174|DRUG|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
218875115|NCT00902174|DRUG|Placebo|Placebo to imatinib 100 mg film coated tablets
219200247|NCT06876090|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The OGTT, in combination with the sarcopenia tests, will allow to explore the relationships between the glucometabolic condition and the muscle quality in the pregnant women, either with GDM or with normal glucose tolerance.
219023987|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 6 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. Arm is closed."
219023988|NCT06742385|DEVICE|MedicWise|"* Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are activated in the active telemonitoring arm.~* Data are collected in both arms at baseline, M3, M6, M9 and M12~* Each center defines who handles alerts internally (physicians, IBD nurses, others, etc.) according to its internal organization. The application does not impose an internal operation.~* the alert thresholds are identical and fixed for all centers during the study. Within the framework of the study, alerts are defined according to the study's modalities but cannot be modified by the centers.~* Participating sites will have no obligation to respond to alerts.~* Randomization will be stratified by centers and by diseases (Crohn and UC) with unbalanced blocks of randomization"
219023989|NCT06894420|PROCEDURE|Surgeon-Initiated Local Anesthetic|In laparoscopic hernia repairs, patients are positioned supine, and the surgical area is cleansed with povidone iodine and covered with sterile green drapes. A 1-centimeter incision will be made 1 centimeter below the umbilical border. A 10-mm trocar will be inserted into the preperitoneal space. The operation was filmed from the front with a 30-degree camera. After observing the preperitoneal space, two five-mm working trocars will be placed midline, two and six centimeters inferior to the symphysis pubis. Next, the cord structures and Cooper ligament will be exposed and the hernia sac freed from surrounding anatomical structures.Prolene mesh will be spread over the preperitoneal area to cover all hernia defects and secured to the Cooper ligament and abdominal wall with an absorbable fixation device. Group 1 patients undergo desufflation via 50 mg of bupivacaine into the preperitoneal space, followed by 10 mg of bupivacaine into each trocar incision and skin closure with sutures.
219023990|NCT06894420|PROCEDURE|Transversus abdominis plane (TAP) block|After the surgery, the anesthesiologist will use a TAP block under ultrasound guidance. Before the patient wakes up, the Hitachi ultrasound probe will be sterilized and positioned between the iliac wing and the costae. An ultrasound shows the skin, fat beneath it, the six abdominal muscle layers, and a support muscle.A thin needle goes through the skin from one side to the other to reach the muscle layers. The location of the block is confirmed by injecting 1-2 ml of 0.09% NaCl followed by negative aspiration. Patients receive 15-20 ml (40-50 mg per quadrant) of bupivacaine 0.5% concentration in a controlled manner with negative aspiration every 5 ml. The block is performed bilaterally.
219023991|NCT05964829|DEVICE|Cionic Neural Sleeve NS-100|The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
219023992|NCT05964829|BEHAVIORAL|Walking Program|15 minutes of walking for 5 days per week for 6 weeks
219023993|NCT05478252|DRUG|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
219200248|NCT06876090|OTHER|Montreal Cognitive Assessment|The MoCA questionnaire, in combination with the sarcopenia tests, will allow to explore the relationships between the cognitive function the presence of the sarcopenia syndrome in the pregnant women, either with GDM or with normal glucose tolerance.
219200249|NCT06705790|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training 5x/week for 12-weeks
219200250|NCT06705088|DRUG|SUVN-I6107|SUVN-I6107 Tablet
219200251|NCT06705088|DRUG|Placebo|A look-alike tablet with no active ingredient.
219494777|NCT01413685|OTHER|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
218875116|NCT02501200|DRUG|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
218875117|NCT02501200|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
218875118|NCT03339973|BIOLOGICAL|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
218875119|NCT03339973|DRUG|Placebo|Solution for injection in pre-filled syringe
219200252|NCT06704919|DEVICE|Use of conduit cages and fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
219200253|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws|"IMF screws will be placed at the junction of the attached and alveolar mucosa, after verifying the root position on the orthopantomogram (OPG) radiograph. One screw in each quadrant was sufficient; all IMF screws will be placed with the patient under local anesthesia or general anesthesia . Cortical perforation with a 1.5-mm drill bit under copious irrigation will be performed or by self-drilling IMF screws and the IMF screws will be tightened on the drilled hole.~After IMFS placement, intraoperative IMF will be achieved by passing round, stainless steel wires through the screw head to achieve satisfactory occlusion."
219494778|NCT00241319|DRUG|R89674 (generic name not yet established)|
218875120|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
218875121|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
218875122|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
218875123|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
218875124|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
218875125|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
218875126|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
218875127|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
218875128|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
218875129|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
218875130|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
218875131|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
218875132|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
218875133|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
218875134|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
218875135|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
218875136|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
218875137|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
218875138|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
219494779|NCT02256319|DRUG|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
218875139|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
218875140|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
218875141|NCT03668405|DRUG|Lu AF20513|Injection
218875142|NCT06934382|BIOLOGICAL|Allogeneic anti-CD7 CAR-T cells (BEAM-201)|The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.
218875143|NCT01353911|DRUG|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
218875144|NCT01353911|DRUG|Boceprevir|Four 200 mg capsules orally three times daily.
219023994|NCT05478252|DRUG|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
219023995|NCT06746805|DIETARY_SUPPLEMENT|CHO+KETONE|Sports drink containing glucose and ketone mono-esters
219023996|NCT06746805|DIETARY_SUPPLEMENT|CHO+PLACEBO|Sports drink containing glucose and placebo
219494780|NCT02256319|DRUG|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
219494781|NCT03668925|RADIATION|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
219494782|NCT03339531|RADIATION|2D radiotherapy|
219494783|NCT04523831|DRUG|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
219494784|NCT04523831|DRUG|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
219494785|NCT02999919|PROCEDURE|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
219494786|NCT01854515|DRUG|Budesonide|
219494787|NCT01854515|DRUG|Dexamethasone acetate|
219494788|NCT01880541|OTHER|hypnosedation|hypnosedation
219494789|NCT01880541|OTHER|general anesthésia|general anesthesia
219494790|NCT01406769|PROCEDURE|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
219494791|NCT01406769|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
219494792|NCT01406769|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
219494793|NCT02322242|DRUG|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
219602538|NCT07187258|DRUG|placebo (100 mL of 0.9% saline).|The pharmacist also prepared indistinguishable infusion bags containing placebo (100 mL of 0.9% saline). The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
218875145|NCT01353911|DRUG|Placebo for Grazoprevir|Orally once daily in AM.
218875146|NCT01353911|DRUG|Placebo for Boceprevir|Four capsules orally three times daily.
218875147|NCT01353911|DRUG|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
218875148|NCT01353911|DRUG|Ribavirin|300 mg to 700 mg orally twice daily.
218875149|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
218875150|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
218875151|NCT00069355|DRUG|Propranolol|
218875152|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
219023997|NCT06745661|DEVICE|RLRL device|Each participant in the intervention group will be provided a repeated low-level red-light therapy (RLRL) device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
219023998|NCT06745661|DEVICE|sham device|Each participant in the sham group will be provided a sham therapy device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
219023999|NCT06774742|DIETARY_SUPPLEMENT|HAFS Supplementation|1 capsule of HAFS per day
219494794|NCT02322242|DRUG|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
219494795|NCT02579369|OTHER|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
219494796|NCT02579369|DEVICE|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
219494797|NCT06365931|DEVICE|Percutaneous neuromodulation|Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
219494798|NCT06365931|DEVICE|Transcutaneous neuromodulation|Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
219494799|NCT06365931|DEVICE|Placebo-percutaneous|Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.
219494800|NCT06365931|DEVICE|Placebo-transcutaneous|patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.
219494801|NCT06365931|DEVICE|Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)|Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.
219494802|NCT00350194|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
219494803|NCT04196582|DEVICE|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
219024000|NCT06774742|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo per day
219024001|NCT01352962|DRUG|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
219024002|NCT01352962|DRUG|Carboplatin|AUC 5\*\* IVPB over 30 min x 1
219494804|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
218875153|NCT04622813|DRUG|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
218875154|NCT04622813|DRUG|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
218875155|NCT01232985|DEVICE|RD047-26|RD047-26 emollient gel
218875156|NCT00005014|DRUG|Risperidone|
219024003|NCT01352962|DRUG|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
219024004|NCT06400121|DRUG|Apimostinel Infusion, Intravenous|Single injection of Apimostinel (10mg)
219024005|NCT06400121|BEHAVIORAL|Cognitive Training|8 sessions of digital active training
219024006|NCT06400121|BEHAVIORAL|Sham Training|8 sessions of digital sham training
219024007|NCT06400121|DRUG|Isotonic Solution, Intravenous|Single injection of placebo
219494805|NCT00006385|BIOLOGICAL|MART-1 antigen|
219494806|NCT00006385|BIOLOGICAL|gp100 antigen|
219494807|NCT00006385|BIOLOGICAL|incomplete Freund's adjuvant|
219602539|NCT07184762|PROCEDURE|open reduction and internal fixation with bone plate|mandibular fracture were reduced and fixed with bone plates.
219602540|NCT07184762|PROCEDURE|z-plates.|mandibular fracture were reduced and fixed with z-plate miniplates.
219024008|NCT06766214|DEVICE|transcranial direct current stimulation|Simultaneous treatment with tDCS and online-based psychotherapy
219024009|NCT06766214|DEVICE|sham transcranial direct current stimulation|Simultaneous treatment with sham-tDCS and online-based psychotherapy
219024010|NCT05171179|PROCEDURE|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
219494808|NCT00006385|BIOLOGICAL|recombinant interferon alfa|
218875157|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
218875158|NCT05647785|DEVICE|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
218875159|NCT05647785|DEVICE|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
218875160|NCT02152774|DRUG|Rho-Kinase Inhibitor|
218875161|NCT04003987|DRUG|Liposomal bupivacaine|20ml
218875162|NCT04003987|DRUG|bupivacaine, 0.125%|60ml
218875163|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
218875164|NCT02706587|DEVICE|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
218875165|NCT02706587|DEVICE|Sham control|No electrostimulation
218875166|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
218875167|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
218875168|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
218875169|NCT06379282|BEHAVIORAL|HIT|Exercise training only
218875170|NCT06379282|BEHAVIORAL|EXE+ Nutritional Guidance|Exercise Training + Nutritional Guidance
219024011|NCT05171179|DEVICE|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
219024012|NCT05171179|DRUG|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
219024013|NCT05171179|DRUG|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in both arms.
219024014|NCT06176352|DRUG|Faricimab|Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
219024015|NCT06176352|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
219494809|NCT00006385|BIOLOGICAL|sargramostim|
219494810|NCT00006385|BIOLOGICAL|tyrosinase peptide|
219494811|NCT00430638|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
219494812|NCT00430638|DRUG|Placebo|Oral tablets administered for once daily for 12 weeks
219494813|NCT00296452|BEHAVIORAL|behavior|
219494814|NCT02780999|DEVICE|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
219494815|NCT02780999|DEVICE|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
219494816|NCT06222411|OTHER|evaluate the impact of organizational interventions for physician development on wellbeing|There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
219024016|NCT06176352|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.
219024017|NCT07087912|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|A single 0.5 mL dose of the live attenuated tetravalent dengue vaccine (Butantan-DV), administered subcutaneously on Day 1. The vaccine contains attenuated viral strains for DENV-1, DENV-3, DENV-4, and a chimeric DENV-2 component. It is manufactured and formulated by the Instituto Butantan (São Paulo, Brazil).
218875171|NCT04110080|PROCEDURE|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
218875172|NCT04110080|OTHER|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
218875173|NCT04110080|OTHER|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
218875174|NCT04110080|PROCEDURE|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
218875175|NCT04110080|PROCEDURE|regional anesthesia|transabdominal plane and rectus sheath nerve block
218875176|NCT03778385|OTHER|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
219200254|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws with surgical guide|"The patient's CBCT images in DICOM format will be converted into stereolithographic (STL) images using the segmentation software.~The converted CBCT STL images will be integrated to obtain the exact tooth morphology Virtual surgical planning (VSP) will be carried out using software to select the exact position of IMF screws placement away from any vital, anatomical or tooth structure.~these locations will be incorporated into the patients specific IMF surgical guides as access holes to direct the IMF screws drill.~Guide will be constructed with a thickness of 2-3 mm and printed using Photopolymer Resin® (Form labs) in the CAD/CAM 3- dimensional (3D) printer"
219200255|NCT06884891|DRUG|QL2108 injection|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W);subcutaneous injection
219200256|NCT06884891|DRUG|Dupixent®|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W); subcutaneous injection
219494817|NCT05517863|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
219494818|NCT02858167|DEVICE|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
219494819|NCT02146235|BEHAVIORAL|Psycho-Music Therapy|
219494820|NCT01189071|DRUG|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
219494821|NCT01488799|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
219494822|NCT02843347|PROCEDURE|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
219602541|NCT07184762|PROCEDURE|conventional miniplates.|mandibular fracture were reduced and fixed with conventional two miniplates.
219200257|NCT06882629|BEHAVIORAL|'Speaking at school, a matter of doing' combined with VR homework exercises|The treatment in this study consists of behavioral therapy for selective mutism (with the protocol 'Speaking at school, a matter of doing') with the addition of the VR homework exercises. The protocol consists of 10 steps that help the child to gain confidence while speaking at school. For every treatment step there are VR homework exercises available. Families receive a VR headset for the duration of the study. Parents are instructed to work on the VR homework exercises at least once a week and encouraged to work on the VR homework exercises several times a week.
219200258|NCT06882304|OTHER|orthodontic treatment|young adult after orthodontic treatment
219200259|NCT06883799|OTHER|Without intervention.|Without intervention
219200260|NCT06884787|DRUG|Conventional nanohybrid multishade composite|Teeth will be restored with conventional multi shade nanohybrid Resin Based Composite (RBC) filtek Z350Xt,3M ESPE, San Paul, MN, USA
218875177|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
218875178|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
218875179|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
218875180|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
218875181|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
218875182|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
218875183|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
219024018|NCT06840834|DRUG|Ivonescimab|Ivonescimab is administered IV Q3W on Day 1 of each cycle. Ivonescimab is given at a dose of 20 mg/kg (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥160 kg). The total duration of ivonescimab treatment is up to 24 months.
219024019|NCT07092514|DRUG|Lenvatinib|Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg daily or 10 mg daily for an unlimited number of cycles.
219024020|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
219024021|NCT05427318|BEHAVIORAL|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
219024022|NCT07183839|BEHAVIORAL|Immersive Virtual Reality|While wearing an immersive VR helmet, participants grabbed virtual objects andd put them into a bowl of virtual water, while memorizing a list of words from the real world.
219024023|NCT07183839|BEHAVIORAL|Plausible control condition|Participant passively viewed the laboratory room they saw while wearing Apple Vision Pro goggles, while memorizing a list of words read to them from the real world.
219494823|NCT01779349|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
219024024|NCT07189962|DRUG|SHR8554 Injection|SHR8554 injection.
219024025|NCT07189793|DRUG|Toripalimab|PD-1 inhibitor administered intravenously every 3 weeks (Q3W) for up to 24 months. Starts during the first intravesical treatment cycle.
219024026|NCT07189793|DRUG|Gemcitabine (GEM)|Intravesical instillation as part of a sequential regimen with mitomycin C: weekly for 6 weeks (induction); if no recurrence at first tumour assessment (\~month 3), maintenance instillations continue monthly up to 24 months.
219024027|NCT07189793|DRUG|Mitomycin C (MMC)|Intravesical instillation immediately after intravesical gemcitabine in the same visit (sequential regimen): weekly for 6 weeks (induction); if eligible, monthly maintenance up to 24 months.
219024028|NCT07190326|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo two sessions per week for 6-weeks."
219024029|NCT07190326|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo two sessions per week for 6-weeks.
219024030|NCT07190196|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
219024031|NCT07190196|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:Oral
219024032|NCT07190196|DRUG|Glucocorticoid|Pharmaceutical form:Tablet, solution, suspension formulations according to local standard practices-Route of administration:Oral
219494824|NCT05302284|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
219024033|NCT07189767|BEHAVIORAL|psychoeducation|The nurse/midwife-led psychoeducation intervention aims to encourage pregnant women to express their feelings about childbirth. It also provides a counseling framework to help women identify and overcome the distressing elements of childbirth. Psychoeducation allows pregnant women to obtain complete, evidence-based information about labor and to discuss their feelings and thoughts about the method of delivery and birth. Providing evidence-based information by nurses/midwives during psychoeducation helps pregnant women make informed decisions about their birth preferences. In addition to evidence-based information, the psychoeducation intervention includes discussing myths and misconceptions, increasing social support, reinforcing positive coping strategies, and focusing on problem solutions. Nurses/midwives encourage pregnant women to develop a positive birth plan through psychoeducation.
219024034|NCT07190807|DEVICE|Boston Scientific WaveWriter Alpha™ SCS Systems|Time Varied Pulse (TVP)-SCS settings
219024035|NCT07191366|PROCEDURE|Handstimulation of breast|Hand stimulation of the breast
219494825|NCT05302284|DRUG|Toripalimab|3.0 mg/kg IV every 2 weeks
219494826|NCT05302284|DRUG|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
219494827|NCT05302284|DRUG|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
219494828|NCT05302284|DRUG|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
219024036|NCT02530034|DRUG|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
219024037|NCT02530034|OTHER|Laboratory Biomarker Analysis|Correlative studies
219024038|NCT02530034|OTHER|Pharmacological Study|Correlative studies
219024039|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
219494829|NCT01972542|DIETARY_SUPPLEMENT|Oral fat tolerance test|
219494830|NCT04297553|PROCEDURE|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
219602542|NCT07185360|OTHER|blood sampling for volunteers|A 38.5 ml blood sample will be taken to test for research taken to test for research
219602543|NCT07185360|OTHER|blood sampling for diabetics patients with F3/F4 fibrosis|32.5 ml will be sampled at inclusion, at one year visit and two year visit
219024040|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
218875184|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
218875185|NCT03974295|BEHAVIORAL|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
218875186|NCT00036257|DRUG|CP-461|
218875187|NCT01818492|BIOLOGICAL|NI-0501|
218875188|NCT05890482|BEHAVIORAL|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
218875189|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
218875190|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
218875191|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
218875192|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
218875193|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
219024041|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
219024042|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
219024043|NCT04726982|DRUG|Acetazolamide|250 mg once daily
219024044|NCT04726982|DRUG|Acetazolamide|500 mg once daily
219024045|NCT04726982|OTHER|Placebo|Once daily
219200261|NCT06884787|DRUG|Single shade nanohybrid composite|Teeth will be restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan)
219494831|NCT04297553|PROCEDURE|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
219494832|NCT04716400|BEHAVIORAL|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
219494833|NCT03291678|PROCEDURE|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
219494834|NCT03291678|PROCEDURE|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
219602544|NCT07185360|OTHER|blood sampling for patients with liver disease|A blood sample of 35.5 mL maximum will be taken for research purposes at the inclusion visit, M1 visit and M3 visit.
219602545|NCT07187011|DRUG|PT150|Glucorticoid antagonist 900 mg
219602546|NCT07187011|DRUG|Placebo|900 mg
219602547|NCT07185672|RADIATION|Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE|Radionuclide Therapy
218875194|NCT02945813|DRUG|Metformin|850mg PO BID; 48 weeks
218875195|NCT02945813|RADIATION|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
218875196|NCT02702687|BEHAVIORAL|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
219024046|NCT06026592|GENETIC|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
219024047|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
219024048|NCT05571059|DRUG|Placebo|Matching oral placebo
219024049|NCT06781619|DIETARY_SUPPLEMENT|Test Product: Plant based high energy high protein ONS|Plant based high energy high protein ONS 2 servings/day for a period of 8 weeks.
219024050|NCT06781619|DIETARY_SUPPLEMENT|Control Product: Dairy based high energy high protein ONS|Dairy based high energy high protein ONS 2 servings equivalent in energy \& protein for a period of 8 weeks.
219024051|NCT05723198|DRUG|Baricitinib|Administered orally
219024052|NCT05723198|DRUG|Placebo|Administered orally
219024053|NCT06552000|DEVICE|NovoTTF-200T System|Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
219200262|NCT06881121|PROCEDURE|Fast-track protocol for hip fracture fixation|Fast-track protocol implication on mortality and morbidities in hip fracture fixation
219200263|NCT06882083|PROCEDURE|paravertebral block|A single-dose bilateral paravertebral block will be administered under ultrasound guidance before the induction of general anesthesia. The block will be performed at an appropriate thoracic level using 20 mL of 0.25% bupivacaine as the local anesthetic.
219602548|NCT07185672|DRUG|Capecitabine plus temozolamide|Chemotherapy
219602549|NCT07185984|DIAGNOSTIC_TEST|Sperm sellection|Small aliquots of 100 fresh human semen samples will be analysed using the SwimCount™ Harvester system, a CE-marked microfluidic technology patented by MCount and designed for routine clinical use.
218875197|NCT02702687|BEHAVIORAL|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
219024054|NCT04449549|DRUG|Nilotinib and Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
218875198|NCT04383275|DRUG|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
218875199|NCT04383275|DRUG|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
218875200|NCT03028935|BEHAVIORAL|Exercise Intervention|Undergo instructor-led exercise program
218875201|NCT03028935|BEHAVIORAL|Nutritional Intervention|Undergo instructor-led nutritional education program
218875202|NCT02325297|OTHER|Letter of condolence|
218875203|NCT03437824|DRUG|Cyanocobalamin|1,000 mg, Once
219024055|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
219024056|NCT00446953|OTHER|placebo|c-section at 39 weeks
219024057|NCT06605599|DRUG|ABBV-932|Oral Capsule
219024058|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
219200264|NCT06884007|BEHAVIORAL|Telepsychiatric Parent Training Program|This study involves a telepsychiatric parent training program for caregivers of children with ADHD. The program includes 9 sessions, each addressing specific topics related to managing ADHD-related behaviors and enhancing parenting strategies. Sessions are primarily delivered through a telepsychiatric platform, such as video conferencing (e.g., Zoom), with additional support provided through text-based communication via platforms like WhatsApp, and, when necessary, follow-up phone calls. The content covers behavior management techniques, stress coping strategies, and skills for managing emotional and behavioral issues in children with ADHD. This intervention is designed to provide accessible, flexible support to caregivers, enhancing their ability to manage their child's condition.
219200265|NCT06884007|OTHER|Routine Treatment|Routine treatment and services (no intervention, participants continue with their usual care)
219200266|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin|Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
219494835|NCT02623426|DRUG|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
218875204|NCT03437824|DRUG|Placebo|0.9% Sodium Chloride, Once
218875205|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
218875206|NCT03358134|DRUG|Secukinumab|anti IL17 therapy (subcutaneous)
219024059|NCT04940052|DRUG|Dabrafenib|Dabrafenib will be administered orally twice daily
219024060|NCT04940052|DRUG|Trametinib|Trametinib will be administered orally once daily
219024061|NCT04940052|DRUG|Trametinib placebo|Trametinib will be administered orally once daily
219024062|NCT04940052|DRUG|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
219024063|NCT06957418|DRUG|AADvac1|AADvac1 tau directed therapy
219024064|NCT06957418|DRUG|Tau2|Tau2 directed therapy
219024065|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
219024066|NCT00708942|DRUG|Placebo|Placebo suppository, for 3-7 hours application
219024067|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
219024068|NCT00708942|DRUG|Placebo|Placebo ointment for 5 hours application
219024069|NCT02902185|DRUG|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
219024070|NCT02902185|DRUG|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
219024071|NCT03664947|OTHER|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
219024072|NCT02189473|RADIATION|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
219024073|NCT01818076|DRUG|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
219024074|NCT06423144|PROCEDURE|TACE/HAIC|TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;
219024075|NCT06423144|DRUG|PD-1/PD-L1 inhibits and anti-angiogenic agents|Agents were administrated based on the instructions recommended
219024076|NCT01955161|DRUG|Placebo|Once daily, matching placebo capsules, orally
218875207|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
218875208|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
218875209|NCT03821116|OTHER|Milk|Swedish milk from cow.
218875210|NCT03821116|OTHER|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
218875211|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
218875212|NCT01729208|DEVICE|Dual Focus Soft Contact Lens|
218875213|NCT01729208|DEVICE|Single Vision Soft Contact Lens|
218875214|NCT02424682|OTHER|No intervention|No intervention administered in this study
219024077|NCT01955161|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
218875215|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
218875216|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
219024078|NCT01227772|BIOLOGICAL|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
219024079|NCT01059474|DRUG|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
219024080|NCT01011517|DIETARY_SUPPLEMENT|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
219024081|NCT04136392|DEVICE|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
219024082|NCT00565968|DRUG|melphalan|
219024083|NCT00565968|DRUG|sorafenib tosylate|
219024084|NCT00565968|GENETIC|gene expression analysis|
219024085|NCT00565968|GENETIC|protein expression analysis|
219024086|NCT00565968|GENETIC|western blotting|
219024087|NCT00565968|OTHER|pharmacological study|
219024088|NCT06024044|BEHAVIORAL|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
219024089|NCT05440279|DEVICE|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
219024090|NCT00087711|DRUG|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
219024091|NCT00087711|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
219024092|NCT00087711|DRUG|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
219024093|NCT00873509|DRUG|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
219024094|NCT00873509|DRUG|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
219024095|NCT00873509|DRUG|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
219200267|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors|Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
218875217|NCT03249103|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
218875218|NCT03249103|DRUG|Placebo oral capsule|Matching placebo capsules.
219200268|NCT06718933|DRUG|SHR-A1811|ADC
219200269|NCT06718933|DRUG|Bevacizumab|bevacizumab biosimilar
218875219|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
218875220|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
219024096|NCT01245270|DIETARY_SUPPLEMENT|Bilberry capsule first, then control cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
219200270|NCT06718933|DRUG|Pyrotinib|anti-HER2 inhibitor
219200271|NCT06722430|DRUG|Icalcaprant|Oral capsule
219200272|NCT06722430|DRUG|Itraconazole (ITZ)|Oral capsule
219200273|NCT06724705|DIETARY_SUPPLEMENT|Lactose|Participants receive lactose to determine whether it changes gut microbial hydrogen production
219200274|NCT06724705|DIETARY_SUPPLEMENT|Sucrose|Participants will consume sucrose which they will consume as a placebo
219200275|NCT06724705|DEVICE|Wear smart underwear|Participants will wear the smart underwear device to measure the microbiome activity index
219024097|NCT01245270|DIETARY_SUPPLEMENT|Control capsule first then bilberry cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
219024098|NCT03852303|DRUG|ivermectin|evaluate effect of ivermectin on frequency of seizures
219024099|NCT01321125|BIOLOGICAL|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
219024100|NCT01321125|OTHER|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
219200276|NCT06887738|DRUG|NM8074|NM8074 will be administered as an intravenous infusion at a dose of 20mg/kg
219200277|NCT06703658|DRUG|AZD5004(Part A)|Single dose of AZD5004 oral on Day1
219200278|NCT06703658|DRUG|Placebo(Part A)|Single dose of placebo oral on Day1
219494836|NCT02623426|DRUG|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
219494837|NCT02623426|DRUG|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
219494838|NCT05886283|PROCEDURE|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
219494839|NCT05886283|PROCEDURE|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
219494840|NCT05886283|PROCEDURE|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
219494841|NCT03791255|DRUG|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
219494842|NCT03791255|DRUG|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
219494843|NCT06617013|OTHER|Discontinuation of GERD therapy|GERD therapy will be discontinued at time of enrollment.
219494844|NCT04659837|BEHAVIORAL|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
219494845|NCT06694571|BEHAVIORAL|Skin cancer prevention educational presentation and activities|"An intervention visit, lasting up to 90 minutes, will take place during fall, immediately following completion of a baseline survey. This intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. During the intervention visit, participants will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity.~One month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text."
219494846|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
219200279|NCT06703658|DRUG|AZD5004(Part B)|AZD5004 will be administered as an oral tablet once daily.
219200280|NCT06703658|DRUG|Placebo(Part B)|Placebo will be administered as an oral tablet once daily.
219494847|NCT06696729|PROCEDURE|Topical Mirabilite Application for Postoperative Gastrointestinal Patients|Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.
219494848|NCT06696729|PROCEDURE|Standard Postoperative Care for Gastrointestinal Patients|Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
218875221|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
218875222|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
218875223|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
218875224|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
219365087|NCT03502187|BEHAVIORAL|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
219494849|NCT06696170|DEVICE|CellFX nano-pFA 360 Endocardial Ablation Catheter System|The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
219494850|NCT06696469|DIAGNOSTIC_TEST|Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients|The applicability and reliability of virtual reality systems are important factors to consider. Based on this, this study aimed to investigate the feasibility of using BeCureTM virtual reality in the evaluation of upper extremity functions after stroke.The feasibility of using BeCureTM virtual reality in stroke patients will be determined according to the System Usability Scale (SUS) score.The safety of the use of BeCureTM virtual reality in stroke patients will be assessed with a patient feedback questionnaire. The relationship between the use of BeCureTM virtual reality and cognitive functions in stroke patients will be determined by the Montreal Cognitive Assessment Scale and Mini Mental State Examination.It was aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications.
219494851|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
219494852|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
219494853|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
219494854|NCT06702085|BEHAVIORAL|Lifestyle Management|patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
219494855|NCT06702098|DRUG|iNK cells|Induced pluripotent stem cells derived NK cells.
219494856|NCT01909752|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
219494857|NCT01909752|BIOLOGICAL|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
219494858|NCT01909752|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
219494859|NCT01909752|DRUG|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
219494860|NCT01909752|BIOLOGICAL|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
219494861|NCT02161939|DRUG|Daclatasvir (BMS-790052)|
219494862|NCT02161939|DRUG|Sofosbuvir|
219494863|NCT06703762|OTHER|He-Ne low level laser (LLL)|Patients in the experimental group will receive treatment with LLLT. The ulcer bed will be irradiated locally with red light (660 nm). The ulcer size and its depth will be used as the basis to calculate the duration of exposure needed to deliver 3-10 J/cm² for 15 to 20 minutes. The application will take place in 3 sessions per week for 4 weeks. Each patient will be asked to lie in a supine position with the ulcer easily exposed to the laser beam, and they will be instructed to wear laser glasses and avoid looking directly at the beam until the end of the session.
218875225|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
218875226|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
218875227|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
218875228|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
218875229|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
218875230|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
218875231|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
219024101|NCT01321125|BIOLOGICAL|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
218875232|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
218875233|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
218875234|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
218875235|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
218875236|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
219024102|NCT04572607|DIETARY_SUPPLEMENT|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
219024103|NCT02654535|OTHER|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
219024104|NCT05773547|DEVICE|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
219024105|NCT04122859|DEVICE|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
219494864|NCT06703762|OTHER|Conventional traditional treatment|All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
219494865|NCT06702306|DIAGNOSTIC_TEST|Ultrasound Surveillance|Lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 and 12 months.
219494866|NCT04920565|DEVICE|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
219494867|NCT05290272|DEVICE|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
219494868|NCT01998035|DRUG|RomiDEPsin 10 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"
219494869|NCT01998035|DRUG|Oral 5-Azacitidine 100 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"
219494870|NCT01998035|DRUG|Romidepsin 14 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"
219494871|NCT01998035|DRUG|Oral 5-Azacitidine 200 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"
218875237|NCT02025439|DEVICE|rTMS|
218875238|NCT02025439|DRUG|Amantadine|
218875239|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
219494872|NCT01998035|DRUG|Oral 5-Azacitidine 300 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"
218875240|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
218875241|NCT00559676|DRUG|capecitabine|
218875242|NCT00559676|DRUG|fluorouracil|
218875243|NCT00559676|DRUG|irinotecan hydrochloride|
218875244|NCT00559676|DRUG|leucovorin calcium|
218875245|NCT00559676|DRUG|oxaliplatin|
218875246|NCT00559676|OTHER|laboratory biomarker analysis|
218875247|NCT00559676|OTHER|pharmacological study|
218875248|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
219024106|NCT02157142|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
219494873|NCT03910010|DRUG|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
219494874|NCT06313294|OTHER|Tracking application app|An app will be implemented for mobile monitoring in patients who use continuous postoperative ambulatory regional analgesia.
219494875|NCT06313294|OTHER|Telephone interview|Patients who use continuous postoperative outpatient regional analgesia will be followed up using the current traditional method of post-discharge telephone call.
219494876|NCT05392712|DEVICE|Magnetometer|inspection equipment for magnetocardiography
218875249|NCT00461461|PROCEDURE|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.~3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
218875250|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
218875251|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
218875252|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
218875253|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
218875254|NCT02073669|PROCEDURE|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
218875255|NCT01257607|DRUG|MIM-D3 Ophthalmic Solution|28 Days, BID
218875256|NCT01257607|DRUG|Placebo Ophthalmic Solution|28 Days, BID
218875257|NCT03683888|BEHAVIORAL|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
218875258|NCT03683888|BEHAVIORAL|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
218875259|NCT00468975|DRUG|PF-610,355|
218875260|NCT00468975|DRUG|Salmeterol|
218875261|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
219024107|NCT02784821|DRUG|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
219024108|NCT02784821|OTHER|Gastric fluid|Microbiome evaluated using gastric aspirate.
219024109|NCT02784821|OTHER|Breast milk|Microbiome will be evaluated using mother's breast milk.
219024110|NCT02784821|OTHER|Stool samples|Microbiome will be evaluated using infant's stool.
219024111|NCT02784821|DRUG|Antibiotics|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
219024112|NCT04706195|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
219024113|NCT01277523|DRUG|tiotropium high dose|2 actuations once daily
219494877|NCT03914937|OTHER|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
219494878|NCT03914937|OTHER|Music|Music of the patient's choice will be played
219494879|NCT05166421|BIOLOGICAL|AZD7442|AZD7442 will be administered via IM route.
218875262|NCT00673283|DEVICE|bi-plane chest radiography|Bi-plane radiography of the thorax
218875263|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
218875264|NCT01093066|DRUG|optimal TURB|The TURB will always try to be optically complete.
219024114|NCT01277523|DRUG|placebo|2 actuations once daily
219024115|NCT01277523|DRUG|tiotropium low dose|2 actuations once daily
219024116|NCT03928847|DRUG|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
219494880|NCT05166421|BIOLOGICAL|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
219494881|NCT05166421|BIOLOGICAL|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
219494882|NCT05166421|BIOLOGICAL|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
219494883|NCT05166421|BIOLOGICAL|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
219494884|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
219494885|NCT02516878|PROCEDURE|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
219024117|NCT06523036|PROCEDURE|Combined chiropractic care and Tai Chi|Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
219024118|NCT06449807|BEHAVIORAL|crossover point intensity exercise|crossover point intensity exercise
219024119|NCT01881230|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
219494886|NCT05027009|PROCEDURE|Physical Examination|Undergo total body exam
219494887|NCT05027009|OTHER|Solar Simulated Light|Undergo exposures to simulated sunlight
219494888|NCT05633537|PROCEDURE|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
219494889|NCT05633537|RADIATION|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
219494890|NCT02588352|DIETARY_SUPPLEMENT|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
219494891|NCT05407337|BEHAVIORAL|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
219494892|NCT00000737|DRUG|Dronabinol|
219494893|NCT00000737|DRUG|Megestrol acetate|
219494894|NCT02546037|DEVICE|FX100 dialyzer|comparison of dialyzers
219494895|NCT02546037|DEVICE|SOLACEA 21H|comparison of dialyzers
218875265|NCT02195167|DRUG|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
218875266|NCT00556270|DRUG|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
218875267|NCT01627028|PROCEDURE|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
218875268|NCT04077931|OTHER|exercises|Walking on treadmill with fixed 0% grade inclination
218875269|NCT04511065|OTHER|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
218875270|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
218875271|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
218875272|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
218875273|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
218875274|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
218875275|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
218875276|NCT01786252|DRUG|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
218875277|NCT01786252|DRUG|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
218875278|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
219024120|NCT01881230|DRUG|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
219024121|NCT01881230|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
219024122|NCT03562039|PROCEDURE|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
218875279|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
219024123|NCT00017303|DRUG|carboplatin|
219024124|NCT00017303|DRUG|oglufanide disodium|
219024125|NCT00017303|DRUG|paclitaxel|
219024126|NCT00017303|PROCEDURE|conventional surgery|
219365088|NCT03502187|DEVICE|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
219494896|NCT03958071|DRUG|Nintedanib|Nintedanib initiators
219494897|NCT03958071|DRUG|Pirfenidone|Pirfenidone initiators
219494898|NCT03958071|OTHER|Untreated Cohort|Untreated
219494899|NCT06497361|BIOLOGICAL|PRG-2311|PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
219494900|NCT00454311|PROCEDURE|Biopsy of Day 3 Embryo|
219494901|NCT00454311|PROCEDURE|· day embryo biopsy|
219494902|NCT02035683|PROCEDURE|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
219494903|NCT03829033|RADIATION|Radiotherapy|Radiotherapy with either photons or protons.
219494904|NCT00294320|DRUG|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
219494905|NCT00294320|OTHER|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
219494906|NCT06116448|OTHER|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
219494907|NCT06116448|OTHER|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
219494908|NCT06116448|OTHER|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
219494909|NCT04725565|BEHAVIORAL|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
219494910|NCT04725565|BEHAVIORAL|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
219494911|NCT02551302|DEVICE|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
219494912|NCT02551302|DEVICE|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
219494913|NCT00127569|DRUG|Rituximab|
218875280|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
218875281|NCT00005994|DRUG|ondansetron|
219024127|NCT02385266|DRUG|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
219024128|NCT02385266|DRUG|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
219494914|NCT05151094|OTHER|Observation|Observation of clinical outcomes and comparison to non-treated patients
219494915|NCT05861440|DRUG|Prednisolone|adjunct steroid per study protocol
219494916|NCT05861440|DRUG|standard anti-tuberculosis agents|standard anti-tuberculosis agents
219494917|NCT03250065|DEVICE|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
219494918|NCT01566474|DRUG|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
218875282|NCT00547027|BEHAVIORAL|print-based physical activity intervention|individually-based, print-based physical activity intervention
218875283|NCT00547027|BEHAVIORAL|usual care|print-based materials of nutritional information
218875284|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
219024129|NCT04504799|DEVICE|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
219024130|NCT03147547|OTHER|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
219494919|NCT01566474|DRUG|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
219494920|NCT04635904|BEHAVIORAL|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
219494921|NCT04635904|BEHAVIORAL|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
219494922|NCT02507258|DEVICE|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
219494923|NCT01858558|BIOLOGICAL|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
218875285|NCT01180517|PROCEDURE|PCI|balloon angioplasty
218875286|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
218875287|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
218875288|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
218875289|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
218875290|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
218875291|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
218875292|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
218875293|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
218875294|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
218875295|NCT03729245|DRUG|sunitinib|Specified dose on specified days
218875296|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
218875297|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
218875298|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
218875299|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
218875300|NCT00875940|OTHER|Diagnostic imaging procedures.|
218875301|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
218875302|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
218875303|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
218875304|NCT02180477|DRUG|UHAC 62 XX - capsules|
218875305|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
219024131|NCT03147547|OTHER|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
219024132|NCT03147547|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
219024133|NCT03147547|OTHER|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
219024134|NCT05542303|DRUG|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
219024135|NCT05542303|DRUG|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
219024136|NCT05542303|DRUG|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
219024137|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
219024138|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
219024139|NCT04474951|DIETARY_SUPPLEMENT|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
219024140|NCT05669560|COMBINATION_PRODUCT|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
218875306|NCT01433094|BEHAVIORAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
218875307|NCT01433094|BEHAVIORAL|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
219024141|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
219024142|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
219024143|NCT00426283|DRUG|Flovent|1760 mcg daily
219024144|NCT00426283|OTHER|Placebo|Placebo
219494924|NCT01858558|DRUG|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
219494925|NCT05140863|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
219494926|NCT05140863|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
219494927|NCT05140863|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
219494928|NCT05079152|BIOLOGICAL|COVAX+PPV23;COVAX+IIV4|1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
219494929|NCT05079152|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
219494930|NCT05079152|BIOLOGICAL|PPV23 for the 1st dose and IIV4 for the 2nd dose|1st dose: PPV23 only; 2nd dose: IIV4 only
218875308|NCT03441503|OTHER|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
219024145|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
219024146|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
219024147|NCT06386614|OTHER|Routine treatment|Both groups were given routine treatment
219024148|NCT06386614|OTHER|Transcranial Direct Current Stimulation|The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
219024149|NCT05326594|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
219494931|NCT03546699|DIAGNOSTIC_TEST|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~* To describe clinical characteristics and outcomes for these patients.~* To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
219494932|NCT02268188|OTHER|education|Attend classes as part of Harvesting Health program
219494933|NCT02268188|OTHER|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
219494934|NCT02268188|BEHAVIORAL|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
219494935|NCT02268188|OTHER|questionnaire administration|Ancillary studies
219494936|NCT02268188|OTHER|laboratory biomarker analysis|Correlative studies
219024150|NCT05326594|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
219024151|NCT05326594|DEVICE|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
219024152|NCT05326594|PROCEDURE|Heat Therapy|superficial heating for 20 minutes
219024153|NCT02954510|DRUG|ferumoxytol|ferumoxytol will assess patency of coronary arteries
219024154|NCT04260737|OTHER|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
219024155|NCT03911440|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
219024156|NCT03911440|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
219024157|NCT01220479|BEHAVIORAL|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
219024158|NCT06308068|DRUG|Diacerein 50 mg Capsule|Diacerein 50 mg Capsule
219024159|NCT03933787|DRUG|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
219024160|NCT03933787|DRUG|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
219024161|NCT03933787|OTHER|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
219024162|NCT02746211|BIOLOGICAL|High Titre Influenza virus|High Titre Influenza virus
219024163|NCT02746211|BIOLOGICAL|Medium - High Influenza virus|Medium - High Influenza virus
219024164|NCT02746211|BIOLOGICAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
219024165|NCT02746211|BIOLOGICAL|Low titre|Low titre
219494937|NCT02268188|OTHER|quality-of-life assessment|Ancillary studies
219494938|NCT04244994|DEVICE|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
219494939|NCT03880929|OTHER|no intervention|no intervention
218875309|NCT05949489|DIAGNOSTIC_TEST|WOMAC pain subscale|"The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale is a self-reported questionnaire that is used to measure pain in people with osteoarthritis (OA). The subscale consists of five items that ask about the intensity, frequency, and duration of pain in the hip and knee joints.~The WOMAC Pain Subscale has been shown to be a reliable and valid measure of pain in people with OA. It has been used in a number of clinical trials and is considered to be a standard measure of pain in OA.~The WOMAC Pain Subscale is scored on a scale of 0 to 4, with 0 indicating no pain and 4 indicating severe pain. The total score for the subscale is the sum of the scores for the five items. A higher score indicates more pain."
218875310|NCT01054625|BIOLOGICAL|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
218875311|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
218875312|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
218875313|NCT03876665|OTHER|No intervention|No intervention
218875314|NCT00614484|RADIATION|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
218875315|NCT00614484|DRUG|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
218875316|NCT00614484|DRUG|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
219024166|NCT01123109|PROCEDURE|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
219024167|NCT02996864|OTHER|Healthy Detours App|"The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
219494940|NCT00299273|BEHAVIORAL|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
218875317|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
218875318|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
219024168|NCT02996864|OTHER|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
219024169|NCT03409926|DIETARY_SUPPLEMENT|Acacia Gum|dietary supplement will be added to the participant's usual diet
219204499|NCT06773442|OTHER|Documentation Protocols Group|"Training and Education Program:Develop and implement a training program for rehabilitation professionals aimed at enhancing their knowledge and skills in shoulder rehabilitation practices and documentation protocols.~Standardization of Protocols:Review and update existing rehabilitation protocols to ensure alignment with current evidence-based guidelines and best practices.~Quality Assurance Measures:Establish a system for ongoing monitoring and evaluation of shoulder rehabilitation practices and documentation protocols.~Patient Education and Engagement:Develop educational materials and resources for patients undergoing shoulder rehabilitation to enhance their understanding of treatment goals, exercises, and self-management strategies.~Outcome Monitoring and Evaluation:Implement a system for monitoring and evaluating patient outcomes, including pain levels, range of motion, functional status, and satisfaction with rehabilitation services."
219494941|NCT02789124|OTHER|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
219494942|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
219494943|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
219494944|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
219494945|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
219494946|NCT06112405|OTHER|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
219494947|NCT06112405|OTHER|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
219494948|NCT01523522|OTHER|Myoblast injection|Autologous myoblast injection in the anal sphincter
219494949|NCT01523522|PROCEDURE|saline solution injection|saline solution injection in anal sphincter
219494950|NCT02268331|OTHER|Active Surveillance|
219494951|NCT02268331|OTHER|Passive Surveillance|
219494952|NCT00918229|DEVICE|balloon implant|Absorbable perirectal spacer implantation
219494953|NCT00918229|PROCEDURE|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
218875319|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
218875320|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
218875321|NCT01218399|DRUG|Symbicort|
218875322|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
218875323|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
218875324|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
218875325|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
218875326|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
219024170|NCT03741036|PROCEDURE|Autogenous bone graft as space filling in immidiate implant placment|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
219024171|NCT03741036|PROCEDURE|Deprotinized bovien as space filling in immidate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
219024172|NCT03741036|PROCEDURE|Nano-hydroxiapatite alloplast in immidiate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
219024173|NCT03096652|PROCEDURE|Approach for cancer resection|
219494954|NCT01864720|BEHAVIORAL|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
218875327|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
219494955|NCT01864720|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
218875328|NCT05339230|DIETARY_SUPPLEMENT|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
219024174|NCT01859494|DEVICE|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
219024175|NCT06846671|DRUG|BGB-16673|Administered orally
219024176|NCT06846671|DRUG|Bendamustine|Administered intravenously
219024177|NCT06846671|DRUG|Idelalisib|Administered orally
219024178|NCT06846671|DRUG|Rituximab|Administered intravenously
219494956|NCT00003682|DRUG|doxorubicin hydrochloride|
218875329|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
218875330|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
218875331|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
219024179|NCT06846671|DRUG|Venetoclax|Administered orally
219204500|NCT06769217|DEVICE|Drug Eluting Coronary Stent|The Drug Eluting Coronary stent is indicated for the treatment of de novo coronary artery lesions in patients with symptomatic ischemic heart disease.
219494957|NCT00003682|DRUG|methylprednisolone|
219494958|NCT00888030|OTHER|there are no interventions currently listed for this study|
219494959|NCT03060148|DEVICE|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
219494960|NCT02598622|DRUG|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
219494961|NCT02598622|DRUG|Placebo|Placebo is taken 2 times a day for days 1 through 21.
219494962|NCT05043727|COMBINATION_PRODUCT|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
218875332|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
218875333|NCT00257972|DRUG|aripiprazole|
218875334|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
218875335|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
219494963|NCT05043727|COMBINATION_PRODUCT|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
219494964|NCT05787210|OTHER|Conventiional Physiotherapy|The Control group will be administered with Conventional Physiotherapy that Includes 5 minutes of trunk control training, 5 minutes walking in the hall with And without the therapist assistance, walker or crutches, and finally 5 minutes of Breathing exercises for Relaxation
219494965|NCT05787210|OTHER|Quadriceps Strength Training|The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
219494966|NCT01252836|DEVICE|AWBAT-D|Application of AWBAT-D bioengineered device
219602550|NCT07185984|DIAGNOSTIC_TEST|DIAGNOSIS TOOL|"The diagnostic tool developed will be validated by analyzing small aliquots of 100 additional fresh semen samples processed with the integrated microfluidic system (SwimCount™ Harvester) and the CASA system with artificial intelligence. To evaluate the diagnostic efficiency of the tool, the results obtained from the semen quality analysis will be compared with those obtained from the analysis of these samples when processed using the reference technique, based on conventional methods employed by fertility specialists. Finally, to determine the effectiveness of the developed tool, the clinical results obtained from assisted reproduction treatment will be compared with the diagnosis predicted by the tool, with the aim of evaluating its predictive capacity.~Translated with DeepL.com (free version)"
219602551|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
219602552|NCT05938621|BEHAVIORAL|behavioral therapy and education|Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
219602553|NCT06308549|BEHAVIORAL|MyDiaMate|MyDiaMate programme
219602554|NCT03598790|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219602555|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
219602556|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
219602557|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
219602558|NCT04092283|DRUG|Carboplatin|Given IV
219602559|NCT04092283|DRUG|Cisplatin|Given IV
219602560|NCT04092283|BIOLOGICAL|Durvalumab|Given IV
218875336|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
218875337|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
218875338|NCT01017445|OTHER|Boonme stick exercise|individual exercise daily
219602561|NCT04092283|DRUG|Etoposide|Given IV
219602562|NCT04092283|DRUG|Paclitaxel|Given IV
219602563|NCT04092283|DRUG|Pemetrexed Disodium|Given IV
219602564|NCT02912559|DRUG|Atezolizumab|Given IV
219602565|NCT02912559|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602566|NCT02912559|PROCEDURE|Computed Tomography|Undergo CT
218875339|NCT04311463|DRUG|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
218875340|NCT04311463|DRUG|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
218875341|NCT05544149|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
218875342|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
218875343|NCT04524624|DEVICE|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
218875344|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
219602567|NCT02912559|DRUG|Fluorouracil|Given IV
219602568|NCT02912559|DRUG|Leucovorin Calcium|Given IV
219602569|NCT02912559|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602570|NCT02912559|DRUG|Oxaliplatin|Given IV
218875345|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
218875346|NCT02195804|DRUG|Ranitidine hydrochloride|
218875347|NCT00737633|DRUG|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
218875348|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
218875349|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
218875350|NCT00440830|DRUG|placebo|placebo patch applied to smokers
218875351|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
218875352|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
218875353|NCT04082780|OTHER|Placebo|Placebo arm
218875354|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
219602571|NCT02912559|OTHER|Quality-of-Life Assessment|Ancillary studies
218875355|NCT04683120|DIAGNOSTIC_TEST|Zenith FLIM Diagnostics|In-vitro
218875356|NCT04651829|OTHER|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
219602572|NCT02834013|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602573|NCT02834013|PROCEDURE|Computed Tomography|Undergo CT
219602574|NCT02834013|PROCEDURE|Echocardiography Test|Undergo ECHO
219602575|NCT02834013|BIOLOGICAL|Ipilimumab|Given IV
219602576|NCT02834013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602577|NCT02834013|BIOLOGICAL|Nivolumab|Given IV
218875357|NCT04651829|OTHER|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
218875358|NCT01300260|BIOLOGICAL|LY2189265|Administered subcutaneously
218875359|NCT01300260|DRUG|Placebo|Administered subcutaneously
218875360|NCT01300260|DRUG|Insulin|Administered intravenously
218875361|NCT01300260|DRUG|Glucose|Administered intravenously
218875362|NCT01300260|DRUG|Glucagon|Administered intravenously
218875363|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
218875364|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
218875365|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
218875366|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
218875367|NCT00377364|DRUG|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
218875368|NCT03048877|DRUG|Apatinib Oral Tablet|Apatinib Mesylate Tablets
218875369|NCT03048877|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
218875370|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
218875371|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
219602578|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
218875372|NCT00003658|BIOLOGICAL|filgrastim|
218875373|NCT00003658|BIOLOGICAL|rituximab|
218875374|NCT00003658|DRUG|cyclophosphamide|
218875375|NCT00003658|DRUG|pentostatin|
218875376|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
218875377|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
218875378|NCT03230682|DRUG|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
218875379|NCT02784769|OTHER|measurement of skin autofluorescence|
219602579|NCT04846829|DRUG|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
219602580|NCT04846829|DEVICE|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
219602581|NCT04846829|DRUG|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
219602582|NCT04846829|DEVICE|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
219602583|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
219602584|NCT04164199|DRUG|Pamiparib|Administered orally.
219602585|NCT04164199|DRUG|Temozolomide|Administered orally.
219602586|NCT04164199|DRUG|Sitravatinib|Administered orally.
219602587|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
219602588|NCT04164199|DRUG|BAT1706|Administered intravenously.
219602589|NCT04164199|DRUG|Fruquintinib|Administered orally.
219602590|NCT04164199|DRUG|BGB-15025|Administered orally.
219602591|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
219602592|NCT04164199|DRUG|BGB-A445|Administered intravenously.
219602593|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
219602594|NCT04164199|DRUG|Lenvatinib|Administered orally.
219602595|NCT04164199|DRUG|LBL-007|Administered intravenously.
218875380|NCT02784769|OTHER|skin biopsy collection|
219494967|NCT05011019|DRUG|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
218875381|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
218875382|NCT02437370|DRUG|Pembrolizumab|Given IV
218875383|NCT02437370|DRUG|Docetaxel|Given IV
218875384|NCT02437370|DRUG|Gemcitabine Hydrochloride|Given IV
218875385|NCT01204762|DRUG|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
218875386|NCT01204762|DRUG|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
218875387|NCT01204762|DRUG|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
218875388|NCT01204762|DRUG|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
218875389|NCT00439374|DRUG|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
218875390|NCT00439374|OTHER|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
218875391|NCT02667470|DRUG|Solifenacin|Oral
218875392|NCT02169856|BEHAVIORAL|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
218875393|NCT02169856|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
218875394|NCT02169856|DRUG|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
218875395|NCT02169856|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
218875396|NCT02169856|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
218875397|NCT02169856|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
218875398|NCT02169856|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
218875399|NCT02169856|DRUG|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
218875400|NCT02169856|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
218875401|NCT05011526|BIOLOGICAL|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
218875402|NCT05011526|BIOLOGICAL|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
218875403|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
218875404|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
218875405|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
218875406|NCT01720238|DRUG|Entecavir|0.5mg qd
218875407|NCT01720238|DRUG|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
218875408|NCT04903366|DRUG|Timolol Maleate|timolol maleate 0.5% gel-forming solution
218875409|NCT02356679|DRUG|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
218875410|NCT02356679|DRUG|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
219494968|NCT00720733|BEHAVIORAL|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
219494969|NCT00720733|BEHAVIORAL|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning \& Purpose.
219494970|NCT01949207|PROCEDURE|EVLA|Endovenous laser ablation of great saphenous vein
219494971|NCT01949207|PROCEDURE|phlebectomies|removal of incompetent veins
219494972|NCT01949207|PROCEDURE|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
218875411|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
218875412|NCT01909765|OTHER|Dorsal slit|Skin and mucosa incision made together
218875413|NCT01909765|OTHER|Double incision|Skin and mucosa incision made separately
218875414|NCT01257035|OTHER|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
218875415|NCT01179165|OTHER|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
218875416|NCT06515262|BIOLOGICAL|Anti-BCMA-GPRC5D CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.
218875417|NCT01626417|DEVICE|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
219494973|NCT01168700|DRUG|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
218875418|NCT02540265|DRUG|N1539|
218875419|NCT02540265|DRUG|Intravenous Placebo|
218875420|NCT04132674|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
218875421|NCT00510978|BIOLOGICAL|Bifidobacterium infantis 35624|1 sachet/day for one year
218875422|NCT00510978|BIOLOGICAL|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
218875423|NCT00510978|BIOLOGICAL|Placebo|1 sachet per day for 1 year
218875424|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
218875425|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
218875426|NCT04203420|OTHER|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
218875427|NCT05563831|OTHER|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
218875428|NCT03157037|BIOLOGICAL|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
218875429|NCT01919216|DRUG|Citalopram|
218875430|NCT05224037|DIAGNOSTIC_TEST|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
218875431|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
219200281|NCT06887686|BEHAVIORAL|Swaddled Bath Intervention Wipe Bath Intervention|"Swaddled Bath Intervention:~In the swaddled bath group, infants are gently wrapped in a soft towel or blanket to maintain a flexed position. They are then immersed in warm water at an appropriate temperature to regulate body temperature. This intervention is designed to reduce stress and pain, particularly for premature infants, and helps to relax the baby's muscles, stabilize body temperature, and increase overall comfort. It is expected to show a more significant effect on physiological and behavioral stabilization than less invasive methods.~Wipe Bath Intervention:~In the wipe bath group, infants are gently wiped with a cloth soaked in warm water. This method is less invasive than the swaddled bath, aiming to maintain body temperature while providing a milder level of relaxation. The wipe bath is effective for skin cleansing but may not provide the same comfort or stress-reducing effects as the swaddled bath. The expected physiological effects, such as body temperature stabilizatio"
219200282|NCT06886750|DRUG|Botulinum toxin type A injection|Injection of toxin
219494974|NCT01168700|DRUG|Placebo|Placebo 1.2 g per day for 12 weeks.
218875432|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
218875433|NCT02346513|DEVICE|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
218875434|NCT02346513|DEVICE|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
218875435|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
218875436|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
218875437|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
218875438|NCT00456651|DEVICE|CPAP (Continuous Positive Airway Pressure)|
218875439|NCT02644382|OTHER|qualitative data collection|qualitative data collection
218875440|NCT02644382|OTHER|survey|survey pre and post-surgical consult
218875441|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
218875442|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
218875443|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
218875444|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
218875445|NCT03323190|BEHAVIORAL|Inpatient COPD education|
218875446|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
218875447|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
218875448|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
218875449|NCT00518193|DRUG|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
218875450|NCT00067782|DRUG|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
218875451|NCT00067782|DRUG|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
219494975|NCT04031066|DRUG|Velmanase Alfa|infusion i.v. treatment
219494976|NCT04031066|DRUG|Placebo|infusion i.v. treatment
219494977|NCT02444156|OTHER|Indoor rowing|
218875452|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
218875453|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
218875454|NCT05238805|RADIATION|Observational heart and kidney on siemens TEP scan|Same as arm description
218875455|NCT03009084|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
218875456|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
218875457|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
218875458|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
218875459|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
219494978|NCT05459051|DIAGNOSTIC_TEST|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
219494979|NCT05459051|DIAGNOSTIC_TEST|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
219602596|NCT06781489|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
218875460|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
218875461|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
218875462|NCT04651127|DRUG|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
218875463|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
218875464|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
218875465|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
218875466|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
218875467|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
218875468|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
218875469|NCT06543329|PROCEDURE|polyglactin 910|75 PARTICIPANT, Vicryl suture was used in subcuticular suture
218875470|NCT06543329|PROCEDURE|poliglecaprone 25|75 PARTICIPANT, monocryl suture was used in subcuticular suture
218875471|NCT06543329|PROCEDURE|polypropylene|75 PARTICIPANT, Prolene suture was used in subcuticular suture
218875472|NCT06543329|PROCEDURE|polyester|75 PARTICIPANT, Polyester suture was used in subcuticular suture
219602597|NCT06781489|DRUG|Gabapentin 300mg|Oral gabapentin capsule
219602598|NCT06781489|DRUG|Ibuprofen Arginine|Oral ibuprofen arginine tablets
219602599|NCT01821690|DRUG|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
219602600|NCT01821690|DRUG|Placebo|The placebo tablets taste and look identical to buspirone.
219602601|NCT06778798|COMBINATION_PRODUCT|Median nerve neural mobilization and oral gabapentin|Manual therapy maneuver performed in the upper limb combined with gabapentin oral capsules.
219602602|NCT06778798|DRUG|Gabapentin 300mg|Gabapentin oral capsules
218875473|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
218875474|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
218875475|NCT00992823|DRUG|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
218875476|NCT00992823|BIOLOGICAL|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
219024180|NCT02210936|OTHER|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
219024181|NCT01027481|DRUG|Lucentis|intravitreally administration of 0.05 ml Lucentis
219024182|NCT00424138|RADIATION|FDG|
219024183|NCT04287504|DIAGNOSTIC_TEST|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
219024184|NCT04287504|DIAGNOSTIC_TEST|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
219024185|NCT05164900|PROCEDURE|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
219024186|NCT05621252|DRUG|PLN-74809|160 mg PLN-74809
219024187|NCT05621252|DRUG|Placebo|Matching placebo
219024188|NCT02389998|OTHER|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
219024189|NCT02389998|DRUG|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
219024190|NCT04071730|DIETARY_SUPPLEMENT|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
219024191|NCT04172246|DRUG|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
219024192|NCT05443191|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
219024193|NCT04387851|BEHAVIORAL|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
219024194|NCT04387851|BEHAVIORAL|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
219024195|NCT04387851|BEHAVIORAL|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
219602603|NCT06778759|COMBINATION_PRODUCT|median nerve neural mobilization combined with oral ibuprofen arginine|Manual therapy maneuver performed in the upper limb combined with ibuprofen arginine oral tablets
218875477|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
218875478|NCT00240383|DRUG|Muraglitazar|
219024196|NCT02769247|DRUG|Naproxen|Oral naproxen vs placebo
219024197|NCT02769247|DRUG|Lidocaine|Intrauterine lidocaine vs normal saline
219024198|NCT02769247|DRUG|placebo|either normal saline or empty oral capsule
219024199|NCT06238479|DRUG|LY4101174|Intravenous
219024200|NCT04101981|PROCEDURE|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
219024201|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
219602604|NCT06778759|DRUG|Ibuprofen Arginine|Ibuprofen arginine oral tablets
219602605|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
219602606|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
218875479|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
218875480|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
218875481|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
219024202|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
219494980|NCT05802095|DEVICE|Supplemental Feeding Tube Device|One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
218875482|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
218875483|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
218875484|NCT00695864|DRUG|Ondansetron and Placebo crossover|
218875485|NCT00005107|DRUG|N-monomethyl-L-arginine|
218875486|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
218875487|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
218875488|NCT00498355|DRUG|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
218875489|NCT04816058|BEHAVIORAL|Determining the level of ankle instability|Ankle instability
218875490|NCT03881904|DRUG|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
219494981|NCT01405885|BIOLOGICAL|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494982|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494983|NCT01405885|BIOLOGICAL|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494984|NCT01405885|BIOLOGICAL|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494985|NCT01405885|BIOLOGICAL|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494986|NCT01405885|BIOLOGICAL|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494987|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
219494988|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
219494989|NCT01405885|BIOLOGICAL|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
218875491|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
218875492|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
218875493|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
218875494|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
219200283|NCT06885723|DEVICE|Vibration Anesthesia Device (VAD)|In conclusion, induction of anesthesia with VAD in patients treated with ITS provided pain palliation in a similar way to other local anesthetic techniques. Moreover, the advantage of VAD application over other anesthetic agents was that it eliminated the need to use local anesthetics that may disrupt wound healing. In addition, inducing anesthesia with VAD can be considered as an alternative method in patients allergic to drugs. Our study will shed light on different techniques such as the application of ventilation tube in anesthesia with VAD.
219200284|NCT06885723|DRUG|local anesthetic cream|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
219494990|NCT01405885|BIOLOGICAL|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
219494991|NCT00543582|DRUG|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
219024203|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
219024204|NCT02595931|DRUG|Berzosertib|Given IV
219024205|NCT02595931|PROCEDURE|Biopsy Specimen|Undergo biopsy
219024206|NCT02595931|PROCEDURE|Biospecimen Collection|Correlative studies
219024207|NCT02595931|PROCEDURE|Computed Tomography|Undergo CT
219024208|NCT02595931|DRUG|Irinotecan Hydrochloride|Given IV
219024209|NCT04940026|DRUG|amcenestrant|Tablet Oral
219024210|NCT04940026|DRUG|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
219024211|NCT04940026|DRUG|[14C]-SAR439859|Powder for oral solution Oral
219024212|NCT06136871|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
219024213|NCT06136871|BEHAVIORAL|Inactive Control Group|An inactive control group will be used to control for maturation and testing effects. Weekly contact will be made via teleconferencing to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce PCS symptoms. The content of each of these meetings will be tracked in intervention notes. Each contact will be recorded for fidelity monitoring to ensure all active ingredients of the CO-OP intervention are avoided.
219024214|NCT04167917|DRUG|NTX-301|oral hypomethylating agent
219024215|NCT06007586|DRUG|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
219024216|NCT04084041|DEVICE|Simeox|Airway clearance device
219024217|NCT04084041|OTHER|CCPT|Conventional chest physiotherapy
219024218|NCT05089682|DEVICE|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
219024219|NCT02909452|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
219024220|NCT02909452|DRUG|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
219024221|NCT05773144|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
219024222|NCT05773144|BEHAVIORAL|Progressive stretching|Static stretching of eight major muscle groups
219024223|NCT00706979|OTHER|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
219200285|NCT06885723|DRUG|lidocaine spray|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
219024224|NCT00706979|BEHAVIORAL|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
219024225|NCT04950569|DRUG|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
219024226|NCT05584150|OTHER|Deep Cleansing Gel|daily use
219024227|NCT05325632|BIOLOGICAL|HER-2 pulsed DC1|Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
219024228|NCT05325632|DRUG|Trastuzumab|8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
219024229|NCT05325632|DRUG|Pertuzumab|840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
219024230|NCT05325632|DRUG|Paclitaxel|80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
219024231|NCT05325632|PROCEDURE|Resection surgery|After week 18, participants will undergo standard of care resection surgery.
219024232|NCT01996826|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
219024233|NCT01996826|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
219024234|NCT04911283|OTHER|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
219024235|NCT04911283|OTHER|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
219602607|NCT02830724|DRUG|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
218875495|NCT03461081|DRUG|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
218875496|NCT05262647|DIAGNOSTIC_TEST|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
218875497|NCT04016077|DRUG|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
218875498|NCT00609739|DRUG|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
218875499|NCT00609739|DRUG|cytarabine|3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
218875500|NCT00609739|DRUG|filgrastim|Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
218875501|NCT00609739|DRUG|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
218875502|NCT00609739|DRUG|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
218875503|NCT00609739|DRUG|mitoxantrone hydrochloride|10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
218875504|NCT00609739|PROCEDURE|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.
218875505|NCT00609739|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
218875506|NCT00609739|DRUG|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
218875507|NCT05321251|DRUG|Insulin|see arm description
218875508|NCT05321251|PROCEDURE|Tarsorrhaphy|see arm description
218875509|NCT00154882|DRUG|Paclitaxel (Phyxol) , Cisplatin|
218875510|NCT02181114|BEHAVIORAL|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
218875511|NCT01433562|DRUG|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
218875512|NCT01433562|DRUG|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
218875513|NCT03772262|DIETARY_SUPPLEMENT|goldenseal|Oral 500 mg capsules
219024236|NCT00518323|DRUG|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
219024237|NCT00518323|DRUG|Placebo|Once daily for 6 weeks
219024238|NCT00518323|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
219024239|NCT00518323|DRUG|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
219024240|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
218875514|NCT03772262|DRUG|Metformin|Oral solution
218875515|NCT03772262|DRUG|Furosemide|Oral solution
218875516|NCT03772262|DRUG|Midazolam oral solution|Oral syrup
219024241|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
219024243|NCT04015245|DRUG|Stronger Neo-Minophagen C|intravenous injection after TACE
219024244|NCT06530342|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in all athletes.
219494992|NCT04036227|DRUG|GS-248|GS-248 oral solution
219494993|NCT04036227|DRUG|Placebo|Placebo oral solution with the same composition to match active drug
219494994|NCT02267850|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
219494995|NCT02267850|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
219494996|NCT02267850|DEVICE|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
219494997|NCT05438290|DRUG|DPCP|topical immunomodulator
219494998|NCT03005379|DRUG|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
219494999|NCT03005379|DRUG|Placebo|Oral capsule-delivered placebo
219495000|NCT02938910|OTHER|non interventional study|Non invasive imaging study without interventional procedures
219495001|NCT01505595|OTHER|Proprioceptive training|12 weeks
219495002|NCT01505595|OTHER|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
219495003|NCT04335110|BEHAVIORAL|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
219495004|NCT01805310|OTHER|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
219495005|NCT01805310|OTHER|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
219495006|NCT01838161|BEHAVIORAL|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
219495007|NCT01838161|BEHAVIORAL|Part III|•video educational
219495008|NCT01838161|BEHAVIORAL|Part I|Parental Interviews
219495009|NCT02595528|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
219024245|NCT05301296|DIAGNOSTIC_TEST|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
219024246|NCT03382119|DEVICE|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
219024247|NCT03382119|DEVICE|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
219024248|NCT03622346|PROCEDURE|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
219495010|NCT02595528|DRUG|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
219495011|NCT02595528|DRUG|AGN-190584 vehicle|Vehicle to AGN-190584
219495012|NCT02595528|DRUG|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
219495013|NCT02595528|DRUG|AGN-199201 vehicle|Vehicle to AGN-199201
219495014|NCT02345928|DRUG|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
219495015|NCT02345928|DRUG|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
219495016|NCT02345928|DRUG|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
219495017|NCT02345928|DRUG|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
219495018|NCT02391883|DRUG|Clopidogrel|
219024249|NCT01514760|OTHER|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
219495019|NCT02177747|OTHER|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
219495020|NCT02177747|DEVICE|Smartphone|
219495021|NCT00407433|DRUG|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
219495022|NCT05103397|DRUG|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
219495023|NCT05103397|DRUG|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
219495024|NCT05103397|DRUG|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
219495025|NCT03639961|BEHAVIORAL|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
219495026|NCT03639961|BEHAVIORAL|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
219495027|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
219495028|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
219495029|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
219495030|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
219602608|NCT02830724|DRUG|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
219602609|NCT02830724|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
219602610|NCT02830724|BIOLOGICAL|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
219602611|NCT06247670|DRUG|CMP-CPS-001|CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
219200286|NCT06885723|OTHER|saline drops|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
219200287|NCT06887816|DEVICE|silver coated device|Patients who will be implanted with prosthesis with a silver coating to counteract infection relapse
219200288|NCT06887816|DEVICE|not silver coated device|Patients who will be implanted with prosthesis without silver coating
219495031|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
219495032|NCT05940883|DRUG|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
219495033|NCT01838083|DRUG|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
219495034|NCT04321733|DRUG|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
219495035|NCT06093828|DEVICE|TriFlo Tricuspid Flow Optimizer|An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
219495036|NCT02292433|DRUG|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
219495037|NCT02292433|DRUG|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
219495038|NCT02292433|DRUG|Placebo|tablets, breakfast plus lunch, 7 days
219495039|NCT04324398|OTHER|Cryotherapy|cold application
219495040|NCT03101293|DRUG|TAK-831|TAK-831 film-coated tablet.
219602612|NCT06247670|OTHER|Placebo|Placebo is 0.9% normal saline solution and will be administered subcutaneously.
219602613|NCT02638090|DRUG|Vorinostat|Administered per treatment arm guidelines.
219602614|NCT02638090|DRUG|Pembrolizumab|Administered per treatment arm guidelines.
219602615|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
219602616|NCT06830577|DRUG|Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy|Intraureteric aminophylline installation prior to ureteric dilatation
219602617|NCT06830577|DEVICE|Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy|traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr
219602618|NCT06830577|OTHER|Aminophylline instillation and Ureteral dilators together|Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B) prior to placing the ureteric access sheath
219602619|NCT06826833|PROCEDURE|Erector Spinae Plane (ESP) Block|A regional anesthesia technique in which 20 mL of 0.25% bupivacaine is injected under ultrasound guidance at the T8-T10 level to provide postoperative pain relief.
219602620|NCT00000971|DRUG|Clarithromycin|
219602621|NCT00000971|DRUG|Zidovudine|
219602622|NCT00000971|DRUG|Didanosine|
218875517|NCT03772262|DRUG|Rosuvastatin Oral Tablet|Oral tablet
218875518|NCT00033488|OTHER|cytology specimen collection procedure|
218875519|NCT00033488|PROCEDURE|annual screening|
218875520|NCT00033488|PROCEDURE|comparison of screening methods|
218875521|NCT02100475|DRUG|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
218875522|NCT02100475|DRUG|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
218875523|NCT05629130|DEVICE|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
218875524|NCT03800238|BEHAVIORAL|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
218875525|NCT03800238|BEHAVIORAL|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
218875526|NCT05342272|DRUG|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
219024250|NCT05096845|BIOLOGICAL|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date"
219495041|NCT06091774|DEVICE|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
219495042|NCT04718857|BEHAVIORAL|Online education|health education
219602623|NCT03575000|DRUG|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
219602624|NCT05384587|DRUG|asciminib|Supplied in 40 mg and 100 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
219602625|NCT06040268|DRUG|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
219602626|NCT06040268|DRUG|Placebo|HFA134a inhaler
219602627|NCT04319237|OTHER|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
219602628|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
219602629|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
219602630|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
218875527|NCT05342272|DRUG|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
218875528|NCT04241484|DEVICE|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
219495043|NCT03637673|OTHER|No intervention|No intervention
218875529|NCT03066414|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
219024251|NCT05096845|OTHER|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
219024252|NCT05185960|OTHER|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
219024253|NCT05185960|OTHER|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
219024254|NCT05185960|OTHER|Sucrose|Table sugar. It will be consumed by diluting it in water.
219495044|NCT03815357|OTHER|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
219495045|NCT01091376|DRUG|Erlotinib|Erlotinib 150mg/day
219495046|NCT01091376|RADIATION|Thoracic radiotherapy|60-70Gy/30-35f
219495047|NCT05088824|PROCEDURE|hernia repair by desarda technique|It involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. This is a physiological repair and is tension free, can be used in strangulated hernia
219495048|NCT00769899|DRUG|AZD7325|Capsule for oral, single dose
219495049|NCT00769899|DRUG|Placebo|Placebo capsule for oral, single dose
219495050|NCT04681456|BEHAVIORAL|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
219024255|NCT02092662|OTHER|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
219024256|NCT02092662|OTHER|Healthy controls|no treatment
219024257|NCT06063577|DEVICE|Stratafix suture|Stratafix symmetric suture
219024258|NCT06063577|DEVICE|Standard of care suture|Standard of care suture
218875530|NCT05479240|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
218875531|NCT05479240|DRUG|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
218875532|NCT05479240|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
219024259|NCT02686879|DEVICE|Multifocal contact lenses|
219200289|NCT06886971|OTHER|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access to that choice through the deployment of the SLAT team. HIV-ASSIST is an interactive tool that offers clinicians comprehensive, individualized validated patient-specific ARV decision support along with evidence-based supporting educational material. The free online, interactive tool is designed to augment interpretation of current HIV clinical practice guidelines (CPG).It will be included in the CHOICE counseling providing participants with patient-centered approach, specifically addresses the patient's expressed needs, problems, issues and concerns with a goal of providing accurate and unbiased information on available choices. After CHOICE counseling, if the participant chooses LAI-ART, the participant is referred to the SAVVY LAI-ART access team (SLAT) to facilitate access.
219200290|NCT06883188|DRUG|talc powder|intrapleural instillation of talc slurry
218875533|NCT05479240|RADIATION|short-range radiotherapy|5\*5Gy，d1-d5
218875534|NCT02184923|OTHER|presentation of visual vertical|
219024260|NCT02686879|DEVICE|Single vision contact lenses|
219024261|NCT05508074|DRUG|IFB-088 50mg/day|Tested product
219024262|NCT05508074|DRUG|Placebo|Placebo
219024263|NCT05508074|DRUG|Riluzole 100mg/day|Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
219200291|NCT06883188|BIOLOGICAL|patient's own venous blood|intrapleural instillation of patient's own venous blood
219200292|NCT06879782|DRUG|Drug placebo|Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.
219200293|NCT06718699|OTHER|resistance exercise tests|One 1RM and three RTF tests (5-8RM, 9-12RM, 13-16RM) on seven resistance training devices
218875535|NCT05584280|DEVICE|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
218875536|NCT05584280|DEVICE|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
218875537|NCT05967650|BIOLOGICAL|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
218875538|NCT05967650|BIOLOGICAL|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
219024264|NCT01091389|PROCEDURE|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
219024265|NCT03646461|DRUG|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
219024266|NCT03646461|DRUG|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
219024267|NCT03646461|DRUG|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
219024268|NCT06490328|DRUG|DKF-MA102|Administered twice at 12-week intervals
218875539|NCT05317065|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
218875540|NCT03634163|BEHAVIORAL|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
218875541|NCT03634163|BEHAVIORAL|Quality of Life Assessment|Completion of baseline measures
219024269|NCT04156568|DRUG|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
219024270|NCT03997149|BEHAVIORAL|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
219024271|NCT03997149|BEHAVIORAL|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
219024272|NCT01754233|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
219024273|NCT00005888|BEHAVIORAL|Fortified Pasteurized Donor Human Milk supplement|
219200294|NCT06885775|DEVICE|DXP01|PCL Dermal Filler
219200295|NCT06885775|DEVICE|Juvederm ULTRA 3|HA Dermal filler
219200296|NCT06725576|PROCEDURE|Ablation|Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
219200297|NCT04780581|DRUG|Dexamethasone|6 mg/24h - 10 days
219200298|NCT04780581|DRUG|Methylprednisolone|250 mg/ 24h - 3 days
219200299|NCT06727240|DEVICE|Intervention|The interventional device is a coupling device intended to prevent mechanical complications during peripheral intravenous infusions. While control will not receive the device.
218875542|NCT04519463|DRUG|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
218875543|NCT04519463|DRUG|Placebo|Sodium Chloride 0.9%
219024274|NCT00005888|BEHAVIORAL|Preterm Formula supplement|
219024275|NCT00045279|BIOLOGICAL|PEG-interferon alfa-2b|
219495051|NCT03914144|OTHER|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
219495052|NCT02288689|DEVICE|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
219024276|NCT06180291|OTHER|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support."
219024277|NCT06001554|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
219495053|NCT05028686|OTHER|No intervention|Observational cohort
219495054|NCT03448809|BEHAVIORAL|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
219495055|NCT03448809|BEHAVIORAL|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
219495056|NCT04075188|DRUG|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
219495057|NCT04987307|DRUG|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
219495058|NCT04987307|DRUG|Placebo|Placebo will be administered by SC injection.
219495059|NCT05319977|BEHAVIORAL|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
219495060|NCT00028938|BIOLOGICAL|epoetin alfa|
219495061|NCT00028938|DRUG|carboplatin|
219495062|NCT00028938|DRUG|paclitaxel|
219495063|NCT00028938|RADIATION|radiation therapy|
219495064|NCT03333382|DEVICE|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
219495065|NCT03333382|DEVICE|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
219495066|NCT02257827|RADIATION|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
219495067|NCT04363294|DIAGNOSTIC_TEST|PYP scan|99mTc-labeled pyrophosphate
219024278|NCT04318990|PROCEDURE|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
219495068|NCT03706274|DRUG|CX-188|CX-188
219495069|NCT03296774|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
219495070|NCT03296774|BEHAVIORAL|Usual Care|
219495071|NCT05110430|OTHER|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
219495072|NCT02554825|BEHAVIORAL|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
219495073|NCT02554825|BEHAVIORAL|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
219495074|NCT05309174|PROCEDURE|USG-guided iSLN block|Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
219495075|NCT06379022|BEHAVIORAL|Plaque control|Subjects are motivated for optimal oral hygiene
219495076|NCT03606239|RADIATION|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
218875544|NCT02246907|OTHER|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
219495077|NCT00685022|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI"
219495078|NCT00685022|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI"
218875545|NCT04142294|DIETARY_SUPPLEMENT|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
218875546|NCT03605446|DIETARY_SUPPLEMENT|Biscuit acceptance|Acceptance of high protein biscuits
218875547|NCT05691114|BIOLOGICAL|hAESCs|human Amniotic Epithelial Stem Cells
218875548|NCT05742607|DRUG|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
218875549|NCT01548508|OTHER|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
218875550|NCT01548508|OTHER|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
218875551|NCT05692102|OTHER|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
218875552|NCT02990039|BEHAVIORAL|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
218875553|NCT03179397|DEVICE|Model SC9|Experimental
218875554|NCT03179397|DEVICE|Model LI61SE|Active Comparator
218875555|NCT02745808|BIOLOGICAL|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
218875556|NCT02745808|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
218875557|NCT04402723|DRUG|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
218875558|NCT06279832|OTHER|trascriptomic profiling|The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
218875559|NCT04599465|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
218875560|NCT04599465|DRUG|IVA|Tablets for oral administration.
218875561|NCT05177367|OTHER|Sequential Variety|3 courses each consisting of a different food
219024279|NCT04318990|PROCEDURE|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
219024280|NCT00391989|DRUG|Dasatinib|
219495079|NCT00670267|DRUG|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
218875562|NCT05177367|OTHER|Simultaneous Variety|3 courses each consisting of 3 foods
218875563|NCT05177367|OTHER|Single Food|3 courses each consisting of the same food
219024281|NCT06793488|DRUG|Disulfiram 250 mg|Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
219495080|NCT02270840|DEVICE|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
219495081|NCT00006096|DRUG|cisplatin|
219495082|NCT00006096|RADIATION|radiation therapy|
219495083|NCT06173986|DRUG|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
218875564|NCT05177367|OTHER|Small portion|Small meal portion size
218875565|NCT05177367|OTHER|Large Portion|Large meal portion size
218875566|NCT04079998|DEVICE|Procellera®|Application of Procellera® dressing.
219024282|NCT06793488|DIAGNOSTIC_TEST|functional MRI|Participants will undergo fMRI scanning. Participants with alcohol use disorder will undergo scanning after 1 week and 3 months of disulfiram maintenance. Healthy volunteer participants will undergo scanning once.
219495084|NCT06173986|DRUG|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
219495085|NCT06173986|RADIATION|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
219024283|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
218875567|NCT04079998|OTHER|Standard of Care|Application of standard of care dressings as prescribed.
219024284|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
219024285|NCT03184415|DRUG|DWC20155|tablet
219024286|NCT03184415|DRUG|DWC20156|tablet
219024287|NCT03184415|DRUG|placebo of DWC20155|tablet
219024288|NCT03184415|DRUG|placebo of DWC20156|tablet
219024289|NCT05161169|GENETIC|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
219200300|NCT06706206|OTHER|Observational trial|"Observational clinical trial. Participants will undergo cardiovascular risk assessment (clinical and blood tests) and coronary CT angiogram.~These results will be compared to a control population without haemophilia (recruited as part of a different clinical trial)."
219495086|NCT00677586|PROCEDURE|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
219495087|NCT00677586|PROCEDURE|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
218875568|NCT04345315|OTHER|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
218875569|NCT04345315|OTHER|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
218875570|NCT04345315|GENETIC|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
219495088|NCT01177319|DRUG|Glutathione|
218875571|NCT04345315|OTHER|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
218875572|NCT02056327|DEVICE|A novel monitoring suite of sensors will be inserted into the standard oral device.|
218875573|NCT03009617|BEHAVIORAL|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
218875574|NCT01354925|DRUG|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
218875575|NCT01354925|DRUG|Standard of care|Standard of care during Ramadan according to physicians decision
218875576|NCT01964625|OTHER|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
218875577|NCT02737345|OTHER|Rotem|
218875578|NCT01835665|DRUG|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
219024290|NCT03797209|DEVICE|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
219024291|NCT06119581|DRUG|LY3537982|Administered orally.
219024292|NCT06119581|DRUG|Pembrolizumab|Administered IV.
219024293|NCT06119581|DRUG|Placebo|Administered orally.
219024294|NCT06119581|DRUG|Cisplatin|Administered IV.
219200301|NCT06881420|PROCEDURE|BASIS technique|Balloon AngioplaSty with the dIstal protection of Stent retriever
219495089|NCT01178112|DRUG|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
219495090|NCT01178112|DRUG|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
218875579|NCT00309270|DRUG|Campath-1H|
219024295|NCT06119581|DRUG|Carboplatin|Administered IV.
219024296|NCT06119581|DRUG|Pemetrexed|Administered IV.
219024297|NCT06493019|DRUG|Pembrolizumab|Chemoradiation Pembrolizumab 200mg IV
219024298|NCT06493019|DRUG|Paclitaxel|Paclitaxel 50 mg/m\^2 IV
219024299|NCT06493019|DRUG|Carboplatin|Carboplatin AUC 2 IV
219024300|NCT06493019|RADIATION|Radiation|Delivered as per institutional standards
219024301|NCT06493019|DRUG|Pembrolizumab|Maintenance Pembrolizumab 400mg IV
219024302|NCT05696288|PROCEDURE|Respiratory Gas Delivery System|Oxygen therapy during general anesthesia for ENT panendoscopy
219024303|NCT00304499|DRUG|Oxybutynin|
219024304|NCT05031533|RADIATION|Dose-Painting Radiation|"Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1\) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
219024305|NCT03338426|DRUG|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
219024306|NCT03338426|DRUG|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
218875580|NCT02754258|DRUG|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
219024307|NCT03338426|DRUG|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
218875581|NCT02754258|DRUG|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
218875582|NCT04188704|PROCEDURE|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
218875583|NCT00954499|BEHAVIORAL|Tactile stimulation added to Standard care|"* Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
218875584|NCT00954499|BEHAVIORAL|Standard care|"* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
218875585|NCT00463619|DRUG|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
218875586|NCT05334407|PROCEDURE|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
218875587|NCT05334407|BEHAVIORAL|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
218875588|NCT05334407|PROCEDURE|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
218875589|NCT05334407|BEHAVIORAL|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
219024308|NCT03338426|DRUG|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
219024309|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
219024310|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
219024311|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
219024312|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
219024313|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
219024314|NCT03678467|COMBINATION_PRODUCT|EB-CMF|Autologous, anatomically shaped bone graft
219024315|NCT04243187|OTHER|Chilean Native Beans|"In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
219024316|NCT02233322|DIETARY_SUPPLEMENT|Iron|All subjects will receive iron supplementation based on iron levels in the blood
219024317|NCT06271252|DRUG|OriCAR-017|Anti-GPRC5D CAR-T cell product
219200302|NCT06730438|DEVICE|Transcranial Pulse Stimulation|Patients will receive TPS once a day for five days a week, each session will be separated from the previous one by 24h. Each stimulation and assessment session will be performed at the same hour of the day, in the morning preferably, to maximize the probability of observing responses to stimuli. Patients will be managed in a quiete room with stable light and temperature.
219495091|NCT01178112|DRUG|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
219495092|NCT01178112|DRUG|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
219495093|NCT01178112|OTHER|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
219495094|NCT04753918|DRUG|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
219495095|NCT04753918|DRUG|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
219495096|NCT04753918|PROCEDURE|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
219495097|NCT04753918|DEVICE|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
219495098|NCT02577900|DEVICE|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
219200303|NCT06634394|DRUG|APVO436|Infusion drug administered as a 4 hour infusion.
219495099|NCT02577900|DEVICE|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
219495100|NCT02577900|DEVICE|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
219495101|NCT04394052|DIAGNOSTIC_TEST|MR imaging|Medical imaging
218875590|NCT02736435|DEVICE|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
218875591|NCT02736435|DRUG|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
219495102|NCT02639507|PROCEDURE|Vitrectomy|
219495103|NCT03851107|BEHAVIORAL|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
219495104|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219495105|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219495106|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219495107|NCT02917928|DIETARY_SUPPLEMENT|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
219495108|NCT02917928|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
219495109|NCT03157310|DRUG|Gefitinib|Daily oral administration of 250 mg Gefitinib
219495110|NCT06327477|PROCEDURE|Biopsy|Undergo biopsy
219495111|NCT06327477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219495112|NCT06327477|PROCEDURE|Computed Tomography|Undergo CT
219495113|NCT06327477|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
219495114|NCT06327477|PROCEDURE|Resection|Undergo surgical resection
219495115|NCT06327477|RADIATION|Spatially-fractionated Radiation Therapy|Undergo P-SFRT
219495116|NCT06280027|OTHER|survey|An online survey was generated to quantitatively evaluate the level of esthetic perception.
218875592|NCT04070417|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
218875593|NCT02567565|OTHER|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
218875594|NCT04979117|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
218875595|NCT02290041|DRUG|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
218875596|NCT02290041|DRUG|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
218875597|NCT04820413|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
218875598|NCT01421953|DEVICE|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
218875599|NCT05246800|OTHER|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
218875600|NCT04927403|OTHER|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
218875601|NCT03430960|OTHER|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
218875602|NCT03430960|OTHER|Mobile App Survey|Participants will be followed-up via mCare mobile app
218875603|NCT04188093|OTHER|PACU discharge criteria and continuous monitoring on the ward|"* PACU discharge criteria (modified aldrete score).~* Continous monitoring of vital signs 96 postoperative hours"
218875604|NCT05865717|BEHAVIORAL|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) \& desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
218875605|NCT05865717|OTHER|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
219024318|NCT00540345|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
218875606|NCT00757822|DRUG|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
218875607|NCT00757822|DRUG|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
218875608|NCT05447481|DIETARY_SUPPLEMENT|chicory inulin-type fructan|Dietary supplement: chicory inulin-type fructan
218875609|NCT03614325|OTHER|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
219024319|NCT00540345|DRUG|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
219024320|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
219024321|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
219024322|NCT05732194|DRUG|ITI-333|ITI-333 oral solution
219495117|NCT01862120|DRUG|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
219495118|NCT01862120|DRUG|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
219495119|NCT01862120|DRUG|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
219495120|NCT01862120|DRUG|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
219495121|NCT02773446|BIOLOGICAL|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
219495122|NCT04378010|DRUG|EDP-305 1.5 mg|Tablet
219495123|NCT04378010|DRUG|EDP-305 2 mg|Tablet
219495124|NCT04378010|DRUG|Placebo|Tablet
219495125|NCT01596816|RADIATION|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
219024323|NCT05732194|OTHER|Placebo|Matching placebo
219024324|NCT00188513|PROCEDURE|conformal intensity modulated radiotherapy (IMRT)|
219200304|NCT06634394|DRUG|Venetoclax|Oral tablet given on days 1 through 22, of a 28 day cycle.
219200305|NCT06634394|DRUG|Azacitidine|Intravenous infusion given on days 1-8 of a 28 day cycle
219200306|NCT06729424|DEVICE|Digital patient education program|The education consists of 8 modules including main themes within osteoporosis, with content aiming to promote behavioural changes including psychoeducation and behavioural activation.
219200307|NCT06889532|PROCEDURE|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.
219495126|NCT01596816|PROCEDURE|Fiducials placement|Placement of intra-prostatic markers for the tracking
218875610|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
218875611|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
218875612|NCT03870399|DRUG|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
218875613|NCT04924270|BIOLOGICAL|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
218875614|NCT04924270|OTHER|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
218875615|NCT04492111|PROCEDURE|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
218875616|NCT04435028|DRUG|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
218875617|NCT06583915|PROCEDURE|TENS|Non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain using electric pulse generator, lead wires and electrodes.
218875618|NCT06583915|PROCEDURE|Dry Needle|Invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.
218875619|NCT04087577|OTHER|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
218875620|NCT04087577|OTHER|mirror therapy|mirror therapy
218875621|NCT02269930|DRUG|peginterferon beta-1a|Administered as subcutaneous injection
219024325|NCT03202147|DRUG|Cromolyn|Active capsules for inhalation.
219024326|NCT03202147|OTHER|Placebo|Non-active capsules for inhalation.
219495127|NCT01596816|RADIATION|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
219495128|NCT02513459|DRUG|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
218875622|NCT02269930|DRUG|Rebif|Administered as subcutaneous injection
218875623|NCT02814175|DRUG|methotrexate (MTX)|
219495129|NCT02513459|DRUG|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
219495130|NCT00838500|DRUG|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
219495131|NCT00838500|DRUG|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
219495132|NCT03237611|DRUG|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
219495133|NCT03237611|DRUG|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
219495134|NCT03237611|DRUG|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
219495135|NCT03237611|DRUG|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
219495136|NCT05450497|DRUG|Propofol|comparing sedative agents
219495137|NCT05450497|DRUG|Dexmedetomidine|comparing sedative agents
219495138|NCT05450497|DRUG|Dexmedetomidine and propofol|comparing sedative agents
219495139|NCT01724476|DRUG|folate with B12|
219495140|NCT01724476|DRUG|placebo|
219495141|NCT01673165|OTHER|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
219495142|NCT01673165|OTHER|Specialized Formula|Infants will receive our standard of care - specialized formula
218875624|NCT02814175|BIOLOGICAL|adalimumab (ADA)|
218875625|NCT00119366|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
218875626|NCT00119366|DRUG|fludarabine phosphate|Given IV
218875627|NCT00119366|RADIATION|total-body irradiation|Undergo TBI
218875628|NCT00119366|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
218875629|NCT00119366|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
218875630|NCT00119366|DRUG|cyclosporine|Given IV or PO
218875631|NCT00119366|DRUG|mycophenolate mofetil|Given PO
218875632|NCT00119366|OTHER|laboratory biomarker analysis|Correlative studies
218875633|NCT00305539|DRUG|adalimumab|40 mg sc / for 3 months
218875634|NCT00305539|DRUG|placebo|placebo
218875635|NCT01438450|DRUG|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
218875636|NCT01438450|OTHER|Supportive|No specific therapy will be given
218875637|NCT01716741|OTHER|Enzyme analysis|
218875638|NCT04406025|PROCEDURE|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
218875639|NCT04406025|PROCEDURE|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
219495143|NCT06382467|DRUG|Remimazolam besylate + propofol MCT|remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
219495144|NCT06382467|DRUG|Propofol MCT|Propofol MCT 2-8 mcg/ml using target-controlled infusion
219495145|NCT04568369|DEVICE|rTMS|See treatment arm description.
219495146|NCT04641572|OTHER|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
219495147|NCT00787566|DRUG|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
219495148|NCT00543790|DRUG|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
218875640|NCT00674414|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
218875641|NCT00674414|DRUG|everolimus|Oral everolimus once daily
218875642|NCT00674414|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
218875643|NCT05242172|DIAGNOSTIC_TEST|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
218875644|NCT06537947|PROCEDURE|Endovascular intervention using the SENTANTE endovascular robotic system|"1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.~2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.~3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel."
218875645|NCT01318837|DRUG|solifenacin|oral
218875646|NCT05582174|DRUG|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
218875647|NCT05582174|DRUG|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
218875648|NCT01673620|DRUG|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
218875649|NCT01673620|DRUG|Placebo|Matching placebo tablet administered once daily
219495149|NCT03094208|OTHER|dual task balance training|balance exercises with cognitive and motor dual tasks
219495150|NCT03094208|OTHER|traditional balance training|balance exercises
219024327|NCT01808053|DEVICE|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
218875650|NCT02643238|DEVICE|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
218875651|NCT04137185|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection|rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
219024328|NCT00212823|DRUG|almotriptan malate|
219024329|NCT02395796|PROCEDURE|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
219024330|NCT00678821|OTHER|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
219024331|NCT03458533|PROCEDURE|Bariatric surgery|
219024332|NCT03458533|BEHAVIORAL|Diet and lifestyle changes|
219024333|NCT04564612|DRUG|BIIB091|Administered as specified in the treatment arm
219024334|NCT04564612|DRUG|Rabeprazole|Administered as specified in the treatment arm
219024335|NCT04564612|DRUG|Itraconazole|Administered as specified in the treatment arm
219024336|NCT04626869|OTHER|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
219024337|NCT02914769|DRUG|Ayahuasca|patients will receive a single dose of ayahuasca.
219024338|NCT02914769|DRUG|placebo|patients will receive a single dose of a passive placebo.
219024339|NCT05219929|DRUG|Tetracycline 500 Mg|500 mg three times daily
219024340|NCT05219929|OTHER|Placebo|Placebo for Tetracycline given same way as Tetracycline.
219024341|NCT05494450|DEVICE|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
219024342|NCT01888146|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
219024343|NCT02876900|DRUG|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
219024344|NCT02876900|DRUG|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
218875652|NCT00610311|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
218875653|NCT00610311|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
218875654|NCT00610311|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
218875655|NCT00610311|BIOLOGICAL|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)
218875656|NCT00610311|BIOLOGICAL|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.
219024345|NCT02876900|DRUG|Placebo|The study will evaluate placebo transdermal patch.
219024346|NCT01592344|DEVICE|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
219024347|NCT01592344|DEVICE|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
219495151|NCT05822700|PROCEDURE|Kirschner wire|Transfixing femoral head Kirschner wire
219024348|NCT06361862|DEVICE|Active alarms from WARD software|Wireless continuous vital sign monitoring with real time staff alerts
219024349|NCT03533192|BEHAVIORAL|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
219024350|NCT00099437|DRUG|Fulvestrant|intramuscular injection
219024351|NCT01393808|DRUG|Paricalcitol|1-month Paricalcitol 2mcg/day
219024352|NCT01393808|OTHER|placebo|1-month Placebo Treatment
219602631|NCT04319237|BEHAVIORAL|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
218875657|NCT05706571|OTHER|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
218875658|NCT04156035|DRUG|Lamotrigine|Orally; 300 mg
218875659|NCT04156035|DRUG|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
218875660|NCT04156035|DRUG|Placebo Pretreatment|Lamotrigine Placebo
218875661|NCT04156035|DRUG|Placebo Infusion|Ketamine Placebo
218875662|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
218875663|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
218875664|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
218875665|NCT01085370|OTHER|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
218875666|NCT05432401|BIOLOGICAL|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
218875667|NCT01597635|DRUG|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
218875668|NCT01597635|DRUG|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
218875669|NCT01597635|DRUG|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
218875670|NCT01597635|DRUG|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
218875671|NCT01597635|DRUG|Placebo (saline)|Administered intravenously to match intervention
219024353|NCT01770483|DRUG|nitazoxanide|nitazoxanide 500mg twice daily
219024354|NCT01770483|DRUG|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
219024355|NCT01770483|DRUG|Ribavirin|ribazole
219024356|NCT05619276|DEVICE|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
219024357|NCT05619276|DEVICE|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
219024358|NCT04052048|DIAGNOSTIC_TEST|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
219024359|NCT05521256|DRUG|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
219024360|NCT05521256|DRUG|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
219024361|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
219024362|NCT05986292|DRUG|LY3556050 ISA|Administered orally
219024363|NCT05986292|DRUG|LY3526318 ISA|Administered orally
219024364|NCT05986292|DRUG|LY3857210 ISA|Administered orally
219024365|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
219495152|NCT01814761|DRUG|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
219495153|NCT06020105|BEHAVIORAL|NURLIFE|After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
219495154|NCT00038883|DRUG|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
219495155|NCT03137082|DRUG|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
219495156|NCT03137082|DRUG|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
219495157|NCT03413527|DEVICE|rTMS|rTMS Treatment
219495158|NCT01416376|DRUG|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
219495159|NCT01416376|DRUG|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
219495160|NCT03214757|OTHER|treatment of anemia.|drug treatment of anemia.
219495161|NCT00206466|DRUG|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
219495162|NCT00206466|DRUG|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
218875672|NCT02624427|DEVICE|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
218875673|NCT03981068|RADIATION|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
218875674|NCT00966212|BEHAVIORAL|parent education|Especially for Daughters audio-cd parent education
218875675|NCT01162811|BEHAVIORAL|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
218875676|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
219024366|NCT05986292|DRUG|Placebo|Placebo administered IV
219024367|NCT03782428|DIETARY_SUPPLEMENT|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
219024368|NCT03782428|OTHER|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
219024369|NCT02488681|DEVICE|Micra Pacemaker Implant|
219024370|NCT03560050|BEHAVIORAL|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
219495163|NCT02768740|DRUG|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
219495164|NCT00544557|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219495165|NCT01535248|OTHER|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
219495166|NCT00214630|DRUG|rosuvastatin calcium|
219495167|NCT00214630|DRUG|atorvastatin|
219495168|NCT03782857|BEHAVIORAL|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
219495169|NCT04091269|DEVICE|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
218875677|NCT04533867|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
218875678|NCT04533867|DRUG|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
218875679|NCT04533867|DRUG|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
218875680|NCT01916343|PROCEDURE|Study Laparoscopic Curriculum|
218875681|NCT02222376|DRUG|Pirfenidone|Twice a day topical application
218875682|NCT02222376|PROCEDURE|Debridement|Weekly ulcer debridement
218875683|NCT03332836|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
218875684|NCT01363661|DRUG|Coruno|Molsidomine 16 mg tablet, per os, once a day
218875685|NCT01363661|DRUG|Placebo|Placebo (16 mg tablet, per os; once-daily)
219024371|NCT03560050|BEHAVIORAL|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
219024372|NCT05144984|DRUG|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
219024373|NCT05144984|DRUG|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
219024374|NCT05144984|DRUG|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
219024375|NCT05144984|DRUG|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
219024376|NCT06646276|BIOLOGICAL|BMS-986489 (BMS-986012+Nivolumab)|Specified dose on specified days
219024377|NCT06646276|BIOLOGICAL|Atezolizumab|Specified dose on specified days
219495170|NCT06502041|PROCEDURE|MARPE with MOP|mini-screw assisted rapid palatal expansion with micro-osteoperforation
219495171|NCT06502041|PROCEDURE|MARPE without MOP|mini-screw assisted rapid palatal expansion without micro-osteoperforation
218875686|NCT02202343|BEHAVIORAL|school based health and nutrition education|
218875687|NCT01971008|DEVICE|Elastic abdominal binder|
218875688|NCT01971008|DEVICE|Placebo binder|
218875689|NCT03416127|DRUG|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
218875690|NCT03416127|DRUG|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
218875691|NCT03416127|DRUG|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
218875692|NCT03704259|OTHER|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
218875693|NCT05223049|OTHER|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
218875694|NCT05223049|OTHER|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
218875695|NCT05223049|OTHER|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
218875696|NCT05223049|OTHER|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
218875697|NCT05223049|OTHER|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
218875698|NCT05223049|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
218875699|NCT00280085|PROCEDURE|MR imaging|
219495172|NCT01362114|DRUG|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
219495173|NCT01362114|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
219495174|NCT03105115|DRUG|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
218875700|NCT00280085|PROCEDURE|Glucose clamp|
218875701|NCT00280085|DRUG|Arginine|
218875702|NCT06201286|OTHER|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
219495175|NCT03105115|DRUG|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
219024378|NCT06646276|DRUG|Carboplatin|Specified dose on specified days
219024379|NCT06646276|DRUG|Etoposide|Specified dose on specified days
219024380|NCT02083731|BIOLOGICAL|MSCs|
218875703|NCT06201286|OTHER|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
218875704|NCT01905449|BEHAVIORAL|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
218875705|NCT02270554|DEVICE|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
218875706|NCT01963845|DRUG|Sitagliptin|
218875707|NCT01963845|DRUG|Placebo|
218875708|NCT02298400|DEVICE|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
219024381|NCT04582110|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
218875709|NCT02298400|DEVICE|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
219024382|NCT02809677|OTHER|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
218875710|NCT02298400|DEVICE|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
218875711|NCT00767806|DRUG|Duloxetine|60 mg orally once daily for 12 weeks
218875712|NCT00767806|DRUG|Placebo|Placebo once daily orally for 12 weeks
218875713|NCT03482037|DRUG|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
218875714|NCT03482037|DRUG|placebo|Each vial content will be administered via the catheter used for the self-catheterization
218875715|NCT05990361|DIAGNOSTIC_TEST|clinical diagnostic test|"The clinical diagnosis tests are Active Straight Leg Rise ASLR, Posterior Pelvic Pain Provocation, Long Dorsal Sacroiliac Ligament Palpation (LDSLP), Pelvic Compression, Pelvic Distraction, Patrick-Faber Test (PF), and Gaenslen Test (GT).~The subjects who had at least one positive result from ASLR and P4 Tests; and at least two positive results from the Pelvic Compression and Distraction, PF, GT and LDSLP tests are classified as with PGP group."
218875716|NCT02489942|DRUG|Jardiance|Empagliflozin
218875717|NCT00532688|DRUG|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
219024383|NCT04969224|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
219024384|NCT04969224|DRUG|IVA|Tablet for oral administration.
219024385|NCT03165110|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
219024386|NCT05533632|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
219024387|NCT02236429|BIOLOGICAL|vaginal flora transplant|
219024388|NCT05784246|DRUG|Mirikizumab IV|Administered IV
219024389|NCT05784246|DRUG|Mirikizumab SC|Administered SC
219495176|NCT01020305|DRUG|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
219495177|NCT01020305|DRUG|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
219495178|NCT04843176|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
219495179|NCT04843176|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
219495180|NCT02184494|DEVICE|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
219495181|NCT00136019|DRUG|SPM 927|
219495182|NCT05245981|DEVICE|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
219495183|NCT02350010|DEVICE|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
219495184|NCT05364099|DRUG|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
219024390|NCT06520865|OTHER|Acoustic paradigms|Acoustic oddball Gap detection
219024391|NCT03968315|PROCEDURE|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
218875718|NCT00858208|DRUG|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
218875719|NCT02484352|DRUG|saline|different dosage of IV oxycodone was given before intubation
218875720|NCT02484352|DRUG|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
218875721|NCT02484352|DRUG|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
218875722|NCT02484352|DRUG|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
218875723|NCT02484352|DRUG|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
218875724|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
219024392|NCT03968315|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219200308|NCT06142409|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
219495185|NCT05364099|DRUG|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
219024393|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
218875725|NCT02196155|DRUG|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
219024394|NCT06545331|DRUG|XB010|IV administration of XB010
219024395|NCT06545331|DRUG|Pembrolizumab|IV administration of Pembrolizumab
219024396|NCT05380401|DIETARY_SUPPLEMENT|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
219024397|NCT05562167|DRUG|KNO3|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
219024398|NCT05562167|DRUG|Placebo|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
219024399|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219024400|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219024401|NCT05578495|OTHER|Accelerometer data|Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
219024402|NCT03771469|OTHER|Sleep study|Sleep study
219495186|NCT05364099|PROCEDURE|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
218875726|NCT02196155|DRUG|cortisone|
219495187|NCT04025970|GENETIC|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
219495188|NCT01815021|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
219495189|NCT01815021|DIETARY_SUPPLEMENT|crystalline calcium supplements|
219495190|NCT01132456|DEVICE|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
219495191|NCT00154037|DRUG|Pioglitazone (drug) and/or candesartan (drug)|
218875727|NCT02196155|DRUG|Saline|
219024403|NCT04410965|DRUG|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
219024404|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft) and InterOss Collagen Guide (Collagen membrane)|Group will receive InterOss Collagen and InterOss Collagen Guide during surgical intervention visit.
219024405|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft)|Group will only receive InterOss Collagen during surgical intervention visit.
219024406|NCT05782283|DEVICE|ACE (AI-Cirrhosis-ECG) 2.0|An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
219024407|NCT02930551|DRUG|Lidocaine|
219024408|NCT02930551|DRUG|Isotonic Saline|
219024409|NCT06803485|DRUG|Venlafaxine|Venlafaxine will be started at a dose of 37.5 mg/day in first week and increased to a stable dose of 75 mg/day from second week and will be continued till 8 weeks.
219024410|NCT06803485|DRUG|Dosulepin|Dosulepin will be started at a dose of 25 mg/day in first week and increased to a stable dose of 50 mg/day from second week and will be continued till 8 weeeks.
219024411|NCT02954874|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219024412|NCT02954874|OTHER|Laboratory Biomarker Analysis|Correlative studies
219024413|NCT02954874|OTHER|Patient Observation|Undergo standard monitoring
219024414|NCT02954874|BIOLOGICAL|Pembrolizumab|Given IV
219024415|NCT02954874|OTHER|Quality-of-Life Assessment|Ancillary studies
219024416|NCT02954874|OTHER|Questionnaire Administration|Ancillary studies
219024417|NCT02954874|RADIATION|Radiation Therapy|Undergo radiation therapy
219024418|NCT05191212|PROCEDURE|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
219024419|NCT01584687|BIOLOGICAL|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
219024420|NCT06214650|OTHER|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
219024421|NCT06214650|OTHER|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
219024422|NCT03192592|OTHER|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
219204501|NCT05019495|BEHAVIORAL|PrOMOTE|This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
219495192|NCT01313728|DRUG|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
219024423|NCT05644249|DRUG|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
219024424|NCT03632655|PROCEDURE|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
219024425|NCT04327388|DRUG|Sarilumab SAR153191|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219024426|NCT04327388|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219024427|NCT06132178|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
219024428|NCT06132178|DEVICE|Accelerated intermittent theta burst (aiTBS) rTMS treatment|A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
219602632|NCT04319237|BEHAVIORAL|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
219602633|NCT04319237|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
219024429|NCT06132178|DRUG|Low-dose psilocybin|A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
219024430|NCT06132178|DEVICE|Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment|The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
219495193|NCT01313728|DRUG|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
219200309|NCT06853704|PROCEDURE|papillary unit advancement|"collagen matrix augmentation in papilla area using tunneling technique, up to my knowledge, it's the first time to use collagen matrix in treating papilla, in less invasive approach, only though tunneling with no primary and secondary incisions.~so, the technique is designed to be less invasive, maximizing papillary blood supply.~and to use xeno collagen matrix instead of connective tissue graft used in previous study. so \~ less morbidity, less postoperative pain with no Donar graft site ."
219024431|NCT04305834|DRUG|Abemaciclib|Given PO
219024432|NCT04305834|OTHER|Questionnaire Administration|Ancillary studies
219024433|NCT06639087|DRUG|AZD5462|Participants will receive AZD5462 on top of dapagliflozin once daily.
219024434|NCT06639087|DRUG|Dapagliflozin|Participants will receive dapagliflozin once daily with AZD5462 or placebo.
219200310|NCT06723613|BEHAVIORAL|Exercise group|"Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.~Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH-Breastfeeding Record System, IMDAT: Breast milk intake level assessment tool scales will be applied to mothers before exercise (8th week after birth) and after exercise (14th week)."
219200311|NCT05636397|DIETARY_SUPPLEMENT|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
219495194|NCT05789303|DRUG|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
219495195|NCT05789303|DRUG|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
219495196|NCT05789303|DRUG|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
219495197|NCT05789303|DRUG|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
219495198|NCT05795062|DRUG|apixaban|patients treated with apixaban
219495199|NCT05795062|DRUG|warfarin|patients treated with warfarin
219495200|NCT02558660|BEHAVIORAL|Education|Educational intervention about an existing SNAP healthy food incentive program
219495201|NCT02558660|BEHAVIORAL|voucher|$10 voucher to spend on produce at farmers markets
219495202|NCT02997969|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
219495203|NCT02997969|BIOLOGICAL|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
219495204|NCT02997969|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
219024435|NCT06639087|OTHER|Placebo|Participants will receive placebo on top of dapagliflozin once daily.
219024436|NCT06497465|DRUG|Dolutegravir 50mg Tab|Participants will receive Dolutegravir 50mg
219024437|NCT06497465|DRUG|Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]|Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
219024438|NCT06497465|DRUG|Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)|Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
219024439|NCT05615649|DEVICE|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
219024440|NCT05074693|OTHER|EASE app|EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
219024441|NCT05074693|OTHER|INSIGHT (Control) App|"A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos."
219024442|NCT05941897|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
219024443|NCT05941897|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion
219024444|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
219024445|NCT04622293|DRUG|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
218875728|NCT06583499|BEHAVIORAL|Sustainable nutrition education based on the transtheoretical model|"Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set.."
218875729|NCT02314832|PROCEDURE|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
218875730|NCT02314832|PROCEDURE|femoral nerve block|ultrasound guided femoral nerve block
218875731|NCT04240158|DRUG|IW-6463|IW-6463 Tablet
218875732|NCT04240158|DRUG|Matching Placebo|Matching Placebo Tablet
218875733|NCT06423924|OTHER|no intervention|no intervention
218875734|NCT03277027|OTHER|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
218875735|NCT01260597|BEHAVIORAL|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
219024446|NCT04622293|DRUG|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
219024447|NCT04933539|DRUG|Dexamethasone|Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles
219024448|NCT04933539|DRUG|Carfilzomib|Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles
219024449|NCT04933539|BIOLOGICAL|Daratumumab|Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
219024450|NCT03288025|BEHAVIORAL|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
219024451|NCT05933577|BIOLOGICAL|Intismeran autogene|IM injection
219602634|NCT04319237|BEHAVIORAL|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
219024452|NCT05933577|BIOLOGICAL|Pembrolizumab|IV infusion
219024453|NCT05933577|OTHER|Placebo|IM injection
219024454|NCT00412763|DRUG|Silymarin (Silybum marianum)|
219602635|NCT04319237|BEHAVIORAL|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
218875736|NCT01260597|BEHAVIORAL|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
218875737|NCT05055817|OTHER|bloody stool group|bloody stool appear in the hospitalized neonate
218875738|NCT05055817|OTHER|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
218875739|NCT02397057|DRUG|Injectafer|
218875740|NCT02397057|OTHER|Placebo|
219602636|NCT04319237|BEHAVIORAL|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
219602637|NCT03686488|DRUG|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
219602638|NCT03686488|DRUG|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
219602639|NCT05720806|OTHER|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
218875741|NCT00099658|BIOLOGICAL|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
218875742|NCT02352623|RADIATION|DXA scan|DXA scan
218875743|NCT02352623|PROCEDURE|Clinical examination|Clinical examination
218875744|NCT04120272|PROCEDURE|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
218875745|NCT04312347|DRUG|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
218875746|NCT01632436|DRUG|Pixantrone|Experimental Drug
218875747|NCT03781453|BEHAVIORAL|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
218875748|NCT00966251|DRUG|CT-011|CT-011
218875749|NCT01393639|DRUG|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
218875750|NCT01393639|DRUG|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
218875751|NCT01393639|DRUG|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
218875752|NCT01393639|DRUG|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
218875753|NCT01393639|DRUG|prednisone|5 mg capsule once daily for 8 weeks
218875754|NCT01393639|OTHER|prednisone|10 mg capsule once daily for 8 weeks
218875755|NCT01393639|OTHER|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
218875756|NCT04473248|DEVICE|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
218875757|NCT01657734|OTHER|MR imaging|MR imaging
218875758|NCT00679172|BIOLOGICAL|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
218875759|NCT00679172|BIOLOGICAL|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
218875760|NCT00679172|BIOLOGICAL|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
218875761|NCT00679172|BIOLOGICAL|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
218875762|NCT00679172|OTHER|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
218875763|NCT04359979|DRUG|Tamsulosin|selective alpha1 receptor antagonist
218875764|NCT00793325|DRUG|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
219024455|NCT00941018|DRUG|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
219024456|NCT00534274|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
218875765|NCT05880498|BEHAVIORAL|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
218875766|NCT01815840|DRUG|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
218875767|NCT01815840|DRUG|Placebo|Vismodegib placebo orally once daily
218875768|NCT06297382|BEHAVIORAL|ChatGPT Based Nursing Process Training|"ChatGPT Based Nursing Process Training topics:~Lesson 1: Use of artificial intelligence and ChatGPT in healthcare Lesson 2: Using ChatGPT in determining nursing diagnoses and goals Lesson 3: Using ChatGPT to determine nursing interventions Lesson 4: Things to consider and ethical principles when using ChatGPT when creating a nursing process."
218875769|NCT02144025|DRUG|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
218875770|NCT00625781|DRUG|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
218875771|NCT02496299|DRUG|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
218875772|NCT02496299|DRUG|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
218875773|NCT00434642|DRUG|Carboplatin|Carboplatin was provided as commercially available drug.
218875774|NCT00434642|DRUG|Gemcitabine|Gemcitabine was provided as commercially available drug.
218875775|NCT00434642|DRUG|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
218875776|NCT00434642|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
218875777|NCT03424356|DRUG|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
218875778|NCT03424356|DRUG|Saline Solution|1-2 ml saline solution
218875779|NCT03424356|DRUG|Fentanyl|1mcg/kg for induction
218875780|NCT03424356|DRUG|Propofol|2-3mg/kg for anaesthetic induction
219024457|NCT06229366|DRUG|[Ac-225]-PSMA-62 (mCRPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."
219024458|NCT06229366|DRUG|[Ac-225]-PSMA-62 (OmHSPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."
219024459|NCT00102544|DEVICE|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
219024460|NCT04669587|DRUG|ZB716|Pharmaceutical form: capsule Route of administration: oral
219024461|NCT04669587|DRUG|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
219024462|NCT05735483|DRUG|Lebrikizumab|Administered SC
219024463|NCT05735483|DRUG|Placebo|Administered SC
219024464|NCT06253507|BIOLOGICAL|Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47|"Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg."
219024465|NCT06466135|DRUG|WAL0921|Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
219602640|NCT05720806|OTHER|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
218875781|NCT03424356|PROCEDURE|cystoscopy|patients will treated with this surgical procedure
219024466|NCT06466135|DRUG|Placebo|Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
219024467|NCT04299490|BEHAVIORAL|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
219495205|NCT00333073|DEVICE|Bulkamid|initial injection with option for second (if required)
219495206|NCT05699577|DIAGNOSTIC_TEST|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
219602641|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
219602642|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
219602643|NCT06756932|DRUG|BGB-21447|Administered orally.
219602644|NCT06756932|DRUG|Fulvestrant|Administered via intramuscular injection.
218875782|NCT04120363|DRUG|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
219024468|NCT04299490|DRUG|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
219495207|NCT04310748|DRUG|Total Intravenous Anesthesia(TIVA)|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded"
219602645|NCT06756932|DRUG|BGB-43395|Administered orally.
219602646|NCT04371445|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
218875783|NCT04120363|DRUG|Sesame Oil|single intramuscular injection of 750 mg sesame oil solution
218875784|NCT04680429|DRUG|RP7214|Participants will receive single and multiple ascending doses of RP7214
218875785|NCT04680429|DRUG|Placebo|Participants will receive single and multiple ascending doses of matching placebo
218875786|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
218875787|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
218875788|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
218875789|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
219602647|NCT04371445|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
219602648|NCT01839435|PROCEDURE|outpatient surgery|
219602649|NCT06957483|BEHAVIORAL|REACH-SCI (Reducing sedEntary Activities to improve Cardiovascular Health in individuals with a Spinal Cord Injury)|The REACH-SCI intervention was co-designed with key stakeholders and aims to reduce and break up sedentary behaviour in individuals with paraplegia. The intervention will last eight weeks and involve (1) a wearable activity tracker to give reminders to break up sedentary behaviour, (2) education around what sedentary behaviour is, how to reduce and break up sedentary behaviour, and the benefits of doing so, (3) a goal setting worksheet related to sedentary behaviour, (4) one-to-one motivational support sessions to help set goals, review progress and give motivation, (5) peer support using a smartphone app, and (6) activity tools to support breaking up sedentary behaviour throughout the day.
219495208|NCT04310748|DRUG|Inhalation Anesthesia|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded."
218875790|NCT02354872|DRUG|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
218875791|NCT02354872|BEHAVIORAL|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
219495209|NCT03456362|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
219495210|NCT00318266|DEVICE|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
218875792|NCT02354872|BEHAVIORAL|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
218875793|NCT02354872|BEHAVIORAL|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
218875794|NCT02354872|OTHER|No Treatment|No Treatment
218875795|NCT00288236|DRUG|Rimonabant (SR141716)|
218875796|NCT00288236|DRUG|Placebo|
218875797|NCT05979922|BEHAVIORAL|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
218875798|NCT05979922|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
218875799|NCT02191332|DRUG|Viramune|
219602650|NCT03735992|BEHAVIORAL|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
219602651|NCT06075277|DRUG|zongertinib|Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.
219024469|NCT04299490|BEHAVIORAL|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
219024470|NCT04299490|BEHAVIORAL|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
219495211|NCT00878137|DEVICE|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
219495212|NCT03628222|DEVICE|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
219495213|NCT03628222|DEVICE|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
219495214|NCT00418756|DRUG|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
219602652|NCT03885635|PROCEDURE|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
219602653|NCT03885635|PROCEDURE|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
219602654|NCT06543693|OTHER|ultrasound training|PoCUS training
218875800|NCT02282280|DRUG|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
218875801|NCT05307809|OTHER|Blood sample collection|Blood sample collection
218875802|NCT05307809|OTHER|Skin sample collection|Skin sample collection
218875803|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
218875804|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
218875805|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
218875806|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
218875807|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
218875808|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
218875809|NCT00527982|DRUG|Celecoxib|600 mg by mouth daily for a total of 12 months.
219495215|NCT04403373|BEHAVIORAL|Waitlist control|waitlist control
219495216|NCT04403373|BEHAVIORAL|Moderate-intensity walking exercise|walking exercise
219495217|NCT04403373|BEHAVIORAL|Vigorous-intensity walking exercise|walking exercise
219602655|NCT05292183|OTHER|Electrical Stimulation|We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
218875810|NCT00771524|DRUG|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
218875811|NCT00003711|DRUG|irinotecan hydrochloride|
218875812|NCT00003711|DRUG|pemetrexed disodium|
218875813|NCT04473664|DRUG|Quizartinib|Single oral dose, 30 mg tablet
218875814|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
218875815|NCT00789672|DEVICE|patching|2 hours daily patching
218875816|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
218875817|NCT05977829|DIAGNOSTIC_TEST|Ultrasound|Transvaginal ultrasound to carry out uterine surveillance
218875818|NCT05977829|DIAGNOSTIC_TEST|Hysteroscopy|Outpatient hysteroscopy to carry out uterine surveillance
218875819|NCT05216471|RADIATION|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
218875820|NCT03392649|DEVICE|Parasym|Tragus stimulation was done using the Parasym device.
219495218|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
219495219|NCT03494205|DRUG|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
219495220|NCT03494205|DRUG|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
219495221|NCT03358732|DEVICE|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
219602656|NCT05075824|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
218875821|NCT00450645|DRUG|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
218875822|NCT03300921|DRUG|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
218875823|NCT03472144|DRUG|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
218875824|NCT03472144|DRUG|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
218875825|NCT03472144|DRUG|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
218875826|NCT02339194|PROCEDURE|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
218875827|NCT00785343|DEVICE|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
218875828|NCT00785343|PROCEDURE|Conventional Therapy|Occupational therapy that is the current standard of care
218875829|NCT01289054|DRUG|Tasigna|
218875830|NCT01289054|DRUG|Gleevec|
218875831|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
218875832|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
218875833|NCT01483911|BIOLOGICAL|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
218875834|NCT01483911|BIOLOGICAL|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
218875835|NCT05336149|PROCEDURE|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
218875836|NCT05336149|PROCEDURE|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
218875837|NCT01620814|DRUG|Dinoprostone|
218875838|NCT01620814|DRUG|misoprostol|
218875839|NCT01620814|DRUG|control|
219495222|NCT03547531|OTHER|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
219495223|NCT03547531|OTHER|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
219495224|NCT00476684|PROCEDURE|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
219495225|NCT00476684|PROCEDURE|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
219495226|NCT02649608|DRUG|0.04 mg Lu AE04621|0.04 mg dose group
218875840|NCT03118089|DIETARY_SUPPLEMENT|Biscuit style oral nutritional supplement|
218875841|NCT03162081|DIAGNOSTIC_TEST|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
219602657|NCT05075824|DRUG|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
219495227|NCT02649608|DRUG|0.08 mg Lu AE04621|0.08mg dose group
219495228|NCT02649608|DRUG|0.2 mg Lu AE04621|0.2 mg dose group
219495229|NCT02649608|DRUG|0.4 mg Lu AE04621|0.4 mg dose group
219495230|NCT02649608|DRUG|0.6 mg Lu AE04621|0.6 mg dose group
218875842|NCT03162081|DIAGNOSTIC_TEST|EQ-5D|Health related Quality of life
218875843|NCT03162081|DIAGNOSTIC_TEST|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
218875844|NCT03162081|DIAGNOSTIC_TEST|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
219024471|NCT04062331|DEVICE|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
219495231|NCT02649608|DRUG|0.8 mg Lu AE04621|0.8 mg dose group
219495232|NCT02649608|DRUG|1.0 mg Lu AE04621|1.0 mg dose group
219602658|NCT02919215|BEHAVIORAL|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as a support for teachers if needed. All participants can access and/or provide usual services. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
219602659|NCT06964412|OTHER|Artificial-intelligence (AI)|Utilizing the addition of artificial intelligence during prostate contouring.
219602660|NCT03501368|DRUG|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
219602661|NCT03501368|DRUG|Trametinib|Participants will take trametinib by mouth at a dose of 2 mg daily
218875845|NCT03162081|DIAGNOSTIC_TEST|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
219602662|NCT05274243|DRUG|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
218875846|NCT03162081|DIAGNOSTIC_TEST|Cognistat|Assessment of cognitive domains
218875847|NCT03162081|DIAGNOSTIC_TEST|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
218875848|NCT03162081|OTHER|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
219495233|NCT02649608|DRUG|1.2 mg Lu AE04621|1.2 mg dose group
219602663|NCT05274243|OTHER|Placebo|Placebo (provided as three capsules) three times a day for 4 weeks
219602664|NCT04610229|RADIATION|Hypofractionation guioded by dose painting|1
218875849|NCT03162081|OTHER|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
218875850|NCT03162081|OTHER|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
219495234|NCT02007187|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
219495235|NCT02007187|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
219495236|NCT02007187|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
219495237|NCT05627349|DEVICE|wrist splinting|standard wrist splinting at night for 2 weeks
219495238|NCT05627349|DEVICE|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
219495239|NCT03014531|OTHER|almond|
219602665|NCT04305145|DRUG|Infliximab|Infusion
219602666|NCT04305145|DRUG|Methylprednisolone|Infusion
219602667|NCT04305145|DRUG|Prednisone|Orally
219602668|NCT00111527|OTHER|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
219602669|NCT00111527|OTHER|normal RV pacing|PM or ICD implant according to patient indication
218875851|NCT05006027|PROCEDURE|Percutaneous coronary intervention via the distal radial approach|Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
219602670|NCT06632496|DEVICE|BD Prevue(TM) II|Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
219602671|NCT05928390|DRUG|Pasireotide Diaspartate|Injectable ampoules
219602672|NCT06634589|DRUG|BGB-16673|Administered orally
219602673|NCT06634589|DRUG|Sonrotoclax|Administered orally
219024472|NCT04062331|DRUG|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
219024473|NCT05848258|DRUG|LY3871801|Administered orally
219024474|NCT05848258|DRUG|Placebo|Administered orally
219024475|NCT06471985|COMBINATION_PRODUCT|Music and pain|In both arms of the study the participant will take the same pain test. They will either listen to Enya or slayer, depending on the arm
219024476|NCT00391274|DRUG|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
219024477|NCT00391274|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
219024478|NCT06612437|DEVICE|continuous theta burst stimulation (cTBS)|Standard 600-pulse continuous theta burst stimulation (cTBS) can inhibit the corticomotor excitability. The cTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
219024479|NCT06612437|DEVICE|intermittent theta burst stimulation (iTBS)|Standard 600-pulse intermittent theta burst stimulation (iTBS) can increase the corticomotor excitability. The iTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
219024480|NCT06612437|DEVICE|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device.
219024481|NCT02786316|OTHER|HIT program|HIT program for the rehabilitation of persons with NSCLBP
219024482|NCT02786316|OTHER|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
219024483|NCT06136702|BEHAVIORAL|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
219495240|NCT03014531|OTHER|high-carbohydrate control food|
219495241|NCT01283607|BEHAVIORAL|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
219495242|NCT02444182|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
219495243|NCT02444182|DIETARY_SUPPLEMENT|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
219495244|NCT03428048|PROCEDURE|Hybrid procedure|Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
219495245|NCT03428048|PROCEDURE|Endocardial ablations|ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
219495246|NCT03428048|PROCEDURE|left atrial appendage occlusion|A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
219495247|NCT02348619|DRUG|JZP-110|
219495248|NCT06452433|DRUG|gumarontinib|300 mg , qd ,po, expect 6 months.
219024484|NCT06136702|BEHAVIORAL|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
219024485|NCT06136702|BEHAVIORAL|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
219024486|NCT05576740|PROCEDURE|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
219602674|NCT06634589|DRUG|Zanubrutinib|Administered orally
219024487|NCT05576740|PROCEDURE|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
219495249|NCT06452433|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|According to the actual situation of patients. Take as recommended, expect 6 months.
219495250|NCT02744625|DRUG|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
219495251|NCT02744625|DRUG|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
219602675|NCT06634589|DRUG|Mosunetuzumab|Administered subcutaneously
219602676|NCT06634589|DRUG|Glofitamab|Administered intravenously
219602677|NCT06634589|DRUG|Obinutuzumab|Administered intravenously
219602678|NCT06021704|BEHAVIORAL|Enhanced home health aide training in dementia and dementia-related behaviors|8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
219602679|NCT05199688|DRUG|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
218875852|NCT01359189|DEVICE|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
219024488|NCT05576740|PROCEDURE|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
219024489|NCT05576740|PROCEDURE|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
219024490|NCT05576740|PROCEDURE|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
219024491|NCT05576740|DEVICE|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
219024492|NCT05576740|OTHER|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
219495252|NCT02744625|DRUG|Propofol for light sedation|Propofol for light sedation
219495253|NCT03631459|DRUG|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
219602680|NCT03975491|BEHAVIORAL|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
219602681|NCT03975491|BEHAVIORAL|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
219602682|NCT06666699|DEVICE|EUS access device|The intervention involves the use of an EUS access device to gain access to the bile duct via hepaticogastrostomy.
219602683|NCT03536312|PROCEDURE|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
219602684|NCT05180773|DRUG|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
219602685|NCT05180773|DRUG|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
219602686|NCT05180773|DRUG|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
218875853|NCT03636646|DEVICE|X.ray|Surgical treatement of posterior acetabular wall fractures
218875854|NCT01286025|BEHAVIORAL|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
219602687|NCT05180773|DRUG|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
219602688|NCT05180773|DRUG|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
219602689|NCT06080477|BEHAVIORAL|Enhanced Usual Care|Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.
219602690|NCT06080477|BEHAVIORAL|Adapted ENHANCE Intervention|Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
218875855|NCT01286025|BEHAVIORAL|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
218875856|NCT00437411|BEHAVIORAL|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
218875857|NCT01320592|DRUG|PD0332991|
219024493|NCT05576740|DEVICE|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
219024494|NCT05576740|PROCEDURE|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
219024495|NCT05576740|PROCEDURE|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10\^6/μL), hematocrit (%), white blood cells (10\^3/μl), platelets (10\^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
219024496|NCT05576740|PROCEDURE|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
219024497|NCT05576740|PROCEDURE|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
219024498|NCT05576740|OTHER|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
219024499|NCT05576740|PROCEDURE|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
219024500|NCT01387347|DRUG|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
219024501|NCT01387347|DRUG|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
219024502|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
219024503|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
219024504|NCT02658357|DRUG|Risperidone Implant|
219024505|NCT01096121|DRUG|Enalapril|"* during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day"
219024506|NCT01096121|DRUG|Placebo|Glucose
219024507|NCT00561080|BIOLOGICAL|Zostavax|
219024508|NCT05775315|OTHER|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
219495254|NCT06537986|BEHAVIORAL|Neurocognitive and psychosocial intervention module|"The module comprised of various intervention methods that include- I. Cognitive Retraining: Pen-and-paper-based cognitive rehabilitation program that is divided into five hierarchically graded modules: Attention, Visual Processing, Memory, Information Processing, and Executive Functions.~2.Cognitive-behavioral interventions. Cognitive-behavioral interventions would be carried out for activities scheduling, problem-solving teachings, anger management techniques, modifications of negative cognitions, stigma address measures, and irrational beliefs about epilepsy, etc.~3\. Marital/Family counseling: Marital/family counseling would be done to ensure family understanding of the patient's illness, his/her treatment, prognosis, and outcome. Family complications arising due to illness would also be discussed. Individual and personal needs of the husband, a wife will also be discussed."
219495255|NCT00811200|DRUG|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
219024509|NCT05775315|OTHER|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
219024510|NCT01190709|PROCEDURE|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
219024511|NCT01190709|PROCEDURE|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
218875858|NCT01320592|DRUG|Paclitaxel|
218875859|NCT03400163|DRUG|BMS-986036|BMS-986036 20 mg QD
218875860|NCT03400163|DRUG|Placebo|Placebo QD
219024512|NCT04460547|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
219024513|NCT04460547|DRUG|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
219024514|NCT04460547|DRUG|DAS181|DAS181 administration to COVID-19 infected patients.
219024515|NCT04460547|DRUG|Ivermectin|Ivermectin administration to COVID-19 infected patients.
219024516|NCT04460547|DRUG|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
219024517|NCT04506476|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
219024518|NCT05543876|PROCEDURE|suturing procedure|Children presenting to the emergency department for suturing
218875861|NCT02241343|DEVICE|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
218875862|NCT04800237|DRUG|VQW-765|oral capsule
219024519|NCT04559815|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219024520|NCT04626635|DRUG|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
219024521|NCT04626635|DRUG|Cemiplimab|Administered concomitantly Q3W by IV infusion or SC injection
219024522|NCT04626635|DRUG|Platinum-based doublet chemotherapy|Administered IV Q3W
219495256|NCT00811200|DRUG|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
219495257|NCT00811200|OTHER|sham|at baseline one sham-injection
219495258|NCT06295575|DIETARY_SUPPLEMENT|probiotics containing Bifidobacterium infantis and Lactobacillus|Patients were provided with probiotics containing Bifidobacterium infantis and Lactobacillus. This intervention was started the day after patients' administration and lasted until the day before discharge.
218875863|NCT04800237|DRUG|Placebo|oral capsule
219495259|NCT06295575|DIETARY_SUPPLEMENT|placebos containing lactose|Patients received lactose as placebo.This intervention was started the day after patients' administration and lasted until the day before discharge.
219495260|NCT00103103|DRUG|bortezomib|
218875864|NCT00122174|BEHAVIORAL|Stress Busting Program for family caregivers|
219495261|NCT00103103|DRUG|fluorouracil|
218875865|NCT03408184|DRUG|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
219495262|NCT00103103|DRUG|leucovorin calcium|
219495263|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
219495264|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
219495265|NCT04833452|PROCEDURE|Endoscopic dacryocystorhinostomy|Endoscopic DCR
218875866|NCT03408184|DRUG|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
218875867|NCT05025878|DIETARY_SUPPLEMENT|[U-13C]Glucose|Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
218875868|NCT02997059|DRUG|Fluconazole|200 mg/ day
218875869|NCT02997059|OTHER|Placebo|
219024523|NCT04626635|DRUG|Bevacizumab|Administered per protocol
219024524|NCT04626635|DRUG|Trifluridine-tipiracil|Administered per protocol
219495266|NCT00712907|DIETARY_SUPPLEMENT|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
219495267|NCT00712907|DIETARY_SUPPLEMENT|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
219495268|NCT00712907|OTHER|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
219495269|NCT04514809|OTHER|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
219495270|NCT04811911|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
219495271|NCT04811911|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
219495272|NCT03526185|DRUG|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
218875870|NCT00174369|DRUG|PD-0325901|15 mg BID
219495273|NCT03526185|DRUG|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
218875871|NCT03579277|PROCEDURE|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
218875872|NCT03579277|PROCEDURE|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
218875873|NCT00753454|DRUG|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
218875874|NCT00614848|DEVICE|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
218875875|NCT06321770|DIETARY_SUPPLEMENT|Bioactive collagen peptides|2,5 g collagen peptides
218875876|NCT06321770|DIETARY_SUPPLEMENT|Placebo|Placebo sachet daily
218875877|NCT01982461|DRUG|Rosuvastatin|10mg,once daily
218875878|NCT01982461|DRUG|Crestor®|10mg,once daily
218875879|NCT03927144|DRUG|AMG334|Subcutaneous Injection
218875880|NCT03927144|DRUG|Oral Prophylactic|SOC Oral Tablet/Capsule
218875881|NCT05346653|DRUG|SGLT2i|dapagliflozin (10 mg daily)
218875882|NCT05346653|OTHER|No SGLT2i|No SGLT2i
218875883|NCT04084847|DIETARY_SUPPLEMENT|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
218875884|NCT04084847|DIETARY_SUPPLEMENT|Placebo|Placebo powder
218875885|NCT06339931|OTHER|SMWLM combined Spinal traction with belt|Group A, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Wrap the traction belt around both your hips and the proximal aspect of the patient's thighs.Apply traction by leaning backward and shifting your body weight onto your posterior leg.
218875886|NCT06339931|OTHER|SMWLM combined spinal traction without belt|Group B, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Manual traction is applied by placing the patient over a rolled pillow while lying sideways. The roll should be 6-8 inches in diameter and should be placed at the level of the spine where the traction or separation is to occur. Pull the patient's legs toward you as you lean your body backward to apply a traction force.
218875887|NCT03858530|DIAGNOSTIC_TEST|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
218875888|NCT01463072|OTHER|Laboratory Biomarker Analysis|Correlative studies
218875889|NCT01463072|DRUG|Nab-paclitaxel|Given IV
218875890|NCT01463072|OTHER|Questionnaire Administration|Ancillary studies
218875891|NCT06962800|DRUG|Felzartamab|Administered intravenously
219495274|NCT04948385|DRUG|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
219495275|NCT04948385|PROCEDURE|No sedation|No sedation
219495276|NCT04688983|DRUG|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
219495277|NCT04688983|DRUG|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
219495278|NCT04688983|DRUG|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
218875892|NCT06962800|DRUG|Tacrolimus|Administered orally
218875893|NCT06962800|DRUG|Standard of Care IST|Administered intravenously and orally
218875894|NCT03240159|DRUG|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
218875895|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
218875896|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
218875897|NCT06578065|DEVICE|Echelon Circular™ Powered Stapler|Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.
218875898|NCT06578065|DEVICE|2-row circular staplers manual|2-row circular staplers manual will be used in colorectal anastomosis.
218875899|NCT04541628|COMBINATION_PRODUCT|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
218875900|NCT03538366|OTHER|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
218875901|NCT00003515|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218875902|NCT02781480|BIOLOGICAL|AAV RPE65|Comparison of different dosages of AAV RPE65
218875903|NCT03312842|DRUG|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
218875904|NCT03842059|DEVICE|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
218875905|NCT03842059|DEVICE|Standard colonoscopy|Standard colonoscopy
218875906|NCT05011058|DRUG|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
218875907|NCT01950312|DRUG|gevokizumab|
218875908|NCT03964688|DRUG|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
218875909|NCT03964688|DRUG|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
219024525|NCT00790881|DRUG|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
218875910|NCT01192412|PROCEDURE|Intervention is blood pressure management approach|1\) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
218875911|NCT01192412|PROCEDURE|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
218875912|NCT02750839|PROCEDURE|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
218875913|NCT05131230|DEVICE|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
218875914|NCT06583694|BEHAVIORAL|Health promotion campaigns to correct the health problems|
218875915|NCT06584227|DRUG|Adebrelimab and Chidamide Combined with Gemcitabine and S1|Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
219024526|NCT00790881|DRUG|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
219024527|NCT01750099|PROCEDURE|Combined Spinal-epidural|See arm description
219024528|NCT01750099|PROCEDURE|Continuous Lumbar epidural|See arm description
219024529|NCT02155647|DRUG|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
219024530|NCT05190731|OTHER|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
219024531|NCT05190731|OTHER|Sham|Touch only, no osteopathic cranial manipulation
219024532|NCT05045976|OTHER|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
219024533|NCT03369054|BEHAVIORAL|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
219602691|NCT05503264|DRUG|Satralizumab|In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
218875916|NCT06583369|DRUG|Liangxue ointment（Traditional Chinese Ointment）|"The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses."
218875917|NCT06583369|DRUG|Urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
218875918|NCT06584201|PROCEDURE|Erector Spinae Plane Block (ESP)|The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
218875919|NCT06584201|PROCEDURE|Paravertebral Block (PVB)|The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
218875920|NCT02103777|DRUG|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
218875921|NCT02085278|DEVICE|Apollo Micro Catheter device|Detachable Tip Micro catheter
218875922|NCT01743820|DRUG|dihydroartemisinin-piperaquine|
218875923|NCT01743820|DRUG|0.125 mg/kg Primaquine|
218875924|NCT01743820|DRUG|0.5 mg/kg Primaquine|
218875925|NCT01743820|DRUG|0.25 mg/kg Primaquine|
218875926|NCT01743820|DRUG|0.0625 mg/kg Primaquine|
218875927|NCT00950898|OTHER|decaff|2 mugs of decaffeinated coffee
218875928|NCT00950898|OTHER|caffcoff|2 mugs of caffeinated coffee
218875929|NCT00950898|OTHER|caffeine|2 mugs of hot water containing caffeine
218875930|NCT00950898|OTHER|placebo|2 mugs of hot water
218875931|NCT05013203|DIAGNOSTIC_TEST|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
218875932|NCT05013203|DIAGNOSTIC_TEST|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
218875933|NCT00038233|DRUG|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
219495279|NCT02981602|DRUG|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
218875934|NCT05670158|BIOLOGICAL|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
218875935|NCT05670158|PROCEDURE|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
218875936|NCT06168682|DEVICE|SuperNO2VA™ Et by Vyaire Medical, Inc.|SuperNO2VA™ Et provides a nCPAP between 3 to 10 cmH20 using a oxygenflowrate of 6l/O2
219495280|NCT02981602|DRUG|Placebo|Placebo
219495281|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
219495282|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.
219495283|NCT04740112|OTHER|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
219495284|NCT00142844|DRUG|Naltrexone|
219495285|NCT00142844|DRUG|Disulfiram|
219495286|NCT00142844|DRUG|Placebo|
219495287|NCT02270931|DEVICE|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
219495288|NCT01489696|DRUG|mirabegron|oral
219495289|NCT01489696|DRUG|tamsulosin|oral
219495290|NCT04839588|OTHER|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
219495291|NCT00238056|DRUG|domperidone Drug|
219495292|NCT00612079|DRUG|Sertindole|oral 3 x 4mg
219495293|NCT00612079|DRUG|Placebo|3 x 4mg Placebo
219495294|NCT00386100|DRUG|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
218875937|NCT06168682|DEVICE|nasal oxygen cannula|Standard Operating Procedure (SOP) for endoscopy: Using a nasal oxygen cannula with oxygenflowrate of 6l/O2
218875938|NCT00383942|DRUG|Misoprostol|Misoprostol,25 micrograms every 4 hours.
219495295|NCT00386100|DRUG|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
219495296|NCT00386100|DRUG|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
219495297|NCT00386100|DRUG|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
219495298|NCT00386100|DRUG|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
219495299|NCT00386100|DRUG|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
219495300|NCT00386100|DRUG|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
219495301|NCT00386100|DRUG|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
219495302|NCT00730470|DRUG|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
219495303|NCT02222285|OTHER|Medical Food : Vayarin_005|
219495304|NCT02222285|OTHER|Placebo|
219495305|NCT04167488|DEVICE|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
219495306|NCT01632683|DEVICE|C-MAC|C-MAC arm
219495307|NCT01632683|DEVICE|Glidescope|Glidescope arm
219495308|NCT00491673|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
219495309|NCT00491673|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
219495310|NCT00970931|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
219495311|NCT00970931|DRUG|placebo|Oral placebo once a day, for 18 months
219495312|NCT04816422|OTHER|Proprioceptive neuromuscular facilitation|"rocedure~1. Bilateral upper extremity pattern for trunk by Chopping, Lifting~2. Bilateral lower extremity pattern for trunk.~3. Trunk lateral flexion.~4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion."
219602692|NCT05503264|OTHER|Placebo|Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
219024534|NCT03369054|BEHAVIORAL|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
219024535|NCT06297109|DEVICE|Patient-specific implants|Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
219024536|NCT06297109|DEVICE|Conventional mini-plates|Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
219495313|NCT04816422|OTHER|Conventional treatment|"Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
219495314|NCT02464085|OTHER|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
219495315|NCT03467828|GENETIC|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
219495316|NCT01706770|DEVICE|enfilcon A|
219495317|NCT01706770|DEVICE|galyfilcon A|
219495318|NCT06462209|OTHER|ladder training|"Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step."
219495319|NCT06462209|OTHER|plyometric training|In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
219495320|NCT00944385|DRUG|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
219495321|NCT02328807|PROCEDURE|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
219495322|NCT02020785|OTHER|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
219495323|NCT02020785|OTHER|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
219495324|NCT03744065|PROCEDURE|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
219495325|NCT03744065|PROCEDURE|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
219495326|NCT01247896|DRUG|PF-05190457|Single Dose 2 mg
219495327|NCT01247896|DRUG|PF-05190457|Single Dose 10 mg
219495328|NCT01247896|DRUG|PF-05190457|Single Dose 30 mg
219495329|NCT01247896|DRUG|PF-05190457|Single Dose 100 mg
219024537|NCT06969443|PROCEDURE|Rehabilitation Procedure|"Rehabilitation procedure list :~1. Passive limb mobilization~2. Active (or active-assisted) limb mobilization~3. Passive transfer to chair~4. Active transfer to chair~5. Sitting on edge of bed~6. Standing table (or similar)~7. Standing on legs~8. Walking~9. Cyclo-ergometer (bed or chair)~10. Electrostimulation"
219024538|NCT06965426|OTHER|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
219024539|NCT00458523|BIOLOGICAL|alemtuzumab|
219024540|NCT00458523|GENETIC|fluorescence in situ hybridization|
219024541|NCT00458523|GENETIC|mutation analysis|
219024542|NCT00458523|OTHER|flow cytometry|
219024543|NCT04990752|DRUG|ulinastatin|In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
219024544|NCT00714519|DRUG|Xenaderm® Ointment|Topical, BID or as needed
219024545|NCT00714519|DRUG|Placebo Comparator|Topical, BID or as needed
219024546|NCT00001877|DRUG|Pentoxifylline|
219024547|NCT00419198|PROCEDURE|Postconditioning|Postconditioning during angioplasty
219024548|NCT00419198|PROCEDURE|standard angioplasty|standard angioplasty without postconditioning
219495330|NCT01247896|DRUG|PF-05190457|Single Dose 300 mg
219495331|NCT01247896|DRUG|PF-05190457|Single Dose 600 mg
219495332|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined with food
219495333|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined
219495334|NCT01247896|DRUG|Placebo|Single Dose Placebo
219495335|NCT02282111|DEVICE|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
218875939|NCT00383942|DEVICE|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
218875940|NCT03219632|DRUG|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
218875941|NCT03322917|BIOLOGICAL|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
218875942|NCT02357121|DEVICE|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
218875943|NCT03433417|DEVICE|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
218875944|NCT03781505|DRUG|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
218875945|NCT03781505|DRUG|Placebo|Caudal ropivacaine
218875946|NCT06303219|OTHER|RADITIONAL MODERATE INTENSITY TRAINING|"It consists of patients who will receive High-intensity interval training, including running as well as walking at 80% to 95% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes"
218875947|NCT06303219|OTHER|HIGH INTENSITY INTERVAL TRAINING|"It consists of patients who will receive Moderate-intensity interval training, including running as well as walking at 60% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes ("
219024549|NCT03322033|DEVICE|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
219495336|NCT02282111|DEVICE|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
219024550|NCT01048021|PROCEDURE|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
219024551|NCT05678829|OTHER|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
219024552|NCT05778786|DEVICE|Acuvue Oasys 1 Day for Astigmatism|CONTROL
219024553|NCT05778786|DEVICE|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
219024554|NCT01602380|DRUG|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
219024555|NCT01602380|DRUG|arimidex 1mg|oral tablet 1 daily
219024556|NCT01602380|DRUG|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
219495337|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
219495338|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
219495339|NCT02729493|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
219495340|NCT00886782|DRUG|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
219495341|NCT02119182|BEHAVIORAL|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
219495342|NCT02119182|BEHAVIORAL|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
219024557|NCT01602380|DRUG|arimidex dummy|oral tablet 1 daily
219024558|NCT05478447|PROCEDURE|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
219024559|NCT00496756|DRUG|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
219495343|NCT02119182|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
218875948|NCT06017791|OTHER|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade. One on each side of the frenum~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
218875949|NCT06303323|OTHER|Qigong Exercise|"Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin.~In the first 2 weeks, two sets of Baduanjin will be performed. Total Duration: 6 weeks Frequency: for 3 days/week. (alternative days) Intensity: low-intensity exercise Total Time: 50 Minutes Type: aerobic training"
219024560|NCT06448910|DRUG|Cadonilimab (AK104)|Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.
219024561|NCT06535711|RADIATION|Acute CT|Acute CT (a CT within 24 h)
219024562|NCT06535711|RADIATION|Deferred CT|Deferred CT (a CT within 3-4 weeks)
219024563|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
219024564|NCT06573086|OTHER|Resistance Training|12-week resistance training
219024565|NCT06632054|BEHAVIORAL|Text Message Reminders|Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
219024566|NCT06422884|DRUG|ENV-101|oral tablet, dosed once a day
219024567|NCT06422884|DRUG|Placebo|oral tablet, dosed once a day
219024568|NCT06399354|DIETARY_SUPPLEMENT|acute intake of medium-chain fatty acids or long-chain fatty acids in patients|The intake of an oil comprising of either medium -chain fatty acids or long-chail fatty acids
219495344|NCT02119182|PROCEDURE|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
219495345|NCT02991261|DRUG|SPARC001 type I|Treatment type I
219495346|NCT02991261|DRUG|SPARC001 type II|Treatment type II
219024569|NCT06399354|DIETARY_SUPPLEMENT|Acute intake of medium-chain fatty acids or long-chain fatty acids in healthy individuals|Acute intake of MCT and LCT in healthy individuals in a cross-over design
219024570|NCT00213850|PROCEDURE|EFR|
219024571|NCT02382822|OTHER|No intervention.|
219024572|NCT06574789|DRUG|Standard dosing of IV ganciclovir|IV ganciclovir at standard dosing
219024573|NCT06574789|DRUG|Personalised dosing of IV ganciclovir|IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app
219024574|NCT03992729|DRUG|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
219024575|NCT03992729|DRUG|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
219024576|NCT04034420|OTHER|Online training platform|Self-paced training and learning materials in relation to family services
219024577|NCT02409992|BEHAVIORAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
219024578|NCT02409992|BEHAVIORAL|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
219024579|NCT05755685|DRUG|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
219024580|NCT03509025|DRUG|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
219024581|NCT01726153|BEHAVIORAL|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
219024582|NCT01064401|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
219024583|NCT01064401|DRUG|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
219024584|NCT01064401|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a for intramuscular injection
219024585|NCT01064401|DRUG|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
219024586|NCT00865774|BEHAVIORAL|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
219495347|NCT02991261|DRUG|Reference001 type I|Hydrocodone-acetaminophen
219495348|NCT02991261|DRUG|Reference001 type II|Hydrocodone Acetaminophen
219024587|NCT00865774|BEHAVIORAL|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
219024588|NCT03096379|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
219024589|NCT03158051|BEHAVIORAL|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
219024590|NCT03158051|BEHAVIORAL|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
219024591|NCT05249361|OTHER|no intervention|no intervention
219024592|NCT06493695|BEHAVIORAL|Both EGChat and CES intervention|"1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform.~2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home"
219024593|NCT06493695|OTHER|Exercise Chatbot|Exercise Chatbot
219024594|NCT06493695|DEVICE|CES (Cranial Electrotherapy Stimulation)|Intervention of CES (Cranial Electrotherapy Stimulation)
219024595|NCT05629390|DRUG|Lotilaner|Lotilaner Ophthalmic Solution
219024596|NCT05629390|DRUG|Vehicle Control|Vehicle of TP-03 ophthalmic solution
219495349|NCT02633761|DRUG|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
219495350|NCT02633761|DRUG|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
218875950|NCT06303323|OTHER|Wu Dang Tai Chi|"Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.~Total Duration: 6 weeks Frequency: 3 times/ week (alternative day ) Intensity: Low to Moderate Intensity Time: 50 Minutes Type: aerobic training"
218875951|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
218875952|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
218875953|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
219024597|NCT04758819|PROCEDURE|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
218875954|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
218875955|NCT04706728|OTHER|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
218875956|NCT02092311|PROCEDURE|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
219024598|NCT02738151|DRUG|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
219495351|NCT02633761|DRUG|Misoprostol 200mcg|Buccal misoprostol 200mcg
219495352|NCT05528289|DEVICE|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
219495353|NCT05528289|DEVICE|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
219602693|NCT05327387|OTHER|model-based electrical brain stimulation|Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
218875957|NCT02092311|PROCEDURE|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
218875958|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
218875959|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
218875960|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
218875961|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
219024599|NCT02738151|DRUG|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
219024600|NCT02738151|DRUG|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
219024601|NCT02588833|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219495354|NCT05691673|OTHER|No intervention|Observational during 16 weeks
218875962|NCT00246246|DRUG|risperidone|
219495355|NCT03933319|DRUG|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
219495356|NCT06319521|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
218875963|NCT00733681|DEVICE|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
218875964|NCT00741403|DRUG|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
218875965|NCT00732108|DRUG|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
218875966|NCT00732108|DRUG|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
219495357|NCT06319521|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218875967|NCT05994079|DEVICE|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
218875968|NCT05994079|OTHER|topical firming creams|medical topical firming creams
218875969|NCT06426836|OTHER|Amoxicillin-clavulanate|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
218875970|NCT06426836|OTHER|Piperacillin-tazobactam|blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
218875971|NCT06426836|OTHER|Meropenem|blood sampling in patients receiving meropenem as part of routine clinical care.
218875972|NCT06426836|OTHER|Cefazolin|blood sampling in patients receiving cefazolin as part of routine clinical care.
218875973|NCT06426836|OTHER|Vancomycin|blood sampling in patients receiving vancomycin as part of routine clinical care.
219495358|NCT06319521|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219495359|NCT06319521|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218875974|NCT06426836|OTHER|Teicoplanin|blood sampling in patients receiving teicoplanin as part of routine clinical care.
218875975|NCT06426836|OTHER|Ciprofloxacin|blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
218875976|NCT06426836|OTHER|Amikacin|blood sampling in patients receiving amikacin as part of routine clinical care.
218875977|NCT01991522|BEHAVIORAL|Curriculum Group|
218875978|NCT01991522|BEHAVIORAL|Self-directed learning group|
218875979|NCT03319004|DEVICE|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
218875980|NCT00002230|DRUG|Hydroxyurea|
218875981|NCT00002230|DRUG|Efavirenz|
218875982|NCT00002230|DRUG|Stavudine|
218875983|NCT00002230|DRUG|Didanosine|
218875984|NCT00258804|DRUG|Insulin glargine|
218875985|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
218875986|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
218875987|NCT04313270|DRUG|Evolocumab|12 weeks of treatment with Evolocumab
218875988|NCT05728398|OTHER|Music|Music played within the fluoroscopy suite during an interventional radiology procedure.
218875989|NCT05728398|OTHER|No Music|No music played within the fluoroscopy suite during an interventional radiology procedure.
218875990|NCT01590693|DRUG|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
219495360|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
219602694|NCT04509934|OTHER|Connective Tissue Manipulation|The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
219602695|NCT06337513|OTHER|Rehabilitation intervention|"The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation offer for 6-months.~The intervention encompasses 3 individual sessions with the PT, if needed individual sessions with the interdisciplinary team (PT, occupational therapist, OT, nurse, and social worker) (a maximum of 6 hours), and patient education in two group seminars."
218875991|NCT05762406|DEVICE|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
218875992|NCT01375023|RADIATION|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
218875993|NCT01375023|BIOLOGICAL|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
218875994|NCT00158691|DRUG|Ethyol|
218875995|NCT01248637|DRUG|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
219024602|NCT02047747|DRUG|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
219024603|NCT04994977|DRUG|Melphalan|Given at 0.5 mg/ml.
219495361|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
219024604|NCT04994977|DRUG|Carboplatin|Given at 5 mg/ml.
219495362|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
219495363|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
219602696|NCT06337513|OTHER|Usual care|Both the intervention and the control group will receive usual care.
219602697|NCT05829317|DRUG|Magnesium sulfate|Intravenous Magnesium sulfate
219602698|NCT05829317|DRUG|Placebo|0.9% NaCl
219602699|NCT05998772|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Application of 82,5 g of glucose monohydrate solved in 300ml water
219602700|NCT05998772|OTHER|Placebo Oral Glucose Tolerance Test|Application of 125mg sucralose solved in 300ml water
219602701|NCT05425511|BEHAVIORAL|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
219024605|NCT04994977|DRUG|Topotecan|Given at 0.2 mg/ml.
219024606|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
219024607|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
219024608|NCT01395433|DRUG|Escitalopram|1 x 20 mg, single dose
219024609|NCT03649711|DRUG|Ticagrelor 90mg|Ticagrelor Pill
219024610|NCT03649711|DRUG|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
219495364|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
219495365|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
219495366|NCT00947245|DRUG|Placebo|Capsules, Oral, Single Dose, One day
219495367|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours, 14 days
219495368|NCT00947245|DRUG|Placebo|Capsules, Oral, Once Daily, 14 days
219495369|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
219495370|NCT04014101|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
219495371|NCT04014101|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor.
219495372|NCT03798522|PROCEDURE|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
219495373|NCT03798522|DRUG|Nalbuphine|in nalbuphine for analgesia after GA
219024611|NCT03649711|DRUG|Aspirin 81 mg|Aspirin Pill
219024612|NCT01892371|DRUG|Azacitidine|Given SC or IV
219024613|NCT01892371|DRUG|Cytarabine|Given SC
219024614|NCT01892371|DRUG|Quizartinib|Given PO
219024615|NCT02606565|BIOLOGICAL|Intervention arm: 4% chlorhexidine|See previous description
219024616|NCT05556447|BEHAVIORAL|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
219024617|NCT03768349|DRUG|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
218875996|NCT04872660|DRUG|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
218875997|NCT04872660|DRUG|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
219495374|NCT06290869|BEHAVIORAL|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention|In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.
219495375|NCT06290869|BEHAVIORAL|E-Referral to the Tobacco Quitline|In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
219495376|NCT03160365|PROCEDURE|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
219495377|NCT01016821|DRUG|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
219602702|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
218875998|NCT01083589|DRUG|Imatinib Mesylate|Oral 400 mg daily
218875999|NCT01083589|DRUG|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
218876000|NCT04979494|OTHER|ultrasound examination|We conduct abdominal ultrasound examinations for each patient.
218876001|NCT02406404|BEHAVIORAL|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
218876002|NCT05838092|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
218876003|NCT05838092|DRUG|Placebo|Placebo
218876004|NCT06124391|OTHER|Long-term follow-up|Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
218876005|NCT02141360|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
218876006|NCT04625764|PROCEDURE|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
218876007|NCT06205082|DRUG|LIT-00814|LIT-00814 is an oral tablet.
218876008|NCT02692001|OTHER|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
218876009|NCT06167707|DRUG|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
218876010|NCT06167707|DRUG|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
218876011|NCT01891474|DEVICE|U-health care|voice inception technique based U-healthcare service
218876012|NCT05641415|OTHER|Imaging|MRI and x-ray of both shoulders
219024618|NCT03768349|DRUG|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
219024619|NCT01864733|OTHER|Physical rehabilitation (exercise).|
219024620|NCT04007094|OTHER|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
218876013|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
218876014|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
218876015|NCT04071158|BIOLOGICAL|RSV Vaccine|RSV vaccine
219024621|NCT04343950|BEHAVIORAL|SMS reminders to enhance colorectal cancer screening|Individual randomization will be used. Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis).
218876016|NCT04071158|BIOLOGICAL|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
218876017|NCT04071158|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
218876018|NCT03439930|OTHER|Balance training|6 weeks lasting balance training program
218876019|NCT01178099|DRUG|Prasugrel|Oral, daily for 12 days
219024622|NCT04343950|BEHAVIORAL|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|Individual randomization will be used. Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis).
219024623|NCT04343950|BEHAVIORAL|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
219495378|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
219495379|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
219495380|NCT00755508|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
219495381|NCT00755508|DRUG|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
219495382|NCT00755508|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
219602703|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
218876020|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
218876021|NCT01149720|DRUG|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
218876022|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
218876023|NCT03288636|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
218876024|NCT03288636|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
219024624|NCT06824506|OTHER|No-intervention|No interventions will be performed by the research team.
219024625|NCT05230615|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219024626|NCT06987058|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
219024627|NCT06409767|OTHER|Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.|The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
219024628|NCT06591533|OTHER|Music therapy + standard care|In the pre-extubation and extubation phase, the musical characteristics will be based on a slow to medium tempo, simple harmonic structures (e.g., tonic-subdominant movements), fluid melodies, and avoiding large intervals or abrupt changes of tonalities. The musical instruments used will be a classical guitar with nylon strings (Yamaha C-40) and the voice of the music therapist without lyrics or words. In the post-extubation phase, the musical characteristics will be based on a moderate tempo, introducing chord progressions aiming at tension-resolution (e.g., dominant-tonic), and a more rhythmic application of melodic or harmonic material.
219602704|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
218876025|NCT03288636|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
218876026|NCT03288636|DRUG|Placebo|Placebo
218876027|NCT03688464|DRUG|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
218876028|NCT03688464|DRUG|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
218876029|NCT03688464|DRUG|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
218876030|NCT05748457|BEHAVIORAL|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
218876031|NCT05748457|BEHAVIORAL|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015)."
218876032|NCT06574516|DRUG|Ibuprofen 200 mg|Ibuprofen every 8 hours for three days post operatively
218876033|NCT06574516|DRUG|paracetamol|Paracetamol PRN for three days
218876034|NCT06041152|DRUG|Psilocybin|2 macrodoses of 25mg separated by one week.
218876035|NCT06041152|DRUG|Placebo|2 doses of placebo separated by one week.
218876036|NCT00307788|PROCEDURE|acupuncture|acupuncture
218876037|NCT05652712|DRUG|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
218876038|NCT02516592|DRUG|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
218876039|NCT02516592|DRUG|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
219602705|NCT04669041|DRUG|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
219602706|NCT04669041|DRUG|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
219602707|NCT04669041|DRUG|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
219602708|NCT04669041|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
219602709|NCT04669041|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
219602710|NCT01282697|DRUG|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
218876040|NCT05916469|DRUG|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
218876041|NCT05916469|DRUG|Norethindrone Acetate|norethindrone acetate 5 mg daily
218876042|NCT02395523|RADIATION|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
218876043|NCT02486965|DEVICE|thermode (TSA-II model)|thermal stimulation with test thermode
218876044|NCT02486965|OTHER|Adapted Physical Activity|
218876045|NCT02486965|OTHER|Physical activity|
218876046|NCT06980623|DRUG|Tirzepatide|Exposure group
218876047|NCT06980623|DRUG|Semaglutide|Referent group
218876048|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
218876049|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
218876050|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 6 months.
218876051|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 18 months.
218876052|NCT01691040|DRUG|NOX-H94|intravenous injection
218876053|NCT01691040|DRUG|Placebo solution|intravenous injection
218876054|NCT01359228|DRUG|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
219602711|NCT02479204|DRUG|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
219602712|NCT02479204|DRUG|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
219602713|NCT02479204|DRUG|Placebo|ACT-33441-matching placebo
219602714|NCT02479204|DRUG|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
219024629|NCT06591533|OTHER|Standard Care (in control arm)|Standard care during the extubation process involves providing usual the medical care provided for patients according to each hospital's guidelines.
218876055|NCT01359228|DRUG|Placebo|Placebo 1 tablet three times a day for 14 days.
218876056|NCT06682494|BEHAVIORAL|Traditional Education|Participants will receive traditional educational handouts focusing on increasing awareness of oral cancer risks, preventive strategies, and the importance of regular dental check-ups. Participants will be provided time to read the handouts based on calculated reading time.
218876057|NCT06682494|BEHAVIORAL|AI-powered Chatbox|The chatbot interaction will be initiated through a provided link, allowing participants to access information and ask questions related to oral health and cancer prevention. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups. Participants will be encouraged to interact with the chatbot for a specified duration
218876058|NCT03592563|BEHAVIORAL|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
218876059|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
218876060|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
219024630|NCT02070744|DRUG|VX-661|Tablet, oral use
219024631|NCT02070744|DRUG|Ivacaftor|Film coated tablet, oral use
219495383|NCT05634018|DIAGNOSTIC_TEST|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
218876061|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
219024632|NCT02070744|DRUG|Placebo matched to VX-661|Tablet, oral use
219602715|NCT02479204|DRUG|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
219602716|NCT06438874|OTHER|Exercise Test|Exercise capacity will be measured as peak oxygen consumption (peakVO2) using an incremental exercise test on a cycle ergometer with an open-circuit spirometry system (TrueOne, Parvo Medics, Sandy, UT) to analyze expired gases. Exercise testing will follow the American College of Sports Medicine and American Heart Association guidelines. The investigators will use a graded protocol, starting with a warm-up at 0 watts for 5 minutes, followed by 15 watt increments every 2 minutes until volitional fatigue.
219602717|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
219024633|NCT02070744|DRUG|Placebo matched to Ivacaftor|Film coated tablet, oral use
219024634|NCT05220137|BEHAVIORAL|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
219024635|NCT05220137|BEHAVIORAL|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
219024636|NCT05220137|BEHAVIORAL|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
219024637|NCT05220137|BEHAVIORAL|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
219024638|NCT05220137|BEHAVIORAL|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
219024639|NCT03745235|OTHER|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
219024640|NCT03745235|BIOLOGICAL|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
219495384|NCT03577652|DRUG|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
219495385|NCT03791918|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
218876062|NCT04735991|BEHAVIORAL|Kapok Initiative|"The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
218876063|NCT00815594|DRUG|bevacizumab|0.05ml, 1.25mg
218876064|NCT01286740|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
218876065|NCT06750484|DRUG|Trastuzumab Deruxtecan|Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
218876066|NCT07058207|BEHAVIORAL|Multimodal weight management program|"This intervention consists of three components:~* Nutritional Counseling:~  * A personalized hypocaloric and high-protein diet is prescribed, based on individual energy requirements with a 20% caloric reduction.~ * The protein intake target is 1.5 g/kg/day to promote fat loss while maintaining muscle mass.~* Exercise Program~  * Home-based, supervised aerobic and resistance training sessions conducted 3 times per week.~ * Each 60-minute session includes: 5 minutes flexibility, 25 minutes aerobic training, 25 minutes resistance training, and 5 minutes balance exercises.~* Behavioral Support~  * Patients receive training in problem-solving strategies, motivation, and emotional self-regulation to improve adherence to both dietary and exercise goals.~ * Health professionals delivering the intervention are trained in behavior change techniques by a clinical psychologist."
218876067|NCT07060339|BEHAVIORAL|Exercise Programme|Midwifery care, breathing exercises, massage and exercise applications were performed on pregnant women in this group during the active phase of labour. Following breathing exercises, massage was applied for 10 minutes using different techniques according to rest and contraction intervals. Pain levels were assessed using the VAS before and after massage. After the massage, the exercise session began; the pregnant woman was first walked along a 50-metre corridor, followed by squatting, squat, four-legged positions, wall stretching movements, and pelvic tilt, swaying, and leg stretching exercises using a Pilates ball. Pain levels were measured using the VAS before and after all exercise applications.
218876068|NCT07060339|BEHAVIORAL|Hot Shower Programme|In addition to midwifery care, breathing exercises, massage, and hot showers were administered in this group. Massage was administered for 10 minutes after the breathing exercises, and pain levels were measured using the VAS before and after the massage. After the massage, considering the risk of the pregnant woman falling, she was seated on a stool in the shower, and warm water at a temperature of 36.5-37.8 °C was applied to the lower abdomen and sacrum region during contractions for 15 minutes. To prevent chills, the application was repeated at 10-minute intervals, and pain levels before and after were again assessed using the VAS.
219024641|NCT03745235|OTHER|psychometric questionnaires|"* Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire"
219024642|NCT03935685|DRUG|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
219024643|NCT07023289|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219024644|NCT07023289|DRUG|Standard of Care|Standard of care treatment based on investigator's judgement to the active surveillance.
219024645|NCT04199117|DRUG|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
219040199|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
219495386|NCT03791918|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
219495387|NCT03791918|PROCEDURE|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
219602718|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
219602719|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
219495388|NCT03791918|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
219495389|NCT03636542|DRUG|liposomal bupivacaine|Experimental
219495390|NCT03636542|DRUG|bupivacaine|Active comparator
219495391|NCT06061718|DRUG|iDose TR|anchored intracameral implant containing travoprost
219495392|NCT02156518|PROCEDURE|Vocal Function Exercises|Vocal Function Exercises
219495393|NCT02156518|PROCEDURE|Vocal Hygiene|Vocal Hygiene
219495394|NCT02773888|DEVICE|HS-1000|
219602720|NCT06215846|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
218876069|NCT07060339|BEHAVIORAL|Combined Application (Exercise + Hot Shower)|In addition to midwifery care, breathing exercises, massage, exercise and hot shower treatments were performed for this group. As in Groups 1 and 2, the application began with breathing exercises, followed by massage, exercise, and hot showers in sequence. Pain levels were assessed using the VAS before and after each application, and measurements were taken again during the massage. Ten-minute breaks were given between applications to allow the pregnant women to rest, and the applications were continued alternately.
218876070|NCT07060339|BEHAVIORAL|Pharmacological Intervention|In this study, the fourth group was evaluated as the intervention 4 group and was followed up in accordance with standard interventions frequently applied during the birth process. Pregnant women in this group received routine midwifery care, massage treatments to promote relaxation, and breathing exercises in accordance with hospital protocols. In addition, pharmacological pain management methods commonly used in the clinic were also applied in this group.
219024646|NCT04199117|DRUG|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
219024647|NCT04199117|BEHAVIORAL|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
219024648|NCT04199117|BEHAVIORAL|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
219024649|NCT04199117|BEHAVIORAL|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
219024650|NCT04199117|OTHER|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
219024651|NCT04199117|OTHER|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
219024652|NCT04199117|BEHAVIORAL|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
219024653|NCT04199117|BEHAVIORAL|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
219024654|NCT06681207|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.
219024655|NCT07025460|DRUG|darbepoetin alfa|Participants receive darbepoetin alfa administered subcutaneously once every 4 weeks for 12 weeks during the evaluation phase. Dose adjustments are made to maintain hemoglobin levels within 10.0-11.0 g/dL.
219200312|NCT06891976|OTHER|Acupressure therapy|It will be applied to the first experimental group, three times per week for 3 weeks, with each session lasting 30 minutes. Each woman will receive a brief explanation about acupressure therapy and its effects to ensure her confidence and cooperation. Before starting, participants will be asked to empty their bladder for relaxation and assume a prone position. The therapy involves applying prolonged, slow, firm pressure with both thumbs on five key points (BL20, GV3, GB30, GB34, and BL25), which are commonly used for low back pain. Each point will receive three cycles of one-minute pressure followed by one minute of relaxation.
219495395|NCT03910582|PROCEDURE|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
219495396|NCT03910582|PROCEDURE|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
219495397|NCT05698420|DEVICE|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
219495398|NCT05698420|DEVICE|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
219495399|NCT03101579|DRUG|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
219495400|NCT03101579|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
219495401|NCT03101579|DRUG|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
219495402|NCT03101579|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
218876071|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
218876072|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
219040200|NCT05585970|DIAGNOSTIC_TEST|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
219495403|NCT00701935|DRUG|placebo|subcutaneous injection, twice a day
219495404|NCT00701935|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
219495405|NCT03912688|DEVICE|acupoint stimulation|
219495406|NCT03912688|DEVICE|single acupoint|
219495407|NCT03912688|DEVICE|dual acupoints|
219495408|NCT02478593|BEHAVIORAL|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
219495409|NCT04373161|DEVICE|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen \<92% or for worsening symptoms.
219495410|NCT00703378|DRUG|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
219495411|NCT00469534|PROCEDURE|IMRT|
219495412|NCT02344134|BIOLOGICAL|NBP607|0.5 mL, intramuscular, a single dose
219495413|NCT02344134|BIOLOGICAL|Agrippal S1|0.5 mL, intramuscular, a single dose
219495414|NCT04952441|BEHAVIORAL|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
219495415|NCT06120452|OTHER|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
219495416|NCT03674827|BIOLOGICAL|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
219495417|NCT04379661|BEHAVIORAL|Online support Group|12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
219495418|NCT01559961|DRUG|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
219495419|NCT05990205|DRUG|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
219495420|NCT05990205|BEHAVIORAL|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
219495421|NCT05751083|OTHER|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises"
219040201|NCT01440738|BEHAVIORAL|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
219040202|NCT02508636|DRUG|Enzalutamide|Given orally
219040203|NCT02508636|DRUG|Leuprolide|Given via intramuscular injection
219495422|NCT05751083|OTHER|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down."
219495423|NCT01783483|DEVICE|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
219495424|NCT01783483|DEVICE|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
219602721|NCT06500962|BEHAVIORAL|Usual Care|Participants will receive a message sent to their electronic health record portal with instructions about how to sign up for a food is medicine program.
219602722|NCT06500962|BEHAVIORAL|Navigation|Participants will receive a weekly phone call from a navigator to promote enrollment in the food is medicine program and address any barriers to participation.
219602723|NCT06500962|BEHAVIORAL|Text Messaging|Participants will receive two text messages per week to promote healthy eating, enrolling in a food is medicine program, and continuing to participate in a food is medicine program.
219024656|NCT06503354|DEVICE|Neural Sleeve and Zeno walkway|"A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course."
219024657|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
219024658|NCT06878326|DEVICE|tDCS|Participant will receive three stimulation conditions: cathodal tDCS of the left DLPFC, anodal tDCS of the left DLPFC and sham-tDCS. The order of the conditions will be randomized and counterbalanced across participants, and the three stimulation conditions will be administered at least a week apart to avoid carry-over effects. The tDCS session will last for 20 minutes.
219024659|NCT06713343|DEVICE|Laryngeal Mask Airways|The 172 patients who will be admitted for elective surgery will be divided into two groups as Group L and Group R by computer-assisted randomization method. Patients in Group L will be ventilated with a classical laryngeal mask airways (cLMA) stored at 10 °C to 12 °C (low temperatures), while patients in Group R will be ventilated with a classical laryngeal mask airways (cLMA) stored at 22 °C to 25 °C (room temperatures).
219024660|NCT06881862|OTHER|The immediate craniocervical flexion and correct posture training|The craniocervical flexion and correct posture training were given immediately during the assessment, with no follow-up sessions or long-term interventions. The focus was solely on providing the training at that moment, without any prolonged or repeated exercises.
219024661|NCT06882824|PROCEDURE|myomectomy with placebo|myomectomy after administration of placebo (control group)
219024662|NCT06882824|PROCEDURE|myomectomy with misoprostol|myomectomiy after administration of misoprostol 400μg PO (experimental group)
219024663|NCT06880159|DEVICE|tDCS with computerized cognitive training|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes.
219024664|NCT06888024|PROCEDURE|non-contrast enhanced abdomen and pelvis MRI|non-contrast enhanced abdomen and pelvis MRI
219495425|NCT02832791|PROCEDURE|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
219495426|NCT02832791|PROCEDURE|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
219024665|NCT06926634|DRUG|Zanzalintinib|Provided by Exelixis
219024666|NCT07054931|BIOLOGICAL|ChAdOx1.tHIVconsv1|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
219024667|NCT07054931|BIOLOGICAL|ChAdOx1.HIVconsv62|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
219024668|NCT07054931|BIOLOGICAL|MVA.tHIVconsv4|suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
219495427|NCT06567093|OTHER|Baby Foot and Leg Massage|"Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down."
219602724|NCT06217874|OTHER|Non-Interventional Study|Non-interventional study
219024669|NCT07054931|BIOLOGICAL|GS-5423|Solution for infusion 2550 mg Arm A, Arm B and Arm C
219024670|NCT07054931|BIOLOGICAL|GS-2872|Solution for infusion 850 mg Arm A, Arm B and Arm C
219024671|NCT07054931|OTHER|Treatment interruption induced viraemia|Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
219024672|NCT07055282|DRUG|Empagliflozin (Jardiance®)|Empagliflozin (Jardiance®), 10 mg tablet taken orally once daily for 4 weeks. Dispensed at baseline by the Investigational Drug Service. It will be administered at home by participants.
219040204|NCT02508636|RADIATION|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
219040205|NCT00696137|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
219495428|NCT00828490|BEHAVIORAL|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
219024673|NCT06892509|BEHAVIORAL|mindfulness-based stress reduction program|In this study, Mindfulness-Based Stress Reduction Programme will be applied to the women to be included in the experimental group as a nursing intervention. For this programme, the researchers participated in the Mindfulness-Based Stress Reduction Programme consisting of eight internationally validated modules consisting of eight sessions given by Tera Consultancy and completed the training. The certificates of the researchers are given in the appendices. The experimental group will receive a mindfulness-based stress reduction programme for a total of eight weeks, 2-1.5 hours per week. The mindfulness programme usually lasts eight weeks because it has been reported that this is an effective period of time to produce noticeable changes in brain structure, stress levels, emotional regulation and general well-being.
219024674|NCT04601740|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219024675|NCT06796907|DRUG|GSK5733584|GSK5733584 will be administered intravenously (IV).
219024676|NCT06796907|DRUG|Anticancer therapy 1|Anticancer therapy 1 will be administered IV.
219024677|NCT06796907|DRUG|Anticancer therapy 2|Anticancer therapy 2 will be administered IV.
219024678|NCT06796907|DRUG|Anticancer therapy 3|Anticancer therapy 3 will be administered IV.
219024679|NCT06796907|DRUG|Anticancer therapy 4|Anticancer therapy 4 will be administered IV.
219495429|NCT00828490|BEHAVIORAL|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
219495430|NCT00828490|BEHAVIORAL|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
219495431|NCT02934269|DRUG|Placebo|
219495432|NCT02934269|DRUG|CC-90006|
219495433|NCT02761265|PROCEDURE|Surgical intervention|Surgery to correct spinal deformity
219495434|NCT02761265|OTHER|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
219602725|NCT03716180|DRUG|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
219602726|NCT03716180|DRUG|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
219024680|NCT03939897|DRUG|Abemaciclib|Given PO
219024681|NCT03939897|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219200313|NCT06891976|OTHER|kinesio tape|It will be applied to the second experimental group, for 3 weeks. The tape, 5cm wide and 0.5mm thick, will be fixed in a standing lumbar flexion position on clean, grease-free skin. Four I-shaped bands, each 0.5mm in width, will be applied. The first 5cm of tape will be carefully placed on the skin without stretching, while the middle portion will be stretched 1-2 inches (50%). Two bands will be applied horizontally, and two more will be placed vertically along the lumbar spine, from the lower iliac crest to the upper twelfth rib. The tape will be rubbed to warm the adhesive, ensuring proper adhesion. It will be replaced every 3 days for 3 weeks.
219495435|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
219495436|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
219602727|NCT03716180|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
219602728|NCT05194111|DRUG|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
219602729|NCT05194111|DRUG|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
219495437|NCT00442715|PROCEDURE|Exercise chalenge test|
219495438|NCT05229315|DRUG|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
219495439|NCT05229315|PROCEDURE|Intensity modulated radiotherapy|Intensity modulated radiotherapy
219495440|NCT01140269|OTHER|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
219495441|NCT06204172|DEVICE|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
219495442|NCT06204172|OTHER|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
219495443|NCT04681222|PROCEDURE|LFCN|LFCN block was performed in combination with PENG block
219495444|NCT04681222|PROCEDURE|Wound infiltration|Wound infiltration was performed in combination with PENG block
219602730|NCT03517475|BEHAVIORAL|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
219602731|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
218876073|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
218876074|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
218876075|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
218876076|NCT04361305|DRUG|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
218876077|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
219024682|NCT03939897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219024683|NCT03939897|DRUG|Copanlisib Hydrochloride|Given IV
219024684|NCT03939897|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
219495445|NCT02095119|DRUG|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
219495446|NCT02095119|DRUG|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is \>/= 60. The administration form will be intravenously.
219495447|NCT02095119|DRUG|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation \< 60). The administration form will be intravenously.
219495448|NCT02095119|PROCEDURE|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
219495449|NCT04130919|DRUG|Tilpisertib|Tablets administered orally once daily
219495450|NCT04130919|DRUG|Placebo|Tablets administered orally once daily
219495451|NCT00458718|DRUG|rimonabant (SR141716)|
219495452|NCT01633749|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
219495453|NCT02624518|DRUG|68Ga-RM2|Imaging with PET/MRI
219495454|NCT02624518|PROCEDURE|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
219602732|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
218876078|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
218876079|NCT05885802|OTHER|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
218876080|NCT02134288|DRUG|Belatacept|
218876081|NCT02134288|DRUG|Everolimus|
218876082|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
218876083|NCT01211314|DRUG|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
219024685|NCT03939897|PROCEDURE|Echocardiography Test|Undergo ECHO
219024686|NCT03939897|DRUG|Fulvestrant|Given IM
219024687|NCT03939897|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219024688|NCT06738355|BEHAVIORAL|PREVENT|The proposed study will assess the feasibility of an RCT for clinic-based outreach to increase vaccination rates for HPV at community clinics in rural counties. The study is a pilot trial that will assign adult parent/caregiver participants to a timeline for receiving the vaccination messaging intervention. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).
219024689|NCT07063693|DRUG|ABY-029|"ABY-029 will be administered via single intravenous injection to subjects with high-grade glioma approximately 1-3 hours prior to surgery.~All research procedures will occur during surgery. The research procedures involve image and measurement data collection and biopsy specimen sampling. Research data collection will occur at 3 or 4 time points during surgery using either standard-of-care tools and methods or non-significant risk experimental devices.~No follow-up visit will be required of participants. Participants will be monitored for possible adverse events for approximately 30 days by the operating surgeon involved in the clinical trial procedures and through review of participant medical records."
219024690|NCT06774573|BEHAVIORAL|CBT-txt-A|8-week automated text-message delivered treatment for Generalized Anxiety Disorder
219495455|NCT02624518|PROCEDURE|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
218876084|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
218876085|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
218876086|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
218876087|NCT02953886|DEVICE|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
219024691|NCT07067697|OTHER|Physical exercise|Progressive, supervised multicomponent physical exercise program, including aerobic resistance, strength, and balance training. Strength training for lower limbs (leg press and knee extension) and upper limbs (seated chest press) will be adapted to each individual's functional capacity.
219024692|NCT07067697|OTHER|Usual Care|"* Hospital physiotherapy for preventing nosocomial disability when necessary.~* Hospital diet modifications appropriate to each participant's clinical situation.~* Oral nutritional supplementation aimed at meeting daily nutritional requirements: 30 kcal/kg body weight, 1.5-2 g protein/kg body weight, 25 g daily fiber.~* Approximate free water intake: women 1.5 L/day, men 2 L/day (unless clinically restricted)."
219024693|NCT02858336|BEHAVIORAL|NEA|Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
219024694|NCT02858336|BEHAVIORAL|DEA|Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
219024695|NCT04929028|PROCEDURE|Anoscopy|Undergo anoscopy
219024696|NCT04929028|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219024697|NCT04929028|DRUG|Capecitabine|Given PO
219024698|NCT04929028|PROCEDURE|Colonoscopy|Undergo colonoscopy
219024699|NCT04929028|PROCEDURE|Computed Tomography|Undergo CT or FDG PET/CT
219024700|NCT04929028|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
219024701|NCT04929028|PROCEDURE|Echocardiography Test|Undergo ECHO
219024702|NCT04929028|OTHER|Fludeoxyglucose F-18|Receive FDG
219024703|NCT04929028|DRUG|Fluorouracil|Given IV
219024704|NCT04929028|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219495456|NCT06314984|OTHER|Group I A (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].
219495457|NCT06314984|OTHER|Group I B (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the conventional needle syringe \[Infiltration\].
219495458|NCT06314984|DEVICE|Group II A (Comfort-in Jet Injector)|The injection site was isolated using a cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].
219495459|NCT06314984|DEVICE|Group II B (Comfort-in Jet Injector)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
219495460|NCT00737321|PROCEDURE|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
218876088|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
219495461|NCT04699643|DRUG|EVER4010001|Please refer to information in arm/group descriptions.
219495462|NCT02947282|OTHER|Educational Workshop|They will attend a 2 hour class on pelvic floor health
219024705|NCT04929028|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
219024706|NCT04929028|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
219024707|NCT04929028|DRUG|Mitomycin|Given IV
219024708|NCT04929028|BIOLOGICAL|Nivolumab|Given IV
219024709|NCT04929028|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT or PET/MRI
219024710|NCT04929028|PROCEDURE|Proctoscopy|Undergo proctoscopy
219024711|NCT04929028|OTHER|Questionnaire Administration|Ancillary studies
219024712|NCT04929028|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219024713|NCT06893510|OTHER|Virtual Reality Based Progressive Muscle Relaxation|Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.
219024714|NCT06893510|OTHER|Face-to-Face Progressive Muscle Relaxation|Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.
219024715|NCT07072988|DRUG|Efgartigimod|Administration of efgartigimod, a neonatal Fc receptor (FcRn) antagonist, given either intravenously (IV) or subcutaneously (SC) to treat patients with generalized Anti-AChR Myasthenia Gravis.
219024716|NCT06767683|DRUG|ALKS 2680, 4mg|Oral tablet containing 4 mg of ALKS 2680 for once daily administration
219495463|NCT01168882|DRUG|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
218876089|NCT05158790|OTHER|Questionnaire|Administration of a questionnaire
218876090|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
218876091|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
218876092|NCT02163421|DRUG|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
218876093|NCT02163421|DRUG|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
219024717|NCT06767683|DRUG|ALKS 2680, 6mg|Oral tablet containing 6 mg of ALKS 2680 for once daily administration
219024718|NCT06767683|DRUG|ALKS 2680, 8mg|Oral tablet containing 8 mg of ALKS 2680 for once daily administration
219024719|NCT06767683|DRUG|ALKS 2680, 10mg|Oral tablet containing 10 mg of ALKS 2680 for once daily administration
219024720|NCT06767683|DRUG|ALKS 2680, 14mg|Oral tablet containing 14 mg of ALKS 2680 for once daily administration
219024721|NCT06767683|DRUG|ALKS 2680, 18mg|Oral tablet containing 18 mg of ALKS 2680 for once daily administration
218876094|NCT03650790|DIAGNOSTIC_TEST|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
219024722|NCT06901349|DRUG|Bimagrumab|Administered SC
219024723|NCT06901349|DRUG|Tirzepatide|Administered SC
219024724|NCT06901349|DRUG|Bimagrumab Placebo|Administered SC
219602733|NCT04795973|BEHAVIORAL|5:2 intermittent fasting|All subjects received 5:2 IF. They followed a normal diet for 5 days each week and practiced IF for 2 days discontinuously. On normal eating days, women consumed 1200 to 1500 kcal/day and men consumed 1500 to 1800 kcal/day, with macro-nutrient distribution of 45% to 50% carbohydrate, 20% protein, and 30% to 35% fat. They consumed 500 kcal and at least 50 g of protein on a light fasting day. Noncaloric beverages like water and unsweetened tea were allowed without restriction. A nutritionist provided diet guidance and documented any discomfort symptoms throughout the study.
218876095|NCT04232436|OTHER|Survival at discharge|Survival at discharge
218876096|NCT04232436|OTHER|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
218876097|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
218876098|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
218876099|NCT00230152|DEVICE|Imaging|
218876100|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
218876101|NCT05850923|OTHER|the soothing music|the soothing music
219024725|NCT06901349|DRUG|Tirzepatide Placebo|Administered SC
219024726|NCT06836752|OTHER|Yoghurt|250 g per day
219024727|NCT06836752|OTHER|Milk|250 g per day
219024728|NCT06746675|DRUG|Healthy Families PrEP Counselling Intervention|Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV. Session 1 focuses on providing information about HIV prevention in the context of reproductive goals (using tools with locally developed images), increasing motivation for behavior change, and developing a safer conception plan (e.g., PrEP uptake, PrEP adherence, couples-based counselling and testing, delaying condomless sex until partner serostatus known and, if living with HIV, virally suppressed). Sessions 2 and 3 (conducted at 1 and 3 months) review the safer conception plan and revise as needed (e.g., changes in readiness to initiate PrEP, partner serostatus knowledge) and engaging in problem-solving barriers (including structural) to plan execution, communication skills training, and motivational strategies for successful plan execution. Participants receive quarterly adherence counseling using tools developed by this team.
219024729|NCT06444048|BIOLOGICAL|EV68-228-N|EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.
219024730|NCT06444048|OTHER|Placebo for EV68-228-N|The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
219024731|NCT06827613|DRUG|STAR0602|solution, intravenous infusion
218876102|NCT01010152|DRUG|Codeine Sulfate|30 mg Tablet
218876103|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
218876104|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
218876105|NCT01432990|DEVICE|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
219024732|NCT06827613|DRUG|Sacituzumab Govitecan (SG)|intravenous infusion, 10mg/kg
219024739|NCT07079111|DEVICE|Formlabs 3D printed occlusal splint|In house 3D printed occlusal splint with Formlabs printer
219024740|NCT07079111|DEVICE|Industry made occlusal splint|Industry made occlusal splint
219024741|NCT06318637|OTHER|Baby Wash/Shampoo|Marketed baby wash/shampoo to be used as needed.
219024742|NCT06318637|OTHER|Daily Activities|Participants to follow their typical daily activities with their baby.
219024743|NCT06318637|OTHER|Body Lotion|Marketed body lotion to be used as needed.
218876106|NCT01432990|OTHER|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
218876107|NCT00002299|DRUG|Interferon beta-1b|
218876108|NCT00002299|DRUG|Ganciclovir|
218876109|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
218876110|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
218876111|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
218876112|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
218876113|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
219024744|NCT03605927|DRUG|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
218876114|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
219024745|NCT03605927|DRUG|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
219495464|NCT05573373|DRUG|Parimparib|The dosage and protocol of the drug were carried out according to the description.
219495465|NCT05573373|DRUG|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
219024746|NCT03605927|DRUG|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
219024747|NCT06680830|DRUG|NEU-411|NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
219024748|NCT06680830|OTHER|Placebo|Orally-administered matched placebo
219024749|NCT07079397|DEVICE|Restylane Injectables|Participants will receive pan-facial treatment in at least one facial area using a Restylane NASHA product and at least one different facial area using Restylane OBT product. Participants will undergo three (3) scheduled MRI scans thoughout the duration of the study post HA injections.
219024750|NCT06859073|DRUG|NNC4004-0002|NNC4004-0002 will be given as a single ascending dose via subcutaneous route.
218876115|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
218876116|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
218876117|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
219024751|NCT06859073|DRUG|Placebo|Placebo matched to NNC4004-0002 will be given via subcutaneous route.
219024752|NCT06791057|BEHAVIORAL|Dyspnea Intervention|Brief behavioral intervention for dyspnea management that includes three nurse-led sessions focused on psychoeducation, behavioral techniques for managing acute breathlessness, and relaxation training for reducing physiological stress as well as a digital health app to reinforce practice of breathing skills.
219024753|NCT06791057|BEHAVIORAL|Enhanced Usual Care|Patients will receive educational materials on the management of symptoms of lung cancer and its treatment as well as any usual care for dyspnea deemed appropriate by the clinical team.
219024754|NCT06752590|DRUG|ONO-1110|ONO-1110 tablets once a day
219024755|NCT06752590|DRUG|Placebo|Placebo tablets once daily
219024756|NCT07083076|OTHER|Short term (10 day) low residue diet restriction|Patients will have an unrestricted diet (as opposed to a low residue diet restriction) 10 days after surgery.
219024757|NCT07083076|OTHER|6 week low residue diet restriction|Patients will be restricted to a low residue diet for 6 weeks after surgery. After this period, their diet will be unrestricted.
219024758|NCT07082270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219024759|NCT07082270|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219495466|NCT05573373|DRUG|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
219495467|NCT00637442|DRUG|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
219495468|NCT01462695|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219495469|NCT01462695|OTHER|Pharmacological Study|Correlative studies
219495470|NCT01462695|DRUG|Sunitinib Malate|Given PO
219495471|NCT02012205|PROCEDURE|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
218876118|NCT05932368|OTHER|evaluation|examining files and taking records
218876119|NCT00016549|BIOLOGICAL|Bevacizumab|
218876120|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
218876121|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
218876122|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
218876123|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
218876124|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
218876125|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
218876126|NCT03936751|DEVICE|CPAP|This is the standard treatment for OSA.
218876127|NCT03936751|DEVICE|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
218876128|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
218876129|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
218876130|NCT03461094|DEVICE|Preload assessment and volume expansion|Fluid therapy perform
219024760|NCT07082270|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219024761|NCT07082270|DRUG|Carfilzomib|Given IV
219024762|NCT07082270|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
219024763|NCT07082270|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
219024764|NCT07082270|DRUG|Dexamethasone|Given PO
219024765|NCT07082270|PROCEDURE|Echocardiography Test|Undergo ECHO
219024766|NCT07082270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219024767|NCT07082270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219024768|NCT07082270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219495472|NCT03355222|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
219495473|NCT04516694|BEHAVIORAL|Financial incentive (gain)|Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
219495474|NCT04516694|BEHAVIORAL|Financial incentive (loss)|Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
219495475|NCT05742061|DRUG|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
219495476|NCT05742061|OTHER|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
219495477|NCT01547637|PROCEDURE|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
219495478|NCT01547637|PROCEDURE|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
219495479|NCT05165017|BIOLOGICAL|AlloRx Stem Cells®|Umbilical cord-derived allogeneic mesenchymal stem cells
219495480|NCT05165017|OTHER|Placebo control|Placebo infusion without mesenchymal stem cells
219495481|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
219495482|NCT00127764|DRUG|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
219495483|NCT00148928|BIOLOGICAL|P501-AS15 vaccine|
219602734|NCT05026177|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
218876131|NCT00488904|DIETARY_SUPPLEMENT|supportan|2 sip feed pr. day
218876132|NCT00488904|DIETARY_SUPPLEMENT|supportan placebo|2 sip feed pr. day
219024769|NCT07082270|OTHER|Questionnaire Administration|Ancillary studies
219024770|NCT07082270|DRUG|Selvigaltin|Given PO
219024771|NCT06903338|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
219024772|NCT06903338|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
219024773|NCT06930560|DEVICE|HEARS-NPS device|Tailored fitting and programming of a personal sound amplifier accompanied by an aural rehabilitation component.
219024774|NCT06930560|BEHAVIORAL|HEARS-NPS program|Tailored aural rehabilitation for participant and care partner.
219024776|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
219024777|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
219024778|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
219040206|NCT01874262|DEVICE|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
219040207|NCT01874262|DEVICE|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
219040208|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
219040209|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
219495484|NCT03886428|OTHER|100% portion size|Entree portion size 100% of baseline
219495485|NCT03886428|OTHER|125% portion size|Entree portion size 125% of baseline
219495486|NCT03886428|OTHER|150% portion size|Entree portion size 150% of baseline
219602735|NCT05026177|DRUG|Placebo|Matching placebo given b.i.d. for 76 weeks
218876133|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
219024779|NCT06930846|BEHAVIORAL|HOBSCOTCH-CA|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-CA is an adaptation of the HOBSCOTCH program for people who are survivors of brain cancer or a brain tumor that incorporates education about the effects from brain cancer/tumor and its treatment on cognition into the education module and gives them the option of enrolling with a Caregiver. CA Participants receive all sessions of HOBSCOTCH-CA. If they enroll with a Caregiver, the Caregiver participates in the education (introductory) session and sessions 1 and 8. The HOBSCOTCH-CA Participant may invite their Caregiver to attend all sessions.
219024780|NCT06880640|BEHAVIORAL|Stress Induction|Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.
219495487|NCT03886428|OTHER|175% portion size|Entree portion size 175% of baseline
219495488|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
219495489|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
219495490|NCT00068237|PROCEDURE|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
219495491|NCT00068237|RADIATION|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
219495492|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
219495493|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
219495494|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
219495495|NCT05728216|OTHER|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
219495496|NCT01358708|DRUG|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
219495497|NCT01358708|DRUG|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
219495498|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
219024781|NCT07085845|OTHER|Inserting a swab 5 cm into the anus during self-sampling|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
219024782|NCT07085845|OTHER|Self-sampling with a swab by inserting the swab 3 cm into the anus.|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
219495499|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid|Ascorbic acid
219495500|NCT03056001|DRUG|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
219495501|NCT03056001|DRUG|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
219495502|NCT01836003|OTHER|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women"
219495503|NCT04162730|OTHER|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
219495504|NCT06542770|DEVICE|Early implant of cardiac monitor|ICM implant 3-4 days after the stroke and prior to discharge. All devices (Abbott Confirm or Jot) were implanted subcutaneously under local anaesthesia in the left chest region and programmed with an specific algorithm for AF detection set at 30 seconds for detection. All patients were included in remote monitoring system (Merlin), which was programmed to send alerts in case of registering episodes qualifying for AF detection, and a monthly routine registration. All ICM recordings were reviewed by a specialized cardiologist.
219495505|NCT06439264|OTHER|bentonite clay gel with hydroxyapatite|bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
219495506|NCT00294632|DRUG|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
219495507|NCT00294632|DRUG|Rituximab|375 mg/m\^2 By Vein Weekly for 4 Weeks
218876134|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
219024783|NCT05069545|DRUG|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
219024784|NCT05069545|DRUG|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
219024785|NCT07089550|RADIATION|PSMA PET/CT scan|All Patients undergoing PSMA PET for pre-treatment disease staging with different radiotracers (\[68Ga\]Ga-PSMA-11, \[18F\]-DCFPyL, \[18F\]-PSMA-1007).
219024786|NCT07088068|DRUG|Teplizumab|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219495508|NCT05959707|BIOLOGICAL|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
219495509|NCT05959707|BIOLOGICAL|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
219495510|NCT05959707|BIOLOGICAL|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
219495511|NCT01162018|PROCEDURE|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
219495512|NCT01162018|OTHER|placebo|
219495513|NCT00492466|DRUG|Interferon-beta-1a|dosage and frequency as per label
219495514|NCT00492466|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
219495515|NCT00363129|DIETARY_SUPPLEMENT|vitamin E|Given orally
219495516|NCT00363129|OTHER|placebo|Given orally
219495517|NCT02162030|BEHAVIORAL|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
219495518|NCT03457337|DRUG|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
219495519|NCT03457337|DRUG|Gefitinib|Gefitinib: 250mg, 1 day, orally
219495520|NCT00344526|DRUG|Melphalan|
219495521|NCT00344526|DRUG|Dexamethasone|
219495522|NCT00344526|PROCEDURE|Autologous stem cell transplantation|
219495523|NCT05584774|PROCEDURE|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
219495524|NCT03707522|BEHAVIORAL|Growth mindset|10 minute interactive article describing neuroplasticity
219024787|NCT07088068|OTHER|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
219024788|NCT01446133|DRUG|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
219024789|NCT01446133|DRUG|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
219024790|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after ENSURE surfactant treatments|Intubating the infant, administering intratracheal surfactant, and then extubating them back to nasal respiratory support (ENSURE method)
219024791|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after LISA surfactant treatments|Delivering surfactant via a thin catheter (5F) directly into the trachea while the infant remains on existing nasal respiratory support, without disconnecting them from it (LISA method)
219040210|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
219495525|NCT03707522|BEHAVIORAL|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
219495526|NCT03707522|BEHAVIORAL|Control|10 minute interactive article describing activity scheduling
219495527|NCT04363736|DRUG|Tociliuzumab|Participants will receive IV TCZ.
219495528|NCT06362304|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
219495529|NCT05980858|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate|Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
219495530|NCT05980858|OTHER|Placebo|Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
219495531|NCT06375837|DEVICE|an alkasite-based restorative material|Cention N
219495532|NCT06375837|DEVICE|hybrid resin composite|Gradia Direct Anterior
219495533|NCT06375837|DEVICE|a highly filled flowable resin composite|G-aenial Universal Flo
219495534|NCT02020655|OTHER|Shear- force model|Shear- force model
219495535|NCT01528046|DRUG|Vincristine|Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
219495536|NCT01528046|DRUG|Irinotecan|Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
219495537|NCT01528046|DRUG|Temozolomide|Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
219495538|NCT01528046|DRUG|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
219602736|NCT04856917|DRUG|Imsidolimab|Humanized Monoclonal Antibody
219602737|NCT04856917|BIOLOGICAL|Placebo|Placebo
218876135|NCT01846650|DRUG|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
218876136|NCT01846650|DRUG|XELODA|Single oral XELODA 2000mg qd
218876137|NCT01805037|DRUG|brentuximab vedotin|Given IV
218876138|NCT01805037|BIOLOGICAL|rituximab|Given IV
218876139|NCT01805037|OTHER|laboratory biomarker analysis|Correlative studies
218876140|NCT00085332|DRUG|docetaxel|
219024792|NCT07095738|DIAGNOSTIC_TEST|thermal images (IT)|The IT images were recorded with an OPTRIS PI 450 IRT camera coupled to Optris PI Connect Software (Germany). The IRT camera has a Noise Equivalent Temperature Difference \<40 mK with 38º x 29º FOV, a wide range of temperature from -20°C to +100°C, spectrum range of 7.5-13 μm, focal plane array sensor size of 382 × 288 pixels, emissivity set at 0.98 and a measurement uncertainty of ± 2% of the overall temperature reading. The size of the capture frame will be 55.4 × 40.63 cm (1.5 mm/px).
219024793|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
219024794|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
219200314|NCT06891976|DRUG|Non-steroidal anti-inflammatory drugs|All the three groups will receive 400mg of Non-steroidal Anti-Inflammatory Drugs (Ibuprofen) once a day on the treatment days two hours before the session.
219200315|NCT06744829|DEVICE|Balloon placement and inflation and removal of the Balloon|STELLA Endogastric ballon will be inserted into the stomach and inflated with sterile saline solution and will remain in place for 6 months. After which the device will be removed
219495539|NCT06110221|OTHER|Periodontal clinical measurements, GCF and saliva sampling|"Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
219495540|NCT04722081|OTHER|physical therapy|physical therapy-specific exercises
219495541|NCT03046147|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
219495542|NCT04528277|DRUG|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
219495543|NCT03797222|DIETARY_SUPPLEMENT|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if \>17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive \<600 IU daily, or for any subjects who prefer liquid medication to capsules.
219495544|NCT05448768|DEVICE|TBS for Amyloid-positive MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
218876141|NCT02562807|DRUG|TAS-303 18mg single-dose|
218876142|NCT02562807|DRUG|Placebo 18mg single-dose|
218876143|NCT02562807|DRUG|TAS-303 9mg single-dose|
218876144|NCT02562807|DRUG|Placebo 9mg single-dose|
218876145|NCT05832749|DEVICE|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
218876146|NCT05832749|DEVICE|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
218876147|NCT03974373|PROCEDURE|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
218876148|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
218876149|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
219495545|NCT05448768|DEVICE|TBS for Amyloid-negative MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
219495546|NCT05590325|DRUG|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
219495547|NCT01548183|BEHAVIORAL|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
219495548|NCT06324214|DIETARY_SUPPLEMENT|Urolithin A (Mitopure)|Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
219495549|NCT06324214|OTHER|Placebo|Placebo.
219495550|NCT04287452|OTHER|Control|Control
219495551|NCT04287452|OTHER|Dog Therapy|Exposure to certified therapy dogs and their handler.
219495552|NCT02889536|OTHER|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
219495553|NCT00261937|DRUG|Inhaled Furosemide vs Placebo (Normal Saline)|
219495554|NCT00712491|DRUG|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
219495555|NCT00712491|DRUG|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
219495556|NCT04084912|DRUG|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
218876150|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
218876151|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
218876152|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
218876153|NCT04409093|PROCEDURE|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
218876154|NCT04409093|PROCEDURE|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
218876155|NCT00935441|BEHAVIORAL|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
218876156|NCT00935441|BEHAVIORAL|usual case management|telephone contact with a case manager
218876157|NCT02964585|DRUG|Canagliflozin|100 mg
218876158|NCT02964585|DRUG|Placebo|1 tablet daily for 16 weeks
218876159|NCT03251950|BEHAVIORAL|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
218876160|NCT03040115|OTHER|Non-Interventional Study|
218876161|NCT02177838|BIOLOGICAL|cetuximab|Given IV
218876162|NCT02177838|DRUG|cisplatin|Given IV
218876163|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
218876164|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
218876165|NCT03517566|DRUG|Placebo|once daily from baseline until week 16
218876166|NCT03517566|DRUG|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
218876167|NCT03517566|DRUG|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
218876168|NCT03517566|DRUG|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
218876169|NCT03517566|DRUG|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
218876170|NCT05172804|BEHAVIORAL|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
218876171|NCT05172804|BEHAVIORAL|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
219024795|NCT07093528|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR)|Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.
219495557|NCT04084912|DRUG|Saline Solution|intravenous injection of one ampoule saline
219024796|NCT07104799|DRUG|Momelotinib|Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles. Dose cohorts (100 mg daily, 150 mg daily, 200 mg daily) will be investigated in the peri-transplant period. Once participants have achieved hematopoietic recovery and are at least Day 21 after HCT, participants will increase the dose to 200 mg daily.
219495558|NCT03567239|DEVICE|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
219495559|NCT06009432|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
219495560|NCT01649245|DRUG|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
219495561|NCT01190826|DRUG|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
218876172|NCT05172804|BEHAVIORAL|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) \[11\]."
219495562|NCT01190826|DRUG|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
218876173|NCT05172804|OTHER|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
218876174|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
218876175|NCT00881465|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
218876176|NCT00881465|BEHAVIORAL|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
218876177|NCT04040621|DRUG|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
218876178|NCT00506168|DRUG|Irinotecan, Capecitabine|
218876179|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
218876180|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
218876181|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
218876182|NCT04777292|DEVICE|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
218876183|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
218876184|NCT01879046|PROCEDURE|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
218876185|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
218876186|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
218876187|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
218876188|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
219495563|NCT01190826|DRUG|Placebo|Placebo administered once by inhalation
218876189|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
218876190|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
219024797|NCT06913608|COMBINATION_PRODUCT|CLBR001 + SWI019|Investigational switchable CAR-T cell therapy for autoimmune disorders
219024798|NCT06913907|DRUG|Methotrexate (MTX)|Single arm study
219024799|NCT07108049|BEHAVIORAL|Let us Grow Together: Economic Wellbeing for Families|Married couples in clusters assigned to the intervention receive a structured program of six community-based sessions. Each session lasts between 2.5 and 3 hours and includes participatory activities, discussions, and exercises. All six sessions would be conducted by the same two facilitators - one male and one female. The content integrates financial literacy (e.g., household budgeting, saving practices, joint financial planning) with gender-transformative training (e.g., equitable household roles, communication skills, conflict resolution, and fostering empathy between spouses). Sessions are delivered by trained facilitators in a group setting with fifteen couples, approximately every 2-4 weeks. Some sensitive content to address economic violence context would be done in a gender segregated manner separately to encourage reflections, ensure safety and reduce defensiveness. Between sessions, SMS reminders and tips are sent to participants' mobile phones to reinforce key messages and e
219024800|NCT06921434|DIETARY_SUPPLEMENT|Monk fruit sweetener mouth rinse|monk fruit mouth rinse 10 grams of sweetener powder and 90 ml of distilled water for 30 participants for 1 minute
219024801|NCT06921434|DIETARY_SUPPLEMENT|Splenda (sucralose) sweetener mouth rinse|10 g of splenda powder with 90 ml of distilled water for 30 participants for 1 minute
219024802|NCT06921434|DIETARY_SUPPLEMENT|Sucrose mouth rinse|10 g of sucrose powder dissolved in 90 ml of distilled water as a positive control group for 30 participants for 1 minute
219024803|NCT06913894|BEHAVIORAL|Supervised Therapy for DRF Rehabilitation|Participants assigned to the Supervised Therapy Group (STG) will receive in-person, supervised rehabilitation sessions in an outpatient clinic. Each session lasts 30-45 minutes and is conducted by a licensed physical therapist. The therapy focuses on progressive range of motion exercises, light strengthening, proprioception training, and functional task practice. In addition, participants are prescribed a daily home exercise program (lasting 10-15 minutes) to reinforce gains made during the clinic sessions. The intervention is provided over a 6-week period following cast removal, with adherence monitored via attendance records and home exercise logs.
219495564|NCT03223285|BEHAVIORAL|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
219495565|NCT03223285|BEHAVIORAL|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
219495566|NCT00924183|OTHER|Treatment-as-usual|
219495567|NCT00725725|BEHAVIORAL|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
219495568|NCT00725725|DRUG|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
219495569|NCT00725725|DRUG|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
219495570|NCT00725725|DRUG|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
218876191|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
218876192|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
218876193|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
218876194|NCT02547168|DEVICE|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
219495571|NCT02614885|DEVICE|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
219495572|NCT01824108|PROCEDURE|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
219495573|NCT01824108|PROCEDURE|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
219495574|NCT01619085|DRUG|Nintedanib|Nintedanib twice a day
218876195|NCT04495725|OTHER|Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products|We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (\>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
218876196|NCT01426776|PROCEDURE|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
218876197|NCT05067738|OTHER|same day discharge|same day discharge
218876198|NCT01288547|DIETARY_SUPPLEMENT|theobromine|700 mg theobromine in gelatin capsules given one time only
218876199|NCT01288547|DIETARY_SUPPLEMENT|Caffeine|120 mg caffeine in capsules given one time only
218876200|NCT01288547|DIETARY_SUPPLEMENT|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
218876201|NCT01288547|DIETARY_SUPPLEMENT|placebo|cellulose in capsules given one time only
218876202|NCT01496755|DRUG|Placebo|Single/multiple doses
218876203|NCT01496755|DRUG|RG7667|Single/multiple ascending doses
218876204|NCT00169091|DRUG|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
218876205|NCT00169091|DRUG|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
218876206|NCT05673525|DEVICE|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
218876207|NCT05808413|BEHAVIORAL|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
218876208|NCT05808413|BEHAVIORAL|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
218876209|NCT05808413|BEHAVIORAL|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
219495575|NCT01672307|DRUG|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
219495576|NCT01672307|DRUG|Placebo|Placebo is applied twice daily to the other eyebrow.
219495577|NCT01887860|OTHER|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
219495578|NCT05100394|RADIATION|Laser Therapy|Therapeutic laser therapy was applied.
219495579|NCT05100394|OTHER|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
219495580|NCT03233373|DEVICE|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
219495581|NCT03994419|PROCEDURE|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
219495582|NCT06537635|DEVICE|Cubii seated compact elliptical trainer|The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
218876210|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
219024804|NCT06913894|BEHAVIORAL|Home-Based Rehabilitation Program for DRF|Participants assigned to the Home-Based Program Group (HBG) will follow a standardized, detailed home exercise program specifically designed for distal radius fracture rehabilitation. The program includes instructions for range of motion, strengthening, and functional tasks similar to the supervised protocol. Participants receive a comprehensive written and online exercise manual, and they are instructed to perform the exercises daily. In addition, they will have weekly telephone or video check-ins (approximately 10 minutes per call) with a research assistant to review progress, address questions, and ensure proper exercise technique. The home program is implemented over a 6-week period following cast removal, with adherence documented via exercise logs submitted by participants.
219495583|NCT05735782|DIAGNOSTIC_TEST|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
219495584|NCT05735782|DIAGNOSTIC_TEST|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
219495585|NCT06588413|DRUG|Olanzapine|Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
219495586|NCT06585943|BEHAVIORAL|Forced Rate Exercise + Rehab|The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
218876211|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
218876212|NCT00671437|PROCEDURE|FDG-PET/CT|
218876213|NCT00671437|DRUG|Cetuximab|
218876214|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
218876215|NCT01722656|DRUG|Aflibercept|
218876216|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
218876217|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
218876218|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
218876219|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
219024805|NCT06913894|BEHAVIORAL|Minimal Educational Intervention for DRF|"Participants assigned to the No Therapy Group (NTG) will receive a minimal intervention consisting solely of general educational material. At the time of cast removal, they will be provided with a simple, standardized educational brochure that contains basic instructions for wrist and hand movement (e.g., move your wrist as tolerated). No additional therapy sessions, home exercise logs, or follow-up telephone calls will be provided beyond routine care. This intervention is intended to reflect the absence of a formal rehabilitation program and serves as the control for evaluating the added benefit of supervised and home-based therapy."
219024806|NCT06916741|DIAGNOSTIC_TEST|Ultrasound with Sacral lift|Intervention includes using a sacral lift during ultrasound to collect femoral vein measurements.
219204502|NCT04546230|PROCEDURE|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure."
219495587|NCT06585943|BEHAVIORAL|Rehabilitation|The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
218876220|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
218876221|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
218876222|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
218876223|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
218876224|NCT03104257|DRUG|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
219024807|NCT06949072|DRUG|Test Dentifrice|Dentifrice containing 5 percent (%) weight by weight (w/w) Potassium nitrate (KNO3) and 1150ppm fluoride as sodium fluoride.
219024808|NCT06949072|DRUG|Reference Dentifrice|Dentifrice containing 1100ppm fluoride as stannous fluoride.
219024809|NCT06949072|DRUG|Negative Control Dentifrice|Dentifrice containing 5% KNO3 with no fluoride.
219024810|NCT04519580|DIAGNOSTIC_TEST|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
219024811|NCT07178366|OTHER|Standard medical therapy (SMT)|Standard medical therapy includes nutritional support (25-30 kcal/kg/day), lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.
219024812|NCT07178366|DEVICE|Double Plasma Molecular Adsorption System (DPMAS)|DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.
219024813|NCT07177313|PROCEDURE|Ureteroscopy|patients presenting with acute ureteral obstruction who undergo primary ureteroscopy (URS).
219495588|NCT02336698|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
219495589|NCT02336698|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
219495590|NCT02336698|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
219495591|NCT02582801|DRUG|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
219495592|NCT00990093|DEVICE|test intermittent catheter|CH 12 hydrophilic coated catheter
218876225|NCT00209794|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
218876226|NCT00756210|OTHER|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
218876227|NCT01943240|DRUG|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
218876228|NCT01943240|DRUG|10 cc of 0.375% ropivacaine pectoral nerve block|
218876229|NCT04505579|DEVICE|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
218876230|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
218876231|NCT00002580|DRUG|cyclophosphamide|
218876232|NCT00002580|DRUG|fluorouracil|
218876233|NCT00002580|DRUG|goserelin acetate|
218876234|NCT00002580|DRUG|leuprolide acetate|
218876235|NCT00002580|DRUG|methotrexate|
218876236|NCT00002580|DRUG|tamoxifen citrate|
218876237|NCT00002580|PROCEDURE|conventional surgery|
218876238|NCT00002580|PROCEDURE|laparoscopic surgery|
218876239|NCT00002580|PROCEDURE|oophorectomy|
218876240|NCT00002580|RADIATION|radiation therapy|
218876241|NCT06349668|DRUG|spinal analgesia with morphine and bupivacaine|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
218876242|NCT06349668|DRUG|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
218876243|NCT00188006|DEVICE|heparin-coated cardiopulmonary bypass|
218876244|NCT04194073|DEVICE|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
219024814|NCT07181135|DRUG|Finerenone (BAY 94-8862)|Finerenone 10 or 20mg in participants with chronic kidney disease not using renin-angiotensin-system inhibitors
219024815|NCT07181135|DRUG|Placebo|Placebo matching finerenone
219024816|NCT07179978|DRUG|Lorazepam|The primary exposure of interest will be oral lorazepam at a dose range of \>1-4 mg/day.
219495593|NCT00990093|DEVICE|Intermittent catheterization|CH 12 hydrophilic catheter
218876245|NCT02528682|BIOLOGICAL|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
218876246|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
218876247|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
218876248|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
218876249|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
218876250|NCT04678791|DRUG|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
218876251|NCT04678791|DRUG|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
218876252|NCT04678791|RADIATION|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
218876253|NCT04678791|RADIATION|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
218876254|NCT02128074|DRUG|KRX-0502|1g tablets of KRX-0502
219024817|NCT07184164|BEHAVIORAL|Educational Program by Using Behavior Change Wheel Model|"The BCW model includes three layers: the behavior system, intervention functions, and policy categories, with the last not being applied in this study. The research was structured into four phases: assessment, planning, implementation, and evaluation.~Phases of the Study Assessment Phase: Researchers introduced themselves to parents and adolescents through personal interviews, explaining the study's significance. They collected demographic data in the forensic and toxicology department, using various tools to assess adolescents' behaviors before the educational program.~Planning Phase: A tailored BCW model encompassed a wide range of educational interventions. The content"
219024818|NCT07184164|BEHAVIORAL|Routine Health Education|Participants in the control group received the routine health education and advice from nurses and healthcare providers working in the study settings
219495594|NCT02218515|PROCEDURE|Open Flap Debridement|Open Flap Debridement (Control Group)
219495595|NCT02218515|BIOLOGICAL|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
219495596|NCT02218515|BIOLOGICAL|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
219495597|NCT04196088|DEVICE|Ultivision Artificial Intelligence Software|Screening Colonoscopy
219495598|NCT04196088|DEVICE|No Artificial Intelligence Software enhancement|Screening Colonoscopy
219495599|NCT03820778|DIAGNOSTIC_TEST|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
218876255|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
219495600|NCT04556838|DRUG|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
219495601|NCT04556838|DRUG|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
219495602|NCT04556838|DRUG|Vehicle|VVN001 Ophthalmic Solution Vehicle
218876256|NCT00293020|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
218876257|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
218876258|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
218876259|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
218876260|NCT05254873|OTHER|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
218876261|NCT05314959|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
218876262|NCT05314959|OTHER|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
218876263|NCT01147848|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
218876264|NCT01147848|DRUG|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
218876265|NCT01147848|DRUG|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
218876266|NCT01147848|DRUG|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
218876267|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
218876268|NCT04538079|DEVICE|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
218876269|NCT03599479|DEVICE|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
218876270|NCT03180307|DRUG|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
218876271|NCT03180307|DEVICE|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
218876272|NCT03180307|PROCEDURE|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
218876273|NCT01057563|DEVICE|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
218876274|NCT01057563|DEVICE|bare-metal stent (BMS)|BMS implantation
218876275|NCT01057563|DEVICE|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
219024819|NCT07183813|DEVICE|Electroacupuncture group|The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance. The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA). Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
219024820|NCT07183813|DEVICE|Sham electroacupuncture|The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad till reaching but without penetrating the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effects of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral An Mian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 3-5 seconds, the electric current will be turned down. Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
219040211|NCT05037838|PROCEDURE|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
219040212|NCT03621878|OTHER|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
219495603|NCT05285631|DEVICE|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
218876276|NCT01005927|DIETARY_SUPPLEMENT|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
218876277|NCT00997360|DRUG|PKI-179|
218876278|NCT04279665|DEVICE|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
219024821|NCT07181226|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency rTMS was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule to localize the target site. Stimulation intensity was set at 100% of the resting motor threshold, determined by visible motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 1500 pulses at 10 Hz, organized into 10 trains of 15 seconds (150 pulses per train) with 50-second inter-train intervals. Total stimulation time per session was approximately 12.5 minutes. A figure-of-eight coil (70BFX-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with the coil positioned at \~45° from the midline, handle pointing posterolaterally.
219024822|NCT07181226|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta-burst stimulation (iTBS) was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule for target localization. Stimulation intensity was set at 100% of the resting motor threshold, determined by motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 600 pulses delivered in bursts of three 50 Hz pulses repeated every 200 ms. Trains of 2 seconds were followed by 8-second inter-train intervals. Total stimulation time per session was approximately 3 minutes and 20 seconds. A figure-of-eight coil (70HF-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with coil orientation \~45° from the midline, handle pointing posterolaterally.
219024823|NCT07181655|OTHER|Modified Intermittent Fasting|Participants in Intervention group will follow a structured intermittent fasting protocol, specifically the 16:8 method, where they fast for 16 consecutive hours each day and restrict their eating to an 8-hour window. The fasting period can be personalized to suit individual schedules. During these fasting hours, participants must abstain from all foods and caloric drinks, but are encouraged to stay hydrated with non-caloric beverages and they will follow a structured, calorie-restricted diet, tailored to them, using a developed Food Frequency Questionnaire tool to select their daily calorie intake across sections to identify appropriate foods and beverages for patients with metabolic conditions. They will be prescribed to engage in at least 150 minutes per week of moderate intensity aerobic activities, such as brisk walking will be measured and evaluated using the mobile application of physical activity recommended by the Ministry of Health in Saudi Arabia.
219024824|NCT07184398|OTHER|Intervention with Consolidated Cysteine (Immunocal) 20 g per day|CRWPI Immunocal® (Immunotec™) was administered at a dose of 20 grams (2 sachets once daily) for 12 consecutive weeks. The research team delivered Immunocal directly to the subjects and instructed them on how to mix and self-administer it.
219024825|NCT07184398|BEHAVIORAL|Cognitive rehabilitation workshops|Neuropsychological rehabilitation consisted of in-person group sessions for 40 adults (18 years or older) to work on cognitive functions such as memory and attention. Each session lasted 45 minutes. These sessions were held three times a week for a period of 12 weeks.
219024826|NCT07190508|OTHER|No Intervention (Observational)|Participants undergo routine diagnostic upper gastrointestinal endoscopy with standard institutional care. No additional intervention is applied beyond usual clinical practice.
219024827|NCT07190976|OTHER|Routine EEG|The study is observational. No intervention is anticipated. Patients will be submitted to EEG recording within the first seven days of stroke
219024828|NCT07190976|OTHER|Routine EEG|The study is observational
219024829|NCT07190521|OTHER|hypnobreastfeeding education|"Hypnobreastfeeding education is an antenatal training method that combines:~Hypnotherapy principles~Guided imagery~Affirmations~Breathing and deep relaxation techniques"
219495604|NCT02680730|BEHAVIORAL|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
219024830|NCT07190521|OTHER|Traditional prenatal education|"Traditional prenatal education programs, often referred to as antenatal or maternity school classes, are structured group sessions provided to pregnant women, typically in clinical or community settings. These classes aim to:~Prepare expectant mothers for labor, birth, and postpartum care,~Provide evidence-based information about breastfeeding, newborn care, and maternal recovery,~Promote positive health behaviors during pregnancy,~Reduce fear and anxiety by increasing knowledge and confidence."
219040213|NCT03621878|OTHER|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
219495605|NCT03760965|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
218876279|NCT01150968|BEHAVIORAL|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
218876280|NCT00642317|BEHAVIORAL|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
219495606|NCT03760965|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
218876281|NCT01181258|DRUG|Rituximab|375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
218876282|NCT01181258|BIOLOGICAL|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
218876283|NCT01181258|BIOLOGICAL|Natural killer cells|administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
218876284|NCT01181258|DRUG|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
218876285|NCT01181258|DRUG|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
219024831|NCT07185087|DEVICE|passive self-ligating, Damon Ultima brackets|Patients will receive Damon Ultima self-ligating brackets (Ormco Corp., Glendora, California, USA) bonded from the second molar to the second molar in each arch. Archwires will follow a standardized sequence: 0.014-inch CuNiTi, 0.018-inch CuNiTi, and 0.014 × 0.0275-inch CuNiTi (Ormco Corp., Glendora, California, USA). All bonding procedures will follow a standardized protocol, including enamel cleaning, acid etching, primer application (Ortho Solo), and adhesive curing (Green Glow).
219024832|NCT07185087|DEVICE|Conventional ligation, MBT brackets|Patients will receive MBT Mini Diamond brackets (Ormco Corp., Glendora, California, USA) bonded in the same manner, with the same archwire sequence.
219024833|NCT07190859|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
219024834|NCT07190859|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
218876286|NCT01181258|DRUG|Fludarabine|25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
218876287|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
218876288|NCT05602077|DEVICE|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
218876289|NCT04496011|OTHER|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
219024835|NCT07191197|OTHER|MRI|structural and functional resting state MRI
219495607|NCT00995930|DRUG|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
218876290|NCT01202058|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
218876291|NCT01202058|DEVICE|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
218876292|NCT03271905|DRUG|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
218876293|NCT03271905|DEVICE|Mesh nebulization|Nebulization with Mesh device.
218876294|NCT00898456|GENETIC|gene expression analysis|
218876295|NCT00898456|GENETIC|molecular genetic technique|
218876296|NCT00898456|GENETIC|polymorphism analysis|
218876297|NCT00898456|GENETIC|protein expression analysis|
219024836|NCT07191197|OTHER|Psychometric|2 cognitive research tasks of semantic learning and neuropsychological assessment
219040214|NCT03621878|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
219040215|NCT01262014|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
219040216|NCT02595853|OTHER|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
219040217|NCT06495918|DRUG|OTX-TKI|Intravitreal Injection of OTX-TKI
219040218|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 2mg of aflibercept
219040219|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 8mg of aflibercept
219495608|NCT00995930|DRUG|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
219495609|NCT03912350|DRUG|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
219495610|NCT06611475|OTHER|MMSE ≤26|A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
219495611|NCT03327142|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
219495612|NCT06114810|BIOLOGICAL|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
219495613|NCT06442826|OTHER|Non-invasive auricular stimulation|"Single session TniAS stimulation will be achieved by applying four stimulation patches. These patches consist of stainless steel spheres with a diameter of 1.2 mm, covered with adhesive circular paper measuring 8 mm in diameter.~Point 1. Located in the Triangular Fossa, upper and central level at the vertex of the Fossa, at junction between the upper root and the lower root of the Antihelix.~Point 2. Located in the inner part of the Cymba (upper) conchae, in the angle formed by the lower root of the antihelix and the ascending branch of the Helix.~Point 3. Located in the middle depression of the Cavum (lower) conchae.~Poinit 4. It is located at the inner superior quadrant of Lobe, below the external curve of the Intertragus notch, in a depression 3-4 mm from the insertion of the lobe to the face."
219495614|NCT06442826|OTHER|Sham auricular stimulation (SAS)|"Sham intervention will be conducted following the exact same procedure as the TniAS group, with the only difference being the use of sham stimulation patches. These sham patches will consist of the same patches utilized in the TniAS group, except for the absence of the stainless steel spheres. During the application of these sham patches, the investigator will adhere to the identical process as in the TniAS group, with the exception that no palpation will be performed to locate the exact points, and only minimal pressure required for patch adherence will be applied to minimize any substantial stimulation. Participants in the SAS group will also be explicitly instructed not to stimulate the points until the removal of the patches.~The removal of the sham stimulation patches will follow the precise protocol applied in the TniAS group, ensuring consistency in the study procedures across both groups."
218876298|NCT00898456|OTHER|diagnostic laboratory biomarker analysis|
218876299|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
218876300|NCT04958226|DRUG|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
218876301|NCT04958226|DRUG|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
218876302|NCT02481609|DRUG|N-acetyl cysteine (NAC)|
218876303|NCT02758327|DRUG|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
218876304|NCT00001410|DRUG|Lysodase|
218876305|NCT05481047|DEVICE|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
218876306|NCT01143584|DRUG|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
218876307|NCT01143584|DRUG|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
219024837|NCT07189754|DIETARY_SUPPLEMENT|Sabroxy™ (Oroxylum indicum extract)|Sabroxy™ is a standardized extract derived from the bark of Oroxylum indicum. In this study, participants will receive Sabroxy™ in capsule form. Each capsule contains a fixed dose of the extract and will be administered orally at a regimen of one capsule twice daily after meals for 12 weeks. The supplement is provided in visually identical containers to maintain blinding and is compared to a placebo control. The intervention is designed to evaluate potential improvements in cognitive function, including memory, attention, and executive performance, as well as effects on circulating Brain-Derived Neurotrophic Factor (BDNF) levels.
219024838|NCT07189754|OTHER|Placebo|The placebo is an inert capsule formulated to be visually identical to the Sabroxy™ capsules in size, shape, color, and packaging. It contains inactive ingredients only, with no active botanical extract. The placebo will be administered orally at the same regimen as the active intervention: one capsule taken twice daily after meals for 12 weeks. The use of a placebo ensures blinding of participants and study staff, allowing accurate comparison of cognitive and biomarker outcomes between groups.
219495615|NCT05381883|OTHER|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
219495616|NCT01458119|DRUG|migalastat hydrochloride|Oral capsule QOD
219495617|NCT05969782|DEVICE|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
218876308|NCT03310385|DRUG|GHX02|Herbal medicine originating from gualouhengryunhwan
218876309|NCT03310385|DRUG|Placebo|Placebo tablets
218876310|NCT02474407|DRUG|diazepam nasal spray|
218876311|NCT02474407|DRUG|diazepam rectal gel|
219495618|NCT01667965|BEHAVIORAL|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
219495619|NCT05003167|DEVICE|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
219495620|NCT01116765|OTHER|no stimulation of the oral structure|
218876312|NCT04894890|DRUG|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
218876313|NCT00988364|DRUG|Simvastatin|Simvastatin 20mg daily for 3 months.
218876314|NCT00988364|DRUG|Vytorin|Vytorin 20/10mg daily for 3 months.
219495621|NCT01116765|OTHER|stimulation of the oral structure|
219495622|NCT03078530|DRUG|Placebo|This is a pill with inactive ingredients
219495623|NCT03078530|DRUG|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
219602738|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
219024839|NCT07191340|DEVICE|Vagus nerve stimulator|Vagus nerve stimulator placed on neck and activated
219024840|NCT07191340|DEVICE|Placebo comparator sham|Vagus nerve stimulator placed on neck and not activated
219024841|NCT07189780|PROCEDURE|Surgical approach|"Control Group:Incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection to enter the dissection plane.~Experimental Group:Incising the peritoneum precisely at the lowest point of the peritoneal reflection (in the rectovesical or rectouterine pouch) to enter the dissection plane."
219024842|NCT07190781|DEVICE|Flow-Diverting Dense-Mesh Stent|Surface-Modified Flow-Diverting Dense-Mesh Stent for Mid-Term Follow-Up Study of Endovascular Embolization Therapy for Cerebral Aneurysms
219040220|NCT02388984|DRUG|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
219040221|NCT02388984|DRUG|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
219495624|NCT03078530|DRUG|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
219040222|NCT04734496|OTHER|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
219495625|NCT02367781|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
219495626|NCT02367781|DRUG|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
219495627|NCT02367781|DRUG|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
219495628|NCT02367781|DRUG|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
219495629|NCT02517099|DRUG|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
219495630|NCT02517099|DRUG|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
219495631|NCT02517099|DRUG|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
219495632|NCT03779685|PROCEDURE|General anesthesia|Sevoflurane and morphine
219495633|NCT03779685|PROCEDURE|Regional anesthesia|Paravertebral block
219495634|NCT01676259|DRUG|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
219495635|NCT01676259|DRUG|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
219495636|NCT01676259|DRUG|Folfirinox|Folfirinox or modified Folfirinox
219495637|NCT05725707|BEHAVIORAL|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
219495638|NCT06177509|OTHER|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
219495639|NCT04667273|PROCEDURE|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
219495640|NCT04667273|PROCEDURE|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
219602739|NCT03793179|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602740|NCT03793179|DRUG|Carboplatin|Given IV
219602741|NCT03793179|PROCEDURE|Computed Tomography|Undergo CT scan
219602742|NCT03793179|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219495641|NCT06248073|BEHAVIORAL|on-line self-management training|To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
219495642|NCT06248073|BEHAVIORAL|onsite task-related training|Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
219495643|NCT00955188|OTHER|computer-assisted intervention|
219495644|NCT00955188|OTHER|educational intervention|
219495645|NCT00955188|OTHER|medical chart review|
219495646|NCT06177041|DRUG|M108 monoclonal antibody|M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
219495647|NCT06177041|DRUG|Placebo|Placebo will be administered as a minimum 2-hour IV infusion.
219495648|NCT06177041|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
219602743|NCT03793179|BIOLOGICAL|Pembrolizumab|Given IV
219602744|NCT03793179|DRUG|Pemetrexed|Given IV
218876315|NCT00988364|DRUG|Placebo|Placebo one tablet daily times 3 months.
218876316|NCT00988364|DRUG|Ezetimibe|Ezetimibe 10mg daily for 3 months.
218876317|NCT05477797|DRUG|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
218876318|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
219495649|NCT06177041|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
218876319|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
218876320|NCT05894447|DRUG|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
219495650|NCT04454957|BEHAVIORAL|Mastering Diabetes|Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
219495651|NCT04626557|PROCEDURE|biopsy|biopsy of the endometrium
219495652|NCT01133392|DRUG|Insulin lispro A|20 units (U) subcutaneously (SC).
219495653|NCT01133392|DRUG|Insulin lispro B|20 U subcutaneously (SC).
219495654|NCT02953132|DRUG|MT-4129|
219495655|NCT02953132|DRUG|Placebo|
219602745|NCT03793179|PROCEDURE|Positron Emission Tomography|Undergo PET scan
218876321|NCT05894447|DRUG|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
219200316|NCT06740695|BEHAVIORAL|Education group|"The training materials were prepared in line with the researchers and expert opinions were obtained. Trainings will be given for two weeks. After the trainings are completed, reminder information will be sent to the pregnant women via text messages every other day to inform them that the trainings are continuing. Reminder information prepared as text messages will be sent to the pregnant women's mobile phones. 4 weeks after the first training, the same training will be reminded again via WhatsApp as a summary training by emphasizing key points.~The trainings will be carried out by an expert researcher in the field. In the training content prepared in line with WhatsApp, the risks that may be seen during pregnancy and Gestational Diabetes Mellitus;~* Sensitivity perception and Seriousness perception, perceived risks that may be seen during pregnancy~* Health motivation perception, the pregnant woman's beliefs and practices regarding being healthy,~* Benefit perception, pregnancy follow"
219200317|NCT01651000|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
218876322|NCT05894447|DRUG|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
219495656|NCT04765189|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
219495657|NCT04765189|DIETARY_SUPPLEMENT|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
219602746|NCT03737981|DRUG|Ibrutinib|Given PO
219602747|NCT03737981|BIOLOGICAL|Obinutuzumab|Given IV
219602748|NCT03737981|OTHER|Observation Activity|Undergo observation
219602749|NCT03737981|DRUG|Venetoclax|Given PO
219602750|NCT06540222|PROCEDURE|Sustained cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
218876323|NCT02185066|DRUG|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
219602751|NCT06540222|PROCEDURE|Routine (< 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
219602752|NCT01169337|OTHER|Clinical Observation|Undergo observation
219602753|NCT01169337|DRUG|Lenalidomide|Given PO
219602754|NCT01169337|OTHER|Quality-of-Life Assessment|Ancillary studies
219602755|NCT03560037|DEVICE|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
219602756|NCT06556563|DEVICE|Optune® device|Optune® device delivering TTFields therapy at 200 kHz.
219602757|NCT06556563|DRUG|Temozolomide|Temozolomide per approved labeling.
219602758|NCT06556563|DRUG|Pembrolizumab|Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
219200318|NCT01651000|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
219495658|NCT04765189|DIETARY_SUPPLEMENT|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
219495659|NCT04765189|DIETARY_SUPPLEMENT|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
219495660|NCT01031134|BEHAVIORAL|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
219495661|NCT01031134|OTHER|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
219495662|NCT06697977|DIETARY_SUPPLEMENT|phytosterols|2 grams of phytosterols given as 7 pills per day
219495663|NCT06697977|DIETARY_SUPPLEMENT|placebo|placebo 7 pills per day
219495664|NCT06696313|DEVICE|Insignia|"* Insignia hip stem~* Trident hemispherical shell~* X3 polyethylene liner~* Metal or ceramic head"
218876324|NCT02185066|DRUG|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
218876325|NCT00007358|DRUG|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
219200319|NCT06739967|BEHAVIORAL|Behavioral Treatment|"The SLT intervention will be entirely administered online through a web-based platform. While each of the treatments will engage semantics, phonology, and orthography, the protocols will be tailored relative to the characteristics of each PPA variant. Patients with svPPA and lvPPA will undergo a lexical retrieval training (LRT) intervention implemented using a training cascade.~Patients with nfvPPA will undergo Video-implemented Script Training (VISTA), a choral reading approach training accurate production of functional scripts. The method is based on that implemented in American-English individuals with PPA and aims at improving grammar and motor aspects of speech production by taking advantage of repetitive practice and automaticity."
219495665|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
219495666|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
219495667|NCT06702345|OTHER|encapsulated 10^4 CFU toxigenic. C. difficile spores|12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.
219495668|NCT06702345|DRUG|Vancomycin|oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
219495669|NCT06702345|DRUG|Clindamycin|oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
219495670|NCT06700837|OTHER|Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea|To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
219495671|NCT06697821|PROCEDURE|D2＋CME|Whether to perform the whole mesogastric excision
219495672|NCT06700772|PROCEDURE|mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone|open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .
219495673|NCT06700772|PROCEDURE|mixing autogenous bone with bovine bone|open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
219602759|NCT06556563|DRUG|Placebo|Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
219602760|NCT03463317|DEVICE|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
219602761|NCT03463317|DRUG|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
219602762|NCT03463317|DRUG|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
219602763|NCT03463317|DRUG|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
218876326|NCT00742417|BIOLOGICAL|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"
218876327|NCT00742417|OTHER|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
219602764|NCT03463317|DRUG|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
219024843|NCT07189676|BEHAVIORAL|Dietary advice (PHD)|It consists of a written document outlining the PHD diet recommendations. Participants will receive: 1) information about the PHD guidelines by EAT-Lancet (a high-quality plant-based diet with a low allowance of intake of eggs, dairy, chicken, and fish, but strictly avoiding red and processed meat) adapted to be nutritionally adequate and culturally accepted in Denmark, 2) a meal planner for their calorie demands (templates for 2000 kcal/day; 2500 kcal/day; and 3000 kcal/day), 3) guidance on alternatives for substituting meat when cooking at home or eating out, and 4) information on seasonal fruits and vegetables. The meal planner will specify the amounts of eggs, dairy, chicken, and fish that each participant should consume based on their total energy demands. The PHD dietary advice focuses on limiting certain food groups (without excluding them) based on their health and environmental impact.
219024844|NCT07189676|BEHAVIORAL|Dietary advice (Ovo-lacto-vegetarian diet)|It consists of a written document outlining the ovo-lacto-vegetarian diet guidelines. Participants will receive information to adhere to a stricter plant-based diet with an intake of eggs and dairy, but avoiding chicken, fish, and red and processed meat, and guidance on alternatives for substituting meat when cooking at home or eating out. Recommendations on food quantity or on consuming local and seasonal foods will not be given to pinpoint differences in the environmental aspect between interventions.
218876328|NCT03833466|DRUG|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
218876329|NCT04373005|DIAGNOSTIC_TEST|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
218876330|NCT03833219|BEHAVIORAL|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
218876331|NCT03833219|BEHAVIORAL|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
218876332|NCT03833219|BEHAVIORAL|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
218876333|NCT03956212|DRUG|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
218876334|NCT03956212|DRUG|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
218876335|NCT05706441|OTHER|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
218876336|NCT02470481|OTHER|No Intervention|This is an obervational study
218876337|NCT05873972|DRUG|Cetuximab|"AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0"
218876338|NCT03775512|DEVICE|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
218876339|NCT02277925|OTHER|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
219024845|NCT07189676|BEHAVIORAL|Dietary advice (control)|It consists of a written document outlining the general recommendations of a healthy diet (i.e. consumption of fruits and vegetables, decreasing the intake of sugar-sweetened beverages, etc.) without any specific advice on the consumption of animal products.
219024846|NCT07189676|BEHAVIORAL|Behavioural support PHD|This component is designed to help participants adhere to the PHD through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type and by season.
218876340|NCT02277925|OTHER|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
219200320|NCT06738550|DIETARY_SUPPLEMENT|inulin|In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided
218876341|NCT00746434|DRUG|Roflumilast cream|Roflumilast cream 0.5%
218876342|NCT00746434|DRUG|Placebo cream|Placebo cream
218876343|NCT01378325|DRUG|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
219602765|NCT03463317|DRUG|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
219602766|NCT03463317|DRUG|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
218876344|NCT01378325|DRUG|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
218876345|NCT01712425|BIOLOGICAL|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
218876346|NCT01712425|BIOLOGICAL|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
218876347|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
218876348|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
218876349|NCT03587441|DRUG|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
218876350|NCT03587441|DRUG|Dextrose 5% in water|intrathecal
218876351|NCT04807335|DRUG|CT001|nasal spray
219200321|NCT06738550|DRUG|Lactulose oral solution|In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
219200322|NCT06739317|RADIATION|Radiation|Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
219200323|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
218876352|NCT04807335|DRUG|Ketamine|iv single dose
218876353|NCT04807335|DRUG|sufentanil|iv single dose
218876354|NCT02374567|DRUG|Phenobarbital|
218876355|NCT02374567|DRUG|Phenytoin|
218876356|NCT02374567|DRUG|Carbamazepine|
218876357|NCT02374567|DRUG|Oxcarbazepine|
218876358|NCT02374567|DRUG|Valproic Acid|
218876359|NCT02374567|DRUG|Lamotrigine|
218876360|NCT02374567|DRUG|Topiramate|
218876361|NCT02374567|DRUG|Gabapentin|
218876362|NCT02374567|DRUG|Levetiracetam|
218876363|NCT02374567|DRUG|Pregabalin|
218876364|NCT02374567|DRUG|Lacosamide|
218876365|NCT02374567|DRUG|Clonazepam|
218876366|NCT02374567|DRUG|Biperiden|
218876367|NCT02374567|DRUG|Levomepromazine|
218876368|NCT02374567|DRUG|Fluphenazine|
218876369|NCT02374567|DRUG|Perphenazine|
218876370|NCT02374567|DRUG|Perazine|
218876371|NCT02374567|DRUG|Thioridazine|
218876372|NCT02374567|DRUG|Haloperidol|
218876373|NCT02374567|DRUG|Melperone|
218876374|NCT02374567|DRUG|Pipamperone|
218876375|NCT02374567|DRUG|Bromperidol|
219200324|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
219495674|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers."
219495675|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
218876376|NCT02374567|DRUG|Benperidol|
218876377|NCT02374567|DRUG|Sertindole|
218876378|NCT02374567|DRUG|Ziprasidone|
218876379|NCT02374567|DRUG|Flupentixol|
219602767|NCT03463317|DRUG|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
219602768|NCT03463317|DRUG|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
218876380|NCT02374567|DRUG|Chlorprothixene|
218876381|NCT02374567|DRUG|Zuclopenthixol|
218876382|NCT02374567|DRUG|Fluspirilene|
218876383|NCT02374567|DRUG|Pimozide|
218876384|NCT02374567|DRUG|Clozapine|
218876385|NCT02374567|DRUG|Olanzapine|
218876386|NCT02374567|DRUG|Quetiapine|
218876387|NCT02374567|DRUG|Sulpiride|
218876388|NCT02374567|DRUG|Tiapride|
218876389|NCT02374567|DRUG|Amisulpride|
218876390|NCT02374567|DRUG|Prothipendyl|
218876391|NCT02374567|DRUG|Risperidone|
218876392|NCT02374567|DRUG|Aripiprazole|
218876393|NCT02374567|DRUG|Paliperidone|
218876394|NCT02374567|DRUG|Diazepam|
218876395|NCT02374567|DRUG|Oxazepam|
218876396|NCT02374567|DRUG|Lorazepam|
218876397|NCT02374567|DRUG|Bromazepam|
218876398|NCT02374567|DRUG|Clobazam|
218876399|NCT02374567|DRUG|Alprazolam|
218876400|NCT02374567|DRUG|Hydroxyzine|
218876401|NCT02374567|DRUG|Buspirone|
218876402|NCT02374567|DRUG|Chloral Hydrate|
218876403|NCT02374567|DRUG|Flurazepam|
218876404|NCT02374567|DRUG|Nitrazepam|
218876405|NCT02374567|DRUG|Triazolam|
218876406|NCT02374567|DRUG|Lormetazepam|
218876407|NCT02374567|DRUG|Temazepam|
218876408|NCT02374567|DRUG|Midazolam|
218876409|NCT02374567|DRUG|Brotizolam|
218876410|NCT02374567|DRUG|Zopiclone|
218876411|NCT02374567|DRUG|Zolpidem|
218876412|NCT02374567|DRUG|Zaleplon|
218876413|NCT02374567|DRUG|Melatonin|
218876414|NCT02374567|DRUG|Clomethiazole|
218876415|NCT02374567|DRUG|Diphenhydramine|
218876416|NCT02374567|DRUG|Promethazine|
218876417|NCT02374567|DRUG|Imipramine|
218876418|NCT02374567|DRUG|Clomipramine|
218876419|NCT02374567|DRUG|Opipramol|
218876420|NCT02374567|DRUG|Trimipramine|
218876421|NCT02374567|DRUG|Amitriptyline|
218876422|NCT02374567|DRUG|Nortriptyline|
218876423|NCT02374567|DRUG|Doxepin|
218876424|NCT02374567|DRUG|Maprotiline|
218876425|NCT02374567|DRUG|Amitriptyline oxide|
218876426|NCT02374567|DRUG|Fluoxetine|
218876427|NCT02374567|DRUG|Citalopram|
218876428|NCT02374567|DRUG|Paroxetine|
218876429|NCT02374567|DRUG|Sertraline|
218876430|NCT02374567|DRUG|Fluvoxamine|
218876431|NCT02374567|DRUG|Escitalopram|
218876432|NCT02374567|DRUG|Tranylcypromine|
218876433|NCT02374567|DRUG|Moclobemide|
218876434|NCT02374567|DRUG|Mianserin|
218876435|NCT02374567|DRUG|Trazodone|
218876436|NCT02374567|DRUG|Mirtazapine|
218876437|NCT02374567|DRUG|Bupropion|
218876438|NCT02374567|DRUG|Venlafaxine|
218876439|NCT02374567|DRUG|Reboxetine|
218876440|NCT02374567|DRUG|Duloxetine|
218876441|NCT02374567|DRUG|Agomelatine|
218876442|NCT02374567|DRUG|Pyritinol|
218876443|NCT02374567|DRUG|Piracetam|
218876444|NCT02374567|DRUG|Donepezil|
218876445|NCT02374567|DRUG|Rivastigmine|
218876446|NCT02374567|DRUG|Galantamine|
218876447|NCT02374567|DRUG|Memantine|
218876448|NCT02374567|DRUG|Nicergoline|
218876449|NCT02374567|DRUG|Acamprosate|
218876450|NCT02374567|DRUG|Lithium|
218876451|NCT00356343|DEVICE|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
218876452|NCT00356343|OTHER|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
218876453|NCT05347706|DIETARY_SUPPLEMENT|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
218876454|NCT02435420|DEVICE|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
218876455|NCT02751476|OTHER|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
218876456|NCT02751476|OTHER|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
218876457|NCT02751476|DEVICE|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
218876458|NCT02751476|OTHER|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
218876459|NCT05627024|DRUG|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
219024847|NCT07189676|BEHAVIORAL|Food boxes PHD|Food boxes will be sent to participants' homes. PHD food boxes will include seasonal and local fruits and vegetables, whole grain products, legumes, nuts, and dairy or milk alternatives. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
219495676|NCT01612052|DRUG|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
219495677|NCT04815408|DRUG|BGB-A317|PD-1 antibody，Tislelizumab (BGB-A317)
219495678|NCT04815408|DRUG|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
219495679|NCT05220904|DEVICE|spectacles|Spectacle is the the most common treatment for refractive errors.
219495680|NCT05220904|DEVICE|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
219495681|NCT01368757|DRUG|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
219602769|NCT05184582|BEHAVIORAL|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
219602770|NCT05118672|DRUG|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
219495682|NCT06702735|BEHAVIORAL|Rainbow tool|The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
219495683|NCT06702735|BEHAVIORAL|Feedback|Feedback sessions with health care professional based on the Rainbow tool.
219495684|NCT06702826|DRUG|Cadonilimab combined with SRS|Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
219495685|NCT06704048|OTHER|Cardiac rehabilitation|Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
219495686|NCT02934568|DRUG|LEE011|Single agent LEE011 or in combination with other treatments
219495687|NCT06702904|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
219495688|NCT06702904|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
219602771|NCT05118672|DRUG|Placebo|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
219602772|NCT06837987|OTHER|Modified transplantation system|Modified transplantation conditioning include: Fludarabine 30mg/m2\*6 day, Melphalan 100mg/m2\*1 day, cyclophosphamide 50mg/kg\*2 day.
219602773|NCT06831760|DEVICE|SOC and Type-I Collagen-based Skin Substitute|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
219200325|NCT06739317|PROCEDURE|operation|If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
218876460|NCT05627024|DRUG|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
218876461|NCT00372697|DRUG|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
218876462|NCT06409143|DEVICE|HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
218876463|NCT06409143|DEVICE|Sham HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
218876464|NCT06409143|OTHER|UE rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
218876465|NCT06409143|DEVICE|HD-tES (Bilateral)|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
219495689|NCT06702904|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
219602774|NCT06831760|DEVICE|SOC and Human Amnion/Chorion Membrane|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
219602775|NCT06188689|DIAGNOSTIC_TEST|Pacing|"1. Ventricular 10 beat burst at 500ms (120bpm)~2. Ventricular 10 beat burst at 400ms (150bpm)~3. Atrial 10 beat burst at 500ms (120bpm)~4. Atrial 10 beat burst at 400ms (150bpm)."
219602776|NCT06154122|DEVICE|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
218876466|NCT05496569|DRUG|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
218876467|NCT05496569|DRUG|TQB3616 placebo|Placebo
218876468|NCT03221842|DRUG|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
218876469|NCT03221842|DRUG|Placebo|Excipients of C1-INH plus albumin
218876470|NCT00901199|DRUG|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
218876471|NCT01181869|DEVICE|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
218876472|NCT05809492|OTHER|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
218876473|NCT00003883|DRUG|fluconazole|
218876474|NCT00003883|DRUG|itraconazole|
218876475|NCT00334984|DRUG|glutamine|
218876476|NCT00334984|PROCEDURE|chemoprotection|
218876477|NCT00334984|PROCEDURE|management of therapy complications|
218876478|NCT00334984|PROCEDURE|therapeutic nutritional supplementation|
218876479|NCT03520907|DRUG|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
218876480|NCT03520907|DRUG|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
218876481|NCT00704288|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
218876482|NCT02435927|DRUG|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
219200326|NCT06885762|DRUG|efgartigimod|efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.
219200327|NCT06747078|OTHER|Neurodevelopmental Therapy (NDT) + Core Stabilization Training|In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, core stabilization training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The core stabilization training session lasted 30 minutes.
218876483|NCT02435927|DRUG|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
218876484|NCT02396563|PROCEDURE|epidural analgesia|
218876485|NCT02396563|DRUG|Ropivacaine|
218876486|NCT06388603|DEVICE|Bioactive Glass|Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
218876487|NCT06388603|OTHER|Standard of Care|The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
218876488|NCT00000228|DRUG|Buprenorphine|
218876489|NCT05248880|DRUG|AGN-151586|Intramuscular Injection
218876490|NCT05248880|DRUG|Placebo|Intramuscular Injection
218876491|NCT05942443|PROCEDURE|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
218876492|NCT05942443|PROCEDURE|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
218876493|NCT03306511|OTHER|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
218876494|NCT03405649|BEHAVIORAL|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
218876495|NCT03405649|BEHAVIORAL|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
218876496|NCT05739461|OTHER|Dental implant|Dental implants with triangular cross-section neck design
218876497|NCT04681963|OTHER|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
218876498|NCT01836302|OTHER|Observation|
218876499|NCT04395690|PROCEDURE|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
218876500|NCT04610398|DRUG|Dexamethasone 4mg|s. arm/group description
218876501|NCT04610398|DRUG|NaCl 0.9%|s. arm/group description
218876502|NCT00197899|DRUG|E. Coli endotoxin|
218876503|NCT02689115|OTHER|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
218876504|NCT00321815|DRUG|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
218876505|NCT00321815|DRUG|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
218876506|NCT06486896|OTHER|Pelvic floor training|It will be in the form of pelvic floor relaxation with biofeedback, as well as stretching exercises for the pelvic floor and the adjacent muscles. The patient will be asked to lie in a comfortable crock lying position. She will be instructed to do diaphragmatic breathing exercises. The vaginal electrode of the biofeedback will be gently introduced into the vagina to start pelvic floor relaxation training. Then, the patient will be asked to perform pelvic floor relaxation by slightly contracting the pubococcygeus muscle. After 10 minutes of pelvic floor relaxation training, the patient will then be instructed to return to the active state gradually, the treatment procedure will be performed 3 times/ week for 8 weeks. Stretching exercises for the pelvic floor and the adjacent muscles: Levator ani \& perineal muscles stretch, hip adductor muscles stretch, piriform muscle stretch, hip flexor muscles stretch, and obturator internus muscle stretch.
218876507|NCT06486896|DEVICE|Interferential current|Each female in the experimental group will receive interferential current, 3o minutes per session, 2 sessions per week, for 8 weeks. The applied parameters will be a frequency of 2000Hz, a modulated amplitude of frequency of 80Hz, pulse width of 200μs, and the intensity is modulated according to the sensory level of each participant. While the participant is in a comfortable crock lying position with abducted hips, the position of the electrodes will be maintained in all sessions
218876508|NCT06486896|BEHAVIORAL|General advice|The patients in both groups will follow general advice to help vaginismus for 8 weeks
218876509|NCT03112655|DIAGNOSTIC_TEST|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
218876510|NCT02120391|OTHER|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
218876513|NCT04086095|DEVICE|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
218876514|NCT05572164|PROCEDURE|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
218876515|NCT05572164|PROCEDURE|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
219602777|NCT06154122|OTHER|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
219602778|NCT04554927|OTHER|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
219602779|NCT04554927|OTHER|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
219602780|NCT05066061|OTHER|control arm|usual process
219602781|NCT05066061|OTHER|anxiolytic and analgesic gas|add relaxing gas
219602782|NCT05066061|DEVICE|Virtual reality mask|use Virtual reality mask Oculus Quest with age-appropriate software
218876516|NCT01186055|BEHAVIORAL|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
218876517|NCT05731479|OTHER|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
218876518|NCT05731479|OTHER|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
218876519|NCT02692755|DRUG|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
218876520|NCT03387020|DRUG|Everolimus|Given PO
218876521|NCT03387020|OTHER|Laboratory Biomarker Analysis|Correlative studies
218876522|NCT03387020|OTHER|Pharmacological Study|Correlative studies
218876523|NCT03387020|DRUG|Ribociclib|Given PO
218876524|NCT02139488|OTHER|Fiducial markers|
218876525|NCT02139488|OTHER|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
218876526|NCT00077324|GENETIC|proteomic profiling|
218876527|NCT00077324|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
218876528|NCT00077324|PROCEDURE|biopsy|
218876529|NCT00077324|PROCEDURE|surgery|
218876530|NCT05045300|PROCEDURE|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
218876531|NCT04139356|PROCEDURE|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
218876532|NCT00629811|DRUG|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
218876533|NCT00629811|DRUG|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
219200328|NCT06747078|OTHER|Neurodevelopmental therapy + Balance Exercises|In addition to NDT, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, balance training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The balance exercise session lasted 30 minutes.
219200329|NCT06747078|OTHER|Neurodevelopmental therapy|NDT was applied for 60 minutes per day, 3 sessions per week, for 8 weeks and a total of 24 sessions.
219602783|NCT06210776|DRUG|Trastuzumab deruxtecan|Intravenous infusion
219602784|NCT05738239|DEVICE|Laser therapy|Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
219602785|NCT04770766|OTHER|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
219602786|NCT03816878|BIOLOGICAL|H5N1 pISV|Administered as an intramuscular (IM) injection
219602787|NCT03038802|BIOLOGICAL|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
219602788|NCT03038802|BIOLOGICAL|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
218876534|NCT04924517|BEHAVIORAL|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
218876535|NCT04924517|BEHAVIORAL|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
218876536|NCT03876119|DRUG|Intraarterial alteplase|See arm/group descriptions.
218876537|NCT03876119|DRUG|Placebo|See arm/group descriptions.
218876538|NCT04183608|DRUG|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
218876539|NCT04183608|DIAGNOSTIC_TEST|Calprotectin|Fecal calprotectin dosing at home with IBDoc
219024848|NCT07189676|BEHAVIORAL|Group visits PHD|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. PHD group visits will cover topics such as PHD principles, and the related environmental and health outcomes.
219024849|NCT07189676|BEHAVIORAL|Behavioural support (Ovo-lacto-vegetarian diet)|This component is designed to help participants adhere to the ovo-lacto-vegetarian through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type.
219024850|NCT07189676|BEHAVIORAL|Food boxes (Ovo-lacto-vegetarian diet)|Food boxes will be sent to participants' homes. Ovo-lacto-vegetarian food boxes will include fruits and vegetables, whole grains, legumes, nuts, soy-based products, eggs, and cheese. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
219495690|NCT06702904|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
219495691|NCT06724939|OTHER|self-adhesive bulk-fill resin composite|surefil one self-adhesive bulk-fill composite
219495692|NCT00452998|PROCEDURE|Q-switched fd Nd:yag in Laser Iridotomy|
218876540|NCT04183608|OTHER|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections"
219495693|NCT01275521|DRUG|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
219495694|NCT01275521|DRUG|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
218876541|NCT04183608|OTHER|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
219024851|NCT07189676|BEHAVIORAL|Group visits (Ovo-lacto-vegetarian diet)|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. Ovo-lacto-vegetarian group visits will cover topics such as plant-based eating and nutritional adequacy.
219495695|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
219602789|NCT05929820|BEHAVIORAL|Protect Your Colon™|Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
219602790|NCT06264180|BIOLOGICAL|Vusolimogene Oderparepvec|Genetically modified Herpes Simplex Type 1 Virus.
219602791|NCT06264180|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
219024852|NCT07189676|BEHAVIORAL|Behavioral support (control)|Participants will attend four short individual dietary visits with a dietitian, where they will review the recorded dietary data. Participants of the control group will not have access a recipe collection or meal planner.
219200330|NCT06751290|DRUG|Cyproheptadine|Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
219200331|NCT06751290|BEHAVIORAL|Nutritional Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
219602792|NCT06264180|BIOLOGICAL|Nivolumab + Relatlimab|Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
218876542|NCT03781440|PROCEDURE|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
218876543|NCT03781440|PROCEDURE|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
219024853|NCT07189676|BEHAVIORAL|Food boxes (control)|Food boxes will be sent to participants' homes. Control food boxes will include fruits and vegetables, potato, nuts, cheese, animal protein products and canned food. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety.
219024854|NCT07189676|BEHAVIORAL|Group visits (control)|Group visits will provide support through general health education, social interaction, and peer learning. Control group visits will cover topics such as the role and importance of controls in RCTs and general well-being.
219495696|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
219495697|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
219495698|NCT02842086|DRUG|F/TAF|200/25 mg tablet administered orally once daily
219495699|NCT02842086|DRUG|F/TDF|200/300 mg tablet administered orally once daily
219495700|NCT02842086|DRUG|F/TAF Placebo|Tablet administered orally once daily
219495701|NCT02842086|DRUG|F/TDF Placebo|Tablet administered orally once daily
219495702|NCT06425146|PROCEDURE|Cytobrush sample|Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients
219495703|NCT06425146|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam
218876544|NCT00868127|DRUG|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
218876545|NCT00868127|DRUG|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
219024855|NCT07191145|DRUG|Eptinezumab|Eptinezumab 300mg IV
219024856|NCT07191145|OTHER|Placebo|Control - placebo IV
219024857|NCT07190898|OTHER|core exercises|The participants performed core exercises three times per week for a total of six weeks
219024858|NCT07190898|OTHER|functional strength exercises|The participants performed functional strength exercises three times per week for a total of six weeks.
219495704|NCT01961635|DEVICE|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
219495705|NCT01961635|DEVICE|Zirconia abutments|place zirconia abutment on the day of implant placement
219495706|NCT01961635|DEVICE|Titanium Abutments|place titanium abutment on the day of implant placement
219495707|NCT01961635|DEVICE|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
219495708|NCT01961635|PROCEDURE|Subcrestal|place implant 2mm below crestal bone
219495709|NCT01961635|DEVICE|platform-switch|abutment platform is narrow than implant diameter
219495710|NCT01961635|PROCEDURE|one-time one-abutment|place the final abutment on the day of surgery and not remove it
219495711|NCT01961635|PROCEDURE|Torque 20 n/cm2|the amount of torque applied to the abutment
219495712|NCT03751124|DRUG|Relugolix|Relugolix 40 mg tablet administered orally once daily
219495713|NCT03751124|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
219495714|NCT03751124|DRUG|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
219495715|NCT03751124|DRUG|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
219495716|NCT04777591|DRUG|Liposomal bupivacaine TAP block|Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
219602793|NCT06264180|BIOLOGICAL|Pembrolizumab|A programmed death receptor-1 (PD-1)-blocking antibody indicated.
219024859|NCT07190898|OTHER|education group|During the educational session, participants were provided with information on proper posture, ergonomic movements, the importance of posture in daily life, and pain management.
219495717|NCT04777591|DRUG|Bupivacain|Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
219495718|NCT05647694|OTHER|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
219495719|NCT04594200|BEHAVIORAL|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
219495720|NCT00555399|DRUG|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
218876546|NCT06510010|DRUG|Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)|"Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid."
218876547|NCT06510010|DRUG|Oxaliplatin With S-1 （SOX）|"Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle."
218876548|NCT03415438|DIAGNOSTIC_TEST|Visual Analogue Scale|intensity of pain perception patients feel
218876549|NCT03415438|DIAGNOSTIC_TEST|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
218876550|NCT03415438|DIAGNOSTIC_TEST|shortness tests for lumbar movements|tape measurement for lumbar movements
218876551|NCT03415438|DIAGNOSTIC_TEST|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
218876552|NCT03415438|DIAGNOSTIC_TEST|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
218876553|NCT03415438|DIAGNOSTIC_TEST|Modify Schober test|tape measurement of spinal flexion between designated regions
218876554|NCT05882461|BEHAVIORAL|90Second Caregiver health letter|Participant receives the weekly health letter via email
218876555|NCT03331757|OTHER|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876556|NCT03331757|OTHER|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876557|NCT03331757|OTHER|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876558|NCT03331757|OTHER|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876559|NCT03331757|OTHER|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876560|NCT03331757|OTHER|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876561|NCT03331757|OTHER|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
218876562|NCT06034561|DRUG|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
218876563|NCT04674488|BIOLOGICAL|TILs|a single center, single-arm, open label, interventional study
219200332|NCT06751290|BEHAVIORAL|Behavioral Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
219495721|NCT00555399|DRUG|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days."
219495722|NCT00555399|PROCEDURE|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
218876564|NCT00927238|DEVICE|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
219200333|NCT06748287|DEVICE|iGrow Hair Growth System|has a helmet-design and headphones to allow for hands-free use and music listening capabilities. Treatment is 25 minutes every other day. three to four times per week for 4 months.
219495723|NCT00555399|DRUG|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
219495724|NCT05525429|BEHAVIORAL|Nutrition Education|Multidimensional nutrition education will be provided.
219495725|NCT04905927|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
219495726|NCT06516549|OTHER|Skipping rope and informational pamphlet|The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
219495727|NCT01215682|DIETARY_SUPPLEMENT|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
219495728|NCT01215682|DIETARY_SUPPLEMENT|placebo|sweetened water
218876565|NCT00927238|OTHER|Lumbar fusion surgery|Lumbar fusion surgery
218876566|NCT04787172|RADIATION|Multi Slice computed tomography|use of MSCT as a diagnostic tool in evaluation of patients with congenital cardiovascular anomalies
218876567|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
218876568|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
218876569|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
218876570|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
219602794|NCT06264180|DRUG|Single-agent chemotherapy|Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
218876571|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
218876572|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
218876573|NCT03722524|DRUG|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
218876574|NCT06530771|DIAGNOSTIC_TEST|ultrasound|Conventional US, SWE, and AP of thyroid nodules were conducted successively with a Supersonic Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) using a 5-14 MHz linear transducer.
218876575|NCT02321761|DRUG|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
218876576|NCT05901883|DRUG|CEL383|Subjects will receive CEL383
218876577|NCT05901883|DRUG|Placebo|Subjects will receive placebo
218876578|NCT04957368|DRUG|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
218876579|NCT04957368|DRUG|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
218876580|NCT04918732|DIAGNOSTIC_TEST|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
218876581|NCT00007891|BIOLOGICAL|filgrastim|
218876582|NCT00007891|PROCEDURE|autologous bone marrow transplantation|
218876583|NCT00007891|PROCEDURE|peripheral blood stem cell transplantation|
218876584|NCT00007891|RADIATION|indium In 111 monoclonal antibody BrE-3|
218876585|NCT00007891|RADIATION|yttrium Y 90 monoclonal antibody BrE-3|
218876586|NCT02188654|DRUG|Metformin|500mg/day retarded formulation of metformin
218876587|NCT02188654|DRUG|Placebo|500 mg/day of placebo tablets
218876588|NCT03513627|PROCEDURE|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
218876589|NCT00185224|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
218876590|NCT00185224|DRUG|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
218876591|NCT03560167|DEVICE|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
218876592|NCT03215199|OTHER|NAPT|Web-based depression and distress monitoring application
218876593|NCT02942485|DRUG|Metronidazole|P/r suppositories
218876594|NCT02942485|DRUG|Tinidazole|P/o tablets
218876595|NCT00687674|DRUG|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
218876596|NCT00687674|DRUG|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
218876597|NCT00687674|DRUG|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
218876598|NCT04844268|BIOLOGICAL|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
218876599|NCT04844268|BIOLOGICAL|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
218876600|NCT04844268|BIOLOGICAL|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
218876601|NCT04844268|BIOLOGICAL|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
218876602|NCT05654454|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
218876603|NCT05654454|DRUG|Paclitaxel|Paclitaxel 175 mg/m2
218876604|NCT05654454|DRUG|Carboplatin|Carboplatin AUC 6
218876605|NCT04518540|DRUG|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
218876606|NCT04518540|DRUG|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
218876607|NCT01122693|DEVICE|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
218876608|NCT01122693|DEVICE|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
218876609|NCT02623582|BIOLOGICAL|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
218876610|NCT02623582|DRUG|Cyclophosphamide|Given IV
218876611|NCT01379196|DRUG|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
218876612|NCT02186678|OTHER|PET-CT|
218876613|NCT05100576|DEVICE|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
218876614|NCT05096689|OTHER|MRI|Magnetic Resonance Imaging
218876615|NCT04369950|DRUG|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
218876616|NCT04369950|DRUG|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
218876617|NCT05839249|OTHER|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
218876618|NCT00989963|DRUG|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
218876619|NCT06038734|DIAGNOSTIC_TEST|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
218876620|NCT00139919|DRUG|Bifeprunox|
218876621|NCT02830321|OTHER|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
218876622|NCT06122038|DIETARY_SUPPLEMENT|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
218876623|NCT06122038|DIETARY_SUPPLEMENT|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
218876624|NCT03326206|OTHER|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
218876625|NCT05485337|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
218876626|NCT05350852|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
218876627|NCT00269867|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
218876628|NCT00269867|DRUG|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
218876629|NCT00269867|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
218876630|NCT04385134|OTHER|No intervention|No intervention
219495729|NCT00546832|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
219495730|NCT00546832|DRUG|celecoxib|
219495731|NCT00546832|OTHER|placebo|
219495732|NCT02316678|OTHER|No intervention|There is no intervention
219602795|NCT03355469|DRUG|Metformin|Oral metformin 2000 mg/d for 16 weeks. Metformin dosage will follow 500 mg/d ramp up progression: Week 1 = 500 mg/d; Week 2 = 1,000 mg/d; Week 3 = 1500 mg/d; Week 4-16 = 2000 mg/d.
218876631|NCT04548791|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
218876632|NCT01240200|DRUG|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
218876633|NCT01240200|DEVICE|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
218876634|NCT00068302|DRUG|sirolimus|3-6 subjects will be enrolled into each dose level
218876635|NCT03548467|BIOLOGICAL|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
218876636|NCT03548467|DRUG|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
218876637|NCT02195141|RADIATION|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
219495733|NCT05897762|BEHAVIORAL|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
219602796|NCT03355469|DRUG|Placebo|Oral placebo for 16 weeks. Placebo tablets will follow a four-stage progression: Week 1 = 1 tablet; Week 2 = 2 tablets; Week 3 = 3 tablets; Week 4-16 = 4 tablets.
218876638|NCT02195141|RADIATION|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
218876639|NCT04269356|DRUG|BMS-986256|Specified dose on specified days
219024863|NCT07190794|DEVICE|OverStitch™ or OverStitch NXT™|The OverStitch™ or OverStitch NXT™ Endoscopic Suturing System was used as part of each patient's ESG procedure within the routine clinical practice.
219024864|NCT07190794|BEHAVIORAL|Lifestyle Modification|Patients participated in a lifestyle modification program for weight loss management.
219024865|NCT07189975|OTHER|High intensity eccentric cycling training|This intervention is a high intensity interval training using an eccentric ergocycle
219024866|NCT07189975|OTHER|Moderate intensity eccentric cycling training|This intervention is a moderate intensity continuous training using an eccentric ergocycle
219602797|NCT03355469|BEHAVIORAL|Low Intensity Exercise|Low intensity exercise will consist of 16 weeks of walking at \~55% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
218876640|NCT04269356|DRUG|Milk of magnesia|Specified dose on specified days
218876641|NCT00765570|RADIATION|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
218876642|NCT00765570|RADIATION|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
218876643|NCT00765570|RADIATION|Standard radiation|15 Standard radiation treatments
219024867|NCT07189975|OTHER|High intensity concentric cycling training|This intervention is a high intensity interval training using a concentric ergocycle
219024868|NCT07190027|DRUG|Arm 1： Standard Synchronous Group|Arm 1: Concurrent PD-1 + Chemotherapy (Standard Synchronous Group) Participants in this group will receive PD-1 inhibitor and chemotherapy on the same day (D1) during each treatment cycle.
219024869|NCT07190027|DRUG|Arm 2：Fixed Delay Group|Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint inhibitor + Chemo (Day 3)
219200334|NCT06748287|DEVICE|Capillus352|has a similar design to a salon hair dryer which hovers over the head to allow for hand-free use. Treatment is 12 minutes, three times per week for 4 months.
219200335|NCT06748287|DEVICE|HairMax Ultima 12 Lasercomb|is comb-like device with hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 8 minutes three times per week for 4 months.
219200336|NCT06748287|DEVICE|HairMax Laserband 82|is headband design device which has unique hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 90-second treatments three times per week for 4 months.
219200337|NCT06744101|RADIATION|Evaluate the effectiveness of Diffusion Weighted MRI (DWI) in detecting breast lesions.|Assess the sensitivity, specificity, and diagnostic accuracy of DWI compared to Ultrasonography (USG) for benign and malignant lesions.
219200338|NCT06744101|RADIATION|Compare Sensitivity and Specificity of DWI and USG|Analyze which modality performs better in lesion detection based on sensitivity and specificity.
218876644|NCT00765570|RADIATION|Standard radiation|standard radiation treatment
218876645|NCT04808739|BIOLOGICAL|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
218876646|NCT01529034|DRUG|USL261|
218876647|NCT03018639|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
218876648|NCT01065701|DRUG|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
218876649|NCT03422497|OTHER|Male sex|Male sex-as listed in the discharge abstract database
218876650|NCT03422497|OTHER|Female sex|Male sex-as listed in the discharge abstract database
218876651|NCT03063281|OTHER|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
218876652|NCT02949063|BEHAVIORAL|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
218876653|NCT00663403|DRUG|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
218876654|NCT06491784|OTHER|Exercise Therapy|12 week personalised exercise, nutrition and wellbeing programme
218876655|NCT01465815|DRUG|erlotinib hydrochloride|Given PO
218876656|NCT01465815|DRUG|linsitinib|Given PO
218876657|NCT01465815|DRUG|placebo|Given PO
218876658|NCT01465815|RADIATION|radiation therapy|Undergo radiation therapy
218876659|NCT01465815|PROCEDURE|therapeutic conventional surgery|Undergo planned surgery
218876660|NCT01465815|OTHER|laboratory biomarker analysis|Correlative studies
218876661|NCT01139177|DEVICE|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
218876662|NCT00646399|DRUG|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
218876663|NCT00646399|DRUG|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
218876664|NCT03791775|DRUG|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
218876665|NCT00351065|DRUG|SK3530|
219495734|NCT00681577|BIOLOGICAL|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
218876666|NCT04138680|BEHAVIORAL|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
218876667|NCT04138680|BEHAVIORAL|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
218876668|NCT02703480|BIOLOGICAL|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
218876669|NCT02703480|BIOLOGICAL|Ti-mesh|Titanium mesh
218876670|NCT04068116|PROCEDURE|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
218876671|NCT06094790|DRUG|CORT125134 150 mg|CORT125134 150 mg (3 X 50 mg current capsule formulation)
218876672|NCT06094790|DRUG|CORT125134 250 mg|CORT125134 250 mg (5 X 50 mg current capsule formulation)
218876673|NCT06094790|DRUG|CORT125134 dose to be determined|CORT125134 current capsule formulation, dose to be determined
218876674|NCT02110862|OTHER|Transittime. Defecography|
218876675|NCT03682692|DRUG|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
218876676|NCT03682692|DRUG|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
218876677|NCT02473367|DRUG|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
218876678|NCT02473367|DRUG|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
218876679|NCT02473367|DRUG|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
218876680|NCT02225834|DRUG|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
218876681|NCT01389037|BEHAVIORAL|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
218876682|NCT01389037|BEHAVIORAL|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
218876683|NCT04384939|DEVICE|magnetic-end Double-J ureteral stent|"* Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
218876684|NCT06172725|OTHER|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
218876685|NCT00771771|OTHER|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
218876686|NCT00771771|OTHER|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
218876687|NCT06127628|PROCEDURE|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
218876688|NCT06726187|OTHER|Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).|Screening questionnaire
218876689|NCT06739044|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
218876690|NCT06739044|DRUG|HDG1901|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
218876691|NCT06894654|PROCEDURE|Skin punch biopsy|Skin punch biopsies are 5mm for this study. Participants with SSc will undergo 4 biopsies (2 in diseased area, 2 in non-diseased area if available). Healthy Volunteers will undergo 2 biopsies.
218876692|NCT06894654|OTHER|blood sampling|10mls blood will be taken for analysis and DNA sequencing
218876693|NCT06894654|BEHAVIORAL|Questionnaire|All participants are required to complete a questionnaire with information on demographics, lifestyle, medical and medication history.
218876694|NCT05716347|BIOLOGICAL|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
219495735|NCT03648086|OTHER|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
219602798|NCT03355469|BEHAVIORAL|High Intensity Exercise|High intensity exercise will consist of 16 weeks of walking at \~85% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
219602799|NCT06476808|DRUG|BMS-986463|Specified dose on specified days
219602800|NCT05780684|OTHER|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
218876695|NCT02105038|OTHER|Spinner knob|
218876696|NCT02105038|OTHER|No Knob|
218876697|NCT02678923|DRUG|MDCO-216|
218876698|NCT02678923|DRUG|Placebo|
218876699|NCT01002274|DRUG|MCS-2|2 soft-gel capsules Qd for 40 weeks
219495736|NCT03875430|DIETARY_SUPPLEMENT|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
219495737|NCT00644098|DIETARY_SUPPLEMENT|soluble fibre complex and medium chain triglycerides|
219495738|NCT00644098|DIETARY_SUPPLEMENT|cellulose and soybean oil|
219495739|NCT00087399|DRUG|gabapentin|
219602801|NCT06365723|BEHAVIORAL|Nature-based Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated nature-based, or 'green', urban environment.
219602802|NCT06365723|BEHAVIORAL|Built-environment/Commercial Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated built-environment/commercial, or 'Gray', urban environment.
218876700|NCT02169765|OTHER|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
218876701|NCT02169765|OTHER|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
218876702|NCT02883101|BEHAVIORAL|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
218876703|NCT01533662|DRUG|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
218876704|NCT01533662|DRUG|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
218876705|NCT06141291|DIETARY_SUPPLEMENT|High protein diet|Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
218876706|NCT06141291|DIAGNOSTIC_TEST|OGTT|Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
218876707|NCT01553643|DRUG|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
218876708|NCT01553643|DRUG|placebo|at a rate of 3g two times per day
218876709|NCT00455143|DRUG|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
218876710|NCT00455143|DRUG|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
218876711|NCT07088497|BEHAVIORAL|dietary control|Subjects are required to have dinner at a specific time on the night before the test and to remain fasting on the next day until the test.
218876712|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
219495740|NCT00087399|DRUG|antidepressant|
219495741|NCT01835470|DRUG|Abatacept|
219495742|NCT01272193|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
219495743|NCT01272193|DRUG|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
219495744|NCT00343811|DRUG|Modafinil|
219495745|NCT04839237|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
219495746|NCT04839237|DRUG|Liraglutide;metformin|The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
219495747|NCT01440647|PROCEDURE|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
219495748|NCT01440647|PROCEDURE|Extubation to CPAP|After extubation infants were placed on CPAP
219495749|NCT05952427|OTHER|ACE Questionnaire|The only intervention consists of completing the validated ACE questionnaire
219495750|NCT02354365|DEVICE|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
218876713|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
218876714|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
218876715|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
218876716|NCT02376023|OTHER|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
218876717|NCT05700032|DIAGNOSTIC_TEST|high MI impulses|patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
218876718|NCT05700032|DIAGNOSTIC_TEST|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
218876719|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
219024870|NCT07190027|DRUG|Arm 3： Individualized Delay Group|"Arm 3: Individualized PD-1 Timing Based on Immune Window Score (IWS) (Individualized Group) Participants in this group will receive chemotherapy on D1 and undergo daily immune monitoring (CD8⁺PD-1⁺ T cells, Treg, IFN-γ, NLR, ALC, CRP).~Based on the immune window score (IWS):~If IWS ≥ 2, PD-1 inhibitor will be administered the same day. If IWS = 1-1.5, dosing may be delayed to D3-D5 depending on immune recovery. If IWS remains 0 by D5, PD-1 inhibitor will be administered on D6 as fallback."
219024871|NCT07189585|DRUG|inulin|Inulin is a fermentable prebiotic fiber derived from chicory root. For this study, inulin is packaged into single-dose sachets containing 5 g, 10 g, or 15 g of powder. Participants in the 10 g arm escalate from 5 g/day for 3 days to 10 g/day, then continue with sachets containing a 2:1 blend of inulin and maltodextrin to provide a daily 10 g inulin dose. Participants in the 15 g arm escalate from 5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day for the remaining 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
219495751|NCT02609282|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|
219495752|NCT02565082|OTHER|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
219495753|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
219495754|NCT02565082|OTHER|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
219495755|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
219495756|NCT01849939|DRUG|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
219495757|NCT01363401|BIOLOGICAL|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
219495758|NCT01363401|OTHER|Control group|No treatment of HYNR-CS inj
219495759|NCT04749810|DRUG|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
219495760|NCT06536790|OTHER|hang clean training|This include hang clean training thrice a week for twelve weeks
219495761|NCT06536790|OTHER|half squat training|This include half squat training thrice a week for twelve weeks
219495762|NCT04170959|DRUG|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
219495763|NCT04170959|OTHER|No metformin|Standard of care without metformin.
219495764|NCT05183100|PROCEDURE|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
219495765|NCT05183100|PROCEDURE|Lying in supine|Lying in supine position for about 13 minutes.
219602803|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
219602804|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
219602805|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
218876720|NCT03038854|OTHER|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
218876721|NCT03038854|OTHER|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
218876722|NCT03038854|OTHER|Cows' milk|Homogenized store-bought full fat cow's milk.
218876723|NCT02092766|DRUG|artesunate|
218876724|NCT02092766|DRUG|quinine|
218876725|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
218876726|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
218876727|NCT01587365|BIOLOGICAL|BMS-962476|
218876728|NCT01587365|BIOLOGICAL|Placebo matching with BMS-962476|
218876729|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
218876730|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
218876731|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
218876732|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
218876733|NCT06253169|DIAGNOSTIC_TEST|HPV DNA self-test|HPV DNA swab from the cervix performed by the patient herself.
218876734|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
219024872|NCT07189585|DRUG|Maltodextrin (Placebo)|Maltodextrin is a carbohydrate powder widely used as a food additive. For this study, maltodextrin is used as the placebo comparator. It is packaged into single-dose sachets identical in appearance and taste to inulin sachets. Participants receive escalating doses (5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day) for a total of 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
219024873|NCT07190300|DRUG|Tulmimetostat|Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
219024874|NCT07190300|DRUG|Darolutamide|600 mg is administered orally BID
219024875|NCT07190300|DRUG|Abiraterone|abiraterone 1000 mg is administered orally QD
219024876|NCT07191210|BEHAVIORAL|Comprehensive Transition Programme (CTP)|A co-designed, multicomponent educational programme delivered over three months to support nurses transitioning into first-line management roles. The programme integrates classroom training modules, online learning, mentorship by senior nurse managers, and structured reflective practice.
218876735|NCT03848767|DEVICE|AID System|AID System
218876736|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
218876737|NCT02904148|PROCEDURE|Shoulder mobilisation|early shoulder mobilisation
218876738|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
218876739|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
218876740|NCT05821725|DEVICE|Control|Hemostatic sponge
219024877|NCT07189442|DIETARY_SUPPLEMENT|L-theanine and paraxanthine|200 mg L-theanine + 200 mg paraxanthine capsule
219024878|NCT07189442|DIETARY_SUPPLEMENT|Placebo|400 mg corn starch capsule
219024879|NCT07191028|DRUG|MLC 901|Oral capsule, 2 capsules 3 times a day for 12 months
219024880|NCT07191028|DRUG|Placebo|Oral capsule, 2 capsules 3 times a day for 12 months
219024881|NCT07191067|DEVICE|Pulsed radiofrequency|Pulsed radiofrequency will be applied to the femoral and sciatic nerves prior to TKA.
219024882|NCT07191067|DEVICE|Non-therapeutic stimulation|Electrical square wave stimulation performed to mimic the duration of the active arm and mimic the procedure for blinding purposes.
219024883|NCT07190456|OTHER|Exposure to neutral images visualization|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing neutral images (landscapes, monuments...)
219024884|NCT07190456|OTHER|Exposure to nocive images visualisation|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing images interpreted as nocive (cutting, jumping, contact...)
218876741|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
218876742|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
218876743|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
219024885|NCT07190456|OTHER|Exposure to anticipated realisation of a feared movement|Before the start of the experimental condition, the patient will be asked to think about their willingness to perform the first movement visualised in the video, while a researcher places a jumping platform inside the laboratory. During the test, the patient will have to walk on a treadmill at their preferred speed for 10 minutes, while watching a video showing a drop jump followed by images interpreted as nocive for the rest of the time.
219024886|NCT07188935|DRUG|ciprofloxacin 500 mg tablet|Administration of oral ciprofloxacin 500 mg twice daily for 7-14 days for the treatment of recurrent urinary tract infections in patients with type 2 diabetes mellitus, following local and international guidelines.
219024887|NCT07189624|OTHER|Exercise|30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
218876744|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
218876745|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
218876746|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
218876747|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
218876748|NCT02145598|DRUG|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
219024888|NCT07190092|PROCEDURE|Deep brain stimulation electrode implantation with an electrode target in the dentate nucleus|The intervention will involve implantation of a directional electrode with a target in the dentate nucleus of the cerebellum, ipsilateral to the limbs affected by spasticity. Electrode implantation will be performed using a stereotaxic frame, following prior planning of the electrode trajectory and tractography of the dento-ruborothalamic tract using a planning station. The procedure will be performed under general anesthesia. The IPG stimulator will be placed in the subclavicular region.
219204503|NCT04546230|PROCEDURE|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
218876749|NCT02145598|DRUG|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
218876750|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
218876751|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
219024889|NCT07190872|BEHAVIORAL|sleep hygiene education|Students in the intervention group will receive face-to-face sleep hygiene training in a total of 4 sessions, once a week for 40 minutes over a period of four weeks. The education is designed within the framework of the Transtheoretical Model and focuses on topics such as the concept of sleep hygiene, regular sleep hours, limiting caffeine and screen use, organizing the sleep environment, and stress management. The training will be provided by a nurse experienced in sleep health.
219024890|NCT07190833|DRUG|OTS-412|1×10E8 pfu, once, 1 cycle, IT
219024891|NCT07190833|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
219024892|NCT07190833|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
219024893|NCT07190833|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days, 1 cycle, PO
219024894|NCT07190833|DRUG|Hydroxyurea (HU)|optimal dose, 14 days, 1 cycle, PO
219024895|NCT07190833|DRUG|Atezolizumab|1,200 mg, once, 1 cycle, IV
219200339|NCT06418347|DRUG|Alpha lipoic acid|"Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects."
219495766|NCT01361906|BEHAVIORAL|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
219495767|NCT02997956|DRUG|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
219495768|NCT02997956|PROCEDURE|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
219495769|NCT03038178|DRUG|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
219495770|NCT01866488|DRUG|Misoprostol|
219602806|NCT05976984|OTHER|Aim 1 (case-cohort study)|"* Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020"
218876752|NCT02303106|DRUG|Lamotrigine|
218876753|NCT01501552|OTHER|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
219024896|NCT07190833|DRUG|OTS-412|3×10E8 pfu, once, 1 cycle, IT
219024897|NCT07190833|DRUG|OTS-412|optimal dose, once, 1 cycle, IT
219024898|NCT07189949|DRUG|HRS-2329 Tablet|Oral HRS-2329 tablet.
219024899|NCT07191093|PROCEDURE|pulmonary valvuloplasty|Pulmonary balloon valvuloplasty (PBV) is the treatment of choice for moderate to severe valvular pulmonary stenosis. It is a minimally invasive, catheter-based intervention that involves dilation of the stenotic pulmonary valve using an appropriately sized balloon. The goal is to relieve obstruction, reduce right ventricular pressure, and prevent long-term complications such as RV hypertrophy, dysfunction, and arrhythmias. The procedure has shown excellent immediate and long-term outcomes, particularly in patients with a pliable, doming pulmonary valve and no significant regurgitation or associated congenital lesions.
219024900|NCT07191444|BIOLOGICAL|Firsekibart|Firsekibart will be administered according to the protocol
219024901|NCT07191444|BIOLOGICAL|Anakinra|Anakinra will be administered according to the protocol
219024902|NCT07189520|OTHER|Artificial Intelligence|Benchmark AI scoring vs expert raters (GEARS/OCHRA κ ≥0.75)• Assess performance gains after GenAI feedback (≥15% improvement)• Measure usability, cognitive load, and ecological footprint reduction
219024903|NCT07191418|DEVICE|Habib™ EndoHPB|This study will hold greater weight compared to previous ones, as it is randomized. It includes 178 patients, exclusively with pancreatic cancer, and is designed as a prospective investigation.
219495771|NCT01866488|OTHER|Placebo|
219495772|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
219495773|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
219495774|NCT00071409|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
219495775|NCT00237328|DRUG|Heparin|Heparin will be used as the intra-operative anticoagulant
219495776|NCT02358954|PROCEDURE|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
219495777|NCT02358954|PROCEDURE|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
219495778|NCT02358954|PROCEDURE|3D Turntable|
219495779|NCT02358954|PROCEDURE|Vection stimulation|
218876754|NCT01501552|OTHER|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
218876755|NCT01501552|OTHER|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
219024904|NCT07191418|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) as part of clinical routine.
219024905|NCT07189715|BEHAVIORAL|Imagery Rescripting Intervention (AI-Generated)|Participants listened to a series of personalized audio scenarios based on their childhood memories of parental criticism and neutral events. At the end of the session, one critical scenario was presented in a modified version that included a therapeutic imagery rescripting (ImRs) intervention. In this script, a therapist figure entered the scene and addressed the child's unmet needs, following the standard rescripting format. The scripts were generated using the Gemini large language model and reviewed by trained experimenters to ensure coherence and therapeutic validity. The intervention aimed to reduce distress and intrusive thoughts related to the memory.
219024906|NCT07189455|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219024907|NCT07189455|DRUG|Topotecan|Topotecan will be administered per local standard of care
219024908|NCT07191262|OTHER|0.12% CHX and Essential Oil mouthrinse|0.12% CHX mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use OTC essential oil mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
218876756|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
218876757|NCT00013169|BEHAVIORAL|Strong Patient Focus|
218876758|NCT02462993|DRUG|Aloe Vera|Local drug delivery of aloe vera gel
218876759|NCT00470418|DRUG|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
219495780|NCT06565728|DRUG|Vitamin D3 2000 UNT Oral Tablet|To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
219495781|NCT02104128|DRUG|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
219495782|NCT00630682|DRUG|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
218876760|NCT00470418|DRUG|Placebo|placebo comparator
219024909|NCT07191262|OTHER|2.6% EDTA and 0.2% EDTA mouth rinse|.6% EDTA mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use 0.2% EDTA mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
219024910|NCT07190365|BEHAVIORAL|GOALS TH|The Goal-Oriented Attentional Self-regulation training involves ten 2-hour sessions of group-based telehealth training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice. It is conducted in a small group format.
219024911|NCT07190365|BEHAVIORAL|EDU TH|The EDU TH training is an active control training matched with GOALS TH for therapist time, homework load, and participation in a group. It involves ten 2-hour telehealth sessions of group-based training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice.
219024912|NCT07190352|DEVICE|iTBS to the DMN|Intermittent theta-burst frequency rTMS (iTBS) targeted to the parietal node of the default mode network.
219495783|NCT00630682|DRUG|Placebo|9 weeks of placebo 60mg capsules QD.
219495784|NCT00948025|DEVICE|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
219495785|NCT00948025|OTHER|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
219495786|NCT06274125|PROCEDURE|Robotic-Assisted Laparoscopic Radical Prostatectomy|To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
219495787|NCT03167814|DIETARY_SUPPLEMENT|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
219495788|NCT03640000|DIAGNOSTIC_TEST|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
219495789|NCT01456585|OTHER|Gemcitabine|
219495790|NCT01456585|DRUG|CP-870,893|
219495791|NCT01140178|DRUG|HPPH|Given IV
219495792|NCT02020733|DEVICE|Balloon catheter|
219495793|NCT02020733|DEVICE|metal cannula|
219495794|NCT01637961|DRUG|Alisertib|Given PO
219495795|NCT01637961|OTHER|Laboratory Biomarker Analysis|Correlative studies
219495796|NCT05827783|PROCEDURE|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
219495797|NCT05827783|PROCEDURE|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
218876761|NCT05028270|PROCEDURE|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
218876762|NCT00938691|PROCEDURE|Intradermal Suture|
218876763|NCT00938691|PROCEDURE|Intradermal Suture|
218876764|NCT00599638|DRUG|pregabalin|75mg bid titrating to 150mg bid on day 4
218876765|NCT00599638|DRUG|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
218876766|NCT00599638|DRUG|Placebo|Placebo
218876767|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
218876768|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
218876769|NCT02825212|DRUG|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
218876770|NCT02825212|DRUG|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
219024913|NCT07190352|DEVICE|cTBS to the DMN|Continuous theta-burst frequency rTMS (cTBS) targeted to the parietal node of the default mode network
219024914|NCT07190352|DEVICE|Sham rTMS|Sham rTMS: coil flipped 180 degrees and applied to the parietal node of the DMN using an iTBS sequence. For this sham condition, rTMS felt and sounded like active stimulation, but no actual stimulation was delivered.
219024915|NCT07190768|OTHER|Kinesio Taping|"Participants received Kinesio Taping (KT) applied to the affected shoulder using standard 5-cm Kinesio Tex tape. Before application, an allergy test was performed by placing a small patch of tape on the contralateral forearm for 15 minutes. The taping procedure included three regions: supraspinatus muscle, deltoid muscle, and glenohumeral joint.~Application technique:~Supraspinatus: Y-strip applied from insertion on the greater tubercle along the muscle to its origin with 20-25% stretch.~Deltoid: Y-strip applied from 3 cm below insertion to the origin, with anterior and posterior tails placed along corresponding edges.~Glenohumeral joint: I-strip applied from the coracoid process, laterally under the acromion, around the posterior deltoid edge.~Schedule: Tape was applied at baseline (Day 0), reapplied at Day 7, and removed permanently at Day 14."
218876771|NCT03730415|PROCEDURE|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
219024916|NCT07190768|OTHER|Dry Needling|"Participants received dry needling (DN) applied with sterile, disposable stainless-steel needles (0.30 mm × 50 mm). Target muscles included the supraspinatus, deltoideus, infraspinatus, subscapularis, and pectoralis major.~Technique: The fast-in, fast-out method (Hong technique) was used. After cleaning the skin with alcohol, the needle was inserted into a palpable taut band until the first local twitch response (LTR) was elicited. The needle was moved vertically (5-10 mm) at \~1 Hz for 25-30 seconds. DN was applied for 45-60 seconds per muscle.~Schedule: Twice per week, for 3 weeks (total of 6 sessions)."
219200340|NCT06418347|DRUG|Letrozole|Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
219200341|NCT06738329|OTHER|Carrageenan gummy sweet|Gummy sweet containing carrageenan and agar as the gelling agents.
219200342|NCT06738329|OTHER|Carrageenan and inulin gummy sweet|Gummy sweet containing agar and carrageenan as gelling agents, with added inulin.
218876772|NCT04713501|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
218876773|NCT04913740|OTHER|Ointment and dressing for external use|"1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
219200343|NCT06738329|OTHER|Placebo agar agar gummy|Gummy sweet containing agar as gelling agents.
219495798|NCT03317145|DEVICE|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
219495799|NCT03317145|DEVICE|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
218876774|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
219495800|NCT04651283|OTHER|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
219495801|NCT04651283|OTHER|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
219495802|NCT01878747|BEHAVIORAL|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
219495803|NCT03602898|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219495804|NCT03602898|DRUG|Busulfan|Given IV or PO
218876775|NCT04882787|DEVICE|BTE hearing aid|Amplification
218876776|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
218876777|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
218876778|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
218876779|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
218876780|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
218876781|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
219495805|NCT03602898|DRUG|Cyclophosphamide|Given IV
219495806|NCT03602898|DRUG|Cyclosporine|Given IV or PO
219495807|NCT03602898|DRUG|Fludarabine Phosphate|Given IV
219495808|NCT03602898|DRUG|Methotrexate|Given IV
219495809|NCT03602898|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
219495810|NCT03602898|OTHER|Quality-of-Life Assessment|Ancillary studies
219495811|NCT03602898|OTHER|Questionnaire Administration|Ancillary studies
219602807|NCT05976984|OTHER|Aim 2 (case-crossover study)|"* Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose"
218876782|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
218876783|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
218876784|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
219495812|NCT03602898|DRUG|Tacrolimus|Given IV or PO
219495813|NCT03602898|RADIATION|Total-Body Irradiation|Undergo TBI
219495814|NCT03671265|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
219602808|NCT05976984|OTHER|Aim 3 (cohort study)|All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
219602809|NCT05137054|DRUG|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
218876785|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
218876786|NCT00001696|DRUG|Genistein|
218876787|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
218876788|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
218876789|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
219024917|NCT07190768|BEHAVIORAL|Exercise Program|"All participants were instructed in a standardized home-based exercise program designed to improve shoulder mobility and stability.~Content: Exercises included active range-of-motion movements, scapular stabilization, and strengthening of rotator cuff and periscapular muscles. Ergonomic advice and posture correction were also provided.~Delivery: Participants were taught the program in person and instructed to perform the exercises at home.~Schedule: Exercises were performed daily for 3 weeks, in addition to the assigned intervention for each study arm."
219495815|NCT03671265|RADIATION|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
219495816|NCT03671265|DRUG|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
219495817|NCT02833857|DRUG|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
219495818|NCT03182920|DRUG|Lasmiditan|Oral administration
219495819|NCT03182920|DRUG|Placebo|Oral administration
219495820|NCT02542150|DRUG|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
219495821|NCT02542150|DRUG|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
219495822|NCT06019130|DRUG|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
219495823|NCT06019130|DRUG|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
219495824|NCT06019130|DRUG|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
219602810|NCT05137054|DRUG|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
218876790|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
218876791|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
218876792|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
219495825|NCT06019130|DRUG|Gemcitabine|Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis
219495826|NCT06019130|RADIATION|Radiotherapy|After induction therapy in all patients
219495827|NCT06019130|DRUG|Interferon beta-1a|In patients \< 26 years after end of radiochemotherapy for 6 months
219495828|NCT06019130|PROCEDURE|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
219495829|NCT06019130|PROCEDURE|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
219495830|NCT06019130|BEHAVIORAL|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
219495831|NCT05610930|OTHER|Front-of-pack label NutriScore 2.0|"Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire."
219495832|NCT06270030|DRUG|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
219495833|NCT06270030|DRUG|LNZ100 (Aceclidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
219495834|NCT06270030|DRUG|Placebo (Vehicle) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
219495835|NCT00370669|DRUG|bevacizumab|
219495836|NCT00370669|DRUG|triamcinolone acetonide|
219495837|NCT00838669|DRUG|Extended release OROS paliperidone|
219602811|NCT05137054|DRUG|Carfilzomib|Carfilzomib is administered by IV infusion
219602812|NCT05137054|DRUG|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
219602813|NCT05137054|DRUG|Bortezomib|Bortezomib is administered by IV infusion or SC injection
219602814|NCT05137054|DRUG|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
218876793|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
218876794|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
218876795|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
218876796|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
219495838|NCT02082912|DRUG|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
219495839|NCT02082912|OTHER|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
219495840|NCT02082912|DEVICE|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
218876797|NCT01262664|DRUG|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
219495841|NCT03426319|DIAGNOSTIC_TEST|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
218876798|NCT04783077|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
218876799|NCT04783077|BEHAVIORAL|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
218876800|NCT04783077|BEHAVIORAL|Docudrama|Participants will be exposed to a document-drama related to blood donation.
218876801|NCT01141491|BIOLOGICAL|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
218876802|NCT01141491|BIOLOGICAL|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
218876803|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
218876804|NCT04130698|BEHAVIORAL|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
218876805|NCT04130698|DRUG|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
218876806|NCT04130698|BEHAVIORAL|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
218876807|NCT00147004|DRUG|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
218876808|NCT00147004|DRUG|Placebo|
218876809|NCT04870918|BEHAVIORAL|self-care intervention|Health education will be carried out by the nurse.
218876810|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
218876811|NCT03739515|OTHER|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
218876812|NCT03739515|OTHER|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
218876813|NCT05943782|PROCEDURE|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
218876814|NCT05943782|PROCEDURE|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
218876815|NCT06195189|DRUG|Sunvozertinib|Sunvozertinib 200mg Quaquedie (QD)
218876816|NCT06195189|DRUG|Chemotherapy|Pemetrexed +platinum
218876817|NCT03689855|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
219602815|NCT05137054|DRUG|Isatuximab|Isatuximab is administered by IV infusion
219602816|NCT05137054|DRUG|Fianlimab|Fianlimab is administered by IV infusion
219602817|NCT05137054|DRUG|Cemiplimab|Cemiplimab is administered by IV infusion
219602818|NCT05137054|DRUG|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
218876818|NCT03689855|DRUG|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
218876819|NCT03689855|PROCEDURE|Peripheral blood draw|-Baseline and Cycle 2 Day 1
218876820|NCT03689855|PROCEDURE|Biopsy|"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
218876821|NCT02654938|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
218876822|NCT02654938|DRUG|Placebo|5% infusion solution of dextrose
218876823|NCT02448290|DRUG|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
218876824|NCT02218944|BEHAVIORAL|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
218876825|NCT02409719|OTHER|Schedule|Illustrative daily planner to point the day that the exercise was performed
218876826|NCT02409719|OTHER|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
218876827|NCT05325385|OTHER|There are no interventions - this is a database study only|There are no interventions - this is a database study only
218876828|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
218876829|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
218876830|NCT00343707|DRUG|vestipitant|
218876831|NCT00343707|DRUG|paroxetine|
218876832|NCT02461082|DEVICE|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
218876833|NCT02461082|OTHER|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
218876834|NCT02479139|BIOLOGICAL|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
218876835|NCT02479139|BIOLOGICAL|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
219602819|NCT05137054|DRUG|Cevostamab|Cevostamab is administered by IV infusion
219602820|NCT05780073|DRUG|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
218876836|NCT01391988|PROCEDURE|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
218876837|NCT01391988|PROCEDURE|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
218876838|NCT02666612|PROCEDURE|Blood samples|
218876839|NCT05201950|OTHER|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
218876840|NCT05201950|OTHER|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
218876841|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
218876842|NCT01767623|DRUG|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
218876843|NCT00764673|DEVICE|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
218876844|NCT02193412|PROCEDURE|noxious stimulus|standardized noxious stimulus with tetanic stimulation
218876845|NCT02193412|PROCEDURE|change in operating table slope: head-down tilt position|-30°
218876846|NCT02193412|PROCEDURE|change in operating table slope: head-up tilt position|+30°
218876847|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
218876848|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
218876849|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
218876850|NCT05945160|DRUG|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
218876851|NCT05945160|DRUG|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
218876852|NCT05380167|DIETARY_SUPPLEMENT|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
218876853|NCT05380167|DIETARY_SUPPLEMENT|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
218876854|NCT01438177|DRUG|Velcade|
219602821|NCT05780073|OTHER|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
219602822|NCT01708941|BIOLOGICAL|Ipilimumab|Given IV
219602823|NCT01708941|OTHER|Laboratory Biomarker Analysis|Correlative studies
219602824|NCT01708941|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV or SC
219602825|NCT01575548|PROCEDURE|Computed Tomography|Undergo CT
219602826|NCT01575548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602827|NCT01575548|DRUG|Pazopanib Hydrochloride|Given PO
219602828|NCT01575548|OTHER|Placebo Administration|Given PO
219200344|NCT06747650|BEHAVIORAL|Dialectical Behavior Therapy for Adolescents|Standard of care (SOC) DBT-A includes approximately six weeks of pretreatment, and approximately six months of DBT-A skills group, individual therapy, and 24/7 phone coaching. During pre-treatment, clients are oriented to the DBT-A model and client commitment to treatment is established. After approximately six weeks, the client enters DBT-A skills group along with their caregiver. This skills group meets weekly for 1.5 hours and clinicians explain the five main DBT-A skills (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path) via PowerPoints and discussion. Clients and their caregivers are assigned weekly homework. At the same time, teens are completing weekly 1-hour individual therapy sessions where they are utilizing the skills learned in group. Both teens and caregivers have access to what DBT-A calls 24/7 phone coaching. This phone coaching is 24/7 access to a therapist when a crisis is arising.
219200345|NCT02765412|OTHER|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
219602829|NCT01575548|OTHER|Questionnaire Administration|Ancillary studies
219602830|NCT05309421|DRUG|EVX-01|Investigational drug given in combination with standard of care
219602831|NCT05309421|DRUG|Pembrolizumab 25 MG/ML|Standard of care
219602832|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
219602833|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
219602834|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida (UCF); Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
219602835|NCT04684368|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
219602836|NCT04684368|DRUG|Carboplatin|Given IV
219602837|NCT04684368|DRUG|Etoposide|Given IV
219602838|NCT04684368|BIOLOGICAL|Filgrastim|Given subcutaneously (SC) or IV
219602839|NCT04684368|DRUG|Ifosfamide|Given IV
219602840|NCT04684368|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218876855|NCT01438177|DRUG|Cyclophosphamide|
218876856|NCT01438177|DRUG|Chloroquine|
218876857|NCT05457088|OTHER|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
218876858|NCT05457088|OTHER|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
218876859|NCT01727336|DRUG|Dalantercept and axitinib|
219602841|NCT04684368|DRUG|Mesna|Given IV or orally
218876860|NCT01727336|DRUG|Placebo and axitinib|
218876861|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
218876862|NCT00849862|DRUG|Keppra®|750 mg Tablet
219602842|NCT04684368|BIOLOGICAL|Pegfilgrastim|Given SC
219602843|NCT04684368|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
219602844|NCT04684368|OTHER|Questionnaire Administration|Ancillary studies
219602845|NCT04684368|RADIATION|Radiation Therapy|Undergo WVSCI radiation therapy
219602846|NCT04684368|RADIATION|Radiation Therapy|Undergo radiation therapy
219602847|NCT04684368|PROCEDURE|Second-Look Surgery|Undergo second-look surgery if needed
219602848|NCT04684368|DRUG|Thiotepa|Given IV
219602849|NCT04175912|DRUG|Carboplatin|Given IV
219602850|NCT04175912|DRUG|Paclitaxel|Given IV
219602851|NCT04175912|DRUG|Pevonedistat|Given IV
219602852|NCT05004311|DRUG|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
219602853|NCT03952585|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219602854|NCT03952585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602855|NCT03952585|DRUG|Cisplatin|Given IV
219602856|NCT03952585|PROCEDURE|Computed Tomography|Undergo CT
219602857|NCT03952585|OTHER|Fludeoxyglucose F-18|Receive FDG
219602858|NCT03952585|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
219602859|NCT03952585|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219602860|NCT03952585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602861|NCT03952585|BIOLOGICAL|Nivolumab|Given IV
219602862|NCT03952585|PROCEDURE|Positron Emission Tomography|Undergo PET
219602863|NCT03952585|OTHER|Quality-of-Life Assessment|Ancillary studies
219602864|NCT03952585|OTHER|Questionnaire Administration|Ancillary studies
219602865|NCT05273307|DIETARY_SUPPLEMENT|Miraculin|Given orally
219602866|NCT05273307|DIETARY_SUPPLEMENT|Miracle Fruit Placebo Cube|Given orally
218876863|NCT03590951|OTHER|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
218876864|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
218876865|NCT01014039|PROCEDURE|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
218876866|NCT00908102|OTHER|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
218876867|NCT00908102|OTHER|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
218876868|NCT00908102|OTHER|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
218876869|NCT00908102|OTHER|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
218876870|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
218876871|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
218876872|NCT04217213|PROCEDURE|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
218876873|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
218876874|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
218876875|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
218876876|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
218876877|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
218876878|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
218876879|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
218876880|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
219602867|NCT02048813|DRUG|Cyclophosphamide|Given IV
218876881|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
218876882|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
218876883|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
218876884|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
219602868|NCT02048813|DRUG|Fludarabine Phosphate|Given IV
219602869|NCT02048813|DRUG|Ibrutinib|Given PO
219602870|NCT02048813|OTHER|Laboratory Biomarker Analysis|Correlative studies
219602871|NCT02048813|OTHER|Pharmacogenomic Study|Correlative studies
219602872|NCT02048813|OTHER|Quality-of-Life Assessment|Ancillary studies
218876885|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
218876886|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
218876887|NCT02678299|DRUG|PREBEN|
219602873|NCT02048813|BIOLOGICAL|Rituximab|Given IV
219602874|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
219602875|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
219602876|NCT04310007|PROCEDURE|Biospecimen Collection|Undergo blood collection
219602877|NCT04310007|DRUG|Cabozantinib S-malate|Given PO
219024918|NCT07190768|DEVICE|Conventional Physical Therapy (TENS/Ultrasound/Heat pack)|"Participants in this arm received conventional physical therapy modalities commonly used for the management of subacromial pain syndrome.~Modalities: Transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, or superficial heat pack were applied based on standard clinical practice.~Additional care: Sessions also included passive mobilization of the shoulder into end range, scapular stabilization exercises, and ergonomic/postural advice.~Schedule: One-hour treatment sessions, 5 days per week, for 3 consecutive weeks."
219024919|NCT07189884|DRUG|Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine|"Pyrotinib Maleate Tablets: 320 mg/day administered continuously from the first day of the first course of treatment, orally within 30 minutes after breakfast, missed doses without refill, every 21 days as a cycle.~Dalpiciclib Isethionate Tablets: 125 mg orally every 28 days as a treatment cycle, with continuous medication for the first 3 weeks (Day 1 to Day 21), and rest (no medication) for the next 1 week (Day 22 to Day 28).~Endocrine therapy: The endocrine therapy drug is selected by the investigator."
219024920|NCT07191496|OTHER|Questionnaire|The questionnaires include the Ferrans and Powers QLI, EORTC QLQ-C30, FCR-7 Scale, HADS, and MOS Social Support Survey.
219024921|NCT07190235|DEVICE|Transcranial Magnetic Stimulation|The repetitive transcranial magnetic stimulation (rTMS) at different frequencies will deliver 10 sessions over 2 weeks. The participants will receive 25 Hz rTMS, 1 Hz rTMS, or sham stimulation protocol to the supplementary motor area while seated using a double-cone coil connected to a transcranial magnetic stimulator.
219024922|NCT07189910|DRUG|Eltrombopag|Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).
219024923|NCT07189910|OTHER|Placebo|Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).
219024924|NCT07191470|DEVICE|The Anaesthetic Conserving Device (AnaConDa)|The Anaesthetic Conserving Device (AnaConDa) was developed to facilitate the use of volatile anesthetics like isoflurane and isoflurane in mechanically ventilated patients outside the operating room. The device functions as a passive vaporizer, conserving anesthetic agents and reducing environmental contamination. Studies have demonstrated that AnaConDa-based inhaled sedation offers several advantages over intravenous sedation like better hemodynamic stability, reduced systemic inflammation, and faster recovery times.
219024925|NCT07189988|OTHER|psilocybin|All study participants were provided low dose psilocybin.
219024926|NCT07191405|DIETARY_SUPPLEMENT|oral Lactobacillus johnsonii (1×10¹¹ CFU, twice daily)|Lactobacillus johnsonii, as a member of gut probiotics, has recently gained attention for its potential role in tumor immunotherapy due to its ability to modulate the immune system and maintain gut microbiota balance. Below is a summary of its possible mechanisms and applications: 1.Modulating Gut Microbiota and Immune Microenvironment. 2.Direct or Indirect Activation of Anti-Tumor Immunity. 3.Enhancing Efficacy of Immune Checkpoint Inhibitors (ICIs) . 4.Anti-Tumor Effects of Microbial Metabolites. 5.Preclinical and Clinical Research Progress.
219024927|NCT07191405|DIETARY_SUPPLEMENT|Placebo|oral take placebo twice a day
219024928|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
219024929|NCT00702403|DRUG|nilotinib|Given PO
219024930|NCT00702403|DRUG|imatinib mesylate|Given PO
219024931|NCT00702403|OTHER|pharmacological study|Correlative studies
219024932|NCT04612647|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
219024933|NCT04612647|BEHAVIORAL|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
219024934|NCT00275210|DRUG|Oxaliplatin (SR96669)|
219024935|NCT02916615|OTHER|High nitrate vegetables|vegetables naturally high in nitrate
219024936|NCT02916615|DIETARY_SUPPLEMENT|Low nitrate vegetables + nitrate|pill containing KNO3
219024937|NCT02916615|OTHER|Low nitrate vegetables|vegetables naturally low in nitrate
219024938|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
219024939|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
219024940|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
219024941|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
219024942|NCT03257553|DIAGNOSTIC_TEST|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
219024943|NCT05798572|DRUG|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
219024944|NCT05798572|PROCEDURE|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
219024945|NCT00861107|BIOLOGICAL|AlloStim-7|intradermal injection once a week for 3 weeks
219024946|NCT00861107|PROCEDURE|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
219024947|NCT00861107|BIOLOGICAL|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
219602878|NCT04310007|PROCEDURE|Computed Tomography|Undergo CT
219602879|NCT04310007|DRUG|Docetaxel|Given IV
219602880|NCT04310007|PROCEDURE|Echocardiography Test|Undergo ECHO
219602881|NCT04310007|DRUG|Gemcitabine Hydrochloride|Given PO
219602882|NCT04310007|DRUG|Nab-paclitaxel|Given IV
219602883|NCT04310007|BIOLOGICAL|Nivolumab|Given IV
219602884|NCT04310007|DRUG|Paclitaxel|Given IV
219602885|NCT04310007|BIOLOGICAL|Ramucirumab|Given IV
218876888|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
218876889|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
218876890|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
218876891|NCT01700712|DIETARY_SUPPLEMENT|Probiotic Lactobacilli reuteri|
218876892|NCT01700712|DIETARY_SUPPLEMENT|Placebo|
218876893|NCT01532869|DRUG|Placebo|Subcutaneously weekly, Weeks 0-48
218876894|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
218876895|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
218876896|NCT03322670|OTHER|Signs of CAP and a positive chest X-Ray|"* collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28"
218876897|NCT03322670|OTHER|Patients directly hospitalized|"* collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90"
218876898|NCT03322670|DIAGNOSTIC_TEST|Control patients|\- bacteriological examinations (urine)
218876899|NCT03322670|OTHER|Patients with partial participation|\- collection of clinical examination data
218876900|NCT03322670|OTHER|Signs of CAP and a negative chest X-Ray|"* collection of clinical examination data~* telephone contact on day 28"
218876901|NCT05047432|OTHER|Non-interventional trial|Non-interventional trial
218876902|NCT05967949|DRUG|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
218876903|NCT00209898|PROCEDURE|Fast initiation procedure|
218876904|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
218876905|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
218876906|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
218876907|NCT03802903|DEVICE|Remo-Wax|topical treatment
218876908|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
219024948|NCT00861107|BIOLOGICAL|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
219024949|NCT05094934|DRUG|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
219024950|NCT06251856|BEHAVIORAL|lymphedema education program|On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
219024951|NCT03303404|DEVICE|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
219024952|NCT03121092|DRUG|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
219024953|NCT05791474|DRUG|ATI-2231|Provided by Aclaris Therapeutics, Inc.
219024954|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
219602886|NCT01708954|DRUG|Cabozantinib S-malate|Given PO
219602887|NCT01708954|DRUG|Erlotinib Hydrochloride|Given PO
218876909|NCT01230138|DRUG|Placebo|Placebo tablets
218876910|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
219495842|NCT06450600|BEHAVIORAL|Multiple Sclerosis Therapeutic Education Program|"The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience."
219495843|NCT01110499|DRUG|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
219495844|NCT01110499|DRUG|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
219495845|NCT01110499|DRUG|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
219495846|NCT01110499|DRUG|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
219495847|NCT01110499|DRUG|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
219495848|NCT01110499|DRUG|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
219602888|NCT01708954|OTHER|Laboratory Biomarker Analysis|Correlative studies
218876911|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
218876912|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
218876913|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
218876914|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
218876915|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
218876916|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
218876917|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
218876918|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
218876919|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
218876920|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
218876921|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
218876922|NCT03201159|DRUG|VLX103|150mg tablets
218876923|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
218876924|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
218876925|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
218876926|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
218876927|NCT02687087|DEVICE|Visco-ease|19.6 mg/mL of LMS-611
218876928|NCT02687087|DEVICE|Placebo|Physiological Saline
218876929|NCT01087216|DEVICE|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
218876930|NCT01087216|DRUG|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
219495849|NCT01110499|DRUG|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
219495850|NCT01110499|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
219495851|NCT02858856|DRUG|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
218876931|NCT01229449|DRUG|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
218876932|NCT01229449|DRUG|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
218876933|NCT01229449|DRUG|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
218876934|NCT01229449|DRUG|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
218876935|NCT01229449|DRUG|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
218876936|NCT02307162|DRUG|RPL554|Phosphodiesterase 3 and 4 Inhibitor
218876937|NCT02307162|DRUG|Placebo|Dummy solution
218876938|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
218876939|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
218876940|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
218876941|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
218876942|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
218876943|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
219602889|NCT05909748|DEVICE|GEMINUS Transcatheter Aortic Valve Implantation system|Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
219602890|NCT05488366|DRUG|Pembrolizumab|Given IV
219602891|NCT05488366|RADIATION|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
219602892|NCT01896999|PROCEDURE|Biopsy Procedure|Undergo biopsy
219602893|NCT01896999|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219602894|NCT01896999|DRUG|Brentuximab Vedotin|Given IV
218876944|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
219024955|NCT05875857|BEHAVIORAL|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
219024956|NCT04110132|PROCEDURE|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
219024957|NCT04110132|PROCEDURE|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
219495852|NCT02986152|BEHAVIORAL|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
218876945|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
218876946|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
219024958|NCT03084029|DRUG|Oxytocin|40 international units
219024959|NCT03084029|DRUG|Placebo|40 international units
219024960|NCT00380978|PROCEDURE|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
219495853|NCT02412956|BEHAVIORAL|SmokefreeMOM Text|
219495854|NCT03604354|DRUG|Tapentadol 100 MG Oral Tablet|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
219495855|NCT03604354|DRUG|Pregabalin 150mg|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
219495856|NCT02881073|OTHER|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
219495857|NCT01929148|PROCEDURE|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
219495858|NCT01929148|PROCEDURE|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
219495859|NCT04383080|PROCEDURE|Acupuncture|acupuncture at specific acupuncture points
219495860|NCT04383080|DEVICE|Low-level laser therapy|low level laser emission on specific acupuncture points
219495861|NCT01454882|BEHAVIORAL|Effects of Clothing|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
219495862|NCT01454882|BEHAVIORAL|Effects of Temperature|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
219495863|NCT01454882|BEHAVIORAL|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
219495864|NCT01454882|BEHAVIORAL|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
219495865|NCT01454882|BEHAVIORAL|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
219495866|NCT04737668|OTHER|Intrathecal pump refill with Virtual Reality|VR game
219495867|NCT04737668|OTHER|Intrathecal pump refill with distraction|Video
218876947|NCT06481085|DRUG|Placebo|Matching placebo will be provided
218876948|NCT00212706|DRUG|ONO-8025 (KRP-197)|
218876949|NCT00685737|DRUG|1-MNA|Capsule
218876950|NCT00685737|DRUG|Placebo|Capsule
218876951|NCT02722707|DEVICE|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
218876952|NCT00028574|DRUG|gabapentin|
219495868|NCT04737668|OTHER|Intrathecal pump refill|daily routine care for pump refill
218876953|NCT00028574|OTHER|placebo|
218876954|NCT05900973|DRUG|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
218876955|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
219495869|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
219495870|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
219602895|NCT01896999|PROCEDURE|Computed Tomography|Undergo CT
218876956|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
219024961|NCT00380978|PROCEDURE|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
219024962|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
219024963|NCT02985229|DRUG|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
219024964|NCT02985229|DRUG|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
219024965|NCT01729754|DRUG|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
219024966|NCT01729754|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
219024967|NCT01729754|DRUG|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
219024968|NCT01729754|DRUG|Etanercept Placebo|Matching placebo to etanercept administered SC
219024969|NCT01729754|DRUG|Etanercept 50 mg|Etanercept 50 mg administered SC
219495871|NCT04156074|DIETARY_SUPPLEMENT|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
219495872|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
219495873|NCT00443950|DRUG|Etanercept|
219495874|NCT05101356|BIOLOGICAL|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
219495875|NCT05101356|BIOLOGICAL|Sargramostim|Given SC
219495876|NCT05101356|BIOLOGICAL|Pembrolizumab|Given IV per standard of care
219495877|NCT01846832|DRUG|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
219495878|NCT01846832|DRUG|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
219495879|NCT01846832|DRUG|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is \< 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is \> or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
219495880|NCT05291156|DRUG|Cetuximab|"Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week."
219495881|NCT05291156|DRUG|Avelumab|Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
219602896|NCT01896999|BIOLOGICAL|Ipilimumab|Given IV
219024970|NCT04371887|OTHER|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
219024971|NCT00690014|DRUG|probenecid|500 mg q 6 hrs
219602897|NCT01896999|BIOLOGICAL|Nivolumab|Given IV
219602898|NCT01896999|PROCEDURE|Positron Emission Tomography|Undergo PET
219602899|NCT04710758|PROCEDURE|Laparoscopic total gastrectomy|LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
218876957|NCT05593627|DRUG|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
218876958|NCT05593627|DRUG|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
218876959|NCT01802307|RADIATION|Brachytherapy|
218876960|NCT02134678|BEHAVIORAL|self-system therapy|
218876961|NCT02134678|BEHAVIORAL|cognitive therapy|
219024972|NCT05149846|PROCEDURE|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
219024973|NCT00773292|DRUG|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
219024974|NCT04666233|PROCEDURE|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
219495882|NCT03709407|OTHER|cervical stimuli|Manouvres Godoy
219495883|NCT03709407|OTHER|terminus|Manouvres Vodder
219495884|NCT03709407|OTHER|Placebo|placebo manouvre
219495885|NCT03709407|OTHER|Control group|lie down
219602900|NCT04710758|PROCEDURE|Open total gastrectomy|OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
219602901|NCT03326492|DRUG|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
219602902|NCT06400251|PROCEDURE|Biopsy Procedure|Undergo biopsy
219602903|NCT06400251|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602904|NCT06400251|PROCEDURE|Computed Tomography|Undergo CT scan
219602905|NCT06400251|DRUG|Ipatasertib|Given PO
219602906|NCT06400251|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602907|NCT06517875|DRUG|Momelotinib|Momelotinib will be administered orally.
218876962|NCT03902119|DEVICE|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
218876963|NCT03902119|OTHER|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
218876964|NCT01590654|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
218876965|NCT01590654|DRUG|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
219602908|NCT06517875|DRUG|Luspatercept|Luspatercept will be administered subcutaneously.
219602909|NCT01794403|RADIATION|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
219602910|NCT01794403|RADIATION|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
219602911|NCT05558124|DRUG|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
219602912|NCT05558124|DRUG|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
218876966|NCT01636128|DRUG|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
218876967|NCT01636128|DRUG|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
218876968|NCT05009667|DEVICE|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
218876969|NCT05009667|DEVICE|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
218876970|NCT04530500|GENETIC|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
218876971|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
218876972|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
218876973|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
218876974|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
218876975|NCT01508260|PROCEDURE|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
218876976|NCT01508260|DRUG|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
218876977|NCT02837042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
218876978|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
218876979|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
218876980|NCT00306709|BEHAVIORAL|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
218876981|NCT03033264|DRUG|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
218876982|NCT03033264|DEVICE|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
218876983|NCT04462965|COMBINATION_PRODUCT|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
219024975|NCT04666233|PROCEDURE|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
219602913|NCT06629103|DIETARY_SUPPLEMENT|life's Omega 1035DS|A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
219602914|NCT06629103|DIETARY_SUPPLEMENT|Fish Oil|Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
219602915|NCT06629103|OTHER|Placebo|The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
219602916|NCT06629103|DIETARY_SUPPLEMENT|life's Omega O3020DS|A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
219495886|NCT01577966|DRUG|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
219495887|NCT06344988|OTHER|The exercise program|The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.
219495888|NCT06344988|OTHER|Online education presentation|This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
219495889|NCT06344988|DEVICE|Smart band|Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
219495890|NCT04278365|BEHAVIORAL|Positive affect training|Behavioral training involving position emotion enhancement
219495891|NCT02177773|PROCEDURE|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
219495892|NCT02177773|DRUG|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
218876984|NCT04462965|COMBINATION_PRODUCT|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
218876985|NCT04484207|OTHER|A short video intervention|Three minutes video of a veteran that shares his personal story
218876986|NCT04484207|OTHER|A vignette intervention|A written description of the content of the video
218876987|NCT03514433|OTHER|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
218876988|NCT04629846|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
218876989|NCT04629846|DRUG|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
218876990|NCT04629846|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
218876991|NCT04629846|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
218876992|NCT04629846|PROCEDURE|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
218876993|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
218876994|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
218876995|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
218876996|NCT03037983|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
218876997|NCT03037983|DEVICE|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
218876998|NCT04114110|OTHER|RTLS data|data extraction from RTLS
218876999|NCT01862549|BEHAVIORAL|Dialectical Behavior Therapy for children|
219495893|NCT02177773|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
218877000|NCT01862549|BEHAVIORAL|Treatment as Usual|
218877001|NCT05032339|DIAGNOSTIC_TEST|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
218877002|NCT05030480|DIAGNOSTIC_TEST|renal functions|urea, creatinine, GFR
219024976|NCT00263146|PROCEDURE|recruitment maneuver|
219495894|NCT02177773|PROCEDURE|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
219495895|NCT02523729|DIETARY_SUPPLEMENT|Anke Malz|non-alcoholic malt drink
219495896|NCT04596462|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
219495897|NCT02540720|DRUG|Dexamethasone|
219495898|NCT02540720|DRUG|Gamma globulin|
219495899|NCT02540720|PROCEDURE|Hemoperfusion|
219495900|NCT03901222|DEVICE|tDCS|20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
219495901|NCT03538522|DRUG|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
219495902|NCT03538522|DRUG|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
219495903|NCT03538522|DRUG|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
218877003|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
218877004|NCT01894022|DRUG|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
219024977|NCT06032247|BEHAVIORAL|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
219024978|NCT06032247|BEHAVIORAL|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
219024979|NCT02417012|BEHAVIORAL|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
219024980|NCT02417012|BEHAVIORAL|Standard care|Standard individual diabetes support
219495904|NCT03538522|DRUG|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
219495905|NCT03512067|DEVICE|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
219495906|NCT00819858|DIETARY_SUPPLEMENT|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
219495907|NCT02206724|RADIATION|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
218877005|NCT03134690|PROCEDURE|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
218877006|NCT03134690|PROCEDURE|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
219024981|NCT00542919|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
219024982|NCT03669692|BEHAVIORAL|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
219024983|NCT03669692|BEHAVIORAL|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
219200346|NCT02765412|OTHER|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
219495908|NCT03635619|OTHER|No intervention|No intervention
219495909|NCT00782275|DRUG|bevacizumab|
219495910|NCT00782275|DRUG|temsirolimus|
219495911|NCT01637259|DRUG|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
219495912|NCT01637259|DRUG|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
219495913|NCT01637259|DRUG|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
219495914|NCT03205007|BEHAVIORAL|Health promotion nutrition program|Health promotion nutrition program
219495915|NCT00406107|DRUG|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
219495916|NCT00004861|DRUG|gemcitabine hydrochloride|
219495917|NCT00004861|DRUG|tacedinaline|
218877007|NCT04499222|DEVICE|Portex|nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.
218877008|NCT04499222|DEVICE|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
219024984|NCT01157507|DRUG|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
219024985|NCT01157507|PROCEDURE|Bladder overdistension|Bladder overdistension
219024986|NCT01157507|DRUG|Placebo|One single injection of placebo
219024987|NCT02670655|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
219024988|NCT02670655|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
219495918|NCT00572247|BEHAVIORAL|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
219495919|NCT04701476|DRUG|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
219495920|NCT04701476|DRUG|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
219495921|NCT04701476|DRUG|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
219495922|NCT00612794|DRUG|exenatide once weekly|subcutaneous injection, once weekly
218877009|NCT04994678|OTHER|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
218877010|NCT04994678|OTHER|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
218877011|NCT04965532|DRUG|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
218877012|NCT04965532|DRUG|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
218877013|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
218877014|NCT05082415|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
219024989|NCT02670655|DRUG|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
219024990|NCT02670655|DEVICE|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
218877015|NCT00410605|BIOLOGICAL|bevacizumab|Given IV
218877016|NCT00410605|DRUG|lenalidomide|Given orally
218877017|NCT00410605|DRUG|dexamethasone|Given orally
218877018|NCT01289366|DEVICE|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
218877019|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
218877020|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
218877021|NCT05228561|OTHER|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
219024991|NCT02670655|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
219024992|NCT00919776|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
219200347|NCT02765412|OTHER|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
219200348|NCT02765412|OTHER|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
219200349|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
219495923|NCT00612794|DRUG|placebo|subcutaneous injection, once weekly
218877022|NCT04883814|DIAGNOSTIC_TEST|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
219024993|NCT00919776|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
219200350|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
219200351|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
219200352|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
219200353|NCT06877390|OTHER|conventional drug and exercise rehabilitation|patients in the control group received antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel, once a day), β-blocker (25-100 mg of metoprolol, twice a day, with the dose adjusted based on the patient's heart rate) and statins (10-20 mg of rosuvastatin, every night). In addition, the patients received exercise rehabilitation (e.g. aerobic, resistance and flexibility training) for 30-60 min, 3-5 times/week.
219200354|NCT06877390|DEVICE|EECP-based rehabilitation regimen|Patients in the rehabilitation group received the same medication and exercise rehabilitation as the control group during the trial period after undergoing DCB-based PCI DCBs; in addition, they were provided with EECP treatment after 7 days of medication. The treatment adopted a P-ECP/TI EECP device with a pressure setting of 0.020-0.035 MPa. Based on patients' actual tolerance, the treatment pressure and inflation and exhaust times were adjusted to a diastolic/systolic blood pressure ratio of \>1.2 and a diastolic/systolic pressure area of 1.5-2.0. The treatment was applied daily for 1 hour, 6 days a week, for a total of 36 hours.
219495924|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
218877023|NCT04855383|DRUG|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
218877024|NCT04058886|BEHAVIORAL|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
218877025|NCT03184285|PROCEDURE|baseline alert 1|measurement in supine position
218877026|NCT03184285|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
218877027|NCT03184285|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
218877028|NCT03184285|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
218877029|NCT03184285|PROCEDURE|passive leg raising|measurement under passive leg raising
218877030|NCT03184285|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
218877031|NCT03184285|PROCEDURE|baseline in narcosis 2|measurement in supine position
218877032|NCT03184285|PROCEDURE|start capnoperitoneum|measurement in supine position
218877033|NCT03184285|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
218877034|NCT03184285|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
218877035|NCT03184285|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
218877036|NCT03184285|PROCEDURE|baseline|measurement in supine position
218877037|NCT03184285|PROCEDURE|baseline alert 2|measurement in supine position
218877038|NCT03184285|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
218877039|NCT03184285|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
218877040|NCT02332291|DRUG|Escitalopram|Escitalopram 10-20mg daily
219495925|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
219495926|NCT01122043|DEVICE|Endoglide|Device
219495927|NCT03432026|DEVICE|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
218877041|NCT02332291|DRUG|Bupropion XL|Bupropion XL 150-450mg daily
218877042|NCT04751877|DRUG|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
218877043|NCT04751877|DRUG|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
218877044|NCT04751877|DRUG|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
218877045|NCT04751877|DRUG|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
218877046|NCT03821194|OTHER|Gua sha|Scrape the skin around the knee joint
218877047|NCT03821194|OTHER|hot pack|hot pack
218877048|NCT05318911|DIETARY_SUPPLEMENT|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
218877049|NCT05318911|OTHER|Placebo Drink|Placebo drink (skimmed milk)
218877050|NCT03328351|OTHER|manual therapy|"1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
218877051|NCT03328351|OTHER|Superficial soft tissue massage|"1\. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
218877052|NCT05036967|DRUG|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
219495928|NCT05654857|DIAGNOSTIC_TEST|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
219495929|NCT06530420|PROCEDURE|Umbilical hernia repair surgery|collected information about: gender, age, comorbidities, body weight, time of surgery, hernia size and treatment methods and reccurence
219495930|NCT03384420|BIOLOGICAL|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
219495931|NCT00289731|BIOLOGICAL|TWINRIX™|Intramuscular injection, 3 doses
219495932|NCT00289731|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
219495933|NCT00289731|BIOLOGICAL|HAVRIX™|Intramuscular injection, 2 doses
219495934|NCT00289731|BIOLOGICAL|HB VAX PRO™|Intramuscular injection, 3 doses
219495935|NCT00289731|BIOLOGICAL|Vaqta™|Intramuscular injection, 2 doses
219495936|NCT06290414|DIAGNOSTIC_TEST|infrared thermal camera|capturing thermographic imaging of gingiva to detect thermal changes due to inflammation as a result of periodontal disease
219495937|NCT05926336|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
219495938|NCT05926336|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
219495939|NCT00403364|DRUG|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
219495940|NCT02019979|DRUG|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
218877053|NCT04118595|BEHAVIORAL|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
219495941|NCT02019979|BEHAVIORAL|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
219495942|NCT00353938|DRUG|3,4-methylenedioxymethamphetamine (125 mg)|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
219495943|NCT00353938|DRUG|3,4-methyelendioxymethamphetamine (25 mg)|Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
219495944|NCT00353938|BEHAVIORAL|Therapy|Non-directive therapy performed by a team of two co-therapists
218877054|NCT04118595|BEHAVIORAL|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
218877055|NCT04118595|BEHAVIORAL|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
218877056|NCT00218972|BEHAVIORAL|Aerobic interval training|
218877057|NCT00218972|BEHAVIORAL|moderate intensity training|
218877058|NCT00218972|BEHAVIORAL|Recommendation of regular exercise|
219495945|NCT00330200|DRUG|ISIS 113715|
219495946|NCT03381885|BEHAVIORAL|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
219495947|NCT03381885|BEHAVIORAL|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
219495948|NCT02600806|DRUG|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
219024994|NCT06429462|DIAGNOSTIC_TEST|smartphone camera sensor tool|The study will involve the development and validation of a computer vision-based approach (using cameras to assess movements) to monitor knee flexion and extension, and a walking pattern assessment.
219495949|NCT02600806|DRUG|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
219495950|NCT05175456|OTHER|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
219495951|NCT05175456|DEVICE|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
219495952|NCT05842083|BEHAVIORAL|On-site supportive communication training|On-site supportive communication training
219495953|NCT02856997|DRUG|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
219495954|NCT00747747|BIOLOGICAL|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
219495955|NCT00747747|DEVICE|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
219495956|NCT04929197|DEVICE|PERSBRA|"After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA."
219495957|NCT04093947|OTHER|Observational study|Observational and prospective study
219495958|NCT03339635|DRUG|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
219495959|NCT03339635|DRUG|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
219495960|NCT03273127|DRUG|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
219495961|NCT03273127|DRUG|Placebo|Abediterol matching placebo without any pharmacological activity.
219495962|NCT00125476|BEHAVIORAL|Exercise|
219495963|NCT00865982|DRUG|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
218877059|NCT04078984|OTHER|Experimental|"* Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
218877060|NCT01505439|DRUG|solifenacin|oral
218877061|NCT01407445|DRUG|Placebo|1 tablet/ oral/ 3 times a day for 90 days
219495964|NCT04042974|DRUG|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
219495965|NCT04042974|DRUG|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
218877062|NCT01407445|DRUG|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
218877063|NCT04928118|OTHER|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
218877064|NCT02854748|DRUG|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
218877065|NCT02854748|DRUG|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
218877066|NCT02854748|DRUG|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
218877067|NCT06334068|OTHER|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
219495966|NCT02784860|DRUG|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
219495967|NCT02784860|DRUG|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
219495968|NCT03806894|DIAGNOSTIC_TEST|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
219495969|NCT04674176|DRUG|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
219495970|NCT02496260|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
219495971|NCT02496260|PROCEDURE|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
219495972|NCT04023994|DRUG|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
219495973|NCT04023994|DRUG|Placebo|Participants will be administered a single intravenous dose of matching placebo.
219495974|NCT03063489|DRUG|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
219602917|NCT04808245|DRUG|Tecentriq 1200 MG in 20 ML Injection|One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
219602918|NCT04808245|BIOLOGICAL|H3K27M peptide vaccine|The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
219602919|NCT04808245|OTHER|Imiquimod (5%)|One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
219602920|NCT03631199|DRUG|canakinumab|canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
218877068|NCT06334068|OTHER|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
218877069|NCT02220712|DRUG|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
218877070|NCT06350305|OTHER|questionnaire survey|subjects fill out questionnaires
218877071|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
218877072|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
218877073|NCT03534622|DRUG|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
219495975|NCT00923195|DRUG|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
219495976|NCT00923195|DRUG|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
219495977|NCT00923195|DRUG|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
219495978|NCT00923195|PROCEDURE|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
219495979|NCT00923195|DRUG|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
219495980|NCT00923195|DRUG|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
218877074|NCT05908201|BEHAVIORAL|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
218877075|NCT03624127|DRUG|BMS-986165|Specified dose on specified days
218877076|NCT03624127|OTHER|Placebo|Specified dose on specified days
218877077|NCT03624127|DRUG|Apremilast|Specified dose on specified days
218877078|NCT00153192|DRUG|Marinol (dronabinol)|
218877079|NCT03954262|BEHAVIORAL|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
219495981|NCT00923195|DRUG|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
219495982|NCT00923195|GENETIC|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
219495983|NCT00923195|GENETIC|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
219495984|NCT03953365|PROCEDURE|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
219495985|NCT04725526|DEVICE|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
219495986|NCT02516631|DRUG|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
219495987|NCT02516631|DRUG|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
219495988|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
219495989|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
219495990|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
219495991|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
218877080|NCT05338879|OTHER|Non-Interventional|No study treatment will be administered on this study.
218877081|NCT02607228|DRUG|Alobresib|Tablet administered orally once daily.
218877082|NCT02607228|DRUG|Enzalutamide|Capsules administered orally once daily.
218877083|NCT03687606|DRUG|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
218877084|NCT03687606|DRUG|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
218877085|NCT04480216|DEVICE|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
218877086|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
218877087|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
218877088|NCT02492282|DEVICE|Closed-Loop propofol and remifentanil system by Bispectral Index|
218877089|NCT02492282|DEVICE|Open-Loop propofol and remifentanil by Target Controlled Infusion|
218877090|NCT02492282|DRUG|propofol|
218877091|NCT02119390|BEHAVIORAL|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
219495992|NCT02314520|DEVICE|peripherally inserted central catheter|Any complication associated with central access
219024995|NCT01430481|DIETARY_SUPPLEMENT|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
219024996|NCT06155591|OTHER|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
219024997|NCT02308462|BEHAVIORAL|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011)."
219024998|NCT03790839|DRUG|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
219200355|NCT06883071|PROCEDURE|Endoscopic ultrasound (EUS)-guided spring plug combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
219495993|NCT02314520|DEVICE|centrally inserted central catheter|Central access not associated with any complication
219495994|NCT02423174|PROCEDURE|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
219495995|NCT02423174|DEVICE|FMwand Surgical System|
219495996|NCT02427373|DIETARY_SUPPLEMENT|fish oil ethyl ester|
219495997|NCT02427373|DIETARY_SUPPLEMENT|fish oil triglyceride|
219495998|NCT02427373|DIETARY_SUPPLEMENT|krill oil|
219495999|NCT06479044|DIAGNOSTIC_TEST|Herrmann Brain Model|The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
219496000|NCT02700802|OTHER|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
219496001|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
219496002|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
219496003|NCT03047382|OTHER|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
219496004|NCT06185712|BEHAVIORAL|Nurse-led disease management education|Nurse-led disease management education was applied to the intervention group
219496005|NCT02002117|OTHER|DNA mass|DNA mass spectrometry
219496006|NCT03205384|PROCEDURE|surgery|
219496007|NCT03309410|DIAGNOSTIC_TEST|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
219496008|NCT06463938|OTHER|Active comparator|CPP-ACP paste will be applied on exposed area
219496009|NCT06463938|DEVICE|Experimental group|Lasotronix will be applied following its protocol
219496010|NCT06463938|COMBINATION_PRODUCT|Combination of laser and paste|This group will receive the combination of above two treatments
219496011|NCT06463938|BEHAVIORAL|Control group|this will be a control group
219496012|NCT03567915|OTHER|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
219496013|NCT05961254|DEVICE|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
219496014|NCT00626483|BIOLOGICAL|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10\^7) is being assessed.
219496015|NCT00626483|DRUG|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
219496016|NCT00140998|DRUG|17 beta estradiol|
219496017|NCT02651896|RADIATION|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
219496018|NCT00467818|DRUG|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
218877092|NCT02119390|OTHER|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
218877093|NCT02119390|OTHER|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
218877094|NCT01020253|DRUG|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
219496019|NCT00467818|OTHER|Placebo|Same dosage as that of omega 3 fatty acids
218877095|NCT05873491|OTHER|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
219496020|NCT06531291|DRUG|Surufatinib|250 mg, po, qd, q3w
218877096|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
218877097|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
218877098|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
218877099|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
218877100|NCT00001967|DRUG|HAART|
218877101|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
218877102|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
218877103|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
218877104|NCT00877396|BIOLOGICAL|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
218877105|NCT00877396|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
218877106|NCT02349750|PROCEDURE|endometrial scratch injury|ESI using No.8 neonatal feeding tube
218877107|NCT00967096|DRUG|Rifaximin|Rifaximin for Bone marrow transplant patients
218877108|NCT03042130|OTHER|Standard of care|standard of care
218877109|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
218877110|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
218877111|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
218877112|NCT03052023|PROCEDURE|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
218877113|NCT03052023|PROCEDURE|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
218877114|NCT03052023|PROCEDURE|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
218877115|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
218877116|NCT01821482|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|
218877117|NCT03100773|OTHER|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
218877118|NCT03100773|PROCEDURE|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
219024999|NCT03790839|DRUG|Dorzagliatin|Glucokinase activator currently under development
219496021|NCT06531291|DRUG|Serplulimab|200 mg, iv, d1, q3w
219025000|NCT00410644|DRUG|OROS Hydromorphone HCI|
219025001|NCT04639609|OTHER|Characterization of Neuromuscular Function and Fatigue|at inclusion
219025002|NCT01689129|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
219025003|NCT01689129|DRUG|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
219025004|NCT00112502|DRUG|Celecoxib|400 mg orally twice a day continuous dosing
219025005|NCT00112502|DRUG|Isotretinoin|40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
219025006|NCT00112502|DRUG|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
219496022|NCT06531291|DRUG|standard chemotherapy|Decided by PI
219496023|NCT04031027|DRUG|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
219496024|NCT05817526|DRUG|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
219496025|NCT05817526|PROCEDURE|Autograft harvesting from chin|Autograft
219496026|NCT05065463|DRUG|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
219602921|NCT03631199|DRUG|canakinumab-matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
218877119|NCT04394650|BIOLOGICAL|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
219496027|NCT03587181|PROCEDURE|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
219496028|NCT00599183|OTHER|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
219496029|NCT04214951|DRUG|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
219496030|NCT04214951|DRUG|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
219496031|NCT00001427|DRUG|9-aminocamptothecin|
219496032|NCT03552120|BEHAVIORAL|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
219496033|NCT03552120|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
218877120|NCT04879173|DEVICE|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
218877121|NCT04995861|PROCEDURE|Adductor canal block and IPACK block|Peripheral nerve blocks
218877122|NCT05974813|DIETARY_SUPPLEMENT|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
218877123|NCT05974813|DIETARY_SUPPLEMENT|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
218877124|NCT02689167|DRUG|Sunitinib|
218877125|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
218877126|NCT04672915|DIAGNOSTIC_TEST|test of HBV DNA|Real time PCR or nested PCR to check
218877127|NCT01990859|BIOLOGICAL|Ipilimumab|
218877128|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
218877129|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
218877130|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
218877131|NCT00102427|BEHAVIORAL|Telephone-based collaborative care management|
218877132|NCT00771056|DRUG|Hydroxychloroquine|400mg by mouth daily x 1 year
218877133|NCT03409250|DRUG|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
218877134|NCT00459654|DRUG|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
218877135|NCT00459654|DRUG|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
218877136|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
219496034|NCT02974374|DRUG|PF-06835919|Single or repeated, escalating dose
219496035|NCT02974374|OTHER|Placebo|Single or repeated, escalating dose
218877137|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
218877138|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
218877139|NCT05407350|DIAGNOSTIC_TEST|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
218877140|NCT02693379|DEVICE|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
219025007|NCT00112502|DRUG|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
218877141|NCT05623358|OTHER|Pharmacist-led HFrEF medication optimization|In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a clinical pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy (OMT) for HFrEF as outlined by the 2021 Canadian Cardiovascular Society (CCS) HF guidelines. This will consist of, where possible, the combination of an angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) at target doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines, unless the patient is unable to tolerate these agents/doses.
218877142|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. The standard pathway in the HF clinic consists of an initial consultation with the multidisciplinary team (cardiologist, physician trainees, registered nurse and clinical pharmacist), follow-up visits approximately every 3 months with the nurse and cardiologist until discharge, along with telehealth nurse calls for medication titrations.
218877143|NCT01338584|BEHAVIORAL|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
218877144|NCT01338584|BEHAVIORAL|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
218877145|NCT04463667|OTHER|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
218877146|NCT05409937|OTHER|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
218877147|NCT05409937|OTHER|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
218877148|NCT05409937|OTHER|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
218877149|NCT06141759|OTHER|Exercise|Cheneau brace and Schroth Best Practice exercise
218877150|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
218877151|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
218877152|NCT00006400|DRUG|Hydroxyurea|Participants will receive hydroxyurea.
219496036|NCT03903640|DEVICE|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
219496037|NCT03903640|BIOLOGICAL|Nivolumab|-Standard of care
218877153|NCT00006400|DRUG|Placebo|Participants will receive placebo.
218877154|NCT02933502|DRUG|DSXS topical product|treatment daily for 28 days
218877155|NCT01201226|OTHER|Removal of half an ovary|Removal of half an ovary
218877156|NCT04365452|DEVICE|Invia Motion|Invia Motion NPWT system at cesarean delivery
218877157|NCT05391256|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|"Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided."
218877158|NCT04536207|OTHER|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
218877159|NCT04372459|BEHAVIORAL|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
218877160|NCT04372459|BEHAVIORAL|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
218877161|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
219025008|NCT01280292|DRUG|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
219496038|NCT03903640|BIOLOGICAL|Ipilimumab|-Standard of care
219496039|NCT00004686|DRUG|methotrexate|
219496040|NCT00004686|DRUG|prednisone|
219496041|NCT01523795|OTHER|Motion-controlled video gaming|Play of motion-controlled video games for one hour
219496042|NCT01523795|OTHER|Traditional video gaming|Participants played traditional video games for one hour
219496043|NCT01523795|OTHER|Television watching|Participants watched television for one hour
219496044|NCT06389279|OTHER|PENG block group|Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
219602922|NCT03631199|DRUG|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
219025009|NCT05719363|DEVICE|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
218877162|NCT03697681|DRUG|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
218877163|NCT03697681|DRUG|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
219025010|NCT01195428|DRUG|Simvastatin|Simvastatin 40 mg daily
218877164|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
218877165|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
218877166|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
218877167|NCT00453804|DRUG|injectable naltrexone|
219025011|NCT01195428|DRUG|Placebo|Placebo
219025012|NCT01496092|DRUG|Keto Acid|12 tablets per day
219025013|NCT01678963|DRUG|Squalamine lactate|Ophthalmic solution 0.2%
219200356|NCT06883071|PROCEDURE|Titanium clip plus EUS-guided spring plug placement for flow limiting combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
219200357|NCT06736951|OTHER|MMSH (Multi-Modal Sleep Hygiene) Bundle|Focus on Noise Reduce Noise Perception, Reduce Hallway Noise, Reduce Noise in Rooms Focus on Light Reduce Lights at Night, Increase Light in Day, Reduce Light Perception Focus on Staff-Patient Interactions Delirium Screening, Avoid Care Procedures at Night, Z-time Plan \&amp; Prep Focus on Daytime Activity Increased Mobility, Increase Patient Engagement Focus on Medications Pain Management, Medication Monitoring, Continue pharmacy protocols, Timing of Medications/Monitoring Labs
219200358|NCT06889909|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
219496045|NCT06389279|OTHER|FIC block group|Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
219496046|NCT06389279|OTHER|Femoral block group|Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
218877168|NCT00453804|DRUG|oral naltrexone|
218877169|NCT06416254|OTHER|Fibre-enriched diet|The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.
218877170|NCT06416254|OTHER|Control diet|The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
218877171|NCT03479710|BIOLOGICAL|FMT infusion|Fecal microbiota transplantation via OGD
219025014|NCT01678963|DRUG|Vehicle control|Ophthalmic solution vehicle control
219200359|NCT06889909|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
219200360|NCT06893497|DEVICE|Low Level Laser Therapy|In this study, which had more patients than other studies, different parameters were evaluated to determine the protocol of LLL therapy. These parameters were the cause of IAN injury, number of sessions, time of treatment start and period of follow-up.
219200361|NCT06894732|PROCEDURE|Rotary induced abortion|Rotary induced abortion under ultrasonic monitoring was performed with intravenous anesthesia.
219496047|NCT06389279|OTHER|Control group|No intervention
219496048|NCT01422733|DRUG|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
219496049|NCT01422733|DRUG|dexamethasone|1 mg PO twice
219496050|NCT01422733|DRUG|Cosyntropin|250 micrograms IV twice
219496051|NCT01422733|DRUG|rhCG|25 mcg IV twice
219496052|NCT01563471|DRUG|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
219496053|NCT01563471|DRUG|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
219496054|NCT06528249|DRUG|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
219496055|NCT01907659|OTHER|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
219496056|NCT01686178|BEHAVIORAL|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
219496057|NCT04999228|DRUG|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
219496058|NCT04999228|DRUG|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
219496059|NCT05305183|DRUG|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
219496060|NCT02143947|DEVICE|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
219496061|NCT02143947|DEVICE|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
219496062|NCT01244815|DRUG|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
219496063|NCT01244815|DRUG|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
218877172|NCT02403232|PROCEDURE|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
219496064|NCT01244815|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
219496065|NCT01887509|DEVICE|Probe-based confocal laser endomicroscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
219496066|NCT01887509|PROCEDURE|Rectoscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
219496067|NCT01887509|PROCEDURE|EUS|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
219496068|NCT01887509|PROCEDURE|Biopsy and resection|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
219496069|NCT02466100|BEHAVIORAL|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
219496070|NCT05122585|PROCEDURE|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
218877173|NCT02403232|DEVICE|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
218877174|NCT02403232|DEVICE|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
218877175|NCT06099834|OTHER|Patients selection|Patient selection were selected according to selected criteria.
218877176|NCT06099834|OTHER|Implnat placement|dental implants were applied as recommended by the manufacturer.
218877177|NCT06099834|OTHER|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
218877178|NCT04725487|OTHER|Standard integration program with social and health promoting intervention|"* Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops"
218877179|NCT04725487|OTHER|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
219200362|NCT06894251|DIETARY_SUPPLEMENT|LIMICOL® NG|All subjects will consume 2 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V2, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 1 tablet in the evening during dinner. If a dose is missed, 2 tablets can be taken at the next dose.
219200363|NCT06750861|DRUG|QL1706|QL1706+AG
219200364|NCT06742372|OTHER|combined inspiratory and aerobic exercise training|combined inspiratory and aerobic exercise training will be performed in healthy individuals
219200365|NCT06742372|OTHER|aerobic exercise training|aerobic exercise training will be performed in healthy individuals
219200366|NCT06748872|DRUG|Lymphodepletion|Cylcophosamide and Fludarabine
219200367|NCT06748872|BIOLOGICAL|TCR-T cells (MDG1015)|TCR-T cells (MDG1015)
219200368|NCT06748469|PROCEDURE|The duration of the intervention will be 240 seconds|Dorsal Root Ganglion pulsed radiofrequency 240sec
219200369|NCT06748469|PROCEDURE|Dorsal Root Ganglion pulsed radiofrequency 480sec|The duration of the intervention will be 480 seconds
219496071|NCT01173159|DRUG|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
218877180|NCT02956798|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
218877181|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
218877182|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
218877183|NCT01892891|DRUG|VBY-036|Cathepsin S inhibitor
218877184|NCT06124794|BIOLOGICAL|PROTOXIN|Clostridium botulinum toxin type A
218877185|NCT02577016|DRUG|Sitagliptin|50 mg tablet administered orally
218877186|NCT02577016|DRUG|Placebo|Placebo to sitagliptin administered orally
218877187|NCT02577016|DRUG|Ipragliflozin|50 mg tablet administered orally as background medication
218877188|NCT04411745|OTHER|No intervention, observational study|
219496072|NCT05172856|DRUG|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
218877189|NCT00345722|PROCEDURE|strawberry dietary intervention|
218877190|NCT00852501|OTHER|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
218877191|NCT04770844|OTHER|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
218877192|NCT02126839|DRUG|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
218877193|NCT02126839|DRUG|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
218877194|NCT02126839|DRUG|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
218877195|NCT02604914|DRUG|ND0612|Subcutaneous solution
218877196|NCT02604914|DRUG|LCIG|Intrajejunal Gel
218877197|NCT01369732|DRUG|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
218877198|NCT01369732|DRUG|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
218877199|NCT00812565|DRUG|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
218877200|NCT00812565|BIOLOGICAL|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
218877201|NCT03824093|BEHAVIORAL|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
218877202|NCT03824093|BEHAVIORAL|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
218877203|NCT02653937|DRUG|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
218877204|NCT04424693|DRUG|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
218877205|NCT03471741|RADIATION|IMRT with concomitant boost|
218877206|NCT03471741|RADIATION|3D-RT with sequential boost|
218877207|NCT00793130|DIETARY_SUPPLEMENT|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
219200370|NCT06751069|BEHAVIORAL|Home-based Pulmonary Rehab|Participants are expected to engage in the home-based PR routine five to six days a week for the entire 12-week study period. The PR routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time is 24 minutes a day followed by a 4-minute mindful breathing meditation/cool down. Exercises may be modified or repeated according to baseline activity level and as conditioning improves.
219200371|NCT06746740|BEHAVIORAL|Exercise|Adapted with input from phase 1
219200372|NCT06755684|DRUG|Befotertinib combined Bevacizumab|Befotertinib combined Bevacizumab
219200373|NCT06755684|DRUG|Befotertinib combined platinum-based double chemotherapy|Befotertinib combined platinum-based double chemotherapy
218877208|NCT00873184|BEHAVIORAL|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
218877209|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
218877210|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
219025015|NCT04134247|DRUG|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
219025016|NCT04134247|DRUG|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
219025017|NCT00870363|DRUG|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
219025018|NCT00870363|DRUG|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
219025019|NCT00870363|DRUG|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
219025020|NCT03974815|DEVICE|ACTIVE|"We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
219025021|NCT03974815|DEVICE|SHAM|"We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
219025022|NCT02663635|DEVICE|Safe'N'Sound|
219025023|NCT02576561|BIOLOGICAL|TVGV-1|Antigen + Adjuvant
219025024|NCT02576561|BIOLOGICAL|GPI-0100|Adjuvant Alone
219025025|NCT02576561|BIOLOGICAL|Placebo|Placebo
219025026|NCT01697865|PROCEDURE|Transfer group|
219025027|NCT01697865|PROCEDURE|Control group|
219204504|NCT06826118|DRUG|Axicabtagene Ciloleucel|"Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene Ciloleucel Injection infusion being Day 0).~Axicabtagene Ciloleucel Injection infusion: A single dose of autologous T cells transduced with chimeric antigen receptor (CAR) in the form of Axicabtagene Ciloleucel Injection will be administered to the subject intravenously. The target dose is 2.0×10\^6 anti-CD19 CAR-T cells/kg body weight. The minimum dose that can be used is 1.5×10\^6 anti-CD19 CAR-T cells/kg body weight. For subjects with a body weight of ≥100 kg, the maximum total dose is 2.0×10\^8 anti-CD19 CAR-T cells"
219496073|NCT01300845|PROCEDURE|Humidification|From randomization, oxygen therapy is humidified
219496074|NCT01300845|PROCEDURE|No Humidification|oxygen therapy is never humidified
218877211|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
218877212|NCT04165629|DRUG|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
218877213|NCT01424033|DRUG|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
218877214|NCT01853605|DEVICE|Anatomically shaped silicone gel-filled breast implants|Surgical implant
218877215|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
218877216|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
218877217|NCT05629468|DRUG|Azithromycin|antibiotic
218877218|NCT05629468|DRUG|Probiotic Formula|probiotics
218877219|NCT05629468|DRUG|Benzoyl Peroxide 4 % Topical Cream|topical cream
218877220|NCT00310622|DEVICE|HyperQ Signal recording|
218877221|NCT06217003|DRUG|Trilaciclib|Preoperative application of trilaciclib during perioperative chemotherapy
218877222|NCT00332891|DRUG|SR58611A|
218877223|NCT04072263|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
219025028|NCT03732885|DEVICE|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
219025029|NCT03732885|DEVICE|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
219025030|NCT01199211|OTHER|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
218877224|NCT04072263|DRUG|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
218877225|NCT04072263|DRUG|Carboplatin|chemotherapy i.v.
219204505|NCT06596772|DRUG|MB04 (proposed biosimilar to etanercept)|MB04 50 mg/week via subcutaneous injection
219204506|NCT06596772|DRUG|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
218877226|NCT04072263|DRUG|Paclitaxel|Chemotherapy i.v.
218877227|NCT00826670|DRUG|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
218877228|NCT00826670|DRUG|Placebo (Decolonization)|Placebo
218877229|NCT06402032|OTHER|Hesperidin|Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.
218877230|NCT06402032|OTHER|Mineral Trioxide Aggregate (MTA)|Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
218877231|NCT00376896|DRUG|GW876008 200mcg|GW876008
218877232|NCT00376896|DRUG|GW876008 20mcg|GW876008 20mcg
219204507|NCT06812117|OTHER|No Drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.
219496075|NCT02352506|OTHER|Blood draw for measurement of MIF|Observational study, no intervention
219496076|NCT02872402|BEHAVIORAL|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
219496077|NCT02872402|BEHAVIORAL|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
219496078|NCT01380314|DRUG|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
219496079|NCT01380314|DRUG|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
219496080|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect \& cigarettes are available.
219496081|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
219496082|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
219496083|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
219496084|NCT04376489|BEHAVIORAL|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
219496085|NCT04376489|BEHAVIORAL|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
219496086|NCT04376489|BEHAVIORAL|Joy|Smart phone app that teaches participants to practice breathing exercise.
219496087|NCT04376489|BEHAVIORAL|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
219496088|NCT04376489|BEHAVIORAL|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
219496089|NCT00697112|DRUG|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
219496090|NCT04847297|PROCEDURE|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
219496091|NCT04847297|PROCEDURE|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
219496092|NCT02841605|PROCEDURE|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
219496093|NCT02841605|PROCEDURE|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
219496094|NCT01946971|DRUG|Lansoprazole|
219496095|NCT01946971|DRUG|Placebo|
219496096|NCT03007537|DRUG|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
219496097|NCT03007537|DRUG|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
219496098|NCT03007537|PROCEDURE|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
219496099|NCT00736333|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles
219496100|NCT04601662|PROCEDURE|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
219496101|NCT04601662|OTHER|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
218877233|NCT00376896|OTHER|Placebo|placebo
218877234|NCT04739579|DIAGNOSTIC_TEST|C-Reactive Protein|C-Reactive Protein trend in post-operative course
218877235|NCT02752373|DEVICE|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
218877236|NCT03977493|DRUG|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
218877237|NCT03977493|DRUG|Placebo - Concentrate|One injection in each muscle.
218877238|NCT05759897|DRUG|HRS-7535|HRS-7535
218877239|NCT05759897|DRUG|Placebo|Placebo
218877240|NCT05066165|GENETIC|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
218877241|NCT05066165|GENETIC|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
218877242|NCT06017726|OTHER|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
218877243|NCT05760859|OTHER|Initial cue|"Symptom volunteered by the patient"
218877244|NCT02484755|DRUG|Gefitinib|See Arm Description
218877245|NCT02305212|BEHAVIORAL|Cogmed|
218877246|NCT00002503|RADIATION|strontium chloride Sr 89|
219025031|NCT03691064|DRUG|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
219496102|NCT05433337|DEVICE|Digital ACT|Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
219496103|NCT05226156|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
219496104|NCT04184479|BEHAVIORAL|LEVAmethod by Bertz et al|Ordinary treatment
219496105|NCT01990898|DRUG|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
219496106|NCT02958748|OTHER|taking blood sample|
219496107|NCT05724316|DIETARY_SUPPLEMENT|Vitamin D supplement|N/A (says not to repeat information here)
219496108|NCT05371418|PROCEDURE|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
219496109|NCT05371418|DEVICE|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
219496110|NCT01220089|BEHAVIORAL|Standard maintenance|Participants will receive written materials in months 7-18
219496111|NCT01220089|BEHAVIORAL|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
219496112|NCT05450042|DEVICE|SELUTION SLR DCB|Sirolimus DCB
219496113|NCT05450042|DEVICE|Paclitaxel DCB|Paclitaxel DCB
219496114|NCT01412710|DRUG|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
219496115|NCT02300818|DEVICE|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
219496116|NCT02300818|DRUG|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
219496117|NCT01457729|BEHAVIORAL|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
219496118|NCT04009473|COMBINATION_PRODUCT|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
219025032|NCT03365817|DRUG|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
219496119|NCT04805281|OTHER|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
219496120|NCT04805281|OTHER|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
219496121|NCT03911089|OTHER|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
219496122|NCT00984906|OTHER|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
219496123|NCT01861119|DRUG|Silicone gel Kelo-cort™;|
219496124|NCT01861119|DRUG|Onion extract gel Contractubex™|
219496125|NCT05606692|DRUG|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
219025033|NCT03365817|DRUG|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
219602923|NCT03631199|DRUG|carboplatin|Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
219602924|NCT03631199|DRUG|cisplatin|75 mg/m\^2 every 3 weeks (non-squamous)
219602925|NCT03631199|DRUG|paclitaxel|200 mg/m\^2 every 3 weeks (squamous)
218877247|NCT03738618|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed"
219602926|NCT03631199|DRUG|nab-paclitaxel|100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
219602927|NCT03631199|DRUG|pemetrexed|500 mg/m\^2 every 3 weeks (non-squamous)
219602928|NCT04127604|BEHAVIORAL|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
218877248|NCT03738618|DRUG|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
218877249|NCT00649428|BIOLOGICAL|Autologous Human Fibroblast (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
218877250|NCT00649428|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face."
218877251|NCT06410456|OTHER|Schroth exercises|Traditional exercise
218877252|NCT06410456|OTHER|Traditional exercises|Adolescents with idiopathic scoliosis performed conventional exercises four days a week for six months.
218877253|NCT00939458|DRUG|Lamotrigine|
218877254|NCT06435923|DRUG|[14C]-darigabat|Oral capsule
219025034|NCT01315756|DEVICE|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
219025035|NCT01315756|DEVICE|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
218877255|NCT00438165|BEHAVIORAL|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
218877256|NCT02255994|DEVICE|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
218877257|NCT02255994|PROCEDURE|No mesh.|Patients in this arm had subvesical plication without reinforcement.
218877258|NCT00627367|DRUG|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
218877259|NCT00627367|DRUG|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
218877260|NCT00680459|DRUG|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
218877261|NCT00680459|DRUG|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
219602929|NCT04127604|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
219602930|NCT05193396|DRUG|Hydrocortisone|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
219602931|NCT05193396|DRUG|Placebo|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
219602932|NCT05004896|DRUG|Ketamine Hydrochloride|36 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
219602933|NCT05004896|DRUG|Midazolam Hydrochloride|36 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
219602934|NCT05787665|OTHER|phone call at 3 months|patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
219602935|NCT06253611|DRUG|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
219602936|NCT06253611|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
219602937|NCT06253611|BIOLOGICAL|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
219602938|NCT06112743|DRUG|Mavacamten|Specified dose on specified days
219602939|NCT05612685|BEHAVIORAL|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
219025036|NCT00006294|DRUG|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
219025037|NCT00006294|DRUG|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
219025038|NCT00006294|DRUG|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
218877262|NCT04566601|DRUG|BI 1358894|Film-coated tablet
219025039|NCT00006294|DRUG|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
219025040|NCT06267404|OTHER|Iliopsoas Positional release therapy|Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
219025041|NCT06267404|OTHER|Conventional exercises|Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
219025042|NCT02631863|DRUG|Aminolaevulinic acid|Aminolaevulinic acid with illumination
219025043|NCT02631863|DRUG|Placebo|Placebo with illumination
219025044|NCT03535428|DIAGNOSTIC_TEST|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
219025045|NCT03492099|DRUG|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
219025046|NCT01217060|DRUG|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
219025047|NCT01217060|DRUG|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
219025048|NCT01217060|RADIATION|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
219025049|NCT01217060|PROCEDURE|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
219496126|NCT05606692|DRUG|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
219496127|NCT04126733|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
219025050|NCT01217060|DRUG|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
219025051|NCT01047956|DRUG|Methadone; NAC|Methadone NAC
219025052|NCT01047956|DRUG|Methadone|Methadone
219025053|NCT05902039|OTHER|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
219025054|NCT00982813|OTHER|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
219025055|NCT05872581|BEHAVIORAL|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
219025056|NCT05872581|BEHAVIORAL|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
219025057|NCT01959542|DEVICE|MRI|
219025058|NCT01959542|OTHER|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
219025059|NCT05750927|PROCEDURE|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
219025060|NCT04093778|OTHER|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
219025061|NCT03202264|OTHER|TAPER|"The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring"
219025062|NCT03388138|COMBINATION_PRODUCT|etafilcon A with ketotifen|Etafilcon A with ketotifen
219496128|NCT04126733|BIOLOGICAL|Nivolumab (Opdivo)|Administered on day 1 of every treatment cycle.
219496129|NCT03346928|PROCEDURE|Head and neck reconstruction|Head and neck free flap reconstruction
219496130|NCT01092390|DIETARY_SUPPLEMENT|Lovaza (fish oil)|4 grams per day
219496131|NCT05880628|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)"
218877263|NCT04566601|DRUG|Placebo|Film-coated tablet
218877264|NCT05835180|DRUG|TVB-2640 - 50 mg|TVB-2640 -50 mg administered orally once daily
218877265|NCT01542710|DRUG|Ganfort|Bimatoprost/Timolol fixed combination
218877266|NCT01542710|DRUG|Duotrav|Fixed combination of Travoprost and Timolol
219025063|NCT03388138|DEVICE|1-Day ACUVUE|1-Day ACUVUE
219025064|NCT00621881|DRUG|naproxcinod|750 mg bid
219025065|NCT04415632|OTHER|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
219025066|NCT04415632|OTHER|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
219025067|NCT05812521|PROCEDURE|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
219025068|NCT05812521|PROCEDURE|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
219025069|NCT01268111|DRUG|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
219025070|NCT01268111|DRUG|Placebo|matching placebo
219025071|NCT01528072|DEVICE|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
219025072|NCT06224842|DRUG|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
219025073|NCT06224842|DRUG|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
219025074|NCT06224842|DRUG|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
219025075|NCT02164305|OTHER|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
219025076|NCT02164305|OTHER|Neuromuscular group|Closed-chain exercise for shoulder muscles
219025077|NCT02164305|OTHER|Control|No exercise training
219025078|NCT04482504|DIAGNOSTIC_TEST|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
219025079|NCT00123539|DRUG|Estrogen Replacement Therapy|
219025080|NCT00123539|PROCEDURE|Surgery|
219365089|NCT03502187|BEHAVIORAL|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
219496132|NCT01538316|DIETARY_SUPPLEMENT|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
219496133|NCT01538316|DIETARY_SUPPLEMENT|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
219025081|NCT02372669|DEVICE|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
219025082|NCT02372669|PROCEDURE|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
219025083|NCT03471195|DIAGNOSTIC_TEST|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
219025084|NCT02560337|DRUG|Cabazitaxel|
219025085|NCT05463185|OTHER|Stretching exercises|Stretching exercises along with manual lymphatic drainage
219025086|NCT05463185|OTHER|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
219025087|NCT00862186|BEHAVIORAL|'Fatigue Facts & Fixes'|"'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
219025088|NCT00365196|BEHAVIORAL|CBT Hostility Reduction Program|
219025089|NCT04073758|DRUG|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
219602940|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
219602941|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
219602942|NCT03681535|RADIATION|Radiation Therapy|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
219602943|NCT05339074|DRUG|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
219602944|NCT02701088|DRUG|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
218877267|NCT04195217|BEHAVIORAL|Art therapy|"When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist."
219025090|NCT03897452|DRUG|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
219025091|NCT02381418|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
219025092|NCT00003681|BIOLOGICAL|epoetin alfa|
219025093|NCT00003681|DRUG|amifostine trihydrate|
219365090|NCT01492673|DRUG|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
218877268|NCT00668837|DRUG|Paliperidone|
218877269|NCT00644488|DRUG|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
219496134|NCT01538316|DIETARY_SUPPLEMENT|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
219496135|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (high dose)|From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
218877270|NCT01450098|DRUG|LY2484595 Reference Formulation (RF)|Administered orally
218877271|NCT01450098|DRUG|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
219496136|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (low dose)|From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
218877272|NCT01905878|DRUG|DLBS1033|
218877273|NCT00257361|DRUG|D-Cycloserine|
218877274|NCT01616680|DRUG|brentuximab vedotin|Given IV
219496137|NCT00459381|DRUG|pazopanib hydrochloride|Given orally
219496138|NCT00459381|OTHER|laboratory biomarker analysis|Correlative studies
219496139|NCT05502068|DIETARY_SUPPLEMENT|Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion|This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
218877275|NCT01616680|OTHER|laboratory biomarker analysis|Correlative studies
219025094|NCT02270164|DIETARY_SUPPLEMENT|Artichoke Leaf Extract|Capsule
219025095|NCT02270164|OTHER|Placebo|Capsule
219025096|NCT01903304|OTHER|Olive Oil|3 months intervention
219025097|NCT04458753|OTHER|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
219025098|NCT04458753|OTHER|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
219025099|NCT01879228|DRUG|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
218877276|NCT01616680|OTHER|pharmacological study|Correlative studies
219496140|NCT02629133|BEHAVIORAL|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
219496141|NCT03216954|DRUG|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
219496142|NCT03216954|DRUG|Placebos|Subjects will receive placebo capsules
219496143|NCT03216954|DRUG|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
218877277|NCT03749811|DEVICE|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
219496144|NCT00276705|DRUG|cisplatin|
219496145|NCT00276705|DRUG|cyclophosphamide|
219496146|NCT00276705|DRUG|doxorubicin hydrochloride|
219496147|NCT00276705|DRUG|thalidomide|
218877278|NCT02630511|DRUG|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
218877279|NCT02630511|DRUG|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
218877280|NCT02630511|DRUG|Placebo|Placebo consists of inhaling humidified air
218877281|NCT02630511|OTHER|Rest|
218877282|NCT02630511|OTHER|Exercise|
218877283|NCT01986608|DRUG|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
218877284|NCT01986608|DRUG|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
218877285|NCT01272635|DRUG|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
218877286|NCT01272635|DRUG|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
218877287|NCT01272635|OTHER|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
218877288|NCT01272635|DRUG|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
218877289|NCT04996251|DRUG|Bupivacaine Injection|0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
218877290|NCT04602442|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
218877291|NCT04602442|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
218877292|NCT04602442|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
218877293|NCT03853863|BEHAVIORAL|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
218877294|NCT03853863|BEHAVIORAL|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
219496148|NCT00276705|PROCEDURE|adjuvant therapy|
219496149|NCT00276705|PROCEDURE|conventional surgery|
218877295|NCT02235896|BEHAVIORAL|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
218877296|NCT06069947|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
219025100|NCT01879228|DRUG|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
219602945|NCT02701088|RADIATION|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
219602946|NCT05229666|OTHER|Cognitive Challenge|Cognitive challenge delivered via computer.
219025101|NCT01609920|DRUG|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
219496150|NCT00276705|PROCEDURE|neoadjuvant therapy|
219496151|NCT02058433|OTHER|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
219496152|NCT02058433|OTHER|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
219496153|NCT05463783|DRUG|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
219496154|NCT05463783|DRUG|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
218877297|NCT05359835|DRUG|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
218877298|NCT02809378|DRUG|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
218877299|NCT02809378|DRUG|sevoflurane|Inhalational anesthetics Halogenated.
218877300|NCT02809378|DRUG|remifentanil|ultra-short acting opioid anesthetics
218877301|NCT02809378|DRUG|pentothal sodium|intra-venous anesthetics for anesthesia induction
218877302|NCT02809378|DRUG|propofol|intra-venous anesthetics for anesthesia induction and maintenance
218877303|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
218877304|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
218877305|NCT01832155|BEHAVIORAL|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
218877306|NCT01832155|BEHAVIORAL|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
218877307|NCT01055314|BIOLOGICAL|Cixutumumab|Given IV
218877308|NCT01055314|DRUG|Cyclophosphamide|Given IV
218877309|NCT01055314|BIOLOGICAL|Dactinomycin|Given IV
218877310|NCT01055314|DRUG|Doxorubicin Hydrochloride|Given IV
218877311|NCT01055314|DRUG|Etoposide|Given IV
218877312|NCT01055314|DRUG|Ifosfamide|Given IV
218877313|NCT01055314|DRUG|Irinotecan Hydrochloride|Given IV
219496155|NCT00135291|PROCEDURE|Leukoreduced blood transfusion|
218877314|NCT01055314|OTHER|Laboratory Biomarker Analysis|Correlative studies
218877315|NCT01055314|DRUG|Temozolomide|Given PO
218877316|NCT01055314|DRUG|Vincristine Sulfate Liposome|Given IV
218877317|NCT04701567|DIAGNOSTIC_TEST|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
218877318|NCT00572013|DRUG|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
218877319|NCT00572013|DRUG|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
218877320|NCT00572013|PROCEDURE|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
218877321|NCT00098683|DRUG|amifostine trihydrate|
219496156|NCT02598193|DRUG|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
219496157|NCT02598193|DRUG|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
219496158|NCT04383704|OTHER|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
219496159|NCT05138198|BEHAVIORAL|Mediterranean Diet & Physical Activity|"At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals"
219496160|NCT05138198|BEHAVIORAL|Usual Care|As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
219496161|NCT03376074|DEVICE|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
219496162|NCT03376074|OTHER|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
219496163|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with lupin protein|\- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
219496164|NCT01598649|DIETARY_SUPPLEMENT|Mannitol|\- Placebo capsules containing mannitol (four capsules per day)
219025102|NCT04091503|DRUG|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
219200374|NCT06752005|BEHAVIORAL|Intervention Group|One of the investigators created a randomization sequence using a simple random numbers table and determined the groups. Another researcher assigned premature infants to the study groups according to the order of hospitalization in the unit, and the same researcher also applied the intervention. Thus, each infant experienced all three positions in a crossover design by the end of the study. Infants in all three groups were positioned for two hours in each posture, totaling six hours by the end of the study. Immediately after positioning in each posture, and at 1, 30, 60, 90, and 120 minutes, heart rate and oxygen saturation (SpO₂) values were recorded from bedside monitors, and respiratory rate was counted over one minute. Comfort and stress scores were assessed immediately after positioning (1 minute) and at 60 and 120 minutes. The Premature Infant Comfort Scale (PICS) was used to assess comfort, while the Neonatal Stress Scale (NSS) was used to evaluate stress.
218877322|NCT06112691|DEVICE|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
218877323|NCT01279616|DRUG|Fludarabine monophosphate|180 mg/m2 over 6 days.
218877324|NCT01279616|DRUG|Rituximab|375 mg/m2 on day -13 and day -3
218877325|NCT01279616|DRUG|Busulfan|AUC 1000-1200 microM.mt
218877326|NCT01279616|DRUG|ATG|2.5 mg/kg for 3 days
218877327|NCT01279616|DRUG|Cyclophosphamide|50 mg/kg on day +3
218877328|NCT01279616|DRUG|Mycophenolate mofetil|15 mg/kg q 8 hours
218877329|NCT01279616|DRUG|Tacrolimus|0.03 mg/kg /d
218877330|NCT04811495|OTHER|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
218877331|NCT02462720|DRUG|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
218877332|NCT02462720|DEVICE|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
218877333|NCT04467281|DRUG|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
219200375|NCT06751797|OTHER|No intervention|No intervention
219496165|NCT01598649|DIETARY_SUPPLEMENT|Arginine|\- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
219496166|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
219025103|NCT04720326|DRUG|Tacrolimus Pill|Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
219025104|NCT04720326|DRUG|Tacrolimus capsule|Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
219025105|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
219025106|NCT06008119|DRUG|Tunlametinib plus Vemurafenib|12mg BID Tunlametinib+720mg BID Vemurafenib
219496167|NCT00002747|DRUG|cisplatin|
219496168|NCT00002747|DRUG|fluorouracil|
219496169|NCT00002747|PROCEDURE|conventional surgery|
219496170|NCT00002747|RADIATION|low-LET cobalt-60 gamma ray therapy|
218877334|NCT04467281|DIAGNOSTIC_TEST|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
218877335|NCT02914665|DRUG|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
219496171|NCT00002747|RADIATION|low-LET photon therapy|
219496172|NCT00006129|DRUG|testosterone|
218877336|NCT02914665|DRUG|Placebo|Placebo administered intravenously once daily for 7 consecutive days
218877337|NCT06582134|BEHAVIORAL|Sham BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
218877338|NCT06582134|BEHAVIORAL|BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g. A-B-C and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
218877339|NCT00972530|BEHAVIORAL|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
218877340|NCT02384733|RADIATION|Loco-regional RT|
218877341|NCT05163652|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
218877342|NCT00183625|BEHAVIORAL|Individual Placement and Support (Supported Employment)|
218877343|NCT00183625|BEHAVIORAL|Social Skills Training|
218877344|NCT00183625|DRUG|Olanzapine|
218877345|NCT00183625|DRUG|Risperidone|
218877346|NCT00156416|BEHAVIORAL|Mindfulness Meditation|8 weeks of meditation training
218877347|NCT04022252|DEVICE|Cheese dental laser|810 nm GaAlAs diode laser device
219025107|NCT06008119|DRUG|Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab|According to investigators' suggestion
219496173|NCT06542692|DEVICE|Whole Body Vibration|treatment duration, frequency
218877348|NCT04022252|DEVICE|OrthoPulse|850 nm LED (light emitting diode)
218877349|NCT04022252|OTHER|Placebo|810 nm GaAlAs diode laser device
219025108|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
219025109|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
219025110|NCT00878007|DRUG|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
219025111|NCT00878007|BEHAVIORAL|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
219025112|NCT00878007|OTHER|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
219025113|NCT06387732|OTHER|Aerobic exercise|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
219025114|NCT06387732|OTHER|Stretching and relaxation|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
219025115|NCT03210610|DIAGNOSTIC_TEST|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
219025116|NCT05095987|PROCEDURE|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
219200376|NCT06755528|DRUG|Chitosan|The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
219025117|NCT04564456|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
219025118|NCT04564456|DRUG|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
219025119|NCT00441844|DRUG|Simvastatin|
219025120|NCT02428660|GENETIC|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
219025121|NCT02428660|OTHER|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
219025122|NCT02428660|OTHER|MTM|Medication Therapy Management
219200377|NCT06755528|DEVICE|shockwave therapy|The participants will receive shockwave with the following parameters: sonic pulses characterized by: high peak pressure, up to 100 mpa (500 bar) or even more, rapid rise in pressure (\<10 ns), short duration (\<10 μs) and a broad range of frequency. The energy flux density was 0.09 to 0.16 mJ/mm2; with a frequency of 5 Hz and 2000 impulses, i session per week for 4 weeks.
219496174|NCT06542692|DEVICE|physical therapy modalities|ultrasound, hot pack, tens
218877350|NCT02681471|OTHER|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
218877351|NCT02681471|OTHER|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
218877352|NCT02681471|DEVICE|monopolar resectoscope|
218877353|NCT02681471|DEVICE|bipolar resectoscope TURis|
219200378|NCT06755164|OTHER|Simultaneous aerobic and cognitive training (SIM)|The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.
219496175|NCT02480855|OTHER|Questionnaire and feedback|
219496176|NCT03992612|OTHER|control group: usual medical care|The patients received usual medical care.
218877354|NCT02769910|DRUG|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
218877355|NCT02769910|DRUG|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
218877356|NCT02769910|OTHER|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
219025123|NCT05780619|DIAGNOSTIC_TEST|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
219025124|NCT05749198|DIAGNOSTIC_TEST|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
219025125|NCT04409743|BEHAVIORAL|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
219496177|NCT03992612|BEHAVIORAL|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
219496178|NCT01684306|DRUG|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
218877357|NCT05215834|DRUG|Remifentanil|"1. Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~2. Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery."
219025126|NCT04165512|COMBINATION_PRODUCT|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
219025127|NCT00245141|BIOLOGICAL|dactinomycin|
219025128|NCT00245141|DRUG|cyclophosphamide|
219025129|NCT00245141|DRUG|vincristine sulfate|
219025130|NCT00245141|RADIATION|radiation therapy|
219025131|NCT03329690|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
219602947|NCT05849454|DEVICE|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
218877358|NCT01969955|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
218877359|NCT01633658|DIETARY_SUPPLEMENT|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
218877360|NCT01633658|DIETARY_SUPPLEMENT|25(OH)D|a single dose of 625 micrograms of 25(OH)D
218877361|NCT00626171|PROCEDURE|Allergen Challenge|Allergen challenge
218877362|NCT00414518|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
218877363|NCT00414518|DRUG|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
218877364|NCT05249569|DRUG|Axitinib|Axitinib to be administered orally BID
218877365|NCT05249569|DRUG|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
219025132|NCT03329690|DRUG|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
219025133|NCT00151320|DRUG|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
219025134|NCT03822676|DEVICE|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
219602948|NCT06351371|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218877366|NCT05249569|DRUG|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
219025135|NCT06326294|DEVICE|Thermal ablation|Thermal ablative uses heat (100°C to 120°C) to cause localized tissue damage at the cervical transformation zone and destroy the abnormal epithelium.
219025136|NCT06326294|PROCEDURE|LOOP ELECTROSURGICAL EXCISION PROCEDURE|Cervical tissue excision
218877367|NCT00189605|DEVICE|Perc-DLR/Perc-DLG|Device technique will be used per IFU
218877368|NCT00189605|DRUG|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
218877369|NCT00337090|DRUG|YM178|
218877370|NCT02450162|PROCEDURE|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
219025137|NCT02882555|BEHAVIORAL|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
219025138|NCT02882555|DRUG|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
219025139|NCT02882555|DRUG|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
219025140|NCT03447808|BIOLOGICAL|Daratumumab|Given IV
219025141|NCT03447808|DRUG|Ibrutinib|Given PO
219025142|NCT03447808|OTHER|Laboratory Biomarker Analysis|Correlative studies
219025143|NCT03447808|OTHER|Pharmacological Study|Correlative studies
219025144|NCT01463371|DRUG|Azithromycin|250 mg three times a week during three months
219496179|NCT01684306|DRUG|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
219602949|NCT06351371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602950|NCT06351371|PROCEDURE|Computed Tomography|Undergo CT
219602951|NCT06351371|DRUG|Erdafitinib|Given orally
219602952|NCT06351371|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219025145|NCT01824186|PROCEDURE|SILC|Underwent single-incision laparoscopic cholecystectomy
219025146|NCT01824186|PROCEDURE|LC|Underwent conventional 4-port laparoscopic cholecystectomy
219025147|NCT06639607|BIOLOGICAL|PEP-CMV vaccine|Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
219025148|NCT06639607|BIOLOGICAL|Tetanus booster|Td 5 flocculation units, Lf
219602953|NCT02179086|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo standard-dose 3D-CRT
218877371|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
218877372|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
218877373|NCT03907150|DIAGNOSTIC_TEST|Strain ultrasound|Post-interpretation of recorded ultrasound loops
219025149|NCT06639607|BIOLOGICAL|Nivolumab|Administered intravenously
219025150|NCT06639607|DRUG|Temozolomide|Administered orally
219025151|NCT02592746|DRUG|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
219025152|NCT02592746|DRUG|Exemestane|Exemestane 25mg, orally once daily
219025153|NCT02592746|DRUG|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
219025154|NCT02592746|DRUG|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
219025155|NCT03176992|DRUG|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
219025156|NCT02507635|DRUG|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
219025157|NCT02507635|DRUG|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
219025158|NCT01959620|BEHAVIORAL|1-Session Exposure Therapy|One exposure therapy session lasting one hour
219025159|NCT01959620|BEHAVIORAL|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
219025160|NCT02302651|DEVICE|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
219025161|NCT01687491|DRUG|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
219025162|NCT01687491|DRUG|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
219025163|NCT04738110|OTHER|MRI|Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
219025164|NCT06477601|OTHER|Assigning cooling agent type cigarettes|This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.
219200379|NCT06755164|OTHER|Sequential aerobic and cognitive training (SEQ)|The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
219200380|NCT06755008|PROCEDURE|bronchial fibroscopy|2 bronchial biopsies will be taken during bronchial fibroscopy
219200381|NCT06753721|DRUG|Doxorubicin liposome combined with CapOX and Bevacizumab|Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
218877374|NCT00252603|DRUG|Galantamine|
218877375|NCT06584526|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).
219025165|NCT06477601|OTHER|Assigning traditional tobacco type cigarettes|This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.
219025166|NCT06477601|OTHER|Assigning menthol type cigarettes|This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
219025167|NCT02418468|DRUG|Indacaterol|Indacaterol 150µg capsules for inhalation daily
219025168|NCT02418468|DRUG|Placebo|Matching placebo indacaterol capsules for inhalation daily
219025169|NCT05044754|PROCEDURE|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
219025170|NCT06268561|OTHER|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
219025171|NCT06268561|OTHER|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
219025172|NCT06268561|OTHER|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
219025173|NCT06268561|OTHER|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
219025174|NCT02935608|DRUG|BIIB074|Administered as specified in the treatment arm
219025175|NCT02935608|DRUG|Placebo|Matched placebo
219025176|NCT01742741|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
219602954|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard-dose IMRT
218877376|NCT06584526|OTHER|Physical Therapy and Aerobic Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
218877377|NCT06584526|OTHER|Physical Therapy and Strength Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
218877378|NCT02082704|BEHAVIORAL|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
218877379|NCT02082704|BEHAVIORAL|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
219025177|NCT02192918|BEHAVIORAL|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
218877380|NCT05412368|OTHER|Focus Groups|Focus Groups
219025178|NCT02192918|BEHAVIORAL|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
219025179|NCT02192918|BEHAVIORAL|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
219025180|NCT04176276|OTHER|no interventions required.|The study does not require any interventions.
219025181|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
219025182|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
219025183|NCT02337907|DRUG|Placebo|for blinding purposes
219025184|NCT02337907|DRUG|Placebo|
219496180|NCT06701500|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
219602955|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
219602956|NCT02179086|OTHER|Laboratory Biomarker Analysis|Correlative studies
219602957|NCT02179086|RADIATION|Photon Beam Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
219602958|NCT02179086|RADIATION|Proton Beam Radiation Therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
218877381|NCT03817112|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
218877382|NCT03817112|DRUG|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
218877383|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
218877384|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
218877385|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
218877386|NCT02140749|DIETARY_SUPPLEMENT|Placebo|Chewing tablets without short-chain Fructooligosaccharides
218877387|NCT01764828|DRUG|Refametinib (BAY86-9766)|
218877388|NCT01764828|DRUG|Gemcitabine|
218877389|NCT05787925|DRUG|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning"
218877390|NCT05787925|DRUG|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
219025185|NCT02337907|DRUG|BI 409306|
219025186|NCT02337907|DRUG|Donepezil|
219602959|NCT02179086|OTHER|Quality-of-Life Assessment|Ancillary studies
219602960|NCT02179086|OTHER|Questionnaire Administration|Ancillary studies
219602961|NCT02179086|DRUG|Temozolomide|Given PO
219602962|NCT03651700|DEVICE|Active TMS|Active TMS will be at 90% motor threshold
219496181|NCT06701500|BEHAVIORAL|Action Sequence Task (AST)|Participants need to press four keys according to the cue location; two keys are associated with high reward, while the other two are associated with low reward in case of correct and timely responses. The explicit goal is to maximize the reward. While in half of the trials the cues are presented in a random order, in the other half of the trials, participants repeatedly perform a fixed action sequence of 12 elements (habit condition). The degree of action sequence chunking (i.e. automation) is assessed via the differences in error rates and reaction times between the random and fixed order condition (habit parameter). Importantly, 15% of all trials are dual- target trials. In these the goal-directed system (press high reward key) and the action sequence (press sequence key) can either be in line (congruent trials) or in conflict (incongruent trials) with each other, thus the interference between goal-directed and habitual control can be tested.
219496182|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Structured Clinical Interview for DSM Disorders (SCID) Current Depression:~  * SCID Mania~ * SCID alcohol use disorder (AUD)~ * SCID tobacco use disorder (TUD)~* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Alcohol quantity-frequency~* Tobacco quantity-frequency~* Cannabis and other substances quantity-frequency"
219602963|NCT03651700|DEVICE|Sham TMS|Sham TMS will be administered
219602964|NCT03651700|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
218877391|NCT04566432|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
218877392|NCT03933228|PROCEDURE|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
218877393|NCT03933228|PROCEDURE|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
218877394|NCT02545764|OTHER|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
218877395|NCT06583278|DEVICE|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
218877396|NCT01119092|OTHER|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
218877397|NCT01119092|OTHER|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
218877398|NCT01447732|DRUG|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
218877399|NCT07087639|DEVICE|Self-expanding Venous Cannula|"The intervention consists of a self-expanding venous drainage cannula made of polyurethane and reinforced with a flexible metallic mesh. It is designed for transfemoral insertion during on-pump cardiac surgery, including minimally invasive procedures. Once positioned, the cannula expands to its functional diameter to facilitate efficient blood drainage into the extracorporeal circulation system. The configuration used in this study is 680/730 mm in length, 24 Fr, 3/8 diameter. The device is sterile, single-use, and is inserted once on the day of surgery (Day 0) and removed at the end of the procedure. The cannula is used continuously during cardiopulmonary bypass for a maximum duration of 6 hours and is not reused."
218877400|NCT07087379|DRUG|Intensive statin treatment|"Intensive statin group:~Atorvastatin 80mg, orally administered 12 hours before surgery Atorvastatin 80mg, orally administered 2 hours before surgery"
218877401|NCT07087379|DRUG|Placebo Control|Placebo, tablets, oral administration 12 hours before surgery Placebo, tablet, oral administration 2 hours before surgery
218877402|NCT04766554|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
218877403|NCT07089732|DIETARY_SUPPLEMENT|GLP-1 formula liquid drink|One glass jar (50 g) of the GLP-1 formula liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
218877404|NCT07089732|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
218877405|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
218877406|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
218877407|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
218877408|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
219025187|NCT02838056|DRUG|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
219025188|NCT00497172|DEVICE|CYPHER Sirolimus-eluting stent|drug-eluting stent
219025189|NCT00497172|DEVICE|Bx SONIC bare metal stent|bare-metal stent
219496183|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorders Identification Test (CUDIT)~* Adult ADHD Self-Report Scale (ASRS)"
219496184|NCT06701500|BEHAVIORAL|Neuropsychology tests|"* Digit-Symbol-Test (DST)~* Go/Nogo Simon task~* Counting Stroop Task~* Value-based decision-making task (VBDM)"
218877409|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
219025190|NCT04811170|OTHER|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
219025191|NCT00629499|DRUG|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
219025192|NCT00629499|DRUG|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
219025193|NCT00629499|DRUG|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
219025194|NCT06362434|DEVICE|Audiovisual stimulation|The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
219025195|NCT06545370|OTHER|Intervention 1 / Nurse-led patients' education|nurse-led education through oral sessions, educational materials, and regular phone calls
219025196|NCT06545370|OTHER|Intervention 2 / Nurse-led patients' & caregivers' education|nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
219025197|NCT00613015|DRUG|Guanfacine|
219025198|NCT00613015|DRUG|Modafinil|
219025199|NCT00613015|DRUG|Placebo|
219025200|NCT05882799|PROCEDURE|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
219025201|NCT05882799|PROCEDURE|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
219496185|NCT01393548|DRUG|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
219496186|NCT01393548|DRUG|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
219496187|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
219496188|NCT04720885|PROCEDURE|kind of surgery|hysteroscopy, curettage, other
219496189|NCT01382901|DRUG|Ferric Carboxymaltose (FCM)|
219496190|NCT01382901|DRUG|Placebo|
219496191|NCT02487979|DRUG|Glembatumumab Vedotin|Given IV
219496192|NCT02487979|OTHER|Laboratory Biomarker Analysis|Correlative studies
218877410|NCT02974049|DRUG|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
218877411|NCT02974049|DRUG|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
218877412|NCT02974049|DRUG|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
219496193|NCT02487979|OTHER|Pharmacological Study|Correlative studies
219496194|NCT00447694|DRUG|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
218877413|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
218877414|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
218877415|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
218877416|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
218877417|NCT01423916|DRUG|Placebo|OPC-34712 placebo
218877418|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
218877419|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
218877420|NCT01896583|DRUG|Placebo|
218877421|NCT04684953|PROCEDURE|Throid autotransplantation|Operative
218877422|NCT04684953|DRUG|Hormone|thyroid hormone replacement therapy
218877423|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
218877424|NCT01656070|DRUG|oral cholecalciferol 1000000 UI (vitamin D3)|
218877425|NCT01656070|DRUG|Placebo|
218877426|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
218877427|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
218877428|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
218877429|NCT01374178|DRUG|LY2963016|Administered subcutaneously
218877430|NCT01374178|DRUG|Lantus|Administered subcutaneously
218877431|NCT00524017|BIOLOGICAL|cetuximab|given IV
218877432|NCT05788497|DRUG|Hemorrane plus|Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
218877433|NCT05788497|DRUG|Hemorrane|Hemorrane 10 mg/g rectal ointment
218877434|NCT05788497|DRUG|Placebo|Rectal ointment
218877435|NCT03277365|OTHER|Receive genetic risk information|Risk scores are provided by ResearchKit app.
218877436|NCT04856904|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
218877437|NCT04856904|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
218877438|NCT02756494|BIOLOGICAL|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
218877439|NCT06358092|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
218877440|NCT06358092|DIAGNOSTIC_TEST|Two-Dimensional Shear Wave Elastography|2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
218877441|NCT02924740|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
218877442|NCT02924740|BEHAVIORAL|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
218877443|NCT01812512|BEHAVIORAL|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
218877444|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
218877445|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
218877446|NCT04029298|BEHAVIORAL|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
218877447|NCT02929212|OTHER|Solid Meal|Subjects will receive solid meals during meal study
218877448|NCT02929212|OTHER|Liquid Meal|Subjects will receive liquid meals, during meal study
218877449|NCT02929212|DRUG|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
218877450|NCT02929212|OTHER|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
218877451|NCT02929212|OTHER|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
218877452|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
218877453|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
218877454|NCT03094715|DEVICE|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
219025202|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
218877455|NCT03094715|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
218877456|NCT04619498|DEVICE|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
218877457|NCT04619498|OTHER|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
218877458|NCT06136065|DIAGNOSTIC_TEST|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
218877459|NCT00439036|BEHAVIORAL|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
218877460|NCT00439036|BEHAVIORAL|Drug Counseling|
218877461|NCT02578173|DEVICE|AVERT PLUS|
218877462|NCT01111279|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
218877463|NCT01111279|BIOLOGICAL|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
218877464|NCT01111279|BIOLOGICAL|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
218877465|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
218877466|NCT02830620|OTHER|Dosage of chimiokines|
218877467|NCT03044184|DRUG|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
218877468|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
218877469|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
218877470|NCT00077649|DRUG|ribavirin [Copegus]|600mg po bid for 48 weeks
218877471|NCT00077649|DRUG|ribavirin [Copegus]|800mg po bid for 48 weeks
218877472|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
218877473|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
218877474|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
218877475|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
218877476|NCT01174212|PROCEDURE|Prophylactic Antibiotics|Preoperative Antibiotics
218877477|NCT01174212|PROCEDURE|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
218877478|NCT00215865|DRUG|PEGIntron plus ribavirin|
218877479|NCT04149678|DRUG|Ozanimod|Ozanimod
218877480|NCT04149678|DRUG|Cyclosporine|Cyclosporine
218877481|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
218877482|NCT00810784|BEHAVIORAL|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
218877483|NCT00804934|DRUG|Lucentis|0.5mg Lucentis every four months
218877484|NCT03275948|OTHER|whole grain|whole grain rye
218877485|NCT03275948|OTHER|reference|white wheat bread
218877486|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
218877487|NCT00480870|DRUG|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
218877488|NCT00480870|DRUG|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
218877489|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
218877490|NCT06050785|DRUG|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
218877491|NCT03631420|BIOLOGICAL|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
218877492|NCT01272765|OTHER|Placebo|Placebo
218877493|NCT01272765|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
218877494|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
218877495|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
218877496|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
218877497|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
218877498|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
218877499|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
218877500|NCT00642863|DIETARY_SUPPLEMENT|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
218877501|NCT00642863|DIETARY_SUPPLEMENT|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
218877502|NCT00642863|DIETARY_SUPPLEMENT|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
218877503|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
218877504|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
219496195|NCT05309707|DEVICE|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
219496196|NCT05730088|OTHER|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
219496197|NCT05730088|OTHER|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
219496198|NCT05730088|OTHER|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
219496199|NCT04437082|DEVICE|optical coherence tomography|imaging structural and vascular features of the eye
219496200|NCT05762263|BEHAVIORAL|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
219496201|NCT03796299|DIAGNOSTIC_TEST|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
219496202|NCT03123211|DRUG|Veliparib|Veliparib will be administered orally.
219496203|NCT02182011|DRUG|Tenecteplase|
219496204|NCT02182011|DRUG|Alteplase|
219496205|NCT02182011|DRUG|Streptokinase|
219602965|NCT04666311|DIAGNOSTIC_TEST|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
218877505|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
218877506|NCT00122655|DRUG|non-nucleoside reverse transcriptase inhibitors|
218877507|NCT00122655|DRUG|nucleoside reverse transcriptase inhibitors|
218877508|NCT00122655|DRUG|protease inhibitors|
218877509|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
218877510|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
219025203|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
219025204|NCT01185938|DRUG|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
219025205|NCT01787227|DEVICE|xTAG RPP|
219025206|NCT00142571|DRUG|Gemcitabine|
219025207|NCT00142571|DRUG|Docetaxel|
219025208|NCT05263700|DRUG|68Ga-FAPi-46|FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
219496206|NCT04896918|BEHAVIORAL|Tobacco use|
219496207|NCT00656396|DEVICE|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
219496208|NCT00656396|PROCEDURE|Control Intervention|Standard care
219496209|NCT01004796|GENETIC|cytogenetic analysis|
219496210|NCT01004796|GENETIC|microarray analysis|
219496211|NCT01004796|GENETIC|mutation analysis|
219496212|NCT01004796|OTHER|immunohistochemistry staining method|
218877511|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
218877512|NCT02445066|DIETARY_SUPPLEMENT|Vitamin D3|
218877513|NCT00166491|DRUG|Insulin|
218877514|NCT02553408|DEVICE|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
219025209|NCT05263700|PROCEDURE|PET/CT imaging|PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
219025210|NCT02429518|DRUG|Miltefosine|
218877515|NCT02895945|BIOLOGICAL|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
218877516|NCT04768803|BIOLOGICAL|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
218877517|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
218877518|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
218877519|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
218877520|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
219496213|NCT01004796|OTHER|immunologic technique|
218877521|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
218877522|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
218877523|NCT03286283|DEVICE|J-Plasma|Dermal resurfacing procedure with J-Plasma.
218877524|NCT00953940|DRUG|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
218877525|NCT05113914|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
218877526|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
218877527|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
218877528|NCT04005079|DRUG|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
218877529|NCT04005079|DRUG|Ofloxacin|Standard of care
218877530|NCT04005079|DRUG|Prednisolone|Standard of Care
219025211|NCT06238232|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
219496214|NCT01004796|OTHER|mass spectrometry|
218877531|NCT03117413|OTHER|Positron emission tomography scan|"* Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
218877532|NCT06010407|OTHER|Survey|"* Working Alliance Inventory~* Attitude Towards Psychiatry-30 Scale"
218877533|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
218877534|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
218877535|NCT00454181|DRUG|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
218877536|NCT00454181|OTHER|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
218877537|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
219025212|NCT04434365|DRUG|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
219025213|NCT04434365|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
219025214|NCT04434365|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
219496215|NCT03066635|DRUG|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
219496216|NCT03066635|DRUG|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
219496217|NCT03496935|DEVICE|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
219496218|NCT02420665|DRUG|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
219496219|NCT02420665|DEVICE|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
219496220|NCT02420665|BEHAVIORAL|Phone Call|Study staff follow up with participant by phone one month after procedure.
218877538|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
218877539|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
218877540|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
218877541|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
219025215|NCT04434365|DRUG|Statin|Statins once daily for 12±1 weeks.
219025216|NCT05757531|DRUG|[¹⁴C]-LY3437943|Administered SC.
219025217|NCT04735120|DEVICE|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
219025218|NCT04535791|DRUG|Cholecalciferol|4,000 IU orally daily for 30 days
218877542|NCT06083818|OTHER|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
218877543|NCT06083818|OTHER|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
218877544|NCT03045341|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
218877545|NCT03045341|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|BWL counseling
218877546|NCT03045341|OTHER|Placebo|Placebo
218877547|NCT05392036|OTHER|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
218877548|NCT05392036|OTHER|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
218877549|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
218877550|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
218877551|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
218877552|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
218877553|NCT04377152|DRUG|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
218877554|NCT04377152|PROCEDURE|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
218877555|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
218877556|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
218877557|NCT05701566|DEVICE|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
218877558|NCT05701566|OTHER|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
218877559|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
218877560|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
218877561|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
218877562|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
219496221|NCT02420665|PROCEDURE|Colposcopy|Colposcopy performed after visual inspection of cervix.
219496222|NCT02420665|DRUG|Acetic Acid|3 - 5% added to cervix before visual inspection.
219496223|NCT04821050|DEVICE|Sacral nerve stimulation|"A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
218877563|NCT04911972|PROCEDURE|Functional muscle transfer|Muscle transfer to restore lower limb function
218877564|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
218877565|NCT01170078|DRUG|Epogen|IV dose 3 times a week
218877566|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
218877567|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
218877568|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
218877569|NCT03505736|BIOLOGICAL|Adenosine|Given IV
218877570|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
218877571|NCT03505736|DRUG|Regadenoson|Given IV
218877572|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
218877573|NCT02357589|PROCEDURE|2D laparoscopic cholecystectomy|
218877574|NCT02357589|PROCEDURE|3D laparoscopic cholecystectomy|
219496224|NCT04821050|DEVICE|Sham stimulation|"Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
219496225|NCT00279578|DRUG|ReFacto (Recombinant factor VIII) and Tranexamic acid|
219496226|NCT02641171|OTHER|Specimen sampling|exhaled air samples blood samples fecal samples
218877575|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
218877576|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
218877577|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
218877578|NCT05954767|DRUG|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
218877579|NCT00072774|DRUG|DVS-233 SR|
218877580|NCT01331291|DRUG|bosutinib|Taken orally
218877581|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
218877582|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
219365122|NCT04297215|DEVICE|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D\&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
219365123|NCT04297215|DEVICE|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
219365124|NCT04297215|DEVICE|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
219365125|NCT00196417|DRUG|Standard heparin (UFH) versus certoparin (LMWH)|
219365126|NCT01897467|BEHAVIORAL|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
219365127|NCT01897467|BEHAVIORAL|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
219365128|NCT03642145|DRUG|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
219365129|NCT05442619|PROCEDURE|Venous blood collection|Venous blood will be drawn from newborns.
219365130|NCT02603744|BIOLOGICAL|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
219365131|NCT01160601|DRUG|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
219365132|NCT01160601|DRUG|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
219365133|NCT06419283|PROCEDURE|Middle Cerebral Artery Stent Implantation|Middle Cerebral Artery Stent Implantation
219365134|NCT06419283|DRUG|standard treatment with aspirin.|standard treatment with aspirin.
219365135|NCT05480319|OTHER|EDICARS|The investigators propose to (1) Embed the EDICAS into our hospital information system (HIS) in real-time at ED triage to identify high-risk patients (EDICAS 6+); and (2) Distribute wearable smart wristbands to high-risk patients to augment vital signs monitoring and send alerts based on GBTM results. The detection and intervention components together form the rapid response system, the Emergency Department In-hospital Cardiac Arrest Response System (EDICARS).
219365136|NCT05480319|OTHER|Usual care|Usual care will be assigned to this arm. No additional interventions.
219365137|NCT01351441|BEHAVIORAL|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
219365138|NCT01351441|OTHER|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
219365139|NCT01351441|OTHER|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
219365140|NCT01351441|BEHAVIORAL|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
219365141|NCT05837741|DIETARY_SUPPLEMENT|Standard hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
219365142|NCT05837741|DIETARY_SUPPLEMENT|Leucine-enriched hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
218877583|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
218877584|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
218877585|NCT02027753|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
218877586|NCT02027753|DRUG|Metformin|Pharmaceutical form: tablet Route of administration: oral
219365143|NCT00002969|DRUG|paclitaxel|
219496227|NCT04822428|OTHER|Osteopathic manipulation|Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
219496228|NCT00639665|OTHER|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
219496229|NCT05375682|OTHER|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
218877587|NCT02027753|DRUG|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
218877588|NCT02027753|DRUG|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
219496230|NCT03126851|OTHER|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
219496231|NCT02059031|DRUG|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
219496232|NCT02059031|DRUG|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
219496233|NCT02059031|DRUG|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
219496234|NCT06640244|OTHER|Sunscreen|To be used by all participants throughout the study
218877589|NCT01026220|BIOLOGICAL|bleomycin sulfate|Given IV or SC
218877590|NCT01026220|DRUG|doxorubicin hydrochloride|Given IV
218877591|NCT01026220|DRUG|liposomal vincristine sulfate|Given IV
218877592|NCT01026220|DRUG|vinorelbine tartrate|Given IV
218877593|NCT01026220|DRUG|cyclophosphamide|Given IV
218877594|NCT01026220|DRUG|etoposide phosphate|Given IV
218877595|NCT01026220|DRUG|prednisone|Given IV
218877596|NCT01026220|BIOLOGICAL|filgrastim|Given IV or SC
218877597|NCT01026220|DRUG|ifosfamide|Given IV
218877598|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
218877599|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
219365144|NCT00323999|PROCEDURE|Hysteroscopic resection of fibroids, polyps and endometrium.|
219365145|NCT05347641|DRUG|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
218877600|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
218877601|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
218877602|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
219365146|NCT02917460|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
219365147|NCT00536172|DRUG|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
219365148|NCT00536172|DRUG|Placebo|Placebo distribution matches the active medication.
219365149|NCT01858233|BEHAVIORAL|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
219365150|NCT03417271|DEVICE|Deep brain stimulation|The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
219365151|NCT05863715|BEHAVIORAL|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
219365152|NCT04139122|DRUG|SJP-0132|SJP-0132 is administered as an eye drop
219365153|NCT04139122|DRUG|Placebo|Placebo is administered as an eye drop
219365154|NCT00212043|DRUG|carboplatin and gemcitabine|
219365155|NCT04205890|DRUG|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
218877603|NCT05032885|OTHER|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
218877604|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
218877605|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
219025219|NCT05215301|DIAGNOSTIC_TEST|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
219025220|NCT01830439|DRUG|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
219025221|NCT01830439|DRUG|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
219025222|NCT04407312|DRUG|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
219025223|NCT04407312|DRUG|placebo|Placebo, tablet, 200mg, once daily, 30 days.
219496235|NCT06640244|OTHER|Cosmetic product G18|Cosmetic face care product
219496236|NCT06640244|OTHER|Cosmetic product N70|Cosmetic face care product
219496237|NCT06640244|OTHER|Cosmetic product D79|Cosmetic face care product
219496238|NCT06640244|OTHER|Cosmetic product E84|Cosmetic face care product
219496239|NCT06640244|OTHER|Cosmetic product C68|Cosmetic face care product
218877606|NCT05930236|DIAGNOSTIC_TEST|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
218877607|NCT05930236|DRUG|Lidocain|Linisol infiltration with depomedrol and omnipaque
218877608|NCT05930236|DRUG|Methylprednisolone|infiltration with linisol and omnipaque
218877609|NCT05930236|DRUG|Omnipaque|infiltration with linisol and methylprednisolone
218877610|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
218877611|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
218877612|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
218877613|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
218877614|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
219025224|NCT04407312|DRUG|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
219025225|NCT04407312|DRUG|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
218877615|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
219025226|NCT00367952|DRUG|apricitabine|800mg apricitabine twice daily orally for 96 weeks
219025227|NCT02456610|BIOLOGICAL|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
219025228|NCT04120974|BEHAVIORAL|Optimal insulin injection|subjects receive training in optimal injection technique.
219496240|NCT02523274|DRUG|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
219496241|NCT02523274|DRUG|Placebo|Vegetable-based cellulose
219496242|NCT02523274|BEHAVIORAL|Exercise|Multi-modal exercise regimen, 3 days/week
219496243|NCT02540473|BEHAVIORAL|Manualized Therapy|Relational psychotherapy mothers
219496244|NCT02540473|BEHAVIORAL|Control Group|one hour of free time to do with as they wish
219496245|NCT00570726|DRUG|Ranibizumab (Lucentis)|
219496246|NCT05154188|DEVICE|Neuro Cochlear Implant system|Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose
219496247|NCT03181178|DIETARY_SUPPLEMENT|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
219496248|NCT03181178|DIETARY_SUPPLEMENT|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
219496249|NCT03181178|BEHAVIORAL|Nutrition education|This intervention provided nutrition education sessions
219496250|NCT04748809|OTHER|Diet 1|Dietary intervention
219496251|NCT04748809|OTHER|Diet 2|Dietary intervention
218877616|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
218877617|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
218877618|NCT02967601|BEHAVIORAL|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
219025229|NCT05837624|DRUG|Estetrol/Drospirenone|6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
218877619|NCT00667667|DEVICE|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
218877620|NCT00667667|DEVICE|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
218877621|NCT00667667|BEHAVIORAL|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
218877622|NCT06186115|COMBINATION_PRODUCT|Gold|Intra articular
218877623|NCT02540993|DRUG|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
218877624|NCT02540993|DRUG|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
218877625|NCT04797962|BEHAVIORAL|Case management|dedicated case management to address social support needs
218877626|NCT02424045|DRUG|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
218877627|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
218877628|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
218877629|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
218877630|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
218877631|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
218877632|NCT00120601|DRUG|Naltrexone|
218877633|NCT00120601|DRUG|Acamprosate|
218877634|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
218877635|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
218877636|NCT03776461|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
218877637|NCT05435417|RADIATION|CBCT radiation|CBCT scanning
218877638|NCT01640262|OTHER|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
218877639|NCT00490048|PROCEDURE|Induced sputum (inhalation of 3.5% saline)|
218877640|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
218877641|NCT01897090|OTHER|Elimination Diet|
218877642|NCT01897090|OTHER|Dietary Guidelines for Americans|
218877643|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
218877644|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
218877645|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
218877646|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
218877647|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
219602966|NCT04666311|DIAGNOSTIC_TEST|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
219602967|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
218877648|NCT00073281|PROCEDURE|Islet transplantation|
219025230|NCT06014242|DIAGNOSTIC_TEST|Peripheral vascular flow reserve measurement|Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
219025231|NCT03338062|DIAGNOSTIC_TEST|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
219025232|NCT06071715|DEVICE|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
219496252|NCT00837031|DRUG|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
219602968|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
219602969|NCT05216432|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
218877649|NCT01009086|DRUG|Placebo|SC injections
218877650|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
219365156|NCT01474694|OTHER|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
219365157|NCT01424735|DRUG|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
219365158|NCT01150084|OTHER|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
219602970|NCT05216432|DRUG|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
219602971|NCT05216432|DRUG|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
218877651|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
218877652|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
218877653|NCT02190890|PROCEDURE|Dry needling|
219365159|NCT01150084|OTHER|delayed treatment|to start at week 10
219365160|NCT03568877|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
219365161|NCT03568877|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
219602972|NCT05216432|DRUG|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
219602973|NCT05216432|DRUG|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
219602974|NCT05216432|DRUG|PF-07220060 100mg|PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
219602975|NCT05216432|DRUG|PF-07220060 300 mg|PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
218877654|NCT02190890|PROCEDURE|Control|
218877655|NCT01415492|BEHAVIORAL|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
218877656|NCT01415492|BEHAVIORAL|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
218877657|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
219025233|NCT06071715|DEVICE|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
219025234|NCT02826707|BEHAVIORAL|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
219025235|NCT02528656|DEVICE|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
219496253|NCT00837031|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
219496254|NCT05759169|OTHER|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
219496255|NCT04106401|OTHER|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
219496256|NCT04106401|OTHER|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
219496257|NCT04106401|OTHER|physical activity monitoring|recording of physical activity by actimetry
219496258|NCT04106401|OTHER|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
219496259|NCT04106401|OTHER|24-hour blood pressure|recorded by ambulatory device
219496260|NCT04506125|OTHER|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
219496261|NCT04506125|OTHER|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
219496262|NCT03763617|DEVICE|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
219496263|NCT04767217|DRUG|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
219496264|NCT04767217|DRUG|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
219025236|NCT02528656|DEVICE|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
219025237|NCT04340362|DRUG|VX-147|Tablets for oral administration.
219025238|NCT01519414|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219025239|NCT01519414|OTHER|Placebo|Given PO
219025240|NCT01519414|DRUG|Tivantinib|Given PO
219365162|NCT04009928|DEVICE|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
219365163|NCT04009928|DEVICE|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
219025241|NCT05797558|PROCEDURE|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
219365164|NCT05906277|DIAGNOSTIC_TEST|Biopsy|Liquid biopsy, re-biopsy, tissue biopsy
219365165|NCT04121845|DEVICE|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
219365166|NCT04121845|OTHER|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
219365167|NCT01245088|DRUG|chondroitin sulfate|400 mg orally three times daily for 8 weeks
219365168|NCT05305807|OTHER|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
219365169|NCT04613726|DRUG|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
219365170|NCT04613726|DRUG|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
219365171|NCT04613726|DRUG|Saline|Control group consisted of patients receiving IV 10 ml normal saline
219365172|NCT06405672|PROCEDURE|Endotracheal tube with stylet|The obese patients who will be intubated with stylet in laparoscopic sleeve gastrectomy
219365173|NCT06405672|PROCEDURE|Endotracheal tube alone|The obese patients who will be intubated without stylet in laparoscopic sleeve gastrectomy
219365174|NCT00501475|DRUG|NAC Bicarbonate|
219365175|NCT05689619|DIETARY_SUPPLEMENT|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
219365176|NCT05689619|OTHER|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
219365177|NCT02611401|BEHAVIORAL|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
219025242|NCT05797558|DRUG|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
218877658|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
219025243|NCT00265954|BEHAVIORAL|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
219025244|NCT03447990|DRUG|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
219025245|NCT03447990|DRUG|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
219025246|NCT00231335|DRUG|escitalopram|
219025247|NCT01627054|DRUG|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
219025248|NCT00148889|DEVICE|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
219025249|NCT02533154|DRUG|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
219025250|NCT02533154|DRUG|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
219025251|NCT02533154|OTHER|Bacterial culture|bacterial cultures obtained with conjunctival swabs
219025252|NCT05023265|RADIATION|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
219025253|NCT02340598|OTHER|cold vest|The lowering of body temperature increases basal metabolic rate
219025254|NCT00893750|BEHAVIORAL|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
219025255|NCT00893750|BEHAVIORAL|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
219025256|NCT00893750|BEHAVIORAL|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
219025257|NCT01721421|OTHER|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
219025258|NCT01721421|OTHER|Standard treatment time|
219025259|NCT03282188|BIOLOGICAL|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
219025260|NCT03282188|DRUG|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
219025261|NCT06478537|DRUG|Hetrombopag Olamine|"Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn."
218877659|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
218877660|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
218877661|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
219025262|NCT06478537|DRUG|Aspirin|Aspirin 100mg, qd
219025263|NCT00300950|BIOLOGICAL|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
219025264|NCT00300950|DRUG|Gemcitabine|Chemotherapy
219025265|NCT04389424|DRUG|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
219025266|NCT04389424|DRUG|Exemestane|Use of exemestane for breast cancer recurrence prevention
219025267|NCT04389424|DRUG|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
219025268|NCT04389424|DIAGNOSTIC_TEST|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
219025269|NCT04389424|DIAGNOSTIC_TEST|Recurrence|Breast cancer recurrence under endocrine therapy
218877662|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
218877663|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
218877664|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
218877665|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
218877666|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
218877667|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
218877668|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
219496265|NCT04188496|OTHER|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
218877669|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
218877670|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
218877671|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
218877672|NCT05501951|OTHER|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
219025270|NCT02953327|BIOLOGICAL|Bacille Calmette-Guerin|Vaccine against tuberculosis
219025271|NCT02953327|BIOLOGICAL|BCG solvent|Simple solvent
219025272|NCT03582020|DIETARY_SUPPLEMENT|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
219496266|NCT04188496|OTHER|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
219496267|NCT01776996|DRUG|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
219496268|NCT05100849|PROCEDURE|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
219496269|NCT05100849|PROCEDURE|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
218877673|NCT05501951|OTHER|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
218877674|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
218877675|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
218877676|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
218877677|NCT02526251|OTHER|observational|No intervention
218877678|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
218877679|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
218877680|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
218877681|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
218877682|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
219025273|NCT02144441|DRUG|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
219025274|NCT05348161|PROCEDURE|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
219025275|NCT05348161|PROCEDURE|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
219025276|NCT05348161|PROCEDURE|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
219025277|NCT05348161|PROCEDURE|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
219025278|NCT05348161|PROCEDURE|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
219025279|NCT05348161|PROCEDURE|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
219602976|NCT04555551|BIOLOGICAL|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
219602977|NCT05512234|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
219602978|NCT05512234|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
219602979|NCT05525390|BEHAVIORAL|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
219602980|NCT05525390|BEHAVIORAL|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
218877683|NCT00438594|BEHAVIORAL|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
218877684|NCT00000713|DRUG|Ampligen|
218877685|NCT00445276|DRUG|Diacerein|
218877686|NCT00372541|DRUG|ceftriaxone|
219025280|NCT03068247|DRUG|Duloxetine|10 week treatment
219496270|NCT01000142|PROCEDURE|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
219496271|NCT01000142|PROCEDURE|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
219496272|NCT03621020|DIAGNOSTIC_TEST|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
219496273|NCT03621020|DIAGNOSTIC_TEST|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
219496274|NCT02179931|DRUG|Flupentixol/melitracen film-coated tablet|
219496275|NCT02179931|DRUG|Flupentixol/melitracen coated tablet (Deanxit®)|
219496276|NCT02354976|DRUG|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
219496277|NCT02354976|DRUG|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
219496278|NCT02354976|DRUG|Fenofibrate 200mg|200mg capsule administered once daily
219602981|NCT05592392|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
219602982|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
219602983|NCT04334941|DRUG|Atezolizumab|Given IV
219602984|NCT04334941|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218877687|NCT05768984|OTHER|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
218877688|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
218877689|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
218877690|NCT02578329|BEHAVIORAL|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
218877691|NCT02578329|BEHAVIORAL|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
218877692|NCT00003552|DRUG|allogeneic lymphocytes|
219496279|NCT02354976|DRUG|Placebo|Placebo matching to fenofibrate 200mg
219602985|NCT04334941|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219602986|NCT04334941|PROCEDURE|Computed Tomography|Undergo CT scan
219602987|NCT04334941|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219602988|NCT04334941|DRUG|Talazoparib|Given PO
218877693|NCT00003552|DRUG|anti-thymocyte globulin|
218877694|NCT00003552|DRUG|cyclophosphamide|
218877695|NCT00003552|DRUG|fludarabine|
218877696|NCT06536556|OTHER|First Assessment|pre-treatment assessment
218877697|NCT06536556|OTHER|Second Assessment|4 days post-treatment assessment
218877698|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
218877699|NCT00180011|DRUG|Omalizumab|injectable medication
218877700|NCT01867138|DRUG|Cefazolin|
218877701|NCT01867138|DRUG|Vancomycin|
219025281|NCT03068247|DRUG|Placebo|10 week treatment
219025282|NCT03106155|DRUG|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
219025283|NCT02865993|OTHER|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
219496280|NCT02693652|BIOLOGICAL|CVI-HBV-002|"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"
219602989|NCT03814603|PROCEDURE|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
219602990|NCT03814603|DRUG|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
218877702|NCT01867138|DRUG|Amikacin|
218877703|NCT03822000|OTHER|Survival|Elderly patients with fall-induced femoral fracture who were survived.
218877704|NCT03822000|OTHER|Death|Elderly patients with fall-induced femoral fracture who were dead.
218877705|NCT02103972|DIETARY_SUPPLEMENT|GM080|
218877706|NCT02103972|DIETARY_SUPPLEMENT|Maltodextrin|
218877707|NCT00855972|DRUG|Low Dose Naltrexone|
218877708|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
218877709|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
218877710|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
218877711|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
218877712|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
218877713|NCT00590577|DRUG|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
218877714|NCT00590577|DRUG|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
218877715|NCT00590577|DRUG|Placebo|Placebo i.m. Days 1, 8, 36, 64
218877716|NCT00590577|DRUG|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
218877717|NCT00844558|OTHER|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
219025284|NCT02865993|OTHER|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
219025285|NCT03214159|DRUG|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
219365178|NCT02611401|BEHAVIORAL|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
219496281|NCT00986154|DRUG|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
219496282|NCT00986154|DRUG|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
219496283|NCT00986154|DRUG|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
219602991|NCT06139809|PROCEDURE|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
218877718|NCT00844558|OTHER|Control|There is no intervention associated with this arm of the study
218877719|NCT03327558|DRUG|Apriso 0.375G ER CAP|ER capsule
219496284|NCT00085852|BIOLOGICAL|BLVR|10 mL Hydrogel
219496285|NCT03944018|BEHAVIORAL|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
218877720|NCT03327558|DRUG|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
218877721|NCT02555384|OTHER|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
218877722|NCT02555384|OTHER|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
218877723|NCT03401060|DRUG|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
218877724|NCT03401060|DRUG|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
218877725|NCT02229526|DIETARY_SUPPLEMENT|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
218877726|NCT02229526|DIETARY_SUPPLEMENT|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
218877727|NCT02229526|DIETARY_SUPPLEMENT|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
218877728|NCT02229526|DIETARY_SUPPLEMENT|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
218877729|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
218877730|NCT04715698|OTHER|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
218877731|NCT04715698|OTHER|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
218877732|NCT02156336|DRUG|Ranolazine|Oral administration, BID; for a maximum of 51 days.
219025286|NCT03214159|DRUG|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
219025287|NCT00014209|DRUG|cisplatin|
219025288|NCT00014209|DRUG|dexamethasone|
219025289|NCT00014209|DRUG|gemcitabine hydrochloride|
218877733|NCT02156336|DRUG|Placebo|Oral administration, BID; for a maximum of 51 days.
218877734|NCT02048488|DRUG|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
218877735|NCT02470884|DEVICE|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
219025290|NCT01237535|DRUG|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
219025291|NCT01237535|DRUG|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
219025292|NCT01237535|PROCEDURE|Insemination without luteal support|Routine insemination procedure without luteal support
219025293|NCT03929861|DRUG|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
219025294|NCT03929861|DRUG|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
219025295|NCT02355119|DRUG|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
219025296|NCT02355119|DRUG|Gemcitabine|
219025297|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
219025298|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
219025299|NCT05663307|DRUG|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
219496286|NCT03726437|BEHAVIORAL|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
219496287|NCT03726437|BEHAVIORAL|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
218877736|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
218877737|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
218877738|NCT03221361|DEVICE|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
218877739|NCT03221361|DEVICE|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
219496288|NCT00623909|DEVICE|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
219496289|NCT00520247|DRUG|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
219496290|NCT00068445|DRUG|lamotrigine|
219496291|NCT00068445|OTHER|Placebo|
219496292|NCT06403566|OTHER|hand massage|three group randomized controlled trials
218877740|NCT05378061|DRUG|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
218877741|NCT05378061|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
219496293|NCT01111630|DRUG|recomon (Epoetin Beta)|administer once weekly
219496294|NCT01111630|DRUG|recomon (Epoetin Beta)|administer three times weekly
219496295|NCT03373266|DRUG|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
219496296|NCT03373266|DRUG|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
218877742|NCT05257902|DRUG|choline alphoscerate|400mg bid/day
218877743|NCT05257902|DRUG|Placebo|Placebo 1T bid/day
218877744|NCT02134730|BEHAVIORAL|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
219025300|NCT03255382|DRUG|Fumaderm|Fumaderm tablet administered orally
219025301|NCT03255382|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
219025302|NCT05507255|OTHER|Relaxation training|Relaxation training in the form of deep breathing exercises
219025303|NCT05507255|OTHER|An aerobic exercise program|An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
219025304|NCT00238121|DRUG|sorafenib tosylate|Given orally
219496297|NCT01887379|DRUG|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
219025305|NCT03816059|DIAGNOSTIC_TEST|Respiratory virus testing|All patients will be tested for respiratory viruses
219025306|NCT02221284|DRUG|Alogliptin|Alogliptin tablets
219025307|NCT02450110|DEVICE|Spinal cord stimulation|
219025308|NCT00140647|DRUG|Ramipril|
219025309|NCT00140647|DRUG|Rosiglitazone|
219025310|NCT04102592|OTHER|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
219025311|NCT04102592|OTHER|Untreated Lesu (baby wrap)|Matching untreated lesu
219025312|NCT04178187|DRUG|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
219025313|NCT04178187|DRUG|Caps Placebo|Caps Placebo
219025314|NCT02711046|PROCEDURE|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
219025315|NCT03706794|BEHAVIORAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
219025316|NCT03706794|BEHAVIORAL|Headache Education|Non-tailored education provided via a smartphone application.
219025317|NCT04385823|DEVICE|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
219025318|NCT02071888|DRUG|CB-839|Glutaminase inhibitor
219025319|NCT02071888|DRUG|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
219496298|NCT05817084|PROCEDURE|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
219496299|NCT05817084|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
219496300|NCT04603079|BEHAVIORAL|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q\&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
219496301|NCT01896700|DRUG|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
219496302|NCT01896700|DRUG|Placebo|Escalating matched dose of placebo
219602992|NCT03683290|OTHER|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
219602993|NCT05398692|OTHER|On Site Exercise Rehabilitation|The subject will receive on site standard pulmonary and exercise rehabilitation, educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques.
219025320|NCT02071888|DRUG|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
219025321|NCT02725242|DRUG|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
219496303|NCT05691699|DRUG|ABBV-903|Capsule; oral
219496304|NCT05691699|DRUG|Placebo for ABBV-903|Capsule; oral
219496305|NCT05691699|DRUG|Itraconazole|Capsule; oral
219496306|NCT00773552|DRUG|solifenacin succinate|5mg PO Qday x 90 days
219496307|NCT00773552|DRUG|placebo|1 tab PO Qday x 90 days
219496308|NCT06133699|PROCEDURE|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
219496309|NCT06133699|DIAGNOSTIC_TEST|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
219602994|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
219025322|NCT02725242|DRUG|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
219496310|NCT02869932|RADIATION|Lung CT scan|Lung CT scan without injection
219496311|NCT00971399|DRUG|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
219496312|NCT00971399|DRUG|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
219496313|NCT01886170|OTHER|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
219025323|NCT02749812|DEVICE|Constant Continuous Positive Airway Pressure|
219025324|NCT02749812|DEVICE|Automatic continuous Positive Airway Pressure|
219025325|NCT01675128|DRUG|ISIS 183750|
219025326|NCT01675128|DRUG|Irinotecan|
219025327|NCT05947201|DRUG|Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil|If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
219025328|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
219025329|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
219025330|NCT02225756|DRUG|Placebo|Oral administration for a short time of placebo
219025331|NCT02162342|OTHER|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
219025332|NCT00832585|DRUG|Alefacept|Alefacept 15mg IM every week for 12 weeks
219025333|NCT03295253|PROCEDURE|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
218877745|NCT02427503|PROCEDURE|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
219025334|NCT00136305|BEHAVIORAL|Pictorial asthma action plan|
219025335|NCT00136305|BEHAVIORAL|Written asthma action plan|
219025336|NCT01396460|OTHER|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
219025337|NCT01487590|OTHER|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
219025338|NCT01487590|OTHER|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
219025339|NCT02360592|DRUG|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
219025340|NCT02360592|DRUG|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
219025341|NCT02360592|DRUG|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
219025342|NCT02360592|DRUG|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
219602995|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
219602996|NCT03793166|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219602997|NCT03793166|PROCEDURE|Bone Scan|Undergo bone scan
219025343|NCT00967993|DRUG|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
219025344|NCT04418999|DRUG|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
219025345|NCT04418999|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
219025346|NCT02784210|DRUG|Methylprednisolone|3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
219025347|NCT02784210|DRUG|Prednisone|3 days of corticosteroids (oral prednisone at 1250 mg/day
219025348|NCT05418192|OTHER|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
219025349|NCT05418192|OTHER|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
219025350|NCT04511793|DEVICE|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
219025351|NCT03525210|BIOLOGICAL|9-valent HPV vaccine|Vaccination
219025352|NCT01648855|OTHER|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
219025353|NCT03830944|DIAGNOSTIC_TEST|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
219025354|NCT03830944|DIAGNOSTIC_TEST|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
219025355|NCT03830944|DIAGNOSTIC_TEST|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
219025356|NCT03830944|DIAGNOSTIC_TEST|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
219025357|NCT04748133|DEVICE|acupuncture needles|"Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
219025358|NCT04748133|OTHER|placebo|no treatment
219025359|NCT01374087|DRUG|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
219025360|NCT01374087|RADIATION|Brachytherapy|Brachytherapy: Low or high dose rate.
219025361|NCT03809507|OTHER|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
219365179|NCT02455401|DRUG|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
219365180|NCT02455401|DRUG|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
219602998|NCT03793166|DRUG|Cabozantinib|Given PO
219602999|NCT03793166|PROCEDURE|Computed Tomography|Undergo CT scan
219603000|NCT03793166|BIOLOGICAL|Ipilimumab|Given IV
218877746|NCT06041633|DIAGNOSTIC_TEST|Clinical|Questionnaire
218877747|NCT04015674|OTHER|Exercise group|Aerobic exercise on a stationary bicycle
218877748|NCT04015674|OTHER|Control group|In a rest
219025362|NCT00004159|DRUG|gemcitabine hydrochloride|
219025363|NCT00004159|DRUG|paclitaxel|
219025364|NCT00606476|DRUG|Bapineuzumab (AAB-001)|IV q13w
219025365|NCT01380509|DRUG|Metronidazole|Capsules, single-dose, fasting
219025366|NCT01380509|DRUG|Flagyl|Capsules, single-dose, fasting
218877749|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
218877750|NCT00418574|BIOLOGICAL|Abagovomab|2 mg/ml SC (subcutaneously)
218877751|NCT00418574|BIOLOGICAL|Placebo|2 mg/ml SC (subcutaneously)
218877752|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
219025367|NCT03011307|DRUG|Oxytocin|spinal injection of oxytocin
219025368|NCT03011307|DRUG|Placebo|spinal injection of placebo
219025369|NCT03526458|DEVICE|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
219025370|NCT01185119|DRUG|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
219025371|NCT01695694|BEHAVIORAL|supporting positive and healthy relationships|
219025372|NCT01695694|BEHAVIORAL|community support group|
219025373|NCT02157155|BIOLOGICAL|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
219025374|NCT00271947|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
219025375|NCT04816695|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
219365181|NCT02455401|DRUG|No remifentanil|Intervention: no remifentanil will be administrated
219603001|NCT03793166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218877753|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
218877754|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
219025376|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
219025377|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
219025378|NCT01824407|DEVICE|Electrohydraulic-generated shock wave|
219025379|NCT01824407|DEVICE|Sham device plus standard of care|
219603002|NCT03793166|BIOLOGICAL|Nivolumab|Given IV
219025380|NCT04325958|DRUG|Cannabis|750mg cigarette of plant material
219025381|NCT04325958|DRUG|Placebos|750mg cigarette of plant material
219025382|NCT02466555|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
219025383|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
219025384|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
219365182|NCT01292655|DRUG|BMS-906024|
219365183|NCT01017510|DEVICE|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
218877755|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
218877756|NCT01506284|PROCEDURE|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
219365184|NCT01017510|DEVICE|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
219365185|NCT00687791|DEVICE|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
219365186|NCT00035204|DRUG|galantamine|
219365187|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
219365188|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
219365189|NCT04058587|DRUG|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
218877757|NCT00700505|DEVICE|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
219025385|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
219025386|NCT04170348|DRUG|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
219025387|NCT04170348|DRUG|Monthly oral vitamin D3, 100,000 IU|Oral vitamin D3, 100,000 IU, will be administered monthly.
219025388|NCT04170348|DRUG|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
219025389|NCT04870333|DRUG|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
219496314|NCT03554642|DEVICE|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
219496315|NCT03554642|BEHAVIORAL|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
219496316|NCT03905499|DEVICE|Robotic assisted therapy with MJS (multi joint system) Tecnobody|The intervention will include 18 30-minutes trainings evenly distributed over a time period of 6 weeks and will be administered by the same two physiotherapists at the Schulthess clinic based on the standardized protocol
219496317|NCT03905499|OTHER|Usual Care|Patients randomized in the usual care will receive standard of care treatment without receiving any active intervention
219496318|NCT01931137|DRUG|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
219603003|NCT03793166|OTHER|Quality-of-Life Assessment|Ancillary studies
219603004|NCT03793166|OTHER|Questionnaire Administration|Ancillary studies
219603005|NCT03698019|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218877758|NCT00006656|DRUG|carmustine in ethanol|
219496319|NCT02583178|DEVICE|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
219496320|NCT04608578|BEHAVIORAL|Silver|A serious game to improve mental health in youth
219496321|NCT03140085|BIOLOGICAL|PYO Phage|Intravescial instillation
219496322|NCT03140085|DRUG|Antibiotics|Oral application
219496323|NCT03140085|OTHER|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
219496324|NCT03523507|DEVICE|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
219603006|NCT03698019|PROCEDURE|Computed Tomography|Undergo CT
219603007|NCT03698019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219603008|NCT03698019|BIOLOGICAL|Pembrolizumab|Given IV
219603009|NCT03698019|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219603010|NCT00588770|BIOLOGICAL|Bevacizumab|Given IV
219603011|NCT00588770|DRUG|Carboplatin|Given IV
219603012|NCT00588770|DRUG|Cisplatin|Given IV
219603013|NCT00588770|DRUG|Docetaxel|Given IV
218877759|NCT00006656|PROCEDURE|conventional surgery|
219603014|NCT00588770|DRUG|Fluorouracil|Given IV
219603015|NCT00588770|OTHER|Laboratory Biomarker Analysis|Correlative studies
219603016|NCT03233711|PROCEDURE|Biopsy Procedure|Undergo biopsy
218877760|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
218877761|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
218877762|NCT01776866|PROCEDURE|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
218877763|NCT00123045|BEHAVIORAL|health education|
218877764|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
218877765|NCT04071678|BEHAVIORAL|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
218877766|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
218877767|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
218877768|NCT03712488|DEVICE|flowcytometry|four colour flowcytometry
218877769|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
218877770|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
218877771|NCT05505409|DRUG|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
218877772|NCT05505409|DRUG|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
218877773|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
218877774|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
218877775|NCT03578328|PROCEDURE|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
219025390|NCT04870333|DRUG|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
219025391|NCT04870333|DRUG|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
219025392|NCT04870333|DRUG|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
219025393|NCT04870333|DRUG|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose."
219025394|NCT04870333|DRUG|Placebo|There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
219025395|NCT03515772|DRUG|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
219025396|NCT02304263|DRUG|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
219025397|NCT03160742|DEVICE|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
219025398|NCT03604042|COMBINATION_PRODUCT|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
219025399|NCT01536314|DRUG|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
219025400|NCT01536314|DRUG|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
219025401|NCT02011347|DRUG|Ketamine|
219496325|NCT03523507|DEVICE|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
219025402|NCT02011347|DRUG|Placebo|
219025403|NCT04308837|DRUG|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
219025404|NCT04308837|DRUG|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
219025405|NCT04308837|DRUG|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
219025406|NCT04308837|DRUG|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
219025407|NCT04308837|DRUG|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
219025408|NCT04308837|DRUG|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
219025409|NCT04308837|RADIATION|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
219025410|NCT04308837|PROCEDURE|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
219025411|NCT04308837|RADIATION|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
219025412|NCT05158868|DIAGNOSTIC_TEST|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
219025413|NCT05481567|OTHER|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
219025414|NCT04424017|BIOLOGICAL|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
219025415|NCT03319355|BEHAVIORAL|cognitive behavioral therapy|exercise therapy
219025416|NCT00868075|PROCEDURE|Chest physiotherapy|Twice daily for 8 weeks
219025417|NCT00868075|PROCEDURE|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
219025418|NCT00529542|DRUG|Lipitor|40mg caplets per day for six weeks
219496326|NCT01217528|DEVICE|device settings for group A|VT zone: 350ms VF zone: 280ms
219496327|NCT01217528|DEVICE|Device settings for group B|VT zone: 320ms VF zone: 250ms
219496328|NCT00423488|DRUG|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
219496329|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
219496330|NCT00423488|DRUG|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
219496331|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
219496332|NCT00423488|DRUG|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
219603017|NCT03233711|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218877776|NCT05387057|BEHAVIORAL|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
218877777|NCT05387057|BEHAVIORAL|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
218877778|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
218877779|NCT02728297|PROCEDURE|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
218877780|NCT02600091|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
218877781|NCT00501865|DRUG|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
218877782|NCT04741763|DIETARY_SUPPLEMENT|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
218877783|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
218877784|NCT01323140|DRUG|testosterone matrix transdermal system|
218877785|NCT01623739|PROCEDURE|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
218877786|NCT03579641|DEVICE|HeartLogic Sensors|HeartLogic Sensors
218877787|NCT02013245|BIOLOGICAL|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
218877788|NCT02013245|BIOLOGICAL|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
218877789|NCT06276166|OTHER|No intervention|No intervention
218877790|NCT03342092|OTHER|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
218877791|NCT04510103|DRUG|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
219025419|NCT00529542|DRUG|Placebo|1 placebo caplet per day for six weeks.
219025420|NCT05463510|DIAGNOSTIC_TEST|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
219025421|NCT01082965|DRUG|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
219025422|NCT01082965|DRUG|Placebo|matching placebo
219365190|NCT03900390|PROCEDURE|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
219603018|NCT03233711|PROCEDURE|Colonoscopy|Undergo colonoscopy
219603019|NCT03233711|PROCEDURE|Computed Tomography|Undergo CT scan
219603020|NCT03233711|PROCEDURE|Digital Rectal Examination|Undergo digital rectal examination
219025423|NCT06213168|OTHER|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
219025424|NCT06213168|OTHER|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
218877792|NCT04510103|OTHER|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
218877793|NCT04510103|PROCEDURE|Regression|2 week regression period after 6 weeks of moisturizer use.
218877794|NCT04510103|PROCEDURE|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
219025425|NCT05350319|RADIATION|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
219025426|NCT02587065|DRUG|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
219365191|NCT02274610|DRUG|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
219365192|NCT02274610|DRUG|Taxotere|Docetaxel
219365193|NCT01987908|DRUG|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
219365194|NCT01987908|OTHER|Placebo|
219365195|NCT03501966|DRUG|Acetazolamide|Medical therapy including diet
219365196|NCT03501966|PROCEDURE|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
219365197|NCT03501966|PROCEDURE|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
219365198|NCT00849667|DRUG|Farletuzumab|Farletuzumab IV infusion.
219365199|NCT00849667|DRUG|Carboplatin|Carboplatin IV infusion.
219365200|NCT00849667|DRUG|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
219365201|NCT00849667|DRUG|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
219365202|NCT00189462|DRUG|Montelukast|
219365203|NCT00189462|DRUG|Placebo|
218877795|NCT00065845|PROCEDURE|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
219025427|NCT01467947|BIOLOGICAL|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
219025428|NCT04252755|BEHAVIORAL|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
219025429|NCT04476979|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
219025430|NCT04476979|DRUG|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
219025431|NCT00243178|DRUG|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
219025432|NCT01136096|BEHAVIORAL|Physical activity promoting intervention|"1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
219025433|NCT01136096|BEHAVIORAL|General instruction and education|"1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist"
219025434|NCT00022828|DEVICE|3-D Laser Imaging Device|
219025435|NCT06970743|DRUG|BGB-16673|Administered orally
219025436|NCT06970743|DRUG|Bendamustine|Administered intravenously
219365204|NCT00553163|BEHAVIORAL|Gut focussed hypnotherapy|Gut focussed hypnotherapy
219365205|NCT00553163|BEHAVIORAL|Control educational sessions|Control educational sessions
218877796|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
219496333|NCT00117585|OTHER|Treatment Phase 1|"* Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma"
218877797|NCT03468647|OTHER|soles|Volunteer must walk this this connected seamless to measure different walking parameters
218877798|NCT03468647|OTHER|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
218877799|NCT03468647|OTHER|gripping force|this machine measure the gripping force of volunteer
218877800|NCT04836247|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
218877801|NCT04836247|BEHAVIORAL|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
218877802|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
218877803|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
218877804|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
218877805|NCT03589222|DRUG|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
218877806|NCT03589222|DRUG|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
219025437|NCT06970743|DRUG|Rituximab|Administered intravenously
219025438|NCT06970743|DRUG|Methylprednisolone|Administered intravenously
219025439|NCT00229255|OTHER|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
219025440|NCT00229255|OTHER|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
218877807|NCT03589222|DRUG|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
219025441|NCT00077103|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
219025442|NCT00077103|BIOLOGICAL|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
219025443|NCT00077103|DRUG|cisplatin|cisplatin IV over 30-60 minutes on day 1
219025444|NCT00077103|DRUG|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
219365206|NCT01821495|BIOLOGICAL|DC-CIK|
219365207|NCT01821495|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
219365208|NCT05641701|DEVICE|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
219365209|NCT05641701|DEVICE|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
219496334|NCT00117585|DRUG|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet"
219603021|NCT03233711|PROCEDURE|High Resolution Anoscopy|Undergo anoscopy
219603022|NCT03233711|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219603023|NCT03233711|BIOLOGICAL|Nivolumab|Given IV
218877808|NCT03589222|DRUG|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
218877809|NCT03085745|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
218877810|NCT00002812|DRUG|asparaginase|Given IV
218877811|NCT00002812|DRUG|cyclophosphamide|Given IV
218877812|NCT00002812|DRUG|cytarabine|Given IV
218877813|NCT00002812|DRUG|daunorubicin hydrochloride|Given IV
218877814|NCT00002812|DRUG|dexamethasone|Given IV
218877815|NCT00002812|DRUG|doxorubicin hydrochloride|Given IV
219496335|NCT00117585|OTHER|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
219496336|NCT02501031|DIETARY_SUPPLEMENT|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
219496337|NCT00056082|DRUG|celecoxib|Celecoxib daily for 12 months
219496338|NCT03118765|DRUG|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
219496339|NCT03118765|DRUG|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
219496340|NCT03118765|DRUG|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
219496341|NCT02569840|DIETARY_SUPPLEMENT|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
219496342|NCT05012735|DRUG|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
219496343|NCT05012735|DEVICE|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
218877816|NCT00002812|DRUG|idarubicin|Given IV
219025445|NCT00077103|DRUG|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
219025446|NCT00077103|RADIATION|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
219025447|NCT04035161|COMBINATION_PRODUCT|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
219025448|NCT04035161|OTHER|Reference Standard|60% (v/v) 1-propanol skin preparation
219496344|NCT00849524|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
218877817|NCT00002812|DRUG|mercaptopurine|Given IV
218877818|NCT00002812|DRUG|methotrexate|Given PO
218877819|NCT00002812|DRUG|pegaspargase|Given IV
218877820|NCT00002812|DRUG|prednisone|Given PO
218877821|NCT00002812|DRUG|thioguanine|Given IV
218877822|NCT00002812|DRUG|vincristine sulfate|Given IV
218877823|NCT00002812|RADIATION|radiation therapy|
218877824|NCT03884647|DEVICE|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
218877825|NCT05930691|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
218877826|NCT00180583|DEVICE|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
218877827|NCT05618418|OTHER|No intervention|No intervention
218877828|NCT05295355|DRUG|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
218877829|NCT00604045|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
218877830|NCT00604045|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
218877831|NCT00254891|DRUG|PF-3512676 + Paclitaxel + Carboplatin|"* PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
219025449|NCT04035161|COMBINATION_PRODUCT|Active Comparator|ChloraPrep® SEPP® skin preparation
219025450|NCT04035161|OTHER|Negative Control|0.9% Normal Saline skin preparation
219496345|NCT04664569|OTHER|observational study|observational study
219603024|NCT03233711|OTHER|Patient Observation|Undergo observation
219603025|NCT03233711|PROCEDURE|Proctoscopy|Undergo proctoscopy
219603026|NCT03233711|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219603027|NCT03233711|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
219603028|NCT06409000|OTHER|Electronic Health Record Review|Medical records reviewed
219603029|NCT06409000|PROCEDURE|Three-Dimensional Imaging|Undergo 3D surface scans
219603030|NCT01856192|DRUG|Cyclophosphamide|Given IV
219603031|NCT01856192|DRUG|Doxorubicin Hydrochloride|Given IV
219603032|NCT01856192|OTHER|Laboratory Biomarker Analysis|Correlative studies
219603033|NCT01856192|DRUG|Lenalidomide|Given PO
218877832|NCT00254891|DRUG|Paclitaxel + Carboplatin|"* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
218877833|NCT04492163|DEVICE|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
219025451|NCT03022292|DRUG|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
219025452|NCT03022292|DEVICE|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
219025453|NCT01328860|BIOLOGICAL|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
219496346|NCT04844996|PROCEDURE|Surgical induction of endometriotic explants|"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"
219496347|NCT01399021|OTHER|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
219496348|NCT01399021|OTHER|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
219496349|NCT01258816|DRUG|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
219496350|NCT00802633|DEVICE|Stapling device during radical cystectomy|Hemostasis
219496351|NCT00802633|DEVICE|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
219496352|NCT00533884|OTHER|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
219496353|NCT00533884|OTHER|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
219496354|NCT00533884|OTHER|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
219496355|NCT02440100|DRUG|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
219496356|NCT02440100|DRUG|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
219496357|NCT02440100|DRUG|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
219496358|NCT01637675|DRUG|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
219603034|NCT01856192|DRUG|Prednisone|Given PO
219603035|NCT01856192|BIOLOGICAL|Rituximab|Given IV
219603036|NCT01856192|DRUG|Vincristine Sulfate|Given IV
219603037|NCT05397951|DEVICE|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
218877834|NCT02804035|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
218877835|NCT01984996|DEVICE|Freedom ProFlor Inguinal Hernia Implant|
218877836|NCT00779207|BEHAVIORAL|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
218877837|NCT00779207|BEHAVIORAL|weight loss|10 percent weight loss through diet and behavioral modification
219025454|NCT05466747|BIOLOGICAL|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
219025455|NCT05466747|BIOLOGICAL|Another Available A1PI|Another available A1PI administered through an IV injection.
219025456|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
219025457|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
219025458|NCT02935790|DRUG|ACY-241|tablet
219025459|NCT02935790|DRUG|nivolumab|infusion
219025460|NCT02935790|DRUG|ipilimumab|infusion
219025461|NCT00445965|GENETIC|DNA analysis|
219025462|NCT00445965|OTHER|immunologic technique|
219025463|NCT00445965|OTHER|pharmacological study|
219025464|NCT00445965|RADIATION|iodine I 131 monoclonal antibody 3F8|
219603038|NCT05397951|DEVICE|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
219603039|NCT05397951|DEVICE|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
219603040|NCT05397951|DEVICE|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
219603041|NCT02642042|DRUG|Docetaxel|Given IV
219603042|NCT02642042|OTHER|Laboratory Biomarker Analysis|Correlative studies
219603043|NCT02642042|DRUG|Trametinib|Given PO
218877838|NCT02781168|DEVICE|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
218877839|NCT03363880|OTHER|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
218877840|NCT03363880|OTHER|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
218877841|NCT01887353|DRUG|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
218877842|NCT01887353|DRUG|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
219025465|NCT00445965|RADIATION|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
219025466|NCT00089349|BIOLOGICAL|alemtuzumab|Given IV
219025467|NCT00089349|DRUG|methotrexate|Given IV
219025468|NCT00089349|DRUG|mercaptopurine|Given PO
219496359|NCT01637675|DRUG|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
219496360|NCT04084054|DIAGNOSTIC_TEST|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
219496361|NCT02011802|DEVICE|Algosteril TM|
219496362|NCT02011802|DEVICE|Sorbact TM|
219496363|NCT02818179|RADIATION|THERMOGRAPHY IMAGING|
219496364|NCT04514770|DRUG|Misoprostol|rupture of membrane early and late
219496365|NCT01498107|BEHAVIORAL|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
219496366|NCT00065897|PROCEDURE|Amniocentesis|
219496367|NCT00065897|PROCEDURE|Transabdominal chorionic villus sampling (TA CVS)|
219496368|NCT02536131|OTHER|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
219496369|NCT05840666|OTHER|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
219496370|NCT05840666|OTHER|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
219496371|NCT05840666|OTHER|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
219496372|NCT01693276|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
219496373|NCT01693276|DRUG|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
219603044|NCT04844190|DIAGNOSTIC_TEST|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
219025469|NCT01528956|GENETIC|DNA methylation analysis|
219025470|NCT01528956|GENETIC|RNA analysis|
219025471|NCT01528956|GENETIC|gene expression analysis|
219025472|NCT01528956|GENETIC|nucleic acid sequencing|
219025473|NCT01528956|GENETIC|polymorphism analysis|
219025474|NCT05667038|DRUG|Probiotic|"The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
219496374|NCT01693276|RADIATION|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
219496375|NCT01340365|BEHAVIORAL|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
219496376|NCT01340365|BEHAVIORAL|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
219496377|NCT00411801|BIOLOGICAL|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
219496378|NCT00411801|BIOLOGICAL|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
219496379|NCT04881591|DEVICE|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
219025475|NCT05667038|DIETARY_SUPPLEMENT|Placebo|"Placebo:~Subjects in the placebo group will receive the placebo consisting of only the carrier of the probiotic product, that is maize starch and maltodextrins.~The sachet is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
219496380|NCT06098222|BEHAVIORAL|Slow breathing exercise training|Slow breathing exercise training will be given by the researcher in a single one-hour session in the meeting room of the unit 24 hours after the PCI and/or the next day. After a 20-minute silent rest in the training, patients will be asked to breathe slowly through the nostrils for 4 seconds and slowly exhale through the mouth for 6 seconds to reach 6-8 breaths/min. The patient will rest for 5 seconds after every 6 slow breaths. During the training period, a stopwatch will be used by observing the patient's chest and abdominal movements in order to determine whether the patients have reached the required respiratory rate.
219496381|NCT00108758|DRUG|activated recombinant human factor VII|
219496382|NCT03810664|DRUG|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
219496383|NCT05862519|DIETARY_SUPPLEMENT|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
219496384|NCT05862519|DIETARY_SUPPLEMENT|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds \& Flaxseed. Taken from Day 7 through Day 21.
218877843|NCT00699335|DRUG|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
218877844|NCT03492801|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218877845|NCT03492801|OTHER|Laboratory Biomarker Analysis|Correlative studies
218877846|NCT00083135|BIOLOGICAL|filgrastim|
218877847|NCT00083135|PROCEDURE|autologous bone marrow transplantation|
218877848|NCT00083135|PROCEDURE|peripheral blood stem cell transplantation|
218877849|NCT00083135|RADIATION|iobenguane I 131|
218877850|NCT01069705|DRUG|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
218877851|NCT00441805|DEVICE|Radio Frequency|
218877852|NCT00292539|DEVICE|Any pacemaker with right ventricular pacing option|
218877853|NCT02726022|DRUG|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
218877854|NCT02726022|DRUG|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
218877855|NCT03989401|OTHER|Multimedia video health education|The experimental group conducted multimedia video education while admission.
218877856|NCT01781780|BEHAVIORAL|General Nutrition Recommendations|
218877857|NCT01781780|BEHAVIORAL|Breakfast Recommendation|
218877858|NCT01781780|BEHAVIORAL|No Breakfast Recommendation|
218877859|NCT06190080|OTHER|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
218877860|NCT03360058|BEHAVIORAL|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
218877861|NCT03360058|BEHAVIORAL|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
218877862|NCT00451516|DRUG|Herbal medicine (St. John's wort and Kava)|
218877863|NCT05772013|DRUG|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
218877864|NCT05772013|DRUG|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
218877865|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
218877866|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
218877867|NCT06474403|PROCEDURE|standard Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
218877868|NCT06474403|PROCEDURE|modified Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
218877869|NCT00762541|DEVICE|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
218877870|NCT02760316|DRUG|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
218877871|NCT02760316|DRUG|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
218877872|NCT02760316|DRUG|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
218877873|NCT02760316|DRUG|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
218877874|NCT02760316|DRUG|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
218877875|NCT02760316|DRUG|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
218877876|NCT02760316|DRUG|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
219496385|NCT05862519|DIETARY_SUPPLEMENT|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
218877877|NCT02760316|DRUG|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
218877878|NCT02760316|DRUG|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
219025476|NCT02950077|BEHAVIORAL|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
219025477|NCT03591016|OTHER|Recording number of IV attempts|Recording number of IV attempts in the operating room
218877879|NCT00187525|DRUG|Memantine|
218877880|NCT01879969|PROCEDURE|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
219025478|NCT02964468|RADIATION|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
219025479|NCT02964468|RADIATION|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
219025480|NCT06059911|DIETARY_SUPPLEMENT|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
219365210|NCT04827641|OTHER|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
219365211|NCT02986594|DRUG|Aspirin|
219365212|NCT02986594|DRUG|Heparin|
219496386|NCT05862519|DIETARY_SUPPLEMENT|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
219496387|NCT04895319|DEVICE|Computer-assisted surgery|The reconstruction was performed with the help of virtual surgical plan and 3D printed models.
219496388|NCT05717283|DIAGNOSTIC_TEST|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
219496389|NCT01638793|DEVICE|Microcap (Oridion, Needham, MA, USA)|
219496390|NCT01638793|DEVICE|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
219496391|NCT02722824|DEVICE|Electro-stimulation|
219496392|NCT02722824|OTHER|Placebo|
219365213|NCT00797693|DRUG|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
219365214|NCT00827190|DRUG|ILS-920|
219365215|NCT01262625|DEVICE|CCTA|Complete diagnostic CCTA per protocol specifications.
218877881|NCT01879969|PROCEDURE|computer assisted orthognathic planning and surgery of asymmetric patients|
218877882|NCT05607862|OTHER|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
219365216|NCT01262625|DEVICE|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
219365217|NCT00110942|DRUG|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
219365218|NCT00110942|OTHER|Placebo|SC placebo injection Q4W for 3 doses
219365219|NCT03089957|DRUG|Ulinastatin|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
219365220|NCT03089957|OTHER|Usual care|Usual care in ICU.
219365221|NCT03153839|BEHAVIORAL|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
219365222|NCT05704478|DRUG|Vericiguat|soluble guanylate cyclase stimulator
219365223|NCT00046787|DRUG|OSI-211 (Liposomal Lurtotecan)|
219365224|NCT02789657|DRUG|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
219365225|NCT02789657|DRUG|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
219365226|NCT02789657|DRUG|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
219365227|NCT02789657|DRUG|carboplatin|AUC 2 administered weekly with no planned treatment breaks
219365228|NCT02789657|PROCEDURE|Breast surgery|breast conserving or mastectomy
218877883|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
218877884|NCT01512992|PROCEDURE|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management."
219025481|NCT06059911|DIETARY_SUPPLEMENT|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
219025482|NCT05252611|OTHER|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
219025483|NCT05104567|DRUG|THOR-707|Solution for infusion: intravenous infusion
219025484|NCT05104567|DRUG|Pembrolizumab|Solution for infusion: intravenous infusion
219025485|NCT05104567|DRUG|Cetuximab|Solution for infusion: intravenous infusion
219025486|NCT03479307|DRUG|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
219025487|NCT03479307|DRUG|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
219025488|NCT03479307|DRUG|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
219025489|NCT03904758|DIAGNOSTIC_TEST|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
219025490|NCT05719012|BIOLOGICAL|UC-MSCs|Intravenous injection three times with one-month interval
219496393|NCT03386149|DRUG|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~* Rehmannia Root 1.7g~* Achyranthes Root 1.0g~* Cornus Fruit 1.0g~* Dioscorea Rhizome 1.0g~* Psyllium Husk 1.0g~* Alisma Rhizome 1.0g~* Hoelen 1.0g~* Moutan Root Bark 1.0g~* Cinnamon Bark 0.3g~* Pulvis Aconiti Tuberis Purificatum 0.3g"
219025491|NCT00733746|DRUG|erlotinib hydrochloride|oral administration
219200382|NCT06754033|DIAGNOSTIC_TEST|Interventional group I|Intervention Details: Participants in this arm will receive a Ganglion Impar Block, a minimally invasive injection aimed at blocking pain signals from the coccyx region (Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance). Participants in this arm will receive a Ganglion Impar Block, a minimally invasive procedure involving the administration of Triamcinolone Acetate (a corticosteroid) and Bupivacaine (a local anesthetic). This is intended to block pain signals originating from the coccyx region. The procedure will be conducted under fluoroscopic guidance to ensure precise delivery. The injection will be complemented by a structured physical therapy program, including heat therapy, ultrasound, posture training, core strengthening exercises, and mobility activities to improve pain relief and functional capacity.
219200383|NCT06754033|COMBINATION_PRODUCT|Interventional group II|Intervention Details: Participants in this arm will receive a Caudal Epidural Steroid Injection Caudal Epidural Steroid Injection using Triamcinolone Acetate (40 mg), Bupivacaine (0.25%), and Normal Saline (6 mL) administered with a 22G Spinal Needle under Fluoroscopic Guidance), designed to deliver anti-inflammatory medication directly to the epidural space, thereby reducing inflammation and pain. This will also be paired with a tailored physical therapy program, focusing on similar modalities as in Arm 1, including heat therapy, ultrasound, posture training, and strengthening exercises. The objective is to enhance pain relief and functional recovery in the context of coccydynia.
219025492|NCT00733746|DRUG|gemcitabine hydrochloride|Intravenous administration
219200384|NCT06769581|PROCEDURE|Infraclavicular Brachial Plexus Blocks|Lateral sagittal technique infraclavicular brachial plexus block
219496394|NCT03386149|DRUG|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
219496395|NCT03386149|PROCEDURE|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
219496396|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
219025493|NCT00733746|PROCEDURE|therapeutic conventional surgery|
219025494|NCT03999892|BEHAVIORAL|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
219025495|NCT02099097|OTHER|web-based video game (Quit IT)|
219025496|NCT02099097|BEHAVIORAL|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
218877885|NCT01601262|DEVICE|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
218877886|NCT05848362|OTHER|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
219025497|NCT02099097|OTHER|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
219025498|NCT06485063|OTHER|Myofascial Reorganization|It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
219025499|NCT06485063|OTHER|PLACEBO Myofascial Reorganization|it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
219025500|NCT00087451|DRUG|AP23573|ridaforolimus
219025501|NCT02295995|BEHAVIORAL|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
219025502|NCT04422028|DRUG|Desogestrel 0.075 MG|Test Drug
219025503|NCT04422028|DRUG|Desogestrel 0.075 MG|Reference Product
219025504|NCT02447081|DEVICE|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
219025505|NCT01787175|OTHER|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
219025506|NCT02942446|DEVICE|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
219025507|NCT05487742|DRUG|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
219025508|NCT05487742|DRUG|placebo salin infusion|salin infused as aplacebo for 72 hours
219200385|NCT06759584|DRUG|Dexamethasone|To Compare clinical outcome of dexamethasone phonophoresis in a (continuous and pulsed) maneuver for management of Temporomandibular Disorders
218877887|NCT02340416|DEVICE|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
218877888|NCT02209896|DEVICE|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
219025509|NCT00819338|DIETARY_SUPPLEMENT|Efamax|5g daily as capsules for 3 months
219025510|NCT03079609|PROCEDURE|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
219025511|NCT03079609|PROCEDURE|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
219025512|NCT05818579|OTHER|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
219025513|NCT05263154|OTHER|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
219025514|NCT05263154|OTHER|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
219025515|NCT01352299|DEVICE|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
219025516|NCT01352299|DEVICE|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
219025517|NCT01352299|DEVICE|Miller|Laryngoscopy performed with Miller Laryngoscope
219025518|NCT01352299|DEVICE|TrueView|Laryngoscopy performed with TrueView laryngoscope
219025519|NCT05511051|DRUG|Fruquintinib|Fruquintinib
219025520|NCT05511051|DRUG|HAIC|HAIC
219025521|NCT04909320|BEHAVIORAL|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
219200386|NCT06756438|OTHER|Study product|Anti-itching, anti-replapse and repairing treatment. Emollient.
219200387|NCT06756438|OTHER|Placebo|Emollient
219200388|NCT06757543|DEVICE|Video laryngoscopy|Video laryngoscopy with C-MAC (Karl Storz, Tuttlingen, Germany)
218877889|NCT01978223|PROCEDURE|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
219200389|NCT06757543|DEVICE|Direct laryngoscopy with standard laryngoscope|Direct laryngoscopy with standard laryngoscope
218877890|NCT02622893|DRUG|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
218877891|NCT02622893|DRUG|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
218877892|NCT02776254|OTHER|START|Point of care testing for rapid ART initiation
218877893|NCT02776254|OTHER|CAG|Community Adherence Group
218877894|NCT02776254|OTHER|UAG|Urban Adherence Group
218877895|NCT02776254|OTHER|FAST-TRACK|Prescription refill only
218877896|NCT02999633|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
218877897|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:pills Route of administration: oral
218877898|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
218877899|NCT02999633|DRUG|acetaminophen|Pharmaceutical form:pills Route of administration: oral
218877900|NCT02999633|DRUG|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
218877901|NCT02999633|DRUG|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
218877902|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
218877903|NCT02258087|RADIATION|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
218877904|NCT02258087|RADIATION|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
218877905|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
218877906|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
218877907|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
218877908|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
218877909|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
219496397|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
219496398|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
218877910|NCT03262441|DRUG|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
218877911|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
218877912|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
218877913|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
218877914|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
218877915|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
218877916|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
218877917|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
218877918|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
218877919|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
218877920|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
218877921|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
218877922|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
218877923|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
218877924|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
218877925|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
218877926|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
218877927|NCT04666194|PROCEDURE|Cold forceps|
218877928|NCT04666194|PROCEDURE|Cold snare|
218877929|NCT04666194|PROCEDURE|Hot snare|
219200390|NCT06762691|DEVICE|MyCRO Band|A 3D-printed cranial remolding orthosis
219200391|NCT06762691|DEVICE|Traditional CRO|A traditionally manufactured cranial remolding orthosis such as the Orthomerica Starband
219200392|NCT00243087|DRUG|BI 2536|
219496399|NCT02953197|RADIATION|FDG-PET guided radiation dose escalation|Selective dose escalation
219200393|NCT06839599|DRUG|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
218877930|NCT01501994|OTHER|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
218877931|NCT01501994|OTHER|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
219025522|NCT04909320|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
219025523|NCT04909320|OTHER|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
219025524|NCT04909320|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
219200394|NCT06839599|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
219200395|NCT05028387|DRUG|medical abortion|medical abortion
219200396|NCT06845930|DRUG|Rectal Diclofenac|Rectal diclofenac, 100mg administered immediately after skin closure then 12 hourly for 24 hours.
219200397|NCT06845930|DRUG|Intramuscular diclofenac|Intramuscular diclofenac, 7mg administered immediately after skin closure then 12 hourly for 24 hours.
219200398|NCT06836791|PROCEDURE|chemical cautrizating agents to stop epistaxis|All procedures were performed as office-based procedures under the influence of local anesthesia.Patients were treated with chemical cauterization. Prior to cauterization, 2 cotton packs soaked in 10% lignocaine spray were introduced into each nostril for 5-10 minutes. Then, a cotton-tipped applicator dipped in chemical cautrizating agents solution was applied to the bleeding point, and the sample was firmly pressed for 1 minute. In the case of bleeding, a second application of chemical cautrizating agents solution was applied to the area, after which a cotton tip applicator was applied to the area for 30 s with cauterization of all the feeding blood vessels around the bleeding point. This was followed by the prescription of an antiseptic soothing cream topically twice daily for 2 weeks.
219200399|NCT06836791|DRUG|Silver Nitrate|silver nitrate is chemical cautrizing agent ,in the study ,the investigators use it in treatment of anterior epistaxis in children by dissolving silver nitrate crystals in normal saline solution before using.
219200400|NCT06836791|DRUG|Trichloroacetic Acid Topical|trichloroacetic acid is well known peeling agent ,in the study the investigators use it as chemical cautrizing agent to treat anterior epistaxis in children .
219200401|NCT06857084|DEVICE|Arthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation|Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue.
219200402|NCT06671392|DRUG|DWC202405|5/20mg, 1 tablet, Oral, Once a day
219200403|NCT06671392|DRUG|DWC202405, DWC202314|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
219200404|NCT06671392|DRUG|DWC202405, DWC202314P|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
219200405|NCT06671392|DRUG|DWC202313, DWC202314|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
219200406|NCT06671392|DRUG|DWC202313, DWC202314P|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
219200407|NCT06887790|OTHER|Education method (ARCS)|The control group will not be intervened in the study. The experimental group will be given structured training with the ARCS method.
219365229|NCT02789657|DRUG|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
219365230|NCT01075880|DRUG|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
219365231|NCT04681404|PROCEDURE|Knee Arthroplasty|Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL
219365232|NCT00424970|DRUG|acetazolamide|
219365233|NCT05647330|DRUG|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
219365234|NCT02198248|DRUG|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
219365235|NCT02198248|DRUG|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
218877932|NCT01501994|PROCEDURE|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
219603045|NCT04844190|DIAGNOSTIC_TEST|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
218877933|NCT02051634|DRUG|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
218877934|NCT02051634|DRUG|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
218877935|NCT03235089|DEVICE|Test Lens|Daily disposable contact lens
218877936|NCT03235089|DEVICE|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
218877937|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
218877938|NCT01595555|BEHAVIORAL|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
218877939|NCT01363115|DIETARY_SUPPLEMENT|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
218877940|NCT01363115|DIETARY_SUPPLEMENT|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
218877941|NCT01363115|BEHAVIORAL|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
218877942|NCT01032499|DRUG|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
218877943|NCT01032499|DRUG|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
218877944|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
219025525|NCT04909320|BEHAVIORAL|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
219025526|NCT04909320|BEHAVIORAL|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
219025527|NCT05096507|PROCEDURE|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
219365236|NCT03973476|OTHER|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
219365237|NCT03228563|OTHER|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
219365238|NCT03628027|DEVICE|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
219603046|NCT06511882|DRUG|Azacitidine|Standard of Care Intravenous (IV) infusion
219603047|NCT06511882|DRUG|Decitabine|Standard of Care Intravenous (IV) infusion
219603048|NCT06511882|DRUG|Venetoclax|Standard of Care PO (By Mouth)
218877945|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
218877946|NCT04654455|OTHER|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
218877947|NCT05997706|PROCEDURE|Testicular biopsy|Testicular biopsy is a clinical procedure for extraction of testicular tissue
218877948|NCT02747368|DEVICE|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
218877949|NCT03337009|BEHAVIORAL|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
218877950|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
219025528|NCT01148121|OTHER|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
218877951|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
218877952|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
218877953|NCT00751855|DRUG|placebo|placebo
218877954|NCT00915291|OTHER|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
218877955|NCT03546088|DEVICE|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
218877956|NCT03546088|DRUG|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
218877957|NCT03546088|DRUG|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
218877958|NCT04735146|OTHER|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
218877959|NCT05061498|DIAGNOSTIC_TEST|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
218877960|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
218877961|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
218877962|NCT00002122|DRUG|Azithromycin|
218877963|NCT00002122|DRUG|Rifabutin|
218877964|NCT00002122|DRUG|Fluconazole|
218877965|NCT03006224|OTHER|One Lung Ventilation|
218877966|NCT03665688|DEVICE|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.
218877967|NCT03665688|DEVICE|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
218877968|NCT05068219|PROCEDURE|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)"
218877969|NCT05068219|PROCEDURE|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
218877970|NCT04775264|PROCEDURE|Pulsed Electric Field Ablation|Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
218877971|NCT03238924|DRUG|Oxytocin|40 IU oxytocin nasal spray, self-administered
218877972|NCT03238924|DRUG|Placebos|Saline nasal spray, self-administered
218877973|NCT04397419|DIETARY_SUPPLEMENT|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
219025529|NCT04730245|DRUG|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
219025530|NCT00827983|DRUG|Progesterone|25 mg, s.c., once à day
219025531|NCT00827983|DRUG|Progesterone|90 mg, vaginally, once à day
219025532|NCT03896243|DIAGNOSTIC_TEST|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
219025533|NCT02124863|DEVICE|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
219025534|NCT03310554|PROCEDURE|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
219025535|NCT03310554|PROCEDURE|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
219025536|NCT03310554|PROCEDURE|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
218877974|NCT04397419|OTHER|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
219025537|NCT02113956|BEHAVIORAL|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
219025538|NCT00535548|BIOLOGICAL|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
219025539|NCT02813603|PROCEDURE|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
219025540|NCT05347316|DRUG|Colchicine|0.5 mg per day colchicine for 12 months
219025541|NCT00575055|DRUG|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
219025542|NCT00575055|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
219025543|NCT00575055|DRUG|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
219603049|NCT03694561|OTHER|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
218877975|NCT04628988|DRUG|CC-90011|Capsule
218877976|NCT04628988|DRUG|Abiraterone|Tablet
218877977|NCT04628988|DRUG|Prednisone|Tablet
218877978|NCT05564806|DRUG|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
218877979|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
218877980|NCT06003088|DRUG|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
218877981|NCT06003088|DRUG|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
218877982|NCT03576716|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
219025544|NCT00939913|DRUG|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
219025545|NCT00939913|DRUG|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
219025546|NCT02406651|DRUG|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
219025547|NCT02406651|DRUG|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
219025548|NCT05995158|PROCEDURE|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
219025549|NCT00620438|DRUG|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
219025550|NCT00620438|DRUG|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
219025551|NCT00620438|DRUG|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
219025552|NCT03004066|DRUG|Daptomycin|standard care
219025553|NCT06212076|DRUG|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
219025554|NCT01234233|PROCEDURE|duration of preoperative active warming|"duration of prewarming by forced air warming"
219025555|NCT00084669|DRUG|venlafaxine|
219025556|NCT00084669|DRUG|zolpidem tartrate|
219025557|NCT00084669|PROCEDURE|management of therapy complications|
218877983|NCT00961194|DRUG|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
218877984|NCT02136628|PROCEDURE|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
219025558|NCT04931485|OTHER|Fluid management according to the REDUCE Fluid Protocol|Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
219025559|NCT04931485|OTHER|Standard of care|Fluid resuscitation and de-resuscitation will be managed according to the standard of care
219025560|NCT04230512|OTHER|Pump prototype|Effects of pump function on gait
219025561|NCT05619718|BEHAVIORAL|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
219025562|NCT05619718|OTHER|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
219025563|NCT06073951|OTHER|Best Practice|Receive usual care
219025564|NCT06073951|OTHER|Exercise Counseling|Receive walking step goals
219025565|NCT06073951|OTHER|Exercise Intervention|Participate in Mates in Motion program
219025566|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Actigraph
219025567|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Garmin activity tracker
219025568|NCT06073951|OTHER|Physical Performance Testing|Undergo walk-test
219025569|NCT06073951|OTHER|Questionnaire Administration|Complete questionnaires
219025570|NCT05734443|BEHAVIORAL|step training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
219025571|NCT05734443|BEHAVIORAL|treadmill training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
219025572|NCT06143956|DRUG|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
219025573|NCT06143956|DRUG|LY3841136|Administered SC. ISA specific interventions will be listed in the ISA.
219025574|NCT06143956|DRUG|Tirzepatide|Administered SC. ISA specific interventions will be listed in the ISA.
219025575|NCT06143956|DRUG|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
219025576|NCT06143956|DRUG|LY3549492|Administered orally. ISA specific interventions will be listed in the ISA.
219025577|NCT05559749|BEHAVIORAL|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
219025578|NCT05559749|BEHAVIORAL|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
219025579|NCT06420778|OTHER|electroacupuncture|The patient takes the supine position, the whole body relaxes, the facial skin is routinely sterilized. Local acupuncture points along the head and face herpes zoster lesion branches with 0.18 × 25 mm millimetre needle series of shallow stabbing method row stabbing method.Han's Acupoint Neurostimulator (model HANS-200) was selected, local acupoints were chosen as Xiaguan+Quanliao or Xiaguan+Jiache, and distal acupoints were chosen as Hegu+Waiguan connected with electroacupuncture, sparse and dense wave 2/100 Hz was selected, and the treatment time was 60 minutes, and the intensity of the current was all to the extent that the patient could tolerate it. The needles were left in place for 60 minutes each time, once every other day, and the treatment was performed 3 times a week for 4 weeks, for a total of 12 treatments.
219025580|NCT06420778|DRUG|Pregabalin|Subjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
219025581|NCT03372733|DRUG|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
219025582|NCT03372733|DRUG|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
219025583|NCT05997615|DRUG|VIR-5500|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
219025584|NCT05997615|COMBINATION_PRODUCT|Enzalutamide|Oral administration
219025585|NCT05997615|COMBINATION_PRODUCT|Darolutamide|Oral administration
219025586|NCT05958355|OTHER|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
219025587|NCT05958355|OTHER|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
219025588|NCT06040567|OTHER|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
219603050|NCT04976621|BEHAVIORAL|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in person in an office at the VA rehabilitation clinic, virtually by VA Video Connect, or in person in the home, depending on the veteran's preference.
219025589|NCT06040567|OTHER|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
219025590|NCT01372280|DRUG|Reminyl|Galantamine Hydrobromide Tablets 4 mg
219025591|NCT02946047|DRUG|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
219025592|NCT02946047|DRUG|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
219025593|NCT02946047|DRUG|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
219025594|NCT02946047|DRUG|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
219025595|NCT04786223|DRUG|C-11 ER-176|Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.
219603051|NCT04976621|OTHER|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
219603052|NCT05992623|DEVICE|Zoll external defibrillator|Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
218877985|NCT05169411|DIAGNOSTIC_TEST|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
218877986|NCT05169411|DIAGNOSTIC_TEST|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
219025596|NCT04786223|DIAGNOSTIC_TEST|Blood Test|Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
219025597|NCT06575920|BEHAVIORAL|Breathing excercizes|The intervention comprised six sessions. The first week involved obtaining informed consent, taking measurements and providing a brief introduction to breath and coherent breathing exercises. This was followed by four weekly sessions, each consisting of 90 minutes combining lectures and breathing exercises. At the final session, measurements and feasibility data were collected.
219025598|NCT00782145|OTHER|educational intervention|
219025599|NCT00782145|OTHER|informational intervention|
219025600|NCT00782145|OTHER|internet-based intervention|
219025601|NCT00782145|OTHER|questionnaire administration|
219025602|NCT00782145|OTHER|study of socioeconomic and demographic variables|
219603053|NCT05992623|DEVICE|Lifepak external defibrillator|Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
219603054|NCT03348631|PROCEDURE|Computed Tomography|Undergo CT scan
219025603|NCT00782145|OTHER|survey administration|
219025604|NCT00782145|PROCEDURE|psychosocial assessment and care|
219025605|NCT00782145|PROCEDURE|quality-of-life assessment|
219025606|NCT00782145|PROCEDURE|standard follow-up care|
219025607|NCT05132829|DRUG|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
219025608|NCT05132829|DRUG|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
219025609|NCT00091351|PROCEDURE|conventional surgery|
219025610|NCT00091351|RADIATION|radiation therapy|
219603055|NCT03348631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219603056|NCT03348631|DRUG|Tazemetostat|Given PO
219603057|NCT04726241|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or bone marrow samples
219603058|NCT06680596|DRUG|trastuzumab derxutecan|T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
219603059|NCT05648500|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
219603060|NCT05648500|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
219603061|NCT05183035|DRUG|Fludarabine|Intravenous (IV) infusion
219025611|NCT04204954|OTHER|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
219025612|NCT04204954|DRUG|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
219603062|NCT05183035|DRUG|Cytarabine|Intravenous (IV) infusion
219603063|NCT05183035|DRUG|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
219603064|NCT05183035|DRUG|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
218877987|NCT03549715|DRUG|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
219025613|NCT04204954|OTHER|Baby shampoo|Twice a day eyelid margin cleansing for three days.
219025614|NCT04204954|OTHER|Blephaclean|Twice a day eyelid margin cleansing for three days.
219025615|NCT06912997|OTHER|Exercise|The home-based inspiratory muscle training (IMT) protocol will use an inspiratory threshold loading device (PowerBreathe Wellness, Southam, United Kingdom). IMT for experimental group will start with a minimal load (\~9 cmH2O) during the first week, aiming for a familiarization process. During the second week, the IMT targeted a moderate load of 45% of maximal inspiratory pressure (MIP) previously defined, which will be gradually increased by 10% of MIP each week until reaching 75% of MIP in the final week.
219025616|NCT06912997|OTHER|Sham Comparator|The Sham group will performer the same training protocol that experimental group, but at 5% of MIP during all weeks. Therefore, the sham group will not increase the training load during the protocol.
219025617|NCT01581307|DRUG|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
219025618|NCT01581307|DEVICE|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
219025619|NCT05556239|BEHAVIORAL|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
219025620|NCT04368819|DRUG|Allopurinol 300 MG|Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
219025621|NCT04368819|DRUG|Placebo oral tablet|Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
219025622|NCT04811313|DRUG|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
219025623|NCT04811313|PROCEDURE|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
219025624|NCT04811313|OTHER|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
219025625|NCT04994444|DRUG|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
219025626|NCT06865820|BEHAVIORAL|Project UPLIFT|Project UPLIFT is a Mindfulness-based Cognitive Behavioral Therapy program teaching participants methods that include challenging thoughts, behavioral activation, coping, problem-solving, and mindfulness. The program is group-based and provides weekly sessions, delivered remotely via telephone or video conferencing platform, over an 8-week period.
219496400|NCT00158327|BEHAVIORAL|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
219496401|NCT00158327|BEHAVIORAL|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
219025627|NCT00378209|DRUG|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
219496402|NCT05278585|PROCEDURE|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
219603065|NCT05183035|DRUG|Venetoclax|Orally via tablet or powder suspension
219603066|NCT05819606|OTHER|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
218877988|NCT03549715|DRUG|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
218877989|NCT03549715|DRUG|MVAC Protocol|"1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1"
218877990|NCT03054324|DIAGNOSTIC_TEST|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
218877991|NCT05913024|BIOLOGICAL|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
219025628|NCT00378209|DRUG|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
219025629|NCT00378209|DRUG|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
219496403|NCT05616611|RADIATION|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
219496404|NCT05616611|OTHER|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
219496405|NCT05616611|RADIATION|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
219496406|NCT06370195|BEHAVIORAL|Comprehensive rehabilitation|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.
219603067|NCT06184399|DRUG|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
218877992|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
218877993|NCT03851055|DRUG|Zinc|One arm will receive Zinc Second arm will receive placebo
218877994|NCT00559988|DRUG|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
218877995|NCT00559988|DRUG|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
218877996|NCT01835834|PROCEDURE|zirconia bridge restoration|
218877997|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
218877998|NCT02249182|DRUG|LDV/SOF|LDV/SOF FDC administered orally once daily
218877999|NCT02249182|DRUG|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
218878000|NCT04942782|OTHER|lumbopelvic stabilization exercises|the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
219025630|NCT02117999|DEVICE|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
219025631|NCT02117999|DEVICE|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
219025632|NCT03084081|DEVICE|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
219025633|NCT03084081|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
219025634|NCT03084081|DEVICE|Thermocoagulator|Thermoablation
219603068|NCT06184399|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
219603069|NCT06184399|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
219603070|NCT06184399|DRUG|Placebo Ivermectin ODT|Placebo for ivermectin ODT
219603071|NCT06145178|BIOLOGICAL|SPYVAC01|Novel vaccine SPYVLP01
218878001|NCT04942782|OTHER|pilates exercise|the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
218878002|NCT04942782|OTHER|conventional therapy|Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
219025637|NCT07024784|DRUG|IMGN151|Intravenous (IV) infusion
219025638|NCT07024784|DRUG|Carboplatin|Intravenous (IV) infusion
219025639|NCT07024784|DRUG|Bevacizumab|Intravenous (IV) infusion
219025640|NCT07024784|DRUG|Olaparib|Oral Tablet
219025641|NCT07034989|OTHER|Exercise|Teach respiratory exercises and function-focused trunk stabilization exercises to individuals with RA-IAH via online platforms. Subsequently, instructional exercise videos will be delivered to the patients online. The respiratory exercise training will include thoracic expansion and diaphragmatic breathing exercises. The program will consist of a warm-up phase including 10 minutes of trunk stabilization exercises, a 40-minute functional exercise session targeting the upper and lower extremities with trunk stabilization, followed by a cooldown phase including 10 minutes of flexibility exercises involving trunk stabilization. The exercise videos related to these phases will be sent to the participants online. Participants will start the exercises with 6 repetitions and will be encouraged to increase to 8 repetitions as the program progresses. The assigned physiotherapist will contact patients once a week by phone to monitor exercise adherence.
219025642|NCT04814433|DRUG|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
219603072|NCT06365736|BEHAVIORAL|Contemplating in nature|"Participants will spend 30 minutes in nature per day for 10 times over 14 days.~Each time, participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes."
219603073|NCT02570594|OTHER|questionary|
219603074|NCT06410313|DEVICE|ChampioNIR Ridaforolimus Eluting Peripheral Stent System|ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
219603075|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
219603076|NCT06535477|DEVICE|Fall risk assessment|"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"
219603077|NCT02595944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219603078|NCT02595944|PROCEDURE|Computed Tomography|Undergo CT
218878003|NCT00653081|PROCEDURE|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
219025643|NCT04814433|DRUG|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
218878004|NCT00653081|PROCEDURE|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
218878005|NCT01497782|OTHER|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
219496407|NCT06370195|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218878006|NCT01032031|DIETARY_SUPPLEMENT|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
219496408|NCT06370195|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219603079|NCT02595944|PROCEDURE|Echocardiography Test|Undergo ECHO
218878007|NCT01032031|DIETARY_SUPPLEMENT|Placebo capsule|One capsule daily for 3 months
218878008|NCT03679026|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
218878009|NCT05367128|OTHER|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
218878010|NCT04708002|OTHER|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
218878011|NCT03050320|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
218878012|NCT03050320|OTHER|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
218878013|NCT04904848|OTHER|Survey evaluation|examine the convergent validity and reliability of a Turkish version
219603080|NCT02595944|BIOLOGICAL|Nivolumab|Given IV
218878014|NCT04029103|OTHER|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
218878015|NCT01868386|RADIATION|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
219025644|NCT04814433|DRUG|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
219496409|NCT06370195|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219603081|NCT02595944|OTHER|Observation Activity|Undergo observation
219603082|NCT02595944|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
218878016|NCT00788710|DRUG|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
219603083|NCT06376682|PROCEDURE|CT-guided bone percutaneous procedure|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).
219603084|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
218878017|NCT00788710|DRUG|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
218878018|NCT00788710|DRUG|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
218878019|NCT00324376|DRUG|Sevelamer hydrochloride|
218878020|NCT01978626|BEHAVIORAL|App modules|
218878021|NCT01978626|BEHAVIORAL|Traditional CBT-I|
218878022|NCT01717326|DRUG|Grazoprevir|100 mg tablet orally QD
218878023|NCT01717326|DRUG|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
218878024|NCT01717326|DRUG|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
218878025|NCT01717326|DRUG|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
218878026|NCT01935414|DEVICE|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
218878027|NCT01935414|DEVICE|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
218878028|NCT06197763|DRUG|Colesevelam|625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
219025645|NCT04814433|DRUG|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
219025646|NCT04814433|DRUG|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
219025647|NCT04206969|BEHAVIORAL|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
219365239|NCT05568589|OTHER|Preoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
219496410|NCT01198119|DEVICE|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared"
218878029|NCT06197763|OTHER|Control Arm|No Treatment: baseline assessment only
218878030|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
218878031|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
218878032|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
218878033|NCT00446082|DRUG|Pasireotide|
218878034|NCT04855019|PROCEDURE|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
218878035|NCT01784718|DRUG|Buphenyl|
218878036|NCT00087854|DRUG|Amonafide L-malate (drug)|
218878037|NCT01577342|DRUG|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
218878038|NCT05049109|BEHAVIORAL|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
218878039|NCT05049109|BEHAVIORAL|Usual post-stroke follow-up care|"* 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
218878040|NCT00605345|DRUG|Darbepoetin alfa|As prescribed
218878041|NCT00605345|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
219496411|NCT01198119|PROCEDURE|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
219496412|NCT01198119|PROCEDURE|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
219496413|NCT00947518|DRUG|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
219496414|NCT00947518|DRUG|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
219496415|NCT01574599|OTHER|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
219496416|NCT05824156|BIOLOGICAL|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
219496417|NCT05824156|OTHER|Placebo|Placebo
219496418|NCT00004582|DRUG|Lopinavir/Ritonavir|
219496419|NCT00004582|DRUG|Efavirenz|
218878042|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
218878043|NCT03485170|DIAGNOSTIC_TEST|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
219025648|NCT06762392|OTHER|Blood Flow Restriction|Blood Flow Restriction (BFR) therapy in this study involves the application of a pneumatic cuff around the proximal thigh to restrict arterial blood flow during specific rehabilitation exercises. The cuff will be inflated to achieve 70-80% of arterial occlusion, while participants perform low-intensity resistance exercises at 15-20% of their one-repetition maximum (1RM). BFR therapy will be used during Phase 2 of rehabilitation (weeks 2-12) alongside a standardized rehabilitation protocol. The intervention will be closely monitored by trained Physical Therapists to ensure safety and efficacy, with pressure adjustments made in real-time based on the participant's exercise performance. This intervention distinguishes itself by its use of BFR, a technique that is not part of conventional ACL rehabilitation
219025649|NCT06762392|OTHER|Standard Rehabilitation|The Standard Rehabilitation (RHB) intervention in this study consists of a structured, evidence-based protocol designed to optimize recovery after anterior cruciate ligament (ACL) reconstruction. This rehabilitation protocol is implemented across four phases. The rehabilitation will be supervised by experienced Physical Therapists, and participants will be given a tailored home exercise program to complement the supervised sessions. The intervention aims to optimize recovery, restore function, and reduce the risk of re-injury.
219025650|NCT07059962|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale captures several physiological signals, which are used to derive multiple biomarkers that reflect a user's hemodynamic and fluid status.
219025651|NCT02928289|DEVICE|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
219025652|NCT02928289|DEVICE|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
219025653|NCT05782907|DRUG|Upadacitinib|Oral Solution/ Tablets
219025654|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
219025655|NCT02496533|PROCEDURE|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
219025656|NCT06300463|DRUG|Botensilimab|75 mg IV Q6W
219025657|NCT06300463|DRUG|Balstilimab|450 mg IV Q3W
219025658|NCT06300463|DRUG|AGEN1423|30 mg/kg IV Q3W
219025659|NCT06300463|RADIATION|Radiation|8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
219025660|NCT06844357|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
219496420|NCT05045794|DEVICE|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
219496421|NCT05045794|OTHER|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
219496422|NCT02173626|BEHAVIORAL|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
219496423|NCT00717873|DEVICE|Airway clearance Device|Provided by the Vest Airway clearance system
219496424|NCT03806322|OTHER|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
219496425|NCT03806322|OTHER|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
219496426|NCT04454970|DEVICE|Urethrotech Urethral catheterisation device (UCD)|Urethral indwelling catheter
219496427|NCT04454970|DEVICE|Bardia Aquafil long term catheter|Urethral indwelling catheter
219496428|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
219025661|NCT06844357|PROCEDURE|Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
219025662|NCT06844357|PROCEDURE|TACE|TACE with epirubicin
219025663|NCT06900153|OTHER|phone questionnaire|the investigator calls the patient and asks her questions about her parental project and her pregnancies
219025664|NCT03488420|DRUG|Edoxaban Pill|Subjects will be taking edoxaban 30 or 60 mg
219496429|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
218878044|NCT02501525|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
218878045|NCT02501525|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
218878046|NCT02572622|OTHER|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
218878047|NCT02572622|OTHER|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
218878048|NCT02572622|OTHER|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
219025665|NCT02556333|DRUG|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
219496430|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
219496431|NCT00063960|DRUG|floxuridine|
219496432|NCT00063960|DRUG|irinotecan hydrochloride|
218878049|NCT02572622|OTHER|exercise|special lumbar stabilization exercises were applied in advanced protocol.
218878050|NCT01506661|DRUG|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
218878051|NCT01221493|PROCEDURE|Cryo biopsy|Cryoprobe, Erbe Company
219496433|NCT01773174|DRUG|dabigatran etexilate|age \& weight adjusted equivalent of adult dose
219603085|NCT03635892|DRUG|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
218878052|NCT05698953|OTHER|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
218878053|NCT05698953|OTHER|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
218878054|NCT02596945|DRUG|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
218878055|NCT06124456|OTHER|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
219025666|NCT06909058|BEHAVIORAL|Study Postoperative Care|The study group will be given general postoperative instructions. They will also receive liberal activity restrictions instructing the patient to resume normal activities of daily living at their own discretion without specific restrictions.
219496434|NCT00879970|DRUG|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
219496435|NCT00879970|DRUG|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
219496436|NCT00879970|DRUG|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
219496437|NCT00879970|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D factor intervention
219496438|NCT00879970|DIETARY_SUPPLEMENT|Placebo|Vitamin D factor intervention
219496439|NCT03492983|DIETARY_SUPPLEMENT|Intervention group|10 g/day of high cocoa content chocolate for six months.
219603086|NCT03635892|DRUG|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
219603087|NCT04955730|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.
219603088|NCT05284266|PROCEDURE|Liposuction early|Liposuction 6-9 months after inclusion
218878056|NCT06124456|OTHER|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
218878057|NCT06124456|OTHER|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
218878058|NCT02542787|DRUG|VSN16R|Small molecule
218878059|NCT02542787|OTHER|Placebo|dummy tablet
218878060|NCT04255641|OTHER|time lapse analysis|grading of the embryos before freezing using time lapse/
218878061|NCT02035527|DRUG|sorafenib tosylate|Given daily PO in the a.m.
218878062|NCT02035527|DRUG|cisplatin|Given IV over 1 hour following Docetaxel administration
218878063|NCT02035527|DRUG|docetaxel|Given IV 1 hour prior to cisplatin administration
219496440|NCT03218735|PROCEDURE|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
219496441|NCT03218735|PROCEDURE|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
219496442|NCT02352740|DIETARY_SUPPLEMENT|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
219496443|NCT02352740|DIETARY_SUPPLEMENT|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
219496444|NCT00729196|BEHAVIORAL|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
219496445|NCT06399419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219496446|NCT06399419|PROCEDURE|Bone Scan|Undergo bone scan
219496447|NCT06399419|BIOLOGICAL|CBM588 Capsules|Given PO
219496448|NCT06399419|PROCEDURE|Computed Tomography|Undergo CT
219496449|NCT06399419|BIOLOGICAL|Ipilimumab|Given IV
218878064|NCT02035527|OTHER|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
218878065|NCT05117190|PROCEDURE|Facial Allotransplantation|
219496450|NCT06399419|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218878066|NCT01769196|DRUG|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
218878067|NCT01769196|DRUG|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
218878068|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
218878069|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
219025667|NCT06906133|OTHER|Urinary-hCG|Ovulation days will be detected using a commercial urine test for luteinizing hormone (LH) (PREGMATE, Ovulation Midstream Test Predictor Kit; sensitivity level:25mlU/mL). Participants will be instructed to use ovulation tests, starting 5 days before the expected ovulation (day 10) and for the next 7-10 days or until the first the first positive results are detected notify the study co-ordinator and share a photo of the results. Then participants will be asked to continue using the ovulation test for 3 more days.
219496451|NCT06399419|BIOLOGICAL|Nivolumab|Given IV
219496452|NCT00401856|DRUG|Eplerenone|50mg oral route
219496453|NCT00401856|DRUG|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
219496454|NCT06479759|DRUG|LM-108 antibody and sintilimab|Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
219496455|NCT06479759|DRUG|LM-108 antibody and sintilimab and chemotherapy|Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
219496456|NCT01431755|DEVICE|Restylane SubQ|Treatment with up to 2 ml of the product
219496457|NCT01431755|DEVICE|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
219496458|NCT02638961|OTHER|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
219496459|NCT02638961|OTHER|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
219496460|NCT02638961|OTHER|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
219496461|NCT00316576|PROCEDURE|Blood sampling for PCR|
219496462|NCT04358731|BIOLOGICAL|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
219496463|NCT04358731|BIOLOGICAL|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
219496464|NCT01770197|DRUG|IV rt-PA|IV rt-PA treatment
219603089|NCT05284266|PROCEDURE|Liposuction late|Liposuction 18-21 months after inclusion
218878070|NCT06206460|OTHER|Online Assessment|"Online Assessment which consists of:~* Sociodemographic data (life changes, medical and gynaecological history)~* German PMS symptom diary retrospectively for last menstrual cycle~* Quality of Life Inventory (SF-12)~* Expectancy of relief"
219025668|NCT06912932|BEHAVIORAL|Preventive|systematically investigate the acute physiological responses induced by three levels of %Pmax intensities (50% and 75% of Pmax and all-out efforts) with three varying rest periods (15, 30, and 45-s) between thirty 4-s sprints.
219025669|NCT06914258|COMBINATION_PRODUCT|Inhibition Compression|"Group A will receive conventional Physiotherapy treatment along with the scapular mobilization which will include;~* Electrotherapy (TENS and hot pack) for 10 min~* Active and passive ROMs for 5 min~* pectoral stretching for 5min~* shoulder joint mobilization. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide were performed to the patient in supine position at a frequency of two to three oscillations/second for one to two minutes. (10 min)~* Manual scapular mobilization will be done in sideline with their back towards the physiotherapist."
218878071|NCT01066728|OTHER|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
218878072|NCT01066728|DRUG|Theophylline|
218878073|NCT02161991|DRUG|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
218878074|NCT02161991|DRUG|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
218878075|NCT00655629|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
219025670|NCT06914258|COMBINATION_PRODUCT|Scapular Mobilization Technique|"Group B will receive the same baseline physiotherapy treatment as in group A along with the Inhibition compression therapy which is a (MET). MET was performed on shoulder. Patient position: supine lying position. Following are the steps involved in application of MET: (1) stretch the muscle to a felt 'barrier' or to their tolerance of stretching (2) create a voluntary contraction that is isometric of the muscle being stretched while being resisted with equal and regulated counterforce by the physiotherapist for 7-10 seconds. (3) a stretch is held for a set amount of time after the muscle relaxes (4) the physiotherapist takes up the slack once the muscle relaxes Duration of treatment was approximately 15-20 minutes."
219025671|NCT06913868|BEHAVIORAL|Consensus-Based Physiotherapy Program|Physiotherapy for fibromyalgia (Baroni et al., 2023 Delphi consensus). Includes pain neuroscience education (PNE), tailored aerobic, strengthening, and sensorimotor exercises (graded exposure), and self-management strategies. 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.Pain Neuroscience Education (PNE): Approximately 20 minutes per session, focusing on explaining the neurobiology of pain in fibromyalgia, emphasizing central sensitization mechanisms, and reconceptualizing pain as an output of the brain rather than solely a marker of tissue damage. PNE aims to reduce threat value associated with pain and improve understanding of pain fluctuations.
219025672|NCT06913868|BEHAVIORAL|Standardized Physiotherapy Care|Standardized physiotherapy for fibromyalgia. Includes general exercise (aerobic, stretching), manual therapy (within guidelines), and basic pain education (excluding PNE). 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.
219025673|NCT06913322|PROCEDURE|flush endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed flush at saphenofemoral junction.
219025674|NCT06913322|PROCEDURE|standard endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed 2 cm distal to saphenofemoral junction.
219025675|NCT07144800|BEHAVIORAL|Parent Weekly Individual Telephone Support|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
219025676|NCT07144800|BEHAVIORAL|Child Education|6 weekly diet/PA education sessions ('Child Education')
219025677|NCT07144800|BEHAVIORAL|Parent Initial Counseling|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
219025678|NCT07144800|BEHAVIORAL|Parent Monthly Group Support|Parents will be invited to join a Spanish language (English if preferred) weekly group videoconference (can join by phone if preferred).
219496465|NCT03966196|OTHER|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
219496466|NCT02368769|DEVICE|During Tele-expertise|
219496467|NCT06530992|OTHER|tucking break|"All participants will provide a semen sample for sperm analysis after 2-7 days of abstinence from ejaculation, a venous blood sample will be taken at the same time, and quality of life will be assessed using a questionnaire.~Participants in the study group are then asked to refrain from tucking or wearing tight underwear for at least 73 days. At least 73 days (10.5 weeks) after the first spermiogram, another semen collection is scheduled after 2-7 days of abstinence from ejaculation for the preparation of a spermiogram, a venous blood sample is taken at the same time, and quality of life is assessed in all participants. At this point, depending on the participant's wishes, it is possible to perform sperm cryopreservation for fertility preservation before starting gender affirming hormonal treatment."
219496468|NCT03479242|OTHER|no interventions|no interventions are planned
219496469|NCT01749033|OTHER|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
219496470|NCT01749033|OTHER|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
219496471|NCT01749033|OTHER|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
219496472|NCT03577119|DIETARY_SUPPLEMENT|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
219603090|NCT05284266|OTHER|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
219496473|NCT03577119|DIETARY_SUPPLEMENT|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
219603091|NCT05284266|OTHER|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
219603092|NCT05223920|DRUG|Bomedemstat|Capsule (oral)
219603093|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
219603094|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
219603095|NCT03790657|BEHAVIORAL|practice of a complex walking task|walking over obstacles
219603096|NCT03790657|DEVICE|Active transcranial direct current stimulation (Active tDCS)|mild electrical stimulation delivered to the frontal region of the brain
218878076|NCT00655629|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
218878077|NCT05810350|DRUG|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
218878078|NCT06238804|PROCEDURE|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
218878079|NCT00889525|DRUG|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
218878080|NCT03255551|DRUG|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
219025679|NCT07146503|DRUG|Esketamine (Intranasal Spray)|Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling
219025680|NCT07151924|OTHER|Questionnaires answers|Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.
219025681|NCT07151924|OTHER|Biological assessment|Collection of HbA1c level and continuous glucose monitoring data
219025682|NCT07148713|BEHAVIORAL|CGM-Augmented FIM|The intervention arm will receive electronic healthy foods vouchers and unblinded, real-time CGM sensors for 16-weeks, in addition to individualized nutrition counseling with a registered dietician for 5-8 sessions (all participants will attend 5 sessions, with up to three additional sessions scheduled as needed based a set of a-priori decision rules).
219025683|NCT07148713|BEHAVIORAL|FIM only|The comparator arm will receive electronic healthy foods vouchers and healthy eating resources and self-directed nutrition education. This group will not receive unblinded CGM sensors or any nutrition counseling for the first 12 weeks. This group will receive 30-days of unblinded CGM sensors to use in the extension phase only.
219025684|NCT07150806|DRUG|Actinium Ac 225 DOTATATE RYZ101|Given IV
219025685|NCT07150806|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219025686|NCT07150806|PROCEDURE|Computed Tomography|Undergo CT scan
219025687|NCT07150806|PROCEDURE|Echocardiography Test|Undergo echocardiography
218878081|NCT01771159|DEVICE|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
218878082|NCT00705367|DRUG|Placebo|Infusion, Intravenous, single dose, Day 1
218878083|NCT00705367|DRUG|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
218878084|NCT00705367|DRUG|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
219025688|NCT07150806|RADIATION|Gallium Ga 68-DOTATATE|Given IV
219025689|NCT07150806|DRUG|L-lysine/L-arginine-containing Amino Acid|Given IV
219025690|NCT07150806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219496474|NCT03998774|BEHAVIORAL|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
219496475|NCT00262184|DRUG|Soy Isoflavone|
219496476|NCT02813785|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
219496477|NCT02813785|DRUG|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
218878085|NCT05813704|DEVICE|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
218878086|NCT01389492|OTHER|frozen meat cutlets meal|250 g of meat cutlets
218878087|NCT01389492|OTHER|meat meals|250 g of meat meal for 4 days
218878088|NCT06977061|DRUG|Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy|no other intervention
219025691|NCT07150806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219025692|NCT07150806|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219025693|NCT07150806|PROCEDURE|Somatostatin Receptor Positron Emission Tomography|Undergo SSTR PET scan
219025694|NCT07155889|OTHER|Educational Competition Method|"This study aims to evaluate nursing students' knowledge levels, practical skills, and the effectiveness of the educational competition method regarding medical waste management. The study consisted of three phases. In the first phase, students were informed, their consent was obtained, the Informative Information Form was completed, and the Knowledge Level Test was administered as a pre-test. In the second stage, the researcher gave a two-hour interactive lecture to all students, explaining the waste classification and separation processes. In the third stage, the Educational Competition Method was applied in Section A. In an arrangement prepared with mock waste and color-coded bins, students placed the waste in the appropriate bins within the specified time. The winner was rewarded at the end of the competition. One week later, a final test and satisfaction form were administered to evaluate the effectiveness of the method."
219025695|NCT07159269|BEHAVIORAL|Cardiac point-of-care ultrasound (POCUS) training and clinical pathway|Participants will complete a cardiac POCUS simulation session and a hands-on observed structured clinical skill exam (OSCE) post-training led by ultrasound-trained faculty. Then as part of standard clinical care, advanced practice providers (APPs) will perform POCUS while supervised by emergency medicine (EM) attending physicians. To assess program feasibility and acceptability, participants will complete a pre/post and 6-month post-survey and semi-structured interview, as well as a knowledge and technical skills assessment.
219496478|NCT05940519|OTHER|Dynamic taping technique|The dynamic taping method as specified in the literature will be applied to the right and left lumbar paravertebral muscles in the dynamic taping group. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
219603097|NCT03790657|DEVICE|Sham transcranial direct current stimulation (Sham tDCS)|30 seconds of mild electrical stimulation delivered to the frontal region of the brain
219603098|NCT03523936|DIETARY_SUPPLEMENT|Prebiotic product|Prebiotic product used during the course of antibiotic treatment
218878089|NCT02554578|OTHER|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
218878090|NCT01391936|PROCEDURE|Tension Band Wiring|AO technique of TBW for fixation of fracture.
219496479|NCT05940519|OTHER|Sham taping|Sham taping will be applied with a surgical patch while the patient is in a comfortable position without any technique or stretching.Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
219496480|NCT01831531|DRUG|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28
218878091|NCT01391936|PROCEDURE|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
218878092|NCT02466009|DRUG|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
218878093|NCT02176161|DRUG|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
218878094|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
218878095|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
218878096|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
218878097|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
218878098|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
218878099|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
218878100|NCT01177566|DRUG|pimecrolimus|pimecrolimus 1% cream twice daily
218878101|NCT01177566|DEVICE|topical medical device|Eletone cream three times daily
218878102|NCT04365933|DRUG|EYP001a|Oral tablets
218878103|NCT04365933|DRUG|Entecavir|Oral tablets
218878104|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
218878105|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
218878106|NCT00303888|DRUG|docetaxel|Given IV
218878107|NCT00303888|DRUG|idronoxil|Given orally
218878108|NCT00303888|OTHER|placebo|Given orally
218878109|NCT06071156|DRUG|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
218878110|NCT05096312|DIETARY_SUPPLEMENT|Zinc gluconate|oral zinc gluconate 200mg
218878111|NCT05096312|DRUG|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
218878112|NCT05096312|OTHER|Placebo|contains cornstarch
218878113|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
218878114|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
218878115|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
218878116|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
218878117|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
219496481|NCT01831531|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
219496482|NCT04380701|BIOLOGICAL|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219496483|NCT04380701|BIOLOGICAL|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219496484|NCT04380701|BIOLOGICAL|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
218878118|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
218878119|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
218878120|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
219603099|NCT03523936|DIETARY_SUPPLEMENT|Placebo|Placebo
218878121|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
218878122|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
219025696|NCT07162129|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD) and Anxiety|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). Each session will be two hours in duration. The 1st hour involves teaching and practice of CBT skills followed by one hour of unstructured discussion about topics relevant to PPD and PPA (sleep, supports, transitions). Each group will be delivered online via Zoom and guided by our intervention manual.
219025697|NCT07170189|DRUG|HU6|HU6 tablet or capsule
219025698|NCT07166120|BEHAVIORAL|Usual care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
219025699|NCT07166120|BEHAVIORAL|Precision treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information, adapted for oncology.
219025700|NCT07167797|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Group II (Treatment) group: received vitamin D single oral dose 300000 IU for age \< 1 year and dose of 600000IU for age\> 1 year in addition to standard treatment
219025701|NCT07167797|DRUG|Standard treatment for rotavirus|Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion
219025702|NCT07166237|BEHAVIORAL|Cognitive Behavioral Therapy for Paternal Perinatal Depression|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The weekly group sessions will be two hours long and take place once a week for 9 consecutive weeks. The first hour of the session will involve teaching and practice of CBT skills, followed by one hour of unstructured discussion around topics relevant to participants with paternal perinatal depression. Each group will be delivered online via Zoom and guided by our intervention manual.
219025703|NCT07172464|DEVICE|Recross P3 Occluder (P3O) System|The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
219025704|NCT07170969|OTHER|An Enhanced Coping-oriented Supportive Programme (E-COSP) for Community-Dwelling People with Spinal Cord Injury|The intervention group will receive eight weekly online group sessions (6-8 participants per group) with one hour for each session using Zoom videoconferencing software. A detailed intervention manual will be used to guide all intervention delivery. The intervention will be led by a registered rehabilitation nurse (who will be employed as a part-time RA2) who has more than three years of work experience in caring for people with SCI. The nurse who delivers the intervention will receive extensive training from the PI and CI, who are experts in coping interventions and relevant psychosocial intervention skills. The intervention providers will also receive training in group dynamics and group intervention skills, and be supervised by the research team and a psychologist during the whole period of the study. Selected audio-taped intervention sessions will be rated by the PI and CI on the fidelity of the intervention delivery
219025705|NCT07177885|BIOLOGICAL|Blood collection|Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
218878123|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
218878124|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
218878125|NCT05840588|DRUG|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
218878126|NCT05840588|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
218878127|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
218878128|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
218878129|NCT04515108|OTHER|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
218878130|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
218878131|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
218878132|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
219025706|NCT07178132|OTHER|tissue floss band|Floss band is wrapped in thigh from distal to proximal for 2 minutes. during this period patient is asked to actively perform movement for 2 minute, after that the band is removed and repeated once more. Immediately followed by flexibility measurements
219025707|NCT07178132|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) Stretching using the hold-relax method: participants perform an isometric contraction of the hamstring at the end of its stretch range , followed by relaxation and passive stretch, then flexibility assessed similarly
219025708|NCT07182058|DEVICE|Transcranial Electrical Stimulation Device|The Sphere V3.0 is a non-invasive transcranial electrical stimulation device that delivers amplitude-modulated transcranial pulsed random noise stimulation (am-tPRNS).
219025709|NCT07182929|PROCEDURE|Lateral Sinus Floor Augmentation with Deproteinized Porcine Bone Mineral|Lateral Sinus Floor Augmentation Using Deproteinized Porcine Bone Mineral (DPBM, test) with Simultaneous Implant Placement and 6-Month CBCT Follow-Up
219025710|NCT01816893|OTHER|Hypoglycemic hyperinsulinemic clamp|
219025711|NCT01816893|OTHER|Euglycemic hyperinsulinemic clamp|
219496485|NCT04380701|BIOLOGICAL|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219496486|NCT00868114|BIOLOGICAL|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
219496487|NCT04564040|DRUG|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
219496488|NCT04564040|DRUG|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
218878133|NCT01742689|DRUG|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
218878134|NCT01742689|DRUG|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
218878135|NCT01742689|DRUG|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
218878136|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
219025712|NCT07191431|DRUG|Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide|"* Orelabrutinib 150mg qd + Selinexor 40mg qw~* Combined chemotherapy (choose one):~  * MTX 3.5g/m² IV d0~ * Temozolomide 150mg/m² PO d1-5~ * Thiotepa 40mg/m² IV d3~* Every 3 weeks for 6 cycles"
219025713|NCT07191275|DEVICE|Experimental continuous 30 Hz thetaburst transcranial magnetic stimulation|"Bilateral continuous theta burst stimulation (cTBS) 30 Hz to the temporo-occipital cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex (MNI: -47, -77, 4; 50, -69, -4)~* Duration: 33.3 seconds for each side~* Timing: Immediately before showing IAPS pictures (off-line)"
219025714|NCT07191275|DEVICE|Control continuous 30 Hz thetaburst transcranial magnetic stimulation|"Active control condition using bilateral continuous theta burst stimulation (cTBS) 30 Hz to the superior parietal cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right superior parietal cortex (MNI: -17, -70, 60; 17, -70, 60)~* Duration: 33.3 seconds~* Timing: Immediately before showing IAPS pictures (off-line)"
219025715|NCT07190417|OTHER|LEDs and laser light|"Experiment 1：Measure the heart rate parameters before, during, and after laser acupuncture or LED light therapy within a 25-minute experimental period, and observe the changes in the subjects' meridian energy before and after the treatment, followed by analysis. Acupoint selections mainly include Daling, Neiguan, and Shenmen.~Experiment 2：randomly assigns subjects to wear either a low-energy LED device or a sham device. The indicators, duty cycles, and sounds of the low-energy LED device and the sham device are all the same.~Experiment 3：Place light sources of different wavelengths on the earlobes or auricles of subjects with different skin tones. By observing the changes in light power before and after, the investigators can infer the effects of skin tone on light attenuation and transmission of light sources with different wavelengths."
219025716|NCT07190183|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
219025717|NCT07189533|BEHAVIORAL|Co-created intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
219025718|NCT07190742|DRUG|TVAX-008|TVAX-008
219025719|NCT07190742|DRUG|Placebo|Placebo
219025720|NCT07191132|BEHAVIORAL|Standardised Verbal Instructions|Participants receive verbal post-extraction care instructions delivered by a trained investigator using a calibrated script. The content includes guidance on bleeding control, diet, oral hygiene, activity restrictions, and medication use.
219025721|NCT07191132|BEHAVIORAL|Verbal Instructions + PDEC-kit|Participants receive the same standardised verbal instructions as the control group, supplemented with the PDEC-kit. The kit includes a two-minute educational video, illustrated flashcards, a live gauze demonstration using a dental model, and a bilingual (English and Bahasa Melayu) illustrated brochure with QR code access to a digital version.
219025722|NCT07190001|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
219025723|NCT07189728|DIAGNOSTIC_TEST|MRI|The MagnaSafe-2 Registry is designed to determine the risks of MRI in patients with limited MRI access not previously addressed in peer-reviewed literature and to improve access for approximately 70% of whom are predicted to have a future clinical need for MRI.
219025724|NCT07189429|DIAGNOSTIC_TEST|PA-100 AST|Results of the PA-100 AST were made available to the treating physician
219025725|NCT07191457|DEVICE|Elimax Green Lotion with Emogreen|"STEP 1:~Apply the lotion to dry hair, completely saturating hair and scalp. Use a towel to cover eyes and exposed skin areas. Massage from the roots to the tips, paying particular attention to the area behind the ears and the hairline at the back of the head. Leave the lotion in the hair for 10 minutes (no longer). In the case of long hair, pin the hair up away from the skin after application.~STEP 2:~Wash out by applying shampoo to the hair and rinsing thoroughly. Repeat if needed to fully rinse out the lotion.~STEP 3:~Comb to remove lice and nits. Part the hair into sections and comb one section at a time. Place the teeth of the comb as close as possible to the scalp and comb away from the scalp to the end of the hair. Use clips to pin back each section of combed hair. Clean the comb during use by wiping onto a tissue. Discard the tissue into a sealable bag. Discard the sealed bag.~Check hair for the following 7 to 10 days. If lice or nits are present, repeat steps 1-3."
219025726|NCT07191457|DRUG|Walgreens Lice Killing Shampoo|"Apply thoroughly to dry hair or other affected area. For head lice, first apply behind ears and to back of neck Allow product to remain for 10 minutes, but no longer Use warm water to form a lather, shampoo, then thoroughly rinse For head lice, towel dry hair and comb out tangles Remove lice and their eggs (nits) Use a fine-tooth or special lice/nit comb. Remove any remaining nits by hand (using a throw-away glove) Hair should remain slightly damp while removing nits If hair dries during combing, dampen slightly with water For head lice, part hair into sections. Do one section at a time starting at the top of the head. Longer hair may take 1 to 2 hours. Lift a 1- to 2- inch wide strand of the hair. Place comb as close as possible to the scalp and comb with a firm, even motion away from the scalp.~Pin back each strand of the hair after combing Clean comb often. Wipe away nits with tissue and discard in a plastic bag. Seal bag and discard bag to prevent lice from coming back."
219025727|NCT07189702|OTHER|Control|Regular Diet with Cancer-Related Wellness Education and Support
219025728|NCT07189702|OTHER|Whole Food, Plant-Based Diet with Behavioral Education and Support|Whole Food, Plant-Based Diet with Behavioral Education and Support
219025729|NCT07190729|DEVICE|Propofol sedation + Audiovisual distraction|The participants will receive standard propofol sedation procedure and the mask -RV Deepsen™
219025730|NCT07190729|OTHER|Propofol sedation|The participants will receive standard propofol sedation procedure
219496489|NCT04564040|DRUG|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
218878137|NCT00932165|DRUG|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
219603100|NCT03439956|PROCEDURE|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
218878138|NCT06005519|OTHER|low AGE diet education|Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
219025731|NCT07189637|OTHER|Face-to-face nutrition education|All participants will receive face-to-face nutrition education from specialist dietitians in accordance with the principles of nutrition for hypertension. Nutrition education will be provided through prepared brochures. The brochures will be given to participants as gifts. Nutrition education will cover topics such as hypertension and nutrition, nutrients, the importance of micronutrients, foods containing salt, reading labels, limiting salt consumption, healthy fat consumption, fibre consumption, water consumption, and healthy cooking methods.
219025732|NCT07189637|OTHER|Intermittent Fasting Diet|Training will be provided to all participants through a food and nutrition photo catalogue so that portions can be recorded correctly and within standard limits when keeping a food diary. Participants will restrict their food intake to a 16-hour period by applying the 16/8 Intermittent Fasting Diet model and will eat and drink whatever they want during the remaining 8 hours. During this 16-hour period, they will consume non-energy drinks consisting of water, unsweetened tea, unsweetened herbal teas and black coffee. It will be recommended that intermittent fasting be maintained from 6:00 p.m. to 10:00 a.m. However, participants may also choose other 16-hour periods, such as 7:00 p.m. to 11:00 a.m. or 8:00 p.m. to 12:00 p.m. Participants will be given a tracking chart to record the first and last times they consume food or energy-containing beverages during the day, and their adherence to the diet will be monitored based on their declarations.
219025733|NCT07189637|OTHER|Mediterranean Diet|Training will be provided to all participants through a food and nutrition photo catalogue to ensure that portions are recorded correctly and within standard limits when keeping a food diary. In addition, the dietician will provide this group with a diet plan calculated for energy, macro and micro nutrients, which will be different each week for the first four follow-ups. The diet plans provided will be prepared in accordance with the Mediterranean Diet food pyramid. Participants' energy requirements will be calculated using the Schofield Equation for basal metabolic rate, with adjustments made according to their physical activity levels. Energy requirements will be met by 45-50% from carbohydrates, 15-20% from protein, and 25-35% from fats.
219025734|NCT07190053|OTHER|Secukinumab|This is an observational study, there is no treatment allocation
219025735|NCT07190690|DEVICE|ihtDEStiny® DES implanted|ihtDEStiny® DES implanted
219025736|NCT07190690|DEVICE|Xience™ DES implanted|Xience™ DES implanted
219025737|NCT07190950|PROCEDURE|Low Level Laser Therapy|Patients will receive LLLT at one side after third molar extraction surgery. There will be 7 sessions at the day of surgery, then first, third, seventh, fourteenth, twenty first, twenty eighth day after surgery.
219200408|NCT06885515|DIAGNOSTIC_TEST|leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method|genomic DNA (2-5 µg) is digested overnight at 37°C with HinfI restriction endonuclease. Fragments are being separated on an agarose gel, transferred to a Hybond N+ membrane. The membrane is being hybridized over night at 50°C with a 5' end-labeled (AACCCT)3 oligonucleotide probe and with ladder probe of 1Kb ladder. Following membrane washes the membrane is exposed to PhosphoImager. The mean telomere length is calculated by the computer program Telotool \[19-20\]. TRF analysis will be conducted at the laboratory of Prof. Yehuda Tzfati at the Hebrew University, which is highly experienced in the field of telomere biology and in telomere length analysis. Blood samples will be taken once from each participant. no genetic sequencing will be performed as part of this study.
219496490|NCT04564040|DRUG|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
219496491|NCT02266966|DRUG|F2695|
219496492|NCT02266966|DRUG|Placebo|
219496493|NCT06569693|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
219496494|NCT06569693|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
218878139|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
218878140|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
218878141|NCT00002140|DRUG|Ethambutol hydrochloride|
218878142|NCT00002140|DRUG|Clarithromycin|
219496495|NCT00383019|DRUG|Xalatan|latanoprost 0.005%, one rop once daily in evening
218878143|NCT00002140|DRUG|Azithromycin|
218878144|NCT00242593|DRUG|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
218878145|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
219496496|NCT00383019|DRUG|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
219603101|NCT05463640|BIOLOGICAL|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
218878146|NCT00005116|BEHAVIORAL|psychotherapy|
218878147|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
218878148|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
218878149|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
218878150|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
218878151|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
219025738|NCT07190222|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe - Route of administration: Subcutaneous injection
219025739|NCT07190222|DRUG|Placebo|Pharmaceutical form:s olution for injection - Route of administration: Subcutaneous injection
219200409|NCT06842251|OTHER|Rotary Crown Down Technique|Root canal treatment with rotary instrument is done using crown down approach and post endodontic pain measured after 4,12,24,48 hours.
219200410|NCT06842251|OTHER|Manual Step Back Technique|Root canal treatment with manual instruments using step back technique and post endodontic pain measured at 4,12,24,48 hours .
219200411|NCT06866730|DEVICE|Serious game|Serious game in which participants manipulate instrumented toys
219200412|NCT06888245|OTHER|Non-animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint support without animation.
219496497|NCT05469503|DIETARY_SUPPLEMENT|TOTUM-854|12 weeks of TOTUM-854 supplementation
219496498|NCT05469503|DIETARY_SUPPLEMENT|Placebo|12 weeks of placebo supplementation
219496499|NCT03952936|OTHER|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
219496500|NCT03823365|BIOLOGICAL|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109"
219496501|NCT03703739|DIETARY_SUPPLEMENT|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
219496502|NCT03703739|DIETARY_SUPPLEMENT|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
219496503|NCT03703739|DIETARY_SUPPLEMENT|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
219496504|NCT03703739|DIETARY_SUPPLEMENT|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
219496505|NCT03703739|DIETARY_SUPPLEMENT|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
219496506|NCT03703739|DIETARY_SUPPLEMENT|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
219496507|NCT03703739|DIETARY_SUPPLEMENT|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
219496508|NCT06007209|OTHER|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
219496509|NCT01389206|DRUG|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
219496510|NCT05353491|BEHAVIORAL|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
219496511|NCT05353491|BEHAVIORAL|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
219496512|NCT01760694|OTHER|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
219025740|NCT07190313|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo a single session."
219025741|NCT07190313|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo a single session.
219025742|NCT07189923|PROCEDURE|Ablative Fractional CO₂ Laser|Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters: 15 W power, 800 µm spacing, 600 µs dwell time, stack level 2. Sessions: 3, each one month apart.
218878152|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
218878153|NCT00288262|DRUG|melatonin 0.5 mg|
218878154|NCT05080374|OTHER|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
219025743|NCT07189923|PROCEDURE|Platelet-Rich Plasma (PRP) With Microneedling|Participants will receive intradermal autologous PRP injections prepared by double-spin centrifugation from 8 mL of venous blood, followed by microneedling with a Dermapen (12-needle cartridge, 1.5 mm depth). Endpoint: pinpoint bleeding. Sessions: 3, each one month apart.
219025744|NCT07190261|DRUG|enatumab|The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.
219025745|NCT07190547|OTHER|ShotBloker|ShotBlocker is a flat, horseshoe-shaped device used to reduce pain during subcutaneous or intramuscular (IM) injections. It features short, blunt, non-sharp projections approximately 2 mm in height and is designed to be placed against the skin, with a central opening that exposes the injection site. The device is applied to the skin just prior to injection, with its textured surface making contact with the skin. Although the projections do not penetrate the skin, they are believed to create a sensory stimulus associated with pain modulation based on the gate control theory.
219200413|NCT06888245|OTHER|Animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint and animation support.
219496513|NCT05001399|BEHAVIORAL|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
219496514|NCT00751972|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
219496515|NCT05005650|PROCEDURE|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
219496516|NCT04207554|DEVICE|Test Device-Strip Format|Sponsor's investigational device
219496517|NCT04207554|DEVICE|Test Device-Cassette Format|Sponsor's investigational device
219496518|NCT04207554|DEVICE|Predicate Device|Commercially available device
218878155|NCT05080374|OTHER|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
218878156|NCT05080374|OTHER|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
218878157|NCT06168266|DEVICE|Eccentric bike|Received eccentric cycling exercise
218878158|NCT06168266|OTHER|conventional group|Received conventional treatment
218878159|NCT06010134|OTHER|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
218878160|NCT03672526|DEVICE|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
218878161|NCT01336023|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
219025746|NCT07190547|OTHER|Helfer skin tap|"Helfer Skin Tap Technique:~After determining the injection site, gently tap the skin several times with the fingertips of the dominant (most commonly used) hand for approximately 5 seconds to relax the muscle. After the skin is wiped with antiseptic solution and stretched, the cap of the syringe in the dominant (most commonly used) hand is opened. A large V is made with the thumb and index finger of the non-dominant hand. The skin is tapped three times quickly using the whole hand to stimulate the major muscle fibers. The nurse/midwife counts to 3, and the needle is inserted into the muscle at a 90-degree angle simultaneously. To remove the needle from the skin, the skin is tapped three times quickly (again in a V shape) with the whole non-dominant hand, and the needle is withdrawn simultaneously with the final tap (tapping)."
219025747|NCT07190495|DRUG|Ginger|Patients will receive 800 mg of oral ginger 2 hours before laparoscopic cholecystectomy
219025748|NCT07190495|DRUG|Placebo|Patients will receive an oral placebo capsule identical in appearance to ginger, administered 2 hours before laparoscopic cholecystectomy
219496519|NCT00667433|DRUG|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
219496520|NCT04834999|OTHER|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
218878162|NCT01336023|DRUG|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
218878163|NCT01336023|DRUG|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
218878164|NCT00099866|DRUG|vildagliptin|
218878165|NCT00099866|DRUG|Metformin Comparator|
218878166|NCT03134131|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
218878167|NCT03951116|DRUG|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
218878168|NCT04805710|DRUG|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
218878169|NCT06527534|DRUG|Filgotinib|Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
218878170|NCT06527534|DRUG|Adalimumab|Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
218878171|NCT03824600|DIAGNOSTIC_TEST|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
218878172|NCT01302197|OTHER|No intervention|longitudinal follow-up after stroke
218878173|NCT05522595|DEVICE|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
218878174|NCT05243589|OTHER|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
218878175|NCT05243589|OTHER|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
218878176|NCT03137329|BEHAVIORAL|Exercise program|Physical therapy for aerobic and resistance training exercises
218878177|NCT03137329|DIETARY_SUPPLEMENT|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
219025749|NCT07190664|OTHER|Patients were randomly grouped|All patients included in the study, were randomized
219603102|NCT02868957|OTHER|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
218878178|NCT03137329|PROCEDURE|WLS|Weight loss surgery as planned
218878179|NCT03837132|BEHAVIORAL|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
218878180|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
218878181|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
218878182|NCT05437432|PROCEDURE|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
218878183|NCT05437432|PROCEDURE|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
218878184|NCT02044861|DRUG|PFK-158|IV dose escalation
218878185|NCT03369002|DRUG|seladelpar|Oral single dose 10 mg
219025750|NCT07190755|OTHER|Remote symptoms moniotring|Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants.
219025751|NCT07191392|DEVICE|Temporal Interference Stimulation (TIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
219025752|NCT07191392|DEVICE|Sham temporal interference stimulation (TIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation
218878186|NCT03034902|DEVICE|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
218878187|NCT00638976|DRUG|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
218878188|NCT00638976|DRUG|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
218878189|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
219025753|NCT07190209|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe Route of administration: Subcutaneous injection
219025754|NCT07190209|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: Subcutaneous injection
219496521|NCT03125915|BEHAVIORAL|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
219496522|NCT03125915|BEHAVIORAL|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
219496523|NCT03125915|BEHAVIORAL|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
219496524|NCT04289584|OTHER|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
219496525|NCT04363931|PROCEDURE|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
219496526|NCT04363931|PROCEDURE|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
219496527|NCT01253876|DIETARY_SUPPLEMENT|soy milk, Caw's milk|
219496528|NCT04455594|DRUG|Almonertinib|Oral, 110mg QD
219496529|NCT04455594|DRUG|Erlotinib|Oral, 150mg QD
219496530|NCT04455594|DRUG|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
219496531|NCT04455594|DRUG|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
218878190|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
218878191|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
218878192|NCT00783458|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
218878193|NCT00783458|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
219603103|NCT02868957|DEVICE|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
219603104|NCT02868957|DEVICE|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
219603105|NCT01656057|DRUG|Acetaminophen|Acetaminophen dissolved in 50 ml of water
219603106|NCT01656057|DRUG|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
219603107|NCT01656057|DRUG|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
218878194|NCT04373746|DEVICE|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
219025755|NCT07191015|BEHAVIORAL|Low-Intensity Continuous Exercise|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
219025756|NCT07191015|BEHAVIORAL|Moderate Intensity Interval Exercise|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
219496532|NCT04455594|DRUG|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
219496533|NCT05219773|DEVICE|NuvoAir Air Next spirometer|"* The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey."
219496534|NCT03996707|OTHER|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery
218878195|NCT04510896|OTHER|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
218878196|NCT04510896|OTHER|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
219025757|NCT07191015|BEHAVIORAL|High-Intensity Interval Exercise|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
219025758|NCT07190248|DRUG|MK-1084|Administered as an oral tablet
219025759|NCT07190248|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered as a SC injection
219025760|NCT07190248|DRUG|Pemetrexed|Administered as an IV Infusion
219025761|NCT07190248|DRUG|Cisplatin|Administered as an IV Infusion
219025762|NCT07190248|DRUG|Carboplatin|Administered as an IV Infusion
219025765|NCT07190651|OTHER|Home questionnaire|Administration of a questionnaire at each 28-days cycle, to select patients who need to access to hospital for clinical visit during treatment with CDK4/6i + hormone therapy for advanced breast cancer.
219025766|NCT07189871|DRUG|177Lu-BetaBart|BetaBart administered by intravenous (IV) infusion every 6 weeks
219025767|NCT07191301|BEHAVIORAL|Functional Strength Training, Kinesio Taping, and Proprioceptive Neuromuscular Facilitation|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. In addition, Proprioceptive Neuromuscular Facilitation (PNF) lower-limb D1 flexion/extension patterns with manual resistance will be performed in 3 sets of 5 repetitions, lasting 35-40 minutes per session.
219025768|NCT07191301|BEHAVIORAL|Functional Strength Training and Kinesio Taping|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. No PNF techniques will be applied.
219603108|NCT01656057|OTHER|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
219025769|NCT07191314|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
219025770|NCT07191249|DRUG|Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.|In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.
219025771|NCT07190846|OTHER|No Intervention (Observational Echocardiographic Evaluation)|This is an observational study. No therapeutic intervention is administered. Participants undergo standard echocardiographic assessment of left ventricular diastolic function during pregnancy.
219025772|NCT07189832|PROCEDURE|Intralesional Injections|Intralesional Injections
219025773|NCT07190989|DIETARY_SUPPLEMENT|Nutritional Supplement|A mixed juice containing 15000 mg cherry juice concentrate, 220 mg cherry extract, 250 mg cocoa extract, 200 mg of tryptophan, 100 mg of L-5-Hydroxytryptophan, 3000 mg of glycine, 300 mg of magnesium, 200 mg of theanine manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/rest-juice).
219025774|NCT07190989|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|A 40g dual-source carbohydrate gel, having a 1:0.8 ratio of maltodextrin and fructose manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/beta-fuel-dual-source-energy-gel-beta-fuel-maltodextrin-fructose).
219040223|NCT04231500|DIAGNOSTIC_TEST|Skin swabs|Pre-moistened skin swabs will be collected before the patient starts the conditioning regimens (before conditioning; start of HSCT = day 0, on the day of the transplantation an the repeated in week 4, 12, 24, 36 and 52 after allo-HSCT. The first swab serves as baseline reference (ideally taken at the earliest one week after a systemic antibiotic treatment). Swabs will be taken from the neck, back, right hip, buccal oral cavity and the genital mucosae. In patients who develop acute or chronic skin-GVHD additional swabs will be taken from affected skin at the time of diagnosis and then again according to the schedule of the non-lesioned skin swabs.
219496535|NCT03996707|OTHER|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot \& ankle surgery
219496536|NCT04741139|DRUG|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
219496537|NCT01123980|DRUG|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
219496538|NCT01123980|DRUG|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
219496539|NCT01123980|DRUG|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
219496540|NCT01123980|DRUG|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
218878197|NCT04510896|OTHER|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
219025775|NCT07189611|BEHAVIORAL|A blended online and offline teaching model for internal medicine nursing practice based on generative artificial intelligence|This study will employ a convergent mixed-methods design. Participants will be convenience-sampled undergraduate nursing students from the 2024 cohort (intervention group) and the 2023 cohort (control group) at Changsha Medical University. The intervention group will experience the new blended model, which includes: 1) Optimizing a GAI-assisted clinical case library with progressive scenarios; 2) Utilizing online resources (Learning Terminal platform, virtual simulation experiments with an AI assistant); 3) Engaging in offline interactive sessions (card-based desktop deduction games and scenario simulations). The control group will receive traditional teaching methods. Quantitative data will include course scores (theoretical knowledge and practical skills) and teaching satisfaction questionnaires. Qualitative data will be collected via semi-structured interviews to explore students' experiences deeply.
219496541|NCT01225991|DRUG|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
219496542|NCT05550675|OTHER|Questionnaires|Disease specific questionnaires
219496543|NCT03491319|PROCEDURE|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
218878198|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
218878199|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
218878200|NCT01046214|DRUG|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
218878201|NCT01046214|DRUG|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
218878202|NCT06543342|BEHAVIORAL|Bystander Brief Motivational Intervention|Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
218878203|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
218878204|NCT01408342|DRUG|Alemtuzumab and Rituximab|"* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21"
218878205|NCT00000382|BEHAVIORAL|Infant-Parent Psychotherapy|
218878206|NCT00000382|BEHAVIORAL|Child Protective Services|
218878207|NCT00000382|BEHAVIORAL|Psychoeducational Home Visitation|
218878208|NCT00000382|BEHAVIORAL|Parent Education|
218878209|NCT04842981|DRUG|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
219025776|NCT07190716|BIOLOGICAL|GR2301 injection|IL15 monoclonal antibody
219496544|NCT03491319|PROCEDURE|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
218878210|NCT04842981|DRUG|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
218878211|NCT02935413|DEVICE|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
218878212|NCT02935413|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
219496545|NCT03491319|PROCEDURE|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
219496546|NCT05329415|DIAGNOSTIC_TEST|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
218878213|NCT03245983|BEHAVIORAL|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
218878214|NCT05304897|PROCEDURE|PRP treatment|PRP treatment for bronchopleural fistula
218878215|NCT02861482|DEVICE|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
218878216|NCT02861482|DRUG|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
218878217|NCT02861482|DRUG|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
219603109|NCT01656057|OTHER|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
219496547|NCT06529276|OTHER|Augmented reality clinical learning|Clinical learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation, using augmented reality immersive learning technology.
219025777|NCT07190404|BEHAVIORAL|A metacognitive strategy for cognitive rehabilitation called the Multicontext Approach.|The Multicontext Approach is a strategy training approach to cognitive intervention provides ways to maintain daily function despite the presence of cognitive deficits. It involves teaching people to use metacognitive, compensatory, or adaptive techniques to optimize information processing or bypass cognitive limitations and achieve task-related goals. Strategy training is recommended for those with mild (vs. more severe) cognitive deficits because it requires learning, capitalizes on existing cognitive resources, and aims to prevent or delay functional decline.
219025778|NCT07190404|BEHAVIORAL|Cognitive (Process) Training|This treatment is functional task training, a widely-used approach in neurorehabilitation153,154 that parallels the cognitive training used in PD to-date but with functional cognitive tasks (vs. computer or paper \& pencil tasks) to improve ecological validity. It has the same structure within and across treatment sessions and uses the same treatment activities as the MC intervention. However, the OT does not use mediated learning techniques or explicitly address strategies, metacognition, or transfer/generalization. Rather, participants practice functional cognitive tasks with knowledge of results feedback and cueing by the OT to improve task performance.
219025779|NCT07190404|BEHAVIORAL|MC Approach Booster Session|MC+B participants will come from the MC Approach group only. They will receive 2 additional treatment sessions with their original OT within the month following their 6mo FU assessment. The OT will review the participant's relevant Post and FU data beforehand for treatment planning purposes. The first session will involve a review of goals, prior learning, and strategies and discussion of successes/challenges related to functional cognitive performance and strategy application since initial treatment. Then the same protocol (treatment activities with metacognitive framework and mediation, strategy bridging discussions, homework action planning and review) will be followed for the rest of the booster treatment to reinforce or re-activate prior learning, address new concerns, and develop supports for maintenance.
219025780|NCT04689048|DRUG|18F fluciclovine|Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
219025781|NCT02650401|DRUG|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
219025782|NCT04282252|DRUG|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
219025783|NCT02410382|DRUG|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
219025784|NCT02410382|DRUG|Placebo|oral placebo
219025785|NCT05311696|OTHER|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
219025786|NCT04952870|OTHER|Inhaled NO|Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
219025787|NCT04952870|OTHER|routine care|Patients treated for respiratory failure
219025788|NCT02064907|DRUG|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
219025789|NCT02064907|DRUG|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
219025790|NCT00265473|BIOLOGICAL|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
219496548|NCT06529276|OTHER|Control arm regular clinical learning|Regular bedside learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation,
219496549|NCT00789828|DRUG|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
219496550|NCT00789828|DRUG|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
219496551|NCT00181116|DRUG|Levetiracetam|
218878218|NCT02861482|DRUG|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
218878219|NCT02861482|PROCEDURE|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
218878220|NCT02861482|PROCEDURE|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
218878221|NCT02861482|PROCEDURE|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
218878222|NCT02861482|PROCEDURE|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
218878223|NCT02861482|PROCEDURE|Hysterectomy|Hysterectomy with all the above measures not working
219496552|NCT04934111|DRUG|LNP-nCOV saRNA-02 Vaccine|a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
219496553|NCT02942173|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
219496554|NCT02094937|DRUG|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
219496555|NCT02094937|DRUG|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
219496556|NCT02094937|DRUG|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
219025791|NCT02409836|DRUG|Marketed Dentifrice|Marketed Dentifrice
219025792|NCT02409836|DRUG|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
219025793|NCT02409836|DRUG|Marketed Flavored Dentifrice|Bubble Gum Flavored
219025794|NCT02259153|BEHAVIORAL|Changes in cholesterol metabolism|
218878224|NCT02861482|DRUG|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
218878225|NCT01122849|DEVICE|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
218878226|NCT01122849|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
218878227|NCT01122849|DEVICE|Placebo Nasal Strip|Placebo strip
218878228|NCT01865383|BEHAVIORAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
218878229|NCT02447978|BIOLOGICAL|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
218878230|NCT02447978|BIOLOGICAL|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
218878231|NCT02447978|BIOLOGICAL|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
218878232|NCT02807688|BEHAVIORAL|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
218878233|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
218878234|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
218878235|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
218878236|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
218878237|NCT00417430|DRUG|ICI 182,780 (Faslodex)|
219025795|NCT02259153|OTHER|Lean red meat diet|
219496557|NCT02094937|DRUG|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
219496558|NCT02094937|DRUG|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
219496559|NCT02094937|DRUG|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
219496560|NCT06682949|BEHAVIORAL|Sleep Extension|Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.
219496561|NCT06682949|BEHAVIORAL|Daytime Routine|Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
219496562|NCT00891501|PROCEDURE|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
219603110|NCT03154125|DRUG|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
219603111|NCT00805324|DRUG|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
218878238|NCT03054779|OTHER|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
218878239|NCT03054779|OTHER|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
218878240|NCT03054779|OTHER|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
218878241|NCT05556694|DIAGNOSTIC_TEST|calculation of cumulative fluid balance|\- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
218878242|NCT02522130|DRUG|Lidocaine|intracervical injection
218878243|NCT02522130|DRUG|oral misoprostol|oral treatment
218878244|NCT02522130|DRUG|naproxen|oral treatment
219025796|NCT02259153|OTHER|Fat red meat diet|
219025797|NCT04802265|PROCEDURE|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
219025798|NCT05575323|OTHER|Same-day SBRT and spinal surgery|SBRT and surgical stabilization with or without decompression within 24 hours
219025799|NCT05575323|OTHER|Standard of care|Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
219025800|NCT05455606|OTHER|Best Practice|Receive usual care
219025801|NCT05455606|OTHER|Chart Abstraction|Ancillary studies
218878245|NCT02522130|OTHER|placebo|oral treatment
218878246|NCT02524873|DEVICE|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
219025802|NCT05455606|OTHER|Educational Intervention|Physicians access genomic testing education materials
219200414|NCT06890052|OTHER|Targeted exercise program|Participants in the active comparator group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen. A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload. The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.
219025803|NCT05455606|PROCEDURE|Genomic Profile|Patients undergo genomic testing
219025804|NCT05455606|OTHER|Interview|Ancillary studies
219025805|NCT05455606|OTHER|Questionnaire Administration|Ancillary studies
219025806|NCT05455606|OTHER|Tumor Board Review|Patients undergo genomic tumor board review
219025807|NCT04095624|BEHAVIORAL|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
219200415|NCT06890052|OTHER|Targeted exercise as part of an integrative therapy program|"Participants in the experimental group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen.~A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload.~The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.~Each session is supplemented with general exercises for the back and trunk muscles (e.g., lat pulldown, abdominal crunch). In addition, participants will receive at least five sessions of therapy, which may include joint mobilization, tissue treatment, stress management, and other therapeutic modalities."
219496563|NCT00891501|PROCEDURE|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
219496564|NCT05416359|DRUG|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
219496565|NCT06701383|DEVICE|Cryoablation|Pulmonary vein isolation using cryoablation
219603112|NCT00984724|BEHAVIORAL|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
219603113|NCT00984724|BEHAVIORAL|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
219603114|NCT00984724|BEHAVIORAL|Quitline|Letter referring participants to a Quitline providing quit smoking services.
219603115|NCT00984724|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
218878247|NCT01678625|DEVICE|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
218878248|NCT00391625|DRUG|GA-GCB|15-60 U/kg every other week via intravenous infusion
218878249|NCT00876434|DRUG|Sirolimus|
218878250|NCT01528722|DRUG|Bupivacaine|0.25% 20ml administered intraperitoneal
218878251|NCT01528722|OTHER|Normal saline|sodium chloride 0.9% solution
218878252|NCT03997825|DEVICE|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
218878253|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
218878254|NCT01361178|DRUG|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
218878255|NCT05151757|OTHER|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
218878256|NCT00383162|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
218878257|NCT00383162|DRUG|Placebo|Matching placebo tablet.
218878258|NCT01089205|DRUG|Metformin|
218878259|NCT00003066|DRUG|docetaxel|
218878260|NCT00003066|DRUG|estramustine phosphate sodium|
218878261|NCT00767819|DRUG|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
218878262|NCT00333918|DRUG|bromfenac ophthalmic solution|
218878263|NCT00333918|DRUG|placebo comparator|
218878264|NCT06457698|PROCEDURE|Double-puncture TMJ arthrocentesis under local anaesthesia|The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
218878265|NCT02082730|DEVICE|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
218878266|NCT02696239|DEVICE|V-lock suture|
218878267|NCT02696239|DEVICE|Vicryl Suture|
219496566|NCT06701786|PROCEDURE|Compressive Sutures (CSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1mm, 2 horizontal incisions of approximately 3mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed . The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones. Three compressive sutures will be placed on the repositioned flap.
219603116|NCT04203134|DEVICE|Mouthguard|The mouthguard is a thin clear acrylic protector fabricated from an impression of a patient's upper teeth and palate. The acrylic protector will be trimmed and will fit onto the patient's upper teeth and palate for use during the day, except when eating to minimize trauma to the tongue that exacerbates burning tongue pain.
219603117|NCT00877591|DRUG|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
219603118|NCT00877591|DRUG|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
218878268|NCT02696239|DEVICE|Lapra-Ty II|
218878269|NCT02588209|BEHAVIORAL|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
218878270|NCT02588209|BEHAVIORAL|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
218878271|NCT01819350|OTHER|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
218878272|NCT01819350|OTHER|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
218878273|NCT01554995|DRUG|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
218878274|NCT01554995|DRUG|Linezolid|Linezolid 600 mg (Cohort 9) none
218878275|NCT05727514|OTHER|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
218878276|NCT04193774|DIAGNOSTIC_TEST|Conjunctival swab|Swab of the conjunctival fornices of both eyes
218878277|NCT04193774|DRUG|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
218878278|NCT04193774|DRUG|artificial tears|One drop of artificial tears in the other eye
218878279|NCT05091515|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
218878280|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
218878281|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
219603119|NCT00877591|DRUG|Rifampin|600 mg once daily for 15 days total
219025808|NCT04095624|OTHER|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
219040224|NCT04231500|DIAGNOSTIC_TEST|Skin punch biopsies|During the first visit, a single skin punch biopsy will be taken to state the skin condition and microbiome before allo-HSCT. Further biopsies will only be taken in case of acute or chronic cutaneous GVHD. A 4-6 mm punch biopsy will be taken from the affected skin area and a second one from a nearby unaffected part of the skin. Before the biopsy, skin disinfection will be performed to avoid contamination with surface bacteria.
218878282|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
218878283|NCT05185414|DIAGNOSTIC_TEST|Venipuncture and skin biopsy for RNA extraction|"* Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)"
218878284|NCT04602247|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
218878285|NCT04602247|DIETARY_SUPPLEMENT|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
218878286|NCT04602247|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
218878287|NCT04602247|DIETARY_SUPPLEMENT|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
218878288|NCT04602247|OTHER|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
218878289|NCT04602247|OTHER|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
218878290|NCT05392803|DEVICE|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
218878291|NCT05392803|DEVICE|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
218878292|NCT04294147|DRUG|Galcanezumab|Administered SC
218878293|NCT04294147|DRUG|Erenumab|Administered SC
219040225|NCT04231500|DIAGNOSTIC_TEST|additional blood sampling|an additional tube of blood (2.7ml) and an additional tube of serum (6ml) will be taken and frozen during visits 1, 2, 3 and 7 in the course of blood collection, in order to be able to carry out any later laboratory tests that may prove to be useful depending on the course of the study.
219040226|NCT03999307|RADIATION|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
218878294|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
218878295|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
219025809|NCT05793528|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone. The injection site is cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is inserted just below the pedicle. It is advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position is confirmed through a lateral view. Using lateral views, the needle is placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
219025810|NCT05793528|PROCEDURE|Ultrasound Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone placed. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a low-frequency convex ultrasound probe. The lateral edge of the relevant vertebral lamina is visualized by sonographic scanning in the horizontal plane. Local anesthesia is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is advanced to the lateral edge of the relevant vertebral lamina under ultrasound image guidance. Then, anteroposterior imaging is performed with fluoroscopy to confirm needle localization when the lamina margin is reached, and the needle is guided into the foramen under the guidance of fluoroscopy. The contrast agent is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 2 mL of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
219025811|NCT00001749|DRUG|Antithymocyte globulin|
219025812|NCT00001749|DRUG|Cyclosporine|
219025813|NCT03012100|DRUG|Cyclophosphamide|Given PO
219025814|NCT03012100|OTHER|Laboratory Biomarker Analysis|Correlative studies
219365240|NCT05568589|OTHER|Intraoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
218878296|NCT00642447|DRUG|helium:oxygen mixture|
218878297|NCT05512780|DRUG|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
219365241|NCT05568589|OTHER|Non Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
219603120|NCT00877591|DRUG|Rifabutin|300 mg once daily for 15 days total
219603121|NCT00877591|DRUG|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
218878298|NCT01939639|DRUG|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
218878299|NCT01939639|DRUG|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
218878300|NCT04581551|PROCEDURE|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
218878301|NCT04581551|PROCEDURE|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
218878302|NCT04581551|PROCEDURE|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
218878303|NCT04581551|PROCEDURE|No stretch intervention|Passive mobilisation of the hemiplegic hand.
218878304|NCT00049660|DRUG|capecitabine|
218878305|NCT00049660|DRUG|vinorelbine tartrate|
218878306|NCT03485196|OTHER|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
218878307|NCT00002218|DRUG|CI-1012|
218878308|NCT01142427|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218878309|NCT01142427|OTHER|Laboratory Biomarker Analysis|Correlative studies
219025815|NCT03012100|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
219025816|NCT03012100|OTHER|Placebo Administration|Given ID
219025817|NCT03012100|BIOLOGICAL|Sargramostim|Given ID
219025818|NCT04439253|DRUG|Crizotinib|Given PO
219025819|NCT06451952|OTHER|Virtual darkness|Chronotheraphy
219025820|NCT04887792|DRUG|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
219365242|NCT01785355|OTHER|Dental treatment|"1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions."
218878310|NCT01886703|BEHAVIORAL|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
219025821|NCT04887792|DRUG|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
219025822|NCT05402150|BEHAVIORAL|Behavioral Activation|"* instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
219025823|NCT05402150|BEHAVIORAL|Mindulness and Gratitude|"* instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
219025824|NCT05402150|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
219025825|NCT03836547|BEHAVIORAL|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
219025826|NCT03836547|BEHAVIORAL|Active Control|Participants will receive usual care for 12 weeks followed by the active intervention.
219025827|NCT06376162|DRUG|Ziftomenib|Oral capsule
219496567|NCT06701786|PROCEDURE|Without Compressive Sutures (WCSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; than then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
219603122|NCT01264510|OTHER|audiological test battery|routine audiological measurements.
218878311|NCT02772185|DEVICE|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
218878312|NCT02772185|DEVICE|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
218878313|NCT02772185|BEHAVIORAL|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
218878314|NCT02772185|BEHAVIORAL|placebo CT|Videos (short films) will be presented during the neurostimulation
218878315|NCT05385250|OTHER|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
219025828|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
219025829|NCT06376162|DRUG|Fludarabine|IV infusion
219040227|NCT03999307|PROCEDURE|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
218878316|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
218878317|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
218878318|NCT02820025|DRUG|doxapram|
218878319|NCT02820025|OTHER|saline|
218878320|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
219040228|NCT03999307|OTHER|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
219040229|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
219040230|NCT00544076|DRUG|sildenafil citrate|Given orally
219040231|NCT00544076|DRUG|alprostadil|Given intraurethrally
219040232|NCT00544076|PROCEDURE|robotic-assisted laparoscopic surgery|Undergo prostatectomy
219040233|NCT00544076|PROCEDURE|quality-of-life assessment|Ancillary studies
219040234|NCT00544076|OTHER|questionnaire administration|Ancillary studies
219040235|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
219040236|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
219040237|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
219040238|NCT05640570|DRUG|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
218878321|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
218878322|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
218878323|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
218878324|NCT00235716|DRUG|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
218878325|NCT04390841|DEVICE|Cardiac Stimulator|The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
218878326|NCT02523573|PROCEDURE|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
218878327|NCT03746041|DRUG|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
219025830|NCT05533853|OTHER|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
219025831|NCT05533853|OTHER|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
219025832|NCT03356496|DEVICE|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
219025833|NCT05546684|OTHER|footbath|footbath for patients before sleeping
219025834|NCT00102674|DRUG|cangrelor|
218878328|NCT03746041|DRUG|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
218878329|NCT03036189|BEHAVIORAL|baa nnilah|7 meetings in the community led by a trained community facilitator
219025835|NCT05714111|OTHER|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
219025836|NCT02753062|DRUG|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
219025837|NCT02245542|DRUG|ALNA®OCAS®|
219496568|NCT06702215|DEVICE|Cross-modal paired associative stimulation (cm-PAS) protocol|The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
218878330|NCT00745433|DRUG|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
218878331|NCT00745433|DRUG|metformin|Start dose and frequency at the discretion of the physician following clinical practice
218878332|NCT00006196|DRUG|Vitamin D|
218878333|NCT01860950|DEVICE|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
218878334|NCT01860950|DEVICE|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
218878335|NCT01860950|DEVICE|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
218878336|NCT00467233|PROCEDURE|Laser Treatment|Laser treatment to half of the face at each study visit
218878337|NCT00467233|PROCEDURE|Acid Peel|Acid peel to half of the face at each study visit
219496569|NCT00049010|GENETIC|comparative genomic hybridization|
219496570|NCT00049010|GENETIC|cytogenetic analysis|
218878338|NCT05316506|OTHER|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
218878339|NCT05316506|OTHER|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
219040239|NCT05518149|DRUG|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
219040240|NCT02052921|PROCEDURE|Rectal resection|Surgical rectal resection
219040241|NCT02052921|OTHER|Observation|
219496571|NCT00049010|GENETIC|fluorescence in situ hybridization|
219496572|NCT00049010|OTHER|immunohistochemistry staining method|
218878340|NCT02992509|DEVICE|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
218878341|NCT05301309|BEHAVIORAL|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
218878342|NCT04967339|DEVICE|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
218878343|NCT04967339|DEVICE|Lateral wedge insoles|Lateral wedge insoles
218878344|NCT00001009|DRUG|Dextran sulfate|
218878345|NCT01204216|BIOLOGICAL|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
219496573|NCT06704113|DRUG|meloxicam 7,5mg|Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
219496574|NCT06702943|DRUG|Tigecycline (Tygacil)|tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
219496575|NCT06702943|DRUG|Colistimethate sodium (CMS)|Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
219496576|NCT06704035|DIAGNOSTIC_TEST|Early OGTT Results Revealed|Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
219496577|NCT06703684|OTHER|Cross-sectional observational study|This is a cross-sectional observational study. No intervention will be given.
219496578|NCT03086642|DRUG|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
219496579|NCT05355831|DEVICE|Active Transcranial Direct Current Stimulation|See arm/group description
219496580|NCT05355831|DEVICE|Sham stimulation|See arm/group description
219496581|NCT00359840|DRUG|darbepoetin alfa|
219496582|NCT04901130|DEVICE|Computer-aided Real-time Automatic Quality Control System (AQCS)|Automatic quality-control system(AQCS), developed based on deep convolutional neural network (DCNN) models, could improve the colonoscopists' performance during withdrawal phase and significantly increase polyp and adenoma detection.
219496583|NCT05775263|PROCEDURE|CT angiogram|CT angiography of the brain 30 minutes from establishment of NRP
219496584|NCT04147052|BEHAVIORAL|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
219496585|NCT01051999|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine powder
219496586|NCT01051999|DIETARY_SUPPLEMENT|L-alanine|L-alanine oral powder
219496587|NCT02917356|OTHER|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
219496588|NCT02917356|OTHER|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
219496589|NCT02917356|OTHER|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
219496590|NCT03470909|PROCEDURE|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
219496591|NCT03470909|PROCEDURE|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
219496592|NCT00256100|DRUG|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
219496593|NCT00515385|DRUG|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
218878346|NCT01204216|BIOLOGICAL|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
218878347|NCT01204216|BEHAVIORAL|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
218878348|NCT02348307|DRUG|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
218878349|NCT02348307|DRUG|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
218878350|NCT04741672|BEHAVIORAL|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
218878351|NCT04741672|BEHAVIORAL|Discharge routine procedure.|Discharge routine procedure.
218878352|NCT03286816|DRUG|SodiumChloride|
218878353|NCT03286816|DRUG|Sodium Lactate|
218878354|NCT01277484|DRUG|Decitabine|"1\. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
218878355|NCT00266682|DEVICE|Pacing Lead|
218878356|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
218878357|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
218878358|NCT02023047|DRUG|Nifedipine 12 mg coated suppositories|
218878359|NCT05553184|DRUG|Formoterol Fumarate 12 micrograms Inhalation Powder|At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
218878360|NCT05553184|DRUG|Nicotinic Acid 50 MG Oral Tablet|a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
218878361|NCT05553184|OTHER|Acute Cold Exposure|Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
218878362|NCT05553184|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
218878363|NCT05553184|DIAGNOSTIC_TEST|Indirect calorimetry|will be repeated every hour, for 20 minutes, using Vmax29n.
218878364|NCT05553184|DIAGNOSTIC_TEST|dual-energy x-ray absorptiometry (DEXA scan)|Whole body scan
218878365|NCT05553184|PROCEDURE|Biopsy|After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
218878366|NCT05553184|PROCEDURE|iv lines|for stable tracer perfusion and blood sampling
218878367|NCT05553184|PROCEDURE|Electromyogram (EMG)|Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
219496594|NCT00515385|DRUG|MGAWN1|Single IV dose
219496595|NCT00515385|OTHER|Placebo|Single IV dose
219496596|NCT02043561|OTHER|induction of urge by rectal distension|
218878368|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
218878369|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
218878370|NCT06292676|OTHER|skills retained for home birth delivery in emergency|skills on mannequin for home birth scenario in emergency
218878371|NCT00004275|DRUG|growth hormone|
218878372|NCT00004275|DRUG|oxandrolone|
218878373|NCT00723359|DRUG|BT062|biologic
218878374|NCT05126849|OTHER|Allogenic transplantation|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
219496597|NCT06017011|OTHER|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
219496598|NCT04149054|BEHAVIORAL|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
219496599|NCT02488902|DRUG|Placebo|Placebo
219496600|NCT02488902|DRUG|Tafenoquine 25mg|Tafenoquine 25mg
219496601|NCT02488902|DRUG|Tafenoquine 50mg|Tafenoquine 50mg
219496602|NCT02488902|DRUG|Tafenoquine 100 mg|Tafenoquine 100 mg
219496603|NCT02488902|DRUG|Tafenoquine 200 mg|Tafenoquine 200 mg
219496604|NCT02488902|DRUG|Mefloquine 250 mg|Mefloquine 250 mg
219496605|NCT03880331|PROCEDURE|Debridement|Aggressive vs Minimal Debridement
218878375|NCT02188849|OTHER|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
218878376|NCT02188849|DRUG|Creatine|Creatine powder 5 g day
218878377|NCT00147303|DRUG|MCI-9042|
218878378|NCT03042884|BEHAVIORAL|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
218878379|NCT03042884|DEVICE|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
218878380|NCT06469528|DRUG|Colchicine 0.5 MG|Low dose daily colchicine
219025838|NCT02121587|BEHAVIORAL|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
219025839|NCT03669835|DIETARY_SUPPLEMENT|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
219025840|NCT03669835|DRUG|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
219025841|NCT05049993|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
219496606|NCT04087382|DEVICE|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
219496607|NCT04087382|OTHER|non intervention group|medical treatment (Asprin, statin, nootropic drug)
219496608|NCT01113294|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
219496609|NCT03978169|DIAGNOSTIC_TEST|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
218878381|NCT03274518|DEVICE|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
219025842|NCT05754606|DIAGNOSTIC_TEST|Audio recordings|Automatica analysis of audio recordings
219496610|NCT02450760|OTHER|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
219496611|NCT05620680|BIOLOGICAL|CD7 CAR-T cells|patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
219496612|NCT02824991|PROCEDURE|detection of local twitch response intensities during dry needling|
218878382|NCT03274518|DEVICE|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
218878383|NCT06405477|DIETARY_SUPPLEMENT|L-arginine|Capsules of 3 grams of L-arginine per Dose
218878384|NCT06405477|DIETARY_SUPPLEMENT|Placebo|Capsules of 3 grams of maize Starch per Dose
218878385|NCT03505528|DRUG|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
218878386|NCT03505528|DRUG|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
218878387|NCT05856019|OTHER|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
219025843|NCT05423067|PROCEDURE|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
218878388|NCT05856019|OTHER|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
219496613|NCT01589029|DRUG|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
219496614|NCT01854073|DRUG|Hyoscine butyl bromide|
218878389|NCT02516228|DEVICE|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
218878390|NCT05150210|DEVICE|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
218878391|NCT00692419|BEHAVIORAL|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
218878392|NCT00692419|BEHAVIORAL|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
218878393|NCT04346849|PROCEDURE|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
218878394|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
219025844|NCT02016625|DRUG|Faldaprevir|
219025845|NCT02016625|DRUG|Faldaprevir|
219025846|NCT02016625|DRUG|Cyclosporine|
219025847|NCT02016625|DRUG|Tacrolimus|
219025848|NCT04874337|OTHER|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
219025849|NCT00009048|DRUG|EMD 128130|
219025850|NCT00009048|DRUG|IV Levodopa|
219040242|NCT03637465|BEHAVIORAL|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
219496615|NCT01854073|DRUG|Normal saline|
219496616|NCT03786874|OTHER|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
219496617|NCT03786874|OTHER|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
219496618|NCT03786874|OTHER|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
219496619|NCT04071392|PROCEDURE|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
219496620|NCT01957631|DRUG|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
219496621|NCT01957631|BIOLOGICAL|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
219603123|NCT04575610|DRUG|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
219603124|NCT04575610|DRUG|Placebo|Matching placebo tablets will be administered.
219603125|NCT05969535|BEHAVIORAL|Birth preparation education according to travelbee human-human relations theory|human-to-human communication and psychoeducation-assisted birth preparation training
219603126|NCT04362228|BEHAVIORAL|Whole-body exercise|10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
219603127|NCT06430593|PROCEDURE|low-flow anesthesia|0,5 l/min \>1 l/min
218878395|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
218878396|NCT01675193|BEHAVIORAL|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
218878397|NCT03937960|OTHER|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
218878398|NCT03937960|OTHER|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
218878399|NCT05368168|DEVICE|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
219496622|NCT02373735|OTHER|crystalloid|Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
219496623|NCT02373735|OTHER|colloid|Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%
219496624|NCT02373735|OTHER|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%
219496625|NCT02373735|OTHER|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
219496626|NCT05053919|DEVICE|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
219496627|NCT05053919|DEVICE|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
219496628|NCT01255579|DRUG|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
219496629|NCT01255579|DRUG|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
219496630|NCT01776450|DEVICE|Endovascular AAA repair|
219496631|NCT02387307|DRUG|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
219496632|NCT05059782|DRUG|chemotherapy, targeted therapeutics, immunotherapy|Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
219496633|NCT05059782|RADIATION|IFRT, IMRT or SBRT|IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）
219496634|NCT02369627|DEVICE|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
219496635|NCT02369627|DEVICE|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
219603128|NCT04835974|DIAGNOSTIC_TEST|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured:~1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio.~2. Glycemia will be assessed : RBS ( random blood sugar ) .~3. Serum Uric acid : S .UA"
219603129|NCT02635412|OTHER|Scheduled timing of delivery|
219025851|NCT05311371|OTHER|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
219496636|NCT02369627|OTHER|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
219496637|NCT04472182|DRUG|Fluoride varnish with xylitol coated calcium and phosphate|Fluoride varnish with xylitol coated calcium and phosphate
218878400|NCT02675530|DRUG|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
219496638|NCT04431531|OTHER|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
218878401|NCT06430723|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
218878402|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
218878403|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
218878404|NCT03515642|BEHAVIORAL|HIIT group|Physical Training
218878405|NCT00727155|BEHAVIORAL|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
218878406|NCT03673020|BIOLOGICAL|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
218878407|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
218878408|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
218878409|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
218878410|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
218878411|NCT01196416|DRUG|Cisplatin|Given IV
218878412|NCT01196416|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219496639|NCT04431531|OTHER|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
218878413|NCT01196416|OTHER|Laboratory Biomarker Analysis|Correlative studies
218878414|NCT01196416|OTHER|Pharmacological Study|Correlative studies
218878415|NCT01196416|DRUG|Temozolomide|Given PO
218878416|NCT01196416|DRUG|Vinblastine Sulfate|Given IV
218878417|NCT04241302|DIAGNOSTIC_TEST|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
218878418|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
218878419|NCT01029041|OTHER|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
218878420|NCT01029041|OTHER|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
218878421|NCT05500430|DEVICE|Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)|Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
218878422|NCT02673684|DEVICE|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
218878423|NCT02673684|DEVICE|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
218878424|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
218878425|NCT02262962|OTHER|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
218878426|NCT06024018|DEVICE|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
218878427|NCT06024018|BEHAVIORAL|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
218878428|NCT01596036|BEHAVIORAL|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
218878429|NCT01596036|OTHER|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
218878430|NCT01092663|DRUG|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
218878431|NCT01092663|DRUG|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
218878432|NCT00085449|BIOLOGICAL|alemtuzumab|
218878433|NCT00085449|DRUG|cyclosporine|
218878434|NCT00085449|DRUG|fludarabine phosphate|
218878435|NCT00085449|DRUG|melphalan|
218878436|NCT00085449|DRUG|mycophenolate mofetil|
218878437|NCT00085449|PROCEDURE|peripheral blood stem cell transplantation|
218878438|NCT00085449|RADIATION|radiation therapy|
218878439|NCT03006692|OTHER|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
218878440|NCT05697796|PROCEDURE|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
218878441|NCT05961137|OTHER|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
218878442|NCT05961137|OTHER|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
218878443|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
219025852|NCT05311371|OTHER|Control group|No intervention
219025853|NCT06838793|PROCEDURE|Single Level Intertransverse Process Block|"Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB.~The thoracic intervertebral levels (T3, T5, T7) will be identified and marked on the patient. Ultrasound gel will be applied to the skin foracoustic coupling and the transducer is placed 2-3 cm lateral to the spinous process, at the target vertebral level, in the t After obtaining the target transverse ultrasound window at the articular process level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 25 ml of LA mixture containing 0.5% ropivacaine with 1: 200,000 adrenaline will be injected slowly in small aliquots."
219025854|NCT06838793|PROCEDURE|Three Level Intertransverse Process Block|Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB. After obtaining the target transverse ultrasound window at the inferior articular process level (described above) at the T7 level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 8 ml of LA mixture containing 0.5% ropivacaine with 1:200,000 adrenaline will be injected slowly in small aliquots. Subsequently, similar injections will be performed at T5 and T3 level with 8 ml and 9 ml LA mixture, respectively (Total LA mixture volume: 25 ml).
219025855|NCT05324995|DRUG|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
219025856|NCT05324995|DRUG|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
219025857|NCT05324995|DRUG|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
219496640|NCT00872391|RADIATION|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
219496641|NCT01373476|DRUG|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
219496642|NCT01373476|DRUG|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
219496643|NCT05025982|PROCEDURE|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
219496644|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered SC
219496645|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered IV
219496646|NCT03053622|BIOLOGICAL|Mirikizumab Reference|Administered SC
219496647|NCT01037101|BEHAVIORAL|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
218878444|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
218878445|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
218878446|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
218878447|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
219025858|NCT00887354|DRUG|Teriparatide|Administered subcutaneously
219025859|NCT00887354|DRUG|Risedronate|Administered orally
219496648|NCT01037101|BEHAVIORAL|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
219496649|NCT01037101|DRUG|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
219496650|NCT01037101|DRUG|Placebo|50 mg placebo administered 30 minutes before the session
219496651|NCT00581386|DEVICE|LTS-D|supra-glottic airway device
219496652|NCT00581386|DEVICE|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
219496653|NCT00581386|DEVICE|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
219496654|NCT01746563|DRUG|Ranibizumab|Intravitreal injection
219496655|NCT01746563|PROCEDURE|Laser therapy|Laser therapy
219496656|NCT02639819|DRUG|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
219496657|NCT01355523|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
219496658|NCT01355523|DRUG|Placebo|6 mg oral placebo daily 1 hour before bedtime
219496659|NCT01278199|OTHER|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 \> 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
219496660|NCT01278199|OTHER|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
219496661|NCT00707122|OTHER|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1\. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
219496662|NCT00707122|OTHER|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
218878448|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
218878449|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
219496663|NCT02221622|DRUG|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
219603130|NCT04529135|DRUG|Dexmedetomidine|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
218878450|NCT00697710|DRUG|50 mg S-777469|S-777469, 50 mg BID
218878451|NCT00697710|DRUG|200 mg S-777469|S-777469, 200 mg BID
219025860|NCT00887354|DRUG|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
219025861|NCT00887354|DIETARY_SUPPLEMENT|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
219025862|NCT00887354|DIETARY_SUPPLEMENT|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
219496664|NCT02221622|DRUG|Placebo injection (intravenous solution)|Placebo intravenous infusion
219025863|NCT00824044|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
219025864|NCT00824044|DRUG|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
218878452|NCT00697710|DRUG|800 mg S-777469|S-777469, 800 mg BID
218878453|NCT00697710|DRUG|Placebo|Matching Placebo
218878454|NCT04328272|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
218878455|NCT04328272|DRUG|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
218878456|NCT04328272|DIETARY_SUPPLEMENT|Glucose tablets|administered orally with water
218878457|NCT02670967|DIETARY_SUPPLEMENT|Soluble Fibre|
218878458|NCT01399710|PROCEDURE|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
218878459|NCT01399710|PROCEDURE|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
218878460|NCT01399710|DEVICE|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
218878461|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
218878462|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
218878463|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
218878464|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
218878465|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
218878466|NCT05485324|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
218878467|NCT03688620|OTHER|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
218878468|NCT01008904|DRUG|magnesium oxide|Given PO
218878469|NCT01008904|OTHER|questionnaire administration|Ancillary studies
218878470|NCT01008904|PROCEDURE|quality-of-life assessment|Ancillary studies
218878471|NCT02769169|DRUG|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
218878472|NCT02769169|DRUG|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
218878473|NCT03190616|DRUG|apatinib|apatinib 500mg/qd, 28d/cycle
219025865|NCT06537349|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
219025866|NCT03742609|OTHER|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
218878474|NCT00128986|PROCEDURE|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
218878475|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
218878476|NCT02097654|OTHER|SENATOR software generated pharmacotherapy advice report.|
218878477|NCT01183065|DRUG|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
219025867|NCT03742609|OTHER|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
219025868|NCT03742609|OTHER|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
219496665|NCT03753373|OTHER|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
219496666|NCT03753373|OTHER|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
219496667|NCT03746301|DRUG|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
219496668|NCT06530043|OTHER|Senobi exercises|Senobi exercise began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.
219496669|NCT06530043|OTHER|Jacobsons Muscular relaxation exercises|Jacobsons Muscular relaxation exercises started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.
219496670|NCT01005264|DEVICE|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
219496671|NCT01005264|DEVICE|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
219496672|NCT01433952|DIETARY_SUPPLEMENT|Thiamine|Vitamin B1
219496673|NCT01433952|DIETARY_SUPPLEMENT|Placebo|Placebo
219496674|NCT00503932|PROCEDURE|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
219496675|NCT00503932|DRUG|Capecitabine|825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
219496676|NCT05221385|DRUG|Gentulizumab|Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
219496677|NCT02107937|BIOLOGICAL|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
219496678|NCT02107937|BIOLOGICAL|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
219496679|NCT02107937|DRUG|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
219496680|NCT02169661|OTHER|Burger and Beetroot Study|50% fat, 10% beetroot extract
219496681|NCT03318328|OTHER|survey|
218878478|NCT01873625|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
218878479|NCT01873625|BIOLOGICAL|placebo|
218878480|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
218878481|NCT02456857|DRUG|Everolimus|Given PO
218878482|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
218878483|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
218878484|NCT00781859|DRUG|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
218878485|NCT00781859|DRUG|Placebo|Placebo intravitreal injection
218878486|NCT01211821|DRUG|metoprolol|Tablets, Oral, 200 mg, once, 1 day
218878487|NCT01211821|DRUG|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
218878488|NCT01029847|DRUG|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
218878489|NCT01029847|DRUG|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
218878490|NCT05546229|PROCEDURE|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
218878491|NCT05747534|DRUG|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
218878492|NCT05747534|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
218878493|NCT01983774|DRUG|Esomeprazole|
218878494|NCT01983774|DRUG|Placebo|Sugar pill
218878495|NCT03402828|DRUG|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
218878496|NCT01008449|DEVICE|Surgical staples|Surgical staples will be used once for wound closure.
218878497|NCT01008449|DEVICE|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
218878498|NCT06502834|DIETARY_SUPPLEMENT|D piger|Probiotic d piger
218878499|NCT06502834|DIETARY_SUPPLEMENT|Placebo|Placebo
218878500|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
219496682|NCT05260983|BEHAVIORAL|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
219496683|NCT05260983|BEHAVIORAL|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
219496684|NCT01308983|DRUG|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
219496685|NCT01497873|DRUG|Topotecan|1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
219496686|NCT01497873|DRUG|Belotecan|0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
219496687|NCT01611168|OTHER|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
219496688|NCT05016076|DRUG|Dexamethasone 8 mg|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
219496689|NCT05016076|DIAGNOSTIC_TEST|Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)|A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
219496690|NCT05016076|DEVICE|Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy|In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
219496691|NCT05016076|DEVICE|Goal-directed hemodynamic therapy targeting cardiac index|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
219496692|NCT05016076|DRUG|Placebo (0.9% sodium chloride)|Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
219496693|NCT01981629|DEVICE|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
219496694|NCT05077683|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
219496695|NCT05077683|DRUG|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
218878501|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
218878502|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
218878503|NCT05113992|OTHER|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
218878504|NCT05113992|OTHER|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
218878505|NCT00761202|DRUG|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
218878506|NCT00761202|DRUG|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
218878507|NCT00524615|DRUG|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
218878508|NCT02386826|DRUG|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
218878509|NCT02386826|BIOLOGICAL|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
219025869|NCT02448238|OTHER|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
219025870|NCT05316012|DEVICE|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
219025871|NCT06065579|OTHER|Well-Being Promotion Program|the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
219025872|NCT02794103|DEVICE|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
219496696|NCT05528926|OTHER|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
218878510|NCT02549131|PROCEDURE|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
218878511|NCT04313478|BEHAVIORAL|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
218878512|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
218878513|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
218878514|NCT00855049|DRUG|Acetaminophen|Intranasal acetaminophen administration
218878515|NCT00855049|DRUG|Acetaminophen|Oral acetaminophen administration
218878516|NCT00406679|DRUG|Paracetamol (acetaminophen) solution experimental|1 gm IV
218878517|NCT00406679|DRUG|paracetamol (acetaminophen) solution commercial|1 gm IV
218878518|NCT00406679|DRUG|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
218878519|NCT03601702|DEVICE|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
218878520|NCT00232856|DEVICE|drug-eluting stent|PCI
218878521|NCT00195156|DRUG|ATRA-IV|
218878522|NCT00195156|DRUG|Depakote|
218878523|NCT02211066|DRUG|Clopidogrel|
219025873|NCT04779255|DRUG|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
219025874|NCT04779255|DRUG|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
219025875|NCT00935870|DEVICE|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
219025876|NCT00895258|BEHAVIORAL|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
218878524|NCT02211066|DRUG|Ticagrelor|
218878525|NCT04434014|DIETARY_SUPPLEMENT|proper diet|diet containing all essential vitamins
219025877|NCT00895258|BEHAVIORAL|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
219025878|NCT05324540|OTHER|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
218878526|NCT01242852|PROCEDURE|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
218878527|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
218878528|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
218878529|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
219025879|NCT04608500|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
219025880|NCT04608500|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
219025881|NCT03371901|OTHER|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
219025882|NCT00655967|DRUG|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
219496697|NCT05528926|OTHER|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
219496698|NCT05528926|DRUG|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
219496699|NCT03008629|DEVICE|Podofix nail brace|Podofix nail brace
219496700|NCT03008629|DEVICE|Combiped nail brace|Combiped nail brace
219496701|NCT03008629|DEVICE|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
219496702|NCT05824468|DRUG|Zimberelimab|Injectable solution
219496703|NCT05824468|DRUG|Lenvatinib|Capsule
218878530|NCT01078844|DRUG|memantine|memantine 5-20 mg daily
219496704|NCT04129034|DEVICE|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
219496705|NCT02543086|DRUG|KAE609|Study drug
219496706|NCT02543086|DRUG|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
219496707|NCT06545734|PROCEDURE|Direct Ischemic Post-conditioning|After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
219496708|NCT06545734|PROCEDURE|Endovascular therapy|Thrombectomy alone.
219496709|NCT00155441|BEHAVIORAL|cognitive-behavioral therapy|
218878531|NCT01078844|DRUG|Placebo|Look-alike placebo
219496710|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
219496711|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
219496712|NCT03134417|DIETARY_SUPPLEMENT|Placebo|Daily placebo are given to participants daily for 12 weeks.
219496713|NCT00240084|DRUG|nesiritide (Natrecor(TM))|administration of IV nesiritide
219496714|NCT05676138|OTHER|Measuring PK and PD indices in patients who receive conventional treatment|Measuring plasma concentration of commonly used antibiotics in NTM-PD
218878532|NCT06035848|PROCEDURE|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
219603131|NCT04529135|DRUG|Remifentanil|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
219603132|NCT00474500|DRUG|Coca, Cola, Diet Coke|
219603133|NCT02832011|DIETARY_SUPPLEMENT|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
219603134|NCT02832011|DIETARY_SUPPLEMENT|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
219603135|NCT04355260|PROCEDURE|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
219603136|NCT04908592|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
218878533|NCT06035848|PROCEDURE|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
218878534|NCT03931798|DIAGNOSTIC_TEST|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
218878535|NCT00857519|DRUG|Melphalan, Carboplatin|Intra-arterial chemotherapy.
218878536|NCT05236244|OTHER|İntervention group|Diaphragmatic Breathing Exercises
218878537|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
219025883|NCT00655967|DRUG|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
218878538|NCT06086834|OTHER|McKenzie Retraction Exercises|McKenzie Retraction exercises 5 days a week and 10-15 times for active exercises and 5-6 repetitions of clinician assisted exercise for a period of 4 weeks and a rest interval of 2 minutes between exercises.
219496715|NCT05506475|PROCEDURE|Blood samples|venous blood collected in a 5 mL EDTA tube
219496716|NCT04897100|PROCEDURE|Achilles tendon tenotomy|Achilles tendon tenotomy during Ponseti treatment for clubfoot
219496717|NCT01011907|DRUG|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
219496718|NCT01011907|DRUG|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
219496719|NCT01027637|OTHER|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
219496720|NCT00969059|DRUG|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
219496721|NCT00969059|DRUG|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
219496722|NCT02685956|DEVICE|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
219496723|NCT00359554|BIOLOGICAL|VAXIGRIPPE|
219496724|NCT02175654|DRUG|Regorafenib|
219496725|NCT02661282|BIOLOGICAL|Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Given IV
219496726|NCT02661282|OTHER|Laboratory Biomarker Analysis|Correlative studies
219496727|NCT02661282|DRUG|Temozolomide|Given PO
219496728|NCT02661282|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219496729|NCT03229382|DRUG|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
219496730|NCT00612482|OTHER|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
219496731|NCT00524576|BIOLOGICAL|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
219603137|NCT04908592|OTHER|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
218878539|NCT06086834|OTHER|Bruegger's Exercise|Bruegger's Exercise will be started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time will be 30 seconds, 4 sets 12 times repetition, for duration of 30 mins per session, 5 days a week for a period of 4 weeks.
219496732|NCT06161740|PROCEDURE|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
219496733|NCT04137991|DEVICE|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
219496734|NCT04137991|OTHER|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
219496735|NCT01406873|DRUG|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
219496736|NCT01406873|DRUG|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
219496737|NCT01497574|DRUG|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
219496738|NCT01497574|DRUG|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
219496739|NCT02194166|DRUG|Trastuzumab|Trastuzumab IV or SC will be administered as described.
219603138|NCT05219448|BEHAVIORAL|Education and self-efficacy coaching|"Children and their caregiver(s) in the intervention communities will receive a culturally-adapted, 5-session program consisting of video-based health education and self-efficacy coaching delivered by an indigenous Community Health Worker. Families will be introduced to sugar-free water enhancers that are commercially available and come in the same flavors as regular Tang and Kool-Aid. The sessions will include conversations on related topics, interactive hands-on activities, and homework assignments. Additionally, four brief check-ins will keep families engaged. Local stores in the intervention communities only will carry the sugar-free water enhancers that are highlighted in the health education."
219603139|NCT02653248|RADIATION|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
218878540|NCT02687698|OTHER|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
218878541|NCT00236756|DRUG|topiramate|
218878542|NCT01299116|DRUG|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
218878543|NCT01299116|DRUG|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
218878544|NCT01299116|DRUG|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
218878545|NCT01299116|DRUG|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
218878546|NCT01299116|DRUG|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
218878547|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
218878548|NCT04088591|DRUG|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
218878549|NCT04088591|DRUG|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
219025884|NCT04171973|DEVICE|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
219025885|NCT04171973|DEVICE|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
219025886|NCT03727503|OTHER|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
219025887|NCT02747420|DEVICE|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
219496740|NCT02194166|DRUG|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
219496741|NCT02194166|DRUG|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
219496742|NCT00184431|BEHAVIORAL|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
219496743|NCT01017458|DRUG|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
219496744|NCT01017458|DRUG|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
218878550|NCT01338857|DRUG|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
219496745|NCT01017458|DRUG|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
219496746|NCT01017458|DRUG|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
219496747|NCT05074563|OTHER|REsOluTioN (Resilience Enhancement Online Training for Nurses)|The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
219496748|NCT05074563|OTHER|Control|Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
219496749|NCT00172302|DRUG|vitamin C, intravenous injection|
219496750|NCT06149195|DIAGNOSTIC_TEST|Standard medical care for heart failure|Standard treatment and care for heart failure patients from the heart failure center of Sichuan Provincial People's Hospital.
219496751|NCT01809795|OTHER|Blueberry Smoothie|
219496752|NCT01809795|OTHER|Sham Smoothie|
219496753|NCT00207714|DRUG|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
219496754|NCT00207714|DRUG|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
219496755|NCT00207714|DRUG|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
219496756|NCT00207714|DRUG|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
219496757|NCT03627195|DRUG|DSP-1349M|DSP-1349M injectable
219496758|NCT03627195|DRUG|placebo|placebo injection
219496759|NCT01968681|PROCEDURE|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
219496760|NCT03254719|OTHER|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
219496761|NCT02939638|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
219496762|NCT02939638|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
219496763|NCT03503708|DRUG|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
219496764|NCT05778708|BEHAVIORAL|Tai-Chi intervention|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
218878551|NCT02708420|DEVICE|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
219496765|NCT05778708|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
219496766|NCT01808014|DRUG|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
219496767|NCT02580318|DEVICE|breathalyzer|
219496768|NCT02165566|DRUG|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
219496769|NCT02165566|DRUG|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
219496770|NCT01503359|DIETARY_SUPPLEMENT|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
219496771|NCT04033900|DEVICE|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
219496772|NCT00538187|DRUG|obatoclax mesylate|Given IV
219496773|NCT00538187|DRUG|bortezomib|Given IV
219496774|NCT00538187|OTHER|laboratory biomarker analysis|correlative study
219496775|NCT00538187|OTHER|pharmacological study|correlative study
219603140|NCT02018419|BIOLOGICAL|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
219603141|NCT02018419|PROCEDURE|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
219603142|NCT02042118|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
218878552|NCT02708420|DEVICE|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
218878553|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
218878554|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
218878555|NCT02237261|DRUG|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
218878556|NCT01123707|DRUG|Aripiprazole|Aripiprazole oral capsules
218878557|NCT01123707|DRUG|Escitalopram|Escitalopram oral capsules
219496776|NCT03951870|BEHAVIORAL|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
219496777|NCT03951870|BIOLOGICAL|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
219496778|NCT04273152|DIAGNOSTIC_TEST|advanced glycation endproducts reader|advanced glycation endproducts reader
218878558|NCT04739878|PROCEDURE|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
218878559|NCT02474251|OTHER|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
218878560|NCT01876693|PROCEDURE|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
218878561|NCT04519853|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
218878562|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
218878563|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
218878564|NCT05683002|DIETARY_SUPPLEMENT|Aronia supplementation|As described in experimental arm
218878565|NCT05683002|DIETARY_SUPPLEMENT|Cellulose supplementation|As described in placebo comparator arm
218878566|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
218878567|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
218878568|NCT04378114|DRUG|Acetominophen|One time administration of acetaminophen.
218878569|NCT05862090|DRUG|RLD2301|Take it once a day per period.
218878570|NCT05862090|DRUG|RLD2007|Take it once a day per period.
218878571|NCT03720002|DIETARY_SUPPLEMENT|HF2|placebo
219496779|NCT01653470|DRUG|Paclitaxel|
219496780|NCT01653470|DRUG|5-Fluorouracil (5FU)|
219496781|NCT01653470|DRUG|Carboplatin|
219496782|NCT01653470|DRUG|Leucovorin|
218878572|NCT01727414|DRUG|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
218878573|NCT01727414|DRUG|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
218878574|NCT03807284|BEHAVIORAL|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
218878575|NCT04793334|PROCEDURE|sleeve gastectomy|routine sleeve gastrectomy
218878576|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
219496783|NCT01653470|DRUG|Irinotecan|
219603143|NCT02042118|DEVICE|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
218878577|NCT02389439|DRUG|Pyronaridine-artesunate|
218878578|NCT04119011|BIOLOGICAL|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
218878579|NCT04119011|OTHER|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
219496784|NCT01653470|DRUG|Paclitaxel|
219496785|NCT01653470|DRUG|BMS-906024|
219496786|NCT00945152|DRUG|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
219496787|NCT00945152|DRUG|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
219496788|NCT00004699|DRUG|insulin-like growth factor I|
219603144|NCT02198937|OTHER|Blood sample|
219603145|NCT02287922|BIOLOGICAL|ALX-0061|
219603146|NCT02287922|BIOLOGICAL|Placebo|
219603147|NCT02287922|BIOLOGICAL|Tocilizumab|
219603148|NCT02881502|OTHER|severe asthma group|No intervention
219040243|NCT00624533|BEHAVIORAL|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
219040244|NCT00624533|BEHAVIORAL|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
219040245|NCT03863613|DEVICE|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
219040246|NCT03863613|PROCEDURE|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
219603149|NCT03409588|DRUG|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
219603150|NCT03337061|OTHER|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
219603151|NCT03347682|OTHER|Satisfaction with Prosthesis -SATPRO|questionnaire 1
219603152|NCT03347682|OTHER|Nottingham Health Profile-NHP|questionnaire 2
219603153|NCT03347682|OTHER|Prosthesis donning and doffing questionnaire|questionnaire 3
219603154|NCT05030792|OTHER|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
219603155|NCT01809912|DRUG|Recombinant human apolipoprotein(a) Kringle V|
219603156|NCT01690702|DRUG|Epirubicin|
219603157|NCT01690702|DRUG|nab-Paclitaxel|
219603158|NCT01690702|DRUG|Cyclophosphamide|
219603159|NCT01690702|DRUG|Docetaxel|
219603160|NCT01864707|OTHER|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
219603161|NCT01864707|OTHER|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
219603162|NCT01864707|OTHER|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
219603163|NCT04767399|BEHAVIORAL|protaper next|rotary systems used on patients need root canal treatment
218878580|NCT01801852|BIOLOGICAL|NKT cells|
218878581|NCT05236504|DIETARY_SUPPLEMENT|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
218878582|NCT05236504|OTHER|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
219040247|NCT03863613|DRUG|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
219040248|NCT04027166|DRUG|Methadone|Methadone will be administered before study procedures
219040249|NCT04027166|DRUG|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
219603164|NCT06821568|OTHER|Personalized Transcranial Direct Current Stimulation (tDCS)|Home-based transcranial direct current stimulation (tDCS) tailored to target the left dlPFC.
219603165|NCT06821568|OTHER|Active-Sham|Stimulation administered in very low-level currents (0.5 mA total) designed to not significantly influence cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
219603166|NCT05114096|DRUG|Celestone + placebo|"After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
218878583|NCT06027450|OTHER|NHIg prescription|Analysis of NHIg prescription
218878584|NCT01975597|PROCEDURE|Bone marrow aspirates and biopsy|
218878585|NCT06524622|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) measurements will be performed for all participants
218878586|NCT02670668|OTHER|Mutation analysis|
218878587|NCT03582995|PROCEDURE|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
219040250|NCT01297868|OTHER|exercise|
219603167|NCT05114096|DRUG|Celestone + Celestone|"After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone."
219603168|NCT05635708|DRUG|Tislelizumab|Administered by intravenous infusion
219603169|NCT05635708|DRUG|BGB-A445|Administered by intravenous infusion
219603170|NCT05635708|DRUG|LBL-007|Administered by intravenous infusion
219603171|NCT05635708|DRUG|Carboplatin|Investigator's choice; administered by intravenous infusion
219603172|NCT05635708|DRUG|Cisplatin|Investigator's choice; administered by intravenous infusion
219603173|NCT05635708|DRUG|pemetrexed|Investigator's choice; administered by intravenous infusion
219603174|NCT05635708|DRUG|Paclitaxel|Investigator's choice; administered by intravenous infusion
219603175|NCT05635708|DRUG|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
219603176|NCT05635708|DRUG|BGB-15025|Administered Orally
219603177|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
219025888|NCT02747420|DEVICE|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
219025889|NCT00914810|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
219025890|NCT00914810|DIETARY_SUPPLEMENT|Placebo|Placebo (sugar pill) daily for 6 weeks
219603178|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
219025891|NCT02469428|OTHER|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
219603179|NCT05831774|DRUG|Intervention - Intraosseous (IO) administration of vancomycin|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus"
219025892|NCT02469428|OTHER|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
219025893|NCT02696642|DRUG|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
219025894|NCT03961607|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
219025895|NCT05375552|DEVICE|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
219025896|NCT03503721|PROCEDURE|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
219603180|NCT05831774|DRUG|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
219603181|NCT06670170|DRUG|PF-07976016 Formulation A|PF-07976016; formulation A - current/reference
219603182|NCT06670170|DRUG|PF-07976016 Formulation B|PF-07976016; Formulation B - new/test
219603183|NCT04223752|DRUG|Ceftolozane/Tazobactam|"Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g)."
219603184|NCT04519164|DRUG|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
219603185|NCT04519164|DRUG|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
218878588|NCT03582995|PROCEDURE|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
219025897|NCT03503721|PROCEDURE|bipolarTURP|the prostate will transurethrally resected using a bipolar current
219025898|NCT06504199|DRUG|Obinutuzumab|No dose adjustment of Obinutuzumab is allowed.
219025899|NCT06504199|DRUG|Zanubrutinib|Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
219025900|NCT06504199|DRUG|Lenalidomide|Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
218878589|NCT02568592|DIETARY_SUPPLEMENT|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
218878590|NCT02568592|DIETARY_SUPPLEMENT|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
218878591|NCT02568592|DIETARY_SUPPLEMENT|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
218878592|NCT03757377|DEVICE|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
218878593|NCT03757377|DEVICE|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
218878594|NCT03465267|DEVICE|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
219025901|NCT06504199|DRUG|Cytarabine|The specific dose is determined by the investigator according to the actual situation of the patient.
219025902|NCT06504199|BIOLOGICAL|CAR-T|zanubrutinib in combination with lenalidomide was allowed for maintenance treatment in high-risk patients for 1 year and zanubrutinib for 2 years after recovery of hemogram 2 months after CAR-T. High-risk Patients with any of the following conditions: Mantle cell lymphoma International Prognostic Index (MIPI-c) high-risk, blastic/pleomorphic type, TP53 mutation/deletion, CDKN2A deletion, MYC amplification/translocation, or incomplete response at induction stage; Non-high-risk group: no high-risk features.
219025903|NCT04139954|OTHER|There is no intervention in the study|There is no intervention in the study
218878595|NCT03465267|DEVICE|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
218878596|NCT00002921|DRUG|suramin|
218878597|NCT00002921|DRUG|therapeutic hydrocortisone|
218878598|NCT06525233|OTHER|Physiotherapy and rehabilitation|The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
218878599|NCT04564677|DEVICE|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
218878600|NCT00243984|DRUG|topiramate|
219025904|NCT00652236|OTHER|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
219025905|NCT06388395|PROCEDURE|Accuracy of full-arch surgical guides|The accuracy of the surgical guides will be assessed by superimposing the pre and post-treatment CBCT scans.
219025906|NCT06388395|PROCEDURE|Survival and complications of the prostheses|Two different prostheses will be assessed (conventional and PEEK). All complications will be recorded for a period of 3 years
219025907|NCT06388395|PROCEDURE|Survival and complications of the implants|The effect of the two different prostheses on implants will be assessed in terms of survival and success rates.
219025908|NCT06388395|PROCEDURE|Conventional (metal-resin) implant-supported prosthesis|Full-mouth implant-supported conventional prosthesis will be constructed and evaluated for up to 3 years.
219025909|NCT06388395|PROCEDURE|PEEK implant-supported prosthesis|Full-mouth implant-supported PEEK prosthesis will be constructed and evaluated for up to 3 years.
219025910|NCT01465022|DRUG|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
219496789|NCT06290700|BEHAVIORAL|Neonatal Care education|Participants who met the study inclusion criteria were provided with information about the purpose and conduct of the study, and their consent to participate was then obtained. The interviews were conducted in the breastfeeding room at the Uşak Dikilitaş Family Health Centre. The data were collected between November 2022 and November 2023. The Family Health Centre has two vaccination rooms, two antenatal care rooms, two observation rooms, and two breastfeeding rooms. Each pregnant woman was individually enrolled in an education session held in the breastfeeding room. The breastfeeding room was approximately 20 m², which was considered standard for accommodating training for an average of three pregnant women. The breastfeeding room was quiet, had a suitable temperature, and was located on the first floor in the middle of the corridor.
219496790|NCT00736099|DRUG|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
219496791|NCT00736099|DRUG|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
219496792|NCT03526952|OTHER|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
219603186|NCT04759703|DRUG|Pramipexole|0.25 mg pramipexole tablets
218878601|NCT01227005|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
218878602|NCT01959243|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
218878603|NCT01959243|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
218878604|NCT01959243|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
218878605|NCT01959243|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
218878606|NCT05502510|BEHAVIORAL|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
218878607|NCT06192680|DRUG|Liposomal irinotecan|70 mg/m² IV
218878608|NCT06192680|DRUG|Capecitabine|1000 mg/m² PO BID
218878609|NCT06192680|DRUG|Bevacizumab|5mg/kg IV
219025911|NCT01465022|DRUG|Progestin-only pill|.35 mg norethindrone once a day orally
219025912|NCT05366439|DRUG|AT-752|Parallel Assignment
219025913|NCT05366439|DRUG|Placebo Comparator|Parallel Assignment
219025914|NCT04009421|DIAGNOSTIC_TEST|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
219025915|NCT00006240|BIOLOGICAL|sargramostim|
219496793|NCT03526952|OTHER|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
219496794|NCT00042042|BEHAVIORAL|Family based educational program|
219496795|NCT01883999|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
219496796|NCT05614999|OTHER|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
219496797|NCT00328042|BEHAVIORAL|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
219496798|NCT00328042|BEHAVIORAL|Information Only|This is an individual self-paced at home study program.
219496799|NCT03564756|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C per day
219496800|NCT03893409|OTHER||this is a observation study, no any intervention in patients
219603187|NCT04759703|DRUG|Placebo|Matching placebo tablets
219496801|NCT05198115|BEHAVIORAL|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
219025916|NCT00006240|DRUG|dexamethasone|
219603188|NCT04954313|DRUG|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
219496802|NCT04275661|PROCEDURE|Ultrasound (US) bi-level erector spinae block|nerve block
218878610|NCT05417191|BEHAVIORAL|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
218878611|NCT05417191|BEHAVIORAL|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
219025917|NCT00006240|DRUG|oral sodium phenylbutyrate|
219496803|NCT04275661|DRUG|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
219496804|NCT04275661|DRUG|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
219496805|NCT04275661|DRUG|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
218878612|NCT00048100|PROCEDURE|Apheresis|Apheresis for T-Cell collection
218878613|NCT00048100|BIOLOGICAL|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
218878614|NCT04956653|OTHER|Without additional intervention|Only patients' information was collected
218878615|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
218878616|NCT03080363|DRUG|Bupivacaine|10 ml %0.5 bupivacaine
218878617|NCT03080363|DRUG|Lidocaine|10 ml %2 lidocaine
218878618|NCT02554981|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
218878619|NCT01108380|PROCEDURE|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
219025918|NCT05717010|DEVICE|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
219200416|NCT06744244|DIAGNOSTIC_TEST|Olfactory Testing|Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.
219496806|NCT05844683|OTHER|2% chlorhexidine digluconate solution|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
219496807|NCT05844683|OTHER|usual baths|Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
219603189|NCT04954313|OTHER|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
219025919|NCT01327300|DRUG|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
219025920|NCT01327300|OTHER|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
219025921|NCT00002137|DRUG|Tecogalan sodium|
219025922|NCT03674060|DRUG|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
219025923|NCT03674060|DRUG|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
219025924|NCT03890770|DRUG|BMS-986165|Oral administration
219025925|NCT03020823|DRUG|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218878620|NCT01114438|DEVICE|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
218878621|NCT06529861|DIAGNOSTIC_TEST|[15O]H2O-PET Imaging|This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
218878622|NCT06528912|OTHER|Radiotherapy|Follow-up
218878623|NCT00005859|DRUG|tipifarnib|
218878624|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
218878625|NCT03450265|DEVICE|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
218878626|NCT03450265|DEVICE|Tachosil|Applied according to the current instruction for use (IFU).
219025926|NCT03676322|DRUG|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
218878627|NCT05801614|OTHER|Low carb diet|Low calori diet
218878628|NCT00428844|DRUG|daptomycin|6 mg/kg
218878629|NCT00428844|DRUG|daptomycin|8 mg/kg
218878630|NCT00428844|DRUG|vancomycin|1 gram
219025927|NCT03676322|DRUG|Placebo|Participants will receive placebo matched to M5049.
219025928|NCT00115973|DEVICE|pump|
219603190|NCT04954313|OTHER|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).
218878631|NCT00428844|DRUG|teicoplanin|6 mg/kg; used only at UK sites
218878632|NCT00428844|DRUG|nafcillin|1-2 gram
218878633|NCT00428844|DRUG|oxacillin|1-2 gram
218878634|NCT00428844|DRUG|flucloxacillin|1-2 mg
218878635|NCT00488826|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
218878636|NCT00488826|BIOLOGICAL|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
218878637|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
218878638|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
218878639|NCT05700227|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
218878640|NCT02292706|DRUG|Sofosbuvir|Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.
218878641|NCT02292706|DRUG|Ribavirin|
218878642|NCT02292706|DRUG|LDV/SOF|Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
219025929|NCT00115973|DRUG|insulin aspart|
219025930|NCT02807350|DEVICE|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
219025931|NCT02807350|DEVICE|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
219025932|NCT03662542|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
219025933|NCT03662542|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
219025934|NCT03662542|DRUG|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
219025935|NCT03662542|DRUG|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
218878643|NCT02292706|DRUG|SOF/VEL|Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
218878644|NCT02292706|DRUG|SOF/VEL/VOX|Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
218878645|NCT02292706|DRUG|Other SOF-Based Regimen|"The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF"
218878646|NCT02292706|OTHER|Ineligible parent treatment|Participants were enrolled from ineligible parent treatment group.
218878647|NCT01378468|OTHER|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
218878648|NCT01229722|DEVICE|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
218878649|NCT01229722|DEVICE|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
219025936|NCT03662542|DRUG|Placebo|Placebo will be administered.
219025937|NCT04149951|DEVICE|Vestal Device|Vestibular nerve stimulator
219496808|NCT02601911|DRUG|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
219496809|NCT02601911|DRUG|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
219496810|NCT02601911|OTHER|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
219496811|NCT02982447|DEVICE|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
219025938|NCT04149951|DEVICE|Placebo device|Sham nerve stimulator
219025939|NCT01437007|DRUG|TKM-080301|
219040251|NCT03729531|PROCEDURE|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
219496812|NCT02982447|DEVICE|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
218878650|NCT04358224|BIOLOGICAL|Dupilumab Prefilled Syringe|open-label
218878651|NCT02725866|DRUG|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
219025940|NCT02034786|PROCEDURE|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
219025941|NCT02034786|BIOLOGICAL|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
219025942|NCT02034786|PROCEDURE|Transdermal injection|Transdermal injection of hyaluronic acid only.
219025943|NCT00006209|DRUG|Tucaresol|
219025944|NCT05891678|RADIATION|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
219025945|NCT01854905|OTHER|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
219025946|NCT03739112|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
219025947|NCT03739112|BIOLOGICAL|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
219025948|NCT02877277|DIETARY_SUPPLEMENT|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
219025949|NCT02877277|DIETARY_SUPPLEMENT|Placebo|Oral intake of placebo tablet daily for 56 days
219025950|NCT05403242|DRUG|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
219025951|NCT05403242|DRUG|S-1|40-60 mg, bid po, d1-10, every 2 weeks
219496813|NCT00833547|DRUG|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
219496814|NCT00833547|DRUG|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
218878652|NCT02725866|DRUG|Dasabuvir|Tablet
218878653|NCT02725866|DRUG|Ribavirin|Tablet
219025952|NCT04709328|DRUG|SCTA01|Diluted by 0.9% normal saline，IV
219025953|NCT04709328|OTHER|Placebo|IV
219025954|NCT04031833|DRUG|MAT2203|Encochleated amphotericin B
219025955|NCT04031833|DRUG|Amphotericin B|Intravenous amphotericin B
219025956|NCT05805761|PROCEDURE|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
219200417|NCT06744244|DIAGNOSTIC_TEST|Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)|Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.
219200418|NCT06744244|DIAGNOSTIC_TEST|Video-EEG|The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).
219200419|NCT06744244|DIAGNOSTIC_TEST|fMRI|Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.
219496815|NCT01735877|OTHER|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
219496816|NCT01735877|OTHER|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
219496817|NCT05105477|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
219025957|NCT05805761|PROCEDURE|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
219025958|NCT03217227|OTHER|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
219496818|NCT05105477|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
219496819|NCT05540977|DRUG|Donepezil|Donepezil 5mg QN
219496820|NCT05540977|OTHER|Usual care|Usual care
219496821|NCT01188954|DRUG|doxycycline|50 ml/mg
218878654|NCT02422849|OTHER|hospital specialist|
218878655|NCT02422849|OTHER|General Practitioner|
218878656|NCT02161419|DRUG|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
218878657|NCT02161419|DRUG|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
219025959|NCT03217227|PROCEDURE|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
219025960|NCT03217227|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
219025961|NCT03217227|DIAGNOSTIC_TEST|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
219025962|NCT03202862|DRUG|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
219025963|NCT03451877|GENETIC|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
219025964|NCT03050619|DRUG|Empagliflozin|
219025965|NCT03050619|DRUG|Other SGLT2 inhibitors|
219025966|NCT03050619|DRUG|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
219025967|NCT03078621|BIOLOGICAL|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
219025968|NCT04354207|DIAGNOSTIC_TEST|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
219025969|NCT04354207|DIAGNOSTIC_TEST|Stool collection|Gut microbiome will be investigated in stool samples.
219496822|NCT01188954|OTHER|No intervention|Normal Saline/Water
218878658|NCT03595527|DIAGNOSTIC_TEST|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
218878659|NCT02413047|DRUG|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
218878660|NCT02413047|DRUG|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
218878661|NCT02413047|DRUG|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
218878662|NCT01549977|DRUG|Febuxostat|Febuxostat tablets
218878663|NCT01549977|DRUG|Placebo|Febuxostat placebo-matching tablets
218878664|NCT05556577|DRUG|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
218878665|NCT05556577|OTHER|placebo|Placebo received at SURMOUNT-CN trial
218878666|NCT04147806|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
218878667|NCT04147806|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
218878668|NCT04147806|DRUG|Dexamethasone|4 mg by mouth on treatment days only
218878669|NCT04147806|DRUG|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
219025970|NCT01530295|DRUG|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
219025971|NCT00078026|DRUG|Apomine|
219025972|NCT01246947|PROCEDURE|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
219025973|NCT01246947|OTHER|Mitral surgery alone|Randomized to Mitral surgery alone
219496823|NCT02521454|BEHAVIORAL|MBRT|
219496824|NCT03569254|DEVICE|Neomedlight Phototherapy Blanket|The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
218878670|NCT05825976|DIETARY_SUPPLEMENT|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
218878671|NCT05825976|OTHER|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
218878672|NCT01705106|DRUG|capecitabine|Given PO
218878673|NCT01705106|DRUG|celecoxib|Given PO
218878674|NCT01705106|OTHER|pharmacological study|Correlative studies
218878675|NCT01705106|OTHER|laboratory biomarker analysis|Correlative studies
218878676|NCT01705106|OTHER|pharmacogenomic studies|Correlative studies
218878677|NCT00379054|BEHAVIORAL|telephone based skills training intervention|
219025974|NCT03815097|PROCEDURE|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
218878678|NCT04443166|COMBINATION_PRODUCT|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
218878679|NCT00671606|PROCEDURE|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
218878680|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
218878681|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
218878682|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
218878683|NCT02401984|OTHER|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
218878684|NCT04667104|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
219025975|NCT06496841|DRUG|Transnasal Sphenopalatine ganglion block|The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
219025976|NCT06496841|DRUG|Ultrasound-guided suprazygomatic sphenopalatine ganglion block|The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
219496825|NCT03569254|DEVICE|Ohmeda-Fiber Optic Phototherapy Blanket|This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
219496826|NCT01400854|DRUG|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
219496827|NCT05102045|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
219496828|NCT05102045|OTHER|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
219496829|NCT05102045|DRUG|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
219496830|NCT05102045|DRUG|Memantine|Memantine were given for Alzheimer's disease. .
219496831|NCT00164606|BEHAVIORAL|Positive Parenting Program (Triple-P)|
219603191|NCT01999634|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
219603192|NCT05961839|DRUG|SGR-2921|SGR-2921 will be administered orally.
219603193|NCT01673412|OTHER|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
219025977|NCT05231590|BIOLOGICAL|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
219496832|NCT05967312|DIAGNOSTIC_TEST|Minuteful Kidney Test Kit|The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
219496833|NCT02459639|OTHER|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
219603194|NCT05093270|DRUG|BGB-23339|Administered orally as a tablet
219603195|NCT05093270|DRUG|Placebo|Administered orally as a tablet
219603196|NCT06427941|DRUG|BGB-B2033|Administered by intravenous infusion
219603197|NCT06427941|DRUG|Tislelizumab|Administered by intravenous infusion
218878685|NCT04667104|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
218878686|NCT04667104|DRUG|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
218878687|NCT04667104|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
218878688|NCT04667104|DRUG|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
218878689|NCT02943421|PROCEDURE|Transverse B-Lynch suture|
218878690|NCT03424603|DRUG|STRO-001|intravenous antibody drug conjugate
218878691|NCT01271374|DRUG|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
218878692|NCT01271374|DRUG|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
219496834|NCT02459639|OTHER|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
219496835|NCT00245622|BIOLOGICAL|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
219496836|NCT00245622|BIOLOGICAL|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
219496837|NCT00686790|BIOLOGICAL|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
219496838|NCT04283747|DIAGNOSTIC_TEST|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
219496839|NCT03392376|DRUG|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
219496840|NCT03392376|OTHER|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
219496841|NCT04595227|DEVICE|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
219496842|NCT00096382|BIOLOGICAL|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
219496843|NCT00096382|BIOLOGICAL|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.
219496844|NCT00096382|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
219496845|NCT00096382|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
219496846|NCT00096382|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
219496847|NCT00096382|RADIATION|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
219496848|NCT04878874|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
219496849|NCT04878874|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
219496850|NCT05837065|OTHER|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
219496851|NCT03295539|DEVICE|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
219496852|NCT04013022|BEHAVIORAL|Exercise History|The groups will be divided based on their exercise history
219496853|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
219496854|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
219025978|NCT05231590|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
219496855|NCT05249010|PROCEDURE|acupuncture and moxibustion|Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
219496856|NCT00274014|DRUG|Tiotropium|
219496857|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
219496858|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
219496859|NCT02108613|BEHAVIORAL|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
219496860|NCT02108613|BEHAVIORAL|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
219025979|NCT03599050|BEHAVIORAL|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
219025980|NCT03009929|OTHER|Observational study|No intervention, observational only
219025981|NCT05016557|DIETARY_SUPPLEMENT|Protein ingestion|Bolus ingestion of 25g protein
219025982|NCT01516957|DRUG|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
219496861|NCT02108613|BEHAVIORAL|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
219496862|NCT01974570|DIETARY_SUPPLEMENT|Marealis refined peptide concentrate|2 tablets, once per day before noon
219496863|NCT01974570|DIETARY_SUPPLEMENT|Placebo|2 tablets, once per day before noon
219496864|NCT04261933|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219496865|NCT05136456|DRUG|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
219496866|NCT05136456|DRUG|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
219496867|NCT05136456|DRUG|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
219496868|NCT03899974|OTHER|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
219496869|NCT01326702|DRUG|Bendamustine Hydrochloride|Given IV
219496870|NCT01326702|OTHER|Pharmacological Study|Correlative studies
219496871|NCT01326702|BIOLOGICAL|Rituximab|Given IV
219496872|NCT01326702|DRUG|Veliparib|Given PO
219496873|NCT03615079|BEHAVIORAL|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
219496874|NCT05489679|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
218878693|NCT04383054|BEHAVIORAL|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
218878694|NCT04383054|BEHAVIORAL|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
218878695|NCT03043651|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
218878696|NCT00017407|BIOLOGICAL|ISIS 3521|
218878697|NCT00017407|DRUG|carboplatin|
218878698|NCT00017407|DRUG|paclitaxel|
218878699|NCT05281055|PROCEDURE|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
219025983|NCT01516957|DRUG|Placebo|Placebo SC (subcutaneous)
219025984|NCT01516957|DRUG|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
219025985|NCT01516957|DRUG|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
219025986|NCT05595681|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
219025987|NCT01290666|DEVICE|Fistula Plug|Bioabsorbable fistula plug
219025988|NCT03285971|OTHER|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
219025989|NCT05811546|DIAGNOSTIC_TEST|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
219496875|NCT04886570|DEVICE|hip arthroplasty|Hip arthroplasty is a kind of joint reconstruction surgery, which has been successfully utilized for treatment of osteoarthritis or hip fracture for decades. In this surgery, implants is applied to reconstruct hip joint, and usually comprised of four components, including femoral stem, femoral head, acetabular cup and liner.
219496876|NCT05683470|DRUG|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
219496877|NCT06373406|DRUG|MHB036C|An antibody-drug conjugate therapy
219496878|NCT06526715|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
219496879|NCT04573400|OTHER|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
219496880|NCT02926378|PROCEDURE|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
219496881|NCT04339088|OTHER|Questionnaires|Questionnaires to assess quality of life
219496882|NCT03630588|COMBINATION_PRODUCT|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
219496883|NCT03630588|COMBINATION_PRODUCT|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
219496884|NCT03524937|DRUG|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
219496885|NCT03524937|DRUG|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
219496886|NCT03524937|DRUG|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
219496887|NCT01835132|DEVICE|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
219496888|NCT00328237|PROCEDURE|Cord Blood Transplant|
219496889|NCT00856778|DEVICE|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
219496890|NCT04133571|DRUG|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
219025990|NCT05368740|DEVICE|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
219025991|NCT05069766|OTHER|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
219025992|NCT04020133|PROCEDURE|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
219025993|NCT04020133|PROCEDURE|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
219025994|NCT04020133|DRUG|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
219025995|NCT04020133|DRUG|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
219025996|NCT00587483|DRUG|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
219025997|NCT00587483|DRUG|Amiodarone|300 mg
219025998|NCT00587483|DRUG|Placebo|Saline
219025999|NCT05855031|DIAGNOSTIC_TEST|Transient Elastography|One transient elastography 1-2 weeks after randomization
219026000|NCT03303846|PROCEDURE|Magnetic Resonance Imaging|Undergo high risk breast cancer screening MRI
219026001|NCT03303846|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219026002|NCT03303846|OTHER|Laboratory Biomarker Analysis|Correlative studies
219026003|NCT02063516|DEVICE|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
219026004|NCT02063516|DEVICE|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
219040252|NCT03729531|PROCEDURE|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
219040253|NCT01051128|DEVICE|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
219496891|NCT01255228|OTHER|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
219496892|NCT02599883|RADIATION|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
219496893|NCT04901754|DRUG|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
219496894|NCT02214498|DRUG|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
219496895|NCT02214498|DRUG|Placebo|
219496896|NCT01294878|DRUG|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
218878700|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
218878701|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
218878702|NCT00006433|DRUG|Doxil|
218878703|NCT00006433|PROCEDURE|heat treatment|
219026005|NCT03446742|OTHER|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
219496897|NCT00877682|PROCEDURE|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
219496898|NCT01333176|PROCEDURE|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If \< 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result \>6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~1. Did the clients who were counseled to do so get follow-up blood tests?~2. Were all the formal diagnostic tests performed?~3. Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~4. Did the family physicians find this useful?"
219496899|NCT01333176|PROCEDURE|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
219496900|NCT01333176|PROCEDURE|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
219496901|NCT01333176|PROCEDURE|Blood test|HbA1c blood test
219496902|NCT01333176|PROCEDURE|Blood test|HbA1c finger poke blood test
219496903|NCT03150030|OTHER|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
218878704|NCT03219684|DIAGNOSTIC_TEST|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
218878705|NCT00162812|DRUG|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
218878706|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
219026006|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
219026007|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
219496904|NCT03150030|DEVICE|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
219496905|NCT03150030|DEVICE|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
219496906|NCT02805374|DRUG|ASP1517|Oral
219496907|NCT03836274|DIETARY_SUPPLEMENT|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
218878707|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
218878708|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
218878709|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
218878710|NCT01630889|DRUG|Roxadustat|Oral capsule
218878711|NCT03595488|DRUG|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
218878712|NCT03605316|PROCEDURE|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
218878713|NCT02372981|DEVICE|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
218878714|NCT00486382|BIOLOGICAL|Leish-111f + MPL-SE Adjuvant|
219496908|NCT00407043|DRUG|Lotemax|
219496909|NCT00407043|DRUG|Restasis|
219496910|NCT00551486|PROCEDURE|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
219496911|NCT03016663|PROCEDURE|Technique of Breast Lipofilling|"1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
219496912|NCT01980082|DRUG|Cefazolin|Antibiotic
219496913|NCT01980082|DRUG|Placebo|Placebo
219496914|NCT02952794|PROCEDURE|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
219496915|NCT00331773|RADIATION|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
219496916|NCT00331773|RADIATION|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
219496917|NCT03810833|DEVICE|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
219496918|NCT03168685|DEVICE|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
219496919|NCT01585233|DRUG|ASKP1240|Intravenous
219026008|NCT03018041|DRUG|Omacor|"As described in Arms."
219026009|NCT03018041|DRUG|Placebo Oral Capsule|"As described in Arms."
219496920|NCT01585233|DRUG|Placebo|Intravenous
219496921|NCT03335709|BEHAVIORAL|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
218878715|NCT04814056|DRUG|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
218878716|NCT03217214|DIAGNOSTIC_TEST|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
218878717|NCT01587235|DRUG|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
218878718|NCT01587235|DRUG|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
218878719|NCT02841462|DEVICE|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
218878720|NCT00435851|DRUG|Thyrogen, thyroid hormone withdrawal, iode 131|
218878721|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
219026010|NCT00003463|DRUG|carmustine|
219026011|NCT00003463|DRUG|irinotecan hydrochloride|
219026012|NCT00003463|DRUG|polifeprosan 20 with carmustine implant|
218878722|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
218878723|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
218878724|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
218878725|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
218878726|NCT01854424|OTHER|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
219026013|NCT00003463|PROCEDURE|surgical procedure|
219026014|NCT03301194|OTHER|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
219026015|NCT03854617|DRUG|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
219026016|NCT03854617|DRUG|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
219496922|NCT03198637|DRUG|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
219496923|NCT03198637|DRUG|clinical assessment|
219496924|NCT06045585|BIOLOGICAL|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
219496925|NCT05948293|DEVICE|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
219496926|NCT05948293|PROCEDURE|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
219496927|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
219496928|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
219496929|NCT05329428|OTHER|Usual Antenatal Care|In early pregnancy (gestational week \<15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
219496930|NCT05478005|PROCEDURE|Femoral nerve block|Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
219496931|NCT05478005|PROCEDURE|Intra-articular block|Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
219496932|NCT02996253|PROCEDURE|FHL transfer|endoscopic transfer og flexor hallucis longus
219496933|NCT04609527|PROCEDURE|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
219496934|NCT05644912|DEVICE|Transanal irrigation (TAI)|Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
219496935|NCT00525031|DRUG|Temozolomide (TMZ)|150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
219496936|NCT00525031|DRUG|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
219496937|NCT04485286|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
219496938|NCT06013709|DEVICE|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
219496939|NCT02490566|OTHER|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
219496940|NCT00652379|DRUG|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
218878727|NCT00848224|BEHAVIORAL|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
219026017|NCT03566368|DIAGNOSTIC_TEST|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
219026018|NCT03566368|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
219026019|NCT03566368|DIAGNOSTIC_TEST|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
219026020|NCT01318447|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
219026021|NCT05916729|DRUG|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
219026022|NCT05916729|DIETARY_SUPPLEMENT|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
219496941|NCT00652379|DRUG|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
219496942|NCT02140164|DRUG|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
219496943|NCT01234259|DEVICE|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
219603198|NCT06048822|BEHAVIORAL|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
219603199|NCT04366934|OTHER|Nasal swab|Nasal swab
219603200|NCT04366934|OTHER|Taste and olfactory function evaluation|Taste and olfactory function evaluation
218878728|NCT04599595|DEVICE|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
218878729|NCT05626127|OTHER|No interventions|As this is a observational study, there are no interventions.
218878730|NCT03905902|BIOLOGICAL|DCVAC/OvCa|activated autologous dendritic cells
218878731|NCT03905902|BIOLOGICAL|DCVAC/OvCa placebo|placebo for activated autologous cells
218878732|NCT05018104|OTHER|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
218878733|NCT05073198|OTHER|Education brochure|In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
219026023|NCT04853745|DEVICE|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
219026024|NCT02307357|BEHAVIORAL|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
219026025|NCT00005831|BIOLOGICAL|trastuzumab|Given IV
219026026|NCT00005831|DRUG|paclitaxel|Given IV
219026027|NCT00005831|DRUG|carboplatin|Given IV
219496944|NCT00780715|DRUG|Gliclazide MR|30mg daily increased to 60mg if HbA1c \> 7% at 3 months
219496945|NCT00780715|DRUG|Sitagliptin|Sitagliptin 100mg daily for 6 months
219496946|NCT00780715|DRUG|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c \>7% at 3 months. 6 months duration
219496947|NCT00780715|DRUG|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
219496948|NCT02468661|DRUG|INC280 single agent|
219496949|NCT02468661|DRUG|erlotinib|
219496950|NCT03339791|PROCEDURE|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
218878734|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
218878735|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
219026028|NCT00005831|DRUG|gemcitabine hydrochloride|Given IV
219026029|NCT00005831|OTHER|laboratory biomarker analysis|Correlative studies
219026030|NCT02702440|OTHER|Liquid calories from sugars|
219026031|NCT00150839|DRUG|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
219026032|NCT00150839|DRUG|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
219026033|NCT02063854|DRUG|NE-58095 IR|NE-58095 IR tablets
219496951|NCT03339791|PROCEDURE|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
219496952|NCT04663126|DRUG|Tc-99m tilmanocept|IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
219496953|NCT03108079|DEVICE|Cystosure Urinary Access System|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
219603201|NCT04186845|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
219603202|NCT04186845|DIAGNOSTIC_TEST|Positron emission tomography scan|Imaging scan with radioligand
218878736|NCT05669651|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
219026034|NCT02063854|DRUG|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
219026035|NCT02063854|DRUG|NE-58095 DR|NE-58095 DR tablets
219026036|NCT02063854|DRUG|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
219026037|NCT01107587|BIOLOGICAL|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
219026038|NCT01107587|BIOLOGICAL|Placebo|Oral, two doses.
219496954|NCT03108079|DEVICE|Foley Catheter|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
219496955|NCT00661674|DRUG|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
219496956|NCT00661674|DRUG|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
219496957|NCT00661674|OTHER|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
219496958|NCT00933660|OTHER|ERC-training by instructor|Standard way of training with an instructor
219603203|NCT03431493|BEHAVIORAL|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
219603204|NCT00938249|DIETARY_SUPPLEMENT|Monascus Garlic Fermented Extract|
219603205|NCT00938249|DIETARY_SUPPLEMENT|Placebo|
219603206|NCT05862727|BEHAVIORAL|Telehealth Intervention|Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
219603207|NCT06463002|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring and Montreal Cognitive Assessment|Noninvasive tests to assess blood pressure control and cognition
219603208|NCT01814553|DRUG|afatinib|Daily treatment starting 40 mg per day
219026039|NCT01462084|DEVICE|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
219026040|NCT01462084|DEVICE|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
219026041|NCT03580850|OTHER|No intervention in this restrospective study|This study is an obervational study
219200420|NCT06744244|DIAGNOSTIC_TEST|Neurodevelopment assessment|Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.
219200421|NCT06744166|DEVICE|TENS-WAA|Patients assigned to the TENS-WAA group will receive transcutaneous electrical nerve stimulation based on Wrist-Ankle Acupuncture theory for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. According to the principles of WAA, two pairs of TENS-WAA (Wuxi Jiajian Medical Device Co., Ltd.) electrode pads will be placed on the upper area 2 and 3 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis. Upper area 3 is between the edge of the radius and the radial artery. Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reach the maximum tolerable level without causing pain.
219496959|NCT00933660|OTHER|Web-based training only|Experimental way of training with a web based training application
219603209|NCT01814553|DRUG|loperamide|Follow cohort assignment and diarrhea management guidelines
219603210|NCT06206629|DIAGNOSTIC_TEST|blink reflex evaluation|A blink reflex evaluation will be performed in all subjects
219026042|NCT03538158|BEHAVIORAL|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
219026043|NCT03538158|BEHAVIORAL|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
219026044|NCT00390533|DRUG|Saredutant|oral administration (capsules)
219603211|NCT02018380|OTHER|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
219603212|NCT06632717|DRUG|Cisplatin|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
219026045|NCT00390533|DRUG|Placebo|oral administration (capsules)
219026046|NCT01537510|BEHAVIORAL|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
219496960|NCT00933660|OTHER|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
219496961|NCT01872689|DRUG|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
219496962|NCT01872689|DRUG|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
219496963|NCT01872689|DRUG|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
219603213|NCT06632717|DRUG|5-fluorouracil|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
219603214|NCT06632717|PROCEDURE|Lipiodol embolization|"Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization."
219603215|NCT02859142|DRUG|Chantix|Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
219603216|NCT02859142|BEHAVIORAL|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
219496964|NCT04835766|DIAGNOSTIC_TEST|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
219496965|NCT01401920|OTHER|leg elevation|bilateral passive leg elevation for 30 seconds
219496966|NCT01401920|OTHER|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
219496967|NCT01401920|OTHER|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
219496968|NCT01401920|OTHER|control group|supine position without passive leg elevation or trendelenburg position
219496969|NCT06118359|BEHAVIORAL|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
219603217|NCT02859142|DRUG|NicodermCQ|Nicotine patches provided over 12 week participation
218878737|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
219026047|NCT00150072|DRUG|imatinib|
219026048|NCT04484233|DEVICE|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
219026049|NCT01977508|DEVICE|ePTFE vascular access grafts|
219026050|NCT02311738|OTHER|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
219603218|NCT02859142|DRUG|Placebo|Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
219603219|NCT06030336|BEHAVIORAL|Home Health Report|The Home Health Report has been described in the intervention arm description.
219603220|NCT03290079|DRUG|Pembrolizumab|200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
219603221|NCT03290079|DRUG|Lenvatinib|20 mg Lenvatinib by mouth every day of each 3 week cycle
219603222|NCT03874728|OTHER|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
219603223|NCT03874728|OTHER|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
219026051|NCT00695396|DRUG|Placebo|Matching volume 2 mLfor 48 weeks
219026052|NCT00695396|DRUG|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
219026053|NCT00695396|DRUG|Placebo|Matching volume 1 mL for 48 weeks
219026054|NCT00695396|DRUG|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
219496970|NCT06530537|DRUG|Cilostazol|Cilostazol 100mg twice daily
218878738|NCT02488993|OTHER|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
218878739|NCT02488993|OTHER|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
218878740|NCT02488993|OTHER|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
218878741|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
218878742|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
218878743|NCT02217917|DRUG|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
218878744|NCT02217917|DRUG|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
218878745|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
218878746|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
218878747|NCT02217917|DRUG|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
218878748|NCT00012168|DRUG|isosulfan blue|
218878749|NCT00012168|GENETIC|polymerase chain reaction|
218878750|NCT00012168|OTHER|immunohistochemistry staining method|
218878751|NCT00012168|PROCEDURE|lymphangiography|
218878752|NCT00012168|PROCEDURE|radionuclide imaging|
218878753|NCT00012168|PROCEDURE|sentinel lymph node biopsy|
219026055|NCT04536155|OTHER|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
219026056|NCT04536155|OTHER|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
219026057|NCT04536155|OTHER|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010)."
219026058|NCT04536155|OTHER|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
219026059|NCT02734979|DEVICE|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
218878754|NCT00012168|RADIATION|technetium Tc 99m sulfur colloid|
218878755|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
218878756|NCT00865319|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
218878757|NCT00865319|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
218878758|NCT06066008|DRUG|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
219026060|NCT06267079|OTHER|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
219496971|NCT06530537|DRUG|Aspirin|Aspirin 100mg once daily
219496972|NCT03859661|DIETARY_SUPPLEMENT|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
219026061|NCT03532919|DIAGNOSTIC_TEST|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
219026062|NCT04640090|BEHAVIORAL|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
219026063|NCT03698474|DRUG|Natrium picosulfate / Magnesium citrate|bowel preparation formula
219026064|NCT03698474|DRUG|Polyethylene glycol / Ascorbic acid|bowel preparation formula
219496973|NCT06546111|DRUG|Placebo|Drug :placebo tab PO BID for 14 days.
218878759|NCT06066008|DRUG|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
218878760|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
218878761|NCT00566254|DRUG|Placebo|
218878762|NCT00238238|BIOLOGICAL|rituximab|Given IV
218878763|NCT00238238|DRUG|lenalidomide|Given orally
219026065|NCT03698474|DRUG|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
219026066|NCT00930995|DRUG|Candesartan|16mg po daily
219026067|NCT00930995|DRUG|Placebo|once daily
219026068|NCT00159640|DRUG|PD-217,014|
219026069|NCT04777708|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
219026070|NCT04777708|BIOLOGICAL|Pembrolizumab|Given IV
219026071|NCT04746703|RADIATION|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
219040254|NCT03862391|DRUG|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
219040255|NCT03862391|DRUG|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
219496974|NCT06546111|DRUG|Daflon|Daflon 500 mg tab PO BID for 14 days.
218878764|NCT03731078|OTHER|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
218878765|NCT03458689|PROCEDURE|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
218878766|NCT01345669|DRUG|Placebo|Once daily
218878767|NCT01345669|DRUG|Afatinib|Once daily
218878768|NCT00888485|BEHAVIORAL|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
218878769|NCT01392209|OTHER|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
218878770|NCT04933461|DEVICE|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
218878771|NCT01793883|DRUG|40 mg Laninamivir Octanoate|
218878772|NCT01793883|DRUG|80 mg Laninamivir Octanoate|
218878773|NCT01793883|DRUG|Placebo|
218878774|NCT00004113|DRUG|temozolomide|
218878775|NCT05448391|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
218878776|NCT02478255|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
218878777|NCT02478255|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
218878778|NCT03484390|BEHAVIORAL|Mindfulness-based stress reduction|
218878779|NCT03484390|BEHAVIORAL|Wellness Group|
218878780|NCT00516165|DRUG|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
218878781|NCT05330091|DIETARY_SUPPLEMENT|Once Daily Women's Probiotic|Active product
218878782|NCT05330091|OTHER|Placebo|Placebo product
218878783|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
218878784|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
218878785|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
218878786|NCT01226576|DEVICE|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
218878787|NCT02012712|BEHAVIORAL|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
218878788|NCT04112394|OTHER|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
218878789|NCT04112394|OTHER|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
218878790|NCT01341028|PROCEDURE|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
218878791|NCT01341028|PROCEDURE|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
218878792|NCT02123368|DRUG|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
218878793|NCT02123368|BIOLOGICAL|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
218878794|NCT02123368|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
219496975|NCT03202628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219496976|NCT03202628|DRUG|Dexamethasone|Given PO
219496977|NCT03202628|DRUG|Ixazomib Citrate|Given PO
219496978|NCT03202628|OTHER|Laboratory Biomarker Analysis|Correlative studies
219496979|NCT03202628|DRUG|Pomalidomide|Given PO
218878795|NCT03736876|BEHAVIORAL|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
219026072|NCT02255981|OTHER|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
219026073|NCT00005010|DRUG|Irbesartan|
219026074|NCT00005010|DRUG|Pravastatin|
219026075|NCT04823039|OTHER|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
219496980|NCT00686374|BIOLOGICAL|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
219496981|NCT05021627|PROCEDURE|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
219496982|NCT05021627|PROCEDURE|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
219496983|NCT03706326|BIOLOGICAL|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
219603224|NCT03874728|OTHER|Barefoot|Participants will conduct the assessments barefoot.
219603225|NCT03874728|OTHER|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
219603226|NCT04114487|OTHER|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
218878796|NCT03100175|BEHAVIORAL|physiotherapy|strength training for upper and lower limbs fitness and balance work out
218878797|NCT02380040|DEVICE|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
218878798|NCT00223249|DRUG|Quetiapine|
219026076|NCT05304754|BIOLOGICAL|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
219603227|NCT01941498|DEVICE|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
219026077|NCT05304754|BIOLOGICAL|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
219026078|NCT00298181|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
219026079|NCT05595889|DRUG|Surufatinib|250 mg/day p.o. QD
219200422|NCT06744166|DEVICE|Sham (No Treatment)|Patients assigned to the sham TENS-WAA group will receive sham stimulation for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. Researchers will attach the electrode patches at the same location, set the parameters to the same frequency, pulse width, and minimum current intensity as the TENS-WAA group, but do not activate the device, leaving it in place for 30 minutes at each time point.
219200423|NCT03937661|BIOLOGICAL|PRP|Autologous PRP intra ovarian infusion
219200424|NCT03937661|BIOLOGICAL|Placebo|Autologous PFP intra ovarian infusion
219200425|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
219496984|NCT03706326|BIOLOGICAL|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
219603228|NCT01941498|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
219603229|NCT00842205|DRUG|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
219603230|NCT00842205|DRUG|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
219603231|NCT05667025|OTHER|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
219603232|NCT05667025|OTHER|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
219496985|NCT03706326|COMBINATION_PRODUCT|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
219603233|NCT02015845|DEVICE|Accuvein|
219496986|NCT00087191|DRUG|EF5|Given IV
219496987|NCT00087191|DRUG|motexafin lutetium|Given IV
219496988|NCT00087191|OTHER|pharmacological study|Correlative studies
219496989|NCT04569955|BEHAVIORAL|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
219496990|NCT04033133|DEVICE|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
219496991|NCT03575559|BEHAVIORAL|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
219496992|NCT03575559|BEHAVIORAL|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
219496993|NCT03575559|BEHAVIORAL|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
219496994|NCT02579083|DRUG|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
219496995|NCT02579083|DRUG|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
219496996|NCT00174499|DRUG|2 mg nicotine gum|2 mg nicotine gum
219496997|NCT00174499|DRUG|4 mg nicotine gum|4 mg nicotine gum
219496998|NCT03888833|DEVICE|ECMO|ECMO installation
219603234|NCT02015845|DEVICE|Routine technique|Placement of peripheral intravenous catheters using the routine technique
219603235|NCT05088785|DRUG|FES|\[18F\]FES PET imaging.
219603236|NCT04391504|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
218878799|NCT04720300|OTHER|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
218878800|NCT04720300|OTHER|No app|students receive no app or housing information
218878801|NCT03223259|BEHAVIORAL|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
219496999|NCT02702752|OTHER|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
219497000|NCT03430089|BIOLOGICAL|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
219603237|NCT05783232|DIETARY_SUPPLEMENT|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
219603238|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
219603239|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
219603240|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
219026080|NCT05595889|DRUG|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
219026081|NCT04324580|OTHER|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
218878802|NCT03222024|OTHER|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
219497001|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
219497002|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
219497003|NCT05084534|DRUG|Midodrine|"Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)"
218878803|NCT01507480|DRUG|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
219497004|NCT05084534|OTHER|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
219497005|NCT03066440|DRUG|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
219497006|NCT03066440|DRUG|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
219497007|NCT03937973|BEHAVIORAL|Social rejection|Social rejection paradigm
219497008|NCT05187312|PROCEDURE|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
218878804|NCT00731471|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
218878805|NCT04518488|OTHER|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
218878806|NCT04518488|OTHER|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
218878807|NCT04597073|PROCEDURE|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
218878808|NCT00525096|DRUG|placebo|2 tablets twice a day per os
218878809|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
218878810|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
218878811|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
218878812|NCT03281083|DRUG|Levothyroxine Sodium|
218878813|NCT00761527|DRUG|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
218878814|NCT03265782|DRUG|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
218878815|NCT03265782|DRUG|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
218878816|NCT04113525|DEVICE|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
218878817|NCT05503056|OTHER|art therapy|six sessions of art therapy with licensed therapists
218878818|NCT05503056|OTHER|nothing|no intervention to this group
218878819|NCT03212456|DRUG|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
219497009|NCT05187312|PROCEDURE|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
219497010|NCT03947788|BEHAVIORAL|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
219497011|NCT01260428|DEVICE|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
219497012|NCT03723590|DEVICE|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
218878820|NCT03212456|DRUG|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
218878821|NCT03212456|PROCEDURE|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
218878822|NCT03212456|PROCEDURE|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
218878823|NCT00051922|BIOLOGICAL|PolyEnv1|Recombinant vaccinia virus vaccine
218878824|NCT01129661|BIOLOGICAL|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
218878825|NCT01129661|BIOLOGICAL|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
218878826|NCT00432770|DRUG|ARC1779|
218878827|NCT02160691|DEVICE|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
218878828|NCT00934674|DRUG|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
218878829|NCT02020317|BEHAVIORAL|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
218878830|NCT01730586|DRUG|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
219026082|NCT04324580|BEHAVIORAL|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
219026083|NCT04324580|BEHAVIORAL|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
219026084|NCT04324580|OTHER|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
219026085|NCT03360370|OTHER|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
219026086|NCT02418507|DIETARY_SUPPLEMENT|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
219026087|NCT02418507|OTHER|Placebo|The placebo is administered to randomized healthy participants
219026088|NCT05411237|DRUG|Pegylated liposomal doxorubicin|PLD 20 mg/m2 on Day 1 of every 21-day cycle
219026089|NCT05411237|DRUG|Paclitaxel|PTX 100 mg/m2 on Day 1 of every 21-day cycle
219026090|NCT06470425|OTHER|Standard therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
219026091|NCT06470425|OTHER|AI-Guided group|Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
219026092|NCT00523250|DRUG|AR-102 0.003% Ophthalmic Solution|
219497013|NCT04882111|BEHAVIORAL|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
219497014|NCT01106352|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
219603241|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
218878831|NCT01477112|DIETARY_SUPPLEMENT|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
218878832|NCT01477112|DIETARY_SUPPLEMENT|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
218878833|NCT02904018|OTHER|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
218878834|NCT02211430|BEHAVIORAL|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
218878835|NCT02211430|BEHAVIORAL|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
218878836|NCT01706783|DRUG|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
218878837|NCT01706783|DRUG|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
219026093|NCT00523250|DRUG|AR-102 0.005% Ophthalmic Solution|
219026094|NCT00523250|DRUG|AR-102 0.01% Ophthalmic Solution|
219026095|NCT00523250|DRUG|AR-102 0.03% Ophthalmic Solution|
219603242|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
219603243|NCT06028295|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
219603244|NCT03305133|OTHER|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
219026096|NCT00523250|DRUG|AR-102 Vehicle Ophthalmic Solution|
219026097|NCT04122092|DIAGNOSTIC_TEST|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
219026098|NCT05864508|DRUG|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
219040256|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
218878838|NCT00061633|DRUG|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
219040257|NCT01116232|BIOLOGICAL|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
218878839|NCT00061633|DRUG|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
218878840|NCT02599233|OTHER|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
219200426|NCT06871475|BIOLOGICAL|sticky bone with coronally advanced flap|using sticky bone with coronally advanced flap in treating the gingival recession
219200427|NCT06871475|PROCEDURE|coronally advanced flap|using coronally advanced flap alone in treating gingival recession
219497015|NCT01106352|DRUG|Docetaxel|Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
219497016|NCT03944707|DRUG|LOU064 100 mg|LOU064 100 mg once daily orally administered as two 50 mg capsules
219497017|NCT03944707|DRUG|Placebo|Placebo once daily administered orally as capsules
219497018|NCT05890326|BEHAVIORAL|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
219497019|NCT05890326|BEHAVIORAL|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
219497020|NCT05890326|BEHAVIORAL|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
219497021|NCT02951884|PROCEDURE|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
219497022|NCT02951884|DRUG|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
219497023|NCT03433326|DRUG|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
219497024|NCT01462474|DRUG|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
218878841|NCT02599233|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
218878842|NCT02599233|OTHER|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
218878843|NCT02050087|DEVICE|Simple sling.|
218878844|NCT02050087|DEVICE|Neutral brace|
218878845|NCT00941122|DEVICE|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
218878846|NCT05845853|OTHER|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
219497025|NCT01462474|DRUG|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
219603245|NCT05680584|DRUG|Melatonin 3 MG|0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
219603246|NCT05680584|DRUG|Hydroxyzine Pill|1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
218878847|NCT01431963|DRUG|Lamictal|No comparison.
218878848|NCT02544659|DRUG|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
218878849|NCT03109184|BEHAVIORAL|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
218878850|NCT05999266|DIAGNOSTIC_TEST|Ultrasonographic Measurements|In patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
218878851|NCT05897606|COMBINATION_PRODUCT|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
218878852|NCT05897606|COMBINATION_PRODUCT|Placebo|Placebo
218878853|NCT00561288|DRUG|acetaminophen|2 x 1000 mg doses per day
218878854|NCT00561288|OTHER|cornstarch|2 x 1000 mg cornstarch per day
218878855|NCT00602420|DRUG|naproxen|Oral naproxen twice daily for 5-8 days.
218878856|NCT00602420|OTHER|placebo|Oral placebo twice daily for 5-8 days.
218878857|NCT01178268|DEVICE|XIENCE V EECSS|Patients who will receive this stent.
218878858|NCT01178268|DEVICE|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
218878859|NCT04017091|DIAGNOSTIC_TEST|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
218878860|NCT02729441|DRUG|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
218878861|NCT02729441|DRUG|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
218878862|NCT00703924|DRUG|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
218878863|NCT00703924|DRUG|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
219026099|NCT02814123|OTHER|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
219026100|NCT01729507|OTHER|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
219026101|NCT01729507|BEHAVIORAL|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
219026102|NCT04528082|DRUG|Apremilast|Participants will receive apremilast orally.
219026103|NCT04528082|DRUG|Placebo|Participants will receive the matching placebo orally.
219497026|NCT01462474|RADIATION|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
219497027|NCT02366065|DRUG|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
219497028|NCT06036654|DEVICE|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
219497029|NCT05330845|BIOLOGICAL|IL6 assessment|Blood IL6 will be assessed during trial
219497030|NCT05330845|BIOLOGICAL|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
219497031|NCT04509752|OTHER|Survey|An online survey will be sent to each clinic to answer the survey questions.
219497032|NCT02429401|BEHAVIORAL|Non-adapted brief motivational interview|1\) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
219497033|NCT02429401|BEHAVIORAL|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
219497034|NCT05178043|DRUG|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
218878864|NCT05856981|DRUG|ADU-1805|anti-SIRPα monoclonal antibody
218878865|NCT05856981|DRUG|Pembrolizumab|Keytruda
218878866|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
219026104|NCT05953454|OTHER|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
219026105|NCT03695510|DRUG|Afatinib Oral Tablet|40mg oral, daily, continuously
219026106|NCT03695510|DRUG|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
219026107|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
219026108|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
219026109|NCT04572074|OTHER|Guided imagery|10 minutes of guided imagery experience
219026110|NCT04572074|OTHER|Virtual reality|10 minutes of virtual reality experience
218878867|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
218878868|NCT01131910|BIOLOGICAL|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
218878869|NCT00323648|DRUG|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
218878870|NCT02809339|OTHER|Questionnaires|
218878871|NCT03592368|DEVICE|IBT|Interpretation bias training
218878872|NCT00772265|BIOLOGICAL|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
218878873|NCT00772265|BIOLOGICAL|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
219026111|NCT01154621|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
219026112|NCT01154621|DRUG|Placebo|Sterile 5% dextrose solution
219026113|NCT01895660|BEHAVIORAL|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
219026114|NCT00625859|DRUG|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
219026115|NCT00625859|DRUG|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
219026116|NCT00625859|DRUG|Placebo|Placebo tablets will be given to subjects.
219026117|NCT00862810|BIOLOGICAL|Received HPV vaccine first|
219026118|NCT00862810|BIOLOGICAL|Received concomitant vaccines first|
219026119|NCT01768351|DRUG|Paricalcitol|Zemplar cp 1 mcg/day per os
219026120|NCT01768351|DRUG|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
219026121|NCT02246673|DRUG|RDEA3170 15 mg|
219026122|NCT02246673|DRUG|RDEA3170 10 mg|
219026123|NCT02246673|DRUG|RDEA3170 2.5|
219026124|NCT02246673|DRUG|RDEA3170 5 mg|
219026125|NCT02246673|DRUG|Febuxostat 40 mg|
219497035|NCT05178043|DRUG|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
218878874|NCT04459377|DRUG|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
219026126|NCT02246673|DRUG|Febuxostat 80 mg|
219026127|NCT01555268|BIOLOGICAL|trebananib|Given IV
219497036|NCT05103085|DIAGNOSTIC_TEST|Rapid diagnostic orientation test (TROD) for Hepatitis C|Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
219497037|NCT02996370|OTHER|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
219026128|NCT01555268|DRUG|cytarabine|Given SC
219026129|NCT01555268|OTHER|laboratory biomarker analysis|Correlative studies
219026130|NCT01555268|OTHER|pharmacological study|Correlative studies
219497038|NCT02996370|OTHER|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
219026131|NCT02490722|OTHER|Patient education|Four times two hours group based patient education
219026132|NCT03911895|DEVICE|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
219026133|NCT03911895|DEVICE|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
219026134|NCT01199744|DRUG|zanamivir|zanamivir
219026135|NCT04567875|OTHER|No Intervention on patients|No Intervention on patients
219026136|NCT00818428|BEHAVIORAL|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
219026137|NCT00818428|BEHAVIORAL|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
219026138|NCT00818428|BEHAVIORAL|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
219026139|NCT00818428|BEHAVIORAL|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
219026140|NCT05322174|BEHAVIORAL|Baby Sleep|See arm description
219026141|NCT05322174|BEHAVIORAL|Baby Care|See arm description
219026142|NCT01909908|DEVICE|ECM|ECM in saline applied to wound
219026143|NCT01909908|BIOLOGICAL|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
219026144|NCT01909908|DEVICE|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
219200428|NCT06815731|PROCEDURE|lateral laparoscopic suspension (LLS)|lateral laparoscopic suspension (LLS)
218878875|NCT04459377|DRUG|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
218878876|NCT04010877|BIOLOGICAL|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
218878877|NCT01107665|DRUG|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
219497039|NCT02996370|OTHER|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
219497040|NCT02996370|OTHER|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
218878878|NCT05632302|DEVICE|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
219497041|NCT02996370|OTHER|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
219497042|NCT00812305|DRUG|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
219497043|NCT00812305|DRUG|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
219497044|NCT02666365|PROCEDURE|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
219497045|NCT02666365|PROCEDURE|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
219497046|NCT00724074|DEVICE|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
219497047|NCT00724074|DEVICE|Usual Care|Usual Care
219497048|NCT02234258|BEHAVIORAL|Cognitive behavioral social skills|
219497049|NCT02234258|BEHAVIORAL|Psychoeducation|
219497050|NCT01431235|BEHAVIORAL|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
219497051|NCT06105619|DRUG|PLB1001|PLB1001 is a capsule in the form of 300mg,twice daily.
219497052|NCT06105619|DRUG|Temozolomide|100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
219497053|NCT06105619|DRUG|Cisplatin combined with Etoposide|Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
219497054|NCT05081752|DEVICE|OTSC Stentfix|Stent placement with fixation of the esophageal stent using OTSC Stentfix.
219497055|NCT05081752|PROCEDURE|Stent Suturing / Endoscopic Clips|Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
219497056|NCT03779594|DRUG|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
218878879|NCT04280796|BEHAVIORAL|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
218878880|NCT04280796|BEHAVIORAL|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
218878881|NCT02035917|DEVICE|Locking plate|
218878882|NCT02035917|DEVICE|Non-Locking plate|
218878883|NCT03565016|OTHER|no interventional study|no interventional study
218878884|NCT00771888|DRUG|lanreotide|lanreotide
219026145|NCT03329495|PROCEDURE|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
219497057|NCT01187160|PROCEDURE|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
218878885|NCT02211612|DIETARY_SUPPLEMENT|PUFA-group|
218878886|NCT02211612|DIETARY_SUPPLEMENT|SFA-group|
218878887|NCT02008227|DRUG|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
218878888|NCT02008227|DRUG|Docetaxel|75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
218878889|NCT04299035|PROCEDURE|Erector spinae plane block|Erector spinae plane block
218878890|NCT03261453|DEVICE|Active Elipse Device|Intervention Device
218878891|NCT03261453|DEVICE|Elipse Sham Device|Control Device
218878892|NCT05687162|BEHAVIORAL|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
218878893|NCT05687162|BEHAVIORAL|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
218878894|NCT05687162|BEHAVIORAL|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
218878895|NCT05687162|BEHAVIORAL|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
218878896|NCT05687162|BEHAVIORAL|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
218878897|NCT05687162|BEHAVIORAL|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
218878898|NCT05687162|BEHAVIORAL|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
218878899|NCT05687162|BEHAVIORAL|Overcoming loneliness SSI 8-minute version|A shortened version of an online self-guided intervention based on principles of CBT for loneliness. The research team created this intervention by cutting lengthy didactic material and exercises from the 23-minute version, while maintaining its core concepts.
218878900|NCT00534963|PROCEDURE|cervical vs. uterine placement of balloon catheter|
218878901|NCT03727932|DEVICE|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
218878902|NCT00962325|BEHAVIORAL|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
218878903|NCT00978146|DRUG|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
218878904|NCT02347306|OTHER|Telephone interview|
218878905|NCT06078436|DEVICE|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
218878906|NCT02944786|BEHAVIORAL|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
218878907|NCT05362760|DRUG|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
219026146|NCT03329495|PROCEDURE|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
219026147|NCT06387992|OTHER|Three-dimensional dental acquisition|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
219497058|NCT04744896|DEVICE|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
219497059|NCT04744896|DEVICE|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
219497060|NCT03214458|DEVICE|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
219497061|NCT05338710|OTHER|STELLA-FTD|Behavioral intervention for caregivers for those with FTD
219497062|NCT03580759|BEHAVIORAL|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
219497063|NCT03957278|DEVICE|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
218878908|NCT05362760|DRUG|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
218878909|NCT03499314|DEVICE|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
218878910|NCT03499314|DEVICE|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
218878911|NCT03499314|OTHER|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
218878912|NCT02583295|BEHAVIORAL|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
218878913|NCT02583295|BEHAVIORAL|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
218878914|NCT03291717|BEHAVIORAL|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
219497064|NCT04627220|DIAGNOSTIC_TEST|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
219497065|NCT03700528|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
218878915|NCT00881348|DRUG|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
219497066|NCT00772252|OTHER|liver support treatment|plasma exchange for liver support treatment
219497067|NCT00618423|DRUG|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
219497068|NCT00618423|DRUG|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
219497069|NCT03172585|OTHER|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
219497070|NCT03172585|OTHER|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
219497071|NCT05986071|DRUG|M1774|• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
219497072|NCT05986071|DRUG|Fulvestrant injection|Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
219497073|NCT01507831|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
219497074|NCT01507831|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
219497075|NCT01507831|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
219497076|NCT01796431|DRUG|Eviplera®|
219603247|NCT05680584|OTHER|Placebo|10 ml apple juice 1 hour before induction of anesthesia
219603248|NCT06371911|OTHER|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
218878916|NCT01874080|DRUG|Saxagliptin/Metformin|
218878917|NCT05760768|BEHAVIORAL|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
218878918|NCT04096287|BIOLOGICAL|PNT001|PNT001 diluted in 5% dextrose
218878919|NCT04096287|DRUG|Placebo|5% dextrose
218878920|NCT04141540|GENETIC|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
218878921|NCT03813264|OTHER|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
218878922|NCT00239889|DRUG|Salmon calcitonin|
219497077|NCT05114226|DRUG|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
219497078|NCT04656522|BEHAVIORAL|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
219497079|NCT03875560|BIOLOGICAL|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
219497080|NCT03875560|DRUG|Placebo|Inactive
219497081|NCT04981405|BIOLOGICAL|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
219497082|NCT02845102|OTHER|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
219497083|NCT04862104|BEHAVIORAL|Intervention group|In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
219497084|NCT02169583|DRUG|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
219497085|NCT02169583|DRUG|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
219497086|NCT02169583|DRUG|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
219497087|NCT02169583|DRUG|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
219497088|NCT01610167|DEVICE|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
219497089|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
219497090|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
219497091|NCT06247293|PROCEDURE|intraperitoneal hyperthermic perfusion chemotherapy|"（1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding."
219497092|NCT00437437|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
219603249|NCT06371911|OTHER|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
219603250|NCT02490501|PROCEDURE|SC0806 and rehabilitation|
219603251|NCT02490501|OTHER|Rehabilitation only|
218878923|NCT05423964|DIAGNOSTIC_TEST|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
218878924|NCT05423964|OTHER|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
218878925|NCT02312297|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
218878926|NCT01271725|DRUG|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
218878927|NCT01271725|DRUG|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
218878928|NCT01271725|DRUG|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
219026148|NCT02488655|DEVICE|Echopulse|HIFU Under ultrasound guidance
219026149|NCT03344042|DRUG|Fentanyl|100mcg Fentanyl
219026150|NCT03344042|DRUG|Sufentanil|10mcg sufentanil
219026151|NCT03501758|DIAGNOSTIC_TEST|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
219026152|NCT03501758|DIAGNOSTIC_TEST|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
219497093|NCT03956511|OTHER|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
219497094|NCT02530879|DRUG|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
219497095|NCT02530879|BEHAVIORAL|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
219497096|NCT02530879|OTHER|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
219497097|NCT02693600|PROCEDURE|Ligamentoplasty with partial trapeziectomy|
219497098|NCT02693600|PROCEDURE|Ligamentoplasty with total trapeziectomy|
219497099|NCT01853007|BEHAVIORAL|COACH Program|
219497100|NCT03453502|BEHAVIORAL|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
219603252|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
219603253|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
219200429|NCT06815731|PROCEDURE|Sacropexy without posterior mesh fixation on the puborrectalis muscle|Sacropexy without posterior mesh fixation on the puborrectalis muscle
219603254|NCT05634707|DRUG|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
219603255|NCT05634707|DRUG|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
219026153|NCT02290106|DRUG|pitavastatin|
219497101|NCT05339828|PROCEDURE|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
219497102|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/vilanterol
219497103|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium
219497104|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol
219497105|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium/vilanterol
219497106|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone propionate/salmeterol
219497107|NCT03662711|DRUG|Bronchodilator Agents|Beclometasone dipropionate/formoterol
219497108|NCT03662711|DRUG|Bronchodilator Agents|Budesonide formoterol
219497109|NCT03662711|DRUG|Bronchodilator Agents|Glycopyrronium
219497110|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium
219497111|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium
219026154|NCT02290106|OTHER|PLACEBO|
219026155|NCT04829773|DRUG|Palovarotene|oral capsules
219026156|NCT04829773|DRUG|midazolam|oral syrup
219026157|NCT00954642|DRUG|bevacizumab|Intravenous repeating dose
219026158|NCT00954642|DRUG|MNRP1685A|Escalating intravenous dose
219026159|NCT00954642|DRUG|paclitaxel|Intravenous repeating dose
219026160|NCT02716558|OTHER|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
219026161|NCT02716558|OTHER|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
219026162|NCT00017264|DRUG|atrasentan hydrochloride|
219026163|NCT00417092|PROCEDURE|Postoperative Pacing|
219026164|NCT04644614|DEVICE|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
219026165|NCT02285907|OTHER|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
219497112|NCT03662711|DRUG|Bronchodilator Agents|Formoterol
219497113|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol glycopyrronium
218878929|NCT01702025|DRUG|Placebo|Yellow corn meal in gel capsules
218878930|NCT01702025|DRUG|Aminophylline|National Drug Code (NDC) 0143-1020-01
218878931|NCT01702025|DRUG|Methazolamide|NDC 0781-1072-01
219026166|NCT02285907|OTHER|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
219026167|NCT02285907|OTHER|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
219026168|NCT02285907|OTHER|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
219026169|NCT00002384|DRUG|Cidofovir|
219497114|NCT03662711|DRUG|Bronchodilator Agents|Salmeterol
219497115|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium olodaterol
219497116|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium/formoterol
219497117|NCT03662711|DRUG|Bronchodilator Agents|Olodaterol
219497118|NCT03662711|DRUG|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
219497119|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
219497120|NCT05377866|OTHER|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
219497121|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
219497122|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: intravenous
219497123|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
219497124|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
219497125|NCT02282826|DRUG|acyclovir|Pharmaceutical form:tablet Route of administration: oral
219497126|NCT05769192|OTHER|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
219497127|NCT05769192|OTHER|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
219497128|NCT04283838|BEHAVIORAL|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
219497129|NCT03105089|PROCEDURE|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
219497130|NCT04180189|OTHER|Weighted fiber blanket|Using weighted blanket for four weeks
219497131|NCT03966469|OTHER|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
219497132|NCT03966469|OTHER|Patient Present Only|Patient presents to their preoperative appointment without a support person.
219497133|NCT02112422|DRUG|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
219497134|NCT02112422|DRUG|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
219497135|NCT01315366|DIETARY_SUPPLEMENT|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
219497136|NCT01315366|DIETARY_SUPPLEMENT|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
219497137|NCT00332345|DRUG|brimonidine/timolol fixed combination|
219497138|NCT04334330|DRUG|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219497139|NCT01856231|BEHAVIORAL|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
219497140|NCT04103411|OTHER|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
219497141|NCT00193570|DRUG|Topotecan|
219497142|NCT00193570|DRUG|Docetaxel|
219603256|NCT02869802|PROCEDURE|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
218878932|NCT01702025|DRUG|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
218878933|NCT03354273|DRUG|PET MPI|Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
218878934|NCT03354273|DRUG|SPECT MPI|SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
218878935|NCT03354273|DRUG|Pharmacological stress agents|Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
219026170|NCT00405873|DRUG|AMT2003|
218878936|NCT04709445|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
218878937|NCT01484535|PROCEDURE|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
218878938|NCT01484535|PROCEDURE|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
218878939|NCT02615340|DRUG|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
218878940|NCT02615340|DRUG|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
218878941|NCT01913002|DRUG|LX4211 800 mg|
218878942|NCT01913002|DRUG|LX4211 2000 mg|
218878943|NCT01913002|DRUG|moxifloxacin 400 mg|
218878944|NCT01913002|DRUG|LX4211 Placebo|
218878945|NCT05875298|OTHER|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
218878946|NCT05875298|OTHER|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
218878947|NCT05875298|OTHER|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
218878948|NCT05494437|COMBINATION_PRODUCT|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
218878949|NCT05494437|COMBINATION_PRODUCT|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
219497143|NCT05569733|DIAGNOSTIC_TEST|simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)|All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).
219497144|NCT02866123|OTHER|ultrasonography|
219497145|NCT02866123|RADIATION|pulmonary radiography|
219497146|NCT04943055|PROCEDURE|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
219603257|NCT02869802|OTHER|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every cycle of chemotherapy or every 4 weeks, whichever is longer, until end of study.
219603258|NCT05953259|DEVICE|Combination of STERN FIX and wires|Closure of the median sternotomy using a combination of at least one STERN FIX device and wires for a total of 5 fixation points.
219603259|NCT05953259|DEVICE|Wires|Closure of the median sternotomy using the standard of care with steel wires.
219603260|NCT06171126|DIETARY_SUPPLEMENT|Placebo|By gastroscopy
218878950|NCT05494437|DRUG|Placebo|Placebo comparator
218878951|NCT05494437|DRUG|Nabilone|CB1 receptor
218878952|NCT05494437|DRUG|Gabapentin|GABAergic modulator
219026171|NCT05755009|RADIATION|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
219026172|NCT02140658|BEHAVIORAL|multiple health education interventions|
219026173|NCT02140658|BEHAVIORAL|conventional health education|
218878953|NCT04788394|OTHER|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
218878954|NCT04788394|OTHER|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
219497147|NCT04943055|PROCEDURE|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
219497148|NCT05201820|DEVICE|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
219497149|NCT00358774|PROCEDURE|homeopathic nasal spray|
219497150|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497151|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497152|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
218878955|NCT03478800|PROCEDURE|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
218878956|NCT05511571|DEVICE|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
219497153|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497154|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497155|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497156|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497157|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
219497158|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
219497159|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
219497160|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
219497161|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
219497162|NCT00899665|GENETIC|fluorescence in situ hybridization|
219497163|NCT00899665|GENETIC|microarray analysis|
219497164|NCT00899665|GENETIC|molecular diagnostic method|
219497165|NCT00899665|OTHER|immunohistochemistry staining method|
219497166|NCT00899665|OTHER|laboratory biomarker analysis|
219497167|NCT00899665|PROCEDURE|biopsy|
219497168|NCT00899665|PROCEDURE|immunoscintigraphy|
219603261|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor A|By gastroscopy
219603262|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor B|By gastroscopy
219603263|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor C|By gastroscopy
219603264|NCT03545464|DRUG|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
219497169|NCT04703725|BEHAVIORAL|Psychosocial Care|"1. First Follow-Up: One of the implementation of the module~2. Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~3. Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~4. Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~5. Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~6. Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~7. Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
219497170|NCT06352931|DEVICE|transcranial and transcranial dopp;er|"All patients will be subjected to Transcranial ultrasound examination and compared with other neuroimaging modalities: CT brain or MRI brain and/or MRA \& MRV.~Patients suspected to have ischemic or hemorrhagic disorder, CNS infection or increase intracranial pressure will be evaluated with transcranial Doppler ultrasound and compared with other neuroimaging modalities."
219497171|NCT03659968|OTHER|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
219497172|NCT01721967|DRUG|Ranolazine|
219497173|NCT03296553|DRUG|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
219497174|NCT03296553|DRUG|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
219497175|NCT05280873|DRUG|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
219497176|NCT05280873|DRUG|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
219497177|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of extended release capsules
219497178|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
219497179|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
219497180|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
219497181|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
219497182|NCT03612401|DRUG|Mirabegron|Beta-3 adenoreceptor agonist
219497183|NCT04981626|OTHER|Clinical and experimental session|"Psychologic profile with standardized interview and scales (see below for details: SCID, BDI, STAI, BPQ, EDE Q, Pictorial Body Image Scale (PBIS) and EDI).~Measure the stomach-brain synchrony during EEG/EGG resting state, the distribution of voluntary actions across the respiratory phase, and the distribution of saccadic eye movements across the cardiac-cycle."
219497184|NCT00406822|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
219497185|NCT00032708|BIOLOGICAL|Dryvax|
219497186|NCT02204683|DRUG|Aflibercept|Intravitreal aflibercept
219497187|NCT04573361|OTHER|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
219497188|NCT04573361|OTHER|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
219497189|NCT01070277|DRUG|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
219497190|NCT01070277|DRUG|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
219497191|NCT02795130|PROCEDURE|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
219497192|NCT04888260|OTHER|Laboratory parameter levels in blood samples|Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
219497193|NCT04352491|OTHER|No intervention|No intervention
219497194|NCT02713243|DRUG|LJN452|Capsules containing LJN452
219497195|NCT02713243|DRUG|Placebo to LJN452|Capsules containing placebo to LJN452
219497196|NCT01469988|DRUG|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
219497197|NCT02087228|DEVICE|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
219497198|NCT02087228|DEVICE|radiofrequency energy ablation device|
219497199|NCT00762983|DRUG|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
219497200|NCT00751153|DRUG|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
219603265|NCT03545464|DRUG|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
219497201|NCT02741362|OTHER|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
219497202|NCT02741362|OTHER|Lipoaspiration|
219497203|NCT02182258|DRUG|BIBF 1120 soft gelatine capsule|
219497204|NCT02182258|DRUG|BIBF 1120 intravenous solution|
219497205|NCT02182258|DRUG|Placebo ampoule|
219497206|NCT02888925|OTHER|Mooney test|
219497207|NCT02888925|OTHER|Benton Face Recognition test|
219497208|NCT02888925|OTHER|Face inversion effect test|
219497209|NCT02888925|OTHER|Face composite effect test|
219497210|NCT02888925|OTHER|Cambridge Face Memory Test|
219497211|NCT02888925|OTHER|Matching different view test|
219497212|NCT02888925|OTHER|Memorizing and recognition of new faces test|
219497213|NCT02888925|OTHER|Memorizing and recognition of new objects test|
219026174|NCT04211701|PROCEDURE|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
219026175|NCT04211701|PROCEDURE|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
219026176|NCT02192255|BEHAVIORAL|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
219026177|NCT05074030|BEHAVIORAL|Personalized Normative Feedback|Normative Feedback on drinking behaviors.
219603266|NCT03545464|DRUG|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
219497214|NCT02888925|OTHER|Recognition of celebrities and access to semantic information test|
219497215|NCT02888925|PROCEDURE|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
219497216|NCT01938300|DRUG|Magnesium Sulfate|
219497217|NCT01938300|DRUG|Normal saline|
219497218|NCT03951597|DRUG|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
219497219|NCT04318002|BIOLOGICAL|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
219497220|NCT05204940|BEHAVIORAL|Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Analyzing mechanisms of the LLD-dementia relationship through fMRI acquisitions and analyses, to capture the specific brain networks implicated in executive function and episodic memory decline.
219497221|NCT05204940|BEHAVIORAL|Neuropsychological Data|Neuropsychological Data, including Montreal Cognitive Assessment (MoCA), Wide Range Achievement Test-4 (WRAT-4) Reading subtest, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Delis-Kaplan Executive Function System (D-KEFS) (Color Word Interference, Trail Making and Verbal Fluency).
219497222|NCT05204940|BEHAVIORAL|Clinical Scales|Clinical scales, including the Everyday Cognition Scale (E-Cog), Global Clinical Dementia Rating (CDR), Performance Assessment of Selfcare Skills (PASS)--CIADL (Cognitive Instrumental Activities of Daily Living) Short version, Patient Health Questionnaire (PHQ-9), and Suicide Risk Assessments (Suicide Questions, Baseline Suicidal Ideation, Suicide Intent Scale, Beck Lethality Scale, Decision Outcome Inventory, Columbia-Suicide Severity Rating Scale, and High Suicide Risk Protocol).
219603267|NCT04697069|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
219603268|NCT04697069|BIOLOGICAL|Placebo|Placebo
219603269|NCT05385705|DRUG|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
219603270|NCT05385705|DRUG|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
219026178|NCT05074030|BEHAVIORAL|Coping-Motive Specific Personalized Feedback Intervention plus an Ecological Momentary Intervention (PFIcope+EMI)|An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
219026179|NCT00003733|DRUG|carboplatin|
219026180|NCT00003733|DRUG|paclitaxel|
219026181|NCT00003733|DRUG|topotecan hydrochloride|
219026182|NCT00783601|DRUG|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
219026183|NCT00783601|DRUG|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
219026184|NCT00783601|DRUG|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
219497223|NCT03901027|BEHAVIORAL|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
219497224|NCT00812227|BEHAVIORAL|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
219497225|NCT05446480|DRUG|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
219497226|NCT05446480|DRUG|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
219497227|NCT05446480|OTHER|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
219497228|NCT01677169|DIETARY_SUPPLEMENT|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
219497229|NCT01677169|DIETARY_SUPPLEMENT|Placebo|
219497230|NCT06536686|GENETIC|Silent myocardial ischemia, STEMI|Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs
219603271|NCT05385705|DRUG|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
219497231|NCT04695639|OTHER|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
219497232|NCT04695639|OTHER|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
219497233|NCT04695639|OTHER|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
219497234|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
218878957|NCT05511571|OTHER|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
218878958|NCT05511571|OTHER|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
219497235|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
219497236|NCT02527616|DEVICE|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
219497237|NCT00606268|DRUG|Micafungin|IV
219497238|NCT03145610|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
219603272|NCT05385705|BIOLOGICAL|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
219603273|NCT05385705|DRUG|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
219603274|NCT04586530|BEHAVIORAL|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
219603275|NCT04586530|BEHAVIORAL|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
218878959|NCT02585921|BEHAVIORAL|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
218878960|NCT02585921|BEHAVIORAL|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
218878961|NCT05126836|DRUG|Cilostazol 100Mg Tab|Cilostazol Twice a Day
218878962|NCT05126836|DRUG|Placebo|Placebo
218878963|NCT06455501|PROCEDURE|Ventral mesh rectopexy|Ventral mesh rectopexy is performed with a superficial peritoneal incision from the right side of the sacral promontory, extended over the right outer border of the mesorectum, towards the deepest part of pouch of Douglas, sparing the right hypogastric nerve. In women, the vagina is retracted anteriorly and a dissection of the rectovaginal septum is performed down to the pelvic floor. A strip of mesh is attached to the ventral part of distal rectum and then fixed upon the sacral promontory.
218878964|NCT05669053|BEHAVIORAL|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
218878965|NCT05669053|BEHAVIORAL|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
218878966|NCT05669053|BEHAVIORAL|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
218878967|NCT05591391|OTHER|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
219603276|NCT07123129|DRUG|SHR-7782 Injection|SHR-7782 injection.
219603277|NCT07132567|DRUG|Poteligeo 20mg|Poteligeo 20mg
218878968|NCT05591391|OTHER|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
219497239|NCT03145610|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
219497240|NCT00627627|DRUG|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
219497241|NCT03445247|OTHER|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
219497242|NCT04918537|DIETARY_SUPPLEMENT|Walnuts|30g of plain walnuts in addition to habitual food intakes
219497243|NCT06583538|OTHER|Giraffe Healthcare|"An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks"
219497244|NCT05088525|PROCEDURE|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
219497245|NCT03567330|BEHAVIORAL|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
219497246|NCT03567330|BEHAVIORAL|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
219497247|NCT05036915|PROCEDURE|Pacifier randomly|"Common Action Steps:~1. Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~2. Inclusion and exclusion criteria are evaluated.~3. Study group is determined in line with the randomization order of the newborn to be included in the study.~4. First part of the patient information and follow-up form is completed.~5. Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~\* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~1. Common procedure steps are applied.~2. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~3. Second part of the patient information and follow-up form is completed daily."
219497248|NCT05036915|PROCEDURE|Pacifier other|"Procedure Steps of the Experimental Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~  1. Common procedure steps are applied.~ 2. Pacifier is given for 5 min before each feeding.~ 3. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~ 4. Second part of the patient information and follow-up form is completed daily."
219497249|NCT05491278|DRUG|Fospropofol disodium for injection|Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
219497250|NCT05491278|DRUG|Propofol|Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
219497251|NCT03355859|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
219497252|NCT05042453|DEVICE|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
219497253|NCT04808765|PROCEDURE|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
219497254|NCT06053879|OTHER|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
219497255|NCT01563432|DRUG|Feburic®|80 mg\*1 tablet
219497256|NCT01563432|DRUG|TMX-67|40 mg\*2 tablets
219497257|NCT02740933|DRUG|Demeclocycline|
219497258|NCT02440932|DIETARY_SUPPLEMENT|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
219497259|NCT02440932|OTHER|Normal (control) diet|Breakfast, lunch and open buffet dinner
219497260|NCT05166655|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
219603278|NCT02963883|OTHER|SVO2 group / control group|
219603279|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
219603280|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
219603281|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
219603282|NCT05968326|DRUG|Autogene cevumeran|Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.
219603283|NCT05968326|DRUG|Atezolizumab|Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.
219603284|NCT05968326|DRUG|mFOLFIRINOX|mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
218878969|NCT06476353|OTHER|Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures|The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
218878970|NCT05377138|OTHER|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
219497261|NCT00202657|PROCEDURE|echocardiography|
219603285|NCT05324332|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
218878971|NCT03761238|DEVICE|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
219603286|NCT05324332|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
218878972|NCT03761238|OTHER|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
218878973|NCT05979519|BEHAVIORAL|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
218878974|NCT05979519|BEHAVIORAL|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
218878975|NCT05979519|BEHAVIORAL|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
218878976|NCT04417231|DEVICE|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
218878977|NCT01468350|DRUG|dalfampridine-ER 10mg|
218878978|NCT01468350|OTHER|Placebo|
218878979|NCT03989362|DRUG|Vopratelimab|Specified dose on specified days
218878980|NCT03989362|DRUG|Ipilimumab|Specified dose on specified days
218878981|NCT03149055|DRUG|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
218878982|NCT01554449|PROCEDURE|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
218878983|NCT01554449|PROCEDURE|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
218878984|NCT06432335|OTHER|E-Socket Monitoring|Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
218878985|NCT04440813|BEHAVIORAL|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
218878986|NCT04440813|BEHAVIORAL|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
218878987|NCT02629822|DRUG|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
218878988|NCT00741013|DRUG|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
218878989|NCT00741013|DRUG|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
218878990|NCT00741013|DRUG|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
218878991|NCT00741013|BIOLOGICAL|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
218878992|NCT02133781|BIOLOGICAL|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
218878993|NCT02133781|BIOLOGICAL|FluMist® 2009-2010 Formula|This vaccine is given intranasally
218878994|NCT00006195|DRUG|risperidone|
218878995|NCT00006195|DRUG|olanzapine|
218878996|NCT02173171|OTHER|Information collection|Q3M Information collection
219497262|NCT00227656|BIOLOGICAL|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
219497263|NCT00227656|DRUG|Capecitabine|1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
219497264|NCT04785833|DRUG|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
219497265|NCT03777787|DIETARY_SUPPLEMENT|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
219497266|NCT03777787|DIETARY_SUPPLEMENT|Water|A single intragastric administration of water
219497267|NCT00883259|DRUG|Metformin|850 mg twice daily
219497268|NCT00883259|OTHER|Placebo|Microcristallyne cellulose 1 table twice daily
219497269|NCT06562530|DEVICE|high tone power therapy|sessions are applied for 30 minutes, 3 times per week, for 3 months
219497270|NCT06562530|DEVICE|transcutaneous electrical nerve stimulation (TENS)|sessions are applied for 30 minutes, 3 times per week, for 3 months
219497271|NCT06562530|OTHER|selected physical therapy program|sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
219497272|NCT06279481|OTHER|Nonpharmacological method|Virtual reality
219497273|NCT03439293|DRUG|Ixazomib|Ixazomib capsule.
219497274|NCT03439293|DRUG|Daratumumab|Daratumumab IV infusion.
219497275|NCT03439293|DRUG|Dexamethasone|Dexamethasone tablets.
219026185|NCT00783601|DRUG|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
219026186|NCT01739582|DRUG|Androxal|
219026187|NCT02971267|OTHER|Observational|None, observational only
219026188|NCT00180895|DRUG|Rituximab|
219026189|NCT03366155|DEVICE|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
219026190|NCT03366155|DRUG|Panitumumab|6 mg/kg, IV
219026191|NCT03366155|DRUG|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
219026192|NCT03366155|DRUG|Oxaliplatin|85 mg/m2, IV
219026193|NCT03366155|DRUG|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
219026194|NCT03366155|DRUG|Irinotecan|150 mg/m2, IV
219026195|NCT03366155|PROCEDURE|HAIP installation|HAI pump installation
219026196|NCT03366155|DRUG|cetuximab|500 mg/m2, IV
218878997|NCT03322410|BIOLOGICAL|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49."
218878998|NCT02189291|PROCEDURE|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
218878999|NCT02189291|PROCEDURE|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
219026197|NCT03366155|DEVICE|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
219026198|NCT04674748|DRUG|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
218879000|NCT01771237|BEHAVIORAL|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
218879001|NCT01771237|BEHAVIORAL|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
218879002|NCT04750304|BEHAVIORAL|Application ARTHe|Patient will use ARTHe Application for 3 months
218879003|NCT02434419|DEVICE|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
219026199|NCT01557296|DIETARY_SUPPLEMENT|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
219026200|NCT01557296|RADIATION|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
219026201|NCT01557296|OTHER|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
219026202|NCT01557296|BIOLOGICAL|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
219026203|NCT01540708|DRUG|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
219026204|NCT01540708|DRUG|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
219026205|NCT01533454|OTHER|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
219497276|NCT00493181|DRUG|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
219497277|NCT00660049|DEVICE|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
219497278|NCT00660049|OTHER|SNaP|Daily use
219497279|NCT00660049|OTHER|SNaP|Daily application per protocol
219497280|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
219603287|NCT05889013|DEVICE|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
218879004|NCT02434419|OTHER|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
218879005|NCT02431078|PROCEDURE|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
218879006|NCT03454607|DEVICE|FREE robot|FREE robot to hold endoscope
218879007|NCT00193180|DRUG|Imatinib|Imatinib
218879008|NCT00193180|DRUG|Docetaxel|Docetaxel
219026206|NCT01923454|PROCEDURE|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
219026207|NCT01923454|DRUG|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
219026208|NCT01923454|PROCEDURE|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
219026209|NCT04518254|BIOLOGICAL|Blood collection|A blood sample will be collected before and after treatment administration
219026210|NCT04518254|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
219026211|NCT04518254|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
219026212|NCT04518254|BEHAVIORAL|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
219026213|NCT04518254|OTHER|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
219026214|NCT04518254|BEHAVIORAL|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
219026215|NCT04518254|DEVICE|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
219026216|NCT04518254|DEVICE|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
219026217|NCT01381133|BEHAVIORAL|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
219497281|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
219497282|NCT05912179|DIAGNOSTIC_TEST|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
219497283|NCT02991833|OTHER|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
219497284|NCT02991833|OTHER|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
219497285|NCT05429853|DIETARY_SUPPLEMENT|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
219497286|NCT04379388|BEHAVIORAL|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
219497287|NCT04128449|DIETARY_SUPPLEMENT|docosahexaenoic acid|5 dragees every 24 hours
219497288|NCT04128449|DIETARY_SUPPLEMENT|Placebo|5 dragees every 24 hours
218879009|NCT01930838|PROCEDURE|Gastric bypass operation|
218879010|NCT05643950|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
219497289|NCT01492712|DRUG|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
219497290|NCT01492712|DRUG|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
219497291|NCT00657397|DRUG|Methadone|Methadone sirup once daily
219603288|NCT04739800|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219603289|NCT04739800|DRUG|Cediranib Maleate|Given PO
219603290|NCT04739800|PROCEDURE|Computed Tomography|Undergo CT
218879011|NCT05643950|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
218879012|NCT01357551|BEHAVIORAL|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
218879013|NCT04587310|DIAGNOSTIC_TEST|Laparoscopic Sleeve Gastrectomy|bariatric surgery
218879014|NCT04522167|DRUG|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
218879015|NCT04522167|DRUG|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
218879016|NCT03698552|BIOLOGICAL|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
218879017|NCT04044339|DRUG|TD-5202|Study Drug to be administered orally
218879018|NCT04044339|DRUG|Placebo|Placebo to be administered orally
218879019|NCT01400568|DRUG|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
218879020|NCT01400568|DRUG|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
218879021|NCT00668603|DRUG|17-b-estradiol|2mg oral daily for 6 months
218879022|NCT00668603|DRUG|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
218879023|NCT00668603|DRUG|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
218879024|NCT00668603|DRUG|placebo pill + gel|placebo daily for 6 months
218879025|NCT02801565|DRUG|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
218879026|NCT01565681|DRUG|ASP1240|infusion
218879027|NCT01565681|DRUG|Placebo|infusion
218879028|NCT04800848|DEVICE|Mask|Physical Fitness is evaluated with the use of a face mask
218879029|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
218879030|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
218879031|NCT06474637|DEVICE|AEON Endoscopic Powered Stapler Handle and Reload|The AEON™ Endoscopic Stapler places two triple-staggered rows of titanium staples while simultaneously transecting between the two triple-staggered rows of staples. The size of the staples and staple line length are based on the selection of the Stapler Reload (2.0mm, 2.5mm, 3.25mm, 4.0mm, 5.0mm and 5.5mm).
218879032|NCT01107314|OTHER|Phlebotomy|Blood draws (total 48 cc blood)
218879033|NCT04346836|BEHAVIORAL|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
218879034|NCT04346836|BEHAVIORAL|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
218879035|NCT02644785|DRUG|protamine|Protamine infusion exposures
218879036|NCT01506999|BIOLOGICAL|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
218879037|NCT03090204|PROCEDURE|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
218879038|NCT01258023|BIOLOGICAL|Fluad 1x|"15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
219497292|NCT00811265|DEVICE|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
219497293|NCT05946642|DRUG|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
219603291|NCT04739800|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
218879039|NCT03529981|OTHER|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
218879040|NCT03529981|OTHER|no active intervention|No intervention will be administered
218879041|NCT03734003|DEVICE|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
218879042|NCT03734003|DEVICE|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
219603292|NCT04739800|BIOLOGICAL|Durvalumab|Given IV
219603293|NCT04739800|PROCEDURE|Echocardiography Test|Undergo ECHO
219603294|NCT04739800|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219603295|NCT04739800|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219497294|NCT05946642|DRUG|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
219497295|NCT01356186|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
219497296|NCT05408533|DEVICE|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
219497297|NCT01086735|BIOLOGICAL|donor lymphocyte infusion|Donor T-cell transduction
219497298|NCT00760188|DEVICE|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
219497299|NCT03143088|BEHAVIORAL|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
219497300|NCT00897429|PROCEDURE|laboratory biomarker analysis|Correlative studies
219497301|NCT03743675|BEHAVIORAL|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
219497302|NCT03743675|BEHAVIORAL|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
219497303|NCT00189267|DRUG|Imiquimod 5 % Cream|
219497304|NCT00447187|DRUG|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
219497305|NCT00447187|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
219497306|NCT04663269|DRUG|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
219497307|NCT04663269|DRUG|Control Test|Peritubal block - standard local analgesic administration
219497308|NCT01866683|BEHAVIORAL|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
219497309|NCT01866683|BEHAVIORAL|1 month waiting period|waiting or detraining period
219497310|NCT00035399|PROCEDURE|Acupuncture|
219497311|NCT01940237|BEHAVIORAL|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
219497312|NCT01771861|OTHER|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
219497313|NCT04857216|DEVICE|Perfusion Index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
219497314|NCT06526130|PROCEDURE|General anaesthesia|Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
219603296|NCT04739800|DRUG|Olaparib|Given PO
219603297|NCT04739800|DRUG|Paclitaxel|Given IV
219603298|NCT04739800|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
218879043|NCT04082715|DRUG|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
218879044|NCT04082715|DRUG|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
219603299|NCT04739800|DRUG|Topotecan Hydrochloride|Given IV
219603300|NCT02779855|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
219603301|NCT02779855|DRUG|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m\^2.
218879045|NCT04082715|DRUG|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
219026218|NCT01381133|BEHAVIORAL|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
218879046|NCT05672706|PROCEDURE|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
218879047|NCT02490592|OTHER|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
218879048|NCT02490592|OTHER|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
218879049|NCT00539305|DRUG|testosterone gel|50-100mg applied topically daily for six months
218879050|NCT00539305|DRUG|placebo gel|applied topically daily for six months
218879051|NCT00921843|DRUG|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
219026219|NCT01381133|BEHAVIORAL|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
219026220|NCT03370003|OTHER|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
219026221|NCT05945277|BEHAVIORAL|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
219026222|NCT06007638|DRUG|LY3876602|Administered IV.
219026223|NCT06007638|DRUG|Placebo|Administered IV.
219026224|NCT00868933|OTHER|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
219026225|NCT00868933|OTHER|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
219497315|NCT06526130|PROCEDURE|Neuraxial anaesthesia|spinal or epidural injections of local anesthetic with or without opioid
219497316|NCT02766400|BEHAVIORAL|Guided Training|
219497317|NCT02766400|BEHAVIORAL|Directed Training|
219603302|NCT06658522|DRUG|Sotatercept|Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks
219603303|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
219026226|NCT04566315|PROCEDURE|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
219497318|NCT00204932|DRUG|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
219497319|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
219497320|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
219603304|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
219603305|NCT00240279|DRUG|Rosuvastatin|
219603306|NCT00240279|PROCEDURE|aortic pulse wave velocity measurements|
219497321|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
219497322|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
219497323|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
219497324|NCT05211752|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
219497325|NCT03593772|BEHAVIORAL|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
219497326|NCT05338437|DEVICE|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
219603307|NCT01224730|DRUG|perifosine|100 mg daily
219603308|NCT01254383|DRUG|Sildenafil Tablet|Tablet, 50 mg, Single Dose
219603309|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
218879052|NCT00921843|DRUG|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
219026227|NCT06325956|DRUG|Metformin|Take metformin for six months.
219026228|NCT05194618|DIETARY_SUPPLEMENT|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
219026229|NCT05194618|DIETARY_SUPPLEMENT|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
218879053|NCT00921843|DRUG|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
218879054|NCT00921843|DRUG|Control|Subjects will not receive methadone as their intraoperative opioid.
219603310|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
218879055|NCT02930304|OTHER|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
219026230|NCT02007564|BEHAVIORAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
219026231|NCT06167993|BEHAVIORAL|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
219026232|NCT03513484|DRUG|Azacitidine|Given IV or SC
219026233|NCT03513484|OTHER|Laboratory Biomarker Analysis|Correlative studies
219026234|NCT03513484|DRUG|Nintedanib|Given PO
219026235|NCT03841734|DRUG|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
219026236|NCT05413369|DRUG|Insulin glargine/Lixisenatide|solution, by subcutaneous injection
219026237|NCT05413369|DRUG|IDegAsp|solution, by subcutaneous injection
219026238|NCT05413369|DRUG|Metformin|Tablet, orally
219026239|NCT05413369|DRUG|SGLT2 inhibitor|Tablet, orally
219026240|NCT06159140|DEVICE|MRI|In vivo MRI
219026241|NCT06460649|OTHER|Progressive relaxation techniques|Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
219026242|NCT06460649|OTHER|Benson relaxation techniques|Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
219026243|NCT02478242|DRUG|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
219026244|NCT02478242|DRUG|Normal saline|
219026245|NCT03084588|DRUG|methadone|Patients will be given methadone at induction of anesthesia
219026246|NCT03084588|PROCEDURE|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
218879056|NCT02930304|OTHER|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
218879057|NCT02930304|OTHER|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
218879058|NCT05909384|OTHER|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
218879059|NCT03979885|BEHAVIORAL|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
219026247|NCT00720057|DRUG|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
219026248|NCT00720057|DRUG|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
219026249|NCT02208856|DRUG|BIBR 796 BS|
219026250|NCT02208856|DRUG|Placebo|
219026251|NCT02208856|OTHER|high fat standardized breakfast|
219026252|NCT02735551|DRUG|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
219026253|NCT02735551|OTHER|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
219026254|NCT02735551|OTHER|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
219026255|NCT04222569|PROCEDURE|T-piece|Spontaneous breath trial with a T-piece
219026256|NCT04222569|PROCEDURE|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
219026257|NCT04222569|PROCEDURE|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
219026258|NCT02726074|DRUG|Perampanel|
219026259|NCT05063110|DRUG|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
219026260|NCT06448559|OTHER|Semi-directive interview|Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis
218879060|NCT03979885|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
218879061|NCT03979885|BEHAVIORAL|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
219026261|NCT01136304|DRUG|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
219026262|NCT06172621|PROCEDURE|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
219603311|NCT05142397|PROCEDURE|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
219603312|NCT01119365|OTHER|Bright light|Light is administered through a custom designed mask with LED lights.
219497327|NCT02224300|BEHAVIORAL|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
218879062|NCT03979885|BEHAVIORAL|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
218879063|NCT05281198|DIETARY_SUPPLEMENT|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
218879064|NCT05281198|DIETARY_SUPPLEMENT|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
218879065|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
218879066|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
218879067|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
218879068|NCT02481531|OTHER|Previously marketed infant formula|
218879069|NCT02481531|OTHER|Previously marketed formula using a similar protein|
219497328|NCT04793828|BEHAVIORAL|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
219497329|NCT03801213|DEVICE|urinary catheterization|Urinary catheterization with pain controlled
219497330|NCT03801213|PROCEDURE|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
219497331|NCT03499249|DRUG|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
219497332|NCT00089115|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219497333|NCT00089115|BIOLOGICAL|rituximab|
219497334|NCT00089115|BIOLOGICAL|sargramostim|
219497335|NCT01297569|DRUG|Ranibizumab|
219497336|NCT05365347|BEHAVIORAL|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
219497337|NCT04135456|DRUG|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
219497338|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
219497339|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
219497340|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
219497341|NCT02503566|DEVICE|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
219497342|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
219603313|NCT04966689|BEHAVIORAL|combined speech and music therapy|he telerehabilitation intervention that include both speech therapy and music therapy at the same time
218879070|NCT04899505|OTHER|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
218879071|NCT02403401|DRUG|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
218879072|NCT05660317|OTHER|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
218879073|NCT06075407|DEVICE|Assessment of fluid responsiveness by electrical cardiometry|"Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler)."
218879074|NCT03168178|DRUG|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
219026263|NCT06172621|PROCEDURE|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
219026264|NCT05861856|OTHER|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
219026265|NCT05861856|OTHER|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
219026266|NCT03064191|COMBINATION_PRODUCT|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
219026267|NCT03064191|OTHER|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
219026268|NCT02414334|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|
219026269|NCT03141242|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
219497343|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
219026270|NCT03141242|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
219026271|NCT01673451|DRUG|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
219026272|NCT01673451|DRUG|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
219026273|NCT00002091|DRUG|Pentoxifylline|
219026274|NCT06543069|DRUG|Sintilimab, Bevacizumab , Pemetrexed , Cisplatin|Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
219497344|NCT00435825|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
219497345|NCT04427930|BIOLOGICAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
219497346|NCT05991245|OTHER|Collecting datas|Blood, Tissue and Urine samples
219497347|NCT00017030|DRUG|trabectedin|
219497348|NCT02313116|DEVICE|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
219497349|NCT02476734|OTHER|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
219497350|NCT04252352|DEVICE|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
219497351|NCT00584896|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
219497352|NCT00378482|DRUG|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
219497353|NCT06701760|DRUG|Sodium Lactate|sodium lactate
219497354|NCT06701760|DRUG|placebo|infusion of sodium chloride
219497355|NCT02521831|DRUG|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
219497356|NCT02521831|DRUG|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
219497357|NCT06700941|BIOLOGICAL|HPV vaccine|"The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated."
219497358|NCT06703411|DRUG|Iron Sucrose IV|IV iron sucrose 200mg per visit
219497359|NCT06703411|DRUG|Standard Medical Therapy|Standard of care (HFrEF 4 pillars treatment)
219497360|NCT06703970|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
219497361|NCT06703970|DEVICE|Platelet Rich Plasma Joint Injection|\~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
218879075|NCT03168178|OTHER|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
218879076|NCT01431053|DRUG|aspirin|Aspirin 50mg po daily
218879077|NCT01431053|DRUG|Exemestane|Exemestane 25mg po daily
218879078|NCT01957813|BEHAVIORAL|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
218879079|NCT01957813|OTHER|Standard Health Services|Peer education and health services
219026275|NCT02555033|OTHER|Resistance training|traditional resistance training
219026276|NCT02555033|OTHER|Instability resistance training|training under unstable conditions
219026277|NCT04429893|DRUG|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
219026278|NCT04429893|DRUG|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
219026279|NCT01788670|DIETARY_SUPPLEMENT|Ethanol|
219026280|NCT01788670|OTHER|Water|
219026281|NCT00463749|DRUG|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
219026282|NCT00463749|DRUG|Placebo|NaCl as placebo
219497362|NCT06703372|OTHER|Diode Laser 980 nm, 0.2W|diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone
219497363|NCT06703372|OTHER|Placebo Diode laser|the tip of the instrument will be sealed with blue rubber to prevent the passage of light
219497364|NCT06703008|OTHER|TEE hemodynamic monitoring|Transesophageal echocardiography monitoring to guide administration of fluids, vasopressor and inotropes during liver transplantation in order to avoid hypotension.
219497365|NCT06702956|PROCEDURE|laser corticotomy|stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy
219497366|NCT06702956|PROCEDURE|Conventional tooth movement|tooth movement us done using wires and brackets
219497367|NCT06512389|DRUG|Oral solution|300 mg taken morning and evening
219497368|NCT06195267|DRUG|Sivelestat|The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
219603314|NCT04966689|BEHAVIORAL|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
218879080|NCT05137028|OTHER|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
218879081|NCT03806686|BIOLOGICAL|Placebo|Sterile normal saline
218879082|NCT03806686|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
219026283|NCT02391155|PROCEDURE|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
219026284|NCT02391155|PROCEDURE|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
219497369|NCT06195267|DRUG|Blank control|Patients only received standard treatment and care.
218879083|NCT00534547|PROCEDURE|Duodenal Exclusion|duodenal-jejunal bypass
218879084|NCT06166199|BEHAVIORAL|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
219026285|NCT05688189|DEVICE|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
219026286|NCT05662566|PROCEDURE|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
219026287|NCT00778011|DRUG|Ondansetron|dosage
219026288|NCT00778011|DRUG|Ondansetron|4 mg
219026289|NCT00778011|DRUG|Metoclopramide|10 mg IV
219026290|NCT01768481|DRUG|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
219026291|NCT01768481|DRUG|sugar pill|placebo controlled arm receives similarly looking placebo.
219497370|NCT05788237|BIOLOGICAL|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
219497371|NCT05788237|BIOLOGICAL|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
219603315|NCT04966689|BEHAVIORAL|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
219603316|NCT04557033|OTHER|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
219603317|NCT01920529|OTHER|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
218879085|NCT06418490|DEVICE|Three-dimensional visualization technology|Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step. The software is called Abdominal Medical Image 3D Visualization Software (MI-3DVS, software copyright registration number: 2008SR18798).The AR-ANS (Software Copyright No.: 2018SR840555) is an intraoperative navigation system that integrates three-dimensional visualization technology.This modification provides visual guidance for surgeons when ligating or protecting critical vascular tissues during surgery.
218879086|NCT00392730|DIETARY_SUPPLEMENT|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
219026292|NCT04263701|OTHER|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
219497372|NCT05788237|BIOLOGICAL|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
219497373|NCT05788237|DRUG|Placebo|0.9% saline for injection
218879087|NCT02166619|DEVICE|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
218879088|NCT00413036|DRUG|lenalidomide|once daily oral capsule
218879089|NCT04435275|OTHER|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
218879090|NCT04435275|OTHER|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
218879091|NCT05454657|DEVICE|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
218879092|NCT05454657|BEHAVIORAL|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
218879093|NCT05532202|BEHAVIORAL|NICU Mom and Baby Net|See arm descriptions.
218879094|NCT05532202|OTHER|NICU Developmental Awareness System|See arm description.
218879095|NCT06530368|OTHER|Calisthenic home exercise programs|Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
218879096|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
218879097|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
218879098|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
218879099|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
218879100|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
218879101|NCT00842543|DIETARY_SUPPLEMENT|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
219026293|NCT04263701|OTHER|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
219026294|NCT03713203|DEVICE|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
219497374|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
219497375|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
219497376|NCT05824975|DRUG|GI-102 subcutaneous (SC)|0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
219497377|NCT05824975|DRUG|GI-102|Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
219603318|NCT05708716|BEHAVIORAL|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
219603319|NCT05708716|BEHAVIORAL|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
219603320|NCT00507533|PROCEDURE|Continuous positive airway pressure|
219603321|NCT05981703|DRUG|BGB-26808|Planned doses administered orally as a tablet daily.
218879102|NCT00842543|DIETARY_SUPPLEMENT|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
218879103|NCT04904874|DEVICE|intense pulsed light|treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
219026295|NCT04256785|DIETARY_SUPPLEMENT|VSL#3|sachets containing probiotic
219026296|NCT04256785|DIETARY_SUPPLEMENT|Placebo|sachets containing placebo
219200430|NCT06725186|BEHAVIORAL|RELAX|The RELAX intervention is a social-emotional intervention consisting of 8 weekly, 1.5 hr sessions and a booster session 1 month and 6 months after the completion of RELAX. During the first 60 minutes of RELAX sessions, parents and adolescents meet separately; during the last 30 minutes combined parent-adolescent discussion and problem-solving activities take place. RELAX is structured such that parents learn emotion regulation/coping skills the week prior to them being taught to the adolescents. Group sessions will involve both didactics and discussion of topics including psychoeducation, basic cognitive/behavioral principles, emotional awareness, emotion regulation strategies, parent emotion socialization practices, coping skills, conflict management strategies, and communication skills.
219603322|NCT05981703|DRUG|Tislelizumab|Planned doses administered by intravenous infusion.
219603323|NCT05981703|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219603324|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
218879104|NCT01838915|DIETARY_SUPPLEMENT|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
218879105|NCT01838915|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, 20 g.
219026297|NCT00257842|PROCEDURE|Standard treatment, sham feedback and biofeedback therapy|
219026298|NCT01738854|PROCEDURE|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
219026299|NCT04043091|PROCEDURE|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
219026300|NCT04034173|DRUG|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
219026301|NCT04034173|DRUG|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
219026302|NCT04034173|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
219026303|NCT04034173|DRUG|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
219026304|NCT03623360|DIAGNOSTIC_TEST|Free breathing DCE-MRI|Free breathing DCE-MRI
219026305|NCT05769790|DIAGNOSTIC_TEST|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
219026306|NCT01413555|OTHER|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
219026307|NCT04051047|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
219026308|NCT04051047|PROCEDURE|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
219026309|NCT05130931|OTHER|Multimodal conservative treatment|"15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week)."
219026310|NCT06260007|DRUG|Tribulus terrestris|Tribulus terrestris
219026311|NCT06260007|OTHER|Placebo|Placebo
219026312|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
219026313|NCT00306605|BEHAVIORAL|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
219026314|NCT01042327|DEVICE|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
219026315|NCT01042327|DEVICE|Fresenius FX100 dialyzer|
219026316|NCT03393546|BEHAVIORAL|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
219497378|NCT05824975|DRUG|doxorubicin|Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
219497379|NCT05824975|DRUG|paclitaxel|Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
219497380|NCT05824975|DRUG|bevacizumab|Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
219497381|NCT05824975|DRUG|eribulin|Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
218879106|NCT06007820|PROCEDURE|Large Volume Thoracocentesis|Large Volume Thoracocentesis
218879107|NCT06007820|PROCEDURE|Pigtail Catheter|Pigtail Catheter
218879108|NCT05301010|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
218879109|NCT05301010|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
218879110|NCT05301010|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
218879111|NCT01486342|RADIATION|PET-CT scan|"PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
218879112|NCT03738891|DEVICE|Zeltiq CoolSculpting System alone|The CoolSculpting System will be used to perform the treatments in Cohort 3.
219497382|NCT05824975|DRUG|trastuzumab deruxtecan (T-DXd)|T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
219497383|NCT05824975|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
219497384|NCT05824975|DRUG|GI-102|Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
218879113|NCT03738891|DEVICE|Electromagnetic Muscle Stimulation alone|The EMS device(s) alone are used in Cohort 1.
218879114|NCT03738891|DEVICE|EMS followed by CoolSculping|Cohort 2 group will be treated with EMS followed by CoolSculpting
218879115|NCT03738891|DEVICE|CoolSculpting followed by EMS|Cohort 4 will be treated first with CoolSculpting, followed by EMS.
218879116|NCT00003411|DRUG|motexafin gadolinium|
218879117|NCT00003411|RADIATION|radiation therapy|
218879118|NCT00003202|DRUG|cisplatin|
218879119|NCT00003202|DRUG|gemcitabine hydrochloride|
218879120|NCT00003202|RADIATION|radiation therapy|
218879121|NCT01749878|DRUG|REGN1500|
218879122|NCT01749878|DRUG|placebo|
219026317|NCT01335581|DEVICE|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
219026318|NCT01335581|DRUG|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
219026319|NCT01899300|DEVICE|Metal Stent (WallFlex™ Esophageal RX)|
219026320|NCT02187601|DEVICE|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
219026321|NCT02187601|DEVICE|BreathID|BreathID is the name of the original Exalenz breath analyzer system
219026322|NCT03762824|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
219026323|NCT03762824|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
219026324|NCT05513495|OTHER|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
219026325|NCT05244577|DRUG|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
219026326|NCT05244577|DRUG|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
219026327|NCT05281991|DEVICE|Doppler ultrasonography|color flow Doppler ultrasonography
219026328|NCT05281991|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
219026329|NCT04675203|PROCEDURE|Tooth extraction|Tooth extraction
219200431|NCT06725186|BEHAVIORAL|Psychoeducational Materials|Infographics with information on emotion regulation development, emotion regulation strategies, and strategies for managing interpersonal conflict, including when different strategies are more or less effective will be provided to participants via email.
219200432|NCT06856356|PROCEDURE|Robot-assisted surgery|Orthopedic surgeons perform total knee arthroplasty using an orthopedic joint surgery navigation system
219200433|NCT06856356|PROCEDURE|Conventional total knee arthroplasty|Orthopedic surgeons perform total knee arthroplasty using a 4 in 1 osteotomy guide
219200434|NCT06876701|DRUG|Bevacizumab|Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
219497385|NCT03235765|DIAGNOSTIC_TEST|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
218879123|NCT00398840|DRUG|ARQ 171|
218879124|NCT01483183|DRUG|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
218879125|NCT01483183|DRUG|Placebo|Placebo dose, 10-minute constant rate IV infusion
218879126|NCT00239928|DRUG|pegaptanib sodium|1 drop per dosed eye per protocol.
218879127|NCT03971565|BIOLOGICAL|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
218879128|NCT03491514|OTHER|Test Granola|51 g Test Granola
218879129|NCT03491514|OTHER|Control Granola|54.1 Control Granola
218879130|NCT05893719|DEVICE|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
218879131|NCT05418088|BIOLOGICAL|Anti-CD19/CD20/CD22 CAR T-Cells|Given IV
218879132|NCT05418088|DRUG|Cyclophosphamide|Given IV
218879133|NCT05418088|DRUG|Fludarabine Phosphate|Given IV
218879134|NCT05418088|PROCEDURE|Echocardiography|Undergo echocardiography
218879135|NCT05418088|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219026330|NCT03352986|BIOLOGICAL|biological analysis|biological analysis will be performed in the 6 groups of patients
219026331|NCT03352986|OTHER|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
219026332|NCT01687959|OTHER|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
219026333|NCT04229615|DRUG|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
219026334|NCT04229615|DRUG|Fluzoparib|Fluzoparib Orally twice daily
219026335|NCT04229615|DRUG|Placebo|Placebo
219026336|NCT04234321|DRUG|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
219026337|NCT04234321|DRUG|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
219026338|NCT04234321|DRUG|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
219026339|NCT02090647|BEHAVIORAL|aesthetic outcome|
219026340|NCT00112593|DRUG|fludarabine phosphate|Given IV
219026341|NCT00112593|RADIATION|total-body irradiation|Undergo TBI
219026342|NCT00112593|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
219200435|NCT06876155|PROCEDURE|Arm 1: The anaesthesiologically performed, ultrasound-guided, 4 quadrant-TAP block ( a combination of a lateral with a subcostal TAP block bilaterally)|Injection of a total of 60 ml ropivacaine 0.2% into the target compartment (2x 20 ml laterally, 2x 10 ml subcostally)
219200436|NCT06876155|PROCEDURE|Arm2: The surgically performed, laparoscopic landmark-based assisted TAP block|Injection of a total of 6 x 10 ml = 60 ml ropivacaine 0.2% into the target compartment (at 3 defined puncture sides bilaterally: at the anterior axillary line at 2 different, fixed heights and at the midclavicular line subcostally)
219200437|NCT06815458|OTHER|Nursing education|Mind mapping based learning
218879136|NCT05418088|PROCEDURE|Biopsy|Undergo tissue biopsy
218879137|NCT05418088|PROCEDURE|Pheresis|Undergo apheresis
218879138|NCT05418088|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
218879139|NCT05418088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218879140|NCT02098265|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
219026343|NCT00112593|DRUG|cyclosporine|Given IV or PO
219026344|NCT00112593|DRUG|mycophenolate mofetil|Given IV or PO
219026345|NCT00112593|OTHER|laboratory biomarker analysis|Correlative studies
219026346|NCT00646529|DRUG|budesonide/formoterol (Symbicort)|
219026347|NCT00646529|DRUG|budesonide (Pulmicort)|
219026348|NCT05014750|OTHER|None intervention|There is no intervention included in this study.
219026349|NCT01320462|DRUG|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
219026350|NCT01320462|OTHER|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
219026351|NCT06202391|PROCEDURE|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
219026352|NCT06202391|PROCEDURE|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
219200438|NCT06856967|DRUG|Nirsevimab|Evaluation of drug exposure in cases and controls
219200439|NCT06783829|DRUG|SHR4394|SHR4394
219200440|NCT06269913|OTHER|FeSC|Iron/yeast complex
219200441|NCT05174650|DRUG|Atezolizumab|Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 20 cycles in total
219603325|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
219603326|NCT06983990|OTHER|No intervention (observational monitoring only)|No intervention is applied. This is an observational study evaluating the correlation between non-invasive monitoring parameters and arterial blood gas values during apnea testing.
218879141|NCT02098265|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
219026353|NCT04135833|DRUG|BPI-7711|BPI-7711 60 mg
219026354|NCT04135833|DRUG|BPI-7711|BPI-7711 180 mg
219026355|NCT04135833|DRUG|Itraconazole|Itraconazole 200 mg
219026356|NCT04135833|DRUG|Rifampicin|Rifampicin 600 mg
219026357|NCT05515757|BEHAVIORAL|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
219026358|NCT03559257|DRUG|Galcanezumab|Administered SC.
219026359|NCT03559257|DRUG|Placebo|Administered SC.
219026360|NCT06040554|OTHER|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
219026361|NCT00445159|DRUG|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
219026362|NCT03104595|DRUG|EC-18|oral administration
219603327|NCT06333236|OTHER|Food for Special Medical Purposes: Kron®|Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
219603328|NCT03340506|DRUG|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
219603329|NCT03340506|DRUG|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
218879142|NCT02098265|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
218879143|NCT02098265|OTHER|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
218879144|NCT02098265|OTHER|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
219026363|NCT03630120|DRUG|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
219026364|NCT03630120|DRUG|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
218879145|NCT02098265|OTHER|Delay|10 week delay before intervention
218879146|NCT02098265|DEVICE|BCI-FES|
219497387|NCT01284569|BIOLOGICAL|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
219497388|NCT01284569|BIOLOGICAL|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
219497389|NCT00115258|OTHER|parenteral nutrition titrated to measured REE|
219497390|NCT05721716|BEHAVIORAL|Mindfulness Booster Course|The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
219497391|NCT05721716|BEHAVIORAL|Usual care|Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
219497392|NCT01915381|OTHER|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
219603330|NCT06235281|DRUG|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
219603331|NCT06235281|DEVICE|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
219026365|NCT03630120|DRUG|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
219200442|NCT05174650|DRUG|Derazantinib|Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 20 cycles in total
219497393|NCT00343642|DRUG|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
219603332|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
219603333|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
219603334|NCT01221389|DRUG|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
219603335|NCT04146103|DRUG|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
218879147|NCT04375059|OTHER|using interactive attention training system|using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
218879148|NCT02794233|OTHER|Impedance measurements|Refer to study description
218879149|NCT04942405|BIOLOGICAL|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
218879150|NCT04942405|BIOLOGICAL|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
219603336|NCT04780178|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
219603337|NCT06578143|OTHER|Placebo|Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
218879151|NCT00208533|DRUG|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
218879152|NCT06583265|DRUG|Observational|To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
218879153|NCT06584266|DIAGNOSTIC_TEST|Transoesophageal echocardiography|Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
219026366|NCT03630120|DRUG|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
219026367|NCT00176007|PROCEDURE|Hypoxia|
219026368|NCT03617081|DRUG|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
219026369|NCT03617081|DRUG|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
219026370|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
219026371|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
219200443|NCT04198129|DRUG|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
219497394|NCT00343642|DRUG|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
219497395|NCT00343642|DIETARY_SUPPLEMENT|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
219497396|NCT05674071|BEHAVIORAL|Articulation/HVT|Osteopathy 1
219497397|NCT05674071|BEHAVIORAL|Soft-tissue massage|Osteopathy 2
219497398|NCT05674071|BEHAVIORAL|Craniosacral techniques|Osteopathy 3
219497399|NCT05674071|BEHAVIORAL|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
219497400|NCT03352219|BEHAVIORAL|Reality Check|
219497401|NCT03352219|BEHAVIORAL|Physical Activity Attention Control|
219497402|NCT05205668|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
219497403|NCT05205668|BIOLOGICAL|Placebo|Placebo administered intravenously
219497404|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus moderate intensity exercise|
219497405|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus health education|
219603338|NCT06578143|OTHER|Synbiotics|Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
219497406|NCT00205465|DRUG|VX-765|
219497407|NCT03634631|OTHER|Focused Ultrasound|Test ultrasound in 7T MRI scanner
219497408|NCT00860574|DRUG|treosulfan|Given IV
219497409|NCT00860574|DRUG|fludarabine phosphate|Given IV
219497410|NCT00860574|RADIATION|total-body irradiation|Low dose starting at 2Gy
219497411|NCT00860574|PROCEDURE|peripheral blood stem cell transplantation|Given IV per institutional standard practice
218879154|NCT06584266|PROCEDURE|Catheter ablation|Cathether ablation of atrial fibrillation substrate using one of available methods.
218879155|NCT06583967|OTHER|Physical Training|Group 1 - Elliptical Trainer Group 2 - Treadmill
218879156|NCT00661817|BEHAVIORAL|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
219497412|NCT00860574|DRUG|tacrolimus|Given IV or PO
219497413|NCT00860574|PROCEDURE|allogeneic bone marrow transplantation|Given IV per institutional standard practice
219497414|NCT00860574|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
219497415|NCT00860574|DRUG|methotrexate|Given IV
219497416|NCT01704235|OTHER|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
219497417|NCT01246986|DRUG|LY2157299|Administered orally
219497418|NCT01246986|DRUG|Sorafenib|Administered orally
219497419|NCT01246986|DRUG|Ramucirumab|Administered IV
219497420|NCT04948255|OTHER|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
219603339|NCT06855212|DRUG|Cemiplimab|Given by IV infusion.
219603340|NCT06855212|DRUG|Cetuximab|Given by IV infusion.
219497421|NCT05948436|PROCEDURE|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
219497422|NCT02006407|RADIATION|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
219497423|NCT02006407|DEVICE|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
219497424|NCT02006407|BEHAVIORAL|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
219497425|NCT01655433|DEVICE|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
219497426|NCT01655433|OTHER|No Hypothermia Treatment|
219497427|NCT02542228|OTHER|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
219497428|NCT04937751|DIAGNOSTIC_TEST|biomarkers|galactomannan, betaDglucan, resistance markers
219497429|NCT04329650|DRUG|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
219497430|NCT04329650|DRUG|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
219497431|NCT03582501|OTHER|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
219497432|NCT00045604|DRUG|cisplatin|
218879157|NCT00661817|BEHAVIORAL|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
218879158|NCT01847976|DRUG|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
218879159|NCT03082092|DRUG|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
218879160|NCT03082092|DRUG|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
218879161|NCT00896025|DRUG|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
218879162|NCT05602701|OTHER|Preoperative assessment|Preoperative assessment of physical fitness
218879163|NCT03887234|PROCEDURE|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
218879164|NCT00642161|DRUG|budesonide|
218879165|NCT00196144|DEVICE|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
218879166|NCT00196144|DEVICE|Nominal PVAB|nominal pacemaker settings
219497433|NCT00045604|DRUG|imatinib mesylate|
219497434|NCT00045604|DRUG|irinotecan hydrochloride|
219497435|NCT02845635|OTHER|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
219497436|NCT03569163|DEVICE|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
219497437|NCT00201734|DRUG|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
219497438|NCT00201734|DRUG|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
219497439|NCT00201734|DRUG|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
219497440|NCT00438958|BIOLOGICAL|filgrastim|Given on day 0.
219497441|NCT00438958|PROCEDURE|allogeneic bone marrow transplantation|Given on day 0
219497442|NCT00438958|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
219497443|NCT02624921|OTHER|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
219497444|NCT06263465|OTHER|Lactobacillus cispatus|10\^9 cfu,5 days
219497445|NCT06263465|OTHER|placebo|0 cfu,5 days
219497446|NCT02911779|PROCEDURE|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
219497447|NCT06250400|BIOLOGICAL|human histaglobulin|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
219497448|NCT06250400|BIOLOGICAL|placebo|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
219497449|NCT06250400|DRUG|Loratadine 10 Mg|orally, 10mg once a day for 4 weeks
219497450|NCT01683552|DRUG|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
219497451|NCT01683552|DRUG|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
219497452|NCT01683552|DRUG|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
219497453|NCT06217952|DRUG|SPL84|SPL84 solution for nebulization
219497454|NCT06217952|OTHER|Placebo|Placebo solution for nebulization
219497455|NCT02410070|PROCEDURE|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
219497456|NCT04551352|DRUG|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
219497457|NCT04551352|DRUG|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
219497458|NCT04551352|DRUG|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
219497459|NCT04551352|DRUG|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
219497460|NCT01335399|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497461|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497462|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497463|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497464|NCT01335399|DRUG|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497465|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497466|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219497467|NCT01416142|DEVICE|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
219497468|NCT01416142|DEVICE|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
219497469|NCT05183399|DEVICE|GORE® VIABAHN® Endoprosthesis|
219497470|NCT00003299|DRUG|cisplatin|
219497471|NCT00003299|DRUG|etoposide|
219497472|NCT00003299|DRUG|paclitaxel|
219497473|NCT02464059|DRUG|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
219497474|NCT02050607|OTHER|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
219497475|NCT05888207|DRUG|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
219497476|NCT05888207|DRUG|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
219497477|NCT03402178|DRUG|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
218879167|NCT03100058|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
218879168|NCT03100058|DRUG|Placebo|Placebo
218879169|NCT03276546|BEHAVIORAL|shared decision-making tool (SHARE-D)|questionnaire
218879170|NCT02792153|DRUG|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
218879171|NCT04357808|DRUG|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
219497478|NCT03402178|DRUG|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
218879172|NCT04357808|OTHER|Standar of care|Usual clinical care
218879173|NCT00136045|DRUG|Rotigotine|
218879174|NCT05302271|BIOLOGICAL|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
218879175|NCT05302271|DRUG|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
218879176|NCT00651638|DRUG|Treatment with ARQ 197|Treatment with ARQ 197
218879177|NCT05244083|OTHER|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
219497479|NCT03503227|DRUG|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
219497480|NCT03503227|DRUG|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
219497481|NCT05755594|PROCEDURE|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
219497482|NCT02557594|DRUG|Viread 300mg|single dose administration after 10hr fasting
219497483|NCT02557594|DRUG|DA-2802 319mg|single dose administration after 10hr fasting
219497484|NCT01698762|OTHER|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
219497485|NCT01698762|OTHER|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
219497486|NCT01698762|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
219497487|NCT01447329|OTHER|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
219497488|NCT01447329|DRUG|Standard Treatment|
219497489|NCT04261478|DEVICE|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
219497490|NCT04261478|DRUG|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
219497491|NCT05469854|DRUG|Linaprazan glurate|"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."
219497492|NCT05469854|DRUG|Placebo|Single dose, oral tablets
219497493|NCT02008331|DIETARY_SUPPLEMENT|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
219497494|NCT06530082|BIOLOGICAL|CircFam53B-219aa DC vaccine|Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.
219497495|NCT06530082|DRUG|camrelizumab|Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
219497496|NCT00820391|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
219497497|NCT00820391|BEHAVIORAL|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
219497498|NCT05148130|DIAGNOSTIC_TEST|oral glucose tolerance test|GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
219497499|NCT03209830|DRUG|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
219497500|NCT03209830|DRUG|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
219497501|NCT00150930|DEVICE|narrowband UVB phototherapy at home|
219497502|NCT02932384|BEHAVIORAL|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
219497503|NCT02932384|BEHAVIORAL|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
219497504|NCT03218410|PROCEDURE|surgical pulmonary embolectomy|
219497505|NCT03218410|COMBINATION_PRODUCT|catheter-directed thrombolysis|
218879178|NCT05244083|OTHER|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
219200444|NCT04198129|DRUG|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
219497506|NCT03036995|DRUG|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
219497507|NCT03036995|OTHER|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
219497508|NCT02112812|DRUG|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
219497509|NCT02112812|DRUG|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
219497510|NCT02112812|DRUG|Eradication therapy for Helicobacter pylori|
219497511|NCT05516212|DIETARY_SUPPLEMENT|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
219497512|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_1 supplementation|"CAFMIPS\_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
219497513|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_2 supplementation|"CAFMIPS\_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
219497514|NCT05516212|DIETARY_SUPPLEMENT|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
219497515|NCT00000512|DRUG|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
219497516|NCT00000512|DRUG|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
218879179|NCT00731146|OTHER|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
218879180|NCT00731146|OTHER|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
218879181|NCT03993522|OTHER|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
218879182|NCT06256744|OTHER|exercise|Resistance exercise
218879183|NCT01317901|DRUG|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
218879184|NCT01317901|DRUG|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
218879185|NCT01317901|DRUG|Rituximab|Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
218879186|NCT03522220|BEHAVIORAL|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
218879187|NCT03522220|BEHAVIORAL|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
219497517|NCT00000512|DRUG|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
219497518|NCT00000512|OTHER|Placebo for colestipol|Placebo for colestipol.
219497519|NCT00000512|OTHER|Placebo for lovastatin|Placebo for lovastatin
219497520|NCT04856995|OTHER|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
218879188|NCT03522220|BEHAVIORAL|No 3D navigation|Participants read on a kindle device (control group)
218879189|NCT05574088|PROCEDURE|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
218879190|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
218879191|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
219200445|NCT04198129|OTHER|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
219497521|NCT02355795|BEHAVIORAL|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
219497522|NCT02355795|BEHAVIORAL|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
218879192|NCT00544791|DRUG|melatonin|5 mg, oral, daily dose for 6 months
218879193|NCT00544791|DRUG|placebo like melatonin tablets|
218879194|NCT05385055|OTHER|THS use|N/A: No intervention was assigned.
218879195|NCT05385055|OTHER|Cigarette smoking|N/A: No intervention was assigned.
218879196|NCT05385055|OTHER|Smoking abstinence|N/A: No intervention was assigned.
218879197|NCT00000358|DRUG|Lofexidine|
218879198|NCT00098579|DRUG|alvocidib|Given IV
218879199|NCT00098579|DRUG|doxorubicin hydrochloride|Given IV
218879200|NCT03494582|PROCEDURE|Sacral Hysteropexy|Abdominal approach for uterine suspension
218879201|NCT03494582|PROCEDURE|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
218879202|NCT01561742|DRUG|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
219497523|NCT02355795|BEHAVIORAL|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
219497524|NCT01615302|PROCEDURE|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
218879203|NCT01561742|DRUG|Placebo|EquivalentPlacebo will be given
218879204|NCT00774800|DRUG|Humalog|
218879205|NCT00774800|DRUG|Humulin-R|
218879206|NCT00774800|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
218879207|NCT00774800|OTHER|Liquid meal|
218879208|NCT03914755|DRUG|Tucatinib|Administered via oral tablet
218879209|NCT01059994|DRUG|Placebo sildenafil|Oral, daily, 1 week.
218879210|NCT01059994|DRUG|Sildenafil|oral, 25mg, daily for 1 week
218879211|NCT04548804|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
218879212|NCT02780544|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
218879213|NCT02780544|DEVICE|incubator|staying in incubator during eye examination.
218879214|NCT02780544|DRUG|Sucrose|oral sucrose before eye examination
218879215|NCT01331109|DRUG|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
219026372|NCT04232072|OTHER|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
218879216|NCT02992392|DRUG|Liposic|one eye of the participant recieved Lipoic
219497525|NCT01615302|OTHER|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
219497526|NCT05692752|OTHER|No intervention|Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
219497527|NCT02060552|DRUG|Diacerein|oral administration of IL-1βinhibitory
219497528|NCT02060552|DRUG|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
219497529|NCT02060552|DRUG|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
219497530|NCT06467500|DRUG|Cadonilimab (AK104)|Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
218879217|NCT02992392|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
218879218|NCT04583332|OTHER|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
218879219|NCT04583332|OTHER|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
218879220|NCT04583332|OTHER|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
218879221|NCT03694704|DEVICE|FineHearing strategy|Cochlear implant with FineHearing strategy
218879222|NCT02779790|OTHER|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
218879223|NCT01435135|BIOLOGICAL|ALVAC-HIV|1 mL per injection containing 10\^6 CCID50/dose administered
219497531|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
218879224|NCT01435135|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
218879225|NCT01435135|BIOLOGICAL|ALVAC-HIV Placebo|1 ml per injection
218879226|NCT01435135|BIOLOGICAL|AIDSVAX B/E Placebo|1 ml per injection
218879227|NCT01558453|DRUG|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
218879228|NCT06363539|DRUG|Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION|steroid used for umblical granuloma
218879229|NCT06363539|DRUG|Silver Nitrate|silver nitrate used for treatment
219026373|NCT04232072|OTHER|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
219497532|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
218879230|NCT01882699|DEVICE|Cereve Sleep System|cerebral hypothermia
219497533|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
218879231|NCT00479856|DRUG|Lapatinib|Small molecule tyrosine kinase inhibitor
218879232|NCT00479856|DRUG|Capecitabine|Chemotherapy
218879233|NCT00479856|DRUG|Docetaxel|Chemotherapy
218879234|NCT00479856|DRUG|nab-Paclitaxel|Chemotherapy
218879235|NCT06583564|PROCEDURE|ICG lymphangiography procedure|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
218879236|NCT04521985|PROCEDURE|thoracolumbar kyphosis surgery|patients receiving surgery or not
218879237|NCT03917914|DRUG|Bisoprolol|As in arm description
218879238|NCT03917914|DRUG|Placebo Oral Tablet|As in arm description
218879239|NCT04845178|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
218879240|NCT04845178|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
218879241|NCT05888753|PROCEDURE|Adrenalectomy|Scheduled adrenal surgery
218879242|NCT00139555|DRUG|amlodipine/benazepril|
218879243|NCT06443983|OTHER|AI-supported case|In the artificial intelligence-supported case lesson, students will listen to audio and visual content prepared by artificial intelligence.
218879244|NCT04047979|BIOLOGICAL|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
218879245|NCT02293603|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
218879246|NCT02440243|DRUG|Purethal|prerseasonal course of SCIT - three years
219026374|NCT01518010|BEHAVIORAL|Play game|Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
219497534|NCT01180842|OTHER|Yoga treatment program|yoga program designed specifically for the patient with CF
218879247|NCT02440243|DRUG|Purethal -placebo|preseasonal course of SCIT - three years
218879248|NCT05037019|PROCEDURE|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
218879249|NCT05326867|DEVICE|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
218879250|NCT05326867|DEVICE|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
218879251|NCT04091243|DRUG|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
218879252|NCT00661622|DRUG|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
218879253|NCT00661622|PROCEDURE|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
218879254|NCT03012711|OTHER|Neuromuscular exercise training|
218879255|NCT06975007|DEVICE|Paro Robotic Companion Seal|Paro is an interactive robotic companion designed to simulate the behaviour of a baby harp seal. It responds to touch, light, sound, posture and temperature, providing tactile and social interaction for stress relief.
218879256|NCT06975007|DEVICE|Weighted Sensory Toy|A soft, weighted animal-shaped toy (dog) designed to provide deep pressure stimulation. Participants hold or interact with the toy for 15 minutes following a stress induction task to promote relaxation and stress reduction.
218879257|NCT06976645|PROCEDURE|Levator muscle resection|Levator muscle resection
219026375|NCT00425230|DRUG|Duloxetine|
219497535|NCT00568152|DIETARY_SUPPLEMENT|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
219497536|NCT00568152|DIETARY_SUPPLEMENT|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
219497537|NCT00568152|DRUG|Aspirin|75mg dispersable aspirin taken daily for 14 days
219497538|NCT05680311|BIOLOGICAL|measurement of serum autotaxin serum level|autotaxin expression
219497539|NCT01281878|DRUG|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
219497540|NCT02642107|RADIATION|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
219497541|NCT02642107|RADIATION|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
219497542|NCT00569283|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218879258|NCT00773773|OTHER|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
218879259|NCT04360876|DRUG|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
218879260|NCT04360876|DRUG|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
218879261|NCT04481217|OTHER|Self-questionnaires battery|"* Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
218879262|NCT04481217|OTHER|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
218879263|NCT04016259|DEVICE|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
218879264|NCT04016259|DEVICE|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
218879265|NCT05393973|OTHER|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
219026376|NCT02589574|OTHER|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
219026377|NCT00605670|BEHAVIORAL|questionnaires|patients will fill out two questionnaires post surgery
219026378|NCT00605670|BEHAVIORAL|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
219497543|NCT02505711|BEHAVIORAL|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
219026379|NCT03437720|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
219026380|NCT03437720|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
219200446|NCT06949462|OTHER|PEAR|"Participants in the intervention arm will receive anaesthesia risk counselling through the PEAR (Patient Education of Anaesthesia Risks) chatbot prior to their face-to-face consultation with an anaesthetist. PEAR is a multilingual, AI-powered conversational tool designed to provide personalized, interactive education on anaesthesia-related procedures, risks, and safety information.~The chatbot delivers content aligned with institutional guidelines and allows patients to explore topics at their own pace, ask questions in natural language, and revisit information as needed. After completing the chatbot interaction, patients proceed with their standard preoperative consultation, where any further questions are addressed by the anaesthetist.~This approach is designed to enhance patient understanding, reduce anxiety, and optimize the in-person consultation by preparing patients in advance."
219497544|NCT03187054|PROCEDURE|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
219497545|NCT00304954|DRUG|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
219497546|NCT00304954|DRUG|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
219497547|NCT00304954|OTHER|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
219497548|NCT00304954|DRUG|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
219603341|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
218879266|NCT05393973|OTHER|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
219026381|NCT01973907|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
219026382|NCT04599894|DRUG|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
219026383|NCT04599894|DRUG|75mg Pregabalin|75mg pregabalin postoperatively
219026384|NCT05302544|OTHER|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
219026385|NCT05302544|OTHER|motor activities|motor activities usually performed
219026386|NCT01067014|DEVICE|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
219026387|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
219026388|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
219026389|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
219026390|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
219497549|NCT01058382|DRUG|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
219497550|NCT01058382|DRUG|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
219497551|NCT00228540|DRUG|Modafinil|
219497552|NCT01692080|BEHAVIORAL|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
219497553|NCT04162392|OTHER|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
219497554|NCT04162392|OTHER|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
219026391|NCT02153112|DRUG|Placebo|Placebo saline solution
219497555|NCT04961229|BIOLOGICAL|The Pfizer mRNA-based BNT162b2 vaccine|"participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response)."
219497556|NCT00894465|DRUG|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
219497557|NCT00894465|DRUG|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
219497558|NCT00781131|DRUG|Pregabalin|pregabalin 75 or 150 mg
218879267|NCT02205528|DRUG|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
219497559|NCT00781131|DRUG|Placebo|lactulose placebo
219497560|NCT03990389|DEVICE|Chatbot Intervention|a chatbot will be used to monitor depression severity
219497561|NCT04133090|PROCEDURE|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
219497562|NCT04133090|PROCEDURE|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
219497563|NCT02149550|OTHER|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
219497564|NCT02149550|OTHER|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
219497565|NCT02149550|OTHER|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
219497566|NCT02149550|OTHER|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
219497567|NCT02149550|OTHER|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
219497568|NCT02149550|OTHER|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
219497569|NCT00699634|DRUG|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
218879268|NCT02205528|DRUG|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
218879269|NCT02205528|DRUG|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
218879270|NCT02205528|DRUG|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
219497570|NCT06298279|BEHAVIORAL|Tunneled Delivery|Participants will be offered a pre-determined pathway to completing the 8-week course
219497571|NCT06298279|BEHAVIORAL|Personalized Delivery|Participants will be able to complete course modules at their own pace and in the order that most interests them.
218879271|NCT03694431|OTHER|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
219497572|NCT06298279|BEHAVIORAL|Standard Resources|Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.
219497573|NCT06298279|BEHAVIORAL|Enhanced Social Learning Resources|Participants will receive additional intervention content.
219497574|NCT06298279|BEHAVIORAL|Transdiagnostic Self-Guided ICBT|An ICBT course that is completed without the guidance of a therapist.
219497575|NCT05064865|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
219497576|NCT05064865|DIETARY_SUPPLEMENT|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
219497577|NCT04340700|DRUG|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
219497578|NCT05543070|RADIATION|Low-dose radiotherapy|Electron Beam/3D-CRT/IMRT/VMAT
219497579|NCT01039285|DRUG|Curosurf|2.5 ml/kg instilled in the trachea
219497580|NCT01039285|OTHER|Air|2.5ml/kg of Air will be instilled in the trachea
219497581|NCT00410852|PROCEDURE|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
219497582|NCT00410852|PROCEDURE|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
219497583|NCT00410852|PROCEDURE|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
219497584|NCT02290028|DEVICE|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
219497585|NCT03202511|DRUG|Probenecid Oral Tablet|Included in arm/group descriptions.
219497586|NCT03202511|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
219497587|NCT00285415|DRUG|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
219497588|NCT03208933|DRUG|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
218879272|NCT03694431|OTHER|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
218879273|NCT06468020|OTHER|The Gather.town gaming intervention|The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 8 sessions and plays a game through the Gather.Town platform.
218879274|NCT03068754|DRUG|Acthar|Repository corticotropin for subcutaneous injection
218879275|NCT03068754|DRUG|Placebo|Matching placebo for subcutaneous injection
218879276|NCT02898298|BEHAVIORAL|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
218879277|NCT04046978|OTHER|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
218879278|NCT04046978|OTHER|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
218879279|NCT04046978|OTHER|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
218879280|NCT04046978|OTHER|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
219026392|NCT00198757|BEHAVIORAL|Medifast Plus for Diabetics Meal Replacement Supplements|
219026393|NCT00198757|BEHAVIORAL|Standard ADA recommended diet for type 2 diabetics|
219026394|NCT01721642|DEVICE|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
219026395|NCT03774277|BEHAVIORAL|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
218879281|NCT04046978|OTHER|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
218879282|NCT03383380|DRUG|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
218879283|NCT04311931|OTHER|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
218879284|NCT04945109|OTHER|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
218879285|NCT04945109|OTHER|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
218879286|NCT02036008|OTHER|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
218879287|NCT02036008|OTHER|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
219026396|NCT04425707|DRUG|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
219026397|NCT01736150|DRUG|Placebo|"* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
219026398|NCT01736150|DRUG|Sevelamer carbonate|"* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
219026399|NCT02176850|DRUG|Micardis®|
219200447|NCT06744504|DRUG|cytarabine|Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.
219200448|NCT06744504|DRUG|daunorubicin|combined with cytarabine and used for induction therapy
219200449|NCT06744504|DRUG|idarubicin|combined with cytarabine and cyclophosphamide and used for post-remission treatment
219200450|NCT06744504|DRUG|cyclophosphamide|combined with cytarabine and idarubicin and used for post-remission treatment
219200451|NCT06952777|OTHER|Non-adhesive capacitively-coupled sensors|Non-adhesive capacitively-coupled sensors which can detect signals of the magnitude of the fetal heart rate and information about fetal movements.
219497589|NCT03476447|OTHER|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
219497590|NCT03476447|OTHER|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
218879288|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
218879289|NCT06547073|OTHER|Virtual reality exercise training|Beat saber
218879290|NCT06547073|OTHER|Traditional exercise training|Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
218879291|NCT04194125|DRUG|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
218879292|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
219497591|NCT06529640|PROCEDURE|SCTG followed by coronally postionting flap|The SCTG will be harvested from the palate followed by coronally postionting flap
219497592|NCT06529640|PROCEDURE|periosteal flap followed by coronally postionting flap|he periosteal pedicle graft obtained is then turned over the exposed root surface then followed by coronally postionting flap
219497593|NCT04242186|OTHER|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
219497594|NCT00004161|DRUG|fenretinide|
219497595|NCT00004161|DRUG|Placebo|
219497596|NCT04537702|BEHAVIORAL|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
219497597|NCT04537702|BEHAVIORAL|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
219497598|NCT00379587|DRUG|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
219603342|NCT07000448|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|For optimal individual PEEP titration, dynamic compliance values observed on the ventilator monitor were recorded when PEEP reached 20 cmH₂O.
219603343|NCT07000448|PROCEDURE|standardized 5 PEEP|Patients in the PEEP 5 group were applied a fixed 5 cmH2O PEEP and no recruitment maneuver was performed.
219603344|NCT04083495|BIOLOGICAL|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
219603345|NCT04083495|DRUG|Bendamustine|70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
218879293|NCT03813992|DRUG|MED2005|Topical Product
218879294|NCT00656435|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
218879295|NCT03869879|OTHER|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
218879296|NCT03869879|OTHER|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
218879297|NCT01377870|BIOLOGICAL|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
218879298|NCT01377870|BIOLOGICAL|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
218879299|NCT00666965|DRUG|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
218879300|NCT02547584|PROCEDURE|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
218879301|NCT02788058|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
218879302|NCT02788058|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
218879303|NCT03752658|DRUG|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
218879304|NCT01653236|DRUG|Boceprevir|
218879305|NCT01653236|DRUG|Peginterferon alfa-2b|
218879306|NCT01653236|DRUG|ribavirin|
219200452|NCT02267993|DRUG|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
219200453|NCT04244175|DRUG|Placebo|Participants received CVL-865 matched placebo tablets orally twice a day (BID) during the Treatment Period.
218879307|NCT01340599|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given PO
218879308|NCT01340599|OTHER|placebo|Given PO
218879309|NCT01340599|OTHER|immunohistochemistry staining method|Correlative studies
218879310|NCT01340599|OTHER|immunoenzyme technique|Correlative studies
218879311|NCT01340599|OTHER|questionnaire administration|Ancillary studies
218879312|NCT01340599|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
218879313|NCT01340599|OTHER|high performance liquid chromatography|Correlative studies
218879314|NCT01340599|OTHER|mass spectrometry|Correlative studies
218879315|NCT02207959|DRUG|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
218879316|NCT02207959|PROCEDURE|White-light examination|standard white light examination
218879317|NCT02207959|PROCEDURE|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
218879318|NCT02533895|BIOLOGICAL|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
219200454|NCT04244175|DRUG|CVL-865|Participants received CVL-865 tablets orally twice a day (BID) up to the maximum dose of 7.5 mg BID or 25 mg BID during the Treatment Period.
219026400|NCT06404606|COMBINATION_PRODUCT|Black cumin and turmeric with Quantum Acoustic Waves (QAW)|Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
219026401|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
219026402|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
219026403|NCT05838885|DRUG|rhGH|rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
219026404|NCT05838885|DRUG|rhGH|rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
219026405|NCT03330522|OTHER|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
219497599|NCT00379587|DRUG|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
219497600|NCT00534092|DEVICE|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
219497601|NCT03808220|BEHAVIORAL|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
219497602|NCT03808220|BEHAVIORAL|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
219497603|NCT03808220|BEHAVIORAL|Side effect|investigate the presence of any side effect
219497604|NCT04146220|DRUG|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
219497605|NCT06527976|DRUG|Dexmedetomidine|dexmedetomedine added to bupivacaine for adductor canal block
219497606|NCT06527976|DRUG|Dexamethasone|dexamethasone added to bupivacaine for adductor canal block
219497607|NCT00628394|DRUG|Atomoxetine|40mg 2po qam
219497608|NCT00628394|DRUG|Placebo|40mg 2po qam
219497609|NCT05999981|PROCEDURE|Transversalis Fascia Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance between transversus abdominis muscle and transversalis fascia bilaterally
219497610|NCT05999981|PROCEDURE|Transversus Abdominis Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally
219497611|NCT02323295|RADIATION|Radiation (Surgical Arm)|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
219497612|NCT02323295|RADIATION|Radiation (Non-surgical Arm)|Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
219497613|NCT02323295|PROCEDURE|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
219497614|NCT00830063|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
219497615|NCT00830063|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
219603346|NCT04083495|DRUG|Fludarabine|30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
219603347|NCT04083495|DRUG|Cyclophosphamide|300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
219026406|NCT03330522|OTHER|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
219026407|NCT00130221|DRUG|2% chlorhexidine gluconate impregnated cloth|
219026408|NCT00130221|OTHER|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
219026409|NCT02692599|BIOLOGICAL|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
219026410|NCT02692599|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
219497616|NCT00830063|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
219497617|NCT00830063|OTHER|placebo|placebo to match tanezumab and naproxen dosing
219497618|NCT03011463|DRUG|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
219497619|NCT03011463|DRUG|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
219497620|NCT03011463|DRUG|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
219497621|NCT03011463|DRUG|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
219497622|NCT00380913|DRUG|Cesamet™ (nabilone)|
219497623|NCT02459613|DRUG|99mTc-Annexin V-128 SPECT|
219026411|NCT02154191|PROCEDURE|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
219026412|NCT05783362|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
219026413|NCT01709851|DEVICE|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
219603348|NCT07002060|BIOLOGICAL|Yellow fever vaccine (live)|Powder and solvent for solution for injection Subcutaneous
219026414|NCT01709851|DEVICE|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
219026415|NCT04392297|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
219026416|NCT04392297|DIAGNOSTIC_TEST|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
219026417|NCT04392297|DIAGNOSTIC_TEST|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
219200455|NCT06281756|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Subjects will receive therapy for 8 weeks
219497624|NCT04562584|DEVICE|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
219497625|NCT03253978|RADIATION|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
219497626|NCT05146466|BEHAVIORAL|E-MATVR|It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
219497627|NCT05146466|BEHAVIORAL|E-MATE|It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
219497628|NCT01155063|OTHER|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
219497629|NCT01314703|DRUG|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
219497630|NCT01314703|DRUG|70% isopropyl alcohol|10.5 ml applicator
219497631|NCT03504332|PROCEDURE|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
219497632|NCT05547815|BIOLOGICAL|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
219497633|NCT03797976|DEVICE|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
219497634|NCT03872960|PROCEDURE|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
219497635|NCT06012591|OTHER|Quality improvement recommendations (action plans)|Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
219497636|NCT04303494|BIOLOGICAL|immunisation|combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
219497637|NCT01551550|PROCEDURE|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
219497638|NCT01551550|PROCEDURE|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
219497639|NCT01551550|PROCEDURE|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
219497640|NCT00881959|DEVICE|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
219497641|NCT04917900|DRUG|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
219497642|NCT03094806|DEVICE|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
219497643|NCT03094806|DEVICE|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
219200456|NCT06281756|DRUG|Trazodone|Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
219497644|NCT02476552|DRUG|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
219497645|NCT02476552|DRUG|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)
219603349|NCT07002060|BIOLOGICAL|YF vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
219603350|NCT04025203|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
219200457|NCT06281756|OTHER|Placebo|Non-remitting subjects will receive placebo for 8 weeks
219603351|NCT04025203|DRUG|Ibuprofen Arginine|Oral tablets
219497646|NCT02476552|DRUG|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
219497647|NCT06404697|RADIATION|Boost irradiation|High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
218879319|NCT02533895|OTHER|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
218879320|NCT05551884|PROCEDURE|Metabolites and HVPG|"HVPG measurement are performed by well-trained interventional radiologists in accordance with standard operating procedures.~All enrolled patients were analyzed for potential differential metabolites using metabolomics."
218879321|NCT04569357|DRUG|Prospekta|Oral administration.
219497648|NCT01780727|PROCEDURE|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
218879322|NCT04569357|DRUG|Placebo|Oral administration.
218879323|NCT03698656|BEHAVIORAL|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
218879324|NCT03845959|DRUG|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
218879325|NCT03845959|DRUG|Placebo oral capsule|Placebo
218879326|NCT00952900|BEHAVIORAL|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
218879327|NCT00952900|BEHAVIORAL|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
218879328|NCT01554800|DRUG|ACP-501|A single dose infusion
218879329|NCT03854383|DRUG|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
218879330|NCT03854383|DRUG|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
218879331|NCT05333380|DEVICE|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
218879332|NCT01267526|DEVICE|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
218879333|NCT02939768|OTHER|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
218879334|NCT02939768|OTHER|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
218879335|NCT02939768|OTHER|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
219200458|NCT06420440|PROCEDURE|Hepatic arterial infusion chemotherapy|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
219497649|NCT02189876|BEHAVIORAL|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
219497650|NCT02189876|BEHAVIORAL|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
219497651|NCT01363791|OTHER|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
219497652|NCT00180830|DRUG|Glivec|
218879336|NCT00665964|DEVICE|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
218879337|NCT00665964|DEVICE|N2Vac polethylene|conventional polyethylene
218879338|NCT02828332|OTHER|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
218879339|NCT02828332|OTHER|Quality of life|Evaluation of the quality of life and comorbidities
218879340|NCT01623388|PROCEDURE|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
218879341|NCT02697188|DRUG|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
218879342|NCT02697188|DRUG|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
219497653|NCT00180830|DRUG|Gleevec|
219497654|NCT00460473|DRUG|Dexmedetomidine|
219497655|NCT00460473|DRUG|Placebo|
218879343|NCT05406102|DRUG|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
219497656|NCT06245616|DIETARY_SUPPLEMENT|Consumption of olive pomace olive oil by alzheimer's patients|Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
219497657|NCT06245616|DIETARY_SUPPLEMENT|Consumption of high-oleic sunflower oil by alzheimer's patients|Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
219497658|NCT03557710|BEHAVIORAL|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
219497659|NCT02770716|DRUG|Terlipressin|Terlipressin solution for injection
219497660|NCT02770716|OTHER|Placebo|Matching placebo solution for injection
219497661|NCT01725113|DRUG|Calcitriol|3 times weekly
219497662|NCT01725113|DRUG|Paricalcitol|3 times weekly
219497663|NCT04697355|DIETARY_SUPPLEMENT|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
219497664|NCT05269719|PROCEDURE|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
219497665|NCT04200703|OTHER|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
219497666|NCT02918838|BEHAVIORAL|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
219497667|NCT02918838|BEHAVIORAL|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
219497668|NCT02918838|BEHAVIORAL|Control Group|
219497669|NCT01710852|DRUG|ISIS CRP Rx|
219497670|NCT01710852|DRUG|Placebo|
219497671|NCT00861237|DRUG|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
219497672|NCT00861237|DRUG|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
219497673|NCT03989115|DRUG|RMC-4630|RMC-4630 for oral administration
219603352|NCT04025203|DRUG|Gabapentin|oral capsules
219603353|NCT04387656|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219497674|NCT03989115|DRUG|Cobimetinib|Cobimetinib for oral administration
219497675|NCT03989115|DRUG|Drug: Osimertinib|Osimertinib for oral administration
219603354|NCT04387656|OTHER|Data Collection|Undergo collection of medical information and imaging
218879344|NCT05406102|DRUG|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
218879345|NCT06432504|OTHER|Caffeine content|Participants will drink the same volume of coffee with different amounts of caffeine.
218879346|NCT01247194|DRUG|PPI-461|capsule, oral, once daily for 3 days
219497676|NCT00077688|DRUG|TOCOSOL Paclitaxel|
219497677|NCT01777685|DRUG|Sulpiride|
219497678|NCT03230032|DEVICE|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
219497679|NCT05559554|DRUG|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
219497680|NCT05559554|DRUG|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
219497681|NCT03367026|DRUG|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
219497682|NCT02135874|DRUG|Clofarabine|Given IV
219497683|NCT02135874|DRUG|Cytarabine|Given IV
219497684|NCT02135874|DRUG|Dexamethasone|Given IV
218879347|NCT01247194|DRUG|Placebo|capsules, oral, once daily for 3 days
218879348|NCT01124955|OTHER|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
219497685|NCT02135874|DRUG|Idarubicin|Given IV
219497686|NCT02135874|BIOLOGICAL|Rituximab|Given IV
219497687|NCT02135874|DRUG|Sorafenib|Given PO
219497688|NCT02135874|DRUG|Sorafenib Tosylate|Given PO
219603355|NCT04387656|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
218879349|NCT01124955|OTHER|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
219603356|NCT04387656|OTHER|Questionnaire Administration|Complete quality of life questionnaires
219026418|NCT05884047|DEVICE|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
219026419|NCT04484363|DRUG|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
219026420|NCT04484363|DRUG|Azacitidine|Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
219603357|NCT06417216|BEHAVIORAL|Head-cancelled virtual reality|Scene in virtual reality moves with the head while performing visual tasks.
219200459|NCT06420440|DRUG|Lenvatinib|Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
219497689|NCT02135874|DRUG|Vincristine|Given IV
219497690|NCT02135874|DRUG|Vincristine Sulfate|Given IV
219603358|NCT07133373|OTHER|Turkish Coffee (unfiltered, boiled)|Standardized Turkish coffee (unfiltered and boiled) was administered once daily for 4 weeks. Each serving was approximately 75 mL, prepared using a consistent protocol without added sugar or milk. The coffee was sourced from the same batch and brewed in a traditional cezve. Compliance and adverse effects were monitored throughout the intervention.
219603359|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 1|55/ 59,4 Gy (intermediate / high risk group)
219603360|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 2|48,4/ 55 Gy (intermediate / high risk group)
219603361|NCT03396718|RADIATION|Standard radio(chemotherapy)|60/ 66 Gy (intermediate / high risk group)
219603362|NCT07133386|DEVICE|transcatheter edge to edge repair|Implantation of a tricuspid transcatheter edge to edge device
219603363|NCT07133386|DEVICE|Placebo|placebo
219603364|NCT06681051|DEVICE|OSTENIL® TENDON|OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.
219603365|NCT06680921|DRUG|SIM0270|Experimental
218879350|NCT02891382|BEHAVIORAL|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
218879351|NCT02891382|BEHAVIORAL|Goal setting|Goals for weight loss and change in levels of HbA1c
218879352|NCT02891382|BEHAVIORAL|Companion Support|Patient has a companion/team support partner to support achieving goals.
218879353|NCT02891382|BEHAVIORAL|Individual Reward|The cash reward is given to the patient with diabetes.
218879354|NCT02891382|BEHAVIORAL|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
218879355|NCT04233619|DIAGNOSTIC_TEST|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
218879356|NCT00395421|DRUG|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
219603366|NCT06680921|DRUG|Everolimus (Afinitor®)|Experimental and Active comparator
219603367|NCT06680921|DRUG|Exemestane tablets|Active Comparator
219603368|NCT06680921|DRUG|Fulvestrant injection|Active Comparator
219603369|NCT07005713|DRUG|BGB-16673|Administered orally
219603370|NCT07005713|DRUG|Placebo|Administered orally
219603371|NCT07006311|DEVICE|Robotic-assisted bronchoscopy under propofol|In this study, patients will undergo a robotic-assisted bronchoscopy under moderate sedation with propofol. While the use of propofol as a sedative is common for manual bronchoscopies, robotic-assisted bronchoscopy is only permitted under general anesthesia. In the study intervention, the investigators want to test the feasibility of the combination of robotic-assisted bronchoscopy under propofol.
219603372|NCT01906515|DEVICE|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
219603373|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
218879357|NCT05709639|OTHER|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
219497691|NCT00542516|DRUG|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
219497692|NCT00542516|DRUG|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
219497693|NCT04417790|DIAGNOSTIC_TEST|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
219603374|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
219603375|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from fiber-reinforced composite resin|Bilateral OT extracoronal attachments will be milled from fiber-reinforced composite resin after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
219026421|NCT06155942|PROCEDURE|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
219026422|NCT03925740|DRUG|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
219026423|NCT03925740|DRUG|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
219026424|NCT03925740|DRUG|1.23% APF|Standard 1.23% APF application
219026425|NCT03594279|BEHAVIORAL|Community Mobilization|Community Mobilization
219497694|NCT04259411|DEVICE|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
218879358|NCT02736981|BEHAVIORAL|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
218879359|NCT02736981|BEHAVIORAL|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
218879360|NCT02736981|BEHAVIORAL|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
218879361|NCT05229029|DRUG|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
218879362|NCT05229029|DRUG|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
218879363|NCT00644111|DRUG|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
218879364|NCT00644111|DRUG|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
219497695|NCT05775809|DRUG|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
219497696|NCT05775809|DEVICE|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
218879365|NCT03555682|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
218879366|NCT03555682|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
218879367|NCT06293313|PROCEDURE|Mindfulness training|Before starting the study, an appointment will be made to meet with the students participating in the mindfulness group with randomization on the specified day and time. The students and the researcher will meet in a quiet, calm room of the school. Students will be informed about the practice of mindfulness and their written and verbal consents will be obtained before participating in the study. Then, a pre-test will be applied to the students who agree to participate in the study.
218879368|NCT06293313|OTHER|Will not be given any application|Before starting the research, the students in the control group determined by the randomization method will be informed about the research. Written and verbal consent will be obtained from the students that the students agree to participate in the research. Afterwards, students will meet in a quiet and calm room of the school on the specified day and time. Before starting the research, students will be given a pre-test. A mid-term test will be performed 8 weeks after the pre-test.
218879369|NCT02561221|BEHAVIORAL|Lifestyle Counseling|"Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
219026426|NCT03594279|BEHAVIORAL|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
219200460|NCT06420440|DRUG|Tislelizumab|Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
219497697|NCT02655354|BEHAVIORAL|Motivational Interviewing|
219497698|NCT02655354|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
219497699|NCT02655354|BEHAVIORAL|Care Management|
219497700|NCT02655354|DRUG|Fluoxetine|Anti-depressant
219497701|NCT02655354|DRUG|Fluvoxamine|Anti-depressant
219497702|NCT02655354|DRUG|Paroxetine|Anti-depressant
219497703|NCT02655354|DRUG|Sertraline|Anti-depressant
219497704|NCT02655354|DRUG|Citalopram|Anti-depressant
219497705|NCT02655354|DRUG|Venlafaxine|Anti-depressant
219497706|NCT02655354|DRUG|Duloxetine|Anti-depressant
219497707|NCT02655354|DRUG|Mirtazapine|Anti-depressant
219497708|NCT02655354|DRUG|Diphenhydramine|Sleep medication
219603376|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from porcelain-fused to metal|Bilateral OT attachments manufactured from porcelain fused to metal by conventional technique after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
219603377|NCT04645862|DIAGNOSTIC_TEST|CT scans|4D CTA imaging
219497709|NCT02655354|DRUG|Trazodone|Sleep medication
219497710|NCT02655354|DRUG|Prazosin|Sleep medication
219497711|NCT03287466|DRUG|Oxygen|targeted oxygen therapy
219603378|NCT07009704|BEHAVIORAL|Mobile-based social support|Participants will be invited to join an encrypted group chat where they will be encouraged to provide and receive social support related to glucose management during early pregnancy. Other study participants and study team members will be in the group chat.
219497712|NCT01808209|DEVICE|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
219497713|NCT01808209|DEVICE|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
219497714|NCT01465776|OTHER|laboratory biomarker analysis|Correlative studies
219497715|NCT01465776|OTHER|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
219497716|NCT00947063|DRUG|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
219497717|NCT00947063|DRUG|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
218879370|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
219026427|NCT03314155|DIAGNOSTIC_TEST|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
219026428|NCT01423487|DRUG|Metformin|0.5g bid 26 weeks
219497718|NCT01987284|DRUG|SER100|
219497719|NCT01987284|DRUG|Placebo|
219497720|NCT05768828|DIAGNOSTIC_TEST|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
219497721|NCT02786498|DRUG|Vitamin D3|
219497722|NCT02786498|OTHER|Placebo|
219026429|NCT01423487|OTHER|Starch tablets|0.5g bid 26 weeks
219026430|NCT01754844|DRUG|AZD7624|Single dose inhaled IMP via a nebulizer
219026431|NCT01754844|DRUG|Placebo to match|Single dose inhaled Placebo via a nebulizer
219026432|NCT03194555|DRUG|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
219026433|NCT03194555|DRUG|Placebo|Twice daily
219497723|NCT04877392|DIETARY_SUPPLEMENT|Lavender essential oil|Use of inhaled lavender essential oil
219497724|NCT05812105|OTHER|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
219497725|NCT01749176|BEHAVIORAL|SMS texting intervention|
219497726|NCT01749176|BEHAVIORAL|Control-Usual Care|
219497727|NCT00003557|DRUG|dolastatin 10|
219497728|NCT02783391|DEVICE|ECoG and intracortical electrodes|
219497729|NCT06047158|DRUG|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
219497730|NCT06529315|OTHER|Point-of-Care Ultrasound|The investigators will use point-of-care ultrasound to exam participants including lungs, heart, liver, spleen, kidney and bladder, etc.
219497731|NCT05033223|OTHER|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
219497732|NCT05940870|DEVICE|Nerivio|Patients with migraine who received the Nerivio device for migraine prevention therapy
219497733|NCT06312774|OTHER|This is observational study|This is observational study
219497734|NCT03263871|DIETARY_SUPPLEMENT|PTM202|PTM202 given twice daily for 30 days.
219497735|NCT03263871|DIETARY_SUPPLEMENT|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
219497736|NCT05959369|DIAGNOSTIC_TEST|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
219497737|NCT02145403|DRUG|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
219497738|NCT02145403|DRUG|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
219497739|NCT06272851|DEVICE|optical coherence tomography|measuring choroidal thickness using optical coherence tomography
219497740|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
219497741|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
219497742|NCT00918632|DRUG|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
218879371|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
218879372|NCT05670418|DEVICE|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
218879373|NCT02592460|OTHER|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
218879374|NCT02592460|OTHER|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
218879375|NCT04869306|DEVICE|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
218879376|NCT04869306|DEVICE|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
218879377|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
218879378|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
218879379|NCT05413148|OTHER|Placebo|Single Subtenon injection of saline for a single eye
218879380|NCT05090852|DEVICE|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
218879381|NCT05492864|PROCEDURE|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
218879382|NCT01496820|DIETARY_SUPPLEMENT|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
218879383|NCT01496820|DIETARY_SUPPLEMENT|Placebo|placebo 1500mg/day for 12weeks
218879384|NCT02841241|DRUG|Esmolol|Esmolol infusion
218879385|NCT04501796|DRUG|Double-Blind NT-I7|Administered by intramuscular (IM) injection
218879386|NCT04501796|DRUG|Double-Blind Placebo|Placebo
218879387|NCT00148941|BIOLOGICAL|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
218879388|NCT00148941|BIOLOGICAL|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
218879389|NCT00148941|BIOLOGICAL|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
218879390|NCT00148941|BIOLOGICAL|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
218879391|NCT00148941|BIOLOGICAL|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
218879392|NCT00148941|BIOLOGICAL|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
218879393|NCT02736565|BIOLOGICAL|pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex|"Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks."
218879394|NCT00011622|DEVICE|Continuous ambulatory subcutaneous glucose monitor|
218879395|NCT03244826|OTHER|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
218879396|NCT03244826|OTHER|Standard Care|The usual care provided by the transplant center at DFCI.
218879397|NCT03051919|OTHER|observation|
218879398|NCT04764318|BEHAVIORAL|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
218879399|NCT04764318|BEHAVIORAL|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
218879400|NCT02668913|OTHER|Diagnostic analysis|Molecular profiling
218879401|NCT00051896|DRUG|GBR 12909|
219497743|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
218879402|NCT03080636|OTHER|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
218879403|NCT03080636|OTHER|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
218879404|NCT03080636|OTHER|Control session|30 minutes seated resting
219026434|NCT03831347|BEHAVIORAL|Hatha Yoga|12 weeks of Hatha Yoga
218879405|NCT06143982|BEHAVIORAL|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
218879406|NCT05571020|OTHER|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
218879407|NCT02971553|DEVICE|Upright Resuscitator with PEEP|
218879408|NCT02971553|DEVICE|Upright Resuscitator|
218879409|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
218879410|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
218879411|NCT00166530|DRUG|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
218879412|NCT00166530|DRUG|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
218879413|NCT00166530|DRUG|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
218879414|NCT04369157|PROCEDURE|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
218879415|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
218879416|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
218879417|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
218879418|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
218879419|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
218879420|NCT00025246|DRUG|imatinib mesylate|Given orally
219497744|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
219026435|NCT00642239|DRUG|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
219026436|NCT00642239|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
219026437|NCT05537077|OTHER|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
219026438|NCT05537077|OTHER|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
219497745|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
219497746|NCT03716102|DEVICE|PCI with implantation with DES|PCI with implantation with DES
219603379|NCT07009704|BEHAVIORAL|Real-time continuous glucose monitoring|Participants will receive a real-time continuous glucose monitor that pairs with an existing smartphone app that shows minute-by-minute glucose levels and records glucose levels in 5 minute increments.
219603380|NCT06873451|PROCEDURE|Surgery First|One month after surgery, patients were called for an appointment and lower and upper brackets were placed. Treatment was completed when right-left Class I canine and molar relationships and ideal overjet and overbite relationships were achieved.
218879421|NCT00025246|OTHER|laboratory biomarker analysis|Correlative studies
218879422|NCT02387008|DEVICE|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
218879423|NCT02387008|DEVICE|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
218879424|NCT02387008|DEVICE|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
218879425|NCT06166108|DRUG|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
218879426|NCT03959917|PROCEDURE|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
219026439|NCT05537077|OTHER|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
219026440|NCT02677987|DEVICE|Intervention systematic light exposure|Bright light using Litebook device.
219026441|NCT02677987|DEVICE|Comparison systematic light exposure|Dim light using modified Litebook device.
219497747|NCT01792856|OTHER|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
219497748|NCT01792856|OTHER|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
219603381|NCT06873451|PROCEDURE|Surgery Early|The patients were directed to surgery with the upper and lower bonds applied at their first appointment and the brackets in their mouths. After surgery, treatment continued until the right-left Class I canine and molar relationship and the ideal overjet and overbite relationship were achieved.
219603382|NCT07013201|DRUG|Delgocitinib cream|Topical application
219603383|NCT07013201|DRUG|Vehicle cream|Topical application
219603384|NCT06684847|BIOLOGICAL|Efgartigimod PH20 SC|subcutaneous efgartigimod PH20 SC given by prefilled syringe
219603385|NCT06684847|OTHER|Placebo PH20 SC|subcutaneous placebo PH20 SC given by prefilled syringe
218879427|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
218879428|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
218879429|NCT04294836|DRUG|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
218879430|NCT04294836|DRUG|Placebo oral tablet|PLACEBO Capsules 500mg
218879431|NCT00094848|DRUG|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
218879432|NCT04770948|DEVICE|19 gauge needle|EBUS-TBNA performed using 19G needle
219026442|NCT03006744|BEHAVIORAL|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
219026443|NCT03006744|BEHAVIORAL|Reading enjoyment training|Training on how to make reading enjoyable for children.
219026444|NCT01531712|DRUG|Gemcitabine|1000mg/m2 / / 40mg/m2
219026445|NCT01531712|RADIATION|Radiotherapy|50.4 Gy
219026446|NCT01531712|DRUG|Tarceva|100mg/day
219026447|NCT01531712|DRUG|Oxaliplatin|100mg/m2 (only in QT)
219603386|NCT07016412|DRUG|Ensifentrine 3 mg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
219603387|NCT07016412|DRUG|Glycopyrrolate 21.25 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
219603388|NCT07016412|DRUG|Glycopyrrolate 42.5 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
219603389|NCT07016412|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
218879433|NCT04770948|DEVICE|22 gauge needle|EBUS-TBNA performed using 22G needle
219026448|NCT06039423|PROCEDURE|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
219026449|NCT06039423|DRUG|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
219026450|NCT02968303|DRUG|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
219200461|NCT06420440|PROCEDURE|Liver resection|Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
219200462|NCT06420440|DRUG|Tislelizumab|Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
219200463|NCT04595331|DEVICE|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
219603390|NCT06619587|DRUG|Phase I Arm A|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
219603391|NCT06619587|DRUG|Phase I Arm B|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
219603392|NCT07018050|DRUG|QLS32015|QLS32015 will be administered subcutaneously
219603393|NCT07018050|DRUG|Pomalidomide|Pomalidomide will be self-administered as a single dose orally
219200464|NCT03710772|DRUG|Cyclophosphamide|Given IV
219200465|NCT03710772|DRUG|Cytarabine|Given IV
219603394|NCT07018050|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously
219603395|NCT07018050|DRUG|QL2109 or Daratumumab|QL2109 or Daratumumab will be administered subcutaneously.
219603396|NCT07018050|DRUG|Bortezomib|Bortezomib will be administered subcutaneously
219603397|NCT07018050|DRUG|Lenalidomide|Lenalidomide will be self-administered as a single dose orally
219603398|NCT06873867|DEVICE|High Purity Type-I Collagen based Skin Substitute|In this wound care is covering with High Purity Type-I Collagen based Skin Substitute followed by a layer of non-adherent and porous dressing. After 5-7 days, wound examined and procedure is repeated as needed
219603399|NCT06873867|DEVICE|Negative Pressure Wound Therapy|In this wound care is by application of Negative Pressure Wound Therapy using a standard polyurethane foam. The NPWT will be removed after 5-7 days, wound examined and procedure is repeated as needed
218879434|NCT01423266|PROCEDURE|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
219026451|NCT05387733|DRUG|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
219026452|NCT05387733|DRUG|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
219200466|NCT03710772|DRUG|Dexamethasone|Given PO or IV
219200467|NCT03710772|DRUG|Doxorubicin Hydrochloride|Given IV
219200468|NCT03710772|DRUG|Ibrutinib|Given PO
219497749|NCT00183469|DRUG|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
219497750|NCT00183469|DRUG|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
219497751|NCT00183469|DRUG|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
219497752|NCT00965913|DRUG|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
219497753|NCT00965913|DRUG|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
219497754|NCT00965913|DRUG|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
219497755|NCT05373433|DRUG|SSD8432 750mg|Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
219497756|NCT05373433|DRUG|SSD8432 placebo|Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
219497757|NCT04229797|PROCEDURE|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
219497758|NCT02577042|DRUG|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
219497759|NCT02577042|DRUG|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
219497760|NCT02577042|DRUG|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
219497761|NCT00751998|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
219497762|NCT02713503|OTHER|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
219497763|NCT02713503|OTHER|VisionCoach|Visual field evaluation using VisionCoach
219497764|NCT05760378|DRUG|Famitinib|TKI
219497765|NCT05760378|DRUG|Camrelizumab|PD1 inhibitor
219497766|NCT05760378|DRUG|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
219497767|NCT03618459|OTHER|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
219497768|NCT05193331|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
219497769|NCT02487368|DEVICE|Needle stimulation pad|
219497770|NCT02955810|DRUG|Daratumumab|
219497771|NCT02955810|DRUG|Cyclophosphamide|
219603400|NCT06692179|DRUG|Orally administered preparation of fecal microbiota (MTP-101P)|As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
218879435|NCT04571996|DRUG|ODM-104|Capsule
218879436|NCT04571996|DRUG|Paracetamol|Rapidly dissolving tablet
218879437|NCT03932630|OTHER|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
219200469|NCT03710772|DRUG|Methotrexate|Given IV
219200470|NCT03710772|BIOLOGICAL|Rituximab|Given IV
219200471|NCT03710772|DRUG|Venetoclax|Given PO
219200472|NCT03710772|DRUG|Vincristine Sulfate|Given IV
219497772|NCT02955810|DRUG|Bortezomib|
219497773|NCT02955810|DRUG|Dexamethasone|
219603401|NCT04125134|DRUG|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
219603402|NCT06687655|DIETARY_SUPPLEMENT|Ketone-IQ|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.
219026453|NCT05945654|PROCEDURE|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
219026454|NCT03006159|DRUG|SHR0534|
219026455|NCT03006159|DRUG|Placebo|
219497774|NCT05867173|OTHER|Experimental Speech Processing Strategy|Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.
219200473|NCT05794399|DRUG|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
219497775|NCT03184103|DIAGNOSTIC_TEST|anti streptolysin o titre and serum complement test|diagnostic lab test
219497776|NCT01965535|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
219497777|NCT01965535|DRUG|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
219497778|NCT01965535|DRUG|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
219497779|NCT01965535|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
219497780|NCT01124682|PROCEDURE|diagnostic cystoscopy|
219497781|NCT01124682|PROCEDURE|diffusion-weighted magnetic resonance imaging|
219497782|NCT01124682|PROCEDURE|implanted fiducial-based imaging|
219497783|NCT01124682|PROCEDURE|quality-of-life assessment|
219497784|NCT01124682|RADIATION|3-dimensional conformal radiation therapy|
219603403|NCT06687655|DIETARY_SUPPLEMENT|Placebo|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
219603404|NCT06872840|BEHAVIORAL|Parent Fear of Recurrence Therapy (Parent-FORT)|7 weekly sessions of 120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
219026456|NCT06180590|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
219026457|NCT01120756|BEHAVIORAL|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
219497785|NCT01124682|RADIATION|image-guided radiation therapy|
219497786|NCT01124682|RADIATION|selective external radiation therapy|
219497787|NCT03786809|DRUG|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
219497788|NCT03786809|DRUG|Placebo|patients of the placebo group will use placebo once a day for 28 days
219497789|NCT04677582|BEHAVIORAL|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
219497790|NCT02983227|DRUG|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
219497791|NCT05622552|DEVICE|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
219497792|NCT05622552|DEVICE|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
219497793|NCT04348344|BEHAVIORAL|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
219497794|NCT01032759|DRUG|Memantine|20 mg, BID
218879438|NCT03932630|OTHER|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
219026458|NCT01120756|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
219026459|NCT03145168|OTHER|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
219026460|NCT03145168|OTHER|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
219026461|NCT01948128|DRUG|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
219497795|NCT01032759|DRUG|Placebo|BID
219497796|NCT01227096|DEVICE|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
219497797|NCT03603431|DRUG|MRG-110|Single ascending doses of MRG-110
219497798|NCT03603431|DRUG|Placebo|Single doses of placebo
219497799|NCT03603431|DRUG|MRG-110|Multiple ascending doses of MRG-110
219497800|NCT03603431|DRUG|Placebo|Multiple doses of Placebo
219497801|NCT04769128|OTHER|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
219497802|NCT00165711|DRUG|Mecobalamin|
219497803|NCT00240305|DRUG|Rosuvastatin|
219497804|NCT01493531|DRUG|Lesinurad|Tablets, 200 mg QD
219497805|NCT01493531|DRUG|Lesinurad|Tablets, 400 mg QD
219497806|NCT01493531|DRUG|Placebo|Tablets, Placebo QD
219497807|NCT01493531|DRUG|Allopurinol|Tablets
219497808|NCT01946282|OTHER|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
219497809|NCT01946282|OTHER|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
219497810|NCT01946282|OTHER|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
219497811|NCT05595174|BIOLOGICAL|self ligating bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed
219497812|NCT05595174|BIOLOGICAL|conventional bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
219497813|NCT05595174|BIOLOGICAL|conventional bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment
219026462|NCT01948128|OTHER|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
219497814|NCT05595174|BIOLOGICAL|self ligating bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
219497815|NCT04668222|DRUG|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
219497816|NCT04668222|DRUG|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
219497817|NCT04668222|DRUG|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
219497818|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
219497819|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
218879439|NCT05414552|DRUG|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
218879440|NCT05167591|DIAGNOSTIC_TEST|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
218879441|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
218879442|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
218879443|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
219026463|NCT04026048|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
218879444|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
219026464|NCT02628795|BEHAVIORAL|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
219026465|NCT02628795|OTHER|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
219026466|NCT00506155|DRUG|Avastin|10 mg/kg by vein over 90 minutes
219026467|NCT00506155|DRUG|Cisplatin|70 mg/m\^2 by vein over 4 hours
219026468|NCT00506155|DRUG|Doxorubicin|30 mg/m\^2 by vein over 15 minutes
219497820|NCT06536634|OTHER|SAES|The experimental intervention consists of SAES with a glove or adhesive electrodes at 20Hz, 300µs, intensity between 2-10mA, during 30 minutes per day, 5x/week, for 5 weeks, combined with conventional occupation therapy. The subsequent therapy sessions will take place at home, with in-between telephone checks.
218879445|NCT04095091|DEVICE|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
218879446|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
219026469|NCT00506155|DRUG|Methotrexate|30 mg/m\^2 by vein over 30 minutes
219026470|NCT00506155|DRUG|Vinblastine Sulfate|3 mg/m\^2 by vein over 30 minutes
219026471|NCT02742987|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
219026472|NCT02742987|DRUG|Clopidogrel|Clopidogrel 150 mg once daily
219026473|NCT02742987|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
219026474|NCT03760146|BIOLOGICAL|20vPnC|20vPnC
219026475|NCT03760146|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
219026476|NCT03760146|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
219026477|NCT03760146|OTHER|Saline|Placebo
219026478|NCT01611181|DRUG|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
219026479|NCT01611181|DRUG|Kräuterblut|40 mg iron, 20 ml twice daily.
219026480|NCT01611181|DRUG|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
219026481|NCT05568784|OTHER|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
219026482|NCT02690610|PROCEDURE|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
219026483|NCT04287777|DRUG|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
219026484|NCT04287777|DRUG|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
219026485|NCT04287777|DRUG|Placebo|Topical administration of Placebo (ointment) TID during 7 days
219026486|NCT00149981|DRUG|everolimus (RAD)|Everolimus
219026487|NCT02081144|OTHER|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
219026488|NCT02081144|DRUG|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
219026489|NCT02081144|DRUG|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
219026490|NCT02081144|BEHAVIORAL|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
219026491|NCT04000204|DEVICE|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
219026492|NCT04000204|DEVICE|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
218879447|NCT02846701|DRUG|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
218879448|NCT00416455|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
218879449|NCT00416455|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
218879450|NCT00416455|PROCEDURE|computed tomography|Undergo FDG PET/CT
219026493|NCT03930446|DRUG|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
218879451|NCT00416455|DRUG|ferumoxtran-10|Undergo femoxtran-10 MRI
218879452|NCT00416455|PROCEDURE|magnetic resonance imaging|Undergo femoxtran-10 MRI
218879453|NCT00416455|PROCEDURE|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
219026494|NCT03930446|OTHER|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
219026495|NCT02847546|DEVICE|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
219026496|NCT04130451|DRUG|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
219497821|NCT06536634|OTHER|TAU|Treatment as usual
219026497|NCT04902755|OTHER|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
219026498|NCT03647228|DRUG|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
219026499|NCT03647228|DRUG|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
219026500|NCT02183831|DEVICE|Insertion of the capsular tension ring|
219026501|NCT01559012|DRUG|Clonidine|transdermal clonidine patch 5 mg q. 5 days
219026502|NCT00946712|BIOLOGICAL|Bevacizumab|Given IV
219026503|NCT00946712|DRUG|Carboplatin|Given IV
219026504|NCT00946712|BIOLOGICAL|Cetuximab|Given IV
219026505|NCT00946712|OTHER|Laboratory Biomarker Analysis|Correlative studies
219026506|NCT00946712|DRUG|Paclitaxel|Given IV
219026507|NCT03401983|OTHER|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
219026508|NCT03401983|OTHER|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
219497822|NCT04380324|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
219497823|NCT04380324|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
219497824|NCT01279590|DRUG|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
219497825|NCT01279590|DRUG|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
219497826|NCT01279590|DRUG|Placebo|2 placebo capsules twice daily for 12 weeks
219497827|NCT05860790|DIAGNOSTIC_TEST|Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery|This is a clinical prediction model that uses perioperative clinical indicators and laboratory tests to predict the occurrence of VTE after neurosurgery.
219026509|NCT02467569|DRUG|Hemay020|
219026510|NCT02291055|DRUG|ADXS11-001|
219026511|NCT02291055|DRUG|MEDI4736|
219026512|NCT00994955|DEVICE|selective retina therapy (SRT)|laser treatment
219026513|NCT01334203|DRUG|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
219026514|NCT03379649|COMBINATION_PRODUCT|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
219026515|NCT03379649|COMBINATION_PRODUCT|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
219497828|NCT01362959|DRUG|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
219497829|NCT01362959|OTHER|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
219603405|NCT07017686|DEVICE|abdominal vagus nerve stimulation (aVNS)|Participants will receive aVNS, delivered by a commercially available stimulator placed under the skin, and a custom-designed electrode array attached to the abdominal vagus nerve. Stimulation will commence 2 weeks after laparoscopic surgical implantation of the device, and occur daily for 22-weeks stimulation in the initial phase of the study.
219603406|NCT06632509|DEVICE|BD SiteRite(TM) 9|Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
219603407|NCT03996070|PROCEDURE|Laser therapy|Erbium YAG laser
219026516|NCT04839094|DIAGNOSTIC_TEST|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
219026517|NCT05566210|DEVICE|acupuncture|acupuncture
219026518|NCT05566210|DEVICE|Sham acupuncture|Sham acupuncture
219026519|NCT03839212|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
219026520|NCT03839212|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
219026521|NCT03839212|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
219497830|NCT00179452|BEHAVIORAL|Yoga|
219497831|NCT00388570|DEVICE|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
219497832|NCT05991570|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
219026522|NCT03839212|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
219026523|NCT01983358|DRUG|JPI-289|PARP-1 inhibitor
219026524|NCT01983358|OTHER|Placebo|Placebo
219026525|NCT03809520|RADIATION|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
219497833|NCT00266552|DRUG|risperidone|
219497834|NCT04337190|BIOLOGICAL|blood sampling|blood sampling at the day of admission, day 3 and day 7
219497835|NCT02857374|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
218879454|NCT00416455|PROCEDURE|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
219026526|NCT00452829|DRUG|Folic Acid and inositol|Folic Acid and inositol
219026527|NCT00452829|DRUG|Folic acid and placebo|Folic acid and placebo
219026528|NCT00739037|DRUG|Placebo|
219026529|NCT00739037|DRUG|PAZ-417|
219026530|NCT00482235|DRUG|MK0359|
219497836|NCT02857374|DRUG|Fluorescein Sodium Injection|Given IV
219497837|NCT02857374|OTHER|Laboratory Biomarker Analysis|Correlative studies
219497838|NCT02857374|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
219497839|NCT00004187|DRUG|capecitabine|
219497840|NCT00004187|DRUG|oxaliplatin|
219497841|NCT03884933|OTHER|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
219603408|NCT06705998|DRUG|BAR502 single dose|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg)."
219603409|NCT06705998|DRUG|Placebo single dose|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
219603410|NCT06705998|DRUG|BAR502 multiple doses|The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
219603411|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
219603412|NCT07135349|DRUG|BW-20507 with/without NUC|• BW-20507 with/without NUCs will be administrated for 48 weeks
219603413|NCT07135349|DRUG|BW-20507 with/without NUC, Peg-IFNa|• BW-20507 with/without NUC will be administrated for 48 weeks, Peg-IFNa will be administrated.
219603414|NCT06706817|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
218879455|NCT06478303|OTHER|Motor imagery|Participants were asked to imagine arm or foot movements.
218879456|NCT06478303|OTHER|Action reading|Participants were asked to read sentences involving arm or foot movements
218879457|NCT06478303|OTHER|Motor localizer|Participants were asked to perform arm or foot movements
218879458|NCT01081743|OTHER|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
218879459|NCT02889445|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
218879460|NCT01620944|DRUG|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
218879461|NCT01620944|DRUG|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
218879462|NCT01620944|DRUG|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
218879463|NCT01620944|DRUG|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
218879464|NCT03852095|OTHER|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
218879465|NCT04611451|OTHER|classic lumbar home exercise|classic lumbar home exercise
218879466|NCT04611451|DEVICE|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
218879467|NCT04611451|OTHER|Whole body vibration exercise|Whole body vibration exercise
218879468|NCT04079114|DEVICE|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
218879469|NCT01364389|DRUG|AIN457|3 mg/kg
218879470|NCT01364389|DRUG|ACZ885|3 mg/kg
218879471|NCT01364389|DRUG|Prednisone|20 mg
218879472|NCT01364389|DRUG|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
218879473|NCT03018977|OTHER|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
218879474|NCT03018977|OTHER|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
218879475|NCT00851461|DRUG|Goserelin|Goserelin 10.8 mg SC every 3 months
218879476|NCT00851461|PROCEDURE|Electrophysiologic study|Nerve conduction study Electromyogram
218879477|NCT00851461|PROCEDURE|tissue biopsy|skin and muscle biopsy before and after treatment every year
218879478|NCT02172404|DEVICE|Placebo capsule administered via the HandiHaler®|
218879479|NCT02172404|DEVICE|Ipratropium metered dose inhaler (MDI)|
218879480|NCT01796821|DRUG|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
218879481|NCT01796821|DRUG|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
219603415|NCT06709469|BIOLOGICAL|Autologous CD19/CD22 CAR T cells|A total of two doses of autologous CD19/CD22 CAR T cells (first dose of up to 0.75x106/kg fresh cells), and a second infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 cytokine-release syndrome (CRS) in the next 72 h; intravenously.
219603416|NCT06709469|BIOLOGICAL|Allogeneic CART-NKG2D cells|A total of up to 3x106/kg allogeneic CART-NKG2D cells divided in three doses of up to 1x106/kg will be infused; intravenously. First infusion of fresh cells, and the 2nd and 3rd infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 CRS (every 48 hours).
219603417|NCT06718101|DRUG|Lutikizumab|Subcutaneous (SC) Injection
218879482|NCT01796821|DRUG|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
218879483|NCT00753363|OTHER|Weight Loss|6 months of weight loss
218879484|NCT00753363|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training
218879485|NCT03875352|PROCEDURE|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
218879486|NCT03875352|PROCEDURE|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
218879487|NCT02508324|BIOLOGICAL|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
218879488|NCT02508324|BIOLOGICAL|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
218879489|NCT06319859|DRUG|Morphine|The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
218879490|NCT06319859|DRUG|Placebo|The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
218879491|NCT00562146|PROCEDURE|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
218879492|NCT05755659|DRUG|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
218879493|NCT04246632|DEVICE|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
218879494|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
218879495|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
218879496|NCT03625999|BEHAVIORAL|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
219603418|NCT06718101|DRUG|Placebo|Subcutaneous (SC) Injection
218879497|NCT04309058|DRUG|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
218879498|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
218879499|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
218879500|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
218879501|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
218879502|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
218879503|NCT04621487|DRUG|according to antibiogram|according to antibiogram
218879504|NCT00000470|PROCEDURE|cardiac surgical procedures|
218879505|NCT00000470|PROCEDURE|cardiopulmonary bypass|
218879506|NCT02620488|BEHAVIORAL|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
218879507|NCT02861859|DRUG|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
218879508|NCT02861859|DRUG|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
218879509|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
218879510|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
218879511|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
218879512|NCT03295019|DEVICE|Test Oral Spray|HA formulation of FDA listed ingredients
219603419|NCT03759717|OTHER|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
219603420|NCT06882785|DRUG|KarXT|Specified dose on specified days
219603421|NCT06882785|OTHER|Placebo|Specified dose on specified days
218879513|NCT03295019|DEVICE|Placebo Oral Spray|Placebo formulation without the active ingredients
218879514|NCT03395002|DRUG|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
218879515|NCT03395002|DRUG|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
218879516|NCT03395002|DRUG|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
218879517|NCT04723680|OTHER|Qualitative interview|Qualitative semi structured interview
218879518|NCT03485521|PROCEDURE|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
218879519|NCT02160145|DRUG|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
218879520|NCT02160145|DRUG|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
219026531|NCT01809873|BEHAVIORAL|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
219026532|NCT02280564|BEHAVIORAL|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
219026533|NCT01650038|OTHER|treatment with faecal transplantation (donor faeces)|faecal transplantation
219026534|NCT01650038|OTHER|treatment with faecal transplantation (own faeces)|faecal transplantation
219026535|NCT04562285|DIAGNOSTIC_TEST|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
219026536|NCT05552872|DIAGNOSTIC_TEST|mNGS, IDSeq UltraTM|pathogen detection
219497842|NCT05145296|COMBINATION_PRODUCT|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
219497843|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
219497844|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
219497845|NCT02481479|DRUG|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
219497846|NCT00845026|DRUG|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
219497847|NCT00845026|DRUG|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
219497848|NCT00845026|DRUG|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
219497849|NCT00845026|DRUG|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
219497850|NCT02393534|OTHER|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
219026537|NCT00679263|DRUG|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
219026538|NCT00679263|DRUG|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
219026539|NCT00679263|DRUG|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
219497851|NCT01325532|DEVICE|Active CES|CES current
219497852|NCT01325532|DEVICE|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
219497853|NCT04032275|OTHER|Chronic hepatitis B infection|Chronic hepatitis B infection patients
219497854|NCT00889785|BEHAVIORAL|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
219026540|NCT02526940|PROCEDURE|rectal biopsies|6 rectal biopsies
219026541|NCT02526940|OTHER|Blood samples|Blood samples
219026542|NCT03309358|DRUG|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
219497855|NCT00889785|BEHAVIORAL|Usual Care|Will receive usual care and monthly phone calls as an active control.
219497856|NCT03012815|DRUG|Gabapentin|Gabapentin administered as a taper
219497857|NCT03012815|DRUG|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
219497858|NCT03012815|DRUG|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
219497859|NCT03187483|PROCEDURE|orthodontic treatment|orthodontic treatment in maxillary crowding
219497860|NCT05178147|DEVICE|Compression bandaging without reference to GraduCheck pressure measurements|To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
218879521|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
219026543|NCT03309358|DRUG|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
219026544|NCT02453763|DEVICE|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
219026545|NCT02453763|PROCEDURE|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
219026546|NCT00649675|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fed
219026547|NCT00649675|DRUG|Mobic® Tablets 15 mg|15mg, single dose fed
219497861|NCT05178147|DEVICE|Compression bandaging using GraduCheck pressure measurements to monitor compression pressure|To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
219497862|NCT01252238|DRUG|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
219497863|NCT01252238|DRUG|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
219497864|NCT01252238|DRUG|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
219497865|NCT05827900|BEHAVIORAL|Metacognitive Training|Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
219497866|NCT02467088|OTHER|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
219497867|NCT02077751|DRUG|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
219603422|NCT04762017|DRUG|OCS-05 +SoC (corticosteroid) IV administration|OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days
219200474|NCT05794399|DRUG|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
219497868|NCT04034199|DRUG|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
219497869|NCT04034199|DRUG|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
219497870|NCT02766387|OTHER|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
219603423|NCT04762017|OTHER|Placebo + SoC (corticosteroid) IV administration|Placebo + SoC (corticosteroid) IV administration for 5 consecutive days
219603424|NCT00925080|DEVICE|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
219603425|NCT07042776|DEVICE|EMMA (Expert Manipulative Massage Automation)|For the EMMA massage, the subject lies down on the robot platform in a prone position. A therapist sets the robot parameters. The EMMA electronic massager applies massage to the focus points on the back of the participants guided by cameras and computer programs. Treatment lasts approximately 20-30 minutes.
219603426|NCT07042776|OTHER|Therapist-delivered massage|For the therapist-delivered massage treatment, the licensed massage therapist will follow standard of care protocol. Treatment lasts approximately 20-30 minutes.
219603427|NCT03553953|DEVICE|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
219603428|NCT03648853|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
219603429|NCT06719128|DRUG|Olomorasib|Administered orally.
219603430|NCT01324531|PROCEDURE|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
219497871|NCT02194231|DRUG|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
219497872|NCT02295280|DRUG|Metoclopramide|IV
219497873|NCT02295280|DRUG|Diphenhydramine|iv
219497874|NCT02295280|DRUG|Codeine|PO
219497875|NCT03229239|PROCEDURE|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
219497876|NCT03382210|OTHER|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
219497877|NCT05535595|DRUG|genotyping and selection of renin-angiotensin system blocker|"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping"
219497878|NCT05535595|DRUG|Perindopril|perindopril 4 mg/d without genotyping
219497879|NCT02219295|DIETARY_SUPPLEMENT|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
219603431|NCT01324531|PROCEDURE|Bankart repair|Bankart repair based on surgeon's preference
219603432|NCT04943276|DEVICE|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
219603433|NCT01190553|DRUG|Amantadine|Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
218879522|NCT00164515|BEHAVIORAL|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
218879523|NCT05021575|OTHER|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
218879524|NCT05021575|OTHER|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
218879525|NCT05021575|OTHER|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
218879526|NCT05021575|OTHER|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
219497880|NCT02219295|DIETARY_SUPPLEMENT|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
219497881|NCT02219295|DIETARY_SUPPLEMENT|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
219497882|NCT02219295|OTHER|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
219497883|NCT02523079|BEHAVIORAL|Cognitive Behavioral Group Therapy for Insomnia|
219497884|NCT02523079|BEHAVIORAL|Cognitive Behavioral Self-help Therapy for Insomnia|
219497885|NCT02523079|BEHAVIORAL|Sleep Hygiene Guidance|
219497886|NCT04700735|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
219497887|NCT05680207|BEHAVIORAL|Diabetes self- management education (DSME) program|We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
219497888|NCT05402319|COMBINATION_PRODUCT|Antibiotic combination therapy|Anti-infective treatment with at least two different types of sensitive antibiotics.
219497889|NCT05504616|OTHER|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
219497890|NCT00558519|DRUG|cyclophosphamide|
219497891|NCT00558519|DRUG|cytarabine|
219497892|NCT00558519|DRUG|daunorubicin hydrochloride|
219497893|NCT00558519|DRUG|dexamethasone|
219497894|NCT00558519|DRUG|doxorubicin hydrochloride|
219497895|NCT00558519|DRUG|mercaptopurine|
219497896|NCT00558519|DRUG|methotrexate|
219497897|NCT00558519|DRUG|pegaspargase|
219497898|NCT00558519|DRUG|thioguanine|
219497899|NCT00558519|DRUG|vincristine sulfate|
219497900|NCT00558519|RADIATION|radiation therapy|
218879527|NCT01674205|BIOLOGICAL|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
218879528|NCT01674205|BIOLOGICAL|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
218879529|NCT01674205|BIOLOGICAL|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
219497901|NCT05862116|OTHER|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
218879530|NCT01674205|BIOLOGICAL|Vaccine placebo (Leibovitz-15 [L-15])|
219497902|NCT00732771|DRUG|LCI699|
219497903|NCT01755611|DRUG|Minocycline 100mg|Test product
218879531|NCT01674205|BIOLOGICAL|Vaccine placebo (FluMist®)|
218879532|NCT05850338|DEVICE|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
218879533|NCT05850338|BEHAVIORAL|autogenic training|Autogenic relaxation for three times a day for eight weeks
218879534|NCT04919096|DRUG|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
218879535|NCT04919096|DRUG|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
218879536|NCT03249987|OTHER|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
218879537|NCT00634062|DRUG|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
218879538|NCT00634062|DRUG|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
218879539|NCT02238860|DRUG|Entacavir|Entacavir-0.5 mg ,OD,for
218879540|NCT02238860|DRUG|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
218879541|NCT02098278|DRUG|CAT-2003|
218879542|NCT02098278|DRUG|Placebo|
218879543|NCT03662516|DRUG|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
218879544|NCT03662516|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
219497904|NCT01755611|DRUG|Minocycline 100mg|Reference product
219603434|NCT03062163|OTHER|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
219603435|NCT03062163|OTHER|Placebo|Transdermal patch loaded with normal saline
219603436|NCT00985491|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
218879545|NCT00064051|DRUG|gemcitabine hydrochloride|
218879546|NCT00064051|DRUG|triapine|
218879547|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
218879548|NCT03706183|DIAGNOSTIC_TEST|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
218879549|NCT03706183|DIAGNOSTIC_TEST|Hearing thresholds|The hearing levels will be determined for each group.
219026548|NCT00311337|DRUG|bortezomib|
219497905|NCT01710878|DEVICE|Intergard Synergy Graft|
219497906|NCT02494687|DRUG|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
219497907|NCT02494687|DRUG|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
219497908|NCT02494687|DRUG|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
219497909|NCT01276028|PROCEDURE|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
219497910|NCT00990028|DRUG|Rosuvastatin|20 mg oral, for 10 days
219497911|NCT00990028|DRUG|Placebo|20 mg vehicle
219497912|NCT02868905|PROCEDURE|Blood sample|
219497913|NCT01535157|DRUG|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
219497914|NCT00397839|DRUG|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
219497915|NCT00397839|DRUG|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
219497916|NCT01800669|OTHER|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
219026549|NCT01464346|DEVICE|Enlite Sensor|This is the Enlite sensor (all subjects)
219026550|NCT02741908|BEHAVIORAL|Calorie counting diet|
219026551|NCT02741908|BEHAVIORAL|Fixed diet plan|
219026552|NCT03621852|DEVICE|Endoultrasound guided FNB|EUS FNB with Aquire TM device
219603437|NCT04139759|OTHER|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
219603438|NCT04139759|OTHER|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
219603439|NCT02106897|DRUG|BIIB059 (litifilimab)|See Arm Descriptions
219603440|NCT02106897|DRUG|Placebo|See Arm Descriptions
219603441|NCT01689727|DRUG|Technetium Tc 99m EC20|
218879550|NCT06470646|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body.By employing specialized catheters and devices,endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the targetsite,without the need for conventional open surgery.
218879551|NCT03326622|OTHER|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
218879552|NCT03326622|OTHER|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
218879553|NCT04356235|PROCEDURE|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
218879554|NCT04356235|PROCEDURE|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
218879555|NCT04356235|PROCEDURE|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
218879556|NCT04356235|PROCEDURE|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
218879557|NCT04356235|PROCEDURE|E: unilateral simple mastectomy|unilateral simple mastectomy
218879558|NCT04356235|PROCEDURE|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
218879559|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
219497917|NCT01800669|OTHER|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
219497918|NCT02445989|DRUG|NuvaRing|Provide NuvaRing to women seeking contraception
219497919|NCT02260141|DIETARY_SUPPLEMENT|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
219497920|NCT02622503|DRUG|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
219497921|NCT03820973|BEHAVIORAL|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
219497922|NCT00690768|DRUG|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
219497923|NCT00690768|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
219497924|NCT04618952|DRUG|Calcium D|calcium D supplementation given to postmenopausal females
219497925|NCT04618952|DRUG|Placebo|Placebo
219497926|NCT05719610|OTHER|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
219497927|NCT05719610|OTHER|Swiss Ball Exercises|Swiss Ball Exercises
219497928|NCT01077115|PROCEDURE|Laparoscopic cholecystectomy|
219497929|NCT01077115|PROCEDURE|Open Surgery|
219497930|NCT03884595|DIAGNOSTIC_TEST|IG, IPF, NRBC, CRP, PCT, presepsin|Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
219497931|NCT04971915|OTHER|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
219497932|NCT05020054|DEVICE|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
219497933|NCT05020054|DEVICE|placebo tecartherapy|tecartherapy with equipment turned off
219497934|NCT02758587|DRUG|Defactinib|cross reference with arm/group descriptions
219603442|NCT00489827|DRUG|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
219603443|NCT00489827|OTHER|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
219603444|NCT06888466|BEHAVIORAL|The result of the Polygenic Risk Score will be communicated to the patient with the aim of encouraging a change in behavior|Blood samples collected for the calculation of the genetic predisposition profile for Cardiovascular risk will be used for DNA extraction and genotyping, and the PRS will subsequently be calculated. Based on the results, individuals will be classified into three main CVD risk categories (high risk, intermediate risk, low risk)
219603445|NCT01377012|BIOLOGICAL|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
218879560|NCT00554372|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
218879561|NCT03036618|DIETARY_SUPPLEMENT|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
218879562|NCT03036618|DIETARY_SUPPLEMENT|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
219026553|NCT01899534|OTHER|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
219026554|NCT04991571|DRUG|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
219026555|NCT04991571|DRUG|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
219026556|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
219026557|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
219026558|NCT01498458|DRUG|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
219026559|NCT05594394|BEHAVIORAL|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, \& Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
219026560|NCT03640585|OTHER|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
219026561|NCT05150353|PROCEDURE|MRI|Wrist MRI
219026562|NCT01815125|DRUG|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
219026563|NCT01815125|DRUG|PLacebo|placebo
219026564|NCT04336891|DRUG|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
219026565|NCT04336891|DRUG|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
219026566|NCT04336891|DRUG|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
219497935|NCT02758587|DRUG|Pembrolizumab|cross reference with arm/group descriptions
219497936|NCT06305637|DRUG|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
219497937|NCT06305637|DRUG|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
219497938|NCT06305637|DRUG|Placebo|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
219497939|NCT00124449|DRUG|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g"
218879563|NCT03489928|DRUG|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
218879564|NCT03489928|DRUG|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
218879565|NCT03489928|DRUG|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
218879566|NCT05713435|DEVICE|intravaginal laser|application of intravaginal laser
218879567|NCT03718858|PROCEDURE|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
219026567|NCT04336891|DRUG|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
219026568|NCT02408393|DRUG|Saline|
219026569|NCT02408393|DRUG|Ropivacaine|
219497940|NCT00124449|DRUG|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
219497941|NCT01254045|DRUG|placebo|intranasal placebo (48 international units)
219497942|NCT01254045|DRUG|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
219497943|NCT01254045|DRUG|oxytocin 48IU|intranasal oxytocin (48 international units)
219497944|NCT02971605|DRUG|Psilocybin|25 mg/70 kg Psilocybin
219497945|NCT03624270|DRUG|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
218879568|NCT03718858|PROCEDURE|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
218879569|NCT03387358|DEVICE|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
218879570|NCT02725541|DRUG|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
218879571|NCT03951558|OTHER|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
218879572|NCT03951558|DRUG|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
218879573|NCT03903887|BIOLOGICAL|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
218879574|NCT02400541|BEHAVIORAL|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
218879575|NCT02400541|OTHER|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
218879576|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
218879577|NCT02476292|OTHER|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
218879578|NCT02541734|DRUG|Gelofusine|Infusion of gelofusine
218879579|NCT02541734|RADIATION|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
218879580|NCT02541734|DRUG|Placebo|
218879581|NCT05583019|DEVICE|GENEActiv Accelerometry Device|a watch like wearable sensor
218879582|NCT05583019|DEVICE|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
218879583|NCT05583019|DEVICE|Apple Watch Accelerometry Device|a watch like wearable sensor
218879584|NCT05583019|DEVICE|Polysomnography|Sleep monitor
219026570|NCT04073381|COMBINATION_PRODUCT|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
219026571|NCT03467113|DRUG|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
219026572|NCT03467113|DRUG|Cannabidiol|Cannabidiol
219497946|NCT03406689|DRUG|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
219497947|NCT03406689|DRUG|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
219497948|NCT03406689|DRUG|Artificial tear|One drop Artificial Tears will be instilled 45' prior to the IVI.
219497949|NCT00601328|DRUG|Calcitriol|
219497950|NCT02341963|DRUG|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
219497951|NCT00028730|BIOLOGICAL|anti-thymocyte globulin|
219497952|NCT00028730|BIOLOGICAL|filgrastim|
219497953|NCT00028730|DRUG|cyclophosphamide|
219497954|NCT00028730|DRUG|fludarabine phosphate|
219603446|NCT01377012|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
219603447|NCT03616145|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
219603448|NCT03616145|OTHER|Light Touch|Comparator Arm
219603449|NCT00286026|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
219497955|NCT00028730|DRUG|thiotepa|
219497956|NCT00028730|PROCEDURE|allogeneic bone marrow transplantation|
219497957|NCT00028730|RADIATION|radiation therapy|
219497958|NCT05485857|PROCEDURE|Arrangement of small intestine order before close the abdomen|After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
219497959|NCT06152159|OTHER|data collection|Data collection
219497960|NCT02540707|DRUG|solifenacin|solifenacin 5 mg per day for 12 weeks
218879585|NCT05583019|DEVICE|Videography|Thermal Camera
218879586|NCT03123991|BEHAVIORAL|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
219603450|NCT00003198|DRUG|ifosfamide|
219603451|NCT00003198|DRUG|topotecan hydrochloride|
219026573|NCT06202781|DRUG|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
219603452|NCT07059325|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 6 to 10 sessions per day (i.e., theta burst; 600 pulses per session; 6000 pulses per day) over 3 to 5 treatment days using a MagVenture MagPro TMS System. Treatment will consist of a total of 30 sessions (18,000 total pulses). A single session is defined as 600 pulses at 50 Hz for 2s (i.e., 5 Hz triplets) and repeated every 10s for a total of 190s per session to l-dlPFC at 120% rMT with 15-minute intersession intervals. TMS will be targeted to Beam F3 for comparison to the bulk of the literature and to most mimic replicable clinical use.
219603453|NCT06749405|BIOLOGICAL|Transfusion algorithm based on Quantra®|"In addition to routine coagulation tests, a Quantra Qstat® analysis will be performed at baseline (before incision), at the end of native liver dissection, and after unclamping of the venous anastomoses. In the event of bleeding, additional Quantra Qstat® analyses may be conducted until bleeding control is achieved.~Transfusion and administration of blood-derived medications will be guided by the results of the Quantra Qstat® analyses."
218879587|NCT03123991|BEHAVIORAL|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
219026574|NCT06202781|PROCEDURE|Gastroscopic biopsy|Gastroscopy and biopsy
219497961|NCT02540707|DRUG|mirabegron|mirabegron 25 mg per day for 12 weeks
219497962|NCT03124056|DEVICE|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
219497963|NCT00995332|DRUG|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
219497964|NCT03275168|BEHAVIORAL|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
219497965|NCT03275168|BEHAVIORAL|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
219497966|NCT03459833|DRUG|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
219497967|NCT02122471|DRUG|Plecanatide|
219497968|NCT02122471|DRUG|Placebo|
219603454|NCT06749405|BIOLOGICAL|Conventional transfusion algorithm|Transfusion and blood-derived medications will be guided by the results of routine coagulation tests.
219603455|NCT04245839|DRUG|Fludarabine|Fludarabine
219603456|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
219603457|NCT04245839|DRUG|JCAR017|JCAR017
219603458|NCT07063511|DEVICE|Restylane Injectables|Participants will receive multilayering treatment (i.e., one product will be placed deep and one in a more superficial plane) in area of primary deficit (i.e., the midface or lower face), in isolation or combination with other treatment areas.
218879588|NCT02567994|DRUG|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
218879589|NCT03913494|DEVICE|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
218879590|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
218879591|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
218879592|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
218879593|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
218879594|NCT02412332|PROCEDURE|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
218879595|NCT02412332|PROCEDURE|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
218879596|NCT05211817|BEHAVIORAL|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
218879597|NCT05211817|DIETARY_SUPPLEMENT|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
218879598|NCT02921087|DEVICE|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
218879599|NCT02921087|DEVICE|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
218879600|NCT00900367|OTHER|high performance liquid chromatography|
218879601|NCT00900367|OTHER|laboratory biomarker analysis|
219026575|NCT01885546|DEVICE|AgaMatrix Blood Glucose Monitor|
219026576|NCT00718328|DRUG|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
219497969|NCT02293811|OTHER|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
219497970|NCT00629486|GENETIC|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
219497971|NCT02001428|DRUG|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
219497972|NCT00890227|PROCEDURE|Traditional technique|All level open instrumented posterior spinal fusions
219497973|NCT00890227|PROCEDURE|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
219497974|NCT04390074|OTHER|COVID-19 and Intensive Care|No intervention, observational.
219497975|NCT04711863|DRUG|Fluvoxamine|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
219497976|NCT04711863|DRUG|Placebo|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
219497977|NCT00061958|DRUG|arsenic trioxide|Given IV
219497978|NCT01336309|BEHAVIORAL|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
219497979|NCT06516393|DEVICE|The radial shock wave device|The r-ESWT+Kinesio Tape Application
219497980|NCT00614458|DRUG|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
219497981|NCT01284595|DRUG|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
219497982|NCT00348218|DEVICE|NeuroVision|
219497983|NCT00869089|DRUG|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
219497984|NCT05571657|BEHAVIORAL|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
219497985|NCT00566215|PROCEDURE|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
219497986|NCT00566215|PROCEDURE|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
219497987|NCT05385796|OTHER|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
219497988|NCT05385796|OTHER|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
219497989|NCT00097084|DRUG|insulin detemir|
219497990|NCT00097084|DRUG|insulin glargine|
218879602|NCT00900367|PROCEDURE|spectroscopy|
219026577|NCT00718328|DRUG|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
219026578|NCT01876485|BEHAVIORAL|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
219026579|NCT01876485|BEHAVIORAL|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
219026580|NCT03011359|OTHER|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
219026581|NCT03011359|OTHER|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
219026582|NCT05706025|DEVICE|EnteroTracker|The EnteroTracker® is a capsule device that includes an absorbent string.
219026583|NCT04873661|BEHAVIORAL|Hypnosis group intervention|See arm description
219603459|NCT06574607|DEVICE|Interactive Educational Material for Decision-Making|Using severe bleeding from abdominal-pelvic trauma as a scenario case, implementing decision-making teaching strategies to guide learners, and examining the intervention through this research
219026584|NCT04873661|BEHAVIORAL|Cognitive trance group intervention|See arm description
219603460|NCT06574607|DEVICE|Interactive Educational Material|Teaching with scenario-based interactive materials without incorporating any teaching strategies
219603461|NCT05698914|BEHAVIORAL|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
219026585|NCT04873661|BEHAVIORAL|Meditation group intervention|See arm description
219026586|NCT06892496|OTHER|Visual Analog scale (VAS) questionnaire|"A Visual Analog Scale (VAS) questionnaire is a type of self-report tool where respondents mark a point on a continuous line to indicate the intensity of a subjective experience, like pain, fatigue, or happiness, between two extreme anchor points (e.g., no pain at one end and worst possible pain at the other), allowing for a more nuanced response compared to a standard Likert scale; essentially, it measures the degree of a symptom along a visual continuum."
219026587|NCT06892496|OTHER|Vacuum-formed retainer (VFR) technique|On the day of surgery, the stent will be positioned to cover the palate and the anterior and posterior teeth, including their occlusal and buccal surfaces bilaterally, to provide retention. Vacuum-formed retainers are a common clinical practice used after harvesting a palatal graft, in order to provide a mechanical barrier to reduce post-operative pain.
219026588|NCT06892496|OTHER|3-D printed acrylic resin stent (3DS) technique|On the day of surgery, the previously made palatal stent (3DS) will be placed in position and stabilized by mechanical retention in the palate and palatal surface of the maxillary teeth, bilaterally.
219200475|NCT06784141|BEHAVIORAL|personalized Cognitive Behavior Therapy including third-wave|In the personalized CBT, patients first complete 21 days of EMA with six assessment points daily to assess relevant processes of CPP models. Person-specific networks are estimated based on the EMA data. A network-based algorithm indicates the treatment target. The individual CBT modules are selected for the participants from a matching matrix that contains experts' module recommendations for specific treatment targets. After that, participants will receive one out of ten CBT modules addressing their treatment target. All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behavior Therapy, Acceptance and Commitment Therapy or Mindful Selfcompassion.
219200476|NCT06784141|BEHAVIORAL|standardized Cognitive Behavior Therapy including third-wave|The standardized CBT intervention is manual-based and contains five sessions of cognitive behavioral therapy. Based on the evaluated manual from EFFECT Back, a short version with 5 modules is used: attention control, relaxation techniques, behavioral activation, cognitive strategies, and consolidation.
219497991|NCT00097084|DRUG|insulin aspart|
219497992|NCT04643782|DEVICE|ANNE Sleep|ANNE sleep system
219497993|NCT02736526|PROCEDURE|recession or resection of the horizontal extraocular muscles|
219497994|NCT02954120|OTHER|no intervention provided|
219497995|NCT04295044|DIETARY_SUPPLEMENT|high protein diet|receive 1.8g protein/kg
219497996|NCT04295044|DIETARY_SUPPLEMENT|normal protein diet|receive 1g protein/kg
219497997|NCT03690726|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
219497998|NCT03690726|OTHER|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
219497999|NCT04888741|DRUG|Thymoglobulin|GVHD prophylaxis
219498000|NCT04888741|DRUG|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
219498001|NCT04888741|DRUG|Cyclosporine|immunosuppressant
219498002|NCT04888741|DRUG|Sirolimus|immunosuppressant
219498003|NCT04888741|DRUG|Mycophenolate Mofetil|immunosuppressant
219498004|NCT00206219|DRUG|Gefitinib|
219498005|NCT00206219|DRUG|methotrexate|
219498006|NCT03390634|OTHER|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
219498007|NCT00324090|BEHAVIORAL|High and low glycemic index|
219498008|NCT02495870|OTHER|Pork|
219498009|NCT03768609|DRUG|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
219498010|NCT03768609|DRUG|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
219603462|NCT05698914|BEHAVIORAL|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
219603463|NCT07077655|OTHER|Marmet Technique|One of the traditional and natural efforts mothers can make to facilitate breast milk production postpartum is the Marmet technique. This technique embraces the principles of massage and stimulation of the milk ejection reflex (Widiastuti et al., 2015; Hairunisyah \& Kusumawaty, 2022). Furthermore, this technique provides a relaxing effect, reactivating the milk ejection reflex, which in turn stimulates spontaneous milk flow (Yuliani et al., 2015). In other words, the Marmet technique is a combination of expressing milk and massaging the breast by emptying the lactiferous sinuses located under the areola. The Marmet technique stimulates prolactin secretion and helps maximize the milk ejection reflex. The more milk that is withdrawn or emptied from the breast, the greater the milk production (Widiastuti et al., 2015).
219603464|NCT07077655|OTHER|Oxytocin Massage|Oxytocin massage is a type of massage performed to increase breast milk production. The massage is applied to the sides of the spine and the fifth to sixth ribs, and it stimulates the prolactin and oxytocin hormones after birth (Kosova et al., 2016). This massage serves to increase the oxytocin hormone, which can calm the mother, leading to an automatic flow of breast milk (Kilci \& Sevil, 2021). Research conducted by Azizah and Ambarika (2022) shows that a combination of the Marmet technique and oxytocin massage can increase breast milk production. Massaging or stimulating the spine sends a message to the hypothalamus in the posterior pituitary by directly stimulating the medulla oblongata via neurotransmitters to release oxytocin, which then causes milk secretion from the breasts (Lestari \& Linar, 2024).
219603465|NCT07077655|OTHER|Plasebo|No intervention will be made to the participants in this group. Superficial touch will be performed on women's wrists, elbows, and shoulders.
218879603|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
218879604|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
218879605|NCT02430987|DIAGNOSTIC_TEST|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of \>23 and \> 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria \> 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
218879606|NCT02430987|DIAGNOSTIC_TEST|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
218879607|NCT02430987|DIAGNOSTIC_TEST|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
218879608|NCT06312319|DEVICE|Respiratory training|Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.
218879609|NCT06312319|OTHER|Orofacial exercises|The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
219026589|NCT06892496|OTHER|Flowable resin composite stent (FRC) technique|On the day of surgery, a layer of flowable composite will be added, covering all the wound dimensions, restricted to the wound (no extension to the adjacent teeth). Flowable composite has been shown to help reduce pain using the same principal of providing a mechanical barrier to protect the palatal wound from the oral cavity
219026590|NCT06892496|OTHER|Photographs of the patient's palate|At the 14-day, 30-day and 3-month follow-up visits, photographs of the patient's palate (Canon EOS 60D DSLR, Canon, USA) will be taken for healing evaluation as well as intraoral scans (TRIOS 4, 3Shape) of the palatal wound for linear and volumetric changes analysis.
219026591|NCT06892496|OTHER|Measuring graft dimensions|The graft dimensions will be measured with the use of a periodontal probe and recorded on the data collection form. The professional preference in regard to technique applied and the time spent by the surgeon to adjust the stent intraorally will also be recorded in the same form.
219200477|NCT02313623|PROCEDURE|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
218879610|NCT04680819|DIETARY_SUPPLEMENT|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
219026592|NCT06913920|DEVICE|Continuous Passive Motion (CPM)|"Materials: A CPM device configured for wrist flexion-extension with an adjustable range of motion set between 0° and 30°.~Procedure:~The participant's wrist is gently secured in the device. The CPM device is programmed to deliver 20 minutes of continuous, passive motion through the set range.~Device settings (e.g., speed) may be modified if the participant reports pain \>4/10 on the NPRS."
219026593|NCT06913920|DEVICE|Intermittent Pneumatic Compression (IPC)|"Materials: An IPC sleeve designed for the forearm-to-hand region with a baseline compression setting of approximately 30 mmHg.~Procedure:~After CPM treatment, the IPC device is applied to the affected limb. The sleeve provides 15 minutes of intermittent compression with programmed intervals of inflation and deflation.~Compression levels may be adjusted based on participant comfort and pain ratings."
219026594|NCT06913920|BEHAVIORAL|Standard Therapy Program|"Procedures:~Active/active-assisted wrist/forearm range of motion exercises led by a certified hand/physical therapist.~Progressive grip-strengthening exercises using resistance bands or putty. Manual edema management techniques, including gentle massage and manual lymphatic drainage, as well as scar mobilization if needed."
218879611|NCT05138887|DRUG|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
219026595|NCT06914284|OTHER|Actigraphy and MRI|All participants will wear a wGT3X-BT actigraph (wGT3x-BT) for 4 days. Actigraphs are collected back at Day 4, after full 96 hours, when coming to the MRI platform. There, they will undergo 45 minutes MRI that acquire MRI signals to quantify degenerative, inflammatory, vascular and functional cerebral features.
219200478|NCT05064514|DEVICE|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
219498011|NCT06070168|OTHER|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
219498012|NCT00120068|BEHAVIORAL|Nursing inservices|
219498013|NCT00120068|PROCEDURE|Academic detailing to MDs; concurrent review and feedback|
219498014|NCT01989195|DRUG|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
219498015|NCT04407468|PROCEDURE|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
219498016|NCT04499235|DRUG|Mometasone furoate|Topical mometasone furoate
219498017|NCT04499235|DRUG|AKST4290|Oral AKST4290
219498018|NCT04499235|DRUG|Placebo|Oral placebo
219498019|NCT05627908|OTHER|Contrast-enhanced ultrasound|Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
219498020|NCT04397250|BEHAVIORAL|High-intensity interval training|Arm-cranking exercise
219498021|NCT02491619|PROCEDURE|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
218879612|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
218879613|NCT00687531|DRUG|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
219026596|NCT01918761|DRUG|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
219026597|NCT06913270|BEHAVIORAL|Immersive Virtual Reality Distraction (IVRD)|"Intervention Description:~Participants assigned to this intervention will receive standard analgesic care per institutional protocol in addition to an immersive virtual reality (VR) distraction intervention. During each burn dressing change, participants will wear a head-mounted display (HMD) that delivers an interactive and engaging virtual environment designed specifically to distract from procedural pain and reduce anxiety. The VR session will last for the entire duration of the dressing change (approximately 10-15 minutes) and will be administered during every session. The VR system is calibrated to provide high levels of sensory immersion to effectively divert attention from painful stimuli."
219026598|NCT06913270|BEHAVIORAL|Nature Video Distraction (NVD)|"Intervention Description:~Participants in this intervention will receive the same standard analgesic care provided to all subjects and, in addition, will watch a nature video on a tablet device during the burn dressing change. The video distraction serves as an active comparator to the immersive VR. The nature video is selected to be calming and engaging, and it will be played continuously during the dressing change session (approximately 10-15 minutes). This intervention allows evaluation of whether immersive VR provides additional benefit in reducing procedural pain and anxiety over a standard video distraction."
219026599|NCT05040360|DRUG|Capecitabine|Given PO
219026600|NCT05040360|DRUG|Temozolomide|Given PO
219026601|NCT07162337|BEHAVIORAL|Increased Plant-Based Diet and Decreased Animal-Based Diet|Self-regulated diet; increased plant-based foods with decreased animal-based foods
219026602|NCT04919278|PROCEDURE|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
219200479|NCT05757492|DRUG|CHS-006 (anti-TIGIT)|Arm A participants will receive CHS-006 administered via IV Q3W.
219498022|NCT03882216|PROCEDURE|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
219498023|NCT03882216|PROCEDURE|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
219498024|NCT03262545|DRUG|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
219498025|NCT03262545|DRUG|Placebos|Physical properties of placebos are consistent with apatinib
219498026|NCT01559818|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
219498027|NCT02537067|DRUG|CHONDRON|"1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
219498028|NCT02731833|OTHER|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
219498029|NCT02731833|OTHER|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
219498030|NCT01565382|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
219498031|NCT00512356|BIOLOGICAL|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
219498032|NCT04703530|OTHER|hot footbath|The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
219498033|NCT02026037|BEHAVIORAL|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
219498034|NCT04071626|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
219603466|NCT03514017|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
219603467|NCT03514017|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
219026603|NCT03103997|PROCEDURE|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
219200480|NCT05757492|DRUG|toripalimab (anti-PD-1)|Arm B participants will receive toripalimab administered via IV Q3W.
219498035|NCT04071626|DRUG|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
219498036|NCT05117866|DRUG|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
219603468|NCT06704191|BIOLOGICAL|BCG Solution|Given intravesically
219603469|NCT06704191|PROCEDURE|Cystoscopy|Undergo cystoscopy
219603470|NCT06704191|DRUG|Docetaxel|Given intravesically
219603471|NCT06704191|DRUG|Gemcitabine|Given intravesically
219603472|NCT06704191|OTHER|Home Health Encounter|Receive access to CCBW home health visits
219603473|NCT06704191|DRUG|Mitomycin|Given intravesically
219603474|NCT06704191|OTHER|Questionnaire Administration|Ancillary studies
219603475|NCT06821815|OTHER|Video Game Based Therapy|Video game based therapy interventions includes active video games for rehabilitation. Leap Motion Controller based rehabilitative games, Xbox Kinect Games and Kinect Based Custom Rehabilitative Games will be applied to the participants
219603476|NCT06821815|OTHER|Bimanual Intensive Therapy|This intervention includes goal directed activity based exercises for upper extremity functions. This intervention also includes exercises for postural control
219603477|NCT05271409|DRUG|Satralizumab|Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
219603478|NCT05271409|OTHER|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
219603479|NCT03389347|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
219603480|NCT03389347|DEVICE|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
219603481|NCT03389347|OTHER|Laboratory Biomarker Analysis|Correlative studies
219603482|NCT06818812|DRUG|INCB186748|INCB186748 will be administered at protocol defined dose.
219498037|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
219498038|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
219498039|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
219498040|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
219603483|NCT06818812|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
219603484|NCT06818812|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
219603485|NCT06818812|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
219603486|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
219603487|NCT05733702|OTHER|All participants will be asked to provide data and samples for collection and analysis.|During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
219603488|NCT07124468|DRUG|Meropenem-Pralubactam|The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam
219603489|NCT06589596|DRUG|BGB-58067|Planned doses administered on specified days per protocol.
219498041|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
219498042|NCT05155020|BIOLOGICAL|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
219498043|NCT05802979|DRUG|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
219603490|NCT06589596|DRUG|BG-89894|Planned doses administered on specified days per protocol.
219026604|NCT07190430|DRUG|PF-08049820|Administered orally
219026605|NCT07190430|DRUG|Midazolam|Administered orally
219200481|NCT05909644|DRUG|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
219603491|NCT06589596|DRUG|Standard of Care Therapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219603492|NCT07104162|DRUG|Cefiderocol/Xeruborbactam|A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam
219603493|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
219603494|NCT03040973|DRUG|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
219603495|NCT03040973|DRUG|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
219603496|NCT03040973|DRUG|Gefitinib|tablets for oral use; 250mg; once a day
219026606|NCT07190430|DRUG|Dabigatran Etexilate|Administered orally
219026607|NCT07190430|DRUG|Portia (EE and LN) or equivalent oral tablet|Administered orally
219498044|NCT02903316|PROCEDURE|Fluids|
219603497|NCT03040973|DRUG|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
219603498|NCT07106125|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Kidney transplant recipients will continue to take TMP-SMX daily from months 6-12 after transplant
219603499|NCT07106125|OTHER|Usual Care|Participants will take a placebo from months 6-12 after transplant and continue to receive all standard usual care related to their kidney transplant status
219603500|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
219603501|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
219603502|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
219603503|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
219603504|NCT06360081|DRUG|Zongertinib manufacturer 1|Zongertinib
219603505|NCT06360081|DRUG|Zongertinib manufacturer 2|Zongertinib
219603506|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
219200482|NCT05909644|DRUG|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
219200483|NCT04472897|DRUG|GSK2556286|GSK2556286 will be administered.
219200484|NCT04472897|DRUG|Placebo|Placebo will be administered
219200485|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
219498045|NCT01374906|DRUG|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).
219498046|NCT01374906|DRUG|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
218879614|NCT01612208|DEVICE|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
218879615|NCT01612208|DEVICE|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
219200486|NCT05280925|BEHAVIORAL|Episodic Future Thinking|Participants will be prompted three times daily to think vividly about personally meaningful future events.
219200487|NCT05280925|BEHAVIORAL|Healthy Information Thinking|Participants will be prompted three times daily to think about their responses to informational health vignettes.
219498047|NCT01374906|DRUG|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
219498048|NCT03812601|PROCEDURE|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
219498049|NCT06545448|PROCEDURE|Percutaneous Coronary Intervention (PCI)|A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
219498050|NCT04887974|PROCEDURE|canine retraction|Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
219498051|NCT04559165|OTHER|sericin and chitosan cream|sericin and chitosan cream
219498052|NCT02505165|BEHAVIORAL|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
219498053|NCT02505165|OTHER|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
219498054|NCT05578833|DIAGNOSTIC_TEST|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
219603507|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
219603508|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
219603509|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
219603510|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
219603511|NCT06596473|DRUG|BG-C477|Administered intravenously.
218879616|NCT03143764|BEHAVIORAL|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
219200488|NCT04521153|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
219200489|NCT04521153|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
219200490|NCT04521153|PROCEDURE|Radical surgery|Radical surgery
219603512|NCT06596473|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219603513|NCT05345002|DRUG|Retifanlimab|Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
219603514|NCT05345002|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
219603515|NCT07109219|COMBINATION_PRODUCT|AZD4512 monotherapy|Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22
218879617|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
219026608|NCT07190638|PROCEDURE|Medullary-only suturing (single-layer)|Only the base layer (medulla) is sutured after tumor excision, Cortical suturing is omitted. Hemostatic agents are applied.
218879618|NCT02484482|DRUG|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
218879619|NCT04088526|COMBINATION_PRODUCT|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
218879620|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
219026609|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0).
219026610|NCT07190638|PROCEDURE|Medullary and cortical suturing (two-layer)|Both medullary and cortical layers are sutured after tumor excision, Performed with robotic assistance using absorbable sutures. Hemostatic agents are applied
219026611|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0), absorbable braided suture (Vicryl™ 0)
219026612|NCT07190638|DEVICE|Hemostatic Agent|Hemostatic agents (e.g., Bleed Stp Plus, Surgicel® Fibrillar, Hemopatch®).
219026613|NCT07190612|DRUG|Dexmedetomidine and propofol|"Dexmedetomidine infusion syringe (50mls): will be filled with 2mls of dexmedetomidine (200µg) diluted in 48 ml of 0.9% normal saline to make a final volume of 50mls and a final dexmedetomidine concentration of 4µg/ml. It will be infused as 1µg~/kg/hr iv. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr."
219498055|NCT05578833|DIAGNOSTIC_TEST|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
219026614|NCT07190612|DRUG|Midazolam and propofol|Midazolam infusion syringe (50mls): will be filled with 10mls of Midazolam (50mg) diluted in 40mls 0.9% normal saline to make a final volume of 50mls to reach a final midazolam concentration of 1mg/ml. It will be administered as a bolus dose of 0.05 mg/kg iv over 2 minutes then infused at a rate of 0.025mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
219200491|NCT03781089|DRUG|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
219498056|NCT05578833|DIAGNOSTIC_TEST|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
219498057|NCT01796041|DRUG|Indocyanine Green|
219498058|NCT04412876|DRUG|Duloxetine|Duloxetine 30 mg qd
219498059|NCT04412876|DRUG|Imipramine|Imipramine 25mg qd
219498060|NCT02453100|BEHAVIORAL|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
219498061|NCT02453100|BEHAVIORAL|Education|Education on simple ways to manage incontinence
219498062|NCT00257088|BEHAVIORAL|whole day first grade program|
218879621|NCT05670613|OTHER|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
219498063|NCT00094315|DRUG|Cocaine (IV)|
219498064|NCT05050357|DEVICE|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
219498065|NCT05050357|DRUG|Progestins Norethindrone|oral ethisteron twice daily for three months
219498066|NCT05706428|DEVICE|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
219498067|NCT05706428|DEVICE|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
219498068|NCT01837485|DRUG|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
219498069|NCT01837485|DRUG|Placebo|Placebo pill was applied 3 times a day for 3 months
219498070|NCT04992338|DEVICE|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
218879622|NCT03309930|BEHAVIORAL|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
218879623|NCT03470753|OTHER|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
218879624|NCT03470753|OTHER|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
218879625|NCT03470753|OTHER|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
218879626|NCT03470753|OTHER|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
218879627|NCT00533624|DRUG|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
219200492|NCT04092634|DEVICE|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
219498071|NCT06037031|DRUG|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
219498072|NCT03175445|OTHER|CBCT scan by planmeca promax|software measurement tool of CBCT
219498073|NCT00902291|BIOLOGICAL|AGS-1C4D4|IV infusion
219498074|NCT00902291|BIOLOGICAL|Gemcitabine|IV infusion
219498075|NCT05436496|BIOLOGICAL|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10\^6 cells/kg body weight via IV
219498076|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with Er:YAG laser|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.
219498077|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with neutral sodium fluoride gel|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
219498078|NCT02830490|OTHER|functional tests|Test-retest reliability of physical function in hemodialysis patients
219498079|NCT00783562|OTHER|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
219498080|NCT00783562|OTHER|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
218879628|NCT00533624|DRUG|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
218879629|NCT03565835|DRUG|Abiraterone Acetate|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
218879630|NCT03565835|DRUG|Prednisone|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
219200493|NCT04092634|DEVICE|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
219200494|NCT04202835|DRUG|Cyclophosphamide|Post Transplant Cyclophosphamide
219498081|NCT01671735|OTHER|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
219026615|NCT07190612|DRUG|ketamine and propofol|Ketamine infusion syringe (50mls): will be filled with 2mls of ketamine (100mg) diluted in 48mls 0.9% normal saline to make a final volume of 50mls to reach a final ketamine concentration of 2mg/ml. It will be administered as a bolus dose of 0.25 mg/kg iv then infused at a rate of 0.25mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
219026616|NCT07189858|DEVICE|Nasal antimicrobial photodisinfection therapy|The Steriwave Nasal Photodisinfection System is applied using a photosensitizer in the nose followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
219026617|NCT07189741|PROCEDURE|hemodialysis|Three times a week.
219026618|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of CF training by evaluating inflammatory markers and oxidative precursors in untrained participants
219498082|NCT02475980|BEHAVIORAL|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
219498083|NCT00000394|PROCEDURE|Acupuncture therapy|
219498084|NCT04307225|DEVICE|Zenicor|Handheld Thumb ECG monitoring device
219498085|NCT04218006|GENETIC|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
219498086|NCT03516838|DRUG|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
219603516|NCT07101172|PROCEDURE|stress ball|Patients will be provided with an explanation, and verbal and written consent will be obtained. A patient identification form will be completed 10 minutes before the procedure. Pain levels will be determined with a pre-test VAS, anxiety levels will be determined with a STAI-S, and vital signs will be measured and recorded. The patient will be undressed and helped into a surgical gown to protect their privacy. The patient will be placed in a left lateral position on a stretcher with both legs drawn up toward their abdomen. The environment will be quiet and free from external stimuli. During the biopsy procedure, the patient will be asked to squeeze and release the Stre ball once every five counts for 10 minutes. Because blood pressure may drop or dizziness may occur after the procedure, the patient will be taken to the recovery room and monitored for bleeding. Fifteen minutes after the procedure, the severity of pain and anxiety levels during the procedure will be determined, and vital
219603517|NCT07108920|OTHER|Functional clinical tests|"Functional clinical tests:~* Time Up and Go test~* Berg Balance Scale (BBS)~* Stair climb and descent time test (SCT)~* Number of falls via a questionnaire"
219603518|NCT07110571|DRUG|Adebrelimab Injection|Adebrelimab injection.
219603519|NCT07110571|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
219603520|NCT07110571|DRUG|SHR-A1904 for Injection|SHR-A1904 for injection.
219603521|NCT07110571|DRUG|SHR-8068 Injection|SHR-8068 injection.
219603522|NCT06903819|DRUG|Ketamine|Participants in this group will receive a single intravenous (IV) dose of ketamine at 0.5 mg/kg, administered within 30 minutes of anesthesia induction during surgical fixation for musculoskeletal trauma. The purpose of the intervention is to evaluate ketamine's effect on postoperative pain, opioid consumption, and psychological recovery, including symptoms of depression and post-traumatic stress disorder (PTSD).
219603523|NCT06903819|DRUG|standard general anesthesia|Participants in this group will receive standard general anesthesia during surgical fixation for musculoskeletal trauma. No ketamine will be administered. This group serves as a comparison to evaluate the effects of ketamine on pain, opioid use, and psychological recovery.
219603524|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)|Active treatment will consist of high-dose iTBS-rTMS to left dmPFC delivered in runs of 600 pulses at an intensity of 120% resting motor threshold (rMT). iTBS triplets at 50 Hz will be delivered for 2 seconds, repeated every 10 seconds for a total of 190 seconds. Each session will be separated by at least 10-15 minutes and a total of 12 sessions will be given on each treatment day (3-4 hours per study day). A total of 43,200 pulses will be delivered over the entire six days of treatment.
219603525|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)|"For the sham stimulation group, a focal electric sham will be used which is indistinguishable from active TMS including a pretreatment individualized sham titration, sham outputs noises synchronized to pulse delivery, and an individualized level of sham stimulation throughout the treatment.~Technicians administering active vs sham TMS will be masked by using a random code generated by the statistician that will indicate whether to use the active or sham side of the coil. Treatments will appear identical to the technician regardless of whether active or sham TMS is administered."
219603526|NCT07113067|OTHER|Brainsight Neuronavigation System|A brainsight neuronavigation system will be used during TMS treatments to target treatment location using individual MRI data
219603527|NCT07112404|OTHER|Dry Needling|Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.
218879631|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
218879632|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
219026619|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of resistance training by evaluating inflammatory markers and oxidative precursors in untrained participants
219026620|NCT07189507|OTHER|Simulated indoor temperature upper limit|Older adults exposed to an 8-hour simulated exposure.
219026621|NCT07189819|DEVICE|Model-Predictive Controller (MPC) Functional Electrical Stimulation (FES)|The model-predictive controller (MPC) determines the timing and intensity of electrical stimulation delivered for FES. MPC combined with real-time ultrasound-based feedback delivers optimal FES intensities and minimizes fatigue. FES is delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
219026622|NCT07189819|DEVICE|Conventional Functional Electrical Stimulation (FES)|For functional electrical stimulation, surface electrodes are placed on the paretic leg on skin overlying the tibialis anterior (TA) muscle, with intensity pre-set to elicit dorsiflexion to neutral against gravity. FES will be delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
219026623|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
219026624|NCT01883414|DEVICE|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
219026625|NCT00939809|BIOLOGICAL|Urokinase-Derived Peptide A6|Given SC
219026626|NCT00939809|OTHER|Laboratory Biomarker Analysis|Correlative studies
219026627|NCT04447417|DRUG|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219498087|NCT03516838|DRUG|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
219498088|NCT01203319|BIOLOGICAL|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
219498089|NCT01203319|BIOLOGICAL|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
219498090|NCT01203319|BIOLOGICAL|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
219498091|NCT05554874|OTHER|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
219498092|NCT05554874|OTHER|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
219498093|NCT01990066|BEHAVIORAL|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
219498094|NCT03079674|OTHER|observational only- no intervention|observational only- no intervention
219498095|NCT00665626|DRUG|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
219498096|NCT00665626|DRUG|Placebo|Placebo, orally, twice-a-day
219498097|NCT04147611|DEVICE|BAHA|Participant's pediatric bone conduction hearing device.
219498098|NCT04147611|DEVICE|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
219498099|NCT04147611|DEVICE|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
219498100|NCT04147611|DEVICE|Hearing Aid|Participant's unilateral hearing aid with contralateral plug.
219498101|NCT01532037|OTHER|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
219498102|NCT01532037|OTHER|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
219498103|NCT03539731|DRUG|Fluorine F 18 DASA-23|Given IV
219498104|NCT03539731|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219498105|NCT01799213|DRUG|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
219498106|NCT01799213|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
218879633|NCT03834935|DRUG|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
218879634|NCT03834935|DRUG|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
218879635|NCT03750643|DRUG|LY3454738|Administered IV
218879636|NCT03750643|DRUG|LY3454738|Administered SC
218879637|NCT03750643|DRUG|Placebo|Administered IV
218879638|NCT02744651|DEVICE|EUS-FNA|"Please note the text in section Arm description"
218879639|NCT02744651|DEVICE|EUS-Endodrill biopsy|"Please note the text in section Arm description"
218879640|NCT01686282|DIETARY_SUPPLEMENT|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
218879641|NCT01686282|DIETARY_SUPPLEMENT|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
218879642|NCT05331794|BEHAVIORAL|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
218879643|NCT05331794|BEHAVIORAL|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
218879644|NCT06153472|DEVICE|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
219026628|NCT05427396|DRUG|JS004|Usage and dosage: Inject 200mg once every 3 weeks
219026629|NCT05427396|DRUG|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
219498107|NCT02665611|BEHAVIORAL|intervention for improvement of adherence|intervention for improvement of adherence
219498108|NCT02665611|BEHAVIORAL|treatment as usual|The control group will be treated according to the usual stadard of care.
219498109|NCT01259700|BEHAVIORAL|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
219498110|NCT01259700|BEHAVIORAL|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
219498111|NCT01188070|BEHAVIORAL|Usual Care|Educational materials
219498112|NCT01188070|BEHAVIORAL|Psycho-education|Educational group sessions
219498113|NCT01188070|BEHAVIORAL|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
219498114|NCT02038400|DEVICE|KINETUBE medical Device|
219498115|NCT02038400|DEVICE|insertion of tympanic ventilation tubes (tympanostomy)|
219498116|NCT04654156|DIAGNOSTIC_TEST|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
219498117|NCT00031837|DRUG|dalteparin|
219498118|NCT00031837|DRUG|gemcitabine hydrochloride|
219498119|NCT00031837|PROCEDURE|quality-of-life assessment|
218879645|NCT04522479|OTHER|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
219026630|NCT02699203|BEHAVIORAL|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
218879646|NCT03253328|DRUG|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
218879647|NCT03253328|DRUG|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
218879648|NCT02607111|DRUG|Dalteparin|
218879649|NCT05407779|BIOLOGICAL|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
219200495|NCT04202835|DRUG|Anti-Thymocyte globulin (rabbit)|Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
219200496|NCT02238808|DRUG|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
219200497|NCT06957886|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219498120|NCT01629693|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
219498121|NCT01629693|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
219498122|NCT01973270|BEHAVIORAL|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
219498123|NCT05598463|DEVICE|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
219498124|NCT03779100|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219498125|NCT03779100|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
219498126|NCT01308658|DRUG|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
219498127|NCT01308658|DRUG|ritonavir|on Day 3
219498128|NCT02134769|DEVICE|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
219498129|NCT03352817|OTHER|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
219498130|NCT01925807|BEHAVIORAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
219498131|NCT05709054|OTHER|Experimental: Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Breathing Retraining Exercises group:~Diaphragm manual therapy will be carried out and consists of a technique intended to stretch and mobilise the diaphragmatic muscle fibers indirectly. The maneuver will be performed in two sets of 10 repetitions, within a 1-minute interval for 10 minutes.~Breathing retraining exercises will be implemented for 30 minutes, consisting of:~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
219498132|NCT05709054|OTHER|Sham Breathing Retraining Exercises Group B|"Sham Breathing Retraining Exercises Group B:~Breathing retraining exercises will be implemented for 30 minutes, consisting of :~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
219603528|NCT07112404|OTHER|Dry needling with high-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with high-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, high-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
218879650|NCT05407779|BIOLOGICAL|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
218879651|NCT05407779|BIOLOGICAL|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
218879652|NCT05407779|BIOLOGICAL|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
218879653|NCT05407779|BIOLOGICAL|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
218879654|NCT05407779|BIOLOGICAL|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
218879655|NCT05407779|BIOLOGICAL|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
218879656|NCT03214042|DEVICE|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
218879657|NCT02353728|DRUG|Nilotinib|
218879658|NCT02872272|DRUG|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
218879659|NCT03147989|DRUG|MultiHance|gadolinium contrast agent
218879660|NCT03167528|BEHAVIORAL|Relaxation|Relaxation
218879661|NCT03167528|BEHAVIORAL|Hypnosis|Hypnosis
218879662|NCT03167528|BEHAVIORAL|Holistic gymnastics|holistic gymnastics
218879663|NCT03167528|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS
218879664|NCT03167528|BEHAVIORAL|Sophrology|Sophrology
218879665|NCT06330337|DRUG|Temozolomide（TMZ） injection or oral administration|Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
218879666|NCT06330337|DRUG|Albumin-Bound Paclitaxel(ABX) intravenous drip|ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
218879667|NCT06330337|DEVICE|Specific mode electroacupuncture stimulation(SMES) intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8."
219603529|NCT07112404|OTHER|Dry needling with low-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with low-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, low-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
219603530|NCT07112885|PROCEDURE|Arthroscopic Microfracture Combined with Autologous SVF Injection|This procedure involved arthroscopic debridement and microfracture of the knee joint. After microfracture, autologous SVF, isolated from adipose tissue through mechanical digestion and centrifugation, was administered intra-articularly under sterile conditions
219603531|NCT07112885|PROCEDURE|Arthroscopic Debridement Followed by Autologous SVF Injection|This procedure included only arthroscopic debridement of the knee joint. After debridement, autologous SVF, isolated in the same manner from adipose tissue, was injected into the joint space intra-articularly without microfracture.
218879668|NCT02301624|BIOLOGICAL|Eculizumab|Intravenous administration of eculizumab.
218879669|NCT02301624|DRUG|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
218879670|NCT04651608|BEHAVIORAL|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
219026631|NCT02699203|BEHAVIORAL|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
219026632|NCT02639104|RADIATION|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
219026633|NCT02639104|OTHER|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
219498133|NCT02151162|BEHAVIORAL|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
219498134|NCT02151162|DIETARY_SUPPLEMENT|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
219498135|NCT02151162|BEHAVIORAL|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
219498136|NCT02151162|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
219498137|NCT01529749|DRUG|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
219603532|NCT06876714|BIOLOGICAL|Trastuzumab (Herceptin)|Given IV or SC
219603533|NCT06876714|BIOLOGICAL|Pertuzumab|Given IV or SC
219603534|NCT06876714|PROCEDURE|Echocardiography|Undergo ECHO
219603535|NCT06876714|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219200498|NCT06957886|DRUG|Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel|Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
219200499|NCT03994471|DRUG|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
219498138|NCT01529749|DRUG|EFV/FTC/TDF|600/200/245 mg, od, oral
219026634|NCT01190254|DRUG|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
219026635|NCT01190254|DRUG|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
219498139|NCT01529749|DRUG|FTC/TDF + MK-0518|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
219498140|NCT01529749|DRUG|FTC/TDF+MK-0518+Losartan|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
219498141|NCT04385199|BIOLOGICAL|Convalescent plasma|One 200mL transfusion of ABO compatible convalescent plasma over 3 hours
219603536|NCT06876714|PROCEDURE|Mammography|Undergo mammography
219603537|NCT06876714|PROCEDURE|Ultrasound|Undergo ultrasound
219603538|NCT06876714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219603539|NCT06876714|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219603540|NCT06876714|OTHER|Questionnaire Administration|Ancillary studies
219603541|NCT07167641|OTHER|Cognitive Behavioral Therapy for Caregivers|"The intervention includes four Foundational Sessions delivered to all participants: Orientation and Engagement, Narrative Exploration, and Goal Setting Sessions at the beginning of treatment, followed by a structured Closing Session at the end of treatment. Beyond the four foundational sessions, caregiver clients complete an additional module based on their top area of need. These modules are called Core Sessions and are selected through a collaborative process that draws on caregiver preferences, clinical judgment, and assessment results to ensure treatment is tailored to each caregiver's unique experiences, interests, and goals."
219603542|NCT07186478|DRUG|Investigational Drug|IFALMIN® is a standardized herbal preparation derived from Channa micropeltes (ikan toman), containing natural albumin. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
219603543|NCT07186478|DRUG|Placebo|Placebo capsule containing inert ingredients (such as starch/lactose), identical in appearance, size, and color to IFALMIN® capsule. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
219603544|NCT07185204|OTHER|Early detection and management of postpartum preeclampsia bundle|Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
219498142|NCT05356351|DRUG|RC48- ADC|RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
219498143|NCT05747833|OTHER|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
219498144|NCT03333681|BIOLOGICAL|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
219498145|NCT03423706|PROCEDURE|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
219498146|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
219498147|NCT00124566|DRUG|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
219498148|NCT00124566|DRUG|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m\^2 per day, once every 3 weeks.
219498149|NCT00124566|DRUG|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
219498150|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
219498151|NCT01318265|DRUG|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
219498152|NCT04918615|PROCEDURE|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
219498153|NCT01988428|DRUG|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
219498154|NCT05485428|OTHER|High-intensity interval training|12-weeks of high intensity interval exercise, 30 minutes thrice weekly
219498155|NCT04972006|BEHAVIORAL|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
219498156|NCT02555059|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
219498157|NCT01140984|DRUG|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
219498158|NCT02778763|DRUG|CBLB612|4 μg CBLB612 SQ
219498159|NCT02778763|DRUG|Placebo|
219498160|NCT00056459|DRUG|Vatalanib|
219498161|NCT04130945|OTHER|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
219498162|NCT02053571|PROCEDURE|TIPS with 3D Overlay|
219498163|NCT05839860|OTHER|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
219498164|NCT05839860|OTHER|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
219498165|NCT05839860|OTHER|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
219498166|NCT02084979|BEHAVIORAL|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
219498167|NCT01354600|OTHER|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
218879671|NCT04651608|BEHAVIORAL|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
219498168|NCT03306784|OTHER|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
219498169|NCT02101320|DEVICE|TRECAM|using the camera during the surgery
219498170|NCT04261517|DRUG|Hydroxychloroquine|Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
219498171|NCT00273247|DRUG|Interferon alpha-2b|
219498172|NCT03855124|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
219498173|NCT01992770|BEHAVIORAL|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
219498174|NCT01992770|BEHAVIORAL|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
219498175|NCT01992770|BEHAVIORAL|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
219498176|NCT04123483|DRUG|EnBrace HR Softgel|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
219498177|NCT02828228|DRUG|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
219498178|NCT02828228|DRUG|Placebo|placebo once a day for 26 weeks
219603545|NCT07187193|DRUG|Cytarabine (Ara-C)|The treatment regimen consists of Ara-C administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
219603546|NCT07187193|DRUG|Thalidomide (100mg)|The treatment regimen consists of AraC administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
218879672|NCT04651608|BEHAVIORAL|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
218879673|NCT04651608|BEHAVIORAL|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
218879674|NCT00895310|DRUG|Ketoconazole|Ketoconazole is taken three times a day by mouth.
219498179|NCT01733719|PROCEDURE|ER plus RFA|
219498180|NCT01733719|PROCEDURE|ER plus APC|2 litres/minute, 70 watts
219498181|NCT00721461|BIOLOGICAL|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
219498182|NCT06338683|DRUG|Olanzapine 2.5 MG|Oral olanzapine 2.5 mg once daily at bedtime until disease progression
219498183|NCT06338683|DRUG|Standard anti-tumor treatment|Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
219498184|NCT06338683|DIETARY_SUPPLEMENT|Nutritional advice|All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition
219498185|NCT00265083|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
219498186|NCT00265083|BIOLOGICAL|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
219498187|NCT00265083|BIOLOGICAL|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
219498188|NCT02757534|DRUG|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
219498189|NCT00047294|DRUG|celecoxib|
219498190|NCT00047294|DRUG|temozolomide|
219498191|NCT00047294|DRUG|thalidomide|
219498192|NCT00047294|PROCEDURE|adjuvant therapy|
219498193|NCT01797419|DRUG|GS-5806|Single dose, oral liquid, .5 mL/kg
219498194|NCT01797419|DRUG|Placebo|Single dose, oral liquid, .5 mL/kg
219498195|NCT05585619|OTHER|Pain treatment|Any pain treatment to include medications, procedures, or referrals
219498196|NCT02976012|DRUG|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
219498197|NCT02976012|PROCEDURE|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
219498198|NCT04928833|OTHER|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
219498199|NCT04928833|OTHER|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
219498200|NCT04303052|DEVICE|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
219498201|NCT04303052|DEVICE|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
219498202|NCT03895593|OTHER|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
219498203|NCT01403454|BEHAVIORAL|Interactive Health Communication Application|web-based application
219498204|NCT04440345|DRUG|IBI362|Administered by subcutaneous injection
219498205|NCT04440345|DRUG|Placebo|Administered by subcutaneous injection
219498206|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product|Coated Tablets
219498207|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product|Coated Tablets
219498208|NCT04636398|BEHAVIORAL|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
219498209|NCT03243539|PROCEDURE|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
219603547|NCT07185659|DEVICE|Elastic band|"Thera-Band® elastic band exercise protocol:~First stage (weeks 1-4): Participants performed leg resistance stretching exercises with a red elastic band. In weeks 1-2, exercises were performed 3 times per week, with 2 sets per session; in weeks 3-4, 3 times per week, with 3 sets per session.~Second stage (weeks 5-8): Participants performed leg resistance stretching exercises with a green elastic band. In weeks 5-6, exercises were performed 3 times per week, with 2 sets per session; in weeks 7-8, 3 times per week, with 3 sets per session.~Third stage (weeks 9-12): Participants performed leg resistance stretching exercises with a blue elastic band. In weeks 9-10, exercises were performed 3 times per week, with 2 sets per session; in weeks 11-12, 3 times per week, with 3 sets per session."
219026636|NCT01190254|DRUG|placebo|asenapine-matched placebo tablets for sublingual administration
219026637|NCT02140437|DRUG|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
219498210|NCT06012058|DIAGNOSTIC_TEST|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
219498211|NCT06012058|DIAGNOSTIC_TEST|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
219603548|NCT07185659|DEVICE|Xiaomi Mi Band 4 wearable device|The Xiaomi Mi Band 4 wearable device has been certified by the National Communications Commission (Certification No. CCAG19LP0080T6). From weeks 1 to 12, participants' daily walking steps were monitored using the Xiaomi Mi Band 4 wearable device.
219603549|NCT07185659|BEHAVIORAL|Walking|Walking exercise plan
219603550|NCT07185763|BEHAVIORAL|Nano-Learning interventional program|AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
219026638|NCT02140437|DRUG|Anastrozole|standard endocrine therapy
219026639|NCT02356783|DEVICE|Pedometer|Wireless pedometer
219498212|NCT05740670|OTHER|Dr. Kellyann's Bone Broth|Participants will have two bone broth phases, each three weeks in length. Bone broth phases will be separated by a one-week maintenance phase. A one-week maintenance phase will also occur after the second bone broth phase. Each week of a broth phase will consist of five feeding days and five fasting days. On feeding days, participants will consume one packet of bone broth, twice each day, as snacks between meals. On fasting days, participants will consume one packet of bone broth every two hours for a total of seven packets each day.
219603551|NCT07186920|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
219498213|NCT02919475|DRUG|JTE-051|Active drug tablets containing JTE-051
219498214|NCT02919475|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
219498215|NCT01683253|DRUG|Levodopa/Carbidopa(200mg/50mg)|
219498216|NCT01683253|DRUG|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
219603552|NCT07186920|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
219603553|NCT07185932|DRUG|Rifaximin (Xifaxan)|Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.
218879675|NCT00895310|DRUG|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
218879676|NCT02772627|DRUG|Nebicapone|Nebicapone 100 mg tablets; oral route.
218879677|NCT02772627|DRUG|Placebo|Placebo tablets; oral route.
219498217|NCT01928446|DRUG|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
219498218|NCT01928446|DRUG|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
219498219|NCT04370184|PROCEDURE|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
219498220|NCT01123785|DRUG|INO-8875|eye drops for 14 days in one eye
219498221|NCT01123785|DRUG|Placebo|Matched vehicle-control
219498222|NCT00532519|DRUG|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
219498223|NCT02473328|DRUG|Atazanavir 200 mg/r|"1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
219498224|NCT03781297|OTHER|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
219603554|NCT07185620|PROCEDURE|Third molar surgery with piezoelectric system|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a piezoelectric system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
219603555|NCT07185620|PROCEDURE|Third molar surgery with Conventional Rotary System|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a conventional rotary system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
219603556|NCT07185191|DEVICE|RDM36|Patients treated with RDM36; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of PN HPT
218879678|NCT06136611|DEVICE|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
218879679|NCT00619307|DRUG|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
218879680|NCT00619307|DRUG|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
218879681|NCT00006026|DRUG|rubitecan|
218879682|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
218879683|NCT03226470|BIOLOGICAL|T512|T512 suppository contain 500 µg of T512 and suppocire.
218879684|NCT00420121|PROCEDURE|laboratory analysis|blood withdrawal for laboratory analysis
218879685|NCT00557453|DRUG|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
219498225|NCT03781297|OTHER|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
219603557|NCT07185191|DRUG|Saline Solution (NaCl 0,9%)|patients treated with saline solution; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of saline solution
219498226|NCT01274728|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
219498227|NCT00425789|PROCEDURE|Treatment with Hyperbaric oxygen|
219498228|NCT03757962|OTHER|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
219498229|NCT03674710|PROCEDURE|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219498230|NCT03674710|PROCEDURE|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219498231|NCT03674710|PROCEDURE|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219603558|NCT07185295|PROCEDURE|To maintain anticoagulant therapy during the polypectomy of colorectal lesions|Group A
218879686|NCT00557453|DRUG|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
218879687|NCT05132777|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
218879688|NCT05132777|DRUG|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
219498232|NCT03674710|PROCEDURE|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219603559|NCT07185230|DRUG|Atosiban|Participants in the atosiban group will receive an intravenous bolus injection of atosiban (37.5 mg/5 mL, , Tractocile®，Ferring Pharma,Geneva, Switzerland) at a rate of 6.75 mg/0.9 mL 30 minutes prior to embryo transfer, followed by a 1-hour intravenous infusion at a rate of 18 mg/h. After 1 hour, the atosiban infusion rate will be reduced to 6 mg/h, with a total dose of 37.5 mg.
219498233|NCT03674710|PROCEDURE|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219603560|NCT07185230|DRUG|Placebo Control|Participants in the placebo group will receive an identical saline infusion over the same timeframe. Specifically, saline will be administered intravenously 30 minutes prior to embryo transfer (ET), followed by a continuous intravenous infusion for one hour. This will be succeeded by a further continuous intravenous infusion of saline for 2.125 hours.
219603561|NCT07185945|DRUG|Zanzalintinib|60 mg orally once daily
219603562|NCT07186504|BEHAVIORAL|Adapted Physical Activity|Group-based, weekly supervised 60-minute sessions including mobility, stability, strengthening, and aerobic exercises adapted for pregnancy and pelvic girdle pain.
219603563|NCT07186504|BEHAVIORAL|Pelvic Floor Rehabilitation|Individual physiotherapy sessions using the PERFECT scheme to assess and retrain pelvic floor muscle function, including education, manual therapy, relaxation, and strengthening
219603564|NCT07186504|OTHER|Standard Care (in control arm)|Usual prenatal care provided by obstetricians or midwives according to local practice.
219603565|NCT07186504|OTHER|Educational Flyer|Written information with evidence-based international guidelines on physical activity during pregnancy.
219603566|NCT07186972|PROCEDURE|Mild therapeutic hypothermia|Before percutaneous coronary intervention, cooling was maintained with venous-arterial extracorporeal membrane oxygenation in patients receiving mild therapeutic hypothermia. By protocol, cooling down to the target temperature of 33°C-34°C was set at the maximum possible cooling rate. After the target temperature was reached, it was maintained for 24 hours with the temperature regulation function of the extracorporeal membrane oxygenation system by central temperature measurement in the urinary bladder. After 24 hours, rewarming was initiated with a speed of 0.25°C/h to a target temperature of 36.5℃ (± 0.3℃). To avoid shivering in the mild therapeutic hypothermia group, the patients were treated with a protocol including deep sedation and optional muscle relaxation.
218879689|NCT00547521|DRUG|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
218879690|NCT00547521|DRUG|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
218879691|NCT06448039|DRUG|Fibroblast Growth Factor 2|Randomized double-blinded placebo-controlled treatment of 20 patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with FGF2 or saline in a 3:1 ratio, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
218879692|NCT06448039|DRUG|Saline control|Randomized double-blinded placebo-controlled treatment of patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with saline, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
218879693|NCT03210961|DRUG|PF-06826647 tablet|PF-06826647 tablet for oral administration
219603567|NCT07186881|OTHER|Recommendation from the infectious diseases team|"No commercial product was evaluated in this study. We are assessing the benefits and consequences of a change in clinical practice implemented at the hospital level. At our institution, it is now recommended that TBE serology be performed in all cases of undocumented meningitis or meningoencephalitis.~The infectious diseases team at our hospital simply advises the clinicians responsible for patient care to perform this test."
219603568|NCT07184879|DEVICE|Conventional Dental Syringe|Palatal infiltration anesthesia using a conventional dental syringe with a 27G needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds following aspiration.
219498234|NCT03674710|PROCEDURE|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
219498235|NCT06156969|DEVICE|Robot-Assisted Gait Training|"Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes."
219498236|NCT04663880|OTHER|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
219603569|NCT07184879|DEVICE|Spring-Activated Syringe (PCJ, PAROJECT™)|Palatal infiltration using a spring-activated push-button syringe (PAROJECT™). Two calibrated 0.2 mL doses of articaine 4% with epinephrine 1:100,000 were administered following aspiration.
219603570|NCT07184879|DEVICE|Needle-Free Jet Injector (NFI, Comfort-in™)|Palatal infiltration using a needle-free jet injector (Comfort-in™). A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was delivered in less than one second at 4-5 bar pressure. Aspiration not applicable.
219603571|NCT07184879|DEVICE|Computer-Controlled Local Anesthetic Delivery (CCLAD, CALAJECT™)|Palatal infiltration using a computer-controlled local anesthetic delivery system (CALAJECT™, Program I) with a 30G, 16 mm needle. AutoFlow rate 0.006-0.009 mL/s, with automatic aspiration after 5 seconds and constant microprocessor-controlled pressure. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered.
218879694|NCT03210961|DRUG|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
218879695|NCT03210961|OTHER|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
218879696|NCT03210961|OTHER|Placebo tablet|Matching placebo tablet
218879697|NCT05187819|DIAGNOSTIC_TEST|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
218879698|NCT03088527|DRUG|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
218879699|NCT03208634|DEVICE|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
219026640|NCT06365021|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.
219498237|NCT04663880|OTHER|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
219498238|NCT04663880|OTHER|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
219498239|NCT03809013|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
219498240|NCT00744887|DRUG|Darunavir|
219603572|NCT07184879|DEVICE|Manual Pressure Syringe (MCJ, ASPIJECT™)|Palatal infiltration using a manual pressure-controlled syringe (ASPIJECT™) with a 30G, 16 mm needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds with aspiration.
219603573|NCT07185217|OTHER|class mate teaching subjects only|the participants receive educational classmate subjects.
219603574|NCT07186036|DEVICE|soft lumbosacral orthosis|The effect of trunk corsets on postural control and walking, GYA independence
219603575|NCT07184697|DEVICE|HD ctACS|Participants received High-Definition closed-loop transcranial Alternating Current Stimulation (HD-ctACS) for 30 minutes daily, 5 days per week. A 4x1 ring electrode montage was used, with the center electrode placed over the bilateral temporal cortices. Stimulation was delivered as a sinusoidal alternating current at a 2 mA peak amplitude, with the frequency individualized for each participant based on their baseline EEG. The stimulation was administered in a closed-loop, task-specific manner: a 500 ms burst of stimulation was triggered only when a subliminal negative facial stimulus was presented and the participant's real-time Nucleus Accumbens gamma power exceeded their baseline by two standard deviations.
218879700|NCT04974801|DEVICE|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
218879701|NCT04974801|DEVICE|Usual Care|Continued Usual Care routines.
218879702|NCT03857100|OTHER|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
218879703|NCT00940758|DRUG|PEP02|Dose escalation: 50-100 mg/m2 biweekly
218879704|NCT02106871|DRUG|Sildenafil|50mg of Sildenafil daily for 4 weeks
218879705|NCT04781686|DRUG|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
219498241|NCT05056337|DRUG|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
219603576|NCT07184697|DEVICE|HD ctACS sham|Participants received High-Definition transcranial Alternating Current Stimulation (HD-tACS) in 30-minute sessions once daily, 5 days per week. A 4x1 ring electrode layout was used to target the bilateral temporal cortices. The stimulation consisted of a sinusoidal alternating current with a 2 mA peak intensity, delivered at an individualized gamma frequency determined from a baseline EEG. The intervention was administered using a closed-loop, task-specific paradigm: upon presentation of a subliminal negative facial stimulus while the real-time Nucleus Accumbens gamma power exceeded a baseline threshold of +2 SD, a 500 ms stimulation was delivered following a random delay of 1000-2000 ms.
218879706|NCT04781686|DRUG|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
218879707|NCT04781686|DRUG|S1|S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
218879708|NCT04781686|DRUG|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
218879709|NCT01926990|DEVICE|perfusion computed tomography|Undergo perfusion CT
219498242|NCT05056337|DRUG|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
219498243|NCT05056337|PROCEDURE|TACE|Hepatic arterial chemoembolization
219498244|NCT05139407|DIAGNOSTIC_TEST|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
219498245|NCT02580578|OTHER|No Intervention|No intervention is administered in this study.
219498246|NCT00116415|DRUG|efavirenz; didanosine EC; lamivudine|
219498247|NCT03337737|DIETARY_SUPPLEMENT|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
219498248|NCT03337737|OTHER|Placebo|
219603577|NCT07185594|DRUG|HRS-2129 Tablets|HRS-2129 tablets.
219603578|NCT07185594|DRUG|Blank Preparation.|Blank preparation.
219603579|NCT07185594|DRUG|Tramadol Hydrochloride SR Tablets|Tramadol Hydrochloride SR tablets.
219603580|NCT07186673|DEVICE|Stainless steel crown placement using Hall Technique|Preformed stainless steel crowns are placed on permanent first molars without local anesthesia, caries removal, or tooth preparation. Orthodontic separators are used as needed, and crowns are cemented with glass ionomer cement
219603581|NCT07186673|DEVICE|Stainless steel crown placement using conventional method|Preformed stainless steel crowns are placed after administering local anesthesia and performing standard tooth preparation, including occlusal and proximal reduction. Crowns are cemented with glass ionomer cement.
219603582|NCT07185165|PROCEDURE|Computed Tomography|Undergo PET/CT
219603583|NCT07185165|DRUG|Fluorine F 18 Flotufolastat|Given IV
219603584|NCT07185165|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219603585|NCT07185165|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo PET/CT/ultrasound fusion biopsy
218879710|NCT04803149|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
218879711|NCT04803149|DEVICE|Conventional Radiofrequency|Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
218879712|NCT00657982|DRUG|RAD001|10mg BID
218879713|NCT02842164|OTHER|Tension group|
219498249|NCT02619071|PROCEDURE|Tumor sampling|Bone marrow aspirate, blood sampling
219498250|NCT02619071|BIOLOGICAL|Constiutional DNA sampling|Buccal swab or Hair follicles
219498251|NCT00775983|DEVICE|laminaria|place device in cervix for dilation
219498252|NCT00775983|DEVICE|Dilapan-S|Place in cervix for dilation.
219498253|NCT04602351|BEHAVIORAL|Communication|policies on communication and informed consent in ICU
219603586|NCT07184801|DRUG|Dexmedetomidine|The patient will receive dexmedetomidine bolus dose of 1 µg /Kg over 10 minutes followed by 0.5 µg /kg/hr infusion titrated to desired sedation level (RSS 3). For patients who do not achieve an RSS of 3, we will give 1 mg bolus of midazolam. All additional boluses will be recorded. The patient will initially receive a bolus of 2 mL 0.9% normal saline intravenously for blinding purpose
219603587|NCT07184801|DRUG|Midazolam|The patient will receive midazolam bolus dose of 2 mg IV. They will receive an infusion of normal saline over 10 minutes for blinding purpose. Further need of sedation (as assessed by RSS) will be met by additional IV boluses of 1 mg midazolam. During the procedure they will receive continuous infusion of normal saline at a rate of 0.5 µg /Kg/Hr as placebo.
218879714|NCT02842164|OTHER|No tension group|
218879715|NCT02842164|OTHER|Foley catheter Balloon|
218879716|NCT06206993|BEHAVIORAL|Resistance training including the Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.
218879717|NCT06206993|BEHAVIORAL|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
218879718|NCT00592124|DRUG|Tenofovir disoproxil fumarate|300 mg tablet daily
218879719|NCT00592124|DRUG|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
218879720|NCT00002868|BIOLOGICAL|filgrastim|
218879721|NCT00002868|BIOLOGICAL|recombinant interferon alfa|
218879722|NCT00002868|DRUG|busulfan|
218879723|NCT00002868|DRUG|cytarabine|
218879724|NCT00002868|DRUG|etoposide|
218879725|NCT00002868|DRUG|hydroxyurea|
218879726|NCT00002868|DRUG|idarubicin|
219498254|NCT02615327|DIETARY_SUPPLEMENT|8 g Polydextrose|8g of Polydextrose
219498255|NCT02615327|DIETARY_SUPPLEMENT|12 g Polydextrose|12 g of Polydextrose
219498256|NCT02615327|DIETARY_SUPPLEMENT|16 g Polydextrose|16 g of Polydextrose
219498257|NCT02615327|DIETARY_SUPPLEMENT|Placebo|0 g of Polydextrose
219498258|NCT03387410|DRUG|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
219498259|NCT04315012|OTHER|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
219498260|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
218879727|NCT00002868|PROCEDURE|peripheral blood stem cell transplantation|
218879728|NCT01606969|DRUG|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
218879729|NCT01606969|DRUG|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
218879730|NCT05314465|OTHER|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times \& repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
218879731|NCT00253123|DRUG|risperidone|
218879732|NCT03712683|DRUG|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
219498261|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
219498262|NCT01402115|DIETARY_SUPPLEMENT|Polycan|polycan 150 mg/d for 12 weeks
219498263|NCT01402115|DIETARY_SUPPLEMENT|Placebo|Placebo 150mg/d for 12 weeks
219498264|NCT04912466|DRUG|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
219498265|NCT02762565|DEVICE|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
219498266|NCT00218686|BEHAVIORAL|psychoeducational|psychoeducational
219498267|NCT00218686|BEHAVIORAL|control|VTC
219498268|NCT00744510|OTHER|Reflexology|10 weekly sessions of 45 minutes each
219498269|NCT02102581|PROCEDURE|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
219498270|NCT02058810|DEVICE|Nasal high flow|
219498271|NCT02058810|DEVICE|Conventional nasal oxygen|
218879733|NCT06344429|DEVICE|Stellest Lenses|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~A Group：Stellest Lenses spectacle (ST)"
218879734|NCT06344429|COMBINATION_PRODUCT|Stellest Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~B Group：Combined Treatment"
219498272|NCT00623623|PROCEDURE|primary PCI|Standard primary PCI
219498273|NCT00623623|DRUG|enoxaparin|Adjunctive treatment
219498274|NCT00623623|PROCEDURE|catheterisation|Routine or rescue coronary intervention
219498275|NCT00623623|DRUG|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
219498276|NCT00623623|DRUG|clopidogrel|Adjunctive treatment
219498277|NCT04504864|DRUG|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
219498278|NCT04504864|DRUG|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
218879735|NCT06344429|DRUG|Single vision Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~C Group：0.05% Atropine with single vision"
218879736|NCT03077919|DRUG|Ropivacaine|0.5% ropivacaine
218879737|NCT03077919|DRUG|Sham treatment|preservative-free normal saline
218879738|NCT05737251|BEHAVIORAL|PoET|PoET consists of two online-sessions, each 3.5 hours within groups of 30 people. The following lessons regarding positive psychology constructs were conducted (including short information on each construct and specific exercises): happiness, hope, humour, optimism, gratitude, self-efficacy, flow, meaningfulness, forgiveness, spirituality and resilience.
218879739|NCT04533321|DRUG|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
218879740|NCT00934219|DRUG|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
219498279|NCT06144814|DRUG|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
219498280|NCT06144814|DRUG|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
219498281|NCT00444132|DRUG|clopidogrel|
219498282|NCT02499354|DRUG|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
219498283|NCT02499354|DRUG|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
219498284|NCT04119583|DEVICE|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
219498285|NCT04119583|OTHER|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
219498286|NCT04119583|OTHER|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
219498287|NCT03900546|DEVICE|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
219498288|NCT01514266|DRUG|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
219498289|NCT01514266|DRUG|Placebo|
219498290|NCT01573923|BIOLOGICAL|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
219498291|NCT01573923|BIOLOGICAL|Conventional therapy|Conventional therapy without cell therapy
219603591|NCT07185334|PROCEDURE|Subcutaneous mastectomy using a fluoropolymer-coated polyester mesh endoprosthesis with simultaneous prepectoral placement of textured implants.|For this group of patients, the planned volume of surgical intervention is: subcutaneous mastectomy using a polyester mesh endoprosthesis with a fluoropolymer coating and one-stage prepectoral installation of textured implants.
219603592|NCT07185334|PROCEDURE|Subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.|This group of patients will undergo surgical intervention in deep subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.
219603593|NCT07186426|DRUG|HSK21542|Patients administrated with HSK21542
219498292|NCT03947606|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
219498293|NCT03010085|PROCEDURE|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
219498294|NCT03010085|PROCEDURE|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
219498295|NCT03422783|DEVICE|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
219498296|NCT03422783|DIAGNOSTIC_TEST|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
219498297|NCT03422783|DIAGNOSTIC_TEST|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
219498298|NCT03422783|BIOLOGICAL|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
219498299|NCT01319097|OTHER|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
219498300|NCT01892995|DRUG|Ketamine|
219603594|NCT07186426|DRUG|Placebo|Patients administrated with placebo
219603595|NCT07186426|DRUG|morphine|Patients administrated with morphine
219498301|NCT01759381|DEVICE|Negative pressure wound therapy (NPWT)|
219603596|NCT07185724|DRUG|Ketorolac 30 mg IV|We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.
219603597|NCT07185373|DRUG|Teniposide|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
219603598|NCT07185373|DRUG|Orelabrutinib|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
219603599|NCT07185373|DRUG|MTX|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
218879741|NCT05388617|DEVICE|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
219498302|NCT02561988|DRUG|Avapritinib|
219498303|NCT04866797|OTHER|cyclic merocyanine|long-UVA absorber
219498304|NCT04866797|OTHER|Placebo|Placebo
219498305|NCT05687305|OTHER|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
218879742|NCT01018485|DRUG|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
218879743|NCT01031979|DRUG|Yohimbine|alpha-2 adrenergic receptor antagonist
218879744|NCT01031979|DRUG|Placebo|Placebo
219200500|NCT03994471|DRUG|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
219498306|NCT01460927|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
219498307|NCT03231527|PROCEDURE|coronary artery bypass grafting (CABG)|myocardial revascularization
219498308|NCT00106262|DRUG|Velcade (bortezomib)|
219498309|NCT00106262|DRUG|Irinotecan|
219498310|NCT00447603|DRUG|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
219498311|NCT00447603|DRUG|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
219498312|NCT00447603|DRUG|Placebo for Losartan|
219498313|NCT00447603|DRUG|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
219498314|NCT02639208|OTHER|PatientsLikeMe (PLM)|
219498315|NCT01396642|OTHER|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
219498316|NCT00701428|DRUG|Losartan|Losartan 50 mg daily during 6 + 6 weeks
219498317|NCT00701428|OTHER|CPAP|CPAP during the second 6 week-period
219498318|NCT02168647|BEHAVIORAL|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
219498319|NCT02168647|OTHER|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
219498320|NCT05861609|PROCEDURE|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
219498321|NCT05861609|PROCEDURE|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
219498322|NCT05861609|PROCEDURE|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
219498323|NCT05139693|DEVICE|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
219603600|NCT07185373|DRUG|Rituximab (R)|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
219603601|NCT07185373|DRUG|Dexamethasone|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
219603602|NCT07184853|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (approximately every 12 hours), with or without food. Dose modifications are allowed according to protocol-defined safety and efficacy criteria. Ruxolitinib may be continued for up to 24 weeks, with tapering guided by patient response and GVHD status.
219603603|NCT07184853|DRUG|Etanercept (Enbrel)|Etanercept will be administered as a subcutaneous injection at a dose of 25 mg twice weekly for 4 weeks (total 8 doses). For patients with partial response at day 28, treatment may be extended once weekly for an additional 2-4 weeks at the investigator's discretion.
219613271|NCT01384474|OTHER|Diffusion of a surgical safety checklist|"* Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~* A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~  * First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~ * Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~* Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
219498324|NCT01697007|BIOLOGICAL|HIVIS DNA vaccine|
219498325|NCT01697007|DEVICE|Zetajet|
219498326|NCT01697007|DEVICE|Derma Vax Electroporation|
219498327|NCT01697007|BIOLOGICAL|Modified Vaccinia Ankara (MVA-CDMR)|
219498328|NCT00374543|DRUG|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
219498329|NCT00374543|DRUG|Placebo|Placebo administered daily for 8 weeks
218879745|NCT03808012|OTHER|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
219498330|NCT06230120|DEVICE|Spinal Cord Stimulation|"Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)"
219200501|NCT06550375|DEVICE|TECNIS Odyssey IOL|Implantation with the TECNIS Odyssey IOL
219200502|NCT06958783|OTHER|Blood lipid monitoring in breast cancer patients during chemotherapy|This intervention is distinguished by its prospective design, enrollment of a clearly defined cohort of adult female patients with newly diagnosed early-stage breast cancer (stage IB-IIIB), administration of a uniform chemotherapy regimen (doxorubicin, cyclophosphamide, paclitaxel), and standardized monitoring of fasting lipid profiles at four precisely scheduled timepoints: pre-chemotherapy, pre-paclitaxel, post-paclitaxel, and three months post-chemotherapy completion
219498331|NCT06230120|DEVICE|Sham|Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
219498332|NCT03086720|PROCEDURE|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
219498333|NCT03086720|PROCEDURE|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
219498334|NCT01427920|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
219603604|NCT07186686|OTHER|Participants will receive the AMENUCED program including medical care, nutritional counseling, and structured sessions focused on behavioral change and diabetes education.|"Medical Attention: Medical management will be provided by a physician who will assess the participant at the beginning and end of the intervention. The physician will be responsible for pharmacological treatment and follow-up throughout the process.~Nutritional Attention: Nutritional consultations will be provided by a registered nutritionist over a three-month period, with sessions held weekly. During each consultation, the participant will receive an individualized nutrition plan based on scientific evidence and dietary recommendations. The plan will be tailored to the participant's specific needs, including metabolic control and a hypocaloric intake (ranging from 1200 to 1800 kcal), with the goal of achieving a 5-10% reduction in body weight.~Behavioral Lifestyle Change Program: The behavior modification program used in the Action for Health in Diabetes Program (Look AHEAD) study will be adapted to include diabetes self-management activities through a structured manual."
219603605|NCT07187050|OTHER|Template-Based LLM Assistant|This study uses CocktailAI, a template-based LLM assistant co-developed by the Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, and Fitting Cloud Inc. (Kyoto, Japan). It is designed to extract relevant information from EHRs using LLMs and embed the extracted content into predefined templates. In this trial, the inputs are six simulated patient records (no real patient data). Text generation uses Gemini-2.0-flash-lite. Templates for discharge summaries and discharge referrals are pre-defined by a team member.
218879746|NCT00301418|DRUG|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
218879747|NCT03831100|BEHAVIORAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
219200503|NCT00756639|RADIATION|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
219200504|NCT00756639|OTHER|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
219200505|NCT05635617|PROCEDURE|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
219200506|NCT05856968|PROCEDURE|continuous subcutaneous tissue closure|The use of continuous subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
219200507|NCT05856968|PROCEDURE|Interrupted subcutaneous tissue closure|The use of interrupted subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
219498335|NCT02788331|OTHER|No intervention|
219498336|NCT04096391|DEVICE|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
219498337|NCT04096391|DRUG|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
219498338|NCT01956357|OTHER|Aquatic exercise|
219498339|NCT01956357|OTHER|Land Exercise|
219603606|NCT07187050|OTHER|Manual Writing|The same document templates are provided; however, all LLM instruction prompts are removed in advance. Clinicians manually write the documents, following the template structure, for each of the six simulated cases.
219603607|NCT07187180|DEVICE|holmium laser|Prostate enucleation will holmium laser (control)
219200508|NCT04487041|BIOLOGICAL|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
219498340|NCT05273385|DEVICE|Nanodropper|Device to apply liquid medication to eyes
219498341|NCT05784571|OTHER|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
219498342|NCT05784571|OTHER|Modified Physical Performance Test|A test of physical functioning
219498343|NCT05784571|OTHER|Hand grip strength|A test of hand grip strength using a hand dynamometer.
219498344|NCT05784571|OTHER|6-minute walk test|Self-paced test of walking capacity.
219603608|NCT07187180|DEVICE|pulsed thulium laser|experimental group - pulsed thulium laser prostate enucleation
219603609|NCT07187128|DEVICE|drug coating balloon angioplasty|The subjects underwent drug coating balloon angioplasty to treat femoropopliteal artery stenosis or occlusive lesions
219603610|NCT07184892|BEHAVIORAL|Daily life actual swallowing movement observation therapy|This group adds the therapy of observing actual swallowing movements in daily life, that is, in real daily life, observing the real eating and swallowing movements of relatives. They select meals that the patient likes or those that are complete in color, aroma and taste and look appetizing. The swallowing movements should be as slow and exaggerated as possible, and a look of savoring and enjoying the food should be shown, so that the patient can better observe the movements of the mouth and larynx during swallowing. Then, the patient imitates the swallowing movements.
219603611|NCT07184892|BEHAVIORAL|Video swallowing action observation therapy|Video swallowing action observation therapy
219603612|NCT07184892|BEHAVIORAL|Traditional swallowing training|Traditional swallowing training
219498345|NCT05784571|PROCEDURE|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
219603613|NCT07185958|DIAGNOSTIC_TEST|Dual-energy CT (DECT)|Additional DECT scan performed for tumor and OAR delineation.
219603614|NCT07185958|DRUG|Iodine-based contrast agent|Administered intravenously with DECT for enhanced imaging.
219603615|NCT07185958|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Additional MRI scan performed for tumor and OAR delineation.
219603616|NCT07185958|DRUG|Gadolinium-based contrast agent|Administered intravenously with MRI for enhanced imaging.
219603617|NCT07186114|DRUG|MEBO Wound Ointment (MEBO)|MEBO® 0.25% Ointment (Gulf Pharmaceutical Industries) to be applied four times a day for two weeks
219603618|NCT07186114|DRUG|Tantum Verde® mouthwash|Tantum verde (EIPICO®) mouthwash. Patients were asked to swish it for at least five minutes, four times daily for two weeks.
219603619|NCT07187232|BEHAVIORAL|massage acupoints|The massage acupoints involved Zusanli (ST36), Fenglong (ST40), Zhongfu (LU1), Tanzhong (CV17), and Feishu (BL13). Each acupoint was massaged for 2 minutes, totaling 10 minutes per session. The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
219603620|NCT07187232|BEHAVIORAL|Routine care|The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
219603621|NCT01290302|DRUG|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
219603622|NCT01290302|DRUG|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
219603623|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
219603624|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
219498346|NCT03918551|DRUG|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
219498347|NCT03918551|DRUG|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
219498348|NCT02732561|DEVICE|Alpha Stim device|cranial electrotherapy stimulation device
219498349|NCT02732561|DEVICE|Sham device|Sham device
219498350|NCT05900661|DRUG|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
219498351|NCT05900661|DRUG|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
219498352|NCT05900661|DRUG|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
219498353|NCT06406647|OTHER|retrocalvicular block|retrocalvicular block in upper limb orthopedic Surgey
219498354|NCT03070210|PROCEDURE|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
219498355|NCT03070210|PROCEDURE|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
219603625|NCT04589845|DRUG|Alectinib|Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
219200509|NCT04487041|BIOLOGICAL|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
218879748|NCT03831100|BEHAVIORAL|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
218879749|NCT04005599|DRUG|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
218879750|NCT04005599|DRUG|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
218879751|NCT03430934|COMBINATION_PRODUCT|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
219026641|NCT06365021|OTHER|Bipolar Disorder Psychoeducation Therapy|The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.
219498356|NCT00263081|DRUG|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
219026642|NCT04798547|PROCEDURE|Short Myotomy|Evaluation of short length myotomy
219498357|NCT00263081|DRUG|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
219498358|NCT03723291|COMBINATION_PRODUCT|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care \[a structured programme of rehabilitation exercises\] for 6 months
219498359|NCT03723291|PROCEDURE|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
219498360|NCT06552377|DEVICE|Ultrasound Attenuation imaging measurement|Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
219498361|NCT02396069|DRUG|JPI-289|PARP-1 inhibitor
219498362|NCT02396069|DRUG|Placebo|Placebo
219498363|NCT01202994|DRUG|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
219498364|NCT02528318|COMBINATION_PRODUCT|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
219498365|NCT02528318|DEVICE|nCPAP alone|nCPAP therapy
219603626|NCT04589845|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
219603627|NCT04589845|DRUG|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
219603628|NCT04589845|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
218879752|NCT02175979|DIETARY_SUPPLEMENT|enriched enteral nutrition|enriched enteral tube feeding perioperative
218879753|NCT02175979|DIETARY_SUPPLEMENT|standard|standard of care
218879754|NCT04131062|BEHAVIORAL|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
218879755|NCT03282513|DRUG|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
218879756|NCT03609411|PROCEDURE|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
218879757|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
218879758|NCT03161106|DIETARY_SUPPLEMENT|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
219026643|NCT04798547|PROCEDURE|Standard Length Myotomy|Standard Length Myotomy
219498366|NCT04540120|DRUG|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
219498367|NCT04540120|DRUG|placebo capsules|Hard opaque capsules containing 0 mg of API.
219603629|NCT04589845|DRUG|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
219603630|NCT04589845|DRUG|Belvarafenib|Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
219498368|NCT05566379|OTHER|Mindfulness - Mindful Awareness Practices ( MAPs)|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
219498369|NCT05366556|BEHAVIORAL|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
219498370|NCT01533857|DIETARY_SUPPLEMENT|hot water|Hot water and placebo capsule
219498371|NCT01533857|DIETARY_SUPPLEMENT|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
219498372|NCT04128878|DRUG|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
219498373|NCT04128878|DRUG|Dofetilide|Same as described above with sotalol.
219498374|NCT02410837|PROCEDURE|Electromagnetic Navigation Bronchoscopy|
219498375|NCT02974413|BEHAVIORAL|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
219498376|NCT02356965|DRUG|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
219603631|NCT04589845|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
219603632|NCT04589845|DRUG|Divarasib|Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
219603633|NCT04589845|DRUG|Camonsertib|Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
219603634|NCT06037018|BIOLOGICAL|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
219603635|NCT06497842|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
219603636|NCT06497842|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
218879759|NCT03161106|DRUG|Lactulose|Lactulose plus diet consumed by patient
218879760|NCT03161106|DIETARY_SUPPLEMENT|Diet|Protein Powder 15 to 20 gm/meal/day
218879761|NCT03811314|DEVICE|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
218879762|NCT03811314|DEVICE|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
218879763|NCT03811314|DEVICE|Isokinetic trinaing|Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second
218879764|NCT03811314|DEVICE|Isotonic training|Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
218879765|NCT01806909|BIOLOGICAL|Ad4-H5-Vtn|
218879766|NCT02453503|DRUG|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
219603637|NCT03706755|DRUG|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
219498377|NCT02356965|DRUG|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
219603638|NCT03706755|DRUG|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
219603639|NCT06290648|BEHAVIORAL|Forging New Paths|The study intervention is Forging New Paths (FNP) a newly developed intervention for people with mental illness with criminal legal system involvement that is designed to be delivered in community mental health settings. FNP combines Cognitive Behavioral Treatment (CBT) techniques with social learning principles in a group format. The intervention is organized into a modular format to create a flexible intervention structure. It includes 5 treatment modules each consisting of two to four group sessions for a total of 14-16 sessions, which may be delivered over multiple meetings at the facilitators' discretion. The intervention is designed to be delivered to 8-12 people by two intervention facilitators. It can be delivered in person, virtually, or in a hybrid format.
219498378|NCT03643406|OTHER|Mental Fatigue|modified stroop task
219498379|NCT03643406|OTHER|Control|documentary
219498380|NCT02603159|DRUG|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
219200510|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
219498381|NCT02603159|RADIATION|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
219498382|NCT00842088|DRUG|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
219498383|NCT00842088|DRUG|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
219498384|NCT03768882|DRUG|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
219498385|NCT03768882|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
219498386|NCT00837577|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
219498387|NCT00837577|DRUG|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
219498388|NCT00837577|DRUG|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
219498389|NCT00118573|PROCEDURE|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
219613272|NCT04672837|PROCEDURE|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
219026644|NCT04729127|BEHAVIORAL|Project ImPACT|Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
219026645|NCT04923503|BEHAVIORAL|diurnal fasting|subject conduct fasting in Ramadan for 30 days
219613273|NCT04672837|PROCEDURE|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
219613274|NCT02809313|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
219613275|NCT02809313|OTHER|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
219498390|NCT00118573|PROCEDURE|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
219498391|NCT02965469|BEHAVIORAL|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
219498392|NCT01212731|RADIATION|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
219498393|NCT01212731|RADIATION|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
219498394|NCT01212731|BEHAVIORAL|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
219498395|NCT01212731|DEVICE|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
219498396|NCT06527573|DEVICE|active repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
219498397|NCT06527573|DEVICE|sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
219498398|NCT02294552|DRUG|Cyclophosphamide|
219498399|NCT02294552|DRUG|Busulfan|
219498400|NCT02294552|DRUG|Fludarabine monophosphate|
219498401|NCT02294552|DRUG|Tacrolimus|
218879767|NCT02453503|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
219498402|NCT02294552|DRUG|Mycophenolate mofetil|
219498403|NCT02294552|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
219498404|NCT05474937|DRUG|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
219498405|NCT05474937|DRUG|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
219498406|NCT01540682|DRUG|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
219498407|NCT01540682|DRUG|Cetuximab|\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
219498408|NCT01540682|RADIATION|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.
219498409|NCT00765323|DRUG|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
219498410|NCT00765323|DRUG|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
219498411|NCT03605537|DRUG|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
219498412|NCT03941171|PROCEDURE|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
219498413|NCT03941171|OTHER|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
219498414|NCT03941171|OTHER|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
218879768|NCT01332253|DRUG|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
218879769|NCT01332253|OTHER|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
218879770|NCT03420274|BEHAVIORAL|NEST|This is a point-of-care shared decision-making instrument.
218879771|NCT03420274|BEHAVIORAL|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
218879772|NCT01277874|DEVICE|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
218879773|NCT01277874|DEVICE|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
218879774|NCT03127176|OTHER|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
219498415|NCT04416828|DEVICE|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
219498416|NCT04416828|DEVICE|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
219498417|NCT04624841|DRUG|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
219498418|NCT01332513|DRUG|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
219498419|NCT01332513|DRUG|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
219498420|NCT01332513|DRUG|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
219498421|NCT01332513|DRUG|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
218879775|NCT01487265|DRUG|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
218879776|NCT05987696|DRUG|CD33/CLL1 dual CAR-NK cell|NK cell therapy
218879777|NCT05987696|DRUG|Cyclophosphamid|Lympho-conditioning Agent
218879778|NCT05987696|DRUG|Fludarabine|Lympho-conditioning Agent
218879779|NCT05987696|DRUG|Cytarabine|Lympho-conditioning Agent
218879780|NCT05987696|DRUG|CD33 CAR-NK cell|NK cell therapy
218879781|NCT05987696|DRUG|super NK cell|NK cell therapy
219603640|NCT04140032|BEHAVIORAL|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
219603641|NCT06526988|BEHAVIORAL|EPIC-HF Patient-facing Tool|A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.
218879782|NCT04995211|DEVICE|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
219498422|NCT01332513|DRUG|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
219498423|NCT01332513|DRUG|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
219498424|NCT00919802|DRUG|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
219498425|NCT00919802|OTHER|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
219498426|NCT01602198|DRUG|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
219498427|NCT01602198|DRUG|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
219498428|NCT03175783|DEVICE|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
219498429|NCT02684383|BIOLOGICAL|rDEN3∆30|10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
219498430|NCT02684383|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
219498431|NCT04075383|PROCEDURE|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
219498432|NCT04075383|PROCEDURE|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
219498433|NCT02910453|PROCEDURE|Pulmonary lobectomy|
219603642|NCT06526988|BEHAVIORAL|PROMPT-HF Clinician-facing Alert|A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
219603643|NCT05410561|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
218879783|NCT04311125|PROCEDURE|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
218879784|NCT04311125|PROCEDURE|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
218879785|NCT04311125|PROCEDURE|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
218879786|NCT02184858|DRUG|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
219498434|NCT01807962|DRUG|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
219498435|NCT01807962|DRUG|sterile saline|Placebo = 5ml of sterile saline solution
219498436|NCT06181682|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine
219498437|NCT06181682|DRUG|Midazolam|Intranasal midazolam
219498438|NCT03501199|OTHER|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
219498439|NCT03501199|OTHER|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
219498440|NCT03501199|OTHER|no extra material|filling the buccal gap with no material after immediate dental implant placement
219498441|NCT03501199|PROCEDURE|tooth extraction|extraction of tooth which is unrestorable
219498442|NCT03501199|PROCEDURE|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
219498443|NCT03501199|OTHER|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
219498444|NCT03501199|PROCEDURE|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
219498445|NCT03031431|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
219498446|NCT04804982|OTHER|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
219603644|NCT05410561|BEHAVIORAL|TeleTx intervention|TeleTx will consist of an initial session and then 8 \~counseling sessions.
219603645|NCT06952868|DRUG|Drug: B10 L-BPA Injection|"The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.~This single arm of the study is designed to evaluate the therapeutic efficacy of BNCT, wherein patients receive B10 L-BPA administration followed by neutron irradiation."
219026646|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
219026647|NCT05721833|DEVICE|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
219498447|NCT03398460|DIAGNOSTIC_TEST|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
219498448|NCT01205529|DRUG|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
219498449|NCT01537965|DEVICE|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~* elastography with Fibroscan®~* ultrasound elastography in supersonic mode with Aixplorer®~* ultrasound analysis of the surface liver with QRS software,~* quantification of acoustic structure with Aplio XG,~* elastography ARFI with Acuson S2000."
219498450|NCT01195389|DEVICE|Resonator|Treatment group vs. Placebo group
219498451|NCT03346031|PROCEDURE|music therapy|patients will listen to music with an MP3 headset
219498452|NCT02128867|OTHER|Assisted Autogenic Drainage (AAD)|
219498453|NCT02128867|OTHER|bouncing and AAD|
219498454|NCT02128867|OTHER|bouncing|
219603646|NCT06782490|DRUG|BMS-986368|Specified dose on specified days
219603647|NCT06782490|DRUG|Placebo|Specified dose on specified days
219498455|NCT03779516|OTHER|Saline|Effect of saline on postoperative sore throat
219498456|NCT03779516|OTHER|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
219498457|NCT01027884|DRUG|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
219498458|NCT01027884|DRUG|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
219498459|NCT01147016|BIOLOGICAL|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
219498460|NCT01147016|DRUG|cyclophosphamide|As prescribed by physician, standard of care.
219498461|NCT01147016|DRUG|doxorubicin hydrochloride|As prescribed by physician, standard of care.
219498462|NCT01147016|DRUG|paclitaxel|As prescribed by physician, standard of care.
219498463|NCT01147016|OTHER|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
219603648|NCT03701282|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219603649|NCT03701282|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
219603650|NCT03701282|PROCEDURE|Computed Tomography|Undergo CT
219498464|NCT01147016|PROCEDURE|neoadjuvant therapy|As prescribed by physician, standard of care.
219498465|NCT01147016|PROCEDURE|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
219498466|NCT03670537|DIAGNOSTIC_TEST|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
219603651|NCT03701282|DRUG|Ibrutinib|Given PO
219603652|NCT03701282|BIOLOGICAL|Obinutuzumab|Given IV
219603653|NCT03701282|OTHER|Quality-of-Life Assessment|Ancillary studies
219603654|NCT03701282|DRUG|Venetoclax|Given PO
219603655|NCT06031441|DRUG|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
219603656|NCT06031441|DRUG|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
219603657|NCT05160129|DEVICE|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
218879787|NCT01040442|OTHER|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
219498467|NCT01925742|OTHER|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
219498468|NCT01925742|OTHER|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
219603658|NCT06242678|DEVICE|SCS trial lead|placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome
219603659|NCT05843500|OTHER|Survey|Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.
219603660|NCT05426525|DRUG|Empagliflozin|Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
219603661|NCT05426525|DRUG|Multivitamin-Placebo|Participants will take 1 multivitamin per day for 13 weeks.
219603662|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219603663|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219603664|NCT04429295|BIOLOGICAL|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
218879788|NCT01822418|DRUG|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
218879789|NCT03875742|DEVICE|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
218879790|NCT03875742|DEVICE|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
218879791|NCT02039284|DEVICE|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
219026648|NCT05721833|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
219498469|NCT01925742|OTHER|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
219498470|NCT01925742|OTHER|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
219603665|NCT04429295|BIOLOGICAL|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
219603666|NCT04429295|BIOLOGICAL|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
219026649|NCT00002233|DRUG|Indinavir sulfate|
219026650|NCT00002233|DRUG|Abacavir sulfate|
219026651|NCT00002233|DRUG|Amprenavir|
219026652|NCT00002233|DRUG|Lamivudine|
219026653|NCT03302013|PROCEDURE|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
219026654|NCT03302013|PROCEDURE|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
219026655|NCT01365507|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
219026656|NCT03503786|DRUG|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
219026657|NCT03503786|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
219026658|NCT03503786|DRUG|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
219026659|NCT01291056|OTHER|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
219603667|NCT04429295|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219603668|NCT04546009|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
219603669|NCT04546009|DRUG|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
219603670|NCT04546009|DRUG|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
219603671|NCT04546009|DRUG|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
219603672|NCT04546009|DRUG|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
219603673|NCT04546009|DRUG|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
219603674|NCT00784004|OTHER|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only"
218879792|NCT02039284|DEVICE|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
218879793|NCT02039284|DEVICE|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
218879794|NCT02039284|DEVICE|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
219498471|NCT01925742|OTHER|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
219498472|NCT00971685|DRUG|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
219498473|NCT05997485|DRUG|Nirmatrelvir/Ritonavir|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
219498474|NCT03241407|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
219498475|NCT03241407|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
219498476|NCT02059187|DRUG|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
219498477|NCT02059187|DRUG|Lantus™|Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
219498478|NCT02059187|DRUG|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
219498479|NCT03774927|DEVICE|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
219498480|NCT03774927|DEVICE|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
219498481|NCT03774927|DEVICE|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
219498482|NCT01039571|PROCEDURE|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
219498483|NCT00032370|PROCEDURE|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
219498484|NCT00032370|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
219498485|NCT00032370|PROCEDURE|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
219498486|NCT02226809|DEVICE|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
219498487|NCT04975282|DEVICE|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
219498488|NCT04975282|DEVICE|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
219498489|NCT03070431|RADIATION|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
219498490|NCT02220140|BEHAVIORAL|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
219498491|NCT01889862|DRUG|BMN165 20mg/day|BMN165 20mg/day self-administered daily
219498492|NCT01889862|DRUG|BMN165 40mg/day|BMN165 40mg/day self-administered daily
219498493|NCT01889862|DRUG|Placebo|Non-drug placebo, self-administered daily
219603675|NCT02018991|PROCEDURE|Everolimus-Eluting Stent (EES)|Patients treated with EES
218879795|NCT01992835|OTHER|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
218879796|NCT01992835|OTHER|placebo|
218879797|NCT02625844|OTHER|No intervention|No intervention administered in this study.
219026660|NCT01291056|DRUG|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
219498494|NCT03598452|DRUG|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
219498495|NCT02087579|DRUG|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
219603676|NCT02018991|PROCEDURE|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
219498496|NCT02087579|DRUG|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
219603677|NCT02018991|PROCEDURE|Biolimus-Eluting-Stent (BES)|Patients treated with BES
219603678|NCT04037280|OTHER|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
219603679|NCT02881398|DEVICE|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
219603680|NCT02881398|OTHER|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
219026661|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
219026662|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
219026663|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
219026664|NCT00192504|OTHER|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
219498497|NCT02087579|DRUG|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
219498498|NCT02087579|DRUG|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
219498499|NCT02087579|DRUG|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
219498500|NCT02087579|DRUG|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
219498501|NCT02087579|DRUG|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
219498502|NCT01517334|DRUG|Minocycline HCl Microspheres|
219498503|NCT02065791|DRUG|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
219498504|NCT02065791|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily
219498505|NCT01090128|DRUG|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
219498506|NCT01090128|DRUG|doxorubicin|50 mg/m2 every 3 weeks
219498507|NCT01090128|DRUG|cyclophosphamide|500 mg/m2 given every 3 weeks
219603681|NCT02905240|DEVICE|nSTRIDE APS|single intra-articular injection
219603682|NCT02905240|DEVICE|Saline|single intra-articular injection
219498508|NCT00272961|DRUG|Placebo|placebo tablet once daily for 12 weeks
219498509|NCT00272961|DRUG|TBC3711|10 mg tablets once daily for 10 weeks
219603683|NCT03758664|DRUG|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
219603684|NCT05797181|OTHER|medical nutrition therapy in kidney diseases|Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
219603685|NCT04802486|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
219603686|NCT06419907|BEHAVIORAL|Type 2 Live Well (structured diabetes self management education programme)|Structured diabetes self management education programme designed to support those with type 2 diabetes self care and prevent long term associated complications.
219603687|NCT04273061|DRUG|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
219603688|NCT04253379|DIAGNOSTIC_TEST|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
219603689|NCT06553209|BIOLOGICAL|CM512|CM512 injection
219603690|NCT06553209|DRUG|Placebo|Placebo
219603691|NCT02311933|DRUG|Endoxifen Hydrochloride|Given PO
219603692|NCT02311933|OTHER|Laboratory Biomarker Analysis|Correlative studies
219498510|NCT00272961|DRUG|TBC3711|50 mg tablet once daily for 10 weeks
219498511|NCT00272961|DRUG|TBC3711|100 mg tablet once daily for 10 weeks
219498512|NCT00272961|DRUG|TBC3711|200 mg tablet once daily for 10 weeks
219603693|NCT02311933|OTHER|Pharmacological Study|Correlative studies
218879798|NCT05349786|OTHER|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
219498513|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
219498514|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
218879799|NCT06271889|DEVICE|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal \& Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
219498515|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
219498516|NCT05603078|RADIATION|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
219498517|NCT00390156|BIOLOGICAL|bevacizumab|5 mg/kg
219603694|NCT02311933|DRUG|Tamoxifen Citrate|Given PO
219603695|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
219603696|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
218879800|NCT01618695|DRUG|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
219200511|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
219498518|NCT00390156|DRUG|cyclophosphamide|Current dose 50 mg
219498519|NCT00390156|DRUG|imatinib|Current dose 400 mg
219498520|NCT00748813|BIOLOGICAL|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
219498521|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
219498522|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
219498523|NCT02265887|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
219498524|NCT02921347|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
219603697|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
219603698|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
219603699|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
219603700|NCT06475742|DRUG|Cenerimod|Film-coated tablets at a dose of 4 mg.
219603701|NCT05420766|BEHAVIORAL|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
219603702|NCT05420766|BEHAVIORAL|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
219603703|NCT05516537|BEHAVIORAL|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
219498525|NCT06468735|DIAGNOSTIC_TEST|sarcopenia assessment|"Quadriceps muscle thickness measurement at the midpoint between the anterior superior iliac spine and the upper pole of the patella.~Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia"
218879801|NCT01618695|DRUG|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
218879802|NCT00068757|BIOLOGICAL|trastuzumab|
219603704|NCT05516537|BEHAVIORAL|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
219603705|NCT05929651|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
218879803|NCT00068757|DRUG|lonafarnib|
219498526|NCT06468735|DIAGNOSTIC_TEST|visceral fat thickness measurement|Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.
219603706|NCT06001814|BEHAVIORAL|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
219200512|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
219603707|NCT06001814|OTHER|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
219603708|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
218879804|NCT00068757|DRUG|paclitaxel|
219603709|NCT06120764|OTHER|guided imagery|The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts. The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing. Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop. Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients. Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery. If there is an object, person, event, situation, or food that will make them feel good,
219603710|NCT06069700|OTHER|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. \*Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. \*Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. \*Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
218879805|NCT00068757|OTHER|pharmacological study|
219026665|NCT03047642|DIAGNOSTIC_TEST|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
219026666|NCT00212732|DRUG|ONO-8025 (KRP-197)|
219026667|NCT02297828|DEVICE|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
219200513|NCT05056818|OTHER|Electronic Health Record Review|Review of medical records and past imaging examinations
219026668|NCT02297828|DEVICE|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
219603711|NCT06069700|OTHER|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
219603712|NCT05929521|OTHER|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
219498527|NCT01377961|DRUG|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
219498528|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
219498529|NCT01377961|OTHER|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
219498530|NCT01377961|OTHER|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
219498531|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
219498532|NCT01377961|OTHER|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
219498533|NCT04669899|DRUG|JTX-8064|Specified dose on specified days
219498534|NCT04669899|DRUG|pimivalimab|Specified dose on specified days
219498535|NCT00001428|DRUG|5-fluorouracil|
219498536|NCT01840683|DEVICE|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
219603713|NCT02186470|RADIATION|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
219603714|NCT02186470|RADIATION|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
218879806|NCT04692519|BEHAVIORAL|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
218879807|NCT03046576|DIAGNOSTIC_TEST|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
219498537|NCT05480527|DEVICE|Transcutaneous pulsed radiofrequency current|Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
219498538|NCT03675191|DRUG|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
219498539|NCT03675191|DRUG|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
219498540|NCT05153291|PROCEDURE|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
219498541|NCT05153291|PROCEDURE|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
219603715|NCT02186470|RADIATION|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
219603716|NCT02186470|PROCEDURE|therapeutic conventional surgery|Lumpectomy
219603717|NCT06436313|OTHER|Educational Sessions|"Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS."
219603718|NCT06565988|DEVICE|Decoria Voluma|"Decoria® Voluma medical device is a sterile, single use Hyaloronic acid based dermal filler intended for aesthetic use, provided in the form of a nonpyrogenic, viscoelastic gel. It is composed of highly purified sodium hyaluronate of high molecular weight, dissolved in a physiological buffer at pH 6.0-7.5. The sodium hyaluronate is derived from microbial fermentation and is stabilized by crosslinking with the chemical agent BDDE (1,4 Butanediol Diglycidyl Ether).~Decoria® Voluma dermal fillers are injected into dermal tissue for the correction of midface volume deficit by tissue augmentation in cheek region, supporting overlying tissue to shape facial contours to desired level of correction. This is possible due to the capacity of HA to attract and bind large amounts of water, forming a viscous gel.~Appropriate injection volume for the cheek region(s) will be determined by the Treating investigator according to IFU."
219603719|NCT04980027|DRUG|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
219603722|NCT04199624|DRUG|Omeprazole 20mg|Omeprazole twice daily x 5 days
219603723|NCT04199624|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid x 1 on day 5
219498542|NCT01094366|PROCEDURE|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
219498543|NCT01094366|PROCEDURE|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
219603724|NCT03757793|DEVICE|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
219603725|NCT06263452|DRUG|Propranolol|Tablet encapsulated to visually look identical to the placebo.
219603726|NCT06263452|DRUG|Placebo|Encapsulated sugar pill to visually look identical to the experimental condition.
219603727|NCT02134652|OTHER|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
219603728|NCT03478722|OTHER|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
219603729|NCT03478722|OTHER|Stable Isotope Amino Acid Infusion|Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
219603730|NCT01602068|DRUG|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
219603731|NCT01602068|DRUG|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
219498544|NCT01423565|DEVICE|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
219603732|NCT04082897|DRUG|Obinutuzumab 25 MG/ML [Gazyva]|Obinutuzumab will be administered from C1 to C8
219603733|NCT04082897|DRUG|Atezolizumab 60 MG/ML [Tecentriq]|Atezolizumab will be administered iv from C1 to C18
218879808|NCT04492501|PROCEDURE|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
219026669|NCT01210365|DRUG|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
219026670|NCT01210365|DRUG|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
219603734|NCT04082897|DRUG|Venetoclax Oral Tablet|Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
219603735|NCT04682392|DEVICE|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|A Delphi Personal Tourniquet system for blood flow restriction (BFR) therapy will be applied to each treatment session for this group. They will do 3-5 exercises with the BFR system on the surgical or both lower extremities for bilateral or unilateral movements.
219603736|NCT04682392|OTHER|Standard ACL rehab|Standard accelerated ACL protocol
219603737|NCT00801567|DEVICE|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
218879809|NCT04492501|BIOLOGICAL|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
218879810|NCT04492501|DRUG|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level \> 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC \< 1000, Platelets \< 50, ALT or AST \> 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
219603738|NCT05807204|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219603739|NCT05807204|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219603740|NCT01261897|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
218879811|NCT04492501|DRUG|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT \> 5 times ULN and GFR \< 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
218879812|NCT04492501|BIOLOGICAL|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
219026671|NCT02723968|OTHER|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
219026672|NCT02723968|PROCEDURE|HGPIV diagnosis test|
219603741|NCT01261897|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
219026673|NCT02723968|PROCEDURE|HOMAR-IR diagnosis test|
219026674|NCT01139450|DRUG|0417|Topical 0417 test product applied twice daily for 4 weeks
219603742|NCT05624645|DEVICE|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
219603743|NCT06550557|BEHAVIORAL|counselling sessions|the counselling sessions were adopted from the health belief model with the cues of action depending on mobile phones as muting notifications, removing social media and using computers instead if possible.
219603744|NCT02983786|DRUG|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
219603745|NCT03321149|OTHER|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
219603746|NCT02847260|DRUG|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
219603747|NCT04160650|BEHAVIORAL|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~1. In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~2. In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~3. In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~4. In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
219603748|NCT02923232|DEVICE|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
219026675|NCT01139450|DRUG|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
219026676|NCT01139450|DRUG|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
219603749|NCT03260660|DEVICE|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
219603750|NCT05644561|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
219026677|NCT00696514|DIETARY_SUPPLEMENT|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
219026678|NCT00696514|DIETARY_SUPPLEMENT|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
219026679|NCT01170182|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
219026680|NCT01170182|DEVICE|Prilosec® 40 mg|Prilosec® 40 mg
219603751|NCT06514534|DRUG|ABL001/Asciminib|"The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration."
219603752|NCT06355674|BEHAVIORAL|Breastfeeding education provided with Lactation Simulation Model|The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
219603753|NCT02898818|OTHER|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
219603754|NCT02898818|OTHER|papa smear|Papnicolaou Papa Smear test
219603755|NCT00925639|DRUG|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
219603756|NCT00925639|DRUG|Placebo|Starch pill
219026681|NCT02670044|DRUG|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
219498545|NCT05450666|OTHER|mobility exercises|Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
219498546|NCT06259942|OTHER|İntervention 1 group (underbody heater group only)|Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
219498547|NCT06259942|OTHER|İntervention 2 group (group using both underbody heater and heated iv liquid)|IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
219603757|NCT06579534|OTHER|Health education strategy|Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
219603758|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
219603759|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
219603760|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
219603761|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w\*6
219603762|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w\*6
219603763|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w\*6
219603764|NCT03374007|BIOLOGICAL|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
219603765|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
219603766|NCT04795947|BEHAVIORAL|Behavioral|There is no intervention in this study
219603767|NCT02031419|DRUG|CC-122|2mg or 3 mg administered orally once daily
219603768|NCT02031419|DRUG|CC-223|20mg or 30mg administered orally once daily.
219498548|NCT06259942|OTHER|Control Group|no active heating treatment was applied in this group
219603769|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
219603770|NCT02031419|DRUG|CC-122|2mg or 3mg administered orally once daily.
219603771|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
219026682|NCT02670044|DRUG|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
219026683|NCT02670044|DRUG|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
219026684|NCT01214707|OTHER|Exercise|Exercise during EMU stay
219603772|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
219603773|NCT02031419|DRUG|CC-223|20mg or 30mg per day administered orally daily.
219026685|NCT04782856|DRUG|Levothyroxine|levothyroxine sodium tablet for oral use
219026686|NCT04782856|DRUG|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
219026687|NCT04782856|DRUG|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
219026688|NCT02564614|DRUG|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
219498549|NCT03315156|DIAGNOSTIC_TEST|Electrogustometery|Taste assessment using EGM
219603774|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
219603775|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
219603776|NCT06438835|DIAGNOSTIC_TEST|PneuFlex AFO Assist|It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
219603777|NCT03231488|OTHER|Mindfulness intervention|A 10 minute mindfulness of breath exercise
218879813|NCT02342899|DEVICE|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
219498550|NCT02236156|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
219498551|NCT02236156|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
219498552|NCT02236156|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
219498553|NCT01947556|DRUG|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
219498554|NCT04816188|OTHER|Exercise Therapy and Activity Modification|Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
219498555|NCT03857685|PROCEDURE|In-vitro model|In-vitro model of posterior capsule opacification by culturing the lens capsule
219498556|NCT04534192|DEVICE|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
219498557|NCT00130481|DRUG|Atorvastatin 20 mg daily for 3 months|
219498558|NCT00095095|DEVICE|Lumbar Interbody Fusion|
219498559|NCT04882683|DRUG|Prednisone|0.75 mg per kilogram per day for three months
219498560|NCT04882683|DRUG|Azathioprine|1 mg per kilogram per day for three months
219498561|NCT04882683|DRUG|Adalimumab|40mg every two weeks for three months
219498562|NCT04882683|BIOLOGICAL|umbilical cord blood mononuclear cells|Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10\^8).
219498563|NCT03077633|PROCEDURE|Cervical Cerclage placement|Cervical Cerclage placement
219498564|NCT03077633|DRUG|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
219498565|NCT02362854|PROCEDURE|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
219498566|NCT02362854|DEVICE|DL application in peri-implantitis|Diode laser application in the diseased implants.
218879814|NCT02342899|DEVICE|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
218879815|NCT01481337|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
218879816|NCT01684319|DIETARY_SUPPLEMENT|Formula milk free of cow's milk protein|
218879817|NCT01684319|DIETARY_SUPPLEMENT|Placebo|Infant formula milk
219498567|NCT01203774|DRUG|Glargine insulin|20-180 units per day
218879818|NCT04346446|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
218879819|NCT04346446|OTHER|Supportive Care|Supportive Care
218879820|NCT04346446|DRUG|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
219498568|NCT04696562|BEHAVIORAL|Deep Breathing Exercise with Triflo|The investigators will do deep breathing exercises 5-10 times an hour with the triflo device.
219498569|NCT06537492|PROCEDURE|REBOA|"The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant."
219498570|NCT06537492|DEVICE|Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)|Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).
219026689|NCT00877695|BEHAVIORAL|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
219498571|NCT06537492|DEVICE|Mechanical Chest Compression Device with Active Chest Decompression|In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.
219498572|NCT06537492|DEVICE|Impedance Threshold Device|In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
219498573|NCT03909321|BEHAVIORAL|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
219498574|NCT03058497|DEVICE|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
219498575|NCT02309203|DEVICE|FRED|Flow Re-Direction Endoluminal Device
219498576|NCT05907200|OTHER|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
219498577|NCT05907200|OTHER|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
219498578|NCT03932487|OTHER|urinary iodine and urine BPA|urinary iodine and urine BPA
219498579|NCT06129552|PROCEDURE|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
219498580|NCT05730985|DIETARY_SUPPLEMENT|Miotrof® formula|1 sachet per day for 4 months
219498581|NCT05730985|DIETARY_SUPPLEMENT|Placebo formula|1 sachet per day for 4 months
219603778|NCT03231488|OTHER|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
219603779|NCT02893085|BIOLOGICAL|bile sample analysis|tumor mutation profile tumor genotype
219026690|NCT01932827|BEHAVIORAL|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
219026691|NCT00164346|BEHAVIORAL|neurocognitive habilitation|
219603780|NCT02893085|BIOLOGICAL|biochemical markers, VEGF and MMPs, in bile samples|
219603781|NCT03345693|DEVICE|MoTrack Therapy|A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
219603782|NCT02461251|DEVICE|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
219603783|NCT05536999|OTHER|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
219603784|NCT04975295|DRUG|LY3361237|Administered SC
219603785|NCT04975295|DRUG|Placebo|Administered SC
219026692|NCT02933242|RADIATION|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
219498582|NCT02565485|DRUG|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
219498583|NCT02712385|OTHER|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
219498584|NCT02712385|DEVICE|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
219498585|NCT02712385|PROCEDURE|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
219603786|NCT01493869|DRUG|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
219603787|NCT00533286|DRUG|benzodiacepine|diazepam (2 x 5 mg/ die)
219603788|NCT04365803|PROCEDURE|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
219603789|NCT02969421|OTHER|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
219603790|NCT02969421|OTHER|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
219603791|NCT02567279|DRUG|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
219603792|NCT02567279|DRUG|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
219026693|NCT06274541|GENETIC|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
219026694|NCT01145768|DRUG|TC-5214|4 mg tablet, oral, BID, group 1
219498586|NCT02712385|BEHAVIORAL|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
218879821|NCT05921565|BEHAVIORAL|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
218879822|NCT02376179|DEVICE|Cuffed ETT|
219498587|NCT02861183|DEVICE|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
218879823|NCT02466984|DRUG|metoclopramide intravenous|Administration route
218879824|NCT03917095|DEVICE|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
219026695|NCT01145768|DRUG|TC-5214|TBD tablet, oral, BID, groups 2-6
219026696|NCT01145768|DRUG|Placebo|
219026697|NCT05930730|BIOLOGICAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
219026698|NCT05930730|BIOLOGICAL|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
219026699|NCT03877627|PROCEDURE|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
219498588|NCT02861183|DEVICE|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
219498589|NCT00411697|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
219498590|NCT04857385|DEVICE|Radial artery hemostasis|Each of the devices will be assessed for radial artery hemostasis.
219498591|NCT03449056|DRUG|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
219498592|NCT06254209|DIETARY_SUPPLEMENT|Botanicals extracts|Powder included in capsules for daily administration
219603793|NCT06250218|OTHER|Video Interactive Guidance (VIG)|"Video interaction guidance (VIG) is a video feedback intervention through which a guider helps a client to enhance communication within relationships. The client is guided to analyse and reflect on video clips of their own interactions."
219603794|NCT05361915|DRUG|Abivertinib|Abivertinib is a small molecule inhibitor
219603795|NCT05361915|DRUG|Abiraterone|Hormone-based chemotherapy
219603796|NCT01407237|DRUG|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
219603797|NCT02276807|BEHAVIORAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
218879825|NCT03917095|DRUG|Glutamine|The medications were infused into the colon
218879826|NCT03917095|DRUG|Mesalazine|The medications were infused into the colon
218879827|NCT05062135|DRUG|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
218879828|NCT06335316|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218879829|NCT06335316|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
219026700|NCT04588987|BIOLOGICAL|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
219026701|NCT04779684|OTHER|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
219026702|NCT00046332|DRUG|GW810781|
219498593|NCT06254209|DIETARY_SUPPLEMENT|Placebo|Maltodextrin included in capsules for daily administration
219498594|NCT01510665|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
219498595|NCT01510665|DIETARY_SUPPLEMENT|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
219498596|NCT01510665|BEHAVIORAL|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
219498597|NCT00430157|DRUG|GSK256066|
219498598|NCT02415010|DEVICE|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
219498599|NCT02415361|OTHER|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
219498600|NCT00630669|PROCEDURE|Rubber band ligation|placing rubber bands around the internal hemorrhoids
219498601|NCT00630669|PROCEDURE|Bipolar coagulation|using electricity to cauterize
219498602|NCT03307512|DRUG|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
218879830|NCT06335316|BEHAVIORAL|Comprehensive therapy|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
218879831|NCT06335316|BEHAVIORAL|placebo|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
219498603|NCT03307512|DRUG|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
219603798|NCT02276807|OTHER|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
219603799|NCT06498882|OTHER|Press Needle Acupoint Stimulation Combined with Breast Massage|Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.
218879832|NCT04077853|DRUG|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
219498604|NCT04837625|OTHER|no interventions|no interventions
219498605|NCT01428024|DEVICE|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
219498606|NCT01428024|DEVICE|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
219498607|NCT02416583|DRUG|Oxytocin|
219498608|NCT02416583|DRUG|Dinoprostone|
219498609|NCT02416583|PROCEDURE|Membrane sweeping|
219498610|NCT04678453|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
219498611|NCT02139345|DEVICE|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
219498612|NCT02139345|DEVICE|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
219498613|NCT02042690|PROCEDURE|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
218879833|NCT02243735|DRUG|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
219498614|NCT02042690|DRUG|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
219498615|NCT04402515|DRUG|TIO/OLO|Tiotropium/Olodaterol
219498616|NCT04402515|DRUG|ICS|inhaled cortocosteroids
219498617|NCT00106028|DRUG|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
219498618|NCT00106028|DRUG|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
219498619|NCT04281056|PROCEDURE|Tooth removal and their replacement by means of a denture|Teeth have been removed and replaced by means of dentures for at least one year
219603800|NCT06498882|OTHER|routine care|Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
219603801|NCT02371382|DEVICE|Arthroplasty hip|Hip replacement
219603802|NCT03971474|DRUG|Docetaxel|Given IV
219603803|NCT03971474|DRUG|Gemcitabine|Given IV
219603804|NCT03971474|DRUG|Gemcitabine Hydrochloride|Given IV
219603805|NCT03971474|BIOLOGICAL|Pembrolizumab|Given IV
219603806|NCT03971474|DRUG|Pemetrexed|Given IV
219603807|NCT03971474|DRUG|Pemetrexed Disodium|Given IV
219603808|NCT03971474|BIOLOGICAL|Ramucirumab|Given IV
219603809|NCT03162874|DRUG|Placebo oral capsule|BID
219603810|NCT03162874|DRUG|PXT002331 - dose 1|Oral
219603811|NCT03162874|DRUG|PXT002331 - dose 2|Oral
218879834|NCT02243735|DRUG|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
219498620|NCT01548469|OTHER|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
218879835|NCT01248741|RADIATION|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
219498621|NCT01548469|OTHER|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
219498622|NCT01280981|DRUG|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
219603812|NCT04623892|DRUG|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
219603813|NCT03251001|PROCEDURE|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
219603814|NCT03251001|DEVICE|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
219603815|NCT00181701|DRUG|Paclitaxel|
219603816|NCT00181701|DRUG|Carboplatin|
219603817|NCT02045901|DRUG|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
219603818|NCT02045901|DRUG|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
219603819|NCT00261950|DRUG|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
219603820|NCT01375946|DRUG|AG200-15|There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
219603821|NCT02237586|BIOLOGICAL|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
219603822|NCT02299323|DEVICE|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
219603823|NCT05661370|OTHER|Dermloop Learn|Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
219603824|NCT04612907|RADIATION|Moderate hypo-fractionation|Patients will receive four weeks of radiotherapy
219603825|NCT04612907|RADIATION|Ultra-hypo-fractionation|Patients will receive two and a half weeks of radiotherapy
219603826|NCT02705261|BEHAVIORAL|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
219603827|NCT00037583|DRUG|Gemtuzumab Ozogamicin|
219498623|NCT04008342|OTHER|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
219603828|NCT01937871|DRUG|5 mg Tadalafil|Administered orally
219498624|NCT06438783|DRUG|1200mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
219603829|NCT01937871|DRUG|Placebo|Administered orally
219603830|NCT01937871|DRUG|0.2 mg Tamsulosin|Administered orally
219603831|NCT05273411|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Single-dose pharmacokinetic study over 4 hours.
219603832|NCT05273411|DIETARY_SUPPLEMENT|Beta-hydroxybutyric acid|Beta-hydroxybutyric acid
219603833|NCT05273411|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
219603834|NCT04754841|OTHER|platelet cryopreservation|The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
219603835|NCT00577863|DRUG|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
219498625|NCT06438783|DRUG|1800mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
219498626|NCT00743691|OTHER|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
219498627|NCT05498831|OTHER|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
218879836|NCT03716219|OTHER|Exercise Training|Physical activity in children and adults with asthma.
219498628|NCT04773171|OTHER|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
219498629|NCT04773171|OTHER|Conventional training programmes|Existing conventional activities in the settings
219498630|NCT05599204|OTHER|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
219498631|NCT05599204|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
219498632|NCT05147285|OTHER|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
219498633|NCT05147285|OTHER|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
219603836|NCT04795895|DIAGNOSTIC_TEST|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
219603837|NCT04795895|DIAGNOSTIC_TEST|Standard routine (SR)|Standard routine (SR)
219603838|NCT00002817|BIOLOGICAL|sargramostim|
218879837|NCT00255541|DRUG|Tesaglitazar|
218879838|NCT00255541|DRUG|Glibenclamide|
219498634|NCT05147285|OTHER|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
219603839|NCT00002817|BIOLOGICAL|vaccinia-GM-CSF vaccine|
218879839|NCT02454478|DRUG|Lenvatinib|
218879840|NCT02454478|DRUG|Everolimus|
218879841|NCT00866073|DRUG|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
218879842|NCT04683367|PROCEDURE|laparoscopic surgery|laparoscopic repair of hernia
218879843|NCT04243993|OTHER|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
218879844|NCT04102527|OTHER|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation"
218879845|NCT04701190|DRUG|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
219603840|NCT06031558|DRUG|SY-5007|a RET selective Inhibitor
219603841|NCT02597829|DRUG|Certolizumab Pegol|Subcutaneous Injection
219603842|NCT01854476|DEVICE|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
219603843|NCT04759196|DRUG|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
219603844|NCT04759196|DRUG|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
219603845|NCT00668317|DRUG|Omeprazole|20 mg BD tablet 8 weeks duration
219498635|NCT02996617|DRUG|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
219498636|NCT02996617|DRUG|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
219498637|NCT04974359|DRUG|Lu AG06466|Lu AG06466 - capsules
219498638|NCT04974359|DRUG|Placebo|Placebo - capsules
219498639|NCT05742854|PROCEDURE|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
219498640|NCT05742854|DRUG|Oxytocin|Oxytocin
219498641|NCT05742854|DRUG|Carbetocin|Carbetocin
219498642|NCT00486499|PROCEDURE|I-125 versus Pd-103 radioactive seed insertion|
219498643|NCT05600179|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
219498644|NCT06043999|PROCEDURE|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
219603846|NCT00668317|DRUG|Ranitidine|300 mg od nocte tablet 8weeks duration
219603847|NCT00398424|DRUG|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
219603848|NCT00064896|PROCEDURE|MRI|
219603849|NCT06052293|DRUG|ANG003|To evaluate four possible combinations of lipase, protease and amylase.
219603850|NCT00248261|DRUG|ziprasidone, sertraline|
219603851|NCT01565356|DRUG|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
218879846|NCT04701190|DRUG|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
218879847|NCT04701190|DRUG|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
218879848|NCT04701190|DRUG|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
218879849|NCT04701190|DRUG|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
218879850|NCT04701190|PROCEDURE|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
218879851|NCT01128192|DRUG|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
218879852|NCT00852865|DRUG|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4\*109 CFU
218879853|NCT00852865|DRUG|Placebo|1 capsule per day
218879854|NCT03590353|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
219026703|NCT03340337|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
218879855|NCT03590353|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
219603852|NCT04247373|DRUG|Ropivacaine|According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
219603853|NCT02254980|DEVICE|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
219603854|NCT02254980|DEVICE|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
219603855|NCT04451148|OTHER|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
219603856|NCT02924831|OTHER|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
219603857|NCT02924831|OTHER|moxibustion|Stimulating acupoints by using burned moxa
219603858|NCT02924831|OTHER|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
219498645|NCT06043999|OTHER|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
219498646|NCT04312919|BEHAVIORAL|Family Based Activity Intervention|Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
219603859|NCT03037593|DRUG|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
219603860|NCT04540653|BIOLOGICAL|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
219603861|NCT04540653|BIOLOGICAL|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
219603862|NCT01894087|BEHAVIORAL|TBI - Cohort 1|
218879856|NCT05693350|DIAGNOSTIC_TEST|DUS|Duplex ultrasound
219498647|NCT03292783|DRUG|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
219498648|NCT04726514|DEVICE|SleepFlex|SleepFlex Program
219498649|NCT04675060|DRUG|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
219498650|NCT03263520|DRUG|Nandrolone Decanoate|Drug administration
219498651|NCT03263520|DRUG|Dexamethasone|Drug administration
219498652|NCT04655482|DRUG|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
219498653|NCT05483439|DRUG|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
219603863|NCT01894087|BEHAVIORAL|TBI - Cohort 2|
219603864|NCT02463266|BEHAVIORAL|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
219603865|NCT02646605|OTHER|depression screening|Patient Health Questionnaire
219603866|NCT05024552|DRUG|Gilteritinib|Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
219498654|NCT05483439|DRUG|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
219498655|NCT05483439|DRUG|traditional herbal medicine|traditional herbal medicine
219498656|NCT02448472|OTHER|Observational study, none intervention|
219498657|NCT06371079|DEVICE|phakic intraocular lens implantation traditional|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of both cohesive and dispersive OVD
219498658|NCT06371079|DEVICE|phakic intraocular lens implantation reduced OVD|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of only cohesive OVD without using dispersive OVD.
219603867|NCT05024552|DRUG|Vyxeos|Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
219603868|NCT05672576|DRUG|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
219603869|NCT05672576|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
219603870|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
219603871|NCT05567367|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
219603872|NCT05567367|DRUG|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
219603873|NCT05888805|OTHER|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
218879857|NCT01721226|DEVICE|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
219498659|NCT05517005|DIETARY_SUPPLEMENT|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
218879858|NCT01721226|OTHER|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
219498660|NCT01256398|BIOLOGICAL|Alemtuzumab|Given IV
219498661|NCT01256398|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
219498662|NCT01256398|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
219498663|NCT01256398|DRUG|Cyclophosphamide|Given IV
219498664|NCT01256398|DRUG|Cytarabine|Given IV
219498665|NCT01256398|DRUG|Dasatinib|Given PO
219603874|NCT03509467|BEHAVIORAL|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
219603875|NCT03509467|BEHAVIORAL|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
219603876|NCT03509467|OTHER|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
219603877|NCT05271630|OTHER|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
219603878|NCT05271630|DRUG|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
219603879|NCT05271630|DRUG|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
219603880|NCT00277693|DRUG|Spironolactone (drug)|
219603881|NCT03892603|OTHER|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
219613276|NCT03823170|RADIATION|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
218879859|NCT02292563|PROCEDURE|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
219498666|NCT01256398|DRUG|Daunorubicin Hydrochloride|Given IV
218879860|NCT02292563|PROCEDURE|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
219498667|NCT01256398|DRUG|Dexamethasone|Given PO or IV
219498668|NCT01256398|DRUG|Etoposide Phosphate|Given IV
219498669|NCT01256398|BIOLOGICAL|Filgrastim|Given SC
219498670|NCT01256398|DRUG|Fludarabine Phosphate|Given IV
219498671|NCT01256398|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
219498672|NCT01256398|OTHER|Laboratory Biomarker Analysis|Correlative studies
219498673|NCT01256398|DRUG|Leucovorin Calcium|Given IV or PO
218879861|NCT03053947|DRUG|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
218879862|NCT05399563|OTHER||
218879863|NCT02975050|OTHER|Location|
218879864|NCT04949594|DEVICE|TENS|application on muscles where pain is situated (cervical)
218879865|NCT04522349|DEVICE|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
218879866|NCT04522349|DEVICE|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
218879867|NCT00746863|DRUG|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
218879868|NCT03229109|DEVICE|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
218879869|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
218879870|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
218879871|NCT04207749|DEVICE|LID015385 contact lenses|Investigational soft contact lenses
218879872|NCT04207749|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses
219026704|NCT03340337|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
219026705|NCT03340337|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
219026706|NCT01160068|DRUG|Metformin|Metformin Tablets 1000 mg
219026707|NCT01160068|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
219498674|NCT01256398|DRUG|Melphalan|Given IV
219498675|NCT01256398|DRUG|Mercaptopurine|Given PO
219498676|NCT01256398|DRUG|Methotrexate|Given IT, IV, or PO
219498677|NCT01256398|BIOLOGICAL|Pegfilgrastim|Given SC
219498678|NCT01256398|OTHER|Pharmacological Study|Correlative studies
219498679|NCT01256398|DRUG|Tacrolimus|Given IV or PO
219498680|NCT01256398|DRUG|Vincristine Sulfate|Given IV
219498681|NCT01552005|DRUG|Saxagliptin|No Intervention
218879873|NCT04207749|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
218879874|NCT06442488|DEVICE|Respiratory Monitoring System|Comparing the SNR and accuracy of measurement (RR, TV, MV, apnea duration) in a noisy external environment when the RMS has adaptive filtering and active noise cancellation turned on versus turned off.
218879875|NCT00370916|BEHAVIORAL|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
218879876|NCT00370916|BEHAVIORAL|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
219498682|NCT06235645|DIAGNOSTIC_TEST|Lung ultrasound (LUS)|"If included, an LUS will be performed by an experienced operator, blinded to the results of the chest CT and PFT.~A linear probe (4 to 12 MHz) will be used. The patient will be installed́ in a semi-seated position with the homolateral arm above the head for the anterior and axillary evaluation then, depending on his comfort, in a seated position or in right then left lateral decubitus, arms alongside the body, for the posterior evaluation. It will be practiced by experienced operators (pneumologist) and according to a validated protocol allowing the exploration of 14 intercostal spaces. LUT will be timed, recorded and anonymized.~The operator will note the 3 ultrasound signs (total number of B lines, pleural line thickening and percentage of pleural line irregularity), their location and severity.~The radiologist, on his part, will evaluate the patient's chest CT (gold standard), blinded to the results of the LUS, to make or not the diagnosis of RA-ILD."
219498683|NCT05854173|DIAGNOSTIC_TEST|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
219498684|NCT05854173|DIAGNOSTIC_TEST|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
219498685|NCT00424931|DRUG|JNJ-17216498|50mg one time
219498686|NCT00424931|DRUG|JNJ-17216498|10mg one time
219498687|NCT00424931|DRUG|Modafinil|200 mg X 2
219498688|NCT01399073|BEHAVIORAL|virtual reality setup|testing for neglect in a virtual reality setup
219498689|NCT01399073|BEHAVIORAL|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
219498690|NCT01399073|OTHER|c-mri|structural and functional (resting state) imaging
219498691|NCT01847625|OTHER|simulator|
219498692|NCT06135519|PROCEDURE|Autologous Mesenchymal stem cells injection|Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
219498693|NCT06135519|PROCEDURE|Homogenized fat injection|Autologous fat will be harvested, homogenized and injected.
219498694|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 1|Single inhaled dose of SP-101 and doxorubicin Dose 1
219498695|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 2|Single inhaled dose of SP-101 and doxorubicin Dose 2
219498696|NCT03216681|DRUG|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
219498697|NCT03216681|DRUG|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
219498698|NCT00420355|DRUG|atazanavir|Atazanavir 300 mg daily on Days 6-12.
219498699|NCT00420355|DRUG|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
219498700|NCT05895214|PROCEDURE|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
219498701|NCT03649906|PROCEDURE|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
219498702|NCT03029000|DRUG|Tbo-filgrastim|solution for subcutaneous injection
219498703|NCT06015217|DRUG|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
218879877|NCT00406172|DRUG|Bevacizumab|
218879878|NCT00668668|DRUG|Lactic acid (Dermacid)|
218879879|NCT03260296|OTHER|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
218879880|NCT02641301|DRUG|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
218879881|NCT02075788|OTHER|Commercial white bread|
218879882|NCT02075788|OTHER|Corn based products (porridge etc.)|
218879883|NCT02075788|OTHER|Millet based products (porridge etc.)|
218879884|NCT05813691|DIAGNOSTIC_TEST|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
218879885|NCT01835223|DRUG|Tivozanib (1mg)|Given PO
218879886|NCT01835223|DRUG|Tivozanib (1.5mg)|Given PO
218879887|NCT05767112|OTHER|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
218879888|NCT03226496|BEHAVIORAL|motivational interviewing|
218879889|NCT01504841|DRUG|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
219498704|NCT00152386|DRUG|Certolizumab pegol (CDP870)|
219498705|NCT01845090|DRUG|Lanthanum carbonate|the effect on serum FGF23
219498706|NCT01845090|DRUG|Calcium Carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
219498707|NCT00296582|BEHAVIORAL|Gastric Motor Function Measurement|
219498708|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
219498709|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
219498710|NCT01874730|OTHER|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
219498711|NCT01874730|DRUG|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
219498712|NCT01874730|OTHER|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
219498713|NCT04615286|OTHER|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
219498714|NCT04615286|OTHER|Standard (long course) of antibiotics|4-6 weeks of antibiotics
219498715|NCT00414986|BEHAVIORAL|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
219498716|NCT00414986|BEHAVIORAL|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
219498717|NCT00414986|BEHAVIORAL|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
219498718|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
219498719|NCT02061709|BIOLOGICAL|Ragweed-SPIRE|
219498720|NCT02061709|BIOLOGICAL|Placebo|
219498721|NCT03022929|BEHAVIORAL|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
219613277|NCT03823170|PROCEDURE|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
219613278|NCT03823170|COMBINATION_PRODUCT|Laser therapy and Fluorotherapy|This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
218879890|NCT03679624|DRUG|Ibrutinib|Ibrutinib, 420mg orally, once daily
219498722|NCT02431715|DRUG|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
219498723|NCT00411762|DRUG|Capecitabine|
219498724|NCT00411762|DRUG|PHY906|
219498725|NCT03448601|OTHER|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
219498726|NCT03448601|OTHER|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
219498727|NCT03276962|BIOLOGICAL|RTS,S/AS01E (Full dose)|Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
219498728|NCT03276962|BIOLOGICAL|RTS,S/AS01E (1/5th dose)|Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
219498729|NCT03276962|BIOLOGICAL|Rabies vaccine|Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
219498730|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
219498731|NCT03399435|COMBINATION_PRODUCT|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
218879891|NCT03679624|DRUG|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
218879892|NCT01610336|DRUG|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
218879893|NCT01610336|DRUG|Gefitinib|Gefitinib 250 mg taken once daily
218879894|NCT05030350|DRUG|PH94B|Nasal spray
218879895|NCT05882149|DIETARY_SUPPLEMENT|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
218879896|NCT05882149|DIETARY_SUPPLEMENT|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
218879897|NCT02139865|BEHAVIORAL|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
218879898|NCT02139865|BEHAVIORAL|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
218879899|NCT05805046|DEVICE|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
218879900|NCT00572208|DRUG|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
218879901|NCT04556279|PROCEDURE|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
218879902|NCT04556279|DRUG|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
219498732|NCT03399435|COMBINATION_PRODUCT|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
219498733|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
219498734|NCT03399435|DRUG|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
219498735|NCT03399435|DRUG|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
219498736|NCT03399435|DRUG|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
218879903|NCT05637788|DIAGNOSTIC_TEST|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
218879904|NCT01928901|DRUG|administration of Sinupret|
218879905|NCT01928901|DRUG|administration of Bronchipret|
218879906|NCT01928901|DRUG|administration of Sinupret Placebo|
218879907|NCT01928901|DRUG|administration of Bronchipret Placebo|
218879908|NCT01193114|BEHAVIORAL|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
218879909|NCT01193114|BEHAVIORAL|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
218879910|NCT05099796|PROCEDURE|Transforaminal epidural steroid injection|
218879911|NCT05099796|PROCEDURE|Caudal epidural steroid injection|
218879912|NCT03594136|DEVICE|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
218879913|NCT01618825|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
218879914|NCT01618825|DRUG|Lamotrigine|2 x 25 mg tablet once a day
218879915|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
218879916|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
219026708|NCT03145896|DIETARY_SUPPLEMENT|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
219498737|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
219498738|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
219498739|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
219498740|NCT06307678|DRUG|Calcium Hydroxide|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
219498741|NCT06307678|DRUG|Calcium Silicate|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
219498742|NCT04664283|DEVICE|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
219498743|NCT02758951|OTHER|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
219498744|NCT02758951|COMBINATION_PRODUCT|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
219498745|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
219498746|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
219498747|NCT02758951|PROCEDURE|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy in case of sufficient clinical condition, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
219498748|NCT02758951|PROCEDURE|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after randomisation.
219498749|NCT05727592|DIETARY_SUPPLEMENT|Althernanthera Sissoo|15g of Althernanthera Sissoo consumed with lunch or dinner per day.
219498750|NCT05727592|BEHAVIORAL|Dietary Consultation|Dietary consultation to improve the intakes of vegetables daily
219498751|NCT01238211|DRUG|Cytarabine|Given IV
219498752|NCT01238211|DRUG|Dasatinib|Given PO
218879917|NCT03783299|DRUG|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
218879918|NCT03783299|DRUG|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
219498753|NCT01238211|DRUG|Daunorubicin Hydrochloride|Given IV
219498754|NCT01238211|OTHER|Laboratory Biomarker Analysis|Correlative studies
219498755|NCT05155072|DRUG|DW1903|DW1903
219498756|NCT05155072|DRUG|DW1903-R1|DW1903-R1
219498757|NCT05155072|DRUG|DW1903-R2|DW1903-R2
219498758|NCT01311310|OTHER|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
219498759|NCT04428502|DRUG|Enbrel|As provided in real world practice
219498760|NCT01933139|OTHER|Audio-visual presentation|
219498761|NCT04658446|DEVICE|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
219498762|NCT04658446|DEVICE|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
219498763|NCT04127968|DRUG|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
219498764|NCT04127968|DRUG|Oil|Children in control group will receive equal volume of oil.
219498765|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
219498766|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
219498767|NCT01468168|DRUG|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
219498768|NCT04839315|BIOLOGICAL|mRNA COVD19 vaccine|Subjects will receive two doses of mRNA based COVID19 vaccines.
219498769|NCT00646178|DRUG|adalimumab|40 mg adalimumab eow Week 0 - Week 12
218879919|NCT03536234|DRUG|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
219026709|NCT04577937|DIAGNOSTIC_TEST|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
219026710|NCT02984033|RADIATION|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
219498770|NCT00646178|DRUG|placebo for adalimumab|placebo eow Week 0 - Week 12
219498771|NCT00000773|DRUG|Atovaquone|
219498772|NCT02488707|PROCEDURE|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
219613279|NCT06362915|DRUG|Lidocaine|* Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
219613280|NCT06362915|DRUG|Bupivacain|• Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist
218879920|NCT00852787|DRUG|Digoxin immune fab|Intravenously one time
218879921|NCT00852787|DRUG|Placebo|Intravenously one time
219026711|NCT03179150|DIAGNOSTIC_TEST|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
219026712|NCT04728269|OTHER|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
219498773|NCT02488707|PROCEDURE|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
219498774|NCT00827073|DRUG|tetracaine 0.5%|betadine 5%
219498775|NCT00827073|DRUG|Lidocaine 2% Jelly|Betadine 5%
219498776|NCT05203588|DRUG|Denosumab 60 mg/ml Injectable Solution [Prolia]|Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
219498777|NCT05203588|DRUG|calcium and vitamin D|calcium (≥1·0 g) and vitamin D (≥400 IU).
219498778|NCT03172260|DEVICE|E Balance Pro Therapy|Micro-current treatment
219498779|NCT02995694|DRUG|Estradiol|Estradiol Vaginal Cream
219498780|NCT02995694|DRUG|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
219498781|NCT02995694|DRUG|Reference|Estrace Vaginal Cream
219498782|NCT03654092|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
219613281|NCT03465059|DRUG|Zanubrutinib|A single oral dose of 80 mg Zanubrutinib will be administered.
219498783|NCT04472065|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
219498784|NCT04472065|OTHER|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
219498785|NCT04307030|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
219498786|NCT03836365|OTHER|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
219498787|NCT03836365|OTHER|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
219498788|NCT02375646|DRUG|Warfarin|
219603882|NCT03892603|OTHER|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
219613282|NCT03822585|DIAGNOSTIC_TEST|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
218879922|NCT06025981|OTHER|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
218879923|NCT06025981|OTHER|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
218879924|NCT06025981|OTHER|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
218879925|NCT01559675|DRUG|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
218879926|NCT01559675|DRUG|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
219026713|NCT04728269|OTHER|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
219026714|NCT03929848|PROCEDURE|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
219498789|NCT02375646|DRUG|LMW Heparin|
218879927|NCT05240365|DEVICE|SDF modified Hall technique|"* Preparation for Hall technique and selection of the crown.~* Clinical application of SDF.~* Cementation of the selected crown."
219026715|NCT01049321|DIETARY_SUPPLEMENT|DASH diet|
219026716|NCT01049321|DIETARY_SUPPLEMENT|a usual diabetic diet|
219026717|NCT05511142|OTHER|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
219026718|NCT05511142|OTHER|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
219026719|NCT05159895|DRUG|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
219498790|NCT02190383|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
219498791|NCT01856374|DEVICE|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
219498792|NCT01856374|DEVICE|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
219498793|NCT01856374|DRUG|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
219498794|NCT01856374|DRUG|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
219498795|NCT01626131|BEHAVIORAL|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
219498796|NCT01626131|BEHAVIORAL|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
219498797|NCT00002973|DRUG|melphalan|
219498798|NCT00002973|PROCEDURE|hyperthermia treatment|
219498799|NCT00449930|DRUG|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
219498800|NCT00449930|DRUG|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
219498801|NCT03550794|DRUG|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
219498802|NCT03550794|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
219498803|NCT06128031|OTHER|questionaire|"Psychiatric interview: this will be assessed by (SCID-5)semi structural clinical interview based on Diagnostic and Statistical manual of Mental disorders-5 criteria~-Psychometric assessment include; Hamilton depression rating scale(7) and Hamilton anxiety rating scale(8) , used to score the symptoms of anxiety or depression Quality of life assessment: will be assessed by the Patient assessment of constipation-quality of life questionnaire"
219498804|NCT05465707|BIOLOGICAL|CM313 2 mg/kg|Once 1 week, intravenous infusion.
219498805|NCT05465707|BIOLOGICAL|CM313 4 mg/kg|Once 1 week, intravenous infusion.
219498806|NCT05465707|BIOLOGICAL|CM313 8 mg/kg|Once 1 week, intravenous infusion.
219498807|NCT05465707|BIOLOGICAL|CM313 16 mg/kg|Once 1 week, intravenous infusion.
219498808|NCT05465707|BIOLOGICAL|Placebo|Once 1 week, intravenous infusion.
219498809|NCT01543815|BEHAVIORAL|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
219603883|NCT03892603|OTHER|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
219603884|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
219603885|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
219603886|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
219603887|NCT05015686|BIOLOGICAL|Placebo|Sodium chloride and distilled water
219603888|NCT03883503|OTHER|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
219603889|NCT03883503|OTHER|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
219603890|NCT03883503|OTHER|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
219603891|NCT03883503|OTHER|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
219603892|NCT00697151|DRUG|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
219603893|NCT00697151|DRUG|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
219603894|NCT05534061|BEHAVIORAL|Connect2Test|Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
219498810|NCT01543815|BEHAVIORAL|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
219498811|NCT01543815|OTHER|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
219498812|NCT02252497|DRUG|Active comparator : Tranexamic Acid (Exacyl)|"* 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours ."
219498813|NCT02252497|DRUG|Placebo comparator : physiologic serum|"* 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours"
219603895|NCT05311904|OTHER|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
219603896|NCT03210792|DEVICE|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
219603897|NCT02253004|DRUG|Cilostazol|Single oral administration of active or placebo one week apart
219603898|NCT02253004|DRUG|Placebo|
219603899|NCT01412086|DRUG|No Intervention|No Intervention.
219498814|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
219498815|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
219498816|NCT06538168|BEHAVIORAL|Diabetes Self-Management Education (DSME)|The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
219498817|NCT06309472|DRUG|Mirtazapine|30mg mirtazapine at night, escalated to 45mg after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
219498818|NCT06309472|DRUG|Placebo|1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
219498819|NCT02786186|DRUG|Secikinumab|
219498820|NCT02688816|DEVICE|Xpert HPV|Point-of-care HPV DNA PCR test
219603900|NCT00309855|DRUG|Placebo|im and orally
219603901|NCT00309855|DRUG|Testosterone|injections
219603902|NCT00309855|DRUG|Anastrazole|orally x 21 days
219603903|NCT00309855|DRUG|Dutasteride|orally x 21 days
218879928|NCT05240365|DEVICE|Conventional pulpotomy and stainless steel crown|"* Teeth will be anesthetized .~* Rubber dam will be used and high suction in pulpotomy procedure.~* Cavity outline will be performed by sterile #330 high speed bur using water spray.~* Caries will be removed by large spoon excavator.~* pulpal exposure will be occurred then the roof of pulp chamber will be removed by low speed round bur. Hemostasis will be obtained by applying pressure with moist cotton pellet with saline.~* Teeth will be treated by using sterile cotton pellet with formcresol for three to five min then, remove it.~* Pulp stumps of will be dressed with reinforced zinc oxide eugenol, IRM®\*~* Tooth Preparation will be done followed by placement of stainless-steel crown"
219026720|NCT03001258|OTHER|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
219026721|NCT04307446|DEVICE|Immersive Virtual Reality|Immersive Virtual Reality
219026722|NCT04067128|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to three phone calls
219603904|NCT01027598|DRUG|Pazopanib|Pazopanib: 600 mg orally daily
219603905|NCT01027598|DRUG|Erlotinib|Erlotinib: 150 mg orally daily
219603906|NCT02829918|DRUG|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
219603907|NCT06970106|DRUG|PYC-001|PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally
219603908|NCT03484091|DRUG|Hyruan-One|single dose intra-articular injection
219603909|NCT03484091|DRUG|Hylan G-F 20|single dose intra-articular injection
219603910|NCT03484091|DRUG|Normal saline|single dose intra-articular injection
219603911|NCT06559215|DRUG|Exparel|Patients will be randomized to receive Exparel intraoperatively via local infiltration.
219603912|NCT05381909|DRUG|BGB-24714|administered orally
219603913|NCT05381909|DRUG|Paclitaxel|administered intravenously
219603914|NCT05381909|DRUG|Carboplatin|administered intravenously
219603915|NCT05381909|DRUG|Docetaxel|administered intravenously
219603916|NCT06421935|DRUG|M9466|Participants will be administered M9466 orally.
219603917|NCT06421935|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
218879929|NCT00636285|DRUG|Placebo|Placebo
218879930|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
218879931|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
218879932|NCT00291018|DEVICE|Total Disc Replacement|Total Disc Replacement using ProDisc-C
219603918|NCT06421935|DRUG|Abiraterone acetate|Participants will be administered with Abiraterone acetate orally.
219603919|NCT06421935|DRUG|Prednisone/Prednisolone|Participants will be administered with prednisone/prednisolone orally.
219603920|NCT06475053|DEVICE|NaturalVue Enhanced Multifocal 1 Day contact lens|Daily disposable multifocal contact lens
219603921|NCT06475053|DEVICE|MiSight 1 Day contact lens|Daily disposable dual-focus contact lens
219603922|NCT06642519|OTHER|Brain Stimulation|Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
219498821|NCT02688816|DEVICE|OncoE6|Point-of-care E6 oncoprotein test
219498822|NCT05269017|DRUG|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
219498823|NCT05269017|DRUG|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
219498824|NCT06457464|DRUG|Chemotherapy|combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
219603923|NCT06132763|BEHAVIORAL|Hydration Intervention|"Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
219498825|NCT03954964|BEHAVIORAL|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
219498826|NCT05792410|DRUG|SHR-A1811 & Dalpiciclib Isethionate Tablets|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral
219498827|NCT05792410|DRUG|SHR-A1811 & Fulvestrant|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
219498828|NCT05792410|DRUG|SHR-A1811 & Bevacizumab injection|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
219498829|NCT00067288|BEHAVIORAL|Meaning-Centered Group Psychotherapy|
219498830|NCT00067288|BEHAVIORAL|Standard Supportive Group Psychotherapy|
219498831|NCT04908956|DRUG|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
219498832|NCT04908956|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
219498833|NCT00029328|DRUG|etanercept|
219498834|NCT03712228|BIOLOGICAL|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
219498835|NCT03712228|DRUG|Placebo|Buffer without active ingredient
219498836|NCT03513978|OTHER|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
219498837|NCT03513978|OTHER|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
219603924|NCT06132763|OTHER|Control - Assessments Only|Assessments only
219603925|NCT05867368|BEHAVIORAL|HABIT-VR|HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
219603926|NCT05867368|BEHAVIORAL|Standard HABIT|HABIT is a camp where children play self-select activities that require both hands to succeed.
219603927|NCT05081193|DRUG|Testosterone Undecanoate|198mg taken twice daily
219603928|NCT05081193|DRUG|Enzalutamide|160mg taken once daily
218879933|NCT00291018|DEVICE|ACDF|Anterior Cervical Discectomy and Fusion
218879934|NCT03953469|DIETARY_SUPPLEMENT|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
218879935|NCT01496469|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
218879936|NCT01496469|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
218879937|NCT05219682|OTHER|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
219498838|NCT04822961|DRUG|Placebo|Senaparib-matched placebo capsules
219498839|NCT04822961|DRUG|Senaparib|20 mg capsules
219498840|NCT01484171|DRUG|idarubicin|idarubicin 10-12 mg/m2 for three days
219498841|NCT01484171|BIOLOGICAL|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
219498842|NCT04660409|DIAGNOSTIC_TEST|Blood test for serum Adropin|Blood test for serum Adropin
219498843|NCT04477083|DRUG|inhalable hydroxychloroquine (HCQ)|inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
219498844|NCT04477083|DRUG|supportive and symptomatic treatment|supportive and symptomatic treatment
219498845|NCT01964105|DEVICE|3D Imaging|
219498846|NCT04001205|DRUG|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
219498847|NCT05798871|PROCEDURE|Subgingival erythritol air polishing|"The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement"
219498848|NCT05798871|PROCEDURE|Conventional root planing|The intervention will start with supragingival debridement followed by root planing by curette.
219498849|NCT03049137|PROCEDURE|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
219603929|NCT03071406|DRUG|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
219603930|NCT03071406|DRUG|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
219603931|NCT03071406|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
219603932|NCT06719869|DEVICE|Midline intravenous catheter|Patients in the intervention group receive a 10 cm PowerGlide Pro™ Midline Catheter (Becton Dickinson). Catheters are inserted with ultrasound-guidance by an anesthesiologist using sterile gloves, mask, and large drape. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. All catheters are secured with using a StatLock™ Stabilization device (Becton Dickinson), and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. Choice of insertion site on arm below or above the elbow avoiding catheter across joints and at the clinician's discretion.
219613283|NCT05751317|DIAGNOSTIC_TEST|Culture|"* Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~* Pink colonies will be inoculated on bile esculin agar medium.~* Enterococci produce blackening of the agar"
219498850|NCT03049137|PROCEDURE|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
219200514|NCT06283108|DEVICE|Standard Child Life Preparation and Support + Meta Quest 2 VR headset with Gurney Journey (a mixed reality experience)|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental or gastrointestinal procedure. Child life specialist's will utilize Gurney Journey as part of their support for induction. Gurney Journey is a mixed reality experience, using the Meta Quest 2 VR headset that was designed to mitigate patient anxiety during transport from pre-admission rooms to the procedure room/operating room for surgical procedures.
219200515|NCT06283108|BEHAVIORAL|Standard Child Life Preparation and Support|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure.
219498851|NCT03049137|DRUG|Platelet-rich fibrin (PRF)|
219498852|NCT03049137|DEVICE|implant|
219498853|NCT05803538|DEVICE|SMS, telephone interview or diary card|SMS, telephone interview or diary card
219498854|NCT04793438|BEHAVIORAL|Motive-specific intervention|Three appointments are made with the patients of the intervention group within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. The time frame of 45 minutes for each intervention must be strictly adhered to. Patients are additionally asked to complete tasks between the sessions. All appointments take place in the Psychiatric University Hospital directly on the ward.
219498855|NCT04793438|BEHAVIORAL|Supportive conversations|Since we want to check whether the patients benefit from the specific intervention and not only from getting more speaking time, patients without the motive-specific intervention should also be given three sessions, in which no intervention takes place. They will be carried out in the sense of supportive conversations (i.e. conversations that do not follow a specific psychotherapy concept). All appointments take place in the Psychiatric University Hospital directly on the ward.
219498856|NCT02898766|OTHER|Enteral Nutrition Formula|
219498857|NCT04171986|DRUG|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
219498858|NCT03001011|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219498859|NCT03001011|DRUG|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
219498860|NCT00567528|DRUG|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
219498861|NCT00567528|DRUG|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
219498862|NCT02875067|BIOLOGICAL|Pembrolizumab|
219498863|NCT02875067|DRUG|Lenalidomide|
219498864|NCT05415826|PROCEDURE|slow-release dexamethasone implant|The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
219498865|NCT00786266|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
219498866|NCT00786266|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
219498867|NCT00065065|DRUG|Rosiglitazone|4mg orally twice daily for 12 weeks
219498868|NCT00065065|DRUG|Placebo|pill that looks identical to rosiglitazone
219498869|NCT04575974|OTHER|No intervention|No intervention
219498870|NCT01241565|DEVICE|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
219498871|NCT00449579|DEVICE|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
219498872|NCT00064779|DRUG|IL13-PE38QQR|
219498873|NCT00064779|PROCEDURE|targeted fusion protein therapy|
219498874|NCT00064779|PROCEDURE|surgery|
219498875|NCT03841565|BIOLOGICAL|Daratumumab|Given IV
219498876|NCT03841565|DRUG|Dexamethasone|Given PO
219498877|NCT03841565|DRUG|Pomalidomide|Given PO
219498878|NCT02873468|DRUG|Florence 30 μg/mL|10 mL, oral, twice a day.
219498879|NCT02873468|DRUG|Florence 60 μg/mL|10 mL, oral, twice a day.
219498880|NCT02873468|DRUG|Florence 90 μg/mL|10 mL, oral, twice a day.
219498881|NCT02873468|OTHER|Placebo|10 mL, oral, twice a day.
219498882|NCT03020836|BEHAVIORAL|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
219498883|NCT03020836|BEHAVIORAL|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
219498884|NCT02135367|BIOLOGICAL|PRP|injections of Platelet rich Plasma
219200516|NCT05660486|OTHER|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
219613284|NCT05751317|DIAGNOSTIC_TEST|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
219613285|NCT05751317|DIAGNOSTIC_TEST|Biochemical reactions:|"* Catalase test.~* Salt tolerance test"
219613286|NCT05751317|DIAGNOSTIC_TEST|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
219613287|NCT05751317|DIAGNOSTIC_TEST|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
219613288|NCT05751317|DIAGNOSTIC_TEST|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
219613289|NCT05751317|DIAGNOSTIC_TEST|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
218879938|NCT01873040|BEHAVIORAL|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
218879939|NCT01873040|BEHAVIORAL|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
218879940|NCT02356718|BEHAVIORAL|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
218879941|NCT02356718|BEHAVIORAL|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
218879942|NCT05502354|DEVICE|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
219026723|NCT04346472|OTHER|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
219026724|NCT05075226|DEVICE|Vivity Extended Depth of Focus|Cataract surgery
219026725|NCT00146874|DEVICE|cardiac resynchronization therapy|
219026726|NCT02253212|DEVICE|SonoCloud|SonoCloud : dose escalation
219200517|NCT05660486|OTHER|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
219026727|NCT02253212|DRUG|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
219026728|NCT04019743|DRUG|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
219200518|NCT05862909|OTHER|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
219200519|NCT05862909|OTHER|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
219498885|NCT03888716|DRUG|KL1333|25 and 100 mg KL1333 encapsulated tablets
219498886|NCT03888716|DRUG|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
219498887|NCT00004158|DRUG|melphalan|
219498888|NCT00004158|PROCEDURE|peripheral blood stem cell transplantation|
219498889|NCT00004158|RADIATION|holmium Ho 166 DOTMP|
219498890|NCT06174519|DEVICE|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
219498891|NCT05723341|DRUG|Bupivacain|%0,25
219026729|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
219026730|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
219026731|NCT05222061|DEVICE|Drug coated balloon for the side brunch|Intervention is explained in group description
219026732|NCT05222061|DEVICE|Conventional balloon for the side brunch|Intervention is explained in group description
219498892|NCT05723341|DRUG|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
219498893|NCT05288673|DRUG|ALXN1210|ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
219498894|NCT05288673|DRUG|Placebo|Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
219498895|NCT03125057|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
219498896|NCT01050673|DEVICE|VERSAJET|Hydro-surgery debridement
219498897|NCT01050673|PROCEDURE|Scalpel or blade|Conventional Surgical Debridement
219498898|NCT02762968|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar to the experimental treatments.
219498899|NCT02762968|DIETARY_SUPPLEMENT|HMB|Capsules containing calcium HMB.
219498900|NCT02762968|DIETARY_SUPPLEMENT|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
219603933|NCT06719869|DEVICE|Central Venous Catheter (CVC):|Patients in the control group receive a Celsite 320 or 315 (B. Braun) or Pressure Injectable Arrowg+ard Blue Plus+ (Arrow). Catheters are inserted with ultrasound-guidance by an anesthesiologist with maximal sterile precautions (cap, mask, gown, gloves, and large drape) using the Seldinger technique. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. Catheters are secured with monofilament sutures, and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. The choice of insertion site is at the clinician's discretion
219603934|NCT04945018|BIOLOGICAL|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
219603935|NCT04945018|DEVICE|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
219603936|NCT05835362|BEHAVIORAL|Question prompt list|A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.
219603937|NCT05835362|BEHAVIORAL|Pre-visit video|The 11-minute video has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD.
219603938|NCT05835362|BEHAVIORAL|Combined question prompt list/video|"A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.~And the video is an 11-minute video that has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD."
219603939|NCT05358795|BEHAVIORAL|Family Connections|Family Connections is based on the WHO endorsed Positive Connections manual.
219603940|NCT05681026|BEHAVIORAL|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
219603941|NCT05681026|BEHAVIORAL|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
219603942|NCT05681026|BEHAVIORAL|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
219603943|NCT06080256|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
219603944|NCT06080256|DRUG|Atorvastatin|Atorvastatin 20-40mg
219603945|NCT04052360|DRUG|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
219603946|NCT04052360|DRUG|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
218879943|NCT02843503|DEVICE|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
218879944|NCT02843503|DEVICE|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
218879945|NCT02843503|DEVICE|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
218879946|NCT00467129|GENETIC|microarray analysis|
218879947|NCT00467129|GENETIC|mutation analysis|
218879948|NCT00467129|GENETIC|polymerase chain reaction|
218879949|NCT00467129|GENETIC|polymorphism analysis|
218879950|NCT00467129|OTHER|laboratory biomarker analysis|
219200520|NCT04611113|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
219613290|NCT05751317|DIAGNOSTIC_TEST|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
218879951|NCT00467129|OTHER|questionnaire administration|
218879952|NCT03045718|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
218879953|NCT01939327|DRUG|Lenalidomide/Rituximab|
218879954|NCT02202538|DEVICE|Indego|Indego
218879955|NCT01453907|DRUG|"ETI-204, Anthim"|intravenously, single dose
218879956|NCT01453907|DRUG|placebo|intravenously, single dose
219026733|NCT02430337|BEHAVIORAL|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
219026734|NCT02430337|BEHAVIORAL|SafeCare|SafeCare, an evidence-based home visiting program
219026735|NCT02477995|BIOLOGICAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
219026736|NCT02477995|BIOLOGICAL|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
219603947|NCT05157594|BIOLOGICAL|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
219603948|NCT04138823|DRUG|BI 891065|film-coated tablets
219603949|NCT03874273|DRUG|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
219603950|NCT02803658|BEHAVIORAL|smoking behavior|
219603951|NCT02803658|BIOLOGICAL|Sperm collection|
219603952|NCT04202055|OTHER|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
219498901|NCT01485224|DRUG|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
219498902|NCT03056352|DRUG|Metoclopramide|Intravenous medication drip
219603953|NCT05942625|DRUG|HS-10390 tablet|Oral administration of specified dose of HS-10390
219603954|NCT05942625|DRUG|Placebo tablet|Oral administration of matching dose ofplacebo
219603955|NCT05326555|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
219603956|NCT05200364|DRUG|STRO-002|intravenous antibody drug conjugate
219603957|NCT05200364|DRUG|Bevacizumab|anti-VEGF agent
219026737|NCT03946735|BEHAVIORAL|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
219026738|NCT03257631|DRUG|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
219026739|NCT03257631|DRUG|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
219200521|NCT04611113|DIETARY_SUPPLEMENT|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
219603958|NCT05264181|DEVICE|Percutaneous pulmonary valve implantation|Percutaneous pulmonary valve implantation using SAPIEN 3 valve in the context of routine care of patients with congenital heart diseases
219603959|NCT03502434|DRUG|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
219603960|NCT03502434|OTHER|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
219603961|NCT03502434|OTHER|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
219603962|NCT03502434|OTHER|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
219498903|NCT03056352|DRUG|Diphenhydramine|Intravenous medication drip
219498904|NCT00447018|DRUG|20% mannitol|
219498905|NCT00447018|DRUG|7.45% hypertonic saline solution|
219498906|NCT02122510|DRUG|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
219498907|NCT02122510|DRUG|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
219603963|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
219603964|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
219603965|NCT01368315|DRUG|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
219603966|NCT01368315|DRUG|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
219603967|NCT01368315|DRUG|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
219603968|NCT01368315|DRUG|No intervention|No intervention to one out of four test fields marked on the patient's back.
219603969|NCT02466685|DRUG|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
219603970|NCT02466685|DRUG|Placebo|placebo tablet daily
219603971|NCT02366273|OTHER|PASI and HOMA index|
219603972|NCT02676765|DRUG|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
219603973|NCT02676765|DRUG|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
219603974|NCT03340974|DRUG|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
219603975|NCT03340974|DRUG|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
219603976|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
219603977|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
219603978|NCT06442215|OTHER|Data collection|Collection of preoperative demographic, clinical, and radiological variables from patients who meet the inclusion criteria in order to identify possible risk factors for suboptimal surgical treatment
219603979|NCT02391987|DEVICE|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
219498908|NCT04322968|DRUG|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
219498909|NCT00796159|DRUG|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
219498910|NCT02529085|OTHER|blood samples|blood samples for the bank
219498911|NCT00691145|DRUG|tacrolimus ointment|transdermal
219603980|NCT05741177|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound score
219603981|NCT02479529|DRUG|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
219603982|NCT02479529|DRUG|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
219603983|NCT04641598|PROCEDURE|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
219498912|NCT02581761|DRUG|CYTOTEC|synthetic prostaglandin E1
219498913|NCT02581761|OTHER|Placebo|no active material
219498914|NCT00949390|BEHAVIORAL|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
219498915|NCT05146869|DRUG|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
219498916|NCT01424774|DRUG|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
219498917|NCT01956682|DIETARY_SUPPLEMENT|HA formula + starch + L. reuteri|
219498918|NCT00597207|DEVICE|AutoPulse|Mechanical device that provides chest compression
219498919|NCT00597207|OTHER|Manual|Manual chest compression
219498920|NCT04036578|DEVICE|A 12-week PFMT bio-assisted surface electromyographic program|
219498921|NCT02917954|DEVICE|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
219498922|NCT00520351|DRUG|ClearCare|contact lens care system
219498923|NCT00520351|DRUG|Optifree Replenish|contact lens care system
219498924|NCT06398080|DRUG|aflibercept 8 mg|No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
219498925|NCT04229277|DIAGNOSTIC_TEST|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
219498926|NCT03845322|DRUG|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
219498927|NCT03845322|DRUG|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
219498928|NCT02996006|PROCEDURE|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
219603984|NCT04641598|PROCEDURE|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
219603985|NCT02965937|OTHER|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
219603986|NCT02965937|OTHER|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
219603987|NCT01799837|DRUG|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
219603988|NCT06164366|DEVICE|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
219603989|NCT06164366|DEVICE|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
219603990|NCT03044626|DRUG|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
219603991|NCT03044626|DRUG|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
219603992|NCT03854630|DRUG|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
219603993|NCT04521738|DRUG|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
219603994|NCT04521738|DRUG|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
219200522|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
219200523|NCT06099405|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
219200524|NCT06099405|BEHAVIORAL|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
219200525|NCT03031262|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
219200526|NCT03031262|DRUG|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
219200527|NCT06833034|PROCEDURE|The novel surgical method|Additional bone removal in intended direction for tooth movement
219498929|NCT02838290|OTHER|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
219603995|NCT03490578|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
219603996|NCT03490578|DEVICE|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
219603997|NCT03010683|DRUG|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
219603998|NCT03010683|DRUG|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
219200528|NCT06833034|PROCEDURE|The conventional surgical method|The conventional method to use surgery
218879957|NCT06289309|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
219603999|NCT02405130|OTHER|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
219604000|NCT02405130|OTHER|no intracoronary epinephrine|patients will receive standard therapy only
219604001|NCT00052598|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
219604002|NCT00052598|BIOLOGICAL|aldesleukin|Given SC
219026740|NCT04965194|PROCEDURE|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
219026741|NCT04965194|PROCEDURE|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
219498930|NCT02838290|OTHER|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
219498931|NCT01977859|DRUG|Nesiritide|
219498932|NCT01977859|DRUG|Saline|
219498933|NCT01993433|DRUG|DRM02|
219498934|NCT01993433|OTHER|Vehicle|
219498935|NCT04170049|BEHAVIORAL|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
219498936|NCT02949778|PROCEDURE|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
219498937|NCT02949778|DRUG|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
219498938|NCT02949778|DRUG|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
219498939|NCT06375031|DRUG|HR011408 injection; HR011408 injection Placebo|"Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum"
219498940|NCT06375031|DRUG|NovoRapid®; HR011408 injection Placebo|"Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum"
219604003|NCT00052598|OTHER|laboratory biomarker analysis|Correlative studies
219604004|NCT00052598|OTHER|flow cytometry|Correlative studies
219604005|NCT03456505|BEHAVIORAL|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
219498941|NCT06375031|DRUG|HR011408 injection Placebo; HR011408 injection|"Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum"
219498942|NCT02717936|PROCEDURE|Immunohistochemistry using Pancytokeratin Staining|
219604006|NCT03456505|BEHAVIORAL|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
219498943|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of placebo
219498944|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
219498945|NCT02803645|BIOLOGICAL|blood sample|
219498946|NCT04009954|OTHER|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
219604007|NCT01563497|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
219498947|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
219604008|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fasted
219604009|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fed
219604010|NCT05299528|BEHAVIORAL|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
219604011|NCT00600587|DRUG|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
219604012|NCT00600587|DRUG|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
219604013|NCT00159224|DRUG|Lopinavir/ritonavir simplification strategy|Simplification
219604014|NCT00314210|DRUG|Quetiapine SR|
219498948|NCT00074009|DRUG|bortezomib|
219498949|NCT01588587|DRUG|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
219498950|NCT01588587|DRUG|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
218879958|NCT01180010|PROCEDURE|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
218879959|NCT03760679|DEVICE|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
219498951|NCT01588587|DRUG|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
219498952|NCT02795780|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
219498953|NCT02795780|PROCEDURE|PET Scan|positron emission tomography (PET) scan
219498954|NCT00373659|DRUG|Ranibizumab (Lucentis)|
218879960|NCT03760679|DEVICE|i-gel evaluation|Device: i-gel evaluation
218879961|NCT01853878|BIOLOGICAL|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
218879962|NCT01853878|BIOLOGICAL|Placebo|Intramuscular administration
218879963|NCT04314011|BIOLOGICAL|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
218879964|NCT04314011|BIOLOGICAL|Placebo|Placebo
218879965|NCT01399866|DRUG|D-cycloserine|2 single weekly doses, 50 mg capsule
219026742|NCT04965194|OTHER|placebo|patients received no regional block
219026743|NCT05978154|OTHER|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
219026744|NCT04667039|BIOLOGICAL|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
219498955|NCT04632693|PROCEDURE|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
219498956|NCT04632693|PROCEDURE|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
219498957|NCT03673475|PROCEDURE|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
219498958|NCT04359186|OTHER|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
219498959|NCT05598645|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
219498960|NCT05598645|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
219498961|NCT01812291|BEHAVIORAL|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement"
219604015|NCT04877457|DRUG|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
219604016|NCT04877457|OTHER|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
218879966|NCT01399866|DRUG|Placebo|
218879967|NCT02443818|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
218879968|NCT04271033|DEVICE|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
218879969|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
218879970|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
218879971|NCT03029091|DRUG|Losartan Potassium|Losartan potassium
219026745|NCT04667039|BIOLOGICAL|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
219498962|NCT01812291|BEHAVIORAL|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
219604017|NCT01888939|OTHER|Walking on a Treadmill|
219604018|NCT01888939|OTHER|Sedendary Activities Only|
219604019|NCT03209895|DIETARY_SUPPLEMENT|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
218879972|NCT00794885|DRUG|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
218879973|NCT00794885|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
218879974|NCT00465647|DRUG|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
218879975|NCT03916081|DRUG|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
218879976|NCT03916081|DRUG|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
218879977|NCT03916081|DRUG|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
219498963|NCT01812291|BEHAVIORAL|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
219498964|NCT01812291|BEHAVIORAL|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes"
219498965|NCT03564535|DEVICE|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
219498966|NCT03564535|DEVICE|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
219498967|NCT04716673|OTHER|Down-phase targeted auditory stimulation|The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
219498968|NCT04582409|DRUG|HSY244|HSY244 concentrate solution for injection via intravenous infusion
219498969|NCT04582409|OTHER|Placebo|Placebo concentrate solution for injection via intravenous infusion
219498970|NCT00016835|PROCEDURE|Supra-gingival scaling and placebo|Included in arm/group description.
219498971|NCT00016835|PROCEDURE|Subgingival scaling and metronidazole|Included in arm/group description.
219498972|NCT00016835|PROCEDURE|Subgingival scaling and doxycycline|Included in arm/group description.
218879978|NCT00881647|OTHER|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
218879979|NCT03225703|BEHAVIORAL|Hopping|A unilateral, hopping based exercise programme lasting six months.
218879980|NCT05018663|OTHER|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
218879981|NCT02272166|DRUG|propofol|
218879982|NCT02272166|DRUG|Sevoflurane|
218879983|NCT03872856|DEVICE|BP-ICAN|"One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff"
218879984|NCT00516867|RADIATION|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
219026746|NCT00940212|DRUG|AZD2423|oral, single administration
219498973|NCT02353429|DRUG|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
218879985|NCT00516867|RADIATION|UV radiation|UVB 1.4 % and UVA 98.6
218879986|NCT02205242|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
219498974|NCT04166669|DRUG|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
219498975|NCT04166669|DRUG|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
219498976|NCT04166669|DRUG|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
219498977|NCT05924568|OTHER|Educational session with Keep Your Move in the Tube and PrimusRS|
219604020|NCT03209895|DIETARY_SUPPLEMENT|Placebo|Palm oil Softgel capsule
219026747|NCT00940212|DRUG|Placebo|oral administration and single dose
219026748|NCT00233623|DRUG|Iressa (Gefitinib)|
219026749|NCT00233623|DRUG|Irinotecan|
219604021|NCT03209895|DIETARY_SUPPLEMENT|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
219604022|NCT03173157|OTHER|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
218879987|NCT02205242|DEVICE|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
218879988|NCT02205242|DRUG|Placebo|
218879989|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
218879990|NCT00487292|BEHAVIORAL|naps and pulses of bright light|
219026750|NCT00233623|DRUG|5Fluorouracil|
219026751|NCT00233623|DRUG|Leucovorin|
219026752|NCT02338869|BEHAVIORAL|Dialogue-based psychosocial rehabilitation|
219200529|NCT02246374|DEVICE|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
219200530|NCT04864899|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
219200531|NCT04864899|DIAGNOSTIC_TEST|Blood test|Blood investigation
219604023|NCT05126329|DRUG|amcenestrant|tablet for oral use
219604024|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
218879991|NCT01708135|BEHAVIORAL|Use of smartphone app|
218879992|NCT06485388|DRUG|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
218879993|NCT06485388|DRUG|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
218879994|NCT06006403|BIOLOGICAL|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
218879995|NCT02168608|OTHER|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
218879996|NCT02168608|OTHER|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
218879997|NCT03825016|DRUG|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
218879998|NCT03825016|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium
219026753|NCT01613521|OTHER|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
219026754|NCT00891358|BEHAVIORAL|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
219498978|NCT01010230|DEVICE|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
219498979|NCT01010230|DEVICE|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
218879999|NCT01112748|DRUG|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
219026755|NCT01254435|PROCEDURE|Colonoscopy|Recording of colonoscopic extubation
219200532|NCT04864899|DIAGNOSTIC_TEST|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
219498980|NCT00530439|OTHER|Lifestyle intervention|Dietician counselling and physical training
219498981|NCT00530439|OTHER|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
219498982|NCT00530439|BEHAVIORAL|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
219498983|NCT01176474|BIOLOGICAL|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
218880000|NCT03368235|DRUG|AZD9567|oral OD SGRM administered as suspension
218880001|NCT03368235|DRUG|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
218880002|NCT05315089|OTHER|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
218880003|NCT05315089|OTHER|Conventional exercises|Conventional exercises
218880004|NCT01799551|BEHAVIORAL|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
218880005|NCT02828020|DRUG|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
218880006|NCT02828020|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
219604025|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
219498984|NCT01176474|DRUG|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
218880007|NCT00391924|DRUG|Dehydroepiandrosterone|
218880008|NCT00216489|DRUG|rabeprazole sodium|
219498985|NCT01176474|BIOLOGICAL|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
219498986|NCT01176474|DRUG|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
219498987|NCT01176474|DRUG|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
219498988|NCT01176474|PROCEDURE|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
219604026|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
219604027|NCT04142086|BIOLOGICAL|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
219604028|NCT01596790|OTHER|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
219604029|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
218880009|NCT00085891|DRUG|Quetiapine Fumarate|
218880010|NCT06039618|OTHER|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
218880011|NCT00682955|DRUG|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
219200533|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
218880012|NCT00682955|DRUG|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
219200534|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
219498989|NCT04728737|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
219498990|NCT04728737|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
219498991|NCT04728737|OTHER|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
219498992|NCT01818037|PROCEDURE|Cataract surgery|
219604030|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
219604031|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
219604032|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
219604033|NCT00769587|DRUG|thalidomide|
219604034|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
219604035|NCT01793493|OTHER|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~* body awakening (10 minutes)~* cognitive stimulation (1 hour and a half) scheduled as follow:~  * temporospatial orientation~ * attentional abilities~ * one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
219604036|NCT01793493|OTHER|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
219604037|NCT04960293|PROCEDURE|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
219604038|NCT04960293|PROCEDURE|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
219604039|NCT04470063|DRUG|DDO-3055 tablets|Multi-dose for DDO-3055 tablets
219604040|NCT04470063|DRUG|Placebo|Multi-dose for Placebo
219604041|NCT03307226|BEHAVIORAL|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
219604042|NCT03307226|BEHAVIORAL|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
219604043|NCT01549717|DEVICE|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
219604044|NCT01199146|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
218880013|NCT02645630|OTHER|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
219498993|NCT04929522|PROCEDURE|local anesthesia|technique for local anesthesia
219498994|NCT04580524|PROCEDURE|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
219604045|NCT04222426|OTHER|89Zr-atezolizumab PET scans|Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
219604046|NCT05930561|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
219604047|NCT05930561|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator
219604048|NCT06245915|BIOLOGICAL|AB-2100|autologous T cell therapy
219604049|NCT02155621|GENETIC|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
218880014|NCT02645630|OTHER|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
218880015|NCT02645630|OTHER|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
218880016|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
218880017|NCT03366467|OTHER|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
218880018|NCT03366467|OTHER|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
219498995|NCT04580524|PROCEDURE|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
219604050|NCT06633380|BEHAVIORAL|Standard Physical Activity - Fasted|30 minutes of walking at a self-selected pace that they must have completed 15 minutes prior to consumption of first meal in the morning.
219498996|NCT03705169|BIOLOGICAL|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
219498997|NCT03705169|BIOLOGICAL|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
219498998|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
219604051|NCT06633380|BEHAVIORAL|Standard Physical Activity - Post-Meal|30 minutes of walking at a self-selected pace to start 30 minutes after the start of the first meal in the morning.
219604052|NCT06633380|BEHAVIORAL|Dispersed Physical Activity|10 minutes of walking at a self-selected pace to start 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
219604053|NCT06633380|BEHAVIORAL|Physical Activity Snacks|2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
219604054|NCT06633380|BEHAVIORAL|Muscle Strengthening|30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body, to start 30 minutes after the start of the first meal in the morning.
219604055|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with capsules containing rosemary and alkylglycerol|
219604056|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with control capsules|
219604057|NCT02914223|DRUG|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
219604058|NCT02895152|BEHAVIORAL|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
218880019|NCT01517386|PROCEDURE|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
218880020|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
218880021|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
219498999|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
219499000|NCT05911347|DIETARY_SUPPLEMENT|Psyllium|15g psyllium added to inulin solution to form a gel
219499001|NCT05911347|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
219604059|NCT05180227|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
219604060|NCT05848011|BIOLOGICAL|lorigerlimab|Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
219604061|NCT05848011|DRUG|docetaxel|Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
219604062|NCT05848011|DRUG|Prednisone|A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
218880022|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
218880023|NCT02239952|DRUG|Sunitinib|50 mg once daily, oral use for 14 days
218880024|NCT02239952|DRUG|vandetanib|300 mg, once daily, oral use for 14 days
218880025|NCT02239952|DRUG|Erlotinib|150 mg, once daily, oral use for 14 days
218880026|NCT00483795|DRUG|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
218880027|NCT06395532|OTHER|Observetional|After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
218880028|NCT05230849|DEVICE|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
218880029|NCT05230849|OTHER|convencional treatment|is a physiotherapy treatment for neurological patients
218880030|NCT01249547|DRUG|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
219604063|NCT03992404|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219604064|NCT03992404|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219604065|NCT01218854|DEVICE|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
219604066|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
219604067|NCT06854562|BEHAVIORAL|Therapeutic Robot Intervention|This intervention involves the use of a therapeutic robot seal, PARO, to interact with pediatric patients in the Pediatric Intensive Care Unit (PICU). The intervention is designed to alleviate stress and anxiety in children during their hospital stay. The robot provides emotional support by engaging in 30-minute sessions, where children can interact with the robot, give it a name, and express their emotions. The therapeutic interaction is repeated twice on consecutive days.
219604068|NCT06854562|BEHAVIORAL|Toy Seal Intervention|In this group, children interact with a plush toy seal. The plush seal is used to provide emotional comfort and reduce anxiety during their stay in the PICU. The interaction happens over two consecutive days for 30 minutes per session.
219604069|NCT06854562|BEHAVIORAL|Standard Care|Children in this group will receive standard care and routine interventions provided by healthcare professionals in the PICU, without the use of therapeutic robots or plush toys.
219499002|NCT05911347|DIETARY_SUPPLEMENT|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
219499003|NCT00560183|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
219604070|NCT05567796|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
219604071|NCT05567796|DRUG|Semaglutide|Participants will recieve semaglutide subcutaneously.
219604072|NCT05567796|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
219604073|NCT05567796|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
219604074|NCT06587204|OTHER|Control Group|Participants will receive standard of care.
219604075|NCT06587204|BEHAVIORAL|Decentralized Group|Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.
219604076|NCT06587204|BEHAVIORAL|Digital Literacy Navigation Group|Participants will receive a one time digital literacy training virtual learning digital health education for the rest of the intervention . The digital literacy training is a digital health education program that will be given 1 hour a day for 3 weeks.
219604077|NCT06587204|BEHAVIORAL|Social Care Navigation Group|Participants will receive a one time social care navigation application that will be used for the rest of the intervention. The Social Care Navigation application is a digital application that provides social care resources in the community to participants. The application is used 1 hour a day, each day.
219604078|NCT06592911|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
219604079|NCT06634264|DEVICE|Soft Oral Appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
218880031|NCT04233450|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
218880032|NCT05322369|OTHER|periodontal charting only|Periodontal charting only
218880033|NCT05041972|DRUG|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
218880034|NCT01504685|PROCEDURE|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
218880035|NCT01504685|PROCEDURE|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
218880036|NCT04983420|OTHER|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
218880037|NCT04983420|OTHER|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
218880038|NCT04983420|OTHER|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
218880039|NCT04983420|OTHER|lemonade|intake of 1 L lemonade per day for 2 weeks
218880040|NCT01339897|DRUG|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
219604080|NCT00321191|DRUG|No nitrous oxide|
219604081|NCT00321191|DRUG|Administration of N2O|
219604082|NCT04204538|OTHER|Dietary habits|Data collected using food frequency questionnaire
219604083|NCT04204538|OTHER|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
218880041|NCT01339897|DRUG|Placebo|Same administration procedures as active
218880042|NCT01339897|DRUG|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
218880043|NCT01339897|DRUG|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
218880044|NCT01138501|DRUG|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
218880045|NCT01138501|DRUG|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
218880046|NCT03809819|PROCEDURE|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
218880047|NCT03809819|DIAGNOSTIC_TEST|FSFI questionnaire|Completion of FSFI questionnaire
218880048|NCT03809819|DIAGNOSTIC_TEST|UDI-6 questionnaire|Completion of UDI-6 questionnaire
218880049|NCT03809819|DIAGNOSTIC_TEST|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
218880050|NCT01656668|DRUG|BC1036|
218880051|NCT04534881|DRUG|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
218880052|NCT04534881|DRUG|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
218880053|NCT00668538|DRUG|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
219499004|NCT00560183|DRUG|Placebo|Capsules
219499005|NCT05214157|PROCEDURE|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
219604084|NCT05139888|DEVICE|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
219200535|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
219499006|NCT02148783|DRUG|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
219200536|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
219499007|NCT02148783|DRUG|Placebo|
219499008|NCT00634192|DRUG|tobramycin|1x300mg/d inhaled
219604085|NCT05139888|DEVICE|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
219604086|NCT00253721|DRUG|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
219604087|NCT01192867|DRUG|Placebo|Placebo will be administered orally QD for 56 weeks
219604088|NCT01192867|DRUG|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
219604089|NCT01192867|DRUG|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
219604090|NCT02875691|DIETARY_SUPPLEMENT|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
219604091|NCT02875691|DIETARY_SUPPLEMENT|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
219604092|NCT05880329|DIAGNOSTIC_TEST|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
219604093|NCT05734651|DEVICE|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
219604094|NCT03899909|DRUG|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
219604095|NCT03899909|DRUG|Placebo SAD|Placebo oral suspension
218880054|NCT00847197|DRUG|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
218880055|NCT00847197|DRUG|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
218880056|NCT01506011|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
218880057|NCT02551029|OTHER|Capsaicin|
218880058|NCT02551029|OTHER|Placebo|
218880059|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
218880060|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
218880061|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
218880062|NCT00013013|PROCEDURE|Systems Support|
218880063|NCT05532605|OTHER|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
218880064|NCT05532605|OTHER|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
218880065|NCT01791101|DRUG|Eltrombopag|
218880066|NCT01124591|BEHAVIORAL|Brief motivational intervention|two session delivered two weeks apart
218880067|NCT03776591|PROCEDURE|Open surgery|
218880068|NCT03776591|PROCEDURE|Right colectomy|
218880069|NCT03776591|PROCEDURE|Laparoscopic surgery|
218880070|NCT03776591|PROCEDURE|Central lymphadenectomy and vascular ligation|
218880071|NCT01906528|DRUG|Mivacurium|Effect of Mivacurium in males vs females
218880072|NCT03395951|DRUG|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
218880073|NCT04617015|DRUG|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
218880074|NCT05443711|OTHER|No intervention, observational study|No intervention, observational study
218880075|NCT04939792|DRUG|Vitamin D|Capsules ingested orally
218880076|NCT04939792|DRUG|Placebo|Capsule ingested orally
218880077|NCT04939792|DRUG|Vitamin D + L-cysteine|Capsule ingested orally
219604096|NCT03899909|DRUG|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
219604097|NCT03899909|DRUG|Placebo MAD|Placebo oral suspension, daily for 13 days
219604098|NCT06859268|DRUG|Retatrutide|Administered SC
219499009|NCT00634192|DRUG|tobramycin|2x300mg/d inhaled
219499010|NCT06157333|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
219499011|NCT06315608|DRUG|MRG-001|MRG-001 is a clear liquid solution for subcutaneous injection
219499012|NCT06684405|DIETARY_SUPPLEMENT|sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)|
219499013|NCT06684405|DIETARY_SUPPLEMENT|Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.|
219499014|NCT05519267|BEHAVIORAL|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
219499015|NCT05519267|BEHAVIORAL|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
219499016|NCT06542003|BEHAVIORAL|Movin' and Groovin' for Wellness|Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
219499017|NCT06703931|DEVICE|Measures performed on all subjects|In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
219499018|NCT03174509|PROCEDURE|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
219499019|NCT03174509|PROCEDURE|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
219499020|NCT02597283|DEVICE|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
219499021|NCT02597283|DEVICE|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
219604099|NCT06859268|DRUG|Placebo|Administered SC
219604100|NCT06984562|RADIATION|Adaptive Radiation Therapy|"Adaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue.~By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects."
219604101|NCT06856499|DRUG|Cirtuvivint|Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of action, including Wnt inhibition.
219604102|NCT06856499|DRUG|Olaparib|NCI Definition - A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
219604103|NCT06670001|BEHAVIORAL|Gamification plus social incentive|Participants in the Gamification plus social incentive intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
219604104|NCT06670001|BEHAVIORAL|Gamification plus competition|Participants in the Gamification plus competition intervention arm will receive gamification and a competition as part of the intervention. See arm descriptions for more detail.
218880078|NCT04939792|DRUG|L-cysteine|Capsule ingested orally
218880079|NCT01098526|DRUG|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
219604105|NCT05159765|DEVICE|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
219604106|NCT05159765|DEVICE|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
219604107|NCT06763341|DRUG|Azacitidine|Given IV
219604108|NCT06763341|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219604109|NCT06763341|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219604110|NCT06763341|DRUG|PCNA Inhibitor AOH1996|Given PO
219604111|NCT06763341|DRUG|Venetoclax|Given PO
218880080|NCT01098526|DRUG|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
218880081|NCT05688020|DRUG|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
218880082|NCT05688020|DRUG|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
218880083|NCT04569981|OTHER|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
219604112|NCT06598332|DRUG|5-Azacytidine|"Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56."
219604113|NCT06860386|DRUG|Pembrolizumab|200 mg every 3 weeks IV infusion (Q3W + or -3 days)
219499022|NCT02657083|DEVICE|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
219499023|NCT02657083|DEVICE|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
219499024|NCT05689034|DRUG|Azvudine|Azvudine po. 5mg daily for 7 days
219499025|NCT05689034|DRUG|Placebo|Placebo po. 5 tablets daily for 7 days
219499026|NCT02232269|OTHER|Black Coffee|
219499027|NCT02232269|OTHER|Grapefruit Juice|
219499028|NCT02232269|OTHER|Water|
219499029|NCT02232269|DRUG|Felodipine|
219499030|NCT06419673|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
219499031|NCT06419673|DRUG|Cisplatin|IV infusion
219604114|NCT06860386|DRUG|Axitinib|5 mg twice daily (BID) by mouth
219613291|NCT06074224|OTHER|Sleep assessment score|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
219499032|NCT06419673|DRUG|Carboplatin|IV infusion
219499033|NCT06419673|RADIATION|Brachytherapy and External Beam Radiotherapy|Brachytherapy and External Beam Radiotherapy
219499034|NCT00293475|DRUG|Carboplatin|Given IA
219499035|NCT00293475|DRUG|Mannitol|Given IA
219499036|NCT00293475|DRUG|Methotrexate|Given IA
219499037|NCT00293475|OTHER|Quality-of-Life Assessment|Ancillary studies
219499038|NCT00293475|BIOLOGICAL|Rituximab|Given IV
219499039|NCT00293475|DRUG|Sodium Thiosulfate|Given IV
219499040|NCT02969733|DRUG|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
219499041|NCT02969733|DRUG|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
219499042|NCT02969733|DRUG|isotonic saline serum intravenous administration|
219499043|NCT01963676|DEVICE|tDCS|
219613292|NCT06074224|OTHER|No Score|The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
218880084|NCT04569981|OTHER|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
219200537|NCT04342572|DRUG|Melphalan|-The drug is commerically available
219499044|NCT01963676|DEVICE|Sham stimulation|
219499045|NCT05402631|PROCEDURE|Epidural Injection|patient receives an epidural injection due to lower back pain
219499046|NCT05402631|PROCEDURE|Periradicular Injection|patient receives a periradicular injection due to lower back pain
219499047|NCT00736931|DRUG|Brivaracetam|Brivaracetam 10 mg tablets
219499048|NCT00736931|DRUG|levetiracetam|500mg tablets
219499049|NCT00736931|DRUG|lorazepam|lorazepam 2 mg over encapsulated tablets
219499050|NCT00736931|OTHER|placebo|placebo capsules
219499051|NCT01246973|DRUG|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
219499052|NCT01246973|DRUG|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
219499053|NCT00766506|DEVICE|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
219499054|NCT00766506|DEVICE|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
219499055|NCT05979051|DRUG|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
219499056|NCT05979051|DRUG|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
219499057|NCT01297192|DRUG|solifenacin succinate|Oral
219499058|NCT01297192|DRUG|mirabegron|Oral
219604115|NCT06861075|DRUG|Carvedilol|"Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a day), day 9 to day 90 (end of study visit): 12.5 mg/day (6.25 mg twice a day).~After the end of the study, treatment with Carvedilol will be prescribed by a cardiologist and continued at the dose of 12.5 mg/day.~The follow-up of the patient will be then done according to the standard practice."
219499059|NCT00769678|DEVICE|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
219499060|NCT02801851|BEHAVIORAL|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
219499061|NCT04817098|BEHAVIORAL|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
219499062|NCT04048720|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
219499063|NCT02686489|OTHER|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
219499064|NCT02686489|OTHER|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
219499065|NCT02228031|DRUG|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
219604116|NCT06993688|BEHAVIORAL|Prognostic Communication-Patient/parent|"* Patient/parent identifies and selects a communication preferences companion (CPC)~* CPC and patient/parent meet for a Communication Preferences Visit (CPV)~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
219604117|NCT06993688|BEHAVIORAL|Prognostic Communication-CPC|"* CPC reviews intervention materials and conversation guide with the research team~* CPC and patient/parent meet for a CPV, and CPC documents patient/parent preferences in a templated form~* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
219604118|NCT06993688|BEHAVIORAL|Prognostic Communication-Oncologist|"* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together"
219604119|NCT06539429|BIOLOGICAL|ANT-301|Administration on Day 1
219604120|NCT06422520|DRUG|BGB-C354|Administered by intravenous infusion
219604121|NCT06422520|DRUG|Tislelizumab|Administered by intravenous infusion
219604122|NCT06674538|DRUG|Moonshot antibodies|Chimeric antibodies
219604123|NCT03910933|OTHER|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
219604124|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
219604125|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
218880085|NCT06226584|DIETARY_SUPPLEMENT|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
219604126|NCT06858501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218880086|NCT05325840|OTHER|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
219604127|NCT06858501|PROCEDURE|Computed Tomography|Undergo PET/CT
219604128|NCT06858501|RADIATION|Florbenguane F18|Given IV
219604129|NCT06858501|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219604130|NCT06858501|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
219604131|NCT06858501|OTHER|Questionnaire Administration|Ancillary studies
219604132|NCT06919354|BIOLOGICAL|GNTI-122|GNTI-122 is an investigational cell therapy manufactured from a participant's own blood cells and is intended to help correct an imbalance of certain types of cells found in participants with Type 1 Diabetes.
219604133|NCT02953119|OTHER|Prehabilitation|
219604134|NCT02042456|DEVICE|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
218880087|NCT02105675|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
218880088|NCT02105675|DRUG|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
218880089|NCT00444340|DRUG|Enbrel (Etanercept)|
218880090|NCT04306653|DRUG|ACTH|patients with acute gout will receive 100 IU ACTH IM
218880091|NCT04306653|DRUG|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
219026756|NCT05678062|DIAGNOSTIC_TEST|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
219026757|NCT06368232|OTHER|püPatients undergoing bariatric surgery|Patients will not be intervened. Only nutritional status after bariatric surgery will be evaluated.The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian dietitian for at least 6 months were included.
219499066|NCT02228031|OTHER|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
219499067|NCT01560091|DRUG|silodosin|8mg PO Qday
219499068|NCT01560091|PROCEDURE|Extra-corporeal shock wave lithotripsy|ESWL
219499069|NCT01560091|DRUG|Tamsulosin|Tamsulosin 0.4mg PO Qday
219499070|NCT06412068|DRUG|Combined anti-PD-1 and R-CHOP|Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
219499071|NCT02038101|BEHAVIORAL|Education and Feedback|"1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email"
219499072|NCT05487872|BEHAVIORAL|Mindfulness skills training to reduce experiential avoidance and anxiety symptoms|The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
219499073|NCT02496221|DRUG|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
219499074|NCT02496221|DRUG|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
219499075|NCT02496221|DRUG|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
219499076|NCT04264559|DIAGNOSTIC_TEST|Infrared thermal imaging|A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
219499077|NCT04264559|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes."
219499078|NCT01114542|DRUG|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
219499079|NCT01114542|DRUG|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
218880092|NCT03992443|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
218880093|NCT03985371|DRUG|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
218880094|NCT03659071|OTHER|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
218880095|NCT03462381|DIETARY_SUPPLEMENT|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
218880096|NCT00348309|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
218880097|NCT00348309|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
218880098|NCT00348309|OTHER|Placebo|Placebo
218880099|NCT00348309|OTHER|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
219026758|NCT05324163|DRUG|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
219499080|NCT06198985|PROCEDURE|Dynamic balance exercise with tecnobody prokin 252 balance device|Dynamic balance exercise with tecnobody prokin 252 balance device
219499081|NCT00332137|DRUG|Tolterodine|
219499082|NCT00185328|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
219026759|NCT05324163|DRUG|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
219026760|NCT05324163|DRUG|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
219026761|NCT01172951|OTHER|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
219499083|NCT03262233|COMBINATION_PRODUCT|nicotine|
219499084|NCT03262233|OTHER|placebo|
219604135|NCT02042456|DEVICE|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
219604136|NCT02042456|DEVICE|Full Field Digital Mammography|
219604137|NCT04005014|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
219604138|NCT07027527|DRUG|APG777|Subcutaneous (SC) injection
219604139|NCT07027527|DRUG|APG990|SC injection
219604140|NCT07027527|DRUG|Dupilumab|SC injection
219499085|NCT03276533|DRUG|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
219499086|NCT03276533|DRUG|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
219499087|NCT03276533|DRUG|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
219604141|NCT05160740|DRUG|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
219604142|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
219604143|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
219604144|NCT07029178|DRUG|Taurine granule|24 grams of taurine granule + 2 Gray radiation dose each time.
219604145|NCT07029178|DRUG|Placebo granule|24 grams of placebo granule + 2 Gray radiation dose each time.
219604150|NCT07022418|DRUG|Formoterol furmarate (20 μg)|Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study.
219026762|NCT01172951|OTHER|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
219499088|NCT03276533|DRUG|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
219604151|NCT03610152|BEHAVIORAL|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
219604152|NCT06879665|BEHAVIORAL|Well-Beans for Caregivers Program|This is a brief behavioral intervention consisting of 3 weekly 2-hour sessions. The sessions are based on Acceptance and Commitment Therapy (ACT) and are designed to improve psychological flexibility in caregivers. This in turn is designed to help them connect with their difficult emotions and experiences in a flexible way, and improve emotional well-being.
219604153|NCT06877663|DEVICE|Virtual Reality Device|Patients who will receive entertainment videos via VR headset in the preoperative room before surgery.
219604154|NCT03307265|DEVICE|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
219604155|NCT03307265|DEVICE|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
219026763|NCT01972269|DRUG|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
219026764|NCT01972269|DRUG|Lidocaine|2% lidocaine
219604156|NCT04479553|DRUG|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
219604157|NCT00146497|DRUG|Budesonide-Surfactant|
219604158|NCT00021827|DRUG|Parathyroid hormone-related protein or ''PTHrP''|
219604159|NCT00990860|DRUG|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
218880100|NCT00622388|DRUG|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
218880101|NCT04518683|DEVICE|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
219499089|NCT02980328|DEVICE|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
219499090|NCT02980328|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
219499091|NCT04945161|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
219499092|NCT04945161|OTHER|Placebo|Placebo
219499093|NCT01893983|BEHAVIORAL|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
219499094|NCT00735033|OTHER|Physiotherapy with Swiss Ball|
219499095|NCT00268151|DRUG|Oxaliplatin|
219499096|NCT00268151|DRUG|Capecitabine|
219499097|NCT02872545|PROCEDURE|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
219499098|NCT02872545|PROCEDURE|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
219499099|NCT02872545|PROCEDURE|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
219499100|NCT03613077|PROCEDURE|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
219499101|NCT03816800|DIETARY_SUPPLEMENT|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
219499102|NCT03816800|DIETARY_SUPPLEMENT|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
219499103|NCT01120600|DRUG|Odanacatib|One 50 mg tablet once weekly
219499104|NCT01120600|DRUG|Placebo for Odanacatib|One 50 mg tablet once weekly
219499105|NCT01120600|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
219499106|NCT01120600|DIETARY_SUPPLEMENT|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
219499107|NCT01165242|BIOLOGICAL|Meningococcal vaccine GSK 134612|One intramuscular injection
219499108|NCT01165242|BIOLOGICAL|Menactra®|One intramuscular injection
219499109|NCT00003070|DRUG|enalapril maleate|
219499110|NCT00003070|PROCEDURE|quality-of-life assessment|
219604160|NCT00990860|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
219604161|NCT04597632|DRUG|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
219604162|NCT01021059|BIOLOGICAL|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
219604163|NCT00524732|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
219604164|NCT03127683|OTHER|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
219604165|NCT03127683|OTHER|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
219604166|NCT03127683|OTHER|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
219604167|NCT03127683|OTHER|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
219026765|NCT04415099|OTHER|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise"
219026766|NCT02312726|PROCEDURE|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
219026767|NCT01223144|BEHAVIORAL|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
219026768|NCT02057471|DRUG|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
219026769|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
219604168|NCT03127683|DEVICE|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
219604169|NCT06887959|DRUG|Suzetrigine|Tablets for oral administration.
219499111|NCT00798785|DRUG|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
219499112|NCT00798785|DRUG|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
219499113|NCT00798785|DRUG|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
219499114|NCT00798785|PROCEDURE|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels \>= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
219499115|NCT03252132|OTHER|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
219499116|NCT03770000|DRUG|Tenalisib|Tenalisib, BID orally daily
219499117|NCT03770000|DRUG|Romidepsin|Romidepsin IV
219499118|NCT02917837|OTHER|Usual QCNL DI utilization report|See arm descriptions.
219499119|NCT02917837|OTHER|New DI utilization report|See arm descriptions.
219499120|NCT02917837|OTHER|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
219499121|NCT03877237|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
219499122|NCT03877237|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
219499123|NCT00944437|DEVICE|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
219499124|NCT00944437|DEVICE|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
219499125|NCT03843437|DEVICE|Tencel Therapeutic Garments|Children age 6 months to 3 years will wear a Tencel full body suit with feet and mittens, while children age 3-6 years will wear Tencel long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
219604170|NCT00911027|DRUG|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
219604171|NCT00911027|PROCEDURE|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
219604172|NCT00135863|DRUG|tinzaparin|
219604173|NCT01085721|DRUG|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
218880102|NCT04518683|DEVICE|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
219604174|NCT01085721|DRUG|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
219604175|NCT07048093|OTHER|Exercise|Average of 10 minutes relaxation exercises guided with a standard audio record based on reciprocal and autogenic muscle inhibition, proprioceptive training and postural training.
219604176|NCT07048093|OTHER|Sham (No Treatment)|This group take no treatment between actual before and after measurements.
219604177|NCT04895982|BIOLOGICAL|BNT162b2|Intramuscular Injection
219604178|NCT00080873|DRUG|Traumeel S|
219604179|NCT00080873|OTHER|Placebo|
219604180|NCT01649960|DRUG|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
218880103|NCT04374955|DIETARY_SUPPLEMENT|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
218880104|NCT04374955|OTHER|Routine care|Routine care of the hospital will be provided.
218880105|NCT04477655|PROCEDURE|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
219499126|NCT03843437|DEVICE|Cotton Therapeutic Garments|Children age 6 months to 3 years will wear a cotton full body suit with feet and mittens, while children age 3-6 years will wear cotton long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
219499127|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started
219499128|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
219499129|NCT01234688|OTHER|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
219499130|NCT03104088|DIAGNOSTIC_TEST|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
219499131|NCT03104088|DIAGNOSTIC_TEST|MOCA|Montreal cognitive assessment (MOCA) in German
219499132|NCT01318785|OTHER|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
219499133|NCT03687437|DIAGNOSTIC_TEST|Blood sample|Complete blood count
219604181|NCT05506150|BEHAVIORAL|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
219604182|NCT05667675|BEHAVIORAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
219604183|NCT05667675|BEHAVIORAL|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
219604184|NCT04693897|DRUG|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
219604185|NCT04693897|DRUG|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
218880106|NCT04477655|PROCEDURE|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
218880107|NCT06384755|BEHAVIORAL|Honest Open Proud program|The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
218880108|NCT03507738|BIOLOGICAL|MT-5625 low dose|Intramuscular injection
218880109|NCT03507738|BIOLOGICAL|MT-5625 middle dose|Intramuscular injection
218880110|NCT03507738|BIOLOGICAL|MT-5625 high dose|Intramuscular injection
219604186|NCT02863783|DEVICE|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
219604187|NCT05786209|OTHER|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
219604188|NCT05786209|OTHER|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
219604189|NCT03460080|DIAGNOSTIC_TEST|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
219604190|NCT02213289|DRUG|Trastuzumab|Trastuzumab
218880111|NCT03507738|BIOLOGICAL|Rotarix|Oral administration
219499134|NCT05058937|DIAGNOSTIC_TEST|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
219604191|NCT02213289|DRUG|ABT-806|ABT-806
219604192|NCT02213289|DRUG|Bemarituzumab|Bemarituzumab
218880112|NCT03507738|BIOLOGICAL|Placebo|Intramuscular injection
218880113|NCT02458443|OTHER|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
218880114|NCT04499287|OTHER|15-minute walk at preferred walking speed.|
218880115|NCT04499287|DIETARY_SUPPLEMENT|Fiber|9 grams soluble fiber
219499135|NCT00973778|OTHER|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
219499136|NCT02464878|DRUG|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
218880116|NCT04499287|OTHER|control|control
219499137|NCT02464878|PROCEDURE|Islet Transplantation|
219499138|NCT02464878|DRUG|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
219499139|NCT02464878|DRUG|Basiliximab|Basiliximab will be used for subsequent transplants.
219499140|NCT02464878|DRUG|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
219604193|NCT02213289|DRUG|Ramucirumab|Ramucirumab
219604194|NCT02213289|DRUG|Nivolumab|Nivolumab
219604195|NCT02213289|DRUG|Standard cytotherapy|FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
218880117|NCT01743040|DIAGNOSTIC_TEST|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
219499141|NCT02878278|DRUG|Chidamide BIW|Chidamide is given 30mg, twice a week
219026770|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
219026771|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
218880118|NCT01894243|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
218880119|NCT02439034|DRUG|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
218880120|NCT02439034|DRUG|Ketoprofen|Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
218880121|NCT03194113|BEHAVIORAL|Trauma-focused treatment|Weekly sessions
219499142|NCT02878278|DRUG|Chidamide QD|Chidamide is given 10mg,QD
219499143|NCT04180254|PROCEDURE|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
219499144|NCT05605028|BEHAVIORAL|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
218880122|NCT03194113|BEHAVIORAL|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
218880123|NCT03194113|BEHAVIORAL|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
219026772|NCT06022250|DRUG|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
219026773|NCT06410209|OTHER|Goal Setting|Set physical activity goals
219026774|NCT06410209|OTHER|Interview|Participate in a one-on-one interview
219026775|NCT06410209|OTHER|Interview|Ancillary studies
219499145|NCT05605028|OTHER|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
219499146|NCT05003128|DEVICE|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
219499147|NCT01073683|PROCEDURE|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
219499148|NCT01073683|DRUG|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
219499149|NCT00959387|DRUG|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
219499150|NCT00959387|RADIATION|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
219499151|NCT04719247|PROCEDURE|Pulpotomy|Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
219604196|NCT04743492|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
219604197|NCT01893346|DRUG|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
219604198|NCT04666389|DRUG|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
219604199|NCT01449812|BIOLOGICAL|Infanrix+Hib™|Intramuscular, one dose
218880124|NCT01640899|DEVICE|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
218880125|NCT03686475|OTHER|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
219026776|NCT06410209|OTHER|Media Intervention|View private social media peer support group content
219026777|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit physical activity tracker
219026778|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a research grade activity measuring device
219026779|NCT06410209|OTHER|Questionnaire Administration|Ancillary studies
219026780|NCT06410209|OTHER|Reward|Receive badges
219026781|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive text messages
219604200|NCT01449812|BIOLOGICAL|Poliorix™|Intramuscular, one dose
219604201|NCT01910246|DRUG|Metformin|
218880126|NCT03686475|OTHER|MTA pulpotomy|MTA pulpotomy
219026782|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive reminders
219026783|NCT03036098|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219026784|NCT03036098|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
219026785|NCT03036098|DRUG|Gemcitabine|Specified Dose on Specified Days
219026786|NCT03036098|DRUG|Cisplatin|Specified Dose on Specified Days
219604202|NCT04207489|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
219604203|NCT03638726|DRUG|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
219604204|NCT03638726|DRUG|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
219604205|NCT05917600|OTHER|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
219604206|NCT00148005|PROCEDURE|Questionnaire and micturition and drinking diaries|
219604207|NCT00148005|PROCEDURE|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
219604208|NCT00148005|BEHAVIORAL|Adaptation of the drinking scheme|
219604209|NCT00148005|DRUG|Anticholinergic therapy|
219604210|NCT00148005|BEHAVIORAL|Micturition clock|
219604211|NCT04239027|DRUG|RTH258/Brolucizumab|"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."
219604212|NCT05391386|PROCEDURE|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
218880127|NCT00828750|DRUG|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
219026787|NCT03036098|DRUG|Carboplatin|Specified Dose on Specified Days
219604213|NCT05551663|OTHER|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
219604214|NCT02037386|DEVICE|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
219604215|NCT04234048|DRUG|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
219604216|NCT03883802|DRUG|Foxy-5|Lyophilized powder for solution for intravenous infusion
219499152|NCT00142454|DRUG|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
219499153|NCT00142454|BIOLOGICAL|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
219499154|NCT04463277|BEHAVIORAL|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
219604217|NCT03883802|DRUG|FOLFOX regimen|6 months treatment regimen
219604218|NCT03883802|PROCEDURE|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
219604219|NCT06738862|OTHER|PET|\[18F\] - FD17 PET imaging
219604220|NCT01579747|PROCEDURE|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
219026788|NCT00708539|DRUG|progesterone|90 mg, vaginal, once daily
219499155|NCT04463277|BEHAVIORAL|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
219604221|NCT01579747|PROCEDURE|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
219604222|NCT07052292|DEVICE|DuraTouch®|Participants will subcutaneously inject the insulin using DuraTouch®.
219026789|NCT00708539|DRUG|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
219026790|NCT02803151|RADIATION|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
219026791|NCT01834287|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
219026792|NCT01834287|BEHAVIORAL|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
219026793|NCT04801771|DEVICE|Inspire Upper Airway Stimulation (UAS) System|The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
219499156|NCT04463277|BEHAVIORAL|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
219499157|NCT03031405|DRUG|Oxytocin nasal spray|
219499158|NCT03031405|DRUG|Placebos|Placebo nasal spray
219499159|NCT02544945|OTHER|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
219499160|NCT02544945|OTHER|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
219499161|NCT00566098|BIOLOGICAL|MILs|
219499162|NCT00566098|DRUG|Melphalan|
219499163|NCT00566098|BIOLOGICAL|PCV13|
219499164|NCT00562692|DRUG|Nesiritide|Nesiritide 4 hour infusion
219499165|NCT00562692|DRUG|Placebo|Placebo infusion
219499166|NCT02971865|BEHAVIORAL|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
219499167|NCT02971865|OTHER|Control group traditional primary care|No change in care usually given
219499168|NCT01860482|DRUG|Newrabell® Tablet 10mg|
219499169|NCT05818631|DIAGNOSTIC_TEST|fusion cognitive prostate biopsy|A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
219499170|NCT02460874|DRUG|Glyburide|1.25mg, twice a day
219499171|NCT02460874|OTHER|Placebo|1.25mg, twice a day
219499172|NCT01690520|DRUG|Cyclophosphamide|Given IV
219499173|NCT01690520|DRUG|Cyclosporine|Given IV or PO
219499174|NCT01690520|BIOLOGICAL|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
219026794|NCT00072618|DRUG|Exisulind|
219026795|NCT00402961|OTHER|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
219499175|NCT01690520|DRUG|Fludarabine Phosphate|Given IV
219499176|NCT01690520|DRUG|Mycophenolate Mofetil|Given IV or PO
219499177|NCT01690520|DRUG|Thiotepa|Given IV
219499178|NCT01690520|RADIATION|Total-Body Irradiation|Undergo high dose or middle intensity TBI
219499179|NCT01690520|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
219499180|NCT05789680|PROCEDURE|Surgical treatment of parathyroid carcinoma|Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
219499181|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine Needle aspiration
219604223|NCT05461989|OTHER|Anthropometric measurement|It will be measured with the Xiaomi Body Composition Scale II, and a total of 9 measurements will be made as a result of the measurements.
219604224|NCT05461989|OTHER|Level of Physical Activity|The scale to be used for this purpose is the Child Physical Activity Questionnaire (CPAQ) developed by Kowalski et al. It is a seven-day self-reported recall scale designed to assess moderate-intensity physical activity in children aged 8-14 years. CFAQ is designed to be implemented throughout the school year.
219613293|NCT04690595|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL
219499182|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
219499183|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
219499184|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
219499185|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
219499186|NCT02945280|DRUG|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
219499187|NCT00006031|PROCEDURE|Needle localized breast biopsy with specimen x-ray|
219499188|NCT00006031|PROCEDURE|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
219499189|NCT05481580|DIAGNOSTIC_TEST|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
219499190|NCT01146730|BEHAVIORAL|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
219499191|NCT01146730|BEHAVIORAL|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
219499192|NCT06274216|DRUG|Vitamin D3|5000 IU of vitamin D3 orally every day for 12 weeks
219499193|NCT06274216|DRUG|Vitamin E 400|400mg of vitamin E orally every day for 12 weeks
219499194|NCT04317963|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
219499195|NCT04317963|DRUG|Standard CDI treatment|Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
219499196|NCT05626010|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
219499197|NCT05626010|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
219499198|NCT00076323|DRUG|Primaquine|
219499199|NCT03634332|DRUG|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
219499200|NCT03634332|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
219499201|NCT05944770|OTHER|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
219499202|NCT05944770|OTHER|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
219604225|NCT05461989|OTHER|Physical Activity Barriers Scale|"It consists of three surveys in total, which are:~A) Scale of Expectations Regarding Physical Activity for Children~B) Children's perception of family support regarding physical activity scale~C) Physical Activity Barriers Scale for Parents"
219604226|NCT05461989|OTHER|Hand Grip Strength|Hand grip strength will be measured using a hand dynamometer (Jamar, Sammons Preston, Rolyon, Bolingbrook, IL).
219499203|NCT00119132|DRUG|artesunate-amodiaquine|
219499204|NCT00119132|DRUG|sulphadoxine-pyrimethamine|
219499205|NCT02009956|DEVICE|Subjects receiving DESyne Novolimus Eluting CSS|
219604227|NCT05461989|OTHER|Arterial stiffness|Arterial stiffness will be evaluated using the pulse wave velocity (PWV) technique with the blood pressure holter-ABPM (Mobil-O-Graph, I.E.M., Stolberg, Germany) device. The measurement is made from the non-dominant arm based on the principle of blood pressure measurement with the appropriate cuff determined according to the arm diameter. After two consecutive measurements taken 30 seconds apart, the average of the measurement values will be recorded.
219604228|NCT06724601|DEVICE|Electrical Impedance Tomography|Electrical Impedance Tomography data and the physiological and clinical parameters will be recorded continuously in three different positions (supine 1, car seat, supine 2) to assess alterations in lung volume and cardiorespiratory events.
219604229|NCT03477604|DEVICE|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
219604230|NCT03477604|DEVICE|Standard PTA|Standard PTA balloon
219604231|NCT05769777|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
219604232|NCT06714253|BIOLOGICAL|RXRG001|Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle
219604233|NCT06714253|BIOLOGICAL|Placebo|Placebo (saline)
219604234|NCT06851754|DRUG|Progesterone|Oral micronized progesterone will be added (100 mg/day for 12 days/month) in the event of spontaneous vaginal bleeding and/or at 12 months over the 2-year protocol.
219604235|NCT06851754|DRUG|Estrogen Patch|participants with POI (n=85) will receive transdermal 17 beta-estradiol (beginning at a dose of 25 microgram/patch applied weekly), with the dose increased at 3 months to 50 microgram, and thereafter every 6 months to 75 and 100 microgram/patch for pubertal induction or estrogen replacement (with 100 microgram/patch representing a full adolescent or young adult estradiol dose). The continued escalation of the estradiol dose and patch strength will be guided by the clinical presentation and physical examination (by the PI or designated AI).
219604236|NCT06858397|DRUG|HM15421/GC1134A|SC
219499206|NCT01656954|PROCEDURE|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
219604237|NCT06750939|OTHER|propofol|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
219604238|NCT06750939|OTHER|ketamine|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
219604239|NCT06764186|DRUG|Fulvestrant|2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
219499207|NCT03213054|BIOLOGICAL|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
219499208|NCT03213054|RADIATION|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
219499209|NCT02236754|DRUG|18 F-FP-DTBZ|The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
219499210|NCT02236754|RADIATION|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
219604240|NCT06764186|DRUG|Capivasertib|400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
219499211|NCT04316897|DEVICE|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
219499212|NCT03197805|DIAGNOSTIC_TEST|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
219499213|NCT04006847|DRUG|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
219499214|NCT04006847|DRUG|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
219499215|NCT03341598|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
219604241|NCT06759649|DRUG|COM503|Intravenous Infusion
219604242|NCT06759649|DRUG|Zimberelimab|Intravenous infusion
219604243|NCT06749145|DIAGNOSTIC_TEST|Portable 1-lead electrocardiogram|Portable 1-lead electrocardiogram (ECG) performed with the FDA-approved AliveCor KardiaMobile device.
219604244|NCT06749145|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed with the FDA-approved VScan Air device.
219604245|NCT06749145|OTHER|AI-ECG risk algorithm|Artificial intelligence (AI) risk algorithm for aortic stenosis using a 1-lead electrocardiogram
219604246|NCT06749145|OTHER|AI-POCUS|Artificial intelligence (AI) risk algorithm for aortic stenosis using cardiac ultrasound plax videos.
219604247|NCT04182334|OTHER|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
218880128|NCT05800912|OTHER|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
218880129|NCT05800912|OTHER|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
218880130|NCT00284310|PROCEDURE|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
218880131|NCT00223704|DRUG|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
218880132|NCT00223704|DRUG|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
218880133|NCT00223704|DRUG|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
219499216|NCT03341598|PROCEDURE|R|Restorative procedure to treat tooth structure loss.
219499217|NCT03341598|PROCEDURE|MC|Xenogenous graft placed in the surgical site.
219604248|NCT04182334|OTHER|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
219604249|NCT06752603|DRUG|ONO-1110|ONO-1110 tablets once a day
219604250|NCT06752603|DRUG|Placebo|Placebo tablets once daily
219604251|NCT04540835|DEVICE|Teethmate Desensitizer (Kuraray)|Calcium phosphate desensitizer applied after caries removal. After restored using an oblique incremental technique with a composite resin (Filtek Z250, 3M Espe, USA)
219604252|NCT02839707|DRUG|Atezolizumab|Given IV
219499218|NCT01082445|DRUG|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
219499219|NCT01082445|DRUG|Placebo|Placebo
219499220|NCT04242381|OTHER|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
219499221|NCT04242381|OTHER|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
219604253|NCT02839707|BIOLOGICAL|Bevacizumab|Given IV
219604254|NCT02839707|PROCEDURE|Computed Tomography|Undergo CT
219604255|NCT02839707|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219604256|NCT02839707|OTHER|Quality-of-Life Assessment|Ancillary studies
219604257|NCT06771336|OTHER|Questionnaires|Quality of life questionnaires, questionnaires for assessing functional results, micro-costing questionnaire, informal support assessment questionnaires
219604258|NCT06604494|BEHAVIORAL|early feeding resumption|Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.
219604259|NCT06604494|BEHAVIORAL|late feeding resumption|Resumption of food on the 7th day post-operatively with a mixed diet.
219613294|NCT04032405|PROCEDURE|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
219499222|NCT04242381|OTHER|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
219499223|NCT04242381|OTHER|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
219499224|NCT05350254|OTHER|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
219499225|NCT05350254|OTHER|Standard chiropractic care|Standard care based on clinician's judgement
219604260|NCT06780033|DRUG|ART-101 - SAD|Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).
219604261|NCT06780033|OTHER|Placebo|Participants will receive matching placebo subcutaneously on Day 1 after 8 hour fast.
219604262|NCT05579470|BEHAVIORAL|NIATx|For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (\<4 weeks).
218880134|NCT05077293|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
219499226|NCT00010933|DRUG|chamomile tea|
219499227|NCT00010933|PROCEDURE|Relaxation/Guided Imagery|
219499228|NCT03980327|DIETARY_SUPPLEMENT|probiotic|Lactobacillus probiotic
219604263|NCT07134686|OTHER|Joint consultation|Joint consultation with pneumologist and ENT at baseline.
219604264|NCT07134686|PROCEDURE|Mucus sampling|Mucus sampling at baseline and one year follow-up
219604265|NCT07134686|PROCEDURE|Nasal brushing|Nasal brushing at baseline and one year follow-up
219604266|NCT07123883|PROCEDURE|Dry Needling|Dry Needling
219604267|NCT07123883|OTHER|sham needling|In the SG, a validated sham needling procedure was simulated.
219604268|NCT06925100|DRUG|Bempedoic acid 180 mg tablet|180 mg tablet, once daily administered for 12 weeks
218880135|NCT05077293|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
218880136|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
219499229|NCT03980327|DIETARY_SUPPLEMENT|medium chain triglyceride oil|
219499230|NCT04512027|OTHER|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
219499231|NCT04512027|OTHER|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
218880137|NCT01710098|DRUG|Degarelix|subcutaneous injection
218880138|NCT03392623|DRUG|Retinoic acid|topical administration in melasma lesions
218880139|NCT03392623|DEVICE|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
218880140|NCT03392623|DRUG|sunscreen|topical administration in melasma lesions
218880141|NCT03392623|DRUG|Niacinamide|topical administration in melasma lesions
218880142|NCT03530501|OTHER|Diet|Very low calorie ketogenic diet followed by low calorie diet
219604269|NCT05351827|OTHER|Mild Intermittent Hypoxia|Participants will breathe 8% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. 100% oxygen and carbon dioxide are titrated into the system to ensure the appropriate hypoxic and hypercapnic stimulus is delivered. The investigators will lower oxygen to 55-60 mmHg and maintain end-tidal carbon dioxide 1-3 mmHg above individual baseline values. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
219604270|NCT05351827|OTHER|Sham|Participants will breathe 21% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. No supplemental oxygen or carbon dioxide will be used during the sham protocol. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
219604271|NCT06257264|DRUG|BG-68501|Planned doses administered orally.
219604272|NCT06257264|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
219604273|NCT06257264|DRUG|BGB-43395|Planned doses administered orally.
219604274|NCT06833138|PROCEDURE|pacemaker implantation|The Medtronic 3830 lead should be used as the Conduction System Pacing lead. However, in case of unsuccessful implantation with the 3830 lead, a stylet-driven lead can be used as an alternative.
219604275|NCT06833138|PROCEDURE|atrioventricular node ablation|Right-sided atrioventricular junction ablation will be attempted first with a radiofrequency catheter. The choice of the catheter will be at the discretion of the physician. The catheter will be advanced to the His Bundle and then slightly withdrawn proximally and caudally in order to target the compact atrioventricular node. Repeated ablation procedures will be recommended during follow-up if regression of atrioventricular block occurs.
219604276|NCT06833138|DEVICE|Pacemaker programming|The pacemaker device will be programmed in VVIR mode at a lower rate of 75 beats per minute in bipolar mode for sensing and pacing
219604277|NCT07089875|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
219604278|NCT07089875|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
219604279|NCT07089888|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
219604280|NCT07089888|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
219604281|NCT07088731|DRUG|Sintilimab|neoadjuvent chemotherapy plus sintilimab for 2 cycles followed by radical surgery
219604282|NCT07088731|RADIATION|Concurrent chemo-radiotherapy|EBRT+BT+cisplatin
219604283|NCT05430477|DEVICE|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
219604284|NCT03739814|BIOLOGICAL|Blinatumomab|Given IV
219499232|NCT04089280|DIETARY_SUPPLEMENT|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
219604285|NCT03739814|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219604286|NCT02193282|OTHER|Clinical Observation|Undergo observation
219499233|NCT04089280|OTHER|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
219499234|NCT01127191|OTHER|military equipment|Military exercise of 24 hours
219499235|NCT03165266|DIAGNOSTIC_TEST|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~1. . Right Ventricle fractional area change.~2. . Tricuspid annular plane systolic excursion .~3. . Tissue Doppler derived tricuspid annular systolic velocity.~4. . Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~* Right ventricular basal, mid ,and longitudinal dimensions.~* Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
219499236|NCT00382291|DRUG|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
219499237|NCT00382291|DRUG|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
219499238|NCT00382291|DRUG|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
219499239|NCT04451382|BIOLOGICAL|OnabotulinumtoxinA (BoNTA)|
218880143|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
218880144|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
218880145|NCT04548518|BIOLOGICAL|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
218880146|NCT04548518|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
218880147|NCT05293236|DRUG|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
218880148|NCT05293236|OTHER|Saline|Saline for intravenous infusion
218880149|NCT04087135|OTHER|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
218880150|NCT04087135|OTHER|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
219499240|NCT04451382|PROCEDURE|Percutaneous tibial nerve stimulation (PTNS)|
219499241|NCT06186440|DRUG|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
219499242|NCT06186440|DRUG|Temozolomide|Temozolomide
219499243|NCT03156517|DEVICE|Deep Brain Stimulation|
219604287|NCT02193282|DRUG|Erlotinib Hydrochloride|Given PO
219604288|NCT02193282|OTHER|Laboratory Biomarker Analysis|Correlative studies
219604289|NCT02193282|OTHER|Placebo Administration|Given PO
219604290|NCT06325202|DEVICE|Omnipod 5 or Medtronic 780G|Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.
219604291|NCT06325202|BEHAVIORAL|My HypoCOMPaSS Education|My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.
219026796|NCT00402961|OTHER|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
219026797|NCT05955118|DEVICE|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
219026798|NCT05112549|DRUG|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
219026799|NCT06293885|DRUG|Dextrose 50|a solution of 50% glucose (D50) will be injected into your pleural space
219499244|NCT06232863|DRUG|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
218880151|NCT04087135|OTHER|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
218880152|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
218880153|NCT00119171|DRUG|Ispinesib|
218880154|NCT00119171|DRUG|Capecitabine|
218880155|NCT06351722|DIAGNOSTIC_TEST|Before non-surgical periodontal treatment|"Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR."
218880156|NCT06351722|PROCEDURE|non-surgical periodontal treatment|Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
218880157|NCT06351722|DIAGNOSTIC_TEST|3rd month after non-surgical periodontal treatment|"All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT."
219026800|NCT06293885|OTHER|Standard of Care - No Dextrose 50|Standard of Care
219026801|NCT03118154|OTHER|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
219026802|NCT03302988|OTHER|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
219026803|NCT03302988|OTHER|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
219026804|NCT06521359|DEVICE|flow cytometry|Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
219026805|NCT01057420|DRUG|oxygen inhalation|Inhalation of 80% oxygen via face mask
219026806|NCT02829463|RADIATION|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
219026807|NCT02382458|BEHAVIORAL|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
219499245|NCT01324063|BIOLOGICAL|sargramostim|
219499246|NCT01324063|DRUG|amsacrine|
219499247|NCT01324063|DRUG|cytarabine|
219499248|NCT01324063|DRUG|daunorubicin hydrochloride|
219499249|NCT01324063|PROCEDURE|quality-of-life assessment|
219499250|NCT01164735|OTHER|Laboratory Biomarker Analysis|Correlative studies
219499251|NCT05471219|OTHER|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
219499252|NCT02309918|DRUG|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
219499253|NCT04551079|DRUG|TAK-994|TAK-994 tablets.
219499254|NCT04551079|DRUG|Placebo|TAK-994 placebo-matching tablets.
219499255|NCT01375010|DRUG|Vitamin D3|2000 mg QD
219499256|NCT01375010|OTHER|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
219499257|NCT01375010|DRUG|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
219026808|NCT02382458|BEHAVIORAL|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
219026809|NCT06209892|PROCEDURE|Extended anticoagulation|This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
219026810|NCT01873001|DRUG|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
219026811|NCT01873001|DRUG|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
219026812|NCT00930579|DRUG|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
219026813|NCT00739544|OTHER|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
219499258|NCT04684810|BEHAVIORAL|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
219499259|NCT05767255|DRUG|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
219499260|NCT05767255|DRUG|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
219499261|NCT05751395|DEVICE|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
219499262|NCT05992649|OTHER|physical therapy|Aquatic physiotherapy in warm water
219499263|NCT00163436|DRUG|Ciclesonide|
219499264|NCT03618966|DEVICE|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
219499265|NCT01050166|OTHER|Transplantation of labeled islets|
219499266|NCT02614703|DRUG|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
219499267|NCT02614703|OTHER|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
219499268|NCT00086879|DRUG|carmustine|
219499269|NCT00086879|DRUG|erlotinib hydrochloride|
219499270|NCT00086879|DRUG|temozolomide|
219499271|NCT02402933|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
219499272|NCT01725815|BEHAVIORAL|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
219499273|NCT01562470|OTHER|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
219499274|NCT00994032|PROCEDURE|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
219499275|NCT00994032|OTHER|Medical treatment|standard antalgic medical treatment
219499276|NCT02580188|DRUG|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
219499277|NCT01440478|DRUG|LY2140023|Administered orally
219499278|NCT01440478|DRUG|Ammonium chloride|Administered orally
219499279|NCT01440478|DRUG|Sodium bicarbonate|Administered orally
219499280|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
219499281|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
219499282|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
219499283|NCT00852956|DRUG|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
219499284|NCT01681771|BEHAVIORAL|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
219499285|NCT01681771|BEHAVIORAL|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
219499286|NCT05006183|PROCEDURE|PCI|Percutaneous coronary intervention with Drug-Eluting Stents
219499287|NCT01917903|BEHAVIORAL|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
219604292|NCT06325202|BEHAVIORAL|HARPdoc Education|The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.
219604293|NCT07089173|DRUG|Intravenous normal saline (NS 0.9)|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using placebo (normal saline) combined with etomidate (0.3 mg/kg).
219604294|NCT07089173|DRUG|intravenous sufentanil|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using sufentanil (0.2μg/kg) combined with etomidate (0.3 mg/kg).
219604295|NCT07089173|DRUG|Intravenous lidocaine|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using lidocaine (1.5 mg/kg) combined with etomidate (0.3 mg/kg).
219604296|NCT07091370|DRUG|Inaticabtagene Autoleucel Injection|"The dose was incremented according to the 3+3 principle, and the three dose levels A, B and C were given in sequence at one time, which were respectively:~A-1 dose group: 0.25×10\^6 CAR-T live cells /kg body weight~Group A (initial dose) : 0.5×10\^6 CAR-T live cells /kg body weight~Group B: 1.0×10\^6 CAR-T live cells /kg body weight~Group C: 1.5×10\^6 CAR-T live cells /kg body weight"
219026814|NCT03016247|BEHAVIORAL|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
219604297|NCT06904365|DEVICE|HyperSight cone beam computed tomography (CBCT) scan|HyperSight is a novel onboard imaging platform with a rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for simulation and treatment.
219026815|NCT03016247|BEHAVIORAL|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
219026816|NCT05890040|OTHER|questionnaire|assessment of anxiety
219026817|NCT04765579|BEHAVIORAL|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
219026818|NCT02884596|DRUG|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
219499288|NCT01917903|BEHAVIORAL|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
219499289|NCT02916160|DRUG|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
219499290|NCT03148288|DIETARY_SUPPLEMENT|Vitamin D|VItamin D
219499291|NCT03148288|DIETARY_SUPPLEMENT|placebo|placebo
219499292|NCT03154333|DRUG|diacerein 1% ointment|diacerein 1% ointment administered topically
219499293|NCT03154333|DRUG|A placebo ointment|vehicle ointment administered topically
219499294|NCT04852991|PROCEDURE|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
219499295|NCT04852991|PROCEDURE|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
219604298|NCT06904365|DEVICE|ETHOS 2.0|ETHOS 2.0, an artificial intelligence treatment planning system, will be utilized in an emulator to create SCRT plans to determine the feasibility of clinically significant ovarian dose reductions in-silico.
219026819|NCT03888196|DIETARY_SUPPLEMENT|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
219026820|NCT03888196|DIETARY_SUPPLEMENT|Placebo Supplementation|500 mg/day of Cellulose
219026821|NCT02204787|DEVICE|transcranial direct current stimulation|
219026822|NCT03066674|OTHER|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
219026823|NCT03066674|OTHER|Control group|TENS,Exercises,Postural education ,Home exercises program.
219026824|NCT01056809|PROCEDURE|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
219026825|NCT01312818|DRUG|Bortezomib|1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
219026826|NCT01312818|DRUG|Vorinostat|180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
219026827|NCT01312818|DRUG|Dexamethasone|6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
219026828|NCT01312818|DRUG|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
219499296|NCT05081076|DEVICE|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain \& Glaze Kit, following the manufacturer's instructions.
219499297|NCT05081076|DEVICE|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
219499298|NCT01773694|BEHAVIORAL|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
219499299|NCT04116294|OTHER|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
219604299|NCT07097792|BEHAVIORAL|CRISP (Concussion Recovery and Support Program)|Mental health intervention targeting suppressed emotion with a goal of facilitating recovery.
219604300|NCT06507137|OTHER|Fractal|Walking in a treadmill while synchronizing their steps with fractal external visual cues
219604301|NCT06507137|OTHER|Isochronous|Walking in a treadmill while synchronizing their steps with isochronous external visual cues
219604302|NCT06507137|OTHER|Control|Walking in a treadmill
219604303|NCT07098910|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA)|While the infant is spontaneously breathing on nasal CPAP, the NICU physician will place the supraglottic airway device (SAD) and assess airway adequacy via CO₂ detection, chest movement, bilateral breath sounds, gastric insufflation, oxygen saturation, and heart rate. Each placement attempt should last no more than 30 seconds, with up to two attempts allowed. Surfactant (Curosurf 200 mg/kg) will be given slowly in 1-2 ml aliquots via a CE-marked preterm-sized SAD, Neo i-gel® (sizes 0.85, 0.75, 0.65; Intersurgical Ltd). The infant should primarily breathe spontaneously with PEEP from a T-piece resuscitator and receive gentle PPV if needed. PPV is continued for 30 seconds after surfactant administration before SAD removal. A reservoir bag may be used secondarily to provide PPV. If surfactant delivery via SALSA fails, the INSURE method (Intubation-Surfactant-Extubation) will be attempted.
219026829|NCT01312818|DRUG|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16."
219026830|NCT04335279|OTHER|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
219026831|NCT01046682|DRUG|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
219026832|NCT06256419|DRUG|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
219499300|NCT06200389|DIAGNOSTIC_TEST|microbiology testing|Vulvovaginal Candidiases patients diagnosed by microbiology testing can be included
219499301|NCT02351973|DRUG|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
219499302|NCT02351973|DRUG|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
219604304|NCT07098910|PROCEDURE|Intubation - Surfactant administration - Extubation (INSURE)|Study participants will receive surfactant therapy administered via brief endotracheal intubation - surfactant administration - and extubation (INSURE). Infants will be ventilated using a T-piece resuscitator with PEEP of 6 cm H20 and positive pressure ventilation (20 cm H20) for a couple of minutes (no more than 15 minutes) with adjustable FiO2. No mechanical ventilation will be used. Secondarily a reservoir-bag will be used for ventilation.
219604305|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
219604306|NCT07093749|DEVICE|Garmin Smartwatch|Garmin Venu 3 - Worn for the duration of antibiotic course
219604307|NCT07082868|DRUG|ibrutinib|Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day
219604308|NCT07082868|DRUG|Epcoritamab|Epcoritamab will be administered at the study site clinic, as a SC injection
219604309|NCT06210815|DRUG|HLX42|HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219604310|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics|The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
218880158|NCT06259539|BEHAVIORAL|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
219499303|NCT02351973|DRUG|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
219499304|NCT00361257|DRUG|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
219604311|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics Placebo|The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.
219604312|NCT07101640|DRUG|montelukast 4 mg granule|Montelukast sodium (4 mg oral granules) dissolved into 5mL of breast milk/formula yielding a solution concentration of 0.8mg/mL. Dosed once daily by weight, montelukast (0.75 mg/kg/day) or placebo .
219604313|NCT07101640|DRUG|Placebo|Plain breast milk or formula
219604314|NCT03951324|OTHER|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
219499305|NCT00361257|DRUG|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
219604315|NCT06920628|DRUG|11C-PS13|Injected IV followed by PET scanning.
219604316|NCT07125053|BEHAVIORAL|Education (self-guided)|"The self-guided eduction program consists of a mailed booklet entitled, Learning to live with COPD, along with two additional mailings with information on the ALA's Patient and Caregiver Network and the Respiratory Health Association's COPD Caregiver's Toolkit."
219604317|NCT07125053|BEHAVIORAL|Education (counselor-led)|The counselor-led education program combines mailings with phone counseling delivered by ALA Lung Helpline counselors. Three phone sessions (20-30 minutes each) are completed over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions offered between 6 and 12-weeks post-randomization. The counselor-led program follows a structured outline of curriculum for each session, focusing on the topic areas of developing a COPD exacerbation action plan, recognizing COPD exacerbations, and coping with breathlessness.
219604318|NCT07125053|BEHAVIORAL|Physical Activity|The physical activity program will consist of a personalized prescription for home-based exercise following published guidelines, consisting of aerobic, strengthening, and flexibility exercises, tailored to participants' current fitness level and dyspnea symptoms. Aerobic exercise will incorporate ground-based walking training, a well-established, safe, and feasible physical activity program for individuals with COPD. Participants will complete three videoconference sessions (30-45 minutes each) over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions between week 6 and 12.
219604319|NCT07125053|BEHAVIORAL|Inhaler Training|Participants will receive inhaler technique education using a virtual teach-to-goal method. In each session, individuals are observed using their inhaler, provided feedback, and then observed again. Inhaler technique is scored using a checklist specific to each inhaler device. Participants will complete two inhaler training sessions via videoconference at week 1 and week 4, with an optional booster session offered at week 8.
219604320|NCT07126951|PROCEDURE|Ultrasound-guided Deep Pharmacopuncture Treatment|"Participants in this group will receive ultrasound-guided deep pharmacopuncture in addition to integrative Korean medicine treatment (acupuncture, herbal medicine, and Chuna therapy). The pharmacopuncture involves injecting 4 cc of herbal extract into deep lumbar tissues, targeting the posterior facet joint of the most symptomatic segment.~Using a real-time ultrasound-guided in-plane technique, the needle path and tip are visualized to ensure accurate and safe delivery. Treatment is administered once daily for up to 3 days (hospital Days 2-4).~This intervention differs from conventional methods by using ultrasound to guide precise, deep-tissue injection, enhancing both safety and treatment accuracy."
219604321|NCT07126951|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
218880159|NCT06418451|PROCEDURE|sacrospinous ligament fixation (SLFF)|SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.
219200538|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Bone Screws as Landmarks|This study uses a dynamic navigation system for implant placement in fully edentulous patients requiring full arch prosthesis rehabilitation. The system incorporates bone screws (placed as reference points on the jaw arch) to guide the accurate placement of implants. Unlike traditional freehand implant placement, this dynamic navigation system aims to minimize deviation from the planned implant positions while also reducing the time required for the surgical procedure. The results will be compared to a group where landmarks are based on remaining teeth to assess accuracy and time efficiency of the system.
219499306|NCT02096029|OTHER|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
219499307|NCT02096029|BEHAVIORAL|Ask, Advise, Refer (physician brief advice)|
219499308|NCT04023630|DRUG|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
219499309|NCT04023630|DRUG|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
219499310|NCT04023630|DRUG|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
219499311|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
219499312|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
218880160|NCT06418451|PROCEDURE|modified ischial spinous fascia fixation (modified ISFF)|The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
218880161|NCT00321633|DRUG|carboplatin|
218880162|NCT00321633|DRUG|docetaxel|
218880163|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
218880164|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
218880165|NCT05282420|DRUG|Ranibizumab|Ranibizumab
218880166|NCT05282420|DRUG|Aflibercept|Aflipercept
218880167|NCT00001088|BIOLOGICAL|APL 400-047|
218880168|NCT00001088|DRUG|Bupivacaine hydrochloride|
218880169|NCT05677009|DEVICE|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
218880170|NCT05677009|OTHER|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
218880171|NCT03704714|DRUG|Cyclophosphamide|Given IV
218880172|NCT03704714|DRUG|Doxorubicin Hydrochloride|Given IV
218880173|NCT03704714|BIOLOGICAL|Nivolumab|Given IV
218880174|NCT03704714|DRUG|Prednisone|Given PO
218880175|NCT03704714|OTHER|Quality-of-Life Assessment|Ancillary studies
219026833|NCT06256419|DRUG|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
219026834|NCT04935112|DRUG|Sitravatinib|100 mg sitravatinib on Day 1
219026835|NCT04935112|DRUG|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
219026836|NCT04935112|DRUG|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
219026837|NCT05549258|DRUG|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
219026838|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
219026839|NCT04977076|OTHER|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
219026840|NCT04977076|OTHER|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
219499313|NCT03157063|DIAGNOSTIC_TEST|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
219499314|NCT00204750|PROCEDURE|Bougie Dilation|Bougie dilation will be performed as standard
219499315|NCT00204750|PROCEDURE|Needle-knife incision|Needle-knife incision will be performed
219499316|NCT03440281|DIAGNOSTIC_TEST|Uterine artery doppler|Uterine artery Doppler pulsatility indices
219499317|NCT03440281|DIAGNOSTIC_TEST|Maternal serum homocysteine estimation|
219499318|NCT00660790|OTHER|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
218880176|NCT03704714|BIOLOGICAL|Rituximab|Given IV
218880177|NCT03704714|DRUG|Vincristine Sulfate|Given IV
219026841|NCT05188651|BEHAVIORAL|face masks|wearing face masks
219026842|NCT01454570|DEVICE|powered exoskeleton|
219499319|NCT03555721|OTHER|Oral examination with incandescent light|Suspicious oral lesions will be identified by oral examination with incandescent light.
219499320|NCT03555721|OTHER|Oral examination with OralID|OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
219499321|NCT03555721|DIAGNOSTIC_TEST|Biopsy|Tissue will be collected to identify pre-cancerous or cancerous cells
219499322|NCT03555721|DIAGNOSTIC_TEST|CytID|CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
219499323|NCT03555721|DIAGNOSTIC_TEST|hpvID|hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
218880178|NCT02634502|PROCEDURE|radiofrequency ablation|
218880179|NCT02634502|DRUG|S-1|
218880180|NCT00830180|BIOLOGICAL|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
218880181|NCT04088110|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
219026843|NCT00772707|DEVICE|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
219026844|NCT00772707|DEVICE|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
219026845|NCT06057792|DEVICE|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~1. Static cup: preparation: Prepare the tissue surrounding the scar. 5min~2. Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
219499324|NCT02323659|DRUG|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
219499325|NCT02323659|DRUG|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
219499326|NCT01093859|DRUG|PRX-105|Sterile solution for intravenous injection
219499327|NCT02791659|RADIATION|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
219499328|NCT06267599|PROCEDURE|ACAR-Style Bladder Suture|In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
219499329|NCT03648333|DRUG|Exforge tab. 10/160mg|
219499330|NCT03648333|DRUG|Lodivixx tab. 5/160mg|
219499331|NCT05008237|DRUG|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
219499332|NCT03840811|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
219499333|NCT03840811|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
218880182|NCT04088110|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
218880183|NCT04088110|DRUG|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
218880184|NCT01832532|DRUG|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
218880185|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
218880186|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
218880187|NCT04016844|DEVICE|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
218880188|NCT06356389|DRUG|JX11502MA|Oral capsule
219499334|NCT03840811|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
219499335|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
219499336|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
219499337|NCT04648761|BIOLOGICAL|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
219499338|NCT00077428|DRUG|bortezomib|Given IV
219499339|NCT00077428|DRUG|doxorubicin hydrochloride|Given IV
219499340|NCT00077428|OTHER|laboratory biomarker analysis|Correlative studies
218880189|NCT06356389|DRUG|Placebo|Oral capsule
219604322|NCT00289120|DRUG|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
218880190|NCT02868047|PROCEDURE|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
218880191|NCT06506825|DIAGNOSTIC_TEST|Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker|Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
218880192|NCT02628561|DEVICE|Transcranial direct current stimulation|
218880193|NCT02628561|BEHAVIORAL|Constraint-Induced Movement Therapy|
218880194|NCT04305561|PROCEDURE|Contrast-enhanced ultrasound|"Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma)."
218880195|NCT06393023|DEVICE|Continuous Positive Airway Pressure|Although this study is designed as an observational cohort study, where patients were not assigned to intervention or non-intervention groups, there is still an intervention project indicator present in the observational cohort. The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
218880196|NCT05278832|DRUG|QLS31905|QLS31905 injection
218880197|NCT00996255|DRUG|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
218880198|NCT05797597|DRUG|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
219026846|NCT05315518|DIAGNOSTIC_TEST|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
219026847|NCT04577287|DEVICE|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
219026848|NCT03134560|DEVICE|Vein Display Instrument|
219026849|NCT03333954|DEVICE|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
219026850|NCT05617560|OTHER|Telemedical care|Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
219026851|NCT04919954|DRUG|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
219026852|NCT01216579|OTHER|mannitol (an airway challenge agent)|
219499341|NCT05774509|BIOLOGICAL|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
219499342|NCT01625845|DRUG|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
219499343|NCT01625845|OTHER|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
219026853|NCT06493864|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
219499344|NCT01625845|BEHAVIORAL|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
219499345|NCT01654146|DRUG|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
219499346|NCT01654146|DRUG|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
219499347|NCT01654146|DRUG|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
219604323|NCT00289120|DRUG|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
219604324|NCT06941376|DRUG|Methotrexate (MTX)|Weekly methotrexate dose of 20 mg (oral or subcutaneous).
219604325|NCT06941376|DRUG|Azathioprine (AZA)|Azathioprine dose will be 2-3 mg/kg body weight per day.
219604326|NCT06941376|BIOLOGICAL|Adalimumab|Adalimumab dose will be 40 mg subcutaneously every 1-2 weeks
219604327|NCT06941376|BIOLOGICAL|Infliximab|Infliximab dose will be 5mg/kg at week 0 and week 2, and then every 4-8 weeks.
219499348|NCT01654146|DRUG|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
219499349|NCT05886699|OTHER|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
219499350|NCT05886699|OTHER|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
219499351|NCT04108169|PROCEDURE|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
219499352|NCT03735784|BEHAVIORAL|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
219604328|NCT06941376|BIOLOGICAL|Tocilizumab|Tocilizumab dose will be 162 mg subcutaneous injection every week or 4-8 mg/kg every 4 weeks
219604329|NCT06940622|DIETARY_SUPPLEMENT|D-Mannose|D-mannose (2g, i.e., 4 x 500mg capsules) daily for 12 months.
219604330|NCT06940622|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 12 months.
219604331|NCT07146932|DEVICE|Pediatric Lower Limb Exoskeleton (Bambini Teens)|The Bambini Teens Exoskeleton is a wearable robotic device developed to assist lower limb movement and facilitate gait training for pediatric patients with mobility impairments such as cerebral palsy. The device provides powered assistance at the hip, knee, and ankle joints, supports adjustable gait parameters, and is designed for use in clinical rehabilitation settings under professional supervision.
219604332|NCT07144618|DEVICE|National Cheng Kung University Abdominal Muscle Group Medical Imaging Analysis Software|Phase 2: The second phase will involve a prospective multicenter clinical trial, enrolling 294 patients with endometrial or ovarian cancer.Patients will be randomized into two groups (at least 147 per group): AI-assisted group (treatment group): Preoperative CT imaging will be used to assess body composition and classify patients into high-risk or low-risk categories.Chemotherapy dosing will be adjusted accordingly to evaluate treatment-related adverse effects and dose modifications. Non-AI-assisted group (control group): Patients will receive chemotherapy chemotherapy dosing adjustments based on standard clinical care.
219026854|NCT05824533|DEVICE|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
219604333|NCT07146191|DRUG|2-[14C]-RE104 for Injection|Single, subcutaneous dose of 2-\[14C\]-RE104 for Injection
219604334|NCT06948175|DEVICE|Abdominal transcutaneous electrical stimulation (TES)|Low-intensity sensory abdominal transcutaneous electrical stimulation (TES)
219604335|NCT07146984|BEHAVIORAL|Behavioral (Educational Training Program)|A structured training program for emergency medicine residents based on the Plan-Do-Check-Act (PDCA) cycle. The intervention includes didactic teaching, simulation-based airway management practice, supervised clinical intubation, iterative performance assessment, and feedback-driven improvement.
219604336|NCT06990867|DRUG|JX10|JX10 is a thrombolytic agent.
219604337|NCT06990867|DRUG|Placebo|Placebo is being used as the comparator.
219604338|NCT07142642|DRUG|Teprotumumab|Administered via IV infusion.
219604339|NCT07142642|DRUG|Placebo|Administered via IV infusion.
219604340|NCT07152730|DRUG|Lutrepulse|Lutrepulse administered via the OmniPod delivery pump
219604341|NCT07153783|DIAGNOSTIC_TEST|AI-human collaboration for CE-CTs diagnosis|The system automatically processes all eligible same-day scans and generates results for review the following day. To maintain efficient AI-human collaboration while preserving the standard clinical workflow, the conventional radiological interpretation process remains unchanged (first-line radiologists provide initial reports followed by senior radiologists' review). A dedicated senior radiologist then evaluates any discordances between AI findings and primary radiological report. For complex cases, the review process escalates to a consensus review panel (i.e., pre-designated senior radiologists, Multidisciplinary Team (MDT)). The MDT can recommend clinical interventions including follow-up (e.g., additional imaging examinations, active surveillance), surgical procedures, or adjustments to adjuvant therapy (initiation or modification of treatment regimens). All discordant cases and their outcomes are systematically documented for longitudinal tracking and follow-up analysis.
219604342|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 2)|Consists of Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, and Osia Fitting Software 2.
219026855|NCT05824533|PROCEDURE|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
219026856|NCT02165436|OTHER|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
219604343|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 3)|Consists of Osia 3 Sound Processor, Osia 3 Sound Processor Magnets, Osia 3 Charger, and Osia Fitting Software 3.
219604344|NCT07154706|DRUG|Taletrectinib|Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.
219026857|NCT02165436|OTHER|Control|No intervention will be assessed for this group.
219026858|NCT01992861|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219026859|NCT01992861|PROCEDURE|Diffusion Weighted Imaging|Undergo DW MRI
219499353|NCT02960074|BIOLOGICAL|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
219499354|NCT03446560|DEVICE|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
219026860|NCT01992861|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
219026861|NCT01992861|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
219026862|NCT01992861|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
219604345|NCT07154706|DRUG|Placebo|Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo
219604346|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
219604347|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
219604348|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
219604349|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
219604350|NCT07169591|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span
219604351|NCT07166393|DRUG|Valproic Acid (VPA)|VPA (in 250 ml 0.9% sodium chloride solution)
219604352|NCT07166393|OTHER|Standard of care treatment + normal saline|Standard of care treatment + normal saline (0.9% sodium chloride solution) vehicle (250 ml)
219604353|NCT07166289|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
219604354|NCT07175454|OTHER|Questionnaire|"Patients/research nurses will complete questionnaires detailing their medical history including mental health and describing their IBD.~Patients will complete baseline scoring questionnaires for depression and anxiety (HADS) and perceived stress (PSS-10).~Patients will also complete a patient reported outcome tool to assess their current disease activity level (PRO-2)"
219604355|NCT07177742|OTHER|Observation|Observation.
218880199|NCT05797597|DRUG|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
218880200|NCT02878837|DRUG|Dexmedetomidine|
218880201|NCT02878837|DRUG|Midazolam|
219604356|NCT07175584|RADIATION|anal canal-sparing techniques|To contour anal canal and rectum separately and deliver different doses as two single OARs in pelvic radiation therapy planning.
219604357|NCT07177365|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (ICBT)|An 8-week Internet-based Cognitive Behavioral Therapy (ICBT) program delivered via the National Health Research Institutes (NHRI) secure online platform. The program consists of 12 sequential modules released every 5 days, covering core CBT techniques such as cognitive restructuring, emotion regulation, behavioral activation, mindfulness, and self-compassion. Participants receive automated email notifications for new modules and supplementary review materials. Progress is monitored through the platform, and participants complete standardized self-report assessments at baseline, mid-intervention (week 5), post-intervention (week 9), and 3-month follow-up.
219604358|NCT07177365|OTHER|Treatment as Usual (TAU) Only|Routine clinical care provided by a psychiatrist, which may include pharmacological treatment, psychoeducation, and regular follow-up visits according to clinical judgment. No ICBT intervention is provided during the study period. Participants follow the same assessment schedule as the experimental group. After the 3-month follow-up, participants in this group may request access to the ICBT program.
218880202|NCT02687581|DEVICE|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
218880203|NCT02687581|DEVICE|patch|6-hour of eye patch on the fellow eye
219026863|NCT01992861|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219026864|NCT04823637|DIAGNOSTIC_TEST|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
219026865|NCT04018833|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
219026866|NCT04018833|DRUG|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
219026867|NCT02081482|RADIATION|18F-FDG PET|
219026868|NCT04708938|OTHER|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
219026869|NCT04708938|OTHER|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
219026870|NCT02905682|DRUG|Desmopressin|
219026871|NCT02905682|DRUG|Placebo|
219026872|NCT03441841|DRUG|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
219026873|NCT03441841|DRUG|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
219026874|NCT03441841|DRUG|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
219026875|NCT02555332|OTHER|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
219026876|NCT04460820|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
219026877|NCT00783445|BEHAVIORAL|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
219026878|NCT00783445|BEHAVIORAL|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
219026879|NCT04342845|BEHAVIORAL|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
219026880|NCT01561820|BEHAVIORAL|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
219026881|NCT00536107|DRUG|Gefitinib|250 mg oral
219604359|NCT07185282|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film twice daily.
219604360|NCT07185282|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film twice daily.
219604361|NCT07186868|BIOLOGICAL|Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab|All participants will receive the study intervention: Iparomlimab and Tuvonralimab (QL1706) at 5.0 mg/kg IV Q3W + Nab-Paclitaxel at 260 mg/m² IV Q3W, with or without Bevacizumab (7.5-15 mg/kg IV Q3W) per investigator's choice, for 6 cycles. This is followed by maintenance therapy with QL1706 ± Bevacizumab until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
219604362|NCT07185425|DEVICE|NeuroCuple|Device around the abdomen over c-section bandages in the PACU
219604363|NCT07185425|DEVICE|Sham|Device around the abdomen over c-section bandages in the PACU
218880204|NCT05474222|OTHER|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
218880205|NCT04797546|PROCEDURE|Adductor Canal Block|Continous peripheral nerve block
218880206|NCT04797546|DEVICE|Morphine Patient Controlled Analgesia|Morphine Patient Controlled Analgesia Delivery System
219026882|NCT00536107|PROCEDURE|CT or MRI|performed at screening and every 6 weeks
219026883|NCT00536107|DRUG|Docetaxel|60mg/m2 intravenous infusion
219026884|NCT03449160|DEVICE|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
219026885|NCT03449160|OTHER|physical therapy|routine physical therapy
219604364|NCT07186803|DEVICE|Artificial Intelligence Guidance Models|The intervention will involve the use of two artificial intelligence (AI) models to provide surgical guidance during laparoscopic cholecystectomy procedures. The AI models will provide real-time feedback based on the live surgical feed (internal patient anatomy captured by laparoscopic camera) displayed on an operating room monitor. The GoNoGoNet model identifies safe and unsafe zones of dissection. This is done by showcasing a green overlay over safe zones of dissection, and a red overlay over unsafe zones of dissection. The DeepCVS model provides text-based feedback based on its assessment of the following three criteria defining the Critical View of Safety: 1) complete clearance of the hepatocystic triangle from fat and fibrous tissue, 2) only two structures visible entering the gallbladder (cystic artery and duct) and 3) the lower third of the gallbladder must be dissected off the liver bed, exposing the cystic plate.
219604365|NCT07186166|COMBINATION_PRODUCT|30% HA+70% β-TCP (Osteon II, Dentium, Korea)|A prospective analysis was performed on a single-arm clinical trial involving 60 posterior maxillary edentulous sites in 42 patients with a residual bone height of \<4 mm. All sites were treated with lateral window sinus floor augmentation (LWSFA), followed by grafting using a 1:1 ratio of 30% HA with 70% β-TCP (Osteon II, Dentium, Korea). At 6 months postoperatively, core biopsies were harvested during implant placement to assess the histological outcomes of the grafted sites.
218880207|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
218880208|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
218880209|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
218880210|NCT05347303|OTHER|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
218880211|NCT05347303|OTHER|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
218880212|NCT01431391|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
218880213|NCT01431391|DRUG|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
218880214|NCT01683578|OTHER|Variable Ventilation|
218880215|NCT04514211|DRUG|Propofol|General anesthesia using propofol infusion
218880216|NCT04514211|DRUG|Sevoflurane|General anesthesia using sevoflurane
219026886|NCT02975219|DRUG|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
218880217|NCT01158391|DEVICE|NTrainer® Intervention|
218880218|NCT01158391|DEVICE|Control Intervention|
218880219|NCT02343198|DEVICE|Custom-built research muscle stimulator|Muscle stimulator
218880220|NCT04849715|DRUG|parsaclisib|parsaclisib will be administered orally once daily.
218880221|NCT04849715|DRUG|rituximab|rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
218880222|NCT04849715|DRUG|bendamustine|bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
218880223|NCT04849715|DRUG|Placebo|placebo will be administered orally once daily
219026887|NCT04455269|DEVICE|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
219026888|NCT04455269|DEVICE|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
219026889|NCT02740166|DRUG|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
219026890|NCT02047357|OTHER|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
219499355|NCT03446560|DEVICE|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
218880224|NCT03302637|OTHER|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
218880225|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
218880226|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
218880227|NCT04929080|BIOLOGICAL|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
218880228|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
218880229|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
219499356|NCT03536676|OTHER|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
219499357|NCT03536676|OTHER|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
219499358|NCT02853929|BIOLOGICAL|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
219499359|NCT01492257|OTHER|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
219499360|NCT00480220|PROCEDURE|Global care and support program|
219499361|NCT02891265|BEHAVIORAL|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
219499362|NCT05460026|OTHER|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
219499363|NCT05460026|OTHER|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
219499364|NCT02305420|DEVICE|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
219499365|NCT02305420|DEVICE|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
219499366|NCT02539030|PROCEDURE|Microfracture|simple microfracture
219499367|NCT02539030|DEVICE|CartiFill|add collagen when doing microfracture
219499368|NCT00526773|OTHER|telephone management plus a motivational intervention|heart failure intervention
219499369|NCT00526773|OTHER|telephone management with standard patient education|heart failure intervention
219499370|NCT05654610|DEVICE|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
219499371|NCT01078623|DRUG|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
219499372|NCT01078623|DRUG|Placebo|Placebo control twice daily
219499373|NCT01078623|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
219499374|NCT01078623|DRUG|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
219499375|NCT01078623|DRUG|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
219499376|NCT02905721|PROCEDURE|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
219499377|NCT02330679|DRUG|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
219499378|NCT02330679|DRUG|Placebo|
219499379|NCT05004818|PROCEDURE|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
219499380|NCT05004818|PROCEDURE|Sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
219499381|NCT00701766|DRUG|BI 2536|
219499382|NCT00463866|DRUG|Budesonide/formoterol|
219604366|NCT07185607|PROCEDURE|Erector spinae plane block (ESPB)|Erector spinae plane block is not a drug or a device. It is a regional method for anesthesia/analgesia. Before block application, patients were placed in a sitting position. A preliminary examination with a high-frequency linear probe was performed to identify the application site. Sterile conditions were then established. An ultrasound probe was longitudinally placed approximately 2 cm lateral to the T11 spinous process. The transverse process was visualized. 1 ml of 2% lidocaine was applied to the estimated needle entry site. The needle was then guided toward the transverse process using an out-of-plane method using a blocking needle (Stimuplex® Ultra 360® 22G 80 mm, Melsungen, Germany). After bone contact was achieved, facial hydrodissection was observed with 1-2 ml of saline solution to verify the correct injection site. 20 ml of 0.25% bupivacaine was injected into the plane. The distribution of the drug was visualised by USG.
219604367|NCT07185126|BEHAVIORAL|Reconsolidation of traumatic memories|"The intervention begins with a parent session to review history, provide orientation, and obtain consent. Each child then attends six individual therapy sessions with a trained RTM specialist. Sessions use imagination exercises, film-like replay of traumatic memories in modified formats (e.g., black-and-white, fast-forward, backwards), and structured state-interruption techniques to reduce fear and distress. Animated instructions and cardboard cinema and skreen models may be used to support comprehension if needed."
219604368|NCT07185074|DRUG|Cisatracurium 0.05 mg/kg IV|Single bolus at induction; used in the experimental arm. Approximate potency reference: 0.05 mg/kg is about 1 x ED95.
219604369|NCT07185074|DRUG|Cisatracurium 0.15 mg/kg IV|Single bolus at induction; used in the active comparator arm. Approximate potency reference: 0.15 mg/kg is about 3 x ED95.
219604370|NCT07185074|DRUG|Lidocaine aerosol 2.4% topical|Three sprays to the glottic area immediately before intubation; used only in the experimental arm.
219604371|NCT07184671|BIOLOGICAL|blood sampling|22mL peripheral blood will be collected
219604372|NCT07184671|BIOLOGICAL|broncho-alveolar lavage sampling|Collected on resected tissue
219499383|NCT03150121|PROCEDURE|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
219499384|NCT03150121|PROCEDURE|Blood sample|5-10mL of blood will be drawn from participants.
219604373|NCT07184671|BIOLOGICAL|lung parenchyma sampling|Collected on resected tissue
219604374|NCT07184788|DRUG|Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Gemcitabine (1000 mg/m2 iv qd d2), Oxaliplatin (100 mg/m2 iv qd d2) as induction therapy.
219026891|NCT04426331|BEHAVIORAL|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
219604375|NCT07186751|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
219499385|NCT03150121|DEVICE|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
219499386|NCT02186808|DEVICE|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
219604376|NCT07186751|DRUG|Pregabalin with venlafaxine|In the pregabalin with venlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Venlafaxine will be administered at 75 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 75 mg per day after 4 days, up to a maximum of 225 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
219604377|NCT07186062|DRUG|Levosimendan|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~•Levosimendan: loading dose 6-12 microgram/ kg then continuous infusion of 0.05-0.2 µg/kg/min."
219604378|NCT07186062|DRUG|Dobutamine|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Dobutamine: continuous infusion starting at 2.5 µg/kg/min, titrated up to 20 µg/kg/min as needed."
219604379|NCT07186062|DRUG|Milrinone|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Milrinone: 50 mcg/kg loading dose, then 0.375-0.75 mcg/kg/min IV according to patient response."
219604380|NCT07186335|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients
219604381|NCT07186322|PROCEDURE|Fat Graft|Non-regenerative standard treatment for post-burn sequelae, involving either corticosteroid injection to reduce scar inflammation and fibrosis, or surgical release for contractures. The procedure type will be chosen based on the clinical indication and severity.
219604382|NCT07186413|DRUG|Trifarotene|Trifarotene cream applied QD topically.
218880230|NCT01734759|DRUG|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
218880231|NCT04379076|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
218880232|NCT04379076|DRUG|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
218880233|NCT06526910|BEHAVIORAL|Swallowing exercises|Standard-of-care swallowing exercises include tongue exercise. The experimental part added in Phase 3 includes some participants completed standard-of-care exercises again and others completing standard-of-care exercises and motor imagery practice of those exercises.
219604383|NCT07186413|DRUG|Vehicle Cream|Vehicle cream applied QD topically.
219026892|NCT04426331|BEHAVIORAL|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
219499387|NCT05270187|OTHER|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
219499388|NCT05270187|OTHER|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
219604384|NCT07184827|DRUG|U101|One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.
219604385|NCT07184827|OTHER|Placebo|One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.
219026893|NCT03945474|OTHER|Sham|See description in sham arm.
219026894|NCT03945474|OTHER|Osteopathic Manipulation, OMT|See description in OMT arm
219026895|NCT02278107|DEVICE|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
219026896|NCT02278107|DEVICE|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
219026897|NCT00105703|BEHAVIORAL|Case management using advanced nurse practitioners|
219026898|NCT02229942|DRUG|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
219026899|NCT02229942|DRUG|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
219026900|NCT03326973|BEHAVIORAL|EuroQoL EQ-5D-3L|Overall QOL
219026901|NCT03326973|BEHAVIORAL|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
219026902|NCT03326973|OTHER|PRO-CTCAE|Additional potential immune-specific symptoms
219604386|NCT07185789|BEHAVIORAL|Healthy and Sustainable Eating|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
219604387|NCT07185789|BEHAVIORAL|Movement behaviors|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
219604388|NCT07185789|BEHAVIORAL|Psychosocial determinants|Workshops on key topics of psychosocial determinants in children, virtual workshops on topics of psychosocial determinants such as obesity and healthy eating.
219026903|NCT03326973|BEHAVIORAL|Fatigue severity score questionnaire|Fatigue severity
219026904|NCT03326973|BEHAVIORAL|The COST|Financial toxicity; satisfaction with ability to work
219499389|NCT04956406|BEHAVIORAL|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
219604389|NCT07185178|OTHER|Video game-based breathing exercises|"Twenty individuals will be enrolled in the video game-based breathing exercise program. Participants in the study group will undergo the Breathing Games exercise program twice a week for 8 weeks, with each session lasting approximately 50 minutes. This video game-based breathing exercise program includes warm-up, cool-down, and five breathing games designed for the target patients.From the second week onward, posture exercises combined with the breathing games will be added.Thus, the exercise program will consist of a warm-up phase lasting approximately 10 minutes, including breathing control, stretching exercises, and rest; 25-30 minutes of five breathing games combined with posture exercises; followed by a cool-down phase of about 10 minutes with breathing control, stretching exercises, and rest.Additionally, participants will be provided with a home exercise program to be performed twice daily for 30 minutes, three days a week, over 8 weeks."
219604390|NCT07185178|OTHER|Control group|"Participants in the control group will receive a 30-45 minute patient education session after the assessment. The content of the education will include:~Providing general information about Asthma-COPD Overlap Syndrome (ACOS) Teaching dyspnea-relieving positions Instruction in diaphragmatic breathing techniques Teaching secretion clearance methods (Active Cycle of Breathing Techniques - ACBT) Educating on energy conservation strategies Providing information on correct posture Counseling on lifestyle modifications (e.g., smoking cessation, physical activity recommendations) To maintain and improve physical activity levels, patients will be advised to engage in walking activities for 30 minutes, twice a week After covering these topics, participants will be given brochures containing this information. Additionally, follow-up will be conducted by phone every two weeks. All assessments will be repeated at the end of the 8-week period."
219604391|NCT07185399|BIOLOGICAL|Moderna RSV vaccine|Participants will receive the MRESVIA vaccine (Moderna RSV vaccine) as part of the study. The vaccine will be administered by trained clinical personnel at the Hope Clinic. MRESVIA is FDA-approved and will be used in accordance with its licensed indication for adults aged 60 years and older. MRESVIA is an mRNA-based RSV vaccine containing 50 micrograms (mcg) of nucleoside-modified mRNA encoding the RSV prefusion F glycoprotein. It is supplied as a frozen injectable suspension in single-dose, pre-filled syringes. The vaccine is administered as a single 0.5 milliliter (mL) intramuscular injection.
218880234|NCT01694836|BIOLOGICAL|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
218880235|NCT03934853|DEVICE|Dynamic Dental Navigation|Aid in dental implant placement in humans
219026905|NCT03326973|BEHAVIORAL|Physician information|Details on outside health providers
219026906|NCT01628601|DRUG|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
219499390|NCT04956406|OTHER|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
219613295|NCT06574451|DEVICE|VR-assisted postoperative analgesia|Patients will receive postoperative analgesic adjunctive therapy software to assist in pain control, with one postoperative analgesic adjunctive therapy software intervention at 24 hours and 48 hours after surgery, and pain evaluation within 30 minutes.
218880236|NCT04919837|OTHER|Low vision aids|the assisting devices fitting for low-vision patients
219026907|NCT00791466|DIETARY_SUPPLEMENT|Placebo|Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
219026908|NCT00791466|DIETARY_SUPPLEMENT|Iodine|Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
219026909|NCT05133219|OTHER|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
219026910|NCT04356963|BEHAVIORAL|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
219026911|NCT04356963|BEHAVIORAL|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
219026912|NCT04356963|BEHAVIORAL|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
219026913|NCT04834947|PROCEDURE|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
219026914|NCT04873752|BIOLOGICAL|UDI-001|2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
218880237|NCT03512392|OTHER|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
218880238|NCT03512392|OTHER|Usual care strategy|Usual care at the discretion of the clinical team
218880239|NCT03993041|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
218880240|NCT01960153|DRUG|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
218880241|NCT01960153|DRUG|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
218880242|NCT06328309|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219499391|NCT02265952|DRUG|REGN1500 250 mg SC/15 mg/kg IV/450 mg SC|Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
219499392|NCT03476356|DRUG|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
218880243|NCT06328309|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
218880244|NCT00187447|DRUG|indomethacin (two different dosing regimens)|
218880245|NCT02913378|PROCEDURE|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
218880246|NCT02913378|PROCEDURE|Sling|Conservative treatment with sling and rehabilitation
218880247|NCT01990612|PROCEDURE|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
218880248|NCT06379269|DEVICE|App healthcare|Self-developed app: includes home stretching and strengthening exercises, muscle release technique instruction.
218880249|NCT06379269|OTHER|Control|general education and home rehab program
218880250|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
218880251|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
218880252|NCT05809362|DEVICE|WHOOP 4.0 Strap|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
218880253|NCT05809362|DEVICE|BioTel ePatch|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
218880254|NCT00079716|DRUG|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
218880255|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
218880256|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
218880257|NCT02974842|DEVICE|MAKO 7|Hysteroscopic cell sampling
218880258|NCT05258916|PROCEDURE|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
218880259|NCT06236490|DIAGNOSTIC_TEST|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
218880260|NCT06236490|DIAGNOSTIC_TEST|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
218880261|NCT06236490|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
219499393|NCT03476356|DRUG|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
219499394|NCT01239147|OTHER|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
219499395|NCT01239147|OTHER|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
219499396|NCT02198677|PROCEDURE|Anterior to posterior pressures|Anterior to posterior pressures
219499397|NCT02198677|PROCEDURE|Lateral glide|Lateral glide
219604392|NCT07185464|DEVICE|tACS|This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity. Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients.
218880262|NCT03968848|DRUG|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
218880263|NCT00879528|OTHER|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
218880264|NCT00879528|OTHER|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~* phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~* phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
218880265|NCT04450095|DRUG|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
218880266|NCT01000324|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
218880267|NCT01000324|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
218880268|NCT01000324|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
218880269|NCT02316886|DEVICE|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
218880270|NCT02316886|DRUG|Optimal Medical treatment|
218880271|NCT00360724|DRUG|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
218880272|NCT00123604|DRUG|Carvedilol|25 mg twice daily for five months.
218880273|NCT00123604|DRUG|Metoprolol|200 mg twice daily for five months.
218880274|NCT01068158|DRUG|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
218880275|NCT01068158|DRUG|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
218880276|NCT02300181|DIETARY_SUPPLEMENT|Placebo|
218880277|NCT02300181|DIETARY_SUPPLEMENT|Bacillus subtilis var natto DC-15|
218880278|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
218880279|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
218880280|NCT03633812|OTHER|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
219499398|NCT01042977|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
219499399|NCT01042977|DRUG|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
219499400|NCT04028583|OTHER|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
219499401|NCT04028583|OTHER|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
219499402|NCT05687045|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
219499403|NCT05687045|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
219499404|NCT01823445|OTHER|Xylitol disk|
219604393|NCT07185464|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
219604394|NCT07185815|DRUG|Cariprazine Depot|One single dose of 22 mg
219499405|NCT04303845|DRUG|Erenumab|140 mg of erenumab via subcutaneous injection
219499406|NCT05170828|DRUG|Cyclophosphamide|pre-transplant conditioning treatment
219499407|NCT05170828|DRUG|Fludarabine|pre-transplant conditioning treatment
219604395|NCT07185815|DRUG|Cariprazine Depot|One single dose of 44 mg
219604396|NCT07185815|DRUG|Cariprazine Depot MTD|Three monthly doses of MTD (maximum tolerated dose)
219604397|NCT07185815|DRUG|Oral Cariprazine 3 mg/day|Oral Cariprazine 3 mg/day for three months
219499408|NCT05170828|RADIATION|Total Body Irradiation|pre-transplant conditioning treatment
219499409|NCT05170828|DRUG|Busulfan|pre-transplant conditioning treatment
219499410|NCT05170828|DRUG|Mesna|given with cyclophosphamide
219499411|NCT05170828|DRUG|Sirolimus|post-transplant treatment for GVHD
219499412|NCT05170828|DRUG|Mycophenolate Mofetil|post-transplant treatment for GVHD
219499413|NCT05170828|DRUG|Filgrastim|post-transplant treatment for GVHD
219499414|NCT05170828|DRUG|Cyclophosphamide|post-transplant treatment for GVHD
219499415|NCT05170828|PROCEDURE|Bone Marrow Transplant|Transplant with investigational bone marrow product
219499416|NCT03192683|DEVICE|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
219604398|NCT07185412|DEVICE|Pulsed Field ablation: Ablation to treat atrial fibrillation|Pulsed Field Ablation
219604399|NCT07186738|DEVICE|EPOCA telemonitoring|EPOCA is a telemonitoring and tele-coordination platform for medical, paramedical, and social care, enabling the follow-up of acute or chronic patients at home-whether after hospital discharge, as an alternative to hospitalization, or for long-term monitoring. The EPOCA solution relies on connected devices, a digital platform for analyzing incoming data, and a team of medical and paramedical professionals for monitoring and coordination. Remote medical monitoring includes teleconsultations, at-home paramedical care, guidance and support for families, nursing homes, or long-term care facilities, and 24/7 management of home emergencies
219604400|NCT07186296|DIAGNOSTIC_TEST|EXoPred|Performing invitro Diagnostics with devices developed by EXoPERT.
219604401|NCT07187154|DEVICE|Smart Symptom Management Program|"During the first six months after surgery, patients in the experimental group will use a WeChat mini-program to proactively self-report their symptoms regularly using the Chinese version of the MD Anderson Symptom Inventory for Esophageal Cancer (MDASI-EC). Based on the reported scores and the pre-defined algorithms in the Post-Esophagectomy Symptom Grading Management Manual, the system will automatically provide personalized self-management guidance for low-grade symptoms. For more severe symptoms, the system will generate alerts to prompt dedicated study nurses to initiate proactive telephone follow-up and provide tailored health coaching."
219604402|NCT07185893|DRUG|Human Interleukin-11|Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.
219499417|NCT03192683|DEVICE|Regular sling|
219499418|NCT02883673|DEVICE|Jada System|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
219499419|NCT02903576|PROCEDURE|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
219499420|NCT02903576|PROCEDURE|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
219604403|NCT07185893|DRUG|Romiplostim N01|Administer Romiplostim N01 subcutaneously in the abdominal area. The initial dose is 3 μg/kg, once a week. The subsequent dose will be adjusted according to the patient's platelet count
219499421|NCT06528574|DEVICE|Conventional root canal treatment|Root canals will be irrigated by only side perforated needle
219499422|NCT06528574|DEVICE|Ultrasonic|Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
219499423|NCT06528574|DEVICE|Apical negative pressure|Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system
219499424|NCT06528574|DEVICE|Combined Ultrasonic and negative pressure|Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
219499425|NCT00499720|DRUG|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
219499426|NCT03955692|DEVICE|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
219499427|NCT06102889|DIAGNOSTIC_TEST|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
219499428|NCT02025582|DEVICE|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
219499429|NCT02424565|DRUG|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
219499430|NCT02424565|OTHER|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
219499431|NCT00647608|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
219499432|NCT00647608|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fed
219499433|NCT02140684|DEVICE|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
219499434|NCT00003966|DRUG|defibrotide|
219499435|NCT00796484|DRUG|XL888|Administered orally
219499436|NCT03650400|DRUG|Fevipiprant|Chewable tablet
219499437|NCT03430700|DRUG|Pembrolizumab|Intravenous infusion
219604404|NCT07185035|BIOLOGICAL|KN5001|"Subjects will receive KN5001 on day0, 3, and 6. Multiple Doses of KN5001 will infused using the 3 + 3 dose-escalation strategy."
219604405|NCT07186582|DIAGNOSTIC_TEST|Coronary physiology assessment using Fractional Flow Reserve (FFR) as per standard of care and angiography-derived FFR|Functional assessment of coronary lesions performed using invasive FFR or angiography-derived FFR during coronary angiography as part of routine clinical care. No active intervention or treatment is assigned by the study.
219604406|NCT07186556|BEHAVIORAL|RISE-YA Intervention|Participants will receive energy conservation (EC) counseling, behavior coaching, and exercise training.
219604407|NCT07186556|BEHAVIORAL|Survivorship Education|During weeks 1-6 and 1 time a week during Weeks 7-12, participants will receive a video call which will last about 60 minutes.
219604408|NCT07186855|OTHER|Blood Sample Collection for CTC Detection|Blood Sample Collection for CTC Detection
219604409|NCT07187063|DIAGNOSTIC_TEST|UroAmp Test (Convergent Genomics, Inc.)|Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.
219604410|NCT07186283|DRUG|CBD soft-gel capsules 600 mg|600 mg
219499438|NCT01768000|BEHAVIORAL|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
219499439|NCT04820959|BIOLOGICAL|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
219604411|NCT07186283|DRUG|CBD soft-gel capsules 900 mg|900 mg
219604412|NCT07186283|DRUG|Epidyolex|25 mg/kg
219604413|NCT07185737|BEHAVIORAL|Adapted RUBI-Telehealth|The Adapted RUBI Parent Training is a culturally tailored version of the Research Units in Behavioral Intervention (RUBI) program, designed for Spanish-speaking caregivers of young autistic children. The intervention consists of 8 weekly sessions delivered virtually in Spanish by trained behavioral therapists. Each session incorporates behavioral skills training methods (instruction, modeling, role-play, and feedback). Caregivers use a Spanish-language RUBI handbook to complete weekly home practice activities and receive feedback during sessions. The program focuses on helping caregivers understand the functions of challenging behavior and apply evidence-based strategies to reduce these behaviors and promote positive child outcomes.
219499440|NCT04820959|BIOLOGICAL|Blood sampling|Pre-operative blood sampling
219499441|NCT05539183|PROCEDURE|Blood withdrawal|Blood withdrawal
219499442|NCT03454633|PROCEDURE|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
219499443|NCT05710302|OTHER|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
219604414|NCT07184684|PROCEDURE|Sinonasal microbiome transplant procedure.|A sinonasal microbiome transplant obtained from a healthy donor and administered as a nasal lavage once daily for five consecutive days.
219604415|NCT07184684|OTHER|Placebo saline transplant|Placebo transplant containing saline administered as a nasala lavage once daily for five consecutive days.
219604416|NCT07185269|DRUG|626|626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.
218880281|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1|packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
218880282|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
219499444|NCT01426256|DIETARY_SUPPLEMENT|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
219604417|NCT07185269|DRUG|626|626 subcutaneous (SC) injection.
219604418|NCT07185269|DRUG|Placebo|Placebo subcutaneous (SC) injection.
218880283|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
218880284|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
219499445|NCT04366700|PROCEDURE|Periapical surgery with autograft and collagen membrane|periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
219499446|NCT04366700|PROCEDURE|Periapical surgery with collagen membrane|periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
219604419|NCT07187076|BEHAVIORAL|body awareness|"Body Awareness Therapy (BAT) is a somatic-based, movement-centered therapeutic approach that aims to improve individuals' physical, emotional, and psychological well-being by enhancing conscious awareness of bodily sensations, posture, breathing, movement, and internal states.~Originating from Scandinavian physiotherapy models - particularly the work of Berit Heir Bunkan, Roxendal, and Dropsy - BAT integrates principles from:~Proprioceptive neuromuscular retraining~Mindfulness-based movement~Sensorimotor integration~Psychomotor physiotherapy~BAT is not simply a set of physical exercises, but a neuropsychophysical method designed to promote:~Postural control and alignment~Somatic grounding and bodily coherence~Emotional regulation through movement~Enhanced interoception (awareness of internal bodily states)"
219604420|NCT07186348|PROCEDURE|Ice packing|10 minutes ice packing application after surgery
219604421|NCT07186348|PROCEDURE|Standard Care (in control arm)|Standard Care (in control arm)
219604422|NCT07185711|DIAGNOSTIC_TEST|Resonance Frequency Analysis (RFA)|Resonance frequency analysis performed with the Osstell™ device. SmartPeg was attached with composite resin to the occlusal surface of the tooth, and ISQ values were recorded in mesio-distal and bucco-lingual directions.
219604423|NCT07185711|DIAGNOSTIC_TEST|Bite Force Sensor|Assessment of maximum bite force using a bite force sensor. Measurements were performed on COD-associated teeth and contralateral healthy controls for comparison.
219499447|NCT01942798|DEVICE|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
219499448|NCT01942798|DEVICE|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
219604424|NCT07185867|BEHAVIORAL|Pandora-1 app with high levels of personalization, interaction, monitoring and feedback|Pandora-1 is a behavioral, self-guided and transdiagnostic intervention delivered via an app. It includes predictive risk algorithms, decision support systems (DSS), monitoring and feedback to implement personalized prevention plans (PPP) for anxiety and depression. The intervention has a biopsychosocial approach and offers 4 interactive modules: move more, sleep better, improve relationships and emotional well-being. Participants will receive personalized feedback at baseline, 1, 6 and 12 months, including their levels of depressive and anxiety symptoms over the past two weeks, their predicted risk of developing these disorders in the next year, and related modifiable risk factors (e.g. sedentary lifestyle, insomnia, low social support, poor mental quality of life). Based on this, the app offers suggestions (via DSS) and guides users to relevant content (PPP). Participants follow recommendations of choice, the app tracks these actions and provides feedback at baseline, 1 and 6 months.
219604425|NCT07185867|OTHER|Pandora-2 app with low levels of personalization, interaction, monitoring and feedback|Pandora-2 is a psychoeducational self-guided and transdiagnostic intervention delivered via an app. This intervention also has a biopsychosocial orientation and includes a set of psychoeducational brochures for the prevention of anxiety and depression that can be used at any time. These read-only brochures will have contents on the same 4 intervention modules (move more, sleep better, improve relationships and emotional well-being). At baseline, 1 and 6, 12 months participants will also receive basic information about their level of depressive and anxiety symptoms over the past two weeks, their risk probability of depressive and anxiety episodes next year and some of their modifiable risk factors associated with such risk (e.g. sedentary lifestyle, insomnia, low social support and poor mental quality of life). However, in Pandora-2 intervention participants will have lower levels of interactive intervention components as suggestions from the DSS about PPP, monitoring and feedback.
218880285|NCT02355210|DIETARY_SUPPLEMENT|galactooligosaccharide|5 g galactooligosaccharide
219499449|NCT01541462|OTHER|Weaning|Decrease assistance provided by the ventilator
219499450|NCT06106503|RADIATION|chest x-ray|chest x-ray after rigid bronchoscopy for patient with foreign body inhalation
219604426|NCT07186569|BEHAVIORAL|Digital Interactive Peer Support|Individually randomized participants receive digital interactive peer support.
219604427|NCT07186569|BEHAVIORAL|Face-to-Face Peer Support|Individually randomized participants receive face-to-face peer support.
219604428|NCT07186569|BEHAVIORAL|Standard Training (Control)|Standard Training (Usual Curriculum)-Participants receive usual curriculum-based training without structured peer support.
218880286|NCT02355210|DIETARY_SUPPLEMENT|Placebo|lactose powder, 5 grams
218880287|NCT04969692|PROCEDURE|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
218880288|NCT00991406|DEVICE|FES|Surface stimulation to contract the muscles in the lower extremity
218880289|NCT02847104|OTHER|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
218880290|NCT02847104|OTHER|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
218880291|NCT03450733|DEVICE|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
219499451|NCT06106503|OTHER|clinical examination|no investigations well be done unless needed
218880292|NCT00151502|DRUG|Atorvastatin|
218880293|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
218880294|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
219499452|NCT05121181|OTHER|delphi project|delphy study
219499453|NCT05842395|DRUG|Vitamin C|Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.
219499454|NCT05842395|DRUG|Placebo|Participants with distal radius fractures will take daily Placebo orally for three months.
219604429|NCT07186764|OTHER|Questionnaires|questionnaires: WHOQOL-BREF (Quality of Life Study Questionnaire), FSFI (Female Sexual Function Index), FSDS-R (The Femala sexual distress scale-revised), Rosenberg scale (self-esteem assessment)
219604430|NCT07186764|OTHER|Semi-directed interview|Semi-directed interview on the treatment pathway and the impact of utero-vaginal aplasia on intimate and personal life
219604431|NCT07184840|DRUG|Intravenous Methylprednisolone (IVMP)|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
219604432|NCT07184840|DRUG|Complement protein C5 inhibitor|"IVMP+Eculizumab arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline).~All enrolled patients will receive antibiotic prophylaxis against N meningitidis."
219604433|NCT07185516|OTHER|Airway ultrasound indices|Tongue thickness, hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), ratio of hyomental distance in both positions (HMDR), thyromental distance (TMD), ratio of tongue thickness to thyromental distance (TT/TMD), epiglottis thickness \&pre-epiglottic space thickness
218880295|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
219499455|NCT00622141|DRUG|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
219499456|NCT06287697|OTHER|No intervention|No intervention
219499457|NCT04738877|DIAGNOSTIC_TEST|Body fat measurement|Body fat measurement using skinfolds
219499458|NCT04738877|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
219499459|NCT04738877|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography
219604434|NCT07185516|OTHER|Clinical airway assessment|Mallampati grading and thyromental distance (TMD). The glottic structures displayed during laryngoscopy will be classified according to the Cormack-Lehane
219604435|NCT07187089|DRUG|dupilumab|Administered per the protocol
219604436|NCT07187206|DEVICE|FETO, Fetal Endoluminal Tracheal Occlusion|Fetal Endoluminal Tracheal Occlusion with Balloon placement for fetuses with congenital diaphragmatic hernia
219604437|NCT07185802|BIOLOGICAL|PRP injection|Ultrasound guided intraarticular PRP is given to the patient with partial ACL tear
219604438|NCT07185802|OTHER|conventional conservative method (physical therapy, functional bracing, lifestyle modification)|conventional conservative method (physical therapy, functional bracing, lifestyle modification)
219604439|NCT07185152|OTHER|mechanical vibration|Mechanical vibration was applied to babies randomized to the mechanical vibration group before and during the vaccination procedure.
219604440|NCT07185152|OTHER|Flick tapping|Before the vaccination procedure, the vaccination site was placed on the nail of the middle finger in the babies randomized to the flick tapping group, and then the vaccination was stimulated with a quick tap using the upper nail part of the middle finger.
219604441|NCT07185997|DRUG|Firmonertinib|240 mg oral, daily firmonertinib tablet
219604442|NCT07185997|DRUG|EGFR-TKI inhibitor based on investigator's choice|osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet
219604443|NCT07187245|DEVICE|Reality PAWS Program via Meta Quest 3 VR|Reality PAWS is a mixed reality (MR) game that allows patients to interact with a virtual dog. It was developed at Children's Hospital Colorado to serve patients under isolation precautions who are unable to be visited by a facility dog in person. Patients can interact with the game through features such as walking the dog, providing commands, outfitting the dog, giving treats, playing fetch, petting the dog, and playing with others.
219604444|NCT07185633|DRUG|Gecacitinib-Corticosteroid|Gecacitinib po. 50mg bid at least 28 days
219604445|NCT07185633|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate IV 2mg/kg/d.
218880296|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
219604446|NCT07184866|DRUG|Vitamin C|Intravenous Vitamin C, 25 mg/kg (maximum 1.5 g) every 6 hours for 5 days, administered in addition to standard medical treatment
218880297|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
219499460|NCT04738877|DIAGNOSTIC_TEST|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
219499461|NCT02693496|OTHER|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
219499462|NCT06165120|PROCEDURE|Bracka's repair using preputial graft|"Staged repair:~1. Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~3. Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
218880298|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
218880299|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
218880300|NCT06267664|DRUG|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
218880301|NCT01300572|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
218880302|NCT01300572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
218880303|NCT01300572|DRUG|Cyclosporine|Given PO or IV
219200539|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Remaining Teeth as Landmarks|In this arm, participants will undergo implant placement using a dynamic navigation system, where the reference points for implant positioning are based on the remaining teeth to be extracted. This approach, in contrast to the bone screw method used in Group 1, relies on the teeth that will be removed as landmarks to guide the accuracy of implant placement. The primary goal is to evaluate the accuracy of the implant placement and the time required for the procedure using this method. The results from this group will be compared to those from Group 1, where bone screws are placed as reference points, to assess the accuracy and time efficiency of both approaches.
219200540|NCT06962033|BEHAVIORAL|Opioid Agonist Therapy|Opioid Agonist Therapy (OAT) as HIV prevention
219200541|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
219200542|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
219499463|NCT06165120|PROCEDURE|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~1. Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~3. Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
219499464|NCT05483920|BEHAVIORAL|One-time educational video|One-time educational video
219499465|NCT05483920|BEHAVIORAL|One-time educational video plus automated text messaging|Educational video plus automated text messaging
219499466|NCT02755480|DEVICE|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
219499467|NCT02784925|DEVICE|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
219499468|NCT04228302|DRUG|EC5026 oral capsule|"5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo."
219499469|NCT04228302|OTHER|Placebo oral capsule|5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
219499470|NCT02406833|DRUG|TGF-β2 antisense oligonucleotide|intravitreal injection
219499471|NCT02406833|PROCEDURE|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
219499472|NCT01990885|DRUG|BL-7010|
219499473|NCT01990885|DRUG|Placebo|
219499474|NCT00497471|DRUG|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
219499475|NCT00497471|DRUG|iron (2 mg/kg/daily)|
219499476|NCT01674478|DIETARY_SUPPLEMENT|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
219499477|NCT01674478|DIETARY_SUPPLEMENT|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
219499478|NCT03967132|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
218880304|NCT01300572|DRUG|Fludarabine Phosphate|Given IV
218880305|NCT01300572|BIOLOGICAL|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
218880306|NCT01300572|OTHER|Laboratory Biomarker Analysis|Correlative studies
219200543|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
219499479|NCT03967132|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
219499480|NCT03967132|OTHER|Reference Group|Human milk, breast feeding ad libitum
219499481|NCT02281409|BIOLOGICAL|Mogamulizumab (KW-0761)|
219499482|NCT06339593|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
219499483|NCT04436328|PROCEDURE|Surgical treatment|Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).
218880307|NCT01300572|DRUG|Mycophenolate Mofetil|Given PO or IV
218880308|NCT01300572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
218880309|NCT01300572|OTHER|Pharmacological Study|Correlative studies
218880310|NCT01300572|RADIATION|Total-Body Irradiation|Undergo TBI
218880311|NCT01300572|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
219604447|NCT07184866|OTHER|Standard of Care (SOC)|Supportive and guideline-based management of ACLF with septic shock and AKI, including antibiotics, fluids, vasopressors, renal replacement therapy as required, and other standard therapies
219604448|NCT04569409|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
219604449|NCT04569409|PROCEDURE|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
219604450|NCT03712605|OTHER|Best Practice|Receive standard of care observation
219604451|NCT03712605|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218880312|NCT01835002|DEVICE|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
219604452|NCT03712605|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
219604453|NCT03712605|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219604454|NCT03712605|BIOLOGICAL|Pembrolizumab|Given IV
219604455|NCT03712605|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219604456|NCT03712605|RADIATION|Radiation Therapy|Undergo radiation therapy
219604457|NCT04228172|GENETIC|DNA/GeneticTesting|Subjects will be tested for GBA and LRRK2 mutation status at baseline.
218880313|NCT03845738|DEVICE|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
219026915|NCT03547388|DEVICE|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
219604458|NCT04228172|RADIATION|FDG PET scan|18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
219026916|NCT01356797|DRUG|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
219604459|NCT04228172|OTHER|MRI scan|Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
219604460|NCT04228172|OTHER|Clinical and neuropsychological assessments|Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
219604461|NCT03584165|GENETIC|BIIB111|Administered as specified in the treatment arm.
219604462|NCT03584165|GENETIC|BIIB112|Administered as specified in the treatment arm.
219604463|NCT05490641|BEHAVIORAL|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
219026917|NCT01356797|DRUG|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
219026918|NCT04790032|DRUG|Cangrelor|All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.
219026919|NCT01679002|DRUG|BIA 2-093|
219200544|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
219604464|NCT05490641|BEHAVIORAL|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
219604465|NCT06517316|DEVICE|Nelfilcon A plano cosmetic contact lenses|Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
219604466|NCT01059786|DRUG|Pentostatin|28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
219604467|NCT01059786|DRUG|Rituximab|Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
219604468|NCT01059786|DRUG|Bendamustine|1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
218880314|NCT02715986|DEVICE|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
218880315|NCT03021772|DRUG|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
218880316|NCT03021772|DRUG|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
219026920|NCT01679002|DRUG|Oxcarbazepine|
219200545|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
219604469|NCT01059786|DRUG|Acetaminophen|Treatment of infusion-related symptoms with acetaminophen is recommended.
219604470|NCT01059786|DRUG|Diphenhydramine|Treatment of infusion-related symptoms with diphenhydramine is recommended.
219026921|NCT05051189|DRUG|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
219026922|NCT00525733|DRUG|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
219026923|NCT00525733|DRUG|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
219026924|NCT00525733|DRUG|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
219026925|NCT00525733|DRUG|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
219604471|NCT01059786|DRUG|Epinephrine|Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
218880317|NCT06320314|OTHER|tested product (2039125 03)|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
219499484|NCT04436328|OTHER|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
218880318|NCT02673502|DIETARY_SUPPLEMENT|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
219200546|NCT06607913|OTHER|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
219499485|NCT02933983|OTHER|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
219499486|NCT02791776|OTHER|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
218880319|NCT02673502|DIETARY_SUPPLEMENT|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
218880320|NCT01086943|DEVICE|LT2420|
218880321|NCT02556060|DRUG|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
218880322|NCT02556060|DRUG|Placebo|Same dosing schedule as study drug
219200547|NCT06164106|BEHAVIORAL|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
219200548|NCT06164106|BEHAVIORAL|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
219200549|NCT06164106|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
219200550|NCT03662022|DRUG|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
219200551|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
219200552|NCT06650163|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
219200553|NCT06650163|PROCEDURE|Brain Surgery|Undergo brain surgery
219200554|NCT06650163|OTHER|Electronic Health Record Review|Ancillary studies
219200555|NCT06650163|PROCEDURE|Immuno-Positron Emission Tomography Scan|Undergo immuno-PET
219200556|NCT06650163|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219200557|NCT06650163|PROCEDURE|Stereotactic Biopsy|Undergo stereotactic image-guided biopsy
219200558|NCT06650163|DIAGNOSTIC_TEST|Zirconium Zr 89 Crefmirlimab Berdoxam|Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
219200559|NCT06601452|DRUG|a compound prescription of Chinese medicine|The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
219200560|NCT06860464|BEHAVIORAL|Remote Ischemic Condtioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are RIC plus training visits.
219499487|NCT00991770|OTHER|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
219499488|NCT00991770|OTHER|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
219499489|NCT05402449|OTHER|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
219604472|NCT01059786|DRUG|Antihistamines|Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
219604473|NCT01059786|DRUG|Corticosteroids|Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
218880323|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
218880324|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
218880325|NCT02239315|OTHER|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
219026926|NCT00525733|DRUG|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
219026927|NCT00205426|DRUG|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
219026928|NCT06490263|DRUG|Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects|Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
219200561|NCT06860464|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are Sham plus training visits.
219499490|NCT05402449|DIETARY_SUPPLEMENT|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
219499491|NCT02008721|DRUG|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
219499492|NCT02008721|DRUG|Placebo|Placebo
219604474|NCT01059786|DRUG|Bronchodilators|Additional treatment with bronchodilators may be indicated.
219604475|NCT01059786|OTHER|Intravenous (IV) Saline|Additional treatment with intravenous (IV) saline may be indicated.
219604476|NCT05291845|BIOLOGICAL|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
219604477|NCT05291845|BIOLOGICAL|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
219604478|NCT05756634|BEHAVIORAL|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
219604479|NCT00449904|DRUG|Liprotamase|Administered orally
218880326|NCT04959305|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
218880327|NCT04959305|DRUG|RLD2003|Take it once daily for 8 weeks orally.
219200562|NCT06860464|BEHAVIORAL|Balance training|All participants will undergo training on a balance board, learning to hold the board level within the 5- degree horizontal range. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
219604480|NCT00263354|DRUG|Oxaliplatin|
219200563|NCT06028776|BEHAVIORAL|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
219604481|NCT04346797|DRUG|Eculizumab|"Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22"
219604482|NCT00048373|DRUG|Etanercept|
219604483|NCT04021238|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
219604484|NCT04021238|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
218880328|NCT04959305|DRUG|RLD2004|Take it once daily for 8 weeks orally.
219604485|NCT04009148|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
219604486|NCT02586688|DEVICE|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
218880329|NCT04959305|DRUG|RLD2005|Take it once daily for 8 weeks orally.
218880330|NCT04959305|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
218880331|NCT04959305|DRUG|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
218880332|NCT03887858|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
218880333|NCT03887858|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
218880334|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
219200564|NCT06862050|BEHAVIORAL|BREATHE Free Curriculum|Curriculum will teach practices: love, perspective, prudence, hope, humility, forgiveness, spirituality, self-control, teamworking, perseverance, gratitude, and joy.
219200565|NCT06860399|DRUG|Vardenafil|Oral Vardenafil
219200566|NCT06860399|DRUG|Sildenafil|Oral Sildenafil
219200567|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 1|Patients in the first dose level will receive a cell dose of 1×10\^6 cells/kg.
219200568|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 2|Patients in the second dose level will receive a cell dose of 2×10\^6 cells/kg.
219200569|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 3|Patients in the third dose level will receive a cell dose of 4×10\^6 cells/kg. Based on these findings, the maximum tolerated dose (MTD) will be determined.
219200570|NCT06862388|BIOLOGICAL|Device: Phase II MTD in Phase I|This group subjects received the MTD obtained in phase I.
219200571|NCT06862388|BIOLOGICAL|Device: Phase II lower than the MTD in Phase I|This group subjects received a dose lower than the MTD
219604487|NCT02586688|DEVICE|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
219604488|NCT05728034|BEHAVIORAL|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
219604489|NCT05728034|BEHAVIORAL|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
219604490|NCT05253053|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
219604491|NCT05253053|DRUG|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
218880335|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
218880336|NCT04558372|OTHER|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
219026929|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with single dose in healthy subjects|Parts Two: Administered by swallowing after meals with four distinct dosage groups.
219499493|NCT05033613|OTHER|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
218880337|NCT04166617|OTHER|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
218880338|NCT04166617|OTHER|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
218880339|NCT01700153|OTHER|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
218880340|NCT01700153|OTHER|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
218880341|NCT00375518|DRUG|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
218880342|NCT00375518|DRUG|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
218880343|NCT02197650|DRUG|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
219026930|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
219026931|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
219499494|NCT00541281|DRUG|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
219499495|NCT00541281|DRUG|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
219499496|NCT00541281|DRUG|prednisone|2x5 mg a day
219499497|NCT02579330|DEVICE|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
219499498|NCT02579330|OTHER|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
219499499|NCT00435695|DRUG|GSK163090|
219499500|NCT01156571|DRUG|cangrelor P2Y12 (platelet) inhibitor|
219499501|NCT01156571|DRUG|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
219499502|NCT01156571|DRUG|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
219499503|NCT03410381|OTHER|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
219499504|NCT03192059|DRUG|Pembrolizumab|Efficacy of the combined treatment
219499505|NCT03192059|RADIATION|Radiation|Efficacy of the combined treatment
219499506|NCT03192059|DRUG|Vitamin D|Efficacy of the combined treatment
219026932|NCT06092099|DEVICE|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
219499507|NCT03192059|DRUG|Aspirin|Efficacy of the combined treatment
218880344|NCT03273309|OTHER|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
219499508|NCT03192059|DRUG|Lansoprazole|Efficacy of the combined treatment
219499509|NCT03192059|DRUG|Cyclophosphamide|Efficacy of the combined treatment
219499510|NCT03192059|DIETARY_SUPPLEMENT|Curcumin|Efficacy of the combined treatment
219499511|NCT00063128|DRUG|insulin|"* Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only."
219499512|NCT00063128|DRUG|human insulin inhalation powder (HIIP)|"* Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
219499513|NCT01266174|DRUG|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
218880345|NCT03273309|OTHER|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
219499514|NCT01266174|DRUG|Placebo|Placebo to match eltoprazine
219499515|NCT04090996|DIAGNOSTIC_TEST|Dual TAsk|"Motor assessment includes:~* posturographic examination in Single-task (ST) and Double-task (DT)~* an analysis of ST and DT walking;~* Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
219499516|NCT02803723|PROCEDURE|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
218880346|NCT00854841|DRUG|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
218880347|NCT02359513|DRUG|Antidepressants|bulimic patients are treated during 3 months
218880348|NCT02359513|DRUG|Positron Emission Tomography (PET)|PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
219026933|NCT06527131|DEVICE|pulsed electromagnetic field therapy|PEMF is regarded as an efficient physical therapy method that has been utilized clinically to treat a variety of orthopedic conditions, including delayed union and nonunion of fractures. According to studies, PEMF has been authorized for its biological effects, which include the mineralization of bone matrix, osteogenic differentiation of mesenchymal stem cells, and osteoblast proliferation
219026934|NCT06527131|DEVICE|Transcutanous electrical nerve stimulation|Electrical stimulation consider a safe and cost-effective method for pain management. It has no side effects and few contraindication in addition to no drug interaction . According to studies ,electrical stimulation decreases pain through reducing central transmission of pain signals because of nociceptive inhibition at the presynaptic level in the dorsal horn.
219026935|NCT06527131|DRUG|Vancomycin|medical antibiotics
219499517|NCT02803723|PROCEDURE|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
219499518|NCT02370966|DIETARY_SUPPLEMENT|Berry powder|Berry and gingivitis trial
219499519|NCT03910803|DRUG|Brodalumab|"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."
219499520|NCT05484375|DRUG|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
219499521|NCT01557270|DRUG|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
219604492|NCT05253053|DRUG|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
219604493|NCT02454608|DRUG|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
219499522|NCT01557270|DRUG|saline|ropivacaine + saline placebo, single shot perineural application
219499523|NCT03825952|DEVICE|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
219499524|NCT04340232|DRUG|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
219499525|NCT00373685|DRUG|Celecoxib|open-label
219499526|NCT00373685|DRUG|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
218880349|NCT02006849|DRUG|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
218880350|NCT03335280|DRUG|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
218880351|NCT02421289|DRUG|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
218880352|NCT02421289|DRUG|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
218880353|NCT02421289|OTHER|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
219499527|NCT03754816|PROCEDURE|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
219499528|NCT03754816|DRUG|Levobupivacaine|Levobupivacaine
219604494|NCT02454608|OTHER|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
218880354|NCT00411632|DRUG|Bexarotene|400 mg/m\^2 by mouth daily x 28 Days
219499529|NCT03774979|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
219499530|NCT00602550|DRUG|Zidovudine|
219499531|NCT01963819|OTHER|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
219499532|NCT00097123|DRUG|Misoprostol|
219499533|NCT06539299|PROCEDURE|Socket Preservation|After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.
218880355|NCT00411632|DRUG|Erlotinib|150 mg by mouth daily x 28 Days
218880356|NCT00003336|BIOLOGICAL|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
218880357|NCT00003336|DRUG|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
218880358|NCT00003336|DRUG|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
218880359|NCT00003336|DRUG|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
219200572|NCT06862271|PROCEDURE|Group 1 ( Caudal block group )|In the caudal block group, after the induction of caudal block with investigations, 0.2% bupivacaine will be applied to the epidural space in a volume of 0.8 mL/kg and a maximum of 20 mL will be injected into the epidural space and the surgical incision will be made at the 15th minute. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
219499534|NCT05064696|OTHER|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
219604495|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
219604496|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
219604497|NCT02333084|DIETARY_SUPPLEMENT|PRN Joint Health Formula|
219604498|NCT02333084|DIETARY_SUPPLEMENT|placebo|
219604499|NCT02333084|DIETARY_SUPPLEMENT|PRN Flex Omega Benefits® combination|
219604500|NCT01944111|DEVICE|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
219604501|NCT06013098|DRUG|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
219604502|NCT06013098|DRUG|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
219604503|NCT05603325|OTHER|Person Centered Practice|"Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme."
219604504|NCT05603325|OTHER|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
219604505|NCT02074280|DRUG|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
219604506|NCT01226030|DRUG|M2ES 7.5mg|M2ES 7.5mg
219604507|NCT01226030|DRUG|M2ES 15mg|M2ES 15mg
219604508|NCT01226030|DRUG|M2ES 30mg|M2ES 30mg
218880360|NCT00003336|DRUG|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
218880361|NCT00003336|PROCEDURE|bone marrow ablation with stem cell support|
218880362|NCT00003336|PROCEDURE|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
218880363|NCT00003336|RADIATION|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
218880364|NCT04338737|OTHER|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
218880365|NCT01108523|DEVICE|HP828-101|
218880366|NCT04492761|BEHAVIORAL|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
219499535|NCT05064696|DEVICE|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
219604509|NCT01226030|DRUG|M2ES 60mg|M2ES 60mg
218880367|NCT04978818|DRUG|Vaxelis|Eligible infants will be block randomized to one of two study arms.
218880368|NCT04978818|DRUG|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
219604510|NCT02371655|PROCEDURE|Diet|A low-fibre diet for three days before the examination
219604511|NCT02371655|DRUG|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
218880369|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
218880370|NCT04517643|OTHER|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
218880371|NCT04186338|DEVICE|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
218880372|NCT06037408|DRUG|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
218880373|NCT06037408|OTHER|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
219499536|NCT01682278|DEVICE|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
218880374|NCT03800511|DIAGNOSTIC_TEST|sliding test|ultrasound detected sliding test before doing repeated caesarean section
218880375|NCT00911339|DRUG|Atorvastatin|Atorvastatin 10 mg associated with stent genous
218880376|NCT00911339|DRUG|Atorvastatin|Atorvastatin 80 mg associated with stent genous
219026936|NCT06162442|DRUG|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
218880377|NCT04277039|OTHER|osteopathic treatment + cognitive training|This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
218880378|NCT04277039|OTHER|osteopathic treatment|manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
218880379|NCT04277039|OTHER|usual care|administration of non-steroid inflammatory drug according to international guidelines
218880380|NCT05252663|PROCEDURE|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
218880381|NCT05252663|PROCEDURE|Traditional chest physiotherapy|postural drainage - percussion
218880382|NCT04557046|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
218880383|NCT04557046|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
219499537|NCT05614388|DIAGNOSTIC_TEST|COVID-19 Self testing and related messaging|Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
219499538|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
218880384|NCT04557046|DIAGNOSTIC_TEST|Throat swab|Collection of one more throat swabs
218880385|NCT04557046|DIAGNOSTIC_TEST|Fingerstick|Collection of capillary blood from one or more fingersticks
219499539|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
219499540|NCT00904189|RADIATION|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
219499541|NCT05841966|DIAGNOSTIC_TEST|Transoral Ultrasound|The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
219499542|NCT05322265|PROCEDURE|laparoscopic surgery for renal and adrenal diseases|type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
219499543|NCT02055183|DRUG|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
219499544|NCT04974645|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
219499545|NCT04974645|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
218880386|NCT04557046|DIAGNOSTIC_TEST|Saliva specimen|Collection of free drool
218880387|NCT00004689|DRUG|amithiozone|
218880388|NCT00004689|DRUG|clarithromycin|
218880389|NCT00004689|DRUG|ethambutol|
218880390|NCT00004689|DRUG|rifampin|
218880391|NCT00004689|DRUG|streptomycin|
218880392|NCT03248089|DIAGNOSTIC_TEST|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
218880393|NCT06128746|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
219026937|NCT04287712|DIAGNOSTIC_TEST|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
219499546|NCT04930198|BEHAVIORAL|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
219499547|NCT02073305|OTHER|No Sleep Apnea|No intervention
219499548|NCT02073305|OTHER|Sleep Apnea - untreated|No intervention
219499549|NCT02073305|DEVICE|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
219499550|NCT01166997|DEVICE|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
219499551|NCT01166997|DRUG|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
219499552|NCT05924451|BEHAVIORAL|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
219499553|NCT00297986|DEVICE|Helmet|Evaluation of different interfaces for NPPV
219499554|NCT01864525|DRUG|Octanoic acid|
219499555|NCT01864525|DRUG|Inactive capsule|
219604512|NCT02371655|DRUG|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
219604513|NCT02371655|PROCEDURE|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
218880394|NCT06128746|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
218880395|NCT05043389|OTHER|myofunctional therapy program|Exercise oral cavity muscle
218880396|NCT01085292|DRUG|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
218880397|NCT01085292|DRUG|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
218880398|NCT03897595|DEVICE|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
219026938|NCT01176266|DRUG|asfotase alfa|
219026939|NCT05434806|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daly oral intake
219026940|NCT04398069|PROCEDURE|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
218880399|NCT01735370|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
218880400|NCT01735370|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
218880401|NCT05118334|DRUG|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
218880402|NCT05118334|DRUG|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
219026941|NCT02229136|DRUG|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
219026942|NCT02229136|DRUG|Prednisolone|Prednisolone oral solution 15 mg/5 ml
219499556|NCT01124526|DRUG|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
219499557|NCT04610073|BEHAVIORAL|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
219499558|NCT00018746|DEVICE|repetitive transcranial magnetic stimulation|
219499559|NCT03156582|OTHER|Data collecting|
219499560|NCT01884116|DRUG|NSAID patch|
219499561|NCT01884116|DRUG|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
219499562|NCT01884116|DRUG|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
219499563|NCT01884116|DRUG|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
218880403|NCT05574842|BEHAVIORAL|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
218880404|NCT01616251|OTHER|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
218880405|NCT04456374|OTHER|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
218880406|NCT01211340|BEHAVIORAL|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
219499564|NCT03138239|RADIATION|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
219499565|NCT06339021|PROCEDURE|OCT-guided PCI|OCT-guided PCI based on MLD MAX algorithm
219499566|NCT06339021|PROCEDURE|Conventional angiography-based PCI|Conventional angiography-based PCI
219499567|NCT06339021|DRUG|DAPT de-escalation|Aspirin and clopidogrel 30 days after DES implantation
219499568|NCT06339021|DRUG|default DAPT regimen|Aspirin and ticagrelor 30 days after DES implantation
219499569|NCT01339884|DRUG|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
219499570|NCT04117217|DIAGNOSTIC_TEST|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
219499571|NCT01890785|DRUG|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
219499572|NCT01094509|BEHAVIORAL|Tai Chi|Tai Chi classes and exercises
219499573|NCT01094509|BEHAVIORAL|Guided autobiography|Autobiographical writing in class and at home
219499574|NCT01094509|BEHAVIORAL|Qigong|Qigong classes and exercises (exploratory)
219499575|NCT01094509|BEHAVIORAL|Successful aging|Seminar series on the theme of successful aging
219499576|NCT01094509|BEHAVIORAL|Combination|Combination of Tai Chi exercises and autobiographical writing
219499577|NCT01094509|BEHAVIORAL|Comparison|No assigned behavioral activity (exploratory)
219499578|NCT05012085|OTHER|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
219499579|NCT00973856|OTHER|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
219499580|NCT00973856|OTHER|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
219499581|NCT01353105|PROCEDURE|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
218880407|NCT00004274|DRUG|Estrogen|
218880408|NCT03755661|BEHAVIORAL|MI&TXT4MSM|brief in-person intervention followed by text messaging
218880409|NCT05612425|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
218880410|NCT05612425|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
219499582|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
219499583|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
219499584|NCT00913588|DRUG|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
219499585|NCT02746705|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
219499586|NCT02746705|DEVICE|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
219499587|NCT02746705|BEHAVIORAL|Cognitive Training Program|
219499588|NCT03545737|OTHER|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
219499589|NCT03545737|OTHER|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
219499590|NCT00368238|DRUG|Recombinant human erythropoietin alfa (drug)|
219499591|NCT00368238|DRUG|Aspirin (drug)|
219499592|NCT00368238|DRUG|Clopidogrel (drug)|
218880411|NCT05047848|DRUG|Chidamide|chidamide 30mg orally，Biw
218880412|NCT05047848|DRUG|Fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
219499593|NCT00575328|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
218880413|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
218880414|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
218880415|NCT02277119|DEVICE|Maestro|OCT machines used for diagnostic purposes
218880416|NCT02277119|DEVICE|iVue|OCT machines used for diagnostic purposes
219026943|NCT01140321|DRUG|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
219026944|NCT04783805|DIAGNOSTIC_TEST|Conservative management with regular follow-up|Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
219026945|NCT04783805|PROCEDURE|Conization|Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
219499594|NCT00575328|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
219499595|NCT02124746|DRUG|Momelotinib|Momelotinib tablets administered orally once daily
219499596|NCT03180346|DEVICE|PICO|Single Use Negative Pressure Dressing
219499597|NCT03180346|DEVICE|Aquacel|Occlusive surgical dressing infused with ionized silver
219499598|NCT05279326|BEHAVIORAL|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
219499599|NCT02205866|OTHER|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
219499600|NCT06134973|DIAGNOSTIC_TEST|ultrasonic testing|ultrasonic testing
219499601|NCT01428726|DRUG|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
219499602|NCT03000868|PROCEDURE|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
219499603|NCT03000868|PROCEDURE|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
219499604|NCT04427514|DEVICE|Telemedicine software for data transmission and analysis in CAPD.|Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
219499605|NCT02487173|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
218880417|NCT02193308|DRUG|Telmisartan/Amlodipine FDC|
218880418|NCT02193308|DRUG|Telmisartan|
218880419|NCT02193308|DRUG|Amlodipine|
218880420|NCT02469519|DRUG|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
218880421|NCT02469519|OTHER|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
218880422|NCT05659472|BEHAVIORAL|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
219026946|NCT03265197|DRUG|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
219499606|NCT02487173|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
219499607|NCT02487173|DEVICE|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
219499608|NCT03301428|OTHER|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
219499609|NCT03301428|OTHER|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
219499610|NCT02680977|OTHER|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
219499611|NCT02680977|OTHER|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
219604514|NCT01433055|DRUG|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
219499612|NCT02680977|OTHER|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
219499613|NCT02680977|DRUG|LD+DDCI|Levodopa plus Benserazide
219604515|NCT01433055|DRUG|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
219604516|NCT02663843|DEVICE|i-gel airway|Fibreoptic intubation via i-gel airway device
219604517|NCT02663843|DEVICE|air-Q airway|Fibreoptic intubation via air-Q airway device
219604518|NCT06032078|DEVICE|Cutera laser machine|1064nm Nd: YAG laser
219499614|NCT02680977|DRUG|LD-DDCI|Levodopa without any DDCI
219604519|NCT05076461|DRUG|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
219604520|NCT00486525|PROCEDURE|Yoga Therapy|Patients will undergo yoga therapy
219604521|NCT01531517|DRUG|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
219604522|NCT01531517|DRUG|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
219604523|NCT06512792|BEHAVIORAL|Telemedicine management through Mobile APP|According to the patient's electronic health records, each participating center researcher conducts personalized medication reminders and follow-up reminders for enrolled patients on a one-on-one basis. Simultaneously, patients are advised to monitor their health at home, regularly record and upload changes in clinical symptoms, medication, diet, exercise, etc., on the Mobile APP platform. Periodically, self-assessment scales are distributed through the Questionnaire Star platform to assess and record the patient's disease activity, quality of life, sleep, psychological status, etc., and update the information in the electronic health records.Based on the patient's clinical symptoms, self-assessment scales, and feedback from medical institution tests and examinations, each participating center researcher will promptly assess potential health risks, send warning alerts, and provide targeted informational support and interventions.
219604524|NCT01366131|DRUG|MEGF0444A|Intravenous repeating dose
219604525|NCT01366131|DRUG|bevacizumab|Intravenous repeating dose
219604526|NCT01366131|DRUG|carboplatin|Intravenous repeating dose
219604527|NCT01366131|DRUG|paclitaxel|Intravenous repeating dose
218880423|NCT05659472|BEHAVIORAL|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
219499615|NCT02680977|OTHER|Placebo|Groundnuts powder
219499616|NCT00571922|DRUG|Acamprosate|2 gr/day (333 mg, TID)
219604528|NCT01366131|DRUG|placebo|Intravenous repeating dose
218880424|NCT03144986|DEVICE|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
218880425|NCT00028236|DRUG|Gene-Transduced Autologous CD34+ Stem Cells|
218880426|NCT01631097|DRUG|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
219499617|NCT00571922|DRUG|placebo|matching placebo
219499618|NCT03768219|BIOLOGICAL|APVO210|APVO210
219499619|NCT03768219|BIOLOGICAL|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
219604529|NCT03573830|BEHAVIORAL|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
219604530|NCT03573830|BEHAVIORAL|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
219499620|NCT03459781|BEHAVIORAL|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
219499621|NCT03459781|BEHAVIORAL|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
219499622|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
219499623|NCT04080882|OTHER|Placebo|Treatment of platysmal bands
219499624|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
219604531|NCT01204567|OTHER|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
219604532|NCT04018378|DRUG|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
219604533|NCT04018378|DRUG|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
219604534|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
219604535|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
219499625|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
219499626|NCT04714099|DRUG|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
219499627|NCT04714099|DRUG|Placebo|Placebo
219604536|NCT02983747|OTHER|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
219604537|NCT02983747|DRUG|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
219604538|NCT03159247|BEHAVIORAL|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
219604539|NCT00005598|DRUG|amifostine trihydrate|
219604540|NCT00005598|DRUG|azacitidine|
219604541|NCT01096797|DRUG|Sevoflurane|"* Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
219604542|NCT01214577|DRUG|PEP005 (ingenol mebutate) Gel|0.015%
219604543|NCT04113577|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
218880427|NCT01494597|DRUG|isavuconazole|oral
218880428|NCT01494597|DRUG|cyclosporine|oral
218880429|NCT05597553|OTHER|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
218880430|NCT05597553|OTHER|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
219499628|NCT02163811|BEHAVIORAL|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
219499629|NCT02163811|BEHAVIORAL|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
219499630|NCT06231797|DIAGNOSTIC_TEST|AI algorithm conducted on 12-lead ECG and transthoracic echocardiography|12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.
219499631|NCT04783259|OTHER|Structured approach|Structured approach with a narrow learning objective. The structured approach concerns a pre-escape room lecture and post-escape room debriefing
219499632|NCT04136197|DIAGNOSTIC_TEST|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
218880431|NCT02215005|DRUG|Telmisartan|
218880432|NCT02215005|DRUG|Ramipril|
218880433|NCT02381340|DEVICE|ACE stapling procedure|Endoscopic trans-oral gastroplication
218880434|NCT01750905|DRUG|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
218880435|NCT01750905|DRUG|Placebo|Vehicle (D5W) SQ
218880436|NCT06145958|DRUG|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
218880437|NCT00116116|DRUG|efavirenz, stavudine extended release, lamivudine|
218880438|NCT00829959|BEHAVIORAL|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
218880439|NCT00002517|DRUG|cytarabine|
218880440|NCT00002517|DRUG|daunorubicin hydrochloride|
218880441|NCT00002517|DRUG|dexamethasone|
219499633|NCT04465383|DEVICE|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
219499634|NCT04465383|DRUG|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
219499635|NCT00350857|DRUG|Extended-Release Carbamazepine|
219499636|NCT00868582|OTHER|PET scanning in cancer|Collection of institutional practice PET imaging data
219499637|NCT02522949|DEVICE|ColdZyme® mouth spray|
219499638|NCT02522949|DEVICE|Placebo|
219499639|NCT05031962|DEVICE|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
219499640|NCT06079853|BEHAVIORAL|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
219604544|NCT01769456|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
218880442|NCT00002517|DRUG|etoposide|
218880443|NCT00002517|DRUG|idarubicin|
218880444|NCT00002517|DRUG|mitoxantrone hydrochloride|
218880445|NCT00002517|DRUG|thioguanine|
218880446|NCT00002517|PROCEDURE|allogeneic bone marrow transplantation|
218880447|NCT00002517|RADIATION|radiation therapy|
218880448|NCT00683839|BEHAVIORAL|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
218880449|NCT00562991|DEVICE|measurement of exhaled NO is used to guide treatment|exhaled NO
218880450|NCT00532506|DRUG|SK-0403|
219499641|NCT05958810|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
218880451|NCT01108198|DRUG|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
218880452|NCT01108198|DRUG|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
218880453|NCT02242383|DRUG|Telmisartan|
218880454|NCT02242383|DRUG|Telmisartan in combination with hydrochlorothiazide|
218880455|NCT03588936|DRUG|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
219499642|NCT05958810|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
218880456|NCT03588936|DRUG|Tocilizumab|Participants will receive 2 doses of tocilizumab
218880457|NCT03588936|DRUG|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
218880458|NCT05894811|DIAGNOSTIC_TEST|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
218880459|NCT05894811|DIAGNOSTIC_TEST|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
218880460|NCT02331017|BEHAVIORAL|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
218880461|NCT05084092|RADIATION|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
219026947|NCT03265197|OTHER|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
219499643|NCT04257240|PROCEDURE|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
219499644|NCT04257240|PROCEDURE|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
219499645|NCT01392859|DRUG|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
219499646|NCT02191579|BIOLOGICAL|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
219499647|NCT02191579|DRUG|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
219499648|NCT00769015|BEHAVIORAL|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
219499649|NCT00769015|BEHAVIORAL|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
219499650|NCT04403191|DRUG|Ondansetron|ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
219499651|NCT04403191|DRUG|isopropyl alcohol 70% inhalation|inhalation every 15 min for 4 times then repeated after 6 hours
219499652|NCT04403191|PROCEDURE|laparoscopic appendectomy|all patients received post operatively after laparoscopic appenectomy
219499653|NCT00389649|DEVICE|heart rate setting|
219499654|NCT02681107|RADIATION|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
219499655|NCT01399424|DRUG|CP|Immunization
219499656|NCT03932435|DRUG|Fisrt period TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
219499657|NCT03932435|DRUG|Fisrt period TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
219499658|NCT03932435|OTHER|Washout period|7 days
219499659|NCT03932435|DRUG|Second period TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
219499660|NCT03932435|DRUG|Second period TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
219499661|NCT06542185|OTHER|online education|online education
219499662|NCT00003669|DRUG|arzoxifene hydrochloride|
219499663|NCT04389619|DEVICE|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
219499664|NCT04389619|PROCEDURE|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
219499665|NCT00203632|DRUG|rosiglitazone/placebo|
219604545|NCT01769456|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
219604546|NCT01068548|OTHER|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
219604547|NCT03688048|DEVICE|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
219604548|NCT03688048|DEVICE|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
219604549|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
219604550|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
219604551|NCT05105997|DRUG|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
219604552|NCT05105997|DRUG|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
219604553|NCT06388005|OTHER|emotional freedom technique (EFT)|The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.
219604554|NCT04005001|OTHER|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
219604555|NCT04005001|OTHER|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
219604556|NCT04348201|OTHER|foot reflexology|foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
219604557|NCT04348201|DIETARY_SUPPLEMENT|dietary modification|diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
219604558|NCT04768192|PROCEDURE|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
219604559|NCT04768192|PROCEDURE|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
219604560|NCT01744301|DRUG|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
219604561|NCT04641104|DRUG|Thiamine 500 MG|A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
219026948|NCT02413541|PROCEDURE|Polymyxin-B Hemoperfusion|Endotoxin removal
219026949|NCT02413541|PROCEDURE|Standard treatment|
219499666|NCT04297488|DIETARY_SUPPLEMENT|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
219499667|NCT00821990|DRUG|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
219499668|NCT00821990|OTHER|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
219499669|NCT00831922|DRUG|masitinib (AB1010)|3 mg/kg/day
219499670|NCT00831922|DRUG|masitinib (AB1010)|6 mg/kg/day
219499671|NCT03940586|DRUG|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
219499672|NCT03940586|DRUG|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
219499673|NCT03940586|DRUG|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
219604562|NCT04641104|DRUG|Placebo|100 ml of NaCl 0.9% will be administered in the placebo group.
218880462|NCT05084092|PROCEDURE|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
219499674|NCT00964223|DRUG|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
219499675|NCT00964223|DRUG|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
219499676|NCT01892423|OTHER|Cetaphil Moisturizing Lotion Daily Advance|
219499677|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA
219499678|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
219499679|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
219499680|NCT04091685|DEVICE|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
219499681|NCT03213561|DEVICE|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
219499682|NCT03077828|DRUG|Carboplatin|Given IV
219499683|NCT03077828|DRUG|Etoposide|Given IV
219499684|NCT03077828|DRUG|Ifosfamide|Given IV
219499685|NCT03077828|OTHER|Laboratory Biomarker Analysis|Correlative studies
219499686|NCT03077828|BIOLOGICAL|Pembrolizumab|Given IV
219499687|NCT05681377|DRUG|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
219499688|NCT03536819|DEVICE|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
219499689|NCT05202691|OTHER|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
219499690|NCT05202691|OTHER|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
219499691|NCT02769000|RADIATION|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
219499692|NCT02769000|RADIATION|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
219499693|NCT03788798|DEVICE|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
219499694|NCT00345683|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
218880463|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
218880464|NCT04699461|DRUG|Idelalisib|Oral tablet
218880465|NCT04071418|RADIATION|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
218880466|NCT00219778|DRUG|mifepristone|
218880467|NCT02072369|OTHER|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
218880468|NCT02072369|OTHER|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
219499695|NCT00345683|BIOLOGICAL|PedvaxHIB|Booster dose by intramuscular injection
219499696|NCT00345683|BIOLOGICAL|Prevnar|Booster dose by intramuscular injection
219499697|NCT00345683|BIOLOGICAL|M-M-R II|Single dose by subcutaneous injection
219499698|NCT00345683|BIOLOGICAL|Varivax|Single dose by subcutaneous injection
219499699|NCT00937053|OTHER|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
219499700|NCT00937053|OTHER|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
219499701|NCT00937053|OTHER|Platelet transfusion|Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
219499702|NCT04288115|DRUG|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
219604563|NCT05895201|DRUG|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
219604564|NCT05895201|DRUG|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
218880469|NCT04478448|DRUG|Flupirava|1 tablet contains 200 mg Favipiravir
218880470|NCT04478448|DRUG|Avigan|1 tablet contains 200 mg Favipiravir
218880471|NCT06031363|DRUG|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
219026950|NCT01756495|DRUG|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
219026951|NCT01756495|DRUG|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
219499703|NCT04288115|OTHER|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
219499704|NCT00842894|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
219499705|NCT00842894|DRUG|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
219499706|NCT04175678|OTHER|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
219499707|NCT04175678|OTHER|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
218880472|NCT00258323|DRUG|cisplatin|20mg/m2d/IV continuous infusion x days
218880473|NCT00258323|DRUG|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
218880474|NCT00258323|DRUG|Iressa|250mg po qd days 1-28 then x 2 years
218880475|NCT00258323|PROCEDURE|conventional surgery|conventional surgery
218880476|NCT00258323|RADIATION|radiation therapy|150 cGy bid
218880477|NCT05399290|DRUG|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
218880478|NCT03068767|DIETARY_SUPPLEMENT|Vitamin D|
218880479|NCT00001644|DRUG|Indinavir|
219499708|NCT04175678|OTHER|Standard care|Observational
219499709|NCT06543017|OTHER|Experimental group|This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
219604565|NCT05895201|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
219604566|NCT05191004|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
219604567|NCT05191004|DRUG|Fulvestrant|Fulvestrant
218880480|NCT00001644|DRUG|Zidovudine|
219604568|NCT05244122|BEHAVIORAL|Feedback|presence or absence of trial by trial feedback
218880481|NCT00001644|DRUG|Lamivudine|
218880482|NCT00001644|DRUG|Nevirapine|
218880483|NCT00001644|PROCEDURE|Blood testing|
218880484|NCT00001644|PROCEDURE|Lymph node biospy|
218880485|NCT00001644|PROCEDURE|Leukapheresis|
218880486|NCT05261009|DRUG|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
219026952|NCT01756495|DRUG|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
219026953|NCT01756495|DRUG|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
219604569|NCT05244122|BEHAVIORAL|Prevalence|"In some blocks, skin cancer target images were present on 50% of trials (high prevalence). In other blocks, disease prevalence was 20%."
218880487|NCT05261009|OTHER|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
218880488|NCT01942070|DEVICE|Bioresorbable vascular scaffold|
218880489|NCT01942070|DEVICE|Durable polymer everolimus-eluting metallic stent|
218880490|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
218880491|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
219026954|NCT00814086|DRUG|Paclitaxel|Given IV or intraperitoneally
219026955|NCT00814086|DRUG|Cisplatin|Given intraperitoneally
219026956|NCT03163888|PROCEDURE|Navigation TKR|Traditional over Conventional TKR
219026957|NCT01179477|DEVICE|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
219026958|NCT00189228|DRUG|Xolair|Patients are administered Xolair
219026959|NCT03031808|DRUG|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
219026960|NCT03031808|DRUG|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
219026961|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
219026962|NCT05601323|DEVICE|Suizenji|HIFU treatment
219026963|NCT05601323|DRUG|Nal-IRI/FL|Nanoliposomal irinotecan, Fluorouracil, Levofolinate
219026964|NCT05601323|DRUG|mFOLFIRINOX|Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
219604570|NCT04809922|DEVICE|cardiac wearable devices|"five cardiac wearable devices~* Apple Watch, Apple Inc., Model Number: A1977 / A1978~* Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~* Fitbit Sense, Fitbit, Inc, Model Number: FB512~* Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~* Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
219499710|NCT03797365|OTHER|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
219604571|NCT00599248|BIOLOGICAL|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
219604572|NCT00599248|BIOLOGICAL|Placebo|Placebo control (DMEM)
219499711|NCT03797365|BEHAVIORAL|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on…
219499712|NCT02720224|DRUG|Estetrol|15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
219499713|NCT00729365|DRUG|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
219499714|NCT00729365|DRUG|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
219499715|NCT00729365|DRUG|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
219499716|NCT03178422|DRUG|CQSS2|Nicotine Replacement Therapy
219499717|NCT03178422|DRUG|NicoDerm CQ Patch|Nicotine Replacement Therapy
219499718|NCT02717338|BEHAVIORAL|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
219604573|NCT02038257|PROCEDURE|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
219604574|NCT02038257|DEVICE|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
219604575|NCT02038257|DEVICE|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
219604576|NCT02038257|DEVICE|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
219604577|NCT02038257|DEVICE|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
219604578|NCT00296972|DRUG|peg interferon plus ribavirin|
219604579|NCT00290004|DRUG|motexafin gadolinium|
219604580|NCT04077554|GENETIC|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
218880492|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
218880493|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
218880494|NCT06446791|PROCEDURE|Mehri Turki Surgical Technique of the Webbed Neck|The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
218880495|NCT03665272|PROCEDURE|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
218880496|NCT00000643|DRUG|Pyrimethamine|
218880497|NCT00000643|DRUG|Leucovorin calcium|
218880498|NCT03125772|DEVICE|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
218880499|NCT03125772|DEVICE|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
218880500|NCT00044902|DRUG|epratuzumab|
218880501|NCT05420649|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
219026965|NCT05601323|DRUG|Gem/nab-PTX|Gemcitabine, nab-Paclitaxel
219026966|NCT00152581|DRUG|Pegylated interferon-alfa2a (Pegasys); ribavirin|
219604581|NCT02750137|DRUG|Tetracaine|Application of Ametop prior to intravenous cannulation
219604582|NCT01491360|PROCEDURE|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
219604583|NCT00910676|DRUG|Diprosone|"* Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks"
219604584|NCT03727789|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IA
219604585|NCT06274294|DRUG|CT-P13|Induction treatment.
219499719|NCT02717338|BEHAVIORAL|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
219499720|NCT02717338|BEHAVIORAL|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
219499721|NCT01770782|PROCEDURE|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
219604586|NCT03525886|DRUG|NBI-74788|Capsule, administered daily.
219604587|NCT02812563|OTHER|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
219604588|NCT00089804|DRUG|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
219604589|NCT00089804|DRUG|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
219604590|NCT00089804|DRUG|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
219604591|NCT06016647|OTHER|Musculoskeletal-specific WSIB programs of care|Clinicians within this network provide care under a standardized framework that limits confounding from different interventions and the researchers will not manipulate treatment decisions.
219604592|NCT05067413|PROCEDURE|Transanterior obturator nerve gateway approach|Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach
218880502|NCT04790071|OTHER|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
218880503|NCT04790071|OTHER|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
218880504|NCT00659230|DRUG|Nepicastat|100-800mg
219499722|NCT01770782|OTHER|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
219604593|NCT05067413|PROCEDURE|Total mesorectal excision approach|Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
219604594|NCT06582082|OTHER|pulmonary rehabilitation|The study group will receive pulmonary rehabilitation
219604595|NCT06582082|OTHER|pursed lip breathing|the control group will stick to pursed lip breathing only
219604596|NCT04545840|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
219604597|NCT04405882|PROCEDURE|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
219604598|NCT02969382|DRUG|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
219604599|NCT02969382|DRUG|Placebo - Cap|One Placebo capsule daily for 4 weeks
219604600|NCT02174640|DIETARY_SUPPLEMENT|Coffee|Coffee Beverage
218880505|NCT00659230|DRUG|Placebo|100-800mg placebo
218880506|NCT00901121|DEVICE|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
218880507|NCT00901121|DEVICE|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
219499723|NCT03343977|DRUG|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
219604601|NCT02174640|DIETARY_SUPPLEMENT|Water|Water
219604602|NCT01692626|DRUG|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
219604603|NCT01692626|DRUG|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
219604604|NCT04169269|DRUG|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
219604605|NCT04169269|DRUG|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
219604606|NCT05803421|DRUG|Orforglipron|Administered orally once daily
219604607|NCT05803421|DRUG|Insulin Glargine|Administered SC once daily
219604608|NCT00143923|BEHAVIORAL|Nutrition, Exercise, Stress Management Counseling|Individualized advice
219604609|NCT00143923|OTHER|usual care|usual care
219604610|NCT04821089|BIOLOGICAL|IPN10200|"Stage 1: Several different doses will be administrated in a dose-escalation manner.~One single injection will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
218880508|NCT02240264|DIETARY_SUPPLEMENT|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
218880509|NCT02240264|DIETARY_SUPPLEMENT|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
218880510|NCT03956524|BIOLOGICAL|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
218880511|NCT03956524|BIOLOGICAL|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
219026967|NCT06529731|DRUG|Interferon gamma-1b|ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.
219499724|NCT03343977|DRUG|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
219499725|NCT00676026|DRUG|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
219499726|NCT00676026|DRUG|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
219499727|NCT00676026|DRUG|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
219499728|NCT02271815|OTHER|Oral Hygiene|Oral Hygiene
219499729|NCT04553484|DIAGNOSTIC_TEST|No intervention|No intervention
219604611|NCT04821089|BIOLOGICAL|IPN10200 Placebo|"Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
218880512|NCT03956524|BIOLOGICAL|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
218880513|NCT06280508|DRUG|Adebrelimab, Apatinib, Gemcitabine, cisplatin|Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
218880514|NCT05072730|DEVICE|Super High Pressure Balloon (OPN NC)|"Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion."
218880515|NCT05072730|DEVICE|Intravascular lithotripsy (IVL)|"Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion."
218880516|NCT02467582|DRUG|Aspirin|Aspirin 100 mg daily
218880517|NCT02467582|DRUG|Placebo|Placebo
218880518|NCT05192460|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
218880519|NCT02008344|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
219499730|NCT03849170|BEHAVIORAL|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
219604612|NCT04821089|BIOLOGICAL|Dysport|Single administration of study intervention in stage 1 / step 2 and 3 only
219604613|NCT05490771|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219604614|NCT05490771|PROCEDURE|Computed Tomography|Undergo CT
219604615|NCT05490771|DRUG|Copanlisib Hydrochloride|Given IV
219604616|NCT05490771|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218880520|NCT02008344|DRUG|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
218880521|NCT02959359|DRUG|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
218880522|NCT02959359|DRUG|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
218880523|NCT01370265|DRUG|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
219499731|NCT03849170|OTHER|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
219499732|NCT01311856|BEHAVIORAL|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
219604617|NCT03994822|DEVICE|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
219604618|NCT03994822|DEVICE|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
219604619|NCT01905436|DRUG|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
218880524|NCT01370265|DRUG|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
218880525|NCT01370265|DRUG|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
218880526|NCT00674674|DRUG|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
219604620|NCT06372184|DRUG|Washed Microbiota Transplantation|Patients take four capsules containing washed microbiota once a day for five consecutive days
219604621|NCT06372184|DRUG|Placebo|Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
218880527|NCT00674674|DRUG|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
218880528|NCT00674674|DRUG|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
218880529|NCT03068702|DEVICE|Optical Coherence Tomography Angiography|
218880530|NCT05958797|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
219026968|NCT06529731|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|Donor lymphocyte infusion is a procedure that transfers healthy white blood cells (lymphocytes) from a bone marrow or stem cell donor to a recipient's blood. An infusion of healthy lymphocytes helps the recipient's immune system get rid of remaining cancer cells if they have a relapse after a bone marrow or stem cell transplant for blood cancer.
219499733|NCT01311856|BEHAVIORAL|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
219499734|NCT01311856|BEHAVIORAL|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
218880531|NCT05958797|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
218880532|NCT03063463|PROCEDURE|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
219499735|NCT01311856|BEHAVIORAL|Exercise and Diet|15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
219499736|NCT02097368|PROCEDURE|tongue strength measurement|tongue strength measurement
219499737|NCT02097368|PROCEDURE|respiratory function measurement|respiratory function measurement
219499738|NCT02097368|PROCEDURE|swallowing tests|swallowing tests
219499739|NCT02097368|OTHER|Magnetic resonance imaging|Magnetic resonance imaging
219499740|NCT04048174|OTHER|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
219499741|NCT04048174|OTHER|Saline irrigation|Nasal and sinus irrigation with saline solution
219499742|NCT02693678|OTHER|Massage|
219499743|NCT02693678|DEVICE|DIathermy|
219499744|NCT02693678|DEVICE|Sham diathermy|
219499745|NCT01298596|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
219604622|NCT03377257|DRUG|zolmitriptan by sublingual administration|Experimental group
219604623|NCT03377257|DRUG|zolmitriptan by oral|Active group
219604624|NCT02720497|BEHAVIORAL|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
219604625|NCT02720497|BEHAVIORAL|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
219604626|NCT04327011|BIOLOGICAL|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
219604627|NCT04327011|DRUG|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
219604628|NCT04071405|OTHER|Non-intervention|Non-intervention observational study
219604629|NCT02422797|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
219604630|NCT02422797|DRUG|RPV 25 mg|"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV."
219604631|NCT02422797|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
219604632|NCT03842644|DEVICE|Tension reduction device|Continue using this device for 3 months post surgery.
219499746|NCT01298596|PROCEDURE|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
219499747|NCT00196443|DEVICE|urea contained compressing stockings|
219499748|NCT00196443|DEVICE|compressing stockings|
219499749|NCT02593734|DRUG|olanzapine|oral antipsychotic drug therapy
219499750|NCT02593734|DRUG|risperidone|oral antipsychotic drug therapy
219499751|NCT02593734|DRUG|amitryptaline|oral antidepressant drug therapy
219499752|NCT02593734|DRUG|fluoxetine|oral drug therapy for depression
219499753|NCT00280501|DRUG|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
219499754|NCT00280501|DRUG|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
219604633|NCT05294666|DRUG|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
219604634|NCT05294666|DRUG|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
219604635|NCT04391296|PROCEDURE|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
219604636|NCT05096650|PROCEDURE|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
219604637|NCT01783795|OTHER|Genetic Analysis|
219604638|NCT01707017|OTHER|Strength training|
219604639|NCT00369941|DRUG|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
219604640|NCT00369941|DRUG|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
219604641|NCT00369941|DRUG|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
219604642|NCT00369941|DRUG|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
219604643|NCT00369941|DRUG|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
218880533|NCT03063463|PROCEDURE|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
219499755|NCT00280501|DRUG|Placebo|Placebo
219499756|NCT05113901|DRUG|Methylprednisolone|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
219499757|NCT05113901|DRUG|Placebo|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
218880534|NCT02469350|OTHER|Serious game|Rehabilitation with serious game
219499758|NCT04128696|DRUG|feladilimab|feladilimab is available as an intravenous infusion.
219499759|NCT04128696|DRUG|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
219499760|NCT04128696|DRUG|Placebo|Placebo is available as an intravenous infusion.
219499761|NCT05294198|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract capsule
219499762|NCT00585039|DRUG|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
219499763|NCT06078995|DRUG|Tenecteplase|Thrombolysis wtih rhTNK-tPA
219499764|NCT06078995|DRUG|Alteplase|Thrombolysis wtih rt-PA
219499765|NCT01782950|DRUG|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
219499766|NCT00951899|DRUG|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
219499767|NCT00951899|OTHER|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
219604644|NCT02186002|DRUG|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604645|NCT02186002|DRUG|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604646|NCT02186002|DRUG|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604647|NCT02186002|DRUG|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604648|NCT02186002|DRUG|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604649|NCT02186002|DRUG|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
219604650|NCT02186002|DRUG|Placebo|
219604651|NCT05477043|DIAGNOSTIC_TEST|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
219604652|NCT01221207|DEVICE|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
219499768|NCT00951899|BEHAVIORAL|Diet|Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
219499769|NCT00951899|DRUG|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
219499770|NCT01585831|DRUG|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
219499771|NCT01585831|DRUG|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
219604653|NCT01221207|DEVICE|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
219604654|NCT01221207|DEVICE|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
219499772|NCT01077349|PROCEDURE|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis \>1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).
219499773|NCT01077349|PROCEDURE|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine \> 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea \> 36 mmol/l OR~* Or life threatening hyperkalemia"
219499774|NCT03222167|DRUG|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
219499775|NCT02046369|DRUG|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
218880535|NCT01748838|DRUG|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
218880536|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430 in capsules
218880537|NCT01748838|DRUG|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
218880538|NCT01748838|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
218880539|NCT01748838|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
218880540|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430
218880541|NCT00866255|DEVICE|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
218880542|NCT04160858|OTHER|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
219026969|NCT05980520|DIETARY_SUPPLEMENT|Taurine+corn starch+white sugar|Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.
219499776|NCT02046369|DRUG|Placebo|Placebo Comparator once daily
219499777|NCT02015299|DRUG|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
219499778|NCT02015299|DRUG|placebo|one tablet matching placebo/day for 26 weeks
219604655|NCT04759807|DRUG|Placebo Comparator|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
218880543|NCT04160858|OTHER|Control|Wait-list control
219499779|NCT06016413|DRUG|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
219499780|NCT06016413|DRUG|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
219499781|NCT06016413|DRUG|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
219499782|NCT03120520|DRUG|Plecanatide|
219499783|NCT03120520|DRUG|Matching placebo|
218880544|NCT02291419|DRUG|ticagrelor|ticagrelor 90 mg bid
218880545|NCT02291419|DRUG|aspirin|aspirin 81 mg daily
218880546|NCT06136013|BEHAVIORAL|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
218880547|NCT05523050|PROCEDURE|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
218880548|NCT04066478|DRUG|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
218880549|NCT04066478|DRUG|Placebo|Placebo
218880550|NCT01115673|DRUG|Acetaminophen|Acetaminophen Caplet - single dose
218880551|NCT01115673|DRUG|Placebo Control|0 mg Caplet - single dose
219499784|NCT05264766|DEVICE|Cooling helmet on|Cooling helmet with circulating cold water
218880552|NCT03949608|OTHER|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
219499785|NCT05264766|DEVICE|Cooling helmet off|Cooling helmet without circulating cold water
219499786|NCT01508156|DRUG|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
219604656|NCT04759807|DRUG|PUR1800 250 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
219604657|NCT04759807|DRUG|PUR1800 500 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
219604658|NCT00403585|DRUG|adefovir dipivoxil 10mg|
219499787|NCT01508156|DRUG|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
218880553|NCT04878965|DEVICE|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
218880554|NCT00965575|DRUG|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
218880555|NCT00965575|DRUG|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
218880556|NCT00771966|PROCEDURE|Standard therapy|Standard therapy
218880557|NCT00771966|PROCEDURE|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
219026970|NCT05980520|DIETARY_SUPPLEMENT|Corn starch+white sugar|0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.
219026971|NCT05980520|BEHAVIORAL|Behavioral rehabilitation therapy|Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
219026972|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
219026973|NCT01755884|DIETARY_SUPPLEMENT|Wheat oral immunotherapy|Cooked spaghetti
219026974|NCT01715311|DRUG|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
219026975|NCT01715311|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
219026976|NCT01715311|DRUG|Tiotropium|Tiotropium capsules for inhalation once daily
219026977|NCT01715311|DRUG|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
219499788|NCT03927781|DRUG|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
219499789|NCT05023954|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
219499790|NCT02551003|DRUG|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
219499791|NCT02551003|DEVICE|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
219499792|NCT06085742|DRUG|Cyclophosphamide|60mg/m2 PO once a day (21 continuous days)
219499793|NCT06085742|DRUG|Methotrexate|10mg/m2 PO BID on days 1, 8, and 15
219499794|NCT06085742|DRUG|Capecitabine|825mg/m2 PO BID on days 1-14
219499795|NCT03707483|COMBINATION_PRODUCT|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
219499796|NCT06460987|DRUG|Finerenone|Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
219499797|NCT06460987|DRUG|RAS inhibitor|Receive RAS inhibitor treatment as specified in the KDIGO guidelines
219499798|NCT06460987|DRUG|Immune Suppressant|Receive immune suppressant treatment as specified in the KDIGO guidelines
219499799|NCT00874900|OTHER|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
219499800|NCT00874900|OTHER|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
219604659|NCT05397678|BIOLOGICAL|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
219604660|NCT05397678|BIOLOGICAL|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
219604661|NCT02191293|DRUG|Viramune® tablets|
219604662|NCT04511585|BEHAVIORAL|Great Live and Move Challenge|Physical activity program for children
219604663|NCT00661193|DRUG|carboplatin|given IV
219604664|NCT00661193|DRUG|erlotinib hydrochloride|given orally
219604665|NCT00661193|DRUG|paclitaxel|given IV
219026978|NCT04317456|DEVICE|Hearing Aids and Hearing Implants|Hearing Aids and Hearing Implants (age at first fitting and implantation and aided audibility)
219026979|NCT04317456|BEHAVIORAL|Family Centred Early Intervention|Family Centred Early Intervention
219026980|NCT00044395|DRUG|Ruboxistaurin mesylate|
219499801|NCT00874900|OTHER|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
219499802|NCT02983526|DEVICE|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
219499803|NCT06025175|RADIATION|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
219499804|NCT06025175|OTHER|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
219499805|NCT04382456|DIETARY_SUPPLEMENT|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
219604666|NCT05792111|DRUG|Trigger point injection (lidocaine)|trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
219604667|NCT05792111|DRUG|Caudal epidural Group (bupivacaine + triamcinolone + NaCl)|It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
219604668|NCT05506293|PROCEDURE|percutaneous paravalvular leak closure|"the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~* Amplatzer vascular plug 3~* occlutech paravalvular leak device~* amplatzer vascular plug 2~* amplatzer muscular ventricular septal defect~* amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design."
219604669|NCT04101409|OTHER|Decision aids|Shared decision making with decision aids
219604670|NCT01108783|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
219604671|NCT01108783|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
219604672|NCT01108783|DRUG|Placebo|(encapsulated) Tablets QD/14 days
219604673|NCT03578393|DEVICE|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
219026981|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
219499806|NCT06225778|OTHER|Exercise|6-week online exercise group
219499807|NCT02028702|DIETARY_SUPPLEMENT|Placebo|water with color
219604674|NCT00843661|DRUG|ezetimibe|10 mg ezetimibe/day
219604675|NCT00843661|DRUG|fenofibrate|200 mg fenofibrate/day
219604676|NCT00843661|DRUG|pravastatin|40 mg pravastatin/day
219604677|NCT00249431|DRUG|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
219604678|NCT00249431|BEHAVIORAL|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
219604679|NCT00980031|DRUG|Eplerenone|25mg PO daily (QD)for 6 months
219604680|NCT00980031|DRUG|Lactose Tablet|Lactose tablet
219604681|NCT00005811|DRUG|topotecan hydrochloride|Given IT
219499808|NCT02028702|DIETARY_SUPPLEMENT|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
219499809|NCT00003290|BIOLOGICAL|gonadotrophin releasing hormone|
219499810|NCT00003290|RADIATION|radiation therapy|
219604682|NCT00005811|OTHER|laboratory biomarker analysis|Correlative studies
219026982|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
219026983|NCT06407544|PROCEDURE|peripheral nerve block|peripheral nerve block guided by ultra sound through Ultrasound-guided quadratus lumborum block versus FICB or fascia iliaca block
219026984|NCT06407544|DRUG|PCA device as rescue medication with IV morphine 1mg if VAS more than 4|PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
219026985|NCT03070574|DRUG|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
219026986|NCT03070574|DRUG|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
219499811|NCT00512187|OTHER|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
219499812|NCT05482087|DRUG|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
219604683|NCT04875351|DIAGNOSTIC_TEST|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
219026987|NCT03070574|OTHER|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
219604684|NCT05063474|DIAGNOSTIC_TEST|No Intervention-Clinical Assessments only|No Intervention. Clinical Assessments include: vital signs, near infrared spectrometry, general leg strength, and 6-minute walking test.
219604685|NCT06101160|DRUG|onaBoNT-A|injection under ultrasonography
218880558|NCT03043391|BIOLOGICAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
218880559|NCT01564147|OTHER|immediate therapeutic education|Access to the course of immediate therapeutic education
218880560|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
219499813|NCT01901211|OTHER|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
219499814|NCT00133315|DRUG|Infliximab|
219499815|NCT00133315|DRUG|Etanercept|
219499816|NCT00133315|DRUG|Adalimumab|
219499817|NCT04316052|OTHER|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
219604686|NCT02964312|DEVICE|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
219604687|NCT04019626|OTHER|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
219604688|NCT04019626|OTHER|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
219604689|NCT04019626|OTHER|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
219026988|NCT01819454|DEVICE|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
219026989|NCT05542875|PROCEDURE|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
219604690|NCT04019626|OTHER|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
219604691|NCT04019626|OTHER|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
219604692|NCT04019626|OTHER|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
219604693|NCT06465836|PROCEDURE|O, lreay suture|bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly two large vicryl stitches were passed using a large sized needle below and lateral to the lower edge of the uterine incision angle in anteroposterior direction and then redirected from back to the front through avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
219604694|NCT06465836|PROCEDURE|modified O, lreay suture|"1. Pack Douglas- pouch with a towel.~2. Straight the used vicryl needle mostly no 1.~3. Try to compress and approximate anterior and posterior uterine walls.~4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament. And we repeat the procedure on the other side. We can repeat this method of uterine ligation at another different plane if needed."
219604695|NCT06113835|PROCEDURE|CTO PCI|percutaneous coronary intervention
218880561|NCT05001204|DRUG|68Ga-NOTA-RM26|68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
219026990|NCT05542875|PROCEDURE|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
218880562|NCT02529163|OTHER|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
219499818|NCT04316052|OTHER|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
219499819|NCT05683314|PROCEDURE|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
219499820|NCT02133352|DRUG|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
219604696|NCT04078321|OTHER|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
219604697|NCT04510532|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
219604698|NCT03240783|DRUG|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
219604699|NCT03240783|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
219604700|NCT03240783|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
219604701|NCT03240783|OTHER|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
219604702|NCT00139893|DRUG|Reglan ODT|
219604703|NCT00512577|OTHER|Red blood cell transfusion|Pre-operative red blood cell transfusion
219604704|NCT03608397|BIOLOGICAL|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
218880563|NCT02529163|OTHER|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
219499821|NCT03137485|PROCEDURE|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
219499822|NCT03137485|PROCEDURE|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
219499823|NCT03137485|DEVICE|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
219499824|NCT00206622|DRUG|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
219499825|NCT00206622|DRUG|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
219604705|NCT03608397|BIOLOGICAL|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
218880564|NCT02388334|OTHER|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~* identify the specific support needs of the caregivers~* study the links between the quality of care as perceived by the professionals, patients and caregivers~* identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
218880565|NCT00488735|BEHAVIORAL|Cognitive-behavioral rehabilitation|
218880566|NCT00488735|BEHAVIORAL|Traditional primary care|
218880567|NCT05257291|DRUG|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
218880568|NCT03443804|DRUG|Test(DW1401)|DW1401+Placebo of Stillen tab.
218880569|NCT03443804|DRUG|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
218880570|NCT00003712|DRUG|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
218880571|NCT02227667|DRUG|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
219200573|NCT06862271|PROCEDURE|Group 2 (Penile block and IV Fentanyl group)|In the penile block and IV fentanyl group, 1 µg/kg fentanyl will be administered by the investigations and 5 minutes later, penile block will be performed using 0.25% bupivacaine at a dose of 0.2 mL/kg. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
219499826|NCT00206622|DRUG|Placebo transdermal|Placebo
219499827|NCT02796898|DRUG|SM88 (Cohort 1)|"* Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
219499828|NCT02796898|DRUG|SM88 (Cohort 2)|"* Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
219499829|NCT02170129|DEVICE|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
219499830|NCT02170129|DEVICE|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
219499831|NCT00471185|DRUG|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
219499832|NCT03782584|OTHER|modified pilates exercise|modified exercises from original pilates exercises.
219499833|NCT03782584|OTHER|daily life advises|they will be given daily life advises to prevent neck pain
219499834|NCT05734170|DIETARY_SUPPLEMENT|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
219499835|NCT05734170|DIETARY_SUPPLEMENT|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
219499836|NCT05734170|DIETARY_SUPPLEMENT|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
219604706|NCT00115453|RADIATION|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
219604707|NCT03001453|DRUG|Liposomal Bupivacaine|266mg liposomal bupivacaine
219604708|NCT03001453|DRUG|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
219604709|NCT03001453|DRUG|Saline|Normal saline
219604710|NCT03270969|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
219604711|NCT03710980|DEVICE|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
219604712|NCT03849157|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
218880572|NCT03295760|DRUG|Q10 Coenzyme|
219200574|NCT03285620|DRUG|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
219499837|NCT00579254|DRUG|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
219499838|NCT01208259|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219499839|NCT01208259|BEHAVIORAL|Interpersonal Therapy (IPT)|
219499840|NCT02557672|DRUG|Prothrombin complex concentrate (Human)|PCC (Kcentra)
219499841|NCT02557672|BIOLOGICAL|Fresh frozen plasma (FFP)|FFP
219499842|NCT00376428|DRUG|Gentamicin|
218880573|NCT01593592|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
218880574|NCT01593592|DIETARY_SUPPLEMENT|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
218880575|NCT01593592|DRUG|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
218880576|NCT01593592|DRUG|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
218880577|NCT01593592|DRUG|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
218880578|NCT01732770|BIOLOGICAL|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
219200575|NCT03285620|DRUG|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
219499843|NCT00875719|DEVICE|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
219499844|NCT00875719|DEVICE|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
219499845|NCT01531868|OTHER|Video|Video of physician
219499846|NCT01531868|OTHER|Video|Video of physician
219499847|NCT01531868|OTHER|Video|Video of physician
219499848|NCT01531868|OTHER|Video|Video of physician
219499849|NCT01531868|OTHER|Video|Video of physician
219499850|NCT01531868|OTHER|Video|Video of physician
219499851|NCT04768023|DRUG|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
219499852|NCT04768023|DRUG|Placebo|Matching amount of vegetable oil to the vitamin D3.
219499853|NCT00595387|OTHER|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
219499854|NCT00595387|OTHER|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
219604713|NCT06551194|OTHER|prevalence of difficult-to-treat IBD|To assess the prevalence and risk factors of difficult-to-treat IBD patients
218880579|NCT01732770|DRUG|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
218880580|NCT01732770|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
218880581|NCT01732770|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
218880582|NCT00389493|DRUG|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
218880583|NCT00389493|BEHAVIORAL|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
218880584|NCT00389493|DRUG|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
219200576|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
219200577|NCT06615674|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
219200578|NCT06997354|DIAGNOSTIC_TEST|Questionnaire|The parents have to complete a questionnaire
219200579|NCT06021678|DRUG|EX103 injection|Administered as specified in the treatment arm.
219499855|NCT05323500|OTHER|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
219499856|NCT06468683|BIOLOGICAL|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
219499857|NCT06424925|OTHER|Artificial intelligence for the prediction of clinical outcomes|Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
219499858|NCT01347398|PROCEDURE|PSG|Sleep study made by PSG (polysomnography)
219499859|NCT01347398|PROCEDURE|MicroMESAM system|Sleep study made by MicroMESAM system
219499860|NCT00420290|DRUG|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
219499861|NCT00420290|DRUG|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
219604714|NCT00317694|DRUG|Fermagate|Film coated tablet 500mg
219604715|NCT00317694|DRUG|Placebo|Oral administration, film coated tablet, 0mg
219604716|NCT05041920|DRUG|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
218880585|NCT03319823|DRUG|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment"
218880586|NCT03319823|DRUG|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
219499862|NCT06703112|DIAGNOSTIC_TEST|An auxiliary diagnostic model for ovarian tumors|Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).
219499863|NCT06703749|DEVICE|Treatment with BTL-899M|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.
219499864|NCT06703749|DEVICE|Treatment with BTL-899M with intensities below therapeutic threshold|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
219499865|NCT03423589|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
219499866|NCT04302428|BIOLOGICAL|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
219499867|NCT04302428|BIOLOGICAL|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
219499868|NCT00560547|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
219499869|NCT03473847|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
219499870|NCT03473847|DEVICE|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
219499871|NCT03473847|DEVICE|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
219499872|NCT03473847|DEVICE|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
219499873|NCT05054166|OTHER|No intervention, it was a retrospective study.|This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.
218880587|NCT03319823|DRUG|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
219026991|NCT05542875|PROCEDURE|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
219026992|NCT01353417|OTHER|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
219499874|NCT00651547|DRUG|budesonide/formoterol|
219499875|NCT00651547|DRUG|budesonide|
219200580|NCT06449183|DIAGNOSTIC_TEST|VIDAS® TBI Test [GFAP and UCH-L1 assays]|The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
219200581|NCT05836012|BIOLOGICAL|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
219499876|NCT00651547|DRUG|formoterol|
219499877|NCT05549128|DEVICE|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
219499878|NCT05549128|DEVICE|Photobiomodulation sham|The red laser (DMC) will be applied off. I
219499879|NCT04168762|OTHER|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
219499880|NCT02172716|PROCEDURE|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
219499881|NCT03456869|DEVICE|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
219499882|NCT01416649|DRUG|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
219499883|NCT01823484|DEVICE|AN 69 ST hemofilter|
219499884|NCT01823484|DEVICE|AN 69 hemofilter|
219499885|NCT04733235|DRUG|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
219499886|NCT03049956|DIAGNOSTIC_TEST|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
219499887|NCT02092961|DRUG|Fostamatinib|Fostamatinib 100mg twice daily.
219499888|NCT02092961|DRUG|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
219499889|NCT02092961|DRUG|Placebo of Fostamatinib|Placebo bid for 6 weeks.
219499890|NCT02092961|DRUG|Placebo of Adalimumab|Placebo injection once every two weeks.
219499891|NCT03560505|DIAGNOSTIC_TEST|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
219499892|NCT01951547|PROCEDURE|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
219499893|NCT01951547|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
219499894|NCT02594345|OTHER|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
219604717|NCT02862730|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
219604718|NCT02862730|DEVICE|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
219604719|NCT02862730|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
219604720|NCT02862730|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
219604721|NCT03484546|PROCEDURE|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
218880588|NCT04332874|PROCEDURE|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
218880589|NCT04332874|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
218880590|NCT04332874|DRUG|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
219499895|NCT02823873|DEVICE|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
219499896|NCT02301780|DRUG|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
219604722|NCT04290455|DEVICE|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
219604723|NCT04290455|PROCEDURE|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
218880591|NCT00924768|BIOLOGICAL|20K EU CCRE|Inhalation of CCRE
219200582|NCT05836012|BIOLOGICAL|Placebo|2 injections - given at 4 months and the second at 6 months of age.
219499897|NCT02301780|DRUG|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
219604724|NCT04290455|PROCEDURE|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
219604725|NCT00368758|DRUG|Probiotic bacteria (Trevis R)|
219604726|NCT01228617|DRUG|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
219604727|NCT01228617|DRUG|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
219604728|NCT05470608|DRUG|SL-1002|SL-1002 injectable solution
219604729|NCT05470608|DRUG|Placebo|Matching placebo injectable solution
218880592|NCT02449161|DRUG|MPA|
218880593|NCT02449161|DRUG|placebo|
218880594|NCT00791089|DRUG|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
218880595|NCT00791089|DRUG|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
218880596|NCT00791089|OTHER|placebo|Control group will receive placebo before \& after ablation.
218880597|NCT02815592|DRUG|BMS-986012|
219499898|NCT00683150|OTHER|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
219499899|NCT06091410|BIOLOGICAL|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
219499900|NCT06091410|BIOLOGICAL|influenza vaccine|inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
219499901|NCT01792284|DRUG|LY2605541|
219499902|NCT01792284|DRUG|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
219499903|NCT05826249|DRUG|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
219604730|NCT03685344|DRUG|Loncastuximab Tesirine and Durvalumab|intravenous infusion
219604731|NCT03839966|BEHAVIORAL|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
219604732|NCT03839966|BEHAVIORAL|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
219604733|NCT03474874|DEVICE|NeoMatriX Collagen Dressing|Collagen wound dressing
219604734|NCT03151174|DRUG|Vitamin D 10000 UNT|10000 IU Vitamin D per day
219604735|NCT03151174|DRUG|Vitamin D 5000 UNT|5000 IU Vitamin D per day
219499904|NCT01652118|DRUG|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
219499905|NCT01652118|DRUG|Saline|
219604736|NCT01936350|DRUG|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
219604737|NCT01936350|DRUG|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
219499906|NCT03551366|BEHAVIORAL|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
219604738|NCT02499796|DEVICE|Hygrovent Gold|
219604739|NCT02499796|DEVICE|Heated and moisture exchanger (HME)|
219604740|NCT02499796|DEVICE|Heated humidifier (HH)|
219604741|NCT03126435|DRUG|EndoTAG-1|twice weekly
219604742|NCT03126435|DRUG|Gemcitabine|once weekly
219604743|NCT02044913|BEHAVIORAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
219604744|NCT03835702|OTHER|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
219604745|NCT03576664|DRUG|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
218880598|NCT02815592|DRUG|Cisplatin|
218880599|NCT02815592|DRUG|Etoposide|
219604746|NCT03576664|DRUG|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
218880600|NCT02815592|DRUG|Platinum|
219499907|NCT03551366|BEHAVIORAL|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
219499908|NCT00145756|DRUG|low sodium high potassium salt substitute|
219499909|NCT00381056|BEHAVIORAL|Labor and Delivery Team Coordination Course|
218880601|NCT02815592|DRUG|Carboplatin|
218880602|NCT04596748|DIETARY_SUPPLEMENT|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
219604747|NCT05373199|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
219604748|NCT05373199|DRUG|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
218880603|NCT04596748|DIETARY_SUPPLEMENT|Placebo|Placebo caps
218880604|NCT03047031|DRUG|Nintedanib|Nintedanib
218880605|NCT03047031|DRUG|Pirfenidone|Pirfenidone
218880606|NCT02474602|DEVICE|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
219499910|NCT03595709|DRUG|3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
219499911|NCT01169649|DRUG|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
219604749|NCT05373199|DRUG|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
219604750|NCT00948532|BIOLOGICAL|biologic, Osteocel Plus|Osteocel® Plus
219604751|NCT03907371|DRUG|Donepezil Hydrochloride|Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).
219499912|NCT05926882|DRUG|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
219499913|NCT06504108|PROCEDURE|Calcium silicate-based sealer full Pulpotomy|Using calcium silicate-based sealer as a capping agent after full pulpotomy
219499914|NCT06504108|PROCEDURE|Calcium silicate-based premixed putty full Pulpotomy|Using calcium silicate-based premixed putty as a capping agent after full pulpotomy
219499915|NCT06504108|PROCEDURE|Full Pulpotomy|Using combination between calcium silicate-based sealer and calcium silicate-based premixed putty as a capping agent after full pulpotomy
219499916|NCT01285531|DEVICE|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
219499917|NCT02304874|OTHER|Phlebotomy|
219499918|NCT05683795|OTHER|Consensus study|Modified-Delphi study and consensus meetings
219499919|NCT01304446|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
219499920|NCT00522327|OTHER|remote simultaneous medical interpreting|remote simultaneous medical interpretation
219499921|NCT00522327|OTHER|usual and customary|usual and customary interpreting
219604752|NCT03907371|OTHER|Placebo|Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
219604753|NCT02497911|PROCEDURE|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
219604754|NCT02497911|PROCEDURE|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
218880607|NCT04832191|DEVICE|CE-SM|contrast enhanced spectral mammography \&contrast enhanced magnetic resonance imaging
218880608|NCT02451020|OTHER|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
219499922|NCT00522327|OTHER|ENglish speaking|English speakers
218880609|NCT00089531|DRUG|VRC-HIVDNA016-00-VP|
218880610|NCT01959841|DRUG|ASP2151|200 mg once daily or 400 mg once daily
219499923|NCT05316103|DEVICE|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
219499924|NCT02915510|DIETARY_SUPPLEMENT|Glycomacropeptide-based protein substitute|
219499925|NCT06346236|DRUG|L-thyroxine at a dose of 7.5 µg/kg/d for THOP|Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
219499926|NCT06346236|OTHER|THOP without treatment|Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.
219499927|NCT06346236|OTHER|NoTHOP|Subjects diagnosed no-THOP (as previously defined)
219499928|NCT01847313|DRUG|Liraglutide|Daily administration of liraglutide for 6 months
219499929|NCT04916925|DRUG|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
219499930|NCT04916925|DRUG|Clomid|CLOMID is adrug used for ovulation induction
219499931|NCT00478361|DRUG|Gemcitabine hydrochloride|Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.
219499932|NCT00478361|DRUG|Paclitaxel|135 mg/m\^2 IV over 1 hour
219604755|NCT02497911|DRUG|Ropivicaine|
219604756|NCT02497911|DRUG|Bupivicaine|
219604757|NCT01458353|PROCEDURE|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
219604758|NCT01458353|PROCEDURE|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
219604759|NCT02574065|DRUG|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
219604760|NCT02574065|OTHER|The placebo consists of an identical formulation without L. reuteri DSM 17938|
219604761|NCT01103492|DEVICE|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
219604762|NCT01848925|BIOLOGICAL|SANGUINATE™|40 mg/mL intravenous infusion.
219604763|NCT01848925|DRUG|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
219604764|NCT00015886|DRUG|docetaxel|75 milligrams per meter squared intraveneously
219604765|NCT00015886|DRUG|fluorouracil|350 milligrams intraveneously
219604766|NCT00052455|DRUG|lomustine|
219604767|NCT00052455|DRUG|procarbazine hydrochloride|
219604768|NCT00052455|DRUG|temozolomide|
219604769|NCT00052455|DRUG|vincristine sulfate|
219604770|NCT01023035|DRUG|Boceprevir|800 mg given three times a day (TID), orally (PO)
219604771|NCT01023035|DRUG|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
219604772|NCT01023035|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
219499933|NCT00478361|DRUG|Doxorubicin hydrochloride|Doxorubicin 40 mg/m\^2 IV over 20 minutes
219499934|NCT00478361|DRUG|Pegfilgrastim|Subcutaneously injection on day 1.
219499935|NCT06192082|PROCEDURE|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
219499936|NCT06192082|PROCEDURE|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
219499937|NCT05091606|PROCEDURE|Perfusion İndex in Patients with Spinal Anesthesia|Comparison of lower and upper extremity perfusion index values
219499938|NCT04891588|DRUG|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
219499939|NCT02962882|DEVICE|Mepilex Border|Multi-layer Foam Dressings
219499940|NCT02999373|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
219499941|NCT01312779|DEVICE|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
219604773|NCT01023035|DRUG|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
219604774|NCT02398864|PROCEDURE|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
218880611|NCT01959841|DRUG|valaciclovir|1000 mg three times daily
218880612|NCT02474420|DRUG|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
218880613|NCT02474420|DRUG|Deferasirox|Deferasirox administered per standard of care by the treating physician
218880614|NCT03234413|DRUG|Botulinum toxin type A|Botulinum toxin type A
219499942|NCT05296681|DRUG|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
219499943|NCT04262310|OTHER|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
219604775|NCT06489210|PROCEDURE|popliteal block|using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
218880615|NCT04579159|DEVICE|Preventicus heartbeat app in combination with wearables|CE certified devices
219604776|NCT00198055|DRUG|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
219604777|NCT00512122|OTHER|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
219604778|NCT00512122|DRUG|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
218880616|NCT04270084|BEHAVIORAL|Alive-Family|All participants receive lifestyle modification through use of m-health app
218880617|NCT00646360|DIETARY_SUPPLEMENT|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
218880618|NCT00646360|DIETARY_SUPPLEMENT|Placebo|2 tablets daily during pregnancy
218880619|NCT00780416|DRUG|MP-424|750 mg every 8 hours for 12 weeks
218880620|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
219499944|NCT00674219|DRUG|Memantine|Namenda 10mg BID for 12 weeks
219499945|NCT01663714|BIOLOGICAL|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
218880621|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
218880622|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
218880623|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
218880624|NCT03849222|PROCEDURE|Apexification|
219200583|NCT04497558|DIAGNOSTIC_TEST|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
219499946|NCT00597584|DRUG|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
219604779|NCT03595007|BEHAVIORAL|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
219604780|NCT00003126|DRUG|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
219604781|NCT05084157|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo Doppler echocardiography
219604782|NCT00524420|DEVICE|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
219499947|NCT00597584|DRUG|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
219499948|NCT05334602|PROCEDURE|Addition of dermal fat graft as protection over bone graft|A barrier membrane
219499949|NCT04063384|OTHER|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
219499950|NCT04063384|OTHER|Placebo beverage|placebo beverage conditions.
219499951|NCT02209779|DRUG|BIBR 796 BS|
219499952|NCT02209779|DRUG|Placebo|
219604783|NCT00524420|DEVICE|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
219604784|NCT00274339|DRUG|Prevacid 30mg BID|
219604785|NCT00274339|BEHAVIORAL|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
218880625|NCT03849222|DRUG|MTA|
218880626|NCT03849222|DRUG|Ca(OH)2|
218880627|NCT03849222|DRUG|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
218880628|NCT05099835|DRUG|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
218880629|NCT05099835|DRUG|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
218880630|NCT04116125|PROCEDURE|Radiotherapy|Adjuvant radiotherapy on axillary region
219200584|NCT03438552|RADIATION|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
219200585|NCT06543238|OTHER|Breastfeeding card game group|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
219200586|NCT05572658|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219604786|NCT01090414|DRUG|Idelalisib|Idelalisib tablets or capsules administered orally
219604787|NCT05036512|DRUG|GBT021601|Administered orally with water as a single dose in the morning.
219604788|NCT03481010|PROCEDURE|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
219604789|NCT03481010|PROCEDURE|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
219200587|NCT05572658|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219604790|NCT03127514|DRUG|AMX0035|AMX0035
219604791|NCT03127514|OTHER|Placebo|Matching Placebo Comparator
219604792|NCT04080739|DRUG|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
219604793|NCT02439021|DEVICE|COBRA|
219604794|NCT02439021|DEVICE|LMA|
219026993|NCT04489576|PROCEDURE|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
219499953|NCT02896088|OTHER|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
219499954|NCT00004797|DRUG|fructose|
219499955|NCT00004797|DRUG|placebo|
219499956|NCT03706677|DEVICE|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
219499957|NCT03706677|DEVICE|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
219499958|NCT06391905|DRUG|PCSK9 inhibitor in combination with standard advanced first-line regimen group|Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
219499959|NCT06391905|DRUG|standard advanced first-line regimen group|Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
219499960|NCT02832297|OTHER|Vectra DA|
219499961|NCT02832297|OTHER|Usual Care|
219499962|NCT04835298|OTHER|Dyspnea|questionnaires
219499963|NCT06481696|DIETARY_SUPPLEMENT|Resveratrol-based multivitamin supplement|Natural polyphenol and vitamins
219499964|NCT06481696|DIETARY_SUPPLEMENT|Folic acid|Supplementation with folic acid at the standard dosage of 0.4 mg/die
219499965|NCT06481696|PROCEDURE|IVF/ICSI|In vitro fertilization/IntraCytoplasmic Sperm Injection
219499966|NCT06481696|DRUG|Follitropin Alfa|Controlled Ovarian Stimulation
219499967|NCT06481696|DRUG|Ganirelix Acetate 0.5 MG/ML [Fyremadel]|GnRH Antagonist
219499968|NCT06481696|DRUG|hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously|For the induction of oocyte maturation
219499969|NCT01901991|PROCEDURE|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
219499970|NCT01901991|PROCEDURE|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
219499971|NCT02754791|DEVICE|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
219499972|NCT02754791|DEVICE|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
219499973|NCT05002465|DRUG|68Ga-PSMA-11|Injection of 68Ga PSMA-11
219499974|NCT05002465|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
219499975|NCT00515073|DRUG|Paclitaxel|50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
219499976|NCT00515073|RADIATION|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
219604795|NCT03408171|DEVICE|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
219499977|NCT00515073|DRUG|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
219499978|NCT00515073|DRUG|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
219499979|NCT00515073|DRUG|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
219499980|NCT04312555|DRUG|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
219499981|NCT00273195|DEVICE|Implantable Cardioverter Defibrillator|
219499982|NCT05510713|DEVICE|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
219499983|NCT03392090|OTHER|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
219499984|NCT01456052|DRUG|Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally.
219499985|NCT01456052|DRUG|Placebo|Matching placebo administered orally.
219499986|NCT02961452|OTHER|Cross reaction detection|
219499987|NCT04536233|BIOLOGICAL|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
219499988|NCT04536233|OTHER|physiological saline|The physiological saline was injected on the wound
219499989|NCT03526107|OTHER|CF Control|CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine
219499990|NCT03526107|OTHER|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
219499991|NCT03526107|OTHER|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
219499992|NCT02947932|DRUG|Resveratrol|pre-ERCP intervention
219604796|NCT03408171|DEVICE|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
219604797|NCT02413229|DRUG|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
219026994|NCT03837561|DRUG|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
218880631|NCT01096693|DRUG|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
218880632|NCT01096693|DRUG|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
219499993|NCT02947932|DRUG|Indomethacin|post-ERCP intervention in high risk patients
219499994|NCT03197961|COMBINATION_PRODUCT|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
219499995|NCT03197961|DRUG|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
219499996|NCT00123383|DRUG|Modafinil|
219604798|NCT02413229|DRUG|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
219604799|NCT02897024|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
219604800|NCT01019434|DRUG|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
219604801|NCT01019434|DRUG|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
219604802|NCT00371436|PROCEDURE|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
219604803|NCT00371436|PROCEDURE|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
218880633|NCT04340544|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
218880634|NCT04340544|DRUG|Placebo|Placebo capsules
218880635|NCT04768543|DEVICE|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
219026995|NCT03837561|DRUG|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
219026996|NCT00199784|DRUG|Phenylephrine|
219499997|NCT01904383|DRUG|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
219499998|NCT05995145|BEHAVIORAL|Active hamstring flexibility exercises with hip flexion mobilization|8 weeks x 5 times per week for 20 min. In the experimental intervention, the exercise program will be based on participant education, home-based individual exercises, and regular group meetings for check-ups by a physiotherapist according to a precise set schedule.
219499999|NCT05237700|OTHER|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
219604804|NCT01416519|PROCEDURE|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
219604805|NCT01416519|PROCEDURE|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
219604806|NCT00699816|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
219604807|NCT02251600|DRUG|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
219604808|NCT02454933|DRUG|AZD9291|Once daily tablet 80 mg
219604809|NCT02454933|DRUG|MEDI4736|10mg/kg q2w (IV) infusion
219604810|NCT03980652|PROCEDURE|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
218880636|NCT02005588|DRUG|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
218880637|NCT02005588|DRUG|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
218880638|NCT02255084|BEHAVIORAL|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
218880639|NCT02255084|BEHAVIORAL|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
218880640|NCT02602119|DRUG|OTL38|Infusion of OTL38 prior to surgery
218880641|NCT04653194|DRUG|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
218880642|NCT04653194|DRUG|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
218880643|NCT03648957|BEHAVIORAL|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
218880644|NCT03648957|BEHAVIORAL|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
219200589|NCT05752474|BEHAVIORAL|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
219200590|NCT05752474|BEHAVIORAL|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
219500000|NCT02134574|BIOLOGICAL|hematologic malignancy|hematologic malignancy with a sampling of blood
219500001|NCT01294592|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
219500002|NCT01294592|DRUG|tamsulosin|Take 1 capsule daily when escalation criteria met
219500003|NCT03955666|BIOLOGICAL|PRV-3279 or placebo|bi-specific antibody-based molecule
219500004|NCT00190866|DRUG|Duloxetine|
219500005|NCT00190866|DRUG|placebo|
219500006|NCT03549130|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
219500007|NCT03549130|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
219500008|NCT04292574|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
219500009|NCT04832074|OTHER|Dry Needling|Real Dry Needling in the most active Myofascial Trigger Point
219500010|NCT04832074|OTHER|Sham Dry Needling|Sham Dry Needling in the same location, but not piercing the skin
218880645|NCT03648957|DEVICE|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
218880646|NCT02411435|DRUG|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
219500011|NCT03446274|DRUG|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
219500012|NCT06482710|DEVICE|Pinwheel|The children in the intervention group were given breathing exercises with pinwheels.
219500013|NCT01113710|DRUG|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
219604811|NCT04727385|DEVICE|Double Crosslink Microgel|"DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min."
219604812|NCT02260661|DRUG|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
219604813|NCT02260661|DRUG|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
219604814|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
219604815|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
219604816|NCT01057511|DRUG|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
219604817|NCT01057511|DRUG|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
219604818|NCT00721071|DRUG|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
218880647|NCT02411435|DRUG|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
218880648|NCT00325117|DRUG|Vildagliptin|
218880649|NCT05344586|OTHER|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
218880650|NCT05344586|OTHER|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
218880651|NCT00666224|DRUG|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
219500014|NCT01026610|DRUG|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
219500015|NCT01026610|DRUG|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
219500016|NCT01026610|DRUG|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
219500017|NCT01729416|OTHER|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
219500018|NCT01729416|OTHER|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
219604819|NCT01644682|OTHER|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
219604820|NCT01644682|OTHER|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
219604821|NCT01644682|OTHER|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
219604822|NCT02224989|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
219500019|NCT05305521|PROCEDURE|transcrestal sinus floor elevation|Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
219500020|NCT05305521|PROCEDURE|Implant placement|"Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament"
219500021|NCT01162590|BIOLOGICAL|Rotarix ™|Oral, single dose
219500022|NCT01162590|BIOLOGICAL|Placebo|Oral, single dose
219500023|NCT04689958|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
219500024|NCT04689958|DRUG|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
219500025|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
219500026|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
219500027|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
219500028|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
219500029|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
219500030|NCT05448859|PROCEDURE|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
219500031|NCT00740259|DRUG|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
219500032|NCT02947061|DRUG|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
219500033|NCT02947061|DRUG|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
219500034|NCT04104711|OTHER|Home visits, health education|
219500035|NCT02785133|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
219604823|NCT03856723|OTHER|Renal Replacement Therapy|"Indications for RRT were defined as previously reported.~1. Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 ;~2. severe sepsis, persistence of hypotension (for more than 6 h) despite preload optimization and use of vasopressors or catecholamines (norepinephrine or epinephrine \>0.1 μg/kg/min),~3. refractory fluid overload (worsening pulmonary edema, PaO2/FiO2 \<300 mm Hg or fluid balance \>10% of body weight),~4. low probability of rapid renal recovery according to the judgment of the intensivists and nephrologists."
219604824|NCT06550817|OTHER|Growth mindset intervention|Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time
218880652|NCT00666224|DRUG|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
218880653|NCT00666224|DRUG|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
218880654|NCT05498519|DRUG|SY-4798|FGFR4 selective inhibitor
219604825|NCT06550817|OTHER|E-health Program|face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
219604826|NCT03370640|DRUG|SEP-363856|An oral 25 or 50mg dose of SEP 363856
218880655|NCT02678507|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
219200591|NCT05752474|BEHAVIORAL|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
219500036|NCT02785133|DRUG|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
219500037|NCT02785133|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
219500038|NCT02685761|PROCEDURE|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
219500039|NCT02685761|PROCEDURE|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
219500040|NCT02630745|PROCEDURE|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
219500041|NCT02630745|PROCEDURE|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
219500042|NCT02300376|DRUG|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
219500043|NCT04356573|DIETARY_SUPPLEMENT|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
219500044|NCT04356573|DIETARY_SUPPLEMENT|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
219500045|NCT03645226|DIAGNOSTIC_TEST|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
219604827|NCT01526655|PROCEDURE|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
219604828|NCT01526655|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
219604829|NCT03233893|OTHER|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
219604830|NCT03067025|DEVICE|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
219604831|NCT00918424|DRUG|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
219604832|NCT00310921|DRUG|Misoprostol|
219604833|NCT02365987|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
219604834|NCT02365987|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
219604835|NCT03203317|DRUG|Insulin|2 h insulin clamp
219604836|NCT03203317|OTHER|Exercise|Cycling exercise
219604837|NCT00955929|DRUG|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
219604838|NCT00955929|DRUG|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
219604839|NCT00955929|DRUG|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
218880656|NCT03466853|DIAGNOSTIC_TEST|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of \<25 is considered as fetal malnutrition.
218880657|NCT03466853|DIAGNOSTIC_TEST|Anthropometric indices|weight, length and head circumference
218880658|NCT03466853|DIAGNOSTIC_TEST|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI \<2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI \<11.2 kg/m2 is considered as malnutrition)
218880659|NCT05253885|DEVICE|Smartphone use|"* Smartphone addiction scale (short version) higher than 33~* Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159\*79\*9 mm."
218880660|NCT01768364|DRUG|Trimetoprim-Sulfa (Bactrim)|
218880661|NCT01768364|OTHER|No antibiotics|
218880662|NCT02032498|DRUG|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
218880663|NCT00654979|DEVICE|SafeFlo IVC Filter|SafeFlo IVC Filter
218880664|NCT02091765|BEHAVIORAL|Internet-based cognitive behavioral therapy.|
218880665|NCT01126944|DEVICE|heart mate II|left ventricular assist device
218880666|NCT03084601|DRUG|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
219026997|NCT04889339|DEVICE|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
219026998|NCT04889339|DEVICE|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
219500046|NCT05139966|DRUG|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
219500047|NCT06222463|DEVICE|Evone|Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
219500048|NCT03952910|OTHER|Online pain education program|Online pain education program
218880667|NCT03084601|DRUG|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
219500049|NCT05314569|DRUG|Ketamine- dexmedetomidine|ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery
219500050|NCT05314569|DRUG|Fentanyl- midazolam|Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
218880668|NCT03521141|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
218880669|NCT03521141|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
218880670|NCT03521141|GENETIC|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
218880671|NCT03521141|GENETIC|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
219026999|NCT01251549|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
219027000|NCT00174655|DRUG|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
219027001|NCT00174655|DRUG|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
219500051|NCT05314569|DRUG|Isoflurane|Anesthetic inhalational gas
218880672|NCT03521141|BEHAVIORAL|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
218880673|NCT05579808|PROCEDURE|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
218880674|NCT04379492|DRUG|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
218880675|NCT04379492|OTHER|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
218880676|NCT03851159|DIETARY_SUPPLEMENT|Nyaditum resae®|Heat-killed Mycobacterium manresensis
218880677|NCT03851159|OTHER|Mannitol|Placebo
219604840|NCT06582303|DEVICE|Virtual reality Game intervention plus conventional physical therapy|The experimental group initially got VR intervention by playing all four easy-level games named hitting a rolling ball, grasping a balloon, swapping hands, and gripping twice for three minutes each during the first and second weeks. This group again underwent VR intervention by playing all four same games with a difficulty level twice 5 min duration for the third, fourth, fifth, and sixth weeks. The experimental group had an intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. During the first two weeks, patients received 24 minutes of VR hand games and 24 minutes of therapy sessions per day and for the next four weeks, this group received 40 minutes of VR hand games and 40 minutes of conventional therapy session per day. This group received conventional physical therapy that consists of range of motion, stretching, resistance, and strengthening exercises. At follow-up of two weeks this group only received conventional physical therapy.
219604841|NCT06582303|DEVICE|Conventional Physical Therapy|The control group received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises by using powerweb, thera putty, and occupational therapy equipment. The CPT group had a conventional intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. The CPT group was given 48 minutes of conventional physical therapy sessions per day for weeks 1 and 2 followed by 80 minutes of conventional physical therapy sessions per day for the next 4 weeks. At follow-up of two weeks, this group also received conventional physical therapy.
218880678|NCT03335774|DRUG|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
219027002|NCT00174655|DRUG|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
219500052|NCT02373384|DRUG|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
219500053|NCT02373384|BEHAVIORAL|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
219500054|NCT02373384|DIETARY_SUPPLEMENT|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
219500055|NCT01814579|DEVICE|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
219500056|NCT01814579|DEVICE|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
219500057|NCT03568500|DEVICE|Digital Medicine System|DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
219500058|NCT03568500|DRUG|Aripiprazole|Dosage determined by the healthcare professionals.
219500059|NCT03568500|DRUG|Olanzapine|Dosage determined by the healthcare professionals.
219500060|NCT03568500|DRUG|Quetiapine|Dosage determined by the healthcare professionals.
219500061|NCT03568500|DRUG|Risperidone|Dosage determined by the healthcare professionals.
219500062|NCT04352842|OTHER|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
219500063|NCT05398575|BEHAVIORAL|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
219500064|NCT03438799|DEVICE|Cordio System|App, cloud and web device
219500065|NCT04480099|DRUG|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
219500066|NCT04480099|DRUG|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
218880679|NCT03335774|DRUG|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
218880680|NCT04561258|BIOLOGICAL|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
218880681|NCT04936815|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
218880682|NCT04685265|DRUG|anle138b|capsule containing excipient and anle138b
218880683|NCT04685265|DRUG|Placebo|matching placebo capsule containing excipient
218880684|NCT04206371|DIAGNOSTIC_TEST|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
219027003|NCT00174655|DRUG|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
219027004|NCT01807897|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
218880685|NCT01994265|DRUG|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
219027005|NCT01807897|DEVICE|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
219027006|NCT01807897|BEHAVIORAL|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
219027007|NCT02014363|DRUG|ETS6103 (low dose)|
219027008|NCT02014363|DRUG|ETS6103 (high dose)|
219027009|NCT02014363|DRUG|Amitriptyline|
219027010|NCT03412760|DIAGNOSTIC_TEST|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
219500067|NCT02081170|PROCEDURE|Autologous platelet concentrate|"1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery"
219500068|NCT01577537|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
219500069|NCT01577537|DRUG|Placebo|Vaginal gel, daily for 7 days
219500070|NCT01181856|BIOLOGICAL|MVA 85A|Single injection of 1 x 108 pfu MVA85A
219500071|NCT04878978|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis will be used to sample the amniotic fluid for Biofire detection of microorganism and to direct antibiotic treatment
219500072|NCT04878978|OTHER|Routine care without amniocentesis|Routine clinical care
219027011|NCT05075850|DEVICE|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
219500073|NCT04800107|BIOLOGICAL|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
219500074|NCT04800107|BIOLOGICAL|Placebo capsule|Placebo capsule
219500075|NCT04716959|PROCEDURE|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
219604842|NCT05716308|BEHAVIORAL|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
219604843|NCT05085379|DEVICE|Ossiview|Imaging of the ear using Optical Coherence Tomography
219604844|NCT06510699|OTHER|genotype-directed dosing with dosing software based on therapeutic drug monitoring|Genotype-directed dosing with dosing software based on therapeutic drug monitoring
219604845|NCT02929771|DEVICE|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
219604846|NCT02929771|DEVICE|iPad|iPad with headphones. Control
219604847|NCT01963546|OTHER|different types of anesthesia|
219500076|NCT04716959|PROCEDURE|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
219500077|NCT01809054|DRUG|Arixtra|
219500078|NCT01809054|DEVICE|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
219500079|NCT01809054|DRUG|Aspirin|
219500080|NCT00950833|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
219500081|NCT00593996|OTHER|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
219500082|NCT04699981|OTHER|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
219604848|NCT01963546|DRUG|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
219604849|NCT02685228|DRUG|Decitabine|decitabine 5mg/m2,d1-d5;
219604850|NCT02685228|DRUG|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
219604851|NCT00717288|DRUG|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
218880686|NCT01994265|DRUG|Dabigatran|
218880687|NCT00003505|DRUG|antineoplaston A10|
218880688|NCT00003505|DRUG|antineoplaston AS2-1|
218880689|NCT00003505|PROCEDURE|alternative product therapy|
218880690|NCT00003505|PROCEDURE|biological therapy|
218880691|NCT00003505|PROCEDURE|biologically based therapies|
218880692|NCT00003505|PROCEDURE|cancer prevention intervention|
218880693|NCT00003505|PROCEDURE|complementary and alternative therapy|
218880694|NCT00003505|PROCEDURE|differentiation therapy|
218880695|NCT02089074|BEHAVIORAL|Drug use counselling|
218880696|NCT03832335|DIAGNOSTIC_TEST|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
218880697|NCT00557635|PROCEDURE|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
219027012|NCT01622361|DRUG|Adriamycin+Cyclophosphamide>Docetaxel|"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle"
218880698|NCT05173909|DEVICE|BIS closed-loop target controlled infusion|BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
218880699|NCT01598909|DRUG|Arnica|Application of Arnica ointment periorbitally
218880700|NCT01598909|DRUG|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
218880701|NCT02915042|DRUG|Dexmedetomidine|Analgesic Efficacy
218880702|NCT02915042|DRUG|Placebo|Saline placebo
218880703|NCT04804163|DEVICE|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
218880704|NCT03719742|OTHER|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
219027013|NCT01622361|DRUG|GnRHa with Tamoxifen|"1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday"
219027014|NCT04540757|PROCEDURE|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
219027015|NCT04540757|PROCEDURE|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
219500083|NCT04699981|OTHER|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
219500084|NCT04965220|DRUG|HLX 208|take orally
219027016|NCT02663609|OTHER|No intervention|No treatment (intervention) was administered.
219500085|NCT04625582|BEHAVIORAL|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
219500086|NCT04625582|BEHAVIORAL|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
219500087|NCT04457869|DRUG|F520|3mg/kg every 3 weeks
219604852|NCT00717288|DRUG|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
219604853|NCT00717288|DRUG|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
219604854|NCT04629378|DRUG|Meropenem Injection|Meropenem IV 6 grams
219604855|NCT04629378|DRUG|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
218880705|NCT00044772|DRUG|Venlafaxine ER|
218880706|NCT03325374|OTHER|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
218880707|NCT02551263|DRUG|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
218880708|NCT04200118|OTHER|Observational|non intervention
218880709|NCT06832280|OTHER|Educational Website Developed by Study Team|This website was developed by the study team in previous research studies.
218880710|NCT06832280|OTHER|Basic Educational Website|This website is a basic education website about hypospadias.
218880711|NCT05148806|DIAGNOSTIC_TEST|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
219604856|NCT04629378|DRUG|Pyrazinamide|Pyrazinamide 20-30mg/kg
218880712|NCT03325959|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 HBOT sessions at 2 ATA 100% oxygen
218880713|NCT03325959|DRUG|Cymbalta / Lyrica treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
219604857|NCT04629378|DRUG|Bedaquiline|Bedaquiline 400mg
219604858|NCT04629378|DRUG|Rifafour|Rifafour (HRZE) Standard dose
219604859|NCT04020887|DEVICE|Alertwatch - Interaction|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
219500088|NCT02798068|DRUG|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
219500089|NCT03101163|BIOLOGICAL|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
219500090|NCT03101163|OTHER|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
219500091|NCT03465410|DRUG|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
219500092|NCT03465410|DRUG|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
219500093|NCT03713710|BEHAVIORAL|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
219604860|NCT00002382|DRUG|Saquinavir|
219604861|NCT02859766|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
219604862|NCT05302531|DRUG|Amoxicillin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
219604863|NCT05302531|DRUG|Levofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
219604864|NCT05302531|DRUG|Ofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
219604865|NCT05302531|DRUG|Sulfamethoxazole trimethoprim|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
218880714|NCT03325959|DEVICE|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
218880715|NCT02950480|DRUG|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
218880716|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
218880717|NCT03251937|DEVICE|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
218880718|NCT01576497|PROCEDURE|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
218880719|NCT01576497|DEVICE|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
219500094|NCT03713710|BEHAVIORAL|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
219500095|NCT04648410|OTHER|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
219500096|NCT02277223|DIETARY_SUPPLEMENT|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
219500097|NCT02277223|DRUG|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
219604866|NCT05211726|OTHER|Low Added Sugar Diet|Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
219604867|NCT05211726|OTHER|High Added Sugar Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
219604868|NCT03886740|PROCEDURE|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
219604869|NCT01335334|DRUG|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
219604870|NCT03857815|RADIATION|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
219604871|NCT02465138|DRUG|Ketorolac|Intravenous ketorolac
219604872|NCT02465138|DRUG|Placebo|Intravenous saline
219604873|NCT02683421|DRUG|Tilmanocept|
219604874|NCT04003493|OTHER|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
219604875|NCT06427850|DRUG|Tranexamic acid|receive an injection of Tranexamic acid into the surgical site
219604876|NCT06427850|DRUG|Normal saline|receive an injection of Normal saline into the surgical site
218880720|NCT01576497|DEVICE|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
219604877|NCT04298268|DEVICE|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
219604878|NCT00511732|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
219604879|NCT00511732|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
219500098|NCT04132232|DIAGNOSTIC_TEST|knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels|Will use the Smokerlyzer® device at each visit and be provided information on exhaled carbon monoxide and fetal carboxyhemoglobin. Risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin level will be provided.
219604880|NCT01845688|DRUG|Losartan Tablets & QingReMoShen Granule|
219604881|NCT01845688|DRUG|Losartan Tablets & Placebo Granule|
219604882|NCT02403258|OTHER|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
219604883|NCT02403258|BEHAVIORAL|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
219604884|NCT02213159|DRUG|Dexmedetomidine|
219604885|NCT02213159|DRUG|Morphine|
219604886|NCT06585501|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
219604887|NCT06180356|DRUG|Niraparib oral tablets|Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
219604888|NCT05422469|DEVICE|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
218880721|NCT06072417|OTHER|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
218880722|NCT06072417|OTHER|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
219027017|NCT01794052|OTHER|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
219027018|NCT00674453|DRUG|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
219027019|NCT00674453|OTHER|Placebo|Matching placebo tablet given once daily for 2 years
219500099|NCT00368537|DRUG|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
219500100|NCT00368537|DRUG|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
219500101|NCT02944643|OTHER|Mindfulness and Support Groups|
219604889|NCT06976320|OTHER|Intravenous morphine patient control analgesia|24-hour morphine consumption will be recorded
219604890|NCT06976320|OTHER|Intravenous patient control analgesia|24-hour morphine consumption will be recorded
219604891|NCT06976320|OTHER|Deep rectus sheath block|Deep rectus sheath block will be administered at the end of the surgery.
219604892|NCT03617458|DRUG|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
219604893|NCT03617458|DRUG|Placebo|A treatment with no active ingredients or therapeutic effect.
219604894|NCT03617458|DEVICE|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
219604895|NCT03617458|DEVICE|Usual Care|Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
219604896|NCT05526885|DIAGNOSTIC_TEST|CAD4TB|A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.
219604897|NCT05526885|DIAGNOSTIC_TEST|POC-CRP|A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing
219500102|NCT04248855|DRUG|KAN-101|Intravenous (IV) infusion
219604898|NCT05526885|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra|Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
219604899|NCT05673226|OTHER|Surface disinfection with Organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
219604900|NCT05061420|DRUG|Pembrolizumab|Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
219604901|NCT05061420|DRUG|SAR444245 (Thor-707)|Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
219604902|NCT05061420|DRUG|Cetuximab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
219604903|NCT06440993|DRUG|Gemcitabine|Gemcitabine, 1,000 mg/m2 IV
219604904|NCT06440993|DRUG|Cisplatin|Cisplatin, 25 mg/m2 IV
219604905|NCT06440993|DRUG|Durvalumab|Durvalumab, 1,500 mg IV
219604906|NCT06440993|PROCEDURE|ID-RFA|endoscopic intraductal RFA
219604907|NCT00576446|BIOLOGICAL|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
219604908|NCT00022282|DRUG|shark cartilage extract AE-941|
219604909|NCT01657812|DRUG|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
219604910|NCT00590512|DIETARY_SUPPLEMENT|High sodium|
219604911|NCT00590512|DIETARY_SUPPLEMENT|Low sodium|
219604912|NCT00422500|BEHAVIORAL|Questionnaire|Surveys about symptoms, mood, and quality of life.
219604913|NCT00422500|BEHAVIORAL|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
219604914|NCT00422500|OTHER|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
219604915|NCT06115772|OTHER|Non-Interventional Study|Non-interventional study
219604916|NCT01509014|BEHAVIORAL|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
219604917|NCT00606164|DRUG|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
219604918|NCT00606164|DRUG|Placebo|A single one-hour intravenous infusion of placebo on Day 1
219604919|NCT05024357|DRUG|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
219604920|NCT01724086|DRUG|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
219604921|NCT01724086|DRUG|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
219500103|NCT04248855|DRUG|Placebo|Intravenous (IV) infusion
219500104|NCT02655627|OTHER|Internet based exercise training|
219500105|NCT02655627|OTHER|group exercise training|
219500106|NCT02655627|OTHER|Physical activity counselling via a brochure|
219500107|NCT01368276|BIOLOGICAL|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
219500108|NCT01368276|DRUG|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
219500109|NCT02856074|BIOLOGICAL|prise de sang|
219500110|NCT02856074|OTHER|quality of life questionnaire|
219500111|NCT01977326|BEHAVIORAL|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
219604922|NCT01724086|DRUG|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
219604923|NCT01724086|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
219604924|NCT01724086|DRUG|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
219604925|NCT01724086|DRUG|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
219604926|NCT02889523|DRUG|Tazemetostat|Tablets 200 mg, to be administrated per os
219604927|NCT02889523|DRUG|Rituximab|375 mg/m²/dose, D1
219604928|NCT02889523|DRUG|Cyclophosphamide|750 mg/m²/dose, D1
219604929|NCT02889523|DRUG|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
219604930|NCT02889523|DRUG|Doxorubicin|50 mg/m²/dose, D1
219604931|NCT02889523|DRUG|Prednisolone|40 mg/m2 in the morning D1 to D5
219604932|NCT00791544|DRUG|AVE1642|intravenous infusion
219604933|NCT00791544|DRUG|sorafenib|oral intake
219604934|NCT00791544|DRUG|erlotinib|oral intake
219500112|NCT01977326|OTHER|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
219500113|NCT04281368|OTHER|Analysis of IUFD|Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy
219500114|NCT05779319|DEVICE|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
219604935|NCT03814655|PROCEDURE|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
219500115|NCT00000819|DRUG|Prednisone|
219500116|NCT01303991|OTHER|Hexvix PDT with Karl Storz T-Light|
219500117|NCT04110795|OTHER|No Intervention|No Intervention
219500118|NCT01989507|DRUG|Nicotine|
219500119|NCT01989507|BEHAVIORAL|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
219500120|NCT03404661|DRUG|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
219500121|NCT03867851|DRUG|IBsolvMIR|Study drug IBsolvMIR
219500122|NCT03867851|DRUG|Heparin|Clinical praxis
219500123|NCT06084507|DRUG|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
219500124|NCT06084507|DRUG|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
219500125|NCT02454309|DIETARY_SUPPLEMENT|Cranberry concentrate|
219500126|NCT02454309|DIETARY_SUPPLEMENT|Placebo|
219500127|NCT03285334|DEVICE|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
219027020|NCT04396431|BEHAVIORAL|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
219500128|NCT03285334|DEVICE|iRace files|rotary mechanical preparation
219500129|NCT04873349|DIETARY_SUPPLEMENT|Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)|two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
219500130|NCT05917093|BEHAVIORAL|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
219500131|NCT05493033|PROCEDURE|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
219604936|NCT03814655|PROCEDURE|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
219500132|NCT05493033|PROCEDURE|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
219500133|NCT06133088|DRUG|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
219500134|NCT03855319|BEHAVIORAL|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
219500135|NCT02021266|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
219500136|NCT05479968|DEVICE|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
219500137|NCT01475669|BIOLOGICAL|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
219500138|NCT01475669|BIOLOGICAL|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
219500139|NCT04248374|OTHER|Taste Intensity|Taste intensity with and without sour adaptation
219604937|NCT03864016|DRUG|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
219604938|NCT03864016|DRUG|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
219604939|NCT03864016|DRUG|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
219604940|NCT02925039|OTHER|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
219604941|NCT02925039|OTHER|Treatment as usual|Treatment as usual
219500140|NCT01373892|PROCEDURE|Bariatric surgery|
219500141|NCT04987671|DRUG|AMX0035|Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
219500142|NCT02039479|DRUG|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
219500143|NCT02039479|DRUG|Placebo|Placebo as ADD-on to every necessary treatment as usual
219500144|NCT03832933|BEHAVIORAL|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
219500145|NCT03832933|BEHAVIORAL|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
219500146|NCT01736410|DRUG|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
219500147|NCT00089310|RADIATION|technetium-99|0.25 mCi in 4 equal doses
219500148|NCT05645679|DEVICE|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
219500149|NCT01188161|DEVICE|Rotating Chair|Subjects will be spun in rotating chair
219604942|NCT04868500|DEVICE|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
219604943|NCT04868500|DEVICE|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
219604944|NCT04169152|PROCEDURE|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
219604945|NCT04144361|PROCEDURE|sleeve with plication|sleeve with plication
219604946|NCT04144361|PROCEDURE|sleeve without plication|sleeve without plication
219604947|NCT06157190|OTHER|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
219027021|NCT02139527|DEVICE|Total Disc Replacement|
219500150|NCT03680482|OTHER|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
219500151|NCT03680482|OTHER|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
219500152|NCT00349882|DEVICE|soft contact lens|
219500153|NCT00349882|DRUG|Marketed multipurpose disinfection regimen|
219500154|NCT00747422|DEVICE|Ulthera™ System|ultrasound treatment
219500155|NCT03362528|DEVICE|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
219604948|NCT05015452|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
219604949|NCT04325932|DRUG|Urinary Kallikrein|
219604950|NCT00548470|DRUG|Varenicline|Varenicline 1-2 mg/day
219604951|NCT00097032|DRUG|risperidone; quetiapine|
219604952|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
219604953|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
219604954|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
219027022|NCT04265781|DRUG|BAY1817080|Three different doses over the course of study
219027023|NCT04265781|DRUG|Matching Placebo|Matching Placebo to BAY1817080
219604955|NCT03436056|DRUG|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
219027024|NCT05147493|DRUG|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
219500156|NCT03365921|BIOLOGICAL|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
219500157|NCT05676879|OTHER|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
219500158|NCT04074473|DRUG|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
219500159|NCT04074473|PROCEDURE|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
219500160|NCT04074473|OTHER|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
219500161|NCT02044276|DRUG|lipegfilgrastim|6 mg
219500162|NCT02044276|DRUG|pegfilgrastim|6 mg
219500163|NCT05273606|DEVICE|MiSight mutifocal soft contact lens|Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.
219500164|NCT05273606|DEVICE|Proclear 1 Day soft contact lens|Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.
219500165|NCT00267007|DRUG|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
219500166|NCT00267007|DRUG|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
219500167|NCT00626587|DEVICE|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
219500168|NCT03359928|BEHAVIORAL|Boxing|as already discussed
219500169|NCT03359928|BEHAVIORAL|Stair stepping|as already discussed
219604956|NCT00004315|DRUG|ursodiol|
219604957|NCT02885766|DRUG|PF-114|
218880723|NCT03828331|OTHER|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
218880724|NCT03121365|BEHAVIORAL|Digital/E-Book Arm|Promotion of early reader digital e-book reading
219027025|NCT05147493|DRUG|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
219500170|NCT03359928|BEHAVIORAL|Stair climbing|as already discussed
219500171|NCT01987661|DEVICE|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
219604958|NCT00150787|DRUG|LEVETIRACETAM|
219604959|NCT00686361|DRUG|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
219604960|NCT04187547|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
219604961|NCT04187547|DRUG|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
219500172|NCT01987661|DEVICE|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
219604962|NCT03122977|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
218880725|NCT03121365|BEHAVIORAL|Standard/Board Book Arm|Promotion of early reader board book reading
218880726|NCT04022863|DIAGNOSTIC_TEST|TEP|Tumor Educated Platelets
219500173|NCT02400073|DEVICE|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
219500174|NCT06568133|DRUG|UIC201603 and co-administration of UIC201603 and UIC201604|"* UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days"
219500175|NCT06568133|DRUG|UIC201604 and co-administration of UIC201603 and UIC201604|"* UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604"
219500176|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
219500177|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
218880727|NCT04022863|DIAGNOSTIC_TEST|ctDNA|circulating tumor DNA
219604963|NCT03122977|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
218880728|NCT04286815|DEVICE|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
218880729|NCT03653988|PROCEDURE|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
218880730|NCT03653988|PROCEDURE|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
218880731|NCT01651325|DRUG|Isavuconazole|oral
218880732|NCT01651325|DRUG|dextromethorphan|oral
218880733|NCT02262702|DRUG|Paracetamol 665 mg|Paracetamol 665 mg tablet
219200592|NCT05752474|BEHAVIORAL|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
219200593|NCT03865992|DIETARY_SUPPLEMENT|Curcumin|Given capsules for oral administration
219200594|NCT03865992|OTHER|Placebo|Given capsules for oral administration
219500178|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
219500179|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
219500180|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
219500181|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
219500182|NCT06568198|DEVICE|Real tACS|α-tACS at a frequency of alpha band at S1
219500183|NCT06568198|DEVICE|Sham tACS|Sham tACS with no stimulation applied
219604964|NCT01307345|BEHAVIORAL|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
219604965|NCT04770675|DIAGNOSTIC_TEST|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
219604966|NCT02770898|BEHAVIORAL|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
218880734|NCT02262702|DRUG|Paracetamol 500 mg|Paracetamol 500 mg tablet
218880735|NCT00656864|DRUG|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
218880736|NCT00656864|DRUG|Placebo|placebo
218880737|NCT06256341|OTHER|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
218880738|NCT00244101|DRUG|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
218880739|NCT00244101|DEVICE|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
219200595|NCT03865992|OTHER|Nanoemulsion|Given nanoemulsion curcumin PO
219200596|NCT03865992|OTHER|Quality-of-Life Assessment|Ancillary studies
219200597|NCT03865992|BEHAVIORAL|Questionnaire|Ancillary studies
219604967|NCT04807400|DRUG|Inclisiran|Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
219604968|NCT04807400|BEHAVIORAL|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
219604969|NCT04807400|DRUG|Background lipid lowering therapy|lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
219500184|NCT03236493|DRUG|PF-06700841|PF-06700841 will be administered as tablet
219500185|NCT03236493|DRUG|Placebo|Matching placebo will be administered as tablet
219500186|NCT02264457|DEVICE|T-flex Aspheric Toric IOL|
219500187|NCT02264457|DEVICE|AT TORBI toric IOL|
219500188|NCT01270373|DRUG|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
219500189|NCT01270373|DRUG|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
219500190|NCT02740673|DEVICE|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
219500191|NCT03673839|OTHER|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
219500192|NCT03673839|OTHER|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
219500193|NCT03673839|OTHER|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
219604970|NCT02750956|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
218880740|NCT00244101|DRUG|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
219500194|NCT03673839|OTHER|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
219500195|NCT02908698|DRUG|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
219500196|NCT02908698|DRUG|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
218880741|NCT05908903|COMBINATION_PRODUCT|Drinks with active ingredients such as poria and GABA|Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.
218880742|NCT01959139|DRUG|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
218880743|NCT01959139|DRUG|Oxaliplatin|85 mg/m\^2, on Day 2, IV over 2 hours
218880744|NCT01959139|DRUG|Leucovorin|400 mg/m\^2, on Day 2, IV over 2 hours
218880745|NCT01959139|DRUG|Irinotecan|180 mg/m\^2, on Day 2, IV over 1.5 hours
218880746|NCT01959139|DRUG|5-fluorouracil|2,400 mg/m\^2, Days 2-4, IV over 46 hours
218880747|NCT04756804|DRUG|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
218880748|NCT04756804|DRUG|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
218880749|NCT00004932|DRUG|imatinib mesylate|
218880750|NCT02317848|OTHER|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
219027026|NCT05147493|DRUG|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
219027027|NCT05147493|DRUG|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
219604971|NCT03482115|RADIATION|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
219604972|NCT03482115|DIAGNOSTIC_TEST|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
219604973|NCT03482115|BIOLOGICAL|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
219604974|NCT03838497|BIOLOGICAL|Prevenar13|Prevenar13 for both arms
218880751|NCT01819896|DRUG|Pacemaker and defibrillator|
219027028|NCT05147493|DRUG|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
219500197|NCT00175383|DRUG|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
219500198|NCT01303874|DRUG|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
219604975|NCT02568605|DIETARY_SUPPLEMENT|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
219604976|NCT02568605|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219604977|NCT02568605|BEHAVIORAL|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
219604978|NCT05712798|OTHER|No intervention|No intervention
219604979|NCT04583189|DIAGNOSTIC_TEST|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
219604980|NCT02186444|OTHER|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
219500199|NCT01303874|DRUG|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
219500200|NCT05666674|OTHER|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
219604981|NCT02186444|OTHER|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
219604982|NCT01255137|DRUG|Axitinib|5 mg tab orally twice a day with food every 28 days
219604983|NCT02096432|BEHAVIORAL|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
219604984|NCT02096432|BEHAVIORAL|Usual Community Care|Community standard care as usual
219604985|NCT03473015|DEVICE|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
219604986|NCT00430066|DRUG|Imatinib Mesylate|400 mg/die for 6 months
219604987|NCT02054286|BIOLOGICAL|THV01-1|Intramuscular injection of THV01-1 (week 0)
219604988|NCT02054286|BIOLOGICAL|THV01-2|Intramuscular injection of THV01-2 (week 8)
218880752|NCT03282929|DEVICE|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
218880753|NCT03282929|DEVICE|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
219500201|NCT03095482|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
219604989|NCT02054286|BIOLOGICAL|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
219604990|NCT00102622|BIOLOGICAL|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
218880754|NCT03282929|DRUG|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
218880755|NCT03282929|DEVICE|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
218880756|NCT03282929|DEVICE|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
218880757|NCT05529836|DEVICE|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
219027029|NCT03194321|DRUG|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
219027030|NCT03792308|DRUG|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
219027031|NCT03792308|DRUG|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
219027032|NCT01204164|DRUG|TG02 citrate|TG02 citrate capsules given orally.
219027033|NCT01204164|DRUG|Carfilzomib|Carfilzomib per PI
219027034|NCT01204164|DRUG|Dexamethasone|Dexamethasone (Oral or IV)
219604991|NCT00102622|DRUG|Paclitaxel|80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
219604992|NCT03912935|OTHER|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
219604993|NCT05123378|BEHAVIORAL|Liberia National Community Health Assistant Program|Through the National Community Health Assistant Program (NCHAP), members of remote communities select Community Health Assistants (CHAs). Once selected, CHAs are trained to deliver direct services which include; treatment of diarrhea, ARI, and malaria following Integrated Community Case Management (iCCM) protocols, referrals for patients with clinical danger signs, family planning for women of childbearing age and birth preparedness and education for pregnant women. CHAs are also trained to deliver indirect services which include; health education, active surveillance, referral for mental health and other special conditions for all age groups. Since 2020 COVID-education has also been included in the CHAs work.
219604994|NCT02443597|OTHER|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
219604995|NCT03068728|DEVICE|Arista|
219604996|NCT03068728|DEVICE|Nexfoam|
219604997|NCT03068728|DEVICE|Nasopore|
219604998|NCT01433367|DEVICE|CerPass® Total Disc Replacement|Single level cervical disc disease
219500202|NCT03095482|BEHAVIORAL|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
219500203|NCT01595074|OTHER|medical chart review|Correlative studies
219500204|NCT01595074|OTHER|laboratory biomarker analysis|Correlative studies
219500205|NCT00465504|PROCEDURE|iontophoresis|See Detailed Description.
219500206|NCT03109522|PROCEDURE|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
219500207|NCT03109522|PROCEDURE|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
219500208|NCT04583839|BEHAVIORAL|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
219500209|NCT06568250|BEHAVIORAL|RAMP program|The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
219604999|NCT03593889|BEHAVIORAL|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
219605000|NCT03593889|OTHER|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
219605001|NCT06099392|DEVICE|digital stimulators (SNM-FDC01, Ningbo MaidaMedical Device, Inc, Ningbo, China)|TEA at Zusanli(ST 36) 45 min when drinking Polyethylene Glycol Electrolytes Powder
219605002|NCT06577922|OTHER|Establishment of a simulation lab and provision of simulation based trainings|In each hospital, the investigators will perform an initial need assessment to identify the existing skills labs' space, equipment and trained human resources. Then, maternal and neonatal health simulation labs will be established in each hospital. One simulation lab will have 5 rooms- one auditorium hall, one debrief room, two simulation rooms, and one high fidelity simulation room. Equipment and manikins required for practicing maternal and neonatal health related skills will be installed in the simulation lab, along with guidance/ checklists for skills practice. After completion of lab set-up, trainings will be provided to trainers/ MNH staff of each hospital on simulation based methodology, especially focusing on Essential Care for Labor and Birth (ECLB), Bleeding after Birth (BAB), and Helping Babies Breathe (HBB) modules. Similarly, the investigators will also provide training for simulation lab operation and maintenance.
219605003|NCT03557112|DRUG|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
218880758|NCT05529836|DEVICE|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
218880759|NCT05529836|DEVICE|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
218880760|NCT01946737|RADIATION|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
218880761|NCT01946737|RADIATION|Active Comparator: Invasive coronary angiography (ICA)|
218880762|NCT00730080|DRUG|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
219500210|NCT06383208|DIAGNOSTIC_TEST|lipid metabolomics|Extract 4 milliliters of fasting peripheral venous blood from enrolled patients for targeted lipid metabolism metabolomics research. Utilize a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system to conduct metabolomics analysis on patient blood samples.
219500211|NCT00764803|DEVICE|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
219605004|NCT03557112|DRUG|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
219605005|NCT02326636|BIOLOGICAL|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
219605006|NCT05983354|DRUG|Oral metoclopramide and ibuprofen|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
219605007|NCT05983354|DRUG|Intravenous metoclopramide and ketorolac|10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
219605008|NCT01497769|BIOLOGICAL|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo
219200598|NCT03640858|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
219200599|NCT06865274|PROCEDURE|Blood draw for the laboratory assessment|Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms
219200600|NCT06864182|DRUG|CX2101A tablet|CX2101A tablet
219200601|NCT06864182|DRUG|CX2101A placebo tablet|CX2101A placebo tablet
219200602|NCT06864182|DRUG|CX2101A enteric-coated tablet|CX2101A enteric-coated tablet
219500212|NCT00764803|DEVICE|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
219500213|NCT03522090|DIAGNOSTIC_TEST|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
219500214|NCT04627870|DEVICE|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
219500215|NCT04627870|DEVICE|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
219500216|NCT01825876|DRUG|Evacetrapib|Oral administration
219500217|NCT01825876|DRUG|Warfarin|Oral administration
219200603|NCT06864182|DRUG|CX2101A placebo enteric-coated tablet|CX2101A placebo enteric-coated tablet
219200604|NCT06864325|OTHER|VR-training|The VR gaming experience is based on the commercial rhythm game Beat Saber, featuring songs by Queen with varying rhythms and tempos. Players receive visual stimuli in the form of colored square blocks and must slice them in time with the music using the corresponding right or left hand. The blocks must be cut with a lightsaber of the same color. To ensure the safety of older adults, heart rate and energy expenditure were monitored throughout each session, while oxygen saturation was assessed before and after the exercises. Participants playe the game in comfortable conditions: the game loaded directly into the headset and VR glasses synchronized with portable screens to allow monitoring and assistance if needed. Before each session, the headset was adjusted to fit the participant's head dimensions, and corrective glasses were provided if required. The VR setup included a Meta Quest 2 headset with goggles and user-friendly controllers equipped with sensors (Meta Platforms, U.S.).
219200605|NCT06863831|DRUG|Yishen Qutong Granules|The patent prescription of Professor Feng Li, the head of the Department of Traditional Chinese Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences.
219200606|NCT06863831|DRUG|Yishen Qutong Simulant Granules|Yishen Qutong Simulant Granules is a preparation with one-tenth the dosage of Yishen Qutong Granules.
219200607|NCT06863467|DRUG|Intravenous Gemini|Single ascending intravenous dose infused once over 10-15 minutes.
219500218|NCT03333460|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
219500219|NCT02289027|BIOLOGICAL|cAd3-EBOZ vaccine|
219500220|NCT02289027|BIOLOGICAL|Placebo (for cAd3-EBOZ vaccine)|Diluent
219200608|NCT06863467|DRUG|Intravenous placebo|Intravenous sugar solution infused in a single dose over 10-15 minutes.
219200609|NCT06864767|OTHER|Neuro-sensory Motor Developmental Assessment|The test used to assess children's development levels evaluates the child's development in six parameters: gross motor function, fine motor function, neurological status, infant movement patterns, postural development and sensory-motor function (tactile, proprioceptive, ocular and vestibular systems) on a scale of 1 to 5. High scores are interpreted as motor dysfunction.
219500221|NCT02272582|DEVICE|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
219500222|NCT02272582|OTHER|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
218880763|NCT01009606|OTHER|Usual strategy|Usual strategy
219605009|NCT01497769|BIOLOGICAL|Intradermal MVA85A|Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
218880764|NCT01009606|OTHER|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
219500223|NCT05350982|DEVICE|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
219500224|NCT04965402|DRUG|BMS-986166|Specified dose on specified days
219500225|NCT04965402|OTHER|Placebo|Specified dose on specified days
219500226|NCT03542318|OTHER|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
219500227|NCT05149287|DRUG|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
219500228|NCT05149287|OTHER|Placebo|1% lidocaine and saline
219500229|NCT00962182|DRUG|STAN1|3-4 capsules/day at meals
219500230|NCT00962182|DRUG|Placebo enzyme|3-4 capsules/day at meals
219500231|NCT00962182|DRUG|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
219500232|NCT02094430|DRUG|biological: human fibrinogen concentrate|
219500233|NCT03374150|BEHAVIORAL|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
219500234|NCT00711867|DEVICE|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
219500235|NCT00711867|DEVICE|Bair Hugger|Arizant Bair Hugger temperature management system.
219500236|NCT01463566|DEVICE|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
219500237|NCT04293640|DIAGNOSTIC_TEST|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
219500238|NCT03230968|BEHAVIORAL|Integral Action Program for Respiration|
218880765|NCT04553900|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
218880766|NCT03996031|DEVICE|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
218880767|NCT00630344|DRUG|RAD001|
218880768|NCT00630344|DRUG|Bicalutamide|
219500239|NCT05161663|BEHAVIORAL|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
219500240|NCT04133519|DEVICE|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
219500241|NCT04133519|DEVICE|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
219605010|NCT00959478|BEHAVIORAL|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
219605011|NCT00302289|DRUG|tyrosine, green tea, caffeine|
219605012|NCT05298865|BEHAVIORAL|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
218880769|NCT04368715|DEVICE|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
218880770|NCT05345275|OTHER|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
218880771|NCT05529069|DRUG|Pirtobrutinib|Given by PO
219500242|NCT05548218|OTHER|Automated health education using a digital health pathway|MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
218880772|NCT05529069|DRUG|Venetoclax|Given by PO
218880773|NCT05362058|DRUG|Insulin Efsitora Alfa|Administered SC
218880774|NCT05362058|DRUG|Insulin Degludec|Administered SC
219500243|NCT04828902|PROCEDURE|cardiac surgery|Any heart surgery on or without cardiopulmonary bypass performed under general anesthesia in the Cardiac Surgical Department, Medical University of Gdańsk.
219500244|NCT04829279|OTHER|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
218880775|NCT05968807|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
218880776|NCT04219592|DIAGNOSTIC_TEST|IgG4 measurement (non-interventional, just obtaining data from medical records)|IgG4 measurement in mg/dL
218880777|NCT05484245|DEVICE|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
218880778|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
218880779|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
218880780|NCT05081206|DRUG|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
218880781|NCT05081206|DRUG|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
218880782|NCT02117180|OTHER|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
218880783|NCT05639530|BIOLOGICAL|IBI333|Intravitreal injection of IBI333
218880784|NCT06583525|OTHER|Intensive Transition Support|A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
218880785|NCT06583356|BEHAVIORAL|Motivational interviewing|Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
218880786|NCT05695885|BEHAVIORAL|STEPS|behavioral counseling
218880787|NCT05695885|BEHAVIORAL|Services as usual (SAU)|behavioral counseling normally provided
219500245|NCT00931567|BIOLOGICAL|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
219605013|NCT05298865|BEHAVIORAL|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
219605014|NCT01772290|DRUG|fluconazole|Multiple oral doses
218880788|NCT04090463|RADIATION|Intraoperative radiotherapy|"IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ"
219500246|NCT00931567|DEVICE|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
219500247|NCT06248034|DEVICE|Smartphone application with tele-monitoring rehabilitation|This Smartphone application includes an automated criterion-based progression based on participant's regular recorded self-measurement of knee range-of-motion and five-repetition-sit-to-stand. The rehabilitation program is designed to (i) increase knee range-of-motion, (ii) strengthen lower limb strength, (iii) improve postural balance, and (iv) improve physical function.
219500248|NCT06248034|PROCEDURE|Hospital-based rehabilitation program|Participants will be provided with the usual preoperative, inpatient physiotherapy and a physiotherapy house visit within the first 2-weeks postoperation. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion.
219500249|NCT02436135|DRUG|Idelalisib|Idelalisib tablets administered orally for 24 weeks
219500250|NCT02436135|DRUG|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
219500251|NCT06496906|PROCEDURE|Tooth extraction|A regular closed tooth extraction was performed with the different devices from each arm.
219500252|NCT06496906|DEVICE|Benex|Benex was used to perform the intervention.
219500253|NCT06496906|DEVICE|Physics Forceps|Physics forceps were used to perform the intervention.
219500254|NCT06496906|DEVICE|Conventional Extraction Forceps|Conventional Extraction Forceps were used to perform the intervention.
219500255|NCT01434706|OTHER|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
219500256|NCT01484665|OTHER|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
219500257|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
219500258|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
219500259|NCT00512174|OTHER|BladderScan BVI 3000|
219500260|NCT00323674|DEVICE|Polysoft Mesh|Polysoft Mesh is used.
218880789|NCT02561442|DRUG|ceftriaxone|
218880790|NCT03258775|OTHER|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
219200610|NCT06864767|OTHER|Functional Oral Intake Scale|It is a scale consisting of a total of 7 levels and two sections, developed by Crary et al. to indicate the functional oral intake of patients with dysphagia. A higher score indicates a better nutritional level.
219500261|NCT00323674|DEVICE|Light Weight Mesh|Light Weight Mesh is used.
219500262|NCT03931057|DRUG|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
218880791|NCT06216210|DRUG|opioid-FREE anesthesia.|"They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,"
218880792|NCT06216210|DRUG|opioid-CONTAINING anesthesia.|The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
219500263|NCT03931057|DRUG|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
219500264|NCT02372682|DEVICE|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
219605015|NCT01772290|DRUG|itraconazole|Multiple oral doses
219605016|NCT01772290|DRUG|rabeprazole|Multiple oral doses
219605017|NCT01772290|DRUG|vismodegib|Multiple oral doses
219605018|NCT00728234|DEVICE|aEEG recording|weekly recordings with aEEG
219605019|NCT04650204|DRUG|Anticonvulsant Agent|Given ASD
219605020|NCT04650204|DRUG|Perampanel|Given PO
219605021|NCT04650204|OTHER|Quality-of-Life Assessment|Ancillary studies
219605022|NCT04650204|OTHER|Questionnaire Administration|Ancillary studies
219605023|NCT01330303|DRUG|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
219605024|NCT01330303|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
219500265|NCT00839020|PROCEDURE|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
219500266|NCT00839020|PROCEDURE|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
219605025|NCT01107197|DIETARY_SUPPLEMENT|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
219605026|NCT01107197|DIETARY_SUPPLEMENT|Control formula|Isonitrogenous isocaloric oral formula
219605027|NCT01708551|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219605028|NCT03726853|DRUG|CKD-497 200mg|CKD-497 200mg
219605029|NCT03726853|DRUG|CKD-497 300mg|CKD-497 300mg
219605030|NCT03726853|DRUG|CKD-497 placebo|Placebo of CKD-497
219500267|NCT05747365|DIAGNOSTIC_TEST|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
219500268|NCT02751060|OTHER|No intervention|
219500269|NCT01558531|DEVICE|DEB|paclitaxel-eluting balloon angioplasty
219500270|NCT01558531|DEVICE|POBA|conventional balloon angioplasty
219500271|NCT01710826|BIOLOGICAL|Genz-682452|Capsules for oral administration.
219605031|NCT03726853|DRUG|Comparator|Comparator
219605032|NCT03726853|DRUG|Comparator placebo|Comparator placebo
219605033|NCT04395066|DIAGNOSTIC_TEST|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
219605034|NCT05349045|DRUG|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
219605035|NCT00054405|BIOLOGICAL|recombinant interleukin-12|Given IV
219605036|NCT00054405|BIOLOGICAL|aldesleukin|Given IV
219500272|NCT01710826|BIOLOGICAL|Placebo|Placebo capsules matching the Genz-682452 capsules.
219605037|NCT06656780|BEHAVIORAL|SIT|"Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt."
219605038|NCT06656780|BEHAVIORAL|DCA-FF|Participants will undergo 8-week Standard Firefighting Training
219605039|NCT00235677|PROCEDURE|Endoscopic gastroplication|
219605040|NCT05475860|DEVICE|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
219500273|NCT03227822|PROCEDURE|Short spot stenting|
219500274|NCT03227822|PROCEDURE|Long lesion stenting|
219500275|NCT03139565|BIOLOGICAL|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
219500276|NCT03139565|BIOLOGICAL|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
219500277|NCT00274755|DRUG|chemotherapy|
219500278|NCT00274755|PROCEDURE|conventional surgery|
219500279|NCT00274755|PROCEDURE|magnetic resonance imaging|
219500280|NCT00274755|PROCEDURE|magnetic resonance spectroscopic imaging|
219500281|NCT00274755|RADIATION|radiation therapy|
219500282|NCT03568825|PROCEDURE|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
219500283|NCT05535712|DEVICE|Lung Anatomic Resection (Da Vinci SP)|To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
219500284|NCT04311138|OTHER|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
219500285|NCT04311138|OTHER|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
219605041|NCT03548337|BIOLOGICAL|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
219605042|NCT03834454|DRUG|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
219605043|NCT03834454|DRUG|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
219605044|NCT00791895|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme
219605045|NCT04305353|OTHER|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
219605046|NCT04305353|OTHER|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
219605047|NCT01061476|DEVICE|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
219605048|NCT01061476|OTHER|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
219605049|NCT01061476|OTHER|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
219605050|NCT02171780|DRUG|BI 1744 CL|
219605051|NCT02171780|DRUG|Placebo|
219605052|NCT02985671|DRUG|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
218880793|NCT05073926|OTHER|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
218880794|NCT00904488|DRUG|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
219500286|NCT02580890|DEVICE|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
219500287|NCT02580890|DEVICE|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
219500288|NCT04567199|OTHER|Observational, retrospective|retrospective analysis of observed results, for both study groups.
219500289|NCT03154528|DIAGNOSTIC_TEST|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
219500290|NCT02996435|BEHAVIORAL|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
219500291|NCT02996435|OTHER|No Intervention|Participants will receive physician- or nurse-guided standard of care.
219500292|NCT00475852|DRUG|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
219500293|NCT00475852|DRUG|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
219500294|NCT04366466|OTHER|suicide attempt patient using PEPS Program|"The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group."
219500295|NCT03850054|PROCEDURE|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
219500296|NCT05187403|DRUG|Laquinimod|Eye-drops
219500297|NCT05187403|DRUG|Placebo|Eye-drops
219500298|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
219500299|NCT02174900|DRUG|Artemether-Lumefantrine (AL) combination|
219500300|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
219500301|NCT02085707|PROCEDURE|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
219500302|NCT02085707|PROCEDURE|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
219500303|NCT05085860|BEHAVIORAL|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
219500304|NCT05085860|BEHAVIORAL|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
219500305|NCT05332626|DIETARY_SUPPLEMENT|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10\^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
219500306|NCT05332626|DIETARY_SUPPLEMENT|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
219500307|NCT02076191|DRUG|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
219605053|NCT02985671|DRUG|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
219605054|NCT02985671|DRUG|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
219605055|NCT02985671|DRUG|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
219605056|NCT01675648|DRUG|Lofexidine|
219605057|NCT01675648|DRUG|Diazepam|
219605058|NCT01675648|DRUG|Placebo for Lofexidine|
219605059|NCT01675648|DRUG|Placebo for Diazepam|
219605060|NCT04548765|BEHAVIORAL|Letter|Recipients receive a letter promoting CRC screening.
219605061|NCT04548765|BEHAVIORAL|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
219605062|NCT04548765|BEHAVIORAL|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
218880795|NCT00904488|DRUG|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
218880796|NCT03415945|DEVICE|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
219500308|NCT02076191|DRUG|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
219605063|NCT04548765|BEHAVIORAL|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
219605064|NCT04548765|BEHAVIORAL|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
219605065|NCT00137176|DRUG|Rebif|Rebif 44mcg TIW
219605066|NCT06613568|DEVICE|Moda-flx Hemodialysis System™|The Moda-flx Hemodialysis System™ is a portable hemodialysis system
219605067|NCT06397911|DRUG|FB825|The study treatment will be administered as 5 SC doses in total 12 weeks
219605068|NCT06397911|DRUG|Placebo|The study treatment will be administered as 5 SC doses in total 12 weeks
219605069|NCT06994676|DRUG|CBX-250|subcutaneous CBX-250
219605070|NCT01562938|DRUG|Placebo|Placebo
219605071|NCT01562938|DRUG|MEDI-557|MEDI-557 low-dose
219605072|NCT01562938|DRUG|MEDI-557|MEDI-557 high-dose
219605073|NCT06992141|BIOLOGICAL|Streptococcus pyogenes M1UK strain MCRI0102|Human challenge with S. pyogenes M1UK strain MCRI0102
219605074|NCT01546454|DRUG|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
219500309|NCT03216200|DEVICE|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
219500310|NCT02512770|PROCEDURE|endoscopic dilatation|
219500311|NCT03433118|DEVICE|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
219500312|NCT05326152|BIOLOGICAL|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
219500313|NCT05326152|BIOLOGICAL|Intralesional saline|Intralesional saline
219500314|NCT03686800|DEVICE|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
219500315|NCT01218737|DRUG|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
219605075|NCT01546454|DRUG|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
219605076|NCT01546454|DRUG|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
219605077|NCT01546454|DRUG|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
219605078|NCT03479801|PROCEDURE|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
219605079|NCT04074187|DRUG|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
219605080|NCT04074187|DRUG|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
218880797|NCT01599013|DRUG|Vinflunine, Gemcitabine|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
219605081|NCT04074187|DRUG|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
219605082|NCT04074187|DRUG|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
219605083|NCT02669797|BEHAVIORAL|In-home Visits and Food Preparation Activities|"Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally, a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
219605084|NCT02669797|BEHAVIORAL|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
219027035|NCT04648345|PROCEDURE|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
219027036|NCT04919577|DIAGNOSTIC_TEST|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
219500316|NCT01218737|DRUG|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
219500317|NCT05599906|OTHER|questionnaires|Completion of 3 questionnaires (HADS; SF-12; FAS) at the beginning and end of the rehabilitation and after 3 months
219500318|NCT04844307|OTHER|Shorter duration higher frequency PT|The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.
219500319|NCT04844307|OTHER|Standard PT|The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
219500320|NCT05485688|OTHER|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
219500321|NCT04405193|DRUG|N-acetyl cysteine|Eligible patients will be randomised to receive N-acetylcysteine or placebo
219027037|NCT02721927|OTHER|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
219027038|NCT01547000|DRUG|placebo|Administered up to 8 weeks.
219027039|NCT01547000|DRUG|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
219500322|NCT04405193|DRUG|Placebo|Matching Placebo
219027040|NCT02333695|DEVICE|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
219500323|NCT05771831|BIOLOGICAL|Thrombosomes®|The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
219500324|NCT05771831|BIOLOGICAL|Standard platelet concentrate|The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
219500325|NCT04394910|DIETARY_SUPPLEMENT|Pomegranate Juice|
219500326|NCT04394910|DIETARY_SUPPLEMENT|Placebo Juice|
219500327|NCT00297479|BEHAVIORAL|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
219500328|NCT00297479|DRUG|Nicotine|6 weeks of nicotine patch therapy
219500329|NCT00297479|BEHAVIORAL|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
219500330|NCT00297479|BEHAVIORAL|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
219500331|NCT01545687|DIETARY_SUPPLEMENT|Lactobacillus brevis CD2 lozenge|Dissolved orally
219500332|NCT01545687|OTHER|placebo|Dissolved orally
218880798|NCT01599013|DRUG|Vinflunine, Carboplatin|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
219605085|NCT02669797|BEHAVIORAL|Feedback on Video-recorded Family Meals|Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
219605086|NCT02669797|BEHAVIORAL|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
219605087|NCT03248310|BEHAVIORAL|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
219605088|NCT00307021|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
219500333|NCT03145883|OTHER|Home-Based Aerobic Exercise|
219500334|NCT03349177|DRUG|Epirubicin|100mg/m2
219500335|NCT03349177|DRUG|Fluorouracil|500mg/m2
219500336|NCT03349177|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
219500337|NCT03349177|DRUG|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
219500338|NCT03221439|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
219605089|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
219605090|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
219605091|NCT01911273|DRUG|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
219605092|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
218880799|NCT04954768|OTHER||This is a observational study, and there is no interventions.
218880800|NCT00380731|BEHAVIORAL|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
219027041|NCT00227162|BEHAVIORAL|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
219027042|NCT00227162|BEHAVIORAL|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
219027043|NCT00227162|BEHAVIORAL|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
219605093|NCT01911273|OTHER|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
219605094|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
218880801|NCT00818051|RADIATION|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
218880802|NCT02181283|BEHAVIORAL|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
219027044|NCT00867451|BEHAVIORAL|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
219027045|NCT00867451|DRUG|Melatonin|Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
218880803|NCT02181283|BEHAVIORAL|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
218880804|NCT00005773|DRUG|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
218880805|NCT00005773|DRUG|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
218880806|NCT01964963|DRUG|Alogliptin|Alogliptin tablets
219500339|NCT03221439|OTHER|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
219500340|NCT04098549|OTHER|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
219605104|NCT05933525|BIOLOGICAL|Travelan|6 Travelan tablets (1200mg) administered orally for 7 days
218880807|NCT00930553|BIOLOGICAL|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
218880808|NCT05668286|DRUG|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
218880809|NCT02183766|DIETARY_SUPPLEMENT|Galactooligosaccharide prebiotic|6 mL once a day
218880810|NCT02183766|DRUG|Maltodextrin|6 mL once a day
218880811|NCT01691157|OTHER|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
219500341|NCT04098549|OTHER|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
219605105|NCT05933525|OTHER|Placebo|6 tablets of placebo (1200mg) administered orally for 7 days
219605106|NCT02950649|DEVICE|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
219605107|NCT02950649|DEVICE|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
219500342|NCT02964897|BEHAVIORAL|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
218880812|NCT01691157|OTHER|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
218880813|NCT03470207|PROCEDURE|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
218880814|NCT03648515|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
218880815|NCT03648515|DIAGNOSTIC_TEST|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
218880816|NCT03648515|DIAGNOSTIC_TEST|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
218880817|NCT04879966|DRUG|Infliximab|Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
218880818|NCT04879966|DRUG|Corticosteroid|Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
218880819|NCT01415141|DRUG|Peginterferon alfa-2a|180ug subcutaneously, weekly
218880820|NCT01415141|DRUG|Ribavirin|"Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg"
218880821|NCT01415141|DRUG|telaprevir|750mg every 8 hours, orally
218880822|NCT00051909|DRUG|LY451395|
219027046|NCT05614375|PROCEDURE|endoscopic surgery|transnasal endoscopic surgery
219500343|NCT02964897|BEHAVIORAL|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
219500344|NCT04728087|DEVICE|ACCEL® Absorbable Hemostat Powder|Up to 2 bellows (10 grams nominal) of ACCEL®
219500345|NCT04728087|DEVICE|Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)|Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
219500346|NCT04819347|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
219500347|NCT04819347|DRUG|3BNC117|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
219500348|NCT01664494|DRUG|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
218880823|NCT05696756|BEHAVIORAL|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
219027047|NCT03773887|OTHER|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
219027048|NCT02433756|DEVICE|CRTD|
219500349|NCT04455074|OTHER|FN scale auto-questionnaire|Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
219605108|NCT02035358|BIOLOGICAL|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
218880824|NCT05696756|BEHAVIORAL|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
219605109|NCT02386293|DRUG|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
218880825|NCT06117865|BEHAVIORAL|Module 1|Module 1: Introduction to IBS by a gastroenterologist.
218880826|NCT06117865|BEHAVIORAL|Module 2|Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.
218880827|NCT06117865|BEHAVIORAL|Module 3|Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.
218880828|NCT06117865|BEHAVIORAL|Module 4|Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).
218880829|NCT06117865|BEHAVIORAL|Module 5|Module 5: Intervention: The low FODMAP diet.
218880830|NCT01109355|OTHER|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
218880831|NCT01109355|OTHER|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
218880832|NCT00005608|DRUG|leucovorin calcium|
218880833|NCT00005608|DRUG|tegafur-uracil|
218880834|NCT06018623|OTHER|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
218880835|NCT00241345|DRUG|Valganciclovir|
218880836|NCT00241345|DRUG|Ganciclovir|
218880837|NCT01235234|DRUG|CF101|orally q12h
218880838|NCT00497406|PROCEDURE|Salivary gland transfer|Retrograde flow method
218880839|NCT00497406|PROCEDURE|Helical Tomotherapy treatment|total of 30 fractions
218880840|NCT00534859|DEVICE|High Risk PCI|High Risk Percutaneous Coronary Intervention
218880841|NCT05405335|OTHER|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
219027049|NCT05127447|DEVICE|ES application|Electrical stimulation (ES) application will be given to the ES group
219027050|NCT05127447|OTHER|Sham application|Only vacuum was applied and no current was given from the applied device
219027051|NCT03893812|DEVICE|MRI|diffusion weighted MR
219027052|NCT03893812|DEVICE|Ultrasound|Color Doppler ultrasound
219605110|NCT02386293|OTHER|Placebo|Sugar pill made to look identical to irbesartan intervention.
219605111|NCT01289379|PROCEDURE|High Frequency Jet Ventilation|
219605112|NCT01289379|PROCEDURE|HFJV|
219605113|NCT02478879|DRUG|ZP-PTH|Patch applied daily for 30 minutes, 14 days
219500350|NCT03196791|DRUG|Sugammadex Sodium|"1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
219500351|NCT04503252|OTHER|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
219500352|NCT04503252|OTHER|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
219500353|NCT04503252|OTHER|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
219500354|NCT04503252|OTHER|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
219605114|NCT02478879|DRUG|FORTEO|Subcutaneous injection administration daily for 14 days
219605115|NCT00869336|DRUG|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
219605116|NCT00869336|DRUG|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
219605117|NCT00869336|DRUG|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
219605118|NCT00869336|DRUG|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
218880842|NCT02636530|BEHAVIORAL|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
219605119|NCT05645133|DEVICE|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
219605120|NCT05375253|BIOLOGICAL|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
219605121|NCT04422041|OTHER|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
218880843|NCT02636530|BEHAVIORAL|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
219027053|NCT01748981|OTHER|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
219605122|NCT04422041|OTHER|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
219605123|NCT00493896|DRUG|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
219605124|NCT00493896|DRUG|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
219605125|NCT06387134|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
219605126|NCT06387134|DRUG|Conventional treatment with Western medicine|"Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021."
219605127|NCT01434914|DRUG|octenisept®|Cutaneous solution
218880844|NCT01184924|BEHAVIORAL|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
219027054|NCT01748981|OTHER|As usual|Controls, not training
219027055|NCT03938584|DIETARY_SUPPLEMENT|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
219605128|NCT01434914|DRUG|Placebo|Cutaneous use
219605129|NCT06253806|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
219605130|NCT06253806|DRUG|Placebo Sham Injection|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
219605131|NCT01024257|RADIATION|beta-irradiation|
219605132|NCT01024257|PROCEDURE|conjunctival autograft|
219500355|NCT04503252|OTHER|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
218880845|NCT04085497|OTHER|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
219500356|NCT04607642|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
219500357|NCT04607642|RADIATION|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
219500358|NCT04607642|DRUG|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
219500359|NCT04607642|OTHER|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
219500360|NCT00362570|DRUG|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
219500361|NCT00133107|DRUG|efalizumab|
219500362|NCT04070456|OTHER|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
219500363|NCT02948478|OTHER|Exposed|Precarious patients
219500364|NCT02948478|OTHER|Non exposed|Non precarious patients
219500365|NCT03786289|BIOLOGICAL|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
219500366|NCT03786289|BIOLOGICAL|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
219500367|NCT02212431|DRUG|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
219500368|NCT01002157|DIETARY_SUPPLEMENT|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
219500369|NCT01002157|OTHER|Placebo capsules|Capsules containing no Menaquinone-7
219500370|NCT01301131|OTHER|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
219500371|NCT01301131|OTHER|control|usual oral care
219500372|NCT03947047|DIAGNOSTIC_TEST|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
219500373|NCT02273206|BEHAVIORAL|Prevention Care Management for Depression and Cancer Screening|
219500374|NCT02273206|BEHAVIORAL|Prevention Care Management for Cancer Screening|
219500375|NCT02238977|DRUG|Fluoxetine|Antidepressant
219500376|NCT02238977|DRUG|Bupropion|Antidepressant
219500377|NCT06189183|RADIATION|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
219500378|NCT01637311|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
219500379|NCT02517359|DRUG|RV6153 single dose|Safety and tolerability of single doses
219500380|NCT02517359|DRUG|RV6153 matching placebo single dose|Safety and tolerability of single doses
218880846|NCT04755036|OTHER|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
218880847|NCT03406013|BEHAVIORAL|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
218880848|NCT03406013|BEHAVIORAL|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
218880849|NCT03406013|BEHAVIORAL|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
219500381|NCT02517359|DRUG|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
219500382|NCT02517359|DRUG|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
218880850|NCT03406013|BEHAVIORAL|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
218880851|NCT02352753|DRUG|Denosumab|Subcutaneous (SC) injection.
219500383|NCT02517359|DRUG|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
219500384|NCT02517359|DRUG|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
219500385|NCT04586790|DRUG|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
219500386|NCT04586790|DRUG|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
219500387|NCT04586790|DRUG|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
219500388|NCT03063632|BIOLOGICAL|Interferon Gamma-1b|Given SC
219605133|NCT02445963|BIOLOGICAL|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
219605134|NCT02128321|DRUG|Isavuconazole|oral
218880852|NCT04578184|DIAGNOSTIC_TEST|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
219027056|NCT03938584|OTHER|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
219500389|NCT03063632|OTHER|Laboratory Biomarker Analysis|Ancillary studies
218880853|NCT05844241|OTHER|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
219200611|NCT06864767|OTHER|Behavioral Pediatrics Feeding Assessment Scale|The scale used to determine eating problems in children evaluates both the child's nutritional status and the parents' feelings about the child's nutritional status. It consists of 35 items in total and is scored from 1 to 5. High scores indicate problematic eating behaviors and habits.
219500390|NCT03063632|BIOLOGICAL|Pembrolizumab|Given IV
219500391|NCT00927888|DRUG|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
219500392|NCT00927888|DRUG|Placebo|placebo is identical in appearance in comparison to active drug.
219500393|NCT02570165|DRUG|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
219500394|NCT02570165|DRUG|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
219500395|NCT02570165|DRUG|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
219500396|NCT00794326|DRUG|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
219500397|NCT01789281|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
219500398|NCT01789281|DRUG|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
219500399|NCT05957718|DRUG|TKTX cream|TKTX cream was used in several studies on Tatto and laser
219500400|NCT04274088|PROCEDURE|Cataract surgery|Phacoemulsification surgery
219605135|NCT02128321|DRUG|Repaglinide|oral
219605136|NCT02128321|DRUG|Caffeine|oral
219605137|NCT00987779|DRUG|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
219605138|NCT00987779|DRUG|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
218880854|NCT05844241|OTHER|Audiobooks|Listening to audiobooks for 30 minutes
218880855|NCT03222297|DEVICE|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
218880856|NCT03222297|DEVICE|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
218880857|NCT04256681|OTHER|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
218880858|NCT02870634|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
219500401|NCT04336488|DRUG|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
219500402|NCT04336488|DRUG|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
219500403|NCT06221345|DRUG|Systane HYDRATION® Preservative-Free Lubricant Eye Drops|The HPG/HA group will receive Systane HYDRATION® Preservative-Free Lubricant Eye Drops and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
219500404|NCT06221345|DRUG|Optive Fusion® Lubricant Eye Drops (Unit Dose)|The CMC/HA group will receive Optive Fusion® Lubricant Eye Drops (Unit Dose) and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
219500405|NCT00091182|DRUG|oxaliplatin|Given IV
219500406|NCT05941468|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
219500407|NCT00821457|DRUG|Juvista|250ng
219605139|NCT01378247|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
219605140|NCT00125515|DRUG|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
219500408|NCT00821457|DRUG|Placebo|Powder for solution for injection
219500409|NCT00821457|DRUG|Juvista|500ng
219605141|NCT00125515|DRUG|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
219500410|NCT05641272|BIOLOGICAL|3,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
219500411|NCT05641272|BIOLOGICAL|9,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
219500412|NCT05641272|OTHER|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
219500413|NCT01535846|BEHAVIORAL|Conscious food tasting intervention|Six weekly 2-hour workshops
219500414|NCT01785186|DRUG|SQ109|SQ109 300 mg
219500415|NCT01785186|DRUG|Rifampicin|Rifampicin 10 to 35 mg/kg
219500416|NCT01785186|DRUG|Moxifloxacin|Moxifloxacin 400mg
219500417|NCT01785186|DRUG|isoniazid|isoniazid 75 mg
219500418|NCT01785186|DRUG|pyrazinamide|pyrazinamide 400 mg
219500419|NCT01785186|DRUG|ethambutol|ethambutol 275 mg
219500420|NCT01785186|DIETARY_SUPPLEMENT|pyridoxine|pyridoxine 25 mg
219500421|NCT04484922|DRUG|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
219500422|NCT04484922|DRUG|Normal saline|continuous infusion of normal saline during the surgery
219500423|NCT00624403|DEVICE|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
219500424|NCT00624403|DEVICE|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
219500425|NCT04393805|DRUG|Low Molecular Weight Heparin|Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
219500426|NCT01823315|DRUG|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
219500427|NCT01823315|DRUG|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, \>4h)
219605142|NCT01957176|DRUG|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
219605143|NCT03964064|RADIATION|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
219500428|NCT01823315|BIOLOGICAL|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
219500429|NCT00188695|PROCEDURE|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
219500430|NCT05447585|DEVICE|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
219500431|NCT05447585|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
219500432|NCT02103647|DRUG|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
219500433|NCT02103647|DRUG|sustained release tablet|sustained release tablet
219500434|NCT04407195|OTHER|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
219500435|NCT05073263|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
219500436|NCT04150588|DRUG|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
219500437|NCT01341522|PROCEDURE|MRI exam|MRI exam
219500438|NCT01341522|PROCEDURE|control|waiting room
219500439|NCT06024863|DIAGNOSTIC_TEST|Screening stress test on a bicycle ergometer (usual practise)|
219500440|NCT04304950|DRUG|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
219500441|NCT04304950|DRUG|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
219500442|NCT00140556|RADIATION|Chemoradiotherapy|External beam radiation daily (M-F)
219500443|NCT00140556|DRUG|Cisplatin|Cisplatin week 1 and 5 of radiation
219500444|NCT00140556|DRUG|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
219500445|NCT00140556|DRUG|Erlotinib|Erlotinib daily during radiation
219500446|NCT00072033|DRUG|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
219500447|NCT05091814|RADIATION|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
219500448|NCT02158910|DRUG|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
219500449|NCT03495700|PROCEDURE|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
219500450|NCT03495700|PROCEDURE|DBBM|The use of bovine xenograft will be analysed
218880859|NCT03190434|DEVICE|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
218880860|NCT04331470|DRUG|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
219605144|NCT03964064|RADIATION|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
218880861|NCT04331470|DRUG|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
219500451|NCT02590978|PROCEDURE|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
219605145|NCT02571192|DRUG|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
219605146|NCT02571192|RADIATION|5.95 μCi RAD|
219605147|NCT06044012|PROCEDURE|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
219500452|NCT02590978|PROCEDURE|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
218880862|NCT00387634|BIOLOGICAL|TBE vaccine for adults|Serology blood draw.
218880863|NCT02330692|OTHER|No intervention|
218880864|NCT00066404|BIOLOGICAL|recombinant adenovirus-hIFN-beta|
219200612|NCT06864767|OTHER|Pediatric Quality of Life Inventory|The PedsQL assesses health-related quality of life in children ages 2 to 18 years with chronic illnesses from both the child's and parents' perspectives. It consists of 25 items and 3 categories (About My Child's Neuromuscular Disease, Communication, About Our Family Resources). The Neuromuscular Module was used to assess the quality of life of the children in our study and was answered by the parents only. The scale is scored from 0 to 4, with higher scores indicating better quality of life.
219500453|NCT01439841|DIETARY_SUPPLEMENT|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
219500454|NCT01439841|DIETARY_SUPPLEMENT|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
219500455|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
219500456|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
219500457|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
219500458|NCT01692418|DRUG|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
219500459|NCT01692418|DRUG|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
219500460|NCT03805178|DRUG|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
219500461|NCT03805178|DRUG|Carfilzomib|20mg/m2 Plasmapheresis
219500462|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
219500463|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
219500464|NCT02475967|OTHER|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
219500465|NCT02475967|OTHER|Control group|The control group patients receive conventional cardiac care alone.
219500466|NCT00057018|PROCEDURE|Constraint-induced movement therapy|
219500467|NCT03938298|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
219500468|NCT03938298|OTHER|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
219605148|NCT01490983|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
219605149|NCT01490983|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
219605150|NCT01941082|DRUG|RO6867461|Single or multiple ascending dose by intravitreal injection
219605151|NCT01458873|DRUG|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
219605152|NCT01458873|DRUG|diluted sodium bicarbonate 2.1%|50ml
219605153|NCT01458873|DRUG|normal saline|50ml
219605154|NCT03654820|DEVICE|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
219605155|NCT03654820|DEVICE|SDF solution|Annual application of 38% SDF solution
219605156|NCT03546920|BEHAVIORAL|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
219605157|NCT00492440|BIOLOGICAL|recombinant interleukin-7|
219605158|NCT00492440|GENETIC|gene expression analysis|
219500469|NCT01412073|DRUG|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
219605159|NCT00492440|GENETIC|polymerase chain reaction|
219605160|NCT00492440|GENETIC|protein expression analysis|
219605161|NCT00492440|OTHER|flow cytometry|
219605162|NCT00492440|OTHER|immunoenzyme technique|
219605163|NCT00492440|OTHER|immunologic technique|
219500470|NCT01412073|DRUG|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
219605164|NCT00492440|OTHER|laboratory biomarker analysis|
219605165|NCT00492440|OTHER|pharmacological study|
219605166|NCT03278691|DRUG|Saline|1 ml saline IV Q6H
219605167|NCT03278691|DRUG|Ketorolac|15 mg (15 mg/ml) IV Q6H
219605168|NCT02359994|DEVICE|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
219500471|NCT02754180|DRUG|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
219500472|NCT02754180|RADIATION|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
219605169|NCT02359994|DEVICE|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
219605170|NCT03399071|DRUG|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
219605171|NCT04859829|OTHER|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
219605172|NCT04859829|OTHER|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
219605173|NCT02304393|DRUG|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
219605174|NCT02304393|DRUG|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
219605175|NCT01810757|RADIATION|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
218880865|NCT04289961|DIAGNOSTIC_TEST|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
218880866|NCT03369912|BIOLOGICAL|CSJ148|Active
219500473|NCT03634488|DRUG|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
219500474|NCT03634488|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
219500475|NCT06539065|DEVICE|VR interactive games|The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
219605176|NCT01810757|RADIATION|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
218880867|NCT03369912|OTHER|Placebo|No Drug
218880868|NCT01255995|DEVICE|Capsular Tension Ring|Capsular Tension Ring
218880869|NCT06960668|BEHAVIORAL|Nature for Body Image|The intervention will include a range of activities in nature (e.g., in a public park), such as meditation, body scans, and grounding exercises.
219500476|NCT05103488|OTHER|Comprehensive palliative care|CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
219500477|NCT05103488|OTHER|Standard of care|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
219500478|NCT03182686|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
219500479|NCT03182686|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
218880870|NCT06960668|BEHAVIORAL|Simple nature exposure|The intervention will simply involve spending time in nature (e.g., in a public park), without specific guidelines.
219605177|NCT00038532|DRUG|Amprenavir/ritonavir|
219605178|NCT00038532|DRUG|Saquinavir/ritonavir|
219605179|NCT00038532|DRUG|Efavirenz|
219605180|NCT00080314|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
219500480|NCT00817466|DRUG|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1\) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
219500481|NCT00817466|DRUG|Isotonic saline|2ml NaCl 9mg/ml.
219500482|NCT06521606|PROCEDURE|Primary open reduction and internal fixation|The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.
219500483|NCT06521606|PROCEDURE|Temporary external fixator|). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
219500484|NCT06355960|DRUG|GROUP Dexmedetomidine|Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
219500485|NCT06355960|DRUG|GROUP B|Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
219605181|NCT00080314|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
219605182|NCT01672216|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
219605183|NCT01672216|DEVICE|EMG-biofeedback alone|
218880871|NCT06960668|BEHAVIORAL|Structured Built Environment Exposure|The intervention will mirror the activities of the structured nature exposure intervention (e.g., meditation, body scans, and grounding exercises), but without any exposure to nature.
218880872|NCT01035281|DRUG|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
218880873|NCT04102072|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
218880874|NCT04102072|DIAGNOSTIC_TEST|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
218880875|NCT04996485|DRUG|Secukinumab Injection|Pathogenetic therapy with biologic drugs
218880876|NCT04996485|DRUG|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
218880877|NCT04996485|DRUG|Dupilumab Injection|Pathogenetic therapy with biologic drugs
219605184|NCT04719455|BEHAVIORAL|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
219605185|NCT04719455|OTHER|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
219605186|NCT04702308|OTHER|Clinical Decision Rule Alerts|The
218880878|NCT04996485|OTHER|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
218880879|NCT02540070|PROCEDURE|Periarticular|
218880880|NCT02540070|PROCEDURE|Motor free|
219500486|NCT06355960|DRUG|GROUP C|Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
218880881|NCT02540070|PROCEDURE|Motor free with dex|
218880882|NCT02540070|DRUG|Ropivacaine|
218880883|NCT02540070|DRUG|epinephrine|
218880884|NCT02540070|DRUG|morphine|
218880885|NCT02540070|DRUG|Ketorolac|
218880886|NCT02540070|DRUG|Dexmedetomidine|
218880887|NCT02540070|DRUG|saline|
219027057|NCT05706142|OTHER|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
218880888|NCT05314907|DEVICE|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
219500487|NCT03909568|PROCEDURE|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
219500488|NCT06542848|OTHER|Physiotherapy and Rehabilitation Practices|The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
219500489|NCT01696474|DRUG|Bortezomib|
219500490|NCT01783925|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
219500491|NCT04672057|OTHER|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
219500492|NCT00475111|BEHAVIORAL|Cognitive Behavior Therapy for Pain (CBT-P)|
219500493|NCT00475111|BEHAVIORAL|Mindfulness Meditation for Emotion Regulation (MM-ER)|
219500494|NCT00475111|BEHAVIORAL|Rheumatoid arthritis education|
219500495|NCT00415961|DEVICE|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
219500496|NCT05053178|BEHAVIORAL|Mindfulness-based mandala activity|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented
219500497|NCT00189345|BIOLOGICAL|anti-EpCAM x anti-CD3 (removab)|
219027058|NCT01172457|PROCEDURE|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
219027059|NCT01172457|PROCEDURE|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
219027060|NCT00975481|DRUG|dimebon|Oral tablet; 20 mg dimebon, single dose
219500498|NCT01154127|DRUG|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
219500499|NCT01154127|DRUG|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
219605187|NCT05822258|OTHER|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
219027061|NCT00975481|DRUG|dimebon|Oral tablet; 40 mg dimebon, single dose
219500500|NCT05209061|OTHER|Biopsy|Participants included in the study, will have a full thickness biopsy of the middle of the appendix taken, after the resected bowel has been removed during surgery.
219500501|NCT01196481|DRUG|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
219500502|NCT01196481|PROCEDURE|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
219500503|NCT03074279|OTHER|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
219027062|NCT00975481|DRUG|dimebon|Oral tablet; 60 mg dimebon, single dose
219027063|NCT00975481|DRUG|placebo|Oral tablet or capsule; placebo, single dose
219500504|NCT01581762|PROCEDURE|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
219027064|NCT00975481|DRUG|alprazolam|Oral capsule; 1 mg alprazolam, single dose
219027065|NCT00975481|DRUG|alprazolam|Oral capsule; 3 mg alprazolam, single dose
219027066|NCT00643682|OTHER|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
219027067|NCT01248442|DRUG|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
219500505|NCT02151396|BEHAVIORAL|Working memory training|
219500506|NCT02151396|DEVICE|Functional magnetic resonance imaging (fMRI)|
219500507|NCT03883971|OTHER|3D printed model|Same as previously reported in arm descriptions
219500508|NCT03883971|OTHER|Placebo|nothing other than the ultrasound
219500509|NCT01335152|BEHAVIORAL|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
219500510|NCT00577954|PROCEDURE|Multimodal MRI|Multimodal MRI
219500511|NCT02623309|BIOLOGICAL|Allogeneic (Allo) hematopoietic stem cell transplantation|
219500512|NCT02390219|DRUG|Lumacaftor|
219500513|NCT02390219|DRUG|Ivacaftor|
219500514|NCT05564702|OTHER|traditional drug treatment|The patients in this arm will be given doctor specified dosage.
219500515|NCT05564702|OTHER|Opt-IVF predicted dosage|The patients in this arm will be given dosage predicted by Opt-IVF.
219027068|NCT01248442|DRUG|Placebo|Matching Placebo
219027069|NCT04846660|OTHER|Production pressure|Participant exposed to production pressure
219500516|NCT01169844|BIOLOGICAL|AIN457A|
219500517|NCT01169844|OTHER|Other|
219500518|NCT06271421|DEVICE|NanoTherm therapy|Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.
219500519|NCT06271421|PROCEDURE|Glioma Resection|Removal of brain tumor - gross total ressection
219605188|NCT01823835|DRUG|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
219605189|NCT01823835|DRUG|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
219027070|NCT03907293|BEHAVIORAL|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
219605190|NCT01823835|DRUG|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
219027071|NCT00206947|DRUG|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
219027072|NCT00206947|DRUG|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
219027073|NCT04311424|DRUG|14C Tirzepatide|Administered SC.
219027074|NCT01895855|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
219027075|NCT01895855|BIOLOGICAL|placebo|
219027076|NCT01079091|DEVICE|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
219027077|NCT01079091|PROCEDURE|Standard Medical Therapy|Standard of care treatment
219027078|NCT05736107|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
219500520|NCT06271421|RADIATION|radiotherapy according to Stupp protocol|The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.
219500521|NCT06271421|DRUG|chemotherapy according to Stupp protocol|Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
219500522|NCT00349310|DRUG|Pramipexole|
219500523|NCT04271683|PROCEDURE|Pressure controlled ventilation with PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
219500524|NCT04271683|PROCEDURE|Manual ventilation without PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
219500525|NCT00201929|PROCEDURE|Standard Decision Board|
219500526|NCT00201929|PROCEDURE|Computer Decision Board|
219500527|NCT00201929|PROCEDURE|Paper Decision Board|
219500528|NCT04736979|DRUG|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
219500529|NCT00754195|OTHER|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
219500530|NCT00271804|DRUG|bortezomib|
219500531|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
219500532|NCT05037409|DRUG|Placebo|Intravenous infusion
219500533|NCT00318344|DRUG|Atuna Racemosa|
219500534|NCT02611245|DRUG|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
219500535|NCT03843255|OTHER|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
219605191|NCT03639454|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
219605192|NCT03639454|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
219605193|NCT04780282|OTHER|Scapular Stabilization Group|Participants will apply the 5 exercises given.
219500536|NCT03843255|OTHER|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
219500537|NCT05358561|DIETARY_SUPPLEMENT|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
219500538|NCT01183845|PROCEDURE|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
219500539|NCT00472706|PROCEDURE|excision|excision 3 mm margin
219500540|NCT00472706|PROCEDURE|Photodynamic therapy|Photodynamic therapy
219500541|NCT05514028|OTHER|Salivary samples|"For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)"
219500542|NCT06097611|DRUG|Tranexamic Acid administration|Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
219500543|NCT03418077|DIETARY_SUPPLEMENT|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
219605194|NCT03115268|BEHAVIORAL|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
219605195|NCT05612373|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
219605196|NCT03017612|DEVICE|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
219605197|NCT04216667|PROCEDURE|Catheter ablation|Catheter ablation
219605198|NCT01682486|DEVICE|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
219605199|NCT01682486|PROCEDURE|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
219605200|NCT01595763|OTHER|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
219605201|NCT07154446|DRUG|Parestat(generic parecoxib)|This arm will receive IV Parestat 40mg during surgery
219605202|NCT07154446|DRUG|Dynastat (original Parecoxib)|This arm will receive IV Dynastat 40mg during surgery
219605203|NCT07153822|DEVICE|Collagen-based adhesion barrier|Porcine Atelocollagen (Type I)
219605204|NCT07153822|DEVICE|Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier|Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)
219605205|NCT07167719|BEHAVIORAL|Cognitive Behavioral Therapy|Brief Cognitive-Behavioral Therapy (CBT) focused on building resiliency in response to the effects of institutionalization
219605206|NCT07161258|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
219605207|NCT07170085|OTHER|positioning|The children will be positioned in the supine and prone position
219605208|NCT07169188|DRUG|Test Fluoride Toothpaste|Toothpaste containing 0.454% SnF2, 0.3% zinc chloride (ZnCl2) and 1% alumina.
219605209|NCT07169188|DRUG|Colgate Cavity Protection Toothpaste|Regular fluoride toothpaste containing 0.76% sodium monofluorophosphate.
219027079|NCT05736107|OTHER|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
219027080|NCT06320145|DEVICE|Cryotherapy|This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
219027081|NCT06320145|OTHER|core stability exercises|core stability exercises
218880889|NCT05314907|OTHER|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
218880890|NCT00709072|BEHAVIORAL|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
219027082|NCT01069146|PROCEDURE|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
219027083|NCT01169610|DRUG|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
219027084|NCT03755414|PROCEDURE|Stem cell transplantation|Standard of care
219027085|NCT03755414|DRUG|Itacitinib|Itacitinib may be taken without regard to food.
219027086|NCT03755414|OTHER|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
219500544|NCT03418077|DIETARY_SUPPLEMENT|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
219500545|NCT00165854|DRUG|E7070|
219500546|NCT02115737|BEHAVIORAL|Dialectical Behavior Therapy Skills Group|
219500547|NCT02115737|BEHAVIORAL|Psychoeducation group treatment|
219500548|NCT03299530|OTHER|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
219500549|NCT02964728|DRUG|Botulinum Neurotoxin Type A|topical injection
219605210|NCT07174258|OTHER|Manual myofascial release group|Manual myofascial release techniques were applied to Group I on the feet, legs, and thighs, twice a week for 4 weeks.
219605211|NCT07174258|OTHER|Graston group|Graston was applied to the gastrocnemius and hamstring muscles, and before the application, solid petroleum jelly was applied to the area to lubricate the surface. A stainless steel Graston instrument was used for the application, using a superficial sweep technique at a 30-degree angle for 2 minutes, followed by a deep sweep for 30 seconds.
219027087|NCT03755414|OTHER|Human Activity Profile|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
218880891|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
218880892|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
218880893|NCT06269939|BEHAVIORAL|STEM|Memory technique training
219027088|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
219500550|NCT02964728|OTHER|Normal saline|topical injection
219500551|NCT03755700|DRUG|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
219500552|NCT03755700|DRUG|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
219500553|NCT03755700|DRUG|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
219500554|NCT03755700|DRUG|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
219500555|NCT03755700|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
219500556|NCT02588131|DRUG|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
219500557|NCT01289938|DRUG|Diphenhydramine|Diphenhydramine 50 mg oral once
219500558|NCT01289938|DRUG|Metoclopramide|10 mg i.v. metoclopramide once
219500559|NCT01773278|DRUG|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
218880894|NCT06028009|PROCEDURE|Injection of platelet-rich plasma|Injection of autologous platelet-rich plasma into anterior vaginal wall
218880895|NCT06028009|PROCEDURE|Injection of saline|Injection of sterile normal saline into anterior vaginal wall
218880896|NCT04878913|DRUG|C21|C21 was administered in the VP-C21-006 trial
218880897|NCT04878913|DRUG|Placebo|Placebo was administered in the VP-C21-006 trial
218880898|NCT03019718|OTHER|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
218880899|NCT04734145|DIAGNOSTIC_TEST|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
219027089|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
219027090|NCT01682902|DRUG|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
219027091|NCT01818154|OTHER|LED phototherapy|
219027092|NCT01818154|OTHER|narrowband UVB phototherapy|
219500560|NCT01773278|DRUG|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
219500561|NCT02056405|DRUG|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
219500562|NCT02056405|DRUG|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
218880900|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
219027093|NCT06536803|OTHER|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
219027094|NCT06536803|OTHER|high-load strength training with routine physiotherapy|high load strength training with routine physiotherapy for 12 weeks
219027095|NCT03597958|GENETIC|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
219027096|NCT04039412|DRUG|Hybrid regimen|two-step (dual-quadruple) treatment
219027097|NCT04039412|DRUG|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
219027098|NCT04039412|DRUG|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
219027099|NCT00014677|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
219027100|NCT00014677|PROCEDURE|conventional surgery|
219027101|NCT02046460|DRUG|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
219027102|NCT02046460|DRUG|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
219500563|NCT03503656|DEVICE|epidural catheter placement|insertion of an epidural catheter using Compuflo System
219500564|NCT02348970|DEVICE|ONIRIS®|sleeping test
219500565|NCT02348970|DEVICE|TALI|sleeping test
219500566|NCT02669628|PROCEDURE|Surgical technique|Laparoscopic surgery
219500567|NCT02669628|PROCEDURE|Alcohol sclerotherapy|US-guided sclerotherapy
219500568|NCT04676516|DRUG|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
219500569|NCT00529568|DRUG|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
219500570|NCT00529568|DRUG|placebo|double-blind matched placebo control daily oral administration
219500571|NCT04446832|OTHER|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
219500572|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
219500573|NCT00796211|DRUG|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
219500574|NCT00796211|DRUG|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
219500575|NCT00796211|DRUG|Nortriptyline|0.1% nortriptyline HCl topical cream
219500576|NCT00796211|DRUG|Calcipotriol|0.005% calcipotriol topical cream
219500577|NCT00796211|OTHER|Placebo|Vehicle of CRx-197 topical cream (placebo)
219500578|NCT01201356|DRUG|Fingolimod|0.5 mg/day
219500579|NCT01210742|DEVICE|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
219500580|NCT01210742|OTHER|Routine management|Routine non-operative management for knee OA (NICE guidelines)
219500581|NCT01783899|DEVICE|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
219500582|NCT00931385|DRUG|BI 1744|BI1744 Respimat Med Dose Once Daily
219500583|NCT00931385|DRUG|bi1744|1744 low dose
219500584|NCT00931385|DRUG|Placebo|Placebo Respimat and Foradil Placebo
219500585|NCT00931385|DRUG|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
219500586|NCT04401787|PROCEDURE|Anterior resection for upper rectal cancer in obese|Anterior resection for upper rectal cancer in obese
219027103|NCT05810792|DRUG|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
219027104|NCT05810792|DRUG|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
219027105|NCT00944450|DRUG|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
219027106|NCT00944450|DRUG|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
219605212|NCT07174258|OTHER|Home based exercise group|Group III received a home exercise program that included stretching exercises. They were asked to perform the exercises twice a week for four weeks, with 15-20 repetitions, without any intervention from a physiotherapist.
219200613|NCT06864923|OTHER|Hot foot bath application group|The intervention group will receive hot foot baths for three consecutive nights starting from the second day of hospitalization. The foot bath will be applied one hour before the patient goes to bed at night. The foot tub will be filled with hot water to approximately 20 cm above the patient's ankle and the temperature of the water will be measured with a water thermometer. The temperature of the water will be kept stable at 41-42°C. This application will be done for 20 minutes. The sleep and fatigue levels of the patients will be measured with measurement tools in the morning (3 times) following each application.
219200614|NCT06863350|DEVICE|patent foramen ovale closure|patent foramen ovale closure
219200615|NCT06864312|DRUG|continuous infusion of levobupivacaine|patients one arm of this study will receive a postoperative continuous infusion of levobupivacaine
219200616|NCT06864312|DRUG|oxycodone|A timed weight appropriate dose of oxycodone will be administered 16 hours postoperatively
219200617|NCT06863675|DEVICE|HAL lenses for children with strabismus|It has been shown that peripheral segmented defocus spectacles can slow myopia progression. The Essilor® Stellest™ lens has been designed with an exclusive and pioneering technology called HALT (Highly Aspherical Lenslet Target). The HALT technology is made of a constellation of 1,021 invisible lenslets. This constellation creates a signal in front of the retina that acts as a shield against eye elongation and, therefore, myopia progression. Studies suggest that children are tolerable against these glasses, and the lenses can slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day. It can be considered as one of the best available myopia control spectacle lens designs, being superior to progressive addition and bifocal lenses.
219200618|NCT06863675|DEVICE|SVL for children with strabismus|SVL for children with strabismus
219500587|NCT00034515|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|
219500588|NCT05215041|OTHER|Non intervention|If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
219605213|NCT07172763|DEVICE|Siliconepad|Plantar pressure measurement
219605214|NCT07172763|DEVICE|Felted foam|Plantar pressure measurement
219605215|NCT07175441|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
219605216|NCT07175441|DRUG|STRIDE (durvalumab + tremelimumab)|STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks
219605217|NCT07177937|DRUG|DXC014|Dose Escalation DXC014, Cohort Expansion DXC014
219605218|NCT07179185|DIAGNOSTIC_TEST|AI-Assisted ECG Interpretation (AI-ECG)|Neural network-based AI software that analyzes ECG tracings and provides a classification as normal suggestion to the interpreting specialist.
219027107|NCT06142435|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
219027108|NCT01718652|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
219500589|NCT03360656|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
219605219|NCT07179185|DIAGNOSTIC_TEST|Specialist ECG Interpretation Without AI|Manual interpretation of ECGs by specialists without AI support, following standard diagnostic procedures
219027109|NCT01718652|DRUG|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
219027110|NCT03019939|DRUG|Isavuconazole|Given PO or IV
219027111|NCT04988711|DIAGNOSTIC_TEST|Hb Oxymeter|Measurement of Hb Oximeter
219200619|NCT06864884|DRUG|ARC-001|Gel formulation containing investigational anesthetic.
219200620|NCT06864884|DRUG|Placebo gel|Gel that contains no active ingredients.
219500590|NCT00952185|OTHER|cytology specimen collection procedure|
219500591|NCT00952185|OTHER|fluorescent antibody technique|
219500592|NCT00952185|PROCEDURE|assessment of therapy complications|
219605220|NCT07179302|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|evaluate the role of the left atrial coupling index (LACI) and left ventricular speckle tracking echocardiography (LVSTE) in enhancing outcome prediction in patients undergoing TAVI.
219500593|NCT04612205|DEVICE|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
219500594|NCT04612205|OTHER|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
218880901|NCT03575611|PROCEDURE|Biopsy|Undergo tumor biopsy
218880902|NCT03575611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219605221|NCT07185451|DEVICE|tACS|"This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity.~Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients."
219605222|NCT07185451|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
219605223|NCT07185529|OTHER|Data of the patients were obtained from patient observation files and hospital information system database.|Data of the patients were obtained from patient observation files and hospital information system database.
219605224|NCT07185698|DIAGNOSTIC_TEST|3D Ultrasound|Virtual Organ Computer-aided AnaLysis (VOCAL) to assess flow and velocity characteristics of the urethral blood supply
219500595|NCT05781477|BEHAVIORAL|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
219500596|NCT02129530|BEHAVIORAL|Community Social Mobilization program|
219500597|NCT05700929|BEHAVIORAL|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
219500598|NCT05587478|DRUG|EDP-323|Oral administration
218880903|NCT03575611|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219500599|NCT05587478|DRUG|Placebo|Placebo to match EDP-323, oral administration
219200621|NCT06863415|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
219200622|NCT06863415|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
218880904|NCT03575611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218880905|NCT03575611|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218880906|NCT03575611|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218880907|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
218880908|NCT05476172|DRUG|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
218880909|NCT05476172|DRUG|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
218880910|NCT03265340|DEVICE|dTMS|
218880911|NCT01458418|DRUG|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
218880912|NCT01458418|OTHER|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
218880913|NCT01458418|DRUG|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
218880914|NCT05168020|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
218880915|NCT05168020|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
218880916|NCT02389036|DRUG|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
219500600|NCT02619734|BIOLOGICAL|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
218880917|NCT02389036|DRUG|SDD Gastric Suspension|2\. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
218880918|NCT02389036|DRUG|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
218880919|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
218880920|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
218880921|NCT00286494|DRUG|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
218880922|NCT04776317|BIOLOGICAL|ChAdV68-S|Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
218880923|NCT04776317|BIOLOGICAL|ChAdV68-S-TCE|Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
218880924|NCT04776317|BIOLOGICAL|SAM-LNP-S|Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
218880925|NCT04776317|BIOLOGICAL|SAM-LNP-S-TCE|Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
218880926|NCT04776317|OTHER|Sodium Chloride, 0.9%|The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
218880927|NCT05257824|DRUG|Aspirin 100mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
219500601|NCT05162885|PROCEDURE|Socket Preservation technique|Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama\&salama Class 3 labial wall defect
219500602|NCT00811070|DRUG|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
218880928|NCT05257824|DRUG|Clopidogrel 75mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
218880929|NCT04207060|DRUG|Indomethacin|One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
219027112|NCT03644745|BEHAVIORAL|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
219200623|NCT06864078|DEVICE|IUD Insertion during Cesarean Section|to evaluate the analgesic effect of diclofenac potassium and lidocaine gel applied to the posterior vaginal fornix before IUD insertion in women who had previously undergone cesarean section. By assessing the efficacy of this pain management strategy, this study seeks to contribute to the optimization of IUD insertion protocols, improving patient comfort and increasing the acceptance of this highly effective contraceptive method.
219200624|NCT06864078|DRUG|lidocaine gel and diclofenac potassium tablets|lidocaine gel and diclofenac potassium tablets
219200625|NCT06864078|DRUG|Placebo|Placebo
219500603|NCT04821492|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD expressed in absolute values as g/cm2 and T-scores
219500604|NCT03821324|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
219500605|NCT05907902|DRUG|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
219500606|NCT01364259|DRUG|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
219500607|NCT01364259|PROCEDURE|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
219500608|NCT03667625|OTHER|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
219200626|NCT06864793|DRUG|QL1012D|A single Subcutaneous injection, 225IU
219500609|NCT03667625|OTHER|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
219500610|NCT04662684|DRUG|Rivaroxaban 10 MG|No intervention
219500611|NCT06536829|OTHER|Myofacial release technique and sciatic nerve slider technique|Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
219500612|NCT06536829|OTHER|Myofacial release technique|0week,6 week, 12 weeks
219500613|NCT04070599|BIOLOGICAL|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
219500614|NCT00393835|DRUG|Azithromycin SR|
219500615|NCT04863326|BEHAVIORAL|Making Proud Choices|
219500616|NCT04863326|BEHAVIORAL|Business as usual|
219500617|NCT00812435|DRUG|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
219500618|NCT03917563|DEVICE|WATCHMAN LAA occluder|WATCHMAN LAA occluder
219500619|NCT01101581|DRUG|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).
219500620|NCT01101581|DRUG|90Y-epratuzumab tetraxetan|
219500621|NCT01101581|DRUG|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
219500622|NCT05182983|OTHER|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
219500623|NCT04621097|DEVICE|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
219500624|NCT04621097|OTHER|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
219500625|NCT04621097|DRUG|Medication|regular medications
219500626|NCT02398500|BIOLOGICAL|LMG324|IVT injection
219500627|NCT02398500|BIOLOGICAL|Ranibizumab 0.5 mg|IVT injection
219500628|NCT02398500|BIOLOGICAL|Sham|Fake injection used for masking purposes
219500629|NCT04147481|OTHER|Group Abdominal Nerve Block with local anesthetics|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
219500630|NCT04147481|OTHER|Group Abdominal Nerve Block with saline|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
219500631|NCT04124978|DEVICE|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
219500632|NCT00198978|DRUG|Cyclophosphamide|
219500633|NCT00198978|DRUG|Dexamethasone / Prednisolone|
219500634|NCT00198978|DRUG|Cytarabine|
219500635|NCT00198978|DRUG|Idarubicin|
219500636|NCT00198978|DRUG|Granulocyte-Colony-Stimulating Factor|
219500637|NCT00198978|DRUG|Mercaptopurine|
219500638|NCT00198978|DRUG|Methotrexate|
219500639|NCT00198978|DRUG|Rituximab|
219500640|NCT00198978|DRUG|HDARAC|
219500641|NCT00198978|DRUG|Vincristine|
219200627|NCT06864793|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
219500642|NCT00198978|DRUG|Depocyte|
219500643|NCT00198978|DRUG|Asparaginase|
219500644|NCT04713228|DEVICE|ARTSENS Pen|ARTerial Stiffness Evaluation for Noninvasive Screening
219500645|NCT04444752|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
219500646|NCT04444752|DRUG|placebo|subcutaneous(SC) injection
219500647|NCT06528327|OTHER|Pre coated impants|Pre coated impants with microstructured bioactive antimicrobial coating with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
219500648|NCT06528327|OTHER|Non coated implant surface|Non-coated implant with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
219500649|NCT03625817|BEHAVIORAL|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having \>800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
219500650|NCT01305317|DRUG|Lipitor|Atorvastatin 20mg daily for 6 months
218880930|NCT04207060|DRUG|Placebo|One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
218880931|NCT04207060|PROCEDURE|Endoscopy for Pancreatic Function Testing|All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
218880932|NCT06025032|GENETIC|HG205|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
218880933|NCT00001894|PROCEDURE|pacemaker implantation|
219500651|NCT05256732|DRUG|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
219500652|NCT05256732|OTHER|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
219500653|NCT05256732|DRUG|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
219500654|NCT05256732|OTHER|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
219500655|NCT05256732|DRUG|AT-527|AT-527 administered twice daily (BID)
219500656|NCT05256732|DRUG|AT-527 single dose|AT-527 single dose fasted/fed cross-over
219500657|NCT01759537|DEVICE|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
219500658|NCT01759537|DEVICE|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
219500659|NCT06703905|PROCEDURE|Expanded pancreaticoduodenectomy surgery|Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
219500660|NCT06703905|PROCEDURE|Pancreaticoduodenectomy|Traditional minimally invasive pancreaticoduodenectomy
219500661|NCT01883518|BIOLOGICAL|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
219500662|NCT04510220|DRUG|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
219500663|NCT04510220|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
219500664|NCT03256175|PROCEDURE|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
219500665|NCT06009900|DEVICE|Low intensity laser treatment|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
219500666|NCT06009900|DRUG|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
219500667|NCT02334956|OTHER|Brain MRI|
219500668|NCT03833037|OTHER|Soft tissue sarcomas in adults|Adult sinovial sarcoma
219500669|NCT00251628|OTHER|Standard Care|standard care
219500670|NCT00251628|OTHER|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
219500671|NCT00251628|OTHER|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
219500672|NCT00251628|OTHER|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
219500673|NCT02270983|DRUG|Linaclotide 145 micrograms|
218880934|NCT00001894|PROCEDURE|percutaneous transluminal septal ablation (PTSA)|
219200628|NCT06863493|DRUG|SFA002|SFA002 760mg
219200629|NCT06863493|DRUG|Otezla|Oral Otezla 30mg
219200630|NCT06863493|DRUG|Placebo|Placebo will be matched to whichever drug is assigned when randomized
219200631|NCT06864897|DEVICE|Total hip prothesis|Total hip prothesis with a Delta-TT cup, H MAX S Stem and a ceramic liner
219500674|NCT02270983|DRUG|Linaclotide 290 micrograms|
219500675|NCT02270983|DRUG|Placebo|Matching placebo
219500676|NCT04317729|DEVICE|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
219500677|NCT02957786|DRUG|Cytisine|Cytisine tablets
219500678|NCT02957786|BEHAVIORAL|Behavioural support|Withdrawal-orientated cessation support
219500679|NCT02957786|DRUG|Varenicline|Varenicline tablets
219500680|NCT00124176|DRUG|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
219500681|NCT00124176|DRUG|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
218880935|NCT04085757|DRUG|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
219027113|NCT00916747|DRUG|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
219500682|NCT00226694|DRUG|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
219500683|NCT00226694|OTHER|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
219500684|NCT02926391|DEVICE|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
219500685|NCT00854620|DRUG|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
219500686|NCT01623830|BEHAVIORAL|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
219500687|NCT03058939|DRUG|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
219500688|NCT03058939|DRUG|Perjeta|Only administered to patients with HER2-positive disease.
219500689|NCT03058939|DRUG|Herceptin SC|Only administered to patients with HER2-positive disease.
219500690|NCT03058939|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
219500691|NCT03058939|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
219500692|NCT03058939|DRUG|LHRH agonist|Administered to all premenopausal patients.
219500693|NCT03058939|DRUG|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
219500694|NCT03058939|DRUG|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
219500695|NCT02468479|OTHER|No relevant intervention.|No relevant intervention.
219500696|NCT06172010|DRUG|Clindamycin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
219500697|NCT06172010|DRUG|Rifampicin and levofloxacin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
219500698|NCT00928252|DRUG|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
219500699|NCT06057285|DEVICE|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
219500700|NCT01904578|OTHER|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
219500701|NCT01904578|OTHER|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
219500702|NCT02519283|BEHAVIORAL|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
219500703|NCT02519283|BEHAVIORAL|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up."
219500704|NCT02754323|DEVICE|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
219500705|NCT05446090|DIAGNOSTIC_TEST|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
218880936|NCT04085757|DRUG|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
218880937|NCT06583746|OTHER|Group1|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
218880938|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
218880939|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
218880940|NCT03238625|DRUG|Lidocaine|Lidocaine injection
219605225|NCT07186985|COMBINATION_PRODUCT|Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy|"Group 1:~* Patients were instructed to identify and sense their pelvic floor muscles and to perform contraction-hold-relaxation exercises.~* Exercises were performed at a frequency of 8 sets per session, 3 sessions per week, progressing from the supine position (month 1), to sitting (month 2), and to standing (month 3). Training was monitored by an electronic diary app. (Appendix)~* Six individual 45-minute intervention sessions at the center using biofeedback, under the supervision of a physical therapy technician. (Appendix)~* The training program consisted of two parts: resistance training and pre-contraction training (the Knack technique). (Appendix)~* Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~* First 4 weeks: insert one 0.5 mg tablet nightly at bedtime.~* Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses"
219605226|NCT07186985|DRUG|Vaginal estrogen|"Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses."
218880941|NCT03238625|DRUG|Sodium cloride 0.9%|Placebo
218880942|NCT02524158|BEHAVIORAL|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
218880943|NCT05122091|DRUG|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
219027114|NCT01136850|DRUG|chloroquine, sulphadoxine pyrimethamine, LLIN|"\> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
219027115|NCT01136850|DRUG|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
219027116|NCT06317155|OTHER|Occupational therapy|Occupation Therapy, specifically interoception informed interventions which aim to improve sensory integration and emotional regulation. Additionally, occupational therapy models which focus on augmenting well-being and functionality, facilitating participation and engagement within communities, and promoting involvement in meaningful activity.
219027117|NCT02474992|BEHAVIORAL|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
219027118|NCT04367688|DRUG|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
219027119|NCT02295033|RADIATION|Boost irradiation|
219027120|NCT06415409|OTHER|Water|Plain water
219027121|NCT06415409|OTHER|Gatorade|Sport Drink Gatorade
219027122|NCT06415409|OTHER|BodyArmor|Sport Drink BodyArmor
219027123|NCT06415409|OTHER|GoodSport|Sport Drink GoodSport
219027124|NCT02496247|OTHER|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
219027125|NCT05221333|DEVICE|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
219027126|NCT02235142|OTHER|Blood sample|
219200632|NCT06864897|DEVICE|Total hip prosthesis|Total hip prosthesis with a Delta TT cup, H MAX S stem and polyethylene liner
219200633|NCT06863688|DEVICE|Tourniquet|Tourniquets will be applied to the thigh of the operative extremity during operative fixation of ankle fractures.
219200634|NCT06863688|OTHER|No Tourniquet|No tourniquet will be inflated on the operative extremity during the operative fixation of ankle fractures.
219200635|NCT06863207|DEVICE|Percutaneous electrical nerve field stimulation|Percutaneously nerve stimulator applied to the external auricle weekly for several consecutive weeks of therapy
218880944|NCT03671304|DEVICE|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
219605227|NCT07185386|DIETARY_SUPPLEMENT|combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus (Vesvein Gambe)|Although there is extensive clinical and pharmacological evidence regarding the activity of the individual components of the product, the specific effect of the fixed combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus as a single entity on quality of life in subjects with symptoms compatible with the early stages of Chronic Venous Disease (CVD) has not yet been explored.
219605228|NCT07186621|DRUG|Sintilimab|concurrent sintilimab 200mg q3w for 2 cycles followed by maintenance sintilimab 200mg q3w for 15 cycles (approximately 1 year total treatment duration) until disease progression or unacceptable toxicity
218880945|NCT05962892|OTHER|No Intervention|No Intervention
219027127|NCT03496948|BEHAVIORAL|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
219605229|NCT07186621|RADIATION|radiotherapy|The experimental group will initiate radiotherapy within 4 months postoperatively with prescribed doses of 44-50Gy in 22-25 fractions to the tumor bed and 56-60Gy in 22-25 fractions to narrow-margin areas adjacent to major blood vessels
219605230|NCT07186621|PROCEDURE|TACE|The control group will receive the first TACE procedure within 4 months postoperatively, with the decision on administering a second TACE to be determined by the investigator based on the patient's condition and first TACE response assessment.
218880946|NCT00626444|DRUG|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
218880947|NCT02718716|DRUG|UCB7665|"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
218880948|NCT04316637|DRUG|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
219027128|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
219027129|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
219027130|NCT05505357|PROCEDURE|Breast surgery omission|For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
219200636|NCT06863207|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy delivered via audio recordings
219200637|NCT06864247|OTHER|No Intervention: Observational Cohort|No intervention
219200638|NCT06863454|DIAGNOSTIC_TEST|Trichoscopy|Trichoscopy will be done on patients with PV disease activity and remission
219200639|NCT06864611|BEHAVIORAL|Pre-Game Safety Huddles|Before every regular season game, participating teams in league randomized to the Pre-Game Safety Huddle condition will hold brief Pre-Game Safety Huddles. Pre-Game Safety Huddles have three core components: (1) Gather (Athletes, coaches, officials, and other stakeholders come together before the start of the game); (2) Share (Opinion leaders (coaches, referees) affirm the importance of seeking care for suspected concussion, and (3) Repeat (Process is repeated before every game)
219200640|NCT06672679|BEHAVIORAL|Juntos|6 week family-based intervention
219500706|NCT05446090|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
219500707|NCT05446090|DIAGNOSTIC_TEST|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
219605231|NCT07185139|DRUG|MSCohi-O Lenses|Each subject will wear MSCohi-O Lenses for 12 hours a day, totally 14 wearings.
219605232|NCT07186088|DEVICE|Eyerising RS-200-2A|Eyerising RS-200-2A,1 time,2 times, 3 times a day
219605233|NCT07186088|DEVICE|Airdoc Sky-n1201|Eyerising RS-200-2A,2 times a day
218880949|NCT02707328|DRUG|Gemcitabine|
218880950|NCT02707328|DRUG|nab-paclitaxel|
218880951|NCT02707328|RADIATION|CyberKnife|
218880952|NCT03111953|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
219200641|NCT06672679|BEHAVIORAL|Resource guide|Active control arm will receive a resource guide
219200642|NCT06859931|DRUG|TQB3702 Tablets|TQB3702 is a selective kinase inhibitor.
218880953|NCT03111953|PROCEDURE|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
219605234|NCT07185048|BEHAVIORAL|Conventional Foot Care Control Group|Standard Foot Care with Regular Follow-up
219605235|NCT07185048|BEHAVIORAL|Digital Foot Care (Low-Intensity)|On the basis of routine management, the digital intervention modules will be added
219605236|NCT07185048|BEHAVIORAL|Digital Foot Care (Moderate-Intensity)|Further integration of AI image analysis for auxiliary judgment and remote physician response.
219605237|NCT07187102|OTHER|SNAG ( sustained natural apopheseal glide )|SNAG : type of mobilization of vertebral coulmn
219605238|NCT07186595|DEVICE|JUVÉDERM VOLUX XC|Injections
219605239|NCT07186595|DEVICE|JUVÉDERM VOLUMA XC|Injections
219605240|NCT07186595|DEVICE|JUVÉDERM VOLBELLA XC|Injections
219605241|NCT07186595|DEVICE|JUVÉDERM VOLLURE XC|Injections
219605242|NCT07186595|DEVICE|SKINVIVE by JUVÉDERM|Injections
219605243|NCT07186595|DEVICE|JUVÉDERM ULTRA XC|Injections
219605244|NCT07186595|DEVICE|JUVÉDERM ULTRA PLUS XC|Injections
219605245|NCT07184736|PROCEDURE|Active Manual Syringe Aspiration|For the Active Manual Syringe Aspiration, the operator manually withdraws pleural fluid using a syringe attached to a 3-way stopcock and transfusion set. The fluid is then expelled into a collection bag.
218880954|NCT00033553|DRUG|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
218880955|NCT00033553|DRUG|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
218880956|NCT00033553|DRUG|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
218880957|NCT00033553|RADIATION|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
219027131|NCT06241079|OTHER|non-intervention|non-intervention
219027132|NCT03343873|DRUG|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
219027133|NCT03343873|DRUG|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
219027134|NCT03343873|DRUG|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
219027135|NCT02360384|DRUG|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
219027136|NCT02360384|DIETARY_SUPPLEMENT|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
219027137|NCT01092182|DRUG|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
219200643|NCT06859931|DRUG|TQB3702 Tablets+TQB3702 Placebo|TQB3702 is a selective kinase inhibitor； A placebo is a simulated drug whose physical properties, such as appearance, size, color, dosage form, weight, taste, and odor are substantially the same as the test drug, but cannot contain the active ingredients of the test drug.
218880958|NCT05160376|OTHER|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
218880959|NCT05160376|OTHER|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
218880960|NCT03935243|BEHAVIORAL|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
219027138|NCT01092182|DRUG|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
219027139|NCT01620710|RADIATION|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
219027140|NCT01620710|RADIATION|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
219200644|NCT06859931|DRUG|TQB3702 Placebo|TQB3702 Placebo without drug substance.
219605246|NCT07184736|PROCEDURE|Passive Gravity Drainage|In Passive Gravity Drainage, after confirming proper needle placement with initial aspiration, the syringe is detached, and pleural fluid is allowed to drain passively by gravity through the transfusion set into a collection bag.
219605247|NCT07186153|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors
219605248|NCT07186816|DEVICE|Behavioral: Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
219605249|NCT07186816|DEVICE|Behavioral: Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
219605250|NCT07186933|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
219500708|NCT05446090|PROCEDURE|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
219500709|NCT05446090|DIAGNOSTIC_TEST|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
219500710|NCT05446090|DIAGNOSTIC_TEST|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
219500711|NCT05446090|DIAGNOSTIC_TEST|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
219500712|NCT05446090|DIAGNOSTIC_TEST|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
219500713|NCT05446090|DIAGNOSTIC_TEST|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
219500714|NCT05446090|OTHER|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
219500715|NCT05446090|OTHER|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
219605251|NCT07186933|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
219605252|NCT07185347|DRUG|Fampridine 10 mg prolonged-release tablet (per os)|Patients randomized in the experimental arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
219605253|NCT07185347|DRUG|Placebo (tablets per os)|Patients randomized in the control arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
219605254|NCT07186829|DEVICE|Percutanous pinning|Similar to arm - closed reduction, two percutaneous pins
219605255|NCT07186829|DEVICE|Locked plate|Similar to arm - open reduction, dorsal approach, 3 screws proximal and distal
218880961|NCT03935243|BEHAVIORAL|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
218880962|NCT01683825|DRUG|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
218880963|NCT00296140|BEHAVIORAL|self management of PSD symptoms|
219200645|NCT06858969|DRUG|Treatment group|Chidamide+XELOX + Bevacizumab+PD-1
219605256|NCT07186829|DEVICE|Intramedullary screw|Similar to arm - 1 cm dorsal incision, closed reduction, internal compression screw
219605257|NCT07185542|PROCEDURE|Superficial parotidectomy|Superficial parotidectomy (SP), the traditional approach, involves facial nerve dissection and removal of the superficial lobe. Though effective, it carries risks like nerve dysfunction, Frey's syndrome, and cosmetic concerns
218880964|NCT00296140|PROCEDURE|screening and treatment of PSD|
218880965|NCT03612765|BEHAVIORAL|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
218880966|NCT03124082|DRUG|Remifentanil|continuous infusion intraop
218880967|NCT03124082|DRUG|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
218880968|NCT03124082|DRUG|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
218880969|NCT03124082|DRUG|Clonidine|clonidine 4 mcg/kg
218880970|NCT01651871|DRUG|S-555739 Dose 1|
218880971|NCT01651871|DRUG|S-555739 Dose 2|
218880972|NCT01651871|DRUG|Cetirizine HCl Dose 1|
218880973|NCT01651871|DRUG|S-555739 placebo|
218880974|NCT01651871|DRUG|Cetirizine HCl placebo|
218880975|NCT02338050|BIOLOGICAL|Moxetumomab Pasudotox|
218880976|NCT01856582|BIOLOGICAL|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
218880977|NCT03144375|OTHER|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
218880978|NCT03144375|PROCEDURE|Standard of Care sinus surgery|
218880979|NCT04165603|PROCEDURE|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
218880980|NCT02596789|DEVICE|"TMS Magpro®, Magventure Inc device"|
218880981|NCT05318872|DEVICE|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
218880982|NCT04871958|DEVICE|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
219027141|NCT01563718|DRUG|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
219500716|NCT05446090|OTHER|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
219500717|NCT05446090|OTHER|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
219500718|NCT05446090|OTHER|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
219500719|NCT05446090|OTHER|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
219605258|NCT07185542|PROCEDURE|Intracapsular parotidectomy (ICP)|"ICP excises the tumor along its capsule without dissecting the facial nerve, thereby minimizing trauma and preserving glandular tissue.~ICP is recommended for small, mobile, and superficially located benign tumors with low suspicion of malignancy. However, concerns remain regarding capsular rupture and recurrence, particularly in pleomorphic adenomas with microscopic extensions"
219605259|NCT07186907|DEVICE|Hydrocolloid dressing|Hydrocolloid dressing was used for diaper dermatitis
219605260|NCT07186907|DRUG|Zinc oxide cream %40|Zinc oxide cream was used in diaper dermatitis.
218880983|NCT02805855|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
218880984|NCT03359252|PROCEDURE|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
218880985|NCT03359252|PROCEDURE|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
218880986|NCT00596830|DRUG|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
218880987|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
218880988|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
218880989|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
219027142|NCT01831154|DRUG|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
219500720|NCT05446090|OTHER|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
219500721|NCT05446090|OTHER|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
219500722|NCT02732587|DRUG|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
219605261|NCT07187284|COMBINATION_PRODUCT|EDN combined with TACE/HAIC and Immuno-Targeted Therapy|"Experimental Intervention (Treatment Group):~This arm evaluates a novel combination strategy. Participants will undergo a single session of Endovascular Denervation (EDN) in conjunction with standard care. The complete intervention includes:~Endovascular Denervation (EDN): A one-time, catheter-based percutaneous procedure for the ablation of peri-arterial sympathetic nerves surrounding the common hepatic artery and/or proper hepatic artery. The procedure utilizes a multi-electrode radiofrequency ablation system (e.g., Netrod®). Ablation parameters are set to 60°C for 120 seconds per site, with a minimum of 20 ablations performed to ensure adequate denervation.~On-demand Transarterial Intervention: Following EDN, participants will receive either Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC), as determined by the treating investigator based on individual patient anatomy and tumor characteristics."
218880990|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
219500723|NCT03695133|BEHAVIORAL|Group-based interventions|"1. Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~2. Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
219500724|NCT06205199|DRUG|Hydromorphone was injected into the subarachnoid space|The dose of hydromorphone is 50 micrograms
219500725|NCT06401200|OTHER|bar retained implant overdenture|use of bar attachment in completely edentulous patient
219500726|NCT02609737|DEVICE|PET/CT Imaging|
219500727|NCT02609737|RADIATION|68Ga-DOTA-JR11|
219500728|NCT02609737|RADIATION|177Lu-DOTA-JR11|
219500729|NCT04047212|DIAGNOSTIC_TEST|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
219500730|NCT04047212|DIAGNOSTIC_TEST|periodontal examination|Periodontal clinical examination to all by periodontal charting
219500731|NCT04543981|DIAGNOSTIC_TEST|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
219500732|NCT00526695|DRUG|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
219500733|NCT06215781|PROCEDURE|Fully digital workflow of prosthetic fixed dental crown|The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
219500734|NCT06215781|PROCEDURE|Combined digital and conventional workflows of prosthetic fixed dental crown|The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
219500735|NCT06215781|PROCEDURE|Fully conventional workflow of prosthetic fixed dental crown|The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
219500736|NCT01605461|DRUG|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
219500737|NCT04296383|DRUG|Azithromycin plus Xiyanping injection|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
219500738|NCT04296383|DRUG|Azithromycin|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
219500739|NCT05730777|DRUG|Bifidobacterium Bifidum Oral Capsule|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
219500740|NCT05730777|DRUG|Cisplatin|Patients in the control group will receive conventional antitumor treatment only.
219500741|NCT05730777|DRUG|Carboplatin|Patients in the control group will receive conventional antitumor treatment only.
219500742|NCT05730777|DRUG|Paclitaxel|Patients in the control group will receive conventional antitumor treatment only.
218880991|NCT00964821|BIOLOGICAL|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
218880992|NCT00964821|OTHER|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
218880993|NCT00964821|OTHER|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
219500743|NCT05730777|DRUG|Atlizumab|Patients in the control group will receive conventional antitumor treatment only.
219500744|NCT00530400|DRUG|cefuroxime|preoperative intravenous 1.5g cefuroxime
218880994|NCT00236236|DEVICE|Cardiac Resynchronization Therapy|
218880995|NCT04617730|DEVICE|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
218880996|NCT04617730|OTHER|Flamigel®|The control arm will be treated according to the standard of care.
219500745|NCT00530400|DRUG|placebo|preoperative intravenous placebo
219500746|NCT01226147|DRUG|Tamibarotene|4mg/day for 24 weeks.
219500747|NCT05611268|DRUG|Pentoxifylline|Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
219500748|NCT02024698|DEVICE|omafilcon A|contact lens
219500749|NCT02024698|DEVICE|etafilcon A|contact lens
219500750|NCT06090747|BEHAVIORAL|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
218880997|NCT04619732|DIAGNOSTIC_TEST|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
218880998|NCT05538676|DIAGNOSTIC_TEST|BPA-PET imaging|PET imaging
218880999|NCT01645410|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
218881000|NCT01428739|DEVICE|MRS|Procedure
219200646|NCT06858969|DRUG|Standard-of-care control group|XELOX + Bevacizumab+PD-1
218881001|NCT05539313|DEVICE|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
218881002|NCT01919801|DRUG|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
218881003|NCT01919801|DRUG|Placebo|
218881004|NCT01843062|DRUG|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
219500751|NCT06090747|BEHAVIORAL|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
219500752|NCT05610605|OTHER|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
219500753|NCT06383377|DEVICE|Tooth extraction and bone graft procedure|"The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated."
219500754|NCT06147219|PROCEDURE|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
219500755|NCT05079854|DRUG|Intraocular Instillation Solution|Intracameral Moxifloxacin 0.5%
219500756|NCT05079854|DRUG|Moxifloxacin Ophthalmic|Topical Moxifloxacin 0.5%
219500757|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
219500758|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
219500759|NCT04158856|DRUG|Pyrotinib|400mg po every day
219605262|NCT07187284|COMBINATION_PRODUCT|TACE/HAIC plus Immuno-Targeted Therapy|This is the active comparator intervention representing the current standard-of-care regimen for the study population. Participants randomized to the control group will receive a combination of locoregional and systemic therapy, specifically excluding the experimental Endovascular Denervation (EDN) procedure.
219605263|NCT07186452|DRUG|HS-20093|All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.
219605264|NCT07186452|DRUG|Itraconazole|Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21
219605265|NCT07185477|BIOLOGICAL|QLS32015|QLS32015 is a GPRC5D × CD3 bispecific antibody.
218881005|NCT01843062|DRUG|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
218881006|NCT01843062|DRUG|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
218881007|NCT04569227|DRUG|EC-18|2000 mg PO daily
219027143|NCT01831154|DRUG|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
219027144|NCT01831154|DRUG|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
218881008|NCT04569227|DRUG|Placebo|PO daily
218881009|NCT01677858|DRUG|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
218881010|NCT01677858|DRUG|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
218881011|NCT00481923|DRUG|rimonabant (SR141716)|
219027145|NCT05297825|BEHAVIORAL|Vegan diet|Healthy vegan diet.
219027146|NCT05297825|BEHAVIORAL|Omnivore diet|Healthy omnivore diet.
219027147|NCT02591147|DEVICE|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
219027148|NCT02591147|DEVICE|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
219027149|NCT01254526|DRUG|GDC-0980|Oral repeating dose
219027150|NCT01254526|DRUG|bevacizumab|Intravenous repeating dose
219027151|NCT01254526|DRUG|paclitaxel|Intravenous repeating dose
219027152|NCT01879774|OTHER|Neuropsychological and motoric tests|"1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)"
219605266|NCT07186608|DIETARY_SUPPLEMENT|Dietary fiber intervention|Ten patients with short bowel syndrome in clinical practice were subjected to dietary fiber intervention. Blood and fecal samples were collected before and after the dietary fiber intervention, and nutritional and intestinal barrier-related indicators were also collected to observe the improvement effect of dietary fiber on these patients.
219605267|NCT07187024|BEHAVIORAL|mCare PTOA Intervention|The mCare PTOA intervention includes five evidence-based modules that focus on 1) basic joint health following injury, 2) self-management strategies, 3) weight management, 4) physical activity, and 5) occupational management. These educational modules will serve as the primary intervention in this study.
219605268|NCT07185880|DRUG|MT-125|This is an investigational new drug under IND 170975.
219500760|NCT04158856|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
219605269|NCT07185854|DRUG|Artificial tears|Topical artificial tears were administered as standard therapy for moderate dry eye disease.
219605270|NCT07185854|OTHER|Traditional Chinese Medicine Acupuncture|Acupuncture therapy performed by a certified specialist using sterile disposable needles at predefined local and systemic acupoints (BL2, ST1, GB1, SJ23, Ex-HN5, LI4, ST36, SP6, LIV3, GB37, GB40, Ex-HN3, Du23, BL64). Sessions were delivered twice weekly for a total of 10 sessions, each lasting 20 minutes. Deqi sensation was obtained by manual stimulation. No additional systemic or topical treatments were provided to participants in this arm.
219605271|NCT07184775|DEVICE|Continuous glucose monitor|Continuous glucose monitors are sensors that detect interstitial blood glucose measurements and relay values from their sensor to a receiver (typically a cell phone) to document values every 5 minutes.
218881012|NCT02893696|OTHER|Various sitting time|Various sitting time
219500761|NCT02855190|OTHER|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
219500762|NCT00740727|DRUG|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
219500763|NCT00740727|PROCEDURE|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
219500764|NCT01360957|DIETARY_SUPPLEMENT|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
219500765|NCT04364165|BEHAVIORAL|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
219500766|NCT04364165|BEHAVIORAL|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
219500767|NCT01080027|DRUG|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
219500768|NCT06484192|DRUG|Naproxen 500 Mg|participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
219500769|NCT06484192|DRUG|Ketorolac|participants will receive Ketorolac (15 mg) immediately after surgery
219500770|NCT06484192|DRUG|OxyCODONE 5 mg Oral Tablet|participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
219500771|NCT06484192|DRUG|Metaxalone 800 MG|participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
219500772|NCT02370784|DRUG|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
219605272|NCT07184775|DEVICE|Glucometer|Glucometer measurement involves a patient performing a finger stick with a lancet to draw blood. They then apply blood to a test strip which is analyzed by a glucometer. The glucose measurement provided by the glucometer is then recorded by the patient in a glucose log.
219605273|NCT07185490|BIOLOGICAL|CT103d|CT103d is a personalized, BCMA-targeted, genetically modified autologous T-cell immunotherapy product.
219605274|NCT07185061|DEVICE|Acoustic Stimulation|Using hearing loss detection and tinnitus matching data as input parameters, the system automatically generates personalized sound stimulation audio signals through composite signal amplitude, frequency, phase control processing, and notch filtering. The audio tone is fine-tuned based on the patient's initial treatment response to identify their most comfortable range.
219605275|NCT07184606|DRUG|¼ of the full (target) dose (solution, 5 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug (parenteral administration)."
219605276|NCT07184606|DRUG|½ of the full (target) dose (solution, 10 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ½ of the full (target) dose of the study drug (parenteral administration)."
219605277|NCT07184606|DRUG|full dose (solution, 20 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive full (target) dose of the study drug (parenteral administration)."
218881013|NCT01472068|DEVICE|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
218881014|NCT02669212|BEHAVIORAL|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
219200647|NCT06859814|PROCEDURE|urinary catheterization|urine samples for culture and sensitivity will be collected in patients having urinary tract infection and we will use sterile container 50cc for urine sampling culture on blood or macconkey medium for detection type of organism .
219500773|NCT02370784|DRUG|Placebo|oral drug of similar appearance to atorvastatin
219500774|NCT04366388|DEVICE|ActivPAL3 VT (PAL Technologies Ltd).|. The ActivPAL will be fitted by a trained research assistant on the mid-thigh of the participants' dominant leg. ActivPALs have an inclinometer that detects the joint angle of the thigh to capture lying, sitting, standing, and stepping activities.
219500775|NCT03100253|DRUG|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
219500776|NCT03100253|DRUG|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
219500777|NCT03100253|DRUG|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
219500778|NCT03100253|DRUG|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
219500779|NCT03100253|DRUG|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
219500780|NCT03100253|DRUG|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
219500781|NCT03645083|BEHAVIORAL|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
219500782|NCT03645083|BEHAVIORAL|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
219500783|NCT03639597|DEVICE|VytronUS Ablation System|
219500784|NCT04126057|DEVICE|SightGlass Vision DOT Spectacle Lenses|Subjects randomized to test vs control, left eyes and right eyes
219500785|NCT03072836|OTHER|analysing microbiota|16SRNA gene sequencing of feces
219500786|NCT00680576|BEHAVIORAL|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
219500787|NCT00680576|BEHAVIORAL|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
219500788|NCT02658682|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
219500789|NCT02658682|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
219500790|NCT03953781|DRUG|Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males|
219500791|NCT03953781|DRUG|Effect of levetiracetam on epileptic males reproductive function|
219500792|NCT03096613|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
219500793|NCT03501784|DEVICE|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
219500794|NCT03501784|DEVICE|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
219500795|NCT02367079|DEVICE|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
219500796|NCT04262375|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
219027153|NCT04703439|BEHAVIORAL|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
219027154|NCT04703439|BEHAVIORAL|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
219027155|NCT03451318|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
219027156|NCT03451318|PROCEDURE|tonsillar adenoidectomy|tonsillar adenoidectomy
219500797|NCT04262375|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
219500798|NCT03246568|PROCEDURE|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
219500799|NCT03246568|PROCEDURE|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
219500800|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
219500801|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
219500802|NCT01110980|OTHER|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
219500803|NCT01110980|OTHER|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
219500804|NCT02706002|DEVICE|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
219500805|NCT02706002|PROCEDURE|hip prosthesis|all patients in the study will undergo hip prosthesis
219500806|NCT00929903|DRUG|pazopanib hydrochloride|Given orally
219500807|NCT00929903|OTHER|pharmacological study|Correlative studies
219500808|NCT05816733|DRUG|Dapagliflozin|Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
219500809|NCT05816733|DRUG|Placebo|Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
219027157|NCT03451318|PROCEDURE|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
219027158|NCT02515045|DRUG|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
219500810|NCT04813900|OTHER|Lung ultrasound|Lung ultrasound in order to calculate lung ultrasound score
219500811|NCT05153356|DEVICE|Personal Kinetigraph, Kinesia 360|10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
218881020|NCT00828763|DRUG|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
218881021|NCT05034601|PROCEDURE|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
218881022|NCT05034601|PROCEDURE|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
218881023|NCT00275067|DRUG|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
218881024|NCT00275067|DRUG|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
218881025|NCT00275067|RADIATION|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
218881026|NCT03549104|BEHAVIORAL|Fear Reduction Intervention|FREE
218881027|NCT03549104|BEHAVIORAL|Attention Control|DSMES
219027159|NCT02515045|DRUG|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
219027160|NCT02515045|DRUG|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
219027161|NCT02515045|DRUG|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
219027162|NCT04552392|OTHER|No intervention|No intervention
219500812|NCT06402747|DRUG|Clopidogrel|Clopidogrel 75mg once daily
219500813|NCT06402747|DRUG|Cilostazol|Cilostazol 200mg per day
219500814|NCT03358394|BEHAVIORAL|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
219500815|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
219500816|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
219500817|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
219027163|NCT03724409|DRUG|[90]Y-DOTATOC|Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
219027164|NCT02448654|DRUG|Tolcapone|Tolcapone will be compared to sugar pill
219027165|NCT02448654|DRUG|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
219027166|NCT03305328|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
219027167|NCT01782664|DRUG|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
219027168|NCT01782664|DRUG|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
219027169|NCT01782664|DRUG|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
219027170|NCT01782664|DRUG|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
219027171|NCT00985842|DEVICE|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
219500818|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
219500819|NCT04398394|DEVICE|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
219500820|NCT01858246|DEVICE|Bonebridge|
219500821|NCT01858246|DEVICE|Bone Anchored Hearing Aid|
219500822|NCT04202302|PROCEDURE|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
219500823|NCT03641118|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
219500824|NCT05760079|DIETARY_SUPPLEMENT|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
219500825|NCT00693784|BIOLOGICAL|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
219500826|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine A dose|Inactivated vaccine against EV71, three doses, 28 days interval
219500827|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine B dose|Inactivated vaccine against EV71, three doses, 28 days interval
219500828|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine C dose|Inactivated vaccine against CVA16, three doses, 28 days interval
219500829|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine D dose|Inactivated vaccine against CVA16, three doses, 28 days interval
219500830|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine E dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
219500831|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine high dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
219500832|NCT04182932|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
219605278|NCT07184606|DRUG|1 ½ of the full (target) dose (solution, 30 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug (parenteral administration)."
219500833|NCT02062606|DEVICE|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
219500834|NCT01508585|BEHAVIORAL|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
219500835|NCT02751333|PROCEDURE|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
219605279|NCT07184606|DRUG|2 full doses (solution, 40 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 2 full (target) doses of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 2 full (target) dose of the study drug (parenteral administration)."
219605280|NCT07184606|DRUG|course administration of the selected dose|10 healthy volunteers will receive course administration of the selected dose, and 1 healthy volunteer will receive placebo.
219605281|NCT07184606|OTHER|Placebo|1 healthy volunteer from the 1st cohort of each group will receive placebo (parenteral administration)
219605282|NCT07187037|DRUG|Methylprednisolone (MP)|Methylprednisolone 1 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of the second twitch in train of four monitoring.
219605283|NCT07187037|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of second twitch in train of four monitoring.
219605284|NCT07184658|PROCEDURE|Ultrasound-guided peritendinous saline injection|Under ultrasound guidance, 1 mL of sterile normal saline will be injected peritendinously at the tendon repair site at 7, 14, and 21 days after surgery to reduce adhesion formation and preserve tendon healing.
219605285|NCT07185321|DRUG|Mosliciguat|Dose level for inhalation
219027172|NCT00985842|DEVICE|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
219500836|NCT02751333|PROCEDURE|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
219500837|NCT02751333|DEVICE|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
219500838|NCT02751333|DEVICE|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
219500839|NCT01331785|DRUG|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
219500840|NCT00326885|DRUG|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
219500841|NCT00736528|DRUG|PF-04447943|05 mg BID for 14 days
219500842|NCT00736528|DRUG|PF-04447943|15 mg BID for 14 days
219500843|NCT00736528|DRUG|PF-04447943|45mg BID for 14 days
219500844|NCT00736528|DRUG|Placebo|Placebo for 14 days
219500845|NCT02287454|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
219500846|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
219605286|NCT07185321|DRUG|14C mosliciguat|Dose level
219605287|NCT07185321|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat
219605288|NCT07186179|DRUG|Mobilization Regimen|"This study will utilize a standard mobilization regimen that is used for peripheral blood stem cell mobilization in patients with a variety of underlying conditions.~Upon study initiation, participants will undergo a peripheral blood draw and bone marrow aspiration and biopsy. They will then begin the following mobilization regimen:~1. Granulocyte-colony stimulating factor (G-CSF; filgrastim) dosed at 10mcg/kg/day administered subcutaneously in the morning for 5-7 days~2. Plerixafor dosed at 0.24mg/kg/day administered subcutaneously in the evening for 1-4 days~Participants will undergo daily blood draws until criteria for study completion is achieved."
219500847|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
219500848|NCT00653497|BEHAVIORAL|Aquatic exercise|"Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration"
219500849|NCT04387747|OTHER|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
219605289|NCT07185568|PROCEDURE|IOUS HydroMark™|"IOUS HydroMarkTM allows marking the tissue during percutaneous breast biopsy. This is a sterile, single-use marker made of resorbable hydrogel, which expands upon contact with bodily fluids and is then gradually absorbed. The hydrogel is visible on ultrasound. Inside the hydrogel, there is a metallic spiral (titanium/steel) that remains permanently visible in radiographic and MRI examinations even after the hydrogel has been fully absorbed.~The HydroMARK Breast Biopsy Site Marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. The hydrogel material is visible under ultrasound. Embedded in the hydrogel is a coiled metallic wire that will be permanently visible under x-ray and MRI when the hydrogel is resorbed. The HydroMARK Biopsy Site Marker is a permanent implant and is not intended to be removed unless the marked tissue is determined to require surgical removal. The marker is supplied pre-loaded in applicator devices designed."
218881028|NCT05536687|DEVICE|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~* In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~* In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~* Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
219605290|NCT07185568|PROCEDURE|Magnetic Sirius Pintuition Seed®|"The Pintuition Localization System is intended as a magnetic soft tissue localization system.~The magnetic Pintuition Seed is indicated for preoperative percutaneous implantation into soft tissue (glandular, fibrous or fatty tissue of breast; lymph nodes in the axillary and inguinal region; subcutaneous tissue and skeletal muscle tissue) for temporary marking (\<180 days) of a tissue of interest (e.g. tumor or a suspected lesion) indicated for surgical removal. Using the Pintuition Detector as magnetic guidance or, alternatively, image guidance (ultrasound or x-ray), the Pintuition Seed can be intra-operatively localized and removed together with the tissue of interest."
219605291|NCT07185568|PROCEDURE|Wire localization (WL)|Single-use, repositionable needle for preoperative localization of breast nodules with a single hook, equipped with a depth limiter. Designed for the localization of non-palpable breast lesions in the preoperative phase. It includes a fixation clamp to stabilize the positioning of the wire.
219027173|NCT00985842|DEVICE|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
219500850|NCT00655005|OTHER|questionnaire administration|Newly diagnosed HNC patients
219500851|NCT00655005|PROCEDURE|quality-of-life assessment|following treatment
218881029|NCT05389176|DRUG|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
219027174|NCT00985842|DEVICE|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
218881030|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
219027175|NCT00985842|DEVICE|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
219027176|NCT00091273|BIOLOGICAL|incomplete Freund's adjuvant|
219500852|NCT03742674|OTHER|Follow up|No intervention
219027177|NCT00091273|BIOLOGICAL|ovarian cancer peptide vaccine|
219027178|NCT00091273|BIOLOGICAL|sargramostim|
219027179|NCT00091273|BIOLOGICAL|tetanus toxoid helper peptide|
219500853|NCT00919958|BIOLOGICAL|PLX-PAD IM injection|Single treatment; multiple injections
219500854|NCT02274467|DEVICE|Trans-catheter electric stimulation test|
219500855|NCT01473758|DRUG|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
219500856|NCT01473758|DRUG|Placebo|tablet, od, oral administration in the morning after breakfast
219605292|NCT07186218|BEHAVIORAL|Electronic patient-reported outcome measure (ePROM) for symptom monitoring|Patients randomized to the ePROM intervention arm will be asked to complete monthly reporting of their CKD-associated symptoms using an electronic version of the Integrated Patient Outcome Scale (IPOS)-Renal survey. Their responses will be provided in summary form to their nephrology clinicians at regular intervals and prior to any nephrology clinic visits. Clinicians will be provided with guidance on symptom management and will have the option to participate in an informational session on how to interpret patient symptom responses.
219605293|NCT07185906|BEHAVIORAL|education|WhatsApp-based training was provided
219500857|NCT04749186|DEVICE|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
219500858|NCT01677910|DRUG|Telotristat etiprate|Telotristat etiprate tablets.
219500859|NCT01677910|DRUG|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
219500860|NCT01713712|BEHAVIORAL|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
219500861|NCT05517512|DIAGNOSTIC_TEST|Estimation of Protein 13|"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."
219605294|NCT07186842|DRUG|BNT329|Intravenous (IV) infusion
219605295|NCT07186842|DRUG|CA19-9-targeting monoclonal antibody|Monoclonal antibody
219605296|NCT07186023|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
219605297|NCT07186023|BEHAVIORAL|MBWC|Mindfulness-Based Well-Being Curriculum
219605298|NCT07186023|BEHAVIORAL|MBCI|Mindfulness-Based Curriculum for Insomnia
218881031|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd|Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
218881032|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w|The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
218881033|NCT01111344|DIETARY_SUPPLEMENT|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
219500862|NCT05499364|BEHAVIORAL|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
219500863|NCT05499364|BEHAVIORAL|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
219500864|NCT03760133|DRUG|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
219500865|NCT05236075|DEVICE|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
219605299|NCT07186023|DEVICE|BSI|Brain Stimulation Intervention
219605300|NCT07186309|DEVICE|Diagnostic Test: Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
219605301|NCT07185438|DEVICE|Experimental target rTMS treatment|Participants will undergo MRI-guided identification of the voxel in the left dorsolateral prefrontal cortex (DLPFC) that is most negatively correlated with the functional connectivity of the subgenual anterior cingulate cortex (sgACC) as the stimulation site.
219605302|NCT07185438|DEVICE|Conventional target rTMS treatment|Participants will undergo MRI-guided identification of the standard F3 target in the dorsolateral prefrontal cortex (DLPFC) as the stimulation site.
219605303|NCT07185438|DEVICE|Sham stimulation treatment|Participants will receive a sham stimulation treatment designed to simulate the rTMS procedure without generating an effective magnetic field output.
219605304|NCT07186959|PROCEDURE|endoscopic gastric purse-string suturing|A dual-tail endoloop will be introduced into the stomach with endoscopic forceps, and will be secured to the gastric wall using endoscopic clips. An endoscope hook was used to tighten both tails of the endoloop until all the clips converged.
219605305|NCT07185243|BIOLOGICAL|recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
219605306|NCT06834698|DRUG|Betamethasone Cream|Betamethasone 0.1% cream was administered to the external meatus twice per day for a duration of 21 days.
219605307|NCT06834698|PROCEDURE|meatotomy|"In the event of steroid therapy failure, a meatotomy was performed under general anesthesia. The procedure involved squashing the ventral aspect of the pinpoint meatus for approximately 3-5 millimeters for 10 seconds and then incising it. The mucosal margins were sutured with absorbable sutures to avoid renarrowing.~Urethral catheterization was not employed, and the procedure was performed on an outpatient basis. Patients were discharged following urination."
219605308|NCT05680740|DRUG|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
219500866|NCT00943800|DRUG|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
219605309|NCT04460885|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
219605310|NCT04460885|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
219605311|NCT04559347|DRUG|Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single shot for erector spinae block
219605312|NCT04559347|DRUG|Ropivacaine (0.5% bolus followed by 0.2% infusion)|Continuous catheter infusion for erector spinae plane block
219605313|NCT04771728|DRUG|Metronidazole vaginal suppositories|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
219605314|NCT04771728|DRUG|Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
219605315|NCT05765877|DRUG|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
219605316|NCT01968772|OTHER|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
219605317|NCT04622605|DEVICE|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
219605318|NCT03340012|DEVICE|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
219605319|NCT03340012|DEVICE|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
219605320|NCT03721523|DIAGNOSTIC_TEST|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
219605321|NCT03721523|DIAGNOSTIC_TEST|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
219605322|NCT03912363|OTHER|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
219605323|NCT03912363|OTHER|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
219605324|NCT06173869|DRUG|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
219500867|NCT00943800|PROCEDURE|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
219500868|NCT00943800|PROCEDURE|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
219500869|NCT00943800|DRUG|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
219500870|NCT00943800|DRUG|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
219605325|NCT06173869|DRUG|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
219500871|NCT04264299|PROCEDURE|T tube drainage|closure of common bile duct over T tube
219500872|NCT04264299|PROCEDURE|Primary closure|Primary closure of common bile duct
219500873|NCT04264299|PROCEDURE|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
219500874|NCT02023632|BEHAVIORAL|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
219500875|NCT02023632|BEHAVIORAL|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
219500876|NCT02023632|BEHAVIORAL|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
219500877|NCT01410383|DRUG|Placebo|Tablets taken daily
219500878|NCT01410383|DRUG|Eprotirome|Tablets taken daily
219500879|NCT01410383|DRUG|Eprotirome|Tablets taken daily
219500880|NCT01104233|DEVICE|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
219500881|NCT02207647|OTHER|no intervention|
219500882|NCT03040076|BEHAVIORAL|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
219500883|NCT03040076|BEHAVIORAL|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
219500884|NCT01666886|DEVICE|Mandibular Advancement Device (MAD)|
219500885|NCT02455700|DEVICE|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
219500886|NCT03027570|BEHAVIORAL|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
219605326|NCT04514679|BEHAVIORAL|Dietician / Health Coach|The order of visit for the two types of providers is first Dietician then Health Coach.
219605327|NCT04514679|BEHAVIORAL|Health Coach / Dietician|The order of visit for the two types of providers is first Health Coach then Dietician.
219605328|NCT03956355|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
219605329|NCT03956355|DRUG|Vehicle Cream|Vehicle cream applied once daily
219605330|NCT06960057|BEHAVIORAL|Virtual Reality Exposure|Participants will be exposed to a standardized 5-minute virtual reality (VR) session using a commercially available VR headset. The session features a calming, immersive environment intended to reduce anxiety and lower office blood pressure (OBP) during a clinical visit. The VR experience is delivered after the return of an ambulatory blood pressure monitoring (ABPM) device and before the final BP measurements are obtained. Blood pressure and anxiety scores are assessed immediately before and after VR exposure.
219605331|NCT06409702|DRUG|Carfilzomib|"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"
219027180|NCT00091273|PROCEDURE|adjuvant therapy|
219500887|NCT03027570|BEHAVIORAL|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
219605332|NCT06409702|DRUG|Daratumumab|"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"
218881034|NCT01111344|DIETARY_SUPPLEMENT|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
219500888|NCT03027570|OTHER|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
219500889|NCT00774332|DRUG|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
219500890|NCT02244437|DRUG|Ibuprofen|
219605333|NCT06409702|DRUG|Lenalidomide|"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"
219605334|NCT06409702|DRUG|Dexamethasone|"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"
219605335|NCT06409702|DRUG|VRD for first-cycle induction therapy|"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"
219605336|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
219605337|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
218881035|NCT06251583|DEVICE|duramesh suture|Duramesh-suture will be used for trocar closure in the experimental group
218881036|NCT05527821|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
219027181|NCT02400502|BEHAVIORAL|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
219027182|NCT03410355|PROCEDURE|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
219027183|NCT03410355|PROCEDURE|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
219027184|NCT01067222|DRUG|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
219027185|NCT01067222|DRUG|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
219027186|NCT01067222|DRUG|Placebo|Placebo oral capsules, 4 capsules per day
219500891|NCT02244437|DRUG|Acetaminophen|
219500892|NCT06528587|PROCEDURE|narrow diameter implant|Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
219500893|NCT00493753|PROCEDURE|Acupuncture|
219500894|NCT02367053|DRUG|ZP4207|
219500895|NCT02367053|DRUG|Glucagon|
219500896|NCT04927754|BEHAVIORAL|Behavioral guidance|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
219500897|NCT04927754|OTHER|Pain assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was assessed the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's pain during dental care.
219605338|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
219605339|NCT01437046|DRUG|Doxazosin|Doxazosin were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
219605340|NCT01437046|DRUG|Placebo|Matched placebo were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin or matched placebo was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
219605341|NCT04952480|RADIATION|Dose-escalated adaptive radiotherapy|Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.
219605342|NCT04952480|DRUG|Chemotherapy|Concurrent standard of care platinum doublet based therapy
219605343|NCT03999996|BIOLOGICAL|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
219605344|NCT03999996|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
219605345|NCT06804018|OTHER|Mandala coloring|Pregnant women who will paint mandalas
219500898|NCT04927754|OTHER|Dental anxiety assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was evaluated the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's dental anxiety during treatment sessions.
219500899|NCT00892697|DRUG|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
219500900|NCT00892697|DRUG|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
219605346|NCT05659173|DIAGNOSTIC_TEST|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
219605347|NCT01557985|DRUG|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
219605348|NCT05192382|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
219605349|NCT05192382|DRUG|Placebo|Placebo, tablets, once daily by mouth
219605350|NCT06137144|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
219500901|NCT00892697|DRUG|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
219500902|NCT04244747|DEVICE|induction of labor by breast stimulation|
219500903|NCT04244747|DEVICE|induction of labor by catheter balloon|
219500904|NCT04450498|BIOLOGICAL|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects \> 2 years of age and have shown to be safe and immunogenic.
219605351|NCT04297761|OTHER|Filtered Air|Ambient air will be filtered and used for control exposure.
219605352|NCT04297761|OTHER|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
218881037|NCT05527821|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
218881038|NCT05527821|RADIATION|Short course radiotherapy|5Gy\*5F short course radiotherapy will be delivered
218881039|NCT02443168|DRUG|AG-221|Part 1: oral solution containing 100 mg \[14C\]-AG-221
218881040|NCT02443168|RADIATION|14C AG-221|5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
218881041|NCT06115590|DIETARY_SUPPLEMENT|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
219605353|NCT02795338|PROCEDURE|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
219605354|NCT01838850|DRUG|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
219605355|NCT01838850|DRUG|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
219605356|NCT02717455|DRUG|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
219605357|NCT00005603|DRUG|asparaginase|
219605358|NCT00005603|DRUG|cyclophosphamide|
219500905|NCT04450498|BIOLOGICAL|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
219500906|NCT06379399|DRUG|Cetuximab|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;
219500907|NCT06379399|DRUG|Trifluridine/Tipiracil|"Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;"
219500908|NCT05777265|OTHER|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
219500909|NCT02400320|DRUG|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
219500910|NCT02400320|DRUG|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
219500911|NCT02400320|OTHER|Saline|Saline
219500912|NCT04767789|DIETARY_SUPPLEMENT|NZ-GHMH-01|Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
219500913|NCT04767789|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
219605359|NCT00005603|DRUG|cytarabine|
219605360|NCT00005603|DRUG|daunorubicin hydrochloride|
219605361|NCT00005603|DRUG|dexamethasone|
219605362|NCT00005603|DRUG|doxorubicin hydrochloride|
219500914|NCT03341273|DRUG|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
219500915|NCT03341273|OTHER|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
219500916|NCT03341273|DEVICE|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
219500917|NCT02558426|PROCEDURE|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
219605363|NCT00005603|DRUG|mercaptopurine|
219605364|NCT00005603|DRUG|methotrexate|
219605365|NCT00005603|DRUG|prednisone|
219605366|NCT00005603|DRUG|thioguanine|
219605367|NCT00005603|DRUG|vincristine sulfate|
219605368|NCT04940988|OTHER|Real-time benefits check|Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.
219605369|NCT01391715|DRUG|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
219605370|NCT01391715|DRUG|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
219605371|NCT02872428|DRUG|Valproic Acid|By infusion over 1 hour
218881042|NCT01578577|BEHAVIORAL|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
219027187|NCT04110093|DRUG|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
219500918|NCT04945720|PROCEDURE|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
219500919|NCT04945720|DRUG|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
219500920|NCT05885230|PROCEDURE|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
219500921|NCT05885230|DRUG|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
219500922|NCT00685919|DRUG|Carbidopa|200 mg every 6 hours for 5 doses given orally
219500923|NCT00685919|DRUG|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
219500924|NCT03435432|DIETARY_SUPPLEMENT|Glucose|Glucose drink
219500925|NCT03435432|DIETARY_SUPPLEMENT|Water|Control
219500926|NCT01717456|OTHER|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
219500927|NCT01717456|DIETARY_SUPPLEMENT|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
219500928|NCT01717456|DRUG|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
219500929|NCT01717456|BEHAVIORAL|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
219500930|NCT01717456|BEHAVIORAL|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
219500931|NCT01717456|BEHAVIORAL|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
219500932|NCT01717456|OTHER|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
219500933|NCT04872426|OTHER|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
219500934|NCT05311852|DIETARY_SUPPLEMENT|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
219500935|NCT05311852|DIETARY_SUPPLEMENT|Placebo|assumption of a placebo product 2 time/day for 8 weeks
219500936|NCT00800098|DRUG|herbal topical cream|
219500937|NCT02447510|PROCEDURE|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
219500938|NCT02447510|PROCEDURE|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
219500939|NCT02447510|PROCEDURE|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
219500940|NCT01857791|BEHAVIORAL|multidisciplinary, behavior modification|
219500941|NCT01844934|OTHER|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
219500942|NCT00149292|DRUG|LY2140023|
219500943|NCT00149292|DRUG|olanzapine|
219500944|NCT00149292|DRUG|placebo|
219500945|NCT05144620|DIAGNOSTIC_TEST|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
219500946|NCT02489890|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
219500947|NCT06244303|DRUG|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)|Toothpaste, toothbrush \& mouthwash regime
219500948|NCT06244303|DRUG|manual toothbrush + Colgate dental cream|toothpaste + toothbrush
219500949|NCT04881955|DRUG|[14C]-Ecopipam|\[14C\]-Ecopipam
219500950|NCT03139214|BEHAVIORAL|Parenting Intervention|
219500951|NCT00282555|DRUG|S-Tenatoprazole-Na (STU-Na)|
219605372|NCT02872428|DRUG|Isotonic saline solution|By infusion over 1 hour
219605373|NCT00573261|DRUG|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
219605374|NCT00573261|DRUG|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
218881043|NCT01578577|BEHAVIORAL|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
219200648|NCT06854354|BEHAVIORAL|HPV Prevention Vaccine|The educational intervention was implemented through a private Facebook group, facilitating access to HPV vaccine information. A user guide was provided and profiles were verified for authenticity using a non-duplicity algorithm. Prior to access, mothers completed questionnaires to assess their knowledge, beliefs and acceptance. The intervention lasted four weeks and included four modules with videos, handouts and infographics. The first session provided information on HPV, its transmission and prevention. The second highlighted the benefits of the vaccine and debunked myths. The third showed testimonials from mothers who had their daughters vaccinated. The last session was a videoconference with group dynamics to resolve doubts. The sessions were held weekly and access and duration were monitored within the group. After finishing, the group was temporarily closed to avoid biases in the second measurement, allowing free access to the contents.
219200649|NCT06854354|OTHER|Placebo|The CG did not have an educational intervention, nor the use of any placebo, the test instruments were applied and a month after this, they were invited to a virtual platform where they were asked to answer again the measurement instruments, once obtained the filling of the questionnaires they were invited and provided the user guide that allowed them to participate and learn about the Facebook group, as well as view the educational materials, to obtain the same benefits as the GE
219200650|NCT06856096|DIAGNOSTIC_TEST|PET/MRI|PET/MR imaging using an integrated TOF PET/MR scanner (Signa, GE Healthcare, WI, USA)
219200651|NCT06859151|OTHER|Reproductive tract microbiota|Reproductive tract microbiota
219200652|NCT06860425|OTHER|RestoreMe|Comprehensive mobile device application
219200653|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
219200654|NCT06671041|DRUG|Preservative Free eye drop|Participants were required to use a lubricating eye drop
219200655|NCT06671535|DEVICE|Polymethylmethacrylate membrane|A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.
219200656|NCT06671535|DEVICE|polysulfone membranes|Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
219200657|NCT06861361|DEVICE|Myval balloon-expandable THV Series|Patients receive Myval balloon-expandable THV Series (TAVR)
219200658|NCT06861361|DEVICE|Surgical bioprosthetic valve|Patients receive any surgical bioprosthetic valve commercially available at the clinical investigation site (SAVR)
219200659|NCT06862661|OTHER|Daily Tips and Advice on the use of LactApp m-health tool throughout the breastfeeding journey.|A tool to track breastfeeding frequency, duration, and baby's weight and offers access to a community forum for peer support along with direct consultations with lactation experts.
219200660|NCT06860711|DRUG|NSAIDs|IV formulation: ketorolac 0.5mg/kg/dose, 15mg maximum, no more than 8 doses total PO formulation: ibuprofen suspension 10mg/kg/dose, 400mg maximum Total duration (IV + PO) will not exceed 5 days.
219200661|NCT06860711|DRUG|Placebo|IV or PO medication, compounded to have similar look, consistency and taste to the corresponding medications
219200662|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
219200663|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
219200664|NCT06864117|OTHER|Body position during urodynamics|"The group defines the body position in which the first and second measurements are taken.~Group A: sitting, lying down (s/l). Group B: lying down, sitting (l/s). According to the ICS standard, the third measurement is always taken in a sitting position."
219200665|NCT06863389|PROCEDURE|Chen's U-suture technique|Initially, an approximately 2 cm cut edge of the pancreas remnant was mobilized and a incision of the jejunal loop was conducted slightly shorter than the pancreatic remnant. Using dual-needle 3-0 prolene suture for anastomosis, needle A went through the entire intestinal wall from the posterior wall about 1.5 cm away from the resection margin of the jejunum loop, then went through the superior boarder of the pancreas from posterior to anterior. To suture the anterior wall of the jejunum loop, the stitch next entered from the resection margin of the jejunum loop and kept it within the seromuscular layer from proximal to distal, and got out from about 1.5 cm away from the resection margin. Needle B repeated the aforementioned procedures with a parallel distance about 1.0 cm between needle A. Generally, the whole anastomosis needed two to four identical stitches. The stitches should overlap each other to reduce pancreatic leakage. Once all the stitches were finished and tighte
219500952|NCT05638152|OTHER|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~* natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~* Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~* Music available to patients~* Comfort Talk communication course for PACU nurses"
219500953|NCT02199652|DRUG|Prazosin|
219500954|NCT02199652|DRUG|Placebo|
219500955|NCT00049634|DRUG|busulfan|
219500956|NCT00049634|DRUG|cyclophosphamide|
219500957|NCT00049634|DRUG|cyclosporine|
219500958|NCT00049634|DRUG|methotrexate|
219500959|NCT00049634|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219500960|NCT04574778|DRUG|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
218881044|NCT06116006|OTHER|Upper limb pointing movements in 3 experimental conditions|Recording of cerebral hemodynamic with fNIRS during upper limb pointing movements with a robotic device in three conditions: movements with robot assistance, movements without robot assistance and movements with robot resistance. Each subject are recorded during 6 trials for each condition (18 trials). The order is counterbalanced among the subjects.
219027188|NCT04959942|OTHER|scapular stabilization exercise|In the supine position, the subject will instruct to take a deep breath to relax the body. In croock-lying position, the subject will raise his dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. In the quadruped position, the subject lifts up his arms alternatively with shoulder abduction and 120 ° flexion. In a sitting position with 90° knee flexion on a stool or bed without back support, the subject held a pair of dumbbells (2 kg) in each hand and laterally lifted them up while maintaining the height of scapulae below 80°. Each stage will instruct to be held for 10 seconds before returning to the starting position and three laps of 10 repetitions with a 30-second break in between will perform. In the sitting position, a mirror will place in front of the patient. The subject will instruct to check and correct his posture by him
219027189|NCT04959942|OTHER|postural correction exercise|The program consisted of two strengthening (deep cervical flexors and scapular retractors) and two stretchings: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall.
219200666|NCT06863389|PROCEDURE|invagination|Firstly, using 3-0 silk sutures, the pancreatic capsule and the serosa of the jejunal loop were anastomosed interruptedly to constitute the posterior outer layer of the anastomosis. Secondly, a jejunotomy with an appropriate size was performed and the inner layer (including posterior and anterior) of invagination was formed by two 5-0 prolene sutures with a continuous running between the pancreatic parenchyma and the full-thickness jejunum. Thirdly, the anterior outer layer was sutured in line with the first step.
219200667|NCT06863389|PROCEDURE|Duct-to-Mucosa|Briefly, Duct-to-Mucosa should make a opening matched to the pancreatic duct and was also performed by two layers. One was the outer layer in both the anterior and posterior walls of the anastomosis which were formed by interrupted 3-0 silk sutures betweent the pancreatic capsule and the jejunal serosa. The other was the inner layer performed in eight to twelve stitches from pancreatic duct to jejunal mucosa with 5-0 prolene sutures.
219200668|NCT06520072|BEHAVIORAL|Children Eating Well (CHEW) mobile app|"The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it."
219200669|NCT06520072|BEHAVIORAL|Beanstalk mobile app|"Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,"
219200670|NCT06756841|DEVICE|PEF treatment|PEF energy delivery via endoscope
219200671|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
219200672|NCT01993810|DRUG|Carboplatin|Given IV
219200673|NCT01993810|DRUG|Cisplatin|Given IV
219500961|NCT00313053|DRUG|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
219500962|NCT00313053|DRUG|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
218881045|NCT06965894|DEVICE|Johnston Pressure Splint|Application of a Johnston pressure splint to the lower extremity.
218881046|NCT06965894|OTHER|Rehabilitation Program|Rehabilitation program including neurodevelopmental therapy and proprioceptive neuromuscular facilitation (PNF) techniques.
219027190|NCT04959942|OTHER|advice|all subjects will be instructed to maintain normal alignment of the cervical vertebry
219027191|NCT01786954|DEVICE|Icare rebound tonometry|
219027192|NCT01786954|DEVICE|Tonopen applanation|
219027193|NCT01786954|DEVICE|Goldmann applanation|
219027194|NCT01522365|DEVICE|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
219027195|NCT01522365|DEVICE|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
219200674|NCT01993810|BIOLOGICAL|Durvalumab|Given IV
219200675|NCT01993810|DRUG|Etoposide|Given IV
219200676|NCT01993810|DRUG|Paclitaxel|Given IV
219500963|NCT02505776|DRUG|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
219500964|NCT00914797|DRUG|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
219605375|NCT03400592|DRUG|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
218881047|NCT06584305|PROCEDURE|AI-Powered Body Dysmorphic Disorder Screening Procedure|The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
219605376|NCT03400592|DRUG|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
219605377|NCT00002376|DRUG|Indinavir sulfate|
219605378|NCT00002376|DRUG|Lamivudine|
219605379|NCT00002376|DRUG|Stavudine|
219605380|NCT00002376|DRUG|Zidovudine|
219605381|NCT00002376|DRUG|Didanosine|
218881048|NCT01597713|DRUG|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
218881049|NCT01597713|DRUG|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
218881050|NCT01597713|DRUG|placebo|Subjects will receive a single dose of oral placebo within each dose group
218881051|NCT01597713|DRUG|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
218881052|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
218881053|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
219605382|NCT00003131|DRUG|chemotherapy|
219605383|NCT00003131|DRUG|gemtuzumab ozogamicin|
219605384|NCT03229226|OTHER|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
219605385|NCT00842166|OTHER|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
219605386|NCT00233948|DRUG|nelfinavir mesylate|Given orally
219605387|NCT00233948|PROCEDURE|biopsy|Correlative studies
219605388|NCT00233948|OTHER|laboratory biomarker analysis|Correlative studies
219605389|NCT00233948|OTHER|pharmacological study|Correlative studies
218881054|NCT04700826|DRUG|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
218881055|NCT06348797|DRUG|α-PD-L1/4-1BB DLL3 CAR-T (BHP01)|Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses; Bridge radiotherapy with 15 Gray (Gy)/5 fractions; α-PD-L1/4-1BB DLL3 CAR-T (BHP01): the first dose was 5x10\^5/kg.
218881056|NCT06976580|PROCEDURE|conventional local anesthetic injection|A conventional infiltration anesthesia will be conducted on the lumbar area of the patient, targeting the epidermis and subcutaneous tissue. A 25G syringe will be used, with the needle angle set between 30° and 45°. 1cc of 1% lidocaine will be injected. The target size of the wheal is 5-10 mm.
218881057|NCT06976580|PROCEDURE|skin stetching technique for local anesthetic injection|Skin stretching techinique will be applied to the local anesthetic injection site by stretching the skin around the needle entry point.
218881058|NCT01093872|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
218881059|NCT01423734|OTHER|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
219200677|NCT01993810|DRUG|Pemetrexed Disodium|Given IV
219605390|NCT00233948|GENETIC|gene expression analysis|Correlative studies
219605391|NCT00233948|GENETIC|western blotting|Correlative studies
219605392|NCT00233948|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
219605393|NCT00233948|OTHER|immunoenzyme technique|Correlative studies
219605394|NCT01728844|DEVICE|beta-tricalcium phosphate alone|
219605395|NCT01728844|DEVICE|GFeBGS 0.1%|
219605396|NCT01728844|DEVICE|GFeBGS 0.3%|
219605397|NCT01728844|DEVICE|GFeBGS 0.4%|
219605398|NCT00073346|BEHAVIORAL|Cognitive Behavioral Treatment|
219605399|NCT03929068|DRUG|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
219605400|NCT03929068|DRUG|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
219605401|NCT03807726|BEHAVIORAL|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
219605402|NCT06306261|OTHER|questionnaire|UC patients will be subjected to a questionnaire each month about their habits.
218881060|NCT02690714|BIOLOGICAL|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
219500965|NCT03870997|BEHAVIORAL|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
219500966|NCT03870997|BEHAVIORAL|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
219500967|NCT05974748|DRUG|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
219027196|NCT00673179|DRUG|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
219027197|NCT00673179|DRUG|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
219027198|NCT00673179|DRUG|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
219027199|NCT00673179|DRUG|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
219027200|NCT00673179|DRUG|Dexrazoxane|Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
219027201|NCT00673179|DRUG|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
219027202|NCT00673179|BEHAVIORAL|Questionnaire|Questionnaires to be completed on 5 different days during the study.
219027203|NCT00673179|DRUG|Gemcitabine|IV over 1 hour, every other week.
219027204|NCT00673179|DRUG|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
219027205|NCT00673179|PROCEDURE|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
219027206|NCT00673179|DRUG|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
219027207|NCT03320772|DRUG|TMVP1-ICG|Detection of SLN
219027208|NCT03320772|DRUG|ICG|Detection of SLN
219027209|NCT04234035|BEHAVIORAL|Decision Aid|Decision aid to facilitated shared decision-making
219027210|NCT04234035|OTHER|Standardized Educational Material (informational pamphlet)|Pamphlet with information about kidney stones
219027211|NCT05836064|DEVICE|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
219027212|NCT05836064|OTHER|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
219027213|NCT01843764|DEVICE|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
219027214|NCT00651755|DRUG|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
219027215|NCT00651755|DRUG|Cyclophosphamide|750 mg/m\^2 By Vein On Day 1
219027216|NCT00651755|DRUG|Doxorubicin|25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
219027217|NCT00651755|DRUG|Vincristine|2 mg By Vein On Day 1
219027218|NCT00651755|DRUG|Prednisone|100 mg PO for 5 Days
219027219|NCT00651755|DRUG|Rituximab|375 mg/m\^2 By Vein On Day 1.
219027220|NCT00651755|DRUG|Ondansetron|8 mg daily for 2 days
219027221|NCT01496547|DRUG|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
219027222|NCT04495127|DRUG|Selumetinib|Selumetinib 25 mg/m2 BID
219027223|NCT01492322|RADIATION|TRODAT|Smoker will receive a TRODAT injection
219027224|NCT05796011|DEVICE|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
219027225|NCT05796011|OTHER|without hearing intervention|neither earing aids nor other heaing treatment were applied.
219027226|NCT05796011|OTHER|healthy control|healthy control
219027227|NCT03642717|DRUG|JARDIANCE DUO®|empagliflozin and metformin
219027228|NCT05375695|OTHER|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
219027229|NCT00149942|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219027230|NCT01073852|DRUG|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
219027231|NCT01073852|DRUG|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
219500968|NCT05974748|DRUG|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
219500969|NCT05455749|DIETARY_SUPPLEMENT|holoBLG|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)
219500970|NCT01178983|DEVICE|surface electromyography|Surface electromyography (SEMG) telebiofeedback
219500971|NCT01178983|DEVICE|surface electromyography|conventional biofeedback
219500972|NCT05778370|DEVICE|Swept Source Optical Coherence Tomography(Topcon DRI Triton)|Topcon DRI Triton
219500973|NCT00275535|DRUG|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
219500974|NCT00275535|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
219500975|NCT00275535|DRUG|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
219500976|NCT00275535|DRUG|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
219500977|NCT00275535|DRUG|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
219500978|NCT02572583|DRUG|Liugan Shuangjie Heji|
219500979|NCT02572583|DRUG|Shufeng Jiedu Capsule|
219500980|NCT02572583|DRUG|Oseltamivir Phosphate Capsule|
219605403|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
219500981|NCT05224921|OTHER|Not applicable (cohort study)|This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
219500982|NCT06539806|DRUG|Losartan 50mg Tab|The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
219500983|NCT02499185|DEVICE|Nephro Check Test|Urine sample
219500984|NCT02499185|OTHER|serum creatinine measurement|Blood sample
219500985|NCT00406432|DRUG|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
219500986|NCT00054015|DRUG|triapine|
219500987|NCT01834573|BEHAVIORAL|physical exercise|10 weeks physical exercise; three times a week
219500988|NCT02438865|DRUG|Immediate instillation of intravesical chemotherapy-Epirubicin-|
219500989|NCT02438865|DRUG|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
218881061|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
218881062|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
219027232|NCT03088254|DRUG|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
219500990|NCT03818919|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
219500991|NCT03818919|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
219500992|NCT03818919|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
219500993|NCT03818919|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
219500994|NCT03818919|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
219500995|NCT03818919|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
219500996|NCT02964065|BIOLOGICAL|Live-Attenuated influenza Vaccine(LAIV)|
219500997|NCT02964065|BIOLOGICAL|Placebo|
219500998|NCT05541601|OTHER|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
219500999|NCT00184964|PROCEDURE|CT-scan, PET-scan|
219501000|NCT05309837|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose-enriched food products
219501001|NCT05309837|DIETARY_SUPPLEMENT|placebo-controlled|Control food products
219501002|NCT06118671|BEHAVIORAL|personalized lifestyle intervention by AI|The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
219501003|NCT03751020|BEHAVIORAL|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
219605404|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
219605405|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
219501004|NCT03751020|BEHAVIORAL|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
219605406|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
219605407|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
219605408|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
219605409|NCT00956111|BIOLOGICAL|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
219200678|NCT01993810|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
218881063|NCT03317782|DEVICE|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.
219027233|NCT03088254|DRUG|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
219200679|NCT01993810|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219501005|NCT03751020|OTHER|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
219605410|NCT00929461|DRUG|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
219605411|NCT06170697|DRUG|Camrelizumab|200mg, iv, d1, q3w
219605412|NCT06170697|DRUG|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
219605413|NCT06170697|DRUG|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
219605414|NCT06170697|DRUG|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
219605415|NCT06170697|DRUG|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
219501006|NCT02134691|BEHAVIORAL|Prolonged Exposure|
219501007|NCT02134691|BEHAVIORAL|Applied Relaxation|
219605416|NCT06170697|RADIATION|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
219605417|NCT03684577|BEHAVIORAL|Hypnotherapy for Agoraphobia|see description of the experimental arm
219605418|NCT00733005|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
219605419|NCT00733005|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
219605420|NCT04827498|DIAGNOSTIC_TEST|Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment|Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
219605421|NCT00136253|BEHAVIORAL|Help dietitians and patients address specific nutritional barriers|
219605422|NCT04552353|DRUG|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
219605423|NCT06011447|OTHER|Device to view the skin|Application of device to help view the wound area better
219027234|NCT03088254|DRUG|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
219605424|NCT02377297|PROCEDURE|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
219605425|NCT02377297|PROCEDURE|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
218881064|NCT03867942|DRUG|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
218881065|NCT03867942|DRUG|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
219027235|NCT05678556|BEHAVIORAL|all2GETHER|all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
219027236|NCT01848756|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
219027237|NCT04546347|RADIATION|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of \[14C\]AZD9833 Solution for Infusion
219027238|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
219027239|NCT04546347|DRUG|AZD9833 Oral Solution|AZD9833 Oral Solution
219027240|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
219027241|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
219027242|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
219605426|NCT02377297|PROCEDURE|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
219605427|NCT00324077|DRUG|Dasatinib in combination with imatinib|
219605428|NCT00387777|DRUG|Patch with centrally acting analgesic|
219605429|NCT00387777|DRUG|Transtec(R) PRO (buprenorphine)|
218881066|NCT01714999|PROCEDURE|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
218881067|NCT01714999|PROCEDURE|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
219200680|NCT01993810|OTHER|Quality-of-Life Assessment|Ancillary studies
219200681|NCT01993810|OTHER|Questionnaire Administration|Ancillary studies
219501008|NCT01740492|DRUG|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
219501009|NCT01740492|DRUG|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
219501010|NCT01740492|OTHER|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
219501011|NCT04938401|OTHER||
219501012|NCT00033631|RADIATION|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
219501013|NCT00033631|RADIATION|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
219501014|NCT05143086|OTHER|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
219501015|NCT05143086|OTHER|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
219501016|NCT05143086|OTHER|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
219501017|NCT05143086|OTHER|Placebo|Use 10 ml of mouthwash without fluoride
219501018|NCT00528879|DRUG|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
219605430|NCT01205087|DRUG|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
219605431|NCT03771287|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
219605432|NCT03771287|DEVICE|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
219605433|NCT00993356|DRUG|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
218881068|NCT01754571|BEHAVIORAL|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
219200682|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
219501019|NCT00528879|DRUG|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
219501020|NCT00528879|DRUG|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
219605434|NCT00993356|PROCEDURE|Transsphenoidal surgery|
219605435|NCT05622487|OTHER|Neural Therapy|Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.
219605436|NCT05622487|OTHER|Kinesio taping|Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance
219605437|NCT00484068|DRUG|enalapril|
218881069|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
218881070|NCT01195480|GENETIC|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10\^8/m2
219200683|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
219501021|NCT04438629|DRUG|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
218881071|NCT01195480|BIOLOGICAL|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
218881072|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
219605438|NCT00484068|PROCEDURE|chicken diet|
219605439|NCT01624025|OTHER|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
218881073|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
219027243|NCT01301495|DEVICE|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
219501022|NCT05347030|OTHER|Acupuncture|During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
219501023|NCT05347030|OTHER|Sham Acupuncture|During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
219605440|NCT04418102|DIETARY_SUPPLEMENT|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
219605441|NCT04418102|DIETARY_SUPPLEMENT|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
219605442|NCT03397225|BEHAVIORAL|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
219605443|NCT06583005|DEVICE|Vibrotactile Coordinated Reset|The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
219605444|NCT02465398|PROCEDURE|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
219605445|NCT02617797|DEVICE|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
219027244|NCT00000586|DRUG|hydroxyurea|
219200684|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
219501024|NCT06458725|DEVICE|Magnetic Resonance Imaging (MRI)|"\- Three MRI :~* two on an MR-Linac 1.5 Tesla (10 to 17 days apart)~* one on a standard 1.5 Tesla MRI"
219501025|NCT05602935|DRUG|Camrelizumab|200mg, intravenously, d1
219605446|NCT02617797|DEVICE|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
219605447|NCT00876330|OTHER|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
219605448|NCT00876330|OTHER|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
219605449|NCT00876330|OTHER|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
219605450|NCT00876330|OTHER|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
219605451|NCT00042601|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
219605452|NCT00042601|DRUG|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
219605453|NCT02480101|BIOLOGICAL|H7N9 live influenza vaccine|H7N9 live influenza vaccine
218881074|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
218881075|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
218881076|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
219027245|NCT02075658|DEVICE|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
219027246|NCT02075658|DEVICE|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
219027247|NCT04414709|OTHER|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
219027248|NCT04414709|OTHER|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
219027249|NCT02865915|DRUG|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
219027250|NCT02865915|DRUG|Placebo|Placebo to match active drug
219200685|NCT06997614|OTHER|Conventional group|The conventional group adhered to conventional nutritional management methods and training
219605454|NCT02480101|BIOLOGICAL|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
219605455|NCT01109446|BIOLOGICAL|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
219605456|NCT01109446|PROCEDURE|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
219605457|NCT01109446|DRUG|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
218881077|NCT02899702|DRUG|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
219027251|NCT00663052|DRUG|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
219501026|NCT05602935|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
219501027|NCT05602935|PROCEDURE|Surgery|Surgery
219501028|NCT00109135|DRUG|taranabant|
219501029|NCT04537819|DRUG|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
219501030|NCT04537819|DRUG|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
219501031|NCT00307619|DRUG|topiramate|
219501032|NCT00078819|DRUG|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
219501033|NCT00078819|DRUG|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
219501034|NCT00667719|DRUG|Aliskiren|300 mg tablet
219501035|NCT00667719|DRUG|Amlodipine|5 mg tablet
219501036|NCT00667719|DRUG|Hydrochlorothiazide|12.5 mg and 25 mg capsule
219501037|NCT04656093|BEHAVIORAL|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
219501038|NCT04656093|BEHAVIORAL|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
219501039|NCT04656093|BEHAVIORAL|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
219605458|NCT06139146|OTHER|Muscle energy technique (MET)|"MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec."
219605459|NCT06139146|OTHER|Core stability exercises:|"Warm up: The cat and camel stretches~Exercises:~* It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~* Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~* Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~* It included a Quadruped position with abdominal bracing for 10 s - 10 reps~* Quadruped position arm lifts with abdominal bracing 10 reps on each side.~* Quadruped position leg lifts with abdominal bracing 10 reps on each side.~* Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~* The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~* Side plank on knees; holding position for 10 s - 5 reps ."
219027252|NCT00663052|DRUG|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
219200686|NCT06997614|OTHER|evidence-based nursing group|The study group implemented the EBN-based protocol alongside structured training
219605460|NCT05954520|DEVICE|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
219605461|NCT00266630|DRUG|olanzapine|oral, daily
219605462|NCT00266630|DRUG|lithium|Dose adjusted according to local package insert
219605463|NCT00266630|DRUG|valproate|Dose adjusted according to local package insert
219605464|NCT00266630|DRUG|carbamazepine|Dose adjusted according to local package insert
219605465|NCT03410056|DRUG|Efavaleukin alfa|Efavaleukin alfa administered as a subcutaneous injection.
219605466|NCT03410056|DRUG|Placebo|Placebo administered as a subcutaneous injection.
219027253|NCT03808168|DRUG|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
219027254|NCT01757119|DRUG|Tardyferon 80 mg|Oral administration (2 tablets)
219027255|NCT01916356|OTHER|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
219200687|NCT01768013|DRUG|LEO 90105|Once daily for four weeks
219501040|NCT04656093|BEHAVIORAL|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
219501041|NCT00956683|PROCEDURE|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
219501042|NCT00956683|PROCEDURE|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
219501043|NCT05693857|OTHER|Cardiovascular prevention guidelines|Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making
219501044|NCT04364724|OTHER|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
219501045|NCT00916422|BIOLOGICAL|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
219501046|NCT00916422|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
219501047|NCT03174041|DRUG|Midazolam|Single dose midazolam
219501048|NCT03174041|DRUG|GDC-0853|Multiple doses GDC-0853 for 6 days
219501049|NCT03174041|DRUG|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
219501050|NCT03174041|DRUG|Rosuvastatin|Single dose rosuvastatin
219605467|NCT00327366|PROCEDURE|Light therapy|
219605468|NCT04983134|BEHAVIORAL|Enhanced CHW Intervention|community-based intervention
219605469|NCT06341816|OTHER|VEXUS score|The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
219605470|NCT06341816|DIAGNOSTIC_TEST|NGAL|Neutrophil gelatinase-associated lipocalin
219605471|NCT05840458|PROCEDURE|PENG Block|Patient will be placed in the supine position and the ultrasound probe will be placed in the transverse plane over the anterior inferior iliac spine (AIIS) and aligned with the pubic ramus by rotating the probe counterclockwise by approximately 45 degrees. A 22-gauge, 100 mm needle will be inserted using the plane approach from lateral to medial, between the psoas tendon anteriorly and the pubic ramus posteriorly. Following a negative aspiration, 20 mL of 0.375% ropivacaine will be injected. The needle position will be confirmed by visualizing the separation of layers with the dispersion of the injected volume.
219605472|NCT06486714|PROCEDURE|Total knee arthroplasty|All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
219605473|NCT04949412|DIAGNOSTIC_TEST|Vitamin D|serum vitamin D level
219605474|NCT02219412|DRUG|ticagrelor|90 mg bid for 2 weeks
219605475|NCT02219412|DRUG|Aspirin|100mg Qd for 2 weeks.
219605476|NCT06581302|DEVICE|Magnetic seizure therapy by Magnetic stimulator|The seizure is induced by Magnetic stimulator of MagPro MST(XP)，MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications
219605477|NCT06581302|DRUG|Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)|It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
219605478|NCT00422110|DRUG|Seletracetam|
219605479|NCT01216735|DRUG|Fluticasone|220 ug twice a day for 3 weeks
219605480|NCT01216735|DRUG|Placebo|Placebo for 3 weeks
219605481|NCT03668678|OTHER|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
218881078|NCT02899702|DRUG|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
218881079|NCT04020497|BEHAVIORAL|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
219200688|NCT06664892|RADIATION|Ultra-hypofractionated radiation|RT, delivered via external beam, 5.2 Gy per fraction for 5 fractions following BCS and neoadjuvant or adjuvant chemotherapy. Specific adjuvant/neoadjuvant therapies are at the discretion of the treating Medical Oncologist.
219501051|NCT03174041|DRUG|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
219501052|NCT03174041|DRUG|Simvastatin|Single dose simvastatin
219501053|NCT03174041|DRUG|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
219501054|NCT03174041|DRUG|GDC-0853|Single dose GDC-0853
219501055|NCT03174041|DRUG|Itraconazole|Multiple doses itraconazole for 6 days
219501056|NCT03174041|DRUG|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
219501057|NCT01353924|BIOLOGICAL|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
219501058|NCT01353924|BIOLOGICAL|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
219501059|NCT03473834|OTHER|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
219501060|NCT03473834|BEHAVIORAL|Medication|The control group will be received the normal medication from their doctor.
219605482|NCT04133857|OTHER|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
219605483|NCT06191289|DRUG|Transdermal Estradiol|"1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test~Other Names:~Climara"
219605484|NCT06191289|OTHER|Placebo|Weekly application of a placebo patch for 14 days starting day 7 after positive urine luteinizing hormone test
219605485|NCT02986529|DRUG|GV-971|
218881080|NCT04020497|OTHER|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
218881081|NCT03902834|OTHER|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
218881082|NCT01810497|PROCEDURE|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
219501061|NCT00139490|BEHAVIORAL|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
219501062|NCT00139490|BEHAVIORAL|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
219501063|NCT00139490|BEHAVIORAL|Control Group|Usual Care
219501064|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period I)
219501065|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period II)
219501066|NCT04494178|OTHER|Placebo|Intervention period I
219501067|NCT04494178|OTHER|Placebo|Intervention period II
219501068|NCT01726478|DRUG|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
218881083|NCT02161757|BIOLOGICAL|Tralokinumab|Subcutaneous injection
218881084|NCT02161757|OTHER|Placebo|Subcutaneous injection
219501069|NCT01726478|DRUG|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
219501070|NCT02908828|DIETARY_SUPPLEMENT|Calanus oil|
219501071|NCT02908828|DIETARY_SUPPLEMENT|placebo dietary oil|
219501072|NCT04000828|DEVICE|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
219501073|NCT00323609|PROCEDURE|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
219605486|NCT02986529|DRUG|Placebos|
219605487|NCT00050128|DEVICE|rTMS, Magstim|
219605488|NCT05309811|DEVICE|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
219605489|NCT05309811|DRUG|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
219605490|NCT02194361|DRUG|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
219605491|NCT02194361|DRUG|Placebo|
219605492|NCT05177185|RADIATION|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
219605493|NCT05177185|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
218881085|NCT01224080|DEVICE|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
218881086|NCT05071014|DRUG|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
218881087|NCT05071014|PROCEDURE|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
218881088|NCT00230503|DRUG|pradefovir mesylate|
219605494|NCT02342301|BEHAVIORAL|Standing Desk|Participants will be provided with a standing desk for 3 months
219605495|NCT02342301|BEHAVIORAL|Traditional Desk|Participants will use a traditional seated desk for 3 months
219605496|NCT00141050|DRUG|Focalin XR|
219605497|NCT05239611|DIAGNOSTIC_TEST|Xenon MRI|Study participants will be randomized to a 12 week exercise intervention versus usual care. Participants will have Xenon MRI at study start and completion to evaluate impact of exercise on lung function. The exercise intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
218881089|NCT00230503|DRUG|adefovir dipivoxyl|
218881090|NCT05862311|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
218881091|NCT01240135|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
219501074|NCT00323609|PROCEDURE|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
219501075|NCT01052805|PROCEDURE|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
219501076|NCT01864473|OTHER|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
219501077|NCT05401331|DEVICE|Treadmilll|Hemodynamic changes before and after treadmill use
219605498|NCT04015271|BEHAVIORAL|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
219501078|NCT05401331|OTHER|mask|mask
219501079|NCT02217345|DRUG|Growth hormone|growth hormone, Genotropin (Pfizer)
219501080|NCT02217345|DRUG|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
219501081|NCT04846218|DRUG|hCG|
219501082|NCT04846218|DRUG|Progesterone|
219501083|NCT04846218|DRUG|Triptorelin|
219501084|NCT03575182|OTHER|Gait retraining program|Supervised gait retraining with verbal and real-time visual feedback.
219501085|NCT00267293|DRUG|Acetaminophen|Given for fever control 15mg/kg
219501086|NCT00267293|DRUG|Ibuprofen|Given for fever control 10 mg/kg
219605499|NCT04015271|BEHAVIORAL|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
219605500|NCT01170988|PROCEDURE|T-Graft|T-Graft
218881092|NCT01240135|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
218881093|NCT01240135|DEVICE|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
219501087|NCT00274144|DRUG|telmisartan 40 mg|
219501088|NCT00274144|DRUG|placebo 40 mg|
219501089|NCT01204060|OTHER|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
219501090|NCT01204060|OTHER|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
219501091|NCT02857725|DRUG|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219501092|NCT02857725|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219501093|NCT04382157|DRUG|Mablet 360 mg|Slow-released magnesium hydroxide
219501094|NCT04382157|DRUG|Placebo|Placebo
219501095|NCT05163379|OTHER|MOBILIZATION|EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
219501096|NCT02844179|DRUG|HTBZ|
219501097|NCT04607603|DRUG|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
219501098|NCT04607603|DRUG|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
219605501|NCT03348878|OTHER|assessment of drug compliance|assessment of drug compliance using electronic monitoring devices (2 months duration)
219501099|NCT05934279|DEVICE|Resistance Training|All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
219501100|NCT00164203|BEHAVIORAL|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
219501101|NCT00164203|BEHAVIORAL|School-based CBT|12 sessions, weekly
219605502|NCT00618488|DIETARY_SUPPLEMENT|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
219605503|NCT00618488|DIETARY_SUPPLEMENT|Placebo|Placebo administered once a day for 6 weeks
219605504|NCT03435887|BEHAVIORAL|Alere q HIV-1/2 Detect for point of care infant testing|The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
219501102|NCT00164203|BEHAVIORAL|activity control condition|weekly games \& activities x 12 weeks
219501103|NCT06547879|BEHAVIORAL|Hypertension Self Management Program|The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
218881094|NCT00002148|DRUG|OPC 14117|
218881095|NCT02376803|DRUG|Warfarin|Morning vs Evening administration
218881096|NCT01371305|DRUG|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
218881097|NCT01371305|DRUG|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
218881098|NCT03682913|BEHAVIORAL|P-CIT protocol|Personalized inhibitory control training for one week.
219501104|NCT05221879|OTHER|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
219501105|NCT01850303|DRUG|Pemetrexed|
219501106|NCT01850303|DRUG|Gemcitabine|
219605505|NCT03435887|BEHAVIORAL|GeneXpert HIV-1 Qual for point of care infant testing|The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to \<24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
219501107|NCT01850303|DRUG|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
219501108|NCT06452823|PROCEDURE|Catheter Ablation|catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
219501109|NCT04926896|PROCEDURE|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
219501110|NCT04926896|PROCEDURE|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
219501111|NCT04863456|PROCEDURE|Total resection|Total resection of HIPA in a single surgery
219501112|NCT04863456|PROCEDURE|Staged resection|HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date
218881099|NCT03682913|BEHAVIORAL|Placebo|without personalized inhibitory control training for one week.
219501113|NCT04863456|PROCEDURE|Subtotal resection followed by stereotactic radiation therapy|HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
219501114|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
219501115|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
219501116|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
219501117|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
219501118|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
219501119|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
219605506|NCT03435887|BEHAVIORAL|HIV DNA PCR testing (Standard of Care)|This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
219605507|NCT00419497|BEHAVIORAL|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
219501120|NCT00950599|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
218881100|NCT03796351|DRUG|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
218881101|NCT03796351|DRUG|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
219605508|NCT01731639|OTHER|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form \> 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
219605509|NCT04844112|PROCEDURE|automatic CT/MRI-US fusion system guided radiofrequency ablation|automatic CT/MRI-US fusion system guided radiofrequency ablation
219605510|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
218881102|NCT01915979|BIOLOGICAL|Plasma rich in growth factors (PRGF)|
218881103|NCT01915979|DRUG|Celestone cronodose (Bethametasone)|
218881104|NCT01618149|RADIATION|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
218881105|NCT05583084|OTHER|Investigation|
218881106|NCT01839149|DRUG|TI-001|TI-001 is intranasal oxytocin
219501121|NCT01514656|OTHER|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
219501122|NCT01514656|OTHER|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
219501123|NCT01514656|OTHER|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
219501124|NCT03596918|BIOLOGICAL|Bleomycin Sulfate|Given IV
219501125|NCT03596918|OTHER|Laboratory Biomarker Analysis|Correlative studies
219501126|NCT03596918|OTHER|Quality-of-Life Assessment|Ancillary studies
219501127|NCT03596918|OTHER|Questionnaire Administration|Ancillary studies
219501128|NCT03596918|DRUG|Vincristine Sulfate|Given IV
219501129|NCT01222806|DEVICE|Repetitive Transcranial Magnetic Stimulation|
219501130|NCT00907036|BIOLOGICAL|alemtuzumab|
219501131|NCT00907036|BIOLOGICAL|donor lymphocytes|
219501132|NCT00907036|DRUG|cyclosporine|
219501133|NCT00907036|DRUG|fludarabine phosphate|
219501134|NCT00907036|DRUG|melphalan|
219501135|NCT00907036|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218881107|NCT01839149|DRUG|Placebo|
218881108|NCT01628965|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
219501136|NCT05499156|OTHER|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
219501137|NCT00971204|DEVICE|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
219501138|NCT00751569|OTHER|blood donation|obtaining cord blood
219501139|NCT05750225|OTHER|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
219501140|NCT05750225|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
219501141|NCT05086081|DRUG|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
219501142|NCT05086081|DRUG|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
219501143|NCT02356081|OTHER|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
219501144|NCT02541695|BIOLOGICAL|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
219501145|NCT03351413|OTHER|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
219501146|NCT05244824|OTHER|Adaptation into Turkish, Examining The Reliability and Validity for People with RA|Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
219501147|NCT05207319|OTHER|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
219501148|NCT02420899|DRUG|rosuvastatin|10mg/d or 20mg/d,po
218881109|NCT02677857|BEHAVIORAL|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
218881110|NCT00311259|DRUG|Melatonin (drug)|
218881111|NCT00311259|DRUG|Laktose|
219027256|NCT05228886|BEHAVIORAL|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
219027257|NCT05228886|BEHAVIORAL|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
219027258|NCT05228886|OTHER|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
219501149|NCT06356870|PROCEDURE|BMAC MIXED WITH ALLOGRAFT|Study group
219501150|NCT06356870|PROCEDURE|Cancellous bone from anterior iliac crest|Control group
219501151|NCT00459082|DRUG|Dexmedetomine|
219501152|NCT02729194|DRUG|Pazopanib|
219501153|NCT02729194|OTHER|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
219501154|NCT01282827|DEVICE|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
218881112|NCT02823379|BEHAVIORAL|Physical Activity|A Smartphone delivered physical activity program
218881113|NCT02823379|BEHAVIORAL|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
218881114|NCT05262283|OTHER|No intervention|No intervention was made.
218881115|NCT00075738|DRUG|cisplatin|
219027259|NCT06057441|DEVICE|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
219027260|NCT06057441|DEVICE|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
218881116|NCT00075738|DRUG|fluorouracil|
218881117|NCT00075738|DRUG|irinotecan hydrochloride|
218881118|NCT00075738|DRUG|leucovorin calcium|
218881119|NCT06347263|OTHER|Entire papilla preservation technique|Minimally invasive periodontal surgery
218881120|NCT05944627|BIOLOGICAL|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
219501155|NCT01282827|DEVICE|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
219605511|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
219501156|NCT06242522|OTHER|Telephone interview|Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
219501157|NCT03689140|BEHAVIORAL|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
219605512|NCT03194919|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
219605513|NCT03911830|OTHER|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
219605514|NCT01231893|PROCEDURE|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
219605515|NCT01231893|OTHER|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
219605516|NCT03897283|DRUG|TQB2450|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
219605517|NCT03897283|DRUG|Anlotinib|Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
219605518|NCT04716647|OTHER|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
219605519|NCT05850325|OTHER|Group 1 Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
219605520|NCT05850325|OTHER|Group 2 Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
219605521|NCT01041144|BEHAVIORAL|lifestyle counseling|supporting diabetes patients using Internet communication
219605522|NCT02720666|DRUG|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
218881121|NCT05944627|BIOLOGICAL|Placebo|placebo administration in Phase 2a clinical trial
219501158|NCT03689140|BEHAVIORAL|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
219501159|NCT03689140|BEHAVIORAL|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
219501160|NCT00493363|DRUG|Artesunate|Artesunate 2 mg/kg/day for 7 days
219501161|NCT00493363|DRUG|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
219605523|NCT03304925|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
219605524|NCT01802021|DRUG|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
219605525|NCT04999059|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
218881122|NCT03691363|BEHAVIORAL|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
219027261|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
219200689|NCT03967158|DEVICE|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
219501162|NCT05521490|OTHER|Usual Care Control|30 minutes of physical activity on each school day.
219501163|NCT05521490|BEHAVIORAL|Physical Activity Enhanced Curriculum|Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
219501164|NCT03803085|BEHAVIORAL|Control condition|Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
219605526|NCT00416390|DIETARY_SUPPLEMENT|lycopene|
219605527|NCT00416390|OTHER|laboratory biomarker analysis|
219605528|NCT00416390|PROCEDURE|biopsy|
219605529|NCT00964067|OTHER|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
219501165|NCT03803085|BEHAVIORAL|Treatment condition|Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
219501166|NCT02118753|DRUG|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
219501167|NCT04073693|DIETARY_SUPPLEMENT|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
219605530|NCT00064987|PROCEDURE|Testicular biopsy|Outpatient surgical procedure.
219605531|NCT00064987|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
218881123|NCT04356352|DRUG|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
219605532|NCT00064987|DRUG|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
219605533|NCT05366452|DEVICE|IMPELLA CP|Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT \>250 s. As soon as the device is in place it will be started.
219605534|NCT05366452|OTHER|Conventional therapy|The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
219605535|NCT00020631|DRUG|pirfenidone|
219605536|NCT01197352|BEHAVIORAL|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
219605537|NCT01197352|BEHAVIORAL|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
218881124|NCT04356352|DRUG|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
218881125|NCT04356352|OTHER|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
218881126|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
218881127|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
219200690|NCT06666725|OTHER|Menu label|Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
219200691|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
219501168|NCT02023502|OTHER|collection of urine and blood sample|
219501169|NCT06536842|OTHER|Postoperative Drain Placement|These drains will be placed with the intention to decrease the incidence of postoperative hematoma
219501170|NCT06536842|OTHER|No Postoperative Drain Placement|Participant will undergo lumbar spine fusion surgery and will not receive a postoperative drain
219200692|NCT06172894|DRUG|APN401|APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
219501171|NCT01987700|DEVICE|FLEX-HD|
219605538|NCT00209040|BEHAVIORAL|Acoustic Startle Testing|See protocol description for methodological details
219605539|NCT04664322|DEVICE|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
219605540|NCT04390776|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
219605541|NCT04045769|DRUG|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
219605542|NCT04045769|DRUG|Placebos|5 tablets of placebo to be administered orally
219605543|NCT04045769|DRUG|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
219605544|NCT04045769|DRUG|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
219605545|NCT05800886|OTHER|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
219501172|NCT01987700|DEVICE|Strattice|
219501173|NCT05743790|DIETARY_SUPPLEMENT|RS2-control-RS4|Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
219501174|NCT05743790|DIETARY_SUPPLEMENT|RS4-control-RS2|Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
219501175|NCT01407679|DRUG|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
219605546|NCT05800886|OTHER|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
219605547|NCT05800886|OTHER|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
218881128|NCT00615173|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
218881129|NCT00615173|DRUG|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
218881130|NCT05122429|BEHAVIORAL|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
219501176|NCT03124485|PROCEDURE|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
219605548|NCT05800886|OTHER|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
219605549|NCT05637372|RADIATION|CBCT|CBCT scan
219501177|NCT03124485|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
219501178|NCT03615456|PROCEDURE|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
219501179|NCT03615456|PROCEDURE|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
219501180|NCT04921683|DEVICE|BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation|"Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total \~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA \<= 190W/cm2, ISPTA \<= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface."
219501181|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
219501182|NCT01684722|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219605550|NCT00347646|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
219605551|NCT00764881|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
219605552|NCT00764881|DRUG|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
218881131|NCT03991429|DIAGNOSTIC_TEST|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
219501183|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D3 placebo
219605553|NCT00764881|DRUG|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
219605554|NCT01696123|DRUG|MLC601|It was described
218881132|NCT03991429|BEHAVIORAL|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
218881133|NCT03991429|OTHER|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
218881134|NCT03991429|DIAGNOSTIC_TEST|Urinalysis|Urine sample
218881135|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
218881136|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
218881137|NCT05150522|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cells infusion
218881138|NCT01402739|OTHER|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
218881139|NCT01402739|OTHER|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
219605555|NCT01214655|DRUG|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
218881140|NCT05006950|DEVICE|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
218881141|NCT03012204|DEVICE|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
219501184|NCT01684722|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219605556|NCT01250210|DRUG|levonorgestrel and ethinyl estradiol|pregnancy prevention
218881142|NCT03012204|DEVICE|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
219605557|NCT02737241|PROCEDURE|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
218881143|NCT03012204|DEVICE|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
218881144|NCT03012204|DEVICE|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
218881145|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
218881146|NCT03422666|DRUG|Teduglutide|Teduglutide
218881147|NCT03422666|DRUG|Placebo|Placebo
218881148|NCT02052401|OTHER|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
218881149|NCT03057782|DEVICE|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
218881150|NCT03057782|DEVICE|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
218881151|NCT03057782|DEVICE|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
219605558|NCT02737241|PROCEDURE|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
219501185|NCT03348046|DRUG|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
219501186|NCT06527495|DRUG|Sorafenib|Sorafenib Tablets (200 -400 mg) twice daily
219501187|NCT01559974|DRUG|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
219605559|NCT01859338|RADIATION|cone-beam computed tomography|Undergo CBCT
219605560|NCT01859338|RADIATION|magnetic resonance imaging|Undergo MRI
219605561|NCT01859338|RADIATION|computed tomography|Undergo fan beam computed tomography
219501188|NCT01559974|DRUG|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
219501189|NCT04302766|DRUG|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
219605562|NCT02031861|DRUG|nifedipine CR tablets (Xin Ran)|
219605563|NCT02031861|DRUG|nifedipine CR tablets (Adalat)|
219605564|NCT02274883|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
219501190|NCT05684250|BEHAVIORAL|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
219501191|NCT00410566|DRUG|rhASM|Single dose of 0.03mg/kg body weight IV
219501192|NCT00410566|DRUG|rhASM|Single dose of 0.1mg/kg body weight IV
219501193|NCT00410566|DRUG|rhASM|Single dose of 0.3mg/kg body weight IV
219501194|NCT00410566|DRUG|rhASM|Single dose of 0.6mg/kg body weight IV
219501195|NCT00410566|DRUG|rhASM|Single dose of 1.0mg/kg body weight IV
218881152|NCT03057782|DEVICE|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
218881153|NCT03057782|DEVICE|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
218881154|NCT02481778|OTHER|Blood sampling|
218881155|NCT00365274|DRUG|Cyclophosphamide|Given IV 750 mg/m\^2 day 1
218881156|NCT00365274|DRUG|Doxorubicin hydrochloride|Given 50 mg/m\^2 IV day 1
218881157|NCT00365274|DRUG|vincristine sulfate|Given 1.4 mg/m\^2 IV
218881158|NCT00365274|DRUG|prednisone|100 mg orally daily days 1 - 5
218881159|NCT00365274|DRUG|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
218881160|NCT03063268|BEHAVIORAL|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
218881161|NCT03063268|BEHAVIORAL|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
219501196|NCT03412019|OTHER|Music|Selections of Mozart piano sonatas
219501197|NCT03979677|BEHAVIORAL|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
219501198|NCT01945099|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
219501199|NCT01945099|DRUG|hyaluronidase|
219501200|NCT01945099|DRUG|Lispro-PH20|
219501201|NCT03295799|OTHER|Patient Self-Management|Patient will manage their own warfarin therapy.
219501202|NCT02445170|PROCEDURE|Amputation|Transmetatarsal or below-knee amputation
219501203|NCT00686478|DRUG|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
219501204|NCT00062556|DRUG|Niacin Extended Release and Lovastatin Tablets|
218881162|NCT03063268|BEHAVIORAL|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
218881163|NCT01884272|DRUG|lesinurad 400 mg|
218881164|NCT01884272|DRUG|naproxen 250 mg|
218881165|NCT01884272|DRUG|indomethacin 25 mg|
218881166|NCT00196508|DEVICE|High Viscosity DERMABOND|
218881167|NCT02277808|DRUG|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
218881168|NCT02277808|DEVICE|Respirgard II|
218881169|NCT02277808|DEVICE|Isoneb®|
219501205|NCT04656015|DEVICE|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~* Regional or global myocardial signal intensity increase in T2-weighted images~* Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~* There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
219501206|NCT00048971|GENETIC|mutation analysis|
219501207|NCT00048971|GENETIC|polymorphic microsatellite marker analysis|
219501208|NCT00248339|DRUG|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
219501209|NCT00248339|DRUG|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
219605565|NCT02274883|DIETARY_SUPPLEMENT|Protein Fractions|Protein fractions
219605566|NCT01116063|DRUG|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
219605567|NCT00300924|DRUG|Rizatriptan co-administered with Acetaminophen|
219605568|NCT06144138|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
219605569|NCT05881824|BEHAVIORAL|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
219501210|NCT00248339|DRUG|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
218881170|NCT03696589|BEHAVIORAL|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
218881171|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
218881172|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
218881173|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
218881174|NCT05412628|DIAGNOSTIC_TEST|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
218881175|NCT00875290|DEVICE|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
218881176|NCT03170193|DRUG|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
219200693|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
219200694|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
219501211|NCT03086239|DRUG|Rovalpituzumab tesirine|Intravenous
219501212|NCT03988725|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800 IU once daily
219501213|NCT04390139|DRUG|XCEL-UMC-BETA|Administration on top of the standard administered treatment
218881177|NCT03170193|DRUG|Placebo|Single doses of matching placebo by SC or IV injection
218881178|NCT01347996|DRUG|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
219501214|NCT04390139|OTHER|Placebo|Administration on top of the standard administered treatment
219501215|NCT06259110|DIAGNOSTIC_TEST|Multiplex PCR|multiplex PCR is a molecular biology technique that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample
219501216|NCT03704779|BEHAVIORAL|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
219501217|NCT05131503|OTHER|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
219501218|NCT05686733|DEVICE|SEAL Device|Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
219501219|NCT03121781|OTHER|respiratory support- interface|change interface to RAM cannula
219501220|NCT03121781|OTHER|respiratory support- interface|change interface to binasal prongs
218881179|NCT01368081|DRUG|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
219605570|NCT03916718|BEHAVIORAL|Care EcoSystem|This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
219605571|NCT06352021|DEVICE|kaleidoscope|The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw. All children in the Kaleidoscope group agreed to participate in the study. All children in the kaleidoscope group were asked to look at the kaleidoscope just before the tourniquet was placed on their arms before the blood sampling procedure and to describe the patterns, they saw in it by turning it slowly during the procedure.
219605572|NCT05230381|DRUG|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
219501221|NCT01885637|OTHER|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
219501222|NCT00947011|DRUG|Placebo|1 tablet 100 mg once a day
219501223|NCT00947011|DRUG|Januvia|1 tablet 100 mg once a day
219605573|NCT05230381|DRUG|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
219501224|NCT03229031|DRUG|ES135|ES135 will be administered via intrathecal
219501225|NCT03366285|DIAGNOSTIC_TEST|Attachment story completion taks (ASCT)|Bonding quality
219605574|NCT05230381|DRUG|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
219605575|NCT02267018|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
219605576|NCT01418417|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
219605577|NCT05989464|DIAGNOSTIC_TEST|Self-swab for genital HPV|Participants will insert a swab in the vagina to collect a sample for HPV testing.
219605578|NCT02330497|PROCEDURE|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
219605579|NCT00005985|BIOLOGICAL|filgrastim|
219605580|NCT00005985|DRUG|carmustine|
218881180|NCT01368081|DRUG|BI 10773|BI 10773 low dose tablet once daily
218881181|NCT01368081|DRUG|Placebo (low dose)|Placebo tablets once daily
218881182|NCT01368081|DRUG|BI 10773|BI 10773 high dose tablet once daily
218881183|NCT01368081|DRUG|Placebo (high dose)|Placebo tablets once daily
218881184|NCT01301859|BEHAVIORAL|TIP|Treatment visits as usual with MD
218881185|NCT01007838|OTHER|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
218881186|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
218881187|NCT01007838|OTHER|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
218881188|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
218881189|NCT02992535|DEVICE|Intense Pulse Light Energy delivery (IPL)|
219200695|NCT06812052|RADIATION|Radiation Therapy|In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).
219501226|NCT01830556|DRUG|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
219501227|NCT06263309|DIAGNOSTIC_TEST|Femoral neck shortening measurement|We examine femoral neck shortening in patients with femoral neck fractures.
219501228|NCT02545413|DRUG|Probiotic VSL#3|
219605581|NCT00005985|DRUG|cyclophosphamide|
219605582|NCT00005985|DRUG|cytarabine|
219605583|NCT00005985|DRUG|dexamethasone|
219605584|NCT00005985|DRUG|etoposide|
219605585|NCT00005985|DRUG|mitoxantrone hydrochloride|
219501229|NCT02545413|DRUG|Placebo|
219605586|NCT00005985|PROCEDURE|peripheral blood stem cell transplantation|
219605587|NCT00005985|RADIATION|radiation therapy|
219605588|NCT05256134|DRUG|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
219605589|NCT05256134|DRUG|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
218881190|NCT06392269|DIAGNOSTIC_TEST|Tasso+SST|Clinical evaluation of capillary blood samples collected using the Tasso+SST device for downstream analyte testing.
219605590|NCT01628432|PROCEDURE|conservative hysterectomy I|conservative hysterectomy for benign disease
218881191|NCT04697732|OTHER|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
218881192|NCT03669237|PROCEDURE|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
218881193|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
218881194|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
219605591|NCT01628432|PROCEDURE|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
219605592|NCT00304252|DRUG|Interferon beta-1a|
219605593|NCT06079411|DEVICE|virtual reality non-embodied|the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
219605594|NCT06079411|DEVICE|virtual reality embodied|the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
218881195|NCT00004245|DRUG|sodium salicylate|
218881196|NCT04225793|DRUG|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
218881197|NCT04225793|DRUG|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
218881198|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
219200696|NCT06812052|RADIATION|Hypofractionationed Radiation Therapy|This group is receiving hypofractionated radiation therapy (shorter course of RT)
219605595|NCT06079411|OTHER|treatment as usual|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises"
219605596|NCT01567462|DEVICE|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
219605597|NCT01567462|DEVICE|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
219605598|NCT05395260|DRUG|FL-101|FL-101 200mg IV
219605599|NCT01818882|OTHER|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
219605600|NCT01818882|DEVICE|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
219605601|NCT03870880|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
219605602|NCT03870880|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
219605603|NCT04369274|DEVICE|Mechanical ventilation with the automated BVM compressor|Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
219605604|NCT05425212|OTHER|Functional activation with kinesio tapping|These exercises will be carried out thrice a week for 4 weeks. The exercises will be performed for approximately 35-45 minutes, 1 to 2 times a day, in sitting or standing position
219605605|NCT05425212|OTHER|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; 4 days a week for 4 weeks
219605606|NCT03412695|DEVICE|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
219605607|NCT00281281|DRUG|vancomycin|
219605608|NCT03820128|OTHER|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
219605609|NCT01307332|DRUG|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
219501230|NCT06035783|DEVICE|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
219501231|NCT03639272|PROCEDURE|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
219501232|NCT04767490|PROCEDURE|Standard Duodenal Switch|
219501233|NCT04767490|PROCEDURE|Single Anastomosis Duodenal Switch|
219501234|NCT02485496|DEVICE|Endovascular abdominal repair|
219605610|NCT00421161|DRUG|olive oil and omega 3 in a combined cream|
219605611|NCT02871011|DRUG|Nitric Oxide|Delivered as a footbath
218881199|NCT02574689|BEHAVIORAL|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
218881200|NCT02574689|BEHAVIORAL|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
219027262|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
219501235|NCT01720628|OTHER|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
219605612|NCT02871011|DRUG|Water|Delivered as a footbath
219605613|NCT05819970|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
219605614|NCT05819970|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
219605615|NCT03613181|DRUG|ANG1005|Investigational drug
218881201|NCT03147534|DEVICE|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
218881202|NCT03147534|DEVICE|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
219501236|NCT00004843|PROCEDURE|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
219501237|NCT00004843|OTHER|Observation|Usual care
219501238|NCT06546683|OTHER|Short-Chain Fatty Acids|Colon-delivery capsules of Short-Chain Fatty Acids will be administered in a ratio of 60:20:20, thus 150 mmol of acetate, 50 mmol of propionate and 50 mmol of butyrate equivalent to 20g of fibers, once daily, one week
219501239|NCT06546683|OTHER|Placebo|Microcrystalline Cellulose will be used as placebo, one daily, one week
219501240|NCT02687204|DRUG|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
219605616|NCT03613181|DRUG|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
219605617|NCT00886015|DEVICE|TT Clamp|trichiasis surgery performed with TT clamp
219605618|NCT00886015|PROCEDURE|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
219605619|NCT00021385|DRUG|carboplatin|
219605620|NCT00021385|DRUG|squalamine lactate|
219605621|NCT03260556|DRUG|Pirfenidone|Increasing doses
219605622|NCT03260556|DRUG|Placebos|Increasing doses
219605623|NCT01977417|DRUG|Salsalate|
219605624|NCT01977417|DRUG|Placebo|
219605625|NCT05928065|OTHER|Collection of datas|Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
219605626|NCT05082818|COMBINATION_PRODUCT|Chemotherapy, Radiotherapy and surgery|Trans urethral resection of the tumour or radical cystectomy
219605627|NCT00022594|DRUG|liposomal lurtotecan|
219605628|NCT03500068|DIAGNOSTIC_TEST|biopsies & blood analyses|They will take blood and a biopsy from the metastase in the patient
219605629|NCT03397589|BEHAVIORAL|Community Health Worker (CHW) services|CHWs are non-clinical people who provide education, care coordination, and support to families.
219501241|NCT02687204|DRUG|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
219501242|NCT00198081|DRUG|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
219605630|NCT03182933|DRUG|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
219605631|NCT03182933|BEHAVIORAL|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
218881203|NCT03147534|DEVICE|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
218881204|NCT03147534|DEVICE|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
218881205|NCT01609881|DRUG|Acuvail|Dosing of drug 3 days prior to surgery
218881206|NCT01609881|OTHER|Placebo|Artificial tears qid for 3 days preoperatively
218881207|NCT05895240|DRUG|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
219501243|NCT00198081|DRUG|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
219501244|NCT04829409|PROCEDURE|Paravertebral block|Patients receive ultrasound-guided paravertebral block
219501245|NCT04829409|PROCEDURE|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
219501246|NCT04829409|PROCEDURE|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
219501247|NCT05195554|OTHER|Psycho-educational intervention|Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
219501248|NCT03057288|DEVICE|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
219501249|NCT03679845|DRUG|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
219501250|NCT04630366|DRUG|NST-1024|NST-1024
219501251|NCT04630366|DRUG|Placebo|Matching placebo to NST-1024
219605632|NCT03182933|OTHER|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
219605633|NCT03182933|DEVICE|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
219605634|NCT02681861|DRUG|ASP6294 Intravenous|Intravenous (IV)
218881208|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
218881209|NCT06396624|RADIATION|Intervention Group photobiomodulation|Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.
218881210|NCT06396624|OTHER|Control Group|The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
218881211|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
218881212|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
219501252|NCT04979065|DIETARY_SUPPLEMENT|Probiotics, Vitamin D|Combination of two supplement that given separately
219501253|NCT04979065|OTHER|Placebo|Placebo with inactive ingredient
219501254|NCT02606682|DRUG|NPT200-11|Single doses of NPT200-11capsules, orally administered
219501255|NCT02606682|DRUG|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
219501256|NCT03060031|DRUG|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
219501257|NCT03060031|DRUG|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
219501258|NCT02825472|BEHAVIORAL|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
219501259|NCT04413669|PROCEDURE|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
218881213|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
218881214|NCT05694299|DEVICE|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
218881215|NCT05694299|OTHER|Nasal patch|Regular adhesive tape for medical use.
219501260|NCT04953481|OTHER|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
219605635|NCT02681861|DRUG|ASP6294 Subcutaneous|Subcutaneous (SC)
219605636|NCT02681861|DRUG|Placebo Intravenous|Intravenous (IV)
219605637|NCT02681861|DRUG|Placebo Subcutaneous|Subcutaneous (SC)
219605638|NCT02748304|OTHER|control|just follow up
218881216|NCT05137977|PROCEDURE|Intensive Care|Invasive ventilation more than 24hs.
219605639|NCT02748304|DRUG|sorafenib|sorafenib 400mg bid po
219605640|NCT02748304|DRUG|aspirin|aspirin 100mg qd po
219605641|NCT00855894|DRUG|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
219605642|NCT00855894|DRUG|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
219605643|NCT05408130|DEVICE|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
219605644|NCT05408130|DEVICE|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
218881217|NCT05329064|BIOLOGICAL|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
218881218|NCT00996983|DRUG|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
218881219|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
218881220|NCT01183455|DRUG|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
218881221|NCT01183455|DRUG|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
219027263|NCT05616741|DEVICE|Cerebri biofeedback|Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
219027264|NCT05616741|OTHER|Cerebri headache diary|Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
219501261|NCT06249217|BEHAVIORAL|Good Nights Sleep Program|The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
219501262|NCT00738010|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
219027265|NCT06428305|OTHER|Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide|As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
219027266|NCT05330325|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
219027267|NCT05330325|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
219027268|NCT06273891|DRUG|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
219501263|NCT00738010|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
219501264|NCT00738010|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
219501265|NCT01384864|DRUG|proflavine|2-6 ml of 0.01% proflavine
219605645|NCT01981460|PROCEDURE|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
219605646|NCT06254716|PROCEDURE|disc resection|disc resection refers to the full-thickness resection of the lesion and the intestinal wall, usually anterior rectal wall. During the operation, the anterior intestinal wall is opened and then sutured or anastomosed with a stapler. Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
218881222|NCT05400304|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
218881223|NCT00478686|PROCEDURE|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
218881224|NCT00003775|DRUG|leflunomide|
219501266|NCT01416207|DRUG|Avonex|4 weekly injections of Avonex (IM)
219501267|NCT00112515|DRUG|modafinil|
219501268|NCT00112515|PROCEDURE|cognitive assessment|
219501269|NCT00112515|PROCEDURE|psychosocial assessment and care|
219501270|NCT00112515|PROCEDURE|quality-of-life assessment|
219501271|NCT01652261|DRUG|ABVD + FDG-PET/CT Scan treatment adaptation|
218881225|NCT04167137|DRUG|SYNB1891|SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
218881226|NCT04167137|DRUG|Atezolizumab|Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
219027269|NCT06273891|DRUG|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
219027270|NCT01719666|PROCEDURE|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
219027271|NCT01719666|PROCEDURE|conventional surgery|conventional surgery: MPFL reconstruction
219501272|NCT01652261|DRUG|BEACOPPesc|
219501273|NCT01316588|OTHER|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
219605647|NCT06254716|PROCEDURE|segmental resection|Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
218881227|NCT04794127|DRUG|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
218881228|NCT04794127|DRUG|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
218881229|NCT02762331|DRUG|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
219027272|NCT05227326|DRUG|PCNA Inhibitor AOH1996|Given PO
219027273|NCT05059067|DEVICE|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
219501274|NCT01316588|OTHER|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
219501275|NCT02688101|DRUG|DpC|iron chelator
219501276|NCT03956667|OTHER|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
219501277|NCT00646087|DRUG|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
219501278|NCT00646087|DRUG|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
219501279|NCT01068873|DRUG|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
219501280|NCT04267016|DIAGNOSTIC_TEST|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
219501281|NCT00479401|DRUG|Pramipexol Extended Release|
219501282|NCT00479401|DRUG|Pramipexol Immediate Release|
219501283|NCT00479401|DRUG|Placebo|
219501284|NCT04825509|DEVICE|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
219501285|NCT06543160|OTHER|Immediate SSC and early breastfeeding during CS|Upon birth, the neonate is promptly placed prone on the mother's chest, with their head turned to one side for optimal skin contact. The drying process begins within 5 seconds and is completed within 20 to 30 seconds while the neonate remains on the mother's chest. Delayed cord clamping is practiced, with the cord clamped approximately 1-3 minutes after birth. Breastfeeding cues such as tongue movements or head turning are monitored, and the obstetric nurse assists the mother in initiating breastfeeding as soon as possible. SSC continues throughout the cesarean procedure, and upon completion, the newborn is temporarily separated from the mother for safety during transfer to the surgical cart. SSC is resumed immediately post-transfer and continues for a cumulative duration of at least 90 minutes. The neonate's skin color, breathing, and feeding responses are continuously observed.
219501286|NCT06543160|OTHER|Delayed SSC and breastfeeding after CS|The neonate is dried within 20-30 seconds after birth, the cord is clamped after 1-3 minutes, and then the neonate is sent to the ward to wait for the mother to complete the surgery. Immediate SSC is initiated within one hour after birth and maintained with the mother for at least 90 minutes post-surgery, during which the neonate's skin color and breathing are continuously monitored. The obstetric nurse supports the mother in initiating breastfeeding at the earliest opportunity.
219605648|NCT03669510|OTHER|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
219605649|NCT03242408|DRUG|LPCN 1021|Oral testosterone undecanoate
218881230|NCT02762331|DRUG|Placebo|Placebo intervention
219027274|NCT00877058|BEHAVIORAL|preventive home visit|
219027275|NCT00877058|BEHAVIORAL|senior meetings|
219027276|NCT00284661|PROCEDURE|FAST FIX|Fast fix repair of a meniscal tear
219027277|NCT00284661|PROCEDURE|Meniscal suturing|standard suturing of meniscal tear
219027278|NCT01722240|DRUG|Liraglutide 1.8mg|
219501287|NCT06543160|OTHER|Routine newborn care|Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
219501288|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
219605650|NCT03660319|OTHER|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
219605651|NCT04427540|DRUG|Oxytocin|Oxytocin 10 micrograms IM
219605652|NCT03386552|DRUG|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
219605653|NCT03386552|DRUG|Buffer|Pertubation solution of Ringer-Acetate buffer
219605654|NCT05514561|DIAGNOSTIC_TEST|Fecal calprotectin|To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
219027279|NCT01722240|DRUG|Placebo|
219027280|NCT03514784|DRUG|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
219027281|NCT03514784|DRUG|Placebo|Maltodextrin
219027282|NCT03514784|DRUG|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
219200697|NCT04905095|OTHER|EWS|Early Warning Score will be implemented in the computer system of the nursing station which belong to this intervention group. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
219200698|NCT04905095|OTHER|usual clinical care|Nurses perform their clinical monitoring activities as usual. EWS will not be implemented in their nursing station
219605655|NCT05514561|DIAGNOSTIC_TEST|Fecal immunochemical test|To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
219605656|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
219605657|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
219605658|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
218881231|NCT02483117|OTHER|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
218881232|NCT01549925|OTHER|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
218881233|NCT01549925|DEVICE|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
218881234|NCT02728466|DIETARY_SUPPLEMENT|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
218881235|NCT02728466|DIETARY_SUPPLEMENT|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
218881236|NCT02728466|DIETARY_SUPPLEMENT|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
218881237|NCT01748825|DRUG|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
219501289|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
219501290|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
219605659|NCT03719768|DRUG|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
219605660|NCT03719768|RADIATION|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
219605661|NCT06069063|DRUG|Zafirlukast|Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
219605662|NCT05308511|DEVICE|PC-I and COLON2|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
219605663|NCT05308511|DEVICE|COLON2 and PC-I|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
219605664|NCT04122040|DRUG|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
219605665|NCT04122040|DRUG|Placebo|Placebo one table oral once dialy
219605666|NCT03241641|DRUG|Tenofovir Alafenamide|25mg, Daily Oral
219605667|NCT03241641|DRUG|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
219501291|NCT02777931|DRUG|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
219501292|NCT02777931|DRUG|Placebo|Matching placebo capsules
219501293|NCT01004120|DIETARY_SUPPLEMENT|Bimuno|5.5g daily intake
219605668|NCT02834325|PROCEDURE|mechanical ventilation|
219501294|NCT01004120|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily intake
219501295|NCT02759211|OTHER|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
219501296|NCT02759211|OTHER|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
219501297|NCT05717088|OTHER|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively."
219501298|NCT01493726|DRUG|ALKS 9072, Low dose|IM injection, given monthly
219501299|NCT01493726|DRUG|ALKS 9072, Med dose|IM injection, given monthly
219501300|NCT01493726|DRUG|ALKS 9072, High dose|IM injection, given monthly
219501301|NCT01493726|DRUG|Placebo|Dosed matched placebo IM injection, given monthly
219501302|NCT03918395|DIETARY_SUPPLEMENT|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
219501303|NCT03918395|DIETARY_SUPPLEMENT|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
219501304|NCT03039374|OTHER|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
219501305|NCT01430104|DRUG|Teriparatide|Administered subcutaneously during the Treatment Period
219501306|NCT01430104|DRUG|Aspara-CA 600 mg|Administered orally throughout the study
219605669|NCT04757597|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
219605670|NCT03395288|DRUG|D-Mannose|A total of 2 g D-mannose daily
219501307|NCT01430104|DRUG|Alfarol 1.0 µg|Administered orally throughout the study
219501308|NCT02226939|DRUG|BILN 2061 ZW|
219501309|NCT02226939|DRUG|Placebo|
219501310|NCT03627182|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
219501311|NCT03627182|DRUG|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
219501312|NCT06485492|PROCEDURE|Implant an aneurysm embolization system|The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
219501313|NCT04811222|DIAGNOSTIC_TEST|Ga-DOTATATE PETMRI scan|Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
219501314|NCT03881579|BEHAVIORAL|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
219501315|NCT04495465|OTHER|Radial Shock Wave Therapy|2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
219501316|NCT04495465|OTHER|Manual Therapy|25 minute massage to neck muscles
219501317|NCT04495465|OTHER|placebo shock waves|3 minutes of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
219501318|NCT01436669|DEVICE|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
219501319|NCT04069104|BEHAVIORAL|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
219501320|NCT04069104|BEHAVIORAL|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
219501321|NCT04069104|BEHAVIORAL|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
219501322|NCT04069104|BEHAVIORAL|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
219501323|NCT01571635|DRUG|SOTATERCEPT (ACE-011)|0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
219501324|NCT03865524|DEVICE|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
219501325|NCT03865524|DEVICE|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
219501326|NCT01462500|DRUG|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
219501327|NCT01722266|DRUG|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
219501328|NCT01722266|DRUG|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
218881238|NCT01849419|DRUG|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
218881239|NCT01849419|DRUG|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
219040258|NCT01116232|BIOLOGICAL|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
219501329|NCT05472285|DIETARY_SUPPLEMENT|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
219501330|NCT05472285|DIETARY_SUPPLEMENT|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
219501331|NCT00047489|DRUG|ABT-751|
219501332|NCT03874806|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
219501333|NCT03874806|DRUG|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
219501334|NCT04821882|DRUG|Dextrose|10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
219605671|NCT05606783|BEHAVIORAL|Telehealth Follow-up Visits|"• Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations"
219501335|NCT06545058|PROCEDURE|Penile block|Penile block with local anesthetics
219501336|NCT04360603|DEVICE|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
218881240|NCT01849419|DRUG|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
218881241|NCT02819687|DRUG|RDX5791|
218881242|NCT02819687|DRUG|Placebo|
218881243|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
218881244|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
218881245|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
218881246|NCT03665311|BIOLOGICAL|25% Albumin fluid|25% Albumin fluid (100 mL)
218881247|NCT03665311|OTHER|Normal Saline|0.9% Normal Saline (100 mL)
218881248|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
218881249|NCT04487652|OTHER|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
218881250|NCT04487652|DRUG|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
219027283|NCT05920577|OTHER|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
219027284|NCT05920577|OTHER|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
219027285|NCT05663866|DRUG|Dexamethasone|Dexamethasone will be administered orally.
219501337|NCT04360603|DEVICE|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
219027286|NCT05663866|DRUG|Montelukast|Montelukast will be administered orally.
219027287|NCT05663866|DRUG|Methotrexate|Methotrexate will be administered subcutaneously.
219027288|NCT05663866|DRUG|Amivantamab|Amivantamab will be administered intravenously.
219501338|NCT01001871|DIETARY_SUPPLEMENT|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
219027289|NCT05663866|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
219040259|NCT01116232|DRUG|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
219501339|NCT01001871|DIETARY_SUPPLEMENT|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
219501340|NCT04396470|DEVICE|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
219501341|NCT04486183|OTHER|capillary blood samples|The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
219501342|NCT06080984|DRUG|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL)."
219501343|NCT06080984|DRUG|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
219501344|NCT03279484|DEVICE|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
219501345|NCT01449058|DRUG|BYL719|taken orally
219501346|NCT01449058|DRUG|MEK162|taken orally
219501347|NCT06286566|DEVICE|Implant placement with soi surface in diabetic subjects|Implants placement with SOI surface in subjects with diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
219501348|NCT06286566|DEVICE|Implant placement with soi surface in healthy subjects|Implants placement with SOI surface in subjects without diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
219501349|NCT05658289|PROCEDURE|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
219501350|NCT05658289|PROCEDURE|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
219501351|NCT02522754|BIOLOGICAL|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
219501352|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
218881251|NCT04487652|DRUG|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
219501353|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
218881252|NCT05595772|DRUG|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
218881253|NCT05595772|DRUG|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
218881254|NCT05595772|PROCEDURE|Surgery: Dental Implant surgery|Immediate implant following extraction
218881255|NCT05595772|PROCEDURE|Tooth extraction|A Traumatic tooth extraction
218881256|NCT05595772|PROCEDURE|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
218881257|NCT04841772|DIETARY_SUPPLEMENT|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
218881258|NCT04841772|DIETARY_SUPPLEMENT|Placebo|Post exercise placebo supplement (32g maltodextrin)
219027290|NCT07130734|BEHAVIORAL|Digital Physical Activity|The Pathverse mobile application platform will be downloaded on each participant's smartphone. Participants will be guided on how to download and use the application, as well as how to interact with the application during the intervention period. Participants will choose approximately five types of physical activity they enjoy before the intervention and will be prompted to complete these physical activities throughout the intervention. Participants will also self-report the duration and type of physical activity performed each day of the intervention.
219027291|NCT06228560|BIOLOGICAL|LP-003|Liquid in vial
219501354|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
219501355|NCT02862535|DRUG|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
219501356|NCT02862535|DRUG|S-1|Administered orally
219501357|NCT02862535|DRUG|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
219501358|NCT02862535|DRUG|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
218881259|NCT05785936|PROCEDURE|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
218881260|NCT05964036|DEVICE|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
218881261|NCT05964036|DEVICE|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
218881262|NCT04927572|DRUG|FMX114|Active Comparator
218881263|NCT04927572|OTHER|Vehicle|Placebo Comparator
218881264|NCT00852241|DRUG|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
218881265|NCT00852241|DRUG|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
218881266|NCT02339792|OTHER|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
219605672|NCT05606783|BEHAVIORAL|Surveys|"A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist"
218881267|NCT02524418|PROCEDURE|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
218881268|NCT03342118|DRUG|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
218881269|NCT03342118|DRUG|Normal saline|The control group was treated with normal saline before endoscopy
219501359|NCT02862535|DRUG|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
219501360|NCT01675869|BEHAVIORAL|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
219501361|NCT01675869|BEHAVIORAL|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
219501362|NCT00947765|BIOLOGICAL|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
219501363|NCT00947765|DRUG|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
219501364|NCT04388033|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
219501365|NCT04388033|DRUG|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
219605673|NCT05606783|DEVICE|Devices|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily"
219605674|NCT02548156|OTHER|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
219605675|NCT02548156|OTHER|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
219501366|NCT04388033|DRUG|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
219501367|NCT04380571|DEVICE|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
219501368|NCT04380571|DEVICE|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
219605676|NCT02548156|OTHER|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
219605677|NCT02548156|OTHER|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
218881270|NCT06440551|BEHAVIORAL|TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)|Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
219027292|NCT06228560|BIOLOGICAL|Placebo|Liquid in vial
219027293|NCT06228560|BIOLOGICAL|Omalizumab|Liquid in vial
219027294|NCT06812481|OTHER|Anticholinergic load was calculated using anticholinergic cognitive load (ACB)|"Bone mineral density was measured using a Dual Energy X-ray Absorptiometry (DEXA) device.~Fracture Risk Assessed with Fracture Risk Assessment Tool (FRAX)."
219027295|NCT00966602|DRUG|VX-809|VX-809 capsule, once daily for 14 days
219501369|NCT04380571|OTHER|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
219605678|NCT02548156|OTHER|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
219605679|NCT01345201|BIOLOGICAL|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
219605680|NCT03766295|DRUG|Masitinib|
219027296|NCT00966602|DRUG|VX-770|VX-770 tablet, once every 12 hours for 14 days
219027297|NCT00966602|DRUG|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
219605681|NCT03766295|DRUG|Gemcitabine|
219605682|NCT03766295|DRUG|Placebo|
219605683|NCT01983566|DRUG|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
219605684|NCT01983566|DRUG|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
219605685|NCT01983566|DRUG|BI 207127|BI 207127 as a single dose in fasted state
219605686|NCT01983566|DRUG|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
218881271|NCT06440551|BEHAVIORAL|TeleSalud General Health Intervention|Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
219501370|NCT02758093|BEHAVIORAL|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
219501371|NCT02758093|OTHER|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
219501372|NCT03501342|OTHER|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
219501373|NCT03501342|OTHER|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
219501374|NCT03929224|DRUG|Medicinal honey|Treat healing surgical site with medicinal honey
219501375|NCT03929224|DRUG|Bacitracin|Treat healing surgical site with bacitracin
219501376|NCT00046371|DRUG|THERATOPE® vaccine|
219501377|NCT04238780|PROCEDURE|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
219501378|NCT04238780|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
219501379|NCT00303381|DRUG|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
219501380|NCT00303381|DRUG|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
219501381|NCT00303381|DRUG|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
218881272|NCT00118430|BEHAVIORAL|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
219027298|NCT00966602|DRUG|Placebo|Matching Placebo
219027299|NCT00772200|PROCEDURE|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
219501382|NCT02850445|DRUG|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
219027300|NCT00772200|OTHER|Quality-of-Life Assessment|Ancillary studies
219501383|NCT02850445|OTHER|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
219501384|NCT02850445|OTHER|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
219501385|NCT02850445|OTHER|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
219027301|NCT06576843|DRUG|INDV-6001|Extended-release subcutaneous injection
219027302|NCT06576843|DRUG|Suboxone|Oral sublingual film
219027303|NCT06576843|DRUG|Sublocade|Extended-release subcutaneous injection
219501386|NCT02276911|DRUG|Ibuprofen|
219501387|NCT02276911|OTHER|normal saline|
219501388|NCT03549663|DRUG|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
219501389|NCT03549663|DRUG|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
219501390|NCT03338270|DIAGNOSTIC_TEST|MRI|MRI sequence without intravenous contrast
219501391|NCT05140018|PROCEDURE|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
219027304|NCT06246539|BEHAVIORAL|VR mindfulness|VR-based mindfulness
219501392|NCT05140018|COMBINATION_PRODUCT|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
219605687|NCT06512753|DRUG|Hydroxychloroquine|HCQ (15) is administered orally at a dosage of 400 mg daily.
218881273|NCT00118430|DRUG|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
218881274|NCT00118430|DRUG|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
219027305|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
219027306|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
219027307|NCT05304585|PROCEDURE|Biopsy|Undergo tumor biopsy
219027308|NCT05304585|PROCEDURE|Bone Scan|Undergo bone scan
219027309|NCT05304585|PROCEDURE|Computed Tomography|Undergo CT scan
219027310|NCT05304585|DRUG|Cyclophosphamide|Given IV
219027311|NCT05304585|BIOLOGICAL|Dactinomycin|Given IV
219027312|NCT05304585|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219027313|NCT05304585|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219027314|NCT05304585|RADIATION|Radiation Therapy|Undergo radiation
219027315|NCT05304585|DRUG|Vincristine|Given IV
219027316|NCT06985069|PROCEDURE|General anesthesia applying multimodal anesthesia|"In the multimodal anesthesia-group a combination of different opioid-sparing drugs are added for general anesthesia, dosages are as follows:~* Magnesium 2g IV~* Dexmedetomidine IV 0.3mcg/kg IBW bolus over 10 minutes, followed by 0.3mcg/kg IBW until 30 min. before the end of surgery or the maximal dosage of 1.4mcg/kg IBW.~* Ketamine IV 0.3mg/kg IBW bolus, followed by 0.3 mg/kg IBW or a max. Dose of 25mg/h, until 30 min. before the end of surgery.~* Lidocaine IV 1mg/kg IBW bolus, followed by 1mg/kg/h IBW until in PACU/ICU"
219027317|NCT06985069|PROCEDURE|General anesthesia using conventional opioid-based regimen|Opioids (Fentanyl, Methadone, Hydromorphone) at the discretion of the treating anesthetist
219501393|NCT05140018|PROCEDURE|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
219501394|NCT03629847|DRUG|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
219501395|NCT06160674|OTHER|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
219605688|NCT06512753|DRUG|Methotrexate|MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
219027318|NCT05042440|DRUG|Efanesoctocog alfa|Solution for injection Intravenous
219027319|NCT05042440|DRUG|Octocog alfa|Solution for injection Intravenous
219027320|NCT05042440|DRUG|Rurioctocog alfa pegol|Solution for injection Intravenous
219027321|NCT04827914|BEHAVIORAL|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
219501396|NCT04898725|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 4800IU daily
218881275|NCT02147288|DEVICE|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
218881276|NCT00171847|DRUG|Letrozole|
218881277|NCT00171847|DRUG|Trastuzumab plus Letrozole|
218881278|NCT00171847|DRUG|Letrozole|
219027322|NCT04827914|BEHAVIORAL|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
219027323|NCT06286280|DEVICE|cytokine adsorber (CytoSorb®)|binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
219027324|NCT05819554|PROCEDURE|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
219027325|NCT04129138|OTHER|Survey Administration|Complete survey
219027326|NCT06654219|OTHER|GLP-1 RA users with prolonged fasting instructions|NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.GLP-1 RA will not be held prior to surgery and usual dosing schedule will be followed prior to procedure.
219027327|NCT06654219|OTHER|GLP-1 RA users with standard NPO instructions|NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids. Last dose of GLP-1 RA no less than 7 days prior to procedure.
219027328|NCT06282562|OTHER|High-Intensity Interval Training (HIIT)|Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
219501397|NCT03348982|BEHAVIORAL|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
219501398|NCT00235833|BIOLOGICAL|adalimumab|40 mg every other week (eow), subcutaneous (sc)
219501399|NCT05478603|DRUG|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
219501400|NCT05578222|DRUG|Pembrolizumab|Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
219605689|NCT02937311|OTHER|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
219605690|NCT02937311|OTHER|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
218881279|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
218881280|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
219200699|NCT03479255|BEHAVIORAL|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patients from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent matters related to their care.
219200700|NCT03479255|BEHAVIORAL|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
219605691|NCT02937311|OTHER|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
219605692|NCT04456777|DRUG|Vortioxetine|vortioxetine will be administreted for 3 months
219200701|NCT04649099|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
219200702|NCT06746519|DRUG|BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine|The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
219200703|NCT04724928|RADIATION|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
219605693|NCT05348083|PROCEDURE|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
219605694|NCT00581750|OTHER|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
219605695|NCT02323425|DEVICE|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
219605696|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Full|Participants in this active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 2.0 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
219605697|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Sham|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) 21% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
219605698|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Partial Pressure|Participants in this partial treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
218881281|NCT00744107|DEVICE|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
218881282|NCT05535829|OTHER|Laboratory analysis of samples|Laboratory analysis of samples
218881283|NCT00669383|DRUG|betamethasone|12 mg IM q 24 hours x 2 doses
219200704|NCT04724928|DRUG|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
218881284|NCT00669383|DRUG|placebo|Placebo IM q 24 hours x 2 doses
218881285|NCT00033891|DRUG|Infliximab|
218881286|NCT04217044|DIAGNOSTIC_TEST|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
219501401|NCT05729100|OTHER|Oral carbohydrate-electrolyte solution|Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)
219605699|NCT03909919|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
219605700|NCT03896529|BEHAVIORAL|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
219501402|NCT05729100|OTHER|Control|Standard clear fluid (water)
219501403|NCT04220034|BIOLOGICAL|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
219501404|NCT04049695|BEHAVIORAL|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
219501405|NCT04049695|BEHAVIORAL|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
219501406|NCT00533520|DRUG|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
219501407|NCT02472977|DRUG|Ulocuplumab|
219501408|NCT02472977|DRUG|Nivolumab|
219501409|NCT03654807|BEHAVIORAL|High Intensity Walking|70-80% HRmax
219501410|NCT03654807|BEHAVIORAL|Casual Speed Walking|Self selected pace
219501411|NCT04525690|BEHAVIORAL|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
219501412|NCT05621200|DEVICE|Transcranial stimulation over the cerebellar hemispheres|Single session of Transcranial stimulation over the cerebellar hemispheres
219501413|NCT06547853|BEHAVIORAL|Physical exercise|Groups will be enrolled in a 12-week exercise program. The intervention will be carried out in a highly complex oncology center in Maceió-AL, using the FITT components of the prescription: frequency (4 days a week), intensity (aerobic part through musical beats, subjective perception scale and resistance exercises through a number of maximum repetitions), the time of each session will be 45 minutes, the type of activity offered will be combined exercise training and aerobic exercise training (i.e., walking).
218881287|NCT02948738|BEHAVIORAL|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
219501414|NCT01893866|DRUG|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
219501415|NCT01893866|DRUG|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
219501416|NCT03185299|OTHER|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
219501417|NCT03185299|OTHER|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
219605701|NCT01068262|DRUG|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
219605702|NCT01068262|DRUG|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
218881288|NCT02948738|BEHAVIORAL|Standard Asthma Education|Basic review of asthma action plan and inhaler use
219501418|NCT05826769|DIETARY_SUPPLEMENT|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
219501419|NCT05882968|DIAGNOSTIC_TEST|kidney function tests|using GFR test according to kdigo guide lines
219501420|NCT01080105|BEHAVIORAL|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
219501421|NCT01080105|BEHAVIORAL|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
219027329|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
219027330|NCT03628703|DEVICE|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
219027331|NCT06818695|OTHER|Imaginal Exposure for Anorexia Nervosa|Imaginal exposure aims to use the power of imagining the fearful situation to heighten anxiety and by not engaging in imaginative restriction or other eating disorder behaviours, the individual, in theory, can habituate to the anxiety until it naturally subsides.
219027332|NCT06818695|OTHER|Treatment as Usual (TAU)|TAU includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs)
219027333|NCT06661850|PROCEDURE|Fusion or TDR determined by investigator.|The surgical treatment will be decided by the treating investigator based on their clinical judgement.
219027334|NCT06198712|DRUG|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
218881289|NCT03960892|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
219501422|NCT01080105|BEHAVIORAL|Educational website|Participants will receive access to a static educational website for 12 weeks.
219501423|NCT01618773|DRUG|0.1% adapalene / 2.5% benzoyl peroxide|topical application
219501424|NCT06538974|DEVICE|Hands-free exoskeleton|During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
219027335|NCT04460209|OTHER|Standard of Care|Standard of care mapping and/or ablation
219027336|NCT06770985|OTHER|Artificial Intelligence|"Ollama (Ollama., 2024, https://ollama.ai/) artificial intelligence program and PYTHON 3 Programming Language and open source libraries will be used for the necessary algorithms for data review and analysis. In case of deficiencies in the data of the patients; the missing data will be edited using Data Imputation techniques. Number of files to be reviewed and/or date range to be covered: Patients who underwent lung resection between January 2023 and October 2024 will be included. An estimated 2000 files are planned to be scanned."
219027337|NCT06985238|DEVICE|MRI|Will receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
219027338|NCT06981884|OTHER|core stabilization exercises|Participants will be given core stabilization exercises 2 days a week, 45 minutes per session, for 2 months. At the end of 2 months, the outcome measurements will be taken by an evaluator physiotherapist who is not present during the treatment.
219027339|NCT06981884|OTHER|motor imagery training group|core stabilization exercise + motor imagery training group Participants will be given core stabilization exercises and motor imagery training 2 days a week, 60 minutes per session, for 2 months. Motor imagery training will be applied for 15 minutes immediately after the core stabilization exercisesAt the end of 2 months, the outcome measurements will be taken by the same evaluator physiotherapist who is not present during the treatment
219027340|NCT06586177|DRUG|Anti-CD20 antibody|Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
219501425|NCT04890704|DRUG|Curcuminoid|Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
218881290|NCT02427776|BIOLOGICAL|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
218881291|NCT02173587|DIETARY_SUPPLEMENT|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
218881292|NCT02173587|DIETARY_SUPPLEMENT|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
218881293|NCT02069392|BEHAVIORAL|Cognitive remediation training|
218881294|NCT02069392|DRUG|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
218881295|NCT02997982|DRUG|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
219027341|NCT01928524|DRUG|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219027342|NCT01928524|DRUG|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219027343|NCT01928524|DRUG|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219027344|NCT01928524|DRUG|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219501426|NCT04890704|DRUG|Placebo|Identical capsules were used for the placebo from the same manufacturer.
219501427|NCT04721756|DRUG|18F-LY3546117 Injection|370 megabecquerel (MBq) intravenous injection
219501428|NCT04721756|PROCEDURE|PET Scan|positron emission tomography (PET) scan
218881296|NCT00269633|DEVICE|Blue Light Box 467 nm|467 nm Blue LED Light
218881297|NCT00269633|DEVICE|Red Light Box 657 nm|657 nm Red LED Light
219501429|NCT04005105|BEHAVIORAL|Intensive management|Management based on premorbid MAP and MPP
219501430|NCT00863369|BIOLOGICAL|rituximab|Given IV
219501431|NCT00863369|DRUG|bortezomib|Given IV
219501432|NCT00863369|DRUG|gemcitabine hydrochloride|Given IV
219501433|NCT00863369|OTHER|questionnaire administration|Ancillary studies
219501434|NCT04582448|DRUG|Insulin icodec|A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
219027345|NCT01928524|DRUG|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219027346|NCT01928524|DRUG|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219605703|NCT05277662|DIAGNOSTIC_TEST|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
219501435|NCT02662322|OTHER|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
219501436|NCT02662322|OTHER|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
219501437|NCT02662322|OTHER|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
219501438|NCT02662322|OTHER|peripheral intravenous catheterization|peripheral intravenous catheterization
219501439|NCT02683733|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
219501440|NCT02683733|DRUG|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
219501441|NCT03876158|DEVICE|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
219501442|NCT01888328|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
219501443|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
219605704|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
219605705|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
219605706|NCT06496880|DIETARY_SUPPLEMENT|Oxyjun TM|One capsule daily to be taken after breakfast for 56 days
219605707|NCT06496880|DIETARY_SUPPLEMENT|Placebo|One capsule daily to be taken after breakfast for 56 days
219027347|NCT01928524|DRUG|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
219027348|NCT06857422|BEHAVIORAL|Hand Fan Application|Participants in the experimental group will be instructed to use a hand fan to cool their face for 10 minutes each day for a period of 6 weeks. The fan should be held approximately 15 cm from the face, focusing on the middle area. This intervention aims to alleviate symptoms of dyspnea and improve psychological well-being, including anxiety, depression, and illness perception. The participants will receive daily reminders to ensure consistent application of the intervention.
219200705|NCT04724928|PROCEDURE|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
219200706|NCT06827353|DRUG|maintenance therapy with bevacizumab|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received bevacizumab after chemotherapy.
219200707|NCT06827353|DRUG|maintenance therapy with niraparib|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received niraparib after chemotherapy.
219501444|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
219501445|NCT05459168|DEVICE|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
219501446|NCT05879900|OTHER|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
219501447|NCT05879900|OTHER|Physical Education classes|Physical Education classes according their previously planned contents.
219501448|NCT00524875|DRUG|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
219501449|NCT03483844|DIAGNOSTIC_TEST|GE CT 750 HD|Low-dose dual-energy CT imaging
219501450|NCT04933669|DRUG|Imatinib|Imatinib neoadjuvant therapy
219501451|NCT03889457|OTHER|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
219501452|NCT02584205|DEVICE|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
219501453|NCT02784717|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
219605708|NCT04405297|DEVICE|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
218881298|NCT00317382|DEVICE|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
218881299|NCT04412707|DRUG|Melphalan|Peripheral versus central administration
218881300|NCT04412707|DRUG|Dexamethasone|Oral tablets
219200708|NCT06119074|OTHER|Gifted Savings|Gifted Savings assets will be in the form of cash, Bitcoin, and/or stock. Participants will receive identical asset portfolios. The asset mix will be determined by Gifted Savings. Participants will not have any control over the assets they receive, nor the proportion of each in their account. After registration on the Gifted Savings website, participants can immediately withdraw $100 USD if they choose. Then, for each of the first two years, participants may withdraw up to $500 USD for an emergency (self-attested) if the value of the account is 50% or more of its value 30 days prior and the account has sufficient funds to fulfill the request. Two years post-enrollment, participants may withdraw the entire value of their GS account or continue holding the assets in their GS account (in perpetuity or until the GS non-profit ceases to exist). GS funds are unconditional; there are no restrictions or limitations on how the money can be spent.
219200709|NCT06674018|DIETARY_SUPPLEMENT|Indole-3-propionic acid|A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
219501454|NCT03010202|DRUG|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
219501455|NCT03010202|DRUG|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
218881301|NCT05532280|DRUG|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
219501456|NCT02295683|DEVICE|Renal Denervation|
218881302|NCT05532280|DRUG|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
218881303|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
218881304|NCT06486415|DIAGNOSTIC_TEST|serum BHCG testing|Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
218881305|NCT02386501|DRUG|ADXS31-164|
218881306|NCT02275442|OTHER|EPICES scale|
218881307|NCT02476006|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
219501457|NCT03374137|BIOLOGICAL|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
219501458|NCT00738920|BEHAVIORAL|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
219501459|NCT00738920|BEHAVIORAL|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
219501460|NCT00738920|BEHAVIORAL|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
219501461|NCT06284707|OTHER|swimming training|2 sessions per week of swimming training
219501462|NCT06284707|OTHER|rhythmic gymnastics training|2 training sessions of rhythmic gymnastics
219501463|NCT05217056|OTHER|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
219501464|NCT03635684|DRUG|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
218881308|NCT02476006|DRUG|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
218881309|NCT02476006|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
218881310|NCT02476006|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
218881311|NCT02476006|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
218881312|NCT02476006|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
218881313|NCT02335593|DIETARY_SUPPLEMENT|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
218881314|NCT02335593|OTHER|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
218881315|NCT02335593|DRUG|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
218881316|NCT02335593|DRUG|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
218881317|NCT03872791|BIOLOGICAL|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
218881318|NCT03872791|DRUG|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
218881319|NCT00240669|DEVICE|Resorbable device PLLA/PGA|
218881320|NCT00240669|DEVICE|Titanium device|
218881321|NCT03831035|OTHER|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
218881322|NCT00997594|PROCEDURE|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
219027349|NCT06857422|OTHER|Standard Care for COPD Patients|Participants in the control group will receive standard care for chronic obstructive pulmonary disease (COPD) patients. This includes routine management and treatment as prescribed by their healthcare providers, such as medication and lifestyle recommendations. They will not be instructed to use a hand fan or any other cooling device during the study period. The control group will continue their regular care without any additional interventions from the research team.
219027350|NCT04350788|OTHER|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
219027351|NCT04350788|OTHER|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
219200710|NCT06674018|DIETARY_SUPPLEMENT|Placebo|Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
219200711|NCT05948657|DIAGNOSTIC_TEST|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
219501465|NCT03371238|BEHAVIORAL|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
219605709|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months
219501466|NCT04742725|DRUG|Placebo|Placebo
219501467|NCT04742725|DRUG|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
219501468|NCT05244382|OTHER|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
219501469|NCT01130805|DRUG|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
219501470|NCT01921036|PROCEDURE|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
219501471|NCT01921036|PROCEDURE|combined exercise|Moderate endurance and resistance exercise once a week over six months
219501472|NCT03271463|BEHAVIORAL|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
219501473|NCT01025193|DRUG|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
219501474|NCT04079842|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
219501475|NCT02904200|DEVICE|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
219605710|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
219605711|NCT06210022|DIAGNOSTIC_TEST|Neuropsychological Assessment|Cognitive evaluation and clinical monitoring of seizure frequency
219605712|NCT02129322|DRUG|Sorafenib|
219200712|NCT05717725|PROCEDURE|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
219200713|NCT05717725|PROCEDURE|Sham procedure|Patients will receive sham procedure, no ablation.
219501476|NCT02904200|DEVICE|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
219605713|NCT02129322|DRUG|S-1|
219605714|NCT02129322|DRUG|Oxaliplatin|
219605715|NCT00743717|DEVICE|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
219605716|NCT00743717|DEVICE|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
219605717|NCT01662219|OTHER|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
219605718|NCT00959218|DRUG|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
219605719|NCT00959218|DRUG|Placebo|oral solution
219605720|NCT00781807|OTHER|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support"
219605721|NCT01873378|DRUG|Triptorelin 3.75 mg|
219605722|NCT00032383|BEHAVIORAL|Tai Chi|
219501477|NCT02225028|BEHAVIORAL|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
219501478|NCT03833453|BEHAVIORAL|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
219501479|NCT03833453|BEHAVIORAL|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
219605723|NCT00452556|DRUG|Docetaxel|Weekly
219605724|NCT00452556|DRUG|Leuprolide Acetate (Eligard®)|2.5 years
219605725|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
219605726|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
219605727|NCT03938909|GENETIC|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
219605728|NCT01105793|DRUG|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
219605729|NCT00444587|DRUG|Second line chemotherapy|As prescribed
219605730|NCT00444587|DRUG|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
219605731|NCT04407273|DRUG|observational|observational study
219501480|NCT02543736|DEVICE|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
219501481|NCT05837598|BEHAVIORAL|Virtual Cancer and Mental Health Tumor Board|The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
219501482|NCT06427330|DRUG|Inotuzumab ozogamicin|"1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2"
219501483|NCT02431884|PROCEDURE|collect body fluids/tissues & med history|collect tissues/fluids \& history
219501484|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
219501485|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
218881323|NCT03064919|BEHAVIORAL|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
218881324|NCT03683342|PROCEDURE|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
219040260|NCT01116232|DRUG|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
219040261|NCT01116232|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219040262|NCT01116232|PROCEDURE|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
219040263|NCT01116232|PROCEDURE|management of therapy complications|management of therapy complications
219200714|NCT05990335|BEHAVIORAL|mHealth application (custom)|Smartphone based application designed to engage user executive functions
219200715|NCT06363045|DEVICE|NIDEK TONOREF III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
219501486|NCT04460599|OTHER|Observation|Observation of recorded neurological signs
219501487|NCT00176683|PROCEDURE|Capnography|device which measures carbon dioxide at intubation
219605732|NCT03512873|DRUG|Tranilast|Subjects will be treated with tranilast
219605733|NCT05952531|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
219605734|NCT04170465|DRUG|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
219605735|NCT04170465|DRUG|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
218881325|NCT03683342|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
218881326|NCT02454777|BEHAVIORAL|Exercise Intervention|Undergo HIT
218881327|NCT02454777|OTHER|Laboratory Biomarker Analysis|Correlative studies
218881328|NCT02454777|OTHER|Quality-of-Life Assessment|Ancillary studies
219501488|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
219501489|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
218881329|NCT02454777|OTHER|Questionnaire Administration|Ancillary studies
218881330|NCT03850028|OTHER|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
218881331|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
218881332|NCT03574883|DEVICE|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
218881333|NCT03574883|DEVICE|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
219040264|NCT01116232|PROCEDURE|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
219501490|NCT01067859|DRUG|Placebo|Infusion of placebo during 48 hours
219501491|NCT01538706|OTHER|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
219501492|NCT06700499|DRUG|AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)|AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
219605736|NCT00261560|DRUG|acetaminophen|
218881334|NCT06087575|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist device (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a HRPCI procedure. The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
218881335|NCT04591158|DEVICE|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
219501493|NCT05756413|BEHAVIORAL|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
219501494|NCT05860712|OTHER|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
219501495|NCT00581594|PROCEDURE|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
219027352|NCT06989658|DEVICE|SCL miniaturized scleral lens positioning|"1. Experimental evaluation:~   1. TESTs withSCL system~      * Before positioning the SCL lens: slit lamp examination~     * After positioning the SCL lens: slit-lamp examination~     * Tests performed on projected screen.~  2. Tests with a conventional oculometer: tests performed on a projected screen.~2. Ophthalmological assessment:~   1. slit lamp examination~  2. An end-of-study follow-up phone call."
219501496|NCT00581594|PROCEDURE|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
219605737|NCT00582660|DRUG|Celecoxib|400 mg twice a day for 7 days prior to surgery
219605738|NCT00582660|DRUG|Placebo|one tablet of placebo will be given for 7 days prior to surgery
219605739|NCT02666729|PROCEDURE|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
219605740|NCT02666729|PROCEDURE|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
219605741|NCT00847964|DEVICE|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
219027353|NCT03253107|DRUG|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
219027354|NCT06912828|OTHER|Med-LFD intervention|In the beginning of the intervention, blood and stool samples will be collected. All participants of the group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs). In the end of intervention, stool samples will be collected again.
219027355|NCT03465241|DIAGNOSTIC_TEST|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
219027356|NCT00170716|DEVICE|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
219027357|NCT00170716|OTHER|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
219040265|NCT03247166|DEVICE|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
219040266|NCT02482103|PROCEDURE|Renal denervation|Catheter based renal nerve ablation
219040267|NCT02953379|DRUG|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
219040268|NCT02953379|DRUG|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
219501497|NCT03875183|DRUG|INL1|Capsules
219501498|NCT03875183|OTHER|Placebo|Capsules
219501499|NCT01999387|DIETARY_SUPPLEMENT|Allergenic food|
219501500|NCT03571854|DEVICE|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
219501501|NCT03571854|DEVICE|Group VCV|Volume controlled ventilation
219501502|NCT03281434|DIETARY_SUPPLEMENT|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
219501503|NCT03281434|DIETARY_SUPPLEMENT|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
219501504|NCT00012584|DRUG|methylphenidate|
219501505|NCT00012584|DRUG|fluvoxamine|
219501506|NCT04582097|DRUG|Ramipril|angiotensin-converting enzyme inhibitor
219501507|NCT04582097|DRUG|placebo|same odor, color and size as the drug but without the active ingredient
219501508|NCT01004484|OTHER|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
219501509|NCT01004484|OTHER|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
219501510|NCT01321112|DRUG|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
219501511|NCT06528223|DIAGNOSTIC_TEST|biopsy or operation|To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
219501512|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
218881336|NCT05095259|DRUG|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
218881337|NCT05095259|DRUG|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
219027358|NCT01498718|BIOLOGICAL|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
219027359|NCT01498718|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
219501513|NCT01575119|BEHAVIORAL|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
219501514|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
219501515|NCT01575119|BEHAVIORAL|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
219501516|NCT03349918|BEHAVIORAL|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
219501517|NCT02544633|DRUG|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
219501518|NCT01977352|DRUG|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
219501519|NCT01977352|DRUG|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
219501520|NCT02115685|OTHER|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
219501521|NCT04549909|OTHER|collect retrospectively data|Analyse the incidence of BPL in these populations
219501522|NCT05559216|OTHER|Plyometric Training|Plyometric training exercises are being given to the participants to see the changes after the 8 week period
219501523|NCT00208910|BEHAVIORAL|Odorant Cue|
219501524|NCT02257632|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
219501525|NCT02257632|DRUG|Aflibercept 2 mg|Administered as an intravitreal injection
219501526|NCT05640310|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
219501527|NCT06382779|PROCEDURE|reverse shoulder arthroplasty|resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty
219501528|NCT00331630|DRUG|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
219501529|NCT00331630|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
219501530|NCT05403021|BEHAVIORAL|GETCare Intervention|This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
219501531|NCT03739359|OTHER|nasal cannula gas flow|High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
219501532|NCT01063478|DRUG|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
219501533|NCT00000695|DRUG|Interferon beta-1b|
219501534|NCT00000695|DRUG|Zidovudine|
219501535|NCT04963465|DIAGNOSTIC_TEST|Ferning on microscopy|Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
219501536|NCT00242762|DRUG|ZD1839 (IRESSA™)|
219501537|NCT00242762|DRUG|Docetaxel|
219501538|NCT00242762|DRUG|Cisplatin|
219501539|NCT03876574|PROCEDURE|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
219501540|NCT03876574|DRUG|Gemcitabine|Given intra-arterially for 30 minutes
219501541|NCT03876574|DRUG|Floxuridine|Given intra-arterially continuously for 14 days
219501542|NCT03876574|DRUG|dexamethasone|Given intra-arterially continuously with 5-FUDR
219501543|NCT01773512|DRUG|Rosuvastatin|All patients will be using rosuvastatin 40 mg
219501544|NCT01059071|DRUG|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
219501545|NCT01059071|DRUG|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
218881338|NCT05095259|PROCEDURE|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
219027360|NCT05447754|OTHER|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
219501546|NCT00171496|DRUG|Cyclosporine microemulsion|
219501547|NCT00171496|DRUG|Tacrolimus|
219501548|NCT02673164|BIOLOGICAL|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
219501549|NCT01536691|DRUG|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
219501550|NCT01536691|DRUG|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
219501551|NCT01092520|DRUG|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
219501552|NCT00826631|PROCEDURE|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
219501553|NCT02909725|OTHER|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
219605742|NCT05356507|OTHER|Patient population|Questionnaires, standard of care
219605743|NCT02229461|DRUG|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
219605744|NCT02229461|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
219605745|NCT01208805|BEHAVIORAL|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
219605746|NCT00667680|DEVICE|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
219605747|NCT01842529|BIOLOGICAL|botulinum toxin injection|
219605748|NCT01842529|BIOLOGICAL|0.9% normal saline injection|
219605749|NCT01842529|DEVICE|Implantable loop recorder|
219605750|NCT02909244|BIOLOGICAL|Biological sampling|Biological sampling
219605751|NCT02633592|OTHER|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
219605752|NCT02633592|OTHER|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
218881339|NCT05095259|PROCEDURE|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
218881340|NCT05095259|DRUG|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
219027361|NCT05447754|OTHER|balance exercises|TBT
219605753|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
219605754|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
219027362|NCT06676072|DEVICE|PFA Ablation catheter|Deliver RF and/or PF energy using the TactFlex PFA system
219027363|NCT01894581|DIETARY_SUPPLEMENT|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
219027364|NCT01894581|DRUG|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
219027365|NCT06872905|DEVICE|GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)|Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure.
219027366|NCT05206617|OTHER|No intervention - pure observational study|No intervention
219027367|NCT07015281|OTHER|Dry Needling with Percutaneous Electrical Nerve Stimulation (PENS) and Therapeutic Exercises.|Patients assigned to this group (n=50) will receive an intervention in which PENS will be applied for 30 minutes with low frequency parameters (2 Hz) and a pulse width of 120 μs. After 30 minutes of PENS in both groups, the needle will be removed and a compression will be applied for 90 seconds. Once the compression will carried out, the technique will be concluded. Patients will develop a session of PENS and a session with therapeutic exercise once a week.
219027368|NCT07015281|OTHER|Therapeutic Exercise|These participants (n=50) will engage in an exercise protocol with aerobic, isometric, resistence, strength, and stretching exercises. Participants will perform these exercises with a frequency of 3 times a week for 6 weeks, with each session lasting 30 minutes.
219027369|NCT03313804|DRUG|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
219027370|NCT03313804|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
219027371|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
219027372|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend + tributyrin|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
219027373|NCT07020494|OTHER|Placebo|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
219027374|NCT01252940|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
219027375|NCT01252940|DRUG|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
219027376|NCT01252940|DRUG|RTV|Ritonavir (RTV) was administered according to prescribing information.
219027377|NCT01252940|DRUG|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
219027378|NCT05864846|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg/ml Cannabidiol Oral solution
219027379|NCT06629259|DRUG|Guanfacine Extended Release (XR)|3mg tablet once daily
219027380|NCT06629259|DRUG|Placebo|placebo tablet once daily
219027381|NCT07022730|DRUG|Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction|noradrenaline will be given at a rate of 0.2 mcg/kg/min that will start 5 minutes before induction
219027382|NCT07021482|DIAGNOSTIC_TEST|10 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 10 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
219027383|NCT07021482|DIAGNOSTIC_TEST|14 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
219027384|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
219027385|NCT00605982|PROCEDURE|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
219027386|NCT06914674|DRUG|Tamoxifen 20 mg|Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.
219027387|NCT06913751|BEHAVIORAL|standard of care|standard of care therapy with behavioural and occupational therapy along with other pharmacological therapy as required
219501554|NCT02909725|OTHER|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
219027388|NCT06913361|DIAGNOSTIC_TEST|Gongs Mobilization|The treatment begins with moist heat for 10 minutes, Gong's mobilization with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks.
219501555|NCT02909725|OTHER|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
218881341|NCT05095259|DEVICE|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
219501556|NCT03763331|DEVICE|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
219501557|NCT03763331|DEVICE|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
219501558|NCT06541392|OTHER|breakfast 6.30 am|This group will have breakfast time from 6.30 to 7.30 am
219501559|NCT06541392|OTHER|breakfast 7.31 am|This group will have breakfast time from 7.31 to 8.31 am
219501560|NCT02958540|BIOLOGICAL|SynGEM|Prime / boost vaccination in each group
219501561|NCT02958540|OTHER|placebo|prime /boost vaccination
219501562|NCT05482672|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
218881342|NCT05095259|PROCEDURE|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
218881343|NCT05095259|PROCEDURE|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
219027389|NCT06913361|COMBINATION_PRODUCT|Reverse Distraction Technique|The treatment begins with moist heat for 10 minutes, Reverse Distraction technique with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks. Position of the patient: side-lying. The patient is lying at the plinth's edge on the unaffected side. In front of the patient is the therapist's position.
219027390|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
219027391|NCT03207945|OTHER|Placebo|Placebo
219027392|NCT06924957|OTHER|3D HRAM|The test will be performed both in supine and sitting position successively, using 3D HR-ARM. Resting, squeeze pressures, and bear down manoeuvre variables will be obtained. Diagnosis of dyssynergic defecation requires \< 20% relaxation of anal sphincter and/or intrarectal pressure\>40 mmHg during bear down manoeuvre.
219501563|NCT05482672|BEHAVIORAL|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
219501564|NCT05482672|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
219501565|NCT05482672|BEHAVIORAL|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
219501566|NCT03654534|DIETARY_SUPPLEMENT|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
219501567|NCT00936884|DRUG|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
219501568|NCT00936884|DRUG|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
219605755|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
219027393|NCT06758232|OTHER|Exercise|It will consist of sessions that include neck anatomy, biomechanics, proper posture, ergonomics and neck exercise training.
219027394|NCT01964703|DRUG|Rubus occidentalis extract|
219501569|NCT04741503|OTHER|Breast Cancer Screening Decision Support Tool|-Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
219501570|NCT04741503|OTHER|National Cancer Institute Breast Cancer Screening PDQ|-Provides current information about breast cancer screening and is meant to inform and help patients
219501571|NCT00217412|DRUG|vorinostat|Given orally
219501572|NCT00217412|DRUG|isotretinoin|Given orally
219501573|NCT05703555|DRUG|Tusamitamab ravtansine|Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
219501574|NCT02241681|DIETARY_SUPPLEMENT|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
219501575|NCT05658614|BIOLOGICAL|Sm14 recombinant vaccine+ GLA-SE adjuvant|rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
219501576|NCT05480618|BEHAVIORAL|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~1. frequency (between 0.25 and 0.1 Hz)~2. Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~3. with and without ujjayi (yogic throat restriction)~4. with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
219501577|NCT02280421|DRUG|ASP2151 400mg + 100mg ciclosporin|
219501578|NCT02280421|DRUG|ASP2151 1200mg + 100mg ciclosporin|
219501579|NCT02797964|DRUG|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
219501580|NCT01859390|DRUG|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
219501581|NCT01859390|DIETARY_SUPPLEMENT|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
219501582|NCT04022070|OTHER|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
219501583|NCT04733352|OTHER|acupuncture|to conduct acupuncture on different acupoints
219501584|NCT01088152|BEHAVIORAL|Celiac school|Structured education of adult celiac patients at 10 sessions.
219501585|NCT01088152|BEHAVIORAL|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
219501586|NCT00840359|PROCEDURE|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
218881344|NCT05095259|PROCEDURE|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
218881345|NCT05095259|DEVICE|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
218881346|NCT05860231|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
219027395|NCT04690751|DRUG|Cenobamate 200Mg Tab Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
219501587|NCT00840359|PROCEDURE|Cryotherapy|Cryotherapy for 2 times 20 sec
219501588|NCT02057952|BEHAVIORAL|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
219501589|NCT04868409|DRUG|Suxamethonium|1 mg/kg for tracheal intubation after 60 seconds
219501590|NCT04868409|DRUG|Rocuronium|1 mg/kg for tracheal intubation after 60 seconds
219501591|NCT01567371|DEVICE|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
219501592|NCT02888769|BEHAVIORAL|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
219501593|NCT02764489|BIOLOGICAL|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
219501594|NCT03526367|DRUG|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
219501595|NCT03526367|DRUG|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
219200716|NCT06363045|DEVICE|Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
219200717|NCT06363045|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
219200718|NCT06864520|DIETARY_SUPPLEMENT|GAMMA-AMINOBUTYRIC ACID - GABA|Food supplement based on GABA and Melissa extract
219200719|NCT06864520|OTHER|Placebo|Placebo based on microcrystalline cellulose, rice bran, bitter cocoa powder
219200720|NCT06668909|DEVICE|WaveLight® EX500|Phorcidies Planned Contoura LASIK
219501596|NCT04618835|DIAGNOSTIC_TEST|40-Steps-test|40 steps performed on the spot
219501597|NCT06064981|BEHAVIORAL|Text message nudges|"Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life)."
219501598|NCT06064981|BEHAVIORAL|Commitment contract|"In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone."
218881347|NCT05860231|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
218881348|NCT00482625|DRUG|erlotinib hydrochloride|Given PO
218881349|NCT00482625|PROCEDURE|conventional surgery|Undergo pancreatectomy
218881350|NCT00482625|OTHER|immunohistochemistry staining method|Correlative studies
218881351|NCT00482625|GENETIC|protein expression analysis|Correlative studies
218881352|NCT00482625|PROCEDURE|biopsy|Correlative studies
218881353|NCT00482625|OTHER|pharmacological study|Correlative studies
218881354|NCT00482625|OTHER|laboratory biomarker analysis|Correlative studies
218881355|NCT06140173|PROCEDURE|Low osmolar contrast|100 mL of 350 mg omnipaque will be administered via nasogastric tube
219027396|NCT04690751|DRUG|Cenobamate Oral Suspension Fed|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
219027397|NCT04690751|DRUG|Cenobomate Oral Suspension Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
219200721|NCT06677242|DIAGNOSTIC_TEST|Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing|These are additional tests, added to the observational study to collect information on tumor characteristics and to pursue early detection of this diagnosis.
219200722|NCT04661137|DRUG|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
219200723|NCT04661137|DRUG|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
219200724|NCT04661137|DRUG|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
219200725|NCT04661137|DRUG|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
219501599|NCT00293670|DRUG|Goserelin (Zoladex)|
218881356|NCT06140173|PROCEDURE|Sterile water|100 mL of sterile water will be administered via nasogastric tube
218881357|NCT00871338|BIOLOGICAL|GSK2197870A|3 doses given at 2, 3 and 4 months of age
219200726|NCT04661137|DRUG|Pomalidomide|4 mg PO daily for 21 days
218881358|NCT00871338|BIOLOGICAL|Prevenar™|3 co-administered doses, intramuscular into right thigh
218881359|NCT00871338|BIOLOGICAL|Menitorix™|1 booster dose at 12 months of age
218881360|NCT00871338|BIOLOGICAL|Pediacel™|3 doses given at 2, 3 and 4 months of age
218881361|NCT00871338|BIOLOGICAL|Menjugate™|2 doses given at 3 and 4 months of age
218881362|NCT06243640|DRUG|Buagafuran capsules, 15mg/ capsule|Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
218881363|NCT06243640|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
219027398|NCT05819515|PROCEDURE|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
219027399|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
219200727|NCT04661137|DRUG|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
219200728|NCT04661137|DRUG|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
219200729|NCT04414215|BEHAVIORAL|Emotional working memory training|Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
219200730|NCT04414215|BEHAVIORAL|Placebo working memory training|Working memory training that does not involve emotional stimuli using an N-back training program
219200731|NCT06672588|DEVICE|Magnetic Seizure Therapy (MST)|MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
219501600|NCT02038634|DRUG|Betamethasone|
219501601|NCT02038634|DEVICE|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
219501602|NCT00860106|OTHER|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
219501603|NCT01664052|DEVICE|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
219501604|NCT01664052|DEVICE|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
219501605|NCT01664052|DEVICE|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
219501606|NCT01072032|DEVICE|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
219501607|NCT03336632|DRUG|Chidamide|20 mg orally, twice weekly from D-7 to D+14
219501608|NCT03336632|DRUG|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
218881364|NCT02391363|BEHAVIORAL|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
218881365|NCT02391363|BEHAVIORAL|Information and referral|Resource counseling and follow-up for mental health and basic needs
218881366|NCT01078363|DRUG|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
218881367|NCT01078363|DRUG|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
218881368|NCT00282659|DRUG|magnesium L-lactate|
218881369|NCT05263414|DEVICE|tVNS|tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
219501609|NCT03336632|DRUG|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
219501610|NCT05141578|BEHAVIORAL|Luci Coach Assisted Intervention|"The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24."
219501611|NCT03649737|BEHAVIORAL|Exercise Intervention|Attend supervised and unsupervised exercise sessions
219501612|NCT03649737|OTHER|Survey Administration|Ancillary studies
219501613|NCT03649737|OTHER|Quality-of-Life Assessment|Ancillary studies
218881370|NCT01054482|DRUG|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
218881371|NCT01054482|OTHER|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
218881372|NCT00001870|DRUG|Acetylcholine|
218881373|NCT04597385|OTHER|Long-term Follow-Up|No intervention
218881374|NCT03178604|OTHER|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
219501614|NCT01369251|BEHAVIORAL|Hygiene|
219501615|NCT01369251|PROCEDURE|Usual alcohol care|
219501616|NCT03651661|DRUG|human insulin|human insulin administered as nasal spray
219501617|NCT03651661|DRUG|placebo|placebo administered as nasal spray
219501618|NCT03651661|DIAGNOSTIC_TEST|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
219501619|NCT01706198|DRUG|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
219501620|NCT01706198|DRUG|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
219605756|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
218881375|NCT03178604|OTHER|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
218881376|NCT02485132|OTHER|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
218881377|NCT02472301|DIETARY_SUPPLEMENT|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
219501621|NCT06524778|RADIATION|brachytherapy|Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
219501622|NCT02052128|DRUG|onapristone|
219501623|NCT00950183|DEVICE|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
219501624|NCT00950183|OTHER|Ice|postoperative cold therapy
219501625|NCT05127811|DRUG|ZN-d5|BION design
219501626|NCT03294083|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
219501627|NCT03294083|BIOLOGICAL|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
219501628|NCT05565183|DIAGNOSTIC_TEST|MRI (with injection of contrast product)|All patients included in the study will undergo two MRI examinations (with injection of contrast product) before and after the ablation procedure.
219501629|NCT02309554|OTHER|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
218881378|NCT02472301|DIETARY_SUPPLEMENT|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
218881379|NCT02472301|DIETARY_SUPPLEMENT|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
218881380|NCT02037516|DEVICE|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
218881381|NCT02037516|DRUG|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
219027400|NCT06912971|BEHAVIORAL|Self-Knowledge Training Program|The intervention consists of a self-knowledge training program based on the Enneagram framework. Participants attend 7 sessions, focusing on self-awareness, emotional regulation, and personal development. The sessions include theoretical explanations, guided self-reflection exercises, and group discussions to help participants better understand their personality patterns and how these influence their perception of pain and well-being.
219027401|NCT06941324|BEHAVIORAL|Behavioral Intervention|Undergo SFBT-C
219501630|NCT02309554|OTHER|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
219605757|NCT05258201|OTHER|Strain-counterstrain|Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
218881382|NCT02037516|DEVICE|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
218881383|NCT05727735|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
218881384|NCT05727735|DRUG|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
219027402|NCT06941324|OTHER|Best Practice|Receive eTAU
219027403|NCT06941324|OTHER|Communication Intervention|Receive check in calls from clinician
219027404|NCT06941324|OTHER|Discussion|Participate in discussions
219027405|NCT06941324|OTHER|Health Promotion and Education|Receive educational manual
219027406|NCT06941324|OTHER|Health Promotion and Education|Receive educational book
219027407|NCT06941324|OTHER|Interview|Ancillary studies
219027408|NCT06941324|OTHER|Questionnaire Administration|Ancillary studies
219027409|NCT06936943|DRUG|ONO-4538|every 4 weeks
219501631|NCT02309554|OTHER|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
219501632|NCT04014998|OTHER|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
219501633|NCT04313283|BEHAVIORAL|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
219501634|NCT00411047|DRUG|gefitinib|oral drug taken daily around the same time
219501635|NCT00903890|OTHER|Survey|Survey asking questions regarding the subjects cardiac and general health.
219605758|NCT05258201|OTHER|Muscle Energy Technique|Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
219605759|NCT05013125|DIAGNOSTIC_TEST|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
219605760|NCT04174625|DIETARY_SUPPLEMENT|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
219605761|NCT01720225|DRUG|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
219200732|NCT06672588|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q or MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
219200733|NCT06586164|BEHAVIORAL|Targeted Cognitive Training|TCT is a computer-based cognitive training program in which participants train on progressively more difficult auditory processing exercises in order to improve speed, accuracy and fidelity of auditory information processing in order to generate gains in cognition and functioning.
219501636|NCT05731102|DIAGNOSTIC_TEST|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
219501637|NCT01374399|BEHAVIORAL|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
219501638|NCT04295460|DRUG|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
219501639|NCT04161794|OTHER|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
219605762|NCT01720225|DRUG|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
219027410|NCT03899948|BEHAVIORAL|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
219027411|NCT03899948|BEHAVIORAL|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
219027412|NCT04364620|DRUG|AB-16B5|AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
219200734|NCT06590480|BIOLOGICAL|RP1|Genetically modified Herpes Simplex Type 1 Virus
219200735|NCT06590480|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
219501640|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
219501641|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
219501642|NCT04189276|BIOLOGICAL|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
219501643|NCT04189276|BIOLOGICAL|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
219501644|NCT02911389|OTHER|Home PT via web-based platform|
219605763|NCT03759938|DRUG|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
219605764|NCT02368418|PROCEDURE|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
219605765|NCT02368418|PROCEDURE|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
219605766|NCT03024788|DEVICE|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
219605767|NCT01473407|BIOLOGICAL|Epoetin Hospira|Variable dose
219605768|NCT01473407|BIOLOGICAL|Epogen (Amgen)|Variable dose
219605769|NCT06068556|BIOLOGICAL|GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition|Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
219027413|NCT04364620|DRUG|Docetaxel|Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
219027414|NCT07162922|OTHER|8 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 8 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
219027415|NCT07162922|OTHER|14 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
219027416|NCT07164183|DRUG|Indole-3-carbinol|Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks
219501645|NCT02911389|OTHER|Home PT via paper manual|
219501646|NCT02911389|OTHER|outpatient PT|
219605770|NCT02825771|BEHAVIORAL|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
219605771|NCT02825771|BEHAVIORAL|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
219605772|NCT00003056|DRUG|cyclosporine|
219605773|NCT00003056|DRUG|cyclosporine and methotrexate|
219605774|NCT03314909|PROCEDURE|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
219200736|NCT06020027|BEHAVIORAL|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
218881385|NCT04803695|DIAGNOSTIC_TEST|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
219027417|NCT07164183|DRUG|Dienogest|Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks
219501647|NCT05299229|DIAGNOSTIC_TEST|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
219501648|NCT02415166|BIOLOGICAL|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
219501649|NCT02415166|OTHER|NaCl-saline placebo|placebo
219501650|NCT06238492|BEHAVIORAL|game-like computerized activities|Experimental
219605775|NCT03314909|PROCEDURE|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
219605776|NCT03314909|PROCEDURE|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
219605777|NCT00002397|DRUG|Nelfinavir mesylate|
219605778|NCT00002397|DRUG|Saquinavir|
219605779|NCT00002397|DRUG|Lamivudine|
219605780|NCT00002397|DRUG|Stavudine|
219605781|NCT03742193|DRUG|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
219605782|NCT03742193|DRUG|GD regimen|"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
219605783|NCT00372814|BEHAVIORAL|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
219605784|NCT00372814|BEHAVIORAL|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
219605785|NCT00829725|DEVICE|screws-internal fixation|3-4-screws-internal fixation
219605786|NCT00829725|DEVICE|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
219027418|NCT07171424|OTHER|Behavioral therapy and transcutaneous posterior tibial nerve stimulation|Behavioral therapy included appropriate fluid intake, bladder training, habit training, pelvic floor muscle exercises (Kegel exercises), prompted voiding, and scheduled voiding. TPTNS will be applied in a biphasic square waveform with a frequency of 20 Hz and 200 cycles/sec in 30-minute sessions. The current intensity will be varied between 0.5-20 mA according to the patient's pain threshold.
219040269|NCT06139159|OTHER|Outreach/navigator|"* Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database"
219501651|NCT06238492|BEHAVIORAL|Placebo|game-like computerized activities
219501652|NCT03208348|OTHER|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
219501653|NCT00463892|PROCEDURE|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
219501654|NCT05028101|PROCEDURE|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
219501655|NCT05028101|BEHAVIORAL|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
218881386|NCT04091880|BIOLOGICAL|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
218881387|NCT04091880|BIOLOGICAL|EV71 vaccine|administrated with EV71 vaccine only
218881388|NCT04091880|BIOLOGICAL|influenza vaccine|administrated with influenza vaccine only
219501656|NCT02099968|BEHAVIORAL|Comprehensive Lifestyle Modification|"* Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
219501657|NCT02099968|BEHAVIORAL|Standard Lifestyle Modification / modified DASH|"* Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation"
218881389|NCT02510001|DRUG|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
218881390|NCT02510001|DRUG|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
218881391|NCT02510001|DRUG|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
219501658|NCT04044846|BEHAVIORAL|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
219501659|NCT04497324|BIOLOGICAL|Convalescent plasma|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
219501660|NCT05085314|PROCEDURE|Ngenuity digital 3D microscope|Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX
219501661|NCT05085314|PROCEDURE|Conventional microscope|Cataract surgery under topical anesthesia with a conventional microscope
219501662|NCT02517710|PROCEDURE|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
219501663|NCT03826381|DIAGNOSTIC_TEST|Magnetic resonance (MR) spectroscopy of the liver|Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
219501664|NCT03826381|DIAGNOSTIC_TEST|Fibroscan|Transient Elastography for Measurement of liver fibrosis.
219501665|NCT03826381|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
219501666|NCT03826381|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
219501667|NCT03826381|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
219501668|NCT03826381|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
219501669|NCT04998643|DIAGNOSTIC_TEST|Muscle ultrasound to estimate lean body mass|The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
219501670|NCT00717210|DRUG|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
218881392|NCT00830492|DRUG|clomiphene citrate|100 mg from cycle day 3 through 7
219200737|NCT06866769|DIAGNOSTIC_TEST|CTA|The levels of biomarkers are determined before (within 30 days prior to the procedure) and after the implantation of the stent (24-48 hours, 1 month, 3 months, 6 months, and at 1 year), along with the performance of a contrast-enhanced ultrasound. Additionally, a follow-up CT angiography is performed to validate the concordance, that is, to assess if there are changes in the biomarker values determined one month after the implantation of the stent compared to the baseline values that may suggest the presence of complications (endoleaks, infection, thrombosis, etc.).
219501671|NCT00717210|RADIATION|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
218881393|NCT00830492|PROCEDURE|Ultrasound|cycle day 8
218881394|NCT00830492|DRUG|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
218881395|NCT00830492|DRUG|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
218881396|NCT00830492|DRUG|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
218881397|NCT00830492|DRUG|rFSH|150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
218881398|NCT03765892|OTHER|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
219200738|NCT06615115|OTHER|Exercise|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises.
219501672|NCT05088512|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219501673|NCT00782236|DEVICE|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
219501674|NCT02788123|DRUG|bismuth tripotassium dicitrate|oral
219501675|NCT02788123|DRUG|pantoprazole|oral
219501676|NCT05434208|OTHER|Nurse-led telephonic calls|active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
219501677|NCT04051138|OTHER|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
219501678|NCT01114113|DRUG|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
219605787|NCT05583825|OTHER|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
218881399|NCT03765892|OTHER|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
218881400|NCT02816801|OTHER|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
219200739|NCT04393350|DRUG|Lenvatinib|Given PO
219200740|NCT04393350|DRUG|Lenvatinib Mesylate|Given PO
219200741|NCT04393350|BIOLOGICAL|Pembrolizumab|Given IV
218881401|NCT00704704|DRUG|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
218881402|NCT02249611|DEVICE|Mobile physical activity promotion tool|"1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel"
219501679|NCT01114113|DEVICE|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
219501680|NCT01114113|DEVICE|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
218881403|NCT02249611|OTHER|Standard care|Counseling on lifestyles with health education material
218881404|NCT02511886|DRUG|Arbaclofen Placarbil|Arbaclofen Placarbil
218881405|NCT02511886|DRUG|Placebo|Placebo matched tablets
218881406|NCT02683434|DEVICE|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
218881407|NCT00491582|DRUG|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
218881408|NCT05121948|DRUG|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
219200742|NCT04393350|OTHER|Quality-of-Life Assessment|Ancillary studies
219501681|NCT01114113|DEVICE|SmartPill capsule|SmartPill capsule
218881409|NCT02199925|DRUG|Gammaplex 5%|
219200743|NCT04393350|OTHER|Questionnaire Administration|Ancillary studies
219501682|NCT04221555|DRUG|Docetaxel, Oxaliplatin, S-1 and Durvalumab|"1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
218881410|NCT04649463|DIAGNOSTIC_TEST|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
219501683|NCT04221555|DRUG|Durvalumab and Tremelimumab|"1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment."
218881411|NCT03629522|DRUG|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
218881412|NCT01121432|PROCEDURE|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
218881413|NCT03912779|BEHAVIORAL|C2Hear RLOs|Freely available online RLOs
218881414|NCT03912779|BEHAVIORAL|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
218881415|NCT01224717|DRUG|PTH134|
218881416|NCT01224717|DRUG|Placebo|
218881417|NCT01224717|DRUG|Forsteo|
218881418|NCT06361017|PROCEDURE|endovascular thrombectomy|All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
218881419|NCT05200676|DEVICE|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
219200744|NCT05454514|DEVICE|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
219200745|NCT05454514|DEVICE|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
219200746|NCT05454514|OTHER|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
219200747|NCT06869382|DRUG|Foster BDP/Formoterol|Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which is used for managing asthma and chronic obstructive pulmonary disease (COPD).
219200748|NCT06869382|DRUG|Omalizimab|Omalizumab is a monoclonal antibody that specifically targets immunoglobulin E (IgE), a key mediator in allergic asthma. By binding to free IgE in the bloodstream, omalizumab prevents it from attaching to FcεRI receptors on mast cells and basophils, inhibiting the allergic inflammatory cascade that contributes to asthma exacerbations and bronchoconstriction. This intervention is particularly useful in patients with severe allergic asthma, who have high levels of IgE and have not responded well to conventional therapies such as inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
219200749|NCT06869629|PROCEDURE|Targeted axillary dissection|Known metastases are marked before surgery and removed together with a sentinel lymph node biopsy
219605788|NCT03581019|PROCEDURE|uterus transplantation|uterus transplantation from deceased donor
219605789|NCT00001021|BIOLOGICAL|rgp120/HIV-1IIIB|
219605790|NCT00001021|BIOLOGICAL|rgp120/HIV-1MN|
219605791|NCT01027702|BIOLOGICAL|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
219501684|NCT04229303|DRUG|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily \[BID\]) or 4 \[20mg BID\]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily \[QD\]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 \[20mg BID\] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
219501685|NCT04229303|DRUG|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
219501686|NCT02705079|OTHER|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
219501687|NCT00606684|DRUG|GW642444 6.25|GW642444 6.25
219501688|NCT00606684|DRUG|GW642444 3mcg|once daily
219501689|NCT00606684|DRUG|GW642444 12.5mcg|GW642444 12.5mcg
219605792|NCT02301390|DRUG|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
219605793|NCT02301390|DEVICE|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
218881420|NCT05200676|DEVICE|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
218881421|NCT05750576|DEVICE|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
218881422|NCT05750576|DEVICE|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
218881423|NCT04345679|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
218881424|NCT05097443|DRUG|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
218881425|NCT05615207|OTHER|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
218881426|NCT04425382|DRUG|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
218881427|NCT04425382|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
218881428|NCT03874572|BIOLOGICAL|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
218881429|NCT04417153|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
218881430|NCT05414630|DRUG|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
218881431|NCT00607867|OTHER|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
218881432|NCT00607867|OTHER|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
218881433|NCT04482582|RADIATION|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
219501690|NCT00606684|DRUG|GW642444 25mcg|GW642444 25mcg
219501691|NCT00606684|DRUG|GW642444 50mcg|GW642444 50mcg
219501692|NCT00606684|OTHER|placebo|placebo
219605794|NCT05443815|DEVICE|HaemoCer-PLUS|HaemoCer-PLUS
219605795|NCT03678571|OTHER|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
219605796|NCT00129571|DRUG|XL820|
219605797|NCT04018651|BEHAVIORAL|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~1. Importance of daily adherence;~2. Three week delay for full effectiveness describing PrEP like taking the birth control pill;~3. Condom use for other sexually transmitted infection (STI) prevention;~4. Pregnancy prevention plans;~5. Plans for follow up calls~6. Referral to other treatment services if necessary"
219200750|NCT06868992|PROCEDURE|Bariatric surgery (Sleeve Gastrectomy or Gastric Bypass)|Patients undergoin bariatric surgery with simultaneous liver biopsy to analyze MAMs alterations in liver and PBMCs. Follow-up assessments at 6 and 12 months.
218881434|NCT04482582|OTHER|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
218881435|NCT00328367|DRUG|aripiprazole|aripiprazole augmentation of clozapine
218881436|NCT00328367|DRUG|placebo|placebo
219027419|NCT07170631|OTHER|Therapeutic exercise|Participants will follow a 3-month therapeutic exercise program combining general exercises with specific upper limb exercises, including hand proprioception and neurodynamic techniques. Two group sessions per week (1 to 1.15 hours each) will be conducted, with at least 24 hours between sessions. Each session includes warm-up, three progressive work blocks with strength, mobility, and balance exercises, and a cool-down. Strength training uses body weight and equipment, with intensity guided by the Rate of Perceived Exertion (RPE) scale, progressing safely from moderate to higher levels. Mobility and balance exercises target trunk, upper and lower limbs, and postural control. Neurodynamic techniques focus on median, radial, and ulnar nerves using neural sliding and intermittent tension, stopping exercises if pain exceeds 4/10. Supervised by experienced physiotherapists, the program aims to reduce lymphedema and neuropathy symptoms in breast cancer patients undergoing cancer treatment.
219027420|NCT07181395|BEHAVIORAL|Hip Internal Rotation Mulligan Mobilization|Mulligan mobilization applied to hip internal rotation using a mobilization belt. Performed in 3 sets of 10 repetitions, twice weekly for 4 weeks, in addition to conventional physiotherapy.
219200751|NCT06870448|DRUG|Methyprednisolone sodium succinate|Methylprednisolone at a dose of 2 mg/kg/day for 3 consecutive days, with a maximum daily dose of 160 mg (4 vials, 40 mg per vial, Hanhui Pharmaceutical Co., Ltd.). The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug be administered before arterial access closure.
219200752|NCT06870448|DRUG|Placebo|Placebo for 3 consecutive days, with a maximum daily dose of 4 vials (Hanhui Pharmaceutical Co., Ltd.)
219200753|NCT06868901|PROCEDURE|Standard angioplasty + drug-eluting balloon technique|Treatment of restenosis of hemodialysis vascular access via the standard angioplasty + drug-eluting balloon technique
219027421|NCT07181395|BEHAVIORAL|Straight Leg Raise Mulligan Mobilization|Mulligan mobilization applied to straight leg raise under manual traction. Performed in 3 sets of 10 repetitions (15-20 seconds hold), twice weekly for 4 weeks, in addition to conventional physiotherapy.
219027422|NCT07181395|BEHAVIORAL|Conventional Physiotherapy|Conventional physiotherapy including transcutaneous electrical nerve stimulation (20 minutes), massage, lumbar stretching and strengthening exercises, postural training, and patient education. Delivered twice weekly for 4 weeks.
219027423|NCT07179887|DEVICE|Remote Ischaemic Conditioning|Cuff inflation to 20mmHg abocve systolic blood pressure for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minte inflation followed by 5 minute deflation. Total session time 40 minutes
219027424|NCT07179887|DEVICE|Sham Remote Ischaemic Conditioning|Cuff inlfation to 20mmHg only for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minute inflation followed by 5 minutes of deflation. Total session time of 40 minutes
219027425|NCT00075166|PROCEDURE|Stereotactic surgery (SRS)|
219027426|NCT00075166|PROCEDURE|Craniotomy|
219027427|NCT05191446|BEHAVIORAL|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use or requested by patient. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
219027428|NCT05191446|OTHER|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
219027429|NCT06190951|DRUG|cemiplimab|Administered per the protocol
219027430|NCT06190951|DRUG|Fixed Dose Combination (FDC) cemiplimab+fianlimab|Or coadministration, depending on availability.
219027431|NCT06190951|DRUG|Placebo|Administered per the protocol
219027432|NCT05311488|DIAGNOSTIC_TEST|neurofilament light chain|Blood test
219027433|NCT05311488|DIAGNOSTIC_TEST|In-vivo Meissner Corpuscle imaging|Imaging
219027434|NCT05311488|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study
219027435|NCT04273776|DRUG|Suvorexant 10 mg|10 mg of suvorexant
219027436|NCT04273776|DRUG|Zolpidem|5 mg of zolpidem
219027437|NCT04273776|DRUG|Placebos|Avicel
218881437|NCT04350996|OTHER|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
218881438|NCT01199809|DRUG|Placebo|multiple doses
218881439|NCT01199809|DRUG|RO5310074|multiple ascending doses
219605798|NCT06581276|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
219605799|NCT03514966|BEHAVIORAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
219605800|NCT06582836|BEHAVIORAL|The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
219027438|NCT05906082|BEHAVIORAL|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
219027439|NCT05906082|BEHAVIORAL|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
219027440|NCT05831761|DRUG|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
219027441|NCT00561756|BIOLOGICAL|plasmid DNA vaccine therapy|
219027442|NCT00561756|OTHER|flow cytometry|
219027443|NCT00561756|OTHER|immunoenzyme technique|
219027444|NCT02423616|OTHER|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
219027445|NCT00002417|DRUG|Amprenavir|
219200754|NCT06868901|PROCEDURE|Atherectomy + drug-eluting balloon|Treatment of restenosis of hemodialysis vascular access via the atherectomy + drug-eluting balloon technique
219200755|NCT06870318|OTHER|No intervention; Observational study|OptiMoM-NForte is meta-analysis study (observational secondary use of data), the investigators will analyze data from the OptiMoM and NForte trials. No interventions form part of this study.
219200756|NCT06869759|BEHAVIORAL|Implementation strategy - Health Promotion and Education-based intervention|Firstly, three broad strategies will be implemented in the intervention arm (use of advisory boards, sensitization, and linkage to care). The advisory board meetings will be held every month to discuss the progress and receive their feedback. Secondly, orientation and capacity building will be done by onsite coaching to community health workers at the health facility level on BSE. Those trained health workers will frequently capacitate FCHVs during monthly meetings. Then, FCHV will visit the community to be aware of BSE as well as they will be involved in a stigma reduction campaign. Sensitization to FCHVs through orientation and capacity building by providing 3 batch training to selected 3 wards, then FCHVs aware and practice the skills of BSE to the recruited participants during home visit and Thirdly, the suspected and identified cases will be linked by strengthening the referral mechanism of the health system and CHWs reminders for follow-up to cases.
219027446|NCT06518746|OTHER|Cryopreservation of gonadal tissue|Patients at risk for primary gonadal tumors will undergo unilateral or bilateral gonadectomy for clinical purposes as a standard of care, and a portion of the surgically removed tissue will be cryopreserved for fertility preservation. The pathologist will assess the tissue using sterile technique and every other section will undergo histologic analysis, including evaluation for the presence of tumor or viable germ cell elements. The sections of the tissue for fertility preservation will be refrigerated and held until a final diagnosis is made on the tissue sections that are being processed for histologic analysis. If no tumor is identified and viable germ cell elements are identified, the tissue sections allotted for preservation will be sent in holding media for processing and cryopreservation.
219027447|NCT04159597|DRUG|Upadacitinib|Upadacitinib will be administered as oral solution.
219027448|NCT04304339|OTHER|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
219027449|NCT02293226|DEVICE|CoopDech|Video-laryngoscopy 1
219027450|NCT02293226|DEVICE|CoPilot|video-laryngoscopy 2
219027451|NCT02293226|DEVICE|Intubrite|Video-laryngoscopy 3
219027452|NCT02293226|DEVICE|Vividtrack|video-laryngoscopy 4
219027453|NCT03759561|PROCEDURE|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
219027454|NCT04320264|PROCEDURE|Weight loss surgery|Severely obese women (BMI \>40) undergo sleeve gastrectomy
219027455|NCT04900064|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
219200757|NCT06869109|DIAGNOSTIC_TEST|serum cxcl10|serum blood sample to measure the cxcl10
219200758|NCT06869109|DIAGNOSTIC_TEST|serum crp|blood sample to measure crp
219200759|NCT06868407|BEHAVIORAL|Psychoeducation about Suicide Crisis Resources (Control Intervention)|The active control intervention includes psychoeducation about suicide crisis services, with a particular focus on breaking down myths and barriers to using suicide crisis services use.
219501693|NCT02254733|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
218881440|NCT01104727|PROCEDURE|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
219501694|NCT02254733|OTHER|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
219605801|NCT01968564|DRUG|Placebo pill|sugar and other inert substances
219605802|NCT01968564|DRUG|High-dose curcumin pill|2000mg curcumin pill/day
219605803|NCT01968564|DRUG|Low-dose curcumin pill|500mg curcumin pill/day
219605804|NCT01875328|OTHER|Telemedicine|Post stroke follow up in home using telemedicine.
219605805|NCT01875328|OTHER|Clinic|Post stroke clinic group follow up
219605806|NCT05786014|BEHAVIORAL|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
218881441|NCT01104727|PROCEDURE|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
218881442|NCT02967510|DRUG|Estriol|
218881443|NCT02967510|DRUG|Placebo|
218881444|NCT03079596|PROCEDURE|ERAS perioperative cares|Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
218881445|NCT03079596|PROCEDURE|Conventional perioperative cares|No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
218881446|NCT01584739|DRUG|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
218881447|NCT01584739|DRUG|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
219501695|NCT02763579|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
219501696|NCT02763579|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
219501697|NCT02763579|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219501698|NCT02763579|DRUG|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
219501699|NCT02144259|DRUG|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
219501700|NCT02144259|DRUG|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
219501701|NCT01178359|DRUG|nitrite|
219605807|NCT05786014|BEHAVIORAL|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
218881448|NCT00437424|DRUG|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
218881449|NCT03005548|DEVICE|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
218881450|NCT03005548|DRUG|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
218881451|NCT02768519|DRUG|OTS167IV|diluted to final concentration with cherry syrup
218881452|NCT02768519|OTHER|Cherry syrup|
218881453|NCT01177189|DIETARY_SUPPLEMENT|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
218881454|NCT03237715|OTHER|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
218881455|NCT04152915|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
218881456|NCT04328220|DIAGNOSTIC_TEST|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
218881457|NCT03606187|DEVICE|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
219200760|NCT06868407|BEHAVIORAL|Experimental: Self-Guided Electronic Safety Plan Intervention|This is a modified version of the E-SPI first created by Methi and colleagues (2024) which was originally adapted from the six primary steps of the Stanely-Brown safety plan (identifying warning signs, internal coping strategies, social distractions, non-professional crisis contacts, professional crisis resources, suicidal means restriction). Modifications to the E-SPI were based on pilot-study participant feedback and feedback from a youth focus group. The intervention was updated in accordance with pilot-study participant feedback and feedback from subsequent youth interviews. Modification examples include updated instruction wording to reduce ambiguity, updated illustrations, and increased accessibility for participants with reading-based learning disabilities.
219501702|NCT02537132|OTHER|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
219501703|NCT02917200|DRUG|Moxifloxacin|Oral route
219501704|NCT02917200|DEVICE|DAV132|Oral route
219501705|NCT02917200|OTHER|Negative control|Oral route
218881458|NCT03606187|DEVICE|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
219501706|NCT04368052|DIAGNOSTIC_TEST|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
219605808|NCT05991791|OTHER|Early Start Denver Model (ESDM)|"Phase A~* 4 individual sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase B :~* 11 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase C :~* 4 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~* All sessions will also be filmed and recorded"
219605809|NCT03027024|DEVICE|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
219605810|NCT03335137|DIAGNOSTIC_TEST|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
219605811|NCT02532309|DRUG|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
219605812|NCT02532309|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
219605813|NCT06550583|DIAGNOSTIC_TEST|Pap smear /Test|"Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.~• A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination"
218881459|NCT02551822|DEVICE|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
218881460|NCT00456287|DEVICE|CPAP (Continuous Positive Airway Pressure)|
218881461|NCT04239742|DIAGNOSTIC_TEST|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
218881462|NCT04239742|DIAGNOSTIC_TEST|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
218881463|NCT03962075|PROCEDURE|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
219200761|NCT06870409|DRUG|Bacteriophage|"Complex drug of 3-4 virulent phages to each type of bacteria, active against:~* Staphylococcus spp. \[Staphylococcus aureus, CoNS (S. epidermidis, S. haemolyticus, S. hominis, S. warneri, S. capitis)\].~* Streptococcus spp. \[Streptococcus viridans (Str. mutans, Str. sanguis, Str. mitis, Str. cristatus, Str. gordonii, Str. oralis, Str. salivarius), Gemella hemolysans, Str. bovis (Str. gallolyticus), Str. constellatus, Str. anginosus, Str. agalactiae\].~* Enterococcus spp. \[E. faecalis, E. faecium\].~* Non-HACEK \[E. coli, A. baumanii, K. pneumoniae, P. aeruginosa\]"
219200762|NCT06871332|OTHER|Progressive relaxation exercise group|Patients in the intervention group performed progressive relaxation exercise for 20 minutes before femoral sheath removal.
219200763|NCT06869200|DEVICE|Concentrated Growth Factor (CGF) Intra-articular Injection|"Preparation Method: The CGF is prepared using an autologous platelet-rich preparation kit specifically designed to concentrate growth factors from the patient's own blood. The process involves a specialized centrifugation technique that yields a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other bioactive molecules.~Rationale: This intervention leverages the body's natural healing response by utilizing autologous growth factors to enhance the repair of cartilage and other joint tissues affected by osteoarthritis. The high concentration of bioactive molecules in CGF is believed to provide a more potent therapeutic effect compared to other platelet-rich therapies."
219200764|NCT06869200|DEVICE|Platelet-Rich Plasma (PRP) Intra-articular Injection|"Preparation Method: The PRP is prepared using a disposable PRP preparation device that separates and concentrates platelets from the patient's blood. This process enriches the plasma with platelets and associated growth factors.~Rationale: PRP has been widely used in clinical practice for its ability to promote tissue healing and reduce inflammation in osteoarthritis. It serves as an active comparator in this study, allowing for a direct comparison of the therapeutic efficacy and safety profile of CGF against a well-established treatment modality."
219200765|NCT06868771|OTHER|topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preparation.|Application of the topical preparation in both groups will be performed twice a day for a total duration of 3 months.
219200766|NCT06869928|OTHER|PIUO Pathway|see arm description.
219200767|NCT06870305|OTHER|MBTP : Mindflulness based training for psychosis|The group-based mindfulness programme is called MBTP (Mindfulness based training for psychosis). The MBTP programme consists of 5 sessions over a period of one month (2 sessions in the first week, then one session a week). Each session lasts approximately 1h30 and is carried out in a group of 5 participants. The sessions cover informal and formal mindfulness tasks, elements of psycho-education on emotions, meditation exercises on emotions, and thought defusion and acceptance tasks. Participants are encouraged to meditate at home between sessions.
219200768|NCT06869005|OTHER|BARF scale|"BARF Scale, validated in paediatrics, is graduated from 0 to 10 and shows 6 increasingly nauseous faces. A child/adolescent will be considered at risk of NV if he/she declares a score greater than or equal to 4 out of 10 on at least one of the 4 observation times.~This scale can be used by the child him/herself, from the age of 4; or by a close adult, usually present at the child's side during treatment."
219501707|NCT00586300|OTHER|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
219605814|NCT04338360|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
219605815|NCT01479231|DRUG|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
218881464|NCT03647644|DIAGNOSTIC_TEST|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
218881465|NCT02675608|BIOLOGICAL|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
218881466|NCT05482230|PROCEDURE|Intubation and bronchial blocker placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, both endotracheal intubation and bronchial blocker placement were performed while the patient remained in the lateral position.
218881467|NCT03450954|PROCEDURE|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
218881468|NCT02668887|BEHAVIORAL|Quality of Life, status of employment|
218881469|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
218881470|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
218881471|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
218881472|NCT06459479|OTHER|Conversational Artificial Intelligence Simulations|Use of Conversational Artificial Intelligence Simulations generate medical scenario.
218881473|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
218881474|NCT02265250|OTHER|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
219501708|NCT00586300|BEHAVIORAL|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
219501709|NCT00586300|OTHER|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
219605816|NCT04292444|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
219605817|NCT04292444|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
219605818|NCT04235244|OTHER|Thermo mechanical device|The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
219605819|NCT04235244|OTHER|local coolant spray|Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
219605820|NCT04235244|OTHER|ıce battery|abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
219605821|NCT04099004|OTHER|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
219605822|NCT05044702|OTHER|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
219605823|NCT05044702|OTHER|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~* prone leg extension~* prone lying chest elevation~* prone extension with alternate arm and leg lift~* supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
219605824|NCT03996902|BEHAVIORAL|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
219605825|NCT03996902|BEHAVIORAL|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
218881475|NCT02265250|OTHER|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
218881476|NCT02265250|OTHER|Laboratory blood test|Cardiovascular biomarkers
218881477|NCT05467228|DEVICE|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
218881478|NCT05870878|OTHER|Standard care|Individual lifestyle consultation
218881479|NCT05870878|OTHER|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
219200769|NCT06865976|PROCEDURE|Non-Surgical Intervention|For non-surgical treatment of peri-implant mucositis, granulation tissues were removed by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA) during mechanical debridement under local anesthesia
219605826|NCT02134990|DRUG|Oshadi D and Oshadi R|Anti cancer agents
219605827|NCT02134990|DRUG|Docetaxel|Chemotheraphy
219605828|NCT02875990|BIOLOGICAL|Blood sample|
219605829|NCT02936908|OTHER|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
218881480|NCT01711450|PROCEDURE|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
218881481|NCT01711450|PROCEDURE|Control sham procedure|Injection of Normal saline into the paravertebral space
218881482|NCT04264364|PROCEDURE|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
218881483|NCT04264364|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
218881484|NCT04803227|DRUG|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
218881485|NCT04803227|OTHER|Placebo|Placebo BID \*days 1-14). Oral (capsule) administration.
218881486|NCT01336413|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
218881487|NCT01336413|DRUG|Placebo|Same as active comparator, except placebo dispensed.
218881488|NCT04954924|OTHER|standardized physiotherapy program and Kinesio tape|
218881489|NCT01440816|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
218881490|NCT01440816|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
219501710|NCT01882400|DRUG|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
219501711|NCT04014400|OTHER|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
219501712|NCT01998685|DRUG|Propofol|
219501713|NCT01998685|DRUG|remifentanyl|
219501714|NCT01998685|DRUG|Midazolam|
219501715|NCT01998685|DRUG|Fentanyl|
219501716|NCT01998685|DRUG|Sevoflurane|
219501717|NCT02684500|DEVICE|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
219501718|NCT01623661|OTHER|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
219501719|NCT03753997|BEHAVIORAL|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
219605830|NCT03409354|BEHAVIORAL|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
219605831|NCT03409354|BEHAVIORAL|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
219605832|NCT03340090|DEVICE|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
219605833|NCT00525980|BEHAVIORAL|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
219605834|NCT00525980|BEHAVIORAL|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
219605835|NCT00525980|OTHER|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
219605836|NCT00525980|BEHAVIORAL|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
218881491|NCT03776201|OTHER|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
218881492|NCT00856544|DRUG|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
218881493|NCT00856544|DRUG|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
218881494|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
218881495|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
219501720|NCT01451905|DRUG|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
218881496|NCT02858947|PROCEDURE|Aelite Flo|Microhybrid flowable composite
218881497|NCT02858947|PROCEDURE|x-tra base|Bulk-fill flowable composite
218881498|NCT00787189|DEVICE|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
218881499|NCT00787189|DEVICE|Placebo Laser|inactive low level laser light therapy with no therapeutic output
218881500|NCT01458262|OTHER|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
218881501|NCT00252408|DRUG|Hormone replacement therapy|
218881502|NCT00313105|DRUG|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
219200770|NCT06865976|PROCEDURE|Surgical peri-implant therapy|In cases requiring surgical intervention for peri-implantitis, mucoperiosteal flaps were elevated on both vestibular and oral aspects after administration of local anesthesia (articaine with epinephrine 1:200,000) to expose the peri-implant defect. Granulation tissue from the bony defect area was meticulously excised using by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA).
219605837|NCT03450473|DEVICE|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
219605838|NCT01153425|OTHER|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
218881503|NCT00313105|BEHAVIORAL|smoking cessation counseling|individual visits
219605839|NCT01153425|DRUG|Teriparatide|Participants are clinically indicated for treatment.
218881504|NCT04430504|BEHAVIORAL|multidisciplinary telerehabilitation|weekly video meetings to instruct and monitor self-exercises at home
219200771|NCT06865976|PROCEDURE|Second stage surgery|Healthy peri-implant mucosa samples were obtained during the second-stage surgery of implant placement procedures. These samples consisted of incisional biopsies of peri-implant mucosa in direct contact with the implant surface.
219501721|NCT01451905|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
219501722|NCT04895618|DEVICE|Erchonia GVL|Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
219501723|NCT05652920|BIOLOGICAL|Ori-C101|Hepatic arterial infusion
219501724|NCT03974594|DRUG|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
219501725|NCT03974594|DRUG|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
219501726|NCT01900873|DEVICE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
219501727|NCT01900873|DEVICE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
219501728|NCT00410722|DIETARY_SUPPLEMENT|Whole wheat and bran muffin|
219501729|NCT00410722|DIETARY_SUPPLEMENT|Mixed tree nuts|
219501730|NCT06536712|BIOLOGICAL|Mesenchymal Stem Cells Derived Exosomes|Mesenchymal Stem Cells Derived Exosomes will be administered intraperitoneally to patients at the end of their surgery
219501731|NCT06536712|OTHER|Placebo|10 patients will receive intraperitoneal placebo at the end of their surgery
219501732|NCT00162383|DRUG|Debrisoquine|
219501733|NCT00162383|DRUG|Mephenytoin|
219501734|NCT00162383|DRUG|Dapsone|
219501735|NCT00162383|DRUG|Caffeine|
219501736|NCT06113523|BIOLOGICAL|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
219605840|NCT01153425|DRUG|Zoledronic Acid|Participants are clinically indicated for treatment.
219605841|NCT05584189|DEVICE|Rapid SARS-CoV-2 Antigen Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.
219605842|NCT03493412|DRUG|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
219605843|NCT03493412|DRUG|Placebo|Placebo
218881505|NCT00811681|DRUG|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
218881506|NCT00811681|DRUG|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
218881507|NCT01687101|DRUG|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
218881508|NCT05322434|OTHER|The Effect Of Online Breastfeeding Counseling Given At The Post-Birth Period On Breastfeeding Behavior|The aim of the study is to investigate breastfeeding behavior and initiation of solid food by giving breastfeeding counseling to women within the framework of the Health Belief Model for 6 months from birth.
218881509|NCT00123175|DEVICE|Intrauterine Device|Mirena and Provera
218881510|NCT00356967|DRUG|dianicline|
218881511|NCT04486014|PROCEDURE|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
218881512|NCT04486014|PROCEDURE|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
218881513|NCT04202237|OTHER|Speckle Doppler imaging|Speckle Doppler Laser imaging
218881514|NCT04202237|OTHER|Blood sample|Blood sampling
218881515|NCT05743361|DIAGNOSTIC_TEST|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
219200772|NCT06866795|DRUG|GT-220F capsule|GT-220F capsule for oral administration
219501737|NCT00910858|DRUG|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
219501738|NCT00910858|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
219501739|NCT03522584|BIOLOGICAL|Durvalumab|Given IV
219501740|NCT03522584|OTHER|Laboratory Biomarker Analysis|Correlative studies
219501741|NCT03522584|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219501742|NCT03522584|BIOLOGICAL|Tremelimumab|Given IV
219501743|NCT03522584|PROCEDURE|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
219501744|NCT04625920|DEVICE|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
219501745|NCT02189694|DEVICE|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
219501746|NCT02189694|DEVICE|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
219200773|NCT06866457|OTHER|Audio hypnosis|"Audio hypnosis via a digital recording (Ellis Traumgeschichte) accessible via QR code"
219200774|NCT06866665|DRUG|Anticoagulation Monotherapy|Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.
219501747|NCT02189694|DEVICE|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
219501748|NCT02844374|OTHER|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
219605844|NCT00956072|DRUG|imatinib mesylate|Patients receive imatinib mesylate
219605845|NCT00956072|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
219605846|NCT00814268|DRUG|Clopidogrel|75mg tablet, oral administration once daily
218881516|NCT06524193|BEHAVIORAL|Telepractice group voice therapy|"* Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
218881517|NCT06524193|BEHAVIORAL|Face-to-face group voice therapy|"* Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
218881518|NCT04909866|COMBINATION_PRODUCT|TACE+Lenvatininb+Camrelizumab|Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
218881519|NCT00627250|DRUG|Amantadine|Amantadine 100 mg every morning and 12 noon
218881520|NCT01766180|DRUG|Fruitflow-II|150 mg/day for 3 months, orally
219501749|NCT04169282|DEVICE|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
219605847|NCT00814268|DRUG|Clopidogrel placebo|Matching tablet, oral administration once daily
219605848|NCT00814268|DRUG|Aspirin|100mg tablet, oral administration once daily
219605849|NCT04081909|DRUG|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
219605850|NCT04081909|DRUG|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
218881521|NCT01766180|DRUG|resVida|150 mg/day for 3 months, orally
218881522|NCT02953574|PROCEDURE|daily sleep enhancement nursing protocol|
218881523|NCT06371846|OTHER|Selected signals from Pacing System Analyzers|Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
218881524|NCT04220944|DRUG|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
219200775|NCT06866665|DRUG|Combination therapy|Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.
219200776|NCT06867276|DEVICE|Excimer laser|Excimer laser patients undergo ultraviolet b phototherapy treatments at a physical medicine clinic twice a week for four weeks. The device uses a 308nm beam of coherent light, with six spot sizes to avoid healthy skin. The radiation exposure time is 10 minutes, with a maximum dose of 0.65 J/cm². Personal protection standards include wearing protective eyewear for the retina and choroid, as they absorb visible light radiation, which can cause keratoconjunctivitis or cataracts. The thermal effect of the laser can cause superficial carbonization of the epidermis, phlyctens, or erythema, so non-flammable gloves are recommended.
219501750|NCT00698022|DRUG|Risperidone|risperidone daily for 28 days
219501751|NCT00698022|DRUG|Mifepristone|mifepristone daily for 28 days
219501752|NCT00698022|DRUG|Risperidone-matched placebo|risperidone-matched placebo daily for 28 days
219605851|NCT00778388|BIOLOGICAL|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
219501753|NCT00698022|DRUG|Mifepristone-matched placebo|mifepristone-matched placebo daily for 28 days
219501754|NCT00621686|BIOLOGICAL|bevacizumab|
219501755|NCT00621686|DRUG|sorafenib tosylate|
219501756|NCT01703741|DRUG|Testosterone Gel (FE 999093)|
219501757|NCT04716114|DRUG|SKLB1028|SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
218881525|NCT04220944|PROCEDURE|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
218881526|NCT04220944|PROCEDURE|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
219501758|NCT04716114|DRUG|Salvage Chemotherapy|Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
219501759|NCT02269202|DRUG|Midazolam, tablet|
218881527|NCT05285540|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
218881528|NCT05285540|DRUG|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
218881529|NCT02181764|DRUG|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
218881530|NCT00336297|PROCEDURE|Woman Abuse Screening Tool|
218881531|NCT00336297|PROCEDURE|Partner Violence Screen|
218881532|NCT00336297|PROCEDURE|Computerized screening|
218881533|NCT00336297|PROCEDURE|Face to face screening|
218881534|NCT00336297|PROCEDURE|Written screening on forms|
218881535|NCT01426022|OTHER|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
218881536|NCT01426022|BEHAVIORAL|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
218881537|NCT05144711|PROCEDURE|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
219501760|NCT02269202|DRUG|Crobenetine, i.v. infusion|
219501761|NCT02269202|DRUG|Placebo|
219501762|NCT01170364|DRUG|Sibutramine|1 week of active sibutramine (15mg)
219501763|NCT01170364|DRUG|Placebo|2 weeks of placebo
219501764|NCT01604213|DRUG|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
219501765|NCT01604213|DRUG|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
219501766|NCT01381900|DRUG|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
218881538|NCT05144711|PROCEDURE|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
218881539|NCT05881954|PROCEDURE|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
218881540|NCT03958357|DEVICE|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
219027456|NCT04900064|BEHAVIORAL|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
219501767|NCT01381900|DRUG|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
219501768|NCT01381900|DRUG|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
219501769|NCT01381900|DRUG|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
219501770|NCT01381900|DRUG|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
218881541|NCT00108316|DRUG|Fluoxetine (Liquid Prozac)|
219027457|NCT06063603|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
219027458|NCT06063603|BEHAVIORAL|Cancer Pain Management|Receive pain clinic referral
219501771|NCT00002806|DRUG|lomustine|
219501772|NCT00002806|DRUG|procarbazine hydrochloride|
219501773|NCT00002806|DRUG|vincristine sulfate|
219501774|NCT00002806|RADIATION|low-LET photon therapy|
219501775|NCT06358352|DIETARY_SUPPLEMENT|Lutein / Zeaxanthin|lutein extract from lutein oral capsules
219501776|NCT06358352|BIOLOGICAL|Platelet rich fibrin|platelet rich fibrin extracted from patient's blood after centrifuging
219501777|NCT05947552|DRUG|Serum ferritin|Serum ferritin in CKD patients
219501778|NCT02222142|DRUG|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
219501779|NCT02056899|DRUG|Gabapentin|
219501780|NCT01617733|DRUG|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
219501781|NCT02911883|DEVICE|Optical Coherence Tomography Angiography|
219501782|NCT05661877|OTHER|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
219501783|NCT05661877|OTHER|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
219501784|NCT01137305|OTHER|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
219605852|NCT00778388|DRUG|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
219027459|NCT06063603|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
219200777|NCT06867276|DEVICE|Bioptron Pro 1|Patients undergone Bioptron light treatment twice weekly for four weeks at a physical medicine clinic. The treatment is administered by a physiatrist following the manufacturer's user guide. Patients sit in a comfortable chair with their hand on an armrest, holding the Bioptron light probe at a 90° angle for 10 minutes.
219200778|NCT06867965|DEVICE|BellySense|BellySense is a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
219200779|NCT06868134|BEHAVIORAL|Web-Based Exercise Group|Participants will follow a structured progressive exercise program through the Physitrack web platform, including stretching, strengthening, and aerobic exercises. The program will be assigned to each participant's profile, and they will complete the exercises three times per week with at least one rest day between sessions. Assessments will be conducted at the beginning and at the end of the 8th week.
219200780|NCT06868134|BEHAVIORAL|Supervised Progressive Exercise Program|Participants in this group will receive a supervised progressive exercise program consisting of stretching, strengthening, and aerobic exercises. The intervention will be conducted three times per week with at least one rest day between sessions.
219200781|NCT06868004|BEHAVIORAL|Holistic Nursing|The intervention in this study is based on Holistic Nursing (HN) for patients with Alzheimer's Disease (AD). It involves a comprehensive approach including psychological support, cognitive rehabilitation, memory enhancement, self-care training, and environmental modifications. Psychological interventions focus on personalized communication and emotional support, aiming to reduce negative emotions and improve trust in the healthcare team. Cognitive interventions include activities like painting, card recognition, and storytelling to enhance cognitive function. Memory interventions use personalized memory aids, and self-care interventions aim to improve daily living skills. The ward environment is adjusted to promote safety and comfort. This multi-faceted approach is designed to improve cognitive function, self-care abilities, and emotional well-being in AD patients.
219200782|NCT06868043|DEVICE|FiberSense System|FiberSense system, a novel CGM system using interstitial fluid (ISF) glucose as an indicator of blood glucose levels by diabetic patients
219027460|NCT06063603|PROCEDURE|Discussion|Participate in focus group
219027461|NCT06063603|OTHER|Educational Intervention|Receive self-guided pain management education materials
219027462|NCT06063603|OTHER|Exercise|Participate in exercise
219027463|NCT06063603|OTHER|Interview|Complete interview
219027464|NCT06063603|PROCEDURE|Massage Therapy|Receive massage
219027465|NCT06063603|BEHAVIORAL|Mindfulness Relaxation|Practice mindfulness
219027466|NCT06063603|PROCEDURE|Pain Therapy|Receive pain treatment/medicine
219027467|NCT06063603|OTHER|Palliative Therapy|Receive palliative care referral
219027468|NCT06063603|BEHAVIORAL|Patient Navigation|Undergo visits with PCM and CHW for pain management
219027469|NCT06063603|OTHER|Referral|Receive pain management referrals
219027470|NCT06063603|PROCEDURE|Spiritual Therapy|Receive spiritual support
219027471|NCT06063603|PROCEDURE|Spiritual Care Referral|Receive spiritual care referral
219027472|NCT06063603|OTHER|Survey Administration|Ancillary studies
219027473|NCT05732389|DRUG|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
219027474|NCT05732389|DRUG|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
218881542|NCT02489383|OTHER|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
219200783|NCT06865703|OTHER|diaphragmatic release technique|The participant lay in the supine position and the therapist stood at the participant's head, the therapist passed his hands (the hypothenar and the lateral 3 fingers) under the costal cartilage of the seventh to the tenth ribs bilaterally, with the therapist's forearm aligned up toward the subject's shoulder. Then, the therapist quietly drew the diaphragm in and upward during the inspiratory phase. The therapist then went deeply with both hands toward the inner costal margin during the expiratory phase to resist the rebounding movement of the thoracic cage. The depth of this manual contact was progressively increased in subsequent respiratory cycles. The maneuver was repeated in 4 sets, each of which consisted of 5 deep breaths with 2-min intervals in between if needed
219200784|NCT06865703|OTHER|rib raising technique in group A|• The patient is in supine position and therapist hand under the thorax The fingertips take up contact with the angular costae and move it up and in lateral traction and maintained and this will repeated until all ribs on the side are mobilized. This movement will be repeated several times until perceives an improvement in the rib flexibility
219501785|NCT03189797|OTHER|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
219501786|NCT02833402|DEVICE|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
218881543|NCT02489383|OTHER|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
219027475|NCT01272609|DRUG|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
219027476|NCT01272609|DEVICE|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
219027477|NCT05966896|DEVICE|implanted epidural stimulator|implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
219200785|NCT06865703|OTHER|THORACIC LYMPHATIC PUMP TECHNIGUE|"* Patient in the supine position and therapist will stand the participant's head, facing The therapist places the thenar eminence of each hand to the pectoral region and infra clavicular and the other fingers were spread around the thoracic cage and angled toward the body's side to create consistent, compressive force across the thoracic cage The participant was then allowed to breathe in deeply and breath out. The therapist slowly reduced the compressive force and withdrew the participant.~* During breath out rhythmic oscillatory compression in the posterior and caudal direction was applied to the chest wall.~* By the end of the expiratory phase, the compressive force was maintained, and ask to take another deep breath. In this way, the participant encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver was repeated for 5 respiratory cycles, then hands to allow for full inspiration."
219200786|NCT06867770|BEHAVIORAL|Observe the frequency of clinical or paraclinical complications during the hospitalization of these children.|The goal is to collect data on the files of infants hospitalized at the HFME from 2017 to 2021 for monitoring a isolated skull. The data that will be collected are an integral part of the child's care and pre-exist the study. This data will be anonymized and no interaction with the patient is envisaged.
219200787|NCT06870474|BEHAVIORAL|Psychoeducational intervention|The psychoeducational intervention has the aim of improving quality of life, problem-solving and social skills, leisure time, self-efficacy and social support of caregivers; and decreasing their depressive symptomology, dysfunctional thoughts, burden and stress. Both mediator and outcome variables will be contemplated.
219501787|NCT02041494|DEVICE|Ventralight|
219501788|NCT02041494|DEVICE|Strattice|
219501789|NCT04558216|DRUG|Vonoprazan|20 mg tablets administered orally
219501790|NCT04558216|DRUG|Rifampin|600 mg (Two 300 mg capsules)
219501791|NCT03599310|BEHAVIORAL|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
219501792|NCT03599310|BEHAVIORAL|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
219501793|NCT00057447|DRUG|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
219501794|NCT00057447|DRUG|Rituximab|375 mg per square meters, IV, 1x per week
219501795|NCT01630200|DRUG|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
219200788|NCT06870474|BEHAVIORAL|Support group|This intervention is a placebo group. It has the typical structure and characteristics of this type of intervention
219200789|NCT06870474|BEHAVIORAL|Control group|Participants were not subject to any intervention. They received the psychoeducational intervention once the study had ended.
219200790|NCT06869486|OTHER|Exercise|"A cardiopulmonary exercise test in a treadmill will be performed after an overnight fasting. Gas exchange, heart rate, and muscle oxygen saturation levels will be assessed continuously during the entire test. Blood pressure and rate of perceived exertion will be recorded prior the end of each stage whereas blood glucose concentration will be assessed before and after the test. All the hemodynamic parameters will be assessed at rest to standardize the cardio-metabolic condition of the participants prior to exercise testing.~Maximal exertion will be requested from all participants except elders, in whom a submaximal test will be applied, following the guidelines provided by the American College of Sports Medicine. From this trial, maximal oxygen uptake, ventilatory thresholds/dynamics, chronotropic and inotropic response, and metabolic flexibility will be examined. A trained exercise physiologist will supervise all the tests and validate the obtained data."
219200791|NCT06869486|OTHER|Bioelectrical Impedance|Bioelectrical impedance analysis will be used to estimate body compartments through a mechanism of resistance and reactance (InBody 770, KOR) . The compartments measured include body cell mass, fat mass, extracellular tissue, lean mass, muscle mass, visceral adipose tissue area, phase angle, among others.
219200792|NCT06869486|GENETIC|Micronucleus Assay|The frequency of micronuclei, nuclear buds, basal cells, binucleated cells, condensed chromatin cells, karyorrhexis, karyolysis, and pyknosis will be determined through microscopic examination of exfoliated oral mucosal cells from each participant.
219200793|NCT06869486|BEHAVIORAL|Physical activity and sedentary time|Physical activity and sedentary time will be assessed through the Spanish version of the International Questionnaire of Physical activity. In half of the analyzed subjects a wearable device (Fitbit luxe, Fit bit Inc) will be also used to record daily steps, energy expenditure and heart rate patterns.
219200794|NCT06869486|BEHAVIORAL|Sleep|Insomnia severity index, sleep quality, somnolence and chronotype will be subjectively assessed in all participants, using validated scales such as the Pittsburgh, Epworth and ISI questionnaires. In half of the participants, sleep quality will be tracked by wearing a Fit band luxe device in the wrist.
219200795|NCT06869486|BIOLOGICAL|blood sampling|"The concentrations of glucose, glycated hemoglobin, and lipid profile will be determined through serum analysis using a blood chemistry analyzer (Spin120, Spinreact, ESP). Serum samples will be obtained by centrifuging peripheral venous blood samples (4-6 mL) collected in Vacutainer tubes at 2500 rpm for 10 minutes. From the same serum samples, circulating levels of insulin, ovarian hormones (estradiol and progesterone), insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF) will be assessed using enzyme-linked immunosorbent assays (ELISA) on a microplate reader (iMark, BIORAD, USA), following the specifications provided by each kit manufacturer (Biotechne, USA; AccuBind, GUA).~Glucose, insulin and triglyceride values obtained from the blood chemistry analyzer and ELISA assays will be used to calculate the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and the triglyceride-glucose index."
219200796|NCT06869486|BEHAVIORAL|psychometrics|Perceived stress will be obtained from the Perceived Stress Scale adapted for Mexican population. Additionally, depression and anxiety scores will be obtained from the Becks Depression Inventory, validated in Mexican adults. Ruminative thinking will be assessed through the short version of the Ruminative Responses Scale and substance abuse will be examined through the 10-items Drug Abuse Screening Test. Social media disorder and screen time will be also investigated from the Social Media Disorder Test and a cell-phone screen capture.
219200797|NCT06869486|BEHAVIORAL|Nutritional Supplement|"A semi quantitative food frequency questionnaire will be applied to collect data about macronutrient intake and supplements consumption. Hierarchical consumption of each food groups will be also assessed.~Last meal consumed prior to exercise testing will be also recorded in conjunction with fasting time."
219200798|NCT06869486|GENETIC|Genotyping|The P10L polymorphism of the OPN4 gene, previously associated with chronic insomnia and severe daytime sleepiness in the Mexican population will be determined using RFLP-PCR assays. DNA will be extracted from previously collected blood samples (4 ml) using the Master Pure DNA purification kit from Epicentre (Illumina Inc., US).
219200799|NCT06871293|OTHER|Functional and cognitive rehabilitation strategy|"The functional and cognitive rehabilitation strategy is a structured, supervised program, designed to improve physical and cognitive function in patients with Long Covid-19 and chronic diseases. Participants will attend weekly in-person sessions for 8 weeks at study sites.~Each session includes:~* Functional Rehabilitation (60 min): Warm-up, aerobic exercise (elliptical/treadmill), muscle strengthening, and cool-down, all supervised by trained healthcare professionals who monitor effort levels and heart rate.~* Cognitive Rehabilitation (30 min): Memory, attention, and executive function exercises, guided by occupational therapists or speech therapists."
219200800|NCT06871293|OTHER|Evidence-Based Informational Support|"The evidence-based informational support intervention provides structured, research-based health information to patients with Long Covid-19 and chronic diseases. Participants receive weekly digital messages for 8 weeks via email or text, covering key topics such as Covid-19 prevention, treatment, follow-up, and prognosis.~Content is derived from high-quality scientific studies and clinical guidelines.~A total of 24 informational pieces are delivered, ensuring comprehensive coverage of essential health recommendations.~This intervention is remote, accessible, and designed to enhance patient knowledge and self-management, distinguishing it from traditional in-person education programs."
219501796|NCT01630200|DRUG|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
219501797|NCT06240962|OTHER|Strength Training|They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
219501798|NCT06240962|OTHER|Mindfulness Exercise|They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
219501799|NCT05547230|OTHER|questionnaires|The same tests will be applied to all participants in an objective way.
219501800|NCT01593527|DRUG|ACZ885|Canakinumab 150 mg s.c.
219501801|NCT01593527|DRUG|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
219501802|NCT03828123|BIOLOGICAL|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
218881544|NCT02489383|BEHAVIORAL|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
219605853|NCT05172115|PROCEDURE|Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)|Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours
219501803|NCT02655172|OTHER|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
219501804|NCT02655172|OTHER|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
219501805|NCT03215485|BEHAVIORAL|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
219501806|NCT03215485|BEHAVIORAL|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
218881545|NCT02289794|BIOLOGICAL|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
218881546|NCT02289794|BIOLOGICAL|Placebo|Single dose, intramuscular injection (0.5 mL)
218881547|NCT03863431|OTHER|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
219501807|NCT03215485|OTHER|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
219501808|NCT04520035|DRUG|camrelizumab|Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
219501809|NCT04520035|DRUG|Paclitaxel|Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
219501810|NCT04520035|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy
219605854|NCT05172115|DRUG|Enoxaparin|Subcutaneous enoxaparin twice-daily (1mg/kg)
219605855|NCT02163265|PROCEDURE|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
218881548|NCT03863431|OTHER|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
218881549|NCT03619772|OTHER|Bilateral|Participants will control game using EMG from both upper limbs.
219027478|NCT03971695|DRUG|BI 706321|Capsule or Oral Solution
219605856|NCT01089465|OTHER|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
219605857|NCT04975204|DRUG|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
219605858|NCT04620408|DRUG|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
219605859|NCT00897910|OTHER|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
218881550|NCT03619772|OTHER|Unilateral|Participants will control game using EMG from the more impaired upper limb.
219027479|NCT03971695|DRUG|Placebo|Capsule or Oral solution
219027480|NCT05059860|DEVICE|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
219027481|NCT06482489|DEVICE|Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).|Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.
219027482|NCT05643716|BEHAVIORAL|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
218881551|NCT01672424|OTHER|Ice Chips|11 ounces of ice chips given to the laboring parturient
219027483|NCT05705284|OTHER|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
219027484|NCT04835025|DRUG|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
219027485|NCT05887765|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
219027486|NCT05887765|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
219027487|NCT05887765|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
219027488|NCT02109614|DRUG|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
219027489|NCT02109614|DRUG|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
219501811|NCT03790085|DRUG|Risperidone|Risperidone tablet
219501812|NCT03790085|DRUG|Olanzapine|Olanzapine tablet
219501813|NCT03790085|DRUG|Aripiprazole|Aripiprazole tablet
219605860|NCT00897910|OTHER|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
219605861|NCT00897910|OTHER|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
218881552|NCT01672424|OTHER|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
218881553|NCT05156957|OTHER|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
218881554|NCT02172378|DRUG|Tiotropium inhalation capsules|
218881555|NCT02172378|DRUG|Placebo inhalation capsules|
218881556|NCT03499834|BIOLOGICAL|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
219501814|NCT03154320|OTHER|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
219605862|NCT02848209|PROCEDURE|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
219605863|NCT02848209|PROCEDURE|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
219605864|NCT02848209|PROCEDURE|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
219605865|NCT04515134|DIAGNOSTIC_TEST|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
219605866|NCT03014843|DRUG|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
219605867|NCT03014843|DRUG|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
219605868|NCT03014843|OTHER|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
219605869|NCT02665221|OTHER|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
219605870|NCT02665221|DRUG|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
219605871|NCT00754078|RADIATION|Tomotherapy|30 fractions of tomotherapy treatment
218881557|NCT04131179|BEHAVIORAL|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
218881558|NCT05179148|BEHAVIORAL|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
218881559|NCT04574401|DRUG|IS-002|Intravenous injection of IS-002 Investigational Drug
218881560|NCT02982421|BEHAVIORAL|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
218881561|NCT02982421|BEHAVIORAL|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
218881562|NCT01402713|BIOLOGICAL|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
218881563|NCT01402713|BIOLOGICAL|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD\_PUR INJ step 2(phase 3)-SK Td vaccine
218881564|NCT04991675|BEHAVIORAL|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
219027490|NCT00047021|BIOLOGICAL|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
219027491|NCT00047021|DRUG|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
219027492|NCT00047021|DRUG|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
219501815|NCT03154320|OTHER|Standard treatment|Standard treatment
219501816|NCT01682174|OTHER|Control Drink|
219501817|NCT01682174|OTHER|Experimental Drink|
219501818|NCT05893212|BEHAVIORAL|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
219501819|NCT05893212|BEHAVIORAL|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
219605872|NCT02932462|DRUG|DSXS|topical product
219605873|NCT02932462|DRUG|Placebo|topical product
218881565|NCT04991675|BEHAVIORAL|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
218881566|NCT01602289|BIOLOGICAL|LY2875358|Administered IV
218881567|NCT01602289|DRUG|Erlotinib|Administered orally
218881568|NCT01602289|DRUG|Gefitinib|Administered orally
218881569|NCT01356459|DEVICE|Mepilex Border Dressing|Soft silicone self adherent dressing
218881570|NCT03205683|OTHER|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
219027493|NCT01010308|DRUG|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
219027494|NCT06787521|OTHER|evidence-based labor guide|Participants will be provided with written education about potential complications and interventions. Information will be provided at the time of admission for labor induction.
219027495|NCT03609515|OTHER|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
219027496|NCT03767920|DRUG|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
219027497|NCT03767920|DRUG|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
219200801|NCT06886217|BEHAVIORAL|Collaborative Life Skills dHealth tool (CLS-D)|The purpose of this adapted intervention is to integrate digital health (dHealth) technology into the Collaborative Life Skills Program (CLS), an established, school-based behavioral intervention for students with ADHD, to make the program accessible to schools that serve students from low-socioeconomic (SES) backgrounds. Existing evidence-based interventions for students with ADHD are often inaccessible in schools with limited resources to support implementation. By adapting CLS to include a dHealth tool-CLS-D-researchers aim to improve the feasibility of intervention implementation in schools with limited resources and mitigate disparities in access to evidence-based interventions among students with ADHD who are from low-SES backgrounds.
219200802|NCT06783712|PROCEDURE|Adductor canal block|Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
219501820|NCT03689296|OTHER|Questionnaires (Phase 3)|"* CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale"
219501821|NCT03689296|OTHER|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
219501822|NCT03689296|OTHER|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
219501823|NCT05057195|RADIATION|Interstitial radiation therapy|From 30 to 50 Gy,
219501824|NCT05057195|RADIATION|Postoperative external beam therapy|50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
219501825|NCT04634110|DRUG|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
219605874|NCT04742829|DIETARY_SUPPLEMENT|INTRAVIT ®|2 tablets per day morning and evening before meals
219605875|NCT01145469|GENETIC|DNA analysis|
219605876|NCT01145469|GENETIC|gene expression analysis|
219605877|NCT01145469|GENETIC|polymorphism analysis|
219605878|NCT01145469|OTHER|laboratory biomarker analysis|
219027498|NCT03767920|DRUG|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
219027499|NCT04733742|DRUG|rhTNK-tPA|intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
219027500|NCT04733742|OTHER|Endovascular treatment|endovascular treatment
219027501|NCT01204476|BIOLOGICAL|Cixutumumab|Given IV
219027502|NCT01204476|DRUG|Everolimus|Given PO
219027503|NCT01204476|OTHER|Laboratory Biomarker Analysis|Correlative studies
219027504|NCT01204476|DRUG|Octreotide Acetate|Given IM
219027505|NCT01204476|OTHER|Pharmacological Study|Correlative studies
219027506|NCT01341600|DRUG|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
219027507|NCT01341600|DRUG|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
219605879|NCT01145469|OTHER|medical chart review|
219605880|NCT04072081|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
219605881|NCT04072081|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
219605882|NCT02037412|DRUG|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
219605883|NCT02037412|DRUG|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
219605884|NCT03064724|BEHAVIORAL|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
219605885|NCT05573958|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban 2.5 mg oral tablet will be administered twice daily
219605886|NCT05573958|DRUG|Clopidogrel tablet|Clopidogrel 75 mg once daily orally
218881571|NCT03205683|OTHER|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
218881572|NCT00064961|BEHAVIORAL|Individualized dietary-control and exercise program|
218881573|NCT00064961|BEHAVIORAL|Weight-management and smoking cessation maintenance|
218881574|NCT00064961|BEHAVIORAL|Smoking Cessation program|
219501826|NCT03807323|BEHAVIORAL|Lifestyle counselling and exercise|"The program consists of:~1. Instructor-led training twice a week,~2. One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~3. Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
219501827|NCT00654706|DRUG|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
218881575|NCT01053494|PROCEDURE|massage therapy|Undergo massage therapy
218881576|NCT01053494|OTHER|questionnaire administration|Ancillary studies
218881577|NCT01053494|PROCEDURE|quality-of-life assessment|Ancillary studies
218881578|NCT01053494|OTHER|intervention by caregiver|Undergo massage by caregiver
219027508|NCT04877275|DRUG|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
219027509|NCT04877275|DRUG|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
219027510|NCT04877275|DRUG|Pegylated liposomal doxorubicin|25 mg/m\^2 intravenously on day 1 , QW
219027511|NCT04877275|DRUG|Dexamethasone|Dexamethasone 40mg/d QW
219501828|NCT00654706|DRUG|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
219501829|NCT04709900|DIAGNOSTIC_TEST|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
218881579|NCT01053494|PROCEDURE|standard follow-up care|Undergo standard follow-up care
218881580|NCT02076282|OTHER|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
218881581|NCT05375721|PROCEDURE|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
218881582|NCT03397342|DEVICE|CPAP machine|Use of CPAP machine during MRI
219501830|NCT01730677|DRUG|Lapatinib|lapatinib 1000mg, once daily
219501831|NCT01730677|DRUG|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
218881583|NCT04417335|BIOLOGICAL|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
218881584|NCT04417335|BIOLOGICAL|Placebo|0.9% NaCl
218881585|NCT02546492|DRUG|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
218881586|NCT03920254|DRUG|TD-1473 Dose A|See Arm description
218881587|NCT03920254|DRUG|TD-1473 Dose B|See Arm description
218881588|NCT03920254|DRUG|TD-1473 Dose C|See Arm description
218881589|NCT03979859|DRUG|WCK 4873|
218881590|NCT03979859|DRUG|Placebo Oral Tablet|
218881591|NCT00823667|OTHER|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
218881592|NCT00823667|OTHER|medical chart review|Occurs at 1 year post study enrollment
218881593|NCT00823667|OTHER|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
218881594|NCT00823667|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
218881595|NCT00823667|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
218881596|NCT00823667|PROCEDURE|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
218881597|NCT03968835|OTHER|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
218881598|NCT03968835|OTHER|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
218881599|NCT05492097|BEHAVIORAL|Exercise Therapy|Traditional exercise therapy and NMES
218881600|NCT05492097|BEHAVIORAL|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
218881601|NCT04090333|OTHER|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
219027512|NCT04877275|DRUG|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
219027513|NCT04749953|PROCEDURE|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
219027514|NCT04014257|DRUG|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
219501832|NCT05923164|DIAGNOSTIC_TEST|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
219501833|NCT05923164|DIAGNOSTIC_TEST|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
219501834|NCT03411590|OTHER|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
219501835|NCT04105790|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
219501836|NCT04317573|DEVICE|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
219501837|NCT05353374|DRUG|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
219501838|NCT05353374|DRUG|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
219501839|NCT05575960|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents (IPT-A)|Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
219501840|NCT00277680|PROCEDURE|Laparoscopic bilateral occlusion of uterine artery|
219501841|NCT00277680|PROCEDURE|Radiological embolization (UFE)|
219501842|NCT02965820|DEVICE|Opti-Free® PureMoist® contact lens solution|
219501843|NCT02965820|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
219501844|NCT02965820|DEVICE|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
219501845|NCT02229240|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
219501846|NCT02229240|DRUG|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
219501847|NCT00567281|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
219501848|NCT00567281|DEVICE|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
219027515|NCT01802957|OTHER|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
219501849|NCT03182608|DIAGNOSTIC_TEST|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
219501850|NCT01891513|BEHAVIORAL|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
218881602|NCT04896281|DIETARY_SUPPLEMENT|Phenylalanine-free milk|Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
219501851|NCT01891513|DRUG|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
219501852|NCT01891513|DRUG|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
219501853|NCT01891513|DRUG|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
219501854|NCT04739449|BEHAVIORAL|Coaching, Cleaning, Communication, Collaboration|"1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise"
219501855|NCT00309075|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
219501856|NCT01694615|PROCEDURE|Cryoprobe biopsy|
219605887|NCT05573958|DRUG|Aspirin tablet|Aspirin 81 mg tablet once daily
219605888|NCT02652949|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
219605889|NCT05531864|PROCEDURE|Ultrasound-guided continuous low serratus anterior plane block|Low anterior serratus plane block, move the mid-axillary line 4 and 5 intercostal puncture points are moved down and the puncture is changed to 7 and 8 intercostal.
218881603|NCT00402467|DRUG|Rivaroxaban (BAY59-7939)|2.5mg bid
218881604|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|5mg bid
218881605|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|10 mg bid
219027516|NCT01802957|OTHER|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
219027517|NCT01802957|OTHER|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
219027518|NCT01802957|OTHER|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
219605890|NCT05531864|PROCEDURE|Ultrasound-guided single serratus anterior plane block|Ultrasound-guided single anterior saw plane block was performed, and a needle was injected between the 4th and 5th costals in the midaxillary line.
219605891|NCT05635487|DRUG|SHR-A1811|SHR-A1811
219605892|NCT05635487|DRUG|Pyrotinib|Pyrotinib
219605893|NCT04040556|OTHER|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
219605894|NCT05212077|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
219605895|NCT05212077|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
219605896|NCT03561077|OTHER|Mindfulness-based interventions (MBI's)|Mindfulness Based Intervention with eight sessions (one session per week) of two hours dedicated to adolescents will be provided. The intervention will focus on skill building and will incorporate mindfulness meditation, exercises and activities specially adapted to teenagers with chronic pain. Topics will include mind body connection, the effect of stress on pain, living in the present moment, focused awareness, responding versus reacting to pain and/ or difficult situations, non judgement, gratitude, kindness and compassion towards self and others.
218881606|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|20mg bid
218881607|NCT00402467|DRUG|Enoxaparine|30mg bid
218881608|NCT00402467|DRUG|Enoxaparine|30mg bid
218881609|NCT03250182|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
218881610|NCT01427426|DIETARY_SUPPLEMENT|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
218881611|NCT01427426|OTHER|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
218881612|NCT03355066|DRUG|SM08502|SM08502 tablets to be administered orally.
218881613|NCT02718209|DEVICE|Mid-Infrared Spectroscopy with ATR|
218881614|NCT05274269|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
218881615|NCT05274269|DRUG|IVA|Tablet for oral administration.
218881616|NCT05274269|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
218881617|NCT05274269|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
219501857|NCT01694615|PROCEDURE|Forceps Biopsy|
219605897|NCT03594071|DEVICE|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
218881618|NCT04375111|PROCEDURE|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
218881619|NCT04375111|PROCEDURE|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
218881620|NCT02255227|BIOLOGICAL|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
218881621|NCT02255227|BIOLOGICAL|Pneumo 23|one dose
219501858|NCT00914433|DRUG|TPI 1100|1 dose only increasing dose
219605898|NCT01546428|DRUG|INC280|
219605899|NCT06133361|BIOLOGICAL|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
218881622|NCT04067258|DIAGNOSTIC_TEST|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
218881623|NCT04612257|OTHER|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
218881624|NCT05243082|DEVICE|Radio frequency ablation|Radio frequency ablation of pancreatic neuroendocrine tumors
218881625|NCT05211206|OTHER|IV fluids|Amount of intravenous fluids delivered
218881626|NCT02115763|DRUG|Caffeine|
218881627|NCT02115763|DRUG|Placebo|
218881628|NCT05917418|DIETARY_SUPPLEMENT|nutritional support|nutritional support
219605900|NCT06133361|PROCEDURE|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
219605901|NCT04436601|DRUG|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
219605902|NCT04436601|DRUG|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
218881629|NCT01621711|BEHAVIORAL|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
218881630|NCT03067389|DIAGNOSTIC_TEST|Diagnostic test|Genetic diagnostic test
218881631|NCT02055378|DRUG|Atropine|topical 0.125% atropine eye drops
218881632|NCT02055378|DEVICE|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
218881633|NCT05816434|BEHAVIORAL|Sleep extension|\>1 hour additional time in bed per night for 1 week.
218881634|NCT05216341|DRUG|OLP-1002|"Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection."
218881635|NCT05159115|OTHER|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
218881636|NCT05159115|OTHER|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
219501859|NCT03929939|BEHAVIORAL|Exercise training and healthy eating (overseen by IEEM research team)|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
219501860|NCT06486363|DRUG|Aspirin combined with clopidogrel|Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
219501861|NCT06486363|DRUG|Aspirin combined with half-dose ticagrelor|Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
219605903|NCT00988416|PROCEDURE|PET-CT|Pancreas Protocol PET-CT
218881637|NCT06507696|OTHER|Ice Application|Drinking water was placed in a syringe and filled in the refrigerator
218881638|NCT06507696|OTHER|Wetted Gauze Application|Sterile gauze soaked with drinking water
219501862|NCT01573091|PROCEDURE|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
219501863|NCT03567720|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
219501864|NCT03567720|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
219501865|NCT03567720|DEVICE|Immunopulse|Device that administers electroporation
219501866|NCT03567720|DRUG|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
218881639|NCT03719911|BEHAVIORAL|Live diabetes coaching program|Live diabetes coaching program
219027519|NCT01802957|OTHER|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
219501867|NCT03567720|DRUG|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
219501868|NCT04082962|DRUG|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
219501869|NCT02472392|DRUG|Rabbit anti-thymocyte globulin|Active treatment
219501870|NCT02472392|DRUG|Busulfan|comparitor
219501871|NCT02472392|DRUG|Melphalan|comparitor
219501872|NCT02472392|DRUG|Fludarabine|comparitor
219501873|NCT02472392|DRUG|Cyclophosphamide|comparitor
219501874|NCT04249089|BEHAVIORAL|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
219605904|NCT06575543|RADIATION|CT|3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
219605905|NCT05436795|DEVICE|Abbott Panbio rapid antigen self-tests|COVID-19 self-testing will be performed using investigational Abbott Panbio rapid antigen self-test kits that require self-sampled nasal swabs.
219605906|NCT05436795|OTHER|COVIDSmart CARE! app|Guided by the application that connects, educates, and communicates a digital, contactless open access strategy, participants will have the opportunity to self-test and assess their risk level of COVID-19 infection, as well as the option to refer their close contacts to testing for those who are COVID-19 positive, through the study platform.
219501875|NCT02718495|DRUG|PTI-428|
219501876|NCT02718495|DRUG|Placebo|
219501877|NCT02079948|DRUG|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression."
219501878|NCT02079948|DRUG|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression"
219501879|NCT02079948|PROCEDURE|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
219501880|NCT02079948|PROCEDURE|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
219605907|NCT03895814|BEHAVIORAL|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
219605908|NCT00486850|OTHER|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
219605909|NCT01937221|OTHER|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
218881640|NCT01858740|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
218881641|NCT01858740|DRUG|Fludarabine Phosphate|Given IV
218881642|NCT01858740|OTHER|Laboratory Biomarker Analysis|Correlative studies
218881643|NCT01858740|DRUG|Methotrexate|Given IV
218881644|NCT01858740|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
218881645|NCT01858740|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
218881646|NCT01858740|DRUG|Tacrolimus|Given IV or PO
218881647|NCT01858740|DRUG|Thiotepa|Given IV
218881648|NCT01858740|RADIATION|Total-Body Irradiation|Undergo TBI
218881649|NCT01080846|DRUG|Misoprostol|600 mcg of sublingual misoprostol
218881650|NCT02994875|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
219501881|NCT03207360|BEHAVIORAL|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
219501882|NCT00372827|DRUG|Brinzolamide 1% added to Travoprost 0.004%|
219605910|NCT05824624|OTHER|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
219605911|NCT05824624|OTHER|Routine Care|Routine nursing care will be provided.
219605912|NCT00494702|PROCEDURE|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
219605913|NCT00494702|PROCEDURE|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
218881651|NCT02994875|OTHER|Placebo|Sugar pill
218881652|NCT00410007|BEHAVIORAL|High Sodium Diet|250-350 mmol
218881653|NCT00410007|BEHAVIORAL|Low Sodium Diet|25-35 mmol
218881654|NCT00410007|BEHAVIORAL|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
218881655|NCT00413790|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
218881656|NCT00413790|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
218881657|NCT00413790|DRUG|Placebo|Placebo tablet once daily
218881658|NCT06960720|OTHER|Resistance Exercises|Twice-weekly resistance exercises completed in 45 minutes using resistance bands and a physical therapy workout plan.
218881659|NCT01625546|DEVICE|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
218881660|NCT04370353|DIETARY_SUPPLEMENT|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
218881661|NCT04370353|DIETARY_SUPPLEMENT|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
218881662|NCT01362829|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
218881663|NCT04570631|DRUG|Eftozanermin alfa|Intravenous (IV) infusion
218881664|NCT04570631|DRUG|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
218881665|NCT04570631|DRUG|Dexamethasone|Oral Tablet
218881666|NCT04441580|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
218881667|NCT04600934|DEVICE|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
218881668|NCT04600934|DEVICE|Plain old balloon angioplasty|POBA
218881669|NCT05345717|DRUG|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
218881670|NCT01009008|DEVICE|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
218881671|NCT03492541|OTHER|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
218881672|NCT00500994|DEVICE|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
219501883|NCT01967888|DRUG|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
219501884|NCT01967888|DRUG|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
219501885|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
219501886|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
218881673|NCT05471089|DEVICE|Diathermy by emission of Radiofrequency|Applied only to experimental group
218881674|NCT05471089|OTHER|Therapeutic exercise|Applied to both arms/groups
218881675|NCT00734968|DRUG|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
218881676|NCT00734968|OTHER|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
218881677|NCT00005084|PROCEDURE|conventional surgery|
218881678|NCT00005084|PROCEDURE|magnetic resonance spectroscopic imaging|
218881679|NCT00005084|RADIATION|radiation therapy|
218881680|NCT00894361|PROCEDURE|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
218881681|NCT00894361|PROCEDURE|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
219501887|NCT02505100|OTHER|Touching relaxant|
219501888|NCT02505100|OTHER|Hypnoses|
219501889|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
218881682|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
219027520|NCT01802957|OTHER|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
219027521|NCT01802957|OTHER|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
219027522|NCT01802957|OTHER|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
219027523|NCT03072966|DEVICE|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
219027524|NCT01277354|BEHAVIORAL|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
219027525|NCT01277354|BEHAVIORAL|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
219027526|NCT03893552|DEVICE|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
219027527|NCT02943733|DRUG|TAS-102|Anti-metabolite agent, taken orally.
219027528|NCT02943733|DRUG|Temozolomide|Oral chemotherapy drug.
219501890|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol/ Triclosan|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
219501891|NCT00553540|DEVICE|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
219501892|NCT05805475|OTHER|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
219501893|NCT05805475|OTHER|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
219501894|NCT06021977|DRUG|Zanubrutinib|Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
219027529|NCT02943733|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
219501895|NCT06087393|DEVICE|CONVIVO|Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
219027530|NCT02943733|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
219027531|NCT04698733|DEVICE|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
219501896|NCT04193059|DRUG|Paclitaxel|paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
219501897|NCT04193059|DRUG|Carboplatin|carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
219501898|NCT04193059|DRUG|Epirubicin|epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
219501899|NCT04193059|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
219501900|NCT04193059|DRUG|Trastuzumab|trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
219501901|NCT04193059|DRUG|Pertuzumab|pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
219605914|NCT01791309|DRUG|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
219200803|NCT06783712|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
219200804|NCT06185777|BEHAVIORAL|Exercise oncology counseling and referal|Identification \& brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
219501902|NCT04193059|DRUG|Docetaxel|docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
219501903|NCT05386745|BEHAVIORAL|physical activity|A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
218881683|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
218881684|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
219501904|NCT02622074|BIOLOGICAL|Pembrolizumab|200 mg administered Q3W as an IV infusion.
219501905|NCT02622074|DRUG|Nab-paclitaxel|125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.
219501906|NCT02622074|DRUG|Anthracycline (doxorubicin)|60 mg/m\^2 administered Q3W as an IV injection.
218881685|NCT04386954|PROCEDURE|observational study|observation study
218881686|NCT06549426|DRUG|anti-seizure medication + sedative agent(s)|"Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)"
218881687|NCT06121089|PROCEDURE|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
219027532|NCT01280552|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
219027533|NCT01280552|BIOLOGICAL|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
219501907|NCT02622074|DRUG|Cyclophosphamide|600 mg/m\^2 administered Q3W as an IV infusion.
219501908|NCT02622074|DRUG|Carboplatin|AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
219501909|NCT02622074|DRUG|Paclitaxel|80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.
219501910|NCT03770871|DRUG|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
219501911|NCT03770871|DRUG|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
219501912|NCT04622384|OTHER|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
219501913|NCT00454974|DEVICE|Wearable artificial kidney|
219501914|NCT02114931|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
219027534|NCT02805335|DEVICE|KTFIX PLUS|
219027535|NCT04529889|OTHER||
219027536|NCT02155738|DRUG|IV Acetaminophen|
219027537|NCT02155738|DRUG|IV normal saline|IV normal saline
219027538|NCT04147065|DRUG|Duration of eradication regimen|14 day eradication regimen
219027539|NCT03160833|DRUG|HMPL-453|oral administrative
219027540|NCT04974658|PROCEDURE|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
219027541|NCT05282550|DRUG|Trazodone|50mg of trazodone administered for 4 weeks.
219027542|NCT05282550|DRUG|Placebo|Placebo administered for 4 weeks.
219501915|NCT03555370|BEHAVIORAL|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
219501916|NCT03555370|BEHAVIORAL|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
219027543|NCT03459664|BEHAVIORAL|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
219027544|NCT03459664|BEHAVIORAL|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
219027545|NCT00422266|DRUG|Omega 3 fatty acids and plant sterol enriched drink|
219027546|NCT00422266|DIETARY_SUPPLEMENT|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
219027547|NCT00234195|DRUG|bupropion extended release (Wellbutrin XL)|
219200805|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
219501917|NCT00590356|DEVICE|StarClose®|Closure device for femoral artery suture site occlusion
219501918|NCT00590356|DEVICE|AngioSeal®|Closure device for femoral artery suture site occlusion
219501919|NCT04572620|DRUG|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
219501920|NCT04572620|DRUG|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
219501921|NCT05394142|DRUG|Placebo|Comparator arm with placebo
219501922|NCT05394142|DRUG|Pioglitazone|Pioglitazone 7.5 mg/day
219501923|NCT05394142|DRUG|Spironolactone|Spironolactone 50 mg/day
219501924|NCT05394142|DRUG|Metformin|Metformin 850 mg/day
218881688|NCT06121089|PROCEDURE|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
218881689|NCT06309589|DRUG|Vitamin D|experimental group received UDCA combined with vitamin D3 (1200 IU per day) treatment
218881690|NCT00133861|DRUG|Botulinum toxin|
218881691|NCT06485323|DEVICE|MRI pelvimetry|MRI of the pelvis
218881692|NCT01871441|RADIATION|Total-body irradiation|Undergo TBI
218881693|NCT01871441|BIOLOGICAL|Donor lymphocytes infusion (DLI)|Undergo DLI
218881694|NCT01871441|DRUG|Cyclophosphamide|Given IV
219027548|NCT03055247|DRUG|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
219027549|NCT03055247|DRUG|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
219501925|NCT05593406|DEVICE|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
219501926|NCT05593406|OTHER|Control Group|NDT treatment 2 sessions per week
218881695|NCT01871441|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
218881696|NCT01871441|DRUG|Tacrolimus|Given IV
218881697|NCT01871441|DRUG|Mycophenolate mofetil|Given IV
218881698|NCT01024842|BIOLOGICAL|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.
218881699|NCT01024842|OTHER|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
218881700|NCT01024842|BIOLOGICAL|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.
218881701|NCT01024842|OTHER|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
218881702|NCT05541679|DEVICE|Right ventricular septal pacing followed by left bundle branch area pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
219027550|NCT03055247|DRUG|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
219027551|NCT02603809|DRUG|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
219027552|NCT02603809|DRUG|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
219501927|NCT02578732|DRUG|FOLFOXA|"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."
219501928|NCT01691755|DRUG|Placebo|oral doses once a day for 26 weeks
219501929|NCT01691755|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
218881703|NCT05541679|DEVICE|Left bundle branch area pacing followed by right ventricular septal pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
218881704|NCT00933465|DRUG|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
218881705|NCT00933465|DRUG|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
218881706|NCT00243711|DRUG|Carboxymethylcellulose sodium and Glycerin|
219501930|NCT03592381|PROCEDURE|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
219501931|NCT03592381|PROCEDURE|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
219501932|NCT04706975|DRUG|difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg administered twice daily
219605915|NCT03022370|BEHAVIORAL|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
219605916|NCT00101426|DRUG|ranirestat, (AS-3201)|
219605917|NCT00894712|OTHER|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
219605918|NCT00894712|DEVICE|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
218881707|NCT00418327|DRUG|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
218881708|NCT02794519|DRUG|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
218881709|NCT02794519|DRUG|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
218881710|NCT02794519|DRUG|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
218881711|NCT03041896|DEVICE|coflex® Interlaminar Technology|Interlaminer Technology
218881712|NCT05512416|DRUG|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
218881713|NCT02638168|DRUG|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
218881714|NCT02638168|DRUG|Placebo|inert placebo ingredient
219027553|NCT02603809|DRUG|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
219501933|NCT04706975|DRUG|Placebo|Oral Placebo administered twice daily
219501934|NCT02115191|DEVICE|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
219501935|NCT02115191|PROCEDURE|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
219501936|NCT04411459|OTHER|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
218881715|NCT06224179|PROCEDURE|ultrasound guided subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,"
218881716|NCT06224179|PROCEDURE|ultrasound guided combined posterior and subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,"
218881717|NCT04903054|BIOLOGICAL|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
219501937|NCT04670757|DRUG|CPL409116|IMP administration, tablets contain CPL409116 as an active ingredient
219501938|NCT04670757|DRUG|Placebo|Placebo comparator
219501939|NCT03911609|OTHER|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
219501940|NCT03911609|OTHER|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
219501941|NCT02875171|DRUG|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
219501942|NCT00535509|RADIATION|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
219501943|NCT00535509|OTHER|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
219501944|NCT00535509|DRUG|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
219501945|NCT06150378|DRUG|Corticosteroid|Patients that receive an injection with corticosteroid
219605919|NCT01002924|DRUG|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
219605920|NCT02962518|DEVICE|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
218881718|NCT04903054|DRUG|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
219501946|NCT06150378|BIOLOGICAL|Plathet rich plasma|Patients that receive an injection with Plathet-rich plasma
219605921|NCT02962518|PROCEDURE|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
219605922|NCT02962518|DRUG|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
219605923|NCT01311687|DRUG|pomalidomide|4 mg pomalidomide capsules administered orally
219605924|NCT01311687|DRUG|Dexamethasone|40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally
219605925|NCT06084793|OTHER|Music|In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
218881719|NCT04903054|BIOLOGICAL|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
218881720|NCT04903054|DRUG|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
218881721|NCT04903054|DRUG|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
218881722|NCT04903054|DRUG|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
218881723|NCT02097030|DEVICE|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
218881724|NCT02097030|DEVICE|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
219501947|NCT03565211|DRUG|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
219501948|NCT01859325|BIOLOGICAL|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
218881725|NCT02097030|DEVICE|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
218881726|NCT00034827|DRUG|CI-1040|
218881727|NCT05289479|PROCEDURE|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
218881728|NCT05289479|PROCEDURE|no pre-heating of resin composite before application|The control group
218881729|NCT03761901|DRUG|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
218881730|NCT03761901|DRUG|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
218881731|NCT03761901|DRUG|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
218881732|NCT00773747|DRUG|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
218881733|NCT00773747|DRUG|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
218881734|NCT00773747|DRUG|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
218881735|NCT04260347|DRUG|Alteplase|Intravenous injection
219027554|NCT02603809|DRUG|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
219027555|NCT02603809|DRUG|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
219501949|NCT01859325|BIOLOGICAL|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
219501950|NCT01859325|BIOLOGICAL|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
219501951|NCT01859325|DRUG|Placebo|
219027556|NCT02603809|DRUG|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
219501952|NCT03335020|DEVICE|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
219501953|NCT03335020|DEVICE|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
219605926|NCT05915260|DIAGNOSTIC_TEST|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
219027557|NCT03127449|DRUG|Alflutinib|patients take Alflutinib orally once per day at different dose
219027558|NCT00238277|DRUG|temozolomide|
219605927|NCT02087657|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
219605928|NCT03017768|DIETARY_SUPPLEMENT|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
219605929|NCT03017768|DIETARY_SUPPLEMENT|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
219605930|NCT03017768|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
219605931|NCT01851083|BIOLOGICAL|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.
219027559|NCT00238277|PROCEDURE|adjuvant therapy|
219027560|NCT00238277|PROCEDURE|chemotherapy|
219027561|NCT00238277|PROCEDURE|radiation therapy|
219027562|NCT00006374|BIOLOGICAL|filgrastim|
219027563|NCT00006374|DRUG|cisplatin|
219027564|NCT00006374|DRUG|etoposide|
219027565|NCT00006374|DRUG|paclitaxel|
219027566|NCT00006374|DRUG|topotecan hydrochloride|
219605932|NCT01851083|OTHER|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
219027567|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
219605933|NCT01618448|DRUG|Tolvaptan|Tolvaptan 15mg once daily
219605934|NCT01618448|DRUG|Placebo|Placebo
219605935|NCT06326346|DRUG|Liporaxel|Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
219605936|NCT03023072|OTHER|Incontinence Detection System|
219027568|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
219027569|NCT05986162|DRUG|Itolizumab|Patients to be treated with Itolizumab.
219027570|NCT03409172|OTHER|CTR|no counseling or nutritional therapy and no exercise
219027571|NCT03409172|OTHER|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
219027572|NCT03409172|OTHER|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
219027573|NCT02637700|DRUG|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
219027574|NCT02637700|DRUG|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
219027575|NCT03775980|DEVICE|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
219027576|NCT02583776|DEVICE|Unblinded - CGM|Data from device will be readable and alarms on
219027577|NCT02583776|DEVICE|Blinded - CGM|Data from device will be blinded and alarms off
219027578|NCT01010906|DRUG|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
219027579|NCT01010906|DRUG|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
219027580|NCT04738773|DRUG|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
219027581|NCT04738773|DRUG|Placebo|Placebo
219027582|NCT03068273|DEVICE|Real-time CGM data|
219027583|NCT06302192|DIAGNOSTIC_TEST|ARDS+AKI|according to the clinical practice Reanl doppler and VeXUS score will be performed
219027584|NCT05871359|DEVICE|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
219027585|NCT05871359|PROCEDURE|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
219501954|NCT03335020|DRUG|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
219605937|NCT00133965|BEHAVIORAL|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
219605938|NCT00133965|BEHAVIORAL|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
218881736|NCT06240949|DEVICE|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
218881737|NCT06240949|DEVICE|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
218881738|NCT02113033|DEVICE|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
218881739|NCT00513942|OTHER|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
219027586|NCT03161431|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
219027587|NCT03161431|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
219027588|NCT01218074|DEVICE|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
219027589|NCT01218074|DEVICE|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
219501955|NCT03335020|OTHER|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
219501956|NCT03335020|DEVICE|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
218881740|NCT04099784|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
218881741|NCT04099784|OTHER|Physical development and General Health|Physical development and General health examination
218881742|NCT04099784|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
218881743|NCT02470325|DRUG|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
218881744|NCT02470325|DRUG|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
219027590|NCT00525174|DEVICE|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
219027591|NCT00525174|DEVICE|Patching|2 hours daily patching of the sound eye
219027592|NCT00525174|PROCEDURE|Near activities|one hour near visual activities
219027593|NCT01652664|DRUG|Travoprost 0.004% PQ ophthalmic solution|
219501957|NCT03811197|BEHAVIORAL|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
219501958|NCT03811197|BEHAVIORAL|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
219501959|NCT03811197|BEHAVIORAL|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
219501960|NCT03845179|OTHER|Placebo|Saline infusion
219501961|NCT03845179|OTHER|GIP receptor antagonist|Used for infusion on study days
219501962|NCT03845179|DRUG|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
218881745|NCT01770171|DRUG|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
218881746|NCT01770171|DRUG|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
218881747|NCT00391027|DRUG|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
219501963|NCT03845179|OTHER|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
219501964|NCT02981797|OTHER|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
219605939|NCT00133965|BEHAVIORAL|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
219605940|NCT00408512|DRUG|thiazides|Up to 25 mg per day
218881748|NCT00391027|DRUG|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
218881749|NCT01916434|OTHER|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
219605941|NCT00408512|PROCEDURE|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
219605942|NCT02532686|DRUG|DAAOI-2|500-2000mg/d, oral, for 6 weeks
219605943|NCT02532686|DRUG|placebo|oral, for 6 weeks
218881750|NCT01916434|OTHER|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
218881751|NCT01916434|OTHER|No salmon|The placebo group will continue to consume their habitual diet.
218881752|NCT02186665|DRUG|calcitriol ointment|
218881753|NCT02186665|DRUG|placebo comparator|
218881754|NCT03570541|DRUG|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
218881755|NCT03570541|DRUG|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
219027594|NCT01652664|DRUG|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to \< 3 years of age received 0.25%
219027595|NCT01652664|DRUG|Travoprost Vehicle|Inactive ingredients used to maintain masking
219027596|NCT02357069|DRUG|Enbrel|Etanercept
219027597|NCT02357069|DRUG|LBEC0101|Etanercept
219027598|NCT01980043|PROCEDURE|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
218881756|NCT03570541|DEVICE|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
218881757|NCT03570541|DRUG|Morphine|intravenously administered morphine via PCA-pump
218881758|NCT03570541|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
218881759|NCT03570541|DIAGNOSTIC_TEST|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
218881760|NCT03570541|BEHAVIORAL|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
218881761|NCT03570541|DIAGNOSTIC_TEST|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
218881762|NCT03618316|DRUG|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
218881763|NCT03618316|DRUG|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
218881764|NCT00663754|BEHAVIORAL|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
218881765|NCT00663754|BEHAVIORAL|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
218881766|NCT06393179|OTHER|pressure-volume curve with a low-flow insufflation of 5 L/min|The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
218881767|NCT06016868|PROCEDURE|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
219200806|NCT06873022|DEVICE|neuromuscular electrical stimulation|"NMES: Two electrode pads were placed on the anterior, middle, and posterior deltoid boundary lines and at a distance of 1cm distal to the lateral margin of the acromion. The operator palpated the deltoid muscle contraction and asked the subjects to perform arm elevation task with NMES. (frequency of 35 Hz and a duration of 250 microseconds.) A verbal cue was given during both th~A verbal cue was given during both the sEMG biofeedback and NMES interventions: Lengthen your arm as if you want to touch the ground, the scapula keeps in the neutral position, and then elevate your arm. Each intervention consisted of 3 sets of 10 repetitions per set, with a 1-minute rest between sets."
219200807|NCT06873022|DEVICE|biofeedback|sEMG biofeedback: Subjects were instructed to monitor the sEMG signals of the D/UT balances ratio on the screen and maintain the D/UT balances ratio above the threshold during arm elevation and lowering. The threshold was set at 1 standard deviation of the ratio average at baseline (before intervention).
219200808|NCT06867068|DRUG|Midazolam Hydrochloride|Short-acting sedative. Benzodiazepine. Gamma-aminobutyric acid (GABA) inhibitor
219501965|NCT01894984|DRUG|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
218881768|NCT06016868|PROCEDURE|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
218881769|NCT04123145|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
218881770|NCT00230841|DEVICE|nebulized humidity|
218881771|NCT00281346|PROCEDURE|Doppler echocardiography|Echocardiography
218881772|NCT02056093|DEVICE|PSV mode|Application of PSV in all patients
218881773|NCT02056093|DEVICE|PAV mode|Application of PAV mode in all patients
218881774|NCT02056093|DEVICE|NAVA|
218881775|NCT03843983|DEVICE|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
218881776|NCT00349869|BEHAVIORAL|yoga|8-week yoga program.
218881777|NCT01763606|DRUG|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
218881778|NCT01763606|DRUG|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
219200809|NCT06867068|DRUG|Fentanyl|Synthetic opioid drug used as an analgesic.
219200810|NCT06867068|DRUG|Ketamine|General Anesthetic. N-methyl-D-aspartate (NMDA) receptor agonist
219200811|NCT06867068|DRUG|Propofol injection|General Anesthetic. GABA receptor modulator and calcium channel blocker
219200812|NCT06867068|DRUG|Nitrous oxide|Modulates a wide range of ligand-gated ion channels and inhibits NMDA receptor-mediated currents
219200813|NCT06869993|DIETARY_SUPPLEMENT|Meal Kit plus Mobile Culinary Medicine Education|This intervention will involve four phases: (1) a baseline assessment; (2) a 7-day monitoring phase, (3) a 30-day intervention phase in which all households receive weekly meal kits delivered to their home in addition to mobile culinary medicine education; and (4) a follow-up assessment.
219501966|NCT01894984|DRUG|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
219501967|NCT01584336|PROCEDURE|LATG|"1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy."
219501968|NCT01791283|PROCEDURE|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
219501969|NCT06521788|DEVICE|AI-assisted breast ultrasound|AI-assisted breast ultrasound in community-based breast cancer screening
219501970|NCT06521788|DEVICE|Routine breast ultrasound|Routine breast ultrasound conducted by primary care physicians
218881779|NCT05343377|DIAGNOSTIC_TEST|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
218881780|NCT04869358|DRUG|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
219501971|NCT05066087|BEHAVIORAL|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
219501972|NCT05066087|OTHER|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
218881781|NCT00160836|DEVICE|"Tissue sampling (G.I.U.M. catheter)"|
218881782|NCT04164732|DRUG|LCZ696|LCZ696 orally twice daily
219027599|NCT02155140|DIETARY_SUPPLEMENT|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
219501973|NCT04093973|DIAGNOSTIC_TEST|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
219200814|NCT06871566|OTHER|Artificial Intelligence-Supported Occupational Therapy Program|The AI-supported occupational therapy program was individually implemented by an occupational therapist over 8 weeks, with 2 sessions per week, each lasting 45 minutes. A touchscreen tablet, touch pen, and external camera were utilized during the sessions. At the beginning of the program, technological devices and artificial intelligence tools were introduced to the children. For the goals and detailed intervention program of the 8-week schedule
219501974|NCT00906685|DRUG|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
219501975|NCT00906685|DRUG|Sham bevacizumab injection|Sham intravitreal injection
219200815|NCT06873412|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
219501976|NCT00580333|DRUG|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
219501977|NCT00580333|DRUG|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
219501978|NCT00580333|DRUG|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
219501979|NCT00580333|DRUG|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
219501980|NCT00580333|DRUG|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
219501981|NCT05851482|DIAGNOSTIC_TEST|High resolution manometry|Standard chicago classification 4.0 HRM protocol
218881783|NCT04164732|DRUG|Placebo|placebo
218881784|NCT06970873|OTHER|Evaluation of Knowledge, Attitude, and Practice of Pediatric Dentists|Evaluation of Knowledge, Attitude, and Practice of pediatric dentists toward Obstructive Sleep Apnea among Children
218881785|NCT06974435|BEHAVIORAL|Interval training and electromagnetic therapy|Combined application of moderate intensity interval training and low frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
218881786|NCT06974435|BEHAVIORAL|Interval exercise training|Application of moderate intensity interval training, in addition to pharmacotherapy.
218881787|NCT06974435|BEHAVIORAL|Electromagnetic therapy|Application of low-frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
218881788|NCT06974435|OTHER|Control group (No intervention group)|Only Pharmacotherapy.
219027600|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
219027601|NCT06214572|RADIATION|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
219501982|NCT06006351|OTHER|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
219501983|NCT06006351|OTHER|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
219501984|NCT05295251|OTHER|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
219501985|NCT00000318|DRUG|Buprenorphine|"1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication"
219501986|NCT00293826|DRUG|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
219501987|NCT00293826|DRUG|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
219501988|NCT00293826|DRUG|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
219501989|NCT00293826|DRUG|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
219501990|NCT03458026|OTHER|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
219501991|NCT03458026|OTHER|Without connected object|Any intervention except follow-up visit
219501992|NCT05792865|DRUG|paxlovid|Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
219501993|NCT05792865|DRUG|No paxlovid|Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
219501994|NCT05792865|DRUG|Paxlovid|Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.
219501995|NCT04916860|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
219501996|NCT01666925|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu
219501997|NCT01666925|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
218881789|NCT04302545|PROCEDURE|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
218881790|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^1 TCID50|SARS-CoV-2, intranasally, (1x10\^1 TCID50)
218881791|NCT04865237|DRUG|Remdesivir|VEKLURY™
218881792|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^2 TCID50|SARS-CoV-2, intranasally, (1x10\^2 TCID50)
219501998|NCT05756868|BEHAVIORAL|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
219501999|NCT00844727|DRUG|Rofecoxib|
219502000|NCT00844727|DRUG|placebo|placebo pills
219502001|NCT00108901|BEHAVIORAL|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
219502002|NCT03840135|DRUG|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
218881793|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^3 TCID50|SARS-CoV-2, intranasally, (1x10\^3 TCID50)
218881794|NCT06975657|BEHAVIORAL|Wellbeing skills for reentry|A 6-week, in-person meditation training program for formerly incarcerated adults, with practices and concepts grounded in the four pillars of the Healthy Minds Program (awareness, connection, insight, and purpose)
218881795|NCT06974630|OTHER|Cervical erector spinae plane block|Patients will receive bilateral ultrasound-guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% on each side.
218881796|NCT06974630|OTHER|Cervical plexus block|Patients will receive bilateral ultrasound-guided superficial cervical block using 15 mL of 0.25% plain bupivacaine on each side of the neck.
219605944|NCT05214625|OTHER|Questionnaire|Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
218881797|NCT06974617|DRUG|Sphenopalatine block|Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
218881798|NCT06974617|DRUG|Botulinum Toxin Type A|Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
218881799|NCT06975449|BEHAVIORAL|Multicomponent Physical Exercise Program (Vivifrail)|Vivifrail physical training, 5 times/week, 50-60 minutes/session for 12 weeks
218881800|NCT06976632|BEHAVIORAL|Helfer Skin Tap Tecnique|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Following this, tetanus vaccination will be administered to the pregnant women in the intervention group using the Helfer Skin Tap technique in accordance with the Helfer Skin Tap IM Injection Procedure Guideline.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by the nurse, and the vital signs of the pregnant women will be measured again. To evaluate the long-term effects of pain, participants will be contacted via a link, and pain assessments will be conducted at the 24th and 48th hours following the vaccination."
219027602|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
219605945|NCT02277535|OTHER|Feedback/Reminder email.|
219605946|NCT01634841|DIETARY_SUPPLEMENT|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
219605947|NCT01634841|OTHER|habitual diet|Dietary information will be provided
219605948|NCT04753216|BIOLOGICAL|Bevacizumab|Given IV
219605949|NCT04753216|DRUG|Irinotecan Sucrosofate|Given IV
219605950|NCT02142608|DRUG|BR55|Ultrasound contrast agent
219605951|NCT02001987|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
219605952|NCT02001987|DRUG|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
219605953|NCT02001987|DRUG|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
219605954|NCT06329570|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and microbubble
219605955|NCT06329570|DRUG|Lumason|Open the BBB using focused ultrasound and microbubble
219605956|NCT06329570|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
219605957|NCT06074393|BEHAVIORAL|Tailored Support Group|Participants engage in a secure, confidential environment, sharing caregiving insights and knowledge. Expert-led sessions, lasting 90 minutes, occur biweekly for 16 weeks, held via Zoom and at the University of Calgary's Cumming School of Medicine. These sessions take place twice annually, emphasizing the structured nature of the support group. Weekly themes include self-care, adaptation, coping skills, emotions, anticipatory grief, forgiveness, mindfulness, boundaries, and closure. Care partners actively participate by sharing experiences and asking questions in each session.
219605958|NCT02613247|DEVICE|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
219605959|NCT01965860|OTHER|additional curriculum (E-learning + simulation)|
219027603|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
219027604|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
219605960|NCT01965860|OTHER|additional E-learning|
219502003|NCT03840135|OTHER|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
219502004|NCT02506725|OTHER|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
219502005|NCT01452113|DRUG|Vildagliptin|one 50 mg tablet per os
219502006|NCT01894113|PROCEDURE|transbronchial lung biopsy|
219502007|NCT05466513|OTHER|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
219502008|NCT01779908|DIETARY_SUPPLEMENT|Vitamin D|
219605961|NCT04571853|BEHAVIORAL|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
219605962|NCT04571853|BEHAVIORAL|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
218881801|NCT06976632|BEHAVIORAL|Local Cold Application|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Subsequently, tetanus vaccination will be administered to the pregnant women in the intervention group using a cold compress gel, based on the Cold Compress Gel IM Injection Procedure Guideline developed in line with the relevant literature.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by nurse, and the vital signs of the pregnant women will be measured again. Pain assessment will be repeated at the 24th and 48th hours following the vaccination."
218881802|NCT06976827|OTHER|Dietary and physical activity monitoring during the 3-months post-hospitalization period|Three consultations with a private dietician, one consultation with the general practitioner, three months of APA monitoring
219027605|NCT06410118|BEHAVIORAL|DreamChanger+IRT|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
219027606|NCT05760807|DRUG|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
219027607|NCT03453684|DRUG|Administration of Vancomycin|Intravenous Vancomycin Administration
219502009|NCT01779908|OTHER|Placebo|
219502010|NCT05956171|OTHER|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
219502011|NCT05956171|OTHER|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
219502012|NCT05612737|PROCEDURE|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
219502013|NCT02605083|DRUG|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
219502014|NCT02455583|BEHAVIORAL|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
219605963|NCT04571853|BEHAVIORAL|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
219605964|NCT04763629|OTHER|Physical exercise|Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
219605965|NCT00876889|DRUG|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
219605966|NCT03936010|DRUG|Canagliflozin|Canagliflozin dispensing claim is exposure
219605967|NCT03936010|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
219200816|NCT06873412|DIETARY_SUPPLEMENT|Placbo|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
219502015|NCT01827371|BIOLOGICAL|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
219502016|NCT03124797|DEVICE|RD DCI Sensor|Noninvasive pulse oximeter sensor
219200817|NCT06872346|OTHER|Visit-based IT reminders to patients and practitioners|"To identify patients due for CCSM, simplify test ordering/referral, and track follow-up, PREDICT will include: 1) automated updating of a patient's problem list with the current cervical screening finding, 2) automated updating of cervical cancer health maintenance topics to the appropriate time interval and follow-up test/ procedure through the use of modifiers, 3) SmartSets to standardize ordering of procedures/ specialty referrals."
219200818|NCT06872346|OTHER|Population outreach|"Patients will be sent a reminder letter 90 days prior to the due date via the patient portal or mailed if no portal account (Outreach 1). If needed, four weeks later a phone call from the outreach coordinator reminds patients of the follow-up date if scheduled or helps establish follow-up (Outreach 2). The coordinator could also place an order for a referral and send a reminder to the practitioner to sign it if appropriate. The coordinator will review and document any alternative care plans discussed by the PCP and patient."
219200819|NCT06872554|OTHER|Supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia.
219200820|NCT06872554|OTHER|Non supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia. This program will be realized for the participants at home, with the use of a specified training App, without the supervision of a sport science professional.
219200821|NCT06263660|DIETARY_SUPPLEMENT|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
219502017|NCT01695798|BIOLOGICAL|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
219605968|NCT05586555|OTHER|Pupillometry (Eve-tracking measurements)|Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
219605969|NCT05204212|OTHER|Left Atrial Appendage closure|Percutaneous closure of the LAA
219200822|NCT06263660|DIETARY_SUPPLEMENT|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
219200823|NCT04986631|DRUG|Topiramate Tablets|Topiramate intervention
219200824|NCT05196347|DRUG|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
219200825|NCT05418647|OTHER|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
219200826|NCT05418647|OTHER|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
219200827|NCT06679543|OTHER|Partial sleep deprivation|Participants will be asked to come to the lab for testing after a night of partial sleep deprivation. Participants will be asked to fall asleep at their habitual bedtime but wake up early (\~40% of normal sleep duration).
219200828|NCT06872918|PROCEDURE|Lever positioning manipulation|The patient was placed in the prone position, and the doctor used one-finger Zen pushing, rolling, pressing and kneading, flicking and plucking methods in the patient's lumbar region and the affected side of the lower limb pain repeated massage treatment for 15min; the patient was placed in the prone open-mouth position, and the operator stood on the right side of his/her body, so that the whole body of the patient's muscles were relaxed. According to the type of herniation, the patient with paracentral lumbar disc herniation performed unilateral triggering mode, and the patient with central lumbar disc herniation performed bilateral triggering mode.
219502018|NCT02122211|DRUG|Betaine supplement|
219502019|NCT00618631|DRUG|Nicotine|
219502020|NCT00618631|DRUG|Carfentanil|
219502021|NCT02887482|BIOLOGICAL|GLS-5700|GLS 5700 at 2 mg DNA/dose
219502022|NCT02887482|BIOLOGICAL|Placebo|
219605970|NCT01018004|OTHER|follow-up care|
219502023|NCT03320473|DEVICE|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
219502024|NCT04433845|DRUG|Psilocybin|Open-label
219605971|NCT01018004|OTHER|questionnaire administration|
219605972|NCT01018004|PROCEDURE|quality-of-life assessment|
219605973|NCT04513301|DRUG|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
219605974|NCT04513301|RADIATION|Radiotherapy|RT 50-60Gy/25-30f
219605975|NCT06251440|DRUG|Fetal Reduction|Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route
219502025|NCT03773094|DRUG|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
219502026|NCT03773094|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
219605976|NCT00522730|OTHER|Parenteral nutrition|Duration : 5 days
219502027|NCT01081483|DRUG|ABT-072|See arm description for more information
219502028|NCT01081483|DRUG|Placebo|See arm description for more information
219502029|NCT04399902|DEVICE|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
219605977|NCT00522730|OTHER|Enteral nutrition|Duration : 5 days
219605978|NCT01483443|PROCEDURE|Oophrectomy|Both oophrectomy
219605979|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 1|2-week ad libitum use of the RELX ENDS tobacco flavor 1
219605980|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 2|2-week ad libitum use of the RELX ENDS tobacco flavor 2
219605981|NCT05134415|OTHER|RELX ENDS Menthol Flavor 1|2-week ad libitum use of the RELX ENDS menthol flavor 1
219605982|NCT05134415|OTHER|RELX ENDS Menthol Flavor 2|2-week ad libitum use of the RELX ENDS menthol flavor 2
219605983|NCT00440661|DRUG|Diacerhein|
219605984|NCT05890651|DIAGNOSTIC_TEST|ECG|Describe the electrocardiography (ECG) changes 24 hours,1,6,12 months after VSD transcatheter device closure in a pediatric population.
219605985|NCT03934346|OTHER|Zinc amino acid complex|Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
219605986|NCT05322772|DEVICE|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants \& children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
219605987|NCT00962819|BIOLOGICAL|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
218881803|NCT06975020|DRUG|Participants will prepare their cannabis product ad libitum and inhale the prepared product as usual for a maximum of 15 minutes.|Participants will prepare and inhale their cannabis product ad libitum for a maximum of 15 minutes. Prior to inhaling cannabis (the baseline), and for three hours thereafter, biological samples (e.g., blood) will be collected. Participants will be asked to complete a series of questionnaires addressing their (subjective) neurocognitive function and well-being, as well as their self-rated driving ability and subjective cannabis effects.
218881804|NCT06975904|PROCEDURE|m-CIMT with VR exer-games by Kinect Xbox 360|Virtual reality workout session will be for about 30 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For week 1-3: Soccer and Space Bubble Pop games will be used For week 4-6: 20,000 Leaks and Rally Ball games will be used 5 minutes will be given for cool down.
218881805|NCT06975904|PROCEDURE|m-CIMT with Task-Specific Functional Training|Begin with low-intensity exercises and progress to moderate to high intensity; session will be for about 30 minutes Warm-up for 5 minutes;one minute of rest for every five minutes of exercise For week 1-3: Assisted standing and weight shifting, Heel raises, Toe taps, Supported stepping, Unassisted standing and balance tasks will be used For week 4-6: Progressive stepping exercises, Heel-to-toe standing,
218881806|NCT06976346|DRUG|HRG2010 Capsule, Sinemet®, Madopar®|In each period under fasting conditions, subjects received oral administration of either HRG2010 Capsule dose 1, HRG2010 Capsule dose 2, Sinemet®, or Madopar®.
218881807|NCT06975579|DEVICE|Ultrasound image processing|The COSIE study examines the coherence of ultrasound to improve the estimation of the backscatter coefficient.
219502030|NCT03474289|DRUG|SHR-1316|Monotherapy
219502031|NCT00240864|DRUG|placebo|
219502032|NCT00240864|DRUG|acetaminophen|
219502033|NCT00240864|DRUG|ibuprofen|
219605988|NCT01366820|DRUG|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
219605989|NCT01366820|DRUG|Placebo|Sodium Chloride 0.9% Injection
219605990|NCT00972374|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
219605991|NCT00972374|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
219502034|NCT00248820|PROCEDURE|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
219502035|NCT02100566|BEHAVIORAL|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
219502036|NCT02100566|BEHAVIORAL|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
219502037|NCT03108391|DEVICE|Ambu AuraGain|
219605992|NCT00972374|OTHER|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
219502038|NCT03108391|DEVICE|LMA Supreme|
219605993|NCT03520257|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
218881808|NCT06977009|PROCEDURE|Occlusal Reduction|"patients will be allocated to either undergo occlusal reduction (Intervention group) where all occlusal contacts on the functional and non-functional cusps as well as on the marginal ridges will be reduced using a diamond bur, or not undergo occlusal reduction (Control group) where all occlusal contacts will remain intact.~The presence or absence of contact will be confirmed using articulating paper where occlusal surfaces will be dried and articulating paper will be held between the teeth with the mandible guided to the centric position. Intact occlusion will be assessed by examining the marks on the teeth.~A high-speed handpiece with copious coolant will be used to remove occlusal contacts (Intervention group) or just moved above the surface of the tooth without contacting the occlusal surface (Control group) to facilitate patient blinding."
218881809|NCT06138990|DIAGNOSTIC_TEST|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
218881810|NCT06138990|DRUG|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
218881811|NCT02482467|OTHER|Hormonal analysis, pelvic US|
218881812|NCT03330639|OTHER|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
218881813|NCT03330639|OTHER|Placebo|This group will receive the saline placebo solution.
218881814|NCT06493903|BEHAVIORAL|Positive Minds, Strong Joints|In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
218881815|NCT05427240|OTHER|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
218881816|NCT05427240|OTHER|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
218881817|NCT05427240|OTHER|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
218881818|NCT03938506|OTHER|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
219502039|NCT00877266|PROCEDURE|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
219502040|NCT05319340|OTHER|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
219502041|NCT03413865|OTHER|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
219502042|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
219502043|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a sham face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
219502044|NCT05064202|DEVICE|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
219502045|NCT05064202|DRUG|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
219502046|NCT06547203|DRUG|Cetuximab|Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks
219502047|NCT06547203|DRUG|Toripalimab|Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
219502048|NCT06547203|DRUG|Irinotecan|Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
219502049|NCT02662608|DRUG|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
219502050|NCT02930109|DRUG|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
218881819|NCT04153916|DEVICE|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
219502051|NCT02930109|DRUG|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
219502052|NCT03364985|DRUG|DWP16001|DWP16001 tablets
219502053|NCT03364985|DRUG|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
219502054|NCT03364985|DRUG|Dapagliflozin|Forxiga®
219502055|NCT04818151|DRUG|Warfarin|Warfarin treatment for VTE
219502056|NCT04818151|DRUG|Apixaban|Apixaban treatment for VTE
219502057|NCT00971672|OTHER|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
219502058|NCT04598672|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
219502059|NCT05061667|PROCEDURE|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
219502060|NCT05061667|PROCEDURE|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
219502061|NCT00509210|DRUG|telaprevir (VX-950)|
219502062|NCT04189419|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
219502063|NCT04189419|OTHER|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
219502064|NCT00700284|DRUG|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
219027608|NCT01319812|DEVICE|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
219502065|NCT00700284|DRUG|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
219502066|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
219502067|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
219502068|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
219502069|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
219502070|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
219502071|NCT00218621|PROCEDURE|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
219502072|NCT05268731|PROCEDURE|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
219502073|NCT05268731|PROCEDURE|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
219502074|NCT05268731|PROCEDURE|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
219605994|NCT03520257|DEVICE|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
219605995|NCT05602220|BEHAVIORAL|Brain training|Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
219605996|NCT05602220|BEHAVIORAL|Paced breathing|After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
219605997|NCT00282646|PROCEDURE|intraarterial stem cell therapy|catheter delivery of stem cells
219502075|NCT05580926|BEHAVIORAL|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
219502076|NCT05580926|OTHER|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
219502077|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
219502078|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
219502079|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
219502080|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
219502081|NCT03826485|DRUG|PRIC|Pranlukast hydrate 50mg
219502082|NCT03826485|DRUG|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
219502083|NCT06416137|DIAGNOSTIC_TEST|Neuropsychological tests|Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
219502084|NCT04056507|PROCEDURE|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
219502085|NCT02757300|DEVICE|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
219502086|NCT02757300|DEVICE|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
219502087|NCT00492388|DRUG|PMI-150 (intranasal ketamine)|intranasal dosing
219502088|NCT00492388|DRUG|placebo|placebo
219502089|NCT00069407|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy
219502090|NCT01361607|DRUG|Nabiximols|
219502091|NCT01361607|DRUG|Placebo (GA-0034)|
219502092|NCT00540709|DRUG|Insulin Glargine|
219502093|NCT01736137|OTHER|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
219502094|NCT05297071|DEVICE|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
219605998|NCT00282646|OTHER|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
219605999|NCT00139451|DRUG|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
219606000|NCT00139451|DRUG|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
219606001|NCT06012188|OTHER|sleep toy|The parents of the children in the experimental group will be given a sleeping companion toy to present to their children. At the end of 15 days, the Children's Sleep Habits scale will be applied as a post-test to evaluate the effect of the sleep companion toy.
219606002|NCT04570332|DRUG|BO-112 plus pembrolizumab|Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
219502095|NCT05297071|DEVICE|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
219502096|NCT03997331|OTHER|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
219606003|NCT04570332|PROCEDURE|Tissue Biopsies|Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
219606004|NCT05023915|DRUG|dexamethasone|40 mg qd for 4 days
219606005|NCT05023915|DRUG|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
219606006|NCT03305965|BEHAVIORAL|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
219606007|NCT02288325|DRUG|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
219606008|NCT02288325|DRUG|Placebo|Dose-matched placebo taken orally once daily.
219606009|NCT03138655|DRUG|Vedolizumab|Vedolizumab IV infusion.
219027609|NCT01319812|DEVICE|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
219606010|NCT03804814|BEHAVIORAL|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
219502097|NCT03997331|OTHER|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
219502098|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
219502099|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
219502100|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
219502101|NCT01809314|DRUG|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
219606011|NCT02565511|BIOLOGICAL|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
219606012|NCT02565511|OTHER|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
219502102|NCT05798858|DIAGNOSTIC_TEST|NIPT|universal nipt in group a, NIPT for intermediate risk in Group B
218881820|NCT04211129|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
218881821|NCT04211129|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
218881822|NCT06975826|PROCEDURE|Laparscopic percutaneous internal ring suturing (PIRS) technique in Management of inguinal hernia|Laparscopic percutaneous internal ring suturing (PIRS) technique
218881823|NCT06975826|PROCEDURE|Laparscopic inguinal herniotomy in pediatrics|Laparoscopic intraperitoneal purse string suture sac closure technique in pediatrics.
218881824|NCT06975384|OTHER|Exposure: sleep disturbance status|"The assessment of sleep disturbance was conducted using Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI). Patients with a PSQI score \> 5 or an ISI score \> 7 were categorized as sleep disturbance patients.~The assessment of chronotype was conducted using reduced Morningness-Eveningness Questionnaire (rMEQ). Patients with an rMEQ score 18-25 were categorized as the morning type, those with an rMEQ score 12-17 as the intermediate type, and those with an rMEQ score 4-11 as the evening type."
218881825|NCT06974994|DIETARY_SUPPLEMENT|Synbiotic Supplement|Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
218881826|NCT06974994|OTHER|Placebo|Maltodextrin
218881827|NCT06975475|DRUG|SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel|SHR-A1811:4.8mg/kg tratuzumab:Initial 8mg/kg followed by 6mg/kg pyrotinib:320mg Nab-Paclitaxel:100-150mg/m2
218881828|NCT01636986|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
218881829|NCT01636986|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
218881830|NCT05118373|BEHAVIORAL|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
218881831|NCT05777135|DRUG|Ringer Lactate prior to surgery and Propofol|Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
218881832|NCT06168617|DIAGNOSTIC_TEST|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
218881833|NCT01537822|PROCEDURE|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
218881834|NCT01537822|PROCEDURE|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
218881835|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
219606013|NCT02565511|DRUG|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
219606014|NCT02565511|OTHER|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
219606015|NCT02565511|OTHER|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
219606016|NCT00638053|GENETIC|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
219502103|NCT01682941|DIETARY_SUPPLEMENT|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
219502104|NCT01682941|DIETARY_SUPPLEMENT|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
219502105|NCT02012179|OTHER|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
219502106|NCT04665479|OTHER|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
219502107|NCT01696383|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
218881836|NCT00002822|DRUG|carboplatin|
218881837|NCT00002822|DRUG|cisplatin|
218881838|NCT00002822|DRUG|cyclophosphamide|
218881839|NCT00002822|DRUG|doxorubicin hydrochloride|
218881840|NCT00002822|DRUG|etoposide|
218881841|NCT00002822|DRUG|ifosfamide|
218881842|NCT00002822|DRUG|mesna|
218881843|NCT00002822|DRUG|vincristine sulfate|
218881844|NCT00002822|RADIATION|radiation therapy|
218881845|NCT02643342|DEVICE|Orthokeratology|
218881846|NCT05675228|OTHER|data collection|Knowledge about genital herpes
218881847|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
218881848|NCT00644436|DEVICE|Tetrix|single topical application
218881849|NCT00644436|DEVICE|Tetrix|Single topical application
218881850|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
219027610|NCT05982054|PROCEDURE|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
218881851|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
218881852|NCT02210416|PROCEDURE|inguinal hernia surgery|
218881853|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
219502108|NCT04922398|BIOLOGICAL|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
219502109|NCT04922398|DRUG|Normal saline|0.9% normal saline will be injected in each ovary
219502110|NCT05953922|OTHER|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
219502111|NCT06417957|OTHER|cultural competence training|The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
219502112|NCT06081725|BEHAVIORAL|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
219502113|NCT06081725|BEHAVIORAL|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
219502114|NCT06081725|BEHAVIORAL|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
219502115|NCT06081725|BEHAVIORAL|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
219502116|NCT03037684|DIAGNOSTIC_TEST|neurophysiology|electrophysiologic measurements of peripheral nerves
219502117|NCT02168075|DRUG|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
219502118|NCT02168075|DRUG|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
219502119|NCT02168075|DRUG|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
219502120|NCT02168075|DRUG|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
219502121|NCT03256383|DEVICE|Lead testing|Fingerstick
219502122|NCT04148183|DRUG|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
219502123|NCT04148183|DRUG|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
219502124|NCT04148183|DRUG|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
219502125|NCT06422611|DEVICE|Impression methods|Both digital and conventional impressions were taken from same patients
219606017|NCT04881487|RADIATION|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
219606018|NCT03656744|DRUG|HTD1801|HTD1801 tablets, 250mg
219606019|NCT03656744|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
219606020|NCT00706589|DRUG|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
219606021|NCT00706589|DRUG|placebo|Initial dose: 2mg, Maximum dose:20mg
218881854|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
219606022|NCT00549432|DEVICE|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
218881855|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
218881856|NCT02251210|DRUG|BIIL 284 BS low dose|
218881857|NCT02251210|DRUG|BIIL 284 BS medium dose|
218881858|NCT02251210|DRUG|BIIL 284 BS high dose|
219027611|NCT02979847|PROCEDURE|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
219027612|NCT02979847|PROCEDURE|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
219027613|NCT05023187|BEHAVIORAL|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
219027614|NCT05023187|BEHAVIORAL|CON|"A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
219027615|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
219027616|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
219027617|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
219027618|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
219027619|NCT05839522|DIAGNOSTIC_TEST|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
219027620|NCT05839522|BEHAVIORAL|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
219502126|NCT04490083|PROCEDURE|Extra corporeal shock wave lithotripsy|ESWL will be performed with a third generation electromagnetic lithotripter (Delta Compact, Dornier Med Tech, Germany) This has both fluoroscopy and ultrasound imaging facility. Radio opaque calculi will be targeted directly while a naso pancreatic tube (NPT) was placed for all radiolucent calculi and contrast was passed through this to localize the calculi. Between 5000 and 6000 shocks were delivered per session with frequency of 90 shocks per minute. The aim will be to fragment the calculi to \<3 mm or demonstrate a decrease in heterogeneity or density of the calculi in the main pancreatic duct. Shocks will be delivered on consecutive days till fragmentation is achieved. If there is no fragmentation after four sessions of ESWL the procedure will be labeled as unsuccessful and patient will be advised surgery. Procedures will be performed under epidural anesthesia.
218881859|NCT02251210|DRUG|Placebo|
218881860|NCT05170178|BEHAVIORAL|inclusion and familiarization|"* presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
219027621|NCT04757727|OTHER|Decriptive study of EDB|data on EDB will be register
219502127|NCT04423653|BEHAVIORAL|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
219606023|NCT00399633|DRUG|sumatriptan|
219606024|NCT04441151|BEHAVIORAL|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
219606025|NCT06458647|OTHER|Video Streaming with Virtual Reality|In the study, patients in the intervention group will be watched videos of natural landscapes such as mountains, beaches and waterfalls with virtual reality goggles before the angiography procedure.
219606026|NCT01696760|DRUG|acetylsalicylic acid|325 mg twice a day
219606027|NCT01696760|DRUG|enoxaparin|40 mg once daily
219027622|NCT05623267|DRUG|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
219027623|NCT05623267|DRUG|Placebo|Placebo of Sugemalimab
219027624|NCT04772222|DRUG|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
219027625|NCT04772222|DRUG|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
219502128|NCT04656951|DRUG|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
218881861|NCT05170178|BEHAVIORAL|fMRI acquisition and closure|"* Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending"
219502129|NCT03031457|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
219502130|NCT00851266|BIOLOGICAL|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1\) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
218881862|NCT03197922|BEHAVIORAL|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
218881863|NCT03197922|DRUG|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
219502131|NCT00851266|BIOLOGICAL|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
219502132|NCT04513340|DRUG|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
219502133|NCT01634022|PROCEDURE|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
219502134|NCT01814137|DRUG|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
219502135|NCT01814137|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
219502136|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
219502137|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
219502138|NCT05935774|BIOLOGICAL|Atezolizumab|Given IV
219502139|NCT05935774|PROCEDURE|Biopsy|Undergo biopsy
219502140|NCT05935774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219502141|NCT05935774|PROCEDURE|Computed Tomography|Undergo CT
219502142|NCT05935774|OTHER|Electronic Health Record Review|Ancillary studies
219502143|NCT05935774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219502144|NCT05935774|DRUG|Trabedersen (OT-101)|Given IV
218881864|NCT03197922|COMBINATION_PRODUCT|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
218881865|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
219502145|NCT02856867|DRUG|Nintedanib|
219502146|NCT02856867|DRUG|Fluorouracil|
219502147|NCT02856867|DRUG|Leucovorin|
219502148|NCT02856867|DRUG|Oxaliplatin|
219502149|NCT02856867|DRUG|Placebo|
219502150|NCT01328392|DRUG|Dexlansoprazole|30mg a day, 3 months
219502151|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
219502152|NCT00219557|DRUG|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
219502153|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
219502154|NCT01042496|DRUG|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
219502155|NCT01042496|PROCEDURE|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
219502156|NCT00833781|BIOLOGICAL|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
219502157|NCT00833781|BIOLOGICAL|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
219606028|NCT01696760|DEVICE|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
219606029|NCT00231543|PROCEDURE|Laparoscopic fundoplication|
218881866|NCT00979225|OTHER|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
218881867|NCT00979225|OTHER|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
218881868|NCT01575925|DRUG|4 mg Oral POM + 40 mg Oral DEX|
218881869|NCT01575925|DRUG|2 mg Oral POM + 40 mg Oral DEX|
218881870|NCT03459638|OTHER|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
218881871|NCT00610389|BIOLOGICAL|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
218881872|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
218881873|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
218881874|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
219502158|NCT03205514|DIAGNOSTIC_TEST|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
219502159|NCT02711150|DEVICE|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
219502160|NCT04848350|OTHER|Lavender essential oil|Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
219502161|NCT00654043|DRUG|Torsemide|tablets, 20 Mg, single-dose
219502162|NCT00654043|DRUG|Demadex|Tablets, 20 mg, single-dose
219502163|NCT01484990|DRUG|Levodopa-Carbidopa|Intestinal Gel
219502164|NCT00417599|BEHAVIORAL|Lifestyle Intervention|lifestyle intervention .
219502165|NCT00417599|OTHER|control group|waiting list control group
219502166|NCT01427803|DRUG|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
219502167|NCT02531828|DEVICE|Application of dressings for surgical correction.|Dressing for surgical correction
219502168|NCT02531828|DEVICE|POLYSHAFT®|
219502169|NCT00912470|PROCEDURE|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
219502170|NCT05871697|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
219502171|NCT05871697|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
219502172|NCT04400695|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
219502173|NCT04400695|DRUG|Paclitaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
219502174|NCT04400695|DRUG|Docetaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
219502175|NCT04400695|DRUG|Vinorelbine Tartrate Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
219502176|NCT04400695|DRUG|Capecitabine Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
219502177|NCT02345486|OTHER|0.9% sodium chloride|
219502178|NCT02345486|OTHER|Physiologically balanced fluid|
219502179|NCT00863057|DRUG|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
219502180|NCT00863057|DRUG|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
219502181|NCT00863057|DRUG|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
219502182|NCT00863057|DRUG|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
219502183|NCT04727346|RADIATION|CBCT|Cone Beam Computed Tomography
219502184|NCT04727346|PROCEDURE|DISE|Drug Induced Sleep Endoscopy
219502185|NCT03163095|DEVICE|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
219502186|NCT03163095|OTHER|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
219502187|NCT04351282|RADIATION|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
219502188|NCT05578573|DEVICE|KARAHOC device|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.
219502189|NCT05578573|DEVICE|Angiocatheter|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
219502190|NCT01919957|OTHER|No intervention|
219502191|NCT02048397|OTHER|Pulmonary Rehabilitation|
219502192|NCT02048397|DIETARY_SUPPLEMENT|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
219502193|NCT02447484|BEHAVIORAL|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
219502194|NCT02447484|BEHAVIORAL|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
218881875|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
218881876|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
218881877|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
219502195|NCT01279642|DEVICE|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
219502196|NCT01279642|OTHER|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
219502197|NCT01445132|DRUG|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
219502198|NCT05511285|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
219502199|NCT03799978|DRUG|ACT-541468|ACT-541468 50 mg film-coated tablets
219502200|NCT04638855|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
218881878|NCT00285168|BEHAVIORAL|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
219040270|NCT06139159|OTHER|Auxiliary to care|"* Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Support patients in attending their clinic visits; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database"
219502201|NCT04638855|DEVICE|Placebo|No device after hysteroscopy surgery
219502202|NCT01692171|DRUG|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
219502203|NCT06168955|OTHER|skin biopsy|skin biopsy for cell culture and N-homocysteinylation study
219502204|NCT05171803|OTHER|No intervention|No intervention, prospective, cohort study.
219502205|NCT04466449|DIAGNOSTIC_TEST|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
219502206|NCT01215123|DRUG|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
219502207|NCT03634670|OTHER|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
219502208|NCT01527539|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
218881879|NCT04830488|BEHAVIORAL|e-learning didactic module|Participants utilize e-learning
219502209|NCT05796622|BEHAVIORAL|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIVST-Chatbot
219502210|NCT05796622|BEHAVIORAL|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIVST-OIC
218881880|NCT04830488|BEHAVIORAL|Personal reflection activities|Participants complete questionnaires
218881881|NCT01844778|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
218881882|NCT01844778|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
218881883|NCT01844778|DRUG|Colistimethate|Colistimethate was administered via nebuliser.
218881884|NCT02681315|DEVICE|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
218881885|NCT02681315|DEVICE|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
218881886|NCT05024903|OTHER|Serious illness medical planning plus the novel e-health platform (PWG 2.0)|"PWG 2.0 consists of the following components:~1. A diagnostic questionnaire, Preparedness for the Future Questionnaire and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement.~2. A comprehensive e-workbook that helps users understand the science behind personal behavior change.~3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A).~4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content.~5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general.~6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator."
218881887|NCT05024903|OTHER|Standard of care|Participants are not planning for their future (PWG 2.0) or using the e-health platform
218881888|NCT05131191|DIAGNOSTIC_TEST|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
218881889|NCT05131191|PROCEDURE|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
218881890|NCT00326248|DRUG|GW679769 (casopitant)|
218881891|NCT03794154|DRUG|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
218881892|NCT03794154|DRUG|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
218881893|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
218881894|NCT01623869|OTHER|Laboratory Biomarker Analysis|Correlative studies
218881895|NCT01623869|BIOLOGICAL|Trebananib|Given IV
218881896|NCT01868334|BEHAVIORAL|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
218881897|NCT01868334|BEHAVIORAL|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
219502211|NCT01993420|DRUG|DRM02|
219502212|NCT01993420|OTHER|Vehicle|
219502213|NCT01939600|OTHER|Starch-free breakfast|Starch-free breakfast alone
219502214|NCT01939600|OTHER|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
219502215|NCT01939600|OTHER|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
219502216|NCT01939600|OTHER|Amioca|Starch-free breakfast plus 56.4g amioca starch
219502217|NCT05266456|BIOLOGICAL|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
219502218|NCT05266456|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
219606030|NCT00231543|PROCEDURE|open Nissen fundoplication|
218881898|NCT01868334|BEHAVIORAL|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
218881899|NCT01868334|BEHAVIORAL|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
219502219|NCT01741857|BIOLOGICAL|human umbilical cord derived MSC transplantation for SLE|
218881900|NCT04607369|DEVICE|EyeCTester|Smartphone app that allows vision testing
218881901|NCT05453045|DRUG|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
218881902|NCT01356199|DIETARY_SUPPLEMENT|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
218881903|NCT01356199|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO. 6 per day for 8 months.
219027626|NCT03213821|OTHER|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
219027627|NCT03696810|DIAGNOSTIC_TEST|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
219027628|NCT05694936|DRUG|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
219027629|NCT05694936|DRUG|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
219027630|NCT05694936|DRUG|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
219027631|NCT01592929|RADIATION|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
219027632|NCT01592929|OTHER|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
219502220|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
219502221|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
219502222|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
219502223|NCT05252806|DIAGNOSTIC_TEST|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
219502224|NCT01787474|DRUG|Cytarabine|Given IV
219502225|NCT01787474|BIOLOGICAL|Filgrastim|Given SC
219502226|NCT01787474|BIOLOGICAL|Filgrastim-sndz|Given SC
219606031|NCT01319526|GENETIC|DNA analysis|
219606032|NCT01319526|GENETIC|RNA analysis|
218881904|NCT05974319|OTHER|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
218881905|NCT05974319|OTHER|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
218881906|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
219502227|NCT01787474|DRUG|Fludarabine Phosphate|Given IV
218881907|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
218881908|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
218881909|NCT01620528|DRUG|elagolix|oral tablet
219502228|NCT01787474|OTHER|Laboratory Biomarker Analysis|Correlative studies
219606033|NCT01319526|OTHER|laboratory biomarker analysis|
219606034|NCT01332292|DRUG|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
219606035|NCT01332292|DRUG|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
219606036|NCT03561324|DEVICE|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
219606037|NCT03979755|OTHER|Application of questionnaires|Application of questionnaires described by telephone.
219606038|NCT04794036|OTHER|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
219606039|NCT04794036|OTHER|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
219606040|NCT03295630|DEVICE|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
219606041|NCT01080183|OTHER|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
219606042|NCT04010474|PROCEDURE|Modified Surgical APGAR Score|"Four intraoperative factors~1. Lowest heart rate (HR),~2. Lowest mean arterial pressure (MAP)~3. Estimated blood loss~4. Operation time"
219606043|NCT00098774|BIOLOGICAL|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC \> or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
219027633|NCT01592929|RADIATION|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
219027634|NCT01592929|RADIATION|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
219027635|NCT01592929|OTHER|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
218881910|NCT01620528|OTHER|placebo|oral tablet
218881911|NCT05733078|DRUG|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
218881912|NCT05733078|DRUG|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
218881913|NCT04975100|DRUG|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
218881914|NCT04975100|DRUG|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
218881915|NCT01254825|PROCEDURE|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
218881916|NCT01254825|PROCEDURE|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
218881917|NCT00597415|DRUG|celecoxib|celecoxib 200mg
218881918|NCT00597415|DRUG|placebo|placebo
219027636|NCT01792947|PROCEDURE|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
219027637|NCT01792947|BEHAVIORAL|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
219027638|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
219027639|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
219027640|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
219027641|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
219027642|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
219027643|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
219027644|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
219027645|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
219027646|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
219502229|NCT01787474|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
219502230|NCT00831727|BEHAVIORAL|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
219027647|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
219502231|NCT00831727|BEHAVIORAL|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
219502232|NCT06007573|DRUG|The control group received oral nimodipine tablets|The control group received oral nimodipine tablets
219502233|NCT02436395|PROCEDURE|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
219502234|NCT02436395|PROCEDURE|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
219502235|NCT00253097|BEHAVIORAL|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
219502236|NCT03084978|PROCEDURE|General Anesthesia|General anesthesia by standard endotracheal intubation.
219502237|NCT03084978|PROCEDURE|Conscious Sedation|Conscious sedation
219502238|NCT02451969|BIOLOGICAL|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
219502239|NCT02451969|BIOLOGICAL|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
219502240|NCT05097378|DRUG|Encorafenib + Binimetinib|"Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity"
219502241|NCT05097378|DRUG|Standard Adjuvant Treatment|Standard Adjuvant Treatment
219502242|NCT00059514|BEHAVIORAL|Modified Project Toward No Tobacco Use|
219606044|NCT00098774|BIOLOGICAL|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2
219502243|NCT03124381|DEVICE|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
219502244|NCT03124381|DEVICE|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
219502245|NCT04684784|DEVICE|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
219502246|NCT04684784|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
219502247|NCT04192617|DRUG|SM03|SM03: 600 mg intravenous (IV)
219502248|NCT04192617|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
218881919|NCT06546852|BEHAVIORAL|education|Patient education will be provide
218881920|NCT01812265|DRUG|PF-06305591|single Dose
218881921|NCT01812265|DRUG|PF-06305591|single Dose
218881922|NCT01812265|DRUG|Placebo|Single Dose
218881923|NCT00696839|BEHAVIORAL|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
218881924|NCT02793791|PROCEDURE|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
218881925|NCT05564585|OTHER|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
218881926|NCT05564585|OTHER|Sham Taping|The sham tape was applied over the calf muscle of either leg.
218881927|NCT05942547|DRUG|Diosmin|diosmin 600mg twice daily
218881928|NCT05942547|DRUG|Placebo|twice daily
218881929|NCT03929640|DRUG|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
218881930|NCT03929640|DRUG|Placebo|Placebo oral tablet every 6 hours
218881931|NCT03929640|DRUG|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
218881932|NCT03261791|DRUG|Apatinib|Apatinib mesylate tablets 500 mg po qd.
218881933|NCT05621993|DRUG|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
218881934|NCT01922791|DIETARY_SUPPLEMENT|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
219027648|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
219502249|NCT04192617|DRUG|Methotrexate|methotrexate: 7.5-20 mg/week oral
219502250|NCT05951517|DRUG|MMF|MMF treat refractory gastrointestinal Henoch-Schönlein purpura
218881935|NCT04584957|DEVICE|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
218881936|NCT03640221|DRUG|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
218881937|NCT03640221|DRUG|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
218881938|NCT03640221|DEVICE|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively."
218881939|NCT03640221|OTHER|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
219027649|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
219027650|NCT03036787|BEHAVIORAL|family based intervention|behavioural advises to family for normal motor development
219027651|NCT00058604|BIOLOGICAL|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
219027652|NCT00654407|DRUG|Rosuvastatin|
219027653|NCT00654407|DRUG|Atorvastatin|
219027654|NCT00654407|DRUG|Simvastatin|
219502251|NCT01132287|OTHER|FID 112903|lubricant eye drop FID 112903
219502252|NCT03392961|DRUG|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
219502253|NCT03392961|OTHER|Placebo comparator|Placebo tablet for oral use
219502254|NCT04496089|DIAGNOSTIC_TEST|89Zr-girentuximab|A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
219502255|NCT03437460|DRUG|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
219502256|NCT03437460|DIETARY_SUPPLEMENT|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
219502257|NCT01936168|DEVICE|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
219502258|NCT01936168|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
219502259|NCT02678221|DRUG|Sildenafil citrate|
219502260|NCT02678221|DRUG|Aspirin|
219502261|NCT05012137|PROCEDURE|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
219502262|NCT05012137|DRUG|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
219502263|NCT01324245|DRUG|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
219502264|NCT01190306|DEVICE|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
219502265|NCT01190306|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
219502266|NCT02883829|BEHAVIORAL|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
219502267|NCT02883829|BEHAVIORAL|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
219502268|NCT05454423|OTHER|the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication|"-Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding"
219027655|NCT03503903|PROCEDURE|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
219027656|NCT04985851|DRUG|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
219502269|NCT05454423|OTHER|traditional physical therapy + anti-hyperuricemia medication|"traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17."
219502270|NCT06307808|DRUG|Tacrolimus|Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus
219502271|NCT06307808|DRUG|Belatacept|Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
219502272|NCT02533999|DEVICE|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
219502273|NCT02533999|DEVICE|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
219502274|NCT01875445|DRUG|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
219027657|NCT04985851|DRUG|Durvalumab|durvalumab
219027658|NCT02618174|BEHAVIORAL|Neutral Control Condition|Message about age of University of Birmingham
219502275|NCT01875445|DRUG|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
219502276|NCT05354245|DIETARY_SUPPLEMENT|Fibre supplement (potato-pectin)|Fibre supplement
219502277|NCT05354245|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219502278|NCT05354245|DIETARY_SUPPLEMENT|High-protein diet|High-protein diet
219502279|NCT01913730|DRUG|Bortezomib|
219502280|NCT01913730|DRUG|Dexamethasone|
219502281|NCT03902756|OTHER|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
219502282|NCT01740856|OTHER|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
219200829|NCT06872918|PROCEDURE|Cluster of pseudo-manipulators|Sham manipulation treatment was given. Recipients take the prone position, the medical practitioner with a finger Zen push method, rolling method, pressing and kneading method, flicking and plucking method in the patient's lumbar region and the affected side of the lower limbs of the pain in the repeated massage treatment for 15min; patients prone position, with traction rope fixed lumbar disc herniation side of the affected limb, so that the affected limb back to the maximum extent of the extension, and then release the traction rope, simulating the backward extension of the force of the lever positioning manipulation, the medical practitioner does not do any manipulation.
219200830|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of unilateral wrenching patterns in lever positioning manipulation|During the unilateral trigger mode operation of the lever positioning manipulation, the operator wears a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand trigger maximum force, elbow compression preload force, and elbow compression maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
219200831|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of bilateral wrenching patterns in lever positioning manipulation|During the bilateral triggering mode operation of the lever positioning manipulation, the operator wore a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand triggering maximum force, elbow pressing preload force, and elbow pressing maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
219502283|NCT01740856|OTHER|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
219502284|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
219502285|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
219502286|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
219502287|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
219502288|NCT00591422|DRUG|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
219502289|NCT01328054|DRUG|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
219502290|NCT01328054|DRUG|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
219502291|NCT00180869|PROCEDURE|transfusion of allogeneic red blood cell concentrate|
219502292|NCT00180869|PROCEDURE|transfusion of leuko-reduced red blood cell concentrate|
219502293|NCT05500495|OTHER|no intervention|no intervention
219502294|NCT03170505|PROCEDURE|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
219502295|NCT00000531|DEVICE|defibrillators, implantable|
219502296|NCT00000531|DRUG|amiodarone amiodarone|
219502297|NCT00000531|DRUG|sotalol|
219606045|NCT00098774|DRUG|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
219606046|NCT00098774|DRUG|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
219606047|NCT00098774|DRUG|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
219606048|NCT00098774|DRUG|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
219606049|NCT00098774|DRUG|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
219606050|NCT03910673|DRUG|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
219502298|NCT05559294|BEHAVIORAL|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
219502299|NCT05559294|BEHAVIORAL|Education and care as Usual (ECAU)|Active control
219502300|NCT06182683|DIAGNOSTIC_TEST|optical coherence tomography and fractional flow reserve|The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.
219502301|NCT06182683|DIAGNOSTIC_TEST|Coronary angiography|The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography
219502302|NCT04341818|OTHER|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
219606051|NCT06581562|DRUG|AB-101|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
219502303|NCT04341818|OTHER|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
219502304|NCT04341818|OTHER|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
219502305|NCT06219382|DEVICE|Neurorehabilitation ecosystem|Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
219502306|NCT04566783|DIAGNOSTIC_TEST|Psychological/psychiatric examination|Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
219502307|NCT04566783|DIAGNOSTIC_TEST|Neurological examination|Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
219502308|NCT04566783|DIAGNOSTIC_TEST|Gynecological/urological examination|Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
219502309|NCT04566783|DIAGNOSTIC_TEST|Laboratory assessment|Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
219502310|NCT04566783|DIAGNOSTIC_TEST|Structural and Functional Magnetic Resonance Imaging|"1. Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~2. Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~3. High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~4. Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~5. Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~6. Functional MRI to assess brain response towards sexual cue reactivity."
219502311|NCT00887627|DRUG|conivaptan hydrochloride|intravenous
219502312|NCT01344395|DRUG|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
219502313|NCT01344395|DRUG|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
219502314|NCT00139204|PROCEDURE|C11 Methionine PET scan|
219502315|NCT01288833|DEVICE|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
219502316|NCT03275701|DRUG|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
219502317|NCT06120010|DEVICE|MRI|To detect prevalence of anatomical variants of dural sinuses by MRV
219502318|NCT04875156|OTHER|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
218881940|NCT03640221|OTHER|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
219502319|NCT02593890|DEVICE|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
219502320|NCT00291330|DRUG|dabigatran etexilate 150 mg|twice daily
219502321|NCT00291330|DRUG|warfarin (INR 2-3)|prn to maintain INR (2-3)
219502322|NCT05884138|OTHER|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
219502323|NCT03765944|DRUG|sirolimus|SIngle administration under fasted condition
219502324|NCT04309955|PROCEDURE|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
219502325|NCT05481060|OTHER|Screen-based simulation|In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
219502326|NCT01877707|OTHER|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
219502327|NCT00492089|DRUG|bevacizumab|Given IV
219502328|NCT00492089|DRUG|placebo|Given IV
219502329|NCT00492089|PROCEDURE|magnetic resonance imaging|
219502330|NCT00492089|PROCEDURE|quality-of-life assessment|
219502331|NCT02631109|DRUG|Pegaspargase|2000U/m2 day5
219502332|NCT02631109|DRUG|doxorubicin|25mg/m2 day1
219502333|NCT02631109|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
219502334|NCT02631109|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
219502335|NCT01593150|DRUG|Pradaxa|Pradaxa for 3 weeks prior to DC
219502336|NCT01593150|PROCEDURE|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
218881941|NCT03640221|OTHER|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
218881942|NCT03640221|OTHER|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
219502337|NCT01593150|OTHER|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
219502338|NCT00757666|DEVICE|Rate adaptive pacemaker|Accelerometer sensor
219502339|NCT00757666|DEVICE|Rate adaptive pacemaker|Minute ventilation sensor
219502340|NCT04537325|DEVICE|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
219502341|NCT02378506|BIOLOGICAL|etanercept|50mg subcutaneous, once weekly, 24 weeks
219502342|NCT01606137|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
218881943|NCT04899453|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
219502343|NCT04522011|OTHER|intraoperative or postoperative hyperthermic intraperitoneal chemotherapy|Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
219502344|NCT02462382|PROCEDURE|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
219502345|NCT02462382|DRUG|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
219502346|NCT02462382|DRUG|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
219502347|NCT04157270|DEVICE|Penumbra System|Penumbra System
219502348|NCT02477007|DRUG|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
219502349|NCT02477007|DRUG|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
219502350|NCT02477007|DRUG|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
219502351|NCT02477007|DRUG|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
219502352|NCT02593188|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
219502353|NCT02880215|BEHAVIORAL|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
219502354|NCT02880215|BEHAVIORAL|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
219502355|NCT04583488|DRUG|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
219502356|NCT03210233|PROCEDURE|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
219502357|NCT06203691|DIETARY_SUPPLEMENT|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre \& post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
219502358|NCT06203691|DIETARY_SUPPLEMENT|Non-Supplementation Group|Intervention will measure strength pre \& post operatively. Intervention group will not receive liquid supplements.
219200832|NCT06871813|BEHAVIORAL|combined the CDIO model with escape room pedagogy|consisting of 16 hours of theoretical instruction delivered in a classroom setting during the first two months, followed by 8 hours of practical skills training in the third month. Practical training covered four core competencies: cardiopulmonary resuscitation (CPR), closed intravenous transfusion, micro-infusion pump operation, and cardiac monitoring operation. The experimental group followed the same syllabus, incorporating an innovative teaching strategy that combined the CDIO model with escape room pedagogy.
218881944|NCT04899453|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
218881945|NCT04899453|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
218881946|NCT02106403|OTHER|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
219200833|NCT06873217|OTHER|Acupuncture|Once a patient with Vertigo and Dizziness came to the emergency department, emergency physicians ask if they were willing to accept acupuncture intervention in addition to the routine western medical care.
219200834|NCT06873503|PROCEDURE|Bracket removal using a Weingart plier with the mouth open|The brackets will be removed using a Weingart plier. The patient will be asked to keep his mouth open during this procedure.
219200835|NCT06873503|PROCEDURE|Biting on a cotton roll during brakcet removal|The brackets will be removed using a Weingart plier. During this procedure, the patient will be asked to bite on a cotton roll.
219200836|NCT06869083|OTHER|AF application enhancing AF education and drug adhrence|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
219200837|NCT06869083|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
219200838|NCT06868849|DRUG|JMT203 Injection|"Drug：JMT203 Injection~* Anti-GFRAL monoclonal antibody~* Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1)."
219502359|NCT06011473|DEVICE|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
219502360|NCT01528566|BEHAVIORAL|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
219200839|NCT06868615|DEVICE|AVAVA|1550nm Non-Ablative Fractional Laser
219502361|NCT01528566|BEHAVIORAL|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
219502362|NCT06340542|OTHER|Thoracic Mobility exercises|Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.
219502363|NCT06340542|OTHER|Manual Release technique|Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
219502364|NCT03839888|DRUG|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
219502365|NCT01846247|OTHER|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
219502366|NCT01846247|OTHER|Standard care|
219502367|NCT04351191|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
219200840|NCT06873555|DRUG|DC05F01|DC05F01 capsule
219200841|NCT06873490|DEVICE|Electric stimulation removabel device|The device will be used to stimulate orthodontic tooth movement through a specific design used to deliver the current to the mucosa around the teeth being retracted.
219200842|NCT06873490|PROCEDURE|Traditional retraction method.|In this intervention, the upper anterior teeth will be retracted together backward using the traditional retraction method. No acceleration devices will be used in conjunction with this procedure.
219502368|NCT04351191|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
219502369|NCT04351191|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
219502370|NCT04351191|DRUG|Placebo|Standard of Care plus placebo
219502371|NCT01213355|DRUG|Placebo|Capsule, single dose, oral, 1 day
219502372|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
219502373|NCT01213355|DRUG|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
219502374|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
219502375|NCT01213355|DRUG|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
219502376|NCT01213355|DRUG|scopolamine|injectable subcutaneous formulation, single dose, 1 day
219502377|NCT01213355|DRUG|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
219502378|NCT01213355|DRUG|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
219502379|NCT01213355|DRUG|Donepezil|Tablet, 10mg, single dose, 1 day
219502380|NCT01213355|DRUG|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
219502381|NCT00355069|BEHAVIORAL|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
219200843|NCT06871514|OTHER|2-DECIDE intervention: decision support for cardiovascular risk management|"The 2-DECIDE intervention consists of:~* Training of healthcare providers in implementing shared decision-making during clinical consultations.~* At least one initial extended outpatient consultation with a trained physician to ensure adequate time for actual understanding of treatment options.~* Decision support based on U-prevent~* Clear communication to the patient is provided in an easily comprehensible format, including pre-visit information, and a post-visit handout of the information and decisions made using the U-prevent medical device. Additionally, the general practitioner receives a letter detailing the outcome and rationale of the shared decision, along with the individual estimates that have informed the treatment choice."
219200844|NCT06871514|OTHER|No Intervention: usual care|Usual care
219502382|NCT01681043|BEHAVIORAL|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks"
219502383|NCT05399719|OTHER||no intervention
219502384|NCT05704218|BIOLOGICAL|blood sample|the patient will have a blood sample in order to perform serology tests
219502385|NCT06496113|PROCEDURE|Minimally invasive liver resection|Patients underwent liver resection either by robotic or laparoscopic approach
219502386|NCT02266706|DRUG|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
219502387|NCT02266706|DRUG|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
219200845|NCT06873269|OTHER|Baseline assessment|demographic information (age, gender, ethnicity), relevant medical, surgical and oncological history (number and types of previous treatments), clinical assessment (including Child Pugh score, BCLC stage), functional assessment (ECOG performance status), baseline laboratory findings (liver and kidney function, AFP tumor marker,..), date of diagnosis, baseline imaging characteristics (number, size, location of lesions, portal vein thrombosis, TNM stage) and if available histopathological diagnosis (grade of differentiation, microvascular invasion).
219200846|NCT06873269|RADIATION|holmium-166 radioembolization|Characteristics of treatment: treatment date, predicted target dose in Gy, predicted non-target dose in Gy, target volume in mL, whole liver volume in mL, administered activity in GBq, tumor absorbed dose, normal liver-absorbed dose Aim of TARE: palliative or curative/downstaging
219200847|NCT06873269|OTHER|Follow-up phase|"The following data on the performed monitoring after the procedure with clinical assessment, imaging modalities and blood samples as determined by the center, will be collected retrospectively:~* Response: tumor response on imaging, tumor marker (AFP levels) at 3, 6 and 12 months after Ho166-TARE, and thereafter every 6 months until last follow-up or death, date of progression, time to progression after treatment~* Toxicity and safety: side effects, adverse events, hepatic function parameters, presence of ascites or hepatic encephalopathy~* Survival: date of last follow-up or death"
219502388|NCT02266706|DRUG|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
219502389|NCT02266706|DRUG|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
219502390|NCT02266706|DRUG|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
219502391|NCT03673384|DEVICE|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
219502392|NCT03673384|DEVICE|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
219502393|NCT03673384|DRUG|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
219502394|NCT03673384|DRUG|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
219502395|NCT06312085|DEVICE|Endofill|Endofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
219502396|NCT02191956|BEHAVIORAL|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
219502397|NCT00612833|PROCEDURE|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
219502398|NCT01071109|PROCEDURE|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
219502399|NCT06232356|DIAGNOSTIC_TEST|Mobile Web App|all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
219502400|NCT05737888|OTHER|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
219502401|NCT05737888|OTHER|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
219502402|NCT05737888|BEHAVIORAL|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
219502403|NCT03405337|DRUG|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
219502404|NCT03405337|DRUG|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
219502405|NCT04933578|BEHAVIORAL|Dental anxiety scales|"* The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (\>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25."
219502406|NCT04741685|DEVICE|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
219502407|NCT04741685|DEVICE|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
219502408|NCT00409188|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
219502409|NCT00409188|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
219502410|NCT00409188|DRUG|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
219502411|NCT00003637|DRUG|cisplatin|
219502412|NCT00003637|DRUG|fluorouracil|
219502413|NCT00003637|RADIATION|radiation therapy|
219502414|NCT01260571|DRUG|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
219502415|NCT05139654|OTHER|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
219502416|NCT05139654|OTHER|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
219502417|NCT05139654|OTHER|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
219502418|NCT02879747|DRUG|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
219502419|NCT00845754|DRUG|ketorolac|15mg IV every6 hours for 4doses
219502420|NCT00845754|DRUG|saline|15mg IV every 6hrs for 4 doses
219606052|NCT06581562|DRUG|Rituximab|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
219606053|NCT06581562|DRUG|Cyclophosphamide|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
219606054|NCT06581562|DRUG|Fludarabine|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
219606055|NCT02158715|DEVICE|Site of smartphone on chest compressor' arm|
219606056|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention face-to-face|
219606057|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention delivered via DVD|
219027659|NCT02618174|BEHAVIORAL|Food-based Control Condition|Message about variety of vegetables in the world
219027660|NCT02618174|BEHAVIORAL|Health Condition|Message about the health benefits of eating vegetables
219502421|NCT03066154|DRUG|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
219027661|NCT02618174|BEHAVIORAL|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
219027662|NCT02618174|BEHAVIORAL|Liking Social Norm|Message suggesting most people like eating vegetables
219027663|NCT02763033|DRUG|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
219027664|NCT02763033|OTHER|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
219027665|NCT05175417|OTHER|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
219027666|NCT06496776|PROCEDURE|Choukroun's technique|Suturing will be done using the method described by Choukroun.
219027667|NCT05299749|OTHER|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
219027668|NCT05299749|OTHER|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
219502422|NCT03066154|DRUG|androgen deprivation therapy|ADT according to the standard of care
219502423|NCT03066154|RADIATION|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
219502424|NCT01950754|BEHAVIORAL|standing with both feet|
219502425|NCT01950754|BEHAVIORAL|descent of the platform|
219502426|NCT01950754|BEHAVIORAL|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
219502427|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
219502428|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
219502429|NCT05651529|DIETARY_SUPPLEMENT|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
219502430|NCT05651529|DIETARY_SUPPLEMENT|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
218881947|NCT02106403|OTHER|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
219027669|NCT05494242|OTHER|Surgical intervention|Pars-plana vitrectomy.
219027670|NCT03811431|PROCEDURE|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
219027671|NCT05017363|PROCEDURE|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
219502431|NCT00308373|DRUG|Metformin vs Thiazolidinedione (Pioglitazone)|
219502432|NCT01119976|BEHAVIORAL|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
219502433|NCT01119976|BEHAVIORAL|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
219502434|NCT00677924|DRUG|Zalutumumab|Solution for infusion
219502435|NCT04859855|PROCEDURE|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
218881948|NCT02106403|OTHER|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
218881949|NCT01303601|DRUG|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
218881950|NCT01303601|DRUG|Starch|
218881951|NCT05642299|DEVICE|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
218881952|NCT06332105|DIETARY_SUPPLEMENT|Glytactin|Glycomacropeptide based protein substitute for dietary treatment of PKU
218881953|NCT06332105|DIETARY_SUPPLEMENT|L-AA|Amino acid based protein substitute for dietary treatment of PKU
219027672|NCT04291651|OTHER|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
219502436|NCT04859855|PROCEDURE|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
219027673|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
219502437|NCT02872181|PROCEDURE|Supine|Placed in Supine position
219502438|NCT02872181|PROCEDURE|Left uterine displacement|Placed in 15 degrees left uterine displacement
219502439|NCT02495610|OTHER|Gait analysis and MRI:|"* Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
219502440|NCT04401319|DEVICE|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
219502441|NCT04401319|DEVICE|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
219502442|NCT04401319|DEVICE|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
219502443|NCT04401319|DEVICE|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
219502444|NCT04401319|DEVICE|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
219502445|NCT04401319|DEVICE|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
219606058|NCT00006286|DRUG|Fluoxetine|
219606059|NCT00006286|BEHAVIORAL|Psychotherapy|
219606060|NCT00380835|DRUG|Amrubicin|
219502446|NCT05697484|DEVICE|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
219502447|NCT02330120|DRUG|propofol|
218881954|NCT03653728|DEVICE|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
219027674|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
219502448|NCT02330120|DRUG|dexmedetomidine|
219502449|NCT01393990|DRUG|LY2228820|Administered orally
219502450|NCT01393990|DRUG|Midazolam|
219502451|NCT01393990|DRUG|Tamoxifen|
219502452|NCT04712006|DRUG|JNJ-64304500|Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
219502453|NCT00645775|DIETARY_SUPPLEMENT|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
219502454|NCT00143754|PROCEDURE|Hydration|
219200848|NCT05818384|BEHAVIORAL|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
219027675|NCT05264623|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
219027676|NCT05704738|DRUG|Rocatinlimab|Subcutaneous (SC) injection
219027677|NCT05704738|DRUG|Placebo|SC injection
219200849|NCT06683196|OTHER|Kinesio Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
219200850|NCT06683196|OTHER|Rigid Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
219502455|NCT05427565|OTHER|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
219502456|NCT05427565|OTHER|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
219502457|NCT03397628|OTHER|FIFA 11 for health|
219502458|NCT00275028|DRUG|cediranib maleate|Given orally
219502459|NCT04966897|DIETARY_SUPPLEMENT|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
218881955|NCT01822392|BEHAVIORAL|Online Parent Management Training (Interactive)|
218881956|NCT01822392|BEHAVIORAL|Online Parent Management Training (Recorded)|
218881957|NCT00473538|BEHAVIORAL|Structured exercise training|
218881958|NCT00473538|BEHAVIORAL|Hypocaloric hyperproteic diet|
219027678|NCT06093009|PROCEDURE|pancreatectomy|
219027679|NCT02672423|DRUG|Abemaciclib Capsules (Reference Formulation)|Administered orally
219027680|NCT02672423|DRUG|Abemaciclib Tablet (Test Formulation)|Administered orally
219027681|NCT06544265|BIOLOGICAL|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
219027682|NCT04484454|DIETARY_SUPPLEMENT|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
219027683|NCT00912990|DRUG|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
219027684|NCT00912990|DRUG|Normal saline|One Intravenous dose
219027685|NCT03533452|DRUG|Ropivacaine|Local anesthetic injection
219200851|NCT06682858|BEHAVIORAL|Group Cognitive Behavioural Therapy|Participants will complete 8 group sessions of a CBT-based intervention designed to help self-regulate sensory difficulties in autistic young people
219200852|NCT06685146|OTHER|Glucagon Infusion|A 240 minutes infusion of glucagon (10 ng/kg/min)
219200853|NCT06685146|OTHER|Glucose clamp|A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
219200854|NCT01652092|DRUG|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
219200855|NCT01652092|DRUG|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
219502460|NCT04966897|DIETARY_SUPPLEMENT|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
219502461|NCT01167855|OTHER|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
219502462|NCT01167855|OTHER|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
219502463|NCT01167855|OTHER|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
219502464|NCT01167855|OTHER|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
219502465|NCT01167855|OTHER|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
219502466|NCT05821712|DRUG|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
219502467|NCT05821712|DRUG|0.057% sodium fluoride Mouthwash|mouthwash
219502468|NCT02720952|DRUG|Infacort®|dry granule formulation of hydrocortisone
219502469|NCT05164549|DRUG|Buprenorphine Injectable Product|Investigational Medicinal Product
219502470|NCT05164549|DRUG|Methadone|Standard of Care
219502471|NCT05164549|DRUG|Buprenorphine|Standard of Care
219502472|NCT05558722|DRUG|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
219502473|NCT04352413|DRUG|PLM60|Administration: Intravenous infusion
219502474|NCT01995617|BIOLOGICAL|Placebo|normal saline, 0.5 mL per dose
219502475|NCT01995617|BIOLOGICAL|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
219502476|NCT01995617|BIOLOGICAL|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
219502477|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
219502478|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
219502479|NCT01995617|BIOLOGICAL|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
219502480|NCT01995617|BIOLOGICAL|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
219502481|NCT01193621|DRUG|haloperidol, PET|"1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
219502482|NCT05971121|DRUG|ciprofol|Ciprofol were used for sedation in ICU hypotensive patients
219502483|NCT04371484|OTHER|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
219502484|NCT03811379|DRUG|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
219502485|NCT05871879|DIAGNOSTIC_TEST|The 5-item modified frailty index|The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
219502486|NCT03895099|DRUG|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
219502487|NCT03895099|DRUG|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
219502488|NCT03895099|DRUG|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
219502489|NCT03895099|DRUG|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
219502490|NCT03895099|DRUG|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
219502491|NCT02257359|DRUG|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
219502492|NCT03089632|OTHER|Gluten-free diet|One-month gluten-free diet
219502493|NCT01044147|BEHAVIORAL|VLM-S|Online program for weight loss - standard
219200856|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
219502494|NCT01044147|BEHAVIORAL|VLM-M|Online program for weight loss - modulated
219502495|NCT01044147|BEHAVIORAL|OGR|Online program for weight loss - resources
219502496|NCT02680795|DRUG|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
219502497|NCT06177678|DRUG|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
219502498|NCT06177678|DRUG|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
219502499|NCT00778947|PROCEDURE|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
219502500|NCT00778947|PROCEDURE|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
219502501|NCT00892398|DRUG|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
219502502|NCT00892398|PROCEDURE|standard care|standard post-operative care after trabeculectomy with mitomycin C
219502503|NCT00720798|DRUG|Tocilizumab|For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
219502504|NCT00720798|DRUG|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
219502505|NCT00720798|DRUG|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
219502506|NCT00720798|DRUG|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
219502507|NCT05461820|DRUG|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
219502508|NCT05235594|DEVICE|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
219606061|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
219200857|NCT01652092|BIOLOGICAL|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg."
218881959|NCT04917913|DIETARY_SUPPLEMENT|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
219200858|NCT01652092|DRUG|Fludarabine phosphate 40 mg|40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
219502509|NCT01455558|DRUG|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
219502510|NCT00433381|BIOLOGICAL|Bevacizumab|Given IV
219502511|NCT00433381|DRUG|Irinotecan Hydrochloride|Given IV
219502512|NCT00433381|DRUG|Temozolomide|Given orally
219502513|NCT01014390|DEVICE|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
219502514|NCT01519609|DRUG|bowel prep before endoscopy|bowel prep before colonoscopy
219502515|NCT00501761|BEHAVIORAL|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
219502516|NCT00501761|BEHAVIORAL|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
219502517|NCT00501761|BEHAVIORAL|Suggested Exercise Program|Exercise program performed over 7 days.
219502518|NCT05381259|BEHAVIORAL|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
219502519|NCT01060774|DRUG|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
219502520|NCT01060774|DRUG|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
218881960|NCT04917913|DIETARY_SUPPLEMENT|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
219502521|NCT05561309|DRUG|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
219502522|NCT03064542|DRUG|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
219502523|NCT05636878|OTHER|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
218881961|NCT01496846|DRUG|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
219200859|NCT01652092|DRUG|Melphalan|140 mg/m\^2 IV on day -3
219200860|NCT01652092|DRUG|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
218881962|NCT01496846|DRUG|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
219200861|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
219200862|NCT01652092|DRUG|Fludarabine phosphate 30 mg|fludarabine 30 mg/m\^2 IV on days -8 through -4
219200863|NCT01652092|DRUG|MESNA|administered as per the standard institutional protocol.
219200864|NCT06682910|DEVICE|Microtech sensor pressure|Microtech sensor implantation
219502524|NCT05963256|DEVICE|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
219502525|NCT00198497|DRUG|Placebo|
219502526|NCT00198497|DRUG|Vitrase|Hyaluronidase 55 IU in saline solution
219502527|NCT00198497|DRUG|Vitrase|Hyaluronidase 75 IU in saline solution
219502528|NCT00466297|BEHAVIORAL|Face-to-face communication interactions|
219502529|NCT03496870|DRUG|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
219502530|NCT03496870|DRUG|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
219502531|NCT02036281|DRUG|Substance P-Saporin|
219502532|NCT04529148|DRUG|Ginkgo biloba dropping pills，best western medicine treatment|oral
219502533|NCT04529148|DRUG|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
219502534|NCT02270879|PROCEDURE|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
219502535|NCT02371798|DRUG|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
219502536|NCT05930574|PROCEDURE|Abdominal surgery|surgical interventions by gastrointestinal emergencies, hepatobiliary emergencies and trauma
218881963|NCT01496846|DRUG|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
219502537|NCT00406757|DRUG|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
219027686|NCT03533452|DRUG|Normal saline|Sham injection
219027687|NCT06167109|RADIATION|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
219502538|NCT00406757|DRUG|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
219606062|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
218881964|NCT01881568|DRUG|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
218881965|NCT01881568|DRUG|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
218881966|NCT00488696|DEVICE|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
218881967|NCT00612196|DRUG|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
218881968|NCT00612196|DRUG|Placebo|
218881969|NCT05290116|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
218881970|NCT04429724|DIAGNOSTIC_TEST|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
218881971|NCT02452450|DRUG|Ibuprofen Acid|
218881972|NCT02452450|DRUG|Ibuprofen Lysine|
218881973|NCT02452450|DRUG|Ibuprofen Sodium|
218881974|NCT02452450|DRUG|Ibuprofen Liquid Capsules|
218881975|NCT02452450|DRUG|Paracetamol|
218881976|NCT01772576|DEVICE|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
219027688|NCT00284479|BEHAVIORAL|Walking 45 mins 2x p.w.|
219027689|NCT00006202|DRUG|Lutein|
219027690|NCT03469479|DRUG|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
219027691|NCT03469479|PROCEDURE|Hepatic resection|R0 resection
219502539|NCT00406757|DRUG|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
219606063|NCT04304092|OTHER|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
219027692|NCT04019314|PROCEDURE|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
219027693|NCT04019314|PROCEDURE|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
219027694|NCT06850636|PROCEDURE|Epidural Analgesia|Labour epidural analgesia
219027695|NCT04846803|BIOLOGICAL|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
219606064|NCT01487525|DEVICE|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
218881977|NCT04955327|DRUG|A. Paniculata|Extract from A. Paniculata
218881978|NCT04955327|DRUG|A. Chilensis|Extract from A. Chilensis
218881979|NCT04955327|DRUG|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
219027696|NCT04846803|BIOLOGICAL|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
219027697|NCT06849986|DRUG|Tislelizumab+liposomal doxorubicin+ifosfamide|Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 Ifosfamide (IFO) 3 g/m2/day on days 1 to 3 Tislelizumab 200mg on day 1, administered by intravenous infusion, every 3 weeks
219027698|NCT05416437|DEVICE|PneumoCool|Device to channel medical air to the patient to alleviate dyspnea
219027699|NCT05416437|OTHER|Current supportive measures that are used in the hospital for standard of care|a room fan, or any other currently used supportive measures can be used for patients in the control arm
218881980|NCT04955327|DRUG|Microcrystalline cellulose|Placebo comparator
218881981|NCT02024724|DRUG|Bupivacaine|4 mL of 0.25% bupivacaine
218881982|NCT02024724|DRUG|Triamcinolone|40 mg of Triamcinolone
218881983|NCT02024724|DRUG|Dexamethasone|4 mg of Dexamethasone
218881984|NCT04854382|BEHAVIORAL|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
219027700|NCT05815121|OTHER|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
219027701|NCT05815121|OTHER|Control|with stickers only on the points, and the points should not be massaged.
219200865|NCT06684119|DEVICE|Electrical Impedance Tomography positive end-expiratory pressure titration|A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
219502540|NCT00406757|DRUG|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
219502541|NCT03250650|DEVICE|TTNS|Transcutaneous tibial electric stimulation
219502542|NCT03250650|DEVICE|ES+TTNS|Transvaginal electric stimulation
219502543|NCT02450942|DRUG|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
219606065|NCT01487525|OTHER|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
218881985|NCT04077515|DRUG|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
218881986|NCT04077515|DRUG|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
218881987|NCT05930184|PROCEDURE|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
218881988|NCT05930184|PROCEDURE|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
218881989|NCT06469606|DEVICE|AI tool|"Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes."
218881990|NCT02019875|DRUG|Rifampin|P450 inducer
218881991|NCT02019875|DRUG|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
218881992|NCT02019875|OTHER|Grapefruit Juice|CYP3A4 inhibitor in intestine
218881993|NCT02019875|OTHER|Placebo|
218881994|NCT02945514|OTHER|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
218881995|NCT03405428|OTHER|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
218881996|NCT03405428|OTHER|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
218881997|NCT03405428|OTHER|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
218881998|NCT00317096|PROCEDURE|FCM|Active comparator: Chemotherapy
218881999|NCT00317096|PROCEDURE|R-FCM|experimental: Chemotherapy with additional rituximab
218882000|NCT00317096|DRUG|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
218882001|NCT00317096|OTHER|observation only|no Intervention after completion of FCM or R-FCM
218882002|NCT01651663|DRUG|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
218882003|NCT01651663|OTHER|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
218882004|NCT01651663|DRUG|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
218882005|NCT01651663|OTHER|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
218882006|NCT05998382|BEHAVIORAL|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
218882007|NCT06212830|DRUG|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
218882008|NCT06212830|DRUG|Targin|Targin 5 mg twice a day after the procedure for 48 hours
218882009|NCT06212830|DRUG|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
218882010|NCT06212830|DRUG|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
219502544|NCT05165251|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
219502545|NCT05165251|DRUG|Amlodipine 5mg|amlodipine 5mg QD
219502546|NCT05165251|OTHER|Lifestyle intervention|Lifestyle intervention
219502547|NCT04460989|PROCEDURE|arthroplasty|total knee replacement
219502548|NCT02604069|DEVICE|Continuous Glucose Monitor|
219502549|NCT05874869|DRUG|Dihydroartemisinin-piperaquine|The drug will be administered once a day for three consecutive days for three months (March, April, and May)
219502550|NCT03432299|PROCEDURE|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
219502551|NCT02982382|OTHER|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
218882011|NCT01304537|DRUG|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
218882012|NCT01304537|DRUG|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
219502552|NCT02982382|OTHER|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
219502553|NCT02982382|OTHER|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
219502554|NCT03575429|BEHAVIORAL|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
219502555|NCT03575429|BEHAVIORAL|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
219502556|NCT04881526|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
219502557|NCT04881526|DIETARY_SUPPLEMENT|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
219502558|NCT04134975|PROCEDURE|Spine surgery|surgery with pedicle screw placement between L1 and S1
219502559|NCT05938452|DRUG|Glyceryl Tribenzoate|Oral Solution
219502560|NCT03355378|PROCEDURE|gum chewing|chewing gum orally for 30 minutes
219502561|NCT01084005|DRUG|linagliptin|patients receive linagliptin 5 mg tablets once daily
219502562|NCT01084005|DRUG|placebo|patients receive placebo matching linagliptin 5 mg once daily
219502563|NCT02967198|DEVICE|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
219502564|NCT02967198|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
219502565|NCT04495777|OTHER|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
219502566|NCT00549198|DRUG|Abacavir/lamivudine and efavirenz|
219502567|NCT00549198|DRUG|Tenofovir/Emtricitabine and efavirenz|
219502568|NCT02245776|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
219502569|NCT01753531|DEVICE|Flu Symptoms|
218882013|NCT01304537|DRUG|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
218882014|NCT05374330|OTHER|Electroacupuncture|Acupuncture needles are inserted into the body at standardized acupuncture points. An electrical current is then applied to 4 needles through 2 channels of electrical current. The sham group receives the same protocol with sham needles and sham electrical current.
218882015|NCT05176834|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
218882016|NCT03298763|GENETIC|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
218882017|NCT03298763|DRUG|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
218882018|NCT04717817|DEVICE|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
218882019|NCT04717817|OTHER|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
218882020|NCT03202134|OTHER|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
218882021|NCT04519697|DRUG|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
218882022|NCT04519697|OTHER|Placebo|Normal Saline
218882023|NCT00357825|DRUG|[S,S]-Reboxetine|
218882024|NCT04771676|DRUG|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
219502570|NCT05574582|PROCEDURE|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
219502571|NCT01483976|OTHER|Oral medical nutritional supplement|orally over a three hour period
219502572|NCT01483976|OTHER|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
219502573|NCT04544891|OTHER|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
219502574|NCT00732329|BEHAVIORAL|Occupational Therapy|"optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy"
218882025|NCT00966550|OTHER|Tomato|Tomato with high carb/fat meal
218882026|NCT00966550|OTHER|Non-tomato|Non-tomato with high carb/fat meal
218882027|NCT06311422|OTHER|resin nanoceramic block|Resin-based CAD/CAM materials
218882028|NCT06311422|OTHER|zirconia-reinforced lithium silicate|zirconia reinforced lithium silicate ceramic
218882029|NCT01128946|DRUG|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
218882030|NCT01128946|DRUG|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
218882031|NCT01128946|DRUG|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
219200866|NCT06682520|OTHER|Postpartum NEST-Rural Program (Hospital based service model)|NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
219502575|NCT01211574|BEHAVIORAL|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
219502576|NCT01211574|BEHAVIORAL|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
219200867|NCT06684639|BIOLOGICAL|GD2-CAR-T cell|Split intravenous infusion of GD2-CAR-T cells \[dose escalating infusion of (1-100)x10\^6 GD2-CAR-T cells/kg\]
219200868|NCT06682702|OTHER|DNS Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions. Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
219200869|NCT06682702|OTHER|Schroth Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions.
219200870|NCT06685692|DRUG|ADX-629|125 mg twice daily for 28 days
219200871|NCT06685692|DRUG|ADX-629|250 mg twice daily for 28 days
219502577|NCT01211574|BEHAVIORAL|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
219502578|NCT02223026|DRUG|Linagliptin/metformin FDC|
219502579|NCT02223026|OTHER|high-fat, high caloric meal|
219200872|NCT06683144|BEHAVIORAL|Exposure feedback|"* Determining the actual SHS exposure risk level and providing feedback.~* Determining the urinary cotinine test result and providing feedback.~* Feedback on the consistency or difference between the perceived SHS exposure risk level and the actual SHS exposure risk level."
219502580|NCT00249548|BEHAVIORAL|Contingency management|
219502581|NCT04755322|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
219502582|NCT04755322|DRUG|Folic acid|5 mg
219502583|NCT04755322|DRUG|Low-dose aspirin|75 mg
219502584|NCT04033939|DRUG|HSK3486|
219502585|NCT04033939|DRUG|Propofol|
219502586|NCT04033939|DRUG|Placebo|
218882032|NCT03999840|DRUG|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
218882033|NCT03999840|DRUG|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
218882034|NCT06085014|OTHER|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
218882035|NCT06085014|OTHER|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
218882036|NCT03404297|OTHER|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
219502587|NCT06503744|PROCEDURE|ablation|ablation
219502588|NCT06044558|DRUG|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
219502589|NCT06044558|DRUG|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
219502590|NCT06044558|DRUG|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
219502591|NCT02189616|BEHAVIORAL|SMS reminder|send weekly mobile phone short message reminders to the intervention group
219502592|NCT02189616|OTHER|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
219502593|NCT02189616|OTHER|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
219502594|NCT00200395|DRUG|Tarceva|OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
219502595|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
219502596|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
219502597|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
219502598|NCT01810796|DRUG|Ranolazine|Ranolazine versus placebo
218882037|NCT00379912|DRUG|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
218882038|NCT00379912|DRUG|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
218882039|NCT00379912|DRUG|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
218882040|NCT00621140|DRUG|linagliptin|active
218882041|NCT00621140|DRUG|placebo|placebo
219502599|NCT01132716|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
219502600|NCT04960696|DIAGNOSTIC_TEST|OSDI|Change of OSDI in distance education
219502601|NCT04960696|DIAGNOSTIC_TEST|tear break up time|Change of tear break up time in distance education
218882042|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
218882043|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
219502602|NCT04960696|DIAGNOSTIC_TEST|schirmer|Change of schirmer in distance education
219502603|NCT02116686|DEVICE|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
219502604|NCT03569319|BEHAVIORAL|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
219502605|NCT03569319|BEHAVIORAL|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
219502606|NCT03569319|BEHAVIORAL|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
219502607|NCT04532541|OTHER|Monogenic lupus screening|This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
218882044|NCT01371734|DRUG|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
218882045|NCT04807257|COMBINATION_PRODUCT|Auger Molecular Therapy (AMT)|The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
218882046|NCT04471324|DEVICE|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
218882047|NCT05226312|OTHER|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
218882048|NCT02073019|DRUG|BL-8040|
218882049|NCT02073019|DRUG|Placebo|
219027702|NCT06518187|OTHER|Assessing the impact of three different catheter advancement techniques on needle tip movement during intravenous insertion|Each participant will perform 3 simulated IV catheter insertions using each of the specified techniques. Participants will use the instrumented 16ga IV catheter to insert into the peripheral vascular access simulator. Needle tip movement (from intent of catheter advancement to 5mm of advancement off the needle) will be measured with 0.2mm accuracy using the electromagnetic tracking technology of the simulator. Data collected will include needle movement after simulated vein punction and during initial catheter advancement off the needle (in mm) which will be recorded within the simulation program and output as a de-identified Excel file
219027703|NCT06505824|DRUG|BL-M14D1|Administration by intravenous infusion for a cycle of 3 weeks.
219027704|NCT06127992|DEVICE|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
219027705|NCT01192282|PROCEDURE|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
218882050|NCT03296449|PROCEDURE|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
219027706|NCT05196841|BEHAVIORAL|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
219027707|NCT04165083|BIOLOGICAL|Pembrolizumab|IV infusion
219027708|NCT04165083|BIOLOGICAL|MK-4830|IV infusion
219027709|NCT04165083|BIOLOGICAL|MK-0482|IV infusion
219027710|NCT05852587|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
219027711|NCT05852587|DRUG|Placebo|The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
219027712|NCT06536257|OTHER|Predictive model|Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
219027713|NCT06570473|DRUG|Empagliflozin|Tablet
219027714|NCT06570473|DRUG|Ranolazine|Tablet
219502608|NCT04605419|PROCEDURE|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
219502609|NCT02480010|DRUG|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
218882051|NCT03296449|PROCEDURE|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
218882052|NCT00360568|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
218882053|NCT00360568|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219027715|NCT04546165|PROCEDURE|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
219200873|NCT06683144|BEHAVIORAL|Interactive education|Slide presentation, video presentation, Q\&A, evaluation of learning and discussion of results
219200874|NCT06683144|BEHAVIORAL|Social media post|Sharing informational materials such as messages, brochures, and videos related to SHS exposure, including ways to protect yourself from SHS exposure and the adverse health effects of SHS exposure.
219502610|NCT05485181|BEHAVIORAL|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
219502611|NCT03015142|DEVICE|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
219502612|NCT02967133|DRUG|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
219502613|NCT02967133|DRUG|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
219502614|NCT05431309|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
219502615|NCT05431309|OTHER|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
219502616|NCT01518452|BEHAVIORAL|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
219502617|NCT01518452|BEHAVIORAL|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
219502618|NCT03016585|OTHER|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
218882054|NCT00360568|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
218882055|NCT00360568|DEVICE|J-tube|jejunal tube
218882056|NCT04887896|DEVICE|GS500|Device: GS500
218882057|NCT04887896|DEVICE|Placebo|Device: Placebo
218882058|NCT03565237|BIOLOGICAL|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
218882059|NCT03565237|BIOLOGICAL|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
218882060|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
218882061|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
218882062|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
218882063|NCT02873338|DRUG|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
218882064|NCT02873338|DRUG|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
219027716|NCT04546165|PROCEDURE|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
219200875|NCT04730518|BEHAVIORAL|Yoga-based group intervention (YoGI)|see above
219200876|NCT06687590|DEVICE|Peripheral balloon angioplasty|Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
219502619|NCT01034137|DRUG|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
219502620|NCT01034137|DRUG|placebo MTX|orally weekly
219502621|NCT01034137|DRUG|placebo TCZ|iv every 4 weeks
219502622|NCT01034137|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
219502623|NCT00005583|DRUG|cisplatin|
219502624|NCT00005583|DRUG|doxorubicin hydrochloride|
219502625|NCT00005583|DRUG|epirubicin hydrochloride|
219502626|NCT00005583|PROCEDURE|adjuvant therapy|
219502627|NCT00005583|PROCEDURE|conventional surgery|
219502628|NCT00005583|RADIATION|radiation therapy|
219502629|NCT01718054|DIETARY_SUPPLEMENT|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
219502630|NCT01718054|DIETARY_SUPPLEMENT|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
219502631|NCT01718054|DRUG|Chloroquine|
219502632|NCT00936377|DRUG|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
219502633|NCT00936377|OTHER|Placebo|Normal saline for five days.
219606066|NCT05933954|RADIATION|5GFR2 non ionizing EMW exposure|"A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not. The exposure time is 20 minutes.~After the exposure, the participants will wait one hour and a 7.5-mm biopsy by punch (two pieces: one 5-mm punch + half a 5-mm punch) will be performed under local anesthesia on each arm. The wound will be closed by a simple suture. A second set of samples will be taken 24h after the exposure, using the same procedure.~For each participant, 1 full biopsy per arm and per time-point will be used for single-cell-RNA-sequencing analysis. The selected method uses generic probed sequencing and does not generate patient-specific genomic information."
219606067|NCT00997867|PROCEDURE|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
218882065|NCT02873338|DRUG|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
219606068|NCT04304040|DRUG|Orelabrutinib|BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
218882066|NCT03657095|DRUG|Esuberaprost|Sodium tablets
218882067|NCT03657095|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
218882068|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
218882069|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
218882070|NCT00245843|BEHAVIORAL|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
218882071|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
218882072|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
218882073|NCT01399320|PROCEDURE|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
218882074|NCT04292314|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
218882075|NCT04292314|DRUG|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
219606069|NCT04304040|DRUG|Recombinant humanized monoclonal antibody MIL62 injection|Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
219606070|NCT02930967|BIOLOGICAL|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
219606071|NCT04928716|OTHER|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
219606072|NCT02662660|DRUG|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
219606073|NCT02662660|DRUG|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
218882076|NCT04292314|DRUG|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
218882077|NCT04292314|DRUG|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
218882078|NCT04292314|DRUG|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
218882079|NCT04292314|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
219502634|NCT01764854|DRUG|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
219502635|NCT01764854|DRUG|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
219502636|NCT01764854|DRUG|AZD1722 (out-patient)|doses between 5 and 45 mg BID
218882080|NCT00627055|DRUG|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
219502637|NCT01764854|DRUG|Placebo|Placebo, size and color matched to experimental drug
219502638|NCT00521898|PROCEDURE|Descemet Membrane Endothelial Keratoplasty (DMEK)|
219502639|NCT03391297|BEHAVIORAL|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
219502640|NCT04372498|DRUG|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
218882081|NCT00627055|DRUG|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
219502641|NCT04211298|DRUG|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
219502642|NCT04211298|DRUG|Propofol|Propofol
219502643|NCT03509298|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
218882082|NCT01642108|DRUG|Sitagliptin|50 mg once per day
219502644|NCT03509298|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
218882083|NCT00393614|DRUG|levetiracetam|20 mg pr. kg a day
218882084|NCT02497690|BEHAVIORAL|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
218882085|NCT02497690|BEHAVIORAL|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
218882086|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
218882087|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
218882088|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
218882089|NCT00973245|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
218882090|NCT02068287|DRUG|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
218882091|NCT05606055|DRUG|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
218882092|NCT04439981|DIETARY_SUPPLEMENT|Ice cream|Curcumin extract was added into ice cream
218882093|NCT03432559|DIAGNOSTIC_TEST|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
218882094|NCT04831177|PROCEDURE|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
218882095|NCT03534375|OTHER|The study is an observational cross sectional study|An intervention will not be performed
218882096|NCT03905850|DRUG|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
219502645|NCT00406198|PROCEDURE|venovenous hemofiltration|
218882097|NCT01401608|DEVICE|RF Ablation|Ablation of arrhythmogenic ventricular tissue
218882098|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
218882099|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
218882100|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 1|
218882101|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 2|
218882102|NCT02929459|OTHER|Placebo|
218882103|NCT05508893|RADIATION|CT Angiography|A CTA will be performed on asymptomatic individuals
218882104|NCT05508893|DIAGNOSTIC_TEST|Exercise stress test|A routine exercise stress test will be performed on a bicycle
219502646|NCT05044442|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
219502647|NCT05044442|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
219502648|NCT04497480|BEHAVIORAL|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
218882105|NCT04006392|DEVICE|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
218882106|NCT04006392|DEVICE|Placebo Laser|Non-therapeutic output.
218882107|NCT03821610|DRUG|Fludarabine|IV
218882108|NCT03821610|DRUG|Melphalan|IV
218882109|NCT03821610|DRUG|Alemtuzumab|IV
218882110|NCT03821610|DRUG|Cyclophosphamide|IV
218882111|NCT03821610|DRUG|Mesna|IV
218882112|NCT03821610|RADIATION|Total Body Irradiation (8Gy)|TBI (8Gy)
218882113|NCT00951652|BEHAVIORAL|CBT|
218882114|NCT00951652|OTHER|Interpersonal and emotional processing therapy|
218882115|NCT00951652|BEHAVIORAL|supportive listening|
218882116|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
219606074|NCT02662660|DRUG|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
219606075|NCT06899126|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
219200877|NCT06688214|OTHER|Kinesio Taping treatment|Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.
219200878|NCT06688214|OTHER|Scapular Stabilization Exercises|"Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period."
219200879|NCT06688721|DEVICE|Driving a bus equipped with EDA|Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
219200880|NCT06687772|DRUG|Thiotepa|Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.
219200881|NCT06687772|DRUG|Carmustine|Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.
219200882|NCT06687772|PROCEDURE|Autologous Stem Cell Transplant|Infusion of autologous peripheral blood stem cells on Day 0.
219200883|NCT06687772|DRUG|Anthracycline-based induction chemotherapy|Standard of care, not dictated by protocol.
219200884|NCT06690112|PROCEDURE|Arm I (Drainage tube removal)|During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.
219200885|NCT06686927|DRUG|corticosteroids combined with immunoglobulin and romiplostim|"Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month."
219200886|NCT06691191|DRUG|Ticagrelor 90 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
219502649|NCT02311426|OTHER|Observational study|Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
219200887|NCT06691191|DRUG|Prasugrel 10 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
219502650|NCT06545240|DIAGNOSTIC_TEST|Mid-upper arm circumference|Mid-upper arm circumference was taken using non-stretchable band SECA 202
219502651|NCT02165579|OTHER|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
219502652|NCT04430270|BEHAVIORAL|Survey|Sequential Assignment
219606076|NCT06899126|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg IV Q3W
219606077|NCT06899126|DRUG|Pemetrexed|Pemetrexed will be administered at a dose of 500 mg/m2 IV Q3W
219606078|NCT06899126|DRUG|Chemotherapy|"One of the following two will be administered in Arm B:~Cisplatin at a dose of 75 mg/m2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV"
218882117|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
219606079|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
219606080|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
219606081|NCT05041309|BIOLOGICAL|Axicabtagene Ciloleucel|No investigational product will be administered
219606082|NCT05041309|BIOLOGICAL|Brexucabtagene Autoleucel|No investigational product will be administered
219606083|NCT05041309|BIOLOGICAL|Anitocabtagene autleucel|No investigational product will be administered
219606084|NCT05041309|BIOLOGICAL|KITE-753|No investigational product will be administered
219606085|NCT05041309|BIOLOGICAL|KITE-197|No investigational product will be administered
219606086|NCT05041309|BIOLOGICAL|KITE-363|No investigational product will be administered
218882118|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
219502653|NCT05101499|PROCEDURE|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
219502654|NCT05101499|PROCEDURE|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
219502655|NCT03377556|OTHER|Laboratory Biomarker Analysis|Correlative studies
219502656|NCT03377556|OTHER|Pharmacological Study|Correlative studies
219502657|NCT03377556|DRUG|Talazoparib|Given PO
219502658|NCT04580056|PROCEDURE|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
219502659|NCT02477761|DIETARY_SUPPLEMENT|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
219502660|NCT04038151|DEVICE|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
219502661|NCT04038151|DEVICE|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
219502662|NCT03830047|DEVICE|nd yag laser|nd yag laser will be applied on the vulval warts
219502663|NCT04027010|OTHER|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
219606087|NCT03640416|DEVICE|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
219606088|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
219606089|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
218882119|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
219027717|NCT04546165|PROCEDURE|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
219027718|NCT00846937|DIETARY_SUPPLEMENT|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
219606090|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
218882120|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
218882121|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
218882122|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
219027719|NCT01508780|DEVICE|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
219502664|NCT04360421|DRUG|Liposomal bupivacaine|"Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia."
219606091|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
219606092|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
219606093|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
219502665|NCT00472446|DRUG|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
219502666|NCT00472446|DRUG|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
219606094|NCT07095283|DIAGNOSTIC_TEST|Short International Consultation on Incontinence Questionnaire (ICIQ-SF)|This is a self-administered questionnaire with four questions and a total score ranging from 0 \[best\] to 21 \[worst\] that identifies people with urinary incontinence and its impact on quality of life.
219606095|NCT07095283|DIAGNOSTIC_TEST|King's Health Questionnaire (KHQ)|The KHQ is a self-administered instrument specifically designed to assess quality of life in women with UI. It consists of 21 items distributed across 9 dimensions: perception of overall health (1 item), impact of UI (1 item), limitations in daily activities (2 items), physical limitations (2 items), social limitations (2 items), personal relationships (3 items), emotions (3 items), sleep/energy (2 items), and severity of UI (5 items). The score range for each dimension is from 0 (lowest impact of UI and therefore best quality of life) to 100 (highest impact, worst quality of life). This questionnaire provides an overall value for the quality of life of the patient with UI (Overall Score-OS) and another specific value for each dimension on a scale with the following range: 0: Best possible quality of life - 100: Worst possible quality of life.
218882123|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
218882124|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
218882125|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
218882126|NCT03813914|DIETARY_SUPPLEMENT|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
218882127|NCT06262243|OTHER|electric blankets|"While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5."
218882128|NCT02794545|PROCEDURE|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
219027720|NCT01508780|DEVICE|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
219027721|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
219027722|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
219027723|NCT03581656|DEVICE|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
219027724|NCT04318236|BEHAVIORAL|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
219027725|NCT05404373|OTHER|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
219027726|NCT05404373|OTHER|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
219502667|NCT00270374|DRUG|nesiritide|
219200888|NCT03547271|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
219502668|NCT05824182|DEVICE|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
218882129|NCT02122224|OTHER|High fiber breakfast|Breakfast will contain 10-11g fiber.
219502669|NCT01532882|DRUG|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
219502670|NCT01532882|DRUG|Placebo|tablet, PO, 1 per day during 28 days
219502671|NCT05653791|DIAGNOSTIC_TEST|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
219502672|NCT00000992|DRUG|Itraconazole|
219502673|NCT01521728|OTHER|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
219502674|NCT01521728|OTHER|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
219502675|NCT01521728|OTHER|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
219502676|NCT01275313|DEVICE|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
218882130|NCT02122224|OTHER|High Protein Breakfast|Breakfast will contain 19-20g of protein.
218882131|NCT02122224|OTHER|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
218882132|NCT00486668|DRUG|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
219502677|NCT01275313|DEVICE|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
219502678|NCT01165684|DRUG|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
219502679|NCT01165684|DRUG|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
218882133|NCT00486668|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
218882134|NCT00486668|DRUG|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
218882135|NCT00486668|DRUG|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
218882136|NCT00486668|DRUG|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
218882137|NCT03455816|DEVICE|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
218882138|NCT03455816|DEVICE|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
219502680|NCT01165684|DRUG|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
218882139|NCT03012867|OTHER|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
218882140|NCT03012867|OTHER|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
218882141|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
218882142|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
218882143|NCT05387668|DRUG|BGB-23339|Administered orally as a tablet.
218882144|NCT05387668|DRUG|Placebo|Administered orally as a tablet.
218882145|NCT01985568|BEHAVIORAL|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
218882146|NCT01985568|BEHAVIORAL|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
218882147|NCT01940081|OTHER|Transthoracic echocardiography|
218882148|NCT01940081|OTHER|Exercise test|
218882149|NCT01940081|OTHER|24-hour Holter electrocardiogram|
218882150|NCT01940081|OTHER|Contrast-enhanced magnetic resonance imaging|
219200889|NCT03547271|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
219200890|NCT03547271|BIOLOGICAL|DTaP-IPV-HB-Hib vaccine|Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
219200891|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (13-valent)|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
219200892|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (10-valent)|Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
219502681|NCT00671879|DRUG|Carisoprodol SR 700 mg|700 mg twice daily tablet
219502682|NCT00671879|DRUG|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
218882151|NCT01940081|OTHER|123-iodine metaiodobenzylguanidine imaging|
219027727|NCT04361162|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
219502683|NCT00671879|DRUG|Placebo|placebo tablet
219502684|NCT03135379|DEVICE|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
219502685|NCT03135379|DEVICE|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
219502686|NCT01081184|BIOLOGICAL|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
219502687|NCT04633837|DEVICE|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
219502688|NCT05043532|PROCEDURE|2 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
219502689|NCT05043532|PROCEDURE|3 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
219502690|NCT00005615|BIOLOGICAL|Interferon alfa|Interferon alfa as outlined in treatment arm.
219502691|NCT00005615|RADIATION|Radiation therapy|Radiation therapy as outlined in treatment arm.
219502692|NCT03179683|DEVICE|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
219502693|NCT00901628|DRUG|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
219502694|NCT00901628|DRUG|morphine sulfate|10mg intraoperative periarticular injection
219502695|NCT00901628|DRUG|ketorolac|30 mg intraoperative periarticular injection
219502696|NCT00901628|DRUG|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
219502697|NCT00901628|DRUG|cefuroxime|750mg intraoperative periarticular injection
219502698|NCT02203747|OTHER|Administration of patient self-assessment|
219502699|NCT05334654|DRUG|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
219502700|NCT05334654|DRUG|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
219502701|NCT00608205|DRUG|cisplatin|Given IV
218882152|NCT01940081|OTHER|Blood samples|
218882153|NCT01940081|GENETIC|Genetic analysis|
218882154|NCT01940081|PROCEDURE|Invasive electrophysiological study|
218882155|NCT01940081|PROCEDURE|Endomyocardial biopsy|
218882156|NCT01940081|PROCEDURE|Intraoperative biopsy|
219027728|NCT04361162|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
219027729|NCT04361162|RADIATION|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
219200893|NCT03547271|BIOLOGICAL|MMR vaccine|Measles, mumps, and rubella vaccine
219502702|NCT00608205|DRUG|fluorouracil|Given IV
219502703|NCT00608205|RADIATION|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
219502704|NCT03965312|DEVICE|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
218882157|NCT01940081|PROCEDURE|Intraoperative mapping and/or ablation|
218882158|NCT03824587|DRUG|Tenapanor|Active Drug
218882159|NCT03824587|DRUG|Placebo|Inactive Drug
218882160|NCT03824587|DRUG|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
218882161|NCT02338700|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
218882162|NCT02338700|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
218882163|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
219502705|NCT03965312|DEVICE|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
219502706|NCT03965312|DEVICE|Patient monitor|Temperature will be measured using a commercially available patient monitor.
219502707|NCT01892774|PROCEDURE|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
219502708|NCT04850638|DRUG|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
218882164|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
218882165|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
218882166|NCT02407782|DRUG|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
219502709|NCT01797120|DRUG|Fulvestrant|"Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
219502710|NCT01797120|DRUG|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
219502711|NCT01797120|DRUG|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
218882167|NCT02407782|DRUG|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
218882168|NCT00986362|DRUG|Ocriplasmin|175µg ocriplasmin intravitreal injection
219502712|NCT00427986|DRUG|Galactose, intravenous|
219502713|NCT03308110|DRUG|PF-06650833|Two formulations of PF-006650833
218882169|NCT00986362|DRUG|Placebo|Placebo intravitreal injection
218882170|NCT02919514|OTHER|Physical training on hard surface.|Physical training on hard surface.
218882171|NCT02919514|OTHER|Physical training on sand surface.|Physical training on sand surface.
218882172|NCT02919514|OTHER|Physical training on soft surface.|Physical training on soft surface.
218882173|NCT01954108|DEVICE|hyaluronic acid sodium salt|
218882174|NCT01954108|DEVICE|ESWT|
218882175|NCT01791478|DRUG|PI3K inhibitor BYL719|Given PO
218882176|NCT01791478|DRUG|letrozole|Given PO
218882177|NCT01791478|OTHER|laboratory biomarker analysis|Correlative studies
218882178|NCT01791478|OTHER|pharmacological studies|Correlative studies
218882179|NCT00260416|PROCEDURE|Primary angioplasty with stent and abciximab|
219502714|NCT02462421|DRUG|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
218882180|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 1|Caffeine content: 200 mg
219502715|NCT00185419|DRUG|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
219502716|NCT00185419|DRUG|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
218882181|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 2|Caffeine content: 400 mg
219502717|NCT05915052|PROCEDURE|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
219606096|NCT07095283|DIAGNOSTIC_TEST|Ultrasound evaluation|A two-dimensional (2D) ultrasound system with B-mode capability and cine-loop function, a 3.5 to 6 MHz curved convex probe transducer, was used for the perineal image. The examination will be performed in the dorsal lithotomy position, with the hips flexed and slightly abducted and the heels placed close to the buttocks, or in a standing position if necessary.
218882182|NCT02255201|DIETARY_SUPPLEMENT|Performance Energy Blend|Caffeine content: 175 mg
218882183|NCT02255201|DIETARY_SUPPLEMENT|Energy Blend|Caffeine content: 200 mg
219606097|NCT01950390|BIOLOGICAL|Bevacizumab|Given IV
219606098|NCT01950390|BIOLOGICAL|Ipilimumab|Given IV
218882184|NCT02255201|DIETARY_SUPPLEMENT|Placebo|Caffeine content: 0 mg
218882185|NCT00384332|DRUG|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
218882186|NCT00384332|DRUG|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
219606099|NCT04684043|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
219606100|NCT05123703|DRUG|Ocrelizumab|Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
219606101|NCT05123703|OTHER|Ocrelizumab Placebo|Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.
218882187|NCT01969032|DRUG|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
218882188|NCT02006979|OTHER|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
218882189|NCT02560012|DRUG|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
218882190|NCT02560012|DRUG|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
218882191|NCT02560012|DRUG|Sorafenib|400 mg (2 tablets) orally twice daily without food
218882192|NCT02560012|DRUG|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
218882193|NCT02560012|DRUG|Everolimus|10 mg orally once daily with or without food
218882194|NCT02560012|DRUG|Axitinib|5 mg orally twice daily
218882195|NCT02861638|DEVICE|Experimental group|Video of the exercises
218882196|NCT02861638|DEVICE|Control group|video of nature scenes
218882197|NCT02861638|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
219606102|NCT05123703|DRUG|Fingolimod|Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
219606103|NCT05123703|OTHER|Fingolimod Placebo|Fingolimod matching placebo will be administered daily as a capsule.
219027730|NCT03491683|BIOLOGICAL|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
219502718|NCT05915052|PROCEDURE|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
219502719|NCT02856256|DIETARY_SUPPLEMENT|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
219502720|NCT02117193|OTHER|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
219502721|NCT02117193|OTHER|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
219502722|NCT00051428|PROCEDURE|Reiki (distant and direct-contact)|
219502723|NCT00886665|DRUG|placebo|placebo, 4 g, powder, oral, 3 times a day
219502724|NCT00886665|DRUG|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
219502725|NCT01895920|OTHER|Blood sample|
219502726|NCT01909466|DRUG|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
218882198|NCT05964543|DRUG|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
218882199|NCT04348006|DRUG|Bortezomib 3.5 MG|"VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)"
219027731|NCT03491683|BIOLOGICAL|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
219200894|NCT03087903|DIETARY_SUPPLEMENT|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
218882200|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
218882201|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
218882202|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
218882203|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
218882204|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
218882205|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
218882206|NCT02725229|PROCEDURE|parasternal block|parasternal block and PCA for sternotomy pain
219502727|NCT01720186|DEVICE|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
219502728|NCT00365612|DRUG|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
219502729|NCT01339910|DRUG|Fludarabine and Busulfan|"(Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
219502730|NCT01339910|DRUG|Fludarabine and Melphalan|"(Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2"
219502731|NCT01339910|DRUG|Busulfan and Fludarabine|"(Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)"
219502732|NCT01339910|DRUG|Busulfan and Cyclophosphamide|"(Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
219200895|NCT06690060|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
219502733|NCT01339910|DRUG|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
219502734|NCT03622502|DRUG|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
219502735|NCT03622502|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
219606104|NCT07109388|DRUG|Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound|Participants in the PENG group will first receive a sham sciatic injection; the needle will be inserted into the subcutaneous tissue and 3 ml of 0.9% NaCl will be injected. They will then receive a PENG nerve block in the supine position. A low-frequency (2-5 MHz) curvilinear ultrasound probe (BK Ultrasound) will be used to identify the anterior inferior iliac spine, the pubic eminence, and the psoas tendon with its fascial plane. A 22-gauge, 50 mm needle (SonoPlex® Pajunk) will be inserted into the fascial plane to inject 20 ml of 0.75% ropivacaine (Fresenius Kabi).
219606105|NCT07109388|DRUG|Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine|Participants in the combined group will first receive a sciatic nerve block performed with the patient in a semi-prone position, the lower limb flexed at 90° (hip and knee), elevated with a cushion placed between the legs. A straight line will be drawn between the greater trochanter and the ischial tuberosity. The sciatic nerve is located approximately at the midpoint of this line. Under ultrasound guidance, the ischial tuberosity will be identified medially, the greater trochanter laterally, the gluteus maximus muscle superficially beneath the adipose tissue, and the quadratus femoris muscle in depth. A 22-gauge, 50 mm needle will then be inserted into the fascial plane to inject 20 ml of 0.375% ropivacaine. The patient is then placed supine for femoral and lateral femoral cutaneous nerve blocks. 15 ml of local anaesthetics will be injected around the femoral nerve and 5 around the lateral femoral cutaneous nerve.
219606107|NCT07122076|BIOLOGICAL|GT719 Injection|GT719 Injection
219606108|NCT06931132|OTHER|Real-life forest bathing|Participants will experience the elements (olfactory, acoustic and haptic) of forest bathing for 30 minutes (sitting) in a forested area. The forests have been previously selected near Stuttgart and Würzburg and are comparable to each other.
219606109|NCT06931132|OTHER|Simulated FOREST bathing (Virtual Reality)|Using virtual reality goggles, a FOREST bathing experience will be simulated. The simulation will have elements of the classic FOREST bathing (olfatory, acoustic and haptic) and will last 30 minutes.
219606110|NCT06931132|OTHER|Imaging FOREST bathing|A therapist will lead an imaginative exercise in which participants will imagine a FOREST bathing. The imaginative exercise will include elements of the classic FOREST bathing (olfactory, acoustic and haptic) and will last 30 minutes.
219606111|NCT07132138|OTHER|Scooter Board Activities|"Scooter board bear walk. Scooter board crab walk. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~Cross sitting on scooter board, pulls along the rope using his/her hands Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8- Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~Supine flexion on scooter board, Clip clothespins to a rope hanging above."
218882207|NCT02725229|DEVICE|TENS group|TENS and PCA for sternotomy pain
218882208|NCT02725229|DEVICE|control group|PCA for sternotomy pain
218882209|NCT04185389|OTHER|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
218882210|NCT00695422|GENETIC|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
218882211|NCT00695422|OTHER|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
219606112|NCT07132138|OTHER|Core Stability Exercises|Bridges Bird-dog Sit-ups on therapy ball Static and dynamic trunk holds
218882212|NCT00695422|OTHER|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
218882213|NCT00695422|PROCEDURE|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
218882214|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
218882215|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
219027732|NCT03491683|BIOLOGICAL|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
219502736|NCT03622502|DRUG|Normal saline|Normal saline was infused over 10 min before end of the surgery
219502737|NCT04999514|BEHAVIORAL|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
219502738|NCT00164879|PROCEDURE|Endoscopic stenting followed by elective laparoscopic resection|
219502739|NCT03150979|OTHER|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
219606113|NCT07132762|DEVICE|Radial Extracorporeal Shock Wave Therapy|"A total of 6 sessions of ESWT, applied twice a week. Each ESWT session will last approximately 15 minutes. ESWT will be administered with the patient in the prone position, using an energy density of 0.15 mJ/mm², at 4 Hz frequency, and 1,500 shock waves per session.~The ESWT application will be performed on the right and left paravertebral muscles between the L3 and S1 segments."
219200896|NCT06686173|OTHER|None-placebo|This is one kind descriptive study. The different donor groups made the cohorts different: the parous female donor and young male donor
218882216|NCT04888013|OTHER|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
219200897|NCT06686173|OTHER|non-intervention study|This study is one kind of non intervention study
219200898|NCT06686173|OTHER|donor selection|the intervention of this study was the different donor groups: the parous female donor and young male donor. All the patients involved in this study were treated by the combination of ATG and PTCy
219200899|NCT04835363|OTHER|Early Occupational Therapy intervention|four-week OT intervention program for patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge about specific care and neurorehabilitation.
219200900|NCT06309238|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication
219200901|NCT06309238|PROCEDURE|Bariatric surgery|Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
219200902|NCT03118037|DEVICE|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
219200903|NCT06686537|DRUG|Estradiol Patches|Estradiol patched will be worn for 7 days.
219502740|NCT03150979|OTHER|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
219502741|NCT04732299|OTHER|MRI examination|Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
219502742|NCT03187652|DIAGNOSTIC_TEST|CT Perfusion Study|Brain and cardiac CT perfusion scan
219502743|NCT03187652|DIAGNOSTIC_TEST|Echocardiogram|Speckle tracking Echocardiography
218882217|NCT00767767|DRUG|Placebos|IV Saline infusion for 2 hours.
219200904|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
219200905|NCT06691594|RADIATION|neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy|"Eligible participants will receive neoadjuvant treatment consisting of:~SBRT: One session of 10Gy radiation to the primary tumor, followed by a 150mg subcutaneous injection of pembrolizumab (PD-1 inhibitor).~Chemotherapy and Immunotherapy: One week after SBRT, participants will undergo 6 cycles of pembrolizumab (400mg), albumin-bound paclitaxel (250mg/m²), and carboplatin (AUC=5).~Surgery: Surgery will be performed 21 days after the last chemotherapy cycle, with either breast-conserving surgery or modified radical mastectomy. Pathological evaluation will assess the treatment response.~Adjuvant Immunotherapy: Four weeks post-surgery, patients will receive pembrolizumab every 3 weeks for up to 1 year."
219200906|NCT02532621|DEVICE|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
219200907|NCT02532621|PROCEDURE|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
219200908|NCT02532621|PROCEDURE|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
219200909|NCT06690736|DIAGNOSTIC_TEST|CXCR4 PET/CT Imaging|Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
219502744|NCT03187652|DIAGNOSTIC_TEST|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
219606114|NCT07132762|OTHER|Conventional rehabilitation|A total of 15 sessions of conventional physical therapy will be administered, five times per week. Each session will include 20 minutes of hot pack application, 20 minutes of conventional transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound therapy at 1.5 W/cm², and core stabilization exercises performed under the supervision of a physiotherapist. The treatment will be applied over a total period of 3 weeks.
218882218|NCT00767767|DRUG|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
219502745|NCT03187652|DIAGNOSTIC_TEST|MRI|MRI to assess white matter changes
219502746|NCT06404593|DIAGNOSTIC_TEST|Blood sampling|Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
219502747|NCT05676333|DRUG|Secukinumab|
219502748|NCT03513354|OTHER|Soil group|Exercises in soil.
219502749|NCT03513354|OTHER|Pool group|Exercises in pool.
219502750|NCT01095757|DRUG|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
219502751|NCT04363125|DIAGNOSTIC_TEST|Pathology result|Pathology result of rectal biopsy
218882219|NCT00767767|DRUG|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
218882220|NCT00767767|DRUG|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
218882221|NCT00767767|DRUG|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
218882222|NCT03238833|OTHER|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
219502752|NCT05107440|OTHER|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
219502753|NCT03836781|DRUG|Ketorolac|Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
219502754|NCT03836781|DRUG|Chlorhexidine 2%|Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
219502755|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502756|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502757|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502758|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502759|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502760|NCT01567306|BIOLOGICAL|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
219502761|NCT00208949|DRUG|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
219502762|NCT00208949|DRUG|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
219502763|NCT03761836|DEVICE|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
219502764|NCT01684566|DEVICE|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
218882223|NCT03238833|OTHER|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
218882224|NCT02724527|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
218882225|NCT02724527|DRUG|Placebo|Matched Placebo capsule
218882226|NCT01805557|DRUG|R-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
218882227|NCT01805557|DRUG|BR-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
218882228|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
218882229|NCT00837850|DEVICE|Bone cement 1|Bone cement SmartSet® HV
218882230|NCT00837850|DEVICE|Bone cement 2|Bone cement Palacos R
218882231|NCT00735722|DEVICE|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
219027733|NCT03491683|RADIATION|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
219502765|NCT01684566|OTHER|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
219502766|NCT04072718|RADIATION|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
219502767|NCT02849821|OTHER|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
219502768|NCT02849821|OTHER|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
219502769|NCT02999464|OTHER|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
219502770|NCT02999464|OTHER|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
219502771|NCT05306379|DRUG|Simvastatin|Oral dose 40 mg
219502772|NCT05306379|DRUG|Voclosporin|Oral dose 23.7 mg twice daily
219502773|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
219502774|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
219606115|NCT07140419|DIAGNOSTIC_TEST|Coronary computed tomographic angiography with CT - derived fractional flow reserve|A non-invasive coronary computed tomography angiography (CCTA) protocol that visualizes coronary anatomy to evaluate the presence, location, and severity of atherosclerotic stenosis, coupled with CT-derived fractional flow reserve (CT-FFR) analysis-a computational fluid dynamics method applied to CCTA datasets-to assess the hemodynamic significance of identified stenoses and identify lesions likely to induce myocardial ischemia.
218882232|NCT04608604|OTHER|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
219606116|NCT06943872|DRUG|Sonrotoclax|Administered orally
218882233|NCT02611817|DRUG|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
218882234|NCT02611817|DRUG|Placebo|Vedolizumab placebo-matching SC injection.
218882235|NCT02611817|DRUG|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
218882236|NCT02919254|DIETARY_SUPPLEMENT|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
218882237|NCT02919254|OTHER|Placebo|Fruit juice cordial containing negligible nitrate
219502775|NCT00138359|DRUG|Niclosamide|
219502776|NCT00004659|PROCEDURE|irradiation|
219502777|NCT00004659|PROCEDURE|radiosurgery|
219502778|NCT04091542|DEVICE|Optiflow/Ventilator|Participants will have 2 days with optiflow, 2 days with ventilator.
219502779|NCT03468036|OTHER|none, does not apply|none: does not apply
219502780|NCT02523911|DRUG|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
219502781|NCT02523911|DRUG|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
218882238|NCT01429701|DRUG|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
219502782|NCT02523911|DRUG|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
219502783|NCT05465915|DEVICE|Electroconvulsive therapy|Patients are treated with ECT.
219502784|NCT00672971|OTHER|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
219606117|NCT06943872|DRUG|Obinutuzumab|Administered intravenously
218882239|NCT01429701|DRUG|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
218882240|NCT04499560|DIETARY_SUPPLEMENT|Supplement Drink|Superfoods based nutritional supplement
219502785|NCT00672971|OTHER|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
219502786|NCT01334788|OTHER|sleep deprivation|Sleep restriction
219502787|NCT01334788|OTHER|Normal sleep|These are subjects who are randomized to sleep normally.
219606118|NCT06943872|DRUG|Rituximab|Administered intravenously
219606119|NCT06943872|DRUG|Venetoclax|Administered Orally
219606120|NCT05192889|DRUG|Venetoclax|Given oral (PO).
219606121|NCT05192889|DRUG|Navitoclax|Given oral (PO).
219606122|NCT05192889|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
219606123|NCT05192889|DRUG|Vincristine|Given intravenously (IV).
219606124|NCT05192889|DRUG|Calaspargase Pegol|Given intravenously (IV).
219606125|NCT05192889|DRUG|Dasatinib|Given oral (PO).
219606126|NCT05192889|DRUG|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
219606127|NCT05192889|BIOLOGICAL|Blinatumomab|Given intravenously (IV).
219606128|NCT05192889|DRUG|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
218882241|NCT04197180|PROCEDURE|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
218882242|NCT00363623|DEVICE|Silicone hydrogel contact lens|
218882243|NCT02836405|DEVICE|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
218882244|NCT00931606|BIOLOGICAL|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
218882245|NCT00931606|DRUG|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
218882246|NCT02549547|BEHAVIORAL|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~* Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~* Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~* Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
219502788|NCT01153061|DEVICE|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
219502789|NCT01153061|DEVICE|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
219502790|NCT00505609|BEHAVIORAL|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
219502791|NCT00738673|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
219606129|NCT05192889|DRUG|Mercaptopurine|Given oral (PO).
218882247|NCT00432406|DRUG|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
218882248|NCT00432406|DRUG|Etanercept|Etanercept 25 mg twice weekly
218882249|NCT00860171|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
218882250|NCT00860171|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV
219027734|NCT03491683|DRUG|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
219027735|NCT03836482|DEVICE|Selective Cytopheretic Device|Treatment will be delivered for 4 hours a day for up to 6 consecutive days.
219502792|NCT03858881|BEHAVIORAL|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
219606130|NCT05192889|DRUG|Cyclophosphamide|Given intravenously (IV).
218882251|NCT00860171|OTHER|Laboratory Biomarker Analysis|Correlative studies
219027736|NCT03211949|PROCEDURE|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
219027737|NCT03211949|DRUG|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
219606131|NCT05192889|DRUG|Etoposide|Given intravenously (IV).
219606132|NCT05192889|DRUG|Leucovorin|Given oral (PO) or intravenously (IV).
219606133|NCT05192889|DRUG|Intrathecal Triples|Given Intrathecal (IT).
219606134|NCT05192889|DRUG|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
219606135|NCT05192889|DRUG|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
219606136|NCT05192889|RADIATION|Radiation|See detailed description section.
218882252|NCT05542758|OTHER|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
218882253|NCT06529913|DIAGNOSTIC_TEST|Collection of environmental, biological, and clinical data|"All enrolled patients/healthy volunteers will undergo:~* measurement of serum and urine concentration of metals (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).~* Patch test to metals.~* Within-breath analysis of oscillometry parameters.~* Measurement of serum zonulin.~* Measurement of serum levels of protein oxidation products."
219027738|NCT01343563|PROCEDURE|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
219027739|NCT00630968|DRUG|Levetiracetam (Keppra)|
219027740|NCT03525015|OTHER|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
219027741|NCT03525015|OTHER|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
219027742|NCT06285695|DEVICE|Clareon Toric IOL|Aspheric hydrophobic acrylic IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery for the visual correction of aphakia and preexisting corneal astigmatism
219606137|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
219606138|NCT04135846|DRUG|Placebo|Matching placebo
219606139|NCT02167334|DEVICE|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
219606140|NCT02167334|PROCEDURE|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
219606141|NCT06951347|DIETARY_SUPPLEMENT|Oral Rehydration Solution|one sachet every day for 3 days
219606142|NCT06767358|DRUG|ketamine hydrochloride|Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
219606143|NCT06767358|OTHER|Normal saline placebo|Normal saline placebo infusion
219606144|NCT04776694|DRUG|Dupilumab|
219606145|NCT07158047|OTHER|Heat therapy|30 sessions of far infrared sauna bathing (45-60C) for up to 45 min
218882254|NCT02560272|BIOLOGICAL|Minhai-HIB|0.5ml, intramuscular
219502793|NCT03858881|BEHAVIORAL|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
219502794|NCT03858881|BEHAVIORAL|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
219502795|NCT06074471|PROCEDURE|ultrasound guided supraclavicular brachial plexus block|"Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))"
219502796|NCT01924871|DRUG|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
218882255|NCT02560272|BIOLOGICAL|Act-HIB®|0.5ml, intramuscular
218882256|NCT02170870|DRUG|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
219502797|NCT01924871|DRUG|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
218882257|NCT02170870|DRUG|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
218882258|NCT02170870|DRUG|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
219502798|NCT02736227|DRUG|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
219502799|NCT00431262|DRUG|antabuse (disulfiram)|
219502800|NCT04531033|DIETARY_SUPPLEMENT|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
219502801|NCT04531033|DIETARY_SUPPLEMENT|Placebo|placebo made to match dietary supplement being tested.
219502802|NCT01188733|DRUG|Long acting octreotide 10mg|Comparison of different doses
219502803|NCT01188733|DRUG|Long acting Octreotide 30mg|Comparison of drug doses
219502804|NCT01188733|DRUG|Saline|Comparison of drug doses
219502805|NCT01765985|DEVICE|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
219606146|NCT07163637|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri DSM 17648|One capsule containing L. reuteri DSM 17648 should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
219606147|NCT07163637|DIETARY_SUPPLEMENT|Placebo|One capsule of placebo should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
218882259|NCT00837070|PROCEDURE|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
218882260|NCT03412812|RADIATION|6 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
218882261|NCT03412812|RADIATION|7 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
219502806|NCT01765985|DEVICE|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
218882262|NCT03412812|RADIATION|8 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
219027743|NCT06285695|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon Toric IOL
219027744|NCT02410954|DEVICE|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
219606148|NCT07185971|DEVICE|PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display|PAVE (Parallactic Visual-Field Enhancement) treatment is visual stimulation using a virtual reality head mounted display. The treatment is weekly and entails two 7 minute session separated by a minimum 1 minute intermission. The actual therapy is preceded by a visual field assessment and is followed by a second visual field assessment.
219606149|NCT07185971|DEVICE|PAVE Placebo|The placebo uses the same PAVE software but the functional aspect of the software that is intended to produce the effect in the test group is absent.
218882263|NCT03412812|RADIATION|9 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
218882264|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
219027745|NCT06544395|DEVICE|Non invasive neuromodulation therapy|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement."
219027746|NCT06544395|OTHER|Manual therapy|Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
219027747|NCT06544395|DEVICE|Placebo with non invasive neuromodulation|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off."
219027748|NCT06468826|DRUG|Avacopan|Oral capsules
219027749|NCT04898465|OTHER|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
219027750|NCT06149286|DRUG|Odronextamab|Administered by intravenous (IV) infusion
219027751|NCT06149286|DRUG|Lenalidomide|Administered orally (PO)
219027752|NCT06149286|DRUG|Rituximab|Administered by IV infusion, or subcutaneously (SC)
219502807|NCT04120194|BIOLOGICAL|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
219502808|NCT04120194|BIOLOGICAL|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
219027753|NCT04940299|BIOLOGICAL|Ipilimumab|Given IV
219027754|NCT04940299|BIOLOGICAL|Nivolumab|Given IV
219027755|NCT04940299|BIOLOGICAL|Tocilizumab|Given SC
219027756|NCT02889874|RADIATION|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
219027757|NCT05334784|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
219200910|NCT06691685|DRUG|ESO-T01 Injection|ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
219502809|NCT04481971|DRUG|Prednisolone|Tablets
219502810|NCT04481971|DRUG|lactose in capsules gelatin|Tablets
218882265|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
218882266|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
218882267|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
218882268|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
219027758|NCT03353584|OTHER|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
219027759|NCT05260463|DEVICE|Implantation|Fractures of the distal fibula are treated with a trauma implant.
219027760|NCT03962153|DIAGNOSTIC_TEST|Obstetric Ultrasonography|Obstetric Ultrasonography
219027761|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
219502811|NCT05448144|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
219027762|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
219502812|NCT00300092|DRUG|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
219502813|NCT00613678|BEHAVIORAL|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
219502814|NCT00613678|BEHAVIORAL|Education|The health education program is based on educational materials from the Arthritis Foundation.
219502815|NCT02469974|DRUG|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
219502816|NCT02469974|DRUG|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
219502817|NCT02469974|DRUG|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
219606150|NCT05004883|BEHAVIORAL|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
219502818|NCT03297359|BIOLOGICAL|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
219502819|NCT05140161|DEVICE|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
219502820|NCT04790305|DRUG|Huaier Granule|The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
219502821|NCT03455023|OTHER|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
219502822|NCT00271999|BEHAVIORAL|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
219502823|NCT01917188|BEHAVIORAL|Full simulation and education|
219502824|NCT01917188|BEHAVIORAL|See simulation room, usual education|
219502825|NCT00123058|BEHAVIORAL|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
219502826|NCT00123058|DEVICE|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
219502827|NCT03701620|DIAGNOSTIC_TEST|HRV monitoring|HRV monitoring derived from electrocardiogram
219502828|NCT04399720|PROCEDURE|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
219502829|NCT00827359|DRUG|Everolimus|Tablet form taken orally once a day
219502830|NCT01340950|DRUG|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
219502831|NCT01340950|DRUG|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
219502832|NCT01802840|DIETARY_SUPPLEMENT|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
219502833|NCT02343016|DEVICE|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
219502834|NCT01159769|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
219502835|NCT02555618|BIOLOGICAL|TAK-850|TAK-850 subcutaneous injection
219502836|NCT02555618|BIOLOGICAL|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
219502837|NCT03076671|BEHAVIORAL|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
219502838|NCT01584726|DRUG|Magnesium Sulfate|single dose of magnesium sulfate nebulization
219502839|NCT02063698|DRUG|auranofin|Given PO
219502840|NCT02063698|OTHER|placebo|Given PO
219502841|NCT02063698|OTHER|questionnaire administration|Ancillary studies
219502842|NCT02734615|DRUG|LSZ102|LSZ102
219502843|NCT02734615|DRUG|LEE011|LEE011
219502844|NCT02734615|DRUG|BYL719|BYL719
219502845|NCT05077306|OTHER|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
219027763|NCT05874752|DIAGNOSTIC_TEST|Transthoracic echocardiography|noninvasive myocardial work
219027764|NCT06212219|BEHAVIORAL|Neurofeedback procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a companion is to provide social presence and emotional support, depending on the user's performance and progress.), of the virtual environment.
219502846|NCT02098356|OTHER|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
219502847|NCT00325494|DRUG|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
219502848|NCT02896868|DRUG|LY3041658|Administered IV.
219502849|NCT02896868|DRUG|Placebo|Administered IV.
219502850|NCT03560622|DEVICE|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
219502851|NCT01005550|DRUG|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
219502852|NCT01005550|DRUG|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
219502853|NCT01005550|DRUG|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
219502854|NCT01005550|DRUG|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
219502855|NCT04317833|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
219502856|NCT04317833|DRUG|Placebo|matched placebo
219502857|NCT05507554|DRUG|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
219502858|NCT05507554|DRUG|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
218882269|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
218882270|NCT05487261|DRUG|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
218882271|NCT05487261|DRUG|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
219027765|NCT06212219|OTHER|Fugl-Meyer test|419 / 5 000 Résultats de traduction Résultat de traduction This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum)
219027766|NCT06212219|OTHER|Intrinsic Motivation Inventory questionnaire|This psychometric motivation questionnaire offers the patient words representative of their motivation to carry out the neurofeedback session and for each proposition they can respond between rather positive (maximum) or rather negative (minimum)
219027767|NCT06212219|OTHER|Hospital Anxiety and Depression Scale|This questionnaire assesses the patient's state of anxiety and depression. Concerning anxiety, to each proposition, the patient can answer a number between 0 at minimum (never/not at all) and 3 at maximum (very often) and about depression, the patient can answer a number between 0 at minimum (often, always) and 3 at maximum (never/not at all) The patient can calculate his score at the end
219027768|NCT06212219|OTHER|State Anxiety Inventory scores|"This questionnaire measures the patient's anxiety at a given time. It features a number of statements that people have previously used to describe themselves. For each statement, choose a grade from 1 (not at all) to 4 (Very much)"
219027769|NCT06212219|OTHER|Acceptability questionnaire (BCI-ACCEPT)|This questionnaire asks the patient about their level of acceptability of NF training using words representative of their motivation to carry out the neurofeedback session and for each proposal they can respond on their feelings regarding the proposals.
219027770|NCT06212219|OTHER|System Usability Scale questionnaire|This questionnaire evaluates the usability of personalized NF procedures compared to standard procedures. To each statement, the patient can respond between a minimum of 1 (strongly disagree) and a maximum of 5 (totally agree).
219027771|NCT06212219|OTHER|NASA Task Load Index questionnaire|"This scale assesses psychological validity from the perspective of mental workload. 6 words are offered to the patient about his mental load and he can respond at least little and at maximum A lot"
219027772|NCT06212219|OTHER|Agency test|Questionnaire in which statements referring to the patient's general feeling and/or beliefs are presented. the patient has the choice between completely disagree (minimum) and totally agree (maximum)
219027773|NCT06212219|OTHER|Visual and Kinesthetic Imagery Questionnaire|"The aim of this questionnaire is to obtain an index of individuals' ability to mentally represent different movements. Different movements to imagine are indicated and the patient responds based on their ability to imagine the movement.~He has the choice between as clear as a film (maximum) and no image (minimum)"
219027774|NCT06212219|OTHER|Technology Locus of Control Assessment Questionnaire|"The questionnaire focuses on patients' opinions on problems related to the use of technical devices. It presents twelve statements that the patient can affirm or deny, depending on their personal point of view. The patient can respond at least disagree at all and at maximum agree completely"
219027775|NCT06212219|OTHER|POSITIVE AFFECTIVITY AND NEGATIVE AFFECTIVITY SCALE|"This scale is made up of a list of words that indicate certain emotions or feelings. The patient must carefully read each of these words and spontaneously indicate at what level he feels this way at the time he responds to this scale. To do this, he can answer at least Very little or not at all and at maximum A lot"
219027776|NCT06212219|OTHER|Self-questionnaire: OCEAN of the five major factors of per- sound (or Big Five model)|"The model for measuring personality factors is the Anglo-Saxon model known as the Big Five or OCEAN in French. It measures 5 major personality traits: openness to experiences, conscientiousness, extroversion, agreeableness and neuroticism. The OCEAN questionnaire is a self-administered questionnaire to be given to a person who wishes to evaluate themselves. It includes 45 items presented in the table below. For each item, patients have 5 response possibilities numbered from 1 to 5: 1 for strongly disapproves and 5 for strongly approves. The patient can calculate his score at the end"
219027777|NCT06212219|OTHER|Feeling VAS scores|"The EVA scale relates to the patient's personal feelings: perceived difficulty, perceived fatigue, perceived ease of learning, level of embodiment, Relevance, Demonstrability of results, Fun aspect, Benefit/risk ratio, Self-efficacy.~For each statement, the patient can respond on a scale ranging from strongly disagree (minimum) to totally agree (maximum)."
219027778|NCT06212219|OTHER|Reaching Performance Scale|This scale analyzes the evolution of speed, precision and range of movement using motion capture tools. For each statement, the patient has a rating between 0 (corresponds to not possible) and 3 (corresponds to entirely possible)
219502859|NCT05507554|DRUG|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
218882272|NCT05487261|DRUG|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
218882273|NCT05487261|DRUG|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
218882274|NCT00491491|DRUG|ibritumomab tiuxetan|0.4 mCi/kg
218882275|NCT00491491|PROCEDURE|BEAM chemotherapy and autologous stem-cell transplantation|
218882276|NCT01350232|DRUG|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
218882277|NCT01350232|DRUG|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
219502860|NCT03875391|DRUG|Oxytocin|Drug: Oxytocin nasal spray
219502861|NCT03875391|DRUG|Placebo|Drug: Placebo nasal spray
219502862|NCT03082391|DEVICE|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
219502863|NCT03082391|DEVICE|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
219606151|NCT05004883|BEHAVIORAL|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
218882278|NCT01350232|DEVICE|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
218882279|NCT01350232|RADIATION|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
218882280|NCT01350232|DRUG|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
218882281|NCT01350232|DRUG|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
218882282|NCT01350232|DRUG|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
218882283|NCT01350232|PROCEDURE|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
218882284|NCT00125957|DRUG|Wellbutrin|
218882285|NCT00125957|DRUG|Placebo|
218882286|NCT03565380|OTHER|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
218882287|NCT03565380|OTHER|Usual post-operative care|No intervention will be provided
218882288|NCT03565380|OTHER|Untreated asymptomatic controls|No intervention will be provided
218882289|NCT02016079|DIETARY_SUPPLEMENT|omega-3|200 ml fruit drink containing omega-3
218882290|NCT00305435|DRUG|Romiplostim (AMG-531)|Romiplostim (AMG-531)
218882291|NCT03130920|PROCEDURE|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
218882292|NCT04971356|DRUG|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
218882293|NCT04971356|DRUG|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
219027779|NCT04779008|OTHER|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
219027780|NCT00916474|DRUG|telaprevir|
219027781|NCT05442944|PROCEDURE|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
219027782|NCT00751348|BIOLOGICAL|PriorixTM|Subcutaneous administration in left upper arm
219027783|NCT00751348|BIOLOGICAL|VarilrixTM|Subcutaneous administration in right upper arm
219027784|NCT00751348|BIOLOGICAL|Priorix-Tetra®|Subcutaneous injection in left upper arm
219027785|NCT03997656|BEHAVIORAL|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
219027786|NCT03997656|OTHER|usual care|standard health education from primary care providers in the clinic
219027787|NCT05976802|DRUG|High dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
219027788|NCT05976802|DRUG|Low dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
219027789|NCT05976802|DRUG|Matching placebo rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
219027790|NCT02869594|OTHER|Data collection|
219027791|NCT01361438|OTHER|Total therapy approach|Total therapy approach
219502864|NCT00428194|DRUG|cisplatin|40 mg/m\^2 every 7 days during radiation
219502865|NCT00428194|DRUG|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
219502866|NCT00428194|PROCEDURE|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
219200911|NCT06628271|DIAGNOSTIC_TEST|Guidelines|Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
219502867|NCT03908983|DEVICE|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
219502868|NCT03335943|DRUG|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
219502869|NCT03111979|DIETARY_SUPPLEMENT|beta-alanine|
218882294|NCT04971356|DRUG|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
219502870|NCT03111979|DIETARY_SUPPLEMENT|Placebo|
219502871|NCT00676585|DRUG|Normal Saline|Normal Saline
219502872|NCT00676585|DRUG|Hydrocortisone|Hydrocortisone 100mg
219502873|NCT00299585|PROCEDURE|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
219502874|NCT02439242|DRUG|fluid challenge of saline|250 ml of saline
219502875|NCT03952156|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
219502876|NCT03952156|GENETIC|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
219502877|NCT02741271|DRUG|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
219502878|NCT02741271|DRUG|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
219502879|NCT02741271|DRUG|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
219502880|NCT02741271|DRUG|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
218882295|NCT04971356|DRUG|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
218882296|NCT04971356|DRUG|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
219027792|NCT01874496|DIETARY_SUPPLEMENT|GDS, no meal|GDS, no meal
219027793|NCT01874496|DIETARY_SUPPLEMENT|GDS, meal|GDS, meal
218882297|NCT02673463|DRUG|Spironolactone|25 mg once daily
218882298|NCT02673463|DRUG|Placebo|Visually identical to spironolactone, once daily
219027794|NCT01874496|DIETARY_SUPPLEMENT|control, no meal|control, no meal
219027795|NCT01874496|DIETARY_SUPPLEMENT|control, meal|control, meal
219027796|NCT04640545|DRUG|LBL-007|LBL-007 will be administered intravenously every two weeks (Q2W) .
219027797|NCT04640545|DRUG|Toripalimab|Toripalimab Injection will be administered by intravenously (Q2W) .
219027798|NCT04640545|DRUG|Axitinib Tablets|Axitinib Tablets On-demand administration
218882299|NCT04329910|OTHER|no intervention|no intervention - observational only
218882300|NCT02934724|PROCEDURE|Self sample from vagina|Self sample using The Rover's Evalyn Brush
218882301|NCT02934724|PROCEDURE|Self sample from the oral cavity|Self sample using COPAN FloqSwab
218882302|NCT02934724|OTHER|Questionnaire|Questionnaire about vaccination status and sexual behaviour
218882303|NCT02744885|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
218882304|NCT02744885|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
219027799|NCT00358085|PROCEDURE|Endovascular Repair of Abdominal Aortic Aneurysm|
219027800|NCT00358085|PROCEDURE|Conventional open repair of Abdominal Aortic Aneurysm|
219027801|NCT04295148|PROCEDURE|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
219027802|NCT04295148|PROCEDURE|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
219027803|NCT04037319|DIAGNOSTIC_TEST|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
219027804|NCT04387227|DRUG|Carboplatin|Given IV
219027805|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
219027806|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
219027807|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219502881|NCT02741271|DRUG|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
219502882|NCT01612156|DRUG|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
219502883|NCT01612156|DRUG|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
219502884|NCT01151787|DRUG|cyclobenzaprine hydrochloride|15mg daily for 3 months
219502885|NCT01151787|DRUG|placebo|placebo
219502886|NCT03989960|PROCEDURE|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
219502887|NCT03989960|PROCEDURE|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
219502888|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
219502889|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
219502890|NCT00665522|DRUG|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
219502891|NCT00665522|DRUG|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
219502892|NCT04915586|DRUG|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
219502893|NCT02831530|DRUG|Abemaciclib|
219502894|NCT00410410|DRUG|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
219502895|NCT00410410|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
218882305|NCT05210387|OTHER|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
218882306|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
218882307|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
219502896|NCT00410410|DRUG|abatacept|"\~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
219027808|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218882308|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
218882309|NCT03828617|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
218882310|NCT00126360|DRUG|Timing of Anastrozole in respect to radiotherapy|
219027809|NCT04280510|GENETIC|Blood sample collection; gastrointestinal biopsy|Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
219027810|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
219502897|NCT03342508|DEVICE|Fetal Pillow|see arm description
219502898|NCT01072019|OTHER|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
219502899|NCT01720940|DRUG|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
218882311|NCT05605106|DIAGNOSTIC_TEST|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
219027811|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
219027812|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
219502900|NCT01720940|DRUG|intermittent vancomycin infusion|
219502901|NCT01232257|DRUG|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
219502902|NCT06483672|DRUG|Furmonertinib|Furmonertinib 80mg, once daily, orally
219502903|NCT06483672|DRUG|Anlotinib|Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
219502904|NCT03666182|OTHER|No Intervention|No Intervention
219502905|NCT01023269|DEVICE|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
219502906|NCT02357550|DRUG|ketone|3-OHB is infused intravenously.
219502907|NCT02357550|DRUG|placebo|Saline infusion.
219502908|NCT05030857|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
219502909|NCT05030857|DRUG|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
218882312|NCT05605106|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
219027813|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
219027814|NCT04419038|PROCEDURE|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
219502910|NCT05340556|GENETIC|Blood sample|Blood sample of 12 ml EDTA plasma.
219502911|NCT05340556|GENETIC|Swap test|receive swab tests for collecting cells from the oral mucosa
219502912|NCT00585091|DRUG|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
219502913|NCT03611114|DIETARY_SUPPLEMENT|Blood orange juice|
219502914|NCT03611114|DIETARY_SUPPLEMENT|Control drink|
219502915|NCT00182221|PROCEDURE|MDA D-Dimer Testing|
219502916|NCT04275219|DRUG|Tongfu capsules|Tongfu capsules include 5 herbals
219502917|NCT04275219|DRUG|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
218882313|NCT04886908|OTHER|Data extraction from medical files|Data extraction from medical files
218882314|NCT05013359|OTHER|No treatment given|No treatment given
218882315|NCT03315312|DRUG|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
218882316|NCT03315312|DRUG|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
218882317|NCT06099431|PROCEDURE|Mandibular marginal resection and reconstruction|Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
218882318|NCT06099431|DEVICE|mandibular osteosynthesis a 2.3mm reconstruction bone plate|a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
219200912|NCT06366633|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 30-45-minute video sessions that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
219200913|NCT06624215|PROCEDURE|Appendectomy|Robotic-assisted or laparoscopic appendectomy for acute appendicitis.
219200914|NCT06666465|OTHER|Operating Room Environment Experienced by Patients Wearing Virtual Reality Glasses Before Surgery The Effect of Surgery Experience on Surgical Fear Level and Care Perceptions|The video, which will be shot for patients to experience the operating environment, will include premedication, an operating room and a post-operative care unit. In the video, the operating room environment will be recorded by the researcher with a voice introduction. The image was shot with a 360-degree camera (Insta 360 One X2), edited with an application program (Insta 360 Studio) and then uploaded to the YouTube VR Pro application as a secret video. The video will be shown to the glasses via an Android phone on the internet via YouTube. People wearing glasses at the screening will be able to look in any direction they want thanks to the 360-degree video. They will be able to watch the video again if they want.
219200915|NCT06618651|DRUG|SHR-3821 injection|SHR-3821 injection
219502918|NCT02758002|PROCEDURE|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
219200916|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
219200917|NCT06623149|BEHAVIORAL|Non-Surgical Intervention|"After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician"
219502919|NCT06370299|OTHER|(exposure of) MDR carriage|The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
219502920|NCT02457624|BEHAVIORAL|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
219606152|NCT05004883|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
218882319|NCT01156766|DEVICE|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
218882320|NCT02470598|OTHER|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
219502921|NCT01833949|PROCEDURE|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
219502922|NCT01833949|PROCEDURE|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
219502923|NCT02166242|DRUG|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
219502924|NCT00022425|DRUG|perillyl alcohol|
219502925|NCT02922114|OTHER|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
219606153|NCT04993313|OTHER|Counseling|Undergo verbal counseling
219606154|NCT04993313|OTHER|Educational Intervention|View photo guide
219606155|NCT04993313|BEHAVIORAL|Questionnaire|Complete questionnaires
219606156|NCT05939713|DEVICE|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
218882321|NCT02311114|OTHER|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
218882322|NCT02311114|OTHER|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
218882323|NCT02311114|OTHER|Survey|Surveys with participants will be conducted using validated survey tools.
218882324|NCT00997282|DRUG|OPC-262 2.5 mg|orally administered once daily for 24 weeks
219502926|NCT04013256|OTHER|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
218882325|NCT00997282|DRUG|OPC-262 5 mg|orally administered once daily for 24 weeks
218882326|NCT00997282|DRUG|Placebo|orally administered once daily for 24 weeks
218882327|NCT02688686|BIOLOGICAL|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
218882328|NCT01559272|DRUG|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
218882329|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
218882330|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
219502927|NCT04013256|OTHER|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
219502928|NCT03090009|DRUG|Flurbiprofen|100 mg twice a day for 14 days
219606157|NCT00548639|OTHER|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
218882331|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
218882332|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
218882333|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
218882334|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
218882335|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
218882336|NCT01559272|DRUG|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
218882337|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
218882338|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
218882339|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
218882340|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
219027815|NCT04419038|PROCEDURE|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
219502929|NCT03090009|DRUG|Placebo Oral Tablet|placebo group
219502930|NCT04735237|PROCEDURE|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
219606158|NCT00548639|OTHER|Control Pamphlet|ADA Diabetes Sheet
219606159|NCT01436097|BEHAVIORAL|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
219606160|NCT01436097|BEHAVIORAL|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
219606161|NCT01436097|BEHAVIORAL|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
219606162|NCT01436097|BEHAVIORAL|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
219606163|NCT05789576|DRUG|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
219606164|NCT06503731|COMBINATION_PRODUCT|Efgartigimod PH20 SC - prefilled syringe|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
218882341|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism - TAM 24|TEST
218882342|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism|CONTROL
219606165|NCT06503731|OTHER|Placebo PH20 SC - prefilled syringe|Subcutaneous placebo PH20 SC given by prefilled syringe
218882343|NCT00844012|DRUG|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
218882344|NCT00844012|DRUG|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
219200918|NCT06623149|PROCEDURE|Current practice|After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
219200919|NCT06391372|DRUG|estriol cream|1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
219200920|NCT02833831|DRUG|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
219200921|NCT02833831|DRUG|Placebo|Matching Placebo will be administered.
219606166|NCT03284723|DRUG|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
219606167|NCT03284723|DRUG|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
219606168|NCT00101634|DRUG|Paliperidone palmitate|
219606169|NCT03517410|OTHER|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
219606170|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
219606171|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
219606172|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
218882345|NCT04311489|DRUG|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
218882346|NCT04311489|DRUG|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
218882347|NCT00704938|BIOLOGICAL|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
218882348|NCT00704938|BIOLOGICAL|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.
219027816|NCT05474378|DRUG|B7-H3CART|"B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12."
219027817|NCT05379439|OTHER|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
219027818|NCT05071859|OTHER|Whole Genome Sequencing|Saliva collection and request for banked blood and tumor samples for sequencing
219027819|NCT05071859|OTHER|Questionnaire Administration|Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.
219027820|NCT05071859|OTHER|Biospecimen collection|Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis
219027821|NCT05071859|OTHER|Laboratory Biomarker Analysis|Saliva collection and request for banked blood and tumor samples for biomarker analysis
219027822|NCT05779878|OTHER|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
219606173|NCT00615199|DRUG|Placebo|administration via oral route twice daily
219606174|NCT05975411|OTHER|Anesthesia Consultation with telemedicine|Anesthesia Consultation with telemedicine
219606175|NCT03065855|PROCEDURE|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
219606176|NCT03065855|PROCEDURE|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
219606177|NCT03519412|DRUG|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
219606178|NCT03519412|BIOLOGICAL|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB\>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
219606179|NCT04321629|COMBINATION_PRODUCT|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
219606180|NCT04321629|COMBINATION_PRODUCT|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
219606181|NCT06582017|BIOLOGICAL|QXL138AM Injection every 2 weeks by IV Infusion|masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
219502931|NCT04735237|PROCEDURE|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
219502932|NCT04647344|DRUG|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
219502933|NCT04647344|DRUG|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
219502934|NCT05806359|DRUG|Danicamtiv|Specified dose on specified days
219502935|NCT05806359|DRUG|Placebo|Specified dose on specified days
219502936|NCT00814658|DRUG|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
219502937|NCT00814658|DRUG|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
219502938|NCT00814658|DRUG|Placebo|Matching placebo three times a day (tid).
219502939|NCT03356587|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
219502940|NCT05272098|OTHER|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
219502941|NCT05272098|OTHER|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
219502942|NCT04745325|BEHAVIORAL|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
219502943|NCT04007588|DRUG|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
219502944|NCT04007588|DRUG|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
219502945|NCT04007588|DRUG|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
219502946|NCT01019005|DEVICE|Catheter|Catheter inserted into either perineural tibial nerve or wound
219502947|NCT04280393|DEVICE|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
219502948|NCT00141531|DRUG|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
219606182|NCT04768660|OTHER|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
219606183|NCT04828174|DRUG|anti-TRBC1 CAR-T cell therapy|TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
219606184|NCT02104570|OTHER|Kinesio taping with tension|
219606185|NCT02104570|OTHER|Kinesio taping without tension|
219606186|NCT02104570|OTHER|Fatigue protocol|
219606187|NCT04385537|DIETARY_SUPPLEMENT|PECAN|Raw pecan halves without other changes to their habitual diet.
218882349|NCT00704938|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
218882350|NCT00704938|BIOLOGICAL|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
218882351|NCT00704938|DRUG|cyclophosphamide|60mg/kg/day (Days-7,-6)
219027823|NCT05779878|OTHER|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
219027824|NCT02778997|PROCEDURE|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
219606188|NCT05743010|DRUG|APL-1401|APL-1401 capsules orally once daily
219606189|NCT05743010|DRUG|Placebo|Placebo capsules orally once daily
218882352|NCT00704938|DRUG|fludarabine phosphate|25mg/m\^2 (Days -5, -4, -3, -2, and -1)
218882353|NCT03652935|BEHAVIORAL|Mindfulness Based Stress Reduction|
218882354|NCT03652935|OTHER|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
218882355|NCT00441246|DRUG|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
219200922|NCT02833831|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
219200923|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219502949|NCT06243081|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
219502950|NCT00807625|DRUG|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
219502951|NCT00807625|DEVICE|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
219502952|NCT00879424|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
219502953|NCT00879424|DIETARY_SUPPLEMENT|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
219502954|NCT03472833|DRUG|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
219502955|NCT03472833|DRUG|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
219502956|NCT00003985|DRUG|KRN7000|
219502957|NCT02868281|DRUG|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
219502958|NCT02868281|DRUG|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
219502959|NCT01313000|PROCEDURE|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
219502960|NCT03545529|OTHER|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
219502961|NCT03582293|DRUG|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
219606190|NCT01439581|DEVICE|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
219606191|NCT01439581|DEVICE|Non-Mapping System|Standard ICU bed with no mapping system
219606192|NCT01833663|DRUG|Solifenacin Succinate Tablets|
219606193|NCT01833663|DRUG|Estrogen|
218882356|NCT02103491|DIETARY_SUPPLEMENT|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
218882357|NCT02103491|DIETARY_SUPPLEMENT|Placebo administration|
219502962|NCT03582293|DRUG|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
219502963|NCT00650559|PROCEDURE|Chest wall enlargement|Widening sternotomy
219502964|NCT02501109|DRUG|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
219502965|NCT00055874|BIOLOGICAL|recombinant interferon alfa|
219502966|NCT00055874|DRUG|cytarabine|
219502967|NCT00055874|DRUG|hydroxyurea|
219502968|NCT00055874|DRUG|imatinib mesylate|
218882358|NCT03410563|BEHAVIORAL|Auditory inputs|Three different auditory inputs
219027825|NCT04324801|OTHER|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
219606194|NCT01699958|BEHAVIORAL|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
219606195|NCT06370741|DEVICE|Stretching with/without device|Participants will be divided into two groups: Achilles tendon stretching and plantar fascia specific stretching. Within these two groups, participants will stretch their dominant side with the help of the designed tool. On the non-dominant side, the Achilles tendon group will complete the Achilles tendon stretching without a tool and the plantar fascia-specific stretching group will complete the self plantar fascia stretching exercise. Each stretching exercise will be performed for 10 seconds and 10 repetitions 3 days a week for 2 weeks.
219606196|NCT05292807|BEHAVIORAL|Imaginal exposure for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
219606197|NCT05292807|BEHAVIORAL|Imaginal exposure for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
219027826|NCT05409781|OTHER|No Intervention|No Intervention
219027827|NCT06393712|DRUG|Placebo|Placebo will be administered intrathecally
219502969|NCT00055874|PROCEDURE|allogeneic bone marrow transplantation|
219502970|NCT00055874|PROCEDURE|autologous bone marrow transplantation|
219502971|NCT00055874|PROCEDURE|peripheral blood stem cell transplantation|
219502972|NCT05037682|OTHER|Dissemination and Implementation Research|The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
219502973|NCT00002777|DRUG|exemestane|
219502974|NCT00002777|DRUG|tamoxifen citrate|
219502975|NCT00773526|DRUG|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
219502976|NCT04964622|DRUG|nurofen|tablet
219502977|NCT04809779|DRUG|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
219502978|NCT05881200|DEVICE|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
219502979|NCT02827513|DRUG|CTN SR1|
219502980|NCT02827513|DRUG|CTN XR1|
219502981|NCT02827513|DRUG|CTN XR2|
219502982|NCT02827513|DRUG|CTN XR3|
219502983|NCT04525157|DRUG|Afamelanotide|
219502984|NCT04525157|DRUG|Placebo|
219502985|NCT00592020|PROCEDURE|Short Transverse Incision|Short Transverse Incision for kidney transplantation
219502986|NCT00592020|PROCEDURE|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
219502987|NCT01457131|DRUG|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
219502988|NCT01457131|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
219502989|NCT01457131|OTHER|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
219502990|NCT03574246|DRUG|chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15|chlorhexidine gluconate + benzydamine hydrochloride oral rinse
219502991|NCT03574246|OTHER|%0.9 NaCl Solution|isotonic sodium chloride
219502992|NCT01604382|DRUG|General Anesthesia|General Anesthesia as described above
219502993|NCT01604382|DRUG|Neuraxial anesthesia|Neuraxial anesthesia as described above
218882359|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
218882360|NCT00265317|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
219502994|NCT00371488|DRUG|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
219502995|NCT00798083|DRUG|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
219502996|NCT04911920|OTHER|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
219502997|NCT03242382|DRUG|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
219502998|NCT04559620|OTHER|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
219502999|NCT01741480|OTHER|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
219503000|NCT01741480|OTHER|routine care|
219503001|NCT01562431|OTHER|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
219503002|NCT02801591|PROCEDURE|Conventional ovarian stimulation proctol without rhGH|
219503003|NCT00334620|PROCEDURE|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
219503004|NCT00096369|DRUG|tamoxifen citrate|
219027828|NCT06393712|DRUG|ALN-APP|ALN-APP will be administered intrathecally
219027829|NCT05602194|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219027830|NCT05602194|DRUG|Calaspargase Pegol|Given standard of care calaspargase pegol
219027831|NCT05602194|DIETARY_SUPPLEMENT|Levocarnitine|Given PO or IV
219503005|NCT06527729|DRUG|sildenafil-loaded liposomes|Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
219503006|NCT06527729|DRUG|minoxidil gel|Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
219503007|NCT00567944|DEVICE|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
219200924|NCT05584202|OTHER|Placebo|0.9% sodium chloride
219200925|NCT06874465|DEVICE|Transcatheter aortic valve implantation|Compare self expendable and balloon expendable valves
219200926|NCT06875466|DEVICE|Sauna bathing|Finnish sauna bathing, participants will sauna once per week for 8 weeks
219200927|NCT02360371|DRUG|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
219027832|NCT05602194|DRUG|Pegaspargase|Given standard of care pegaspargase
219503008|NCT06363201|DIETARY_SUPPLEMENT|Ocoxin Oral solution|Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
219027833|NCT05602194|OTHER|Quality-of-Life Assessment|Ancillary studies
219027834|NCT04829318|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
219027835|NCT04829318|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
219027836|NCT06350773|DRUG|tadalafil 20 mg then 40 mg if tolerated|Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
219027837|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
219027838|NCT03306680|RADIATION|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
219027839|NCT05577403|BEHAVIORAL|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention."
219200928|NCT06875505|OTHER|Dynamic PAPE|In this protocol, the load determined for footballers during knee extension will be applied as 90% of their one repetition maximum (1TM). After a standard warm-up session at the beginning, the protocol will be performed by performing 1 set of 3 repetitions with the previously determined 1TM 90% load without resting between repetitions. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
219503009|NCT00609895|DRUG|INSULIN GLARGINE|
219503010|NCT04021901|DEVICE|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
219503011|NCT00425659|DEVICE|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
219503012|NCT00425659|DEVICE|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
219503013|NCT00425659|DEVICE|CPAP|usual practice
219503014|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative PPI|sleeve + preoperative PPI
219503015|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative Placebo|sleeve + preoperative Placebo
219503016|NCT05127603|BEHAVIORAL|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
219503017|NCT01841359|DRUG|Pramlintide|See description above (arm description).
219503018|NCT04368585|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
219503019|NCT04368585|DRUG|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
219503020|NCT04368585|DRUG|Omeprazole|40 mg (1 x 40 mg capsule) omeprazole administered QD
219503021|NCT05093283|DEVICE|Virtual Reality Glasses|Virtual Reality Glasses
219503022|NCT02151461|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
218882361|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
219606198|NCT05292807|BEHAVIORAL|Imagery rescripting for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
218882362|NCT00265317|DRUG|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
219606199|NCT05292807|BEHAVIORAL|Imagery rescripting for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
219503023|NCT02151461|DRUG|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
219503024|NCT02151461|DRUG|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
219503025|NCT02151461|DRUG|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
219503026|NCT05846828|OTHER|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~1. Verbal ability.~2. Abstract/Visual ability.~3. Quantaitive potential.~4. Short-Term Memory Scales"
219503027|NCT00740467|BIOLOGICAL|anti-thymocyte globulin|
219606200|NCT04465981|DIAGNOSTIC_TEST|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
219606201|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
219606202|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
219606203|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
219606204|NCT00205387|PROCEDURE|cardiac elastography and echocardiography|standard echocardiogram
218882363|NCT01262859|DRUG|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
218882364|NCT05027867|DRUG|KRT-232|Administered by mouth
219027840|NCT06964464|DRUG|Metoprolol Succinate|Metoprolol succinate is a beta-blocker used for the management of heart failure with reduced ejection fraction (HFrEF). In this study, participants in the metoprolol succinate group will remain on their current treatment regimen with metoprolol succinate. The dose will be titrated to the recommended target dose as per the study protocol. The intervention aims to evaluate the effectiveness of continued use of metoprolol succinate in patients with heart failure and an implantable cardioverter defibrillator (ICD).
219200929|NCT06875505|OTHER|Isometric PAPE|Isometric contraction will be used in the protocol. On the leg extension machine, the protocol will be performed by applying 3 sets of 3 seconds against the lever arm only with 1TM 90% load, 2 minutes rest will be applied between sets. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
219503028|NCT00740467|DRUG|busulfan|
219606205|NCT03833778|OTHER|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
219503029|NCT00740467|DRUG|cyclophosphamide|
219503030|NCT00740467|DRUG|cyclosporine|
219503031|NCT00740467|DRUG|fludarabine phosphate|
219503032|NCT00740467|DRUG|mycophenolate mofetil|
219503033|NCT00740467|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219503034|NCT01783769|BEHAVIORAL|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
219503035|NCT02248532|BIOLOGICAL|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
219503036|NCT04780737|PROCEDURE|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
219503037|NCT02168270|DIETARY_SUPPLEMENT|ascorbic acid|Given IV
219503038|NCT02168270|DRUG|temozolomide|Given PO
218882365|NCT03826186|DEVICE|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
218882366|NCT03826186|DEVICE|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
218882367|NCT00051376|DRUG|L-Arginine|
218882368|NCT06831513|DEVICE|Serkel 3D CRO|Serkel 3D CRO is intervention for those with deformational plagiocephaly and already qualified for a cranial remolding orthosis
218882369|NCT05658588|DEVICE|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
218882370|NCT04042324|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
218882371|NCT04042324|DRUG|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
219503039|NCT02168270|OTHER|quality-of-life assessment|Ancillary studies
219503040|NCT02168270|OTHER|laboratory biomarker analysis|Correlative studies
219503041|NCT04571957|OTHER|No Intervention|No Intervention
219503042|NCT05031481|DRUG|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
219503043|NCT05031481|DRUG|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
219503044|NCT05031481|DRUG|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
218882372|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
219027841|NCT06964464|DRUG|Carvedilol|Carvedilol is a non-selective beta-blocker with alpha-blocking activity used in the treatment of heart failure. In this study, participants assigned to the carvedilol group will switch from metoprolol succinate to carvedilol at an equivalent dose. The carvedilol dose will be titrated to recommended target doses according to the study protocol. This intervention aims to compare the effectiveness of carvedilol versus metoprolol succinate in improving clinical outcomes in patients with heart failure and ICDs.
219027842|NCT00004323|DRUG|anti-thymocyte globulin|
219027843|NCT00004323|DRUG|cyclophosphamide|
219503045|NCT05031481|DRUG|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
219503046|NCT01102777|BEHAVIORAL|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
219503047|NCT01102777|OTHER|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
219503048|NCT05837559|OTHER|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
219503049|NCT06107088|DIETARY_SUPPLEMENT|Active 1|lactase enzyme
219503050|NCT06107088|DIETARY_SUPPLEMENT|Active 2|lactase-bacterial strain combination
219503051|NCT06107088|DIETARY_SUPPLEMENT|Active 3|bacterial strain alone
219503052|NCT06107088|DIETARY_SUPPLEMENT|Placebo|placebo
219503053|NCT04804332|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
219503054|NCT04804332|OTHER|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
219503055|NCT00771901|DRUG|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
219027844|NCT00004323|DRUG|cyclosporine|
219503056|NCT00771901|OTHER|placebo|7 pills daily for 4 weeks
219503057|NCT00771901|DRUG|sodium phenylbutyrate|20g/day for four weeks.
219503058|NCT00001144|DRUG|Modified bone marrow stem cell transplantation|
219503059|NCT03036033|DEVICE|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
219503060|NCT03922659|COMBINATION_PRODUCT|Transcranial magnetic stimulation and Cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
219503061|NCT01965652|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
218882373|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
218882374|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
218882375|NCT05904067|BIOLOGICAL|COVID Convalescent Plasma|200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
218882376|NCT02737124|DRUG|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
219027845|NCT00004323|DRUG|mesna|
219027846|NCT00004323|DRUG|methotrexate|
219027847|NCT00004323|DRUG|methylprednisolone|
219027848|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
219027849|NCT02914652|DRUG|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
219027850|NCT02914652|DRUG|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
219503062|NCT01965652|DRUG|Placebo|Placebo tablet taken orally once a day
219503063|NCT05073900|PROCEDURE|Rhomboid intercostal block|two regional anesthesia block techniques are applied
219503064|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
219606206|NCT01930201|PROCEDURE|Caudal epidural block|
219503065|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
219503066|NCT02922803|DRUG|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
219503067|NCT02922803|DRUG|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
219503068|NCT02583620|GENETIC|blood sample|A blood test is realized on the subject
219503069|NCT05588830|DRUG|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
219503070|NCT05588830|DRUG|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
219503071|NCT06424678|OTHER|Only data collection in the Utstein template|The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
219503072|NCT03493698|DRUG|Midazolam|Midazolam
219503073|NCT03493698|DRUG|Inarigivir|Inarigivir
219503074|NCT03760510|DEVICE|Tube Fastener|Endotrachel tube secured with tube fastener
219503075|NCT03760510|DEVICE|Adhesive Tape|Endotracheal tube secured with adhesive tape.
219503076|NCT01491659|DIETARY_SUPPLEMENT|Idoform Plus|orally once daily
219503077|NCT01491659|DIETARY_SUPPLEMENT|Placebo|orally once daily
219503078|NCT03111888|DEVICE|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
219606207|NCT01930201|OTHER|General anesthesia|
219606208|NCT02121652|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
219606209|NCT02121652|BEHAVIORAL|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
219606210|NCT04814173|OTHER|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
219027851|NCT03933150|DEVICE|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
219027852|NCT03054584|OTHER|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
219027853|NCT05782673|DEVICE|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
219027854|NCT03919071|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219027855|NCT03919071|DRUG|Dabrafenib Mesylate|Given PO
219027856|NCT03919071|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219027857|NCT03919071|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219027858|NCT03919071|RADIATION|Radiation Therapy|Undergo RT
219027859|NCT03919071|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219027860|NCT02951338|BEHAVIORAL|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
219503079|NCT01016860|DRUG|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
219503080|NCT01016860|DRUG|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
219606211|NCT04814173|OTHER|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
219606212|NCT04814173|OTHER|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
219606213|NCT04798092|PROCEDURE|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
219503081|NCT03080194|DRUG|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
219503082|NCT03080194|DRUG|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
219503083|NCT00987987|PROCEDURE|donor lymphocyte infusion|regulatory T cells depletion
219503084|NCT02112903|DRUG|Encapsulated vortioxetine IR tablet, 20 mg|
219606214|NCT05808322|DRUG|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
219606215|NCT05808322|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
219606216|NCT01379846|BIOLOGICAL|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
219606217|NCT01379846|BIOLOGICAL|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
219606218|NCT01525914|DRUG|Dutasteride|dutasteride 0.5mg daily
219606219|NCT05697614|DRUG|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
218882377|NCT02737124|OTHER|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
218882378|NCT03333629|BEHAVIORAL|Enhanced early detection|standardized screening
219503085|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 5.5)|
219503086|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 6.0)|
219606220|NCT05697614|DRUG|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
219606221|NCT05697614|DRUG|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
219606222|NCT05697614|DRUG|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
219606223|NCT05697614|DRUG|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
219606224|NCT05697614|DRUG|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
219606225|NCT02941835|RADIATION|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
219606226|NCT01901926|PROCEDURE|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
219606227|NCT00003610|DIETARY_SUPPLEMENT|capsaicin|
219606228|NCT00003610|OTHER|placebo|
218882379|NCT04637425|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
218882380|NCT04637425|DRUG|Placebo|Matched tablets without any active substance.
218882381|NCT04561908|DEVICE|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
218882382|NCT04561908|DEVICE|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
218882383|NCT04428957|OTHER|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
218882384|NCT01183949|DRUG|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
218882385|NCT01183949|DRUG|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
218882386|NCT06370013|DRUG|Tinengotinib|Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
218882387|NCT04327726|DRUG|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
218882388|NCT04327726|OTHER|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
218882389|NCT02744196|BIOLOGICAL|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
218882390|NCT02744196|DRUG|Placebo|Placebo solution will look identical to the Acellbia solution.
218882391|NCT02744196|DRUG|Methotrexate|
218882392|NCT03567746|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
218882393|NCT03567746|PROCEDURE|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
218882394|NCT01822262|PROCEDURE|minimally invasive cholecystolithotomy with gallbladder reservation|
218882395|NCT01822262|PROCEDURE|laparoscopic cholecystectomy|
219503087|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 7.0)|
219503088|NCT06319391|OTHER|CYP3A5*1*、CYP3A5*1*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
219503089|NCT06319391|OTHER|CYP3A5*3*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
219503090|NCT05512325|DRUG|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
219503091|NCT04649801|PROCEDURE|Atrial fibrillation ablation|Catheter ablation
219503092|NCT00566709|PROCEDURE|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
219606229|NCT00003610|RADIATION|radiation therapy|
219606230|NCT05153525|DRUG|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
219606231|NCT05153525|DRUG|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
219606232|NCT02275169|DRUG|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
219606233|NCT02275169|OTHER|Placebo|Placebo ampoules administered three times a week for three months
219606234|NCT04254848|OTHER|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
219606235|NCT03719625|DRUG|Ephedrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
219606236|NCT03719625|DRUG|Norepinephrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
219027861|NCT02951338|OTHER|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
219027862|NCT04431479|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219027863|NCT04431479|OTHER|Medical Chart Review|Review of medical chart
219027864|NCT04431479|OTHER|Quality-of-Life Assessment|Ancillary studies
219200930|NCT06874777|OTHER|Aromatherapy group|It is known that aromatherapy is used in symptom management in chronic diseases. When the literature is examined, it is seen that aromatherapy application is effective in relieving anxiety and fatigue in cardiovascular diseases. Currently, there is no symptom management method other than pharmacological treatment that is widely used or recommended by health professionals for ICD patients. The literature review reveals that there is no study examining the effect of lavender oil aromatherapy in relieving anxiety and fatigue in individuals with ICD implantation. In this context, the aim of this study is to determine the effect of aromatherapy applied by inhaling two drops for two minutes before going to bed for one month on anxiety and fatigue levels in individuals with ICD implantation.
219027865|NCT04431479|OTHER|Questionnaire Administration|Complete questionnaire
219200931|NCT06867978|DEVICE|cCeLL In vivo|Dosage Form: Intravenous injection Dosage: 0.1 - 0.5 mg/kg of Indocyanine Green (ICG) Frequency: Single administration during surgery Duration: Real-time imaging performed immediately after ICG injection and used intraoperatively for tumor margin assessment
219200932|NCT06867978|DRUG|Indocyanine Green|fluorescence dye for staining tissue
219200933|NCT06872502|BEHAVIORAL|Mindfulness-Based Meditation (Integral Meditation - IM)|The intervention consists of 12 in-person mindfulness-based meditation sessions over a period of six weeks, with each session lasting one hour, twice per week. The practice, called Integral Meditation (IM), includes focused breathing, body relaxation, emotional awareness, and acceptance exercises.
219200934|NCT06874569|PROCEDURE|TAP Block:|TAP Block: A linear high-frequency probe (6-13 MHz) was placed transversely along the midaxillary line to visualize the external oblique, internal oblique, and transversus abdominis muscles. Using an in-plane approach, a 21G SonoPlex, STIM (PAJUNK, Germany), was advanced, and after hydro-dissection with 1-2 mL saline, 20 mL of 0.25% bupivacaine (Marcaine, AstraZeneca, Sweden) was injected into the plane between the internal oblique and transversus abdominis muscles.
219200935|NCT06874569|PROCEDURE|TFP Block:|TFP Block: With a linear probe, the transversalis fascia was identified between the internal oblique and transversus abdominis muscles. An in-plane technique was used to insert a 21G needle, and following confirmation of correct placement with hydro-dissection, 20 mL of 0.25% bupivacaine was administered bilaterally.
219200936|NCT06874569|PROCEDURE|QLB:|QLB: A low-frequency curvilinear probe (2-5 MHz) was used to identify the quadratus lumborum muscle and adjacent structures. The needle was advanced in-plane until it reached the targeted region adjacent to the quadratus lumborum, where after hydro-dissection, 20 mL of 0.25% bupivacaine was injected bilaterally.
219200937|NCT06875869|OTHER|Jones technique|In the Jones technique, pressure will be applied on the tender point and the patient's head will be flexed laterally to the side of the tender point, followed by a shoulder abduction of approximately 90 degrees. This position will be held for 90 s and then patient position will be passively returned to the initial position. This will be repeated three times in each session. Patients will receive two treatment sessions per week for 6 weeks
219200938|NCT06875869|OTHER|Ischemic compression therapy|Patients will receive ischemic compression of the trigger points of the upper trapezius and sternocleidomastoid muscle with hold time varying between 30 seconds to 1 minute repeated 3 to 5 times in each session. Patients will receive two treatment sessions per week for 6 weeks
219200939|NCT06873646|COMBINATION_PRODUCT|Tri-Gnate Alginate Dressing|Patient will receive dressing product (Tri-Gnate Alginate) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
219200940|NCT06873646|COMBINATION_PRODUCT|Dressing product from Manuka honey|Patient will receive other type of dressing product (Manuka honey product) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
219200941|NCT06873646|COMBINATION_PRODUCT|Bactigras + Dermacyn|Patient will receive standard dressing product (bactigras + dermacyn) for the management of wound. The product will be changed everyday. Wound condition will be monitored from T0 - T6 on alternate day basis.
219503093|NCT04157634|DIAGNOSTIC_TEST|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
219503094|NCT05385029|DRUG|Thyroxine|treatment for hypothyroidism or hyperthyroidism
219503095|NCT01829295|DRUG|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.
219503096|NCT01829295|DRUG|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
219503097|NCT01829295|DRUG|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
219503098|NCT05766215|BEHAVIORAL|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
219503099|NCT03028194|PROCEDURE|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
219503100|NCT03028194|PROCEDURE|Placebo|No procedure after delivery of the placenta
219503101|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
218882396|NCT00724984|DRUG|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
218882397|NCT00000422|BEHAVIORAL|Cognitive-behavioral psychotherapy and physical exercise|
219503102|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 3, single dose
219503103|NCT01387308|DRUG|Fostamatinib|Oral tablets, 100 mg, single dose
219503104|NCT01387308|DRUG|Fostamatinib|Oral tablets, 150 mg, single dose
219503105|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
218882398|NCT00721188|DRUG|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
218882399|NCT04814121|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
218882400|NCT04814121|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
218882401|NCT00385138|DRUG|Cangrelor|cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
218882402|NCT00385138|DRUG|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
219503106|NCT01653197|BEHAVIORAL|Control|No scratch off element
219503107|NCT01653197|BEHAVIORAL|Curiosity|The recipient will be prompted to scratch off for answer to question.
219503108|NCT01653197|BEHAVIORAL|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
219503109|NCT01340274|BEHAVIORAL|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
219503110|NCT01340274|BEHAVIORAL|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
219503111|NCT02355548|OTHER|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
219503112|NCT04776174|DEVICE|Ultrasound using the telerobotic Melody system|The children will first have a telerobotic ultrasound abdominal, pulmonary or cardiac followed by a classical ultrasound.
219503113|NCT01754181|DRUG|Insulin|the intervention is applied only at the dose of insulin
219503114|NCT02178449|DRUG|Dexamethasone acetate|
219503115|NCT02178449|DRUG|Placebo|
219027866|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
219027867|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
219503116|NCT02178449|DRUG|Ropivacaine|
219503117|NCT03443869|DRUG|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
219503118|NCT03443869|DRUG|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
219503119|NCT03443869|DRUG|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
219503120|NCT03443869|DRUG|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
219503121|NCT03443869|DRUG|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
219503122|NCT03443869|DRUG|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
219503123|NCT00001622|PROCEDURE|investigate the relationship between in vivo and in vitro vascular responses|
219503124|NCT05509322|OTHER|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
219503125|NCT05509322|OTHER|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
219503126|NCT04755881|OTHER|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
219027868|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
219503127|NCT00035165|DRUG|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
219503128|NCT04052399|DEVICE|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
219503129|NCT04052399|DEVICE|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
219027869|NCT05687994|BEHAVIORAL|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
219503130|NCT04052399|DEVICE|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
219503131|NCT00299728|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
219503132|NCT01951183|DRUG|Placebo|RO681135 placebo subcutaneously daily
219503133|NCT01951183|DRUG|RO6811135|Subcutaneously daily
219503134|NCT01626378|DRUG|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
219503135|NCT01626378|DRUG|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
219503136|NCT00301106|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
219503137|NCT06528028|DRUG|CAZ/AVI|continuous infusion is used
219503138|NCT06528028|DRUG|CAZ/AVI|2h-infusion is used
219503139|NCT01718210|DRUG|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
219503140|NCT01718210|DRUG|CONTROL|group of controls treated with a standard IVF medium
219503141|NCT06330428|BEHAVIORAL|Sexuality-Based Family Planning Education via Podcast|The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
219503142|NCT03372083|DRUG|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
219503143|NCT01122472|DRUG|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
219503144|NCT01122472|DRUG|Placebo|Daily for 3 weeks every 4 weeks for 24 months
219503145|NCT00802750|DEVICE|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
219503146|NCT00802750|DEVICE|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
219503147|NCT01224756|DRUG|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
219503148|NCT01224756|DRUG|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
219503149|NCT03967483|DRUG|Indometacin|patient who are taken indomatacin for headaches and migraine
219503150|NCT05464290|PROCEDURE|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
219503151|NCT01725945|BEHAVIORAL|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
219503152|NCT02123056|DRUG|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
218882403|NCT00385138|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
219503153|NCT02123056|DRUG|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
219503154|NCT01438723|DRUG|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
219503155|NCT01438723|DRUG|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
219503156|NCT04117308|PROCEDURE|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
218882404|NCT00385138|DRUG|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
218882405|NCT00385138|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
219503157|NCT04117308|PROCEDURE|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
219503158|NCT05186610|PROCEDURE|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
219503159|NCT00133718|DRUG|Combined lifestyle intervention and optimisation of pharmacological treatment|"1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care"
219503160|NCT05647486|OTHER|30-day postoperative outcome|The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
218882406|NCT00303485|DRUG|Placebo|po monthly for 6 months
218882407|NCT00303485|DRUG|Vitamin D and calcium supplementation|As prescribed
218882408|NCT00303485|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
218882409|NCT03928717|BEHAVIORAL|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
218882410|NCT03928717|BEHAVIORAL|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
218882411|NCT00584259|OTHER|Coffee|3 cups of coffee over a 24 hour period
218882412|NCT02759250|DRUG|ARGX-110|
218882413|NCT03161080|DEVICE|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
218882414|NCT03161080|DEVICE|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
218882415|NCT03161080|DEVICE|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
218882416|NCT04064762|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
218882417|NCT02110667|DEVICE|Transperineal Ultrasound|
218882418|NCT01304004|OTHER|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)"
218882419|NCT00730808|DIETARY_SUPPLEMENT|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
218882420|NCT04196465|DRUG|IMC-001|IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys
219503161|NCT04591418|DEVICE|Rotary handpieces|Dental Caries removal
219503162|NCT04591418|DEVICE|Er:YAG laser|Dental Caries removal
219503163|NCT02429154|OTHER|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
219503164|NCT02429154|OTHER|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
219503165|NCT03601247|DEVICE|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
218882421|NCT02013297|RADIATION|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
219503166|NCT03293927|DRUG|Fentanyl|The patient will receive IV fentanyl
219503167|NCT03293927|DRUG|Dexmedetomidine|The patient will receive IV dexemedetomidine
218882422|NCT06239103|DEVICE|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
218882423|NCT06239103|DEVICE|Sham treatment|Sham treatment, using the same PEMF device
218882424|NCT04120402|DRUG|EP-104IAR 25 mg|Single 5 mL intra-articular injection
218882425|NCT04120402|DRUG|Vehicle|Single 5 mL intra-articular injection
219503168|NCT03103581|DRUG|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
218882426|NCT00648362|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fasting
218882427|NCT00648362|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fasting
218882428|NCT03432169|OTHER|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
218882429|NCT03432169|OTHER|Stretching|Stretching alone
218882430|NCT01362894|DEVICE|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
218882431|NCT01362894|DEVICE|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
218882432|NCT02289807|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
218882433|NCT02289807|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
218882434|NCT02780284|BEHAVIORAL|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
218882435|NCT02709811|DRUG|Electrochemotherapy|
219200942|NCT06875661|OTHER|Schroth|Patients in the experimental group exercised for 90 minutes a day, three days a week. Schroth exercises were performed in an asymmetrical position to improve the symmetry of the trunk. These exercises include stretching, flexion, spinal lengthening, derotation, strengthening, and rotational breathing exercises. The respondents combined these exercises with everyday life activities. In the control group, subjects were taught Schroth exercises under the supervision of an authorized physiotherapist, and they were asked to practice the exercises as regularly as possible at home.
218882436|NCT04522596|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
219200943|NCT06875193|DRUG|DW6012(Dasidiem tab. 10/100mg)|Once a day, Oral administration
219503169|NCT05271201|OTHER|treadmill exercise (mild)|mild intensity treadmill training.
219503170|NCT05271201|OTHER|treadmill exercise (moderate)|moderate-intensity treadmill training
219503171|NCT04634721|DRUG|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
218882437|NCT04522596|OTHER|Placebo|Placebo inhaled once a day
218882438|NCT04355819|BEHAVIORAL|Disclosure timing|When patients are told that a hernia was present on the CT scan
218882439|NCT05320172|DRUG|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
218882440|NCT04099615|PROCEDURE|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
219503172|NCT02025309|DEVICE|Neuromuscular monitorisation|
219503173|NCT00827827|OTHER|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
218882441|NCT00897468|OTHER|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
219027870|NCT05687994|BEHAVIORAL|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
219503174|NCT00827827|OTHER|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
219503175|NCT04018144|DIAGNOSTIC_TEST|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
219503176|NCT01517724|DRUG|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
219503177|NCT03690479|DEVICE|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
219503178|NCT03690479|DEVICE|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
219503179|NCT01617564|DRUG|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
219503180|NCT01617564|OTHER|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
219503181|NCT00318552|DRUG|Meropenem|
219503182|NCT01823549|OTHER|questionnaire administration|Ancillary studies
219503183|NCT02884206|DRUG|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
218882442|NCT00897468|OTHER|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
218882443|NCT06040164|OTHER|Observational study|No intervention will be performed
218882444|NCT00082407|DRUG|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
218882445|NCT00082407|DRUG|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
219503184|NCT02884206|DRUG|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
218882446|NCT02253953|DRUG|BILR 355 BS, D1|
218882447|NCT02253953|DRUG|BILR 355 BS, D2|
218882448|NCT02253953|DRUG|BILR 355 BS, D3|
218882449|NCT02253953|DRUG|BILR 355 BS, D4|
219503185|NCT02884206|DRUG|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
219503186|NCT02884206|DRUG|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
218882450|NCT02253953|DRUG|BILR 355 BS, D5|
218882451|NCT02253953|DRUG|BILR 355 BS, D6|
218882452|NCT02253953|DRUG|BILR 355 BS, D7|
218882453|NCT02253953|DRUG|BILR 355 BS, D8|
218882454|NCT02253953|DRUG|BILR 355 BS, D10|
218882455|NCT02253953|DRUG|Placebo|
218882456|NCT02253953|OTHER|high-fat breakfast|
218882457|NCT02253953|DRUG|Ritonavir|
218882458|NCT04629651|DRUG|Captopril|Oral, to be administered per the dose escalation scheme.
219027871|NCT06247787|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219027872|NCT06247787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219027873|NCT06247787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219027874|NCT06247787|DRUG|Cytarabine|Given IV and IT
219027875|NCT06247787|PROCEDURE|Echocardiography Test|Undergo ECHO
219027876|NCT06247787|DRUG|Fludarabine|Given IV
219027877|NCT06247787|DRUG|Hydrocortisone Sodium Succinate|Given IT
219027878|NCT06247787|BIOLOGICAL|Imetelstat|Given IV
219503187|NCT04866589|BEHAVIORAL|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
219503188|NCT05166993|DEVICE|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
219503189|NCT01140074|DRUG|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
219503190|NCT04253431|DEVICE|Droplet lancing device (HTL-Strefa S.A.)|
219503191|NCT04253431|DEVICE|Microlet 2 lancing device (Bayer)|
219503192|NCT04253431|DEVICE|OneTouch Delicia lancing device (LifeScan)|
219503193|NCT04253431|DEVICE|ReliOn lancing device (ReliOn)|
219503194|NCT04253431|DEVICE|Accu-Chek Softclix lancing device (Roche)|
219503195|NCT04253431|DEVICE|BGStar lancing device (Sanofi Aventis)|
219503196|NCT04253431|DEVICE|Ultra-Fine 33G lancets (BD)|
219503197|NCT04253431|DEVICE|Droplet 33G lancets (HTL-Strefa S.A.)|
219503198|NCT04253431|DEVICE|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
219503199|NCT04253431|DEVICE|HaemoFine 33G lancets (HTL-Strefa S.A.)|
219503200|NCT04253431|DEVICE|Softclix 28 G lancets (Roche)|
219503201|NCT04253431|DEVICE|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
219503202|NCT04253431|DEVICE|GlucoJect Dual S lancing device (Menarini)|
219503203|NCT04253431|DEVICE|Microlet 28G lancets (Bayer)|
219503204|NCT04253431|DEVICE|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
219503205|NCT01508026|DRUG|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
219503206|NCT01508026|DRUG|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
219503207|NCT01508026|DRUG|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
219503208|NCT01508026|DRUG|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
219503209|NCT01508026|DRUG|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
219503210|NCT01508026|DRUG|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
219503211|NCT01508026|DRUG|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
219503212|NCT01508026|DRUG|Placebo|Dose matched placebo, oral administration
219503213|NCT02699580|DEVICE|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
219503214|NCT02699580|PROCEDURE|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
219503215|NCT00045448|DRUG|alvocidib|
219503216|NCT00045448|DRUG|docetaxel|
219503217|NCT03038113|DRUG|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
219503218|NCT03038113|DRUG|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
219503219|NCT03038113|DRUG|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
219503220|NCT01461200|OTHER|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
219503221|NCT03258359|BIOLOGICAL|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
219503222|NCT05117099|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
219503223|NCT04138459|OTHER|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork"
219503224|NCT02925273|OTHER|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand"
219503225|NCT02925273|OTHER|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
219606237|NCT05477836|DEVICE|MiWEndo-assisted colonoscopy|"All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
218882459|NCT02586948|DEVICE|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
218882460|NCT02611843|BEHAVIORAL|Peer-Supported Web CBT|
218882461|NCT02611843|BEHAVIORAL|Self-Managed Web CBT|
219503226|NCT02333409|PROCEDURE|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
219503227|NCT02789007|OTHER|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
219503228|NCT02125188|DRUG|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
219503229|NCT02125188|DRUG|saline|saline 100ml ivdrip before surgery
219503230|NCT00813371|DEVICE|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
219503231|NCT00813371|DEVICE|ARDSnet protocol|ARDSnet protocol
219503232|NCT00570856|DRUG|Folic acid|Folic acid 5 mg/day
219503233|NCT00570856|DRUG|Placebo|Placebo similar to the folic acid tablets, 1/day
219503234|NCT05726773|PROCEDURE|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
219503235|NCT05726773|PROCEDURE|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
219606238|NCT03894644|OTHER|Simulation technology|The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
218882462|NCT04190901|BEHAVIORAL|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
218882463|NCT04190901|BEHAVIORAL|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
218882464|NCT04190901|BEHAVIORAL|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
219027879|NCT06247787|DRUG|Leucovorin Calcium|Given IV or PO
219027880|NCT06247787|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219503236|NCT04063618|PROCEDURE|Osteopathic Manipulative Therapy|The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.
219503237|NCT04063618|PROCEDURE|Standard of Care Concussion Treatment|Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
219503238|NCT01418352|DRUG|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
219503239|NCT01418352|DRUG|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
219606239|NCT00381979|OTHER|Supportive Expressive Therapy|
219606240|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
219606241|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
219027881|NCT06247787|DRUG|Methotrexate|Given IT
219027882|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
219606242|NCT05209529|DRUG|olaparib|olaparib 300 mg per os BID
219606243|NCT05209529|DRUG|Durvalumab|durvalumab 1500 mg IV Q4 weeks
219606244|NCT03517501|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
219606245|NCT03517501|DRUG|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
219200944|NCT03073395|DRUG|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
219200945|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
219200946|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
219200947|NCT05807958|DEVICE|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
219027883|NCT05225272|OTHER|Enhanced Recovery Program for on-pump cardiac surgery|Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
219200948|NCT06055686|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
219200949|NCT06624696|DRUG|Penehyclidine hydrochloride|The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
218882465|NCT04190901|BEHAVIORAL|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
219027884|NCT05370313|BEHAVIORAL|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
219200950|NCT06624696|DRUG|Normal Saline|The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
219200951|NCT04874428|DRUG|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
219503240|NCT00407459|DRUG|Bevacizumab, Pemetrexed, Carboplatin|"* Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
218882466|NCT01626092|DRUG|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
218882467|NCT01626092|DRUG|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
219027885|NCT05370313|BEHAVIORAL|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
219027886|NCT05370313|BEHAVIORAL|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
219027887|NCT05370313|BEHAVIORAL|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
219027888|NCT05370313|BEHAVIORAL|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
219503241|NCT00619619|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
219503242|NCT02787226|DRUG|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
219503243|NCT02787226|DRUG|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
219503244|NCT02195960|DIETARY_SUPPLEMENT|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
218882468|NCT01626092|DRUG|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
218882469|NCT01626092|RADIATION|Total Body Irradiation with Marrow Boosting|"1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
218882470|NCT01626092|BIOLOGICAL|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
218882471|NCT01626092|DRUG|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
218882472|NCT01626092|DRUG|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
219503245|NCT02195960|DIETARY_SUPPLEMENT|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
218882473|NCT06788119|BEHAVIORAL|Cognitive behavioral therapy with in vivo exposure|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure.In this condition participants will receive CBT treatment and be exposed to in vivo situations.
218882474|NCT06788119|BEHAVIORAL|Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure. In this condition participants will receive CBT treatment and be exposed to in vivo situations with the support of SYMPTOMS-JIT.
218882475|NCT01358058|RADIATION|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
218882476|NCT04647123|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
218882477|NCT00891228|DRUG|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
218882478|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
218882479|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
218882480|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
218882481|NCT02014168|BIOLOGICAL|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
218882482|NCT02014168|BIOLOGICAL|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
218882483|NCT02088489|DEVICE|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
218882484|NCT02088489|DEVICE|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
218882485|NCT03694834|DRUG|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
219027889|NCT05382338|PROCEDURE|Audiometric Test|Ancillary studies
219027890|NCT05382338|PROCEDURE|Auditory Brainstem Response|Ancillary studies
219027891|NCT05382338|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219027892|NCT05382338|DRUG|Cisplatin|Given IV
219027893|NCT05382338|DRUG|Cyclophosphamide|Given IV
219027894|NCT05382338|DRUG|Lomustine|Given PO
219027895|NCT05382338|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219027896|NCT05382338|OTHER|Quality-of-Life Assessment|Ancillary studies
219503246|NCT01735591|DIETARY_SUPPLEMENT|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
219503247|NCT01735591|DIETARY_SUPPLEMENT|Probiotic|Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
219503248|NCT03381066|DRUG|gefitinib, pemetrexed,cisplatin|"* Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~* Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
219503249|NCT03381066|DRUG|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
219503250|NCT03628352|DRUG|Tricaprilin|Tricaprilin with flavoring agents added
219503251|NCT05035485|DRUG|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
219503252|NCT05035485|DRUG|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
219503253|NCT03786913|DIAGNOSTIC_TEST|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
219503254|NCT06240845|OTHER|High-level laser therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
219503255|NCT06240845|OTHER|Low-level laser therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
219503256|NCT06321666|OTHER|WB-MRI|All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
219503257|NCT01092702|DRUG|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
219503258|NCT05678621|DRUG|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
219503259|NCT05678621|DRUG|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
219503260|NCT05678621|DRUG|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
219503261|NCT01434459|DRUG|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
219503262|NCT04283383|OTHER|Primary Care Clinical Ultrasound Classroom (AECAP)|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
219503263|NCT06180811|OTHER|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
219503264|NCT06180811|OTHER|Usual Standard of Care|Participants will receive the usual standard of care.
219503265|NCT03804801|DIETARY_SUPPLEMENT|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
219503266|NCT00384696|DRUG|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke \>10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
219503267|NCT00384696|BEHAVIORAL|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
219503268|NCT05903599|OTHER|Anodal transcranial direct current stimulation|The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.
219606246|NCT00555165|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
219606247|NCT01044550|PROCEDURE|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
218882486|NCT03694834|PROCEDURE|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
218882487|NCT00118742|DRUG|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
218882488|NCT00118742|DRUG|Tacrolimus|As prescribed, for 12 months
218882489|NCT00118742|DRUG|Cyclosporine|As prescribed, for 12 months
218882490|NCT00118742|DRUG|Sirolimus|2-4 mg orally once daily for 9-11 months
219027897|NCT05382338|RADIATION|Radiation Therapy|Undergo radiation therapy
218882491|NCT02688985|DRUG|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
218882492|NCT02688985|PROCEDURE|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
218882493|NCT02688985|DRUG|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
219200952|NCT04874428|DRUG|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
219606248|NCT01044550|OTHER|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
218882494|NCT02688985|DRUG|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
218882495|NCT02445326|DRUG|Dexamethasone|
218882496|NCT02445326|OTHER|Placebo Vehicle|
218882497|NCT03434158|DRUG|Olaparib|300 mg twice a day
218882498|NCT02386163|BIOLOGICAL|MSC from synovial membrane and infrapatellar Fat Pad|
218882499|NCT06233006|OTHER|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
218882500|NCT00081055|BIOLOGICAL|autologous expanded mesenchymal stem cells OTI-010|
219027898|NCT05382338|DRUG|Sodium Thiosulfate|Given IV
219027899|NCT05382338|OTHER|Survey Administration|Ancillary studies
219027900|NCT05382338|DRUG|Vincristine|Given IV
219200953|NCT04618406|DEVICE|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
219503269|NCT05903599|OTHER|Sham Stimulation|"postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises."
219503270|NCT00000606|PROCEDURE|Lung volume reduction surgery|
218882501|NCT00081055|DRUG|busulfan|
219503271|NCT05452538|DEVICE|Transfusion|Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
219503272|NCT02749019|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
219503273|NCT05206136|DEVICE|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
219503274|NCT01691365|DIETARY_SUPPLEMENT|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
219503275|NCT01691365|DRUG|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
218882502|NCT00081055|DRUG|cyclophosphamide|
218882503|NCT00081055|DRUG|cyclosporine|
218882504|NCT00081055|DRUG|methotrexate|
218882505|NCT00081055|PROCEDURE|peripheral blood stem cell transplantation|
218882506|NCT00081055|RADIATION|radiation therapy|
218882507|NCT02665572|BEHAVIORAL|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
219503276|NCT01566799|DRUG|Metformin|metformin 500 mg/day po for 24 weeks.
219503277|NCT02324985|DRUG|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
219503278|NCT02324985|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
219503279|NCT06546878|PROCEDURE|Cardiac Rehabilitation (Phase I) - nurse intervention|"The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT\_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver."
219503280|NCT06038188|BEHAVIORAL|SIT LESS Booster|"Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote"
219503281|NCT05445115|DEVICE|Mollie device|medical device
219503282|NCT00002185|DRUG|Nelfinavir mesylate|
219606249|NCT03295955|DRUG|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
219606250|NCT01542814|DEVICE|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
219606251|NCT01542814|DEVICE|2D FFDM|Standard of care screening mammogram.
219606252|NCT00436410|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
219606253|NCT00436410|OTHER|electron microscopy|
219606254|NCT00436410|OTHER|pharmacological study|
219606255|NCT00436410|PROCEDURE|conventional surgery|
219606256|NCT00165555|DRUG|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
219606257|NCT00165555|DRUG|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
219606258|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
219606259|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
219606260|NCT06371625|PROCEDURE|Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block|The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.
218882508|NCT02061514|PROCEDURE|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
218882509|NCT02061514|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
219503283|NCT03998228|DIAGNOSTIC_TEST|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~* Radiological examination of BMD;~* Calculation of the FRAX® score;~* Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
219503284|NCT00103870|PROCEDURE|Electrodermal stimulation|
219503285|NCT00103870|PROCEDURE|Music listening task|
219503286|NCT01047085|PROCEDURE|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
219503287|NCT03845478|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
219503288|NCT03845478|BEHAVIORAL|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
219503289|NCT01405170|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
219503290|NCT01405170|DRUG|methylprednisolone|tablets 32 mg single dose
219606261|NCT06371625|PROCEDURE|Pectoral Nerves (PECS) Block|Patients positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The skin point of and once the structures are identified with ultrasound, the probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D). We will inject 10ml of 0.25% bupivacaine between the pectorals muscles first, then inject 20ml of 0.25% bupivacaine.
219606262|NCT06045013|DRUG|5% dextrose injection|Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
218882510|NCT01726582|DRUG|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
218882511|NCT01726582|RADIATION|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
218882512|NCT01726582|DRUG|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
218882513|NCT01726582|RADIATION|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
219027901|NCT05919940|DIETARY_SUPPLEMENT|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards"
219027902|NCT05919940|DEVICE|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
219027903|NCT05919940|OTHER|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
219027904|NCT01265849|BIOLOGICAL|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
219027905|NCT01265849|DRUG|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
219200954|NCT04618406|OTHER|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
219503291|NCT03551678|DEVICE|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
219503292|NCT06090578|OTHER|TabCAT Brain Health Assessment Clinical Pathway|Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates who will then perform the TabCAT-BHA tablet-based test. The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline. The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate. Nursing support is available to support the PCP in making the diagnosis and to consult to the family via telephone post-diagnosis to address immediate care needs.
219503293|NCT04758871|DRUG|Dydrogesterone 10 MG Oral Tablet|10 mg three times daily
219503294|NCT04758871|DRUG|Micronized progesterone|2x 200 mg vaginal tablets two times daily
219503295|NCT03652961|DRUG|Abatacept|Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
219503296|NCT03652961|DRUG|DMARDs|Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
219503297|NCT01856985|DRUG|Misoprostol|
219606263|NCT06045013|DRUG|5% dextrose injections with methylprednisolone acetate 40 mg/ml|Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
219606264|NCT06272721|DIAGNOSTIC_TEST|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
219503298|NCT01856985|DRUG|Mifepristone|
219606265|NCT01232452|DRUG|Pemetrexed|Administered intravenously (IV)
219606266|NCT01232452|DRUG|Cisplatin|Administered IV
219606267|NCT01232452|DRUG|Cixutumumab|Administered IV
219606268|NCT02807337|DRUG|Caphosol|
219027906|NCT01265849|DRUG|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
219027907|NCT01265849|DIETARY_SUPPLEMENT|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
219027908|NCT01265849|PROCEDURE|Surgery|Excise tumor and nodes
219027909|NCT01265849|DRUG|Cisplatin|Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
219027910|NCT01265849|RADIATION|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
219027911|NCT01172184|PROCEDURE|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
219027912|NCT02440477|OTHER|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
219027913|NCT06403735|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
219027914|NCT04843748|DEVICE|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
219027915|NCT06110780|OTHER|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
219027916|NCT02857478|DRUG|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
219503299|NCT03506009|DRUG|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
219606269|NCT02807337|DRUG|0,9% NaCl|
219606270|NCT03076632|DEVICE|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
219606271|NCT03076632|DEVICE|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
219606272|NCT03076632|DEVICE|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
219606273|NCT00013442|PROCEDURE|Auditory Evoked Response|
219606274|NCT01662687|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
219606275|NCT01662687|DRUG|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4."
219606276|NCT05751707|DEVICE|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
218882514|NCT01726582|DRUG|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
219503300|NCT03506009|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
219503301|NCT02818556|DRUG|Restalyne Silk|
219503302|NCT02818556|DRUG|Belotero Balance|
218882515|NCT01726582|RADIATION|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
218882516|NCT01726582|DRUG|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
218882517|NCT01726582|RADIATION|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
219027917|NCT02857478|DRUG|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
219027918|NCT05728346|DRUG|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
219027919|NCT05748756|OTHER|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
219027920|NCT05748756|OTHER|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
219027921|NCT05871827|PROCEDURE|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
219027922|NCT06484244|OTHER|5 Sessions of Split-belt Treadmill-based Locomotor Adaptation|Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
219027923|NCT05543525|OTHER|Echocardiography|Transthoracic echocardiography
219027924|NCT05543525|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
219027925|NCT00814398|PROCEDURE|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
219027926|NCT00814398|PROCEDURE|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
219027927|NCT02436551|OTHER|Observation|
219200955|NCT05938127|DEVICE|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
219503303|NCT03725787|DEVICE|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
219503304|NCT04778527|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
219503305|NCT04778527|DRUG|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
219606277|NCT04492228|OTHER|Ketogenic diet|Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: \<30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: \<30g/day)
219606278|NCT05886205|DRUG|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
218882518|NCT01726582|DRUG|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
219200956|NCT05938127|DEVICE|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
219200957|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
219200958|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
219200959|NCT04722263|RADIATION|Radiotherapy|15 Gy in 3 fractions
219200960|NCT05933772|DEVICE|Lens A (comfilcon A toric lens)|One month wear
219503306|NCT02109926|OTHER|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
219503307|NCT03892681|OTHER|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
219606279|NCT02258711|DEVICE|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
218882519|NCT01726582|RADIATION|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
218882520|NCT01726582|RADIATION|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
219503308|NCT01712412|DRUG|IW-9179|
219503309|NCT01712412|DRUG|Placebo|
219503310|NCT04340414|DEVICE|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
219503311|NCT03276910|DRUG|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
219503312|NCT03276910|DRUG|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
219503313|NCT04497610|DIAGNOSTIC_TEST|Breath sample|Patient will blow into a tube 5 times.
219503314|NCT01783496|DEVICE|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
219503315|NCT01893502|BEHAVIORAL|Telephone counselling from Quitline|
219503316|NCT03114189|PROCEDURE|footbath|
219503317|NCT03114189|BEHAVIORAL|care of sleep|
219503318|NCT00988234|PROCEDURE|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
219503319|NCT00988234|PROCEDURE|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
219503320|NCT00988234|PROCEDURE|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
219503321|NCT00988234|PROCEDURE|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
219503322|NCT00229112|DRUG|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
219503323|NCT00229112|DRUG|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
219503324|NCT02561312|OTHER|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
219503325|NCT02561312|OTHER|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
219503326|NCT06481826|DRUG|Glofitamab|Glofitamab given in standard dosage
219606280|NCT05024747|DRUG|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
218882521|NCT01726582|DRUG|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
219200961|NCT05933772|DEVICE|Lens B (lehfilcon A toric lens)|One month wear
219200962|NCT06874023|OTHER|Passive heating in hot conditions|Participants performed seated passive heating in 54C conditions
219200963|NCT06874023|OTHER|Active heating + passive heating in hot conditions|Participants performed 30 minutes of biking exercise in 43C + 30 min of passive seated heating in 54C conditions.
219200964|NCT06874023|OTHER|Active heating in hot conditions|Participants performed 60 minutes of biking exercise in 43C.
219503327|NCT01953783|DRUG|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
219503328|NCT03535883|DRUG|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
219503329|NCT03553277|OTHER|transfluthrin|passive emanator with formulated transfluthrin
219503330|NCT03553277|OTHER|placebo|passive emanator with formulated inert ingredients
219503331|NCT06256250|PROCEDURE|pulpectomy treatment will be done using the adaptive xp endo shaper.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
219503332|NCT06256250|PROCEDURE|pulpectomy treatment will be done using FANTA AF baby files.|"the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~* BTF1: #20, taper 04, Yellow~* BTF2: #25, taper 04, Red~* BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown."
219606281|NCT05024747|DRUG|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
219606282|NCT03073824|DEVICE|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
219606283|NCT05924724|DEVICE|Flash Glucose Monitoring|The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
219606284|NCT04667624|DRUG|Twynsta|Manufactured by Boehringer Ingelheim
219606285|NCT04667624|DRUG|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
219606286|NCT03786887|DRUG|Nalbuphine|dosage of nalbuphine
218882522|NCT01726582|DRUG|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
218882523|NCT01726582|OTHER|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
219200965|NCT06874023|OTHER|Active heating at room temperature|Participants performed active heating through biking exercise for 60 minutes at room temperature.
219606287|NCT00662649|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
219606288|NCT00662649|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
219606289|NCT01494259|DRUG|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
219200966|NCT06874023|OTHER|Cool vest|Cool vest (18°C) with 500 mL (16 fl oz) ice water consumption
219200967|NCT06874023|OTHER|Damp neck towel combined with arm cool water immersion|Damp neck towel (24°C) combined with arm (i.e. hand, forearm and half of upper arm) cool water immersion (15°C) and 500 mL (16 fl oz) ice water consumption
219503333|NCT06256250|PROCEDURE|pulpectomy treatment will be done using hand k files.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
219503334|NCT04800055|OTHER|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
219503335|NCT02627014|OTHER|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
219503336|NCT02627014|OTHER|Home physical therapy|once a day: 15 minutes
219503337|NCT02627014|OTHER|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
219503338|NCT02627014|OTHER|Home physical therapy in cervical region|once a day: 15 minutes
219503339|NCT03231618|DIETARY_SUPPLEMENT|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
219503340|NCT02361021|OTHER|- Weaning from mechanical ventilation|
219503341|NCT02449603|DRUG|Exenatide|
219503342|NCT02449603|DRUG|Biphasic insulin Aspart 30|
219606290|NCT01494259|DRUG|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
219606291|NCT02728700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219606292|NCT02728700|OTHER|Laboratory Biomarker Analysis|Correlative studies
219200968|NCT06874023|OTHER|Combination of cooling interventions|Combination of cool vest (18°C), damp neck towel (24°C) with arm cool water immersion (15°C), and 500 mL (16 fl oz) ice water consumption
219200969|NCT06874023|OTHER|Control in thermoneutral room without cooling|A control with participant sitting in a thermoneutral room (20°C air temperature) without any additional cooling intervention.
219200970|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
219200971|NCT06627088|DRUG|[14C]-LY4100511 (DC-853) Administered oral dose|Administered oral dose
219200972|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
219200973|NCT06627088|DRUG|[14C]-LY4100511 (DC-853)|Administered IV infusion
219503343|NCT04897971|DIAGNOSTIC_TEST|Medium enriched for newly synthesized antibodies in spine infection|Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
219503344|NCT02539563|OTHER|peanut shaped birthing ball|peanut ball will be utilized
219503345|NCT05007691|DEVICE|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
219503346|NCT00686920|DRUG|Rifaximin|Oral
219503347|NCT04597606|OTHER|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
219503348|NCT04597606|DEVICE|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
219503349|NCT04597606|DEVICE|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
219503350|NCT02832908|OTHER|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
219503351|NCT02752256|DRUG|Tissue Plasminogen Activator|
219503352|NCT03779399|OTHER|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
219503353|NCT00132431|DRUG|Sensipar|
219503354|NCT02159859|DRUG|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
219503355|NCT04788589|OTHER|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
219606293|NCT02728700|DRUG|Mycophenolate Mofetil|Given IV
219606294|NCT02728700|DRUG|Sirolimus|Given PO
219606295|NCT04019171|BEHAVIORAL|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
219606296|NCT00657189|DRUG|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
219606297|NCT00657189|DRUG|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
219606298|NCT00657189|DRUG|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
219606299|NCT00657189|DRUG|MEDI-545|100 mg every week × 13 doses
219606300|NCT00657189|DRUG|Placebo|SC Placebo every week × 13 doses
219503356|NCT05092711|BEHAVIORAL|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
219503357|NCT05092711|DRUG|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
218882524|NCT04086199|PROCEDURE|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
218882525|NCT03274544|OTHER|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g"
219200974|NCT06875804|OTHER|baseline physical therapy treatment|Group A focuses on pain relief, muscle relaxation, and strengthening. Hot packs and TENS are applied to the lateral thigh and knee for 20 minutes to reduce pain and muscle tension. Hip strengthening exercises include side-lying hip abduction, clam-shells, prone hip extension, bridging, and lunges. Quadriceps exercises involve straight leg raises, prone terminal knee extension, and mini-squats. Each exercise is done in 2-3 sets of 10-15 repetitions, holding stretches for 5 seconds.
219200975|NCT06875804|OTHER|Compressive myofascial release of vastus lateralis.|The experimental group receives an additional session of Compressive Myofascial Release (CMFR) for the Vastus Lateralis to address lateral patellar tracking in PFPS patients. The patient lies on their side, and the therapist identifies tight areas, applying firm pressure for 20-30 seconds. Deeper pressure is held for 30-60 seconds, followed by 1-2 minutes of cross-fiber friction. The session includes muscle shaking for 30 seconds and stretching the Vastus Lateralis by extending the hip and flexing the knee for 30-60 seconds, repeated 2-3 times. Patient response is documented for progress tracking.
219200976|NCT04951856|DRUG|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
219503358|NCT06288165|DEVICE|Coronary Sinus Reducer Implantation|Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
219503359|NCT01930084|OTHER|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
219503360|NCT01930084|OTHER|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
219503361|NCT01930084|BEHAVIORAL|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
219503362|NCT01930084|OTHER|Non-cash Financial Incentives|Non-cash Financial Incentives
219503363|NCT02008110|DRUG|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
219503364|NCT02008110|DRUG|CA125 guided strategy|Consider statins in all patients in the active arm
219503365|NCT02008110|DRUG|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
219503366|NCT02008110|OTHER|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
219503367|NCT02008110|DRUG|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
219503368|NCT02008110|DRUG|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
219503369|NCT01199406|DRUG|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
219503370|NCT03150836|DRUG|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
219503371|NCT03150836|DRUG|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
219503372|NCT03150836|RADIATION|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
219503373|NCT03654898|BEHAVIORAL|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
219503374|NCT03654898|BEHAVIORAL|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
219503375|NCT01271933|DRUG|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
219503376|NCT01271933|DRUG|placebo|matching placebo tablet; given once daily
218882526|NCT01181817|OTHER|fMRI and MRS|fMRI and MRS
218882527|NCT05181644|DEVICE|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
219200977|NCT04951856|DRUG|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
219200978|NCT06622538|DEVICE|Orotracheal intubation|Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
218882528|NCT05181644|PROCEDURE|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
219503377|NCT00442585|DRUG|S(+)-ibuprofen|
219503378|NCT02067715|DRUG|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
218882529|NCT02135237|BEHAVIORAL|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
219503379|NCT00190307|DRUG|aspirin 75 mg/day|aspirin 75 mg/day
219503380|NCT01513785|DRUG|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
219503381|NCT01513785|DRUG|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
219503382|NCT01424956|DEVICE|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
219503383|NCT04497090|DEVICE|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
219503384|NCT04497090|DEVICE|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
219503385|NCT06526767|DEVICE|Vibrabot capsules twice a week|Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
219503386|NCT06526767|DEVICE|Vibrabot capsules three times a week|Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
219503387|NCT06526767|DEVICE|Vibrabot capsules five times a week|Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
219503388|NCT06526767|DEVICE|Vibrabot capsules loading dose|Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
219503389|NCT06276179|DRUG|Oxycodone|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
219503390|NCT06276179|DRUG|Bupivacaine|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
219503391|NCT04009057|OTHER|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
219503392|NCT03856671|DRUG|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
219606301|NCT04893473|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
218882530|NCT02135237|BEHAVIORAL|Standard Care|
218882531|NCT02906397|DRUG|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
218882532|NCT02906397|RADIATION|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
218882533|NCT03058055|BEHAVIORAL|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
218882534|NCT03058055|BEHAVIORAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
219503393|NCT01433133|BIOLOGICAL|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
219503394|NCT00404586|DRUG|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
219503395|NCT00404586|DRUG|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
219503396|NCT00404586|DRUG|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
219503397|NCT05350683|PROCEDURE|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
219503398|NCT02059577|DIETARY_SUPPLEMENT|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
219503399|NCT03062865|OTHER|No intervention|
219503400|NCT06546436|DRUG|CARC-101C|Subjects enrolled in the project will received a one-dose injection of CARC-101C
219503401|NCT03110952|BIOLOGICAL|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
219503402|NCT03110952|BIOLOGICAL|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
219503403|NCT03110952|OTHER|Placebo|0.5 mL vial
219503404|NCT02839356|DRUG|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
219503405|NCT02839356|DRUG|normal saline|20-mL irrigation with physiological saline over the entire papilla
219503406|NCT05496114|DEVICE|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
219606302|NCT03252067|DRUG|azithromycin eyedrop|Tear samples will be collected using the strips.
219606303|NCT00269646|BEHAVIORAL|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
219606304|NCT02688946|OTHER|Not provided|
219606305|NCT02411825|DRUG|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219606306|NCT02411825|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218882535|NCT03058055|BEHAVIORAL|Reading|Book club that includes weekly one hour meetings and daily reading assignments
218882536|NCT04789369|BEHAVIORAL|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
218882537|NCT05300789|OTHER|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
218882538|NCT06393972|DRUG|Tofacitinib 5 MG BID|Tofacitinib 5 MG BID
218882539|NCT01247168|DRUG|AZD2461|oral capsules, continuous dosing and intermittent dosing
219503407|NCT01138150|DRUG|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
219503408|NCT01138150|DRUG|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
219503409|NCT01897597|DRUG|BI 144807 high dose|oral solution
219503410|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
219503411|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
219503412|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
219503413|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
219503414|NCT01897597|DRUG|BI 144807 intermediate dose|oral solution
219503415|NCT01897597|DRUG|BI 144807 high dose|tablet
219503416|NCT01620983|BEHAVIORAL|Pain Coping Skills Training|
219503417|NCT01620983|BEHAVIORAL|Arthritis Education|
219503418|NCT01620983|OTHER|Usual Care|
219503419|NCT05085054|DRUG|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
219503420|NCT00819650|DRUG|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
219503421|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
219503422|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
219503423|NCT01713153|DRUG|Misoprostol|600 mcg misoprostol oral
219503424|NCT01713153|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
218882540|NCT02268825|DRUG|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
218882541|NCT03100591|DRUG|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
219503425|NCT03944486|DEVICE|Feasibility of OnTrack|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
219503426|NCT01566292|DRUG|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
219503427|NCT03548376|OTHER|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
218882542|NCT00043732|DRUG|SCIO-469|
218882543|NCT01961622|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
218882544|NCT01961622|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
218882545|NCT00711971|DRUG|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
218882546|NCT00711971|DRUG|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
219503428|NCT05200702|DEVICE|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
219503429|NCT06344442|DRUG|Arginine vasopressin|low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
219503430|NCT06344442|DRUG|Norepinephrine|Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
219503431|NCT02880904|OTHER|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
219503432|NCT03873519|OTHER|Chromatic Environment|Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
219503433|NCT03873519|OTHER|Room Orientation|Room will be facing North or South
218882547|NCT00711971|DRUG|placebo|control arm
218882548|NCT01363908|DRUG|SPD602|
218882549|NCT02644343|DEVICE|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
219503434|NCT01788722|DRUG|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
219503435|NCT03676023|DRUG|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
219503436|NCT05085964|DRUG|RNA antisense oligonucleotide for intravitreal injection|"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
219503437|NCT04841239|OTHER|Herbal topical formulation|
219503438|NCT01670461|BEHAVIORAL|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
219606307|NCT02411825|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219606308|NCT03170934|BEHAVIORAL|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
219606309|NCT04376658|OTHER|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
219606310|NCT03399513|DRUG|Ibrutinib Oral Capsule [Imbruvica]|Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
219200979|NCT06691880|BEHAVIORAL|MindPod Dolphin VGT|"The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game."
219200980|NCT06691880|BEHAVIORAL|Bimanual Arm Trainer VGT|"The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement."
219200981|NCT06693830|DEVICE|Phased Variant Enrichment and Detection Sequencing (PhasED-seq)|PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
219606311|NCT03399513|DRUG|R-CHOEP chemotherapy|Immunochemotherapy
218882550|NCT01909089|DRUG|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
219200982|NCT06693830|OTHER|Standard of Care Treatment|Standard of Care Treatment for cycles 1-6
218882551|NCT05769205|DEVICE|MRI|MRI with contrast
218882552|NCT05076890|DIETARY_SUPPLEMENT|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
219200983|NCT06693830|OTHER|De-escalated Treatment|Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
219606312|NCT04584684|OTHER|0.9% w/v NaCL Saline|saline placebo rinse
219606313|NCT04584684|DRUG|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
219606314|NCT04584684|DRUG|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
219606315|NCT04584684|DRUG|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
219606316|NCT04584684|DRUG|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
219606317|NCT04584684|DRUG|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
219606318|NCT04349202|DIAGNOSTIC_TEST|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
219606319|NCT04051203|BIOLOGICAL|Autologous Platelet Rich Plasma Injection|60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.
219606320|NCT04051203|DRUG|Depo-Medrol and lidocaine|Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
219606321|NCT04051203|OTHER|Normal Saline|2mL normal saline.
219606322|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
219606323|NCT04816643|BIOLOGICAL|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
219503439|NCT01670461|BEHAVIORAL|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
219503440|NCT01040221|DRUG|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
219503441|NCT00545233|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
219503442|NCT00545233|DRUG|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
219503443|NCT00545233|DRUG|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
219503444|NCT04525742|OTHER|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
219503445|NCT02914366|DRUG|Ambroxol|
219503446|NCT02914366|OTHER|Placebo|
219606324|NCT04816643|BIOLOGICAL|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
219606325|NCT04816643|OTHER|Placebo|Intramuscular injection
219606326|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
218882553|NCT05076890|DIETARY_SUPPLEMENT|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
219027928|NCT01425957|PROCEDURE|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
219027929|NCT03886012|DEVICE|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
219503447|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
219503448|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
219606327|NCT02726659|DRUG|Celecoxib|Adjunct celecoxib
218882554|NCT01198639|DEVICE|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
218882555|NCT01198639|DEVICE|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
218882556|NCT00738751|DRUG|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
219027930|NCT03886012|DEVICE|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
219027931|NCT01798472|PROCEDURE|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
219027932|NCT01798472|PROCEDURE|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
219503449|NCT02394431|OTHER|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
219503450|NCT02394431|OTHER|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
219503451|NCT02394431|OTHER|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
219503452|NCT00390988|PROCEDURE|blood sampling|
219503453|NCT04539509|BEHAVIORAL|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
219606328|NCT02726659|DRUG|Placebo|Adjunct placebo
219606329|NCT00457132|DEVICE|APOS biomechanical gait system|
219606330|NCT03249532|DEVICE|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
219606331|NCT03249532|DEVICE|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
219606332|NCT03249532|DEVICE|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
219606333|NCT03249532|DEVICE|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
219200984|NCT06692920|OTHER|DBS stimulation|"* Standard of care DBS surgery~* stimulation through the DBS lead during their DBS lead surgery, the study team will use 2 sets of stimulation settings on each participant:~  1. Stimulation through the DBS contact whose electrical activity is the MOST similar to the area of the brain that controls movement~ 2. Stimulation through the DBS contact whose electrical activity is the LEAST similar to the area of the brain that controls movement"
219200985|NCT04194216|DRUG|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
219200986|NCT04194216|DRUG|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
219200987|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
219200988|NCT02213497|DRUG|Carboplatin|
219200989|NCT02213497|DRUG|Paclitaxel|
219200990|NCT04881110|DRUG|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
219503454|NCT04539509|BEHAVIORAL|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
219503455|NCT04539509|DEVICE|Monitoring|Activity monitoring using a Fitbit.
219503456|NCT01089049|DIETARY_SUPPLEMENT|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
219606334|NCT04970615|DEVICE|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
219606335|NCT00379314|PROCEDURE|TVT and TVT-O minimally invasive surgical procedures|
218882557|NCT00738751|DRUG|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
218882558|NCT05587192|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
218882559|NCT04843761|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
218882560|NCT04843761|DRUG|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
219200991|NCT04881110|OTHER|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
219200992|NCT06246344|RADIATION|Adaptive Boost Radiotherapy|"The choice of adaptive protocol and delivery system is based on individual tumor characteristics, patient anatomy and institutional capabilities. This approach provides flexibility in treatment planning while adhering to evidence-based dose constraints. Adaptive radiotherapy is delivered using one of the following advanced platforms: the Elekta Unity MRI Linac (MR-guided) or Varian Ethos (CBCT-guided), or the United Imaging uRT-linac 506c (FBCT-guided).~ART Option 1 (simultaneous integrated boost, SIB):~GTVp+GTVn: A total dose of 60-65 Gy delivered in 25 fractions using a simultaneous integrated boost approach.~CTV: A total dose of 45-50 Gy delivered in 25 fractions.~ART Option 2 (sequential boost, SB) GTVp+GTVn: An initial hypofractionated boost with a total dose of either 9-12 Gy delivered in 3 fractions or 10 Gy delivered in 2 fractions.~CTV: Followed by standard fractionation delivering 45-50 Gy in 25 fractions."
218882561|NCT04843761|BIOLOGICAL|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
219200993|NCT06246344|RADIATION|Long course non-ART radiotherapy|Conventional long-course radiotherapy administered in a non-adaptive manner without dose escalation. Treatment will be targeted to the pelvic lymphatic drainage region only. A total dose of 45-50 Gy will be delivered in 25 fractions over the course of treatment.
219503457|NCT05649631|DIETARY_SUPPLEMENT|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
219503458|NCT02197182|DRUG|LUXSOL copper containing cream|Active comparator arm
219503459|NCT02197182|DRUG|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
219503460|NCT01208402|DRUG|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
219503461|NCT02077192|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
219503462|NCT02106169|BEHAVIORAL|Therapeutic education group|
219503463|NCT03559010|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
219503464|NCT06134739|OTHER|No intervention.|Observational study, no intervention.
219503465|NCT04271150|DEVICE|Self-etch|Universal adhesive with self-etch mode
219503466|NCT04271150|DEVICE|Total-etch|Universal adhesive with total-etch mode
219503467|NCT00012155|BIOLOGICAL|NV1020|
219606336|NCT00379314|PROCEDURE|Surgery for female stress urinary incontinence|
219606337|NCT02009722|DRUG|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
219606338|NCT02009722|DRUG|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
219503468|NCT03999281|OTHER|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
219606339|NCT06568510|PROCEDURE|Continuous peripheral nerve block|A perineurial catheter is placed to a nerve structure through a Touchy needle
219503469|NCT06321237|DEVICE|Vagus nerve stimulation for 8 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks
219503470|NCT06321237|DEVICE|Vagus nerve stimulation for the first 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks
219503471|NCT06321237|DEVICE|Vagus nerve stimulation for the last 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks
219503472|NCT06321237|DEVICE|Pseudostimulus|The patient is given some electrical stimulation but not vagus nerve stimulation
219503473|NCT03156270|DEVICE|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
219606340|NCT02955212|DRUG|Upadacitinib|Tablets for oral administration
219606341|NCT02955212|DRUG|Placebo|Tablets for oral administration
219606342|NCT05712239|OTHER|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
218882562|NCT04843761|DRUG|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
218882563|NCT04843761|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
218882564|NCT05022966|OTHER|No intervention|Individuals did not received any intervention.
218882565|NCT02868411|OTHER|Rectal Swab|
218882566|NCT03437577|DRUG|immediate-release tacrolimus|Standard of care for transplant patients
218882567|NCT03437577|DRUG|extended release tacrolimus|Experimental care
218882568|NCT02746640|PROCEDURE|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
218882569|NCT04720521|DIAGNOSTIC_TEST|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
218882570|NCT04246658|OTHER|conventional physical therapy program|traditional physical therapy program
218882571|NCT04246658|OTHER|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
218882572|NCT03683017|DEVICE|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
218882573|NCT03683017|DEVICE|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
218882574|NCT03683017|DEVICE|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
218882575|NCT03683017|DEVICE|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
218882576|NCT04880655|DEVICE|WSD|Post debridement and within 24 hours of injury, wound care and WSD applied daily
218882577|NCT04880655|DEVICE|Dressed with bacitracin and petrolatum gauze|Post debridement and within 24 hours of injury, wound care and dressing applied daily
219503474|NCT04343911|DEVICE|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
219503475|NCT01888471|PROCEDURE|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
219503476|NCT01888471|OTHER|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
219503477|NCT00644371|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
219503478|NCT01768078|PROCEDURE|Intravitreal injection of Betamethasone + antibiotics|
219503479|NCT01768078|PROCEDURE|Intravitreal injection of antibiotics|
219503480|NCT04708405|OTHER|Observation|Follow up and observe under standard of care given
219503481|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
218882578|NCT01848119|DRUG|Gabapentin|
218882579|NCT01848119|DRUG|lactose|
219503482|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
219503483|NCT00591253|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
218882580|NCT04280627|OTHER|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
219503484|NCT02005354|DEVICE|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).
219503485|NCT02005354|DRUG|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
218882581|NCT01984502|RADIATION|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
219503486|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
219503487|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
219503488|NCT03986749|PROCEDURE|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
219503489|NCT03428659|OTHER|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
219503490|NCT03811249|DEVICE|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
219503491|NCT04826185|DRUG|IMB-1018972|Modified release (MR) oral tablet
219503492|NCT04826185|DRUG|Placebo|Matching oral tablet
219503493|NCT01712230|DRUG|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
218882582|NCT00458458|DRUG|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
219503494|NCT01712230|BEHAVIORAL|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
218882583|NCT00458458|DRUG|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
218882584|NCT00513149|DRUG|Clopidogrel|Clopidogrel 600 mg loading
219503495|NCT01712230|DRUG|Placebo|Placebo
219503496|NCT01504867|DRUG|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
218882585|NCT02210858|OTHER|Laboratory Biomarker Analysis|Correlative studies
218882586|NCT02210858|DRUG|Tipifarnib|Given PO
218882587|NCT02238158|DRUG|Atrovent® inhalets|
218882588|NCT06231368|BIOLOGICAL|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
218882589|NCT01423292|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
219503497|NCT01504867|DRUG|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
219503498|NCT06021262|OTHER|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
219503499|NCT04182139|OTHER|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
218882590|NCT01423292|DRUG|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
218882591|NCT01423292|DRUG|Placebo|placebo
218882592|NCT03871244|PROCEDURE|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
218882593|NCT03871244|PROCEDURE|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
219200994|NCT06246344|DRUG|Concurrent chemotherapy|Capecitabine (825 mg/m2, po, twice daily)
219606343|NCT05712239|OTHER|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
219503500|NCT06527716|OTHER|Teaching Strategy|"Experimental group:~Get involved in the LINE digital media course learning platform.~1. LINE digital media course study period:~   Research subjects need to complete the aforementioned three pre-measurement forms before they can join the LINE digital media course. In this lesson plan design, at the end of a single class, there will be a summary of the key points of the class; after the end of a single class, there will be 5 to 10 questions accompanying the class. When the research subjects have finished answering, Regardless of whether the answer is correct or not, the system will display Problem Solution Analysis. The study time for this stage is 1 month.~2. WorkShop Learning~Control group:~Intervention in regular education course learning platform. The above-mentioned digital media courses will be placed on the educational platform of the college for research subjects to watch and learn."
219503501|NCT02519972|DEVICE|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
219503502|NCT03525665|OTHER|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
219503503|NCT05209490|PROCEDURE|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed."
219503504|NCT05209490|PROCEDURE|femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
219503505|NCT01583751|PROCEDURE|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
219503506|NCT04072978|DEVICE|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
219503507|NCT05881109|DRUG|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
219503508|NCT00003633|DRUG|docetaxel|
219503509|NCT00003633|DRUG|estramustine phosphate sodium|
219503510|NCT00003633|DRUG|mitoxantrone hydrochloride|
219503511|NCT00003633|DRUG|prednisone|
219606344|NCT05712239|OTHER|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
219027933|NCT01798472|PROCEDURE|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
219606345|NCT02570802|PROCEDURE|Ultrasonographic examination|
219606346|NCT03342885|BEHAVIORAL|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
219606347|NCT03342885|BEHAVIORAL|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
219200995|NCT06246344|DRUG|Consolidation Chemotherapy|Following the completion of concurrent chemoradiotherapy, consolidation chemotherapy will commence 7 to 10 days later. Patients will receive two cycles of the CAPEOX regimen. Each cycle comprises: Capecitabine: 1.0 g/m² administered orally twice daily on days 1 through 14, and Oxaliplatin: 130 mg/m² administered intravenously on day 1.
219200996|NCT06246344|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision surgery
219200997|NCT06450626|OTHER|Listening Music Intervention|Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
219200998|NCT05817006|GENETIC|Device|research of the long-COVID-19 in the children
219200999|NCT06684691|OTHER|Intervention group|The escape room game will be applied to the students in the intervention group after the theoretical training.
218882594|NCT04656743|PROCEDURE|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
218882595|NCT04656743|PROCEDURE|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
219201000|NCT06684691|OTHER|Control group|The escape room game will not be applied to the students in the control group after the theoretical training.
219503512|NCT06000189|PROCEDURE|Standardized skin surface biopsies (SSSB)|Skin samples will be obtained from four regions of the participants' faces, including the forehead, right cheek, left cheek, and the nose, before phototherapy and after 20 sessions of phototherapy. The SSSB will be performed as follows: a 1 cm² square will be drawn on a glass slide using a ruler. The skin areas to be sampled will be gently swabbed with a dry gauze to induce irritation by this way to obtain more mites. Then, one drop of cyanoacrylate adhesive will be dropped onto the marked area on the glass slide, and the adhesive surface of the slide will be pressed onto the skin surface for approximately one minute. Afterwards, the slide will be gently lifted, and the sampled area will be examined under a light microscope at x10 and x40 magnifications after applying immersion oil. The presence of more than five Demodex mites per square centimeter will be defined as increased Demodex density.
219503513|NCT04336267|DEVICE|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
219503514|NCT04336267|DEVICE|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
219606348|NCT01591083|DRUG|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
219606349|NCT02477956|DIETARY_SUPPLEMENT|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
219606350|NCT02477956|DIETARY_SUPPLEMENT|vitamin D|
218882596|NCT00536471|DRUG|Duloxetine hydrochloride|
218882597|NCT00536471|DRUG|Placebo|
219364365|NCT01358032|BEHAVIORAL|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) \& 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
219503515|NCT00871169|DRUG|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
219503516|NCT05474612|OTHER|kinesiology taping with conventional therapy|Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
219503517|NCT05474612|OTHER|Instrument assisted soft tissue mobilization with conventional therapy|IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
219503518|NCT05425108|DEVICE|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
219204508|NCT06503198|BEHAVIORAL|Virtual care|"Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions."
219503519|NCT03724721|PROCEDURE|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
219503520|NCT03239275|PROCEDURE|Biocreative therapy|
219606351|NCT03692507|DIETARY_SUPPLEMENT|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.
219503521|NCT01040013|PROCEDURE|Laparoscopy|Laparoscopic Left-Colectomy
219503522|NCT01040013|PROCEDURE|left colectomy by laparotomy|PatientS will be operated by laparotomy
219503523|NCT05531045|DIAGNOSTIC_TEST|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
219503524|NCT01365845|RADIATION|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
219503525|NCT01365845|RADIATION|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
219503526|NCT06336889|PROCEDURE|Pelvic Angioembolization|Embolization is performed by placing a small catheter inside the blood vessels that supply the area that is bleeding. Carefully navigating the catheter, under image guidance, to the safest and farthest point, a variety of different materials can then be used to block the bleeding vessels.
219503527|NCT01993394|OTHER|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
219606352|NCT03692507|DIETARY_SUPPLEMENT|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
219606353|NCT03692507|DIETARY_SUPPLEMENT|ERAS|Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
219606354|NCT03995277|DIETARY_SUPPLEMENT|Biotin|Daily intake of 10 mg or 50 µg per day
219606355|NCT00835393|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
218882598|NCT00811616|DEVICE|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
219027934|NCT01798472|PROCEDURE|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
219503528|NCT01993394|OTHER|gas mixture|breathing air, 44.5%O2 or 100%O2
219027935|NCT00271609|DRUG|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
219027936|NCT00500851|DEVICE|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
219503529|NCT00786110|DRUG|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
219503530|NCT00786110|DRUG|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
219503531|NCT05910710|GENETIC|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
219503532|NCT04482010|OTHER|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
219503533|NCT05063019|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging and enterography before surgery
219606356|NCT00835393|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
219606357|NCT02603016|DRUG|GLSE compound|
218882599|NCT00811616|DEVICE|Supralimus™ Core™ Sirolimus eluting stent|Supralimus™ Core™ Sirolimus eluting stent intended to treat coronary artery disease.
218882600|NCT03704688|DRUG|Trametinib 0.5 mg|0.5mg PO q daily
218882601|NCT03704688|DRUG|Trametinib 1 MG|1.0 mg PO q daily
218882602|NCT03704688|DRUG|Trametinib 1.5 MG|1.5mg PO q daily
218882603|NCT03704688|DRUG|Trametinib 2 mg|2 mg PO q daily
218882604|NCT03704688|DRUG|Ponatinib 15 MG|15mg PO q daily
218882605|NCT03704688|DRUG|Ponatinib 30 MG|30mg PO q daily
219027937|NCT00500851|DEVICE|Endoscopy|Endoscopic placement of jejunal feeding tubes
219503534|NCT04664608|DEVICE|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
219503535|NCT03210259|DRUG|Humira®|Duration - 58 weeks
219503536|NCT03210259|DRUG|BI 695501|Duration - 58 weeks
219503537|NCT03782649|DEVICE|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
219503538|NCT02110706|DRUG|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
219606358|NCT02603016|DRUG|Maitake mushroom extract compound|
219606359|NCT02603016|DRUG|Ginseng compound|
219606360|NCT03556124|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
219503539|NCT02110706|DRUG|Placebo|The placebo group will receive a vehicle control infusion
219503540|NCT02087059|DRUG|Ruxolitinib|
219503541|NCT06251128|BEHAVIORAL|Stroke Self management Program|"Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants"
219503542|NCT03465228|DEVICE|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
219503543|NCT03465228|DEVICE|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
219503544|NCT03465228|OTHER|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
219503545|NCT00252187|DRUG|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
219503546|NCT00252187|OTHER|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
219503547|NCT03334487|DRUG|Dexamethasone|Oral
219503548|NCT03334487|DRUG|Rovalpituzumab tesirine|Intravenous
218882606|NCT00394550|PROCEDURE|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
218882607|NCT00394550|PROCEDURE|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
218882608|NCT01985750|DRUG|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
218882609|NCT01985750|DRUG|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
218882610|NCT04847934|BEHAVIORAL|distraction methods|distraction methods
218882611|NCT05981027|OTHER|Mulligan bent leg raise technique|In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
218882612|NCT05981027|OTHER|Static stretching exercise|The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
218882613|NCT06088719|PROCEDURE|axillary surgery|one group undergoes axillary surgery
218882614|NCT01359202|BIOLOGICAL|rfVIIa|80ug/kg IV bolus
218882615|NCT01359202|OTHER|Standard saline solution|Saline
218882616|NCT03908359|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
219027938|NCT00369551|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
219027939|NCT00369551|DRUG|paclitaxel|Given IV
219027940|NCT00369551|BIOLOGICAL|bevacizumab|Given IV
219027941|NCT00369551|DRUG|carboplatin|Given IV
219027942|NCT00369551|OTHER|laboratory biomarker analysis|Correlative studies
219027943|NCT03391596|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
219027944|NCT03391596|BEHAVIORAL|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
219606361|NCT03556124|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
219606362|NCT03556124|DEVICE|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
218882617|NCT03908359|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
218882618|NCT06488105|DRUG|Statin (rosuvastatin 10 or 40 mg daily, depending on risk)|moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
218882619|NCT06488105|BEHAVIORAL|Healthy Lifestyle Counseling|Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
218882620|NCT06488105|OTHER|Outpatient Followup|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
218882621|NCT04878211|DRUG|Ofatumumab|3 loading doses followed by monthly administrations
218882622|NCT04878211|BIOLOGICAL|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
218882623|NCT04878211|DRUG|interferon or glatiramer acetate|iDMT
218882627|NCT00328614|DRUG|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
218882628|NCT00328614|DRUG|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
218882629|NCT00328614|DRUG|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
218882630|NCT00328614|DEVICE|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
218882631|NCT01473628|OTHER|Clinical Observation|Undergo observation
218882632|NCT01473628|RADIATION|Radiation Therapy|Undergo radiation therapy
218882633|NCT01473628|BIOLOGICAL|Rituximab|Given IV
218882634|NCT05550194|DRUG|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
218882635|NCT05550194|BIOLOGICAL|Shingrix|Vaccine indicated for prevention of herpes zoster
218882636|NCT04774926|DRUG|Brolucizumab|120 mg/ml solution for intravitreal injection
218882637|NCT05623241|DIAGNOSTIC_TEST|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
218882638|NCT00477646|BEHAVIORAL|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
218882639|NCT02783599|DRUG|Olaratumab|Administered IV
218882640|NCT02783599|DRUG|Doxorubicin|Administered IV
219027945|NCT03391596|BEHAVIORAL|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
219606363|NCT03556124|DEVICE|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
219606364|NCT01113723|DEVICE|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
219606365|NCT01113723|DEVICE|CMAC|CMAC Device
219606366|NCT01471743|DIETARY_SUPPLEMENT|Impact Advance Recovery (R)|
219027946|NCT02188589|DEVICE|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
219027947|NCT05077592|DRUG|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
219027948|NCT04971473|BIOLOGICAL|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
219027949|NCT03866343|OTHER|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
219204509|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month pre-intervention visit
219204510|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month post-intervention visit
218882641|NCT02783599|RADIATION|External Beam Radiotherapy|
218882642|NCT06210100|DEVICE|Active iTBS|Mag-TD stimulator
218882643|NCT06210100|DEVICE|Sham iTBS|Mag-TD stimulator
218882644|NCT04760405|OTHER|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
218882645|NCT05643339|DIAGNOSTIC_TEST|microvascular flow imaging|microvascular flow imaging
218882646|NCT03453580|RADIATION|multislice computed tomography portography|imaging modality
218882647|NCT05133765|DEVICE|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
218882648|NCT00633529|DRUG|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
218882649|NCT03536559|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
218882650|NCT03536559|DRUG|Placebo|Placebo is liquid with identical color and taste
218882651|NCT01770236|DRUG|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
218882652|NCT03630757|OTHER|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
219364366|NCT03969875|DEVICE|Interscalene catheter|rescue catheters attached to a PCA pump
219364367|NCT03969875|DRUG|Liposomal bupivacaine|10 cc
219364368|NCT03969875|DRUG|Dexamethasone|1 cc of 4mg
219364369|NCT03969875|DRUG|Bupivacaine|0.5% bupivacaine
218882653|NCT00847886|DRUG|LX3305|Daily oral intake of LX3305 for 14 days.
218882654|NCT00847886|DRUG|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
218882655|NCT00847886|DRUG|Methotrexate|Once weekly stable-dose methotrexate.
218882656|NCT06353282|DRUG|MDMA|MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
218882657|NCT06353282|BEHAVIORAL|Psychotherapy|Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
218882658|NCT05356780|DEVICE|Aligner|A method of straightening teeth without fixed braces
218882659|NCT00391313|DRUG|Chloroquine|
218882660|NCT03492606|PROCEDURE|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
218882661|NCT01401517|DRUG|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
218882662|NCT01000259|OTHER|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
218882663|NCT00728091|DRUG|Satavaptan|tablets
218882664|NCT00728091|DRUG|placebo|tablets
219503549|NCT01901315|PROCEDURE|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
219503550|NCT01901315|PROCEDURE|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
219503551|NCT03764059|DEVICE|Filtek™ Bulk Fill Posterior Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
219503552|NCT03764059|DEVICE|Filtek™ Z350XT Universal Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
219503553|NCT00767689|DRUG|Vitamin B 6|vitamin b6 100 mg po daily
219503554|NCT00767689|DRUG|placebo|placebo is given in the placebo arm
219503555|NCT01608633|OTHER|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
218882665|NCT05899400|DIAGNOSTIC_TEST|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
218882666|NCT00288678|PROCEDURE|Health Education|
219503556|NCT02720315|PROCEDURE|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
219503557|NCT04111133|DRUG|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
218882667|NCT01032720|PROCEDURE|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
218882668|NCT01032720|PROCEDURE|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
218882669|NCT05501834|OTHER|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
218882670|NCT01849094|DRUG|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
219027950|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
219204511|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 3-months post-intervention visit
219204512|NCT06858657|DRUG|HSK44459|Dose 1 to Dose 5
219204513|NCT06858657|DRUG|placebo|dose 1 to dose 5
218882671|NCT01849094|DRUG|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
218882672|NCT01849094|DRUG|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
219204514|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
219503558|NCT04111133|DRUG|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
219503559|NCT00001951|DRUG|TMTDS|
219503560|NCT04797715|DRUG|AXS-05|AXS-05 tablets, taken twice daily
219503561|NCT04797715|DRUG|Placebo|Placebo tablets, taken twice daily
219503562|NCT05079893|OTHER|Case control study|Observational case control study
219503563|NCT04604483|DEVICE|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
219503564|NCT03974984|PROCEDURE|Colon Resection|All patients undergo laparoscopic colon cancer resection.
219606367|NCT01471743|DIETARY_SUPPLEMENT|Ensure Plus (R)|
218882673|NCT04236362|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
218882674|NCT04236362|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
219027951|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
219027952|NCT05829486|PROCEDURE|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
219201001|NCT06624566|OTHER|Experimental: Implementation of an intensive therapeutic group exercise program in the neurorehabilitation process|Description: The variables will be measured prior to group assignment The age and sex variables and the satisfaction survey will be measured at the beginning of the program, the other variables at 20 sessions, at 40 sessions, at 60 sessions and/or at hospital discharge. Before the patient starts the program, he/she is classified in group A - patients who have seated trunk control for at least 2 minutes (with supervision) and no standing control (Berg scale item 3.3) - or in group B - patients who have standing trunk control for 2 minutes (with supervision) (Berg scale item 2.3). There is a maximum of 4 patients per group with 1 physiotherapist per group.. There is a maximum of 4 patients per group with 1 physiotherapist per group.. The difference with respect to the usual treatment of the neurorehabilitation service of the HMS is that in the EINTER program, strength and endurance exercises will be implemented in addition to the usual care plan
219201002|NCT05645276|DRUG|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
219503565|NCT03974984|PROCEDURE|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
219503566|NCT03974984|DRUG|NSAID|NSAID administered according to standard operating procedure postoperatively
219503567|NCT00706706|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
219503568|NCT06531096|BEHAVIORAL|v-DOT|Video directly observed therapy
219503569|NCT04938206|PROCEDURE|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
219503570|NCT02693184|OTHER|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
219503571|NCT02693184|OTHER|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
219503572|NCT05017493|COMBINATION_PRODUCT|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
219503573|NCT01943461|DRUG|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
219503574|NCT01943461|DRUG|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
219503575|NCT01943461|DRUG|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
219503576|NCT03534297|DRUG|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
219503577|NCT03534297|DRUG|Placebo capsules|Hard opaque capsules containing 0 mg of API.
219503578|NCT02232451|DEVICE|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
219503579|NCT02232451|DEVICE|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
219503580|NCT02175966|DRUG|DCV/ASV/BMS-791325|
218882675|NCT00104624|DRUG|docetaxel|
218882676|NCT00104624|PROCEDURE|quality-of-life assessment|
218882677|NCT02369393|BEHAVIORAL|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
218882678|NCT02369393|BEHAVIORAL|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
218882679|NCT00398034|DRUG|Testosterone Gel|
219027953|NCT00345137|DRUG|Ng-monomethyl-L-arginine (drug)|
219027954|NCT05133518|DRUG|MELT-300|Sublingual tablet
219027955|NCT05133518|DRUG|Midazolam alone|Sublingual tablet
219027956|NCT05133518|DRUG|Ketamine alone|Sublingual tablet
219027957|NCT05133518|DRUG|Placebo|Sublingual tablet
219027958|NCT02838680|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
219503581|NCT02175966|DRUG|Ribavirin|
219503582|NCT02175966|DRUG|Sofosbuvir|
219503583|NCT02175966|DRUG|Peginterferon α-2a|
219503584|NCT02807766|BEHAVIORAL|Behavior modification|Each group has 30 subjects and experiences six months' training.
219503585|NCT02807766|BEHAVIORAL|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
219503586|NCT02807766|BEHAVIORAL|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
219503587|NCT02807766|BEHAVIORAL|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
219503588|NCT04405206|DRUG|Oxaliplatin|OXA 130mg/m2
218882680|NCT04240574|DEVICE|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
218882681|NCT05904574|OTHER|Autologous blood patch|Approximately 3-4 pieces were taken with the 18 G core biopsy needle until sufficient tissue was obtained. In the autologous blood patch technique, approximately 6-7 ml of blood was taken from the patient with a 10 ml syringe before the procedure. By attaching a 3-way tap to the injector from which the blood is drawn, blood is drawn into a second injector to ensure that the clotted blood is dispersed and homogenized. The prepared autologous blood patch was given through the coaxial needle (approximately 1 ml of autologous blood patch was applied for every 1 cm when the coaxial needle was withdrawn) and the tract formed by the biopsy needle in the parenchyma, pleura, and under the skin was closed with the patient's autologous blood.
218882682|NCT05904574|OTHER|Percutaneous transthoracic biopsy|After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.
218882683|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
219503589|NCT04405206|DRUG|Capecitabine|Cape 1000mg/m2
219503590|NCT04405206|RADIATION|intensity modulated radiotherapy|IMRT 50.4Gy/22f
219503591|NCT04405206|PROCEDURE|DRE-Endoscopy-MRI-CEA|examination process in follow up
219503592|NCT04405206|PROCEDURE|Nonoperative Management|Watch and Wait
219503593|NCT04405206|PROCEDURE|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
219503594|NCT04405206|PROCEDURE|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
219503595|NCT04405206|BEHAVIORAL|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
219503596|NCT00557973|DRUG|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
218882684|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
218882685|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
218882686|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
219027959|NCT00984243|PROCEDURE|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2"
219027960|NCT04324060|DRUG|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months
218882687|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
219027961|NCT04324060|DRUG|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
219027962|NCT05950789|OTHER|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
219027963|NCT01002950|DRUG|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
219503597|NCT00557973|DRUG|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
219503598|NCT00557973|DRUG|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
219503599|NCT00557973|DRUG|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
219503600|NCT01708876|DRUG|Artesunate-mefloquine|
219503601|NCT01708876|DRUG|Chloroquine|
219503602|NCT01708876|DRUG|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
219503603|NCT02122094|BEHAVIORAL|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
219503604|NCT00564369|OTHER|CDC HIV testing recommendations|Current vs. prior CDC recommendations
219503605|NCT02082613|PROCEDURE|Lord´s procedure|
219503606|NCT02082613|PROCEDURE|Sclerotherapy|
219503607|NCT04657510|OTHER|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
219606368|NCT02664181|DRUG|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
219606369|NCT02664181|DRUG|oral decitabine|oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
219606370|NCT02664181|DRUG|Tetrahydrouridine|Oral THU \~10 mg/kg twice weekly on consecutive days
218882688|NCT02106494|DRUG|APF530|
218882689|NCT02106494|DRUG|Ondansetron|
218882690|NCT02106494|DRUG|Ondansetron placebo|
218882691|NCT02106494|DRUG|APF530 placebo|
218882692|NCT02106494|DRUG|Fosaprepitant|
219606371|NCT01705795|DRUG|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
219606372|NCT01705795|DRUG|Placebo|Nacl four times over four months
219606373|NCT01988181|DEVICE|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
218882693|NCT02106494|DRUG|Dexamethasone|
218882694|NCT01068769|DRUG|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
218882695|NCT06959758|DIETARY_SUPPLEMENT|Probiotic Arm|It is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period. The study evaluates whether BioKid LR® helps maintain normal bowel movements after stopping PEG.
218882696|NCT06959758|DRUG|Placebo|A placebo maltodextrin powder is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period.
218882697|NCT01877213|BEHAVIORAL|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
218882698|NCT01020552|OTHER|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
218882699|NCT03371784|DRUG|Hydrocortisone|I.V. administration
218882700|NCT03371784|DRUG|Placebo|I.V. administration
218882701|NCT05240625|DEVICE|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
219201003|NCT06004440|DEVICE|Ion Endoluminal System|Subjects will under a planned procedure with the Ion Endoluminal System
218882702|NCT05240625|PROCEDURE|Standard colonoscopy|Standard colonoscopy procedure.
218882703|NCT02764658|DEVICE|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
218882704|NCT02764658|OTHER|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
218882705|NCT02764658|OTHER|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
218882706|NCT00709618|DRUG|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
218882707|NCT02116452|DIETARY_SUPPLEMENT|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
218882708|NCT01578655|DRUG|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
218882709|NCT01578655|DRUG|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
218882710|NCT01578655|DRUG|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
218882711|NCT05842252|PROCEDURE|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
219364370|NCT04278885|DRUG|Lanadelumab|300mg Lanadelumab s.c. administration every 2 weeks
219364371|NCT03817203|OTHER|Kinesio tape application|Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
219364372|NCT03817203|OTHER|Sham tape application|Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
219364373|NCT02186184|DEVICE|Orthokeratology|
219364374|NCT02186184|DEVICE|Spectacle|
219364375|NCT03513653|DIAGNOSTIC_TEST|Echocardiography with speckle-tracking imaging|"1. Measurement of left ventricular ejection fraction and global longitudinal strain~2. Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~3. Measurement of right ventricular global longitudinal strain"
219364376|NCT05242250|DEVICE|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
219364377|NCT03064672|DEVICE|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
219364378|NCT00657384|DRUG|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
219364379|NCT00657384|DRUG|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
219364380|NCT01307033|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
219364381|NCT01307033|DRUG|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
219364382|NCT01307033|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
219364383|NCT01307033|DRUG|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
219364384|NCT02208245|DEVICE|Ultrasound: Axillary block|Ultrasound guided axillary block
219027964|NCT01002950|DRUG|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
219503608|NCT06175195|BEHAVIORAL|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
219503609|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
219503610|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
219503611|NCT01478503|DRUG|mirabegron OCAS|oral
219503612|NCT01478503|DRUG|Placebo|oral
219503613|NCT01708928|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219503614|NCT03807154|BEHAVIORAL|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
219503615|NCT03807154|BEHAVIORAL|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
219503616|NCT01525706|DRUG|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
219503617|NCT04499456|OTHER|Personalised Normative Feedback|The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
219606374|NCT01988181|DEVICE|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
219606375|NCT00545714|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
219606376|NCT00545714|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
218882712|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
219027965|NCT02722850|BEHAVIORAL|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
219503618|NCT04109157|DIAGNOSTIC_TEST|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
219503619|NCT01154153|DRUG|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
219503620|NCT01154153|DRUG|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
219503621|NCT01154153|DRUG|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
219503622|NCT01154153|DRUG|Claritin® Syrup|Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
219503623|NCT01665053|DEVICE|PROMUS Element Plus|A drug eluting coronary stent system
219606377|NCT00545714|DRUG|Rituximab|Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
218882713|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
218882714|NCT01948063|DRUG|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
218882715|NCT01948063|DIETARY_SUPPLEMENT|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
218882716|NCT03124576|DEVICE|Implantable loop recorder|Continuous rhythm monitoring Medtronic
218882717|NCT06406023|OTHER|Conventional treatment|"Hot pack will be applied for 10 minutes. AROM's of Hip (5 reps x 2 sets each). Piriformis stretch 3 reps x 20 sec hold x 2 sets. SLR (5reps x 10 sec hold x 2 sets). Sciatic nerve stretch (5 reps x 10 sec hold x 2 sets) for 3 days/ week for 2 weeks.~Strengthening exercises will be performed after 2 weeks of previous intervention of Hip abductors (Hip abduction with band in sitting, standing, side-lying hip raise), and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each).~SLR (5 reps x 10 sec hold x 2 sets) each exercise will be performed 3 days/ week for 2 weeks.~Total treatment protocol will be followed for 4 weeks. Each session will be of 30 minutes."
219364385|NCT02208245|DEVICE|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
219503624|NCT01665053|DEVICE|SYNERGY|A drug eluting coronary stent system
219503625|NCT03139747|DRUG|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
219503626|NCT03139747|DRUG|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
219503627|NCT00006081|DRUG|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
219503628|NCT00006081|DRUG|Paclitaxel (Taxol)|80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
219606378|NCT02244281|DRUG|tamsulosin hydrochloride|
219606379|NCT02244281|DRUG|Placebo|
218882718|NCT06406023|OTHER|Instrument assisted soft tissue mobilization|Instrument assisted soft tissue mobilization IASTM with Graston tool along with conventional treatment in first 6 sessions. Apply hot pack for 10 mins on low back as passive warm up then AROM's of Hip (5 reps x 2 sets each) will be performed. Apply Graston tool at 30-60 degrees angle along the length of following muscles Piriformis, Gluteus medius and Hamstrings after applying emollient for 40-120 seconds.
218882719|NCT01848327|DIETARY_SUPPLEMENT|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
218882720|NCT01848327|DIETARY_SUPPLEMENT|Placebo|Placebo (40 gram packet orally once a day for 90 days)
218882721|NCT02920749|DRUG|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
219027966|NCT00003641|BIOLOGICAL|interferon alfa-2b|Given IV
219027967|NCT00003641|OTHER|observation|Patients undergo observation for 4 weeks.
219364386|NCT02208245|DRUG|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
219364387|NCT04376437|DRUG|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
219027968|NCT04962009|COMBINATION_PRODUCT|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
219027969|NCT05476341|DRUG|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
219027970|NCT05476341|DRUG|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
219364388|NCT03964584|OTHER|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
219364389|NCT00693199|DRUG|amlodipine|amlodipine 5mg once daily for 28 days
219364390|NCT00693199|DRUG|terazosin|terazosin 2 mg once daily for 28 days
219364391|NCT00693199|DRUG|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
219364392|NCT00555087|DRUG|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
219364393|NCT04956900|DRUG|Aurase Wound gel|Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
219364394|NCT01126255|DRUG|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
219364395|NCT01126255|DRUG|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
219364396|NCT02321293|DIETARY_SUPPLEMENT|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
219364397|NCT02321293|DRUG|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
219364398|NCT02321293|DRUG|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
219364399|NCT01231555|DRUG|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
219364400|NCT01231555|DRUG|GSK2248761 200 mg once daily|2x100 mg capsules
219364401|NCT01231555|DRUG|Efavirenz 600 mg once daily|1x600mg tablet
219503629|NCT04698122|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
219503630|NCT04698122|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219503631|NCT04698122|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
219503632|NCT02152787|DRUG|Injection of propofol 1.0mg/kg|
219503633|NCT02152787|DRUG|propofol 0.5mg/kg|
219503634|NCT02152787|DRUG|normal saline|
219503635|NCT02854683|DRUG|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
219503636|NCT02854683|DIETARY_SUPPLEMENT|Oral Rehydration Solution|1 liter of ORS solution given by mouth
219503637|NCT01203683|BEHAVIORAL|Active computer-based training|8 sessions across 4 weeks.
219606380|NCT02593617|OTHER|Addiction Profile Index|
218882722|NCT02920749|DRUG|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
218882723|NCT02920749|DRUG|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
219503638|NCT01203683|BEHAVIORAL|Inert computer training|8 sessions across 4 weeks.
219503639|NCT01033383|DIETARY_SUPPLEMENT|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
219503640|NCT01033383|DIETARY_SUPPLEMENT|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
219503641|NCT03787745|PROCEDURE|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
219503642|NCT03787745|PROCEDURE|Conventional|State of the art primary PCI, however thrombectomy is not allowed
219503643|NCT02638857|PROCEDURE|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
219503644|NCT02638857|BIOLOGICAL|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
219503645|NCT02638857|DRUG|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
219503646|NCT02638857|DRUG|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
219503647|NCT02638857|DRUG|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
219503648|NCT02638857|BIOLOGICAL|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
219503649|NCT02376985|PROCEDURE|Oral management|
219503650|NCT02376985|DRUG|Everolimus|
218882724|NCT02920749|DRUG|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
218882725|NCT03856827|DRUG|IW-6463|IW-6463 Tablet
218882726|NCT03856827|DRUG|Matching Placebo|Matching Placebo Tablet
218882727|NCT03642496|BIOLOGICAL|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
218882728|NCT03642496|BIOLOGICAL|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
218882729|NCT03642496|BIOLOGICAL|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
219027971|NCT04814758|DIAGNOSTIC_TEST|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
219027972|NCT00116532|DRUG|Escitalopram|
219503651|NCT01261533|DEVICE|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
218882730|NCT03536832|PROCEDURE|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
219027973|NCT05546047|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
219027974|NCT02441608|DEVICE|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
219503652|NCT00778557|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
219606381|NCT02593617|OTHER|Alcohol Use Disorders Identification Test|
219606382|NCT02593617|OTHER|Barratt Impulsiveness Scale|
219503653|NCT05287659|DIETARY_SUPPLEMENT|meal replacements or supplementation with leucine|meal replacements or animal protein or supplementation with leucine
219503654|NCT00210626|DRUG|PROCRIT|40,000 IU/mL/week for max of 12 weeks
219503655|NCT00210626|DRUG|Placebo|40,000 IU/mL/week for max of 12 weeks
219606383|NCT02593617|OTHER|Zuckerman Sensation Seeking Scale|
219606384|NCT02593617|OTHER|Energy Drink Consumption Questionnaire|
219606385|NCT02319317|BEHAVIORAL|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
219606386|NCT02319317|BEHAVIORAL|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
218882731|NCT03536832|PROCEDURE|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
218882732|NCT05775731|DIAGNOSTIC_TEST|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
218882733|NCT05606276|OTHER|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
218882734|NCT05606276|OTHER|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
218882735|NCT03831217|PROCEDURE|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
218882736|NCT03969927|DEVICE|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
218882737|NCT03969927|DEVICE|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
218882738|NCT01894932|BEHAVIORAL|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
218882739|NCT01894932|BEHAVIORAL|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
218882740|NCT00550966|BEHAVIORAL|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
218882741|NCT03245398|DRUG|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
218882742|NCT00002201|DRUG|Ritonavir|
219503656|NCT01792258|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
219503657|NCT02629952|OTHER|Blueberry Tea|Blueberry Tea
219503658|NCT04452799|DRUG|Hesperidin and Diosmin mixture|Interventional Clinical Trial
219606387|NCT04428034|BEHAVIORAL|Learning Skills Together|Information provided in arm/group description.
219606388|NCT00995124|DRUG|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
218882743|NCT00002201|DRUG|Nelfinavir mesylate|
218882744|NCT04362423|DEVICE|fNIRS|Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
219606389|NCT00995124|DRUG|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
219027975|NCT00451386|DRUG|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
219606390|NCT00995124|DRUG|Moov Head Lice Solution|Single application for head lice with 10 min application time.
219027976|NCT00451386|DRUG|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
219027977|NCT05461651|PROCEDURE|Knee arthroplasty|total or unilateral knee arthroplasty
219027978|NCT05844189|PROCEDURE|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
219503659|NCT04052100|OTHER|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must\_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
219606391|NCT04873596|DRUG|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
219204515|NCT06861569|PROCEDURE|Positive end expiratory pressure|Positive end-expiratory pressure (PEEP) is a value that can be set up in patients receiving invasive or non-invasive mechanical ventilation. 5cmH2O PEEP will be applied to the PEEP group participants.
219606392|NCT04873596|DRUG|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
219606393|NCT02484937|OTHER|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
219606394|NCT02484937|OTHER|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
219606395|NCT03528616|DRUG|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
219606396|NCT03409237|DRUG|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
219606397|NCT03409237|DRUG|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
219606398|NCT02017470|OTHER|Gender-tailored women's heart health outpatient programme|
219606399|NCT00261287|DRUG|Ciclesonide|
218882745|NCT00887926|BIOLOGICAL|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
218882746|NCT02461940|BEHAVIORAL|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
218882747|NCT01406197|DRUG|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
218882748|NCT01406197|DRUG|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
218882749|NCT01406197|DRUG|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
218882750|NCT00880191|DRUG|dexamethasone|Given orally
218882751|NCT00880191|DRUG|gabapentin|Given orally
218882752|NCT00880191|OTHER|placebo|Given orally
218882753|NCT05499468|OTHER|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
218882754|NCT01090440|DRUG|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
218882755|NCT01633164|BEHAVIORAL|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
219027979|NCT05844189|DEVICE|CRMRF|"CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts"
219027980|NCT05844189|DEVICE|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
219027981|NCT02154581|DEVICE|SLActive implant|
219027982|NCT01039233|DRUG|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
219503660|NCT04052100|OTHER|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
218882756|NCT01633164|OTHER|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
218882757|NCT06210230|DIETARY_SUPPLEMENT|MLCT supplementation|MLCT 25g/d for 6 months
218882758|NCT06210230|DIETARY_SUPPLEMENT|Olive oil|Matching placebo (olive oil) 25g/d for 6 months
219027983|NCT00817115|DEVICE|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
219503661|NCT05140642|OTHER|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
219503662|NCT05140642|OTHER|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
219503663|NCT00343850|DRUG|Asacol (mesalamine)|
219606400|NCT00634699|PROCEDURE|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
219606401|NCT02329028|DEVICE|Prehospital mini-EEG|Observational
219503664|NCT00738556|DEVICE|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
219503665|NCT05206032|OTHER|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
219503666|NCT01671787|DRUG|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
219503667|NCT01671787|DRUG|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
219503668|NCT01886456|DEVICE|Laser trabeculoplasty|
219503669|NCT03951428|DIAGNOSTIC_TEST|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
218882759|NCT04343456|PROCEDURE|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
218882760|NCT03547895|DRUG|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
219503670|NCT02060656|DRUG|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
219503671|NCT02060656|DRUG|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
219503672|NCT02060656|DRUG|Rituximab|375mg/m2 IV D1, D15 every 28 days
218882761|NCT03547895|DRUG|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
218882762|NCT01661894|DEVICE|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
218882763|NCT03078855|DIETARY_SUPPLEMENT|Vitamin D|vitamin D3 2,000 IU daily
218882764|NCT03078855|BIOLOGICAL|Rituximab|Administered weekly x 4
218882765|NCT03078855|OTHER|Placebo|methylcellulose
218882766|NCT01938833|DRUG|Romidepsin|
218882767|NCT01938833|DRUG|Abraxane|
218882768|NCT03765450|DRUG|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
218882769|NCT02816489|DEVICE|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
218882770|NCT02816489|DEVICE|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
218882771|NCT04124705|DRUG|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
218882772|NCT04124705|DRUG|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
218882773|NCT03343834|BIOLOGICAL|biological collection|"At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
218882774|NCT01711125|DRUG|Baclofen 30mg/day|30mg/day 10 mg t.i.d
218882775|NCT01711125|DRUG|Baclofen 75mg/day|75mg/day 25 mg t.i.d
218882776|NCT01711125|DRUG|Placebo|Placebo 3 matched tabs/day
218882777|NCT03010280|DIETARY_SUPPLEMENT|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
218882778|NCT03010280|DIETARY_SUPPLEMENT|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
218882779|NCT01771523|PROCEDURE|Thyroidectomy|total thyroidectomy or lobectomy
218882780|NCT01771523|DEVICE|use of drain|drain will be used
218882781|NCT01973998|DRUG|Roflumilast|PDE4 inhibitor
219503673|NCT02060656|DRUG|Cisplatin|100mg/m2 IV D15 every 28 days
219503674|NCT02060656|DRUG|Lenalidomide|25mg PO D1-21 every 28 days
219503675|NCT05808556|DEVICE|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
219503676|NCT05808556|DEVICE|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
218882782|NCT01973998|DRUG|Placebo|Inactive substance.
218882783|NCT03821467|DEVICE|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
219503677|NCT00794261|DRUG|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
219503678|NCT00794261|DRUG|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
219503679|NCT00200928|BIOLOGICAL|BCG|
219503680|NCT03500770|DEVICE|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
219503681|NCT02350530|DRUG|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
219503682|NCT02350530|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
219503683|NCT03720756|OTHER|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
219503684|NCT02473510|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
219503685|NCT02473510|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
219503686|NCT01306253|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
218882784|NCT03821467|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
219503687|NCT02568995|DRUG|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
219503688|NCT01690065|DRUG|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
219503689|NCT00003747|DRUG|carboplatin|
219503690|NCT00003747|DRUG|temozolomide|
219503691|NCT03736395|BEHAVIORAL|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
219606402|NCT05714878|BEHAVIORAL|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
219606403|NCT03345771|COMBINATION_PRODUCT|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
219606404|NCT03345771|DEVICE|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
218882785|NCT03821467|DEVICE|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
218882786|NCT06976684|PROCEDURE|Extended Reality (XR)-Assisted CT-Guided Localization|This study plans to collect approximately 20 localization cases from multiple centers within our hospital. Initially, two sets of preoperative simulated CT scans (at end-inhalation and end-exhalation) will be performed in the CT suite to construct a usable model of the surgical posture and the lesion. Subsequently, in the hybrid operating room, a digital twin model will be applied to the patient using a metaverse platform. Guided by virtual localization lines, percutaneous injection of Patent Blue dye will be carried out at end-exhalation for accurate marking of the lesion. Immediately after the injection, intraoperative CT within the hybrid operating room will be used to verify the localization. If the accuracy is suboptimal (with a deviation greater than 2 cm), standard CT-guided Patent Blue dye localization will be performed as a supplementary measure to complete the localization and proceed with surgery.
219503692|NCT03736395|BEHAVIORAL|Control|Schools in this condition will receive a four-day training session about SWPBIS.
219503693|NCT06537856|OTHER|Health Belief Model Based Cardiovascular Disease Risk Factor Prevention Education|"In line with the literature review, Health Belief Model-Based Cardiovascular Disease Risk Factor Prevention Training was created in order to increase the level of knowledge of firefighters regarding cardiovascular disease risk factors, improve their awareness and positively affect their quality of life. This training was given in 3 different sessions by meeting face-to-face with firefighters in the training hall of the fire stations. Each session lasted 40 minutes. Answers were given to the questions asked at the end of the session. The training was organized under the following main headings:~Perceived Sensitivity, Perceived Seriousness, Perceived Barriers, Perceived Self-Efficacy, Health Motivation/Activators"
219503694|NCT06537856|BEHAVIORAL|Reminder Short Messages|After the Health Belief Model-Based health education, 39 text messages were sent via WhatsApp application 3-4 times a week for 3 months to increase the effectiveness of the education and the motivation of firefighters in CVD prevention.
219606405|NCT04944173|DRUG|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
219606406|NCT04944173|RADIATION|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
219606407|NCT04944173|DIAGNOSTIC_TEST|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
219606408|NCT04478929|DIAGNOSTIC_TEST|Gastroscopy|Routine gastroscopy
218882787|NCT05985967|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
218882788|NCT05985967|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
218882789|NCT05985967|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
218882790|NCT05985967|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
219503695|NCT05587101|DIAGNOSTIC_TEST|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
219201004|NCT06161324|OTHER|PFM exercises program through the Mobile app in cooperation with the superficial sensor|"The mobile app will offer a personalized progressive protocol to the user based on his needs, via 12 levels of games(from the easiest to the hardest).The cooperating PFM superficial sensor will indicate the activity of the PFMs during the contraction.Νο face-to-face meetings will be incurred between participants and therapist.~Participants will follow a program for 12 weeks(3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).Endurance training will involve slow velocity contraction and speed training will involve quick (i.e.1 sec duration) strong contractions.Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)."
219201005|NCT06161324|OTHER|Face-to face PFM exercises program in Healthcare environment|"The therapy will include face-to-face meetings weekly, regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc).~Participants will follow a personalized progressive PFM exercise program for 12 weeks (3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).The endurance training will involve slow velocity contraction and the speed training will involve quick (i.e.1 sec duration) strong contractions. The Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks.It will be followed the order of supine, side, prone, quadruped support, sitting and standing position"
219201006|NCT06161324|OTHER|PFM exercises program via home-leaflet(without suprevision)|"The participants of the CG will be advised to follow a personalized PFM exercise program at home based on their 1st meeting assessment. They will receive a comprehensive leaflet, with instructions and images about the PFM exercises at home. The PFM exercise program will last 12 weeks (3 times weekly, 1-5 sessions daily), without meetings, guidance and supervision by the physiotherapist. Similarly to the other two intervention groups, the program will contain endurance training (slow velocity contraction), speed training (quick contractions), Knack maneuver training (pre-contraction before coughing), and changing positions every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)"
219201007|NCT04157517|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
219201008|NCT04157517|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
219201009|NCT06694311|DEVICE|CPAP|"12 cmH2O for 48 hours (at least 10 hours of therapy per day). Nasobucal interface will be the preferred route with complete facial mask being also an acceptable device. If needed, therapy breaks will be delivered with HFNO at 50 L/min.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although CPAP will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
219201010|NCT06694311|DEVICE|HFNO 50 L/min|"HFNO 50 L/min for 48 hours. Therapy breaks with oxygen facemask will be allowed as per clinician decision but the protocol will advise against this practice.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although HFNO will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
219606409|NCT03098160|DRUG|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
219606410|NCT03098160|DRUG|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
219606411|NCT03715920|DEVICE|Electrical currents|The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
219606412|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
219606413|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
219606414|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
219606415|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
219503696|NCT05587101|DIAGNOSTIC_TEST|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
218882791|NCT06576206|OTHER|Bin therapy and finger gnosia|Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
218882792|NCT06576206|OTHER|conventional therapy|schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
219503697|NCT05587101|DIAGNOSTIC_TEST|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
219503698|NCT03312725|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
219503699|NCT01001663|DEVICE|FemoSeal®|Closure device for femoral artery access closure
219503700|NCT01001663|OTHER|Manual compression|Conventional manual compression
219606416|NCT00560391|DRUG|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
218882793|NCT06976294|OTHER|Cognitive Behavioral Approach-Based Psychoeducation|The 'Socio-Demographic Characteristics Form', the 'Post-Traumatic Growth Inventory', the 'Psychological Resilience Scale for Adults', and the 'Event-Related Rumination Inventory' will be administered to individuals in both the intervention and control groups. No intervention will be applied to the control group. For the intervention group, psychoeducation groups based on the cognitive behavioral approach will be formed for the primary caregivers. Eight face-to-face sessions, each lasting 60 to 90 minutes, will be conducted
218882794|NCT02450292|PROCEDURE|Bioabsorbable screw fixation|
218882795|NCT05107570|OTHER|Cold exposure|Cold air exposure (\~ 9°C, maximum 1 hour duration)
218882796|NCT02328534|BEHAVIORAL|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
218882797|NCT02328534|PROCEDURE|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
218882798|NCT02328534|PROCEDURE|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
218882799|NCT04867733|OTHER|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
218882800|NCT03700437|OTHER|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
219027984|NCT03659981|OTHER|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
218882801|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
218882802|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
218882803|NCT02291588|DRUG|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
218882804|NCT02291588|DRUG|Placebo|contains no active drug
218882805|NCT02152319|DEVICE|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
218882806|NCT02152319|PROCEDURE|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
218882807|NCT00500825|PROCEDURE|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
219027985|NCT02070835|DEVICE|autologous skin cell|autologous skin cell and skin graft
219027986|NCT02070835|PROCEDURE|skin graft|split-thickness skin graft
219503701|NCT01261325|DRUG|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
219503702|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
219503703|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
219606417|NCT05778201|BIOLOGICAL|Baby Drink group|1 packge (20 ml)/ day for 1 month
219606418|NCT02952469|DRUG|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
219503704|NCT01261325|DRUG|Antiepileptic drugs with market authorization available per country|
219503705|NCT03844568|DEVICE|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
218882808|NCT02602418|OTHER|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
218882809|NCT02602418|OTHER|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
218882810|NCT01005758|DRUG|cyclophosphamide|
218882811|NCT01005758|DRUG|cytarabine|
219503706|NCT01878656|DRUG|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
219503707|NCT01878656|DRUG|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
218882812|NCT01005758|DRUG|dexamethasone|
218882813|NCT01005758|DRUG|doxorubicin hydrochloride|
218882814|NCT01005758|DRUG|etoposide phosphate|
218882815|NCT01005758|DRUG|hydrocortisone sodium succinate|
218882816|NCT01005758|DRUG|imatinib mesylate|
218882817|NCT01005758|DRUG|mercaptopurine|
219503708|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
219606419|NCT05187104|BIOLOGICAL|Cultured retinal stem and progenitor cells|Cultured retinal stem and progenitor cells injected subretinally
219606420|NCT05187104|OTHER|Standard treatment according to the clinical protocols|Standard treatment of age-related macular degeneration according to the clinical protocols
218882818|NCT01005758|DRUG|methotrexate|
219606421|NCT02556801|BIOLOGICAL|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
218882819|NCT01005758|DRUG|methylprednisolone|
218882820|NCT01005758|DRUG|pegaspargase|
218882821|NCT01005758|DRUG|prednisolone|
218882822|NCT01005758|DRUG|prednisone|
218882823|NCT01005758|DRUG|vincristine sulfate|
218882824|NCT01005758|OTHER|laboratory biomarker analysis|
218882825|NCT01005758|RADIATION|radiation therapy|
218882826|NCT03940391|DRUG|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
218882827|NCT03940391|DRUG|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
218882828|NCT06131138|OTHER|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
218882829|NCT06131138|OTHER|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
218882830|NCT04146935|DRUG|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
218882831|NCT02683863|DRUG|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
218882832|NCT05189028|DRUG|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
218882833|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
218882834|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
218882835|NCT03207633|PROCEDURE|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
218882836|NCT04038567|BEHAVIORAL|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
218882837|NCT05846555|PROCEDURE|urologic surgery|surgery
218882838|NCT03828851|OTHER|Domiciliary care - Activities of Daily Living|Home-based ADL training.
219027987|NCT01680718|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
219027988|NCT01680718|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
219503709|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
219503710|NCT01017679|DRUG|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
219503711|NCT03718156|OTHER|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
219606422|NCT04826367|OTHER|Telerehabilitation-based relaxation exercise group (EG)|the participants in this group will perform the relaxation exercises thrice a week, for 6 weeks.
219606423|NCT03369769|OTHER|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
219503712|NCT00692926|BIOLOGICAL|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
219503713|NCT04521400|DRUG|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
219027989|NCT01680718|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
219027990|NCT01817933|BEHAVIORAL|physical therapy|
219503714|NCT04521400|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
219503715|NCT04521400|DRUG|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
219606424|NCT05217212|RADIATION|Radiochemotherapy|Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.
219606425|NCT02744872|DRUG|Felodipine|Felodipine 10 mg once daily or identical placebo
219606426|NCT02744872|DRUG|Placebo|Placebo
219606427|NCT01101412|DRUG|Edetate Calcium Disodium|Given through CVC or PVC.
219606428|NCT01101412|DRUG|Ethanol|Given through CVC or PVC
218882839|NCT03799276|OTHER|Opticare study|"Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
218882840|NCT00995995|DRUG|Rosiglitazone|Rosiglitazone
219027991|NCT00001758|DRUG|Abacavir|
219027992|NCT00001758|DRUG|Amprenavir|
219027993|NCT00001758|DRUG|Efavirenz|
219027994|NCT03942354|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
218882841|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
218882842|NCT02128880|BEHAVIORAL|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
218882843|NCT02128880|BEHAVIORAL|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
218882844|NCT05138315|DEVICE|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
218882845|NCT04590716|OTHER|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
219027995|NCT03942354|DRUG|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
219027996|NCT03942354|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
219027997|NCT03942354|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
219027998|NCT03942354|DRUG|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
219027999|NCT03942354|DRUG|Directly observed therapy (DOT)|Standard therapy
219028000|NCT03659916|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT
219503716|NCT02725970|OTHER|survey|Cross-sectional survey
219503717|NCT01609660|DIETARY_SUPPLEMENT|Saccharomyces boulardii|100mg daily for seven days prior to surgery
219503718|NCT06479304|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
219503719|NCT06479304|DRUG|Prednisone tablet|Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
219503720|NCT03348215|OTHER|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
219503721|NCT04800445|DIAGNOSTIC_TEST|Salivary CRP|Salivary C reactive protein in neonatal sepsis
219503722|NCT00728559|DRUG|bupivacain 0.5%|trocar site injection
219503723|NCT01742325|BEHAVIORAL|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
219606429|NCT01101412|DRUG|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
219606430|NCT01101412|OTHER|Hypertonic Saline|Given through CVC or PVC
219606431|NCT00580450|DRUG|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
219606432|NCT03997812|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
219606433|NCT03997812|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
219606434|NCT02287714|PROCEDURE|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
219503724|NCT01548950|DRUG|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
219503725|NCT00249457|BEHAVIORAL|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
219503726|NCT05642559|OTHER|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
219503727|NCT05682794|PROCEDURE|transanal total mesorectal excision|transanal TME
218882846|NCT01303926|DRUG|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
218882847|NCT01303926|DRUG|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
218882848|NCT02816229|DEVICE|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
218882849|NCT03585049|OTHER|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
219503728|NCT05723627|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
219503729|NCT05723627|DRUG|Propofol|Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
218882850|NCT00302913|DRUG|Adjustment of clopidogrel dose|
218882851|NCT00336414|DRUG|cyclophosphamide-prednisone-azathioprine|
218882852|NCT03057652|DEVICE|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
218882853|NCT03057652|DEVICE|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
218882854|NCT03057652|DEVICE|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
219503730|NCT00468923|DRUG|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
219503731|NCT00468923|DRUG|Rosuvastatin|Rosuvastatin 10 mg once daily
219503732|NCT01815411|DIETARY_SUPPLEMENT|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
219606435|NCT02287714|PROCEDURE|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
218882855|NCT02425514|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
219028001|NCT00657007|BIOLOGICAL|belimumab|"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
219606436|NCT03198338|DRUG|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
219606437|NCT03198338|DRUG|Normal Saline|0.9% Normal Saline
219503733|NCT00194818|DRUG|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
219503734|NCT03357432|OTHER|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
219503735|NCT00776633|DRUG|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
219606438|NCT03198338|DEVICE|Ultrasound|Ultrasound guided TAP block
218882856|NCT02425514|DEVICE|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
218882857|NCT05191108|BEHAVIORAL|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
219503736|NCT00776633|DRUG|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
219503737|NCT00776633|DRUG|oral anticoagulation|
219503738|NCT03564899|BEHAVIORAL|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
219503739|NCT03564899|BEHAVIORAL|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
219503740|NCT02524106|DRUG|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
219503741|NCT02524106|DRUG|Placebo|placebo
219503742|NCT02799316|OTHER|HBV core antibodies testing. • Real time PCR testing.|"* HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies."
219503743|NCT03853083|DEVICE|Hypoxi Equipment|Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
219503744|NCT03853083|DEVICE|Recumbent Bicycle|Recumbent bike is a piece of exercise equipment used as the comparison group
219503745|NCT00293969|DRUG|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
219503746|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
219503747|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
219503748|NCT03721848|BEHAVIORAL|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
218882858|NCT02464514|OTHER|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
219503749|NCT03721848|BEHAVIORAL|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
219503750|NCT03469271|DRUG|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
218882859|NCT02464514|OTHER|High fat meal|58% fat, 17% protein, and 25% carbohydrate
218882860|NCT03846284|DRUG|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
218882861|NCT03846284|DRUG|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
218882862|NCT03846284|DRUG|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~\+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
218882863|NCT02564224|PROCEDURE|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
218882864|NCT02564224|PROCEDURE|Conventional Wound Closure|Procedure: Conventional Wound Closure
218882865|NCT02564224|DEVICE|prolene|
218882866|NCT02253784|DRUG|Dexamethasone|
218882867|NCT02253784|DRUG|Bupivacaine|
219028002|NCT00657007|BIOLOGICAL|belimumab|"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
219028003|NCT00657007|BIOLOGICAL|belimumab|"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
219028004|NCT00657007|BIOLOGICAL|belimumab|"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
219028005|NCT00657007|BIOLOGICAL|Placebo|"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
219028006|NCT04684381|DRUG|L-glutamine|Pharmacokinetic study
219503751|NCT03469271|OTHER|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
219503752|NCT03469271|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
219503753|NCT03469271|OTHER|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
219503754|NCT03469271|DEVICE|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
219503755|NCT02382978|OTHER|nurse-provided well child visit|
218882868|NCT02027948|OTHER|nutritional and functional assessments|"Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention."
218882869|NCT02502825|OTHER|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
218882870|NCT02502825|DEVICE|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
218882871|NCT02502825|DEVICE|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
219028007|NCT00878709|DRUG|neratinib|
219028008|NCT00878709|OTHER|placebo|
219028009|NCT00123591|DRUG|activated recombinant human factor VII|
219028010|NCT01347541|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
219028011|NCT01347541|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
219028012|NCT01347541|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
219028013|NCT01347541|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
219028014|NCT03886220|DRUG|Elagolix|Oral; Tablet
219028015|NCT03886220|DRUG|Placebo|Oral; Tablet
219028016|NCT02146547|DRUG|Aripiprazole|Administration in once-a-day schedule without regard to meals.
219028017|NCT02146547|DRUG|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
219201011|NCT06693999|DEVICE|Google-Pixel Watch 3|The participant will wear Google-Pixel Watch 3 for at least 10 hours during the 3-month intervention and will receive goal reminders and motivational and coping messages through those watches. At baseline and after 3-months intervention, demographics (standard questionnaire pertaining to subjects' age, sex, race, education and income), technology literacy (eHealth Literacy Scale pertaining to subjects' ability to perform a number of tasks such as turning on the device, using internet and communication), and wearables affinity (pertains to how the subject currently uses wearable in their daily living tasks) will be measured.
219201012|NCT06693999|BEHAVIORAL|Exercise prompts|The participants will receive goal reminders.
219201013|NCT06629701|DEVICE|External support for vein grafts|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
218882872|NCT02913495|DRUG|Vaginal Progesterone|
218882873|NCT02913495|DRUG|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
218882874|NCT00439062|DRUG|Roxithromycin|
218882875|NCT02567019|OTHER|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
219028018|NCT02146547|DRUG|Paliperidone|Administration once a day orally standardised in relation to food intake.
219028019|NCT02146547|DRUG|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
219028020|NCT00532584|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
219201014|NCT06694675|DRUG|Sevoflurane (Volatile Anesthetic)|Sevoflurane 1%\~3.5%
219503756|NCT01174641|OTHER|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
219503757|NCT01174641|OTHER|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
219503758|NCT03841721|DRUG|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
219503759|NCT06458686|DRUG|Vit D|Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
219503760|NCT06458686|OTHER|Placebo|Placebo is a non drug formulation
218882876|NCT03779581|OTHER|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
218882877|NCT03779581|DEVICE|orthotic devices|the orthotic devices designed to correct the scoliosis curve
218882878|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
218882879|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
218882880|NCT03851432|DEVICE|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
218882881|NCT04382222|PROCEDURE|prenatal ultrasound|prenatal cardiac ultrasound
218882882|NCT06371521|DIETARY_SUPPLEMENT|Sportlegs|Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).
218882883|NCT06371521|DIETARY_SUPPLEMENT|Placebo|Empty Capsules to serve as a placebo control
219201015|NCT06694675|DRUG|propofol|Propofol 9\~15mg/kg/h
218882884|NCT04429698|DIAGNOSTIC_TEST|Point of care ultrasonography|Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
219201016|NCT06695650|OTHER|Mandala Coloring|Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period
219503761|NCT04976868|DRUG|Pimecrolimus 1% Top Cream|Elidel® as prescribed within routine clinical practice
219503762|NCT02761369|DEVICE|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
219503763|NCT00990561|DRUG|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
218882885|NCT05708339|OTHER|virtually fabricated ear prosthesis|virtually designed ear prosthesis
218882886|NCT05708339|OTHER|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
218882887|NCT02493231|DRUG|Nefopam|
218882888|NCT02493231|DRUG|Ketamine|
218882889|NCT02493231|DRUG|Saline|
218882890|NCT05191875|DRUG|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"
218882891|NCT05191875|DRUG|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
218882892|NCT03731247|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
218882893|NCT03731247|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
218882894|NCT03368846|DRUG|Varlitinib|\[14C\]-Varlitinib
218882895|NCT00714311|BEHAVIORAL|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
218882896|NCT00714311|BEHAVIORAL|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
218882897|NCT00058682|DRUG|Anidulafungin|
218882898|NCT03052816|DRUG|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
218882899|NCT03052816|DRUG|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
218882900|NCT00820417|DRUG|Cetuximab/Gefitinib combination and/or monotherapy|
218882901|NCT01533142|PROCEDURE|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
218882902|NCT01533142|PROCEDURE|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
218882903|NCT00820716|OTHER|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
218882904|NCT06049030|DRUG|HS-10516|Oral HIF-2α inhibitor
218882905|NCT03803436|PROCEDURE|Liver transplant|Liver transplant from cadaveric donors
218882906|NCT03803436|DRUG|Chemotherapy|mFOLFOX
218882907|NCT03803436|DRUG|Chemotherapy|Panitumumab
218882908|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
219503764|NCT00990561|DRUG|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
219503765|NCT05494554|DEVICE|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
218882909|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
219503766|NCT06530485|DIETARY_SUPPLEMENT|Microbiota-directed food|MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.
218882910|NCT01278797|DRUG|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
219503767|NCT06530485|DIETARY_SUPPLEMENT|Khichuri|Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.
218882911|NCT01278797|DRUG|Amlodipine Monocomponent|Active Comparator
218882912|NCT00963794|OTHER|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
218882913|NCT02259894|DRUG|BIRT 2584 XX|
219503768|NCT04249206|PROCEDURE|Root Canal Treatment|
218882914|NCT02259894|DRUG|Placebo|
218882915|NCT06180707|DRUG|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
218882916|NCT06180707|DRUG|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
219503769|NCT03876756|OTHER|postpartum acute urinary retention|Collection of risk factors
218882917|NCT06180707|OTHER|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
219028021|NCT02146573|BEHAVIORAL|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
219503770|NCT03876756|OTHER|no postpartum acute urinary retention|Collection of risk factors
219503771|NCT03920436|DIETARY_SUPPLEMENT|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
219503772|NCT03920436|DIETARY_SUPPLEMENT|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
218882918|NCT03073993|PROCEDURE|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
219201017|NCT06694662|DIETARY_SUPPLEMENT|PKU EASY Microtabs Plus|"PKU EASY Microtabs Plus is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in patients from 3 years of age upwards.~PKU EASY Microtabs Plus is a microtablet form, slow-release, phenylalanine-free protein substitute containing a blend of essential and non-essential amino acids, vitamins, minerals and trace elements."
219201018|NCT06691750|DEVICE|Barbed suture|Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.
219201019|NCT06691750|DEVICE|Conventional smooth suture|Size 1 smooth multifilament absorbable polyglactin suture.
219503773|NCT01572961|DRUG|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
218882919|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
218882920|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
219503774|NCT01572961|DRUG|Placebo|
219503775|NCT05455970|OTHER|Rhythmic auditory stimulation (RAS)|A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
219503776|NCT02778178|DRUG|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
219503777|NCT02778178|DRUG|Placebo|20 mL saline 0.9%, per side
219503778|NCT02778178|DEVICE|ultrasound|
219503779|NCT06359678|DEVICE|NorthStar|Throughout the real-time MRI-guided ablation procedure, the operator will assess the precision of the NorthStar 3D navigation software. Before commencing the actual ablation, the operator will confirm the alignment of the 3D anatomical shell, generated in NorthStar through specific electrical signals. Post the ablation procedure, a secondary alignment verification will be conducted to detect any potential drift or shift.
219606439|NCT02392585|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
219503780|NCT04076306|OTHER|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
219503781|NCT03474705|DEVICE|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
219503782|NCT03958981|DRUG|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
218882921|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
219503783|NCT03958981|DRUG|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
219503784|NCT02826603|DRUG|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
219503785|NCT02826603|DRUG|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
219503786|NCT04846556|OTHER|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
219503787|NCT02531230|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
219503788|NCT01269983|OTHER|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
219503789|NCT03221946|DRUG|Diclofenac Sodium|tablet of 50mg,
219503790|NCT03221946|DRUG|Diclofenac sodium|Transdermal patch 100 mg
219503791|NCT03221946|DRUG|Diclofenac|intra muscular injection 100mg
219503792|NCT03654209|DEVICE|Argon Plasma Coagulation|APC will be applied to the perimeter of the resection site
219503793|NCT03654209|DEVICE|Snare Tip Soft Coagulation|STSC will be applied to the perimeter of the resection site
218882922|NCT02982941|DRUG|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
219503794|NCT03681106|DEVICE|Kinesio Tex|Kinesio Tex tape on the operated limb
219606440|NCT02392585|PROCEDURE|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
219606441|NCT01751256|DEVICE|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
218882923|NCT04219644|DEVICE|Breatheasy device|
218882924|NCT03918525|OTHER|Sindhi families|It is an observational study and no intervention is involved
218882925|NCT02071069|DRUG|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
218882926|NCT02071069|DRUG|irinotecan|180 mg/m2 IV every 2 weeks
218882927|NCT02071069|DRUG|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
219503795|NCT01337050|DRUG|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
219503796|NCT00003102|BIOLOGICAL|Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)|cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.
219503797|NCT00583596|DEVICE|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
219503798|NCT00583596|OTHER|Objective Performance Criteria|Compare results of device closure to objective performance criteria
219503799|NCT01955603|DRUG|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
218882928|NCT03817268|DRUG|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
219503800|NCT01955603|DRUG|placebo|Placebo administered corresponding to NNC0215-0384 treatment
219503801|NCT04939974|DIETARY_SUPPLEMENT|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
219503802|NCT06194097|PROCEDURE|adenoidectomy versus endoscopic sinus surgery with adenoidectomy|adenoidectomy versus endoscopic sinus surgery
219503803|NCT03502421|DRUG|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
219503804|NCT00656019|DRUG|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
219503805|NCT00054119|DRUG|Cositecan|Given IV
219606442|NCT03668808|DRUG|Insulin Degludec|Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
218882929|NCT01931163|DRUG|Everolimus|
219503806|NCT00054119|OTHER|Pharmacological Study|Correlative studies
219503807|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
219606443|NCT03668808|DRUG|Insulin Glargine|Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
219503808|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
219606444|NCT03668808|DEVICE|TRESIBA® FLEXTOUCH®|Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
219606445|NCT03668808|DEVICE|LANTUS® SOLOSTAR® INSULIN PEN|Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
218882930|NCT02464722|DRUG|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
218882931|NCT02464722|DRUG|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
218882932|NCT02464722|DRUG|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
218882933|NCT02464722|DRUG|Propofol|Anesthesia was induced with propofol 2 mg kg-1
218882934|NCT02464722|DRUG|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
218882935|NCT04794023|DEVICE|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
218882936|NCT01441323|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
219503809|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
219028022|NCT02146573|BEHAVIORAL|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action"
219201020|NCT06630143|OTHER|Combined Virtual and Clinical Simulation|Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
219201021|NCT06630143|OTHER|virtual simulation|Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
219201022|NCT06630611|BIOLOGICAL|NMA-LD regimen|The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
219503810|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
219503811|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
219503812|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
219503813|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
219503814|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
219503815|NCT00787670|OTHER|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
219503816|NCT00787670|PROCEDURE|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
219503817|NCT00787670|OTHER|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
219503818|NCT01503242|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219503819|NCT01503242|DRUG|Cyclosporine|Given PO
219503820|NCT01503242|DRUG|Fludarabine Phosphate|Given IV
219503821|NCT01503242|DRUG|Mycophenolate Mofetil|Given IV or PO
219503822|NCT01503242|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219503823|NCT01503242|RADIATION|Total-Body Irradiation|Undergo TBI
219503824|NCT01503242|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
219503825|NCT04060472|DRUG|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
218882937|NCT01441323|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
219503826|NCT02972970|DEVICE|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
219503827|NCT00096486|DRUG|everolimus|
219503828|NCT00096486|DRUG|gefitinib|
219503829|NCT02808806|OTHER|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
219028023|NCT00768300|DRUG|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
219503830|NCT06320899|DEVICE|SpineShape System IV straight rod elastic|Implantation of SpineShape System IV straight rod elastic
219503831|NCT06320899|DEVICE|SpineShape System IV straight rod medium|Implantation of SpineShape System IV straight rod medium (mid-flex)
219606446|NCT06252883|OTHER|Serial bedside video call communication|Bedside video call with audio features, given to NICU parent/guardian 2-3 days a week for an 8-week period or till infant is discharged, whichever comes first.
218882938|NCT00206713|DRUG|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
218882939|NCT00206713|DRUG|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
218882940|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
218882941|NCT01940627|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
218882942|NCT01940627|DIETARY_SUPPLEMENT|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
218882943|NCT01726985|OTHER|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge"
219028024|NCT00768300|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
219503832|NCT06320899|DEVICE|SpineShape System IV straight rod stiff|Implantation of SpineShape System IV straight rod stiff (low-flex)
219503833|NCT01645228|RADIATION|coronary calcium score measurement|
219503834|NCT01645228|BIOLOGICAL|high sensitivity C reactive protein measurement|
219503835|NCT01645228|PROCEDURE|ankle brachial index measurement|
219503836|NCT01306461|DRUG|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
219503837|NCT01306461|DRUG|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
219503838|NCT04528628|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
219503839|NCT04528628|DRUG|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
219503840|NCT04528628|COMBINATION_PRODUCT|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
219503841|NCT03558997|DRUG|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
219503842|NCT03558997|DRUG|Timothy Grass SCIT|Timothy grass extract was administered SC.
219503843|NCT03558997|DRUG|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
219503844|NCT03558997|DRUG|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
219028025|NCT05821842|DEVICE|Sonu|Acoustic energy delivery
219028026|NCT04002596|DEVICE|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
219028027|NCT03332576|BIOLOGICAL|DPX-Survivac|SubQ injection
219028028|NCT03332576|BIOLOGICAL|DPX-Survivac(Aqueous)|SubQ injection
219028029|NCT03332576|DRUG|Cyclophosphamide|PO BID
219028030|NCT00003814|DRUG|eflornithine|
219028031|NCT02664909|DRUG|Tranexamic Acid|
219028032|NCT02664909|DRUG|Placebo (saline)|
219503845|NCT04101136|DRUG|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
218882944|NCT04465292|DRUG|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
219503846|NCT00174759|DRUG|Clopidogrel|
219503847|NCT02589769|OTHER|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
219503848|NCT02589769|OTHER|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
219503849|NCT06304870|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
219503850|NCT06304870|DRUG|Lidocaine|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
219503851|NCT06304870|PROCEDURE|Injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process.
219503852|NCT00934037|PROCEDURE|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
219606447|NCT05274178|DEVICE|"Audeo P hearing aid labeled as Prescriptive"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant."
219606448|NCT05274178|DEVICE|"Audeo P hearing aid labeled as OTC"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant."
218882945|NCT02146625|DRUG|CJ-40002|
218882946|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
218882947|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
218882948|NCT05367323|DEVICE|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
219028033|NCT00495833|BEHAVIORAL|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
219028034|NCT00495833|BEHAVIORAL|Promotional gift|half of participants who go to a fire station will receive a gift card.
219028035|NCT01599871|DRUG|theophylline|theophylline 100 mg, twice at day
219028036|NCT01599871|OTHER|placebo|Placebo
218882949|NCT00197925|BIOLOGICAL|Onco-peptide loaded autologous dendritic cells|
218882950|NCT00208351|DEVICE|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
219028037|NCT00983151|DRUG|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
219028038|NCT03518333|DEVICE|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
219028039|NCT02541747|BEHAVIORAL|massage|massage
219028040|NCT04380259|BEHAVIORAL|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
219606449|NCT04362670|DRUG|OTX-CSI|OTX-CSI intracanalicular insert
219606450|NCT04362670|OTHER|Placebo Vehicle|Hydrogel Vehicle intracanalicular insert
219606451|NCT00485511|DRUG|Hydroxyurea|
219606452|NCT06081478|DRUG|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
219606453|NCT01133730|DRUG|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
219606454|NCT01133730|DRUG|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
219606455|NCT03203967|PROCEDURE|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
219606456|NCT03203967|PROCEDURE|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
218882951|NCT00208351|DEVICE|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
218882952|NCT00208351|DEVICE|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
218882953|NCT00208351|DEVICE|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
218882954|NCT04375514|DRUG|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
218882955|NCT04375514|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
218882956|NCT04193592|DRUG|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
218882957|NCT03869606|DEVICE|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
218882958|NCT02215824|DRUG|BIWH 3|
219028041|NCT04011501|PROCEDURE|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
219028042|NCT01057017|BIOLOGICAL|intervention|
219028043|NCT00064207|DRUG|gemcitabine hydrochloride|
219028044|NCT00064207|PROCEDURE|adjuvant therapy|
219028045|NCT00064207|RADIATION|radiation therapy|
219028046|NCT03475966|OTHER|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
219028047|NCT03475966|OTHER|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
219028048|NCT03475966|BEHAVIORAL|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
219028049|NCT00888095|PROCEDURE|deep brain stimulation|electrode implantation in either STN or cZI
219028050|NCT02694406|DEVICE|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
219028051|NCT03822208|BIOLOGICAL|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
219028052|NCT03822208|OTHER|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
219028053|NCT02287064|DRUG|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
219028054|NCT00263068|DRUG|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
219201023|NCT06630611|BIOLOGICAL|Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion|On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
219503853|NCT00934037|OTHER|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
219503854|NCT02033876|DRUG|Ursodiol|
219503855|NCT03780933|DIETARY_SUPPLEMENT|vitamin c|vitamin c IV 10 G
219503856|NCT02711189|DRUG|Oxytocin|Oxytocin nasal spray given in dose 80
219503857|NCT02711189|OTHER|Placebo|
219503858|NCT01569503|DEVICE|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
219503859|NCT04779411|OTHER|Weekly Food Frequency Questionnaire|A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.
219503860|NCT04779411|OTHER|Monthly Food Frequency Questionnaire|A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
218882959|NCT02215824|DRUG|Placebo|
218882960|NCT01778101|DRUG|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
218882961|NCT01736618|DEVICE|S-ICD System|
218882962|NCT02634827|DRUG|Decitabine|Given IV
218882963|NCT02634827|OTHER|Laboratory Biomarker Analysis|Correlative studies
218882964|NCT02634827|DRUG|Midostaurin|Given PO
218882965|NCT04046731|DIAGNOSTIC_TEST|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
219503861|NCT04779411|OTHER|24-Hour Diet Recall|the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.
219503862|NCT04779411|OTHER|Electronic Device Use Questionnaire|1\. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.
219503863|NCT04779411|OTHER|24-Hour Electronic Device Use Diary|Participants asked to record their electronic device use in hours and minutes over 24 hours.
219503864|NCT03793075|DRUG|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
219503865|NCT03793075|DRUG|Propofol|propofol 17 mcg /kg/min
219503866|NCT02230085|OTHER|Administration of the questionnaire and monitoring of CPAP adherence|
219503867|NCT02144493|OTHER|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
218882966|NCT03291860|PROCEDURE|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
219503868|NCT02144493|OTHER|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
219503869|NCT01015911|DRUG|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
219503870|NCT01986790|BEHAVIORAL|Plain Language|
219503871|NCT01986790|BEHAVIORAL|Plain Language + Visuals|
219503872|NCT01986790|BEHAVIORAL|Plain Language + Narratives|
219606457|NCT03203967|PROCEDURE|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
219606458|NCT03203967|DRUG|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
218882967|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
218882968|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
218882969|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
218882970|NCT03637517|DRUG|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
218882971|NCT03409341|OTHER|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
218882972|NCT00819117|DEVICE|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
218882973|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
218882974|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
218882975|NCT03975569|OTHER|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
218882976|NCT00400569|DRUG|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
218882977|NCT03028779|PROCEDURE|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
219201024|NCT06630611|BIOLOGICAL|High dose IL-2|"Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration."
219503873|NCT01968616|DRUG|Ranibizumab, 0.5mg, Intravitreal|
219503874|NCT01360632|DRUG|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
219503875|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
219503876|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
219503877|NCT01491490|DRUG|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
218882978|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
219503878|NCT01491490|DRUG|Placebo|Capsules taken once a day for 6 weeks
219503879|NCT00137085|DRUG|ketamine|
219503880|NCT00897533|GENETIC|gene mapping|
219503881|NCT00897533|GENETIC|polymorphism analysis|
219503882|NCT00897533|OTHER|diagnostic laboratory biomarker analysis|
219503883|NCT00897533|OTHER|immunohistochemistry staining method|
219503884|NCT03479385|BEHAVIORAL|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
219503885|NCT03479385|BEHAVIORAL|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
219503886|NCT00196222|PROCEDURE|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
219503887|NCT00196222|PROCEDURE|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
219503888|NCT00280774|DRUG|Memantine|
219503889|NCT02672774|PROCEDURE|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
219503890|NCT02672774|DEVICE|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
219606459|NCT01404546|OTHER|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
219606460|NCT01404546|OTHER|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
219606461|NCT06582004|DIETARY_SUPPLEMENT|CH2 vaginal gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
218882979|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
218882980|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
218882981|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
219028055|NCT02474108|PROCEDURE|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
219028056|NCT02474108|DEVICE|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
219028057|NCT00624052|DRUG|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
219028058|NCT00624052|DRUG|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
219028059|NCT02404285|DRUG|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
219028060|NCT02404285|DRUG|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
218882982|NCT02474953|DIETARY_SUPPLEMENT|Proprietary Curcumin Formulation|
218882983|NCT02474953|DIETARY_SUPPLEMENT|Unformulated Comparator Curcumin Product|
218882984|NCT02919527|OTHER|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
218882985|NCT02919527|OTHER|Stretching|Static Stretching performed at the anterior thigh
219028061|NCT02294344|OTHER|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
219201025|NCT06630611|BIOLOGICAL|IL-2 analog|"Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg."
219606462|NCT06582004|DIETARY_SUPPLEMENT|Placebo hyaluronic acid gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
219606463|NCT04855968|OTHER|In addition to standard post-op medication patient will have access to the head space meditation application.|Patients will receive access to head space meditation application in addition to standard pain medication post surgery.
219606464|NCT04855968|OTHER|Patients will take standard post-op pain medication|Standard post-op pain medication
219606465|NCT02839772|OTHER|Current skin care regimen plus 2% glycerine added to soaking water|
219606466|NCT02839772|OTHER|Current skin care regimen|
219606467|NCT03359655|DRUG|Misoprostol|Rectal administration 2 jours before the procedure
218882986|NCT05002179|DRUG|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
218882987|NCT02113358|DRUG|Intravenous colloid bolus with Voluven|
219503891|NCT03268031|DIAGNOSTIC_TEST|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
219503892|NCT04729218|BEHAVIORAL|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
219503893|NCT03101423|DRUG|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
219503894|NCT03101423|DRUG|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
219503895|NCT01920373|DRUG|Group A (corticosteroid injection group)|
219503896|NCT01920373|BIOLOGICAL|Group B (platelet rich plasma injection group)|
219503897|NCT02173301|DRUG|XP23829 400 mg QD|active dose 1
219503898|NCT02173301|DRUG|XP 23829 800 mg QD|active dose 2
219503899|NCT02173301|DRUG|XP23829 400 mg BID|active dose 3
219503900|NCT02173301|DRUG|Placebo|control
219503901|NCT00481962|DRUG|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
219503902|NCT02340156|GENETIC|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
219503903|NCT02340156|DRUG|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
219503904|NCT05715606|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
219503905|NCT03016078|DEVICE|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
219503906|NCT04504929|DEVICE|Sham tape|Use sham type on the pitching shoulder
219503907|NCT04504929|DEVICE|Dynamic tape|Use dynamic type on the pitching shoulder for supporting internal rotation
219503908|NCT00681408|DRUG|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
219503909|NCT00681408|DRUG|Placebo|Fish oil placebo pills
219503910|NCT06208761|OTHER|Triphala capsule supplementation and high-intensity interval training|Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
219503911|NCT02885935|OTHER|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
219503912|NCT02885935|OTHER|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
219028062|NCT02294344|DRUG|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
219028063|NCT02576288|DRUG|Sitagliptin|anti-inflammatory properties
219028064|NCT02576288|DRUG|Placebo|No anti-inflammatory properties
219503913|NCT06702540|DEVICE|Biosensor chip|An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
219503914|NCT00764998|BIOLOGICAL|Fluviral|
219503915|NCT03608072|DRUG|BI 690517|3 sequential dose groups
219606468|NCT03359655|DRUG|Hyoscine butyl bromide|Rectal administration 2 jours before the procedure
219606469|NCT00004981|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
219606470|NCT00004981|DRUG|Lamivudine/Zidovudine|
219606471|NCT00004981|DRUG|Abacavir sulfate|
219503916|NCT03608072|DRUG|Placebo|3 sequential dose groups
219503917|NCT00405977|DRUG|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
219503918|NCT00405977|DRUG|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
219503919|NCT01574989|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
219503920|NCT01574989|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35\^2 electrodes.
219503921|NCT04862390|DEVICE|Continuous glucose monitoring|Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan
219503922|NCT03057587|DEVICE|NIRS Monitoring|NIRS data will be collected throughout the surgery
219503923|NCT04921033|DIETARY_SUPPLEMENT|EEN (Nestle Modulen®)|35kcal/kg/day for every patient
219606472|NCT00897650|GENETIC|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
219606473|NCT00897650|GENETIC|Protein expression analysis|Lung tumor tissue will be collected.
219606474|NCT00897650|PROCEDURE|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
219606475|NCT00897650|PROCEDURE|Blood sample|Patients will be asked for a venous blood sample
218882988|NCT02714283|DRUG|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
218882989|NCT02714283|DRUG|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
218882990|NCT05192655|OTHER|Observation|Observation Study
218882991|NCT02790424|DEVICE|Imaging devices|technological adjustment tests
218882992|NCT03408964|OTHER|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
219503924|NCT04921033|DRUG|Standart of care|"* Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
219503925|NCT04177069|DIETARY_SUPPLEMENT|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
219503926|NCT05924711|OTHER|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
219503927|NCT06105281|BEHAVIORAL|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
219503928|NCT00325403|DRUG|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
219503929|NCT00325403|OTHER|Placebo|Placebo oral tablet twice daily
219503930|NCT05177757|OTHER|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
219606476|NCT02721342|DRUG|Ramipril, Irbesartan and Atorvastin|
219606477|NCT00302861|BIOLOGICAL|MyVax|
219606478|NCT00149461|BEHAVIORAL|Written Asthma Action Plan|
219606479|NCT03544723|DRUG|Ad-p53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
218882993|NCT00264264|PROCEDURE|Closure Device|
218882994|NCT00264264|PROCEDURE|Direct Compression|
218882995|NCT00006158|DRUG|Testosterone|
218882996|NCT01072253|PROCEDURE|eye amputation|
218882997|NCT00620113|DRUG|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
219028065|NCT03541265|DRUG|Exparel|long-acting Bupivacaine extended release liposome compound
218882998|NCT00620113|DIETARY_SUPPLEMENT|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
218882999|NCT00620113|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
218883000|NCT00620113|DRUG|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
219028066|NCT03541265|PROCEDURE|Adductor block protocol|Adductor block using Exparel
219606480|NCT04186312|BEHAVIORAL|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
219606481|NCT00554034|DRUG|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
219606482|NCT00280735|DRUG|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
219606483|NCT00280735|DRUG|docetaxel|75 mg/m² intravenously, once, every 3 weeks
219606484|NCT03524170|DRUG|Bintrafusp Alfa|Given IV
218883001|NCT02171741|DRUG|BIBW 2992|continuous daily dosing for 20 or 13 days
218883002|NCT02171741|DRUG|Docetaxel|single infusion on day 1
218883003|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
218883004|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
218883005|NCT05586841|DRUG|Dalpiciclib|Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
218883006|NCT05586841|DRUG|Chidamide|Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
218883007|NCT02929940|OTHER|No intervention|No Intervention, observational
218883008|NCT02065505|OTHER|Mat Pilates|
219606485|NCT03524170|RADIATION|Radiation Therapy|Undergo radiation therapy
219606486|NCT03648099|BEHAVIORAL|Labor dance|The dance group which involved pregnant women who performed the labor dance
219606487|NCT03648099|BEHAVIORAL|Music|The music group involving pregnant women who were exposed to music.
219503931|NCT02681965|BEHAVIORAL|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
219503932|NCT00465686|DEVICE|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
219503933|NCT00465686|DEVICE|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
219503934|NCT05644691|OTHER|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
219503935|NCT05644691|OTHER|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
219503936|NCT03596996|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
219503937|NCT03596996|DIETARY_SUPPLEMENT|Placebo|Placebo with identical appearance comparison intervention arm
219503938|NCT02739815|DRUG|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
219606488|NCT04975711|DRUG|HIP2105|Test drug
219606489|NCT04975711|DRUG|RLD2104|Reference drug
218883009|NCT02065505|OTHER|Water Pilates|
218883010|NCT02973516|DRUG|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
218883011|NCT02973516|DRUG|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
219503939|NCT02739815|DRUG|Tranexamic Acid|Tranexamic acid
218883012|NCT02268994|DRUG|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
218883013|NCT02268994|DRUG|Placebo|Matching placebo
219028067|NCT03541265|PROCEDURE|peri-articular injection protocol|peri-articular injection using Exparel
219503940|NCT05958277|DRUG|Vitamin B3|Vitamin B3 upto 16 mg/day
219503941|NCT05958277|DRUG|Vitamin B12|Vit B12 upto 250 mcg per day
219503942|NCT04371614|BEHAVIORAL|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
219503943|NCT02717975|PROCEDURE|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
219503944|NCT02717975|PROCEDURE|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
219606490|NCT00301197|BEHAVIORAL|Behavioral Skills Maintenance|
219606491|NCT00301197|BEHAVIORAL|Social Facilitation Maintenance|
219606492|NCT01895777|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
219606493|NCT01895777|DRUG|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
218883014|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
219503945|NCT00673985|OTHER|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
218883015|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
219028068|NCT04064918|OTHER|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
218883016|NCT03968263|DEVICE|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
219028069|NCT04064918|OTHER|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
219028070|NCT03190655|DEVICE|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
219028071|NCT03190655|DEVICE|Hydrogel|Hydrogel based wound dressing
219028072|NCT01438918|DRUG|SD-6010|200 mg tablets once a day for 2 years
219028073|NCT01438918|DRUG|SD-6010|50 mg tablets once a day for 2 years
219028074|NCT01438918|DRUG|Placebo|Placebo tablets once a day for 2 years
219028075|NCT03084887|BEHAVIORAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
219028076|NCT05409144|PROCEDURE|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
219028077|NCT05409144|DEVICE|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
219028078|NCT05409144|DEVICE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
219028079|NCT00281684|DRUG|SB705498 400 mg|SB705498 400 mg
219028080|NCT00281684|DRUG|SB705498 1000 mg|SB705498 1000 mg
219028081|NCT00281684|DRUG|Placebo|Placebo
219028082|NCT00281684|DRUG|Co-Codamol|Co-Codamol
219028083|NCT02685631|OTHER|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
219028084|NCT04022096|DRUG|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
219028085|NCT04022096|DRUG|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
219503946|NCT00673985|DEVICE|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
219503947|NCT03999437|DRUG|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
219503948|NCT03999437|DRUG|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
219503949|NCT03999437|DRUG|Vehicle Control|Topical liquid solution
218883017|NCT03968263|DEVICE|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
218883018|NCT03968263|DEVICE|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
218883019|NCT03968263|DEVICE|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
219028086|NCT05162209|DIETARY_SUPPLEMENT|Synbiotic|Oral sachet, for 12 weeks
219028087|NCT01297907|OTHER|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
219028088|NCT01297907|OTHER|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
219028089|NCT01297907|OTHER|Blood Test|Blood Tests (Eosinophil Count)
219503950|NCT00851032|OTHER|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
219503951|NCT03775356|OTHER|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
219503952|NCT00174733|DRUG|Ciclesonide (XRP1526)|
219503953|NCT04756609|PROCEDURE|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
218883020|NCT00211887|DRUG|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
219503954|NCT04756609|OTHER|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
219503955|NCT00359853|DRUG|Oral norfloxacin|
219503956|NCT05322564|OTHER|Standardized opiate prescription|The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
219503957|NCT03833596|DRUG|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
219503958|NCT03833596|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
219503959|NCT01093079|PROCEDURE|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
219503960|NCT01093079|PROCEDURE|Open partial nephrectomy|Open partial nephrectomy
219503961|NCT02477566|DRUG|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
219503962|NCT02477566|DRUG|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
218883021|NCT00211887|DRUG|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
218883022|NCT00211887|OTHER|placebo|an inactive substance
218883023|NCT05526339|DEVICE|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
218883024|NCT05526339|DEVICE|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
218883025|NCT00679874|OTHER|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
218883026|NCT05784519|DRUG|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
218883027|NCT02078128|DIETARY_SUPPLEMENT|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
218883028|NCT02078128|DRUG|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
219028090|NCT01297907|OTHER|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
219028091|NCT05422677|DRUG|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
219028092|NCT05228145|GENETIC|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
219503963|NCT00996866|DRUG|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
219503964|NCT00996866|DRUG|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
219503965|NCT04948190|BEHAVIORAL|Testing with medical detection dogs|Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
219503966|NCT03958279|DIAGNOSTIC_TEST|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
219503967|NCT03958279|DIAGNOSTIC_TEST|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
219503968|NCT01765556|DRUG|ketoconazole|multiple doses of ketoconazole in Period B and C
219503969|NCT01765556|DRUG|vemurafenib|single dose of vemurafenib in Period A and C
219503970|NCT06303583|DRUG|paclitaxel|paclitaxel, 50 mg/m2, QW\*5
219028093|NCT03056391|DRUG|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
219028094|NCT04177602|COMBINATION_PRODUCT|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
219503971|NCT06303583|DRUG|carboplatin|area under the curve of2mg/mL/min, QW\*5
219503972|NCT06303583|DRUG|tislelizumab|200mg Q3W, 2cycles
219503973|NCT06303583|RADIATION|radiotherapy|41.4Gy in 23 fractions
219503974|NCT02326428|DEVICE|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
219503975|NCT02326428|DRUG|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
219503976|NCT02596997|DRUG|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
219503977|NCT00892827|DRUG|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
219503978|NCT05117892|OTHER|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
219503979|NCT00112489|DRUG|carboplatin|
219503980|NCT00112489|DRUG|paclitaxel|
219503981|NCT04744844|PROCEDURE|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
219503982|NCT02979379|OTHER|Pain|
219503983|NCT04806984|OTHER|Participant outreach|Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
219503984|NCT02233179|DEVICE|Removable cast walker|Offloading device that can be removed by patients.
219503985|NCT02233179|DEVICE|Irremovable cast walker|Offloading device that cannot be removed by patients.
219503986|NCT02447536|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
219503987|NCT02447536|BIOLOGICAL|BCG-Russia-I (Serum Institute of India)|See above
218883029|NCT01979133|DRUG|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
219503988|NCT03646981|DEVICE|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
219503989|NCT00484523|PROCEDURE|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
219503990|NCT05291143|BEHAVIORAL|Short videos on blood pressure monitoring|Short videos on blood pressure monitoring
218883030|NCT01106235|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
218883031|NCT01106235|BIOLOGICAL|aldesleukin|Given SC
218883032|NCT01106235|DRUG|cyclophosphamide|Given IV
218883033|NCT01106235|PROCEDURE|biopsy|Optional correlative studies
218883034|NCT00486824|DRUG|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
218883035|NCT00486824|DRUG|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
218883036|NCT00285402|DRUG|AST-726 Low dose|
219028095|NCT04177602|COMBINATION_PRODUCT|Capecitabine based chemoradiation|Capecitabine based chemoradiation
219503991|NCT01200056|DRUG|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
218883037|NCT00285402|DRUG|AST-726 High dose|
218883038|NCT00285402|DRUG|AST-726 Placebo|
219028096|NCT01215370|OTHER|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
219028097|NCT01215370|OTHER|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
219028098|NCT01215370|OTHER|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
219028099|NCT01215370|OTHER|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
219503992|NCT01549288|BEHAVIORAL|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
219503993|NCT01549288|OTHER|no dietetic input|continuation of anti-epileptic medication without any dietetic input
219503994|NCT03418883|OTHER|Mirror therapy|
219503995|NCT00716183|BIOLOGICAL|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
219503996|NCT00716183|BIOLOGICAL|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
219503997|NCT00716183|BIOLOGICAL|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
219503998|NCT00716183|DRUG|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
219503999|NCT04156269|BIOLOGICAL|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219504000|NCT05218863|OTHER|No intervention|No intervention
219504001|NCT05751629|DRUG|Dostarlimab|Dostarlimab was administered.
219504002|NCT05751629|DRUG|Bevacizumab|Bevacizumab was administered.
219504003|NCT05751629|DRUG|Niraparib|Niraparib was administered.
219504004|NCT01136226|DRUG|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
219606494|NCT04010851|BEHAVIORAL|Peer co-led educational group|The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.
218883039|NCT00715767|BEHAVIORAL|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
219201026|NCT03788369|PROCEDURE|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
219201027|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
219504005|NCT02553239|DEVICE|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
219606495|NCT04010851|BEHAVIORAL|Comparator treatment as usual|Control group will receive treatment as usual, including different treatment options that can help alleviate the symptoms of ADHD and arm families with the tools needed to better handle problem behaviors when they arise. These interventions include: medication, psychotherapy, or a combination of these two approaches.
219606496|NCT05056116|DRUG|Surufatinib Toripalimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
219606497|NCT05487950|DRUG|Rivaroxaban group|Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
219606498|NCT03412721|PROCEDURE|Laser analgesic procedure|"Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s."
219606499|NCT03412721|PROCEDURE|Placebo analgesic procedure|Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
218883040|NCT00980759|RADIATION|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
219201028|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
219504006|NCT02971410|OTHER|Laboratory Biomarker Analysis|Correlative studies
219504007|NCT02971410|OTHER|Quality-of-Life Assessment|Ancillary studies
219504008|NCT02971410|DRUG|Simvastatin|Given PO
219504009|NCT02775890|BEHAVIORAL|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (\>85 grams).
219504010|NCT00287287|DRUG|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
219504011|NCT00225199|DRUG|Visanne (BAY86-5258, SH T00660AA)|orally once daily
219504012|NCT00225199|DRUG|Placebo|orally once daily
218883041|NCT00980759|RADIATION|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
219201029|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
219201030|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
219201031|NCT06873425|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
219201032|NCT06873425|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
219201033|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
219504013|NCT00908752|DRUG|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
219504014|NCT00908752|OTHER|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
219504015|NCT00908752|PROCEDURE|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
219504016|NCT05582733|OTHER|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
219504017|NCT05582733|OTHER|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
219504018|NCT02840656|OTHER|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
219504019|NCT02840656|OTHER|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
219504020|NCT03316859|DRUG|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
219504021|NCT03316859|OTHER|Placebo pill|Placebo pill administered 1 hour pre-operatively
219504022|NCT00035633|DRUG|Entecavir|
219504023|NCT00295854|DRUG|MN-001 BID|Eligible patients received 500 mg MN-001 bid
219504024|NCT00295854|DRUG|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
219504025|NCT00295854|DRUG|Placebo|Eligible patients received placebo
219504026|NCT00672620|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
219504027|NCT00672620|DRUG|Duloxetine|Duloxetine capsules
219504028|NCT00672620|DRUG|Placebo|Placebo-matching capsules
219504029|NCT00772577|DRUG|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
219504030|NCT00772577|DRUG|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
219504031|NCT05986877|DRUG|STSA-1201 Subcutaneous injection|Subcutaneous injection
219504032|NCT05986877|DRUG|Placebo|Subcutaneous injection
219504033|NCT03211156|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
219504034|NCT03211156|OTHER|Placebo|Placebo
219504035|NCT00048360|DRUG|Extended-release bupropion hydrochloride|
219504036|NCT02051127|OTHER|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
219504037|NCT05671289|DIAGNOSTIC_TEST|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
219504038|NCT02123927|DRUG|TAK-438|TAK-438 tablets
219504039|NCT02123927|DRUG|Placebo|TAK-438 placebo-matching tablets
219504040|NCT04577274|DIETARY_SUPPLEMENT|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
219504041|NCT04577274|DIETARY_SUPPLEMENT|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
219504042|NCT04577274|DIETARY_SUPPLEMENT|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
219504043|NCT05813782|BEHAVIORAL|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
219504044|NCT04893148|DRUG|IGlarLixi|Changing to iGlarLixi from insulin glargine
219504045|NCT04893148|DRUG|Dulaglutide|Add dulaglutide to insulin glargine
219504046|NCT04604665|OTHER|High frequency postural change|"Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs."
219504047|NCT04604665|OTHER|Conventional care|Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
219504048|NCT02598648|OTHER|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
219504049|NCT02598648|OTHER|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
219504050|NCT00448955|DRUG|ARD-0403|ARD-0403
218883042|NCT04241263|DEVICE|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
218883043|NCT04241263|DEVICE|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
218883044|NCT04316026|DEVICE|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
218883045|NCT00913926|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
219504051|NCT04435613|OTHER|protective mechanical ventilation strategies|1\. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
219504052|NCT01616303|DRUG|Carboplatin|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
219504053|NCT01616303|DRUG|Paclitaxel|Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
219504054|NCT01616303|BIOLOGICAL|oregovomab|oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
219504055|NCT04648579|DEVICE|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
219504056|NCT04648579|OTHER|Control|Hospital usual care regarding vital signs collection and TRR activation.
219504057|NCT04892459|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
219504058|NCT04892459|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
219504059|NCT03804099|DRUG|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
219504060|NCT01454700|DEVICE|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
219504061|NCT01454700|OTHER|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
219504062|NCT01338428|BEHAVIORAL|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
219504063|NCT01338428|BEHAVIORAL|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
219504064|NCT00815451|DIETARY_SUPPLEMENT|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
219504065|NCT00815451|DIETARY_SUPPLEMENT|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
219504066|NCT04568447|DEVICE|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
219504067|NCT00829413|DRUG|SonoVue®|SonoVue (2.4 mL)
219504068|NCT03104790|BIOLOGICAL|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
219504069|NCT02688894|OTHER|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
219504070|NCT00281294|DRUG|Fontolizumab|
219504071|NCT02203565|DRUG|Dakin's solution|Applied topically
219504072|NCT02203565|RADIATION|radiation therapy|Undergo radiation therapy
219504073|NCT02203565|OTHER|questionnaire administration|Ancillary studies
219504074|NCT02203565|OTHER|laboratory biomarker analysis|Optional correlative studies
218883046|NCT04085913|DRUG|Lidocaine Epinephrine|Preincision injection, as is current practice
218883047|NCT04085913|DRUG|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
218883048|NCT04085913|DRUG|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
218883049|NCT04866901|BEHAVIORAL|Slow-Paced Breathing (SPB)|see arm description
218883050|NCT04866901|BEHAVIORAL|Mindfulness (M)|see arm description
218883051|NCT04866901|BEHAVIORAL|Yogic Breathing (SPB+M)|see arm description
218883052|NCT01467830|PROCEDURE|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
218883053|NCT03521245|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
218883054|NCT03521245|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
218883055|NCT03521245|DRUG|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
218883056|NCT03521245|DRUG|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
218883057|NCT01012778|BEHAVIORAL|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
219504075|NCT06541366|OTHER|case-control study|physical examination and Survey Form
219504076|NCT00535522|DRUG|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
219504077|NCT00535522|DRUG|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
219504078|NCT01414465|DRUG|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
219504079|NCT02757586|GENETIC|shRNA|Using shRNA interfered the expression of the gene of CLL
219504080|NCT03487796|BEHAVIORAL|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
219606500|NCT06100523|BEHAVIORAL|Visioconsulation|Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)
219504081|NCT03487796|OTHER|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
219504082|NCT04871217|DIAGNOSTIC_TEST|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
219504083|NCT01831063|BEHAVIORAL|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
219201034|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
219504084|NCT04057781|PROCEDURE|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
219504085|NCT04057781|PROCEDURE|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
219504086|NCT04833712|RADIATION|Stereotactic Radioablation|Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
219504087|NCT02949323|OTHER|urinary stone|patients of group one have urinary stones
219504088|NCT02129023|DEVICE|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
219504089|NCT00030108|DRUG|ixabepilone|
219504090|NCT01871779|OTHER|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
219504091|NCT01871779|OTHER|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
219504092|NCT04272775|DRUG|Ixazomib|Ixazomib capsules.
219504093|NCT04272775|DRUG|Lenalidomide|Lenalidomide capsules.
219504094|NCT04272775|DRUG|Dexamethasone|Dexamethasone tablets.
219504095|NCT04999332|DRUG|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
219504096|NCT01492270|PROCEDURE|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
219504097|NCT01492270|PROCEDURE|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
219504098|NCT01492270|PROCEDURE|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
219504099|NCT01492270|PROCEDURE|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
219504100|NCT02507206|DRUG|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
219504101|NCT02507206|DRUG|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
219504102|NCT01530685|DIETARY_SUPPLEMENT|Glycabiane|2 gelule per day for 4 months
219504103|NCT01530685|DIETARY_SUPPLEMENT|placebo|2 gelules per day for 4 months
219504104|NCT02197533|OTHER|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
219504105|NCT00719381|DRUG|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
219504106|NCT03650582|DRUG|Glucagon|Intranasal glucagon
219504107|NCT03650582|DRUG|Placebo|Intranasal placebo
219504108|NCT00124020|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
218883058|NCT01072994|DIETARY_SUPPLEMENT|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
218883059|NCT05293158|DRUG|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
219504109|NCT00124020|DRUG|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
219504110|NCT04665674|OTHER|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
219504111|NCT00418873|DRUG|Zotepine|Oral
219504112|NCT00418873|DRUG|Risperidone|Oral
219504113|NCT02587702|OTHER|β-Palmitate Content|
219504114|NCT02587702|OTHER|Placebo|
219504115|NCT02587702|OTHER|β-Palmitate Content Naturely in Human Milk|
219504116|NCT05865509|OTHER|Escape room|Students were given training on stress response using the escape room method.
219504117|NCT05865509|OTHER|Storytelling|Students were given training on stress response using the storytelling method.
219504118|NCT03872037|PROCEDURE|Selective removal of carious tissue and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
219504119|NCT03872037|PROCEDURE|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
218883060|NCT05340790|DRUG|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
218883061|NCT05340790|DRUG|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
218883062|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
218883063|NCT01447953|OTHER|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
218883064|NCT01447953|OTHER|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
218883065|NCT00968877|DRUG|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
219364402|NCT03324204|OTHER|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
218883066|NCT04560153|OTHER|karate kata|sessions of karate kata every week during 4 months
218883067|NCT01874444|DEVICE|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
219364403|NCT03324204|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
219364404|NCT00947531|DRUG|Cerebrolysin|
219364405|NCT00947531|DRUG|0.9% Saline Solution|
219364406|NCT06018779|OTHER|Cryoultrasound therapy plus high-intensity laser therapy|Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
219364407|NCT06018779|OTHER|diathermy plus high-intensity laser therapy|Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
219364408|NCT01226290|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
219364409|NCT04223245|BEHAVIORAL|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
219364410|NCT04223245|BEHAVIORAL|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
219364411|NCT05750992|PROCEDURE|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
219364412|NCT05750992|PROCEDURE|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
219364413|NCT03948230|BIOLOGICAL|Salt with / without water|Drinks with and without a salt containing capsule
219364414|NCT04257331|BEHAVIORAL|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
219364415|NCT03856944|DEVICE|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
219364416|NCT00212173|DRUG|Sibutramine|
219364417|NCT00212173|DIETARY_SUPPLEMENT|Slim Fast|
219364418|NCT02023658|OTHER|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
219364419|NCT03902678|PROCEDURE|EUS guided fine needle aspiration of portal vein thrombus|endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
219364420|NCT02130713|DRUG|Third generation fluoroquinolone|Prulifloxacin 600 mg
219364421|NCT02130713|DIETARY_SUPPLEMENT|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
219364422|NCT02835885|DEVICE|Digitmer High Voltage Stimulator model DS7A TENS unit|
219364423|NCT03743831|DEVICE|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
219504120|NCT04701697|DRUG|Recombinant Human Albumin Injection|Participants will receive Recombinant Human Albumin Injection of intravenous infusion
219504121|NCT04701697|DRUG|HumanAlbumin|Participants will receive HumanAlbumin of intravenous infusion
219504122|NCT01051609|OTHER|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
219504123|NCT01051609|OTHER|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
219504124|NCT01051609|BEHAVIORAL|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
219504125|NCT01051609|OTHER|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
219504126|NCT01051609|PROCEDURE|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
219504127|NCT04277611|PROCEDURE|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
219504128|NCT04299997|OTHER|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
219504129|NCT02043366|DRUG|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
219504130|NCT02043366|DRUG|Butorphanol|Butorphanol is intravenously administrated
219504131|NCT02043366|DRUG|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
219504132|NCT02043366|DRUG|Remifentanil|Remifentanil is intravenously administrated
219504133|NCT02043366|DRUG|Sufentanil|Sufentanil is intravenously administrated
219504134|NCT05819567|DEVICE|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
219504135|NCT06542965|OTHER|Non-Interventional Research|Non-Interventional Research
219504136|NCT02079792|PROCEDURE|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
219504137|NCT02079792|PROCEDURE|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
219504138|NCT00521248|DRUG|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
218883068|NCT01874444|DEVICE|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
218883069|NCT01874444|DEVICE|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
218883070|NCT01874444|DEVICE|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
218883071|NCT02990676|BEHAVIORAL|Computerised cognitive training|Computerised cognitive training regime
218883072|NCT02955342|OTHER|no intervention|no intervention
218883073|NCT02922426|DRUG|ALKS 3831|Daily dosing for 21 consecutive days
218883074|NCT02922426|DRUG|Olanzapine|Daily dosing for 21 consecutive days
218883075|NCT02922426|DRUG|Placebo|Daily dosing for 21 consecutive days
218883076|NCT02536222|OTHER|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
218883077|NCT00305630|DRUG|Periocular injection of triamcinolone acetonide 40mg|
219028100|NCT01215370|OTHER|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
219504139|NCT00521248|DRUG|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
219504140|NCT04572568|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
219504141|NCT01127581|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219504142|NCT01127581|DRUG|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219504143|NCT00772564|DRUG|Atorvastatin|Oral Atorvastatin
219504144|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
219504145|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seeds|4.1 grams (1½ teaspoons/\~0.15ounces) of pumpkin seeds
219504146|NCT01313390|DRUG|docetaxel|
218883078|NCT06445816|DRUG|chemotherapy|"* Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers."
218883079|NCT04635514|PROCEDURE|Lateral colporrhaphy|
218883080|NCT00965419|DRUG|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
218883081|NCT00386321|DRUG|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
218883082|NCT00500396|PROCEDURE|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
218883083|NCT04415411|OTHER|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
218883084|NCT00545896|PROCEDURE|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
219028101|NCT05750355|DRUG|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
219028102|NCT05750355|DRUG|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
219028103|NCT05750355|DRUG|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
219028104|NCT05750355|DRUG|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
219201035|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
219201036|NCT04252482|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 12 weeks
219201037|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
219504147|NCT01313390|DRUG|everolimus|
218883085|NCT04598412|OTHER|No intervention|Cross-sectional
218883086|NCT02927938|PROCEDURE|Allogeneic HCT|Allogeneic HCT
218883087|NCT02927938|DRUG|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
218883088|NCT01332747|DRUG|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
218883089|NCT01332747|DRUG|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
218883090|NCT01332747|DRUG|Atorvastatin|atorvastatin 10 mgs once daily
219028105|NCT03098173|PROCEDURE|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
219028106|NCT03098173|PROCEDURE|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
219504148|NCT01313390|OTHER|laboratory biomarker analysis|
219028107|NCT01207518|BEHAVIORAL|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
219028108|NCT01207518|BEHAVIORAL|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
219028109|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
219028110|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
219504149|NCT01313390|OTHER|pharmacological study|
219504150|NCT01567215|PROCEDURE|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
219504151|NCT01567215|DRUG|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
219504152|NCT01567215|PROCEDURE|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
219504153|NCT00891774|DEVICE|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
218883091|NCT04129892|BEHAVIORAL|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
218883092|NCT03322150|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
218883093|NCT03322150|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
218883094|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
218883095|NCT03018613|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
219201038|NCT06807892|OTHER|Synergistic management|In synergistic management, exercises are carried out in a synergistic way: 40 minutes of exercises involving both physical and cognitive stimulation.
218883096|NCT03018613|OTHER|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
218883097|NCT00623870|DRUG|RO5045337|Multiple ascending doses
218883098|NCT02509845|DRUG|C16G2|Antimicrobial peptide
218883099|NCT02509845|OTHER|Placebo|Placebo
218883100|NCT05741398|DEVICE|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
218883101|NCT01694056|OTHER|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
218883102|NCT01694056|OTHER|Control diet|4 weeks high mixed protein diet (20 en%)
218883103|NCT05924347|DIAGNOSTIC_TEST|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
218883104|NCT05924347|DIAGNOSTIC_TEST|Scolioscan|3D ultrasound of the spine
218883105|NCT05924347|DIAGNOSTIC_TEST|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
219364424|NCT03743831|DEVICE|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
218883106|NCT01563263|BIOLOGICAL|IC43|100 mcg
218883107|NCT01563263|DRUG|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
218883108|NCT02231619|BEHAVIORAL|Baseline verbal instruction on LSUPT|
218883109|NCT02798978|DRUG|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
219364425|NCT05845359|DRUG|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
219364426|NCT01773421|DRUG|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
219364427|NCT01773421|DRUG|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
219364428|NCT03502330|DRUG|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
219364429|NCT03502330|DRUG|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
219364430|NCT03502330|DRUG|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
219364431|NCT02265484|DRUG|Lactulose+Rifaximin +Bromocriptine|
219364432|NCT01486576|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
219364433|NCT01486576|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
219364434|NCT02310048|DRUG|MT-1303-FormA|
219364435|NCT02310048|DRUG|MT-1303-FormB|
219364436|NCT02804763|DRUG|Placebo|Solution for infusion, 0,9% saline
219364437|NCT02804763|DRUG|Dapirolizumab pegol (DZP)|Solution for infusion
219364438|NCT06310148|COMBINATION_PRODUCT|The Chronic Disease Co-Care (CDCC) Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
219364439|NCT02507479|DRUG|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
219364440|NCT01992809|DIETARY_SUPPLEMENT|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
219364441|NCT00067756|DRUG|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
219364442|NCT04224935|PROCEDURE|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
219504154|NCT05488184|DIETARY_SUPPLEMENT|Flavoured Oral Nutritional Supplement (ONS)|Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
219504155|NCT01174056|DRUG|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
219504156|NCT01174056|DRUG|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
219504157|NCT01174056|DRUG|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
219504158|NCT01174056|DRUG|Pioglitazone|PPAR-gamma agonist
219504159|NCT00004143|DRUG|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
219504160|NCT02236533|DIETARY_SUPPLEMENT|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
219504161|NCT01977092|BEHAVIORAL|Motivational interviewing case management|
219504162|NCT01977092|BEHAVIORAL|Resource referrals|
219504163|NCT02927847|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
219504164|NCT02927847|DRUG|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
218883110|NCT02798978|DRUG|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
219606501|NCT06100523|BEHAVIORAL|self-assessment questionnaire|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
218883111|NCT00826618|DRUG|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
218883112|NCT01557088|OTHER|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
219504165|NCT02927847|BEHAVIORAL|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
219504166|NCT02927847|BEHAVIORAL|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
219606502|NCT06100523|BIOLOGICAL|hair sampling|hair sampling from the 2 members of the couple
218883113|NCT01557088|PROCEDURE|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
219504167|NCT03619252|BIOLOGICAL|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
218883114|NCT03712787|DRUG|Tilavonemab|solution for IV infusion
218883115|NCT00732875|BIOLOGICAL|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
218883116|NCT03470090|BEHAVIORAL|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
219504168|NCT03619252|DRUG|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
219504169|NCT01501942|DRUG|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
219504170|NCT01501942|DRUG|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
219606503|NCT06100523|BEHAVIORAL|self-assessment questionnaire on dedicated application|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
219606504|NCT06100523|BEHAVIORAL|Specialized follow-up|proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application
219606505|NCT06100523|BEHAVIORAL|self-assessment questionnaire for follow-up|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
218883117|NCT03470090|BEHAVIORAL|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
218883118|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
218883119|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
218883120|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
218883121|NCT03790059|DRUG|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
219504171|NCT00723554|DRUG|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
219504172|NCT00723554|DRUG|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
218883122|NCT03790059|PROCEDURE|RFA|Treat the samll HCC with the RFA.
218883123|NCT00635167|DRUG|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
218883124|NCT02901418|BIOLOGICAL|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
218883125|NCT00917618|OTHER|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
218883126|NCT00917618|OTHER|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
218883127|NCT02630472|DRUG|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
218883128|NCT02630472|DRUG|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
218883129|NCT01110356|DRUG|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
219028111|NCT04300595|PROCEDURE|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
219028112|NCT06189222|DEVICE|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
219028113|NCT00736008|OTHER|Observational|Data summary only
219028114|NCT04597307|COMBINATION_PRODUCT|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
219504173|NCT00672022|DRUG|Zavesca (Miglustat)|
219504174|NCT03994588|PROCEDURE|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
219606506|NCT02526667|DRUG|Chlorhexidine gluconate|2% CHG solution on cloth
219606507|NCT02526667|DRUG|DynaHex-2|2% CHG solution
219606508|NCT02526667|OTHER|Vehicle|Excipients of CHG product only
219606509|NCT02665793|OTHER|DBPCFC to peanut cookie|
218883130|NCT01110356|OTHER|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
218883131|NCT01077401|DRUG|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
219606510|NCT02665793|OTHER|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
219606511|NCT02665793|OTHER|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
219504175|NCT00698178|OTHER|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
219504176|NCT00593138|DRUG|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
219504177|NCT03113058|COMBINATION_PRODUCT|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
219504178|NCT06544798|GENETIC|AAV2-hAQP1|Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
219504179|NCT01405820|DRUG|natalizumab IV|natalizumab for IV Infusion
219504180|NCT01405820|DRUG|natalizumab SC|natalizumab for Subcutaneous Injection
219504181|NCT01405820|DRUG|IV Placebo|Intravenous placebo to natalizumab
219504182|NCT01405820|DRUG|SC Placebo|Subcutaneous placebo to natalizumab
219504183|NCT03421652|DRUG|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
219504184|NCT03421652|RADIATION|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
219504185|NCT05120011|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
219504186|NCT05120011|DIETARY_SUPPLEMENT|L-leucine|L-leucine
219504187|NCT06158061|DIAGNOSTIC_TEST|tryptase enzyme level|"In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy."
219504188|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin)|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
219504189|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
219504190|NCT02165670|DEVICE|Coronary stenting with CE-marked stent|
219504191|NCT02619799|DRUG|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
219504192|NCT02619799|DRUG|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
219606512|NCT03867240|DRUG|Gabapentin|Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients \<50 kg and 200 mg for patients \> 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
219606513|NCT03867240|OTHER|Placebo|Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
219606514|NCT01576354|DRUG|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
219606515|NCT01576354|DRUG|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
219606516|NCT00631215|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
219606517|NCT04209452|BEHAVIORAL|Rehearsal strategy|Teaching children to cumulatively rehearse numbers as they are being said.
219606518|NCT04209452|BEHAVIORAL|Reinforcement|Providing reinforcement for correct recall after a delay.
219606519|NCT04209452|BEHAVIORAL|Rehearsal strategy and reinforcement|Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
219606520|NCT00576589|DRUG|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
219606521|NCT00576589|DRUG|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
219504193|NCT05373875|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
219504194|NCT01142297|DEVICE|dental implant and modified dental implant|standard SLA surface and chemically modified surface
218883132|NCT01077401|DRUG|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
219504195|NCT01635985|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
219504196|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
219504197|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
219504198|NCT01635985|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
219504199|NCT01635985|DRUG|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
218883133|NCT03544255|PROCEDURE|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
219028115|NCT03645551|DIAGNOSTIC_TEST|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
219504200|NCT01635985|DRUG|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
219504201|NCT01614509|PROCEDURE|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
219606522|NCT06008184|OTHER|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~* blood: sampling every 20 minutes (through a venous catheter)~* ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~* Sweat : collection of 1 to 3 samples at 4 differents timepoints~* Saliva : sampling every hour (except during the night)"
219606523|NCT06008184|OTHER|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
219606524|NCT02411916|BIOLOGICAL|misoprostol|rectal insertion
219606525|NCT01740245|DEVICE|Chlorhexidine vaginal suppositories|
219504202|NCT01614509|PROCEDURE|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
219504203|NCT02336997|PROCEDURE|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
219606526|NCT01740245|DEVICE|Polyhexamethylene biguanide vaginal suppositories|
218883134|NCT03517228|DEVICE|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
218883135|NCT03387774|DRUG|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
219606527|NCT04348877|OTHER|Antibody-Rich Plasma from COVID-19 recovered patients|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
219606528|NCT06225219|BEHAVIORAL|Counseling|To introduce a model of holistic care to the patient populations served by the GCAC through chaplain interventions that focus on spiritual and emotional health.
219606529|NCT01880892|PROCEDURE|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
219606530|NCT01880892|DIAGNOSTIC_TEST|PH probe Testing|24 hour PH probe testing, which will measure acid reflux following cricopharyngeal myotomy.
219606531|NCT04526015|PROCEDURE|Iliohypogastric and ilioinguinal nerve block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
219606532|NCT04526015|PROCEDURE|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
219606533|NCT05479825|PROCEDURE|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
219028116|NCT02049333|PROCEDURE|Phacoemulsification|
219028117|NCT02049333|PROCEDURE|Endoscopic Cycloplasty (ECPL)|
219028118|NCT00449644|DRUG|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
219504204|NCT02336997|PROCEDURE|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1\*10e6 cells/cm2.
219504205|NCT02336997|PROCEDURE|PLACEBO|Saline will be injected into expanded skin.
219504206|NCT04468087|DRUG|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
219504207|NCT04468087|DRUG|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
219504208|NCT04468087|DRUG|Sofusbuvir + Daclastavir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
219504209|NCT04468087|DRUG|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
219504210|NCT04468087|DRUG|Placebo Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
219504211|NCT04468087|DRUG|Placebo Sofusbuvir + Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
219504212|NCT04988659|OTHER|Exposures|Exposures
219504213|NCT01319682|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
219504214|NCT01319682|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
219504215|NCT05698381|DIETARY_SUPPLEMENT|Liquid vinegar|2 tablespoons consumed twice daily with meals
219504216|NCT05698381|DIETARY_SUPPLEMENT|Vinegar pill|2 pills consumed upon waking
219504217|NCT05124431|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
219504218|NCT05124431|DRUG|everolimus|5mg po，qd
219504219|NCT02778568|BEHAVIORAL|Resistance training|Resistance training exercises
219504220|NCT02778568|BEHAVIORAL|Control|Stretching exercises
219504221|NCT05103267|DEVICE|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
219504222|NCT00878449|DRUG|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
219504223|NCT00878449|DRUG|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
219504224|NCT02015923|PROCEDURE|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
219504225|NCT02015923|DRUG|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
219504226|NCT00004871|DRUG|azacitidine|
219504227|NCT00004871|DRUG|sodium phenylbutyrate|
219504228|NCT02627365|BEHAVIORAL|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
218883136|NCT03387774|RADIATION|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
219606534|NCT00419991|DRUG|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
219606535|NCT03735121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
219606536|NCT03735121|DRUG|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
219028119|NCT00449644|DRUG|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
219364443|NCT05513014|DRUG|Secukinumab|Patients with Psoriasis who initiated Secukinumab
219364444|NCT03371563|DRUG|Antibiotics|Patients were treated with antibiotics for Lyme disease.
219606537|NCT05721014|OTHER|OsteoStrong|"This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 10-15 seconds 1-3 times on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor."
219504229|NCT03263819|DIAGNOSTIC_TEST|Oral glucose tolerance test|75 grams of glucose
219504230|NCT01319071|OTHER|Blood sample|Extraction of blood sample from top-level athletes
219364445|NCT03371563|OTHER|no intervention|controls were not given antibiotics
219364446|NCT01809548|OTHER|Early intervention group|solid food will be introduced between week 10 and 12
219364447|NCT01809548|OTHER|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
219364448|NCT05246540|OTHER|Data collection|Data collection
219364449|NCT04274348|OTHER|Skin biopsies and blood samples|Two skin biopsies and 30 ml of blood will be collected.
219364450|NCT03443167|BEHAVIORAL|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
219504231|NCT00125931|DRUG|Talwin Nx|Talwin NX 50mg po twice
219504232|NCT03269175|OTHER|Brain MRI|Brain MRI will be performed
219504233|NCT03269175|OTHER|Blood sampling|Blood samples will be taken
219504234|NCT06528678|DEVICE|Intraocular lens|Lens exchange with an intraocular lens
218883137|NCT03387774|DRUG|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
219504235|NCT03119064|DRUG|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
219504236|NCT03119064|DRUG|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
219504237|NCT03208283|DIAGNOSTIC_TEST|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
219504238|NCT03208283|DIAGNOSTIC_TEST|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
219504239|NCT04242966|OTHER|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
219504240|NCT04242966|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
219504241|NCT04242966|OTHER|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
219504242|NCT01637025|DEVICE|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
219504243|NCT01637025|DEVICE|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
219504244|NCT02170701|DRUG|BIBR 1048|Ascending doses (in mg) given twice daily
219504245|NCT02280356|RADIATION|external beam radiation therapy|
218883138|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
218883139|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
218883140|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
218883141|NCT04204811|OTHER|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
218883142|NCT00887510|DRUG|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
218883143|NCT00887510|DRUG|Trandolapril|4 mg tablet once daily for 6 weeks
219504246|NCT02280356|RADIATION|brachytherapy|
218883144|NCT03832751|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
218883145|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
218883146|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
218883147|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
218883148|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
218883149|NCT04063163|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
219504247|NCT02280356|BEHAVIORAL|questionnaires|
219504248|NCT01906099|OTHER|nutritional intervention|
219504249|NCT01906099|OTHER|life style modification|
219504250|NCT02611206|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
219504251|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
219504252|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
218883150|NCT04063163|DRUG|carboplatin and etoposide|chemotherapeutics
219504253|NCT03089099|OTHER|Blood drawing|Blood drawing
219504254|NCT02958878|DRUG|Tamsulosin|
218883151|NCT04063163|DRUG|placebo|placebo
218883152|NCT04728607|DEVICE|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
218883153|NCT05518357|BIOLOGICAL|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
218883154|NCT00955539|DEVICE|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
218883155|NCT00955539|DEVICE|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
218883156|NCT00757055|DRUG|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
218883157|NCT00757055|DRUG|Placebo|No active treatment given
218883158|NCT06802835|DRUG|EGFR Antibody|6 cycles for combined therapy. Maintenance for 1 year.
218883159|NCT06802835|DRUG|PD-1 antibody|6 cycles for combined therapy. Maintenance for 1 year.
218883160|NCT06802835|DRUG|Gemcitabine, Cisplatin|6 cycles for combined therapy.
218883161|NCT06802835|RADIATION|IMRT|IMRT for primary lesion
219504255|NCT02958878|DRUG|Placebo Oral Capsule|
218883162|NCT04951583|COMBINATION_PRODUCT|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
219504256|NCT03670407|PROCEDURE|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
219504257|NCT00412815|BEHAVIORAL|Exercise training|
219504258|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
219504259|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
219504260|NCT03785483|BEHAVIORAL|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
219504261|NCT02971514|BEHAVIORAL|Flossing before Brushing|
218883163|NCT05366634|BIOLOGICAL|MDK-703 or Placebo|Injection
218883164|NCT02595905|DRUG|Cisplatin|Given IV
218883165|NCT02595905|OTHER|Laboratory Biomarker Analysis|Correlative studies
218883166|NCT02595905|OTHER|Placebo Administration|Given PO
218883167|NCT02595905|DRUG|Veliparib|Given PO
218883168|NCT03781414|BIOLOGICAL|CFZ533|Comparison with standard of care immunosuppression
218883169|NCT03781414|DRUG|Tacrolimus - MMF - corticosteroids|Standard of care immunosuppresive regimen
219504262|NCT02971514|BEHAVIORAL|Brushing before Flossing|
219504263|NCT00029185|DRUG|Dehydrex|
219504264|NCT00306631|DRUG|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
219504265|NCT00067158|DRUG|nicotine transdermal system|
219504266|NCT04976049|PROCEDURE|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
219504267|NCT02277821|DEVICE|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
219504268|NCT03370484|DIETARY_SUPPLEMENT|Control|Water with 80 mg sucralose
219504269|NCT03370484|DIETARY_SUPPLEMENT|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
219504270|NCT01011322|DRUG|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
219504271|NCT01011322|DRUG|placebo|placebo
219504272|NCT01806883|BEHAVIORAL|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
219606538|NCT05721014|OTHER|Individually Adapted and Combined Physical Training|"This training method is based on the current recommendations on physical activity for people with osteoporosis.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor. The participants also have the option to do a home based exercise programme that they could do in a few cases when they were unable to attend the physical group training."
219606539|NCT04024046|DIETARY_SUPPLEMENT|Uqora|Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
219606540|NCT04024046|DIETARY_SUPPLEMENT|Group1|Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
219606541|NCT04024046|DIETARY_SUPPLEMENT|Group 2|Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
219606542|NCT06480292|OTHER|telerehabilitation exercise|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
219606543|NCT06480292|OTHER|routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
219028120|NCT00449644|DRUG|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
219028121|NCT00000560|DRUG|adrenergic beta antagonists|
219504273|NCT01806883|BEHAVIORAL|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
219504274|NCT04053478|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
219504275|NCT04053478|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
219504276|NCT04053478|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
219504277|NCT04053478|DRUG|Vasopressin|Vasopressin, at applicable concentrations based on literature
219504278|NCT00648856|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
219504279|NCT00648856|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fed
219504280|NCT02528578|DEVICE|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
219504281|NCT02528578|OTHER|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
219504282|NCT05371301|DRUG|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
219504283|NCT05371301|PROCEDURE|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
219504284|NCT04759495|DEVICE|Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)|rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
219504285|NCT04759495|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)|FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
219504286|NCT02277795|DEVICE|AccuCirc|Circumcision with the use of the AccuCirc device.
219504287|NCT05447429|PROCEDURE|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
219504288|NCT05447429|DRUG|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
219504289|NCT02182960|DRUG|Ibuprofen syrup|
219504290|NCT02182960|DRUG|Brufen syrup|
219504291|NCT03786510|BEHAVIORAL|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
219606544|NCT05440890|OTHER|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
219504292|NCT03786510|BEHAVIORAL|Intensive + Maintenance program|"Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
219504293|NCT03786510|BEHAVIORAL|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
219028122|NCT04954547|BEHAVIORAL|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
219504294|NCT03767673|DIAGNOSTIC_TEST|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
219504295|NCT03767673|DIAGNOSTIC_TEST|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
219504296|NCT03767673|DIAGNOSTIC_TEST|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
219028123|NCT04954547|BEHAVIORAL|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
219028124|NCT05034107|OTHER|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
219504297|NCT03767673|DIAGNOSTIC_TEST|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
219504298|NCT03767673|DIAGNOSTIC_TEST|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
219504299|NCT03767673|DIAGNOSTIC_TEST|weight|Determined by Kilogram on a medical weight scale
219504300|NCT03767673|OTHER|age|Determination of age by patient's Report and past medical history
219504301|NCT03496532|DEVICE|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
219504302|NCT03496532|DEVICE|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
219504303|NCT03496532|DEVICE|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
219504304|NCT03496532|DEVICE|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
219504305|NCT03496532|DEVICE|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
219606545|NCT05440890|OTHER|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
219028125|NCT04535895|RADIATION|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
219028126|NCT04750031|PROCEDURE|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
219201039|NCT06807892|OTHER|Sequential management|In sequential management, exercises are performed sequentially: 20 minutes of physical exercises and 20 minutes of cognitive exercises.
219201040|NCT02461134|DRUG|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
219504306|NCT04624022|DIAGNOSTIC_TEST|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
219504307|NCT04456465|OTHER|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
219504308|NCT01016496|OTHER|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
219504309|NCT01016496|OTHER|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
219504310|NCT01437137|DEVICE|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
219504311|NCT01437137|DEVICE|i-gel™|Insertion of I-gel
219504312|NCT04171388|DRUG|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
219504313|NCT04171388|DIETARY_SUPPLEMENT|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) \>=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC \<23 cm
219606546|NCT04384835|BIOLOGICAL|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
219606547|NCT04384835|BIOLOGICAL|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
219606548|NCT05042258|DRUG|Dupilumab|12 week dupilumab administration
219504314|NCT04171388|DRUG|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
219504315|NCT04171388|OTHER|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
219504316|NCT01051622|OTHER|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
219504317|NCT02586545|OTHER|Shared care|
219504318|NCT04976140|BIOLOGICAL|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
219504319|NCT00000295|DRUG|Micronized Progesterone|
219504320|NCT02022371|PROCEDURE|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
219504321|NCT05252078|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
219504322|NCT05252078|DRUG|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
219504323|NCT00236327|DRUG|fentanyl|
219504324|NCT06066307|OTHER|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
219504325|NCT03605615|OTHER|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
219504326|NCT03361956|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
218883170|NCT05782322|BEHAVIORAL|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
218883171|NCT05782322|BEHAVIORAL|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
218883172|NCT00156390|DEVICE|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
218883173|NCT00156390|OTHER|LV lead placement as per standard of care (without echo guidance)|
218883174|NCT06583863|DRUG|Echinacea Extract|175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
219504327|NCT03361956|DRUG|Placebo|Participants will receive matching placebo tablet orally.
219504328|NCT03361956|DRUG|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
219504329|NCT03385187|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
219504330|NCT00408876|DRUG|Duloxetine|
219504331|NCT00408876|DRUG|Placebo|
219504332|NCT02006147|DRUG|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
219504333|NCT03198988|DEVICE|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
219504334|NCT02767622|PROCEDURE|Liver transplantation|
219504335|NCT00263978|DRUG|Defibrotide|
219504336|NCT04698057|DRUG|Placebo|The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
219504337|NCT04698057|DRUG|Amoxicillin Clavulanate|Will be administred to all patients
219504338|NCT04698057|DRUG|Ciprofloxacin|Will be administred to patients in the standard of care arm
219504339|NCT02793063|OTHER|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
219504340|NCT01488019|DRUG|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
219606549|NCT05581381|BEHAVIORAL|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
219504341|NCT01488019|DRUG|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
219504342|NCT02758054|BEHAVIORAL|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
219504343|NCT06214026|DEVICE|META-Arc foot locked|Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.
219504344|NCT06214026|DEVICE|META-Arc foot unlocked|Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
219504345|NCT02400710|BEHAVIORAL|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
219504346|NCT02400710|BEHAVIORAL|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
219504347|NCT00657878|DRUG|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
219504348|NCT00657878|DRUG|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
219504349|NCT00657878|DRUG|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
219504350|NCT00657878|DRUG|Topotecan|dosing and schedule according to Institutional guidelines
219504351|NCT00657878|DRUG|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
219504352|NCT00871728|DRUG|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
219504353|NCT02561390|PROCEDURE|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
219504354|NCT02561390|OTHER|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
219504355|NCT03158428|OTHER|CSD170202AA|A moist snuff product
219606550|NCT04328701|BEHAVIORAL|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
219606551|NCT02040077|BEHAVIORAL|Computer + Fluency|
219606552|NCT02040077|BEHAVIORAL|Computer Only|
218883175|NCT06583863|DRUG|MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]|500 mg of metronidazole was provided as an oral tablets twice daily
218883176|NCT06584461|DRUG|Lidocaine (drug)|IV lidocaine, administered once during the induction of anesthesia.
218883177|NCT06584461|DRUG|Saline (NaCl 0,9 %) (placebo)|IV placebo (normal saline), administered once during the induction of anesthesia.
218883178|NCT06584370|PROCEDURE|Pericardial insufflation with carbon dioxide through a transatrial microcatheter|Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
218883179|NCT02960464|DEVICE|Transcranial direct current stimulation|
219504356|NCT03158428|OTHER|CSD170202AB|A moist snuff product
219504357|NCT04346290|DRUG|Dexmedetomidine|Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
219504358|NCT02546284|DRUG|lenzilumab|
219504359|NCT04204486|BEHAVIORAL|Exercise|Functional strength training, 1 hour, 3 times a week.
219504360|NCT04147715|DRUG|S-648414|Tablet for oral administration
219504361|NCT04147715|DRUG|Placebo|Tablet for oral administration
219504362|NCT04147715|DRUG|Midazolam|Solution for oral administration
219504363|NCT04147715|DRUG|Dolutegravir|Tablet for oral administration
219504364|NCT00949130|DRUG|NXL103|BID for 7-14 days
219504365|NCT00949130|DRUG|Linezolid|BID for 7-14 days
219504366|NCT03404206|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
219504367|NCT03404206|DRUG|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
219504368|NCT03404206|DRUG|Placebo|Matching placebo, 2 tablets, oral, single dose
219504369|NCT01248312|DEVICE|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
219504370|NCT01248312|DEVICE|sentec monitor|transcutaneous monitoring
219504371|NCT02756000|PROCEDURE|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
219504372|NCT02756000|PROCEDURE|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
219504373|NCT05621642|OTHER|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
219504374|NCT05621642|OTHER|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
219504375|NCT05621642|OTHER|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
219504376|NCT02024828|OTHER|Early/Slow|
219504377|NCT02024828|OTHER|Early/Fast|
219504378|NCT02024828|OTHER|Late/Slow|
219504379|NCT02024828|OTHER|Late/Fast|
219504380|NCT01004081|DRUG|BIIB021|BID orally for 28 days
219504381|NCT01004081|DRUG|BIIB021|TIW orally for 28 days
219504382|NCT01004081|DRUG|exemestane (Aromasin)|Daily in tablet form for 28 days
219606553|NCT02040077|BEHAVIORAL|Treatment as Usual|
219606554|NCT03044821|PROCEDURE|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
219606555|NCT05323669|DIAGNOSTIC_TEST|Molecular testing|Molecular testing of thyroid nodules
218883180|NCT02960464|DEVICE|Sham Transcranial direct current stimulation|
218883181|NCT02644577|DRUG|Metformin|
218883182|NCT02644577|OTHER|Starch|
218883183|NCT02742376|OTHER|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
218883184|NCT02742376|OTHER|Floor|A marked path on the floor where the subject is instructed to walk.
218883185|NCT02742376|OTHER|Kyboot shoes|Special shoes will be worn by the subject.
218883186|NCT01439594|DEVICE|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
218883187|NCT00235144|DEVICE|sirolimus-coated Bx Velocity stent|drug-eluting stent
219504383|NCT03032497|DEVICE|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
219504384|NCT04596449|OTHER|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
219504385|NCT00014521|DRUG|karenitecin|
219504386|NCT03187080|PROCEDURE|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
219504387|NCT03187080|OTHER|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
219504388|NCT03187080|PROCEDURE|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
219504389|NCT03187080|DRUG|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
219504390|NCT06039670|PROCEDURE|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
219504391|NCT03872700|DRUG|Intranasal fentanyl|Fentanyl Citrate
219504392|NCT03872700|DRUG|Placebo|Sterile Water Up to 5Cc
219504393|NCT02439606|DEVICE|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
219504394|NCT02439606|DEVICE|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
219606556|NCT00344448|DRUG|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
219606557|NCT02816983|RADIATION|SBRT|
218883188|NCT00235144|DEVICE|uncoated Bx Velocity stent|bare-metal stent
218883189|NCT06165042|OTHER|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
218883190|NCT06165042|OTHER|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
218883191|NCT06451081|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
218883192|NCT06451081|BEHAVIORAL|Opt-out active referral|Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
218883193|NCT06451081|BEHAVIORAL|Behavioral economic mobile messaging|Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
218883194|NCT06451081|BEHAVIORAL|Opt-in active referral|Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
219504395|NCT05205785|DIETARY_SUPPLEMENT|Human Milk Oligosaccharide Mix|Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.
219504396|NCT05205785|OTHER|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
219504397|NCT00163410|DRUG|Ciclesonide|
219504398|NCT04188925|DEVICE|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
219504399|NCT04188925|DEVICE|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
219504400|NCT04888650|OTHER|questionnaire|electronic questionnaire
219504401|NCT01270022|OTHER|Implementation|
219504402|NCT01270022|OTHER|dissemination|
219504403|NCT02541656|PROCEDURE|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
219504404|NCT00577759|OTHER|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
219504405|NCT00577759|OTHER|Passive Intervention|Provision of tools to help with referrals to community resources
219504406|NCT00577759|OTHER|No intervention|No intervention
219504407|NCT02893852|BEHAVIORAL|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
219504408|NCT02893852|BEHAVIORAL|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
219504409|NCT06358378|DEVICE|Aktiia SA Bracelet|The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
219504410|NCT03849794|OTHER|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
219504411|NCT03849794|OTHER|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
219606558|NCT01060241|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
219606559|NCT06387420|DRUG|AK117|Subjects receive AK117 intravenously.
219606560|NCT06387420|DRUG|Azacitidine|Subjects receive azacitidine subcutaneously.
219606561|NCT06387420|DRUG|Venetoclax|Subjects receive venetoclax orally.
219606562|NCT06387420|OTHER|Placebo|Subjects receive placebo intravenously.
219606563|NCT00067041|DRUG|Remodulin (treprostinil sodium) Injection|
219606564|NCT05317338|BEHAVIORAL|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
219606565|NCT02535286|DRUG|Umbralisib|A once daily oral agent
219606566|NCT02535286|BIOLOGICAL|ublituximab|IV anti-CD20 monoclonal antibody
219606567|NCT02535286|BIOLOGICAL|TG-1501|IV immunotherapy for cancer
219504412|NCT00242775|DRUG|Budesonide/formoterol Turbuhaler|
218883195|NCT04752358|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
219028127|NCT01828892|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
219028128|NCT01828892|PROCEDURE|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
219504413|NCT00242775|DRUG|Salmeterol/fluticasone Diskus|
219504414|NCT01626859|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
219504415|NCT01626859|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
219504416|NCT01626859|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
219504417|NCT01545219|DIETARY_SUPPLEMENT|Prebiotic|8g/day xylo-oligosaccharide
219504418|NCT01545219|DIETARY_SUPPLEMENT|Bi-07|10\^9 CFU B. lactis / day
219504419|NCT01545219|DIETARY_SUPPLEMENT|Synbiotic|8g/day xylo-oligosaccharide + 10\^9 CFU Bi-07
219504420|NCT01545219|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
219504421|NCT00039507|PROCEDURE|conventional surgery|
219504422|NCT00039507|PROCEDURE|radiofrequency ablation|
219504423|NCT04025619|DEVICE|tape|Sports tape
219504424|NCT02629965|DRUG|tiotropium|fixed dose combination
219606568|NCT01528007|DRUG|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
219606569|NCT01528007|DRUG|Placebo|Placebo pill with no active ingredients.
219606570|NCT03411135|OTHER|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
219606571|NCT04409314|DRUG|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
219606572|NCT04409314|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219606573|NCT05517538|DEVICE|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
218883196|NCT01049529|DIETARY_SUPPLEMENT|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
218883197|NCT01049529|DIETARY_SUPPLEMENT|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
218883198|NCT00274508|DRUG|tiotropium bromide|
218883199|NCT06549660|DEVICE|Active PBMT|Active with a dose of 165 J per site, resulting in a total dose of 495J.
218883200|NCT06549660|DEVICE|Placebo PBMT|Placebo, without therapeutic dose.
218883201|NCT04132505|DRUG|Binimetinib|Given PO
218883202|NCT04132505|DRUG|Hydroxychloroquine|Given PO
219504425|NCT02629965|DRUG|olodaterol|fixed dose combination
219504426|NCT02629965|DRUG|tiotropium|
219504427|NCT02103738|OTHER|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
219504428|NCT05426252|DRUG|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
219504429|NCT05426252|DRUG|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
219504430|NCT00141284|DRUG|nelfinavir 1,250 mg twice daily|
219504431|NCT00141284|DRUG|Zidovudine 300 mg twice daily|
219504432|NCT00141284|DRUG|Lamivudine 150 mg twice daily|
219504433|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
219504434|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
219504435|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
219504436|NCT02189083|DRUG|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
219504437|NCT00918697|PROCEDURE|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
219504438|NCT00918697|PROCEDURE|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
219606574|NCT05517538|DRUG|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
219606575|NCT04495881|DRUG|Sitagliptin 100mg|Sitagliptin 100mg Qd
219606576|NCT01008189|BEHAVIORAL|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
219028129|NCT01828892|DRUG|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
219028130|NCT01828892|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
219504439|NCT05738109|OTHER|Self-Talk Journals|Participants randomized to the intervention group will receive a physical copy of the 91-day self-talk journal during the baseline meeting. Participants will also be introduced the purpose of the journal and its intended usage (i.e., daily journaling). Intervention participants will not be offered guidance or feedback on the journal after these initial instructions, in order to emulate an ad libitum usage. Control group participants will not receive any contact with the researchers outside of the planned questionnaires and to receive their journal at the three-month timepoint.
219504440|NCT02330081|DEVICE|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood."
219504441|NCT00722111|DEVICE|lingual press|lingual press (high-intensity, oral, non-swallowing)
219504442|NCT00722111|BEHAVIORAL|effortful swallowing|effortful swallowing (high-intensity swallowing)
219504443|NCT00722111|BEHAVIORAL|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
219504444|NCT00722111|BEHAVIORAL|non-oral sham (control) exercise|non-oral sham (control) exercise
219504445|NCT00700869|PROCEDURE|mechanical ventilation|mechanical ventilation
219504446|NCT04916171|OTHER|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
219504447|NCT00002189|DRUG|Paclitaxel|
219504448|NCT00111189|DRUG|Placebo|Placebo every 4 wk up to 24 mo
219606577|NCT01008189|BEHAVIORAL|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
218883203|NCT05536570|DRUG|IncobotulinumtoxinA 100 UNT|Scalene injection
218883204|NCT04491539|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
219028131|NCT01746927|OTHER|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
219028132|NCT01375387|DRUG|Lacosamide|100 mg oral tablet, single dose
218883205|NCT05679739|OTHER|Individualized blood pressure strategy|An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
218883206|NCT00719355|BEHAVIORAL|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
218883207|NCT00719355|BEHAVIORAL|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
218883208|NCT01835158|DRUG|Cabozantinib S-malate|Given PO
219028133|NCT01375387|DRUG|Lacosamide|Lacosamide 2 X 100 mg tablet
219028134|NCT01375387|DRUG|Lacosamide|Lacosamide 4 X 100mg tablet
219028135|NCT01375387|OTHER|Placebo 3|Placebo - 3 tablets
219028136|NCT01375387|OTHER|Placebo 4|Placebo - 4 tablets
219504449|NCT00111189|DRUG|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
219504450|NCT00654303|DRUG|Rosuvastatin|
219504451|NCT04117152|OTHER|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
219504452|NCT03210675|DIAGNOSTIC_TEST|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
219504453|NCT03682783|DIAGNOSTIC_TEST|Fundus Image|Fundus image of optic nerve
219504454|NCT01811797|DEVICE|Low Intensity Shockwave by Renova|
219504455|NCT01811797|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
219028137|NCT01375387|OTHER|Placebo 2|Placebo - 2 tablets
219028138|NCT00853723|DRUG|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
219028139|NCT00853723|DRUG|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
219028140|NCT00853723|DRUG|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
219504456|NCT04809428|PROCEDURE|vNOTES salpingectomy|Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
219504457|NCT04809428|PROCEDURE|Laparoscopic salpingectomy|Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
219504458|NCT00657956|DEVICE|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
219504459|NCT00007241|DEVICE|Isometric exercise|
219504460|NCT00005091|DRUG|exatecan mesylate|
219606578|NCT00030706|DRUG|ixabepilone|
219606579|NCT00383305|DEVICE|Cool-Cap|
219606580|NCT05435690|DEVICE|Computer-assisted arthroplasty|Computer-assisted arthroplasty
219606581|NCT02850185|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
219606582|NCT02850185|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
218883209|NCT01835158|OTHER|Laboratory Biomarker Analysis|Correlative studies
219504461|NCT02707432|BEHAVIORAL|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
219504462|NCT00636428|DRUG|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
219504463|NCT02059733|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
219504464|NCT04928911|BIOLOGICAL|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
219504465|NCT00905489|DRUG|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
219504466|NCT00905489|DRUG|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
219504467|NCT04887545|DIAGNOSTIC_TEST|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
219504468|NCT01273103|DRUG|200mg [14C]- GSK2248761|single oral suspension dose of \[14C\]- GSK2248761 200 mg
219504469|NCT04523415|OTHER|without intervention, just retrospectively review the data about patients|without intervention
219504470|NCT00088777|BEHAVIORAL|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
219504471|NCT00088777|BEHAVIORAL|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
219504472|NCT02934828|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
219504473|NCT02934828|DRUG|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
219504474|NCT02874963|PROCEDURE|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
219504475|NCT02874963|DEVICE|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
219606583|NCT02850185|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
219606584|NCT04087915|DRUG|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
218883210|NCT01835158|DRUG|Sunitinib Malate|Given PO
218883211|NCT04322617|DRUG|Anlotinib plus the same Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
218883212|NCT04322617|DRUG|Anlotinib plus the new Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
219028141|NCT03041246|PROCEDURE|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
219028142|NCT02616042|OTHER|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
219028143|NCT02616042|OTHER|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
219040271|NCT06139159|OTHER|Stepped care and task shifting|"* Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
219040272|NCT03828812|BEHAVIORAL|Breakfast promotion|Recommendation of having breakfast daily
219201041|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
219504476|NCT02874963|DRUG|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
219606585|NCT00978614|DRUG|Neramexane|"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
218883213|NCT04322617|DRUG|Anlotinib|Anlotinib, 8mg po qd, D1-D14 every 21days.
218883214|NCT03623568|DRUG|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
218883215|NCT03256201|BEHAVIORAL|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
219201042|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
219606586|NCT06632652|BEHAVIORAL|Health Education|"Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months."
219606587|NCT01426074|DRUG|Bevacizumab 5 mg/kg|Intravenously every two weeks
219504477|NCT05935800|BEHAVIORAL|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
219504478|NCT01957657|DRUG|BI 207127|oral administration
219504479|NCT01957657|DRUG|faldaprevir|oral administration
219504480|NCT01957657|DRUG|BI 207127|oral administration
219504481|NCT01957657|DRUG|BI 207127|oral administration
218883216|NCT03256201|BEHAVIORAL|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
218883217|NCT03256201|BEHAVIORAL|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
218883218|NCT06152588|OTHER|Time restricted eating|"3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions.~9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives."
218883219|NCT04054375|DRUG|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
218883220|NCT03364738|BIOLOGICAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
218883221|NCT00766714|DEVICE|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
219504482|NCT01957657|DRUG|BI 207127|oral administration
219504483|NCT01957657|DRUG|faldaprevir|oral administration
218883222|NCT00766714|DEVICE|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
218883223|NCT02932748|DIETARY_SUPPLEMENT|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
218883224|NCT02932748|BEHAVIORAL|Group Phone (GP)|Weight management program delivered via group conference call.
218883225|NCT02932748|DIETARY_SUPPLEMENT|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
218883226|NCT02932748|BEHAVIORAL|Individual Phone (IP)|Weight management program delivered via individual phone call.
218883227|NCT02932748|BEHAVIORAL|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
219040273|NCT03828812|BEHAVIORAL|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
219504484|NCT01957657|DRUG|faldaprevir|oral administration
219504485|NCT01957657|DRUG|faldaprevir|oral administration
219504486|NCT02668302|COMBINATION_PRODUCT|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
219504487|NCT02668302|OTHER|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
219504488|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
219504489|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
219504490|NCT03338465|DEVICE|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
219504491|NCT03207659|PROCEDURE|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
219504492|NCT03207659|PROCEDURE|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
219606588|NCT05752825|RADIATION|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
219504493|NCT03496454|OTHER|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
219504494|NCT02407756|DRUG|Dupilumab|
219504495|NCT01030276|OTHER|Bright light therapy|Bright light therapy
219606589|NCT05752825|RADIATION|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
219606590|NCT05752825|DIAGNOSTIC_TEST|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
218883228|NCT04543695|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
218883229|NCT04543695|DRUG|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
218883230|NCT04543695|DRUG|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
218883231|NCT04543695|PROCEDURE|TME|Total mesorectal excision
218883232|NCT02130596|BEHAVIORAL|Acceptance-Based Behavioral Intervention|
219028144|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
219028145|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
219028146|NCT01531387|DRUG|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
219028147|NCT03873870|DIAGNOSTIC_TEST|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
219040274|NCT02357940|DRUG|Experimental Product|1% Colloidal Oatmeal Balm
219040275|NCT03304847|OTHER|ablation|radio-frequency applications on arrhythmogenic substrate
219201043|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks
219504496|NCT01030276|OTHER|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
219504497|NCT02535052|BIOLOGICAL|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
219504498|NCT06407895|OTHER|Lower Limb Fitness Program|the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity
219504499|NCT06407895|OTHER|Routine Therapy|In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
219504500|NCT02783742|BEHAVIORAL|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
219504501|NCT01674842|RADIATION|Radiation Therapy|Once daily, Monday - Friday for six weeks
219606591|NCT05752825|DIAGNOSTIC_TEST|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
219606592|NCT05752825|DIAGNOSTIC_TEST|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of \>13,5 seconds is associated with an increased risk of falls.
219606593|NCT05752825|DIAGNOSTIC_TEST|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
219606594|NCT05752825|DIAGNOSTIC_TEST|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
219504502|NCT01674842|DRUG|Cisplatin|Intravenously, once weekly for six weeks
219504503|NCT00895583|DRUG|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
219504504|NCT00895583|DRUG|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
219504505|NCT00895583|DRUG|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
219504506|NCT00616928|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
219504507|NCT00616928|BIOLOGICAL|Placebo|Two intramuscular injections at Days 0 and 21.
219504508|NCT04624269|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
219504509|NCT04109378|PROCEDURE|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
219606595|NCT05752825|DIAGNOSTIC_TEST|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
219606596|NCT05835674|DIAGNOSTIC_TEST|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
219606597|NCT03240029|OTHER|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
219606598|NCT00796757|DRUG|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
219606599|NCT00796757|DRUG|interferon alfa-2a|3 MIU sc t.i.w.
219606600|NCT04201730|PROCEDURE|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
219606601|NCT03792022|BEHAVIORAL|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
219606602|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
219606603|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
219606604|NCT05134363|DRUG|Placebo|equal volume of normal saline
219606605|NCT02324582|DRUG|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
219606606|NCT01312558|BEHAVIORAL|Prudent diet group|
219606607|NCT01312558|BEHAVIORAL|Mediterranean diet group|
219606608|NCT00062530|BIOLOGICAL|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
219606609|NCT00365703|PROCEDURE|Feeding tube insertion|"1. Orogastric feeding tube~2. Nasogastric feeding tube"
219606610|NCT03272178|DEVICE|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
219606611|NCT03272178|DEVICE|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
219504510|NCT04163692|OTHER|Progressive relaxation exercises|"Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things."
219504511|NCT03333525|OTHER|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
219504512|NCT04593680|DRUG|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
219504513|NCT04120168|GENETIC|Laboratory Tests|"* Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
219606612|NCT00698711|BIOLOGICAL|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
219606613|NCT01277211|DRUG|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
219606614|NCT01277211|DRUG|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
219606615|NCT02939794|DRUG|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
219606616|NCT02939794|DRUG|Placebo|Saline (normal saline, sodium chloride)
218883233|NCT02130596|OTHER|Nutritional Counselling|
219606617|NCT02022878|PROCEDURE|PCI of CTO|
219606618|NCT04109144|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
219606619|NCT04109144|BIOLOGICAL|Albumin|Albumin will be used during the 1st and 3rd paracentesis
219606620|NCT04109144|PROCEDURE|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
218883234|NCT03700489|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
218883235|NCT00475904|DRUG|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
218883236|NCT00475904|DRUG|Gabapentin Capsules|1800mg/day capsules for 4 weeks
218883237|NCT00475904|DRUG|placebo|placebo cream and caps
218883238|NCT06473792|OTHER|Probiotic Toothpaste|"Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily."
218883239|NCT03009734|DRUG|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
218883240|NCT03579043|OTHER|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
218883241|NCT03579043|OTHER|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
219040276|NCT02275481|DRUG|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
219504514|NCT03509051|BIOLOGICAL|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
219504515|NCT06223581|OTHER|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
219504516|NCT04453566|OTHER|Online Survey|Online Survey
219504517|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
219504518|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
219504519|NCT02260375|BIOLOGICAL|Mesenchymal Stromal Cells|
218883242|NCT03579043|OTHER|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
218883243|NCT05716360|DIAGNOSTIC_TEST|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
218883244|NCT05716360|PROCEDURE|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
218883245|NCT05716360|PROCEDURE|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
218883246|NCT02750319|DRUG|Amiodarone|
218883247|NCT02750319|DRUG|N-Acetylcysteine|
218883248|NCT02750319|DRUG|Placebo|
218883249|NCT05370872|DIAGNOSTIC_TEST|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
218883250|NCT02523781|OTHER|information pamphlet|The intervention group receives the information pamphlet
218883251|NCT01147354|DIETARY_SUPPLEMENT|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
218883252|NCT01147354|OTHER|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
218883253|NCT01023360|DRUG|Clopidogrel and proton pump inhibitors|"baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week"
218883254|NCT04118049|OTHER|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
218883255|NCT04118049|OTHER|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
218883256|NCT01847989|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
219504520|NCT05830448|BEHAVIORAL|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
219040277|NCT02275481|DRUG|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
218883257|NCT01847989|DRUG|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
218883258|NCT03629353|PROCEDURE|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
218883259|NCT03629353|PROCEDURE|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
218883260|NCT02156414|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
218883261|NCT02156414|PROCEDURE|Extended Lymphadenectomy|Extended Lymphadenectomy
218883262|NCT02663830|DRUG|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
218883263|NCT02663830|DRUG|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
218883264|NCT00066963|DEVICE|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
219040278|NCT06363565|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
219040279|NCT06363565|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
219504521|NCT05830448|BEHAVIORAL|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
219504522|NCT05062109|BEHAVIORAL|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~* Muscle rehabilitation developed with a physiotherapist or physical activity monitor~* Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~* Cognitive and physical stimulation Exergame~* Psychological support by a psychologist~* Information in the form of videos on the main risks and important points to know and prepare before and after surgery~* Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~* One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
219504523|NCT01164423|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
219504524|NCT05752305|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
219504525|NCT05752305|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
219504526|NCT03640936|BEHAVIORAL|Induced Sputum|Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
219504527|NCT00548353|DRUG|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
219504528|NCT00548353|DRUG|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
219504529|NCT02328261|DRUG|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
219028148|NCT02517996|DRUG|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
219028149|NCT02517996|DRUG|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
219028150|NCT03837873|DRUG|Rituximab|rituximab 750mg/m2 i.v. on day 0
219504530|NCT04049552|DRUG|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
219504531|NCT04049552|DRUG|Placebo|Petrolatum ointment placebo
218883265|NCT03377153|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
219028151|NCT03837873|DRUG|Etoposide|50mg/m2, continuous i.v. on day 1-4
219028152|NCT03837873|DRUG|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
219028153|NCT03837873|DRUG|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
219028154|NCT03837873|DRUG|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
219028155|NCT03837873|DRUG|Cyclophosphamide|750mg/m2, i.v. on day5
219028156|NCT03837873|DRUG|Lenalidomide|25mg/day, p.o. on day 0-9
219028157|NCT03837873|DRUG|Cisplatin|100mg/m2 continuous i.v. on day 1
219028158|NCT03837873|DRUG|Cytarabine|2g/m2 q12h, i.v. on day 2
219028159|NCT00046696|DRUG|NM-3|
219504532|NCT03421860|DRUG|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
219504533|NCT03421860|DRUG|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
218883266|NCT03377153|OTHER|control|no supplementation
218883267|NCT00988091|DEVICE|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
218883268|NCT00988091|DEVICE|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
219504534|NCT03421860|DRUG|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
219504535|NCT03421860|DRUG|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
218883269|NCT00093652|DRUG|gefitinib|
218883270|NCT00093652|DRUG|oxaliplatin|
219028160|NCT00002173|BIOLOGICAL|HIV-1 Immunogen|
219028161|NCT03336775|PROCEDURE|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
219028162|NCT06584396|OTHER|Non-Interventional Study|Non-interventional study
219028163|NCT00000766|DRUG|Foscarnet sodium|
219028164|NCT00000766|DRUG|Ganciclovir|
219504536|NCT05175079|DEVICE|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
219504537|NCT05175079|OTHER|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
219504538|NCT04960475|OTHER|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
219504539|NCT04960475|OTHER|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
219504540|NCT04960475|OTHER|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
218883271|NCT00093652|PROCEDURE|conventional surgery|
219504541|NCT00333333|PROCEDURE|Cord blood|Cord blood will be obtained at the time of delivery.
219504542|NCT01934374|BEHAVIORAL|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
219504543|NCT05707429|OTHER|The Arabic version of The International Index of Erectile Function (IIEF-5)|The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of \< 22 is defined as ED .
219504544|NCT05707429|OTHER|The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)|was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
219504545|NCT05707429|OTHER|Assessment of depression and anxiety|Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
218883272|NCT00093652|PROCEDURE|neoadjuvant therapy|
218883273|NCT00093652|RADIATION|radiation therapy|
218883274|NCT03023293|OTHER|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
218883275|NCT05999500|BEHAVIORAL|Temple stay experience|Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
218883276|NCT00994422|DRUG|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
218883277|NCT00994422|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
218883278|NCT01520376|BEHAVIORAL|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
218883279|NCT05118698|DRUG|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
218883280|NCT05118698|OTHER|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
218883281|NCT06207526|BEHAVIORAL|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
218883282|NCT00276809|BIOLOGICAL|alemtuzumab|
218883283|NCT00276809|BIOLOGICAL|filgrastim|
218883284|NCT00276809|DRUG|carmustine|
219504546|NCT05707429|OTHER|The Fatigue assessment scale (16)|It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
218883285|NCT00276809|DRUG|cyclophosphamide|
218883286|NCT00276809|DRUG|cytarabine|
219504547|NCT05707429|OTHER|• Quality of life assessment|Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
219504548|NCT05707429|OTHER|The Female Sexual Function Index (FSFI)|The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
219504549|NCT02523365|PROCEDURE|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
219504550|NCT04323007|DIAGNOSTIC_TEST|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
219504551|NCT00922337|DEVICE|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
219504552|NCT00931853|DRUG|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
219504553|NCT05168059|DRUG|Clevidipine 0.5 MG/ML Intravenous Emulsion|Effectiveness and safety of clevidipine
219504554|NCT01677442|PROCEDURE|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
219504555|NCT01677442|PROCEDURE|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
219504556|NCT04591769|DEVICE|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
219504557|NCT02717286|PROCEDURE|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
219606621|NCT06449976|BEHAVIORAL|blue light defocus and blue light filtering|Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.
219504558|NCT04548895|DEVICE|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
219504559|NCT01710306|BEHAVIORAL|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
219504560|NCT03287479|PROCEDURE|Gavi® Vitrification|A closed, semi-automated vitrification system
218883287|NCT00276809|DRUG|dexamethasone|
218883288|NCT00276809|DRUG|etoposide|
218883289|NCT00276809|DRUG|fludarabine phosphate|
218883290|NCT00276809|DRUG|melphalan|
218883291|NCT00276809|PROCEDURE|autologous bone marrow transplantation|
219028165|NCT02642432|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
219028166|NCT02871388|BEHAVIORAL|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
219504561|NCT03287479|PROCEDURE|Cryotop® Vitrification|An open, manual vitrification system
219606622|NCT00594373|DRUG|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
218883292|NCT00276809|PROCEDURE|peripheral blood stem cell transplantation|
218883293|NCT00276809|RADIATION|radiation therapy|
218883294|NCT06109207|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
219028167|NCT00260858|DRUG|Test Meal: Reference food (glucose or white bread)|
219028168|NCT00260858|DRUG|Test Meal: Pirate's Booty|
219028169|NCT00260858|DRUG|Test Meal: Ceaprove wafer|
219028170|NCT00260858|DRUG|Test Meal: Stretch Island Strawberry Fruit Leather|
219504562|NCT01247688|DRUG|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
219504563|NCT01247688|DRUG|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
219504564|NCT01247688|RADIATION|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
219504565|NCT01247688|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
219504566|NCT02247570|PROCEDURE|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
219606623|NCT00594373|DRUG|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
219606624|NCT02898376|OTHER|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
219606625|NCT02898376|DRUG|Pentoxifylline|400 mg bid during at least 6 months
219606626|NCT02898376|DRUG|Tocopherol acetate|500 mg bid during at least 6 months
219606627|NCT01777178|OTHER|Low bicarbonate dialysis|
218883295|NCT06109207|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
218883296|NCT06109207|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
218883297|NCT02087111|DRUG|Telaprevir|375 mg film coated tablets
218883298|NCT02087111|DRUG|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
219504567|NCT03700710|BEHAVIORAL|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
219606628|NCT01382888|DRUG|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
219606629|NCT01382888|DRUG|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
219606630|NCT00283478|DRUG|Iscar Quercus|
219606631|NCT00283478|DRUG|Gemcitabine|
219606632|NCT00879086|DRUG|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
218883299|NCT02087111|DRUG|Ribavirin|200 mg tablets
218883300|NCT05698602|DEVICE|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~* measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~* store the measurements in the embedded memory~* extract from the measurement basic respiratory markers:~* detect if and when a patient is using the respiratory assist device,~* calculate leakage~* calculate respiratory frequency~* transmit the measured values via the NivolisBox component to NivolisPortal"
219606633|NCT00879086|DRUG|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
219606634|NCT06359301|DEVICE|DELTA Revision acetabular cup|Total hip arthroplasty
219606635|NCT03390335|OTHER|Pressure|Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
218883301|NCT05698602|DEVICE|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 \& tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
218883302|NCT00765180|DEVICE|TRE vs. NBI|TRE NBI
218883303|NCT04526041|OTHER|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
219201044|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~\- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
219606636|NCT03390335|OTHER|Breathing Gas|Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
219606637|NCT02990429|PROCEDURE|Forced Air warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room"
219606638|NCT02990429|PROCEDURE|Intravenous Fluid Warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room"
219606639|NCT01872923|DRUG|Amphinex|Photosensitiser
219606640|NCT01872923|DRUG|Bleomycin|Anticancer agent
219606641|NCT01872923|DEVICE|Laser|Laser that emits red light at 652 nm.
219606642|NCT02333903|OTHER|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
219606643|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
219606644|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
219606645|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
219606646|NCT00320203|OTHER|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
219028171|NCT04444414|OTHER|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
219028172|NCT04444414|OTHER|Control group|The control group received no treatment, they only attended the evaluations.
219504568|NCT03700710|BEHAVIORAL|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
219504569|NCT02479828|DRUG|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
219504570|NCT02479828|DRUG|Ropivacaine|
219504571|NCT02479828|DEVICE|ultrasound|
219504572|NCT02479828|DRUG|Placebo|
219504573|NCT02123459|DRUG|Cephalexin|Administered orally
219504574|NCT05009628|PROCEDURE|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
219504575|NCT05009628|PROCEDURE|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
219504576|NCT05009628|PROCEDURE|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
219028173|NCT03204513|DEVICE|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
219028174|NCT03204513|DEVICE|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
219028175|NCT04366037|OTHER|Routine training|Training will be defined by each club coach
219028176|NCT04366037|OTHER|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
219040280|NCT05223855|OTHER|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
219040281|NCT02338765|BEHAVIORAL|mHealth Physical Activity|
218883304|NCT04526041|OTHER|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
218883305|NCT04526041|OTHER|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
218883306|NCT04526041|OTHER|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
218883307|NCT00300313|DRUG|Escitalopram|10 to 20 mg / day
218883308|NCT00300313|DRUG|Placebo|1-2 capsules
218883309|NCT01162902|DRUG|Diltiazem treated group|Diltiazem 180mg for 9 months
218883310|NCT01162902|DRUG|Bisoprolol treated group|Bisoprolol 5mg for 9 months
218883311|NCT01162902|DRUG|Candesartan treated group|Candesartan 32mg for 9 months
218883312|NCT06364462|OTHER|lifestyle intervention|Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating components (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable. Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence.
218883313|NCT04423692|OTHER|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
219504577|NCT03553784|OTHER|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
219504578|NCT06526897|PROCEDURE|Biopsy|Undergo biopsy
219504579|NCT06526897|PROCEDURE|Chest Computed Tomography|Undergo chest CT
219504580|NCT06526897|PROCEDURE|Chest Radiography|Undergo CXR
219606647|NCT04521894|DEVICE|Positron emission tomography/computerized tomography (PET/CT)|"1. Genetic factors and age:~   Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~2. Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~3. Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~4. Infection:~5. Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~6. Daily diet: The corrective mechanism of diet in PCa is not very clear.~7. Drinking history:"
218883314|NCT03637478|BEHAVIORAL|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
219504581|NCT06526897|OTHER|Quality-of-Life Assessment|Ancillary studies
219504582|NCT06526897|OTHER|Questionnaire Administration|Ancillary studies
219504583|NCT03658278|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
219504584|NCT06527053|DEVICE|obturator|special maxillofacial device to close hollow defects
219504585|NCT00643110|DRUG|D50 glucose|D50 glucose would be administered, if necessary.
219504586|NCT00036777|DRUG|carboplatin|Given IV
219504587|NCT00036777|DRUG|7-hydroxystaurosporine|Given IV
219504588|NCT00036777|OTHER|pharmacological study|Correlative studies
219504589|NCT01191255|DRUG|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
219504590|NCT05555082|OTHER|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
219028177|NCT04366037|OTHER|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
219028178|NCT05705492|DRUG|Olanzapine|Given PO
219028179|NCT05705492|DRUG|Placebo Administration|Given PO
219028180|NCT05705492|OTHER|Questionnaire Administration|Ancillary studies
219028181|NCT04980677|DEVICE|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
219606648|NCT01385774|PROCEDURE|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
219028182|NCT03245008|DRUG|MT-5547|Solution for injection in pre-filled syringe
219504591|NCT05163002|BEHAVIORAL|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
219504592|NCT06525441|OTHER|Plant-based Diet|Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
219504593|NCT06525441|OTHER|Animal-based Diet|Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
218883315|NCT03100604|DRUG|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
219504594|NCT00920335|OTHER|tumoral sample|Ependymoma tumoral sample
219504595|NCT05744661|OTHER|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
219504596|NCT05744661|OTHER|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
219504597|NCT02196506|DRUG|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
219504598|NCT02196506|DRUG|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
219504599|NCT01396759|PROCEDURE|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
219504600|NCT01396759|PROCEDURE|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
219504601|NCT01396759|PROCEDURE|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
219504602|NCT00202553|DRUG|Perindopril|
219504603|NCT05738564|DRUG|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
219504604|NCT01494220|DEVICE|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
219504605|NCT05602233|OTHER|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
219504606|NCT05602233|OTHER|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
219504607|NCT00368329|DRUG|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
219504608|NCT00368329|DRUG|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
219504609|NCT00368329|DRUG|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
219504610|NCT00368329|DRUG|Carboplatin|AUC 2, based onCalvert formula IV infusion
219504611|NCT00254397|DRUG|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
219504612|NCT00254397|BIOLOGICAL|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
219504613|NCT00254397|BIOLOGICAL|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
219028183|NCT03245008|DRUG|MT-5547-matching placebo|Solution for injection in pre-filled syringe
219504614|NCT00323583|DRUG|paclitaxel|
219040282|NCT02338765|BEHAVIORAL|Buddy-partnered exercise|
219504615|NCT00323583|DRUG|oxaliplatin|
219504616|NCT00323583|DRUG|leucovorin|
219504617|NCT00323583|DRUG|5-fluorouracil|
219504618|NCT00323583|DRUG|glutathione|
218883316|NCT03100604|DRUG|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
218883317|NCT03084835|BEHAVIORAL|Usual Care|Brief cessation counseling
218883318|NCT03084835|BEHAVIORAL|WEB+TXT|Access to Become an Ex website plus text messaging
218883319|NCT03084835|BEHAVIORAL|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
219504619|NCT00323583|DRUG|calcium and magnesium|
218883320|NCT01806675|DRUG|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
218883321|NCT01806675|DRUG|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
218883322|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
218883323|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
219504620|NCT00323583|PROCEDURE|Chemotherapy|
219504621|NCT00323583|PROCEDURE|Chemoprotection|
219504622|NCT00323583|PROCEDURE|Complementary and alternative therapy|
219606649|NCT01385774|OTHER|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
219504623|NCT04624191|OTHER|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
219504624|NCT00973037|DRUG|Tamoxifen|Tamoxifen 20mg qd
219504625|NCT06344702|DEVICE|CPAP|70% of nights use CPAP for more than 4 hours
219504626|NCT05953285|OTHER|Sleep restriction|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
219504627|NCT02926183|DRUG|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
219504628|NCT00528437|DRUG|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
219504629|NCT03242993|DRUG|[18F]-AzaFol|\[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
219504630|NCT03242993|DRUG|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
219504631|NCT04181996|DRUG|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
219504632|NCT04181996|DRUG|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
219606650|NCT06331169|DRUG|Anlotinib|Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
219606651|NCT06331169|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
218883324|NCT03422536|BIOLOGICAL|Cetuximab|Given IV
218883325|NCT03422536|DRUG|Ficlatuzumab|Given IV
218883326|NCT00087659|DRUG|zoledronic acid|
218883327|NCT00587704|PROCEDURE|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
218883328|NCT00587704|PROCEDURE|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
219028184|NCT01139736|DIETARY_SUPPLEMENT|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
219028185|NCT03209427|DRUG|Morphine 100 μg|Intrathecal injection of morphine100 μg
219504633|NCT03727464|BEHAVIORAL|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
219504634|NCT03727464|BEHAVIORAL|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
219504635|NCT03727464|BEHAVIORAL|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
219504636|NCT03727464|DRUG|Propofol|Propofol general anesthesia
218883329|NCT00209703|DRUG|Oxaliplatin|
218883330|NCT00209703|DRUG|l-Leucovorin|
219028186|NCT03209427|DRUG|Morphine 200 μg|Intrathecal injection of morphine 200 μg
218883331|NCT00209703|DRUG|5-Fluorouracil|
218883332|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
219040283|NCT03387163|DRUG|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
219504637|NCT03727464|DRUG|Sevoflurane|Sevoflurane general anesthesia
218883333|NCT05711524|BIOLOGICAL|Traditional Cryoprecipitate|This is the cryoprecipitate already currently being given to patients with a cryo order.
218883334|NCT05711524|BIOLOGICAL|Pathogen-Reduced Cryoprecipitate|This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
219504638|NCT06481553|DRUG|first line treatment|Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
219504639|NCT05843838|PROCEDURE|Hypotension during spinal anesthesia for cesarean section|Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value
219504640|NCT05843838|DIAGNOSTIC_TEST|Mini-mental test|"A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated."
219504641|NCT05843838|PROCEDURE|Spinal anesthesia|It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
219606652|NCT00492505|DRUG|cisplatin|
219606653|NCT00492505|DRUG|sorafenib tosylate|
219606654|NCT00492505|DRUG|tamoxifen citrate|
219606655|NCT00492505|PROCEDURE|adjuvant therapy|
219606656|NCT06064305|OTHER|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
219504642|NCT05843838|DIAGNOSTIC_TEST|The Bromage scale|"The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet"
219504643|NCT05843838|DRUG|Heavy Bupivacaine for spinal anesthesia|Routine clinical heavy bupivacaine doses
219504644|NCT04087083|OTHER|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
219504645|NCT04087083|OTHER|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
219504646|NCT00094783|PROCEDURE|MRI|
219504647|NCT03165643|DIAGNOSTIC_TEST|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
219504648|NCT06325982|DRUG|Triethanolamine cream|"Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months.~Preparation method: Pull out the syringe piston, add 15ml triethanolamine cream, add 30ml normal saline, gently pat, shake well.~Specific methods of retention enema: at night before going to bed, empty urine and feces, prepare enema liquid into the syringe, connect the special catheter, and insert the other end of the special catheter into the anus (the special catheter can be applied with lubricant such as tea oil before insertion). The patient remained prone and semi-seated. Use a special catheter, insert a special catheter about 15cm from the anus, and inject enteral liquid while withdrawing, so that the liquid is retained in the rectum; The above treatment was performed before bed and retained overnight."
219504649|NCT04344054|BIOLOGICAL|RV3-BB|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
219504650|NCT04344054|BIOLOGICAL|Trivalent P2-VP8|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
219504651|NCT04344054|BIOLOGICAL|Rotarix|1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
219504652|NCT04344054|BIOLOGICAL|RV3-BB birth dose|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
219504653|NCT04344054|BIOLOGICAL|Trivalent P2-VP8 Booster dose|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
219504654|NCT05617820|DRUG|Estradiol|Vaginal Insert, 4 mcg tablet
219504655|NCT05617820|DRUG|Imvexxy|Estradiol 4 mcg Vaginal Insert
219504656|NCT05617820|DRUG|Placebo|Vehicle Vaginal Insert
219504657|NCT00967200|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219504658|NCT00967200|OTHER|pharmacogenomic studies|pharmacogenomic studies
219504659|NCT06432621|PROCEDURE|using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation|patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
219606657|NCT03694756|DEVICE|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
219606658|NCT03694756|PROCEDURE|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
219606659|NCT05274633|DRUG|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
219606660|NCT02928445|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
219028187|NCT01286012|DRUG|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
219028188|NCT01286012|DRUG|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
219504660|NCT02116491|DEVICE|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
219504661|NCT03644602|DIETARY_SUPPLEMENT|low FODMAPs diet|Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
219504662|NCT01035320|DRUG|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
219040284|NCT06032312|OTHER|description|no intervention, just description of the groups
219504663|NCT03994094|OTHER|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
219606661|NCT02928445|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
219606662|NCT04031755|DRUG|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
219504664|NCT05898282|OTHER|observation|since this is a cross sectional observational study any form of intervention was not applicable
219504665|NCT04953585|PROCEDURE|radical gastrectomy|According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
219504666|NCT00344630|DEVICE|TAXUS Stent and Cypher Stent|
219504667|NCT03501550|DRUG|CDI-31244|investigational drug
219504668|NCT03501550|DRUG|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
219504669|NCT04158479|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
219504670|NCT01386879|DRUG|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
219504671|NCT01724970|DEVICE|ProSeal|Patients will be ventilated with PLMA
219504672|NCT01724970|DEVICE|Supreme LMA|Patients will be ventilated with SLMA
219504673|NCT03903484|OTHER|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
219504674|NCT01743677|DRUG|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
219606663|NCT04031755|DRUG|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
219028189|NCT01286012|DRUG|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
219028190|NCT01286012|DRUG|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
219028191|NCT04476433|OTHER|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
219028192|NCT00032643|DRUG|DITPA|
219504675|NCT01743677|DRUG|Placebo|Single dose placebo tablets (5 tablets)
219504676|NCT01743677|DRUG|Moxifloxacin|Single dose Avelox 400 mg tablet
219504677|NCT06680089|DRUG|[18F]RCCB6|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
219504678|NCT01715415|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219504679|NCT01715415|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
219504680|NCT01715415|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
219028193|NCT03567707|BIOLOGICAL|C-section -Vaginal seeding|"Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
219040285|NCT02829593|OTHER|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
219040286|NCT02661360|BEHAVIORAL|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
219040287|NCT02661360|BEHAVIORAL|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
219040288|NCT01495585|DRUG|Lonafarnib|Commercially approved products used to test the research hypothesis
219504681|NCT01715415|DRUG|Placebo for ABT-333|Tablet
219504682|NCT01715415|DRUG|Placebo for ribavirin|Capsule
219504683|NCT00563303|DRUG|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
219504684|NCT00563303|DRUG|NaCl|48mL from Day 1 to Day 6
219504685|NCT01244607|DRUG|Placebo|single i.v. administration
219504686|NCT01244607|DRUG|NI-0801|single i.v. administration
219504687|NCT01418729|DRUG|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
219040289|NCT01495585|OTHER|Placebo|Placebo control
219040290|NCT05769959|DRUG|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
219040291|NCT05769959|DRUG|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
219504688|NCT02818478|OTHER|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
219504689|NCT05463458|OTHER|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
219504690|NCT01438333|DIETARY_SUPPLEMENT|lactobacillus brevis tablets|5 tablets a day for 6 weeks
219504691|NCT01438333|DIETARY_SUPPLEMENT|PLACEBO|5 tablets a day for 6 weeks
219504692|NCT00990119|DEVICE|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
219504693|NCT00990119|DEVICE|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
219504694|NCT06418087|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]|"Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit."
219504695|NCT05185687|BEHAVIORAL|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
219504696|NCT05185687|BEHAVIORAL|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
219504697|NCT05185687|BEHAVIORAL|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
219504698|NCT05028751|DRUG|Lanraplenib|Orally via tablets
219504699|NCT05028751|DRUG|Gilteritinib|Orally via tablets
219504700|NCT03092089|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
219504701|NCT03092089|DEVICE|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
219504702|NCT03092089|PROCEDURE|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
219504703|NCT03586830|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
219504704|NCT03586830|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
219504705|NCT03586830|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
219504706|NCT03586830|DRUG|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
219504707|NCT04578548|DRUG|GLPG2737|Capsules administered orally
219504708|NCT04578548|DRUG|Placebo|Matching placebo capsules administered orally
219504709|NCT06346054|DIAGNOSTIC_TEST|Breath analysis|Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
219504710|NCT06346054|DIAGNOSTIC_TEST|Blood analysis|Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
219040292|NCT01991002|BEHAVIORAL|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
219040293|NCT00006211|DRUG|Capravirine|
219504711|NCT02248285|DEVICE|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
219504712|NCT00288171|DRUG|Placebo|placebo capsule twice daily for one month
219504713|NCT00288171|DRUG|Allopurinol|Allopurinol 200mg twice daily for one month
219504714|NCT06421623|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
219504715|NCT00395083|BEHAVIORAL|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
219504716|NCT05452577|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
219504717|NCT05452577|DRUG|Estazolam 1Mg Tab|1mg tablet once daily
219504718|NCT00972153|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
219504719|NCT00972153|DEVICE|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
219606664|NCT05671458|OTHER|intraoperative navigation and creation of tumor resection maps|TRM are based on intraoperative navigation data and yield anatomically accurate marks of the tumor resection margin and potential residual tumor areas on clinical imaging. These marks will be annotated with histopathological information. Subsequently, the resulting 3-dimensional TRM will be imported into the radiotherapy planning system as part of a multidisciplinary workflow.
219606665|NCT02864355|DEVICE|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
219606666|NCT00719186|DRUG|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
219606667|NCT00719186|DRUG|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
219606668|NCT02818101|BEHAVIORAL|Hypnosis session|
219606669|NCT01558960|DRUG|IVit Melphalan|IVit injections of Melphalan
219606670|NCT04502212|DEVICE|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
219606671|NCT00111241|DRUG|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
219504720|NCT01078415|DEVICE|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
219606672|NCT06550765|DEVICE|Biodegradable Magnesium Metal Clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
219606673|NCT05443178|DRUG|Nivaquine ® (Chloroquine)|dose escalation and extension trial
219606674|NCT02462863|DIETARY_SUPPLEMENT|Arginine and fish oil|Dietary supplements
219504721|NCT00482313|DRUG|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
219606675|NCT04912232|DEVICE|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
219606676|NCT03927456|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219606677|NCT03927456|DRUG|Placebo|Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219028194|NCT03567707|DRUG|C-section - Placebo Seeding|"Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
219028195|NCT03567707|OTHER|Standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
219028196|NCT01395329|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
219028197|NCT01395329|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
219606678|NCT03927456|DRUG|Fulvestrant|Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
219606679|NCT06677359|DIETARY_SUPPLEMENT|Creatine Group|Micronized creatine monohydrate supplementation.
219606680|NCT06677359|DIETARY_SUPPLEMENT|Placebo Group|Participants will recieved placebo supplementation
219606681|NCT06677359|OTHER|Multicomponent Training|Multicomponent physical exercise intervention
219606682|NCT03108885|OTHER|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
219028198|NCT01395329|DRUG|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
219028199|NCT01395329|OTHER|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
219040294|NCT00006211|DRUG|Nelfinavir mesylate|
219040295|NCT00089570|DRUG|terlipressin|
219040296|NCT00089570|DRUG|Placebo|
219040297|NCT01274403|DRUG|Melphalan, Prednisone and Thalidomide|
219040298|NCT02769702|DRUG|Acthar|Acthar 80 IU SC twice a week
219504722|NCT00482313|DRUG|Placebo|Sugar pill
219504723|NCT05576909|DRUG|Donafenib|"0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy"
219504724|NCT05576909|PROCEDURE|TACE|For downstaging treatment
219504725|NCT00002594|BIOLOGICAL|Sargramostim|Given IV
219504726|NCT00002594|DRUG|cyclophosphamide|Given IV
219504727|NCT00002594|DRUG|melphalan|Given IV
219504728|NCT00002594|PROCEDURE|autologous bone marrow transplantation|
219504729|NCT00002594|PROCEDURE|bone marrow ablation with stem cell support|
219504730|NCT00002594|PROCEDURE|peripheral blood stem cell transplantation|
219201045|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~\- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
219201046|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
219504731|NCT05273398|DRUG|nasal diazepam|Nasal administration of diazepam
219201047|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
219504732|NCT03354156|DRUG|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
219504733|NCT02204215|DEVICE|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
218883335|NCT06977048|OTHER|Mobile Application-Based Educational Program|"Week 0:~Participants are informed about the study and trained in the use of the mobile application.~The mobile app is installed on their smartphones.~Educational animation videos and modules are watched with the researcher in a predefined order.~Questions about animations are answered.~Videos are downloaded to the participant's phone.~DFU photographs are recorded.~Weeks 1-12:~Participants are instructed to use the app regularly between weeks 5-12.~Video watching days and durations are logged using a tracking form.~Weekly push notifications remind participants to use the app.~Weekly phone calls are made to assess engagement using a structured checklist.~DFU photographs are taken at weeks 8 and 12.~At week 12, data are collected in person, including:~DFU size (length × width) with disposable paper ruler~Metabolic parameters from blood tests~Wagner-Meggitt classification~Re-ulceration assessment"
219201048|NCT02994927|DRUG|Azathioprine|Orally administered
219201049|NCT06634160|DIAGNOSTIC_TEST|Fibroscan|Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
219201050|NCT06634160|OTHER|Sample collection|20 mL whole blood sample
219201051|NCT06406452|DEVICE|Bioresorbable Tracheobronchial Splint|"Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires."
219201052|NCT06365099|DEVICE|Single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere while participants rest quietly with their eyes open
219504734|NCT02204215|OTHER|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
219504735|NCT03904498|DRUG|Tolcapone|Tolcapone 100 mg tablets
219504736|NCT03904498|DRUG|Placebo|Placebo tablets
219504737|NCT06394921|PROCEDURE|2 day cardiopulmonary exercise test|Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
219504738|NCT04136626|DEVICE|Perspectives OCD|The app-delivered cognitive behavioral therapy (CBT) in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
219504739|NCT04136626|DEVICE|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
219504740|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
219504741|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
219504742|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
219504743|NCT00628745|OTHER|None. Observational Study.|
219504744|NCT06384365|BEHAVIORAL|Physical activity|The control and the athletic group differ in the degree of physical acitvity
219504745|NCT03570580|OTHER|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
219504746|NCT02386410|BEHAVIORAL|Group parent training for anxious parents|
219504747|NCT02386410|BEHAVIORAL|Internet delivered parent training for anxious parents|
219504748|NCT03522779|DIETARY_SUPPLEMENT|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
219504749|NCT03522779|OTHER|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
219504750|NCT03522779|OTHER|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
219504751|NCT03322462|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
219504752|NCT03322462|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
219504753|NCT04289220|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
219504754|NCT05126381|BEHAVIORAL|Smoking|The Study contains patients who are allowed to smoke
219504755|NCT05126381|BEHAVIORAL|non-somking|The Study contains patients who are not allowed to smoke
219504756|NCT02874495|BEHAVIORAL|Psychological tests|Related to affective and cognitive dimensions of pain.
219504757|NCT02874495|DEVICE|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
219504758|NCT02874495|BEHAVIORAL|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
219504759|NCT01025856|OTHER|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
219504760|NCT01025856|OTHER|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
219504761|NCT01025856|OTHER|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
219504762|NCT01025856|OTHER|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
219504763|NCT04812509|DRUG|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
219504764|NCT04812509|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
219504765|NCT04459663|DRUG|Toripalimab injection combine with Axitinib|The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
219504766|NCT03350048|DIAGNOSTIC_TEST|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
219504767|NCT00598559|DRUG|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
219504768|NCT03381248|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
219028200|NCT01395329|OTHER|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
219028201|NCT01395329|OTHER|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
219028202|NCT01395329|OTHER|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
219201053|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
219201054|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
219028203|NCT01395329|OTHER|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
219028204|NCT01722253|PROCEDURE|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
219201055|NCT06045819|BIOLOGICAL|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
219201056|NCT04466241|DRUG|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
219201057|NCT04466241|DRUG|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
219201058|NCT04466241|DRUG|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
219201059|NCT06692335|PROCEDURE|High-Intensity Focused Ultrasound (HIFU)|The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
219201060|NCT06692335|PROCEDURE|myomectomy|Laparoscopic or open or hysteroscopic myomectomy will be performed.
219201061|NCT06867614|PROCEDURE|Total laparoscopic hysterectomy|Removal of uterus and cervix by laparoscope
219201062|NCT03250676|DRUG|H3B-6545|Oral capsules by mouth once daily
219504769|NCT03381248|OTHER|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
219504770|NCT03381248|OTHER|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
219504771|NCT05760703|DRUG|STSG-0002 Injection|Intravenous infusion
219504772|NCT01368003|DRUG|STA9090|200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
219504773|NCT01368003|DRUG|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
219504774|NCT04816097|DRUG|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
219504775|NCT03715595|OTHER|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
219504776|NCT02419859|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
219504777|NCT02419859|DRUG|Insulin, Asp(B28)-|a fast-acting analog of human insulin
219504778|NCT00548990|BEHAVIORAL|cardiovascular exercise training|
219504779|NCT00548990|BEHAVIORAL|flexibility/balance control|
219504780|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
219504781|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
219504782|NCT03974152|OTHER|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
219504783|NCT05586620|PROCEDURE|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
219504784|NCT05586620|PROCEDURE|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
219504785|NCT00418782|DRUG|naproxen|
219504786|NCT00418782|DRUG|CE-224535|
219504787|NCT00418782|DRUG|placebo|
219504788|NCT03164863|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
219504789|NCT00647049|DRUG|methotrexate|8000mg/m2 i.v., max. 2 cycles
219504790|NCT00647049|DRUG|Rituximab|375mg/m2, max. 8 times
219504791|NCT00647049|DRUG|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
219504792|NCT00647049|DRUG|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
219504793|NCT00647049|DRUG|Carmustin|400mg/m2 i.v. for 1 day
219504794|NCT04484597|DIAGNOSTIC_TEST|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
219504795|NCT04579497|OTHER|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
219504796|NCT04579497|OTHER|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
219606683|NCT03109561|OTHER|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
219606684|NCT03109561|GENETIC|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
219606685|NCT03109561|DIAGNOSTIC_TEST|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
219606686|NCT03109561|OTHER|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
219606687|NCT06583057|PROCEDURE|Thermal ablation|Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
219201063|NCT06879496|DRUG|Oral ketamin|Patients will be received oral ketamine before operation
218883336|NCT06977048|OTHER|Standard care|"Participants provide consent and receive baseline information.~DFU photographs are taken at baseline, week 8, and week 12.~At week 12, the same outcome measures as the intervention group are collected.~After the study ends, participants are provided with access to the mobile application."
218883337|NCT06975566|PROCEDURE|radial artery catheterization|
219201064|NCT06879496|DRUG|Oral Midazolam|Patients will be received oral Midazolam
219504797|NCT04579497|OTHER|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
219504798|NCT04579497|OTHER|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
219606688|NCT06583057|PROCEDURE|Thyroid lobectomy|Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
219606689|NCT05276362|DEVICE|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
219504799|NCT05992545|DEVICE|Mobile application 'DangDang Care' under usual care|"The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care."
219504800|NCT06104930|OTHER|Explorative biomarker study|Analysis of blood biomarker
219504801|NCT01405950|DRUG|Zanaflex Capsules|0.025 mg/kg
219201065|NCT06879496|DRUG|Oral dexmedetomidine|Patients will be received oral dexmedetomidine
219504802|NCT01405950|DRUG|Zanaflex Capsules|0.05 mg/kg
219504803|NCT01405950|DRUG|Zanaflex Capsules|0.075 mg/kg
219504804|NCT01405950|DRUG|Zanaflex Capsules|0.1 mg/kg
219606690|NCT05276362|DEVICE|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
219504805|NCT05261113|PROCEDURE|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
219504806|NCT02171936|OTHER|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
219606691|NCT02193217|DRUG|MT-1303-Low|
219606692|NCT02193217|DRUG|MT-1303-High|
219606693|NCT02193217|DRUG|Fingolimod|
218883338|NCT06975917|DRUG|Chemotherapy|Any chemotherapy regimen that is used in the adjuvant setting
218883339|NCT06974500|PROCEDURE|Daily efferent limb stimulation for at least two weeks prior to surgery using saline solution and a thickering agent|"Participants in the intervention group will undergo daily stimulation of the efferent limb for a minimum of two weeks prior to ileostomy closure. The procedure involves the instillation of a solution composed of saline and a thickening agent through the efferent limb of the ileostomy via the inactive orifice. This is performed by the patient at home following specific training and instructions provided during a preoperative consultation.~The stimulation begins the day after the pre-anaesthesia consultation and is carried out once per day. Patients are supported with a structured follow-up, including one physical consultation in the stoma clinic, telephone contact with the research team every 48 hours, and access to an email address for queries. The objective of the intervention is to recondition the excluded colon before the restoration of intestinal continuity in order to reduce postoperative complications."
218883340|NCT06976190|DRUG|MRG003 + Pucotenlimab|MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.
218883341|NCT06976190|DRUG|Gemcitabine, Docetaxel, or Capecitabine|"Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle).~Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle).~Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle)."
219028205|NCT05053529|OTHER|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
219028206|NCT05053529|OTHER|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
219028207|NCT00564655|PROCEDURE|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
219504807|NCT04485000|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
219504808|NCT02410252|DEVICE|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
219504809|NCT06529263|OTHER|newborn massage|Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
219504810|NCT01396941|BEHAVIORAL|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
219504811|NCT01753479|OTHER|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
219504812|NCT03877055|DRUG|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
219504813|NCT03877055|DRUG|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
219606694|NCT02193217|DRUG|Placebo|
219606695|NCT01461447|BIOLOGICAL|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
219606696|NCT04511598|DEVICE|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
219606697|NCT04511598|DEVICE|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
219606698|NCT07017959|DIETARY_SUPPLEMENT|LpD3.5 supplementation.|Dietary Supplement: LpD3.5 are in the form of capsule where LpD3.5 contains 167 mg of LpD3.5, with the remaining portion consisting of inactive ingredients like maltodextrin
219606699|NCT07017959|DIETARY_SUPPLEMENT|Placebo|Placebo capsules contain only inactive ingredient maltodextrin
219504814|NCT01336010|DRUG|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
219504815|NCT01336010|DRUG|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
219504816|NCT01125995|RADIATION|early CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
219504817|NCT01125995|RADIATION|late CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
219504818|NCT02224521|DRUG|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
219504819|NCT02224521|DRUG|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
219504820|NCT02224521|DRUG|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
219504821|NCT02224521|DRUG|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
219504822|NCT02224521|DRUG|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
219504823|NCT02224521|DRUG|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
219504824|NCT00387712|OTHER|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
219504825|NCT00387712|OTHER|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
219504826|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|15 Gy in one treatment
219504827|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
219201066|NCT06876831|OTHER|Shared decision making for LDCT (3 potential outcomes LDCT on discharge, scheduled date of LDCT, or Lung Cancer Screening referral)|These interventions will be facilitated as an inpatient
219504828|NCT01433900|DRUG|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
219504829|NCT01433900|DRUG|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
219504830|NCT03943342|DRUG|Ibrutinib|Given PO
219504831|NCT03943342|DRUG|Venetoclax|Given PO
219504832|NCT06541470|PROCEDURE|Cutting needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
219504833|NCT06541470|PROCEDURE|Abrams needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
219504834|NCT01783106|DRUG|Ciprofloxacin|experimental
219504835|NCT01783106|DRUG|Doxycycline|experimental
219504836|NCT01783106|DRUG|Hydroxychloroquine|oral
219504837|NCT01783106|DRUG|Budesonide|active comparator
219606700|NCT03516656|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
219606701|NCT03516656|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
218883342|NCT06975254|OTHER|"On the basis of routine nursing, the Internet + nursing program based on the FLS model is implemented"|1\) During hospitalization: After the patient is admitted to hospital, the coordinator will establish wechat contact with the patient face to face and establish a good trust relationship with the patient; The coordinator and the doctor will collect the patients' cases together, and then according to the patients' conditions and wishes, the diagnosis and treatment plan will be formulated jointly by multiple disciplines, including medicine, rehabilitation and nutrition management. 2) Before discharge: the coordinator helps the patient to make an appointment for return visit; Issue business cards of the team's online and offline services to patients and guide them to use wechat and online service application procedures (such as Zheli Care and Dr. Nari); 3) After discharge: patients keep in touch with the liaison staff at any time, and any abnormal situation will be contacted by the liaison staff; Team members supervised the patient's medication situation by punching in the mini program
218883343|NCT06975033|OTHER|Video|Participants will watch video.
218883344|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
218883345|NCT06576401|DRUG|[14C] HDM1002|Administered orally
219201067|NCT06876831|BEHAVIORAL|Inpatient Tobacco Cessation Counseling (Handouts, NYC Quits number, Medication Recommendations to primary team, Smoking cessation referral)|Active smokers only will received inpatient tobacco cessation counseling/risk reduction
219504838|NCT03119532|OTHER|Receive metric feedback email|If the provider received an email about the participants performance metrics
219504839|NCT00171509|DRUG|Cyclosporine microemulsion|
219606702|NCT06405594|BEHAVIORAL|Language Condition|The intervention involves asking participants to speak and understand words and sentences with different linguistic manipulations such as morphological, semantic, phonological priming, predictability of the subject and object nouns associated with verbs, naming of verbs and nouns, production of sentences with past, future or present tense. Accuracy, response times and brain activity are the outcome measures.
219606703|NCT05632926|DRUG|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
219606704|NCT05632926|DRUG|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
219606705|NCT05632926|DRUG|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
219606706|NCT03697863|PROCEDURE|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
219504840|NCT03818737|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
219504841|NCT03818737|BIOLOGICAL|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
219504842|NCT03818737|BIOLOGICAL|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
219504843|NCT03818737|DRUG|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
219504844|NCT00322309|OTHER|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
219504845|NCT00322309|DRUG|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
219504846|NCT01907737|OTHER|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
219504847|NCT01907737|OTHER|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
219606707|NCT05102812|BEHAVIORAL|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
219606708|NCT04407208|BIOLOGICAL|Convalescent plasma|The minimum titer of specific antibody is 1/80
219606709|NCT05323279|DEVICE|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
219504848|NCT01907737|OTHER|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
218883348|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
219504849|NCT01907737|OTHER|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
219606710|NCT04635527|DRUG|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
219028208|NCT00564655|PROCEDURE|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
219028209|NCT06647953|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219028210|NCT06647953|PROCEDURE|Biospecimen Collection|Tumor tissue is collected and centrally reviewed by a study pathologist
219028211|NCT06647953|PROCEDURE|Bone Scan|Undergo bone scan
219028212|NCT06647953|PROCEDURE|Computed Tomography|Undergo CT
219028213|NCT06647953|DRUG|Cyclophosphamide|Given IV
219028214|NCT06647953|BIOLOGICAL|Dactinomycin|Given IV
219028215|NCT06647953|DRUG|Dexrazoxane|Given IV
219028216|NCT06647953|DRUG|Doxorubicin|Given IV
219606711|NCT04635527|PROCEDURE|cTACE|conventional transarterial chemoembolization
219606712|NCT04635527|DRUG|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
219201068|NCT05536726|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
219201069|NCT05536726|DRUG|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
219201070|NCT05536726|DRUG|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
219201071|NCT06878105|OTHER|Data collection on interventions performs as per medical routine|No intervention other than routine medical practice
219201072|NCT06876987|OTHER|Routine care|Receiving routine care.
219201073|NCT06876987|OTHER|Retraining Program|Retraining program using a mobile-based training system.
219504850|NCT03491878|PROCEDURE|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
219504851|NCT03491878|PROCEDURE|Open|Open cholecystectomy including segments IVB and V
219504852|NCT00752661|DRUG|Tramadol Hydrochloride; JNS013|
219504853|NCT00891683|DRUG|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
218883349|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
218883350|NCT06511349|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
219504854|NCT04675983|DRUG|Sintilimab|Administered IV
219504855|NCT04675983|DRUG|Ramucirumab|Administered IV
219504856|NCT04675983|DRUG|Cisplatin|Administered IV
219504857|NCT04675983|DRUG|5-fluorouracil|Administered IV
219504858|NCT04675983|DRUG|Oxaliplatin|Administered IV
219504859|NCT04675983|DRUG|Capecitabine|Administered orally
219504860|NCT03929211|DRUG|CPI-613|Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
219504861|NCT03929211|DRUG|Hydroxychloroquine|Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
219504862|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
219504863|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
219504864|NCT02405611|BEHAVIORAL|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
219606713|NCT03651830|DEVICE|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
219201074|NCT06708663|DRUG|HX009+IN10018|"The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily."
219606714|NCT03651830|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
219606715|NCT06049979|OTHER|Acute gastrointestinal injury|AGIUS score\>2
219606716|NCT04421300|BEHAVIORAL|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
219201075|NCT06715436|DIETARY_SUPPLEMENT|Mediterranean Diet|The MedDiet will be planned according to the Mediterranean diet pyramid
219201076|NCT06715436|DIETARY_SUPPLEMENT|Ketogenic Diet|Modified Atkins diet with a maximum of 20 g of carbohydrates per day.
219201077|NCT06715436|DIETARY_SUPPLEMENT|Control group|The control group will be asked to continue their dietary and lifestyle habits
219201078|NCT06714071|DIAGNOSTIC_TEST|CRP and Albumin and coagulation profile|CRP and Albumin and coagulation profile
219504865|NCT03104153|PROCEDURE|Early-drain removal|Drain removal at hospital discharge
219504866|NCT04155697|DRUG|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
219504867|NCT04155697|DRUG|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
219504868|NCT05869097|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
219504869|NCT05869097|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
219504870|NCT01890083|BEHAVIORAL|Exercise|
219504871|NCT01890083|BEHAVIORAL|Health Education|
219504872|NCT00682383|DRUG|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
219504873|NCT03867591|OTHER|Gastro-AD®|"The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents."
219504874|NCT03867591|OTHER|Placebo|The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
219504875|NCT02384681|OTHER|Exposure to auditory fatigue|12-hour auditory exposure
219504876|NCT02030574|DRUG|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
219504877|NCT02363582|OTHER|formula|An infant formula contains prebiotics and lactoferrin
219606717|NCT04421300|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
219606718|NCT06398275|DRUG|Remimazolam 20 MG Injection [Byfavo]|Remimazolam 0.1 mg/kg intravenous injection
219606719|NCT06398275|DRUG|NaCl 0.9%|NaCl 0.9% 0.04 mL/kg
219606720|NCT02943928|DEVICE|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
219606721|NCT02943928|DEVICE|traditional method by experience|Operator inserted the double lumen tube by experience
219606722|NCT02167854|DRUG|BYL719|
219028217|NCT06647953|PROCEDURE|Echocardiography Test|Undergo ECHO
219028218|NCT06647953|DRUG|Ifosfamide|Given IV
219504878|NCT01772368|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
219606723|NCT02167854|DRUG|LJM716|
219606724|NCT02167854|DRUG|TRASTUZUMAB|
219606725|NCT04807647|OTHER|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
218883351|NCT05696795|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
219028219|NCT06647953|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219028220|NCT06647953|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219606726|NCT05629897|OTHER|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
218883352|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
218883353|NCT02023996|DEVICE|PET imaging|
218883354|NCT06976658|DRUG|Dorzagliatin|Dorzagliatin 50mg bd
218883355|NCT06976658|DRUG|matched placebo|matched placebo
219028221|NCT06647953|OTHER|Patient Observation|Undergo observation
219028222|NCT06647953|PROCEDURE|Positron Emission Tomography|Undergo PET
219028223|NCT06647953|DRUG|Topotecan|Given IV
219028224|NCT06647953|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219028225|NCT06647953|DRUG|Vincristine|Given IV
219028226|NCT06923774|DEVICE|Ion endoluminal system|Lung nodule biopsy and/or localization procedure using the Ion endoluminal system per sites' standard of care
219028229|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
219028230|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
219028231|NCT07024615|DRUG|ASP2138|Subcutaneously
219606727|NCT00001028|DRUG|Pentamidine isethionate|
219606728|NCT00001028|DRUG|Dapsone|
219606729|NCT05567276|BEHAVIORAL|Non-Violent Resistance parental training|Non-Violent Resistance parental training
219504879|NCT01772368|DRUG|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
219504880|NCT01772368|DRUG|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
219504881|NCT01772368|DRUG|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
219504882|NCT01452529|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
219504883|NCT01452529|DRUG|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
219504884|NCT02449291|DRUG|APD421|
219504885|NCT02449291|DRUG|Placebo|
219504886|NCT05325892|COMBINATION_PRODUCT|This is an observational study|This is an observational study
219504887|NCT00227825|BEHAVIORAL|Motivational interviewing|
219504888|NCT06178146|DRUG|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
219504889|NCT06178146|DRUG|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
219504890|NCT03551730|COMBINATION_PRODUCT|PRT064445/Enoxaparin|
219504891|NCT03551730|COMBINATION_PRODUCT|Placebo/Enoxaparin|
219606730|NCT03638544|DIETARY_SUPPLEMENT|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
219606731|NCT02045589|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
219028232|NCT07024615|DRUG|Oxaliplatin|Injection
219028233|NCT07024615|DRUG|Leucovorin|Injection
219028234|NCT07024615|DRUG|5-FU|Injection
219504892|NCT03551730|DRUG|Placebo|
219606732|NCT02045589|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
219606733|NCT02045589|DRUG|Abraxane®|125 mg/m2 intravenous administration
219606734|NCT06633952|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
219606735|NCT06633952|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
219606736|NCT06633952|DEVICE|noninvasive neurostimulation device|A noninvasive neurostimulation device will be used to deliver theta frequency stimulation or sham stimulation to the frontal part of the brain.
219606737|NCT06633952|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
219028235|NCT07024615|DRUG|Irinotecan|Injection
219028236|NCT07024615|DRUG|Gemcitabine|Intravenously
219028237|NCT07024615|DRUG|Nab-paclitaxel|Intravenously
219028238|NCT07024615|DRUG|Capecitabine|Oral
219028239|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
219028240|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
219028241|NCT06879340|DRUG|DuoCAR20.19.22-D95|Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell surface antigens CD19/20/22.
219028242|NCT06879340|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
219504893|NCT01981486|DRUG|Placebo Tablets|BID modified-release tablets
219504894|NCT01981486|DRUG|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
219504895|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
219504896|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
219504897|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
219504898|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
219504899|NCT00403286|DRUG|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
219504900|NCT00403286|DRUG|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
219504901|NCT00403286|DRUG|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
219504902|NCT00403286|DRUG|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
219504903|NCT06286839|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L.
219606738|NCT01855828|DRUG|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
219606739|NCT01855828|DRUG|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
219606740|NCT01855828|DRUG|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
219606741|NCT01855828|DRUG|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
219606742|NCT01855828|DRUG|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
219606743|NCT01855828|DRUG|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
219606744|NCT01866098|DRUG|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
219606745|NCT01866098|DRUG|Placebo|
219606746|NCT03649347|BEHAVIORAL|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
219028243|NCT06879340|DRUG|Cyclophosphamide (Conditional therapy)|Lymphodepletion chemotherapy
219028244|NCT05781698|DRUG|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
219028245|NCT05781698|DRUG|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
219028246|NCT06710340|DIETARY_SUPPLEMENT|Nuts in the first meeting|30g of walnuts
219028247|NCT06710340|OTHER|Nuts in the second meeting|30g of walnuts
219606747|NCT02851745|DRUG|Linagliptin|
219606748|NCT02851745|DRUG|Placebo|
219606749|NCT04215276|OTHER|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
219606750|NCT04215276|OTHER|Control|patient was not given any intervention
219028248|NCT06887231|OTHER|VR+TENS|Patients will perform task-oriented movements in an immersive scenario while receiving congruent electrical stimulation. During each session, multiple games will be played, with the type and difficulty calibrated based on the patient's level of impairment.
219028249|NCT06887231|OTHER|Conventional rehabilitation|Patients will perform dose-matched conventional rehabilitation (aligned with the intervention group), which will include physiotherapy, occupational therapy, and physical therapy.
219028250|NCT03442738|PROCEDURE|Endocuff group|Endocuff Vision cap on Standard colonoscope
219028251|NCT06894225|DRUG|ACT001|Patients recruited and have signed informed consent will be initiated on ACT001 400mg twice a day. Treatment course will repeat every 28 days in the absence of disease progression or unacceptable toxicity
219028252|NCT04369846|DRUG|GM-XANTHO onitment|Onitment application
219028253|NCT04369846|DRUG|Placebo onitment|Onitment application
219028254|NCT06788028|BEHAVIORAL|Usual Care|All participants receive the usual care via standard mental health services offered by the NMHC to the public free of charge. Participants will have access to these public services regardless of whether or not they choose to participate in this study. If they refuse to participate in the research study, they will still have access to usual care.
219504904|NCT02363010|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
219504905|NCT02363010|BEHAVIORAL|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
219504906|NCT02363010|BEHAVIORAL|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
219504907|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
219504908|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
219606751|NCT04392427|DRUG|Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :|"Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days"
219606752|NCT03629080|BIOLOGICAL|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
219606753|NCT03629080|BIOLOGICAL|placebo|Saline will be used for placebo.
219606754|NCT01948531|DRUG|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
219606755|NCT00224289|DRUG|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
219504909|NCT00472550|DRUG|esomeprazole 20 mg|
219504910|NCT03854084|OTHER|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
219364451|NCT03443167|BEHAVIORAL|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
219504911|NCT03854084|OTHER|Control group|Simulation of the techniques was used in the interventional group
219504912|NCT00330421|DRUG|sorafenib tosylate|Given PO
219504913|NCT00330421|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219504914|NCT00330421|OTHER|laboratory biomarker analysis|Correlative studies
219504915|NCT00330421|OTHER|pharmacological study|Correlative studies
219504916|NCT00330421|PROCEDURE|computed tomography|Correlative studies
219504917|NCT00330421|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
219504918|NCT03154879|DEVICE|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
219504919|NCT04549259|BEHAVIORAL|Group-Based Social Support|This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
219606756|NCT03361774|DRUG|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
219606757|NCT03361774|DRUG|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
219606758|NCT01505582|OTHER|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
219364452|NCT05136274|DRUG|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
219364453|NCT03105739|OTHER|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
219364454|NCT02078479|PROCEDURE|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
219364455|NCT02078479|PROCEDURE|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
219364456|NCT04172090|OTHER|Control|Normal physical activity and standard energy intake
219364457|NCT04172090|OTHER|SIT+E|Reduced physical activity and standard energy intake
219364458|NCT04172090|OTHER|SIT=E|Reduced physical activity and reduced energy intake
219364459|NCT06005584|DEVICE|Spinal Cord Stimulation - High Frequency SCS|"High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks."
219364460|NCT06005584|DEVICE|Spinal Cord Stimulation - Burst SCS|"Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks."
219364461|NCT06005584|DEVICE|Spinal Cord Stimulation - Sham SCS|This intervention will last up to 6 weeks.
219364462|NCT00875758|PROCEDURE|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
219364463|NCT00875758|PROCEDURE|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
219364464|NCT05035121|DIETARY_SUPPLEMENT|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
219364465|NCT05035121|DIETARY_SUPPLEMENT|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
219364466|NCT05035121|BEHAVIORAL|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
219364467|NCT01113151|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
219364468|NCT01113151|OTHER|Placebo|3 placebo tablets daily for 12 weeks
219504920|NCT04549259|BEHAVIORAL|HIV Stigma Reduction|"This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011)."
219364469|NCT03010540|DRUG|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
219504921|NCT04549259|BEHAVIORAL|Strengths-Based Case Management (SBCM)|The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
219504922|NCT04549259|BEHAVIORAL|Personalized Technology Detailing|Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
219504923|NCT02509728|DIETARY_SUPPLEMENT|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
219504924|NCT02509728|DIETARY_SUPPLEMENT|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
219504925|NCT02509728|DIETARY_SUPPLEMENT|standard nutrition|standard nutrition
219504926|NCT01988311|DRUG|psilocybin|dose manipulation as described in the protocol
219504927|NCT02600728|BEHAVIORAL|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
219606759|NCT01505582|OTHER|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
219606760|NCT05389631|OTHER|no intervention|no intervention
219606761|NCT04639492|DIETARY_SUPPLEMENT|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
219606762|NCT02483546|DEVICE|Laerdal®|simulation- based educational intervention
219040299|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
219040300|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
219040301|NCT01750580|DRUG|Lirilumab|
219040302|NCT01750580|DRUG|Ipilimumab|
219040303|NCT03350503|DEVICE|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
219040304|NCT03350503|PROCEDURE|Cataract surgery|Removal of cataractous lens and implantation of IOL
219040305|NCT00098111|DRUG|azathioprine|
219040306|NCT01166828|BEHAVIORAL|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
219364470|NCT03010540|DRUG|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
219364471|NCT04656990|BEHAVIORAL|Integrated Intervention|Gross motor and social-emotional integrated intervention
219364472|NCT01269164|PROCEDURE|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
219364473|NCT02174718|DIETARY_SUPPLEMENT|Transdermal D Patch|
219364474|NCT02174718|DIETARY_SUPPLEMENT|Oral vitamin D3|
219364475|NCT02174718|DIETARY_SUPPLEMENT|Placebo patch|
219364476|NCT02174718|DIETARY_SUPPLEMENT|Oral placebo|
219364477|NCT03657459|BEHAVIORAL|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities) that reflect patient behaviors
219364478|NCT04833803|BEHAVIORAL|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
219504928|NCT02600728|BEHAVIORAL|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
219504929|NCT03216733|DEVICE|COMBO|PCI with COMBO stent
219504930|NCT03216733|DEVICE|ORSIRO|PCI with ORSIRO stent
219504931|NCT02668783|DRUG|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
219606763|NCT02483546|BEHAVIORAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
219606764|NCT02483546|BEHAVIORAL|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
219606765|NCT05410886|OTHER|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
218883356|NCT06975397|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|This training and research project was conducted over eight weeks and started 6 - 8 weeks after natural childbirth. All study participants were included in the exercise program designed for postpartum females. Exercises included four sets that changed every two weeks and were held individually with a physiotherapist three times a week, every two to three days, for 45 minutes each unit. All participants performed breathing exercises, body posture correction, abdominal muscle strengthening exercises (transverse, oblique, and rectus abdominis muscles), and engaged other muscles to improve overall physical fitness.
218883357|NCT06975397|OTHER|kinesio taping|The Kinesiology Tape used in this study has a European quality certificate (CE). Before the exercise program, on the day of the first ultrasound, participants had tapes placed on their abdomens. The tape length for each participant was 20 cm to ensure the ends were located on the lateral edges of the rectus abdominis muscles. Both ends of the tape were simultaneously attached to the abdomen, with two attached from the navel line upwards and one below it Each participant in the tape group was asked to breathe in using the abdominal muscles, and after a maximal stretch of the abdominal integuments, three tapes were attached at 50% tension or without tension. The taping procedure was repeated once per week, with the tapes attached for six days and removed at the end of the 6th day. The placebo and tape groups had a break on the 7th day
218883358|NCT06975813|DRUG|masseter muscle|masseter muscle trigger points injection by magnesium sulphate
218883359|NCT06975813|DRUG|masseter and sternocleidomastoid muscle|masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate
218883360|NCT04766775|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
219028255|NCT06788028|BEHAVIORAL|Family Strengthening|Families will engage in 12 weekly (1-1.5 hours) of family strengthening sessions, led by trained facilitators from the Research and Education Center. Groups will be composed of approximately 5 caregiver-child dyads. Sessions are designed to improve family functioning, strengthen child-parent relationships, enhance parenting strategies, and prevent emotional and behavioral problems among at-risk children.
219028256|NCT06788028|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children will receive 12 sessions of individual mental health services. Clinicians are trained in the Attachment, Regulation, and Competency (ARC) framework. Services include a clinical assessment performed by a psychiatrist, development of an individual care plan, and corresponding mental health services, informed by ARC.
219028257|NCT06788028|OTHER|Economic Empowerment|Child Development Accounts (CDAs) will be opened to facilitate family savings. The project will provide $50 as seed money to open a savings account in the child's name. Savings of up to $20 per month will be matched with study funds at a rate of 2:1 and placed in the CDA account. Caregivers and children will also engage in 12 weekly (1-1.5 hours) of financial education sessions, led by facilitators from the Research and Education Center.
219504932|NCT02668783|DRUG|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
218883361|NCT06974461|PROCEDURE|Blood Flow Restriction (BFR) Walking|Participants in this group will undergo a supervised treadmill walking program with blood flow restriction (BFR) applied using BFR pressure cuffs. The cuffs are applied to the proximal thighs, and the training pressure starts at 50% of the participant's arterial occlusion pressure (AOP), increasing every two weeks up to 200 mmHg. Walking is performed at 60% of the maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
219504933|NCT02668783|DRUG|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
219504934|NCT06524791|OTHER|bacteriophage detection|bacteriophage detection
219504935|NCT00046423|DRUG|ABI-007|
219606766|NCT02517463|DRUG|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
219201079|NCT06712992|DEVICE|Trans-spinal Direct Current Stimulation|Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.
219201080|NCT06712992|OTHER|Conventional Exercises|"1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine"
219201081|NCT06712992|DRUG|SHAM Trans-spinal Direct current stimulation|"For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs ."
219201082|NCT06882122|DRUG|Atogepant 60 mg|Atogepant 60 mg daily for 3 months
219504936|NCT02519426|PROCEDURE|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
219504937|NCT04746014|DIAGNOSTIC_TEST|Clearblue Pregnancy Test|Urine Pregnancy Test
219504938|NCT06349720|BEHAVIORAL|respiratory rehabilitation|"Emote respiratory rehabilitation:Patients wear monitoring devices and upload real-time monitoring data such as vital signs through the FREE rehabilitation app installed on their personal phones. Medical staff monitor changes in patients' vital signs in real time through the FREE rehabilitation app on the medical end, and adjust respiratory rehabilitation plans based on their phone or video guidance.~Outpatient respiratory rehabilitation:Traditional outpatient respiratory rehabilitation is based on a group approach, with individualized intensity determined based on baseline assessment results, and is conducted under supervision twice a week for a period of 12 weeks."
219504939|NCT01492582|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
219504940|NCT01492582|OTHER|laboratory biomarker analysis|Correlative studies
219504941|NCT01492582|OTHER|survey administration|Ancillary studies
219504942|NCT01492582|OTHER|medical chart review|Ancillary studies
218883362|NCT06974461|PROCEDURE|Sham Blood Flow Restriction (Sham-BFR) Walking|Participants in this group will follow the same supervised treadmill walking protocol as the BFR group but with minimal cuff pressure (20 mmHg), which does not restrict blood flow. This simulates the sensation of BFR without physiological impact. The purpose is to serve as a placebo comparator. Walking is performed at 60% of maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
218883363|NCT06974474|DRUG|Guselkumab|Guselkumab
218883364|NCT06975527|OTHER|Breastfeeding guidelines|"All participants will be instructed by the following guidelines:~* Hold the breast so the nipple brushes the center of the infant's lips and wait for the infant to open the mouth.~* Infant's mouth should be opened wide, as with a yawn and should cover the entire areola, or a large amount of the areola.~* Both breasts are used in each feeding, usually 10 to 15 minutes on the first side, followed by burping before beginning the second side.~* Break suction by placing finger in the corner of infant's mouth and quickly remove breast.~* Apply breast massage before breastfeeding.~* The neonate is nursed shortly after birth and approximately every 2 to 3 hours thereafter for a total of 8 to 12 feedings a day.~* Lactating women needs about 8 to 10 glasses of fluids per day while breastfeeding.~* Caffeine consumption should be limited to 2 cups of coffee, tea or cola per day.~* Lactating mother should consume a healthy diet which is varied, balanced, and natural."
218883365|NCT06975527|OTHER|Aerobic exercise|The participants will be engaged in a supervised moderate aerobic exercise in the form of walking on a treadmill for 40 minutes/ day, 3 days/ week, for 6 weeks beginning 6:8 weeks postpartum. Each exercise session will be divided into 3 phases. The warm-up phase begins with walking at low speed (within resting heart rate) on a treadmill for 5 minutes. The active phase continues for 30 minutes at a moderate intensity of 60 to 70% of maximal heart rate (HRmax). Gradual increase and adjustment of speed will be applied for each woman according to her prescribed intensity based on HRmax. HRmax is calculated by subtracting the age from 220. The program will be terminated with 5 minutes cool-down phase, during which the treadmill speed will be gradually decreased until the heart rate resumes its resting level.
219028258|NCT07078656|BEHAVIORAL|Postoperative management|"The patients who agreed to participate in the study will be asked to fill out a Patient Introduction Form by the researchers after obtaining permission from the experimental group with the Informed Consent Form the day before the surgery. On the 2nd day after laparoscopic colorectal surgery, virtual reality glasses will be worn by the patients and they will watch a 10-minute training video on the care of the patient after colorectal surgery. The training content will consist of topics such as dressing the surgical area, signs of infection in the surgical area (redness, swelling, discharge, color, temperature increase), pain management, unexpected situations (fever, nausea, abdominal pain, shivering, chan)"
219028259|NCT06903845|PROCEDURE|video call|Conduct video training every two weeks emphasizing medication adherence.
219028260|NCT06903845|DEVICE|Medication reminder app|Medication reminder app will remind patients to take your medication.
219028261|NCT07090330|DRUG|ORKA-001 Induction Dose|ORKA-001 Induction Dose, administered by subcutaneous (SC) injection
219028262|NCT07090330|OTHER|Placebo|Placebo administered by subcutaneous (SC) injection
219028263|NCT07090330|DRUG|ORKA-001 Maintenance Dose|ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection
219504943|NCT00356720|DRUG|Azithromycin|
219504944|NCT03035838|DRUG|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
218883366|NCT05758402|DIAGNOSTIC_TEST|Routine practice group|Routine practice group
219504945|NCT03136991|DRUG|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
219504946|NCT03136991|DRUG|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
219504947|NCT03341286|DRUG|TK3|Tryptophan and thiamine as on oral supplement
219504948|NCT06191367|OTHER|Aerobic Exercises|Aerobic Exercises
219504949|NCT06191367|DEVICE|Incentive Spirometer Device|is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.
219504950|NCT06191367|OTHER|Traditional Chest Physiotherapy|"1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration."
219504951|NCT02867904|DRUG|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
219504952|NCT02867904|DRUG|Marcaine (4ml 0.5%, injection)|Control
219606767|NCT00764686|OTHER|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
218883367|NCT05758402|DIAGNOSTIC_TEST|EARP group|EARP group
218883368|NCT02208375|DRUG|Capivasertib|Given PO
218883369|NCT02208375|OTHER|Laboratory Biomarker Analysis|Correlative studies
218883370|NCT02208375|DRUG|Olaparib|Given PO
218883371|NCT02208375|OTHER|Pharmacological Study|Correlative studies
218883372|NCT02208375|DRUG|Vistusertib|Given PO
218883373|NCT01325688|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
218883374|NCT01325688|DEVICE|Aluminium disk|
218883375|NCT01325688|DEVICE|OpSite(TM) disk|
218883376|NCT04529343|OTHER|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
218883377|NCT04529343|OTHER|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
218883378|NCT02613585|OTHER|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
218883379|NCT06842888|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
218883380|NCT06842888|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
218883381|NCT05795985|DIAGNOSTIC_TEST|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
218883382|NCT04099121|DEVICE|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
218883383|NCT03565146|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
218883384|NCT06866041|PROCEDURE|mpMRI-targeted confirmatory biopsy|mpMRI-targeted confirmatory biopsy after one year from the diagnosis, according to the international guidelines
218883385|NCT04788316|BEHAVIORAL|CBI and Text messaging|A computerized brief intervention (2 sessions) followed by six months of personalized text messaging
218883386|NCT06524427|PROCEDURE|Robot-assisted lobectomy|Patients will receive robot-assisted lobectomy using Da Vinci surgical system
218883387|NCT06524427|PROCEDURE|Video-assisted lobectomy|Patients will receive video-assisted lobectomy
218883388|NCT06626022|DEVICE|MRI|Standard prostate mpMRI.
218883389|NCT06626022|DEVICE|ExactVu|microUltrasound
218883390|NCT06622512|DEVICE|Radial Pressure Wave Therapy|Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
219201083|NCT06881160|DIAGNOSTIC_TEST|mi-RNA analysis|To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.
219606768|NCT00764686|OTHER|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
219606769|NCT02002286|DRUG|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
219504953|NCT02437214|OTHER|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
219504954|NCT01003886|DRUG|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
219504955|NCT06014450|RADIATION|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
219504956|NCT02444312|BEHAVIORAL|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
219504957|NCT02444312|BEHAVIORAL|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
218883391|NCT06702410|BEHAVIORAL|mental health gap action program intervention guide (mhGAP-IG)|The mhGAP-IG is an evidence-based intervention developed by WHO. It was designed for non-specialists to scale up high quality mental health services. Although more than 90 countries worldwide have implemented mhGAP-IG, this study is the first to evaluated if it works for scaling up CMBDs services in China. Investigators have cultrually adapted the mhGAP-IG according Chinese context.
218883392|NCT03405519|PROCEDURE|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
219504958|NCT03824210|OTHER|App|Mobile phone app
219504959|NCT01499914|BIOLOGICAL|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
219504960|NCT00027469|PROCEDURE|MRI|
219504961|NCT04212702|DRUG|Hormonal therapy-based treatments|Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only
219504962|NCT03666637|PROCEDURE|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
219504963|NCT02613637|OTHER|Registry|
218883393|NCT01716455|DRUG|SSP-004184|
218883394|NCT04412447|DEVICE|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
219504964|NCT06031311|DIAGNOSTIC_TEST|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
219504965|NCT02095847|PROCEDURE|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
219504966|NCT02095847|DRUG|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
219504967|NCT02318498|PROCEDURE|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
219504968|NCT04467697|DRUG|SOV2012-F1|Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
219504969|NCT02691897|DRUG|Melatonin|Melatonin 3mg once daily at bedtime
219504970|NCT02691897|DRUG|Placebo|Placebo 1 tablet once daily at bedtime
219504971|NCT02506790|DRUG|metformin|
218883395|NCT06077890|OTHER|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
219504972|NCT02506790|DRUG|Melatonin|
219504973|NCT02506790|DRUG|Toremifene|
219504974|NCT02490423|OTHER|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
219504975|NCT04523558|DEVICE|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
219504976|NCT01172600|OTHER|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
219504977|NCT01172600|OTHER|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
219504978|NCT03907280|DRUG|BI 1265162 (T1)|oral solution
219504979|NCT03907280|DRUG|BI 1265162 (T2)|Solution for inhalation
219504980|NCT03907280|DRUG|BI 1265162 (R)|concentrate for i.v. solution
219504981|NCT03907280|DRUG|BI 1265162 (T3)|Solution for inhalation
219504982|NCT01056757|DRUG|Ribavirin|1000 mg bid, po, q28days
219028264|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
219504983|NCT03554421|PROCEDURE|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
219028265|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
219028266|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
218883396|NCT06077890|OTHER|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
218883397|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
218883398|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
218883399|NCT00395850|DRUG|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
218883400|NCT02333019|BEHAVIORAL|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
218883401|NCT02333019|BEHAVIORAL|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
218883402|NCT00820872|BIOLOGICAL|trastuzumab|
218883403|NCT00820872|DRUG|carboplatin|
218883404|NCT00820872|DRUG|docetaxel|
218883405|NCT00820872|DRUG|lapatinib ditosylate|
218883406|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
219028267|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
219028268|NCT06907186|OTHER|Psychological Support|Carrying out a systematic and organized path of psychological support interviews on a monthly basis in person or remotely.
218883407|NCT02816619|BEHAVIORAL|Free practice of physical activity|
218883408|NCT03973762|DEVICE|DR Grading with CAD|A CAD system is used to make DR grading.
218883409|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
219504984|NCT04854720|DEVICE|Fuji® II LC CAPSULE|"Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions."
219504985|NCT04854720|DEVICE|Clinpro™ XT Varnish|"Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions."
219504986|NCT04854720|DEVICE|Beautifil Flow|"Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions."
219504987|NCT04854720|DEVICE|Fuji Triage® CAPSULE|"Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions."
219504988|NCT05571527|BIOLOGICAL|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
219028269|NCT06911034|DRUG|Iron Carboxymaltose|In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
219028270|NCT06911034|DRUG|Iron Sucrose Injection|Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
219028271|NCT06906965|OTHER|Carob beverage|The participants consumed a carob beverage made with 30gr of Imera carob cultivar powder in water
219028272|NCT06906965|OTHER|Sucrose beverage|The participants consumed a sucrose beverage made with 14gr of sugar in alike concentration with sugars in the experimental beverage
219028273|NCT06912594|DEVICE|PCOS-App|The PCOS-App helps to implement multimodal self-help measures in the daily lives of PCOS patients through various functions such as symptom diary and interactive exercises.
219028274|NCT06914076|COMBINATION_PRODUCT|Structured Psychosocial Counseling|"Group A (Experimental Group):~Participants in the Experimental group will be divided into groups with the persons having visual acuity 6/60, counting fingers and light perception will receive low vision aids etc and structured psychosocial counseling tailored for individuals with low vision. Counseling will be delivered over a 12-week period, consisting of weekly 60-minute sessions conducted by trained counselors. The program will focus on the following:~Coping mechanisms for depression and anxiety. Strategies to improve functional independence and daily living skills. Social integration techniques to enhance participation in community activities. Low visions aids under supervision of low vision specialist."
219028275|NCT06914076|DIAGNOSTIC_TEST|Standard Care|Group B (Control Group): The control group will continue receiving standard care, including referrals and informational support.
219028276|NCT06913673|OTHER|Bio-c Temp|Intra-canal medication
219028277|NCT06913673|OTHER|Metapex|Intra-canal medication
219028278|NCT06913504|DIAGNOSTIC_TEST|Blue cut filter|Group 1 will be prescribe with blue cut filter feature
219028279|NCT06913504|DIAGNOSTIC_TEST|blue cut glasses|Group 2 will be prescribed with blue cut glasses
219028280|NCT06914063|COMBINATION_PRODUCT|Rapid-Onset Cycloplegic Drops|Rapid-Onset Cycloplegic Drops (e.g., tropicamide with phenylephrine) to assess patient comfort, anxiety, and satisfaction with quicker onset and shorter duration.
219504989|NCT05571527|DRUG|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
219504990|NCT00909727|DRUG|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
219504991|NCT00909727|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
219201084|NCT06881212|BEHAVIORAL|THERAPEUTIC APPROACH TRAINING|"This study focuses on pre- and post-operative training for open-heart surgery patients, aiming to reduce anxiety, agitation, and discomfort during intubation and recovery.~In the meeting phase, the nurse introduces herself, explains the research, and obtains written/verbal consent. The patient's anxiety level is assessed.~In the study phase, patients are informed about the surgical process, breathing exercises, Intensive Care Unit conditions, and postoperative care. They are encouraged to express fears and concerns to improve psychological preparedness.~Key topics include:~Fasting before surgery Breathing exercises to ease extubation Use of mechanical ventilation Intensive Care Unit environment \& pain management Early mobilization \& recovery timeline Patients receive guidance on their role in recovery, ensuring better adaptation and reduced distress post-surgery."
219201085|NCT06881095|PROCEDURE|socket shield technique group (study group)|"immediate implant installation with socket shield technique: After administration of local anesthesia, the root will be sectioned in a mesio-distal direction along its long axis, sectioning divided the tooth root into one facial third and two palatal thirds.~Periotomes will then be inserted between the palatal root section and the alveolar socket wall to sever the PDL and this section of root was then carefully delivered so as not to disturb the facial root section, the remaining root section was then reduced coronally to 1 mm above the alveolar crest.~The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants, and the root section was checked for immobility with a sharp probe.~After completion of the previous steps, the tooth root here will be known as the socket- shield (SS). An osteotomy was then sequentially prepared according to manufacturer"
219504992|NCT04113395|OTHER|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
219504993|NCT03801629|DRUG|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
219504994|NCT03801629|DRUG|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
219028281|NCT06914063|DIAGNOSTIC_TEST|Conventional Cycloplegic Drops|Conventional Cycloplegic Drops (e.g., cyclopentolate) to provide a baseline for comparison with the rapid-onset treatment.
219028282|NCT06914310|DRUG|Memantine|Memantine will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily
219028283|NCT06914310|DRUG|Mannitol|Mild to moderate TBI patients will receive mannitol in case of brain edema to reduce brain swelling and analgesic for headache such as; acetaminophen.
219504995|NCT04676191|DEVICE|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
219504996|NCT04676191|DEVICE|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
219504997|NCT02033265|PROCEDURE|Brachial plexus block|Ultrasound guided axillary brachial plexus block
219504998|NCT04120220|OTHER|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
219504999|NCT04120220|OTHER|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
219505000|NCT01764620|OTHER|Elastic taping applied with tension|
219505001|NCT01764620|OTHER|Elastic taping applied without tension|
219505002|NCT01764620|OTHER|Fatigue protocol|
219505003|NCT01103557|PROCEDURE|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
219505004|NCT05042635|DRUG|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
219505005|NCT05042635|DRUG|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
219028284|NCT06914219|BEHAVIORAL|Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program|A combined a) screening/diagnosis, b) Cognitive Behavior Therapy +/- pharmacotherapy, and c) interdisciplinary team approach for managing disordered eating in patients post-weight loss surgery.
219028285|NCT06914388|OTHER|Self-Management Strategies|Stretching exercises, strengthening exercises, massage, relaxing exercises, breathing exercises, patient education
219028286|NCT06914037|DRUG|CHT101|CD70 UCAR-T
219028287|NCT06913036|DEVICE|Low-frequency fatigue - Myocene|Low frequency fatigue will be measured using Myocene
219028288|NCT06913309|DEVICE|Bright light therapy（High light intensity）|"In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention.~Participants randomly assigned to the high light density intervention group will receive bright white light therapy interventions with light intensities of 10000 lux, and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source."
219201086|NCT06881095|PROCEDURE|conventional immediate implant without socket shield technique|• After administration of local anesthesia, atraumatic tooth extraction by extraction forceps and Periotomes, an osteotomy was then sequentially prepared according to manufacturer instructions and a suitable implant then inserted and placement of cover screw. However, the soft tissue contour formed after healing may need some modification prior to impression taking. Suturing around the healing abutment, suture will be removed one week post surgically and then healing abutment and final prosthetic loading will be done after 4-6 months.
219505006|NCT04228510|PROCEDURE|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
219505007|NCT02231710|BIOLOGICAL|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
219505008|NCT03540810|DRUG|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
219505009|NCT03540810|DRUG|Placebo|The patients will receive placebo with their usual treatment
219505010|NCT01385410|BEHAVIORAL|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
219505011|NCT03004521|DRUG|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
219505012|NCT03004521|DRUG|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
219505013|NCT05825118|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
219505014|NCT05747079|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
219505015|NCT05747079|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
219505016|NCT05747079|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
219505017|NCT00520507|DRUG|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
219505018|NCT00520507|DRUG|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
219505019|NCT04081337|DRUG|Tirzepatide|Administered SC
219505020|NCT04081337|DRUG|Placebo|Administered SC
219505021|NCT00525109|OTHER|No Intervention|No intervention
219505022|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
219505023|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
219505024|NCT04485988|DRUG|Beta blocker|Duration of medication
219505025|NCT02903433|OTHER|High-intake avocados|Families will receive 14 avocados on a weekly basis.
219505026|NCT02903433|OTHER|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
219505027|NCT02903433|BEHAVIORAL|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
219505028|NCT02903433|BEHAVIORAL|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
218883410|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
219505029|NCT04463433|BEHAVIORAL|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
218883411|NCT02141139|DRUG|NSAIDS (ketorolac and ibuprofen)|
218883412|NCT05788913|BIOLOGICAL|Heparin|subcutaneous Heparin
218883413|NCT03574402|DRUG|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
219505030|NCT04463433|BEHAVIORAL|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
219505031|NCT00819728|DRUG|Docetaxel|35mg/m2 IV each week for 4 weeks
219505032|NCT00819728|DRUG|Irinotecan|50mg/m2 IV each week for 4 weeks
219505033|NCT02563483|BEHAVIORAL|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
219505034|NCT02716883|PROCEDURE|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
219505035|NCT01843283|BEHAVIORAL|Daily Enhancement Meaningful Activity (DEMA)|
219505036|NCT01843283|BEHAVIORAL|Information Support (IS)|
219606770|NCT02002286|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
218883414|NCT03574402|DRUG|Afatinib|40mg orally once a day, 28 days as one cycle.
219606771|NCT04920500|DRUG|Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
219606772|NCT04920500|DRUG|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
219606773|NCT04752059|DRUG|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
218883415|NCT03574402|DRUG|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
219505037|NCT00527189|BEHAVIORAL|Balance Exercises|Home based balance exercises based on Otago Exercise programme
219606774|NCT05758233|PROCEDURE|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
218883416|NCT03574402|DRUG|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
218883417|NCT03574402|DRUG|Chidamide|30mg orally twice weekly, 28 days as one cycle.
218883418|NCT03574402|DRUG|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
219505038|NCT03204591|OTHER|No intervention|No intervention
218883419|NCT03574402|DRUG|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
219505039|NCT01234779|DRUG|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
219505040|NCT01234779|DRUG|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
219505041|NCT01234779|DRUG|olanzapine|15 mg orally daily, 4 weeks
219505042|NCT01234779|DRUG|placebo|orally daily, 4 weeks
219505043|NCT00815490|DEVICE|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
219505044|NCT02028000|PROCEDURE|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
219505045|NCT02028000|PROCEDURE|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
219201087|NCT06881628|DRUG|Tranexamic Acid and vitamin K|"Tranxemic acid (1 g loading dose followed by 3 g maintenance dose over 24- 48 hours) and intravenous injection (10 mg daily of vitamin K for 24-48 h) along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
219505046|NCT02028000|PROCEDURE|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
219505047|NCT06203899|BEHAVIORAL|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
219505048|NCT06203899|BEHAVIORAL|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
219606775|NCT05758233|PROCEDURE|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
219606776|NCT00060983|PROCEDURE|Body weight supported locomotor training|
219606777|NCT00060983|PROCEDURE|Functional electrical stimulation|
219606778|NCT01241747|BEHAVIORAL|Walking Exercise|3 times per week for 3 months
219606779|NCT01241747|BEHAVIORAL|Control|Resistance training 3 times per week for 3 months
219606780|NCT01363882|OTHER|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
219606781|NCT01363882|OTHER|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
219606782|NCT06329427|OTHER|Dragon Ambient eXperience (DAX) Copilot|The tool (DAX) listens to the conversation between a clinician and patient/caregiver during their visit, provides transcriptions between different speakers for the clinician to review, edit, and included in the final EHR notes.
219606783|NCT02535793|OTHER|blood test (four dry tubes 7ml) and prick tests|
219505049|NCT00673361|DRUG|Concurrent decrescendo biochemotherapy regimen|"* Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days"
219606784|NCT04492657|OTHER|no intervention|Natural exposure of iodine.
219606785|NCT03349086|BEHAVIORAL|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
219606786|NCT02713555|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
219606787|NCT02713555|PROCEDURE|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
219606788|NCT02735785|BEHAVIORAL|Harnessing Online Peer Education (HOPE) Social Media Intervention|
219505050|NCT00673361|DRUG|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
219505051|NCT01352650|DRUG|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
219505052|NCT01352650|DRUG|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
219606789|NCT05959252|DRUG|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
219606790|NCT05959252|DRUG|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
219606791|NCT03449446|DRUG|SEL|18 mg tablet administered orally once daily without regard to food
219606792|NCT03449446|DRUG|FIR|20 mg tablet administered orally once daily without regard to food
219606793|NCT03449446|DRUG|CILO|30 mg tablet administered orally once daily without regard to food
219606794|NCT03449446|DRUG|Placebo to match FIR|Tablet administered orally once daily without regard to food
218883420|NCT03574402|DRUG|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
218883421|NCT03574402|DRUG|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
218883422|NCT03574402|DRUG|Pemetrexed|500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
218883423|NCT03574402|DRUG|Cisplatin|75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
218883424|NCT03574402|DRUG|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
218883425|NCT03574402|DRUG|Gemcitabine|1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
218883426|NCT03574402|DRUG|Gemcitabine|1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
218883427|NCT03574402|DRUG|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
218883428|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
218883429|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
218883430|NCT01354366|OTHER|Infant formula|
219505053|NCT06422117|DRUG|HSK16149 20mg-40mg BID|Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
219505054|NCT06422117|DRUG|Placebo|Placebo, oral, 2 capsules twice daily
219505055|NCT03252795|PROCEDURE|uterus transplantation|transplantation of a uterus from a deceased donor
219505056|NCT01578707|DRUG|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
219028289|NCT06913309|DEVICE|Bright light therapy（Low light intensity）|In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention. Participants randomly assigned to the low light density intervention group will receive bright white light therapy interventions with light intensities of 5,000 lux,and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
219505057|NCT01578707|DRUG|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
219505058|NCT04887883|BEHAVIORAL|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
219505059|NCT01799590|DRUG|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
219028290|NCT06913309|DEVICE|Dim red light placebo-controlled intervention|In this study, participants randomly assigned to the placebo-controlled group will receive dim red light therapy interventions with light intensities of 100 lux, and the main wavelength of light source is 690.4nm. The placebo-controlled intervention plan is to receive 40 minutes of red light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
219028291|NCT06912750|OTHER|4-7-8 Breathing Exercise with Teach-Back Method|"In the experimental group, patients will be provided with information regarding the purpose and significance of the 4-7-8 breathing technique using the Teach-Back method one day before surgery. To confirm comprehension, patients will be asked to repeat the information. The exercise will be demonstrated in a one-on-one session using the Teach-Back method, and patients will be guided through practical application. Following the training, patients will be instructed to perform the exercise independently, with the researcher monitoring its correct implementation. Each patient will be given a 4-7-8 Breathing Exercise Application Guide, which outlines the exercise steps based on relevant literature.~Before surgery, patients will complete the Patient Information Form, the Visual Analog Scale (VAS) for pain, the State-Trait Anxiety Inventory (STAI), and the Richards-Campbell Sleep Questionnaire (RCSQ). Postoperatively, the VAS and STAI will be administered both before (pre-test) and after"
219028292|NCT06914843|BEHAVIORAL|OptimalWork|An online intervention that teaches concepts of cognitive restructuring, mindfulness, and behavioral activation as they apply in one's daily life and work. Users are given personalized content recommendations based on their inventory results and instructed to complete 15-25 minutes of content per day, 5 days/week for 4 weeks. (optimalwork.com)
219028293|NCT06914843|BEHAVIORAL|Podcast Listening|A curated series of podcasts on topics unrelated to cognitive behavioral therapy or mindfulness, modeled after a similar control from a study of a mindfulness based intervention (Basso et al. 2019). Users are instructed to complete one podcast per day on a digital platform (\~15 minutes/day), 5 days/week for 4 weeks.
219505060|NCT02780778|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
219505061|NCT02780778|DRUG|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
219505062|NCT04561128|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
219028294|NCT06913543|COMBINATION_PRODUCT|Group 1 (Experimental Group - OKC + NMES)|"OKC Knee Extension Exercises:~Seated Knee Extensions:~Resistance bands or machine, 10-15 reps, 2-3 sets.~Straight Leg Raises:~With or without ankle weights, 12-15 reps, 2-3 sets.~Quadriceps Isometric Holds:~Held for 5-10 seconds, 10 reps, 2-3 sets.~Neuromuscular Electrical Stimulation (NMES):~Electrode Placement:~Over the motor points of the quadriceps.~Frequency:~35-50 Hz.~Pulse Duration:~200 microseconds.~Intensity:~Adjusted for strong yet tolerable contractions.~On-Off Cycle:~10 seconds on, 20 seconds off."
219028295|NCT06913543|DIAGNOSTIC_TEST|Group 2 (Control Group - OKC Only|Open Kinetic Chain Knee Extension Exercises without NMES. Method \& Details: The same OKC exercises as the experimental group but without NMES. All exercises are supervised by trained physiotherapists.
219505063|NCT04561128|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels
219505064|NCT02231190|DRUG|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
219505065|NCT02231190|DRUG|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
219505066|NCT00352495|DRUG|carboplatin|
219505067|NCT00352495|DRUG|vinblastine sulfate|
219505068|NCT02320279|DEVICE|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
219505069|NCT03706638|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
219505070|NCT01489956|BIOLOGICAL|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
219606795|NCT03449446|DRUG|Placebo to match CILO|Tablet administered orally once daily without regard to food
219606796|NCT03449446|DRUG|Placebo to match SEL|Tablet administered orally once daily without regard to food
219606797|NCT04419012|OTHER|observation|observation
219606798|NCT02318212|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
219606799|NCT04493567|DRUG|BMS-986036|Specified dose on specified days
219606800|NCT00001946|PROCEDURE|Magnetic resonance angiography|
219505071|NCT01489956|BIOLOGICAL|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
219505072|NCT01489956|BIOLOGICAL|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
219606801|NCT01453179|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
219606802|NCT01453179|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
219606803|NCT06176651|DRUG|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
219606804|NCT02448368|DRUG|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
219606805|NCT02448368|DRUG|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
219606806|NCT02448368|DRUG|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
219606807|NCT02448368|DRUG|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
218883431|NCT05533970|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
218883432|NCT05120141|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
218883433|NCT05120141|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
218883434|NCT05120141|OTHER|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
218883435|NCT05120141|OTHER|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
218883436|NCT05120141|OTHER|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
218883437|NCT05120141|OTHER|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
218883438|NCT05120141|OTHER|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
218883439|NCT05178485|DRUG|Bupivacain|FDA approved drug
218883440|NCT05178485|OTHER|Normal Saline|FDA approved
218883441|NCT02692378|DRUG|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
218883442|NCT05111028|BIOLOGICAL|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
218883443|NCT05111028|BIOLOGICAL|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
218883444|NCT06527417|DEVICE|Neuro Trac Myo Plus Pro|Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
218883445|NCT06527417|OTHER|Trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
218883446|NCT00225095|DRUG|Mesenchymal Stem Cells|
218883447|NCT00225095|DRUG|Hyaluronan|
218883448|NCT01238328|DRUG|Conditioning regimen|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
219505073|NCT05072301|BEHAVIORAL|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
219606808|NCT02448368|DRUG|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
218883449|NCT01238328|DRUG|Graft-versus-host disease (GVHD) prophylaxis|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
219028296|NCT06913881|DRUG|GLP-1|We will compare people who have picked up GLP1 to those who have picked up insulin at any Swedish pharmacy
219505074|NCT05072301|BEHAVIORAL|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
219606809|NCT01958073|DRUG|Conjugated Estrogen Vaginal Cream|
219606810|NCT01958073|DRUG|Estradiol Ring|
219606811|NCT01958073|DRUG|Placebo|
219505075|NCT03502629|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
219505076|NCT02162329|BEHAVIORAL|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
219606812|NCT03146429|DIAGNOSTIC_TEST|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
219505077|NCT02162329|PROCEDURE|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
219505078|NCT02162329|PROCEDURE|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
219606813|NCT05332873|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
218883450|NCT01238328|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
218883451|NCT02077400|DRUG|Cephazolin|Cephazolin
218883452|NCT05199961|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
218883453|NCT06526559|DEVICE|Barbed suture|Use of two absorbable barbed sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
218883454|NCT06526559|DEVICE|PGA suture|Use of two absorbable polyglactin sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
218883455|NCT04354883|PROCEDURE|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
218883456|NCT05656482|OTHER|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
218883457|NCT05095168|DRUG|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
219505079|NCT02162329|BEHAVIORAL|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
219505080|NCT02383147|DEVICE|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
218883458|NCT05095168|DRUG|Placebo|placebo
218883459|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
218883460|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
218883461|NCT00558181|DRUG|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
218883462|NCT01622777|DRUG|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
218883463|NCT01622777|DRUG|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
218883464|NCT05040074|DEVICE|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
218883465|NCT00742755|BEHAVIORAL|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
219028297|NCT06914115|COMBINATION_PRODUCT|TANS Group|The TANS Group will receive low-frequency electrical stimulation (20-30 Hz) via a TENS device on the auricular vagus nerve for 30 minutes, 3-4 times per week for 8 weeks. This non-invasive therapy aims to reduce spasticity, enhance neuroplasticity, and improve motor function and independence, assessed through standardized scales.
219505081|NCT02383147|DEVICE|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
219606814|NCT04525573|DEVICE|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
219606815|NCT06634329|OTHER|Oro or Nasogastric tube feeding|Parental involvement in their premature baby's feeding
218883466|NCT02416895|OTHER|In vivo immunity model|A measure of in vivo immune function.
218883467|NCT00808548|OTHER|counseling, emotional support|
218883468|NCT00808548|OTHER|emotional support|emotional support during the interview
218883469|NCT00808548|OTHER|emotional support|emotional supporting during the interview
219505082|NCT06483607|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
219505083|NCT06483607|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
219505084|NCT03777475|PROCEDURE|transarterial infusion|transarterial infusion
219505085|NCT04689477|DEVICE|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
219505086|NCT00730522|DRUG|CPP-109 vigabatrin|tablets, bid for 12 weeks
219505087|NCT00730522|DRUG|Matching Placebo|tablets, bid, 12 weeks
219505088|NCT02775968|DRUG|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
219505089|NCT05045209|OTHER|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
219505090|NCT03175120|DRUG|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
219505091|NCT03175120|DRUG|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
219505092|NCT00678392|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
219505093|NCT00678392|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
219505094|NCT00954967|BEHAVIORAL|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
219606816|NCT04201626|PROCEDURE|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
219606817|NCT00351455|BEHAVIORAL|smoking cessation|
219505095|NCT00477828|DEVICE|Continuous positive airway pressure|
219606818|NCT00351455|BEHAVIORAL|tighter diabetic control|
218883470|NCT04007419|BEHAVIORAL|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
218883471|NCT01569048|DRUG|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
218883472|NCT01569048|DRUG|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
219606819|NCT00351455|BEHAVIORAL|diet and exercise program|
219505096|NCT02099279|DEVICE|echocardiography examination|patients underwent echocardiography examination
219606820|NCT03281395|PROCEDURE|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
219606821|NCT03281395|PROCEDURE|No rapid ventricular pacing|
219505097|NCT06136052|OTHER|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
219505098|NCT05817799|DRUG|L-Carnitine 500Mg thrice daily|L-Carnitine 500mg oral thrice daily
219505099|NCT05817799|DRUG|1g L-Carnitine IV three times a week|1g IV L-Carnitine three times a week
218883473|NCT01846741|DEVICE|M106 VNS Therapy System|
219505100|NCT01235052|RADIATION|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
219505101|NCT00514137|DRUG|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
219505102|NCT03603756|DRUG|SHR-1210|a novel anti-PD-1 antibody
219606822|NCT06019884|DEVICE|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
218883474|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
218883475|NCT03664765|OTHER|Sham exercise|Daily sham exercises
218883476|NCT04260945|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
218883477|NCT01153698|DRUG|dabigatran|anticoagulation
218883478|NCT01090063|DRUG|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
218883479|NCT00088894|DRUG|gemcitabine hydrochloride|Given IV
218883480|NCT00088894|BIOLOGICAL|bevacizumab|Given IV
218883481|NCT00088894|OTHER|placebo|Given IV
218883482|NCT00088894|OTHER|laboratory biomarker analysis|Correlative studies
218883483|NCT00088894|OTHER|pharmacogenomic studies|Correlative studies
218883484|NCT00088894|OTHER|pharmacological study|Correlative studies
219505103|NCT03603756|DRUG|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
219505104|NCT03603756|DRUG|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
219505105|NCT03603756|DRUG|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
219505106|NCT03603756|DRUG|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
219505107|NCT03341507|DEVICE|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
219505108|NCT03341507|DEVICE|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
219505109|NCT03761433|DEVICE|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
218883485|NCT01093391|DEVICE|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
218883486|NCT01093391|DEVICE|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
218883487|NCT04844853|DEVICE|electroencephalography|128-channel electroencephalography
218883488|NCT04844853|DEVICE|Tactile stimulation|Vibrotactile sequence on the forearm
219505110|NCT00938652|DRUG|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
219505111|NCT00938652|DRUG|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
219606823|NCT06019884|DEVICE|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
219028298|NCT06914115|COMBINATION_PRODUCT|Body Rocking Exercise|Group 2: Body Rocking Exercise Group Participants will perform rhythmic body rocking exercises for 20-30 minutes, 3-4 times per week for 8 weeks to reduce spasticity and improve motor coordination. Group 3: Control Group (Usual Rehabilitation) Participants will receive standard stroke rehabilitation (therapy, stretching, functional training) for 20-30 minutes, 3-4 times per week for 8 weeks as a baseline comparison.
219505112|NCT05106933|OTHER|Plain water|Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
219028299|NCT06914687|DRUG|Tislelizumab|recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip，d1, q3w
219505113|NCT05106933|OTHER|Carborie|carbohydrate drink
219028300|NCT06914687|DRUG|S-1|40\~60mg Bid，d1\~14, q3w
219505114|NCT01522352|PROCEDURE|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
219505115|NCT04787406|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period."
219505116|NCT01743365|DRUG|Cisplatin-5FU-Afatinib|
219505117|NCT01664195|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
219505118|NCT02038985|OTHER|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
219505119|NCT01186783|DRUG|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
219505120|NCT03235583|DEVICE|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
219505121|NCT00505505|DRUG|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
219505122|NCT03255031|OTHER|Ketogenic Diet (KD)|For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
219505123|NCT03255031|OTHER|Standard American (SA) Meals and Shakes|For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
219606824|NCT06019884|OTHER|Referral pathway: User fee removal|The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
218883489|NCT04844853|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
218883490|NCT04844853|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
218883491|NCT04844853|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
218883492|NCT04844853|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
218883493|NCT04844853|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
218883494|NCT03533244|DRUG|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
218883495|NCT03533244|DRUG|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
219028301|NCT06914687|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
219028302|NCT06914687|DRUG|Docetaxel|Docetaxel at a dose of 20 mg/m2 or paclitaxel at a dose of 40 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
219028303|NCT06914687|DRUG|Paclitaxel|Paclitaxel at a dose of 40 mg/m2 or docetaxel at a dose of 20 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
219028304|NCT06913647|DRUG|Canagliflozin 300 MG|Canagliflozin 300 mg once daily
219505124|NCT01228396|DRUG|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
218883496|NCT03533244|DRUG|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
218883497|NCT03676907|PROCEDURE|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
218883498|NCT01478724|DIETARY_SUPPLEMENT|Milk proteins fraction|capsules, one per day, 24 months
219028305|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
219505125|NCT04304326|OTHER|Resistence Exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
219505126|NCT05394558|DRUG|AsiDNA|Administration of AsiDNA followed by radiotherapy
219606825|NCT06019884|OTHER|Referral pathway: Conventional referral|Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
219606826|NCT04691154|COMBINATION_PRODUCT|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
219606827|NCT01734161|DRUG|Dexamethasone|8mg IV dexamethesone given
219606828|NCT01734161|DRUG|Placebo|Subjects randomized to placebo receive 50cc normal saline
219606829|NCT03448887|DEVICE|Theranova|Extended HD with theranova
219606830|NCT03448887|DEVICE|Online hemodiafiltration|Online hemodiafiltration
219028306|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
219028307|NCT06914427|DIAGNOSTIC_TEST|PET/CT|Scanning time: acquisition starts 60±10 minutes after 68Ga/18F probe injection; 10-20 minutes after 11C-MET injection; 60 minutes after 11C-CFT injection; Scanning parameters: whole-body imaging (cranial vault to mid-thigh), routine single-nuclide 3 min/bed; dual-nuclide 5-10 min/bed.
219028308|NCT06914622|BEHAVIORAL|Mental Health Recovery Star (MHRS)|"The personal recovery-oriented treatment is the Mental Health Recovery Star (MHRS), a recovery-oriented tool developed in England to support and monitor personal recovery. It features a 10-point star representing life dimensions grouped into four areas: health, functioning, self-image, and social networks. Residents assess their progress on each point using a Scale of Change  with five recovery stages, from feeling stuck to self-reliance.~After assessment, residents and professionals set recovery goals (up to three at a time) and create a shared care plan.~The MHRS shows good psychometric properties, with strong validity, consistency, and ease of use, despite some inter-rater reliability issues. It is best suited for shared rehabilitation plans rather than clinical monitoring.~Peer review meetings will be provided. The personal recovery-oriented treatment will last six months and will be considered complete upon follow-up evaluation."
219028309|NCT06914830|OTHER|Musical video demonstration with virtual reality glasses|The research was explained to the patient before the operation. The patient was started to watch a video with music with virtual glasses at the 5th minute of the operation and watched it throughout the operation. Two hours after the surgery, the patient who underwent ureteroscopy completed the Data Collection Form, Surgery Specific Anxiety Scale and Perianesthesia Comfort Scale.
219028310|NCT06913439|DIAGNOSTIC_TEST|Exercise Group|technique was implemented with three sets of ten repetitions on each treatment occasion for a period of 3 days/ week for 8 weeks. In this group, the adjustable couch was used to treat the patients effectively. During MWM, position of the patients was prone lying and high sitting position with swinging bilateral leg out of the couch at available various range of motion of affected knee joint. In prone lying position, the therapist was stand just behind the patient towards the affected knee joint. The mulligan belt placed at proximal tibia ends which already wrapped with the lower back of the therapist. In high or couch sitting position, the therapist was sitting on rest chair. The method using of mulligan belt was same as in prone lying position. After stabilization, the mobilization with movement (MWM) started in order with the therapist mobilized the knee joint followed by active movement of knee joint performed by the patients
219028311|NCT06913439|COMBINATION_PRODUCT|Parafin Wax Bath|Group B will receive Paraffin Wax Bath Therapy in combination with standard care exercises. In this treatment, the affected knee joint will be immersed in warm paraffin wax to deliver thermotherapy, which helps reduce joint stiffness, improve circulation, and enhance joint mobility. Each paraffin wax session will last 15-20 minutes. Following the thermotherapy, participants will perform standard care exercises targeting knee mobility, flexibility, and strength. These sessions will also occur 3 times per week over a period of 8 weeks.
219028312|NCT06913725|DRUG|FCN-159|An investigational oral MEK inhibitor
219028313|NCT06913257|DEVICE|ESWT Combined with Standard Rehabilitation|Participants in the experimental arm will receive a combination intervention comprising ESWT delivered by certified technicians using a validated device for post-burn scars, along with standard rehabilitation therapy. ESWT sessions will be standardized (e.g., 3,000 pulses per session, weekly for 8 weeks) and will be integrated with a comprehensive rehabilitation program encompassing physical therapy, scar management exercises, and patient education. The specific parameters (e.g., energy level, frequency) will be reported based on established guidelines.
219505127|NCT05509634|DRUG|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
219606831|NCT01965054|DIETARY_SUPPLEMENT|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
219606832|NCT01450683|DRUG|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
219606833|NCT03403647|DIETARY_SUPPLEMENT|Vitamin D|Oral daily vitamin D
219606834|NCT03739047|BEHAVIORAL|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
219505128|NCT05509634|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
219505129|NCT02514187|DRUG|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
219505130|NCT02514187|DRUG|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
219505131|NCT04050800|DRUG|Carbon 11 Butanol|Two sequential administrations of a PET tracer
219505132|NCT03151499|DRUG|BI 409306|Reference and Test Treatment
219505133|NCT03151499|DRUG|Rifampicin|Test Treatment
219505134|NCT04448691|DIAGNOSTIC_TEST|CCTA|requested follow up CCTA
219505135|NCT01689974|DRUG|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
219606835|NCT03739047|BEHAVIORAL|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
218883499|NCT04043650|BEHAVIORAL|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
218883500|NCT05758350|BEHAVIORAL|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
218883501|NCT01817959|DRUG|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
219606836|NCT00386347|DRUG|GSK364735 oral solution and oral tablets|
218883502|NCT01817959|DRUG|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
218883503|NCT02326233|BIOLOGICAL|Pen of SB5|
219028314|NCT06913257|BEHAVIORAL|Standard Rehabilitation Therapy Alone|Participants in the control arm will receive the institution's standard rehabilitation therapy for managing post-burn scars, including physical therapy, occupational therapy, and scar-massage techniques. Treatment frequency and duration will mirror the experimental arm's rehabilitation component to ensure consistency. No ESWT will be provided.
219028315|NCT06913348|PROCEDURE|Popliteal sciatic nerve block|Procedure/Surgery: Patients will receive either an ultrasound-guided sciatic popliteal nerve block or an ultrasound-guided erector spinae plane block for anesthesia during endovascular management of critical lower limb ischemia.
219505136|NCT01689974|RADIATION|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
219505137|NCT00229450|DRUG|Estrogen|0.625 mg/day of conjugated Estrogen
219505138|NCT03334565|DEVICE|Low efficiency air filtration systems|Subjects were exposed to low-efficiency filtered air.
219505139|NCT03334565|DEVICE|High efficiency air filtration systems|Subjects were exposed to high-efficiency filtered air.
219505140|NCT03334565|DEVICE|Air filtration systems without filters (sham)|Subjects were exposed to unfiltered air.
219505141|NCT00002119|DRUG|WF10|
219505142|NCT05228119|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
219505143|NCT03563027|BEHAVIORAL|Social Incentive Gamification|Game-based intervention with points and levels
219606837|NCT05222698|PROCEDURE|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
219606838|NCT00324727|DRUG|melphalan|Given throug isolated hepatic artery infusion
219505144|NCT03563027|BEHAVIORAL|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
219505145|NCT03563027|BEHAVIORAL|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
219505146|NCT03670979|PROCEDURE|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
219505147|NCT05360433|DRUG|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
219505148|NCT00000452|DRUG|naltrexone (Revia)|
219505149|NCT00000452|BEHAVIORAL|Compliance Enhancement Tech.|
219505150|NCT00000452|BEHAVIORAL|Cognitive Behavior Therapy|
219505151|NCT00415532|DRUG|Medical Standard of Care for ITP|
219505152|NCT00415532|BIOLOGICAL|Romiplostim|
219505153|NCT05048732|DRUG|18F-FluorApoTrace|-The dose of 18F-FluorApoTrace to be given is 5 mCi
219505154|NCT04121000|PROCEDURE|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
219505155|NCT04878406|DRUG|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
219505156|NCT04878406|DRUG|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
219505157|NCT04878406|DRUG|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
219505158|NCT04878406|DRUG|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
219505159|NCT00135642|BIOLOGICAL|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
219505160|NCT00135642|PROCEDURE|Venepuncture: 20 ml blood sample taken on 2 separate visits|
219505161|NCT04155788|BEHAVIORAL|Food Exposure|Participants will complete a meal exposure using one of their feared foods.
219505162|NCT05863988|OTHER|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
218883504|NCT02326233|BIOLOGICAL|PFS of SB5|
218883505|NCT05494034|DEVICE|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
219505163|NCT05863988|OTHER|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
219505164|NCT03058978|DEVICE|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
218883506|NCT03440489|DIAGNOSTIC_TEST|Six-minute walking test|physical performance of the muscle measured by these tests
218883507|NCT03440489|DIAGNOSTIC_TEST|30 seconds chair stand test|physical performance of the muscle measured by these tests
218883508|NCT06260306|OTHER|Hip activation home exercise program|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
218883509|NCT06260306|OTHER|Hip activation plus core stabilization home exercise program|The hip activation plus core stabilization HEP group will receive the same hip exercises, plus core stabilization exercises used by previous researchers. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
218883510|NCT00923845|DRUG|Pentostatin|Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
219505165|NCT06010056|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
219505166|NCT06010056|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
219505167|NCT00894985|BIOLOGICAL|heparin sodium - blausiegel|heparin sodium 5.000UI
219606839|NCT00324727|DRUG|regional chemotherapy|Patients receive the best alternative therapy
219606840|NCT00324727|DRUG|systemic chemotherapy|Patients receive the best alternative therapy
219606841|NCT00324727|PROCEDURE|hepatic artery embolization|Patients receive the best alternative therapy
218883511|NCT00923845|DRUG|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
218883512|NCT00923845|DRUG|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
218883513|NCT00923845|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
218883514|NCT00923845|PROCEDURE|Th2 rapa cells|Th2 rapa cell Transplantation
218883515|NCT00923845|PROCEDURE|Donor Lymphocyte Harvest|Apheresis
218883516|NCT00923845|PROCEDURE|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
218883517|NCT00923845|PROCEDURE|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
218883518|NCT00923845|PROCEDURE|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
218883519|NCT02632487|BEHAVIORAL|Exercise|Center-based walking + balance, stretching, and light resistance
218883520|NCT02632487|BEHAVIORAL|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
218883521|NCT00748319|OTHER|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
218883522|NCT00917488|OTHER|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
218883523|NCT01810315|DRUG|TFV 1% gel|
218883524|NCT01810315|DRUG|Estradiol vaginal cream|
218883525|NCT05026216|DRUG|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
219505168|NCT00894985|BIOLOGICAL|heparin sodium - APP|heparin sodium 5.000 USP - APP
219505169|NCT03409185|DEVICE|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
219505170|NCT03409185|DEVICE|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
219505171|NCT05954078|DRUG|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
219505172|NCT05954078|DRUG|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
219505173|NCT01584778|OTHER|eosinophil cationic protein|Serum eosinophil cationic protein levels
219505174|NCT03765671|DRUG|Elafibranor|120mg oral single dose
219606842|NCT05475327|OTHER|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
219606843|NCT05475327|OTHER|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
219606844|NCT00002231|BIOLOGICAL|APL 400-003|
219606845|NCT03511092|DIETARY_SUPPLEMENT|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
218883526|NCT00008528|DRUG|Enfuvirtide|
218883527|NCT02356848|BEHAVIORAL|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
218883528|NCT02356848|BEHAVIORAL|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
218883529|NCT00961714|DEVICE|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
218883530|NCT04807049|OTHER|Observational|Observational
218883531|NCT00639626|DRUG|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
218883532|NCT03470402|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
218883533|NCT03470402|OTHER|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
218883534|NCT03470402|OTHER|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
218883535|NCT03470402|OTHER|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
218883536|NCT03470402|OTHER|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
218883537|NCT04503824|DIAGNOSTIC_TEST|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
218883538|NCT02537184|PROCEDURE|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
218883539|NCT00016991|DRUG|gefitinib|
218883540|NCT02457949|OTHER|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
218883541|NCT02457949|OTHER|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
219028316|NCT06914466|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
219028317|NCT06912763|DRUG|Pravastatin (drug)|Given PO
219028318|NCT06912763|DRUG|Pentoxifylline|Given PO
219028319|NCT06912763|DRUG|ketoprofen|Given PO
219028320|NCT06912763|DRUG|Pirfenidoneone|Given PO
219028321|NCT06912763|OTHER|Standard of Care (SOC)|SOC
219606846|NCT03511092|DIETARY_SUPPLEMENT|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
219028322|NCT06912763|DRUG|tocopherol|Given PO
219028323|NCT06913816|DIAGNOSTIC_TEST|Grouyp 1 (without blinking exercises).|Group B (Control Group) The control group will continue receiving only the routine rehabilitation (without blinking exercises). Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.
219028324|NCT06913816|COMBINATION_PRODUCT|EXP group (Routine CVS treatment)|"Group A (Experimental Group): Individuals in the Experimental group will receive Routine CVS treatment with optimized blinking exercise.~Routine rehabilitation includes the 20-20-20 rule, blue light-blocking glasses, and polyvinyl eye drops.~The blinking exercise involved the individuals looking at an object 6 meters away for 5 seconds, followed by complete eyelid closure for 5 seconds. This cycle was repeated for 5 minutes, twice a day."
219028325|NCT06913582|BEHAVIORAL|Yoga|A 12-week pregnancy yoga program was delivered to experimental group (n=30) including one weekly 60-minute remote online yoga class and followed by 2 times of DVD yoga exercise.
219028326|NCT06913296|PROCEDURE|parathyroidectomy|typical open parathyroidectomy
219028327|NCT06913621|DRUG|amino acid formula|amino acid formula for 6 months
219028328|NCT06913621|DRUG|low bile acid binding blenderized diet|low bile acid binding blenderized diet for 6 months
219028329|NCT06913621|DRUG|high bile acid binding blenderized diet|high bile acid binding blenderized diet for 6 months
219028330|NCT06912958|DIETARY_SUPPLEMENT|Drinking of matcha tea|Japanese tea that will take twice daily for one month
219028331|NCT06912958|DIETARY_SUPPLEMENT|Organic Japanese Matcha, Jade Leaf, Japan|dietary intake
219505175|NCT00421785|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
219505176|NCT00170885|DRUG|Everolimus|
219505177|NCT02307409|OTHER|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
219505178|NCT04050332|BEHAVIORAL|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
219505179|NCT04290078|DEVICE|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
219505180|NCT04290078|OTHER|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
219505181|NCT01698320|DRUG|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
219505182|NCT01698320|DRUG|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
219505183|NCT00359970|DRUG|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
218883542|NCT03684382|OTHER|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
219505184|NCT00359970|DRUG|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
219505185|NCT00359970|DRUG|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
219505186|NCT00359970|OTHER|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
219505187|NCT06527482|PROCEDURE|Autologous Osteoperiosteal Transplantation|After full exposure of the lesion, the center of the cystic lesion was determined and drilled perpendicularly using a 2-mm pin. Then, a 4.5-mm cannulated bore was used to drill the lesion until the cyst was reached, and a small bone socket was created. A harvester tube matching the diameter of the cyst was used to enlarge the bone socket with care to avoid damage to the adjacent normal cartilage. The cystic lesion was debrided thoroughly, and the sclerotic wall of the cyst was freshened using a curette. The harvester tube with a matched diameter was driven in to a depth of 15 to 20 mm at the 2-cm proximal part of the anterior superior iliac spine perpendicularly without violation of the lateral wall of the crest. When necessary, small pieces of cancellous bone were also harvested from the iliac crest using a bone curette then grafted into the peripheral area of the cyst to fill up the remaining space of the cyst around the bone socket in the talus.
219505188|NCT01952574|DRUG|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
219505189|NCT01952574|DRUG|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
219505190|NCT01952574|DRUG|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
219505191|NCT01952574|DRUG|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
219505192|NCT05158491|DRUG|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
219505193|NCT01189240|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219505194|NCT01189240|BIOLOGICAL|bevacizumab|Given IV
219505195|NCT01189240|OTHER|laboratory biomarker analysis|Correlative studies
219505196|NCT01189240|OTHER|pharmacological study|Correlative studies
218883543|NCT04787991|DRUG|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
218883544|NCT04787991|DRUG|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
219505197|NCT02692430|OTHER|No intervention is studied|
219505198|NCT03522740|OTHER|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
219505199|NCT01264211|DRUG|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
219505200|NCT01264211|DRUG|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
218883545|NCT04787991|DRUG|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
219505201|NCT04726917|BEHAVIORAL|Pulmonary rehabilitation|Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
219505202|NCT03107351|DEVICE|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
219505203|NCT03107351|DEVICE|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
219505204|NCT04585555|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
219505205|NCT05733650|BIOLOGICAL|Epcoritamab|Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
219505206|NCT01916564|OTHER|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
219505207|NCT01916564|OTHER|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
219606847|NCT03511092|DIETARY_SUPPLEMENT|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
219606848|NCT03511092|OTHER|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
219606849|NCT02614274|DIETARY_SUPPLEMENT|Nutraceutical joint health formulation|A Proprietary Blend
219505208|NCT03564925|PROCEDURE|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
219505209|NCT03564925|PROCEDURE|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
219505210|NCT00502541|DRUG|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
219505211|NCT00502541|PROCEDURE|Standard of Care|Repeat macular grid laser or observation
219505212|NCT00386724|DEVICE|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
219028332|NCT06913803|DIAGNOSTIC_TEST|Stretching|The group A contains 34 patients and received STM for twice a week for three weeks with each session lasting approximately 20 min.focusing on mobilizing soft tissue to enhance circulation, reduce scar tissue and improve tissue flexibility.
219505213|NCT00386724|DEVICE|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
219505214|NCT02477904|OTHER|Ketogenic Diet|Dietary
219028333|NCT06913803|COMBINATION_PRODUCT|Soft Tissue Mobilization|Group B received both STM and stretching twice a week for three weeks with each session lasting approximately 20 min.encourage the patient to breathe deeply and slowly to promote relaxation.The stretching of tight muscles 1 set of 10 repetitions hold of 5 second of each exercise,then breathing for 1 min
219028334|NCT06913829|COMBINATION_PRODUCT|base-out exercising prisms|"Participants in the experimental group will use base-out exercising prisms as their primary intervention. This involves:~1. Procedure:~   * Wearing customized prism glasses designed to increase the convergence demand during near tasks.~  * Performing near vision activities such as reading or viewing objects while wearing the prisms.~2. Schedule:~   * Prisms will be prescribed based on individual clinical measurements.~  * Participants will use the prisms during near tasks for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks.~3. Monitoring:~   * Initial training will be provided to ensure proper use of the prisms.~  * Adherence will be checked during weekly follow-up visits, where adjustments to the prism strength will be made if necessary."
219028335|NCT06913829|DIAGNOSTIC_TEST|pencil pushup exercises|Participants in the control group will perform pencil pushup exercises as their primary intervention. This involves: 1. Procedure: o Holding a pencil or similar object vertically at arm's length and focusing on a letter or small mark on it. o Gradually moving the pencil closer to the nose until the participant experiences visual blur or sees double. o Returning the pencil to the starting position and repeating the process. 2. Schedule: o Exercises will be prescribed for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks. 3. Monitoring: o Participants will receive instructions during the initial session and periodic supervision at follow-up visits to ensure proper technique and adherence. o Progress will be monitored weekly through symptom reporting and clinical measurements.
219028336|NCT06913218|BIOLOGICAL|AK154|AK154 is neotigeon personalized mRNA vaccine
219028337|NCT06913218|BIOLOGICAL|Cadonilimab|a PD-1/CTLA-4 bispecific antibody
219028338|NCT06913218|BIOLOGICAL|Ivonescimab (SMT112 or AK112) Injection|a PD-1/VEGF bi-specific antibody
219028339|NCT06913218|DRUG|mFOLFORINOX|mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin
219028340|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
219040307|NCT05687435|DRUG|Changyanning tablet|"Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
219505215|NCT02501239|BEHAVIORAL|Accept Yourself!|
219505216|NCT02501239|BEHAVIORAL|Weight Watchers|
219505217|NCT06544486|PROCEDURE|Caries Removal|The cavity preparation and restoration were performed by a single operator. Infected dentin tissue was selectively removed. The differentiation between infected and affected dentin was determined by the clinician through the visual-tactile method.Isolation was achieved with cotton rolls and suction.
219505218|NCT06544486|PROCEDURE|Filling|Sectional matrix systems and interdental wedges were used to achieve an anatomical contour and contact. Then, the selected materials were placed in the cavity according to the manufacturers' recommendations.
219606850|NCT06174467|BEHAVIORAL|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
219505219|NCT06123403|DIAGNOSTIC_TEST|blood methotrexate level and Cystatin C level|blood methotrexate level and Cystatin C level
219505220|NCT02232503|GENETIC|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
219505221|NCT01475188|DRUG|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
219505222|NCT01475188|OTHER|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
219505223|NCT05208411|BEHAVIORAL|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll \& Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
219505224|NCT01409356|BEHAVIORAL|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
219505225|NCT00305370|DRUG|Aripiprazole|
219505226|NCT01172353|DRUG|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
219505227|NCT01172353|DRUG|saline|hydration with saline 1ml/Kg/h for 6 hours
218883546|NCT04787991|DRUG|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
218883547|NCT04787991|DRUG|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
218883548|NCT04787991|DRUG|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
218883549|NCT05266391|OTHER|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
218883550|NCT04770792|OTHER|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
218883551|NCT04770792|OTHER|Mineral trioxide aggregate.|Mineral trioxide aggregate.
218883552|NCT02484222|DRUG|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
219028341|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
218883553|NCT02065817|OTHER|stable isotope of cholesterol|
218883554|NCT03312426|DRUG|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
218883555|NCT05861661|OTHER|The study do not include an intervention|The study do not include an intervention
219505228|NCT01991587|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
219505229|NCT01991587|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
219505230|NCT01991587|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
219505231|NCT01991587|BIOLOGICAL|Placebo|A single dose of placebo
218883556|NCT04715971|DIAGNOSTIC_TEST|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
218883557|NCT04001283|DRUG|Sodium Nitrite|Intravenous drug infusion
218883558|NCT04001283|DRUG|0.9% Sodium-chloride|Matched placebo
218883559|NCT00153465|BEHAVIORAL|Motivational intervention, parent training|
218883560|NCT00234169|DRUG|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
218883561|NCT04218591|OTHER|PRP|Platelet rich plasma
218883562|NCT04218591|OTHER|Placebo|Saline
218883563|NCT04132596|DEVICE|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
218883564|NCT04132596|OTHER|Activity Based Therapy|Physical therapy
218883565|NCT06134843|COMBINATION_PRODUCT|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
219028342|NCT07110519|DRUG|[18F]-fluoromannitol|\[18F\]-fluoromannitol is an investigational, novel radiotracer for use with PET scan imaging to help detect disease or infection.
219028343|NCT07134127|DRUG|placebo|Placebo (without active ingredients) (cohort1, 2,4) Method of administration: oral, fasted administration. Placebo (without active ingredients) (cohort3) Method of administration: oral, administration after meal.
219505232|NCT03877874|DRUG|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
219505233|NCT02232048|OTHER|Transthoracic Echocardiogram|
219505234|NCT00240357|PROCEDURE|Lifestyle Regulation|
219505235|NCT02684695|OTHER|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
219505236|NCT02684695|OTHER|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
218883566|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
218883567|NCT05239767|DRUG|NSAID|We will administer oral NSAIDs
219505237|NCT03985501|OTHER|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
219505238|NCT00770991|DRUG|Black raspberry (BRB) Slurry|20 grams BRB Slurry
219606851|NCT06174467|BEHAVIORAL|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
218883568|NCT04479124|DIAGNOSTIC_TEST|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
219606852|NCT05176444|BEHAVIORAL|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
218883569|NCT05735535|DRUG|Antiviral Agents|two-drug one-pill once day
218883570|NCT04398550|OTHER|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
218883571|NCT04398550|OTHER|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
218883572|NCT01452581|OTHER|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
219505239|NCT00770991|DRUG|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
219505240|NCT00770991|DRUG|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
219505241|NCT03563950|DRUG|Rifampin|Specified dose on specified days
219606853|NCT02945969|BEHAVIORAL|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
219606854|NCT03131804|OTHER|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
219606855|NCT03883035|OTHER|automatic quality-control system|Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
219606856|NCT00451646|DRUG|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
219606857|NCT02108912|OTHER|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
219606858|NCT02108912|OTHER|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
219606859|NCT06425965|OTHER|Advanced life support training with high reality simulator|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with a high reality simulator in line with the information (15 min), scenario implementation (15 min) and debriefing sessions (30 min), respectively.
218883573|NCT01452581|DRUG|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
218883574|NCT00177255|DRUG|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
219505242|NCT03563950|DRUG|BMS-986224|Specified dose on specified days
219505243|NCT02275988|DRUG|K-877|
219505244|NCT02275988|DRUG|Clarithromycin|
219505245|NCT01126515|PROCEDURE|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
219505246|NCT01126515|PROCEDURE|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
219505247|NCT02555709|DRUG|VTP-43742|VTP-43742 administered as an oral capsule once daily
219505248|NCT02555709|DRUG|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
219505249|NCT02555709|DRUG|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
219505250|NCT00132509|DRUG|DFIL|Alteplase : 0.8mg/kg over 90 minutes
219606860|NCT06425965|OTHER|Advanced life support training with web-based simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out by web-based simulation method. Students participate in the web-based simulation application developed by the researcher.
218883575|NCT00177255|DRUG|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
218883576|NCT01500304|PROCEDURE|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
218883577|NCT00330681|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
218883578|NCT00330681|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
219505251|NCT00132509|DRUG|NINDS|Alteplase : 0.9mg/kg over 60 minutes
218883579|NCT03976206|BIOLOGICAL|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
218883580|NCT04038450|OTHER|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
218883581|NCT05248139|DRUG|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
218883582|NCT05248139|DRUG|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
218883583|NCT01140061|DRUG|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
218883584|NCT01140061|DRUG|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
218883585|NCT01140061|DRUG|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
218883586|NCT01140061|DRUG|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
218883587|NCT01140061|DRUG|Plain patch|Plain patch containing no MK-0873 or placebo
218883588|NCT00959556|OTHER|laboratory biomarker analysis|
218883589|NCT00003354|PROCEDURE|conventional surgery|
218883590|NCT00003354|PROCEDURE|laparoscopic surgery|
218883591|NCT03671915|DEVICE|Continuous Glucose Monitoring|collection of glucose data
218883592|NCT03671915|DEVICE|External Insulin Pump|Insulin delivery
219028344|NCT07134127|DRUG|IBI3032|IBI3032: (cohort1, 2,4) Method of administration: oral, fasted administration. IBI3032: (cohort3) Method of administration: oral, administration after meal.
219505252|NCT01687309|DRUG|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
219505253|NCT01687309|DRUG|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
219505254|NCT01687309|OTHER|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
219505255|NCT01687309|OTHER|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
219505256|NCT02129374|PROCEDURE|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
219505257|NCT03801733|DRUG|Vadadustat|Oral dose of 600 mg QD
219505258|NCT03801733|DRUG|Simvastatin|Oral Simvastatin
219505259|NCT03801733|DRUG|Rosuvastatin|Oral Rosuvastatin
219505260|NCT03801733|DRUG|Atorvastatin|Oral Atorvastatin
219505261|NCT03801733|DRUG|Pravastatin|Oral Pravastatin
219505262|NCT03801733|DRUG|Sulfasalazine|Oral Sulfasalazine
219606861|NCT06425965|OTHER|Advanced life support training with hybrid simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with the hybrid simulation method in which high reality simulator and web-based simulation method are applied together. Students first apply the web-based simulation developed by the researcher. Then they perform the practice on the high reality simulator.
219505263|NCT02045628|BEHAVIORAL|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
219505264|NCT00310778|DRUG|high sodium diet|high sodium diet
219505265|NCT00310778|DRUG|low sodium diet|low sodium diet
219505266|NCT00310778|DRUG|ramipril 10 mg|ramipril 10 mg
219505267|NCT00310778|DRUG|valsartan 160 mg|valsartan 160 mg
219505268|NCT00310778|DRUG|candesartan 8 mg|candesartan 8 mg
219505269|NCT00310778|DRUG|atenolol 50 mg|atenolol 50 mg
219505270|NCT02957409|DRUG|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
219505271|NCT02733237|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
219505272|NCT02733237|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
219505273|NCT05267574|DRUG|REN001|Once daily dosing
218883593|NCT03671915|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
218883594|NCT03671915|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
219505274|NCT05431283|DRUG|Tofacitinib|This study aims to assess the effectiveness of TOFA
219505275|NCT06547723|OTHER|MBSR and physiotherapy|"In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures."
219505276|NCT06547723|OTHER|physiotherapy|In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
219505277|NCT00859625|PROCEDURE|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
219505278|NCT03212196|PROCEDURE|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
219606862|NCT02523300|PROCEDURE|TEVAR|The patients will be undertaken TEVAR
219606863|NCT02523300|DRUG|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
219606864|NCT02523300|DRUG|saline|The other 120 patients will be given saline as control group
218883595|NCT00075556|DRUG|capecitabine|
218883596|NCT00075556|PROCEDURE|conventional surgery|
218883597|NCT00075556|PROCEDURE|neoadjuvant therapy|
218883598|NCT00075556|RADIATION|radiation therapy|
218883599|NCT06514833|BEHAVIORAL|lifestyle recommendations to nap regularly|Participants will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00
218883600|NCT06514833|OTHER|No recommendations to nap regularly|No lifestyle recommendations to nap regularly
219505279|NCT03212196|PROCEDURE|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
219606865|NCT01794559|DEVICE|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
219606866|NCT04871256|PROCEDURE|Septorhinoplasty|This intervention will be performed by the same surgeon, after signing of patient inform consent.
219028345|NCT00483223|DRUG|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
219028346|NCT00483223|DRUG|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
219505280|NCT06011421|DEVICE|Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant
219505281|NCT00696358|RADIATION|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
219505282|NCT00696358|RADIATION|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
219505283|NCT04450303|BEHAVIORAL|Telehealth CBT|The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
219505284|NCT03605706|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
219505285|NCT03605706|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
219505286|NCT03605706|DRUG|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
219505287|NCT01405976|DEVICE|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
219028347|NCT06935474|BIOLOGICAL|C-CAR168|This is a multi-center, Phase 1/2, open-label, dose-escalation and dose-expansion study evaluating C-CAR168 for the treatment of autoimmune diseases refractory to standard therapy. A traditional 3+3 design is used to identify the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) in disease-specific cohorts.
219028348|NCT06913049|OTHER|Social Engagement Support System|In this protocol, we will develop and deploy a set of machine learning models that use multiple individual- and community-level data sources to predict which members use the emergency department to fulfill social or non-urgent needs as opposed to treatment for urgent medical conditions. These models will identify individuals whose social needs are driving inappropriate utilization so that high-risk individuals will be given enhanced outreach services to facilitate completion of a comprehensive social needs assessment. We will also develop and deploy an engagement support system that identifies and displays the characteristics of members that prevent them from engaging with a Community Based Organization (CBO). This system will use artificial intelligence techniques to identify characteristics of individuals who have historically disengaged from the social service pipeline before receiving social services and suggest potential strategies for increasing engagement.
219028349|NCT00709774|DEVICE|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
219505288|NCT04741360|OTHER|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
219505289|NCT06441981|BEHAVIORAL|Education|Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
219505290|NCT03291457|DRUG|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
219505291|NCT03291457|DRUG|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
219505292|NCT02631928|DRUG|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
219505293|NCT02631928|DRUG|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
219505294|NCT04665505|BEHAVIORAL|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
219505295|NCT04665505|BEHAVIORAL|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
219505296|NCT06230471|DRUG|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
219505297|NCT06230471|DRUG|Pembrolizumab and Lenvatinib|Pembrolizumab and Lenvatinib
219505298|NCT06230471|DRUG|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
219606867|NCT05194098|DEVICE|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
219606868|NCT05194098|DEVICE|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
219606869|NCT03366441|OTHER|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
218883601|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
218883602|NCT03937492|OTHER|GMI protocol|"This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
218883603|NCT03937492|OTHER|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
218883604|NCT03296150|BEHAVIORAL|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
218883605|NCT06507826|BEHAVIORAL|Self-Compassionate Writing for Caregivers of Older Adults|Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
218883606|NCT01534195|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
219505299|NCT04630197|BEHAVIORAL|e-CBT|The description is provided in the treatment arm description.
219505300|NCT02040766|DRUG|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
219505301|NCT02040766|DRUG|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
219606870|NCT03366441|OTHER|SMS|Text messages were sent to an equal number of donors in the SMS group
219606871|NCT01739127|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
219606872|NCT01739127|DRUG|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
219505302|NCT02040766|DRUG|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
219606873|NCT01182376|DRUG|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
219606874|NCT01182376|DRUG|Placebo|Placebo will be administered by the patient's team according to established guidelines.
219606875|NCT06633627|OTHER|Recording of brain activity using electroencephalography (EEG)|Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
219606876|NCT04619212|DEVICE|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
219505303|NCT02040766|DRUG|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
219505304|NCT02040766|DRUG|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
219505305|NCT02974114|DRUG|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
219505306|NCT02974114|DRUG|Paracetamol|Test product containing 500 mg paracetamol
219505307|NCT02974114|OTHER|Placebo|Placebo to match paracetamol 665mg sustained release tablets
219505308|NCT00914888|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
219505309|NCT00914888|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
219505310|NCT00914888|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
219505311|NCT00914888|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
219505312|NCT03720483|DRUG|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
219505313|NCT03720483|DRUG|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
219505314|NCT04051632|DEVICE|Medtronic 670G insulin pump|"* percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range"
219606877|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
219606878|NCT04977479|OTHER|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
219606879|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
219028350|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
219028351|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
219028352|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
219028353|NCT03759379|DRUG|Patisiran|Patisiran will be administered by IV infusion.
219028354|NCT03759379|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
219606880|NCT04796298|PROCEDURE|Ballistic Hamstring Stretching|Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
219028355|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
219606881|NCT04796298|PROCEDURE|Hamstring Extender Exercise|Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
219606882|NCT04796298|PROCEDURE|Kinesiotape|Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
219606883|NCT03633097|OTHER|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
219606884|NCT03633097|DRUG|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
219606885|NCT00727597|DRUG|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
219505315|NCT03543033|DRUG|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
219505316|NCT05238506|DRUG|Intravenous lidocaine|Intraoperative intravenous lidocaine infusion.
219505317|NCT05238506|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
219505318|NCT05887830|DRUG|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
219606886|NCT00727597|DRUG|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
219505319|NCT05887830|OTHER|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
219505320|NCT05070520|DRUG|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
219505321|NCT04652921|DIETARY_SUPPLEMENT|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
219505322|NCT04652921|OTHER|Inulin|A dietary supplement provided as powder dissolved in a glass of water
218883607|NCT01534195|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
218883608|NCT05029739|DEVICE|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
218883609|NCT02669121|BIOLOGICAL|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
219505323|NCT03282435|BIOLOGICAL|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
218883610|NCT02669121|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
218883611|NCT02558777|OTHER|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
218883612|NCT03216746|BEHAVIORAL|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
219028356|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
219505324|NCT03282435|OTHER|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
219505325|NCT03282435|BIOLOGICAL|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
219505326|NCT01580020|BIOLOGICAL|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
219505327|NCT01580020|DRUG|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
219505328|NCT00075894|DRUG|L-alanosine|
219606887|NCT00001797|DRUG|Recombinant human interleukin-10|
219505329|NCT03834584|DRUG|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
219505330|NCT03238950|OTHER|Porcine model|participants to conduct training on porcine model
219505331|NCT03238950|OTHER|Synthetic model|participants to conduct training on synthetic model
219505332|NCT04482114|RADIATION|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
219505333|NCT01724359|DRUG|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
219505334|NCT00224250|PROCEDURE|One- versus two-layer hysterotomy closure|
219505335|NCT04694040|DEVICE|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
219505336|NCT06014632|OTHER|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
219505337|NCT06014632|OTHER|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
219505338|NCT03626610|BEHAVIORAL|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
219505339|NCT05544747|OTHER|Action Observation Therapy|"following phases will be included in action observation therapy group:~1. upper limb active range of motion (AROM) exercises.~2. reaching movement or object manipulation.~3. upper limb functional tasks."
219505340|NCT05544747|OTHER|Mirror Therapy|"following phases will be included in mirror therapy group:~1. AROM exercises),~2. reaching movement or object manipulation, and~3. functional task practice"
219505341|NCT01534975|DIAGNOSTIC_TEST|contrast agent|we are randomizing patients to different contrast agents.
219505342|NCT02448628|DRUG|CS-3150|
219505343|NCT02658409|BIOLOGICAL|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
219505344|NCT02658409|BIOLOGICAL|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
219505345|NCT06432205|PROCEDURE|surgery|any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery
219505346|NCT06536933|DIAGNOSTIC_TEST|Abdominal Ultrasound|Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis
219505347|NCT03503474|OTHER|No intervention|There is no intervention, this is observational only
219505348|NCT01408407|OTHER|Aveeno cream|Apply cream on irradiated area twice a day
219505349|NCT01408407|OTHER|Alkagin paste|Apply Alkagin paste three times a day.
219505350|NCT01517568|DRUG|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
219606888|NCT02699073|DRUG|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
219606889|NCT02018965|DRUG|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
219606890|NCT02018965|DRUG|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
219028357|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
219505351|NCT04921150|OTHER|standardization management|Apply standardization management to improve the outcomes of pregnancy
219505352|NCT01334736|BEHAVIORAL|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
219505353|NCT01334736|BEHAVIORAL|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
219606891|NCT04975854|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
219606892|NCT04975854|OTHER|Information Session|This includes 20-minute information session about general principles of exposure therapy before the start of the study.
219606893|NCT04449211|DEVICE|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
219606894|NCT01845727|DRUG|Topical Amphotericin B at 3%|
219606895|NCT02344082|OTHER|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
219606896|NCT03305627|OTHER|Short PAP|Perioperative antibiotic prophylaxis for 24h
219606897|NCT03305627|OTHER|Extended PAP|Perioperative antibiotic prophylaxis for \>48h
219028358|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
219028359|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
219028360|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
219028361|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
219028362|NCT00268138|DRUG|elmex gel|elmex gel once a week
219505354|NCT01334736|BEHAVIORAL|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
218883613|NCT03216746|BEHAVIORAL|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
218883614|NCT03216746|BEHAVIORAL|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
218883615|NCT03216746|BEHAVIORAL|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
219201088|NCT06881628|DRUG|Placebo|"Intravenous saline over 24-48 hours along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
219201089|NCT06881485|OTHER|Very Low Calorie Diet|This is a parallel multicentric longitudinal randomized controlled trial in which prospective data will be collected from the electronic health record. The inclusion and exclusion criteria will be checked and afterwards patients will be randomized to (unblinded) medication only or combination with VLCKD. Both arms include NB and lifestyle changes for 26 weeks but the patients belonging to the experimental arm must follow a VLCKD in the first 10 weeks on top of it. Like the other arm, the remaining 16 weeks will consist of NB combined with lifestyle interventions. Afterwards there is a follow-up extension of 26 weeks.
219028363|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
219028364|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
219505355|NCT01334736|BEHAVIORAL|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
219505356|NCT03863652|PROCEDURE|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
219505357|NCT02189395|DRUG|NPH and regular insulin|
219505358|NCT02189395|DRUG|glargine and humalog|
219505359|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
219028365|NCT06233474|DRUG|Allocetra|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
219028366|NCT06233474|OTHER|Placebo|The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
219201090|NCT06879769|OTHER|Metoprolol I.V.|The participant will receive intravenous Metoprolol (up to 15 mg) during the CT examination, administered directly at the CT table prior to CCTA.
219201091|NCT06879769|OTHER|Metoprolol I.V. and 1 hour waiting.|The Participant will rest in the waiting room for 1h and then receive intravenous Metoprolol, up to 15 mg.
219505360|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
219606898|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
219505361|NCT00384358|OTHER|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
219606899|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
219606900|NCT05293821|DIAGNOSTIC_TEST|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
218883616|NCT04384523|DRUG|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
219028367|NCT05280535|BEHAVIORAL|Cue Reactivity Task|In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.
219028368|NCT05280535|BEHAVIORAL|Computerized Visual Dot Probe|In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).
219028369|NCT05280535|BEHAVIORAL|Choice Task|In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
219028370|NCT06835803|RADIATION|Dose-escalated radiation therapy|Dose-escalated radiation therapy involves higher doses of radiation therapy each day of treatment over the three week course of radiation therapy
219028371|NCT06835803|RADIATION|Standard hypofractionated radiation|Standard hypofractionated radiation therapy over 3 weeks
219028372|NCT06174805|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
219201092|NCT06879769|OTHER|Music Intervention, Seloken (Recordati) orally and Metoprolol I.V.|The participant will receive Seloken (Metoprolol) according to clinical routine (up to 100 mg) and Metoprolol I.V. (up to 15 mg). The participant will also receive noise-canceling headphones and an iPad (or their own device) to select calming music and listen to it one hour before and during the CT scan.
219505362|NCT01162395|DRUG|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
219505363|NCT01595490|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
219505364|NCT01335464|DRUG|placebo|placebo matching BIBF1120, BID
219505365|NCT01335464|DRUG|BIBF 1120|BIBF1120 BID (twice daily)
219505366|NCT00919139|OTHER|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
219606901|NCT00931645|PROCEDURE|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
219606902|NCT00931645|PROCEDURE|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
219606903|NCT00931645|PROCEDURE|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
219606904|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
219606905|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
219606906|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
219606907|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
219606908|NCT05379244|BEHAVIORAL|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
219606909|NCT02754843|DEVICE|Phonak's equivalent newly developped power BTE|
219606910|NCT02754843|DEVICE|Equivalent competitor device|
218883617|NCT04384523|DRUG|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
218883618|NCT04384523|DRUG|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
218883619|NCT04384523|DRUG|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
218883620|NCT04384523|DRUG|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
218883621|NCT04384523|OTHER|Placebo|Normal Saline (0.9% Sodium Chloride)
218883622|NCT02782221|DRUG|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
218883623|NCT02782221|DRUG|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
218883624|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
218883625|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
218883626|NCT06524323|DRUG|5-fluorouracil Injection|The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
218883627|NCT06524323|DRUG|Triamcinolone Acetonide|The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
218883628|NCT02113332|DRUG|Liraglutide|
218883629|NCT02113332|DRUG|Placebo|
218883630|NCT02629003|DRUG|[11C]Cimbi-36|
218883631|NCT02629003|DRUG|[11C]Cimbi-36-5|
219505367|NCT05725278|BEHAVIORAL|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
219505368|NCT05725278|OTHER|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
219505369|NCT00002571|BIOLOGICAL|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
219505370|NCT00002571|BIOLOGICAL|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
219505371|NCT00002571|DRUG|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
219505372|NCT00002571|DRUG|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
219505373|NCT00002571|DRUG|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
219505374|NCT00002571|DRUG|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
219505375|NCT00002571|DRUG|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
219505376|NCT00002571|DRUG|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
219505377|NCT00002571|DRUG|prednisone|60 mg/m2 po QD x 14days for 6 cycles
219505378|NCT00002571|DRUG|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
219505379|NCT00002571|DRUG|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
219505380|NCT00002571|RADIATION|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
219505381|NCT00002571|DRUG|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
219505382|NCT05927805|OTHER|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
219606911|NCT03189992|DRUG|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
219505383|NCT05927805|OTHER|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
219505384|NCT02971345|PROCEDURE|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
219505385|NCT02971345|DEVICE|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
219505386|NCT02971345|DEVICE|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
219505387|NCT02971345|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
219505388|NCT02971345|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
219505389|NCT02971345|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
219606912|NCT03189992|DRUG|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
219606913|NCT06278480|DEVICE|MegaCarti®|Medical devices containing allogeneic cartilage
219606914|NCT06278480|PROCEDURE|microfracture|microfracture
219606915|NCT00001630|DEVICE|Isolex 300i|
219606916|NCT02890355|DRUG|Fluorouracil|Given IV
219606917|NCT02890355|DRUG|Fluorouracil|Given IV bolus
219606918|NCT02890355|DRUG|Irinotecan Hydrochloride|Given IV
219606919|NCT02890355|OTHER|Laboratory Biomarker Analysis|Correlative studies
219505390|NCT00446654|DRUG|CGC-11047|16.5 mg (3.3%) subconjunctival injection
219505391|NCT02175407|DRUG|ASP1707|oral
219505392|NCT02175407|DRUG|itraconazole|oral
219505393|NCT05478811|DEVICE|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
219606920|NCT02890355|DRUG|Leucovorin Calcium|Given IV
219606921|NCT02890355|DRUG|Veliparib|Given PO
219606922|NCT06138873|PROCEDURE|Ablation-index guided ventricular tachycardia ablation|As described in arms descriptions
219606923|NCT06138873|PROCEDURE|Ventricular tachycardia ablation with no AI-guidance|As described in arms descriptions
219606924|NCT05707377|DRUG|Zanubrutinib|Zanubrutinib capsules administered orally.
219606925|NCT05707377|DRUG|Tacrolimus|Tacrolimus capsules administered orally.
219606926|NCT06575673|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for smokers with psychological distress
219606927|NCT06575673|BEHAVIORAL|Monthly health education|General health information and sharing sessions
219505394|NCT05478811|DEVICE|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
219505395|NCT03047954|DRUG|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
219505396|NCT03047954|DRUG|Placebo - Cap|Matching Placebo capsule administered
219505397|NCT05086120|OTHER|eCARIBOU|A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
219505398|NCT02332135|PROCEDURE|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
219505399|NCT02332135|DRUG|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
219505400|NCT06282796|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software
219505401|NCT04190238|OTHER|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
219505402|NCT04190238|OTHER|Physical therapy|specific for spasticity
219505403|NCT05535517|OTHER|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
219028373|NCT06835283|DEVICE|Brain Stimulation|This intervention is distinct because it combines two non-invasive brain stimulation techniques, intermittent theta burst stimulation (iTBS) and transcranial direct current stimulation (tDCS), in a sequential manner. Unlike studies that evaluate these techniques individually, this study explores their combined and complementary effects, with iTBS priming the brain to enhance the subsequent impact of tDCS. The sequential design leverages different mechanisms of action: iTBS delivers magnetic pulses to targeted brain areas to modulate neural activity, while tDCS applies a low electrical current for sustained modulation. This approach specifically targets neuropsychiatric symptoms (e.g., mood swings, apathy, and agitation) in individuals with Alzheimer's Disease and related dementias (ADRD), a population often underserved by traditional interventions. The study also evaluates the feasibility of at-home tDCS administration, making it unique in combining clinical and caregiver-managed treat
219028374|NCT03485378|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
219028375|NCT04579380|DRUG|tucatinib|300 mg orally twice daily
219028376|NCT04579380|DRUG|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
219028377|NCT04579380|DRUG|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
219028378|NCT05686317|DEVICE|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
219028379|NCT05686317|DIAGNOSTIC_TEST|Sham procedure|CS angiography
219028380|NCT06083883|DRUG|Fludarabine phosphate|Given by IV (vein)
219028381|NCT06083883|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by IV (vein)
219028382|NCT06083883|DRUG|Cyclophosphamide|Given by IV (vein)
219028385|NCT02717624|DRUG|Acalabrutinib in combination with BR|
219028386|NCT02717624|DRUG|Acalabrutinib in combination with VR|
219028387|NCT03115983|DEVICE|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
219028388|NCT03115983|DEVICE|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
219028389|NCT03115983|PROCEDURE|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
219028390|NCT03115983|PROCEDURE|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
219028391|NCT04938765|DRUG|Magnesium sulfate|Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
219028392|NCT04938765|DRUG|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
219028393|NCT06394531|DIETARY_SUPPLEMENT|Jaboticaba Peel Extract|Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
219505404|NCT05535517|OTHER|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
219028394|NCT06394531|OTHER|Placebo|Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
219505405|NCT05535517|OTHER|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
219505406|NCT05535517|OTHER|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
219505407|NCT05535517|OTHER|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
219505408|NCT05535517|OTHER|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
219505409|NCT04246190|DRUG|CKD-501 and D759|Reference drug, CKD-501 1T and D759 1T, QD, PO
219028395|NCT05722873|BEHAVIORAL|Fasting arm|Study participants will fast one day per week for 12 weeks
219505410|NCT04246190|DRUG|CKD-396|Reference drug, CKD-396 1T, QD, PO
219505411|NCT03096574|OTHER|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
219505412|NCT06326268|DEVICE|Phototherapy system CareMin650TM|"* As part of preventive treatment: Photobiomodulation sessions will be carried out at a dose of 3 joules for 1 minute 51 seconds, 3 times a week (for a maximum duration of 4 to 6 weeks).~* As part of curative treatment (i.e. for patients developing mucositis, from grade I): photobiomodulation will be carried out at a curative dose of 6 joules daily (for a maximum duration of 4 to 6 weeks ) for 3 minutes 34 seconds."
219505413|NCT02291107|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
219505414|NCT02291107|OTHER|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
218883632|NCT06293768|DEVICE|continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)|Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
218883633|NCT06526091|OTHER|Cerebral NIRS monitoring at delivery|Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
218883634|NCT00461279|BEHAVIORAL|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
218883635|NCT00461279|BEHAVIORAL|Interpersonal Psychotherapy|Established psychotherapy for depression
218883636|NCT05411939|OTHER|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
218883637|NCT05411939|OTHER|Video|Short video that describes knee osteoarthritis and possible treatment options.
219028396|NCT05722873|BEHAVIORAL|Weight maintenance|Study participants will be counseled to maintain body weight
219028397|NCT05722873|BEHAVIORAL|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
219028398|NCT06500052|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
219028399|NCT06401330|PROCEDURE|Bone Scan|Undergo bone scan for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
219028400|NCT06401330|DRUG|Carboplatin|Given IV
219028401|NCT06401330|PROCEDURE|Computed Tomography|Undergo CT
219028402|NCT06401330|DRUG|Cyclophosphamide|Given IV
219028403|NCT06401330|BIOLOGICAL|Dactinomycin|Given IV
219028404|NCT06401330|DRUG|Doxorubicin|Given IV
219505415|NCT00078468|DRUG|PELITREXOL/AG-2037|
219505416|NCT03099967|DEVICE|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
219505417|NCT00503126|DRUG|bivalirudin|anticoagulation
219505418|NCT00168337|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
219505419|NCT00168337|OTHER|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
219505420|NCT02748005|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|one cap once a day
219505421|NCT02963298|PROCEDURE|Continuous renal replacement therapy|
219505422|NCT04949867|DRUG|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
219505423|NCT04949867|DEVICE|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
219505424|NCT00707915|DRUG|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
219505425|NCT00360867|DRUG|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
219505426|NCT04988945|PROCEDURE|TACE|Procedure of TACE will be standardized.
219505427|NCT04988945|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
219505428|NCT04988945|DRUG|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
219505429|NCT04988945|DRUG|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
219505430|NCT01082198|BIOLOGICAL|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
219505431|NCT01082198|BIOLOGICAL|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
219505432|NCT01082198|BIOLOGICAL|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
219505433|NCT01082198|BIOLOGICAL|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
219505434|NCT01082198|BIOLOGICAL|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
219606928|NCT06560359|DIETARY_SUPPLEMENT|F&V|The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet). Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
218883638|NCT05411939|OTHER|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
219505435|NCT01082198|OTHER|flow cytometry|
219505436|NCT01082198|PROCEDURE|adjuvant therapy|
219505437|NCT00231049|DRUG|AG-707|
219505438|NCT03900611|DEVICE|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
219505439|NCT01207128|DRUG|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
219505440|NCT02765828|OTHER|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
219505441|NCT00001728|DRUG|Fosamax (Alendronate)|
218883639|NCT01794676|GENETIC|Blood draw|Blood draw
218883640|NCT06468670|DRUG|sintilimab，programmed death 1 monoclonal antibody|"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"
219505442|NCT05625711|DEVICE|The endovascular interventional surgical instrument control system|The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
219505443|NCT03286647|PROCEDURE|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
218883641|NCT04405076|BIOLOGICAL|Biological: mRNA-1273|Sterile liquid for injection
218883642|NCT04405076|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
218883643|NCT04405076|BIOLOGICAL|mRNA-1273.351|Sterile liquid for injection
218883644|NCT01153360|DRUG|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
218883645|NCT01153360|DRUG|placebo|vitamin B12
219028405|NCT06401330|DRUG|Etoposide|Given IV
219028406|NCT06401330|DRUG|Irinotecan|Given IV
219028407|NCT06401330|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219028408|NCT06401330|PROCEDURE|Nephrectomy|Undergo nephrectomy
219505444|NCT00648453|DRUG|Clopidogrel (Plavix)|
219505445|NCT03343106|BEHAVIORAL|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
219505446|NCT03343106|BEHAVIORAL|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
219505447|NCT00593333|DEVICE|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
219505448|NCT00593333|DEVICE|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
219505449|NCT04362033|DIAGNOSTIC_TEST|Passive Leg Raising (PLR) and PEEP increment (PEEP)|PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position
219505450|NCT05909306|OTHER|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
219505451|NCT02327520|OTHER|Colitis with CDI treatment|All patients will be treated with standard treatment
219505452|NCT01448031|DRUG|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
219505453|NCT01448031|DRUG|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
219505454|NCT01752920|DRUG|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
219505455|NCT01752920|DRUG|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
219505456|NCT01752920|DRUG|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
219505457|NCT01752920|DRUG|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
219505458|NCT00384891|DEVICE|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
219505459|NCT00384891|DRUG|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
219505460|NCT03483181|DRUG|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
219505461|NCT03483181|DRUG|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
219505462|NCT04236310|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
219505463|NCT04236310|DRUG|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
219505464|NCT04236310|DRUG|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
219505465|NCT04236310|DRUG|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
219505466|NCT01738581|DEVICE|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
219505467|NCT01738581|BEHAVIORAL|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
219606929|NCT06560359|DIETARY_SUPPLEMENT|No F&V|The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
219505468|NCT01738581|BEHAVIORAL|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
219505469|NCT02500017|DIETARY_SUPPLEMENT|Melatonin|5mg rapid release melatonin capsule
219505470|NCT02500017|OTHER|Placebo|matching placebo capsule
219505471|NCT03603236|DIAGNOSTIC_TEST|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
219505472|NCT03603236|DIAGNOSTIC_TEST|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
219505473|NCT03286413|PROCEDURE|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
219505474|NCT00604656|DRUG|insulin aspart|
219505475|NCT02595333|DRUG|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
219505476|NCT02595333|DRUG|Group S1|sufentanil was administered for analgesia in primary cesarean section
219505477|NCT02595333|DRUG|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
219505478|NCT02595333|DRUG|Group S2|sufentanil was administered for analgesia in repeated cesarean section
219505479|NCT03164590|DRUG|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
219505480|NCT03164590|DRUG|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
219505481|NCT03164590|DRUG|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
219606930|NCT07076277|DEVICE|Clareon PanOptix Pro and Clareon Vivity Intraocular Lens|Bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lens in one eye and Alcon Clareon Vivity (or Vivity Toric) intraocular lens i
219606931|NCT07076277|DEVICE|Clareon PanOptix Pro Intraocular Lenses|Bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lenses in both eyes. All surgeries target emmetropia with residual astigmatism ≤0.50 diopters using toric IOLs or arcuate incisions as needed.
219606932|NCT07082439|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
219028409|NCT06401330|OTHER|Patient Observation|Undergo observation after nephrectomy
219028410|NCT06401330|PROCEDURE|Positron Emission Tomography|Undergo PET for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
219028411|NCT06401330|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219028412|NCT06401330|DRUG|Vincristine|Given IV
219028413|NCT06401330|PROCEDURE|X-Ray Imaging|Undergo X-ray
219028414|NCT06153797|BEHAVIORAL|PATH-C|PATH-C, a phone-delivered positive psychology intervention for caregivers of patients undergoing HSCT, consists of the following nine sessions: 1) Enhancing gratitude and increasing awareness for physical activity; 2) Expressing gratitude and goal setting for physical activity; 3) Integrating gratitude and goals for physical activity; 4) Personal strengths and environmental scan to enhance physical activity; 5) Enhancing strengths via reflection on past successes; 6) Integrating strengths to enhance well-being and physical activity; 7) Engaging in enjoyable and meaningful activities; 8) Promoting optimism and integrating long-term activity habits; 9) Integrating meaning for sustainable physical activity goals. Each session takes about 30 minutes, and a trained interventionist will guide participants to complete the sessions.
219028415|NCT05950633|OTHER|Standard of Care|Participants will receive standard of care postoperative instructions
219028416|NCT05950633|OTHER|Active Recovery|Participants will receive instructions to increase their fitness to walking at least 30 minutes a day for 5 days a week following surgery and abdominal and pelvic floor exercises will focus on abdominal wall strengthening and abdominal pressure management, urinary urgency and retention, bowel and constipation management
219028417|NCT05872620|DRUG|Orforglipron|Administered orally
219028418|NCT05872620|DRUG|Placebo|Administered orally
219028419|NCT03595124|DRUG|Axitinib|Given PO
219028420|NCT03595124|BIOLOGICAL|Nivolumab|Given IV
219028421|NCT04728893|DRUG|Nemtabrutinib|Nemtabrutinib tablets administered orally QD.
219028422|NCT06312735|DEVICE|VR (Reducept)|Reducept is a novel VR intervention that consists of a combination of pain neuroscience education (PNE) and pain management techniques. It includes different psychological therapy modalities (e.g. acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and hypnotherapy) into a single application.
219028423|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
219028424|NCT04293562|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
219028425|NCT04293562|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
219028426|NCT04293562|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219028427|NCT04293562|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
219028428|NCT04293562|PROCEDURE|Bone Marrow Biopsy|BM biopsy
219028429|NCT04293562|PROCEDURE|Computed Tomography|Undergo CT
219028430|NCT04293562|DRUG|Cytarabine|Given IV or IT
219028431|NCT04293562|DRUG|Daunorubicin Hydrochloride|Given IV
219505482|NCT02916381|PROCEDURE|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
219505483|NCT02916381|PROCEDURE|General anaesthesia|
219028432|NCT04293562|DRUG|Dexrazoxane Hydrochloride|Given IV
219028433|NCT04293562|DRUG|Etoposide|Given IV
219028434|NCT04293562|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
219505484|NCT06503796|DRUG|Lamivudine|4mg/kg/d, oral
219505485|NCT06503796|DRUG|Interferon|Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
219505486|NCT00696709|BIOLOGICAL|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
219505487|NCT00696709|BIOLOGICAL|Comparator: Placebo|Placebo; 4-dose regimen administered \~30 days apart.
219505488|NCT03201471|DRUG|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
219505489|NCT02347878|DRUG|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
219505490|NCT02775253|OTHER|Chronic cold acclimation|
219201093|NCT06878781|OTHER|High carbohydrate challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 479.6 kcal; Carbohydrate, 83.6%; Lipids, 12.4%, and Protein, 4.0% (70 g of hot cake, 100 g of mango, 270 ml of peach nectar, and 40 g of strawberry jam). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
219505491|NCT05278377|BEHAVIORAL|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
219505492|NCT00377026|BEHAVIORAL|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
219606933|NCT07082439|DRUG|Odetiglucan|Odetiglucan 4 mg/kg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
219606934|NCT07110922|DIAGNOSTIC_TEST|Angiography only|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region
219606935|NCT07110922|DIAGNOSTIC_TEST|Angiography and ECG|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region and correlate with electrogram guidance for BBP
219505493|NCT00887003|DRUG|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
219505494|NCT00887003|DRUG|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
219505495|NCT00887003|DRUG|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
219606936|NCT01061801|BEHAVIORAL|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
219606937|NCT04904133|OTHER|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
219606938|NCT04904133|OTHER|Placebo Group|Water
219606939|NCT02506127|DEVICE|Neuronetics XPLOR system|Transcranial magnetic stimulation system
219606940|NCT01128179|DRUG|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
219606941|NCT01128179|DRUG|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
219606942|NCT01682811|DRUG|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
219606943|NCT01682811|DRUG|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
219606944|NCT01682811|DRUG|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
219028435|NCT04293562|DRUG|Gemtuzumab Ozogamicin|Given IV
219028436|NCT04293562|DRUG|Gilteritinib Fumarate|Given PO/NG/G-tube
219028437|NCT04293562|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219028438|NCT04293562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219028439|NCT04293562|DRUG|Methotrexate|Given IT
219028440|NCT04293562|DRUG|Mitoxantrone Hydrochloride|Given IV
219028441|NCT04293562|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
219028442|NCT04293562|OTHER|Questionnaire Administration|Ancillary studies
219028443|NCT04293562|DRUG|Therapeutic Hydrocortisone|Given IT
219028444|NCT05373043|DIETARY_SUPPLEMENT|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
219028445|NCT05373043|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
219028446|NCT05489705|DRUG|Mavacamten|As per product label
219028447|NCT05489705|DRUG|Non-mavacamten symptomatic oHCM therapy|Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
219028448|NCT01536379|DRUG|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
219028449|NCT01536379|DRUG|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
219028450|NCT04993781|BEHAVIORAL|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
219028451|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
219028452|NCT06117774|DRUG|Tarlatamab|Intravenous (IV) infusion
219028453|NCT06117774|DRUG|Placebo|IV infusion
219505496|NCT00887003|DRUG|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
219505497|NCT00887003|DRUG|Depo-Medrol|80mg Depo-Medrol
219606945|NCT01682811|DRUG|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
219606946|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
219606947|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
219505498|NCT02682290|OTHER|Expectoration and measurement of sputum rheological properties|
219505499|NCT02006966|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
219505500|NCT02006966|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
218883646|NCT06315127|DIETARY_SUPPLEMENT|Human donor milk|The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.
218883647|NCT06315127|DIETARY_SUPPLEMENT|Formula|The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
218883648|NCT02661867|BEHAVIORAL|delivery|delivery either vaginal or by cesarean section
218883649|NCT00492336|DRUG|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
218883650|NCT00492336|DRUG|Placebo|Placebo 1 tablet each day
218883651|NCT00500955|DRUG|Rosiglitazone|
218883652|NCT00392990|DRUG|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
218883653|NCT00392990|DRUG|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
218883654|NCT01802190|GENETIC|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
218883655|NCT02381275|DRUG|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
219028454|NCT05581056|DRUG|CFTR modulators|Introduction of CFTR modulators by pneumologists for pneumologic issues
219505501|NCT03183466|PROCEDURE|arthroscopic repair|
219505502|NCT03183466|PROCEDURE|arthroscopic debridement|
219505503|NCT01186978|RADIATION|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
219505504|NCT04283578|DRUG|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
219028455|NCT03752307|DRUG|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
219505505|NCT04283578|DRUG|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
219505506|NCT03677778|PROCEDURE|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
219505507|NCT03677778|OTHER|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
219505508|NCT03822962|DRUG|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
219201094|NCT06878781|OTHER|High lipid challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 1043.4 kcal; Carbohydrate, 4.9%; Lipids, 86.8%, and Protein, 8.3% (60 g of manchego cheese, 25 g of egg, white, dried, 24 g of bacon, 5 ml of oil, 65 g of cream cheese, 70 g of cream, and 16 g of poblano pepper). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
219201095|NCT06878781|OTHER|High proteinchallenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 441.3 kcal; Carbohydrate, 1.6%; Lipids, 5.1%, and Protein, 93.3% (2 scoop Isopure Zero Carb, 180 g of chicken breast, 20 g of lettuce and 24 g of ham turkey breast). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
219201096|NCT06715540|DRUG|BCD-261, dose 1|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219505509|NCT03822962|OTHER|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
219201097|NCT06715540|DRUG|BCD-261, dose 2|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219201098|NCT06715540|DRUG|BCD-261, dose 3|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219201099|NCT06715540|DRUG|BCD-261, dose 4|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219201100|NCT06715540|DRUG|BCD-261, dose 5|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219505510|NCT01227668|DRUG|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
219201101|NCT06715540|DRUG|BCD-261, dose 6|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219505511|NCT01227668|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
219505512|NCT04487756|DRUG|Atezolizumab 1200 mg in 20 ML Injection|"\- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~\- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)"
219505513|NCT04487756|BIOLOGICAL|ADC Vaccine|\- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
219505514|NCT04487756|DRUG|Carboplatin|\- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
218883656|NCT00241904|BEHAVIORAL|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
219201102|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
219201103|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
219201104|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose Y|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
219201105|NCT06882564|DRUG|resveratrol mouthwash|"the participants where instruct to rinse their mouth twice daily with 10 ml of assigned mouthwash for 60 seconds for 7 days. There is currently no published research on the use of resveratrol as a mouthwash for halitosis treatment.~This study aims to fill this gap by evaluating its effectiveness in reducing oral malodor through antibacterial action and the potential of volatile sulfur compounds ( VSCs)"
219201106|NCT06882564|DRUG|Chlorhexidine mouthwash (0.2%)|The second group will given chlorhexidine 0.2% mouthwash as an active comparator, and will asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice per day for 7 days, and will instructed to refrain from eating and drinking for 30 min after rinsing.
219201107|NCT06882564|DRUG|Placebo|the third group will given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice daily for 7 days and will be instructed to refrain from eating and drinking for 30 min after rinsing.
218883657|NCT00241904|DRUG|Antiplatelet Agents|Aspirin 81 mg q day
219505515|NCT03979209|DRUG|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
219505516|NCT02925767|DEVICE|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
219505517|NCT02925767|DEVICE|308-nm excimer laser|XTRAC, PhotoMedex, US
218883658|NCT00241904|DRUG|Beta Blocker|Oral medication
218883659|NCT00241904|DRUG|ACE Inhibitors|Oral medications, received 1-2 times per day
218883660|NCT02116088|BEHAVIORAL|Teacher Coaching|
218883661|NCT03764683|DRUG|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
219505518|NCT04998253|DRUG|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
219505519|NCT03871400|PROCEDURE|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
219505520|NCT01033864|DRUG|MMF|1 g per day b.i.d. p.o. for at least 1 month
219505521|NCT01033864|DRUG|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
219201108|NCT04768777|BEHAVIORAL|Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
219505522|NCT01033864|DRUG|Prednisone|5 mg per day p.o.
219505523|NCT01754090|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
219505524|NCT01754090|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
219505525|NCT01754090|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
219505526|NCT03491605|OTHER|peripheral EBV-DNA load|No intervention
219505527|NCT02305368|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
219505528|NCT04556669|BIOLOGICAL|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
219505529|NCT06302712|BEHAVIORAL|Traditional Islamically Integrated Psychotherapy|Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.
219505530|NCT01709383|DEVICE|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
219606948|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
219606949|NCT06509503|DRUG|Combined oral contraceptive|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
218883662|NCT03764683|DRUG|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
218883663|NCT01337544|OTHER|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
218883664|NCT02639520|DRUG|Canephron® N|2 tablets 3 times a day for 7 days
218883665|NCT02639520|DRUG|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
219505531|NCT01709383|DEVICE|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
219505532|NCT02245191|DRUG|Ephedrine|5mg after Spinal Anesthesia
219505533|NCT02245191|DRUG|Phenylephrine|100mcg after Spinal Anesthesia
219505534|NCT02245191|DRUG|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
218883666|NCT02639520|DRUG|Canephron® N-placebo|2 tablets 3 times a day for 7 days
218883667|NCT02639520|DRUG|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
218883668|NCT03576911|DIETARY_SUPPLEMENT|Coenzyme Q10|
218883669|NCT03576911|OTHER|Placebo|
219201109|NCT06719037|PROCEDURE|Endo-Surgi Plus endoscopic surgery|Endo-Surgi Plus endoscopic surgery, as a new type of percutaneous endoscopic lumbar discectomy (PELD), features a larger working channel and represents an optimized single-channel endoscopic technique. However, it still has the limitations inherent in single-channel endoscopy.
219505535|NCT01109459|OTHER|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
219505536|NCT01109459|OTHER|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
219505537|NCT00119977|PROCEDURE|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
219505538|NCT04402554|BEHAVIORAL|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
219505539|NCT02136732|OTHER|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
219505540|NCT02136732|OTHER|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
219505541|NCT02724137|BEHAVIORAL|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
219505542|NCT02724137|OTHER|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
219606950|NCT06509503|DRUG|Vaginal Ring|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
219606951|NCT04886661|OTHER|CHRONIC NECK PAIN|Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
218883670|NCT06393166|DRUG|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
218883671|NCT01947764|BEHAVIORAL|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
218883672|NCT01467921|DRUG|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
218883673|NCT00308971|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
218883674|NCT00308971|DRUG|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
218883675|NCT00308971|DRUG|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
218883676|NCT00308971|DRUG|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
218883677|NCT03441230|DEVICE|Balloon characteristics|Different size balloon
218883678|NCT03633266|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
218883679|NCT03633266|PROCEDURE|PRP|vitreoretinal surgery combined with intraoperative PRP
218883680|NCT01107847|PROCEDURE|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
219201110|NCT06719037|PROCEDURE|Unilateral biportal endoscopic surgery|Unilateral biportal endoscopic discectomy (UBE) is characterized by its separate endoscopic and working channels, and the ability to use traditional open instruments, making it a convenient and versatile technique. It is a commonly used spinal endoscopic surgery in clinical practice.
219606952|NCT06551883|PROCEDURE|different bowel preparation regime|Patients in Group B receive the 3L of PEG in a single dose
219606953|NCT06551883|PROCEDURE|traditional bowel preparation regime|Patients in Group A receive the 3L of PEG in a split dose
219606954|NCT03357744|OTHER|distress barometer|not applicable, observational study
219606955|NCT00413881|PROCEDURE|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
219606956|NCT00413881|PROCEDURE|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
219505543|NCT05092334|OTHER|proprioceptive exercises|proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
219505544|NCT05092334|OTHER|Strengthening exercise|strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
219505545|NCT05634187|DEVICE|Functional endoscopy|Transnasal endoscopy by an ultrathin video endoscope
218883681|NCT01150565|DRUG|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
218883682|NCT05608551|BEHAVIORAL|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
219505546|NCT01038583|DRUG|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
219505547|NCT01038583|DRUG|Placebo|100 mg enteric-coated placebo
219505548|NCT03264066|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
219606957|NCT00855907|OTHER|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
219606958|NCT00134004|DRUG|cyclophosphamide|
218883683|NCT05608551|BEHAVIORAL|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
218883684|NCT02685904|BIOLOGICAL|ENIA11|
218883685|NCT02685904|BIOLOGICAL|Placebo|
218883686|NCT06183333|BEHAVIORAL|Heidelberg Emotion Regulation Training|The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
218883687|NCT02128412|DEVICE|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
218883688|NCT02128412|DEVICE|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
218883689|NCT01870310|PROCEDURE|Catheterised renal denervation|
218883690|NCT02980133|DRUG|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
218883691|NCT02980133|DRUG|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
218883692|NCT02980133|DRUG|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
218883693|NCT04200144|DEVICE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
218883694|NCT04420403|OTHER|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
219028456|NCT03752307|DRUG|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
219028457|NCT03752307|DRUG|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
219505549|NCT03264066|DRUG|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
219505550|NCT03264066|DRUG|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
219505551|NCT00382330|DRUG|Ciclopirox|
219606959|NCT00134004|DRUG|fludarabine phosphate|
219606960|NCT00134004|DRUG|mycophenolate mofetil|
219606961|NCT00134004|DRUG|tacrolimus|
219028458|NCT00417794|DRUG|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
219028459|NCT00417794|DRUG|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
219040308|NCT05687435|OTHER|Changyanning tablet placebo|"Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
219040309|NCT06071455|OTHER|Platelet-rich fibrin|injected distal to the canine on the experimental side.
219505552|NCT04305223|PROCEDURE|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
219505553|NCT04305223|OTHER|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
219505554|NCT00686803|DRUG|PL3994|Study drug
219606962|NCT00134004|PROCEDURE|allogeneic bone marrow transplantation|
218883695|NCT04420403|OTHER|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
218883696|NCT01509911|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
218883697|NCT01509911|DRUG|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
218883698|NCT05141084|OTHER|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
218883699|NCT04282525|OTHER|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
218883700|NCT02572765|OTHER|PET/CT scan|PET/CT scan
218883701|NCT01997671|OTHER|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
218883702|NCT03797300|DEVICE|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
218883703|NCT00825812|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
218883704|NCT00825812|DRUG|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
218883705|NCT05100446|DRUG|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
218883706|NCT05100446|DRUG|Pylera|Eradication with Pylera, for 10 days.
218883707|NCT05100446|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
218883708|NCT01631396|DRUG|Sugammadex vs. Neostigmine|"* Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
218883709|NCT03865784|OTHER|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
219028460|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
219028461|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
219028462|NCT00143702|DRUG|d4T|See Detailed Description.
219028463|NCT00143702|DRUG|Abacavir|See Detailed Description.
219028464|NCT00143702|DRUG|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
219028465|NCT02822521|OTHER|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
219505555|NCT00686803|DRUG|Placebo|Placebo
219505556|NCT06220461|DIETARY_SUPPLEMENT|Folic acid|Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
219505557|NCT00729235|DEVICE|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
219505558|NCT00729235|DEVICE|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
219505559|NCT03140306|DIAGNOSTIC_TEST|Patients who have had split dose CT|Computed tomography
219505560|NCT02602340|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
219606963|NCT00134004|RADIATION|radiation therapy|
219606964|NCT01260701|DRUG|Akt Inhibitor MK2206|Given PO
219606965|NCT05755347|OTHER|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
219505561|NCT04829695|DRUG|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
219505562|NCT04829695|DRUG|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
219505563|NCT06126042|DRUG|Test Product|DRL\_AB, Pre Filled Syringe; Solution for injection
219505564|NCT06126042|DRUG|Reference product|USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
219505565|NCT06126042|DRUG|Reference Medicinal Product|EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
219505566|NCT04237571|BEHAVIORAL|CANE Meal Program|Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
219505567|NCT03016559|OTHER|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
219505568|NCT04269278|DRUG|0 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
219505569|NCT04269278|DRUG|0.25 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
219505570|NCT04269278|DRUG|0.5 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
219505571|NCT04269278|DRUG|0.75 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
219505572|NCT03331965|DRUG|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
219505573|NCT03331965|DRUG|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
219505574|NCT00924066|DRUG|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
219505575|NCT01152281|BEHAVIORAL|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
219606966|NCT05755347|OTHER|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
219606967|NCT05755347|OTHER|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
219606968|NCT05755347|OTHER|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
219606969|NCT05755347|OTHER|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
219606970|NCT05411146|DRUG|[14C]-etrumadenant|Administered as specified in the treatment arm.
219606971|NCT06138691|COMBINATION_PRODUCT|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
218883710|NCT03865784|OTHER|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
218883711|NCT03075709|OTHER|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
218883712|NCT04223414|DEVICE|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
219028466|NCT02822521|OTHER|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
219606972|NCT05440201|OTHER|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
218883713|NCT02371031|DRUG|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
218883714|NCT02371031|DEVICE|PET/MRI|
218883715|NCT02371031|PROCEDURE|Surgical resection (standard of care)|
218883716|NCT05545839|BEHAVIORAL|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
218883717|NCT00364741|DRUG|Oxygen|During and 2 hours after surgery
218883718|NCT06325865|OTHER|Interview|Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.
219028467|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
219028468|NCT02619890|OTHER|Brain Glioma Registry|
219028469|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
219040310|NCT06071455|OTHER|Vitamin D3|injected distal to the canine on the experimental side.
219505576|NCT01152281|BEHAVIORAL|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
219505577|NCT01152281|BEHAVIORAL|Minimal Control|Control messages to increase awareness of HIV risk
219505578|NCT01152281|BEHAVIORAL|Instrumental|Instrumental messages with stories of people living with HIV
219505579|NCT01152281|BEHAVIORAL|Empowering|Empowering messages with stories of people living with HIV
219505580|NCT00790075|DRUG|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was \>30 minutes.
219505581|NCT00125567|DRUG|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
219606973|NCT00720382|DRUG|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
219606974|NCT00720382|DRUG|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
219606975|NCT01443897|DIETARY_SUPPLEMENT|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
219606976|NCT01443897|DIETARY_SUPPLEMENT|placebo capsule|0 IU vitamin D2
219606977|NCT01443897|OTHER|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
219606978|NCT01443897|OTHER|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
219028470|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
219606979|NCT01443897|OTHER|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
219606980|NCT03493256|OTHER|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
219606981|NCT07164612|OTHER|Occupation-Based Bilateral Upper Limb Training (OBBT)|Intervention sessions for experimental group will be conducted 5 times per week over 6 weeks. OBBT will be used to engage both upper limbs simultaneously in simulate real-life functional tasks which tailored to individual needs, focusing on improving the patient's ability to perform daily activities such as dressing, washing, and cooking. The training will emphasize occupation-specific repetitive practice for at least two selected occupations and encouraged active participation of both hands during functional tasks to improve use of both upper limb motor functions and activity participation. Additionally, it will seek to support stroke survivors in their pursuit of an independent, productive, and functional recover.
219028471|NCT05643235|DEVICE|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
219606982|NCT07164612|OTHER|Conventional therapy group|Conventional therapy includes passive and active range of motion exercises, strengthening exercises, basic functional activities and mobility training, and activities designed to improve muscle tone and mobility in the affected upper limb among stroke survivors. The conventional therapy sessions will be delivered 5 times per week for 90 minutes over 6 weeks. Therapy sessions will be individualized to the participant's needs and will be provided by senior occupational therapists.
219606983|NCT07186075|BEHAVIORAL|Phubbing and Mental Health Literacy Education for Adolescents|Phubbing and Mental Health Literacy Education for Adolescents
219028472|NCT00292864|DRUG|SNS-032 Injection|
219606984|NCT07186075|BEHAVIORAL|no training was provided|no training was provided
219028473|NCT00156533|DRUG|Zolpidem|10 mg of Zolpidem
219028474|NCT00156533|DRUG|Sugar Pill|
219028475|NCT04700358|OTHER|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
219606985|NCT07184502|DRUG|ZT003|ZT003 is administered as a single subcutaneous injection at different dose levels.
219028476|NCT00715325|DEVICE|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
219028477|NCT02732483|DRUG|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
219028478|NCT06629662|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy with laparoscopic or robotic approach
219505582|NCT00125567|DRUG|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
219505583|NCT01315483|OTHER|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
219505584|NCT03980795|OTHER|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
219505585|NCT03655210|DRUG|HL151|HL151(1Tab) once a day for 4 weeks of treatments
219505586|NCT03655210|DRUG|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
219505587|NCT01226875|PROCEDURE|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
219505588|NCT01015612|DEVICE|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
219505589|NCT00066807|DRUG|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
219505590|NCT00066807|DRUG|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
219505591|NCT00066807|DRUG|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
219505592|NCT00066807|DRUG|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
219505593|NCT00066807|PROCEDURE|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
219606986|NCT07184502|DRUG|ZT003|ZT003 administered as multiple subcutaneous injections at different dose levels.
219606987|NCT07184502|DRUG|Placebo|Matching placebo administered subcutaneously.
219606988|NCT07184905|BIOLOGICAL|Oral administration of inactive Bifidobacterium longum group|1×10\^11 CFU of inactive Bifidobacterium longum was given orally once daily for one month
219606989|NCT07184905|BIOLOGICAL|Oral Bifidobacterium longum group|1×10\^11 CFU of Bifidobacterium longum was given orally once daily for one month
219606990|NCT07185750|OTHER|Questionnaire application for JIA cases and their parents|Scales will be applied to cases diagnosed with JIA and their parents
218883719|NCT02606058|PROCEDURE|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
218883720|NCT05244551|DRUG|ABSK061|In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
218883721|NCT05002491|OTHER|High protein diet|Normal vs high protein dietary feeding
218883722|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
218883723|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
218883724|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
218883725|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
218883726|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
218883727|NCT02514148|BEHAVIORAL|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
218883728|NCT02514148|OTHER|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
218883729|NCT02514148|OTHER|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
219028479|NCT00734279|DRUG|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
219505594|NCT00066807|PROCEDURE|ovarian irradiation|Bilateral ovarian irradiation.
219505595|NCT06012175|DIETARY_SUPPLEMENT|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
219505596|NCT06012175|DIETARY_SUPPLEMENT|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
219505597|NCT03177356|PROCEDURE|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
219505598|NCT03177356|PROCEDURE|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
219606991|NCT07185113|DRUG|GEn-1124|GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.
219505599|NCT05787977|OTHER|Visual Feedback and Rhythmic Auditory Cue|Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
219505600|NCT05550558|DRUG|Anlotinib + Camrelizumab|Anlotinib PO plus Camrelizumab IV
219505601|NCT00644605|DRUG|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
219505602|NCT00644605|DRUG|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
219505603|NCT00644605|DRUG|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
218883730|NCT02514148|OTHER|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
218883731|NCT05144867|RADIATION|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
218883732|NCT02391519|PROCEDURE|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
218883733|NCT01224743|DIETARY_SUPPLEMENT|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
218883734|NCT01224743|DIETARY_SUPPLEMENT|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
218883735|NCT01224743|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
218883736|NCT00898833|OTHER|laboratory biomarker analysis|
219201111|NCT06719037|PROCEDURE|Microdiscectomy|Microdiscectomy (MD) is a mature minimally invasive technique that uses a microscope to treat lumbar spinal stenosis. As early as 1999, prospective randomized controlled studies confirmed that it has equally excellent clinical efficacy compared to open surgery, with less surgical trauma. It is currently the classic minimally invasive surgical approach for treating lumbar spinal stenosis.
219505604|NCT00644605|DRUG|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
219505605|NCT06246851|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
219505606|NCT04825080|DIAGNOSTIC_TEST|duplex ultrasound and computed tomography angiography|Identification of carotid artery stenosis \> 60% NASCET criteria
218883737|NCT00888953|OTHER|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
218883738|NCT00888953|OTHER|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
219201112|NCT06716983|DIAGNOSTIC_TEST|fMRI|fMRI in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
219201113|NCT06716983|DIAGNOSTIC_TEST|EEG-MEG|EEG-MEG in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
218883739|NCT04115137|DEVICE|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
218883740|NCT02779413|DRUG|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
218883741|NCT05357508|BEHAVIORAL|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
219201114|NCT06716983|DIAGNOSTIC_TEST|registration of local field potentials|registration of local field potential in patients with dystonia implanted with deep brain stimulation
219505607|NCT05738356|COMBINATION_PRODUCT|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
219505608|NCT04203706|OTHER|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
219505609|NCT03369756|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
219505610|NCT03805204|PROCEDURE|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
219505611|NCT02468557|DRUG|Idelalisib|Tablets administered orally twice daily
219505612|NCT02468557|DRUG|Nab-paclitaxel|125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
219505613|NCT02468557|DRUG|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
219505614|NCT00519012|DRUG|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
219505615|NCT00519012|DRUG|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
219505616|NCT03786666|PROCEDURE|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
219505617|NCT00982410|BEHAVIORAL|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
219505618|NCT00982410|BEHAVIORAL|educational supportive group|A control condition providing social support and education about pain and/or drug use.
219606992|NCT07185503|DRUG|liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole|The intervention in this study is a tailored antifungal regimen combining liposomal amphotericin B (L-AmB) (3-5 mg/kg/day IV) with posaconazole or isavuconazole (300 mg/200 mg daily, oral or IV), designed to optimize efficacy and safety in immunocompromised adults with blood cancers and mucormycosis. Dosing and duration are personalized based on clinical response, immune recovery, and organ function, with a focus on transitioning to oral therapy to reduce hospitalization. The study emphasizes rigorous safety monitoring, prohibited unauthorized antifungal co-medications, and explores prognostic factors to advance treatment strategies for this high-risk population.
219606993|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - active|rTMS session active on the primary motor cortex
219606994|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - inactive|rTMS session inactive on the primary motor cortex
219606995|NCT07184645|DRUG|OPA-15406|0.3% foam or 1% foam, topical, twice daily, for 8 weeks
219606996|NCT07184645|DRUG|Vehicle|vehicle, topical, twice daily, for 8 weeks
219606997|NCT05220163|DIAGNOSTIC_TEST|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
219606998|NCT05220163|DIAGNOSTIC_TEST|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
219606999|NCT01758081|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
219607000|NCT01758081|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
219607001|NCT01758081|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
218883742|NCT05357508|BEHAVIORAL|Control brochure|Provide participants with general information about options for colorectal cancer screening.
218883743|NCT05456620|OTHER|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
218883744|NCT05456620|OTHER|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
219201115|NCT06716983|DIAGNOSTIC_TEST|genetic panel|genetic panel for dystonia
219607002|NCT01758081|DIETARY_SUPPLEMENT|fish oil placebo|
219607003|NCT03983837|OTHER|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
219607004|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
219607005|NCT06548776|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS) Scan|Participants will receive MRS Scan
219201116|NCT06695299|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, balance exercises
219505619|NCT04262596|OTHER|Interactive Consulting System|Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
219505620|NCT04262596|OTHER|A traditional patient decision aid brochure|Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
219505621|NCT02878850|OTHER|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
219505622|NCT03316079|OTHER|Chest physiotherapy techniques|Respiratory manual CPT
219505623|NCT03316079|DEVICE|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
219505624|NCT04967313|BEHAVIORAL|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
219505625|NCT03247296|DRUG|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
219505626|NCT03167099|PROCEDURE|Full Weight Bearing|full weight bearing after fixation of a distal femur fracture
219505627|NCT02687282|OTHER|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
219201117|NCT06695299|OTHER|Kinesthetic and Visual Motor Imagery Training|Kinesthetic and Visual Motor Imagery Training During kinesthetic imagery, the participants were asked to feel their body parts without any body motion. During visual imagery, the participants were asked to perform a visual presentation of the motion without any body motion.
219505628|NCT05087394|OTHER|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
219505629|NCT05188040|OTHER|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
219505630|NCT03574155|BEHAVIORAL|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
219607006|NCT05509439|OTHER|Home Transfusion Program Components|The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment \& administration, (4) usual elements of hospice
219201118|NCT06719778|OTHER|Two-stage nutritional therapy concept|"1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect."
219201119|NCT00556777|PROCEDURE|axillary lymph node dissection|
219201120|NCT00556777|PROCEDURE|conventional surgery|
219505631|NCT00770003|DRUG|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
219505632|NCT00770003|DRUG|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
219505633|NCT04524299|RADIATION|chest radiation(IMRT)|Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
219505634|NCT04524299|DRUG|Concurrent chemotherapy twice a week|"During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy"
219505635|NCT04524299|DRUG|Concurrent chemotherapy once a week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
219505636|NCT01093742|DRUG|HM10560A|Subcutaneously administrate at 0 hour on Day 1
219505637|NCT01093742|DRUG|Placebo|Placebo
219505638|NCT01280799|BEHAVIORAL|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
219505639|NCT01016652|DEVICE|etafilcon A multifocal contact lens|low-add multifocal contact lens
219505640|NCT01016652|DEVICE|etafilcon A Contact Lens|standard sphere contact lens
219505641|NCT04388059|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
219607007|NCT06268080|BEHAVIORAL|Depth of anesthesia titration using pEEG|Titration of maintenance anesthetic agent (propofol infusion)
219607008|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
219607009|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
219505642|NCT04014959|DEVICE|Transcranial Magnetic Stimulation|"Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. Repetitive TMS (rTMS) is FDA-approved for depression treatment.~TMS is administered over 5 study visits: an initial TMS/fMRI session, a 3-day TMS intervention regimen, and a post-intervention TMS/fMRI session. During TMS/fMRI sessions, participants receive single pulses of TMS pre/post a short round of Intermittent Theta Burst Stimulation (iTBS), a modified rTMS protocol. Throughout the 3-day intervention regimen, participants receive two full rounds of iTBS daily.~All study participants receive active TMS."
218883745|NCT01959438|DRUG|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
219505643|NCT02060461|DEVICE|FS200 femtosecond laser LASIK|
219505644|NCT02060461|DEVICE|IntraLase femtosecond laser LASIK|
219505645|NCT04190654|DRUG|KW-6356|Single oral dose of KW-6356
219505646|NCT03822052|OTHER|Lactated ringers|IV fluid
219505647|NCT03822052|OTHER|5% dextrose lactated ringers|IV fluid
219505648|NCT01271114|DRUG|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
219505649|NCT01271114|DRUG|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
219505650|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
219505651|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
218883746|NCT01959438|DRUG|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
218883747|NCT04573608|DRUG|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
218883748|NCT04573608|DRUG|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
218883749|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
218883750|NCT01488201|DRUG|Placebo|
218883751|NCT01488201|DRUG|KHK4827|
218883752|NCT00408434|DRUG|CS-7017|CS-7017 0.05mg and 1.0mg tablets
219028480|NCT00734279|DRUG|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
219028481|NCT00734279|DRUG|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
219028482|NCT00734279|DRUG|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
219028483|NCT05447156|BEHAVIORAL|Tailored QuitGuide app|This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.
219028484|NCT05447156|BEHAVIORAL|Standard QuitGuide app|This is an app available to the public.
219028485|NCT02143440|BEHAVIORAL|The initial assessment of daily insulin dose.|
219028486|NCT02029833|OTHER|Regular Canola Oil|
219028487|NCT02029833|OTHER|High Oleic Canola Oil|
219028488|NCT02029833|OTHER|Western Type Diet - Common Dietary Oils|
219028489|NCT01254227|DRUG|Deferasirox and Deferoxamine|
219028490|NCT02002364|PROCEDURE|tracheal intubation|
219028491|NCT04372667|BEHAVIORAL|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up"
219028492|NCT01948817|DRUG|Deferasirox|Deferasirox 20mg/kg taken BID
219505652|NCT00876278|DEVICE|*AT.Smart 46LC|Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
219505653|NCT06546241|BEHAVIORAL|Celebrandome|This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
219505654|NCT04857307|DRUG|Alprazolam|"* Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points."
219505655|NCT02034799|BIOLOGICAL|Bioseal Fibrin Sealant|
219505656|NCT02034799|OTHER|Standard of Care (SoC)|
219505657|NCT01976390|DRUG|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
219505658|NCT01976390|DRUG|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
219505659|NCT00916890|DRUG|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
219505660|NCT00916890|DRUG|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
219505661|NCT00916890|DRUG|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
219505662|NCT00916890|DRUG|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
219505663|NCT06544551|DRUG|Peginterferon Alfacon-2|Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
219607010|NCT06335953|BEHAVIORAL|Pharmacist-led deprescribing intervention|The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
219607011|NCT05679050|DRUG|AG Followed by FOLFIRINOX|"AG（every 28 days) Nab-paclitaxel 125 mg/m2 i.v. over 30 min, gemcitabine hydrochloride 1g/m2 i.v. over 30 min, D1, 8 and 15 ; FOLFIRINOX(every 42 days) Oxaliplatin: 65 mg/m2 i.v. over 2h on D1, 15, 29; Tetrahydrofolate: 400 mg/m2 i.v.2h on D1, 15, 29; Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29; 5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31; After one round of above therapy, patients achieving stable disease and above without disease progression or unacceptable toxicity underwent pancreatectomy within 4-8 weeks; Patients who did not achieve stable disease and above were treated another round , and patients who achieved stable disease and above underwent pancreatectomy at 4-8 weeks.~Following pancreatectomy, patients underwent AG regimen (2 rounds, 56 days) followed by FOLFIRINOX regimen (42 days) in the absence of disease progression or unacceptable toxicity, and AG and FOLFIRINOX dosing as the preoperative therapy."
219607012|NCT03015246|DRUG|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
219607013|NCT03015246|DRUG|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
219607014|NCT03015246|DRUG|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
218883753|NCT05817032|BEHAVIORAL|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
219201121|NCT00556777|PROCEDURE|sentinel lymph node biopsy|
219201122|NCT00556777|RADIATION|intraoperative radiation therapy|
219505664|NCT06544551|DRUG|Peginterferon Alfacon-2 placebo|Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
219505665|NCT02265848|OTHER|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
219505666|NCT02265848|OTHER|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
219607015|NCT03015246|DRUG|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
219505667|NCT04142346|BEHAVIORAL|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
219505668|NCT03321058|BEHAVIORAL|Assessment|Assessment of patients' medication organisation and comprehension of generics
219505669|NCT01704664|DIETARY_SUPPLEMENT|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
219505670|NCT01704664|DRUG|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
219505671|NCT01704664|DIETARY_SUPPLEMENT|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
219505672|NCT01704664|DRUG|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
219505673|NCT02660411|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
219505674|NCT02660411|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
219505675|NCT06544083|DIAGNOSTIC_TEST|Proteomics|Proteomic is performed on all blood samples.
219505676|NCT02127047|DRUG|Sitagliptin|
219505677|NCT02127047|DRUG|Exercise|
219505678|NCT01133821|DRUG|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
218883754|NCT05817032|BEHAVIORAL|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
218883755|NCT00681928|DRUG|anastrozole|As determined by the subject's physician
218883756|NCT00681928|DRUG|letrozole|As determined by the subject's physician
218883757|NCT00681928|OTHER|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
218883758|NCT00681928|PROCEDURE|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
218883759|NCT00681928|PROCEDURE|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
218883760|NCT00588354|DRUG|Clonidine|200 or 400 micrograms clonidine
218883761|NCT00588354|DRUG|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
218883762|NCT00588354|DRUG|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
219201123|NCT06724887|BEHAVIORAL|Brain Health Strategy Training and Education|Initial training strategies cover Strategic Memory Advanced Reasoning Tactics (SMART), and subsequent training extends the SMART principles to other life-applications such as stress management, sleep, and lifestyle. Virtual and in-person workshops will expand on topics such as stress management, sleep, resilience, and mental well-being, with an emphasis on how practicing and implementing brain healthy strategies can impact everyday life. For faculty/staff, we will also offer interactive workshops on how to create a brain healthy environment and classroom, including ways to implement and provide brain-healthy strategies and resources in their everyday operations involving students.
219028493|NCT06241339|OTHER|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
219040311|NCT02355327|DEVICE|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
219201124|NCT06882772|DRUG|2 mL SunButyrate-TG|"Participants randomized into the 2 milliliter (mL) SunButyrate-TG will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
219201125|NCT06882772|DRUG|Placebo|Participants randomized into the Placebo arm will take the oil-based placebo once daily for 3 weeks prior to cardiac surgery
219201126|NCT06882772|DRUG|4 mL SunButyrate-TG|"Participants randomized into the 4 mL SunButyrate-TG arm will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
219505679|NCT01133821|DRUG|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
219505680|NCT00580359|DRUG|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
219607016|NCT03015246|DRUG|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
218883763|NCT02724709|PROCEDURE|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
218883764|NCT02724709|PROCEDURE|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
219201127|NCT06887478|OTHER|Exercise|A progressive resistance exercise program focusing on strengthening the flexor hallucis longus (FHL) muscle in elderly participants.
219201128|NCT06882759|OTHER|No intervention (observational study)|This is an observational study. No intervention.
219607017|NCT03015246|DRUG|Placebo stressor|Lactose
219607018|NCT01659957|BEHAVIORAL|Group Couples Counseling|
219607019|NCT01659957|BEHAVIORAL|One-on-One Couples Counseling|
219201129|NCT06881719|DEVICE|The Adventures of Apollo & Rosetta|"The new APP The Adventures of Apollo and Rosetta consists of 7 exercises (1. Explorer; 2. Deciphering codes; 3. Particle accelerator tunnel; and 4. Leaping asteroids, - 5. Galactic art; 6. Stellar Laboratory; 7. Challenge of opposites).~The training program provides for the application of 36 mini-game sessions lasting 15-20 minutes each (alternating the first 4 and the last 3 games) over 12 weeks (the child must practice 3 times a week).~The training via APP can be administered in the first sessions on an outpatient basis, then it can be delegated to parents who take care of the exercises 3 times a week (20-15-20 minutes). A work diary will be kept monitoring the progress of the activities."
219201130|NCT06879951|OTHER|Participants are not assigned an intervention as part of the study.|Participants are not assigned an intervention as part of the study.
219201131|NCT06886438|PROCEDURE|RVS|Revascularization
219201132|NCT06886438|PROCEDURE|L-PRF|Regenerative endodontic procedure with L-PRF application
219201133|NCT06886438|PROCEDURE|i-PRF|Regenerative endodontic procedure with i-PRF application
219201134|NCT06887257|OTHER|Telematic cardiac rehabilitation program, that includes exercise, educational and psychological sessions during 3 months|"2 group and telematic exercise sessions/week, 1 educational session/week and 1 psychological session/week, during 3 months.~There are no drugs or devices involved in the intervention."
219607020|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
219607021|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
219607022|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
218883765|NCT04000581|OTHER|Best Practice|Receive standard of care
218883766|NCT04000581|OTHER|Physical Activity|Walk for minimum 30 minutes per day
218883767|NCT04000581|OTHER|Questionnaire Administration|Ancillary studies
219505681|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
219505682|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
219505683|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
219505684|NCT04320459|DIAGNOSTIC_TEST|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
219505685|NCT04320459|DIAGNOSTIC_TEST|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
219505686|NCT04320459|DIAGNOSTIC_TEST|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
219505687|NCT02200133|OTHER|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
219505688|NCT06092606|DRUG|Control group:DH001 placebo|Dosage: DH001 placebo (8 tablets)
219505689|NCT06092606|DRUG|Trial group: DH001 low-dose group|Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)
219607023|NCT06583226|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
219607024|NCT06583226|PROCEDURE|Gelatin sponge stabilization with suture and cyanoacrylate and coconut oil application|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) and coconut oil (test group)
219607025|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
219607026|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
219607027|NCT02653625|DRUG|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
219607028|NCT03860974|DRUG|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
219607029|NCT03860974|DRUG|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
219607030|NCT01348048|OTHER|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
219607031|NCT03707626|OTHER|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
219201135|NCT06887257|OTHER|Standard recommendations|Standard recommendations about exercise, educational and psychologicla advice
219201136|NCT06886867|OTHER|Exergaming|Exergaming: Participants will perform different exercises through videogames
219201137|NCT06886867|OTHER|Usual physical therapy care|Usual care: Different exercises will be performed
218883768|NCT04283591|PROCEDURE|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
218883769|NCT04283591|OTHER|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
218883770|NCT03477838|DEVICE|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
218883771|NCT02110264|DRUG|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
218883772|NCT02110264|BEHAVIORAL|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
218883773|NCT02110264|BEHAVIORAL|ETAU|Participants assigned to the ETAU group will receive drug education.
218883774|NCT00141128|DRUG|SS-RBX|
218883775|NCT04649684|DEVICE|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
219505690|NCT06092606|DRUG|Trial group: DH001 high-dose group|Dosage: DH001 400mg (8 tablets).
219201138|NCT06886386|DEVICE|Trans-spinal direct current stimulation|Patients with a neurological level above T10 will receive cervical tsDCS (anode electrode at C7, and the cathode electrode on the right shoulder). Patients with a neurological level from T10 onwards will receive thoracic tsDCS (anode electrode at T10, and the cathode electrode at the iliac crest). (i) Experimental group (active tsDCS): electrical stimulator (Neuroconn/Germany) connected to a pair of saline-soaked sponge electrodes (35 cm²) with a current intensity of 2.5 mA for 20 minutes. (ii) Control group (sham tsDCS) with electrodes positioned at the same locations as active tsDCS, for 30 seconds (the setup will remain for the full 20 minutes). Thus, patients will experience the initial sensations at the stimulated site, without inducing an effect. Physical therapy will be performed during tsDCS (45 minutes), based on scientific evidence, considering patient preferences, and respecting motor learning theory and neuroplasticity principles, focusing on motor function recovery.
219505691|NCT00306969|DRUG|bexarotene|
219607032|NCT04783402|OTHER|e-OTCAT program|"The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions."
219505692|NCT00306969|DEVICE|photopheresis|
219505693|NCT05426122|OTHER|Barley rice protein concentrate shake|At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
219505694|NCT05426122|OTHER|Pea protein concentrate shake|At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
219505695|NCT05426122|OTHER|Whey protein concentrate shake|At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
219505696|NCT06234046|DRUG|Rifaximin 550Mg Tab|group (1) received Rifaximin as 550 mg twice daily dosage for six months.
219505697|NCT06234046|DRUG|Ciprofloxacin 750 MG|group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.
219505698|NCT06234046|DIAGNOSTIC_TEST|ascitic fluid sample|aspiration of ascitic fluid sample and analysis for differential cell count
219505699|NCT04596501|OTHER|Early and late postmenopausal women|The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.
219505700|NCT04767269|DRUG|Cuminum Cyminum|Cuminum Cyminum mouthwash in chronic gingivitis patients
219505701|NCT04767269|DRUG|herbal Mouthwash|herbal mouthwash in chronic gingivitis patients
219505702|NCT02943681|BIOLOGICAL|Measles vaccine|
219505703|NCT02501850|DRUG|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
219505704|NCT02501850|DRUG|metformin|Treatment with metformin and/or sulphonilurea
219607033|NCT04783402|OTHER|Educational handbook and standard care|At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
219028494|NCT00891644|OTHER|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
219505705|NCT03500939|DRUG|Medical oxygen|inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
219505706|NCT03500939|OTHER|Standard of care|e.g. thrombectomy, thrombolysis
219505707|NCT00711906|DRUG|Cotrimoxazole|Cotrimoxazole
219505708|NCT00711906|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
219505709|NCT03129737|PROCEDURE|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
219505710|NCT03129737|PROCEDURE|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
219505711|NCT03572933|DRUG|ganaxolone|active drug
219505712|NCT03572933|DRUG|Placebo|inactive
219505713|NCT02685605|PROCEDURE|Standard surgery|
219505714|NCT02685605|RADIATION|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
219505715|NCT02685605|RADIATION|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
219505716|NCT02685605|DRUG|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
219505717|NCT02089828|OTHER|autologous purified CD34+ cells|
219607034|NCT06499402|OTHER|massage|sacral massage
219607035|NCT05377749|BEHAVIORAL|FACT|Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
219607036|NCT00174304|DRUG|Amlodipine/atorvastatin single pill|
218883776|NCT04649684|DEVICE|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
219201139|NCT06718179|DRUG|Short duration of aspirin and prasugrel|aspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year
219505718|NCT02089828|OTHER|autologous peripheral blood mononuclear cells|
219505719|NCT01501383|DRUG|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
219505720|NCT01501383|DRUG|Placebo|Matching placebo
219505721|NCT01501383|DRUG|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
219505722|NCT00003833|GENETIC|DNA stability analysis|
219505723|NCT00003833|GENETIC|gene mapping|
219505724|NCT00004110|BIOLOGICAL|monoclonal antibody 3F8|
219505725|NCT00004110|DRUG|etoposide|
219505726|NCT00004110|DRUG|isotretinoin|
219505727|NCT01414946|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
219505728|NCT01414946|OTHER|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
219505729|NCT00739479|DIETARY_SUPPLEMENT|Weight Loss|Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
219505730|NCT01847573|DRUG|HT-100|May be administered in either fed or fasted state
219505731|NCT01761526|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
219505732|NCT02625766|PROCEDURE|LC fracture surgical fixation|
219505733|NCT02625766|PROCEDURE|LC fracture non-operative management|
219505734|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 1.5mg/ day|Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
219505735|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 2.0mg/ day|Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
219607037|NCT03194269|DEVICE|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
219607038|NCT02042352|OTHER|pH glove|
219607039|NCT00096629|BIOLOGICAL|human prostate-specific membrane antigen plasmid DNA vaccine|
219607040|NCT00096629|BIOLOGICAL|mouse prostate-specific membrane antigen plasmid DNA vaccine|
218883777|NCT00713895|BEHAVIORAL|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
218883778|NCT00713895|BEHAVIORAL|Standard Self-Help|standard smoking cessation self-help manual
218883779|NCT02409771|DEVICE|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
218883780|NCT02389400|DRUG|methotrexate|Single Group Assignment
218883781|NCT00839761|DIETARY_SUPPLEMENT|iron fortified rice|
219201140|NCT06718179|DRUG|Conventional duration of aspirin and prasugrel|aspirin 75 mg/day lifelong plus prasugrel 10 mg/day (5 mg/day) for 1 year
219201141|NCT06726343|DEVICE|Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
218883782|NCT00839761|DIETARY_SUPPLEMENT|iron drops|
219505736|NCT04443322|DRUG|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
219505737|NCT04443322|DRUG|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
219607041|NCT06150248|OTHER|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
219505738|NCT01527448|DRUG|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
219505739|NCT02413073|PROCEDURE|Whole Body Vibration|We wil use vibration in patients with kidney disease
219505740|NCT01467063|DIETARY_SUPPLEMENT|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
218883783|NCT05185050|DIAGNOSTIC_TEST|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
219201142|NCT06726343|DEVICE|Investigational Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
219201143|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction|"The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment"
219505741|NCT01467063|DIETARY_SUPPLEMENT|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
218883784|NCT00856804|DRUG|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
218883785|NCT02519595|DRUG|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
219201144|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction plus inertial exercises|"The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group."
219201145|NCT06706791|DRUG|Empagliflozin 10 MG|participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
219201146|NCT05145881|DIETARY_SUPPLEMENT|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
219505742|NCT02714686|BEHAVIORAL|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
218883786|NCT02519595|DRUG|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
218883787|NCT02519595|DRUG|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
219505743|NCT01466686|RADIATION|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
219505744|NCT01466686|DRUG|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
219505745|NCT03575039|DEVICE|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
219505746|NCT05399810|OTHER|Computer Application (ICOGNI) Training|Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
219505747|NCT00064181|DRUG|FOLFIRI regimen|
219505748|NCT00064181|DRUG|capecitabine|
218883788|NCT04678388|DRUG|Reference drug|1 Cap., single oral administration under fasting condition
218883789|NCT04678388|DRUG|Test drug 1|1 Tab., single oral administration under fasting condition
218883790|NCT04678388|DRUG|Test drug 2|1 Tab., single oral administration under fasting condition
219201147|NCT05145881|DIETARY_SUPPLEMENT|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
219201148|NCT06727721|BIOLOGICAL|mesenchymal stem cells with OCN-19|The patient received mesenchymal stem cells with OCN-19 three times
219505749|NCT00064181|DRUG|celecoxib|
219505750|NCT00064181|DRUG|fluorouracil|
219505751|NCT00064181|DRUG|irinotecan hydrochloride|
219505752|NCT00064181|DRUG|leucovorin calcium|
219607042|NCT06150248|OTHER|No intervention|They will have their regular curriculums and normal physical activity routine.
219607043|NCT01795404|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
219607044|NCT00314704|DRUG|dopamine versus norepinephrine|
219607045|NCT01499095|DRUG|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
219505753|NCT05717881|DIETARY_SUPPLEMENT|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
219505754|NCT05717881|DIETARY_SUPPLEMENT|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
219505755|NCT05472610|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
219505756|NCT02850523|OTHER|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
219505757|NCT03306108|DEVICE|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
219505758|NCT03729765|DEVICE|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
219505759|NCT03978702|OTHER|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
219505760|NCT01087879|DRUG|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
219505761|NCT01087879|DRUG|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
219607046|NCT01499095|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
219607047|NCT02724514|OTHER|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
219607048|NCT02762929|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam), via injection.
219607049|NCT02762929|BIOLOGICAL|Saline Placebo|Saline placebo via injection.
219607050|NCT02762929|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam), via injection or instillation.
219607051|NCT02762929|DRUG|HTX-002|HTX-002, via injection.
219607052|NCT02762929|DRUG|Bupivacaine HCl|Bupivacaine HCI, via injection.
219607053|NCT02762929|DRUG|HTX-009|HTX-009, via injection.
219607054|NCT03617094|DEVICE|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
219607055|NCT03617094|DEVICE|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
219607056|NCT05021900|DRUG|Tenalisib 800mg|Tenalisib will be administered 800mg BID, orally
219607057|NCT05021900|DRUG|Tenalisib 1200mg|Tenalisib will be administered 1200mg BID, orally
219607058|NCT01873352|PROCEDURE|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
219201149|NCT06727721|BIOLOGICAL|Mesenchymal stem cells|Ordinary mesenchymal stem cells were given
218883791|NCT02191813|DRUG|Seresis®|
218883792|NCT02191813|DRUG|Placebo|
219201150|NCT06727721|BIOLOGICAL|albumin injection|Placebo
218883793|NCT04028141|DRUG|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
218883794|NCT00387036|DRUG|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
218883795|NCT00387036|DRUG|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
218883796|NCT02846441|PROCEDURE|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
218883797|NCT06439303|DRUG|Cytisine 1,5 mg|Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
218883798|NCT02969460|BEHAVIORAL|Neurotrack Virtual Cognitive Health Program|
219505762|NCT01087879|DRUG|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
219505763|NCT01271764|OTHER|no drug|The role of G9a protein in patients with endometrial cancer
219505764|NCT05001490|OTHER|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
219505765|NCT03389984|DIAGNOSTIC_TEST|cutaneous|SKIN BIOPSY
219505766|NCT00763984|BEHAVIORAL|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
218883799|NCT06258408|DRUG|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
218883800|NCT01760772|DRUG|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
218883801|NCT01760772|DRUG|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
219505767|NCT00763984|BEHAVIORAL|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
219505768|NCT06177379|OTHER|healthy volunteer|Volunteers age between 50 and 75 years
219505769|NCT00439608|DRUG|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
219505770|NCT04517006|BEHAVIORAL|Self-focused acts|Completion of daily acts for personal enjoyment.
219028495|NCT00891644|OTHER|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
219201151|NCT06880146|OTHER|Blood sample Truculture|"blood sample added to the standard blood test at visit Inclusion and Month 6. This project will use the TruCulture® Whole Blood Stimulation System to assess the Whole Blood Oxylipin Response (WBOR).~WBOR is the ability of patients to produce oxylipins in response to an immune stimulus. One tube is conditioned with LPS stimulant and a control tube is conditioned with no stimulant (Null)."
219201152|NCT06889272|OTHER|blood transfusion|Red blood cell suspension replacement during surgery
219505771|NCT04517006|BEHAVIORAL|Prosocial acts|Completion of daily acts for the benefit of others.
219505772|NCT01486706|DRUG|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
219505773|NCT01486706|DRUG|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
218883802|NCT01760772|OTHER|saline|Constant infusion
218883803|NCT03139344|OTHER|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
218883804|NCT03139344|OTHER|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
219505774|NCT01486706|DRUG|Placebo drugs|will titrate medications similar to the active drug group
219505775|NCT05896059|DRUG|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
218883805|NCT01477489|DRUG|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
219505776|NCT05896059|DRUG|Anlotinib|Anlotinib，12mg，oral administration，QD.
219505777|NCT00040859|DRUG|capecitabine|
219505778|NCT00040859|DRUG|oxaliplatin|
219505779|NCT01464359|DRUG|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
219505780|NCT01464359|DRUG|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.
218883806|NCT01477489|RADIATION|Standard radiation treatment|Limited to 60 Gy.
219505781|NCT01464359|RADIATION|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
218883807|NCT03188510|BIOLOGICAL|LY3074828|Administered SC
218883808|NCT03113981|DEVICE|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
218883809|NCT03300063|OTHER|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
219505782|NCT01464359|DRUG|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
219505783|NCT01464359|DRUG|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
219505784|NCT01464359|DRUG|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours
219028496|NCT00891644|OTHER|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
219607059|NCT01873352|PROCEDURE|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
219028497|NCT01511523|DIETARY_SUPPLEMENT|RGMA001|3 capsules administered BID once a day.
219028498|NCT01511523|DIETARY_SUPPLEMENT|Sugar Pill|Placebo
219028499|NCT01940809|DRUG|Dabrafenib|Given PO
219028500|NCT01940809|BIOLOGICAL|Ipilimumab|Given IV
219028501|NCT01940809|OTHER|Laboratory Biomarker Analysis|Correlative studies
219505785|NCT01464359|BIOLOGICAL|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
219505786|NCT01464359|BIOLOGICAL|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
219505787|NCT03453359|DEVICE|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
219505788|NCT03453359|DEVICE|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
219505789|NCT00279942|DIETARY_SUPPLEMENT|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
218883810|NCT04254094|OTHER|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
219028502|NCT01940809|BIOLOGICAL|Nivolumab|Given IV
219028503|NCT01940809|DRUG|Trametinib|Given PO
219028504|NCT01263301|DEVICE|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
219028505|NCT03265249|DEVICE|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
219028506|NCT04592029|DRUG|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
218883811|NCT04414566|DRUG|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
218883812|NCT04414566|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
219028507|NCT05339620|PROCEDURE|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
219028508|NCT00834210|DRUG|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
219028509|NCT00834210|DRUG|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
219028510|NCT01914185|OTHER|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
219028511|NCT00001053|BIOLOGICAL|HIV p17/p24:Ty-VLP|
219028512|NCT00001053|BIOLOGICAL|Aluminum hydroxide|
219028513|NCT02890979|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
219028514|NCT02890979|OTHER|Laboratory Biomarker Analysis|Correlative studies
219505790|NCT00279942|OTHER|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
219505791|NCT06417606|DRUG|Lenvatinib|Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
219505792|NCT00633152|DRUG|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
219505793|NCT00633152|DRUG|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
219505794|NCT00633152|DRUG|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
219505795|NCT02049359|OTHER|Texting|Bidirectional texting once weekly for 12 weeks
219607060|NCT05733767|OTHER|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
218883813|NCT04414566|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
219505796|NCT03273387|DRUG|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
219505797|NCT03273387|DRUG|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
219505798|NCT00195806|DRUG|divalproex sodium|
219505799|NCT01907087|BIOLOGICAL|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
219505800|NCT01556685|OTHER|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
218883814|NCT02261766|DEVICE|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
218883815|NCT01989806|DEVICE|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
218883816|NCT01989806|DEVICE|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
218883817|NCT01031173|BIOLOGICAL|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
218883818|NCT04182672|DRUG|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
219028515|NCT02890979|OTHER|Quality-of-Life Assessment|Ancillary studies
219028516|NCT02890979|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
219028517|NCT02608268|DRUG|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
219028518|NCT02608268|DRUG|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
219028519|NCT02608268|DRUG|Decitabine|commercially available chemotherapy
219505801|NCT01556685|OTHER|Blood Sample|For evaluation of interferon-related Nab
219505802|NCT01556685|GENETIC|Blood Sample|genetic evaluation - predisposition to Nab generation
219607061|NCT05733767|OTHER|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
218883819|NCT06407531|OTHER|VR-G|Patients watched videos with virtual glasses before undergoing colonoscopy
219364479|NCT01693445|DRUG|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
219364480|NCT01800721|BEHAVIORAL|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
219607062|NCT03248687|OTHER|Follow up|The intervention will be method of follow up.
219607063|NCT00402077|DRUG|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
219607064|NCT00402077|DRUG|sibutramine|oral tablet, once a day, 10mg
219607065|NCT00402077|DRUG|phentermine|oral tablet, once a day, 37.5mg
219607066|NCT00402077|DRUG|placebo|subcutaneous injection, three times a day
219607067|NCT01834625|DIAGNOSTIC_TEST|PET scan|
219607068|NCT00422825|DRUG|imatinib|
219607069|NCT03825718|BIOLOGICAL|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
219607070|NCT04159246|DEVICE|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course"
218883820|NCT02624531|DRUG|Taxane|NACT and Fertility-sparing Treatment Strategy
218883821|NCT02624531|PROCEDURE|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
218883822|NCT03150420|DRUG|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
218883823|NCT03150420|DRUG|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
218883824|NCT02975258|PROCEDURE|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
218883825|NCT02975258|OTHER|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
218883826|NCT02975258|PROCEDURE|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
218883827|NCT02975258|PROCEDURE|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
218883828|NCT02975258|RADIATION|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
218883829|NCT02975258|PROCEDURE|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
218883830|NCT02975258|PROCEDURE|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
218883831|NCT02975258|PROCEDURE|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
219364481|NCT01800721|BEHAVIORAL|SNAP Control|Behavioral: SNAP control 7 group sessions
219607071|NCT04159246|DRUG|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
219364482|NCT02512458|DRUG|Cabazitaxel|
219364483|NCT00282243|DRUG|tacrolimus modified release (MR)|Oral
219364484|NCT00282243|DRUG|tacrolimus|Oral
219364485|NCT03453892|DRUG|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
219364486|NCT03453892|DRUG|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
219364487|NCT03453892|RADIATION|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
219607072|NCT02738138|DRUG|ABT-493 coformulated with ABT-530|Tablet
219364488|NCT03453892|DRUG|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
218883832|NCT02343809|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
218883833|NCT02343809|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
219607073|NCT01088958|DIETARY_SUPPLEMENT|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
218883834|NCT02343809|OTHER|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
218883835|NCT01755728|DRUG|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
219028520|NCT06250023|OTHER|Early shift til oral antibiotic treatment for osteomyelitis|To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
219607074|NCT00012922|BEHAVIORAL|Low Literacy Intervention for Colorectal Cancer Screening|
219607075|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
219607076|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
219028521|NCT02994732|DRUG|[14C]-BVD-523|\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
219028522|NCT04428892|BEHAVIORAL|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
219607077|NCT00786214|OTHER|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
218883836|NCT01755728|DRUG|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
219028523|NCT04602637|OTHER|Training load|Monitoring training load during covid
219364489|NCT01383031|PROCEDURE|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
219028524|NCT03684512|BEHAVIORAL|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
219028525|NCT03684512|BEHAVIORAL|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
219028526|NCT03684512|BEHAVIORAL|Facebook Group|Facebook group for parents to provide additional support and education
219028527|NCT01196546|DRUG|vildagliptin/metformin|
219028528|NCT05963087|DRUG|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
219028529|NCT05627882|DIAGNOSTIC_TEST|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
219028530|NCT03163745|PROCEDURE|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
219028531|NCT02539381|PROCEDURE|Formal Perimetry (Goldman or Octopus visual Field)|
219028532|NCT02539381|PROCEDURE|Albert's visual inattention test|
219028533|NCT02539381|PROCEDURE|Star cancellation visual inattention test|
219028534|NCT02539381|PROCEDURE|Visual field assessment to confrontation|
219364490|NCT01383031|PROCEDURE|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
219364491|NCT03151889|DEVICE|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
219364492|NCT03242655|BEHAVIORAL|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
219364493|NCT01734148|BEHAVIORAL|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
218883837|NCT01755728|PROCEDURE|Closure of PDA|Open surgery for closure of PDA
218883838|NCT00005120|DRUG|Calanolide A|
218883839|NCT02564809|BEHAVIORAL|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
218883840|NCT02564809|BEHAVIORAL|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
219028535|NCT02539381|PROCEDURE|Visual inattention assessment to bilateral stimuli|
219028536|NCT02539381|DEVICE|Digital tumbling E visual accuity assessment|
219028537|NCT02539381|DEVICE|Digital visual field assessment|
219028538|NCT02539381|DEVICE|Digital line crossing assessment|
219028539|NCT02539381|DEVICE|Digital shape cancellation assessment|
219028540|NCT01441674|BEHAVIORAL|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
219028541|NCT05301088|OTHER|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
219028542|NCT06055855|PROCEDURE|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
219028543|NCT06055855|PROCEDURE|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
219028544|NCT03873987|DRUG|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
219505803|NCT05124756|DEVICE|Bioelectric stimulation|The sessions will include 20 minutes for stimulation of the thigh muscles and 45 minutes for stimulation of the kidneys. The electrodes will be placed on the motor point of the quadriceps muscle in both lower limbs. The neuromuscular electric stimulation will be applied by symmetrical biphasic pulsed current, at an 80 Hz frequency, 400 ms pulse width, 10 s contraction time, rest time decreasing as the protocol advanced, at reciprocal mode. The intensity will be individually adjusted to produce visible muscle contraction. Concomitant, two electrodes will be placed in the abdominal corresponding to the kidney anatomical site and two electrodes on the dorsal region at the level of the 10th thoracic vertebra. The stimulation of the kidneys will include in addition to Klotho, precise signals for several pro-regenerative proteins. The intensity of the electric current will be individually adjusted to sensory stimulation.
219505804|NCT01317732|DEVICE|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
219505805|NCT04843085|OTHER|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
219505806|NCT02345278|DRUG|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
219505807|NCT02345278|OTHER|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
219505808|NCT05489185|DRUG|Tranexamic acid|Intravenous or topical administration
219505809|NCT05489185|OTHER|Physiologic saline|Placebo
219505810|NCT04705909|DRUG|Pitavastatin|Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
219607078|NCT00786214|OTHER|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
219607079|NCT03757858|DEVICE|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
218883841|NCT02564809|BEHAVIORAL|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
219028545|NCT03873987|DRUG|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
219028546|NCT03559712|OTHER|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
219028547|NCT04369794|BIOLOGICAL|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
218883842|NCT03025243|DEVICE|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
219505811|NCT04705909|DRUG|placebo|patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
219505812|NCT03273985|OTHER|Dry needling|Trigger point deep dry needling
219505813|NCT03273985|OTHER|Ischemic compression|Trigger point ischemic compression
219505814|NCT05216978|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
219505815|NCT02180061|BIOLOGICAL|Pembrolizumab|IV infusion
218883843|NCT03052049|DEVICE|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
218883844|NCT03361982|OTHER|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
218883845|NCT02913716|DRUG|defactinib|Single oral dose of 400 mg \[14C\]-defactinib
218883846|NCT01366729|DEVICE|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
219028548|NCT04369794|BIOLOGICAL|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
219028549|NCT01442415|BEHAVIORAL|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
219028550|NCT05739851|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
219028551|NCT05739851|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
219028552|NCT05646511|RADIATION|SCRT|5x5 Gy: 25 Gy
219505816|NCT03232528|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
219505817|NCT03232528|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
218883847|NCT01366729|DEVICE|Cane walking|All walking activities must take place with cane from waking until sleeping
218883848|NCT01418742|DRUG|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
219028553|NCT05646511|DRUG|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
219505818|NCT00840983|PROCEDURE|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
218883849|NCT01418742|DRUG|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
219028554|NCT05646511|DRUG|CAPOXIRI|Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks
219028555|NCT00930150|BEHAVIORAL|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
219028556|NCT00930150|BEHAVIORAL|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
219028557|NCT00930150|BEHAVIORAL|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
219028558|NCT00930150|BEHAVIORAL|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
219028559|NCT02804984|GENETIC|ICUS|
219040312|NCT02355327|BEHAVIORAL|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
219505819|NCT01877928|DEVICE|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
218883850|NCT05271760|PROCEDURE|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
219505820|NCT01877928|DEVICE|standard CPAP|Standard of care postoperative treatment for OSA.
219505821|NCT04108377|DRUG|Roflumilast|Roflumilast capsule
219505822|NCT04108377|DRUG|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
219505823|NCT00217854|PROCEDURE|Bronchoscopic|Bronchoscopic procedure
219505824|NCT00437151|OTHER|More frequent than normal office visits|Mode of patient reminder
219505825|NCT00437151|OTHER|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
219505826|NCT00437151|OTHER|Parenteral involvement / intervention reminders|Mode of patient reminder
219505827|NCT00437151|OTHER|No intervention or reminders|Mode of patient reminder
218883851|NCT05271760|PROCEDURE|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
219505828|NCT00594633|OTHER|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
218883852|NCT05271760|PROCEDURE|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
218883853|NCT00999518|BIOLOGICAL|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
218883854|NCT00999518|BIOLOGICAL|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
218883855|NCT00999518|BIOLOGICAL|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
218883856|NCT00999518|BIOLOGICAL|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
218883857|NCT00999518|OTHER|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
218883858|NCT00003569|DRUG|cisplatin|
219028560|NCT05686213|BEHAVIORAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
219040313|NCT02986620|GENETIC|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
219040314|NCT05452395|OTHER|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
219364494|NCT05381506|DRUG|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
218883859|NCT00003569|DRUG|dimesna|
218883860|NCT00003569|DRUG|paclitaxel|
219040315|NCT01371097|OTHER|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
219364495|NCT01070329|DRUG|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
219364496|NCT01070329|DRUG|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
219364497|NCT00492219|DEVICE|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
218883861|NCT02146391|DRUG|Androxal 25 mg Capsules|
218883862|NCT01189591|DEVICE|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
218883863|NCT00122369|BEHAVIORAL|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
218883864|NCT00122369|BEHAVIORAL|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
218883865|NCT00496639|PROCEDURE|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
218883866|NCT00496639|PROCEDURE|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
219040316|NCT01399593|DRUG|Eculizumab|
219040317|NCT02214277|DEVICE|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
219040318|NCT02214277|DEVICE|TAVR|
219040319|NCT03420703|OTHER|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
219364498|NCT00492219|DEVICE|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
219364499|NCT02758964|OTHER|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
219364500|NCT01504932|DIETARY_SUPPLEMENT|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
219364501|NCT01504932|OTHER|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
219364502|NCT01504932|OTHER|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
219364503|NCT01504932|OTHER|pharmacological study|Correlative studies
218883867|NCT01918059|PROCEDURE|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
218883868|NCT01918059|PROCEDURE|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
218883869|NCT01918059|PROCEDURE|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
218883870|NCT05003596|DRUG|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
218883871|NCT05003596|OTHER|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
218883872|NCT02055300|DRUG|LY03005|
218883873|NCT02055300|DRUG|Placebo|
218883874|NCT02055300|OTHER|Meal|
218883875|NCT02055300|DRUG|Pristiq|
218883876|NCT01679886|RADIATION|Rubidium PET|Rubidium PET
218883877|NCT05905731|BIOLOGICAL|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
218883878|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
218883879|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
218883880|NCT03617146|BEHAVIORAL|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
218883881|NCT03617146|OTHER|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
219028561|NCT05686213|BEHAVIORAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
219028562|NCT00175721|PROCEDURE|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
219028563|NCT04475133|OTHER|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
219028564|NCT02164227|OTHER|Respiratory pattern|
219028565|NCT03232385|DEVICE|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
219028566|NCT03232385|PROCEDURE|Renal Biopsy or Ablation|Standard of Care
219028567|NCT03468907|DRUG|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
219505829|NCT04511351|DRUG|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
219505830|NCT01129154|DRUG|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
219028568|NCT03468907|DRUG|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
219028569|NCT04357210|PROCEDURE|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
219028570|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
219505831|NCT03093545|BIOLOGICAL|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
219607080|NCT03757858|BIOLOGICAL|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
218883882|NCT00544427|DEVICE|Optical coherence tomography|Optical coherence tomography imaging
218883883|NCT00332228|DRUG|depot naltrexone|long-acting depot parenteral formulation of naltrexone
218883884|NCT00332228|BEHAVIORAL|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
218883885|NCT00332228|DRUG|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
218883886|NCT04891484|DRUG|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
219028571|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
219028572|NCT02292290|DRUG|Sulfonylurea or Pioglitazone|Addition to Metformin
219028573|NCT02292290|DRUG|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
219028574|NCT02998801|OTHER|IPAD|Patients undergoing surgery will watch the video using an PAD
219028575|NCT02998801|OTHER|VR Goggles|Patients undergoing surgery will watch the video using goggles
219028576|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
219028577|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
219028578|NCT00017433|DRUG|arsenic trioxide|
219607081|NCT03757858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
218883887|NCT04891484|DRUG|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
218883888|NCT03186417|BIOLOGICAL|2 million hMSC/kg|2 million hMSCs/kg infusion
218883889|NCT03186417|BIOLOGICAL|4 million hMSC/kg|4 million hMSC/kg infusion
218883890|NCT03186417|BIOLOGICAL|6 million hMSC/kg|6 million hMSC/kg infusion
218883891|NCT03186417|BIOLOGICAL|placebo|placebo infusion
218883892|NCT02825199|DIETARY_SUPPLEMENT|Caffeine|capsule: 300mg caffeine
218883893|NCT02825199|DIETARY_SUPPLEMENT|Non caffeine|capsule: placebo (maize starch)
219028579|NCT04014075|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
219028580|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
219028581|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
219028582|NCT05954052|DRUG|Glutathione|Giving supplement orally
218883894|NCT01088399|DRUG|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
219028583|NCT01957462|DEVICE|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
218883895|NCT02861599|OTHER|proprioceptive therapy|
218883896|NCT02861599|OTHER|speech therapy|
219028584|NCT01957462|DEVICE|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
219028585|NCT02541071|BEHAVIORAL|Stress Film|
218883897|NCT04832880|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.
218883898|NCT04832880|DRUG|Remdesivir|Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
218883899|NCT04832880|DRUG|Dexamethasone|Intravenous dexamethasone 6 mg for 10 days
219607082|NCT03757858|DRUG|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
219607083|NCT01995513|DRUG|Enzalutamide|160 mg by mouth once daily
219607084|NCT01995513|DRUG|Abiraterone|1000 mg by mouth once daily
219607085|NCT01995513|DRUG|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
219607086|NCT01995513|DRUG|Prednisone|5 mg by mouth twice daily
218883900|NCT06141265|DRUG|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
218883901|NCT06333366|DEVICE|Intra-gastrointestinal monitoring device (PDT)|The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
218883902|NCT03752749|OTHER|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
218883903|NCT03752749|OTHER|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
218883904|NCT03120715|DRUG|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
219028586|NCT02541071|DRUG|Yohimbine|
219028587|NCT02541071|DRUG|Clonidine|
219028588|NCT02541071|DRUG|placebo|
219028589|NCT03528746|OTHER|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
218883905|NCT03120715|DRUG|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
219028590|NCT03528746|OTHER|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
219505832|NCT03093545|BIOLOGICAL|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
219505833|NCT03392597|BEHAVIORAL|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
219505834|NCT03392597|BEHAVIORAL|Programming-as-Usual|Usual afterschool programming.
219505835|NCT02557945|DRUG|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
219505836|NCT02557945|DRUG|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
219505837|NCT06262698|BEHAVIORAL|Experiment group|The experimental group will receive six weeks of HBM-based training.
219505838|NCT06262698|OTHER|Pre-post test|The TCM Attitude Scale (CACMAS), Medication Health Belief Scale
219505839|NCT02429869|DRUG|everolimus|
219505840|NCT03238768|OTHER|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
219505841|NCT03238768|OTHER|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
219607087|NCT05452018|OTHER|Intervention group|In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
219607088|NCT00960219|DRUG|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
219607089|NCT00960219|DRUG|placebo|1# BID, oral, for 6 weeks
219607090|NCT05460702|DIAGNOSTIC_TEST|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
218883906|NCT03120715|DRUG|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
218883907|NCT03120715|DRUG|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
218883908|NCT00782483|DEVICE|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
218883909|NCT00782483|DEVICE|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
218883910|NCT00782483|DEVICE|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
218883911|NCT00774683|DRUG|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
218883912|NCT05313737|OTHER|Automated message|Automated message via phone call (audiocare)
218883913|NCT05313737|OTHER|Opt-out scheduling|Scheduling via non-automated phone call
218883914|NCT00349778|DRUG|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
218883915|NCT00349778|DRUG|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
219028591|NCT04090593|OTHER|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
219028592|NCT04377282|OTHER|Food-1|Cooked buckwheat
219028593|NCT04377282|OTHER|Food-2|Cooked couscous
219028594|NCT04377282|OTHER|Food-3|Water
219505842|NCT00658320|DRUG|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
219505843|NCT00658320|DRUG|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
219505844|NCT00658320|DRUG|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
219505845|NCT00658320|DRUG|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
219505846|NCT00658320|DRUG|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
219505847|NCT02831062|OTHER|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
219505848|NCT04093180|PROCEDURE|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
219505849|NCT04093180|PROCEDURE|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
219607091|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
219607092|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
219607093|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
219607094|NCT05177679|DIETARY_SUPPLEMENT|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
219607095|NCT05177679|DIETARY_SUPPLEMENT|Placebo control|Placebo control supplement
219505850|NCT06405776|DRUG|lidocaine|Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
219505851|NCT06405776|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
219505852|NCT02956720|DEVICE|UltraShape Power|non-invasive body contouring procedure
219505853|NCT00131989|DRUG|sorafenib tosylate|Given orally
219505854|NCT00131989|OTHER|pharmacological study|Correlative studies
219505855|NCT00131989|OTHER|laboratory biomarker analysis|Correlative studies
219505856|NCT01923246|BEHAVIORAL|Single WEB intervention|Brief WEB intervention recieved once
219505857|NCT01923246|BEHAVIORAL|Repeated WEB intervention|WEB intervention recieved twice.
219505858|NCT01923246|BEHAVIORAL|Single IVR intervention|IVR intervention recieved once
219505859|NCT01923246|BEHAVIORAL|Repeated IVR intervention|IVR intervention recieved twice
219505860|NCT06462157|OTHER|Compassionate Mind Training|Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
219505861|NCT05868057|DRUG|SHR7280 tablets|SHR7280 tablets 1 time
219505862|NCT05868057|DRUG|SHR7280 dry suspension|SHR7280 dry suspension 1 time
218883916|NCT00349778|DRUG|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
218883917|NCT00349778|DRUG|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
218883918|NCT00349778|DRUG|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
219028595|NCT02584504|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
219505863|NCT00652873|DRUG|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
219505864|NCT00652873|DRUG|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
219505865|NCT00093639|DRUG|everolimus|
219505866|NCT00093639|DRUG|imatinib mesylate|
219505867|NCT02727140|BEHAVIORAL|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
218883919|NCT06071481|DRUG|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
218883920|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
218883921|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
218883922|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
218883923|NCT00005030|DRUG|SCH 66336|
219028596|NCT02584504|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
219028597|NCT02584504|DRUG|Atorvastatin|Atorvastatin 5 mg tablet orally.
219028598|NCT02584504|DRUG|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
219028599|NCT02584504|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
219505868|NCT02727140|BEHAVIORAL|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
219505869|NCT03712969|DRUG|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
219028600|NCT04659746|DEVICE|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
219505870|NCT00003235|DRUG|carboplatin|
219505871|NCT00003235|DRUG|paclitaxel|
219505872|NCT00003235|RADIATION|radiation therapy|
219505873|NCT04361019|OTHER|On-Line Survey|A survey has been sent by email to the students of the participating universities
219505874|NCT00736619|OTHER|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
219505875|NCT01169090|DRUG|SK-0403|SK-0403
219505876|NCT01169090|DRUG|Placebo|Placebo
219505877|NCT01169090|DRUG|Sitagliptin|Sitagliptin
219505878|NCT02210884|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
219505879|NCT02577081|OTHER|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
219505880|NCT06045481|DRUG|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
219505881|NCT02229006|RADIATION|18F-NaF PET-CT|
219505882|NCT01429402|DRUG|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
219505883|NCT01429402|DRUG|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
218883924|NCT00005030|PROCEDURE|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
218883925|NCT03438136|BEHAVIORAL|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
218883926|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
218883927|NCT04594928|DRUG|Placebo|Matching placebo capsules
218883928|NCT04534270|DRUG|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
219028601|NCT03810066|DRUG|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
219028602|NCT03102918|DRUG|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
219505884|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
219505885|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
219505886|NCT06543602|DIAGNOSTIC_TEST|multi-model monitoring and alert|All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
219607096|NCT04534452|DRUG|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
219028603|NCT03102918|DRUG|Placebo|Participants will receive placebo over a 6-week treatment period.
219028604|NCT01716013|DEVICE|BondEase|topical skin adhesive
219028605|NCT01716013|PROCEDURE|CWCD|traditional closure methods of sutures, staples or adhesive strips
219028606|NCT02506335|DRUG|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
219028607|NCT01138280|DEVICE|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
219028608|NCT01268384|DRUG|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
219505887|NCT01371513|OTHER|continuous screening|practice patterns for screening prostate cancer
219505888|NCT05585359|OTHER|injectable platelet rich fibrin augmented with Vitamin C|According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
219607097|NCT00575237|PROCEDURE|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (\> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
219607098|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
219607099|NCT01037452|DRUG|Lansoprazole|Tablet
219607100|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide|Tablet
219607101|NCT01037452|DRUG|Placebo|Tablet
219607102|NCT05423132|DRUG|Ropivacaine injection|The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
218883929|NCT01893775|BIOLOGICAL|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
218883930|NCT00595010|BEHAVIORAL|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
219505889|NCT01373606|DRUG|Terlipressin|
219505890|NCT02960815|BIOLOGICAL|Intanza|
219505891|NCT02960815|BIOLOGICAL|Mutagrip|
219607103|NCT05423132|DRUG|Physiological serum injection|The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
219607104|NCT06582537|PROCEDURE|Participants sample collection|A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
218883931|NCT02650102|DRUG|Risperidone|a kind of antipsychotics
219028609|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
219028610|NCT05850650|OTHER|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
219028611|NCT05850650|OTHER|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
219028612|NCT02627612|BEHAVIORAL|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
219040320|NCT03420703|DEVICE|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
219040321|NCT04915404|DRUG|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
219040322|NCT05111366|DRUG|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
219040323|NCT05111366|DRUG|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
218883932|NCT02650102|DRUG|Olanzapine|a kind of antipsychotics
218883933|NCT02650102|DRUG|Quetiapine|a kind of antipsychotics
218883934|NCT02650102|DRUG|Aripiprazole|a kind of antipsychotics
219028613|NCT02627612|BEHAVIORAL|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
219028614|NCT03839589|BEHAVIORAL|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
219028615|NCT03430583|DRUG|Udenafil|Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.
219028616|NCT03762655|DEVICE|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
219028617|NCT03595410|OTHER|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
219028618|NCT05947851|DRUG|Nemtabrutinib|5 and 20 mg tablets
219028619|NCT05947851|DRUG|Venetoclax|10, 50, and 100 mg tablets
219028620|NCT05947851|BIOLOGICAL|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
219028621|NCT01217970|DRUG|Ibudilast 20mg|Ibudilast 20mg BID
219028622|NCT01217970|DRUG|Ibudilast 50mg|Ibudilast 50mg BID
219028623|NCT01217970|DRUG|Placebo oral tablet|
219028624|NCT03144492|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
219028625|NCT05629338|COMBINATION_PRODUCT|Autologous Spray Dried Plasma|Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
219028626|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
219028627|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
219028628|NCT05268289|DRUG|Iptacopan (part 1)|Taken for 52 Weeks
219028629|NCT05268289|DRUG|Iptacopan (part 2)|Taken for 52 Weeks
219028630|NCT05268289|DRUG|Placebo + standard of care|Taken for 52 Weeks
219028631|NCT05268289|DRUG|Iptacopan + placebo|Taken for 52 Weeks
219028632|NCT01686841|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219028633|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
219028634|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
219028635|NCT04970901|DRUG|Glofitamab|IV infusion
219028636|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
219028637|NCT04970901|DRUG|Obinutuzumab|IV infusion
219505892|NCT02960815|DRUG|Aldara|
218883935|NCT02650102|DRUG|Ziprasidone|a kind of antipsychotics
218883936|NCT00284362|PROCEDURE|Arthroscopic or open surgery for hallux rigidus|
218883937|NCT02036866|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
218883938|NCT02036866|OTHER|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
219028638|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
219028639|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
219028640|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
219028641|NCT06289101|BEHAVIORAL|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
219028642|NCT03446040|BIOLOGICAL|BMS-986258|Specified dose on specified days
218883939|NCT02036866|OTHER|No Intervention|Patients will be instructed to maintain their usual activity level.
218883940|NCT02419820|DRUG|APD791|Temanogrel
218883941|NCT02419820|DRUG|Clopidogrel|Clopidogrel
218883942|NCT02419820|DRUG|Aspirin|Aspirin
218883943|NCT02419820|DRUG|Placebo for APD791|Placebo for APD791
218883944|NCT04932642|BEHAVIORAL|HIIT+RT experimental group|Each experimental group will be compared with their another contrast order session group
218883945|NCT04932642|BEHAVIORAL|RT+HIIT experimental group|Each experimental group will be compared with their another contrast order session group
218883946|NCT03536507|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219028643|NCT03446040|BIOLOGICAL|Nivolumab|Specified dose on specified days
219028644|NCT03446040|DRUG|rHuPH20|Specified dose on specified days
219028645|NCT03548792|RADIATION|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
219505893|NCT05849428|DEVICE|Freestyle Libre 3|Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
219505894|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
219505895|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
218883947|NCT03536507|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
218883948|NCT04937283|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
218883949|NCT04937283|PROCEDURE|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
219028646|NCT03548792|BEHAVIORAL|Clinical comparison|ActivePAL, walking speed
219505896|NCT04528095|DRUG|Clozapine|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
219505897|NCT04528095|DEVICE|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
219505898|NCT04528095|DEVICE|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
219505899|NCT02011594|DRUG|Nimotuzumab|400mg Q2W intravenously
219505900|NCT02011594|DRUG|Placebo|Normal saline
218883950|NCT04833595|BEHAVIORAL|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
218883951|NCT03044808|DRUG|Lidocaine|
219505901|NCT01583387|OTHER|1-Increased water intake regimen|Arm 1-Intervention
219505902|NCT01583387|OTHER|2-Non-modified water intake regimen|Arm 2-Control
219505903|NCT04316858|DRUG|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
219505904|NCT04316858|DIETARY_SUPPLEMENT|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
219505905|NCT04316858|DIETARY_SUPPLEMENT|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
219505906|NCT00225082|DRUG|Nucleoside analogue switch|stavudine switched to tenofovir
218883952|NCT03044808|DRUG|Saline|
218883953|NCT03156374|DEVICE|Test use|Use of home ovulation test to predict ovulation
218883954|NCT06094400|OTHER|Meditation|Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.
218883955|NCT06094400|OTHER|Control|Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
219028647|NCT05961735|OTHER|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
219028648|NCT05961735|OTHER|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
219028649|NCT01820481|DRUG|WIN-901X dose level 1|100mg Bid, PO, 12weeks
219028650|NCT01820481|DRUG|WIN-901X dose level 2|200mg Bid, PO, 12weeks
219028651|NCT01820481|DRUG|WIN-901X dose level 3|300mg Bid, PO, 12weeks
219028652|NCT01820481|DRUG|Placebo|Bid, PO, 12weeks
219028653|NCT02066467|DEVICE|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
219028654|NCT04919356|GENETIC|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
218883956|NCT05084898|OTHER|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
218883957|NCT05084898|OTHER|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
219505907|NCT05661929|OTHER|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
218883958|NCT01900808|DEVICE|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
218883959|NCT01900808|DEVICE|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
218883960|NCT01900808|DEVICE|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
218883961|NCT02653547|OTHER|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
218883962|NCT02653547|OTHER|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
218883963|NCT02653547|OTHER|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
219505908|NCT03779191|DRUG|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
218883964|NCT02653547|OTHER|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
218883965|NCT01704404|DRUG|TD-4208|
218883966|NCT01704404|DRUG|Placebo|
218883967|NCT04254666|BEHAVIORAL|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
218883968|NCT01695434|OTHER|MRI|All subjects will undergo a MRI.
218883969|NCT00025558|BIOLOGICAL|filgrastim|
218883970|NCT00025558|DRUG|carboplatin|
218883971|NCT00025558|DRUG|temozolomide|
218883972|NCT00025558|DRUG|thiotepa|
218883973|NCT00025558|PROCEDURE|autologous bone marrow transplantation|
218883974|NCT00025558|PROCEDURE|peripheral blood stem cell transplantation|
218883975|NCT00114855|DRUG|HYPOCOL®|
218883976|NCT01921504|DEVICE|Acupuncture|"Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
218883977|NCT05968768|DRUG|Naxitamab|Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
218883978|NCT02475278|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
218883979|NCT01199224|DRUG|veliparib|veliparib formulation A
218883980|NCT01199224|DRUG|veliparib|veliparib formulation B
218883981|NCT01199224|DRUG|veliparib|veliparib formulation C
218883982|NCT01199224|DRUG|veliparib|veliparib formulation C
218883983|NCT03069157|PROCEDURE|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
218883984|NCT00557999|OTHER|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
219040324|NCT00684853|DRUG|bevacizumab|1.25 mg of bevacizumab intravitreal
219505909|NCT03779191|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
219505910|NCT06021548|OTHER|Blood sample|Finger stick blood spots will be collected at V0 and M12
219505911|NCT06021548|OTHER|Saliva sample|Saliva sample will be collected at V0
219505912|NCT06021548|OTHER|Hair sample|Hair sample will be collected at V0 (optional)
218883985|NCT04744922|DIETARY_SUPPLEMENT|Extracts of citrus peels standardized in AUR and NAR (phytocomplex).|One capsule a day for 9 months
218883986|NCT03940729|DRUG|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
219607105|NCT04108299|BEHAVIORAL|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
218883987|NCT00797849|DEVICE|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
218883988|NCT00797849|DEVICE|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
218883989|NCT04449627|OTHER|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
218883990|NCT01937260|DRUG|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
219028655|NCT06175273|DIETARY_SUPPLEMENT|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
219028656|NCT06175273|DIETARY_SUPPLEMENT|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
219028657|NCT06175273|DRUG|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
219028658|NCT06175273|DRUG|Olanzapine|2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
219505913|NCT00557882|DEVICE|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
219505914|NCT05539573|DEVICE|Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.|"The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure."
219505915|NCT04834557|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219607106|NCT04108299|BEHAVIORAL|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
219607107|NCT00247676|DRUG|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
219607108|NCT04123405|DRUG|acetylcysteine|600 mg tablet
219028659|NCT06175273|OTHER|Standard of Care|Diet education on high protein, high calorie food consumption
219028660|NCT01482793|PROCEDURE|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
219505916|NCT04834557|DRUG|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219607109|NCT04123405|DRUG|Placebo|Placebo to acetylcysteine
219607110|NCT06366763|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
219607111|NCT06582290|DIAGNOSTIC_TEST|Oxford Virtual Autism Assessment Tool (OVAAT)|The OVAAT is an online ASD diagnostic tool that has been designed to identify both the external/observable features of autism but also the internal/experiential features of autism.
219607112|NCT06278896|DRUG|Cessation of antibiotics|Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
218883991|NCT03688074|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218883992|NCT03688074|OTHER|Placebo|Placebo subcutaneous injection
218883993|NCT03306719|BIOLOGICAL|Blood sampling|Serial blood sampling
218883994|NCT03154996|DRUG|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
218883995|NCT03154996|DRUG|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
218883996|NCT03154996|DEVICE|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
218883997|NCT03982680|DRUG|Toripalimab|3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total
218883998|NCT03982680|DRUG|Gemcitabine|1250mg/m2 on d1 and d15 q4W\*4cycles
218883999|NCT03982680|DRUG|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
219028661|NCT02617823|PROCEDURE|lateral position|patients placed on their left side after epidural catheter insertion
219040325|NCT00684853|DRUG|vetaporfin|full fluence of vetaporfin
218884000|NCT02544919|DRUG|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
218884001|NCT05164627|DRUG|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
218884002|NCT05164627|DRUG|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
219505917|NCT04834557|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
218884003|NCT05164627|DRUG|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
218884004|NCT05580939|OTHER|Intervention group|They use Web-based Simulation Application for 4 weeks
219505918|NCT04894422|OTHER|Observational intervention|Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
219505919|NCT00969839|DEVICE|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
219505920|NCT00820235|DEVICE|OsseoSpeed™|OsseoSpeed™ implant
219505921|NCT00820235|DEVICE|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
219505922|NCT00820235|DEVICE|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
219505923|NCT02491788|DRUG|Suvorexant|
219505924|NCT02491788|DRUG|Placebo|
219028662|NCT02195076|OTHER|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
219028663|NCT01316276|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
219505925|NCT04537676|OTHER|No intervention, this is an observational study|No intervention
219505926|NCT03140592|PROCEDURE|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
219505927|NCT03065127|BEHAVIORAL|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
219505928|NCT03065127|BEHAVIORAL|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
218884005|NCT02775448|DRUG|Carduus marianus 6cH|
219028664|NCT04820972|DRUG|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
219028665|NCT02817165|DIETARY_SUPPLEMENT|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
219028666|NCT02817165|OTHER|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
218884006|NCT02775448|DRUG|Carduus marianus 12cH|
218884007|NCT02775448|DRUG|Carduus marianus 30cH|
218884008|NCT02775448|DRUG|Placebo|
218884009|NCT02775448|BEHAVIORAL|Exercise|aerobic exercise, 30 minutes, daily
218884010|NCT02775448|OTHER|Diet|1600 calories
219028667|NCT06414967|OTHER|Music Intervention|Music therapy carried out with Music Care
219040326|NCT02152410|DEVICE|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
219040327|NCT02152410|DRUG|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
219040328|NCT06125821|OTHER|questionnaire|questionnaire
219040329|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219040330|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219040331|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219040332|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
218884011|NCT02580461|BEHAVIORAL|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
219505929|NCT03065127|BEHAVIORAL|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
219505930|NCT00389506|BIOLOGICAL|LMB-2 immunotoxin|
219505931|NCT00389506|DRUG|cyclophosphamide|
219505932|NCT00389506|DRUG|fludarabine phosphate|
219505933|NCT00389506|OTHER|pharmacological study|
219505934|NCT04272359|DRUG|Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas|"Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety."
219505935|NCT01464827|DRUG|ABT-450|ABT-450 tablets
219505936|NCT01464827|DRUG|ABT-333|ABT-333 tablets
219505937|NCT01464827|DRUG|ABT-267|ABT-267 tablets
219505938|NCT01464827|DRUG|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
219505939|NCT01464827|DRUG|Ritonavir|Ritonavir capsules
219505940|NCT05721144|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
219505941|NCT03175237|OTHER|Mirror Therapy|
219505942|NCT00000275|DRUG|Flupenthixol|
219505943|NCT01945632|DEVICE|conventional gracey curettes|
219505944|NCT01945632|DEVICE|Vertically oscillating ultrasonic device|
219505945|NCT01945632|DEVICE|piezoelectric ultrasonic scraper|
219505946|NCT05487456|OTHER|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
219505947|NCT05487456|OTHER|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
219505948|NCT05487456|OTHER|CIG|Ad libitum use of subject's own preferred brand of cigarettes
219505949|NCT05487456|OTHER|Smoking Abstinence|Abstention from cigarette smoking
219505950|NCT00688285|OTHER|automated clinical alerts|automated clinical alerts in the electronic medical record
219505951|NCT00688285|OTHER|provider education|PCP education session on CKD
219505952|NCT00981253|BEHAVIORAL|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
219505953|NCT00981253|BEHAVIORAL|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
219505954|NCT03882047|DRUG|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
219505955|NCT03882047|DRUG|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
219505956|NCT03882047|DRUG|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
219505957|NCT03882047|DRUG|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
219505958|NCT00218309|DRUG|Hydromorphone|
219505959|NCT04690777|PROCEDURE|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
219505960|NCT04690777|PROCEDURE|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
219505961|NCT04206852|PROCEDURE|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
219505962|NCT05113225|PROCEDURE|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
219505963|NCT02152020|BEHAVIORAL|Survey|
219505964|NCT04109911|DIETARY_SUPPLEMENT|Fermented oyster extract|Fermented oyster extract 1,200 mg/day for 12 weeks
219505965|NCT04109911|DIETARY_SUPPLEMENT|Placebo|Placebo
219505966|NCT06484023|OTHER|Survey|quality of life questionnaire
219505967|NCT04931420|DRUG|Standard of Care Chemotherapy|"* If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
219505968|NCT04931420|PROCEDURE|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
219505969|NCT04931420|PROCEDURE|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
219505970|NCT04931420|RADIATION|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
218884012|NCT01128244|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will receive vitamin B6 supplementation.
218884013|NCT01128244|PROCEDURE|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
218884014|NCT05260827|OTHER|Heated tobacco product|Sham heated tobacco product
218884015|NCT04693286|BIOLOGICAL|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
218884016|NCT04693286|OTHER|Placebo|Placebo contains no active ingradients, only sucrose in buffer
218884017|NCT05217394|OTHER|OTHIG|Occupational Therapy Handwriting Intervention Guideline
218884018|NCT00031759|DRUG|imiquimod|
219505971|NCT04931420|RADIATION|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
219505972|NCT04931420|PROCEDURE|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
219505973|NCT04931420|PROCEDURE|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
219505974|NCT04931420|OTHER|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
219505975|NCT04480203|OTHER|Stressproffen cognitive based stress management|The participants will download an app (Stressproffen 2A) with cognitive based stress management.
219505976|NCT04480203|OTHER|Stressproffen mindfulness based intervention|The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
218884019|NCT00031759|PROCEDURE|Ablative or excisional therapy|
218884020|NCT02774369|BEHAVIORAL|Physical exercise|Individualized aerobic intervention program
218884021|NCT02774369|BEHAVIORAL|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
218884022|NCT00101985|DRUG|talnetant|
219028668|NCT03506750|DRUG|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
219028669|NCT03506750|PROCEDURE|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
219028670|NCT03506750|PROCEDURE|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
218884023|NCT00334243|DRUG|Microflare protocol for IVF|
218884024|NCT00334243|DRUG|Antagonist protocol for IVF|
218884025|NCT00334243|DRUG|Demi-halt protocol for IVF|
218884026|NCT02219334|DEVICE|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
218884027|NCT06109064|BIOLOGICAL|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
218884028|NCT06109064|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
218884029|NCT06109064|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
218884030|NCT06109064|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
218884031|NCT04003740|DEVICE|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
218884032|NCT02891395|DRUG|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
218884033|NCT04293185|GENETIC|bb1111|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
218884034|NCT01108913|DRUG|Bimosiamose|
218884035|NCT01108913|DRUG|Placebo|
219028671|NCT03506750|PROCEDURE|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
218884036|NCT05182697|DRUG|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
219201153|NCT06731647|PROCEDURE|pleurodesis procedures|All pleurodesis procedures will be conducted with a general anesthesia. The choice of hypnotic, analgesic and neuromuscular drugs will be at the discretion of the physician. Selective orotracheal intubation will be done for all patients with a double lumen tube or a blocker according to centers habits. Regional anesthesia (serratus block, paravertebral block and erector spinae block) will be allowed and chosen at the discretion of the physician. Multimodal pain management will be allowed with the use dexamethasone, ketamine and antinociceptive drugs (nefopam, tramadol, paracetamol at the discretion of the physician. After the surgical procedure, the pleural production of liquid or air will be monitored with a chest tube connected to pleural drainage device according to centers habits. Pain will be monitored with during the hospital stay every 12 h using the pain rate scale graded from 0 to 10. Neuropathic pain will be screened at 48h, 1 months, 6 months and 1 year after the inclusion
219201154|NCT06731647|DRUG|KETOPROFEN(RP19583)|one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)
219201155|NCT06731647|DRUG|Placebo|placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
219201156|NCT06730373|DRUG|Disitamab Vedotin|2.5 mg/kg IV every 3 weeks
219201157|NCT06730373|DRUG|Sintilimab|200 mg IV every 3 weeks
219201158|NCT06730373|DRUG|S-1|40-60 mg BID for 14 days, every 3 weeks
219201159|NCT06730373|DRUG|Trastuzumab|First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
219505977|NCT04480203|OTHER|Control|The participants will receive no app. (They will be able to download it after the end of the 3 year study).
219505978|NCT00881270|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
219505979|NCT00441584|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
219505980|NCT00441584|DRUG|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
219505981|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
218884037|NCT05182697|DRUG|Oral CBD oil|CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
218884038|NCT03886714|DIAGNOSTIC_TEST|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
218884039|NCT03886714|DIAGNOSTIC_TEST|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
218884040|NCT05873842|DEVICE|Trans-femoral TAVI|Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
218884041|NCT02397200|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
218884042|NCT02397200|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
218884043|NCT02380443|BIOLOGICAL|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
218884044|NCT02380443|PROCEDURE|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
218884045|NCT06501703|OTHER|Instruments|instruments used as different techniques in final irrigation after root canal preparation
218884046|NCT06166667|PROCEDURE|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
218884047|NCT06292130|BEHAVIORAL|refresh|A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
218884048|NCT05811169|GENETIC|Next generation sequencing|Next generation sequencing
218884049|NCT04166916|OTHER|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
219505982|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
219505983|NCT00678067|DIETARY_SUPPLEMENT|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
218884050|NCT04166916|OTHER|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
218884051|NCT06374706|BEHAVIORAL|Morning Walk training for stroke|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.
219201160|NCT06730373|DRUG|Oxaliplatin|130 mg/m2 Q3W
219201161|NCT06730373|DRUG|Capecitabine|1000 mg/m² Q3W
219201162|NCT06730373|DRUG|5-FU|800 mg/m²
219201163|NCT06730373|DRUG|Cisplatin|80 mg/m²
219201164|NCT06872606|DRUG|Pucotenlimab|Pucotenlimab (200 mg IV, q3w)
219505984|NCT00678067|OTHER|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
218884052|NCT06374706|BEHAVIORAL|Morning Walk training for healthy|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
219201165|NCT06872606|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg IV, q3w)
219201166|NCT06872606|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m² IV, q3w)
219505985|NCT04296864|DRUG|Dupilumab|monoclonal antibody
219505986|NCT04560764|DEVICE|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
219505987|NCT04560764|DEVICE|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
219505988|NCT04560764|DEVICE|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
219505989|NCT04560764|OTHER|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
219505990|NCT01584609|DEVICE|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
219505991|NCT01584609|DEVICE|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
219607113|NCT03532152|DEVICE|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
219607114|NCT03532152|DEVICE|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
218884053|NCT06284668|DRUG|normal Saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
218884054|NCT06284668|DRUG|Esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
218884055|NCT06284668|DRUG|Remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
218884056|NCT05495867|PROCEDURE|implant placement|implant placement in edentulous area
218884057|NCT03409783|DEVICE|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
218884058|NCT03409783|DEVICE|Sham Device|Sham Device
218884059|NCT06774378|BEHAVIORAL|Minds@Work-ADHD-Quality of Life|Minds@Work-ADHD-Quality of Life
218884060|NCT06774378|BEHAVIORAL|Minimal contact|Weekly 15-minute scripted phone calls made individually by a member of the research team to offer minimal support, without any active intervention.
218884061|NCT05707208|DRUG|ST-01|A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
218884062|NCT05707208|DRUG|1% Lidocaine HCL|Currently approved lidocaine
218884063|NCT05036317|DRUG|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
218884064|NCT05036317|OTHER|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
218884065|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
218884066|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
218884067|NCT01038167|DRUG|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
218884068|NCT01038167|DRUG|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
218884069|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
218884070|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
218884071|NCT04150094|OTHER|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
219201167|NCT06872606|DRUG|Trifluridine/Tipiracil Hydrochloride|TAS-102 (25 mg/m² orally, days 1-5 and 8-12).
219201168|NCT06872606|RADIATION|Short-course radiotherapy|(25 Gy/5 fractions)
219201169|NCT06872606|RADIATION|intracavitary brachytherapy|brachytherapy (3 Gy/3 fractions).
219201170|NCT05576129|DEVICE|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
219505992|NCT04615676|OTHER|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
219505993|NCT02307474|RADIATION|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
219505994|NCT02307474|DRUG|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
219505995|NCT00147264|DRUG|Telmisartan (Micardis®) vs. Placebo|
219505996|NCT00147264|BEHAVIORAL|Low-Glycemic Index Diet vs. Control Diet|
219505997|NCT01891591|PROCEDURE|Roux-en-Y gastric bypass (RYGP)|
218884072|NCT04150094|OTHER|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
219028672|NCT02206425|DRUG|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028673|NCT02206425|DRUG|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028674|NCT02206425|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028675|NCT02206425|DRUG|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028676|NCT02206425|DIETARY_SUPPLEMENT|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028677|NCT02206425|DRUG|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219505998|NCT03216330|OTHER|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
219505999|NCT02387320|OTHER|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
219028678|NCT02206425|DRUG|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028679|NCT02206425|DRUG|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
219028680|NCT00183300|BEHAVIORAL|Prolonged Exposure Therapy|
219028681|NCT05875233|OTHER|Elix Daily Harmony|"Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus.~Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food."
219506000|NCT03465891|DRUG|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
219607115|NCT00257400|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
219607116|NCT00257400|BEHAVIORAL|Individual Psychotherapy|Individual Psychotherapy
219028682|NCT05875233|OTHER|Elix Cycle Balance|A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.
219506001|NCT03465891|RADIATION|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
219506002|NCT01841320|OTHER|Integrated methadone and antiretroviral therapy (iMART) clinic|
219607117|NCT05345106|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
219607118|NCT00440349|DRUG|Tamoxifen|
219607119|NCT00440349|DRUG|Prednisone|
219607120|NCT05927870|PROCEDURE|pigtail|placing a small amount of local anaesthetic subcutaneously at the site of the gallbladder, a skin incision was made through which the catheter was introduced. A 7-Fr pigtail catheter was used in all cases . If possible, the catheter was introduced into the gallbladder after passing through the liver. The catheter was thereafter fixed, either by an internal locking device or by means of a suture to the skin. The catheter was rinsed with saline solution daily in order to prevent clogging.
219607121|NCT01927900|DIETARY_SUPPLEMENT|HMO|
219607122|NCT01927900|DIETARY_SUPPLEMENT|Glucose|
219607123|NCT05027152|OTHER|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
219607124|NCT05027152|OTHER|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
218884073|NCT00004223|DRUG|docetaxel|
218884074|NCT00004223|DRUG|gemcitabine hydrochloride|
218884075|NCT02761343|OTHER|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
219607125|NCT02172807|DRUG|Tiotropium low|Tiotropium 18 µg inhalation capsule
219607126|NCT02172807|DRUG|Tiotropium high|Tiotropium 36 µg inhalation capsule
219506003|NCT03109990|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
219506004|NCT03109990|DRUG|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
219607127|NCT02172807|DRUG|Placebo MDI|Placebo metered dose inhaler (MDI)
219607128|NCT02172807|DRUG|Placebo inhalation capsule|
219607129|NCT02172807|DRUG|Oxitropium|Oxitropium MDI (100 µg/puff)
219607130|NCT02581605|DEVICE|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
219607131|NCT02713685|PROCEDURE|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
219607132|NCT02713685|PROCEDURE|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
219607133|NCT01026194|DRUG|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
218884076|NCT04985461|DEVICE|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
219028683|NCT06434662|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
219028684|NCT06434662|DRUG|Cytarabine|Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
219028685|NCT06434662|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
219028686|NCT00020696|DRUG|cisplatin|
219028687|NCT00020696|DRUG|tirapazamine|
219028688|NCT02433236|DRUG|Fostamatinib Disodium tablet 100 mg|
219028689|NCT02433236|DRUG|Fostamatinib Disodium tablet 150 mg|
219607134|NCT01026194|DRUG|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
219607135|NCT05081050|OTHER|Only Follow-up|No intervention is planned.
219607136|NCT01750190|DRUG|Roxadustat|Oral tablets
219607137|NCT01750190|DRUG|Placebo|Oral tablets
219607138|NCT01851252|DEVICE|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
218884077|NCT00000355|DRUG|Buprenorphine|
218884078|NCT03994874|DRUG|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
219028690|NCT03741556|OTHER|questionaire|a questionaire is sent to each participans
219028691|NCT01094496|BIOLOGICAL|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
219028692|NCT01094496|DRUG|Chemotherapy|
219028693|NCT00002259|DRUG|Mitoxantrone hydrochloride|
219028694|NCT06546904|DEVICE|Artificial intelligence empowers anesthesia with ultrasound assistance|Artificial intelligence empowers anesthesia with ultrasound assistance
219028695|NCT04283006|DRUG|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
219607139|NCT05736055|DIAGNOSTIC_TEST|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
219028696|NCT02795728|OTHER|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
219028697|NCT02795728|OTHER|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
219028698|NCT02717988|DRUG|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
219028699|NCT02717988|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
219506005|NCT00614159|DRUG|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
219506006|NCT00614159|DRUG|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
219506007|NCT01001169|BIOLOGICAL|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
219506008|NCT05872074|DIAGNOSTIC_TEST|Coronary angiography plus percutenous coronary intervention|"1. wire both branches, MV and SB, with two coronary guide wires.~2. Main branch pre-dilation~3. Side branch pre-dilation using (ordinary balloon in group A and Drug coated balloon in group B for the side branch)~4. Main vessel stenting~5. Proximal optimization technique (POT) of the main vessel stent"
219607140|NCT02271932|OTHER|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
219607141|NCT03606343|BEHAVIORAL|Teaching Academic Skills to Kids|Group treatment
219607142|NCT04149821|DRUG|Umbralisib|"* Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)"
218884079|NCT04548856|PROCEDURE|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
218884080|NCT04548856|PROCEDURE|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
218884081|NCT05766826|OTHER|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
219201171|NCT05576129|DEVICE|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
219201172|NCT06727058|BIOLOGICAL|Pandemic flu H5 mRNA vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)"
218884082|NCT05766826|OTHER|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
218884083|NCT04515901|DRUG|2% lidocaine|Viscous lidocaine
218884084|NCT04515901|OTHER|Placebo|Methylcellulose and cherry flavouring
218884085|NCT04698603|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
218884086|NCT05021770|DRUG|Orelabrutinib|150mg or 200mg orally daily
219028700|NCT05505032|DRUG|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
219028701|NCT05505032|DEVICE|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
218884087|NCT05021770|DRUG|Orelabrutinib|RP2D
219028702|NCT01126996|PROCEDURE|Venepuncture|"1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional)."
219028703|NCT04724954|DEVICE|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
219201173|NCT06727058|OTHER|Placebo|"Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)"
219201174|NCT06726447|DEVICE|Artificial Intelligence Tool|The intervention in this study consists of the implementation of an artificial intelligence tool for clinical registration during outpatient consultations. This technology facilitates the documentation of interactions in real time, optimizing the workflow of professionals and enabling more patient-centered care.
219201175|NCT06706336|OTHER|radon mitigation system|standard radon mitigation system used to reduce radon in homes
218884088|NCT05021770|DRUG|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
218884089|NCT03954821|DEVICE|prefabricated insoles|
219028704|NCT04724954|GENETIC|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
219028705|NCT03131336|DRUG|PeproStat|solution for local application
219028706|NCT03131336|DRUG|Saline|solution for local application
219028707|NCT03314727|OTHER|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
219201176|NCT06706336|OTHER|Sham (No Treatment)|inactive radon mitigation system
219201177|NCT06733701|DEVICE|VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)|The participant will be able to select between four VR environments: beach, lake, forest, or mountain scenery. Each provides an immersive audio and visual environment designed to reduce anxiety and promote relaxation. Each scene is rendered in a high-resolution and life-like fashion which participants can experience in a full 360 degrees. Participants will wear the headset for the duration of the egg retrieval procedure which is approximately 15-20 minutes.
219506009|NCT01945138|DEVICE|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
219506010|NCT00645489|BEHAVIORAL|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
219506011|NCT00645489|OTHER|wait list|Wait list
219506012|NCT01608295|DRUG|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
218884090|NCT02677272|OTHER|Appropriateness of NH resident's transfer to ED|
218884091|NCT04370106|OTHER|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
219028708|NCT02596854|DEVICE|Neurological MRI|Neurological MRI image collection
219506013|NCT01608295|DRUG|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
218884092|NCT04094857|DRUG|HBN-1|Intravenous infusion
219028709|NCT00107211|BIOLOGICAL|therapeutic autologous dendritic cells|
219028710|NCT00107211|PROCEDURE|conventional surgery|
219028711|NCT00107211|PROCEDURE|neoadjuvant therapy|
219201178|NCT06733701|DEVICE|VR headset without any scenery|VR headset without any scenery
219201179|NCT06732037|OTHER|Conventional physical therapy program|The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.
219506014|NCT04418141|DRUG|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
219506015|NCT01249105|DRUG|MK-2206|Taken orally once a week
219506016|NCT00635388|OTHER|Placebo|oral, placebo, once/day for 12 weeks
219506017|NCT00635388|OTHER|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
219506018|NCT00635388|OTHER|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
219506019|NCT04777773|OTHER|dual-task training|dual-task training
219506020|NCT02448459|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
219506021|NCT04086706|PROCEDURE|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
219607143|NCT04149821|DRUG|Ublituximab|-Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
219607144|NCT05695001|DEVICE|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
218884093|NCT05838157|BIOLOGICAL|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
218884094|NCT00473200|DIETARY_SUPPLEMENT|S-adenosylmethionine|1200 mg daily
219028712|NCT00632333|BIOLOGICAL|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
218884095|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
218884096|NCT05614349|DRUG|Antioxidant|Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
219506022|NCT04638686|DRUG|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
219506023|NCT04638686|DRUG|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
219506024|NCT00798889|DRUG|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
219506025|NCT01641744|BEHAVIORAL|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
219506026|NCT01641744|BEHAVIORAL|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
219506027|NCT04111237|BEHAVIORAL|Two Finger technique|two finger method for chest compression provuision
218884097|NCT05711823|DRUG|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
218884098|NCT05711823|DRUG|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
218884099|NCT00519272|BEHAVIORAL|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
218884100|NCT03930602|DRUG|BMS-986165|Participants will receive BMS-986165.
218884101|NCT03930602|DRUG|Fluvoxamine|Participants will receive fluvoxamine.
218884102|NCT05871099|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Experimental group receive HIPEC two times after laproscopic gastrectomy
218884103|NCT00036634|DRUG|Tenofovir DF|Tenofovir DF tablet administered orally once daily
219506028|NCT04111237|BEHAVIORAL|Two Thumb Technique|Two thumb technique
219506029|NCT04944602|BIOLOGICAL|SYN008|injection of 300 mg
218884104|NCT00036634|DRUG|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
218884105|NCT03362749|OTHER|RFA, MWA, cryo and IRE|local tumor ablation
218884106|NCT02047214|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
218884107|NCT02047214|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
219506030|NCT04944602|BIOLOGICAL|Omalizumab for injection|injection of 300 mg
219506031|NCT02116283|BEHAVIORAL|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
219506032|NCT02116283|OTHER|Smartphone|Participants will use an Android-based smartphone as their own for one month
219506033|NCT05259111|OTHER|Home hospital|Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
219506034|NCT00358826|DRUG|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
218884108|NCT04174690|DEVICE|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
219506035|NCT00358826|DRUG|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
219506036|NCT02950753|DRUG|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
219506037|NCT02950753|DRUG|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
218884109|NCT02206035|DRUG|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
218884110|NCT02206035|DRUG|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
218884111|NCT02206035|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
219201180|NCT06732037|OTHER|Kinetic control training|The Kinetic Control Retraining Program will be received for 8 weeks by the experimental group. It focuses on addressing uncontrolled movement (UCM) and muscle synergy retraining. UCM retraining starts with patient education on movement deficiencies, their symptoms, and adherence to training. Movement coordination is retrained in test positions, progressing to challenging ones using feedback from mirrors, walls, or hands. Corrections focus on lower cervical flexion, upper cervical extension, mid-cervical translation/extension, side-bending, and rotation, emphasizing controlled dissociation in supported and unsupported postures. Muscle synergy retraining targets global stabilizers (e.g., deep neck flexors and extensors) and mobilizers (e.g., sternocleidomastoid and suboccipital muscles) to enhance coordination, stability, and motor control.
219506038|NCT00097071|DRUG|insulin lispro|
219506039|NCT00097071|DRUG|insulin aspart|
219506040|NCT03485131|DEVICE|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
219506041|NCT03485131|DEVICE|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
219506042|NCT01234428|PROCEDURE|Laparoscopic surgery|Gastric banding
219506043|NCT01234428|PROCEDURE|gastric banding|laparoscopic gastric banding
218884112|NCT01934010|DRUG|AM-101|AM-101 gel for intratympanic injection
218884113|NCT04609631|BEHAVIORAL|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
218884114|NCT04609631|BEHAVIORAL|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
218884115|NCT02936024|PROCEDURE|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
218884116|NCT02936024|PROCEDURE|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
218884117|NCT06521372|OTHER|Magenta AI image analysis tool|MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
218884118|NCT01709370|DRUG|Letrozole, PD 0332991|
218884119|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1%|
219201181|NCT05293912|DRUG|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
219201182|NCT06889675|DRUG|YB1-X7 Injection (IT)|Intratumoral injection
219201183|NCT06889675|DRUG|YB1-X7 Injection (IV)|Intravenous infusion
219201184|NCT06884904|DRUG|Low-dose experimental group|2.0\*10\^6/kg
219201185|NCT06884904|DRUG|High-dose experimental group|4.0\*10\^6/kg
219506044|NCT06282588|DRUG|Darolutamide|2x300 mg tablets twice daily, for up to 96 weeks
219506045|NCT06282588|DRUG|Darolutamide matched placebo|2x300 mg tablets twice daily, for up to 96 weeks
219506046|NCT06282588|RADIATION|Radiotherapy|Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
219607145|NCT01472692|DRUG|Febuxostat|80mg PO daily for 8 weeks
218884120|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
219506047|NCT06282588|DRUG|Zoladex 3.6Mg Implant|3.6 mg, subcutaneous use
219506048|NCT06282588|DRUG|Zoladex LA|10.8 mg, subcutaneous use
219506049|NCT06282588|DRUG|Decapeptyl sustained release 22.5 mg|22.5 mg, intramusculair injection
219506050|NCT06282588|DRUG|Decapeptyl sustained release 11.25 mg|11.25 mg, intramusculair injection
219506051|NCT06282588|DRUG|Depo-Eligard 45 mg|45 mg, subcutaneous use
219506052|NCT06282588|DRUG|Depo-Eligard 22.5 mg|22.5 mg, subcutaneous use
219506053|NCT06282588|DRUG|Depo-Eligard 7.5 mg|7.5 mg, subcutaneous use
219506054|NCT06282588|DRUG|Firmagon 120 MG Injection|120 mg, subcutaneous use
219506055|NCT06282588|DRUG|Firmagon 80 MG Injection|80 mg, subcutaneous use
219506056|NCT06282588|DRUG|Docetaxel|75 mg per square m, IV infusion
219506057|NCT02118701|OTHER|Shared Decision-Making educational training|
219607146|NCT03934541|BIOLOGICAL|MPER-656 Liposome Vaccine|Administered by intramuscular injection
219607147|NCT03934541|BIOLOGICAL|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
218884121|NCT01342588|PROCEDURE|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
219607148|NCT06236425|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
219607149|NCT06236425|DRUG|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
219607150|NCT06236425|DRUG|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
218884122|NCT03061435|PROCEDURE|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
218884123|NCT03061435|PROCEDURE|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
218884124|NCT05943249|PROCEDURE|magnetic resonance|
218884125|NCT00870181|BIOLOGICAL|ADV-TK/GCV|gene therapy
218884126|NCT00870181|PROCEDURE|Surgery|
218884127|NCT00870181|DRUG|systemic chemotherapy|
218884128|NCT01548027|PROCEDURE|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
218884129|NCT01548027|PROCEDURE|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months
218884130|NCT01548027|OTHER|No intervention|No intervention
218884131|NCT06419088|OTHER|Preoperative individualized education|Based on the identified individual education needs, the researcher implemented audio-visual education to the intervention group in the ward.
218884132|NCT03945461|OTHER|Chewing gum|xylitol based, peppermint flavored gum
218884133|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
218884134|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
218884135|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
218884136|NCT05186740|DEVICE|ProVee Urethral Expander System|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
218884137|NCT05186740|PROCEDURE|Urethral Access Sheath|The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
218884138|NCT01393821|DRUG|menadione topical lotion|Given topically
218884139|NCT01393821|OTHER|placebo|Given topically
218884140|NCT01393821|OTHER|questionnaire administration|Ancillary studies
218884141|NCT01393821|PROCEDURE|management of therapy complications|Given menadione topical lotion
218884142|NCT04339621|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
218884143|NCT05004220|PROCEDURE|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
218884144|NCT03515096|DRUG|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
218884145|NCT03515096|DRUG|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
219607151|NCT06236425|DRUG|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
219607152|NCT06236425|DRUG|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
219607153|NCT06236425|DRUG|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
219607154|NCT05515536|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
218884146|NCT02211248|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
218884147|NCT02211248|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
218884148|NCT02338089|DRUG|Oxytocin|Oxytocin, 100 micromolar solution
218884149|NCT05034250|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
218884150|NCT00657579|DRUG|DE-104 ophthalmic solution, low concentration|
218884151|NCT00657579|DRUG|DE-104 ophthalmic solution, medium concentration|
218884152|NCT00657579|DRUG|DE-104 ophthalmic solution, high concentration|
218884153|NCT00657579|DRUG|DE-104 vehicle|
218884154|NCT01189695|DRUG|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
218884155|NCT01189695|DRUG|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
218884156|NCT03503760|DEVICE|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
219506058|NCT01217203|DRUG|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
219506059|NCT00003054|DRUG|paclitaxel|
219506060|NCT02755545|DRUG|Product A|Product A applied topically to the entire face or other affected area of the skin once daily
219506061|NCT02755545|DRUG|Product B|Product B applied topically to affected area of the skin 1 to 3 times daily
219506062|NCT01716754|DRUG|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
219506063|NCT01716754|DRUG|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
219506064|NCT01716754|DRUG|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
219506065|NCT00481247|DRUG|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
219506066|NCT00481247|DRUG|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
218884157|NCT04282707|PROCEDURE|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
219506067|NCT00376142|BEHAVIORAL|Psychological theory-based behaviour change interventions|
219506068|NCT00565370|DRUG|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
219506069|NCT02535000|DRUG|Duloxetine|duloxetine 60 mg
219506070|NCT02535000|DRUG|Placebo|placebo
219506071|NCT01918709|DRUG|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
219506072|NCT01918709|DRUG|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
219506073|NCT01918709|DRUG|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
219506074|NCT01918709|DRUG|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
218884158|NCT04282707|OTHER|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
218884159|NCT04852198|PROCEDURE|OAGB|Simplified gastric bypass procedure
218884160|NCT04852198|PROCEDURE|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
218884161|NCT00105690|BEHAVIORAL|Telemedicine intervention|
218884162|NCT03991455|DEVICE|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
218884163|NCT05299008|DRUG|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
219028713|NCT05853250|OTHER|Reiki/manual therapy|Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
219201186|NCT06884904|DRUG|Low-dose placebo control group|Equivalent volume of solvent calculated at 2.0×10\^6/kg
219201187|NCT06884904|DRUG|High-dose placebo control group|Equivalent volume of solvent calculated at 4.0×10\^6/kg
219506075|NCT01918709|DRUG|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
219506076|NCT01918709|DRUG|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
219506077|NCT05771311|DEVICE|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
219506078|NCT05771311|DEVICE|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
219506079|NCT04317781|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219506080|NCT06462001|BIOLOGICAL|Bacillus Calmette-Guerin Vaccine Intravesical|BCG (Oncotice) is administered intravesically as per usual standard of care
219506081|NCT06462001|DRUG|Mitomycin|MMC is administered intravesically as per usual standard of care
219506082|NCT01620489|DRUG|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
219506083|NCT01620489|DRUG|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
219506084|NCT03705884|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
219506085|NCT03705884|DRUG|Prednisolone|Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
219506086|NCT03378349|BEHAVIORAL|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
218884164|NCT04040920|DEVICE|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
219506087|NCT03378349|BEHAVIORAL|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
219506088|NCT06460428|BEHAVIORAL|Interactive video usage|The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
219506089|NCT02157233|BEHAVIORAL|Rest|
219506090|NCT02157233|BEHAVIORAL|Exercise|
219506091|NCT05343949|OTHER|HIIT exercise program ABC|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
219506092|NCT05343949|OTHER|HIIT exercise program CAB|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
219506093|NCT05343949|OTHER|HIIT exercise program BCA|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
219506094|NCT01810926|BIOLOGICAL|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
218884165|NCT04040920|OTHER|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
219506095|NCT01810926|DRUG|Rituximab|single infusion of200 mg/m2 on day -1
219506096|NCT01810926|DRUG|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
218884166|NCT06451991|OTHER|Use of concept map in clinical practice in nursing students|Concept map will be used in clinical practice in nursing students.
218884167|NCT03239444|DEVICE|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
218884168|NCT00760318|DRUG|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
218884169|NCT02463682|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
218884170|NCT02463682|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
219506097|NCT01810926|DRUG|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
219506098|NCT01810926|DRUG|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
219506099|NCT01810926|DRUG|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
219506100|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
218884171|NCT02336672|DEVICE|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
218884172|NCT01204021|BEHAVIORAL|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
218884173|NCT01204021|BEHAVIORAL|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
218884174|NCT01652339|DRUG|Exforge tab. 10/160mg|
218884175|NCT01652339|DRUG|Lodivixx tab. 5/160mg|
218884176|NCT01851629|BEHAVIORAL|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
218884177|NCT01851629|OTHER|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
218884178|NCT00317330|DRUG|Isoniazid|
218884179|NCT00317330|DRUG|Pyrazinamide|
218884180|NCT00317330|DRUG|Rifampin|
219201188|NCT06886854|DEVICE|Mode of delivery|"Retrieval of delivery data, typically recorded by midwives - retrieval of data per delivery and post-delivery - Consultation of medical data on labor duration, labor onset method, estimated fetal weight, etc.~Data collected for each delivery, identical in both groups."
219506101|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
219506102|NCT02947113|DRUG|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
219506103|NCT02947113|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
218884181|NCT05533164|DRUG|Rituximab|1000mg rituximab in 250ml NaCl 0.9% intravenously
219607155|NCT06373263|OTHER|Plain-language summary|Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
219607156|NCT06373263|OTHER|Dissemination Tool (Infographic)|The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
219607157|NCT06027294|PROCEDURE|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
219607158|NCT05968924|DEVICE|Podimetrics SmartMat|Participants receive training for stepping on SmartMat each day for 6 months. Monthly phone calls will be conducted to assess foot health and mat.
219607159|NCT06088199|DRUG|Apremilast|Oral tablet
219607160|NCT06495060|OTHER|No intervention (Only observation)|No intervention
219607161|NCT00271232|DEVICE|Cardiac resynchronization therapy|
218884182|NCT05533164|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously
219506104|NCT02947113|DRUG|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
219506105|NCT02947113|DRUG|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
219506106|NCT03999125|DRUG|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
218884183|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
219506107|NCT03999125|DRUG|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
219506108|NCT03999125|DRUG|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
219506109|NCT01873768|DRUG|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
219506110|NCT01873768|DRUG|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
219506111|NCT00321711|DRUG|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
219506112|NCT00321711|BIOLOGICAL|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
219506113|NCT00321711|DRUG|Azacitidine|hypomethylating agent
219506114|NCT00321711|DRUG|Decitabine|hypomethylating agent
219506115|NCT02141178|DRUG|Bupivacaine|
219506116|NCT02141178|DRUG|Exparel|
219506117|NCT00670878|DRUG|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
219506118|NCT00670878|DRUG|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
219506119|NCT00005042|DRUG|semaxanib|
219506120|NCT01696864|DEVICE|Hand tutor rehabilitation device|A rehabilitation device for the hand
219506121|NCT01696864|DEVICE|Arm tutor rehabilitation device|A rehabilitation device for the arm
219506122|NCT06546280|DRUG|Camrelizumab|Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
219506123|NCT06546280|DRUG|Apatinib|Apatinib 250 mg will be taken orally once daily.
219506124|NCT00005782|DRUG|Granulocyte colony-stimulating factor|
219506125|NCT00005782|PROCEDURE|Leukapheresis|
219506126|NCT00133302|DRUG|Standard CHOP|
219506127|NCT00133302|DRUG|Bi-CHOP (dose intensified CHOP)|
219506128|NCT00522288|DEVICE|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
219506129|NCT00522288|DEVICE|Spectacle|Spectacles for the treatment of myopia
219506130|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
218884184|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
219506131|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System Containing Placebo Product
219506132|NCT00058357|DRUG|lidocaine|
219506133|NCT00058357|OTHER|placebo|
219607162|NCT03041428|DEVICE|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
219607163|NCT04168879|DRUG|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
219607164|NCT04168879|DRUG|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
218884185|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
219607165|NCT00390637|BEHAVIORAL|High or low Glycemic Index and high or low Protein Diet|
219607166|NCT00601887|DRUG|Meloxicam|
219201189|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
219506134|NCT05081674|DRUG|Alectinib|600mg 1OD
219506135|NCT05081674|DRUG|Pembrolizumab|200mg every 21 days
219506136|NCT05081674|DRUG|Nivolumab|6mg/kg every 4 weeks
219506137|NCT05081674|DRUG|Erlotinib|150mg
219506138|NCT02325700|PROCEDURE|Aortic repair|Aortic bypass
219506139|NCT05157607|BEHAVIORAL|Family Connections Protocol for Relatives of Patients with SBD.|Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
219506140|NCT05157607|BEHAVIORAL|Treatment as Usual Optimized Protocol (TAU-O)|Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.
219506141|NCT03846271|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
219506142|NCT03846271|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
219607167|NCT01926405|PROCEDURE|saliva collection|collection of saliva
219607168|NCT05889429|DIAGNOSTIC_TEST|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
219506143|NCT05882981|OTHER|Sit and reach test|It will be used to measure the flexibility of the participants.
218884186|NCT04428619|DEVICE|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
219201190|NCT06733844|DIETARY_SUPPLEMENT|Weekly iron folic acid supplementations|In the intervention arm, adolescent girls will receive weekly iron and folic acid supplements (WIFAS), nutrition education, and group counseling sessions. WIFAS will be delivered quarterly, with each girl consuming one supplement at the facilitation center and the remaining 12 at home, once a week. The supplements contain 60mg of iron and 2.8mg of folic acid. A quarterly cash transfer of PKR 1,000 will be given to the mother, conditional on the girl's WIFAS consumption and attendance at the quarterly education and counseling sessions. The girl will report her supplement intake at each visit and receive 13 more supplements. The intervention will last 18 months.
219201191|NCT06721754|PROCEDURE|Negative Pressure Wound Treatment|Negative Pressure Wound Treatment promotes healing by applying subatmospheric pressure to reduce inflammatory exudate and stimulate granulation tissue.
218884187|NCT04428619|DEVICE|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
218884188|NCT05473871|BEHAVIORAL|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
218884189|NCT05473871|BEHAVIORAL|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
218884190|NCT05473871|BEHAVIORAL|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
218884191|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
218884192|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
218884193|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
219201192|NCT06736210|OTHER|Muscle Elastic Properties Measurement|Using the MyotonPro device, the elastic properties, including stiffness, elasticity, and tone, were evaluated for the tibialis anterior, gastrocnemius medialis, gastrocnemius lateralis, and peroneus longus muscles. Measurements were performed in a controlled laboratory setting.
219201193|NCT06736210|OTHER|Muscle Oxygen Saturation (SmO2)|Muscle oxygenation levels were measured before and after a standardized exercise protocol using the MOXY device. The exercise protocol consisted of a light-intensity dynamic task tailored to minimize fatigue and mimic functional activity.
219201194|NCT06736210|OTHER|Plantar Pressure Analysis|Plantar pressure was assessed both statically and dynamically using a pressure-mapping platform. This provided data on pressure distribution, contact times, and high-pressure areas across the foot during various conditions.
219201195|NCT06735703|DRUG|To provide ampicillin sulbactam to pregnant women with premature rupture of membrane|To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
219201196|NCT06735963|DEVICE|Meta Quest 3 Virtual Reality|Immersive virtual reality Meta Quest 3 device
219201197|NCT06735963|PROCEDURE|Exercise|Traditional exercise program for knee OA patients
219506144|NCT05882981|OTHER|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
219506145|NCT05882981|OTHER|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
219506146|NCT05882981|OTHER|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
219506147|NCT05882981|OTHER|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
219506148|NCT01684449|DRUG|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
219506149|NCT02801448|DRUG|sulforaphane|sulforaphane-containing broccoli sprout extracts
219506150|NCT02801448|DRUG|Placebo|Maltodextrine-based placebo without sulforaphane
219506151|NCT03985033|OTHER|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
219607169|NCT05889429|BEHAVIORAL|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
219607170|NCT03992365|DRUG|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
219607171|NCT03992365|DRUG|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
219607172|NCT00349219|DRUG|erlotinib|erlotinib 150 mg taken orally daily until disease progression
218884194|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
218884195|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
219607173|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
218884196|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
219201198|NCT06735963|DEVICE|Electrotherapy|Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
219201199|NCT06505746|OTHER|No intervention|No investigational drug will be administered to participants in this study.
219201200|NCT03587805|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
219201201|NCT06711198|OTHER|virtual reality simulation|The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.
219201202|NCT06884878|OTHER|Multi-omic approach to cancer diagnosis.|To assess the impact of intratumoral heterogeneity on the effectiveness of targeted therapies and immunotherapy.
219201203|NCT06734793|DEVICE|Wearable stethoscope|The device is a soft, wearable stethoscope designed for continuous, comfortable monitoring of patients for abnormal breath sounds, such as wheezing, which can indicate asthma exacerbations. It automatically detects and diagnoses abnormal breath frequencies, wirelessly transmitting data for analysis. Preliminary materials have shown biocompatibility, ensuring the device is safe for use in children. A key feature is its machine-learning algorithm, which can classify and differentiate normal from abnormal sounds with an expected accuracy above 80%. Initial in vivo tests will compare the device's findings to those of a commercial-grade stethoscope in healthy subjects and individuals with asthma. Breath sound data will be used to improve the detection of wheezing sounds from these continuous recordings based on frequency and amplitude analysis of the recordings.
219201204|NCT06734793|OTHER|Routine Clinical lung Auscultation|The study PI will auscultate the participant's lungs at enrollment to ensure that wheezing is present before beginning the continuous recording of the participant's lung sounds. The PI will assess the participant's respiratory status daily at the start of each breath sound recording session.
219607174|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
219607175|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
219607176|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
219607177|NCT00349219|DRUG|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
219607178|NCT02845648|DRUG|anticholinergic|Initial anticholinergic therapy to all patients
219607179|NCT06685029|DEVICE|Clear aligner treatment|Clear aligners are appliances that allow the teeth to be gradually moved to the desired final position, as planned in the computer program, in a way that each aligner will perform a part of the total movement with its use.
218884197|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
218884198|NCT06800820|DIETARY_SUPPLEMENT|Chondractiv™ Plus (Hydrolyzed chicken cartilage)|One oral dose
218884199|NCT04909164|DRUG|Immunnotherapy group|Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
218884200|NCT05844358|DEVICE|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
218884201|NCT01858766|DRUG|SOF|400 mg tablet administered orally once daily
218884202|NCT01858766|DRUG|VEL|Tablet administered orally once daily
218884203|NCT01858766|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218884204|NCT05715307|OTHER|Intensive training for endocrinologists in T2DM management|"One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings."
218884205|NCT05715307|OTHER|Regular training for endocrinologists in T2DM management|"Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training."
218884206|NCT00180765|PROCEDURE|Up to 100ml blood will be taken by venupuncture.|
218884207|NCT01340053|DRUG|RDX5791|Capsule, QD
218884208|NCT06361914|BEHAVIORAL|Digital CBT-I|"Sleep restriction includes behavioral instructions to limit the time spent in bed to increase sleep drive and further reduce time awake in bed.~Stimulus control therapy entails behavioral instructions to strengthen the association between bed and sleep and to eliminate conditioning of non-sleep behavior and bed.~Deactivation/relaxation training involves methods to reduce somatic tension and limit intrusive thought processes that interfere with sleep.~Cognitive therapy helps to identify, challenge, and modify dysfunctional beliefs about sleep.~Sleep hygiene education entails specific information relating to lifestyle and environmental factors that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake."
218884209|NCT06361914|BEHAVIORAL|Digital Sleep hygiene education|Sleep hygiene education entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake.
218884210|NCT02882828|DRUG|switched from Prograf® to Envarsus®|
218884211|NCT04615650|PROCEDURE|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
218884212|NCT04615650|DEVICE|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
219506152|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
219506153|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
218884213|NCT06213454|DRUG|TAP Anesthesia|ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
218884214|NCT06213454|DRUG|Surgeon-Initiated Local Anesthetic|266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
218884215|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
218884216|NCT06347679|OTHER|Aroma diffuser with single-note sweet orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
219506154|NCT02351128|DRUG|Lanreotide|
219506155|NCT02956824|OTHER|Standard care|Current care
219506156|NCT06016933|DRUG|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
219506157|NCT06016933|PROCEDURE|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
218884217|NCT06347679|OTHER|Aroma diffuser with single-note tea tree essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
218884218|NCT06347679|OTHER|Aroma diffuser with water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
218884219|NCT04814147|PROCEDURE|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
218884220|NCT01635881|DEVICE|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
219201205|NCT06737250|DRUG|R2P -> RP|"Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14"
219506158|NCT03110393|DEVICE|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
219506159|NCT03110393|DEVICE|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
219506160|NCT04749524|DIAGNOSTIC_TEST|Medial-Olivocochlear Reflex (MOCR) Strength Measurement|Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.
218884221|NCT00939562|DRUG|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
219607180|NCT06685029|DEVICE|Fixed Orthodontic Appliance Treatment|Fixed orthodontic treatment is a type of orthodontic treatment performed by applying brackets and wires to the teeth and is considered the gold standard for orthodontic treatments.
219607181|NCT06657768|DRUG|LY4006895|Administered IV
219607182|NCT06657768|DRUG|Placebo|Administered IV
219607183|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
218884222|NCT00939562|DRUG|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
219028714|NCT05340881|BEHAVIORAL|Bright Light Exposure|Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
219028715|NCT05340881|BEHAVIORAL|Dim Light Exposure|A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
219028716|NCT05340881|OTHER|Cognitive Assessment|Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
219028717|NCT04701281|COMBINATION_PRODUCT|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
219028718|NCT06187467|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
219028719|NCT04028206|DIETARY_SUPPLEMENT|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
219028720|NCT04028206|DEVICE|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
219028721|NCT04028206|BEHAVIORAL|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
219028722|NCT06580847|BEHAVIORAL|Group Singing|12 week choir program consisting of 1.5 hours of in-person instruction per week.
219028723|NCT06580847|BEHAVIORAL|Audiobook Club|12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
219028724|NCT02364544|BEHAVIORAL|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
219028725|NCT02364544|BEHAVIORAL|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
219201206|NCT06739642|OTHER|Education|caregivers in the intervention group received an individualized educational program intervention. The content of the educational program was developed by the researcher through a review of the literature and interviews with caregivers. The educational program, during three months, was delivered in 6 sessions of 40 minutes each. The topics of the training content were as follows: 1. General Nutrition Information, 2. Changes Affecting Nutrition During Old Age and Nutrition Principles, 3. Anthropometric Measurements and Scans, 4. Nutritional Problems in the Patient with Dementia, Dementiamendations for Increasing Nutritional Intake in Dementia Patients, 6. Alternatives for Severe Feeding Problems. Covering general topics was held as group education; carried out in two separate groups. Another individual session was planned for caregivers who could not attend the group education program, and the missing topics were completed.
219607184|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
218884223|NCT00152308|DEVICE|2% rapamycin-eluting YUKONdes PEARL-stent|
218884224|NCT00152308|DEVICE|1% rapamycin-eluting YUKONdes PEARL-stent|
218884225|NCT00152308|DEVICE|YUKONdes PEARL-stent coated with placebo (ethanol)|
218884226|NCT04543292|DEVICE|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
218884227|NCT00943332|PROCEDURE|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
218884228|NCT05564312|DEVICE|Transabdominal ultrasonographic guidance at embryo transfer.|During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
218884229|NCT06557239|DRUG|Lysergic Acid Diethylamide (LSD)|one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
218884230|NCT00836186|RADIATION|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
218884231|NCT00147121|DRUG|Rituximab + Standard CHOP|Rituximab + Standard CHOP
218884232|NCT00147121|DRUG|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
218884233|NCT02203994|DEVICE|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
219028726|NCT02364544|BEHAVIORAL|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
219028727|NCT02364544|BEHAVIORAL|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
218884234|NCT02954614|BEHAVIORAL|Active play in after school programs (ASP)|"* A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
219506161|NCT04182750|OTHER|Pharmacist consultation|"The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use."
219506162|NCT03294512|BEHAVIORAL|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
219506163|NCT05055791|DRUG|SYHX1903|SYHX1903 tablets, orally, qd
219506164|NCT01484028|DEVICE|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
219506165|NCT01484028|DEVICE|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
219506166|NCT01484028|DEVICE|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
219506167|NCT02414425|PROCEDURE|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
219506168|NCT02414425|PROCEDURE|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
219506169|NCT02414425|DRUG|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
219506170|NCT04495387|DRUG|Chemotherapy|standard adjuvat chemotherapy for reast and colo cancer
219506171|NCT01956227|BEHAVIORAL|Home-based exercise|exercise to look at balance and lower limb strength record in diary
219506172|NCT01956227|BEHAVIORAL|Education|sessions to discuss self-management ideas to modify risk of falling
219506173|NCT01956227|BEHAVIORAL|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
219506174|NCT00047242|DRUG|7-hydroxystaurosporine|
218884235|NCT03864302|BEHAVIORAL|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
218884236|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
219506175|NCT00047242|DRUG|irinotecan hydrochloride|
218884237|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
218884238|NCT00532298|BIOLOGICAL|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
218884239|NCT00532298|BIOLOGICAL|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
219506176|NCT01165814|DRUG|Naproxen Tramadol|
219506177|NCT05562336|DEVICE|Optical coherence tomography angiography|Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
219506178|NCT03500965|BEHAVIORAL|text-only PWL|control condition (no image)
219506179|NCT03500965|BEHAVIORAL|graphic PWL|pictorial warning
219506180|NCT03500965|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
219506181|NCT03500965|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
219506182|NCT01308281|PROCEDURE|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
219506183|NCT01308281|PROCEDURE|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
219506184|NCT04235647|OTHER|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
218884240|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
218884241|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
218884242|NCT06540794|OTHER|PEEP TITRATION|Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
218884243|NCT02032225|OTHER|Skin biopsy|
219028728|NCT02364544|OTHER|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
219028729|NCT05867628|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
219028730|NCT04829565|DRUG|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
219028731|NCT04829565|DRUG|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
219201207|NCT06740227|PROCEDURE|Virtual Reality-Based Balance Training|Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.
219201208|NCT06740227|PROCEDURE|Conventional Balance Training|one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
219201209|NCT04626427|DEVICE|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
219201210|NCT06735989|OTHER|Lecture on moral reasoning|One and a half-hour long lecture on moral justification and moral reasoning
219201211|NCT06735989|OTHER|Lecture on logical reasoning|One and a half-hour long lecture on logical and argumentative principles
219201212|NCT06734195|DRUG|dexmedetomidine + propofol|Comparison of caudal dexmedetomidine + propofol sevoflurane-related emergence agitation in children undergoing congenital hernia repair.
219201213|NCT06734195|DRUG|Propofol alone|30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.
219201214|NCT06734195|DRUG|Dexmedetomidine|patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
219506185|NCT04235647|OTHER|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
219506186|NCT02922959|BEHAVIORAL|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
219506187|NCT02922959|DRUG|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
219506188|NCT02922959|BEHAVIORAL|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
219506189|NCT01266382|DEVICE|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
219506190|NCT01272557|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
219506191|NCT01272557|DRUG|Sorafenib|Sorafenib 400 mg bid (oral) continuously
219028732|NCT05181449|BEHAVIORAL|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
219028733|NCT02981628|DRUG|Asparaginase Erwinia chrysanthemi|Given Asparaginase Erwinia chrysanthemi
219028734|NCT02981628|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219028735|NCT02981628|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
219028736|NCT02981628|DRUG|Calaspargase Pegol|Given IV
219028737|NCT02981628|DRUG|Cyclophosphamide|Given IV
218884244|NCT00761696|DRUG|IPI-926|Oral daily dosing
218884245|NCT05759858|OTHER|None of intervention|None of the interventions was applied.
218884246|NCT03301610|OTHER|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
218884247|NCT03301610|OTHER|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
218884248|NCT06970340|BEHAVIORAL|Online MedEd Intern Bootcamp|6 months of online access plus biweekly live sessions
218884249|NCT05799066|DIAGNOSTIC_TEST|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
218884250|NCT05799066|DIAGNOSTIC_TEST|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
218884251|NCT06968676|OTHER|Conventional Upper Limb Treatment|Control group (CG) will receive two 60-minute sessions per week for a period of ten weeks (a total of 20 sessions per group). The CG will receive a specific conventional physiotherapy intervention by a physiotherapist with expertise in the care of people with MS. This intervention will be based on conventional physiotherapy exercises \[23\], including shoulder, elbow, wrist and finger joint mobilization, forearm and hand muscle strengthening exercises, gross and fine motor work and functional task practice with the aim of mimicking the movements included in the settings specifically designed for the experimental intervention.
218884252|NCT06968676|OTHER|Experimental intervention with mixed reality|Experimental group will receive the same conventional physiotherapy treatment (40 minutes) in addition to a mixed reality protocol, using Meta Quest 3.0. glasses (20 minutes), by retraining on tasks specifically designed for this project and linked to the specific locations (kitchen, bathroom, living room, bedroom and garden-terrace. The intervention will be carried out by a physiotherapist skilled in the use of the technology. The patient's initial position will be seated facing a table at mid-trunk height, with the elbow at 90° of flexion and the forearm in neutral pronation-supination. The therapist will provide manual assistance as needed, moving to upright-high seated or standing positions as the protocol progresses and as tasks require, and work will be done bilaterally.
218884253|NCT05592379|DRUG|Psilocybin|The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).
219028738|NCT02981628|DRUG|Cytarabine|Given IV or SC
219028739|NCT02981628|PROCEDURE|Diagnostic Imaging|Undergo imaging
219028740|NCT02981628|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219028741|NCT02981628|DRUG|Leucovorin Calcium|Given PO or IV
219028742|NCT02981628|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219028743|NCT02981628|DRUG|Methotrexate|Given IT
219506192|NCT01193517|DRUG|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
219506193|NCT01193517|DRUG|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
219506194|NCT01193517|DRUG|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
219607185|NCT04660994|OTHER|Educational game|"The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month."
219607186|NCT03740347|BEHAVIORAL|Questionnaires|"Response to questionnaires evaluating chronic pain and its repercussion :~* anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~* depression questionnaire (Children's Depression Inventory score),~* sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~* quality of life questionnaire (Pediatric Quality of Life inventory score)."
219607187|NCT04682145|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
219028744|NCT02981628|DRUG|Pegaspargase|Given IV or IM
219028745|NCT02981628|DRUG|Vincristine|Given IV
219028746|NCT06380751|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
219028747|NCT06380751|DRUG|Camizestrant|Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
219028748|NCT06380751|DRUG|Abemaciclib|CDK4/6 Inhibitor
219028749|NCT06380751|DRUG|Ribociclib|CDK4/6 Inhibitor
219506195|NCT01193517|DRUG|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
219506196|NCT02208583|DRUG|Docetaxel & Prednisone|Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
219028750|NCT06380751|DRUG|Palbociclib|CDK 4/6 Inhibitor
219028751|NCT06380751|DRUG|Fulvestrant|Endocrine Therapy
219028752|NCT06380751|DRUG|Letrozole|Endorcine Therapy
219028753|NCT06380751|DRUG|Anastrozole|Endocrine Therapy
219028754|NCT06380751|DRUG|Exemestane|Endocrine Therapy
219028755|NCT00163475|DRUG|Roflumilast|
219028756|NCT04692428|PROCEDURE|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
219028757|NCT02062333|DRUG|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
219028758|NCT02062333|DRUG|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
219028759|NCT02397421|DRUG|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
219028760|NCT02397421|DRUG|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
219607188|NCT04850755|DRUG|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
219028761|NCT01688258|PROCEDURE|Diagnostic swab|
219506197|NCT02208583|DRUG|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
219607189|NCT05108298|OTHER|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
219607190|NCT02441686|DRUG|Bortezomib|
219607191|NCT02441686|DRUG|Lenalidomide|
218884254|NCT05592379|DRUG|Clonidine|Clonidine will be administered orally in a 0.2mg dose
218884255|NCT05592379|OTHER|Saline|The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
218884256|NCT06109714|OTHER|Goal Directed Fluid Therapy|Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
218884257|NCT04929249|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
218884258|NCT06974526|DRUG|Oxandrolone|Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)
218884259|NCT06974526|DRUG|Placebo|Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)
218884260|NCT06976281|OTHER|conventional exercise Program|Exercises include shoulder flexion, shoulder abduction, leg extension, and hand grip. Start with 1-3 sets of 12 reps at 30% of 1-repetition maximum, increasing by 10% according to patient endurance. Cycling is a 30-minute chair or bedside cycle ergometer exercise 2 time/weak for 2 consecutive months
218884261|NCT06976281|OTHER|blood flow restriction training|Patients received the same conventional exercise program, which included isometric, aerobic, and resisted exercise individualized for every patient with blood flow restriction by 50% of limb occlusion pressure. Training will be conducted for 2 time/weak for 2 consecutive month
219607192|NCT02441686|DRUG|Dexamethasone|
219607193|NCT02441686|PROCEDURE|Stem Cell Mobilization|
219607194|NCT02441686|PROCEDURE|Autologous Stem Cell Transplant|
219607195|NCT02501733|DEVICE|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
218884262|NCT06974487|DRUG|GZR102 injection|Participants will get a single dose of GZR102 injection （fixed-ratio combination of GZR4 and GZR18）.
218884263|NCT06974487|DRUG|GZR4 injection|Participants will get a single dose of GZR4 injection
219028762|NCT02327858|OTHER|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
219028763|NCT00206453|DRUG|Taxotere|Chemotherapy IV
219028764|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
219028765|NCT02761707|OTHER|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
219506198|NCT02208583|DRUG|cisplatin & Etoposide|cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
219607196|NCT04875702|DRUG|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
219607197|NCT04875702|DRUG|Naproxen 250 MG|Naproxen 250 mg p.o. twice daily
219607198|NCT04875702|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg p.o. once daily
218884264|NCT06974487|DRUG|GZR18 injection|Participants will get a single dose of GZR18 injection
218884265|NCT06816524|DIETARY_SUPPLEMENT|Iron syrup|Iron syrup administered daily from 6 to 10 months of age.
218884266|NCT06816524|DIETARY_SUPPLEMENT|Multivitamin syrup|Multivitamin syrup administered daily from 6 to 10 months of age.
218884267|NCT06816524|BIOLOGICAL|R21-Matrix/M Vaccine (malaria vaccine)|R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.
218884268|NCT06816524|BIOLOGICAL|Measles-Rubella vaccine|Measles-Rubella vaccine administered at 9 months of age.
218884269|NCT06800963|BIOLOGICAL|Intravesical Recombinant Mycobacterium (rMBCG)|19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)
218884270|NCT04580693|OTHER|PET Scan|PET scan using a tracer that is under a physician sponsored IND.
219506199|NCT02208583|DRUG|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
218884271|NCT05730972|DEVICE|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
218884272|NCT05730972|DEVICE|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
219506200|NCT01360450|DRUG|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.
219607199|NCT04875702|DRUG|Colchicine 1.2 mg|Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
219607200|NCT04875702|DRUG|Naproxen 500 Mg|dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
218884273|NCT05730972|DRUG|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
219607201|NCT04875702|DRUG|Prednisone 40 mg|For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
219607202|NCT03005743|RADIATION|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines \[Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A\]
219506201|NCT01360450|DRUG|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
218884274|NCT01349764|DRUG|Vitamin D3|
218884275|NCT01561053|BIOLOGICAL|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
218884276|NCT01561053|BIOLOGICAL|Albumin 20%|Low volume plasma exchange with human albumin 5%
218884277|NCT01561053|BIOLOGICAL|Immunoglobulin|Intravenous human immunoglobulin 5%
218884278|NCT03921177|DIETARY_SUPPLEMENT|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
219028766|NCT02761707|OTHER|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
219506202|NCT00209209|DRUG|Rituximab|antibody
218884279|NCT03921177|DRUG|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
218884280|NCT02130505|DIETARY_SUPPLEMENT|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
218884281|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
218884282|NCT05529329|PROCEDURE|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
218884283|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
218884284|NCT03311347|OTHER|+Gz accelerations and positive pressure breathing|
219506203|NCT00209209|DRUG|Cyclophosphamide|chemotherapy
219506204|NCT00209209|DRUG|Doxorubicin|chemotherapy
219506205|NCT00209209|DRUG|Vincristine|chemotherapy
218884285|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
218884286|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
218884287|NCT00428870|PROCEDURE|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
218884288|NCT00351507|DRUG|Vildagliptin|
218884289|NCT04098861|DRUG|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
219506206|NCT00209209|DRUG|Prednisone|coricosteroide
219506207|NCT00209209|DRUG|Fludarabine|chemotherapy
219506208|NCT00209209|DRUG|Interferon-alpha|cytokine
219506209|NCT00209209|DRUG|pegylated formula Interferon-alpha 2b|cytokine
219506210|NCT00209209|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
219506211|NCT00209209|PROCEDURE|chemotherapy: R-FC|immuno-chemotherapy
219506212|NCT00209209|PROCEDURE|Interferon maintenance|cytokine
219607203|NCT03005743|RADIATION|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder \& rectum ICRU point dose constraints
219607204|NCT01326468|DRUG|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
218884290|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
218884291|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
218884292|NCT03784807|DIAGNOSTIC_TEST|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
218884293|NCT02122367|OTHER|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
218884294|NCT06144047|DEVICE|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
219506213|NCT00209209|PROCEDURE|Rituximab maintenance|antibody
218884295|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
218884296|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
219506214|NCT00790374|DRUG|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
219506215|NCT00790374|DRUG|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
219506216|NCT00790374|DRUG|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
218884297|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
218884298|NCT03937414|DEVICE|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
218884299|NCT02353390|OTHER|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
218884300|NCT00964561|DRUG|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
218884301|NCT00964561|DRUG|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
218884302|NCT00964561|OTHER|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
218884303|NCT04780464|DRUG|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
219506217|NCT03717389|OTHER|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
219607205|NCT01326468|DRUG|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
218884304|NCT04780464|DRUG|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
218884305|NCT04780464|DRUG|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
218884306|NCT04780464|DRUG|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
218884307|NCT04780464|DRUG|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
218884308|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
218884309|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
219506218|NCT02115256|DRUG|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
219506219|NCT02115256|DRUG|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
219506220|NCT06424847|BEHAVIORAL|Lifestyle intervention (physical activity and diet)|"The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet."
219607206|NCT01326468|DRUG|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
219607207|NCT01326468|DEVICE|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
219506221|NCT06424847|BEHAVIORAL|Lifestyle (physical activity and diet) and Sleep intervention|"Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits."
219506222|NCT06424847|BEHAVIORAL|Health education intervention|Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
219607208|NCT06372119|PROCEDURE|Letrozole-stimulated cycle strategy|"Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
218884310|NCT03355677|PROCEDURE|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
218884311|NCT03355677|PROCEDURE|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
219506223|NCT03058510|PROCEDURE|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
218884312|NCT03355677|OTHER|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
218884313|NCT02211456|PROCEDURE|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
218884314|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
218884315|NCT04212689|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
219028767|NCT02761707|OTHER|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
219028768|NCT02761707|OTHER|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
219506224|NCT00617435|DIETARY_SUPPLEMENT|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
219028769|NCT03442621|DRUG|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
219028770|NCT03442621|DRUG|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
219028771|NCT03442621|DRUG|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
219028772|NCT03240679|DEVICE|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
219506225|NCT00617435|DIETARY_SUPPLEMENT|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
219506226|NCT00617435|DIETARY_SUPPLEMENT|control diet|Mixed of different oil
219028773|NCT00405587|DRUG|PLX4032|Oral capsules administered BID
218884316|NCT04212689|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
218884317|NCT02461888|DRUG|Ixazomib|Chemotherapy
218884318|NCT02461888|DRUG|Cyclophosphamide|Chemotherapy
219506227|NCT06503042|DRUG|Chemotherapy combined with immunotherapy|Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
219506228|NCT06503042|DRUG|Chemotherapy only|Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
219506229|NCT02393196|DRUG|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
219506230|NCT02393196|DRUG|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
219506231|NCT03495193|OTHER|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
219506232|NCT03495193|BEHAVIORAL|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
219506233|NCT01581983|BEHAVIORAL|Internet Mindfulness Meditation|one hour session each week for six weeks
219506234|NCT01581983|BEHAVIORAL|Individual Mindfulness Meditation|one hour session each week for six weeks
219506235|NCT03561948|PROCEDURE|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
219506236|NCT03561948|PROCEDURE|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
219506237|NCT02185781|OTHER|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
219506238|NCT03775681|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
219506239|NCT03775681|OTHER|Interview|Ancillary studies
219506240|NCT03775681|DEVICE|Laryngeal Mask Airway|Wear LMA
219506241|NCT03151239|DIETARY_SUPPLEMENT|NMN supplement|Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
219506242|NCT03151239|OTHER|Placebo|Intervention will last at least 8 weeks in the form of two capsules.
219506243|NCT01855126|OTHER|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
219506244|NCT01855126|OTHER|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
219506245|NCT06496087|DIETARY_SUPPLEMENT|DEPREXIL|The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
219506246|NCT01063530|DEVICE|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
219506247|NCT01063530|DEVICE|DIstilled water|Application of distilled water in cervical lesions
219506248|NCT06537895|OTHER|EDCRN questionnaires|Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset.
219506249|NCT01149616|DRUG|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
218884319|NCT02461888|DRUG|Dexamethasone|Chemotherapy
218884320|NCT02295605|OTHER|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
218884321|NCT02295605|OTHER|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
219506250|NCT01149616|DRUG|placebo|2 ml normal saline IV x1
219506251|NCT02387814|DRUG|Abemaciclib|Administered Orally
218884322|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
219028774|NCT05061979|DRUG|BAY1747846|Solution for intravenous (IV) injection, single dose
218884323|NCT01520025|RADIATION|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
218884324|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
218884325|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
218884326|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
218884327|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
218884328|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
218884329|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
218884330|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
218884331|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
218884332|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
218884333|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
218884334|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
218884335|NCT02973308|OTHER|Observer|Observer A and observer B
218884336|NCT04199143|DRUG|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
218884337|NCT04199143|DEVICE|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
218884338|NCT04199143|DEVICE|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
218884339|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
219028775|NCT06027866|DEVICE|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
219506252|NCT00900809|BIOLOGICAL|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
219506253|NCT03621085|DRUG|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
218884340|NCT02732431|OTHER|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
218884341|NCT03393949|DRUG|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
218884342|NCT03393949|DRUG|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
218884343|NCT02274740|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
218884344|NCT02274740|DRUG|metformin|Pharmaceutical form:tablet Route of administration: oral
219028776|NCT03721341|RADIATION|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
219028777|NCT03721341|DRUG|Chemotherapy|Chemotherapy may be given as indicated.
219506254|NCT03621085|OTHER|Placebo|Subjects will receive placebo
218884345|NCT01620762|DRUG|Cat-PAD|1 dose every 4 weeks
218884346|NCT01620762|DRUG|Placebo|1 dose every 4 weeks
218884347|NCT01298271|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
218884348|NCT02836431|DRUG|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
219028778|NCT03721341|DRUG|Immunotherapy|Immunotherapy may be given as indicated.
219028779|NCT03721341|DRUG|Hormones|Hormones may be given as indicated.
219506255|NCT06410937|PROCEDURE|thyroidectomy without drain|thyroidectomy without subcutaneous suction drain
218884349|NCT02836431|DRUG|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
219506256|NCT06410937|PROCEDURE|thyroidectomy with drain|hyroidectomy with subcutaneous suction drain
219506257|NCT05608590|DRUG|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
219506258|NCT05585502|OTHER|Training (minute oscillation stretching)|The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
219506259|NCT05351385|PROCEDURE|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
219506260|NCT05351385|PROCEDURE|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
219506261|NCT05351385|PROCEDURE|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
219506262|NCT05351385|PROCEDURE|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
218884350|NCT02836431|DRUG|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
218884351|NCT03521479|DRUG|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
218884352|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
218884353|NCT00057408|DRUG|Placebo|Matching Placebo
218884354|NCT00705146|DEVICE|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
218884355|NCT00705146|DEVICE|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
218884356|NCT02910102|DRUG|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
218884357|NCT02910102|DRUG|Placebo|Placebo once daily, oral
218884358|NCT00095173|DRUG|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
219028780|NCT03721341|OTHER|Observation|Observation only is acceptable if this is the standard practice.
219506263|NCT05351385|PROCEDURE|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
219506264|NCT05351385|PROCEDURE|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
219506265|NCT05491564|DEVICE|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
219506266|NCT02086656|DRUG|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
218884359|NCT00095173|DRUG|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
219506267|NCT01512979|DRUG|metformin|1000 mg to 2000 mg per day
219506268|NCT01512979|DRUG|linagliptin|5 mg daily
219506269|NCT01512979|DRUG|metformin placebo|0 to 2 tablets daily
218884360|NCT00095173|DRUG|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
218884361|NCT04585607|DEVICE|A medium cut-off dialyzer (Theranova) will be used for HDx.|"A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)"
218884362|NCT04585607|DEVICE|A synthetic high-flux dialyzer (Polyflux)|A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
218884363|NCT02658773|DRUG|lidocaine-Prilocaine cream|
218884364|NCT02658773|DRUG|placebo cream|
218884365|NCT06300268|DEVICE|AdvaPro Sirolimus Eluting Coronary Stent System|Cardiac Stent
219028781|NCT03721341|RADIATION|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
219028782|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia. Patients in this group will also receive a sham ILAI procedure with 60 mL of saline (performed by the operating surgeon).
219028783|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
219028784|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
219028785|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
219506270|NCT01512979|DRUG|metformin placebo|4 tablets daily
219506271|NCT05363124|OTHER|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
218884366|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
218884367|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
218884368|NCT03777319|DRUG|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
218884369|NCT03777319|DRUG|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
218884370|NCT04672122|DEVICE|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
218884371|NCT03659877|BEHAVIORAL|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
218884372|NCT01745042|OTHER|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
218884373|NCT00328861|DRUG|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
218884374|NCT00328861|BIOLOGICAL|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
218884375|NCT00328861|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
219028786|NCT01906710|OTHER|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
219028787|NCT00507442|DRUG|VELCADE (bortezomib)|bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
219028788|NCT00507442|DRUG|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
219028789|NCT00507442|DRUG|cyclophosphamide|cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
219028790|NCT00507442|DRUG|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
219028791|NCT05434260|DEVICE|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
219028792|NCT05434260|DEVICE|Sterile saline|Use of sterile saline as a irrigation solution during surgery
218884376|NCT00328861|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
218884377|NCT04897178|DIAGNOSTIC_TEST|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
218884378|NCT02089126|DRUG|Gemigliptin/Glimepiride combination|
218884379|NCT00897221|DRUG|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
218884380|NCT00897221|DRUG|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
218884381|NCT03406117|DRUG|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
218884382|NCT03406117|OTHER|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
218884383|NCT00315016|DRUG|eplerenone|active comparator
218884384|NCT00315016|DRUG|fosinopril|doubling of fosinopril dose
219028793|NCT02806310|OTHER|Blood draw|blood sampling for biomarker levels
219028794|NCT01839552|DRUG|Fentanyl Citrate Nasal Spray (FCNS)|
219028795|NCT03959085|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219028796|NCT03959085|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219028797|NCT03959085|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219028798|NCT03959085|PROCEDURE|Bone Scan|Undergo bone scan
219028799|NCT03959085|DRUG|Calaspargase Pegol|Given IV
219028800|NCT03959085|PROCEDURE|Computed Tomography|Undergo CT
219028801|NCT03959085|DRUG|Cyclophosphamide|Given IV
219028802|NCT03959085|DRUG|Cytarabine|Given IV, IT, or SC
219028803|NCT03959085|DRUG|Daunorubicin Hydrochloride|Given IV
219028804|NCT03959085|DRUG|Dexamethasone|Given PO or IV
219028805|NCT03959085|DRUG|Doxorubicin Hydrochloride|Given IV
219028806|NCT03959085|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219028807|NCT03959085|DRUG|Leucovorin Calcium|Given PO or IV
219028808|NCT03959085|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218884385|NCT00315016|DRUG|placebo|placebo (double dummy)
218884386|NCT02286232|BEHAVIORAL|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
219201215|NCT06742606|BIOLOGICAL|Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab|"All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment~• response to treatment Frequency of relapses,~Regular assessment will be:~Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems:~pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index~Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by:~Disease activity:~Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing."
218884387|NCT02286232|BEHAVIORAL|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
218884388|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
218884389|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
218884390|NCT04698993|DIAGNOSTIC_TEST|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
218884391|NCT02578186|DRUG|Diphenhydramine Hydrochloride|30 mL at bedtime
218884392|NCT02578186|DRUG|Placebo|30 mL at bedtime
218884393|NCT04487925|DRUG|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
218884394|NCT04487925|DRUG|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
218884395|NCT00527904|DRUG|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
218884396|NCT00527904|DRUG|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
218884397|NCT03323801|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
218884398|NCT06514404|OTHER|observational study|Observational study of the effects on anxiety and empathy of personality the situation of start academic year in health sciences
218884399|NCT06191172|BEHAVIORAL|Reminiscence Therapy|Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.
218884400|NCT06191172|BEHAVIORAL|Montessori application|Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop
219028809|NCT03959085|DRUG|Mercaptopurine|Given PO
219028810|NCT03959085|DRUG|Methotrexate|Given IT or IV
218884401|NCT06191172|BEHAVIORAL|Environmental Layout|Dining place Music Lighting Heat
218884402|NCT06191172|BEHAVIORAL|Application of contrast ergonomic special equipment|White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
218884403|NCT00514371|DRUG|tanespimycin|High dose
218884404|NCT00514371|DRUG|Bortezomib|Mid dose, and low dose
218884405|NCT01122615|DRUG|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
218884406|NCT01122615|DRUG|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
219028811|NCT03959085|DRUG|Pegaspargase|Given IV or IM
219028812|NCT03959085|PROCEDURE|Positron Emission Tomography|Undergo PET
219028813|NCT03959085|DRUG|Prednisolone|Given PO or IV
219028814|NCT03959085|OTHER|Questionnaire Administration|Ancillary studies
219028815|NCT03959085|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
219028816|NCT03959085|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
219028817|NCT03959085|DRUG|Thioguanine|Given PO
219028818|NCT03959085|DRUG|Vincristine Sulfate|Given IV
219028819|NCT00048607|DRUG|aprepitant|
219028820|NCT00048607|DRUG|Comparator: paroxetine HCL|
219028821|NCT00048607|DRUG|Comparator: Placebo (Unspecified)|
219028822|NCT05442554|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion.
219028823|NCT04061811|DIAGNOSTIC_TEST|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
218884407|NCT03728179|COMBINATION_PRODUCT|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
218884408|NCT05889637|DIAGNOSTIC_TEST|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
218884409|NCT01154426|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219028824|NCT01569958|OTHER|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
219028825|NCT01569958|OTHER|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
219506272|NCT05363124|OTHER|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
219506273|NCT04967716|OTHER|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
219607209|NCT06372119|PROCEDURE|Artificial cycle strategy|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
219607210|NCT05565638|BEHAVIORAL|Prolonged Fasting Intervention|promote a 14-hour fast during the nighttime hours
218884410|NCT01154426|DRUG|Gemcitabine Hydrochloride|Given IV
218884411|NCT01154426|OTHER|Pharmacological Study|Correlative studies
219028826|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
219028827|NCT04548596|DIAGNOSTIC_TEST|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
219028828|NCT05947682|OTHER|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
219028829|NCT01761214|DRUG|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
219028830|NCT01761214|DRUG|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
219607211|NCT05565638|BEHAVIORAL|EDUCATION CONTROL|introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
219607212|NCT06488911|DRUG|FDC tablet (OCA 5 mg + BZF 400 mg SR)|Participants will be administered with FDC tablets once daily.
219607213|NCT01137994|DRUG|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
218884412|NCT01154426|DRUG|Veliparib|Given orally
218884413|NCT00005824|BIOLOGICAL|filgrastim|
218884414|NCT00005824|DRUG|busulfan|
219028831|NCT04266197|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)|RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
219028832|NCT06799416|BIOLOGICAL|ARGX-109|administrations of ARGX-109
219028833|NCT06799416|OTHER|Placebo|administrations of placebo comparator
219028834|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
219028835|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
219028836|NCT03011814|DRUG|Lenalidomide|Given PO
219028837|NCT05533931|OTHER|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
219506274|NCT04967716|OTHER|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
218884415|NCT00005824|DRUG|cyclophosphamide|
218884416|NCT00005824|PROCEDURE|peripheral blood stem cell transplantation|
218884417|NCT05284344|DRUG|Anti-Diabetics|The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
218884418|NCT00428389|DRUG|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
218884419|NCT00428389|DRUG|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
218884420|NCT04582955|DRUG|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
218884421|NCT02337881|DRUG|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
219028838|NCT05533931|OTHER|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
219028839|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
219028840|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
219028841|NCT03605797|OTHER|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
219028842|NCT05820932|GENETIC|Blood-based assay|Blood samples will be collected
219028843|NCT05820932|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessments will be both participant- and partner-reported
219028844|NCT05820932|OTHER|Quality of Life Surveys|Participant-reported Quality of Life Surveys
219028845|NCT02296385|DIETARY_SUPPLEMENT|Triple Strength Fish Oil|Triple Strength Fish Oil
218884422|NCT02337881|DRUG|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
219028846|NCT06046729|DRUG|Eltrekibart|Administered SC
219028847|NCT06046729|DRUG|Placebo|Administered SC
219028848|NCT05400928|DEVICE|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
219028849|NCT04380610|DIAGNOSTIC_TEST|iohexol GFR|We will perform mGFR in 400 SCA patients
219028850|NCT04583891|BEHAVIORAL|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
218884423|NCT01500668|DRUG|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
218884424|NCT01500668|DRUG|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
218884425|NCT02012660|OTHER|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
219028851|NCT04583891|BEHAVIORAL|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
219028852|NCT04583891|BEHAVIORAL|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
219028853|NCT06325150|DEVICE|Light emitting glasses|Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
219028854|NCT04251026|DRUG|tividenofusp alfa|Intravenous repeating dose
219028855|NCT04098354|DIAGNOSTIC_TEST|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
219028856|NCT02097355|OTHER|TriVox for clinical care|Use TriVox disease modules to manage patients
219506275|NCT01657487|DRUG|Fluticasone/Salmeterol high dose|
219506276|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
218884426|NCT05864937|OTHER|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
218884427|NCT04687371|OTHER|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
218884428|NCT04687371|OTHER|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
218884429|NCT04687371|OTHER|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
218884430|NCT01306383|OTHER|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
218884431|NCT06137651|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218884432|NCT06137651|PROCEDURE|Computed Tomography|Undergo CT scan
219028857|NCT05207995|BIOLOGICAL|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
219028858|NCT05207995|OTHER|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
219028859|NCT05811442|DRUG|50561 high dose|study drug
219028860|NCT05811442|DRUG|50561 low dose|study drug
219028861|NCT05811442|DRUG|Placebo|Non-active study drug
219028862|NCT05603273|BEHAVIORAL|non-weight bearing exercise|exercise on a non-weight bearing device at 50% of peak capacity, 3 days per week for 6 weeks
219028863|NCT05172544|BIOLOGICAL|HydroVax-002 YFV|Inactivated YFV vaccine
219028864|NCT05172544|OTHER|Placebo|NaCl 0.9%, Normal Saline
219201216|NCT06741852|PROCEDURE|nCLE assisted endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|Patients received 2.5mL of 10% Fluorescite intravenously during nCLE. The CLE probe was preloaded into a puncture dilation catheter and locked into position with 2mm being exposed beyond the tip. puncture dilation catheter. The lymph node was punctured and the needle positioned at its center. The probe was advanced and locked, and the needle was advanced to the contralateral edge of the lymph node. Image acquisition began at the lymph node capsule, and then the subcapsular region, followed by the cortical sinus. When the image showed granuloma or malignant characteristics, the location will be recorded in EBUS, and retract the CLE probe, leaving the sheath of puncture dilation catheter as a tunnel between airway wall and target lymph node. Then, a 1.1-mm cryoprobe was inserted into the target lymph node through this tunnel under the EBUS guidance. The probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue.
219201217|NCT06741852|PROCEDURE|Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Broncus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
219201218|NCT06133231|DIETARY_SUPPLEMENT|Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
219028865|NCT04090567|DRUG|Cediranib|Given PO
219201219|NCT06743451|OTHER|Health workers training on GMP guideline|One day training will be conducted to health workers on updated GMP guideline for the health workers primarily engaged in Growth monitoring and promotion of the children.
219201220|NCT06743451|OTHER|Female community health volunteers' mobilization for inviting mothers and caretakers|Female community health volunteers will be mobilized for inviting mothers and caretakers for two consecutive months for enhancing GMP practices in the municipality
219201221|NCT06743945|DRUG|POLA-R-CHP|Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
219607214|NCT01137994|BIOLOGICAL|Trastuzumab|monoclonal antibody directed to HER2 receptor
219607215|NCT01137994|DRUG|Docetaxel|Taxane chemotherapy
219607216|NCT01137994|DRUG|Paclitaxel|Taxane chemotherapy
219607217|NCT01137994|DRUG|Vinorelbine|Vinka alkaloid
219607218|NCT05272423|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
219028866|NCT04090567|DRUG|Ceralasertib|Given PO
219607219|NCT03735004|DEVICE|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
219607220|NCT03151304|DRUG|Pracinostat|45 mg capsule
219607221|NCT03151304|DRUG|Azacitidine|SC or IV injection
219028867|NCT04090567|DRUG|Olaparib|Given PO
219028868|NCT04716387|OTHER|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
219028869|NCT04716387|OTHER|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
219028870|NCT04716387|OTHER|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
219028871|NCT04716387|OTHER|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
219028872|NCT05224973|BEHAVIORAL|speech therapy|speech therapy during 2 months
219028873|NCT06533332|DRUG|ERX-315|Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
218884433|NCT06137651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219506277|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
219506278|NCT03266549|PROCEDURE|botulinum toxin augmented surgery|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
218884434|NCT06137651|RADIATION|Radiation Therapy|Undergo radiation therapy
218884435|NCT06137651|PROCEDURE|Resection|Undergo surgery
218884436|NCT06137651|DRUG|Trotabresib|Given PO
218884437|NCT06137651|DRUG|Vinorelbine|Given IV
218884438|NCT01574885|DEVICE|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
218884439|NCT01574885|DEVICE|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
218884440|NCT03067623|DRUG|PRP|PRP intrauterine infusion
218884441|NCT03067623|DEVICE|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
218884442|NCT03546114|OTHER|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
218884443|NCT04870372|DRUG|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
218884444|NCT02302872|DEVICE|ARTO System|
219028874|NCT06966258|BEHAVIORAL|Inspire HER Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
219028875|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219028876|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219028877|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219201222|NCT06744231|OTHER|Usual Care|Prior to implementation of the Thriving Hearts package of services, people living in participating counties will receive usual care for pregnancy, birth, and postpartum services. The study team will quantify existing services using a study-developed usual care assessment instrument.
219506279|NCT03266549|PROCEDURE|conventional surgery|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia. The standard correction tables will be used as a guide for the amount of muscle recession and, or resection.
219506280|NCT05497011|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
218884445|NCT02356289|DRUG|Placebo|
218884446|NCT02356289|DRUG|MYK-461|
218884447|NCT03062111|PROCEDURE|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
219506281|NCT05547893|OTHER|simulation|participating a simulated clinical ethical situation with simulation patients
218884448|NCT03062111|PROCEDURE|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
218884449|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
218884450|NCT02708355|DRUG|Placebo|Placebo capsules
219028878|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219028879|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219506282|NCT03031522|RADIATION|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
219506283|NCT05250349|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography with standard measurements
219506284|NCT05250349|DIAGNOSTIC_TEST|Doppler sonography|Transcarotid and transcranial Doppler sonography
219607222|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Low Dose|
219607223|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Medium dose|
219607224|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) High dose|
219607225|NCT01123915|OTHER|Dimethyl Sulfoxide|
218884451|NCT03052595|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
218884452|NCT03052595|DIAGNOSTIC_TEST|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
218884453|NCT03052595|DIAGNOSTIC_TEST|Stroop test|Stroop test will be used to test cognitive function
219506285|NCT05250349|DIAGNOSTIC_TEST|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
219506286|NCT04413747|BEHAVIORAL|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
218884454|NCT01320202|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
219506287|NCT04413747|BEHAVIORAL|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
219506288|NCT04413747|BEHAVIORAL|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
219506289|NCT03776409|DRUG|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
219506290|NCT03776409|DRUG|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
219506291|NCT03799887|BEHAVIORAL|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
219506292|NCT03799887|BEHAVIORAL|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
219506293|NCT03799887|BEHAVIORAL|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
218884455|NCT01320202|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
218884456|NCT00635882|DRUG|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
219028880|NCT00362115|DRUG|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
219506294|NCT04082975|DRUG|NVP-1203|Oral dose for 7 days
219506295|NCT04082975|DRUG|NVP-1203-R|Oral dose for 7 days
219506296|NCT04082975|DRUG|NVP-1203 placebo|Oral dose for 7 days
218884457|NCT00635882|DRUG|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
218884458|NCT00635882|DRUG|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
218884459|NCT00635882|DRUG|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
218884460|NCT00635882|DRUG|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
218884461|NCT00635882|DRUG|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
218884462|NCT01440205|BEHAVIORAL|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
218884463|NCT01440205|BEHAVIORAL|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
218884464|NCT01440205|BEHAVIORAL|Control|No check box element
218884465|NCT06526065|OTHER|no intervention|no intervention
219028881|NCT00362115|DRUG|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
219028882|NCT01001611|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
219028883|NCT01001611|DRUG|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
219028884|NCT06473259|DRUG|Docetaxel|6 courses of docetaxel 75 mg/sqm iv
219506297|NCT04082975|DRUG|NVP-1203-R placebo|Oral dose for 7 days
219607226|NCT06319027|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
219607227|NCT06319027|OTHER|Fluciclovine F18|Given IV
219028885|NCT06473259|DRUG|Apalutamide Oral Tablet|240 mg /daily orally
219028886|NCT06473259|DRUG|Enzalutamide Oral Tablet|600 mg /daily orally
219028887|NCT06473259|DRUG|Abiraterone acetate tablets|1000 mg /daily orally
219028888|NCT06473259|DRUG|Darolutamide Oral Tablet|600 mg/daily orally
219028889|NCT06473259|RADIATION|radiotherapy|radical radiotherapy on primary tumor
219028890|NCT06473259|DRUG|Triptorelin|3,75 mg im/4 w
219028891|NCT01741181|DRUG|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
219506298|NCT02161952|DRUG|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
219506299|NCT02161952|DRUG|Matched equivalent placebo|
219364504|NCT03045003|BEHAVIORAL|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
219506300|NCT04841278|DEVICE|EUS/ERCP|EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
219506301|NCT00050895|DRUG|Lopinavir/ritonavir|
218884466|NCT00665548|RADIATION|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
218884467|NCT03515564|BEHAVIORAL|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
218884468|NCT04202887|DRUG|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
218884469|NCT04202887|DRUG|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
218884470|NCT04202887|DEVICE|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
218884471|NCT05526287|OTHER|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
219506302|NCT00050895|DRUG|Efavirenz|
219506303|NCT00050895|DRUG|Stavudine|
219506304|NCT00050895|DRUG|Zidovudine|
219506305|NCT00050895|DRUG|Lamivudine|
219506306|NCT00050895|DRUG|Tenofovir disoproxil fumarate|
219506307|NCT03475732|DRUG|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
219506308|NCT04185831|DRUG|Atezolizumab|PD-L1 inhibitor
219506309|NCT04185831|DRUG|Everolimus|MTOR inhibitor
219607228|NCT06319027|DRUG|Gadolinium-Chelate|Receive gadolinium-based contrast agent
219607229|NCT06319027|PROCEDURE|Magnetic Resonance Spectroscopy|Undergo MR spectroscopy
219607230|NCT06319027|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219607231|NCT01721304|OTHER|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
219607232|NCT03796052|OTHER|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
218884472|NCT05526287|OTHER|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
218884473|NCT05188131|DRUG|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
219028892|NCT01741181|DRUG|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
219028893|NCT06335381|OTHER|Northwell Pregnancy & Peds Chats|The Northwell Pregnancy \& Peds Chats is a personalized care digital chatbot delivered via the Conversa platform. At Northwell, patients are enrolled automatically to receive the chats when they initiate prenatal care. Chats are accessible on a smartphone, tablet, and computer. During the prenatal and postpartum periods, participants receive a weekly chat via text message or email with a link to the platform. Each chat begins with asking if there are any updates the patient wants to share regarding their pregnancy. The chats provide timely, brief educational tools and resources. They are also designed to capture clinical, behavioral health, and social health concerns that triggers yellow flags (e.g., lack of transportation to obstetrics appointment) or red flags (e.g., elevated blood pressure) that go to a 24/7 nurse-led call center who follows up to connect the participant to clinical, behavioral health, or social services as needed.
219506310|NCT04185831|DRUG|Cobimetinib|MEK inhibitor
219506311|NCT04185831|DRUG|Niraparib|PARP inhibitor
219506312|NCT01893151|DRUG|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
219506313|NCT01893151|DRUG|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
219607233|NCT06115083|OTHER|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
219607234|NCT03519087|OTHER|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
219607235|NCT03519087|OTHER|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
219607236|NCT03519087|OTHER|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
219607237|NCT03694899|BEHAVIORAL|phone contact|patients will be called prior to their outpatient appointment
219607238|NCT04529837|OTHER|Gauze|placement of gauze
219607239|NCT04529837|OTHER|No gauze|no gauze
218884474|NCT05188131|DRUG|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
218884475|NCT01340573|DRUG|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
218884476|NCT01340573|DRUG|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
218884477|NCT05836467|PROCEDURE|Valvular interventions|Any kind of intervention on heart valves
218884478|NCT03191045|DIAGNOSTIC_TEST|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
218884479|NCT05681494|PROCEDURE|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
219028894|NCT06335381|BEHAVIORAL|Prenatal Telehealth Visits|The MOMs CMC/RN (interventionists) will deliver up to 12 bi-weekly self-management support telehealth visits during the prenatal period. The first telehealth visit will be 30-45 minutes in duration and follow-up visits will be 15-20 minutes. These telehealth visits will involve clinical and behavioral health check-ins; navigation to clinical, behavioral health, and social services as needed; screening for social needs during the initial telehealth visit; follow-up on referrals to resources to address social needs; and self-management support. MOMs CMCs/RNs will assess progress with engagement in self-management behaviors including asking about minutes and type of physical activity, self-monitoring (blood pressure, blood sugar, weight), and taking medications. The MOMs CMC/RN will provide brief maternal health education and support the participant in establishing behavior change goals and facilitating problem solving to address barriers to achieving goals each session.
219364505|NCT02863848|DIETARY_SUPPLEMENT|OraftiR inulin-type fructans|
218884480|NCT05681494|PROCEDURE|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
218884481|NCT05439538|DIAGNOSTIC_TEST|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
219364506|NCT02863848|DIETARY_SUPPLEMENT|Placebo|maltodextrin
218884482|NCT04941846|DRUG|nimodipine and euvolemia|administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration
218884483|NCT04331002|DRUG|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
218884484|NCT04331002|OTHER|Placebo|5 mL normal saline
218884485|NCT03332446|OTHER|cold water immersion|10 min at 12-15°C
219364507|NCT05424393|DRUG|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
219364508|NCT05424393|DRUG|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
219364509|NCT04584177|BEHAVIORAL|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
219364510|NCT04584177|BEHAVIORAL|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
219364511|NCT00425490|DRUG|sitagliptin|
219364512|NCT02247869|DRUG|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
219364513|NCT05997277|DRUG|Deucravacitinib|Deucravacitinib is a stable deuterium-containing compound (where deuterium is a stable, nonradioactive isotope of hydrogen) and a potent, highly selective small molecule inhibitor of TYK2. Deucravacitinib has a unique mode of binding that provides the high selectivity over the other members of the JAK family of nonreceptor tyrosine kinases. 1 active oral tablet (6mg) in the morning and evening for 16weeks.
219607240|NCT02290457|BEHAVIORAL|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
219607241|NCT01137071|BIOLOGICAL|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
219607242|NCT06325605|DRUG|Bifidobacterium|3 capsules, 3 times a day, for 8 consecutive weeks
219028895|NCT06335381|OTHER|Postpartum Telehealth Visits|The MOMs CMC/RN will conduct a telehealth visit (with navigation as needed) by phone 24 and 72 hours after labor and delivery. After the 72-hour call, telehealth visits with navigation will occur bi-weekly until 6 weeks postpartum. These telehealth visits will be 15-20 minutes in duration. Telehealth visits will include a brief clinical and behavioral health check-in, screening for social needs, navigation to clinical, behavioral health, and social services as needed, and follow-up on referrals to community resources and social services. During each visit, participants will be asked if they have experienced any signs or symptoms of concern (e.g., pain, discomfort, headaches, bleeding), screened for depression and anxiety, and be reminded about upcoming medical appointments. The CMC or RN will navigate the participant to the appropriate provider (e.g., OB, cardiologist, behavioral health) or services (e.g., emergency, social, community-based resources) as needed in a timely manner.
219607243|NCT06325605|DEVICE|High-frequency rTMS|"In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
218884486|NCT02999412|PROCEDURE|Comprehensive medication review|"* A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
218884487|NCT02999412|PROCEDURE|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
219028896|NCT06335381|OTHER|Home Blood Pressure Monitor|Participants will receive an Omron 10 home blood pressure monitor to use throughout the study period. Along with the cuff, participants will receive written (postcard) and video instructions (https://youtu.be/p9UEDv6nvwU) on how to accurately measure their blood pressure. Participants with diagnosed chronic hypertension or preeclampsia during the prenatal period will be encouraged to measure their blood pressure twice a day; participants without these conditions will be encouraged to measure their blood pressure twice a week. During the postpartum period, participants will be encouraged to follow their provider recommendations in terms of how often they should measure their blood pressure. Participants will be allowed to keep the blood pressure monitor after the study has completed.
219028897|NCT06335381|OTHER|Fitbit|Participants will receive a Fitbit to use during the study period. Participants will be asked to wear the Fitbit on their wrist throughout the day to track all activity (e.g., walking, other physical activity, sedentary activity, and sleep). All data including minutes of activity and step counts will be stored on a secure web-based platform that aggregates data from the Fitbit device. Participants will be encouraged to sync their Fitbit device every 5 days with their phone to ensure data is up to date. Participants will be allowed to keep the Fitbit after the study has completed.
219028898|NCT04078685|PROCEDURE|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
219028899|NCT04078685|PROCEDURE|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
219028900|NCT06851559|DRUG|Vonoprazan|Vonoprazan will be administered orally as a tablet
219028901|NCT06851559|DRUG|Placebo|Placebo will be administered orally as tablet
219028902|NCT06368817|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219028903|NCT06368817|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219028904|NCT06368817|DRUG|Carboplatin|Given IV
219028905|NCT06368817|DRUG|Etoposide|Given IV
219201223|NCT06744231|BEHAVIORAL|Thriving Hearts|"Thriving Hearts is a collaboration among LHDs in ten North Carolina counties. At the individual level, pregnant individuals will self-screen for HDP risk during prenatal visits, and those at risk will be provided a Mama Hearts Care Kit, including a home blood pressure monitor, low dose aspirin, and culturally tailored educational materials.~At the healthcare provider level, burnout and compassion fatigue will be addressed through skill-building activities, including training in the Community Resilience and Mindfulness-Based Stress Reduction.~At the community level, Loving Connection will provide proactive material and social support through Community Health Workers, text messaging-based communication, a medical legal partnership, and capacity-building support for community-based organizations."
219201224|NCT06736678|DIETARY_SUPPLEMENT|Oral Immunonutrition|Patients receive enteral immunonutrition, Oral Impact® Nestle for 6 weeks from one week before radiotherapy;
218884488|NCT02999412|PROCEDURE|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
218884489|NCT01616368|BEHAVIORAL|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
218884490|NCT05567926|DIETARY_SUPPLEMENT|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
218884491|NCT05567926|DIETARY_SUPPLEMENT|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
218884492|NCT00627133|DRUG|levetiracetam|2 gram iv load, 500mg bid
219028906|NCT06368817|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219028907|NCT06368817|PROCEDURE|Lumbar Puncture|Undergo LP
219028908|NCT06368817|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219506314|NCT05529719|OTHER|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
219506315|NCT04633759|OTHER|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
219506316|NCT00162786|DRUG|Rupatadine|
219506317|NCT00162786|DRUG|Hydroxyzine|
219506318|NCT00162786|DRUG|Placebo|
219506319|NCT01488266|DRUG|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
219506320|NCT01488266|DRUG|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
219028909|NCT06368817|OTHER|Questionnaire Administration|Ancillary studies
219506321|NCT00961051|DEVICE|Investigational MPS|Multi-purpose solution
219028910|NCT06368817|PROCEDURE|Surgical Procedure|Undergo second-look surgery
219028911|NCT05109728|DRUG|[177Lu]Lu-DOTA-TATE|"Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
219028912|NCT05109728|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
219028913|NCT05109728|OTHER|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
219028914|NCT05109728|OTHER|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
218884493|NCT02371408|DRUG|ravidasvir hydrochloride|200 mg
218884494|NCT02371408|DRUG|sofosbuvir|400 mg
218884495|NCT02371408|DRUG|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
218884496|NCT05641922|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
218884497|NCT01500486|DEVICE|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
218884498|NCT01960517|DEVICE|ACS Catheter|
218884499|NCT02741206|BEHAVIORAL|Bellevue ROSE Intervention|
219028915|NCT06363851|DRUG|Kylo-11|Administered SC.
219028916|NCT06363851|DRUG|Placebo|Administered SC.
218884500|NCT02741206|BEHAVIORAL|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
219028917|NCT06971289|OTHER|blood test|blood test as part of routine care
219028918|NCT06971146|OTHER|Nurse-Led Self-Management Support|"The intervention offers four distinct support options. Patients are free to choose the option that best suits their preferences and needs.~I1: App-Based Monitoring - Patients receive an app that provides relevant health information, including short educational videos, images, and other resources. Every three months, the app sends a pop-up reminder.~I2: Reminder by Letter - Patients receive a friendly reminder every three months via e-Boks or postal mail (for those without e-Boks access) encouraging continued treatment adherence.~I3: SMS Reminder - Patients receive a text message every three months to remind them to continue their treatment.~I4: Phone Call Check-In - A nurse contacts the patient by phone three times per year at scheduled intervals to provide support and ensure they remain on track with their treatment."
218884501|NCT02741206|BEHAVIORAL|One Psycho-education session and usual, standard of care Control|
219028919|NCT06971146|OTHER|GP-follow up|Patients in the control group will be discharged from the hospital and continue with routine care provided by their general practitioner (GP). The GP will receive a discharge letter outlining the recommended treatment plan. In addition, patients will receive a letter containing key information about their condition, along with a recommendation to consult their GP annually for ongoing disease monitoring.
219028920|NCT03803774|PROCEDURE|Biopsy Procedure|Undergo biopsy
219028921|NCT03803774|DRUG|Birinapant|Given IV
219364514|NCT05997277|DRUG|Placebo|Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
218884502|NCT01925248|DIETARY_SUPPLEMENT|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
218884503|NCT01925248|DIETARY_SUPPLEMENT|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
218884504|NCT02080299|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
218884505|NCT02080299|PROCEDURE|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
218884506|NCT03287427|DRUG|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
219364515|NCT03790943|DIAGNOSTIC_TEST|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
219364516|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
219364517|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
219364518|NCT01072409|DEVICE|Nucleus 5 Cochlear implant|Cochlear implant surgery
219364519|NCT01072409|DEVICE|Cochlear implantation|Implantation
219364520|NCT05464745|DRUG|PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
219364521|NCT05464745|DRUG|Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
219364522|NCT05030727|DIAGNOSTIC_TEST|record of pNGAL|Preoperative (0.hour baseline), postoperative 24.,48. BUN, Creatinine, Lactate values in the blood of the patients at 1 hour, and for plasma NGAL, blood samples will be taken at the preoperative, postoperative 6th and 24th hours. And the results will be recorded.
219364523|NCT03588741|DRUG|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
219364524|NCT05892887|DRUG|Bupivacaine 0.25% Injectable Solution|Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
219364525|NCT04547257|DEVICE|Seraph 100|Bloodfiltration with Seraph 100
219364526|NCT04148092|DRUG|ripretinib|orally administered solid dosage form
219364527|NCT06496672|PROCEDURE|Modified long arm cast|A shorter cast that frees the wrist
219364528|NCT06496672|PROCEDURE|Traditional long arm cast|Current standard of care where the cast extends up to the palmar bar
219364529|NCT03416283|BEHAVIORAL|Remote Monitoring|Remote BP monitoring and medication adherence
219364530|NCT03416283|BEHAVIORAL|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
219364531|NCT04364204|OTHER|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
219364532|NCT04364204|OTHER|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
219364533|NCT02410694|DRUG|Ixazomib|
219364534|NCT02410694|DRUG|Thalidomide|
219364535|NCT02410694|DRUG|Dexamethasone|
219364536|NCT03239431|OTHER|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
219364537|NCT00263263|DEVICE|sirolimus-eluting stent|
219364538|NCT00263263|DEVICE|bare metal stent|
219364539|NCT02374866|OTHER|closer monitoring|
219506322|NCT00961051|DEVICE|Opti-Free|Multi-purpose solution
219028922|NCT03803774|PROCEDURE|Computed Tomography|Undergo CT scan
219506323|NCT02746159|DEVICE|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
219506324|NCT05448703|OTHER|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
219506325|NCT04605952|DIAGNOSTIC_TEST|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
219506326|NCT03944785|DRUG|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
219506327|NCT01357356|DRUG|SER120 (750 ng/day)|
219607244|NCT06325605|DRUG|Escitalopram Oxalate|Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
219607245|NCT06215235|OTHER|Bright light therapy|for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.
219607246|NCT02057887|DRUG|HM10660A|
219607247|NCT02057887|DRUG|Pegasys|180 mcg Pegasys SC once weekly
218884507|NCT03287427|DRUG|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
218884508|NCT01454765|OTHER|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
218884509|NCT00147316|DRUG|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
218884510|NCT00082199|DRUG|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
218884511|NCT00082199|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks.
218884512|NCT05620264|DIAGNOSTIC_TEST|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
218884513|NCT02112864|DRUG|Dexamethasone|10 mg (2.5 ml)
218884514|NCT02112864|DRUG|Normal Saline|2.5 mL normal saline
218884515|NCT03504631|OTHER|No intervention|no intervention
219028923|NCT03803774|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRRT
219506328|NCT01357356|DRUG|SER120 (1000 ng/day)|SER120 (1000 ng/day)
219506329|NCT01357356|DRUG|SER120 (1500 ng/day)|
219506330|NCT01357356|DRUG|Placebo|
219506331|NCT01363609|DRUG|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
219506332|NCT01363609|DRUG|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
219607248|NCT04805515|BEHAVIORAL|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
219607249|NCT01960309|OTHER|Minimal invasive cardiac imaging|"* Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography"
218884516|NCT00538070|DIETARY_SUPPLEMENT|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
218884517|NCT03370666|OTHER|HFNT|High flow nasal therapy
218884518|NCT03370666|OTHER|NIV|Noninvasive ventilation
218884519|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
218884520|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
218884521|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
218884522|NCT01540669|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
218884523|NCT04410406|DRUG|Ivermectin|Ivermectin (IVM) 200 µg/kg
219028924|NCT03803774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219028925|NCT03803774|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219028926|NCT06531824|DRUG|BI 690517|BI 690517
219028927|NCT06531824|DRUG|Placebo matching BI 690517|Placebo matching BI 690517
219028928|NCT06531824|DRUG|Empagliflozin|Empagliflozin
219028929|NCT02558712|OTHER|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
219506333|NCT01363609|DRUG|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
219607250|NCT03491657|BEHAVIORAL|virtual reality distraction (Yes VR)|
219607251|NCT03491657|BEHAVIORAL|music distraction (No VR)|
219607252|NCT03080870|OTHER|Art|Multicomponent art intervention
218884524|NCT04410406|DRUG|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
218884525|NCT04410406|DRUG|Albendazole|Albendazole (ABZ) 400 mg
218884526|NCT04410406|DRUG|Moxidectin|Moxidectin (Mox) 8 mg
218884527|NCT04530864|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
218884528|NCT02177474|BEHAVIORAL|Telephone based peer support|
219028930|NCT00841529|DEVICE|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
219028931|NCT05525845|OTHER|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
219028932|NCT05525845|OTHER|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
219028933|NCT05525845|OTHER|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
219028934|NCT05525845|OTHER|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
219028935|NCT04278079|PROCEDURE|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
219028936|NCT06421779|BEHAVIORAL|Virtual reality (VR)|Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
219028937|NCT05894421|DRUG|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
218884529|NCT01964638|PROCEDURE|Targeted Biopsy|
219028938|NCT01834014|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219364540|NCT00705978|DRUG|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
218884530|NCT04607811|BEHAVIORAL|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
218884531|NCT00691184|DRUG|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
218884532|NCT00691184|DRUG|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
218884533|NCT00691184|DRUG|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
218884534|NCT00691184|DRUG|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
218884535|NCT00268970|DRUG|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
218884536|NCT01601665|DEVICE|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
218884537|NCT01601665|DEVICE|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
219028939|NCT01834014|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219028940|NCT01834014|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219364541|NCT00705978|DRUG|Placebo|placebo
219364542|NCT00548548|DRUG|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
219364543|NCT00548548|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
219364544|NCT00548548|DRUG|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
219364545|NCT00548548|DRUG|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
219364546|NCT00548548|DRUG|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
219364547|NCT05657184|DRUG|REGEND001|Transplantation of REGEND001 for dose escalation.
219364548|NCT01823068|DRUG|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
219364549|NCT01222650|DRUG|KSO-0400|
219364550|NCT01222650|DRUG|KSO-0400|
219364551|NCT01222650|DRUG|Silodosin|
219364552|NCT01222650|DRUG|Placebo|
219364553|NCT03082001|DRUG|12% Sucrose|
219364554|NCT03082001|DRUG|24% Sucrose|
219364555|NCT01705691|DRUG|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
219364556|NCT01705691|DRUG|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
219364557|NCT01705691|DRUG|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
219364558|NCT01705691|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
219364559|NCT04399382|DRUG|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
219201225|NCT06740097|DEVICE|Aspirate tissue monitoring|This multicenter controlled clinical trial investigates the clinical performance and outcomes from using an aspirate tissue monitor (ATM, Marginum Ltd HIVEN™) that detects cancerous tissue from the suction waste during the surgical treatment of suspected high-grade gliomas. The ATM provides near real-time audible feedback to the surgeon when tumor-related fluorescence is detected in the aspirated tissues. The trial investigates if the use of ATM to detect 5-ALA induced fluorescence contributes to faster tumor removal, less blood loss, less unintended residual tumor, less morbidity, longer survival and the frequency of local reoperations. The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls). The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
218884538|NCT01601665|DEVICE|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
218884539|NCT01601665|DEVICE|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
218884540|NCT01601665|DEVICE|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
218884541|NCT01658761|PROCEDURE|vitrectomy|Surgery
218884542|NCT00172042|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
218884543|NCT05688332|DRUG|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
218884544|NCT05688332|DRUG|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
219028941|NCT01834014|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219028942|NCT01834014|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219028943|NCT01834014|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219028944|NCT06010940|DIETARY_SUPPLEMENT|Dietary supplement|nasogastric tube and oral care
219028945|NCT06010940|OTHER|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
219028946|NCT01776775|DEVICE|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
219028947|NCT01209364|DEVICE|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
219607253|NCT05676515|OTHER|culture media|spliting of biological material and use of three culture media
218884545|NCT01748721|BIOLOGICAL|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
219201226|NCT06740097|DEVICE|Fluorescence-guided surgery|Resection utilizing conventional visual fluorescence-guided surgery.
219364560|NCT03492684|PROCEDURE|total hip arthroplasty|total hip arthroplasty and EMG
219607254|NCT02443987|OTHER|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
219607255|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
219607256|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
219607257|NCT04194645|DRUG|BI 474121 tablet|BI 474121 tablet
218884546|NCT01748721|OTHER|pharmacological study|Correlative studies
218884547|NCT01748721|OTHER|laboratory biomarker analysis|Optional correlative studies
218884548|NCT02400021|DRUG|Prometrium|
218884549|NCT01770015|PROCEDURE|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
218884550|NCT01770015|PROCEDURE|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
219028948|NCT00002067|DRUG|Megestrol acetate|
219040333|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
218884551|NCT01770015|PROCEDURE|endotracheal aspiration|fungi and bacteria endotracheal aspiration
218884552|NCT02956941|BEHAVIORAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
218884553|NCT00658463|DRUG|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
219201227|NCT06739525|COMBINATION_PRODUCT|Blue Light-Blocking Glasses (Intervention Group)|Participants in this arm wore blue light-blocking glasses designed to filter out a portion of short-wavelength blue light. These lenses were intended to reduce eye strain and protect against blue light exposure, especially during prolonged screen time. Participants used blue light-blocking glasses consistently throughout the study period to assess their effect on contrast sensitivity and visual fatigue.
219201228|NCT06739525|DIAGNOSTIC_TEST|Standard Lenses (Control Group)|Participants in this arm wore standard lenses without any blue light-blocking properties. These lenses allow the full spectrum of visible light to pass through and serve as a baseline control to measure against the blue light-blocking glasses. Participants used these lenses under the same conditions to assess contrast sensitivity and visual fatigue without blue light filtration.
219201229|NCT06741540|OTHER|tDCS|"Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that modulates cortical excitability by applying a weak direct current through electrodes placed on the scalp. This technique usually lasts for 20-30 minutes and can affect brain function by altering cortical excitability, local cerebral blood flow, synaptic plasticity, and the balance of cortical excitation/inhibition.~tDCS is widely used in clinical settings and has shown some clinical efficacy in treating common psychiatric and neurological disorders. It is also used to improve motor, perceptual, and cognitive processes, as well as to treat a variety of neurological and psychiatric diseases."
219201230|NCT06743360|DEVICE|Insertion|Twenty orthodontic mini-implants (n=20) (AbsoAnchor SH 1312-08, Dentos, Daegu, South Korea) were randomly chosen (every third screw from a sample of 60) numbered consecutively, and embedded in polivynyl siloxane impression material Variotype heavy putty (Kulzer, Hanau, Germany).
219201231|NCT06743360|DEVICE|Scanning|After the planned movement is achieved, the mini-implant will be removed and provided to laboratory analysis. All screws were sputtered (0.6µm CaCO₄) and scanned in blue-light technology, using a 3D optical scanner (Atos III, Triple Scan, GOM, Germany) to the nearest 2 micrometres. Due to regularly performed calibration procedures, recommended by the manufacturer, an error study was superfluous. Subsequently, the scans were superimposed using GOM Inspect Software (GOM, Braunschweig, Germany) in order to verify the shape and size repeatability.
219201232|NCT03982186|DRUG|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
219201233|NCT03982186|DRUG|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
219201234|NCT03982186|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
219201235|NCT03982186|DRUG|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
219201236|NCT03982186|DRUG|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
219201237|NCT06741813|PROCEDURE|ASCT|The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).
219201238|NCT06741813|PROCEDURE|Allo-HSCT|"Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg/kg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg/kg, days -4 to -2).~All MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg/kg, q12h, intravenous \[i.v.\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng"
219201239|NCT06893432|DEVICE|hearing aids|Hearing aids are a common intervention method used to address age-related hearing loss, providing amplified sound to improve hearing clarity and communication abilities for elderly individuals.
219201240|NCT06741319|BEHAVIORAL|Demographic characteristics|"* Gender identity~* Sex assigned at birth~* Age~* Address~* History of study enrollment(s)"
219364561|NCT02913313|DRUG|BMS-986207|Specified dose on specified days
219364562|NCT02913313|BIOLOGICAL|Nivolumab|Specified dose on specified days
219364563|NCT02913313|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219506334|NCT05368142|DRUG|Nocardia rubra Cell Wall Skeleton|Nocardia rubra cell wall skeleton for external application
219506335|NCT05368142|DRUG|Silver ions dressing|Silver ions dressing for external application
219506336|NCT03201783|OTHER|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
219506337|NCT03201783|OTHER|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
219506338|NCT01748890|DEVICE|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
218884554|NCT00658463|DRUG|Placebo|Placebo
218884555|NCT01500902|OTHER|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
218884556|NCT01500902|OTHER|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
218884557|NCT01771250|BIOLOGICAL|Insulin Peglispro|Daily doses administered SC.
218884558|NCT01771250|BIOLOGICAL|Insulin Glargine|Daily doses administered SC.
219506339|NCT06483152|OTHER|Metro Transit Pass|A transit pass that enables riders to use the Minneapolis Metro Transit system that will paid for by the study for 6 months
219506340|NCT06483152|OTHER|Standard of Care|The current standard of care for Ryan White eligible clients is to receive two $10 bus cards a month from a case manager
219607258|NCT04194645|DRUG|Placebo tablet|Placebo tablet
219506341|NCT03967236|OTHER|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
219506342|NCT02347930|OTHER|kidney ultrasound|kidney ultrasound
219506343|NCT04003870|DEVICE|CASO|Customized arch support orthoses (CASO)
219506344|NCT04003870|DEVICE|HL|Orthotic Heel Lift (HL)
219506345|NCT00526890|DIETARY_SUPPLEMENT|selenomethionine|Oral Twice daily
219506346|NCT00526890|DRUG|carboplatin|Weekly IV
219506347|NCT00526890|DRUG|paclitaxel|Weekly IV
219506348|NCT00526890|OTHER|laboratory biomarker analysis|Correlative Study
219506349|NCT00526890|RADIATION|radiation therapy|Undergoing radiation Therapy
218884559|NCT03778450|DRUG|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
218884560|NCT03778450|DRUG|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
219201241|NCT06741319|BEHAVIORAL|Social and sexual behaviors|"* Places where clients go for shopping, dining out, exercise, entertainment~* Places where clients meet their sexual partner(s)~* Places where clients obtain condoms and lubricants~* Social networking and other online services clients regularly use and purposes of using~* Lifetime and current sexual practices and condom use~* Number and types of sexual partners~* Self-perceived HIV risk level~* Disclosure of HIV or sexual orientation status"
219201242|NCT06741319|BEHAVIORAL|Psychosocial characteristics|"* Sexual orientation~* Educational level~* Occupation and income~* Attitude towards and use of HIV testing and sexual health services~* Use of injecting drugs, recreational drugs, and alcohol"
219506350|NCT04984109|PROCEDURE|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
218884561|NCT04674657|DRUG|blood drug concentration|blood drug concentration
219506351|NCT04984109|PROCEDURE|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
219506352|NCT05720481|OTHER|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
219506353|NCT05720481|OTHER|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
219506354|NCT00328874|DRUG|Coenzyme Q10|
219506355|NCT04706871|DEVICE|taVNS|"taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear."
219506356|NCT04706871|DEVICE|tnVNS|"tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear."
219506357|NCT03529955|DRUG|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
219506358|NCT03740685|DIAGNOSTIC_TEST|High sesitive C reactive protien|High sesitive C reactive protien will be evaluated at admission time and after 36 hours
219506359|NCT00580983|RADIATION|IMRT|
219506360|NCT00580983|DRUG|Paclitaxel|
219506361|NCT00580983|DRUG|Carboplatin|
219506362|NCT00580983|DRUG|Cisplatin|
219506363|NCT00580983|DRUG|5-Fluorouracil|
219607259|NCT04194645|DRUG|BI 474121 oral solution|BI 474121 oral solution
219607260|NCT04194645|DRUG|Placebo solution|Placebo solution
219607261|NCT01601340|DRUG|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
219607262|NCT01601340|DRUG|Placebo|Placebo tablets, twice daily for 48 weeks
219607263|NCT00645892|DRUG|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
219607264|NCT00645892|DRUG|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
219506364|NCT02746458|OTHER|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
219506365|NCT02746458|DEVICE|Delfi PTSII Tourniquet System|
218884562|NCT02451462|DRUG|Zoledronic acid|
218884563|NCT00307203|DRUG|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
218884564|NCT00307203|BEHAVIORAL|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
219506366|NCT03363282|PROCEDURE|Pterygium Excision|Pterygium excision is the first step for repair
219506367|NCT04437069|OTHER|Decision Aid|Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).
219506368|NCT04437069|OTHER|Values Clarification Exercise|The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
219506369|NCT01986842|DIETARY_SUPPLEMENT|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
219506370|NCT00642031|DRUG|Triciribine|15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
219506371|NCT05186350|PROCEDURE|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
219506372|NCT05186350|PROCEDURE|ESWL+ ERCP|ESWL + Stone removal through ERCP
218884565|NCT00307203|DRUG|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
218884566|NCT02925624|PROCEDURE|Pulmonary vein isolation|
218884567|NCT05026203|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
218884568|NCT05026203|DRUG|Midazolam|Midazolam
218884569|NCT03006874|DRUG|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
218884570|NCT03006874|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
218884571|NCT03006874|DRUG|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
218884572|NCT00483938|DRUG|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
218884573|NCT00483938|DRUG|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
219506373|NCT03740100|DRUG|Bimiralisib|Bimiralisib capsules
219607265|NCT05982171|DEVICE|Exo + TSCS|Participants will receive TSCS delivered with the ONWARD Lift system at 1ms using a 10kHz carrier frequency delivered at 30Hz, with an amplitude set for each participant based on their ability to increase voluntary movement output.
218884574|NCT06128603|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
218884575|NCT00894946|PROCEDURE|Lipiodol + IVF|IVF preceded by lipiodol
218884576|NCT00894946|PROCEDURE|IVF|IVF alone
218884577|NCT02534246|DEVICE|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
218884578|NCT02534246|DEVICE|Ultrasound biopsy needle SharkCore|
218884579|NCT03111329|OTHER|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
218884580|NCT05360745|DIETARY_SUPPLEMENT|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
218884581|NCT05360745|DIETARY_SUPPLEMENT|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
218884582|NCT04382378|DEVICE|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
219607266|NCT05982171|DEVICE|Exo + Sham|The ONWARD Lift system will also be used to deliver sham stimulation which will also be delivered at 1ms using a 10kHz carrier frequency delivered at 30Hz, and an amplitude of 1ma which has been used in other sham stimulation protocols and is not sufficient to induce activation of lumbosacral neuronal pools.
218884583|NCT03581838|BEHAVIORAL|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
218884584|NCT05777512|PROCEDURE|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
218884585|NCT05777512|PROCEDURE|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
219506374|NCT03368495|BIOLOGICAL|Co-administration of MMR/YF|Both MMR \& yellow fever vaccines administered on Day 0.
218884586|NCT04591444|DRUG|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
218884587|NCT04591444|DRUG|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
218884588|NCT04591444|OTHER|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
218884589|NCT02373644|OTHER|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
218884590|NCT02373644|OTHER|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
218884591|NCT01973725|DRUG|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
218884592|NCT02218008|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218884593|NCT02218008|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218884594|NCT02038075|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|
218884595|NCT02038075|BEHAVIORAL|Treatment As Usual (TAU)|
218884596|NCT00106353|DRUG|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
218884597|NCT02346617|BIOLOGICAL|IFN-γ positive selected T-cells|No intervention
218884598|NCT00032357|PROCEDURE|Ferritin reduction to 25 ng/ml by phlebotomy|
218884599|NCT03940118|DEVICE|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
218884600|NCT03940118|COMBINATION_PRODUCT|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
218884601|NCT03940118|DEVICE|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
218884602|NCT03940118|COMBINATION_PRODUCT|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
218884603|NCT05186168|DEVICE|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
218884604|NCT05186168|DEVICE|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
218884605|NCT00015808|DRUG|Idebenone|
218884606|NCT00850538|RADIATION|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
218884607|NCT00850538|PROCEDURE|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
219201243|NCT06741319|BEHAVIORAL|Clinical characteristics|"* Medical history, including gender dysphoria and hormone therapy~* HIV counseling and testing~* Diagnosis and treatment of sexually transmitted diseases (STD)~* Sample collection information~* Laboratory results~* Gender dysphoria and mental health history~* Body hair pattern~* Bridging therapy~* Fertility and reproductive issues~* Gender transition effects"
219201244|NCT06741319|BEHAVIORAL|Referral and linkage to care for HIV-positive clients|"* Health insurance scheme~* Initiation and continuation of antiretroviral treatment"
219506375|NCT03368495|BIOLOGICAL|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
218884608|NCT03382808|BEHAVIORAL|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
219506376|NCT03368495|BIOLOGICAL|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
219506377|NCT01472588|BEHAVIORAL|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
218884609|NCT03382808|BEHAVIORAL|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
218884610|NCT03970291|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
218884611|NCT01907425|OTHER|Blood samples|
218884612|NCT06496165|DRUG|Remimazolam|Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
218884613|NCT06496165|DRUG|Propofol|Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
218884614|NCT02083497|OTHER|rigid bandage|
218884615|NCT02083497|OTHER|elastic bands|
218884616|NCT02083497|OTHER|without the use of banding|
218884617|NCT00376857|DRUG|Surgery with and without the aid of Indocyanine Green (ICG)|
218884618|NCT00958646|OTHER|Osteopathic Manipulation|Standardized rib raising protocol
218884619|NCT00958646|OTHER|Placebo|Light touch control procedure
219028949|NCT05300906|BEHAVIORAL|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
219506378|NCT01472588|BEHAVIORAL|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
219506379|NCT01472588|OTHER|Self Help|Public education/information booklet on weight management.
219607267|NCT03076775|OTHER|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
218884620|NCT05476029|DIAGNOSTIC_TEST|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
218884621|NCT01291407|DRUG|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
218884622|NCT01291407|DRUG|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
218884623|NCT01291407|DRUG|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
218884624|NCT01291407|DRUG|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
219028950|NCT05300906|BEHAVIORAL|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
219201245|NCT06741319|BEHAVIORAL|Characteristics associated with service implementation|\- Facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation as identified by clients and healthcare providers
219028951|NCT03874520|OTHER|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
219028952|NCT02258321|DRUG|PPI-668 tablet|
219028953|NCT02258321|DRUG|PPI-668 capsule|
218884625|NCT01291407|DRUG|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
218884626|NCT01291407|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
218884627|NCT02328027|DRUG|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
218884628|NCT04107207|DIETARY_SUPPLEMENT|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
218884629|NCT04107207|DIETARY_SUPPLEMENT|Ginger Water|Placebo
218884630|NCT04995549|DEVICE|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
218884631|NCT01357252|DRUG|vildagliptin|
218884632|NCT01357252|DRUG|Placebo|
218884633|NCT02922179|DRUG|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
218884634|NCT00930228|DRUG|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
218884635|NCT00930228|DRUG|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
218884636|NCT03319212|DEVICE|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
218884637|NCT00250276|BIOLOGICAL|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
218884638|NCT06156241|BIOLOGICAL|Stem Cell|Stem cells derived from human cord tissue.
218884639|NCT00201942|PROCEDURE|PET scan|
218884640|NCT00286871|DRUG|Neoral|
218884641|NCT00286871|DRUG|Tacrolimus|
218884642|NCT04591847|DRUG|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
218884643|NCT04591847|DRUG|Placebo drug|Placebo drugs 1 tab oral weekly
218884644|NCT00465777|BEHAVIORAL|Guideline adherence and financial incentive|
218884645|NCT04057846|DEVICE|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
218884646|NCT04949074|OTHER|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
218884647|NCT02313974|PROCEDURE|Renal Biopsy|
218884648|NCT03372174|DEVICE|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
218884649|NCT03372174|DEVICE|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
218884650|NCT01811186|DRUG|Oxycodone/naloxone|Oxycodone/naloxone titration
218884651|NCT06130462|DIAGNOSTIC_TEST|Aluminum|Different concentrations of aluminium added to the blood test in vitro
218884652|NCT06130462|DIAGNOSTIC_TEST|Tetanus toxoid|Used as control substance
218884653|NCT01092052|DRUG|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
219201246|NCT06739135|BEHAVIORAL|Visual feedback training|Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees
219506380|NCT05544851|OTHER|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
219607268|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
219028954|NCT01638806|PROCEDURE|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
219028955|NCT00469560|DRUG|Deferasirox|
218884654|NCT05065853|DIAGNOSTIC_TEST|urine self-sampling group|collection of urine and vaginal samples
218884655|NCT05065853|DIAGNOSTIC_TEST|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
218884656|NCT01979458|DEVICE|PSE|
218884657|NCT00306540|DRUG|Quetiapine Fumarate|oral flexible dose
218884658|NCT00306540|DRUG|quetiapine fumarate placebo|oral 0 mg
218884659|NCT00378261|PROCEDURE|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
218884660|NCT04213716|COMBINATION_PRODUCT|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
218884661|NCT04213716|COMBINATION_PRODUCT|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
218884662|NCT05623657|OTHER|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
218884663|NCT05623657|OTHER|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
218884664|NCT01448499|DRUG|Clozapine|escalating dose of clozapine up to 900 mg/day
219028956|NCT02598427|DRUG|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
219028957|NCT02598427|DRUG|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
219028958|NCT02692781|DRUG|MOD-6031|
219028959|NCT02692781|OTHER|Placebo control|
218884665|NCT01448499|DRUG|Amisulpride|escalating dose of amisulpride up to 800 mg/day
218884666|NCT01448499|DRUG|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
219028960|NCT02084147|DEVICE|positron emission tomography|Undergo PET
219028961|NCT02084147|DEVICE|computed tomography|Undergo CT
219028962|NCT02084147|DEVICE|magnetic resonance imaging|Undergo MRI
218884667|NCT02300740|DIETARY_SUPPLEMENT|Nicotinamide riboside|NIAGEN, ChromaDex
218884668|NCT01670773|DRUG|CAT-1004|
218884669|NCT01670773|DRUG|Salsalate + DHA|
218884670|NCT01670773|DRUG|Placebo|
218884671|NCT03669289|OTHER|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
218884672|NCT00688272|DRUG|Ciprofloxacin|Given 500mg BID x 6 days
218884673|NCT00688272|DRUG|Eltrombopag|Given QD x 6 days
218884674|NCT00688272|DRUG|Placebo|Given QD x 6 days
218884675|NCT05416736|PROCEDURE|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
218884676|NCT05416736|PROCEDURE|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
218884677|NCT01800136|DEVICE|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
218884678|NCT06420180|PROCEDURE|hip arthroscopy|"CT rotational profile Will be used for measurement of LL rotational abnormality.~MRI will be evaluated for the presence of labral tears, chondral lesions, ligamentum teres pathology, and other soft-tissue disorders."
218884679|NCT03369236|DRUG|Danicopan|Danicopan was administered as an oral tablet.
218884680|NCT03369236|DRUG|Placebo|Matching placebo was administered as an oral tablet.
218884681|NCT02248636|DRUG|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
218884682|NCT02248636|DRUG|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
218884683|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
218884684|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
219028963|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
219028964|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
219506381|NCT06186167|PROCEDURE|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
219506382|NCT06527001|OTHER|No intervention|This is an observational study and did not involve interventions.
219506383|NCT02457728|DEVICE|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
218884685|NCT01219062|DRUG|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
219607269|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
218884686|NCT01219062|OTHER|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
218884687|NCT01219062|DRUG|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
218884688|NCT05969340|DIAGNOSTIC_TEST|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
218884689|NCT03806608|PROCEDURE|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
218884690|NCT03806608|PROCEDURE|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
219028965|NCT01826487|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
219028966|NCT01826487|DRUG|Placebo|Placebo will be administered as per the schedule specified in the arm.
218884691|NCT05293925|BEHAVIORAL|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
218884692|NCT03334812|BIOLOGICAL|LNA043|LNA043 Single dose
218884693|NCT03334812|BIOLOGICAL|placebo to LNA043|placebo to LNA043 single dose
219028967|NCT04142554|DRUG|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
218884694|NCT04223908|OTHER|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
218884695|NCT01153724|DRUG|BI 1744|10 mcg solution for oral inhalation
219506384|NCT01984281|BEHAVIORAL|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
219506385|NCT02678897|DRUG|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
219506386|NCT02678897|DRUG|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
219506387|NCT03089528|DEVICE|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
219506388|NCT03089528|DEVICE|laringoscope|the trachea will be intubated with a laringoscope
219506389|NCT03518697|BEHAVIORAL|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
219607270|NCT01783886|PROCEDURE|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
219607271|NCT04542057|DRUG|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
219607272|NCT04542057|DRUG|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
219607273|NCT01140165|OTHER|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
219607274|NCT00104572|DRUG|Androgel (Testosterone Gel)|1 mg tablet for 12 months
218884696|NCT01153724|DRUG|Fluconazole|400 mg capsule
218884697|NCT03969186|BEHAVIORAL|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
218884698|NCT03850535|DRUG|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
219028968|NCT05701410|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
219201247|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 1|Investigational varicella vaccine of Lot 1 administered subcutaneously.
219607275|NCT00104572|DRUG|Anastrozole (Aromatase Inhibitor)|
219607276|NCT00104572|DRUG|Placebo tablet|Daily for 12 months
219607277|NCT00104572|DRUG|Placebo gel|Daily for 12 months
219607278|NCT00104572|DIETARY_SUPPLEMENT|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
219607279|NCT03815526|OTHER|Dynamic tape|Dynamic tape apply 1 time
219607280|NCT03815526|OTHER|Kinesio tape|Dynamic tape apply 1 time
219607281|NCT03815526|OTHER|Sport tape|Dynamic tape apply 1 time
219607282|NCT04045353|BEHAVIORAL|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
219607283|NCT04045353|BEHAVIORAL|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
219607284|NCT04469777|DRUG|erythropoietin|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
219607285|NCT04167111|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D
219607286|NCT04708015|OTHER|No Intervention|A retrospective chart review of medical records
219607287|NCT02934464|DRUG|RAMUCIRUMAB|
219607288|NCT02934464|DRUG|Paclitaxel|Paclitaxel
219607289|NCT02934464|DRUG|FOLFOX 4|
219607290|NCT02934464|DRUG|mFOLFOX 6|
219506390|NCT02836340|DRUG|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
219506391|NCT01337154|DRUG|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
219506392|NCT01337154|DRUG|Placebo|Tablets, orally, daily
219506393|NCT03387059|DEVICE|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
219506394|NCT00141596|DRUG|Cardura XL 4 mg bd|
219506395|NCT00141596|DRUG|Amiloride 5 mg bd|
219506396|NCT00141596|DRUG|Furosemide 40 mg bd|
219506397|NCT04877184|DEVICE|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~* transcranial ultrasound stimulation: during 4 weeks~* rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
219506398|NCT04877184|DEVICE|Rehabilitation|"The participants in control group would received rehabilitation therapy.~\- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
219607291|NCT02934464|DRUG|XELOX|
219607292|NCT03104855|DRUG|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
219607293|NCT02914353|DRUG|EP=7041|Factor X!a Inhibitor
218884699|NCT03850535|DRUG|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
218884700|NCT03850535|DRUG|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
218884701|NCT03850535|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
218884702|NCT01742806|DEVICE|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
218884703|NCT00003864|DRUG|carboplatin|
219506399|NCT01263899|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
219506400|NCT06064253|BEHAVIORAL|health education|adherence to treatment
219506401|NCT05482984|OTHER|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
219506402|NCT04823871|PROCEDURE|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
219506403|NCT03287596|DEVICE|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
219506404|NCT01873079|DRUG|Esomeprazole|
219506405|NCT01873079|OTHER|Standard care|No PPI or other study medication given
219607294|NCT02914353|DRUG|Placebo|Normal Saline
219607295|NCT01918566|DIETARY_SUPPLEMENT|tap water|
218884704|NCT00003864|DRUG|docetaxel|
218884705|NCT00242099|PROCEDURE|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
218884706|NCT03701919|DRUG|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
219506406|NCT01653574|DRUG|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
219506407|NCT06306495|OTHER|International Physical Activity Survey|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
219506408|NCT06189261|OTHER|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
219607296|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
219607297|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
219607298|NCT01918566|DIETARY_SUPPLEMENT|25g Fructose in 300ml tap water|
219607299|NCT01918566|DIETARY_SUPPLEMENT|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
219607300|NCT01918566|DIETARY_SUPPLEMENT|300ml tap water with 450ppm lactisole|
219607301|NCT00940316|BIOLOGICAL|panitumumab|Given intravenously 6mg/kg every 2 weeks
219607302|NCT00940316|DRUG|erlotinib hydrochloride|Given orally 150mg daily
219607303|NCT00940316|DRUG|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
219607304|NCT01907256|PROCEDURE|inverted V incision|It is a type of incision
219607305|NCT01907256|PROCEDURE|stair step incisions|It is a type of incision
219607306|NCT00425204|DRUG|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
218884707|NCT03701919|DRUG|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
218884708|NCT00524472|OTHER|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
218884709|NCT00524472|OTHER|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
218884710|NCT02508428|DEVICE|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
218884711|NCT02508428|DEVICE|Hip Replacement with noncrosslinked Enduron polyethylene|
218884712|NCT04833296|DRUG|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
218884713|NCT00209300|DRUG|Pentasa|
218884714|NCT02430116|PROCEDURE|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
218884715|NCT04554771|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
218884716|NCT04554771|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
218884717|NCT04554771|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
218884718|NCT04554771|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
218884719|NCT02210975|DEVICE|LES-Stimulation Device|
219506409|NCT06073795|PROCEDURE|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
219607307|NCT03897634|DEVICE|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
218884720|NCT05426941|BEHAVIORAL|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
219607308|NCT02375165|PROCEDURE|phlebotomy|phlebotomy for collection of plasma and serum, \~30 cc
219607309|NCT00685386|OTHER|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
218884721|NCT05426941|BEHAVIORAL|Music Listening|Up to 15 participants will be randomized to independent music listening.
218884722|NCT04031989|DEVICE|CorVista Capture|The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
218884723|NCT03842241|DEVICE|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
218884724|NCT02748070|DRUG|Prednisone|
218884725|NCT02748070|DRUG|Flonase|
218884726|NCT02785068|DRUG|MM-151|Oligoclonal antibody
219040334|NCT06848686|BEHAVIORAL|Prevention Ambassadors|Delivery of prevention supplies and information on local services plus training to build the capacity of PWUD to distribute HIV self-testing (HIVST) kits with information and referrals to other PWUD in their social networks to promote HIV testing and HIV service engagement among PWUD.
219040335|NCT06848686|BEHAVIORAL|SSP Standard of Care|Delivery of prevention supplies and information on local services.
218884727|NCT02785068|DRUG|nal-IRI|Nanoliposomal irinotecan
218884728|NCT02785068|DRUG|Leucovorin|folinic acid
218884729|NCT02785068|DRUG|5-FU|Chemotherapy
219040336|NCT05844163|OTHER|observation|observation
219040337|NCT05942326|BEHAVIORAL|Sleep GOALS|Web-based interventions
219040338|NCT05942326|BEHAVIORAL|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
219506410|NCT01531348|OTHER|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
219607310|NCT00685386|OTHER|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
219607311|NCT04097873|OTHER|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
219607312|NCT04097873|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
218884730|NCT00928694|DRUG|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
218884731|NCT00928694|DRUG|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
218884732|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
218884733|NCT02215304|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
218884734|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
219506411|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
219506412|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
218884735|NCT02215304|DIETARY_SUPPLEMENT|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
219028969|NCT06258655|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
219607313|NCT05146648|DEVICE|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
218884736|NCT01315444|DRUG|Stop PPI gradually|
218884737|NCT01315444|DRUG|Stop PPI gradually|
218884738|NCT00534976|DRUG|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
218884739|NCT00534976|DRUG|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
219028970|NCT01408030|DRUG|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
219028971|NCT01408030|DRUG|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
219028972|NCT01408030|DRUG|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
219028973|NCT01408030|DRUG|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
219028974|NCT06435533|DEVICE|low energy argonplasma coagulation|see above
219028975|NCT06420479|PROCEDURE|Bariatric surgery|A well-known intervention known to induce substantial weight loss
219028976|NCT00825045|DRUG|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
219028977|NCT06316141|OTHER|Aqua Jogging|This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
219028978|NCT06316141|OTHER|Land based Jogging|This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
218884740|NCT03799939|DEVICE|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
219028979|NCT03642223|OTHER|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
219028980|NCT00000976|DRUG|CD4-IgG|
219028981|NCT00000976|DRUG|Zidovudine|
219028982|NCT00758030|DRUG|Paliperidone ER OROS|
219028983|NCT04689295|OTHER|exercise programme 1|Schroth three dimensional scoliosis therapy method
219028984|NCT04689295|OTHER|exercise programme 2|Traditional scoliosis exercises
219028985|NCT05023525|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
219028986|NCT05023525|DRUG|Placebo, tablet|Matching placebo
219028987|NCT02910076|DRUG|Hydroxychloroquine|200 MG Plaquenil three times a day
219028988|NCT02101047|DRUG|Phenylephrine|
219506413|NCT06140511|DIAGNOSTIC_TEST|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study \[Ferri et al. Sleep 2018:zsy187\] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
219506414|NCT03654261|BEHAVIORAL|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
219506415|NCT02856815|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
219506416|NCT02139683|DEVICE|HIFU treatment|HIFU treatment in patients with fibroadenoma
218884741|NCT04364152|BEHAVIORAL|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
219040339|NCT03133650|DRUG|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
219040340|NCT05669508|DEVICE|RISES-T System|Non-invasive closed-loop electrical stimulation of the spinal cord through the skin
219607314|NCT04457037|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
219607315|NCT02976948|OTHER|No intervention|
219607316|NCT04309617|PROCEDURE|nephrectomy|Surgery performed within the study period
219607317|NCT05748587|DIAGNOSTIC_TEST|Serum Iron|Serum iron levels in study groups
219607318|NCT05748587|DIAGNOSTIC_TEST|RBCs Alpha-synuclein|α-syn levels in RBCs
218884742|NCT01281033|PROCEDURE|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
218884743|NCT01281033|PROCEDURE|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
218884744|NCT05972746|DEVICE|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
218884745|NCT05972746|OTHER|Standard of care|Standard of care
218884746|NCT06183073|PROCEDURE|caudal block|bupivacaine 0.25% in a dose of (1 ml / kg)
218884747|NCT06183073|DRUG|Dexmedetomidine|dexmedetomidine 1μg/ kg.
218884748|NCT06183073|PROCEDURE|TAP|analgesia
219028989|NCT06294964|BEHAVIORAL|sleep education, behavioral education|Provide health education materials which covering sleep education, behavioral education, chronic diseases such as cardiovascular diseases. Topics touch on such as why you need healthy sleep? What methods can be used to regulate insomnia, and how to regulate sleep breathing problems? How do the elderly maintain a good sleep? What are the risk factors for cardiovascular and cerebrovascular diseases? How to reduce the risk of developing sleep disorders or chronic diseases through changing everyday life?
219028990|NCT04156776|OTHER|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
219506417|NCT02272348|OTHER|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
219506418|NCT02272348|OTHER|Usual diabetes management.|
219506419|NCT05700357|PROCEDURE|TPVB with 20 ml|The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
219607319|NCT05748587|DIAGNOSTIC_TEST|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
219607320|NCT05748587|RADIATION|Brain computed tomography|Brain CT of patients after admission
218884749|NCT06183073|DRUG|Bupivacain|bupivacaine 0.25% in a dose of (0.5 ml / kg
218884750|NCT05793242|DEVICE|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
218884751|NCT05793242|DEVICE|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
218884752|NCT05793242|DEVICE|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
218884753|NCT05793242|OTHER|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
219040341|NCT05669508|OTHER|Occupational/Physical Therapy|Exercise therapy to improve function of upper and/or lower limbs
219040342|NCT06589440|DRUG|SR-8541A|SR-8541A administered orally in combination with intravenous botensilimab and balstilimab
219506420|NCT05700357|PROCEDURE|TPVB with 25 ml|The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
219506421|NCT05700357|PROCEDURE|TPVB with 30 ml|The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
219506422|NCT03208257|DRUG|Esmolol|Esmolol hydrochloride infusion
219506423|NCT02896660|DEVICE|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
219506424|NCT03787108|OTHER|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
219506425|NCT04969952|OTHER|For interventional module|Using vedio to assist physicians introducing advance care planning to cancer patients
219506426|NCT00470444|PROCEDURE|Transfusion with Red Blood Cells|Units of donated Red blood cells
219506427|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of red blood cells
219506428|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of donated red blood cells
219506429|NCT04822662|BEHAVIORAL|Epilepsy Education Programme|Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
219506430|NCT01402583|DRUG|PEG IFN/Ribavirin|PEG IFN/Ribavirin
219607321|NCT05748587|DIAGNOSTIC_TEST|Brain Iron|Iron in brain homogenate of rats
219607322|NCT05748587|DIAGNOSTIC_TEST|Brain Alpha-synuclein|α-syn expression in rat's brain
219607323|NCT05748587|DIAGNOSTIC_TEST|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
219607324|NCT05748587|DRUG|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
218884754|NCT03422965|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
218884755|NCT03422965|DIAGNOSTIC_TEST|Blood test|Blood test, systemic markers
218884756|NCT03422965|DIAGNOSTIC_TEST|Urine test|Urine test, systemic markers
218884757|NCT03797456|DRUG|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
219506431|NCT06066385|PROCEDURE|Small bites technique|Closure of the fascia after midline laparotomy using a slowly resorbalbe 2.0 suture, with 0.5 cm bites, and 0.5 cm between the stitches, at least resulting in a 1:4 wound length:suture length ratio.
219506432|NCT06066385|PROCEDURE|Conventional large bites closure|Closure of a midline laparotomy using a slowy resorbable thick suture (e.g. PDS loop) with large bites and large steps (\>= 1 cm).
219506433|NCT02002247|DRUG|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
219607325|NCT03595046|PROCEDURE|erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)|In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
219607326|NCT03595046|PROCEDURE|thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)|2\) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
218884758|NCT02929238|OTHER|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
218884759|NCT02929238|OTHER|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
218884760|NCT02834247|DRUG|TAK-659|TAK-659 Tablets.
218884761|NCT02834247|DRUG|Nivolumab|Nivolumab intravenous infusion.
218884762|NCT03556709|DEVICE|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
218884763|NCT03626961|OTHER|readmission|Readmission after 48 hours
218884764|NCT03626961|OTHER|discharge|Discharge
218884765|NCT01574066|PROCEDURE|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
218884766|NCT03343626|DRUG|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
218884767|NCT03343626|BIOLOGICAL|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
218884768|NCT02856048|DRUG|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
219028991|NCT04156776|OTHER|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
219028992|NCT04156776|OTHER|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
219028993|NCT02130661|DRUG|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
219506434|NCT02002247|DRUG|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
219506435|NCT01859702|DRUG|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
218884769|NCT00673335|DRUG|letrozole|
218884770|NCT00673335|DRUG|Placebo|
218884771|NCT03919357|BEHAVIORAL|BMT-i|Passing the BMT-i test
219506436|NCT05840497|OTHER|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
219506437|NCT00005960|BIOLOGICAL|filgrastim|
219506438|NCT00005960|DRUG|cyclophosphamide|
219506439|NCT00005960|DRUG|docetaxel|
219506440|NCT00005960|DRUG|doxorubicin hydrochloride|
219506441|NCT00005960|PROCEDURE|pain therapy|
219506442|NCT03995303|OTHER|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
219506443|NCT06110585|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
219028994|NCT02130661|DRUG|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
219028995|NCT02130661|DRUG|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
219028996|NCT05245760|DRUG|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
219028997|NCT05245760|DRUG|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
219506444|NCT06110585|PROCEDURE|Sham|A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
219506445|NCT04192799|BEHAVIORAL|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
219506446|NCT04192799|BEHAVIORAL|ED admission|Process of pediatric admission is through the emergency department
219506447|NCT05385744|BIOLOGICAL|BCD-132|anti-CD20 monoclonal antibody
219506448|NCT05385744|DRUG|Teriflunomide|Teriflunomide 14 mg
219506449|NCT06316960|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
219506450|NCT06316960|DRUG|Azacitidine Injection|75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
219506451|NCT06316960|DRUG|Decitabine Injection|20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
219506452|NCT06316960|DRUG|Idarubicin Hydrochloride|5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
219028998|NCT05245760|RADIATION|Fractionated radiation|Concurrent with chemo, x5 weeks
219506453|NCT06316960|DRUG|Cytarabine|10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
219506454|NCT06316960|DRUG|Granulocyte Colony-Stimulating Factor|300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
219028999|NCT05245760|PROCEDURE|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
219029000|NCT00244946|BIOLOGICAL|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
219029001|NCT00244946|DRUG|carmustine|
219029002|NCT00244946|DRUG|cytarabine|
219029003|NCT00244946|DRUG|etoposide|
219029004|NCT00244946|DRUG|melphalan|
219029005|NCT00244946|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|
219029006|NCT05436847|OTHER|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
219029007|NCT05436847|OTHER|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
219029008|NCT03755687|OTHER|Art Therapy Intervention|Standardized mixed media art directives.
219029009|NCT02786628|OTHER|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
219040343|NCT05965349|BEHAVIORAL|Healthy Mind, Healthy Living|A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
219040344|NCT04814225|OTHER|Test Product 1|Pea Protein powder
219040345|NCT04814225|OTHER|Test Product 2|Pea \& Oat Protein Powder
219040346|NCT04814225|OTHER|Test Product 3|Oat Protein Powder
219040347|NCT04814225|OTHER|Comparator|Whey Protein Isolate
219040348|NCT06045091|DRUG|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
219040349|NCT00368264|DRUG|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
219040350|NCT00368264|DRUG|placebo|azathioprine (2 mg/kg) plus four placebo infusions
219040351|NCT06872697|OTHER|whole body vibration|In the group receiving whole-body vibration in addition to conventional treatment, the whole-body vibration will be performed with the patient's hips and knees in approximately 20° flexion, and the bed inclined to 25-30°. The vibration platform will be fixed at the end of the bed, and the patients will apply pressure with their feet on the platform. The whole-body vibration will be administered for 3 minutes, 1-4 sets, at a frequency of 20-25 Hz, 5 days a week, for 4 weeks, depending on the protocol, in addition to conventional physiotherapy.
218884772|NCT04051853|DRUG|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
218884773|NCT04051853|OTHER|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
218884774|NCT04051853|OTHER|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
218884775|NCT04978584|DRUG|Acalabrutinib|Given PO
218884776|NCT04978584|DRUG|Cyclophosphamide|Given IV
218884777|NCT04978584|DRUG|Doxorubicin Hydrochloride|Given IV
218884778|NCT04978584|DRUG|Lenalidomide|Given PO
218884779|NCT04978584|DRUG|Prednisone|Given PO
218884780|NCT04978584|BIOLOGICAL|Rituximab|Given IV
218884781|NCT04978584|BIOLOGICAL|Tafasitamab|Given IV
219506455|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium"
219506456|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS)|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected"
218884782|NCT04978584|DRUG|Vincristine|Given IV
218884783|NCT05831488|OTHER|Non-Interventional|Non Interventional
218884784|NCT01416948|DRUG|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
218884785|NCT01416948|DRUG|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
218884786|NCT01416948|DRUG|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
218884787|NCT00003346|DRUG|acetaminophen|
218884788|NCT00003346|DRUG|acetylcysteine|
218884789|NCT00003346|DRUG|carmustine|
218884790|NCT03402724|OTHER|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
218884791|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
219506457|NCT03878355|PROCEDURE|functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique with middle turbinate preservation
218884792|NCT01865448|DIETARY_SUPPLEMENT|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
218884793|NCT01865448|OTHER|Placebo|Patients in control group take daily 2 placebo capsule
218884794|NCT04205682|DRUG|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
218884795|NCT04205682|DRUG|Placebo|Placebo capsules administered BD for 5 days
218884796|NCT00952081|DRUG|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
218884797|NCT00439296|DRUG|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
218884798|NCT00439296|DRUG|Dexamethasone|"In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14."
218884799|NCT00439296|DRUG|PEG-asparaginase|"In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15."
218884800|NCT00439296|DRUG|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
218884801|NCT00439296|DRUG|Cytarabine|"* Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
218884802|NCT00439296|DRUG|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
219506458|NCT04058678|DRUG|Danazol/Placebo|This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
219506459|NCT04058678|OTHER|Without intervention|Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
218884803|NCT00439296|DRUG|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
218884804|NCT00439296|DRUG|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
218884805|NCT06442384|OTHER|Tobacco and non-tobacco e-cigarettes|Participants with no e-cigarette restrictions.
218884806|NCT06442384|OTHER|Tobacco only e-cigarettes|Participants restricted to tobacco flavored e-cigarettes only.
218884807|NCT05111249|DRUG|Branaplam|messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.
219029010|NCT02512432|DEVICE|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
219029011|NCT05603689|DIETARY_SUPPLEMENT|Isocaloric ketogenic diet|The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
219506460|NCT01745328|DRUG|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
219506461|NCT01745328|DRUG|TCM|Subject is treated with TCM for 4 weeks.
219506462|NCT01745328|DRUG|LVX-AMX|treatment with placebo from 2 to 4 weeks.
219506463|NCT06210412|BEHAVIORAL|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
219506464|NCT02004847|DEVICE|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
219506465|NCT05763433|OTHER|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
219506466|NCT02946957|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
219506467|NCT02946957|BEHAVIORAL|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
219607327|NCT03282500|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
219607328|NCT02827734|DEVICE|multiple breath washout tests|
218884808|NCT05111249|DRUG|Placebo|Matching placebo oral solution once weekly
218884809|NCT02378688|DRUG|MT-1303|
218884810|NCT02378688|DRUG|Placebo|
218884811|NCT05128578|BEHAVIORAL|Liver Education About Pain (LEAP)|LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
218884812|NCT05128578|BEHAVIORAL|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
219029012|NCT04474860|DIAGNOSTIC_TEST|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
219029013|NCT03168308|DRUG|Sugammadex|Sugammadex 2 mg/kg
219607329|NCT02827734|DEVICE|impulse oscillometry|
219607330|NCT02827734|DEVICE|body plethysmography|
219607331|NCT01924559|OTHER|standard clothing|
219607332|NCT01924559|OTHER|Biohazard gear|
219607333|NCT01924559|DEVICE|Direct Laryngoscopy|
219607334|NCT01924559|DEVICE|Glidescope|
218884813|NCT06413238|DRUG|curcumin, saffron, Combination of saffron and curcumin and placebo|This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
218884814|NCT06274047|DRUG|Apalutamide|Given by PO
219029014|NCT03168308|DRUG|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
219029015|NCT02258230|DEVICE|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
219029016|NCT02258230|DEVICE|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
219607335|NCT01924559|DEVICE|Supraglottic Airway|
219607336|NCT01660425|BEHAVIORAL|Enhancement with psychosocial intervention|
219607337|NCT05548387|DRUG|HCP2202|Take it once per period.
219506468|NCT04261257|OTHER|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out."
219506469|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
219506470|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
219506471|NCT02026414|DIETARY_SUPPLEMENT|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
219506472|NCT02026414|OTHER|Exercise|
219506473|NCT03616834|DRUG|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
219506474|NCT04892966|DIAGNOSTIC_TEST|TXI Light Imaging|Standard Colonoscopy using TXI imaging
219506475|NCT04892966|DIAGNOSTIC_TEST|WLI Imaging|Standard Colonoscopy using White Light Imaging
219506476|NCT05321810|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
219506477|NCT05321810|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
219506478|NCT00830674|DRUG|Placebo|single dose IV or SC administration
219506479|NCT00830674|DRUG|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
219506480|NCT04043520|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
219506481|NCT04043520|DRUG|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
219506482|NCT04043520|DRUG|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
219506483|NCT04043520|DRUG|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
219506484|NCT01956279|DRUG|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
219506485|NCT01956279|DRUG|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
219506486|NCT03192774|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
219506487|NCT03083210|DRUG|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
219506488|NCT02404597|DEVICE|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
219506489|NCT01479452|PROCEDURE|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
219506490|NCT01479452|OTHER|Usual care|Non-surgical obesity treatment
219506491|NCT06527352|DEVICE|glottis mask airway|the glottis mask airway is used for maintaining ventilation during general anesthesia
218884815|NCT06274047|DRUG|Androgen Deprivation Therapy|Given by PO
218884816|NCT05078398|BEHAVIORAL|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
218884817|NCT05078398|BEHAVIORAL|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
218884818|NCT01043211|DRUG|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
219506492|NCT06527352|OTHER|tulip shaped|the tulip shaped mask airway is with a tulip shaped tip
219506493|NCT06527352|OTHER|classical shaped|the classical shaped mask airway is with a water-drop shaped tip
219506494|NCT00240006|PROCEDURE|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
219506495|NCT05168956|OTHER|Collect data of medical record|"Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
218884819|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
218884820|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
218884821|NCT05701020|OTHER|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
218884822|NCT02756676|PROCEDURE|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
218884823|NCT04344275|OTHER|-Scapular endurance test|The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
218884824|NCT04344275|OTHER|-Muscle strength test|Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
218884825|NCT04911894|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
218884826|NCT03004911|DEVICE|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
218884827|NCT03004911|DEVICE|Paper booklet|A 64-page booklet with content similar to the mobile application
218884828|NCT04526223|OTHER|comprehensive treatment regimen|"1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d"
218884829|NCT00014079|GENETIC|DNA stability analysis|
219506496|NCT05858385|OTHER|Intervention based on key factors identified by the severe RIOM prediction model|Intervention based on key factors identified by the severe RIOM prediction model
219506497|NCT02989766|BEHAVIORAL|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
219506498|NCT00401219|DRUG|conjugated estrogens/progestin (MPA)|
219506499|NCT03961464|DRUG|d-cycloserine|Single dose
218884830|NCT00014079|GENETIC|loss of heterozygosity analysis|
218884831|NCT00014079|GENETIC|microsatellite instability analysis|
219201248|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 2|Investigational varicella vaccine of Lot 2 administered subcutaneously.
219201249|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 3|Investigational varicella vaccine of Lot 3 administered subcutaneously.
219201250|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 1|Marketed varicella vaccine of Lot 1 administered subcutaneously.
219201251|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 2|Marketed varicella vaccine of Lot 2 administered subcutaneously.
219506500|NCT03961464|DRUG|Placebo|Single dose
218884832|NCT00431015|DRUG|IPI-504|IV Hsp90 inhibitor
218884833|NCT00154440|DRUG|proton pump inhibitor|
218884834|NCT00154440|DRUG|clarithromycin|
218884835|NCT00154440|DRUG|amoxicillin|
218884836|NCT00154440|DRUG|metronidazole|
218884837|NCT00154440|PROCEDURE|radiation therapy|
218884838|NCT01051336|DEVICE|TARIS Placebo|
218884839|NCT01051336|PROCEDURE|Sham Procedure|
219607338|NCT05548387|DRUG|RLD2202|Take it once per period.
219607339|NCT05548387|DRUG|RLD2203|Take it once per period.
219029017|NCT00690092|BIOLOGICAL|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
219029018|NCT01568931|DRUG|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
219029019|NCT01568931|DRUG|Saline|intracoronary, saline, bolus 1 cc
219607340|NCT00005805|DIETARY_SUPPLEMENT|St. John's wort|
219607341|NCT03916705|OTHER|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
219029020|NCT04826770|DRUG|BNT162b2|vaccination against COVID-19
219029021|NCT04826770|DRUG|AZD 1222|vaccination against COVID-19
219029022|NCT04826770|DRUG|mRNA-1273|vaccination against COVID-19
219029023|NCT03498625|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
219029024|NCT05218473|DIAGNOSTIC_TEST|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
219607342|NCT02290405|BEHAVIORAL|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
219607343|NCT03789929|BEHAVIORAL|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
219506501|NCT01892579|BEHAVIORAL|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
219607344|NCT03789929|BEHAVIORAL|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
219607345|NCT02460146|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
218884840|NCT04769570|PROCEDURE|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
218884841|NCT04769570|PROCEDURE|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
218884842|NCT04769570|PROCEDURE|Group Control|consist of the patient group without any procedure.
219029025|NCT05218473|DIAGNOSTIC_TEST|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
219607346|NCT02460146|OTHER|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
219607347|NCT04393714|PROCEDURE|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
219607348|NCT01609868|DIETARY_SUPPLEMENT|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
219607349|NCT01609868|DIETARY_SUPPLEMENT|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
219029026|NCT00955942|DIETARY_SUPPLEMENT|flaxseed|Given orally
219029027|NCT00955942|OTHER|placebo|Given orally
219029028|NCT06201533|BEHAVIORAL|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
219607350|NCT05925998|OTHER|Observational study: no interventions|Not applicable as observational study with no intervention
219607351|NCT02016183|DRUG|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
219029029|NCT03879382|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
219607352|NCT06490978|RADIATION|CT Brain|Patient needs follow up ct brain , cbc , CRP
219607353|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, one single dose
219607354|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, once daily for 5 days
219607355|NCT02535689|DRUG|Tofacitinib|Oral administration of tofacitinib, 5 mg
219607356|NCT02535689|DRUG|Placebo|
219607357|NCT00996489|DEVICE|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
219607358|NCT03142191|DRUG|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
219607359|NCT03142191|OTHER|Placebo|Placebo
219607360|NCT05149391|BIOLOGICAL|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
218884843|NCT04755608|OTHER|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
218884844|NCT04755608|OTHER|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
218884845|NCT00659932|BEHAVIORAL|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
219029030|NCT03879382|DRUG|Fludarabine|30mg/m2/d
219607361|NCT05682612|OTHER|outcome|hospital survivors and nonsurvivors
219607362|NCT05682612|OTHER|Subtype of COVID-19|Different subtype of COVID-19
218884846|NCT00659932|BEHAVIORAL|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
219029031|NCT03879382|DRUG|Cyclophosphamide|300mg/m2/d
219029032|NCT06210490|DRUG|Disitamab Vedotin|Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.
219506502|NCT01892579|OTHER|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
219607363|NCT06329739|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
219201252|NCT06740630|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
219506503|NCT04388891|DEVICE|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
219506504|NCT02506166|DEVICE|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
219506505|NCT04296357|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
219506506|NCT04296357|OTHER|Physical development and General Health|Physical development and General health examination
219506507|NCT04296357|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
219201253|NCT06740630|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
219201254|NCT06740630|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219607364|NCT00825786|DRUG|Ropivacaine|ropivacaine (15 ml).
219607365|NCT00825786|DRUG|Mepivacaine|One syringe will contain mepivacaine (15 ml)
219607366|NCT02257281|DEVICE|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
219607367|NCT02257281|DEVICE|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
219506508|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
219506509|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
219506510|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
219522661|NCT05628675|OTHER|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
219607368|NCT06582550|PROCEDURE|Minor Hand Procedure|Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)
218884847|NCT02610777|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
218884848|NCT02610777|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
218884849|NCT06825832|DEVICE|high power laser therapy|The MLS® Laser Therapy device used in this study is M6 (ASA srl -Arcugnano, Italy), equipped with both a robotized multidiode head (up to 3,3W), able to perform automatic scanning treatments, and an MLS® handpiece (up to 1,1W), aimed to perform manual point to point or scanning treatments. Each treatment includes two stages: the scanning of the frontal and dorsal shoulder area of 93 cm2 each with a robotized multidiode head and a point-by-point process with the manual handpiece with 7 points of 3,14 cm2 area.
218884850|NCT06825832|DEVICE|pulsed electromagnetic field therapy|the PEMF application, with application of low intensity and frequency pulsed electromagnetic fields (PEMF), the portable device PMT QS (ASA Srl, Arcugnano) is used, equipped with Flexa applicators (36 x 21 x 2 cm (L x P x H) - 1.2 kg), programmable frequency from 0.5 to 100 Hz and variable magnetic field intensity from 5% to 100% (from \~2.5 to \~40 Gauss)), two solenoid applicators are placed at the anterior and posterior positions in the patient's shoulders and applied for 25 min at 25 G intensity at a frequency of 50 Hz.
218884851|NCT06825832|OTHER|Exercise|The conventional exercise program for hemiplegic shoulder pain (HSP) is stretching exercise therapy, joint stabilization exercise therapy.
219607369|NCT02445534|BIOLOGICAL|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
219607370|NCT02569190|DEVICE|Walkbot|Robot assisted gait training
219506511|NCT03987438|BEHAVIORAL|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
219506512|NCT04782102|BEHAVIORAL|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
219506513|NCT03592875|BEHAVIORAL|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
219506514|NCT06484036|PROCEDURE|periodontal treatment strategy|Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
219029033|NCT06210490|RADIATION|Radiotherapy|Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.
219506515|NCT03445975|PROCEDURE|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
219506516|NCT02806232|DRUG|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
219506517|NCT02806232|DRUG|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
219029034|NCT06210490|OTHER|Standard of Care|Standard of Care
219029035|NCT01256554|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
219506518|NCT02806232|DRUG|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
219506519|NCT05583383|DRUG|camrelizumab|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
219506520|NCT00387998|OTHER|AHRQ staying healthy booklet|educational booklet about prevention
219029036|NCT01256554|BEHAVIORAL|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
219029037|NCT02081079|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
219029038|NCT05363384|DRUG|CT-L01|FDC tablet, single dose, oral administration
219506521|NCT00387998|OTHER|Risk primer|Know your chances booklet
219522662|NCT03927066|OTHER|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
219029039|NCT05363384|DRUG|Alogliptin Benzoate 25 mg|Alogliptin Benzoate 25 mg, oral administration
219029040|NCT05363384|DRUG|Metformin HCl XR 1,000 mg|Metformin HCl XR 1,000 mg, oral administration
219029041|NCT03456596|OTHER|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
219029042|NCT01712854|DRUG|Budesonide|budesonide 80 mcg
219029043|NCT01712854|DRUG|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
219029044|NCT04094467|DRUG|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
219029045|NCT04094467|DRUG|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
219029046|NCT05195723|DRUG|WP1122|Oral solution
219029047|NCT05195723|DRUG|Placebo|Oral solution
219522663|NCT04486066|BEHAVIORAL|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
219522664|NCT04486066|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
218884852|NCT02451917|DRUG|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
219506522|NCT04586647|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
218884853|NCT02451917|DRUG|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
218884854|NCT00493259|BEHAVIORAL|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
218884855|NCT00493259|BEHAVIORAL|Depression Scale for Children (CES-DC)|questionnaire
218884856|NCT05474573|DEVICE|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
218884857|NCT05474573|DEVICE|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
218884858|NCT01460134|DRUG|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
218884859|NCT01460134|DRUG|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
218884860|NCT01460134|DRUG|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
218884861|NCT02324283|DRUG|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
218884862|NCT02324283|DRUG|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
218884863|NCT01316874|DRUG|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
218884864|NCT02038335|DRUG|DMPA|Depot medroxyprogesterone acetate
219506523|NCT05073653|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
219506524|NCT05073653|DIAGNOSTIC_TEST|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
219607371|NCT02166710|DEVICE|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
218884865|NCT02038335|DRUG|NET-EN|Norethisterone enantate
218884866|NCT02038335|DRUG|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
218884867|NCT02038335|DEVICE|LNG-I|Levonorgestrel subdermal implant
218884868|NCT02038335|DEVICE|ENG-I|Etonogestrel subdermal implant
218884869|NCT02038335|DEVICE|Cu-IUD|Copper IUD
218884870|NCT03666871|BIOLOGICAL|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
218884871|NCT03666871|BIOLOGICAL|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
218884872|NCT05694455|DIAGNOSTIC_TEST|Starling Stroke Volume (Starling SV)- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an Starling SV device to look at Stroke Volume change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
218884873|NCT05694455|DIAGNOSTIC_TEST|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging performed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
218884874|NCT05694455|DIAGNOSTIC_TEST|Venous Excess Ultrasound Scoring (VExUS)|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the Inferior Vena Cava diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
218884875|NCT05694455|OTHER|Urine Collection|The urine assay is collected passively from the patient will be ran through a Dimethylmethylene blue (DMMB assay)- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
218884876|NCT03032263|DEVICE|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
218884877|NCT03032263|DEVICE|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
218884878|NCT03385148|DRUG|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
218884879|NCT02432586|BEHAVIORAL|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
218884880|NCT06384157|DRUG|INDV-2000|INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
218884881|NCT06384157|OTHER|Placebo|This is a randomized, double-blind, placebo-controlled study.
218884882|NCT02300259|DRUG|LY2623091|Administered orally
218884883|NCT02300259|DRUG|Itraconazole|Administered orally
218884884|NCT02300259|DRUG|Simvastatin|Administered orally
218884885|NCT02300259|DRUG|Tadalafil|Administered orally
218884886|NCT02300259|DRUG|Diltiazem|Administered orally
218884887|NCT03951272|DEVICE|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
218884888|NCT04737278|DRUG|Cunermuspir|"Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide"
218884889|NCT04737278|OTHER|Placebo|same non-medical ingredients and encapsulation as Intervention 1
218884890|NCT02737475|DRUG|BMS-986178|Specified dose on specified days
219201255|NCT06740630|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219506525|NCT04133181|DEVICE|3D guide|Use of a 3D guide in endodontic surgery
218884891|NCT02737475|DRUG|Nivolumab|Specified dose on specified days
218884892|NCT02737475|DRUG|Ipilimumab|Specified dose on specified days
218884893|NCT02737475|BIOLOGICAL|Tetanus vaccine|Specified dose on specified days
218884894|NCT02737475|BIOLOGICAL|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
218884895|NCT02737475|DRUG|Cyclophosphamide|Specified dose on specified days
218884896|NCT04867551|DRUG|KDT-3594|oral administration, dose titration
219506526|NCT04133181|DEVICE|Mock guide|Use of a mock guide in endodontic surgery
218884900|NCT05048316|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
218884901|NCT06244472|DEVICE|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
218884902|NCT06244472|DEVICE|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
218884903|NCT06244472|DEVICE|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
218884904|NCT06244472|DEVICE|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
218884905|NCT02338986|DRUG|Plasma|Plasma
218884906|NCT05147805|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
218884907|NCT05147805|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
218884908|NCT04227093|DRUG|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
218884909|NCT04227093|DRUG|Placebo|Matching placebo tablets taken twice daily.
218884910|NCT02741141|OTHER|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
218884911|NCT02741141|OTHER|Classical partograph|Classical partograph used as standard care
218884912|NCT06146829|OTHER|no intervention|no intervention
218884913|NCT00410930|BIOLOGICAL|Subcutaneous immunotherapy - Recombinant birch pollen|
218884914|NCT00546000|DRUG|Fluticasone propionate 0.05% lotion|Daily applications
219029048|NCT02225743|OTHER|Observation Of Temperature|Participants temperature will be recorded perioperatively.
219506527|NCT00759148|DRUG|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
219506528|NCT00759148|OTHER|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
219506529|NCT03308448|DRUG|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
219201256|NCT06740630|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219506530|NCT01817348|PROCEDURE|Lidocaine group|"* Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
219506531|NCT01817348|OTHER|Physiotherapy (PT)|\- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
219506532|NCT06430879|DEVICE|VICTORY PATCH|Drug- free, non-invasive patch (VICTORY Patch) with haptic vibrotactile trigger technology (VTT)
219506533|NCT06430879|DEVICE|Sham Patch without VTT|Sham Patch without haptic vibrotactile trigger technology (VTT)
218884915|NCT00959595|DRUG|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
219506534|NCT02954679|OTHER|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
218884916|NCT00959595|DRUG|EMLA cream|50g applied according to description of intervention
218884917|NCT05054426|DRUG|Methotrexate|intravenous versus intrathecal methotrexate
218884918|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
219201257|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
219506535|NCT04593290|DEVICE|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
218884919|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
218884920|NCT00654082|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
218884921|NCT00654082|DRUG|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
219201258|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
218884922|NCT03231852|OTHER|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
218884923|NCT05213520|OTHER|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
219364564|NCT02970695|DEVICE|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
219506536|NCT00846378|PROCEDURE|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
219506537|NCT00846378|PROCEDURE|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
219506538|NCT05207215|OTHER|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
219506539|NCT00803959|OTHER|Office evaluation|Office evaluation
219506540|NCT00803959|OTHER|UDS|Urodynamics
218884924|NCT05213520|OTHER|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
219506541|NCT03213756|DEVICE|Isometric exercises using Hand grip and elastic bands|"* Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~* Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
219506542|NCT03803709|DIETARY_SUPPLEMENT|inulin|inulin given at different dosis from day 3 to day 20
218884925|NCT02255461|DRUG|palbociclib isethionate|Given PO
218884926|NCT02255461|OTHER|pharmacological study|Correlative studies
218884927|NCT02255461|OTHER|laboratory biomarker analysis|Correlative studies
218884928|NCT04648683|BEHAVIORAL|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
219506543|NCT03803709|DIETARY_SUPPLEMENT|placebo|maltodextrine given at different dosis from day 3 to day 20
219506544|NCT05293028|DRUG|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
218884929|NCT04648683|BEHAVIORAL|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
218884930|NCT01736670|DRUG|Triamcinolone Acetonide spray|
218884931|NCT01736670|DRUG|Triamcinolone acetonide cream|
218884932|NCT01736670|DRUG|Alcohol spray|
218884933|NCT05236673|DRUG|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
219506545|NCT05409911|DRUG|S-217622|Tablet for oral administration
218884934|NCT03056339|DRUG|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
218884935|NCT03056339|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
218884936|NCT03056339|DRUG|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
218884937|NCT03056339|BIOLOGICAL|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
218884938|NCT03056339|DRUG|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
218884939|NCT01048658|DRUG|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
218884940|NCT01048658|OTHER|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
218884941|NCT00195533|DRUG|piperacillin-tazobactam|
218884942|NCT00195533|DRUG|glycopeptide|
218884943|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
218884944|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
218884945|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
218884946|NCT01504412|DRUG|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
218884947|NCT01504412|DRUG|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
218884948|NCT03529968|PROCEDURE|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
218884949|NCT05224453|OTHER|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)
218884950|NCT05224453|OTHER|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
218884951|NCT04055909|DRUG|nangibotide low dose|nangibotide 0.3 mg/kg/h
218884952|NCT04055909|DRUG|nangibotide high dose|nangibotide 1.0 mg/kg/h
218884953|NCT04055909|DRUG|placebo|matching placebo
218884954|NCT02075151|PROCEDURE|Bronchial Thermoplasty|Bronchial thermoplasty
218884955|NCT05945446|DIAGNOSTIC_TEST|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
218884956|NCT03770221|BEHAVIORAL|CATCH|Brief, intensive case management service.
218884957|NCT03770221|OTHER|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
218884958|NCT02581735|OTHER|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
218884959|NCT00999440|DRUG|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
219506546|NCT00861783|DRUG|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
219506547|NCT00861783|DRUG|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
219506548|NCT05133128|OTHER|blood samples|blood samples
219506549|NCT00434161|DRUG|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
219506550|NCT00434161|DRUG|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
219506551|NCT00434161|DRUG|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
219506552|NCT01580761|BEHAVIORAL|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
219506553|NCT03342898|BIOLOGICAL|YF-17D|YF-17D SC injection.
219506554|NCT03342898|BIOLOGICAL|TDV|TDV SC injection.
218884960|NCT03374371|DIAGNOSTIC_TEST|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
218884961|NCT03833063|DRUG|botulinum toxin A|glabellar injections with botulinum toxin A
218884962|NCT03833063|DRUG|Placebos|glabellar injections with sodium chloride
218884963|NCT05314335|OTHER|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
218884964|NCT05314335|OTHER|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
218884965|NCT03975686|OTHER|neuromuscual realigning exercise|neuromuscular realigning exercise
218884966|NCT02148055|OTHER|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
218884967|NCT01805479|OTHER|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
219506555|NCT03342898|DRUG|Placebo|Normal Saline (0.9% NaCl) SC injection.
219506556|NCT01387282|DRUG|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
219506557|NCT01387282|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
218884968|NCT01805479|OTHER|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
219506558|NCT05866146|OTHER|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
218884969|NCT01983085|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
218884970|NCT01983085|DEVICE|Standard of Care|Dressing changed as per normal clinical practice
218884971|NCT03654508|GENETIC|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
218884972|NCT03654508|OTHER|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
218884973|NCT05935332|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
219201259|NCT06739109|PROCEDURE|Therapy-guided internet-based treatment program|eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
219201260|NCT06739200|PROCEDURE|Platelet-Rich Fibrin (PRF) Membrane|The Platelet-Rich Fibrin (PRF) membrane is a biocompatible material derived from the participant's own blood and prepared through centrifugation. It is applied at the surgical site during periapical surgery to promote tissue regeneration, enhance wound healing, and reduce postoperative swelling and pain. Unlike synthetic materials, PRF is autologous and does not require additional chemical additives or processing. This study aims to evaluate its effectiveness in improving recovery outcomes compared to surgery without PRF membrane placement.
219201261|NCT06887998|DRUG|Gabapentin 600 mg capsules|21 patients will receive 600 mg oral gabapentin one hour before induction.
219201262|NCT06887998|DRUG|Gabapentin 400 mg capsules|21 patients will receive 400 mg oral gabapentin one hour before induction.
219506559|NCT05866146|OTHER|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
219506560|NCT00311818|DRUG|Insulin glargine|
219506561|NCT03565549|BEHAVIORAL|Mnemonic|A mnemonic used as a memory aid
219506562|NCT03565549|BEHAVIORAL|CCHR rule|A list of the CCHR items
218884974|NCT05935332|OTHER|Placebo|placebo
218884975|NCT04406675|OTHER|neuropsychological test|neuropsychological test
218884976|NCT03261219|DEVICE|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
218884977|NCT03261219|DEVICE|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
218884978|NCT00939536|DRUG|Zolpidem Tartrate Tablets 10 mg|
218884979|NCT02527785|DRUG|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7"
218884980|NCT05403671|OTHER|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
219506563|NCT04936971|DRUG|Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm|Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
219506564|NCT04936971|OTHER|no intervention|Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
219506565|NCT01903577|OTHER|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
219506566|NCT01903577|OTHER|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
219506567|NCT00000654|DRUG|Fialuridine|
219506568|NCT00043706|DRUG|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
219506569|NCT02745002|DEVICE|navigated bronchoscopy|
219506570|NCT02100865|DEVICE|Solar powered oxygen|
219506571|NCT02100865|DEVICE|Oxygen from cylinders|
219506572|NCT00295126|PROCEDURE|cellular therapy : Autologous platelet concentrate (APC)|
219506573|NCT03165565|BEHAVIORAL|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
219506574|NCT03165565|BEHAVIORAL|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
218884981|NCT00589771|DRUG|Saccharomyces boulardii|"1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
218884982|NCT00589771|DRUG|Placebo|"1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
218884983|NCT01692977|OTHER|neuropsychological assessment|
218884984|NCT05729932|DRUG|Inhaled vaporized cannabis|Double-blind cannabis and placebo doses, administered through vaporizer
218884985|NCT05729932|DRUG|Intransal opioid|Double-blind opioid and placebo doses, administered intranasal route
218884986|NCT04729075|OTHER|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
218884987|NCT03231007|OTHER|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
219506575|NCT01604044|DRUG|Meropur 150 a day|one subcutaneous injection a day
219506576|NCT01604044|DRUG|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
219506577|NCT02661126|DRUG|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
219506578|NCT03997448|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
219506579|NCT03997448|DRUG|Abemaciclib|Abemiciclib 150mg PO
219506580|NCT05408286|BEHAVIORAL|administration of questionnaires|administration of questionnaires
219506581|NCT03110666|BIOLOGICAL|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
218884988|NCT01120106|DRUG|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
218884989|NCT01120106|DRUG|placebo|saline continuous infusion
219201263|NCT06887998|DRUG|Placebo|21 patients will receive placepo one hour before induction.
219201264|NCT06889155|DRUG|Oxytocin|10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.
219201265|NCT06747286|OTHER|Virtual Game Simulation|A virtual computer game that enables participation in a clinical scenario to measure competence.
219506582|NCT03778866|OTHER|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
219506583|NCT01921426|DRUG|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
219506584|NCT04208139|DIAGNOSTIC_TEST|IVUS|IVUS
219506585|NCT00040872|BIOLOGICAL|filgrastim|
219506586|NCT00040872|BIOLOGICAL|monoclonal antibody 3F8|
219506587|NCT00040872|BIOLOGICAL|sargramostim|
219506588|NCT00040872|DRUG|carboplatin|
219506589|NCT00040872|DRUG|cisplatin|
219506590|NCT00040872|DRUG|cyclophosphamide|
219506591|NCT00040872|DRUG|doxorubicin hydrochloride|
219506592|NCT00040872|DRUG|etoposide|
219506593|NCT00040872|DRUG|isotretinoin|
219506594|NCT00040872|DRUG|thiotepa|
219506595|NCT00040872|DRUG|topotecan hydrochloride|
219506596|NCT00040872|DRUG|vincristine sulfate|
218884990|NCT06172179|OTHER|No interventions|All procedures are observation. No intervention in this study.
218884991|NCT04157803|DIAGNOSTIC_TEST|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
219364565|NCT02970695|DEVICE|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
219364566|NCT04088409|DRUG|Baricitinib|Administered orally
219506597|NCT00040872|PROCEDURE|autologous bone marrow transplantation|
219506598|NCT00040872|PROCEDURE|bone marrow ablation with stem cell support|
219506599|NCT00040872|PROCEDURE|conventional surgery|
219506600|NCT00040872|PROCEDURE|drug resistance inhibition treatment|
219506601|NCT00040872|PROCEDURE|peripheral blood stem cell transplantation|
219506602|NCT00040872|PROCEDURE|syngeneic bone marrow transplantation|
219506603|NCT00040872|RADIATION|radiation therapy|
219506604|NCT04581538|DEVICE|Intervention of parallel arm 2|"This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care."
219506605|NCT04581538|DEVICE|Intervention of parallel arm 3|"Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed."
219522665|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
219522666|NCT01183585|DRUG|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
219506606|NCT03932084|BEHAVIORAL|Control group|"During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
219522667|NCT00079625|DRUG|Th2/Tc2 Cells|
218884992|NCT00644150|BEHAVIORAL|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
219201266|NCT06751134|DRUG|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
219522668|NCT00898508|GENETIC|gene expression analysis|
219522669|NCT00898508|GENETIC|mutation analysis|
219522670|NCT00898508|GENETIC|proteomic profiling|
219522671|NCT00898508|GENETIC|reverse transcriptase-polymerase chain reaction|
219522672|NCT00898508|OTHER|fluorescent antibody technique|
218884993|NCT00644150|DRUG|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
219029049|NCT06054087|PROCEDURE|Basal therapy+EA|"1. Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~2. Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25\*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
219029050|NCT06054087|OTHER|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
219029051|NCT02535845|BEHAVIORAL|Project Voice|Project Voice tablet-based intervention plus informational video
219029052|NCT02535845|BEHAVIORAL|HPV Informational Video|Informational video only
219201267|NCT06048783|BEHAVIORAL|Program of systematic and periodic spiritual accompaniment and care|Systematic and periodic spiritual accompaniment and care
219201268|NCT06747013|DEVICE|Point Ablation Catheter|a point ablation catheter using a pulse field energy
219201269|NCT05564130|DRUG|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
219201270|NCT05564130|DRUG|Sodium chloride|Sodium chloride 9 mg/mL
219522673|NCT00898508|OTHER|immunohistochemistry staining method|
219522674|NCT00898508|OTHER|laboratory biomarker analysis|
219522675|NCT00898508|OTHER|liquid chromatography|
219522676|NCT00898508|OTHER|mass spectrometry|
219522677|NCT00898508|OTHER|medical chart review|
219522678|NCT00898508|PROCEDURE|quality-of-life assessment|
219522679|NCT06569615|OTHER|shock wave therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks."
219522680|NCT06569615|OTHER|LASER Therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
219522681|NCT06569615|OTHER|Cryotherapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
218884994|NCT00644150|BEHAVIORAL|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
218884995|NCT02926989|DRUG|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
218884996|NCT02926989|DRUG|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
218884997|NCT05043753|OTHER|Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)|"Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016)."
218884998|NCT06251297|OTHER|Foot reflexology|30 minutes reflexology session
218884999|NCT05357521|OTHER|stress test|TSST- psychosocial stress test
218885000|NCT05485038|PROCEDURE|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
219607372|NCT02166710|DEVICE|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
219607373|NCT05766137|PROCEDURE|Alveolar ridge preservation|Socket preservation
219607374|NCT04652778|DEVICE|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
219607375|NCT04298632|BEHAVIORAL|Safety Education Program|this is a pesticide safety education program
219607376|NCT00676832|DRUG|Placebo|Placebo solid capsule dosage form administered orally once daily.
218885001|NCT05485038|PROCEDURE|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
218885002|NCT05294445|PROCEDURE|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
218885003|NCT06489951|DRUG|Solifenacin|The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
219029053|NCT00322842|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
219029054|NCT02518867|OTHER|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
219364567|NCT04088409|DRUG|Adalimumab|Administered SC
219364568|NCT03025256|PROCEDURE|Biospecimen Collection|Correlative studies
219607377|NCT00676832|DRUG|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
219607378|NCT02547532|OTHER|collection of sputum|
219607379|NCT01946932|OTHER|Temperature treatment|
219607380|NCT05574361|DEVICE|Hypothermic Machine Perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
218885004|NCT06489951|DIETARY_SUPPLEMENT|vitamin D|The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants
218885005|NCT06489951|BEHAVIORAL|Standard behavioral therapy|Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
218885006|NCT06765590|DRUG|T, 260 mg/m2, paclitaxel for injection (albumin-bound)|T, 260 mg/m2, paclitaxel for injection (albumin-bound)
218885007|NCT06765590|DRUG|R, 260 mg/m2, paclitaxel for injection (albumin bound).|R, 260 mg/m2, paclitaxel for injection (albumin bound).
218885008|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
219364569|NCT03025256|PROCEDURE|Computed Tomography|Undergo CT
219364570|NCT03025256|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture for cerebrospinal fluid collection
219364571|NCT03025256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of brain and spine
219364572|NCT03025256|BIOLOGICAL|Nivolumab|Given IV or IT
219364573|NCT03025256|PROCEDURE|Positron Emission Tomography|Undergo PET
219364574|NCT04233229|DEVICE|t:slim X2 with Control-IQ|closed-loop in patients at home for three months
219364575|NCT04233229|OTHER|home healthcare services|home healthcare services from Air Liquide in patients at home for three months
219607381|NCT00428233|PROCEDURE|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
218885009|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
218885010|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
218885011|NCT04171219|DRUG|Talabostat Mesylate|Given PO
219506607|NCT03932084|BEHAVIORAL|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
219506608|NCT04758650|DRUG|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
219506609|NCT04632823|COMBINATION_PRODUCT|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
219506610|NCT04363983|BIOLOGICAL|Blood sampling|"Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,…; methylation) and circulating tumor cells."
219506611|NCT04363983|PROCEDURE|Liver biopsy|"An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.~This biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.~This biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed."
219506612|NCT04363983|BIOLOGICAL|Stool collect|"Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Analysis will be performed for microbiota and metabolism analysis."
219506613|NCT01182233|RADIATION|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
219506614|NCT01544790|PROCEDURE|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
219607382|NCT05975528|DRUG|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
218885012|NCT05430113|DEVICE|Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)|2-4 leads FDA-approved for treatment of symptoms of refractory pain
219607383|NCT05975528|DRUG|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
219607384|NCT00770328|DRUG|Pentoxifylline|400mg PO TID x 8 weeks
219607385|NCT00770328|DRUG|Placebo|PO TID x 8 weeks
219607386|NCT03688633|DRUG|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
219607387|NCT03688633|OTHER|Usual care|patients will be followed as usual
219607388|NCT05208489|OTHER|there is no intervention involved in this study|there is no intervention involved in this study.
219607389|NCT05709210|OTHER|Recording of smartphone usage data|Recording of smartphone usage data
219607390|NCT05015829|DIAGNOSTIC_TEST|Dobutamine Stress Echocardiography|Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
218885013|NCT03988764|OTHER|None AHT|No further intervention planned for either group as part of the current study.
218885014|NCT06234254|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
218885015|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
218885016|NCT06291480|BEHAVIORAL|Neurologic Music Therapy|Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
219506615|NCT03892759|OTHER|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
218885017|NCT06474312|BEHAVIORAL|Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
218885018|NCT05637398|DRUG|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
219506616|NCT04383002|DRUG|Nitric Oxide|iNO will be given at 160ppm for 6 hours, once a day, for 2 days
219506617|NCT02269215|DRUG|BIII 890 CL|
219506618|NCT02269215|DRUG|Placebo|
219522682|NCT06569615|OTHER|Exercises|The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
219522683|NCT05876156|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
219522684|NCT05876156|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
219522685|NCT05632640|OTHER|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
218885019|NCT02444052|DEVICE|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
218885020|NCT02444052|DEVICE|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
218885021|NCT04276519|PROCEDURE|Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen|Opening of the mechanical interface of the nerve root, neurodynamics
218885022|NCT02837185|PROCEDURE|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
218885023|NCT02837185|OTHER|Physiological measures|These include TMS and EMG measurements
218885024|NCT04694560|OTHER|Treatment Free Observation|Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
218885025|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
218885026|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
218885027|NCT05477680|DEVICE|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
218885029|NCT06583707|PROCEDURE|Dry needling with and without ultrasound guidance|The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
218885030|NCT04543227|BEHAVIORAL|Opioid Use 90-Days Post Treatment|Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
218885031|NCT05097495|PROCEDURE|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~* Materials shall be prepared (napkins, non-sterile gloves, pacifier)~* Hands shall be washed; gloves shall be worn.~* The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
218885032|NCT05097495|PROCEDURE|NNS Combined with Breast Milk|"* Before the procedure, the Premature Infant Comfort Scale shall be filled out.~* Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~* Hands shall be washed; gloves shall be worn.~* The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
219506619|NCT02917447|BEHAVIORAL|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
219506620|NCT02917447|BEHAVIORAL|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
219506621|NCT05163509|COMBINATION_PRODUCT|Unity-based MR-Linac guided Radiotherapy|The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
219506622|NCT02482805|BEHAVIORAL|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
219506623|NCT00440154|DRUG|AVE5530|
219506624|NCT00440154|DRUG|placebo|
219506625|NCT00440154|DRUG|ezetimibe|
219506626|NCT02314533|DRUG|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
219506627|NCT02934295|BIOLOGICAL|Determination of Anti-Rubella Antibody, E1|
219506628|NCT05710185|DRUG|Deucravacitinib|See arm/group description
219506629|NCT06081751|BEHAVIORAL|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
219029055|NCT02518867|OTHER|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
219029056|NCT02518867|OTHER|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
219029057|NCT02068222|DRUG|ABT-450/ritonavir (r)|Tablet
219029058|NCT02068222|DRUG|ABT-530|Tablet
219029059|NCT02068222|DRUG|Ribavirin (RBV)|Tablet
219029060|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
219029061|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
219522686|NCT05632640|DEVICE|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
219522687|NCT05118178|DIAGNOSTIC_TEST|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
219607391|NCT04500717|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219029062|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
219029063|NCT06161805|DRUG|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].
219029064|NCT06161805|DRUG|Placebo|8 hour infusion with saline (NaCl 0.9%)
219029065|NCT04706143|BIOLOGICAL|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
219029066|NCT03807011|DRUG|fentanyl group|fentanyl 2 μg/kg
219029067|NCT03807011|DRUG|remifentanil group|remifentanil 0.2 μg/kg/min
219029068|NCT04665050|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219029069|NCT04665050|BIOLOGICAL|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219029070|NCT00302458|DRUG|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
219029071|NCT00302458|DRUG|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
219029072|NCT00302458|DRUG|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
219029073|NCT03766854|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
219029074|NCT03766854|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
219029075|NCT06284226|DRUG|Allogeneic NK（CCT-ANK-11)|allogeneic natural killer cells
219029076|NCT02867709|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
219522690|NCT01113268|OTHER|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
219522691|NCT01491581|DIETARY_SUPPLEMENT|food bar|milk based food bar enriched with micronutrients
219522692|NCT01648166|OTHER|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
219506630|NCT06081751|BEHAVIORAL|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
219506631|NCT04538963|DEVICE|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
219506632|NCT03049683|OTHER|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
219506633|NCT00977925|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
219506634|NCT00977925|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
219506635|NCT04544176|OTHER|Observational|There will be no interventions in this study, it is purely observational using data already collected.
219506636|NCT00821392|DRUG|Febuxostat|
219506637|NCT06544304|DEVICE|PMMA|PMMA 30%
219506638|NCT00352157|BEHAVIORAL|Revival Soy Dietary Supplement|
219506639|NCT05533346|BEHAVIORAL|with WISE (Walking Instruction based on Self-Efficacy)|Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
219607392|NCT04500717|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
219607393|NCT03452943|DRUG|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
218885033|NCT03029923|BEHAVIORAL|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
219607394|NCT03452943|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
219607395|NCT01130493|DRUG|IPX066|experimental product
219607396|NCT01130493|DRUG|CLE|active comparator
219607397|NCT02589730|DEVICE|Welltang App|This App is a large platform of individualized diabetic management
219029077|NCT02867709|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
219029078|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 1|Accessorized Pre-Filled Syringe (Solution for injection)
219029079|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 2|Accessorized Pre-Filled Syringe (Solution for injection)
219029080|NCT06824987|COMBINATION_PRODUCT|Placebo|Accessorized Pre-Filled Syringe (Solution for injection).
219364576|NCT04233229|OTHER|usual care for daily insulin treatment|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
219364577|NCT00841763|BIOLOGICAL|Placebo (PL)|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
219364578|NCT00841763|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
219364579|NCT00841763|BIOLOGICAL|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
219364580|NCT00841763|BIOLOGICAL|Adjuvanted trivalent influenza virus vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
219364581|NCT02505282|OTHER|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
219364582|NCT04628923|OTHER|QUADRATUS LUMBORUM BLOCK|QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
219364583|NCT02631538|DRUG|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
219364584|NCT02631538|DRUG|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
219364585|NCT02631538|DRUG|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
219364586|NCT02631538|DRUG|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
219364587|NCT04677439|DRUG|Flumatinib|600 mg of Flumatinib orally daily for 24 months
219364588|NCT01609595|DRUG|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
219506640|NCT05533346|BEHAVIORAL|without WISE (Walking Instruction based on Self-Efficacy)|The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
219506641|NCT01489722|DRUG|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
219506642|NCT05503004|BEHAVIORAL|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
219029081|NCT06824987|DEVICE|APOL1 Genotyping Clinical Trial Assay|The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.
219029082|NCT06292780|DRUG|Linvoseltamab|anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
219029083|NCT04317417|BEHAVIORAL|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
219506643|NCT05503004|BEHAVIORAL|Standard care|Standard care before surgery
219506644|NCT04155164|DRUG|Metformin|Participants will receive Metformin at 1000mg for 12 months.
219029084|NCT06002958|DEVICE|Horyzons USA|Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
219029085|NCT04781088|DRUG|Lenvatinib|Given PO
219029086|NCT04781088|DRUG|Paclitaxel|Given IV
219029087|NCT04781088|BIOLOGICAL|Pembrolizumab|Given IV
219506645|NCT04155164|DRUG|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
219506646|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
219029088|NCT04481893|BEHAVIORAL|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~* The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~* The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
219029089|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
219029090|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
219029091|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
219029092|NCT06117813|DEVICE|Nu.T|Participants receive visual perceptual training using the Nu.T software.
219029093|NCT06117813|OTHER|No-Treatment Control|No-treatment was administered during control period.
219029094|NCT06095011|DEVICE|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
219506647|NCT00147381|DRUG|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
219506648|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
219506649|NCT01267266|DRUG|saracatinib|Given orally
219506650|NCT01267266|OTHER|hydrocortisone/placebo|Given orally
219506651|NCT03557138|BEHAVIORAL|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
219506652|NCT03492073|BEHAVIORAL|Emotional Supportive Mindfulness-based Program|Mindfulness training
219506653|NCT03492073|BEHAVIORAL|Emotional Supportive Program|Narrative-orientated therapy.
219607398|NCT01531088|BEHAVIORAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
219607399|NCT04138381|DRUG|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
219029095|NCT04105933|OTHER|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
219506654|NCT00002582|DRUG|CMF regimen|
219506655|NCT00002582|DRUG|cyclophosphamide|
219506656|NCT00002582|DRUG|doxorubicin hydrochloride|
219506657|NCT00002582|DRUG|fluorouracil|
219506658|NCT00002582|DRUG|goserelin acetate|
219506659|NCT00002582|DRUG|leuprolide acetate|
219506660|NCT00002582|DRUG|methotrexate|
219506661|NCT00002582|DRUG|tamoxifen citrate|
219506662|NCT00002582|PROCEDURE|oophorectomy|
219506663|NCT00002582|RADIATION|radiation therapy|
219506664|NCT00708929|PROCEDURE|Squatting|Squatting for 6 minutes
219506665|NCT04376723|OTHER|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
219607400|NCT04138381|DRUG|Imatinib|imatinib 400 mg, once daily (Cohort A)
219607401|NCT05031585|DEVICE|Roncoliv|The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.
218885034|NCT03029923|BEHAVIORAL|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
218885035|NCT02381015|GENETIC|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
219506666|NCT06544213|BEHAVIORAL|Control Group|60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.
219506667|NCT06544213|BEHAVIORAL|Countermeasure Supine Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position."
219506668|NCT06544213|BEHAVIORAL|Countermeasure AG-Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.~The supine bike exercise is performed in a short arm centrifuge in rotation. Volunteers will start pedalling and the centrifuge will start at 0.15 Gz less than individual's threshold.~Every 4 minutes thereafter, the AG will be increased by 0.15 Gz, synchronized with the ramping up of cycle ergometer interval intensity. The AG will increase only up to 70 % of their tolerance level,.~It will then decrease by 0.15 Gz every 4 minutes, and until the 30-minute exercise is completed."
219506669|NCT01470794|BIOLOGICAL|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
219506670|NCT01470794|DRUG|Toca FC|
219506671|NCT01555281|DRUG|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
219506672|NCT01555281|DRUG|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
219506673|NCT01555281|DRUG|Dexamethasone|40 mg (for patients \<75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
219506674|NCT03657199|DIAGNOSTIC_TEST|Cardiac computed tomography|Routine computed tomography of the heart before discharge
219506675|NCT00783679|DEVICE|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
219506676|NCT03306056|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
219506677|NCT03306056|OTHER|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
219506678|NCT03306056|OTHER|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
219029096|NCT04105933|OTHER|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
219506679|NCT03306056|OTHER|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks"
219506680|NCT06243978|BEHAVIORAL|liebria|Participants will receive access to the digital health intervention liebria in addition to TAU
219506681|NCT06243978|OTHER|information brochure on hypertension|Participants will receive an information brochure on hypertension
218885036|NCT02381015|GENETIC|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
218885037|NCT02381015|BEHAVIORAL|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
218885038|NCT02381015|BEHAVIORAL|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
219607402|NCT05031585|DEVICE|Placebo|The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
219029097|NCT06591949|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
219029098|NCT06591949|OTHER|Control group|Control group will be followed up with a home exercise program, and notes will be taken.
219029099|NCT06593600|DRUG|REGN7544|Subcutaneous (SC) administration
219607403|NCT03730207|DEVICE|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
218885039|NCT02084550|DIETARY_SUPPLEMENT|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
218885040|NCT02084550|OTHER|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
218885041|NCT02779049|OTHER|Blood examination|blood sampling
218885042|NCT06011837|DEVICE|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
219029100|NCT06593600|DRUG|Placebo|SC administration
219029101|NCT00119418|DRUG|TU 025 Keishi Bukuryo Gan|
219506682|NCT00213954|PROCEDURE|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
219506683|NCT00878345|DRUG|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
218885043|NCT00002203|DRUG|Lamivudine/Zidovudine|
218885044|NCT00002203|DRUG|Lamivudine|
218885045|NCT00002203|DRUG|Zidovudine|
218885046|NCT01449006|DRUG|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
218885047|NCT03350815|DRUG|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
219029102|NCT02653560|DRUG|Potassium chloride powder|
219201271|NCT06588842|OTHER|Cluster Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
219201272|NCT06588842|OTHER|Traditional Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
219201273|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Focal Muscle Vibration|\- Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. -Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. -SMV (15 minutes): Administered during the last part of each physiotherapy session. Experimental Group: SMV is applied to the trapezius (middle/descending fibers) and quadratus lumborum bilaterally at 80 Hz with an amplitude of 0.5 mm.
219029103|NCT02653560|DRUG|Potassium magnesium Citrate (KMgCit)|
219029104|NCT02653560|DRUG|Potassium citrate powder|
219029105|NCT02653560|DRUG|Placebo|
219029106|NCT06611072|PROCEDURE|Bone marrow aspiration|Bone marrow samples (40 ml) will be obtained from the sternum or the iliac crest according to standard practice by experienced operators during the surgery patients will undergo as part of their medical treatment. BM mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single-cell RNA- sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
219506684|NCT00878345|DRUG|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
219506685|NCT05058144|DIETARY_SUPPLEMENT|Drinkable solution|the volunteer will consume the volume 300 ml of water with
219506686|NCT05118282|BEHAVIORAL|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
219506687|NCT05118282|BEHAVIORAL|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
219506688|NCT00401882|DRUG|Epinephrine|Epinephrine (1 mg) IV additional doses
219506689|NCT00401882|DRUG|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
218885048|NCT03350815|DRUG|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
218885049|NCT03350815|DRUG|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
218885050|NCT00863499|DRUG|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
218885051|NCT00863499|DRUG|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
218885052|NCT00350688|RADIATION|Helical tomotherapy IMRT|Helical tomotherapy IMRT
218885053|NCT01015781|PROCEDURE|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
219029107|NCT06611072|PROCEDURE|Vena puncture|Whole blood (60 ml) will be collected and peripheral blood mononuclear cells (PBMC) will be isolated using Ficoll-Paque. Cellular subpopulations will be purified using negative selection of monocytes with PanMonocyte beads by MACS.
219029108|NCT06611072|PROCEDURE|Peritoneal fluid|Peritoneal fluid will be collected during the surgery.
219506690|NCT02802514|DRUG|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
219506691|NCT02802514|DRUG|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
219506692|NCT02802514|DRUG|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
219506693|NCT02802514|DRUG|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
219506694|NCT01828255|DEVICE|SENSIMED Triggerfish®|
219506695|NCT03242122|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
219506696|NCT03242122|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
219607404|NCT03730207|DEVICE|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
218885054|NCT01015781|PROCEDURE|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
218885055|NCT03132701|DRUG|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
219029109|NCT06611072|PROCEDURE|Spleen biopsy|Spleen samples will be obtained by experienced surgeons during the debulking surgery. Spleen mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Cellular subpopulations will be further purified using negative selection of monocytes with PanMonocyte beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single- cell RNA-sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
219506697|NCT03242122|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
219506698|NCT03242122|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
219506699|NCT03242122|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
219506700|NCT06530069|OTHER|exposures|exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
219607405|NCT02920801|DRUG|saxagliptin|5mg per day for 12 weeks
219607406|NCT02920801|DRUG|Metformin|1500mg per day for 12 weeks
219607407|NCT06451185|OTHER|A haemostatic mineral powder product.|The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
219607408|NCT04594681|DRUG|Placebo|Placebo is administered once daily or three times daily.
219607409|NCT04594681|DRUG|KHK4951|KHK4951 is administered once daily or three times daily.
218885056|NCT03132701|DRUG|Saline|Same volume of saline is infused until 5 minutes before surgery ends
218885057|NCT04857580|DEVICE|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
218885058|NCT05659927|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
218885059|NCT05659927|DRUG|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
219029110|NCT06611072|PROCEDURE|Tumor biopsy|During debulking surgery, all visible tumor tissue will be removed by experienced surgeons.
219029111|NCT06611072|PROCEDURE|Omental biopsy|During debulking surgery, an omental biopsy will be done.
218885060|NCT03484247|OTHER|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
219029112|NCT03615105|RADIATION|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
219029113|NCT03615105|DRUG|Thiotepa|Thiotepa 5 mg/kg IV
219029114|NCT03615105|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
219029115|NCT03615105|DRUG|Busulfan|Busulfan (adult/ped dose)
219029116|NCT03615105|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV
219029117|NCT03615105|DRUG|Melphalan|Melphalan 70 mg/m2 IV
219029118|NCT03615105|DRUG|Clofarabine|Clofarabine 20-30 mg/m2 IV
219506701|NCT02542124|BIOLOGICAL|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
218885061|NCT03484247|OTHER|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
218885062|NCT05104125|DRUG|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
218885063|NCT05104125|DRUG|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
218885064|NCT05104125|DRUG|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
218885065|NCT05104125|DRUG|Placebo|Placebo orally once daily for 12 weeks.
218885066|NCT02023957|BEHAVIORAL|Interactive computer-assisted screening (iCAS)|
218885067|NCT04947241|DRUG|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
218885068|NCT06270914|BEHAVIORAL|Inclusive Positive Behavior Interventions and Supports|The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
219029119|NCT03615105|PROCEDURE|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
219201274|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Sham Focal Muscle Vibration|Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. SMV (15 minutes): Administered during the last part of each physiotherapy session. Control Group: Sham SMV using disconnected terminals produces sound but no vibration, ensuring blinding.
219201275|NCT06878521|OTHER|Emotional Regulation Skills|"This intervention is inspired by and incorporates elements of Dialectical Behavior Therapy (DBT). It consists of eight weekly group sessions, each lasting approximately 1.5 to 2 hours, held on school premises. Each group includes 8 to 10 adolescents. The sessions are facilitated by two psychologists and/or senior psychology students who have been specifically trained to deliver the intervention.~The sessions focus on developing various emotional regulation skills, which participants are encouraged to practice both during and between sessions. Some of the key skills covered include Mindfulness, Wise Mind, and Problem-Solving, among others."
219201276|NCT06877260|DIAGNOSTIC_TEST|Computer based task with EEG|Participants will undergo EEG recording while performing a computer based neuropsychological task evaluating cognitive control
218885069|NCT05472922|DEVICE|Placement of MiniMizer Gastric Ring|Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
218885070|NCT05472922|PROCEDURE|Normal MGB-OAGB|No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
219029120|NCT03615105|DRUG|Rituximab|Rituximab 200 mg IV flat dose
218885071|NCT05322720|BIOLOGICAL|EOC202|EOC202 will be SC injection
218885072|NCT05322720|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
218885073|NCT01703507|DRUG|Ipilimumab|Given IV
218885074|NCT01703507|RADIATION|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
218885075|NCT01703507|RADIATION|Stereotactic Radiosurgery (SRS)|Undergo SRS
219029121|NCT03615105|DEVICE|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
219201277|NCT06746376|OTHER|Occupational Therapy|"Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality."
219201278|NCT06822621|OTHER|Control|Dietary intervention with common white wheat bread in mildly hypecholesterolemic subjects following a hypocaloric diet.
219201279|NCT06822621|OTHER|Intervention|Dietary intervention with white wheat bread enriched with oat beta-glucans in mildly hypecholesterolemic subjects following a hypocaloric diet.
219201280|NCT06869733|OTHER|Scooping Mobilization|Group A treated with only scooping mobilization with frequency of 2 to 3 times in a week for consecutive 4 weeks.
219201281|NCT06869733|OTHER|Scooping Mobilization with Scapulothoracic mobilization|Group B treated with scooping mobilization with scapulothoracic mobilization, which was given 2 to 3 times in a week for consecutive 4 weeks.
218885076|NCT04138446|OTHER|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
218885077|NCT02154919|PROCEDURE|Percutaneous coronary intervention|
218885078|NCT06571266|DRUG|Risankizumab|• Subcutaneous Injection via prefilled syringe
218885079|NCT03600441|DRUG|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
218885080|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
218885081|NCT00407472|DEVICE|ATS-1 needle free device|
218885082|NCT03574636|DEVICE|OCT guidance|OCT guide stent implantation
218885083|NCT03574636|DEVICE|IVUS guidance|IVUS guide stent implantation
218885084|NCT03574636|DEVICE|QCA|QCA guide stent implantation
218885085|NCT02695693|BEHAVIORAL|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
218885086|NCT02695693|BEHAVIORAL|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
219201282|NCT06859021|OTHER|follow up call|A follow-up call is made to the patient 30 days (+ 5 days) after inclusion to check for the occurrence of an Major Cardio Vascular Event.
219201283|NCT06760260|DRUG|Human Derived anti-CI135 CAR-T Injection|Autologous genetically modified anti-CI135 CAR transduced T cells
219201284|NCT06814535|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum toxin type A
219201285|NCT06814535|DRUG|Platelet rich plasma|Plasma that contains concentrated platelets
219201286|NCT06814535|DRUG|Saline -- placebo comparator|Physiological saline .9 %
219201287|NCT06735170|PROCEDURE|biologic tuberoplasty|a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain
219201288|NCT06735170|PROCEDURE|subacromial balloon spacer|a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
219201289|NCT06735339|OTHER|Clinic for Multimorbidity|"The patient is assigned a healthcare coordinator. A review of the patient's medication history and a medication review are conducted. A functional assessment is performed, along with relevant measurements, and the patient consults with a specialist physician. A multidisciplinary team (MDT) conference is held with selected specialists, depending on the patient's needs. This may include a cardiologist, endocrinologist, pulmonologist, gastroenterologist, rheumatologist, nephrologist, geriatrician, clinical pharmacologist, psychiatrist, pain nurse, physiotherapist, occupational therapist, and the patient's GP.~The handover of information to the GP is agreed upon at the time of referral and can be carried out in writing, through virtual MDT participation, or by telephone.~In agreement with the patient, the clinic may initiate follow-up actions, such as counseling on medication or disease management. Additionally, the clinic may facilitate cross-sectoral activities, such as therapy."
219506702|NCT04556110|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
218885087|NCT02695693|BEHAVIORAL|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
218885088|NCT02695693|BEHAVIORAL|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
218885089|NCT04656457|DEVICE|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
218885090|NCT04656457|OTHER|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
218885091|NCT00297323|DRUG|Topiramate|75 patients over the age of 2 years old with epilepsy.
218885092|NCT01112787|DRUG|Tazarotene Foam|Tazarotene Foam
218885093|NCT01112787|DRUG|Vehicle Foam|Vehicle Foam
218885094|NCT01112787|DRUG|Sodium Laural Sulfate|Sodium Laural Sulfate
218885095|NCT01112787|DRUG|Distilled Water|Distilled Water
218885096|NCT05367791|OTHER|POSTUR|Training sessions without any stimulation
219201290|NCT06760299|OTHER|%25 tension Kinesio tape|"I shaped Kinesio tape application with 25% tension"
219201291|NCT06760299|OTHER|75% tension Kinesio tape|"I shaped Kinesio tape application with 75% tension"
219201292|NCT06813170|DIETARY_SUPPLEMENT|Metarecod|Policaptil Gel Retard: Metarecod®. The medical device will be given as 1 sachet twice daily
219201293|NCT06813170|OTHER|Diet|Diet program will be planned to achieve a ≥8% body weight relative reduction over 12 months and tailored calculating a 20% caloric relative decrease from habitual energy intake, corresponding to an average energy deficit of approximately 500 kcal/daily (approximately a total of 1,200-1,500/daily Kcal for women and 1,500-1,800/daily Kcal for men), with \<30% of total calories from fat (\<10% from satured fats) and at least 15% of total calories from proteins. For carbohydrate intake, low glycemic index food will be preferred to high glycemic index food, to prevent higher post prandial glycemic excursions
219201294|NCT06940739|BIOLOGICAL|IOV-3001|IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.
218885097|NCT05367791|OTHER|Localised Vibration|Training sessions with localized vibration
218885098|NCT05367791|OTHER|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
218885099|NCT05596604|OTHER|survey- no intervention|survey- no intervention
218885100|NCT05761990|OTHER|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
219201295|NCT06143046|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219201296|NCT06143046|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219506703|NCT04556110|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
219201297|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
219201298|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
219201299|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
219201300|NCT06628687|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
219201301|NCT05743231|PROCEDURE|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
219201302|NCT03586453|DRUG|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression"
219201303|NCT06562712|PROCEDURE|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
219506704|NCT03467412|DRUG|FOL-005|intradermal injection
219201304|NCT06562712|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
219201305|NCT06427434|OTHER|Strengthening and stretching exercises to the back and abdominal muscles|Strengthening and stretching exercises to the back and abdominal muscles will be performed for 30 min, three times per week for 4 weeks.
219201306|NCT06427434|OTHER|Modified Lumbar Sustained Natural Apophyseal Glide|Modified Sustained Natural Apophyseal Glide will be applied on the affected lumbar level for 30 sec three times per week for 4 weeks.
218885101|NCT05761990|OTHER|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
218885102|NCT04054076|DEVICE|Prefabricated insoles|The participants received prefabricated insoles
218885103|NCT04054076|DEVICE|Soft custom-made insoles|The participants received soft custom-made insoles
218885104|NCT04054076|DEVICE|Hard custom-made insoles|The participants received hard custom-made insoles
218885105|NCT02094092|OTHER|ProTectis drops (five drops per day) for 21 days|
219201307|NCT05620875|DIAGNOSTIC_TEST|Cerebral injury markers|Blood tests at given time points perioperatively.
219201308|NCT05620875|DIAGNOSTIC_TEST|Cerebral oximetry index|Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
219506705|NCT03467412|DRUG|Placebo|intradermal injection
219506706|NCT06528041|OTHER|Inulin|12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
219506707|NCT06528041|OTHER|Maltodextrin|6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
219506708|NCT01100684|DRUG|Asimadoline|0.5 mg Asimadoline BID
219506709|NCT01100684|DRUG|Placebo|Placebo
218885106|NCT02094092|OTHER|Placebo drops (five drops per day) for 21 days|
218885107|NCT06135935|OTHER|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
218885108|NCT06135935|OTHER|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
219364589|NCT04475692|BEHAVIORAL|Repetitive, task-specific upper limb practice|A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.
219506710|NCT00789802|DRUG|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
219506711|NCT00789802|DRUG|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
219506712|NCT00789802|DRUG|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
219506713|NCT05765955|DRUG|POLB 001|Investigational Medicinal Product
218885109|NCT02458573|OTHER|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
218885110|NCT02458573|OTHER|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
219607410|NCT04894370|BIOLOGICAL|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
218885111|NCT02664506|BEHAVIORAL|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
218885112|NCT03525691|DEVICE|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
218885113|NCT03733613|OTHER|no intervention|no intervention
218885114|NCT03258086|DIAGNOSTIC_TEST|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
218885115|NCT03040674|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
218885116|NCT00002359|BIOLOGICAL|HIV-1 Immunogen|
218885117|NCT00330005|BEHAVIORAL|Group Psychotherapy|
219029122|NCT06620302|BIOLOGICAL|Bcl-XL Proteolysis Targeting Chimera DT2216|Given IV
219029123|NCT06620302|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218885118|NCT00749723|DRUG|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
218885119|NCT00749723|DRUG|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
219506714|NCT05765955|DRUG|Placebo|Matching Placebo
219607411|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
218885120|NCT00749723|DRUG|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
218885121|NCT00749723|DRUG|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
218885122|NCT00749723|DRUG|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
218885123|NCT00749723|PROCEDURE|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
218885124|NCT00749723|DRUG|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
218885125|NCT00749723|DRUG|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
218885126|NCT06342518|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.
218885127|NCT06342518|DEVICE|Sham ESWT|The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock
218885128|NCT06342518|BEHAVIORAL|Resting Splint , Exercises and ice|Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
219029124|NCT06620302|DRUG|Irinotecan|Given IV
219029125|NCT05214768|DRUG|CC-93538|Specified dose on specified days
219029126|NCT05214768|DRUG|Placebo|Specified dose on specified days
219029127|NCT07007962|DRUG|rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
219029128|NCT07003594|OTHER|Jigsaw IV technique|The Intervention Group receives training in cardiothoracic examination using the Jigsaw IV technique.
219029129|NCT05041322|DRUG|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
219029130|NCT05041322|DRUG|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
219029131|NCT06381141|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
219029132|NCT05926947|DIETARY_SUPPLEMENT|Verum A|Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
219029133|NCT05926947|DIETARY_SUPPLEMENT|Verum B|Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
219201309|NCT05715255|BEHAVIORAL|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
219201310|NCT05715255|BEHAVIORAL|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
219201311|NCT04083534|DRUG|REGN5459|Administered by intravenous (IV) infusion
219201312|NCT03697408|DRUG|Itacitinib|A JAK 1 selective small molecule inhibitor
218885129|NCT02059304|DEVICE|Measurement of cervical length with embryo transfer catheter|
219201313|NCT03697408|DRUG|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
219201314|NCT06752746|DRUG|9MW3011|Multiple dose
218885130|NCT04625439|BEHAVIORAL|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
218885131|NCT05176236|OTHER|Pictographic tracheostomy care handouts|The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
219029134|NCT05926947|DIETARY_SUPPLEMENT|Placebo|Micro crystalline cellulose
219029135|NCT06682208|PROCEDURE|ES catheter|ES catheter for postoperative pain control
219029136|NCT06682208|PROCEDURE|Intercostal nerve cryoablation (INC)|INC used for postoperative pain control
219506715|NCT04434313|DEVICE|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
219506716|NCT01975090|DEVICE|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
219029137|NCT07016620|PROCEDURE|Transperineal Laser Ablation (TPLA)|Outpatient treatment with Transperineal Laser Ablation (TPLA) as a salvage therapy after previous Minimally Invasive Surgical Therapies (MIST)
219029138|NCT07010406|DRUG|Povetacicept|Injection for Subcutaneous Administration.
219029139|NCT06485843|DRUG|OA-SYS|OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
219029140|NCT07007312|DRUG|Ziftomenib|Oral administration
219029141|NCT07007312|DRUG|Placebo|Oral administration
219029142|NCT07007312|DRUG|Venetoclax|Oral administration
219029143|NCT07007312|DRUG|Azacitidine (AZA)|Intravenous or subcutaneous administration
219029144|NCT07007312|DRUG|Daunorubicin|Intravenous administration
219029145|NCT07007312|DRUG|Cytarabine (Ara-C)|Intravenous administration
219029146|NCT04686435|OTHER|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
219029147|NCT04686435|PROCEDURE|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
219201315|NCT05624138|DRUG|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
219201316|NCT05624138|DRUG|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
219201317|NCT04845529|DEVICE|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
219029148|NCT07012187|OTHER|They will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).|Students will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).
219029149|NCT07022600|DEVICE|Diaphragmatic ultrasound|diaphragmatic excursion will be conducted at baseline and at 2 and 24 hours postoperatively
219029150|NCT04383743|DRUG|Cisplatin|Given IV
219029151|NCT04383743|DRUG|Doxorubicin|Given IV
219029152|NCT04383743|DRUG|Methotrexate|Given IV
219029153|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
219029154|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
219029155|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
219201318|NCT04957576|BEHAVIORAL|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
219029156|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
219201319|NCT06496061|DRUG|Norepinephrine|Norepinephrine infusion with 0.05 mg/kg/h
219201320|NCT06496061|PROCEDURE|Leg wrapping|Elastic leg wrapping
219029157|NCT06692036|OTHER|Adaptive Blood Purification (ABP)|Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration-adsorption (PFAD) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, PFAD-RRT treatment is used.
219201321|NCT01508390|RADIATION|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
219201322|NCT06315023|DEVICE|DETOUR System|Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
219201323|NCT04707183|DRUG|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
219201324|NCT04707183|DRUG|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
219201325|NCT06299267|OTHER|dual task conditions|dual task conditions on manual skill tests
219506717|NCT03408600|OTHER|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
219029158|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
219029159|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
219029160|NCT06271967|DEVICE|TactiFlex™ Ablation Catheter Sensor Enabled™|Pulsed field ablation (PFA)/radiofrequency (RF) ablation with the TactiFlex™ Ablation Catheter Sensor Enabled™
219029161|NCT07030465|DEVICE|The press needle, antihistamine, and moisturizer therapy|Device: Press Needle (PN) PN is applied unilaterally on acupoints LI11, SP10, ST36, and SP6 alternately. It consists of an adhesive patch with a small sterile needle retained for 3-4 days before replacement. This procedure is repeated over a 4-week period. Needle sizes is 0.22 × 1.5 mm), and all procedures follow standard aseptic protocols. PN provides prolonged stimulation with cumulative effects in a minimally invasive manner. Participants continue their routine hemodialysis and conventional treatments for CKD-associated pruritus (CKDaP).
219029162|NCT07030465|DEVICE|The sham press needle, antihistamine and moisturizer therapy|Sham PN uses adhesive patches without needles, applied to the same acupoints (LI11, SP10, ST36, and SP6) with the same retention schedule (3-4 days over 4 weeks) as the intervention group. All procedures, including placement and instructions, are performed identically to maintain blinding. There is no skin penetration or real acupoint stimulation. Participants continue their routine hemodialysis and conventional treatments for CKDaP.
219029163|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
219029164|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
219029165|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
219029166|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
219201326|NCT04591002|DRUG|Osimertinib 80 MG|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. Osimertinib will be administered orally as one 80 mg tablet once a day (1 cycle is 28 days). Cycles are repeated until disease progression, unacceptable toxicity, or until 1 year after the initiation of osimertinib administration.
219201327|NCT05447078|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
219506718|NCT04763837|DEVICE|Intraureteral stent|This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
219506719|NCT04763837|DEVICE|Conventional Double-J stent|This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
219506720|NCT05598437|DEVICE|Dry eye device|Dry eye analysis
219201328|NCT05447078|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
219201329|NCT04725383|DRUG|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
219201330|NCT06551545|DIETARY_SUPPLEMENT|Tryptophan intake|There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
219201331|NCT06550986|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
219201332|NCT06208813|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
219201333|NCT04109365|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
219506721|NCT01889511|BEHAVIORAL|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
219506722|NCT00544583|PROCEDURE|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
219506723|NCT00544583|PROCEDURE|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
219029167|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
219029168|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
219029169|NCT07036003|DRUG|Somatropin (recombinant human growth hormone)|Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).
219029170|NCT07036003|DRUG|bacteriostatic saline placebo|Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.
219029171|NCT07036445|PROCEDURE|Epidural Steroid Injection|Intervention consists of interlaminar CT guided epidural steroid injection
219029172|NCT07036445|PROCEDURE|Epidural platelet-rich plasma injection|Intervention consists of interlaminar CT guided epidural platelet-rich plasma injection after recovery of plasma by blood sampling and centrifugation
219029173|NCT07038733|PROCEDURE|Peripheral Blood Sample for Immune Analysis|A peripheral blood sample will be collected at the time of surgery.
219029174|NCT07038733|PROCEDURE|Tumor Sample for Analysis|Extra tumor which is left over following clinical diagnoses will be collected.
219029175|NCT07038733|PROCEDURE|Adjacent non-malignant kidney for analysis|Extra normal tissue which is left over following clinical diagnoses will be collected.
219029176|NCT07038733|PROCEDURE|Draining lymph node(s) for analysis|Draining lymph nodes which have been identified by the surgeon visually, potentially using a tracer (injection of up to 5mg of ICG into the peritumor kidney) will be collected.
219029177|NCT07038733|PROCEDURE|Regional non-draining lymph node(s) for analysis|Regional lymph nodes which have been deemed as non-draining by the surgeon will be collected.
219029178|NCT07037901|DRUG|IMG-007|Participants will receive IMG-007 subcutaneously.
219029179|NCT07037901|DRUG|Placebo|Participants will receive a placebo subcutaneously.
219029180|NCT06704347|BIOLOGICAL|XT-150|XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).
219029181|NCT06721091|DRUG|VNA-318|"Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel"
219029182|NCT06721091|DRUG|Placebo|"Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)"
219029183|NCT07036705|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
219029184|NCT07036705|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
219029185|NCT07039721|OTHER|Evaluation of echogenicity|Patients ongoing a routine 2nd or 3rd trimester ultrasound will have an extra 5 minutes of ultrasound with a specific intestinal setting
219029186|NCT06704152|DRUG|SOC + BSB-1001 Dose Escalation Cohort|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).
219506724|NCT05890066|PROCEDURE|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
219506725|NCT00000898|DRUG|Ritonavir|
219506726|NCT00000898|DRUG|Nelfinavir mesylate|
219506727|NCT00000898|DRUG|Saquinavir|
219607412|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
219607413|NCT03541317|BEHAVIORAL|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
219607414|NCT03541317|BEHAVIORAL|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
219607415|NCT02556957|BEHAVIORAL|HealthScouts|
219506728|NCT00746668|BEHAVIORAL|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
219506729|NCT00746668|BEHAVIORAL|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
219506730|NCT00746668|BEHAVIORAL|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
219029187|NCT06704152|DRUG|SOC+BSB-1001 Expansion Dose|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
219029188|NCT07042802|DRUG|LBL-024 for Injection|LBL-024 Intravenous infusion.
219029189|NCT07042802|DRUG|Paclitaxel Injection|Paclitaxel Intravenous infusion.
219029190|NCT06885073|DEVICE|CPMX2|CPMX2 - Non-invasive pressure estimation
219029191|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, cognitive restructuring, and SRT in one of the intervention groups. The protocol is based on previous studies of CBT-I for school-aged children.
219029192|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia without SRT|This intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, and cognitive restructuring. Sleep Restriction Therapy will not be included in the intervention. The protocol is based on previous studies that delivered CBT-I to school-aged children.
219029193|NCT06599580|BEHAVIORAL|Training caregivers to screen children for malnutrition relapse|Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.
219029194|NCT06599580|OTHER|Reduced follow-up schedule|Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
219029195|NCT06731998|PROCEDURE|Local Anesthesia|For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.
219029196|NCT06731998|PROCEDURE|Laparoscopic Transversus Abdominis Plane block|Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
219029197|NCT04837131|DRUG|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
219029198|NCT04292288|DIAGNOSTIC_TEST|Biochemical observational|no intervention - observational
219029199|NCT01275495|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK II)|
219029200|NCT01275495|BEHAVIORAL|Information, Support, and Referral (ISR)|
219029201|NCT06742190|BIOLOGICAL|Empasiprubart|Intravenous infusion of empasiprubart
219029202|NCT06742190|BIOLOGICAL|IVIG (Intravenous Immunoglobulin)|Intravenous infusion of IVIg
219029203|NCT06742190|OTHER|Empasiprubart-placebo|A placebo resembling the empasiprubart treatment
219029204|NCT06742190|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
219029205|NCT06888505|DRUG|Dapagliflozin (Forxiga)|Participants in the dapagliflozin arm received dapagliflozin 10 mg tablets, administered orally once daily for 4 months, in addition to their standard anthracycline-based chemotherapy regimen. This treatment was given continuously throughout the chemotherapy period to evaluate its cardioprotective effects against anthracycline-induced cardiac toxicity.
219029206|NCT06888505|OTHER|Placebo|Participants in the control arm received a placebo tablet identical in appearance, dosage form, frequency, and duration to dapagliflozin, but containing no active ingredients. The placebo was administered orally once daily for 4 months alongside the participant's standard anthracycline-based chemotherapy regimen and served as the control to evaluate the cardioprotective efficacy of dapagliflozin.
219029207|NCT07049276|PROCEDURE|Index lymph node resection|The largest lymph node affected with melanoma
219029208|NCT07049276|PROCEDURE|Therapeutic lymph node dissection|Removal of all nodes in the melanoma affected lymph node basin
219201339|NCT06087783|DIETARY_SUPPLEMENT|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
218885132|NCT03356678|DRUG|Pralatrexate|"* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
218885133|NCT05260268|BEHAVIORAL|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
219506731|NCT03385096|DRUG|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
218885134|NCT02936843|DRUG|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
219029209|NCT07059455|OTHER|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Under general anesthesia, patients in the ESP group will be positioned in the left or right lateral decubitus position, depending on the side of the surgical procedure. After the T10 spinous process is identified by manual examination, sterile conditions will be established. The transverse process and erector spinae muscles will be visualized using an ultrasound probe. Using an in-plane technique, 20 ml of 0.25% bupivacaine will be injected between the transverse process and erector spinae muscles using a 22-gauge blocking needle.
219506732|NCT03385096|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
219201340|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
219506733|NCT03385096|DRUG|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
219201341|NCT06257056|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
219506734|NCT03385096|DRUG|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
219506735|NCT01423435|DRUG|TRK-100STP|oral
219506736|NCT00373724|PROCEDURE|radiofrequency denervation|
219506737|NCT01007916|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
219506738|NCT01007916|DEVICE|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
219506739|NCT05333419|DRUG|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
219506740|NCT02660190|DRUG|hexaminoavolunate|
219506741|NCT02660190|PROCEDURE|WL cystoscopy|
219201342|NCT05020353|DEVICE|OraQuick® HIV Self-Test|OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.
219506742|NCT00958581|DRUG|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
219506743|NCT00958581|DRUG|Normal Saline|Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
218885135|NCT02936843|DRUG|PLACEBO|Placebo for Salsalate; 2 Tablets, 3 times daily by mouth (total of 3 grams daily)
218885136|NCT04336033|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
218885137|NCT04336033|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
219201343|NCT05536414|DRUG|Centanafadine|capsule
219201344|NCT05536414|DRUG|Escitalopram|capsule
219201345|NCT05536414|DRUG|Placebo|capsule
219506744|NCT00958581|DRUG|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
219506745|NCT00380003|DRUG|EVT 201|
219506746|NCT00349895|DEVICE|Coronary stent implantation|Percutaneous Coronary Intervention
219506747|NCT04254523|DEVICE|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
219506748|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
219506749|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
219506750|NCT00551564|DRUG|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
219506751|NCT02546713|OTHER|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
219506752|NCT02546713|OTHER|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
219506753|NCT02193984|BEHAVIORAL|Peer support|
219506754|NCT00682721|DRUG|Placebo|Matching placebo two pills once daily
219506755|NCT00682721|DRUG|Valacyclovir|1 gram daily x number of days active in the study
219607416|NCT02556957|OTHER|Standard of Care|
218885138|NCT04336033|OTHER|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
218885139|NCT05777395|PROCEDURE|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
219029210|NCT07059455|OTHER|Quadratus Lumborum (QL) Block|Following standard anesthesia monitoring, patients will be placed in the lateral decubitus position. After the field is sterilized, a 2-5 MHz convex ultrasound probe (Samsung, HM70 EVO) will be placed between the iliac crest and costal arch at the level of the posterior axillary line. The transverse process of the L4 vertebra, erector spinae, QL, and PM muscles will be visualized. After inducing local anesthesia with 2% lidocaine (2 ml), a blocking needle (22G\*100 mm, Braun) will be advanced from posterolateral to anteromedial, inserting it between the QL and PM muscles, and 20 ml of 0.25% bupivacaine will be injected.
219201346|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
219201347|NCT03417284|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
219201348|NCT03417284|BIOLOGICAL|Filgrastim-sndz|Given SC
219201349|NCT03417284|DRUG|Melphalan Hydrochloride|Given IV
219201350|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
219201351|NCT05942417|PROCEDURE|Echoguided percutaneous neuromodulation plus exercise|This group is taking the EPNM and the exercise program
219201352|NCT05942417|PROCEDURE|Strength program|This group is taking the exercise program
219201353|NCT05937854|DRUG|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
219506756|NCT03971942|BEHAVIORAL|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
219522693|NCT05631366|BEHAVIORAL|Alcohol Avoidance Training|Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
219522694|NCT01714648|DRUG|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
219201354|NCT05937854|DRUG|Placebo|one or two encapsulated tablets of placebo po QD
219201355|NCT06206759|DRUG|administration of vitamin C|administration of vitamin C to ICU patients
219201356|NCT05543512|DEVICE|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
219201357|NCT05543512|OTHER|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
219201358|NCT06212583|DRUG|niraparib/abiraterone acetate|Patients on Arm 2 to receive drug for 6 months
219201359|NCT06212583|RADIATION|Stereotactic ablative radiation therapy (SABR)|Both arms will receive SABR
219201360|NCT06212583|DRUG|Androgen deprivation therapy (ADT)|All ADT is provided as best prescribed for patient per their medical oncologist.
219201361|NCT06308380|PROCEDURE|Specific protocol of rehabilitation exercise|Specific protocol of rehabilitation exercise
219201362|NCT06308380|PROCEDURE|Short gastrocnemius surgery.|During surgery, a partial release of the gastrocnemius muscle tendon is performed to relieve tension and allow greater range of motion. This procedure is typically performed on an outpatient basis and under local or regional anesthesia, which allows for a quicker recovery compared to more invasive surgeries.
219201363|NCT06339190|DIAGNOSTIC_TEST|Venepuncture|A single blood draw at the time of presentation to clinic or whilst an inpatient.
219201364|NCT05968144|BEHAVIORAL|Dietary recommendations|One-on-one meeting with a nutritionist to discuss and personalize dietary recommendations for patients with prostate cancer undergoing ADT.
219201365|NCT05968144|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
218885140|NCT05777395|PROCEDURE|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation"
218885141|NCT05777395|PROCEDURE|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
219029211|NCT03283449|DRUG|18F-AV-1451|
219029212|NCT03283449|DEVICE|PET|PET scanner for brain imaging
219029213|NCT06311227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219201366|NCT05147597|OTHER|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
219201367|NCT04887467|DRUG|Apomorphine|"Assigned Interventions:~* blood sampling~* blood collection~* systolic, diastolic, mean blood pressure and heart rate measure"
219201368|NCT03998657|DEVICE|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
218885142|NCT03218436|PROCEDURE|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
219201369|NCT06288906|OTHER|mechanical thrombectomy of caval and iliofemoral veins|investigate efficacy, safety of mechanical thrombectomy systems used in symptomatic acute and subacute ileofemoral and caval thrombosis
218885143|NCT01385241|BEHAVIORAL|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
219029214|NCT06311227|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219029215|NCT06311227|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219029216|NCT06311227|PROCEDURE|Computed Tomography|Undergo CT scan
219029217|NCT06311227|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219029218|NCT06311227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219029219|NCT06311227|DRUG|Venetoclax|Given PO
219201370|NCT03357757|DRUG|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
219201371|NCT03357757|BIOLOGICAL|Avelumab|10 mg/kg IV
219201372|NCT03811405|DEVICE|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
219201373|NCT03811405|DEVICE|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
219201374|NCT03811405|DEVICE|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
219506757|NCT03971942|BEHAVIORAL|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
219506758|NCT04576806|OTHER|Body temperature|Warming of administered fluid bolus
219607417|NCT06336265|DIAGNOSTIC_TEST|Diaphragm ultrasound|Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment.
219607418|NCT02959125|OTHER|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
219607419|NCT02959125|DIETARY_SUPPLEMENT|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
219607420|NCT02959125|BEHAVIORAL|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
219607421|NCT02959125|OTHER|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
218885144|NCT05624073|DEVICE|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
219029220|NCT04303780|DRUG|AMG 510|21 day cycles
219029221|NCT04303780|DRUG|Docetaxel|21 day cycles
219029222|NCT06887049|BEHAVIORAL|ARISE Learning Community Diabetes Distress Screening and Intervention|In-depth training for frontline community health center staff on ARISE algorithm to screen for degree of diabetes distress using T2-DDAS Core. If positive, screen for sources of diabetes distress using T2-DDAS Sources. Discuss results with patient and make any relevant referrals.
219029223|NCT06887049|BEHAVIORAL|ARISE Enhanced Care brief training|Brief training on American Diabetes Association guidelines for screening for diabetes distress using the 7A's model
219029224|NCT06828120|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
219029225|NCT06828120|DRUG|Fluimucil 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
219029226|NCT07074756|DRUG|Chemotherapy|Receive standard of care chemotherapy
219029227|NCT07074756|PROCEDURE|Computed Tomography|Undergo CT
219506759|NCT04576806|DRUG|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
219506760|NCT04576806|OTHER|Room temperature|Cooling of administered fluid bolus
219506761|NCT04658875|DIETARY_SUPPLEMENT|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
219506762|NCT04658875|OTHER|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
219506763|NCT04658875|OTHER|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
218885145|NCT05624073|DEVICE|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
218885146|NCT03151330|OTHER|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
218885147|NCT03386487|DRUG|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
218885148|NCT03386487|DRUG|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
218885149|NCT05696886|DRUG|Pethidine|Group A received Pethidine alone in the period between January 2021 and December 2021
218885150|NCT05696886|DRUG|Tramadol with pethidine|Group B got Tramadol with pethidine in the period between January 2022 and December 2022
218885151|NCT00260884|BEHAVIORAL|conventional gastrectomy or radical lymph node dissection|
218885152|NCT03081871|OTHER|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
218885153|NCT03081871|OTHER|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
218885154|NCT03081871|OTHER|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
218885155|NCT00273065|DRUG|Neosaxitoxin|
218885156|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
218885157|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
218885158|NCT00729963|DRUG|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
218885159|NCT00729963|DEVICE|CPAP|
218885160|NCT05502445|OTHER|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
218885161|NCT05050461|OTHER|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
218885162|NCT02694900|OTHER|Manually chest compressions|Chest compressions performed manually without any device
218885163|NCT02694900|DEVICE|Cardiopump|Chest compressions performed with Cardiopump
218885164|NCT02694900|DEVICE|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
218885165|NCT02703324|DRUG|LY900014|Administered subcutaneously (SC)
218885166|NCT02703324|DRUG|Insulin Lispro|Administered SC
218885167|NCT01883544|DRUG|ALXN1007|
218885168|NCT00606619|OTHER|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
218885169|NCT00606619|OTHER|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
218885170|NCT00891241|DRUG|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
218885171|NCT06310421|DIAGNOSTIC_TEST|Screening SMA test|Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
219607422|NCT02959125|DIETARY_SUPPLEMENT|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
219607423|NCT04359394|OTHER|biological sampling|In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
219607424|NCT04359394|OTHER|Phenotypic description|Phenotypic characterization of the patient's clinical features
218885172|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
218885173|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
219607425|NCT04359394|OTHER|Photography|All affected areas will be photographed at each visit with 2-dimensional standardized photography
218885174|NCT04078555|DRUG|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
218885175|NCT04078555|DRUG|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
218885176|NCT04303572|DRUG|Eloctate ITI|This is a factor VIII-Fc infusion protein.
218885177|NCT04303572|DRUG|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
218885178|NCT06312592|BEHAVIORAL|Entrepreneurship School with Gender Lens|"The Entrepreneurship School with Gender Lens (ESGL) is an approach that targets gender based violence survivors and women at-risk to help them develop business ideas, access needed support for the prevention of and response to GBV, exploitation and trafficking, and improve participants' overall self-reliance. Participants will go through a general business curriculum, work on business plans and learn gender issues and ways to mitigate GBV risks. Upon training completion, participants are eligible to pitch their business idea to a panel of experts and receive $800 of seed capital. They will also receive follow-up business advisory support for at least six months, focusing on access to markets and finance and building support networks, in order to continue building self-reliance.~The ESGL will also include a mental health and psychosocial support module."
218885179|NCT05889377|PROCEDURE|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
218885180|NCT00274963|DRUG|bendamustine hydrochloride|
218885181|NCT00274963|DRUG|mitoxantrone hydrochloride|
218885182|NCT03266406|DRUG|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
218885183|NCT00498589|DRUG|methotrexate|25 mg per week IM or SC during 24 weeks
218885184|NCT00498589|DRUG|placebo|one intramuscular injection per week
218885185|NCT05952206|DEVICE|Angiolite: Sirolimus-eluting stent|The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
218885186|NCT05952206|DEVICE|Xience: Everolimus-eluting stent|The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
218885187|NCT05952206|DRUG|1-month DAPT|"DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.~The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC"
219029228|NCT07074756|OTHER|Internet-Based Intervention|Receive access to the remote chemotherapy management and patient monitoring platform
219029229|NCT07074756|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219029230|NCT07074756|PROCEDURE|Neurologic Examination|Ancillary studies
219029231|NCT07074756|OTHER|Questionnaire Administration|Ancillary studies
219029232|NCT07074756|BEHAVIORAL|Surveillance|Undergo surveillance
219029233|NCT06470542|DRUG|2 x 20 ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
219029234|NCT06470542|DRUG|2 x 20ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
219029235|NCT06633016|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
219029236|NCT06633016|OTHER|Placebo|Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
219029237|NCT06595238|DRUG|AZD6234|IMP injected subcutaneously, once a week. Unit dose strength as per CSP
219029238|NCT06595238|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once a week.
219029239|NCT04586023|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
219029240|NCT04586023|DRUG|Teriflunomide|Participants will receive teriflunomide.
219029241|NCT04586023|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
219029242|NCT06759935|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
219029243|NCT06759935|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
219029244|NCT06759935|OTHER|physiotherapy/exercise protocol|physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
219029245|NCT07082998|BEHAVIORAL|heated yoga|12-weeks of twice weekly 90-min heated yoga classes in the community
219029246|NCT07082998|BEHAVIORAL|sauna|12-weeks of twice weekly 40-min sauna sessions in the community
219029247|NCT07082998|BEHAVIORAL|mindfulness app|12-weeks of 80-mins a week of a mindfulness app
219201375|NCT06174701|BEHAVIORAL|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
219201376|NCT06174701|BEHAVIORAL|Enhanced Usual Care|"Participants in the control arm will receive enhanced usual care. They will receive additional mental health education in the form of educational handouts mailed or emailed to them."
219201377|NCT06024642|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
219201378|NCT06024642|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
219201379|NCT03785574|OTHER|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
219201380|NCT03785574|DRUG|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
219201381|NCT06193083|OTHER|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
219201382|NCT06193083|OTHER|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis of Phase 1 Qualitative of the protocol, three additional questions~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
219607426|NCT03422614|DIAGNOSTIC_TEST|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
219607427|NCT05514223|OTHER|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
218885188|NCT05952206|DRUG|12-month DAPT (Standard of care)|DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
218885189|NCT04400565|BEHAVIORAL|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
218885190|NCT02399774|DEVICE|Leboride|"1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
219029248|NCT07123753|OTHER|EXERCİSE|The aim of this study is to examine the effects of classical foot exercises and foot core exercises on pain, balance, gait and lower extremity performance in adolescents with pes planus. This study is planned to be a randomized controlled trial. Participants will be randomly divided into 2 groups. Classic foot exercises will be applied to individuals in the classical foot exercises group for 12-15 minutes, and foot core exercises will be applied to individuals in the core exercises group for 12-15 minutes twice a week for a total of 8 weeks. Pes planus status of individuals included in the study will be evaluated with the navicular drop test. Pain will be evaluated with the foot function test, balance with the star balance test, gait analysis with the footprint method and lower extremity muscle performance with the functional muscle strength assessment for individuals in both groups before and after the application. The evaluations will be applied face to face by the same physiotherapi
219029249|NCT06902454|DEVICE|densah drill technique|ten patients with maxillary sinus pneumatization will be undergo sinus floor elevation using densah drill technique with implant placement
219029250|NCT06898957|DRUG|YL201|YL201 will be administered as an IV infusion.
219029251|NCT06898957|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
219029252|NCT06898957|DRUG|Atezolizumab|Atezolizumab will be administered as an IV infusion.
219506764|NCT04658875|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
219506765|NCT04658875|OTHER|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
219506766|NCT00793052|DRUG|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
219506767|NCT01663909|BEHAVIORAL|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
219506768|NCT02509871|OTHER|Body composition measurement|DXA, impedance
219201383|NCT06193083|OTHER|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
219201384|NCT06095271|DIAGNOSTIC_TEST|serum Neurofilament Filament Light chain (sNfL) monitoring|the intervention consist of a blood draw and providing the sNfL information to the treating physician
218885191|NCT06241105|DRUG|Lenvatinib+Toripalimab.|Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
219201385|NCT05554107|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
219201386|NCT05067348|DRUG|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
219201387|NCT06448312|DRUG|SKB264|IV Infusion
219201388|NCT06448312|DRUG|Pembrolizumab|IV Infusion
219201389|NCT06548698|OTHER|escape room|Nursing students in the intervention group analyzed the breast cancer surgery case with the escape room experience.
219201390|NCT06114680|DEVICE|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
218885192|NCT04696679|OTHER|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
218885193|NCT04696679|OTHER|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
218885194|NCT01979952|DRUG|Matching Placebo|twice daily dosing
219201391|NCT06114680|DEVICE|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
219201392|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
219201393|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
219506769|NCT00054483|DRUG|bortezomib|Given IV
219506770|NCT00054483|OTHER|laboratory biomarker analysis|Correlative studies
218885195|NCT01979952|DRUG|Nintedanib|gelating capsule
219506771|NCT00054483|OTHER|pharmacological study|Correlative studies
219506772|NCT05728177|COMBINATION_PRODUCT|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
219506773|NCT01409850|DEVICE|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
219506774|NCT01409850|DEVICE|Soft splint|
219506775|NCT03339882|DRUG|Remifemin|Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
219506776|NCT03765268|PROCEDURE|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
219506777|NCT03765268|PROCEDURE|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
219201394|NCT05564325|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
219201395|NCT05564325|DEVICE|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
219201396|NCT03938090|DEVICE|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
219201397|NCT03938090|DEVICE|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
219201398|NCT06959251|DIETARY_SUPPLEMENT|Glycine|Patients will receive for 6 months an oral supplement of 0.5 g/kg/day glycine, up to 25 g/day, divided in three daily intakes.
219201399|NCT06959251|DIETARY_SUPPLEMENT|Magnesium+thiamine|Patients will receive for 6 months an oral supplement of up to 400 mg/day, according to age, of elementary magnesium (formulated as magnesium citrate) plus up to 10 mg/day of thiamine (formulated as benfotiamine), divided in three daily intakes.
219201400|NCT06959251|OTHER|Placebo|Patients will receive for 6 months placebo (sugar glass), in a similar daily amount as in experimental arms, and divided in three daily intakes.
219201401|NCT01880515|DRUG|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
219201402|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
219201403|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
219201404|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
219201405|NCT04166799|DEVICE|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
219201406|NCT05877053|DRUG|CK-4021586|CK-4021586
219201407|NCT05877053|DRUG|Placebo for CK-4021586|Placebo for CK-4021586
219201408|NCT02115295|DRUG|Cladribine|Given IV
219201409|NCT02115295|DRUG|Cytarabine|Given IV
219201410|NCT02115295|DRUG|Gilteritinib|Given PO
219201411|NCT02115295|DRUG|Idarubicin|Given IV
219201412|NCT02115295|OTHER|Laboratory Biomarker Analysis|Correlative studies
219201413|NCT02115295|DRUG|Midostaurin|Given PO
219201414|NCT02115295|DRUG|Venetoclax|Given PO
219201415|NCT00641381|DRUG|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
219201416|NCT00641381|DRUG|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
219201417|NCT00641381|DRUG|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
219201418|NCT00641381|OTHER|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
219201419|NCT00641381|PROCEDURE|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
219201420|NCT00641381|PROCEDURE|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
219201421|NCT06562348|OTHER|Standard of care|Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
219201422|NCT06562348|OTHER|ctDNA-RECIST guided palliative systemic treatment|"Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule."
219201423|NCT04734197|DRUG|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
219201424|NCT04734197|DRUG|Mycophenolic Acid 0.1%|topical immunosuppressant
219201425|NCT04734197|DRUG|Mycophenolic Acid 0.3%|topical immunosuppressant
219201426|NCT04734197|DRUG|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
219201427|NCT04734197|DRUG|Placebo Comparator: Vehicle|topical vehicle solution
219201428|NCT04734197|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
219201429|NCT04734197|DRUG|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
219201430|NCT01098955|BEHAVIORAL|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
219201431|NCT01098955|BEHAVIORAL|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
219201432|NCT01098955|DRUG|Varenicline|2 mg daily for 12 weeks
219506778|NCT00913965|DRUG|Atenolol Tablets 100 mg (Cord Laboratories)|
219506779|NCT00913965|DRUG|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
219506780|NCT02342444|DRUG|Enoxaparin Sodium Injection 30 mg BID|
219506781|NCT02342444|DRUG|Enoxaparin Sodium Injection 40 mg QD|
219506782|NCT01038557|BIOLOGICAL|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
219506783|NCT01411267|DRUG|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
219506784|NCT01411267|DRUG|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age"
219506785|NCT01411267|DRUG|Etoposide|150 mg/m2/day IV on days 1 through 5.
219506786|NCT01411267|DRUG|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
219506787|NCT00631865|BIOLOGICAL|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
219522695|NCT00883090|BIOLOGICAL|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
218885196|NCT03661333|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
218885197|NCT05421481|OTHER|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
218885198|NCT02813239|OTHER|hCG|Oocyte maturation with hCG
218885199|NCT02813239|OTHER|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
218885200|NCT05851820|OTHER|comparison of outcomes/exposure|analysing if diabetes mellitus have an impact on the primary outcomes: hospital stay, admission to the ICU, death.
218885201|NCT04379206|DIAGNOSTIC_TEST|HIV self-test kit|fingerprick and oral fluid HIV self-tests with optional on-site or hotline staff assistance
218885202|NCT04379206|OTHER|Graphical User Interface|Gamification or neumorphism user interface
218885203|NCT04489199|OTHER|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
218885204|NCT06149871|BEHAVIORAL|Physical activity|resistance, aerobic, and flexibility exercises
218885205|NCT05375448|OTHER|Neural mobilisation|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
218885206|NCT03560089|DEVICE|Serious game|Serious game with movements
218885207|NCT03560089|DEVICE|Placebo serious game|Serious game without movement
218885208|NCT06490133|DIETARY_SUPPLEMENT|Polyhpenol extract|Three capsules in fasting conditions 15 minutes prior breakfast
218885209|NCT06490133|DIETARY_SUPPLEMENT|Placebo|Three capsules in fasting conditions 15 minutes before breakfast
218885210|NCT05254431|BEHAVIORAL|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
218885211|NCT05462574|OTHER|No Intervention|No Intervention
218885212|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
218885213|NCT05438576|OTHER|Digital stethoscope electrocardiogram|Digital stethoscope artificial intelligence enabled electrocardiogram (AI-ECG). An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
218885214|NCT01028846|DRUG|Diazoxide|4 mg/kg body weight total dosage administered orally
218885215|NCT01028846|DRUG|Placebo|Oral saline
218885216|NCT00391612|DEVICE|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
219029253|NCT06898957|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
219029254|NCT06436183|DRUG|Camoteskimab|Drug Product
219029255|NCT06436183|DRUG|Placebo|Inactive substance
219029256|NCT06792734|DRUG|BTM-3566|Oral Solution
219029257|NCT06797453|BEHAVIORAL|Shared Medical Visits|Shared group medical visits over eight weeks and two cooking classes.
219506788|NCT05581186|OTHER|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
219506789|NCT05581186|OTHER|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
219522696|NCT01683175|DRUG|Erlotinib|
219522697|NCT01683175|DRUG|cis-platinum|
218885217|NCT00391612|DEVICE|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
218885218|NCT03466736|DIAGNOSTIC_TEST|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
218885219|NCT05431504|DRUG|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
218885220|NCT06583330|DRUG|Low Molecular Weight Heparin (dalteparin)|All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
218885221|NCT06583902|DRUG|Intravenous iron|Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
218885222|NCT06583902|OTHER|Retrospective case-control analysis|the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
218885223|NCT06583889|DRUG|Heparin|The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
218885224|NCT06583889|PROCEDURE|Endovascular treatment|Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
218885225|NCT06584162|DRUG|Vedolizumab Injection|"Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week"
218885226|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
218885227|NCT01966835|BEHAVIORAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
218885228|NCT00544336|OTHER|questionnaire administration|no intervention
218885229|NCT00544336|OTHER|survey administration|no intervention
218885230|NCT00544336|PROCEDURE|quality-of-life assessment|no intervention
218885231|NCT05971927|BEHAVIORAL|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
219522698|NCT01683175|DRUG|Vinorelbine|
219607428|NCT01805843|OTHER|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
219607429|NCT04970303|DRUG|Methylphenidate|Retina or Concerta
219607430|NCT00199017|DRUG|Dexamethasone/Prednisolone|
219607431|NCT00199017|DRUG|Cyclophosphamide|
219607432|NCT00199017|DRUG|Vincristine|
219607433|NCT00199017|DRUG|Daunorubicin|
219607434|NCT00199017|DRUG|Asparaginase|
219607435|NCT00199017|DRUG|G-CSF|
219201433|NCT06890091|OTHER|Fatigue assessment|Fatigue score measured by the EORTC QLQ-FA 12 fatigue self-assessment scale
219201434|NCT01709292|DRUG|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
219201435|NCT01709292|DRUG|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
219201436|NCT01709292|OTHER|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
219201437|NCT06470984|BEHAVIORAL|Educational intervention|Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.
219201438|NCT06635642|BEHAVIORAL|Dichotic Interaural Intensity Difference (DIID) Training|A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
219201439|NCT06313632|DRUG|Bupivacaine injection|Erector spinae plane block with bupivacaine (0.5%) 30 mL once
219201440|NCT06313632|DRUG|Placebo|ESP with matching saline placebo
219201441|NCT06313632|OTHER|Monitored Anesthesia Care|Standard monitored anesthesia care
219201442|NCT06545279|PROCEDURE|Hall Crown Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation.
219201443|NCT06545279|PROCEDURE|Modified Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation but with interproximal slicing.
219201444|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
219201445|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
219201446|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
219201447|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
218885232|NCT05159570|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
219201448|NCT04310423|DRUG|Placebo|Matched to endotoxin
219201449|NCT04310423|BIOLOGICAL|Endotoxin|Bolus dose of 0.8 ng/kg
219201450|NCT03664453|DRUG|omaveloxolone|Omaveloxolone 50 mg capsules
219506790|NCT05581186|OTHER|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
218885233|NCT05159570|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
218885234|NCT01407666|PROCEDURE|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
218885235|NCT03941717|OTHER|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
219201451|NCT04850729|OTHER|non-intervention|non-intervention
219201452|NCT05201352|DRUG|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
219201453|NCT05201352|DRUG|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
219201454|NCT00550849|DRUG|RTA 402|5 mg oral capsules
219201455|NCT00550849|DRUG|RTA 402|25 mg oral capsules
219201456|NCT00550849|DRUG|RTA 402|50 mg oral capsules
219506791|NCT02001779|DEVICE|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
219506792|NCT02001779|DEVICE|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
219506793|NCT01055249|DRUG|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
219506794|NCT01055249|DRUG|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
218885236|NCT03941717|OTHER|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
219201457|NCT02436941|RADIATION|Proton or Photon|
219506795|NCT05830006|PROCEDURE|Microfat grafting|Microfat grafting in cleft lip nasal deformities
219506796|NCT01768728|PROCEDURE|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
219201458|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly administration)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with active filters (HyperHEPA technology). Dose adjustments are permitted in the study where noise disturbance is an issue for participants. The air filtration therapy will be delivered in doses decreasing sequentially in terms of speed mode. Participants will be instructed to keep doors and windows of the bedroom closed during each session at night, and to follow a similar bedtime routine.
219201459|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly and daily administration)|Portable air purifier set up with active filters (HyperHEPA technology) is continuously in operation (24 hours for 14 days) at 275 m³/h in bedrooms with the door and windows closed. During this open-labell phase, the participants will be asked to remain in the bedroom for as long as possible and to keep an activity log for the outdoor locations. Dose adjustments are permitted.
218885237|NCT04278976|OTHER|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
218885238|NCT01511068|DRUG|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
218885239|NCT03616509|DRUG|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
218885240|NCT03616509|DRUG|Placebo|2 months on placebo, sodium chloride 0,9% injections
219201460|NCT06778122|DEVICE|Air filtration system without filters (sham)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with a sham filter, which is identical in appearance and noise as the HyperHEPA filter (active filter) when the air purifier is in operation. Dose adjustments are permitted in the study where noise disturbance is an issue for participants.
218885241|NCT00465088|DRUG|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
218885242|NCT00465088|DRUG|atorvastatin|40 mg at bedtime
218885243|NCT02716623|OTHER|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
218885244|NCT02716623|BEHAVIORAL|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
219201461|NCT05036018|DEVICE|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
219506797|NCT01768728|PROCEDURE|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
219506798|NCT03602690|DRUG|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
219506799|NCT00679523|DRUG|AN2690 Solution, 5.0%|Once daily application for 180 days
219506800|NCT00679523|DRUG|AN2690 Solution, 7.5%|Once daily application for 180 days
219607436|NCT00199017|DRUG|Mercaptopurine|
218885245|NCT04035239|DEVICE|BGS goggles|BGS goggles use for 3-6 weeks
218885246|NCT06512168|BEHAVIORAL|AAC Generative Language Intervention|Aided AAC Language Input/Output Intervention
218885247|NCT00973687|DRUG|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
218885248|NCT00973687|DRUG|Dexamethasone|
218885249|NCT02813161|BIOLOGICAL|cellular and tissue based therapy|
218885250|NCT02813161|DEVICE|negative pressure wound therapy|
218885251|NCT02813161|PROCEDURE|debridement|
218885252|NCT02813161|PROCEDURE|advanced wound therapy|
218885253|NCT02813161|DIETARY_SUPPLEMENT|Nutritional screening|
218885254|NCT02813161|DEVICE|off-loading|
218885255|NCT02813161|DEVICE|Hyperbaric oxygen Therapy|
218885256|NCT04191317|OTHER|Pain Neuroscience Education and gradual exposure|Education covering the pathophysiology of apin and exercises based on the gradual exposure principle
218885257|NCT04191317|OTHER|Pilates and postural education|Postural education and pilates exercises
219607437|NCT00199017|DRUG|Cytarabine|
219607438|NCT00199017|DRUG|Methotrexate|
219607439|NCT00199017|DRUG|VP16|
219607440|NCT00199017|DRUG|Vindesine|
218885258|NCT01067144|DRUG|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
218885259|NCT01067144|DRUG|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
218885260|NCT01067144|DRUG|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
219607441|NCT00199017|DRUG|Adriamycin|
219607442|NCT00199017|DRUG|Thioguanine|
219607443|NCT00199017|DRUG|HDARAC|
219607444|NCT00199017|PROCEDURE|CNS irradiation|
219607445|NCT00199017|PROCEDURE|Mediastinal irradiation|
219607446|NCT00199017|DRUG|Cladribine|
219607447|NCT03415646|OTHER|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
219607448|NCT03415646|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
219607449|NCT06459024|OTHER|Registration into the STREAM platform|All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
218885261|NCT05971537|DRUG|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
218885262|NCT05971537|DRUG|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
218885263|NCT06160934|BEHAVIORAL|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, \& Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
218885264|NCT02978196|PROCEDURE|Injection of 99mTc-NM-01|Patient is injected with micro-dose of 99mTc-NM-01
218885265|NCT02978196|PROCEDURE|Injection of 68Ga-NM-01|Patient is injected with micro-dose of 68Ga-NM-01
218885266|NCT04182243|OTHER|Evaluation of job satisfaction in emergency health care providers by questionnaire|
218885267|NCT04215900|BEHAVIORAL|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
218885268|NCT00010283|DRUG|beclomethasone dipropionate|
218885269|NCT00475709|DEVICE|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
218885270|NCT01732315|BEHAVIORAL|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
218885271|NCT04583527|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
218885272|NCT00555672|DRUG|5-fluorouracil|5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
218885273|NCT00555672|DRUG|cisplatin|Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
218885274|NCT00555672|DRUG|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
218885275|NCT03079089|DRUG|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
218885276|NCT03079089|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at DO
218885277|NCT03079089|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
218885278|NCT03079089|DRUG|Care supports|According to the protocols of each center
219029258|NCT06797453|BEHAVIORAL|Full Plate Living|Online modules teaching how a high-fiber diet can lead to more energy, lower cholesterol, better blood sugar, and easier weight loss.
219029259|NCT06152250|OTHER|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
219029260|NCT05658510|DRUG|BXCL501|Sublingual Film
219029261|NCT05658510|DRUG|Matching Placebo|Sublingual Placebo Film
219506801|NCT02046291|DRUG|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
219506802|NCT01927757|BIOLOGICAL|Etanercept|Administered by subcutaneous injection
219506803|NCT01927757|DRUG|Methotrexate|Background methotrexate at least 15 mg weekly
219506804|NCT05134064|DEVICE|total-body PET/CT|PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
218885279|NCT03079089|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II."
219506805|NCT00338247|DRUG|lapatinib + capecitabine|Experimental
219607450|NCT05378958|OTHER|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
219201462|NCT05036018|PROCEDURE|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
219201463|NCT05036018|DEVICE|CoreValve Evolut Pro, Pro+ and FX|The Evolut Pro, Pro+ or FX valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
219506806|NCT06301555|BEHAVIORAL|Reinforcement learning algorithm powered cognitive and behavioral intervention|Reinforcement learning algorithm powered cognitive and behavioral intervention
219506807|NCT06301555|BEHAVIORAL|cognitive and behavioral intervention|cognitive and behavioral intervention
219506808|NCT04392089|DEVICE|Masimo, LidCO|"* Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO"
219506809|NCT00268346|DRUG|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
218885280|NCT03632772|DRUG|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
218885281|NCT03632772|DRUG|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
218885282|NCT04759157|BEHAVIORAL|Couples-based treatment|Couples will attend 3, video based sessions for couples-based treatment
218885283|NCT04759157|OTHER|Standardized education|Patients will receive standardized educational materials
218885284|NCT05380440|BEHAVIORAL|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
218885285|NCT05380440|BEHAVIORAL|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
218885286|NCT06528431|DRUG|Clinical tapering strategy|Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
218885287|NCT06528431|DRUG|Step Wedge trial|Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
218885288|NCT01479361|DRUG|Atovaquone 750 mg twice daily|
219607451|NCT02286843|RADIATION|89Zr-trastuzumab|
219607452|NCT02286843|DEVICE|PET/CT scan|
219607453|NCT02286843|RADIATION|89Zr-pertuzumab|
219607454|NCT06115993|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
219607455|NCT06115993|DRUG|Placebo|Placebo will be administered subcutaneously.
219607456|NCT04905693|DRUG|Inhaled Treprostinil|Inhaled Treprostinil (6 mcg/breath) administered QID
219607457|NCT04905693|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
218885289|NCT01479361|DRUG|Atovaquone 1500 mg twice daily|
218885290|NCT00921791|DEVICE|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
218885291|NCT00921791|DEVICE|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
219506810|NCT03092908|DIETARY_SUPPLEMENT|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
219506811|NCT03092908|DIETARY_SUPPLEMENT|placebo (water)|Administer 5 ml placebo (water) three times a day.
219506812|NCT02776007|DEVICE|Libre Flash CGMS|
219506813|NCT02776007|DEVICE|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
219506814|NCT06325878|GENETIC|Genome-wide association study|Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP
219607458|NCT05501821|DRUG|KBA1412|Part A, B, C
218885292|NCT00921791|BEHAVIORAL|Pharmaceutical care|consultations with the pharmacists
218885293|NCT00921791|OTHER|Usual care|Consultation with the physician.
218885294|NCT06360848|OTHER|surgery|SURGICAL TREATMENT OF PSEUDARTHROSIS OF THE HUMERUS
218885295|NCT04259008|OTHER|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
218885296|NCT04259008|OTHER|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
219201464|NCT05036018|PROCEDURE|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
219201465|NCT06150716|DRUG|ION356|Administered as intrathecal (IT) injection.
219201466|NCT06848465|RADIATION|Low Dose Radiotherapy|10 Gy in 5 fractions, 15 Gy in 3 fractions, 20 Gy in 10 fractions respectively in three Cohorts from Day1
218885297|NCT01415401|DRUG|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
218885298|NCT02899091|BIOLOGICAL|CB-AC-02|"Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)"
219506815|NCT06193278|DEVICE|Neuromodulation|Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
218885299|NCT02899091|BIOLOGICAL|Placebo|"Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)"
219506816|NCT02254148|DRUG|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
219506817|NCT02254148|DRUG|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
218885300|NCT02397148|RADIATION|Computed Tomography|imagery with ionizing radiation
219029262|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
219506818|NCT02254148|DRUG|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
219201467|NCT06848465|RADIATION|Short course Radiotherapy|25 Gy in 5 fractions from Day1
219201468|NCT06848465|DRUG|XELOX|Oxaliplatin: 130mg/m2 IV Q3W on day 1 of each cycle. Capecitabine: 1000mg/m2 Q3W Dose of 1000mg/m2 on day 1-14 of each cycle.
219201469|NCT06848465|DRUG|Tislelizumab|200mg IV Q3W on day 1 of each cycle.
219201470|NCT06848907|DRUG|ganzhixiao capsule|Ganzhixiao Capsule is mainly composed of Bupleurum chinense, Herba Artemisiae, Polygonum cuspidatum, Rhubarb and Hawthorn.Take 3 capsules each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
219201471|NCT06848907|DRUG|placebo capsule|Take 3 palcebo capsule each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
219607459|NCT05501821|DRUG|Pembrolizumab|Part C only
219607460|NCT06166524|PROCEDURE|Catheter ablation for atrial fibrillation using pulsed-field energy|Patients will undergo pulmonary vein isolation using pulsed-field energy
219607461|NCT06166524|PROCEDURE|Conservative arm|Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
218885301|NCT02397148|RADIATION|Cone Beam Computed Tomography|imagery with ionizing radiation
218885302|NCT03746717|DEVICE|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
218885303|NCT03746717|DEVICE|conventional wound closure|wound closure with surgical staples
218885304|NCT01860313|BEHAVIORAL|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
218885305|NCT01860313|BEHAVIORAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
218885306|NCT02465372|BEHAVIORAL|CSPAP|Comprehensive School Physical Activity Program.
218885307|NCT00119470|PROCEDURE|EUS-FNA|
218885308|NCT00119470|PROCEDURE|Conventional Surgical Technique|
218885309|NCT06268938|PROCEDURE|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
218885310|NCT02923856|DEVICE|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
218885311|NCT02923856|DEVICE|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
219029263|NCT07094334|OTHER|Action Observation|This study, in contrast to prior research, will examine both the acute effects of action observation therapy and its impacts at the peripheral level.
219029264|NCT07094334|OTHER|Action Observation combined with Motor Imagery|This study, in contrast to prior research, will examine both the acute effects of action observation therapy combined with motor imagery and its impacts at the peripheral level.
219029265|NCT07094334|OTHER|Sham (No Treatment)|Participants in this intervention group will watch landscape and nature-themed videos for the duration corresponding to the intervention period applied in the other groups.
219201472|NCT06462638|OTHER|Neurobehavioral states and physiological parameters evaluation|"Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded."
219201473|NCT06462638|OTHER|Maternal vocal pitch evaluation to assess depressive/anxious state|"Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research)."
219201474|NCT05650619|OTHER|Biospecimen collection|Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.
219201475|NCT05650619|OTHER|Data collection|Data collection for all groups
219201476|NCT01746979|DRUG|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
219506819|NCT02254148|DRUG|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
218885312|NCT02923856|DEVICE|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
218885313|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
218885314|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
218885315|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
218885316|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
218885317|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
218885318|NCT01870505|DRUG|BYL719|
218885319|NCT01870505|DRUG|Letrozole|
218885320|NCT01870505|DRUG|Exemestane|
218885321|NCT03667469|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
218885322|NCT03667469|DIETARY_SUPPLEMENT|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
218885323|NCT04067609|DRUG|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
218885324|NCT04067609|OTHER|placebo|100mL of normal saline (placebo)
218885325|NCT04765202|PROCEDURE|AG Tx|Control treatment that is meshed autograft alone applied to a burn area.
218885326|NCT04765202|BIOLOGICAL|SOMA Tx|Meshed autograft applied to the burn area and covered with StrataGraft.
218885327|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
218885328|NCT06855355|DIETARY_SUPPLEMENT|Clostridium butyricum MIYAIRI 588|A butyrate-producing probiotic, has demonstrated potential anti-inflammatory and anti-tumorigenic effects.
219029266|NCT03482791|RADIATION|Proton beam therapy|"* The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used."
218885329|NCT06975709|OTHER|Questionnaire and Physical Exam|"The diagnostic questionnaires will be administered and the participants' responses will subsequently be analyzed, evaluating the presence of temporomandibular disorders (DTMs) in patients with sleep disorders.~The questionnaires will be administered to patients with a previous diagnosis of sleep disorder carried out at a specialist centre, consecutively belonging to the outpatient clinics of both centers U.O of Neurology-Sleep Disorders Center and U.O of Dentistry."
218885330|NCT06976489|DRUG|PA-111|PA-111 1Tab., Per Oral
218885331|NCT04459468|DRUG|Lipiodol|Lipiodol TACE procedure
219029267|NCT03482791|OTHER|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
219029268|NCT06908616|DIAGNOSTIC_TEST|Cord blood|Cord blood samples will be collected during routine G6PD testing. An additional 3 mL will be obtained non-invasively from the umbilical cord to determine the expression of Duffy antigens using serologic gel testing.
219201477|NCT01746979|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
219201478|NCT01746979|DRUG|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
219201479|NCT06966427|DEVICE|Dosing Guidance System to be used with both time and amount of insulin as input|Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
219506820|NCT02254148|DRUG|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
219506821|NCT02254148|DRUG|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
219506822|NCT02254148|DRUG|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
219506823|NCT05736965|DRUG|Selinexor|Selinexor 60mg, PO d3,10,17
219506824|NCT05736965|DRUG|Azacitidine|Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
219506825|NCT05736965|DRUG|Venetoclax|Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
219506826|NCT00103675|PROCEDURE|Acupuncture|
218885332|NCT06548373|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Point-of-Care Echocardiography|"A wireless, AI-guided handheld ultrasound probe will be used on adult male patients who present with a clinical indication for peri-anesthesia point-of-care echocardiography examination.~Residents will document personal interpretation of the completed point-of-care ultrasound (POCUS) examination, important clinical findings, and assessment of whether obtaining a formal echocardiogram is warranted on an exam assessment form. The residents will complete 11 examinations with 10 specific scans each. The first 10 examinations will be AI-guided, and the final 11th examination will be done via a standard (non-AI guided) ultrasound system to gauge the resident's growth in point-of-care echocardiography skill."
219506827|NCT06503341|OTHER|Cardiovascular risk assesment|ASCVD Score and WHO Cardiovascular Risk score.
219506828|NCT03813485|OTHER|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
219506829|NCT03813485|OTHER|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
218885333|NCT06594198|DEVICE|Cerebral monitor|The study procedure consists of monitoring the values of 3 cerebral parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor. These 3 parameters will be recorded and compared after the intervention with 3 parameters considered as standard: SctO2 measured by the INVOS 7100 cerebral oximeter, the bispectral index (BIS) measured by the BIS monitor and the ANI measured by the MDoloris monitor. These 3 reference parameters are once again usually monitored and recommended for all cardiac surgery.
219506830|NCT00001228|DRUG|Interferon|
219506831|NCT02179684|PROCEDURE|Baby-sitter surgery N. fascialis|
219506832|NCT02179684|OTHER|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
219506833|NCT00427622|OTHER|physiologic testing|
219506834|NCT01557647|DRUG|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
219506835|NCT01557647|DRUG|Placebo|placebo inhalation solution
218885334|NCT02687139|DRUG|18F-DCFPyL|
218885335|NCT02687139|PROCEDURE|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
218885336|NCT01224366|DRUG|Vildagliptin|
218885337|NCT01224366|DRUG|Placebo|
218885338|NCT06658132|DRUG|0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.|Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
218885339|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
218885340|NCT05854368|PROCEDURE|Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine care.|Collection of an additional blood volume (9 mL) as part of a blood sampling performed during routine care or specific for the research if not part of routine care.
218885341|NCT05854368|PROCEDURE|Blood collection|Blood sample collection (10 mL)
218885342|NCT01707082|DRUG|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
218885343|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
218885344|NCT01707082|DRUG|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
218885345|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
219506836|NCT05388682|DEVICE|Percutaneous transluminal pulmonary angioplasty|Percutaneous transluminal pulmonary angioplasty
219506837|NCT05694468|OTHER|Psychomotor Relaxation|Psychomotor relaxation sessions.
219506838|NCT01958281|DRUG|SOF|Tablet(s) administered orally once daily
218885346|NCT01707082|DRUG|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
218885347|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
218885348|NCT01707082|DRUG|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
218885349|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
218885350|NCT01707082|DRUG|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
218885351|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
219506839|NCT01958281|DRUG|RBV|200 mg tablet administered orally once daily
219506840|NCT01958281|DRUG|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
219506841|NCT02784106|DRUG|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
219506842|NCT02784106|DRUG|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
219506843|NCT02784106|DRUG|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
219506844|NCT05677607|DIAGNOSTIC_TEST|Magnetic resonance imaging|Imaging diagnostics mainly based on Magnetic resonance imaging.
218885352|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
218885353|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
218885354|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
218885355|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
218885356|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
218885357|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
218885358|NCT06155539|OTHER|No intervention|No intervention
218885359|NCT03114384|OTHER|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
218885360|NCT05107622|OTHER|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
218885361|NCT05107622|OTHER|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
218885362|NCT02305238|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
218885363|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
218885364|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
219029269|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
219029270|NCT06911424|DRUG|Fusidic Acid 1%|Fusidic acid 1%
219029271|NCT06911424|DRUG|Placebo|Placebo ophthalmic solution
219029272|NCT06909968|OTHER|palliative care|"As this study is intended to be observational (not interventional), the patient's medical record will be the source of all data to be recorded.~No additional procedures/patient visits should be planned in the study with respect to clinical practice.~Two tools will be used to to analyze appropriateness and timeliness of progressive palliative care approach: NECPAL CCOMS-ICO(©), specific for the assessment of needs in palliative care, and the PaP score, for the assessment of prognosis."
219029273|NCT07095114|OTHER|Magic Ink|A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant
219029274|NCT07101809|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
219029275|NCT07101809|DEVICE|Standard Ureteroscopy (URS)|Arm Description: This is a treatment in which the urologist uses a laser to break a kidney stone into very small pieces and then places a tool called a stent to allows the remaining pieces to fall out.
219029276|NCT03089801|OTHER|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
219029277|NCT06913426|COMBINATION_PRODUCT|Pelvic Tilt, Hip and Knee Focused Exercises (Intervention Group)|The treatment program is between one to six weeks with strictly 18 sessions with at least thrice in a week to give room to recuperate from muscle fatigue. This protocol is set in a 45 minutes session that involves a series of exercises and stretches. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. After that the patient is to perform exercises for pelvic tilt in three approaches, each made in 10 to 15 repetitions.
219040352|NCT06872697|DEVICE|Neuromuscular Electrical Stimulation|In this group, neuromuscular electrical stimulation (NMES) will be applied to the targeted muscle groups. The application will be carried out with the patient in a comfortable seated or lying position. Stimulation parameters will be set as follows: a frequency of 35-50 Hz, a pulse duration of 200-400 microseconds, and an intensity adjusted to elicit visible muscle contractions without causing discomfort. NMES will be applied for 20-30 minutes per session, 3-5 times a week, for 4-6 weeks, depending on the protocol, in addition to conventional physiotherapy.
219506845|NCT00805909|DRUG|NI-0401|5 daily infusions with escalating doses of NI-0401
219506846|NCT04897828|DEVICE|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
219506847|NCT05635149|RADIATION|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
218885365|NCT02513472|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
219607462|NCT04574687|OTHER|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
219607463|NCT04574687|OTHER|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
219607464|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
218885366|NCT02513472|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
218885367|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
218885368|NCT04367090|DRUG|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
218885369|NCT04367090|DRUG|Pyrotinib|Pyrotinib 400/320 mg orally daily
218885370|NCT04683445|DRUG|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
218885371|NCT04683445|DRUG|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
218885372|NCT04683445|DRUG|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
218885373|NCT04683445|DRUG|Pyrotinib|Pyrotinib，400mg，oral，every day
218885374|NCT04683445|DRUG|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
218885375|NCT04683445|DRUG|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
219029278|NCT06913426|DIAGNOSTIC_TEST|Hip and Knee Focused Exercises(Control Group)|The treatment program covers a time frame of one to six weeks, three sessions a week, total of 18 sessions, over six weeks. Each session takes 45 minutes and contains a schedule of activities. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. Then Patient performs hip exercises; hip abductor as well as hip extension, which are done in three sets of 10 to 15 repetitions each. Likewise, the knee-focused workouts such as quad sets, straight leg raises and step-up are conducted in the same 3 sets of 10-15 repetitions style. Static flexibility exercises includes Hip Flexor Stretch, IT Band Stretch and these exercises are performed with 5 sets of 30 seconds.
219029279|NCT06912815|BIOLOGICAL|ustekinumab and semi enteral nutrition|Preoperative treatment optimization involves a single intravenous induction with UST, followed by 6 weeks of oral/nasal feeding with semi-enteral nutrition.
219029280|NCT06912815|OTHER|Exclusive enteral nutrition|Preoperative optimized treatment with 6 weeks of oral/nasal feeding of exclusive enteral nutrition alone.
219029281|NCT06914414|PROCEDURE|Using the flow model in cerebral aneurysm embolization|"Since the 1970s-1980s, surgical techniques for intracranial aneurysms have evolved. In recent years, endovascular embolization of aneurysms has demonstrated a better approach to the pathology, as well as better results in terms of both vital prognosis, but also in terms of quality of life (disability, logical disorders, etc.). However, this treatment modality remains little known to the general public, and generates a high level of anxiety for patients.~The anxiety of these patients could be reduced by the addition of a paramedical consultation and the use of a flow model to explain and visualize the procedure.~The study will include 72 patients per group (i.e. a total of 144 patients, with a 10% loss of blood pressure) to achieve a two-point reduction in the anxiety score measured by the APAIS grid."
219029282|NCT06911385|DEVICE|Arm Remote Ischemic Conditioning plus Pneumatic Compression lower limb|Arm Remote Ischemic Conditioning (4 cycles) plus Pneumatic Compression lower limb (100 mmHg for 1 hour)
219029283|NCT07112872|DRUG|RO7795081|RO7795081 will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.
219607465|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
219607466|NCT04826692|DRUG|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
219607467|NCT04826692|DRUG|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
219607468|NCT00775619|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
219607469|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
219607470|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
218885376|NCT01380834|DRUG|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
218885377|NCT01380834|DRUG|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
218885378|NCT02088021|DEVICE|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
218885379|NCT01418079|DEVICE|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
218885380|NCT00049712|BIOLOGICAL|etaracizumab|
218885381|NCT04310566|DEVICE|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
218885382|NCT04310566|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL
218885383|NCT02657447|DRUG|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
218885384|NCT02657447|DRUG|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
218885385|NCT04720742|DRUG|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
219506848|NCT04117165|DIAGNOSTIC_TEST|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
219506849|NCT04117165|DRUG|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
218885386|NCT03554447|DRUG|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
218885387|NCT03554447|DRUG|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
218885388|NCT04565951|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
218885389|NCT04565951|BEHAVIORAL|Sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
218885390|NCT03076294|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
218885391|NCT03076294|OTHER|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
218885392|NCT04165499|COMBINATION_PRODUCT|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
218885393|NCT04165499|COMBINATION_PRODUCT|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
218885394|NCT02748928|DEVICE|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
218885395|NCT04677504|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
218885396|NCT04677504|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
219029284|NCT07112872|DRUG|Semaglutide|Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.
219029285|NCT07112872|DRUG|Placebo|Placebo will be taken orally QD during the 30-week treatment period.
219029286|NCT06916598|OTHER|Delphi study|This Delphi study involves multiple iterative rounds until a stable consensus or dissensus is reached on all the statements.
219029287|NCT06916598|OTHER|Structured Interview|"Structured interviews will be conducted by members of the steering committee and an independent qualitative research expert. A pilot-tested case vignette along with a Likert scale-based questionnaire, will be employed to gather insights regarding the impact and severity of PPCs. The impact of the individual components of PPCs will be evaluated on a 7-point Global Rate of Change (GRC) scale (from very much worse to very much better) to calculate the minimal clinical important difference. Patient care representatives will be engaged in anonymous voting on the questionnaire. PPCs' rankings and key themes synthesised from the interviews will be shared with the panel in the second Delphi round, facilitating the integration of patient perspectives into the consensus process."
219029288|NCT06920381|DRUG|Gebauer's Ethyl Chloride Topical Spray|Prior to injection of lidocaine, the investigator will apply ethyl chloride spray, Gebauer's Ethyl Chloride Topical Spray, continuously for 4 to 10 seconds until the skin turns white. This application will be done from a distance of 8 to 18 cm (3 to 7 inches) to the right side of the tumor lesion.
219029289|NCT06914505|BEHAVIORAL|visual restoration therapy|In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.
219029290|NCT06907290|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
219029291|NCT06907290|DRUG|Brelovitug 900 mg|Route of administration- Subcutaneous Injection
219029292|NCT06907290|DRUG|Delayed Treatment with Brelovitug 300mg|Route of administration- Subcutaneous Injection
219029293|NCT06912893|DEVICE|radial shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with radial shock wave therapy with 1500 impulses, 5 Hz and 1,5 bar
219201480|NCT06966427|DEVICE|Dosing Guidance System to be used with only time of insulin as input|any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
219506850|NCT05353556|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
219506851|NCT05353556|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
219506852|NCT01694511|PROCEDURE|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
219506853|NCT01694511|PROCEDURE|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
219029294|NCT06912893|DEVICE|focused shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with focused shock wave therapy with 1500 impulses, 5 Hz and 0,05 mJ/mm²
219029295|NCT07118891|BIOLOGICAL|ABCL635|Participants will receive SC administrations of ABCL635
219201481|NCT06224088|OTHER|VV ECMO|treatment with VV ECMO in the ICU
219506854|NCT02920164|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
219029296|NCT07118891|BIOLOGICAL|Placebo|Participants will receive SC administration of placebo (5% dextrose solution)
219029297|NCT07119112|DEVICE|Surgical drain stripping device|We have developed a device to fully compress the surgical drain tubing without compromising the integrity of the tubing to clear the drain fluid/debris more effectively than the current standard of care.
219029298|NCT07119112|OTHER|Standard of Care (Investigator Choice)|Current standard of care for surgical drain tube stripping involves running fingertips down the length of the tubing compressing the drain tubing to clear fluid/debris.
219029299|NCT06919094|BEHAVIORAL|Life Story Club|Virtual group reminiscence therapy will be provided by the Life Story Club©. Participants will meet virtually via Zoom© with their group (6-10 people) weekly for one hour over a 12-week period to exchange life stories and share in conversation. Groups will be conducted in entirely in English or Spanish, based on participant preference. Each week, the LSC© facilitator will guide the group with question prompts to encourage participants to share personal information, build friendships \& rapport, and create a sense of community. LSC© facilitators are trained in group interview techniques, technology management, and know how to respond appropriately to sensitive information that may emerge during group exchanges.
219029300|NCT06913686|BEHAVIORAL|Music intervention|"experimental controlled study will be conducted at the La Marsa tennis club in Tunis, Tunisia, utilizing a rigorous methodology to collect data from competitive young tennis players aged 12-18. This study employs a three-phase design: first, participants' musical preferences are profiled to create personalized music sequences; second, their mental performance is evaluated through pre- and post-intervention questionnaires measuring perception of success, emotional state, emotion regulation, and flow, with a 45-minute training session followed by a music-accompanied exercise; and third, physical performance is assessed using a battery of tests for muscular strength, endurance, agility, and flexibility, conducted both with and without music to determine its impact.~Data collection will be done using a questionnaire that has been developed based on the literature."
219029301|NCT06914362|PROCEDURE|global postural reeducation|"Global postural reeducation included the following GPR postures according to the Souchard approach \[7\]: lying on back with the legs extended and arms folded, lying on back with the legs flexed and arms folded, lying on back with the legs extended and arms open, lying on back with the legs flexed and arms open, sitting with legs extended and standing with the back against the wall.~Each posture was performed by the patient under the physiotherapist supervision and was held for 15 to 20 minutes.~Besides, each patient was asked to repeat the exercises daily at home."
219029302|NCT06914362|PROCEDURE|conventional rehabilitation|"Conventional reeducation included manual therapy approaches such as spinal mobilization which aims to restore joint mobility and alleviate muscular tension.~It included also exercise therapy focusing on strengthening core muscles, improving lumbar flexibility, and enhancing posture to stabilize the spine and reduce strain on surrounding structures.~Modalities like heat therapy, cold therapy, and transcutaneous electrical nerve stimulation (TENS) were also used to manage pain and promote muscle relaxation. Additionally, education on ergonomic principles was part of the program to adopt healthy habits and prevent recurrence of pain."
219029303|NCT05017506|OTHER|A survey will be made.|A survey will be made.
219029304|NCT03627533|PROCEDURE|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
219029305|NCT07123467|DRUG|Low-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Low-dose participants receive 5 milligram/kilogram/day throughout. The intervention targets emotion regulation circuitry and symptom improvement.
219029306|NCT07123467|DRUG|Placebo Matched to Moderate-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the moderate-dose cannabidiol arm, dosing starts at 5 mg/kg/day and titrates to 10 milligram/kilogram/day (divided twice a day) after 6 days.
219029307|NCT07123467|DRUG|Moderate-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Moderate-dose participants receive 5 milligram/kilogram/day for 6 days, then titrate to 10 milligram/kilogram/day. The intervention targets emotion regulation circuitry and symptom improvement.
219029308|NCT07123467|DRUG|Placebo Matched to Low-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the low-dose cannabidiol arm, dosing is maintained at 5 milligram/kilogram/day (divided twice a day) throughout the treatment period. No titration is required.
219029309|NCT06932640|DEVICE|- Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)|Near-Infrared Spectroscopy (NIRS) monitors, provided by Edwards Lifesciences, is a monitoring technique. It will be connected to consented patients, automatically capturing brain oxygen as waveform output, and stored in Sickbay system. The NIRS is a non-invasive monitoring method, in which adhesive pads will be applied to forehead. 4 hours continuous monitoring will be recorded on day 1 after SAH (or on presence to NICU), then every three days from day 3 to day 14 (within the DCI window), to 1 to 2 recordings from day 15 to day 21.
219029310|NCT05078866|BIOLOGICAL|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Given IM
219029311|NCT05078866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219029312|NCT05078866|PROCEDURE|Endoscopic Biopsy|Undergo endoscopy with biopsy
219029313|NCT05078866|BIOLOGICAL|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Given IM
219029314|NCT05078866|OTHER|Questionnaire Administration|Ancillary studies
219201482|NCT05512650|DEVICE|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
219506855|NCT02920164|DEVICE|Placebo acupuncture|Placebo acupuncture with placebo needles
219607471|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
219607472|NCT04716868|DIETARY_SUPPLEMENT|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
218885397|NCT04677504|OTHER|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
218885398|NCT04677504|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
218885399|NCT04677504|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
219201483|NCT05512650|DEVICE|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
219201484|NCT03964441|BIOLOGICAL|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
219201485|NCT03964441|BIOLOGICAL|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
219201486|NCT03964441|OTHER|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
219201487|NCT03964441|OTHER|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
219201488|NCT03964441|OTHER|professional interviews (optional organizational study)|interview to understand how the decision is formed
219201489|NCT03964441|OTHER|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
219201490|NCT06055608|DRUG|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
219201491|NCT06055608|BIOLOGICAL|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
219201492|NCT06055608|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
219201493|NCT06055608|DRUG|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
219201494|NCT06055608|DRUG|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
219201495|NCT06055608|DRUG|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
219364590|NCT04475692|OTHER|Conventional care|Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
219364591|NCT01901835|PROCEDURE|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
218885400|NCT04067414|BIOLOGICAL|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells."
219364592|NCT01901835|OTHER|survey administration|Ancillary studies
219364593|NCT01901835|PROCEDURE|quality-of-life assessment|Ancillary studies
219364594|NCT03416361|DIETARY_SUPPLEMENT|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
218885401|NCT03301298|DRUG|SXC-2023|Oral capsule
219364595|NCT06419114|DEVICE|Optical Coherence Tomography|Comparing the localization ability of OCT and R-EBUS in Peripheral Pulmonary Lesions and the predictive ability of lung cancer pathological classification
219364596|NCT02090712|PROCEDURE|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
219364597|NCT05122637|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
218885402|NCT03301298|DRUG|Placebo oral capsule|Placebo given as oral capsule.
218885403|NCT00066027|DRUG|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
218885404|NCT00066027|DRUG|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
218885405|NCT02735954|OTHER|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
218885406|NCT03801603|BEHAVIORAL|HPV vaccination training and education|1\) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
219364598|NCT05122637|DEVICE|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
219364599|NCT00648167|DRUG|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
219506856|NCT03075033|DEVICE|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
218885407|NCT06121024|PROCEDURE|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
218885408|NCT01265303|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
218885409|NCT01711645|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
219029315|NCT06933498|PROCEDURE|PREOPERATIVE ESPB|After 0.03 mg/kg IV midazolam sedation is applied to patients who will undergo preoperative ESPB, bilateral ultrasound-guided ESPB (in-plane approach) will be applied over the vertebral level that is equidistant from the highest and lowest vertebral levels planned for surgery in the prone position. ESPB will be performed by experienced anesthesiologists. After sterilization of the skin with povidone iodine, the probe with a sterile sheath is placed 3 cm lateral to the spinous process and the trapezius, rhomboid major, erector spinae muscles and the transverse process of the vertebrae are visualized. The needle is placed in the fascial plane on the deep surface of the erector spinae muscle on the bone shadow of the transverse process of the vertebra. A total of 40 mL of 0.25% bupivacaine is administered bilaterally after the LA spread is seen. After waiting for the effect of the block for 30 minutes, the patients will be taken to the operating room.
219029316|NCT06933498|PROCEDURE|INTRAOPERATIVE ESPB|Intraoperative ESPB will be performed by the neurosurgeon after LDH repair, starting from the level of the operated vertebra and covering all surgical segments. This procedure will be repeated for the other side (right/left). A total of 40 mL of 0.25% bupivacaine will be used for both sides.
219029317|NCT00508807|DRUG|RTA 402|5 mg by mouth (PO) daily for 21 days
219029318|NCT00640445|BEHAVIORAL|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
219029319|NCT00640445|BEHAVIORAL|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
219029320|NCT01344161|DIETARY_SUPPLEMENT|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
219029321|NCT01344161|DIETARY_SUPPLEMENT|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
219029322|NCT07143370|DEVICE|Thermoformed clear aligner|All participants will receive a thermoformed aligner fabricated from polyethylene terephthalate glycol (PETG) material. This aligner is made from using an intraoral scan to print a 3D model of their maxillary dentition, that is then used for the thermoforming process. This aligner will be worn 20-22 hrs/day for 1 week.
219029323|NCT07143370|DEVICE|3D printed clear aligner TC-85|All participants will receive a 3D printed aligner fabricated from TC-85 resin. This aligner will be made using an Stereolithography (STL) file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
219029324|NCT07143370|DEVICE|3D printed clear aligner TA-28|All participants will receive a 3D printed aligner fabricated from TA-28 resin. This aligner will be made using an STL file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
219029325|NCT06942754|DEVICE|post-surgical functional bracing|Quadriceps Autograft ACL Reconstruction with the use of post-surgical functional bracing, using the DonJoy Defiance Pro brace
219029326|NCT06950385|DRUG|eRapa (encapsulated rapamycin)|0.5 mg capsules for oral use; white opaque capsule filled with off-white powder; Trial intervention will be provided in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
219029327|NCT06950385|DRUG|Placebo|Capsules in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
219029328|NCT07151261|DIETARY_SUPPLEMENT|Ashwagandha|Sustained-Release, lower-dosage (150mg) Ashwagandha Supplement, 1 capsule 1 time per day.
219506857|NCT03075033|DEVICE|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
218885410|NCT01548066|DRUG|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
218885411|NCT01548066|DRUG|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
218885412|NCT04836884|PROCEDURE|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
218885413|NCT05320003|DIAGNOSTIC_TEST|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
219029329|NCT07151261|OTHER|Placebo|This placebo does not contain any of the interventional dietary supplement. The placebo consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.
219029330|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
219029331|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
219201496|NCT05367037|DEVICE|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
219201497|NCT05367037|DEVICE|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
219201498|NCT06510816|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT injection
219201499|NCT06510816|OTHER|Sham Administration|Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
219201500|NCT06093061|COMBINATION_PRODUCT|CCRT with Maintenance Tislelizumab and Metronomic Capecitabine|"CCRT: Radiotherapy will be delivered once daily, for 5 days per week, over 6 to 7 weeks. During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).~Maintenance: Tislelizumab 200mg, day 1 per 3-week cycle, intravenous (IV) infusion and capecitabine 650 mg/m2, days 1-21 per 3-week cycle, bidaily, oral, for a total of 12 months (17 cycles)."
219506858|NCT01665170|DRUG|Passiflora incarnata|3 x 1 tablet per day for 3 days
219506859|NCT01665170|DRUG|Placebo|3 x 1 ablet per day for 3 days
219506860|NCT03222141|DEVICE|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
219506861|NCT03541564|DRUG|BMS-986165|Specified dose on specified days
219506862|NCT03541564|DRUG|Moxifloxacin|Specified dose on specified days
219506863|NCT03541564|OTHER|Placebo|Specified dose on specified days
219506864|NCT04023279|OTHER|TENS|100 Hz and 100 usec for 20 minutes
219506865|NCT04023279|OTHER|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
219506866|NCT03379077|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
219506867|NCT02002780|BEHAVIORAL|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
219201501|NCT04587674|DEVICE|Spinal Cord Stimulation|Lead(s) and Implant Pulse Generator
219201502|NCT06303128|DRUG|Amoxicillin 250 MG|Liquid amoxicillin 250mg PO
219201503|NCT06303128|DRUG|Placebo|Given prior to amoxicillin 250mg in one-dose group
219201504|NCT06303128|DRUG|Amoxicillin 62.5mg|Given first in two-dose group, liquid amoxicillin 62.5mg PO
219506868|NCT02003040|DEVICE|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
218885414|NCT05320003|DIAGNOSTIC_TEST|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
219201505|NCT06303128|DRUG|Amoxicillin 187.5mg|Given second in two-dose group, liquid amoxicillin 187.5mg PO
219201506|NCT05852990|COMBINATION_PRODUCT|Glutamine plus L. reuteri|Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
219201507|NCT05807997|OTHER|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
219201508|NCT05598034|DEVICE|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
219506869|NCT01840956|BIOLOGICAL|HAVG|HAVG is implanted into patients' arm.
219506870|NCT00261157|DEVICE|InTouch Telerounding Robot|
219506871|NCT03891056|PROCEDURE|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
219506872|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
219506873|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
219506874|NCT00604110|OTHER|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF\<45%), is hemodynamically favourable.
219506875|NCT03457025|DRUG|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
219506876|NCT03457025|DRUG|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
218885415|NCT05320003|DIAGNOSTIC_TEST|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
218885416|NCT03878784|DRUG|Imigran|All patients will undergo this intervention on one of two study days
218885417|NCT03878784|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
219506877|NCT03457025|DEVICE|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
218885418|NCT05628909|PROCEDURE|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
218885419|NCT05628909|PROCEDURE|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
219029332|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
219029333|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
219506878|NCT02673671|DEVICE|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
219506879|NCT04849026|DRUG|Clozaril 100 mg (Clozapine)|2 Doses/Day for 10 days
219029334|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
219506880|NCT04849026|DRUG|WID-CLZ18|2 Doses/Day for 10 days
219506881|NCT00945425|DRUG|AZD7325|oral capsule, once or twice daily, 7 days
218885420|NCT05628909|PROCEDURE|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
218885421|NCT02327494|DRUG|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
218885422|NCT00662116|DRUG|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
219029335|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
219506882|NCT00945425|DRUG|Placebo|oral capsule, once or twice daily, 7 days
219506883|NCT01767441|PROCEDURE|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
218885423|NCT00662116|DRUG|placebo|placebo tablets - two tablets taken twice daily
218885424|NCT03460912|DEVICE|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
219506884|NCT01767441|PROCEDURE|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
218885425|NCT00637962|BIOLOGICAL|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
218885426|NCT00637962|BIOLOGICAL|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
218885427|NCT02109809|RADIATION|total nodal irradiation|Undergo TLI
218885428|NCT02109809|OTHER|laboratory biomarker analysis|Correlative studies
218885429|NCT02109809|OTHER|questionnaire administration|Ancillary studies
219201509|NCT05598034|DEVICE|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
219201510|NCT05598034|BEHAVIORAL|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
219506885|NCT01767441|PROCEDURE|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
219506886|NCT01767441|OTHER|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
219607473|NCT04274257|DRUG|Double-Blind Placebo|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
219506887|NCT01638936|DRUG|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
218885430|NCT05150717|DRUG|[14C]-Jaktinib|Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
218885431|NCT01041521|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
218885432|NCT06204081|DEVICE|CSO_without cueing|The sole is worn without using the cueing application
218885433|NCT06204081|DEVICE|CSO_cueing|The sole is worn with using the cueing application
218885434|NCT03691662|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
218885435|NCT03691662|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
218885436|NCT05254249|DRUG|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
219029336|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
219029337|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
219029338|NCT05904665|DIAGNOSTIC_TEST|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
219029339|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
219029340|NCT04269759|OTHER|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
218885437|NCT05254249|OTHER|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
218885438|NCT02978950|OTHER|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
218885439|NCT02978950|OTHER|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
218885440|NCT02983864|BEHAVIORAL|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
219029341|NCT04269759|OTHER|dental care|pregnant women will have a dental care
219029342|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
219029343|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
219201511|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
219201512|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
219201513|NCT05952141|BEHAVIORAL|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
219201514|NCT05952141|BEHAVIORAL|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
219201515|NCT05952141|BEHAVIORAL|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
219506888|NCT03483285|DEVICE|airtraq|airtraq videolaryngoscope
219506889|NCT03483285|DEVICE|storz|storz videolaryngoscope
219506890|NCT00500409|DRUG|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
219506891|NCT00500409|DRUG|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
219506892|NCT01280370|PROCEDURE|Abdominal surgery|intraoperative mesh implantation
219607474|NCT04274257|DRUG|Double-Blind Rituximab|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
219607475|NCT02536846|DRUG|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
219607476|NCT04607057|DRUG|Parenteral Nutrition Solutions|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
219607477|NCT03405922|DRUG|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
219506893|NCT02648373|BEHAVIORAL|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
219506894|NCT02648373|OTHER|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
219506895|NCT02022007|DRUG|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
219506896|NCT02022007|DRUG|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
219506897|NCT02022007|DRUG|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
218885441|NCT02983864|BEHAVIORAL|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
218885442|NCT02983864|BEHAVIORAL|Relaxation|A one session intervention focused on increasing relaxation skills
218885443|NCT02983864|BEHAVIORAL|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
218885444|NCT01746173|DRUG|Cyclophosphamide|
218885445|NCT01746173|DRUG|Doxorubicin|
218885446|NCT01746173|DRUG|Vincristine|
218885447|NCT01746173|DRUG|Etoposide|
218885448|NCT01746173|DRUG|Prednisone|
218885449|NCT01746173|DRUG|Filgrastim|
218885450|NCT01746173|DRUG|Plerixafor|
219029344|NCT01935765|OTHER|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
219029345|NCT01935765|OTHER|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
219029346|NCT01935765|OTHER|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
219029347|NCT01935765|OTHER|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
219029348|NCT01935765|OTHER|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
219029349|NCT01935765|OTHER|Electrocardiogram (ECG)|Electrocardiogram (ECG)
219029350|NCT01935765|OTHER|Carotid echography|Carotid echography
219029351|NCT01935765|OTHER|Blood pressure|Blood pressure
219029352|NCT03806413|OTHER|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
219029353|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
219029354|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
219506898|NCT06482970|OTHER|Neuromuscular exercise plus pain neuroscience education|"The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).~Pain neuroscience education will take an active, person-centered approach through their own fear-avoidance beliefs."
219506899|NCT06482970|OTHER|Neuromuscular exercise|The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).
219506900|NCT06482593|DRUG|Zinc-Oxide Eugenol Sealer|Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
219607478|NCT03405922|DRUG|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
218885451|NCT01746173|PROCEDURE|Stem Cell Collection|
218885452|NCT01746173|DRUG|Palifermin|
218885453|NCT01746173|DRUG|Gemcitabine|
218885454|NCT01746173|DRUG|Busulfan|
218885455|NCT01746173|DRUG|Melphalan|
218885456|NCT01746173|PROCEDURE|Stem Cell Transplant|
218885457|NCT05063682|BIOLOGICAL|EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes|ICV administration
218885458|NCT03771274|DEVICE|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
218885459|NCT05557305|DEVICE|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
218885460|NCT05557305|OTHER|Conventional therapy|Occupational therapy with different play materials
218885461|NCT02646813|PROCEDURE|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
218885462|NCT02646813|PROCEDURE|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
219506901|NCT06482593|DRUG|AH-Plus Epoxy Resin Sealer|Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
219506902|NCT06482593|DRUG|Bio-C Sealer|Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
219506903|NCT00655421|OTHER|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
219506904|NCT00655421|DEVICE|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
219607479|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.
218885463|NCT00567411|DRUG|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
218885464|NCT00567411|DRUG|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
218885465|NCT04033783|OTHER|6MWT - accompanied|Assessor walks behind the patient
219506905|NCT00655421|OTHER|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
218885466|NCT04033783|OTHER|6MWT - not accompanied|Assessor does not walk behind the patient
218885467|NCT00982839|PROCEDURE|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
218885468|NCT00982839|PROCEDURE|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
218885469|NCT01600937|BEHAVIORAL|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
218885470|NCT02917395|DEVICE|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
218885471|NCT01371552|DEVICE|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
218885472|NCT01371552|DEVICE|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
218885473|NCT01371552|DEVICE|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
218885474|NCT00128115|DRUG|MK0677|
219040353|NCT06872697|OTHER|Conventional Physiotherapy|The conventional treatment program will include normal range of motion, airway clearance techniques, breathing exercises, and mobilization.
219040354|NCT04813159|DEVICE|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
219506906|NCT02896465|OTHER|Oral rehydration solution|
219506907|NCT02896465|OTHER|Zinc|
219506908|NCT02896465|OTHER|Human milk oligosaccharides|
218885475|NCT01750723|DRUG|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
218885476|NCT05684029|DEVICE|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
218885477|NCT05684029|DIAGNOSTIC_TEST|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
218885478|NCT01359501|DRUG|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
218885479|NCT01359501|DRUG|Placebo|Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
218885480|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
218885481|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
218885482|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
218885483|NCT01545440|DRUG|placebo|subcutaneous dose every 4 weeks
218885484|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
218885485|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
218885486|NCT01737216|DRUG|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
218885487|NCT01737216|DRUG|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
219506909|NCT02896465|OTHER|Breastfeeding|
219506910|NCT05778279|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
219506911|NCT03198299|DEVICE|MEI BIN insoles|wearing insoles for 12 weeks
219506912|NCT06207825|DIAGNOSTIC_TEST|Test images and videos|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.
219506913|NCT03508895|OTHER|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
219506914|NCT03508895|OTHER|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
218885488|NCT00761722|DRUG|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
218885489|NCT05665803|PROCEDURE|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
219029355|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
219029356|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
219029357|NCT06456593|DRUG|Obefazimod|Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
219029358|NCT06456593|OTHER|Placebo|Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
219029359|NCT04774523|PROCEDURE|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~1. Standard AV programming: perform echo for AoVTI assessment.~2. Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~3. AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
219029360|NCT04774523|PROCEDURE|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
219029361|NCT04774523|PROCEDURE|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
219506915|NCT03508895|OTHER|Casein protein|The intervention was provided in the form of a smoothie.
218885490|NCT05665803|PROCEDURE|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
218885491|NCT02518633|DEVICE|Continuous positive airway pressure devices|overnight use of CPAP device
218885492|NCT04241406|DEVICE|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
218885493|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
218885494|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
218885495|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
218885496|NCT04771637|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
218885497|NCT00544037|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
219029362|NCT04774523|OTHER|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
219029363|NCT04216719|BEHAVIORAL|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
219029364|NCT06075316|OTHER|Symptom monitoring|Alerts will be sent to providers via email and/or the electronic medical record at pre-specified response thresholds. Providers will be instructed to respond to and document the management of alerts per their clinical routine.
219029365|NCT01284725|DRUG|mycophenolate mofetil or azathioprine|
219029366|NCT01284725|OTHER|immunosuppressive treatment discontinuation|
219506916|NCT00362986|DRUG|sunscreen|
219506917|NCT00362986|OTHER|placebo|
219506918|NCT04427696|BEHAVIORAL|Aerobic walking intervention|Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
219607480|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
218885498|NCT00523081|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
219029367|NCT05802004|DEVICE|Acoustic Stimulation (STIM)|During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
219029368|NCT05802004|DEVICE|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
219029369|NCT05802004|DEVICE|Daily acoustic stimulation (STIM2)|During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
219029370|NCT05802004|DEVICE|No daily acoustic stimulation (SHAM2)|During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
219029371|NCT02967692|BIOLOGICAL|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
219029372|NCT02967692|OTHER|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
219029373|NCT02967692|DRUG|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
219029374|NCT02967692|DRUG|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
219029375|NCT05223413|DEVICE|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
219029376|NCT05223413|DEVICE|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
219029377|NCT05828108|DRUG|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
219029378|NCT06783881|DRUG|Kylo-12|Administered SC.
219029379|NCT06783881|DRUG|Placebo|Administered SC.
219029380|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
219029381|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
219029382|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
219029383|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
219029384|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
219029385|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
219029386|NCT05948930|BEHAVIORAL|Progressive aerobic exercise|Progressive aerobic exercise
219029387|NCT05948930|BEHAVIORAL|Adaptive cognitive training|Adaptive cognitive training
219506919|NCT01107535|BIOLOGICAL|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
219506920|NCT03673189|DEVICE|sensors|Acquisition and transmission of exploitable recordings in the public targeted by the DS, that is to say which allow to draw clinical information in relation to the objectives of the DS (detection of the cardiac rhythm): data without artefact (saturation), in a good signal to noise ratio.
219506921|NCT00425529|DEVICE|Module AOX (attached to Sondalis ISO)|
218885499|NCT00523081|BEHAVIORAL|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
218885500|NCT03458156|BIOLOGICAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
218885501|NCT03458156|BIOLOGICAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
218885502|NCT03458156|OTHER|the control group|The patients will be assigned to the control group.
218885503|NCT02975674|DEVICE|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
218885504|NCT02975674|DEVICE|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
219029388|NCT05948930|BEHAVIORAL|Combined|Combine adaptive cognitive and progressive aerobic exercise training
219029389|NCT04916600|DEVICE|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
219029390|NCT04804189|BEHAVIORAL|Guardians 4 Health|Clubs will implement Guardians 4 Health's intervention into their community by incorporating Guardians 4 Health materials into standard Club educational activities.
219029391|NCT06258876|OTHER|PrEP in general practice|Prescription and follow-up of PrEP in general practice
219029392|NCT06307275|OTHER|Fasting|Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
219029393|NCT06307275|OTHER|non fasting|Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
219029394|NCT03598608|BIOLOGICAL|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
219029395|NCT03598608|BIOLOGICAL|Favezelimab|Administered as an IV infusion Q3W
219029396|NCT06315699|DRUG|Clemastine Fumarate Tablets|The dose was administered 2mg once daily in a double-blind random crossover method
219029397|NCT06315699|DIETARY_SUPPLEMENT|fructose|The dose was administered 2mg once daily in a double-blind random crossover method
219029398|NCT05761379|DEVICE|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
219029399|NCT05761379|DEVICE|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
219506922|NCT04777630|DIAGNOSTIC_TEST|None, neuroimaging|Observation only to observe differences in neuroimaging
219506923|NCT02320474|DRUG|Aflibercept|
219506924|NCT04811261|DRUG|Intravenous Infusion of UCLSCs|The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
219607481|NCT03840564|OTHER|Point of care (POC)|All the analyzes will be done in delocalized
218885505|NCT04703491|BEHAVIORAL|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
218885506|NCT04703491|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
218885507|NCT04703491|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
218885508|NCT01629758|BIOLOGICAL|Denenicokin|
218885509|NCT01629758|BIOLOGICAL|Nivolumab|
219029400|NCT00066066|PROCEDURE|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
219029401|NCT00066066|DRUG|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
219029402|NCT00066066|DRUG|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
219040355|NCT04813159|DEVICE|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
219040356|NCT04305951|PROCEDURE|Comprehensive acupuncture therapy (CAT)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes."
218885510|NCT00446173|DRUG|Busulfan|130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
219029403|NCT00066066|DRUG|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
219029404|NCT02268409|DRUG|luspatercept|subcutaneous injection
219029405|NCT05352828|DRUG|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
219201516|NCT05952141|BEHAVIORAL|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
219506925|NCT03931083|DIAGNOSTIC_TEST|Screening for CIN2+/HSIL|The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
219506926|NCT01638702|OTHER|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
219201517|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
219201518|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
219201519|NCT06702631|DRUG|Nitrous oxide|After a no-drug control period, subjects will inhale nitrous oxide, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the drug condition, subjects will receive low-dose nitrous oxide (% corresponding to Minimum Alveolar Concentration).
219201520|NCT06702631|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
219506927|NCT00621179|DRUG|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
218885511|NCT00446173|DRUG|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
218885512|NCT00446173|DRUG|G-CSF|10 mcg/kg Subcutaneously Once Daily
219029406|NCT05352828|DRUG|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
219029407|NCT05352828|DRUG|Fludarabine|Dose: 30 mg/m2/day x 3 days
218885513|NCT00446173|DRUG|GM-CSF|250 mcg/kg Subcutaneously Once Daily
218885514|NCT04560387|BEHAVIORAL|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
218885515|NCT04560387|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
218885516|NCT05852236|OTHER|Assigned Interventions|Pressure ulcer care package application.
219029408|NCT05352828|DRUG|Bendamustine|Dose: 70 mg/m2/day x 3 days
219029409|NCT02143115|PROCEDURE|Optical colonoscopy|Examination of the colon with a colonoscope
219029410|NCT02143115|RADIATION|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
219029411|NCT03657888|BEHAVIORAL|Family Club Denmark (FCD)|Participation in Family Club Denmark
219201521|NCT06806553|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT) With Motor Relearning Program (MRP)|"Intensive training sessions of 3 hours/day for 6 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016).~MRP: Standard physiotherapy sessions of 1 hour/day for 6 weeks, including exercises for both affected and unaffected arm. Focus on improving strength, range of motion, and coordination through repetitive task practice, neuromuscular re-education and compensatory strategies (Brkić, 2016; Ghrouz et al., 2023)."
219506928|NCT00621179|OTHER|No intervention|
218885517|NCT02487862|BEHAVIORAL|Stress Reduction Protocol|Stress Reduction Protocol
218885518|NCT04994548|PROCEDURE|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
218885519|NCT04839549|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
218885520|NCT04839549|DRUG|Fluoromethalone .01%|Fluoromethalone .01%
219506929|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
219506930|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
219506931|NCT02916979|DRUG|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
219506932|NCT02916979|DRUG|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
219506933|NCT02916979|BIOLOGICAL|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
219506934|NCT02916979|DRUG|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
218885521|NCT02022436|DRUG|Contrast Ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
218885522|NCT01879943|DEVICE|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
218885523|NCT01879943|PROCEDURE|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
218885524|NCT04741490|DRUG|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
218885525|NCT04741490|RADIATION|radiotherapy|45-55Gy/1.8～2.0Gy
219029412|NCT03657888|OTHER|Wait-list control|Participants on the waiting list
219029413|NCT06162754|OTHER|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
219029414|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
219029415|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
219029416|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
219029417|NCT05515939|DEVICE|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
219029418|NCT06145542|BEHAVIORAL|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
219029419|NCT06145542|BEHAVIORAL|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
219029420|NCT04678245|BEHAVIORAL|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
219029421|NCT06030921|OTHER|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
219029422|NCT02953990|BEHAVIORAL|MOMS Program|
219029423|NCT06530849|DRUG|GC012F Injection|GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
219029424|NCT04171817|DRUG|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
219029425|NCT02505230|BEHAVIORAL|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
219029426|NCT00002733|BIOLOGICAL|aldesleukin|
219029427|NCT00002733|BIOLOGICAL|recombinant interferon alfa|
219029428|NCT00002733|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219029429|NCT00002733|DRUG|cimetidine|
218885526|NCT01894438|BEHAVIORAL|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
218885527|NCT01894438|BEHAVIORAL|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
218885528|NCT03294850|PROCEDURE|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
218885529|NCT03294850|DEVICE|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
218885530|NCT05750550|OTHER|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
219506935|NCT00192699|DEVICE|Bimetric femoral stem|Cemented Bi-Metric femoral stem
219506936|NCT02988752|DEVICE|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
219201522|NCT06806553|BEHAVIORAL|Bobath Therapy|The first step in the Bobath approach is a thorough assessment of the individual's movement patterns, muscle tone, strength, coordination, and functional abilities. This assessment helps in identifying specific impairments and setting goals for treatment. Bobath therapists use specific handling techniques to facilitate normal movement patterns and inhibit abnormal muscle tone. These hands-on techniques aim to promote efficient movement and improve motor control. The Bobath approach emphasizes task-oriented training, where functional activities relevant to the individual's daily life are incorporated into therapy sessions. This helps in improving motor skills in a context that is meaningful to the individual (Grozdek Čovčić et al., 2022; Kuciel et al., 2021).
219201523|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
219201524|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient's arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
219201525|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient's blood and analyzed to detect mutations in BRAF and other prognostic genes.
219201526|NCT06592703|DRUG|Adipose tissue-derived Mesenchymal Stromal Cells|repeated allogenic ASCs IT injections
219201527|NCT05932628|OTHER|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
218885531|NCT00039663|DRUG|Pravastatin|
218885532|NCT00039663|DRUG|Gemfibrozil|
218885533|NCT00039663|DRUG|Rosiglitazone|
219029430|NCT01614990|DRUG|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
219029431|NCT01614990|DRUG|Placebo|placebo (Powerade®) daily for 7 days.
219029432|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
219201528|NCT06602778|OTHER|Biomarkers / blood|Analysis of routine biochemical parameters
219506937|NCT02988752|DEVICE|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
219506938|NCT04615442|DEVICE|Epihunter|Subjects wear epihunter during routine video EEG
219506939|NCT03672500|DRUG|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
219506940|NCT03672500|OTHER|Sham injection|Sham injection of the perineum
219506941|NCT01117961|BEHAVIORAL|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
218885534|NCT01605110|DRUG|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
218885535|NCT01605110|DRUG|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
218885536|NCT01364311|DIETARY_SUPPLEMENT|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
219506942|NCT00192296|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
219506943|NCT00192296|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
218885537|NCT03295617|PROCEDURE|Thoracoscopy|Thoracoscopy surgery
218885538|NCT02731443|PROCEDURE|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
219029433|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
219029434|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
219029435|NCT04699682|OTHER|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
219029436|NCT04699682|OTHER|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~\- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
219029437|NCT04843709|DRUG|MRG004A|Administrated intravenously
219201529|NCT06602778|OTHER|Questionnaire|Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.
219201530|NCT06594120|BEHAVIORAL|Multimodal rehabilitation with additional work specific training|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
219201531|NCT06765304|BEHAVIORAL|Transtheoretical education intervention group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
219201532|NCT06765304|BEHAVIORAL|Preconceptional Period Healthy Life Behaviours Classical Education Intervention Group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
219201533|NCT06765304|BEHAVIORAL|Placebo|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
218885539|NCT02731443|PROCEDURE|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
218885540|NCT01600989|OTHER|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
218885541|NCT01600989|OTHER|blood sampling|Blood samples will be taken twice at a 7 day interval
218885542|NCT02619643|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
218885543|NCT01351155|DEVICE|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
219029438|NCT05129488|DEVICE|All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
219201534|NCT06654843|BEHAVIORAL|Comparator Arm|In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.
219201535|NCT06654843|BEHAVIORAL|Enhanced intervention arm|"In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages."
219201536|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
219201537|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
219506944|NCT00192296|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
219506945|NCT00192296|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
219506946|NCT04805684|DEVICE|LUS Twelve area|Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
219506947|NCT04805684|DEVICE|LUS Fourteen area|Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
219506948|NCT00735241|DEVICE|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
219029439|NCT02307851|BIOLOGICAL|Quadrivalent VLP Vaccine|
219506949|NCT00735241|DRUG|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
219506950|NCT00735241|DRUG|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
219506951|NCT00735241|DRUG|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
219506952|NCT00962299|DRUG|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
219506953|NCT00962299|DRUG|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
219506954|NCT05783583|DEVICE|Remote Digital Slit Lamp|Slit Lamp Examination
219029440|NCT02307851|BIOLOGICAL|Comparator TIV|
218885544|NCT00426543|DRUG|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
218885545|NCT00426543|DRUG|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
218885546|NCT04314674|DRUG|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
218885547|NCT04314674|DRUG|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
218885548|NCT04314674|DRUG|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
218885549|NCT00429533|DRUG|Dapsone|
219201538|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
218885550|NCT02547558|PROCEDURE|Arterial blood gases|Measured through radial arterial catheter
218885551|NCT02547558|PROCEDURE|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
218885552|NCT02547558|PROCEDURE|Vital signs|As measured in clinical practice
218885553|NCT02547558|PROCEDURE|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
218885554|NCT02547558|PROCEDURE|Spirometry|In a daily calibrated spirometer.
218885555|NCT02547558|DRUG|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
218885556|NCT01824433|DRUG|venlafaxine|venlafaxine 75-225mg qd
218885557|NCT01824433|DRUG|fluoxetine|fluoxetine 20-60mg qd
219029441|NCT01012622|DRUG|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
219029442|NCT02535741|DEVICE|Triathlon CR Total Knee System|Primary total knee replacement
219029443|NCT00729729|DRUG|PCA|Placebo tablet, once
219029444|NCT00729729|DRUG|PCA|PO, 700mg, once
219029445|NCT00729729|DRUG|PCA|PO, 1000mg, once
219029446|NCT00749320|OTHER|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
218885558|NCT01438606|BIOLOGICAL|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
218885559|NCT01438606|BIOLOGICAL|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
218885560|NCT01555333|DRUG|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
218885561|NCT02491606|DRUG|Tafenoquine|Tafenoquine 200mg and 400 mg
218885562|NCT02491606|OTHER|Placebo|Placebo
218885563|NCT02505113|DRUG|Montelukast|Montelukast (10mg, q.d., p.o.)
218885564|NCT03154749|DRUG|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
218885565|NCT01217372|DIETARY_SUPPLEMENT|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
218885566|NCT04757545|OTHER|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
218885567|NCT05599243|DRUG|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
218885568|NCT05599243|OTHER|Placebo|Vehicle excipient
219029447|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
219029448|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
219029449|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
219029450|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
219029451|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
219201539|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
219364600|NCT05561790|BEHAVIORAL|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
218885569|NCT00870545|BEHAVIORAL|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
218885570|NCT00364143|DRUG|IHL-305 (irinotecan liposome injection)|
218885571|NCT00470925|DRUG|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
218885572|NCT05409898|DEVICE|smart wearable device|screening masked hypertension with smart wearable devices
218885573|NCT04248088|BEHAVIORAL|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
219201540|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
218885574|NCT01160913|PROCEDURE|Continuous wound infusion|
218885575|NCT01160913|PROCEDURE|Continuous wound|
218885576|NCT00216216|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
218885577|NCT02859441|DRUG|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
218885578|NCT02859441|DRUG|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
218885579|NCT00006208|DRUG|Efavirenz|
218885580|NCT00006208|DRUG|Emtricitabine|
218885581|NCT00006208|DRUG|Stavudine|
219029452|NCT00798369|DRUG|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
219029453|NCT05563753|DRUG|ABT|any antibiotic therapy in the first week of life
219029454|NCT04566419|DEVICE|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
219029455|NCT04566419|OTHER|Oxygen|oxygen delivered by Venturi mask
219029456|NCT03573986|BIOLOGICAL|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
219029457|NCT03573986|DRUG|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
219029458|NCT03573986|RADIATION|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
219029459|NCT06020560|DRUG|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
219029460|NCT06020560|DRUG|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
219029461|NCT04475588|DRUG|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
219029462|NCT04475588|DRUG|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
219201541|NCT02375802|BIOLOGICAL|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
218885582|NCT00006208|DRUG|Didanosine|
218885583|NCT04480632|BIOLOGICAL|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
218885584|NCT02848391|OTHER|Environmental|hypobaric flight simulation
218885585|NCT00214058|DRUG|Carboplatin|
219029463|NCT02407769|DIETARY_SUPPLEMENT|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
219029464|NCT04311879|DEVICE|Soft tissue Diode laser application|post-operative soft tissue diode laser application
219029465|NCT04311879|OTHER|Placebo|mock diode laser application
219029466|NCT00001487|DRUG|Dehydroepiandrosterone|
219201542|NCT02375802|DRUG|Adipose-derived stromal cells|
219201543|NCT05755997|DRUG|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
219607482|NCT06287398|DRUG|Epcoritamab|"Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg"
218885586|NCT00214058|DRUG|Docetaxel|
218885587|NCT06077942|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
218885588|NCT03981627|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
219029467|NCT01119989|DIETARY_SUPPLEMENT|Fructose+maltodextrin placebo|
219029468|NCT01119989|DIETARY_SUPPLEMENT|amino-acid + fructose|
219029469|NCT05277246|OTHER|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
219029470|NCT05277246|DRUG|NaOCI|NaOCI
219201544|NCT05755997|DRUG|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
218885589|NCT03981627|DRUG|NovoRapid®|Subcutaneous injection of insulin aspart
218885590|NCT00724633|OTHER|Lowering the dialysate sodium|Please see above
218885591|NCT03666221|DRUG|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
218885592|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
218885593|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
218885594|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
218885595|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
218885596|NCT06223126|OTHER|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
218885597|NCT06223126|OTHER|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
218885598|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
218885599|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
218885600|NCT04649177|DEVICE|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
218885601|NCT04966520|OTHER|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
218885602|NCT02566317|DEVICE|Sit-Stand workstation|Installation of a sit-stand desk at work
218885603|NCT02566317|BEHAVIORAL|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
218885604|NCT03005132|OTHER|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
219607483|NCT05575232|BEHAVIORAL|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
219607484|NCT04940572|DRUG|Depakine|Refer to arm description.
219607485|NCT05547997|OTHER|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
219607486|NCT05547997|OTHER|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
219607487|NCT03987997|DEVICE|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
219607488|NCT06442046|OTHER|Active Case Management|A case manager will work with families post-discharge to ensure that youth are connected to an appropriate community support. Case managers will also work with families to identify any social needs and provide support in accessing services as needed.
219607489|NCT06442046|OTHER|Treatment as usual|Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.
219607490|NCT05152147|DRUG|Zanidatamab|Administered IV
219607491|NCT05152147|DRUG|Tislelizumab|Administered IV
219607492|NCT05152147|DRUG|Trastuzumab|Administered intravenously (IV)
219607493|NCT05152147|DRUG|Capecitabine|Administered orally (PO bid)
219607494|NCT05152147|DRUG|Oxaliplatin|Administered IV
218885605|NCT01103388|DRUG|Rituximab|375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
218885606|NCT01740024|BIOLOGICAL|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
218885607|NCT03987516|OTHER|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
219029471|NCT06112028|DRUG|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
219029472|NCT06112028|OTHER|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
219607495|NCT05152147|DRUG|Cisplatin|Administered IV
219607496|NCT05152147|DRUG|5-Fluorouracil|Administered IV
219607497|NCT06808477|DRUG|BBT001|BBT001 will be administered
219607498|NCT06808477|DRUG|Placebo|Placebo will be administered
219607499|NCT05467085|DEVICE|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
219607500|NCT00778882|DRUG|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
218885608|NCT02880098|BIOLOGICAL|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
219029473|NCT03302585|DRUG|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
219029474|NCT03302585|DRUG|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
219029475|NCT05102110|DIAGNOSTIC_TEST|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
219029476|NCT02082210|DRUG|Emibetuzumab|Administered Intravenously (IV)
219029477|NCT02082210|DRUG|Ramucirumab|Administered Intravenously (IV)
219029478|NCT01591291|DRUG|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
219029479|NCT01591291|DRUG|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
219029480|NCT03229265|DRUG|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
219029481|NCT01504321|DRUG|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
219029482|NCT01504321|DRUG|Placebo|Encapsulated lactose powder
219029483|NCT03320252|DEVICE|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
219029484|NCT00099125|DRUG|irinotecan hydrochloride|
219029485|NCT00099125|DRUG|temozolomide|
219029486|NCT00099125|PROCEDURE|adjuvant therapy|
219029487|NCT00099125|RADIATION|radiation therapy|
219029488|NCT03656419|PROCEDURE|photodynamic therapy|aPDT with methylene blue and red led irradiation.
219029489|NCT03656419|PROCEDURE|Tongue scraper|Tongue scraper 10 times from de back to the top.
219029490|NCT03335982|PROCEDURE|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
219029491|NCT02088983|DIETARY_SUPPLEMENT|CDP-Choline|Capsule
219029492|NCT02088983|DIETARY_SUPPLEMENT|Cellulose|Capsule
218885609|NCT00600210|DRUG|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
219201545|NCT06815939|DIAGNOSTIC_TEST|HPV Test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
219201546|NCT06815939|DEVICE|EVA System|Digital colposcope
218885610|NCT00600210|DRUG|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
218885611|NCT00600210|RADIATION|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
218885612|NCT03475485|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
218885613|NCT03475485|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
218885614|NCT03475485|DEVICE|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
218885615|NCT04141423|DRUG|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
218885616|NCT00227409|DRUG|calcium disodium EDTA (edetate calcium disodium)|
218885617|NCT06196606|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
218885618|NCT03487744|OTHER|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
219201547|NCT06815939|PROCEDURE|Visual Inspection with Acetic Acid (VIA)|unaided visual inspection with acetic acid
219029493|NCT01063764|DRUG|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
219029494|NCT01878201|DRUG|Fimasartan|Fimasartan 30 mg
219029495|NCT01878201|DRUG|Valsartan|Valsartan 80 mg
219201548|NCT06815939|DIAGNOSTIC_TEST|Automated Visual Evaluation (AVE)|Digital diagnostic classification, quality classifier using captured images from EVA System
219201549|NCT06815939|OTHER|Image Capture with Mobile Phone|Compare performance of AVE installed on a mobile phone vs. on the EVA System
219201550|NCT06815939|DIAGNOSTIC_TEST|Pregnancy test|Urine based pregnancy test
219506955|NCT01545635|DRUG|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
219506956|NCT01545635|DRUG|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
219506957|NCT05418348|DRUG|GTX-104|new formulation of nimodipine injection for IV infusion
219506958|NCT05418348|DRUG|Nimodipine Capsules|Nimodipine capsules (reference formulation)
219506959|NCT03564548|DRUG|PPP001|Group assigned to PPP001
219506960|NCT03564548|DRUG|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
218885619|NCT03487744|OTHER|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
218885620|NCT01354717|DRUG|Brand Carac|treatment of actinic keratosis
219029496|NCT02174458|PROCEDURE|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
219029497|NCT01185795|DIETARY_SUPPLEMENT|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
219506961|NCT04495491|OTHER|pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
219506962|NCT04495491|OTHER|plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
219506963|NCT04495491|OTHER|mixing mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
219506964|NCT06201624|DRUG|Isotretinoin|Patients will receive 1mg/kg/day for 3 months
218885621|NCT01354717|DRUG|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
218885622|NCT01354717|OTHER|Placebo cream|treatment of actinic keratosis
218885623|NCT05725083|PROCEDURE|Lower thoracic epidural|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
218885624|NCT05725083|PROCEDURE|Erector spinae plane block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
218885625|NCT00620724|DRUG|Placebo|Placebo three times daily
218885626|NCT00620724|DRUG|Nifedipine|20 mg of slow-release Nifedipine three times daily
218885627|NCT03009422|DRUG|Local application pentostam|
218885628|NCT03009422|DRUG|intra-lisional pentostam|
218885629|NCT03009422|DEVICE|fractional CO2 laser|
219029498|NCT01185795|DIETARY_SUPPLEMENT|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
219029499|NCT00697515|DRUG|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
219029500|NCT00697515|DRUG|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
219029501|NCT05377021|BEHAVIORAL|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
219029502|NCT04029714|PROCEDURE|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
219029503|NCT01088009|DRUG|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
219029504|NCT01088009|DRUG|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
219029505|NCT01088009|DRUG|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
219029506|NCT01810666|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
219029507|NCT05506202|OTHER|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
219029508|NCT05506202|OTHER|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
219029509|NCT03455465|OTHER|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
219506965|NCT06201624|DRUG|Triple combination formula|Patients are instructed to apply the triple combination formula at night daily for 3 months
219506966|NCT00751374|DRUG|gentamicin|topical gentamicin cream on daily basis
219506967|NCT00751374|DRUG|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
218885630|NCT03965741|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
218885631|NCT03965741|DRUG|Apixaban(Eliquis)|Follow clinical administration
219506968|NCT03674164|OTHER|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
219506969|NCT00188370|PROCEDURE|high frequency ultrasound imaging|
219506970|NCT00617461|DRUG|GEn 1200mg/day|1200mg/day gabapentin enacarbil
219506971|NCT00617461|DRUG|GEn 3600mg/day|3600mg/day gabapentin enacarbil
219506972|NCT04657484|DRUG|Medium dose prednisolone|Same as arm description
219506973|NCT04657484|DRUG|Low dose prednisolone|Same as arm description
219506974|NCT03833388|DRUG|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
219506975|NCT03833388|DRUG|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
218885632|NCT03965741|DRUG|Pradaxa (Dabigatran etexilate)|Follow clinical administration
218885633|NCT02031263|PROCEDURE|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
218885634|NCT02124694|BEHAVIORAL|HTUG|HTUG is a group psychotherapy...
218885635|NCT03257839|DEVICE|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
218885636|NCT03257839|DEVICE|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
218885637|NCT03257839|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
218885638|NCT00910780|DRUG|Aripiprazole|via oral tablets, everyday
218885639|NCT00910780|DRUG|Zyprexa|via oral tablets, taken once daily
218885640|NCT00910780|DRUG|Risperdal|via oral tablets, taken once daily
218885641|NCT04627363|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
218885642|NCT04627363|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
218885643|NCT04627363|DRUG|Toripalimab|240mg intravenously every 3 weeks
218885644|NCT04338308|DEVICE|new-DES|with ot without embolic protection device
218885645|NCT04338308|DEVICE|BMS|with ot without embolic protection device
218885646|NCT04005157|PROCEDURE|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
218885647|NCT04005157|DEVICE|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
218885648|NCT02259465|BEHAVIORAL|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
218885649|NCT02259465|DIETARY_SUPPLEMENT|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
218885650|NCT02259465|DIETARY_SUPPLEMENT|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
219029510|NCT04398758|DRUG|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
219029511|NCT02528162|BEHAVIORAL|education|Evaluation of education for GDM
219029512|NCT06226727|DRUG|BR1019|One tablet administered alone
218885651|NCT02924493|OTHER|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
219506976|NCT02381821|OTHER|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
218885652|NCT02638324|PROCEDURE|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
218885653|NCT03152695|DEVICE|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
219029513|NCT06226727|DRUG|BR1019-1|One tablet administered alone
219029514|NCT06226727|DRUG|BR1019-2|One tablet administered alone
219029515|NCT01727141|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
219029516|NCT01727141|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219029517|NCT01727141|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219029518|NCT01727141|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219506977|NCT02381821|DRUG|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
219506978|NCT05895370|BIOLOGICAL|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
219506979|NCT05895370|DRUG|Interleukin-2|500,000IU/m\^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
219506980|NCT04414501|BEHAVIORAL|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
219506981|NCT03314766|DEVICE|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
219506982|NCT00455663|BEHAVIORAL|Cognitive Adaptation Training|Environmental supports for all independent living skills
219506983|NCT00455663|BEHAVIORAL|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
219029519|NCT03054857|DRUG|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
218885654|NCT04889508|BEHAVIORAL|Socio-emotional mental training|Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
218885655|NCT04889508|BEHAVIORAL|Mindfulness-based mental training|Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
218885656|NCT03128242|DRUG|Oxytocin|intranasal administration of oxytocin (24IU)
218885657|NCT03128242|DRUG|placebo|intranasal administration of placebo (24IU)
219029520|NCT03054857|DRUG|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
219029521|NCT00448071|DRUG|MTR107|
219029522|NCT01957748|BEHAVIORAL|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
219506984|NCT00455663|OTHER|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
219506985|NCT03289975|OTHER|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
218885658|NCT00941915|RADIATION|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
219506986|NCT00638170|BIOLOGICAL|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
219506987|NCT00638170|BIOLOGICAL|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
219506988|NCT00903383|DRUG|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
219506989|NCT00903383|DRUG|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
219506990|NCT00903383|DRUG|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
218885659|NCT01016600|DRUG|Lenalidomide|
218885660|NCT01016600|DRUG|Azacitidine|
218885661|NCT00872599|DRUG|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
218885662|NCT00872599|DRUG|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
218885663|NCT02679755|DRUG|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
218885664|NCT02679755|DRUG|Letrozole|2.5 mg/d tablets orally on a continuous regimen
218885665|NCT03779659|DEVICE|Synapse TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
219029523|NCT03812692|DEVICE|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
219029524|NCT02477501|DRUG|Norepinephrine|continuous infusion
219029525|NCT02477501|DRUG|Ephedrine|continuous infusion
219029526|NCT03488316|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
219029527|NCT03488316|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
219029528|NCT03488316|DRUG|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
219029529|NCT03488316|DRUG|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
219029530|NCT03488316|PROCEDURE|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
219029531|NCT03488316|PROCEDURE|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
219029532|NCT03488316|PROCEDURE|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
219029533|NCT03488316|PROCEDURE|Definitve restoration|Definitve restoration confecction.
219029534|NCT03740425|PROCEDURE|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
219029535|NCT03462316|BIOLOGICAL|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
219029536|NCT00469482|OTHER|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
219029537|NCT00469482|OTHER|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
219029538|NCT03291210|OTHER|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
218885666|NCT03779659|DRUG|Topical anesthetic gel|"The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures.~The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure"
218885667|NCT03245125|BEHAVIORAL|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
219506991|NCT00903383|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
219506992|NCT01195922|DRUG|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
219506993|NCT04687163|DRUG|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
219506994|NCT04687163|DRUG|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
218885668|NCT00801229|DRUG|Vyvanse|Vyvanse 30, 50, or 70 mg daily
218885669|NCT00801229|DRUG|Placebo|Placebo 30, 50, 70 mg daily
218885670|NCT00725049|DEVICE|Dental Implant (Nanotite)|Root form titanium dental implant
218885671|NCT03854838|DRUG|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
218885672|NCT03854838|RADIATION|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
218885673|NCT05263557|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
218885674|NCT05263557|DIETARY_SUPPLEMENT|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
218885675|NCT00563459|DRUG|carisbamate|400-1200 mg/day for 12 months
218885676|NCT00563459|DRUG|topiramate|200-400mg/day for 12 months
218885677|NCT00563459|DRUG|levetiracetam|1000-3000mg/day for 12 months
218885678|NCT01212393|BEHAVIORAL|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
218885679|NCT00889824|DEVICE|balance prosthesis|vibrotactile stimulation
218885680|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
218885681|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
218885682|NCT00660179|DRUG|placebo|Matching placebo, once daily
218885683|NCT04236752|RADIATION|Stereotactic Ablative Body Radiation (SBRT)|
218885684|NCT05833997|PROCEDURE|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
219029539|NCT03291210|OTHER|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
219029540|NCT02603432|BIOLOGICAL|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
219029541|NCT02603432|OTHER|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
219506995|NCT04687163|DRUG|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
219029542|NCT02603432|BIOLOGICAL|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
219029543|NCT03756298|DRUG|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
219029544|NCT03756298|DRUG|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
219029545|NCT03462212|DRUG|Carboplatin|chemotherapy medication
219506996|NCT00997581|DRUG|apremilast|apremilast 20 mg taken twice daily by mouth
219506997|NCT00997581|DRUG|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
219506998|NCT01727479|OTHER|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
219506999|NCT01727479|OTHER|Placebo|
219507000|NCT05128409|DRUG|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
218885685|NCT05833997|PROCEDURE|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
218885686|NCT00650403|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
218885687|NCT00650403|DRUG|Paxil® 40 mg Tablet|40mg, single dose fed
218885688|NCT01800630|DRUG|Gemcitabine HCl Oral Formulation|
219201551|NCT06815939|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
218885689|NCT02312050|DRUG|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
218885690|NCT02312050|DRUG|Placebo|
218885691|NCT03326700|PROCEDURE|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
218885692|NCT02832635|DRUG|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
218885693|NCT02832635|RADIATION|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
218885694|NCT02832635|RADIATION|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
219029546|NCT03462212|DRUG|Paclitaxel|chemotherapy medication
219029547|NCT03462212|DRUG|Bevacizumab|Angiogenesis inhibitor
219029548|NCT03462212|DRUG|Rucaparib|PARP inhibitor
219029549|NCT02666183|BEHAVIORAL|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
219507001|NCT05128409|DRUG|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
219507002|NCT00743067|DRUG|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
218885695|NCT05878054|OTHER|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
218885696|NCT02974257|DRUG|Thiamine|Thiamine 500mg IV twice daily for 2 days
219029550|NCT02666183|BEHAVIORAL|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
219029551|NCT02666183|BEHAVIORAL|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
219029552|NCT06304142|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
219507003|NCT01110681|DEVICE|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
219507004|NCT01821625|DRUG|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
219507005|NCT03868449|OTHER|Question Prompt List|Question prompt list
219507006|NCT03868449|OTHER|3 questions|3 questions from the AskShareKnow model
219507007|NCT04170166|PROCEDURE|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
219507008|NCT04170166|PROCEDURE|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
219507009|NCT04571242|DEVICE|DTM Programming|DTM-SCS programming
219507010|NCT04571242|DEVICE|Conventional SCS programming|Conventional SCS programming
219507011|NCT02837978|DRUG|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
219507012|NCT02837978|DRUG|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
219507013|NCT03019393|OTHER|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
219201552|NCT06815939|PROCEDURE|Colposcopy with biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
219201553|NCT06815939|PROCEDURE|Thermal Ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
219201554|NCT06815939|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|LEEP is utilized to remove abnormal tissue from the cervix. This may include tissue with precancerous cells (called cervical dysplasia) or cancerous cells. The loop is heated using electricity to remove the tissue. LEEP may also be called a loop excision or large loop excision of the transformation zone (LLETZ).
219201555|NCT06820125|DEVICE|Cognitive rehabilitation: CG group|60 minutes of cognitive training with a computerized device
219201556|NCT06820125|DEVICE|Motor rehabilitation: MG group|60 minutes of robot-assisted gait training with the G-EO System
219201557|NCT06820125|DEVICE|Combined rehabilitation: CbG group|30 minutes of cognitive training with a computerized device + 30 minutes of robot-assisted gait training with the G-EO System. To mitigate the effects of fatigue in sequential training, the patients included in this group will undergo the cognitive (treatment CG) and motor (treatment MG) sessions in a counterbalanced order (half of the participants will follow the CG-MG sequence, and the other half will follow the MG-CG sequence). Five-minute breaks will be provided between the cognitive and motor sessions.
219201558|NCT06816810|DRUG|Hydroxychloroquine (HCQ)|The intervention involves hydroxychloroquine (HCQ), administered orally in 200 mg tablets, with a dosing schedule of 200 mg twice daily (400 mg per day). The treatment duration is 48 weeks, after which participants will enter a 4-week safety follow-up period. HCQ will be taken alongside stable doses of Parkinson's disease (PD) medications, with no anticipated changes during the study. Monitoring for adverse events, laboratory assessments, and efficacy evaluations will occur regularly throughout the 12-month period. The study does not include a placebo group or other treatment arms.
219201559|NCT06817577|DRUG|NG004|repeated intrathecal injections of NG004
219201560|NCT06817057|DEVICE|Virtual Reality headset + headphones|The intervention involves patient use of a Virtual Reality headset (the Oculus Quest 2) and headphones (Beats Ep Wired On-Ear) during their wide-awake hand operation.
218885697|NCT02974257|OTHER|placebo|100mL normal saline IV every 12 hours for 2 days
218885698|NCT05130151|BEHAVIORAL|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
218885699|NCT05140460|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
219201561|NCT04510129|DIAGNOSTIC_TEST|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
219201562|NCT06816628|OTHER|comedy therapy|After patients came to the clinic after transplantation surgery and their condition was stable, 10-minute Turkish comedy films prepared by the researchers were shown.
219201563|NCT06820411|BEHAVIORAL|Young Stroke Clinic Lifestyle Intervention|"The Young Stroke Clinic Lifestyle Intervention is a structured program designed for young adults (18-65 years) recovering from ischemic stroke or high-risk TIA. It includes:~* Personalized risk factor management targeting blood pressure, cholesterol, smoking cessation, and lifestyle habits.~* Intensive lifestyle counseling to improve diet, physical activity, and overall cardiovascular health.~* Wearable device monitoring (Whoop 4.0) to track heart rate variability, sleep patterns, and physical activity.~* Regular follow-up visits at a dedicated stroke clinic with tailored guidance from neurologists."
219201564|NCT06820411|OTHER|Standard Post-Stroke Care|"The Standard Post-Stroke Care group will receive usual medical management based on current clinical guidelines for secondary stroke prevention. This includes:~* Routine follow-up visits with healthcare providers.~* Standard medical treatment for stroke risk factors (e.g., blood pressure, cholesterol, diabetes).~* General lifestyle recommendations on diet, physical activity, and smoking cessation as part of routine clinical care."
218885700|NCT05140460|BEHAVIORAL|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
218885701|NCT00657163|DRUG|fluoxetine|fluoxetine per os 20 mg daily
218885702|NCT00657163|DRUG|placebo|placebo per os daily
218885703|NCT03921931|OTHER|White light stimulation|Stimulation of the retina with white light
218885704|NCT05196191|BIOLOGICAL|VIAGENEX Max|Collagenous membrane derived from umbilical cord
219201565|NCT06891664|PROCEDURE|Day surgery regimen for patients|The protocol includes admission on the evening of Day -1 and the execution of the surgery on the morning of Day 0 under general anesthesia. The surgery will be performed with the aid of the Da Vinci Single-port robotic system with extraperitoneal access.
218885705|NCT05196191|PROCEDURE|Hibiclens wash|Antiseptic skin cleanser
218885706|NCT05415007|BEHAVIORAL|GOLD Program|Participant will receive a 2-hour interventional session
218885707|NCT05415007|BEHAVIORAL|Treatment as usual (TAU)|Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
218885708|NCT01866358|PROCEDURE|Intraosseous infusion|Using intraosseous infusion for resustation in this group
218885709|NCT01866358|PROCEDURE|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
219201566|NCT06891664|OTHER|Ordinary management|Management of patients undergoing robotic radical prostatectomy in an inpatient setting based on a minimum of two nights of hospitalization
219201567|NCT04241666|DIAGNOSTIC_TEST|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
219507014|NCT02388178|DRUG|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
219201568|NCT04241666|DIAGNOSTIC_TEST|renal doppler sonography|doppler ultrasound of both kidneys
219201569|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
219201570|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
218885710|NCT02586870|DEVICE|Intravascular Ultrasound|
219201571|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D-3 (cholecalciferol), 2000 IU|
219201572|NCT01653678|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
218885711|NCT05610527|OTHER|Proposed study design and randomization scenarios|Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
218885712|NCT05610527|OTHER|Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments|We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
218885713|NCT05610527|OTHER|Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing|In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
218885714|NCT03053570|DEVICE|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
218885715|NCT03053570|DEVICE|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
218885716|NCT00237497|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
218885717|NCT00237497|DRUG|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
218885718|NCT00237497|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
218885719|NCT05355662|OTHER|Age|The study was retrospective and did not involve the application of interventions.
218885720|NCT03336294|RADIATION|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
218885721|NCT06841328|PROCEDURE|Stem cells|The administration of stem cell or stem cell-derived exosome therapy as a regenerative treatment for gonadal failure in both men and women. The intervention involves a single intra-gonadal injection (testicular or ovarian) of adipose-derived stem cells (ADSCs) or exosomes.
218885722|NCT04386941|PROCEDURE|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
219507015|NCT02388178|DRUG|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
219201573|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D placebo|
218885723|NCT04386941|PROCEDURE|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
218885724|NCT05213702|DEVICE|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
219201574|NCT01653678|DRUG|Fish oil placebo|
219201575|NCT06663631|DRUG|chlorpromazine and promethazine|C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
219201576|NCT06663631|DRUG|Placebo group|50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
219201577|NCT06663631|PROCEDURE|endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
219201578|NCT06663631|DRUG|rt-PA|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
219201579|NCT06497764|DEVICE|Vibrational Anesthesia (VA) Device|The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.
219201580|NCT06497764|PROCEDURE|PRP Treatment|PRP (a needle-related procedure) will be delivered per routine standard of care.
219201581|NCT06600386|OTHER|Alveolar recruitement|PEEP after alveolar reruitment maneuvres
219201582|NCT06600386|OTHER|Standard PEEP|PEEP 5 cmH2O
219201583|NCT06599086|DRUG|2 cc:(1 cc betamethasone dipropionate+1cc physiological saline)|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
219201584|NCT03610906|PROCEDURE|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
219201585|NCT06842472|DRUG|Ursodeoxycholic Acid (URSO)|UDCA 250 mg twice daily, starting 7 days before radiotherapy and continuing for 1 month after completion.
219507016|NCT02388178|DRUG|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
218885725|NCT00139048|BEHAVIORAL|Decision Aid|
218885726|NCT06114199|BEHAVIORAL|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
218885727|NCT06114199|BEHAVIORAL|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
218885728|NCT01191177|DRUG|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
218885729|NCT01191177|DIETARY_SUPPLEMENT|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
219201586|NCT06842472|RADIATION|Radiotherapy|Radiotherapy (SBRT) with a dose of 24Gy/3 fractions within 3 weeks after the first immunotherapy dose.
219201587|NCT06842472|DRUG|Adebrelimab (PD-L1 inhibitor)|Adebrelimab (PD-L1 inhibitor) 1200 mg on Day 1, every 3 weeks.
219201588|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (beta-tACS)|"The study intervention is transcranial alternating current stimulation (tACS).~The electrode montage will include one electrode positioned on the scalp over the left or right motor cortex (either C3 or C4 using the international 10-20 EEG system), depending on the location of the stroke, and a second electrode over posterior area (Pz). A low intensity of stimulation (max. 4 mA peak to peak amplitude) will be used for up to 30 minutes in total (delivered in short bouts of up to 5 seconds based on the timing of movement of the upper limb)."
219201589|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (sham)|The comparator is sham stimulation. Stimulation is delivered for a very short duration or timed in such a way relative to movement to mimic the scalp sensations of the active stimulation without delivering stimulation that would be anticipated to impact relevant brain activity rhythms.
219507017|NCT05029323|DIAGNOSTIC_TEST|Fast HUTT|Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
219507018|NCT05029323|DIAGNOSTIC_TEST|Conventional HUTT|Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
219201590|NCT06842277|BIOLOGICAL|Injectable albumin platelets rich fibrin|Using injectable albumin platelets rich fibrin which is minimally invasive non surgical technique with autogenous , slow degradable and rich in leukocytes and growth factors material .
219201591|NCT06810752|DIETARY_SUPPLEMENT|thyme honey|Topical application on the oral mucosa
219201592|NCT06810752|DRUG|Triamcinolone Acetonide|Topical application on the oral mucosa
218885730|NCT05509426|BEHAVIORAL|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
219201593|NCT05043259|BIOLOGICAL|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
219201594|NCT05043259|BIOLOGICAL|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
219201595|NCT05043259|BIOLOGICAL|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
219507019|NCT00320593|DEVICE|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
218885731|NCT04984486|DEVICE|dental implant|"The procedure used to accomplish its intended use is as follows :~* The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~* After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
219029553|NCT06304142|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219029554|NCT06304142|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
219029555|NCT04906785|DRUG|CKD-385|Test Drug
219201596|NCT06147336|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
219029556|NCT04906785|DRUG|D744|Reference Drug
219029557|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
219029558|NCT01785576|BEHAVIORAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
219029559|NCT00898703|OTHER|flow cytometry|
219029560|NCT00898703|OTHER|immunoenzyme technique|
219029561|NCT00898703|OTHER|laboratory biomarker analysis|
219029562|NCT05433779|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
219029563|NCT06579586|BEHAVIORAL|Survey study|The Parent's State and Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index-3 (AS-3), and Pain Catastrophising Scale for Parents (PPS-PPS) were completed one day before the operation to measure anxiety level.
219029564|NCT01469286|DEVICE|TEA|Electroacupuncture at ST36
219029565|NCT01469286|DEVICE|Sham-TEA|Electroacupuncture at sham-points
219364667|NCT03683394|BEHAVIORAL|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
219507020|NCT00320593|DEVICE|Single Vision Lenses (SVLs)|Single vision lenses
219507021|NCT00977964|OTHER|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
218885732|NCT00001212|DRUG|prednisone|
218885733|NCT00001212|DRUG|cyclophosphamide|
218885734|NCT00001212|DRUG|cyclosporin A|
218885735|NCT05681065|DEVICE|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
218885736|NCT05230472|DRUG|Simvastatin|simvastatin 60 mg tab
218885737|NCT00318799|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
218885738|NCT00318799|DRUG|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
218885739|NCT03376737|DRUG|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
218885740|NCT02092792|DRUG|DLYE5953A|Escalating doses of DLYE5953A
219029566|NCT04332328|DIETARY_SUPPLEMENT|Diet|Group of diet types
219029567|NCT04765358|OTHER|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
219029568|NCT02731729|DRUG|ipilimumab|
219029569|NCT02731729|DRUG|nivolumab|
219029570|NCT05658744|BEHAVIORAL|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
219507022|NCT00977964|OTHER|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
219507023|NCT00977964|OTHER|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
219507024|NCT00977964|OTHER|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
219507025|NCT00977964|OTHER|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
218885741|NCT02092792|DRUG|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
218885742|NCT00398567|DRUG|HKI-272|HKI-272 by mouth
218885743|NCT00398567|DRUG|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
218885744|NCT02837029|OTHER|Laboratory Biomarker Analysis|Correlative studies
218885745|NCT02837029|BIOLOGICAL|Nivolumab|Given IV
218885746|NCT02837029|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
218885747|NCT06304623|BIOLOGICAL|Autologous adipose-derived SVF IV administration|Subjects received an intravenous injection of autologous adipose-derived SVF.
218885748|NCT02397538|DRUG|Fimasartan|
218885749|NCT02397538|DRUG|Amlodipine|
218885750|NCT02397538|DRUG|Rosuvastatin|
218885751|NCT01969695|DRUG|ABT-199|ABT-199 continuous once daily dosing
218885752|NCT04108611|PROCEDURE|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
218885753|NCT02034877|BIOLOGICAL|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
218885754|NCT02034877|PROCEDURE|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
218885755|NCT05408715|OTHER|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
218885756|NCT00526591|DRUG|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
218885757|NCT00526591|PROCEDURE|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
218885758|NCT05624580|DRUG|NNC0582-0001|Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.
218885759|NCT05624580|DRUG|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
218885760|NCT01057186|DIETARY_SUPPLEMENT|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
218885761|NCT01057186|DRUG|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
218885762|NCT03524014|OTHER|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
218885763|NCT01731366|OTHER|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
218885764|NCT01731366|OTHER|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
218885765|NCT06403267|DRUG|NoNO-42|a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
219029571|NCT03073096|PROCEDURE|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
219029572|NCT04625608|DRUG|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
219029573|NCT04625608|OTHER|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
219507026|NCT00977964|OTHER|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
219507027|NCT01928654|DEVICE|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
219507028|NCT01928654|DEVICE|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
219201597|NCT06392867|DEVICE|intermittent theta-burst stimulation (iTBS)|"iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en\_eur/products/magpro-x100/ ) and a Cool-B65 A/P Butterfly Coil is used in this study."
219201598|NCT06667167|DRUG|Induction Carboplatin|Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
219201599|NCT04819191|BEHAVIORAL|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
219201600|NCT06610747|PROCEDURE|Home-based Care Monitoring|For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. The results of the visual acuity and OCT measurements will be transmitted to the clinician at the hospital. An online discussion between the clinician and the participant will be held. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
219201601|NCT06610747|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
219201602|NCT06610747|PROCEDURE|Laser Treatment|Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
219201603|NCT06610747|PROCEDURE|Standard Hospital/clinic-based Care Monitoring|For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the \&amp;amp;amp;#39;pro re nada\&amp;amp;amp;#39; (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. A discussion between the clinician and the participant will be held in clinic. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
219201604|NCT06611358|OTHER|Kinesiology Taping and Exercise|Individuals meeting the inclusion criteria will receive kinesio taping applied to the temporomandibular joint by a physiotherapist every three days for two weeks. The kinesio tape will be applied along the origin-insertion line with zero tension. In addition to the kinesio taping, participants will follow a exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol
219201605|NCT06611358|OTHER|Convansionel Exercise|This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol.
219201606|NCT06610032|PROCEDURE|Mesotherapy|A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.
219201607|NCT06610032|PROCEDURE|Intra-articular steroid injection|Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
219201608|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Early Testing|Participants in Cohort A will receive PrecivityAD2 testing at Visit 1, with results disclosed shortly after testing.
219201609|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Delayed Testing|Participants in Cohort B will receive PrecivityAD2 testing at Visit 2, with results disclosed shortly after testing.
219507029|NCT03086668|PROCEDURE|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
219507030|NCT03086668|PROCEDURE|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
218885766|NCT06457425|DRUG|Flonoltinib 50mg|Flonoltinib 50mg, QD
219507031|NCT00662714|DRUG|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
218885767|NCT06457425|DRUG|Flonoltinib 100mg|Flonoltinib 100mg, QD
219507032|NCT00662714|DRUG|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
219507033|NCT00457665|DRUG|Nelfinavir|
219507034|NCT00457665|DRUG|Efavirenz|
219507035|NCT03998085|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
218885768|NCT06457425|DRUG|Ruxolitinib|For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
218885769|NCT06334718|BEHAVIORAL|Interviews and simulation|Work package 1: interview study Work package 2: simulated cardiac arrest study with AED delivered by drone following a simulated emergency (999) call.
218885770|NCT05055843|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D MRI
218885771|NCT05945524|OTHER|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
218885772|NCT05989230|BEHAVIORAL|Emotional Awareness and Expression Therapy|The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
218885773|NCT05396248|BEHAVIORAL|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
218885774|NCT05396248|BEHAVIORAL|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
218885775|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
218885776|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
218885777|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
219507036|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
219507037|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
219507038|NCT02587156|DIETARY_SUPPLEMENT|Meal serving|To investigate impact of habituated protein level
219507039|NCT01847196|DEVICE|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
218885778|NCT03906071|BIOLOGICAL|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
218885779|NCT03906071|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
218885780|NCT03906071|DRUG|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
218885781|NCT03750227|PROCEDURE|Conventional Surgery|Undergo surgery
218885782|NCT03750227|OTHER|Questionnaire Administration|Ancillary studies
218885783|NCT03750227|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
219029574|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
219029575|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
219029576|NCT00485446|PROCEDURE|blood analysis|
219029577|NCT03167762|DEVICE|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
219029578|NCT04377256|PROCEDURE|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
218885784|NCT03750227|PROCEDURE|Computed Tomography|Undergo CT
218885785|NCT03750227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218885786|NCT03750227|PROCEDURE|Biospecimen Collection|Undergo blood sample, tissue and CSF sample collection
218885787|NCT02700386|COMBINATION_PRODUCT|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
218885788|NCT05328596|BEHAVIORAL|CBT-treatment|Cognitive Behavioral Treatment for Gaming Disorder.
218885789|NCT05328596|BEHAVIORAL|Wait list control|No intervention
219040357|NCT04305951|PROCEDURE|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
219040358|NCT06816940|OTHER|CONTROL GROUP:|will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated before any intervention is carried out
218885790|NCT04168372|OTHER|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
219029579|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they move from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~Most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
219201610|NCT06696638|DEVICE|EIT-guided Phigh settings during APRV|The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.
219507040|NCT04127591|OTHER|exosome|Collect exosomes in peripheral blood of patients and extract miRNAs from them.
219507041|NCT03208959|DRUG|HTI-1090|IDO/TDO inhibitor
219607501|NCT06978972|OTHER|Cognitive Stimulation Therapy|"CST is an evidence-based, cognitively stimulating therapeutic group intervention for individuals with mild-to-moderate dementia. Individuals participate in CST 2 times per week for 7 weeks. The CST sessions are administered by a variety of professionals who become certified through the St. Louis School of Medicine. The general structure of each session will follow the CST Manual called Making a Difference 1. Each session will be based on a theme and will include an introduction, theme song, current affairs activity, the main activity (physical games, sounds, food, being creative, word and number games, team quizzes, orientation, current affairs, ect.), suggested activities for home, and closure. These sessions are highly structured and will follow the introduction, theme song, current affairs activity, the main activity, suggested activities for home, and closure organization strictly. The participants will spend 45 minutes in each session."
219607502|NCT06982625|PROCEDURE|Ultrasound guided supra inguinal fascia iliaca block|The ultrasound probe is placed in a cephalo-caudal orientation, over the inguinal ligament, lateral to the femoral nerve. The iliacus muscle, which is covered caudally by the sartorius muscle and cephalically by the internal oblique muscle, is visualized in depth. Between these two muscles, an area is identified where the iliacus muscle is covered only by subcutaneous tissue. The needle is introduced in a cranio-caudal direction, and the injection is initiated in this area, beneath the fascia iliaca. The needle then advances through the space created by the injection, as far as possible in a cephalic direction, beneath the internal oblique muscle. An injection of 40 ml of 0.1% ropivacaine is administered.
219029580|NCT05124860|DIAGNOSTIC_TEST|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
219029581|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
219029582|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
219029583|NCT03205059|BEHAVIORAL|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
219201611|NCT06841146|PROCEDURE|routine cesarean section|cesarean section
219201612|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
219201613|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
219507042|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
219507043|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
219507044|NCT06163833|OTHER|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
218885791|NCT04168372|OTHER|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
218885792|NCT04168372|OTHER|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
218885793|NCT04168372|OTHER|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
218885794|NCT05949957|BEHAVIORAL|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
219029584|NCT03205059|BEHAVIORAL|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
219029585|NCT04341909|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
218885795|NCT05949957|BEHAVIORAL|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
219029586|NCT04070391|DIETARY_SUPPLEMENT|vitamin B6|oral administration
219507045|NCT01283633|DEVICE|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
219507046|NCT03622333|GENETIC|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
219607503|NCT06982625|PROCEDURE|Placebo Injection|Five milliliters of saline are injected subcutaneously under ultrasound guidance
219201614|NCT06858202|BEHAVIORAL|Mindfulness Intervention|Guided meditation or guided expressive writing
219201615|NCT06858202|BEHAVIORAL|Non-mindfulness Intervention|Standard inpatient and outpatient resources available for Huntsman Cancer Institute patients through social work and the Wellness and Integrative Health Center. Participants will be encouraged to ask their providers for more information or if appropriate more consults to the appropriate resources if interested.
219201616|NCT06283706|OTHER|Tryptophan|There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
219201617|NCT00503971|DRUG|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
218885796|NCT05949957|BEHAVIORAL|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
219029587|NCT04070391|OTHER|control|oral administration
219029588|NCT02602587|BIOLOGICAL|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
219029589|NCT02602587|BIOLOGICAL|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
219029590|NCT00456521|DRUG|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
219029591|NCT00456521|DRUG|Placebo|
219029592|NCT00456521|BEHAVIORAL|Intensive group lifestyle modification counseling|
219029593|NCT02451228|OTHER|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
219029594|NCT00605475|DRUG|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
219029595|NCT00605475|DRUG|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
219029596|NCT00605475|DRUG|Metformin|Participants continued on their stable daily dose of metformin throughout the study
219029597|NCT00992082|DRUG|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
219029598|NCT00992082|DRUG|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
219029599|NCT06329479|BEHAVIORAL|Cognitive behavioural therapy for Insomnia (CBT-I)|A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.
219029600|NCT06329479|DEVICE|Bright Light Therapy|Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.
219029601|NCT06329479|BEHAVIORAL|Individualised activity plan|An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.
219201618|NCT04866472|DEVICE|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
219507047|NCT01210183|DRUG|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
219507048|NCT03801837|DIETARY_SUPPLEMENT|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\]
218885797|NCT06448026|DRUG|Cemiplimab|Given by IV
218885798|NCT06448026|DRUG|Cetuximab|Given by IV
218885799|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
218885800|NCT06378957|DRUG|D-Limonene|Oral Limonene administered via capsule
219029602|NCT06329479|OTHER|Clincial review|Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
219607504|NCT06982625|PROCEDURE|Surgical and anesthetic protocol|"All patients receive standard general anesthesia:~* Induction of anesthesia by sufentanil, ketamine, propofol and tracrium if needed,~* Maintenance of anesthesia by sevoflurane and sufentanil if needed,~* Prevention of PONV by dexamethasone and droperidol,~* Post-operative analgesia by paracetamol, ketoprofene, nefopam, as indicated. Total hip arthroplasty is performed by anterior or postero-lateral approach, depending on surgeon preference.~In the post-anesthesia care unit, if numerical pain rating scale at rest is \>=4, patients are randomized to receive experimental or placebo intervention."
219607505|NCT05603533|OTHER|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
219607506|NCT02593110|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
218885801|NCT06378957|DRUG|Delta-9-THC|Oral delta-9-THC in ethanol vehicle administered via capsule
218885802|NCT06378957|DRUG|Placebo|Placebo (cellulose) administered via capsule
218885803|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
218885804|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
218885805|NCT05613257|DEVICE|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
218885806|NCT05613257|PROCEDURE|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
218885807|NCT05380505|BEHAVIORAL|Racially Congruent Ads|Facebook food ads that are racially congruent.
218885808|NCT05380505|BEHAVIORAL|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
219029603|NCT03849404|BIOLOGICAL|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
218885809|NCT06071650|BEHAVIORAL|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
218885810|NCT00192816|BEHAVIORAL|reaction to pain|
218885811|NCT04054141|DEVICE|Mag Stim|rTMS
218885812|NCT01647893|DRUG|CTB-001|IV bolus or IV infusion
218885813|NCT03653143|BEHAVIORAL|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
218885814|NCT00783614|DRUG|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
219029604|NCT04187560|DRUG|LB-102|(N-Methyl amisulpride)
219607507|NCT02593110|DRUG|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
219607508|NCT02593110|OTHER|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
218885815|NCT00783614|DRUG|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
219029605|NCT02109146|DRUG|Prophylactic Transcatheter Arterial Chemoembolization|Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
219029606|NCT02109146|OTHER|Observation|Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
219029607|NCT00775931|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
219029608|NCT00775931|DRUG|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
219029609|NCT00775931|RADIATION|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
219029610|NCT00775931|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
219040359|NCT06816940|OTHER|EXPERIMENTAL GROUP|will be provided therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks, and rurgery was also performed using the dry needlig
218885816|NCT05426070|BEHAVIORAL|Strength training-based exercise|Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
218885817|NCT00694018|OTHER|Education and standard care|Educational program for individuals with chronic back pain.
218885818|NCT00694018|BEHAVIORAL|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
218885819|NCT04618289|DIETARY_SUPPLEMENT|Vitamin D3-fortified fruit juice supplement|Vitamin D3-fortified fruit juice supplement
218885820|NCT01331980|DEVICE|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
218885821|NCT01331980|DEVICE|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
218885822|NCT01564732|DEVICE|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
218885823|NCT01564732|DEVICE|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
218885824|NCT01159015|DRUG|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
219029611|NCT00775931|DRUG|Busulfan|patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
219029612|NCT00775931|DRUG|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
219029613|NCT00775931|PROCEDURE|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
219201619|NCT04866472|DEVICE|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
219201620|NCT04984421|BEHAVIORAL|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
219201621|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
219607509|NCT02593110|DRUG|Placebo|
218885825|NCT01159015|DRUG|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
219029614|NCT06409559|DEVICE|Pelvic reconstruction plate without interfragmentary screws|The posterior wall fracture will be operatively stabilized with a pelvic reconstruction plate and interfragmentary screws placed through the plate.
218885826|NCT03139123|OTHER|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
218885827|NCT01036321|DRUG|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
218885828|NCT01036321|DRUG|Methyl cellulose blend|Placebo - Take 2 capsules daily
218885829|NCT01425125|DRUG|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
218885830|NCT03456232|OTHER|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
218885831|NCT03456232|OTHER|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
218885832|NCT01351116|RADIATION|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
218885833|NCT01351116|RADIATION|EBR|EBR of 20 Gy in 5 daily fractions over one week
218885834|NCT00838240|DRUG|clofarabine|Given IV
218885835|NCT00838240|DRUG|cytarabine|Given IV
218885836|NCT00838240|DRUG|idarubicin|Given IV
218885837|NCT01942174|BIOLOGICAL|Prevenar 13|Vaccination at the beginning of the study (day 0)
219201622|NCT05592223|DRUG|BCG Vaccine USP|2x10\^6 cfu Tice® BCG (ID)
219201623|NCT05592223|DRUG|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
219201624|NCT05592223|DRUG|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
219201625|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
218885838|NCT01942174|BIOLOGICAL|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
218885839|NCT01942174|DRUG|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
219201626|NCT06997874|PROCEDURE|Phacovitrectomy|Participants will undergo phacovitrectomy to remove the lens (phacoemulsification and intraocular lens implantation) and to repair the RRD (vitrectomy). Although a phacovitrectomy is done in the same manner whether the condition to be treated is macular hole or RRD, the calculations required for the surgeon to select which intraocular lens should be implanted are different if there is a RRD with a detached macula. For this reason, a Standard Operating Procedure (SOP) will be prepared for the phacovitrectomy group to guide surgeons on how to best determine the intraocular lens under these circumstances (17). Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care.
219201627|NCT06997874|PROCEDURE|Vitrectomy|Participants will receive vitrectomy to repair their RRD. The vitrectomy would be done as per standard care. Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care. Then, if a cataract develops, phacoemulsification and intraocular lens implantation will be done as per standard clinical practice.
219507049|NCT03801837|DIETARY_SUPPLEMENT|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
218885840|NCT01942174|DRUG|Methotrexate - Delay|"For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13"
219029615|NCT06409559|DEVICE|Pelvic reconstruction plate with interfragmentary screws|The posterior wall fracture will be operatively fixed with a buttress plate applied under compression without interfragmentary lag or position screws.
219029616|NCT04634864|DEVICE|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
219029617|NCT04634864|DEVICE|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
219029618|NCT04200807|DEVICE|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
219507050|NCT04256993|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
219507051|NCT04256993|DRUG|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
219507052|NCT01766011|OTHER|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
219507053|NCT02818283|DIETARY_SUPPLEMENT|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
219507054|NCT02818283|OTHER|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
219507055|NCT02804828|DIETARY_SUPPLEMENT|Individualized mitochondrial cocktail|Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
218885841|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
218885842|NCT04808141|OTHER|Conventional physical therapy|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled physical therapy sessions.
218885843|NCT00381693|DRUG|azacitidine|
218885844|NCT06237400|DRUG|ZG19018|ZG19018 Given by PO (mouth)
218885845|NCT02598297|DRUG|Ruxolitinib|5 mg tablet for oral use
219507056|NCT02804828|DIETARY_SUPPLEMENT|Placebo|6 months for the double-blind phase
219507057|NCT04443283|OTHER|No intervention|This is a observation study, with no intervention
219507058|NCT01944228|DEVICE|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
219507059|NCT01944228|DEVICE|Sham Stimulation|Catheter placed in the IJV without stimulation
219507060|NCT03668028|BIOLOGICAL|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
219201628|NCT06857097|PROCEDURE|single anastomosis sleeve jejunal bypass|sleeve was created starting devascularization of greater gastric curve 6 cm proximal to pylorus. Devascularization was done via either a harmonic scalpel or a ligasure device. Dissection was continued proximally till reaching the left diaphragmatic crus. Afterwards that the stomach was resected along the greater curvature via an endostapler over a 36-Fr bougie. After creating the sleeve, two meters of the small bowel were counted starting from the ligament of Treitz, and an antecolic isoperistaltic gastrojejunostomy (4-cm wide) was created with the antrum via linear stapler, and the anterior wall defect was closed by sutures.
219507061|NCT03668028|PROCEDURE|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
219507062|NCT02544061|BIOLOGICAL|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
219201629|NCT06857097|PROCEDURE|One anastomosis gastric bypass|dissection started just distal to the crows' foot till reaching the lesser sac. A long narrow gastric pouch was created by the endostapler. After that, a longitudinal gastrojejunostomy (4-cm wide) was created at 200 cm distal to the Treitz ligament as the SASJ group.
219201630|NCT06864039|DIAGNOSTIC_TEST|SF36 test|Assessment of quality of life by administering the SF36 test
219201631|NCT06864039|DIAGNOSTIC_TEST|WAIS IV test|Assessment of cognitive abilities by administering the WAIS IV test
219201632|NCT06864039|DIAGNOSTIC_TEST|SCL-90 psychopathological screening questionnaire|Assessment of any psychopathological conditions by means of the SCL-90 psychopathological screening questionnaire
219201633|NCT06864039|DIAGNOSTIC_TEST|CBCL questionnaire|For patients up to 18 years of age: CBCL questionnaire to be administered to parents to describe the patient's behavior
219201634|NCT06864039|DIAGNOSTIC_TEST|bioimpedance analysis|Assessment of body composition by performing bioimpedance analysis
219201635|NCT06863181|DEVICE|Radiofrequency ablation|Genicular nerve neurolysis with heat
219201636|NCT06616597|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg/ day
219507063|NCT02544061|DRUG|Placebo|single subcutaneous dose
219607510|NCT02836210|DEVICE|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
219607511|NCT06399744|PROCEDURE|sclerotherapy|injection of sclerosing agent (tetracycline or polidocanol) into ovarian cyst after aspiration of its contents
218885846|NCT02598297|DRUG|Ruxolitinib Placebo|5 mg placebo tablet for oral use
218885847|NCT04677010|OTHER|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
218885848|NCT02766712|PROCEDURE|Pace During 1st Half of Lesion|
218885849|NCT02766712|PROCEDURE|Pace During 2nd Half of Lesion|
218885850|NCT01222780|DRUG|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
218885851|NCT05651867|DEVICE|EPIONE device|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
218885852|NCT00345865|DRUG|carmustine|Day -6, 300 mg/m\^2 over 2 hour
218885853|NCT00345865|DRUG|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
219201637|NCT06616597|DRUG|Dexamethasone|Dexamethasone 0.5mg/day
219201638|NCT06616597|DRUG|Metronidazole|Metronidazole 1500mg/ per day
219201639|NCT03333915|DRUG|Pamiparib|Pamiparib is provided as oral capsules
219201640|NCT06342726|DEVICE|PAX Warming Blanket|Electric resistive active external warming blanket
219201641|NCT06342726|DEVICE|Passive insulation|3-layered wrapping model
219507064|NCT00189397|DRUG|azathioprine and corticosteroids for Parthenium dermatitis|
219507065|NCT06206733|DRUG|ASKB589|ASKB589 will be administered as a minimum 3-hour IV infusion
219507066|NCT06206733|DRUG|Oxaliplatin|Oxaliplatin will be administered as a minimum 2-hour IV infusion
219507067|NCT06206733|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
219507068|NCT06206733|DRUG|Tislelizumab|Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
219507069|NCT06206733|DRUG|Placebo|Placebo will be administered as a minimum 3-hour IV infusion
219201642|NCT06388824|DRUG|normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
219201643|NCT06388824|DRUG|Esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
219201644|NCT06388642|DRUG|Afamelanotide 16mg implant|afamelanotide 16mg implant will be administered to each patient during the study.
219507070|NCT05425966|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
219507071|NCT02804269|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
219507072|NCT02804269|OTHER|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
219507073|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
219201645|NCT06613217|DRUG|zelenirstat|Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
218885854|NCT00345865|DRUG|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
218885855|NCT00345865|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
218885856|NCT00345865|RADIATION|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."
219201646|NCT05740007|DRUG|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
218885857|NCT00345865|BIOLOGICAL|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."
219029619|NCT03225911|DEVICE|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
219029620|NCT03225911|DEVICE|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
219029621|NCT03225911|DEVICE|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
219029622|NCT03330431|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
219029623|NCT03100708|PROCEDURE|PIPAC|"* Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
219029624|NCT05102786|OTHER|40007388|A non-combusted cigarette used with heated tobacco device 20020064
219029625|NCT05102786|OTHER|40007385|A non-combusted cigarette used with heated tobacco device 20020064
219201647|NCT05740007|DRUG|Placebo|Placebo rectal foam administered daily for 12 weeks
219201648|NCT06673810|OTHER|Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises|Group A will have free ankle weighted cuffs while performing routine physical therapy. These weighted cuffs will be above of the child's ankle and child will be encouraged to perform his/her routine physical activities. Ankle weights will correspond to 2% to 3% of the individual's body weight (sandbags) will be attached at 5 cm above the left and right ankle joints
219201649|NCT06673810|OTHER|Routine Physical Therapy Exercises|Group B will perform all the routine physical exercises which include jogging, walk/run interval training, treadmill training and cycling . Intervention period will be of 6 weeks comprising of 3 sessions per week of 30 to 45 minutes per session
219201650|NCT06746207|OTHER|Informed Consent Process Evaluation|This study does not involve a clinical intervention. Instead, it focuses on evaluating the existing process of informed consent in a surgical setting. Patients and caregivers will be surveyed to assess their understanding, satisfaction, and perceptions of the informed consent process. The study examines factors such as clarity of information provided, patient and caregiver involvement, and overall satisfaction with the process, without altering the current practices. The goal is to identify areas for improvement in communication and documentation, ensuring that patient rights and autonomy are respected.
219201651|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
219201652|NCT06597942|DEVICE|TMS|rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates
219201653|NCT06597942|DEVICE|Transcranial Magnetic Stimulation Sham|Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
219201654|NCT03601897|DRUG|Rebastinib|Administered orally
218885858|NCT00345865|DRUG|Cytarabine|100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
218885859|NCT00005024|DRUG|carboplatin|
218885860|NCT00005024|DRUG|cyclophosphamide|
219201655|NCT03601897|DRUG|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m\^2
219201656|NCT06608108|OTHER|Non-intervention|Non-intervention
219201657|NCT03518554|DRUG|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
218885861|NCT00005024|DRUG|doxorubicin hydrochloride|
218885862|NCT00005024|DRUG|granisetron hydrochloride|
218885863|NCT03114332|PROCEDURE|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
218885864|NCT02553395|DEVICE|Phenacite (Test) contact lens|
218885865|NCT02553395|DEVICE|comfilcon A contact lens|
218885866|NCT05771740|DEVICE|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
218885867|NCT02159976|DRUG|Pantoprazole|Pantoprazole 40mg bid
218885868|NCT02159976|DRUG|Amoxicillin|Amoxicillin 1000mg bid
218885869|NCT02159976|DRUG|Clarithromycin|Clarithromycin 500mg bid
218885870|NCT02159976|DRUG|Metronidazole|Metronidazole 500mg tid
218885871|NCT02159976|DRUG|Tetracycline|Tetracycline 1000mg bid
218885872|NCT02159976|DRUG|Bismuth|Bismuth 600mg bid
218885873|NCT04576026|BEHAVIORAL|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
218885874|NCT04576026|BEHAVIORAL|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
218885875|NCT04576026|BEHAVIORAL|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
218885876|NCT05044858|PROCEDURE|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
218885877|NCT05044858|PROCEDURE|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
218885878|NCT03060278|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials.
219029626|NCT05102786|OTHER|40007387|A non-combusted cigarette used with heated tobacco device 20020064
219029627|NCT05102786|OTHER|40007386|A non-combusted cigarette used with heated tobacco device 20020064
219029628|NCT00297037|DRUG|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
219029629|NCT00076011|DRUG|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
219029630|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme|Pre-Workout Dietary Supplement
219029631|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
219029632|NCT02952014|DIETARY_SUPPLEMENT|Placebo|Pre-Workout Dietary Supplement
219029633|NCT03804112|DIAGNOSTIC_TEST|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
219029634|NCT03804112|BIOLOGICAL|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
219029635|NCT00581776|DRUG|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
219029636|NCT00581776|DRUG|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
219029637|NCT00581776|DRUG|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
219029638|NCT00581776|DRUG|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
219029639|NCT00581776|DRUG|Vincristine|1 mg administered by IV on day 3 of each cycle.
219029640|NCT00581776|DRUG|Dexamethasone|40 mg orally on days 1-4 of each cycle.
219029641|NCT06019156|BEHAVIORAL|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
219029642|NCT06019156|BEHAVIORAL|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
219029643|NCT06236711|DEVICE|tDCS|tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
219029644|NCT05992168|DEVICE|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
219029645|NCT06513962|OTHER|Best Practice|Receive standard chemotherapy
219029646|NCT06513962|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219029647|NCT06513962|OTHER|Electronic Health Record Review|Ancillary studies
219029648|NCT06513962|OTHER|Survey Administration|Ancillary studies
219029649|NCT06513962|DRUG|Triptorelin Pamoate|Given IM
219201658|NCT06856278|DRUG|NKG2D CAR-NK with PD-1 Antibody|Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
219201659|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion
218885879|NCT03060278|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
218885880|NCT03060278|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
218885881|NCT03060278|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
218885882|NCT00933868|DRUG|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
218885883|NCT00933868|DRUG|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
219201660|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
218885884|NCT02914574|OTHER|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
218885885|NCT04270799|DIAGNOSTIC_TEST|Machine Learning Classification|Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
218885886|NCT00394706|DEVICE|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
218885887|NCT00394706|DEVICE|Sham ITD|Sham ITD
218885888|NCT00394706|OTHER|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
218885889|NCT00394706|OTHER|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
219029650|NCT04345614|DRUG|Auxora (Part 1)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
219029651|NCT04345614|DRUG|Standard of Care (Part 1)|Patients received standard of care
218885890|NCT02466282|DEVICE|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
219029652|NCT04345614|DRUG|Auxora (Part 2)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
219029653|NCT04345614|DRUG|Placebo (Part 2)|Placebo will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Placebo will be administered intravenously (IV) over 4 hours.
219029654|NCT04922918|BIOLOGICAL|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
219029655|NCT04322318|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219029656|NCT04322318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219029657|NCT04322318|PROCEDURE|Bone Scan|Undergo a bone scan
219029658|NCT04322318|DRUG|Carboplatin|Given IV
219029659|NCT04322318|PROCEDURE|Computed Tomography|Undergo a CT scan
219029660|NCT04322318|DRUG|Cyclophosphamide|Given IV
219029661|NCT04322318|DRUG|Doxorubicin|Given IV
219029662|NCT04322318|DRUG|Etoposide|Given IV
219029663|NCT04322318|DRUG|Ifosfamide|Given IV
219029664|NCT04322318|DRUG|Irinotecan|Given IV
219029665|NCT04322318|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219029666|NCT04322318|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219029667|NCT04322318|RADIATION|Radiation Therapy|Undergo RT
219029668|NCT04322318|PROCEDURE|Surgical Procedure|Undergo surgery
219029669|NCT04322318|DRUG|Topotecan|Given IV
219029670|NCT04322318|PROCEDURE|Transabdominal Ultrasound|Undergo abdominal ultrasound
219029671|NCT04322318|DRUG|Vincristine|Given IV
219029672|NCT04322318|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
219029673|NCT05469100|DRUG|Selpercatinib|Administered orally
219029674|NCT05156879|DRUG|Aspirin|75mg, one time/day
219029675|NCT05156879|DRUG|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
219029676|NCT04538703|BEHAVIORAL|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
219029677|NCT06154447|DRUG|VX-828|Suspension for Oral Administration
219029678|NCT06154447|DRUG|Placebo|Suspension for Oral Administration
219029679|NCT06154447|DRUG|Itraconazole|Solution for Oral Administration
219029680|NCT06154447|DRUG|Midazolam|Syrup for Oral Administration
219029681|NCT06154447|DRUG|Tezacaftor|Tablets for Oral Administration
219029682|NCT06154447|DRUG|VX-118|Tablets for Oral Administration
219029683|NCT06154447|DRUG|Placebo|Suspension and Tablets for Oral Administration
219029684|NCT06154447|DRUG|Deutivacaftor|Tablets for Oral Administration
219029685|NCT06154447|DRUG|VX-828|Tablets for Oral Administration
219029686|NCT04588649|DRUG|THK-5351|\[18F\]THK-5351 PET Imaging
219029687|NCT04588649|DRUG|AV-45|\[18F\]AV-45 PET Imaging
219029688|NCT04109638|DEVICE|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
219029689|NCT00668941|DRUG|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
219029690|NCT00668941|DRUG|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
219029691|NCT00668941|DIETARY_SUPPLEMENT|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
219029692|NCT00668941|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
219201661|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
219507074|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
219507075|NCT04813822|DRUG|Miconazole Nitrate 2%|Active Comparator
219507076|NCT04451265|OTHER|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
219507077|NCT03459326|OTHER|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)"
218885891|NCT02466282|DEVICE|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
218885892|NCT01649934|BEHAVIORAL|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
218885893|NCT01649934|BEHAVIORAL|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
218885894|NCT03737539|DIAGNOSTIC_TEST|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
218885895|NCT01469273|DRUG|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
218885896|NCT05185999|DRUG|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
218885897|NCT06113055|DRUG|L-serine|Active comparator
218885898|NCT06113055|DRUG|Placebo|Placebo comparator
218885899|NCT04684069|DEVICE|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
218885900|NCT04684069|DEVICE|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
218885901|NCT06165328|DIAGNOSTIC_TEST|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
218885902|NCT03369249|BEHAVIORAL|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
219029693|NCT05230082|OTHER|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
219029694|NCT04461015|DRUG|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
219029695|NCT04461015|DRUG|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
218885903|NCT02003534|DRUG|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
219040360|NCT05724134|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
219040361|NCT05724134|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
219040362|NCT05724134|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
219040363|NCT05724134|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
219040364|NCT05724134|OTHER|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
219607512|NCT06459492|BEHAVIORAL|puzzle game strategies|"One innovative approach uses puzzle game strategies, including crosswords, Sudoku, and other brain-teasing activities. These strategies have been shown to help maintain attention, improve memory, and keep older adults' thoughts clear and sharp. Additionally, engaging in these activities can provide psychological benefits by offering a sense of achievement, reducing stress, and fostering social interactions.~Given puzzle games' potential to enhance cognitive and psychological health, exploring their effectiveness as a non-pharmacological intervention for community-dwelling older adults is essential. This research aims to fill the gap by empirically investigating the impact of puzzle game strategies on cognitive functioning and psychological well-being in this demographic."
218885904|NCT01247961|DRUG|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
218885905|NCT01247961|OTHER|Placebo|Normal saline
218885906|NCT02133885|DRUG|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
218885907|NCT02133885|OTHER|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
218885908|NCT00640497|BIOLOGICAL|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
219507078|NCT05941091|BEHAVIORAL|HafifMod Programme|"MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos."
218885909|NCT01817023|RADIATION|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
218885910|NCT01817023|DRUG|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
218885911|NCT05139784|OTHER|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
218885912|NCT04054986|DIAGNOSTIC_TEST|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
218885913|NCT04054986|OTHER|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
218885914|NCT01497301|BEHAVIORAL|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
219029696|NCT06416618|PROCEDURE|Surgical|Surgical group: After osteosynthesis, they will be provided with a sling and swathe immediately after the surgery. From the first postoperative day, only the sling will be used. Two weeks postoperatively, patients will undergo clinical and radiological follow-up in the outpatient clinic. They will be referred to post-operative rehabilitation in the municipalities. At 12 weeks postoperatively, patients will have another clinical and radiological follow-up. This is the current standard care for surgical treatment with a plate or intramedullary nail.
219029697|NCT06416618|PROCEDURE|Non surgical|Non-surgical group: Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit, 10-14 days post-injury. Patients will be referred to rehabilitation in the municipalities. At week 6 post-injury, all patients will undergo clinical and radiological follow-up. This represents the current standard care for non-surgical treatment of displaced PHF at the departments.
219029698|NCT06490029|DIAGNOSTIC_TEST|Auditory, vestibular and electrophysiological investigations|otoacoustic emissions, electrocochleography, vocal audiometry in noise and high-frequency tonal audiometry, impedancemetry
219029699|NCT06490029|DIAGNOSTIC_TEST|Biologic investigations; seric proteins|seric proteins
219029700|NCT01633892|PROCEDURE|Fat Grafting|
219029701|NCT03899584|DRUG|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
219029702|NCT03899584|DRUG|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
219201662|NCT06860373|BIOLOGICAL|[18F]MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection.
219201663|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
219507079|NCT05941091|BEHAVIORAL|Distribution of printed material|In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
219507080|NCT04756141|DEVICE|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
219507081|NCT04221581|DEVICE|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
219507082|NCT04177810|DRUG|Cemiplimab|Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
219507083|NCT04177810|DRUG|Plerixafor|Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
219507084|NCT04166981|PROCEDURE|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
219507085|NCT04166981|PROCEDURE|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
219507086|NCT00417313|DEVICE|periosteal electro-acupuncture (osteopuncture).|
219507087|NCT03267030|DRUG|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
219507088|NCT01851590|DEVICE|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
219507089|NCT01851590|DRUG|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
218885915|NCT00117260|DRUG|Seasonale (levonorgestrel and ethinyl estradiol)|
219507090|NCT01851590|DRUG|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
219607513|NCT05019287|BIOLOGICAL|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
219607514|NCT05019287|OTHER|Intravenous saline injection|Intravenous saline injection in addition to standard care
219607515|NCT00549744|DRUG|GSK256066|
218885916|NCT06535620|OTHER|red wine with alcohol|200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
218885917|NCT06535620|OTHER|red wine without alcohol|200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
218885918|NCT03056742|BIOLOGICAL|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
218885919|NCT01862523|BIOLOGICAL|Capsaicin|Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
218885920|NCT01862523|BIOLOGICAL|diluent|diluent
219029703|NCT04234282|PROCEDURE|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
219607516|NCT02554162|OTHER|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
218885921|NCT05020080|OTHER|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
218885922|NCT01947751|PROCEDURE|CVC exchange|CVC exchange when related infection is suspected
218885923|NCT01947751|DRUG|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
218885924|NCT00542607|DRUG|levocetirizine dihydrochloride|
219029704|NCT05257811|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
219029705|NCT00146146|DRUG|testosterone undecanoate alone|1000 mg/12 weeks
219029706|NCT00146146|DRUG|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
219029707|NCT00146146|DRUG|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
219029708|NCT00464568|DRUG|GSK256066|
219029709|NCT04878523|DIETARY_SUPPLEMENT|multi berries juice|Testing product
219029710|NCT04878523|DIETARY_SUPPLEMENT|Placebo drink|Blank
219029711|NCT02494427|DEVICE|CAD/CAM manufactured fixed unitary dental prostheses|
219029712|NCT02494427|DEVICE|Conventionally manufactured unitary dental prostheses|
219029713|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
219029714|NCT02140099|BEHAVIORAL|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
219029715|NCT02140099|BEHAVIORAL|Control Condition (Classroom Activities)|
219029716|NCT03615326|BIOLOGICAL|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
219029717|NCT03615326|BIOLOGICAL|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
218885925|NCT05154318|PROCEDURE|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
218885926|NCT05154318|PROCEDURE|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
219029718|NCT03615326|DRUG|Cisplatin|80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
219029719|NCT03615326|DRUG|5-FU|800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
219029720|NCT03615326|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
219029721|NCT03615326|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
219029722|NCT03615326|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
219029723|NCT03615326|BIOLOGICAL|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
219029724|NCT02435472|BEHAVIORAL|Exercise|This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
219507091|NCT05571761|BEHAVIORAL|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
219507092|NCT00394745|DRUG|Valsartan|
219607517|NCT02965417|DRUG|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
219607518|NCT05450419|DIETARY_SUPPLEMENT|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 \& week 4.
218885927|NCT04253002|BEHAVIORAL|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
218885928|NCT04253002|BEHAVIORAL|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
218885929|NCT04120961|DRUG|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
218885930|NCT04120961|DRUG|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
218885931|NCT05267119|PROCEDURE|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
218885932|NCT03271502|PROCEDURE|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
218885933|NCT03271502|PROCEDURE|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
218885934|NCT00972725|BIOLOGICAL|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
218885935|NCT00972725|DRUG|Chloroquine|One dose of 300 mg
218885936|NCT00248586|BEHAVIORAL|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
218885937|NCT00248586|BEHAVIORAL|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
218885938|NCT05876468|DEVICE|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~* First CACC : the applied pressure is equal to the one observed in the prone position~* Second CACC : The applied pressure is set at 60 - 80 cmH20"
218885939|NCT05900232|DIAGNOSTIC_TEST|Anti _KU antibodies|aim of the work is to determine the relationship between Anti\_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
218885940|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
219029725|NCT02435472|OTHER|Cardiopulmonary Exercise Test (CPET)|Exercise capacity test to assess peak oxygen consumption (VO2peak)
219029726|NCT04796376|PROCEDURE|combined partial fistulectomy or fistulotomy and cutting seton procedure|Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
218885941|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
218885942|NCT03549377|BEHAVIORAL|Deception|Participants will be deceived during delayed gratification task.
218885943|NCT00694668|BEHAVIORAL|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
218885944|NCT00694668|BEHAVIORAL|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
218885945|NCT02548338|PROCEDURE|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
218885946|NCT04853719|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
218885947|NCT03936257|OTHER|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
218885948|NCT03936257|OTHER|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
218885949|NCT03936257|OTHER|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
218885950|NCT04703764|DRUG|HSG4112|Once-daily, 14-day multiple oral administration
218885951|NCT04703764|DRUG|Placebo|Once-daily, 14-day multiple oral administration
219029727|NCT02258126|OTHER|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
219507093|NCT01714505|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
219507094|NCT01513057|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
219507095|NCT01513057|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
219507096|NCT01438554|DRUG|Pazopanib|
219607519|NCT05450419|DIETARY_SUPPLEMENT|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 \& week 4.
219029728|NCT00547742|PROCEDURE|PET/CT Scan|
219029729|NCT00547742|PROCEDURE|phlebotomy|
219029730|NCT02004028|DRUG|VS-6063|
219029731|NCT03697668|DRUG|Imatinib|triple combination for the treatment of malaria
219029732|NCT03697668|DRUG|Dihydroartemisinin-piperaquine|standard malaria treatment
219029733|NCT04464122|DRUG|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
219029734|NCT03826862|RADIATION|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
219029735|NCT03284996|DEVICE|Doppler ultrasonography|Examination of the whole cases \& controls by doppler ultrasound to measure renal resistive index.
219029736|NCT01012687|DRUG|perindopril erbumine|8 mg tablet
219029737|NCT05943912|OTHER|Single Vision Spectacle Lens|36 months of therapy
219029738|NCT05943912|OTHER|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|36 months of therapy
219029739|NCT06424912|PROCEDURE|Vivifi's Surgical Procedure|"Subjects undergo Vivifi's surgical procedure for treatment of BPH. The study procedure will be performed in the operating room, under general anesthesia.~Subject will undergo a bilateral anastomosis of the internal spermatic vein to the inferior epigastric vein and ligation of the deferential vein via bilateral inguinal/subinguinal incision.~The investigators can use of a coupler with appropriate ring size (to be measured intra-operatively based on vessel size) to perform the vascular anastomosis and standard sutures for ligation. The coupler is an FDA approved commercial device. Alternatively, the anastomosis can also be performed using sutures. Incision closure will proceed per institution standard of care."
219029740|NCT04696939|DRUG|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
219029741|NCT04696939|DRUG|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
219029742|NCT04696939|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
219029743|NCT04323280|DRUG|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
219029744|NCT04323280|DRUG|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
219029745|NCT05471518|OTHER|No intervention|No intervention
219029746|NCT04306315|BIOLOGICAL|Brodalumab|Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
219029747|NCT04665037|DRUG|Posaconazole IV 6 mg/kg|POS 6 mg/kg body weight by IV infusion
219029748|NCT04665037|DRUG|Posaconazole PFS 6 mg/kg|POS nominal 6 mg/kg body weight based on weight bands taken orally
219029749|NCT05563077|OTHER|Moderate-intensity interval training (MIIT)|MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.
219029750|NCT05563077|OTHER|Moderate-intensity continuous training (MICT)|MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
219029751|NCT06320730|OTHER|Observational study, records of blood glucose level after reperfusion|Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
219029752|NCT00829374|DRUG|Dimebon|5 mg orally three times daily
219029753|NCT00829374|DRUG|Dimebon|20 mg orally three times daily
219029754|NCT00829374|DRUG|Placebo comparator|Placebo orally three times daily
219029755|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
219040365|NCT05724134|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
219040366|NCT05724134|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
219040367|NCT05724134|DIETARY_SUPPLEMENT|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
219507097|NCT01438554|DRUG|GSK1120212|
219507098|NCT03082456|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
219607520|NCT02885402|OTHER|MRI Sodium ( 23Na )|
219607521|NCT04198259|PROCEDURE|interventional devascularization|Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
218885952|NCT03077230|BEHAVIORAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
218885953|NCT03238690|DEVICE|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
218885954|NCT00437814|DRUG|Ketamine, effect on intracranial pressure|
218885955|NCT05170763|DRUG|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
218885956|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
218885957|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
218885958|NCT05170763|DRUG|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
218885959|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
218885960|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
219029756|NCT05601986|OTHER|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
219029757|NCT04896320|DRUG|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
219029758|NCT06098807|BEHAVIORAL|Family Centered Treatment for Problematic Gaming and Excessive Screen Use|Based on earlier implementation research with parents and children the treatment is likely to consist of a low number of sessions ;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
219029759|NCT02885142|PROCEDURE|Local excision for early rectal cancer|
218885961|NCT05170763|DRUG|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
218885962|NCT02144857|DRUG|etanercept|50 mg
218885963|NCT02144857|DRUG|ustekinumab|45 mg
218885964|NCT02144857|DRUG|cyclosporine|Cyclosporine 2.5-3 mg/kgr
218885965|NCT02144857|DRUG|Secukinumab|300 mg
218885966|NCT02144857|DRUG|Apremilast|30mg
218885967|NCT01004289|PROCEDURE|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
218885968|NCT01004289|PROCEDURE|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
218885969|NCT02919046|BIOLOGICAL|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
219029760|NCT02631954|DRUG|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
218885970|NCT05059509|BIOLOGICAL|FB825|FB825, 5mg/kg, by 1 hour IV infusion on Day 1
219029761|NCT02631954|DRUG|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
218885971|NCT02177188|DEVICE|LBNP Lower Bodi Negative Pressure Chamber|
218885972|NCT04030572|DRUG|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
218885973|NCT03660761|DRUG|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
218885974|NCT03660761|DRUG|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
219201664|NCT05418478|BEHAVIORAL|Intervention transtheoretical model group|"The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change)."
219201665|NCT06676839|OTHER|the complete ICOPE program|"The participant benefits from a personalized intervention, including 1) a screening to be repeated every 6 months, based on the use of the ICOPE tool, allowing an assessment of the 6 functions necessary for an autonomous lifestyle; 2) a comprehensive assessment step for the 6 functions 3) a personalized intervention step aimed at correcting the trajectory of functional decline, based on the participants' preferences; 4) a follow-up step for this intervention.~Participants will benefit from telephone follow-up 1.5 months after the start of the program and between each annual visit to support them in implementing their personalized intervention plan.~At each contact, the ICOPE nurse reviews the participant's implementation of the personalized intervention plan recommendations and their adherence to the program.~The results of the assessment and the proposed intervention are communicated and discussed with the primary care physician and a summary letter is also sent."
218885975|NCT04014985|OTHER|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
218885976|NCT05704790|OTHER|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
218885977|NCT05227430|OTHER|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
218885978|NCT05292131|DRUG|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
218885979|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|32 mg
219029762|NCT03905122|DEVICE|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
219029763|NCT05771207|DIETARY_SUPPLEMENT|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
219029764|NCT05771207|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
219029765|NCT05771207|DIETARY_SUPPLEMENT|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
219029766|NCT06365853|DRUG|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
219201666|NCT02456233|PROCEDURE|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
219201667|NCT02456233|PROCEDURE|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
219201668|NCT06524024|BIOLOGICAL|Tumor polypeptide pool induced DC-CTL cell injection|In this study, DC-CTL cells were injected once a day for two consecutive days, 1-2 days after study participants received a conventional antitumor regimen, and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells. A total of about 4-6 cycles of cell infusion are required
219201669|NCT06865001|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
219201670|NCT06865001|OTHER|Graded motor imagery|"Graded motor imagery consists of three stages:~1. limb lateralization task~2. an imaginary limb movement task (motor imagery) and~3. mirror therapy. Each session will consist of 12-15 minutes and 3 sets, with 5 minutes between sessions to rest and relax the limb. The application is planned for 30 minutes."
219507099|NCT03082456|DIAGNOSTIC_TEST|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
219507100|NCT03082456|DIAGNOSTIC_TEST|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
219507101|NCT03229993|DIAGNOSTIC_TEST|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
218885980|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|48 mg
218885981|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|64 mg
218885982|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|80mg
218885983|NCT03198494|OTHER|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
218885984|NCT03198494|OTHER|Sham Background Noise|Background Noise used as a control
218885985|NCT06555575|DRUG|Ubiquinone 200 Mg Oral Capsule|By mouth three times daily for three months
218885986|NCT06555575|DRUG|Ubiquinol 100 MG Oral Capsule|By mouth three times daily for three months
218885987|NCT06092047|BIOLOGICAL|UTAA09 cells for infusion|Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.
218885988|NCT06092047|DRUG|Fludarabine|30 mg/m\^2/day×4 days
219029767|NCT06365853|DRUG|Lubricating Eye Drops|Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
219029768|NCT06365853|DRUG|Prednisolone acetate ophthalmic suspension 1% eye drops|Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
218885989|NCT06092047|DRUG|Cyclophosphamide|1000 mg/m\^2/day×3 days
218885990|NCT06506487|BEHAVIORAL|Doll Therapy|Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
218885991|NCT05882214|DIETARY_SUPPLEMENT|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
218885992|NCT05882214|DIETARY_SUPPLEMENT|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
218885993|NCT04438889|OTHER|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
218885994|NCT06170853|OTHER|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
218885995|NCT05658484|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
218885996|NCT04468919|BEHAVIORAL|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
218885997|NCT04468919|BEHAVIORAL|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
218885998|NCT04468919|BEHAVIORAL|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
218885999|NCT04468919|BEHAVIORAL|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
218886000|NCT06101030|DEVICE|Signal On|InSee monitor patient signals are on.
218886001|NCT05588648|DRUG|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
219507102|NCT03103009|DRUG|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
219507103|NCT00359437|DRUG|Satavaptan|oral administration once daily
219507104|NCT00359437|DRUG|placebo|oral administration once daily
219507105|NCT03128593|DRUG|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
219507106|NCT05618483|DEVICE|Nasal Spray|The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
219029769|NCT06365853|DRUG|Brimonidine tartrate ophthalmic solution eye drops|Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
219029770|NCT06107413|DRUG|ABBV-400|Intravenous (IV) Infusion
219029771|NCT06107413|DRUG|Bevacizumab|IV Infusion
219029772|NCT06107413|DRUG|Folinic Acid|IV Infusion
219507107|NCT01735045|DEVICE|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
219507108|NCT01735045|DEVICE|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
219029773|NCT06107413|DRUG|Fluorouracil|IV Infusion
219029774|NCT06107413|DRUG|Irinotecan|IV Infusion
219040368|NCT05724134|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
219507109|NCT02611752|DRUG|CAM2038|CAM2038 subcutaneous injection
219507110|NCT04300777|DEVICE|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
219507111|NCT02047942|BEHAVIORAL|Center-based cardiac rehabilitation|
219507112|NCT02047942|BEHAVIORAL|Home-based training with telemonitoring guidance|
219507113|NCT00310856|BIOLOGICAL|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
219507114|NCT00310856|BIOLOGICAL|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
219507115|NCT00310856|BIOLOGICAL|DTaP-Hib-IPV|
218886005|NCT06086626|DRUG|Cefiderocol|Administered via intravenous (IV) infusion
218886006|NCT06086626|DRUG|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
219040369|NCT05724134|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
219040370|NCT06122246|BEHAVIORAL|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
219040371|NCT06122246|OTHER|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
218886007|NCT03829449|DRUG|rVA576|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
219507116|NCT00310856|BIOLOGICAL|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
219507117|NCT00310856|BIOLOGICAL|MMR|
219507118|NCT00310856|BIOLOGICAL|Varicella|
218886008|NCT02557542|OTHER|One Stop Vein Clinic|Same day diagnosis and treatment
218886009|NCT02557542|DEVICE|Radiofrequency ablation|Venous ablation
218886010|NCT02557542|DEVICE|Endovenous laser ablation|Venous ablation
218886011|NCT02557542|DRUG|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
218886012|NCT05880771|OTHER|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
218886013|NCT05600543|DEVICE|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
218886014|NCT05600543|DEVICE|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt.|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt could be worn during the third addtional visit proposed to the healthy subject.
218886015|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
218886016|NCT03976882|DRUG|Hetrombopag|Hetrombopag
218886017|NCT03976882|DRUG|Placebo|Placebo
218886018|NCT06641791|RADIATION|Standard Radiotherapy (SRT)|2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week
218886019|NCT06641791|RADIATION|Stereotactic Body Radiotherapy (SBRT)|4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
218886020|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case Group - Tomato-free diet|Nutritional intervention without tomatoes and sauce
219029775|NCT06813872|BIOLOGICAL|ABRYSVO Vaccination|"The primary exposure of interest for the TND study is maternal history of vaccination with Pfizer's ABRYSVO vaccine during pregnancy with the infant who presented for care. Infants will be considered exposed to ABRYSVO if their birth parent has documented evidence of receiving ABRYSVO ≥14 days before the date of the infant's birth, during the licensed gestational age window of 32 0/7 to 36 6/7 weeks."
219029776|NCT03425331|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
219029777|NCT03425331|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
219029778|NCT05235165|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
219029779|NCT05235165|PROCEDURE|Computed Tomography|Undergo CT
219029780|NCT05235165|OTHER|Questionnaire Administration|Ancillary studies
219507119|NCT02984839|DEVICE|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
219507120|NCT02657993|BEHAVIORAL|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
218886021|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case group - Diet enriched with tomatoes|Nutritional intervention enriched with tomatoes and souce
218886022|NCT06643403|DRUG|Oxygen 100% Gas for Inhalation|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes"
218886023|NCT05141721|DRUG|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
218886024|NCT05141721|DRUG|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
218886025|NCT05141721|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
218886026|NCT05141721|DRUG|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
219029781|NCT05235165|PROCEDURE|Thoracoscopy|Undergo video-assisted thoracoscopic surgery or VATS
219029782|NCT05235165|PROCEDURE|Thoracotomy|Undergo open thoracic surgery
219029783|NCT00979888|OTHER|educational intervention|
219029784|NCT00979888|OTHER|informational intervention|
219029785|NCT00979888|OTHER|psychosocial support for caregiver|
219029786|NCT00979888|OTHER|questionnaire administration|
219029787|NCT00979888|PROCEDURE|dyspnea management|
219029788|NCT00979888|PROCEDURE|management of therapy complications|
219029789|NCT04483908|DIAGNOSTIC_TEST|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
219029790|NCT04483908|DIAGNOSTIC_TEST|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
219029791|NCT04483908|DIAGNOSTIC_TEST|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
219201671|NCT06617299|BEHAVIORAL|Intervention Identifies and Responds|"The treatment of Experimental Group is described, which is made up of eight individual sessions taught over three months. Session one will be in face-to-face format, the content, resources and activities are described in tables 2 and 3. The remaining seven sessions will be follow-up sessions (four sessions by message (WhatsApp®) where motivational messages and reinforcement information will be sent; and 3 sessions by phone call for feedback, see details of time, content, activities and resources in tables 2 and 3.~The design of the intervention is aimed at increasing the practice of Responsive Feeding in mothers with children under 6 months of age, is based on the methodology of Sidani and Braden (2021); on CHW (Bandura, 1986); and behavior change techniques to help people have healthy eating habits (Michie et al., 2011)."
219201672|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
219201673|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
219201674|NCT02777593|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
219201675|NCT06672900|DRUG|Carbamazepine|Commercially available supply.
219201676|NCT06672900|DRUG|Itraconazole (Sporanox)|Commercially available supply.
219201677|NCT06672900|DRUG|ALG-000184|Study Investigational Product
218886027|NCT05141721|DRUG|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
218886028|NCT05141721|DRUG|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
218886029|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
218886030|NCT06136897|PROCEDURE|Biopsy Procedure|Undergo biopsy
219029792|NCT04483908|DIAGNOSTIC_TEST|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
218886031|NCT06136897|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218886032|NCT06136897|PROCEDURE|Echocardiography Test|Undergo ECHO
218886033|NCT06136897|BIOLOGICAL|Pertuzumab|Given IV
218886034|NCT06136897|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219029793|NCT00470574|BIOLOGICAL|QS21|
219029794|NCT00470574|BIOLOGICAL|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
219029795|NCT00470574|OTHER|immunoenzyme technique|
219029796|NCT00470574|OTHER|immunologic technique|
219201678|NCT06671379|DRUG|SHR-A2009 monotherapy|SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
219201679|NCT06671379|DRUG|platinum-based dual-agent chemotherapy|Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
219201680|NCT05256641|DRUG|Acalabrutinib|Given PO
219201681|NCT05274919|DEVICE|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
219201682|NCT05274919|DEVICE|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
219201683|NCT05274919|COMBINATION_PRODUCT|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
218886035|NCT06136897|BIOLOGICAL|Trastuzumab|Given IV
218886036|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
218886037|NCT04228367|DEVICE|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
218886038|NCT06532565|DRUG|GS-2121|Tablet administered orally
218886039|NCT06532565|DRUG|Zimberelimab|Administered intravenously
218886040|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana administered through vaporizer
218886041|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist administered intranasally
218886042|NCT03705559|DRUG|Placebo|Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
218886043|NCT03559647|DRUG|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
219029797|NCT00470574|OTHER|laboratory biomarker analysis|
219029798|NCT06519188|OTHER|Nebulization application with 5 ml isotonic sodium chloride|Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
219029799|NCT06004700|OTHER|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
219029800|NCT06002347|BEHAVIORAL|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
219201684|NCT05274919|OTHER|Question list|Questionnaire for contra-indications for an MR examination.
219201685|NCT06866899|PROCEDURE|Surgery for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF)|All of the patients were operated for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF). The study is two center study, one center has the routine of RAAB (regional anesthesia with axillary block) and the other has the routine of WALANT (wide awake local anesthesia no tourniquet) for the mentioned surgeries.
219201686|NCT06866899|PROCEDURE|Regional Anesthesia|Regional anesthesia with axillary block
219607522|NCT04198259|PROCEDURE|TIPS|TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
218886044|NCT00583063|DRUG|sunitinib|25 mg daily (oral dosing)
219029801|NCT02864251|BIOLOGICAL|Nivolumab|Specified dose on specified days
218886045|NCT00583063|DRUG|rapamycin|4 mg daily (oral dosing)
219607523|NCT00562523|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
218886046|NCT04384029|OTHER|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
219029802|NCT02864251|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219029803|NCT02864251|DRUG|Pemetrexed|Specified dose on specified days
218886047|NCT04027751|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
218886048|NCT04027751|DRUG|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
218886049|NCT04891523|DIETARY_SUPPLEMENT|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
218886050|NCT04891523|OTHER|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo \[inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)\] in form of a lozenge, daily, during 3 weeks.
218886051|NCT03357016|OTHER|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
219029804|NCT02864251|DRUG|Cisplatin|Specified dose on specified days
219029805|NCT02864251|DRUG|Carboplatin|Specified dose on specified days
219029806|NCT00299260|BIOLOGICAL|CMV gB vaccine|20 micrograms
219029807|NCT00299260|DRUG|Placebo|normal saline
219029808|NCT01701115|PROCEDURE|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
219029809|NCT01701115|PROCEDURE|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
219029810|NCT01701115|DRUG|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
219029811|NCT01701115|DRUG|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
219029812|NCT03506373|DRUG|Ibrutinib|Given PO
219029813|NCT03506373|DRUG|Ixazomib Citrate|Given PO
219029814|NCT03506373|OTHER|Laboratory Biomarker Analysis|Correlative studies
219029815|NCT03506373|OTHER|Pharmacodynamic Study|Correlative studies
219029816|NCT03506373|OTHER|Pharmacokinetic Study|Correlative studies
219029817|NCT06848803|BEHAVIORAL|AI- driven simulation platform|This investigation will draw upon existing literature exploring the intersection of AI in education, reflective practice, emotional intelligence, and professional integration. By synthesizing these perspectives, we aim to provide a comprehensive overview of the transformative potential of AI-driven SLPs in shaping future professionals. Furthermore, this analysis will consider the ethical implications of using AI in education, including issues related to data privacy, algorithmic bias, and the potential displacement of human interaction.
219029818|NCT05779475|OTHER|No treatment given|Participants will not receive any investigational treatment in this study.
219029819|NCT04349618|OTHER|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
219029820|NCT04349618|OTHER|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
219029821|NCT05920421|PROCEDURE|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
219029822|NCT00885755|DRUG|Standard taxane therapy|As prescribed
219029823|NCT00885755|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
219029824|NCT00885755|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
219029825|NCT04572230|DEVICE|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
219029826|NCT04315337|BEHAVIORAL|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
219029827|NCT00913471|OTHER|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
219029828|NCT04478006|GENETIC|RNA-seq|Gene expression and fusion transcripts analysis
219029829|NCT04478006|GENETIC|whole exon sequencing|Genetic alternation analysis
219029830|NCT04478006|OTHER|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
219029831|NCT05612412|OTHER|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
219029832|NCT05612412|OTHER|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
219029833|NCT03067181|OTHER|Best Practice|Undergo observation
218886052|NCT05727813|DEVICE|cryoablation|cryoablation of breast cancer smaller than 2 cm
218886053|NCT05373264|DRUG|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
219029834|NCT03067181|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
219029835|NCT03067181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219507121|NCT02657993|BEHAVIORAL|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
219507122|NCT02462070|DRUG|IDP-118 Lotion|Lotion
219507123|NCT02462070|DRUG|IDP-118 Vehicle Lotion|Lotion
219029836|NCT03067181|BIOLOGICAL|Bleomycin Sulfate|Given IV
219029837|NCT03067181|DRUG|Carboplatin|Given IV
219507124|NCT00443352|DRUG|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
218886054|NCT05373264|DRUG|Placebo|A matching oral capsule containing placebo
218886055|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
218886056|NCT01581398|DRUG|Pegasys|sc, qw, 24 weeks.
218886057|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
218886058|NCT01581398|DRUG|Pegasys|sc, qw, 48 weeks.
218886059|NCT02195375|DRUG|Flutiform 500/20 µg BID|
218886060|NCT02195375|DRUG|Flutiform 250/10 µg BID|
218886061|NCT02195375|DRUG|Seretide Accuhaler 50/500 µg BID|
219029838|NCT03067181|DRUG|Cisplatin|Given IV
218886062|NCT04930900|DRUG|ARS-1 with URTI|ARS-1
218886063|NCT04930900|DRUG|ARS-1 without URTI|ARS-1 without URTI
219029839|NCT03067181|PROCEDURE|Computed Tomography|Undergo a CT scan
219029840|NCT03067181|DRUG|Etoposide|Given IV
218886064|NCT06206161|BEHAVIORAL|Indicated Prevention, Clinical Staff|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
219029841|NCT03067181|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219029842|NCT03067181|OTHER|Pharmacogenomic Study|Correlative studies
219029843|NCT03067181|PROCEDURE|Pulmonary Function Test|Undergo a pulmonary function test
219029844|NCT03067181|OTHER|Quality-of-Life Assessment|Ancillary studies
219029845|NCT03067181|OTHER|Questionnaire Administration|Ancillary studies
219029846|NCT05030298|RADIATION|Radiation Therapy|Undergo radiation therapy
219029847|NCT05030298|RADIATION|Radiosurgery|Undergo radiosurgery
219029848|NCT05030298|PROCEDURE|Stereotactic Biopsy|Undergo MRI-guided stereotactic biopsy
219029849|NCT05030298|DRUG|Temozolomide|Drug
219029850|NCT05030298|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTF
219029851|NCT05030298|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219029852|NCT05030298|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219029853|NCT05030298|PROCEDURE|Biopsy|Undergo biopsy
219029854|NCT05030298|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219029855|NCT05784506|OTHER|Macronutrients|Four successive food tolerance tests (glucose, protein, butter and olive oil) at one-week intervals.
219029856|NCT05784506|OTHER|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
219029857|NCT04165798|DIAGNOSTIC_TEST|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
219029858|NCT04165798|PROCEDURE|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
219029859|NCT04165798|PROCEDURE|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)"
219029860|NCT04591574|BIOLOGICAL|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
219029861|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
219029862|NCT04965545|DIETARY_SUPPLEMENT|low copper diet|All patients with wilson disease should receive low copper diet
219029863|NCT04859751|DRUG|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
219029864|NCT00703612|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
219029865|NCT04585087|OTHER|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
219029866|NCT05869604|BEHAVIORAL|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
219029867|NCT05869604|OTHER|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
219029868|NCT05087147|DEVICE|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
219507125|NCT03954028|PROCEDURE|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
219507126|NCT00508378|BEHAVIORAL|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
219507127|NCT00508378|BEHAVIORAL|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
219507128|NCT01643083|DRUG|Rifaximin|Rifaximin 400mg tid for 2 wk
219507129|NCT01643083|DRUG|Placebo|Placebo for 2 week
219507130|NCT05544383|BEHAVIORAL|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
219507131|NCT05544383|OTHER|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
218886065|NCT06206161|BEHAVIORAL|Selective Prevention|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
219201687|NCT06866899|PROCEDURE|Local Anesthesia|Wide awake local anesthesia no tourniquet
219201688|NCT06865807|PROCEDURE|PDS 2/0 vs Monomax 2/0|We will include in the study patients who require an emergency midline laparotomy by the General and Digestive Surgery Department of the University Hospital Nuestra Señora de Candelaria. Patients will be randomized based on their medical record number: those with an even number will undergo laparotomy closure using PDS 2/0, and those with an odd number will receive Monomax 2/0.
219507132|NCT03449628|DIETARY_SUPPLEMENT|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
219507133|NCT03449628|DIETARY_SUPPLEMENT|PLACEBO|1 capsule, b.i.d. for 12 weeks
219507134|NCT02843074|DRUG|elotuzumab|Given intravenously (IV)
219507135|NCT02843074|DRUG|Lenalidomide|Given by IV
219507136|NCT02843074|DRUG|Dexamethasone|Given orally (PO) or by IV
219507137|NCT02843074|PROCEDURE|autologous stem cell transplantation|
219507138|NCT00059995|BIOLOGICAL|iratumumab|
219507139|NCT01832090|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
219507140|NCT05049889|OTHER|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
218886066|NCT06206161|BEHAVIORAL|Expanded Paraprofessional Workforce|Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
218886067|NCT03109639|DEVICE|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
218886068|NCT03109639|DEVICE|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
218886069|NCT00034086|DRUG|Lopinavir/Ritonavir|
218886070|NCT00034086|DRUG|Lamivudine/Zidovudine|
218886071|NCT00034086|DRUG|Tenofovir disoproxil fumarate|
218886072|NCT00034086|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
218886073|NCT00034086|DRUG|Lamivudine|
218886074|NCT00034086|DRUG|Stavudine|
218886075|NCT00034086|DRUG|Zidovudine|
218886076|NCT00034086|DRUG|Didanosine|
218886077|NCT00034086|BIOLOGICAL|Lyme Disease Vaccine Recombinant OspA|
218886078|NCT00034086|BIOLOGICAL|Haemophilus B Conjugate Vaccine|
218886079|NCT05206760|PROCEDURE|Brain biopsy|Biopsy of brain tissue
218886080|NCT04590573|BEHAVIORAL|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
218886081|NCT02134444|BEHAVIORAL|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
218886082|NCT02134444|BEHAVIORAL|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
218886083|NCT06248333|DEVICE|STN-DBS ON|Stimulation ON
218886084|NCT06248333|DEVICE|STN-DBS OFF|Stimulation OFF
218886085|NCT06433479|DRUG|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
218886086|NCT05017467|DRUG|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
218886087|NCT01821859|DRUG|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
218886088|NCT01821859|DRUG|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
218886089|NCT05383456|DIAGNOSTIC_TEST|Diagnostic Test|Standard diagnostic tests.
218886090|NCT05383456|DRUG|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
218886091|NCT00203424|DRUG|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
218886092|NCT04741919|PROCEDURE|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
218886093|NCT05844267|BEHAVIORAL|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
219201689|NCT06865937|BEHAVIORAL|Mobile Intervention for Social Recovery in Serious Mental Illness|mSITE is a blended intervention that integrates a brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. Participants will attend weekly, in-person sessions for 8 weeks and then 15-minute, remote coaching sessions for 10 weeks. The intervention begins with setting a meaningful recovery goal and then the generic cognitive model is introduced and a simple thought challenging skill is trained to specifically address social avoidance behaviors and facilitate work toward recovery goals. Defeatist attitudes, social threat and avoidance behaviors that interfere with working on the goal are then modified using CBT skills and practiced using role-plays.
219201690|NCT06865937|BEHAVIORAL|Supportive Contact|The SC arm will match the mSITE arm on the same amount of individual in-person and coaching, and mobile device contact. Coaching sessions will be semi-structured and consist of setting recovery goals, check-in about symptoms and potential crisis management, flexible discussion involving psychoeducation, instructions for accessing community crisis lines and community resources, and symptom management behaviors that grow out of discussions, with only minimal therapist guidance.
219507141|NCT05049889|OTHER|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
219507142|NCT05049889|DEVICE|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
219507143|NCT05049889|DEVICE|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
218886094|NCT05844267|BEHAVIORAL|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
218886095|NCT05796895|BEHAVIORAL|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
218886096|NCT05796895|BEHAVIORAL|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
218886097|NCT01053988|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
218886098|NCT01053988|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
218886099|NCT01053988|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
219507144|NCT05049889|BIOLOGICAL|Blood collection|Several blood samples will be collected at visit 1 and 2.
219507145|NCT02343887|OTHER|neuropsychological tests|
219507146|NCT02343887|OTHER|STAI-Y scale for anxiety|
219507147|NCT02343887|OTHER|Beck scale for depression|
219507148|NCT02343887|OTHER|without intervention|
218886100|NCT01053988|DRUG|Placebo|Placebo
218886101|NCT04385459|OTHER|Coronary artery disease|Exposure
218886102|NCT06412783|DIAGNOSTIC_TEST|blood test|performing blood tests on the participants for specific markers.
218886103|NCT00013741|BEHAVIORAL|Tailored Education Messages|
218886104|NCT01824355|DEVICE|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
218886105|NCT06852859|PROCEDURE|Transurethral resection of the prostate|Thermocoagulation is used in contrast to the other methods
218886106|NCT06852859|PROCEDURE|Transurethral vaporization of the prostate|Heat is used to vaporize prostate
219507149|NCT00947856|DRUG|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
218886107|NCT06852859|PROCEDURE|GreenLight laser enucleation of the prostate|laser is used in contrast to the other methods
218886108|NCT05490030|DRUG|TNO155|Single oral dose of TNO155 on Day 1
218886109|NCT06419504|OTHER|SAP block group|US-guided SAP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
218886110|NCT06419504|OTHER|PECS II block group|US-guided PECS II block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
218886111|NCT06419504|OTHER|ESP block group|US-guided ESP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
218886112|NCT06419504|OTHER|Control group|No intervention
218886113|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
218886114|NCT04406649|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
218886115|NCT04763941|DIAGNOSTIC_TEST|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
219029869|NCT05087147|DEVICE|Banded space maintainer|band and loop space maintainer
219029870|NCT06961266|DRUG|JZP441|Administered orally
219029871|NCT06961266|DRUG|Matching Placebo|Administered orally
219029872|NCT06962826|DRUG|Empagliflozin|Empagliflozin
219029873|NCT02301273|OTHER|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
219029874|NCT02301273|OTHER|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
219029875|NCT06538818|DEVICE|Ultra Phonophoresis|"Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks."
219029876|NCT06138730|BEHAVIORAL|Appa Complete|Weekly mentorship meetings \& guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
219029877|NCT06138730|BEHAVIORAL|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
219029878|NCT04343521|OTHER|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
219507150|NCT01536756|OTHER|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
218886116|NCT04806737|DRUG|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
218886117|NCT02576795|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
218886118|NCT04742361|DRUG|[18F]PSMA-1007|diagnostic radiopharmaceutical for PET scan
219201691|NCT06866951|DRUG|Chemo-immunotherapy|"Post-radical surgery for cervical cancer, the first cycle of PD-1 inhibitor combined with chemotherapy will begin 2 to 3 weeks after surgery. Each treatment cycle lasts 21 days, with a total of 6 cycles. A complete imaging efficacy evaluation will be conducted after every 3 treatment cycles. For patients with lymph node metastasis ≥3 or para-aortic lymph node metastasis, 6 cycles of chemotherapy combined with immunotherapy will be administered. Other patients will receive 3 cycles of chemotherapy combined with immunotherapy.~Treatment regimen:~Day 1:~Paclitaxel (albumin-bound) for injection: 260 mg/m², administered intravenously over 30 minutes.~Day 1 to Day 2:~Cisplatin 75-80 mg/m², administered intravenously at a 1 mg/min rate.~Day 3:~PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes."
219201692|NCT06866951|RADIATION|CCRT|"The overall chemoradiotherapy (including EBRT and brachytherapy) should typically be completed within 6 weeks (with a maximum extension to 10 weeks in case of anticipated delays). External beam radiotherapy (EBRT) should be at least three-dimensional conformal radiotherapy, with image-guided (CT or MR) intensity-modulated conformal radiotherapy techniques recommended, at a 45-50 Gy dose.~Concurrent Chemotherapy:~Cisplatin (40 mg/m²) is preferred on a weekly schedule (administered before the planned EBRT on the same day, once a week \[±1-day window\], for a total of 5-6 infusions). Carboplatin can be used as an alternative if cisplatin toxicity is not tolerated."
219607524|NCT06469632|OTHER|Active Comparator: Experimental Group 1|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique."
219607525|NCT06469632|OTHER|Experimental: Experimental Group 2|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.~Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes."
219607526|NCT04358952|DIAGNOSTIC_TEST|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
219607527|NCT04237935|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
219607528|NCT04237935|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
219201693|NCT06862765|PROCEDURE|transcatheter tricuspid valve replacement|The LuX-valve was implanted under fluoroscopic and echocardiographic guidance via the transjugular vein approach. Once the delivery system was introduced, it was adjusted within the right heart chamber to be perpendicular to the tricuspid annulus. The anterior leaflet was grasped using two leaflet graspers, and the ventricular portion of the device component was gradually released. After deploying the atrial disc to ensure the elimination of TR, septal anchoring was performed, and the delivery system was subsequently withdrawn.
219201694|NCT06865794|OTHER|Questionnaire and Physical Exam|Rosenberg self-esteem scale pre-operatively, at 3 and 12 months post-op
219201695|NCT06865794|OTHER|Questionnaire and Physical Exam|FACE-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
218886119|NCT05650905|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
218886120|NCT05650905|DEVICE|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
218886121|NCT05650905|DEVICE|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
218886122|NCT05650905|DEVICE|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
218886123|NCT05650905|DIAGNOSTIC_TEST|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
218886124|NCT06967792|DEVICE|Terahertz (THz) scanning using THz Imaging system.|The Terahertz (THz) scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
218886125|NCT01897948|OTHER|Milk-based beverage without DHA|
218886126|NCT01897948|OTHER|Milk-based beverage with DHA at mid level|
218886127|NCT01897948|OTHER|Milk-based beverage with DHA at high level|
218886128|NCT03830346|OTHER|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
218886129|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
218886130|NCT04427072|DRUG|Capmatinib|400 mg, capmatinib tablets, administered orally twice daily
218886131|NCT04427072|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 by intravenous infusion every 21 days
218886132|NCT02284087|DEVICE|PAS|
218886133|NCT05232864|DRUG|Secukinumab|300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
218886135|NCT06975241|DIETARY_SUPPLEMENT|EPA 2.4g/day|EPA from fish oil will be supplemented to an equal number of males and females for 12 weeks.
218886136|NCT06974708|OTHER|Home Healthcare Virtual Simulation Training System|Interactive Virtual Occupational Safety Training Software Program for Home Healthcare Workers and Agencies
218886137|NCT06975215|DEVICE|Concomitant embolization|This will include EVAR, following the standard pathway of care, associated with embolization. The decision to perform side-branch embolization or aneurysm sac embolization will be left to each participating centre/physician.
218886138|NCT06975215|PROCEDURE|EVAR|Endovascular aortic aneurysm repair
219029879|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
219029880|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
219029881|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
219029882|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
219029883|NCT00301210|DRUG|Tramadol|oral doses four times per day
219029884|NCT01917201|PROCEDURE|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
219029885|NCT01917201|PROCEDURE|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
219029886|NCT03405779|PROCEDURE|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
219029887|NCT05679518|BEHAVIORAL|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
219029888|NCT05679518|BEHAVIORAL|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
219029889|NCT05679518|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
218886139|NCT06976385|DIETARY_SUPPLEMENT|White tea|White tea mouth rinse applied topically twice daily.
218886140|NCT06976385|DIETARY_SUPPLEMENT|Wheat grass solution|wheat grass solution mouth rinse applied topically twice daily.
218886141|NCT06976671|DRUG|Bevacizumab|intra-articular bevacizumab
218886142|NCT06974578|PROCEDURE|phacoemulsification|cataract extracton with phacoemulsification
218886143|NCT06974578|DEVICE|CTR|insertion of capsualr tension ring
218886144|NCT06974578|DEVICE|hydrophilic IOL|implantation of hydrophilic IOL
218886145|NCT06974578|DEVICE|Hydrophobic IOL|insertion of hydrophobic IOL
218886146|NCT06976866|PROCEDURE|implant surgery|surgery
218886147|NCT06976333|DIAGNOSTIC_TEST|Tumor-infliltrating lymphocyte (TIL) percentage|TIL percentage was calculated as the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]
219507151|NCT01536756|OTHER|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
219507152|NCT05332210|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
219507153|NCT04202900|OTHER|phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
219507154|NCT01075620|DEVICE|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
219507155|NCT01075620|DEVICE|LPS RP|non-posterior stabilized rotating platform design
218886148|NCT06976333|DIAGNOSTIC_TEST|Grey level co-occurrence matrix (GLCM)|The GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterized more structured images with distinct TIL patterns.
219507156|NCT01211769|DRUG|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
219507157|NCT01211769|DRUG|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
218886149|NCT06976333|DIAGNOSTIC_TEST|Fractal dimension (FD)|Quantification of the complexity of TIL
218886150|NCT05723263|BEHAVIORAL|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
218886151|NCT05723263|BEHAVIORAL|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
219029890|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
219029891|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
219029892|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
219029893|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
219029894|NCT00107198|PROCEDURE|Conventional Surgery|Undergo surgery
219029895|NCT00107198|DRUG|Cyclophosphamide|Given IV
219029896|NCT00107198|DRUG|Doxorubicin Hydrochloride|Given IV
219029897|NCT00107198|DRUG|Prednisone|Given IV or PO
219029898|NCT00107198|RADIATION|Radiation Therapy|Undergo IFRT
219029899|NCT00107198|DRUG|Vincristine Sulfate|Given IV
219201696|NCT06865794|OTHER|Questionnaire and Physical Exam|BREAST-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
219201697|NCT06865794|OTHER|Questionnaire and Physical Exam|BSIQ-SF pre-operatively, at 3 and 12 months post-op
219507158|NCT01211769|DRUG|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
219507159|NCT01211769|DRUG|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
218886152|NCT05723263|OTHER|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 U.S. Dollars (USD) per test) and no community engagement component
218886153|NCT06975111|DRUG|Metformin|Metformin will be given to participants who have a elevated HbA1c and also for weightloss.
218886154|NCT06975111|DRUG|semaglutide|Overweight women and women with obesity will take Semaglutide for weight-loss
219507160|NCT00349063|DEVICE|soft contact lens|
219507161|NCT00349063|DRUG|Soft contact lens multipurpose disinfection regimen|
219507162|NCT06383559|DRUG|Lenvatinib and Sintilimab|XELOX regimen combined with Sintilimab and Lenvatinib
219507163|NCT05053893|DRUG|Roxadustat;Sacubitril Valsartan Sodium Tablets;|Select the appropriate dose according to the patient's situation
218886155|NCT06975111|DRUG|Anti-hypertensives|a. Antihypertensives, with the goal of maintaining blood pressure at 130/80 or lower per ACC guidelines19. Per current clinical guidelines and standard of care, hypertension will be treated first with monotherapy using either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium channel blocker, or a thiazide diuretic provided that are no contraindications.
218886156|NCT06975111|DRUG|Lipid Lowering Medication|. First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.
218886157|NCT06975111|BEHAVIORAL|Life style intervention|will simply be followed and given preventive advice (maintenance of a normal BMI and physical activity, moderation in salt intake, and no more than 1 alcoholic drink per day). They will be provided with a wearable activity monitor. This advice will be based on guidelines by the American Heart Association and the Menopause Society.
218886158|NCT06975111|DRUG|Fezolinetant|Women with menopausal symptoms will be treated with hormone therapy (estrogen and progesterone) if appropriate, or with a neurokinin receptor antagonist (Fezolinetant). This can be treatment for women in any arm of the study as well as an arm by its self.
218886159|NCT06975111|DRUG|Hormonal therapy|Participants will be treated with estrogen and/or progesterone for treatment of hot flashes in women during the study.
218886161|NCT06974669|DRUG|oral steroid-dexamethasone|this study is the first according to the best of our knowledge assessing the value of adding mini oral pulse steroid therapy to non cultured epidermal suspension in treatment of stable acral and difficult to treat vitiligo
218886162|NCT06974669|PROCEDURE|non cultured epidermal suspension|this is the best surgical technique for surgical treatment of vitiligo that would be done for both arms
218886163|NCT00870987|BIOLOGICAL|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
218886164|NCT00870987|BIOLOGICAL|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
218886165|NCT03812315|COMBINATION_PRODUCT|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
218886166|NCT03812315|COMBINATION_PRODUCT|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
218886167|NCT03427723|DEVICE|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
219029900|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
219029901|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
219507164|NCT05053893|DRUG|EPO; ACEI / ARB|Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
219507165|NCT04978285|OTHER|Anemia|Depends on Day 3 Hb result
218886168|NCT03427723|OTHER|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
218886169|NCT06009835|OTHER|Recommended treatment plan|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
218886170|NCT06356922|DRUG|Experimental drug [177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
218886171|NCT06974890|OTHER|Shuttle Balance Training|Shuttle balance training is a form of dynamic balance exercise that uses a shuttle system-often a platform or track with resistance bands or gliders-to help improve stability, coordination, and strength. In children, this type of training plays a significant role in enhancing gait, balance, and posture by engaging core and lower limb muscles in controlled, functional movements. It encourages proprioceptive development, helping children become more aware of their body's position in space, which is crucial for maintaining upright posture and walking efficiently. Through repetitive and playful activities, shuttle balance training can aid in correcting abnormal gait patterns, improving postural alignment, and boosting confidence in physical activities.
219029902|NCT03916627|DRUG|fianlimab|Administered IV
219029903|NCT06554795|DRUG|DB-1419|Administered Injection of Vein (I.V.)
219029904|NCT02788461|RADIATION|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
219029905|NCT02788461|RADIATION|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
219029906|NCT04131634|RADIATION|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
219029907|NCT02053467|OTHER|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
219507166|NCT02659878|PROCEDURE|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
219201698|NCT06865794|OTHER|Questionnaire and Physical Exam|FLZ psychological sub-scale pre-operatively, at 3 and 12 months post-op
219507167|NCT05727293|OTHER|noting|Non intervention
219507168|NCT00270699|BIOLOGICAL|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
219507169|NCT00270699|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-200,201
219507170|NCT04639687|BEHAVIORAL|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
219507171|NCT01348542|DRUG|Trazodone|50 mg once a day, for 3 months
218886172|NCT06974890|OTHER|Baseline Treatment|"Baseline treatment sets a foundation for managing the patient's condition effectively. It ensures that the patient receives appropriate care based on current medical knowledge and guidelines, with the goal of improving health outcomes and quality of life. Duration of session will be 45 min and 3 sessions per week.~Control Group Considerations: Clarifying how participants assigned to the control group will receive standard care or placebo intervention to maintain ethical standards and enable comparison with the intervention group."
218886173|NCT06975332|RADIATION|Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)|Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.
218886174|NCT06976996|DRUG|normal saline|normal saline (0.15 ml/kg)
218886175|NCT06976996|DRUG|esketamine|esketamine (0.15 mg/kg)
218886176|NCT06976996|DRUG|propofol|propofol (2 mg/kg)
218886177|NCT06976996|DRUG|etomidate-ciprofol (EC) mixture|etomidate-ciprofol (EC) mixture (0.2 ml/kg)
218886178|NCT06976996|DRUG|ciprofol|ciprofol (0.5 mg/kg)
219507172|NCT01348542|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
219507173|NCT00038519|DRUG|Amprenavir/ritonavir|
219507174|NCT00038519|DRUG|Saquinavir/ritonavir|
219507175|NCT03409679|DRUG|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
219507176|NCT03409679|DRUG|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
219507177|NCT04996810|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
219507178|NCT04996810|BIOLOGICAL|Botox®|Botulinum toxin Type A
219607529|NCT01168752|DRUG|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
219607530|NCT02986477|OTHER|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
218886179|NCT06976996|DRUG|etomidate-propofol (EP) mixture|etomidate-propofol (EP) mixture (0.2 ml/kg)
218886180|NCT06976931|DRUG|YY2201|This is a multicenter, open-label, dose-escalation phase I study. participants will receive one single target dose of YY2201 on Cycle 0 Day 1 (C0D1) to observe safety and collect PK blood samples up to 48 h post-dose. On the third day after the first dose (Cycle 1 Day 1, C1D1), subjects will start to receive multiple doses of YY2201 orally twice daily (approximately 12 h interval) for 3 days followed by 4 days off in a 21-days treatment cycle.
218886181|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
218886182|NCT06078059|OTHER|Knee aspiration|Knee aspiration
218886183|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
218886184|NCT03375489|OTHER|Telehealth Palliative Care|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
218886185|NCT03375489|OTHER|In-person Palliative Care|"In-person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
218886186|NCT06975202|OTHER|No intervention|No intervention
218886187|NCT04283097|DRUG|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
218886188|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
218886189|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
218886190|NCT05370443|BEHAVIORAL|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
219507179|NCT04866485|DRUG|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
219507180|NCT00884130|PROCEDURE|laparoscopic colorectal resection|
219507181|NCT00884130|PROCEDURE|open colorectal resection|
219507182|NCT03402893|DRUG|ONEXTON Topical Gel|Onexton gel applied once daily to face
218886191|NCT04140045|OTHER|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
218886192|NCT05010603|GENETIC|Blood Draw|Collection of blood samples for genetic testing
218886193|NCT05010603|OTHER|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
219029908|NCT02127242|PROCEDURE|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
219029909|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
219507183|NCT00852085|BEHAVIORAL|Enhanced community service|Two educational sessions and volunteering at a local community service site
219507184|NCT00852085|BEHAVIORAL|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
219507185|NCT00016055|BIOLOGICAL|lymphokine-activated killer cells|
219607531|NCT00000691|DRUG|Foscarnet sodium|
219607532|NCT04663191|PROCEDURE|anatomical resection|Anatomical resection with systematic lymph-node dissection
218886194|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
219029910|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
219201699|NCT06868017|DRUG|Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses|Cohort A will receive initumab at initial load dose of 8mg/kg and maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 4 cycles of administration
219201700|NCT06868017|DRUG|Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses|The initial loading dose of initumab was 8mg/kg, and the maintenance dose was 6mg/kg, which was administered intravenously on the first day of every three weeks. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 6 cycles of administration
219201701|NCT06865924|OTHER|Use of assembloids as in vitro models to test new pharmacological approaches|Using extracellular vesicles containing the CRISPR/Cas9 genome editing system that by faithfully reproducing the in vivo part will allow a more faithful response than the use of conventional 2D model, organoids or animal model.
219201702|NCT06866496|BEHAVIORAL|Motivational interviews|Three short and structured motivational enhancement interviews to aid alcohol cessation.
219201703|NCT06866496|OTHER|Standard of Care (SOC)|Standard of care including medical treatment of decompensation, nutrition support, medical treatment of alcohol withdrawal symptoms and craving
219201704|NCT06867016|OTHER|Combined Cognitive & Aerobics Training|The ACT combined training will consist of simultaneous aerobic exercise and cognitive training in a dual-task format, conducted twice a week for 8 weeks. The aerobic training (AT) will consist of twice-weekly sessions that include yoga, brisk walking, pedaling exercises, and step aerobics, alongside cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, 4th week, and 8th week.
219507186|NCT00016055|DRUG|temozolomide|
219507187|NCT04139174|PROCEDURE|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
219507188|NCT05197010|OTHER|Home based exercise program via a smartphone application|Daily home based exercise program (30min/day, 7days/week for 6 weeks).
219507189|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
219507190|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
219507191|NCT00926289|DRUG|Hydrochlorothiazide|Hydrochlorothiazide25mg
219507192|NCT00981604|PROCEDURE|SILS|Single Incision Laparoscopic Cholecystectomy
219507193|NCT00981604|PROCEDURE|Standard Laparoscopic Cholecystectomy|4 port technique
219607533|NCT04388553|PROCEDURE|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
219607534|NCT02123446|DRUG|Cephalexin|Administered orally.
219507194|NCT01555606|OTHER|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
219607535|NCT04604795|DRUG|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
219607536|NCT04604795|DRUG|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
219607537|NCT04604795|DRUG|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
219029911|NCT04592913|DRUG|Durvalumab|Human monoclonal antibody
219029912|NCT04592913|DRUG|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
219029913|NCT02143609|DRUG|oxygen|Nocturnal nasal oxygen during stay at 2048 m
219029914|NCT02143609|DRUG|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
219029915|NCT01948973|DEVICE|Subsensory|The stimulation is here set to 90% of the sensory threshold
219029916|NCT01948973|DEVICE|OFF|The stimulation is here turned OFF
219507195|NCT03361514|BEHAVIORAL|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
219607538|NCT04604795|DRUG|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
219607539|NCT04604795|OTHER|Water|Participants will be administered with GSK3915393 along with water orally
219607540|NCT04604795|OTHER|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
219607541|NCT01000948|DRUG|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
219029917|NCT01948973|DRUG|Suprasensory|The stimulation is here set suprasensory
219029918|NCT04466540|DRUG|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
219029919|NCT04466540|DRUG|Placebo|Hydroxychloroquine placebo
218886195|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
218886196|NCT03591315|DIAGNOSTIC_TEST|resting state fMRI|Define the visual resting state network.
219507196|NCT03361514|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
218886197|NCT03591315|DIAGNOSTIC_TEST|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
218886198|NCT03591315|DIAGNOSTIC_TEST|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
218886199|NCT03591315|DIAGNOSTIC_TEST|automated visual field|Identify the existence and type of visual field defect.
218886200|NCT03591315|DIAGNOSTIC_TEST|visual acuity|Assess the visual acuity by using ETDRS scales.
219201705|NCT06867016|OTHER|Cognitive Training|Cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, the 4th week, and the 8th week.
219201706|NCT06867796|DRUG|TL-001|Intravenously administered
219201707|NCT06867796|DRUG|Placebo|Intravenously administered
219201708|NCT06867536|DRUG|Glofitamab + Obinutuzumab|"Obinutuzumab An initial 1000 mg dose of obinutuzumab will be administered as pretreatment 7 days prior to the first glofitamab step-up dose~Glofitamab:~Glofitamab was administered intravenously as step-up doses on day 8 (2.5 mg) and day 15 (10 mg) of cycle 1, followed by a dose of 30 mg on day 1 of cycles 2 through 8, maximum of 12 cycles (Q3W). The efficacy is evaluated after 2 cycles of glofitamab. Those with disease progression will be withdrawn from the study. The remaining patients continue with an additional two cycles of glofitamab (4 cycles in total) and then perform efficacy assessment. If the patients achieve a CR or PR, they will continue to complete the remaining treatment as planned. Patients are recommended to treat for 12 cycles (at least 8 cycles, depending on tumor regression in patients) or until disease progression or unacceptable toxicity, whichever occurs first"
219201709|NCT04130789|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
219201710|NCT04130789|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
219201711|NCT01960751|OTHER|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
218886201|NCT06706219|DRUG|Sacituzumab tirumotecan plus pembrolizumab|"Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients."
218886202|NCT01350245|RADIATION|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
218886203|NCT01350245|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
218886204|NCT01350245|DRUG|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
218886205|NCT01350245|DRUG|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
218886206|NCT01350245|DRUG|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
218886207|NCT01350245|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
218886208|NCT04351724|DRUG|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
218886209|NCT04351724|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
218886210|NCT04351724|OTHER|Best standard of care|best standard of care
219201712|NCT06878274|RADIATION|Post-operative radiotherapy|Mediastinal post-operative radiotherapy to a dose of 40 Gy in 15 fractions
218886211|NCT04351724|DRUG|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
218886212|NCT04351724|DRUG|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
218886213|NCT04351724|DRUG|Candesartan|starting dose 4mg once daily, titrated to normotension
219201713|NCT06675162|OTHER|Pilates Reformer Training|Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
219201714|NCT04335682|DRUG|Darolutamide|Patients randomized to darolutamide.
219201715|NCT04335682|DRUG|Enzalutamide|Patients randomized to enzalutamide.
219201716|NCT06673758|OTHER|tai chi exercises|tai chi exercises of three basic levels will be given with sessions of two weeks five time a day and follow efftects of tai chi exercises by 6minute walk test and time up and go test and check the results before and after exercises
219201717|NCT06673758|OTHER|Art and crafts activity|Art and crafts activity will be given to control group and check cardiorespiratory fitness before and after arts and crafts activity
219201718|NCT06673927|DRUG|YZJ-1139|Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
219201719|NCT06673927|DRUG|YZJ-1139|Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
219201720|NCT06673927|DRUG|Placebo|Placebo administration
219201721|NCT05257356|BEHAVIORAL|psychophysical tasks|"Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
219201722|NCT03076021|DRUG|Isotretinoin|Drug interaction study
219201723|NCT03076021|DRUG|dextromethorphan|Drug interaction study
219201724|NCT06681233|DEVICE|Comparison of HyperSight CBCT imaging to conventional CBCT imaging.|Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.
219201725|NCT06680141|OTHER|Virtual reality glasses|control group
219201726|NCT05451810|DRUG|Epcoritamab|Subcutaneous Injection (SC)
219201727|NCT06680284|OTHER|Staff Education Program|A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
219201728|NCT06681428|OTHER|Allograft|Placental-based Allografts
219201729|NCT06679816|DRUG|Hormone replacement therapy|Perioperative Hydrocortisone Reduction Therapy
219201730|NCT06679816|DRUG|Placebo|Perioperative placebo Reduction Therapy
219201731|NCT06483256|DIAGNOSTIC_TEST|radiographic control|Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
218886214|NCT04351724|DRUG|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
219201732|NCT02311959|PROCEDURE|Nipple sparing mastectomy|"Standardized surgical procedure by :~* Nipple sparing mastectomy with nipple core histopathology.~* Immediate breast reconstruction (flap and/or implant).~* +/- lymph node evaluation (sentinel node procedure or axillary dissection)."
218886215|NCT04351724|DRUG|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
218886216|NCT04351724|DRUG|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
218886217|NCT04351724|DRUG|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
218886218|NCT04351724|DRUG|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
218886219|NCT04351724|DRUG|Pentaglobin|7ml/kg/day for 12h for 5 days
219201733|NCT05227352|BEHAVIORAL|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
219201734|NCT05254314|DRUG|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
219201735|NCT05254314|OTHER|Placebo|Once weekly subcutaneous injection
219201736|NCT05256472|DRUG|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
219201737|NCT05256472|DRUG|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
219201738|NCT04704700|DEVICE|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
219201739|NCT04704700|DEVICE|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
219201740|NCT03856528|OTHER|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
219201741|NCT06138184|BEHAVIORAL|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
219201742|NCT06138184|BEHAVIORAL|Control Group: Standard of Care|This will be the current practice for patient education
219201743|NCT06676371|PROCEDURE|Conventional hemiarch replacement|Conventional open hemiarch replacement
219201744|NCT06676371|PROCEDURE|E-vita® Open Neo; Artivion|E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.
219607542|NCT02831426|DEVICE|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
219607543|NCT02831426|DEVICE|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
218886220|NCT06842901|DEVICE|Portable Rehabilitation (PoRi) device|Once the calibration is complete, the device moves the fingers to close and open the hand for a total of 20 minutes.
218886221|NCT02104947|DRUG|idarucizumab|idarucizumab
218886222|NCT05998577|DEVICE|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
218886223|NCT00883441|OTHER|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
218886224|NCT02610452|OTHER|Clown therapy|"The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
218886225|NCT04846465|OTHER|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
218886226|NCT00145574|DRUG|colesevelam HCl|Tablets
218886227|NCT00145574|DRUG|placebo|Matching Tablets
218886228|NCT03998969|DRUG|Pantoprazole|Pantoprazole 40mg tablet
218886229|NCT03998969|DRUG|DA-5204|DA-5204 tablet
218886230|NCT03998969|DRUG|Placebo|Film-coated tablet manufactured to mimic DA-5204
219029920|NCT03451149|DEVICE|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
219029921|NCT00725556|OTHER|Speech Therapy|Speech Therapy
219029922|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
219029923|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
219040372|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
219040373|NCT06697496|DEVICE|QuitBot Smoking Cessation Chatbot Program|Participate in Quitbot chatbot program
219040374|NCT06697496|DEVICE|QuitBot Smoking Cessation Text Messaging Program|Participate in Quitbot texting program
219040375|NCT06697496|OTHER|Survey Administration|Ancillary studies
219040376|NCT06697496|OTHER|Interview|Ancillary studies
219507197|NCT05551377|OTHER|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
219507198|NCT01000857|DRUG|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
219507199|NCT02273674|DEVICE|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
219507200|NCT02273674|DEVICE|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
219507201|NCT01297257|DEVICE|Stent implantation|Single arm, open label stent implantation
219507202|NCT00146770|BIOLOGICAL|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
219507203|NCT00146770|BIOLOGICAL|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
219507204|NCT00146770|BIOLOGICAL|placebo|Placebo for 26 weeks
219507205|NCT02478060|BIOLOGICAL|Birch-SPIRE|
219507206|NCT02478060|BIOLOGICAL|Placebo|
219507207|NCT01398579|PROCEDURE|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
219507208|NCT01789008|OTHER|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
218886231|NCT02021955|BEHAVIORAL|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
218886232|NCT03727906|OTHER|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
218886233|NCT03727906|OTHER|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
218886234|NCT03727906|OTHER|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
218886235|NCT00001317|DRUG|interferon-gamma|
218886236|NCT03002714|OTHER|Exercise|
218886237|NCT01366885|DRUG|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
218886238|NCT05386693|PROCEDURE|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
219040377|NCT06697496|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
219040378|NCT06877520|DEVICE|Pivot Extend Tricuspid Regurgitation Spacer Device|The Pivot Extend Tricuspid Regurgitation Spacer Device is an investigational implant designed to reduce tricuspid regurgitation (TR) by occupying the regurgitant orifice and improving leaflet coaptation. The device is implanted via a transcatheter procedure under imaging guidance. Following implantation, participants will undergo post-procedural monitoring for at least 24 hours to ensure safety and device stability. The device is intended for long-term placement, with scheduled follow-up assessments at designated intervals over a 12-month period to evaluate its safety and efficacy. Device removal may be performed if adverse events occur or if deemed necessary by the investigator.
219040379|NCT06878872|BEHAVIORAL|T1DAL Program|T1DAL is a 16-week behavioral program. Teens meet in virtual groups and individually with a health coach throughout the program. Teens learn healthy lifestyle behaviors specific to living with type 1 diabetes and get opportunities to connect with other teens who are living with type 1 diabetes.
219040380|NCT06879106|OTHER|Intervention group|"The Mindfulness-Based Cognitive Therapy (MBCT) intervention is an educational program consisting of the themes Mindfulness and Autopilot, Living in Our Mind, Focusing the Distracted Mind, Recognizing Hate, Allowing, Thoughts Are Not Real, How Can I Best Take Care of Myself, and Sustaining and Expanding New Learning."
219040381|NCT07030322|DEVICE|Overground Robotic Exoskeleton|Participants will have received training on their personal exoskeleton device prior to data collection. There is no required use dosage of the Ekso Indego Personal for this observational study.
219040382|NCT06880601|DRUG|Teclistamab|"Participants are planned to receive Te monotherapy during the first 5 cycles of treatment (1 cycle= 28 days) Participants will receive Te sc monotherapy consisting of 2 step-up doses (0.06 and 0.3 mg/kg) followed by a weekly treatment dose of 1.5 mg/kg for the first 2 cycles From cycle 3 Day 1, participants will receive Te sc Q2W at the dose of 3 mg/kg- From cycle 7 Day 1, participants will receive Te sc Q4W at the dose of 3 mg/kg.~After cycle 5, participants in PR or better will continue treatment with Te in combination with 4 Ali infusions (cycles +6, +9, +12, +15). The four doses of ALI will be administered with increasing dosage during Te treatment as follows:~* before Te Cycle 6: ALI 10 x 10\^6/kg~* before Te Cycle 9: ALI 20 x 10\^6/kg~* before Te Cycle 12: ALI 30 x 10\^6/kg~* before Te Cycle 15: ALI 40 x 10\^6/kg~Teclistamab single agent will be continued until progression, unacceptable toxicity or patients refusal."
219040383|NCT06685887|DRUG|HIPEC|HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
219040384|NCT06685887|DRUG|SOX|Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w
219040385|NCT06685887|DRUG|Immune Checkpoint Inhibitors|Tislelizumab, 200 mg, q3w
219040386|NCT06709456|PROCEDURE|Ultrasonography-guided pleural drainage|Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
219040387|NCT06714292|PROCEDURE|Endoscopic Clipping|localization of colon lesion with fluorescent clip
219040388|NCT06714292|PROCEDURE|ICG injection|localization of colon lesion with ICG(indocyanine green) through endoscopic tattooing
218886239|NCT00858637|DRUG|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
218886240|NCT00858637|DRUG|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
218886241|NCT00858637|DRUG|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
218886242|NCT00858637|DRUG|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
218886243|NCT00289081|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
218886244|NCT00289081|DEVICE|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
218886245|NCT05813002|OTHER|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
218886246|NCT05813002|OTHER|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
218886247|NCT05813002|OTHER|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
218886248|NCT02371603|DRUG|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
218886249|NCT02371603|DRUG|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
218886250|NCT02371603|DRUG|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
218886251|NCT02371603|DRUG|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
219029924|NCT02955979|OTHER|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
219201745|NCT06676371|PROCEDURE|Thoraflex Hybrid; Terumo|The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
219507209|NCT04984850|OTHER|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
219507210|NCT04319666|DEVICE|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
219507211|NCT03867383|DRUG|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
219507212|NCT03867383|DRUG|Placebo|60 milliliters normal saline
218886252|NCT05910008|PROCEDURE|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
219507213|NCT02861352|OTHER|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
219507214|NCT03291977|DRUG|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
219507215|NCT03291977|PROCEDURE|White-light surgery|The surgery will be performed under classical conditions
219507216|NCT04185558|DEVICE|ActiGraft|Whole Blood Clot (WBC) gel
218886253|NCT05910008|PROCEDURE|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
218886254|NCT02642380|DRUG|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
218886255|NCT02642380|DRUG|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
218886256|NCT03263338|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
218886257|NCT03153995|PROCEDURE|soft tissue expansion|"Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months"
218886258|NCT04083157|BIOLOGICAL|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
218886259|NCT04083157|BIOLOGICAL|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
218886260|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
218886261|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
219201746|NCT06805188|OTHER|Acupuncture|"The intervention was performed by two licensed acupuncturists with at least 10 years of clinical experience who received two weeks of training in standardized intervention methods prior to the trial. Acupoints location refers to the WHO Standard Acupuncture Point Locations in the Western Pacific Region (WHO Standard)〔41〕.The acupuncture group will receive the following acupoints (Figure 3, Table 2): the affected side of Chize(LU5), Quchi (LI11), Dubi (ST35), Fengshi (GB31), and Xiyangguan (GB33).~Needling was performed with 0.30mm x 40mm disposable Huatuo brand sterile acupuncture needles.After the needles were inserted, needle manipulation was performed at all acupuncture points to achieve the sensations of soreness, numbness, distension, and heaviness.Each acupoint was manipulated for about 30 seconds, and the acupuncture treatment was performed for one 30-minute session."
219507217|NCT04185558|DEVICE|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
219507218|NCT05388188|DRUG|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
219507219|NCT01213719|DIETARY_SUPPLEMENT|creatine|20g/d throughout 10 days
219507220|NCT01213719|DIETARY_SUPPLEMENT|betaine|2g/d throughout 10 days
218886262|NCT00888342|DRUG|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
218886263|NCT00888342|DRUG|zopiclone|5 mg sedative given approximately 1 hour before sleep
219201747|NCT06805188|OTHER|Sham acupuncture|The device's sham needling operation mimics real needling through appearance and tactile sensation, making it difficult for patients to distinguish, meeting the requirement of blinding and effectively controlling the patients' cognitive bias towards the type of intervention. Patients in the sham acupuncture group received this sham acupuncture intervention, which was designed to ensure that only the actual biological effects of acupuncture differed between the experimental group and the control group, and to exclude the psychological implication effects caused by the patients' expectation effects or the operation itself, so as to enhance the scientific validity and reliability of the research results.
218886264|NCT00888342|OTHER|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
218886265|NCT05547308|DEVICE|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
218886266|NCT04560075|BEHAVIORAL|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
218886267|NCT04560075|BEHAVIORAL|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
218886268|NCT05311787|PROCEDURE|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
218886269|NCT05504993|OTHER|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
219507221|NCT01213719|DIETARY_SUPPLEMENT|dextrose|dextrose (placebo), 20 g/d throughout 10 days
219507222|NCT01213719|DIETARY_SUPPLEMENT|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
219507223|NCT04083014|DRUG|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
218886270|NCT05118399|DRUG|Bupivacaine Injection [Marcaine]|Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
218886271|NCT05118399|DRUG|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
218886272|NCT04924998|DRUG|current treatment of AL-CM|current treatment of AL-CM
218886273|NCT05266677|OTHER|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
218886274|NCT05266677|OTHER|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
218886275|NCT00082914|BIOLOGICAL|denileukin diftitox|
218886276|NCT02186145|DRUG|Association of metronidazole; nystatin and dexamethasone|
218886277|NCT02186145|DRUG|Flagyl|Vaginal cream of metronidazole and nystatin
218886278|NCT04044742|DRUG|Resiniferatoxin|Receiving Resiniferatoxin injection
218886279|NCT04044742|DRUG|Placebo|Receiving Placebo injection
218886280|NCT03897855|OTHER|Post Traumatic Stress Disorder|"The test Think / No-Think"
218886281|NCT05914207|BEHAVIORAL|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
218886282|NCT05914207|OTHER|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
218886283|NCT05091125|DIAGNOSTIC_TEST|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
219201748|NCT04519814|PROCEDURE|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
218886284|NCT04238507|DEVICE|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
218886285|NCT04238507|DEVICE|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
219364668|NCT03683394|BEHAVIORAL|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
219364669|NCT02279030|OTHER|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
218886286|NCT04887987|OTHER|Pilates training + active PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
219029925|NCT04850014|OTHER|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
219029926|NCT04850014|OTHER|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
219029927|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
219029928|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
219029929|NCT05774860|OTHER|No intervention|No intervention
219029930|NCT05726552|OTHER|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
219364670|NCT02224131|DRUG|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
219364671|NCT02224131|DRUG|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
219364672|NCT00110019|DRUG|Carboplatin|Given IV
219364673|NCT00110019|OTHER|Laboratory Biomarker Analysis|Correlative studies
219364674|NCT00110019|DRUG|Paclitaxel|Given IV
219364675|NCT00110019|OTHER|Pharmacological Study|Correlative studies
219364676|NCT00110019|OTHER|Placebo|Given PO
219364677|NCT00110019|DRUG|Sorafenib Tosylate|Given PO
219364678|NCT03897751|DEVICE|ABT12 Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
219364679|NCT03897751|DEVICE|COMPLETE Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
219364680|NCT03897751|DEVICE|Sensitive Eyes® Rewetting Drops|For use as needed during the study.
219364681|NCT02455635|PROCEDURE|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath \& 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
219364682|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with No/Mild Sleep Apnea|Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.
219364683|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with Moderate/Severe Sleep Apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
219364684|NCT03649399|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
219364685|NCT03229720|DEVICE|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
219364686|NCT04435223|BIOLOGICAL|biological assays in particular on the lipid metabolism|bioassays carried out on samples already collected and conserved
219364687|NCT02736032|PROCEDURE|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
219364688|NCT02736032|PROCEDURE|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
219364689|NCT02736032|DRUG|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
219201749|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Full intervention|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm include the full intervention.
219201750|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Cognitive rehabilitation only|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm includes the cognitive rehabilitation only.
219201751|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
219201752|NCT06412757|DRUG|Silexan|Participants in the Silexan arm will take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning in addition to their usual medications. No modifications of allocated interventions will be made for any trial participants; if appropriate (i.e following the emergence of adverse events) participants will be withdrawn from the intervention.
219201753|NCT06412757|OTHER|Placebo|Participants in the placebo arm will take two capsules containing an inert placebo daily orally in the morning in addition to their usual medications. The placebo capsules will contain a sub-therapeutic amount of lavender oil to mimic the odor of the experimental drug (Silexan).
219201754|NCT06014580|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
219201755|NCT01315106|DEVICE|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
219507224|NCT04881890|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
219507225|NCT04502875|DRUG|PRP|Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
219507226|NCT04502875|DRUG|PPP|PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
219507227|NCT01505465|DRUG|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
219507228|NCT01505465|DRUG|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
219507229|NCT05133895|DRUG|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
219507230|NCT02742779|DRUG|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
219507231|NCT02742779|DRUG|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
219507232|NCT03013166|OTHER|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
219507233|NCT01179282|BIOLOGICAL|dust mite extract or placebo|intervention will be to stop study drug or placebo
219507234|NCT04058483|OTHER|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
219507235|NCT04140006|DRUG|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
219507236|NCT04140006|DRUG|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
218886287|NCT04887987|OTHER|Pilates training + sham PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
218886288|NCT04887987|OTHER|Multicomponent training + active PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
218886289|NCT04887987|OTHER|Multicomponent training + sham PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
218886290|NCT00442221|DRUG|Sumatriptan and Naproxen sodium|
218886291|NCT00112125|DEVICE|OPTIMIZER System|
218886292|NCT01710631|DRUG|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
218886293|NCT01710631|DRUG|placebo|placebo
219201756|NCT04825288|BIOLOGICAL|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
218886294|NCT00778908|RADIATION|Late-course accelerated hyperfractionated IMRT|"1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
218886295|NCT00778908|DRUG|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
218886296|NCT00778908|RADIATION|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
218886297|NCT05818267|DRUG|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
218886298|NCT03668093|OTHER|ICCM|comprehensive system for caries management
218886299|NCT03668093|OTHER|CAMBRA|Caries risk assessment model
218886300|NCT04292613|OTHER|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
219029931|NCT04194346|PROCEDURE|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
219029932|NCT02046408|OTHER|Computer Tablet|
219029933|NCT04394663|DRUG|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
219029934|NCT04394663|DRUG|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
219029935|NCT03170128|PROCEDURE|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
219201757|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
219507237|NCT04140006|DRUG|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
219507238|NCT04140006|DRUG|Control|Flapped surgery for insertion of dental implant without topical application of any gel
218886301|NCT03600532|BEHAVIORAL|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
219029936|NCT03170128|BEHAVIORAL|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
219029937|NCT00232258|DRUG|Nolpitantium besylate|
219029938|NCT06381531|DIAGNOSTIC_TEST|Imaging with CT and MRI|Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor
219507239|NCT04078230|PROCEDURE|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
219507240|NCT00708630|BEHAVIORAL|Extended information on side effects|More detailed information on possible side effects of vaccine
219507241|NCT00146289|DRUG|MICARDIS® (telmisartan)|
219507242|NCT02360657|DRUG|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
218886302|NCT06523244|PROCEDURE|PHOTODYNAMIC THERAPY|Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
218886303|NCT04078581|OTHER|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
218886304|NCT02133092|OTHER|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
219507243|NCT02360657|DRUG|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
219507244|NCT02360657|DRUG|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
219507245|NCT01211847|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
218886305|NCT03676140|DRUG|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
218886306|NCT03676140|DRUG|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
218886307|NCT03676140|DRUG|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
218886308|NCT03676140|DRUG|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
218886309|NCT03676140|DRUG|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
218886310|NCT02720406|DRUG|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
218886311|NCT02720406|DRUG|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
218886312|NCT02720406|DRUG|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
218886313|NCT02720406|DRUG|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
218886314|NCT02718092|DEVICE|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
218886315|NCT02718092|DEVICE|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
218886316|NCT01325805|BEHAVIORAL|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
218886317|NCT01325805|BEHAVIORAL|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
218886318|NCT05504005|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
218886319|NCT01665391|DRUG|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
218886320|NCT01665391|DRUG|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
218886321|NCT01665391|DRUG|Placebo|Placebo administered to match active treatment group
218886322|NCT04448769|BIOLOGICAL|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
218886323|NCT03543137|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
218886324|NCT03543137|DRUG|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
218886325|NCT04247295|DEVICE|Traditional Cast|Application of a traditional cast
218886326|NCT04247295|DEVICE|Woodcast|Application of a woodcast
219029939|NCT06639412|BEHAVIORAL|Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.|The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.
219029940|NCT06639412|OTHER|Usual care|The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
219507246|NCT01211847|DRUG|Placebo|Placebo matching DCCR
219507247|NCT04078139|DRUG|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219607544|NCT05488093|DEVICE|X-sens sensor|"the procedure will include:~* 7 to 8 sensors (Foot, leg, thigh, pelvis and chest possibly).~* 5 movements/exercises for the patients, each exercise performed 3 times except walking~* Analysis of 20m walking cycle (normal speed, most natural arm movement, 4 return trips of 20m):~* Climbing up and down stairs (using the public stairs of the rheumatology access department, 6 steps of 20 cm height, at normal speed, without using the handrail)~* Getting up from a chair without the help of hands (start standing, then the patient sits, leans and stands up, feet together, without taking the feet off the floor, using one and the same chair for each patient with a height of 50 cm)"
219607545|NCT02998086|BEHAVIORAL|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
218886327|NCT03154437|BIOLOGICAL|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
218886328|NCT00002847|BIOLOGICAL|aldesleukin|
218886329|NCT00002847|BIOLOGICAL|recombinant interferon alfa|
218886330|NCT00002847|PROCEDURE|conventional surgery|
218886331|NCT03779087|DRUG|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
218886332|NCT03779087|DRUG|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
218886333|NCT03193736|DEVICE|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
218886334|NCT00988572|OTHER|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
218886335|NCT03939936|OTHER|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
218886336|NCT03939936|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
219029941|NCT00367081|DRUG|TMX-SMX (Bactrim(R))|
219029942|NCT00367081|DRUG|Pyrimethamine plus Sulfadiazine plus leucoverin|
219029943|NCT02175420|BIOLOGICAL|BCG|
218886337|NCT03939936|OTHER|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
218886338|NCT03268291|OTHER|Standard outpatient observation|Outpatient management according to Ministry of health standards
218886339|NCT03268291|BEHAVIORAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
219029944|NCT02175420|BIOLOGICAL|TFV|
219029945|NCT01062282|DRUG|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
219029946|NCT02989350|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
219029947|NCT02989350|DIETARY_SUPPLEMENT|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
219029948|NCT05617365|COMBINATION_PRODUCT|Osteopathic Manipulative Therapy and Exercise Therapy|"At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head."
219029949|NCT03169647|BEHAVIORAL|Listening-based intervention|Participants will listen to pre-specified material on a CD
219029950|NCT05308446|BIOLOGICAL|Cetuximab|Given IV
219029951|NCT05308446|DRUG|Encorafenib|Given PO
219029952|NCT05308446|BIOLOGICAL|Nivolumab|Given IV
219029953|NCT04994717|DRUG|Blinatumomab|Continuous intravenous (cIV) infusion
219029954|NCT04994717|DRUG|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
219029955|NCT04994717|DRUG|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
219029956|NCT01191580|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
219607546|NCT00611624|RADIATION|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
219607547|NCT05629819|DEVICE|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
219607548|NCT03906110|BEHAVIORAL|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
219607549|NCT03906110|BEHAVIORAL|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
219607550|NCT03906110|BEHAVIORAL|Personalized One on One Education|"* Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
219607551|NCT03906110|DIAGNOSTIC_TEST|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
219607552|NCT02109653|DRUG|LGX818|Oral LGX818 300mg daily
219607553|NCT03182777|PROCEDURE|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
219607554|NCT06588478|DRUG|Pirtobrutinib|Administered Orally.
219607555|NCT03264807|PROCEDURE|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
219029957|NCT01191580|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
219029958|NCT01191580|BEHAVIORAL|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
219029959|NCT06166277|PROCEDURE|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
219029960|NCT05064033|OTHER|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
219029961|NCT05064033|OTHER|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
219029962|NCT02391103|DEVICE|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
219029963|NCT02391103|DEVICE|sham-stimulation|no electricity applied
219029964|NCT05858788|DRUG|SAR441566|Tablet
219029965|NCT05735223|PROCEDURE|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
219029966|NCT00510354|DRUG|Imatinib mesylate|
219029967|NCT02694146|DRUG|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
219029968|NCT02694146|DRUG|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
219029969|NCT05624437|OTHER|data record|data record
219029970|NCT01852812|DRUG|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
219029971|NCT01852812|DRUG|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
219029972|NCT02567006|BEHAVIORAL|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
219029973|NCT02567006|OTHER|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
219364690|NCT02736032|DRUG|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
219364691|NCT02736032|DRUG|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
218886340|NCT05825391|DRUG|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
218886341|NCT00267852|OTHER|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
218886342|NCT00423449|DRUG|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
218886343|NCT00423449|DRUG|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
218886344|NCT00423449|DRUG|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
218886345|NCT06195410|OTHER|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
218886346|NCT01670435|DRUG|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
218886347|NCT00344422|DRUG|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
218886348|NCT03162237|OTHER|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
218886349|NCT03162237|OTHER|Autologous Treg|Autologous Treg: 2x10\^6/Kg
218886350|NCT04230213|DRUG|PF-06410293|SC injection
218886351|NCT04230213|DRUG|adalimumab|SC injection
218886352|NCT02860572|OTHER|follow-up without intervention|
218886353|NCT02860572|OTHER|fluid bolus|
218886354|NCT04481360|DEVICE|CT of the chest|Degree of affection on the lung infected by COVID19
218886355|NCT01394913|DRUG|Reumatocept (etanercept)|50mg each week for 30 weeks
218886356|NCT01394913|DRUG|Enbrel (etanercept)|50mg each week for 30 weeks
218886357|NCT02178696|OTHER|Placebo, identified as placebo to participants|White tablets
218886358|NCT02178696|DRUG|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
218886359|NCT02178696|OTHER|"Placebo, identifed to participants as Active medication"|Blue Capsule
218886360|NCT04230824|DIETARY_SUPPLEMENT|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
218886361|NCT04230824|OTHER|Placebo|placebo product consumed prior and after exercise
218886362|NCT04230824|OTHER|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
218886363|NCT04883034|PROCEDURE|adductor canal block in outpatient clinic|perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
218886364|NCT04883034|DRUG|Analgesics, etoricoxibe|anaelgetic oral intake
218886365|NCT03252002|DRUG|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
218886366|NCT03252002|DRUG|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
218886367|NCT03876899|DIETARY_SUPPLEMENT|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
218886368|NCT03876899|DIETARY_SUPPLEMENT|Placebo|Pill
218886369|NCT04236739|DRUG|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
218886370|NCT05814952|GENETIC|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
218886371|NCT03473899|DEVICE|rESWT|"rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
219364692|NCT01631669|DRUG|Celecoxib|200 mg Q 12 hours orally
219364693|NCT02730156|OTHER|Altitude exposure|Altitude exposure
219364694|NCT01815645|BEHAVIORAL|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
218886372|NCT03473899|DEVICE|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
218886373|NCT02037906|RADIATION|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
218886374|NCT02037906|RADIATION|Constant Energy SWL|Constant dose at 20 kv
219201758|NCT06869473|DRUG|Cetuximab/avelumab|"Study Maintenance therapy: AVEC (each cycle every 2 weeks) Cetuximab will be administered at 500 mg/m2 dose (as a 2-hour intravenous infusion) every 2 weeks until disease progression or unacceptable side effects.~Cetuximab will be administered by IV infusion over 120 minutes. The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min.~Avelumab will be administered at 800 mg flat dose (as a 1-hour intravenous fusion) every 2 weeks until disease progression or unacceptable side effects."
219201759|NCT06622720|PROCEDURE|surgery|The colorectal surgery of any type conducted in any approach in the timeframe
218886375|NCT02037906|RADIATION|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
218886376|NCT01580202|DRUG|Entecavir|Entecavir 0.5mg daily per os
218886377|NCT01580202|DRUG|Lamivudine|lamivudine 100mg daily per os
218886378|NCT05271448|OTHER|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
218886379|NCT05271448|OTHER|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
218886380|NCT01462396|DEVICE|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
218886381|NCT05024708|OTHER|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
218886382|NCT00861471|DRUG|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."
218886383|NCT00861471|DRUG|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
218886384|NCT02157077|DRUG|Aflibercept|Intravitreal Injection
218886385|NCT00571805|DRUG|varencline|2.0 mg/day varencline (1.0 mg BID)
218886386|NCT00571805|DRUG|placebo|matching placebo
218886387|NCT04198077|DRUG|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
218886388|NCT01445080|OTHER|Laboratory Biomarker Analysis|Correlative studies
218886389|NCT01445080|OTHER|Pharmacological Study|Correlative studies
218886390|NCT01445080|DRUG|Sorafenib Tosylate|Given orally
219029974|NCT01684371|OTHER|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
219029975|NCT02182362|DRUG|BI 201335 NA|
218886391|NCT01799824|BIOLOGICAL|ANT-1403|
219029976|NCT02182362|DRUG|Placebo|
219201760|NCT06869694|DEVICE|computerized tomography|mpMRI and Photon-counting Detector CT scan
218886392|NCT01799824|BIOLOGICAL|placebo|
218886393|NCT05367843|DRUG|PRIME-2-CoV_Beta|Intramuscular (IM) injection
219029977|NCT00005926|DRUG|Gemcitabine|
219029978|NCT00005926|DRUG|Herceptin|
219201761|NCT06869174|DRUG|Pucotenlimab combined with MRG002|Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W
218886394|NCT04787354|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
218886395|NCT04787354|DRUG|Capecitabine|Capecitabine: 2,000 mg/m2/day
218886396|NCT02757118|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
218886397|NCT02757118|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
218886398|NCT05095350|BIOLOGICAL|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
218886399|NCT05095350|BIOLOGICAL|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
218886400|NCT03275038|BEHAVIORAL|Tai-Chi exercise|Behavioral: Tai-Chi exercise
218886401|NCT03275038|BEHAVIORAL|Aerobic exercise|Behavioral: Aerobic exercise
218886402|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
218886403|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
218886404|NCT01398748|DRUG|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
218886405|NCT03857542|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
219029979|NCT00005926|PROCEDURE|Radiation therapy|
219029980|NCT03463564|DEVICE|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
219029981|NCT03463564|DRUG|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
218886406|NCT03857542|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
218886407|NCT01548196|PROCEDURE|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
218886408|NCT01301170|PROCEDURE|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
219029982|NCT03610932|DIETARY_SUPPLEMENT|Vitamin C|Taken as 3 500mg capsules.
219029983|NCT03610932|OTHER|Placebo|Taken as 3 500mg capsules.
219029984|NCT04903327|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
219029985|NCT04903327|DRUG|Placebo|Excipient solution
219029986|NCT04760912|DRUG|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
219029987|NCT04760912|PROCEDURE|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
219029988|NCT01707953|DRUG|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
219029989|NCT01707953|DRUG|Placebo|Placebo capsule to mimic midodrine
219029990|NCT05922631|PROCEDURE|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
219029991|NCT05922631|PROCEDURE|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
219029992|NCT03966755|BEHAVIORAL|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
219029993|NCT00019396|DRUG|flt3 ligand|
219029994|NCT00019396|DRUG|gp100 antigen|
219029995|NCT00019396|DRUG|MART-1 antigen|
219029996|NCT00019396|DRUG|Montanide ISA-51|
219029997|NCT00019396|DRUG|tyrosinase peptide|
219029998|NCT00097799|DRUG|Tipranavir|500 mg twice daily
219029999|NCT00097799|DRUG|Ritonavir|200 mg twice daily
219030000|NCT01572337|PROCEDURE|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
219030001|NCT01572337|OTHER|Standard care|
219030002|NCT00821470|PROCEDURE|core decompression|core decompression procedure only
219030003|NCT00821470|PROCEDURE|Bone marrow implantation into the necrotic lesion|
219364695|NCT01815645|BEHAVIORAL|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
219030004|NCT05462028|DEVICE|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
219030005|NCT05462028|BEHAVIORAL|ergometer exercise|ergometer exercise training
219030006|NCT02067910|DRUG|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
219030007|NCT02250443|DRUG|BYM338 (Bimagrumab)|
219030008|NCT01549964|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
219030009|NCT01549964|DRUG|Sitagliptin|Sitagliptin tablets
219030010|NCT01549964|DRUG|Placebo|Placebo-matching tablets
219030011|NCT00521196|DEVICE|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
219364696|NCT04013594|DIETARY_SUPPLEMENT|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
219364697|NCT03996330|DIAGNOSTIC_TEST|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
219364698|NCT00073320|DRUG|Paliperidone Palmitate|
219364699|NCT03074929|BEHAVIORAL|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
219364700|NCT00639080|OTHER|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
219364701|NCT02468336|DEVICE|AngioDefender|
219364702|NCT02468336|DEVICE|Ultrasound|
219201762|NCT06869291|PROCEDURE|Multi level and multi tunnel puncture treatment|"Multi level and multi tunnel puncture treatment steps~1. Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times;~2. Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area;~3. Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels;~4. Cover the injection site with gauze and maintain for 6-8 hours."
219201763|NCT06869291|PROCEDURE|Heparin Sodium Injection|"(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to insert the needle from the edge of the lesion near the eyebrow, so that it will not cover the field of view with gauze after injection; (4) The injection depth is the gap between the epidermal layer and the dermis layer, forming an orange peel appearance after injection, and completely covering the lesion area; (5) Cover the injection site with gauze and maintain for 6-8 hours."
219201764|NCT06869291|PROCEDURE|Multi Level and Multi Tunnel Puncture Treatment + Heparin Sodium Injection|(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area; (4) Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels; (5) Cover the injection site with gauze and maintain for 6-8 hours.
219201765|NCT06868576|DRUG|Dydrogesterone Oral Tablet|Dydrogesterone 20mg tablets daily in PPOS protocol in ovarian stimulation starting from day 2 or 3 of the menstrual cycle until the triggering day
219201766|NCT06868576|DRUG|Cetrorelix (Cetrotide)|This will be the conventional antagonist in ovarian stimulation given from day 6 of the menstrual cycle until the triggering day
219201767|NCT06869720|DEVICE|Eccentric bike|Received eccentric cycling exercise
219201768|NCT06869720|OTHER|conventional group|Received conventional treatment
219201769|NCT06867874|PROCEDURE|Blood sample|Blood sample
219201770|NCT06869044|DEVICE|omafilcon A lens|Participants will be randomized to wear omafilcon A lens for 15 minutes.
218886409|NCT03002883|BEHAVIORAL|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
218886410|NCT03002883|BEHAVIORAL|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
219201771|NCT06869044|DEVICE|Low ADD power somofilcon A lens|Participants will be randomized to wear low ADD power somofilcon A lens for 15 minutes.
219201772|NCT06869044|DEVICE|Medium ADD power somofilcon A lens|Participants will be randomized to wear medium ADD power somofilcon A lens for 15 minutes.
219507248|NCT04078139|DRUG|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
219507249|NCT00634283|DRUG|venlafaxine|venlafaxine IR 150mg
219607556|NCT03264807|PROCEDURE|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
219607557|NCT01850251|DIETARY_SUPPLEMENT|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
219030012|NCT04181333|DRUG|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
218886411|NCT03002883|BEHAVIORAL|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
218886412|NCT02358226|BEHAVIORAL|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
218886413|NCT02358226|BEHAVIORAL|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
219030013|NCT02290821|DRUG|placebo|
219030014|NCT02290821|DRUG|Placebos|
219507250|NCT06541535|DRUG|Fluid resuscitation with isotonic saline only|"Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
219607558|NCT01850251|DIETARY_SUPPLEMENT|Standard nutritional supplement|High protein, high calorie nutritional supplement.
218886414|NCT06186986|DRUG|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
219607559|NCT01632397|BEHAVIORAL|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
218886415|NCT04859374|BEHAVIORAL|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
219607560|NCT01632397|BEHAVIORAL|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
218886416|NCT04859374|DRUG|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
219607561|NCT06489236|BEHAVIORAL|Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations|Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
219607562|NCT03022916|DRUG|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
218886417|NCT05820984|OTHER|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
218886418|NCT05820984|OTHER|Usual practice|Peer review as it is usual practice at the journal
218886419|NCT02123576|DRUG|Pentoxyfylline|
218886420|NCT02123576|DRUG|Placebo|
218886421|NCT02123576|DRUG|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
218886422|NCT02477189|PROCEDURE|Silicone Block|
218886423|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 60 degrees.
218886424|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
218886425|NCT03203434|DIAGNOSTIC_TEST|Urinary volatile organic compound analysis|
218886426|NCT05781464|PROCEDURE|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
218886427|NCT05781464|PROCEDURE|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
218886428|NCT03811301|DEVICE|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
219030015|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
219030016|NCT05231785|DRUG|Placebo|Placebo will be administered IT
219030017|NCT03672331|OTHER|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
219030018|NCT03672331|OTHER|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
219030019|NCT03672331|OTHER|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
219030020|NCT03672331|OTHER|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
219030021|NCT06502275|BEHAVIORAL|Mobile Health Management Frailty Care Program|"Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise."
219030022|NCT02438722|DRUG|Afatinib Dimaleate|Given PO
219030023|NCT02438722|BIOLOGICAL|Cetuximab|Given IV
219030024|NCT02438722|OTHER|Laboratory Biomarker Analysis|Correlative studies
219030025|NCT03559322|DEVICE|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
218886429|NCT00934128|DEVICE|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
218886430|NCT00934128|DEVICE|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
219201773|NCT06869044|DEVICE|High ADD power somofilcon A lens|Participants will be randomized to wear high ADD power somofilcon A lens for 15 minutes.
219507251|NCT06541535|DRUG|Fluid resuscitation with Ringer Lactate|"Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
219607563|NCT03022916|OTHER|Nail polish|Application of nail polish only to both big toe nails
219607564|NCT03022916|DRUG|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
218886431|NCT01001793|DEVICE|Levacor Ventricular Assist Device|Surgical procedure
218886432|NCT05137769|BEHAVIORAL|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
219030026|NCT00909779|DRUG|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
219607565|NCT03022916|DRUG|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
219607566|NCT00694200|DRUG|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
219607567|NCT00694200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
219607568|NCT02796053|DRUG|TAB08|The TAB08 will be administered intravenously, by infusion.
219607569|NCT02796053|OTHER|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
219607570|NCT04725851|PROCEDURE|High concentration Oxygen therapy|FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
219607571|NCT04725851|PROCEDURE|Control: Room Air or Low concentration Oxygen|FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
219607572|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Oppanol
219607573|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
219607574|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
218886433|NCT05840536|DRUG|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
219030027|NCT00909779|DRUG|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
219030028|NCT04330560|DEVICE|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
219030029|NCT04330560|DEVICE|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
219030030|NCT04330560|DEVICE|Exercise teleconsultation|Conducted through smartphone video call app.
219201774|NCT06870240|DRUG|Neurosteroid enantiomer|A non-natural synthetic neurosteroid enantiomer considered a new chemical entity
219201775|NCT06865729|BEHAVIORAL|Music therapy|Music therapy will be performed by the researchers for 4 days (average length of stay for inpatients is 4 days), starting from the first day the patients start their inpatient treatment. Music therapy will be performed in the evening hours (between 20:00 and 21:00) and in the patients' own rooms, so as not to disrupt the patients' routine follow-up and treatment. Music therapy will be performed passively using an MP3 music player and headphones provided by the researchers. Therapy time will be limited to 30 minutes. Music therapy will be performed in one session per day for 4 days, and the patients will listen to the same music in each session.
219201776|NCT03715959|PROCEDURE|Aspiration of Breast|Undergo NAF
219607575|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
219607576|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Vistanex
219607577|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
219607578|NCT04625244|OTHER|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
219607579|NCT06551337|DRUG|Vitamin D3|The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
219607580|NCT06397495|OTHER|Education|Cervical region manual therapy training will be given with flipped learning models.
219607581|NCT00426439|DRUG|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
218886434|NCT05840536|DRUG|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
219030031|NCT04330560|PROCEDURE|Other CR components|Including dietary, psychology, education conducted at the center.
219507252|NCT02995837|OTHER|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
219507253|NCT02995837|OTHER|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
219607582|NCT00426439|DRUG|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
219607583|NCT00893269|DRUG|eszopiclone|Oral capsule at dose recommended for adults
219607584|NCT00893269|DRUG|Placebo|Participants receive placebo prior to sleep
219030032|NCT04330560|PROCEDURE|Standard care|Undergoing standard care by cardiac rehabilitation at the center
219030033|NCT02449174|BIOLOGICAL|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
219030034|NCT02449174|BIOLOGICAL|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
218886435|NCT02199561|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
219030035|NCT06115863|OTHER|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
219030036|NCT03710655|DRUG|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
219030037|NCT03710655|DRUG|Placebo|Intradermal injection of 0.01 microliters
219607585|NCT00893269|DRUG|ramelteon|ramelteon
219607586|NCT00893269|DRUG|zolpidem|zolpidem
218886436|NCT00241592|DRUG|Cannabis|
218886437|NCT01985425|DRUG|Colchicine 0.6 mg|
218886438|NCT01985425|DRUG|Placebo Colchicine|
218886439|NCT02340910|PROCEDURE|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
219030038|NCT02730572|DRUG|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
219607587|NCT01994785|DIAGNOSTIC_TEST|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
219607588|NCT00215423|DRUG|Formoterol Fumarate|
219030039|NCT02730572|DRUG|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
219030040|NCT02730572|DRUG|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
219201777|NCT03715959|PROCEDURE|Biospecimen Collection|Undergo NAF
219201778|NCT06870981|OTHER|Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.|
219201779|NCT06870552|DEVICE|Single-pulse TMS|A single pulse TMS is delivered at different time points when processing words or numbers.
218886440|NCT02340910|PROCEDURE|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
218886441|NCT01428531|DRUG|Fondaparinux Sodium|
218886442|NCT02797782|OTHER|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
218886443|NCT00571974|DEVICE|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
219507254|NCT02995837|OTHER|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
218886444|NCT00571974|DRUG|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
218886445|NCT00571974|PROCEDURE|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
218886446|NCT01390896|DRUG|Fondaparinux Sodium|
218886447|NCT00851617|DEVICE|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
218886448|NCT04632771|OTHER|N/A (observational study)|N/A (observational study)
218886449|NCT00312026|DRUG|efalizumab|
218886450|NCT00918099|PROCEDURE|Avaulta mesh|Insertion of a mesh vs conventional repair
218886451|NCT00918099|PROCEDURE|Anterior repair|Conventional repair
218886452|NCT01281540|DRUG|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
218886453|NCT01281540|DRUG|Placebo|one placebo tablet 4 times a day for 8 weeks
218886454|NCT06362018|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
218886455|NCT01946152|DRUG|Dexamethasone|Given PO
219030041|NCT00949325|DRUG|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
219030042|NCT03273881|DRUG|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
218886456|NCT01946152|BIOLOGICAL|Filgrastim-sndz|Given SC
218886457|NCT01946152|OTHER|Laboratory Biomarker Analysis|Correlative studies
218886458|NCT01946152|DRUG|Pomalidomide|Given PO
218886459|NCT03742583|OTHER|Square Knot|Standard square knot
218886460|NCT03742583|OTHER|RHAP Knot|Reversing half-hitch alternating post knot
218886461|NCT01867502|DRUG|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
218886462|NCT01867502|DRUG|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
218886463|NCT01698814|DRUG|AL-4943A Ophthalmic Solution|
218886464|NCT01698814|DRUG|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
218886465|NCT05168033|OTHER|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
219030043|NCT03273881|DRUG|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
219607589|NCT00952731|DRUG|oral placebo|Oral placebo taken daily for 4-10 weeks.
218886466|NCT05168033|OTHER|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
218886467|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
218886468|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
218886469|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
218886470|NCT05902988|DRUG|VLS-1488|VLS-1488 tablets will be given orally.
218886471|NCT03392246|DRUG|Osimertinib|"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
218886472|NCT03392246|DRUG|Selumetinib|"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
218886473|NCT05241093|DRUG|HYML-122; cytarabine|HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
219507255|NCT02995837|OTHER|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
219507256|NCT02657720|DEVICE|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
218886474|NCT02574273|BEHAVIORAL|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
218886475|NCT02574273|OTHER|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
218886476|NCT06278766|DRUG|ABBV-552|Oral Solution
218886477|NCT00961363|DRUG|Sitagliptin|sitagliptin 100 mg per day
218886478|NCT00961363|DRUG|Placebo|Placebo
218886479|NCT00252070|BEHAVIORAL|Functional Exercise for People with Arthritis (FEPA)|
218886480|NCT06362317|DRUG|Toripalimab|Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.
218886481|NCT06362317|DRUG|Lenvatinib|When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
218886482|NCT06362317|DRUG|Gemox Chemotherapy（Gemox or GC）|"Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1."
218886483|NCT01186991|DRUG|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
218886484|NCT01186991|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
218886485|NCT01186991|DRUG|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
218886486|NCT01186991|DRUG|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
218886487|NCT01186991|DRUG|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
218886488|NCT05083429|DRUG|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
218886489|NCT05083429|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference
219507257|NCT02657720|DEVICE|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
219507258|NCT02657720|DEVICE|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
219507259|NCT03687021|DRUG|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
218886490|NCT02346461|DRUG|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
219507260|NCT04801602|DIAGNOSTIC_TEST|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
219507261|NCT01573247|DRUG|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
219507262|NCT02975271|DRUG|Serlopitant|
219507263|NCT02975271|DRUG|Placebo|Matching placebo
219507264|NCT00609778|DEVICE|LUCAS|Mechanical chest compression
218886491|NCT02346461|DRUG|ManNAc|At doses of 6 g twice daily (12 g per day).
219507265|NCT00609778|OTHER|Conventional manual resuscitation method|Manual compression
219507266|NCT02267733|DRUG|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
219507267|NCT05723497|OTHER|Elderberry juice|Participants will consume elderberry juice 1-week.
219507268|NCT05723497|OTHER|Placebo beverage|Participants will consume placebo for 1-week.
219507269|NCT01439100|DRUG|Oxycodone/Naloxone Prolonged Release tablets|
218886492|NCT00406601|DRUG|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
218886493|NCT02750852|PROCEDURE|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
218886494|NCT03933813|OTHER|Iron Sucrose|Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
218886495|NCT04803266|RADIATION|Internal mammary node irradiation|Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
219507270|NCT01439100|DRUG|Placebo|Dummy tablet
219507271|NCT04968743|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
219507272|NCT01551329|DRUG|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
218886496|NCT04803266|RADIATION|No internal mammary node irradiation|Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
218886497|NCT02621307|DIETARY_SUPPLEMENT|Salba|
218886498|NCT02621307|DIETARY_SUPPLEMENT|Flax|
218886499|NCT02621307|DIETARY_SUPPLEMENT|Control|
218886500|NCT00389844|BEHAVIORAL|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
218886501|NCT00389844|BEHAVIORAL|Plus component (motivation) of the Exercise Plus Program|Motivation only
218886502|NCT00389844|BEHAVIORAL|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
218886503|NCT00799266|DRUG|Zoledronic acid|intravenous infusion
218886504|NCT00799266|DRUG|Placebo|intravenous infusion
218886505|NCT01966822|DRUG|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
218886506|NCT01966822|DRUG|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
219507273|NCT01077713|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
219507274|NCT01077713|DRUG|cisplatin|60mg/m2 on day 1 of each 3 week cycle
219507275|NCT01077713|DRUG|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
219507276|NCT01077713|DRUG|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
219507277|NCT00289458|BEHAVIORAL|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
219507278|NCT00289458|BEHAVIORAL|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
218886507|NCT02669342|DEVICE|Radiance™ Clear Sharklet® Silicone Foley Catheter|
218886508|NCT02669342|DEVICE|Silicone Foley Catheter|
218886509|NCT05508022|BEHAVIORAL|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
218886510|NCT02883374|DRUG|Chidamide|
218886511|NCT02535325|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
219507279|NCT00289458|BEHAVIORAL|Control|no exercise
219507280|NCT06224582|DRUG|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
219507281|NCT06224582|DRUG|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
219507282|NCT00874757|DRUG|Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
219507283|NCT04733131|DRUG|Conversion to a belatacept regimen|belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
219507284|NCT03827213|DRUG|Exparel|A shot of long acting local anesthetic for post operative pain management
219507285|NCT03827213|DEVICE|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
219507286|NCT03781856|BEHAVIORAL|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
219507287|NCT03781856|BEHAVIORAL|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
219507288|NCT04725149|OTHER|500 ml base solution|Color, taste, aroma, and calorie matched water base
219507289|NCT04725149|OTHER|500 ml containing 30 ml tart cherry concentrate diluted with water and base solution|Montmorency cherry concentrate
219507290|NCT04725149|OTHER|500 ml containing 60 ml tart cherry concentrate diluted with water only|Montmorency cherry concentrate
219507291|NCT03698526|DEVICE|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
219507292|NCT02912013|DEVICE|Me Mini|Home use hair removal device
219507293|NCT03916653|PROCEDURE|osseous resection using piezoelectric device in surgical crown lengthening|In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
219507294|NCT03916653|PROCEDURE|Osseous resection using conventional rotary instruments in surgical crown lengthening|For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
219507295|NCT02361190|DRUG|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
219507296|NCT02361190|DRUG|Placebo|Administration of 1ml aqueous saline spray
218886512|NCT02535325|DRUG|Cisplatin|Given IV
218886513|NCT02535325|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218886514|NCT02535325|DRUG|Methoxyamine|Given PO
218886515|NCT02535325|DRUG|Methoxyamine Hydrochloride|Given PO
218886516|NCT02535325|DRUG|Pemetrexed|Given IV
218886517|NCT02535325|DRUG|Pemetrexed Disodium|Given IV
218886518|NCT01779232|DRUG|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
219030044|NCT00210821|DRUG|topiramate|
218886519|NCT01779232|DRUG|placebo|administered daily like the active comparator
219030045|NCT01758653|OTHER|No study intervention|There is no study-related intervention.
219201780|NCT06867211|DIAGNOSTIC_TEST|Use of Ultrasonography for Measuring Achilles Tendon Thickness|Achilles tendon ultrasonography was performed on healthy volunteers included in the study by an emergency physician trained in both basic and advanced ultrasonography techniques. Measurements were conducted using a Butterfly iQ (Butterfly Network, Inc., Guilford, CT) ultrasound device in B-mode with a musculoskeletal preset, using biplane imaging. For Achilles tendon measurement, the image depth was set to 2.0 cm. A linear probe was placed longitudinally and perpendicular to the tendon. The distal portion of the Achilles tendon and the calcaneus were visualized in the long axis, whereas the short axis was used to center the Achilles tendon on the screen for an optimal measurement view. The measurement site was determined as 2 cm proximal to the Achilles tendon insertion at the calcaneus. In biplane imaging, Achilles tendon thickness was measured in the long axis, whereas thickness, width, and cross-sectional area were measured in the short axis. Measurements were performed bilaterally
219201781|NCT06885086|OTHER|Control group - 1|Patient data will be collected retrospectively from the records.
219201782|NCT06885086|DRUG|Observation group -2|In the literature, multimodal analgesia strategies-as recommended by ERAS guidelines and supported by recent studies-are implemented. In the intraoperative period, patients receive paracetamol, NSAIDs, and local surgical wound infiltration analgesia. In the postoperative period, oral paracetamol and NSAIDs are routinely continued, with opioids administered as needed.
219030047|NCT00798109|BEHAVIORAL|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
219030048|NCT00798109|BEHAVIORAL|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
218886520|NCT00954993|DRUG|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
219030049|NCT04739007|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
219030050|NCT04739007|DEVICE|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
219030051|NCT00387478|BIOLOGICAL|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
219030052|NCT02009631|DRUG|Veliparib (ABT-888)|
219030053|NCT02009631|DRUG|Placebo|
219030054|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
219030055|NCT01914406|OTHER|continuous moderate training|Continued exercise 45 min.
219030056|NCT01520363|DRUG|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
219030057|NCT01520363|DRUG|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
219201783|NCT05726929|OTHER|Osteopathic treatment|Osteopathic Manual Treatment
219507297|NCT04914715|DEVICE|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
219507298|NCT04914715|DEVICE|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
219507299|NCT01151813|DRUG|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
219507300|NCT01151813|DRUG|Placebo|Placebo
219030058|NCT05268588|BEHAVIORAL|MESSSSAGE intervention|group mHealth education and social support intervention
219030059|NCT06508333|BEHAVIORAL|alarm therapy|These patients will receive alarm therapy for 8 weeks.
219030060|NCT06508333|DRUG|Vitamin D3|These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) (combined with alarm therapy) for 8 weeks.
219030061|NCT04174287|DRUG|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
219030062|NCT06050499|DEVICE|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
219030063|NCT01272830|DRUG|Placebo|Two capsules taken twice daily with meals
219030064|NCT01272830|DRUG|Apatone®B|Two capsules taken twice daily with meals
219030065|NCT02658136|OTHER|Cardiac Computed tomography|
219030066|NCT05711667|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219030067|NCT05711667|DRUG|Letermovir|Given PO or IV
219201784|NCT05726929|OTHER|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
219201785|NCT05785130|OTHER|white noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
219201786|NCT06869902|BIOLOGICAL|Colostrum|Use of the patient's mother's inhaled colostrum during the frenotomy
219507301|NCT02194309|DRUG|Telmisartan low|
218886521|NCT03112265|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
218886522|NCT03112265|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
218886523|NCT03112265|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
218886524|NCT03501732|BEHAVIORAL|Values Affirmation|Experimental Group selects two values and describes why they are important
218886525|NCT03501732|BEHAVIORAL|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
219507302|NCT02194309|DRUG|Telmisartan high|
219507303|NCT02194309|DRUG|amlodipine|
218886526|NCT04548466|DEVICE|PEP bottle|
218886527|NCT02227004|DIAGNOSTIC_TEST|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
218886528|NCT05482828|DRUG|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
218886529|NCT05482828|DRUG|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
218886530|NCT01061359|DRUG|Epirubicin: Observational Study|Observational: Chemotherapy
218886531|NCT01182155|PROCEDURE|Exhaled Breath Sampling|Standard of care
219507304|NCT00521456|DRUG|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
219507305|NCT01361399|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
218886532|NCT00062179|DRUG|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
218886533|NCT00062179|DRUG|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
218886534|NCT00062179|DRUG|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
218886535|NCT00062179|OTHER|Placebo|placebo 3-7 days before first dose of chemotherapy
218886536|NCT04230915|OTHER|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
218886537|NCT02826343|DRUG|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
218886538|NCT02826343|DRUG|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
218886539|NCT02826343|DRUG|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
218886540|NCT03353844|BEHAVIORAL|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
218886541|NCT01975363|DIETARY_SUPPLEMENT|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
219030068|NCT01336075|PROCEDURE|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
219030069|NCT01336075|PROCEDURE|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
219030070|NCT04579042|PROCEDURE|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
219030071|NCT05152888|DRUG|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
219030072|NCT00080743|DRUG|gefitinib|250 mg po once daily
219030073|NCT00080743|DRUG|tamoxifen citrate|20 mg po once daily
219030074|NCT00080743|DRUG|Placebo|One pill po once daily
219507306|NCT01361399|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
219607590|NCT00952731|DRUG|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
219607591|NCT00952731|DRUG|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
219030075|NCT05695521|BIOLOGICAL|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
219030076|NCT05695521|OTHER|Excipient|Excipient
219030077|NCT01861496|DRUG|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
219030078|NCT01498952|DRUG|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
219030079|NCT01498952|DRUG|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
219030080|NCT06348303|DRUG|Metaxalone m640 mg oral tablet|Metaxalone partially micronized 640 mg tablet
219030081|NCT06348303|DRUG|Metaxalone 800 mg oral tablet|Metaxalone non-micronized 800 mg oral tablet
219030082|NCT00579826|DRUG|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
219507307|NCT01361399|DRUG|Lidocain|Single oral application of Lidocain (as lozenge)
219507308|NCT01361399|DRUG|Placebo|Single oral application of Placebo (as lozenge)
218886542|NCT01975363|OTHER|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
219201787|NCT06861634|PROCEDURE|Nol index|Morphinomimetics will be administered according to NOL Index values or according to the usual criteria.
219201788|NCT06677138|DRUG|gefurulimab|Participants will receive gefurulimab subcutaneously (SC).
219507309|NCT02620345|DRUG|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)"
219507310|NCT02620345|DRUG|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)"
219507311|NCT00395798|DEVICE|Soft or stiff cervical collar(device), neck school(behavior)|
219507312|NCT00423956|PROCEDURE|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
219507313|NCT00617110|OTHER|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
219507314|NCT00617110|OTHER|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
219201789|NCT06625671|DRUG|DB-2304|DB-2304
219201790|NCT06625671|DRUG|Placebo|Placebo
219507315|NCT06044181|PROCEDURE|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
219607592|NCT00952731|DRUG|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
218886543|NCT01975363|OTHER|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
219030083|NCT00579826|DRUG|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
219030084|NCT02284646|OTHER|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
219030085|NCT06470464|DRUG|Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)|The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
219030086|NCT04258943|DRUG|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~\- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
219030087|NCT04191382|DRUG|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
219030088|NCT04191382|DRUG|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
219030089|NCT02939963|PROCEDURE|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
219201791|NCT06625671|DRUG|Prednisone|Prednisone
219201792|NCT03351998|DRUG|Lipitor 20Mg Tablet|20 mg/day pills.
219201793|NCT03351998|DRUG|Lipitor 80Mg Tablet|80 mg/day pills.
219201794|NCT03351998|DRUG|Placebo Oral Tablet|Matching placebo pill.
219201795|NCT06440447|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
219507316|NCT01519583|BEHAVIORAL|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
219507317|NCT01519583|BEHAVIORAL|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
219607593|NCT00999427|DRUG|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
218886544|NCT01975363|OTHER|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
219507318|NCT01519583|BEHAVIORAL|Control Group|Maintain usual physical activity, and return for follow-up measures.
218886545|NCT01776034|BEHAVIORAL|SystemCHANGE Group Lifestyle counseling|
218886546|NCT01776034|BEHAVIORAL|Phone Lifestyle Counseling|
218886547|NCT02505659|BEHAVIORAL|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
218886548|NCT04014062|COMBINATION_PRODUCT|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
218886549|NCT04014062|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
219201796|NCT06440447|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
219201797|NCT04832412|DIETARY_SUPPLEMENT|BrainPhyt|BrainPhyt low dose supplementation during 6 months
219201798|NCT04832412|DIETARY_SUPPLEMENT|100 % Maltodextrin|100 % Maltodextrin
219201799|NCT06078891|BIOLOGICAL|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
219201800|NCT04814654|BEHAVIORAL|CHALO! 2.0|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
219201801|NCT04814654|BEHAVIORAL|Attention-matched control (AMC)|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
219201802|NCT04814654|BEHAVIORAL|Digital coupon only (DCO)|"The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers."
219201803|NCT05376527|BIOLOGICAL|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"
219201804|NCT04703920|DRUG|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
219201805|NCT04703920|DRUG|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
219507319|NCT02772536|OTHER|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
219507320|NCT00600197|BEHAVIORAL|back school|A kind of educational program for low back pain
219507321|NCT06338397|OTHER|SCANN|Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
219507322|NCT01428505|RADIATION|[18F]PBR111|radioligand to assess binding to TSPO
219507323|NCT00087061|DRUG|gimatecan|
219507324|NCT06267261|DEVICE|KOLMI® surgical face mask (OP-Air)|12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
218886550|NCT02737579|PROCEDURE|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
218886551|NCT02930902|DRUG|Gemcitabine Hydrochloride|Given IV
218886552|NCT02930902|OTHER|Laboratory Biomarker Analysis|Correlative studies
218886553|NCT02930902|DRUG|Nab-paclitaxel|Given IV
218886554|NCT02930902|DRUG|Paricalcitol|Given IV
218886555|NCT02930902|BIOLOGICAL|Pembrolizumab|Given IV
218886556|NCT02930902|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
218886557|NCT03488966|BEHAVIORAL|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
218886558|NCT02477124|DEVICE|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
218886559|NCT02477124|OTHER|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
218886560|NCT05425329|DIETARY_SUPPLEMENT|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
218886561|NCT05425329|DIETARY_SUPPLEMENT|Placebo treatment|Capsule containing maltodextrin.
218886562|NCT00629863|DRUG|cisplatin|
218886563|NCT00629863|DRUG|fluorouracil|
218886564|NCT00629863|OTHER|questionnaire administration|
218886565|NCT00629863|PROCEDURE|diagnostic endoscopic procedure|
218886566|NCT00629863|PROCEDURE|neoadjuvant therapy|
218886567|NCT00629863|PROCEDURE|quality-of-life assessment|
218886568|NCT00629863|PROCEDURE|therapeutic conventional surgery|
218886569|NCT00629863|PROCEDURE|therapeutic endoscopic surgery|
218886570|NCT00629863|PROCEDURE|ultrasound imaging|
218886571|NCT00629863|RADIATION|radiation therapy|
218886572|NCT00629863|RADIATION|radioisotope therapy|
218886573|NCT03469648|PROCEDURE|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
218886574|NCT02637583|DRUG|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
218886575|NCT02637583|DRUG|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
218886576|NCT04450940|BEHAVIORAL|PACV survey|
218886577|NCT04450940|BEHAVIORAL|Placebo survey|
218886578|NCT03571126|DRUG|Olanzapine|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
218886579|NCT03571126|DRUG|Placebos|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
219507325|NCT05938153|OTHER|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
218886580|NCT03038126|OTHER|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
218886581|NCT03038126|OTHER|Usual care|Standard clinical care
218886582|NCT03847935|PROCEDURE|surgery|A1 pulley release of finger
219030090|NCT02939963|PROCEDURE|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
219030091|NCT05035173|OTHER|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
219030092|NCT05035173|OTHER|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
219507326|NCT02347670|BEHAVIORAL|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
219030093|NCT05035173|OTHER|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
219030094|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
219030095|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
219030096|NCT06254014|DRUG|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
218886583|NCT03847935|PROCEDURE|corticosteroid injections|corticosteroid injection to A1 pulley
218886584|NCT03847935|OTHER|Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
218886585|NCT03847935|OTHER|Modality Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
218886586|NCT01635595|PROCEDURE|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
218886587|NCT01635595|PROCEDURE|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
218886588|NCT04011657|OTHER|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
218886589|NCT01831167|OTHER|dynamic light|
218886590|NCT00808119|DRUG|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
218886591|NCT01980329|DRUG|Maraviroc|
218886592|NCT05076201|BEHAVIORAL|Patients with completed rehab|The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
218886593|NCT01724866|DRUG|SPI-2012|SPI-2012 SC injection.
218886594|NCT01724866|DRUG|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
218886595|NCT01724866|DRUG|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
219507327|NCT02347670|BEHAVIORAL|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
219507328|NCT04590469|OTHER|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
219607594|NCT03909880|OTHER|Kinesio tape|"Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping."
219607595|NCT02712580|DEVICE|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
219607596|NCT02712580|DEVICE|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
219030097|NCT06538766|OTHER|Strength training with an internal focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific internal focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
219030098|NCT06538766|OTHER|Strength training with a proprioceptive external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific proprioceptive external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
219030099|NCT06538766|OTHER|Strength training with a visual external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific visual external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
219030100|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
219030101|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
219030102|NCT05237206|BIOLOGICAL|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
219030103|NCT05433623|PROCEDURE|Surgery|It will be documented if the patient underwent surgery for their vascular issue
219030104|NCT05846516|DRUG|VSV-GP154|VSV-GP154
219030105|NCT05846516|DRUG|ATP150|ATP150
219030106|NCT05846516|DRUG|ATP152|ATP152
219030107|NCT05846516|DRUG|Ezabenlimab|Ezabenlimab
219030108|NCT05846516|DRUG|ATP162|ATP162
219030109|NCT05067634|DRUG|Xcopri|Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
219030110|NCT06460519|OTHER|Non-invasive blood pressure measurements|Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
219030111|NCT04079179|DRUG|Cobimetinib|Cobimetinib will be administered at a maximal dose of 60 mg daily for patients \<18 years old and a flat dose of 40 mg daily for patients ≥18 years for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
219030112|NCT01966640|BIOLOGICAL|Basophil Activation Test|blood sample for Basophil Activation Test
219030113|NCT04569903|DEVICE|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
219030114|NCT03042052|DRUG|detrusor infection of Botulinum toxin|detrusor injection
219030115|NCT06050252|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219030116|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219030117|NCT06050252|DRUG|Cisplatin|Given IV
219030118|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
219030119|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
219030120|NCT06050252|DRUG|Gemcitabine|Given IV
219030121|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219030122|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
219030123|NCT01187927|BIOLOGICAL|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
219030124|NCT01771146|DRUG|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
219040389|NCT07027865|BEHAVIORAL|Sip & Snack Better (SSB) Intervention|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week health coaching intervention to reduce added sugar intake. Parents and teens will participate in 6 health coaching sessions (in weeks 1, 3, 5, 7, 9, and 12; 30-45 minutes, online via Zoom). Teens will participate in four in-person groups sessions (in weeks 2, 4, 6, and 8) and receive text-messages to reinforce intervention content.
219607597|NCT02712580|DEVICE|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
218886596|NCT01724866|DRUG|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
218886597|NCT04094974|DEVICE|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
218886598|NCT06288048|PROCEDURE|Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|"Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization"
218886599|NCT06288048|PROCEDURE|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
218886600|NCT03824002|DRUG|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
218886601|NCT03824002|DRUG|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
218886602|NCT03824002|DRUG|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
219607598|NCT02712580|DEVICE|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
218886603|NCT03824002|DRUG|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
218886604|NCT03824002|DRUG|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
219030125|NCT06301711|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
219030126|NCT06301711|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219030127|NCT06301711|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219030128|NCT01646515|DRUG|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
219030129|NCT01646515|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
219030130|NCT04537000|DIAGNOSTIC_TEST|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
219607599|NCT00006183|PROCEDURE|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
219607600|NCT00006183|PROCEDURE|Thoracic Surgery|
218886605|NCT04724863|PROCEDURE|Angioscan|"The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination."
218886606|NCT01424501|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
218886607|NCT01424501|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
218886608|NCT01980095|DRUG|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
218886609|NCT01980095|DRUG|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
218886610|NCT06390683|OTHER|Rewilding|Yards of the assisted living centers will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
218886611|NCT04951752|DRUG|Ropivacaine injection|Transmuscular quadratus lumborum block - active
218886612|NCT00640848|DRUG|almorexant|1 dose of 400 mg in two treatment sequences
218886613|NCT00640848|DRUG|almorexant|1 dose of 200 mg in two treatment sequences
218886614|NCT00640848|DRUG|almorexant|1 dose of 100 mg in two treatment sequences
219030131|NCT04516083|DIAGNOSTIC_TEST|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
219030132|NCT01637974|DRUG|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
219030133|NCT04721990|DEVICE|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
219507329|NCT03890185|COMBINATION_PRODUCT|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
219507330|NCT03890185|DRUG|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
218886615|NCT00640848|DRUG|almorexant|1 dose of 50 mg mg in two treatment sequences
218886616|NCT00640848|DRUG|almorexant|1 dose of 1000 mg in two treatment sequences
218886617|NCT02772744|DRUG|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
218886618|NCT02772744|DRUG|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
218886619|NCT02772744|DRUG|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
218886620|NCT03148041|OTHER|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2\. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
218886621|NCT00002399|DRUG|Posaconazole|
218886622|NCT00002399|DRUG|Fluconazole|
218886623|NCT03079063|BIOLOGICAL|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
218886624|NCT03079063|BIOLOGICAL|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
218886625|NCT04046146|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
219030134|NCT00728130|PROCEDURE|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
219030135|NCT04521972|DEVICE|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
219030136|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
219030137|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
219030138|NCT06064643|OTHER|Online Survey|All participants will be asked to complete an online survey
219030139|NCT06064643|OTHER|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
219030140|NCT06064643|OTHER|Bleed Diary|50 participants will complete a 30 day bleed diary
219507331|NCT01972022|DEVICE|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
218886626|NCT04046146|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
218886627|NCT00531869|BEHAVIORAL|biases towards products|
218886628|NCT01382238|DRUG|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
218886629|NCT01382238|DRUG|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
218886630|NCT04364295|DEVICE|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
218886631|NCT00491933|PROCEDURE|Quantiferon-TB Gold assay|
219030141|NCT05762900|RADIATION|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
219507332|NCT01972022|DEVICE|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
219030142|NCT04991935|DRUG|CC-93538|CC-93538
219507333|NCT01144663|BIOLOGICAL|Nimenrix™|4- or 3-dose intramuscular injection
219507334|NCT01144663|BIOLOGICAL|Menjugate®|3-dose intramuscular injection
219507335|NCT01144663|BIOLOGICAL|NeisVac-CTM|3-dose intramuscular injection
219507336|NCT01144663|BIOLOGICAL|Infanrix™ hexa|4-dose intramuscular injection
219507337|NCT01144663|BIOLOGICAL|Synflorix™|4-dose intramuscular injection
218886632|NCT00491933|PROCEDURE|Tuberculin skin test|
218886633|NCT05015569|DEVICE|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
218886634|NCT05015569|OTHER|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
218886635|NCT01669772|DRUG|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
219030143|NCT00729183|DRUG|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
219030144|NCT00729183|DRUG|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
219030145|NCT00729183|DRUG|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
219030146|NCT00729183|DRUG|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
219030147|NCT00699556|DRUG|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
219030148|NCT00699556|DRUG|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
219030149|NCT00699556|DRUG|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
219030150|NCT00181012|DRUG|Lidocaine|
219030151|NCT06585449|DRUG|ALN-HTT02|ALN-HTT02 will be administered intrathecally
219030152|NCT06585449|DRUG|Placebo|Placebo will be administered intrathecally
219030153|NCT05287451|OTHER|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
219030154|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
219030155|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
219030156|NCT06591377|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
219030157|NCT06591377|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
219030158|NCT06591377|DRUG|Aspirin 75mg|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
219030159|NCT06591377|DRUG|Aspirin 75mg|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
219030160|NCT05166109|DRUG|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
219030161|NCT05166109|DRUG|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
219030162|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
219507338|NCT05518435|OTHER|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
218886636|NCT01669772|DRUG|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
218886637|NCT02363621|DRUG|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
218886638|NCT02363621|DRUG|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
219201806|NCT05265520|PROCEDURE|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
218886639|NCT01361100|DEVICE|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
218886640|NCT00003727|BIOLOGICAL|filgrastim|
219201807|NCT05265520|PROCEDURE|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
219030163|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
219201808|NCT06336291|DRUG|L19TNF|7 μg/kg
219201809|NCT06336291|DRUG|L19TNF|10 μg/kg
219201810|NCT06336291|DRUG|L19TNF|13 μg/kg
219201811|NCT06336291|DRUG|Lomustine|90 mg/m2
219201812|NCT06336291|DRUG|Lomustine|110 mg/m2
219607601|NCT04820660|OTHER|Task orientated strengthening training|"1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
218886641|NCT00003727|BIOLOGICAL|recombinant interferon alfa|
218886642|NCT00003727|BIOLOGICAL|sargramostim|
218886643|NCT00003727|BIOLOGICAL|therapeutic autologous lymphocytes|
218886644|NCT00003727|DRUG|carmustine|
218886645|NCT00003727|DRUG|cyclophosphamide|
218886646|NCT00003727|DRUG|etoposide|
218886647|NCT00003727|DRUG|gemcitabine hydrochloride|
218886648|NCT00003727|DRUG|melphalan|
218886649|NCT00003727|PROCEDURE|bone marrow ablation with stem cell support|
218886650|NCT00003727|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
218886651|NCT02697318|DRUG|Timolol maleate 0.5% ophthalmic solution|
218886652|NCT00002357|DRUG|HBY 097|
219030164|NCT06287866|PROCEDURE|Pinch Graft|In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
219030165|NCT04234568|PROCEDURE|Biospecimen Collection|Correlative studies
219030166|NCT04234568|PROCEDURE|Computed Tomography|Undergo CT
219201813|NCT06872203|DEVICE|Deep brain stimulation|Deep Brain Stimulation programming
219201814|NCT06872424|BEHAVIORAL|psychosocial skills-oriented group psychoeducation|A 5-session Psychosocial Skills Focused Group Psychoeducation will be implemented, each session lasting approximately 60-90 minutes. In order to make the training more active and effective, the experimental group will be divided into small groups and divided into 3 groups and each group will be given 5 sessions of Psychosocial Skills Focused Group Psychoeducation once a week.
219201815|NCT06870461|PROCEDURE|Liver surgery / ablation|Any type of liversurgery or CT-guidede liver ablation
219201816|NCT06870188|OTHER|Composite Restoration|The study included premolar or molar teeth with Class 1 and Class 2 cavity types and a remaining wall thickness of at least 3 mm, which had undergone endodontic treatment from volunteer participants. The teeth randomly assigned were divided into two groups: Group 1: fiber-reinforced composite restoration (FRCR), Group 2: composite restoration (CR). Direct composite restorations with or without fiber reinforced material were applied. The restorations were evaluated at 6 and 12 months using the FDI criteria.
218886653|NCT00002357|DRUG|Zidovudine|
218886654|NCT02002741|DRUG|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
218886655|NCT02002741|DRUG|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
218886656|NCT05334628|PROCEDURE|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
218886657|NCT05334628|PROCEDURE|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
218886658|NCT03226834|DEVICE|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
219030167|NCT04234568|DRUG|Lutetium Lu 177 Dotatate|Given IV
219030168|NCT04234568|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219030169|NCT04234568|DRUG|Triapine|Given PO
219030170|NCT05775614|DEVICE|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
219030171|NCT05775614|DEVICE|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
219201817|NCT06870188|OTHER|Clinical evaluation|The restorations were evaluated by two experienced and fully blinded observers according to the functional, esthetic, and biological criteria. The criteria were scored from 1 to 5 (sufficient/acceptable= score 1 to 3, insufficient/inacceptable but repair possible= score 4, and insufficient/inacceptable but repair not possible/reasonable= score 5). Scores of 4 and 5 were considered as failure in the restoration.
219507339|NCT05905848|DRUG|administering RASI (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
218886659|NCT03226834|OTHER|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
218886660|NCT03676244|DEVICE|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
218886661|NCT00193817|PROCEDURE|Two field vs Three field lymphadenectomy|
219507340|NCT05905848|DRUG|administering CCB (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
218886662|NCT04279535|DRUG|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
218886663|NCT04564157|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
218886664|NCT04564157|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
218886665|NCT04564157|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
218886666|NCT06164665|DRUG|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
218886667|NCT06164665|OTHER|Placebo|100% microcrystalline cellulos
218886668|NCT02155777|DRUG|OrthoNovum 1/35|
219030172|NCT06285370|DRUG|Mogamulizumab|Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
219030173|NCT06501118|OTHER|Education|"1. Standardized materials to discuss the rationale and procedural aspects of the intervention, including details on the specific oxygen target-related modifications to the mechanical ventilation order-set prior to starting the intervention phase.~2. Virtual respiratory therapist (vRT) - directed real-time feedback on adherence to the SpO2 target range as a part of the mechanical ventilation order-set embedded in UCHealth EHR (EPIC)."
219030174|NCT03878446|DRUG|Somapacitan|Somapacitan injected under the skin once a week.
219030175|NCT03878446|DRUG|Norditropin®|Norditropin® injected under the skin once a day.
219030176|NCT06914128|DRUG|BAY 3713372|Daily oral administration
219507341|NCT03081767|DIAGNOSTIC_TEST|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
219507342|NCT04437342|OTHER|PHQ-9 (Patient Health Questionnaire) Depression Scale|9 question questionnaire for assessment of depression
219030177|NCT06673004|PROCEDURE|Ovarian tissue allo-transplantation|Participants will receive donor ovarian tissue with immunosuppression
219507343|NCT04437342|OTHER|GAD-7 (General Anxiety Disorder) scale|7 question questionnaire for assessment of General Anxiety Disorder
219507344|NCT04437342|OTHER|38 questions questionnaire|38 questions questionnaire
219507345|NCT04437342|OTHER|EPDS (Edinburgh Postnatal Depression Scale)|10 questions scale for detection of postpartum depression
218886669|NCT00624273|DRUG|Sildenafil therapy|oral use
218886670|NCT03499184|DIETARY_SUPPLEMENT|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
218886671|NCT03499184|DIETARY_SUPPLEMENT|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
218886672|NCT03499184|DRUG|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
218886673|NCT03499184|DRUG|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
219201818|NCT06872879|OTHER|VEMS Simulation|"Students in the VEMS (Visually Enhanced Mental Simulation) group will receive a structured training programme to improve their PPH management skills. This process consists of three main stages: Theoretical training, skills training and simulation practice.~1.1 hour theoretical training will be given to the students to remind them the basic information about PPH management.~2\. PPH management will be mentally visualised step by step using VEMS materials. Students will be individually involved in the scenario and will apply the steps of PPH management in a mental simulation environment. After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
218886674|NCT00601497|DEVICE|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
218886675|NCT00354393|DRUG|Cisplatin|
219201819|NCT06872879|OTHER|Hybrit Simulation|"Students in the hybrid simulation group will receive a simulation-based training in which the standard patient and part task trainer are used together. This process consists of three main stages: theoretical training, skills training and simulation practice.~1.1 hour theoretical training to remind basic information about PPH management. 2. Standard patient and part task trainers will be used in the skills training of the students. Students will make patient assessment, check vital signs and plan necessary interventions by contacting the standard patient.After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
219201820|NCT06871995|PROCEDURE|spinal block|All patients will receive spinal anesthesia via midline approach with patients in sitting position established by assistant under complete aseptic conditions. A subcutaneous bleb using Lidocaine 1% through the needle of an insulin syringe followed by minor skin scratch to will help avoiding possible intrathecal dermoid implantation . A lumbar puncture will be performed in L4-L5 or L5- S1 interspace using 25-G 25-mm pencil-point spinal needle . Depth of epidural space is anticipated at 0.1 mm/kg . After getting free flow of cerebrospinal fluid (CSF) hyperbaric bupivacaine (0.5%) in a dose of 0.5 mg/kg (0.1 ml/kg) will be slowly injected in the subarachnoid space . The end of the injection will be taken as time zero for further data recording.
219201821|NCT06872164|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based psychotherapy for PTSD that provides education and teaches skills to challenge the trauma-related beliefs that maintain PTSD symptoms. In this study, CPT has been adapted to include content on the relationship between substance use and PTSD and a focus on harm reduction.
219507346|NCT04826796|BEHAVIORAL|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
219507347|NCT03775395|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
218886676|NCT00354393|DRUG|Methotrexate|
219507348|NCT03775395|DRUG|Sorafenib|400mg BID daily oral dosing
219507349|NCT03775395|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219507350|NCT01335477|DRUG|placebo|placebo matching BIBF 1120 BID
219507351|NCT01335477|DRUG|BIBF 1120|BIBF 1120 BID (twice daily)
219507352|NCT03780894|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
218886677|NCT00354393|DRUG|Vinorelbine ditartrate|
218886678|NCT00354393|PROCEDURE|Adjuvant therapy|
219507353|NCT03780894|BIOLOGICAL|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
218886679|NCT00354393|PROCEDURE|Conventional surgery|
218886680|NCT00354393|PROCEDURE|Neoadjuvant Therapy|
218886681|NCT00354393|RADIATION|3-dimensional conformal radiation therapy|
218886682|NCT00354393|RADIATION|Intensity-modulated radiation therapy|
218886683|NCT03012048|DEVICE|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
218886684|NCT03012048|DEVICE|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
219507354|NCT03780894|DRUG|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
219507355|NCT02881476|OTHER|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
218886685|NCT03012048|DEVICE|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
218886686|NCT05855369|DEVICE|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
219201822|NCT02422147|PROCEDURE|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
219201823|NCT06681922|DRUG|Cyclophosphamide, Bortezomib, Abatacept|Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
218886687|NCT05855369|OTHER|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
218886688|NCT05855369|OTHER|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
219201824|NCT06682273|OTHER|Thread-embedding acupuncture|Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.
219507356|NCT04505514|DRUG|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
219507357|NCT04505514|DRUG|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
219507358|NCT04505514|DRUG|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
219507359|NCT05702359|OTHER|Glucose as reference food|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507360|NCT05702359|OTHER|Control juice|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507361|NCT05702359|OTHER|Juice with vitamin D3|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507362|NCT05702359|OTHER|Juice with n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507363|NCT05702359|OTHER|Juice with probiotics|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507364|NCT05702359|OTHER|Juice with probiotics, vitamin D3, and n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
219507365|NCT02889328|DRUG|Regorafenib|Regorafenib 100mg continuous dosing arm
219507366|NCT05434481|OTHER|Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases|"* For each patient: a segment of aorta will be sampled and cutted into 4 parts~  * 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.~ * 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.~ * 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.~* For each patient, 2 arterial blood samples will be collected before general anaesthesia~  * One tube of whole blood stored at -80°C for metabolomic analysis.~ * One tube of blood stored at -80°C for plasma cytokines"
219030178|NCT06626269|DIAGNOSTIC_TEST|Blood sample|"In cohort A: 3 or 4 blood samples (for plasma and PBMC collection) : at baseline (before immunotherapy initiation); at 3 months ; at 12 months; on case of severe or unexpected toxicity.~In cohort B: 3 blood sampes (for plasma and PBMC collection): at baseline (before treatment initiation); at 3 months ; at 12 months~In cohort C: 2 blood samples (for plasma and PBMC collection) : at baseline (at the time of surgery); at 3 months (after surgery)"
219030179|NCT06626269|OTHER|Tumor tissue|Cohort A and B: 1 tumor block in paraffin at diagnosis + 1 tumor block in paraffin at progression (optional) Cohort C: Fresh tumoral tissue fragments for TIL and CAF + 1 tumor block in paraffin at time of surgery.
219030180|NCT06762730|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zolendric acid will be provided to HIV naïve patients with documented osteopnia
219030181|NCT07056166|PROCEDURE|epidural catheter|Epidural catheter placement for labor analgesia
219030182|NCT07056166|PROCEDURE|spine ultrasonography|An ultrasound scan will be performed on the spine to identify anatomical characteristics of potential interest
219030183|NCT07059182|BIOLOGICAL|Inactivated whole-cell Streptococcus pneumoniae vaccine|Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine
219030184|NCT07059182|DRUG|Placebo|Single intramuscular injection of 0.5 mL placebo
218886689|NCT05690555|OTHER|Preoperative and Postoperative Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
218886690|NCT05690555|OTHER|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
219201825|NCT06682273|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.
219201826|NCT06682273|OTHER|Sham thread-embedding acupuncture|Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.
219201827|NCT06682273|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.
219201828|NCT04107116|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
219201829|NCT04107116|OTHER|Usual Care|Usual care as provided by local oncologists
219201830|NCT06682286|OTHER|NIV mask A|Bridge free face mask
219201831|NCT06682286|OTHER|NIV mask B|Full face mask
219201832|NCT06684470|DRUG|Mirtazapine|mirtazapine will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
219201833|NCT06684470|OTHER|Placebo|Placebo will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
219201834|NCT06685224|DIAGNOSTIC_TEST|Ultrasound Assessment of the aeration of lung tissue and Parasternal Intercostal Muscle Thickness|Examine the predictive value of lung ultrasound in assessing the success of SBTs and tracheal extubation among patients receiving mechanical ventilation in the intensive care unit (ICU)
219201835|NCT05471947|DRUG|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
219201836|NCT06685289|DRUG|Donafenib|200mg, oral, twice daily, continuous medication for 6 months
219201837|NCT06685289|DRUG|capecitabine|1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
219201838|NCT05925621|DRUG|Lecanemab|Observational study
219201839|NCT06407700|PROCEDURE|Brugger's exercise.|Participant was in a high sitting position. An elastic resistance band was be wrapped on each hand of the participant leaving the palm open and instructed to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant were instructed to perform scapular retraction with chin tucked in ,shoulder external rotation, elbow extension, shoulder abduction, and extension. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds, 4 sets 12 times repetitions.
219507367|NCT00003533|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219507368|NCT01724398|OTHER|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
219507369|NCT01724398|OTHER|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
219507370|NCT01724398|OTHER|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
219507371|NCT01724398|OTHER|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
219507372|NCT00623025|DRUG|Creon 25000|6 to 9 capsules Creon 25000 per day
219507373|NCT00623025|DRUG|Placebo|6 to 9 capsules placebo per day
219201840|NCT06407700|PROCEDURE|Kendall Exercise.|Kendall exercises with the frequency 5 sets of consisting of 12 repetitions of postures, each taking 30 seconds,3 times a week for total of 6 weeks.
219201841|NCT05473663|DEVICE|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
219201842|NCT05473663|DEVICE|Sham|Is performed identically to the active treatment but without the application of the RFA current
219201843|NCT05301881|PROCEDURE|Surgery|resection of the oligometastatic lesion(s)
219201844|NCT05301881|RADIATION|Radiotherapy|radiation of the oligometastatic lesion(s)
219201845|NCT05301881|OTHER|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
219201846|NCT04189146|BEHAVIORAL|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
219201847|NCT06243835|DRUG|Kindolor Tosylate|Kindolor Tosylate enteric coated tablets containing the specified amount of drug product
219201848|NCT06243835|DRUG|Placebo|Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
218886691|NCT05690555|OTHER|Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
218886692|NCT06114888|DIAGNOSTIC_TEST|MeMed BV + Usual Care|We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
218886693|NCT06114888|OTHER|Usual Care Alone|Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
218886694|NCT05873998|DIAGNOSTIC_TEST|Slow pressure-volume curve|Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
218886695|NCT06532279|OTHER|Best Practice|Receive usual symptom management
218886696|NCT06532279|PROCEDURE|Biospecimen Collection|Undergo collection of blood, serum, and/or plasma samples
218886697|NCT06532279|DRUG|Cisplatin|Given cisplatin
219201849|NCT06686992|BEHAVIORAL|Vaccination|The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
219201850|NCT06691282|OTHER|Mindful self-compassion intervention|Participants will receive six weekly sessions of training by a trainer in mindful self-compassion (MSC). Each session lasting around 90 minutes and will be conducted face-to-face at the Hong Kong Metropolitan University. The content of the intervention will include an introduction of mindfulness and self-compassion, practice of body awareness and loving kindness, skills to deal with challenging experiences, and methods for relating to positive aspects of the self.
219201851|NCT03048084|DRUG|Levetiracetam|Antiepileptic drug levetiracetam
219201852|NCT03048084|DRUG|Valproic Acid|Antiepileptic drug valproic acid
219201853|NCT06691828|DRUG|NX-5948|NX-5948 will be given once by IV and then given once by mouth.
219201854|NCT06690554|OTHER|Education Group|"Women will be given a five-day training in line with the health promotion model.~Information will be provided to women who apply to the hospital. Written consent documents will be obtained from women who agree to participate in the study.~Women assigned to the intervention group will attend classes in groups of 8-10. Women will be given a 60-minute training once a day for five days. The total training duration is five hours. Scales will be applied to women who complete the training at the end of the fifth day.~Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test."
219201855|NCT06688162|OTHER|Usual Care|During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
219507374|NCT04642950|DRUG|Sargramostim|250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.
219507375|NCT04642950|DRUG|Placebo|2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
218886698|NCT06532279|PROCEDURE|Computed Tomography|Undergo CT
218886699|NCT06532279|RADIATION|Image Guided Radiation Therapy|Undergo image-guided radiation therapy
218886700|NCT06532279|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
218886701|NCT06532279|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218886702|NCT06532279|DRUG|MnSOD Mimetic BMX-001|Given SC
218886703|NCT06532279|DRUG|Placebo Administration|Given SC
218886704|NCT06532279|OTHER|Questionnaire Administration|Ancillary studies
218886705|NCT06367699|BEHAVIORAL|Usual Care|Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
218886706|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
219030185|NCT07066371|BEHAVIORAL|Emotional freedom technique|"Emotional Freedom Technique Application Guidelines~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
219030186|NCT07067788|DIAGNOSTIC_TEST|Breast Imaging|Intervention using an FDA-approved mammogram machine.
219201856|NCT06688162|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
219030187|NCT07070479|DRUG|Ivonescimab|Ivonescimab 10 mg/kg via intravenous infusion, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
219201857|NCT00692939|BIOLOGICAL|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
219201858|NCT00692939|DRUG|Alemtuzumab|Transplant conditioning
219201859|NCT00692939|DRUG|ATG|Transplant conditioning
219201860|NCT00692939|DRUG|Melphalan|Transplant conditioning
219201861|NCT00692939|DRUG|Thiotepa|Transplant conditioning
219201862|NCT00692939|DRUG|Rituximab|Transplant conditioning
219201863|NCT00692939|DRUG|Cyclophosphamide|Mobilization
219201864|NCT00692939|DRUG|G-CSF|Mobilization
219607602|NCT04820660|OTHER|Balance training exercises|"1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s."
219607603|NCT02329626|DEVICE|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
219030188|NCT07070479|DRUG|Nimotuzumab|Nimotuzumab 400 mg via intravenous infusion, Q3W, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
219030189|NCT07070479|DRUG|Irinotecan liposome|Irinotecan liposome 50mg/m2 via intravenous infusion, D1, D15, Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
219030190|NCT07070479|DRUG|S-1|S-1, D1-D14, BID, p.o., (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose), Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
219030191|NCT07070479|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone hydrochloride liposome 20mg/m2 via intravenous infusion, Q3W for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first
219030192|NCT07070479|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) , Q3W for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
219201865|NCT00692939|DRUG|Mesna|Mobilization
219201866|NCT06619392|DRUG|HRS-2129|HRS-2129
219201867|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
219201868|NCT06622668|BIOLOGICAL|Biological NTLA-3001|IV administration of AAV and CRISPR/Cas9 gene editing system
219201869|NCT03522298|DRUG|Paxalisib (GDC-0084)|Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
219201870|NCT06874062|PROCEDURE|Neoputty MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Neoputty MTA was placed."
218886707|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
219607604|NCT04697082|PROCEDURE|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
219030193|NCT07160491|OTHER|A novel artificial intelligence assisted mobile application|A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc.The thrombolytic drug used in this study is tenecteplase (manufacturer: CSPC Pharmaceutical Group Limited, China ).
219030194|NCT05416307|DRUG|ELA026|Multiple doses of ELA026
219607605|NCT04697082|PROCEDURE|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
219030195|NCT07164989|BEHAVIORAL|Motivational Interviewing-Based Counseling|Motivational interviewing (MI) is a structured, patient-centered counseling technique that helps individuals explore and resolve ambivalence toward behavior change. In this study, MI sessions will be delivered by trained pediatric dental professionals during routine orthodontic visits. Each session will last approximately 10-15 minutes and will be guided by a standardized MI protocol, focusing on improving oral hygiene behavior and increasing personal motivation and responsibility for oral care among adolescent participants. Sessions will be conducted at multiple time points during the course of treatment.
219030196|NCT07164989|BEHAVIORAL|Standard Oral Health Education|Participants in this group will receive the conventional oral hygiene education typically provided in orthodontic clinics. This includes verbal instructions and printed educational materials on topics such as toothbrushing technique, flossing with braces, and the importance of maintaining oral hygiene during orthodontic treatment. Education will be delivered by pediatric dental staff during scheduled orthodontic appointments at the same time points as the intervention group (baseline, 1-month, and 6-month visits). No motivational interviewing techniques will be used. This approach reflects routine care and serves as the comparator for evaluating the added value of MI.
219030197|NCT07180264|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
219030198|NCT07181538|DRUG|JLP-2302|taking JLP-2302
219030199|NCT07181538|DRUG|JP-1366|taking JP-1366
219030200|NCT07179588|BEHAVIORAL|Nutrition Education Program|The participants will attend a monthly nutrition education session for 4 months (total 4 sessions). The sessions will be available in person and over teleconference platforms (i.e., Zoom). Each session will be up to 1-hour, which will include nutrition guidelines to manage diet quality.
219030201|NCT07179588|BEHAVIORAL|Nutrition Counseling|Participant will meet with a registered dietitian for one-on-one diet consults once a month for 4 months. These sessions can be in-person or via Zoom. Each session will be up to 1 hour, and will be done to assess if the nutrition guidelines taught during the education sessions are being implemented.
219030202|NCT07180927|BIOLOGICAL|4SCAR DLL3 T cells|Infusion of 4SCAR DLL3 T cells at 10\^6 cells/kg body weight via intravenous route
219030203|NCT07181369|DRUG|GTX-B001|Single infusion of one of up to five dosages of GTX-B001
219030204|NCT07181369|DRUG|Normal Saline|Single infusion of normal saline
219030205|NCT07181824|OTHER|Diagnostic tedst|"* Radiologic signs: 2 consecutive thorax x-ray with new onset pneumonia AND~* One of the following criteria~  * Fever \>38,3°C without any other cause~ * Leucocytes \< 4000/mm3 or ≥ 12000 /mm3~* AND at least two of the following~  * Purulent secretions~ * Cough or dyspnoea~ * Desaturation or increase in FiO2 (+20%)"
219030206|NCT07180732|PROCEDURE|Injection moulding technique|A dental technique that uses a transparent silicone index or stent to inject a low-viscosity composite into a pre-planned and approved tooth shape.
219030207|NCT07180732|DIAGNOSTIC_TEST|Digital smile design|A modern approach that uses digital imaging, videos, and software to create a customized, virtual 3D model of a patient's ideal smile before any treatment begins
219030208|NCT07179822|BEHAVIORAL|Motor Evoked Potential (MEP) Operant Conditioning|Operant conditioning is a method to induce behavioral learning based on the consequence (reward) of the behavior. With operant conditioning of the motor evoked potential (MEP), the neuronal excitability and behavior of the corticospinal pathway that involves production of MEP is targeted and trained (i.e., up-trained with up-conditioning). The individual is rewarded only for changing the target muscle's MEP size without changing background muscle activity. Since MEP size reflects the corticospinal excitability at or just before the time of stimulation, during MEP up-conditioning trials, the individual is urged to increase the corticospinal excitability for the target muscle.
219030209|NCT07180108|DRUG|Psilocybin (high dose)|25 mg pill
219201871|NCT06874062|PROCEDURE|ProRoot MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, ProRoot MTA was placed."
219201872|NCT06874062|PROCEDURE|Theracal PT Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Theracal PT was placed."
219201873|NCT06874062|PROCEDURE|Stainless Steel Crown Application|After pulpotomy treatment, the pulpotomy material was covered using a capsule-form glass ionomer (EQUIA Forte®, GC, Tokyo, Japan). In the same session, preparation was performed for the placement of a stainless steel crown (SSC), and an appropriately sized SSC (3M ESPE, Seefeld, Germany) was selected based on visual estimation. After trial fitting on the tooth, the crown was cemented using a capsule-form glass ionomer (Riva, SDI Ltd., Victoria, Australia).
219201874|NCT04661280|DRUG|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
219201875|NCT06874257|BIOLOGICAL|Laboratory tests and in vitro studies|Cell models, co-culture condition set-up and functional validation, Single-cell RNA sequencing and NGS, Metabolomics analysis, metabolomics validation and intracellular metabolomics analysis, Metabolic ImmunoProfiling and epigenetic profile, CyTOF immune and signaling profiling, Monocyte, macrophages and MSCs in vitro assays.
219201876|NCT04151368|PROCEDURE|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
218886708|NCT06367699|BEHAVIORAL|ECA-HPV App with Adolescent Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
219507376|NCT04822870|PROCEDURE|quadratus lumborum block|Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
219201877|NCT06874049|DRUG|Vaginal misoprostol|the vaginal misoprostol solution will be prepared by complete crushing of one misoprostol 200 µg tablet into powder then adding the powder into a clean urine specimen cup then adding 20 cc of KY gel measured by a 20 ml syringe then mix the contents together to ensure adequate distribution of the powder , each patient will receive only 2.5cc of the mixture vaginally (inserted into the posterior fornix,) by using medical 3ml syringes equal to 25 mcg misoprostol 4 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023) and remain recumbent for 10-20 minutes
219201878|NCT06874049|DRUG|Oral misoprostol solution (OMS)|the solution will be prepared by dissolving one 200 µg tablet in 200 ml of tap water , each member will receive 25 cc misoprostol solution equal to 25 mcg misoprostol 2 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023)
219201879|NCT04795245|DRUG|afatinib|afatinib
219507377|NCT04822870|PROCEDURE|iliohypogastric/ilioinguinal nerve block|Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
219507378|NCT04822870|PROCEDURE|epidural analgesia|Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
219607606|NCT04697082|OTHER|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
219607607|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
219607608|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
219507379|NCT05584475|BEHAVIORAL|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
219607609|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
219607610|NCT01012310|DRUG|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
218886709|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
219607611|NCT02826512|DRUG|Niraparib|niraparib 300 mg QD continuously
218886710|NCT05327686|BIOLOGICAL|Avelumab|Given IV
218886711|NCT05327686|DRUG|Axitinib|Given PO
219507380|NCT01400269|BEHAVIORAL|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
219607612|NCT02568839|DRUG|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
219607613|NCT02568839|DRUG|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
219607614|NCT06451211|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
219607615|NCT06451211|DRUG|Oxaliplatin|Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
219607616|NCT06451211|DRUG|S-1|S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
218886712|NCT05327686|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218886713|NCT05327686|PROCEDURE|Bone Scan|Undergo bone scan
218886714|NCT05327686|DRUG|Cabozantinib|Given PO
218886715|NCT05327686|PROCEDURE|Computed Tomography|Undergo CT
218886716|NCT05327686|BIOLOGICAL|Ipilimumab|Given IV
218886717|NCT05327686|DRUG|Lenvatinib|Given PO
218886718|NCT05327686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218886719|NCT05327686|BIOLOGICAL|Nivolumab|Given IV
219030210|NCT07180108|BEHAVIORAL|Playlist 1|Six hour playlist
219030211|NCT07180108|BEHAVIORAL|Playlist 2|A six hour playlist
219030212|NCT07180108|BEHAVIORAL|Playlist 3|A six hour playlist
219030213|NCT07180108|BEHAVIORAL|Playlist 4|A six hour playlist
219030214|NCT07180108|BEHAVIORAL|Playlist 5|A six hour playlist
219030215|NCT07181187|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film once or twice daily.
219030216|NCT07181187|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film once or twice daily.
219030217|NCT07180381|OTHER|PSA and MRI-monitoring|Men with PI-RADS 3 or 4 lesions and a PSA density ≤ 0.15 ng/mL² are actively monitored with PSA testing every six months and MRI annually, instead of undergoing immediate prostate biopsy.
219030218|NCT07181434|DEVICE|The patient will be equipped with VR headsets|The patient will be equipped with VR headsets showing one of the six scenes from the HealthyMind® program in 3D, accompanied by hypnotic speech during the procedure.
219030219|NCT07180069|OTHER|diet education|Individualized dietary education focused on reducing phosphate intake (food choices, portion control, additives).
219030220|NCT07180615|DRUG|Rifaximin (Xifaxan)|Preoperative gut decolonization protocol based on oral Rifaximin 2x550mg 10 am and 10 pm on the day preceding the surgery
219030221|NCT07180615|DRUG|Metronidazole|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
219030222|NCT07180615|DRUG|Neomycin Sulfate|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
219030223|NCT07179666|OTHER|Neural moblization group|The intervention will involve neural mobilization of the tibial nerve, beginning with distal sliding through ankle dorsiflexion and foot eversion, followed by dorsiflexion of the toes. The movement will then be reversed into plantarflexion to allow proximal nerve excursion. In addition, a tensioner technique will be applied, in which participants will perform 45° hip flexion combined with ankle dorsiflexion and eversion, followed by knee extension, to place a controlled tensile load along the tibial nerve pathway.
218886720|NCT05327686|BIOLOGICAL|Pembrolizumab|Given IV
218886721|NCT05327686|RADIATION|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
218886722|NCT03827057|BEHAVIORAL|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
218886723|NCT03827057|BEHAVIORAL|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
218886724|NCT05437562|PROCEDURE|Ewing Below Knee Amputation|Ewing Below Knee Amputation
218886725|NCT05437562|PROCEDURE|Standard Below Knee Amputation|Standard Below Knee Amputation
218886726|NCT04784143|DRUG|Midomafetamine|120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
218886727|NCT04784143|BEHAVIORAL|Psychotherapy|Manualized psychotherapy performed by therapist team
218886728|NCT05484739|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
218886729|NCT05484739|OTHER|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
219030224|NCT07179666|OTHER|Conventional therapy group|The intervention will include manual therapy techniques such as myofascial release and soft tissue mobilization to reduce fascial tension and improve local circulation. Stretching exercises will be prescribed to target the plantar fascia, Achilles tendon, and gastrocnemius-soleus complex in order to enhance flexibility and reduce mechanical strain. In addition, ultrasound therapy will be utilized for its thermal and non-thermal effects to promote tissue healing and reduce inflammation.
219607617|NCT06451211|DRUG|Capecitabine|Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
219507381|NCT00583869|DRUG|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
218886730|NCT05484739|OTHER|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
218886731|NCT05484739|OTHER|Control|Participants will NOT receive either water spray or a fan exposure.
219607618|NCT00930163|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
219607619|NCT00930163|DRUG|placebo|Subcutaneous repeating dose
219607620|NCT00745784|BEHAVIORAL|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
218886732|NCT04502966|BIOLOGICAL|Dupixent®|An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.
218886733|NCT04502966|BIOLOGICAL|Grazax®|"One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA."
218886734|NCT04502966|DRUG|Dupixent® Placebo|"Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient."
219030225|NCT07180602|BEHAVIORAL|Heart Math Biofeedback Breathing Practices|Phase I and II (0-6 months): Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
218886735|NCT04502966|DRUG|Grazax® Placebo|"One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units."
218886736|NCT05195541|DRUG|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
219030226|NCT07180602|BEHAVIORAL|Nutrition Counseling combined with Exercise Counseling|Phase II (3-6 months): Dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Nutrition counseling includes nutrition supplementation to correct deficiencies. Study participants will have a blood test to examine vitamins and minerals and identify deficiencies. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the ACSM and the AAP. Study participants and parents will be provided with a handout with exercise recommendations to follow at home and links to a website for additional suggestions for developmentally-appropriate physical activities and a tracking tool to assist parents with determining if their child is following the guidelines.
219030227|NCT07180459|PROCEDURE|E-TACE|The 70/100μm drug-loaded microspheres were loaded with anthracyclines (30mg-50mg Idarubicin) at 2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded anthracyclines (30mg-50mg Idarubicin) with 2mL/3mLto embolize the tumor supplying arteries at different grades and diameters.
219030228|NCT07180459|DRUG|Donafenib|400mg QD
219030229|NCT07180225|OTHER|Conventional therapy+manual therapy|Conventional therapy contains TENS and physiotherapist-supervised exercise program. These exercises are Wand exercises (15 repetitions each), codman exercises (1 minute in each direction), shoulder wheel exercises (5 minutes total), finger ladder exercises (10 repetitions), isometric exercises (10 repetitions each), capsular stretching exercises (10 repetitions each), pectoral muscle stretching and stabilization exercises (10 repetitions), shoulder stabilization exercises (5 minutes total), and strengthening exercises for the shoulder flexor, extensor, abductor, adductor, internal rotator, and external rotator muscles (15 repetitions each). In addition to them, manual therapy were applied to the shoulder region.
219030230|NCT07180225|OTHER|Conventional therapy+manual therapy+breathing exercises|In addition to the treatment program of Group I, breathing exercises were added. Each manual therapy technique was performed with 10 repetitions per participant. Similarly, participants were instructed to perform each breathing exercise with 10 repetitions. They were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
219030231|NCT07179952|DRUG|Slow Release DHEA|Slow-release dehydroepiandrosterone capsule
219030232|NCT07179952|DRUG|Placebo|placebo capsule
219030233|NCT07180303|OTHER|Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies. Ongoing support services,|"Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies.~Ongoing support services, such as regular knowledge updates and technical consultations."
219607621|NCT03048552|BEHAVIORAL|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
219607622|NCT06080854|DRUG|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
219607623|NCT06080854|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
219607624|NCT06080854|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
219607625|NCT06080854|OTHER|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
219607626|NCT04667754|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
218886737|NCT06455852|BIOLOGICAL|oral cholera vaccine or typhoid conjugate vaccine|One group of participants will receive a 2 dose oral cholera vaccine, the other set will receive a typhoid conjugate vaccine
218886738|NCT05757557|DRUG|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
219607627|NCT01499433|DRUG|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
219607628|NCT03172494|DRUG|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
219607629|NCT03172494|DRUG|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
219607630|NCT03172494|DRUG|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
219607631|NCT01670591|BEHAVIORAL|PS - Prevention in School|
219607632|NCT04190017|OTHER|Cranial MRI|Cranial MRI
219030234|NCT07180303|OTHER|Continuation of routine healthcare services without any additional training interventions.|Continuation of routine healthcare services without any additional training interventions.
219030235|NCT07181642|BEHAVIORAL|Diaphragmatic Breathing Program|Participants will learn diaphragmatic breathing exercises and practice them daily for 4 weeks before bedtime.
219030236|NCT07181642|BEHAVIORAL|Neutral Music Listening|Participants will listen to neutral music of the same duration before sleep. This activity does not include any therapeutic breathing exercises and is intended as a control
219030237|NCT07180134|BEHAVIORAL|symptom management health informatics plus Resistance band exercise training|"Access to educational videos and an instant messaging platform for real-time communication, delivered over 12 weeks.~plus Structured resistance band exercise, 3 times per week, \~30 minutes per session, for 12 weeks under research team guidance."
219030238|NCT07180134|BEHAVIORAL|Usual Care Group|Standard postoperative nursing care and education routinely provided by the clinical team. No additional interventions will be given.
219030239|NCT07181928|BEHAVIORAL|Mentalization-Based Therapy (MBT)|MBT is a manualized psychodynamic therapy based on attachment theory, designed to restore adolescents' mentalizing in general and in emotionally stressful situations and relationships. It targets to rebuilt epistemic trust, to successfully mentalize oneself and others.
219030240|NCT07181928|BEHAVIORAL|Treatment-as-usual-plus (TAU-plus)|The adolescents receive supportive child psychiatric consultations. For the parents the EFST sessions combine mindfulness, theoretical input, and experiential practice. Parents learn and apply four core skills: validation, repair, motivation, and setting boundaries.
219030241|NCT07181512|OTHER|Deep Learning Analysis of Non-contrast Chest CT|Analysis of clearly visualized coronary segments on non-contrast chest CT using deep learning models, compared with CCTA reference standard.
218886739|NCT05757557|DRUG|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
219030242|NCT07180394|DRUG|Botox injection into extraocular muscles|Botulinum toxin in various doses by injecting it into the overacting extraocular musces in strabismus patients, especially pediatric, but also adult cases, to use it as an alternative for strabismus surgery. For children, it will be administered under sedation or general anesthesia and in adults, under topical anesthesia. The pre-operative measurements of the type of strabismus, patterns, deviation, and post-operative results will be studied both in the short and long-term.
219030243|NCT05367544|BEHAVIORAL|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
219030244|NCT05367544|BEHAVIORAL|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
219030245|NCT05367544|BEHAVIORAL|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
218886740|NCT03974945|DEVICE|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
219030246|NCT04860141|DRUG|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
219030247|NCT04860141|DRUG|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
218886741|NCT03974945|DEVICE|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
218886742|NCT06794619|DIETARY_SUPPLEMENT|Placebo|Placebo
218886743|NCT06794619|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing probiotic and prebiotic ingredients
218886744|NCT06507943|BEHAVIORAL|Promotora Home Visit|For each participating family, Promotora home visits will be scheduled 6-8 weeks apart, with in-person or virtual visits conducted per the family's preference. The visits will begin with a survey which will evaluate concerns related to asthma for the child and the family, including their asthma control (via the ACT), their home environment (via screening for environmental exposures), and quality of life for the child. These surveys will be available in both online or physical forms for potential connectivity concerns, and Promotoras will have IPads for the online forms. The Promotoras, who have received specialized asthma training, will then address concerns raised by families, using the Clinical Pathway which will have resources for asthma-related concerns that are raised.
219030248|NCT04917042|DRUG|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
218886745|NCT06796452|OTHER|Ribs Mobilization|Three sets of 6-8 repetitions in each session and conventional(Baseline) Physical therapy Treatment.
218886746|NCT06796452|OTHER|Conventional treatment|"* Hot pack for 8 min~* Maitland Generalized Cervical Mobilizations (6-8 REPS,3 sets)~* Isometric Strengthening Exercise"
218886747|NCT05576818|DRUG|Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers|Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
218886748|NCT02983461|DRUG|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
219030249|NCT03031171|BEHAVIORAL|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
219030250|NCT03031171|BEHAVIORAL|Non-Navigated|Randomly matched sample of non-navigated clinic patients
218886749|NCT02983461|DRUG|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
219030251|NCT00643422|DEVICE|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
219030252|NCT01154309|BEHAVIORAL|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
219030253|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
219030254|NCT06104566|DRUG|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
219030255|NCT06104566|DRUG|BTK inhibitor|BTK inhibitor
219030256|NCT04076800|PROCEDURE|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
219030257|NCT02493699|OTHER|physical exercise- based intervention (Karate techniques training)|
219030258|NCT01257373|DEVICE|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
219030259|NCT03023033|BEHAVIORAL|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
219030260|NCT03023033|BEHAVIORAL|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
219030261|NCT00593307|OTHER|high GI|high GI and high carb breakfast
219030262|NCT00593307|OTHER|Low GI|low GI, high carb breakfast
219030263|NCT00593307|OTHER|Low GI Low Carb|low GI low carb breakfast
219030264|NCT00593307|OTHER|High GI Low carb|high GI low carb breakfast
219030265|NCT00685243|PROCEDURE|Laser treatment|Fraxel and pulsed dye laser
219030266|NCT00324831|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219030267|NCT00324831|DRUG|cyclophosphamide|
219030268|NCT00324831|DRUG|doxorubicin hydrochloride|
219030269|NCT00324831|DRUG|prednisone|
219030270|NCT00324831|DRUG|rituximab|
219030271|NCT00324831|DRUG|sargramostim|
219030272|NCT00324831|DRUG|vincristine|
219030273|NCT00324831|PROCEDURE|Intervention/procedure|
219030274|NCT00324831|PROCEDURE|antibody therapy|
219030275|NCT00324831|PROCEDURE|biological therapy|
219030276|NCT00324831|PROCEDURE|chemotherapy|
219030277|NCT00324831|PROCEDURE|colony-stimulating factor therapy|
219030278|NCT00324831|PROCEDURE|cytokine therapy|
219030279|NCT00324831|PROCEDURE|monoclonal antibody therapy|
219030280|NCT00324831|PROCEDURE|non-specific immune-modulator therapy|
219030281|NCT00324831|PROCEDURE|therapeutic procedure|
219030282|NCT00324831|PROCEDURE|tumor cell derivative vaccine|
219030283|NCT00324831|PROCEDURE|vaccine therapy|
219030284|NCT01230931|DEVICE|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
219030285|NCT01230931|PROCEDURE|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
219030286|NCT04638465|PROCEDURE|Transoral robotic surgery|Transoral resection with neck dissection
218886750|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
218886751|NCT06476548|DEVICE|EMI|Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
218886752|NCT06184503|DRUG|Velmanase Alfa|Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
218886753|NCT05384015|DRUG|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
218886754|NCT05384015|DRUG|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
218886755|NCT05384015|DRUG|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
219507382|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
219507383|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
219507384|NCT02497391|DRUG|Evacetrapib|administered orally
219507385|NCT00004576|DRUG|LY300164|
218886756|NCT05384015|DRUG|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
218886757|NCT04040088|PROCEDURE|Computed Tomography|Undergo PET/CT
219030287|NCT04638465|DRUG|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
219030288|NCT04638465|DRUG|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
219030289|NCT04638465|RADIATION|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
219030290|NCT04638465|RADIATION|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
219030291|NCT06450548|OTHER|Parametric acquisition|Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
219030292|NCT04270981|DRUG|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
219030293|NCT03593408|DRUG|Dexmedetomidine|Administered for sedation management per hospital protocol
219030294|NCT03593408|DRUG|Fentanyl|Administered for sedation management per hospital protocol
219030295|NCT03593408|DRUG|Midazolam|Administered for sedation management per hospital protocol
219030296|NCT03593408|DRUG|Morphine|Administered for sedation management per hospital protocol
219030297|NCT00489853|DRUG|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
219030298|NCT00489853|DRUG|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
219030299|NCT00489853|OTHER|Placebo|Placebo, 1 inhalation twice daily
219030300|NCT00518908|DRUG|Sevoflurane|3.2 Vol % for postconditioning
219030301|NCT03324763|OTHER|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
219030302|NCT03650907|BEHAVIORAL|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
219030303|NCT03650907|BEHAVIORAL|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
219030304|NCT04760210|OTHER|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
219607633|NCT00933361|DRUG|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
218886758|NCT04040088|DRUG|Gallium Ga 68-DOTATATE|Given IV
218886759|NCT04040088|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218886760|NCT03274414|DRUG|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
218886761|NCT03274414|RADIATION|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
218886762|NCT03274414|PROCEDURE|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
218886763|NCT03274414|DRUG|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
218886764|NCT01744548|BEHAVIORAL|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
218886765|NCT06845527|OTHER|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
218886766|NCT05138029|DRUG|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
218886767|NCT05138029|PROCEDURE|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
218886768|NCT05138029|DRUG|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
218886769|NCT02124213|DRUG|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
218886770|NCT02124213|DRUG|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
218886771|NCT02124213|DRUG|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
219030305|NCT04760210|OTHER|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
219030306|NCT04760210|OTHER|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
219030307|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
219607634|NCT03086551|DEVICE|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
219607635|NCT03086551|DEVICE|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
218886772|NCT03262168|OTHER|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
218886773|NCT03835299|BEHAVIORAL|Fear Intervention|Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
219030308|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
219030309|NCT03780153|OTHER|No intervention|Observation study. No intervention
219030310|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
219030311|NCT05751798|DRUG|Part A: OSE-279 100mg|Human IgG4 mAb against PD-1
219030312|NCT05751798|DRUG|Part A: OSE-279 300mg|Human IgG4 mAb against PD-1
219030313|NCT05751798|DRUG|Part A: OSE-279 600mg|Human IgG4 mAb against PD-1
219030314|NCT05751798|DRUG|Part B: OSE-279 600 mg and OSE2101|OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
219030315|NCT05751798|DRUG|Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive|OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
219030316|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 positif|OSE-279: Human IgG4 mAb against PD-1
219030317|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 negative|OSE-279: Human IgG4 mAb against PD-1
219030318|NCT05704361|DRUG|RO7121932 IV|Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.
219030319|NCT05704361|DRUG|RO7121932 SC|Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.
218886774|NCT03401255|OTHER|Partosure test|To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal swab provided in the PAMG-1 Detection Test Kit.After removing the swab from its packaging, hold the swab in the middle of the stem and carefully insert the end of the swab into the vagina over a length of 5-7cm (using a speculum). Is not necessary for sampling), when the patient is lying down.Remove the swab from the vagina after 30 seconds. Once the swab has been removed, immediately place the end in the solvent vial provided for this purpose, then rinse the swab by repeating several rotations for 30 seconds. The strip is removed as soon as two bands are clearly visible in the test area, or after 5 minutes.Two bands in the test area indicate a positive result, while a line in the test area indicates a negative result. It is not recommended to read or interpret results beyond 10 minutes of immersion.
219201880|NCT06875297|DIAGNOSTIC_TEST|FPG500|A cancer genome profiling with FPG500 will be performed on samples available from surgery or biopsy. Specimen are reviewed to assess tumor cell fraction. All H\&E slides are digitized before nucleic acid extraction. Semi-automated process is used for DNA/RNA extraction, DNA fragmentation, quantification, library preparation, and sequencing. Profiling is done with the TruSight Oncology 500 assay, analyzing 523 genes for single nucleotide variants, insertions/deletions, copy number variations, and fusions/splicing variants in 55 genes. It also evaluates genomic signatures like microsatellite instability and tumor mutational burden. Sequencing data are processed using Illumina software and a custom pipeline. Post-sequencing quality control is performed. Variants are classified according to the Human Genome Variation Society and clinical actionability guidelines. Genomic report is reviewed by an institutional Molecular Tumor Board.
218886775|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
218886776|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
218886777|NCT01136408|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
219201881|NCT06874140|DRUG|Chuanhong Zhongfeng capsule|Basic treatment (refer to China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018) + Chuanhong Zhongfeng capsule
218886778|NCT01090193|PROCEDURE|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
218886779|NCT02828436|DEVICE|Precision Spectra System|Spinal Cord Stimulation
218886780|NCT02828436|BEHAVIORAL|Exercise Intervention|Standard Exercise
218886781|NCT03867357|DRUG|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
218886782|NCT03310814|OTHER|Personalized nutrition|Receives individualized nutrition information
218886783|NCT05490576|RADIATION|[18F] PI-2620 Tau Ligand|Tau binding ligand
218886784|NCT02502942|BEHAVIORAL|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
219030320|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
219030321|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
219201882|NCT06343688|OTHER|"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO"|"Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot."
219030322|NCT05689788|DEVICE|High-intensity laser therapy|punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
219030323|NCT05689788|PROCEDURE|Stretching exercise|Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
219030324|NCT05689788|DEVICE|Sham High-intensity laser therapy|Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
219030325|NCT06797440|OTHER|Dual tasks of digital technology|The intervention activities of this study were cognitive and physical activity training using Nintendo Switch twice a week, 60 minutes each time (5 minutes of warm-up and cool-down exercises, 10 minutes of stretching exercises, and 40 minutes of exercise combined with cognitive training) for a total of 8 weeks. train. Both groups filled in basic data (demographics and disease characteristics) and underwent cognitive function measurements and physical activity function measurements at pretest (T0), 4th week (T1), and 8th week (T2).
219030326|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
219030327|NCT03181828|OTHER|No treatment|No treatment
219030328|NCT06958731|DEVICE|TuoRen Ultrasonic System|The Single-operator Laser-assisted T-shaped probe consisted of TuoRen Ultrasonic System (TUR200, Shenzhen Tuoren Bio-Medical Electronics Co., LTD) with a T-shaped probe (L38T7C), a 3D-printed probe-carrying enclosure with a linear laser transmitter ( ZLM120AL650-22130BXS, Shenzhen Zhonglai Technology Co., Ltd.) and ultrasonic probe manipulator.
219607636|NCT03086551|BEHAVIORAL|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
219607637|NCT02764151|DRUG|PF-06840003|Daily Oral PF-06840003
219607638|NCT05478577|OTHER|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
218886785|NCT02502942|BEHAVIORAL|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
219507386|NCT03091530|OTHER|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
218886786|NCT03461640|OTHER|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
218886787|NCT03461640|BEHAVIORAL|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
218886788|NCT01299181|DRUG|Atorvastatin|80mg once daily orally
218886789|NCT02761122|PROCEDURE|Human biological samples|"* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
218886790|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection low dose administered by subcutaneous injection
218886791|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection medium dose administered by subcutaneous injection
218886792|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection high dose administered by subcutaneous injection
218886793|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection lowest dose administered by subcutaneous injection
219030329|NCT06958731|DEVICE|Huasheng Color Ultrasonic Diagnostic System|Ultrasonic (Huasheng Color Ultrasonic Diagnostic System, Navi s, Shenzhen Huasheng Medical Technology Co., LTD.) and a 4.0MHz phased probe were used for the short-axis out-of-plane internal jugular vein catheterization
219030330|NCT06958744|OTHER|Functional Inspiratory Muscle Training (FIMT) group|Training will be given with the Powerbreath inspiratory muscle training device. Unlike traditional inspiratory muscle training, the exercises given in FIMT aim to integrate the functional capacity of respiratory muscles into daily life activities and include dynamic exercises in different positions with variable resistances. In this respect, it is defined as functional. Preparatory training will be given 4 weeks before starting FIMT: participants will be taught basic respiratory muscle training, respiratory control and exercises, and will be taught to perform the exercises while maintaining the spine in a neutral position. Patients will then be taken to FIMT for 3 days/6 weeks with a physiotherapist. On the other 3 days of the week, only inspiratory muscle training will be performed. The intensity of inspiratory muscle training will be increased from mild to moderate (Mild: Effort level between 20-40% of MIP or between Borg 2-3, Moderate: 50-60% of MIP or Borg 4-6).
219030331|NCT06958744|OTHER|Control group|Thoracic expansion exercise will be performed for 10 weeks. The participant will be asked to practice 4 times a day as a home program.
218886794|NCT06425341|DRUG|HRS-5635 Injection (low dose) and Peg-IFN-α|HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection
218886795|NCT06425341|DRUG|HRS-5635 Injection (high dose) and Peg-IFN-α|HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection
218886796|NCT06425341|DRUG|Peg-IFN-α|Peg-IFN-α, administered by subcutaneous injection
219030332|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
219030333|NCT06470399|OTHER|Standard therapy group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
219030334|NCT06470399|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
219030335|NCT03913754|OTHER|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
219030336|NCT06958458|BEHAVIORAL|Mother Integrated Care|In order to empower mothers whose premature infants have been hospitalized in the neonatal intensive care unit (NICU) for at least three days, a four-step neonatal care training program will be provided. Through the empowerment of the mother, the empowerment of the family will also be supported. The family will no longer be considered as visitors but will be involved in the infant's care in the NICU as parents. Data collection forms will be completed before the training begins, one day prior to discharge, and one week after discharge.
219030337|NCT05267626|DRUG|AU-007|Monoclonal Antibody Targeting IL-2
219030338|NCT05267626|DRUG|Aldesleukin|IL-2
219030339|NCT05267626|DRUG|Avelumab|Monoclonal Antibody Targeting PD-L1
219030340|NCT05267626|DRUG|Nivolumab|Monoclonal Antibody Targeting PD-1
219030341|NCT06793371|DRUG|CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)|CK-4021586 administered orally
219030342|NCT06793371|DRUG|Placebo to match CK-4021586|Placebo administered orally
219201883|NCT06361238|DRUG|Liraglutide injection|Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
219030343|NCT01572233|BEHAVIORAL|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
219201884|NCT06361238|DRUG|Placebo injection|Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
219201885|NCT05323591|DRUG|Filgotinib|Tablets are administered in accordance with the product label
219201886|NCT04298216|DIAGNOSTIC_TEST|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
219507387|NCT03091530|OTHER|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
219507388|NCT03031899|PROCEDURE|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
219201887|NCT04817969|DEVICE|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
219201888|NCT05191862|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
219201889|NCT05191862|DRUG|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
219201890|NCT06871384|DIETARY_SUPPLEMENT|Nonalcoholic red wine group (Intervention group)|Mediteranean diet + nonalcoholic red wine (300 mL wine/day, equivalent to a daily dose of 150 mg red wine polyphenols/day, during meals)
219201891|NCT06871384|DIETARY_SUPPLEMENT|Drinking water group (Control group)|Mediterranean diet + drinking water (300 mL/day, during meals)
219507389|NCT03031899|DIAGNOSTIC_TEST|Rose Bengal|the lesions stained positive were subjected to biopsy
219507390|NCT03031899|DIAGNOSTIC_TEST|toluidine blue|the lesions stained positive were subjected to biopsy
219507391|NCT05772299|RADIATION|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
218886797|NCT04273893|RADIATION|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
218886798|NCT04273893|RADIATION|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
219030344|NCT00256945|PROCEDURE|dental restorative material surface preparation|
219030345|NCT04723381|OTHER|web based education|Expert support and consultancy were received for the design and preparation of the web page.
219030346|NCT01216527|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Surgery|"1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
219201892|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
219201893|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
219201894|NCT06875284|BEHAVIORAL|Sexual Communication and Consent (SCC)|SCC combines universal classroom instruction with tailored web-based content. Based on sociodemographic characteristics and prior sexual assault experiences, Cadets receive tailored content that addresses either primary victimization prevention, revictimization prevention, or healthy relationships and bystander intervention promotion.
219201895|NCT06875284|BEHAVIORAL|Alcohol eCHECKUP TO GO (eCHECKUP TO GO)|eCHECKUP TO GO is a personalized, online intervention designed to reduce cognitive risk factors for alcohol misuse. eCHECKUP TO GO is brief, self-guided, and provides individualized feedback based on a user's self-reported alcohol use patterns and consequences.
219507392|NCT05772299|DEVICE|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
219507393|NCT03401645|OTHER|Wrist Alarm|Wrist device with alarm timer
218886799|NCT04273893|DIAGNOSTIC_TEST|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
219030347|NCT01216527|PROCEDURE|surgery|two field lymphadenectomy
219201896|NCT06875284|BEHAVIORAL|Training as usual (TAU)|TAU involves universal classroom instruction focused on developing knowledge, attitudes, and skills to promote personal resilience, increase potential for success, and develop healthy and rewarding personal relationships.
219201897|NCT03124303|PROCEDURE|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
219201898|NCT03124303|PROCEDURE|Magnetic Resonance Imaging|MRI scan of brain
219201899|NCT03124303|PROCEDURE|Blood specimen collection|Blood will be collected from participants
219201900|NCT03124303|DIAGNOSTIC_TEST|Pupillometry|A pupillometer is a device that measures the size of the pupils.
219201901|NCT06691867|BEHAVIORAL|I-STRONG|"I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance.~I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills."
219507394|NCT03401645|BEHAVIORAL|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
219507395|NCT03740698|DEVICE|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
219201902|NCT06691867|OTHER|Enhanced Usual Care (EUC)|The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.
219201903|NCT06692426|DRUG|MyoPAXon|MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2
218886802|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
218886803|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
218886804|NCT03657290|DRUG|vadadustat|Vadadustat Tablets
218886805|NCT00225498|DRUG|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
218886806|NCT02497729|PROCEDURE|Written Checklist|Use of a written checklist pre and peri-intubation
218886807|NCT02497729|PROCEDURE|Head of Bed Up|Raising the patient's head of bed to 25 degrees
219030348|NCT05853601|DRUG|Single Dose Theophylline|Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
219030349|NCT05853601|DRUG|Repeat Dose Theophylline|Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
219030350|NCT01541969|DEVICE|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
219201904|NCT06692426|DRUG|Tacrolimus|Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
219507396|NCT03740698|DEVICE|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
218886808|NCT04775641|OTHER|questionnaire|questionnaire
218886809|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
218886810|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
218886811|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
218886812|NCT04577430|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
218886813|NCT03919474|DIAGNOSTIC_TEST|microvascular markers|follow up of microvascular biomarkers during patient follow up
218886814|NCT01957202|DRUG|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
218886815|NCT01957202|DRUG|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
219507397|NCT03732105|RADIATION|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
219507398|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
219507399|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
219507400|NCT00489203|DRUG|beclomethasone dipropionate|Given orally
219507401|NCT00489203|DRUG|placebo|Given orally
219507402|NCT00489203|DRUG|tacrolimus|Given after transplant
219507403|NCT00489203|DRUG|methotrexate|Given after transplant
219507404|NCT00489203|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
219507405|NCT02457013|DEVICE|HFNC|Hygh flow nasal canula HFNC
219507406|NCT02457013|DEVICE|nCPAP|nasal nCPAP
219507407|NCT03940001|BIOLOGICAL|Sintilimab|Other Name: (IBI308)
219507408|NCT03940001|DRUG|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
219507409|NCT03940001|RADIATION|Radiation|IMRT or VMAT
219507410|NCT03238027|DRUG|Axatilimab|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
219507411|NCT03238027|DRUG|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
218886816|NCT01957202|DRUG|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
218886817|NCT01957202|DRUG|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
218886818|NCT05639296|OTHER|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
218886819|NCT05550935|DEVICE|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
218886820|NCT01671033|BEHAVIORAL|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
218886821|NCT01671033|BEHAVIORAL|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
218886822|NCT05547126|DEVICE|Transcranial direct current stimulation|"It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy."
218886823|NCT02398604|DRUG|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
218886824|NCT02398604|DRUG|Placebo|Placebo
218886825|NCT04355403|DEVICE|Hyalo Gyn gel in prefilled applicators|One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
218886826|NCT04517565|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
218886827|NCT04517565|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
218886828|NCT02859103|DRUG|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
218886829|NCT00935311|DRUG|ABT-712 Extended-release|ABT-712 extended-release tablet
218886830|NCT00935311|DRUG|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
218886831|NCT00935311|DRUG|Placebo|Placebo tablet
218886832|NCT04336072|BEHAVIORAL|RFPP|
219507412|NCT06218420|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
218886833|NCT04336072|BEHAVIORAL|TFCBT|
218886834|NCT00729625|DEVICE|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
219507413|NCT02779582|DRUG|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
219507414|NCT02779582|DRUG|Placebo|pill with no effect
219507415|NCT03788525|BEHAVIORAL|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
219507416|NCT03788525|BEHAVIORAL|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
219201905|NCT06692361|BIOLOGICAL|FMT capsule|The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
218886835|NCT04498442|BEHAVIORAL|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
218886836|NCT04498442|BEHAVIORAL|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
219507417|NCT00397319|DRUG|Growth Hormone|
218886837|NCT04846322|DIAGNOSTIC_TEST|PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)|"1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan."
218886838|NCT04429191|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
218886839|NCT03094741|OTHER|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
218886840|NCT05878535|DRUG|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
218886841|NCT05878535|DRUG|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
218886842|NCT05232331|DIETARY_SUPPLEMENT|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming \~ 350 mg of nitrate daily from vegetables
218886843|NCT00411372|DRUG|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
218886844|NCT05981482|DIAGNOSTIC_TEST|OxVPS|Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
218886845|NCT03202719|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
218886846|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
218886847|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
218886848|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
218886849|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
219030351|NCT01541969|DEVICE|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
219030352|NCT05900050|DRUG|VS-01 on top of SOC|Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
219030353|NCT05900050|OTHER|SOC (Control Group)|Patients will receive SOC for decompensated cirrhosis and ACLF
219030354|NCT04382833|OTHER|HOT APPLICATION|HOT APPLICATION
219030355|NCT04382833|OTHER|MASSAGE|
219030356|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
219030357|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
219030358|NCT04642456|DIAGNOSTIC_TEST|MRI spine/pelvis|We will be capturing 3D Magnetic Resonance (MR) images of the subject lying supine with extended knees, using a T1 weighted spine-echo (SE) sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weighted images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
219030359|NCT04642456|DIAGNOSTIC_TEST|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
219507418|NCT04942041|OTHER|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
219507419|NCT02902731|DRUG|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
219507420|NCT02902731|DRUG|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
219507421|NCT02565342|PROCEDURE|Interscalene brachial plexus block|
218886850|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
218886851|NCT01330329|BEHAVIORAL|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
218886852|NCT01330329|BEHAVIORAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
218886853|NCT00529425|DRUG|Ropivacaine|
218886854|NCT03523767|BIOLOGICAL|S.typhi Injection|0.5 ml of S.typhi injection
218886855|NCT03523767|BIOLOGICAL|Normal Saline Injection|0.5 ml of normal saline injection
219030360|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
219030361|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
219030362|NCT05123222|BIOLOGICAL|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain (San Jose Rio Puerto)
219030363|NCT05123222|BIOLOGICAL|Experimental: ZIKV-Nicaragua/2016 Strain|Zika Virus Strain (Nicaragua)
219030364|NCT05123222|BIOLOGICAL|Placebo|Saline
219030365|NCT05630274|DRUG|Selpercatinib|Administered orally
219507422|NCT01469364|DRUG|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
219507423|NCT01469364|PROCEDURE|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
219507424|NCT05266781|PROCEDURE|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
219507425|NCT05266781|PROCEDURE|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
219507426|NCT00565981|DRUG|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
219507427|NCT00565981|DRUG|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
219507428|NCT05628623|DRUG|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
219507429|NCT05628623|DRUG|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
219507430|NCT05628623|DRUG|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
219507431|NCT05628623|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
219507432|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
219507433|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
219507434|NCT03005470|DEVICE|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
218886856|NCT03162822|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
218886857|NCT03162822|OTHER|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
218886858|NCT03162822|OTHER|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
219030366|NCT05630274|DRUG|Moxifloxacin|Administered orally
219030367|NCT05630274|DRUG|Placebo|Administered orally.
219030368|NCT02255500|DRUG|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
219030369|NCT02255500|DRUG|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
219030370|NCT04059731|DIETARY_SUPPLEMENT|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
219030371|NCT00265343|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
218886859|NCT03162822|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
218886860|NCT02849119|PROCEDURE|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
218886861|NCT01664182|BIOLOGICAL|Bevacizumab|Given IV
219030372|NCT00265343|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
219030373|NCT04865354|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
219030374|NCT04865354|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
219030375|NCT02423863|BIOLOGICAL|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
219030376|NCT01840774|DRUG|Low-dose pain medication (Ketalar) and saline placebo|
219030377|NCT01925404|BEHAVIORAL|Free physical activity classes|100 hours of free activity classes will be provided
219030378|NCT01925404|BEHAVIORAL|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
219030379|NCT00706641|DRUG|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
219030380|NCT00706641|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
219030381|NCT05047081|BEHAVIORAL|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
219030382|NCT05047081|OTHER|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
219030383|NCT06145360|DRUG|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
219030384|NCT06145360|DRUG|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
219030385|NCT01990274|PROCEDURE|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
219030386|NCT01990274|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
219030387|NCT03646110|PROCEDURE|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
219030388|NCT04173026|OTHER|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
219607639|NCT03912597|DEVICE|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
219030389|NCT04173026|OTHER|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
219030390|NCT01483105|BEHAVIORAL|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
219030391|NCT04991545|DEVICE|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared"
219030392|NCT01112527|DRUG|PF-00299804|Taken orally once a day
219030393|NCT01475630|PROCEDURE|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
219030394|NCT01475630|PROCEDURE|control|relaxation
219030395|NCT00588822|BIOLOGICAL|Rituximab|Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
219201906|NCT06692361|DRUG|Escitalopram (Lexapro)|Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
218886862|NCT01664182|DRUG|Pazopanib Hydrochloride|Given PO
218886863|NCT01664182|DRUG|Sorafenib Tosylate|Given PO
219201907|NCT06692361|BIOLOGICAL|Corn Starch capsules|The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.
218886864|NCT01664182|DRUG|Sunitinib Malate|Given PO
218886865|NCT01664182|BIOLOGICAL|Trebananib|Given IV
218886866|NCT00351910|DRUG|Quetiapine|
218886867|NCT00351910|DRUG|Amitriptyline|
218886868|NCT00351910|DRUG|Bupropion|
218886869|NCT00351910|DRUG|Citalopram|
218886870|NCT00351910|DRUG|Duloxetine|
218886871|NCT00351910|DRUG|Escitalopram|
218886872|NCT00351910|DRUG|Fluoxetine|
218886873|NCT00351910|DRUG|Paroxetine|
218886874|NCT00351910|DRUG|Sertraline|
218886875|NCT00351910|DRUG|Venlafaxine|
219507435|NCT03005470|DEVICE|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
218886876|NCT01854034|DRUG|AUY922|AUY922 administered intravenously once a week at 70mg/m2
218886877|NCT02036125|DEVICE|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
218886878|NCT02036125|DRUG|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
218886879|NCT05648292|BEHAVIORAL|Neuropsychological tests and psychological questionnaires|"* The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
219607640|NCT03912597|DEVICE|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
218886880|NCT06029049|DRUG|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
218886881|NCT06029049|DRUG|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
218886882|NCT00287508|DEVICE|Carotid artery stenting with filter (interventional)|
218886883|NCT02016651|BEHAVIORAL|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
218886884|NCT06467903|DEVICE|SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .|second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
218886885|NCT04119180|DRUG|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
218886886|NCT04119180|DRUG|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
218886887|NCT04119180|PROCEDURE|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
219030396|NCT01948739|DEVICE|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
219030397|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030398|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030399|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030400|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030401|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030402|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030403|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030404|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030405|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219201908|NCT04926792|DEVICE|Leadless Pacemaker|Leadless pacemaker implantation
219201909|NCT04893096|DRUG|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
219201910|NCT06279975|DIAGNOSTIC_TEST|non-invasive device-supported, automated pupillometry|non-invasive device-supported, automated pupillometry with a precise quantitative measurement of the pupils within the range of micrometers
219507436|NCT03005470|DEVICE|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
219507437|NCT03005470|OTHER|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
219201911|NCT05155605|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
219201912|NCT01897441|DRUG|Cyclophosphamide|Given IV
219507438|NCT05455242|BEHAVIORAL|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
219507439|NCT06437132|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
219507440|NCT02067793|DRUG|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
219507441|NCT02067793|DRUG|Placebo|Single intravenous injection into the arm on Day 0
219507442|NCT02067793|DRUG|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
219507443|NCT02067793|DRUG|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
219507444|NCT01206361|DRUG|XALACOM|Xalacom eye drops
219507445|NCT01206361|DRUG|Duotrav|Duotrav eye drops
218886888|NCT02221674|DRUG|Tapentadol|
218886889|NCT04891809|DRUG|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
219507446|NCT01206361|DRUG|Ganfort|Ganfort eye drops
218886890|NCT04891809|DRUG|Lenalidomide|"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
218886891|NCT04891809|DRUG|Dexamethasone Oral|"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
218886892|NCT04390880|DRUG|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
218886893|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
218886894|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
219030406|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030407|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
219030408|NCT04190134|BEHAVIORAL|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
219030409|NCT02397330|DRUG|bupivacaine|
219030410|NCT02397330|DEVICE|ultrasound|ultrasound guided nerve blocks
219030411|NCT02397330|DRUG|morphine|
219030412|NCT06311890|DRUG|N-chlorin e6 triglumine|a photodynamic therapy with chlorin-e6
219030413|NCT06311890|PROCEDURE|acne removal surgery|acne removal surgery will be given before red light exposure
219040390|NCT07027865|OTHER|Sip & Snack Better (SSB) Tech-Only Comparison|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week technology-only comparison arm. Parents and teens will receive information about added sugar intake and healthy eating once via email or text message (based on preference) in weeks 1, 3, 5, 7, 9, and 12. Teens will receive informational text messages 3 times per week .
219040391|NCT03216447|DRUG|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
219040392|NCT03216447|DRUG|Prograf|Tacolimus capsules (q12h)
219040393|NCT06722443|DIETARY_SUPPLEMENT|Probiotic|Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months
219040394|NCT06722443|DIETARY_SUPPLEMENT|Prebiotic|Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months
219040395|NCT06722443|DIETARY_SUPPLEMENT|Synbiotic|A pill with a combination of prebiotic and probiotic at the same doses during 6 months
219040396|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
219040397|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
219040398|NCT06923709|DRUG|amiloride|5mg twice daily for 7 days
219040399|NCT06923709|DRUG|Placebo|1 tablet twice daily for 7 days
219040400|NCT06884254|DRUG|EG1206A|EG1206A 420mg is ongoing to be administered after 840mg loading dose.
219040401|NCT06884254|DRUG|Perjeta|Perjeta 420mg is ongoing to be administered after 840mg loading dose.
219040402|NCT06589505|DEVICE|Software as a Medical Device|The subject will undergo treatment using the Software as a Medical Device
219040403|NCT04413162|OTHER|Kinect motion tracking system|Kinect motion tracking system is used to measure shoulder range of motion compared to goniometric measurement.
219040404|NCT02940431|OTHER|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
219201913|NCT01897441|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218886895|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
218886896|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
219030414|NCT01168635|BEHAVIORAL|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
219030415|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
219030416|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
219030417|NCT03493828|PROCEDURE|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
219030418|NCT05041296|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
219030419|NCT00942396|DEVICE|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
219030420|NCT00003120|DRUG|paclitaxel|135 mg/m2 IV every 28 days
219030421|NCT03146988|DRUG|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
219030422|NCT02520011|DRUG|Alvocidib|
219030423|NCT02520011|DRUG|Cytarabine|
219201914|NCT01897441|DRUG|Doxorubicin Hydrochloride|Given IV
219201915|NCT01897441|OTHER|Laboratory Biomarker Analysis|Correlative studies
219201916|NCT01897441|DRUG|Paclitaxel|Given IV
219201917|NCT01897441|BIOLOGICAL|Trastuzumab|Given IV
219201918|NCT01897441|DRUG|Endocrine therapy|Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
219201919|NCT06693934|GENETIC|Risk assessment with biogenetic and clinical test to predict diabetes risk|All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).
219201920|NCT06693934|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors|High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.
219201921|NCT06693934|DRUG|Medication|Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
219201922|NCT06693934|DEVICE|Continuous glucose monitoring (CGM) devices and/or weighing scale|All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.
219507447|NCT00222677|DRUG|aspirin|100 mg daily
219507448|NCT04380220|DIAGNOSTIC_TEST|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
219507449|NCT04522414|OTHER|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
219201923|NCT06693934|BEHAVIORAL|Visit to family doctor with nurse education|All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.
219201924|NCT06693934|DIAGNOSTIC_TEST|Joint Asia Diabetes Evaluation (JADE) assessment|Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.
219201925|NCT06693934|BEHAVIORAL|Education webinars, workshops and health messages|All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.
219201926|NCT06630741|OTHER|alternative midwifery units (AMU)|"Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room"
219030424|NCT02520011|DRUG|Mitoxantrone|
219201927|NCT06690658|DEVICE|incorporating robotic system for upper body physical training of people with lower limb orthopedic condition|A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
219030425|NCT00002052|DRUG|Ceftriaxone sodium|
219030426|NCT00002052|DRUG|Ampicillin sodium|
219030427|NCT00002052|DRUG|Amoxicillin trihydrate|
219030428|NCT05442164|BEHAVIORAL|DANAKIR support network|"The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
219030429|NCT05215743|DRUG|Antioxidant therapy|Active therapy
219030430|NCT05215743|DRUG|NaCl 0.9%|Placebo
219030431|NCT02850458|DEVICE|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
219030432|NCT02094716|DRUG|Permethrin Foam 4%|Topical application, whole-body treatment
219030433|NCT02094716|DRUG|Permethrin Foam 5%|Topical application, whole-body treatment
219030434|NCT02094716|DRUG|Vehicle Foam|Topical application, whole-body treatment
219030435|NCT00485238|PROCEDURE|Argon laser Iridoplasty|
219030436|NCT00485238|DRUG|Intravenous acetazolamide|
219030437|NCT02261636|DRUG|mesalazine|
219030438|NCT03547713|BEHAVIORAL|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
219030439|NCT03547713|BEHAVIORAL|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
219030440|NCT03547713|BEHAVIORAL|Reward vs. punishment task|Reception of monetary gains vs. losses
219030441|NCT03547713|BEHAVIORAL|Emotional reactivity task|Exposure to emotional faces vs. shapes
219030442|NCT04296552|OTHER|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
219030443|NCT00748475|BEHAVIORAL|Neurofeedback|
219030444|NCT00149916|DRUG|Mycophenolate sodium (enteric coated)|
219030445|NCT01734564|BIOLOGICAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
219030446|NCT01734564|RADIATION|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
219030447|NCT02310919|DRUG|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
219030448|NCT02310919|DRUG|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
219030449|NCT05160688|BEHAVIORAL|Contingency management|Participants will be paid to abstain from cannabis use.
219030450|NCT01340157|DRUG|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
219030451|NCT04157946|DIAGNOSTIC_TEST|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
219030452|NCT03127657|DRUG|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
219030453|NCT00912314|PROCEDURE|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
219201928|NCT06688630|DEVICE|The laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is the application of a Reimers \& Janssen LaserPen, with a power of 150mW and a wavelength of 810nm, alternating between Nogier frequencies A and C. The dosage is 2 joules per point, with a therapy duration of 26 seconds per point, targeting bilateral acupuncture points BL2, TE23, ST2, LI4, and ST36. The LaserPen is applied without pressing the laser probe onto the body surface.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
218886897|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
218886898|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
219030454|NCT01412203|BEHAVIORAL|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
219030455|NCT03858491|DRUG|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
219030456|NCT02436759|DRUG|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
219030457|NCT02436759|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
219201929|NCT06688630|DEVICE|The sham laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is a procedure using the same device but without activating the laser, so no energy is emitted. Performed at the same points as laser acupuncture therapy.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
218886899|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
218886900|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
219201930|NCT06689215|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
219201931|NCT06687564|PROCEDURE|Biopsy|A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
219201932|NCT06632145|OTHER|Cog Fun Ageing intervention|Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
219201933|NCT06688968|BEHAVIORAL|neuropsychologist interview|"It will take place either at the hospital or at the participant's home.~This interview will consist of :~* socio-demographic data collection~* neuropsychological tests:~  * MMSE test (Mini Mental State Examination) cognitive function~ * RL-RI-16 test (16-item free recall/indexed recall test)~ * BECS test (Semantic knowledge assessment battery )~ * WCST test (Wisconsin Card Sorting Test )~ * Musical Cognition Test~ * Help from the participant's relative to answer certain questions, in particular the MuseEQ-24 questionnaire"
218886901|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
219030458|NCT00978328|DRUG|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
219201934|NCT06688968|BEHAVIORAL|questionnaire|"The participant answers questionnaires:~* Questionnaire MusEQ-24 self reported (Music Engagement Questionnaire)~* Questionnaire BMRQ (Barcelona Reward Music Questionnaire)~* Questionnaire SHAPS (Snaith-Hamilton Pleasure Scale)~* Questionnaire LARS (Lille's Apathy Rating Scale)~* Questionnaire PHQ-9 (Patient Health Questionnaire 9 items)"
219201935|NCT06686329|BEHAVIORAL|Control (CON)|Standardized meal with insulin administered 15 minutes before eating
219201936|NCT06686329|BEHAVIORAL|Missed Dose (MISS)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM
219201937|NCT06686329|BEHAVIORAL|Missed Dose + 15min walk (MISS+EX)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM with a 15-minute walk performed immediately after insulin administration
219201938|NCT06688266|OTHER|Nerve Gliding Exercises|"This group will receive 25-minute session of nerve gliding exercises per session five days a week for six weeks. It will include: Warm-Up (5 minutes)~Neural Gliding of the upper quadrant:~Median nerve glide (5 minutes) Ulnar nerve glide (5 minutes) Radial nerve glide (5 minutes) Cool Down (5 minutes)"
219201939|NCT06688266|OTHER|Hand Grip Strength Exercises|"This group's participants will also receive a 25 -minute session five days per week (for six weeks). Warm-Up (5 minutes) Conventional Grip Strength Exercises (15 Minutes)~* Tendon gliding sequence of exercises for hand~* Squeezing a rubber ball or stress ball~* Dead Hang Cool Down (5 Minutes)"
219201940|NCT06685822|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
219201941|NCT06250933|OTHER|Postpartum Maternal Care and Premature Infant Care Training|"Training and counseling were provided. In this context, training consisting of three sessions of 100 minutes in total was provided and counseling was provided in the following weeks by conducting 3-4 telephone interviews.~The intervention involves the provision of a training and counseling program designed to increase women's breastfeeding and maternal self-efficacy and reduce the risk of postpartum depression.~In the training phase, women will receive training on postpartum maternal care and premature infant care."
219201942|NCT04840394|DRUG|BDB018|BDB018 is an immunotherapy agent.
219201943|NCT04840394|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
219201944|NCT02933762|DRUG|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
219507450|NCT01806974|OTHER|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
219507451|NCT04910230|DRUG|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
219507452|NCT03395444|DEVICE|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
219507453|NCT03085082|DIAGNOSTIC_TEST|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
219507454|NCT01506089|OTHER|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
219507455|NCT05692674|RADIATION|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
219607641|NCT03912597|DEVICE|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
219607642|NCT01315327|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
219607643|NCT01315327|DRUG|Olive oil|Placebo
219607644|NCT04860180|PROCEDURE|adrenalectomy|
219607645|NCT02389231|DRUG|Interleukine-2|"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
218886902|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
218886903|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
219607646|NCT01091324|DRUG|Dextromethorphan|60 mg, bid
218886904|NCT03785405|DRUG|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
218886905|NCT06635980|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
218886906|NCT06635980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218886907|NCT06635980|PROCEDURE|Breast Surgery|Undergo breast surgery
218886908|NCT06635980|DRUG|Chemotherapy|Receive SOC chemotherapy
218886909|NCT06635980|PROCEDURE|Computed Tomography|Undergo CT
219507456|NCT01977430|DRUG|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
218886910|NCT06635980|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEDM
219030459|NCT00322010|PROCEDURE|early PT OT|"1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
219201945|NCT02933762|DRUG|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
219201946|NCT06872827|DRUG|Herbal toothpaste|Intervention
219201947|NCT06871982|BEHAVIORAL|PNF+ PBI|Parents of participating students assigned to the PNF+ PBI condition will receive an email invitation to sign up for a Parent-Based Intervention app. This app features six personalized normative feedback (PNF) quizzes and provides tailored videos and readings based on responses to these quizzes. Parents will create an account and complete the first PNF quiz, after which they will immediately receive their initial set of tailored content. They can then explore additional app content at their convenience, including access to five more quizzes that will yield further customized reading lists and access to a general resource library. For approximately six weeks, parents will receive weekly app notifications and email reminders alerting them to additional unengaged content (e.g., PNF quizzes, readings). Parents in this condition will maintain access to the app throughout their student's first year of college.
219507457|NCT03607630|OTHER|Imagery Rescripting|psychological therapy
219507458|NCT04721457|DRUG|Distilled Water|Control group
219507459|NCT04721457|DRUG|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
219507460|NCT04721457|DRUG|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
219507461|NCT04721457|DRUG|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
219507462|NCT04721457|DRUG|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
219507463|NCT04721457|OTHER|No rinse group|second control group
219507464|NCT00551122|BIOLOGICAL|filgrastim|
219507465|NCT00551122|BIOLOGICAL|lenograstim|
219507466|NCT00551122|BIOLOGICAL|pegfilgrastim|
219507467|NCT00551122|DRUG|cisplatin|
219507468|NCT00551122|DRUG|gemcitabine hydrochloride|
219507469|NCT00551122|DRUG|ifosfamide|
219507470|NCT00551122|DRUG|paclitaxel|
218886911|NCT06635980|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiotherapy
218886912|NCT06635980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218886913|NCT06635980|PROCEDURE|Positron Emission Tomography|Undergo PET
218886914|NCT06635980|OTHER|Survey Administration|Ancillary studies
218886915|NCT06635980|PROCEDURE|Tissue Collection|Undergo tissue collection
218886916|NCT06635980|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
218886917|NCT02584270|DEVICE|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and articulation therapy are necessary for this therapy to be effective.
218886918|NCT02584270|OTHER|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy in either arm.
219030460|NCT00902564|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
219507471|NCT03043274|DRUG|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
219507472|NCT06379074|BEHAVIORAL|Improving sleep health and resilience during pregnancy|"Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician.~Sessions' contents:~1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy;~2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques;~3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques;~4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques;~5. Sleep in the postpartum and the development of sleep regulation in children;~6. Relapse prevention and focus on acquired skills and how to prioritize sleep."
219607647|NCT01091324|DRUG|Silymarin|150 mg , tid
219607648|NCT01091324|DRUG|sugar pill|placebo
219607649|NCT00364936|PROCEDURE|Palliative care service|
219607650|NCT00100880|DRUG|lenalidomide|Given PO
219607651|NCT00100880|PROCEDURE|perfusion-weighted magnetic resonance imaging|Correlative studies
218886919|NCT04923568|DEVICE|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
218886920|NCT00133601|BEHAVIORAL|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
219607652|NCT00100880|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
218886921|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
219607653|NCT00100880|OTHER|laboratory biomarker analysis|Correlative studies
219607654|NCT04848727|OTHER|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
218886922|NCT05109624|PROCEDURE|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
218886923|NCT03825302|DIAGNOSTIC_TEST|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
219607655|NCT03458182|OTHER|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
218886924|NCT03825302|DIAGNOSTIC_TEST|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
218886925|NCT05605912|OTHER|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
218886926|NCT05605912|DEVICE|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
218886927|NCT05394831|DRUG|JIN-A02|PO, QD
218886928|NCT02881762|DRUG|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
218886929|NCT00795236|DRUG|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
218886930|NCT02856204|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood
218886931|NCT02856204|OTHER|Laboratory Biomarker Analysis|Correlative studies
218886932|NCT03269058|DRUG|Dapagliflozin|Dapagliflozin 10 mg daily per os
218886933|NCT03269058|DRUG|Placebos|Placebo of Dapagliflozin per day per os
218886934|NCT01922271|DRUG|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
218886935|NCT01922271|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
218886936|NCT01922271|DRUG|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
218886937|NCT01922271|DRUG|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
218886938|NCT01922271|DRUG|Salbutamol|Used as resuce medication
218886939|NCT05933668|BIOLOGICAL|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
218886940|NCT01103570|PROCEDURE|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
218886941|NCT01103570|PROCEDURE|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
218886942|NCT03276897|OTHER|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
218886943|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
218886944|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
219030461|NCT02915653|OTHER|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
219030462|NCT06496802|OTHER|no intervention|no intervention
219030463|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
219030464|NCT02793518|BEHAVIORAL|psychological tests|
218886945|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
218886946|NCT06206915|DRUG|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
218886947|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
218886948|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
218886949|NCT05703581|PROCEDURE|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
218886950|NCT01865643|DEVICE|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
218886951|NCT03475589|DRUG|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
218886952|NCT03854513|DEVICE|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
219030465|NCT05727228|OTHER|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
219201948|NCT06871982|BEHAVIORAL|SNMC+ PBI|Parents of participating students randomized to this condition will receive a series of 6 emails (delivered weekly) in August and September. Each email will include risk-reducing normative facts and a relevant tip for communicating with students about alcohol-related risks.
219201949|NCT06871982|BEHAVIORAL|PH+ PBI|Parents of participating students randomized to this condition will receive an email introducing the PBI including a link to access the Handbook online. Parents can explore the Handbook at their own pace.
219507473|NCT06379074|BEHAVIORAL|Information on pregnancy-related issues|"Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions."
219507474|NCT03433001|DRUG|Ixazomib|Ixazomib capsules
219507475|NCT03433001|DRUG|Lenalidomide|Lenalidomide capsules
219507476|NCT03433001|DRUG|Dexamethasone|Dexamethasone tablets
219507477|NCT02815904|OTHER|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
219507478|NCT02815904|OTHER|Conventional handling|Positioning of preterm infants for optimal physiological development
219507479|NCT02815904|OTHER|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
219507480|NCT02815904|OTHER|Kangaroo Mother Care|Providing skin to skin human touch
218886953|NCT05822180|DRUG|NANOS1 , argent colloïdal ,|orally, during 5 day
218886954|NCT01151371|DEVICE|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
219607656|NCT02487225|DRUG|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
219607657|NCT02487225|DRUG|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
218886955|NCT01151371|DEVICE|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
218886956|NCT01151371|DEVICE|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
218886957|NCT02712528|DRUG|remifentanil-based|
218886958|NCT02712528|DRUG|sevoflurane-sufentanil balanced|
218886959|NCT04210622|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
218886960|NCT06974812|DRUG|IBI3014|12 mg/kg D1 IV Q3W
218886961|NCT06974812|DRUG|IBI3014|6 mg/kg D1 IV Q3W
218886962|NCT06974812|DRUG|IBI3014|1 mg/kg D1 IV Q3W
218886963|NCT06974812|DRUG|IBI3014|15 mg/kg D1 IV Q3W
218886964|NCT06974812|DRUG|IBI3014|9 mg/kg D1 IV Q3W
218886965|NCT06974812|DRUG|IBI3014|3 mg/kg D1 IV Q3W
219201950|NCT06868706|BEHAVIORAL|VR-Supported Video Modeling|Participants receive virtual reality (VR) supported video modeling training in addition to traditional swimming training.
218886966|NCT06975995|DIETARY_SUPPLEMENT|Yi'en Yuan Honey Fermented Drink|The oral postbiotics product used in the trial is called Yi'en Yuan Honey Fermented Drink. The product is made from water, edible brown sugar, and honey as raw materials. It is fermented by a mixture of plant lactic acid bacteria and coagulating Bacillus, and then inactivated at high temperature. The product meets the food and beverage standard. Participants will receive the product for 150ml per day.
219201951|NCT06868706|BEHAVIORAL|Traditional Swimming Training|Participants receive only traditional swimming training. Individuals in this group learn swimming techniques through traditional methods (practising in the water under the supervision of an instructor).
219201952|NCT06873074|PROCEDURE|anterior long segment cervical fixation|
219201953|NCT06873074|PROCEDURE|posterior long segment cervical fixation|
219201954|NCT06873074|PROCEDURE|combined anterior and posterior fixation|
219201955|NCT06871644|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of
219201956|NCT06872177|OTHER|Measurements|On existing identified chart records: measurements on CBCT and panographic radiographs.
219201957|NCT06287268|OTHER|eltrombopag|This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
219201958|NCT06124664|DIAGNOSTIC_TEST|Radionuclide venography|With the patient in an upright position, 370 MBq of 99mTc pertechnetate is injected into one of the dorsal veins of the foot after applying a tourniquet in the area of the ankle joint. Then, with the help of a gamma camera detector, the movement of the radiopharmaceutical is monitored in the following segments: tibial (muscular-venous pump of the lower leg), popliteal, femoral and iliocaval. To study the evacuation function of the muscular-venous pump (MVP) of the leg, using an analytical computer program, areas of interest are identified in the tendon, muscle parts of the veins of the leg and the popliteal vein. The time of evacuation of the radiopharmaceutical from the MVP of the leg is estimated - the average transport time of the isotope.
219201959|NCT06124664|DIAGNOSTIC_TEST|single-photon emission computed tomography|"SPECT of the pelvic veins with in vivo-labelled red blood cells (RBCs). For radionuclide assessment of the state of the pelvic veins, 2 ml of Perfotech solution is injected into the cubital vein for subsequent labeling of red blood cells in vivo. In 20 minutes. 370 MBq of 99mTc-pertechnetate is injected into one of the veins of the dorsum of the foot and radionuclide venoscintigraphy is performed according to the method presented above. 20 minutes after the administration of the radiopharmaceutical and the venography, SPECT of the pelvic veins is performed. Tomography of the distribution of labeled erythrocytes in the pelvic veins is carried out in a circular orbit with the gamma camera detector rotated 360°. The analysis of the obtained information is carried out using the standard ECT Protocol software package, which allows obtaining sections in 3 projections (sagittal, transversal and coronal) with a slice step of 8 mm."
219201960|NCT06697405|OTHER|Prolonged ≥ 120 minutes|No intervention, regular therapy
219201961|NCT04296955|OTHER|Motivational interview as a new health communication intervention|Same as intervention name
219201962|NCT06229119|DEVICE|Implantable Collamer Lens|The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
219201963|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
219201964|NCT05074056|DRUG|Ketorolac|We will administer intraoperative ketorlac.
218886967|NCT06975124|DEVICE|transcutaneous auricular vagus nerve stimulation|Ear clip electrodes attached to the left cymba conchae to target vagus nerve branches.
219201965|NCT03460665|PROCEDURE|Arteriography|knee arteriography
219507481|NCT02386592|DRUG|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
218886968|NCT06975124|DEVICE|Sham condition|Electrode placement attached on the left earlobe.
218886969|NCT06350123|DRUG|Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
218886970|NCT06350123|DRUG|Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
218886971|NCT06350123|DRUG|Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
218886972|NCT01635855|DEVICE|Belotero®|Hyaluronic acid dermal filler
218886973|NCT06340672|OTHER|Augmented Reality Enhanced Preoperative Counseling|For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.
218886974|NCT06340672|OTHER|Standard preoperative counseling|Control patients will undergo standard preoperative counseling.
219201966|NCT03475134|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
219201967|NCT03475134|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219201968|NCT03475134|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219201969|NCT03475134|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
219201970|NCT03475134|DRUG|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
219201971|NCT01106183|DIETARY_SUPPLEMENT|transfer factor|capsules, 2 per day by mouth for 7 weeks.
218886975|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
219201972|NCT01106183|DIETARY_SUPPLEMENT|Placebo|cornstarch, 2 capsules per day by mouth.
219201973|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
219201974|NCT06701721|DRUG|THN391 MAD|Route of administration- IVT injection
219201975|NCT05650177|BEHAVIORAL|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
219507482|NCT02386592|BEHAVIORAL|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
219507483|NCT02386592|BEHAVIORAL|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
219507484|NCT02386592|OTHER|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
219507485|NCT00228904|PROCEDURE|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
219507486|NCT00228904|PROCEDURE|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
219507487|NCT04144296|DIAGNOSTIC_TEST|Study procedure|"* Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line"
218886976|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
218886977|NCT04203004|PROCEDURE|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
218886978|NCT04174196|DRUG|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
218886979|NCT04174196|DRUG|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
219507488|NCT05585463|PROCEDURE|acupuncture|Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
219507489|NCT01162499|DRUG|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
219507490|NCT01162499|OTHER|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
219607658|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
219607659|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
219607660|NCT04983186|DEVICE|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
219607661|NCT02128672|PROCEDURE|Spinal Cord Stimulator Lead Placement|
218886980|NCT04174196|RADIATION|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
218886981|NCT06600581|BIOLOGICAL|IMM01-STEM|IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
218886982|NCT06600581|OTHER|Placebo|Saline. This intervention is given 2mL twice a week.
219201976|NCT06700330|OTHER|no intervention, observational study|Only data from the patient file.
219201977|NCT06700460|DEVICE|Laser-assisted in Situ Keratomileusis|LASIK
219201978|NCT06700460|DEVICE|Implantable Collamer Lens placement|EVO ICL
219201979|NCT06701526|DRUG|Eptinezumab|Solution for infusion
219201980|NCT04761198|DRUG|Etigilimab|IV infusion of IV etigilimab every 2 weeks
219201981|NCT04761198|DRUG|Nivolumab|IV infusion of nivolumab every 2 weeks
219201982|NCT06633029|DEVICE|Prismaflex HF20|CRRT fluid management and reduction of uremic toxins.
219201983|NCT06633029|DEVICE|Prismaflex M60|CRRT fluid management and reduction of uremic toxins.
219201984|NCT05846464|DEVICE|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
219201985|NCT06633445|PROCEDURE|botulinum toxin type A injection in lateral pterygoid muscle|"* Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle."
219201986|NCT06633445|PROCEDURE|botox injection in lateral pterygoid muscle|"* A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound."
218886983|NCT06600581|BIOLOGICAL|IMM01-STEM alternating with placebo (saline)|This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
218886984|NCT05803720|BEHAVIORAL|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
219507491|NCT05774106|BEHAVIORAL|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
219507492|NCT04381585|DEVICE|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
219507493|NCT05855915|DIAGNOSTIC_TEST|Kinesio taping|Kinesotaping will be applied with routine physical therapy
219507494|NCT05855915|DIAGNOSTIC_TEST|Sham taping|Sham taping will be applied with routine physical therapy
218886985|NCT06170372|DRUG|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
218886986|NCT06170372|DRUG|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
218886987|NCT06129903|OTHER|referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.|The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
218886988|NCT06921993|DIAGNOSTIC_TEST|LUNG ULTRASOUND|"All subjects randomly assigned to the investigational arm will undergo lung ultrasound (LUS) .~Ultrasound still images and ultrasound clips will be acquired according to the study protocol. Detailed methodology of the ultrasound examination and parameters is provided as appendix to the study protocol"
218886989|NCT03922893|OTHER|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
218886990|NCT03922893|GENETIC|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
219030466|NCT04049942|OTHER|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
219030467|NCT04049942|BEHAVIORAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
219030468|NCT00218374|DRUG|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
219030469|NCT05250024|DEVICE|UHMWP Cranioplasty|patient specific cranial implant
219030470|NCT05250024|DEVICE|PEEK Cranioplasty|patient specific cranial implant
219030471|NCT00922766|DRUG|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
219201987|NCT03875339|BEHAVIORAL|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
219201988|NCT06802939|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
219507495|NCT02040428|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|
219507496|NCT02040428|BIOLOGICAL|Topical hemostat|
219507497|NCT01417897|DRUG|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
219507498|NCT01417897|DRUG|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
219507499|NCT01417897|DRUG|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
219201989|NCT06822322|PROCEDURE|Percutaneous Coronary Angioplasty|"A Percutaneous Coronary Intervention is used in both arms, with the drug Zotarolimus for stenting strategy and Paclitaxel for balloon strategy.~Coronary guide wires are passed into both the distal main vessel (distal MV) and side branch (SB) and predilation of MV on a 1:1 basis is required.~The device component dilates the vessel lumen by Percutaneous Transluminal Coronary Angioplasty (PTCA), while the drug is intended to reduce the proliferative response associated with restenosis."
219201990|NCT06822322|DEVICE|Stepwise Provisional Stent Strategy|In the stepwise provisional stent strategy, stenting of the MV is undertaken with a wire jailed in the SB. Then, non-compliant balloons sized to the diameter of the distal MV and SB are sequentially inflated at high pressure, and then simultaneously at low pressure (kissing balloon inflation ; KBI).
219201991|NCT06822322|DEVICE|Drug Coated Balloon Strategy|In the drug coated balloon (DCB) strategy, SB is prepared with a balloon at a 1:1 diameter, followed with a 1:1 sized DCB inflation for 60 seconds at nominal pressure. Then, MV is re-evaluated and treated with DCB at nominal pressure only, sized 1:1 with the proximal MV, for 60 seconds.
219201992|NCT06822322|DEVICE|Cross-Over Stepwise Provisional Stent Strategy|Following Drug Coated Balloon treatment in the Main vessel (MV) in the Drug Coated Balloon Arm, if the result is unacceptable in the MV, with either TIMI\>3 flow and/or dissection propagation, MV stenting is mandatory followed with Kissing Balloon Inflation (KBI), where non-compliant balloons sized to the diameter of the distal main and side branch are sequentially inflated at high pressure, and then simultaneously at low pressure. If the cross-over stent implantation in the MV is used, a further SB treatment with either DCB or stent implantation is used, according to operator preference.
219201993|NCT06118099|DRUG|Amlitelimab|Injection solution SC injection
219201994|NCT06118099|DRUG|Placebo|Injection solution SC injection
218886991|NCT03922893|GENETIC|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
218886992|NCT03922893|OTHER|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
218886993|NCT03711760|BEHAVIORAL|telepsychology|CBT delivered by telepsychology
219030472|NCT00843713|DRUG|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
219030473|NCT00843713|DRUG|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
219030474|NCT00277069|DRUG|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
219507500|NCT01508273|BEHAVIORAL|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
219201995|NCT05967416|BIOLOGICAL|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
219201996|NCT05967416|RADIATION|External-beam radiotherapy (XRT)|Radiotherapy given by external beam to the IT-injected lesion only
219030475|NCT00277069|DEVICE|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
219030476|NCT00277069|DRUG|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
219507501|NCT01508273|BEHAVIORAL|Website|Website access given that allows participant to track exercise behavior and help to set goals.
219507502|NCT01508273|BEHAVIORAL|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
219507503|NCT01508273|BEHAVIORAL|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
219607662|NCT04015310|DEVICE|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
219607663|NCT01015469|PROCEDURE|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
218886994|NCT05399212|DRUG|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
218886995|NCT06863194|DRUG|Probiotic Supplementation (Lactobacillus plantarum)|"Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. The dose is one tablet daily for 6 months.~This probiotic is intended to modulate gut microbiota, reduce systemic inflammation, and decrease uremic toxins (indoxyl sulfate) in CKD patients. The intervention will be compared to a placebo to evaluate its effectiveness in slowing CKD progression and improving metabolic and inflammatory markers."
218886996|NCT06863194|DRUG|Placebo Tablets|"Participants in this group will receive an inert placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. The dose is one tablet daily for 6 months.~The placebo serves as a control to compare the effects of the probiotic intervention. Both groups will undergo identical monitoring and follow-up assessments to determine whether the probiotic has a significant effect on kidney function, inflammation, and gut microbiota composition."
218886997|NCT00998088|OTHER|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
219030477|NCT00802399|PROCEDURE|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
219030478|NCT05381584|PROCEDURE|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
219030479|NCT05531435|DRUG|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
219030480|NCT03508856|DRUG|Ingenol Mebutate (Picato®) 0.015% gel|
219507504|NCT01508273|BEHAVIORAL|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
219507505|NCT01165996|OTHER|flow cytometry|Correlative studies
219507506|NCT01165996|OTHER|DNA methylation analysis|Correlative studies
219507507|NCT01165996|OTHER|cytogenetic analysis|Correlative studies
219507508|NCT01165996|DRUG|decitabine|Given subcutaneously
219507509|NCT01165996|GENETIC|microarray analysis|Correlative studies
219507510|NCT01165996|GENETIC|gene expression analysis|Correlative studies
219507511|NCT01165996|OTHER|pharmacological study|Correlative studies
218886998|NCT00998088|DRUG|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
219507512|NCT01165996|GENETIC|polymorphism analysis|Correlative studies
219607664|NCT01015469|PROCEDURE|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
219607665|NCT00043810|PROCEDURE|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
219607666|NCT00043810|DRUG|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
218886999|NCT00998088|DEVICE|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
218887000|NCT00998088|DEVICE|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
218887001|NCT00998088|OTHER|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
219030481|NCT01044602|OTHER|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
219030482|NCT01044602|OTHER|Best Medical Management|Standard of care.
219030483|NCT01044602|PROCEDURE|Roux-en-Y gastric bypass surgery|Surgical treatment.
219030484|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
219040405|NCT02940431|OTHER|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
219040406|NCT05427695|DRUG|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
219507513|NCT01135771|OTHER|glucose and insulin IV to alter blood glucose|
219507514|NCT04373109|BEHAVIORAL|Observation|Observation of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
219507515|NCT03471962|OTHER|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
219507516|NCT06398782|DEVICE|body composition assessment|body composition of cancer survivors were assessed by Dual-energy X-ray absorptiometry
219507517|NCT02585674|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218887002|NCT00998088|OTHER|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
218887003|NCT00998088|DEVICE|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
218887004|NCT06977022|DEVICE|Chest wall reconstruction|Extended resection of chest wall tumors with subsequent biodegradable polycaprolactone (PCL) 3D-printed rib prosthetic reconstruction
218887005|NCT06725238|OTHER|Acute-to-chronic glycemic ratio|This ratio could be related to diabetic foot ulcer
218887006|NCT06725589|OTHER|metabolic disease|metabolic disease
218887007|NCT06727292|DIETARY_SUPPLEMENT|Food supplement|Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).
218887008|NCT06727292|DIETARY_SUPPLEMENT|Placebo|Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
218887009|NCT06726213|OTHER|Walk and talk|An hour long walk at a slow pace lead by a trained walking leader.
218887010|NCT06725134|BEHAVIORAL|Therapy dog presence|A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
218887011|NCT06725134|BEHAVIORAL|Standard-of-care basic behavior guidance|Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
219040407|NCT05427695|OTHER|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
219040408|NCT06909643|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect magnetic resonance imaging and pathological slides of resected tumor of the enrolled patients. Analyze the data using the AI model to generate diagnostic results (sensitive or insensitive to the neoadjavant therapy). No intervention to patients would be performed in this diagnostic test study.
219507518|NCT02585674|DEVICE|MyStar DoseCoach|Glucose meter
219507519|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered as a single dose
219507520|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered as a single dose
218887012|NCT07048132|DIAGNOSTIC_TEST|Headache Screening Questionare|"The Headache Screening Questionnaire (HSQ) is a 10-item tool developed to screen for migraine and tension-type headache (TTH), based on the ICHD-3 beta criteria.~Each item reflects a diagnostic criterion for migraine or TTH. Participants complete the HSQ and are also evaluated by a neurologist for diagnosis.~A score of 6 or higher suggests probable migraine or probable TTH."
218887013|NCT07046702|DIAGNOSTIC_TEST|68Ga-MY6349|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
219030485|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
219030486|NCT03616912|DRUG|Baricitinib|Administered orally.
219030487|NCT03616912|DRUG|Placebo|Administered orally.
219201997|NCT05339269|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
219201998|NCT06871709|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
219201999|NCT06871709|OTHER|MTA-Anglus|Mineral Trioxide Aggregate (MTA) has been the gold standard material for primary tooth pulpotomy. MTA has antimicrobial properties, excellent sealing ability, is biocompatible and has a dentinogenic effect on pulp tissue by stimulating the release of cytokines from bone cells, which promotes hard tissue formation. Furthermore, MTA maintains pulp tissue integrity while having no cytotoxic effects. Nevertheless, the clinical application of MTA has been limited due to some properties such as its long setting time, difficulty in its handling, being washed out, discoloration, and increased cost. These urged the search for an alternative pulpotomy material to MTA
219202000|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
219202001|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
219202002|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
219202003|NCT04831320|DRUG|nab-paclitaxel|Supplied by Celgene Corporation
219202004|NCT04831320|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
219030488|NCT02867540|OTHER|MRI enterography|
219202005|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
219202006|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
219202007|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
219202008|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
219507521|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered as a single dose
219507522|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered as a single dose
219507523|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered as a single dose
219507524|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered daily for 14 days
219507525|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered daily for 14 days
219507526|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered daily for 14 days
219507527|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered daily for 14 days
218887014|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
218887015|NCT06893068|DEVICE|AI-based clinical intelligent management system|The clinical intelligent management system, integrated with AR glasses and powered by a multimodal foundational model, is designed to improve the quality of outpatient care at community health service centers.
219030489|NCT02848677|BEHAVIORAL|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
219030490|NCT02848677|BEHAVIORAL|usual care|usual care of hypertensive patients.
219030491|NCT02967250|DRUG|ursodeoxycholic acid|Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
219507528|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered daily for 14 days
219507529|NCT02110420|DRUG|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
219507530|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered as a single oral dose
219507531|NCT02110420|DRUG|CC-90001|CC-90001 720mg will be administered as a single oral dose
219507532|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered daily for 14 days
219507533|NCT04990622|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
218887016|NCT06526819|DRUG|SMP3124LP|Liposomal encapsulation formulation of SMP-3124
218887017|NCT06714851|DIETARY_SUPPLEMENT|Chondractiv Move|The dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day.
218887018|NCT06714851|OTHER|Placebo|Placebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day.
218887019|NCT06897241|OTHER|Resistant starch|Participants will consume 80 grams of carbohydrates from resistant starch during the meal challenges and two times daily during the 14-day intervention period
218887020|NCT06897241|OTHER|Slow digestible starch|Participants will consume 80 grams of carbohydrates from slow digestible starch during the meal challenges and two times daily during the 14-day intervention period
218887021|NCT06897241|OTHER|Rapid digestible starch|Participants will consume 80 grams of carbohydrates from rapid digestible starch during the meal challenges and two times daily during the 14-day intervention period
218887022|NCT03828019|BIOLOGICAL|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
218887023|NCT03828019|DRUG|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
219507534|NCT06465823|DRUG|Bumetanide|"Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing."
218887024|NCT07065565|PROCEDURE|non-intubated tracheal and carinal reconstruction|non-intubated tracheal and carinal reconstruction
218887025|NCT07065565|PROCEDURE|intubated tracheal and carinal reconstruction|intubated tracheal and carinal reconstruction
219030492|NCT02972216|DRUG|Nolbaxol|
219030493|NCT02972216|DRUG|Taxotere|
219030494|NCT02972216|DRUG|cisplatin|
219030495|NCT02782416|OTHER|Examination of latent tuberculosis|
219030496|NCT01649375|DRUG|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
219030497|NCT01649375|DRUG|Placebo|Placebo
219030498|NCT01649375|DRUG|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
219030499|NCT04257812|DRUG|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion."
219030500|NCT04982666|OTHER|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
219030501|NCT04982666|OTHER|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
219030502|NCT01124604|DRUG|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
219030503|NCT01124604|DRUG|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
219030504|NCT03938194|PROCEDURE|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
219030505|NCT04939727|OTHER|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
219030506|NCT01856790|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
219030507|NCT01856790|DRUG|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
219030508|NCT01776788|DRUG|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
219030509|NCT01776788|DRUG|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
219030510|NCT00733109|PROCEDURE|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
219030511|NCT00733109|OTHER|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
219607667|NCT00043810|DRUG|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
219202009|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
218887026|NCT07065474|OTHER|education material|For students in Grades 6 to 7, the intervention comprises a coloring book that integrates storytelling and coloring assignments designed to explain key concepts related to ARF and RHD. In addition, students in these grades will watch video sessions that cover the symptoms, causes, prevention, and treatment of ARF and RHD. These videos serve to visualize the information introduced in the books. Complementing these materials, the intervention includes interactive classroom sessions facilitated by the trained field team, during which students will participate in guided discussions and activities to enhance their understanding and retention of health messages. For students in Grades 8 to 9, the intervention uses a more advanced format tailored to older adolescents. These students will receive an activity book that includes heart anatomy coloring assignments and games such as puzzles, scrambled words, and maze runs that incorporate facts and concepts about RHD.
218887027|NCT07066280|DRUG|Skin Repairing Cream|Skin Repairing Cream containing natural weak-acid
218887028|NCT07066280|OTHER|Cetaphil® Moisturizing Cream as Inactive Control|Cetaphil® Moisturizing Cream
218887029|NCT07065396|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
218887030|NCT07065396|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
218887031|NCT07065396|PROCEDURE|Placebo CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
218887032|NCT07065318|BEHAVIORAL|LV-HIIT (Low-Volume High-Intensity Interval Training)|30-sec intervals at 85-100% peak workload, 30-sec rest at 40%, total 20-30 min.
218887033|NCT07065318|BEHAVIORAL|MICT (Moderate-Intensity Continuous Training)|Continuous cycling at 60-80% peak workload for 20-30 min.
218887034|NCT07065318|DEVICE|Ergometer cycle|Electronically Ergometer cycle custo ec5000, CustoMed used for all exercise sessions. Calibrated before each trial.
218887035|NCT07065994|DEVICE|Virtual Reality Glasses Application|The day before the surgery, you will be shown a video of nature images with relaxing music for 10-15 minutes using virtual reality glasses.
218887036|NCT07066462|OTHER|Fatigue Exercise Protocol with Biosignal Monitoring|Participants will complete two fatiguing exercises, including static bicycling and dumbbell squats. During each exercise, surface electromyography (sEMG), electroencephalography (EEG), and heart rate (HR) will be recorded to analyze fatigue levels.
219030512|NCT01582997|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
219030513|NCT04091646|DRUG|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
219030514|NCT04091646|DRUG|Vehicle foam|Vehicle foam for topical application.
218887037|NCT07065825|PROCEDURE|robot-assisted partial nephrectomy|Robotic-Assisted Partial Nephrectomy (RAPN) is a minimally invasive surgical procedure performed with the help of a robotic system to remove a kidney tumor while preserving as much healthy kidney tissue as possible. It is commonly used to treat small to medium-sized kidney tumors. Thanks to the precision of robotic technology, RAPN offers faster recovery, less postoperative pain, and fewer complications compared to traditional open surgery.
218887038|NCT07066059|DRUG|Shouhui Tongbian Capsules|2 pills twice daily from admission to the night before surgery, then resuming after bowel sound recovery and oral intake postoperatively, with a 3-day post-discharge regimen
218887039|NCT07066787|BEHAVIORAL|psychological group|fill the psychological section
218887040|NCT07066787|DIAGNOSTIC_TEST|somatic|fill the somatic section
218887041|NCT07065097|OTHER|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.
219030515|NCT03012113|DRUG|Mirabegron|
219030516|NCT03012113|OTHER|Short term mild cooling|
219030517|NCT03012113|DRUG|Placebo Oral Capsule|
219030518|NCT03068975|DRUG|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
219030519|NCT03068975|DRUG|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
219030520|NCT02224911|DEVICE|Laser Interstitial Thermal Therapy|
219030521|NCT02606591|PROCEDURE|Electroencephalograph|EEG performed at beginning and end of school year.
219030522|NCT02606591|BEHAVIORAL|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
219030523|NCT02606591|OTHER|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
218887042|NCT07065383|DRUG|Semaglutide administration plus dietary counselling and physical activity encouragement|Semaglutide administration plus dietary counselling and physical activity encouragement
218887043|NCT07065383|DRUG|Semaglutide plus a personalised and supervised program of resistance and endurance training|Semaglutide administration plus a personalised and supervised program of resistance and endurance training.
218887044|NCT07064798|DEVICE|Paxman Limb Cryocompression System|An investigational device designed to provide controlled cooling and compression to participant limbs during chemotherapy administration. The device is comprised of a control unit, connecting hose, and two limb wraps. The customizable limb wraps delivers continuous-flow cooling-and-compression to participant extremities
218887045|NCT07066072|DEVICE|Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer).|the Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer) will be assigned to TECAR group
218887046|NCT07066072|OTHER|standard pharmacological therapy in sickle cell disease like hydroxyurea,paracetamol,ibubrofen and blood transfusion if needed|this is the standard medical care assigned to control group
218887047|NCT07066423|OTHER|Ai prediction photo of the patients|Ai prediction photo generated by specially designed ai model to help patients see how they will look after orthodontic extraction and retraction
218887048|NCT07066423|PROCEDURE|Fixed orthodontic brackets with premolars extraction|Subjects will undergo orthodontic fixed brackets treatment, four premolar extractions from the mandibular and maxillary arches, followed by anterior segment retraction. This treatment will achieve dental alignment, profile, and facial enhancement.
219507535|NCT06465823|DRUG|Placebo|Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
219507536|NCT01399723|DRUG|Amoxicillin|Oral 45mg/kg 12 hourly
218887049|NCT07066137|DEVICE|CAREN|"The interventions include proprioceptive stimuli combined with specific rehabilitation protocols, such as Tabata training, plyometric training, and visual-cognitive-motor enhancement with the S.V.T.A. method.~Healthy subjects and athletes (about 50) will participate in intensive aerobic and anaerobic training, including sensory-motor-cognitive training and exercises on the CAREN platform. Another 25 participants will have TMS/tDCS and music therapy added to their regimen.~Regarding neurological patients, 50 participants will undergo posture and gait rehabilitation using the CAREN platform, while 25 will receive non-invasive neuromodulation to enhance their rehabilitation outcomes. This arm of the study focuses on the recovery of motor and cognitive functions.~This study uses the CAREN system as a tool for physical rehabilitation in neurological and healthy participants. The device is not being investigated for new indications and the study is conducted entirely in Italy."
219030524|NCT01762943|DRUG|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
219030525|NCT01762943|DRUG|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
219030526|NCT01762943|DRUG|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
219030527|NCT00294164|DRUG|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
219030528|NCT00294164|DRUG|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
219030529|NCT00079924|DRUG|teriparatide|
219030530|NCT00079924|DRUG|aldrenodate|
219030531|NCT00079924|DRUG|raloxifene|
219030532|NCT02734888|OTHER|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
219030533|NCT02484495|OTHER|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
219030534|NCT02280980|OTHER|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
219030535|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
219030536|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
219030537|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
219040409|NCT06924892|BEHAVIORAL|Music Therapy|Independent music therapy 45-minute sessions provided weekly for 3 months
219040410|NCT06924892|OTHER|Wellness Concerts|Wellness Concerts provided at partner sites (Carnegie Hall Weill Music Institute, Cooper Union College, Third Street Music Settlement).
219507537|NCT01399723|DRUG|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
219507538|NCT02935075|DRUG|Tenofovir disoproxil fumarate|Oral daily
219507539|NCT02935075|DRUG|Lamivudine|Oral daily
218887050|NCT07066137|OTHER|Control group|"the control group is typically the group that does not receive the experimental treatment or intervention, serving as a baseline to compare the effects of the intervention. However, in the context you're describing with healthy subjects and athletes, here's how it's structured:~Healthy subjects and athletes (around 50 participants) will undergo:~Intensive aerobic and anaerobic training Sensory-motor-cognitive training~Additionally, 25 of these participants will receive:~Transcranial Magnetic Stimulation (TMS) Transcranial Direct Current Stimulation (tDCS) Music therapy This approach allows for a comparison between the effects of the physical and cognitive training alone versus the enhanced effects when combined with neuromodulation (TMS, tDCS) and music therapy. This design will help in assessing the added value of these interventions on performance"
219507540|NCT02935075|DRUG|Efavirenz|Oral daily
219507541|NCT00118300|DRUG|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
219030538|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
219202010|NCT06872528|OTHER|Recording the amount of medication and the number of complications according to observational follow-up|Observational monitoring of patients and recording data for 24 hours
218887051|NCT07066800|BEHAVIORAL|Mindfulness-Based Online Training Program|"A 4-week web-based mindfulness program developed by the research team, designed to improve attention, emotional regulation, and mental health in adults with a history of maltreatment.~* The intervention includes:~  * Weekly educational videos (5-10 minutes each)~ * Weekly mindfulness practice videos (5-10 minutes each)~ * Assigned home practices each week~ * Optional support via KakaoTalk channel for Q\&A and participant engagement~* Weekly themes include:~  * Breathing and muscle relaxation~ * Mindfulness breathing meditation~ * Body scan meditation~ * Mindful walking"
218887052|NCT06660173|DRUG|Maridebart Cafraglutide|Solution for subcutaneous injection.
219030539|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
219507542|NCT00118300|RADIATION|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)\* intracavitary brachytherapy once weekly in weeks 4-8.
219507543|NCT00118300|RADIATION|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
219507544|NCT02386059|DRUG|PLACEBO|received normal saline, intravenously
219507545|NCT02386059|DRUG|Dexamethasone|4 mg, intravenously, at the start of surgery
219507546|NCT02386059|DRUG|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
219507547|NCT02386059|DRUG|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
219030540|NCT06301100|OTHER|Dual energy CT after routine simulation|Dual energy CT after routine simulation
219202011|NCT06872411|OTHER|HealthyDads Digital Intervention|HealthyDads is a prototype bilingual self-guided psychoeducational Digital Intervention with accurate and easily accessible information on topics related to mental health, parenting and health behaviors, along with strategies to optimize each.
219202012|NCT06684418|DIAGNOSTIC_TEST|chest enhanced CT|This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.
219202013|NCT04093869|BEHAVIORAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
219507548|NCT01727245|OTHER|Obese|gastric bypass
219507549|NCT01727245|OTHER|Control group|Cholecystectomy and anti-reflux surgery
219507550|NCT05074082|PROCEDURE|Flap reconstruction|Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
219507551|NCT04259606|DIETARY_SUPPLEMENT|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
218887053|NCT06660173|DRUG|Placebo|Solution for subcutaneous injection.
218887054|NCT05996185|DRUG|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
219507552|NCT04259606|OTHER|Calcined magnesia|White, odor, color and flavorless thin powder.
219507553|NCT03051256|DRUG|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
219507554|NCT03051256|DRUG|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
219507555|NCT02457858|DRUG|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
219507556|NCT02311023|OTHER|Intermittent fasting|
219507557|NCT04395365|DRUG|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
219507558|NCT04395365|DRUG|Placebo oral tablet|Placebo
219507559|NCT03804320|OTHER|Active Surveillance|
219507560|NCT01554761|PROCEDURE|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
219507561|NCT01554761|DEVICE|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
219507562|NCT00294723|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
219507563|NCT00294723|DRUG|glimepiride|8 mg capsule
219507564|NCT00294723|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
219507565|NCT00294723|DRUG|placebo|Glimepiride placebo, 8mg capsule
219507566|NCT00294723|DRUG|placebo|Liraglutide placebo, 200 mcl
219507567|NCT00294723|DRUG|placebo|Liraglutide placebo, 300 mcl
219202014|NCT04093869|BEHAVIORAL|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
219507568|NCT00752791|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
219507569|NCT00004193|DRUG|ISIS 2503|
219202015|NCT06688292|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
219507570|NCT01992107|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
219507571|NCT01992107|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
218887055|NCT05996185|DRUG|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
218887056|NCT07066527|COMBINATION_PRODUCT|The addition of sodium hyaluronate to poly (cinnamyl alcohol-RRB- produces a more stable foam|According to the study, the half-life of 1% poly (cinnamyl alcohol-RPol(POL) foam with a liquid-to-gas ratio of 1:4 was 142.8(64.32) seconds, in this study, the half-life of the foam made from 1% POL containing 0.05% hyaluronic acid (HA) was 390.4(613.06) seconds, human blood contains a certain amount of HA, according to the literature reported that 0.05% concentration of HA injected into human blood is safe, so this more stable foam preparation method was patented, and published in international journals.
218887057|NCT07065526|BEHAVIORAL|Emodin|Following the pre-test in the first encounter, the participants were administered the first EFT lasting 30-40 minutes by the first author, who is a certified EFT facilitator, followed by the CPS. Afterwards, a total of 4 sessions of EFT were administered at 1-week intervals. The CPS was applied before and after each EFT. After the last EFT session, SUE, PSQI and MENQOL post-tests were administered.
218887058|NCT07065630|DRUG|Volrustomig|500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.
218887059|NCT07065630|DRUG|Carboplatin|100mg/m2 IV day 1 and day 8.
219030541|NCT04113499|PROCEDURE|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
219030542|NCT04113499|PROCEDURE|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
219202016|NCT06688292|DRUG|Actein effervescent 600mg|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
219202017|NCT06687304|DEVICE|Light enhancement|Light recipe that mimics the varying daylight of the day
219202018|NCT06688201|OTHER|Other neurosurgical techniques|Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.
219202019|NCT06688201|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
219202020|NCT06873464|OTHER|Three cycles of tDCS combined with motor tasks|"Three cycles of 2 weeks duration each combining tDCS and motor task.~Initial Assessment (V0): Collect demographic data and EDSS, MFIS, MSQOL-54, and BBS results.~First Cycle: 2 weeks, Monday to Friday, with a weekend break. Post-First Cycle Assessment (V1): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month without tDCS. Second Cycle: 2 weeks, Monday to Friday, with a weekend break. Final Assessment after Second Cycle (V2): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month. Third Cycle: 2 weeks. Final Assessment after Third Cycle (V3): Reassess MFIS, MSQOL-54, and BBS."
219507572|NCT01992107|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
218887060|NCT07065630|DRUG|Paclitaxel|AUC 5 IV day 1
219507573|NCT00804609|DRUG|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
218887061|NCT06756230|OTHER|Pulmonary Rehabilitation|"8 weeks, 2 sessions per week,~Aerobic training will be provided as treadmill walking. It will be performed either downhill or on a flat treadmill, depending on the group.~Warm-up and stretching exercises~Resistance exercises will be performed with a load equivalent to 50% of 1 maximum repetition. 10 repetitions will be performed in sets, one set in each session. Based on the differences in the general condition of the patients, different workloads and modifications will be used when creating an exercise program for each patient. Resistance exercises will focus on both upper and lower extremity muscles."
219202021|NCT06873464|OTHER|Two cycles of tDCS combined with motor tasks|"Initial assessment (V0): Prior to the first tDCS cycle, demographic data and results from the EDSS, MFIS, MSQOL-54, and BBS scales will be collected.~First cycle: 2 weeks Post-first cycle assessment (V1): Reassess MFIS, MSQOL-54, and BBS scales. Washout period: 1 month without tDCS treatment. Second cycle: 2 weeks, with sessions from Monday to Friday and a weekend break. Final assessment (V2): After the second cycle, reassess MFIS, MSQOL-54, and BBS scales.~Follow-up assessment (V3): 45 days after treatment completion."
219202022|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
218887062|NCT06756230|OTHER|Downhill Walking|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Downhill walking training will continue with a constant -10% incline.
219030543|NCT00528723|DRUG|salbutamol 100 mcg|To be used as needed for symptom relief
219030544|NCT00528723|DRUG|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
219202023|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
219202024|NCT06699654|OTHER|Placebo gel|A gel without active Spirulina components applied as a control intervention.
218887063|NCT06756230|OTHER|Treadmill Walking without incline|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Traditional walking training will initially involve walking with a neutral incline.
219030545|NCT00528723|DRUG|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
219202025|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Gel|A conventional Spirulina gel formulation applied as a periodontal therapy.
219202026|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Nanoparticles Gel|A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
218887064|NCT03400176|DRUG|VAY736|Experimental
218887065|NCT03400176|DRUG|ibrutinib|Approved medication
218887066|NCT05719675|BEHAVIORAL|Intervention|"The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
218887067|NCT06920641|OTHER|Tagatose|"Sachet containing 10g tagatose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
218887068|NCT06920641|OTHER|Placebo|"Sachet containing 10g sucrose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
219202027|NCT06699056|DEVICE|15-minutes of sitting during COR ECG Acquistion|"Participants will follow a standardized protocol during a 15-minute seated session using the Peerbridge COR™ device. Participants will sit comfortably in an upright chair with a straight back; armrests are optional. Their feet must remain flat on the floor with legs uncrossed to ensure unobstructed blood flow and a stable posture. Arms should be relaxed and placed in their lap, on a flat surface (e.g., table), or on the armrest, ensuring they are not tensed or elevated. Participants will maintain a straight back with relaxed shoulders throughout the session.~To begin, participants will press the Event Button on the Peerbridge COR™ mobile device, marking the start of the session. They will remain seated in this position for 15 minutes. At the end of the session, participants will press the Event Button again to mark the conclusion of the seated event. This protocol ensures consistent data collection across all participants."
219202028|NCT06504043|DRUG|HST101|HST101 is a novel anti-PCSK9 fusion protein
219202029|NCT06194227|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
219202030|NCT06194227|BEHAVIORAL|Traditional Yoga|Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
219202031|NCT04274361|DRUG|Ketamine|Ketamine infusion
219202032|NCT04274361|DRUG|Placebo|Placebo infusion
218887069|NCT06913387|COMBINATION_PRODUCT|Lipid Based Artificial Tears|30 participants received lipid-based artificial tears (Recuro) in this study arm. The intervention involved the administration of RECURO EYE DROPS, which contain Sodium carboxymethylcellulose 0.5%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
219030546|NCT01620073|OTHER|HIV counseling and testing|Male partner HIV counseling and testing
219030547|NCT03897179|DEVICE|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
219202033|NCT01159782|OTHER|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
219202034|NCT06880380|BIOLOGICAL|HIV-CAR-T|Intravenous Infusion of CAR-T Cells
219202035|NCT06879366|DRUG|Aloe vera gel|10% aloe-vera gel will be prepared under well-controlled laboratory checks
219202036|NCT06879366|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|Benzydamine Hydrochloride 0.15% Oral gel
219202037|NCT06880224|BEHAVIORAL|Testing Peer navigation|Peer navigators will promote HIV testing in YMSM and linkage to care if HIV-positive
219202038|NCT06880224|BEHAVIORAL|PrEP Intervention|Motivational-interviewing to promote uptake of PrEP among those who test HIV-negative
219202039|NCT06880224|BEHAVIORAL|Treatment Peer Navigation|Peer navigators will provide assistance and support to youth with HIV to optimize adherence to ART
218887070|NCT06913387|COMBINATION_PRODUCT|Aqueous Based Artificial Tears|30 participants received aqueous-based artificial tears (Softeal) in this study arm. The intervention involved the administration of SOFTEAL EYE DROPS, which contain Hydroxypropylmethyl Cellulose 0.3%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
219030548|NCT06231212|DRUG|ECa 233|Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
219030549|NCT06231212|DRUG|Ibuprofen|Ibuprofen group was given capsules containing 200 mg of ibuprofen
219202040|NCT06880224|BEHAVIORAL|Social Media Outreach|Social media outreach to identify youth at risk for HIV
219507574|NCT00804609|DRUG|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
218887071|NCT03399474|DRUG|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
219030550|NCT06231212|OTHER|Placebo|Placebo-controlled group received capsules containing 250 mg of lactose
219030551|NCT05552677|OTHER|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
219030552|NCT04710706|OTHER|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
219202041|NCT06880224|BEHAVIORAL|SMS Test messaging|Text (SMS) messages to remind and encourage youth to adhere to their ART
219030553|NCT04053101|DEVICE|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
219030554|NCT05138133|DRUG|Anifrolumab|Anifrolumab intravenous infusion (IV)
219030555|NCT05138133|DRUG|Placebo|Placebo intravenous infusion (IV)
219030556|NCT05968690|DRUG|Propranolol|Propranolol will be administered to patients in all cohorts.
219030557|NCT05968690|DRUG|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
219030558|NCT05972551|DRUG|Romosozumab|Subcutaneous (SC) injection
219030559|NCT05972551|DRUG|Bisphosphonate|Administration determined by investigator according to the local standard of care
219202042|NCT06880224|OTHER|Adherence standard of care|Standard of care HIV treatment adherence
219202043|NCT06877325|BEHAVIORAL|PFMT|The training is divided into three phases. The first phase is the foundation phase (Weeks 1-4), which primarily activates the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Builds muscular endurance and control by increasing contraction duration. Consolidation Phase (Weeks 9-12): Enhances overall stability and strength through functional movements.
219202044|NCT06877325|BEHAVIORAL|QGPFMT|The training is divided into three phases: Foundation Phase (Weeks 1-4): Focuses on breath regulation and activation to promote energy flow and awaken the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Combines core stability training to enhance muscle strength and flexibility. Consolidation Phase (Weeks 9-12): This phase strengthens core control while incorporating standing meditation and breathing exercises to harmonize body and mind, improving overall stability and endurance.
219202045|NCT06877325|BEHAVIORAL|Qigong|"The training is divided into three phases. The first phase (Weeks 1-4) focuses on breathing regulation and relaxation to enhance blood circulation and promote body recovery. Strengthening Phase (Weeks 5-8): Utilizes Dao Yin techniques to improve flexibility and stimulate energy flow. Consolidation Phase (Weeks 9-12): Emphasizes overall enhancement and core strengthening and incorporates extended deep breathing meditation to harmonize body and mind."
219202046|NCT06878599|COMBINATION_PRODUCT|Hyaluronic Acid (HA)|Adding Hyaluronic acid to dexamethasone as intratympanic injection
219202047|NCT06878599|DRUG|Dexamethasone|Intratympanic injection of Dexamethasone
219202048|NCT06875999|BEHAVIORAL|animal assisted therapy|The Children's Emotional Indicator Scale (Facial expression, Vocalization, Activity, Interaction and Cooperation Level) will be used to provide a simple, objective and consistent method to determine children's emotional behavior during stressful medical procedures. The FLACC scale will be used for pain. In addition, all physiological parameters including pulse rate, saturation value and respiration will be measured and recorded with a pulse oximeter device. Animal assisted therapy will be applied to the participants in the study group to reduce the stress of the children. In animal-assisted therapy, the child will be shown a fish in a glass bowl and a red fish song will accompany the process. In the study, participant children will be randomly assigned to intervention and control groups.
219202049|NCT06693258|PROCEDURE|thyroidectomy by robotic surgery via axillary approach|thyroidectomy
219202050|NCT06693258|PROCEDURE|thyroidectomy by standard conventional surgery|thyroidectomy by standard conventional surgery
218887072|NCT03399474|DRUG|Dexmedetomidine 0.5 ug/kg|pecedex
218887073|NCT03399474|DRUG|Dexmedetomidine Injection 0.25 ug/kg|pecedex
218887074|NCT00119821|BEHAVIORAL|Weight Reducing Diet|Behavioral intervention
218887075|NCT00119821|BEHAVIORAL|Exercise|Moderate exercise implemented plus behavioral intervention.
219030560|NCT05676749|BIOLOGICAL|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
219030561|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
219030562|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
219030563|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
219030564|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
218887076|NCT00119821|BEHAVIORAL|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
218887077|NCT03180970|DRUG|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
218887078|NCT03180970|DRUG|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
218887079|NCT03180970|DRUG|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
218887080|NCT03180970|DRUG|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
218887081|NCT03180970|DRUG|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
218887082|NCT01262534|OTHER|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
218887083|NCT01262534|OTHER|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
218887084|NCT01262534|OTHER|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
218887085|NCT03107494|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
218887086|NCT06351059|DIAGNOSTIC_TEST|InModi acoustic emission analysis|All diagnosis tests
218887087|NCT03430232|DRUG|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
219202051|NCT06712888|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy|"Drug: Toripalimab 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Other Names:~JS001 PD-1 antibody~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP~Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
219202052|NCT06712888|DRUG|GP plus placebo induction therapy|"Drug: Placebo 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
219507575|NCT01723956|PROCEDURE|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
219507576|NCT01723956|PROCEDURE|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
219030565|NCT02529618|DEVICE|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
219030566|NCT02529618|DEVICE|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
219202053|NCT06882694|BEHAVIORAL|Pelvic Floor Imagery Questionairre|This intervention consists of a questionairre
219507577|NCT05877820|BIOLOGICAL|Tislelizumab|Intravenous infusion
219507578|NCT05877820|DRUG|Lenvatinib|Oral tablet
219507579|NCT00799006|DRUG|Placebo|Subjects will be given placebo or PF-04620110
218887088|NCT03430232|DRUG|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
218887089|NCT03430232|DRUG|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
218887090|NCT03430232|DRUG|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
218887091|NCT03430232|DRUG|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
218887092|NCT03430232|DRUG|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
218887093|NCT03430232|DRUG|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
218887094|NCT03430232|DRUG|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
218887095|NCT03430232|DRUG|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
219607668|NCT04208750|DEVICE|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
219507580|NCT00799006|DRUG|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
219507581|NCT04951050|DEVICE|Rapamycin target eluting stent|Rapamycin target eluting stent
219507582|NCT02087046|DEVICE|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
219507583|NCT02862639|DEVICE|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
218887096|NCT03430232|DRUG|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
218887097|NCT03430232|DRUG|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
219507584|NCT02862639|DEVICE|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
219507585|NCT00296114|PROCEDURE|Serum and DNA Samples|To collect serum and DNA samples from subjects
219507586|NCT00818714|RADIATION|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
219507587|NCT00740064|DRUG|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
219507588|NCT01214603|DRUG|LY2090314|Administered intravenously
219507589|NCT00471406|PROCEDURE|Photodynamic Therapy with Verteporfin|
219507590|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
218887098|NCT03430232|DRUG|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
218887099|NCT03430232|DRUG|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
218887100|NCT00206440|DRUG|esomeprazole|nexium
218887101|NCT00206440|OTHER|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
218887102|NCT05998174|OTHER|Faecal Microbiota Transplantation|treatment with capsules
218887103|NCT03815565|PROCEDURE|continuous femoral block|infusion of anesthetic by PCA pump
218887104|NCT03870412|DRUG|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
218887105|NCT01298765|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
218887106|NCT04152798|PROCEDURE|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
218887107|NCT04152798|PROCEDURE|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
218887108|NCT06354478|DRUG|Dexmedetomidine Hydrochloride 0.5 MG/ML|Will be used either alone or in combination of gabapentin
218887109|NCT06354478|DRUG|Gabapentin|Will be used either alone or in combination of Dexmedetomidine
218887110|NCT03723109|PROCEDURE|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
218887111|NCT03401671|DRUG|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
218887112|NCT03259061|DEVICE|Flexible fiberoptic nasopharyngoscopy|"1. Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~2. Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
218887113|NCT00959738|PROCEDURE|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
218887114|NCT00959738|PROCEDURE|diverting loop ileostomy without rod|diverting loop ileostomy without rod
218887115|NCT03302247|BIOLOGICAL|Nivolumab|Monoclonal antibody against non small cell lung cancer
218887116|NCT03302247|DRUG|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
218887117|NCT02681289|OTHER|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
218887118|NCT04090242|DEVICE|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
218887119|NCT03931694|DEVICE|e-DOL|e-health program (smartphone and web platform)
218887120|NCT02487004|DEVICE|hemodialysis|
218887121|NCT03214406|DRUG|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
218887122|NCT03214406|DRUG|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
218887123|NCT01898013|DRUG|Pregnenolone|
218887124|NCT01898013|DRUG|Placebo|
218887125|NCT04030793|DEVICE|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
218887126|NCT04030793|DEVICE|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
218887127|NCT01957410|DRUG|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
218887128|NCT01957410|DRUG|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
219607669|NCT04208750|DEVICE|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
219607670|NCT06632366|OTHER|Sexual Dysfunction in the Postpartum Period|The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
219607671|NCT00442455|DRUG|Erlotinib chlorhydrate|150 mg/day for 7 weeks
218887129|NCT03761342|BEHAVIORAL|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
218887130|NCT03761342|BEHAVIORAL|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
218887131|NCT05351866|DEVICE|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
218887132|NCT05351866|DEVICE|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
218887133|NCT01098305|DRUG|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
218887134|NCT01098305|BEHAVIORAL|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
219607672|NCT00442455|DRUG|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
219607673|NCT00442455|PROCEDURE|Radiation therapy|63 Gy, five days a week, for 7 weeks
218887135|NCT02536924|BEHAVIORAL|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
218887136|NCT02536924|BEHAVIORAL|Treatment as usual.|The patient will receive treatment as usual.
219607674|NCT05429866|DRUG|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
218887137|NCT03447847|OTHER|Water|1 liter of water in meals; 1 liter out of meals
218887138|NCT00325390|DRUG|clopidogrel (SR25990C)|
218887139|NCT02964442|OTHER|Capsinoids|12 mg of Gel capsules
218887140|NCT02964442|OTHER|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
218887141|NCT01100775|DRUG|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
218887142|NCT01100775|DRUG|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
218887143|NCT01716780|OTHER|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
218887144|NCT03803384|OTHER|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
219507591|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
219607675|NCT01119664|DRUG|SCH 721015|
219607676|NCT00108706|DRUG|Candesartan|
219607677|NCT02201277|DEVICE|Filter Placed|
219607678|NCT03590054|DRUG|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
219607679|NCT03590054|BIOLOGICAL|Pembrolizumab|Given IV on day 1 of every 21 day cycle
219202054|NCT06881394|DEVICE|Polymer Skin Barrier|A cyanoacrylate polymer will be applied topically once or twice a day to the palmar surface of hands to prevent perspiration
219202055|NCT06882070|OTHER|Vaccine|Trivalent P2-VP8 subunit rotavirus vaccine
219202056|NCT06705907|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|Intervention targeting academic executive functioning
218887145|NCT02322970|DEVICE|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
219202057|NCT06705907|BEHAVIORAL|Building Essential Social Skills for Teens (BESST)|Intervention targeting social skills
219202058|NCT06705426|OTHER|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
219202059|NCT06705426|OTHER|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
219202060|NCT06719856|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
219202061|NCT06884566|DIETARY_SUPPLEMENT|Taurine supplementation|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
219202062|NCT06884566|DIETARY_SUPPLEMENT|Placebo|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
219202063|NCT06883474|OTHER|Osteosclerotic Changes on Computed Tomography|Osteosclerotic Changes on Computed Tomography
219507592|NCT06103526|DIETARY_SUPPLEMENT|Immunonutrition|enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
219507593|NCT06542926|PROCEDURE|liver resection|Resection of non-colorectal liver metastases
219507594|NCT05851235|OTHER|Prehabilitation course|During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
218887146|NCT04623814|OTHER|Food|HEC113995 20mg will be taken orally fasted or with food
218887147|NCT04623814|DRUG|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
219202064|NCT06881914|BEHAVIORAL|Intervention group:|There were 5 sessions for the intervention group. All sessions took place in the participant's home. The first 4th sessions involved participant sharing a particular time of their life event, such as childhood, adolescence, adulthood, and the current stage. Transcripts were prepared and compiled following the completion of the interviews. The participants will proofread their life-story book before sending it for printing. In the 5th session, they were given their life storybooks. A self-report questionnaire was used in every session to collect participants' quality of life, life satisfaction, and depression scores.
219202065|NCT06885021|DRUG|HDM1002 200mg, oral, once daily, 52 weeks|HDM1002 200mg, oral, once daily, 52 weeks
219202066|NCT06885021|DRUG|HDM1002 400mg, oral, once daily, 52 weeks|HDM1002 400mg, oral, once daily, 52 weeks
219202067|NCT06885021|DRUG|HDM1002 placebo, oral, once daily, 52 weeks|HDM1002 placebo, oral, once daily, 52 weeks
219202068|NCT06882798|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
219202069|NCT06882798|BEHAVIORAL|SCBT-SB + CHW|The New Clinical Model consist of one clinician delivering the SCBT-SB and one CHW per each family. The assigned clinician \& CHW will meet at the beginning of treatment to discuss their assigned case and will have follow-up meetings as needed and at a minimum, once monthly. CHWs will support family engagement in treatment. CHWs will assess each family's social needs and concerns about treatment. The CHW intervention will 1) Assess social determinants of mental health; 2) Provide referrals and serve as a bridge to other community resources; 3) Provide psychoeducation on mental health and services to decrease stigma; and 4) Follow-up and provide support on recommended actions.
219507595|NCT05588206|RADIATION|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
219507596|NCT01388647|DRUG|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
219507597|NCT01388647|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
219507598|NCT01388647|DRUG|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
219202070|NCT06879223|BEHAVIORAL|Oral Health Educational Program|Providing the children with an educational program through a data show presentation when and how to brush their teeth, causes of dental caries and how to prevent its occurrence. A flyer will be distributed including simple language about preventive measure of dental caries and schedule of teeth brushing to ensure retention of information.
219202071|NCT06886711|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
218887148|NCT04623814|DRUG|placebo|The placebo will be administered fasted or with food for 10 days.
218887149|NCT03910114|DRUG|Magnevist|GBCA enhancement
218887150|NCT03910114|DRUG|Dotarem|GBCA enhancement
218887151|NCT03910114|DRUG|Gadovist|GBCA enhancement
218887152|NCT01162915|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
218887153|NCT01481077|DRUG|Latanoprost-PPDS|Sustained release for 12 weeks
218887154|NCT01196832|PROCEDURE|blood sample|blood sample for fibrocytes analysis
218887155|NCT01196832|PROCEDURE|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
218887156|NCT03227666|BEHAVIORAL|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
219030567|NCT02529618|DEVICE|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
219030568|NCT02859051|DEVICE|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
219202072|NCT06886711|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
219202073|NCT06891742|DRUG|OriC902|Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent preparation of CAR T cells
219202074|NCT06736054|DRUG|Copper 61-PSMA PET/CT|TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
218887157|NCT04682535|OTHER|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
218887158|NCT01061502|DEVICE|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
219202075|NCT06737913|PROCEDURE|HAI Adebrelimab|Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
219202076|NCT06737913|DRUG|intravenous infusion (IV) of Adebrelimab (ADE)|intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)
219202077|NCT06737913|DRUG|intravenous infusion (IV) of Bevacizumab (Bev.)|intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)
218887159|NCT01061502|DEVICE|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
218887160|NCT06447402|DRUG|Normal saline|5 mL of normal saline will be nebulised in the control arm
218887161|NCT06447402|DRUG|Amphotericin B deoxycholate|2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
218887162|NCT05018078|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
219030569|NCT06225661|BEHAVIORAL|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
219030570|NCT06225661|BEHAVIORAL|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
219030571|NCT02120950|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
219030572|NCT02120950|OTHER|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
219202078|NCT06737913|PROCEDURE|HAIC with FOLFOX regimen|HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)
218887163|NCT05466357|PROCEDURE|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
218887164|NCT03182907|BIOLOGICAL|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
218887165|NCT03182907|DRUG|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
218887166|NCT03182907|DRUG|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
218887167|NCT00429169|DRUG|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
218887168|NCT00429169|DRUG|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
218887169|NCT04161261|PROCEDURE|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
218887170|NCT02183233|DRUG|Eschscholtzia Californica|
218887171|NCT02183233|DRUG|Eschscholtzia Californica Placebo|
218887172|NCT02513576|OTHER|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
218887173|NCT03634254|OTHER|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
218887174|NCT06279507|DRUG|Sodium Hyaluronate|Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
218887175|NCT06279507|DRUG|Normal Saline|0.9% sodium chloride 2 mL prepared in plastic syringe
218887176|NCT06279507|DRUG|Triamcinolone Acetonide 10mg/mL|10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
218887177|NCT02296255|BIOLOGICAL|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
218887178|NCT03747640|DEVICE|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
218887179|NCT03747640|BEHAVIORAL|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
219030573|NCT02424383|DEVICE|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
219030574|NCT00382954|DRUG|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
219202079|NCT06737913|DRUG|Adebrelimab and bevacizumab maintainance treatment|The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity
219507599|NCT02444533|DRUG|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
219507600|NCT02945462|BIOLOGICAL|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
219507601|NCT04455568|DEVICE|use EKG Wisdom bracelet|Non-invasive Wearable Device (use EKG Wisdom bracelet)
219607680|NCT05745597|OTHER|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
218887180|NCT03747640|DEVICE|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
218887181|NCT03747640|BEHAVIORAL|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
218887182|NCT01652131|OTHER|Tetrastarch (130/0.4)|
218887183|NCT04984577|DRUG|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
218887184|NCT04984577|DRUG|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
218887185|NCT04984577|DRUG|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
218887186|NCT04984577|DRUG|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
218887187|NCT03964324|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
218887188|NCT03416452|DEVICE|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
218887189|NCT03416452|DEVICE|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
218887190|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
219030575|NCT00382954|DRUG|Idarubicin|I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
219202080|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg, 600mg
218887191|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
218887192|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
218887193|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
218887194|NCT03401268|DRUG|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
218887195|NCT02721095|OTHER|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
218887196|NCT02721095|OTHER|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
218887197|NCT00759421|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
218887198|NCT00759421|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
218887199|NCT00296920|DEVICE|Deep Brain Stimulation|
219202081|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg
219202082|NCT06744686|DRUG|Placebo|Placebo
219202083|NCT06739577|DIAGNOSTIC_TEST|Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))|"To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task."
219202084|NCT06739577|DIAGNOSTIC_TEST|Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.|Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).
219202085|NCT06735326|DRUG|Fluzoparib|Fluzoparib capsule (50mg per capsule) 150mg po BID
219202086|NCT06735326|DRUG|Bevacizumab|Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W
219202087|NCT06735326|DRUG|Paclitaxel|Paclitaxel injection 135-175mg/㎡ ivdrip Q3W
219202088|NCT06735326|DRUG|Carboplatin|Carboplatin injection AUC=4-5 ivdrip Q3W
219202089|NCT06893692|OTHER|Otago exercise program|Experimental group: Group A will perform the Otago Exercise Program. The training protocol consisted of ten repetitions, with a 60-second rest interval between sets. The training protocol consisted of three sessions per week for 12 weeks.
219202090|NCT06893692|OTHER|Balance Training Exercises|Controlled group: Group B will perform Balance Training Exercises for 12 weeks of three sessions per week. BT included exercises such as a single-leg stance with eyes open and closed, standing on heels or toes, tandem and semi-tandem foot stance, tandem walking, walking backward and forward, and weight shifting.
219202091|NCT06042153|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
218887200|NCT02815644|DRUG|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
218887201|NCT03663335|BIOLOGICAL|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
218887202|NCT03663335|DRUG|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
218887203|NCT02777489|DRUG|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
218887204|NCT01180296|DRUG|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
219202092|NCT06042153|DRUG|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
219202093|NCT06746636|DEVICE|High velocity nasal insufflation|• HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].
219202094|NCT05866926|DRUG|FAB122|FAB122 Daily dose 100 mg
219607681|NCT01984827|DRUG|Moxifloxacin|"1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
219607682|NCT01984827|OTHER|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
219607683|NCT03007992|DRUG|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
219607684|NCT03762694|DEVICE|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
218887205|NCT01180296|DRUG|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
218887206|NCT05015270|DIAGNOSTIC_TEST|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
218887207|NCT02396355|DEVICE|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
218887208|NCT02396355|DEVICE|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
218887209|NCT02396355|DEVICE|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
219607685|NCT00869076|OTHER|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
219030576|NCT02816060|PROCEDURE|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
219202095|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical ventilation APRV mode ( Airway Pressure Release Ventilation )
219202096|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical Ventilation in BiPAP mode (Bi-Level Positive Airway Pressure Ventilation )
219202097|NCT06761989|DRUG|Intrathecal morphine injection|A single dose of intrathecal morphine is administered prior to induction of general anesthesia. The patient is placed in the lateral decubitus position on the bed and a 25 guage quincke spinal needle is inserted intrathecally at the L4/5 median or paramedian approach to administer 0.2 mg of morphine.
219202098|NCT06761989|DEVICE|Continuous wound infiltration|Prior to closure of the abdominal wall, a catheter is placed in the preperitoneal space lateral to the surgical incision through the tunneler. The catheter is connected to a prepared infusion pump (275 ml of 0.5% ropivacaine, 4 ml/hr/catheter), and the remaining catheter protruding from the abdomen is secured with a catheterization dressing. The preperitoneal catheter is removed in the afternoon of postoperative day 3.
219202099|NCT05997784|OTHER|Performing lung function tests (spirometry and fraction of exhaled nitric oxide (FeNO))|"Performing lung function tests and FeNO following European Respiratory Society (ERS) standardized guidelines, through the MIR portable spirometer and the NIOX Vero®, respectively.~Spirometry is performed using a portable spirometer. All manoeuvres are performed according to the American Thoracic Society and European Respiratory Society (ATS/ERS) standards.~FeNO test is a quick and non-invasive test that is easy for children to do. To take the test, the child have to blow into a handheld device (NIOX Vero®). More in detail, children are asked to inhale ambient air through a nitrogen oxide scrubber to total lung capacity, and then exhale for 10 seconds. The test results are available right away."
219202100|NCT05997784|OTHER|Filling of standardized questionnaires|"(Baseline, Follow-up, Quality of life and Final) allowing to collect data on sociodemographic characteristics, health outcomes, potential risk factors, lifestyle and living environment.~Health outcomes will consider general health (general status, infections, allergies), respiratory health (asthma symptoms, diagnosis, control, triggers, medications, etc.), perception of health and well-being."
219202101|NCT05997784|OTHER|Using an App on a device|"Children will have to answer a daily questionnaire on cell phone, tablet, computer...), with the help of parents/caregivers.~To encourage children to answer the questions, the questionnaires will be incorporated into a game that will also teach them about environmental challenges and pollutants in Europe.~There will be a general health questionnaire with 3 questions assessed on a Likert scale.~The application will also include 2 questions on respiratory health, with Yes/No answers. If the answer is Yes to one of the questions, the intensity of symptoms will be assessed on a visual analog scale from 0 to 100 (0 almost no symptoms and 100 the most intense symptoms imaginable)."
219030577|NCT01097018|DRUG|Capecitabine|1000 mg/m2 BID/ Days 1-14
219030578|NCT01097018|DRUG|Perifosine|50 mg daily x 21 days
219030579|NCT01097018|DRUG|Placebo|1 pill daily x 21 days
219030580|NCT01578889|BIOLOGICAL|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
219030581|NCT01578889|BIOLOGICAL|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
219030582|NCT01578889|BIOLOGICAL|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
219030583|NCT01578889|BIOLOGICAL|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
219030584|NCT01578889|DEVICE|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
219030585|NCT04615611|DRUG|salbutamol|inhalation of salbutamol
219030586|NCT04615611|DRUG|Placebo|administration of placebo
219202102|NCT05997784|OTHER|Urine sample|On a voluntary basis, a urine sample will be collected, as well.
219202103|NCT05997784|OTHER|Sensors and devices will be used to assess air pollutants in classrooms during the survey|"* Particulate matter (PM) will be assessed with a counter as a well as a remote sensor (Canarin) .~* Volatile Organic Compound (VOCs) with a passive sampler (Radiello).~* Virus and bacteria will be collected with a pump.~The devices will be attached to the classroom wall.~In addition, dust pollution will be assessed by collecting dust with a vacuum cleaner in order to assess phthalates (Dimethyl phthalate, diethyl phthalates, Di(2-ethylhexyl) phthalate)."
219202104|NCT05039697|OTHER|oxygen|deliver high flow oxygen (10L/min)
219607686|NCT00869076|OTHER|Usual care|Patient was managed by their primary care physician as usual
219607687|NCT05965973|OTHER|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
219607688|NCT05965973|OTHER|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
219607689|NCT02637531|DRUG|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
219030587|NCT02179996|BIOLOGICAL|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
219030588|NCT02179996|BIOLOGICAL|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
219030589|NCT00793364|DIETARY_SUPPLEMENT|Stanol ester spread|Stanol ester spread 20 g every day
219030590|NCT00793364|DIETARY_SUPPLEMENT|Placebo spread|Placebo spread 20 g every day
219030591|NCT00793364|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet every day
219030592|NCT03850873|DRUG|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
219030593|NCT05164458|DRUG|IBI 308 injection|IBI308 IV 200mg Q3W Day1
219030594|NCT05164458|DRUG|IBI 389 Injection|IBI 389 IV Q2\~Q3W Day 1
219507602|NCT04409366|OTHER|Conventional Crown Lengthening (CCL)|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days
218887210|NCT00169208|DRUG|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
218887211|NCT00169208|DRUG|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
218887212|NCT00169208|DRUG|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
218887213|NCT01921764|BEHAVIORAL|Workplace physical exercise|
218887214|NCT01921764|BEHAVIORAL|Home physical exercise|
218887215|NCT01718444|DRUG|Progestin|
218887216|NCT01718444|DRUG|Clomiphene Citrate|
218887217|NCT01511081|RADIATION|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
218887218|NCT01511081|RADIATION|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
218887219|NCT00038558|DRUG|Filgrastim SD/01|
218887220|NCT00038558|DRUG|Adriamycin|
218887221|NCT00038558|DRUG|Bleomycin|
218887222|NCT00038558|DRUG|Vinblastine|
218887223|NCT00038558|DRUG|DTIC|
218887224|NCT00379067|DRUG|Tamsulosin OCAS|Adrenoceptor antagonist
218887225|NCT00379067|DRUG|Placebo|placebo
218887226|NCT04138290|DEVICE|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
218887227|NCT05009290|DRUG|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
219030595|NCT04150276|PROCEDURE|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
219030596|NCT04150276|PROCEDURE|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
219030597|NCT00117559|BEHAVIORAL|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
219030598|NCT00208962|PROCEDURE|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
219030599|NCT03685084|DRUG|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
219030600|NCT03685084|DRUG|Saline 0.9% infusion|Vehicle infusion
219030601|NCT03685084|DRUG|Piperacillin i.v.|piperacillin 3 g i.v.
219030602|NCT03685084|DRUG|Cefepime i.v.|cefepime 1 g i.v.
219030603|NCT00789893|DEVICE|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
219030604|NCT04264910|BEHAVIORAL|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
219030605|NCT01743287|DRUG|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
219030606|NCT01743287|DRUG|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
219030607|NCT02608931|DRUG|Dronabinol|
219030608|NCT02608931|OTHER|Placebo|placebo
219030609|NCT03031093|RADIATION|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
219030610|NCT03031093|DEVICE|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
219030611|NCT06093412|PROCEDURE|unilateral epidural anesthesia|The patients received unilateral epidural anesthesia
219030612|NCT06093412|PROCEDURE|combined lumbar and epidural anesthesia|The patients received combined lumbar and epidural anesthesia
219030613|NCT04912934|PROCEDURE|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
219030614|NCT06419387|DEVICE|Self-Therapy Mobile App|Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
219030615|NCT06419387|OTHER|Psycho-education Videos|Psycho-education Videos include guidelines for increasing emotion regulation skills.
219607690|NCT02637531|DRUG|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
218887228|NCT05009290|DRUG|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
219030616|NCT04418986|PROCEDURE|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
219030617|NCT02653456|DEVICE|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
219030618|NCT02738333|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219030619|NCT02738333|DRUG|SOF|400 mg tablet administered orally once daily
219202105|NCT06814587|DIAGNOSTIC_TEST|Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)|HP-13C MRI is a metabolic imaging technique that enables real-time assessment of myocardial substrate utilization by tracking the conversion of hyperpolarized \[1-13C\] pyruvate to metabolic intermediates such as bicarbonate and lactate. This imaging modality provides insights into oxidative metabolism and mitochondrial function, facilitating the identification of metabolically active and ischemic myocardial regions in patients with ischemic cardiomyopathy.
219202106|NCT06814587|DIAGNOSTIC_TEST|[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|FDG-PET is a molecular imaging technique used to assess myocardial viability by quantifying glucose uptake in cardiac tissue. This method differentiates viable myocardium, which retains metabolic activity, from non-viable scar tissue. FDG-PET is widely used in ischemic cardiomyopathy for viability assessment to guide revascularization decisions.
219507603|NCT04409366|OTHER|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
219507604|NCT04087668|PROCEDURE|Monitored Anesthesia Care|MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
219607691|NCT06623474|DIAGNOSTIC_TEST|diagnosed by traditional diagnostic markers（such as AFP or CT etc.）|A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
219607692|NCT03451214|OTHER|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
219607693|NCT05967884|DRUG|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
219607694|NCT03649984|BEHAVIORAL|Symptom Navi© Program|Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
219030620|NCT02738333|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
219030621|NCT04979741|OTHER|No interventions|Observational study, no intervention is required
219030622|NCT00574054|RADIATION|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
219202107|NCT06766773|PROCEDURE|Compound heating strategy|After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.
219202108|NCT06766773|PROCEDURE|perioperative mandatory warming measures|perioperative mandatory warming measures
219202109|NCT06862687|OTHER|Cooling Spray|"A cooling spray containing propan-butane-pentane was applied 25 cm from the cannulation site until mild whitening/frosting appeared.~The standard AVF cannulation procedure was performed. Pain levels were measured immediately after the procedure using VAS."
219202110|NCT06862687|OTHER|Cold Aloe Vera Gel Application|1 ml of cold aloe vera gel was applied to a 5x5 cm area over the fistula site. The standard AVF cannulation procedure was conducted. Pain levels were assessed post-procedure using VAS.
219030623|NCT02003131|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
219030624|NCT00791518|DRUG|No intervention|No intervention
219030625|NCT05632549|DRUG|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
219030626|NCT05632549|DRUG|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
219030627|NCT05632549|DRUG|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
219030628|NCT05936866|OTHER|Pelvic floor stretching|Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
218887229|NCT05226299|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
218887230|NCT05226299|BIOLOGICAL|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
219202111|NCT06862687|OTHER|Standard Procedure (Control Condition)|"No additional pain-relief intervention was applied. The nurse performed the standard AVF cannulation procedure, including hand hygiene, thrill assessment, and site disinfection.~Pain levels were assessed immediately after cannulation using the Visual Analog Scale (VAS)."
219202112|NCT06742814|DEVICE|stress ball|Stress ball: It is a ball with moderate hardness and softness, about 6 cm, which can be held and pressed by hand.
219202113|NCT06835582|DRUG|Methadone|Comparing methadone point of care test to LC-MS to evalutate methadone and its metabolite levels pre dosing and after dosing using the patient's current methadone prescription.
219202114|NCT06840145|DEVICE|repetitive transcranial magnetic stimulation|Intermittent theta Burst stimulation will be performed as detailed in the Real arm description
219202115|NCT06654128|DIAGNOSTIC_TEST|artificial intelligence|patients will undergo tandem colonoscopy with artificial intelligence
219202116|NCT06811818|OTHER|complete denture with bilateral balanced occlusion|Participants in this group will be given complete dentures with bilateral balanced occlusion
219202117|NCT06811818|OTHER|complete denture with lingualized occlusion|Participants in this group will be given complete dentures with lingualized occlusion
219202118|NCT06810154|BIOLOGICAL|Multi-strain probiotics|Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.
218887231|NCT04326049|DEVICE|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
218887232|NCT04326049|DEVICE|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
218887233|NCT03364309|DRUG|Ixekizumab|Administered SC
218887234|NCT03364309|DRUG|Placebo|Administered SC
218887235|NCT04747587|OTHER|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
218887236|NCT01850407|BEHAVIORAL|Education Counseling|
218887237|NCT03413709|OTHER|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
218887238|NCT02430883|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
218887239|NCT01882504|DRUG|gevokizumab|
219030629|NCT05936866|OTHER|Pelvic floor strengthening|"Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze"
219030630|NCT00311896|DRUG|Bemiparin|
219030631|NCT00311896|DRUG|Placebo|
219202119|NCT05920330|OTHER|Nasal Plug|Please see the arm description for details.
219202120|NCT06811649|DIAGNOSTIC_TEST|Ultrasound guided injection with local anaestethic|"Experimental treatment consists of ultrasound assessment combined with palpatory assessment to identify the most suitable space for epidural catheter insertion.~The conventional neuroaxial technique relies on palpation of the spinous processes and iliac crests to recognize the midline and height of the lumbar interspace to be used to perform a neuroaxial block.~With the echo-assisted technique, in aid of the conventional technique, a preprocedure (Prepuncture) is performed for the purpose of combining classic anatomical findings with useful sonographic findings that should improve the success of the neuroaxial technique."
218887240|NCT04014569|DEVICE|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
218887241|NCT03145948|DRUG|ABBV-553|It is administered orally.
218887242|NCT03145948|DRUG|Placebo|It is administered orally.
219030632|NCT02859233|OTHER|Lack of hyperhydration|
219030633|NCT01212718|DRUG|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
219030634|NCT01212718|DRUG|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
218887243|NCT05268952|OTHER|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
218887244|NCT05268952|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
219030635|NCT05450887|DRUG|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
219030636|NCT05450887|DRUG|UDCA|UDCA：13\~15 mg/kg/day
219507605|NCT04087668|PROCEDURE|General Anesthesia|Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
218887245|NCT05995236|DRUG|PSMA radionuclide therapy|Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
218887246|NCT03482492|DRUG|Tramadol|Tramadol iv
218887247|NCT03482492|DRUG|Paracetamol|Paracetamol iv
218887248|NCT00810992|BEHAVIORAL|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
219030637|NCT05450887|DRUG|Placebo|Placebo：Once a day (QD) by mouth (PO).
219030638|NCT04914390|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
219030639|NCT04914390|DRUG|Tislelizumab|200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
219030640|NCT04914390|DRUG|Anlotinib|8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
219030641|NCT01430013|DRUG|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
219030642|NCT05940480|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
219030643|NCT05940480|BEHAVIORAL|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
219030644|NCT02280590|DRUG|Rosuvastatin(Cresnon®)|10mg
219030645|NCT02280590|DRUG|Rosuvastatin(Crestor®)|10mg
219030646|NCT03880903|DRUG|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
219030647|NCT03880903|DRUG|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
219030648|NCT03880903|DRUG|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
219030649|NCT05210790|DRUG|Placebo|Placebo
219030650|NCT05210790|DRUG|Rusfertide|Experimental drug
219030651|NCT04189458|OTHER|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
219030652|NCT04000048|GENETIC|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
219030653|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
219030654|NCT00446433|DRUG|CC-5013|
219030655|NCT06254742|DRUG|HHPG-19K Injection|first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
219030656|NCT01748643|DRUG|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
219030657|NCT01748643|DRUG|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
219030658|NCT05612633|DRUG|zelavespib|Oral zelavespib 100 mg will be administered once daily
219030659|NCT02701647|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
219507606|NCT04087668|PROCEDURE|Induction Without Neuromuscular Blockade|Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
219507607|NCT01544166|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants \<2 years of age.
218887249|NCT00810992|BEHAVIORAL|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
218887250|NCT00167310|DRUG|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
218887251|NCT00167310|DRUG|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
218887252|NCT00365040|PROCEDURE|Prk with mitomycin vs Lasik|
218887253|NCT06197620|OTHER|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
218887254|NCT03540199|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
218887255|NCT03540199|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
218887256|NCT04954157|DIAGNOSTIC_TEST|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
218887257|NCT04954157|DIAGNOSTIC_TEST|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
218887258|NCT05921799|PROCEDURE|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
219507608|NCT05265026|BEHAVIORAL|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at \> 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: \>85% of HRmax).
219030660|NCT02701647|OTHER|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
219030661|NCT01369979|PROCEDURE|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
219030662|NCT02653807|OTHER|mobilization with movement|manual therapy intervention
219030663|NCT02653807|OTHER|osteopathic mobilization|manual therapy intervention
219030664|NCT06542952|OTHER|seizure|epileptic children
219030665|NCT06422260|OTHER|Prosthesis superstructure|Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
219030666|NCT00454987|BIOLOGICAL|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
219030667|NCT00454987|BIOLOGICAL|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
219030668|NCT02205333|BIOLOGICAL|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
219030669|NCT02205333|BIOLOGICAL|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
219030670|NCT02205333|BIOLOGICAL|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
219030671|NCT02205333|BIOLOGICAL|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
219030672|NCT05272904|PROCEDURE|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
219030673|NCT05272904|PROCEDURE|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
219030674|NCT01476696|DRUG|Prasugrel|Administered orally
219507609|NCT00260325|DRUG|valdecoxib|
219507610|NCT05635825|OTHER|Observational Survey|Collection of a 4-day food record
218887259|NCT04921904|DRUG|Abemaciclib|150mg dose administered orally twice daily every day
218887260|NCT04921904|DRUG|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
218887261|NCT04320901|DEVICE|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
218887262|NCT04320901|DEVICE|Harmonic|Harmonic ACE 7+
218887263|NCT00795301|DRUG|Capecitabine, Cetuximab, Oxaliplatin|
218887264|NCT03304873|DRUG|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
218887265|NCT03304873|DRUG|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
218887266|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with tumor lysate|
218887267|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with MUC-1/WT-1 peptides|
218887268|NCT05037617|DRUG|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
218887269|NCT02267161|OTHER|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
218887270|NCT01294969|DRUG|AL-4943A|Once daily topical ocular allergy medication used for 7 days
219030675|NCT05024500|OTHER|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
219030676|NCT05024500|OTHER|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
219030677|NCT05024500|OTHER|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
219030678|NCT04818190|PROCEDURE|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
219030679|NCT04836299|DRUG|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
219030680|NCT04836299|DRUG|Placebo|Participants will be randomly assigned to receive a single of placebo.
219030681|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
219030682|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
219030683|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
219030684|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
219507611|NCT06187922|DRUG|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
219507612|NCT06187922|PROCEDURE|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
218887271|NCT01546688|DRUG|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
218887272|NCT01546688|DRUG|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
218887273|NCT06203769|DRUG|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
219030685|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
219030686|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
219030687|NCT00827970|BEHAVIORAL|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
219030688|NCT01275274|DRUG|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
219030689|NCT01275274|DRUG|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
219030690|NCT03747432|DRUG|Propofol|Procedural sedation during TAVR procedure using propofol
219030691|NCT03747432|DRUG|Dexmedetomidine|Procedural sedation during TAVR procedure using dexmedetomidine
219030692|NCT02128191|DRUG|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
219030693|NCT02128191|DRUG|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
219030694|NCT04242004|DRUG|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
219030695|NCT04242004|DIETARY_SUPPLEMENT|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
219030696|NCT02009046|BEHAVIORAL|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
219030697|NCT02009046|BEHAVIORAL|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
218887274|NCT06203769|DRUG|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
218887275|NCT00648700|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
218887276|NCT00648700|DRUG|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
218887277|NCT00667849|DEVICE|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
219507613|NCT02064426|DRUG|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
218887278|NCT00667849|DEVICE|Sham|sham device identical to active device with the exception of administration of ultrasound
218887279|NCT01178203|DRUG|Placebo|Placebo
218887280|NCT01178203|DRUG|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
218887281|NCT01178203|DRUG|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
218887282|NCT01178203|DRUG|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
218887283|NCT01895959|DRUG|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
218887284|NCT01895959|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
218887285|NCT06040853|DRUG|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
218887286|NCT06040853|DRUG|Saline|Participant was given intravenous 100 ml saline
218887287|NCT03116256|DIETARY_SUPPLEMENT|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
218887288|NCT03116256|OTHER|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
219030698|NCT02009046|BEHAVIORAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
219030699|NCT02009046|BEHAVIORAL|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
219040411|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
219507614|NCT02064426|BIOLOGICAL|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
219507615|NCT03567057|DRUG|ADS-5102, 274 mg|Oral capsules
219507616|NCT01745978|PROCEDURE|Precut papillotomy|
219507617|NCT01480856|PROCEDURE|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
219507618|NCT01480856|PROCEDURE|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
219507619|NCT04931628|DRUG|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
219507620|NCT04931628|DRUG|0.9% NaCl|0.9% NaCl
219507621|NCT04217278|DRUG|Vyxeos|Vyxeos administered by intravenous infusion
219507622|NCT04217278|DRUG|Fludarabine|Fludarabine administered by intravenous infusion
219507623|NCT04217278|DRUG|Busulphan|Busulphan administered by intravenous infusion
219507624|NCT04217278|DRUG|Thiotepa|Thiotepa administered by intravenous infusion
218887289|NCT03116256|OTHER|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
218887290|NCT00995423|DEVICE|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
218887291|NCT00995423|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent
218887292|NCT00465023|PROCEDURE|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
218887293|NCT02366156|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
218887294|NCT02366156|DIETARY_SUPPLEMENT|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
218887295|NCT02366156|DIETARY_SUPPLEMENT|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
218887296|NCT00118950|DRUG|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
218887297|NCT00118950|DRUG|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
218887298|NCT00118950|DRUG|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
218887299|NCT00118950|DRUG|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
219202121|NCT06762639|BEHAVIORAL|Personalized Sleep Prehabilitation (PSP)|"Sleep prehabilitation will consist of usual care prehabilitation (exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care) with the addition of sleep support. This support will consist of:~* Brief behavioural treatment for insomnia~* Sleep hygiene~* Behaviour change support (e.g., goal-setting, use of a wearable tracker to modify behaviour)"
218887300|NCT00118950|OTHER|Diet-only.|Diet-only treatment. Duration: One month.
218887301|NCT01760343|BIOLOGICAL|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
218887302|NCT01760343|BIOLOGICAL|CSL830|CSL830 is a formulation of Berinert.
218887303|NCT01052077|DRUG|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
218887304|NCT01052077|DRUG|Placebo|Placebo
218887305|NCT01052077|DRUG|ADT|
218887306|NCT05155774|DEVICE|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
218887307|NCT00520156|DEVICE|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
219202122|NCT06762639|BEHAVIORAL|Standard of Care Prehabilitation|Exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care delivered by regulated health professionals included Kinesiologists, Dietitians, Clinical Psychologists, etc.
219507625|NCT04217278|DRUG|Cytarabine|Cytarabine administered by intravenous infusion
219507626|NCT01760278|DRUG|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
219507627|NCT00244920|DRUG|bicalutamide|
219507628|NCT00244920|DRUG|leuprolide acetate|
219507629|NCT00244920|DRUG|squalamine lactate|
219507630|NCT00244920|PROCEDURE|adjuvant therapy|
218887308|NCT06025409|DRUG|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
218887309|NCT03512379|DEVICE|TIANJI Robot|A robotic system for spinal surgery
218887310|NCT03512379|DEVICE|Fluoroscopy|For fluoroscopy-based free hand surgery
218887311|NCT03512379|DEVICE|Navigation|For navigation-assisted spinal surgery
218887312|NCT00202956|DRUG|Bugusan|
218887313|NCT03288922|PROCEDURE|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
218887314|NCT03288922|PROCEDURE|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
218887315|NCT04534322|DRUG|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
219507631|NCT00244920|PROCEDURE|antiandrogen therapy|
219507632|NCT00244920|PROCEDURE|antiangiogenesis therapy|
218887316|NCT04534322|DRUG|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
218887317|NCT01775605|DRUG|Synera|Synera Pain Patch
218887318|NCT03172572|PROCEDURE|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
218887319|NCT03172572|PROCEDURE|Open pancreatoduodenectomy|Open resection
218887320|NCT02465203|DRUG|Previous treatment in DEB025 study|Follow-up after DEB025 active study
218887321|NCT00042991|DRUG|gefitinib|Given orally
218887322|NCT00042991|RADIATION|radiation therapy|Undergo standard brain irradiation
219202123|NCT06750640|DIAGNOSTIC_TEST|Infrared thermography|A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.
219507633|NCT00244920|PROCEDURE|conventional surgery|
219507634|NCT00244920|PROCEDURE|neoadjuvant therapy|
219507635|NCT00244920|PROCEDURE|releasing hormone agonist therapy|
219507636|NCT00708331|DEVICE|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
219507637|NCT01159327|DRUG|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
218887323|NCT00042991|OTHER|pharmacological study|Correlative studies
218887324|NCT00042991|OTHER|laboratory biomarker analysis|Correlative studies
219202124|NCT06817018|DIETARY_SUPPLEMENT|Placebo|Placebo (Sabinsa)
218887325|NCT06394245|OTHER|Progressive muscle exercises|The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
218887326|NCT05819320|OTHER|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
218887327|NCT03689816|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
219030700|NCT06488963|OTHER|NatraCure Cold Therapy gloves and socks|These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
219030701|NCT00142870|DRUG|Bupropion|150 mg, twice a day
219040412|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
218887328|NCT03689816|PROCEDURE|gastric bypass|gastric bypass
218887329|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
219040413|NCT06399146|DEVICE|Picterus App|Take a photo off the patient's skin (sternum).
219040414|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
218887330|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
218887331|NCT02223806|BEHAVIORAL|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
219040415|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
219040416|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
219040417|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
219040418|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
219040419|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
219040420|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
219040421|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
219040422|NCT00213174|BEHAVIORAL|school playgrounds|
219040423|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
219040424|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
219040425|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
219040426|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
219040427|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
219040428|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
219040429|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
218887332|NCT02223806|BEHAVIORAL|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
218887333|NCT04188145|DRUG|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
218887334|NCT04188145|DRUG|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
218887335|NCT03770117|PROCEDURE|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
218887336|NCT03770117|PROCEDURE|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
218887337|NCT05506527|OTHER|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~\- Children of the study group B will receive sensorimotor program alone."
218887338|NCT04072887|DRUG|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
219030702|NCT05217251|OTHER|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
219030703|NCT01525147|BIOLOGICAL|YHB1411-2: Level 2|IV infusion
219030704|NCT01525147|BIOLOGICAL|YHB1411-2: Level 3|IV infusion
219030705|NCT01525147|BIOLOGICAL|YHB1411-2: Level 4|IV infusion
219030706|NCT01525147|BIOLOGICAL|YHB1411-2: Level 5|IV infusion
219030707|NCT01525147|BIOLOGICAL|Placebo|IV infusion
219030708|NCT01525147|BIOLOGICAL|YHB1411-2: level 1|IV infusion
219030709|NCT01153243|DRUG|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
219030710|NCT01153243|DRUG|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
218887339|NCT04072887|DRUG|Placebo|Placebo oral capsules administered twice a day for 24 weeks
218887340|NCT04072887|DRUG|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
218887341|NCT02697435|OTHER|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
219030711|NCT00801125|DRUG|natalizumab|
219030712|NCT04867265|PROCEDURE|Mout-to-mouth ventilation|we will record the visibility of chest rising
219030713|NCT04867265|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
219030714|NCT03413553|DEVICE|immediate implant|Patient will receive immediate implant alone.
219030715|NCT03413553|BIOLOGICAL|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
219030716|NCT03413553|BIOLOGICAL|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
219030717|NCT02436278|OTHER|4MGS|Usual walking speed measured over 4 metres
219030718|NCT02177448|DRUG|BIBR277 low dose|
219030719|NCT02177448|DRUG|BIBR277 medium dose|
219030720|NCT02177448|DRUG|BIBR277 high dose|
219030721|NCT02177448|DRUG|Enalapril low dose|
219030722|NCT02177448|DRUG|Enalapril medium dose|
219030723|NCT02177448|DRUG|Enalapril high dose|
219030724|NCT02177448|DRUG|Placebo matching BIBR277|
219030725|NCT02177448|DRUG|Placebo matching enalapril|
219030726|NCT02159664|OTHER|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
219030727|NCT02154555|PROCEDURE|debridement|post-operative debridement at 1 week follow-up visit
219030728|NCT03198741|DRUG|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
219030729|NCT03198741|DRUG|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
219030730|NCT03198741|DRUG|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
219030731|NCT06672874|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Fermented Papaya Preparation (FPP) is administered in this study as a dietary supplement aimed at assessing its potential benefits for cognitive function and driving performance in older adults. Participants consume FPP as a 3-gram powder dose taken orally three times daily (morning, afternoon, evening) for a total of 8 weeks. FPP is known for its antioxidant and anti-inflammatory properties, which may influence cognitive domains essential for safe driving, such as attention, memory, reaction time, and executive function. This intervention is specifically designed to explore FPP's potential impact on reducing driving errors and improving psychomotor skills in a high-fidelity driving simulation environment.
219030732|NCT06122090|DRUG|Bimatoprost|Bimatoprost will be delivered with laser
218887342|NCT02697435|OTHER|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
218887343|NCT03433352|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
218887344|NCT03433352|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
218887345|NCT00053872|DRUG|cisplatin|
218887346|NCT00053872|DRUG|lomustine|
218887347|NCT00053872|DRUG|vincristine sulfate|
218887348|NCT00053872|PROCEDURE|adjuvant therapy|
218887349|NCT00053872|RADIATION|radiation therapy|
218887350|NCT00411814|DRUG|GSK679586|Active Drug
218887351|NCT00411814|DRUG|Placebo|Saline
218887352|NCT06444802|DRUG|Linezolid|Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
218887353|NCT04371666|DRUG|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
218887354|NCT04371666|DRUG|Placebo|Matching placebo per schedule specified in the arm description
218887355|NCT04371666|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
218887356|NCT00240500|BIOLOGICAL|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
218887357|NCT06070909|DEVICE|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
218887358|NCT01781559|DIETARY_SUPPLEMENT|phenolic acid|phenolic acid
218887359|NCT05665907|OTHER|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
218887360|NCT01835730|DRUG|PE0139 Injection|
218887361|NCT01835730|DRUG|Placebo|
218887362|NCT05826847|PROCEDURE|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
218887363|NCT05826847|PROCEDURE|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
218887364|NCT05826847|PROCEDURE|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
219030733|NCT06122090|DRUG|Saline|Saline control will be delivered with laser
219030734|NCT00776646|DRUG|hydrochlorothiazide 50 mg tablet|
219030735|NCT05686265|DRUG|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
219030736|NCT05946538|DIAGNOSTIC_TEST|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
219030737|NCT05946538|DIAGNOSTIC_TEST|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
219030738|NCT01674231|OTHER|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
219030739|NCT01674231|OTHER|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
219030740|NCT02132325|BEHAVIORAL|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
219030741|NCT02730299|DRUG|NiCord® (omidubicel)|
219030742|NCT02730299|OTHER|Cord Blood Unit|Cord blood unit
219030743|NCT05102383|DEVICE|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
219030744|NCT05102383|DEVICE|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
219030745|NCT06054555|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.
219507638|NCT01507896|BIOLOGICAL|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
219507639|NCT06143735|DRUG|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
219507640|NCT02131896|OTHER|Interventional arm-Mediterranean diet|
219507641|NCT02131896|OTHER|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
219507642|NCT02801058|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
219507643|NCT00735683|DRUG|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
218887365|NCT04043078|OTHER|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
219030746|NCT06054555|DRUG|Nivolumab|Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
219030747|NCT00620828|OTHER|Placebo saline injection|20 cc of sterile, injectable saline
218887366|NCT05686564|DRUG|ALXN1840|bis-choline tetrathiomolybdate
218887367|NCT00445770|DRUG|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
218887368|NCT00445770|DRUG|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
218887369|NCT00445770|DRUG|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
219607695|NCT03777163|BIOLOGICAL|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
218887370|NCT00451256|DRUG|AVI-5126|
218887371|NCT03969095|BEHAVIORAL|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
218887372|NCT03058692|BIOLOGICAL|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
218887373|NCT03058692|OTHER|Placebo|Placebo is saline injection
218887374|NCT03058692|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
218887375|NCT05515835|DEVICE|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
218887376|NCT01392547|DRUG|vatreptacog alfa (activated)|1-3 doses per bleeding episode
218887377|NCT01392547|DRUG|eptacog alfa (activated)|1-3 doses per bleeding episode
219030748|NCT00620828|DRUG|Ropivicaine 0.5%|Ropivicaine
219030749|NCT03475381|DRUG|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
219030750|NCT06640478|OTHER|NUTRI-Beta Counseling|Dietary Counseling focused on anti-inflammatory foods
219030751|NCT06640478|DIETARY_SUPPLEMENT|Standard dietary counseling|Standard of Care therapy: Nutrition counseling per the ADA clinical guidelines and USDA MyPlate model
219030752|NCT06640478|DIETARY_SUPPLEMENT|Free weekly produce foods|Free weekly produce
219030753|NCT01096810|DRUG|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
219040430|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
219040431|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
219040432|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
219040433|NCT05626036|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
219040434|NCT05626036|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
219040435|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
219040436|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
219040437|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
219040438|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
219040439|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
219040440|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
219040441|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
219040442|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
219040443|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
219040444|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
219040445|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
219040446|NCT02064452|OTHER|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
218887378|NCT02736201|DEVICE|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
218887379|NCT02736201|OTHER|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
219202125|NCT06817018|DRUG|Ginger|Ginger root extract
219202126|NCT06625619|OTHER|Non-Interventional Study|Non-interventional study
219202127|NCT06825624|DRUG|HS-20093|administered as an IV infusion
218887380|NCT01735266|OTHER|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
218887381|NCT01735266|OTHER|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
218887382|NCT01042925|DRUG|XL147 (SAR245408)|administered orally once daily as tablet(s)
218887383|NCT01042925|BIOLOGICAL|trastuzumab|administered by IV once every 3 weeks
219202128|NCT06825624|DRUG|Bevacizumab|administered as an IV infusion
219202129|NCT06825624|DRUG|5-FU|administered as an IV infusion
219202130|NCT06825624|DRUG|Leucovorin|administered as an IV infusion
218887384|NCT01042925|DRUG|paclitaxel|administered by IV once every week
218887385|NCT00841334|BEHAVIORAL|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
218887386|NCT00841334|BEHAVIORAL|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
218887387|NCT02754921|PROCEDURE|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
218887388|NCT02754921|PROCEDURE|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
218887389|NCT01718457|DEVICE|Endobarrier|
218887390|NCT01759797|BIOLOGICAL|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
218887391|NCT04012541|PROCEDURE|active dental procedure|scaling and root planing
218887392|NCT04012541|DRUG|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
218887393|NCT04012541|RADIATION|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
219030754|NCT02970279|BEHAVIORAL|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
219030755|NCT00509782|DRUG|ZIO-101|Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
219030756|NCT03365310|DRUG|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
219030757|NCT03365310|OTHER|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
219030758|NCT01626807|BEHAVIORAL|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
219030759|NCT02073279|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
219030760|NCT02073279|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
219030761|NCT03972280|BIOLOGICAL|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
219030762|NCT01428180|DRUG|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
219202131|NCT06825624|DRUG|Capecitabine|administered orally
219202132|NCT06825624|DRUG|Oxaliplatin|administered as an IV infusion
219507644|NCT00735683|DRUG|Placebo|includes diet, physical activity, and lifestyle modification
219507645|NCT00490061|DRUG|Lapatinib|1500 mg po daily orally
219507646|NCT00490061|PROCEDURE|Radiotherapy (radiation)|Standard of Care
219507647|NCT00490061|DEVICE|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
219507648|NCT00490061|DEVICE|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
219507649|NCT01433835|DRUG|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
219507650|NCT01433835|OTHER|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
219507651|NCT00631111|DRUG|effervescent ibuprofen tablets|
219507652|NCT00631111|DRUG|effervescent Aspirin plus Vitamin C tablets|
219507653|NCT00631111|DRUG|ibuprofen tablets|
219507654|NCT00631111|DRUG|placebo|
219507655|NCT03820193|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
219507656|NCT03820193|DRUG|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
219507657|NCT03820193|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
219507658|NCT03820193|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
218887394|NCT04081922|PROCEDURE|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
218887395|NCT05852067|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
218887396|NCT05852067|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
218887397|NCT03476148|DEVICE|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
218887398|NCT03476148|OTHER|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
218887399|NCT04130321|DIETARY_SUPPLEMENT|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
219030763|NCT01428180|PROCEDURE|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
219030764|NCT01428180|DRUG|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
219030765|NCT02206555|DRUG|emtricitabine/tenofovir disoproxil fumarate|
219030766|NCT02492529|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood"
219030767|NCT02492529|DEVICE|A cranial MRI|
219030768|NCT02492529|OTHER|Experimental procedure|
219030769|NCT01311193|OTHER|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
218887400|NCT04130321|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo daily during 12 weeks
218887401|NCT01105208|DRUG|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
218887402|NCT01105208|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
218887403|NCT04791436|DIAGNOSTIC_TEST|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
218887404|NCT04791436|DIAGNOSTIC_TEST|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
218887405|NCT04734717|DIAGNOSTIC_TEST|Neurology test|movement examination of patients with covid19 disease
218887406|NCT02638649|PROCEDURE|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
218887407|NCT02638649|DEVICE|ultrasound|
218887408|NCT03571555|BEHAVIORAL|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
218887409|NCT00270062|DRUG|epoetin alfa|
218887410|NCT04220554|OTHER|Improved support by health-care professionals|Improved support to patients prescribed topical antipsoriatic drugs
218887411|NCT01485328|DRUG|AMARGOL®|per oral solution, 40 mL single dose
218887412|NCT05615740|DIAGNOSTIC_TEST|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
218887413|NCT04615039|DEVICE|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
218887414|NCT00002984|DRUG|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
218887415|NCT00002984|DRUG|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
219030770|NCT05823571|DRUG|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
219030771|NCT05927714|OTHER|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
219030772|NCT05927714|OTHER|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
219030773|NCT01983527|PROCEDURE|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
219030774|NCT01983527|DRUG|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
218887416|NCT00002984|DRUG|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
218887417|NCT00002984|PROCEDURE|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
218887418|NCT00002984|RADIATION|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
218887419|NCT05440422|DRUG|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
218887420|NCT05440422|OTHER|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
218887421|NCT00655616|DRUG|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
218887422|NCT00655616|DRUG|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
218887423|NCT04421482|OTHER|Standard room temperature (RTS) feeding of milk/formula|Standard room temperature (RTS) milk/formula will be given for an entire feeding (15-20 minutes).
218887424|NCT04421482|OTHER|Cold temperature (CS, at 4-9°C) of milk/formula|If the infant shows signs of dysphagia cold temperature (CS, at 4-9°C) milk/formula will be given for an entire feeding (15-20 minutes).
218887425|NCT05604027|DIAGNOSTIC_TEST|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
218887426|NCT03736941|OTHER|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
218887427|NCT02085694|DRUG|Lactobacillus brevis CD2|
218887428|NCT02780492|OTHER|Set of assessment tools|
219030775|NCT03342547|PROCEDURE|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
219030776|NCT03342547|PROCEDURE|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
219030777|NCT03357692|PROCEDURE|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
219202133|NCT06754722|OTHER|App to guide self-acupressure|The intervention is delivered via a mobile health app. EnergyPoints app, on iOS and Android, educates and guides use of acupressure rituals to self-manage fatigue and sleep disturbances. The intervention involves using the app daily for 6 weeks. A follow-along format guides correct point stimulation for two acupressure rituals (stimulating and relaxing). The app synchronizes symptom self-reports with fitness tracker (e.g., an Apple Watch or Fitbit) sleep and activity data, allowing evaluation of response to acupressure. The dashboard provides options to tailor the rituals and pressing time (½, 1 or 2 min. per point) according to symptom experience, lifestyle, and schedule. Individuals can choose to use enhancements such as aromatherapy (including an instructional safety video), relaxing music, and/or visuals during each ritual and connect with other users via the social engagement feature.
218887429|NCT03550274|DEVICE|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
219030778|NCT05705531|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219030779|NCT05705531|OTHER|Electronic Health Record Review|Undergo medical record abstraction
219030780|NCT05705531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219030781|NCT05705531|OTHER|Survey Administration|Complete surveys
219030782|NCT00973479|DRUG|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
219030783|NCT00973479|OTHER|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
219507659|NCT03820193|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
219607696|NCT03777163|BIOLOGICAL|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
218887430|NCT05287425|DRUG|Gentamicin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
218887431|NCT05287425|DRUG|Ciprofloxacin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
218887432|NCT05287425|DRUG|Povidone Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
218887433|NCT05287425|DRUG|Povidone and Benzalkonium Chloride Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
218887434|NCT03329092|DRUG|ATM-AVI|"(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
218887435|NCT03329092|DRUG|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
218887436|NCT03329092|DRUG|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
218887437|NCT03329092|DRUG|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
218887438|NCT05786508|OTHER|Partners4Pain program|"Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
218887439|NCT05786508|OTHER|Key to Wellbeing program|"Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
218887440|NCT05969067|PROCEDURE|Tunneling Technique during RA SCP|As described in the intervention arm above
218887441|NCT05969067|PROCEDURE|Dissection Technique during RA SCP|As described in the intervention arm above
218887442|NCT06359210|BEHAVIORAL|Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
218887443|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
218887444|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
218887445|NCT05547048|BEHAVIORAL|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
218887446|NCT05547048|COMBINATION_PRODUCT|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
218887447|NCT05833438|DRUG|VEN+AZA-5|Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
219040447|NCT02064452|BEHAVIORAL|Placebo Comparator|Enhanced Usual Community Care-Waitlist
219507660|NCT03820193|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
219507661|NCT01155583|DRUG|azacitidine|Given by subcutaneous injection (SC)
219507662|NCT01155583|DRUG|lenalidomide|Given orally
219507663|NCT01155583|DRUG|dexamethasone|Given orally
219507664|NCT01155583|OTHER|DNA methylation analysis|Correlative studies
219507665|NCT01155583|OTHER|gene expression analysis|Correlative studies
219507666|NCT01155583|OTHER|bone marrow aspiration|Correlative studies
219507667|NCT01155583|OTHER|immunohistochemistry staining method|Correlative studies
219507668|NCT01155583|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
219507669|NCT01155583|OTHER|flow cytometry|Correlative studies
219507670|NCT06364605|DEVICE|Rehabilitation with the iReach novel multisensory medical device|From the results of Phases 1,2 and 3, in Phase 4 a medical device for spatial and sensorimotor rehabilitation in infants aged 3 to 36 months will be tested and developed.
219507671|NCT00843453|OTHER|blood collection|blood collection
219507672|NCT00843453|DRUG|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
219507673|NCT05505123|DRUG|Sevoflurane|induction and maintenance with sevoflurane for deep sedation
219507674|NCT05505123|DRUG|Propofol|induction and maintenance with propofol for deep sedation
219507675|NCT00471835|PROCEDURE|computed tomography|
219507676|NCT00471835|PROCEDURE|positron emission tomography|
219507677|NCT00471835|RADIATION|stereotactic body radiation therapy|
219507678|NCT03316313|DIAGNOSTIC_TEST|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
219507679|NCT04852536|DEVICE|Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS|5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.
219507680|NCT01189864|DRUG|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
219607697|NCT01049646|DRUG|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
219607698|NCT01049646|DRUG|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
219607699|NCT01958138|DRUG|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
218887448|NCT04426318|BEHAVIORAL|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
218887449|NCT05350644|OTHER|Primary exposure variable|"1. Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~2. Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
218887450|NCT05350644|OTHER|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
218887451|NCT04239235|BEHAVIORAL|CRAFT|CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
218887452|NCT02081313|OTHER|Biopsy|
218887453|NCT02081313|OTHER|Blood sample|
218887454|NCT04395079|BIOLOGICAL|Durvalumab|Given IV
218887455|NCT04395079|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
218887456|NCT04395079|BIOLOGICAL|Tremelimumab|Given IV
218887457|NCT04075981|DRUG|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
218887458|NCT04075981|OTHER|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
218887459|NCT06005844|DIAGNOSTIC_TEST|Cerebellar Cognitive-Affective Syndrome Scale|The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
219607700|NCT04843696|DEVICE|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
219607701|NCT04843696|BEHAVIORAL|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
218887460|NCT00390039|DRUG|Intranasal Morphine|MNS075 7.5mg q1h PRN
218887461|NCT00390039|DRUG|Placebo|IN Placebo q1h PRN
218887462|NCT00390039|DRUG|IV morphine|IV morphine 7.5mg q3h PRN
218887463|NCT00390039|DRUG|Placebo|IV Placebo q3h PRN
218887464|NCT00390039|DRUG|Intranasal morphine|MNS075 15mg q3h PRN
218887465|NCT00390039|DRUG|Placebo|IN Placebo q3h PRN
218887466|NCT01295957|BEHAVIORAL|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
218887467|NCT01295957|BEHAVIORAL|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
219030784|NCT00973479|DRUG|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
219030785|NCT06037421|OTHER|Human breast milk sampling|Human breast milk sampling
219030786|NCT06037421|OTHER|Saddle sampling|Saddle sampling
219030787|NCT06037421|OTHER|Skin sampling|Skin sampling
219030788|NCT06037421|OTHER|Saliva sampling|Saliva sampling
219030789|NCT06037421|OTHER|blood sampling|blood sampling
219030790|NCT05463796|OTHER|Samples|"Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues"
219030791|NCT06008509|PROCEDURE|Gastric echography preoperative|Patients with acute abdomen that are going to surgery, are going to recieve a gastric echography in the surgery room before the start of anesthesia. This procedure include vision of the stomach during supine position and lateral position with curve transductor.
219030792|NCT01712607|OTHER|Preoperative Warm-Up training|Preoperative Warm-Up training
219030793|NCT05702645|PROCEDURE|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
219030794|NCT05702645|OTHER|Clinical Evaluation|Undergo a clinical assessment
219030795|NCT05702645|OTHER|Neurocognitive Assessment|Undergo neurocognitive assessment
219030796|NCT05702645|OTHER|Questionnaire Administration|Ancillary studies
219030797|NCT05702645|OTHER|Survey Administration|Ancillary studies
219030798|NCT00003799|DRUG|fluorouracil|Given IV
219030799|NCT00003799|DRUG|oxaliplatin|Given IV
219030800|NCT00003799|RADIATION|radiation therapy|Undergo radiotherapy
219030801|NCT00003799|DRUG|leucovorin calcium|Given IV
219030802|NCT00003799|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219030803|NCT00335972|DRUG|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
219030804|NCT00335972|DRUG|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
219030805|NCT03355586|COMBINATION_PRODUCT|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
219030806|NCT06125288|OTHER|lab investigation and radiation|"1. . Full history taking including~   * Environmental factors such as long term exposure to environmental hazards as bacteria, fungi, chemicals, tobacco smoke and air pollution.~  * Host factors Family history (you have a higher risk of ILD if a close relative has ILD). History of recurrent chest infection. History of exposure to medication such as radiation and chemotherapy. History of Multisystem autoimmune diseases~2. Full examination general and systemic especially chest examination~3. investigation~   * pulse oximetry.~  * lab investigation include complete blood count parameters .~  * radiological investigation including ( echocardiography - MSCT chest - chest -x ray"
219030807|NCT01170806|DRUG|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
219040448|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
219040449|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
219040450|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
219040451|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
219040452|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
219040453|NCT03734120|OTHER|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
219040454|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
218887468|NCT01295957|OTHER|control|advise and informal counseling
218887469|NCT02353715|DRUG|Enzalutamide|
218887470|NCT02353715|DRUG|Abiraterone acetate|
219507681|NCT01189864|DRUG|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
218887471|NCT02353715|DRUG|Sipuleucel-T|
218887472|NCT01761019|DRUG|Taclonex Topical Suspension|topical medication for psoriasis
218887473|NCT03120130|BIOLOGICAL|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
218887474|NCT04861935|DEVICE|ultrasound evaluation|ultrasound evaluation of normal patients and patients who have a sacral dimple
218887475|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
218887476|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
218887477|NCT01561521|DRUG|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
219507682|NCT01189864|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
219507683|NCT00952484|BIOLOGICAL|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
219507684|NCT00952484|BIOLOGICAL|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
218887478|NCT05478083|DRUG|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
218887479|NCT05878847|DIETARY_SUPPLEMENT|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
218887480|NCT05878847|DIETARY_SUPPLEMENT|Placebo|Placebo
218887481|NCT04270968|DEVICE|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
218887482|NCT04270968|DRUG|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
218887483|NCT00960492|DRUG|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
218887484|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
219507685|NCT02641613|PROCEDURE|retroclavicular block|retroclavicular block for forearm or hand surgery
218887485|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
218887486|NCT00960492|RADIATION|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
218887487|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
219040455|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
219507686|NCT02641613|PROCEDURE|supraclavicular block|supraclavicular block for forearm or hand surgery
219607702|NCT03308812|BEHAVIORAL|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
218887488|NCT03316638|DRUG|W0101 - Cohort A1|Administered once every 2 weeks
218887489|NCT03316638|DRUG|W0101 - Cohort A2|Administered every 3 weeks
218887490|NCT03316638|DRUG|W0101 - Expansion Phase|Administered according to the recommended dose for expansion
218887491|NCT02770924|DEVICE|AT LISA TRI TORIC|phacoemulsification with IOL implantation
218887492|NCT02770924|DEVICE|AT LISA TRI|phacoemulsification with IOL implantation
218887493|NCT03045523|DRUG|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
218887494|NCT03045523|DRUG|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
218887495|NCT03045523|DRUG|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
218887496|NCT05330832|DIAGNOSTIC_TEST|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
218887497|NCT04473027|DIAGNOSTIC_TEST|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
218887498|NCT03441386|BEHAVIORAL|Physical Exercise Session|
218887499|NCT00445185|BIOLOGICAL|Henogen HB vaccine|Month 12, 24 and 36
218887500|NCT00445185|BIOLOGICAL|Fendrix vaccine|Month 12, 24 and 36
219040456|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
219040457|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
219040458|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
219040459|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
219040460|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
219040461|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
219507687|NCT02242513|DEVICE|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
219607703|NCT03308812|BEHAVIORAL|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
219607704|NCT03062384|DIETARY_SUPPLEMENT|AT-001|
219607705|NCT03062384|DIETARY_SUPPLEMENT|Placebo|
218887501|NCT02652156|DRUG|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
219030808|NCT05876741|DIAGNOSTIC_TEST|history taking , vital signs and labaratory investigations|"1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score."
219030809|NCT04629248|DRUG|Obinutuzumab|Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
219030810|NCT04629248|DRUG|Tacrolimus|Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
219030811|NCT04629248|DRUG|Methylprednisolone|Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
219030812|NCT04629248|DRUG|Acetaminophen|Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
219030813|NCT04629248|DRUG|Diphenhydramine|Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
219030814|NCT04804397|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened soft drinks
219030815|NCT00001086|DRUG|Indinavir sulfate|
219030816|NCT00001086|DRUG|Abacavir sulfate|
219030817|NCT00001086|DRUG|Efavirenz|
219030818|NCT03965962|BIOLOGICAL|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
219507688|NCT02242513|DRUG|Xylocaine|
219507689|NCT03179618|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
219507690|NCT03179618|DRUG|Lipid Regulating Drugs|Mainly including statins
219507691|NCT03179618|DRUG|Coronary Vasodilator|Mainly including nitrates
219507692|NCT03179618|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
219507693|NCT05085613|BEHAVIORAL|Corrective message framing and humor|The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
219507694|NCT00927459|DRUG|PRO-040201|Single dose IV infusion
219607706|NCT02297256|PROCEDURE|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
219607707|NCT02297256|PROCEDURE|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
219607708|NCT00272051|DRUG|SR57746A|
219607709|NCT06281197|PROCEDURE|Conventional|Le Fort I osteotomy performed with conventional Le Fort
219607710|NCT06281197|PROCEDURE|Subspinal|Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts
219607711|NCT00273897|DEVICE|Phoresor II|
219607712|NCT05808478|BEHAVIORAL|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
219607713|NCT05808478|BEHAVIORAL|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
219607714|NCT02561117|DRUG|Metronidazole|Administration once daily
219607715|NCT03778073|DRUG|Cosibelimab|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
219030819|NCT03965962|BIOLOGICAL|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
218887502|NCT02652156|DRUG|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
218887503|NCT02652156|DRUG|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
219507695|NCT00927459|DRUG|Placebo|placebo
218887504|NCT00342849|DRUG|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
218887505|NCT00342849|DRUG|Placebo|
218887506|NCT04031859|DRUG|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
218887507|NCT04405973|DEVICE|vv-ECMO|vv-ECMO required in severe COVID-19 ARDS
218887508|NCT00002695|GENETIC|DNA stability analysis|
218887509|NCT00002695|GENETIC|microsatellite instability analysis|
218887510|NCT00002695|GENETIC|mutation analysis|
219030820|NCT03965962|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
219030821|NCT03965962|BIOLOGICAL|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
218887511|NCT00002695|OTHER|laboratory biomarker analysis|
218887512|NCT03709004|OTHER|Pacifier|Pacifier given to mom.
218887513|NCT04513548|DRUG|Ligelizumab|One injection every four weeks
218887514|NCT04513548|DRUG|Placebo|One injection every four weeks
218887515|NCT05697562|PROCEDURE|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
218887516|NCT05697562|PROCEDURE|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
219030822|NCT02145728|BEHAVIORAL|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
219030823|NCT02145728|BEHAVIORAL|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
219030824|NCT02039674|BIOLOGICAL|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
219030825|NCT02039674|DRUG|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
219030826|NCT02039674|DRUG|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
219030827|NCT02039674|BIOLOGICAL|Bevacizumab|IV on Day 1 of each 3-week cycle
219030828|NCT02039674|DRUG|Pemetrexed|IV on Day 1 of each 3-week cycle
219030829|NCT02039674|BIOLOGICAL|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
219030830|NCT02039674|DRUG|Erlotinib|Orally tablet once daily
219030831|NCT02039674|DRUG|Gefitinib|Oral tablet once daily
219507696|NCT02422290|DRUG|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
219507697|NCT04402749|OTHER|Nephrectomy|Patients underwent nephrectomy
219030832|NCT04028752|BIOLOGICAL|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
219030833|NCT06029634|DIAGNOSTIC_TEST|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
219030834|NCT00864149|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
219507698|NCT01375933|BIOLOGICAL|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
219202134|NCT06753539|DEVICE|ILM forceps - membrane grasping|grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
219202135|NCT06739096|DEVICE|Short Wave Diathermy|Shortwave diathermy (SWT) is a form of electromagnetic therapy that causes the movement of ions, the disruption of molecules, and the generation of eddy currents, which ultimately produce heat in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain.
218887517|NCT05697562|PROCEDURE|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
218887518|NCT01073449|PROCEDURE|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
219202136|NCT06739096|OTHER|Exercise|range of motion, strengthening and stretching exercises
219202137|NCT06739096|DEVICE|Sham Short Wave Diathermy|Sham protocol
218887519|NCT06209827|BEHAVIORAL|Intervention for reducing benzodiazepines long-term use.|"Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor."
219202138|NCT06876389|DIETARY_SUPPLEMENT|Probiotic|In group A, children with iron deficiency received standard therapy. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and L Bio as 2 packs per day and Saccharomyces boulardii given 2 capsules per day (dose 2 x 250 mg or 2 x (2.5 x109 cells/cfu)) for ages 1 year - 18 years for 30 days.
219030835|NCT00864149|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
219030836|NCT05487482|OTHER|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
219202139|NCT06876389|OTHER|Placebo|In group B, children with iron deficiency received standard therapy with placebo. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and placebo for 30 days.
219202140|NCT06764030|OTHER|Educational web-based application|BRIDGES is a patient-directed computerized universal education on RC that is delivered within the FP setting, and that does not require the patient to disclose RC experiences to learn about RC.
219030837|NCT03239587|BEHAVIORAL|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
219030838|NCT03239587|PROCEDURE|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
219030839|NCT03239587|BEHAVIORAL|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
219030840|NCT04085198|PROCEDURE|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
219030841|NCT04085198|PROCEDURE|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
219202141|NCT06729385|DIAGNOSTIC_TEST|The blood Proteome Profiling|Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
219202142|NCT02129244|OTHER|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients"
219507699|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
219507700|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
219507701|NCT00953979|DRUG|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
218887520|NCT00195286|DRUG|piperacillin/tazobactam|
218887521|NCT02593942|DRUG|Remifentanil|0.1-0.5 mcg/kg/min infusion
218887522|NCT02593942|DRUG|Propofol|75-200 mcg/kg/min infusion
218887523|NCT00936000|DIETARY_SUPPLEMENT|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
218887524|NCT04107532|OTHER|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
218887525|NCT01071421|DEVICE|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
219202143|NCT05486585|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
219202144|NCT05778591|DRUG|Placebo|Placebo.
219202145|NCT05778591|DRUG|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
219202146|NCT06776679|DRUG|[14C]-BGB-16673|Administered orally as suspension in lipid vehicle
219202147|NCT05900895|DRUG|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
219202148|NCT05900895|DRUG|17b-estradiol|17b-estradiol will be taken orally three times per day.
218887526|NCT03932695|DIETARY_SUPPLEMENT|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
219202149|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
219507702|NCT02246842|BIOLOGICAL|D-Gam® (human anti-D immunoglobulin)|
219507703|NCT02246842|BIOLOGICAL|Rhophylac® (human anti-D immunoglobulin)|
218887527|NCT03932695|DIETARY_SUPPLEMENT|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
219507704|NCT01292200|BEHAVIORAL|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
219507705|NCT01292200|BEHAVIORAL|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
219507706|NCT01413399|DRUG|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
219507707|NCT00362700|DRUG|Clevudine|
218887528|NCT03932695|DIETARY_SUPPLEMENT|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
218887529|NCT05781074|DRUG|Sintilimab|a PD-1 immune checkpoint inhibitor
219202150|NCT02620852|OTHER|Complete a health questionnaire|Complete a health history questionnaire.
219202151|NCT02620852|DEVICE|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
219507708|NCT00650156|BIOLOGICAL|adalimumab|40 mg single sc dose
219507709|NCT00650156|BIOLOGICAL|adalimumab|80 mg single sc dose
219507710|NCT05233683|DRUG|Caudal block|Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
219507711|NCT05233683|DRUG|Dorsal penile nerve block plus ring block|"It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective."
219507712|NCT05233683|PROCEDURE|Circumcision with Plastibell|Circumcision with Plastibell
219507713|NCT05233683|PROCEDURE|Conventional Dissection Method|Conventional Dissection Method
219507714|NCT00886483|DEVICE|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
219507715|NCT00886483|DEVICE|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
218887530|NCT05781074|DRUG|Lenvatinib|Lenvatinib capsules
218887531|NCT05781074|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
218887532|NCT02342223|DEVICE|Voluma|
219202152|NCT02620852|OTHER|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
219202153|NCT02620852|OTHER|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
219202154|NCT05515497|DEVICE|BMT4me 2.0 app|The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
219507716|NCT02160197|DEVICE|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
219507717|NCT02160197|DEVICE|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
219507718|NCT01725477|DRUG|methylen blue &normal saline|Washing after dye injection
219507719|NCT01725477|DRUG|methylene blue|
219507720|NCT01725477|DRUG|metheylne blue with normal saline|
219030842|NCT03388229|BEHAVIORAL|not an intervention|it was observation not intervention
219607716|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
218887533|NCT02223338|DRUG|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
219030843|NCT04327219|OTHER|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
218887534|NCT02223338|DRUG|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
218887536|NCT03636789|OTHER|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
219030844|NCT05046886|BEHAVIORAL|Standardized|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.
219030845|NCT05046886|BEHAVIORAL|Usual Care Control (UCC)|Participants are instructed to follow a Mediterranean-style diet,
219202155|NCT05954832|DIAGNOSTIC_TEST|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
219607717|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
219607718|NCT01959373|PROCEDURE|electroencephalograms (EEG)|
219607719|NCT01959373|PROCEDURE|electro-myography (EMG)|
218887537|NCT05725980|DIAGNOSTIC_TEST|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
218887538|NCT03101254|DRUG|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
218887539|NCT03101254|DRUG|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
218887540|NCT03101254|DRUG|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
218887541|NCT01200368|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
218887542|NCT01200368|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
218887543|NCT01200368|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
218887544|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
218887545|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
218887546|NCT01675518|DRUG|ASP7991|oral
218887547|NCT01675518|DRUG|Placebo|oral
218887548|NCT00856063|DRUG|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
219030846|NCT05046886|BEHAVIORAL|Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on their predicted PPGR to meals and snacks at the time they enter them into their smart phone. PPGR predictions will be generated from a gut microbiome-based machine learning algorithm.
219202156|NCT06497010|DRUG|Biological: PD-1|Intravenous (IV) infusion
219202157|NCT06497010|DRUG|Biological: InnoPCV|Intramuscular (IM) injection
219202158|NCT06462651|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
219507721|NCT01982383|DEVICE|Micropulse Laser Treatment|
219507722|NCT01982383|OTHER|No treatment|
219507723|NCT00548977|OTHER|Drawing blood to study genetic polymorphism|
219507724|NCT04347447|OTHER|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
219507725|NCT04192825|PROCEDURE|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
219507726|NCT02033525|DRUG|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
218887549|NCT00108862|OTHER|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
218887550|NCT00108862|OTHER|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
218887551|NCT06144554|DEVICE|Omnipod 5|"The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs.~Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment."
219607720|NCT03672591|OTHER|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
219607721|NCT01512160|DRUG|PF-04531083|2000 mg oral solution
219607722|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
218887552|NCT03534141|DEVICE|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
218887553|NCT03534141|OTHER|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
218887554|NCT03534141|OTHER|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
219030849|NCT05497284|DRUG|LTP001|LTP001 administered once daily in the morning
219030850|NCT05497284|DRUG|Placebo|Placebo to LTP001 administered once daily in the morning
219030851|NCT05497284|DRUG|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
219030852|NCT06804239|BEHAVIORAL|User guide with prompts|A user guide and prompts to assist use of an Online Pain-Management Resource
219030853|NCT06143878|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
219030854|NCT06143878|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
219030855|NCT06143878|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
219030856|NCT06143878|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
219030857|NCT05687591|DEVICE|Amplatzer Amulet Left Atrial Appendage Occlusion Device|The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
219030858|NCT06590740|DRUG|Budesonide-Formoterol treatment|Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
219030859|NCT06860516|OTHER|blood draw|a blood draw for testing of HLA-DRB1\*04:01
219030860|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
219030861|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
219202159|NCT06462651|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
219202160|NCT00640978|DRUG|RAD001|30 mg orally weekly for 4 weeks
219202161|NCT00640978|DRUG|Erlotinib|150 mg by mouth daily for 28 Days
219202162|NCT06525363|DRUG|Chitosan|chitosan nanoparticles 1%w/w will be formulated in form of spray for oral application twice daily
219607723|NCT01512160|DRUG|PF-04531083|1000 mg oral solution
219607724|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
219607725|NCT01512160|DRUG|Ibuprofen|2 x 200 mg tablets
219607726|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
219607727|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
219202163|NCT02111538|OTHER|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
219202164|NCT06200896|DEVICE|Self Forming Magnets used to Create A Compression Anastomosis|Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
219202165|NCT05448014|BEHAVIORAL|Compassion focused group therapy online|Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.
219202166|NCT05425355|DRUG|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
219202167|NCT05425355|DRUG|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
219202168|NCT02354547|GENETIC|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
219202169|NCT02354547|DRUG|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
219202170|NCT02354547|DRUG|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
219202171|NCT02047500|DRUG|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
219202172|NCT02047500|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
219202173|NCT02047500|DRUG|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
218887555|NCT04459871|BIOLOGICAL|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
218887556|NCT04459871|BIOLOGICAL|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
218887557|NCT05642520|PROCEDURE|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
218887558|NCT05642520|PROCEDURE|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
218887559|NCT04475120|DRUG|liposomal lactoferrin|oral and intra-nasal formulation
218887560|NCT04475120|DRUG|SOC therapy|oral administration
218887561|NCT00004030|DRUG|VX-853|
218887562|NCT00004030|DRUG|pegylated liposomal doxorubicin hydrochloride|
218887563|NCT05094648|OTHER|high flow nasal therapy|effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
219202174|NCT05965414|DRUG|CS6253 Solution for Injection|Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
219507727|NCT02033525|OTHER|Rehabilitation|Standard rehabilitation program
219507728|NCT03077997|BEHAVIORAL|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, \& diabetes distress in people with type 2 diabetes mellitus.
219507729|NCT00585351|DRUG|Ranitidine|50 mg single dose injection of Ranitidine
218887564|NCT05081232|DEVICE|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
218887565|NCT00260624|DRUG|Escitalopram (Lexapro)|
219507730|NCT00585351|DRUG|Placebo|50 mg single dose injection of normal saline (placebo)
219507731|NCT00585351|OTHER|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
219507732|NCT00585351|OTHER|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
218887566|NCT04471506|OTHER|interval training|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
218887567|NCT04471506|OTHER|diet recommendations|the control group will follow diet recommendations for 12 weeks
218887568|NCT04471506|OTHER|mindfulness breathing|Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
218887569|NCT00632619|BEHAVIORAL|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
219030862|NCT02707705|DEVICE|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
219030863|NCT02707705|DEVICE|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
219030864|NCT02707705|PROCEDURE|Disinfection|The ear is disinfected by applying Chlorhexidine®.
219030865|NCT05382286|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219030866|NCT05382286|DRUG|Pembrolizumab|Administered intravenously
219030867|NCT05382286|DRUG|Paclitaxel|Administered intravenously
219202175|NCT05965414|DRUG|Placebo|Physiological saline solution for intra-venous injection
219202176|NCT06070051|BIOLOGICAL|VRON-0200-AdC6|VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
219202177|NCT06070051|BIOLOGICAL|VRON-0200-AdC7|VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
219607728|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
219030868|NCT05382286|DRUG|nab-Paclitaxel|Administered intravenously
219202178|NCT06070051|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
219030869|NCT05382286|DRUG|Gemcitabine|Administered intravenously
219030870|NCT05382286|DRUG|Carboplatin|Administered intravenously
219202179|NCT06070051|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
219202180|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
219202181|NCT05782374|DRUG|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
219607729|NCT01320501|DRUG|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
219607730|NCT02537691|DRUG|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
218887570|NCT00632619|DRUG|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
219202182|NCT03174314|BEHAVIORAL|Standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
219202183|NCT03174314|DEVICE|VIS4ION System|"When in Assistive Mode, participants will navigate campus while receiving navigation assistance (acquiring data and simultaneously providing assistance/audio feedback). When in Passive Mode, participants will navigate campus wearing the backpack without receiving navigation assistant."
219607731|NCT02537691|DRUG|LABA|LABA will be administered as per investigator discretion.
219607732|NCT02537691|DRUG|LTRA|LTRA will be administered as per investigator discretion.
219607733|NCT02537691|DRUG|LAMA|LAMA will be administered as per investigator discretion.
219607734|NCT02537691|DRUG|Theophylline|Theophylline will be administered as per investigator discretion.
219607735|NCT02537691|DRUG|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
218887571|NCT00632619|BEHAVIORAL|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
218887572|NCT05541575|OTHER|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
218887573|NCT00566852|DRUG|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
218887574|NCT00566852|OTHER|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
218887575|NCT00566852|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
218887576|NCT03165916|DEVICE|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
218887577|NCT00577824|DRUG|exenatide|subcutaneous injection, 5mcg, twice a day
218887578|NCT00577824|DRUG|exenatide|subcutaneous injection, 10mcg, twice a day
218887579|NCT00577824|DRUG|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
218887580|NCT01378442|OTHER|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
218887581|NCT04079816|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
218887582|NCT00785473|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
218887583|NCT00785473|DIETARY_SUPPLEMENT|calcium carbonate|calcium carbonate 500 mg daily for 2 years
218887584|NCT01434849|DRUG|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
218887585|NCT01434849|DRUG|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
219030880|NCT06858475|DEVICE|CONTROL-IQ (Tandem™)|interaction with the CONTROL-IQ (Tandem™) hybrid closed-loop (HCL) system in individuals with type 1 diabetes
219030881|NCT06673264|DEVICE|Soft Neural Probe|sub-acute insertion of the soft neural probe with neural signal recording
219030882|NCT06588322|OTHER|Blood samples will be taken on several times (36 mL of blood taken at each time):|"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."
219030883|NCT07000708|BEHAVIORAL|TRE: Time-restricted eating|The daily eating pattern is reduced to 8 h/day. The first meal will be before 10:00 AM.
219030884|NCT06356857|DIAGNOSTIC_TEST|Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT|Re-scan for comparison with initial scan
219030885|NCT06622655|DEVICE|Powered orthosis|Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.
219030886|NCT01502423|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
219030887|NCT00567892|DEVICE|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
219030888|NCT06743503|GENETIC|UB-VV400|UB-VV400 is a third-generation, self-inactivating (SIN), replication-incompetent, lentiviral vector (LVV) investigational drug product
219030889|NCT06743503|DRUG|Rapamycin|In DF Stage 2, Rapamycin will be given in combination with UB-VV400. For subjects receiving rapamycin, rapamycin dosing will be once daily with a planned start date of Day 4 (approximately 72 hours after the administration of UB-VV400) and continuing for up to 60 days, as tolerated.
219030890|NCT06748053|DRUG|GSK5784283|GSK5784283 will be administered.
219030891|NCT06748053|DRUG|Placebo|Placebo will be administered.
219030892|NCT07055269|OTHER|liver metabolic flux|All participants will be given heavy water (2H2O, deuterium-labelled) and \[U-13C6\]-fructose orally, each followed by the collection of one blood plasma sample. Additional biochemical and clinical parameters including liver fat content by MRI, liver fibrosis and cirrhosis by ultrasound imaging and plasma biochemical profiles will be analyzed.
219030893|NCT07055269|OTHER|ureagenesis capacity|urea and urea cycle metabolites and their enrichment after oral administration of a stable isotope tracer 15NH4Cl will be measured to examine the liver's ability to detoxify ammonia.
219030894|NCT06894979|DRUG|ATM Kinase Inhibitor AZD1390|Given PO
219030895|NCT06894979|PROCEDURE|Biospecimen Collection|Undergo blood and cerebrospinal fluid collection
219030896|NCT06894979|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219030897|NCT06894979|RADIATION|Radiation Therapy|Undergo radiation therapy
219030898|NCT06894979|OTHER|Survey Administration|Ancillary studies
219030899|NCT05588609|DRUG|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
219030900|NCT05588609|DRUG|Enzalutamide Pill|second-generation androgen receptor antagonist
219030901|NCT05588609|DRUG|Abiraterone acetate tablets|androgen synthesis inhibitor
218887586|NCT00638495|DRUG|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
219030902|NCT05588609|BIOLOGICAL|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
219030903|NCT07052903|DRUG|Nucresiran|Nucresiran 300 mg administered SC q6M
219607736|NCT06551662|DEVICE|Paclitaxel drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
219607737|NCT06551662|DEVICE|Sirolimus drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
219202184|NCT04314544|DRUG|TILD|one 1 mL injection of study medication
219607738|NCT06551662|DEVICE|New generation drug-eluting stent|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
219607739|NCT00316927|DRUG|acetylsalicylic acid|
219607740|NCT00316927|DRUG|dexamethasone|
219607741|NCT00316927|DRUG|diethylstilbestrol|
219607742|NCT05708430|DRUG|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
219030904|NCT07052903|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) administered SC once q6M
219030905|NCT06055231|BEHAVIORAL|Vape device|Consume THC via vape defice
219030906|NCT06055231|BEHAVIORAL|Joint|Consume THC via joint
219030907|NCT06055231|DRUG|Marijuana via vape device|Given via vape device
219030908|NCT06055231|DRUG|Marijuana via joint|Given via joint
219030909|NCT05286814|DRUG|Floxuridine|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
219030910|NCT05286814|DRUG|5-Fluorouracil|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
219030911|NCT05286814|DRUG|Irinotecan|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
219030912|NCT05286814|DEVICE|Intera 3000 Hepatic Artery Infusion Pump (HAIP)|Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
219202185|NCT04314544|DRUG|matching placebo injections|one 1 mL injection of placebo
219202186|NCT06435780|PROCEDURE|DIPRF|Denuded interpositional pedicled rolled flap technique
219202187|NCT05294172|DRUG|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
219202188|NCT05294172|DRUG|Gemcitabine|4-6 cycles for combined therapy
219202189|NCT05294172|DRUG|Cisplatin|4-6 cycles for combined therapy.
219202190|NCT05294172|DRUG|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
219202191|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
219607743|NCT00852202|DRUG|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
219607744|NCT00852202|DRUG|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
219607745|NCT00852202|DRUG|placebo|placebo capsules, oral administration, once daily dosing
219607746|NCT05884502|DRUG|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
219607747|NCT05884502|DRUG|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
219607748|NCT01246310|DIETARY_SUPPLEMENT|Inositol|
219607749|NCT01246310|DIETARY_SUPPLEMENT|Placebo|
219607750|NCT00453050|DRUG|imiquimod|
219607751|NCT00453050|DRUG|indocyanine green solution|
219607752|NCT00453050|OTHER|flow cytometry|
218887587|NCT00638495|DRUG|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
218887588|NCT06069414|OTHER|Type of anesthesia induction|Patients will receive inhalatory or intravenous anesthesia at their choice; both groups will be evaluated with lung ultrasound after induction to detect ultrasonografic signs of atelectasis
218887589|NCT04137731|DEVICE|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
219202192|NCT05712824|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
219202193|NCT06149624|BEHAVIORAL|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
218887590|NCT04057430|DEVICE|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
218887591|NCT04057430|DEVICE|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
218887592|NCT01435486|DRUG|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
218887593|NCT01435486|DRUG|Normal saline|Placebo with an equivalent volume of normal saline.
218887594|NCT00192413|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
218887595|NCT00192413|BIOLOGICAL|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
218887596|NCT02457468|DEVICE|coflex|
219030913|NCT05286814|DRUG|Oxaliplatin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
219030914|NCT05286814|DRUG|Leucovorin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
219030915|NCT05286814|DRUG|PDS01ADC|PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
219030916|NCT05286814|DRUG|Gemcitabine|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
218887597|NCT02750488|DRUG|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
218887598|NCT02750488|OTHER|Untreated skin|One site is patched without treatment as control
218887599|NCT04746820|OTHER|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
218887600|NCT06965361|DRUG|carboplatin|carboplatin use due to its effectiveness in increasing pathological complete remission (pCR) rates and improving survival outcomes
219030917|NCT05286814|DRUG|Dexamethasone|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
219030918|NCT07057596|DRUG|Tebentafusp|"Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Tebentafusp will be administered at 20 micrograms on W1D1, 30 micrograms on W2D1, and 68 micrograms once every week thereafter.~After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy (surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If progressioh disease (PD) occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal."
219030919|NCT06771453|OTHER|Video Educational Tool Regarding Prenatal Genetics|Video education about prenatal genetics will include content regarding aneuploidy screening and diagnostic testing options, how to make a values-based choice, and specifics of risks/benefits/limitations of each type of testing option.
219030920|NCT07066384|OTHER|breathing yoga|"Yoga Breathing Exercises:~1. Sama Vritti or Equal Breathing:~2. Abdominal Breathing Techniques:~3. Nadi Shodhana or Alternating Breathing:~4. Kapalabhati or Skull Shining Breath:~5. Progressive Muscle Relaxation:~6. Guided Visualization:"
219030921|NCT07066384|OTHER|PMRTs-Progressive Muscle Relaxation Techniques|While patients are breathing in and out, tightening and releasing exercises are applied to 11 different muscle groups. It is applied for 15-20 minutes.
219030922|NCT06776926|BEHAVIORAL|Carbetocin|Use of carbetocin
219030923|NCT06413680|DRUG|REGN10597|Administered as an intravenous (IV) infusion
219607753|NCT00453050|OTHER|immunologic technique|
219607754|NCT00453050|OTHER|laboratory biomarker analysis|
219607755|NCT03980535|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219607756|NCT03980535|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219607757|NCT04671121|PROCEDURE|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
219607758|NCT04671121|PROCEDURE|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
218887601|NCT06965361|DEVICE|carboplatin|used in the treatment of triple-negative breast cancer (TNBC) due to its effectiveness in achieving pathological complete response (pCR) and breast-conserving surgery (BCS) rates.
218887602|NCT05956652|DEVICE|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
218887603|NCT06967701|BEHAVIORAL|Exercise program|Participants will receive a free Garmin smartwatch and a free program membership providing exercise coaching + personalized feedback about the relationship among their insulin, carbohydrates, exercise, sleep, and blood sugar.
218887604|NCT06967701|BEHAVIORAL|Self-monitoring|Wear a fitness watch and keep daily health diary
218887605|NCT06969469|DIETARY_SUPPLEMENT|Give the Placebo and test article|"Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.~Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days."
219030924|NCT07084402|DRUG|Contezolid|contezolid 800mg po q12h for 6 months
219030925|NCT07084402|DRUG|Azithromcyin|azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.
219030926|NCT07084402|DRUG|Rifampicin (RIF)|rifampicin 600mg po tiw for 6 months.
219030927|NCT07084402|DRUG|Ethambutol|ethambutol 25mg/kg po tiw for 6 months.
219202194|NCT06149624|BEHAVIORAL|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
219030928|NCT02265978|DEVICE|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
219030929|NCT07088913|DRUG|Capivasertib|Capivasertib will be administered orally twice in Period 2.
219030930|NCT07088913|DRUG|Rosuvastatin|Rosuvastatin will be administered orally once in both Period 1 and Period 2.
219030931|NCT05730036|DRUG|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
219202195|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
219202196|NCT05055011|OTHER|Survey Administration|Complete survey
219202197|NCT05044975|BEHAVIORAL|Sleep restriction|Participants will receive sleep restriction intervention
219607759|NCT00836784|OTHER|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
219607760|NCT00836784|OTHER|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
219202198|NCT05044975|BEHAVIORAL|Stimulus control|Participants will receive stimulus control intervention
219607761|NCT00022113|DRUG|cilengitide|Given IV
219607762|NCT00022113|OTHER|pharmacological study|Correlative studies
219607763|NCT00022113|OTHER|laboratory biomarker analysis|Correlative studies
219607764|NCT04639011|DRUG|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
218887606|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
218887607|NCT02877303|DRUG|Cyclophosphamide|Given IV
218887608|NCT02877303|DRUG|Cytarabine|Given IT and IV
218887609|NCT02877303|DRUG|Dexamethasone|Given PO
218887610|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
218887611|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
218887612|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
218887613|NCT02877303|DRUG|Mercaptopurine|Given PO
218887614|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
218887615|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
218887616|NCT02877303|DRUG|Prednisone|Given PO
218887617|NCT02877303|BIOLOGICAL|Rituximab|Given IV
219030932|NCT05730036|DRUG|Elotuzumab|Elotuzumab will be administered by IV infusion
219030933|NCT05730036|DRUG|Pomalidomide|Pomalidomide capsules will be administered by mouth (PO)
219030934|NCT05730036|DRUG|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
219030935|NCT06379217|DRUG|[68Ga]Ga-PSMA-11|\[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
219030936|NCT06379217|DRUG|[68Ga]GA-DOTA-TATE|\[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
219030937|NCT06379217|DRUG|[68Ga]Ga-NeoB|\[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
219030938|NCT06379217|DRUG|[177Lu]Lu-PSMA-617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
219030939|NCT06379217|DRUG|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
219030940|NCT06379217|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
219030941|NCT06379217|DRUG|L-Lysine HCl-L-Arginine HCl, 2.5 %,|sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
219607765|NCT04639011|OTHER|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
219607766|NCT04639011|OTHER|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
219607767|NCT02442180|DRUG|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
218887618|NCT02877303|DRUG|Vincristine Sulfate|Given IV
218887619|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
218887620|NCT00310817|BIOLOGICAL|MenACWY polysaccharide vaccine|
218887621|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
218887622|NCT03225378|OTHER|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
218887623|NCT03225378|OTHER|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
218887624|NCT01702246|DRUG|Simvastatin|40 mg, orally, once daily for 3 months
218887625|NCT02290977|RADIATION|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
218887626|NCT02523378|BEHAVIORAL|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
218887627|NCT02523378|BEHAVIORAL|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
218887628|NCT01587040|DRUG|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
218887629|NCT01587040|DRUG|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
218887630|NCT04667741|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
218887631|NCT00432341|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
218887632|NCT00432341|BIOLOGICAL|botulinum toxin type A|500 Units at Visit 1 (Day 1)
219507733|NCT02659202|DEVICE|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
219507734|NCT03662919|DRUG|Infliximab|Administered as specified in the treatment arm.
219507735|NCT03662919|DRUG|Adalimumab|Administered as specified in the treatment arm.
219507736|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
219507737|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
219507738|NCT03510299|DEVICE|Mcgrath|McGrath assisted insertion of LMA flexible
219507739|NCT03510299|DEVICE|Control|Digital manipulation technique of LMA flexible insertion
219507740|NCT02741492|PROCEDURE|Transversus Abdominis Plane Block|Continuous Nerve Block
219607768|NCT02442180|DRUG|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
219607769|NCT02442180|DRUG|placebo|equivalent to G-CSF doses
219607770|NCT04884373|DIAGNOSTIC_TEST|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
219607771|NCT05796076|DEVICE|Virtual reality|Participants in the intervention group will be received VR during the suturing procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
218887633|NCT00933998|OTHER|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
219030942|NCT06379217|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
219030943|NCT06379217|DRUG|GnRH antagonists|abarelix, degarelix, or relugolix
219030944|NCT06379217|DRUG|Antiemetics & antinauseants|ATC code A04A
219030945|NCT06379217|DRUG|Metoclopramide|ATC code A03FA01
219030946|NCT06906822|DRUG|enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg be administered on Days 1,8,22 and 29 of every 6-week cycle by IV infusion given over approximately 30 minutes.
219507741|NCT02741492|PROCEDURE|Sham Block|Continuous Sham Catheter
219607772|NCT02285374|DRUG|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
219607773|NCT04650594|PROCEDURE|MUTARS® modular reconstruction prostheses|Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
219607774|NCT03513094|OTHER|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
219607775|NCT05054504|DEVICE|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
219607776|NCT00372840|OTHER|educational intervention|
219607777|NCT00372840|PROCEDURE|psychosocial assessment and care|
219607778|NCT00372840|PROCEDURE|quality-of-life assessment|
218887634|NCT04886778|DIETARY_SUPPLEMENT|Low-carbohydrate diet|Participants will be instructed to maintain a daily dietary energy intake of less than 1600 kcal.Based on the low-carbohydrate diet model, the proportion of daily intake of carbohydrate was about 30%, and this ratio was up to 30%, 40% of protein and fat respectively.Participants should choose unprocessed whole grains, potatoes, vegetables, meat, fish, eggs, soy products, sugar-free dairy products, designated varieties of low-GI fruits and nuts, etc. as breakfast, and avoid processed meats and high-fat red meat and poultry skins. Standard nutritious meal instead of daily lunch and dinner meals, that is to say, participants should take one nutritional bar for lunch and dinner (310 kcal totally, provided by Guangzhou Nanda Fett Nutrition and Health Consulting Co., Ltd.), and avoid starchy foods. Other food varieties are required to be the same as breakfast. Plant oil is the main cooking oil, and participants will be instructed to drink 2L water every day.
218887635|NCT04886778|DIETARY_SUPPLEMENT|Probiotic compound preparations|The probiotic compound preparation，named Junyi Yili® Probiotics，is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus and Bifidobacterium lactis, and resistant dextrin contained water-soluble dietary fiber. The subjects will take this probiotic compound preparations with purified water after three meals every day, 1 sachet each time.
218887636|NCT04886778|DIETARY_SUPPLEMENT|Placebo|Placebo is made of resistant dextrin which contained water-soluble dietary fiber. The subjects were taken this placebo with purified water after three meals every day, 1 sachet each time.
218887637|NCT05385003|DIETARY_SUPPLEMENT|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
218887638|NCT05385003|DIETARY_SUPPLEMENT|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
218887639|NCT05385003|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
218887640|NCT05039944|DRUG|SI-B001|In Arm\_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort\_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
218887641|NCT05039944|DRUG|Irinotecan|Administration by intravenous infusion, 180 mg/m2 Q2W.
218887642|NCT05039944|DRUG|FOLFIRI Protocol|FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
218887643|NCT05039944|DRUG|FOLFOX Protocol|FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
218887644|NCT00970437|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
219030947|NCT06906822|DRUG|pembrolizumab|Pembrolizumab 400 mg on day 1 of each 42-day cycle (Q6W)
219030948|NCT06743659|DEVICE|Alert-based computerized decision support|"A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with definite, probable, or possible diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data:~1. Maximum LDL-C level in the laboratory results~2. Abnormal genetic testing for FH in the laboratory results~3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis~4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD~5. Family history of premature CAD, cerebrovascular disease, or PAD~In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made."
219030949|NCT06235697|RADIATION|Radiation|"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate OR 25Gy / 5 fractions of EBRT to pelvis and prostate (ultrahypofractionation EBRT (SBRT)) + LDR or HDR boost to prostate.~\+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"
219030950|NCT06235697|RADIATION|Radiation SBRT only|25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT) (ultrahypofractionation EBRT (SBRT))
219030951|NCT06235697|DRUG|ADT|Assigned at enrollment
218887645|NCT00970437|BEHAVIORAL|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
218887646|NCT03485235|PROCEDURE|D&C|Dilatation and curettage
218887647|NCT03485235|PROCEDURE|ICSI|Intra Cytoplasmic Sperm Injection
218887648|NCT03081650|DEVICE|Airvo Humidifier|
218887649|NCT06970158|OTHER|AI-Designed Passive Plate Therapy|A removable passive orthopedic plate designed using an AI-assisted digital workflow based on intraoral scan data. The design process is automated via a Blender-based software plugin that identifies anatomical landmarks and generates a custom-fit plate. The plate is 3D printed using biocompatible material and fitted shortly after birth. It is worn continuously until primary surgical repair, typically around 4 months of age. The intervention aims to reduce cleft width prior to surgery without requiring traditional impressions or extensive manual design effort.
219030952|NCT07100782|DRUG|Relugolix CT|Study medication will be provided by Sumitomo in pill bottles containing an 84-day supply of relugolix 40mg, estradiol 1mg, norethindrone acetate 0.5mg (Relugolix Combination therapy).
219030953|NCT06910579|DRUG|topical application of oxygenated gel|patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days
218887650|NCT05209438|DEVICE|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
219030954|NCT06910579|DRUG|topical application of Triamcinolone acetonide gel|patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
219030955|NCT07108725|OTHER|Magnetic Resonance Cholangiopancreatography|Patients who are scheduled for magnetic resonance cholangiopancreatography and have undergone conventional imaging
219202199|NCT05044975|BEHAVIORAL|Systematic light exposure|Participants will receive systematic light exposure intervention
219202200|NCT04963803|DEVICE|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
219030956|NCT07110558|RADIATION|Without prophylactic neck irradiation|Intensity-modulated radiotherapy restricted to the primary tumor, omitting prophylactic neck irradiation.
219202201|NCT04963803|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
219202202|NCT04963803|BEHAVIORAL|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
219202203|NCT05803109|OTHER|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
219202204|NCT06960759|BEHAVIORAL|Behavioral cough suppression therapy combined with inactive inhaled drug (BCS+Sham)|Behavioral cough suppression therapy plus inactive inhaled drug. Treatment given twice per week for 12 sessions.
219202205|NCT06960759|COMBINATION_PRODUCT|Behavioral cough suppression therapy combined with capsaicin inhalation (BCS+CAP)|Behavioral cough suppression therapy combined with inhaled capsaicin (cough stimulant). Treatment given twice per week for 12 sessions.
219202206|NCT06960759|DRUG|Inhaled capsaicin (CAP)|Repeated inhalation of diluted capsaicin in increasing concentrations. Treatment given twice per week for 12 sessions.
219202207|NCT06237686|DEVICE|CP363|All subjects will test both Test product A and B, with a minimum of 7 days apart. In total, each subject will be enrolled in the investigation for 8 days +3 days.
219202208|NCT05980884|DIETARY_SUPPLEMENT|L-carnitine|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.
219202209|NCT05773690|OTHER|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
219202210|NCT05773690|OTHER|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
219202211|NCT05838066|DRUG|Recombinant Humanized Bispecific antibody against HER2，KN026|IV infusion
219202212|NCT05838066|DRUG|HB1801|IV infusion
219202213|NCT05838066|DRUG|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
219202214|NCT05838066|DRUG|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
219030957|NCT07110558|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab 240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy after CCRT
219030958|NCT07110558|DRUG|Cisplatin|Cisplatin 100mg/m2(every three weeks), Day 1, Day 22, Day 43 of intensity modulated radiotherapy
219202215|NCT05838066|DRUG|Docetaxel|75 mg/m\^2, D1 Q3W, IV infusion
219202216|NCT06419257|DEVICE|VRDS|VRDS is an augmented virtual reality driving simulator.
219202217|NCT05825937|DEVICE|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
219202218|NCT06550050|BEHAVIORAL|Radiation|Standard of care
219202219|NCT02521103|DEVICE|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
219202220|NCT04028401|DRUG|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
219202221|NCT04198870|DEVICE|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
219202222|NCT04198870|PROCEDURE|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
219507742|NCT00882622|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
219607779|NCT05725863|OTHER|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
219607780|NCT02972892|DEVICE|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
218887651|NCT06967662|PROCEDURE|Selective plasma adsorption of extracellular DNA|Selective plasma adsorption of extracellular DNA using NucleoCor® sorption columns (Pocard Ltd., Russia) on the Spectra Optia™ Apheresis System (Terumo Blood and Cell Technologies, USA). NucleoCor® is a sorption column for plasma adsorption containing porous spherical agarose beads with a ligand that selectively binds extracellular DNA. This medical device has a Registration Certificate No. РЗН 2022/18982 in Russian Federation. Participants will receive selective plasma adsorption of extracellular DNA twice: once during the tumor removal surgery (the procedure will be initiated at the time of pancreatic tumor mobilization and will be stopped an hour after removal of the organ complex) and once on the day after the surgery.
219607781|NCT02972892|DEVICE|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
219607782|NCT05022212|DRUG|LACTIN-V|administered vaginally
218887652|NCT06968312|OTHER|Cognitive Processing Therapy + Hexadecanal|Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.
219030959|NCT06913933|BEHAVIORAL|Static Progressive Splinting for Persistent Wrist Stiffness|"A commercially available static progressive splint with a turnbuckle mechanism allowing fine-tuned adjustments in wrist flexion and extension.~Instructional materials for home use including written guidelines and an adjustment log."
219030960|NCT06913933|BEHAVIORAL|Dynamic Splinting for Persistent Wrist Stiffness|"Materials:~A commercially available dynamic (spring-loaded) splint designed for the wrist. An instructional manual and daily usage log for participants."
219030961|NCT06917313|DRUG|Fezolinetant|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
219030962|NCT06917313|DRUG|Placebo|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
219030963|NCT06915753|DRUG|TYRA-430|Oral TYRA-430 given daily.
219507743|NCT00882622|PROCEDURE|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
219507744|NCT01482624|DEVICE|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
219607783|NCT05022212|DRUG|Placebo|administered vaginally
219607784|NCT03878212|OTHER|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
219607785|NCT03878212|OTHER|mHealth application|a mHealth device
219607786|NCT03104712|OTHER|Glucose #1|50g available carbohydrate
218887653|NCT06968312|OTHER|Hexadecanal - Molecule Distribution in the Therapy room|Distribution of a naturally secreted molecule from body odor (Hexadecanal).
219030964|NCT02195440|DRUG|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
219030965|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
219040462|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
219607787|NCT03104712|OTHER|Glucose #2|50g available carbohydrate
219040463|NCT05361044|BIOLOGICAL|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
219607788|NCT03104712|OTHER|Glucose #3|50g available carbohydrate
219607789|NCT03104712|OTHER|Spaghetti|50g available carbohydrate
219607790|NCT03104712|OTHER|Rice|50g available carbohydrate
219040464|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
219507745|NCT01482624|PROCEDURE|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
219507746|NCT01842958|DEVICE|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
219507747|NCT01842958|DEVICE|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
219507748|NCT01332409|DRUG|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
219507749|NCT01016509|DRUG|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.
219507750|NCT01016509|DRUG|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
218887654|NCT05059535|DRUG|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
218887655|NCT06080061|RADIATION|Hypofractionated accelerated radiation therapy|Hypofractionated accelerated radiation therapy
218887656|NCT04390399|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
218887657|NCT04390399|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
219030966|NCT06930885|DRUG|Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)|"Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin~1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg~   or~3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg~   or~5. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   or~6. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)"
219030967|NCT06930885|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg once daily
219030968|NCT06930885|DRUG|Usual Care Group|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.
219030969|NCT06930885|DRUG|Colchicine-placebo 0.5 mg|Matching Colchicine-placebo 0.5 mg once daily
219030970|NCT06935110|PROCEDURE|Cryopreserved aortic patch|After identifying the tracheal or bronchial defect with standard surgical techniques, the airway gap is reconstructed with a patch of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An silicon stent is inserted to prevent collapse for the aortic graft.
219202223|NCT06962735|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
219202224|NCT05190679|OTHER|None/Observational Studies|This is an observational study and there is no intervention.
219202225|NCT06207071|DIETARY_SUPPLEMENT|DHA|DHA supplementation
219202226|NCT02076009|DRUG|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
218887658|NCT04390399|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
218887659|NCT04390399|DRUG|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219030971|NCT07142382|BEHAVIORAL|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath
219507751|NCT05433428|DRUG|Lubricant Eye Drops|Prolonged use of lubricant eye drops pre and post-op.
219607791|NCT03104712|OTHER|Spaghetti + Tomato Sauce|50g available carbohydrate
219607792|NCT03104712|OTHER|Rice + Tomato Sauce|50g available carbohydrate
219607793|NCT03104712|OTHER|Spaghetti + Pesto|50g available carbohydrate
219607794|NCT03104712|OTHER|Rice + Pesto|50g available carbohydrate
219607795|NCT01362543|OTHER|Cognitive behavioural therapy (stress management)|Following a manual
219607796|NCT01362543|OTHER|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
219607797|NCT00191607|DRUG|Gemcitabine|
219607798|NCT00191607|DRUG|liposomal doxorubicin|
219607799|NCT00367978|DRUG|Amlodipine/benazepril|
219607800|NCT01971047|DRUG|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
219607801|NCT01971047|DRUG|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
218887660|NCT04390399|DRUG|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
218887661|NCT04390399|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
218887662|NCT04390399|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
218887663|NCT04390399|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
218887664|NCT04390399|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
218887665|NCT04390399|DRUG|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
218887666|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
218887667|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
218887668|NCT06058013|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
218887669|NCT06058013|DRUG|Placebo|Placebo will be administered orally
218887670|NCT04275973|DEVICE|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
218887671|NCT04275973|DEVICE|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
218887672|NCT04275973|DEVICE|Footwear|Different footwear will be used.
218887673|NCT05499533|PROCEDURE|implant site preparation|a hole were created in the edentulous ridge area before implant placement
218887674|NCT06352645|DEVICE|Bixdo Ultra Compact Water Flosser|Use of water flosser, in addition to standard tooth brushing, twice a day for 8 weeks.
218887675|NCT06352645|DEVICE|Manual toothbrush|For those in the control group, they will be asked to use only the study-provided manual toothbrush, twice a day for 8 weeks.
218887676|NCT06468618|BEHAVIORAL|DREAMS Program Video and Care Kit|A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
218887677|NCT06665347|OTHER|Progressive muscle relaxation|The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.
219030972|NCT07141303|DRUG|The methylprednisolone sodium succinate|Patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization from thrombectomy in anterior circulation large vessel occlusion. Then, intravenous administration with methylprednisolone sodium succinate 2mg/kg in the next 3 days.
219030973|NCT07141303|DRUG|Placebo|The placebo group patients will receive intra-arterial and intravenous sterile water for injection.
219607802|NCT04610333|BEHAVIORAL|Modified MBSR programme|1 hour group session once a week in 10 weeks
219607803|NCT01979991|PROCEDURE|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
219607804|NCT04525937|OTHER|Patient Questionnaire|Patient Questionnaire
218887678|NCT06665347|OTHER|Yoga|The participants will receive yoga for 30 minutes/session, 3 sessions/week for 8 weeks. The session will begin with 5 minutes for warming up. Twenty minutes of wind relieving position (pavanmuktasana), corpse position (savasana), standing side stretch position, seated forward bend (paschimothanasana), cobra position (bhujangasana), and chair position (utkatasana). Five minutes of cooling down.
219030974|NCT06948318|DRUG|Mezagitamab|Mezagitamab injection administered SC.
218887679|NCT05092009|OTHER|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
219030975|NCT07147829|BEHAVIORAL|digital detox|The digital detox intervention differs from other clinical interventions in several key aspects. Unlike pharmacological treatments or traditional psychotherapy, it focuses on behavioral modification by intentionally reducing or eliminating engagement with digital devices and social media for predetermined periods. The intervention emphasizes mindful technology use, limits screen time, and encourages offline activities to restore emotional balance and improve sleep quality. Additionally, it targets the cumulative effects of constant digital exposure, such as information overload, social comparison, and digital dependency, which are not typically addressed in standard mental health interventions. This unique focus on managing digital behavior positions digital detox as a complementary strategy for promoting psychological well-being in young adults.
219040465|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
219040466|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
219040467|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
219040468|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
219040469|NCT06476223|DRUG|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
219040470|NCT06476223|DRUG|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
218887680|NCT06974006|OTHER|Devices: Kardia Mobile 6L; Omron M7 BP ; Beurer PO30; Datospir Peak-10; NUTRILAB BIA 101 BIVA® PRO; JAMAR® Smart.|Use of the Kardia Mobile 6L portable device to assess electrocardiogram; Omron M7 BP for blood pressure; Beurer PO30 for oxygen saturation; Datospir Peak-10 for peak flow; NUTRILAB BIA 101 BIVA® PRO for body composition; questionnaires for the nutritional status (Mini-Nutritional Assessment, Malnutrition Universal Screening Tool), JAMAR® Smart for handgrip strength; The Short Physical Performance Battery for frailty status and fall risk; the Geriatric Depression Scale to evaluate depression status; the Fried's frailty phenotype to assess the frailty status; the International Physical Activity Questionnaire for the physical activity levels; SARC-F to identify older adults at risk of sarcopenia; and the Timed-Up and Go for mobility, walking ability and fall risk.
218887681|NCT06968442|PROCEDURE|Venipuncture|Simple blood collection
218887682|NCT06668454|PROCEDURE|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
218887683|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
218887684|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
218887685|NCT00764062|DRUG|Amoxicillin|Amoxicillin :drug
219030976|NCT07155525|DRUG|Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)|"* Standard duct-to-mucosa pancreaticojejunostomy performed~* Application of 0.5-1.0 mL modified N-butyl-2-cyanoacrylate around the anastomotic site~* Adhesive applied circumferentially around the pancreaticojejunal anastomosis~* Allow 2-3 minutes for polymerization before proceeding~* Standard placement of peritoneal drains"
219030977|NCT07155525|PROCEDURE|Standard(duct-to-mucosa) Pancreaticojejunostomy|"* Patients undergo duct-to-mucosa pancreaticojejunostomy without additional adhesive following pancreaticoduodenectomy.~* Standard placement of peritoneal drains~* All other aspects of surgical care identical to experimental arm"
219030978|NCT07158515|BEHAVIORAL|Tailored cardiac rehabilitation|The program will address the core components of CR.21 Each of the program components will have an individualized assessment with plan and goals set at the program intake visit. The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions. Group sessions will address physical activity, nutrition, and other program topics. Duration of the program was chosen to resemble a typical 12-week cardiac rehabilitation intervention. However, the program will have a greater emphasis on cultural tailoring, language concordance, lowering burden of real-time in-person attendance, motivational coaching, and addressing psychosocial needs.
219030979|NCT07158515|BEHAVIORAL|Referral to an external cardiac rehabilitation program|Participants will be referred to an external cardiac rehabilitation program outside of the safety net setting. This is the current standard of care.
219030980|NCT07158970|DEVICE|Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.|Standard care
219030981|NCT07164313|DRUG|ZW251|Administered intravenously
219030982|NCT07168343|DRUG|One icodextrin exchange|One icodextrin fill volume of 550ml/m2 body surface area which is optimal for most paediatric patients is recommended. The minimum dwell time for an icodextrin exchange will be 7 hours, and range between 7-10 hours.
219030983|NCT07168343|DRUG|Two icodextrin exchanges|In two icodextin exchanges, the dwell times can vary but must be a minimum of 7 hours.
219030984|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (monovision strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -0.5 D in the dominant eye and -2.0 D in the non-dominant eye. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method . Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
219040471|NCT06285539|DRUG|Filgotinib|Filgotinib
219040472|NCT05492084|OTHER|without Intervention|without Intervention
219202227|NCT02076009|DRUG|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
219202228|NCT02076009|DRUG|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
219507752|NCT05433428|DRUG|Preservative Free|Preservative free eye drops
219507753|NCT05433428|DRUG|Preservative|Eyedrops with preservatives
219507754|NCT01829477|DRUG|TAK-875|TAK-875 50 mg tablets
219507755|NCT01829477|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
219507756|NCT01829477|DRUG|Glimepiride|Glimepiride tablet.
219507757|NCT06264947|DEVICE|laser acupuncture|wavelength: 808nm energy: 18j power: 100mw
219507758|NCT06264947|DEVICE|sham laser acupuncture|wavelength: 0nm energy: 0j power: 0mw
218887686|NCT04683653|RADIATION|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
218887687|NCT04683653|OTHER|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
218887688|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
218887689|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
218887690|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
219202229|NCT06542419|DEVICE|Brain Cooling|Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
219202230|NCT06511219|DEVICE|maxillary segmental distalization|maxillary segmental distalization using skeletal anchored digitally printed appliances
219202231|NCT04220203|DRUG|Tucatinib|300 mg orally two times per day
218887691|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
219030985|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (bilateral myopia strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -2.0 D in both eyes. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method. Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
219030986|NCT07170670|BEHAVIORAL|CBIP - Cognitive-Behavioral Intervention Package|"Before the procedure, the researcher initiated social interaction with the child (cognitive distraction). Next, suggestions regarding the procedure were provided (guidance). A volunteer parent sat beside the child, providing support by holding the child's non-procedural hand. While the nurse performed the port catheter insertion, the researcher applied one of the behavioral distraction techniques chosen by the child during the pre-procedure phase, such as counting, singing, reading a poem, or answering questions (behavioral distraction). Upon completion of the procedure, the researcher provided positive reinforcement by praising the child (Well done! and You were very brave!) and rewarding the child with a star and smiley face sticker on the collar (positive reinforcement)."
219030987|NCT07171320|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
219030988|NCT07171320|DRUG|Pregabalin with desvenlafaxine|In the pregabalin with desvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Desvenlafaxine will be administered at 50 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 50 mg per day after 3 days, up to a maximum of 400 mg per day after 7 days. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
219030989|NCT07162207|PROCEDURE|Pinhole surgical technique|A pinhole is created in the site of recession, the grafting material (Bi-layer collagen membrane versus connective tissue graft) is trimmed to fit the size of the recession defect, followed by graft insertion in the tunnel.
219030990|NCT07164820|OTHER|Su Jok Application|Description: The newborn's hands will be used for the application. Su Jok therapy will be administered by applying massage and seeds to the corresponding reflection points on the hand prior to the he
219030991|NCT07165951|DRUG|TQB2868 Injection|TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody
219507759|NCT01919268|DEVICE|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
219507760|NCT01919268|DEVICE|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
219507761|NCT00002175|DRUG|Dinitrochlorobenzene|
219030992|NCT07165951|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules
219030993|NCT07165951|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine Hydrochloride Injection
219030994|NCT07165951|DRUG|Paclitaxel for Injection|Paclitaxel for Injection
219030995|NCT07165951|DRUG|TQB2868 Placebo|TQB2868 Placebo without drug substance
219202232|NCT04220203|DRUG|Capecitabine|1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle
219202233|NCT04220203|DRUG|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
219202234|NCT01473485|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
219202235|NCT03834818|BEHAVIORAL|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation"
219202236|NCT06346860|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
219607805|NCT04525937|OTHER|Provider Questionnaire|Provider Questionnaire
218887692|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
218887693|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
218887694|NCT03724890|DRUG|M3814|Participants received M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
218887695|NCT03724890|DRUG|M3814|Participants received M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
218887696|NCT03724890|DRUG|Avelumab|Participants received avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
218887697|NCT03724890|RADIATION|Radiotherapy|Participants received radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
218887698|NCT06043063|PROCEDURE|Topical lidocaine|Topical anesthetic
218887699|NCT06043063|PROCEDURE|EMLA cream|Topical anesthetic
218887700|NCT06043063|PROCEDURE|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
218887701|NCT02314221|DEVICE|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
218887702|NCT06209736|DRUG|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
218887703|NCT06370819|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
218887704|NCT04607837|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
219202237|NCT04215952|BEHAVIORAL|Semantic Feature Analysis Treatment|On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
219202238|NCT05970562|DEVICE|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
219202239|NCT05970562|BEHAVIORAL|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
219607806|NCT06191029|BEHAVIORAL|Urdu translated cognitive failure questionnaire|Urdu Translated version of cognitive failure questionnaire will be given to adults to fill it accordingly and then it's reliability and validity will be checked
219607807|NCT03426189|PROCEDURE|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
219202240|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
219202241|NCT02271828|PROCEDURE|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
219202242|NCT06500208|DRUG|Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide|Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
219202243|NCT06632938|DRUG|ABBV-382|Subcutaneous (SC) Injection
219202244|NCT06632938|DRUG|ABBV-382|Intravenous (IV) Infusion
218887705|NCT04607837|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
219202245|NCT06632938|DRUG|Placebo for ABBV-382|IV Infusion
219202246|NCT06632938|DRUG|Placebo for ABBV-382|SC Injection
218887706|NCT06260943|BEHAVIORAL|Target Navigation Pilot Program|Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.
218887707|NCT06184438|DRUG|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
218887708|NCT06184438|DRUG|Placebo|Received placebo after surgery.
218887709|NCT06975930|PROCEDURE|Percutaneous Coronary Intervention (PCI)|"Patients with Aortoostial coronary lesion undergoing PCI will be blindly randomized into 2 groups Conventional group: patients who will undergo 2D convnetional angiography Aorto-ostial coronary stenting.~Floating Wire group: Patients who will undergo Aorto-ostial coronary stenting with Floating wire technique."
218887710|NCT06976125|DEVICE|Decision Aid-prediction model|"ER physician will input the necessary de-identified data into the decision aid application.~The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics.~Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture.~The culture call-back team, consisting of clinical pharmacists, will be notified."
218887711|NCT06975462|COMBINATION_PRODUCT|SHR-A1811 and radiotherapy|SHR-A1811:4.8mg/kg radiotherapy: 800cGY\*5
218887712|NCT06974825|DRUG|BGM0504 Administered SC|5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
218887713|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
218887714|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
218887715|NCT06974825|DRUG|Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
218887716|NCT06974825|DRUG|Placebo Administered SC|Placebo Comparator: Placebo Placebo administered SC once a week.
218887717|NCT06976749|DEVICE|myobrace appliance|functional appliance
218887718|NCT06976749|DEVICE|Twin block|functional appliance
218887719|NCT06976983|DEVICE|Portable ergonomic helmet for real tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
218887720|NCT06976983|DEVICE|portable ergonomic helmet for placebo tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
219202247|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
219202248|NCT05023772|PROCEDURE|Stereotactic Laser Ablation|MR Guided laser ablation therapy
219202249|NCT05023772|RADIATION|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
219202250|NCT05023772|DIAGNOSTIC_TEST|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
218887721|NCT06975228|BEHAVIORAL|TRUST|Six-session psychological intervention focussing on values and imagery Session 1: Assessment, formulation and psychoeducation Session 2: Values and values-based goals Session 3-5: Harnessing imagery to pursue values and imagery focussed strategies to change negative beliefs about self and others Session 6: Review
218887722|NCT04857502|DRUG|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
218887723|NCT04857502|PROCEDURE|Computed Tomography|Undergo SPECT/CT
218887724|NCT04857502|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
218887725|NCT06975306|PROCEDURE|autologous bone grafts|group will be treated with autologous bone graft for BTB ACLR
218887726|NCT06975306|OTHER|Demineralized bone matrix (DBM)|Demineralized bone matrix (DBM) is a biologic allograft product derived from bone tissue that has undergone a process of demineralization to remove inorganic mineral components while retaining the organic matrix, including proteins and growth factors.
218887727|NCT06975488|PROCEDURE|LASER Lithotripsy ( Fragmentation modality)|Group-A patients will be treated with fragmentation modality utilizing Holmium YAG laser.
218887728|NCT06975488|PROCEDURE|LASER lithotripsy (Dusting Modality)|Group-B patients will be treated with dusting modality utilizing Holmium YAG laser.
218887729|NCT06976593|DIAGNOSTIC_TEST|Functional Exercise Testing and Muscle Oxygen Saturation Measurement|Participants will complete three physical performance tests: (1) the 6-Minute Walk Test (6MWT), (2) the 30-Second Sit-to-Stand Test, and (3) a submaximal treadmill test. Muscle oxygen saturation (SmO2) will be continuously monitored during the tests using near-infrared spectroscopy (NIRS) devices placed on the intercostal, quadriceps, and triceps surae muscles. Additional variables such as heart rate, perceived exertion, respiratory pressures, pulmonary function, and fatigue will be assessed during or after the tests.
218887730|NCT06974851|DRUG|HRS9531|HRS9531
219202251|NCT06448208|DIAGNOSTIC_TEST|positron emission tomography (PET) scans|Before and after treatment.
219202252|NCT06208371|PROCEDURE|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
219202253|NCT06208371|DRUG|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
219202254|NCT06956950|DRUG|Bupivacaine + Magnesium sulfate|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml 10% magnesium sulfate
219202255|NCT06956950|DRUG|Bupivacaine + saline|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml normal saline
219202256|NCT02089880|DEVICE|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
218887731|NCT06974851|DRUG|HRS9531placebo|HRS9531placebo
219507762|NCT02511236|BEHAVIORAL|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
219507763|NCT02511236|BEHAVIORAL|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
219507764|NCT02511236|DRUG|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
219507765|NCT00003942|BIOLOGICAL|RevM10 gene|
219507766|NCT00003942|BIOLOGICAL|RevM10/polAS gene|
219507767|NCT00003942|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219507768|NCT00003942|PROCEDURE|peripheral blood stem cell transplantation|
219507769|NCT00380471|DEVICE|Bath PUVA|
218887732|NCT04493203|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
218887733|NCT04493203|DRUG|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
218887734|NCT01407198|DRUG|Nilotinib|Orally, daily 200 - 400 mg BID
218887735|NCT01407198|RADIATION|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
218887736|NCT06783413|BEHAVIORAL|Intervention group (Laughter Yoga)|Laughter yoga is a practice that includes physical laughing exercises and breathing techniques. Sessions will be conducted as group therapy with a trained guide. The intervention will be applied to evaluate changes in participants' fatigue, sleep quality and psychological well-being.
218887737|NCT06783413|OTHER|Control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
218887738|NCT02123823|DRUG|Everolimus|10mg dose
218887739|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
218887740|NCT02123823|DRUG|BI 836845|1000 mg, recommended dose per Phase Ib part. Human monoclonal antibody. Dose escalation in Phase Ib. 2 dose levels (high or low) depending on the dose cohort explored
218887741|NCT05650879|DRUG|ELVN-002|capsule
219507770|NCT02210351|DEVICE|MRI test|
219507771|NCT04459481|DEVICE|bending angle|patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
219607808|NCT03426189|PROCEDURE|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
218887742|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
218887743|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
218887744|NCT06169982|DRUG|LY3209590|Administered SC
218887745|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)
218887746|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).
218887747|NCT05176808|BEHAVIORAL|Early Achievements- Parent Coaching Intervention|Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
218887748|NCT05154773|BEHAVIORAL|Kidney donation and transplant information made easy|Same as arm description
218887749|NCT06503653|DIAGNOSTIC_TEST|syncope channel|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation."
219030996|NCT07165106|BEHAVIORAL|Aerobic Exercise|"Participants in this group will receive conventional rehabilitation in combination with supervised treadmill-based aerobic exercise three times per week for 6 weeks. Each exercise session will consist of a 5-minute warm-up, a 15-minute main exercise phase, and a 5-minute cool-down. Walking speed will be individualized based on participant tolerance and progressively increased under clinical supervision. Exercise intensity will be monitored using the modified Borg Rating of Perceived Exertion (scale 6-20).~Weeks 1-2: Main exercise at Borg 10-11 (light-moderate).~Weeks 3-4: Main exercise at Borg 11-12 (moderate).~Weeks 5-6: Main exercise at Borg 12-13 (moderate-high).~Cardiorespiratory responses will be monitored during all sessions, and treadmill speed will be gradually adjusted in accordance with improvements in exercise tolerance while maintaining safety."
219030997|NCT07165106|BEHAVIORAL|Resistance Exercise|Participants in this arm will receive conventional rehabilitation combined with supervised resistance training using elastic bands, 3 times per week for 6 weeks. Exercises target major upper- and lower-limb and hip muscles. Each exercise is performed for 3 sets of 10 repetitions with 60-90 seconds rest. Initial band tension is set at the highest tolerable level and progressively increased. The program includes shoulder press, biceps curl, triceps extension, seated leg extension, calf raise, and lateral band walk. All sessions are supervised, emphasizing correct posture, controlled full range of motion, and avoidance of compensatory movements. Patients are guided with verbal and visual cues when necessary.
219507772|NCT06103409|BIOLOGICAL|Implantation of allogeneic MSCs on burn wounds|Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
219507773|NCT01338844|DIETARY_SUPPLEMENT|Myo-inositol|
219507774|NCT01338844|DIETARY_SUPPLEMENT|D-chito-Inositol|
219607809|NCT06384833|DRUG|Ascorbic acid|Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
219607810|NCT06384833|DRUG|N-acetyl cysteine|NAC (effervescent) 600mg 1 tab PO OD for 45 days
219607811|NCT06384833|OTHER|placebo|pharmacologically inactive substance
219607812|NCT00917774|DEVICE|Standard LPS flex TKA|TKA by Standard LPS flex TKA
219607813|NCT00917774|DEVICE|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
219607814|NCT02385474|DRUG|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
219607815|NCT02385474|DRUG|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
218887750|NCT06503653|DIAGNOSTIC_TEST|routine care|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals"
219607816|NCT03708094|DIAGNOSTIC_TEST|molecular diagnosis|whole exome sequencing and data analysis to elucidating molecular diagnosis
218887751|NCT06975280|BEHAVIORAL|Trauma - Focused Cognitive Behavioral Therapy|TF-CBT is a comprehensive, evidence-based, short-term therapeutic protocol aimed at reducing trauma-related symptoms in children and adolescents aged 3-18. The protocol consists of 12 double sessions conducted with both the child and their caregiver. Developed for children who have experienced sexual abuse and multiple traumas, TF-CBT has since been successfully applied to a variety of traumatic experiences. Core components of the protocol include psychoeducation, relaxation techniques, emotional regulation, cognitive processing, trauma narrative, in vivo exposure, conjoint child/caregiver sessions, and safety planning. The intervention is culturally informed and flexible to meet individual needs. Adjustments have been made in the context of unaccompanied minors (UAMs), where caregiver involvement is not feasible, due to specific circumstances in accommodation centers and Supportin Greece.
218887752|NCT06975280|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual (TAU) approach involves routine clinical management and psychological support, without the use of a structured therapeutic framework. This intervention consists of general, non-specific support provided by clinical staff, including informal counseling and monitoring of the child's psychological well-being. Unlike more structured therapeutic protocols, TAU does not follow a predefined set of interventions or techniques, allowing for a flexible and individualized approach, though lacking the formal therapeutic focus of interventions like TF-CBT.
218887753|NCT06974799|DIAGNOSTIC_TEST|Fatty acids measurement|Serum analysis for metabolomic biomarker identification
218887754|NCT06976034|DEVICE|Optical Transmission Tomography (OTT)|Multiple imaging sessions added by research using the systems described (OTT) will be carried out by two different operators at different positions during these sessions.
218887755|NCT06976034|DEVICE|Optical Coherence Tomography (OCT)|Multiple imaging sessions (OCT) already used in standard of care will be performed by two different operators at different positions during these sessions.
218887756|NCT06976034|DEVICE|Specular Microscopy (SM)|Multiple imaging sessions (SM) already used in standard of care will be performed by two different operators at different positions during these sessions.
219030998|NCT07165106|BEHAVIORAL|Conventional Rehabilitation|Participants in this group will receive conventional rehabilitation only, 5 days per week, 1 hour per day, for 6 weeks. The program includes upper and lower limb range of motion exercises, stretching, walking practice, balance and coordination training, proprioceptive exercises, posture correction, obstacle crossing, and turning in place. All sessions are delivered under clinical supervision, with emphasis on correct posture, safety, and full range of motion
219030999|NCT07168642|BEHAVIORAL|Mothering from the Inside Out|Mothering from the Inside Out (MIO) is an evidence-based individual psychotherapy designed to help caregivers in recovery build stronger relationships with their children. In MIO, caregivers are helped to build their ability to reflect on their own mental states and how they arose. Often, we find that the thoughts and feelings that drive caregiving behavior are actually triggered by early experiences of being cared for. MIO thus aims to provide a safe, therapeutic space where caregivers' internal experiences are taken seriously and clinicians are genuinely interested, curious, and collaborative. MIO also involves helping caregivers to reflect on the possible mental states underlying their children's behavior. We find that by providing some information about child development through an attachment lens, this can help parents see through their children's eyes and feel less stressed.
219031000|NCT07168733|DEVICE|Inspiratory muscle training|The POWERbreathe® device is a pressure-threshold IMT device that provides resistance during inhalation. The user breathes in through a mouthpiece against an adjustable spring-loaded valve, which opens only when the inspiratory pressure exceeds the set threshold, thereby strengthening the inspiratory muscles over time. Following a one-week familiarization period, the IMT protocol was performed twice daily (morning and evening), five days per week, for four weeks. Each session consisted of 30 breathing cycles, resulting in a total of 60 cycles per day. Prior to training, the device resistance was calibrated to 40% of each participant's maximal inspiratory pressure (MIP), as reported by Çelikel et al. (2025) to promote increases in muscle size and thickness. MIP was reassessed weekly and resistance was increased by 10%; progression was paused if participants experienced excessive strain.
219031001|NCT07168733|OTHER|Control|The group that continues with their normal daily routines
219031002|NCT07171775|PROCEDURE|Experimental - Nanohydroxyapatite|Following selective caries removal under local anesthesia and rubber dam isolation, nanohydroxyapatite paste will be applied directly onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol.
219031003|NCT07171775|PROCEDURE|Active Comparator - Biodentine|Following selective caries removal under local anesthesia and rubber dam isolation, Biodentine will be mixed according to the manufacturer's instructions and applied onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol. This comparator is distinguished by the use of a calcium silicate-based bioactive material with well-established clinical performance, serving as the reference standard against which nanohydroxyapatite is evaluated.
219031004|NCT07171723|BIOLOGICAL|Liver-Expressed Antimicrobial Peptide 2 (LEAP2)|Continuous intravenous infusion of LEAP2 (Liver-Expressed Antimicrobial Peptide 2), an endogenous inverse agonist and competitive antagonist of the ghrelin receptor (GHSR), administered at 40 pmol/kg/min for 6 hours. LEAP2 inhibits ghrelin-mediated signaling involved in hunger regulation, gastric motility, and growth hormone secretion. This intervention enables investigation of the physiological relevance of ghrelin receptor activity during semaglutide-induced appetite suppression
219031005|NCT07171723|OTHER|Placebo (saline)|Continuous intravenous infusion of isotonic saline (0.9% sodium chloride) for 6 hours. This placebo comparator is used to match the volume, rate, and duration of the active intervention (LEAP2) in a randomized, double-blind, crossover design. The placebo enables assessment of the physiological effects of ghrelin receptor blockade by LEAP2 in individuals with obesity treated with semaglutide
219607817|NCT00779831|DRUG|120 mg Pseudoephedrine hydrochloride extended release tablets|
219507775|NCT01073436|OTHER|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
219202257|NCT02089880|DEVICE|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
219202258|NCT05444465|DEVICE|Isolated Bioinductive Repair|Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant
219202259|NCT05444465|PROCEDURE|Completion and Repair|Standard surgical repair using the 'Completion and Repair' technique.
219202260|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
219202261|NCT04243759|BEHAVIORAL|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
218887757|NCT06975345|OTHER|Multicomponent intervention. Hip flexors stretching, Strengthening exercises and education and medical treatment (Medication and medical counselling)|"Hip flexors stretching (Adaptation from Evjenth and Hamberg)~Strengthening Exercise~* Deep squats~* Flexo-extension of the ankle on a step over the head of metatarsal bones~* Plank~* Strengthening knee flexors and hip extensors~* Lunges with a stick behind the patient back~Education Pain relieving positions identified will be taught to the patient to use when they feel their pain.~Identifying and learning to avoid pain positions or activities that increase pain.~When the pain occur self stretching of hip flexors on the couch or the chair must be done"
218887758|NCT06975345|DRUG|Medical treatment.|A medical doctor will prescribe the treatment following the standard of care in Polish public health services. Treatment will consist of medication and counseling.
219031006|NCT07170540|DRUG|Cashew sublingual immunotherapy|Glycerinated cashew extract for use in sublingual immunotherapy
219031007|NCT07170540|DRUG|Placebo sublingual immunotherapy|Glycerinated saline for placebo sublingual immunotherapy
219031008|NCT07171762|DEVICE|Ozonytron XP|This intervention involves the use of ozonated water as a final irrigation solution during root canal treatment in teeth diagnosed with asymptomatic apical periodontitis. Following standard chemomechanical preparation, ozonated water is delivered into the root canal system using a 30-gauge side-vented needle. The aim is to assess the biochemical changes in periapical tissues by evaluating oxidative stress markers (TAS, TOS, MDA, 8-OHdG) in the apical fluid samples collected before and after irrigation. The ozonated water is generated via a medical-grade ozone generator, and its application is designed to minimize cytotoxicity while maximizing antimicrobial and oxidative stress modulation properties. The outcomes are compared to a control group receiving saline irrigation under identical procedural conditions.
219202262|NCT04243759|BEHAVIORAL|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
219202263|NCT04243759|BEHAVIORAL|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
219202264|NCT04422743|DIETARY_SUPPLEMENT|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
219202265|NCT05280639|DEVICE|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
219507776|NCT01664689|PROCEDURE|Microcoaxial Phacoemulsification|
219507777|NCT05026515|BEHAVIORAL|Parents|To observe the influence of the parents/caregivers behavior on their child during dental treatment
219507778|NCT01649141|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
219507779|NCT05670652|OTHER|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
219507780|NCT02746263|DRUG|IV acetaminophen|
219507781|NCT02746263|DRUG|Oral acetaminophen|
219507782|NCT02746263|DRUG|Morphine|Patient controlled analgesia
219507783|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
219507784|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
219507785|NCT00818623|DRUG|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
219507786|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
219507787|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
218887759|NCT06976047|BEHAVIORAL|Tell-Show-Do|"The inferior alveolar nerve block will be administered utilizing a combination of the Tell-Show-Do technique and verbal distraction. Initially, the procedure will be explained to the child in simple, age-appropriate language to reduce fear and foster understanding (Tell). This will be followed by a demonstration of the materials and sensations involved, using models or non-threatening demonstrations on the child's hand (Show). Once the child appears comfortable, the actual administration of the nerve block (Do) will proceed exactly as explained, maintaining consistency between the explanation and the action. Throughout the process, verbal distraction will be continuously employed, engaging the child in non-procedural conversation, offering positive reinforcement, and using calming, encouraging language."
219031009|NCT07171762|OTHER|Physiological saline solution (0.9% NaCl)|Physiological saline solution (0.9% NaCl) was used as the final irrigation agent in root canal treatment.Saline Irrigation Group (Control)
219031010|NCT07173998|OTHER|Survey|SF-36, TSQM-9, qualitative questions
219031011|NCT07161622|OTHER|Low-Level Laser Therapy (LLLT)|"Participants received LLLT using a gallium-aluminium-arsenide (Ga-Al-As) diode laser device (BTL-5000, UK). The laser operated at a wavelength of 830 nm and a power output of 100 mW. Irradiation was applied at three sites (anterior capsule, posterior capsule, subacromial area) using a stationary-contact technique for 60-90 seconds each, delivering 4 J/cm² per site. Sessions were administered three times weekly for eight weeks.~Conventional Therapy (for both groups):~15 minutes of moist heat (Chattanooga Hydrocollator)~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
219031012|NCT07161622|OTHER|Muscle Energy Technique (MET)|"Participants received MET for major shoulder muscles (internal/external rotators, flexors, extensors). Each contraction was performed at \~20% of maximum effort, sustained for 10 seconds, followed by 5 seconds relaxation, and then passive stretch to new end range. Three to five cycles per muscle group were performed. Sessions lasted \~20 minutes, three times weekly for eight weeks.~Conventional Therapy (same as Arm A):~15 minutes of moist heat~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
219031013|NCT07180420|DRUG|naloxone IM|naloxone IM to the EDC/forearm muscle
219031014|NCT07179640|DRUG|ALE1|Specified dose on specified days
219031015|NCT07179640|DRUG|Placebo|Specified dose on specified days
219031016|NCT07179562|OTHER|"motivational interviewing"|"Randomization for motivational interviewing"
219031017|NCT07180550|OTHER|High-intensity interval training, running|Six sets of 2-minute runs will be performed at an intensity of 90-95% of the maximal aerobic speed (MAS) on a treadmill. The recovery between each set will be 2 minutes, during which the subject will walk at an intensity of 50-60% of MAS.
219031018|NCT07180550|OTHER|High-intensity interval training, cycling|Six sets of 2-minute cycling will be performed at an intensity of 90-95% of the maximal heart rate on a stationary bike. The recovery between each set will be 2 minutes, during which the subject will cycle at an intensity of 50-60% of maximal heart rate.
219031019|NCT07180550|OTHER|High-intensity functional training|Three sets of six repetitions will be performed at 80% of the one repetition-maximum (1-RM) for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
219031020|NCT07180550|OTHER|Moderate-intensity functional training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
219031021|NCT07180550|OTHER|Moderate intensity traditional strength training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
219031022|NCT07180550|OTHER|High intensity traditional strength training|Three sets of six repetitions will be performed at 80% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
219031023|NCT07181525|DRUG|anti-cytokine antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-cytokine antibodies)
219031024|NCT07181525|DRUG|anti-integrin antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-integrin antibodies)
219031025|NCT07181876|DEVICE|inguinal hernia repair|Robotic-assisted inguinal hernia repair with the DEXTER robotic surgery system
219031026|NCT07180784|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|An intervention group offered to students that teaches meditation and yoga techniques, stress physiology, and mindfulness practices. Each group includes 5-6 participants and met once a week for 1.5 hours over a period of 8 consecutive weeks.
219507788|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
219507789|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
219507790|NCT00818623|DRUG|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
219507791|NCT00602030|DRUG|Entinostat|Entinostat tablets on Days 1 and 15 of a 28-day cycle.
219507792|NCT00602030|DRUG|Placebo|Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
219507793|NCT00602030|DRUG|Erlotinib|Erlotinib 150 mg tablets once daily.
219507794|NCT03263299|DRUG|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
219507795|NCT03263299|DRUG|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
219507796|NCT03263299|DRUG|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
219507797|NCT00371800|DRUG|cinnamon|
219507798|NCT00650299|DRUG|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
218887760|NCT06976047|BEHAVIORAL|Visual distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The light in the thumb sleeve is controlled by pressing a battery that turns the light on and off. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. Once the child appears comfortable, the actual administration of the nerve block will proceed."
218887761|NCT06976047|BEHAVIORAL|Sensory distraction|During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure.
219607818|NCT00457548|BEHAVIORAL|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
219607819|NCT04611633|COMBINATION_PRODUCT|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
218887762|NCT06976047|BEHAVIORAL|Visual and sensory distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure."
218887763|NCT06081920|BIOLOGICAL|IBI363|IBI363 monotherapy
218887764|NCT03453489|OTHER|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
219031027|NCT07180784|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Traditional CBT-I was offered in small group sessions of 5 to 6 participants and lasted 1.5 hours each. They were held once a week over a period of 8 consecutive weeks.
219031028|NCT07181746|PROCEDURE|leg exercises|The patient in study group will offer 72 planned sessions along 16-week period, each session consisted of 5 minutes walking as a warm-up, followed by 30 to 45 minutes of resistance exercises tolerated by the patient, time maintained until the end of the intervention. Each participant will receive about two to three, personal training session regarding the technique of resistance training until they are perfect in performing the exercises. Participants will receive a booklet with instructions on the Pilates training illustrated by colored pictures. The sessions during the staying the patient's in the hospital will be supervised by the researchers
219031029|NCT07180901|OTHER|Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)|Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: - pre-operative dental consultation for fast-track - pre-operative oncology consultation for fast-track with high-risk features - target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.
219031030|NCT07181109|DRUG|Zilebesiran|Zilebesiran will be administered SC
219031031|NCT07181109|DRUG|Placebo|Placebo will be administered SC
219031032|NCT07180576|BEHAVIORAL|Nutrition counseling|Weekly standardized nutrition counseling will be provided by a study RDN to promote adherence and address barriers to adherence, acceptability, and adverse events. The RDN will also document any changes to the CRT regimen and hospitalizations.
219031033|NCT07180576|DRUG|Fresubin Supportan|Two bottles per day of Fresubin Supportan, a fish oil-enriched high calorie, high protein oral nutrition supplement.
219031034|NCT07180654|DEVICE|transcranial magnetic stimulation|Subjects will receive a series of 60 10s trains that will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz). iTBS will be administered at 100% of the motor threshold (MT).
219031035|NCT07181915|OTHER|Generic email - control|A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
219031036|NCT07181915|OTHER|Personalised email - Intervention|A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.
219031037|NCT07180160|DRUG|QL1706|QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).
219607820|NCT02694328|DRUG|ALKS 3831|Daily dosing
219607821|NCT02694328|DRUG|Olanzapine|Daily dosing
219607822|NCT01845480|BEHAVIORAL|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
218887765|NCT03453489|OTHER|Laboratory Biomarker Analysis|Correlative studies
218887766|NCT03453489|PROCEDURE|Positron Emission Tomography|Undergo AMT-PET
218887767|NCT03453489|DRUG|Telotristat Etiprate|Given PO
219202266|NCT05280639|OTHER|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
218887768|NCT04668872|RADIATION|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
219202267|NCT05569759|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
219202268|NCT05569759|DRUG|placebo|Subcutaneous injection of placebo
219202269|NCT05569759|DRUG|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
219202270|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
219202271|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
219202272|NCT05014971|BEHAVIORAL|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
219202273|NCT00449748|DRUG|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
219202274|NCT05046600|DEVICE|Products listed in cohort description|Depending on approved indication per product
218887769|NCT04668872|DIAGNOSTIC_TEST|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
218887770|NCT04668872|DIAGNOSTIC_TEST|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
218887771|NCT06363240|DEVICE|Broadband Light|Broadband Light treatment
218887772|NCT02989584|DRUG|Atezolizumab|
218887773|NCT02989584|DRUG|Gemcitabine|
219202275|NCT06307184|PROCEDURE|Natural proliferative phase frozen embryo transfer|When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
219202276|NCT02339168|DRUG|Enzalutamide|Given PO
219507799|NCT00650299|DRUG|Xanax XR® Tablets 3 mg|3mg, single dose fed
218887774|NCT02989584|DRUG|Cisplatin|
219202277|NCT02339168|DRUG|Metformin Hydrochloride|Given PO
218887775|NCT06253923|DRUG|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
218887776|NCT06253923|DRUG|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
218887777|NCT06074159|BEHAVIORAL|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
218887778|NCT04827992|DRUG|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
218887779|NCT04827992|BEHAVIORAL|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
218887780|NCT04346654|DRUG|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
218887781|NCT04346654|DRUG|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
218887782|NCT05470374|PROCEDURE|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
219202278|NCT05266040|DRUG|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
219507800|NCT05747638|BEHAVIORAL|Revised Children's Manifest Anxiety Scale (RCMAS)|All participants will be invited to complete a paper questionnaire.
219507801|NCT00910182|PROCEDURE|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
219507802|NCT01684410|BIOLOGICAL|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
219507803|NCT01684410|BIOLOGICAL|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
219507804|NCT01684410|BIOLOGICAL|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
219607823|NCT00890604|OTHER|Stepwise normothermia protocol|Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
218887783|NCT05286346|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
219607824|NCT00890604|DRUG|Ibuprofen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
219607825|NCT00890604|DRUG|Acetominophen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
219607826|NCT03558438|OTHER|No interventions|No interventions
219607827|NCT00612092|RADIATION|Spiral image acquisition|standard spiral scan protocol
219607828|NCT00612092|RADIATION|sequential image acquisition|sequential CT scan protocol
219607829|NCT06468241|OTHER|Progressive relaxation exercise|For the progressive relaxation exercise group, a progressive relaxation exercise session will be applied to the participants 3 times a week for four weeks.
218887784|NCT05286346|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
218887785|NCT02093962|DRUG|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
218887786|NCT02093962|DRUG|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
219607830|NCT06468241|OTHER|Listening to music|"For the music listening group, the participants will listen to the Turkish music makams (uşşak and rast) three times a week for four weeks."
219607831|NCT04280640|OTHER|Blood Draw|A blood sample will be collected once, prior to treatment.
218887787|NCT03930121|OTHER|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
218887788|NCT05814328|OTHER|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
218887789|NCT03201861|DRUG|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
218887790|NCT03201861|DRUG|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
218887791|NCT06482112|DRUG|Efinopegdutide|SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
218887792|NCT06976905|PROCEDURE|Total laparoscopic hysterectomy|Hysterectomy by laparoscope using uterine manipulator or myoma screw as a manipulator of large uterus
218887793|NCT00585520|DRUG|Progesterone|200mg BID for 5 days
218887794|NCT00585520|DRUG|Placebo|Placebo
218887795|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
218887796|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
218887797|NCT05941741|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.
218887798|NCT05941741|DRUG|Chemotherapy|Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles
218887799|NCT05941741|BIOLOGICAL|Immune checkpoint inhibitor|Cadonilimab: 10mg/kg, Q3W, 3 cycles
219031038|NCT07180160|DRUG|CDK4/6 inhibitor|palbociclib OR ribociclib OR abemaciclib OR dalpiciclib
219031039|NCT07180160|DRUG|Fulvestrant|SERD
219031040|NCT07180706|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
219031041|NCT07180771|DRUG|BR101801|Patients will receive 200mg capsules (100mg+100mg)
219031042|NCT07180862|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
219031043|NCT07180862|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
219031044|NCT07181083|DEVICE|Rheolytic thrombectomy|Rheolytic thrombectomy via AngioJet ZelanteDVTTM Catheter (Boston Scientific Co., USA).
219031045|NCT07180485|BEHAVIORAL|whole body vibration training|whole body vibration training and health education booklet
219031046|NCT07180485|BEHAVIORAL|control group|health education booklet
219031047|NCT07179965|OTHER|Observation|IBD patients
219031048|NCT07180173|RADIATION|Salvage Neck Treatment|Salvage neck treatment, including neck dissection with or without re-irradiation and/or systemic therapy, administered to patients with stage N3 nasopharyngeal carcinoma after completion of definitive concurrent chemoradiotherapy (CCRT) or induction chemotherapy followed by radiotherapy/CCRT.
219031049|NCT07180953|DRUG|NaCl 0.9%|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 2ml 0.9% NaCl iv
218887800|NCT05941741|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy will be performed to study group, with the use of IMRT.
218887801|NCT03953300|BIOLOGICAL|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
218887802|NCT03953300|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
218887803|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
219607832|NCT04526847|BEHAVIORAL|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
219607833|NCT04526847|BEHAVIORAL|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
219607834|NCT03459456|BEHAVIORAL|Provocation OC task (Provoc)|used to evoke OC-related distress
218887804|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
218887805|NCT06974838|DEVICE|intermittent theta burst stimulation|stimulatory protocol
218887806|NCT06976164|PROCEDURE|The standard antenatal care.|Antenatal Protocol.
218887807|NCT06976164|PROCEDURE|Foot reflexology.|A manual therapy technique.
218887808|NCT06337032|DRUG|F/TAF (High Dose Tablet)|200/25 mg fixed-dose combination (FDC) tablet administered orally
218887809|NCT06337032|DRUG|F/TAF (Low Dose Tablet)|200/10 mg FDC tablet administered orally
218887810|NCT06337032|DRUG|F/TAF (Lowest Dose Tablet)|120/15 mg FDC tablet administered orally
218887811|NCT06337032|DRUG|F/TAF (High Dose TOS)|60/7.5 mg tablet for oral suspension (TOS) administered orally
218887812|NCT06337032|DRUG|F/TAF (Low Dose TOS)|30/3.75 mg TOS administered orally
218887813|NCT06337032|DRUG|F/TAF (Lowest Dose TOS)|15/1.88 mg TOS administered orally
218887814|NCT06337032|DRUG|E/C/F/TAF|150/150/200/10 mg tablet administered orally
218887815|NCT06337032|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg tablet administered orally
218887816|NCT06337032|DRUG|Cobicistat (High Dose)|150 mg tablet administered orally
218887817|NCT06337032|DRUG|Cobicistat (Low Dose)|90 mg tablet administered orally
218887818|NCT06337032|DRUG|Cobicistat (TOS)|30 mg TOS administered orally
218887819|NCT06337032|DRUG|B/F/TAF (High Dose)|50/200/25 mg FDC tablet administered orally
218887820|NCT06337032|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablet administered orally
218887821|NCT06337032|DRUG|B/F/TAF (High Dose TOS)|15/60/7.52 mg TOS administered orally
218887822|NCT06337032|DRUG|B/F/TAF (Low Dose TOS)|7.5/30/3.76 mg TOS administered orally
218887823|NCT06337032|DRUG|B/F/TAF (Lowest Dose TOS)|3.76/15/1.88 mg TOS administered orally
218887824|NCT06337032|DRUG|3rd ARV Agent|A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
218887825|NCT06337032|DRUG|Nucleos(t)ide reverse transcriptase inhibitors (NRTI)|NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
218887826|NCT06337032|DRUG|ATV|Administered according to the prescribing information
218887827|NCT06337032|DRUG|DRV|Administered according to the prescribing information
218887828|NCT06337032|DRUG|Lopinavir Boosted with ritonavir (LPV/r)|Administered according to the prescribing information
218887829|NCT04200417|PROCEDURE|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
218887830|NCT04200417|DRUG|Mitomycin C|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
218887831|NCT04200417|DRUG|Lipiodol|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
218887832|NCT04200417|DRUG|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
218887833|NCT01985919|OTHER|Obtaining human tissue for basic research or biospecimen bank|
218887834|NCT00219505|PROCEDURE|acupuncture|
218887835|NCT05408091|DRUG|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
219607835|NCT03459456|BEHAVIORAL|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
218887836|NCT06393647|OTHER|Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
218887837|NCT05484219|DEVICE|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
218887838|NCT03190460|OTHER|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
218887839|NCT03190460|OTHER|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
218887840|NCT05870865|DRUG|ASN008|ASN008 topical gel applied twice daily.
218887841|NCT05870865|OTHER|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
218887843|NCT06251115|DRUG|QY-1-T|QY-1-T is a TCR-T drug targeting HBV-related HCC
219607836|NCT03459456|BEHAVIORAL|Exposure provocation task|used to elicit overt OCD rituals
219607837|NCT02971020|OTHER|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
218887844|NCT04551807|PROCEDURE|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
218887845|NCT04551807|PROCEDURE|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
219607838|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
218887846|NCT01480310|DRUG|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
218887847|NCT01480310|DRUG|Placebo|may receive up to 3 subcutaneous doses of placebo
218887848|NCT06672003|DIAGNOSTIC_TEST|4 meter walking speed and hand grip strength|4 meter walking seconds are noteed for each of participants
218887849|NCT06671821|DRUG|HRS-7535|HRS-7535
218887850|NCT06705257|DIAGNOSTIC_TEST|Studying the effects of varying levels of PEEP using Electrical impedance tomography|Feasibility of using EIT, to study the effect of varying levels of PEEP/Continous distending pressure on lung recruitment as measured by changes in functional lung scores and silent spaces in preterm infants (\<32 weeks) who are on mechanical ventilation or receiving primary or post extubation CPAP support.
218887851|NCT06727123|OTHER|motivational interviewing|Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
218887852|NCT06727123|OTHER|Control|No application will be made. Routine follow-ups will be made.
218887853|NCT06390007|DEVICE|Sham press needle|The plester used is a round plaster that resembles the shape of an acupuncture press needle.
218887854|NCT06390007|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
219031050|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 4mg Dexamethasone iv
219031051|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 2mg Dexamethasone) + 2ml 0.9% NaCl iv
219031052|NCT07181460|OTHER|Exercises Program|A program of low-intensity, safe, and functional movements was designed for older adults. It included a warm-up, breathing exercises, chair exercises, strength and mobility exercises, balance exercises, stretching, and a cool-down.
219031053|NCT07180628|BEHAVIORAL|Speech Production During functional magnetic resonance imaging (MRI)|Participants will complete a speech production task with 2 conditions (stuttered, non-stuttered) while undergoing functional MRI to assess brain activity. Brain activity will be compared within subjects for the 2 conditions. The intervention is the combination of tasks delivered to all participants. The speaking task is the intervention (modifying agent) and the MRI is a measurement tool, not a therapeutic or modifying agent.
219031054|NCT07181174|DEVICE|Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer.|-Renal Resistive Index Measurement Method: Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer. First, the kidney is localised in the flanks with conventional B-mode ultrasonography, after which, color doppler images are acquired. The interlobar arteries were visualised, with the wavelength obtained by creating a 90-degree right-angle with the interlobar artery using a power doppler. After the manual determination of the peak systolic and end-diastolic velocities \* RRI will be calculated by the device using the formula: RRI = (peak systolic velocity - end-diastolic velocity) / (peak systolic velocity). RRI will be measured three times for each kidney and averaged
219031055|NCT07181213|PROCEDURE|Adrenalectomy|Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension
219031056|NCT07180290|BEHAVIORAL|Psychotherapy|Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
219607839|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
219202279|NCT05266040|DRUG|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
219607840|NCT01298414|GENETIC|RNA analysis|
219607841|NCT01298414|OTHER|laboratory biomarker analysis|
219607842|NCT02303912|DRUG|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
219202280|NCT04276246|DEVICE|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
219607843|NCT00054457|DRUG|capecitabine|
219202281|NCT04276246|DEVICE|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
219607844|NCT00054457|DRUG|docetaxel|
219607845|NCT05296174|OTHER|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
219607846|NCT05296174|OTHER|health education activities program|The control group was offered health education activities once a week.
219607847|NCT04536376|BEHAVIORAL|Resilience Program|Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
219607848|NCT06525207|DEVICE|Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography|Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
219607849|NCT05496491|RADIATION|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
219607850|NCT05496491|DRUG|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
219607851|NCT05496491|DRUG|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
219607852|NCT05552625|DRUG|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
218887855|NCT06726746|DEVICE|Fractional CO2 laser|". Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic."
219202282|NCT05583422|GENETIC|DPYD or UGT1A1 variants|any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
219202283|NCT01932125|DRUG|Bevacizumab|Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
219202284|NCT06965829|DRUG|Tislelizumab|Neoadjuvant immunotherapy (tislelizumab 200 mg d1, q3w × 2 cycles)
219607853|NCT05552625|DRUG|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
219607854|NCT06294821|DRUG|4-Aminopyridine|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
219607855|NCT06294821|OTHER|Placebo|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
219607856|NCT06775704|DEVICE|Hip resurfacing system|Hip resurfacing with ROMAX system
219607857|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening, lateral excursion, and range of motion of shoulder abduction, neck joint
218887856|NCT06726499|DEVICE|Spherical CRT|Contact lens for myopia progression
218887857|NCT06726499|DEVICE|Toric CRT|Contact lens for myopia progression
218887858|NCT07051850|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
218887859|NCT07051850|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
218887860|NCT07051850|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
219202285|NCT06965829|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Neoadjuvant chemotherapy (nad-paclitaxel 260 mg/m2 d1 + carboplatin AUC = 5 d1, q3w × 2 cycles) and node sparing radiotherapy (41.4Gy/23 times: 1.8Gy d1-5, qw × 4-5 cycles)
219202286|NCT06964880|BEHAVIORAL|Exercise with video on media platform|12-week structured video-guided exercise and peer support program
219202287|NCT06964880|BEHAVIORAL|Printed Educational Handout|12-week printed health education handout program
219202288|NCT06966232|DRUG|Entecavir|anti hepatitis B virus
219607858|NCT06362265|DRUG|LY3209590|Administered SC.
219607859|NCT05291091|DRUG|Sevasemten 10 mg|Sevasemten is administered orally once per day
219607860|NCT05291091|DRUG|Sevasemten 5 mg|Sevasemten is administered orally once per day
219607861|NCT05291091|DRUG|Sevasemten 12.5 mg|Sevasemten is administered orally once per day
219202289|NCT06966115|BEHAVIORAL|Multiple Sclerosis Vocational Rehabilitation (MSVR)|"MSVR involves an initial assessment (including vocational goal setting), followed by up to 10 hours of individually tailored support over six months according to need. The support will focus on supporting the person with MS to remain at work by addressing topics such as:~* Understanding MS~* Advice on reasonable adjustments~* Support requesting reasonable adjustments~* Fatigue management~* Managing cognition at work~* Information about legal rights~* Disclosure~* Long-term career planning~* Managing mood difficulties~* Signposting to local and national resources. MSVR addresses the individual needs of the person with MS and offers advice remotely (e.g., via telephone, videoconference, or email). The sessions will be arranged at a time convenient for the person, and the support needed will vary according to the complexity of their workplace difficulties."
219607862|NCT05291091|DRUG|Placebo|Placebo is administered orally once per day
219607863|NCT06338995|DRUG|LY3650150|Administered SC.
219607864|NCT06338995|DRUG|Placebo|Administered SC.
219607865|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
219607866|NCT05861999|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
219607867|NCT05292664|DRUG|Venetoclax|Tablet taken orally
219607868|NCT05292664|DRUG|Azacitidine|Taken intravenously
218887861|NCT07051850|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
218887862|NCT07051850|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
218887863|NCT07051850|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
218887864|NCT03491787|DEVICE|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
219607869|NCT05292664|DRUG|Cytarabine|Lumbar Puncture
219607870|NCT05292664|DRUG|Methotrexate|Lumbar Puncture
219607871|NCT05292664|DRUG|Hydrocortisone|Lumbar Puncture
219607872|NCT05292664|DRUG|Leucovorin|Taken Orally or intravenously
219607873|NCT05292664|DRUG|Dexamethasone|Taken Orally or intravenously
218887865|NCT06757764|DRUG|Aspirin|"Aspirin 100mg qd (21days)~* In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
218887866|NCT06757764|DRUG|Clopidogrel|"Clopidogrel 75mg qd (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
218887867|NCT06757764|DRUG|Cilostazol|"Cilostazol SR 100mg x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
218887868|NCT06757764|DRUG|Placebo|"Placebo x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
218887869|NCT01073202|DRUG|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
218887870|NCT01073202|DRUG|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
218887871|NCT06784375|BEHAVIORAL|Unblinded CGM/Nutrition Therapy|Personalized nutrition counseling based on CGM data
218887872|NCT06784375|BEHAVIORAL|Blinded CGM/Nutrition Therapy|Standard nutrition education which does not incorporate CGM data
218887873|NCT06784375|BEHAVIORAL|Unblinded CGM/No Nutrition Therapy|CGM and general diabetes education (no nutrition education)
218887874|NCT06784375|BEHAVIORAL|Blinded CGM/No Nutrition Therapy|General diabetes education (no nutrition education)
218887875|NCT06748950|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks
218887876|NCT06748950|OTHER|Diet-as-Usual (DAU)|Participant's usual diet
218887877|NCT07052305|DRUG|NT-I7|Provided by NeoImmune Tech
218887878|NCT07052305|BIOLOGICAL|CAR T-cell therapy|Will be given on day 0
218887879|NCT07065682|DRUG|Aloevera + dutasteride|Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day
218887880|NCT07065682|DRUG|Dutasteride (0.5mg)|Control
218887881|NCT07066592|BEHAVIORAL|Prehabilitation education provided via mobile compatible website|The prehabilitation education delivered through a mobile-compatible website was developed specifically for patients who are candidates for stem cell transplantation. Through this platform, patients can easily and quickly access accurate information on managing potential symptoms during the transplant process, as well as guidance on nutrition and exercise aimed at improving their quality of life.
218887882|NCT07064772|OTHER|First Rib Mobilization|Participants in the mobilization group will receive either a seated or supine three stage progressive muscle energy technique (MET) plus a singular high-velocity, low-amplitude thrust (HVLAT) mobilization technique directed to their first rib on their symptomatic side based on the discretion of the treating physical therapist.
219607874|NCT05292664|DRUG|Vincristine|Taken intravenously
219607875|NCT05292664|DRUG|Doxorubicin|Taken intravenously
219607876|NCT05292664|DRUG|Dexrazoxane|Taken intravenously
219607877|NCT05292664|DRUG|Calaspargase Pegol|Taken intravenously
219607878|NCT05292664|DRUG|Erwinia asparaginase|Given as intramuscular injection
219607879|NCT06341192|PROCEDURE|Single-bundle ACL combined anterolateral ligament reconstruction|"Single-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~The single ACL bundle is typically positioned to replicate the anatomic footprint of the native ACL.~For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a gracilis tendon graft.~This combines an intra-articular ACL reconstruction with an extra-articular lateral tenodesis to improve rotational instability."
219202290|NCT06965985|OTHER|Mulligan mobilization therapy|While the mobilization belt is placed around the patient's proximal forearm and looped over the therapist's shoulder, the distal humerus will be stabilized with one hand. A lateral glide will be applied to the forearm through the belt and maintained for approximately 5 to 10 seconds. The patient will perform repeated wrist extensions against the manual resistance provided by the therapist's hand. Once a pain-free wrist extension is achieved, the lateral glide will be released. A total of 6 repetitions will be performed with 15-second rest intervals between repetitions. This protocol will be applied three times per week for two weeks.
219202291|NCT06965985|OTHER|Myofascial release therapy|"The patient will be placed in a supine position with the shoulder internally rotated, the elbow in pronation and approximately 15 degrees of flexion, and the palm resting flat on the table. The therapist will stand beside the table at the level of the patient, facing the patient's ipsilateral arm and shoulder. The treatment will be administered for 10 minutes, three sessions per week for two weeks.~The therapist will begin the treatment from just proximal to the lateral epicondyle, on the humerus, and proceed distally along the path of the common extensor tendon to the extensor retinaculum of the wrist. Using the fingertips, the therapist will engage the periosteum and maintain contact as the technique continues along the common extensor tendon and further distally along the extensor retinaculum of the wrist."
219202292|NCT06965985|OTHER|Exercise Therapy|"All patients will be provided with a home exercise program consisting of eccentric strengthening exercises targeting the wrist extensors, with resistance gradually increased each week. Patients will be instructed in strengthening exercises for the wrist extensors as well as forearm pronation and supination. The home program will consist of 3 sets of 10 repetitions per day.~The exercises will be demonstrated in person by the physician, and each patient will receive a printed handout detailing how to perform the exercises. During weekly treatment sessions and after the treatment period, patients will be contacted by phone to assess adherence to the exercise program and to reinforce the importance of compliance.~Patients with exercise compliance below 75-80% will be excluded from the study."
219202293|NCT06853327|DRUG|Ketorolac|The experimental condition to be examined by this study is the timing of administration of ketorolac prior to IUD insertion. Ketorolac 20mg PO has proven beneficial at certain timepoints during IUD insertion in prior studies, but pharmacokinetics indicate that it could require more time until peak analgesia.
219202294|NCT06853327|DRUG|Placebo|Placebo will be used to control the timing of administration and be used to compare ketorolac to baseline standard pain control regimens
219202295|NCT04215029|BEHAVIORAL|Exercise Intervention|Receive exercise plan
219202296|NCT04215029|OTHER|Informational Intervention|Receive printed exercise materials
219202297|NCT04215029|OTHER|Informational Intervention|Receive physical activity and healthy eating information/materials
219507805|NCT05305209|OTHER|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
219507806|NCT05305209|OTHER|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
219507807|NCT01669395|OTHER|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
219607880|NCT06341192|PROCEDURE|Double-bundle ACL combined anterolateral ligament reconstruction|"Double-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL\&#39;s anteromedial and posterolateral bundles.~Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~The double-bundle ACL reconstruction aims to better restore the ACL\&#39;s complex anatomic footprint and bundles\&#39; tension patterns."
219202298|NCT04215029|OTHER|Interview|Participate in interview
219202299|NCT04215029|OTHER|Nutritional Assessment|Complete nutrition counseling sessions
219202300|NCT04215029|OTHER|Questionnaire Administration|Ancillary studies
219202301|NCT04215029|BEHAVIORAL|Telephone-Based Intervention|Receive coaching calls
219202302|NCT06965335|BIOLOGICAL|BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC|Description of clinicophatological features of EO-CRC vs SO-CRC
219202303|NCT06965400|DEVICE|Automatic Cuff Pressure Control|he IntelliCuff® system (Hamilton Medical, Switzerland) continuously monitored and automatically adjusted cuff pressure to keep it within the target range of 15-25 cmH₂O. Manual intervention was only required upon system alert.
219202304|NCT06013241|DRUG|Brensocatib|Film-coated tablet.
219202305|NCT06013241|DRUG|Placebo|Film-coated tablet.
219202306|NCT06013241|DRUG|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
219202307|NCT06381739|BIOLOGICAL|ChAd-triCoV/Mac|Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.
219202308|NCT06381739|OTHER|Control|A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
219202309|NCT06020040|DEVICE|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
219202310|NCT05525676|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
219202311|NCT05525676|BEHAVIORAL|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
219202312|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
219507808|NCT01669395|OTHER|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
219031057|NCT07180446|BEHAVIORAL|Cardiovascular Exercise|Participants will complete a 12-week supervised cardiovascular exercise program at the TCU Recreation Center. Exercise will occur 5 days per week, beginning with 30 minutes per session and progressing to 60 minutes. Intensity will start at 50% of estimated maximal heart rate and gradually increase to 80% by week 8, remaining at that level through week 12. Exercise modalities may include treadmill walking/running, rowing, elliptical, or cycling, based on participant preference and fitness level. Certified trainers will supervise all sessions to ensure safety, proper technique, and adherence to the intensity targets. Participants will wear ActiGraph heart rate monitors to verify exercise intensity throughout the intervention.
219507809|NCT06135532|PROCEDURE|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
219031058|NCT07180446|DIETARY_SUPPLEMENT|Butyrate|Participants will take a dietary supplement containing sodium butyrate during the final 4 weeks (weeks 8-12) of the 12-week intervention. The supplement will be provided in capsule form, with participants instructed to take six capsules per day-two with each meal. This daily dose is equivalent to 3.6 g of butyric acid, which provides 939 mg of sodium, delivered as sodium butyrate. The supplement is intended to support gut health and potentially enhance insulin sensitivity in individuals who do not respond to exercise alone. Participants will receive a 4-week supply during their 8-week study visit, along with instructions for proper use and monitoring of any side effects.
219202313|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
219202314|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
219202315|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
219202316|NCT06156865|BEHAVIORAL|Intervention to address late talking|this intervention is designed to support both speech and language development in children who are toddlers. Given the age group of children their parents are part of the intervention program. Importantly the frequency of the intervention can range from once to twice per week, with timing also designed to complement the particular agency
219202317|NCT02986087|DEVICE|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.
219507810|NCT00338494|DRUG|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
219507811|NCT04881422|BEHAVIORAL|B-HIPE (Brief High Impact Preparatory Experience)|The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
219607881|NCT06524401|DEVICE|Limpet|Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
219607882|NCT06524401|DEVICE|Control|Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
219607883|NCT05740059|OTHER|Adjusted Transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
219031059|NCT07181616|BEHAVIORAL|Adapted W2W|HIV education sessions and questionnaires.
219031060|NCT07181616|BEHAVIORAL|Waitlist Control|HIV education sessions and questionnaires given 4 weeks after W2W intervention.
219031061|NCT07181343|DRUG|HS-10374 tablets|From Day 8 to Day 19, participants will orally take HS-10374 Tablets 12 mg（6 mg×2） once daily under fasting conditions
219607884|NCT05126238|DRUG|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
219607885|NCT05126238|DRUG|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
219607886|NCT06191965|DRUG|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality\_safety/quality\_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
219607887|NCT06191965|DRUG|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
219607888|NCT06029244|DEVICE|EyeControl-Pro|Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
219607889|NCT06029244|OTHER|Control|No intervention
219607890|NCT04100148|DEVICE|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
219607891|NCT04100148|DEVICE|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
219607892|NCT03516279|DRUG|Dasatinib|Given PO
219607893|NCT03516279|DRUG|Imatinib Mesylate|Given PO
219607894|NCT03516279|OTHER|Laboratory Biomarker Analysis|Correlative studies
219607895|NCT03516279|DRUG|Nilotinib|Given PO
219031062|NCT07181343|DRUG|Drospirenone and Ethinyl Estradiol tablets|On Day 1 and Day 14, participants will orally take one tablet of Drospirenone and Ethinylestradiol Tablets under fasting conditions.
219031063|NCT07179783|DRUG|Sacituzumab Tirumotecan|Drug reduction will be implemented according to the research plan.
219031064|NCT07179783|DRUG|Tagitanlimab|Treatment with Sacituzumab Tirumotecan (SKB264, 5mg/kg IV d1 Q2W) and Tagitanlimab (KL-A167 , 900mg IV d1 Q2W) until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terminate treatment, or other treatment termination criteria specified in the protocol (based on the first patient), with a maximum treatment duration of 24 months for Tagitanlimab. Drug reduction will be implemented according to the research plan.
219031065|NCT07179848|DEVICE|Temporal Interference Stimulation - Treatment first|Receive treatment stimulation for 5 consecutive days, followed by a 2-days washout period, then complete the remaining 5 days of sham stimulation
219031066|NCT07179848|DEVICE|Temporal Interference Stimulation - Sham first|Receive sham stimulation for 5 consecutive days, followed by a 2-days washout period, then undergo 5 days of treatment stimulation
219031067|NCT07181577|DEVICE|Special blanket|Special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
219031068|NCT07181577|DEVICE|Different special blanket|Different special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
219031069|NCT07179991|DRUG|Desmopressin after protamine reversal|"Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB).~Platelet function will be assessed by TEG (Thromboelastography) platelet mapping at the following points:~1. T1 TEG6s: after arterial line insertion before skin incision.~2. T2 TEG6s: after protamine (baseline function after CPB)~3. T3 TEG6s: 30 minutes after desmopressin~4. T4 TEG6s: 6 hours after (intensive care unit) ICU admission~5. T5 TEG6s: 24hours after ICU admission"
219031070|NCT07180667|BEHAVIORAL|Intervention 1: Aerobic Running (AR) Warm-Up|15-minute aerobic running protocol. Heart rate maintained at 60-75% of age-predicted maximum (HRₘₐₓ). Includes 7 minutes light jogging followed by slight intensity increase.
219031071|NCT07180667|BEHAVIORAL|Intervention 2: Static Stretching (SS) Warm-Up|5 minutes light jogging followed by static stretches of six lower-limb muscles (gastrocnemius, quadriceps, hamstrings, hip flexors, adductors, gluteals). Each muscle stretched twice for 30 seconds, finishing with 3-4 minutes of light dynamic movements.
219607896|NCT03516279|BIOLOGICAL|Pembrolizumab|Given IV
219031072|NCT07180667|BEHAVIORAL|Intervention 3: Dynamic Stretching (DS) Warm-Up|5 minutes light jogging followed by dynamic stretches targeting the same six muscle groups over 10-15 meters with brief rest between repetitions.
219607897|NCT06275555|DRUG|bivalirudin|bivalirudin as an anticoagulant
219607898|NCT06275555|DRUG|unfractionated heparin|unfractionated heparin as an anticoagulant
219607899|NCT03750708|DEVICE|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
219607900|NCT06138587|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
219607901|NCT06138587|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
218887883|NCT07064772|OTHER|Sham Comparator|Participants in the sham mobilization (control) group will be placed in a supine, hook-lying position identical to the mobilization group; however, they will be instructed to inhale and exhale 3 times using diaphragmatic breathing (avoiding upper chest recruitment) as the physical therapist gently rests his or her hand over the area of the upper trapezius muscle just proximal to the first rib to simulate a sham mobilization hand placement. Therefore, physical therapists will not use any significant compressive force to the musculature, perform any tactile cueing for upper chest breathing, perform any mobilizations, nor perform any HVLAT techniques to participants in the sham mobilization group.
218887884|NCT07066982|BIOLOGICAL|CD146/HER2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/HER2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD146/HER-2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/HER-2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
219607902|NCT04190706|OTHER|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
218887885|NCT07065435|DRUG|Disitamab Vedotin (RC48)|A HER2-targeted antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via a cathepsin-cleavable MC-VC-PAB linker to the microtubule inhibitor MMAE (drug-to-antibody ratio ≈4). Administered intravenously at 2.0 mg/kg every 2 weeks.
219031073|NCT07180667|BEHAVIORAL|Intervention 4: Movement Preparation (MP) Warm-Up|Description: Combination of light jogging, multi-joint mobility drills (e.g., lateral shuffles, inchworms), submaximal sprinting (80-90% max velocity), and low-intensity balance drills adapted from FIFA 11+ and HarmoKnee.
219031074|NCT07180433|DIAGNOSTIC_TEST|FAPI PET/MR|The patients will be injected intravenously with 2 MBq/kg 18F-FAPI, 60 minutes before the PET/MRI acquisition. The PET/MRI examinations will be performed on a Siemens Biograph mMR (Siemens Healthcare, Erlangen, Germany) with software version VE11P. Static PET will be acquired simultaneously with MRI using two protocols; a one bed position protocol in prone position covering the breast and a whole body 4-5 bed position protocol in supine position covering brain to thighs. Total acquisition time of the breast protocol will be approximately 20 minutes. Total acquisition time of the whole-body protocol will be approximately 30 minutes.
219031075|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession (BLR Recession)|This procedure involved recession of both lateral rectus muscles to reduce large-angle exotropia.
219031076|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession with Upward Transposition|This procedure involved bilateral lateral rectus recession combined with upward transposition of the insertion to enhance ocular alignment in patients with large-angle exotropia.
219031077|NCT07181252|DIAGNOSTIC_TEST|Working length of root|"EAL Group: Working length was measured using the Root ZX apex locator (J. Morita Corp., Kyoto, Japan), following the manufacturer's instructions. A #15 K-file was connected to the device and advanced until the display indicated APEX, confirming the location beyond the apical foramen.~DR Group: Working length was determined using a #15 K-file inserted 1 mm short of the estimated radiographic apex. A digital periapical radiograph was taken, and the working length was adjusted accordingly. Repeated radiographs were obtained until the file tip was 1 mm short of the radiographic apex."
219031078|NCT07180277|DRUG|Placebo|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
219031079|NCT07180277|DRUG|Methylprednisolone (MP)|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
219031080|NCT07179809|OTHER|Demographics/Lifestyle Survey|Participants will complete all sessions and instruments
219031081|NCT07179913|DRUG|Esketamine|For the subjects in the experimental group, esketamine 50mg/2ml was diluted with normal saline up to 50ml (with a concentration of esketamine at 1mg/ml), anesthesia induction begins with intravenous infusion of esketamine 0.25mg/kg (0.375ml/kg•h drug preparation solution), with a pumping duration of 40 minutes.After the operation, esketamine 0.25mg/kg and sufentanil 1.5ug/kg were added to the postoperative analgesic pump dilute to 100ml with normal saline, with a background dose of 2ml/h and a single booster dose of 2ml.
219031082|NCT07179913|DRUG|Dexmedetomidine|For the control group subjects, dexmedetomidine at a dose of 0.2mg/2ml was diluted with normal saline up to 50ml(dexmedetomidine concentration of 4μg/ml), anesthesia induction begins with intravenous infusion of 0.5μg/kg (0.083ml/kg•h), with a pumping duration of 40 minutes. The postoperative analgesic pump was added after the operation dilute with normal saline at a dose of 0.5μg/kg of dexmedetomidine and 1.5 μg/kg of sufentanil 100ml, with a background dose of 2ml/h and a single booster dose of 2ml.
219031083|NCT07179536|PROCEDURE|Ambulation after ProGlide Closure|Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.
219031084|NCT07181785|COMBINATION_PRODUCT|Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy|Anthracycline-based combinations followed or not by involved-field radiotherapy
219031085|NCT07180355|DRUG|SGT-212|Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)
219031086|NCT07180979|DRUG|0.9% Sodium chloride|"Sham ultrasound-guided pericapsular nerve group (PENG) block, lateral femoral cutaneous nerve (LFCN) block, lumbar erector spinae plane block (L-ESPB), and sacral erector spinae plane block (S-ESPB).~At each anatomical site, under ultrasound guidance, a block needle will be inserted to the correct position, and 1-2 mL of preservative-free normal saline (0.9% NaCl) will be injected to mimic the sensation of an active block. No local anesthetic will be administered. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
219607903|NCT04190706|OTHER|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
219202318|NCT06978413|OTHER|Integrated Treatment with Digital Tools|"Patients will undergo a 6-week remote telerehabilitation program. The recommended frequency of treatment is a minimum of 3 sessions per week, but patients may adjust the schedule in agreement with their assigned therapist. If a patient is unable to complete at least 18 sessions due to clinical reasons, they will be considered as a dropout.~Moreover, one session per week will be conducted synchronously, with the therapist remotely supervising the patient's activities in real time, while the remaining sessions will be asynchronous, allowing the patient to complete the exercises independently."
219507812|NCT06056700|BEHAVIORAL|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
219507813|NCT01999790|PROCEDURE|blepharotomy|upper eyelid surgery by blepharotomy
219202319|NCT06978413|OTHER|Home-Based Educational Program|Patients will be monitored over a six-week period through weekly phone calls to assess their progress and overall condition. Additionally, participants are required to maintain an activity diary to document their engagement with the prescribed activities.
219507814|NCT01999790|PROCEDURE|posterior approach|upper eyelid surgery by posterior approach
219202320|NCT06603870|DRUG|Apixaban|Apixaban is Health Canada approved for routine treatment and secondary prevention of VTE. Upon enrollment and during follow-up, patients will be managed with a prophylactic dose of apixaban (2.5 mg orally twice daily) as long as either a CVC or active cancer is present. Apixaban will be stopped at the time of CVC removal and when cancer is in remission. Patients will be instructed to contact the study team when their CVC is removed (to determine if apixaban should be continued, based on cancer status at the time), or any thrombotic or bleeding concerns were to occur in between visits. The investigators will record loss to follow-up, drop out, or death during the study.
219202321|NCT03902002|DRUG|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
219607904|NCT05453942|DRUG|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
219607905|NCT05453942|DRUG|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
219202322|NCT06987526|BEHAVIORAL|Mindfulness-Based Relapse Prevention|Renewed Recovery is a web-based Mindfulness-Based Relapse Prevention (MBRP) continuing care intervention adapted from the original MBRP curriculum by Bowen et al. It consists of 8 weekly modules designed to teach mindfulness and relapse prevention strategies for individuals with alcohol use disorder. The intervention includes educational content, guided meditations, and practical exercises. Modules are delivered asynchronously online, supplemented by two live Zoom sessions for group meditation practice. The purpose of the curriculum is to teach mindfulness and relapse prevention techniques to the participants with the aim of reducing the risk for relapse. The module titles are as follows: (1) Automatic Pilot and Relapse, (2) Awareness of Triggers and Craving, (3) Mindfulness in Daily Life, (4) Mindfulness in High Risk Situations, (5) Acceptance and Skillful Action, (6) Seeing Thoughts as Thoughts, (7) Self-Care and Lifestyle Balance, and (8) Social Support and Continuing Practice.
219202323|NCT06986070|BIOLOGICAL|Stem cells|The suspension of stem cells will be put in a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. This means that the participants will breathe in the mist containing the SMS cells, produced by the nebulizer machine. This is a Phase I First-in-Human study, which indicates that this treatment is being studied for the first time in humans.
219202324|NCT06098716|BEHAVIORAL|Self Regulation|How to plan for Family PA
219202325|NCT06098716|BEHAVIORAL|PA Support & Family Social Identity|"Exercises that strengthen parents' PA-support identity and a shared active-family identity through values reflection, role-modelling, visualization, and visible active family cues."
219202326|NCT06098716|BEHAVIORAL|Education|Information about healthy living (e.g., PA, sleep hygiene and healthy eating)
219507815|NCT00212771|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
219507816|NCT00212771|DRUG|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
219507817|NCT06039787|BEHAVIORAL|single bout of moderate intensity continuous training (MICT)|the MICT consists of 60 min continuous cycling
218887886|NCT07065435|DRUG|Bevacizumab|A recombinant humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. Administered intravenously at 7.5 mg/kg every 2 weeks in combination with RC48.
218887887|NCT07065435|DRUG|Pyrotinib|An irreversible pan-HER tyrosine kinase inhibitor targeting HER1, HER2, and HER4, inhibiting downstream PI3K/Akt and MAPK signaling. Administered orally at 320 mg once daily (post-meal) in combination with RC48.
219507818|NCT06039787|BEHAVIORAL|single bout of High Intensity Interval Training (HIIT)|HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
219507819|NCT06039787|BEHAVIORAL|waiting control|sitting in a waiting room for 60 min
219507820|NCT04371419|BEHAVIORAL|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later."
219202327|NCT03816397|BIOLOGICAL|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8 mL and 40mg/0.8 mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
219202328|NCT03816397|OTHER|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The volume-matched (0.8mL) placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
219202329|NCT06455358|DRUG|61Cu-NODAGA-LM3|Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
218887888|NCT07066878|PROCEDURE|treatment received in the group of patients suffering from malignant lesions of the head and neck.|This protocol focuses on a retrospective, single-center analysis, analyzing the factors that influence survival as the main objective, and secondarily the development of complications and the quality of life based on the treatment received in the group of patients suffering from malignant lesions of the head and neck.
218887889|NCT07064733|OTHER|Music Therapy|"The music therapy intervention consists of listening sessions using specially recorded handpan music, designed to promote relaxation and reduce anxiety in pregnant women. The handpan is a melodic percussion instrument known for its soothing and harmonic sound qualities.~Participants will listen to a 30-minute handpan music recording at home, in a quiet and dimly lit room, while resting in a semi-fowler or left lateral position. The sound volume will be kept below 60 decibels to ensure comfort and prevent overstimulation. Sessions will be scheduled three times per week, in the morning and evening, over a two-week period.~Before each session, participants will be reminded by phone and instructed to measure their blood pressure immediately prior to and at 0, 30, and 60 minutes after the music listening. The therapy aims to create a calming environment that encourages positive thoughts and bonding with the fetus."
219031087|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block, with sham lumbar and sacral ESPBs.~PENG block: 20 mL of 0.2% ropivacaine. LFCN block: 5 mL of 0.2% ropivacaine. Sham lumbar ESPB: 1-2 mL preservative-free normal saline at lumbar ESPB site. Sham sacral ESPB: 1-2 mL preservative-free normal saline at sacral ESPB site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
219202330|NCT06455358|OTHER|Comparator|Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
219202331|NCT06984276|DRUG|Control|Patients will receive o.5 ug/kg/hr fentanyl infusion all through the whole operation.
219202332|NCT06984276|OTHER|Pectoral nerves (PECS)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus ultrasound guided bilateral pectoral nerves (PECS) Block which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
219202333|NCT06984276|OTHER|Transversus thoracic muscle plane block (TTPB)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus Ultrasound guided bilateral transversus thoracic muscle plane block (TTPB) which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
219202334|NCT03931590|DRUG|[14C]-Omaveloxolone|\[14C\]-Omaveloxolone 50 mg capsules
219202335|NCT06987734|DRUG|Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab|Patients will receive 3-4 cycles of neoadjuvant treatment with preoperative suglizumab in combination with chemotherapy, followed by surgery. After surgery, patients will receive 1-4 cycles of platinum-containing adjuvant chemotherapy，followed by 1 year of adjuvant sugemalimab.
219202336|NCT06859606|OTHER|Lower molar distalization|"Lower Distalization Protocol included extraction of the lower third molars before starting treatment and a 50% sequential lower distalization with two teeth being distalized at a time. The distalization started with the movement of lower second molars, followed by the first molars halfway through the process, and so on. Once the canine reached the right position, the en masse retraction of the four incisors completed the treatment plan. The protocol comprised the use of Class III intermaxillary elastics to support the distalization movement and to control the proclination of lower incisors"
219202337|NCT06859606|OTHER|Class III elastics|Non-Distalization Protocol featured extraction of the lower third molars before starting treatment, transversal dento-alveolar coordination, strategic interproximal reduction (IPR) in the anterior segment of the lower arch, and the addition of Class III elastics
219031088|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided lumbar erector spinae plane block (L-ESPB) and sacral erector spinae plane block (S-ESPB), with sham PENG and LFCN blocks.~Lumbar ESPB: 20 mL of 0.2% ropivacaine at L3 transverse process level. Sacral ESPB: 20 mL of 0.2% ropivacaine at sacral intermediate crest. Sham PENG block: 1-2 mL preservative-free normal saline at PENG site. Sham LFCN block: 1-2 mL preservative-free normal saline at LFCN site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
219202338|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
219202339|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
219202340|NCT06990815|OTHER|Kinesio Taping|"In the application over the sacrum, one I-strip of kinesio tape will be applied with 25% tension using the fascia correction technique, which requires oscillatory movements between the tape and the skin.~In the application over the suprapubic region, two I-strips will be applied with 25% tension, also using the fascia correction technique, involving oscillations between the tape and the skin."
219507821|NCT02987595|OTHER|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
219507822|NCT02987595|OTHER|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
219507823|NCT02931565|DRUG|Olinciguat|oral tablet
219507824|NCT02931565|DRUG|Matching Placebo|oral tablet
219202341|NCT06990815|OTHER|Sham|"In the application over the sacrum, one I-strip will be applied without tension.~In the application over the suprapubic region, two I-strips will be placed without tension."
218887890|NCT07064733|OTHER|warm water foot bath therapy|"The warm water foot bath therapy involves soaking the participant's feet in water heated to 37-40°C for 10-15 minutes per session. This therapy is designed to promote relaxation, improve peripheral circulation, and reduce anxiety symptoms.~Participants will perform the foot bath in a safe and comfortable setting, ensuring water temperature is monitored with a thermometer before each session. After soaking, feet should be thoroughly dried to prevent slipping, and participants are advised to have a companion nearby when standing up to avoid falls.~The intervention will be applied three times weekly, in the morning and evening, over a two-week period. Blood pressure measurements will be taken immediately before and at 0, 30, and 60 minutes after each session."
218887891|NCT07065071|OTHER|Mentalization-Based Therapy|Group MBT that takes place as part of treatment as usual within Derbyshire Healthcare NHS Foundation Trust's Older Adult Community Mental Health Team's service.
218887892|NCT07066904|DIAGNOSTIC_TEST|Standard echocardiography|Routine ultrasound examination with standardized recordings for the study, incorporating volumetric assessment techniques
218887893|NCT07066904|DIAGNOSTIC_TEST|2D phase-contrast magnetic resonance imaging|A cardiac MRI will be performed on a 1.5 Tesla system, including a biventricular function study with a series of short-axis slices, three long-axis slices, a 2D phase-contrast acquisition orthogonal to the aortic root. Additionally, standard T1 mapping sequences will be acquired on three short-axis slices, 15 minutes after the injection of 0.2 mmol/kg of body weight of gadolinium, for myocardial and blood T1 measurements.
218887894|NCT07066904|DIAGNOSTIC_TEST|4D flow magnetic resonance imaging|A sagittal 4D flow acquisition lasting between 6 and 10 minutes of free breathing to cover all four cardiac chambers is added to the 2D acquisition.
218887895|NCT07066904|DIAGNOSTIC_TEST|Cardiac ultrafast ultrasound imaging|Ultrafast sequences are added to the standard echocardiography acquisition.
218887896|NCT07066839|DIETARY_SUPPLEMENT|LipoMicel Chrysin|A maximum single oral dose of 1000 mg chrysin
218887897|NCT07066839|DIETARY_SUPPLEMENT|Non-Micellar Chrysin|A maximum single oral dose of 1000 mg chrysin
218887898|NCT07066839|DIETARY_SUPPLEMENT|Standard/Unformulated Chrysin|A maximum single oral dose of 1000 mg chrysin
218887899|NCT07067073|OTHER|Anti-Dynamic Line Cream|Topical cream (Formula# 899675 44A) applied to the full face and neck twice daily for 8 weeks. Participants apply 1 g each time in the morning and evening after cleansing, with massage on wrinkle-prone areas. Used after a 2-week wash-out period with standard skincare.
218887900|NCT07065539|DRUG|GnRH-a-1M|Pre-treatment with one dose GnRH agonist before endometrial preparation.
219031089|NCT07181304|BEHAVIORAL|PROMOTE|"PROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care.~1. Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months.~2. RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F.~3. A monthly report of peer support activities and RPM data will be sent to participants' primary care providers."
219202342|NCT06996743|OTHER|reformer pilates group|Reformer Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
219202343|NCT06996743|OTHER|Mat pilates group|Mat Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
219202344|NCT06996743|OTHER|Lifestyle change group|After the doctor's check-up, routine application continued. The patient was informed about physical activity. In addition; a physical activity-based brochure prepared by the Specialist Physiotherapist was distributed to the participants in this group.
219202345|NCT06993922|OTHER|Scalp block|Patients will receive a scalp block with bupivacaine alone.
219202346|NCT06993922|OTHER|Scalp block + Dexmedetomidine|Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.
219202347|NCT06996379|DEVICE|Experimental J-Tip Needle-Free Injection System|This experimental intervention arm will include use of the J-Tip needle-less device to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
219202348|NCT06996379|DEVICE|Control (Standard treatment)|The control intervention arm will include use of a 25-gauge needle (standard of care) to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
218887901|NCT07065539|DRUG|GnRH-a-2M|Pre-treatment with two doses GnRH agonist before endometrial preparation.
218887902|NCT07065539|DRUG|GnRH-a+LE-1M|Pre-treatment with one dose GnRH agonist, along with daily 2.5 mg letrozole for 28 days before endometrial preparation.
219202349|NCT06091332|DRUG|Sirolimus|Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
219202350|NCT06091332|DRUG|Starch flake|The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
219202351|NCT03338387|DRUG|Acipimox|Acipimox
219202352|NCT03338387|DRUG|Placebo|Placebo Other Names: Placebo (for Olbetam)
219202353|NCT05985395|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
219202354|NCT06864416|DRUG|dexmedetomidine as adjuvant to bupivacaine|the efficacy of addition of dexmedetomidine as adjuvants to bupivacaine in femorosciatic nerve block
219202355|NCT06864416|DRUG|Fentanyl as adjuvant to bupivacaine|the efficacy of addition of fentanyl as adjuvants to bupivacaine in femorosciatic nerve block
219202356|NCT06864442|PROCEDURE|Catgut Thread Embedding|Catgut Thread Embedding involved implanting chromic catgut size 4.0 thread, which is attached to a 23G guide needle, into subcutaneous tissue at EX-HN21 acupoint. The guide needle was removed after insertion, while the thread remained and dissolved over 10-15 days to provide continuous stimulation.
219202357|NCT06864442|PROCEDURE|Electroacupuncture|Electroacupuncture was administered using four needles (0.3 × 25 mm, diameter × length) inserted at GV-20, EX-HN21, external EX-HN12, and external EX-HN13 acupoints. Electrical stimulation was delivered via the KWD-808I Multipurpose Health Device (Changzhou Yingdi Electronic Medical Device Co., China) with parameters set at 3 Hz frequency and 0.6 ms pulse width, the intensity was adjusted according to the patient's perception. Electroacupuncture was performed daily, except on Saturdays, Sundays, and Vietnamese national holidays, over a treatment course of 30 days.
218887903|NCT07065539|DRUG|GnRH-a+LE-2M|Pre-treatment with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation.
218887904|NCT07066436|DRUG|MRI contrast-enhancing agents|"1. Ferumoxytol will be injected as an off-label MRI contrast agent at a dose of 4 mg/kg body mass. For safety (in accordance with prior research), ferumoxytol will be diluted 1:4 in saline, and administered slowly over at least 15 minutes, with patient monitoring during and post injection.~2. ImmunoMRI will be performed using an iron sensitive fat-suppressed, fast spoiled gradient echo T2\* mapping sequence. At each time point (i.e. pre-treatment and post-treatment), T2\* mapping will be performed before and \~24h after ferumoxytol injection."
218887905|NCT07065201|DEVICE|Mobile application for preoperative patient guidance|The mobile application provides patients with tailored information during the preoperative period until seven days after surgery. 1) Before the preoperative outpatient clinic visits, patient will receive information regarding the preoperative screening process and an overview of available anesthesia techniques through videos embedded in the app. 2) After approval for surgery and during the period leading up to the day of surgery, they will receive instructions concerning medication adjustment, lifestyle modifications, fasting rules, and hygiene measures.
219031090|NCT07181304|BEHAVIORAL|DSMES|Diabetes Self-Management Education and Support delivered virtually.
219031091|NCT07180940|DRUG|0.9%NaCl|2 x 20ml 0.2% ropivacaine with 2ml of 0.9% NaCl
219031092|NCT07180940|DRUG|Dexamethasone 4mg|2 x 20ml 0.2% ropivacaine with 2mg of dexamethasone
219031093|NCT07180940|DRUG|Dexmedetomidine|2 x 20ml 0.2% ropivacaine with 25ug Dexmedetomidine
219202358|NCT06864975|DRUG|Advate®|Non-daily dose FVIII 50IU/kg.QoD or 100IU/kg.QoD
219202359|NCT06864975|DRUG|Advate®|Daily dose FVIII 50IU/kg.QD or 100IU/kg.QD
219202360|NCT06864975|DRUG|Advate®|Low dose FVIII 50IU/kg.QD or 100IU/kg.QoD
219202361|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD
219202362|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD with immunosuppressant agent(s)
219202363|NCT06863805|DIAGNOSTIC_TEST|4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA|"For each patient enrolled in the present study, 4 EDTA tubes of peripheral blood will be collected to be used to obtain molecular profiling during scheduled laboratory controls as per normal clinical practice according to the following time schedule:~* T0 = basal collection before initiation of systemic treatment;~* T1 = sampling at 1 month after the start of systemic treatment;~* T2 = sampling at 3 months (+/- 1 month) after the start of systemic treatment at the first instrumental re-evaluation of disease;~* T3 = sampling at 6 months (+/- 1 month) from the start of systemic treatment at the time of instrumental disease reassessment;~* T4 = sampling at the time of evidence of instrumental disease progression within 24 months of treatment initiation.~The following analyses will be conducted on the samples thus collected:~* multigenic analysis on ccf-DNA and ccf-RNA at baseline, i.e., before the initiation of systemic treatment;~* isolation, counting and analysis of CTCs at baseline vi"
219031094|NCT07181330|DIAGNOSTIC_TEST|SE-SPTM-PCR microRNA assay|SE-SPTM-PCR (Selective Enrichment and Specific Probe Terminal Mediated PCR) is a microRNA-based diagnostic assay designed to detect hcmv-miR-UL22A-5p in human plasma. In this retrospective observational study, the assay is used on archived plasma samples collected from patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). The purpose is to evaluate the diagnostic performance of this method in identifying CMV reactivation, compared to standard CMV DNA qPCR testing. This test was not assigned or administered as part of patient care but is the primary focus of retrospective laboratory analysis.
219031095|NCT07180498|DRUG|Chlorhexidine Gluconate 0.12% Mouthwash|Participants will be prescribed to gargle with chlorhexidine, which is the routine recommendation after brushing their teeth 3 times a day for 7 days after the impacted tooth extraction.
219202364|NCT06865183|BEHAVIORAL|Positive Parenting Seminar Series|Selected Child Triple P Positive Parenting Seminar Series Delivered Through Telehealth
219202365|NCT06857669|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy and Photoacoustic imaging,|The photoacoustic imaging/diffuse reflectance spectroscopy techniques used in this study have a broader wavelength spectrum. The photoacoustic set-up can generate an optical and an ultrasound image simultaneously.
219202366|NCT06856239|OTHER|Graphene|The study follows an in-vitro experimental design with 76 specimens divided into two groups (conventional PMMA and G-PMMA). These samples will be further divided into two group, the one which undergo thermocycling (simulating oral temperature changes) and the other which don't undergo thermocycling. Flexural strength and modulus will be tested on all these by using a three-point bending test.
219507825|NCT03759769|OTHER|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
219507826|NCT03759769|OTHER|Video game|'Kart' driving video game
219507827|NCT03016182|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
219031096|NCT07180498|DRUG|Tea Tree Oil mouthwash|Participants will be prescribed to gargle with tea tree oil-containing water after brushing their teeth three times a day for 7 days following the extraction of an impacted tooth.
219507828|NCT03016182|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
219507829|NCT00638157|DRUG|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
219507830|NCT00638157|DRUG|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
219507831|NCT06252194|DRUG|Metformin and doxycycline|Metformin 500 mg tablet twice daily
219031097|NCT07181278|OTHER|Mobile unit with quasi point of care HPV testing and immediate triage + treatment|"A mobile team consisting of one or two midwives and a lab technician with a Genexpert platform visits the health centres on a regular basis.~After informed consent is granted, participants perform a vaginal self-sample, which is immediately analyzed with the Genexpert plateform. Participants who test HPV positive are invited for immediate triage and treatment if required."
219031098|NCT07181278|OTHER|Centralized screening|Self-collected samples are sent to a reference laboratory for HPV testing. Results are communicated to the participants and HPV positive women are invited to go to the reference centre where triage and treatment (when required) are performed.
219031099|NCT07181161|DRUG|AZD0516|AZD0516 will be administered via intravenous infusion.
219202367|NCT06860256|OTHER|Basic Body Awareness Therapy|"In TBFT sessions, physiotherapists improve the patient's contact with self by focusing on basic movement principles while performing simple daily movements such as lying, sitting, standing, walking, use of sound and massage. Mental awareness, postural balance and free breathing are considered key elements. The patient is invited to explore and integrate flow, rhythm and intentionality in coordinated movements in relation to time, space and energy. TBFT is practiced 2 days a week, 60 minutes, 5-12 weeks, depending on the patient."
219202368|NCT06860256|OTHER|High Intensity Interval Training|Tabata exercise protocol is an 8 repetition training program with 20 seconds of work and 10 seconds of rest. Warm-up and cool-down exercises of 5 minutes each should be done to prevent injuries and negativities. Although the application varies according to the patient, YŞİA is applied 2 days a week, 15-30 minutes, in processes ranging between 2-12 weeks.
219202369|NCT06860256|OTHER|Classic Exercise and Lifestyle Tips|Classical Exercise (CE) and Lifestyle Recommendations (LSR), Classical exercises used in PD include abdominal, pelvic floor muscles, hip flexors, whole body stretching. Non-pharmaceutical strategies for pain management in LRS include adopting relaxation (rest, warm-up, massage, music, etc.), antalgic positions, and distraction techniques. Common techniques that facilitate relaxation and thus reduce pain include physical rest, hot showers, various heat applications such as thermal seed bags, electric blankets, and drinking hot herbal teas such as chamomile tea.
219031100|NCT07181161|DRUG|AZD9574|AZD9574 will be administered orally.
219031101|NCT07181382|DRUG|Placebo|Matching capsule containing placebo
219031102|NCT07181382|DRUG|Seralutinib|Capsule containing seralutinib
219031103|NCT07181382|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
219031104|NCT07181564|DRUG|Propofol / Remifentanil|Maintenance of general anesthesia with propofol and remifentanil; no ketamine or magnesium administered.
219031105|NCT07181564|DRUG|Ketamine + Magnesium sulfate (drug combination)|Continuous intraoperative infusion per protocol.
219202370|NCT06672315|DIAGNOSTIC_TEST|transesophageal echocardiography|Confirmation of chest compression positioning via transesophageal echocardiography (TEE)
219607906|NCT06894849|BEHAVIORAL|Text-based depression screening|Starting 1 week prior to the scheduled clinic appointment, patients will receive a text message invitation from HCC to complete depression screening. Participants will be asked to click to continue to the screening PHQ-2. For text message screening cadence, reminder texts will be sent daily for 3 days. Those who screen positive (PHQ-2 \>/= 3) will complete the remainder of the items (i.e., PHQ-9).
219607907|NCT06894849|BEHAVIORAL|Usual care (UC)|Usual care (UC) will consist of in-person assessment of depression using a validated brief screening tool (e.g., PHQ-2) synchronous with a clinical encounter with the outpatient oncology team. Although the person completing the screening (e.g., nurse, medical assistant) and other workflow may vary slightly across settings, the 2-items are generally presented orally to the patient during routine intake for a clinical encounter and entered into the EHR. Patients who screen positive will be asked to complete the full PHQ-9.
219507832|NCT02649231|DRUG|Ketamine|0.8 mg/kg ketamine
219507833|NCT02649231|DRUG|Placebo|0.9% saline
219607908|NCT04186039|DIAGNOSTIC_TEST|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
219031106|NCT07181564|DRUG|Sevoflurane and Remifentanil|Continuous intraoperative infusion per protocol.
219607909|NCT06964009|DRUG|DT2216|A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.
219031107|NCT07181759|PROCEDURE|VISOR|Surgery will be performed using the VISOR through a 14Fr UAS
219031108|NCT07181759|PROCEDURE|fURS|Surgery will be performed using a standard single-use electronic ureterorenoscope through a 14Fr UAS
219031109|NCT07181096|DIAGNOSTIC_TEST|assessment of frailty|"This study is a prospective cross-sectional study to assess the prevalence of frailty among 80 cases of renal transplanted patients.~Specific tests will include:~1. Assessment of frailty by Clinical Frailty Scale.~2. Assessment of nutritional status using Patient Generated Subjective Global Assessment (PG-SGA).~3. Comorbidity assessment using Charlson comorbidity score.~4. Six minutes walk test.~5. Muscle strength assessment using hand grip strength (HGS) dynamometer."
219031110|NCT07180745|DRUG|Pioglitazone (PIO)|30 mg orally once daily
219031111|NCT07180745|DRUG|Empagliflozin|10 mg orally once daily
219031112|NCT07180745|DRUG|Statin (Atorvastatin)|20 mg orally once daily
219507834|NCT02649231|BEHAVIORAL|Psychological Therapy|Manualised relapse prevention based CBT
219507835|NCT02649231|BEHAVIORAL|Alcohol Education|Simple education about alcohol effects
219507836|NCT00280787|DRUG|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
219507837|NCT00280787|DRUG|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
219507838|NCT00280787|DRUG|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
219507839|NCT00280787|DRUG|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
219507840|NCT00280787|RADIATION|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
219607910|NCT06964009|DRUG|Paclitaxel|An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.
218887906|NCT07065201|DEVICE|Mobile application and standard care|Patients in the control group will be asked to download the same mobile app but they will not receive the same tailored information as those in the intervention group. Instead, they will be provided with standard preoperative information and instructions. In addition, they will be asked to fill out the same questionnaire as the intervention group.
218887907|NCT07065786|OTHER|Generative model|Prospectively enroll pretreatment imaging data from patients with unresectable hepatocellular carcinoma undergoing TACE in combination with immunotherapy plus targeted therapy. Utilize a generative model to create virtual images that represent optimal treatment responses, and compare these virtual images with actual treatment response images collected during follow-up to evaluate the reliability of the generative model.
218887908|NCT06900205|DRUG|Esketamine|loading dose:intravenous infusion of 0.25mg/kg esketamine after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail+1mg/kg esketamine diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
218887909|NCT06900205|DRUG|0.9 % saline|loading dose:intravenous infusion the same volume of 0.9% saline as the other group after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
219031113|NCT07180745|DRUG|Empagliflozin plus Statin (Atorvastatin)|Orally once daily of each (10 mg, 20 mg respectively)
219507841|NCT01871987|DRUG|FK949E|oral
219031114|NCT07180745|DRUG|Pioglitazone plus Atorvastatin|Orally once daily of each (30mg and 20mg respectively)
219031115|NCT07180251|BEHAVIORAL|CARE program|The CARE program is an 8-week intervention using reflection assisted with CGM. The Abbott factory-calibrated Freestyle Libre Flash Glucose Monitoring (Freestyle Libre 2) system will be used to evaluate glycemic variability.
219507842|NCT04370145|DRUG|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
219507843|NCT04370145|DRUG|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
219607911|NCT05645861|PROCEDURE|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
219031116|NCT07180251|OTHER|Usual Care|Usual care means the participants will receive care from their primary care physicians and nurses during clinic visits at the surgical OPD.
219031117|NCT07179939|DRUG|Trastuzumab rezetecan|Trastuzumab rezetecan is a lyophilized powder for injection intravenously. Administered according to label.
219031118|NCT07179939|DRUG|Pyrotinib|320 mg/d, q.d., p.o. A course of treatment need 21 days.
219031119|NCT07179939|DRUG|Dalpiciclib|125 mg/d, q.d., p.o. day 1-21, every 28 days.
219031120|NCT07179939|DRUG|Trastuzumab|Administered according to label.
219031121|NCT07179939|DRUG|ET: Letrozole/ Anastrozole/ Exemestane/ Fulvestrant/ Leuprorelin/ Goserelin.|Administered according to label.
219031122|NCT07180082|DRUG|Pyrotinib|anti-HER2 tyrosine kinase inhibitor
219031123|NCT07180511|DRUG|10mg QY201 Placebo tablet|10mg QY201 Placebo tablet
219031124|NCT07180511|DRUG|20mg QY201 Placebo tablet|20mg QY201 Placebo tablet
219031125|NCT07180511|DRUG|10mg QY201 tablet|10mg QY201 tablet
219031126|NCT07180511|DRUG|20mg QY201 tablet|20mg QY201 tablet
219031127|NCT07181863|BEHAVIORAL|Health coaching|Health coaching is the active component of TECC-DM. In weekly 1-hour sessions, the coach builds a therapeutic relationship, supports goal-setting and behaviour change, addresses mental health needs, coordinates resources, and empowers participants to navigate care. Coaching is delivered according to a standardized protocol, in consultation with the virtual care team, and targets improvements in quality of life and goals of care. Coaches do not provide pharmacological treatment or replace usual diabetes care.
219031128|NCT07181863|OTHER|Educational emails|Participants receive usual diabetes care (e.g., primary care, endocrinology, community supports) plus 10 standardized educational emails over 12 weeks, delivered according to a consistent protocol. Unlike TECC-DM, this approach does not involve a therapeutic relationship, health coach, or interdisciplinary care team.
219031129|NCT07180043|BEHAVIORAL|Structured Behavioral Therapy|Structured patient education, lifestyle modification counseling, and headache diary maintenance without pharmacological prophylaxis.
219031130|NCT07180043|DRUG|Propranolol|Oral propranolol, 1-3 mg/kg/day in two divided doses, titrated according to response, for 12 weeks.
219031131|NCT07180095|DRUG|Intranasal dexmedetomidine|intranasal dexmedetomidine 2mcg/kg
219031132|NCT07180095|DRUG|Intranasal ketamine|intranasal ketamine 2mg/kg
219031133|NCT07179835|PROCEDURE|Full pulpotomy in adults ≥18 years with restorable mandibular first or second molars diagnosed with irreversible pulpitis, with or without apical periodontitis.|Comparison of full pulpotomy with MTA in teeth with and without apical periodontitis
219031134|NCT07179679|DRUG|TQB2934 injection (subcutaneous injection)|TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody，and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
219507844|NCT04370145|DRUG|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
219507845|NCT06527092|DEVICE|Virtual Reality|VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems
219507846|NCT06527092|DEVICE|Bubbles|A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
219507847|NCT01801696|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
218887910|NCT07065162|OTHER|Subtle Touch Technique|3 cycles of ACBT along with subtle touch technique for 15 minutes 3 times daily for 8 weeks, in addition to the standard COPD care and medication.
218887911|NCT07065162|OTHER|Active Cycle of Breathing Technique|3 cycles of ACBTs technique for 15 minutes 3 times daily for 8 weeks, along with standard COPD care and medication.
219202371|NCT06864286|BEHAVIORAL|Move for Health|"This multi-domain health promotion intervention utilizes the Community-Based Health Promotion Program for Older Adults - Healthy Exercise Class developed by the Health Promotion Administration (Taiwan). This intervention emphasizes a multi-dimensional health approach, focusing on healthy aging, exercise, and cognitive interventions, supplemented by elements of oral health, nutrition, and social participation. The program aims to promote older adults' health self-management capabilities. This 12-week program meets once weekly for two hours per session. Healthy aging curriculum covers important health issues for older adults, such as fall prevention, healthy eating, oral health, vision care, dementia prevention, medication safety, and knowledge related to healthy lifestyle behaviors including home-based exercise."
219202372|NCT06017973|DIAGNOSTIC_TEST|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
218887912|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
218887913|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
218887914|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
218887915|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
218887916|NCT06772064|DRUG|Rifaximin (drug)|Rifaximin 0.4g bid for 2 weeks
218887917|NCT05715242|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
218887918|NCT05715242|BEHAVIORAL|Easier Step Goal|Participants will receive an easier daily step goal.
218887919|NCT05715242|BEHAVIORAL|Harder Step Goal|Participants will receive a more challenging daily step goal.
218887920|NCT05715242|BEHAVIORAL|Easier Calorie Goal|Participants will receive an easier daily calorie goal.
218887921|NCT05715242|BEHAVIORAL|Harder Calorie Goal|Participants will receive a more challenging daily calorie goal.
219202373|NCT06017973|DIAGNOSTIC_TEST|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
218887922|NCT05715242|BEHAVIORAL|Easier Eating Window Goal|Participants will receive an easier daily eating window goal.
218887923|NCT05715242|BEHAVIORAL|Harder Eating Window Goal|Participants will receive a more challenging daily eating window goal, akin to time-restricted eating.
219031135|NCT07181629|OTHER|Control|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months).
219031136|NCT07181629|BEHAVIORAL|Dysphagia Management Education|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months). The intervention group received dysphagia management training after the questionnaires were administered at the first meeting.
219031137|NCT07179926|DIAGNOSTIC_TEST|morphometric spine radiography|Patients already on treatment with Pasireotide LAR or Pegvisomant will be evaluated using morphometric spine radiography and lumbar and femoral densitometry. Patients will undergo a 1-year follow-up.
219031138|NCT07179653|DRUG|TVAX-008|TVAX-008
219202374|NCT06017973|DIAGNOSTIC_TEST|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
219202375|NCT05217680|BIOLOGICAL|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
219202376|NCT05217680|BIOLOGICAL|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
219202377|NCT04439032|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
219202378|NCT03298178|PROCEDURE|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
218887924|NCT05715242|BEHAVIORAL|Easier Red Zone Food Goal|Participants will receive an easier daily Red Zone Food goal.
218887925|NCT05715242|BEHAVIORAL|Harder Red Zone Food Goal|Participants will receive a more challenging daily Red Zone Food goal.
218887926|NCT06661798|PROCEDURE|orthognathic surgery|Mandibular setback, Maxillary advancement, Bilateral sagital split osteotomy
218887927|NCT06661798|PROCEDURE|USG examination|Comparison of blood flow in the mental foramen before and 1week, 1 month and 3 month after orthognathic surgery using ultrasound examination
219031139|NCT07179653|DRUG|Placebo|Placebo
219031140|NCT07181603|BEHAVIORAL|Resilience Enhancement Training Program|A structured 10-week behavioral training program designed to improve resilience and reduce perceived stress among nursing students. The program includes 10 sessions covering self-awareness, self-regulation, stress and coping strategies, cognitive restructuring, self-compassion, gratitude practice, optimism training, self-esteem, and a wrap-up with evaluation. Each session aims to strengthen coping skills and psychological adaptability.
219031141|NCT07181681|DRUG|BG-C0902|Administered by intravenous infusion
218887928|NCT06661798|PROCEDURE|Subjective evaluation - Neuro-sensitivity tests|Direction determination, two-point separation, pinprick, and brush tests, along with neurosensitivity VAS and pressure VAS, were applied to the patients. These tests were performed before surgery (T0), seven days after surgery (T1), one month after surgery (T2), and three months after surgery (T3).
219202379|NCT03298178|PROCEDURE|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
219202380|NCT06371261|OTHER|Biological analyses|"A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion.~The micro-organisms will be quantified.~The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021)."
219202381|NCT06675240|BEHAVIORAL|MediNF|Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
219202382|NCT05361980|DEVICE|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
219031142|NCT07180888|DIAGNOSTIC_TEST|Echocardiography|diastolic dysfunction in ESKD in hemodialysis by echocardiography
219202383|NCT06862518|DRUG|Control group|Patients will receive general anesthesia alone
219202384|NCT06862518|DRUG|Serratus Anterior Plane Block (SAPB) group|Patients will receive general anesthesia (GA) with ultrasound guided serratus anterior plane block 0.5 ml/kg 0.25% bupivacaine.
219202385|NCT06862518|DRUG|Erector Spinae Plane Block (ESPB) group|Patients will receive general anesthesia (GA) with ultrasound guided erector spinae plane block 0.5 ml/kg 0.25% bupivacaine
219202386|NCT06862284|DRUG|Upadacitinib (ABT-494)|Upadacitinib 15mg Qd for 52 weeks
219202387|NCT06862284|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine 200mg Bid for 52 weeks
219202388|NCT05977751|DEVICE|FemBloc|Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
219202389|NCT05003583|BEHAVIORAL|Speaking after viewing pictures with negative and neutral valence|"Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations."
219202390|NCT06677385|RADIATION|diode laser as adjunctive to conventional scaling and debridement|diode laser as adjunctive to conventional scaling and debridement for old age patients
219202391|NCT06677385|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
219507848|NCT01801696|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
219507849|NCT01982487|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
219507850|NCT01982487|DRUG|IDO1 inhibitor INCB024360|Given PO
219507851|NCT01982487|OTHER|laboratory biomarker analysis|Correlative studies
219507852|NCT01982487|OTHER|pharmacological study|Correlative studies
219507853|NCT01077206|DRUG|Simvastatin|80mg daily versus 40mg daily, for 21 days.
219507854|NCT05303142|OTHER|Heat Tolerance Assessment|60-90 minutes exercise in hot (34 °C; 45% R.H.) conditions at 60%VO2max
219507855|NCT01387100|BEHAVIORAL|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
219507856|NCT04025385|OTHER|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
219507857|NCT00939133|DRUG|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
219507858|NCT00939133|DRUG|vehicle gel|Placebo
219507859|NCT03393442|DIAGNOSTIC_TEST|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
219507860|NCT01799733|OTHER|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
219507861|NCT01799733|OTHER|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
219507862|NCT03158259|OTHER|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
219507863|NCT04905979|DRUG|AD113|Two oral capsules administered before bed
219031143|NCT07180888|DIAGNOSTIC_TEST|Echocardiographic assessment of diastolic dysfunction|non invasive transthoracic echocardiography including doppler and tissue doppler imaging will be used to assess left ventricular diastolic dysfunction parameters in hemodialysis patient
219031144|NCT07181265|DRUG|Amiodarone Hydrochloride Tablets|Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone
219031145|NCT07181265|DRUG|Febuxostat Tablets|Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets
219031146|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
219031147|NCT03392116|BIOLOGICAL|NGM120|Subcutaneous Injection
219031148|NCT03392116|OTHER|Placebo|Subcutaneous Injection
219031149|NCT00004888|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
219031150|NCT00004888|DRUG|docetaxel|Given IV
219507864|NCT04905979|DRUG|Atomoxetine|Two oral capsules administered before bed
219507865|NCT01214330|DEVICE|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
219507866|NCT02689895|OTHER|modified directly administered anti-retroviral therapy (mDAART)|As described before
219507867|NCT04965610|OTHER|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
219507868|NCT04965610|OTHER|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
219507869|NCT02140489|DRUG|amosartan|
219507870|NCT02140489|DRUG|rosuvastatin|
219507871|NCT02140489|DRUG|amosartan and rosuvastatin|
218887929|NCT07066085|DEVICE|Serial Blood Count Study|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
219031151|NCT00004888|BIOLOGICAL|trastuzumab|Given IV
219031152|NCT00004888|OTHER|laboratory biomarker analysis|Correlative studies
219031153|NCT02579265|DRUG|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
219031154|NCT02579265|DRUG|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
219031155|NCT03087968|DRUG|GS-4997|Experimental drug
219031156|NCT03087968|DRUG|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
219031157|NCT03087968|DEVICE|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
219031158|NCT03087968|DRUG|Placebo|Placebo
219031159|NCT02174848|DRUG|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
219031160|NCT02229318|DIETARY_SUPPLEMENT|FruitiVits|Daily administration of FruitiVits dietary supplement
219031161|NCT04230837|DEVICE|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
219031162|NCT02799758|DRUG|NK-104-CR|NK-104-CR 8 mg for 52 weeks
219031163|NCT02799758|DRUG|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
219031164|NCT02799758|DRUG|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
219031165|NCT02799758|DRUG|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
219031166|NCT00615277|DIETARY_SUPPLEMENT|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
219031167|NCT05279586|DRUG|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
219031168|NCT05279586|DRUG|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
219031169|NCT04881357|OTHER|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
219031170|NCT04881357|OTHER|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
219031171|NCT00644969|DRUG|placebo|Randomization 2:1 treatment to placebo
219031172|NCT00644969|DRUG|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
219507872|NCT02419482|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
219507873|NCT02419482|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
219507874|NCT00841256|BIOLOGICAL|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
219507875|NCT00841256|DRUG|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
218887930|NCT07066085|DEVICE|Athelas Home device|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
218887931|NCT06906185|BEHAVIORAL|Calm Moms-V|Calm Moms-V is the trauma-informed treatment developed and refined by the PI and being tested in the current study. Calm Moms-V is an online treatment program for trauma-exposed pregnant Veterans designed to target anxiety, stress, low mood, and trauma-related symptoms using empirically supported CBT techniques. Calm Moms-V includes four sessions and a booster session closer to delivery/postpartum. Sessions 1-4 are designed to be completed across four weeks (one session delivered each week). Each session is self-paced and designed to take approximately 45 minutes to complete.
219507876|NCT05105711|BEHAVIORAL|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
219507877|NCT05350098|OTHER|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
219507878|NCT05350098|OTHER|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
219507879|NCT00496106|BEHAVIORAL|Telephone counseling|6 telephone counseling sessions
219507880|NCT00496106|BEHAVIORAL|Telephone interview|telephone interview
219507881|NCT01504828|DRUG|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
219507882|NCT05664750|DRUG|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
219507883|NCT05664750|DRUG|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
219507884|NCT01996176|BEHAVIORAL|Intervention group|"The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
219507885|NCT01996176|BEHAVIORAL|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
219031173|NCT04226066|BIOLOGICAL|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
219031174|NCT04226066|COMBINATION_PRODUCT|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
219031175|NCT05430490|PROCEDURE|MRI|Multimodal neuroimaging on 3T Prisma Fit MRI
219031176|NCT05430490|OTHER|NeuroPsychological Testing|A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
219031177|NCT05430490|PROCEDURE|Blood Draw|Laboratory reports (CMP, CBC, Lipids)
219031178|NCT05430490|OTHER|Questionnaires|Life history, current behaviors, and substance use surveys
219031179|NCT05430490|PROCEDURE|Lumbar Puncture|Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
219031180|NCT04998591|BEHAVIORAL|Fasting|fasting for 7 days (caloric intake \<500 kcal in liquid form)
219031181|NCT05883904|DRUG|Fedratinib|Fedratinib administered after AIFA reimbusement approval
219031182|NCT01302574|DIETARY_SUPPLEMENT|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
219031183|NCT02515942|DRUG|CLG561|
219031184|NCT02515942|DRUG|LFG316|
219031185|NCT02515942|DRUG|Sham injection|Empty syringe (without a needle) placed against the eye
219031186|NCT00654277|DRUG|Ondansetron|ODT, 8 mg, single-dose
219031187|NCT00654277|DRUG|Zofran|ODT, 8 mg, fasting conditions
219031188|NCT00919399|DRUG|Exemestane|25mg a day during 4 months
218887932|NCT06906185|BEHAVIORAL|Care As Usual|"The control condition will be Care As Usual (CAU). CAU at SLVHCS involves participation in available services chosen by the patient with input from their providers. Further, for all pregnant Veterans that use VHA maternity benefits, CAU includes routine phone calls (throughout pregnancy and up to one-year postpartum) conducted by the site MCC to coordinate maternity benefits, facilitate additional services, and arrange for specific supplies (e.g., breast pump). Further, the SLVHCS MCC mails each pregnant Veteran enrolled in VHA a welcome packet that includes national, local, and VHA MH and physical health resources that may be useful to them during the perinatal period. Veterans in the CAU condition will be assessed at the same intervals as those in the active condition."
218887933|NCT06903936|OTHER|Group 1: GNB (GENICULAR NERVOUS NERVOUS BLOCK) group:|6 ml of solution consisting of 5 ml 2% lidocaine hydrochloride and 1 ml 40 mg triamcinolone acetonide will be injected equally into the superomedial, inferomedial and superolateral genicular nerve branches using a 23G (0.6\*60mm) needle under ultrasound guidance.
218887934|NCT06903936|OTHER|Group 2: PT (PHYSICAL THERAPY) group|Group 2: PT (PHYSICAL THERAPY) group: In the PT group, all interventions will be performed with the patient supine and knees in extension. First, superficial heating will be applied using a hotpack for 20 minutes, followed by therapeutic ultrasound in continuous mode at a frequency of 1 MHz and 1.5 Watt/cm2 for 5 minutes to achieve deep thermal effects. Then traditional transcutaneous electrical nerve stimulation (TENS) will be applied for 15 minutes for a total of 15 sessions.
218887935|NCT06903936|OTHER|Group 3: Exercise group|Group 3: Control group: For 3 weeks, exercise therapy will be applied by the patient. Knee range of motion exercises, quadriceps strengthening exercises, hamstring stretching exercises will be taught to the patients by the doctor and they will be asked to do them every day, 2 times a day, 10 repetitions for a total of 3 weeks. The use of NSAIDs will be restricted during the treatment period.
219031189|NCT00919399|DRUG|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
219031190|NCT01901003|DRUG|Lorazepam|
219031191|NCT01901003|OTHER|no premedication|
219031192|NCT01901003|DRUG|Placebo (microcrystalline celluloses)|
219202392|NCT06677606|PROCEDURE|PENG block|The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle
219507886|NCT04222322|DEVICE|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
219202393|NCT06677606|PROCEDURE|PAI block|LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
219202394|NCT06676982|BIOLOGICAL|anti-CD19 CAR-T|All subjects were intravenous administrated with CNCT19 CAR-T.
219202395|NCT06878729|PROCEDURE|CTO PCI using ADR strategy|CTO recanalization using ADR performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
219202396|NCT06878729|PROCEDURE|CTO PCI using retrograde strategy|CTO recanalization using retrograde approach performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
219202397|NCT03851640|DRUG|HC-1119|oral
219607912|NCT04204915|PROCEDURE|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
218887936|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
218887937|NCT06913075|DRUG|GnRH agonist downregulation|Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval
219031193|NCT02200848|DRUG|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
219202398|NCT03851640|DRUG|placebo|oral
219507887|NCT04222322|OTHER|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
219507888|NCT01730859|OTHER|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
219507889|NCT01055444|DRUG|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
218887938|NCT06913075|DRUG|GnRH agonist and Letrozole|Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts
218887939|NCT06917014|PROCEDURE|360°|reset the proximal and distal part of the niche, widely 360° coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
219202399|NCT06858228|PROCEDURE|Continuous Ablative Radiofrequency|Continuous ablative radiofrequency is a minimally invasive neuroablative procedure that targets the sensory genicular nerves to manage pain in knee osteoarthritis. Under ultrasound guidance, a radiofrequency probe is inserted percutaneously near the target nerves. The procedure delivers continuous thermal energy at 80°C for 120 seconds, creating a controlled lesion that disrupts pain signal transmission. This technique is distinct from pulsed radiofrequency, as it aims for permanent nerve ablation rather than neuromodulation. The expected outcome is prolonged pain relief and improved function in patients with chronic knee osteoarthritis refractory to conservative treatments.
219202400|NCT06858228|DRUG|Chemical Denervation with Absolute Alcohol|Chemical denervation with absolute alcohol is a minimally invasive neurolytic procedure targeting the sensory genicular nerves to manage chronic knee osteoarthritis pain. Under ultrasound guidance, a percutaneous injection of absolute alcohol 66% is administered near the targeted nerves. The neurolytic effect of alcohol induces axonal degeneration and Wallerian degeneration, leading to prolonged disruption of pain signal transmission. This intervention differs from radiofrequency ablation as it achieves chemical neurolysis rather than thermal ablation, with potential for a distinct duration of analgesia and varying nerve regeneration patterns. The expected outcome is long-lasting pain relief and improved function in patients with knee osteoarthritis who have not responded to conservative treatments.
219202401|NCT06859411|PROCEDURE|visual acuity comparaison|Data collection
219202402|NCT06054906|DRUG|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
219202403|NCT01211964|DRUG|LEO 22811|Oral administration of solution and tablet.
219202404|NCT06536764|OTHER|Progressive Muscle Relaxation Exercises|Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .
219202405|NCT06536764|OTHER|Conventional Therapy(Hot pack,TENS,Patient Education)|Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
219202406|NCT06094413|BEHAVIORAL|Multicomponent Training Intervention|The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
219202407|NCT06334523|DEVICE|Ventilation with Dead Space Washout via Continuous Tracheal Gas Insufflation (CTGI)|"The intervention involves adding a device which allows CTGI (the CTGI-device) to washout the dead space in preterm mechanically ventilated infants. Dead space washout using the CTGI-device is an option added to standard ventilation, to reduce or even cancel anatomical dead space due to respiratory prostheses in intubated preterm infants."
219202408|NCT05520749|DRUG|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
219202409|NCT04559685|COMBINATION_PRODUCT|SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
219202410|NCT04559685|DEVICE|MR-Guided Focused Ultrasound device (MRgFUS)|MR-Guided Focused Ultrasound device (MRgFUS) alone
219507890|NCT04164485|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
219507891|NCT04164485|BIOLOGICAL|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
219507892|NCT00001128|DRUG|Interleukin-12|
218887940|NCT06917014|PROCEDURE|traditional|reset the proximal part of the niche, and coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
218887941|NCT03265457|OTHER|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
218887942|NCT06917989|OTHER|Relaxation Exercise|Jacobson muscle relaxation technique
218887943|NCT06917989|OTHER|Virtual Reality Application|Virtual Reality Application will be done using virtual reality glasses
219031194|NCT02134873|OTHER|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
219031195|NCT02597556|DRUG|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
219507893|NCT00001128|DRUG|Paromomycin sulfate|
219507894|NCT00001128|DRUG|Azithromycin|
219507895|NCT03842371|OTHER|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
219507896|NCT00686036|DRUG|vandetanib|300 mg orally, once daily for up to 18 months
219507897|NCT00686036|DRUG|Placebo|
219031196|NCT02597556|DRUG|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
219507898|NCT00674180|BEHAVIORAL|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
218887944|NCT06917989|OTHER|Patient Education|Participants will be informed about oral care, food consumption, nutrition and sleeping position.
218887945|NCT06919380|DRUG|MSC-exos Nebulization Therapy|"The intervention in this study, Nebulized MSC-exos for Anti-MDA5+ RP-ILD Treatment, is distinguished by its use of mesenchymal stem cell-derived exosomes (MSC-exos) for direct pulmonary delivery via nebulization. This targeted approach aims to modulate immune responses and reduce inflammation specific to lung diseases, offering a novel therapeutic strategy. This method stands out for its potential to provide a safer and more effective treatment for RP-ILD compared to traditional therapies."
218887946|NCT06922344|DRUG|Fluconazole|Oral fluconazole prescribed to group A
218887947|NCT06922344|DRUG|Itraconazole|Oral itraconazole prescribed to Group B
218887948|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
218887949|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
219031197|NCT00666757|DRUG|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
219031198|NCT00666757|DRUG|fluoxetine|20-80 mgs orally daily for 12 weeks
219031199|NCT00666757|DRUG|citalopram|20-40 mgs orally daily for 12 weeks
219031200|NCT00666757|DRUG|paroxetine|20-50 mgs orally daily for 12 weeks
219031201|NCT00666757|DRUG|sertraline|50-200 mgs orally daily for 12 weeks
219031202|NCT06312878|OTHER|Describe the anatomy of the IVC in the case of an anatomical variant|Evaluated technique by collecting data from the medical record.
219031203|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
219031204|NCT06517147|DEVICE|Cryogenx cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
219031205|NCT06517147|DEVICE|Regular cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
219031206|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
219031207|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
219031208|NCT01231581|DRUG|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
219031209|NCT01231581|DRUG|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
219031210|NCT01231581|DRUG|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
219031211|NCT00889954|BIOLOGICAL|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
219031212|NCT00576277|DRUG|AV411|
219031213|NCT05855564|BEHAVIORAL|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
219031214|NCT02142686|DEVICE|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
219031215|NCT02142686|DEVICE|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
219507899|NCT00674180|BEHAVIORAL|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
219031216|NCT02142686|DEVICE|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
219031217|NCT04426565|BEHAVIORAL|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
219202411|NCT05178056|DEVICE|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
219202412|NCT05178056|OTHER|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
219202413|NCT06678971|OTHER|FIFA 11+|The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system.
219202414|NCT06678971|OTHER|Basket-Up|"The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. Like the FIFA 11+ program, it is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes.~Phase 1 includes three exercises aimed at improving mobility. Phase 2 features six exercises focused on strength, direction changes, and plyometric activities. Phase 3 consists of six exercises designed to enhance agility and neurocognitive skills."
219202415|NCT06547346|DIETARY_SUPPLEMENT|Alfamino Junior|To recruit 15 children and evaluate the acceptability (including gastrointestinal tolerance), palatability and compliance of a hypoallergenic amino acid powdered formula (neutral and vanilla flavours) with HMO's for the dietary management of presumed cows' milk allergy, multiple food protein allergies and other conditions where an amino acid formula is recommended in children ≥1 year of age.
219507900|NCT00674180|BEHAVIORAL|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
219202416|NCT05656742|DIETARY_SUPPLEMENT|Vitamin D|oral vitamin D3
219507901|NCT00294424|PROCEDURE|Short waiting time|
219507902|NCT00294424|PROCEDURE|Non-fixed waiting time|
219507903|NCT02972411|BEHAVIORAL|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
219507904|NCT02972411|DRUG|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
219507905|NCT03676374|DRUG|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
219507906|NCT03676374|DRUG|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
219507907|NCT01927081|BEHAVIORAL|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
219507908|NCT01927081|BEHAVIORAL|gentle exercise|Patients learn gentle exercise and breathing techniques
219507909|NCT02261571|OTHER|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
219507910|NCT00891878|DRUG|capecitabine|Given orally
219507911|NCT00891878|DRUG|sunitinib malate|Given orally
219507912|NCT04899856|DEVICE|TransAeris|TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
219507913|NCT01478633|DRUG|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
219507914|NCT02251587|OTHER|Standard Weight Management Program|Standard Diet program based on diet and exercise.
219507915|NCT02251587|OTHER|Sensible Weigh Program|Weight loss program designed for low income women.
219507916|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
219507917|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
219507918|NCT05178589|DEVICE|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
219507919|NCT05178589|DEVICE|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
219507920|NCT05928000|DRUG|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
219507921|NCT00258973|PROCEDURE|Carotid Ultrasound performed in office practice|
219507922|NCT00492206|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
219507923|NCT01199601|BEHAVIORAL|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
219507924|NCT03107949|DEVICE|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
219507925|NCT00036413|DRUG|TCH346|
219507926|NCT01842048|OTHER|Hyperthermia|
219507927|NCT01842048|RADIATION|External-beam radiotherapy|
219507928|NCT05235308|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
218887950|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
219507929|NCT03120156|DEVICE|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
219507930|NCT03120156|DEVICE|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
219507931|NCT03120156|OTHER|No insoles|control group with no insoles in the shoes
218887951|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
218887952|NCT02915978|DRUG|Fentanyl|Fentanyl delivered via sublingual spray
218887953|NCT02915978|DRUG|Placebo|Matching placebo delivered via sublingual spray
218887954|NCT03605914|DRUG|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
219031218|NCT04426565|BEHAVIORAL|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
219031219|NCT04426565|BEHAVIORAL|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
219031220|NCT04426565|BEHAVIORAL|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
219031221|NCT03647540|PROCEDURE|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
219031222|NCT03647540|PROCEDURE|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
219031223|NCT04512248|BEHAVIORAL|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
219031224|NCT03897400|OTHER|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
219031225|NCT01995695|BIOLOGICAL|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
219031226|NCT01995695|BIOLOGICAL|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
219202417|NCT04936620|PROCEDURE|Duroplasty|Expansion Duroplasty
219202418|NCT04936620|PROCEDURE|Spinal surgery|Spinal surgery including laminectomy
219507932|NCT03830528|DRUG|KW-6356 Low Dose|KW-6356 will be administered as single doses.
219507933|NCT03830528|DRUG|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
219507934|NCT03830528|DRUG|KW-6356 High Dose|KW-6356 will be administered as single doses.
219507935|NCT03830528|DRUG|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
219507936|NCT03830528|DRUG|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
219507937|NCT03830528|DRUG|Placebo|All study cohorts (except Part C) are placebo controlled.
219507938|NCT00788619|PROCEDURE|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
219507939|NCT00788619|PROCEDURE|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
219507940|NCT00314379|DRUG|Vitamin E 400IU/day|
219507941|NCT01960933|PROCEDURE|Percutaneous coronary intervention|
219507942|NCT01960933|PROCEDURE|FFR|
219507943|NCT02410148|DEVICE|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
219507944|NCT02669264|DRUG|ADCT-402|Intravenous infusion
219607913|NCT05355532|GENETIC|different variants of SNPs that may be associated with the coronary microvascular obstruction development|Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
219607914|NCT06311721|DRUG|ABP 234|Intravenous administration
219202419|NCT06866522|DEVICE|Whole-body Photobiomodulation Therapy|Whole-body Photobiomodulation Therapy applied for approximately 10 minutes, being 5 minutes with the red wavelength and 5 minutes with the infrared wavelength.
219202420|NCT05815043|BEHAVIORAL|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
219202421|NCT05815043|DIETARY_SUPPLEMENT|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
219202422|NCT06085131|DEVICE|Argos|Argos Biometer
219507945|NCT02521675|BEHAVIORAL|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
219507946|NCT02521675|BEHAVIORAL|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90min after lunch These activities shall not exceed one hour"
219507947|NCT02521675|BEHAVIORAL|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
219607915|NCT06311721|DRUG|Pembrolizumab (US)|Intravenous administration
219607916|NCT06311721|DRUG|Pembrolizumab (EU)|Intravenous administration
219607917|NCT06443567|DEVICE|impedance threshold device|impedance threshold device (ResQPOD, Zoll) applied to airway
219507948|NCT02521675|DEVICE|Holter Glycemic Ipro2, Medtronic|
218887955|NCT03605914|DRUG|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
218887956|NCT03262636|DRUG|Indocyanine Green|Indocyanine Green
219607918|NCT03244072|DRUG|Moxifloxacin|Intracameral injection
219607919|NCT03244072|DRUG|Placebo|intracameral injection
219607920|NCT05808634|DRUG|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
219607921|NCT06448572|DRUG|EXL01|1 capsule / day
219607922|NCT06788756|DRUG|Placebo in combination with Cytarabine Injection|placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
219607923|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
219607924|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
218887957|NCT06945263|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath blocks using an in-plane ultrasound-guided technique with 0.25% bupivacaine with epinephrine 1:200 000 at 0.8 mL/kg (half of total volume per side) up to a maximum of 20 mL prior to the incision.
218887958|NCT06945263|DRUG|Local Anesthetic at the Umbilical Port Site|0.25% bupivacaine with epinephrine 1:200 000. Total dose of 0.8 mL/kg (maximum 20 mL) at the umbilical port site.
218887959|NCT06945263|DRUG|Intravenous Dexamethasone|Intravenous Dexamethasone delivered concurrent to the RSB. Total dose of 150 mcg/kg up to a maximum of 8 mg.
218887960|NCT06945263|DRUG|Local Anesthetic at the Incision Site|The remaining volume of local anesthetic (0.2 mL/kg) can be infiltrated at each of the incision sites at the discretion of the surgeon up to a maximum of 10 mL.
218887961|NCT04811482|BEHAVIORAL|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
219202423|NCT04752696|DRUG|Onvansertib|Oral capsule
219202424|NCT04752696|DRUG|Nanoliposomal irinotecan|Intravenous infusion
219202425|NCT04752696|DRUG|Leucovorin|Intravenous infusion
219607925|NCT06788756|DRUG|Liposomal Annamycin for Injection in combination with Cytarabine Injection.|optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
219607926|NCT04205812|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
219607927|NCT04205812|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
219607928|NCT04205812|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
219607929|NCT04205812|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
219607930|NCT04205812|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
219607931|NCT04205812|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
219202426|NCT04752696|DRUG|Fluorouracil|Intravenous infusion
219507949|NCT03731351|PROCEDURE|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
219507950|NCT00002407|DRUG|Indinavir sulfate|
218887962|NCT02275156|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
218887963|NCT03257683|DRUG|Ranolazine|Study group will receive additional therapeutic dosing of drug.
218887964|NCT03779815|DRUG|[18F]Florbetaben|"* Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously"
219507951|NCT00002407|DRUG|Nevirapine|
218887965|NCT03392818|OTHER|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
218887966|NCT03392818|OTHER|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
218887967|NCT03392818|DEVICE|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
218887968|NCT00200668|DRUG|FDG = fluorodeoxyglucose|
218887969|NCT00902707|DRUG|Mucinex 1200mg|Compared to Placebo
218887970|NCT00902707|DRUG|Placebo|Compare to active Mucinex
219031227|NCT02935465|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
219031228|NCT02935465|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
219031229|NCT02245256|DRUG|Precedex|infusion of 0.1mcg/kg/hr of precedex
219031230|NCT02245256|DRUG|placebo control|placebo
219031231|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
219031232|NCT04242888|OTHER|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
219031233|NCT02410499|DRUG|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
219031234|NCT02410499|DRUG|MLN1202|MLN1202 solution for SC injection
219031235|NCT06440031|BEHAVIORAL|CaMaPi|CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
219031236|NCT06440031|OTHER|TAU|Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
219031237|NCT00957203|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
219031238|NCT06127082|DEVICE|Echocardiography|Do echocardiography to obese patient
219031239|NCT04707261|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
219031240|NCT04707261|DRUG|Placebo|Participants will receive placebo 10 mg once daily
219031241|NCT06332716|OTHER|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
219031242|NCT02134132|BIOLOGICAL|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
219031243|NCT02134132|OTHER|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
219031244|NCT02510794|DRUG|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
219507952|NCT00002407|DRUG|Lamivudine|
219507953|NCT00002407|DRUG|Stavudine|
219507954|NCT00002407|DRUG|Didanosine|
219507955|NCT03577184|DRUG|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
219507956|NCT04978025|DRUG|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
219507957|NCT04978025|DRUG|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
219507958|NCT04501471|BEHAVIORAL|SAAF-T|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
219507959|NCT04501471|BEHAVIORAL|Fuel for Families|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
219507960|NCT02100852|DRUG|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
218887971|NCT02343406|DRUG|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
218887972|NCT02343406|DRUG|Temozolomide|Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
218887973|NCT02343406|DRUG|Lomustine|Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
218887974|NCT02816528|BEHAVIORAL|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
218887975|NCT04216576|OTHER|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
218887976|NCT04216576|OTHER|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
218887977|NCT05510336|PROCEDURE|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
218887978|NCT02451124|DEVICE|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
218887979|NCT02451124|OTHER|Questionnaire Administration|Ancillary studies
218887980|NCT02451124|OTHER|Laboratory Biomarker Analysis|Correlative studies
218887981|NCT02451124|PROCEDURE|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
218887982|NCT00262899|BEHAVIORAL|counseling intervention|
218887983|NCT00262899|OTHER|educational intervention|
218887984|NCT00262899|PROCEDURE|psychosocial assessment and care|
218887985|NCT00273429|DRUG|timolol maleate 0.5%|
219031245|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
219507961|NCT04275947|OTHER|nCapp, a cell phone-based auto-diagnosis system|Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
219507962|NCT05718388|OTHER|Physical therapy exercises|For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
218887986|NCT00273429|DRUG|dorzolamide/timolol maleate fixed combination|
218887987|NCT00273429|DRUG|latanoprost 0.005%|
219507963|NCT05718388|OTHER|Isokinetic training|Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
219607932|NCT04205812|DRUG|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
219607933|NCT04111809|BIOLOGICAL|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
219607934|NCT05221320|DRUG|Ulixertinib|small molecule ERK 1/2 inhibitor
219607935|NCT05221320|DRUG|Hydroxychloroquine|Autophagy inhibitor
218887988|NCT00273429|DRUG|placebo|
218887989|NCT00268541|BEHAVIORAL|Physical activity|
218887990|NCT01324362|DRUG|Placebo|Twice daily dosing
218887991|NCT01324362|DRUG|Placebo|Twice daily dosing
218887992|NCT01324362|DRUG|FP 100mcg|Twice daily dosing
218887993|NCT01324362|DRUG|FP 250mcg|Twice daily dosing
218887994|NCT01324362|DRUG|FP 500mcg|Twice daily dosing
218887995|NCT01324362|DRUG|FSC 100/50mcg|Twice daily dosing
218887996|NCT01324362|DRUG|FSC 250/50mcg|Twice daily dosing
218887997|NCT01324362|DRUG|FSC500/50mcg|Twice daily dosing
218887998|NCT05463250|DEVICE|Smartwatch|Wearing a smartwatch and having access to its data
218887999|NCT04585841|DRUG|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
218888000|NCT00196456|PROCEDURE|photosensitisation|
218888001|NCT00004050|BIOLOGICAL|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
218888002|NCT00958165|DEVICE|CardioFocus EAS-AC|PVI for PAF
218888003|NCT01189981|BEHAVIORAL|Lifestyle counseling|One health conversation at baseline
219031246|NCT01889784|DEVICE|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
219507964|NCT03716505|DEVICE|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
219507965|NCT03716505|DEVICE|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
219507966|NCT06226454|DRUG|VX-993|Suspension for oral administration.
219507967|NCT06226454|DRUG|Placebo|Suspension for oral administration.
219507968|NCT01688037|DRUG|NBI-98854|25 mg capsule
219507969|NCT01688037|DRUG|NBI-98854|50 mg capsule
219507970|NCT01688037|DRUG|Placebo|
219507971|NCT04646122|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography parameters
219507972|NCT01577095|OTHER|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
219507973|NCT01577095|DRUG|TZD|Rosiglitazone 8 mg single dose
219507974|NCT02502409|OTHER|Standard care with blood and urine sample collection|
219507975|NCT04179591|OTHER|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
219507976|NCT04179591|OTHER|Orthesis|Customized arch support insoles
219507977|NCT03035227|PROCEDURE|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
219507978|NCT03035227|DRUG|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
219507979|NCT03776851|DRUG|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
219507980|NCT00457379|BEHAVIORAL|physical exercise|
219507981|NCT03458507|DEVICE|Switch of nocturnal NIV interface|"1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
219507982|NCT02100956|DRUG|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
219507983|NCT02100956|DRUG|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
219507984|NCT02473991|RADIATION|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
219507985|NCT02405910|DRUG|Nab-paclitaxel|
219507986|NCT02405910|DRUG|Gemcitabine|
219607936|NCT05063708|DEVICE|Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|In the present study, VitalStim equipment will be used (VitalStim Therapy; Chattanooga Group, Chattanooga, TN, USA). Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation.
218888004|NCT01189981|BEHAVIORAL|eHealth intervention|SMS based encouragements to intensive exercise
218888005|NCT02017925|BEHAVIORAL|exercise intervention|Undergo pulmonary rehabilitation
218888006|NCT02017925|PROCEDURE|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
218888007|NCT02017925|PROCEDURE|quality-of-life assessment|Ancillary studies
218888008|NCT02017925|OTHER|questionnaire administration|Ancillary studies
218888009|NCT02799498|DEVICE|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
218888010|NCT02799498|OTHER|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
218888011|NCT02799498|DRUG|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
218888012|NCT02085304|PROCEDURE|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
218888013|NCT02085304|RADIATION|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
218888014|NCT02085304|RADIATION|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
219507987|NCT04914793|DEVICE|Antimicrobial prescribing guideline mobile phone application (MicroGuide)|This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
219507988|NCT04373759|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
219202427|NCT06875531|OTHER|Creative Drama trainings|"* The experimental group will be trained with the creative drama method and the control group will be trained with the traditional teaching method in line with the learning objectives on the topics of human dignity, responsibility, taking action, safety, autonomy.~* Creative Drama trainings will be carried out by the creative drama leader and the trainings will be continued in line with the creative drama training steps, starting with the warm-up phase, and continuing with the game, activity, improvisation and evaluation phases. Creative drama methods will be used in accordance with each topic. For each stage of the training, students will be divided into equal groups so that group members will change. Each session of creative drama training; 10 minutes for the warm-up stage, 30 minutes for the game activity stage, 30 minutes for the improvisation stage, 20 minutes for the formation and evaluation stages, and each topic will be carried out for a total of 90 minutes."
219507989|NCT04373759|OTHER|Modified Rankin score|"0 - no symptoms at all~1. \- no significant disability despite symptoms; able to carry out all usual duties and activities~2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. \- Moderate disability; requiring some help, but able to walk without assistance~4. \- Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. \- Dead"
219607937|NCT05063708|DEVICE|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation. The training was given according to the manual of the manufacturer, the VitalStim certification course (http://www.vitalstim.com).
219607938|NCT06473519|BIOLOGICAL|RSVpreF MDV|RSVpreF with 2-PE formulated in an MDV
219607939|NCT06473519|BIOLOGICAL|RSVpreF SDV|RSVpreF without 2-PE formulated in an SDV
219607940|NCT03976843|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
219607941|NCT05924763|DEVICE|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
219507990|NCT00859469|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
219507991|NCT00859469|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
219507992|NCT03091166|DRUG|Dexmedetomidine|
219507993|NCT03890250|OTHER|Aerobic exercise|A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
219607942|NCT05630469|OTHER|Electroconvulsive therapy|repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
219607943|NCT05238623|DIAGNOSTIC_TEST|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
219607944|NCT06246253|PROCEDURE|Virtual implant placement following safe angle concept|Virtual implant placement following safe angle concept in anterior maxillary teeth.
219607945|NCT06246253|PROCEDURE|actual implant placement following safe angle concept|actual implant placement following safe angle concept in anterior maxillary teeth
219607946|NCT04582149|DEVICE|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
219607947|NCT02514447|DRUG|Trilaciclib|
219607948|NCT02514447|DRUG|Placebo|
219607949|NCT02514447|DRUG|Topotecan|
219031247|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
219607950|NCT05644548|OTHER|No intervention|No intervention
219607951|NCT06846450|RADIATION|Intensity-modulated proton radiation therapy|Intensity-modulated proton therapy, will be delivered to the high risk area with a dose of 56 GyRBE in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 GyRBE in 28 fractions.
219607952|NCT06846450|RADIATION|Intensity-modulated photon radiation therapy|Intensity-modulated photon therapy, will be delivered to the high risk area with a dose of 56 Gy in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 Gy in 28 fractions.
219607953|NCT06846450|RADIATION|Intensity-modulated carbon ion radiation therapy|Intensity-modulated carbon ion radiation therapy will be delivered as a boost with a dose of 17.5 GyRBE in 5 fractions to gross tumor.
219607954|NCT06846450|DRUG|Concurrent chemotherapy|Concurrent chemotherapy will be administered on a weekly basis.
219607955|NCT06846450|DRUG|Induction chemotherapy|Cisplatin-based induction chemotherapy will be administered every three weekly.
219607956|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
219607957|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
218888015|NCT02085304|DRUG|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
218888016|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
218888017|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
218888018|NCT02302391|OTHER|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
219031248|NCT01889784|DEVICE|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
219031249|NCT03974230|OTHER|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
219031250|NCT03974230|BIOLOGICAL|blood sample|Blood sample will be performed (genetic analyses).
219031251|NCT03974230|OTHER|slit lamp examination|Slit lamp examination will be performed.
219031252|NCT04409288|DRUG|Apalutamide|Androgen receptor inhibitor.
219202428|NCT06874582|DEVICE|silicone hand or finger prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
219202429|NCT06874582|DEVICE|silicone foot and foot toe prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
219202430|NCT06874920|OTHER|No intervention (observational study)|No intervention (observational study)
218888019|NCT04673578|DRUG|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
218888020|NCT04673578|OTHER|Placebo|Microcrystalline cellulose
218888021|NCT00053144|DRUG|cytarabine|
218888022|NCT00053144|DRUG|irinotecan hydrochloride|
218888023|NCT06284733|DEVICE|Whole-body vibration plus conservative care|Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.
219031253|NCT04409288|DRUG|Enzalutamide|Androgern receptor inhibitor
219031254|NCT00052728|DRUG|tamoxifen citrate|
219031255|NCT00052728|DRUG|tipifarnib|
219031256|NCT04145258|DRUG|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
219031257|NCT04145258|DRUG|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
219031258|NCT04145258|DRUG|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
219202431|NCT06875726|BEHAVIORAL|Sidekick|Sidekick is a just-in-time adaptive intervention that sends behavior change messages based on personalized sleep and physical activity goals.
219031259|NCT04145258|DRUG|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
219202432|NCT06874166|OTHER|Electroencephalography (EEG)|Recording of resting state EEG will be collected
219507994|NCT03890250|OTHER|Neuromuscular electrical stimulation|Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
219507995|NCT02220907|DRUG|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
219507996|NCT03376958|DRUG|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
219507997|NCT00468741|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
219507998|NCT00468741|BEHAVIORAL|CHESS|informational services of CHESS available to subject
219507999|NCT00468741|BEHAVIORAL|CHESS|CHESS informational services and social support available to subject
219508000|NCT03982849|DRUG|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
219508001|NCT03982849|DRUG|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
219031260|NCT00231101|DRUG|Quetiapine|
219508002|NCT00366379|DRUG|GK Activator (2)|25-200mg po bid for 20 weeks
219508003|NCT01701778|DRUG|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
219508004|NCT01701778|DRUG|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
219508005|NCT01701778|DRUG|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
219508006|NCT01701778|DRUG|sevoflurane|Induction and maintain anaesthesia
219508007|NCT03111147|DEVICE|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
219508008|NCT03111147|DEVICE|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
219508009|NCT04266678|BEHAVIORAL|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
218888024|NCT06284733|OTHER|conservative care|"1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care."
218888025|NCT00952393|DRUG|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
218888026|NCT06388798|OTHER|Education|Psychoeducational training
218888027|NCT01279603|DRUG|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
218888028|NCT06479941|OTHER|antibiotic treatment|AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
219202433|NCT06874166|OTHER|Social Cognition Tasks|Comfort-Distance Task: it will be used to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality environment Interoception will be measured through an auditory match task based on participants heart-beat A measure emotion processing will be collected through the emotion priming visual task, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming
219202434|NCT06874725|DRUG|Rifapentine and Isoniazid for 3 months|tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
219202435|NCT06874725|DRUG|Isoniazid (INH) daily for 9 months|tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)
219202436|NCT06870656|OTHER|Low-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 10 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
219202437|NCT06870656|OTHER|Medium-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 20 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
219202438|NCT06870656|OTHER|High-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 30 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
219202439|NCT06871202|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in cervical, thoracic and upper limbs; second, lumbar, pelvic and lower limbs; and finally, only spine. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
219202440|NCT06871202|OTHER|Sham Protocol|The placebo protocol places the hands on the same areas as the experimental one and for the same application time but without making a manipulative intervention.
218888029|NCT05636761|DIAGNOSTIC_TEST|Heart rate variability|Collection and Analysis of Heart Rate Variability
219202441|NCT06871202|OTHER|Control-no treatment|Control group without treatment or manual contact
219202442|NCT06868784|OTHER|Evaluations|Evaluations of executive functions and occupational performance
219202443|NCT05755113|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
219202444|NCT06875401|PROCEDURE|Abdominal cerclage (open or laparoscopic)|Participants who have had either an open transabdominal cerclage or laparoscopic abdominal cerclage procedure performed.
219202445|NCT06099873|DRUG|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
219202446|NCT06099873|DRUG|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
219508010|NCT05921084|BEHAVIORAL|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
218888030|NCT04440657|BEHAVIORAL|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
219031261|NCT06115928|DEVICE|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
219031262|NCT02658890|DRUG|BMS-986205|
219031263|NCT02658890|DRUG|Nivolumab|
219031264|NCT02658890|DRUG|Ipilimumab|
219031265|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
219031266|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
219508011|NCT05921084|BEHAVIORAL|General dietary advice|General dietary advice
219508012|NCT00902824|BIOLOGICAL|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)
219508013|NCT00902824|BIOLOGICAL|TBC-M4|Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
219508014|NCT00902824|OTHER|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
219508015|NCT06008405|DRUG|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
219508016|NCT05004857|BEHAVIORAL|Book reading|Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
219031267|NCT01660893|DRUG|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
219031268|NCT01660893|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
219508017|NCT02140073|DRUG|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
219508018|NCT02140073|DRUG|omeprazole|40mg in the morning
219508019|NCT06049667|DRUG|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
219508020|NCT05379569|DRUG|Fludarabine|The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
219031269|NCT01660893|DRUG|Placebo|3 unilateral intranasal sprays per dose
219031270|NCT04498793|BIOLOGICAL|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
219031271|NCT04498793|DRUG|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
219031272|NCT04498793|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
219031273|NCT04498793|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
219031274|NCT04498793|DEVICE|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
219031275|NCT00691496|BEHAVIORAL|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
219031276|NCT04929652|DRUG|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
219031277|NCT03266068|GENETIC|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
219031278|NCT03266068|PROCEDURE|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
219031279|NCT03266068|PROCEDURE|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
219031280|NCT03266068|DIAGNOSTIC_TEST|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
219031281|NCT00458653|BIOLOGICAL|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
219031282|NCT00159588|DRUG|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
219031283|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
219607958|NCT04523987|DRUG|Ciprofloxacin|Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
219607959|NCT05494346|DEVICE|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
218888031|NCT06480318|DEVICE|TENS|The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
218888032|NCT02249039|DRUG|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
218888033|NCT06301932|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
218888034|NCT05182268|PROCEDURE|endoscopic ear surgery|a ear surgery via endoscopic
218888035|NCT05182268|PROCEDURE|microscopic ear surgery|a ear surgery via microscopic
219031284|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
219031285|NCT02727348|PROCEDURE|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
219508021|NCT03780569|DEVICE|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
219508022|NCT03780569|RADIATION|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
218888036|NCT05758428|DRUG|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
219031286|NCT02727348|PROCEDURE|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
219031287|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
219031288|NCT01571661|DRUG|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
219031289|NCT01571661|OTHER|Placebo|Placebo
219508023|NCT03780569|DRUG|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m\^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m\^2 in the absence of toxicity."
219508024|NCT01420835|OTHER|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
219508025|NCT01420835|OTHER|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
219508026|NCT00618397|DRUG|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
219508027|NCT03065283|PROCEDURE|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
219508028|NCT03065283|PROCEDURE|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
219508029|NCT02886975|BEHAVIORAL|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
219508030|NCT04650607|OTHER|Adverse event after injection of phages|rate and description of adverse event after injection of phages
219508031|NCT00095199|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
219508032|NCT00095199|BIOLOGICAL|Cetuximab|Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
219508033|NCT00095199|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
219202447|NCT06873685|OTHER|Rehabilitation|"After surgery, patients will undergo a personalized rehabilitation program incorporating both conventional and robotic-based approaches. Depending on tumor location, rehabilitation will focus on either the upper or lower limbs.~For lower limb rehabilitation, robotic or technological devices will be utilized for gait training with bodyweight support, as well as for balance and proprioception training. Upper limb rehabilitation will involve robotic or sensor-based devices enabling passive, active, and active-assistive movements of the shoulder, elbow, and hand.~Treatment will be provided in various settings- inpatient, outpatient, or home-based- tailored to each patient's specific needs. Sessions will be conducted daily for 45 minutes, five days per week, over a two-month period."
219202448|NCT06873932|DEVICE|Arm 1: Beveled Attachments|Beveled attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
218888037|NCT05758428|DRUG|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
218888038|NCT00274677|DRUG|Placebo|Experimental treatment arm
219202449|NCT06873932|DEVICE|Conventional Rectangular Attachments|Conventional rectangular attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
219202450|NCT01833039|DRUG|Ibrutinib|Ibrutinib
218888039|NCT00274677|DRUG|lamotrigine|Experimental treatment
218888040|NCT00766051|OTHER|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
218888041|NCT06120439|COMBINATION_PRODUCT|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
219031290|NCT06436846|OTHER|Biospecimen sample collection during standard-of-care surgery|Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
219031291|NCT05696834|PROCEDURE|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
219031292|NCT04173117|DIETARY_SUPPLEMENT|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
219031293|NCT02599181|OTHER|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
219202451|NCT03412058|PROCEDURE|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
219202452|NCT03412058|PROCEDURE|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
219202453|NCT03412058|PROCEDURE|Biopsy|To be performed at disease progression if medically feasible
219202454|NCT06624657|OTHER|vitamin D supplements fo 16 weks|subjects exercised by HIIT-exercise for 16 weeks
219607960|NCT06070233|RADIATION|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
219202455|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
219202456|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
219202457|NCT03255434|DRUG|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
219202458|NCT03255434|DRUG|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
219202459|NCT05795231|DEVICE|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
219202460|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
219202461|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
219202462|NCT06701305|DRUG|Efinopegdutide|Subcutaneous injectable solution
219202463|NCT06701305|DRUG|Placebo|Subcutaneous injectable solution
219202464|NCT06701305|DRUG|Acetaminophen|Oral solution
219202465|NCT05908084|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|ATEV implantation
218888042|NCT06120439|COMBINATION_PRODUCT|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
218888043|NCT03007602|OTHER|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
218888044|NCT06272123|OTHER|no intervention|no intervention
218888045|NCT02233023|DRUG|Pramipexole|
218888046|NCT02233023|DRUG|Bromocriptine and other dopamine agonists|
218888047|NCT05712954|OTHER|music group|music
218888048|NCT05712954|OTHER|video group|video
219508034|NCT02659267|BEHAVIORAL|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
218888049|NCT05651672|DRUG|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
218888050|NCT03240770|DEVICE|VPro5 device|Use of the VPro5 device for 5 minutes a day
219508035|NCT04036383|OTHER|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
218888051|NCT03240770|OTHER|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
218888052|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
219031294|NCT01998048|PROCEDURE|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
219202466|NCT05908084|OTHER|AVF|AVF creation procedure
219202467|NCT06700044|DIETARY_SUPPLEMENT|GutMagnific|Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
219508036|NCT04036383|OTHER|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
219508037|NCT04036383|OTHER|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
219508038|NCT00217828|DRUG|citalopram|
219607961|NCT06070233|OTHER|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
219607962|NCT05760612|DRUG|Trastuzumab and neratinib|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
219607963|NCT05760612|DRUG|Trastuzumab and Pertuzumab|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.
219607964|NCT06218550|DRUG|Delta-9-THC|Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
218888053|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
218888054|NCT06525584|OTHER|Control|Without ketamine
218888055|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
218888056|NCT01969630|DEVICE|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
218888057|NCT01969630|DEVICE|PES|Systematic Paclitaxel eluting stent angioplasty
218888058|NCT00002138|DRUG|Tecogalan sodium|
218888059|NCT05050864|PROCEDURE|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
218888060|NCT05050864|PROCEDURE|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
219031295|NCT01998048|PROCEDURE|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
219031296|NCT03945812|DRUG|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
219508039|NCT03754491|BEHAVIORAL|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
219508040|NCT06385977|BEHAVIORAL|lifestyle|Life habits and personal preferences
219508041|NCT06385977|BEHAVIORAL|sexual habits|Sexual experience and activities
219508042|NCT06385977|DRUG|medication|use of medication
219508043|NCT02032290|PROCEDURE|Assessment of Coronary Flow Reserve|
219607965|NCT06218550|DRUG|Delta-8-THC|Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
219607966|NCT06218550|DRUG|Placebo|Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
219031297|NCT03945812|OTHER|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
219031298|NCT03945812|OTHER|Saline|Saline 9%
219031299|NCT06457555|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|This study is a mixed method research conducted to determine the knowledge levels and experiences of nurses working in adult intensive care units regarding the prevention of pressure sores. In accordance with the purpose of the study, parallel data type in convergent parallel mixed design will be used as the research design. The quantitative phase will be conducted as a descriptive survey, and the qualitative phase will be conducted as a descriptive case study design. In this mixed design, equal priority, parallel timing and combining results during interpretation are planned.
219031300|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219031301|NCT00516724|DRUG|Carboplatin|intravenous injection
219031302|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
219508044|NCT02032290|PROCEDURE|Percutaneous coronary intervention|
219508045|NCT02032290|DRUG|ticagrelor loading|
219031303|NCT00516724|DRUG|Paclitaxel|Intravenous injection
219607967|NCT06439277|DRUG|Tirzepatide|Administered SC
219607968|NCT06439277|DRUG|Placebo|Administered SC
219031304|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
219031305|NCT00516724|DRUG|Paclitaxel + Carboplatin|Intravenous injection
219031306|NCT03253848|OTHER|Simplified Patient Care Strategy|Treatment per Acute Promyelocytic Leukemia (APL) Treatment Guidelines plus discussion between doctors and APL expert
219031307|NCT03253848|OTHER|Laboratory Biomarker Analysis|Correlative studies
219031308|NCT06315569|BEHAVIORAL|Run 3000 meters|Participants in both groups were asked to do two 3,000-meter runs at different intervals
219031309|NCT05352815|DRUG|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
219508046|NCT02032290|DRUG|Clopidogrel loading|
219508047|NCT03646253|OTHER|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
219508048|NCT05684926|OTHER|Telerehabilitation yoga|Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
219508049|NCT01493297|OTHER|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
219508050|NCT01879800|BEHAVIORAL|Acceptance and Commitment Therapy plus Illness Management|
219508051|NCT01896297|DRUG|Pradaxa, dabigatran etexilate|75mg BID by oral
219607969|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
219607970|NCT06400329|OTHER|Pain Neuroscience Education|PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active
219607971|NCT06400329|OTHER|Standard Pain Education|In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
219607979|NCT05405790|PROCEDURE|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
219508052|NCT02514590|DEVICE|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
219508053|NCT00846196|DRUG|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
219508054|NCT00846196|DRUG|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
219607980|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
219607981|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
219607982|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
219607983|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
219607984|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
219607985|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
219031310|NCT05352815|DRUG|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
219031311|NCT02165020|DEVICE|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
219031312|NCT05719207|DEVICE|Balloon dilation of eustachian tube|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system or the Stryker Audion ET dilation system will be used.
219031313|NCT05719207|OTHER|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
219031314|NCT05402657|PROCEDURE|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
219031315|NCT05402657|PROCEDURE|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
219031316|NCT04371679|OTHER|No interventions planned|No interventions planned. Observational.
219031317|NCT05923853|OTHER|FiO2 titration using electronic alert system|In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
219031318|NCT02759120|DRUG|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
219031319|NCT02759120|OTHER|No Intervention: Standard of Care|Standard of care
219031320|NCT02861794|PROCEDURE|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
219031321|NCT04133168|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
219031322|NCT04792697|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
219031323|NCT04792697|OTHER|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
219031324|NCT04792697|BEHAVIORAL|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
219031325|NCT04792697|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
219031326|NCT01474044|DRUG|Gastropylor Complex Capsules|3 pills, three times a day, after meal
219031327|NCT01474044|OTHER|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
219031328|NCT02657460|BIOLOGICAL|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
219508055|NCT02401893|BIOLOGICAL|Influenza Vaccine|Everyone immunized as recommended by current guidelines
219508056|NCT03429296|OTHER|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
219508057|NCT04277195|DIAGNOSTIC_TEST|SPAG5 Assay|Testing for SPAG5 expression in the tumour.
219031329|NCT02657460|DRUG|cisplatin|cisplatin is a traditional drug for lung cancer
219508058|NCT03473470|DEVICE|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
219508059|NCT03473470|DEVICE|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
218888061|NCT02930915|DEVICE|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
219031330|NCT02152501|OTHER|Exercise Energy Expenditure 300 kcal/day|
219031331|NCT02152501|OTHER|Exercise Energy Expenditure 600 kcal/day|
219031332|NCT03056755|DRUG|Alpelisib|300 mg of alpelisib film-coated tablets administered orally once daily
219031333|NCT03056755|DRUG|Fulvestrant|500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
219031334|NCT03056755|DRUG|Letrozole|2.5 mg of letrozole film-coated tablets administered orally once daily
219031335|NCT03056755|DRUG|Goserelin|3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
219031336|NCT03056755|DRUG|Leuprolide|7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
219031337|NCT04463550|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
219031338|NCT04630951|OTHER|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
219031339|NCT04630951|OTHER|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
219031340|NCT06469775|DEVICE|Low intensity shock wave|6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.
219508060|NCT04062461|OTHER|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
219508061|NCT04062461|OTHER|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
219508062|NCT00388882|DRUG|tiotropium|
219508063|NCT00388882|DRUG|ipratropium bromide / albuterol|
219508064|NCT03719183|DIAGNOSTIC_TEST|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
219607986|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
219607987|NCT05621096|RADIATION|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
219607988|NCT05621096|BIOLOGICAL|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
219607989|NCT05621096|RADIATION|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
219607990|NCT04710043|DRUG|BNT152|intravenous
219607991|NCT04710043|DRUG|BNT153|intravenous
219607992|NCT04681131|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
219607993|NCT04681131|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
219031341|NCT06469775|COMBINATION_PRODUCT|Control|Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
219031342|NCT00969787|DRUG|DWP05195|tablets, oral administration, single and multiple administrations
219202468|NCT06700044|DIETARY_SUPPLEMENT|Placebo|Participants will take one stick/placebo per day from gestational week 12 until partus.
219202469|NCT06276387|BEHAVIORAL|Mindfulness Program|Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
219202470|NCT06699030|DRUG|Functional fatty acids|Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids
219202471|NCT06699030|OTHER|Placebo|Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
219202472|NCT06627244|DRUG|Tebentafusp|Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
219202473|NCT06627244|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
219202474|NCT06627959|DEVICE|Statseal|This is a vascular closure device which works independently of the clotting cascade to seal access sites
219202475|NCT06627959|DEVICE|Figure of eight suture|The figure of eight suture is commonly used for vascular access closure
219202476|NCT06627192|PROCEDURE|NSPT, clinical and biochemical assesment|Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample
219202477|NCT02459717|OTHER|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
219202478|NCT02459717|OTHER|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
219202479|NCT05357222|BEHAVIORAL|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2\. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3\. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4\. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
219202480|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
219202481|NCT06054802|DEVICE|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
219202482|NCT05927142|BIOLOGICAL|Durvalumab|Human anti-PD-L1 antibody
219202483|NCT05927142|DRUG|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
219607994|NCT05078957|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
219607995|NCT05078957|OTHER|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
218888062|NCT00550693|DEVICE|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
218888063|NCT00001094|DRUG|Lamivudine/Zidovudine|
219202484|NCT06186102|DIETARY_SUPPLEMENT|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
219202485|NCT06186102|OTHER|Placebo|Placebo capsule. 3 capsules daily.
219202486|NCT06242002|PROCEDURE|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
219202487|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
218888064|NCT00001094|DRUG|Nelfinavir mesylate|
218888065|NCT00001094|DRUG|Saquinavir|
218888066|NCT00001094|DRUG|Delavirdine mesylate|
218888067|NCT00195663|BIOLOGICAL|Adalimumab|
218888068|NCT00195663|DRUG|Methotrexate|
218888069|NCT00195663|BIOLOGICAL|Adalimumab placebo|
218888070|NCT00195663|DRUG|Methotrexate placebo|
218888071|NCT00604695|DRUG|Tenecteplase|Intracoronary injection of IV tenecteplase.
218888072|NCT00604695|DRUG|Sterile Saline|Intracoronary injection of IV sterile saline
218888073|NCT04659525|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
218888074|NCT04659525|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
218888075|NCT04659525|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
219202488|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
219202489|NCT06439342|DRUG|Maribavir|Maribavir tablets
219508065|NCT03719183|DIAGNOSTIC_TEST|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements"
218888076|NCT04551950|DRUG|M7824|Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
219202490|NCT00077584|DRUG|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
219202491|NCT00077584|DRUG|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
219202492|NCT00077584|DRUG|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
219202493|NCT05068960|DRUG|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
219202494|NCT05068960|DRUG|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
219202495|NCT06875323|OTHER|ECHO-FostrSpace|Six ECHO-FostrSpace session training for CASA volunteers.
219202496|NCT06875323|OTHER|Informational Session|One ECHO-FostrSpace session training for CASA volunteers.
219202497|NCT06873750|DEVICE|Transcranial Alternating Current Stimulation|Application of low amplitude alternating electric current across the participant's scalp.
218888077|NCT04551950|DRUG|Carboplatin|Carboplatin was administered intravenously as per standard of care.
219202498|NCT06871787|DRUG|Indocyanine Green|Indocyanine green (ICG), administered intravenously at a dose of 2.5 mg/ml, will be used during surgery to evaluate bowel anastomosis perfusion through near-infrared fluorescence imaging.
219202499|NCT06871787|DEVICE|Near-Infrared Fluorescence Imaging System|A near-infrared fluorescence imaging device will be used intraoperatively to visualize indocyanine green (ICG) fluorescence, assessing the perfusion of bowel anastomoses during gynecologic oncology surgery.
219202500|NCT06875258|DRUG|Sildenafil|Taken daily or on demand. First two weeks dosage of 75mg to manage side effects. If side effects are bearable, dosage will be adjusted to 100mg
219202501|NCT06875258|DEVICE|Erectile vacuum device|5 days a week, generating 5 erections per day
219202502|NCT06874881|OTHER|Aquatic Exercises|The aquatic exercise intervention consists of structured, supervised, water-based exercises designed and delivered by an experienced physiotherapist specifically for individuals with chronic low back pain. Sessions are conducted in a temperature-controlled swimming pool with proper warm-up and cool-down. The intervention follows a progressive intensity approach with easy, medium, and hard approaches.
218888078|NCT04551950|DRUG|Paclitaxel|Paclitaxel was administered intravenously as per standard of care.
218888079|NCT04551950|DRUG|Bevacizumab|Bevacizumab was administrated as indicated for standard of care.
218888080|NCT04551950|DRUG|Cisplatin|Cisplatin was administered intravenously as per standard of care.
218888081|NCT04551950|RADIATION|Radiotherapy|Participants received radiotherapy as per standard of care.
219202503|NCT06874881|OTHER|Land Exercises|The land-based exercise intervention mirrors the aquatic exercise protocol regarding exercise type, duration, frequency, and progression but is performed on land.
219202504|NCT06868498|OTHER|A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.|Students will participate in a special topics course resulting in a CHW certification with the state of Texas. The course will focus on behavioral activation interventions. Undergraduate Bachelor of Social Work (BSWs) students will then be deployed to the health system as certified CHWs with mental health training to provide a sufficient level of care for many, and an entry point to clinical care for those who have needs that are currently unaddressed.
219202505|NCT06592482|DRUG|AZD0780|"A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water."
219508066|NCT03719183|DIAGNOSTIC_TEST|Multiplex FISH (M-FISH)|24-color karyotyping
219508067|NCT02496871|BEHAVIORAL|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
219508068|NCT02496871|BEHAVIORAL|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
218888082|NCT04070612|OTHER|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
218888083|NCT03501940|PROCEDURE|Computed Tomography|Undergo 18F-DCFPyL PET/CT
218888084|NCT03501940|RADIATION|Fluorine F 18 DCFPyL|Given IV
218888085|NCT03501940|OTHER|Laboratory Biomarker Analysis|Correlative studies
218888086|NCT03501940|PROCEDURE|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
218888087|NCT03167021|OTHER|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
219031343|NCT05955339|OTHER|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
219031344|NCT05955339|OTHER|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
218888088|NCT00014833|OTHER|No intervention|No intervention
219031345|NCT04659850|OTHER|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
219031346|NCT04659850|OTHER|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
219031347|NCT04659850|OTHER|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
219031348|NCT04659850|OTHER|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
219031349|NCT02347267|BEHAVIORAL|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
219508069|NCT04896359|DIETARY_SUPPLEMENT|Vitamin C|12.5 grams of ascorbic acid
219202506|NCT03493542|BIOLOGICAL|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
219202507|NCT05485935|DEVICE|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
219202508|NCT05485935|DEVICE|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
219202509|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
219202510|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
219202511|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
219202512|NCT06753981|DRUG|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
219202513|NCT06781645|OTHER|The system involves a digital table with a tactile and interactive surface, providing several play areas. It simulates a village and offers different types of serious cognitive games: semantic memory|Each patient included will benefit from a series of 6 sessions of cognitive stimulation with the interactive digital table of cognitive games 'Le Village de Verdurable'©, and a series of 6 sessions of 'classic' weekly cognitive stimulation at the rate of one session per week, i.e. without the digital table and using the methods of cognitive stimulation normally used in the department. The weekly session used as a comparator in the usual condition will be a session based on concentration and attention with target finding or error finding. The order in which these 2 series of 6 sessions will be carried out will be defined randomly (by drawing lots) before the start of the trial.
219202514|NCT06277141|BEHAVIORAL|Standard message|Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.
219202515|NCT06277141|BEHAVIORAL|Radiology booking site link.|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.
219202516|NCT06277141|BEHAVIORAL|Radiology practice telephone numbers|Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices
219202517|NCT06277141|BEHAVIORAL|Radiology site link and telephone numbers|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
219202518|NCT05007847|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
219607996|NCT05078957|OTHER|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
219202519|NCT06870136|DIETARY_SUPPLEMENT|Lion's Mane Study Product|The Lion's Mane Study product contains vegetable cellulose (capsules), Certified organic Lion's Mane (Hericium erinaceus) fruiting body and mycelial biomass cultured on certified whole oats (Avena sativa). Screening assessments, scales and surveys during baseline and during the use of the study product/placebo and end of study experience survey data will be collected.
219607997|NCT02015117|OTHER|Laboratory Biomarker Analysis|Correlative studies
219202520|NCT05567120|OTHER|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
219508070|NCT04896359|OTHER|Placebo|vehicle
219508071|NCT04783363|OTHER|Snoezelen session|before one of two repeated invasive care
219508072|NCT02429700|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
219508073|NCT02429700|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
219508074|NCT02429700|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
219508075|NCT02429700|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
219508076|NCT02429700|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
219508077|NCT01343628|DRUG|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
219508078|NCT01343628|DRUG|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
219031350|NCT02347267|BEHAVIORAL|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
219031351|NCT02121288|DRUG|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
219031352|NCT02121288|DRUG|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
219031353|NCT03986320|DEVICE|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
219508079|NCT00864942|DRUG|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
219508080|NCT00864942|DRUG|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
219508081|NCT00864942|DRUG|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
219508082|NCT00864942|DRUG|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
219508083|NCT01098240|DRUG|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
219508084|NCT01098240|OTHER|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
219508085|NCT01070394|DRUG|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
219607998|NCT02015117|OTHER|Pharmacological Study|Correlative studies
219607999|NCT02015117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
219608000|NCT02015117|DRUG|Trametinib|Given PO
219031354|NCT02523846|DRUG|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
219031355|NCT02523846|BEHAVIORAL|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
219031356|NCT05271955|DEVICE|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
219031357|NCT05271955|BEHAVIORAL|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
219031358|NCT01865279|DRUG|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
219031359|NCT01865279|DRUG|placebo|Ascending single doses - 5 dose levels
219031360|NCT01865279|DRUG|insulin degludec|A single dose corresponding to that of isophane human insulin
219031361|NCT01865279|DRUG|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
219031362|NCT06387914|DEVICE|Stimulation ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus at a level with potential to provide pain relief
219031363|NCT06387914|DEVICE|Stimulation Pseudo-ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus S at a low level, not designed to provide pain relief
219031364|NCT00390325|DRUG|Sorafenib Tosylate|Given PO
219031365|NCT02419742|DRUG|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
219031366|NCT02419742|DRUG|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
219031367|NCT02419742|DRUG|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
219031368|NCT02419742|DRUG|Doxorubicin|Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
219031369|NCT02419742|DRUG|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
219031370|NCT02419742|DRUG|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
219031371|NCT06404632|BEHAVIORAL|Lev-g|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
219031372|NCT01280214|DRUG|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
219608001|NCT02015117|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
219608002|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
219608003|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
219031373|NCT06045806|BIOLOGICAL|idecabtagene vicleucel|Specified dose on specified days
219202521|NCT06362382|BEHAVIORAL|tele-rehabilitation training|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily （a total of 3 months）training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency.~The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved."
219202522|NCT06362382|BEHAVIORAL|health propaganda and education|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
219202523|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Additive-Manufactured Personalized Titanium Mesh|Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.In the bone grafting surgery, the additive-manufactured personalized titanium mesh is used to secure the bone substitutes, with fixation screws used to secure the titanium mesh.
219202524|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Prefabricated Titanium Mesh|In bone grafting surgery, prefabricated titanium mesh is used to fix the bone substitutes, and fixation screws are used to secure the titanium mesh.
219202525|NCT06693895|BIOLOGICAL|Investigational varicella vaccine|1 dose of investigational varicella vaccine administered subcutaneously.
219202526|NCT06693895|BIOLOGICAL|Marketed varicella vaccine|1 dose of marketed varicella vaccine administered subcutaneously.
219202527|NCT06693895|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
219202528|NCT06693895|BIOLOGICAL|Hepatitis A vaccine|1 dose of hepatitis A vaccine co-administered intramuscularly.
219508086|NCT01623232|BIOLOGICAL|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~1. Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~2. Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~3. Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
219508087|NCT01623232|BIOLOGICAL|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4\. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
219508088|NCT04989062|DIAGNOSTIC_TEST|Fibroscan|Controlled attenuation parameter and liver stiffness measurement are measured.
219508089|NCT04989062|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
219508090|NCT04989062|DIAGNOSTIC_TEST|Urine unclear magnetic resonance metabolomics|Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
219508091|NCT04989062|DIAGNOSTIC_TEST|Hand grip strength|Hand grip strength in both hands is measured by hand-held dynamometer.
219508092|NCT03280537|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
219608004|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
219608005|NCT05336695|DIAGNOSTIC_TEST|PET/MR Imaging|PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
219608006|NCT05336695|DRUG|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
219608007|NCT05587127|BEHAVIORAL|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
219031374|NCT06045806|DRUG|Lenalidomide|Specified dose on specified days
219031375|NCT06045806|DRUG|Fludarabine|Specified dose on specified days
219031376|NCT06045806|DRUG|Cyclophosphamide|Specified dose on specified days
219031377|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
219031378|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
219031379|NCT01758185|BIOLOGICAL|recombinant hepatitis b vaccine|0.5ml intramuscular
219031380|NCT01758185|BIOLOGICAL|Aleph influenza vaccine|0.5ml intramuscular
219608008|NCT05705570|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
219608009|NCT05705570|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
219608010|NCT05705570|BIOLOGICAL|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
219608011|NCT06157814|OTHER|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
219508093|NCT03280537|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
219508094|NCT05181137|DRUG|SHR0302|Oral tablets taken once daily (QD)
219202529|NCT06693895|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219508095|NCT05181137|DRUG|Placebo|Oral tablets taken once daily (QD)
219508096|NCT01860391|DEVICE|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
219508097|NCT02281630|DRUG|KWA-0711|
219508098|NCT02281630|DRUG|Placebo|
219508099|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
219508100|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
219508101|NCT06360731|OTHER|4-7-8 breathing exercise technique and informative session on tinnitus|Participants in experimental group will be individually provided with informative session on tinnitus for one hour by researchers. During the informative session, the participants will be given general information about tinnitus and will be informed about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus. In the same session, after one hour of informative session, the 4-7-8 breathing exercise method will be demonstrated by the same researchers. In addition, a video showing how to perform the 4-7-8 breathing exercise technique will be sent as a text message to their cell phones.
219508102|NCT06360731|OTHER|Informative session on tinnitus|Participants in control group will be individually provided with informative session on tinnitus only for one hour by researchers G.K. and G.S.U. from both clinics. During the informative session, the participants will be given general information about tinnitus and inform about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus.
219608012|NCT06157814|OTHER|Usual Care|Patients and caregivers NOT given access to the web-based application.
219608013|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
219608014|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
219608015|NCT06221007|PROCEDURE|Use of bone cement in otosclerosis surgery|Surgical technique; It involves separating the sclerosed stapes from the oval window and incus under an endoscope or microscope and replacing it with a Teflon piston, which is a middle ear prosthesis. In this way, a new connection between the incus and the oval window ensures the transmission of sound to the inner ear. Bone cement has long been used in primary and revision ossiculoplasty, including stapedotomy of the middle ear. During stapedotomy, the part of the Teflon piston that places the teflon piston on the incus is fixed with bone cement, aiming to keep the prosthesis in place for a long time and prophylactic treatment of incus necrosis.
219608016|NCT06344000|OTHER|inapplicable|inapplicable
219031381|NCT04974112|OTHER|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
219031382|NCT00070265|DRUG|oxaliplatin|Given IV
219031383|NCT00070265|DRUG|capecitabine|Given orally
219031384|NCT00070265|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219031385|NCT00070265|OTHER|laboratory biomarker analysis|Correlative studies
219031386|NCT00102700|DRUG|ARQ 501 in combination with gemcitabine|
219031387|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
219031388|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
219202530|NCT06693895|BIOLOGICAL|PCV 20|1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219202531|NCT06693895|BIOLOGICAL|Vaxneuvance|1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
218888089|NCT06015087|OTHER|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
218888090|NCT04443309|DRUG|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
218888091|NCT04443309|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
218888092|NCT00407303|DRUG|Obatoclax mesylate|30 mg, 45 mg
219031389|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
219508103|NCT01880645|PROCEDURE|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
218888093|NCT00407303|DRUG|Bortezomib|1.0mg/m2, 1.3 mg/m2
218888094|NCT05848427|OTHER|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
218888095|NCT04180332|DIAGNOSTIC_TEST|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
218888096|NCT02277912|DEVICE|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
218888097|NCT02277912|DEVICE|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
219031390|NCT04434131|DRUG|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
219031391|NCT03768596|BEHAVIORAL|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
219031392|NCT03768596|OTHER|vaccination form|a form about vaccination
219031393|NCT06182826|PROCEDURE|Core Stability protocol|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
219031394|NCT06182826|PROCEDURE|Routine exercise therapy|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
219031395|NCT01135758|DRUG|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
219031396|NCT03851042|DEVICE|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
219031397|NCT03851042|OTHER|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
219031398|NCT04236804|DEVICE|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
219031399|NCT06214156|BIOLOGICAL|T3011|T3011 will be given intratumorally， Q2W；
219031400|NCT05115110|DRUG|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
219031401|NCT05115110|DRUG|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
219031402|NCT05115110|DRUG|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
219031403|NCT03870828|DIAGNOSTIC_TEST|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
219031404|NCT03870828|DIAGNOSTIC_TEST|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
219031405|NCT03870828|DIAGNOSTIC_TEST|Arterial blood gas|If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
219031406|NCT03870828|PROCEDURE|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
219031407|NCT06567626|OTHER|Decision Support Tool (DECIDE-CAD)|DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
219508104|NCT01880645|PROCEDURE|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
219508105|NCT01880645|PROCEDURE|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
218888098|NCT02277912|DEVICE|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
218888099|NCT03579810|OTHER|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
218888100|NCT03579810|OTHER|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
219508106|NCT05765045|DIAGNOSTIC_TEST|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
219202532|NCT06693284|DRUG|mirdametinib and vorinostat|short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
219202533|NCT06693362|DRUG|Placebo|The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
219202534|NCT06693362|DRUG|Drug therapy|The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
219508107|NCT03908112|BEHAVIORAL|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
219508108|NCT03908112|BEHAVIORAL|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
219508109|NCT03908112|BEHAVIORAL|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
219508110|NCT04365283|PROCEDURE|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
219508111|NCT04365283|OTHER|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
219031408|NCT06169813|OTHER|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
219031409|NCT06169813|OTHER|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
219031410|NCT06169813|BEHAVIORAL|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
219031411|NCT06113133|DIAGNOSTIC_TEST|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
219031412|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
219031413|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
219031414|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
219031415|NCT05071183|DRUG|TPX-0005|Oral TPX-0005 capsules
219031416|NCT05071183|DRUG|Trametinib|Oral trametinib tablets
219031417|NCT02969824|BEHAVIORAL|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
219031418|NCT01904708|OTHER|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
219031419|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
219031420|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
219031421|NCT03638310|PROCEDURE|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
219031422|NCT03638310|PROCEDURE|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
219031423|NCT02256761|DRUG|BIRT 2584 XX - multiple escalating dose|
219508112|NCT01526915|PROCEDURE|Bone curettage + PRF|Bone curettage and PRF insertion
219508113|NCT01526915|PROCEDURE|Bone curettage alone|Bone curettage without PRF insertion
219508114|NCT06541275|DIAGNOSTIC_TEST|brain MRI and CT|The diagnostic tests will be conducted at 6, 12, and 24 months of follow-up.
219508115|NCT03083132|DRUG|modafinil 50mg|1 capsule oral daily
218888101|NCT03360474|BEHAVIORAL|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
218888102|NCT01354119|PROCEDURE|Aortic stent-graft|Early intervention with aortic stent-graft
218888103|NCT05695274|BEHAVIORAL|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
218888104|NCT05789563|OTHER|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
218888105|NCT02058563|BIOLOGICAL|Priorix®|1 dose administered as a subcutaneous (SC) injection.
218888106|NCT02058563|BIOLOGICAL|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
218888107|NCT03702036|DRUG|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
218888108|NCT05942599|BIOLOGICAL|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
218888109|NCT00166439|DRUG|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
218888110|NCT04326582|OTHER|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
219031424|NCT02256761|DRUG|Placebo|
219508116|NCT03083132|DRUG|Placebo oral capsule|1 capsule oral daily
219508117|NCT00206206|PROCEDURE|Hyperglycemia Protocol Procedure|
219202535|NCT06693362|OTHER|Standard Treatment|"Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary."
219031425|NCT02256761|DRUG|BIRT 2584 XX - single dose|
219508118|NCT03118739|DRUG|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
219508119|NCT03118739|DRUG|Placebo|Capsule administered orally, once daily for 24 weeks
219508120|NCT02938806|OTHER|No intervention|No intervention
219508121|NCT03804645|DRUG|Treatment A|Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
218888111|NCT01999725|DRUG|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
218888112|NCT01999725|DRUG|Placebo|Matching placebo capsules or matching suspension
218888113|NCT02481817|PROCEDURE|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
218888114|NCT02481817|PROCEDURE|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
218888115|NCT02481817|PROCEDURE|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
218888116|NCT05463016|DEVICE|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
218888117|NCT05463016|DEVICE|Placebo Group 1: Placebo Lenses|Placebo Lenses
218888118|NCT05463016|DEVICE|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
219031426|NCT02256761|OTHER|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
219031427|NCT01759108|DRUG|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
219031428|NCT06832098|COMBINATION_PRODUCT|Nicotine patches plus nicotine mouth spray|Transdermal HABITROL® patches (21mg/24 hrs) plus NICORETTE® QUICKMIST mouth spray (1mg nicotine/spray dose)
219031429|NCT06832098|OTHER|Nicotine Tapering Plan|Tapering plan based on their current e-juice nicotine concentration and frequency of vaping upon entry to the trial. Participants will use their own vapes and nicotine e-liquid.
219031430|NCT01371474|DRUG|Paroxetine|
219508122|NCT03804645|DRUG|Treatment B|Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
219508123|NCT03804645|DRUG|Treatment C|Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
219508124|NCT03804645|DRUG|Treatment D|Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
218888119|NCT05463016|DEVICE|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
218888120|NCT05463016|DEVICE|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
218888121|NCT04039217|DRUG|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
218888122|NCT00406536|DIETARY_SUPPLEMENT|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
219202536|NCT06692270|DRUG|Tislelizumab|Tislelizumab 200mg Q3W, D1 ; 2 cycles
219202537|NCT06872710|OTHER||There are no interventions. Samples were collected by the Biobank since 2013.
218888123|NCT00406536|DIETARY_SUPPLEMENT|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
218888124|NCT04575207|DIAGNOSTIC_TEST|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
219202538|NCT05153421|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
218888125|NCT04575207|DIAGNOSTIC_TEST|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
218888126|NCT00496288|RADIATION|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
218888127|NCT05613023|RADIATION|SBRT|Stereotactic Body Radiotherapy
218888128|NCT01833572|DRUG|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
218888129|NCT04864951|DIAGNOSTIC_TEST|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
218888130|NCT04864951|OTHER|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
218888131|NCT00615992|DRUG|Tiotropium|
218888132|NCT03802591|DRUG|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
219031431|NCT06834360|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219202539|NCT04365114|DIAGNOSTIC_TEST|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
219202540|NCT04365114|DIAGNOSTIC_TEST|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
219202541|NCT04365114|DIAGNOSTIC_TEST|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
219202542|NCT05886452|DEVICE|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
219202543|NCT06695702|OTHER|the effect of work-based learning on the level of knowledge|The benefit of workbased learning on nursing students' knowledge of oncology symptom management
218888133|NCT03802591|DRUG|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
218888134|NCT03802591|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
218888135|NCT03802591|DRUG|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
219031432|NCT06834360|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219202544|NCT06695390|OTHER|Nursing students' humanistic care competence|A cross-sectional study with nursing students
219031433|NCT06834360|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
219031434|NCT02808130|OTHER|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
219031435|NCT02981823|PROCEDURE|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
219031436|NCT05228522|BEHAVIORAL|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
218888136|NCT02518373|BIOLOGICAL|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
218888137|NCT02518373|DRUG|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
218888138|NCT05056506|PROCEDURE|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
218888139|NCT05056506|PROCEDURE|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
218888140|NCT01868477|DRUG|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
218888141|NCT01868477|DRUG|Erythropoietin alpha|
218888142|NCT01868477|DRUG|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
218888143|NCT01618006|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
218888144|NCT01618006|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
218888145|NCT01618006|DRUG|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
218888146|NCT05510674|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
218888147|NCT01802125|OTHER|laboratory biomarker analysis|Correlative studies
218888148|NCT04685525|BEHAVIORAL|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
219031437|NCT02133950|PROCEDURE|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
219031438|NCT02133950|PROCEDURE|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
219031439|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
219031440|NCT01229423|DRUG|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
219031441|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
219031442|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
219031443|NCT01516944|DRUG|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
219031444|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
219031445|NCT06171776|DRUG|RetroMTA|calcium silicate lining material work as dentin substitute
219202545|NCT06686745|DRUG|SIM0508 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
218888149|NCT02819791|OTHER|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
218888150|NCT02819791|BEHAVIORAL|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
218888151|NCT04387578|DEVICE|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
218888152|NCT05260762|DIETARY_SUPPLEMENT|Arabinoxylan|Dietary fiber product
218888153|NCT05260762|DIETARY_SUPPLEMENT|Control|Potato starch
218888154|NCT04059120|OTHER|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
218888155|NCT04059120|OTHER|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
218888156|NCT02219074|DEVICE|Sebacia microparticle and laser treatment|
218888157|NCT02219074|DEVICE|Vehicle and laser treatment|
219031446|NCT06171776|DRUG|TheraCal|calcium silicat material light cured
219031447|NCT06171776|DRUG|Fuji IX|filling material bonded chemically to the tooth structure
219031448|NCT01232920|DRUG|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
219202546|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
219031449|NCT01232920|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
219031450|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 2 dose efficacy|Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
219508125|NCT06338020|OTHER|Adaptive variable-resistance training|"The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
219031451|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|Will be comparison group for 2 dose efficacy group.
219031452|NCT04609566|DRUG|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
219031453|NCT04609566|DRUG|pembrolizumab|200 mg given intravenously every 3 weeks
219031454|NCT05224674|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
219031455|NCT00636909|DRUG|Cyclophosphamide|preparative cytoreduction
219031456|NCT00636909|DRUG|fludarabine|preparative cytoreduction
219031457|NCT00636909|DRUG|cyclosporine|immunosuppressive therapy
219031458|NCT00636909|DRUG|methotrexate|immunosuppressive therapy
219031459|NCT00636909|BIOLOGICAL|G-CSF|foster engraftment
219031460|NCT04608903|DIETARY_SUPPLEMENT|L-sulforaphane 1%|Administration of 4g L-sulforaphane per day, for 2 months
219031461|NCT04608903|DIETARY_SUPPLEMENT|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
219031462|NCT06846710|DRUG|HS-20118|Single and multiple ascending doses of HS-20118 orally
219031463|NCT06846710|OTHER|HS-20118 placebo|Single and multiple ascending doses of HS-20118-matched placebo orally
219031464|NCT05221606|BEHAVIORAL|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
219031465|NCT05221606|BEHAVIORAL|Usual Care|Binder of written supportive care materials
219031466|NCT02563678|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen therapy
219031467|NCT02563678|OTHER|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
219031468|NCT02563678|OTHER|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
219031469|NCT05616104|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
219031470|NCT05682261|DIETARY_SUPPLEMENT|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
219031471|NCT05682261|DIETARY_SUPPLEMENT|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
219031472|NCT05682261|OTHER|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
219031473|NCT04018092|DEVICE|Active NIR-PBM|Near infrared light was delivered to the head using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Intranasal stimulation was delivered using..
219031474|NCT04018092|DEVICE|Sham NIR-PBM|The MedX sham and Vielight interventions device are identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 12-week period, following the identical procedures described in the active condition
219031475|NCT06392984|DIAGNOSTIC_TEST|Pectus deformity study form|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 6-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
219031476|NCT06392984|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. Investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second) (Liter-L), FEV1 (%predicted), FVC (Forced Vital Capacity) (Liter-L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
218888158|NCT02462018|DEVICE|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
218888159|NCT03311789|DRUG|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
218888160|NCT06284512|DIAGNOSTIC_TEST|Sonography, color fundus photography|Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
218888161|NCT02528786|OTHER|No Intervention|No study drug will be administered in this study.
218888162|NCT04289792|DRUG|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
218888163|NCT04289792|RADIATION|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
218888164|NCT01076387|PROCEDURE|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
218888165|NCT01076387|PROCEDURE|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
218888166|NCT03862235|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
218888167|NCT03862235|DIAGNOSTIC_TEST|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
218888168|NCT01821703|DRUG|LY3045697|Administered as oral solution
218888169|NCT01821703|DRUG|Placebo|Administered as oral solution
218888170|NCT01821703|DRUG|Spironolactone|Administered as capsule
218888171|NCT01821703|DRUG|Placebo|Administered as capsule
219508126|NCT06338020|OTHER|Standard physical therapy|The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
218888172|NCT01453608|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
218888173|NCT01453608|DRUG|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
218888174|NCT05417087|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
219031477|NCT06392984|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity-TLC) (millimeter-mm)) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
219031478|NCT04979169|BEHAVIORAL|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
219031479|NCT05794152|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
219031480|NCT05794152|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
219031481|NCT05794152|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
219508127|NCT00893542|DRUG|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
219508128|NCT03982056|OTHER|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
218888175|NCT05417087|DRUG|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
218888176|NCT00903305|OTHER|medical chart review|
218888177|NCT00903305|OTHER|questionnaire administration|
218888178|NCT00903305|PROCEDURE|fatigue assessment and management|
218888179|NCT00903305|PROCEDURE|psychosocial assessment and care|
218888180|NCT00903305|PROCEDURE|quality-of-life assessment|
218888181|NCT06009328|OTHER|fundamental movement skills|measured by test of gross motor development
218888182|NCT02387554|DRUG|HGP0904|
218888183|NCT02387554|DRUG|HGP0608|
218888184|NCT02387554|DRUG|HGP1405|
218888185|NCT05526898|DEVICE|SyntrFuge System|Microsized Adipose Tissue
219508129|NCT03764410|PROCEDURE|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
218888186|NCT05526898|DRUG|Triamcinolone Injection|Corticosteroid
218888187|NCT05797636|DEVICE|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
218888188|NCT00856297|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
218888189|NCT00856297|BIOLOGICAL|Licensed comparator|
219031482|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
219202547|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
219202548|NCT06687785|PROCEDURE|Entire Papilla Preservation Technique|A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.
219508130|NCT00669955|DRUG|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
219508131|NCT00669955|DRUG|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
219508132|NCT04066179|DRUG|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
219031483|NCT03970590|BEHAVIORAL|CTC Intervention|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
219031484|NCT03970590|BEHAVIORAL|Control|6-month HTN management assessment text messages without narrative component
219508133|NCT04066179|DRUG|Prednisolone|Prednisolone 40 mg for initial 7 days
219031485|NCT03840083|BEHAVIORAL|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
219031486|NCT01206179|BIOLOGICAL|cell injection|Injection of mesenchymal cells in fractured zone
219031487|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program.|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
219031488|NCT06104059|DEVICE|Nociception level index (NOL™)|If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
219202549|NCT06687785|PROCEDURE|Conventional Flap Surgery Technique|After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
219202550|NCT06673745|OTHER|IASTM|"Group A received IASTM treatment, which will be given by the Edge tool, that is an ergonomically designed stainless steel instrument and offers several different hand holds, eliminating operator fatigue. Prior to the treatment, the IASTM therapeutic effects will be explained. The scanning assessment will be done to identify areas of restrictions directed by the gritty sensations using the Edge tool. Each restriction will be treated with the tool for 30-60 sec and given. This treatment will be given for 30 minutes for 3 days per week for 4 weeks"
219508134|NCT03311009|DRUG|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
219508135|NCT03311009|DRUG|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
219508136|NCT03311009|DRUG|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
219508137|NCT03311009|DRUG|Placebo|Matching placebo provided as oral tablets q.d.
219508138|NCT00367406|DEVICE|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
219508139|NCT01208142|OTHER|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
219508140|NCT01208142|DEVICE|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
219508141|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
218888190|NCT05165758|OTHER|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
218888191|NCT04374006|DRUG|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
218888192|NCT04374006|DRUG|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
218888193|NCT04374006|OTHER|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
219508142|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
219508143|NCT01066481|DRUG|Placebo|Placebo three times daily for 6 months
218888194|NCT01459744|BEHAVIORAL|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
218888195|NCT01459744|OTHER|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
218888196|NCT02659436|OTHER|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
218888197|NCT02659436|OTHER|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
218888198|NCT00305149|PROCEDURE|interim therapy scintigraphy study gallium scan or PET/CT|
218888199|NCT00305149|PROCEDURE|"interim gallium or PET/CT"|
219202551|NCT06673745|OTHER|Dynamic cupping therapy|On the contrary, group B the patient will be seated in a chair with the elbow flexed on the plinth to relax the forearm muscles. The area around the elbow joint will be cleaned with alcohol to remove any foreign bodies from the treated area. Dynamic cupping therapy for elbow stiffness will begin with an assessment of the patient\&amp;#39;s condition, where factors such as the extent of stiffness and range of motion in the elbow joint will be evaluated. Following this assessment, lubricant will be applied to the skin surrounding the elbow to facilitate smooth movement of the cups. Cups of suitable size and material will then be strategically placed around the elbow joint, and suction will be created inside each cup to create a vacuum effect. Once thesecurely attached, the practitioner will move them around the elbow area using gentle techniques such as gliding or pumping motions.
218888200|NCT03296943|COMBINATION_PRODUCT|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
219031489|NCT06104059|OTHER|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
219031490|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
219202552|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|In the current study, the impact of Digital Mental Health Intervention (DMHI) would be examined through Insight Timer application, focusing on just its one aspect (Reiki healing techniques). Through the usage of DMHIs in the young population, youth would be better able to express their psychological issues with the healthcare professionals instead of the fear of being labelled or stigmatization.
219202553|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|Digital Mental Health Intervention (DMHI) was provided to the sample of young adults who were experiencing psychological distress. DMHI was being given through Insight Timer application that only focused on reiki healing techniques. Insight Timer is a mobile app that provides guided meditations to calm the mind, alleviate anxiety, manage stress, achieve deep sleep, and enhance well-being and happiness. Additionally, it offers calm and soothing music, educational courses, live events, and workshops in multiple languages. (Insight Network, Inc., n.d.). The app is FREE to download with an email allowing access to their collection of meditation recordings. Insight Timer's free-to-use feature is most suitable for community groups.
219202554|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
219202555|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
218888201|NCT03296943|COMBINATION_PRODUCT|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
218888202|NCT03296943|BEHAVIORAL|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
218888203|NCT03325036|DIAGNOSTIC_TEST|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
218888204|NCT03345537|OTHER|Non interventional study|Non interventional study - only data collected and one blood sample additional
219202556|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
219202557|NCT05761769|OTHER|no intervention|no intervention
219508144|NCT05491174|BEHAVIORAL|DBT-Informed skills group|10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
219508145|NCT05480917|OTHER|Patients receiving PsoPlus care|As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
219508146|NCT02743442|DEVICE|da Vinci® Si™|
219508147|NCT00228462|DRUG|Seroquel (quetiapine)|
218888205|NCT04008251|GENETIC|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
218888206|NCT04701736|DEVICE|Picture Medication Calendar|
218888207|NCT04227132|DEVICE|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
218888208|NCT04227132|DEVICE|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
218888209|NCT04499989|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
218888210|NCT04499989|DRUG|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
218888211|NCT03865641|DEVICE|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
218888212|NCT01497249|DIETARY_SUPPLEMENT|A dietary fiber (FCHO)|15 g twice per day in beverage
218888213|NCT01497249|DIETARY_SUPPLEMENT|Placebo|Placebo drink
219031491|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
218888214|NCT03514875|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
218888215|NCT03514875|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
218888216|NCT03256318|OTHER|No intervention|No intervention; surveys/questionnaires only
218888217|NCT00912457|DRUG|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
218888218|NCT00912457|DRUG|placebo|placebo 1 p/day for 28 days
218888219|NCT01273324|DEVICE|ADM Cup|ADM Cup
218888220|NCT05370833|DEVICE|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
218888221|NCT05352425|DEVICE|MobiusHD|The MobiusHD® device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
218888222|NCT02818049|PROCEDURE|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
218888223|NCT06137599|OTHER|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
219202558|NCT06700850|DEVICE|Prototype dressing rectangle|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 30x10cm. Topical application. Single use.
219202559|NCT06700850|DEVICE|Marketed dressing rectangle|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 30x10cm. Topical application. Single use
219508148|NCT02022501|DRUG|DE-120|
219508149|NCT00003938|DRUG|liposomal amphotericin B|
218888224|NCT05485285|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
218888225|NCT03483545|COMBINATION_PRODUCT|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
219508150|NCT03591549|DRUG|Faslodex|intramuscular injection monthly
219508151|NCT03591549|DRUG|Zoladex|intramuscular injection monthly
219508152|NCT01033344|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
219508153|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
218888226|NCT06077032|DRUG|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
218888227|NCT06077032|DRUG|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
219508154|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
219508155|NCT03061760|PROCEDURE|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
219508156|NCT03061760|DIAGNOSTIC_TEST|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
219508157|NCT03061760|DIAGNOSTIC_TEST|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
219508158|NCT01432132|BEHAVIORAL|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
219508159|NCT01432132|BEHAVIORAL|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
218888228|NCT06077032|DRUG|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
218888229|NCT00801398|DRUG|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
218888230|NCT00028327|DRUG|Lamivudine/Zidovudine|
219508160|NCT03323632|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
218888231|NCT00028327|DRUG|Nelfinavir mesylate|
218888232|NCT00028327|DRUG|Efavirenz|
218888233|NCT00028327|DRUG|Lamivudine|
218888234|NCT00028327|DRUG|Zidovudine|
218888235|NCT01022099|PROCEDURE|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
218888236|NCT01885624|BIOLOGICAL|TAB08|monoclonal antibody
218888237|NCT04009395|OTHER|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
218888238|NCT04009395|OTHER|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
218888239|NCT01179152|DRUG|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
218888240|NCT05407155|COMBINATION_PRODUCT|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
218888241|NCT00138775|DRUG|D-serine|
218888242|NCT00979771|DRUG|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
218888243|NCT00979771|DRUG|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
219031492|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
219031493|NCT01014429|DRUG|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
219031494|NCT03980769|DRUG|Thiotepa|Given IV
219031495|NCT03980769|DRUG|Treosulfan|Given IV
219031496|NCT03980769|DRUG|Fludarabine Phosphate|Given IV
219031497|NCT03980769|BIOLOGICAL|Rabbit Anti-Thymocyte Globulin|Given IV
219031498|NCT03980769|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
219031499|NCT03980769|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219508161|NCT05974020|OTHER|Control|No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
218888244|NCT00370565|DRUG|Inhaled Human Insulin|
218888245|NCT02161055|DRUG|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
218888246|NCT03274856|DRUG|GLWL-01|Oral administration of 3 capsules, twice a day
218888247|NCT03274856|DRUG|Placebo|Oral administration of 3 capsules, twice a day
218888248|NCT01714401|DRUG|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
218888249|NCT01714401|DRUG|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
218888250|NCT03121703|OTHER|lumbar stabilization exercise|lumbar stabilization exercise
218888251|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
218888252|NCT06300073|DEVICE|Experimental: U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
218888253|NCT06300073|DEVICE|Placebo Comparator: Soft Manual Toothbrush|Twice daily brushing for 2 minutes with fluoride toothpaste
218888254|NCT00030862|DRUG|cisplatin|
218888255|NCT00030862|DRUG|irinotecan hydrochloride|
218888256|NCT02260947|DRUG|PF-06273340|PF-06273340 50 mg
219031500|NCT03980769|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218888257|NCT02260947|DRUG|PF-06273340|PF-06273340 400 mg
218888258|NCT02260947|DRUG|Pregabalin|Pregabalin 300 mg
218888259|NCT02260947|DRUG|Ibuprofen|Ibuprofen 600 mg
218888260|NCT02260947|DRUG|Placebo|Matching Placebo
218888261|NCT05711472|OTHER|birth ball exercise|birth ball exercise used in childbirth
219031501|NCT03980769|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219031502|NCT03980769|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219508162|NCT05974020|OTHER|Intrinsic Muscle Training|"In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program."
219031503|NCT02211131|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
219031504|NCT02211131|PROCEDURE|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
219031505|NCT02952339|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
219031506|NCT02952339|BIOLOGICAL|Placebo|Administered as nose drops
219031507|NCT00696852|BEHAVIORAL|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
219031508|NCT00696852|BEHAVIORAL|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
219031509|NCT00696852|BEHAVIORAL|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
219031510|NCT05504941|DIAGNOSTIC_TEST|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
219031511|NCT03162978|OTHER|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
219031512|NCT03162978|OTHER|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
219031513|NCT04493060|BIOLOGICAL|Dostarlimab|Given IV
219031514|NCT04493060|DRUG|Niraparib|Given PO
219031515|NCT05492110|DEVICE|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
219031516|NCT05492110|OTHER|Sham-procedure|Implantation procedure with no device implanted
219508163|NCT05974020|OTHER|Aerobic Exercise|In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
218888262|NCT00741442|DRUG|RDEA806|Uricosuric agent for the treatment of gout
218888263|NCT00741442|DRUG|Placebo|Matching Placebo.
218888264|NCT04859816|OTHER|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
218888265|NCT04859816|OTHER|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
218888266|NCT04859816|OTHER|MRS|Magnetic resonance spectroscopy of liver fat content
218888267|NCT04859816|OTHER|Feces collection|4-day feces collection
218888268|NCT00630435|DRUG|Premarin®/MPA formulation A|
218888269|NCT00630435|DRUG|Premarin®/MPA formulation B|
218888270|NCT00630435|DRUG|Premarin®/MPA formulation C|
218888271|NCT00630435|DRUG|Premarin®/MPA currently marketed product|
218888272|NCT00543335|DRUG|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
218888273|NCT00543335|PROCEDURE|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
218888274|NCT03759691|BEHAVIORAL|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
218888275|NCT01808235|BEHAVIORAL|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
218888276|NCT04688255|BEHAVIORAL|MSTEP|Aerobic exercise that is advanced weekly
219031517|NCT05492110|DIAGNOSTIC_TEST|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
219031518|NCT04165070|BIOLOGICAL|Pembrolizumab|IV infusion
219031519|NCT04165070|DRUG|Carboplatin|IV infusion
219031520|NCT04165070|DRUG|Paclitaxel|IV infusion
219031521|NCT04165070|DRUG|Pemetrexed|IV infusion
219031522|NCT04165070|BIOLOGICAL|Vibostolimab|IV infusion
218888277|NCT04688255|BEHAVIORAL|Stretching|Stretching exercises that are advanced weekly
218888278|NCT00811174|DRUG|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
218888279|NCT03833726|PROCEDURE|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
218888280|NCT03833726|PROCEDURE|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
218888281|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
218888282|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
218888283|NCT02804126|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
218888284|NCT02804126|PROCEDURE|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
218888285|NCT02804126|DRUG|Bupivacaine|In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
218888286|NCT02804126|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
219031523|NCT04165070|BIOLOGICAL|Boserolimab|IV infusion
219031524|NCT04165070|BIOLOGICAL|MK-4830|IV infusion
219031525|NCT04165070|BIOLOGICAL|MK-0482|IV Infusion
219031526|NCT04165070|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
219031527|NCT04165070|BIOLOGICAL|HER3-DXd|IV Infusion
219031528|NCT05414045|PROCEDURE|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If the patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate, the investigators will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
219031529|NCT00971347|OTHER|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
219031530|NCT00971347|BEHAVIORAL|nutrition brochure|one-time at baseline visit
219031531|NCT04553432|DEVICE|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
219202560|NCT06700850|DEVICE|Prototype dressing square|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 7.5x7.5cm. Topical application. Single use.
219508164|NCT04261296|OTHER|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
219508165|NCT04261296|OTHER|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
219508166|NCT04261296|OTHER|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
218888287|NCT02804126|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
218888288|NCT02804126|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
218888289|NCT02804126|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
218888290|NCT02804126|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
218888291|NCT03223337|DRUG|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
219031532|NCT04553432|DEVICE|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
218888292|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
218888293|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
218888294|NCT01362608|DRUG|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
218888295|NCT01362608|DRUG|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
219031533|NCT02939560|DEVICE|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
219031534|NCT04606576|OTHER|Placebo|Fish Oil
219031535|NCT04606576|DRUG|ORMD-0801 QD|Oral Insulin once per day
219031536|NCT04606576|DRUG|ORMD-0801 BD|Oral Insulin, twice per day
219202561|NCT06700850|DEVICE|Marketed dressing square|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 7.5x7.5cm. Topical application. Single use.
219202562|NCT06699810|DEVICE|Continuous Glucose Monitoring|After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
219202563|NCT06699810|DRUG|Insulin|Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
219202564|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.
219202565|NCT06702241|OTHER|Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
219508167|NCT01170260|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
218888296|NCT03403439|DRUG|BI 1015550|Reference and Test Treatment
218888297|NCT03403439|DRUG|itraconazole|Test treatment
218888298|NCT01679132|DEVICE|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
218888299|NCT00877240|BEHAVIORAL|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
218888300|NCT00863005|DRUG|K201|Cream
218888301|NCT00863005|DRUG|K201|
218888302|NCT01336140|DRUG|Aminophylline|75 mg of intravenous aminophylline
218888303|NCT01336140|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
218888304|NCT01978041|OTHER|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
218888305|NCT01978041|OTHER|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
218888306|NCT01978041|OTHER|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
218888307|NCT01978041|OTHER|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
218888308|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
219031537|NCT05398432|OTHER|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
219031538|NCT06389747|OTHER|BFR technique|For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
219031539|NCT05608421|BEHAVIORAL|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
219031540|NCT05608421|BEHAVIORAL|1MoreStepControl|This is an equal attention control group.
219031541|NCT01170494|DRUG|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
219031542|NCT01170494|DRUG|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
219031543|NCT01170494|DRUG|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
219031544|NCT01170494|DRUG|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
219031545|NCT01170494|DRUG|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
219031546|NCT01170494|DRUG|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
219031547|NCT01170494|DRUG|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
219031548|NCT01170494|DRUG|placebo orally everyday|placebo orally everyday
219031549|NCT03340025|DEVICE|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
218888309|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
218888310|NCT05115032|DEVICE|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
218888311|NCT05115032|BEHAVIORAL|At-home rehabilitation exercises|6 weeks of daily rehabilitation exercises involving nodding and shaking of the head
219031550|NCT03340025|DEVICE|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
219508168|NCT01170260|BEHAVIORAL|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
218888312|NCT03814408|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
218888313|NCT00971139|BEHAVIORAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
218888314|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
218888315|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
218888316|NCT06797128|PROCEDURE|One Anchor|Participant will receive one standard anchor
218888317|NCT06797128|PROCEDURE|Two Mini Anchors|Participant will receive two mini anchors
218888318|NCT04506502|DEVICE|The ZELTIQ System|The MMS device will be used to perform the treatments.
218888319|NCT06794021|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for seven days
218888320|NCT06794021|OTHER|Placebo|Eligible subjects will receive Placebo to take daily for seven days
219202566|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
219202567|NCT06702241|OTHER|Cycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
218888321|NCT05475522|DEVICE|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
218888322|NCT05475522|DEVICE|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
218888323|NCT05411120|OTHER|Western Diet|Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.
218888324|NCT05411120|OTHER|CLEAN-MED|Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
218888325|NCT06796491|OTHER|Post Isometric relaxation|Group A will receive Post Isometric Relaxation (PIR) Patient applied the sub-maximal contraction almost 20%. Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained.4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week for 4 weeks conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
219031551|NCT02443142|DRUG|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
219031552|NCT02443142|DRUG|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
219031553|NCT01366339|DRUG|Oral methylnaltrexone|
219031554|NCT01366339|DRUG|Oral placebo|
219202568|NCT06699875|OTHER|Trak exercise prescription protocol at home|Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.
219202569|NCT06699875|OTHER|Conventional rehabilitation plan at home|Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
219031555|NCT00755131|OTHER|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
219031556|NCT02567955|BIOLOGICAL|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
219031557|NCT02567955|BIOLOGICAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
219031558|NCT01630512|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
219031559|NCT01630512|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
219031560|NCT03491995|DRUG|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
219202570|NCT06700928|OTHER|External focus training|External focus training
219202571|NCT06700928|OTHER|Internal focus training|internal focus training
219202572|NCT06700928|OTHER|No attentional focus training|no attentional focus training
219202573|NCT04177771|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
219202574|NCT04177771|DEVICE|SofPort LI61AO IOL|Control treatment group will receive SofPort LI61AO IOL
219202575|NCT04177771|DEVICE|Tecnis ZCB00 or ZTC150 IOL|Control treatment group will receive Tecnis ZCB00 or ZTC150 IOL
219202576|NCT02806726|DEVICE|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
218888326|NCT06796491|OTHER|Post Facilitation stretch|Group B will receive Post Facilitation Stretch (PFS) Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained. 4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week 4 weeks. for hamstring flexibility conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
218888327|NCT05446220|BEHAVIORAL|Lifestyle intervention|Dietary advise and/or advise on physical activity monitored by pedometer
218888328|NCT04073420|DEVICE|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
219202577|NCT02806726|DEVICE|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
218888329|NCT04073420|DEVICE|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
218888330|NCT02275741|BIOLOGICAL|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
218888331|NCT01378767|DIETARY_SUPPLEMENT|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
218888332|NCT03526146|BEHAVIORAL|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
218888333|NCT03769558|OTHER|Non-Interventional|Non-Interventional
218888334|NCT00971074|DRUG|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
218888335|NCT00971074|OTHER|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
218888336|NCT05556668|DEVICE|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
219031561|NCT03491995|DRUG|Classic treatment|Omeprazole, amoxycillin, clarithromycin
219031562|NCT03205410|PROCEDURE|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
219031563|NCT03205410|PROCEDURE|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
219031564|NCT06802029|GENETIC|Whole Genome Sequencing Analysis|Laboratory blood analysis
219031565|NCT06801912|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
219031566|NCT03063892|DRUG|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
219031567|NCT03063892|DRUG|Saline solution|Saline solution is used as the placebo comparator
219031568|NCT04773158|BEHAVIORAL|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
219031569|NCT00017147|DRUG|carmustine|"40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
219031570|NCT00017147|RADIATION|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
219031571|NCT00017147|DRUG|O6-Benzylguanine|120 mg/m\^2 IV over 1 hour on day 1 of each cycle
219031572|NCT06009263|OTHER|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
219031573|NCT06009263|OTHER|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
219202578|NCT03443791|DIAGNOSTIC_TEST|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
219202579|NCT03443791|DIAGNOSTIC_TEST|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
218888337|NCT05947617|DRUG|VIX001|"This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes."
218888338|NCT03564652|DIETARY_SUPPLEMENT|Balanced energy-protein (BEP)|Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
218888339|NCT03564652|DRUG|Azithromycin|A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
218888340|NCT05096065|DRUG|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
218888341|NCT05096065|DRUG|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
218888342|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
218888343|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
218888344|NCT05096065|DRUG|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
219031574|NCT06009263|OTHER|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
219031575|NCT03035123|BEHAVIORAL|Therapeutic education|Interventional arm
219202580|NCT03966586|BEHAVIORAL|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
219202581|NCT03966586|BEHAVIORAL|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
218888345|NCT02305771|DEVICE|Electroencephalography|
218888346|NCT02305771|DEVICE|MRI|
219031576|NCT02420691|OTHER|Laboratory Biomarker Analysis|Correlative studies
219031577|NCT02420691|OTHER|Pharmacological Study|Correlative studies
219031578|NCT02420691|DRUG|Ribociclib|Given PO
219202582|NCT03966586|BEHAVIORAL|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
218888347|NCT04627155|DRUG|LY03003|Rotigotine,extended-release microspheres
218888348|NCT02030522|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
219031579|NCT04390477|DIETARY_SUPPLEMENT|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
219031580|NCT03002012|DRUG|Sertraline|sertraline 400mg/day
219031581|NCT03002012|DRUG|Placebo Oral Tablet|matched placebo tablet
219508169|NCT01170260|BEHAVIORAL|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
219508170|NCT05919459|BEHAVIORAL|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
218888349|NCT01870115|DIETARY_SUPPLEMENT|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
218888350|NCT01870115|DIETARY_SUPPLEMENT|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
219508171|NCT05919459|BEHAVIORAL|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
218888351|NCT01569620|BEHAVIORAL|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
218888352|NCT01569620|BEHAVIORAL|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
218888353|NCT01569620|BEHAVIORAL|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
218888354|NCT05078372|DRUG|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
218888355|NCT05078372|DRUG|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
218888356|NCT02214290|DRUG|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
218888357|NCT02214290|DRUG|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
218888358|NCT02214290|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
218888359|NCT03158324|DRUG|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
219031582|NCT03002012|DRUG|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
219031583|NCT06113198|BIOLOGICAL|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
219031584|NCT03636347|DRUG|Placebo Oral Tablet|twice daily administration
219031585|NCT03636347|DRUG|Alvelestat oral tablet - dose 1|twice daily administration
219031586|NCT03636347|DRUG|Alvelestat oral tablet - dose 2|twice daily administration
219031587|NCT03167879|BEHAVIORAL|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
219031588|NCT04814576|BEHAVIORAL|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
219031589|NCT02129985|DRUG|Exenatide|Exenatide (10 ug/bid for 3 months)
219031590|NCT02129985|DRUG|Metformin|Metformin 850 mg/bid for 3 months
219031591|NCT00854945|DRUG|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
219031592|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
219031593|NCT01480076|DRUG|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
219031594|NCT00704535|DRUG|Ezetimibe|1 tablet of 10 mg once daily
219031595|NCT01923415|PROCEDURE|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
219031596|NCT01923415|PROCEDURE|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
219031597|NCT01923415|PROCEDURE|No intervention, urine collection|Urine will be collected from all participants.
219031598|NCT04508790|DRUG|Dexamethasone|Given PO
219031599|NCT04508790|DRUG|Leflunomide|Given PO
219031600|NCT04508790|DRUG|Pomalidomide|Given PO
219031601|NCT02503332|DRUG|Pegcetacoplan|
219031602|NCT02503332|OTHER|Sham Procedure|
219031603|NCT05457257|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
219031604|NCT05457257|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
219031605|NCT05457257|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
219031606|NCT05457257|DRUG|Prednisone|5mg(5mg x 1 tablet) twice daily
219031607|NCT05169385|BEHAVIORAL|Parent SMART|Parent SMART experimental intervention
219031608|NCT05169385|BEHAVIORAL|Treatment as Usual|Residential treatment as usual
219508172|NCT06278402|DRUG|Tofacitinib|Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
219508173|NCT03507439|DEVICE|AVIVO Mobile Patient Management (MPM) System|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
218888360|NCT05159518|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion
219508174|NCT03507439|DEVICE|VitalPatch biosensor|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
218888361|NCT00941317|DEVICE|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
218888362|NCT02517541|DEVICE|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
219508175|NCT03507439|DEVICE|DynaPort Move Monitor|Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study
219202583|NCT03966586|BEHAVIORAL|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
218888363|NCT02083536|RADIATION|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
219508176|NCT04274192|OTHER|Synchronized HFNC at 6 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
219508177|NCT04274192|OTHER|Continuous HFNC at 6 liters per minute (LPM)|Standard HFNC therapy at 6 LPM
218888364|NCT02083536|DRUG|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
218888365|NCT00699608|DRUG|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
219508178|NCT04274192|OTHER|Synchronized HFNC at 8 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
219508179|NCT04274192|OTHER|Continuous HFNC at 8 liters per minute (LPM)|Standard HFNC therapy at 8 LPM
219508180|NCT06210269|DRUG|Moxifloxacin 400mg|Oral antibiotic
219508181|NCT06210269|OTHER|Placebo|Oral placebo
218888366|NCT06023706|DRUG|Capsaicin 179 Mg Cutaneous Patch|1 patch applied once for 1 hour
219508182|NCT01848652|DRUG|infusion of MYOCET|
219508183|NCT06526871|PROCEDURE|Low-Level Laser acceleration|This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .
218888367|NCT06023706|DRUG|Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)|1 patch applied once for 1 hour
218888368|NCT01426672|OTHER|Monovision Correction (with the help of glasses or contact lenses)|
218888369|NCT01510158|DRUG|Lesinurad|Tablets, 200 mg once daily (qd)
218888370|NCT01510158|DRUG|Lesinurad|Tablets, 400 mg qd
218888371|NCT01510158|DRUG|Placebo|Tablets, Placebo qd
218888372|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
218888373|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
218888374|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
218888375|NCT00566462|DRUG|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
218888376|NCT00566462|DRUG|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
219031609|NCT06562296|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
219031610|NCT06562296|OTHER|Amnion-Chorion-Amnion|Dehydrated human placental trilayer allograft derived from donated human tissue.
219031611|NCT06562296|PROCEDURE|Standard of Care|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
219031612|NCT04661748|DEVICE|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
219031613|NCT01413360|DRUG|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
219031614|NCT00521768|BEHAVIORAL|Prolonged exposure|
219031615|NCT06370156|DRUG|Adalimumab|To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
219031616|NCT04045496|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
219031617|NCT05228288|PROCEDURE|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
219031618|NCT05228288|PROCEDURE|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
219031619|NCT05228288|PROCEDURE|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
219031620|NCT00864877|DEVICE|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
219031621|NCT00815438|PROCEDURE|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
219202584|NCT03966586|BEHAVIORAL|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
219202585|NCT03966586|BEHAVIORAL|Usual clinical care and counseling|Usual clinical care and counseling
219202586|NCT06877182|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To evaluate the possibility to improve the neuroradiologic workflow with AI models
219202587|NCT06879691|DRUG|Nimotuzumab|nimotuzumab group nimotuzumab, 200mg/w, for 6 weeks
218888377|NCT02245945|DRUG|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
219202588|NCT06879691|DRUG|cis-platinum|30mg/m2/w, for 6 weeks
219508184|NCT06526871|PROCEDURE|clear aligner therapy|Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
219508185|NCT03908021|DIAGNOSTIC_TEST|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
219508186|NCT01557595|DEVICE|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
218888378|NCT02245945|DRUG|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
218888379|NCT03827603|DRUG|Ibrutinib|Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
219202589|NCT06879691|RADIATION|IMRT combine with cisplatin concurrent chemotherapy|IMRT, 66～70Gy (2Gy/F, 35F), for 6 weeks
219202590|NCT06879691|DRUG|painkiller|three ladders pain analgesic( First step: For mild pain, non-opioid agents (excluding nonsteroidal anti-inflammatory drugs \[NSAIDs\]) combined with adjuvant analgesics are administered; Second step: For moderate pain, weak opioids combined with NSAIDs and adjuvant analgesics are prescribed;Third step: For severe pain, strong opioids combined with NSAIDs and adjuvant analgesics are used.)
219202591|NCT06880289|DRUG|Cisplatin IV on days 1, 22, 43, at a dose of 100 mg/m2|Chemoradiotherapy will be performed from day 1 to day 49 regardless of the arm.
219202592|NCT06878469|DEVICE|RehaCom|Participants will receive a personalized neuro-cognitive rehabilitation program using the RehaCom software. Sessions will last approximately 30/40 minutes and will be held twice a week for 8 weeks. The rehabilitation will be aimed at enhancing and/or recovering cognitive functions that may have been compromised by the neurosurgical intervention.
219202593|NCT06877481|OTHER|Geriatric Pain Measurement Short Form|Geriatric Pain Measure - Short Form (GPM-SF) is a validated pain assessment tool designed specifically for older adults. It is a 12-item questionnaire that evaluates pain intensity, interference with daily activities, and emotional impact of chronic pain in geriatric patients. The short form provides a quick and reliable assessment of pain-related disability in older populations.
219202594|NCT06877312|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219202595|NCT06877312|DEVICE|30 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 30 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219508187|NCT06114433|OTHER|3D printed educational model|Slide-based presention plus 3D printed educational model
219508188|NCT06114433|OTHER|Traditional model education|Slide-based presention plus traditional model
219508189|NCT01717898|DRUG|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
218888380|NCT00449124|DRUG|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
218888381|NCT00449124|BIOLOGICAL|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
218888382|NCT03782701|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
219508190|NCT01717898|DRUG|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
219508191|NCT01717898|DRUG|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
219508192|NCT03632174|OTHER|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
219508193|NCT03632174|OTHER|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
219508194|NCT03265470|DRUG|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
219508195|NCT03265470|DRUG|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
219508196|NCT01607775|DEVICE|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
219508197|NCT01607775|DEVICE|PMMA-cage|The in-house produced cervical cage will be implanted
219508198|NCT04219202|RADIATION|Proton radiation|Therapeutic radiation Treatment with Protons
219508199|NCT04219202|RADIATION|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
218888383|NCT03782701|OTHER|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
218888384|NCT04555564|PROCEDURE|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
219508200|NCT03673826|DRUG|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
219031622|NCT04415281|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
219031623|NCT04415281|DEVICE|sham THOR® laser system|sham THOR® laser system
219031624|NCT01202825|DRUG|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
219508201|NCT03673826|DRUG|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
219508202|NCT03673826|DRUG|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
219508203|NCT01883089|BEHAVIORAL|Motivational Enhancement Therapy|
219508204|NCT02986763|BIOLOGICAL|Questionnaire, blood, urine, hair and dust samplings|
219508205|NCT04606563|DRUG|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
219508206|NCT04606563|DRUG|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
219508207|NCT04606563|DRUG|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
219031625|NCT01202825|DRUG|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
219031626|NCT01202825|DRUG|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
219031627|NCT01202825|DRUG|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
219031628|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
219031629|NCT01202825|DRUG|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
219508208|NCT04606563|DRUG|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
219508209|NCT04606563|DRUG|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
219508210|NCT04606563|DRUG|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
219508211|NCT04606563|DRUG|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
219508212|NCT04606563|DRUG|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
219508213|NCT04230226|DIETARY_SUPPLEMENT|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
219508214|NCT04230226|OTHER|Placebo|Placebo product consumed prior and after exercise
219508215|NCT05659550|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
219508216|NCT00258622|DRUG|NS1209|
219508217|NCT00258622|DRUG|Lidocaine|
219508218|NCT02770950|DRUG|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
219508219|NCT02770950|DRUG|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
219508220|NCT02770950|DRUG|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
218888385|NCT06123000|PROCEDURE|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
219031630|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
219508221|NCT01621490|BIOLOGICAL|Nivolumab|
219508222|NCT01621490|DRUG|Ipilimumab|
219031631|NCT01202825|DRUG|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
219202596|NCT06877312|DEVICE|50 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 50 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219202597|NCT06877312|DEVICE|70 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 70 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219202598|NCT06877312|DEVICE|90 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 90 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219508223|NCT02253277|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
219508224|NCT02253277|DRUG|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
219508225|NCT05870553|DRUG|CTP0301-A|Bowel Preparation
218888386|NCT06123000|PROCEDURE|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
219031632|NCT01202825|DRUG|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
219031633|NCT01202825|DRUG|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
219031634|NCT05831202|DEVICE|The SEAL™ Saccular Endovascular Aneurysm Lattice System|All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
219031635|NCT00100243|DRUG|Plenaxis|
219031636|NCT02196285|BIOLOGICAL|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
219202599|NCT06877312|DEVICE|Transcranial Random Noise Stimulation (tRNS)|"A light electrical current with random noise waveform (tRNS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
219508226|NCT05870553|DRUG|CTP0301-B|Bowel Preparation
219508227|NCT05870553|DRUG|Cool prep|Bowel Preparation
219508228|NCT00461500|DRUG|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
219508229|NCT00461500|DRUG|Fluticasone propionate|FP 100
219031637|NCT02927379|DRUG|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
219508230|NCT01240005|BIOLOGICAL|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
219508231|NCT00002252|DRUG|Octreotide|
219508232|NCT05215899|OTHER|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
219508233|NCT05031728|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
218888387|NCT03502473|DEVICE|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer"
218888388|NCT01013194|OTHER|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2."
219031638|NCT02927379|DRUG|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
219031639|NCT02927379|DRUG|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
219031640|NCT01488097|DRUG|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
219031641|NCT03999411|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
219031642|NCT03999411|BEHAVIORAL|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
218888389|NCT03010319|DEVICE|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
218888390|NCT03010319|DEVICE|Secondary Dressings|Dressings to ensure moist wound environment
218888391|NCT03010319|DEVICE|Offloading device|Offloading device to decrease pressure to wound area
218888392|NCT02682732|PROCEDURE|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
218888393|NCT00087334|DRUG|capecitabine|
218888394|NCT00087334|DRUG|gefitinib|
219031643|NCT03999411|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
219031644|NCT03999411|BEHAVIORAL|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
219031645|NCT03999411|BEHAVIORAL|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
219031646|NCT02701972|DEVICE|BACE Device|Implanted BACE device
219031647|NCT02016482|BIOLOGICAL|Adalimumab|
219031648|NCT02016482|OTHER|Placebo|
219031649|NCT06146582|BEHAVIORAL|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
219031650|NCT01167231|DRUG|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
219031651|NCT03054870|DRUG|Xe-133|Xe-133 ventilation scintigraphy
219031652|NCT03054870|DRUG|Technegas|Technegas ventilation scintigraphy
219031653|NCT00924872|OTHER|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
219031654|NCT02918851|BIOLOGICAL|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
219508234|NCT04360811|DIAGNOSTIC_TEST|COVID 19 diagnostic test by PCR|"1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis"
219508235|NCT00879554|BIOLOGICAL|CVX-045|Weekly, intravenous dose
219508236|NCT04154709|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
219508237|NCT05925153|OTHER|No intervention|No intervention
218888395|NCT00087334|DRUG|oxaliplatin|
218888396|NCT04121702|PROCEDURE|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
218888397|NCT04770038|BEHAVIORAL|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
219202600|NCT06877143|DIETARY_SUPPLEMENT|100% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
219202601|NCT06877143|DIETARY_SUPPLEMENT|120% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
219202602|NCT06880315|BEHAVIORAL|Pre-Generated Personalized LLM Coaching Impact|After the initial 7 days, participants will switch to the other type of prompting for another 7 days. This means that participants who initially received personalized LLM-generated prompts will then receive generic activity prompts, and vice versa. This crossover design allows for each participant to experience both types of interventions, providing a within-subject comparison of the effectiveness of personalized versus generic prompts in increasing physical activity levels.
219202603|NCT06876805|DIAGNOSTIC_TEST|CEUS or Contrast enhanced Ultrasound|CEUS performed as normal clinical practice
219202604|NCT06878053|PROCEDURE|ethanol sclerotherapy|The originality of this project consists in evaluating the effectiveness of ethanol sclerotherapy of endometrioma(s) in infertile patients before IVF/ICSI, excluding patients who have previously had an ovarian cystectomy. To date, no prospective randomized comparative study between ethanol sclerotherapy of endometriomas and therapeutic abstention has been carried out.
219202605|NCT06684275|PROCEDURE|Pulsed Radiofrequency (PRF)|Participants will receive pulsed radiofrequency (PRF) treatment targeting the trigeminal nerve to manage pain associated with trigeminal neuralgia. This non-ablative technique uses electrical pulses to modulate nerve function, aiming to provide pain relief without creating a thermal lesion.
219202606|NCT06684275|PROCEDURE|Pulsed and Thermal Radiofrequency (PRF + TRF)|Participants will receive a combination of pulsed radiofrequency (PRF) and thermal radiofrequency (TRF) treatments targeting the trigeminal nerve. This approach combines the non-ablative effects of PRF with the thermal lesioning of TRF to provide long-term pain relief for trigeminal neuralgia.
218888398|NCT01908478|DRUG|Veliparib|
218888399|NCT01908478|DRUG|Gemcitabine|
218888400|NCT01908478|RADIATION|Intensity modulated radiation therapy|
218888401|NCT03371693|DEVICE|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
219508238|NCT01806597|BIOLOGICAL|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
219508239|NCT01806597|BIOLOGICAL|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
218888402|NCT03371693|DEVICE|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
218888403|NCT03371693|DEVICE|IVCT|platinum-based intravenous chemotherapy
218888404|NCT01817426|DRUG|Infliximab|
218888405|NCT01817426|OTHER|Placebo|
218888406|NCT02128724|DRUG|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
218888407|NCT01347242|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
218888408|NCT02644317|DEVICE|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
218888409|NCT03897556|DIETARY_SUPPLEMENT|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
218888410|NCT03897556|OTHER|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
218888411|NCT02057172|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
218888412|NCT02057172|DRUG|liraglutide|Liraglutide is a GLP-1 agonist.
219202607|NCT06758414|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
219202608|NCT06758414|BEHAVIORAL|Health & Wellness (H&W)|Health \& Wellness (H\&W) was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
219202609|NCT06686576|BIOLOGICAL|QL1706|Phase Ib/Ⅲ： QL1706 will be administered
218888413|NCT02057172|DRUG|Placebo|Placebo
218888414|NCT03368586|DEVICE|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (\<4.0 mmol/L) or high (\>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
219202610|NCT06686576|DRUG|CAPEOX|Phase Ⅲ：CAPEOX will be administered
219202611|NCT03527537|DRUG|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
219202612|NCT06526663|BEHAVIORAL|vignette exposure|"Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes."
219202613|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
219202614|NCT06704945|PROCEDURE|No axillary surgery|BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.
219202615|NCT06704945|PROCEDURE|Axillary surgery|BCS with SLNB(+/-ALND)
219202616|NCT05259605|OTHER|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
219202617|NCT06707610|DRUG|ALK202|Administered intravenously, once every 3 weeks
219202618|NCT06712329|OTHER|extracorporeal shock wave therapy|ESWT (Inceler Medical, Modus Focused ESWT, Turkey) was conducted by a single investigator in accordance with a standardised protocol. The patients were positioned prone on the examination table, with the affected limb placed in a supported position. The focused shockwave was applied in a circular motion along the insertion site of the plantar fascia and over the plantar fascia itself. The participants received 1,800 to 2,000 focused shock waves (0.15-0.25 mJ/mm² session with a frequency of 3-4 Hz). The frequency of the pulses was increased in a gradual manner, in accordance with the maximum tolerable degree of pain for each patient. A minimum dose of 1,000 mJ/mm² was administered. The ESWT was conducted in three sessions, with a two-week interval between each session.
219608017|NCT05820438|DEVICE|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
219608018|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
218888415|NCT06492590|BEHAVIORAL|Multicomponent intervention|Multicomponent intervention based on psycho-education and physical rehabilitation.
218888416|NCT04961112|DEVICE|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
218888417|NCT04961112|DEVICE|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
218888418|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
218888419|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
218888420|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
218888421|NCT06500715|DEVICE|Acupuncture|Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
218888422|NCT05817305|OTHER|Medical history and functional evaluation|During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
218888423|NCT05817305|OTHER|Health education|Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
218888424|NCT04770116|DEVICE|Auditory Stimulation|The device records biosignals and precisely plays tones to enhance sleep slow waves.
218888425|NCT02312817|OTHER|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
219202619|NCT06712329|OTHER|Prolotherapy|The solution employed for dextrose prolotherapy comprised 1.5 ml of 30% dextrose and 1.5 ml of 0.9% isotonic sodium chloride solution, resulting in a total of 3 ml of 15% dextrose solution. . All procedures were conducted by the same investigator. A dextrose solution was infused into the centre and around the damaged area using a peppering technique. Following the procedure, patients were advised to remain in a supine position with their feet restrained for a period of 15 minutes.. Prolotherapy was repeated on three occasions, with each session occurring at a two-week interval
219202620|NCT06707220|OTHER|Heart failure medication|Treated with optimal guideline-directed medical therapy
219031655|NCT02918851|BIOLOGICAL|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
219031656|NCT02918851|BIOLOGICAL|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
219031657|NCT00304356|DRUG|Nitazoxanide|500 mg bid
219031658|NCT00362908|BEHAVIORAL|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
219031659|NCT00362908|BEHAVIORAL|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
219031660|NCT02687984|DRUG|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
219031661|NCT03169465|PROCEDURE|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
219031662|NCT03169465|PROCEDURE|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
219031663|NCT02864849|DRUG|Oxaliplatin|
219031664|NCT02864849|DRUG|Capecitabine|
219031665|NCT02864849|RADIATION|Intensity modulated radiotherapy|
219031666|NCT02864849|PROCEDURE|Total mesorectal excision|
219031667|NCT04311099|DRUG|Active drug|Injection of Ropivacaine
219031668|NCT04311099|DRUG|Placebo|Injection of Saline solution
219031669|NCT04311099|PROCEDURE|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
219031670|NCT04311099|PROCEDURE|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
219031671|NCT04311099|PROCEDURE|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
219031672|NCT04311099|PROCEDURE|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
219031673|NCT05356702|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
219031674|NCT06529406|DRUG|Ozanimod|De-escalation of anti-CD20 treatment using ozanimod.
219031675|NCT06557889|DRUG|Pembrolizumab + Cisplatin/Carboplatin + 5-FU|"* 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1)."
219031676|NCT02676505|BEHAVIORAL|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
219031677|NCT02676505|BEHAVIORAL|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
218888426|NCT02312817|OTHER|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
219608019|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
219608020|NCT06430866|DRUG|ABP 234|Administered by intravenous (IV) injection.
218888427|NCT04662554|DEVICE|1-mm Resolution Clinical PET camera|1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
218888428|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
218888429|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
218888430|NCT04299282|DEVICE|CanGaroo|CIED ECM envelope
218888431|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
218888432|NCT03574779|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
218888433|NCT03574779|BIOLOGICAL|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
218888434|NCT03574779|BIOLOGICAL|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
218888435|NCT03574779|DRUG|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
218888436|NCT03574779|DRUG|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
218888437|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
218888438|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
218888439|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
218888440|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
218888441|NCT04587050|DIAGNOSTIC_TEST|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
218888442|NCT04587050|DIAGNOSTIC_TEST|Cervical cytology|Cervical cytology
218888443|NCT04587050|DIAGNOSTIC_TEST|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
218888444|NCT02588261|DRUG|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
218888445|NCT02588261|DRUG|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
219031678|NCT01154218|DRUG|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
218888446|NCT02588261|DRUG|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
218888447|NCT05716932|PROCEDURE|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
218888448|NCT00004052|BIOLOGICAL|QS21|
218888449|NCT00004052|BIOLOGICAL|bcr-abl peptide vaccine|
218888450|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
219031679|NCT00951028|BEHAVIORAL|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
219031680|NCT00951028|BEHAVIORAL|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
219031681|NCT00951028|BEHAVIORAL|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
219608021|NCT06430866|DRUG|Pembrolizumab|Administered by IV injection.
219031682|NCT00881933|OTHER|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
219031683|NCT03688750|OTHER|no intervention|
219031684|NCT00820157|PROCEDURE|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
219031685|NCT00820157|PROCEDURE|TACE|TACE alone or TACE followed by downstage resection for MNHCC
218888451|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
218888452|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
218888453|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
218888454|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
218888455|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
218888456|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
218888457|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
218888458|NCT06104111|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
218888459|NCT03213288|DIETARY_SUPPLEMENT|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
218888460|NCT03213288|DIETARY_SUPPLEMENT|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
218888461|NCT03213288|DIETARY_SUPPLEMENT|Placebo|No anthocyanins
219202621|NCT06708286|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))|1 dose of Tdcp vaccine (0.5ml) on day 0
219202622|NCT06708286|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (PPV23)|1 dose of PPV23 vaccine (0.5ml) on day 0
219202623|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
219202624|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
218888462|NCT01101789|PROCEDURE|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
218888463|NCT01101789|PROCEDURE|regular sutures for surgical wound closure|
219202625|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
219202626|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
219508240|NCT01806597|BIOLOGICAL|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
219608022|NCT05102760|PROCEDURE|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
218888464|NCT04359160|DEVICE|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
218888465|NCT04359160|OTHER|Questionnaire|Paper questionnaire follow-up, with questions and score
218888466|NCT05082246|OTHER|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
218888467|NCT05082246|OTHER|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
218888468|NCT05082246|OTHER|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
218888469|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
218888470|NCT01035619|DRUG|moxidectin|Single Dose Moxidectin 4 mg
218888471|NCT05600244|PROCEDURE|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
218888472|NCT05600244|PROCEDURE|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
219202627|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
219202628|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
219202629|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
219202630|NCT06708286|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine (DTaP)|1 dose of DTaP vaccine (0.5ml) on day 0
219202631|NCT06708559|OTHER|Breast-fed infants|Immune system characterization via blood and stool samples collection
219202632|NCT06707662|DEVICE|Pacemaker and defibrillator|Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).
219202633|NCT06353269|DRUG|Estring Vaginal Product|estradiol vaginal ring, exchanged every 12 weeks
219508241|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia With Tragus Pressure|Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
218888473|NCT05600244|PROCEDURE|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
218888474|NCT02287467|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
218888475|NCT02287467|BIOLOGICAL|Placebo for IVIG|Administered IV as 500 mL of normal saline
218888476|NCT00255788|DRUG|everolimus|
218888477|NCT03781778|OTHER|Dietary Intervention (resistant starch)|Eat foods with resistant starch
218888478|NCT03781778|OTHER|Dietary Intervention (regular starch)|Eat foods with regular corn starch
218888479|NCT03781778|OTHER|Questionnaire Administration|Ancillary studies
218888480|NCT02272712|BEHAVIORAL|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
218888481|NCT00609570|DIETARY_SUPPLEMENT|NanoGreens|fruits and vegetables
219031686|NCT03812887|DIAGNOSTIC_TEST|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
218888482|NCT00609570|DIETARY_SUPPLEMENT|Whey protein|Whey
218888483|NCT00609570|DIETARY_SUPPLEMENT|Calcium pills|CA
218888484|NCT03956966|DRUG|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
218888485|NCT03956966|DRUG|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
219031687|NCT02736045|DEVICE|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
219031688|NCT00159055|BIOLOGICAL|CMV vaccine|
219031689|NCT04087252|BIOLOGICAL|tumor neoantigen|tumor neoantigens
219031690|NCT00002504|BIOLOGICAL|aldesleukin|
219202634|NCT06353269|DRUG|Vagifem|vaginal estrogen tablet, used twice per week
219202635|NCT06353269|DRUG|Estrace 0.01% Vaginal Cream|vaginal estrogen cream, used twice per week
219031691|NCT00002504|BIOLOGICAL|recombinant interferon alfa|
219031692|NCT01028157|BEHAVIORAL|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
219031693|NCT01028157|BEHAVIORAL|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
219202636|NCT06712121|DRUG|decitabine plus venetoclax|decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
219202637|NCT06715904|OTHER|Womens with Morton´s Extension|Morton extension application
219508242|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia Without Tragus Pressure|Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
219508243|NCT05627609|DEVICE|311 nm narrowband UVB irradiation|Participants will be irradiated with 311nm UVB for 5 days per week and 4 weeks in total.
219508244|NCT01909622|DIETARY_SUPPLEMENT|Vitamin D|
219508245|NCT01909622|DIETARY_SUPPLEMENT|No vitamin D|
218888486|NCT03956966|DRUG|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
219202638|NCT06713304|BEHAVIORAL|A community-based Protective Behavioral Strategies program|"A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking."
219202639|NCT06717269|DRUG|NX-5948 capsule|NX-5948 in capsule form
219202640|NCT06717269|DRUG|NX-5948 tablet|NX-5948 in tablet form
219202641|NCT06717269|DRUG|Esomeprazole|Esomeprazole capsule, once daily
219202642|NCT06713577|DEVICE|CEREC Cercon 4D|"One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations."
219202643|NCT06713707|OTHER|Manuel dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using 9-HPT, and JTHFT.
219202644|NCT06713707|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
219202645|NCT06713005|PROCEDURE|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve pulsed rf
219202646|NCT06713005|PROCEDURE|suprascapular nerve block and 9 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
219508246|NCT03873480|PROCEDURE|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
219202647|NCT06698835|DIETARY_SUPPLEMENT|Turnip Consumption|Turnip Consumption and Qigong Exercise with educational Program about loss of weight
219202648|NCT05129501|BEHAVIORAL|Experimental|The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
219202649|NCT04429347|DRUG|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
218888487|NCT01517555|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
219202650|NCT04429347|DRUG|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
219202651|NCT04429347|DRUG|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
219202652|NCT06881667|DEVICE|Home PSG Assessment|Testing of the Onera STS in the home environment with the current device shipment method and instructions.
219202653|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 45 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
219508247|NCT06094868|DRUG|Fruquintinib|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
219508248|NCT05116995|DRUG|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
219508249|NCT05116995|DRUG|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
219608023|NCT05102760|PROCEDURE|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
218888488|NCT01517555|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
218888489|NCT01517555|DRUG|paracetamol|One single dose of 1 g. Tablet
218888490|NCT01456169|DRUG|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
219608024|NCT04903288|GENETIC|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
219608025|NCT04776148|DRUG|pembrolizumab|IV infusion
219608026|NCT04776148|DRUG|lenvatinib|oral capsule
218888491|NCT01456169|DRUG|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
218888492|NCT01888224|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
218888493|NCT02984917|PROCEDURE|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
218888494|NCT02984917|PROCEDURE|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
219031694|NCT05792228|OTHER|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
219031695|NCT00922883|DRUG|Eltrombopag|
219031696|NCT01583335|BEHAVIORAL|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
219031697|NCT01907477|OTHER|Samples taken at the clinical hematology unit|
219031698|NCT00142675|BEHAVIORAL|Physical Activity|
219031699|NCT05074238|OTHER|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
219031700|NCT06369168|DEVICE|auricular acupuncture|two auricular acupuncture methods are compared with each other and with no treatment
219031701|NCT06967181|BIOLOGICAL|CVM150|CVM150- Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
219031702|NCT06967181|BIOLOGICAL|CVM26|CVM26: A live, attenuated MuV vaccine based on Iowa strain genetically edited to remove the V and SH protein expression. Formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
219031703|NCT06967181|OTHER|Placebo|Placebo: 0.9% normal sterile saline (purchased commercially).
219031704|NCT06970925|DIETARY_SUPPLEMENT|Sucrosomial Iron (SI)|The Sucrosomial Iron (SI) you may receive is a considered a supplement, so it has not been approved by the U.S. Food \& Drug Administration (FDA) for sale. However, it is available for over-the-counter purchase. Sucrosomial Iron (SI) has been developed by PharmaNutra.
219031705|NCT00083681|DRUG|Thalidomide|
219031706|NCT00083681|DRUG|Dexamethasone|
219031707|NCT00083681|DRUG|Cytoxan|
219031708|NCT00083681|DRUG|Etoposide|
219031709|NCT00083681|DRUG|Cisplatin|
219031710|NCT00083681|DRUG|G-CSF|
219031711|NCT01321268|DIETARY_SUPPLEMENT|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
219031712|NCT01321268|DIETARY_SUPPLEMENT|Viatmin E|oral, twice daily in morning and evening for 6 months
219031713|NCT01649531|PROCEDURE|1 Implant|
219031714|NCT01649531|PROCEDURE|2 Implants|
219031715|NCT02724475|PROCEDURE|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
219031716|NCT02724475|PROCEDURE|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
219031717|NCT03902535|OTHER|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
219031718|NCT03902535|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
219031719|NCT03902535|OTHER|Questionnaire Administration|Complete questionnaires
219031720|NCT05721963|DIAGNOSTIC_TEST|No interventions.|No interventions.
219031721|NCT01778933|DRUG|EC17|
219031722|NCT03303378|DRUG|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
219031723|NCT03303378|DRUG|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
219031724|NCT05654155|OTHER|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
219031725|NCT01519453|BEHAVIORAL|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
219608027|NCT04776148|DRUG|regorafenib|oral tablet
219608028|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
219608029|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
218888495|NCT00412243|DRUG|Clofarabine|40 mg/m\^2 Daily for 3 Days
218888496|NCT00412243|DRUG|Cyclophosphamide|Beginning dose 200 mg/m\^2 every 12 hours for 3 days
219508250|NCT04276038|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
218888497|NCT05021146|OTHER|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
218888498|NCT05021146|OTHER|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
218888499|NCT05021146|OTHER|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
218888500|NCT03223116|PROCEDURE|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
218888501|NCT00870012|DRUG|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
218888502|NCT00870012|OTHER|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
218888503|NCT01593124|DRUG|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
218888504|NCT01593124|OTHER|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
218888505|NCT01593124|DRUG|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
219031726|NCT05397054|BEHAVIORAL|Education|\- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
219031727|NCT05397054|BEHAVIORAL|Reformulation|\- Reformulation: Dietary recommendation in low sodium intake
219031728|NCT05397054|BEHAVIORAL|Environmental change|\- Environmental change: Encourage about low sodium intake in community
219031729|NCT05397054|DEVICE|Salt meter|\- Used salt meter: at least 3 times/wk
219031730|NCT05397054|BEHAVIORAL|standard treatment|standard treatment
219031731|NCT02743650|DIETARY_SUPPLEMENT|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
219031732|NCT03675802|DRUG|misoprostol|giving misoprostol to this group
219031733|NCT03675802|DRUG|dinoprostone|giving dinoprostine
219031734|NCT01844609|BEHAVIORAL|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
219031735|NCT01844609|BEHAVIORAL|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
219031736|NCT01253759|PROCEDURE|TTT + ICG-based PDT|
219031737|NCT05232240|DIAGNOSTIC_TEST|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
219031738|NCT00446407|OTHER|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
219031739|NCT00446407|OTHER|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
219031740|NCT05195463|OTHER|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
219508251|NCT04000503|BEHAVIORAL|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
219508252|NCT02149303|DRUG|Dabigatran 75 mg|PO BID
219508253|NCT02149303|DRUG|Dabigatran 150 mg|PO BID
219508254|NCT04491149|DEVICE|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
219508255|NCT02247479|DRUG|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
219508256|NCT02247479|OTHER|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
219608030|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
219508257|NCT03849313|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
219508258|NCT04552574|DIETARY_SUPPLEMENT|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
219508259|NCT00226720|PROCEDURE|Outpatient detoxification program|Outpatient detoxification program
219508260|NCT05389410|DEVICE|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
219508261|NCT05389410|DEVICE|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
219508262|NCT06214377|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.
219608031|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
219031741|NCT05195463|OTHER|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
219031742|NCT05195463|OTHER|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
218888506|NCT00321451|BEHAVIORAL|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
218888507|NCT00321451|BEHAVIORAL|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
218888508|NCT00321451|OTHER|Usual care|3 outpatient visits with study physician
218888509|NCT04287387|DRUG|Glucophage 500Mg Tablet|0.5g three times daily
218888510|NCT04287387|DRUG|Acarbose Tablets|50mg three times daily
218888511|NCT04287387|DRUG|Sitagliptin tablet|100mg once daily
218888512|NCT04287387|DRUG|Dapagliflozin Tablet|10mg once daily
218888513|NCT04287387|DRUG|Pioglitazone Tablets|30mg once daily
218888514|NCT04287387|DRUG|Glimepiride Tablets|2mg once daily
218888515|NCT02178761|DEVICE|drug-eluting balloon|angioplasty completed with drug-eluting balloons
218888516|NCT02178761|DEVICE|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
218888517|NCT02178761|DEVICE|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
218888518|NCT02178761|DEVICE|Stent System|stenting with either bare-metal stents or drug-eluting stents
218888519|NCT05564455|OTHER|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
219031743|NCT01209442|DRUG|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
219031744|NCT01209442|DRUG|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
219031745|NCT01209442|RADIATION|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
219031746|NCT02532296|BEHAVIORAL|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
219031747|NCT02532296|BEHAVIORAL|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
218888520|NCT05564455|OTHER|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
218888521|NCT00496080|DEVICE|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
218888522|NCT03349125|BEHAVIORAL|Collar On|
218888523|NCT03349125|BEHAVIORAL|Collar Off|
218888524|NCT05189119|DIAGNOSTIC_TEST|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
218888525|NCT00909506|DRUG|Placebo|"Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day)."
219508263|NCT06214377|DEVICE|Sham Transcranial Direct Current Stimulation|The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
219508264|NCT06214377|DRUG|Dopaminergic medication|After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
219508265|NCT04611256|BIOLOGICAL|MSC|Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach
218888526|NCT00909506|DRUG|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks."
219608032|NCT04770935|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
218888527|NCT00909506|DRUG|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day)."
218888528|NCT00570310|DRUG|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
218888529|NCT00570310|DRUG|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
218888530|NCT03647826|BEHAVIORAL|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
218888531|NCT05435664|BEHAVIORAL|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
218888532|NCT00988988|DRUG|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
218888533|NCT00988988|DRUG|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
218888534|NCT00988988|DRUG|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
218888535|NCT05715164|DEVICE|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
218888536|NCT05715164|DRUG|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
218888537|NCT05715164|OTHER|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
218888538|NCT00756249|DRUG|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
218888539|NCT00756249|DRUG|Placebo|Vials with solution for IV infusion
218888540|NCT06206525|OTHER|Initial insulin dosing using the calculator|Participants will receive initial insulin doses by the calculator on hospital admission.
218888541|NCT00024180|DRUG|romidepsin|
218888542|NCT00900666|DRUG|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
218888543|NCT00900666|DRUG|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
218888544|NCT02807207|DRUG|A: pacritinib|Treatment A
218888545|NCT02807207|OTHER|B: Placebo|Treatment B
218888546|NCT02807207|DRUG|C: moxifloxacin|Treatment C
218888547|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.
218888548|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in controls|Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.
218888549|NCT05421208|DIAGNOSTIC_TEST|Effect on inflammation after chronic PNS stimulation|Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
218888550|NCT03472950|DRUG|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
218888551|NCT03472950|DRUG|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
219031748|NCT05383547|DRUG|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
219031749|NCT01709695|DRUG|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
219031750|NCT01709695|DRUG|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
219031751|NCT00911261|DRUG|Oxymorphone Extended Release|"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
219031752|NCT06481514|OTHER|Interpretation of the CTG using FRI score|At each of the components of the score will be assigned a score of 1 if the variable evaluated is considered normal, 0 if classified as abnormal. To encourage a simplified clinical interpretation of the different scores obtained (score from 1 to 8) they will be classified into 3 risk categories: Score 5-8: green zone, Score 3-4: zone yellow, Score 1-2: red zone. An FRI of 1-2 (red zone) is to be considered as anomalous
219508266|NCT04611256|DRUG|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
219508267|NCT02705053|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
218888552|NCT05829109|DRUG|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~* Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~* Step 2: Bowel preparation with 10 ounces of magnesium citrate.~* Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
218888553|NCT02608463|BEHAVIORAL|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
218888554|NCT02608463|BEHAVIORAL|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
218888555|NCT02608463|BEHAVIORAL|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
218888556|NCT02608463|BEHAVIORAL|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
219031753|NCT06481514|OTHER|Classic interpretation of the CTG|evaluate the CTG of group B patients according to the usual internal management protocols
219031754|NCT02802592|DRUG|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
219031755|NCT02802592|DRUG|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
219031756|NCT04557657|DRUG|Active bio Activa|Cement that release fluoride
219031757|NCT04557657|DRUG|Resin Cement|Resin Cement Convinonal
219031758|NCT04650802|DEVICE|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
219031759|NCT03604640|OTHER|Physical Training|Physical exercise program and health education
219031760|NCT02220933|DRUG|MD1003 100mg capsule|
219031761|NCT02220933|DRUG|Placebo|
219031762|NCT03274531|BEHAVIORAL|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
219031763|NCT06209151|OTHER|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation \& mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
219031764|NCT06043076|DEVICE|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
219031765|NCT06043076|DEVICE|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
219031766|NCT02605707|DRUG|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
219031767|NCT04503759|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
219031768|NCT00039754|DRUG|Holmium-166-DOTMP|
219031769|NCT03817385|DEVICE|repetitive TMS|rTMS x 10 times
219031770|NCT03817385|DEVICE|robotic GT|robotic gait training for 20 times
219031771|NCT02882854|DRUG|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
219031772|NCT02882854|DRUG|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
219031773|NCT04288648|DIAGNOSTIC_TEST|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
219202654|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
219508268|NCT02705053|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
219508269|NCT01572649|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
219202655|NCT06881056|BEHAVIORAL|symptomatic and supportive treatment|symptomatic and supportive treatment
219202656|NCT06881615|DEVICE|MTA PLACEMENT FOR PP|MTA PLACEMENT FOR PP
219202657|NCT06881615|DEVICE|PUTTY PLACEMENT FOR PP|PUTTY PLACEMENT FOR PP
218888557|NCT02608463|BEHAVIORAL|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
218888558|NCT02608463|BEHAVIORAL|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
218888559|NCT02608463|DEVICE|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
219031774|NCT01761656|DRUG|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
219031775|NCT01761656|DRUG|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
219508270|NCT01572649|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
219031776|NCT00374881|DRUG|Morphine|Morphine
219508271|NCT04112251|DIETARY_SUPPLEMENT|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
219508272|NCT03699267|OTHER|US-guided Bilateral TAP block|
219508273|NCT04807127|DRUG|Immune checkpoint blockade|ICI, administered as standard-of-care treatment
219508274|NCT04807127|DRUG|Targeted therapy|TKI, administered as standard-of-care treatment
219031777|NCT00374881|DRUG|Morphine|Morphine low dose
219031778|NCT00374881|DRUG|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
219031779|NCT00374881|DRUG|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
219031780|NCT00374881|DRUG|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
219031781|NCT03722550|OTHER|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
219031782|NCT03722550|OTHER|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
219508275|NCT04807127|RADIATION|Radiotherapy|RT, administered as standard-of-care treatment
219508276|NCT01840189|OTHER|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
219508277|NCT01840189|OTHER|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
219508278|NCT00135213|BEHAVIORAL|training in smoking cessation|
219508279|NCT01073020|DEVICE|Allergan Adjustable Gastric Band Surgery|
219508280|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group
219508281|NCT01073020|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) Surgery|
219508282|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
219031783|NCT03722550|OTHER|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
219031784|NCT03272607|OTHER|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
219031785|NCT00788892|DRUG|CPX-351|
219031786|NCT00788892|DRUG|Cytarabine|
219031787|NCT00788892|DRUG|Daunorubicin|
219202658|NCT06880887|OTHER|nervus vagus stimulation|Vagus stimulation was applied bilaterally through the ear in a transcutaneous manner. transcutaneous auricular VNS (taVNS) was performed using the Vagustim device. The stimulation was applied for 20 minutes with a pulse width of 300 microseconds, a frequency of 10 Hz, and in a biphasic manner. The electrodes were placed on the concha and tragus parts of the ear, and the current was increased until the participant could feel it.
219202659|NCT06878950|PROCEDURE|Early Feeding Protocol|The intervention includes removal of Replogle within 24 hours of abdominal closure and the initiation of introductory feeds within 48 hours of abdominal closure.
219508283|NCT03961776|DEVICE|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
218888560|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 16mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
219202660|NCT06702384|DIAGNOSTIC_TEST|biopsy|Baseline biopsy and biological specimens
219202661|NCT06877286|DIAGNOSTIC_TEST|Sirtuin-1 Level Measurement|Measurement of serum Sirtuin-1 levels using ELISA in hemodialysis patients to evaluate the relationship between Sirtuin-1 levels and erythropoietin resistance
219202662|NCT06879262|BIOLOGICAL|CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）|Administer a single infusion of CAR1922T2 T cells to this group of patients following fludarabine plus cyclophosphamide (F+C) lymphodepletion
218888561|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 8mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
218888562|NCT06519604|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU
218888563|NCT03071822|DRUG|cisplatin|PIGLETs
218888564|NCT03071822|DRUG|ifosfamide|PIGLETs
218888565|NCT03071822|DRUG|gemcitabine|PIGLETs
218888566|NCT03071822|DRUG|L-asparaginase|PIGLETs
218888567|NCT03071822|DRUG|etoposide|PIGLETs
218888568|NCT03071822|DRUG|dexamethasone|PIGLETs
218888569|NCT05187039|OTHER|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
218888570|NCT00517361|DRUG|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
218888571|NCT00517361|DRUG|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
218888572|NCT00894868|DRUG|vildagliptin|
218888573|NCT00894868|DRUG|placebo of vildagliptin|
218888574|NCT01156103|BEHAVIORAL|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
218888575|NCT00669708|DEVICE|cooling compound (ph5 Eucerin)|application twice daily to the skin
218888576|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
219031788|NCT00251446|DRUG|Vinflunine|320 mg/m2 as a 20-minute IV infusion
219031789|NCT03541824|BEHAVIORAL|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
219031790|NCT06493708|OTHER|Trauma focused psychotherapy: EMDR|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
218888577|NCT02898896|BIOLOGICAL|blood test|Additional 21 ml of blood will be collected
218888578|NCT04364360|DIETARY_SUPPLEMENT|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
218888579|NCT04064060|DRUG|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
219031791|NCT00425867|BEHAVIORAL|PAR1 polymoprhisms and placental invasion|
219031792|NCT01278485|DRUG|Sulphonylurea|SU administered according to usual practice.
219031793|NCT01278485|DRUG|Metformn|Metformin administered according to usual practice.
219031794|NCT04097093|OTHER|No intervention|No intervention
219031795|NCT02561637|BEHAVIORAL|Case management|
219031796|NCT02561637|BEHAVIORAL|Control group|
219031797|NCT01358357|DRUG|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
219031798|NCT01358357|DRUG|Placebo|20-80 mg flexible dose
219031799|NCT01902264|DRUG|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
219031800|NCT04225299|DRUG|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
219202663|NCT06880029|OTHER|Morning pembrolizumab infusions|Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon).
219202664|NCT06882499|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy
219202665|NCT06882499|OTHER|Physician's choice of systemic treatment|Physician's choice of systemic therapy does not mandate a change in systemic therapy, however, SABR is not permitted for management in this arm
219202666|NCT06882538|OTHER|awareness-based psychoeducation|The aim of psychoeducation is to create a change in knowledge and behaviour towards healthy lifestyle behaviours (1- Self-actualisation, 2- Health responsibility, 3- Exercise, 4- Nutrition, 5- Interpersonal support, 6- Stress management) by reducing internalised stigma. Therefore, it will be evaluated whether the applied psychoeducation programme creates the intended change in knowledge and behaviour.
219202667|NCT06881875|BEHAVIORAL|AI-guided breathing practices|Participant will obtain a wristband with a built-in breathing practices program when assigned to the intervention group. Four kinds of breathing practices are included, which are bee breathing, diaphragmatic breathing, box breathing and 4-7-8 breathing. A specially prompted AI chat bot interviews the participant and designs a personalized daily breathing practice plan according to participant's preference and daily stress. Participant follows the plan in the following 28-day intervention period. Plan is adjusted weekly based on participant's feedback.
218888580|NCT00195091|DRUG|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
218888581|NCT02466763|PROCEDURE|Cochlear implant surgery|Surgical placement of a cochlear implant device.
219031801|NCT03021850|PROCEDURE|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
219202668|NCT06881875|BEHAVIORAL|Progressive muscle relaxation|Participant practices progressive muscle relaxation for 5 minutes daily.
219202669|NCT06881550|DRUG|Shenbailing|Adjuvant therapy with Shenbailing granules, starting from 1 day after surgery.
219202670|NCT06715384|DIAGNOSTIC_TEST|Polyp size measurement using autonomous AI measurement or AI-assisted human measurement with the CAM system|The study of real-time polyp size measurement using the CAM system will be conducted in two phases. Phase I (pilot phase, n=24 polyps, about 27 patients) will be used to assess the feasibility of applying the CAM system in real-time in a clinical video in order to obtain pilot data on the relative accuracy of assessing polyp sizes using autonomous AI measurement and AI-assisted human measurement and to determine the relative accuracy of assessing polyp size in Phase II of the study ( Randomized Controlled Trial) to assess the sample size and reference standards for the CAM system. The sample size for the second phase of the randomized controlled trial (comparing AI-assisted human measurement to non-scaled device) will be based on pilot data in order to compare the relative accuracy of polyp size measurement with AI-assisted human measurement versus non-scaled device in clinical practice.
219202671|NCT06712836|DRUG|MET097|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
219031802|NCT02475551|DRUG|IdeS|Intravenous infusion
219031803|NCT01618409|BEHAVIORAL|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
219031804|NCT06390969|OTHER|Survey|Cross-sectional online survey
219031805|NCT03098537|DRUG|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
219202672|NCT06712836|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
219202673|NCT06281327|DRUG|Avatrombopag|"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
219202674|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
218888582|NCT00856765|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
219202675|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
219508284|NCT00889590|DRUG|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
219508285|NCT01218620|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219508286|NCT01218620|DRUG|Ketoconazole|Given PO
219508287|NCT01218620|DRUG|Rifampin|Given PO
219508288|NCT01218620|DRUG|Midazolam Hydrochloride|Given IV
219508289|NCT01218620|DRUG|Omeprazole|Given PO
219508290|NCT01218620|DRUG|Tolbutamide|Given PO
219508291|NCT01218620|DRUG|Dextromethorphan Hydrobromide|Given PO
219508292|NCT01218620|OTHER|Pharmacological Study|Correlative studies
219508293|NCT01218620|OTHER|Laboratory Biomarker Analysis|Correlative studies
218888583|NCT00856765|DEVICE|Bare metal stent|Bare metal stent
218888584|NCT00856765|DEVICE|Drug eluting stent|Paclitaxel eluting stent
219031806|NCT03098537|OTHER|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
219031807|NCT04405648|BEHAVIORAL|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
219508294|NCT05989360|DIAGNOSTIC_TEST|Lung Clearance Index|Normative values in healthy children from ethnic backgrounds
219508295|NCT00276874|DRUG|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
219508296|NCT00276874|DRUG|Placebos|Placebo; 0 mg; oral; daily
219508297|NCT03807882|OTHER|Bilateral M-ECT|Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
219508298|NCT03807882|DRUG|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
219508299|NCT02607761|OTHER|Video|Video-Audio Media
218888585|NCT05413161|BIOLOGICAL|ADL-018|150 mg/mL, Solution for injection in PFS
218888586|NCT05413161|BIOLOGICAL|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
218888587|NCT05413161|BIOLOGICAL|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
219608033|NCT06557863|BEHAVIORAL|WeCareToFeedDysphagia web tool|The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
219608034|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
219608035|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
218888588|NCT00945256|OTHER|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
218888589|NCT00945256|DRUG|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
218888590|NCT00945256|DIETARY_SUPPLEMENT|Amino Acid Drink|7.5 gram Amino Acid drink
218888591|NCT01814475|DRUG|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
218888592|NCT01814475|DRUG|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
218888593|NCT06330168|DRUG|bupivacaine-calcitonin-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml).
218888594|NCT06330168|DRUG|Bupivacaine-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
218888595|NCT05468437|BEHAVIORAL|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
219031808|NCT02136576|DEVICE|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
219031809|NCT02136576|DEVICE|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
219031810|NCT02136576|DEVICE|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
219031811|NCT01330485|BEHAVIORAL|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
219031812|NCT01330485|BEHAVIORAL|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
219031813|NCT04408482|DEVICE|Biliary cannulation|Cannulation of biliary duct by sphincterotome
219508300|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
219508301|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
219508302|NCT03287050|DRUG|Pembrolizumab|200 mg IV q 21 days
219508303|NCT03287050|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
219508304|NCT05680350|PROCEDURE|Laparoscopic Exploration|Laparoscopic Exploration to diagnose \& grade endometriosis
219608036|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
219608037|NCT05399992|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
219608038|NCT03367572|DRUG|Dexamethasone|Given PO
219608039|NCT03367572|OTHER|Laboratory Biomarker Analysis|Correlative studies
219608040|NCT03367572|DRUG|Netupitant/Palonosetron Hydrochloride|Given PO
219608041|NCT03367572|DRUG|Olanzapine|Given PO
219608042|NCT03367572|OTHER|Placebo|Given PO
219608043|NCT03367572|DRUG|Prochlorperazine|Given PO
219608044|NCT03367572|OTHER|Quality-of-Life Assessment|Ancillary studies
218888596|NCT05788094|DRUG|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
218888597|NCT05788094|DRUG|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
218888598|NCT05788094|DRUG|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
219031814|NCT05543122|DRUG|either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe|This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
219202676|NCT04701112|DEVICE|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
219608045|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
219202677|NCT06714344|DEVICE|KITGuideMe: W61-MD41-AIT, version 1.0.0|"We are planning to conduct a prospective, 1:1 randomized study within the HM program.~Randomization occurs at the level of network physicians. Network physicians participating in the study are randomly assigned to either the AMPEL group (access to the module) or the non-AMPEL group (no access to the module) using a permuted block randomization scheme to ensure that there are the same number of patients in each study arm. Logical checks within the module ensure that once a network physician is assigned to an arm, he or she remains in that arm for the remainder of the stud"
219202678|NCT05359263|DRUG|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
219202679|NCT05359263|DRUG|Placebo|The comparator arm consists of placebo orally once daily
219202680|NCT06883773|BEHAVIORAL|Multipurpose Online Tool|The intervention consists of 6 psychoeducational modules, on the Canvas teaching platform. They are automated, requiring no interaction with others (except for communication between participants and the team). Participants go through the psychoeducational modules, then do the corresponding exercise, and then access their rewards (if they belong to the experimental or comparative groups).
219202681|NCT06883773|OTHER|No intervention|The participants will be assessed but without any intervention
219202682|NCT06880172|BEHAVIORAL|WeCare|"Individual level: Problem identification, Linking Mental health and minority stress, medication adherence, developing an action plan, complementing the plan, and follow-up.~Group level: Social support and self acceptance in MSM, coping with stigma and minority stress, support for medication adherence"
219031815|NCT01656590|OTHER|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily"
219202683|NCT06880172|BEHAVIORAL|Standard of Care|Access to services offered at the POP INN Wellness Clinic including psychoeducation for all individuals who enroll in PrEP or ART services, free medication, and enrollment in their standard drop-in. Mpowerment support groups, as well as referrals to mental health services on request
219202684|NCT06883058|BEHAVIORAL|Caregivers-patients support intervention for advanced cancer (CASA)|The Caregivers-Patients Support Intervention for Advanced Cancer (CASA) will be delivered to patients and caregivers. The sessions follow a protocol and will be held weekly or bi-weekly for a total of 5 sessions.
219031816|NCT00271089|PROCEDURE|PBSC Collection|
219031817|NCT00271089|PROCEDURE|Bone Marrow Harvest|
219031818|NCT00271089|DEVICE|CliniMacs Cell Selection System|
219031819|NCT02299986|OTHER|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
219031820|NCT04317911|OTHER|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
219031821|NCT00537381|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
219031822|NCT00537381|DRUG|Prednisone|Prednisone 5 mg orally twice daily.
218888599|NCT05370014|BEHAVIORAL|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
219202685|NCT06883058|BEHAVIORAL|Placebo|Usual care will be provided to participants in the control group. The usual care consists of symptom management once a week and 5 sessions.
219202686|NCT06883266|DEVICE|transcranial direct current stimulation (tDCS)|2 mA will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
219202687|NCT06883266|DEVICE|Sham (No Treatment)|For 30 seconds, the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex
218888600|NCT03667092|BIOLOGICAL|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
218888601|NCT02627989|DRUG|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
218888602|NCT02627989|DRUG|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
219202688|NCT06883435|PROCEDURE|closed reduction and percutaneous ﬁxation of medial malleolus|No incision is made for fracture reduction, a pointed reduction clamp is applied to reduce the fracture, two 4 mm partially threaded cannulated cancellous screws are inserted over guide wires through stab incisions. Fluoroscopy is used to assess reduction.
219202689|NCT06883435|PROCEDURE|open reduction and screw fixation of medial malleolus|An incision is made over the fracture; the MM fracture is reduced under direct vision. fixation is performed with two 4mm cannulated partially threaded cancellous screws. fluoroscopy is used to confirm reduction.
219508305|NCT05680350|DIAGNOSTIC_TEST|Estimation of Plasma Expression level of MICRO RNA 203 & 210|"estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR"
219508306|NCT02275923|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
219508307|NCT02452060|DRUG|Ketamine|0.4mg/kg infusion
219508308|NCT02452060|OTHER|Placebo Comparator|0.4mg/kg infusion
219508309|NCT02951663|DIETARY_SUPPLEMENT|Protein|
219031823|NCT00537381|BIOLOGICAL|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
219031824|NCT00537381|DRUG|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
219031825|NCT00491010|PROCEDURE|radiofrequency catheter ablation|
219031826|NCT03192943|DRUG|BMS-986205|Specified dose on specified days
219031827|NCT03192943|BIOLOGICAL|Nivolumab|Specified dose on specified day
219031828|NCT02590939|DEVICE|CEFALY Active|Active external trigeminal nerve stimulation
219031829|NCT02590939|DEVICE|CEFALY Placebo|Placebo external trigeminal nerve stimulation
219031830|NCT00625976|BEHAVIORAL|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
219031831|NCT00625976|BEHAVIORAL|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
219031832|NCT03558243|PROCEDURE|Patent Hemostasis arm|Patent hemostasis with TR BAND
219031833|NCT03558243|PROCEDURE|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
219031834|NCT03558243|DEVICE|Hemostatic disc arm|StatSeal disc plus TR Band
219031835|NCT03297385|DRUG|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
219031836|NCT02273895|DRUG|Scopolamine|0.3 mg/mL, intravenously, once
219031837|NCT03434847|OTHER|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
219031838|NCT02266459|DEVICE|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is \< 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
219031839|NCT00763347|DRUG|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
219031840|NCT00763347|DRUG|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
219031841|NCT00763347|DRUG|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
219508310|NCT04160078|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) Intervention|"* 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
219031842|NCT00763347|DRUG|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
219031843|NCT00763347|DRUG|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
219031844|NCT00763347|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
219031845|NCT02965274|DRUG|Torrent's Fluoxetine Tablets|
219031846|NCT02965274|DRUG|Warner Chilcott LLC's Sarafem Tablet|
219031847|NCT05552768|PROCEDURE|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
219031848|NCT05552768|PROCEDURE|Biological width-driven placement guidelines|Biological width-driven placement guidelines
218888603|NCT00003512|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218888604|NCT04658043|OTHER|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
219508311|NCT03120585|OTHER|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR \>4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
218888605|NCT00245037|BIOLOGICAL|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
218888606|NCT00245037|DRUG|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
218888607|NCT00245037|DRUG|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~\- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
219031849|NCT03403959|DEVICE|light therapy|6 weeks morning treatment with bright light therapy in own home.
219031850|NCT00368654|DRUG|Methotrexate|Initial dose 5 mg, then 15 mg per week
219031851|NCT00368654|DRUG|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
219031852|NCT03774433|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
219031853|NCT01285245|DRUG|kineret|once daily 100 mg of kineret subcutaneously for 8 days
219031854|NCT00108160|DRUG|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
219031855|NCT00108160|DRUG|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
219031856|NCT00680433|DRUG|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
219031857|NCT00680433|DRUG|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
219031858|NCT05025111|DEVICE|Entia Liberty|Home monitoring device
219031859|NCT00731770|DRUG|Advair 250|1 puff bid inhaled
219031860|NCT00731770|DRUG|Placebo- matched|1 puff bid inhaled
219031861|NCT00731770|DRUG|Placebo|Placebo 1 puff bid inhaled
219031862|NCT00731770|DRUG|Advair 250 - matched|i puff bid inhaled
219031863|NCT03817242|PROCEDURE|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
219031864|NCT03817242|PROCEDURE|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
219031865|NCT03184350|RADIATION|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
219031866|NCT04718142|DEVICE|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
219031867|NCT00930566|DRUG|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
219031868|NCT00930566|PROCEDURE|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
219031869|NCT04690504|OTHER|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
218888608|NCT00245037|DRUG|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments."
219608046|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
219608047|NCT06472973|OTHER|Post-transplant addiction intervention|The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or \< 6 months) and young age (\< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has \<3 risk factors, an addictology consultation every 6 months at most will be proposed.
219608048|NCT06561334|PROCEDURE|Botulinum toxin injections|Botulinum toxin injection to ease spasms of vocal cord
219608049|NCT06568042|DRUG|LY3848575|Administered SC
219608050|NCT06568042|DRUG|Placebo|Administered SC
218888609|NCT00245037|DRUG|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
219608051|NCT05866432|DRUG|Datopotamab deruxtecan|Will be given until PD or withdraw
219608052|NCT03504644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219608053|NCT03504644|PROCEDURE|Computed Tomography|Undergo CT scan
219608054|NCT03504644|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218888610|NCT00245037|PROCEDURE|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
218888611|NCT00245037|RADIATION|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
219031870|NCT05057442|OTHER|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
219031871|NCT05196542|PROCEDURE|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
219031872|NCT02694237|BEHAVIORAL|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
219031873|NCT02694237|BEHAVIORAL|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
219031874|NCT02694237|BEHAVIORAL|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
219031875|NCT01517672|BEHAVIORAL|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
219031876|NCT04826146|DEVICE|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
219031877|NCT04099160|OTHER|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
219031878|NCT04130230|DRUG|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
219031879|NCT04130230|DRUG|Standard therapy|Standard therapy for sepsis and septic shock
219031880|NCT00798538|OTHER|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
219608055|NCT03504644|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219608056|NCT03504644|DRUG|Venetoclax|Given PO
219608057|NCT03504644|DRUG|Vincristine Liposomal|Given IV
219608058|NCT03504644|DRUG|Vincristine Sulfate|Given IV
219608059|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
219202690|NCT04342260|OTHER|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
219202691|NCT04342260|OTHER|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
219202692|NCT06882590|OTHER|Compassionate-focused therapy|A 9-session therapy intervention targeting negative thinking, feelings of guilt and shame, and cultivating compassion for self and others.
219508312|NCT05773079|DRUG|Toripalimab|Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
218888612|NCT00245037|DRUG|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
218888613|NCT00245037|DRUG|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
219202693|NCT06883942|PROCEDURE|prosthetic group performs the entire protocol with their own prosthesis|"The 1st session is the enrolment and functional evaluation one. The following 2 we test the algorithm functionality verification; one session for both platforms. The last 2 sessions are necessary to acquire prognostic markers for falls; one session for both platforms.~The balance disturbance tests will take place on two platforms:~* The sliding platform consists of a metal supporting structure and a wooden cover, which has a manual release mechanism that allows the activation of the tile responsible for simulating the events that occur during sliding.~* The stumbling platform consists of a metal supporting structure and a wooden cover, which features an electronically activated plastic and foam tripping mechanism that simulates the sequence of events that occur during a stumble."
219508313|NCT01039220|BIOLOGICAL|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
218888614|NCT00245037|DRUG|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
219031881|NCT00798538|OTHER|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
219031882|NCT04941456|OTHER|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
219031883|NCT04941456|DEVICE|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
219508314|NCT05852782|OTHER|White Light therapy|Participants will be exposed to broadband light for one hour
219031884|NCT05837416|DRUG|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
219031885|NCT05837416|DRUG|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
219031886|NCT05837416|DRUG|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
219508315|NCT05852782|OTHER|Blue light therapy|Participants will be exposed to blue light for one hour
219508316|NCT05852782|OTHER|Red light therapy|Participants will be exposed to re light for one hour
219508317|NCT05852782|OTHER|Darkness|Participants will be in complete darkness for one hour
219508318|NCT00469820|BIOLOGICAL|autologous tumor cell vaccine|
219508319|NCT00469820|BIOLOGICAL|peripheral blood lymphocyte therapy|
219508320|NCT00514293|DRUG|bexarotene|
219508321|NCT00514293|DRUG|capecitabine|
219508322|NCT00514293|DRUG|carboplatin|
219508323|NCT00514293|DRUG|cisplatin|
219508324|NCT00514293|DRUG|docetaxel|
219508325|NCT00514293|DRUG|tretinoin|
219508326|NCT04289636|BEHAVIORAL|Behavioral weight loss program|Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
219508327|NCT04289636|BEHAVIORAL|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
219508328|NCT04289636|BEHAVIORAL|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
219031887|NCT03082599|DEVICE|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
219031888|NCT01742507|DEVICE|Resolute Integrity Stent|Resolute Integrity Stent
219031889|NCT01742507|DEVICE|Biomatrix stent|Biomatrix stent
219031890|NCT04745598|BEHAVIORAL|Control group: Dental Model|\- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
219031891|NCT04745598|BEHAVIORAL|Computer-assisted teaching format group|\- Patients receive a Powerpoint presentation containing:
219031892|NCT04745598|BEHAVIORAL|Plaque-disclosing group|\- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
219031893|NCT04745598|BEHAVIORAL|Intra-oral camera group|\- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
219031894|NCT05899907|DRUG|Telitacicept|160mg once a week for 48 weeks
219508329|NCT00289627|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
219508330|NCT04385810|PROCEDURE|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
219508331|NCT01045499|DEVICE|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
219508332|NCT01573520|OTHER|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
219508333|NCT04543045|OTHER|not an intervention|not an intervention
219508334|NCT04137263|OTHER|DOSE formulation|over-the-counter topical
219508335|NCT02371083|OTHER|Extended timing of pessary care|
219508336|NCT00322257|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
219508337|NCT00322257|DRUG|insulin detemir|Injection s.c., 50% of daily dose
219508338|NCT00322257|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
219508339|NCT00190853|DRUG|Duloxetine|
219508340|NCT00495118|DRUG|risperidone|
219508341|NCT06153524|BEHAVIORAL|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
219031895|NCT05899907|DRUG|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
219031896|NCT03057665|DEVICE|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
219031897|NCT04803669|PROCEDURE|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
219031898|NCT04803669|PROCEDURE|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
219031899|NCT00075426|DRUG|arsenic trioxide|
219031900|NCT01825382|DEVICE|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
219031901|NCT02347189|DEVICE|Melody Transcatheter Pulmonary Valve PB1016|
219031902|NCT03384550|BEHAVIORAL|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
219508342|NCT06153524|BEHAVIORAL|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
219508343|NCT00312000|DRUG|capecitabine-irinotecan|"1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
219508344|NCT00312000|DRUG|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
219508345|NCT03000400|BEHAVIORAL|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
219508346|NCT03000400|BEHAVIORAL|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
219508347|NCT01590433|DRUG|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
219508348|NCT01590433|DRUG|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
219508349|NCT01590433|BEHAVIORAL|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
219508350|NCT03309800|DRUG|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
219508351|NCT03309800|DRUG|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
219508352|NCT03926078|OTHER|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
219508353|NCT03926078|RADIATION|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
219508354|NCT03926078|RADIATION|CT scan|CT scans will be acquired and used to calculate the HI and EHI
218888615|NCT04786795|DRUG|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
218888616|NCT04786795|DRUG|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
219031903|NCT03384550|BEHAVIORAL|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
219202694|NCT06883942|DEVICE|Experimental Group|The fall detection algorithm will be evaluated first. In a second step, the experimentally obtained prognostic markers of fall risk will be studied. The markers thus obtained shall be validated by comparison with markers already established in clinical practice or in the literature.
219202695|NCT06882915|DRUG|Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab|"TAS-102: Use at the recommended dose of 35 mg/m² each time, twice a day on the 1st to 5th day and the 8th to 12th day every 28 days, with meals.~Bevacizumab: Once a day on the 1st and 15th day every 28 days, at the recommended dose of 5 mg/kg each time, with meals.~Putlimumab: At the recommended dose of 200 mg/time, intravenous drip, infusion time is 60 minutes, once every 28 days."
219508355|NCT04468971|BIOLOGICAL|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
219508356|NCT04468971|DRUG|Placebo|Expicient
219608060|NCT05967624|OTHER|Teleconsultation|Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
219031904|NCT03384550|BEHAVIORAL|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
219031905|NCT03384550|BEHAVIORAL|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
219031906|NCT05188209|DRUG|MRG003|Administered intravenously
219031907|NCT05084573|DRUG|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
219508357|NCT05480878|DRUG|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219608061|NCT06961331|DRUG|Tucatinib|As provided in real world practice.
219608062|NCT06961331|DRUG|Trastuzumab|As provided in real world practice.
218888617|NCT04438317|PROCEDURE|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
218888618|NCT04438317|PROCEDURE|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
218888619|NCT04734067|OTHER|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
218888620|NCT03031366|OTHER|3d roadmap guidance|TIPS was established using 3d roadmap
218888621|NCT03031366|OTHER|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
219031908|NCT05084573|DRUG|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
219202696|NCT06884345|DRUG|METR-NK cells combined with Solvatinib|"Sorafenib 250mg po qd, 3 weeks as a course, a total of 3 courses, the drug was stopped 3 weeks before cytoreduction of intermediate tumor.~Dilute METR - 200 mL of NK cells in 37 ℃ 1500 mL of 0.9% sodium chloride physiological saline, intraperitoneal infusion, flow rate \> 150 drops/min, each METR - venous back to the throughput of NK cells is lower than 2 x 107 cells/kg, abdominal cavity to throughput of no less than 4 x 107 cells/kg, Three days of continuous infusion was taken as a course of treatment, and four courses of continuous infusion (the first course of infusion did not use METR-NK cells) were given, with an interval of 14 days for each course. The position was switched every 15 min after the completion of each infusion to ensure uniform distribution of cells to the tumor surface."
219202697|NCT06703203|BIOLOGICAL|26-Valent pneumococcal conjugate vaccine|As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
219508358|NCT05480878|DRUG|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219508359|NCT05480878|DRUG|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219508360|NCT00555009|DRUG|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
219508361|NCT00555009|DRUG|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
219508362|NCT00367315|DRUG|Lumiracoxib|
219608063|NCT06961331|DRUG|Capecitabine|As provided in real world practice.
218888622|NCT03604796|DRUG|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
218888623|NCT03604796|DRUG|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
218888624|NCT02246426|OTHER|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
218888625|NCT02246426|OTHER|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
219031909|NCT03394482|DRUG|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
219031910|NCT03394482|DRUG|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
219031911|NCT03394482|DRUG|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
218888626|NCT00032981|BEHAVIORAL|Behavior Therapy|
218888627|NCT00684775|COMBINATION_PRODUCT|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
219031912|NCT03394482|DRUG|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
219031913|NCT03394482|DRUG|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
219031914|NCT03394482|DRUG|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
219031915|NCT03293732|BIOLOGICAL|DCB07010|A protein based adjuvant originated from prokaryotic organism.
219508363|NCT05079737|OTHER|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
219202698|NCT06703203|BIOLOGICAL|23-Valent pneumococcal polysaccharide vaccine|As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.
219202699|NCT06703203|BIOLOGICAL|13-Valent pneumococcal conjugate vaccine|As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
219508364|NCT01786811|BEHAVIORAL|Training|"1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
219508365|NCT04568928|DEVICE|OLTP/PE + FES|12 sessions OLTP/PE + FES
219202700|NCT06878911|DEVICE|Ultrasound Scans|10 seconds scanning for one block region
219202701|NCT06879990|BEHAVIORAL|Retrograde normal saline irrigation|Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
219202702|NCT06879990|BEHAVIORAL|Without Retrograde normal saline irrigation|Without Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
219202703|NCT06882551|DRUG|Intravitreal Bevacizumab IVB|Intravitreal bevacizumab alone
218888628|NCT05906433|DRUG|Kenalog with bupivacaine Injection|Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
219031916|NCT03293732|BIOLOGICAL|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
219031917|NCT03187457|OTHER|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
219202704|NCT06882551|DRUG|intravitreal bevacizumab and suprachoroidal triamcinolone acetonide|Combination of Intravitreal bevacizumab and suprachoroidal triamcinolone acetonide
219202705|NCT06884748|DRUG|Ursodiol 500 MG|Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.
219508366|NCT05944705|DIETARY_SUPPLEMENT|Immune Support Supplement|Cannabinoid and co-active emulsion
218888629|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
219031918|NCT03187457|OTHER|Control: no treatment|Healthy women without Bacterial Vaginosis
219031919|NCT01277952|DEVICE|Deep Brain Stimulation|Brain pace maker, implanted in the brain
219031920|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 1
219031921|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 2
219031922|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 3
219031923|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
219031924|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
219202706|NCT06884735|OTHER|exposure to virtual reality|exposure to virtual reality
219202707|NCT03830918|BIOLOGICAL|Atezolizumab|Given IV
219202708|NCT03830918|DRUG|Niraparib|Given PO
219202709|NCT03830918|OTHER|Quality-of-Life Assessment|Ancillary studies
219202710|NCT03830918|OTHER|Questionnaire Administration|Ancillary studies
219202711|NCT03830918|DRUG|Temozolomide|Given PO
219508367|NCT02545153|DRUG|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
219508368|NCT02545153|DRUG|Control|No fibrin sealant applied
219508369|NCT05198128|DRUG|Calcium intravenous infsuion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
219508370|NCT05198128|DRUG|0.9 % saline|0.9 % saline
219508371|NCT04727697|OTHER|Augmented Reality|Patients will receive the preoperative AR experience during their immediately preoperative office visit. The duration of the exposure is approximately 15 minutes.
219508372|NCT04727697|OTHER|Standard of Care preoperative teaching and handouts|At preoperative appointments, patients receive verbal teaching and written handouts about day of surgery instructions and expectations.
219508373|NCT02450565|OTHER|Questionnaire|
219508374|NCT00992264|BEHAVIORAL|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
219508375|NCT00992264|BEHAVIORAL|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
219508376|NCT00992264|BEHAVIORAL|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
219508377|NCT00992264|BEHAVIORAL|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
219508378|NCT01216111|DRUG|Paclitaxel Cisplatin|"Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6"
219508379|NCT01216111|DRUG|fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
219508380|NCT03454971|OTHER|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
219508381|NCT04050397|OTHER|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
218888630|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
218888631|NCT05376176|DRUG|Placebo (Vehicle) BID|Placebo (vehicle) BID
218888632|NCT05723471|OTHER|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
218888633|NCT05982496|DRUG|FES|16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
218888634|NCT05982496|PROCEDURE|PET/MRI A|An additional FES PET/MRI will be performed before surgery.
218888635|NCT05982496|PROCEDURE|PET/MRI B|Two additional PET/MRI will be performed before and after induction ET.
218888636|NCT05982496|PROCEDURE|PET/MRI C|Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
218888637|NCT05982496|PROCEDURE|PET/MRI D|Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
218888638|NCT05982496|GENETIC|Translational analysis|Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
218888639|NCT01991236|BEHAVIORAL|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
218888640|NCT01991236|BEHAVIORAL|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
218888641|NCT00666406|DRUG|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
218888642|NCT00666406|DRUG|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
218888643|NCT06577506|BEHAVIORAL|Deaf Diabetes Can Together|10-week diabetes self-management telehealth intervention for deaf adults with diabetes.
218888644|NCT02843672|PROCEDURE|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
218888645|NCT02843672|PROCEDURE|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
218888646|NCT06964165|DRUG|Niraparib|Niraparib will be administered
218888647|NCT06964165|DRUG|Carboplatin|Carboplatin will be administered
218888648|NCT06964165|DRUG|Paclitaxel|Paclitaxel will be administered
218888649|NCT05730413|DRUG|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
218888650|NCT05730413|DRUG|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
218888651|NCT04298957|PROCEDURE|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
218888652|NCT01546662|DIETARY_SUPPLEMENT|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
218888653|NCT01546662|DIETARY_SUPPLEMENT|Placebo|1/ 2 capsules, twice daily for 12 weeks
219508382|NCT04050397|OTHER|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
219508383|NCT05400265|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
218888654|NCT00907504|DRUG|CP-751,871|CP-751,871 20mg/kg every 3 weeks
218888655|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
218888656|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
218888657|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
218888658|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
218888659|NCT03084003|DIETARY_SUPPLEMENT|Almonds|
218888660|NCT03084003|DIETARY_SUPPLEMENT|Graham crackers|
218888661|NCT02732782|OTHER|Isometric exercise|
218888662|NCT02732782|OTHER|Eccentric exercise|
218888663|NCT02440685|DRUG|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
218888664|NCT02440685|DRUG|ASN002 RD|Recommended dose of ASN002 from Part A
218888665|NCT04887519|OTHER|No Intervention|This is a non-interventional study.
218888666|NCT02434562|OTHER|Serum (with or without urine) samples|
218888667|NCT04289311|BEHAVIORAL|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
218888668|NCT03321422|OTHER|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
218888669|NCT01514201|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219031925|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
219031926|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
219031927|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
219031928|NCT04368988|OTHER|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
219031929|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
219031930|NCT02912234|DRUG|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
219031931|NCT02912234|DRUG|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
219031932|NCT01478126|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
219031933|NCT01478126|DRUG|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
219031934|NCT04087187|DRUG|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
219031935|NCT04087187|DRUG|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
219031936|NCT04087187|DRUG|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
219031937|NCT05004155|DIAGNOSTIC_TEST|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
219031938|NCT00735878|DRUG|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
219031939|NCT04754776|BIOLOGICAL|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
219031940|NCT00994240|PROCEDURE|Electrodessication & Curettage|Electrodessication \& Curettage 1 or 3 cycles
219031941|NCT02662881|DEVICE|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
219031942|NCT02662881|DEVICE|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
219508384|NCT05400265|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
219508385|NCT04152629|DRUG|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
219508386|NCT04152629|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
218888670|NCT01514201|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218888671|NCT01514201|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218888672|NCT01514201|OTHER|Pharmacological Study|Correlative studies
218888673|NCT01514201|DRUG|Temozolomide|Given PO
218888674|NCT01514201|DRUG|Veliparib|Given PO
219031943|NCT01424423|DRUG|Placebo|Placebo
219031944|NCT01424423|DRUG|GSK1223249|I.V. Infusion
219031945|NCT00104455|DRUG|activated recombinant human factor VII|
219031946|NCT03266991|DRUG|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
219031947|NCT03266991|DRUG|Isoniazid|Treatment with daily isoniazid in 6 months
219031948|NCT05106244|OTHER|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
219031949|NCT05572112|DEVICE|Venous access port implantation|Venous access port implantation
219031950|NCT00031889|DRUG|Exemestane|Exemestane
219031951|NCT00031889|DRUG|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
219031952|NCT05584865|OTHER|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
218888675|NCT05888181|OTHER|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
218888676|NCT00398099|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
218888677|NCT04647968|PROCEDURE|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
218888678|NCT04647968|PROCEDURE|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
218888679|NCT02421718|RADIATION|Radiotherapy|
218888680|NCT04890288|PROCEDURE|Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.|Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 \> 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).
218888681|NCT03054649|DEVICE|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
218888682|NCT03054649|PROCEDURE|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
218888683|NCT00756990|DRUG|Depot Naltrexone|228mg of injectable naltrexone
218888684|NCT02534909|BIOLOGICAL|LFG316|"LFG316 20 mg/kg was administered to all patients enrolled in the study:~* Treatment Periods 1 to 3: LFG316 20 mg/kg as i.v. infusion every 2 weeks~* Treatment Period 4: LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions)."
219031953|NCT05584865|OTHER|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
219031954|NCT01544751|DRUG|Low dose metformin|500 mg twice a day
219031955|NCT01544751|DRUG|Metformin|1000 mg twice a day
219031956|NCT01544751|DRUG|Atorvastatin|20 mg/day
219031957|NCT03637803|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
219031958|NCT03637803|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
219031959|NCT00267722|DRUG|Visilizumab|
219031960|NCT01365390|OTHER|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.
219031961|NCT01365390|OTHER|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
219508387|NCT06546644|BEHAVIORAL|Structured school-based intervention|A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
219508388|NCT01838902|DRUG|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
218888685|NCT02534909|DRUG|LNP023|Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.
218888686|NCT01625000|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
218888687|NCT01625000|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
218888688|NCT01625000|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
218888689|NCT01625000|DRUG|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
218888690|NCT01625000|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
218888691|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
219202712|NCT05808218|OTHER|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~1. Triggering:~   * Village transect walks and open defecation site mapping~  * Demonstrations of food contamination and medical expense calculations~2. Development of a Community-Action Plan and identification of natural leaders~3. Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~* Train a cadre of local masons on sanitation construction~* Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
219202713|NCT05808218|OTHER|Care Groups|"* Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~* Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
219202714|NCT06715462|DRUG|N0750|N0750 caps + Cymbalta placebo caps + Lyrica placebo caps
219202715|NCT06715462|DRUG|Cymbalta®|Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
219202716|NCT06715462|DRUG|Lyrica®|Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps
219202717|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
218888692|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
218888693|NCT00904904|DRUG|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
218888694|NCT00904904|DRUG|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
218888695|NCT05681806|DIETARY_SUPPLEMENT|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
218888696|NCT05681806|DIETARY_SUPPLEMENT|Creatine Monohydrate|5g creatine monohydrate
219031962|NCT03976063|DRUG|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
219031963|NCT03976063|DRUG|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
219031964|NCT03027895|DEVICE|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
219031965|NCT03027895|DEVICE|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
219202718|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
219202719|NCT06716645|DRUG|Robitussin Maximum Strength Nighttime Cough DM|Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
219202720|NCT04380454|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
218888697|NCT02535143|OTHER|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
218888698|NCT02535143|DRUG|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
218888699|NCT02535143|OTHER|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
218888700|NCT02535143|DIETARY_SUPPLEMENT|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
219031966|NCT04500184|OTHER|cardiac rehabilitation|rehabilitation performed by professional trainers
219031967|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
219031968|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
219031969|NCT06281847|GENETIC|CCTx-001|Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
219031970|NCT03425929|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
219031971|NCT03425929|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
219508389|NCT01838902|DRUG|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
219508390|NCT01838902|DRUG|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
219508391|NCT01838902|DRUG|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
219508392|NCT03069079|PROCEDURE|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
218888701|NCT05100914|OTHER|Couple-based family nursing|Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
219031972|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
219202721|NCT04380454|OTHER|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
219202722|NCT06715111|DEVICE|Laser acupuncture|A study used a laser acupuncture device to deliver treatment to 27 participants in Group A. The device, was designed for high power, non-thermal treatment. The device had a Class IV- high power, non-thermal laser with a wave length of 808-905 and a 650 nm wavelength. It had an ergonomic handpiece, high efficiency aiming beam, and adjustable emission intensity range. The device also included two laser safety goggles, a touchscreen stylus, and a retractable banner. Participants were instructed to relax and accurately detect acupoints before application. The device was adjusted for safety and both participants and researchers wore laser goggles.
219508393|NCT01499875|DRUG|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
219508394|NCT03265899|DRUG|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
219508395|NCT03265899|DRUG|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
219508396|NCT05411042|DEVICE|Dance somatosensory game|dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
218888702|NCT00362648|BIOLOGICAL|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
219031973|NCT05093231|DRUG|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
219031974|NCT05093231|DRUG|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
219031975|NCT05644262|DRUG|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
219031976|NCT05644262|DRUG|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
219031977|NCT06730347|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
219031978|NCT04726852|DEVICE|Concurrent comparison|Concurrent comparisons at defined procedure events
219031979|NCT06279871|BIOLOGICAL|ARCT-2303|Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
219031980|NCT06279871|BIOLOGICAL|Influenza vaccine|Licensed cell-based influenza vaccine
219031981|NCT06279871|BIOLOGICAL|Influenza vaccine, adjuvanted|Licensed influenza vaccine, adjuvanted
219031982|NCT06279871|OTHER|Placebo|0.9% saline
219508397|NCT00604409|RADIATION|SIRT|Undergo SIRT
219508398|NCT00604409|DRUG|capecitabine|Given PO
219508399|NCT05226520|DIETARY_SUPPLEMENT|Experimental probiotic product|Probiotic supplementation
219508400|NCT05226520|OTHER|Placebo comparator|Placebo
219508401|NCT00062140|DRUG|cyclophosphamide|
219508402|NCT00062140|PROCEDURE|allogeneic bone marrow transplantation|
219508403|NCT00062140|PROCEDURE|peripheral blood stem cell transplantation|
219508404|NCT00062140|RADIATION|radiation therapy|
219508405|NCT05730686|PROCEDURE|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
219508406|NCT04356521|PROCEDURE|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
218888703|NCT00362648|BIOLOGICAL|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
218888704|NCT04828278|DIETARY_SUPPLEMENT|Arginine|Bonded Arginine Silicate
218888705|NCT04828278|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
218888706|NCT06537726|DIAGNOSTIC_TEST|Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)|Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
218888707|NCT05737654|OTHER|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
218888708|NCT05074940|DRUG|Amivantamab|Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
218888709|NCT03983304|DEVICE|The ZELTIQ EMS System|The Zeltiq EMS device will be used to perform treatments for abdominal and gluteal toning.
218888710|NCT00799435|DRUG|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
218888711|NCT04137458|BIOLOGICAL|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
218888712|NCT03885024|OTHER|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
218888713|NCT05332847|DEVICE|POC-US|Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
218888714|NCT01518374|DRUG|Florbetapir F 18|370 MBq (10 mCi)
218888715|NCT01737125|RADIATION|Magnetic Resonance Imaging (MRI)|"* spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~* MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
218888716|NCT06577792|PROCEDURE|Lobectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.
218888717|NCT06577792|PROCEDURE|Lymphadenectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
218888718|NCT04300309|DRUG|artemether:lumefantrine (2.5 mg:30 mg)|Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.
218888719|NCT03035331|PROCEDURE|Cryosurgery|Undergo cryosurgery
219031983|NCT06979193|BEHAVIORAL|SAATHI intervention (Augmented PM+ counseling)|Study participants in this arm will attend six weekly peer-led sessions, each approximately 90-minutes in length, designed to empower them to make decisions about their lives and build resilience. PM+ is a psychological intervention developed by the World Health Organization, based on principles of cognitive behavioural therapy. It includes components such as understanding adversity and psychoeducation on mental health, managing stress, problem-solving, behavioural activation, and strengthening social support. The PM+ model in this study is augmented with additional elements, including self-empowerment strategies, motivational interviewing, psychoeducation on intimate partner and community violence, mindful meditation and safety planning. Participants will also be introduced to best practices and lessons learned that support danger assessments and avoidance of risk of future violence. The intervention aims to improve participants' overall circumstances and mental well-being.
218888720|NCT03035331|BIOLOGICAL|Dendritic Cell Therapy|Given IT
218888721|NCT03035331|OTHER|Laboratory Biomarker Analysis|Correlative studies
218888722|NCT03035331|BIOLOGICAL|Pembrolizumab|Given IV
218888723|NCT03035331|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
218888724|NCT03035331|OTHER|Quality-of-Life Assessment|Ancillary studies
219508407|NCT04356521|PROCEDURE|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
219508408|NCT03295643|DEVICE|Mobile smoking cessation program and CO breath sensor device|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
218888725|NCT06974188|OTHER|AI-risk Stratification|With the results being disclosed as 'high-risk' or 'low-risk' in the experimental arm, clinicians have to adhere to a specific 'high-risk' and 'low-risk' management protocol for participants.
218888726|NCT06483854|DIAGNOSTIC_TEST|HIV counseling and testing from a traditional health practitioner|Healer provided HIV counseling and testing services offered to clients
218888727|NCT06799390|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
218888728|NCT06799390|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
218888729|NCT06575660|BEHAVIORAL|Mental health support session|a single AI-VR mental health support session using the XAIA application
218888730|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
218888731|NCT06976957|DEVICE|MyPlan / Movisalud App|Those patients in experimental arm will be followed through a mobile app that offers different functionalities designed to improve clinical-patient communication, empower the patient in the management of his disease and treatment, detect symptoms early and individualize the interventions of professionals thanks to the patient records on the platform
218888732|NCT06976619|DRUG|Liraglutide Pen Injector|Liraglutide 0.6mg
218888733|NCT06976619|OTHER|Saline Injections|Saline in syringes to serve as placebo for single blind study
219508409|NCT06314321|OTHER|Baduanjin exercise|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
219508410|NCT00899288|PROCEDURE|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
218888734|NCT06975540|OTHER|Multidomain physical exercise|The intervention includes a daily intake of two 200-mL of Meritene nutritional supplements (199 Kcal, 16g of protein, 25g of carbs, 3.6g of fats, and enriched with vitamins and minerals/bottle) plus a supervised and personalized multicomponent exercise program. Multicomponent exercise program (MEP) includes endurance, strength, coordination, balance, and flexibility exercises. The sessions last 65 min a day, 3 days/week for 24 weeks. All the sessions are supervised and delivered in groups by sports scientists.
218888735|NCT06976021|DIAGNOSTIC_TEST|Baseline 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
219202723|NCT06715111|OTHER|conventional pelvic floor exercise|The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.
218888736|NCT06976021|DIAGNOSTIC_TEST|Proteomic assay|Assessment of the proteomic profile before and periodically after treatment
218888737|NCT06976021|DIAGNOSTIC_TEST|Follow-up 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy
219202724|NCT06718907|BEHAVIORAL|Simulated stimuli|Participants will be exposed to a video stimuli in order to assess biophysiological and physiological responses to the stressor and relaxant.
219202725|NCT06718907|BEHAVIORAL|Stress Management|Participants will practice stress management and stress reduction at home, independently.
219202726|NCT06716034|OTHER|Personalized Nutrition Plan and Support|The intervention is a virtually-delivered, personalized nutrition plan and support to improve dietary intake of healthy food (fruit, vegetables and whole grains), based on the principles of a Mediterranean-style diet. Components of the intervention include nutrition counselling, menu planning and the provision of groceries, delivered biweekly, face-to-face, by a registered dietitian over 8 weeks, using a virtual platform. The nutrition counselling structure is grounded in evidence-based behaviour change theory for dietary interventions. Youth and parents will co-develop a personalized menu plan. In addition to biweekly nutrition counselling, participants will receive a food pantry basket, and weekly grocery deliveries to support the menu plan.
218888738|NCT06976788|OTHER|Tomography exam|Brain imaging examination
218888739|NCT06976151|DRUG|Non-steroidal anti-inflammatory drugs (NSAID)|The participants will receive non-steroidal anti- inflammatory drugs (NSAID), Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.
218888740|NCT06976151|OTHER|Transcutaneous Electrical Acupoint Stimulation (TEAS)|"The participants will receive transcutaneous electrical acupoint Stimulation (TEAS). These acupoints will include large intestine 14 (LI4) , gall bladder 34 (GB34), large intestine 11 (LI11), Gall bladder 39 (GB39) and stomach 36 (ST 36). The session will be applied for 30 minutes / 3 days/ week, in addition to Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.~."
218888741|NCT06975553|DEVICE|endotracheal intubation-type end-tidal carbon dioxide sampling tube|In addition to routine monitoring (ECG, NIBP, and SpO2), an endotracheal intubation-type end-tidal carbon dioxide sampling tube is used for end-tidal carbon dioxide IPI monitoring.
218888742|NCT06578663|OTHER|conventional physical therapy|including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)
218888743|NCT06578663|OTHER|Electrical Dry Needling|In electrical dry needling, needle electrodes are used to deliver an electric current to the taut muscle band or the pain-generating trigger point. Low-frequency currents are thought to improve the physiological effects of the therapy by using electrical stimulation to enhance certain physiological reactions and achieve a speedier analgesic and anesthetic effect than that obtained with standard dry needling.
219202727|NCT06718946|BIOLOGICAL|IDOV-SAFE|Intravenous administration of oncolytic virus every 3 weeks until tumor progression
219202728|NCT06717659|OTHER|probiotic supplementation intervention|probiotic supplementation will be administered, while participants continue undergoing routine pulmonary rehabilitation therapy
219202729|NCT06717659|OTHER|standard pulmonnary rehabilitation|undergo routine pulmonary rehabilitation without probiotics intervention
219508411|NCT00676000|PROCEDURE|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
219508412|NCT00676000|PROCEDURE|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
219508413|NCT04676932|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
219202730|NCT07039240|PROCEDURE|Dry needling|The dry needling intervention will follow the fast-in and fast-out technique using disposable stainless-steel needles (0.35 × 40 mm). After insertion with a quick thrust, the needle will be manipulated in multiple directions to elicit at least one local twitch response (LTR). Once the first LTR is obtained, the needle will be moved vertically within a range of 3-5 mm, without rotation, until a total of three LTRs are elicited. The intervention is expected to last approximately 25-30 seconds.
219202731|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Hydrogen-rich water|Hydrogen-rich water with 12 mg of hydrogen per serving
219202732|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Control water|Control water with 0 mg of hydrogen per serving
219202733|NCT06723626|DRUG|Metabolic resuscitation agent|Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
219202734|NCT06723626|DRUG|Hydrocortisone|Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
218888744|NCT06578663|OTHER|Glucosamine sulfate iontophoresis|Galvanic current mode will be used to deliver the cream through the skin. One gram of GS will be placed on positive electrode (being positively charged using Trans-arthral electrode placement technique) for administration of Iontophoresis \[40mA-min (2mA x 20minutes)\].
218888745|NCT06575647|DRUG|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
219031984|NCT06979193|BEHAVIORAL|SAATHI intervention with Peer-Led Group Meetings|"These 11-monthly peer-led group sessions are designed to enhance social support, build resilience, and reinforce the application of augmented PM+ strategies in daily life. They provide a safe space for reflection and mutual encouragement among study participants. The group sessions focus on managing stress, strengthening self-regulation, building self-esteem, fostering social connectedness, and promoting positive identity development.~Group sessions involve identifying and discussing the barriers and facilitators related to practicing slow breathing techniques, problem-solving strategies, maintaining physical activity, navigating intimate partner and community violence, understanding social support networks, and planning for safety in various situations faced by sexual and gender minorities."
219031985|NCT06988241|OTHER|positional release|All participants in group (A) will receive the same program of group B added to positional release . In order to make the positional release , the therapist will pick up the trigger points by palpation in the upper trapezius muscle by pincer palpation method and distinguished with dots on the skin. Participants will be made supine lying and relaxed by maintaining the cervical spine in a neutral position. Lateral flexion of subject's head toward the side of a tender point, the therapist grasps the subject's forearm and abducts shoulder to approximately 90° and adds slight flexion or extension to fine-tune.The most comfortable position achieved will be held for 90 seconds and after that passive return of the body part to an anatomically neutral position will be maintained for 5 minutes. All participants will be treated three times per week for 4 consecutive weeks and will be instructed to maintain their normal activities while avoiding any undue stress to the neck.
219031986|NCT06988241|OTHER|Posture correction|Posture correction advices during lactation + posture correction exercises
219031987|NCT06753175|DEVICE|underwater galvanic stimulation by 4-cell bath|"Underwater Galvanic Stimulation:~* Equipment: 4-cell bath~* Procedure: Patients will immerse their affected limbs in the 4-cell bath. Electrical stimulation will be applied at a frequency of 15 Hz and intensity of 20 mA for 20 minutes, 3 times per week (Han et al. 2020)."
219031988|NCT06753175|OTHER|Complete Decongestive Therapy (CDT):|"Complete Decongestive Therapy (CDT):~* Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week.~* Compression Therapy: Multilayer bandaging applied after MLD.~* Exercise: Specific exercises performed with compression in place.~* Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020)."
219031989|NCT07169357|DRUG|Gengigel|The use of Gingigel or 0.2% hyaluronic gel is expected to enhance healing and decrease discomfort in the post-operative period. It exhibits viscoelastic characteristic which serves as osteo-conductive, anti-edematous, antifungal and bacteriostatic effects.
219202735|NCT06722209|OTHER|polyethylene glycol (Protocol I)|Intestinal preparation protocol with polyethylene glycol (Protocol I)
219202736|NCT06530238|PROCEDURE|Russian Currents|Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
219202737|NCT06723340|DEVICE|Scar gel|Scar gel (medical device - topical application)
219202738|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.3 mg/kg , administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
219202739|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.6 mg/kg, administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
219202740|NCT06887556|DIAGNOSTIC_TEST|ELISA|Mpox-specific antibody ELISA
219508414|NCT01297647|PROCEDURE|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
219508415|NCT03717285|PROCEDURE|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
218888746|NCT04964947|DRUG|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
218888747|NCT06974747|DIETARY_SUPPLEMENT|Imunoglukan P4H® chewable tablets|IMG® 50 mg + Zinc 5 mg + Vitamin D 10 μg in 1 tablet
218888748|NCT06974747|DIETARY_SUPPLEMENT|Placebo chewable tablets|Zinc 5 mg + Vitamin D 10 μg in 1 tablet
218888749|NCT06974552|PROCEDURE|microbead-filled support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using microbead-filled support surfaces. This support surface will remain in place throughout the duration of the surgery.
219202741|NCT06887556|DIAGNOSTIC_TEST|Lateral flow assay|Dried blood spot lateral flow assay for Mpox antibody
219202742|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous normal meal replacement|The normal meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
219202743|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous low-valine meal replacements|The low valine meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
218888750|NCT06974552|PROCEDURE|Jel support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using jel support surfaces. This support surface will remain in place throughout the duration of the surgery.
218888751|NCT06976840|DEVICE|Intermittent theta burst stimulation|Aimed at potentiating the stimulation target.
219031990|NCT07169357|DEVICE|LASER|PBMT has markedly been effective in reducing pain, inflammation, edema and postoperative discomfort. It is said to be a natural and effective alternative approach to minimize medicaments prescription such as analgesics, anti-inflammatory or antibiotic drugs. With that said, negative outcomes such as drug side effects, bacterial resistance and post-operative complications can be prevented, thus increasing the success of medical care and assuring a better quality of life
219031991|NCT07173790|OTHER|Patient-Reported Outcomes Survey|Participants will complete validated questionnaires including EORTC QLQ-C30, EQ-5D-5L, and disease-specific modules (QLQ-CLL17, QLQ-NHL). Responses will be used to assess quality of life and psychological distress during watchful waiting.
219031992|NCT07173855|DRUG|Magnesium sulfate administration|Magnesium sulfate is used in both arms for magnesium replacement.
219031993|NCT07173855|DRUG|Magnesium oxide|In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.
219031994|NCT07173855|DRUG|Magnesium glucoheptonate|Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.
219031995|NCT07175831|BEHAVIORAL|Low-Intensity Continuous Training|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
219202744|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent normal meal replacement|The normal meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
219202745|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent low valine meal replacement|The low valine meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
219508416|NCT03717285|PROCEDURE|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
219508417|NCT02760550|OTHER|No intervention|Participants of all three groups completed a questionnaire.
218888752|NCT06976840|DEVICE|Sham theta burst stimulation|No effect is expected on stimulation target
218888753|NCT06976840|DEVICE|Continuous theta burst stimulation|Aimed at depotentiating the stimulation target
218888754|NCT05061862|DEVICE|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure and/or non-invasive diagnostic collection at follow-up visits, as applicable.
218888755|NCT05216263|DRUG|Atogepant|Oral Tablet
218888756|NCT05499871|BEHAVIORAL|Gait retraining intervention|Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.
218888757|NCT05499871|DEVICE|Transition to minimalist footwear.|Participants will receive a running minimalist footwear.
218888758|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
219031996|NCT07175831|BEHAVIORAL|Moderate intensity Interval training|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
219031997|NCT07175831|BEHAVIORAL|High-Intensity Interval Training|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
219031998|NCT07180719|BEHAVIORAL|Dementia anti stigma intervention|The intervention is a train-a-trainer programme contextually developed, for delivery (via demonstrations and role-plays) by lay providers such as community health workers. It includes four sessions that promote: (i) understanding of dementia, (ii) demystifying myths and misconceptions, (iii) empathetic connections using videos of people with dementia and carers (virtual social contact) and (iv) social inclusion through a case vignette and discussions. It is delivered bi-weekly in a group setting and each session ranges between 1.5 to 2 hours.
219202746|NCT06883552|DRUG|Tislelizumab Injection|During treatment cycles 1-18, Tislelizumab Injection will be administered in combination with Tislelizumab Injection. From cycle 19 onward, treatment will continue with Tislelizumab Injection monotherapy. The specific regimen is as follows: Tislelizumab Injection: 600 mg (initial dose) - 300 mg (subsequent doses), subcutaneously (SC), every 3 weeks (Q3W), for a total of 18 doses (1 year). Tislelizumab: 200 mg, intravenously (IV), every 3 weeks (Q3W).
218888759|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
218888760|NCT05773222|DRUG|Apixaban|Single Group Assignment
218888761|NCT06554743|BEHAVIORAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
218888762|NCT06554743|BEHAVIORAL|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
218888763|NCT06975774|DRUG|Purified Protein Derivative of BCG（BCG-PPD）|Thirty subjects were randomized, double-blinded to perform a homogeneous double-arm BCG-PPD skin test.
218888764|NCT06974539|DIAGNOSTIC_TEST|Multiparametric ultrasound with contrast (Sonovue and Optison)|Participants will receive 3D mpUS using both Sonovue and Optison contrast agents during a single transrectal imaging session.
218888765|NCT06975839|DRUG|Metformin|local application of metformin gel after surgical removal of lower third molar tooth
218888766|NCT06975839|DRUG|non metformin gel|local application of placebo gel after surgical removal of lower third molar tooth
219031999|NCT07180823|DEVICE|Bronchoscopy with Lung Vision navigation system|The procedure begins with inspection of the airways up to the subsegmental branches using a flexible bronchoscope. During the procedure, augmented fluoroscopy will be used as a guidance tool, which is already in use at our operating unit as part of normal clinical practice, and will be combined with radial ultrasound using a mini probe. Once the peripheral lesion has been located, a cytological and histological sample will be taken using a needle and/or forceps and/or cryoprobe under augmented fluoroscopic guidance and with R-EBUS, as per normal current clinical practice. If atypical cells or malignant tumour cells are found during the extemporaneous cytological examination, the FM, acquired specifically for the study, will be positioned to mark the pulmonary nodule. A coil-tailed FM will be used. Enhanced fluoroscopy will be used via the LungVision system.
219032000|NCT07180329|DIETARY_SUPPLEMENT|Myrin P Fort|Patient took Myrin P Fort
219032001|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se supplemented cookies|patients took Zn + Se supplemented cookies
219032002|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se + Myrin P Fort|"patients took Zn + Se~\+ Myrin P Fort"
219032003|NCT07180186|DRUG|Mesalamine|Patients with ulcerative colitis in remission treated with oral mesalamine.
219032004|NCT07180186|DRUG|Probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).
219032005|NCT07180186|DRUG|Mesalamine and probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).
219032006|NCT07179705|DEVICE|Hypotensive prediction index|The HPI, developed by Edwards Lifesciences and integrated into the HemosphereⓇ hemodynamic monitoring system, is an algorithm-based tool that predicts hypotensive events before they occur, allowing earlier intervention. While this tool has shown benefit in surgical and post-operative settings, it has not been tested in ICU patients undergoing dialysis.
219032007|NCT07179705|DEVICE|Standard of care monitoring|"Standard of Care~* Monitoring via conventional invasive BP and clinical judgment~* Use of physical exam, CVP, PPV, and response-based decisions (fluid bolus, vasopressors)"
219032008|NCT07181421|PROCEDURE|Tissue flossing with Therapeutic exercises|"Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall. The Red TheraBand from Thera Tool (2m \* 5cm \* 1.3mm) will be used. The band will be wrapped starting from the tibial tuberosity and extending to 5 cm above the femoral epicondyle. Care will be taken to ensure that the patella remains uncovered.~* The band will be wrapped with 50% tension and 50% overlap.~* Flossing Duration: The floss band will be kept on for 2 minutes, and during this time, the patient will perform the exercises mentioned above. The number of repetitions for each exercise will depend on the patient's tolerance level, with a reference of 10 repetitions per exercise (based on similar tissue flossing protocols, though adapted for knee OA patients)."
219032009|NCT07181421|PROCEDURE|Therapeutic Exercises|Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall.
219032010|NCT07179718|DEVICE|neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) is a treatment method in which electrical conduction via surface electrodes is used to stimulate muscle contraction.
219032011|NCT07179718|DEVICE|bicycle ergometer|Exercise training will be performed using the bicycle ergometer method, under the supervision of a physiotherapist, for 30 minutes a day for 5 consecutive days, at the earliest stage when the patient is clinically stable.
219032012|NCT07181018|OTHER|Trial within cohort (TWIC)|"Educational intervention based on a protocol specifically developed for the TWINS.PL cohort, aimed at activating and engaging the participant in the intervention process.~Intervention group: Phenotypically concordant participants from the TWINS.PL STUDY cohort, randomized to receive an educational intervention designed to actively engage them in modifying selected health-relevant endpoints.~Control group: The co-twin of the participant randomized to the intervention arm, serving as the control.~1. TWINS-TWIC HL: Research Question: Does participation in a structured, participant-activating educational intervention program influence health literacy indicators among participants of the TWINS.PL study? Study Design: A randomized controlled trial embedded within a prospective observational twin cohort (TWiC study in a twin cohort).~2. TWINS-TWIC DIET Research Question: Does participation in a structured, participant-activating educational intervention focused on dietary habits influence the"
219032013|NCT07180836|OTHER|No Intervention (Observational Study)|This is an observational, cross-sectional study. Patients with suspected or confirmed hemoglobinopathies were evaluated for prevalence and hematological characteristics using laboratory investigations, without any experimental treatment or therapeutic intervention applied.
219508418|NCT04189094|DRUG|Sintilimab|Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
219508419|NCT04189094|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
219508420|NCT04189094|DRUG|Cisplatin|cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
219508421|NCT04189094|RADIATION|radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
219032014|NCT07181772|BEHAVIORAL|virtual escape room|Triage training will be taught to students in the experimental group for the first time through a virtual escape room game.
219032015|NCT07181772|BEHAVIORAL|with Power point education|The control group was trained using the traditional method using power point.
218888767|NCT06974513|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the auditory localization performance in patients with a first episode of psychosis. Results of this Arm 1 will be compared to those of Arm 2.
219032016|NCT07181811|OTHER|Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments|The cognitive and fatigue assessments administered in this study are not currently part of the standard clinical care for multiple sclerosis patients on Ocrelizumab. By prospectively assigning participants to undergo these additional assessments, this aspect of the study is considered investigational, and findings may contribute to clinical decision-making regarding the incorporation of cognitive and fatigue assessments into routine management of multiple sclerosis conditions.
219032017|NCT07180056|DRUG|CDK4/6 inhibitor|abemaciclib OR ribociclib
219032018|NCT07181590|PROCEDURE|Pulsed Field Ablation|Pulsed Field Ablation using the Volt PFA
219032019|NCT07181057|OTHER|one-meal-a-day (OMAD)|"Arm Title: Morning Meal (08:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 08:00.~Arm Title: Midday Meal (12:30)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 12:30.~Arm Title: Evening Meal (18:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 18:00."
219508422|NCT02827903|DRUG|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
219508423|NCT02827903|DRUG|Metformin + placebo|Group II: Metformin + placebo,
219508424|NCT02827903|DRUG|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
219508425|NCT02984306|DIETARY_SUPPLEMENT|Cherry powder|
219508426|NCT02984306|DIETARY_SUPPLEMENT|Placebo|
218888768|NCT05858892|OTHER|usual care|usual care(rehabilitation program)
218888769|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
218888770|NCT06665035|BIOLOGICAL|TDV|TDV SC injection.
218888771|NCT06665035|OTHER|Placebo|Placebo SC injection.
218888772|NCT03960177|DRUG|Glucarpidase|Given IV
218888773|NCT03960177|OTHER|Quality-of-Life Assessment|Ancillary studies
218888774|NCT05836259|GENETIC|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
218888775|NCT06974643|OTHER|Thoracic epidural block|Patients will preoperatively receive an awake thoracic epidural block.
218888776|NCT06974643|OTHER|Paravertebral block|Patients will preoperatively receive a paravertebral block.
218888777|NCT05380349|DRUG|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
218888778|NCT03106324|DRUG|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
218888779|NCT06128369|DRUG|Dexamethasone Ophthalmic Suspension|Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
218888780|NCT06128369|OTHER|Vehicle of OCS-01|inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
218888781|NCT06674525|DRUG|626|Single subcutaneous injection
218888782|NCT06674525|DRUG|Placebo|Single subcutaneous injection
218888783|NCT01768195|DRUG|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
218888784|NCT06921538|DEVICE|AscenZ-IV neuromodulation device|AscenZ-IV neuromodulation device is a novel treatment modality that utilizes 2 non-invasive neuromodulation technologies - tPCS and TENS - concurrently within a device. The home-based, non-invasive AscenZ-IV Stimulator therapy has been shown to improve spasticity and motor function
218888785|NCT06684587|BEHAVIORAL|Exercise Program|In this 10-week intervention, participants will be given strengthening exercises and neuromuscular re-education exercises.
218888786|NCT06684587|BEHAVIORAL|Mindful Exercise|In this 10-week intervention, mindfulness meditation will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis.
218888787|NCT06627205|BEHAVIORAL|Sleep Restriction Therapy|Therapist led sleep restriction therapy sessions.
218888788|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
218888789|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
218888790|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
218888791|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
218888792|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
218888793|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
218888794|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
219508427|NCT00422656|DRUG|Perifosine|
219508428|NCT05737056|OTHER|Management of rheumatoid purpura|Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
219508429|NCT01173809|DRUG|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
219508430|NCT01173809|DRUG|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
219508431|NCT06358183|OTHER|No intervention|no intervention used
218888795|NCT04838236|OTHER|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
218888796|NCT04838236|OTHER|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
218888797|NCT06876233|BEHAVIORAL|Wellth App|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
218888798|NCT06876233|BEHAVIORAL|Action Planning|"Participants will learn about habits and the importance of contextual cues for triggering their AH pill taking, and be asked to complete an electronic worksheet with a detailed description of their personalized contextual cue in terms of its: 1) location (e.g., where in the participant's house or office does this cue occur); 2) time of day; 3) preceding action (e.g., I usually go to the bathroom before making coffee); and 4) a visual cue (e.g., my coffee cup will trigger pill taking)."
219032020|NCT07181356|OTHER|RIPerC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
219032021|NCT07181356|OTHER|RIPC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
219032022|NCT07179796|BEHAVIORAL|Observation|Personalized physical activity program tailored to each participant, with variations in frequency, duration, and type of activity based on their preferences, goals, fitness level, and physical ability.
219032023|NCT07181486|DRUG|Live Biotherapeutic Product L. jensenii 1153-1666|"The vaginally administered MucoCept-CVN contains Lactobacillus jensenii 1153-1666, a natural component of the human vaginal microbiota that has been modified to continuously express the potent HIV entry inhibitor modified-cyanovirin-N (mCV-N) right at the site of infection.~MucoCept-CVN is supplied as a prefilled vaginal applicator containing Lactobacillus jensenii 1153-1666, a modified strain of L. jensenii 1153 by integrating a modified cyanovirin-N gene into its chromosome to enhance the strain's ability to inhibit HIV. Each applicator contains 200 mg of MucoCept-CVN powder (1 x 109 CFU), and an inactive preservation matrix."
219032024|NCT07181486|DRUG|Placebo|Each placebo applicator contains 200 mg of placebo powder comprising the same inactive ingredients of the preservation matrix as the study product.
219032025|NCT07181850|OTHER|Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)|Adults with biopsy-confirmed ESCC received standard neoadjuvant immunochemotherapy before surgery (e.g., camrelizumab with paclitaxel plus cisplatin or carboplatin, typically 2 cycles every 2-3 weeks). Treatments were routine clinical care at participating centers and were not assigned by study protocol; this record captures the exposure for observational modeling of pathological complete response (pCR). Surgery (R0) occurred \~6-8 weeks after therapy.
219032026|NCT07174232|OTHER|Russian current and muscle energy techniques|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment and were positioned comfortably, typically in a supine or seated position, depending on the muscle group being targeted. This positioning ensured stability and allowed for the effective application of the MET .
219032027|NCT07174232|OTHER|Russian Current|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment. For the biceps, one electrode will be placed on the middle of the muscle, about halfway between the shoulder and elbow, while the second electrode will be placed slightly above it, closer to the shoulder
219202747|NCT06886555|PROCEDURE|Epidural analgesia for labour pain|Patients were divided into two groups according to repertorised cervical dilatation at the start of analgesia: Group A \< 4 centimetres (latent stage according to National Institute for Health and Care Excellence guidelines) and Group B between 4 and 6 centimetres.
219202748|NCT06716567|BIOLOGICAL|Influenza vaccine|Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.
219508432|NCT05822596|DEVICE|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
219508433|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
219032028|NCT07180537|BEHAVIORAL|Creating Health Online Course|Immediate access to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
219032029|NCT07180537|BEHAVIORAL|Delayed access to Creating Health Online Course|Delayed access (12-week delay) to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
219032030|NCT07180563|DRUG|Participants were treated with doxycycline + berberin for chronic endometritis (intervention group).|Diagnosed chronic endometritis according to endometrial biopsy pathology , the specific medication plan for the intervention group was to use doxycycline 100mg, bid + berberin 100mg, tid, continuously for 14 days.
219032031|NCT07180563|DRUG|At present, the commonly used clinical treatment for chronic endometritis is oral doxycycline|11After hysteroscopic diagnosis of chronic endometritis, patients received monotherapy with doxycycline hydrochloride capsules for 14 days.
219032032|NCT07181317|OTHER|Questionnaires|"Assessment of stress and anxiety and quality of life after myocardial infarct:~* Stress score: Perceived Stress Scale-4 (PSS-4)~* Anxiety score: Generalized Anxiety Disorder-7 (GAD-7)~* Depression score: Patient Health Questionnaire-9 (PHQ-9)~* Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)"
219032033|NCT07181317|OTHER|Major events|Collection of information related to major events occurring since inclusion in the WAMIF study
219032034|NCT07181239|DRUG|CM336 Injection|Specified dose on specified days
219032035|NCT07181239|DRUG|Standard Of Care( SOC)|Specified dose on specified days
219032036|NCT07179731|PROCEDURE|subcostal transversus abdominis plane block|Under ultrasound guidance, 30 ml of bupivacaine is injected along the fascia of transversus abdominis muscle.
219032037|NCT07179731|PROCEDURE|External Oblique Intercostal Plane Block|Under ultrasound guidance, 30 ml of bupivacaine is injected between the fascias of external oblique and intercostal muscles.
219032038|NCT07179731|PROCEDURE|external oblique intercostal plane block and subcostal transversus abdominis plane block combination|The combination of the two blocks will be applied in 15 ml of volume for each.
219032039|NCT07181291|PROCEDURE|PVI|pulmonary-vein isolation
218888799|NCT06876233|BEHAVIORAL|Wellth + Cue|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in (plus evidence of their contextual cue) within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
218888800|NCT06727357|DRUG|Chemotherapy|in according to institutional guidelines
219032040|NCT07179900|DRUG|QL1706|Apololitovoreli monoclonal antibody (QL1706) 7.5mg/kg intravenous infusion, once every 3 weeks
219032041|NCT07179900|RADIATION|Radiotherapy|41.4-50.4Gy/1.8Gy/23-28F
219032042|NCT07179900|DRUG|Sintilimab|200mg q3w
219032043|NCT07179900|DRUG|Bevacizumab|15mg/kg q3w
219032044|NCT05866237|DEVICE|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 and Flu vaccinations through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
219032045|NCT05113537|DRUG|Abemaciclib|Given Orally
219032046|NCT05113537|DRUG|Lutetium Lu 177-PSMA-617|Given IV
219032047|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
219032048|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
219032049|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
219032050|NCT06075485|OTHER|Ketocal|ketogene diet
219032051|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
219032052|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
219032053|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
219032054|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
219032055|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
219032056|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
219032057|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
219032058|NCT05833165|BEHAVIORAL|Feasibility of a supportive approach|Evaluating reasons for patients to use the approach
219032059|NCT04709575|DRUG|REGN5713|Administered subcutaneously
219032060|NCT04709575|DRUG|REGN5714|Administered subcutaneously
219032061|NCT04709575|DRUG|REGN5715|Administered subcutaneously
219032062|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
219032063|NCT06051942|DEVICE|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
218888801|NCT06726304|BEHAVIORAL|Baby Carrier Intervention|Mothers in the intervention group will have the opportunity to choose between two different soft ergonomic baby carriers and will receive instructions on how to use the carrier of their choice. Infants will be placed chest-to-chest in the carrier, supported by the mother's upper torso for a prescribed amount of time during the period of six weeks.
218888802|NCT05379673|OTHER|Oxygen Gas for Inhalation|Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
219202749|NCT06886685|OTHER|Near Infrared spectroscopy (NIRS)|NIRS is used as a non-invasive light-based optical technology to measure placental oxygenation and metabolism
219202750|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• High Intensity TENS (50-150 Hz)"
219202751|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• Low Intensity TENS (5 Hz)"
218888803|NCT06722014|BEHAVIORAL|STAMP + CBT|A mobile health, smartphone application that provides tailored multi-media, cancer pain psycho-education and pain management coping skills using algorithm-based technology to provide in the moment symptom monitoring and feedback.
218888804|NCT06722014|BEHAVIORAL|Digital Cancer Pain Education Packet|Packet including Articles from the Association for Clinical Oncology and the National Cancer Institute and the pain and medication monitoring form.
218888805|NCT05604989|DRUG|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
218888806|NCT05604989|DRUG|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
218888807|NCT06742281|BIOLOGICAL|CVXGA (CVXGA50)|CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
218888808|NCT06742281|BIOLOGICAL|COMIRNATY®|COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
218888809|NCT05747027|PROCEDURE|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
219032064|NCT03181399|DRUG|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
218888810|NCT05747027|PROCEDURE|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
218888811|NCT06893666|OTHER|Play based therapy|Experimental group was given pay based therapy. Total of 4 sessions were given each session of 40min.
218888812|NCT06893666|OTHER|Child centered play therapy|Control group was given child centered play therapy. Total of 4 sessions were given each session of 40min.
218888813|NCT06067269|DRUG|Apalutamide|Given PO
218888814|NCT06067269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218888815|NCT06067269|PROCEDURE|Computed Tomography|Undergo PSMA-PET/CT
219032065|NCT05771480|BIOLOGICAL|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
219032066|NCT05771480|DRUG|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
219032067|NCT05771480|DRUG|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
219032068|NCT05771480|DRUG|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
219508434|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
219508435|NCT00449072|DRUG|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
219508436|NCT00449072|DRUG|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
219508437|NCT02410525|DRUG|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
218888816|NCT06067269|OTHER|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
218888817|NCT06067269|RADIATION|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
218888818|NCT06067269|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
218888819|NCT06067269|PROCEDURE|Positron Emission Tomography|Undergo PSMA-PET/CT
218888820|NCT06067269|OTHER|Questionnaire Administration|Ancillary studies
219508438|NCT02410525|DRUG|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
219508439|NCT02410525|DRUG|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
219508440|NCT02326077|OTHER|Ultrasound|Monitoring of the mechanism of labor
219508441|NCT02326077|OTHER|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
219202752|NCT06718010|OTHER|No intervention (observational study)|The study respects the investigator's choice of treatment, without specifying which drugs should be used, the dosage, the administration mode (including monotherapy, combination therapy, or sequential therapy), or the duration of treatment.
219202753|NCT06727110|DEVICE|PILP Cement|PILP cement liner.
219202754|NCT06727110|DEVICE|PILP Conditioner|PILP solution.
218888821|NCT04748289|DEVICE|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~1. ICU Cockpit COVID-19 for remote monitoring of isolated patients,~2. ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~3. ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
218888822|NCT07061392|OTHER|standardized-patient simulation|"Intervention Arm (Group M) Participants randomized to Group M (n = 45 enrolled; 43 analyzed) first completed baseline assessments of meaningful learning self-awareness , perceived learning, and stoma-care skill , as well as a 10-item demographic survey. They then attended a two-hour didactic session-covering stoma indications, types, perioperative care, evidence-based practices, complications, and the stoma-care nurse's role-delivered by a certified stoma-care nurse in small groups.~Immediately following the lecture, each nurse participated in a two-hour hands-on simulation with a trained standardized patient. The standardized patient had been prepared with a realistic stoma moulage (transparent drape and egg-biscuit mixture) and received two hours of role-training. Simulation sessions adhered to INACSL Standards (pre-briefing, in-scenario, observation, and debrief"
218888823|NCT07061392|OTHER|a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model|"Control Arm (Group K) Participants randomized to Group K (n = 45 enrolled; 44 analyzed) underwent the identical sequence of baseline assessments and the same two-hour didactic session as Group M. For the practical component, they performed stoma-care simulation on a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model.~Hands-on practice was structured in small groups over two hours and included:~Pre-briefing: Overview of objectives and materials.~In-scenario: Individual stoma-care performance on the mannequin, guided by the certified stoma-care nurse with cueing as needed.~Observation: Peers observed from a separate area with scenario summaries.~Debriefing: Reflection and feedback using the PEARLS framework to consolidate learning and discuss transfer to clinical practice.~Immediate post-training assessments using the same three scales captured outcomes in meaningful learning self-awareness, perceived learning, and stoma-care skill level."
218888824|NCT07061483|BEHAVIORAL|Experimental (Gratitude Journaling)|60-Day Gratitude Journaling With Guided Prompts
218888825|NCT07061483|BEHAVIORAL|Control (journaling without gratitude)|60-Day Journaling Without a Gratitude Focus
218888826|NCT06811922|BEHAVIORAL|GBE (Ghya Bharaari Ekatra) intervention|"Ghya Bharaari Ekatra (Marathi for Take a flight together) intervention~The intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of sessions are 2 hours.~GBE will be delivered to a total of 500 dyads."
218888827|NCT06811922|BEHAVIORAL|Ethical standard of care|Ethical standard of care includes information on IPV and mental and reproductive/sexual health resources) to prevent IPV experience. This intervention will be delivered to a total of 350 dyads.
219032069|NCT05771480|DRUG|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
219508442|NCT02326077|OTHER|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
219032070|NCT05771480|DRUG|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
219032071|NCT05771480|DRUG|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
219032072|NCT05771480|DRUG|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
219508443|NCT03395821|BEHAVIORAL|Conventional training|traditional training according to residency program
219508444|NCT03395821|BEHAVIORAL|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
219508445|NCT03739190|DEVICE|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
219508446|NCT01323348|BEHAVIORAL|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~* Measurement of HbA1c in office with immediate feedback~* Measurement of blood pressure with immediate feedback~* Assessment of retinopathy risk with immediate feedback~* Personalized risk assessment reports based on current HbA1c~* Brief assessment of patient understanding of key issues with immediate feedback~* Supplemental diabetes management educational materials (provided at baseline only)~* Feedback to primary care provider~* Email reminder to study participants with email access of individualized risk assessment findings"
219508447|NCT02391428|PROCEDURE|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
219508448|NCT02391428|DIETARY_SUPPLEMENT|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
219508449|NCT00000882|DRUG|Indinavir sulfate|
219508450|NCT00000882|DRUG|Delavirdine mesylate|
219508451|NCT00000882|DRUG|Lamivudine|
219508452|NCT00000882|DRUG|Stavudine|
218888828|NCT07056751|DEVICE|Air negative ion intervention study|The observation group received air negative ion intervention every night for one week before entering the plateau (from 22:00 to 06:00). Before entering the plateau, they were in Putian City, China, where the temperature was about 28°C, humidity was about 68%, and the concentration of negative ions was approximately 800/cm³. The air negative ion converter used was the Mi Energy ET-21 model from RELTEC Medical Devices Corporation. Air negative and positive ion concentrations were measured using an ion detector (NKMH-103, HOKUTO, Japan) to ensure that each participant's room had a negative ion concentration of around 100,000/cm³.
218888829|NCT07056751|DEVICE|No air negative ion intervention|No air negative ion intervention
218888830|NCT05376267|DEVICE|Therapeutic Hypothermia|"Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours."
218888831|NCT06895629|BEHAVIORAL|PRO-MAMAS (Promoting participation, health and wellbeing through meaningful maternal-role activities after stroke)|PRO-MAMAS - a novel occupational therapy intervention program to promote participation, health and wellbeing of older mothers with chronic stroke.
218888832|NCT06771921|DRUG|GEN1078|Specified dose on specified days.
218888833|NCT07064720|DRUG|Dexmedetomidine with Mannitol|receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
218888834|NCT07064720|DRUG|Mannitol (20%)|receive 0.5 g/kg of mannitol
218888835|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 14 G Needle|Each participant underwent Percutaneous Tru-cut Biopsy with 14G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
219032073|NCT06211374|BEHAVIORAL|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
219032074|NCT01050738|PROCEDURE|Position of catheter|Position of catheter for administration of local anestesia.
219032075|NCT05448482|PROCEDURE|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
219032076|NCT05717140|BIOLOGICAL|Aerosol Sargramostim|Given via inhalation with nebulizer
219032077|NCT05717140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219032078|NCT05717140|PROCEDURE|Computed Tomography|Undergo CT
219032079|NCT05717140|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219032080|NCT05717140|OTHER|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
218888836|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 16G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 16 tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
219032081|NCT05717140|BIOLOGICAL|Nivolumab|Given IV
219032082|NCT02857010|BIOLOGICAL|Allogenic mesenchymal stem cells|Cell therapy
219032083|NCT02857010|OTHER|Placebo|Serum without stem cells
218888837|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 18G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 18G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
218888838|NCT07066241|DEVICE|Virtual Reality Glasses|The Effect of Virtual Reality on Stress, Pain Levels and Vital Signs in Patients with Hyperthyroidism Undergoing Fine Needle Biopsy
218888839|NCT07065006|DIAGNOSTIC_TEST|Qor-40 test (The recovery quality test)|Scale of postoperative recovery quality at first 24th hour. Minimum score is 40=bad ,maximum score is 200=good
219032084|NCT03770572|GENETIC|Low dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at low dose
219032085|NCT03770572|GENETIC|High dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at high dose
219032086|NCT05384093|DEVICE|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
219032087|NCT00476021|DEVICE|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
219032088|NCT04274647|DEVICE|NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
219032089|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
219032090|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
219032091|NCT02665871|BIOLOGICAL|placebo|
219032092|NCT02665871|BIOLOGICAL|placebo|
219508453|NCT00000882|DRUG|Zidovudine|
219032093|NCT00514267|DRUG|YM 155|IV
219032094|NCT00514267|DRUG|Docetaxel|IV
219032095|NCT00514267|DRUG|Prednisone|Oral
219032096|NCT05817136|DIAGNOSTIC_TEST|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
219032097|NCT01285648|PROCEDURE|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
219032098|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
219032099|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
219032100|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
219032101|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
219032102|NCT06441409|BEHAVIORAL|Lifestyle intervention|"Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day."
219032103|NCT05477875|DRUG|oral cannabinoid|dronabinol
219032104|NCT05477875|COMBINATION_PRODUCT|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
219508454|NCT04318470|DIAGNOSTIC_TEST|mNGS|Metagenomic next generation sequencing for microbial DNA
219508455|NCT00885690|DRUG|Sertindole|Sertindole 16-24 mg once daily
219508456|NCT00885690|DRUG|Olanzapine|Olanzapine 10-20 mg
219202755|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (lower dose)|20 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
219202756|NCT06707389|DRUG|Methylprednisolone|40mg of methylprednisolone was dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water. Intratympanic injection of methylprednisolone was performed three times a week.
219202757|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (higher dose)|50 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
219202758|NCT06709196|DRUG|Pivmecillinam|Orally administered pivmecillinam 400mg
219202759|NCT06709196|DRUG|Pivmecillinam|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202760|NCT06709196|DRUG|Amoxicillin clavulanic acid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202761|NCT06709196|DRUG|Amoxicillin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202762|NCT06709196|DRUG|Cefuroxime|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219508457|NCT00041574|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
219508458|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
219508459|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
219508460|NCT04356859|DRUG|Albumin Human|Addition of albumin during acute resuscitation following burn injury
219508461|NCT00153088|DRUG|Telmisartan capsule 40 mg|
219508462|NCT00153088|DRUG|Placebo|
219508463|NCT00153088|DRUG|Telmisartan capsule 80 mg|
218888840|NCT07065006|OTHER|Calculation of postoperative opioid consumption|Postoperative opioid consumptions on the pca (patient controlled analgesia) device of the patients will be recorded in Postoperative 30.min,1.,6.,12.,24. Opioid consumptions on the pca device of the patients will be recorded in 30.min,1.,6.,12.,24. hours.
218888841|NCT07065877|DRUG|vit D mixed with xenograft|Topical application of vitamin D solution mixed with xenograft in the jumping gap around immediate implant
218888842|NCT07065877|DRUG|only xenograft without vit D|grafting the jumping gap with xenograft only around immediate implant
219032105|NCT06796075|BEHAVIORAL|Mom♥Health|12-week intervention involving 1) weekly phone calls to mothers regarding education and counseling related to heart healthy lifestyle, as well as strategies for stress reduction; 2) referral to clinical care for identified needs (e.g., elevated blood pressure); and 3) referral to available social resources (e.g., food pantry for identified food insecurity).
219508464|NCT05091788|DEVICE|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
219508465|NCT01943071|BEHAVIORAL|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
219032106|NCT01838031|OTHER|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
219032107|NCT04479956|PROCEDURE|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
219032108|NCT03961100|DRUG|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
219032109|NCT03961100|DRUG|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
219032110|NCT03961100|DRUG|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
219032111|NCT03961100|DRUG|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
219032112|NCT02990169|DEVICE|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
219032113|NCT02990169|DEVICE|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
219032114|NCT03567837|OTHER|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
219032115|NCT01548131|BEHAVIORAL|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
218888843|NCT07065578|OTHER|STAR condition 1|"* Basic module: HF information and doing symptom awareness exercises.~* Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse~* Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse~* Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse"
219032116|NCT00433056|OTHER|STI|CD4 guided treatment interruption
219032117|NCT00433056|DRUG|stable HAART|continuous therapy
219032118|NCT01339351|BEHAVIORAL|Therapeutic Group by Teleconference|10 sessions
218888844|NCT07065578|OTHER|STAR condition 2|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
218888845|NCT07065578|OTHER|STAR condition 3|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
218888846|NCT07065578|OTHER|STAR condition 4|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
218888847|NCT07065578|OTHER|STAR condition 5|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; written feedback HF nurse
218888848|NCT07065578|OTHER|STAR condition 6|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
218888849|NCT07065578|OTHER|STAR condition 7|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
219032119|NCT06377397|DRUG|Antibiotics|"In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment"
219032120|NCT00322192|BEHAVIORAL|Conventional UK Physical therapy|
219508466|NCT01829009|OTHER|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
219508467|NCT04299854|DRUG|Dinoprostone 10mg|Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
219508468|NCT04299854|DEVICE|single balloon Foley catheter|A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
219032121|NCT00322192|BEHAVIORAL|Increased intensity of UK conventional physical therapy|
219032122|NCT00322192|BEHAVIORAL|UK conventional physical therapy plus functional strength training|
219032123|NCT05616858|BEHAVIORAL|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
219032124|NCT01074164|OTHER|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
219032125|NCT01074164|DEVICE|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
219032126|NCT05595512|BEHAVIORAL|Naser Al-Husban|depressive symptoms within 6 months of delivery
219032127|NCT04421911|DRUG|Ketoprofen topical|Ketoprofen topical for 21days
219032128|NCT04421911|DRUG|Diclofenac Topical|Diclofenac topical for 21days
219032129|NCT00544258|DRUG|PEP005|
219032130|NCT05457374|PROCEDURE|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
219032131|NCT05457374|PROCEDURE|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
219032132|NCT03365596|OTHER|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
219202763|NCT06709196|DRUG|Ciprofloxacin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
218888850|NCT07065578|OTHER|STAR condition 8|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
219508469|NCT04906577|OTHER|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
219032133|NCT05422781|DRUG|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
219032134|NCT02342483|DIETARY_SUPPLEMENT|MSM|
219032135|NCT04254978|DRUG|Bomedemstat|Oral administration
219032136|NCT03796780|DIETARY_SUPPLEMENT|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
219032137|NCT03796780|DIETARY_SUPPLEMENT|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
219508470|NCT04906577|OTHER|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
219508471|NCT01024933|BEHAVIORAL|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
219508472|NCT01024933|BEHAVIORAL|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
219608064|NCT06453213|DRUG|Cenobamate|"The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day)."
218888851|NCT07064759|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
218888852|NCT07064759|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
218888853|NCT07065942|DRUG|Lactulose oral solution|Oral, 30 mL once daily administered during breakfast.
219032138|NCT02993003|DEVICE|Nasopharyngeal probe|nasopharyngeal probe insertion
219032139|NCT04931056|DEVICE|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
219032140|NCT04931056|DEVICE|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
219032141|NCT04931056|DEVICE|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
219032142|NCT04931056|DEVICE|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
219032143|NCT04918212|DEVICE|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
219032144|NCT01992731|OTHER|Drug: Follitropine Bèta|
219032145|NCT00211458|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
219032146|NCT00741481|PROCEDURE|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
219508473|NCT00303745|DRUG|capecitabine|
219508474|NCT00303745|DRUG|irinotecan hydrochloride|
219508475|NCT01787825|DEVICE|PillCam SB2 capsule|Capsule Endoscopy system
219508476|NCT01787825|DEVICE|CapsoCam SV-1|Capsule endoscopy
219508477|NCT05731427|DIAGNOSTIC_TEST|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
219508478|NCT05731427|DRUG|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
219508479|NCT06396468|DRUG|sevoflurane|sevoflurane (1-1.2 MAC)
219032147|NCT05420246|DRUG|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
219032148|NCT00001445|BIOLOGICAL|HIV-1 Immunogen|
219508480|NCT06396468|DRUG|propofol|100-400 mcg/kg /min of propofol
219508481|NCT00032162|DRUG|carboplatin|AUC 6 q4w
219032149|NCT03375541|OTHER|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
219508482|NCT00032162|DRUG|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
219508483|NCT04281680|DRUG|Pasireotide 0.9 MG/ML|900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
219032150|NCT00414804|DEVICE|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
219032151|NCT00414804|PROCEDURE|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
219508484|NCT01555320|DRUG|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
219508485|NCT01555320|DRUG|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
219508486|NCT02547857|OTHER|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
219508487|NCT02323490|PROCEDURE|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
219508488|NCT02323490|PROCEDURE|without microfractures|standard procedure meniscal repair without augmentation.
219508489|NCT06340464|OTHER|GNRI, PNI, MNA|Nutrition scoring systems
219508490|NCT03493737|BEHAVIORAL|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
219608065|NCT06479070|OTHER|Blood samples|"A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment."
219608066|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
219608067|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
219608068|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
219608069|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
219608070|NCT01742975|DEVICE|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
219608071|NCT06312020|DRUG|HZN-1116|Subcutaneous Administration
219608072|NCT06312020|DRUG|Placebo|Subcutaneous Administration
219608073|NCT05403216|OTHER|no intervention|
219608074|NCT03784781|BIOLOGICAL|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
219608075|NCT03784781|BIOLOGICAL|Blood collection|Blood collection (+15mL/ current care)
219608076|NCT03784781|BIOLOGICAL|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
219608077|NCT06397378|OTHER|short videos related to HPV and the HPV vaccine|"Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status.~Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format."
219032152|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
219032153|NCT04411433|DRUG|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
219032154|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
219202764|NCT06709196|DRUG|Linezolid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202765|NCT06709196|DRUG|Nitrofurantoin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219508491|NCT04394754|DEVICE|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
219202766|NCT06709196|DRUG|Trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219508492|NCT04394754|OTHER|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
219508493|NCT04394754|OTHER|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
219508494|NCT00989261|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
219508495|NCT03535909|DIAGNOSTIC_TEST|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
219032155|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
219032156|NCT04411433|DRUG|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
219032157|NCT04411433|DRUG|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
219032158|NCT02940171|PROCEDURE|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
219508496|NCT04943809|DEVICE|POD 26P AY FT|Routine cataract surgery
219508497|NCT04943809|DEVICE|POD 26P AY F|Routine cataract surgery
219508498|NCT06401083|DRUG|Caffeine citrate|20 mg/kg caffeine-citrate before the planned extubation.
219508499|NCT02459054|DEVICE|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
219508500|NCT05289765|OTHER|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
219508501|NCT05289765|OTHER|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
219508502|NCT04807114|DRUG|Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)
219508503|NCT04807114|DRUG|Chemotherapy + Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
219508504|NCT00718159|DRUG|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
219508505|NCT04024956|DEVICE|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
219032159|NCT02940171|PROCEDURE|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
219032160|NCT00277212|DRUG|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
219032161|NCT00277212|DRUG|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
219032162|NCT03336216|BIOLOGICAL|Cabiralizumab|specified dose on specified days
219032163|NCT03336216|DRUG|Nab-paclitaxel|specified does on specified days
219508506|NCT00929409|DRUG|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
219508507|NCT00929409|DRUG|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
219508508|NCT03912207|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
219508509|NCT03912207|OTHER|Saline placebo|Saline is a routinely used placebo.
219202767|NCT06709196|DRUG|Sulfamethoxazole trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202768|NCT06709196|DRUG|Fluconazole|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
219202769|NCT06719674|PROCEDURE|Professional mechanical plaque removal and Laser|A diode laser will be used as an adjunct to mechanical plaque removal.
218888854|NCT07065942|DRUG|Live Combined B. Subtilis and E. Faecium Enteric-coated Capsules|Oral, 2 tablets (500 mg per tablet) three times daily (TID).
218888855|NCT07065175|DRUG|Kangfupen (liquid dressing) retention enema administration|"Dosage: 50 mL per administration, once daily Duration: 3-6 months of continuous therapy~Procedure:~Enema depth determined by colonoscopy-identified lesion location Administered as retention enema (minimum 30-minute retention time)"
218888856|NCT07065656|DEVICE|Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH)|Oxygen therapy will be given via the Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH) using a small-bore cannula, with a flow rate of up to 45 L/min, starting temperature of 37oC and FiO2 of up to 1.0.
219032164|NCT03336216|DRUG|Onivyde|specified dose on specified days
219032165|NCT03336216|BIOLOGICAL|Nivolumab|specified dose on specified days
219032166|NCT03336216|DRUG|Fluorouracil|specified dose on specified days
219032167|NCT03336216|DRUG|Gemcitabine|specified dose on specified days
219032168|NCT03336216|DRUG|Oxaliplatin|specified dose on specified day
219032169|NCT03336216|DRUG|Leucovorin|Specified dose on specified days
219032170|NCT03336216|DRUG|Irinotecan Hydrochloride|Specified dose on specified days
219032171|NCT06076694|DRUG|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
219032172|NCT06076694|DRUG|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
219508510|NCT03125083|BIOLOGICAL|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
219608078|NCT06397378|OTHER|CDC HPV Fact Sheet|"We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format.~Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos.~Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC\_AAref\_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html"
219032173|NCT06076694|DRUG|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
219032174|NCT02166190|PROCEDURE|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
219032175|NCT02166190|PROCEDURE|Stenting only|Stenting only
219032176|NCT04774978|DEVICE|TTE|Transthoracic echocardiography
219032177|NCT05005390|DEVICE|TTIP ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
219032178|NCT05005390|DEVICE|Mask Ventilation|In mask ventilation, a mask is placed over the nose and mouth.
219032179|NCT03239470|BIOLOGICAL|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
219032180|NCT03239470|BIOLOGICAL|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
219032181|NCT01347138|OTHER|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
219032182|NCT00539838|DRUG|Prednisone|Oral repeating dose
219032183|NCT00539838|DRUG|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
219508511|NCT02210767|OTHER|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
219608079|NCT06352411|DRUG|BI 456906|Solution for injection
219508512|NCT02210767|OTHER|Walnut Control Diet|2-3% ALA but no walnuts provided
219508513|NCT02210767|OTHER|Low ALA Diet|ALA replaced by oleic acid
219608080|NCT06567249|PROCEDURE|Intracoronary hypothermia|This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
218888857|NCT07065656|DEVICE|Respironics Vision V60|Ventilation will be performed with the Respironics Vision V60 (Philips Healthcare, Murrysville, PA) using an oronasal mask of appropriate size, with FiO2 (up to 1.0), inspiratory (IPAP 12 to 20 cmH2O) and expiratory (EPAP 5 to 10 cm H2O) pressures titrated to alleviate patient's respiratory distress.
218888858|NCT07066488|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
218888859|NCT07066943|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
218888860|NCT07064967|DIAGNOSTIC_TEST|Magnetoencephalography|Participants will undergo magnetoencephalography scan in both resting and tasking state.
218888861|NCT07065604|PROCEDURE|Non-intubated VATS for mediastinal neoplasm|Non-intubated VATS for mediastinal neoplasm
218888862|NCT07065604|PROCEDURE|Intubated VATS for mediastinal neoplasm|Intubated VATS for mediastinal neoplasm
218888863|NCT07064889|DRUG|Dexamethasone|Dexamethasone, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
218888864|NCT07064889|DRUG|Upadacitinib|Upadacitinib 15mg qd for 12 weeks
219032184|NCT00539838|DRUG|Methylprednisolone|Intravenous repeating dose
219032185|NCT00539838|DRUG|Ocrelizumab|Intravenous repeating dose
219032186|NCT00539838|DRUG|Placebo|Intravenous repeating dose
219608081|NCT06567249|OTHER|Standard percutaneous coronary intervention|Percutaneous coronary intervention is performed in a standard manner.
219608082|NCT03830775|PROCEDURE|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
219608083|NCT05821777|DRUG|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
219608084|NCT06538324|DIETARY_SUPPLEMENT|Omega-3|Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.
219608085|NCT06538324|DIETARY_SUPPLEMENT|HOSO|Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.
219608086|NCT05253339|PROCEDURE|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
219032187|NCT00880529|DEVICE|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
219032188|NCT00880529|DRUG|IV opioid administration|Patient controlled analgesia with IV narcotics
219032189|NCT04227184|DRUG|Trospium|Drug to treat overactive bladder
219032190|NCT04227184|DRUG|Placebo oral tablet|Placebo tablet containing no active drug
219032191|NCT02534831|PROCEDURE|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
219032192|NCT02347566|BEHAVIORAL|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
219032193|NCT02347566|OTHER|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
219032194|NCT03318991|PROCEDURE|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
219032195|NCT00581074|BEHAVIORAL|diet (grapefruit or grapefruit juice)|weight loss diet
219032196|NCT02759068|BEHAVIORAL|sounds and odors|presentation of sounds and odors
219032197|NCT00017134|DRUG|fenretinide|
219032198|NCT00017134|PROCEDURE|conventional surgery|
219608087|NCT05253339|PROCEDURE|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
219608088|NCT06504264|BEHAVIORAL|phonemic segmentation|during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.
219608089|NCT04946370|DRUG|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
219608090|NCT04946370|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
219608091|NCT04946370|DRUG|Androgen receptor inhibitor|Patients will receive an oral androgen receptor inhibitor (ARI). Examples include enzalutamide, apalutamide, darolutamide. Dosing will be the standard dosing, as described by the package insert.
219608092|NCT04946370|DIAGNOSTIC_TEST|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
219608093|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
219608094|NCT03937635|BIOLOGICAL|Daratumumab|Given IV
219608095|NCT03937635|DRUG|Dexamethasone|Given PO
219608096|NCT03937635|DRUG|Lenalidomide|Given PO
219608097|NCT03937635|OTHER|Quality-of-Life Assessment|Ancillary studies
219608098|NCT03937635|OTHER|Questionnaire Administration|Ancillary studies
219608099|NCT06350721|DEVICE|DizzyVR|Each patient will receive a total of 8 sessions of vestibular rehabilitation with the DizzyVR system. Each session will last for 50 minutes, with a frequency of one session per week. The total duration of the intervention will be 10 weeks, with the initial assessment/T0 taking place in the first week and the final assessment/T2 in the tenth week. Similarly, the total expected participation time for each participant is set at 12 weeks (T3).
219608100|NCT04694248|DRUG|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
219608101|NCT04694248|DRUG|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
219608102|NCT02495090|GENETIC|Exome sequencing|Plain DNA sequencing
219608103|NCT06470815|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
219608104|NCT06286046|DRUG|Mitapivat|Tablets
219608105|NCT04578483|OTHER|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
219608106|NCT05022147|DEVICE|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
219608107|NCT05022147|DEVICE|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
219508514|NCT05162404|BEHAVIORAL|Video Education Program|"The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
219608108|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
218888865|NCT07065812|OTHER|Surgical team familiarity|Surgical team familiarity: the degree of collaboration within the surgical team is statistically described based on data regarding team personnel and composition, which is used to calculate the Intraoperative Familiarity Score (IFS)-the core component of this study. The specific methodology includes IFS=（X1+X2+X3+X4+X5+X6…）/ N N=nCr=n!/r!(n-r)! Here, X represents the number of times a pair of team members has worked together over a specified period (this process is repeated for all possible pairings in the team), and N is the total number of possible pairwise combinations in the team.
218888866|NCT07065812|OTHER|Composition and Dynamics of the Surgical Team|"Basic indicators reflecting surgical team personnel and composition:~1. Number of surgical, anesthesia, and nursing team members participating in procedures: are obtainable via the Anesthesia Information Management System (AIMS).~2. Shift changes among surgical, anesthesia, and nursing teams during individual procedures: can be tracked through the AIMS.~3. Gender ratio within surgical, anesthesia, and nursing teams: will be derived from the Hospital Information System (HIS)."
218888867|NCT07065864|DIETARY_SUPPLEMENT|Ketone ester|Standardized light meal, questionnaires, blood measurements (finger stick), resting physiology and steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo (in randomized order).
218888868|NCT07065864|OTHER|Placebo|steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo
219032199|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
219032200|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
219032201|NCT00992810|PROCEDURE|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
219608109|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
218888869|NCT07065279|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.
219032202|NCT00992810|PROCEDURE|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
219202770|NCT06719674|PROCEDURE|Professional mechanical plaque removal|The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
219032203|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
219032204|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
219032205|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
219032206|NCT03090100|DRUG|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
219508515|NCT00417274|DRUG|Quinacrine|100 mg daily
219508516|NCT06076681|DRUG|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
219608110|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
219032207|NCT03090100|DRUG|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
219202771|NCT06633146|BEHAVIORAL|Therapies in nature|Therapeutic tasks in nature specifically designed for the study
219508517|NCT06076681|DRUG|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
218888870|NCT07064837|OTHER|Conecta Familia|The Conecta intervention is a Spanish language contraceptive need screening and referral process that includes a screener and referral to social needs navigation bundled with developmental screener in 0-12 month old pediatric well visit for written completion by the mother of the patient
218888871|NCT07064837|OTHER|Contraceptive need survey|brief survey describing demographic information and contraceptive need, use, and experience
218888872|NCT07067047|BEHAVIORAL|Nursing Decision Support System|A behavioral intervention involving a nurse-led decision support system designed to manage fluid volume overload in heart failure patients. The intervention guided nursing care planning, monitoring, and evaluation during hospitalization and through home follow-up visits.
218888873|NCT06915571|OTHER|Plantar Fascia Stretching.|It consists of participants who will undergo plantar fascia stretching.
218888874|NCT06915571|OTHER|Graston Technique|It consists of participants who will underwent graston technique application.
218888875|NCT07066826|DRUG|Huperzine A Controlled-Release Tablets|During the trial, the patients should take huperzine A controlled-release tablets in the morning
218888876|NCT07066826|DRUG|Donepezil hydrochloride tablets|During the trial, the patients should take donepezil hydrochloride tablets before going to bed in the evening
218888877|NCT07066826|DRUG|Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo|During the trial, the patients should take huperzine A controlled-release tablets placebo in the morning and donepezil hydrochloride tablets placebo before going to bed in the evening
218888878|NCT07063290|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
218888879|NCT07065266|OTHER|Binary pain questionnaire|Post-operative questionnaire that asks if pain is 'tolerable' or 'intolerable'
219032208|NCT03090100|DRUG|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
219032209|NCT00344383|DRUG|Norgestimate/Ethinyl Estradiol tablet|
218888880|NCT07065266|OTHER|Numerical Pain Rating Scale (NPRS)|Standard 10-point pain scale used post-operatively to assess pain
218888881|NCT07066930|PROCEDURE|Magneto-Dynamic Ridge Expansion|A ridge expansion technique using the Magnetic Mallet device. Controlled magneto-dynamic impulses are applied to split the alveolar ridge and compact bone prior to immediate implant placement.
218888882|NCT07066930|PROCEDURE|Osseodensification with Versah Drills|"A ridge expansion method using Versah drills (Densah burs) in osseodensification mode. The drills densify bone without removing it, enhancing bone density and implant stability.~Arm Assignment: Versah Osseodensification (Active Comparator arm)"
218888883|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
219032210|NCT06143332|OTHER|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
219508518|NCT06076681|DRUG|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
218888884|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
218888885|NCT07065032|DRUG|ZT002 Placebo|Participants will receive the same volume as the study drug in each cohort.
218888886|NCT07064993|OTHER|Observation|Routine monitoring and observation
219508519|NCT01038570|DRUG|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
219508520|NCT01038570|DRUG|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
218888887|NCT07064993|PROCEDURE|Experimental|Administration of tramadol and dexmethasone to arthroscopy solution
218888888|NCT07064681|PROCEDURE|Surgery with and without the aid of Indocyanine Green (ICG)|Enrolled patients will receive surgery and be follow up for 2 years
218888889|NCT04988880|OTHER|Multiple Sclerosis Expert Patient Program of Catalonia|It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
218888890|NCT07065734|DEVICE|NWPT group|Patients submitted to negative pressure wound therapy
218888891|NCT05178303|DRUG|SB-1121(1)|The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
218888892|NCT05178303|DRUG|SB-1121(2)|The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
218888893|NCT06927583|OTHER|sensory integration therapy|sensory integration therapy include 2 categories that comprised of 9 strategies.
218888894|NCT06927583|OTHER|Traditional Speech therapy|Control group was given traditional speech therapy .total number of 5 sessions give t o each participant that comprised of 30 minutes.
219032211|NCT05828277|DRUG|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
219032212|NCT02047799|DIETARY_SUPPLEMENT|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
219032213|NCT02047799|DIETARY_SUPPLEMENT|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
219032214|NCT05925491|DRUG|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
219508521|NCT03659409|BEHAVIORAL|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
218888895|NCT06923410|DEVICE|AI model|The clinical intelligent AI system is equipped with an AI agent doctor, enabling patients to conduct self-consultations and receive care anytime and anywhere without the need for a real doctor.
218888896|NCT06904963|DEVICE|Motivation for oral hygiene through oral scanner|The oral scanner is used to create a digital model of the patient's mouth with which the operator will provide personalized oral hygiene instructions.
218888897|NCT07066670|BEHAVIORAL|Strain Counterstrain with Routine Physical Therapy|This intervention involves applying the Strain Counterstrain (SCS) technique in combination with standard physical therapy. SCS targets tender points through passive positioning to reduce muscle tension and pain. The patient is positioned in a position of comfort for 90 seconds while monitoring the tender point. This is followed by gradual return to neutral. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), strengthening (short arc quads, terminal knee extension), and stretching exercises. The therapy is administered 5 days per week over 8 weeks.
219032215|NCT05925491|DRUG|Cisplatin|Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.
218888898|NCT07066670|BEHAVIORAL|Muscle Energy Technique with Routine Physical Therapy|This intervention combines Muscle Energy Technique (MET) with routine physical therapy. MET involves voluntary muscle contractions against resistance, followed by stretching to restore range of motion and relieve pain. Techniques include post-isometric relaxation and slow eccentric isotonic stretching, particularly targeting hamstring and quadriceps tightness. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), as well as structured strengthening and stretching exercises. The intervention was delivered 5 days a week for 8 weeks.
219032216|NCT05925491|DRUG|Docetaxel|Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.
219032217|NCT05925491|DRUG|Carboplatin|Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
219032218|NCT06438861|DRUG|Vibegron 75mg|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
219032219|NCT06438861|DRUG|Placebo|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
219032220|NCT03674866|DRUG|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
219508522|NCT03659409|BEHAVIORAL|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
218888899|NCT07065370|DEVICE|Group I ( volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.|Volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.
218888900|NCT07065370|DEVICE|Group II: (volume-controlled ventilation with tidal volume 6-8ml/kg )|group received volume-controlled ventilation with tidal volume 6-8ml/kg predicted body weight with respiratory rate 18-20 cycle/minute
218888901|NCT06902636|BEHAVIORAL|Geriatric trauma care program|The experiment group will implement the Geriatric trauma care program (GTCP) and routine care. The GTCP will be implemented by a nurse practitioner and equipped with digitalized educational material, including six units of intervention for older adults with traumatic injuries who live alone.
218888902|NCT06907147|DEVICE|Multi-Organ Denervation Gemini System|After angiography according to standard procedures, subjects are treated with renal denervation followed by hepatic denervation.
218888903|NCT06158815|OTHER|proprioceptive neuromuscular facilitation exercise|The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
219032221|NCT00271479|BIOLOGICAL|A, C, Y, W135 meningococcal polysaccharide vaccine|
219032222|NCT01438970|DEVICE|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
219032223|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
219032224|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
219032225|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
219032226|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
219032227|NCT00952341|DRUG|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
219032228|NCT00952341|DRUG|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
219032229|NCT00952341|DRUG|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
219032230|NCT00952341|DRUG|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
219032231|NCT00952341|DRUG|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
219032232|NCT00079833|DRUG|Esomeprazole magnesium (Nexium)|
219032233|NCT04069403|OTHER|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
219202772|NCT06883916|BEHAVIORAL|Virtual reality tour|The glasses have a pre-loaded video containing nature images in their memory. The patient feels like they are walking in the natural environment shown in the video.
219508523|NCT05893056|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
219508524|NCT05893056|DRUG|Tislelizumab|a PD-1 immune check inhibitor
219508525|NCT05893056|DRUG|Lenvatinib|Lenvatinib capsules
219202773|NCT06883916|BEHAVIORAL|Massage|A hand massage was applied by the researcher for 5 minutes for each hand. The massage, which was performed using baby oil and a paper towel, lasted 10 minutes in total for both hands.
219202774|NCT06889961|DIETARY_SUPPLEMENT|Mixed spices|Mixed spices 4.00 g capsules of spice mixture contain 1.0 g (25%) turmeric, 1.5 g (37.5%) cinnamon, 0.5 g (12.5%) oregano, 0.5 g (12.5%) black pepper, 0.3 g (7.5%) sage and 0.2 (5%) thyme
218888904|NCT02741765|BEHAVIORAL|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
218888905|NCT02741765|OTHER|Real rTMS|Subjects will participate in a combination of rTMS
219032234|NCT06368674|OTHER|Intervention group Case Manager (CM)|The CM will be informed about the discharge plan from the nurse at the geriatric ward, as will the municipality for those with need of home help care. An outline of the intervention has been created with managers from primary care and rehabilitation within primary care and municipality care. Core components in the intervention will be active follow-up of the discharge, rehabilitation and care plans. If there are plans that have not been executed or unmet needs, the CM will take adequate contacts to ensure that actions are made to meet the needs. These contacts can be, e.g. the GP for medical needs, the rehabilitation unit in primary or municipality care for unmet rehabilitation needs, and the home help service for unmet care needs. The CM will have a network of contact persons in hospital, primary and community care, as well as in rehabilitation in primary and community care, in order to facilitate for prompt actions to meet the needs.
219032235|NCT06368674|OTHER|Control Group|The participants in the control group with a planned follow-up by a primary health care centre within the catchment area of the Sahlgrenska University Hospital that does not have CMs designated for active follow up of discharged frail older people. Thus, the participants in the control group will not actively be followed-up after discharge.
219202775|NCT06889961|OTHER|Placebo|4.00 g maltodextrin capsules
219202776|NCT06731608|BEHAVIORAL|OPTIONS|OPTIONS is a multimodal intervention approach that includes providing clinical decision support (CDS) for healthcare providers, patients, and their caregivers focused on exercise, nutrition, and bone-enhancing medications using CDS in SNFs that use the same electronic health record system (PointClickCare).
219202777|NCT06731608|BEHAVIORAL|Enhanced usual care|Enhanced usual care includes access to the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit, a fall prevention program from the CDC.
218888906|NCT02741765|BEHAVIORAL|Supervised aerobic exercise|
218888907|NCT07066319|BEHAVIORAL|Gait Training with Proprioceptive Neuromuscular Facilitation (PNF)|A physiotherapeutic intervention combining structured gait training with Proprioceptive Neuromuscular Facilitation (PNF) techniques. Sessions include rhythmic initiation, diagonal movement patterns, and resistance-based facilitation to enhance lower limb motor control and balance in stroke survivors. Delivered 3 times/week for 12 weeks, 45 minutes per session.
218888908|NCT07066319|BEHAVIORAL|Gait Training with Conventional Physiotherapy|A rehabilitation protocol integrating traditional gait training (step drills, overground walking) with conventional physiotherapy exercises focused on lower limb strength, range of motion, and postural balance. Conducted over 12 weeks, 3 sessions per week, 45 minutes each.
219032236|NCT04573036|DRUG|HRS4800 tablets|single oral administration
219032237|NCT04573036|DRUG|Placebo tablets|single oral administration
219202778|NCT06731023|DRUG|Bismuth|Bismuth 0.6g bid
219202779|NCT06731023|DRUG|Vonoprazan|vonoprazan 20mg bid
219202780|NCT06731023|DRUG|Amoxicillin|Amoxicillin 1g bid
219202781|NCT06731023|DRUG|Rifabutin|Rifabutin 0.15g bid
219202782|NCT06731023|DRUG|Metronidazole|Metronidazole 400mg qid
219202783|NCT06731023|DRUG|Other antibiotics|The selection of other antibiotics is based on the results of drug susceptibility testing.
218888909|NCT07066319|BEHAVIORAL|Combined PNF and Conventional Physiotherapy (without direct gait training)|This intervention blends Proprioceptive Neuromuscular Facilitation (PNF) with conventional physiotherapy, excluding dedicated gait tasks. It includes rhythmic stabilization, functional mobility drills, and resistance-based exercises aimed at improving neuromuscular re-education, balance, and independence. Delivered 3 times/week for 12 weeks, 45 minutes per session.
218888910|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
218888911|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
218888912|NCT04752332|DRUG|Abemaciclib|Administered orally.
218888913|NCT04752332|DRUG|Standard Adjuvant ET|Administered according to label instructions.
218888914|NCT04752332|DRUG|Placebo|Administered orally.
218888915|NCT06914778|OTHER|Blood draw for the laboratory assessment|Blood plasma collection for for lipidomic and metabolomic analysis
218888916|NCT06914778|OTHER|Urine sample|Urine sampling for aqueous metabolomics
218888917|NCT06920576|DRUG|Esketamine|Intravenous esketamine 0.25 mg/kg was administered 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
218888918|NCT06920576|DRUG|Magnesium sulfate|Intravenous magnesium sulphate 30 mg/kg was administered within 10 min before induction of anaesthesia, followed by continuous pumping at 30 mg/(kg-h) until the end of the operation
218888919|NCT06920576|DRUG|Saline|Pumping equal volumes of saline over the same time period
218888920|NCT04843904|DRUG|Venetoclax|Tablet, taken by mouth
218888921|NCT04843904|DRUG|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
218888922|NCT04843904|DRUG|Rituximab|Given as an infusion into the vein (intravenous, IV).
218888923|NCT06768515|OTHER|No interventtion|to enhance the understanding of the factors associated with the number of organs retrieved from patients admitted to the ICU for organ donation
218888924|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
218888925|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
218888926|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
218888927|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
218888928|NCT03465995|DEVICE|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
218888929|NCT00048347|DRUG|AVONEX|30µg IM every week for 12 weeks
218888930|NCT02450513|DRUG|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
218888931|NCT00484978|PROCEDURE|Stereotactic Radiosurgery|
218888932|NCT03908814|DRUG|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
218888933|NCT01523509|DEVICE|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
218888934|NCT03193710|DRUG|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
218888935|NCT03193710|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
218888936|NCT03193710|DRUG|Remifentanil|Remifentanil will be used for analgesia in both groups.
218888937|NCT05630677|DRUG|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
218888938|NCT05630677|DRUG|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
218888939|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
219032238|NCT01391390|DRUG|Melatonin|10mg/day, 12-week treatment
219032239|NCT01391390|DRUG|Placebo|10mg/day, 12-week treatment for TD
219032240|NCT04011527|PROCEDURE|Rotational Atherectomy in Coronary Lesion/s|
219032241|NCT03051048|PROCEDURE|Reperfusion|
219032242|NCT04537858|DEVICE|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
219032243|NCT04537858|DEVICE|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
219032244|NCT04220372|DRUG|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
219032245|NCT04220372|DRUG|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
219032246|NCT05993611|PROCEDURE|Biopsy|Undergo biopsy
219032247|NCT05993611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219032248|NCT05993611|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
219032249|NCT05993611|PROCEDURE|Computed Tomography|Undergo CT
219032250|NCT05993611|PROCEDURE|Echocardiography|Undergo ECHO
218888940|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
219508526|NCT01258491|DRUG|Nicotinic Acids|
219508527|NCT00192127|BIOLOGICAL|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
218888941|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
218888942|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
218888943|NCT03460561|PROCEDURE|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
219032251|NCT05993611|OTHER|Electronic Health Record Review|Ancillary studies
219032252|NCT05993611|PROCEDURE|Leukapheresis|Undergo leukapheresis
219508528|NCT00192127|OTHER|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
219508529|NCT01880710|PROCEDURE|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
219508530|NCT01880710|PROCEDURE|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
219608111|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
219608112|NCT05022147|DRUG|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
219608113|NCT05022147|DRUG|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
219608114|NCT04015596|DRUG|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
219608115|NCT04015596|OTHER|Placebo|Participants take placebo pills twice daily, for 8 weeks.
219608116|NCT05585164|BEHAVIORAL|Engage & Connect (E&C)|"Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation."
219608117|NCT05585164|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
219608118|NCT05806164|DRUG|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
219608119|NCT05806164|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
219032253|NCT05993611|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219032254|NCT05993611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
219032255|NCT05993611|OTHER|Quality-of-Life Assessment|Ancillary studies
219032256|NCT05993611|BIOLOGICAL|Tafasitamab|Given IV
219032257|NCT05993611|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219032258|NCT03293251|PROCEDURE|Trabeculectomy with MMC|glaucoma surgeries
219032259|NCT02826681|DRUG|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
219032260|NCT02826681|DRUG|Placebo (Normal Saline)|Normal Saline Solution
219508531|NCT01268176|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU once per month for 3 months
219608120|NCT06644846|RADIATION|Spatially fractionated radiation therapy|"Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk."
219608121|NCT02731638|DRUG|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
219608122|NCT02731638|DRUG|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
219608123|NCT06577636|PROCEDURE|Propofol anesthesia|EEG-guided infusion of anesthestetics
219608124|NCT05160597|PROCEDURE|Biopsy of Prostate|Undergo image-guided prostate biopsy
219608125|NCT05160597|OTHER|Gallium Ga 68 Gozetotide|Given IV
219608126|NCT05160597|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
219608127|NCT05844033|OTHER|Screening|Blood tests
219608128|NCT03909737|DRUG|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
219608129|NCT03909737|DRUG|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
219608130|NCT03909737|OTHER|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
219608131|NCT03909737|OTHER|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
219608132|NCT03909737|OTHER|No intervention to pregnant women|No intervention to pregnant women
219508532|NCT01252433|OTHER|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
219608133|NCT05510622|OTHER|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
218888944|NCT03460561|PROCEDURE|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
218888945|NCT04967027|DEVICE|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
218888946|NCT03818451|DIETARY_SUPPLEMENT|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
218888947|NCT02240602|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
218888948|NCT02240602|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
218888949|NCT02240602|DRUG|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
218888950|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
218888951|NCT06329206|DRUG|GH2616 Tablets|GH2616 tablets will be given orally
218888952|NCT04386694|DEVICE|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
218888953|NCT04386694|DEVICE|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
218888954|NCT04522141|BEHAVIORAL|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
219032261|NCT02062762|BEHAVIORAL|Online-MBSR|8 week mindfulness based stress reduction online
219032262|NCT02062762|BEHAVIORAL|Expressive Writing Online|Online distributed expressive writing intervention as active control
219032263|NCT04333810|DEVICE|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
219032264|NCT03267862|OTHER|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
219032265|NCT06200727|PROCEDURE|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
219202784|NCT05773833|BEHAVIORAL|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
219202785|NCT06737224|OTHER|Fasting + Exercise (FAST+EX): fasting + exercise condition|Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.
219202786|NCT06737224|OTHER|Fasting only (FAST): Non-exercise fasting condition|Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.
219202787|NCT06741332|DEVICE|Methinks software|Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.
219508533|NCT03905291|DRUG|MT921|Formulated as an injectable solution
219032266|NCT06200727|PROCEDURE|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
219508534|NCT03905291|DRUG|Placebo|normal saline
219508535|NCT02278679|PROCEDURE|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
219508536|NCT02971956|DRUG|Pembrolizumab|Immune checkpoint inhibitor
219508537|NCT04243174|BEHAVIORAL|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
219608134|NCT06516510|DRUG|lutetium (177Lu) rhPSMA 10.1 and Pluvicto®|Radiopharmaceutical
219608135|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
219202788|NCT06741332|OTHER|Normal CT scans evaluation|The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.
219202789|NCT06741098|BIOLOGICAL|NCR100|Subjects will receive multiple intra-articular NCR100 injections.
219202790|NCT06741098|OTHER|0.9% Normal saline|Subjects will receive multiple intra-articular 0.9% Normal saline injections.
219202791|NCT06739187|DEVICE|Virtual reality platform on head mounted display|Enhance Virtual Reality platform on a Meta Quest head mounted display
219202792|NCT06739603|OTHER|pharmaceutical analysis|pharmaceutical analysis
219608136|NCT05626231|BEHAVIORAL|Training Intervention|"The training intervention is a modular online asynchronous training intervention designed to increase mental health providers' use of evidence-based practices with youth patients (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (youth, their parents, mental health providers). In this open trial, the training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
218888955|NCT04522141|BEHAVIORAL|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
219608137|NCT06801834|DRUG|Sacituzumab Govitecan (SG)|Administered intravenously
219608138|NCT06801834|DRUG|Topotecan|Administered intravenously
218888956|NCT02597387|DRUG|Mitoxantrone HCL Liposome Injection|
218888957|NCT02048085|DRUG|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
219608139|NCT06801834|DRUG|Amrubicin (Japan only)|Administered intravenously
219608140|NCT06527404|DRUG|Rocatinlimab|SC Injection
219608141|NCT06527404|DRUG|Placebo|SC Injection
219608142|NCT06433219|DRUG|Tuvusertib (M1774)|Tuvusertib will be administered orally.
219608143|NCT06433219|DRUG|Niraparib|Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib.
219608144|NCT06433219|DRUG|Lartesertib (M4076)|Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib
218888958|NCT02048085|DRUG|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
218888959|NCT03508609|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34 cells
218888960|NCT04563962|BEHAVIORAL|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
218888961|NCT04563962|BEHAVIORAL|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
219032267|NCT06200727|PROCEDURE|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
219032268|NCT06200727|PROCEDURE|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
219032269|NCT06200727|PROCEDURE|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
219032270|NCT06200727|PROCEDURE|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
219032271|NCT06200727|PROCEDURE|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
219032272|NCT06200727|PROCEDURE|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
219032273|NCT06484998|BEHAVIORAL|Dental anxiety level and child's compomer colors selection|Patients without any syndromes or systemic disorders, without mental retardation, who needed restorative treatment for primary molars were included in the study. The examination forms of 275 patients requiring restorative treatment of primary teeth were analysed at the session they came for restorative treatment. To determine the child's anxiety, the Modified Child Dental Anxiety Scale-faces version was administered to the children before restorative treatment. The children were asked to choose from a scale consisting of 9 colours (pink, blue, gold, silver, orange, yellow, green, purple, white) for the compomer restoration color selections. The patients were asked what their favourite color was after the compomer restoration color selection so that the previous question would not have any effect on the child's restoration color selection.
219032274|NCT04471636|DEVICE|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
219032275|NCT00946426|OTHER|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
219032276|NCT03406858|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV
219032277|NCT03406858|OTHER|Laboratory Biomarker Analysis|Correlative studies
219032278|NCT03406858|BIOLOGICAL|Pembrolizumab|Given IV
219032279|NCT06358105|PROCEDURE|Simulator-based training|A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
219032280|NCT06358105|PROCEDURE|Standard training|Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
219202793|NCT06738732|DRUG|CBD: GT4 Transdermal Delivery System|CBD: GT4 Transdermal Delivery System
219202794|NCT06734845|PROCEDURE|Total Knee Arthroplasty|Total Joint (Knee or Hip) Arthroplasty
219608145|NCT06242912|BEHAVIORAL|QOL - quality of life|QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
219608146|NCT06242912|DIAGNOSTIC_TEST|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
218888962|NCT05633173|PROCEDURE|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
218888963|NCT05633173|PROCEDURE|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
219508538|NCT00850278|OTHER|FLT-PET imaging|Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
218888964|NCT00555217|DRUG|losartan|50 or 100mg/day
218888965|NCT00555217|DRUG|lisinopril|10, 20 or 40 mg/day
218888966|NCT05860153|DRUG|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
218888967|NCT05860153|DRUG|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
219032281|NCT06276959|DIAGNOSTIC_TEST|intraoral scanning|The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
218888968|NCT01653990|DRUG|moxifloxacin|oral dose of 400mg moxifloxacin
218888969|NCT01653990|DRUG|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
218888970|NCT00976833|OTHER|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
218888971|NCT00976833|OTHER|Usual Care|Usual Physical Therapy care
219032282|NCT06276959|DIAGNOSTIC_TEST|clinical oral examination|Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
219032283|NCT06276959|DIAGNOSTIC_TEST|cone-beam computed tomography|All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
219032284|NCT05877092|DEVICE|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
219032285|NCT00455507|DRUG|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
219032286|NCT00455507|DRUG|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
219032287|NCT00455507|DRUG|Placebo|Two placebo tablets orally once daily for 12 weeks
219032288|NCT06453629|DEVICE|Floreo VR|12 week VR program to help children with ASD to reduce the core symptoms of Autism
219032289|NCT06453629|DEVICE|VR Control|12 week program administered in VR
219032290|NCT06453629|DEVICE|VR Control Crossover|If opt in, this group will crossover at the end of 12 weeks to the Floreo VR program
219032291|NCT06201754|OTHER|Measure air quality|Measure air quality, including PM2.5、PM10
219032292|NCT03875378|DRUG|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
219032293|NCT03875378|DRUG|Placebos|Placebo weekly patch
219032294|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
219032295|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
219032296|NCT00076687|DRUG|saline|Saline injection at Day 1, Week 12, Week 18
219032297|NCT05953428|OTHER|Opioid Sparing Anesthesia Protocol (OSA)|OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
219032298|NCT05953428|OTHER|Opioid Based Anesthesia Protocol (OBA)|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
219202795|NCT06734845|PROCEDURE|Total Joint Arthroplasty|Participants will be patients undergoing first total knee or total hip replacement
219202796|NCT06734403|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
219508539|NCT02370706|DRUG|PIM447|pan-pim inhibitor
219508540|NCT02370706|DRUG|Ruxolitinib|JAK1/JAK2 inhibitor
219508541|NCT02370706|DRUG|LEE011|CDK4/6 inhibitor
219508542|NCT03437759|BIOLOGICAL|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
219032299|NCT02674971|BEHAVIORAL|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
219508543|NCT05289622|DEVICE|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
219032300|NCT05355415|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
219032301|NCT03760796|DEVICE|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
219032302|NCT03136003|DRUG|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
219032303|NCT03136003|BEHAVIORAL|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
219032304|NCT06023576|OTHER|antihypertensive medications|"One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics"
219032305|NCT06023576|DIAGNOSTIC_TEST|Blood pressure measurement|Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
219508544|NCT00427492|DRUG|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
219508545|NCT00427492|DRUG|Placebo|
219508546|NCT00164320|BEHAVIORAL|TEAM|
219032306|NCT06023576|DIAGNOSTIC_TEST|Echocardiogram|At baseline, month 6, and month 12
219032307|NCT06023576|OTHER|Symptom-limited cardiopulmonary exercise test|Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
219032308|NCT06023576|OTHER|Quality of Life Measures|FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
219032309|NCT06023576|DIAGNOSTIC_TEST|Biomarkers|Research blood samples will be collected at baseline, 3 months, and 6 months
219508547|NCT01761357|OTHER|answering to questionnaires of quality of live|
219508548|NCT01806233|PROCEDURE|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
219032310|NCT02836600|DRUG|LY3039478|Administered orally
219032311|NCT02029001|DRUG|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
219032312|NCT02029001|DRUG|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
219032313|NCT02029001|DRUG|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
219032314|NCT02029001|DRUG|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
219508549|NCT01806233|PROCEDURE|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
219508550|NCT00101608|DRUG|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
219508551|NCT00597233|DRUG|insulin aspart|
219508552|NCT00597233|DRUG|soluble human insulin|
219508553|NCT00597233|DRUG|insulin NPH|
219508554|NCT01608009|DRUG|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
218888972|NCT03863808|BEHAVIORAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
218888973|NCT03863808|OTHER|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
218888974|NCT03680183|DRUG|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
219032315|NCT02029001|DRUG|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
219032316|NCT02029001|DRUG|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
219032317|NCT02029001|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
219032318|NCT02532647|DRUG|Remimazolam|
219032319|NCT02532647|DRUG|Midazolam|
219032320|NCT02532647|DRUG|Placebo|
219032321|NCT01820416|RADIATION|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
219032322|NCT01820416|OTHER|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
219032323|NCT02492269|DRUG|Dexmedetomidine|
219032324|NCT02492269|DRUG|Placebo|
219032325|NCT00003752|DRUG|bexarotene|
219032326|NCT02126956|DRUG|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
219032327|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
219032328|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
219032329|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
219032330|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
219032331|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
219032332|NCT05243654|DRUG|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
219032333|NCT05243654|DRUG|Placebo|Placebo + standard-of-care MDT
219032334|NCT03788096|BEHAVIORAL|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
219032335|NCT03788096|BEHAVIORAL|Usual Care Group|Usual care.
219032336|NCT06576063|DEVICE|Lumoral Treatment|Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
219032337|NCT06576063|BEHAVIORAL|Standard oral hygiene methods|Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
219032338|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
219032339|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
219032340|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
219032341|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
219508555|NCT04715607|DIAGNOSTIC_TEST|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
219508556|NCT03784456|DIETARY_SUPPLEMENT|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
219032342|NCT04682626|DIETARY_SUPPLEMENT|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
219032343|NCT05694546|BEHAVIORAL|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
219032344|NCT03350854|BEHAVIORAL|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
219032345|NCT03375411|DEVICE|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
219032346|NCT00296933|DRUG|Escitalopram|
219202797|NCT06734286|OTHER|CogMed|CogMed which is a computerized working memory training program developed by Karolinska University.
219202798|NCT06735144|DRUG|FH-006|Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
219202799|NCT06735144|DRUG|FH-006|administered once every 3 weeks (Q3W), with a treatment period of 21 days
219202800|NCT06742164|DRUG|Ivabradine 5mg Tab|Ivabradine (5 mg twice daily) orally or via nasogastric tube
219202801|NCT06742164|DRUG|control|Patients didn't receive Ivabradine .
219202802|NCT06742489|DEVICE|Percutaneous tibial nerve stimulation device|T-PTNS primarily delivers electrical stimulation to the sacral voiding center via the tibial nerve through the S2-S4 sacral plexus via skin-surface electrodes to improve patients' symptoms of urinary frequency, urgency, and urge incontinence.
219202803|NCT06742489|DEVICE|Sham group device|The device in the sham group is manufactured by the same company and has the same appearance, display interface, and operation method as the device in the treatment group. These devices have the output circuit disconnected and no actual current output.
219202804|NCT06893159|DEVICE|INSTI HIV-1/2 Antibody Test|The INSTI HIV-1/HIV-2 Antibody Test is a single use, rapid, in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1 and/or Type 2 (HIV-1/HIV-2) in human venipuncture whole blood, fingerstick blood, or plasma specimens. The test is intended for use by trained personnel in point of care and laboratory situations to aid in the diagnosis of HIV infections. If multiple rapid HIV tests are available, this test is suitable for use in appropriate multi-test algorithms.
219032347|NCT00296933|DRUG|Bupropion XL|
219032348|NCT04682184|DRUG|Propranolol|Administered orally.
219032349|NCT04682184|DRUG|Pseudoephedrine|Administered orally.
219032350|NCT04682184|DEVICE|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
219032351|NCT00749372|OTHER|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
219032352|NCT05506852|BEHAVIORAL|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
219508557|NCT03784456|DIETARY_SUPPLEMENT|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
219508558|NCT03199248|PROCEDURE|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
219508559|NCT06380465|OTHER|"The water extract of Biang variety purple sweet potato"|"Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring"
219508560|NCT03718338|PROCEDURE|Evaluation|Undergo clinical evaluations
219508561|NCT03718338|OTHER|Quality-of-Life Assessment|Ancillary studies
219508562|NCT03181438|PROCEDURE|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
219508563|NCT03181438|PROCEDURE|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
219608147|NCT05770622|OTHER|First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)|CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or \>20mg/L) and, if required, recommends a new adjusted dose.
219608148|NCT06486376|BEHAVIORAL|Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia|Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
219608149|NCT06628440|OTHER|oral condition assessment tool|Use of the Mat assessment tool by a nurse on the participant
219608150|NCT06121375|DRUG|OCA|OCA will be administered.
219608151|NCT06121375|DRUG|Matching Placebo|Matching Placebo will be administered.
219608152|NCT04560322|DRUG|Venetoclax|Tablet, taken by mouth
219508564|NCT06054932|DRUG|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
219508565|NCT06054932|DRUG|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
219508566|NCT00612326|PROCEDURE|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
219608153|NCT04560322|DRUG|Obinutuzumab|Intravenous infusion
219508567|NCT05178407|DIETARY_SUPPLEMENT|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
218888975|NCT02741427|OTHER|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
218888976|NCT02741427|OTHER|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
218888977|NCT02741427|OTHER|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
218888978|NCT04659473|OTHER|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
218888979|NCT04771702|DEVICE|Edmon|Exhaled air will be analyzed for propofol
218888980|NCT00397436|PROCEDURE|UV Irradiation|UV irradiation
218888981|NCT01963156|BEHAVIORAL|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
218888982|NCT04036929|DRUG|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
218888983|NCT04036929|DRUG|Placebo oral tablet|Placebo oral tablet
218888984|NCT05505864|BEHAVIORAL|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
218888985|NCT01135095|RADIATION|low-dose imaging|"The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
218888986|NCT03920943|OTHER|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
218888987|NCT03057860|OTHER|No study intervention|
218888988|NCT03524638|OTHER|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
218888989|NCT03524638|PROCEDURE|Colorectal Surgery|Colorectal surgery alone
219032353|NCT05506852|BEHAVIORAL|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
219508568|NCT05178407|DIETARY_SUPPLEMENT|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
218888990|NCT03483415|DRUG|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
218888991|NCT03483415|DRUG|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
218888992|NCT03320135|PROCEDURE|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
218888993|NCT03320135|PROCEDURE|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
219032354|NCT01589445|DRUG|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
219032355|NCT01589445|DRUG|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
219508569|NCT02619604|OTHER|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
219508570|NCT00289601|DRUG|eptifibatide|
219608154|NCT04560322|DRUG|Acalabrutinib|Capsule, taken by mouth
218888994|NCT00367835|DRUG|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
218888995|NCT00367835|DRUG|Placebo|Placebo
219508571|NCT02498522|DRUG|Metformin|83 patients will continue metformin until end of 1st trimester
219508572|NCT03330756|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
219508573|NCT03330756|PROCEDURE|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
219508574|NCT03933657|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
219508575|NCT04573842|OTHER|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
219508576|NCT02649283|DEVICE|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
219508577|NCT02649283|PROCEDURE|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
219508578|NCT02756312|OTHER|IV Anesthesia|The patients will receive intravenous anesthesia
219508579|NCT02756312|OTHER|IH anesthesia|The patients will receive inhalation anesthesia
219508580|NCT00684333|DEVICE|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
219508581|NCT00624156|BEHAVIORAL|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
218888996|NCT04119193|DEVICE|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
218888997|NCT04338971|DEVICE|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
218888998|NCT02091843|PROCEDURE|DBS of the Basolateral Nucleus of the Amygdala|
218888999|NCT02091843|DEVICE|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
218889000|NCT05458804|DEVICE|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
218889001|NCT04478604|OTHER|applied forms to pregnant women|
218889002|NCT02397044|PROCEDURE|Implant surgery|Compare surgical protocols
218889003|NCT01900743|DRUG|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
218889004|NCT01900743|DRUG|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
218889005|NCT03920930|PROCEDURE|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
219508582|NCT00624156|BEHAVIORAL|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
219508583|NCT03678636|DEVICE|Silver antimicrobial dressing|Silver dressing suitable for exudate level
219508584|NCT03678636|DEVICE|Standard care|Usual care for wound type and condition
219508585|NCT03463525|DRUG|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
219508586|NCT03463525|DRUG|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
218889006|NCT03920930|PROCEDURE|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
218889007|NCT01025830|DRUG|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
218889008|NCT01025830|DRUG|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
219508587|NCT02553369|OTHER|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
219508588|NCT04061889|OTHER|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
219508589|NCT01224210|DRUG|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
219508590|NCT00354510|DRUG|GW842470X cream|
219508591|NCT04861896|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
218889009|NCT03642730|DEVICE|TransThoracic Echocardiography imaging|ultrasound scanning
218889010|NCT01229306|PROCEDURE|Ablation|Ablation of atrial fibrillation
219032356|NCT03559179|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
219032357|NCT03148418|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
219032358|NCT03148418|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
218889011|NCT05843929|DIAGNOSTIC_TEST|LSCI|"1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
219032359|NCT05962229|DRUG|(S)-Nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
219508592|NCT03803722|DEVICE|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
219508593|NCT02229266|BIOLOGICAL|NK cells|
219508594|NCT02229266|DRUG|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
219608155|NCT05211466|OTHER|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
219032360|NCT05962229|DRUG|(R)- nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
219032361|NCT05962229|DRUG|Racemic nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
219032362|NCT04404738|PROCEDURE|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
219032363|NCT04404738|PROCEDURE|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
219032364|NCT00555607|DRUG|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
219032365|NCT00325754|DEVICE|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
219032366|NCT00325754|DEVICE|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
219032367|NCT03999190|DRUG|NPA radiotracer|"\[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
219032368|NCT03999190|DRUG|Raclopride radiotracer|"\[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
219508595|NCT00451932|DRUG|FK778|
219508596|NCT03801096|BEHAVIORAL|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).
219608156|NCT05135702|DIETARY_SUPPLEMENT|Sodium Propionate|a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
219608157|NCT05135702|DIETARY_SUPPLEMENT|Placebo|a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
219608158|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
219608159|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
219202805|NCT06893159|DEVICE|INSTI Multiplex HIV-1/2 Syphilis Antibody Test|The INSTI MULTIPLEX HIV-1/2 Syphilis Ab Test is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1/ Type 2 and Treponema pallidum in human fingerstick blood and serum. The INSTI Multiplex Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. Although suitable for near-patient point-of-care (POC) testing, the INSTI Multiplex Test is not suitable for self-testing.
219202806|NCT06893159|DEVICE|Multiplo Complete Syphilis (TP/nTP) Antibody Test|"Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) is a single use, manually performed, visually interpreted, qualitative immunoassay based on Rapid Vertical Flow Technology® for the detection of antibodies to Treponema pallidum (TP), the causative agent of syphilis, and to nontreponemal (nTP; \[RPR titer ≥ 1:8\]) antigens in human serum, plasma, or fingerstick whole blood specimens. Nontreponemal antibodies are called reagins and they are generated after the tissue damage caused by syphilis infection.~Multiplo® TP/nTP is intended for use by healthcare professionals as an aid in the diagnosis of active syphilis infection."
219202807|NCT06741137|PROCEDURE|inhaled nitric oxide combined with prone position ventilation|inhaled nitric oxide combined with prone position ventilation
218889012|NCT03866564|DIAGNOSTIC_TEST|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
218889013|NCT03866564|DIAGNOSTIC_TEST|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
219202808|NCT06749834|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
219202809|NCT06750133|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells(6-10×10\^7 CNK+ cells/kg). The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
219508597|NCT03801096|BEHAVIORAL|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
219508598|NCT01798485|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
219508599|NCT01798485|DRUG|Ganetespib|Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
219508600|NCT01916785|DRUG|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
219508601|NCT03582371|PROCEDURE|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
219508602|NCT03582371|PROCEDURE|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
219508603|NCT02125578|DRUG|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
218889014|NCT03866564|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
218889015|NCT03866564|DIAGNOSTIC_TEST|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
218889016|NCT06229327|BEHAVIORAL|THERAPEUTICGAMES|THERAPEUTICGAMES
218889017|NCT03761810|DRUG|S6G5T-3|Once a day topical cream
218889018|NCT03761810|DRUG|S6G5T-8|Once a day topical cream
218889019|NCT04792411|BEHAVIORAL|Prehabilitation|Multimodal, tailored prehabilitation programme
218889020|NCT06273397|DRUG|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
218889021|NCT06273397|DRUG|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
219508604|NCT02125578|DRUG|Placebo|Each participant will receive placebo every other week or every 4 weeks.
219202810|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones music|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After general anesthesia induction, noise-cancelling headphones (Sony WH-1000XM3) were fully covered with both ears, and MP3 (GoGear, Philips) was connected to play music continuously until the headphones were removed after the operation.
219202811|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After induction of general anesthesia, noise-cancelling headphones (Sony WH-1000XM3) were applied to cover both ears completely until the headphones were removed at the end of the procedure.
219202812|NCT06790914|OTHER|Flurbiprofen exate on a drip|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline at 60 drops /min.
219202813|NCT04270786|PROCEDURE|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
219202814|NCT04270786|PROCEDURE|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
219202815|NCT06786624|DRUG|NBI-1065845|NBI-1065845 tablets
219202816|NCT06786624|DRUG|Placebo|Matching placebo tablets
219202817|NCT06794320|OTHER|NF Protocol|The daily practice of physicians in evaluating and treating patients with sNF.
218889022|NCT06273397|DRUG|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
218889023|NCT05749328|DIETARY_SUPPLEMENT|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
219202818|NCT06794320|OTHER|ASTERIC protocol|i. Risk-assessment tools
219202819|NCT06794320|OTHER|ASTERIC protocol|ii. Fast track absolute neutrophil counts turnaround service
219202820|NCT06794320|OTHER|ASTERIC Protocol|iii. A decision tool for patient management and initial antibiotic use
218889024|NCT03229733|DEVICE|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
218889025|NCT03229733|BEHAVIORAL|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
219032369|NCT03999190|DRUG|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
219032370|NCT02373787|DEVICE|creos xenoprotect|Implant placement with simultaneous bone augmentation
218889026|NCT01574651|DRUG|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
219032371|NCT02373787|DEVICE|Bio-Gide|resorbable collagen membrane
219032372|NCT00982709|BEHAVIORAL|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
219032373|NCT04361981|OTHER|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
219032374|NCT01334723|DRUG|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
219032375|NCT01334723|DRUG|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
219032376|NCT06339073|DEVICE|mechanical ventilation|Abdominal trauma patients were treated with mechanical ventilation according to their conditions.
219032377|NCT02174068|DRUG|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
219032378|NCT05659810|DRUG|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
219032379|NCT02891707|DEVICE|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
219032380|NCT01912144|OTHER|Coffee|
219032381|NCT01675687|BEHAVIORAL|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
219202821|NCT06794320|OTHER|ASTERIC Protocol|iv. A decision tool for patient management and subsequent antibiotic use
219202822|NCT06794320|OTHER|ASTERIC Protocol|v. An educational package
219202823|NCT06794320|OTHER|ASTERIC Protocol|vi. A decision tool for patient disposal - discharge or emergency department ward observation
219202824|NCT05417165|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
219508605|NCT01732965|OTHER|Phototherapy|
219508606|NCT01732965|OTHER|Phototherapy and Photochemotherapy|
218889027|NCT01574651|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
218889028|NCT01574651|DRUG|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
218889029|NCT01574651|DRUG|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
218889030|NCT01574651|DRUG|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
218889031|NCT01574651|DRUG|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
218889032|NCT03887221|DRUG|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
218889033|NCT03887221|DRUG|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
218889034|NCT04926246|DRUG|R1: Reference Product X|under fasted conditions
218889035|NCT04926246|DRUG|T1: Test Product M|under fasted conditions
218889036|NCT04926246|DRUG|T2: Test Product N|under fasted conditions
218889037|NCT04926246|DRUG|T3: Test Product O|under fasted conditions
218889038|NCT04926246|DRUG|T4: Test Product O|under fed conditions
218889039|NCT04926246|DRUG|R2: Reference Product Y|under fasted conditions
219032382|NCT05771233|OTHER|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
219032383|NCT06297174|DRUG|Racecadotril 100 mg Capsules|Racecadotril 100 mg Capsules (test drug)
219032384|NCT06297174|DRUG|HIDRASEC®|HIDRASEC® (reference drug)
219032385|NCT05517499|DRUG|Dexamethasone|Randomized clinical trial
219032386|NCT04139707|DEVICE|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
219508607|NCT00872560|DEVICE|NovoFine® needle 6 mm|
218889040|NCT04926246|DRUG|T5: Test Product P|under fasted conditions
219508608|NCT00872560|DEVICE|NovoFine® needle 8 mm|
219508609|NCT00857025|BIOLOGICAL|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
219508610|NCT00857025|OTHER|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
219508611|NCT00857025|OTHER|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
218889041|NCT04926246|DRUG|T6: Test Product P|under fed conditions
218889042|NCT04926246|DRUG|T7: Test Product Q|under fasted conditions
218889043|NCT04926246|DRUG|R3: Reference Product Z|under fasted conditions
218889044|NCT04926246|DRUG|T8: Test Product S|under fasted conditions
218889045|NCT04926246|DRUG|T9: Test Product S|under fed conditions
218889046|NCT04926246|DRUG|T10: Test Product U|under fasted conditions
218889047|NCT02134470|DRUG|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
218889048|NCT04454242|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
218889049|NCT02487030|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
218889050|NCT02487030|DRUG|RBV|Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218889051|NCT02092025|DRUG|Azilsartan|Azilsartan tablets
218889052|NCT03308253|DEVICE|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
218889053|NCT03308253|DRUG|Vancomycin|0.5 g Vancomycin per patient
218889054|NCT03308253|DRUG|Tobramycin|120 mg tobramycin per patient
219032387|NCT04139707|OTHER|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
219508612|NCT00857025|OTHER|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
219202825|NCT05417165|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
219202826|NCT01265537|DRUG|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
219202827|NCT01265537|DRUG|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
219202828|NCT05719909|BEHAVIORAL|Cognitive Training|8 sessions of web-based cognitive training
219202829|NCT05719909|BEHAVIORAL|Sham Training|8 sessions of web-based sham training
219202830|NCT01815359|PROCEDURE|Cytoreductive Surgery|Optimal Surgical Debulking
219202831|NCT01815359|DRUG|HIPEC with Mitomycin-C|
219202832|NCT01815359|DRUG|EPIC with FUDR and Leucovorin|
218889055|NCT03308253|OTHER|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
218889056|NCT06260553|DRUG|tislelizumab and metronomic oral vinorelbine|tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
218889057|NCT01478308|DRUG|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
219032388|NCT01817725|BIOLOGICAL|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
219032389|NCT02606188|DEVICE|Modified High-flow nasal cannula|Modified High-flow nasal cannula
218889058|NCT01478308|DRUG|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
218889059|NCT01478308|DRUG|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
219032390|NCT02606188|DEVICE|nasal cannula|Conventional oxygen therap
219032391|NCT04777162|DRUG|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
219032392|NCT04777162|DRUG|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
219202833|NCT06396949|DIAGNOSTIC_TEST|Fibromyalgia study form|Fibromyalgia study form, consisting of clinical measurement, Fibromyalgia impact questionnaire (FIQ), Beck Anxiety Questionnaire and Beck Depression Questionnaire, Short-Form (SF)-36, who applied to the outpatient clinic with fibromyalgia will be filled in detail.
219202834|NCT06396949|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
219202835|NCT06396949|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity) (millimeter-mm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
219202836|NCT06754592|DEVICE|Ultrasound|evaluate the effectiveness of dynamic high-resolution ultrasonography in identifying various abnormalities of the shoulder impingement syndrome, especially the subacromial type, and to determine the added value of dynamic ultrasonography compared to static examination of such cases. Furthermore, we will compare these findings to MRI
219202837|NCT06754449|OTHER|Art therapy group|Application of different applications of art therapy such as painting, drawing, cutting to children
219202838|NCT06752954|DEVICE|Viabahn endoprosthesis group|Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
219202839|NCT06752954|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
219202840|NCT06738095|DEVICE|daily low-level red-light|Daily low-level red-light is a kind of myopia intervention. Red-light typically using 650-nm wave of length. The treatment duration last 3 minutes each time, every day children were anticipated to use two times, at home.
219508613|NCT06543225|OTHER|No intervention|No intervention
219508614|NCT00737230|OTHER|educational intervention|
219508615|NCT00737230|OTHER|questionnaire administration|
219508616|NCT00737230|PROCEDURE|assessment of therapy complications|
219508617|NCT00737230|PROCEDURE|gastrointestinal complications management/prevention|
219508618|NCT00737230|PROCEDURE|management of therapy complications|
219508619|NCT00737230|PROCEDURE|quality-of-life assessment|
219508620|NCT00681863|DRUG|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
219508621|NCT00681863|DRUG|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
219508622|NCT00681863|DRUG|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
219508623|NCT00681863|DRUG|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
219202841|NCT06766474|DRUG|Bupivacain|to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
219202842|NCT06761014|OTHER|Instrumental assisted soft tissue mobilization|instrument will be held at 45° angle and the IASTM treatment will be administered for about 20 seconds in a direction parallel to the muscle fibers being treated with deep strokes
219202843|NCT06761014|OTHER|Sustained stretching|The therapist will apply the pressure or ask to maintain the stretch. A total of thirty seconds, divided into three sets of stretches at each intervention, with ten seconds of rest in between
219508624|NCT00681863|DRUG|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
219508625|NCT06253468|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
219202844|NCT04490057|DRUG|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
219202845|NCT04490057|DRUG|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
219202846|NCT04490057|BEHAVIORAL|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
219202847|NCT06770803|PROCEDURE|High Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
219202848|NCT06770803|PROCEDURE|Low Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
219202849|NCT06772649|OTHER|Compression sleeve|The Bauerfeind compression sleeve is a fabric sleeve designed to support the ankle during movement. It's made of a compressive knit material that increases sensorimotor feedback, enhances blood circulation, and stimulates metabolism. The design helps reduce ligament strain, activates the foot's stabilizing muscles more quickly, and improves joint coordination.
219508626|NCT01677455|DRUG|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
218889060|NCT02145065|DRUG|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
219202850|NCT04974268|OTHER|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
218889061|NCT02145065|DEVICE|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
218889062|NCT04673539|DIAGNOSTIC_TEST|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
218889063|NCT02164266|DRUG|Placebo|Matching placebo daily oral administration
219032393|NCT01813669|BEHAVIORAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
219202851|NCT04604418|OTHER|No intervention. It is observational|No intervention. It is observational
219364703|NCT02239822|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks."
219508627|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
219508628|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
219508629|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
219508630|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
218889064|NCT02164266|DRUG|RO6799477|Daily oral administration of RO6799477
218889065|NCT05805891|DRUG|bortezomib|bortezomib 2mg/week subcutaneous injection
218889066|NCT02399657|DRUG|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
219032394|NCT06452095|DEVICE|Hyperbaric Oxygen therapy|The SECHRIST INDUSTRIES mono-place Hyperbaric Chambers OR Sigma Series mono-place Hyperbaric Chambers
218889067|NCT03451123|DRUG|FET PET/MRI|FET PET/MRI scan before and after surgery
218889068|NCT00264537|DRUG|Placebo injections|SC injections
219508631|NCT03294161|DRUG|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
219508632|NCT03294161|DRUG|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
219608160|NCT03191682|DRUG|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
219608161|NCT06796686|BIOLOGICAL|426c.Mod.Core-C4b|426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.
218889069|NCT00264537|DRUG|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
219608162|NCT06796686|BIOLOGICAL|HxB2.WT.Core-C4b|HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial
219608163|NCT06796686|BIOLOGICAL|3M-052-AF adjuvant|immune response modifier (IRM)
219608164|NCT06796686|OTHER|Aluminum hydroxide suspension (Alum) adjuvant|Alhydrogel.
218889070|NCT00264537|DRUG|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
218889071|NCT00264537|BIOLOGICAL|Golimumab 50 mg injections|SC injections
218889072|NCT00264537|BIOLOGICAL|Golimumab 100 mg injections|SC injections
218889073|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
218889074|NCT05695144|DEVICE|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
219032395|NCT06297278|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the active (moderate intensity) exercise condition will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as participants staying within a zone of 60-80% AAMHR with the target being to attain and maintain 70-75% AAMHR while briskly walking and/or jogging depending on current fitness status, is reached for a total of 30 min.
219032396|NCT05868486|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219032397|NCT05868486|GENETIC|Genetic Testing for Cancer Risk|Undergo germline testing
219032398|NCT05868486|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy testing
219032399|NCT05868486|PROCEDURE|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
219032400|NCT05868486|OTHER|Survey Administration|Complete surveys
219032401|NCT00837655|DRUG|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
219032402|NCT00837655|DRUG|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
219032403|NCT02746562|PROCEDURE|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
219032404|NCT01888796|DRUG|Linagliptin|
219032405|NCT01888796|DRUG|placebo|
219032406|NCT05700682|DEVICE|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
219032407|NCT05845879|OTHER|delivery|delivery
219032408|NCT01116297|DEVICE|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
219032409|NCT03350360|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
219032410|NCT03350360|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
219032411|NCT01837628|DRUG|Lidocaine Gel|
219032412|NCT01837628|DRUG|Paraffin Oil|
219032413|NCT00000644|DRUG|Clarithromycin|
219032414|NCT03836963|BEHAVIORAL|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
219032415|NCT03836963|BEHAVIORAL|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
219032416|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
219508633|NCT03741218|OTHER|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
219508634|NCT04810195|DEVICE|Boston Scientific Acurate neo2 TAVR device|The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.
219508635|NCT03035279|DRUG|SC-006|Intravenous
219508636|NCT03035279|DRUG|ABBV-181|Intravenous
218889075|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
218889076|NCT05695144|DEVICE|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
218889077|NCT06141876|DRUG|APEX-002-A02|Active
218889078|NCT06141876|OTHER|Placebo|placebo
219032417|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
219032418|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
219032419|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
219032420|NCT01829776|BEHAVIORAL|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
219032421|NCT00177970|DRUG|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
219032422|NCT00177970|DRUG|Placebo|Placebo to be given IV to patients with C-Diff
219032423|NCT05638685|OTHER|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
219032424|NCT03548402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
219032425|NCT02916563|DEVICE|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
219032426|NCT05235334|DEVICE|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
219032427|NCT03608514|DRUG|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
219032428|NCT03375021|DRUG|CX717 200 mg|CX717 200 mg capsules BID
219032429|NCT03375021|DRUG|CX717 800 mg|CX717 4 X 200 mg capsules BID
219032430|NCT03375021|DRUG|Placebo|Placebo 200 mg or 800 mg capsules BID
219032431|NCT02149173|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
219508637|NCT01333033|DRUG|Oxaliplatin|Given IV
219508638|NCT01333033|DRUG|Leucovorin Calcium|Given IV
219608165|NCT06796686|OTHER|Diluent|Tris-NaCl buffer
219608166|NCT04954261|DIAGNOSTIC_TEST|CAPD|CAPD evaluation every day per 12hours during their stay in PICU
219608167|NCT05878093|DRUG|Dupilumab|solution for subcutaneous injection
219608168|NCT05878093|DRUG|Placebo|solution for subcutaneous injection
219608169|NCT05878093|DRUG|Budesonide|nasal spray (suspension)
219608170|NCT04190563|BEHAVIORAL|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
218889079|NCT00932867|DRUG|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
219032432|NCT02149173|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219032433|NCT02149173|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
219032434|NCT02149173|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
219032435|NCT02149173|OTHER|Laboratory Biomarker Analysis|Correlative studies
219032436|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
219032437|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219032438|NCT01733446|OTHER|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
219032439|NCT00703885|DRUG|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
219032440|NCT00703885|DRUG|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
219608171|NCT04190563|BEHAVIORAL|Pain Education|Experimenter-administered education.
219608172|NCT06173388|OTHER|Structured exercise training program + The swallow resistance exercise program.|Structured exercise training program + The swallow resistance exercise program.
218889080|NCT05495165|OTHER|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
219202852|NCT06831318|BEHAVIORAL|Community Health Worker (CHW) Guided Support|"The CHW conducts a family assessment, which identifies caregiving stressors, social support, and needs as related to social determinants of health, dementia education, care navigation, caregiver health and burden. Closer to discharge, dyads receive an individualized dementia caregiving toolkit including the post-discharge care planning checklist, tracking sheets for patient medications, tests, and procedures, and info on local resources. All meetings will be done in person, telephone, or zoom.~Within one week of discharge, the CHW meets the dyad via phone or Zoom to review their goals and to identify any additional needs for coaching, education, or navigation support. In the first month after discharge, the CHW provides weekly or bi-weekly check-ins. For the next two months, the CHW provides about four additional bi-weekly check-in sessions. Each check-in session will last approximately 30-45 minutes. The exact number of meetings will be determined by need and caregiver availability"
219202853|NCT05589402|DRUG|Lidocaine Cream 5%|Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
218889081|NCT00391950|DRUG|Zoledronic acid|
218889082|NCT02908750|DRUG|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
218889083|NCT02908750|DRUG|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
218889084|NCT04136730|BEHAVIORAL|Home-based|Resistance exercise carried out unsupervised at home
218889085|NCT00627341|BEHAVIORAL|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
219032441|NCT00703885|DRUG|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
219032442|NCT01100242|DRUG|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
219032443|NCT03823053|OTHER|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
219032444|NCT03823053|OTHER|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
219032445|NCT06195397|OTHER|Evidence-Based Education intervention|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
219032446|NCT06482021|DEVICE|Low-intensity extracorporeal shock wave|Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
219202854|NCT05589402|OTHER|Rehabilitation Movement Training|reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
219202855|NCT06581900|OTHER|Vitamin B12|Quantification of Vitamin B12
219202856|NCT06871436|OTHER|Aerobic Exercice and muscular reinforcement|Aerobic exercise and muscle strengthening to increase weekly physical activity at moderate and vigorous intensities
218889086|NCT00627341|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
219032447|NCT02725047|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
219508639|NCT01333033|DRUG|Fluorouracil|Given IV
219508640|NCT01333033|DRUG|Carboplatin|Given IV
219508641|NCT01333033|DRUG|Paclitaxel|Given IV
219508642|NCT01333033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219508643|NCT01333033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219508644|NCT01333033|RADIATION|Radiation Therapy|Undergo RT
219202857|NCT06746610|DIAGNOSTIC_TEST|Genetic Screening for Monogenic Diabetes|"This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen：~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement."
219202858|NCT06757491|DEVICE|repeated transcranial magnetic stimulation treatment|"IBS patients received repetitive transcranial magnetic stimulation at~1 Hz/s for 20 minutes for 2 weeks."
219202859|NCT03782116|DEVICE|Transcutaneous electrical stimulation (Elitone)|Transcutaneous perineal area electrical stimulation
218889087|NCT05419544|BEHAVIORAL|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
218889088|NCT02395614|DRUG|Chlorhexidine irrigation|\- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
218889089|NCT02395614|DRUG|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
218889090|NCT00851929|DRUG|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
218889091|NCT03228212|DEVICE|CONTROL|ACUVUE OASYS
219202860|NCT06754215|BEHAVIORAL|Focus Group|Participate in focus group
219202861|NCT06754215|OTHER|Interview|Participate in semi-structured interview
219508645|NCT03693690|PROCEDURE|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
219608173|NCT06173388|OTHER|Only the swallow resistance exercise program.|Only the swallow resistance exercise program.
218889092|NCT03228212|DEVICE|TEST|senofilcon A with new UV blocker
218889093|NCT04205617|OTHER|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
218889094|NCT02468349|OTHER|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
218889095|NCT05297513|DRUG|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
218889096|NCT04678947|BEHAVIORAL|Baxter Retching Faces (BARF) scale|"* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
218889097|NCT01674777|DRUG|ASP1941|oral
219032448|NCT02725047|OTHER|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
219032449|NCT02625090|DRUG|UCB0942|"* Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral"
219202862|NCT06754215|BEHAVIORAL|Smoking Cessation Intervention|Participate in feasibility study of intervention components
219202863|NCT06754215|OTHER|Survey Administration|Complete survey
219202864|NCT06756126|DRUG|AK120|AK120 subcutaneous injection
219508646|NCT01439503|BEHAVIORAL|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
219508647|NCT04793503|OTHER|conventional complete denture|the complete denture constructed by packing technique
219508648|NCT04793503|OTHER|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
219508649|NCT04793503|OTHER|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
219508650|NCT02323906|DRUG|CC-122|Investigational new drug
219202865|NCT06756048|PROCEDURE|Rhomboid Intercostal Nerve Block|"Following standard ASA monitoring, patients were positioned on the surgical table with their backs facing the operator. Skin antisepsis was achieved using povidone. A high-frequency 8-18 MHz linear ultrasound probe was used.~After palpating the rhomboid muscles and intercostal spaces at the T6-T7 levels, the medial border of the scapula and the vertebral column were identified. The ultrasound probe was placed horizontally along the medial border of the scapula. Using ultrasound guidance, the ribs, rhomboid muscles, intercostal muscles, and pleura were visualized. Once these anatomical structures were clearly identified, a 50 mm, 22G regional block needle was advanced in-plane from caudal to cranial under ultrasound guidance until the interfascial plane beneath the rhomboid muscles was reached and total of 20 ml of 0.25% bupivacaine (Marcaine® 0.5%, AstraZeneca PLC, London, UK) was injected."
218889098|NCT04861376|DRUG|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
219202866|NCT06754527|BEHAVIORAL|ON-TRAC|Online tablet-based intervention that teaches youth emotion regulation skills and integrates substance use prevention content
219202867|NCT06751628|DEVICE|Insides system|The miniaturization of the pump proposed by Insides System enables the patient to perform CR independently and to carry the pump anywhere, thus facilitating outpatient implementation of CR.
219202868|NCT06758557|DRUG|HB0025|HB0025 IV every 3 weeks (q3w)
219202869|NCT06758557|DRUG|Pemetrexed|500 mg/m² iv d1
219202870|NCT06758557|DRUG|Paclitaxel|175 mg/m² iv d1
219202871|NCT06758557|DRUG|Carboplatin|AUC 5 iv d1
219202872|NCT06758180|BEHAVIORAL|verbal basic life support training|"Both groups will be given verbal adult basic life support training simultaneously, on a day and time that will not conflict with the students' class schedules. The Adult Basic Life Support Training presentation published by the Ministry of Health in 2021 will be used in the training and will last approximately 40 minutes.~A week after the verbal training, a basic life support application for adults will be held in the Faculty of Medicine Skills Laboratory."
219202873|NCT06758180|BEHAVIORAL|Interactive game intervention|"The interactive game group will be given reinforcement training before the laboratory application. Here, each student will play the game accompanied by a researcher.~Lifesaver is an educational game developed by the Resuscitation Council (UK), offered in English and completely free of charge. The game can be downloaded to computers, phones or tablets from Google Play or the App Store. Lifesaver includes four different interactive video scenarios to help users develop their lifesaving skills. The Harry scenario to be used in this research is based on a real case. In the scenario, Harry, a high school student who has a sudden heart attack while playing football, is given heart massage, CPR and defibrillation by his friends.~The game offers different options at each stage to improve the players' knowledge and skill levels. If a wrong choice is made, the same section is played again until the correct step is performed. The completion time of the game may vary average 15 minutes."
219202874|NCT06758180|BEHAVIORAL|video training|"One week after all students are given verbal adult basic life support training, a video titled Adult Basic Life Support will be shown to the students in the video training group before the laboratory application. The video will be shown by the researcher using a projector. After the video watching process is completed, each student will apply basic life support on the adult training model in turn and the applications will be evaluated individually. In the video training, the video titled Basic Life Support and AED Use - Adult (TYD), which was published as open access on the 'paramedic online' YouTube channel on May 31, 2023 and prepared in accordance with the 2021 ERC guideline, will be used (Paramedic online, 2023). This video covers the topics of heart massage, artificial respiration and automatic external defibrillator use within the scope of basic life support."
219202875|NCT06758375|DRUG|Low-dose teclistamab|NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.
218889099|NCT04861376|DRUG|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
218889100|NCT04861376|OTHER|Placebo|The placebo group will take the same dose as the other two groups.
218889101|NCT06043973|DRUG|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
218889102|NCT05247281|DIAGNOSTIC_TEST|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
218889103|NCT05247281|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
218889104|NCT05186506|DRUG|Ensatinib|225 mg administered once daily orally for two years.
218889105|NCT05186506|DRUG|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
218889106|NCT03222401|DRUG|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
218889107|NCT03222401|DRUG|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
218889108|NCT03222401|DRUG|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
218889109|NCT01807299|DIETARY_SUPPLEMENT|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
218889110|NCT01807299|OTHER|Physical Training|
218889111|NCT04519281|DRUG|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
218889112|NCT01984918|OTHER|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
218889113|NCT01984918|OTHER|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
218889114|NCT00675220|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218889115|NCT05413720|OTHER|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
219202876|NCT06757101|OTHER|Vojta Therapy|Exercises will be performed in supine, lateral, decubitus and reflex crawling. Exercises will include Stretching's, ROMs Exercises, Stimulation of 10 different zones for locomotion \& gentle pressure applied to stimulation areas. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
219202877|NCT06757101|OTHER|Bobath Therapy|Exercises will be performed in supine, lateral, prone and standing position. Exercises includes stretching Exercises, ROMs, Quadruped imbalance exercise, Imbalance from the kneeling exercise, Cervant Knight exercise, Tandem walk, Kicking a ball, Step climbing, marching at one place with alternate foot Frequency of exercises will be 2 times a week, duration 40 minutes per day.
219608174|NCT05353322|BEHAVIORAL|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
218889116|NCT04730531|PROCEDURE|Local infiltration with 0.25% bupivacaine and epinephrine|The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
218889117|NCT04730531|PROCEDURE|Placebo of equal volume injectable saline|An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
218889118|NCT04503720|DEVICE|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
218889119|NCT04503720|DEVICE|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
219608175|NCT05353322|BEHAVIORAL|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
219608176|NCT05353322|BEHAVIORAL|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
219608177|NCT06227052|DEVICE|Num Vapocoolant Spray|This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. The investigators are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
219608178|NCT06227052|OTHER|Placebo|This is the placebo. This group will receive Natures tear normal saline spray.
218889120|NCT04578067|BEHAVIORAL|Lifestyle intervention|on physical activity and healthier eating
219032450|NCT03198377|DEVICE|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
219032451|NCT03198377|DEVICE|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
219032452|NCT03198377|DEVICE|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
219032453|NCT03198377|DEVICE|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
219032454|NCT01801150|DEVICE|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
219032455|NCT01242956|BEHAVIORAL|verum group|video-based training after stroke
219202878|NCT06757101|OTHER|Combined Vojta and Bobath Therapy|Combined Vojta and Bobath exercises along with the conventional treatment. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
219202879|NCT04084496|DRUG|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
218889121|NCT03217994|DRUG|gel HP|gel of hygrogen peroxide for teeth bleaching
218889122|NCT06230939|OTHER|Examination|"Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method."
219032456|NCT01242956|BEHAVIORAL|Placebo group|non-video group
219508651|NCT02323906|DRUG|Sorafenib|Kinase inhibitor
219508652|NCT03687125|DRUG|Tinostamustine|Participants received tinostamustine IV injection.
218889123|NCT01938040|DRUG|ibuprofen|single preoperative dose prior to surgery
218889124|NCT01938040|OTHER|sugar water/placebo|single preoperative dose prior to surgery
218889125|NCT00013520|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
218889126|NCT00013520|DRUG|Atazanavir|
218889127|NCT00013520|DRUG|Lamivudine/Zidovudine|
218889128|NCT00013520|DRUG|Abacavir sulfate|
218889129|NCT00013520|DRUG|Efavirenz|
218889130|NCT00013520|DRUG|Nevirapine|
218889131|NCT00013520|DRUG|Lamivudine|
218889132|NCT00013520|DRUG|Stavudine|
218889133|NCT00013520|DRUG|Zidovudine|
218889134|NCT00013520|DRUG|Didanosine|
218889135|NCT05628142|RADIATION|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
218889136|NCT05011812|DRUG|PBI-0451 Dose 1|Dose level 1 of PBI-0451
218889137|NCT05011812|DRUG|PBI-0451 Dose 2|Dose level 2 of PBI-0451
218889138|NCT05011812|DRUG|PBI-0451 Dose 3|Dose level 3 of PBI-0451
218889139|NCT05011812|DRUG|PBI-0451 Dose 4|Dose level 4 of PBI-0451
218889140|NCT05011812|DRUG|Ritonavir|Ritonavir will be co-administered with the study drug in Treatments J and K
218889141|NCT05011812|DRUG|Midazolam|Midazolam will be co-administered with the study drug in Treatment L
218889142|NCT05011812|DRUG|Placebo|Placebo to match
218889143|NCT05011812|DRUG|PBI-0451|Dose level of PBI-0451 with a projected exposure
218889144|NCT05011812|DRUG|PBI-0451 Dose 5|Dose level 5 of PBI-0451
218889145|NCT03552666|DIETARY_SUPPLEMENT|vitamin D3|
218889146|NCT00074334|BIOLOGICAL|TGFa-PE38 immunotoxin|
218889147|NCT00074334|PROCEDURE|conventional surgery|
218889148|NCT02611726|OTHER|Acupuncture|Acupuncture
218889149|NCT03481335|OTHER|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
218889150|NCT04864639|OTHER|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
218889151|NCT00004561|BEHAVIORAL|exercise|
218889152|NCT06492434|BEHAVIORAL|Peer decision coaching|Peer Decision Coaching is a brief, personalized intervention grounded in evidence-based decision- and peer support principles. During the intervention, a trained peer specialist supports the young person in identifying a decision related to community participation that they need to make, such as whether to work or go to school, helping them address decision-making needs, and assisting them with developing and implementing a decision-making plan. Ultimately, the intervention aims to support young people in pursuing their community participation interests and goals.
219032457|NCT02858219|DRUG|Botulinum Toxin Type A|
219032458|NCT02858219|OTHER|Saline solution|
219032459|NCT02858219|OTHER|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
219032460|NCT00731887|PROCEDURE|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
219508653|NCT03687125|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
219508654|NCT06112457|OTHER|Survey|Anonymous self-administered questionnaire
219508655|NCT00720850|DRUG|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
219508656|NCT04037566|GENETIC|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
219508657|NCT04037566|DRUG|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
219508658|NCT04037566|DRUG|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
219508659|NCT00000616|BEHAVIORAL|diet, sodium-restricted|
219508660|NCT00000616|BEHAVIORAL|diet, fat-restricted|
219508661|NCT00000616|BEHAVIORAL|exercise|
219508662|NCT00000616|BEHAVIORAL|diet, reducing|
219508663|NCT00000616|BEHAVIORAL|alcohol drinking|
219508664|NCT01403350|DEVICE|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
219508665|NCT01919294|DRUG|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
219202880|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
218889153|NCT00267215|DRUG|Lumiracoxib|
218889154|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
218889155|NCT03771651|DRUG|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
218889156|NCT00615017|DRUG|AZD9773 (CytoFab)|intravenous infusions
218889157|NCT00615017|OTHER|Placebo|Placebo
218889158|NCT00806988|PROCEDURE|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~1. All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~2. The heart will be arrested with cardioplegia.~3. A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
218889159|NCT00806988|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
218889160|NCT01550536|BEHAVIORAL|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
218889161|NCT04658329|DRUG|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
219032461|NCT02418195|DRUG|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
219032462|NCT04338438|DRUG|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
219202881|NCT06761027|DRUG|Anlotinib combined with Sintilimab|Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
219202882|NCT06752200|DEVICE|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
219202883|NCT06752200|DEVICE|Occlusal splints fabricated using a combined digital workflow using a conventional bite technique|upper and lower arches will be scanned intraorally. The bite will be registered at centric by using rubber base bite registration material after patient deprogramming with Lucia jig. Then the bite will be scanned. The splint will be designed and printed in the same workflow as the intervention group.
218889162|NCT06060795|DIAGNOSTIC_TEST|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
219032463|NCT02467556|DRUG|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
219032464|NCT02467556|BEHAVIORAL|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
219032465|NCT02467556|OTHER|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
219202884|NCT06753500|PROCEDURE|Autonomic neural blockade|"Autonomic nerve block performed with:~* Bupivacaine: 20 mL of 0.5%.~* Dexamethasone: 8 mg."
218889163|NCT02310412|BIOLOGICAL|INTERCEPT treated platelets|
218889164|NCT02534545|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
218889165|NCT02534545|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
218889166|NCT01429493|RADIATION|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
218889167|NCT01429493|RADIATION|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
218889168|NCT01429493|RADIATION|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
218889169|NCT06429150|BIOLOGICAL|CAR-T cells|Infusion of multi-CAR-T cells
218889170|NCT02908126|DRUG|Oxytocin|Oxytocin drug
218889171|NCT00938678|DRUG|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
218889172|NCT00938678|DRUG|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
219032466|NCT00647127|DRUG|Buprenorphine|Buprenorphine: 20microg/h
219032467|NCT00647127|DRUG|Fentanyl|Fentanyl: 25microg/h
219032468|NCT00647127|DRUG|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
219202885|NCT06809673|OTHER|blood sampling|"blood sampling at baseline, 1,3,6 months after surgery and eventually when recurrence is detected.~If adjuvant treatment is planned, blood sampling at baseline, 1 month after surgery, 1,3,6 months after the last fraction of RT and eventually when recurrence is detected."
218889173|NCT05804669|DRUG|atumelnant|Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
218889174|NCT02685306|BIOLOGICAL|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
219032469|NCT03687203|DIAGNOSTIC_TEST|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
219032470|NCT06204458|OTHER|mild hyperthermia group|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
219032471|NCT06204458|OTHER|sham group|Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
219032472|NCT02076828|DRUG|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
219032473|NCT02076828|DRUG|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
219032474|NCT02076828|DRUG|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
219032475|NCT03970863|DIAGNOSTIC_TEST|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
219032476|NCT03000699|BEHAVIORAL|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
219032477|NCT04396093|BEHAVIORAL|psychological support|specific questionnaires administration: EORTC QLQ 30, EORTC- PAN 26, HADS, Millon Clinical Multiaxial Inventory
219032478|NCT03524807|DEVICE|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
219032479|NCT03493984|OTHER|Ginger exosomes|Naturally occurring plant exosomes from ginger
219032480|NCT03493984|OTHER|Aloe exosomes|Naturally occurring plant exosomes from aloe
219032481|NCT03493984|OTHER|Placebo|Exosome placebo tablet
219032482|NCT02439320|DRUG|Lasmiditan 100 mg|
219032483|NCT02439320|DRUG|Lasmiditan 200 mg|
219202886|NCT06672068|DRUG|TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
219202887|NCT06672068|DRUG|TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
218889175|NCT02685306|DRUG|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
218889176|NCT00257699|DRUG|Metronidazole placebo|
218889177|NCT00257699|DRUG|ciprofloxacin placebo|
219032484|NCT02439320|DRUG|Placebo (matches lasmiditan doses)|
219032485|NCT01433510|DRUG|Grazax|1 tablet/day - pre and co-seasonal
219032486|NCT03169946|PROCEDURE|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
219032487|NCT03169946|PROCEDURE|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
218889178|NCT00257699|DRUG|ciprofloxacin|500 mg bid po
218889179|NCT00257699|DRUG|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
218889180|NCT05597774|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
218889181|NCT05597774|OTHER|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
218889182|NCT05597774|OTHER|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
218889183|NCT00842556|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
218889184|NCT00842556|DRUG|Glimepiride|Tablets, Oral, 4 mg, Single Dose
218889185|NCT00842556|DRUG|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
219508666|NCT01164033|DRUG|RO5045337|single oral dose
219508667|NCT05074589|DRUG|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
218889186|NCT01181466|DEVICE|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
219202888|NCT06792513|DEVICE|Clear Aligner|In this intervention, clear aligners were digitally designed using three-dimensional models for the upper jaw. Attachments were applied to the patients, specifically placed on the incisors exhibiting a crossbite relationship and on the permanent first molars in the posterior region. The series of clear aligners were replaced every 10 days. The aligners were used full-time, except during meals and tooth brushing.
219202889|NCT06792513|DEVICE|Labiolingual Spring Hawley Appliance|In this intervention, a custom-made labiolingual spring Hawley appliance was designed for the upper jaw. It included two Adams clasps, a vestibular arch, and an active labiolingual spring positioned on the palatal side of the incisor in crossbite. The spring was activated every 10 days. The appliance was used full-time, except during meals and tooth brushing.
219202890|NCT06845176|DEVICE|Tendon vibration (TV)|We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
219202891|NCT06845176|OTHER|Kinesthetic motor imagery (kMI)|kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.
218889187|NCT04930523|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
218889188|NCT04930523|OTHER|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
218889189|NCT03853135|DIAGNOSTIC_TEST|measurement of serum endocan|measurement of serum levels of endocan
218889190|NCT04001413|DRUG|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
219202892|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
219202893|NCT04997525|DRUG|Progesterone|Combined with estradiol
218889191|NCT04001413|DRUG|Durvalumab|Durvalumab is an investigational drug in this study.
218889192|NCT02610686|DRUG|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
219032488|NCT01100099|DIETARY_SUPPLEMENT|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
219032489|NCT02928510|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
219202894|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
219202895|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
219202896|NCT06756672|DEVICE|HPI guidance|patients with HPI guidance
219202897|NCT06756672|DEVICE|No HPI guidance|patients without HPI guidance
219202898|NCT06855784|BEHAVIORAL|Time-Restricted Eating 16h/8h|Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
219202899|NCT06855784|BEHAVIORAL|Active Control|Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
219202900|NCT06858020|PROCEDURE|Prophylactic polypropylene onlay mesh|The patients in the mesh group are closed with small bites technique and in addition receiving an onlay polypropylene mesh when closing the fascia in midline laparotomies.
219508668|NCT05074589|DRUG|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
219508669|NCT03316937|PROCEDURE|Types of scalers|Scaling
218889193|NCT03461107|OTHER|No intervention|
218889194|NCT06202495|DEVICE|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
219202901|NCT06824337|OTHER|mobilization training and targeted mobilization|In the first interview with the patients, the content of the early mobilization training given to the patients, what early mobilization is, why it is important, what benefits it provides, what the mobilization goals determined for the patient within the scope of the research, the benefits of walking and the expected results will be explained. It will be explained how to benefit from the smartphone during the mobilization process. In addition to all the training, the patients in the intervention group will be given detailed information about what they need to record in the mobilization diary (total time they walked, how many steps they took in the pedometer application after each mobilization, positive/negative situations they experienced while standing up and walking) and all the forms that will be used in the data collection phase.
219202902|NCT05155943|DEVICE|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
219202903|NCT06754891|DRUG|TQH3906 capsules|TQH3906 is an allosteric inhibitor targeting kinase.
219202904|NCT06866821|OTHER|SMWAM's and PNF C-R Technique|"Treatment provided 3 days every week in 6 total weeks with 1 meeting per day, 3 bunches of 10 times repeat and resting period of one minute among bunches. This group received Mulligan's spinal mobilization with arm movement and proprioceptive neuromuscular facilitatin contract-relax technique. Previous to mobilization, all patients got hot pack (10 minutes) and active range of motion warm up exercises (2 sets of 10 repetitions) and did isometric neck exercise as a home plan of care.~Mobilisation (22) was done depending on the side of involvement, the corresponding spinous process would be mobilised combined with different movements of shoulder (flexion/ abduction/ horizontal abduction/ horizontal adduction).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
218889195|NCT06202495|OTHER|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
218889196|NCT03094117|OTHER|News items with spin|Interpretation of news items with spin
218889197|NCT03094117|OTHER|News items without spin|Interpretation of news items without spin
218889198|NCT04327791|DRUG|Baloxavir|administered PO once
218889199|NCT04327791|DRUG|Placebos|administered PO once
219202905|NCT06866821|OTHER|PNF C-R Technique and PT Protocol|"Treatment provided 3 days every week in 6 weeks with 1 meeting per day, 5 clusters of 3 times repeat and resting period of one minute among clusters. Regime of training involved PNF (proprioceptive neuromuscular facilitation) contract-relax method along with the standard physical therapy protocol which includes passive stretching (3 sets of 10 repetitions) and isometric strengthening exercises (2 sets of 10 repetitions).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
218889200|NCT03072264|BEHAVIORAL|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
218889201|NCT03072264|DRUG|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
218889202|NCT03072264|BEHAVIORAL|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
219202906|NCT06764966|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg Once Daily with previously prescribed Non Selective Beta-Blocker
219202907|NCT06764966|DRUG|Placebo|Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
219202908|NCT06883253|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
219508670|NCT01811277|DRUG|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
219508671|NCT03378622|OTHER|Anchor|Anchor technique for mesh attachment
218889203|NCT01493401|PROCEDURE|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
218889204|NCT02722200|DRUG|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
218889205|NCT02722200|OTHER|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
218889206|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
218889207|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
218889208|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
218889209|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
218889210|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
218889211|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
218889212|NCT00855959|DRUG|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
218889213|NCT00855959|DRUG|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
218889214|NCT05541146|COMBINATION_PRODUCT|Intraperitoneal chemotherapy|Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
218889215|NCT02813889|DEVICE|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
218889216|NCT02917785|DEVICE|Karman curettage|
218889217|NCT03845127|DEVICE|Revivent TC Ventricular Enhancement System|Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
218889218|NCT03845127|DRUG|GDMT|Guideline Directed Medical Therapy
218889219|NCT00368641|DRUG|Extraneal|Periotneal Dialysis
218889220|NCT04668885|DRUG|CPX-351|"Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
218889221|NCT03633110|BIOLOGICAL|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
218889222|NCT03633110|DRUG|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
218889223|NCT03633110|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
219032490|NCT02928510|PROCEDURE|Colonoscopy|Undergo colonoscopy
218889224|NCT02857608|DRUG|Lymphoseek|
219032491|NCT02928510|PROCEDURE|Colposcopic Biopsy|Undergo colposcopic biopsy
219032492|NCT02928510|DRUG|Idelalisib|Given PO
219032493|NCT02928510|OTHER|Laboratory Biomarker Analysis|Correlative studies
219032494|NCT02928510|OTHER|Pharmacological Study|Correlative studies
218889225|NCT05155813|DEVICE|WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.
218889226|NCT00381758|DRUG|Methylphenidate Extended Release Capsules|
218889227|NCT06499493|OTHER|Myofascial induction in gastrocnemius muscle|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
218889228|NCT03202342|OTHER|Water|Water, 300 ml, at room temperature
218889229|NCT03202342|OTHER|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
218889230|NCT03202342|OTHER|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
218889231|NCT03202342|OTHER|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
218889232|NCT03202342|OTHER|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
219032495|NCT02928510|PROCEDURE|Physical Examination|Undergo physical examination
219032496|NCT02928510|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219032497|NCT01238614|OTHER|CHICA PSF plus JIT|
219032498|NCT01238614|OTHER|CHICA maternal depression PSF|
219032499|NCT01238614|OTHER|Control|
219032500|NCT02972632|DRUG|Vortioxetine|Vortioxetine tablet
219032501|NCT03857087|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
219032502|NCT03857087|PROCEDURE|Magnetic Resonance Imaging (MRI)|Given PET/MRI
219032503|NCT03857087|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/MRI
219032504|NCT02245841|DRUG|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
219032505|NCT03307733|BEHAVIORAL|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
219032506|NCT02032147|DRUG|NGF group|This group will be treated with NGF 18u per day im for 60 days
219032507|NCT05865288|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
219032508|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219032509|NCT04362917|OTHER|There is no intervention|There is no intervention
219032510|NCT01363596|OTHER|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
219032511|NCT01936935|OTHER|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
219032512|NCT01936935|OTHER|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
219032513|NCT02609022|BIOLOGICAL|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
219032514|NCT02609022|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
219032515|NCT03688412|DEVICE|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
219508672|NCT03378622|OTHER|Suture|Suture technique for mesh attachment
218889233|NCT06063694|DEVICE|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
218889234|NCT06835647|DEVICE|Investigational Fetal Monitor|Investigational Fetal Monitoring Device Device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
218889235|NCT06835647|DEVICE|Ultrasound Imaging Device|The Ultrasound imaging device is a general-purpose diagnostic ultrasound system for use in measurement, display and analysis of the human body and fluid.
218889236|NCT00776854|DEVICE|Noveon laser|870 and 930nm wavelengths
218889237|NCT03058926|OTHER|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
218889238|NCT06237959|DIETARY_SUPPLEMENT|Keranat™|300 mg/capsule(proso millet and wheat extract 600 mg/day)
219508673|NCT03757455|PROCEDURE|ERAS protocol preoperative actions|"First appointment:~\- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
218889239|NCT06237959|DIETARY_SUPPLEMENT|placebo|300 mg/capsule(600 mg/day as placebo)
218889240|NCT01186185|DRUG|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
218889241|NCT00031473|DRUG|Virazole (Ribavirin) Inhalation Solution|
219508674|NCT03757455|PROCEDURE|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
219508675|NCT03757455|PROCEDURE|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~\- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
219508676|NCT03401905|PROCEDURE|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
219508677|NCT03401905|PROCEDURE|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
219508678|NCT01836835|OTHER|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
219508679|NCT01836835|OTHER|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
219508680|NCT02408666|OTHER|Interview|
219032516|NCT04609410|PROCEDURE|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
219032517|NCT03806439|OTHER|Radical cystectomy.|Adult patients undergoing radical cystectomy.
218889242|NCT01186302|OTHER|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
218889243|NCT05921435|DRUG|CKD-341, D958|A single dose of 1tablet under fasting condition
218889244|NCT01793623|OTHER|atrial tissue|retrieval of discarded atrial tissue
218889245|NCT05531981|OTHER|detect HPV E7 ctDNA|Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR
218889246|NCT01285934|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
218889247|NCT01285934|DRUG|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
218889248|NCT03671213|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
218889249|NCT00681889|DRUG|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
219032518|NCT02030379|BEHAVIORAL|QPL-CT|Use the QPL-CT to prioritize questions
219032519|NCT01960946|DIETARY_SUPPLEMENT|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
219032520|NCT03720912|BEHAVIORAL|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
219032521|NCT06080386|DIAGNOSTIC_TEST|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
218889250|NCT03275324|DEVICE|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
218889251|NCT06351449|OTHER|The patch under study is photographed using the SkinCam®|Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.
218889252|NCT04257526|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
218889253|NCT05547568|PROCEDURE|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
218889254|NCT05726006|OTHER|No Intervention in This study|No Intervention in This study
218889255|NCT01717872|DEVICE|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
218889256|NCT01615016|OTHER|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
218889257|NCT01929382|DRUG|interferon gamma 1b|Standard therapy vs dose titration
218889258|NCT05303818|DRUG|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
218889259|NCT06514001|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
218889260|NCT01067274|DRUG|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
218889261|NCT01067274|DRUG|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
218889262|NCT01067274|DRUG|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
218889263|NCT03078556|DRUG|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
218889264|NCT03078556|DRUG|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
218889265|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
218889266|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
218889267|NCT00068614|BIOLOGICAL|HER-2/neu peptide vaccine|
218889268|NCT04593758|DRUG|CPI-613 + Hydroxychloroquine|"dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg"
218889269|NCT04542954|OTHER|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
218889270|NCT05718856|DRUG|TPO-RAs|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.
218889271|NCT05718856|DRUG|TPO-RAs combining anti-CD 20 monoclonal antibody|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater."
218889272|NCT04633382|COMBINATION_PRODUCT|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
218889273|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
219202909|NCT05578963|OTHER|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
219202910|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
219202911|NCT03328026|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
219202912|NCT03328026|DRUG|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
219202913|NCT03328026|DRUG|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
219202914|NCT03328026|DRUG|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
218889274|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
218889275|NCT03314987|DIETARY_SUPPLEMENT|L-carnosine|a naturally occurring di-peptide
218889276|NCT03314987|OTHER|placebo|an identically appearing supplement
218889277|NCT03769259|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|Participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
219032522|NCT02735161|OTHER|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
219032523|NCT02735161|OTHER|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
219032524|NCT01835743|DEVICE|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
219032525|NCT01835743|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
219032526|NCT02999256|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|
219032527|NCT02999256|OTHER|Placebo|
219032528|NCT03532997|OTHER|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
219032529|NCT06200675|OTHER|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
219032530|NCT06200675|OTHER|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
219032531|NCT06200675|OTHER|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
219032532|NCT02823275|OTHER|Functional mobilisation|functional mobilisation
219032533|NCT02823275|OTHER|Short term plaster cast fixation|2 weeks cast immobilisation
219032534|NCT04126395|DIAGNOSTIC_TEST|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
219032535|NCT04126395|DIAGNOSTIC_TEST|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
219032536|NCT04126395|DIAGNOSTIC_TEST|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
219032537|NCT04126395|OTHER|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
219202915|NCT06818123|OTHER|Education Intervention along with the doctor's consultation|This educational intervention will assess the improvement menstrual hygiene knowledge and practices among women at slums who are illiterate and can empower individuals to manage their periods with dignity and comfort.
219202916|NCT06818123|OTHER|Control group with doctor's consultation only|Baseline Knowledge will be assessed in this arm about the menstruations hygiene and practices.
219508681|NCT05585658|BIOLOGICAL|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
219508682|NCT00323947|DRUG|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
219508683|NCT04044430|DRUG|Binimetinib|Given PO
219508684|NCT04044430|DRUG|Encorafenib|Given PO
219508685|NCT04044430|BIOLOGICAL|Nivolumab|Given IV
218889278|NCT03769259|BEHAVIORAL|Present-Centered Therapy (PCT)|Participants in PCT will receive will include 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. PCT consists of (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors among military personnel; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions.
219032538|NCT01339728|PROCEDURE|far-infrared ray|The duration of far-infrared ray is 20 minutes.
219508686|NCT04044430|OTHER|Questionnaire Administration|Ancillary studies
219508687|NCT05743283|DEVICE|SynEx Wound Cleanser|SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
219508688|NCT05743283|OTHER|Saline|The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.
219508689|NCT03327896|OTHER|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
219508690|NCT01695070|DRUG|Melatonin|4mg prolonged release melatonin oral tablets twice daily
219508691|NCT01076166|DRUG|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
219508692|NCT03075657|DRUG|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
219032539|NCT02894177|PROCEDURE|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
219032540|NCT04713098|DEVICE|Peripheral Nerve Stimulation|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
219032541|NCT04713098|DEVICE|Sham|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
219032542|NCT00370253|DRUG|Terlipressin|1mg/4 h per day
219032543|NCT00370253|DRUG|Noradrenalin|0,1 mcg/kg/min
219032544|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
219032545|NCT01451775|DRUG|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
219032546|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
219032547|NCT06496126|DEVICE|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Hybrid Ceramic Block
219032548|NCT06496126|DEVICE|EverX Flow (GC Coop, Tokyo, Japonya)|Fiber Reinforced Composite Resin
219032549|NCT06496126|DEVICE|: G-CEM ONE (GC Coop, Tokyo, Japonya)|Universal Self Adhesive Resin Cement
219032550|NCT06496126|DEVICE|G-Premio Bond (GC Coop, Tokyo, Japonya)|Universal Adhesive
219032551|NCT06496126|DEVICE|G-ænial A'CHORD|Conventional Composite Resin
219032552|NCT00191828|DRUG|olanzapine|
219032553|NCT04407910|COMBINATION_PRODUCT|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
219032554|NCT04407910|COMBINATION_PRODUCT|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
219032555|NCT00542152|DRUG|CYCLOSPORINE VS INFLIXIMAB|"* Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6"
219032556|NCT00001893|DRUG|TNFR:Fc|
219032557|NCT02812316|DEVICE|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
219032558|NCT04483713|BEHAVIORAL|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
219032559|NCT04483713|BEHAVIORAL|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
218889279|NCT03769259|BEHAVIORAL|Treatment as Usual (TAU)|"All participants will receive the following interventions or procedures, regardless of treatment assignment:~* Suicide risk assessment using the Columbia Suicide Severity Rating Scale~* VA's safety planning intervention, which include Military Crisis Line contact information and lethal means access reduction~* Caring contacts and outreach~* Psychotropic medication, group therapy, substance abuse counseling, and other mental health interventions provided routinely as a part of treatment as usual"
219508693|NCT03075657|DRUG|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
219508694|NCT03075657|DRUG|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
219508695|NCT03075657|DRUG|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
219508696|NCT02235428|DRUG|Ipratropium bromide|
218889280|NCT05462860|OTHER|Suprathel®|Application of standard of care dressing.®
218889281|NCT02751580|OTHER|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
219032560|NCT03553407|DEVICE|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
219608179|NCT05351983|PROCEDURE|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
219608180|NCT03751566|OTHER|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
219608181|NCT03751566|DRUG|Standard supportive therapy|Standard supportive therapy
219608182|NCT04886895|OTHER|Let's Move Motor Intervention|Let's Move intervention will be administered and videotaped with infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, we will attempt to schedule two clinic-based sessions followed by 2 telehealth-based sessions
219608183|NCT05144828|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
218889282|NCT02751580|OTHER|Questionnaire Administration|Ancillary studies
219032561|NCT03553407|DEVICE|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
219032562|NCT03553407|DEVICE|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
219032563|NCT03441633|DRUG|apixaban|current or new medication
219032564|NCT03441633|DRUG|dabigatran|current or new medication
219032565|NCT03441633|DRUG|VKA|current or new medication
219202917|NCT06856837|DRUG|Fruquintinib|highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3
218889283|NCT04778826|PROCEDURE|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
218889284|NCT03020706|DRUG|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
218889285|NCT02630303|DEVICE|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
219032566|NCT03441633|DRUG|rivaroxaban|current or new medication
219202918|NCT06856837|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
219508697|NCT02235428|DRUG|Placebo|
219508698|NCT02235428|DRUG|Salbutamol|
219508699|NCT02532777|DRUG|Prednisone|
219508700|NCT02532777|DRUG|Cyclophosphamide(CTX)|
219508701|NCT02532777|DRUG|Mycophenolate mofetil(MMF)|
219508702|NCT02532777|DRUG|Leflunomide(LEF)|
219508703|NCT02532777|DRUG|Angiotensin-converting enzyme inhibitor(ACEI)|
219508704|NCT02532777|DRUG|Methylprednisolone|
218889286|NCT02630303|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
218889287|NCT03106636|BEHAVIORAL|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
219032567|NCT05446402|COMBINATION_PRODUCT|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
219202919|NCT06856837|DRUG|Trifluridine/tipiracil|trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor
219202920|NCT06856837|DRUG|Bevacizumab|recombinant humanized anti-VEGF monoclonal antibody composed of human IgG1 framework regions and antigen-binding, complementarity-determining regions from a murine monoclonal antibody (muMAb VEGF A4.6.1)
219608184|NCT05144828|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
219032568|NCT05446402|COMBINATION_PRODUCT|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
219032569|NCT03883932|BEHAVIORAL|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
219032570|NCT03883932|BEHAVIORAL|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
219032571|NCT00944151|PROCEDURE|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
219032572|NCT01909596|DEVICE|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
219202921|NCT06881524|DRUG|First-line licorice and lotus root powder combined with low-dose amoxicillin|For first-line experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
219608185|NCT06479135|DRUG|Navtemadlin|Navtemadlin is an investigational MDM2 inhibitor
219032573|NCT01909596|DEVICE|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
219032574|NCT01909596|DEVICE|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
219032575|NCT04076995|OTHER|Water Intake|Increased water intake during the 11 h protocol
219032576|NCT00178841|DRUG|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
219032577|NCT01251380|BIOLOGICAL|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
219032578|NCT01650662|DRUG|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
219032579|NCT02122536|DRUG|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
219032580|NCT02122536|DRUG|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
219202922|NCT06881524|DRUG|First line high-dose amoxicillin|For first-line active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
219508705|NCT04992052|DEVICE|Bone wax|The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
219508706|NCT00162435|DRUG|Warfarin|
219508707|NCT02531022|BEHAVIORAL|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
219508708|NCT02531022|BEHAVIORAL|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
219508709|NCT05717829|PROCEDURE|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
219508710|NCT03843177|OTHER|No intervention|No intervention will be performed. Only assessment will be done.
219608186|NCT06479135|DRUG|Navtemadlin placebo|Navtemadlin placebo
219608187|NCT06479135|DRUG|Ruxolitinib|Ruxolitinib is a janus kinase 1/2 inhibitor
219608188|NCT03690388|DRUG|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
219608189|NCT03690388|DRUG|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
219608190|NCT04291703|DRUG|Antithymocyte Globulin|Thymoglobulin
219608191|NCT04291703|DRUG|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
218889288|NCT03106636|BEHAVIORAL|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
218889289|NCT00974623|DEVICE|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
218889290|NCT01915173|DRUG|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
218889291|NCT01915173|DRUG|Placebo|Lactose tablets
218889292|NCT01915173|BEHAVIORAL|Expanded Interview|
218889293|NCT01915173|BEHAVIORAL|Standard Interview|
218889294|NCT05668598|DIAGNOSTIC_TEST|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
218889295|NCT03421912|OTHER|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
218889296|NCT03421912|OTHER|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
218889297|NCT03079895|BEHAVIORAL|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
218889298|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue
218889299|NCT01494077|OTHER|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
218889300|NCT02639442|DEVICE|ClearRing™|
218889301|NCT01011140|BEHAVIORAL|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
219032581|NCT06416696|DRUG|Toripalimab|"1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration."
219032582|NCT05067296|OTHER|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
219032583|NCT04383210|DRUG|Seribantumab|Anti-HER3 monoclonal antibody
219032584|NCT02367703|PROCEDURE|laparoscopic hysterectomy|
219032585|NCT05776121|DRUG|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
219032586|NCT05776121|DRUG|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
219032587|NCT05695716|DEVICE|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
219032588|NCT02473315|OTHER|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
219032589|NCT01318031|DRUG|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
219032590|NCT01318031|DRUG|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
219032591|NCT02085187|OTHER|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
219032592|NCT00417807|DRUG|Imatinib mesilate|
219032593|NCT03038815|DEVICE|VACOped|restriction of ankle joint motion
219032594|NCT03038815|DEVICE|Ortho Tri|restriction of ankle joint motion
219032595|NCT02447133|DEVICE|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
219032596|NCT05562973|DRUG|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
219032597|NCT05990400|DRUG|Finasteride|finasteride topical 0,1%
219032598|NCT05990400|DRUG|Minoxidil|minoxidil topical 5%
219032599|NCT05693285|OTHER|No intervention|No intervention
219032600|NCT03398720|DRUG|HTI-1066 dose level 1|Starting dose level
219032601|NCT03398720|DRUG|HTI-1066 dose level 2|2nd dose level
219032602|NCT03398720|DRUG|HTI-1066 dose level 3|3rd dose level
219032603|NCT03398720|DRUG|HTI-1066 dose level 4|4th dose level
219032604|NCT06516276|DEVICE|Mobile App M.I.O|This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
218889302|NCT04679194|BIOLOGICAL|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
219508711|NCT05583175|DRUG|Venetoclax plus RIC|Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.
219508712|NCT00956228|RADIATION|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
218889303|NCT05184634|OTHER|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
218889304|NCT05184634|OTHER|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
218889305|NCT05184634|OTHER|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
219032605|NCT00844272|BEHAVIORAL|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
219032606|NCT01419548|DRUG|ABT-888|
219032607|NCT01419548|DRUG|Carboplatin|
219032608|NCT01419548|DRUG|Paclitaxel|
219032609|NCT01814306|DEVICE|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
219032610|NCT01814306|DEVICE|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
219032611|NCT03448965|DIAGNOSTIC_TEST|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
219032612|NCT02822469|OTHER|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
219032613|NCT02822469|DEVICE|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
219032614|NCT01611987|OTHER|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
219508713|NCT04447274|DRUG|Camrelizumab and Apatinib|Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
219508714|NCT03237585|BEHAVIORAL|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
219508715|NCT04179071|DRUG|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
219508716|NCT04179071|DRUG|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
219508717|NCT00219856|DRUG|Propofol|"* Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~* Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
219508718|NCT00219856|DRUG|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
219508719|NCT00219856|DRUG|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
219508720|NCT02600169|DRUG|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
218889306|NCT05184634|OTHER|QUALITY OF LIFE|To determine the quality of life of MetS individuals
218889307|NCT02292446|DRUG|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
218889308|NCT01311609|OTHER|Systane|Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
218889309|NCT04524234|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of cardiac function
218889310|NCT02124681|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
218889311|NCT02124681|OTHER|Placebo|Placebo PO for 13±1 weeks
218889312|NCT02735148|OTHER|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~1. Body Weight Supported Treadmill Training,~2. Conventional Training and~3. Combined Training."
218889313|NCT02735668|OTHER|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands)."
218889314|NCT02735668|OTHER|Multimodal Physiotherapy|"The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
219202923|NCT06881524|DRUG|Rescue licorice and lotus root powder combined with low-dose amoxicillin|For rescue experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
219202924|NCT06881524|DRUG|Rescue high-dose amoxicillin|For rescue active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
218889315|NCT02735668|OTHER|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
218889316|NCT02735668|BEHAVIORAL|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
218889317|NCT04407988|DRUG|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
218889318|NCT04803851|DRUG|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
218889319|NCT01810003|DIETARY_SUPPLEMENT|High DHA|10 week supplementation period
218889320|NCT01810003|DIETARY_SUPPLEMENT|High EPA|10 week supplementation period
218889321|NCT01810003|DIETARY_SUPPLEMENT|Placebo|10 week supplementation period
219508721|NCT05358210|BEHAVIORAL|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
219508722|NCT05358210|BEHAVIORAL|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
218889322|NCT01403155|BIOLOGICAL|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
218889323|NCT04359199|RADIATION|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
218889324|NCT04359199|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
218889325|NCT04359199|DRUG|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
218889326|NCT04359199|DRUG|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
218889327|NCT00554450|DRUG|Dapagliflozin|Tablets, Oral, once daily
218889328|NCT02340065|PROCEDURE|standard colonoscopy|examination of the colon with a conventional colonoscope
218889329|NCT02340065|PROCEDURE|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
219202925|NCT06859463|DEVICE|Muscle function|Functional evaluation First, the patients will fill the Fysisk Aktivitet Questionnaire, the o Klinisk Oral Fysiologi (KU) Questionnaire and the Harvard Trauma Questionnaire. Then, the evaluator will applicate the Total Tenderness Score (TTS) for evaluating their tenderness in different spots of the head and neck regions. The next evaluation comprehends the evaluation of the maximal voluntary isometric contraction (MVIC) for the different neck movements and the rate of force development (RFD) of the shoulder elevation. After this, patients will perform the cranio-cervical flexion test (CCFT), and, finally, the Ito test to evaluate the lumbar endurance.
219202926|NCT06879847|PROCEDURE|Salvage Allogeneic Hematopoietic Stem Cell Transplantation|"1. TBI+BUMEL (IBM) Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally, Day -7; Day -6: Total Body Irradiation (TBI) 4Gy, in two parts, Day -6; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion~2. Donor Stem Cell Infusion (Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
219508723|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
219202927|NCT06876870|DRUG|Anesthesia Maintenance Agent|Difference in renal blood flow (RBF) between Propofol and Sevoflurane groups. Quantified by specific Multiparametric MRI metrics (e.g., (Renal blood flow by phase contrast imaging) (regional perfusion by Arterial Spin labeling (ASL) and global and regional oxygenation by Blood oxygen dependent signal (BOLD))
219202928|NCT06738069|OTHER|Participants are not assigned an intervention as a part of the study|Participants are not assigned an intervention as a part of the study
219202929|NCT06750510|BEHAVIORAL|Digitally Delivered Parent Training|The intervention is a universal, digitally delivered parenting program, including 5 themes with recommended length of 1 week each. The total length of the intervention is 8 weeks. The program focuses on positive parenting, encouraging to develop parenting skills that strengthen their relationships and communication with their children.
219202930|NCT06751836|OTHER|Infection and no infection|No intervention apart from the dengue infection
218889330|NCT01822457|DEVICE|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
218889331|NCT00091234|DRUG|gemtuzumab ozogamicin|
218889332|NCT03691597|DIAGNOSTIC_TEST|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G"
218889333|NCT04258826|DRUG|LY3154207|LY3154207 administered orally.
218889334|NCT04258826|DRUG|Placebo|Placebo administered orally.
218889335|NCT04870502|DRUG|Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG|In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
218889336|NCT02931032|PROCEDURE|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
218889337|NCT00472901|DRUG|Afamelanotide (CUV1647)|16mg implant
218889338|NCT06147141|BEHAVIORAL|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
218889339|NCT06147141|BEHAVIORAL|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
218889340|NCT01290757|DRUG|Dabigatran etexilate|150 mg Capsugel (T)
218889341|NCT01290757|DRUG|Dabigatran etexilate|150 mg Qualicaps (R)
218889342|NCT01751009|DIETARY_SUPPLEMENT|Vitamin A supplements|Sprinkles with Vitamin A
219202931|NCT06753630|BEHAVIORAL|Extensor Muscle Strengthening Exercise|A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
219202932|NCT06753630|PROCEDURE|Extracorporeal Shockwave Therapy|A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.
218889343|NCT01751009|DIETARY_SUPPLEMENT|Sprinkles without Vitamin A|Active comparator
219202933|NCT06753630|DRUG|Saline injection (Octreotide LAR placebo)|A 3mL injection of saline solution used as a placebo in the study.
219508724|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
218889344|NCT05318703|BEHAVIORAL|tai ji quan|cognitively enhanced tai ji quan exercise
218889345|NCT05318703|BEHAVIORAL|Stretching|Stretching exercise
218889346|NCT00887549|DRUG|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
218889347|NCT00887549|DRUG|cisplatin|Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
218889348|NCT03348280|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
219202934|NCT06753630|DRUG|Polydeoxyribonucleotide Injection|A 3mL injection of polydeoxyribonucleotide (5.625mg/3mL) used to enhance the healing process and improve outcomes in lateral epicondylitis treatment.
219508725|NCT00875368|DRUG|maraviroc|maraviroc dose dependent on co-medication
219508726|NCT00875368|DRUG|Placebo|Placebo drug
219508727|NCT05476679|DRUG|RZL-012|50mg/ml drug formulation
219608192|NCT06274411|PROCEDURE|Standby cannulated ECMO|Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.
219608193|NCT06274411|PROCEDURE|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
219202935|NCT06870097|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein
219508728|NCT05476679|DRUG|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
218889349|NCT01372566|DEVICE|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
219508729|NCT05476679|DRUG|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
219608194|NCT06544733|DRUG|GS-1720|Tablets administered orally without regard to food
218889350|NCT01372566|OTHER|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
218889351|NCT05599737|RADIATION|Integrated boost|Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
218889352|NCT00352001|DRUG|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
218889353|NCT00352001|DRUG|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
218889354|NCT02637765|BEHAVIORAL|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
218889355|NCT00759161|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
218889356|NCT00759161|DRUG|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
218889357|NCT06527781|DRUG|PD5K3|Six dose levels will be evaluated. intravenous injection
218889358|NCT06527781|DRUG|Placebo|intravenous injection
218889359|NCT06527781|DRUG|Pegaspargase|Six dose levels will be evaluated. intramuscular injection
218889360|NCT03329846|DRUG|BMS-986205|specified dose on specified day
218889361|NCT03329846|BIOLOGICAL|Nivolumab|Specified dose on specified day
218889362|NCT03329846|DRUG|Placebo|Specified dose on specified day
218889363|NCT00479336|DRUG|OPC-41061 7.5mg|7.5mg, 1 tablet a day
218889364|NCT00479336|DRUG|OPC-41061 placebo|placebo, 1 tablet a day
218889365|NCT00479336|DRUG|OPC-41061 15mg|15mg, 1 tablet a day
218889366|NCT00479336|DRUG|OPC-41601 30mg|30mg, 1 tablet a day
219202936|NCT06870097|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein
219202937|NCT06740474|DRUG|ABI-6250|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
219508730|NCT05476679|DRUG|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
219508731|NCT05476679|DRUG|RZL-012+facial and neck wrap|Universal Facial Band
219508732|NCT02768623|OTHER|Pharmacist led Asthma Management|
219508733|NCT02768623|OTHER|Pharmacist Intervention (when requested by patient)|
219508734|NCT03991832|DRUG|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
219608195|NCT06544733|DRUG|GS-4182|Tablets administered orally without regard to food
219608196|NCT06544733|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
219508735|NCT03991832|DRUG|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
219608197|NCT06544733|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
219608198|NCT06544733|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
219608199|NCT06544733|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
218889367|NCT03066193|DRUG|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
218889368|NCT02158871|BEHAVIORAL|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
218889369|NCT02158871|BEHAVIORAL|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
218889370|NCT03718026|OTHER|The timed 360° turn test|"* The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
218889371|NCT02021643|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
218889372|NCT02021643|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
218889373|NCT02021643|DRUG|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
218889374|NCT02118974|PROCEDURE|Hysterectomy|Hysterectomy
218889375|NCT04995536|BIOLOGICAL|CpG-STAT3 siRNA CAS3/SS3|Given intratumorally
218889376|NCT04995536|RADIATION|Radiation Therapy|Undergo radiation therapy
219032615|NCT01611987|OTHER|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
219032616|NCT05787314|BEHAVIORAL|Low Glycemic Index Diet|"1. Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~2. The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI \> 55) were excluded from the diet and only low GI (GI \< 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
219032617|NCT06822907|BIOLOGICAL|Early intervention|"In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia.~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
218889377|NCT03331900|DRUG|COR388|Administered as oral capsule
218889378|NCT03331900|DRUG|Placebo|Administered as oral capsule
218889379|NCT06162780|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.
218889380|NCT06162780|PROCEDURE|TEER|Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.
219032618|NCT06822907|BIOLOGICAL|Delayed intervention|"In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20).~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
219032619|NCT02495311|PROCEDURE|myomectomy or adenomyomectomy|
219032620|NCT04027738|OTHER|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
219032621|NCT04112017|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid
219202938|NCT06740474|DRUG|Placebo|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
219202939|NCT06917950|DRUG|Roxadustat|Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for treating anemia associated with chronic kidney disease in patients on dialysis based on hemoglobin levels.
219202940|NCT06917950|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
219204474|NCT06739954|COMBINATION_PRODUCT|Mulligan's Two Leg Rotation technique|The participants will undergo Mulligan's Two Leg Rotation technique, performing 10 repetitions with a 30-second hold for each repeat. There will be a 1-minute rest period between each stretch. The therapist positions themselves on the affected side of the supine patient lying on the treatment table and holds onto the side of the table with their hand on the opposite side. Both legs will be bent so that the feet are raised from the plinth. Maintaining the subject's shoulders on the bed, he gradually moves the subject's legs to the side, considering the restricted flexibility of the hamstring muscles. Once the patient reaches their maximum, the therapist applies extra pressure to sustain the posture for 30 seconds. Then, the legs are lowered to the plinth. A 1-minute interval was provided between each stretch, and the stretches were performed for a total of 10 repetitions. The identical technique is performed on the opposite side to address insufficient flexibility in the hamstrings.
219204475|NCT06739954|DIAGNOSTIC_TEST|Dry Needling|The DN technique, based on previous research, involved slowly inserting and removing the needle in the muscle or tendon to elicit a specific response. This response could be a local twitch, a dull ache, a feeling of heaviness or distension, or the reproduction of the participant's symptoms. The needle is manipulated in and out of the targeted tissue five times every five minutes for a total of fifteen minutes. After the treatment, sterile gauze is applied and pressed on the DN site, and sterile non-stick pads are used to cover the treated areas. The number of needles used varied depending on the participant's condition. The knee muscles that will be included in the dry needling intervention are the Quadriceps and Hamstrings .
218889381|NCT05154110|OTHER|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
218889382|NCT05154110|OTHER|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
219204476|NCT06746571|DIAGNOSTIC_TEST|complete blood count|measure cbc and blood ratios to compare their values with respone of patients to treatment
219204477|NCT06748963|BEHAVIORAL|Fasted Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
219204478|NCT06748963|BEHAVIORAL|Postprandial Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
219204479|NCT06752265|BEHAVIORAL|Peran sadar application|The PERAN SADAR application is an android-based SACA prevention application containing material related to SACA prevention which is given in a series for nine days using multimedia video stories and songs, documents, and tiktok in an attractive package, so that it attracts someone's interest in listening to the contents of the message. Social media applications are educational methods that are popular with all ages
218889383|NCT05523336|OTHER|observation|observation and prospective data collection
218889384|NCT03122210|DEVICE|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
218889385|NCT01946217|OTHER|questionnaire administration|Ancillary studies
219508736|NCT06095258|DRUG|Traditional Chinese medicine treatment|About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
219202941|NCT05738486|DRUG|Donanemab|Administered IV
219202942|NCT05738486|DRUG|Placebo|Administered IV
219202943|NCT05738486|DRUG|Dexamethasone|Administered IV
219202944|NCT03698669|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
219202945|NCT03698669|BEHAVIORAL|Health Education (HE)|Participants randomized to the control HE condition are offered six telephone sessions led by the Behavioral Health Specialists. The first health session is around nutrition. At the remaining sessions, participants choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
218889386|NCT05659823|DRUG|Bupivacaine-fentanyl-morphine elective group|Guideline recommended analgesia in elective caesarian section.
218889387|NCT05659823|DRUG|Bupivacaine-fentanyl elective group|Current analgesia in elective caesarian section.
218889388|NCT05659823|DRUG|Bupivacaine-fentanyl emergency group|Current analgesia in emergency caesarian section.
218889389|NCT00043511|BIOLOGICAL|pGA2/JS2 Plasmid DNA Vaccine|
219032622|NCT03530475|DIAGNOSTIC_TEST|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3\. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
219032623|NCT06454110|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
219508737|NCT06095258|DRUG|Western medicine treatment|Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
219032624|NCT05774158|OTHER|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
219032625|NCT00917709|OTHER|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
218889390|NCT02768779|OTHER|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
218889391|NCT00988078|DRUG|Placebo|Capsule (without biologic action) administered three times a day for six months
218889392|NCT00988078|DRUG|Metformin|Metformin 500mg three times a day for six months
218889393|NCT00697931|BIOLOGICAL|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
218889394|NCT00697931|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
219032626|NCT00917709|OTHER|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
219032627|NCT00917709|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
219032628|NCT00285597|DRUG|Ursodeoxycholic Acid|
219032629|NCT04179695|OTHER|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
219032630|NCT04179695|OTHER|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
219032631|NCT04136925|OTHER|questionnaire|questionnaire before and after race
219202946|NCT05372042|BEHAVIORAL|CBT Text Messages|CBT skills based text messages delivered 3x per week for four weeks
219202947|NCT01564056|DRUG|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
218889395|NCT04854551|DRUG|Naltrexone|Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
219202948|NCT01564056|DRUG|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
219202949|NCT04879342|BEHAVIORAL|VIP Program|This intervention will engage the participants with psychoeducational material once a week. This material will include didactic instruction as well as participant engagement in developmentally appropriate activities.
219202950|NCT04947462|DEVICE|Chronically Implanted Neural and Muscular Interface|Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
219508738|NCT02390622|OTHER|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
219508739|NCT04122222|BIOLOGICAL|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
219508740|NCT06485037|BEHAVIORAL|Time-restricted eating|Self-selected 10-hour eating window for 2 months
219508741|NCT02184949|PROCEDURE|Percutaneous Coronary Intervention|
219202951|NCT00983307|DRUG|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
219508742|NCT02184949|PROCEDURE|Primary Percutaneous Coronary Intervention|
219508743|NCT00788528|DRUG|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
219508744|NCT00125996|DRUG|Venofer (intravenous iron sucrose)|
219508745|NCT01569828|DRUG|LCZ696A|
218889396|NCT04854551|OTHER|Placebo|Placebo will be used to control for expectancy effects
218889397|NCT02631551|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
218889398|NCT02631551|DRUG|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
218889399|NCT02631551|DRUG|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
218889400|NCT02631551|DRUG|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
218889401|NCT05821244|BEHAVIORAL|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
218889402|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
218889403|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
218889404|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
218889405|NCT01935635|BIOLOGICAL|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
218889406|NCT02949726|DRUG|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
218889407|NCT02949726|DEVICE|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
218889408|NCT04341714|OTHER|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
218889409|NCT05170451|DRUG|CBD|Topical CBD 50 mg/ml applied in 1mL amounts twice daily
218889410|NCT05170451|OTHER|Control|Topical shea butter applied in 1mL amounts twice daily
218889411|NCT02444949|DRUG|endostar|
218889412|NCT02444949|RADIATION|intensity modulated radiation|
218889413|NCT02444949|DRUG|cisplatin|
218889414|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
218889415|NCT00349817|BEHAVIORAL|web-based learning, didactic lecture and role-play|
218889416|NCT01405300|DIETARY_SUPPLEMENT|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.
218889417|NCT01405300|DIETARY_SUPPLEMENT|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
218889418|NCT04112303|DRUG|SOF/VEL|Tablets administered orally once daily
218889419|NCT01373658|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
219508746|NCT01569828|DRUG|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
219508747|NCT00523393|DRUG|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
219508748|NCT00523393|DRUG|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
219508749|NCT01973114|DRUG|Latanoprost|
219508750|NCT01973114|OTHER|Placebo|
219508751|NCT04359992|OTHER|Extra blood sample|3 extra blood samples at day 0, 2 and 7
219508752|NCT00236782|DRUG|norelgestromin + ethinyl estradiol; mercilon|
219202952|NCT00983307|RADIATION|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
219202953|NCT06087237|DRUG|Pentoxifylline|"Two 400 mg extended-release pentoxifylline oral tablets are administered 2 hours before surgery, then one tablet three times per day after surgery, and continued for four weeks after the surgery.~Standard of care for pain management, including paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours."
219202954|NCT06087237|DRUG|paracetamol +ketorolac|"Patients receive the usual treatment only:~paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours"
219202955|NCT06954480|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.
219202956|NCT06954480|DRUG|Durvalumab|Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.
219508753|NCT03717610|PROCEDURE|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
219508754|NCT03579147|DEVICE|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
219202957|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
219202958|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard\_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
219202959|NCT04522544|DRUG|Tremelimumab|300 mg Tremelimumab C1D1
219202960|NCT04522544|DRUG|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
219202961|NCT04522544|PROCEDURE|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
219202962|NCT04522544|PROCEDURE|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
219202963|NCT06184880|BEHAVIORAL|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
219202964|NCT06184880|OTHER|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
219508755|NCT02413697|DEVICE|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
219608200|NCT06425510|BEHAVIORAL|Translation: Living the Advantages of Technological Assistance (VIVE-AT)|It comprises 2-hour small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected assistive technology devices (ATDs). The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding, and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals; providing information on ATDs, resources, and services; reflection on the advantages and disadvantages of using these ATDs; hands-on practice with selected ATDs; goal setting and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
219202965|NCT06421012|PROCEDURE|Experimental : Patients without additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will not receive additional preoxygenation before any endotracheal suctioning; their FiO2 value will be maintained constant
219202966|NCT06421012|PROCEDURE|Active Comparator : Patients with additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will receive additional preoxygenation at 100% FiO2 for a systematic 2-minute duration prior to any endotracheal suction. Subsequently, the FiO2 will be reset to the previous default value.
219202967|NCT00447980|DRUG|NT-501|Low Dose
219202968|NCT00447980|DRUG|NT-501|High Dose
219508756|NCT02413697|DEVICE|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
219508757|NCT02077959|DRUG|lenalidomide|Given PO
219608201|NCT06425510|OTHER|Attention calls|Ten minutes of attention calls, once a week for six weeks, to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
219608202|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
219508758|NCT02077959|BIOLOGICAL|pidilizumab|Given IV
219508759|NCT02077959|OTHER|pharmacological study|Correlative studies
219508760|NCT02077959|OTHER|laboratory biomarker analysis|Correlative studies
219202969|NCT05325424|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy was performed by the same surgical team.
218889420|NCT01022658|DRUG|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
218889421|NCT02285335|DIETARY_SUPPLEMENT|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
218889422|NCT03106064|BEHAVIORAL|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
218889423|NCT03106064|OTHER|Usual Care|Usual hospital care
218889424|NCT01855737|DRUG|Warfarin|Prescribe warfarin to the patients who are needed.
218889425|NCT03355846|DRUG|Centella|after meals twice a day for 15 days
218889426|NCT03355846|DRUG|Proctocella|after hygiene treatment for 4 weeks;
218889427|NCT03355846|DRUG|Flavonil® cps|after meals twice a day for 15 days
219202970|NCT05963997|DRUG|Samuraciclib|Samuraciclib capsules by mouth once a day
219202971|NCT05963997|DRUG|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
219202972|NCT06134921|DEVICE|transcranial direct current stimulation (Active)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down."
219202973|NCT06134921|DEVICE|transcranial alternating current stimulation (active)|Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.
219202974|NCT06134921|DEVICE|transcranial electrical stimulation (sham)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes."
219508761|NCT03792971|DRUG|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
219508762|NCT03792971|DRUG|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
219202975|NCT06134921|OTHER|Conventional physical therapy program|A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
219202976|NCT03952520|OTHER|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
219202977|NCT03952520|OTHER|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
219202978|NCT03635567|BIOLOGICAL|Pembrolizumab|IV infusion
219202979|NCT03635567|DRUG|Paclitaxel|IV infusion
219202980|NCT03635567|DRUG|Cisplatin|IV infusion
219202981|NCT03635567|DRUG|Carboplatin|IV infusion
219508763|NCT00877175|DRUG|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
219508764|NCT04919083|OTHER|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
219608203|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
218889428|NCT03355846|DRUG|Flavonil® Cream|"treatment for 4 weeks;~."
218889429|NCT03355846|DRUG|Rectalgan Mousse|for 4 weeks
218889430|NCT05703321|BEHAVIORAL|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
218889431|NCT04569292|OTHER|No intervention on patients|No intervention on patients
218889432|NCT01137032|DRUG|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
218889433|NCT04218409|DRUG|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
219202982|NCT03635567|BIOLOGICAL|Bevacizumab|IV infusion
219508765|NCT04919083|OTHER|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
219508766|NCT05442983|DRUG|PanCytoVir™ (probenecid)|Active drug
219508767|NCT05442983|DRUG|Placebo|Matching placebo
219508768|NCT00058279|BIOLOGICAL|aldesleukin|
219508769|NCT00058279|BIOLOGICAL|ipilimumab|
219508770|NCT01498484|BIOLOGICAL|EBV-specific T cells (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
219508771|NCT00319956|DRUG|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
219508772|NCT00319956|DRUG|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
219608204|NCT01221610|DEVICE|Passeo-18 Lux DRB|
219508773|NCT01146132|DIETARY_SUPPLEMENT|Conventional diet +/- wine|usual eating habits
219508774|NCT01146132|DIETARY_SUPPLEMENT|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
219508775|NCT04616417|PROCEDURE|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
219508776|NCT00256542|DRUG|Alkalinized Lidocaine-Heparin|
219508777|NCT00753714|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219508778|NCT00753714|DRUG|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219508779|NCT00753714|DRUG|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219508780|NCT02607800|DRUG|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
219508781|NCT02607800|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
219508782|NCT03432195|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
219508783|NCT03256513|OTHER|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
219508784|NCT03256513|OTHER|conventional controlling|control blood pressure by conventional strategy
219508785|NCT02907112|BEHAVIORAL|Meat reduction|Advice, Motivational material and food products provided to participants
219508786|NCT02122081|RADIATION|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
219608205|NCT01221610|DEVICE|Standard PTA (POBA)|
219608206|NCT03514290|RADIATION|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
219508787|NCT02122081|DRUG|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
219608207|NCT03514290|OTHER|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
219202983|NCT03635567|DRUG|Placebo to pembrolizumab|IV infusion
219202984|NCT06953063|DRUG|DA-302168S|A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.
219202985|NCT06953063|DRUG|Placebo of DA-302168S|Matching placebo tablet will be provided
219202986|NCT06563622|PROCEDURE|Pericapsular Nerves Group Block|USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
219202987|NCT06563622|PROCEDURE|Caudal Epidural Block|USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
219202988|NCT05717842|RADIATION|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
219202989|NCT00730509|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
219202990|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
219202991|NCT05157841|DRUG|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
219508788|NCT02122081|BIOLOGICAL|anti-thymocyte globulin|
219508789|NCT02122081|DRUG|tacrolimus|Given IV or PO
219508790|NCT02122081|DRUG|methotrexate|Given IV
219508791|NCT02122081|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
219508792|NCT02122081|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
219508793|NCT02122081|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
219508794|NCT02122081|OTHER|laboratory biomarker analysis|Correlative studies
219508795|NCT02486796|BIOLOGICAL|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
219508796|NCT02486796|DRUG|Coenzyme Q10|Preparation of coenzyme Q10
219508797|NCT02486796|DRUG|Melatonin|Preparation of melatonin
219508798|NCT05593198|PROCEDURE|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
219608208|NCT03514290|OTHER|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
219608209|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
219608210|NCT04100018|BIOLOGICAL|Nivolumab|Specified dose on specified days
219608211|NCT04100018|DRUG|Prednisone|Specified dose on specified days
219608212|NCT04100018|DRUG|Docetaxel|Specified dose on specified days
219202992|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
219202993|NCT02662907|PROCEDURE|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
219202994|NCT02662907|BEHAVIORAL|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
218889434|NCT04218409|DRUG|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
218889435|NCT04218409|OTHER|Placebo Oxycodone|Oxycodone 0 mg orally
218889436|NCT04218409|OTHER|Placebo oxytocin|Intranasal placebo administration
218889437|NCT04218409|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
218889438|NCT05419232|OTHER|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
218889439|NCT05419232|OTHER|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
218889440|NCT06212024|BEHAVIORAL|Mentalization Based Treatment-early|MBT-early is an early intervention program for young people at risk for developing BPD that has been developed as an adaptation of MBT, an empirically supported treatment for BPD. MBT-early is a time-limited intervention that has been designed for early-stage BPD and focuses on improving personality functioning. MBT-early is a two-phase treatment that integrates interventions at the individual, family, and context level. MBT-early provides a combination of treatment modalities, including individual and family sessions, case management, and treatment reviews. Interventions are tailored to the specific needs of the young person and his/her family. The treatment consists of 16 weekly individual sessions, 3 family sessions, and case management. The initial treatment phase (16 weeks) is followed by a booster period (6 months) with 4 booster sessions. Since MBT-early involves a flexible approach, this standard package may be downscaled in cases of rapid improvement, or upscaled when needed.
219032632|NCT05707117|OTHER|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
219032633|NCT05707117|OTHER|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
219032634|NCT06850168|DEVICE|SVL|Dispensed to one eye in Year 1
219032635|NCT06850168|DEVICE|SVL with passive red-light emission|Dispensed to the contralateral eye in Year 1.
219032636|NCT06850168|DEVICE|MCL|Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).
218889441|NCT02595255|OTHER|No intervention|No intervention
219032637|NCT06850168|DEVICE|MCL with passive red-light emission|Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).
219032638|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
219032639|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
219032640|NCT04227821|OTHER|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
219032641|NCT00176592|DRUG|Betaseron|Betaseron 250 micrograms injected SQ every other day
219032642|NCT00176592|DRUG|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
219032643|NCT03207932|PROCEDURE|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
219032644|NCT03414463|BEHAVIORAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
219202995|NCT02662907|DEVICE|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
219202996|NCT02662907|DEVICE|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
219202997|NCT02662907|BEHAVIORAL|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
219202998|NCT02662907|DRUG|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
219202999|NCT05768958|OTHER|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
219203000|NCT05768958|OTHER|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
219608213|NCT04100018|OTHER|Placebo|Specified dose on specified days
219608214|NCT06550414|DRUG|Dexmedetomidine|Active comparator: dexmedetomidine group
219608215|NCT06550414|DRUG|Bupivacain|Placebo comparator: bupivacaine group
219608216|NCT02257775|GENETIC|n/a - observational|
219508799|NCT05593198|PROCEDURE|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
218889442|NCT02879825|DEVICE|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
219032645|NCT04650477|PROCEDURE|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
219203001|NCT04889417|BEHAVIORAL|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
219203002|NCT04889417|BEHAVIORAL|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
219203003|NCT01242228|DRUG|ipragliflozin|oral
219203004|NCT01242228|DRUG|DPP-4 inhibitor|oral
219203005|NCT06836388|PROCEDURE|ultrasound guided bougie insertion|The anesthesiologist will use a high-frequency linear ultrasound probe at the level of the suprasternal notch to identify the tracheal rings. The probe will then be moved cephalad and placed over the cricothyroid membrane to visualize the vocal folds in the transverse view with the patient in the supine position. Using a C-mac laryngoscope, the intubator will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea and assess the real-time visualization of the bougie on the ultrasound screen as a linear echogenic structure moving through the hypoechoic lumen of the trachea then the tube will railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform will be maintained for five breaths.
219032646|NCT04368247|DIAGNOSTIC_TEST|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
219032647|NCT01643993|OTHER|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
219032648|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
219032649|NCT05749042|DRUG|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
219032650|NCT05749042|RADIATION|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
219032651|NCT02596269|DRUG|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
219508800|NCT01513668|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
219032652|NCT02596269|DRUG|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
219204480|NCT06741930|DRUG|Ketamine|The Ketamine group received IV ketamine at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
219508801|NCT01185288|BIOLOGICAL|Adalimumab|Adalimumab in pre-filled syringes
219508802|NCT01185288|DRUG|Methotrexate|Methotrexate capsule
218889443|NCT01318408|DRUG|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
218889444|NCT00377858|DRUG|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
219032653|NCT05933928|OTHER|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
219032654|NCT05628077|OTHER|No intervention|No intervention
219032655|NCT06327958|OTHER|Cormack-Lehane (C&L)|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
219204481|NCT06741930|DRUG|Midazolam|The Midazolam group received IV midazolam at a titrated dose of 0.15-0.40 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
219508803|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
219508804|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
219508805|NCT05881148|OTHER|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
219508806|NCT05881148|OTHER|Standard carbon-free sprinting spiked-shoes|cf
219508807|NCT03108105|DEVICE|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
219508808|NCT00278512|BIOLOGICAL|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
219508809|NCT00278512|BIOLOGICAL|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
219508810|NCT00278512|DRUG|Cyclophosphamide|Causes prevention of the cell division
219508811|NCT00278512|DRUG|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
219508812|NCT00278512|DRUG|G-CSF|Hematopoietic growth factor
219508813|NCT00278512|DRUG|Campath-1h|Humanized monoclonal antibody against CD52 antigen
219508814|NCT00278512|DRUG|Fludarabine|inhibits DNA synthesis or repair
218889445|NCT00377858|DRUG|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
219203006|NCT06836388|PROCEDURE|Conventional methods for bougie insertion|The anesthesiologist will perform the bougie insertion using a C-mac laryngoscope, and he will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea while feeling the tracheal clicks as a sign of correct its placement, the intubator will advance it gently till feel resistance then withdraw 2-3 centimeters. If the depth of the bougie reaches 30 centimeters from the angle of the mouth without feeling the resistance, the bougie will be removed and reinserted. Then, the tube will be railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform is maintained for five breaths.
219204482|NCT06741930|DRUG|Propofol|The Propofol group received IV propofol at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
219204483|NCT06755645|OTHER|Lifestyle intervention|A technological smart platform (app) that integrates diets, physical activity programs, sleep habits and other lifestyle interventions
219508815|NCT00278512|DRUG|Tacrolimus|immune suppressive drug
219508816|NCT00278512|DRUG|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
219508817|NCT05240339|OTHER|Observation of minor phenomena|observation twice a year over 3 years
219608217|NCT05736861|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
218889446|NCT05636852|DRUG|Altropane (123I) Injection|Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.
218889447|NCT05225857|DRUG|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
218889448|NCT05225857|DRUG|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
219032656|NCT06327958|OTHER|POGO score|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
219032657|NCT00625677|BIOLOGICAL|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
219032658|NCT00625677|BIOLOGICAL|Menjugate (Meningococcal C conjugate vaccine)|Dosage
219032659|NCT00563953|DRUG|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
219032660|NCT00589953|DRUG|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
219032661|NCT00589953|DRUG|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
219032662|NCT02437019|DRUG|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
219032663|NCT00129129|BIOLOGICAL|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
219508818|NCT00002719|BIOLOGICAL|filgrastim|
219032664|NCT00129129|BIOLOGICAL|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
219032665|NCT00129129|BIOLOGICAL|Pediarix|Primary phase: 3 IM doses
219032666|NCT00129129|BIOLOGICAL|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
219032667|NCT00129129|BIOLOGICAL|Menomune|Primary phase: 1 SC dose
219032668|NCT03345589|DRUG|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
219032669|NCT03345589|DRUG|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
219032670|NCT05470699|PROCEDURE|Computed Tomography|Undergo PET/CT
219032671|NCT05470699|OTHER|Fluorine F 18 Piflufolastat|Given IV
219032672|NCT05470699|DEVICE|Positron Emission Tomography|Undergo PET/CT
219032673|NCT01647633|OTHER|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
219032674|NCT02958150|DRUG|Dexmedetomidine|
219032675|NCT02958150|PROCEDURE|Standard Clinical Practice|
219032676|NCT03089606|DIAGNOSTIC_TEST|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
219032677|NCT03089606|DIAGNOSTIC_TEST|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
219032678|NCT03089606|DRUG|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
219032679|NCT03089606|DIAGNOSTIC_TEST|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
219508819|NCT00002719|DRUG|amsacrine|
219508820|NCT00002719|DRUG|carmustine|
219508821|NCT00002719|DRUG|cytarabine|
219508822|NCT00002719|DRUG|etoposide|
219508823|NCT00002719|DRUG|idarubicin|
219508824|NCT00002719|DRUG|mitoxantrone hydrochloride|
219508825|NCT00002719|PROCEDURE|peripheral blood stem cell transplantation|
219508826|NCT00781755|DRUG|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
219508827|NCT00781755|BEHAVIORAL|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
218889449|NCT06064695|DEVICE|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
218889450|NCT02630914|DEVICE|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
218889451|NCT06127719|OTHER|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
218889452|NCT04521244|OTHER|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
218889453|NCT04521244|OTHER|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
219032680|NCT01482247|DIETARY_SUPPLEMENT|L-Arginine|Dietary Supplement
219032681|NCT01482247|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary Supplement
219032682|NCT06067386|OTHER|Dissemination of a selective reporting for antibiotic susceptibility testing|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
219032683|NCT06067386|OTHER|Standard antibiotic susceptibility testing report|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
219508828|NCT01202747|DEVICE|LipiFlow System|In-office treatment for meibomian gland dysfunction
219508829|NCT00838474|OTHER|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
219508830|NCT01620177|DRUG|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
219608218|NCT05736861|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219608219|NCT03583476|DRUG|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
219032684|NCT05641233|RADIATION|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
219032685|NCT04540289|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure"
219032686|NCT04540289|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
219032687|NCT03963115|DRUG|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
219032688|NCT02708147|OTHER|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
219032689|NCT02708147|OTHER|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
219032690|NCT01103687|BIOLOGICAL|Ad26.ENVA.01 (rAd26)|5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
219032691|NCT01103687|BIOLOGICAL|Placebo Vaccine|Placebo vaccine delivered IM
219608220|NCT04622748|BEHAVIORAL|Trier Social Stress Test|8-min oral calculation and 5-min speech
219608221|NCT00036361|DRUG|Aripiprazole|
218889454|NCT05959460|OTHER|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
219032692|NCT02872779|PROCEDURE|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
219508831|NCT01620177|DRUG|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
219508832|NCT05617859|DRUG|Lenvatinib mesylate capsule|Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
219508833|NCT04041609|DRUG|LYR-210|A single administration of LYR-210 depot
219508834|NCT04041609|OTHER|Sham comparator|Sham comparator
218889455|NCT02564185|OTHER|Usual practice|
218889456|NCT02564185|OTHER|Education program|
219508835|NCT01268449|RADIATION|Low dose laser|5mv laser with a wavelength of 650nm
219508836|NCT01268449|RADIATION|Placebo|The act of radiating laser to the ear is done while the set is off.
219508837|NCT06209788|PROCEDURE|experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
218889457|NCT05503342|OTHER|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
218889458|NCT05503342|OTHER|Asthma control assessment|Asthma control assessment questionnaire application in paper format
218889459|NCT04146662|DIAGNOSTIC_TEST|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
218889460|NCT03631758|OTHER|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
218889461|NCT03631758|BEHAVIORAL|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
218889462|NCT03631758|OTHER|Sham information|Educational information not specific to mammography or cancer screening
218889463|NCT05370053|DIAGNOSTIC_TEST|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
219032693|NCT04427774|DRUG|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
219032694|NCT00178035|DRUG|paroxetine|
219032695|NCT00178035|BEHAVIORAL|One night of Total Sleep Deprivation|
219032696|NCT01678417|DRUG|131I-rituximab|
219032697|NCT01376271|DRUG|Paroxetine|
219032698|NCT00973024|DRUG|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
219032699|NCT00973024|DRUG|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
219032700|NCT00973024|DRUG|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
219032701|NCT00973024|DRUG|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
219032702|NCT00973024|DRUG|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
219032703|NCT03289507|DIETARY_SUPPLEMENT|Treatment1|Longvida Capsule formulation A
219032704|NCT03289507|DIETARY_SUPPLEMENT|Treatment2|Longvida Capsule formulation B
219032705|NCT03289507|DIETARY_SUPPLEMENT|Treatment3|Curcuma longa extract of Rhizomes
219032706|NCT04976634|DRUG|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
219032707|NCT04976634|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
219032708|NCT04976634|DRUG|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
219032709|NCT04022772|OTHER|Best Practice|Receive standard of care
219032710|NCT04022772|OTHER|Medical Chart Review|Ancillary studies
219032711|NCT04022772|OTHER|Quality-of-Life Assessment|Ancillary studies
219032712|NCT04022772|OTHER|Questionnaire Administration|Ancillary studies
219032713|NCT04022772|PROCEDURE|Supportive Care|Participate in PACK Health program
219032714|NCT02335723|DEVICE|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
219032715|NCT02335723|DEVICE|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
219032716|NCT02484963|DRUG|Zolpidem|
219203007|NCT06352840|BEHAVIORAL|My Pelvic Plan Website|This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.
219203008|NCT06352840|BEHAVIORAL|Control Group website|Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
219203009|NCT02937662|DRUG|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
219203010|NCT02937662|DRUG|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
219203011|NCT02937662|DRUG|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
218889464|NCT04200690|OTHER|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
219203012|NCT02937662|DRUG|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
219203013|NCT03237377|DRUG|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
219203014|NCT03237377|DRUG|Tremelimumab|75mg via IV infusion every 4 weeks
219203015|NCT03237377|RADIATION|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
219203016|NCT03237377|PROCEDURE|lobectomy|patients may proceed to surgery post drug and radiation intervention for lung lobectomy
219203017|NCT03237377|DRUG|Standard of care adjuvant chemotherapy|patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
218889465|NCT04200690|OTHER|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
218889466|NCT01685697|PROCEDURE|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
218889467|NCT01685697|PROCEDURE|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
218889468|NCT01435213|DRUG|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
219203018|NCT03278119|DIAGNOSTIC_TEST|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
219203019|NCT05354531|PROCEDURE|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
218889469|NCT01435213|DRUG|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
219203020|NCT05583513|DIAGNOSTIC_TEST|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
219203021|NCT05583513|DIAGNOSTIC_TEST|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
219203022|NCT04363853|DRUG|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
219203023|NCT05909709|DRUG|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
219203024|NCT05909709|DRUG|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
219203025|NCT05909709|DRUG|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
219203026|NCT06305143|DRUG|Conbercept|participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
219203027|NCT05709782|PROCEDURE|Spine Radiosurgery|scan
219203028|NCT05709782|DEVICE|Magnetic Resonance imaging|scan
219203029|NCT05709782|RADIATION|MR-LINAC|scan
218889470|NCT01435213|DRUG|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
218889471|NCT01435213|OTHER|Cold pressor test|30-45 min cold pressor test of the foot
218889472|NCT01435213|DRUG|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
218889473|NCT01435213|DRUG|Placebo|A single dose of placebo (capsules) administered orally
219203030|NCT06356584|DRUG|Immunotherapy (Sintilimab)|Sintilimab
218889474|NCT04321434|OTHER|Hyperoxia|
218889475|NCT04321434|OTHER|Normoxia|
218889476|NCT04321434|DEVICE|laser Doppler|laser Doppler
219032717|NCT02484963|DRUG|placebo|
219032718|NCT01632969|BEHAVIORAL|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
219032719|NCT04341142|DIAGNOSTIC_TEST|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
219032720|NCT00418132|DRUG|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
219203031|NCT06356584|DRUG|Targeted Therapy Agent (Fruquintinib)|Fruquintinib
219203032|NCT06356584|RADIATION|Radiotherapy (SBRT and LDRT)|SBRT and LDRT
219203033|NCT05941988|PROCEDURE|pre grafting partial maxillary expansion with post grafting expansion|pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
219203034|NCT06687369|DRUG|MB12 (Proposed Pembrolizumab Biosimilar)|200mg IV, every 3 weeks on Day 1
219608222|NCT00966472|DRUG|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
218889477|NCT05276258|DEVICE|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
219203035|NCT06687369|DRUG|EU-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
219203036|NCT06687369|DRUG|US-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
219203037|NCT06687369|DRUG|Pemetrexed|500 mg/m2 IV, every 3 weeks on Day 1
219203038|NCT06687369|DRUG|Carboplatin|Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
219203039|NCT06687369|DRUG|Cisplatin|75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
219203040|NCT04867525|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
219203041|NCT05178849|OTHER|Hypnosis|Hypnosis
219032721|NCT00418132|DRUG|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
219032722|NCT04830787|OTHER|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
219032723|NCT06497114|OTHER|ABILHAND-Kids questioner|questioner
219032724|NCT03741660|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
219203042|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
219203043|NCT06802653|DIAGNOSTIC_TEST|not provided|
219203044|NCT06390657|OTHER|Planning CT, MRI|"SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only."
219203045|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
219204484|NCT06755333|BEHAVIORAL|Oral hygiene motivation|the patient underwent a professional oral hygiene session before starting chemotherapy, as part of the routine pre-transplant procedure. Patients then received oral hygiene instructions.
219204485|NCT06738043|DRUG|Dexmedetomidine infusion|A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
219204486|NCT06738043|DRUG|Ketamine infusion|A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
219032725|NCT03741660|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
219032726|NCT04119856|OTHER|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
219032727|NCT01144442|DRUG|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
219508838|NCT01004692|DEVICE|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
219508839|NCT05803278|OTHER|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
219508840|NCT02048254|RADIATION|brachytherapy|
219508841|NCT02048254|RADIATION|IMRT|
219508842|NCT00160030|DRUG|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
219508843|NCT00160030|DRUG|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
219508844|NCT00310427|DRUG|LY686017|50 mg administered orally on a daily basis
219508845|NCT00310427|DRUG|Placebo|Administered on a daily basis
219508846|NCT06271811|PROCEDURE|Flossing band|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
219508847|NCT06271811|OTHER|Conventional physiotherapy|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
219508848|NCT04985214|OTHER|Questionnaire|Questionnaire on the quality of life
219508849|NCT05834790|OTHER|Mobile Augmented Reality (MAR) for oral health education program|MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
219508850|NCT05834790|OTHER|Lecture-based oral health education program|The oral health education program that will be delivered by traditional lecture-based process
219032728|NCT01144442|OTHER|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
219032729|NCT01144442|PROCEDURE|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
219032730|NCT01144442|DRUG|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
219508851|NCT02127996|DRUG|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
219508852|NCT02127996|DRUG|placebo|Normal saline
219508853|NCT02088528|DEVICE|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
219508854|NCT02088528|PROCEDURE|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
219508855|NCT02539095|DEVICE|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
219032731|NCT01144442|DRUG|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
219032732|NCT02368795|DEVICE|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
219032733|NCT02368795|DRUG|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
219032734|NCT02368795|DRUG|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
219032735|NCT02368795|DRUG|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
218889478|NCT05276258|DRUG|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
218889479|NCT00117039|DRUG|Aranesp®|
218889480|NCT02848534|BIOLOGICAL|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
218889481|NCT01103583|DRUG|Hydroxyurea|500 mg/die per os for two years
218889482|NCT01103583|OTHER|placebo|500 mg/die per os for two years
218889483|NCT04208555|DRUG|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
218889484|NCT04208555|DRUG|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
218889485|NCT01646281|DRUG|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
218889486|NCT01646281|DRUG|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
218889487|NCT02460809|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
218889488|NCT00398697|DRUG|Perifosine|
218889489|NCT00398697|DRUG|Gemcitabine|
218889490|NCT02795585|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
218889491|NCT04381169|DRUG|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
219032736|NCT02344030|DEVICE|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
219032737|NCT02344030|DEVICE|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
219508856|NCT02539095|DEVICE|Normal saline|"1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
219508857|NCT06484959|OTHER|Assigned Interventions|Assigned Interventions
219508858|NCT02072564|OTHER|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
219508859|NCT05690568|OTHER|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
219508860|NCT02587442|DRUG|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
219508861|NCT03272256|DRUG|IM156|Sequential 3+3 design.
218889492|NCT06530199|PROCEDURE|Enamel matrix derivative|connective tissue graft and Enamel matrix derivative in the defect area
218889493|NCT05974930|DEVICE|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
218889494|NCT01076036|DEVICE|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
218889495|NCT01076036|DEVICE|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
218889496|NCT03698227|DRUG|Olaratumab|iv infusion
218889497|NCT03698227|DRUG|Dexrazoxane|iv infusion
218889498|NCT03698227|DRUG|Doxorubicin|iv infusion
218889499|NCT00640965|DRUG|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
218889500|NCT00640965|DRUG|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
219032738|NCT01682590|PROCEDURE|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory."
219508862|NCT06454500|OTHER|Clinical decision support|A 48 hour expiration on orders placed for indwelling urinary catheters.
219508863|NCT03027336|DIETARY_SUPPLEMENT|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
219508864|NCT03027336|DIETARY_SUPPLEMENT|Placebo|patients will take one tablet daily for 12 weeks.
219508865|NCT01911585|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
219508866|NCT04389879|OTHER|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
219508867|NCT01004211|PROCEDURE|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
218889501|NCT00726232|DRUG|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
218889502|NCT05341115|DRUG|Leuprorelin Acetate Depot 3M|Leuprorelin Acetate Depot 3M SC injections.
218889503|NCT05501704|DRUG|Tamoxifen|Taken orally
218889504|NCT05501704|DRUG|Anastrozole|Taken orally
218889505|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
218889506|NCT05501704|DRUG|Abemaciclib|Taken orally
219508868|NCT01004211|PROCEDURE|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
218889507|NCT05637593|BEHAVIORAL|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
218889508|NCT05637593|BEHAVIORAL|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
219032739|NCT04092790|DEVICE|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
219032740|NCT03978585|DEVICE|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
219032741|NCT03978585|DEVICE|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
219204487|NCT06738043|DRUG|Normal Saline Infusion (Placebo)|A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
219032742|NCT03221920|OTHER|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
219032743|NCT02182531|DRUG|Epinastine|
219508869|NCT01297010|DRUG|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
219508870|NCT01297010|DRUG|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
219508871|NCT01199432|DRUG|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
219508872|NCT01199432|DRUG|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
219508873|NCT01199432|DRUG|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
219508874|NCT04773093|DRUG|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
219508875|NCT04773093|DRUG|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
219508876|NCT03083249|OTHER|Gardasil|None-data gathering only
219508877|NCT05783479|DRUG|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
219508878|NCT05783479|DRUG|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
219032744|NCT02182531|DRUG|Pseudoephedrine|
219032745|NCT02182531|DRUG|Epinastine + Pseudoephedrine combination|
219032746|NCT05103215|DRUG|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
219032747|NCT05103215|DRUG|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
219032748|NCT00100126|DRUG|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
219032749|NCT03238638|DRUG|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
219032750|NCT03238638|DRUG|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
219032751|NCT06233487|DIAGNOSTIC_TEST|Repeat hip ultrasound measurements|See earlier
219032752|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- low dose|
219032753|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- High dose|
219032754|NCT01150123|BIOLOGICAL|Placebo- Saline|
219032755|NCT01977170|BIOLOGICAL|Hib/PRP-T vaccine|Hib liquid vaccine
219032756|NCT00206869|BEHAVIORAL|exercise|
219032757|NCT00206869|BEHAVIORAL|heat|
219032758|NCT00206869|PROCEDURE|red light illumination|
219032759|NCT03076957|DRUG|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
219032760|NCT01035944|DEVICE|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
219032761|NCT01035944|DEVICE|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
218889509|NCT05396911|BEHAVIORAL|UP2UTobacco|The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. UP2UTobacco targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
218889510|NCT01201720|PROCEDURE|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
218889511|NCT01543074|DIETARY_SUPPLEMENT|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
219203046|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
218889512|NCT01543074|DIETARY_SUPPLEMENT|Garlic oil|1 pill = 30 mg garlic oil/day
218889513|NCT01543074|DRUG|BSE|2 pills = 200 micromoles of Sulforaphane/day
218889514|NCT01543074|DIETARY_SUPPLEMENT|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
218889515|NCT04713163|DRUG|covid19 vaccine|Vaccine
219203047|NCT03932032|BEHAVIORAL|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
219203048|NCT03932032|BEHAVIORAL|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
219203049|NCT05701098|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
219203050|NCT06364423|BIOLOGICAL|Autologous HuCD19 ( Anti-CD19)CAR T cells|1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
219203051|NCT06364423|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
219203052|NCT06364423|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
219203053|NCT06364423|DRUG|Rituximab|500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
219203054|NCT06463691|DRUG|BGB-11417|Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule
219203055|NCT06463691|DRUG|BGB-3111|Zanubrutinib, orally, 320 mg total daily dose
219203056|NCT06463691|DRUG|CD20|CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
219203057|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
219508879|NCT00629616|DRUG|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
218889516|NCT03083301|OTHER|Medical Files data extraction|Medical Files data extraction
218889517|NCT06090565|DRUG|Cefixime|Two 400 mg tablets will be administered orally to equal a 800 mg dose.
219508880|NCT00629616|DRUG|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
219508881|NCT01494688|DRUG|Paclitaxel|Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
218889518|NCT06090565|DRUG|Doxycyclin|One 100 mg tablet will be administered orally twice a day for 7 days
218889519|NCT06090565|DRUG|Ceftriaxon|Dose of 1 g intramuscular one time
218889520|NCT06090565|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 g dose.
218889521|NCT04034004|BEHAVIORAL|Mindfulness|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
218889522|NCT04034004|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
218889523|NCT04034004|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
218889524|NCT04034004|BEHAVIORAL|Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
218889525|NCT02726412|PROCEDURE|Acute vs elective|non-intverention study
218889526|NCT04723017|OTHER|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
219608223|NCT06034119|BEHAVIORAL|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
219608224|NCT06034119|BEHAVIORAL|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
218889527|NCT04723017|OTHER|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
218889528|NCT02212041|OTHER|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
219203058|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
219203059|NCT05961436|PROCEDURE|PENG block|Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
219508882|NCT01494688|DRUG|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
219508883|NCT06206499|PROCEDURE|soft tissue augmentation|"Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants."
219608225|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
219608226|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
219608227|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|50 mg
218889529|NCT01688375|DRUG|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
218889530|NCT03667157|DRUG|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
218889531|NCT03667157|DRUG|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
218889532|NCT05900544|OTHER|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
218889533|NCT02931552|BEHAVIORAL|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
218889534|NCT00183105|BEHAVIORAL|Brief Intervention (adaptation of motivational interviewing)|
219608228|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|200 mg
219608229|NCT00038077|DRUG|Placebo|
219608230|NCT05383612|PROCEDURE|Warm compresses|Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.
219608231|NCT05383612|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
219608232|NCT00063024|BEHAVIORAL|Increased calcium intake|
219608233|NCT00063024|BEHAVIORAL|Weight-bearing physical activity|
219608234|NCT00467974|PROCEDURE|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
219608235|NCT00467974|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
219608236|NCT06428396|DRUG|Belzutifan|Belzutifan 120 mg administered QD as an oral tablet.
219608237|NCT06428396|DRUG|Fulvestrant|Fulvestrant 500 mg administered as an IM injection.
219608238|NCT06428396|DRUG|Everolimus|Administered at 10mg via oral tablets QD.
219608239|NCT06428396|DRUG|Exemestane|Administered at 25 mg via oral tablets QD.
218889535|NCT03084692|BEHAVIORAL|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
218889536|NCT00005857|BIOLOGICAL|trastuzumab|
218889537|NCT00005857|DRUG|docetaxel|
218889538|NCT05007756|RADIATION|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
218889539|NCT05985486|BEHAVIORAL|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
218889540|NCT05985486|BEHAVIORAL|Health Education|Monthly health education sessions delivered remotely.
218889541|NCT02346175|DRUG|SHR3824|
218889542|NCT02346175|DRUG|Placebo|
218889543|NCT06161129|DEVICE|Lenses|The filter lenses will be worn by participants for one month all day.
218889544|NCT03391934|DRUG|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
218889545|NCT01167374|RADIATION|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
218889546|NCT03936153|DRUG|abexinostat|abexinostat tablet
218889547|NCT00695526|DIETARY_SUPPLEMENT|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
218889548|NCT00726635|BEHAVIORAL|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
218889549|NCT00726635|OTHER|Control group|A one hour conversation with a nurse
219032762|NCT05823623|DRUG|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
219032763|NCT05823623|DRUG|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
219203060|NCT05961436|PROCEDURE|FN block|Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
219203061|NCT06447376|DRUG|Siltuximab|Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
218889550|NCT00726635|OTHER|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
218889551|NCT01561235|OTHER|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
218889552|NCT04034784|DEVICE|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
218889553|NCT04034784|OTHER|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
218889554|NCT00985868|DRUG|multikinase inhibitor AT9283|
218889555|NCT00985868|OTHER|enzyme-linked immunosorbent assay|
218889556|NCT00985868|OTHER|immunohistochemistry staining method|
218889557|NCT00985868|OTHER|laboratory biomarker analysis|
218889558|NCT00985868|OTHER|pharmacological study|
218889559|NCT02445872|DRUG|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
218889560|NCT02445872|DRUG|Palonosetron|
218889561|NCT02445872|DRUG|Dexamethasone|
218889562|NCT03547310|BEHAVIORAL|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
218889563|NCT03766659|DIAGNOSTIC_TEST|MOSE|EUS-FNB with MOSE
218889564|NCT03766659|DIAGNOSTIC_TEST|ROSE|EUS-FNA with ROSE
218889565|NCT02304523|DRUG|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
218889566|NCT02304523|DRUG|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
218889567|NCT02304523|DRUG|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
219032764|NCT05823623|DRUG|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
219203062|NCT06447376|DRUG|Epcoritamab|"Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg"
219203063|NCT05276388|OTHER|biological bank|biological bank of subjects vaccinated against SARS-CoV-2 infection
219203064|NCT06082986|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
218889568|NCT02896283|RADIATION|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
218889569|NCT02896283|RADIATION|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
218889570|NCT02168907|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
218889571|NCT02168907|DRUG|bendamustine hydrochloride|Given IV
218889572|NCT02168907|BIOLOGICAL|rituximab|Given IV
218889573|NCT02168907|OTHER|laboratory biomarker analysis|Correlative studies
218889574|NCT01787630|DEVICE|Hyaluronic acid|Injection in connection with ultrasound
218889575|NCT06022796|OTHER|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
218889576|NCT06022796|OTHER|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
218889577|NCT02539901|BEHAVIORAL|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
218889578|NCT02539901|BEHAVIORAL|Free hearing test categorization|Free hearing test categorization evaluation
218889579|NCT02539901|BEHAVIORAL|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
218889580|NCT02539901|BEHAVIORAL|psychomotor infancy development scale|
218889581|NCT02539901|BEHAVIORAL|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
219508884|NCT02691806|OTHER|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
219508885|NCT03556917|COMBINATION_PRODUCT|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
218889582|NCT02182934|DRUG|Ginsana|
218889583|NCT02182934|DRUG|Placebo|
218889584|NCT06171685|DRUG|Teclistamab Monotherapy|standard of care
218889585|NCT06171685|DRUG|Teclistamab|investigational doses compared to SOC
218889586|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
218889587|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
218889588|NCT05651932|DRUG|Cohort A1 & A2: KTX-1001|KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
218889589|NCT05651932|DRUG|Cohort B1 & B2: KTX-1001+Mezigdomide|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly
218889590|NCT05651932|DRUG|Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle
218889591|NCT05651932|DRUG|Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle
218889592|NCT01966289|DRUG|CY|CY is administered intravenously at 200 mg/m2
218889593|NCT01966289|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
218889594|NCT01966289|DRUG|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
218889595|NCT00793507|OTHER|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
218889596|NCT01957371|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
218889597|NCT02549001|DRUG|P-3058 10%|
218889598|NCT02549001|DRUG|vehicle of P-3058 10%|
218889599|NCT02549001|DRUG|amorolfine 5%|
218889600|NCT01022138|BIOLOGICAL|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
218889601|NCT01022138|DRUG|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
218889602|NCT01022138|OTHER|Laboratory biomarker analysis|The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
218889603|NCT04117529|OTHER|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
218889604|NCT05447663|DRUG|Siremadlin|Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
219203065|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
219508886|NCT00756847|DRUG|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
219508887|NCT00756847|DRUG|paclitaxel|Intravenous injection dosed once every three weeks
219508888|NCT00756847|DRUG|carboplatin|Intravenous injection dosed once every three weeks
218889605|NCT05662956|DRUG|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
219032765|NCT06520930|BEHAVIORAL|breathing exercise therapy|Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
219508889|NCT03746678|OTHER|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
219508890|NCT00948402|DRUG|Metformin|metformin 1250 mg three times daily
219508891|NCT00948402|DRUG|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
219508892|NCT03645070|DEVICE|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
219508893|NCT03645070|DEVICE|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
219508894|NCT01252628|DRUG|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
219508895|NCT01252628|DRUG|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
219508896|NCT01252628|DRUG|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
219508897|NCT01252628|DRUG|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
219508898|NCT00367185|DRUG|Thalidomide|
219032766|NCT02522208|DRUG|BiDil XR|fixed combination capsule
219032767|NCT02522208|DRUG|BiDil Immediate Release (IR)|fixed combination tablet
219032768|NCT00374296|DRUG|MGCD0103|MGCD0103 administered orally three-times per week
219032769|NCT02831166|PROCEDURE|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
219032770|NCT02831166|PROCEDURE|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
219032771|NCT00566150|DRUG|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
219032772|NCT00566150|DRUG|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
219032773|NCT05497492|DRUG|propofol|single administration of propofol
219508899|NCT01626885|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
219508900|NCT02141386|OTHER|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
219508901|NCT02362906|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
219508902|NCT02362906|DRUG|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
219508903|NCT02362906|DRUG|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
219508904|NCT02362906|DRUG|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
219508905|NCT02362906|DRUG|second generation cephalosporin|
219508906|NCT02362906|DRUG|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
219508907|NCT02362906|DRUG|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
219508908|NCT05092061|OTHER|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
219508909|NCT05092061|OTHER|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
219508910|NCT02493725|DRUG|Eculizumab|
219508911|NCT02493725|DRUG|Placebo|
218889606|NCT03501225|PROCEDURE|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
219032774|NCT05497492|DRUG|propofol and sufentanil|administration of propofol and sufentanil in combination
219032775|NCT05497492|DRUG|propofol and esketamine|administration of propofol and esketamine in combination
219032776|NCT05497492|DRUG|propofol and lidocaine|administration of propofol and lidocaine in combination
219032777|NCT00352846|DRUG|Zoledronic Acid|4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
219032778|NCT00352846|DRUG|Vitamin D|400 mg by mouth daily
219032779|NCT00352846|DRUG|Calcium Carbonate|1200 mg by mouth daily
219032780|NCT05735301|PROCEDURE|Endovascular|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
219032781|NCT05735301|DRUG|Drug|best drug conservative therapy could be uesd in patients who with no indication of surgery
219032782|NCT05211713|DEVICE|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
219032783|NCT02233244|DRUG|CTX-4430|
219032784|NCT02233244|DRUG|Midazolam|
219032785|NCT00464425|PROCEDURE|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
219032786|NCT00464425|PROCEDURE|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
219032787|NCT00464425|OTHER|No Acupuncture|Control
219032788|NCT02213393|DIETARY_SUPPLEMENT|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
219032789|NCT02213393|DIETARY_SUPPLEMENT|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
219032790|NCT01527682|DRUG|Latanoprost, Dorzolamide|"* Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
219032791|NCT04931433|DRUG|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
219032792|NCT04931433|DRUG|Normal saline|Group B will receive saline of similar volume and rate as Group A
219032793|NCT02038582|OTHER|POC CD4 Testing|Point of Care CD4 testing
219032794|NCT02038582|OTHER|CD4 Referral|Referral to CD4 testing
219032795|NCT02038582|BEHAVIORAL|Lay Counselor Follow-up|Follow-up from a lay counselor
219032796|NCT02038582|BEHAVIORAL|Clinic Accompaniment|Accompaniment to the clinic by a counselor
219032797|NCT02038582|BEHAVIORAL|Clinic Referral|Referral to clinic
219032798|NCT02038582|BEHAVIORAL|SMS Reminder|SMS reminder for male circumcision
219032799|NCT02038582|BEHAVIORAL|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
219032800|NCT02038582|OTHER|POC VL|POC VL testing for HIV infected persons on ART
219032801|NCT02038582|OTHER|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
219032802|NCT00763165|DRUG|Triclosan|Brush twice daily
219032803|NCT00763165|DRUG|Fluoride|Brush twice daily
219032804|NCT00763165|DRUG|Fluoride|Brush twice daily
219032805|NCT05887882|BIOLOGICAL|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
219032806|NCT05887882|PROCEDURE|Implantation|Undergo placement of Ommaya reservoir
219032807|NCT05887882|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
219032808|NCT05887882|OTHER|Quality-of-Life Assessment|Ancillary studies
219508912|NCT04636749|DEVICE|Erbium laser|Vaginal laser therapy
219508913|NCT04636749|DEVICE|Sham laser|Sham laser therapy
219508914|NCT05725590|PROCEDURE|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
219508915|NCT05725590|PROCEDURE|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
218889607|NCT03501225|PROCEDURE|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
218889608|NCT00506688|DRUG|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
218889609|NCT00506688|DRUG|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
219508916|NCT05645458|OTHER|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
219508917|NCT03619161|OTHER|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
219508918|NCT03619161|OTHER|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
219508919|NCT04053881|DRUG|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
219508920|NCT05979181|PROCEDURE|Cesarean hysterectomy|Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
219508921|NCT03277781|OTHER|Screening|Screening for AAA
218889610|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
218889611|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
218889612|NCT00226382|DRUG|Pegylated Interferon-alfa-2a|Pegasys once weekly
218889613|NCT01397461|DRUG|ozenoxacin placebo|cream
218889614|NCT01397461|DRUG|retapamulin 1% ointment|ointment
218889615|NCT01397461|DRUG|ozenoxacin 1% cream|1% cream
218889616|NCT01124279|DRUG|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
218889617|NCT03604029|DEVICE|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
218889618|NCT00391144|PROCEDURE|intravitreal triamcinolone injection of avastin (1.25 mg)|
218889619|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
219032809|NCT01660854|BIOLOGICAL|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
219032810|NCT01660854|DRUG|Malarone treatment|Three days: 4 tablets 250/100mg per day
219032811|NCT05213923|PROCEDURE|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
219032812|NCT00433823|DRUG|Atorvastatin, Ezetimibe|
219032813|NCT06264206|DIAGNOSTIC_TEST|Killer-cell immunoglobulin-like receptors (KIRs) testing|patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
219032814|NCT04896710|DEVICE|SD Biosensor|Nasal swab SD biosensor to be self administered
219032815|NCT01296295|BEHAVIORAL|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
219032816|NCT01296295|BEHAVIORAL|Smoking cessation advice|Brief smoking cessation advice
219032817|NCT04390594|DRUG|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
219032818|NCT01024907|RADIATION|proton beam radiation therapy|Undergo radiation
219032819|NCT01024907|PROCEDURE|quality-of-life assessment|Ancillary study
219032820|NCT01024907|OTHER|questionnaire administration|Ancillary study
219032821|NCT05768152|DEVICE|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
219032822|NCT05264194|OTHER|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
219508922|NCT02397681|OTHER|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
219508923|NCT00673790|DRUG|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
219508924|NCT00673790|DRUG|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
219203066|NCT06241352|DRUG|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
219508925|NCT00673790|DRUG|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
219508926|NCT05105165|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
219508927|NCT06545422|OTHER|St. John's wort oil|To examine the effect of regularly applied St. John's Wort oil on skin moisture.
218889620|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
219032823|NCT03263416|OTHER|Dedicated and coordinated follow-up|"* Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires"
219508928|NCT06545422|OTHER|Barrier Cream|To examine the effect of regularly applied barrier cream on skin moisture.
219508929|NCT01785784|DRUG|rhGM-CSF Gel|
219508930|NCT04326842|PROCEDURE|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
219032824|NCT03263416|OTHER|Standard follow-up|\- Completion of QLQ-C30 and GIRERD questionnaires
219508931|NCT04326842|DEVICE|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
219508932|NCT04165278|OTHER|hyperthermic baths|Taking hyperthermic baths
219508933|NCT04032678|DEVICE|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
219508934|NCT04032678|DEVICE|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
219608240|NCT01665001|OTHER|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients \<55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD\>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD \<0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients \>55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
219608241|NCT01257620|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
219032825|NCT04713826|DRUG|BAY2586116|160 µg, nasal spray administration.
219032826|NCT04713826|DRUG|Placebo|Placebo matching BAY2586116, nasal spray administration.
219032827|NCT03803280|PROCEDURE|ERAS program|ERAS pathway according to the Spanish Via RICA
219032828|NCT03054662|OTHER|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
219508935|NCT01533428|DRUG|Capsaicin 8%|Capsaicin 8% transdermal delivery system
219508936|NCT01533428|DRUG|Placebo|Placebo Patch
219508937|NCT02234297|DRUG|BLZ-100|
219508938|NCT03247283|DRUG|BMS-986205|Carbon 14 tagged BMS-986205
219508939|NCT00004451|DRUG|Glucose|
219508940|NCT00094133|PROCEDURE|hot flashes attenuation|
219508941|NCT00094133|PROCEDURE|hypnotherapy|
219508942|NCT01492062|DEVICE|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
219508943|NCT01692158|DRUG|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
219508944|NCT04309409|DRUG|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
219508945|NCT01104519|DRUG|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
219508946|NCT01104519|DRUG|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
219608242|NCT04821726|DEVICE|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
219608243|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
219608244|NCT05397080|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
219203067|NCT04227379|BEHAVIORAL|Intervention 1- DSMS+|Participants in this group were signed up for an interactive, patient-centered, and customizable diabetes self-management support texting intervention (DSMS+). This arm received the same daily educational content as the DSMS arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging th
218889621|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
219508947|NCT01364870|DEVICE|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
219608245|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU)~* 4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia."
219608246|NCT05610540|DEVICE|TECNIS Synergy IOL|Implanted in one eye
219608247|NCT05610540|DEVICE|AcrySof PanOptix Trifocal IOL|Implanted in one eye
219608248|NCT00795262|DRUG|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
219608249|NCT00795262|DRUG|accupril, placebo|accupril 40 mg
218889622|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
219608250|NCT00795262|DRUG|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
219608251|NCT04636476|PROCEDURE|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
219608252|NCT04251104|OTHER|Images' personal relevance effectiveness in objective and subjective mood recovery|"After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery."
219608253|NCT03499639|DRUG|Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet|"* Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."
219608254|NCT04413786|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
219608255|NCT04413786|DRUG|placebo treatment|intranasal administration of placebo (24IU)
219608256|NCT02090725|DRUG|3-4 Diaminopyridine|
219608257|NCT00218946|DRUG|Sucrose|30 % sucrose
219608258|NCT00218946|DEVICE|Pacifier|
219608259|NCT00218946|OTHER|sterile water|
219608260|NCT05517421|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219608261|NCT05517421|DRUG|Placebo|Matching Placebo
219608262|NCT04234308|DRUG|Polyglycolic Acid|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
219608263|NCT04234308|DRUG|Catgut|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
219608264|NCT04234308|DRUG|Polytetrafluoroethylene|Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
219608265|NCT04234308|DRUG|Polyamide|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
219608266|NCT01512017|DEVICE|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
219608267|NCT01512017|DEVICE|Vaseline|External use
218889623|NCT01997424|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
219203068|NCT04227379|BEHAVIORAL|Comparison - DSMS|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Self-Management Support (DSMS), comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSMS messages could not be customized. There was no interactive content for the DSMS arm other than a once monthly message asking whether the messages had been helpful."
219203069|NCT06644131|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate
219203070|NCT06644131|DIETARY_SUPPLEMENT|Sugar Pill (Placebo)|Placebo - sugar pill
219203071|NCT06964945|BEHAVIORAL|Auricular Acupressure with Vaccaria Seeds|Auricular Acupressure with Vaccaria Seeds Participants in this group receive auricular acupressure using 2 mm Vaccaria seeds adhered to five specific auricular acupoints (TF4, CO15, Extra5, LO4, LO4) with 7 mm × 7 mm adhesive patches. Each session lasts 10-20 minutes, with seeds left in place for 5-7 days. A total of 12 weeks, along with standardized sleep hygiene education.
219608268|NCT04688645|DRUG|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
219608269|NCT04688645|DRUG|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
219608270|NCT02037425|DRUG|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
218889624|NCT01997424|DEVICE|FibroScan, Echosens, Paris, France|
219032829|NCT03054662|DIAGNOSTIC_TEST|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
219032830|NCT03054662|DRUG|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
219203072|NCT06964945|BEHAVIORAL|Sham Auricular Acupressure (No Seeds)|Participants in this group receive sham auricular acupressure using identical adhesive patches without Vaccaria seeds, applied to the same five auricular points. Procedures, duration, frequency, and sleep hygiene education are identical to those in the experimental group to maintain blinding.
219203073|NCT03944915|DRUG|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
219608271|NCT01817296|PROCEDURE|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
218889625|NCT04430569|DRUG|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
218889626|NCT04430569|DRUG|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
218889627|NCT05729568|DRUG|Teropavimab|Administered intravenously
218889628|NCT05729568|DRUG|Zinlirvimab|Administered intravenously
219032831|NCT03054662|OTHER|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
219032832|NCT00549562|DRUG|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
219032833|NCT01519882|OTHER|Placebo|"Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
219032834|NCT01519882|OTHER|Rotigotine|"Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
219032835|NCT00827879|BEHAVIORAL|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
219032836|NCT00827879|BEHAVIORAL|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
219203074|NCT03944915|DRUG|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
218889629|NCT05729568|DRUG|Lenacapavir Tablet|Administered orally
218889630|NCT05729568|DRUG|Lenacapavir Injection|Administered subcutaneously
218889631|NCT05729568|DRUG|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
218889632|NCT05287646|DEVICE|Suction Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
219032837|NCT00323115|BIOLOGICAL|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
219032838|NCT00323115|DRUG|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
219508948|NCT01364870|DEVICE|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
219508949|NCT01999309|DRUG|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
218889633|NCT05287646|DEVICE|Elevated Vacuum Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
218889634|NCT04181762|DRUG|secukinumab|STUDY DRUG
218889635|NCT04181762|DRUG|Placebo|Placebo
219032839|NCT00323115|PROCEDURE|Radiotherapy|RT is standard of care (SOC) post surgery
219032840|NCT00323115|BIOLOGICAL|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
219032841|NCT02062918|DEVICE|Abdominal belt|
219203075|NCT03944915|DRUG|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
219508950|NCT01999309|DRUG|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
219508951|NCT02834065|DEVICE|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
218889636|NCT05720390|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
218889637|NCT05720390|OTHER|L-leucine|L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
218889638|NCT05720390|OTHER|Combination of quinine and L-leucine|In this condition, both quinine and L-leucine will be administered as 'active'.
218889639|NCT05720390|OTHER|Control|In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
218889640|NCT06041919|DRUG|RESP301|Nitric Oxide agent
218889641|NCT06041919|DRUG|HRZE|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
218889642|NCT05948631|BEHAVIORAL|MISC intervention|MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
218889643|NCT05948631|BEHAVIORAL|Treatment as Usual (TAU)|TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
218889644|NCT02845323|DRUG|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
218889645|NCT02845323|DRUG|Nivolumab monotherapy|Two cycles of Nivolumab alone
218889646|NCT05996328|OTHER|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
218889647|NCT05996328|OTHER|Study -defined standard of care|study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
218889648|NCT03519633|DRUG|Sugammadex|Reversal of deep NMB
218889649|NCT03519633|DRUG|Neostigmine|Reversal of moderate NMB
218889650|NCT05844475|PROCEDURE|Conventional Free Gingival Graft Approach (FGG)|Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting
218889651|NCT05844475|PROCEDURE|Buccal Strip Graft with a collagen matrix (bSG + CM)|A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
218889652|NCT03750266|OTHER|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
218889653|NCT06050135|OTHER|Roadmap to Parenthood|web-based decision support
218889654|NCT06050135|OTHER|Informational Booklet|web-based informational booklet about young adult cancer survivorship
218889655|NCT05463406|OTHER|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
218889656|NCT05463406|OTHER|Usual care|Management as usual
219032842|NCT06151704|RADIATION|High intensity laser therapy|The subject will receive high-intensity laser therapy in a prone position with a cushion under the abdomen and eye protection. The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated. A GaAlAs laser device will be used, with a power of 1.6 watts and a wavelength of 808nm. The initial dose will be 10 joules/cm², with an increment of 2 joules after every three sessions. The final dose will be 16 joules/cm².
218889657|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
219032843|NCT06151704|OTHER|Motor control exercise|Motor control exercise is defined as an exercise to increase control and coordination of the spine and pelvis. Normally, Motor control exercise increases the weak deep trunk muscles, such as transversus abdominis and multifidus, and reduces the overactive large external trunk muscles, such as rectus abdominal and erector spinae muscles. . All subjects participate in a foundational treatment regimen involving motor control exercises: isolated and combined contractions of the transverse abdominis and multifidus muscles in various positions. Contractions will initially be performed up to a maximum of 10 repetitions per movement, with each contraction sustained for a duration of 10 seconds. Commencing from the third week, the subject should be capable of comfortably executing 10 repetitions, sustaining the contraction for 10 seconds, and progressively increasing the intensity.
219203076|NCT03944915|RADIATION|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
219203077|NCT03944915|DRUG|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
219508952|NCT03476915|OTHER|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
219508953|NCT01200394|DRUG|PF-00489791|Tablet, 20 mg once daily for 12 weeks
219203078|NCT03944915|DRUG|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
219203079|NCT03944915|DRUG|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
219508954|NCT01200394|DRUG|Placebo|Tablet, placebo once daily for 12 weeks
219508955|NCT02666430|DRUG|Mylan's insulin glargine|
219508956|NCT02666430|DRUG|Lantus®|
219508957|NCT02056730|DRUG|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
219508958|NCT02297906|DRUG|Ketorolac|Non-steroidal anti-inflammatory drug
219508959|NCT02847533|PROCEDURE|blood sample|blood sample for concentration levels of inflammatory markers
219508960|NCT02847533|BEHAVIORAL|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
219508961|NCT06144359|OTHER|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~\- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
219508962|NCT03828461|BEHAVIORAL|Facilitated group therapy with behavioral practice; 16 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
219508963|NCT00576199|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
219508964|NCT00576199|PROCEDURE|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
219508965|NCT02116413|PROCEDURE|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
219508966|NCT02116413|PROCEDURE|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
219508967|NCT06155799|DEVICE|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
219608272|NCT03885843|PROCEDURE|Renal nerve stimulation, mapping and denervation|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
218889658|NCT06042920|DRUG|Deucravacitinib|Specified dose on specified days
219508968|NCT03687099|OTHER|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
219508969|NCT04434859|OTHER|No intervention|No intervention
219508970|NCT02867020|DRUG|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
219508971|NCT02867020|DRUG|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
218889659|NCT06042920|DRUG|Placebo|Specified dose on specified days
218889660|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
219508972|NCT02867020|DRUG|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
218889661|NCT06516159|DIAGNOSTIC_TEST|MBI-C Scale in French|"The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes."
218889662|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
218889663|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
218889664|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
219032844|NCT05191680|DRUG|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
219032845|NCT05191680|DRUG|Placebo|Placebo to match apalutamide
219032846|NCT00920114|BIOLOGICAL|blood sample|
219032847|NCT06593522|DRUG|AMG 193|Film-coated tablet
219032848|NCT05656768|OTHER|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
219032849|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight
219032850|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight
219032851|NCT06664762|BEHAVIORAL|Left lateral position intervention|Patients will be randomized and asigned to start and remain in left lateral position during the colonoscopy
219032852|NCT06664762|BEHAVIORAL|Supine position intervention|Patients will be randomized and asigned to start and remain in supine position during the colonoscopy
219032853|NCT06663345|PROCEDURE|Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block|Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
219032854|NCT06985654|DRUG|Lactated Ringers|A bolus of Lactated Ringers (15mL/kg of ideal body weight) will be given to patients prior to anesthesia induction.
219032855|NCT06594315|DRUG|Deuterated Glucose|Given orally
219032856|NCT06594315|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure performed at University of California, San Francisco
219032857|NCT06594315|PROCEDURE|Blood Sample|Capillary blood from the fingertip
219032858|NCT06594315|PROCEDURE|MR spectroscopy (MRS)|Imaging procedure performed at University of California, San Francisco
219032859|NCT06198556|DRUG|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
219508973|NCT02867020|DRUG|Prednisone|Subjects will receive prednisone 10mg/day.
219508974|NCT01168128|OTHER|Tailored Change Strategy|e.g. Education, decision support tools
219508975|NCT02611999|BEHAVIORAL|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
219508976|NCT02611999|BEHAVIORAL|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
219508977|NCT04317053|BEHAVIORAL|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
219508978|NCT06447454|RADIATION|radiotherapy|radiotherapy
219508979|NCT06447454|DRUG|gemcitabine + cisplatin|Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.
219508980|NCT06447454|DRUG|slulimumab|Slulimumab, 4.5mg/kg intravenous infusion, Q3W
219508981|NCT06324253|PROCEDURE|bilateral Erector spine block,A dose of 30 ml 0.125% Bupivacaine will be injected.|will receive bilateral Erector Spinae Block after induction of anesthesia
219508982|NCT06324253|PROCEDURE|Thoracic epidural analgesia|will receive Thoracic Epidural Block before induction of anesthesia .a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour
219508983|NCT04847609|DEVICE|GentleCath™ Air catheter|Patients
218889665|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
219032860|NCT06985355|DRUG|MHB046C|IV administration of MHB046C Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219032861|NCT06494449|OTHER|Higher protein|An acute mixed meal containing higher protein
219032862|NCT06494449|OTHER|Lower protein|An acute mixed meal containing lower protein
219032863|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
219032864|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
219032865|NCT00310583|DRUG|Pregabalin|
219508984|NCT04965649|GENETIC|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
219508985|NCT05286528|DRUG|Bosutinib|Bosutinib as prescribed in real world
219508986|NCT05286528|DRUG|Imatinib|Imatinib as prescribed in real world
219608273|NCT03885843|PROCEDURE|Sham Procedure: Renal angiography|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
219608274|NCT04358081|DRUG|HCQ|Hydroxychloroquine Monotherapy
219608275|NCT04358081|DRUG|HCQ+AZT|Hydroxychloroquine with azithromycin
219608276|NCT04358081|DRUG|Placebo|Placebo
218889666|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
218889667|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
219508987|NCT05286528|DRUG|Nilotinib|Nilotinib as prescribed in real world
219508988|NCT05286528|DRUG|Dasatinib|Dasatinib as prescribed in real world
219508989|NCT05286528|DRUG|Ponatinib|Ponatinib as prescribed in real world
219508990|NCT00406978|DRUG|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
219508991|NCT00406978|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
219608277|NCT00221338|DRUG|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
219608278|NCT01287806|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
219608279|NCT01287806|DRUG|blank group|standard treatment
219608280|NCT04040036|BEHAVIORAL|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
219608281|NCT01348256|DRUG|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
219608282|NCT02346656|DEVICE|Implantation with the commercially available Axium neurostimulator|
219608283|NCT05124470|OTHER|cognitive remediation by musical training sessions|"The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises."
219608284|NCT03652402|PROCEDURE|kidney transplantation|samples additional to the standard of care' (SOC)will be taken at each visit (Day 0, Month 3, Month12, clinical indication)
218889668|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
218889669|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
218889670|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
218889671|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
218889672|NCT06341556|DRUG|Zanubrutinib|Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
218889673|NCT03965143|DEVICE|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
218889674|NCT05802862|DRUG|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
218889675|NCT02197663|PROCEDURE|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
218889676|NCT00983320|DRUG|quetiapine|flexible dosage (50 to 300 mg)
218889677|NCT00983320|DRUG|placebo|placebo
218889678|NCT04981652|DIETARY_SUPPLEMENT|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
218889679|NCT04981652|DIETARY_SUPPLEMENT|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
219608285|NCT00626353|OTHER|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
219608286|NCT00626353|OTHER|Standard care|Standard care during hospital stay and in the municipality after discharge
219608287|NCT02600975|BIOLOGICAL|R21 with ASO1B|R21 with ASO1B
219608288|NCT00431470|BEHAVIORAL|Six classroom based character building education lessons|
219608289|NCT01130532|DRUG|Tadalafil|Administer orally
219608290|NCT01130532|DRUG|Placebo|Administer orally
219608291|NCT00404287|DRUG|Fluvastatin|
219608292|NCT02691754|OTHER|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
219608293|NCT01278186|PROCEDURE|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
219608294|NCT01278186|PROCEDURE|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
219608295|NCT02656303|BIOLOGICAL|Ublituximab|Ublituximab IV infusion
219508992|NCT00406978|DRUG|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
219508993|NCT00406978|DRUG|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
219508994|NCT06104696|PROCEDURE|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
219508995|NCT04027764|DRUG|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
219508996|NCT00506753|BEHAVIORAL|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
219508997|NCT00506753|BEHAVIORAL|RT/SU|Relaxation Training followed by Treatment as Usual
219508998|NCT00125359|DRUG|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
219508999|NCT01150448|DRUG|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
219509000|NCT01150448|DRUG|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
219509001|NCT03182257|DRUG|ONO-7579|ONO-7579 Tablets
219608296|NCT02656303|DRUG|Umbralisib|Umbralisib tablets
219608297|NCT01479075|DRUG|intransal insulin|4x 40mU intranasal insulin
219608298|NCT01479075|DRUG|Placebo|
219608299|NCT01479075|DEVICE|taVNS|
219608300|NCT01479075|DEVICE|sham stimulation|
218889680|NCT04981652|DIETARY_SUPPLEMENT|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
218889681|NCT02500953|DRUG|ASP3325|
219608301|NCT03041311|DRUG|Trilaciclib|Trilaciclib IV
219608302|NCT03041311|DRUG|Placebo|Placebo IV
219608303|NCT03041311|DRUG|Carboplatin|Carboplatin IV
219608304|NCT03041311|DRUG|Etoposide|Etoposide IV
219608305|NCT03041311|DRUG|Atezolizumab|Atezolizumab IV
219608306|NCT01842438|BEHAVIORAL|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
218889682|NCT02500953|DRUG|Placebo|
218889683|NCT00314964|DRUG|PD-0299685|
218889684|NCT01502228|DRUG|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
218889685|NCT01502228|DRUG|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
218889686|NCT01502228|PROCEDURE|Positron Emission Tomography|PET Scan
218889687|NCT01502228|DRUG|Sunitinib|
218889688|NCT04175028|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
218889689|NCT00584519|OTHER|non-interventional|non-interventional
218889690|NCT06648772|DRUG|Roflumilast Cream 0.3%|Roflumilast Cream 0.3%
218889691|NCT06648772|DRUG|Vehicle cream|Vehicle cream
218889692|NCT02655549|BIOLOGICAL|Px563L, RPA563, or placebo|Two intramuscular injections
218889693|NCT03954080|DEVICE|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
218889694|NCT02542826|OTHER|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
219509002|NCT02451670|BEHAVIORAL|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
219509003|NCT01513551|BIOLOGICAL|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
219509004|NCT01513551|BIOLOGICAL|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
218889695|NCT04488926|DIETARY_SUPPLEMENT|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
219032866|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
219032867|NCT04166721|DRUG|Atezolizumab|Immunotherapy
219032868|NCT06513780|OTHER|Observation|No intervention were made.
219032869|NCT05366803|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
219032870|NCT06914271|COMBINATION_PRODUCT|Kendall Exercise|The Kendall Exercises focus on correcting posture, strengthening the core, and re-educating muscles to improve spinal alignment and reduce pain .These exercises primarily target specific muscles and joint actions to help patients regain their range of motion.
218889696|NCT04488926|OTHER|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
218889697|NCT04488926|DRUG|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
218889698|NCT04488926|DRUG|Rescue Drug|Use as needed allowed
218889699|NCT02037334|DEVICE|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
218889700|NCT04007263|DRUG|Placebo|Placebo via 30 minute infusion once daily for 5 days
218889701|NCT04007263|DRUG|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
218889702|NCT00291603|DEVICE|FX-class of dialyser|
218889703|NCT02503228|PROCEDURE|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
218889704|NCT05765123|DIAGNOSTIC_TEST|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
219032871|NCT06914271|COMBINATION_PRODUCT|Kabat Exercises|The principle of the Kabat exercises is based on a series of neuromuscular facilitation techniques that emphasize dynamic movement patterns, flexibility, and coordination to enhance functional mobility and alleviate pain.
219032872|NCT00001598|DRUG|Dehydroepiandrosterone|
219032873|NCT06997042|PROCEDURE|Terminolateral anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a terminolateral anastomotic suture.
218889705|NCT00653588|DRUG|Rosuvastatin|40mg
218889706|NCT00653588|DRUG|Atorvastatin|80mg
218889707|NCT06020781|DRUG|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
218889708|NCT06020781|DRUG|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
218889709|NCT06020781|DRUG|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
218889710|NCT02526004|DRUG|Ceftazidime|
218889711|NCT02526004|DRUG|Tobramycin|
219032874|NCT06997042|PROCEDURE|Piggyback anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a piggyback anastomotic technique.
219032875|NCT04365556|BEHAVIORAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
218889712|NCT06268964|DRUG|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
218889713|NCT06268964|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
218889714|NCT06268964|OTHER|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
218889715|NCT06457841|BEHAVIORAL|Direct Interpersonal Exchange|Simulated a negative personally relevant interpersonal experience that is received directly from a perpetrator, commonly experienced in everyday lives
218889716|NCT06457841|BEHAVIORAL|Vicarious Interpersonal Exchange|Hearing or observing a negative personally relevant interpersonal experience that is reported by another person of the same background
218889717|NCT06457841|BEHAVIORAL|Daily Hassles|Day-to-day stressors associated with school, work, finances
219032876|NCT06672445|DRUG|ARO-ATXN2 Injection|single dose of ARO-ATXN2 by intrathecal (IT) administration
219509005|NCT01513551|BIOLOGICAL|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
219509006|NCT03150251|OTHER|Cereal - oats|Consumption of one cereal in the beginning of each visit
219509007|NCT03150251|OTHER|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
219509008|NCT06442683|DIAGNOSTIC_TEST|TTE simulation-based medical training|half-day simulation-based neonatal echocardiography training.
219509009|NCT04393506|DRUG|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
219509010|NCT04393506|DRUG|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
219509011|NCT04393506|PROCEDURE|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
219509012|NCT04393506|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
219509013|NCT05569148|COMBINATION_PRODUCT|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
219509014|NCT03202836|DRUG|progesterone|vaginal utrogestan
219509015|NCT03202836|DRUG|Tocolytics|tocolysis for 48 hours
219509016|NCT03202836|DRUG|Steroids|antenatal corticosteroids for 48 hours
219608307|NCT01622257|DEVICE|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm\^2 adjustable, 60W with 20cm\^2 active surface).
219509017|NCT00116922|DRUG|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
219509018|NCT00003908|DRUG|carboplatin|
219509019|NCT00003908|DRUG|docetaxel|
219608308|NCT01622257|DRUG|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
219608309|NCT01622257|OTHER|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
218889718|NCT04999436|BEHAVIORAL|APOL1 Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
219608310|NCT00782626|DRUG|everolimus|
219608311|NCT02126514|DRUG|AZD3293|7 subjects will receive AZD3293
219608312|NCT05439096|OTHER|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
219608313|NCT05439096|OTHER|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
219608314|NCT00562848|DRUG|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
218889719|NCT05706220|DIAGNOSTIC_TEST|Eye tracking|Eye tracker will be used to evaluate eye movements
218889720|NCT05706220|DIAGNOSTIC_TEST|Microperimetry|Perimetric examination with Expert Exam strategy Microperimetry be used for fixation test
218889721|NCT05706220|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Macular Cube 512x128 or 200x200 scan. OCT will be used to analysis of retinal nerve fiber layer, ganglion cell complex and ganglion-cell/inner plexiform layer
219032877|NCT06672445|DRUG|Placebo|calculated volume to match active treatment by IT administration
219032878|NCT06995508|OTHER|Best Practice|Given standard of care symptom management
219032879|NCT06995508|DRUG|Olanzapine|Given PO
219032880|NCT06995508|OTHER|Questionnaire Administration|Ancillary studies
219032881|NCT05410873|DRUG|MitoQ Compound|Mitoquinol mesylate
219032882|NCT05410873|DRUG|Placebo|Placebo
219032883|NCT06529835|DEVICE|NeuroSpan Bridge|"The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump."
219032884|NCT06529835|DEVICE|NeuroGen Nerve Guide|The NeuraGen Nerve Guide is a resorbable implant for the repair of 0.5-1.0cm peripheral nerve discontinuities. NeuraGen Nerve Guide provides a protective environment for peripheral nerve repair after injury. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap. The semi-permeable type 1 collagen membrane allows for controlled resorption, appropriate nutrient diffusion and retention of representative Nerve Growth Factor.
219032885|NCT06529835|DEVICE|Nerve Autograft|A nerve autograft is a surgical procedure that involves transplanting a segment of a patient's own sensory nerve tissue to repair a damaged peripheral nerve injury measuring 1.1-3.0cm. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap
219032886|NCT02280941|OTHER|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
218889722|NCT05706220|DIAGNOSTIC_TEST|Visual processing speed test|"Visual processing speed test will be used for assessing subject visual stimulus search and reach times.~Thirty-two different everyday visual stimuli divided in four complexity groups that were presented along 8 radial visual field positions at three different eccentricities."
218889723|NCT05621551|DRUG|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
218889724|NCT06821620|DIETARY_SUPPLEMENT|Breakfast|Breakfast in one condition will be high carbohydrate and in the other protein enriched
218889725|NCT06617936|DRUG|neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)
218889726|NCT06617936|PROCEDURE|surgery|Patients who are discussed by the MDT panel to evaluate surgical resection will undergo surgery.Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
218889727|NCT06617936|DRUG|Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.
218889728|NCT06617936|OTHER|Standard Treatment|Patients assessed by the MDT panel as inoperable for surgical treatment will be selected by the investigator for a standard treatment protocol determined by the MDT discussion
218889729|NCT04477759|RADIATION|50 Gy Radiation Therapy|Ionizing radiation
218889730|NCT04477759|RADIATION|55 Gy Radiation Therapy|Ionizing radiation
218889731|NCT04477759|RADIATION|60 Gy Radiation Therapy|Ionizing radiation
218889732|NCT04477759|DRUG|Concurrent Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
218889733|NCT04477759|DRUG|Adjuvant Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year.
219203080|NCT03944915|DRUG|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
219203081|NCT06064812|DRUG|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
219608315|NCT00562848|DRUG|Placebo|Subjects will receive placebo.
219608316|NCT04909853|DRUG|PF-07321332/ritonavir|PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
218889734|NCT06494358|OTHER|liquid biopsies and surgery specimen analysis|liquid biopsies and surgery specimen analysis
218889735|NCT06049303|OTHER|Paraffin wax bath therapy and Maitland joint mobilization techniques|"In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)"
219203082|NCT06064812|DRUG|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
219203083|NCT03796793|PROCEDURE|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
219203084|NCT03796793|OTHER|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
219203085|NCT06968091|OTHER|Trendelenburg position|After the loss of consciousness during general anesthesia, the 10° Trendelenburg position is adopted.
219203086|NCT06968091|OTHER|Supine Horizontal Position|After the loss of consciousness during general anesthesia, the Supine Horizontal Position is adopted.
219203087|NCT06967246|COMBINATION_PRODUCT|Kinesio tape|Kinesio tape applied to one surgical site
219608317|NCT02253511|DRUG|Cidan capsule|
219608318|NCT04054765|DEVICE|videogame|Invite Only VR videogame
219608319|NCT04054765|OTHER|treatment as usual|treatment as usual
219608320|NCT02264678|DRUG|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
219608321|NCT02264678|DRUG|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
218889736|NCT06049303|OTHER|Maitland knee joint mobilization|"Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above"
218889737|NCT04043039|PROCEDURE|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
218889738|NCT04043039|PROCEDURE|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
218889739|NCT05383716|DRUG|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
218889740|NCT01407757|GENETIC|DNA analysis|
218889741|NCT01407757|GENETIC|gene expression analysis|
218889742|NCT01407757|OTHER|laboratory biomarker analysis|
218889743|NCT01407757|OTHER|pharmacogenomic studies|
218889744|NCT03221244|DEVICE|VR Treatment|Distractors
218889745|NCT03221244|DEVICE|VR Active Control|No distractors
218889746|NCT04211441|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
219032887|NCT00721773|DRUG|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
218889747|NCT03758534|OTHER|No intervention|This is a retrospective chart review study.
218889748|NCT02000297|PROCEDURE|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
219032888|NCT00721773|DRUG|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
219032889|NCT00721773|DRUG|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
219032890|NCT00721773|DRUG|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
219032891|NCT03072615|DIAGNOSTIC_TEST|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
219032892|NCT02208609|OTHER|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
219032893|NCT02208609|OTHER|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
219032894|NCT05903378|OTHER|Relational touch practice|Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
219032895|NCT06783309|DRUG|CNP-103|CNP-103
219032896|NCT06783309|DRUG|Placebo|0.9% sodium chloride for injection
219203088|NCT06967246|COMBINATION_PRODUCT|non-elastic tape|The non-elastic tape with only adhesive properties was used as the placebo tape on the other side
219032899|NCT07066852|RADIATION|x ray|we performed pelvis ap and frog leg x ray to child in 6 month and 1 age
219032900|NCT07066852|DIAGNOSTIC_TEST|ultrasound|we will perform ultrasound in 6 week and 3 month
219608322|NCT02264678|DRUG|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
219608323|NCT02264678|DRUG|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
218889749|NCT02000297|PROCEDURE|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
218889750|NCT03643627|DRUG|SYNT001|single IV infusion
218889751|NCT03643627|DRUG|Placebo|single IV infusion
218889752|NCT03939975|DRUG|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
218889753|NCT03700567|OTHER|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
218889754|NCT00303225|DRUG|Vaccine: SIGA-246|
219032901|NCT06774027|PROCEDURE|Specimen collection|Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis
219032902|NCT06774027|DRUG|Non-Investigational Antibody-Drug Conjugates (ADC)|ADC given under usual care for the treatment of cancer
219032903|NCT06774027|OTHER|Medical Record Review|Prospective and retrospective medical chart reviews will be conducted to obtain data for analysis.
219032904|NCT06810934|BIOLOGICAL|CoTend-BXBB (SARS2-30404)|Ad35-vectored SARS-CoV-2 RBD (XBB.1.5) vaccine
219608324|NCT02264678|DRUG|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
219608325|NCT02264678|DRUG|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
218889755|NCT00779493|DIETARY_SUPPLEMENT|curcumin|curcumin 900mg twice daily by mouth
218889756|NCT00779493|DIETARY_SUPPLEMENT|placebo|placebo capsule to simulate 900mg curcumin capsule
218889757|NCT04563195|DRUG|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
218889758|NCT05905367|DRUG|Fentanyl|Symptom-inhibited IV fentanyl induction
218889759|NCT05905367|DRUG|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
218889760|NCT05905367|DRUG|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
218889761|NCT05822622|OTHER|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
218889762|NCT02661243|DEVICE|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
218889763|NCT01712802|OTHER|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
218889764|NCT01712802|OTHER|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
218889765|NCT01712802|OTHER|Saline|work as control for Denture Adhesives: Cream and Powder
218889766|NCT05505006|DRUG|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
218889767|NCT05505006|DRUG|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
218889768|NCT05505006|DRUG|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
218889769|NCT05035732|RADIATION|18F-fluciclovine|IV
218889770|NCT03977103|BIOLOGICAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
219032905|NCT06810934|BIOLOGICAL|CoTend-s3BXBB (SARS2-17032)|Ad35-vectored s3-SARS-CoV-2 RBD (XBB.1.5) vaccine
219032906|NCT06810934|BIOLOGICAL|Placebo|Sterile sodium chloride 0.9% for injection, preservative free
219032907|NCT05231473|OTHER|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
219032908|NCT07070206|BEHAVIORAL|The health professionals in the capacity building arm will receive in-service training about culturally customized maternal nutrition education.|The health professionals in the routine capacity building arm will receive in-service training given through the health are system.
219032909|NCT07089628|OTHER|Assessment|There is no intervention in this study. Participants will only undergo assessments.
219032910|NCT06913400|COMBINATION_PRODUCT|Stereopsis Recovery|This prospective longitudinal observational study aims to assess stereopsis recovery in strabismic patients at one month and three months post-corrective surgery
219032911|NCT07110363|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
219032912|NCT06917079|DRUG|BBO-11818|Participants will receive assigned dose of BBO-11818 orally (PO)
219032913|NCT06917079|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
219032914|NCT06917079|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)
219032915|NCT06917079|DRUG|Pemetrexed|Patients will receive IV pemetrexed
219032916|NCT06917079|DRUG|Cetuximab|Patients will receive IV cetuximab
219032917|NCT06937177|DRUG|TCMCB07|TCMCB07 is will be provided in single-use vials for subcutaneous administration
219032918|NCT06937177|DRUG|Placebo|Matching placebo
219204488|NCT06761391|DIAGNOSTIC_TEST|Pain Pressure Threshold|A hand-held pressure algometer will be used to record the pressure pain threshold (PPT), defined as the level at which gradually increasing pressure becomes painful. Pressure algometry has shown high intratest reliability in asymptomatic individuals over the suboccipital area and upper trapezius. PPT levels will be measured bilaterally over the neck angle over the middle of the anterior surface of the upper trapezius; and over the rectus capitis posterior major (RCPM) muscle. The physiotherapist will use an increasing pressure of approximately 1 kg/cm²/s. The average of three measurements with a 30-second rest period will be taken for analysis. Two measurements will be taken, before and after.
219608326|NCT02264678|DRUG|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).
219608327|NCT02264678|DRUG|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
219608328|NCT04945395|DEVICE|FES and Conventional training|The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
219608329|NCT04945395|DEVICE|AFO and Conventional training|The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
219608330|NCT04994769|DEVICE|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling.
219608331|NCT01198769|BIOLOGICAL|Rotarix TM|Oral, 2 doses
219509020|NCT03914313|DEVICE|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
218889771|NCT04983355|DIETARY_SUPPLEMENT|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
218889772|NCT04983355|DIETARY_SUPPLEMENT|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
218889773|NCT05799768|BEHAVIORAL|Ketogenic diet|Ketogenic diet counseling
218889774|NCT05715216|DRUG|Nivolumab|Given by IV (vein)
218889775|NCT05715216|DRUG|Etigilimab|Given by IV (vein)
218889776|NCT03890744|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
218889777|NCT00420069|DEVICE|MRTX device|device for ventilation
218889778|NCT05971069|PROCEDURE|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
218889779|NCT05971069|PROCEDURE|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
218889780|NCT05971069|PROCEDURE|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
218889781|NCT06127589|BEHAVIORAL|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
218889782|NCT06127589|DRUG|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
218889783|NCT06127589|BEHAVIORAL|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
218889784|NCT06127589|BEHAVIORAL|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for \>2 times) at 3-month follow-up.
218889785|NCT06127589|BEHAVIORAL|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
219203089|NCT05381766|OTHER|CSA Model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
219203090|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
219203091|NCT06805214|OTHER|post tracheostomy fever|incidence of post tracheostomy fever and whether retrospectively the increased temperature indicated development of sepsis or not (no intervention)
219203092|NCT06853041|DRUG|Esketamine|A single slow intravenous injection of low-dose esketamine (0.15 mg/kg) over 10 minutes using an infusion pump.
219203093|NCT06853041|DRUG|Ketamine|A single slow intravenous injection of low-dose ketamine (0,3 mg/kg) with an infusion pump, during 10 minutes
219203094|NCT00942734|DRUG|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
219608332|NCT04857658|PROCEDURE|extraction orthodontic treatment plan|patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
219608333|NCT06128447|DRUG|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
219608334|NCT06128447|DRUG|Placebo|Matching placebo
219203095|NCT00942734|DRUG|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
219608335|NCT04446962|DRUG|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
219608336|NCT04446962|DRUG|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
219509021|NCT04585321|DRUG|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
219509022|NCT04585321|DRUG|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
219509023|NCT04053790|DRUG|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
219509024|NCT04053790|OTHER|placebo|a tablet of placebo every 12 hours given by mouth
219509025|NCT05909475|DIETARY_SUPPLEMENT|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
219509026|NCT05909475|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
219509027|NCT00099736|DRUG|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
219509028|NCT00099736|DRUG|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
219509029|NCT00099736|DRUG|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
219509030|NCT00649870|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
219509031|NCT00649870|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fed
218889786|NCT06127589|BEHAVIORAL|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
218889787|NCT01922908|BIOLOGICAL|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
218889788|NCT01922908|BIOLOGICAL|Placebo Comparator|Normal saline
218889789|NCT05293184|OTHER|Observational study only|
218889790|NCT01444846|DRUG|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
218889791|NCT01444846|DRUG|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
218889792|NCT01444846|DRUG|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
218889793|NCT01444846|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
218889794|NCT01221350|DIETARY_SUPPLEMENT|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
218889795|NCT01221350|DIETARY_SUPPLEMENT|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
218889796|NCT02524002|DIETARY_SUPPLEMENT|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
218889797|NCT02524002|DIETARY_SUPPLEMENT|Usual clear diet|Usual clear liquids
218889798|NCT02624453|DRUG|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
218889799|NCT02624453|DRUG|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
218889800|NCT00369213|DEVICE|Additional spermicidal lubricant to condoms|
219032920|NCT07144111|DRUG|Inavolisib|Participants will receive a single oral dose of inavolisib
219032921|NCT07150143|OTHER|Exercise|Each exercise session lasts 50 minutes, consisting of a 10-minute warm-up, 30 minutes of stabilization exercises, and a 10-minute cool-down. Stabilization exercises are selected from an exercise pool according to the individual's needs, with progression ensuring throughout the program. The exercises will be administered face-to-face twice a week for eight weeks, and participants will be provided with illustrated brochures and instructed to perform a one-hour home exercise program daily.
219032922|NCT07150143|OTHER|Connective tissue massage|Connective tissue massage will be applied, starting from the basic regions and gradually incorporating other regions.
219032923|NCT07150143|OTHER|Infrared therapy|Infrared therapy will be applied for 20 minutes
219608337|NCT05116072|PROCEDURE|total pancreatectomy|"The total pancreatectomy will be performed in two steps: The pancreatectomy will begin by a standard pancreaticoduodenectomy procedure.~The section margin will be sent for intraoperative histological analysis to confirm the absence of invasion of the left remnant pancreas.~When absence of tumor invasion is confirmed and the high-risk of postoperative pancreatic fistula is validated intraoperatively, the extended left distal pancreatectomy will be performed, with splenic preservation when possible.~Then, the left side of the pancreas will be resected and cooled (4-6°) in the preservation solution and shipped to Lille Biotherapy platform to perform islet isolation and purification. The reconstruction after total pancreatectomy will be done as usually performed by center expert surgeon."
219608338|NCT05116072|BIOLOGICAL|intraportal islet autotransplantation|The final islet preparation will be cultured and shipped 48 hours after total pancreatectomy from the Lille laboratory to the surgical center, and finally transplanted into the patient through a venous catheter placed in the portal trunk (91% of the total islet mass) and at the same time, a small fraction of the isolated islet (5% of the total islet mass) will be transplanted into the forearm muscle.
219608339|NCT05303337|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and W52
219608340|NCT05303337|OTHER|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
219608341|NCT06413706|DRUG|Abemaciclib|Administered orally
219608342|NCT06413706|DRUG|Temozolomide|Administered orally or IV
218889801|NCT04906304|DRUG|Everolimus Pill|standard dose versus low dose Sandimun
218889802|NCT04906304|DRUG|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
219608343|NCT04927832|OTHER|SUDOSCAN and EMG (electromyogram)|The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
219608344|NCT04821453|DEVICE|NAVA|NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.
219608345|NCT04821453|DEVICE|CMV|CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode
219608346|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
219608347|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
219608348|NCT06412874|OTHER|Screening tool|Participants will complete a screening tool survey
219608349|NCT06958822|DRUG|Ferric Carboxymaltose (FCM)|As this is an observational study, ferric carboxymaltose recipients are determined based on routine medical care practices. The researchers do not define which participants will receive ferric carboxymaltose.
219608350|NCT04182490|BIOLOGICAL|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
219608351|NCT04182490|DRUG|Placebo|Identical appearing placebo
219608352|NCT04925960|DRUG|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
219608353|NCT04925960|DRUG|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
219608354|NCT05645549|BEHAVIORAL|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
219608355|NCT00853099|BIOLOGICAL|adalimumab|
219608356|NCT00853099|DRUG|placebo|
219608357|NCT02489097|DRUG|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
219608358|NCT02489097|OTHER|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
219608359|NCT00511823|DRUG|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
218889803|NCT02352844|DRUG|Everolimus|
218889804|NCT00590863|DRUG|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
219203096|NCT06989203|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
219608360|NCT00511823|DRUG|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
218889805|NCT00590863|DRUG|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
218889806|NCT00590863|DRUG|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
219203097|NCT06989203|BEHAVIORAL|Calorie-restricted balanced diet|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes and APP-connected scale will be used to monitor their weight changes during interventions.
219203098|NCT06989203|DRUG|semaglutide|Participants will receive semaglutide as medically prescribed
219203099|NCT06989203|DIETARY_SUPPLEMENT|Dietary protein supplementation|participants will receive 30 g/day of dietary protein supplementation
219608361|NCT00511823|DRUG|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
219608362|NCT00511823|DRUG|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
219203100|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
219203101|NCT04643769|DRUG|Placebo|Oral tablet - placebo
219203102|NCT06997510|BEHAVIORAL|Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS)|"Personalized lifestyle intervention that integrates artificial intelligence (AI), polygenic risk scores (PRS), and real-time behavioral and environmental data. MyBETTER4U dynamically adapts to individual needs by combining genetic and biological profiling (e.g., PRS, microbiome, metabolomics), behavioral determinants (e.g., eating habits, physical activity, sleep patterns), sociodemographic and environmental context, technology-assisted self-monitoring through wearable devices and digital tools, and AI-driven decision-support systems that generate ongoing, individualized recommendations.~Intervention group participants will receive personalized recommendations via the Better4U Platform, based on the AI model and, when available, their PRS and genetic data. Since genotyping results depend on sample processing timelines, baseline visits should be scheduled when results are available or expected within 1.5 months to ensure inclusion in the next visit."
219203103|NCT06997510|BEHAVIORAL|Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.|"Participants will receive feedback and counselling from the implementers on their weight status and lifestyle behaviours, based on their measurements/responses during the screening assessment. This counselling will be based on the general healthy eating (based on the Mediterranean diet) and healthy lifestyle recommendations for physical activity, sedentary time, and sleep (based on WHO recommendations) and will be considered the standard care. Those recommendations will also be handed in to them in the form of a standard care leaflet to take home. Participants will also be provided with a standard hypocaloric diet based on their needs for weight loss, aiming for a ≥ 5% reduction in body weight at the end of the 6-month intervention period."
219203104|NCT06996912|DRUG|HSK44459|HSK44459 will be administered orally twice daily
219203105|NCT06996912|DRUG|Placebo|Placebo will be administered orally twice daily
219203106|NCT06996938|DIAGNOSTIC_TEST|Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis|"The following information will be collected :~* Socio-demographic characteristics~* Lifestyle~* Health status~* Access to care and support in care~* Life events/violence~Knowledge of HIV prevention will be assessed~It will be proposed to screen for potentially serious STIs in the absence of specific management. If one of these infections is detected, the women will be referred and accompanied to a specialized consultation in the medical centers participating in the study~Women's needs in terms of health and access to care will be assessed: infections, gynecology, psychology, management of individual violence, sexual in particular, prophylaxis with regard to HIV"
219608363|NCT02353910|PROCEDURE|Ultrasound|
219608364|NCT00313079|DRUG|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
219608365|NCT00313079|DRUG|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
219613296|NCT04468022|PROCEDURE|Toric Trifocal IOL|Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
218889807|NCT03491111|OTHER|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
218889808|NCT03491111|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
218889809|NCT03491111|OTHER|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
218889810|NCT00305487|DRUG|Ciclesonide nasal spray|
219509032|NCT01768806|BEHAVIORAL|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
219509033|NCT01768806|BEHAVIORAL|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
218889811|NCT05194800|OTHER|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
218889812|NCT06383416|OTHER|Neck pain by VAS|chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index.
218889813|NCT03838081|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
218889814|NCT03838081|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
219509034|NCT04782115|BIOLOGICAL|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
219509035|NCT04782115|BIOLOGICAL|Conbercept|KH902(Conbercept）
219509036|NCT05587088|DRUG|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
219509037|NCT05587088|DRUG|Placebo|Placebo in pill
219509038|NCT01298388|OTHER|medical chart review|
219509039|NCT01298388|OTHER|questionnaire administration|
219613297|NCT06425588|OTHER|Surgical/Procedure Mask Fit Testing|All participants will wear a surgical/procedure mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
219613298|NCT06425588|OTHER|KN95 Mask Fit testing|All participants will wear a KN95 mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
218889815|NCT03838081|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
219032924|NCT07150143|OTHER|Continuous ultrasound|Continuous ultrasound will be applied to the right and left sides for 7 minutes each at an intensity of 2 W/cm².
219032925|NCT07150143|OTHER|Conventional TENS|20 minutes of conventional TENS will be administered to the painful area.
219203107|NCT06997185|OTHER|Statement communicating uncertainty with a single arm trial|Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
219509040|NCT01298388|OTHER|study of socioeconomic and demographic variables|
219509041|NCT00094302|DRUG|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
219509042|NCT00094302|DRUG|Placebo|Placebo of spironolactone
219509043|NCT04852003|DRUG|SHR0410 Injection|SHR0410 Injection
219509044|NCT04852003|DRUG|Placebo|Placebo for SHR0410 Injection
219509045|NCT04852003|DRUG|Morphine|Morphine
219509046|NCT06354803|OTHER|proprioceptive training|Proprioceptive training using swiss ball for 12 sessions
219509047|NCT00005520|DRUG|Hydrochlorothiazide|
219509048|NCT00005520|DRUG|Candesartan|
219509049|NCT03881826|OTHER|collection of clinical data and biological samples|"* nutritional assessement~* cachexia symptoms~* urine, feces and blood samples"
219509050|NCT03056326|DRUG|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
219509051|NCT03056326|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
219509052|NCT03056326|DRUG|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
219509053|NCT03056326|DRUG|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
219509054|NCT01928914|DRUG|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
219509055|NCT01928914|DRUG|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
219509056|NCT01928914|DRUG|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
219509057|NCT01928914|DRUG|moxifloxacin|moxifloxacine given on Day 3 only
219509058|NCT01928914|DRUG|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
219509059|NCT01928914|DRUG|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
219509060|NCT04561310|OTHER|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
219203108|NCT06997185|OTHER|Statement communicating uncertainty with limited study duration|Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
218889816|NCT03838081|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
218889817|NCT03688516|BEHAVIORAL|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
218889818|NCT03688516|BEHAVIORAL|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
218889819|NCT03688516|BEHAVIORAL|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
218889820|NCT03124836|DEVICE|Pulse Oximeter Sensor|
218889821|NCT00003154|DRUG|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
218889822|NCT05377619|DRUG|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
218889823|NCT05377619|DRUG|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
218889824|NCT05377619|DRUG|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
218889825|NCT00646425|DRUG|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
218889826|NCT00646425|DRUG|Placebo|Placebo to match basiliximab
218889827|NCT01902329|DRUG|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
219509061|NCT04561310|OTHER|Active release technique|"Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
219509062|NCT06201481|PROCEDURE|anterior and posterior full coverage crowns|Teeth preparation,crown fitting and cementation
219509063|NCT06302855|DIAGNOSTIC_TEST|dental expertise|dental visit based on dental expertise
218889828|NCT01902329|DRUG|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
218889829|NCT03715244|PROCEDURE|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery \< 90 minutes
218889830|NCT03715244|PROCEDURE|General anesthesia (current standard)|General anesthesia in patients with duration of surgery \< 90 minutes
218889831|NCT03827525|BEHAVIORAL|Cognitive and Behavioral Therapy|9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
218889832|NCT04975776|BEHAVIORAL|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
218889833|NCT04975776|BEHAVIORAL|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
218889834|NCT02735343|DRUG|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
218889835|NCT02735343|DRUG|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
218889836|NCT00637416|DRUG|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
218889837|NCT00637416|OTHER|Placebo|placebo taken by mouth daily for 3 months
218889838|NCT00311883|DRUG|hydroxychloroquine|
218889839|NCT03852667|BEHAVIORAL|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
218889840|NCT03852667|OTHER|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
218889841|NCT02563236|OTHER|Parabolic flight|
218889842|NCT02595619|DEVICE|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
218889843|NCT05842148|OTHER|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
218889844|NCT05842148|OTHER|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
218889845|NCT05842148|OTHER|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
218889846|NCT01804881|BEHAVIORAL|Lifestyle counseling|Six week program to address problematic eating
218889847|NCT01389869|BIOLOGICAL|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
218889848|NCT01389869|BIOLOGICAL|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
219032926|NCT07167212|OTHER|Diaphragm Training|The diaphragm serves dual roles in respiration and postural control, yet its contribution is often overlooked in core stability exercise (CSE) programs for low back pain (LBP) rehabilitation. Abdominal hollowing, or the 'tummy tuck,' targets TrA and lumbar multifidus. Diaphragmatic breathing (DB) increases intra-abdominal pressure, contributing to lumbar stability. The intervention included four progressive weeks: Week 1-Supine and Crocodile breathing; Week 2-Supine and Crocodile with TheraBand; Week 3-Seated and 90/90/90 breathing; Week 4-Seated and 90/90/90 with TheraBand. Supine emphasized diaphragmatic expansion with resistance at the thoracolumbar junction; Crocodile focused on lateral rib expansion; Seated required upright posture with rib control; 90/90/90 integrated deep breathing with resisted stabilization. This study evaluates DB combined with CSE on pain, disability, muscle activity, and sleep quality in chronic LBP.
219032927|NCT07167212|OTHER|Myofascial Release Technique|The myofascial release technique for the diaphragm was performed with the participant lying supine and limbs relaxed. The therapist, positioned at the head, placed the pisiform, hypothenar, and last three fingers bilaterally under the seventh to tenth rib costal cartilages, forearms aligned toward the shoulders. During inspiration, gentle traction was applied cephalad and slightly laterally, accompanying rib elevation. On exhalation, pressure was directed inward along the costal margin to maintain resistance. With each breath, traction was gradually deepened to improve release. The maneuver consisted of two sets of 10 deep breaths with a 1-minute rest between sets. Figure 1 illustrates the manual diaphragm release technique (source: author's photo). This method, adapted from Rocha et al. (2015), emphasizes progressive traction and controlled resistance to facilitate diaphragmatic mobility and rib cage expansion.
219032928|NCT07169929|OTHER|Measurement of fetal transverse thalamic diameter by 2dimensional abdominal ultrasound|"All pregnant women attending the feto-maternal unit with gestational age from 18 weeks to 36 weeks in the obstetrics and gynecology department in the faculty of medicine Cairo university Using curvilinear 2D transabdominal ultrasound probe of ultrasound machine either Voluson E10 GE or Nuewa I9 Elite Mindray.~The investigators will take all the biometry (Biparietal diameter, head circumference, abdominal circumference, femur length and trans-cerebellar diameter) and exclude any congenital anomalies in the scan.~Transverse thalamic diameter is to be measured by 2D ultrasound at the standard axial trans-cerebellar plane. A guitar shape representative structure is presented to demarcate the thalamic diameter.~Calculate the gestational age using transverse thalamic diameter from this equation Transverse thalamic Diameter( in mm)=0.912 x Gestational age in weeks -1.134) ( Sridar P, et al 2020)"
219032929|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
219032930|NCT02376946|DEVICE|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
219032931|NCT02376946|DEVICE|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
219032932|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
219032933|NCT03425812|DRUG|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
219032934|NCT03425812|DRUG|To continue NSAIDs therapy|NSAIDs therapy will be continued.
219509064|NCT00796237|DEVICE|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
219509065|NCT00796237|OTHER|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
219509066|NCT00337805|OTHER|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
219203109|NCT06997185|OTHER|Statement communicating uncertainty with a limited study population|Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
219608366|NCT06582979|BEHAVIORAL|Computer-Based Game Therapy|Computer-based game intervention will be done three times a week, every morning before school lessons begin or during break time. Researchers will give a brief explanation of the rules on how to play the game before the intervention begins. In the game, participants will act as a fruit truck delivery driver and will have to sort out fruit delivery to different houses according to the instructions of the game. For example, the instruction starts with delivering a yellow-colored banana to a house with a red-colored roof, or delivering a purple-colored grape to a house with a blue-colored roof. Participants will first have to finish a minimum of three tutorial rounds reaching ≥75% correct delivery. Instructions will be divided into four stages; visual stimulus, auditory stimulus, visual stimulus with an obstacle, auditory stimulus with an obstacle. Each round will last for 2 minutes. Total time needed to complete a single computer-based intervention session is around 30-45 minutes.
219203110|NCT06997185|OTHER|Statement communicating uncertainty with an unvalidated surrogate endpoint|Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
219608367|NCT06582979|BEHAVIORAL|High-Intensity Interval Training|HIIT will be done two times a week during physical education hours (in the school's sports field) led by the school's physical education teacher and also certified physical trainers who have undergone training supervised by a sports medicine physician. Before the start of each HIIT session, participants will have their pulse rate assessed with a pulse oximetry and then undergo warm-up for 5 minutes. The duration of each HIIT session will be continuously extended starting at around 4 minutes (1 tabata block/8 moves) during the first week to 8 minutes (2 tabata block/16 moves) during the final week. A single tabata block moveset incorporates 8 total moves; squat jump, push up, high skipping, burpees, isometric front plank, multi jumps on bench, mountain climber in hand plank and lateral sprint (5m). Each move will be done for 20 seconds, followed by a 10 second rest. Pulse rate will be assessed again after the HIIT session and then participants will undergo cooling down and relaxation.
218889849|NCT01389869|BIOLOGICAL|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
218889850|NCT01389869|BIOLOGICAL|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
219032935|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
219032936|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
219032937|NCT03689361|COMBINATION_PRODUCT|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
219032938|NCT03689361|DIAGNOSTIC_TEST|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
219032939|NCT03689361|OTHER|telephone consultation|telephone consultation
219032940|NCT03898349|OTHER|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
219203111|NCT06997185|OTHER|Statement communicating uncertainty with treatment effect size|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
219203112|NCT06996093|DRUG|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
219203113|NCT06996093|DRUG|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
219203114|NCT06997861|OTHER|Medication Review Type III|The MR arm will receive four MR interviews. In the first MR, information about the patient's personal and medical history, along with current health problems, relevant lab exams and medication will be gathered. This will be used to proceed with medication review process and assessment of Drug Related Problems (DRP) that may lead to negative medication results. A personalized care plan will be developed to correct any detected DRP, delivered in writing/e-mail to the patient and carefully explained. Some DRP's may need the physician's intervention to correct. In these cases, a detailed recommendation will be sent to the patient's physician via email. All physicians' recommendations acted upon or not, will be recorded. Subsequent interviews will assess patient compliance with the care plan and if necessary, adjustments will be made accordingly.
219509067|NCT03191721|PROCEDURE|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
218889851|NCT01443702|DRUG|Lapis Judaicus|2 g capsule per day.
218889852|NCT01443702|DRUG|Placebo|2 g capsule per day.
219032941|NCT03898349|OTHER|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
218889853|NCT06236386|OTHER|VR Experience|VR headset and video experience.
218889854|NCT04635917|OTHER|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
219032942|NCT03898349|OTHER|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
218889855|NCT04635917|OTHER|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
219032943|NCT03606681|DRUG|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
219032944|NCT03606681|DRUG|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
219032945|NCT03606681|DRUG|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
219032946|NCT06164132|OTHER|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
219032947|NCT06361628|BEHAVIORAL|multicomponent intervention on vaccination awareness|Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
219203115|NCT06997861|OTHER|Usual Care|The UC arm will receive an intervention by the investigator at the same time frame defined for the MR arm. The intervention will also consist of interviews, although MR will not be conducted. The investigator will ask questions to the patient about is drug therapy in a similar fashion to what would happen in the community pharmacy. Simple advice and information will be carried out (i.e., reinforcement of adherence, explanation about indication of drugs etc.)
219203116|NCT06997588|DRUG|Alpelisib|"Oral Film-Coated Tablet (FCT):~* Group 1: 250 mg once daily~* Group 2, 6 to \<18 years: 125 mg once daily (starting dose)~Granules:~• Group 2, 2 to \<6 years: 50 mg once daily (starting dose)"
219203117|NCT06855433|DRUG|Colchicine Pill|Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily
219509068|NCT03191721|PROCEDURE|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
219509069|NCT03191721|PROCEDURE|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
219509070|NCT03191721|DRUG|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
219608368|NCT05509517|DIAGNOSTIC_TEST|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
219032948|NCT05527431|DEVICE|high flow nasal cannula|high flow nasal cannula
219032949|NCT05527431|DEVICE|noninvasive ventilation|noninvasive ventilation
218889856|NCT06149078|DIAGNOSTIC_TEST|serum uric acid|to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
219032950|NCT01023581|DRUG|Alogliptin|Alogliptin tablets.
219032951|NCT01023581|DRUG|Metformin|Metformin capsules
219032952|NCT01023581|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets.
219032953|NCT01023581|DRUG|Metformin Placebo|Metformin placebo-matching capsules.
219032954|NCT00763074|BEHAVIORAL|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~\----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day"
219032955|NCT00763074|BEHAVIORAL|Diet restriction|"Education for diet and exercise every 2 weeks~\----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
219032956|NCT00763074|BEHAVIORAL|Exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
219203118|NCT06855433|DRUG|Placebo|Placebo capsule, taken by mouth once daily
219203119|NCT06856993|PROCEDURE|standardized medical care of cardiac arrest|The standardized medical care for cardiac arrest includes early cardiopulmonary resuscitation (CPR), defibrillation, advanced cardiac life support (ACLS), post-resuscitation care, and continuous monitoring of the patient's vital functions.
219509071|NCT03191721|DRUG|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
219608369|NCT02641652|DRUG|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
219608370|NCT02641652|DRUG|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
219608371|NCT04676360|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
218889857|NCT02411019|BIOLOGICAL|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
218889858|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
218889859|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
218889860|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
218889861|NCT05929287|PROCEDURE|Tablet-based CT|This group will perform digital CT tasks.
219032957|NCT00763074|BEHAVIORAL|Diet and exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise education like as exercise group and diet education like as diet group"
219509072|NCT03191721|PROCEDURE|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
219032958|NCT00803881|OTHER|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
219032959|NCT03339609|DIAGNOSTIC_TEST|Uroflow|Isolated uroflow measurement
219032960|NCT03339609|DIAGNOSTIC_TEST|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
219509073|NCT05107284|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
219509074|NCT05107284|BEHAVIORAL|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
219032961|NCT03339609|DIAGNOSTIC_TEST|US|Ultrasound of post void residual urine
219032962|NCT02280174|DRUG|linagliptin|linagliptin 5 mg/d for12 weeks
219032963|NCT06310577|DEVICE|Leak-free bronchoscope adapter|Bronchoscopy using both a standard adapter and a leak-free adapter will be performed.
219032964|NCT03568357|PROCEDURE|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
219032965|NCT01468766|OTHER|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
218889862|NCT05929287|PROCEDURE|Paper-and-pencil CT group|This group will perform paper-and-pencil CT tasks.
218889863|NCT04449510|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
218889864|NCT06559826|DRUG|Ketamine|Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
218889865|NCT06559826|BEHAVIORAL|Psychotherapy|Each week following KAP, there will be a separate 60-minute integration session 1-6 days afterwards. Integration sessions will focus on processing experiences and material that emerged in KAP sessions (such as assimilating challenging experiences, making meaning of experiences and imagery, working through memories and emotions, and exploring emerging relational patterns) as well as strengthening insights. Within one week of the completion of all KAP sessions, there will be one additional integration session focused on consolidating the insights and improvements gained from KAP treatment.
218889866|NCT06174129|OTHER|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
218889867|NCT04891133|DRUG|Baricitinib|4 mg baricitinib (2 tablets of 2 mg) once daily
218889868|NCT04891133|DRUG|Placebo|4 mg placebo (2 tablets of 2 mg) once daily
218889869|NCT04444466|DRUG|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
219032966|NCT01468766|OTHER|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
218889870|NCT04444466|OTHER|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
219032967|NCT02975921|DRUG|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
219032968|NCT04115943|OTHER|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
219032969|NCT04115943|OTHER|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
218889871|NCT01493973|DRUG|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
218889872|NCT01493973|DRUG|Placebo|Placebo
219032970|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
219203120|NCT06858098|OTHER|Exercise programme|6 week pre-operative graded prehabilitation programme, delivered by video and performed by participant up to 4 times a week at home or in a gym setting
219032971|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
219509075|NCT01127490|DRUG|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
219509076|NCT01127490|PROCEDURE|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
219608372|NCT04710615|DEVICE|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
219608373|NCT03513991|OTHER|Infant formula|
219608374|NCT02295501|BIOLOGICAL|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
219608375|NCT04812301|RADIATION|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
219032972|NCT02008448|PROCEDURE|Pulmonary vein isolation|
219032973|NCT02008448|PROCEDURE|Linear Lesion Ablation|
219032974|NCT02008448|DRUG|BT injection|
219032975|NCT03483935|OTHER|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
219032976|NCT02674620|OTHER|Aerobic Exercise|Patients are treated with progressive exercise
219032977|NCT02693574|DRUG|Clarithromycin|
219032978|NCT02693574|DRUG|Levofloxacin|
219032979|NCT03571087|DRUG|HL140 5/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032980|NCT03571087|DRUG|HL140 10/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032981|NCT03571087|DRUG|HL140 20/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032982|NCT03571087|DRUG|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032983|NCT03571087|DRUG|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032984|NCT03571087|DRUG|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
219032985|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
219203121|NCT06858098|DEVICE|Wearable smart device|Participants will wear a wearable smart device (wrist or ring worn) for a period for 14 weeks; 2 weeks prior to prehabilitation, 6 weeks during pre-operative prehabilitation and 6 weeks post operative monitoring,
219509077|NCT03942510|OTHER|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
219608376|NCT04812301|RADIATION|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
219608377|NCT02595801|OTHER|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
219608378|NCT03845192|DEVICE|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
219608379|NCT02771769|OTHER|blood draw|Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
219608380|NCT01811472|DRUG|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
219608381|NCT01811472|DRUG|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
219608382|NCT05664269|DIETARY_SUPPLEMENT|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
219608383|NCT05664269|BEHAVIORAL|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
218889873|NCT04339673|PROCEDURE|masseteric nerve block|regional bloc of masseter
218889874|NCT04339673|PROCEDURE|trigger point injection|trigger point injection with local anesthetic
218889875|NCT04339673|PROCEDURE|dry needling|needling with acupuncture needles of trigger points in masseter
219032986|NCT02242838|DRUG|Telmisartan|
219032987|NCT01462669|DRUG|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
219509078|NCT02319681|BEHAVIORAL|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
219509079|NCT02319681|BEHAVIORAL|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
219509080|NCT00784212|DRUG|BGG492|
219608384|NCT03505086|DIAGNOSTIC_TEST|Blood withdrawal|"* Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular."
219509081|NCT00784212|DRUG|BGG492|
219509082|NCT00784212|DRUG|Placebo|
219509083|NCT03548714|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
219509084|NCT03548714|OTHER|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
219509085|NCT02203136|PROCEDURE|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
219608385|NCT03505086|OTHER|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
218889876|NCT05710042|DEVICE|Revivent TC System|The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.
218889877|NCT00135889|DRUG|Femoral perineural infusion|
218889878|NCT04806074|BEHAVIORAL|Experimental Group|Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
218889879|NCT04806074|BEHAVIORAL|Comparison Group|Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
219032988|NCT01462669|DRUG|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
219032989|NCT01462669|DRUG|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
219032990|NCT01462669|DRUG|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
219032991|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
219032992|NCT03532464|DRUG|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
219032993|NCT03532464|DRUG|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
219032994|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
219032995|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
219032996|NCT00024089|DRUG|gefitinib|
219032997|NCT03570866|DIAGNOSTIC_TEST|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
219608386|NCT03280264|DRUG|KHK7580|oral administration
219613299|NCT04703595|GENETIC|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
219203122|NCT06861985|DEVICE|BOBY|high-frequency multi-band harmonic electromagnetic stimulation device
219203123|NCT06861985|OTHER|Control|placebo group
219509086|NCT02203136|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
219032998|NCT03570866|PROCEDURE|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
219032999|NCT04920123|DEVICE|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
219033000|NCT05828446|DEVICE|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
219033001|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
219033002|NCT06450171|OTHER|GRAIL Galleri Test|A multi-cancer early detection (MCED) blood test.
219203124|NCT06674486|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).
219033003|NCT06343311|BIOLOGICAL|EB103|EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
219033004|NCT00136149|PROCEDURE|Immediate implants|Immediate implants are used.
219033005|NCT06116331|OTHER|Data collection|Participants will answer questionnaires and submit stool samples.
219203125|NCT06674486|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
219203126|NCT03032588|BIOLOGICAL|sIPV|Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.
219203127|NCT03032588|BIOLOGICAL|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
219203128|NCT06494878|DRUG|Aspirin|75-100 mg taken once daily by mouth.
219203129|NCT06494878|DRUG|Low-molecular-weight heparin|Low-molecular-weight heparin injections daily as prescribed by the treating physician.
219608387|NCT05855603|PROCEDURE|Cardioneuroablation|"Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase \>20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase \<10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response."
219608388|NCT05855603|DEVICE|Permanent pacemaker therapy|All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
219608389|NCT02574832|DRUG|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
219608390|NCT01248676|OTHER|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
219033006|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
219033007|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
219033008|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
219033009|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
219033010|NCT06203639|OTHER|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
219203130|NCT06606405|DIAGNOSTIC_TEST|scapular dyskinesis test|Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
219203131|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
218889880|NCT05178602|BEHAVIORAL|Tai Chi Intervention Group|Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
219033011|NCT06203639|OTHER|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
219033012|NCT03679910|DIAGNOSTIC_TEST|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
219033013|NCT03679910|DIAGNOSTIC_TEST|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
219033014|NCT03395158|DIAGNOSTIC_TEST|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
219033015|NCT04713124|BEHAVIORAL|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
219203132|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
219509087|NCT03717766|DEVICE|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
219608391|NCT02071030|PROCEDURE|Third molar removal|Surgically removing the third molar in the lower jaw
219608392|NCT06033391|DEVICE|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|"GGOC was originally designed to challenge maladaptive beliefs that underline OCD symptoms in adult population. It was adapted to adolescent population. It consists of statements that are presented to the user, and that can portray either negative (I can't trust myself) or positive beliefs (I have a lot of good characteristics). Users have to respond by either pulling these towards Accept or Reject."
219613300|NCT05832203|OTHER|Counseling on planetary health diet with calorie restriction|Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
218889881|NCT05622565|DIAGNOSTIC_TEST|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
218889882|NCT05154526|OTHER|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
219033016|NCT04713124|OTHER|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
219033017|NCT03231787|DIAGNOSTIC_TEST|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
218889883|NCT05154526|OTHER|Exercise Program|Exercise program
218889884|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
218889885|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
218889886|NCT00234923|DRUG|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
218889887|NCT00234923|DRUG|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
218889888|NCT05349357|OTHER|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
218889889|NCT05349357|OTHER|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
218889890|NCT05349357|OTHER|Stretching exercises|Stretching exercises
218889891|NCT05349357|DEVICE|TENS|TENS
218889892|NCT02204072|DRUG|BI 836845|
218889893|NCT02204072|DRUG|Enzalutamide|
218889894|NCT02204072|DRUG|Enzalutamide|
218889895|NCT03319134|DEVICE|active anodal HD-tDCS|1\) active anodal HD-tDCS with memory task
219509088|NCT02611284|PROCEDURE|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
219509089|NCT02611284|PROCEDURE|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
218889896|NCT03319134|DEVICE|sham HD-tDCS|2\) sham HD-tDCS with memory task
218889897|NCT03319134|DEVICE|active cathodal HD-tDCS|3\) active cathodal HD-tDCS with memory task
218889898|NCT02428569|BEHAVIORAL|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
218889899|NCT05888987|BIOLOGICAL|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
219203133|NCT00071708|DRUG|Duloxetine Hydrochloride|
218889901|NCT05710549|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
218889902|NCT05710549|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
218889903|NCT06976814|OTHER|Neuro muscular electrical stimulation|electrical stimulation to facial nerve to improve facial palsy
218889904|NCT06976814|OTHER|Beckmann's oral motor exercises|Oral motor exercises to improve facial palsy.
218889905|NCT06975150|DRUG|HK-660S 100mg|Administered orally
218889906|NCT06975150|DRUG|HK-660S 200mg|Administered orally
218889907|NCT06975150|DRUG|Placebo|Administered orally
218889908|NCT06975514|DRUG|YZJ-1139|YZJ-1139 20mg tablets, once daily in the evening
218889909|NCT06975514|DRUG|Zolpidem|Zolpidem 10mg tablets, once daily in the evening
218889910|NCT06976177|DRUG|MT1013|MT1013 is a novel calcimimetic agent
218889911|NCT06977035|DEVICE|Nerve Conduction Study|Sensory and Motor Nerve Conduction study on upper and lower limbs.
218889912|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
218889913|NCT06603012|BEHAVIORAL|GET Up PD|"* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-3 sets, 8-12 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GET Up PD program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
218889914|NCT06603012|BEHAVIORAL|Stretching and Flexibility|"* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GET Up PD program, and account for activity, social-contact, and attention.~* Other components of the Stretching and Flexibility program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GET Up PD program."
218889915|NCT06584357|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
218889916|NCT06584357|RADIATION|MK6240|Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
218889917|NCT06990737|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Participants will have SLNs excised from the affected area(s) per standard of care
219509090|NCT04669821|DRUG|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
219509091|NCT04669821|DRUG|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
218889918|NCT06990737|PROCEDURE|Lymphadenectomy|Surgeon preference will dictate the order of the surgery for resecting the primary tumor. Elective neck dissection (END) will include nodal basins based on the primary site of disease, at-risk nodal basins, and any additional dissection per the surgeon's discretion. In the event of a positive SLN, the completion neck dissection (CND) should be completed.
218889919|NCT06990737|DRUG|Adjuvant Definitive Therapy|Use of chemotherapy will depend on the specific phase of treatment and high-risk features as per standard of care and NCCN Head and Neck Cancer-Clinical Practice Guidelines in Oncology
218889920|NCT06999304|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Intermittent theta burst - Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Continuous theta burst - Number of pulses per session: 1800 pulses; Pulse frequency in burst: 50 Hertz
218889921|NCT06999928|BEHAVIORAL|Enhanced Mentor Mother Strategy|The enhanced Mentor Mother strategy introduces a structured approach to differentiated PMTCT support, led by trained peer counselors/Mentor Mothers (MM). Mentor Mothers will be trained on how to perform risk stratification, and they will use a standardized form to identify and document psychosocial and clinical risk factors. Based on these, MMs then deliver tailored interventions, including additional counseling, community outreach, and referrals. Fidelity assessments and a process of audit and feedback will be used to further refine the strategy, which builds on national differentiated service delivery guidelines and integrates into routine care without requiring added clinic staff.
218889922|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
218889923|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT)|This application includes rehabilitation methods frequently used in pediatric rehabilitation.
219033018|NCT03343184|PROCEDURE|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
219033019|NCT03343184|PROCEDURE|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
219033020|NCT03343184|PROCEDURE|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
219033021|NCT03343184|PROCEDURE|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
219033022|NCT00278954|BIOLOGICAL|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
219033023|NCT00351260|PROCEDURE|Coronary Angioplasty|
219033024|NCT01147861|DRUG|GSK256073|5mg in the AM and 5mg in the PM
219033025|NCT01147861|DRUG|GSK256073|10mg in the AM
219033026|NCT01147861|DRUG|GSK256073|50mg in the AM
219033027|NCT01147861|DRUG|GSK256073|25mg in the AM and 25mg in the PM
219033028|NCT01147861|OTHER|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
219033029|NCT01370226|BEHAVIORAL|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
219509092|NCT03657979|DRUG|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
219033030|NCT01370226|BEHAVIORAL|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
219033031|NCT03930888|DIETARY_SUPPLEMENT|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
219509093|NCT03657979|DRUG|Placebo|TAP-block with placebo
219509094|NCT02089542|OTHER|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
219509095|NCT05126875|RADIATION|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
218889924|NCT07001449|BEHAVIORAL|Pain Neuroscience Education with Communication Training|"This intervention includes individualized physiotherapy based on a Pain Neuroscience Education (PNE) framework delivered by physiotherapists who completed the full Algo(S)Therapy training program. The training includes education in the neurophysiology of pain, clinical reasoning for chronic musculoskeletal pain management, and structured communication skills development (e.g., motivational interviewing, empathy, active listening). The intervention is delivered twice per week over 5 weeks (10 sessions total)."
219033032|NCT06317753|BEHAVIORAL|Aerobic Exercise|Participants allocated to the Aerobic condition will be following a 4 month-intervention aerobic exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
219033033|NCT06317753|BEHAVIORAL|Agility-Cognitive Exercise|Participants allocated to the Agility-Cognitive condition will be following a 4 month-intervention agility-cognitive exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
219033034|NCT06317753|BEHAVIORAL|Stretching/relaxation|Participants allocated to the stretching control condition will be following a 4 month-intervention protocol of 1 weekly session with a 50 minutes duration
219033035|NCT00324467|DRUG|Cyclophosphamide|"Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
219033036|NCT00324467|DRUG|Doxorubicin|"Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
219203134|NCT06997380|DEVICE|Injection of the investigational product via needle|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via needle
219203135|NCT06997380|DEVICE|Injection of the investigational product via cannula|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via cannula
218889925|NCT07001449|BEHAVIORAL|Pain Neuroscience Education without Communication Training|"A structured PNE program focusing on the neurophysiology and clinical management of chronic musculoskeletal pain. Delivered by physiotherapists trained only in the scientific modules of the Algo(S)Therapy program. Does not include communication skills training. Includes 10 sessions (2/week for 5 weeks), alongside standard physiotherapy care."
218889926|NCT07001449|BEHAVIORAL|Usual Physiotherapy Treatment|"Usual care based on medical referral and physiotherapy assessment. Delivered by physiotherapists who have not received training in Pain Neuroscience Education or communication techniques. No components of the Algo(S)Therapy program are included."
219033037|NCT00324467|DRUG|Vincristine|"Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
219033038|NCT00324467|DRUG|Prednisone|"Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
219033039|NCT00324467|DRUG|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
219033040|NCT00324467|DRUG|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
219033041|NCT00324467|DRUG|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
219033042|NCT00324467|DRUG|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
219033043|NCT00324467|DRUG|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
219033044|NCT00324467|DRUG|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
219033045|NCT00324467|DRUG|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
219033046|NCT00324467|DRUG|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
219033047|NCT00324467|DRUG|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
219033048|NCT00324467|DRUG|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
219033049|NCT00324467|DRUG|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
219033050|NCT00324467|DRUG|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
219033051|NCT00324467|DRUG|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
219203136|NCT06997380|PROCEDURE|Clinical assessment|Clinical assessment of facial skin condition
219203137|NCT06997380|PROCEDURE|Ultrasound measurement|Ultrasound measurement of facial skin thickness
219203138|NCT06997380|PROCEDURE|Multispectral imaging|Multispectral imaging and analysis of facial skin
219203139|NCT03343431|DRUG|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
219203140|NCT06528990|BEHAVIORAL|Telehealth Intervention|This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.
219203141|NCT06528990|OTHER|Standard of care|standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
218889927|NCT03427749|DIAGNOSTIC_TEST|SPECT Imaging with 99mTc-Tetrofosmin Research Imaging|This is an observational study; patients will be managed according to the standard clinical care of the local site. Study end will be defined as completion of all SPECT imaging at rest and stress. Studies will be acquired at 6 initial sites with mixed prior experience at MBF imaging, to demonstrate feasibility of use in a clinical setting.
218889928|NCT06867991|DRUG|Ofatumumab combined with daratumumab|All participants will begin acute first-line therapy prior to randomization, and participants who were receiving oral or intravenous corticosteroids at baseline will need to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Patients will be randomly assigned to receive ofatumumab followed by daratumumab or ofatumumab followed by repeated intravenous globulin. The ofatumumab group will receive subcutaneous ofatumumab at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24, while the ofatumumab-daratumumab group will receive daratumumab intravenously (on the second day of ofatumumab) in addition to ofatumumab, with a dose of 8 mg/kg at weeks 0, 1, 2, and 4, and a dose of 4 mg/kg at weeks 8, 12, 16, 20, and 24. The study will investigate the effects of up to 24 cycles of daratumumab.
218889929|NCT06867991|DRUG|Ofatumumab|All participants were started on acute first-line therapy before randomization, and participants who were receiving oral or intravenous glucocorticoids at baseline were required to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Ofatumumab was administered subcutaneously at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24 in the ofatumumab group.
218889930|NCT06867991|DRUG|Repeated intravenous immunoglobulin/plasma exchange therapy|Repeated intravenous immunoglobulin/plasma exchange therapy
218889931|NCT07009626|OTHER|Computer-based high-validity birth simulator|Computer-based high-validity birth simulator: All students in the intervention group underwent the same scenario of birth. Initially, the aim was to diagnose shoulder dystocia by ensuring that the shoulders were not delivered after the fetal head was delivered.
218889932|NCT07008105|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain through reframing thoughts and encouraging behavioral change.
218889933|NCT07008105|BEHAVIORAL|Pain Reprocessing Therapy|PRT advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and bodily injury and providing education on the neuroscience of pain.
219033052|NCT00324467|DRUG|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
219509096|NCT00006170|DRUG|Bupropion|smoking cessation medication aid
219509097|NCT00006170|DRUG|Placebo|A matched placebo pill
219033053|NCT00324467|OTHER|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
219033054|NCT01725425|OTHER|Control|The control is designed to determine average mood.
219033055|NCT01725425|OTHER|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
219033056|NCT01725425|OTHER|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
219033057|NCT01725425|OTHER|Mixed Portions|The purpose is to determine if a change in mood will occur.
219033058|NCT02255370|DRUG|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
219033059|NCT04193722|DRUG|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
219033060|NCT04196140|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
218889934|NCT07008105|BEHAVIORAL|Emotion Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
219033061|NCT06180447|BIOLOGICAL|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
219509098|NCT00006170|BEHAVIORAL|weight concerns intervention|cognitive behavioral treatment to address weight concners
219509099|NCT00006170|BEHAVIORAL|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
219509100|NCT04449042|PROCEDURE|airway management during sedation or general anesthesia|airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
219033062|NCT05042947|DEVICE|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
219033063|NCT05042947|DEVICE|Titanium Clip|the Titanium Clip
219033064|NCT06484712|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
219033065|NCT05900440|OTHER|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
219509101|NCT05965193|DEVICE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
219509102|NCT05965193|DEVICE|Nasal oxygen|For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
219509103|NCT05965193|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
219203142|NCT04178915|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
219203143|NCT04178915|DIAGNOSTIC_TEST|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
219203144|NCT06618417|DEVICE|sleep apnea home-evaluation|Participants will receive a home-monitoring device by mail to test for sleep apnea at home
219203145|NCT03283137|DRUG|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
219203146|NCT03283137|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
219203147|NCT06685536|OTHER|Safety and efficacy assessments|Safety evaluations,disease-specific assessments,and assessments to monitor for long-term complications of autologous transplant
219203148|NCT05475600|BEHAVIORAL|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
219203149|NCT05475600|BEHAVIORAL|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
219203150|NCT05475600|BEHAVIORAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
219203151|NCT03861676|RADIATION|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
219509104|NCT01205698|OTHER|Nutritional drink|
219509105|NCT00793728|PROCEDURE|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
219509106|NCT00543361|DRUG|MK0767|Duration of Treatment: 52 Weeks
218889935|NCT06867497|DRUG|BR2021|intravenous administration for 30 minutes
218889936|NCT06867497|DRUG|BR2021-1|intravenous administration for 30 minutes
218889937|NCT07010341|DIAGNOSTIC_TEST|ntra-operative Indocyanine Green (ICG) Fluorescence Quantification|After a single intravenous bolus of indocyanine green (25 µg/kg), a near-infrared sensor records raw fluorescence intensity from the superior parathyroid gland and the ipsilateral common carotid artery at 60-120 seconds. No images are stored; only peak intensity values are logged to calculate the perfusion ratio R = PTG / CCA. The measurement is observational, adds ≤2 minutes to operative time, and involves no therapeutic intent.
218889938|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
218889939|NCT06491238|BEHAVIORAL|Light Intensity Exercise|12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
218889940|NCT06491238|BEHAVIORAL|Moderate Intensity Exercise|12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
218889941|NCT04205838|BIOLOGICAL|Anakinra|Given SC
218889942|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
219033066|NCT05900440|OTHER|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
218889943|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
218889944|NCT04205838|DRUG|Fludarabine|Given via infusion
218889945|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
219033067|NCT04534010|DEVICE|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
219203152|NCT03861676|DRUG|(18F)DCFPyL|18F-DCFPyl PET/CT scan
219509107|NCT00543361|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
219509108|NCT00543361|DRUG|Comparator: metformin|Duration of Treatment: 52 Weeks
219509109|NCT02058628|DRUG|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
219509110|NCT02058628|DRUG|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
219509111|NCT01225328|BEHAVIORAL|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
219509112|NCT01006668|DRUG|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
219509113|NCT01006668|DRUG|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
219509114|NCT03355742|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
219509115|NCT03355742|DRUG|DAPT|1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
219203153|NCT04494958|DRUG|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
219203154|NCT05292404|DRUG|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
219203155|NCT05292404|OTHER|conventional treatment|conventional treatment were given according to international uniformguidelines
219203156|NCT05826002|BEHAVIORAL|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
219203157|NCT05812781|DRUG|VTX2735|Dose A
218889946|NCT06725979|DEVICE|maxillary expansion using hyrax expander|The rapid expansion of the upper jaw will be performed using palatal expander with hyrax screw, which will be activated 2x a day, until the needed width is reached (according to the cast analysis).
219203158|NCT05812781|DRUG|VTX2735|Dose B
218889947|NCT01397942|OTHER|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
219203159|NCT06430177|BEHAVIORAL|Su Jok|Su Jok will be done
219203160|NCT05930860|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
219203161|NCT05145868|BEHAVIORAL|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
218889948|NCT04379401|DEVICE|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
218889949|NCT00601549|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery
218889950|NCT00601549|PROCEDURE|Traditional open surgery|Open surgery
218889951|NCT02562859|DRUG|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
218889952|NCT02562859|DRUG|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
218889953|NCT00338923|DRUG|HO/03/03|
218889954|NCT05128201|RADIATION|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
218889955|NCT03621657|DRUG|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
218889956|NCT03621657|DRUG|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
218889957|NCT03621657|DRUG|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
218889958|NCT00999544|DRUG|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
218889959|NCT00999544|DRUG|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
218889960|NCT00999544|DRUG|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
218889961|NCT00999544|DRUG|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
218889962|NCT00999544|DRUG|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
218889963|NCT00999544|DRUG|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
218889964|NCT00999544|DRUG|Oxycodone 0mg, IN|Oxycodone 0mg, IN
218889965|NCT00999544|DRUG|Oxycodone 15mg, IN|Oxycodone 15mg, IN
218889966|NCT00999544|DRUG|Oxycodone 30mg, IN|Oxycodone 30mg, IN
218889967|NCT02601404|DEVICE|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
218889968|NCT00112632|DRUG|imatinib mesylate|
219203162|NCT05145868|OTHER|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
219203163|NCT04809363|OTHER|CDPATH™|Crohn's disease risk prediction tool.
219203164|NCT04809363|OTHER|Blood Draw|Three blood samples will be drawn.
219203165|NCT05035316|DRUG|acetylsalicylic acid|Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
219203166|NCT05035316|DRUG|Calcium|Oral tablet: calcium, 1 tablet/day
219203167|NCT04254484|BEHAVIORAL|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
219203168|NCT04254484|DIAGNOSTIC_TEST|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
219204489|NCT06761391|DIAGNOSTIC_TEST|Cervical Range of Motion|The degrees obtained as a result of the Range of Motion (ROM) measurements are made with a universal manual goniometer. Goniometer is still the most commonly used method for ROM measurements. For all ROM measurements to be performed, the necessary measurements can be taken based on the American Academy of Orthopaedic Surgeons (AAOS) guidelines . The flexion, extension, right and left rotation angles of the cervical region will be measured and recorded with the goniometer in the sitting position of the person. The measurement will be made twice, before and after the application.
219509116|NCT04661462|OTHER|online survey|We invite volunteers after COVID-19 to participate in an online survey.
219608393|NCT06033391|DEVICE|GGN-AD (GG Neutral - Adolescents)|"it was designed to have a comparison group. It consists of neutral statements such as Madrid is a Spanish city, that ought not to produce changes in the direction of our hypothesis. These have to be Accepted or Rejected based on their veracity."
219608394|NCT01043887|DRUG|ridaforolimus|single oral dose administration 10 mg ridaforolimus
219608395|NCT01377220|DRUG|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
219608396|NCT04030208|DEVICE|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
219608397|NCT04030208|DEVICE|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
218889969|NCT00112632|PROCEDURE|conventional surgery|
218889970|NCT00112632|PROCEDURE|neoadjuvant therapy|
218889971|NCT03196804|DRUG|LC28-0126|LC28-0126
218889972|NCT03196804|DRUG|Placebo|Placebo
218889973|NCT01827150|DRUG|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
218889974|NCT00574717|PROCEDURE|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
218889975|NCT04958369|DEVICE|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
218889976|NCT04958369|DEVICE|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
218889977|NCT06302582|BIOLOGICAL|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm
218889978|NCT06302582|OTHER|Control group|Standard therapy for patients with stage 3 and 4 stress injury
218889979|NCT05733858|DEVICE|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
218889980|NCT05733858|DEVICE|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
218889981|NCT05733858|DEVICE|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
218889982|NCT05733858|BEHAVIORAL|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
218889983|NCT03415204|OTHER|acupuncture|acupuncture for post operative pain
218889984|NCT05456737|OTHER|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
219203169|NCT06688279|OTHER|Plyometric Exercise|". The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
219613301|NCT05832203|OTHER|Counseling on balanced nutrition diet with calorie restriction|Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
218889985|NCT00199121|DRUG|Zidovudine (drug)|
218889986|NCT02688244|PROCEDURE|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
218889987|NCT02688244|PROCEDURE|No irrigation|Suction only, using suction device
218889988|NCT01387126|DIETARY_SUPPLEMENT|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
218889989|NCT05889715|OTHER|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
218889990|NCT04683835|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
219509117|NCT04530786|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
218889991|NCT06062979|DRUG|rilpivirine/cabotegravir|WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
218889992|NCT02697266|OTHER|No intervention|This is an observational study.
219203170|NCT06688279|OTHER|Standard exercises protocol|"The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
219203171|NCT06689943|DRUG|Tylenol|Tylenol for children
219509118|NCT05216614|DRUG|Fluvoxamine|Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
219203172|NCT04198701|DEVICE|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
219203173|NCT05190341|DRUG|Ibuprofen 800 mg oral|1 hour before HSG
219203174|NCT05190341|DRUG|Ketorolac 30mg oral|1 hour before HSG
219203175|NCT04733183|DRUG|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
219509119|NCT05216614|DRUG|Placebo|lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
219509120|NCT04141410|DRUG|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
219509121|NCT04141410|DEVICE|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
219509122|NCT06320379|DIETARY_SUPPLEMENT|Zypan|The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosol™ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals
219509123|NCT06320379|DIETARY_SUPPLEMENT|Placebo Comparator|The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%\*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)
219608398|NCT05938114|OTHER|Bonalive|Bonalive® is a bioactive glass synthetic bone substitute material that has been shown to have a low substitution rate and antibacterial properties. It has been used successfully in the orthopaedics, craniofacial and ear nose and throat (ENT) specialities for the treatment of osteomyelitis, sinusitis and bony cyst cavities. There have also been a few maxillofacial surgery case reports on its usage in the jaws.
219203176|NCT04733183|DRUG|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
219203177|NCT06681246|OTHER|Antibiotic treatment|10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day
219509124|NCT00855452|PROCEDURE|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
219608399|NCT05938114|OTHER|Bio-Oss®|Bio-Oss® is a bovine xenogeneic bone graft substitute that is widely used in regenerative dentistry. Bio-Oss® is very similar to human bone in its structure and chemical make-up. The material's porosity allows for vascularisation and new bone formation.
218889993|NCT04950361|OTHER|talocalcaneal coalition|patients with talocalcaneal coalition
219203178|NCT06681246|OTHER|Placebo|consist of a combination of agarose in normal saline/glycerol
219203179|NCT06681662|DRUG|Ephedrine Hydrochloride 30 mg/ml|0.15 mg/kg during induction.
219203180|NCT06681662|DRUG|Saline (NaCl 0,9 %) (placebo)|1 ml during induction.
219203181|NCT06681701|PROCEDURE|Combined Manual Therapy and Pulmonary Exercises|"Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"
219203182|NCT06679829|DRUG|Siltuximab|11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
219509125|NCT03957733|DRUG|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
219509126|NCT03588156|DRUG|Benapenem|Dose-escalation For 11 level dose groups A1 \~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
219509127|NCT03588156|DRUG|Placebo|Placebo
219509128|NCT04336956|OTHER|hospitalized children with Covid19|All patients under 18 years hospitalized with a covid19 diagnosis
219608400|NCT00295893|DRUG|cyclophosphamide|Given IV
219608401|NCT00295893|DRUG|docetaxel|Given IV
219608402|NCT00295893|DRUG|doxorubicin hydrochloride|Given IV
218889994|NCT02407223|DRUG|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
219509129|NCT00955032|DEVICE|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
218889995|NCT02407223|DRUG|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
219509130|NCT00955032|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
219509131|NCT05875415|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
219509132|NCT05875415|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
219033068|NCT06447493|OTHER|Osteopathic Manipulative Treatment-Spencer's Technique (Modified)|Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
219033069|NCT06447493|OTHER|Rest|10 minute rest period.
219033070|NCT05757687|DEVICE|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
219203183|NCT06679829|DRUG|Melphalan|"Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2"
219203184|NCT05797480|OTHER|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
219203185|NCT05797480|OTHER|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
219203186|NCT06872216|PROCEDURE|cupping therapy|After the initial vascular occlusion test and a subsequent 10-minute rest period, the plastic therapy cup was placed on the forearm, 5 cm away from the medial and lateral epicondyles by a certified cupping therapist. The size of used cup was determined according to the size of the volunteer's forearm which cover 50% of the area. The cup was vacuumed two times full pumping with a manual hand pump and remained in place for 5 minutes. And then the air was removed by releasing the cups through the release valve.
219364704|NCT02239822|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
219509133|NCT04527471|DRUG|Ensifentrine Dose 1|Study drug delivered twice daily via pMDI
219509134|NCT04527471|DRUG|Placebo pMDI|Placebo delivered twice daily via pMDI
219509135|NCT03244956|DRUG|Trametinib|2mg daily for a maximum of 6 weeks of treatment
219509136|NCT03244956|DRUG|Dabrafenib|150mg twice daily
219509137|NCT03244956|RADIATION|131I|5.5 GBq
219509138|NCT03244956|DRUG|rhTSH|0.9mg on two consecutive days after 35 days of treatment
219509139|NCT05313828|DRUG|Acyclovir|acyclovir 4 times /day
219509140|NCT05313828|DRUG|Tobramycin|tobramycin 4 times /day
219608403|NCT00295893|BIOLOGICAL|Trastuzumab|Given IV
219608404|NCT00295893|DRUG|Carboplatin|Given IV
219608405|NCT00295893|DRUG|Paclitaxel|Given IV
218889996|NCT02407223|DRUG|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
219509141|NCT05313828|DRUG|Fluorometholone|Fluorometholone 4 times/ day
219509142|NCT05313828|DRUG|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
219509143|NCT05432271|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
219509144|NCT05432271|BEHAVIORAL|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
218889997|NCT01845935|DEVICE|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
218889998|NCT04130607|OTHER|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
218889999|NCT01056939|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
218890000|NCT01056939|DEVICE|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
219509145|NCT05432271|BEHAVIORAL|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
219509146|NCT05432271|BEHAVIORAL|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
219033071|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
219033072|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
219033073|NCT06158191|BEHAVIORAL|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
219509147|NCT05432271|BEHAVIORAL|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
219509148|NCT05147454|OTHER|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
219509149|NCT03158298|OTHER|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
218890001|NCT02582645|PROCEDURE|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
218890002|NCT02582645|PROCEDURE|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
219033074|NCT04877249|BEHAVIORAL|Split-belt treadmill training|1\. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
219033075|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
219509150|NCT01753037|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
219509151|NCT01753037|OTHER|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
219509152|NCT05720871|DEVICE|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
219509153|NCT05720871|DEVICE|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
219608406|NCT00599365|OTHER|Pharmacy care arm|"* The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~* You will need to give a complete list of medications to the pharmacist.~* You will need to describe how you take these medications.~* The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~* The pharmacist will give you a medication schedule, and other papers about your medications."
218890003|NCT02507323|DRUG|ticagrelor|A platelet aggregation inhibitor
218890004|NCT02507323|DRUG|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
218890005|NCT02507323|DRUG|Placebo|placebo
218890006|NCT01459445|DRUG|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
218890007|NCT05342558|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcgs|Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
219033076|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
219033077|NCT06644144|OTHER|No Interventions|No intervention so not applicable.
219509154|NCT02721797|PROCEDURE|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
219033078|NCT05669820|DIETARY_SUPPLEMENT|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
219033079|NCT05669820|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
219509155|NCT06135285|DEVICE|Control subjects|The subject will be repositioned from the prone to recovery position
219509156|NCT04251182|DRUG|15mg T3D-959|Oral administration once daily in the morning
219509157|NCT04251182|DRUG|30 mg T3D-959|Oral administration once daily in the morning
219509158|NCT04251182|DRUG|45 mg T3D-959|Oral administration once daily in the morning
219509159|NCT04251182|DRUG|Placebos|Oral administration once daily in the morning
219509160|NCT03215173|BEHAVIORAL|Fit After Baby|Mobile application
219608407|NCT02550301|OTHER|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
219608408|NCT03514095|OTHER|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
219608409|NCT05193838|DRUG|Allopurinol Tablet|examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
218890008|NCT05342558|DRUG|Umeclidinium/Vilanterol 62.5/25 mcgs|Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
219033080|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
219033081|NCT04627701|DEVICE|Omega|Omega Implantation
218890009|NCT00858026|OTHER|Breastmilk|Exclusively breastfed babies
218890010|NCT00858026|OTHER|Standard milk|Weaning babies fed with the standard formula
219033082|NCT05664490|BEHAVIORAL|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
219033083|NCT06338189|OTHER|The 5Ad Diet|Participants are to follow the 5Ad diet.
219033084|NCT06338189|OTHER|The Low FODMAP Diet|Participants are to follow the active phase of the Low FODMAP diet.
219033085|NCT04733651|DRUG|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
219509161|NCT03215173|BEHAVIORAL|Text4Baby Control Group|Receive free text messages
219509162|NCT01466803|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
219509163|NCT01466803|DRUG|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
219509164|NCT04280172|OTHER|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
219509165|NCT04280172|OTHER|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
219509166|NCT00624767|DRUG|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
219509167|NCT00624767|DRUG|NovoLog|NovoLog at doses up to 30 IU
219509168|NCT03799601|DRUG|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
219509169|NCT03799601|DRUG|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
219509170|NCT03799601|DRUG|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
218890011|NCT00858026|OTHER|Fermented milk|Weaning babies fed with the fermented formula
218890012|NCT00905463|PROCEDURE|Lung transplantation|Lung transplantation
219509171|NCT03020472|BIOLOGICAL|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
219509172|NCT03636321|PROCEDURE|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
219509173|NCT01021995|DRUG|echinacea|drops, 0.9 ml, tid for 4 months
219509174|NCT01021995|DRUG|placebo|drops, 0.9 ml tid for 4 months
219608410|NCT02120196|DRUG|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
219608411|NCT02120196|DRUG|Norfloxacin|FDA approved:400mg once daily
219608412|NCT03105518|DRUG|Fentanyl|0.5, 1 mcg/kg
219608413|NCT03105518|DRUG|Acetaminophen|Single + Oxycodone
219203187|NCT06872216|DIAGNOSTIC_TEST|Vascular occlusion test|A blood pressure cuff was placed on the upper arm. The adult probe of the NIRS device (Covidien INVOS™ 5100C Cerebral/Somatic Oximeter, Dublin) was placed on the thenar region of the ipsilateral hand and the regional oxygen value was recorded during all study term. Baseline arterial pressure and oxygen saturation were monitored (GE Healthcare Oy, Helsinki, Finland) from the side of dominant hand and recorded. After a 3-minute stabilization period, the vascular occlusion protocol was started. The blood pressure cuff was rapidly inflated within 3-4 seconds to 50 mmHg above baseline systolic blood pressure and kept at this pressure during 3 minutes. Following this, the cuff was deflated within 1 second. Five minutes after cupping therapy this protocol had done again.
219203188|NCT06874946|BIOLOGICAL|CD5-targeted CAR-T cells|"Phase I: Eligible patients will receive a single infusion of CD5-targeted CAR-T cells at one of three dose levels (0.5 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine and cyclophosphamide (FC) lymphodepleting chemotherapy. A 3+3 dose-escalation design will be used to determine the recommended Phase II dose (RP2D) based on safety, dose-limiting toxicities (DLTs), and preliminary efficacy.~Phase II: Patients will receive CD5-targeted CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
219509175|NCT00096265|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
219608414|NCT03105518|DRUG|Oxycodone|With Acetaminophen
219608415|NCT03652337|DEVICE|BlephEx|Electronic lid margin debridement
219608416|NCT03652337|DEVICE|Manual debridement|Manual lid margin debridement
219608417|NCT04841837|BEHAVIORAL|Time-restricted feeding|limit daily food intake to a period of 10 hours
219608418|NCT05675098|DRUG|Methylphenidate|This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
219608419|NCT05675098|DRUG|Modafinil|This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
219608420|NCT05675098|OTHER|Placebo|Participant will receive placebo tablets (Methylphenidate and Modafinil shape)
219608421|NCT05387889|BEHAVIORAL|Mindfulness Meditation for Pulmonary Hypertension (MMPH)|Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
219608422|NCT00208442|DEVICE|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
219608423|NCT00208442|DEVICE|Enduron|Standard polyethylene liner in a modular acetabular component
219509176|NCT00096265|DRUG|Erlotinib Hydrochloride|Given orally
219509177|NCT00096265|RADIATION|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
219509178|NCT00096265|DRUG|Temozolomide|Given orally
219509179|NCT01506323|BEHAVIORAL|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
219509180|NCT01506323|BEHAVIORAL|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
219509181|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
219509182|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
219509183|NCT05385679|PROCEDURE|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
219608424|NCT00634868|OTHER|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
219608425|NCT00634868|DEVICE|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
219608426|NCT02276456|BEHAVIORAL|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
219608427|NCT06217913|DEVICE|wearable device to monitor the blood pressure|Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.
219509184|NCT05646121|DEVICE|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
219033086|NCT04733651|DRUG|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
219033087|NCT04773444|BEHAVIORAL|Eccentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
219509185|NCT04381884|DRUG|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
219509186|NCT02891200|OTHER|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
219509187|NCT02891200|OTHER|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
219509188|NCT03465371|OTHER|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
219033088|NCT04773444|BEHAVIORAL|Concentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
219509189|NCT03465371|OTHER|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
219509190|NCT03465371|OTHER|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
219509191|NCT04499183|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|15 gram/day fructo- and galacto-oligosaccharides
219033089|NCT05109663|DRUG|SKLB1028|SKLB1028, capsule, oral
219509192|NCT00246974|DRUG|Gemcitabine|intravenous
219509193|NCT00246974|DRUG|Cisplatin|intravenous
219033090|NCT04381845|DIAGNOSTIC_TEST|COVID19 immunization testing|serological COVID19 test with confirmation at J15 during hospitalization
219033091|NCT00559546|DRUG|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
219033092|NCT04541433|DRUG|AZD9833|AZD9833 taken orally
219033093|NCT01425554|OTHER|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
219509194|NCT00246974|DRUG|Gefitinib|oral
219509195|NCT02318927|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
219608428|NCT05519748|BEHAVIORAL|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
219608429|NCT05777993|DRUG|Mitapivat|Tablets
219608430|NCT00002425|DRUG|Saquinavir|
219608431|NCT02071225|DRUG|bendamustine|70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
219033094|NCT01425554|OTHER|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
219033095|NCT01425554|OTHER|Air-plethysmography of the neck|Air-plethysmography of the neck
219033096|NCT01425554|OTHER|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
219033097|NCT03412084|BEHAVIORAL|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
219033098|NCT00218673|BEHAVIORAL|Peer mentor intervention|groups sessions, 8
219033099|NCT03255343|DEVICE|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
219033100|NCT01512953|DRUG|Lansoprazole|Lansoprazole 30 mg once a day
219033101|NCT00225381|DEVICE|connection of measuring device to anesthesia circuit|same as name
219033102|NCT00225381|PROCEDURE|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
219033103|NCT00225381|PROCEDURE|changing operating room bed position (head down and up position)|same
218890013|NCT06054100|DRUG|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
219033104|NCT00225381|PROCEDURE|adding PEEP during anesthesia|same
219033105|NCT00225381|PROCEDURE|placement of esophageal Doppler for cardiac output measurements|same
219033106|NCT00225381|DEVICE|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
219203189|NCT06874972|DEVICE|Music played|Music is played in the study group, and no music is played in the control group.
219203190|NCT06874738|DRUG|Liuwei Dihuang pills|Conventional treatment （Hormones, selective 5-hydroxytryptamine reuptake inhibitors, etc.）+ Liu Wei Di Huang Pills
219203191|NCT06875583|DEVICE|Radiation|The use of RAMPART radiation protection device
219203192|NCT06873854|DRUG|LM-108|Q3W, Intravenous Drip
219203193|NCT06873854|DRUG|Toripalimab|Q3W, Intravenous Drip
219203194|NCT01466478|DRUG|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
219203195|NCT01466478|DRUG|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
219203196|NCT01466478|DRUG|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
219203197|NCT01466478|DRUG|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
219509196|NCT04921280|BEHAVIORAL|Internet based Cognitive Behavioural Therapy|"The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures."
219033107|NCT00225381|DEVICE|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
219033108|NCT00225381|DEVICE|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
219033109|NCT00225381|DEVICE|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
219033110|NCT03689166|DIETARY_SUPPLEMENT|Probiotic|Reduce preterm birth with this dietary supplement
219033111|NCT03689166|OTHER|Placebo|Placebo
219033112|NCT01912846|BEHAVIORAL|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
219203198|NCT01466478|DRUG|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
219203199|NCT01466478|DRUG|Daivonex® ointment|once daily application, 4 weeks
219608432|NCT02071225|DRUG|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
219608433|NCT02130908|OTHER|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
218890014|NCT02309944|PROCEDURE|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.
218890015|NCT02309944|DEVICE|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
218890016|NCT03049917|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
218890017|NCT01480622|DRUG|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
219203200|NCT01466478|DRUG|Diprosone® ointment|once daily application, 4 weeks
219203201|NCT05545878|DEVICE|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
219203202|NCT06395740|OTHER|Enteral nutrtion|enteral nutrition via nasogastric tube.
219203203|NCT06395740|OTHER|TPN|of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
219203204|NCT06864715|BEHAVIORAL|Tele-delivered Behavioral Activation by lay counselors after Stroke (Tele-BA-S)|The Tele-BA-S intervention will comprise 5 weekly video-conferenced BA sessions delivered by trained lay counselors, homework, and 2 monthly follow-up booster calls.
219203205|NCT06864715|BEHAVIORAL|Treatment as Usual|Participants will receive an educational packet and blood pressure (BP) monitor prior to hospital discharge. They will be contacted by a Licensed Clinical Social Worker (LCSW) at 48-72 hours to determine if they have received their medications and appointments. The stroke practitioner will evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
219203206|NCT06624878|DRUG|esketamine|0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
219203207|NCT06624878|DRUG|placebo|a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
219203208|NCT05613426|DRUG|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
219203209|NCT05613426|DRUG|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
219203210|NCT05751226|DRUG|BI 1820237|BI 1820237
219203211|NCT05751226|DRUG|semaglutide|semaglutide
219203212|NCT05751226|DRUG|Placebo|Placebo
219203213|NCT05751226|DRUG|BI 456906|BI 456906
219203214|NCT02415933|BEHAVIORAL|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods."
219203215|NCT02415933|BEHAVIORAL|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
219203216|NCT04955990|OTHER|PAH Therapies|No Drug will be administered as part of this study. Real world data will be collected in participants who newly initiate PAH therapies in routine clinical setting or have already been receiving macitentan 10 mg for at least 3 months prior to the index date.
219203217|NCT06031025|OTHER|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
219203218|NCT05718687|DRUG|GBT021601|Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
218890018|NCT03947177|BEHAVIORAL|GMIT|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
219203219|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
219203220|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
219203221|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
219203222|NCT03628677|DRUG|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
219203223|NCT03628677|DRUG|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
219203224|NCT06502951|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
219509197|NCT05966857|DEVICE|Wearable: Smartwatch|The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
219509198|NCT01811446|DEVICE|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
219509199|NCT00268320|DEVICE|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
219509200|NCT05729750|DIAGNOSTIC_TEST|Trans abdominal ultrasound for assess biophysical profile|The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
218890019|NCT03947177|BEHAVIORAL|GMIT+|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
218890020|NCT03742765|BEHAVIORAL|Incentivizing planning|Participants receive bonus incentives for planning their workouts
218890021|NCT03742765|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
218890022|NCT00771199|DRUG|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
218890023|NCT04614727|COMBINATION_PRODUCT|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
218890024|NCT03332381|BEHAVIORAL|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
219203225|NCT06502951|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
219203226|NCT01611896|DIETARY_SUPPLEMENT|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
219203227|NCT01611896|OTHER|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
219203228|NCT06690957|DIAGNOSTIC_TEST|68Ga/18F-TATE/JR11/LM3|Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.
219203229|NCT06701890|OTHER|Blood sample collection|16 mL at inclusion 16 mL at 1 month after return from travel
219203230|NCT06701890|OTHER|Fecal sample collection|"1 sample at inclusion~1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel"
219203231|NCT06701422|PROCEDURE|Intraoperative stimulation of the cervical spinal cord|The surgeon will place spinal cord electrodes on the epidural surface, with stimulation sites identified using preoperative MRI. Recruitment curves will be generated by systematically increasing the stimulation intensity across various parameter combinations, including frequency, pulse count, pulse shape, and electrode-specific properties such as size, separation, and arrangement.
219203232|NCT06633562|DRUG|Nezavist SDD|Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
219203233|NCT06633562|DRUG|Placebo|Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
219203234|NCT06875414|BEHAVIORAL|Nursing care model|Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.
219203235|NCT06875622|BEHAVIORAL|Automated online weight loss program|Participants receiving this program are given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Computer-generated, personalized feedback is based upon self-monitoring data, and provided weekly during months 1-3, twice per month during months 4-6, and monthly thereafter. Participants are also instructed to view a new multi-media video lesson weekly during months 1-3, 2x/month during months 4-6, and monthly thereafter (24 lessons in total). These videos are 10-15 minutes in duration and are intended to teach behavioral principles for losing weight, healthy eating, and exercise.
219203236|NCT06875622|BEHAVIORAL|Individual coaching|Participants will receive monthly, one-on-one coaching sessions (12 in total) throughout the 12-month intervention period. Coaching sessions will be conducted via videoconference and the initial coaching session will be approximately 30 minutes and all remaining sessions will be approximately 15 minutes. The structure of the coaching sessions will be similar across participants, but the content will be tailored to the individual. Coaches will use goal setting, problem solving, and motivational interviewing to help facilitate adherence and achievement of weight loss program goals.
219203237|NCT06875622|BEHAVIORAL|Group-based, videoconference-delivered weight loss|Participants receiving this program will be instructed to attend interactive group videoconference sessions (60 minutes each) focused on behavioral strategies for changing diet and exercise to promote weight loss. Classes will be weekly during months 1-3, twice per month during months 4-6, and monthly during months 7-12. These classes are designed to allow participants to interact with, support, and learn from one another. Participants are also given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Semi-automated, personalized feedback, based on self-monitoring data, is provided by the group instructor at the same frequency as group sessions are held.
219203238|NCT06692153|DEVICE|An AID System.|The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
219203239|NCT06692153|OTHER|Standard of Care (SC)|Participants will continue to use their current therapy for T2D.
219203240|NCT06686433|OTHER|Novel infant formula|Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.
219203241|NCT06686433|OTHER|Standard infant formula|Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.
219364705|NCT04240587|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
218890025|NCT03332381|BEHAVIORAL|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
218890026|NCT02232022|DEVICE|Reveal LINQ Insertable Cardiac Monitor|
218890027|NCT00478842|DEVICE|Deep brain stimulation|Deep brain stimulation
218890028|NCT02947386|OTHER|Laboratory Biomarker Analysis|Correlative studies
218890029|NCT02947386|BIOLOGICAL|Nimotuzumab|Given IV
219364706|NCT04328506|DRUG|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
219364707|NCT04328506|DRUG|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
219364708|NCT01995929|PROCEDURE|transnasal functional endoscopy|
218890030|NCT02947386|BIOLOGICAL|Nivolumab|Given IV
218890031|NCT06525779|DEVICE|Use of macintosh laryngoscope|The requirement of external laryngeal manipulation recorded in use of macintosh vs mcGrath laryngoscope in double lumen tube insertion
218890032|NCT06525779|DEVICE|Use of mcGarth laryngoscope|Use of mcGarth laryngoscope
218890033|NCT01922713|OTHER|white maize and a corn oil capsule|\~ 0 ug RAE/d
218890034|NCT01922713|OTHER|orange maize and a corn oil capsule|\~600 ug RAE/d
218890035|NCT01922713|OTHER|white maize and a vitamin A capsule|600 ug RAE/d
218890036|NCT01218581|DRUG|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
218890037|NCT05229185|DEVICE|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
219203242|NCT04212234|DEVICE|ultrasound propagation velocities, ultrasound fetal quality|"Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al."
219203243|NCT06700278|BEHAVIORAL|auricular acupressure|auricular acupressure was performed three times daily, with each acupoint massaged for three minutes at an optimal pressure level that induced sensations of soreness, numbness, distension, or mild pain. This was conducted five days a week for three weeks, in addition to regular rehabilitation therapy provided five days per week.The selected auricular acupoints include Shenmen (TF4), Subcortex (AT1), Liver (CO12), and Sympathetic (AH6a).
219509201|NCT02240758|PROCEDURE|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
219509202|NCT00017563|DRUG|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
219203244|NCT06700278|BEHAVIORAL|body acupoint massage|The control group will receive acupoint massage three times daily, with each acupoint being massaged for three minutes. The applied pressure will be adjusted to induce sensations of soreness, numbness, fullness, or mild pain. The intervention will be conducted five days per week for a total of three weeks. The selected body acupoints include Quchi (LI11), Hegu (LI4), Sanyinjiao (SP6), and Zusanli (ST36).
219203245|NCT03624790|BIOLOGICAL|rRSV A/Maryland/001/11|10\^5 PFU; delivered intranasally
219509203|NCT00017563|DRUG|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
219509204|NCT00017563|PROCEDURE|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
219509205|NCT05779150|OTHER|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
219509206|NCT05779150|OTHER|Standard Cream|placebo cream
219203246|NCT06878794|COMBINATION_PRODUCT|Using medical biological glue for filling And Using the meniscus suture system|Using medical biological glue for filling And Using the meniscus suture system
219203247|NCT06878794|PROCEDURE|Using the meniscus suture system|Using the meniscus suture system
219509207|NCT00511563|DRUG|GW876008 and GSK561679|GW876008 and GSK561679
218890038|NCT06157866|OTHER|Electroacupuncture|During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. A low-amplitude, sub-sensory electrical current will be activated by the acupuncturist.
219509208|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
219509209|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
219509210|NCT00444795|DRUG|sunitinib malate|Sunitinib : dosing not pre-determined
219509211|NCT01908114|BEHAVIORAL|Enhanced Community mobilization|
219509212|NCT01908114|BIOLOGICAL|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
219509213|NCT03788681|DRUG|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
219509214|NCT03788681|DRUG|Placebo Oral Tablet|placebo
219509215|NCT00545012|DRUG|Levetiracetam|
218890039|NCT06157866|BEHAVIORAL|Cognitive Training|Cognitive training with a pain specialist.
218890040|NCT06157866|BEHAVIORAL|Education Training|Education training with a pain specialist.
218890041|NCT04973072|BEHAVIORAL|One large reward treatment|Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
219509216|NCT00988169|DRUG|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
219509217|NCT00003361|DRUG|decitabine|
219509218|NCT04674098|DEVICE|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
219509219|NCT03265496|PROCEDURE|Clinical exam|Clinical exam is performed before treatment start
219509220|NCT03265496|PROCEDURE|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
219608434|NCT02130908|OTHER|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
219509221|NCT03265496|PROCEDURE|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
219509222|NCT03265496|DRUG|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
219509223|NCT03265496|PROCEDURE|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
219509224|NCT03265496|BIOLOGICAL|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
218890042|NCT04973072|BEHAVIORAL|Small wins treatment|The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
218890043|NCT04945759|DEVICE|Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon|Evaluation and treatment will be done with the Cybex humac device.
218890044|NCT01478971|DRUG|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
218890045|NCT01478971|DRUG|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
218890046|NCT05940116|DRUG|HS-20117|"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"
219509225|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
219509226|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
219509227|NCT02642627|DEVICE|Bellafill|
219509228|NCT01400282|DEVICE|High frequency spinal cord stimulation|
218890047|NCT04399395|DRUG|Naltrexone/bupropion|Approved drug for obesity treatment
218890048|NCT04399395|OTHER|Lifestyle|Lifestyle
219033113|NCT01912846|BEHAVIORAL|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
219033114|NCT04249037|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
219033115|NCT04249037|DRUG|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
219509229|NCT02414880|DRUG|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
219033116|NCT06367465|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
219033117|NCT05112692|DRUG|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
219033118|NCT05112692|DRUG|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
219033119|NCT05112692|DRUG|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
219033120|NCT05112692|DRUG|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
219033121|NCT05112692|DRUG|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
219509230|NCT02414880|DRUG|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
219033122|NCT05112692|PROCEDURE|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
219509231|NCT02414880|DRUG|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
219509232|NCT02067780|DRUG|Levofloxacin 500mg|One tablet per day for 7days.
219509233|NCT05371522|RADIATION|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain \[18F\]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
219509234|NCT01383525|DEVICE|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
219608435|NCT02130908|OTHER|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
219509235|NCT03522922|DEVICE|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
219509236|NCT03522922|DRUG|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
219509237|NCT01989065|BEHAVIORAL|Lifestyle counseling|see arm description
219509238|NCT01989065|BEHAVIORAL|Text Messaging|See Arm Description
219509239|NCT02943525|PROCEDURE|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
219509240|NCT05764122|DRUG|BIIB131|Administered as specified in the treatment arm.
219509241|NCT05764122|DRUG|Placebo|Administered as specified in the treatment arm.
219033123|NCT05112692|DRUG|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
219033124|NCT04129788|DRUG|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
219033125|NCT04129788|DRUG|Placebo oral tablet|three doses taken, one per day on three consecutive days
219033126|NCT02656108|PROCEDURE|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
219033127|NCT02656108|PROCEDURE|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
219033128|NCT03684915|DEVICE|Rotary files|using rotary files in cleaning root canals of infected primary molars
219203248|NCT06878157|BEHAVIORAL|ontological coaching|Group session: This session will provide an overview of coaching and the following topics will be covered: 1) Experience coaching in teams, 2) The Ideal Life, 3) The Coaching Distinction, 4) Introduction to Body, Emotions, Language (BEL), 5) Deeper understanding of BEL, 6) Applying BEL to clinical scenarios, 7) The coaching perspective in Nursing, 8) Re-visit the Ideal Life, 9) Explore mental/emotional/physical challenges in practicing nursing, 10) Time and stress management, work-life balance; Individual Session: This individualized session will cover the discussions on the topic brought up by novice nurses. The aim of this session is to: 1) Help novice nurses design the steps in their journey towards what they care about, 2) Explore the nurses' world by asking encouraging and evoking questions, 3) Collaborate with nurses in a stimulating and imaginative manner that help them to optimize their potential, 4) Co-create with nurses the professional and personal identity they strive for
219203249|NCT06876948|DIAGNOSTIC_TEST|Psychological tests, EEG, Magnetic Resonance|Patients are administered some psychological tests, if they are positive they move on to the next stage, otherwise the patients leave the practice. If they are positive, EEG, MRI and other psychological tests are also administered.
219509242|NCT05159310|PROCEDURE|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
219509243|NCT01241409|DRUG|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
219608436|NCT01417637|RADIATION|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
219608437|NCT01417637|RADIATION|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
219608438|NCT00458744|DRUG|talotrexin|
219608439|NCT00458744|PROCEDURE|chemotherapy|
219613302|NCT06458517|DEVICE|Photobiomodulation session - intraoral|use of CareMin650TM lightbox(NeoMedLight) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
219509244|NCT01241409|DRUG|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
219509245|NCT01241409|DRUG|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
219509246|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Treat)|Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.
219509247|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Placebo)|Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.
219509248|NCT00580853|DRUG|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
219509249|NCT00580853|DRUG|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
219509250|NCT00580853|DRUG|Placebo|Placebo
219509251|NCT02710071|DRUG|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
218890049|NCT05307354|OTHER|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
218890050|NCT05307354|OTHER|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
218890051|NCT00584012|DRUG|Lovastatin|Given PO
219033129|NCT05806294|BEHAVIORAL|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
219509252|NCT02710071|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
219608440|NCT03327844|DRUG|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
218890052|NCT00584012|DRUG|Docetaxel|Given IV
218890053|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
218890054|NCT01525615|DRUG|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
218890055|NCT01525615|DRUG|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
219033130|NCT00640705|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
219033131|NCT00640705|DRUG|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
219033132|NCT06424262|DEVICE|CI622D|A dexamethasone-eluting Slim Straight electrode
219033133|NCT06424262|DEVICE|CI622|A standard Slim Straight electrode
219509253|NCT03270176|DRUG|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
219509254|NCT03270176|DRUG|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
219613303|NCT06458517|DEVICE|Photobiomodulation session - transcutaneous|use of ATP38® phototherapy device (Swiss Bio Inov Europe) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
219613304|NCT04902001|BEHAVIORAL|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
219033134|NCT06231550|DRUG|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
219033135|NCT01565330|DRUG|florbetapir F 18|single dose IV injection
219033136|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
219033137|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
219033138|NCT00401765|DRUG|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
219509255|NCT01633827|DRUG|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
219509256|NCT01633827|DRUG|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
219509257|NCT01633827|OTHER|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
219509258|NCT01633827|OTHER|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
219509259|NCT03306576|DEVICE|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
219509260|NCT03306576|DEVICE|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
219509261|NCT05713474|DIAGNOSTIC_TEST|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
219509262|NCT05713474|DIAGNOSTIC_TEST|Conventional EMG|Diagnostic EMG exam with conventional EMG
219509263|NCT03581474|DEVICE|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
219509264|NCT01626820|BIOLOGICAL|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
218890056|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
218890057|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
219509265|NCT02470195|BEHAVIORAL|workshop|workshop for procedural simulation for education in difficult airway situation
218890058|NCT01525615|DRUG|placebo to tiotropium+olodaterol|comparator
219509266|NCT04266691|OTHER|nonIntervention|nonIntervention
218890059|NCT06362096|DRUG|Trastuzumab+pyrotinib+taxene|Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes
218890060|NCT04658004|DRUG|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
218890061|NCT04050618|DEVICE|fanfilcon A test lens|Silicone hydrogel contact lens
218890062|NCT04050618|DEVICE|ocufilcon D control lens|hydrogel contact lens
218890063|NCT04050618|DEVICE|etafilcon A control lens|hydrogel contact lens
218890064|NCT04404556|BEHAVIORAL|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
218890065|NCT04404556|BEHAVIORAL|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
218890066|NCT01217762|DEVICE|IRay|Low voltage stereotactic radiotherapy system
218890067|NCT06555952|DIETARY_SUPPLEMENT|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
218890068|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
218890069|NCT00006116|DRUG|cisplatin|
218890070|NCT00006116|DRUG|gemcitabine hydrochloride|
218890071|NCT02334293|DRUG|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
218890072|NCT04403412|PROCEDURE|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
218890073|NCT04403412|PROCEDURE|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
218890074|NCT04403412|PROCEDURE|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
218890075|NCT04184830|DEVICE|non-invasive brain stimulation|
219033139|NCT00401765|DRUG|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
219033140|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
219033141|NCT01883401|DIETARY_SUPPLEMENT|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
219033142|NCT01883401|DIETARY_SUPPLEMENT|Dietary fiber|4g or 8g dietary fiber blended in water
219033143|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
219033144|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
219033145|NCT02023151|DRUG|Omalizumab|
219033146|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
219033147|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
219033148|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
219509267|NCT04579926|OTHER|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
219509268|NCT04032873|OTHER|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
219509269|NCT04032873|OTHER|Physician|The monetary cost information is relayed by the patient's physician
219509270|NCT04032873|OTHER|Study Team|The monetary cost information is relayed by a member of the study team
219613305|NCT01094704|DRUG|sodium chloride (7%)|4mL nebulized 7% sodium chloride
219613306|NCT00245518|DRUG|Isoflavone|
219613307|NCT00245518|DRUG|Placebos|
218890076|NCT05031793|OTHER|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
218890077|NCT05031793|OTHER|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
218890078|NCT00649506|DRUG|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
218890079|NCT00649506|DRUG|Macrodantin® 100 mg Capsules|100mg, single dose fed
218890080|NCT03777059|DRUG|Atogepant|Atogepant tablet
218890081|NCT03777059|DRUG|Placebo|Placebo-matching atogepant tablets
218890082|NCT02219854|PROCEDURE|Laparoscopic gastrectomy|
218890083|NCT02219854|PROCEDURE|Open gastrectomy|
219613308|NCT05509530|OTHER|anti-BCMA/GPRC5D CAR-T CELL|anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
218890084|NCT02322437|OTHER|Home treatment|Patients are treated at home whenever possible and appropriate
218890085|NCT02322437|OTHER|Treatment As Usual|Patients are treated at a mental hospital
218890086|NCT06834971|DRUG|Colistimethate sodium (CMS)|CMS (colistimethate sodium, 75mg, solubilized in 4 mL 0.9% saline), twice daily. Nebulization will be performed using a vibrating mesh nebulizer (Aeroneb solo, Aerogen, Galway, Ireland) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry for three consecutive days of mechanical ventilation. To ensure the experiment is conducted under blind conditions, the Nebulizer will be covered by stickers. A filter will be placed on the expiratory limb to protect the ventilator.
218890087|NCT01026012|DRUG|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
218890088|NCT05589610|DRUG|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
218890089|NCT03685227|OTHER|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
218890090|NCT05927844|DRUG|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
219033149|NCT04064294|DRUG|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
219033150|NCT06328790|OTHER|Multidisciplinary Rehabilitation Training|34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).
219033151|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and patients with structural/organic diseases|Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.
219033152|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and healthy controls (HC)|Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
219033153|NCT03001921|OTHER|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
219033154|NCT03450707|DRUG|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
219033155|NCT03450707|OTHER|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
219033156|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
219033157|NCT02302196|PROCEDURE|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
219033158|NCT02302196|OTHER|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
219033159|NCT02635464|BIOLOGICAL|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
219033160|NCT02635464|BIOLOGICAL|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
219033161|NCT02635464|PROCEDURE|CABG|Patients underwent CABG alone.
219033162|NCT03930706|OTHER|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
219033163|NCT00481195|DRUG|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
219033164|NCT00481195|DRUG|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
219033165|NCT05715567|OTHER|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
219033166|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
218890091|NCT05927844|DRUG|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
218890092|NCT03214575|DEVICE|Conventional method|
218890093|NCT03214575|PROCEDURE|GPS Method|
218890094|NCT02607618|DRUG|Iclaprim|Experimental treatment
218890095|NCT02607618|DRUG|Vancomycin|Active comparator
218890096|NCT03730532|OTHER|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
218890097|NCT03730532|OTHER|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
218890098|NCT02720341|DEVICE|ARMin|single sessions of about one hour each
218890099|NCT03168828|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
218890100|NCT00655538|DRUG|Placebo|po daily for 36 weeks
218890101|NCT00655538|DRUG|dalcetrapib|600mg po daily for 36 weeks
219033167|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
219033168|NCT04146064|OTHER|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
219033169|NCT03047109|DRUG|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
218890102|NCT04452630|OTHER|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
218890103|NCT02451943|DRUG|Olaratumab|Administered IV
218890104|NCT02451943|DRUG|Doxorubicin|Administered IV
218890105|NCT02451943|DRUG|Placebo|Administered IV
218890106|NCT00211016|DRUG|doripenem|
218890107|NCT06322199|BEHAVIORAL|ASSIP (Attempted Suicide Short Intervention Program) flex|"ASSIP is a specific therapy for patients after a suicide attempt. The brief therapy ASSIP consists of 3-4 sessions of approximately 50 min. each. ASSIP flex delivers ASSIP in the patient's personal environment as an outreach home treatment. The structure of the ASSIP is the same as in the regular ASSIP, but the program is delivered in the patient's environment.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her personal story, which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
218890108|NCT03148327|DRUG|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
218890109|NCT03148327|RADIATION|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
219033170|NCT03047109|DRUG|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
219033171|NCT03343483|BEHAVIORAL|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
219033172|NCT03343483|BEHAVIORAL|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
219033173|NCT04758377|PROCEDURE|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
219033174|NCT03500146|DRUG|Anticholinergic|Patients prescribed medication for OAB
219033175|NCT03500146|PROCEDURE|PTNS|Patients prescribed PTNS for OAB
219033176|NCT04846725|OTHER|Data collection|"Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
219033177|NCT01505608|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
219033178|NCT01505608|DRUG|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
219033179|NCT01505608|DRUG|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
219033180|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
219033181|NCT04851795|OTHER|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
219509271|NCT04032873|OTHER|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
219203250|NCT04569942|DRUG|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
219203251|NCT04569942|OTHER|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
219203252|NCT06876116|DRUG|Fluorometholone 0.1% ophthalmic solution|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with fluorometholone 0.1% once a day for 8 weeks.
219203253|NCT06876116|DRUG|Cyclosporine 0.05% eye drops|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with cyclosporine 0.05% twice a day for 8 weeks.
219203254|NCT06878963|PROCEDURE|PENG Block|The PENG block will be performed on the patient with the injection of local anesthesia under ultrasound guidance in the femoral region, beneath the biceps tendon.
219203255|NCT06878963|PROCEDURE|SIFICB Block|The SIFIB block will be performed on the patient with the injection of local anesthetic between the iliac fascia and iliac muscle in the femoral region, under ultrasound guidance.
218890110|NCT05294913|BEHAVIORAL|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
219033182|NCT04851795|OTHER|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
219033183|NCT03149250|DIAGNOSTIC_TEST|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
219203256|NCT06877741|OTHER|Group A (Heavy Slow Resistance exercises)|Pre - assessment will be taken. Heavy slow resistance exercises will be given to group A and exercises of 4 sets of 10-20 repetitions will be given
219203257|NCT06877741|OTHER|: Group B (Eccentric exercises)|Sessions should be conducted 2 times per week, similar to Group A, in 3 sets of 10-20 repetitions. Exercises focus solely on eccentric loading, such as eccentric squats, eccentric leg presses, and step-down exercises.
219203258|NCT06692517|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
219203259|NCT06692842|DEVICE|CONEMO App|The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
219203260|NCT06879743|OTHER|Suboccipital release|"The ptients in this group recieve suboccipital release. The patient is positioned in a supine (lying on their back) position, allowing full relaxation of the cervical spine.~The therapist places their fingertips or hands under the patient's occiput, making contact with the suboccipital muscles.~Using gentle, sustained pressure, the therapist allows the weight of the head to create a release, often holding for 1-5 minutes.~Subtle adjustments may be made, such as slight traction or rocking, to facilitate myofascial release and relaxation."
218890111|NCT05294913|BEHAVIORAL|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
218890112|NCT01494792|DEVICE|In Vitro Diagnositc aid for diagnosis|
219033184|NCT05585034|BIOLOGICAL|XmAb®808|Monoclonal bispecific antibody
219203261|NCT06879288|DRUG|Bupivacaine|Patients received intraperitoneal bupivacaine only at the end of the operations.
219203262|NCT06879288|DRUG|Dexmedetomidine|Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
219203263|NCT06879288|DRUG|Magnesium sulfate|Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
219613309|NCT04482764|DRUG|Valproic Acid|Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
219613310|NCT02389179|DRUG|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
218890113|NCT03351647|BIOLOGICAL|Evaluation of biological predictive factors of clinical response to ustekinumab|The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
218890114|NCT01003847|DRUG|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
218890115|NCT00000424|PROCEDURE|Tidal lavage vs. sham lavage of the knee|
219033185|NCT05585034|BIOLOGICAL|Keytruda® (pembrolizumab)|Monoclonal antibody
218890116|NCT06244667|PROCEDURE|facet median block with prilocain|facet median block with prilocain
219203264|NCT06876493|OTHER|Aerobic Exercise Programme|The aerobic exercise programme was shown to female students with premenstrual syndrome on the first day by the researcher (D.A.) at the sports centre. Participants were advised to drink water and wear running shoes during exercise. Warm-up exercises were performed for 10 minutes before the exercise. Exercise intensity was determined by the Karvonen formula (HRmax=220-age, HRR=HRmax-HR rest, 60% THR=(0.60xHRR)+HR rest). .According to the pulse rate of the exercise, pulse values are monitored on the treadmill and km/hour speeds are adjusted according to pulse values. The exercise programme started with low aerobic exercise intensity on the treadmill, gradually increased at 5-minute intervals and completed at 40-60% of the heart rate, and finally 5 minutes of light stretching movements were performed to return to the initial state. In the following sessions, the participants performed the exercise programmes individually at the sports centre for 45 minutes (10 min warm-up, 30 min walk,
219203265|NCT06876493|OTHER|Whole Body Vibration Training Programme|The WBV programme used a frequency of 25 Hz and an amplitude of 2 mm (low amplitude). The Power Plate® (pro5TM) machine provided the device's vibration. This device provides a three-plane oscillatory motion. The programme lasted eight weeks and was performed three days a week. There was at least one day's rest between each session. Before and after each vibration, stretching exercises (warm-up and cool-down programme) were performed for 5 minutes, particularly for the quadriceps and trunk extensors
219203266|NCT06876571|DIAGNOSTIC_TEST|IdentiClone Dx TRG Assay|"The IdentiClone Dx TRG Assay (Assay) is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers."
219033186|NCT05891509|PROCEDURE|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
219203267|NCT06878885|BEHAVIORAL|Acute psychological stress task (Paced Auditory Serial Addition Task)|Volunteers will complete a 4-minute Paced Auditory Serial Addition Task which is a standardized laboratory challenge that is widely used to monitor cardiovascular, neuroendocrine, and inflammatory responses in the laboratory.
219203268|NCT06880471|BIOLOGICAL|TheraCal PT pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, TheraCal PT material will be placed. According to the manufacturer's instructions, the irradiation time is 10 seconds. It is dual-cure. Its content is based on calcium silicate modified with resin.
219203269|NCT06880471|BIOLOGICAL|MTA pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, ProRoot MTA material will be placed. After waiting for 15 minutes for it to set, the restorative treatment will be performed. MTA consists of the main components: tricalcium silicate, dicalcium silicate, tricalcium aluminate, tricalcium oxide, silicate oxide, and calcium sulfate dihydrate.
219203270|NCT06880471|BIOLOGICAL|Biodentine pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, Biodentin material will be placed. After waiting for 12 minutes according to the manufacturer's instructions for it to set, the restorative treatment will be performed. Biodentin is a two-component material. The powder primarily consists of tricalcium silicate.
219203271|NCT06880237|OTHER|Singing|"The programme consists of nin 75-min-long singing sessions spread across 8 weeks (8 sessions are practice sessions and 1 session is a full dress rehearsal), and a final performance. The final rehearsal session and showcase performance will be held at a concert venue, while the 8 practice sessions will be conducted at the nursing home.~Each session will kick off with a Hello song, followed by warm-up activities and vocal exercises. Participants will then sing different songs to explore and rehearse as a group, before concluding with a Goodbye song. All sessions throughout the programme are similarly structured to provide consistency for participants."
219203272|NCT06880328|DRUG|Ralmitaront|Participants were given a once 150 mg daily dose of Ralmitaront orally during the 14 day treatment period.
219509272|NCT04032873|OTHER|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
219509273|NCT03709082|DRUG|Palbociclib 75mg|Oral Administration
219509274|NCT03709082|DRUG|Letrozole 2.5mg|Oral Adminstration
219509275|NCT03709082|DRUG|T-DM1|Intravenous Administration
219509276|NCT03709082|DRUG|Palbociclib 100mg|Oral Administration
219509277|NCT03709082|DRUG|Palbociclib 125mg|Oral Administration
219509278|NCT03709082|DRUG|Palbociclib|Oral Administration
219509279|NCT02637557|DRUG|IW-3718|
219033187|NCT05891509|OTHER|Best Medical Therapy|Best medical therapy
219509280|NCT02637557|DRUG|Matching Placebo|
219509281|NCT02637557|DRUG|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
219509282|NCT01773148|DEVICE|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
219509283|NCT03940430|DRUG|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
219509284|NCT03940430|DRUG|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
219509285|NCT00613574|DRUG|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
219509286|NCT02267057|DRUG|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
219509287|NCT02267057|DRUG|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
219033188|NCT02110342|DRUG|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
219033189|NCT06418841|PROCEDURE|Computer-Assisted Paramedian Approach Technique|Computer-Assisted Paramedian Approach Technique
219033190|NCT06418841|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
219033191|NCT05631405|DRUG|Dexamethasone|Patients treated with dexamethasone
219509288|NCT02267057|DRUG|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
218890117|NCT06244667|PROCEDURE|facet median block with lidocaine|facet median block with lidocaine
218890118|NCT02420704|PROCEDURE|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
218890119|NCT01793766|DEVICE|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
218890120|NCT01793766|DEVICE|Sham modulation|
219203273|NCT06880328|OTHER|Radiolabeled PET tracer [18F]-DOPA|\[18 F\]-DOPA solution for injection is manufactured by the PET imaging centers according to specifications established for the tracer at the site. The injection will happen prior to the scan being done and will last for approximately 30 seconds.
219203274|NCT06880328|DRUG|Placebo|Participants were given a daily dose of the placebo during the 14 day treatment period.
219509289|NCT02267057|DRUG|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
219613311|NCT00741000|PROCEDURE|Cervical Stairstep|Cervical low force mobilization procedure.
219613312|NCT02963779|DRUG|LY2775240|Administered orally
219613313|NCT02963779|DRUG|Placebo|Administered orally
219613314|NCT02963779|DRUG|Apremilast|Administered orally
218890121|NCT05813457|OTHER|PRESTO Early Identification Program|"The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
218890122|NCT02029911|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
218890123|NCT03785704|DRUG|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
218890124|NCT01002651|DIETARY_SUPPLEMENT|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
218890125|NCT01002651|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
218890126|NCT00483470|BIOLOGICAL|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
218890127|NCT00483470|BIOLOGICAL|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
218890128|NCT03373149|DRUG|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
218890129|NCT03373149|DRUG|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
218890130|NCT00825188|DRUG|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
218890131|NCT00825188|DRUG|eplerenone|Eplerenone 25-50mg daily x 8 weeks
218890132|NCT00825188|DRUG|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
218890133|NCT00825188|DRUG|amlodipine|amlodipine 5-10mg daily for 8 weeks
218890134|NCT05065359|DRUG|Rodatristat Ethyl 300 mg BID|Tablets, oral, 300 mg, BID 14 days
218890135|NCT05065359|DRUG|Rodatristat Ethyl 600 mg BID|Tablets, oral, 600 mg, BID 14 days
218890136|NCT05065359|DRUG|Placebo|Tablets, oral, 0 mg, BID for 14 days
218890137|NCT02379169|DIETARY_SUPPLEMENT|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
218890138|NCT02379169|DIETARY_SUPPLEMENT|Placebo|Triglycerides of medium chain fatty acids
218890139|NCT00040170|BIOLOGICAL|MVA-MUC1-IL2|
218890140|NCT05402670|OTHER||
218890141|NCT03113994|DRUG|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
218890142|NCT03113994|DRUG|Placebo Oral Tablet|Placebo, daily for 12 months
218890143|NCT03113994|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg CoQ10, daily for 12 months
218890144|NCT03113994|DIETARY_SUPPLEMENT|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
218890145|NCT03113994|DIETARY_SUPPLEMENT|Vitamin D|2000IU Vitamin D, daily for 12 months
218890146|NCT03594682|OTHER|Intervention/treatment|"experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd"
218890147|NCT06504810|OTHER|light|light level
218890148|NCT03787121|PROCEDURE|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
218890149|NCT05930652|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
219509290|NCT00176904|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
219509291|NCT00176904|DRUG|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
219509292|NCT03534986|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
218890150|NCT01101035|DRUG|Febuxostat|Febuxostat tablets
218890151|NCT01101035|DRUG|Allopurinol|Allopurinol tablets
219509293|NCT03534986|DEVICE|Hill-Rom The Vest|High-frequency chest wall oscillation vest
219509294|NCT03534986|DEVICE|Respirtech inCourage|High-frequency chest wall oscillation vest
219509295|NCT03534986|DEVICE|Electromed SmartVest|High-frequency chest wall oscillation vest
219203275|NCT06880211|OTHER|physical activity recommendations|The participants (bus and tram drivers) in the control group will receive the latest World Health Organization recommendations for physical activity in written form.
219203276|NCT06880211|OTHER|activitysnippets|Participants (bus and tram drivers) in the intervention group will receive the ActivitySnippets toolbox. The toolbox was developed through collaborative workshops with the target group, sports scientists and physiotherapists to create a sustainable, occupation-specific and evidence-based physical activity promotion. The toolbox, which provides simple incentives to integrate physical activity into everyday working life, consists of 30 to 40 activity snippets (exercise cards). The design of the toolbox allows for individualization and variation of the exercise cards. The aim of the exercises is to improve muscle strength, increase physical activity levels at work and reduce stress. All exercises can be performed for between 10 and 60 seconds, allowing for realistic implementation in everyday working life. Participants are encouraged to incorporate the exercises into their daily work routine as often as possible.
219203277|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
219203278|NCT06879561|PROCEDURE|Angiography-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesion to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or any flow-limiting dissection.
219203279|NCT06879561|PROCEDURE|Pressure wire-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesions to achieve an optimal procedural result, as determined by the pressure gradient across the target lesion. An optimal procedural result is defined as pressure gradient less than 10 mmHg, measured using a Pressure Wire.
219509296|NCT02588573|DEVICE|etafilcon A (control)|contact lens
219509297|NCT02588573|DEVICE|somofilcon A (test)|contact lens
219509298|NCT06543641|DIAGNOSTIC_TEST|Coronary computed tomography angiography|All patients received coronary computed tomography angiography.
219613315|NCT05433142|BIOLOGICAL|XmAb819|Monoclonal Bispecific Antibody
219613316|NCT02423200|DRUG|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
219613317|NCT01999920|DRUG|Vilazodone|10mg to 40mg per day for 12 weeks
218890152|NCT00210782|DRUG|topiramate, phenytoin|
218890153|NCT02802839|DEVICE|Virtual Reality|
218890154|NCT06337695|BIOLOGICAL|Vedolizumab|300 mg IV at weeks 0, 3, 6, 14, and 22
218890155|NCT06337695|BIOLOGICAL|Placebo|300 mg IV at weeks 0, 3, 6, 14, and 22
218890156|NCT00226057|DRUG|Raptiva|Open Label
218890157|NCT00915863|PROCEDURE|Billroth-II-type reconstruction|surgical procedure
218890158|NCT00915863|PROCEDURE|Isolated Roux-en-Y type reconstruction|surgical procedure
218890159|NCT01694381|DRUG|M5|single point mutant of serine protease prourokinase
218890160|NCT01694381|DRUG|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
218890161|NCT00763386|DEVICE|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
218890162|NCT00763386|DEVICE|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
218890163|NCT00555880|DRUG|Midodrine hydrochloride|one dose, 10-30mg, given orally
218890164|NCT00555880|DRUG|Placebo|Placebo
218890165|NCT00890747|DRUG|sunitinib malate|Given PO
218890166|NCT00890747|OTHER|pharmacological study|Correlative studies
218890167|NCT00890747|OTHER|laboratory biomarker analysis|Correlative studies
218890168|NCT03558919|DRUG|Mirabegron 25mg|
218890169|NCT03558919|DRUG|Solifenacin Succinate 5 MG|
218890170|NCT03157375|DEVICE|Intraocular Lens Implantation|
218890171|NCT02385747|PROCEDURE|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
218890172|NCT01172626|DRUG|valproate sodium|oral administration,15-30mg/kg,daily
218890173|NCT01172626|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
218890174|NCT01172626|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
218890175|NCT00277771|BEHAVIORAL|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
218890176|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
218890177|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
218890178|NCT01681160|OTHER|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
218890179|NCT01681160|OTHER|conventional therapy|patients receive ordinary treatment for diabetic foot
218890180|NCT02859259|DRUG|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
218890181|NCT02859259|DRUG|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
219033192|NCT05631405|DRUG|Placebo|Patients treated with placebo
219033193|NCT00780325|DRUG|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
219033194|NCT00780325|DRUG|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
219033195|NCT00780325|DRUG|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
219033196|NCT00780325|DRUG|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
219033197|NCT00780325|DRUG|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
219033198|NCT00780325|DRUG|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
219033199|NCT00310531|DRUG|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
219033200|NCT00310531|DRUG|Raloxifene|Raloxifene tbl. (60 mg/day)
219033201|NCT06821867|DEVICE|PN + HA (Newest)|"PN+HA (Newest) is a viscoelastic, sterile, single-use gel for intradermal use. PN+HA is a medical device containing the combination of polynucleotides (10 mg/ml) and hyaluronic acid (10 mg/ml).~PN+HA is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques such as linear threading, serial punctures, crosslinked, radial fanning or mixed can be used. The injection site must consist of healthy skin. PN+HA can also be administered by means of non-invasive techniques (iontophoresis, electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application. Then remove the disinfectant with sterile saline."
219033202|NCT00056563|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
219033203|NCT00056563|OTHER|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
219033204|NCT01708174|DRUG|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
219033205|NCT01708174|DRUG|TMZ|Temozolomide capsules were obtained locally by the Investigator
219033206|NCT02922907|DIETARY_SUPPLEMENT|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
219033207|NCT02922907|DIETARY_SUPPLEMENT|Placebo for arabinoxylan rice bran|inactive product
219033208|NCT00075582|PROCEDURE|conventional surgery|Some patients may undergo second-look surgery
218890182|NCT04058041|PROCEDURE|Neural Mobilization|neural exercise Will be performed in the patients
218890183|NCT04058041|PROCEDURE|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
219033209|NCT00075582|DRUG|dactinomycin|Given IV
218890184|NCT04058041|PROCEDURE|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
218890185|NCT05374239|OTHER|Multi-component implementation intervention|The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
218890186|NCT00681629|DRUG|Quetiapine XR|400-800 mg, oral, bid
218890187|NCT00681629|OTHER|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
218890188|NCT04427865|DRUG|prophylactic lactoferrin daily|200 mg oral lactoferrin daily
218890189|NCT03160339|BIOLOGICAL|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
219033210|NCT00075582|DRUG|cyclophosphamide|Given IV
219033211|NCT00075582|DRUG|vincristine sulfate|Given IV
219033212|NCT00075582|RADIATION|radiation therapy|Undergo radiotherapy
219033213|NCT05045144|COMBINATION_PRODUCT|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
219033214|NCT05045144|COMBINATION_PRODUCT|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
219033215|NCT05045144|COMBINATION_PRODUCT|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
219608441|NCT03327844|DRUG|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
219608442|NCT01769248|DEVICE|Fine needle aspiration|Fine needle aspiration
218890190|NCT03160339|BIOLOGICAL|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
218890191|NCT02588235|DRUG|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
218890192|NCT02588235|DRUG|Atorvastatin|atorvastatin (20 mg/day）
218890193|NCT01764711|DRUG|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
218890194|NCT00002092|DRUG|Cimetidine|
218890195|NCT01398007|PROCEDURE|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
218890196|NCT00411671|DRUG|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
218890197|NCT00883961|OTHER|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
218890198|NCT03556163|PROCEDURE|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
218890199|NCT03556163|PROCEDURE|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
218890200|NCT03796637|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
218890201|NCT05931926|DEVICE|Fluispotter®|The Fluispotter® has been developed for automated extraction, collection and storage of up to 20 dried venous dried blood spot samples of 3-10 μl over the course of up to 20 hours. The system is attached to the patient through a multilumen microcatheter inserted into a peripheral vein in the arm. The Fluispotter will be inserted in both healthy subjects and patients with adrenal insufficiency.
218890202|NCT02898363|OTHER|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
218890203|NCT05089643|DRUG|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
219033216|NCT03668626|OTHER|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
219033217|NCT04318509|DIETARY_SUPPLEMENT|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
219033218|NCT00298207|BEHAVIORAL|Walking (behavior)|
219033219|NCT01466387|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
219033220|NCT01466387|BIOLOGICAL|Yellow Fever Vaccine|One dose of yellow fever vaccine.
219033221|NCT01466387|BIOLOGICAL|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
219033222|NCT01466387|BIOLOGICAL|Rabies Vaccine|Three doses of Rabies vaccine.
219033223|NCT01466387|BIOLOGICAL|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
219033224|NCT04471389|OTHER|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
219033225|NCT03486093|DEVICE|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
219608443|NCT01769248|DEVICE|Fine needle biopsy|FNB
219608444|NCT05902286|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
219613318|NCT01999920|DRUG|Placebo|One to two pills per day for 12 weeks
218890204|NCT05089643|DRUG|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
218890205|NCT01173601|DRUG|LY2216684|
218890206|NCT01173601|DRUG|Placebo|
218890207|NCT01173601|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
218890208|NCT04403451|BEHAVIORAL|True North|Love Notes, Financial Stability, Jobs
218890209|NCT02042521|DRUG|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
219033226|NCT03486093|BEHAVIORAL|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
219033227|NCT03159481|BEHAVIORAL|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
219033228|NCT04628676|DRUG|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
219033229|NCT04628676|DRUG|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
219033230|NCT05083793|DRUG|Pregabalin 150mg|The effect of pregabalin on post-operative pain
219033231|NCT05083793|OTHER|Placebo|patients will receive placebo one hour before operation
219033232|NCT05441527|DEVICE|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
219033233|NCT05441527|DEVICE|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
219033234|NCT05068128|OTHER|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~\- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
219033235|NCT05068128|OTHER|PERFUSION TEST|"The test will be performed will include:~* Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~* Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~* Recording of the opening pressure for 10 minutes~* The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~* At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~* The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
219033236|NCT03014323|DRUG|Galantamine|Galantamine 4 mg twice a day for 4 weeks
219033237|NCT03014323|DRUG|Placebo|Placebo 1 capsule twice a day for 4 weeks
219033238|NCT01866514|PROCEDURE|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
219033239|NCT01866514|DRUG|2% preservative-free lidocaine|
219033240|NCT01866514|DEVICE|EZ-IO|
219033241|NCT00897988|GENETIC|gene expression analysis|
219033242|NCT00897988|GENETIC|mutation analysis|
219033243|NCT00897988|GENETIC|polyacrylamide gel electrophoresis|
219033244|NCT00897988|GENETIC|polymerase chain reaction|
219033245|NCT00897988|GENETIC|protein expression analysis|
219033246|NCT00897988|GENETIC|reverse transcriptase-polymerase chain reaction|
219033247|NCT00897988|OTHER|flow cytometry|
219033248|NCT00897988|OTHER|immunoenzyme technique|
219033249|NCT00897988|OTHER|immunologic technique|
219033250|NCT00897988|OTHER|laboratory biomarker analysis|
219033251|NCT00897988|OTHER|pharmacological study|
219033252|NCT00827255|DRUG|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
219509299|NCT06543641|DIAGNOSTIC_TEST|Invasive coronary angiography|According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
219509300|NCT04604184|DRUG|BI 764198|BI 764198
219509301|NCT04604184|DRUG|Placebo|Placebo
219509302|NCT02051803|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
219509303|NCT02051803|BEHAVIORAL|Health Education (HE)|
219509304|NCT01751412|RADIATION|Proton Radiation|
219509305|NCT05382923|BEHAVIORAL|Bright Light|3 consecutive days of 1 hour bright light
219509306|NCT05382923|BEHAVIORAL|Bright Light + Exercise + Melatonin|3 consecutive days of bright light, exercise, and melatonin
219509307|NCT05382923|BEHAVIORAL|Control|3 consecutive days of dim red light + light stretching + placbo
219613319|NCT00364767|DIETARY_SUPPLEMENT|A|Alcohol consumption (32 g/day) for 4 weeks
219203280|NCT06877871|OTHER|WBV utilizes mechanical vibrations to excite muscle, nerves. Abdominal binders are to help patients who have suffered abdominal trauma to stabilize core muscles, reduce pain, and improve mobility|(WBV) is a therapeutic modality that utilizes mechanical vibrations to excite muscle, nerve and tissue structures in the body. WBV was developed initially for fitness and physical rehabilitation and has been moving into other areas of healthcare such as pain management and neurological recovery and improving circulation.However, this activation can help to elevate intestinal motility, reduce bloating and help overall digestion.
219613320|NCT00364767|DIETARY_SUPPLEMENT|B|Water
219613321|NCT00343525|DRUG|bavituximab|
219033253|NCT04891900|DRUG|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
219033254|NCT04404855|OTHER|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
219033255|NCT04404855|PROCEDURE|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
219033256|NCT03209063|DIAGNOSTIC_TEST|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
219033257|NCT00386087|DRUG|Enzastaurin Hydrochloride|
219033258|NCT05870033|DEVICE|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
219033259|NCT02064010|DRUG|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
219033260|NCT02064010|DRUG|Placebo|Placebo tablet, administered orally for 4 weeks
219033261|NCT01085799|BEHAVIORAL|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
219033262|NCT02158390|BEHAVIORAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
219033263|NCT03320564|DIAGNOSTIC_TEST|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
219033264|NCT05190198|OTHER|Proprioceptive neuromuscular facilitation|"* Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible."
219033265|NCT05190198|OTHER|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
219033266|NCT01760512|PROCEDURE|Gastric bypass|Gastric bypass
219033267|NCT00860782|BEHAVIORAL|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
219033268|NCT01886183|OTHER|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
219033269|NCT01886183|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises.
219033270|NCT00788827|BIOLOGICAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
219033271|NCT01344187|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
219033272|NCT01344187|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
219033273|NCT01344187|DEVICE|KXL System|30 mW/cm2
219033274|NCT02331147|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment
219033275|NCT02331147|OTHER|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
219033276|NCT02242708|BEHAVIORAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
219033277|NCT01218555|DRUG|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
219033278|NCT01218555|DRUG|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
219203281|NCT06877754|BEHAVIORAL|Self-Acupressure|Both groups received general health education videos. The experimental group performed SP6 acupressure starting one week before menstruation, 10 minutes per session, twice daily, until the fifth day of menstruation. The control group maintained their usual routines.
219613322|NCT02892630|OTHER|No intervention|
219613323|NCT01722630|DRUG|Dopamine|
219613324|NCT04937881|DRUG|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
219613325|NCT04937881|DRUG|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
219613326|NCT06158893|DRUG|Salbutamol|inhalation anaesthesia
219613327|NCT06158893|DRUG|Budesonide|inhalation anaesthesia
219613328|NCT06158893|OTHER|Saline|saline
218890210|NCT02042521|DRUG|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
218890211|NCT03089021|OTHER|mulligan mobilization|mobilization with movement for spinous process or facet joint.
218890212|NCT03089021|OTHER|maitland mobilization|posterioanterior of spinous process or facet joint.
219509308|NCT01711021|DRUG|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
219203282|NCT06877351|DRUG|Amoxicillin|Participants randomized to the intervention group will receive oral amoxicillin at a dose of 40-50 mg/kg/day (maximum 1500 mg/day), administered in three doses daily for 14 days for early syphilis and 21 days for late syphilis or syphilis of unknown duration.
219203283|NCT06877351|DRUG|Penicillin G, Benzathine|Participants randomized to the control group will receive intramuscular procaine benzathine penicillin (PGB) at a dose of 50,000 IU/kg (maximum 2,400,000 IU/day), administered as a single dose for early syphilis and as three consecutive weekly doses for late syphilis or syphilis of unknown duration.
219203284|NCT06703060|BEHAVIORAL|Peer Navigation Group|Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
219203285|NCT06874907|PROCEDURE|Glucose monitoring|Glucose monitoring
219509309|NCT01711021|DRUG|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
219509310|NCT00035009|DRUG|MK0869, aprepitant|
219608445|NCT05902286|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
219608446|NCT02303457|PROCEDURE|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
218890213|NCT03951077|DRUG|Elagolix|Capsule administered orally
218890214|NCT03951077|DRUG|Placebo|Capsule administered orally
218890215|NCT00748670|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
219509311|NCT00035009|DRUG|Comparator: paroxetine HCL|
218890216|NCT00889512|DRUG|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
218890217|NCT00889512|DRUG|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
218890218|NCT03147352|DEVICE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
219509312|NCT01784133|DRUG|omiganan|
219509313|NCT01784133|DRUG|placebo|
219509314|NCT02137083|DRUG|Docetaxel|75mg/m2 D2 every 21 days
219509315|NCT02137083|DRUG|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
219509316|NCT02840383|OTHER|Delayed Intervention|Schools not receiving intervention until two years after implementation.
218890219|NCT02297386|DRUG|[18F] DIHYDRO-TESTOSTERONE|
218890220|NCT02297386|DEVICE|PET scan|
218890221|NCT02297386|DEVICE|MRI|
218890222|NCT02297386|OTHER|Blood draw|
218890223|NCT02009488|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
218890224|NCT02009488|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
218890225|NCT02009488|DRUG|Placebo|One placebo capsule (inactive medication) once daily.
218890226|NCT02399709|DRUG|simvastatin|
218890227|NCT02399709|DRUG|Placebo|
218890228|NCT00488540|DRUG|Paracetamol|Suppository
218890229|NCT00488540|DRUG|Placebos|Suppository
218890230|NCT01001117|DEVICE|LensAR laser surgery|Use of laser for cataract surgery
219509317|NCT02840383|OTHER|Intervention|intervention at the beginning of study.
219509318|NCT00306345|BEHAVIORAL|Outreach|
219509319|NCT01844583|DRUG|Alisertib|Alisertib tablets
219509320|NCT01844583|DRUG|Esomeprazole|Esomeprazole capsules
219509321|NCT01844583|DRUG|Rifampin|Rifampin capsules
219509322|NCT01625377|DRUG|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
219608447|NCT02303457|PROCEDURE|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
219608448|NCT04525534|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment
219608449|NCT02902224|DIETARY_SUPPLEMENT|Tap water|300ml tap water via nasogastric tube
219509323|NCT01625377|DRUG|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
219509324|NCT01625377|DRUG|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
219509325|NCT01625377|DRUG|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
219608450|NCT02902224|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose via nasogastric tube
219608451|NCT02902224|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g fructose via nasogastric tube
218890231|NCT01001117|DEVICE|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
218890232|NCT02922335|BEHAVIORAL|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
218890233|NCT02922335|BEHAVIORAL|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
218890234|NCT01395901|DRUG|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
218890235|NCT01395901|DRUG|Ondansetron|"Single dose Ondansetron IV:~* 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg;~* 13 years to less than 17 years dose: 4 mg"
218890236|NCT01395901|DRUG|Placebo to Ondansetron|
218890237|NCT01395901|DRUG|Placebo to Palonosetron|
218890238|NCT03923790|BEHAVIORAL|Educational Packet|The patient will receive an educational packet.
218890239|NCT03923790|BEHAVIORAL|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
218890240|NCT03923790|BEHAVIORAL|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
218890241|NCT03923790|BEHAVIORAL|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
218890242|NCT03923790|DIAGNOSTIC_TEST|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
218890243|NCT05759494|DIAGNOSTIC_TEST|rapid diagnostic test (multiplex PCR filmArray)|"novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis."
218890244|NCT04775485|DRUG|Tovorafenib|Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.
218890245|NCT00873600|DRUG|chemotherapy|
218890246|NCT00873600|OTHER|medical chart review|
219509326|NCT01625377|DRUG|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
219509327|NCT03231254|DEVICE|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
219509328|NCT01997554|OTHER|Blood sample|An extra blood sample of 10 ml is collected
219509329|NCT03513497|OTHER|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
219509330|NCT01000753|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219608452|NCT02368964|DRUG|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
219608453|NCT02368964|DRUG|high dose hCG 500 mcg|Treatment for triggering
219608454|NCT03925675|DRUG|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
219608455|NCT04795037|DRUG|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
219613329|NCT03877835|PROCEDURE|Peripheral nerve blocks|LSIB + SSNB
219613330|NCT01280643|DRUG|fluorouracil|Given IV
219203286|NCT06877130|OTHER|Aerobic exercise with BFR|"To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device.~Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises."
219203287|NCT06877130|OTHER|Aerobic training|"HR max = 206.9 - (0.67 x age).~Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate"
219203288|NCT06876922|OTHER|Thoracic mobility exercises Group|Thoracic mobility exercises Group: Conventional physiotherapy exercises were given to individuals participating in the control group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Thoracic mobility exercises were applied to individuals participating in the study group in addition to conventional physical therapy exercises.
219509331|NCT03028662|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
219509332|NCT03368989|DRUG|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
219509333|NCT00445289|DEVICE|SmartCare/PS|
219509334|NCT06202157|OTHER|LMB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
219608456|NCT04795037|DRUG|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
218890247|NCT00873600|OTHER|questionnaire administration|
219203289|NCT06876922|OTHER|the Conventional physiotherapy exercises Group|the Conventional physiotherapy exercises Group: Conventional physiotherapy exercises were given to individuals participating in the Conventional physiotherapy exercises group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Use this module to add descriptions of each arm in the study and to list the interventions being studied.
219203290|NCT06879158|DRUG|BR3409|One tablet administered alone
219203291|NCT06879158|DRUG|BR3409-1|One tablet administered alone
219203292|NCT06879158|DRUG|BR3409-2|One tablet administered alone
219203293|NCT06878508|DEVICE|DuoCor Ventricular Assist System|The DuoCor VAS is used to provide hemodynamic support by shareing some or all the workload of the left and right ventricles during the support period.
219203294|NCT06879938|DEVICE|High-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid|five treatment sessions of high-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid 2 weeks apart with a duration of approximately 15 minutes
219203295|NCT06879938|DEVICE|hyaluronic acid-based gel (Hydeal-D®)|hyaluronic acid-based gel (Hydeal-D®) applied once every three days for 12 weeks
219203296|NCT06880497|PROCEDURE|total knee arthroplasty|Replacement of knee articulating surface for patients with end-stage osteoarthritis.
219203297|NCT06827873|DIETARY_SUPPLEMENT|ARA (Arachidonic Acid) Supplementation|Oral ARA (Arachidonic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsule composition includes: C14:0 (0.15%), C16:0 (6.08%), C16:1 (0.15%), C18:0 (4.57%), C18:1 (19.65%), C18:2 (38.46%), C18:3 (0.87%), C20:0 (0.50%), C20:3 (2.00%), C20:4 (18.66%), C22:0 (1.81%), C24:0 (4.05%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
219203298|NCT06827873|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|Oral Double Wood brand TUDCA (Tauroursodeoxycholic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsules primarily contain TUDCA, with 500 mg per serving (two capsules), other ingredients include gelatin and rice powder. Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
219203299|NCT06827873|DIETARY_SUPPLEMENT|Placebo Supplementation|Oral placebo capsules identical in appearance and smell, dosage 1000 mg/person/day. Placebo capsule composition includes: C14:0 (0.09%), C16:0 (6.12%), C16:1 (0.03%), C18:0 (3.50%), C18:1 (28.06%), C18:2 (59.40%), C20:0 (0.27%), C22:0 (0.76%), C24:0 (0.26%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue taking placebo until Day 24.
219608457|NCT04795037|DRUG|Placebo|Placebo matched to CU06-1004, oral capsule
219608458|NCT04960371|DIAGNOSTIC_TEST|coronary flow reserve (CFR)|Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
219608459|NCT05156671|BIOLOGICAL|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
219608460|NCT05156671|DRUG|Placebo|Drip infusion over 60 minutes
218890248|NCT00873600|PROCEDURE|adjuvant therapy|
218890249|NCT00873600|PROCEDURE|assessment of therapy complications|
218890250|NCT00873600|PROCEDURE|cognitive assessment|
218890251|NCT00873600|PROCEDURE|psychosocial assessment and care|
218890252|NCT00873600|PROCEDURE|quality-of-life assessment|
218890253|NCT02279667|DRUG|BIA 2-093|oral suspension 50 mg/mL
218890254|NCT02279667|DRUG|BIA 2-093|200 mg tablet
218890255|NCT02279667|DRUG|BIA 2-093|800 mg tablet
218890256|NCT03686293|OTHER|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
219203300|NCT06827873|BIOLOGICAL|Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine|Administer Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine, produced by Shanghai Biological Products Research Institute Co., Ltd. , specification 0.5ml/dose, containing 15.0 μg hemagglutinin (for each influenza virus strain), suitable for intramuscular injection in individuals 6 months and older. Administer one dose to all study participants on Day 3. Closely observe and record any potential adverse reactions after vaccination.
218890257|NCT01267305|DRUG|Fondaparinux|2.5mg IH qd(8AM) after operation
219203301|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
219509335|NCT06202157|OTHER|DHB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
219509336|NCT00020891|PROCEDURE|computed tomography|
219509337|NCT00020891|RADIATION|radiation therapy|
219509338|NCT04509973|DRUG|Dexamethasone|ATC code: H02AB02
219509339|NCT03246230|BIOLOGICAL|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
218890258|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
218890259|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
218890260|NCT00713544|DRUG|AZD5672|20 mg oral, once daily
218890261|NCT00713544|DRUG|Etanercept|50 mg, subcutaneous injection, weekly
218890262|NCT00713544|DRUG|Placebo|placebo, oral, once daily
218890263|NCT00713544|DRUG|AZD5672|50 mg oral, once daily
218890264|NCT00713544|DRUG|AZD5672|100 mg oral, once daily
218890265|NCT00713544|DRUG|AZD5672|150 mg oral, once daily
218890266|NCT04799249|DRUG|Trilaciclib|Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
218890267|NCT04799249|DRUG|Placebo|Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
218890268|NCT04799249|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
219033279|NCT05643261|OTHER|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
219033280|NCT03667365|PROCEDURE|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
219033281|NCT03667365|OTHER|strict clinical surveillance|strict clinical surveillance strategy
219033282|NCT05228392|OTHER|listening to music|listening to lullaby or other music types
219033283|NCT05540834|DRUG|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
219033284|NCT02595086|PROCEDURE|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
219033285|NCT02595086|PROCEDURE|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
219033286|NCT03630809|BIOLOGICAL|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
219033287|NCT03889769|DIAGNOSTIC_TEST|OSNA test|Analysis of lymph node with OSNA
219033288|NCT01083212|DRUG|AZD1656|Single dose,oral tablet
219033289|NCT01083212|DRUG|Gemfibrozil|Oral tablet bid on day 1 - 5.
219033290|NCT01083212|DRUG|Placebo|Oral tablet bid on day 1-5
219033291|NCT03463746|DEVICE|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
219033292|NCT03463746|DEVICE|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
219033293|NCT03843879|PROCEDURE|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
219033294|NCT03843879|DRUG|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
219033295|NCT01093911|BIOLOGICAL|CDP7657|Ascending single doses of CDP7657
219033296|NCT01093911|OTHER|Placebo|Placebo: 0.9% sodium chloride aqueous solution
219033297|NCT01586819|DRUG|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
219033298|NCT01586819|PROCEDURE|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
219033299|NCT05044455|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
219033300|NCT05696912|GENETIC|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
219033301|NCT05696912|GENETIC|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
219203302|NCT06691087|BEHAVIORAL|Influence of the parameters of the sound timbre on the perception of a sound|"The experiment consists of evaluating the sound level of n complex stimuli, then equalising them in loudness, in order to measure a loudness curve in function of timbre descriptors.~The stimuli will then be listened to again in pairs. The task is there to compare the stimuli using a VAS to indicate how different the two sounds are."
219203303|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test|The experiment consists in identifying the parameters of the sound timbre that most disturb the understanding of complex sound scenes, by asking the participants to identify sounds whose timbre has been modified.
219203304|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test with hearing aids|The experiment will be identical to intervention 2. This time, the modification of the stimulus timbres will focus on the most problematic dimensional modifications, i.e. those where the difference between normal-hearing and hearing-impaired listeners is greatest. We will then modify the signal processing parameters of the hearing aid simulator (for example, the size of the averaging window or the gain balance of the filters), to observe their impact on the salience of certain stimuli.
219203305|NCT05495984|BEHAVIORAL|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
219203306|NCT05495984|BEHAVIORAL|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
219203307|NCT06705465|BEHAVIORAL|video conference|video conference
219203308|NCT06706440|OTHER|no intervention, observational study|Only data will be taken of patient's file.
219203309|NCT04731233|BIOLOGICAL|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
219203310|NCT04731233|DRUG|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
219203311|NCT05292027|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
219203312|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
219203313|NCT06708702|DRUG|Copaíba mouthwash|"A 15% aqueous solution of copaíba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula of copaíba oil (Copaifera Officinalis Resin) 15%, liquid mint aroma 5%, tween 80 1%, aqueous solution (Distilled water + Nipagin 0.1%) qsp 100%.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
219203314|NCT06708702|DRUG|Placebo mouthwash|"Placebo will be used, under the formula of liquid mint flavor 5%, Nipagim 0.1%, and distilled water qsp 60 ml, packed in packaging compatible with that of the product under investigation, maintaining the same physical characteristics to maintain blinding. The product will be stored at room temperature and stored in the INCA pharmacy.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
219203315|NCT06712069|DEVICE|Multimodal Intraoperative Neurophysiologic Monitoring (MIONM)|"Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) is a real-time, device-based intervention used during neurosurgical procedures to monitor and preserve the integrity of neural pathways. It combines the following modalities:~Somatosensory Evoked Potentials (SSEP): Monitors sensory pathways by stimulating peripheral nerves and recording cortical responses.~Motor Evoked Potentials (MEP): Assesses motor pathways via transcranial stimulation and muscle response evaluation.~Electromyography (EMG): Detects nerve irritation and monitors muscle activity during surgery.~This intervention provides critical real-time feedback to the surgical team, enabling immediate adjustments to prevent neurological damage and enhance surgical outcomes. The Cascade IOMAX system is the primary device used in this study for implementing MIONM."
219203316|NCT06712667|OTHER|Caffeine content|Participants will drink the same volume of water or coffee with different amounts of caffeine.
219203317|NCT06707376|OTHER|Early Kangaroo Mother Care|"* Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants."
219203318|NCT06709040|DRUG|Somapacitan|Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.
219203319|NCT06709131|DRUG|CAR-T cells（ chimeric antigen receptor T cells）|CAR-T cells（ chimeric antigen receptor T cells）
219203320|NCT06710834|DEVICE|Hemoadsorption cartridge|HA 130 cartridge
219203321|NCT06710834|DEVICE|Hemodiafiltration|Postdilutional hemodiafiltration
219509340|NCT03246230|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
219613331|NCT01280643|DRUG|leucovorin calcium|Given IV
218890269|NCT04799249|DRUG|Carboplatin|Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
219203322|NCT06710028|DEVICE|NORA|NORA app will be downloaded on the patient's mobile device, tablet or computer for clinical monitoring after discharge from the hospital at 3, 6 and 12 months after stroke. At the time of discharge, the patient will be provided with all the information and training necessary for its use. This application has been clinically validated in stroke patients, demonstrating to improve communication between professionals and patients. It improves the adherence of patients to prescribed therapy and their control of cardiovascular risk factors, with the the goal of preventing new episodes. Stroke patients have actively participated in the development of NORA, its use is simple and intuitive, and there are no age restrictions for its use. Through NORA patients will receive questionnaires to evaluate their clinical outcomes after stroke (Patient Reported Outcome Measures- PROMs and Patient Reported Experience Measures- PREMs).
219203323|NCT06707805|OTHER|Traditional Physical therapy|Conventional treatment protocol including moist Heating pad for low back pain for 15 minutes. TENS for pain for 10 minutes. Stretchings of tight muscles would be 1 set of 5-7 reps with 5 sec. hold 3 times a week. Strengthing of weak muscles would be 2-3 times a weak with 10-15 reps.Stretching protocol will be followed for Iliopsoas and erector spinae muscles. Strengthening protocol will be followed for weak abdominals and Gluteus maximus muscles
219203324|NCT06707805|OTHER|lumber SNAGS|": Lumber mobilizations with conventional treatment protocol.~* Lumber Mulligan(SNAGs) technique~* Technique applied at L4-L5, L5-S1 level.~* Techniques applied for flexion ,extension, side bending and rotation 6 to 8 cycles per session"
219203325|NCT06707753|DRUG|AL-001|Administered via suprachoroidal space injection.
219509341|NCT04990830|DRUG|Inhaled Low molecular weight heparin|Application with Soft Mist Inhaler
219509342|NCT04990830|DRUG|Standard Treatment|Control Group
219509343|NCT00279448|DRUG|exemestane|On tablet of 25 mg per day during 5 years
219509344|NCT00279448|DRUG|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
219509345|NCT05096325|DEVICE|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
219613332|NCT01280643|DRUG|oxaliplatin|Given IV
218890270|NCT06303102|OTHER|Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.
218890271|NCT06303102|OTHER|Manual PT/Conventional PT Treatment|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
218890272|NCT02380287|DRUG|humanized monoclonal antibody against human IL-17|
218890273|NCT05767840|OTHER|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
218890274|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
218890275|NCT04293341|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
218890276|NCT04293341|BEHAVIORAL|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
219033302|NCT01359254|DRUG|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
219033303|NCT01359254|DRUG|Fludarabine|Fludarabine is given through the vein daily for 5 days.
219033304|NCT01359254|DRUG|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
219033305|NCT01359254|DRUG|Busulfan|Busulfan is given daily for 4 days.
219033306|NCT01359254|DRUG|Total Body Irradiation (TBI)|TBI is given twice on the last day.
219033307|NCT01203228|OTHER|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
219033308|NCT01203228|OTHER|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
219033309|NCT04498728|OTHER|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
219033310|NCT05752110|DRUG|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
218890277|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
218890278|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
218890279|NCT03384368|DEVICE|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
218890280|NCT01641601|DEVICE|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
218890281|NCT04768621|OTHER|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
218890282|NCT04577469|DRUG|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
218890283|NCT04577469|DRUG|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
218890284|NCT04977713|OTHER|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
218890285|NCT04977713|OTHER|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
218890286|NCT00037492|PROCEDURE|home-based sessions/family meetings with trained clinician|
219033311|NCT05752110|OTHER|Saline|0.09% Saline (0.05ml/kg) intravenously administered
219033312|NCT01571895|DRUG|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
219033313|NCT01457885|DRUG|Clofarabine/Busulfan x 4|"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
219033314|NCT01457885|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
219033315|NCT02770586|DIAGNOSTIC_TEST|Breast PET|imaging of the breast using the Breast PET system
219033316|NCT05832333|BIOLOGICAL|VaxigripTetra®|Suspension for injection Injection intramuscular
219033317|NCT06160063|BEHAVIORAL|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
219033318|NCT04668950|DRUG|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
219033319|NCT04668950|DRUG|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
219033320|NCT02064881|DRUG|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
219033321|NCT02064881|DRUG|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
219033322|NCT03379207|OTHER|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
219033323|NCT03379207|OTHER|Tracheal Aspirates|Only for mechanically ventilated participants.
219033324|NCT03379207|OTHER|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
219033325|NCT03745092|DEVICE|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
219033326|NCT03745092|DEVICE|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
219033327|NCT03979638|DRUG|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
219033328|NCT03979638|DRUG|Placebo|Matching placebo for BLU-5937
219033329|NCT02227342|BIOLOGICAL|Fecal Microbiota Transplant|serial FMT
219033330|NCT04255355|OTHER|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
219509346|NCT02470039|DRUG|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
219509347|NCT02470039|DRUG|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
219509348|NCT02470039|DRUG|placebo|Administered once daily
218890287|NCT05185726|BEHAVIORAL|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
219033331|NCT04255355|OTHER|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
219033332|NCT04255355|OTHER|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
219203326|NCT06706739|OTHER|Online art game intervention group|The researchers conducted a prospective randomized controlled trial in which elderly patients with mild cognitive impairment combined with subthreshold depression who met the inclusion exclusion criteria were randomized into an online art game intervention group and a health education control group, with each group receiving an individualized intervention for 12 weeks. Participants in the experimental group created comic strips through an art game platform developed by the researchers' research team.
219203327|NCT06708000|DIAGNOSTIC_TEST|Clinical Likelihood (CL) Model-Based Diagnostic Strategy|The Clinical Likelihood (CL) model-based diagnostic strategy utilizes two models: the RF-CL model and the CACS-CL model. These models assess the pre-test probability of obstructive coronary artery disease (CAD) based on patient factors such as age, sex, symptoms, and traditional cardiovascular risk factors like smoking, diabetes, and hypertension. The CACS-CL model incorporates coronary artery calcium scoring to further refine the risk assessment. Patients identified with a low likelihood of CAD may avoid unnecessary diagnostic testing, such as cardiac CT, while maintaining diagnostic accuracy and safety. This approach aims to optimize resource use, reduce patient burden, and focus on other potential causes of symptoms when CAD is unlikely.
219033333|NCT01064492|DRUG|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
219033334|NCT00945581|OTHER|Experimental Nutritional Powder Formula|Powder twice a day
219033335|NCT00945581|OTHER|Placebo comparator|Powder twice a day
219203328|NCT06708000|DIAGNOSTIC_TEST|Standard of care treatment|Patients will follow the standard diagnostic pathway, which includes the use of cardiac CT and other advanced diagnostic procedures based on clinical guidelines. This approach is the current standard of care for patients with suspected obstructive coronary artery disease (CAD). The control group allows for comparison of outcomes with those in the intervention arm, particularly in terms of resource utilization, patient safety, and diagnostic accuracy.
219203329|NCT06707636|BEHAVIORAL|Experimental: Black Women's Stress and Wellness (B-SWELL) arm|The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
219203330|NCT06707636|BEHAVIORAL|Active Comparator: Wellness (WE) arm|This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.
219033336|NCT04130399|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
219203331|NCT06707233|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT.
219203332|NCT06707987|DRUG|Non-immunogenic staphylokinase|Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
219203333|NCT05172180|DRUG|Reamberin|the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
219509349|NCT01448135|OTHER|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
219509350|NCT01448135|OTHER|Osmolite 1.2|High protein enteral formula
219509351|NCT03340168|OTHER|Bisphenol-S|Oral and dermal exposure in volunteers
219509352|NCT02025114|DRUG|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
219509353|NCT03422146|OTHER|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
219509354|NCT03422146|OTHER|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
219509355|NCT02271555|DRUG|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
219509356|NCT02271555|DRUG|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
219509357|NCT02271555|DRUG|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
219509358|NCT00821210|DEVICE|Sham CPAP|CPAP with pressure of 3cm H2O
219203334|NCT05172180|DRUG|Ringer's solution|Ringer's solution at an average daily dose of 8.1 ml/kg/day
218890288|NCT05185726|BEHAVIORAL|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
218890289|NCT05185726|BEHAVIORAL|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
218890290|NCT05158517|DRUG|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
219033337|NCT04130399|DRUG|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
219033338|NCT04461782|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Oral food supplement
219203335|NCT06713408|OTHER|Experimental (Music)|Audio recordings consisting of pentatonic music and neva makam will be uploaded to the patients' phones by the researcher. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
219203336|NCT06713408|OTHER|Experimental (Affirmation)|Patients in this group will be asked to listen to the audio recording with pentatonic music and neva makam in the background, along with the affirmation sentences provided in the appendix. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
219203337|NCT05379855|DRUG|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
219203338|NCT05379855|DRUG|placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)|using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
219203339|NCT05379855|DRUG|0.05% atropine eye drops|using 0.05% atropine eye drops for both eyes every night
219203340|NCT05656586|OTHER|observational-- no intervention|observational
219033339|NCT02576028|OTHER|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
219033340|NCT02576028|OTHER|standard active exercises|two sessions of 45 minutes of active exercises
219203341|NCT01543659|DRUG|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
219203342|NCT06877858|DRUG|Methadone hydrochloride|Methadone loading dose initiation (vs. standard initiation in the TAU arm)
219203343|NCT06881186|PROCEDURE|Intra-articular injection|Intra-articular injection of a cell-free collagenic gel matrix into the trapeziometacarpal joint
219203344|NCT06881576|OTHER|Compare VCI scale|Compare VCI scale
219203345|NCT06879015|PROCEDURE|Tension Band Plate (TBP) Surgery|A guided growth procedure in which a non-locking 8-plate is placed extraperiosteally across the physis (growth plate) with two screws, one in the epiphysis and one in the metaphysis. This allows for gradual correction of coronal angular deformities without causing permanent growth arrest.
219033341|NCT05112380|OTHER|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
219033342|NCT00901758|DRUG|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
219509359|NCT00821210|DEVICE|CPAP of optimal pressure|CPAP of optimal pressure
219033343|NCT00901758|DRUG|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
219033344|NCT03465332|OTHER|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
219033345|NCT03465332|OTHER|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
219033346|NCT02620514|BEHAVIORAL|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
219509360|NCT01412541|PROCEDURE|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
219033347|NCT02620514|BEHAVIORAL|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
219033348|NCT02620514|BEHAVIORAL|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
219033349|NCT02620514|BEHAVIORAL|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
219033350|NCT00272571|PROCEDURE|External counter pulsation therapy|
219033351|NCT00713336|DRUG|ZD4054|ZD4054 10mg Tablet
219033352|NCT00713336|DRUG|Moxifloxacin|400 mg capsule
219033353|NCT00713336|DRUG|ZD4054 Placebo|3 tablets
219033354|NCT00713336|DRUG|Moxifloxacin placebo|1 capsule
219033355|NCT00713336|DRUG|ZD4054 Placebo|2 tablets
219033356|NCT00713336|DRUG|ZD4054|30mg tablet
219033357|NCT00713336|DRUG|ZD4054|10mg tablet
219033358|NCT05810090|PROCEDURE|Total knee arthroplasty|patient who received a TKA in our hospital
219033359|NCT03341195|BEHAVIORAL|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
219033360|NCT00550095|DRUG|valsartan|
219033361|NCT02790970|DEVICE|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
219033362|NCT02790970|OTHER|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
219033363|NCT06215404|OTHER|Liberal group|Fluid challage to keep stroke volume variation \< 10%
219033364|NCT06215404|OTHER|restrictive group|Fluid challage to keep stroke volume variation \< 18%
219033365|NCT01416727|OTHER|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
219033366|NCT01416727|OTHER|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
219033367|NCT01983579|PROCEDURE|Intraocular anti-VEGF injection|
219033368|NCT01983579|DEVICE|SENSIMED Triggerfish|
219033369|NCT00355862|DRUG|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
219033370|NCT00355862|DRUG|Sirolimus|Sirolimus based immunosuppression
219509361|NCT01412541|DEVICE|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
219613333|NCT01280643|DRUG|irinotecan hydrochloride|Given IV
219033371|NCT04248933|BEHAVIORAL|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
219033372|NCT04010721|DEVICE|Experiment 1|Stimulation of one electrode at a time
219033373|NCT04010721|DEVICE|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
219033374|NCT04010721|DEVICE|Experiment 3|Stimulation total duration from 10 to 600 ms
219033375|NCT04196946|DRUG|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
219033376|NCT04196946|DRUG|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
219033377|NCT04391387|PROCEDURE|prone position|a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
219033378|NCT03569332|OTHER|Alarm|"1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
219033379|NCT03569332|OTHER|Nurse's dashboard|"1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display."
219033380|NCT04874974|BEHAVIORAL|Metacognitive and Defusion Training|Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
219033381|NCT05004376|BEHAVIORAL|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
219509362|NCT05876702|DEVICE|endoscopy|use of upper endoscopy with i-scan specially , in diagnosis of esophageal lesions and comparison of results with histopathology.
219509363|NCT03616613|DIAGNOSTIC_TEST|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
218890291|NCT01591941|OTHER|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
218890292|NCT02123849|DRUG|Aspirin|Given PO
218890293|NCT02123849|OTHER|Laboratory Biomarker Analysis|Correlative studies
218890294|NCT02123849|OTHER|Placebo|Given PO
219203346|NCT06879015|PROCEDURE|Percutaneous Epiphysiodesis by Transphyseal Screw (PETS) Surgery|A minimally invasive procedure in which a partially threaded cannulated screw is inserted across the growth plate (transphyseal) to slow growth on one side of the bone. This technique allows for gradual correction of genu valgum and genu varum.
219203347|NCT06878287|OTHER|Light exposure|30 minutes morning exposure to light (10 000 lux) using a light-box device filtering UV (CE marking)
219203348|NCT06878287|OTHER|Placebo light|30 minutes exposure to the same device using a filter inactivating light intensity (\< 10 lux)
219203349|NCT06880003|OTHER|During delivery, blood samples will be collected from the umbilical cord|During delivery, blood samples will be collected from the umbilical cord of pregnant women who agree to participate in the study.
219203350|NCT06876038|DRUG|5-Amino Levulinic Acid|5-ALA (Gleolan) orally (20 mg/kg BW 5-ALA HCl) 2 to 4 hours prior to undergoing image-guided SITOS-based PDT treatment
219509364|NCT03294538|DRUG|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
219509365|NCT03294538|DRUG|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
218890295|NCT00950846|DRUG|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
218890296|NCT00950846|DRUG|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
218890297|NCT00950846|DRUG|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
218890298|NCT00950846|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
219033382|NCT01422863|BEHAVIORAL|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
219033383|NCT01087047|DEVICE|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
219033384|NCT04026607|DIETARY_SUPPLEMENT|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
219033385|NCT02038595|RADIATION|PET imaging|
219033386|NCT05184374|DRUG|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
219033387|NCT06162156|OTHER|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
219509366|NCT03294538|DRUG|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
218890299|NCT05809843|DEVICE|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
218890300|NCT05041283|OTHER|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
218890301|NCT05041283|OTHER|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
218890302|NCT01278563|BEHAVIORAL|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
218890303|NCT05408390|OTHER|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
218890304|NCT05408390|OTHER|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
218890305|NCT05408390|OTHER|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
218890306|NCT05408390|OTHER|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
218890307|NCT01799226|OTHER|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
219203351|NCT06876350|OTHER|Woodcasting Splint|This is the experimental group so we could see the outcomes and preference for patients using surveys and compliance scores
219203352|NCT06876350|OTHER|Control (Standard treatment)|Thermoplastic splints are standard of care treatment for patients after CMC arthroplasty. We will use the data from this group as the comparator to the experimental group.
219203353|NCT06877936|PROCEDURE|EOS exam|The EOS procedure will consist of taking 3 x-rays per side (6 in total) while the patient is standing (oriented at 35° to the x-ray) with the arm in position 0°, then at 45° and finally at 90° elevation in the frontal plane for 20 seconds per position.
219203354|NCT06877936|OTHER|Questionnaires Constant et ASES|There will be 2 questionnaires : Constant and American Shoulder and Elbow Surgeons to determine their pain level and functional limitations.
219203355|NCT05178498|PROCEDURE|Follow-Up|Undergo follow up
219509367|NCT03329118|DRUG|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
219509368|NCT03881813|DEVICE|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
218890308|NCT01799226|OTHER|Triclosan|this intervention will use Colgate Total which contains triclosan
219509369|NCT04247490|DIAGNOSTIC_TEST|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
218890309|NCT02137824|PROCEDURE|sinus floor elevation|
218890310|NCT02987751|DRUG|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
218890311|NCT02987751|DRUG|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
218890312|NCT01115868|DRUG|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
218890313|NCT01115868|DRUG|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
218890314|NCT01115868|DRUG|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
218890315|NCT01115868|DRUG|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
218890316|NCT02178995|DRUG|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
218890317|NCT05699824|DRUG|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
218890318|NCT05699824|OTHER|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
218890319|NCT05699824|DRUG|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
218890320|NCT01637155|DRUG|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
218890321|NCT05961657|DIAGNOSTIC_TEST|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
219033388|NCT02586896|BEHAVIORAL|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
219033389|NCT02586896|BEHAVIORAL|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
219033390|NCT04666064|DIAGNOSTIC_TEST|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
219033391|NCT04666064|OTHER|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
219033392|NCT00578942|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
219033393|NCT01166477|DRUG|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
219033394|NCT01166477|DRUG|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
219033395|NCT04070131|OTHER|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
219033396|NCT03075670|DRUG|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
219033397|NCT03075670|DRUG|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
219033398|NCT03747965|BIOLOGICAL|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
219033399|NCT05725512|DRUG|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
219033400|NCT05725512|DRUG|Placebo|Placebo identical to prednisolone tablets
219033401|NCT00589316|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given via central line
219033402|NCT00589316|DRUG|Cyclophosphamide|Given IV
219033403|NCT00589316|DRUG|Fludarabine Phosphate|Given IV
219509370|NCT02366221|OTHER|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
219509371|NCT02366221|OTHER|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
218890322|NCT02274792|DRUG|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
218890323|NCT05635513|DEVICE|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
218890324|NCT04080102|OTHER|High Intensity Interval Training|Exercise
218890325|NCT04080102|DIETARY_SUPPLEMENT|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
218890326|NCT04080102|OTHER|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
218890327|NCT05809193|BEHAVIORAL|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
218890328|NCT03189160|BIOLOGICAL|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
218890329|NCT03189160|BIOLOGICAL|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
218890330|NCT03189160|OTHER|Non-treatment control group|
218890331|NCT03010033|OTHER|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
218890332|NCT00476827|DRUG|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
219203356|NCT05178498|PROCEDURE|Physical Examination|Complete physical measurements
219203357|NCT05178498|OTHER|Questionnaire Administration|Complete questionnaires
219203358|NCT06879613|DIETARY_SUPPLEMENT|Breastmilk|Breastmilk from the mother of the infant was given for pain
219203359|NCT06879613|PROCEDURE|Massage|The spot that was vaccinated was massaged by the mother/carer of the infant
218890333|NCT00476827|DRUG|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
218890334|NCT00476827|DRUG|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
218890335|NCT00476827|DRUG|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
218890336|NCT00476827|DRUG|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
219203360|NCT06881082|PROCEDURE|endoscopic band ligation with cross-section technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the cross-section banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.
219509372|NCT04964999|OTHER|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
219613334|NCT01280643|BIOLOGICAL|bevacizumab|Given IV
218890337|NCT00476827|DRUG|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
219033404|NCT00589316|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
219033405|NCT00589316|OTHER|Laboratory Biomarker Analysis|Correlative studies
219033406|NCT00589316|DRUG|Mycophenolate Mofetil|Given IV or PO
219033407|NCT00589316|DRUG|Tacrolimus|Given IV or PO
219033408|NCT00589316|RADIATION|Total-Body Irradiation|Undergo TBI
219033409|NCT00600938|DRUG|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
219033410|NCT00600938|DRUG|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
219033411|NCT00600938|DRUG|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
219033412|NCT00600938|DRUG|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
219033413|NCT00600938|DRUG|Deferasirox|
219033414|NCT00600938|DRUG|Deferoxamine|
219033415|NCT02897674|DIETARY_SUPPLEMENT|Palm olein|two thirds of the 30% fat calories will come from palm olein
219033416|NCT02897674|DIETARY_SUPPLEMENT|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
219033417|NCT02897674|DIETARY_SUPPLEMENT|soybean oil|two thirds of the 30% fat calories will come from soybean oil
219033418|NCT01065519|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
219033419|NCT01065519|DEVICE|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
219033420|NCT00255593|DRUG|rituximab|
218890338|NCT04479332|PROCEDURE|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
218890339|NCT02104466|PROCEDURE|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
218890340|NCT05258149|DEVICE|JJVC Investigational Multifocal Contact Lenses|TEST
218890341|NCT05258149|DEVICE|Dailies Total 1® Multifocal Contact Lenses|CONTROL
219203361|NCT06881082|PROCEDURE|Endoscopic band ligation using stepladder technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the stepladder banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment
219203362|NCT06881173|DRUG|Bu Zhong Yi Qi Tang|The experimental group took 15g of Buzhong Yiqi Decoction concentrated powder, 3 times a day, 1 packet each time.
219203363|NCT06881173|DRUG|caramel dyed starch placebo|The control group took 15 grams of caramel dyed starch placebo, 1 pack at a time, 3 times a day.
219203364|NCT06881355|DIAGNOSTIC_TEST|Bruxism diagnosis|The presence of bruxism was determined based on the participant's self-reported statements and intraoral findings.
219203365|NCT06881355|DIAGNOSTIC_TEST|Clinical evaluation|The PCRs on the relevant teeth were evaluated according to the revised FDI criteria
219203366|NCT06881108|OTHER|CHAT Core Functions|CHAT is a virtually delivered patient-level intervention designed to improve health insurance and cost-related literacy
219203367|NCT06881108|OTHER|LIFT Core Functions|LIFT (Lessening the Impact of Financial Toxicity), an intervention developed to coordinate access to existing financial assistance programs.
219203368|NCT06881108|OTHER|Member-Checking Process|Based on the findings from Steps 1 and 2, investigators will develop a document that outlines the points of overlap, harmony, or conflict identified by participants.
218890342|NCT03370042|PROCEDURE|semilunar coronally positioned flap with free gingival graft|
218890343|NCT03370042|PROCEDURE|semilunar coronally positioned flap alone|
218890344|NCT03590314|DEVICE|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
218890345|NCT03590314|OTHER|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
218890346|NCT00832416|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
218890347|NCT00832416|DRUG|Placebo|One Placebo tablet daily.
218890348|NCT00227812|DRUG|Bupropion|
218890349|NCT01912196|DRUG|MSI-195|
218890350|NCT01912196|DRUG|Placebo|
218890351|NCT05549830|OTHER|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
218890352|NCT03741972|DRUG|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
218890353|NCT00261027|DRUG|Exemestane|
219203369|NCT06881303|OTHER|preoperative stoma identification and education|The guide to good stoma therapy practice recommends that the site of the future stoma should be marked out preoperatively, in the lying, sitting and standing positions, so that the patient can see the stoma. What's more, the psychological impact of the stoma is such that preoperative and regular postoperative education is essential. This identification and initiation of education is carried out by stoma nurses and/or surgeons.
219203370|NCT06879600|DEVICE|High-flow nasal cannula therapy application|Patients will undergo HFNC preoxygenation for 3 minutes with a flow rate of 60 L/min of heated and humidified pure oxygen (100% FiO₂, 37°C - Optiflow; Fisher \& Paykel Healthcare, Auckland, New Zealand). To minimize air contamination, large or medium nasal cannulae will be selected based on the patient's nostril size
219203371|NCT06879600|DEVICE|Traditional facemask|Patients will undergo preoxygenation for 3 minutes using a face mask (sized appropriately to fit the patient and ensure an airtight seal) connected to an Aisys CS2 ventilation system (General Electric, GE Healthcare, Oy, Finland). In this group, the ventilation system will be set with a fresh gas flow of 10 L/min, FiO₂ = 100%, without inspiratory support or expiratory positive pressure. The face mask (Economy, Intersurgical, Fontenay-sous-Bois, France) will be removed after induction to enable intubation.
219203372|NCT06882343|OTHER|Beautiful Flow Plus X|Shofu's Beautifil Flow Plus X F03 is an advanced injectable bioactive composite that merges the adaptability of flowable composites with the mechanical properties of hybrid composites
219613335|NCT01280643|BIOLOGICAL|cetuximab|Given IV
219613336|NCT01280643|DRUG|capecitabine|Given PO
218890354|NCT01761448|DEVICE|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
218890355|NCT01761448|DEVICE|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
218890356|NCT01761448|DEVICE|Control group training without Guided Exercise system at home|
218890357|NCT01278992|DIETARY_SUPPLEMENT|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
218890358|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
218890359|NCT03545438|BIOLOGICAL|LIB003|LIB003 or placebo
218890360|NCT05887050|DIETARY_SUPPLEMENT|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
218890361|NCT05887050|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
218890362|NCT05504044|OTHER|Glucose control|50 g glucose dissolved in 250 mL water
219203373|NCT06882343|OTHER|Dentsply Nanohybrid flowable composite|a conventional nano hybrid flowable composite
219203374|NCT06881771|DIAGNOSTIC_TEST|Clinical phenotyping|"* Visual acuity assessment~* Contrast sensitivity evaluation~* Slit-lamp photography~* Specular microscopy~* Scheimpflug tomography~* Anterior segment optical coherence tomography~* In vivo confocal microscopy~* Spatio-temporal optical coherence tomography"
219203375|NCT06881771|GENETIC|CTG18.1 Expansion Status Genotyping|"Genotyping for trinucleotide repeat in the TCF4 gene (CTG18.1) and other genetic biomarkers using blood or saliva derived genomic DNA. This includes:~* Short tandem repeat - PCR~* Triplet-repeat primed - PCR~* Genome-wide single nucleotide polymorphism genotyping~* Ultra-deep locus-specific next-generation sequencing"
219203376|NCT06882707|OTHER|Median Nerve Mobilization|"Passive neuromobilisation of the median nerve and functional self-exercises. The procedure started with the patient in the supine position. The following steps were taken in sequence: shoulder girdle depression; slight abduction of the elbow extension with arm lateral rotation and forearm supination; wrist, finger and thumb extensions were added; and the shoulder was taken into further extension.~To apply maximum stretch opposite cervical side flexion was done, and, in the end, the wrist was repeatedly moved into and out of stretch by performing a few degrees of flexion and extension at the wrist.~This mobilization technique will be performed by an experienced physician/physiotherapist three times a week for 3 weeks, and the patients will be given 3 sets of 15 cycles with a 1-minute rest period in each set."
219203377|NCT06882707|OTHER|Ultrasound therapy|In control group, patients will received only ultrasound therapy. The patient will be in a sitting position with his/her face facing the physiotherapy technician, elbow in 90 degree flexion, forearm in supination, wrist in neutral position and supported by placing a towel under the patient's extremity and will be applied in Us intermittent mode with an intensity of 0.8 W/cm2 in 1 MHZ frequency in 1:4 mode for 10 minutes, moving in a way to draw an infinity sign for 10 seconds. Treatment will be given 5 days a week for 3 weeks and a total of 15 sessions.
219203378|NCT06691386|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
219203379|NCT06691386|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
218890363|NCT05504044|OTHER|Bread control|91.4 g white bread
218890364|NCT05504044|OTHER|Almond paste|88.7 g white bread and 15 g almond paste
218890365|NCT05504044|OTHER|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
218890366|NCT05504044|OTHER|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
218890367|NCT05392309|OTHER|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
218890368|NCT05392309|OTHER|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
219203380|NCT06691386|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
219613337|NCT01280643|GENETIC|mutation analysis|Correlative studies
218890369|NCT01442714|DRUG|Azacitidine|Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
218890370|NCT01442714|DRUG|Lenalidomide|Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
218890371|NCT00116220|DRUG|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
218890372|NCT00116220|RADIATION|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
218890373|NCT02229188|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
218890374|NCT02229188|BEHAVIORAL|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
218890375|NCT02229188|BEHAVIORAL|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
218890376|NCT03641170|BEHAVIORAL|Physical activity|Interval walking performed after each main meal.
218890377|NCT03641170|BEHAVIORAL|Inactivity|Inactivity after each main meal.
218890378|NCT03641170|OTHER|Fixed diet.|Participants will receive a fixed diet through out the intervention period and control period.
218890379|NCT02889211|BEHAVIORAL|Gambling Task|
218890380|NCT03173404|PROCEDURE|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
218890381|NCT04306510|DRUG|TEGSEDI|SC injection.
218890382|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
218890383|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
218890384|NCT05395741|DRUG|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
218890385|NCT01409447|DEVICE|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
219033421|NCT00433563|RADIATION|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
219033422|NCT00433563|RADIATION|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
219033423|NCT04894396|DEVICE|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
219033424|NCT04894396|DEVICE|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
219033425|NCT05094219|OTHER|No intervention will be offered|No intervention will be offered
219033426|NCT00139828|DRUG|human coagulation Factor IX|
219033427|NCT01124643|BIOLOGICAL|Replagal|0.2 mg/kg administered intravenously \[IV\] every other week
219033428|NCT00977132|DRUG|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
219033429|NCT00977132|DRUG|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
219033430|NCT05544838|DEVICE|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
219033431|NCT04903405|OTHER|No intervention|No intervention is involved in this study
219033432|NCT03215329|PROCEDURE|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
219033433|NCT04220411|DRUG|AR100DP1|topical ointment
219033434|NCT03762382|DRUG|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
219033435|NCT03762382|DRUG|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
219033436|NCT03762382|DRUG|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
219033437|NCT02487212|DRUG|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
219033438|NCT02487212|DRUG|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
219033439|NCT02487212|DEVICE|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
219033440|NCT02704078|DEVICE|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
219033441|NCT02704078|DEVICE|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
219033442|NCT03322215|DRUG|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
219033443|NCT03322215|DRUG|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
218890386|NCT05726487|BEHAVIORAL|ACTION Intervention|Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
219203381|NCT06691386|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
218890387|NCT05726487|OTHER|Education Control|Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
218890388|NCT06068426|DIAGNOSTIC_TEST|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
218890389|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
218890390|NCT06173154|OTHER|Routine care|standard care without any specific system in place
219033444|NCT03322215|DRUG|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
219203382|NCT06691386|OTHER|Test Product E|Use of Test Product E in controlled use and ad libitum use sessions
219203383|NCT06691386|OTHER|Reference Product F: Subjects' OBMST|Use of Reference Product F in controlled use and ad libitum use sessions. The subjects' Own Brand Moist Smokeless Tobacco (OBMST) reference products used in this study were commercially available and had been reported by the subjects as the brands they usually consume.
219203384|NCT06719284|OTHER|HFO&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order|HFO\&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order
219033445|NCT02363725|DRUG|Colchimax®|
219203385|NCT06719284|OTHER|HFOV at the settings applied prior to the study|HFOV at the settings applied prior to the study
219203386|NCT06264245|OTHER|Audiological profile|Video otoscopy Tympanometry High-frequency tonal audiometry
219033446|NCT02363725|DRUG|Conventional treatment|
219203387|NCT06264245|OTHER|Hearing self-assessments|Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
219033447|NCT00002115|DRUG|Adefovir|
219033448|NCT02427321|DEVICE|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
219033449|NCT02803307|DRUG|TLC599|Single dose via intra-articular injection
219033450|NCT03858946|PROCEDURE|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
219033451|NCT03858946|PROCEDURE|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
219203388|NCT06264245|OTHER|Objective and subjective audiological tests|Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
219203389|NCT06264245|OTHER|Self-assessment of exposure sound quality|A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
219203390|NCT06716242|PROCEDURE|Peripheral blood collection|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
219203391|NCT05876780|GENETIC|SRP-9003|Single IV infusion of SRP-9003
219203392|NCT06677957|DRUG|Digoxin|Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period
219509373|NCT04646174|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
219509374|NCT04646174|BEHAVIORAL|American Lung Association self-management strategies for smoking cessation|Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
219509375|NCT03799263|PROCEDURE|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
219203393|NCT06677957|DRUG|Divarasib|Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period
219509376|NCT05282160|DEVICE|Epino|The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
219509377|NCT05589935|DIETARY_SUPPLEMENT|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
219509378|NCT00409890|DRUG|Hyoscine Butyl Bromide|
219509379|NCT01460251|DRUG|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
219509380|NCT00636831|DRUG|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
218890391|NCT06440629|DRUG|Therapeutic drug monitoring (TDM) of adalimumab|"In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range:~* Serum drug level within therapeutic range : keep dose~* Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week~* Low drug levels, ADAb high levels : Switch to another therapy~* High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks"
218890392|NCT02461927|DRUG|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
219033452|NCT02680639|DEVICE|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
219608461|NCT05740111|OTHER|Annual surveillance|Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
218890393|NCT02461927|DRUG|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
218890394|NCT02461927|DRUG|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
218890395|NCT03765541|DRUG|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\])."
219033453|NCT05744349|PROCEDURE|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
219033454|NCT01063595|BIOLOGICAL|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
219033455|NCT01063595|BIOLOGICAL|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
219033456|NCT01663415|DRUG|Enzalutamide|oral
219203394|NCT06677957|DRUG|Rosuvastatin|Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
219203395|NCT06373250|BEHAVIORAL|Membrane stripping group|An information form will be filled in for admission to the Primipar participating maternity unit. Membrane stripping will be performed during a vaginal examination at least once during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
219509381|NCT00532597|PROCEDURE|On-line hemodiafiltration|
219509382|NCT00532597|PROCEDURE|Low flux hemodialysis|
219509383|NCT00195598|DRUG|VENLAFAXINE|
219509384|NCT00195598|DRUG|Paroxetine|
219509385|NCT04191239|DEVICE|GE ventilator with two different modes|GE ventilator with two different modes
219608462|NCT02064296|DEVICE|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
219608463|NCT02064296|DEVICE|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
219608464|NCT02119013|DRUG|Octeotride|
219608465|NCT02119013|DRUG|Placebo|
219608466|NCT03552510|PROCEDURE|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
218890396|NCT03765541|DRUG|Amsacrine|"* Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])"
218890397|NCT03765541|DRUG|Cytarabine|"Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
218890398|NCT03765541|DRUG|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
219509386|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light|A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
219509387|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light|The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
219509388|NCT06384144|OTHER|Expectant Management of First Trimester Miscarriage|Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
219509389|NCT06384144|OTHER|Medical Management of First Trimester Miscarriage|Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
219509390|NCT03304509|OTHER|Telematic follow-up|Telematic follow-up by using a platform with videoconference
219509391|NCT04752436|BEHAVIORAL|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
219509392|NCT01338636|DRUG|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
219509393|NCT01021436|DRUG|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
219509394|NCT02385526|DEVICE|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
219509395|NCT03532009|DRUG|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
219509396|NCT03532009|DRUG|Placebo|Oral use for approximately 3 months
218890399|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
218890400|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
218890401|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
218890402|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
218890403|NCT04489810|DIETARY_SUPPLEMENT|Placebo|Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules
218890404|NCT04489810|DIETARY_SUPPLEMENT|Elevase®|1 capsule containing 350 mg of Elevase®
219033457|NCT03389464|BEHAVIORAL|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
219033458|NCT03152370|DRUG|E7046|oral administration
219033459|NCT03152370|RADIATION|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
219509397|NCT04725084|OTHER|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
219509398|NCT04725084|OTHER|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
219509399|NCT04725084|OTHER|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
219608467|NCT03099109|DRUG|LY3321367|Administered IV
218890405|NCT04489810|DIETARY_SUPPLEMENT|DE111®|1 capsule containing Bacillus subtilis DE111
218890406|NCT04489810|OTHER|Meal A|Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
218890407|NCT04489810|OTHER|Meal B|Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
219033460|NCT03152370|RADIATION|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
219509400|NCT04421794|DEVICE|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
219509401|NCT04421794|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
219509402|NCT02035137|RADIATION|131I-MIBG|
219509403|NCT02035137|DRUG|Vincristine|
219509404|NCT02035137|DRUG|Irinotecan|
219509405|NCT02035137|DRUG|Vorinostat|
219509406|NCT01288859|OTHER|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
219608468|NCT03099109|DRUG|LY3300054|Administered IV
219608469|NCT01240759|DRUG|S-707106 Dose A|One S-707106 A tablet
219608470|NCT01240759|DRUG|S-707106 Dose B|One S-707106 B tablet
219608471|NCT01240759|DRUG|S-707106 Dose C|Four S-707106 4 X B tablets
219608472|NCT01240759|DRUG|Placebo A tablet|Up to 4 Placebo A tablets
219608473|NCT01240759|DRUG|Metformin|The standard of care dose of metformin for each patient
219613338|NCT01280643|GENETIC|gene expression analysis|Correlative studies
219509407|NCT01288859|OTHER|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
219509408|NCT01288859|OTHER|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
219509409|NCT01288859|OTHER|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
219509410|NCT01288859|OTHER|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
219509411|NCT01288859|OTHER|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
219509412|NCT05639387|PROCEDURE|actual tVNS|Active tVNS (stimulation on cymba conchae --\> nervus vagus stimulation)
219509413|NCT05639387|PROCEDURE|sham tVNS|Sham tVNS (stimulation on earlobe --\> no nervus vagus stimulation)
219509414|NCT02663089|DRUG|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.
219509415|NCT02663089|DRUG|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
219509416|NCT02663089|DRUG|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
219509417|NCT05610501|PROCEDURE|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
219509418|NCT04061564|DEVICE|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
219509419|NCT00568269|PROCEDURE|Open repair|Open repair is according to the Lichtenstein technique
219033461|NCT03152370|DRUG|capecitabine|chemotherapy
219509420|NCT00568269|PROCEDURE|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
219033462|NCT03152370|DRUG|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
219509421|NCT04011969|DIAGNOSTIC_TEST|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
219509422|NCT04011969|DIAGNOSTIC_TEST|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~1. Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~2. NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
219033463|NCT00747435|DEVICE|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
219509423|NCT04011969|DIAGNOSTIC_TEST|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~1. Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~2. Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
219509424|NCT06467422|DEVICE|tTIS on dACC, theta frequency (5 Hz)|"Device: Transcranial electric stimulation device~The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.006 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 6 Hz can be generated in the target area. The experimental group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model."
219613339|NCT01280643|OTHER|laboratory biomarker analysis|Correlative studies
218890408|NCT05230524|DEVICE|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
218890409|NCT04914533|DEVICE|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
218890410|NCT06139601|BEHAVIORAL|Virtual single session intervention|A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
218890411|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
218890412|NCT06535958|BEHAVIORAL|OHI|All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
218890413|NCT06535958|PROCEDURE|OHI+PMPR|Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
218890414|NCT02468726|DEVICE|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
219033464|NCT02678676|OTHER|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
219033465|NCT02678676|OTHER|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
219033466|NCT04318782|DEVICE|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
218890415|NCT02468726|DRUG|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
218890416|NCT01898429|DEVICE|SCC DBS|Deep Brain Stimulator
218890417|NCT00149903|DRUG|Mycophenolate sodium (enteric coated)|
218890418|NCT05705427|DRUG|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
218890419|NCT05705427|BIOLOGICAL|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
218890420|NCT05705427|DRUG|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
218890421|NCT04829916|DRUG|RMC-035|Multiple dosing during 48 hours following cardiac surgery
218890422|NCT04829916|DRUG|Placebo|Multiple dosing during 48 hours following cardiac surgery
218890423|NCT04233541|DIAGNOSTIC_TEST|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
218890424|NCT04890470|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
218890425|NCT04890470|DRUG|Vasopressin|intranasal administration of vasopressin (20 IU)
219203396|NCT06373250|OTHER|Control group|You will be asked to fill in an information form to be admitted to the Primipar participating maternity unit. No membrane stripping are applied and no cervical interventions are made during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the VAS and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
219203397|NCT06704516|DRUG|Menopausal hormone therapy|"Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)"
219509425|NCT06467422|DEVICE|tTIS on dACC, High frequency|The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The sham group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.
219509426|NCT03426930|OTHER|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
219509427|NCT03426930|OTHER|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
218890426|NCT04890470|DRUG|Placebo|intranasal administration of placebo
218890427|NCT00830466|DRUG|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
219509428|NCT01006707|DRUG|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
218890428|NCT05599971|DRUG|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
219509429|NCT00219661|PROCEDURE|drainage of subglottic secretions (HiLo Evac tube)|
218890429|NCT05599971|DRUG|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
218890430|NCT05599971|OTHER|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
218890431|NCT02152761|DRUG|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
218890432|NCT02152761|OTHER|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
218890433|NCT04343755|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
218890434|NCT01255618|DEVICE|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
218890435|NCT03755882|DEVICE|ACUVUE® DEFINE™ Vivid Style|TEST Lens
218890436|NCT03755882|DEVICE|LACELLE™ Sparkling Brown|CONTROL Lens
218890437|NCT05639140|OTHER|Data collection|Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
219203398|NCT04750616|DRUG|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
219203399|NCT04750616|DRUG|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
219203400|NCT06706908|OTHER|Health questionnaires|Participants are expected to complete a series of health questionnaires (i.e. numerical rating scale, Oswestry Disability Index) relevant to their treatment using a SI-BONE implant.
219203401|NCT06704477|OTHER|Survey|Eight questions about protein intake
219203402|NCT06707909|DRUG|Menaquinone|the socket will be filled with crushed capsule of vitamin k2 menaquinone in study group
219203403|NCT06711510|OTHER|Clinical, behavioral and cognitive evaluation|Questionnaries and tests
219203404|NCT06711510|OTHER|blood sampling|blood sampling (56ml max)
219509430|NCT00704223|DRUG|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
219608474|NCT03044028|DEVICE|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
219509431|NCT05403411|OTHER|Distance education for nursing students on critical thinking|The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
219509432|NCT04523805|BEHAVIORAL|Adapted judo programme|"The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~* Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~* Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~* Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~* Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting)."
219509433|NCT02307383|DRUG|Lactitol|
219509434|NCT02307383|DRUG|Lactobacillus|
219509435|NCT00788190|PROCEDURE|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
219509436|NCT00788190|OTHER|Conservative Management|Conservative management of Distal Radius Fractures
219509437|NCT03931096|OTHER|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
219608475|NCT06372717|DRUG|APL-4098|APL-4098 is administered orally in 28-day cycles
219608476|NCT06372717|DRUG|Azacitidine and APL-4098|Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
219608477|NCT06461026|BIOLOGICAL|L9LS|Administered intramuscularly one time.
219608478|NCT06461026|OTHER|Normal Saline|Administered intramuscularly one time.
218890438|NCT05900908|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
218890439|NCT05900908|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
218890440|NCT00224588|DRUG|Ketamine (or placebo : isotonic saline solution)|
219033467|NCT04059146|OTHER|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
219033468|NCT04059146|OTHER|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
219033469|NCT04909775|DRUG|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
218890441|NCT04848272|DRUG|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
218890442|NCT04848272|OTHER|Saline control|Saline control
219033470|NCT04909775|DRUG|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
219033471|NCT04909775|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
219033472|NCT06327399|DRUG|Dexmedetomidine infusion|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
219203405|NCT06711510|OTHER|brain MRI|brain MRI (35 to 70 minutes)
219203406|NCT06711510|OTHER|olfactory swab sampling with nasal brush|olfactory swab sampling with nasal brush
219203407|NCT06711510|OTHER|skin punch biopsy|skin punch biopsy (optional intervention)
219509438|NCT02887209|BEHAVIORAL|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
219608479|NCT04383262|DRUG|Fosamprenavir Calcium|A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).
219608480|NCT04383262|OTHER|Placebo|Non-active placebo pill formulation
219608481|NCT06838689|OTHER|Comparison of two standard of care regimens|Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement (PPCI) in Qualitative Research: PAQ and CAB (Community Advisory Boards)
219608482|NCT00644215|DRUG|5-FU and Mitomycin|"* 5-FU injection 5mg~* Mitomycin drop 0.02%"
219608483|NCT00218387|DRUG|Modafinil|200mg Modafinil
219608484|NCT00218387|DRUG|Modafinil|400mg Modafinil
219608485|NCT00218387|DRUG|Matching Placebo|Matching Placebo
219509439|NCT02224209|DEVICE|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~1. The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~2. Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
218890443|NCT03506997|DRUG|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
218890444|NCT05663463|DRUG|Fluzone High-Dose - 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
218890445|NCT05663463|DRUG|Fluzone High-Dose - 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
218890446|NCT05722548|DRUG|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
218890447|NCT05722548|OTHER|Standard Medical Treatment|Standard Medical Treatment
219509440|NCT02224209|DEVICE|a balloon, stent|"Routine stenting procedure:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
219509441|NCT04020107|OTHER|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
219509442|NCT04310410|COMBINATION_PRODUCT|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
219509443|NCT06138535|DEVICE|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
219509444|NCT05034731|DEVICE|Remote Fitting|Processors will be programmed using remote fitting application.
218890448|NCT02538601|BEHAVIORAL|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
218890449|NCT02538601|BEHAVIORAL|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
218890450|NCT03372967|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
218890451|NCT03372967|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
218890452|NCT03372967|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
218890453|NCT03599791|DRUG|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
218890454|NCT03599791|DRUG|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
219509445|NCT05034731|DEVICE|In-Office Fitting|Processors will be programmed using standard Target CI application.
219509446|NCT03020602|OTHER|Laboratory Biomarker Analysis|Correlative studies
219509447|NCT03020602|OTHER|Pharmacological Study|Correlative studies
219509448|NCT03020602|DRUG|Ubidecarenone Injectable Nanosuspension|Given IV
219608486|NCT03525561|DRUG|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
219608487|NCT03525561|DRUG|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
219608488|NCT06025123|DEVICE|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
219608489|NCT04145128|DRUG|AG881|AG-881 tablets.
219608490|NCT04466280|DRUG|Hydroxychloroquine|200 mg of hydroxychloroquine daily for participants in the intervention group 1
219608491|NCT04466280|DRUG|Mucodentol|Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
219608492|NCT04466280|DEVICE|Personal protective equipment|Personal protective equipment such as masks, gloves, protective shields
218890455|NCT03599791|DRUG|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
219203408|NCT06711510|OTHER|lumbar puncture for CSF sampling|lumbar puncture for CSF sampling (optional intervention)
219203409|NCT06381453|DRUG|Belimumab Auto-Injector [Benlysta]|Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector
218890456|NCT00106327|BEHAVIORAL|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
218890457|NCT00106327|BEHAVIORAL|Diet|11 nutrition education sessions
218890458|NCT01366599|DRUG|HEC or MEC|Any HEC or MEC, including aprepitant
219033473|NCT06327399|DRUG|Dexmedetomidine bolus|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
219203410|NCT06720012|DEVICE|Patient specific instrumentation (PSI)|Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.
218890459|NCT04267835|PROCEDURE|MIDCAB|Surgery: MIDCAB
219033474|NCT06327399|DRUG|Atropine Sulfate|If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
219203411|NCT06720012|DEVICE|Conventional instruments|Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.
219509449|NCT05317156|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
219509450|NCT04414956|DIAGNOSTIC_TEST|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
219203412|NCT06720012|PROCEDURE|Cemented Total Knee Arthroplasty|A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
219608493|NCT01031329|PROCEDURE|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
219608494|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
219608495|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
219608496|NCT01350362|DRUG|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
218890460|NCT04267835|PROCEDURE|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
218890461|NCT00214513|BEHAVIORAL|Home-based exercise training|
219033475|NCT06327399|DRUG|Ephedrine|If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
219509451|NCT04414956|DIAGNOSTIC_TEST|AFP|AFP will be tested using serum sample every 6 months.
219509452|NCT04414956|DIAGNOSTIC_TEST|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
218890462|NCT02968342|DEVICE|Vaginal progesterone 8%|vaginal self application
218890463|NCT06172647|DIAGNOSTIC_TEST|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
218890464|NCT03516422|PROCEDURE|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
219033476|NCT06327399|DRUG|Propofol|Propofol 20 mg boluses till loss of contact
219033477|NCT01978028|DRUG|ferric carboxymaltose|
219033478|NCT01978028|DRUG|placebo|
219033479|NCT00385242|PROCEDURE|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
219033480|NCT00385242|OTHER|PET imaging|PET viability imaging
219033481|NCT03454984|DRUG|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
219033482|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga
219033483|NCT00492310|BEHAVIORAL|cognitive therapy|cognitive behavioral therapy once weekly
219033484|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
219033485|NCT00492310|BEHAVIORAL|wellness|wellness program with smoking cessation
219033486|NCT00109395|DRUG|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
219509453|NCT04414956|DIAGNOSTIC_TEST|Sonography|Sonography will be tested by experts every 6 months.
219608497|NCT01350362|DRUG|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
219608498|NCT00918866|DRUG|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
219608499|NCT05663125|PROCEDURE|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
218890465|NCT03516422|OTHER|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
218890466|NCT02473900|DRUG|HIP1403|Oseltamivir 75mg
218890467|NCT02473900|DRUG|HGP0919|Oseltamivir phosphate 75mg
218890468|NCT03255317|BEHAVIORAL|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
219033487|NCT00109395|DRUG|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
219033488|NCT00109395|DRUG|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
219033489|NCT04038515|DRUG|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
219033490|NCT04038515|DRUG|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
219033491|NCT04038515|DRUG|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
219033492|NCT04038515|DRUG|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
219033493|NCT04038515|OTHER|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
219033494|NCT04038515|OTHER|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
219033495|NCT04038515|OTHER|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
219033496|NCT04038515|OTHER|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
219033497|NCT04038515|OTHER|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
219033498|NCT02976974|OTHER|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
219033499|NCT02976974|OTHER|Therapeutic exercise|"* Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension"
219033500|NCT04694313|DEVICE|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
219033501|NCT00851799|DRUG|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
219033502|NCT00851799|DRUG|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
219033503|NCT00851799|DRUG|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
219033504|NCT00851799|DRUG|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
219033505|NCT00851799|DRUG|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
219033506|NCT04751149|PROCEDURE|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
219033507|NCT02455271|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
219509454|NCT04414956|DIAGNOSTIC_TEST|CT|Contrast-enhanced CT will be tested annually.
219033508|NCT00855491|PROCEDURE|Phaco|AcrySof Single-Piece IOL
219033509|NCT03079323|RADIATION|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
219033510|NCT05300295|BEHAVIORAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
219613340|NCT01280643|OTHER|immunohistochemistry staining method|Correlative studies
219613341|NCT01280643|GENETIC|nucleic acid sequencing|Correlative studies
219613342|NCT01280643|GENETIC|protein expression analysis|Correlative studies
219613343|NCT01280643|GENETIC|polymerase chain reaction|Correlative studies
219613344|NCT01280643|GENETIC|DNA analysis|Correlative studies
219613345|NCT04512664|OTHER|cold application|cold application with gel pacs
219509455|NCT03156166|PROCEDURE|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
219509456|NCT01934296|DEVICE|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
219509457|NCT05002907|OTHER|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
219509458|NCT05002907|OTHER|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
219509459|NCT05002907|OTHER|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
219608500|NCT05663125|DRUG|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
218890469|NCT03255317|BEHAVIORAL|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
218890470|NCT06345625|DIAGNOSTIC_TEST|Cognition|"1. The CatchU® app quantitatively and objectively measures the ability to integrate visual-somatosensory information using reaction time test data.~2. Digit Symbol Substitution test assesses processing speed and attention by requiring individuals to match symbols with corresponding numbers within a specified time frame.~3. Trail Making Test part 1 and 2: assesses cognitive flexibility, visual attention, and task-switching by having individuals connect numbered circles in sequence (part 1) and then alternate between numbers and letters (Part 2).~4. Go/No Go test measures an individual's ability to inhibit a prepotent response (No-Go) and execute a response when required (Go). This test provides insights into executive functioning, particularly inhibitory control."
218890471|NCT06345625|DIAGNOSTIC_TEST|Sensory function|"1. Cervical Sensorimotor control will be measured through a wireless wearable sensor 3D-cervical trainer by Sensamove on the placed on the head of the participant. The 3DCT registers cervical position sense by the Head Repositioning Accuracy test where the subject must relocate the head to the previously memorized (neutral) head position with the eyes closed and the joint position error degrees are registered. Cervical movement sense is examined using 'The Fly'-test where the subject ought to follow a movement pattern displayed on the screen in front of them. The movement of the neck-head unit is there upon tracked by the 3DCT and projected on the screen.~2. Vestibular function will be assessed through 3D-video Head Impulse Testing (vHIT), examining the state of the three semicircular canals by delivering the vestibulo-ocular reflex (vor) gain and vor gain asymmetry.~3. For the assessment of static and dynamic visual acuity, functional Head Impulse Testing (fHIT) will be used."
218890472|NCT06345625|DIAGNOSTIC_TEST|Frailty|Frailty will be assessed using the Fried criteria, comprising 5 categories (each accounting for 1 point if scored positive): Unintentional weight loss (interview), weakness (grip strength with hand-held dynamometer), poor endurance and energy (two statements of the CES-D Depression Scale), slowness (walking speed over 15ft through gait analysis) and low physical activity level (Minnesota Leisure Time Activity questionnaire)(Fried et al., 2001).
218890473|NCT06345625|OTHER|Biomechanical movement analysis|Markers will be placed on the predefined anatomical locations and surface electrodes for electromyography will be applied at the predefined muscle locations following the SENIAM-guidelines. The Microsoft HoloLens 2 is fixated on the participant's head which will, on one hand, provide the cue to the participant for the head movement and on the other hand track eye and head movements. A safety harness is attached to the body and the ceiling of the lab. At the start of the trial, the subject will see a projection by the HoloLens 2 on the real environment moving to the left; right; upward; downward (cue in randomized order) which the participant is ought to follow with eyes and head. First while standing still and second while walking the 10-meter overground walkway at a self-preferred walking speed.
219033511|NCT04056195|DRUG|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
219033512|NCT04056195|DRUG|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
219033513|NCT05948202|BEHAVIORAL|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
219033514|NCT01599507|DRUG|FG-4592|TIW dosing, capsule
219033515|NCT01599507|DRUG|Placebo|TIW dosing, capsule
219033516|NCT05403879|PROCEDURE|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
219033517|NCT00118976|DRUG|Lisinopril|
219033518|NCT00108056|DRUG|Enzastaurin (LY317615) monohydronchloride|
219033519|NCT01951339|DRUG|Sitagliptin|100 mg sitagliptin
219033520|NCT01951339|DRUG|Glimepiride|"Active Comparator~2mg glimepiride"
219033521|NCT01951339|DRUG|Placebo|2 mg placebo once daily
219033522|NCT01951339|DRUG|Placebo|100 mg placebo once daily for three months
219033523|NCT05133687|DRUG|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
219509460|NCT05002907|OTHER|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
219509461|NCT05002907|OTHER|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
219509462|NCT05002907|OTHER|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
219033524|NCT03190070|DIETARY_SUPPLEMENT|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
219033525|NCT01034449|OTHER|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
219033526|NCT04457609|DRUG|Oseltamivir|Current standardized treatment for Covid-19
219033527|NCT04457609|DRUG|Azithromycin|Current standardized treatment for Covid-19
219033528|NCT04457609|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
219033529|NCT04280367|DIAGNOSTIC_TEST|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
219033530|NCT04280367|DIAGNOSTIC_TEST|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
219033531|NCT04280367|DIAGNOSTIC_TEST|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
219033532|NCT02853240|PROCEDURE|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
219033533|NCT00392431|DRUG|amiodarone|
219033534|NCT04794790|DRUG|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
219033535|NCT05209022|DIETARY_SUPPLEMENT|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
219033536|NCT00302133|DRUG|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
219033537|NCT00302133|OTHER|Placebo|Placebo arm
219033538|NCT01852266|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
219033539|NCT01852266|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
219033540|NCT04702490|DRUG|MET409 Active|MET409 Active (50mg)
219033541|NCT04702490|DRUG|MET409 Placebo|MET409 Placebo (50mg)
219033542|NCT04702490|DRUG|Empagliflozin|Empagliflozin (10mg)
219033543|NCT06254053|OTHER|zirconia reinforced glass ionomer|Restorative material
219033544|NCT06254053|OTHER|Glass ionomer cement|Restorative material
219033545|NCT05797493|DRUG|Atezolizumab|Upfront chemo-immunotherapy
219033546|NCT06502743|DRUG|Nesuparib|Nesuparib 150mg or 100mg, QD, PO
219033547|NCT06502743|DRUG|Pembrolizumab|Pembrolizumab 400mg, IV, Q6W
219033548|NCT01001442|DRUG|BT062|intravenous administration
219033549|NCT03774589|PROCEDURE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
219033550|NCT03774589|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
219033551|NCT01988116|DRUG|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
219033552|NCT01988116|DRUG|Placebo|
219033553|NCT05478070|DEVICE|Dexcom G6|Continuous glucose monitor
219033554|NCT02522390|OTHER|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
219033555|NCT01321775|DRUG|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
219033556|NCT03437109|DIAGNOSTIC_TEST|Laboratory tests|Testosterone HSBG Hb1Ac LH
219033557|NCT00187746|DRUG|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
219033558|NCT02753699|DRUG|Alisporivir|Intervention of interest; follow-up after ALV-active study
219033559|NCT02418858|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
219033560|NCT00457938|OTHER|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
219033561|NCT00457938|OTHER|Diet|10 % versus 35 % fat in diet
219033562|NCT00162565|DRUG|beta-blocker treatment|beta-blocker treatment
219203413|NCT06721208|BEHAVIORAL|"use the Move for Knee APP"|"The mobile APP called Move Your Knee allows the collection of data entered by patients, useful for understanding their lifestyle habits and daily physical activity level, and information relating to KOA pathology.~At the end of the questionnaire, the algorithm integrated into the APP's computer code will allow the calculation of the patient's presumed level of physical activity. This will then be followed by the assignment of a specific form which includes the exercises and the related execution parameters (i.e. weekly frequency), and useful advice for safely carrying out the exercises to achieve the specific functional objectives."
219203414|NCT06720168|DEVICE|Erythritol air polisher|Dental prophylaxis with erythritol air polisher in patients with dental black stain
219203415|NCT06720168|DEVICE|Dental prophylaxis with ultrasonic treatment|Dental prophylaxis with ultrasonic treatment in patients with dental black stain
219203416|NCT05317819|DRUG|ADI-PEG20|Treatment for hepatocellular carcinoma
219203417|NCT05317819|OTHER|Placebo|Treatment for hepatocellular carcinoma
219203418|NCT04454203|DRUG|Mepivacaine|An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
219203419|NCT04454203|DRUG|Saline|An infiltration of saline superomedially to the femoral artery via perineural catheter.
219203420|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
219203421|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
219203422|NCT06719700|DRUG|Chemotherapy|Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
218890474|NCT06345625|OTHER|Screening|"The researcher will visit the possible participants (at their home, community centre, etc.) and after written consent on screening procedure is provided, the tests for eligibility will be performed.~1. Interview: asking about age (years), gender (male/female), medical history and the number of falls in the last 12 months .~2. Timed Up-and-Go (TUG) to check walking ability. TUG is a sensitive and specific measure for identifying risk for falls (Shumway-Cook et al., 2000)."
218890475|NCT06345625|OTHER|Follow up|Participants are followed up for 12 months. They fill in a fall diary and telephone reminders will be performed monthly to encourage participants to complete and return their diaries.
218890476|NCT06097026|PROCEDURE|Alveolar recruitment maneuver|Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.
218890477|NCT06097026|DRUG|Nitric Oxide|Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
218890478|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
218890479|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
218890480|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
218890481|NCT06323109|DEVICE|MRI-UDS; US-UDS; MCUD|Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
218890482|NCT00051493|DRUG|ALIMTA|
218890483|NCT00051493|DRUG|Carboplatin|
218890484|NCT04484870|DRUG|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
218890485|NCT05484011|BIOLOGICAL|odetiglucan|Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
218890486|NCT05484011|BIOLOGICAL|CDX-1140|A fully human agonist anti-CD40 monoclonal antibody
219203423|NCT06719700|DRUG|Immunotherapy|Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
219203424|NCT06719700|DRUG|Angio-immuno kinase inhibitor|Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
219203425|NCT06719700|RADIATION|radiotherapy|Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
219203426|NCT06719700|RADIATION|Prophylactic Cranial Irradiation|PCI is recommended after the completion of chemoradiotherapy.
219203427|NCT06719700|DRUG|Consolidation Therapy with Toripalimab and Surufatinib|Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
219203428|NCT06719752|OTHER|Placebo|Placebo intervention; the therapy will mimic exceptional mobilization.
219509463|NCT05002907|OTHER|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
219509464|NCT00283686|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
219509465|NCT00283686|DRUG|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
219509466|NCT00283686|DRUG|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
218890487|NCT03449069|DRUG|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
218890488|NCT03418636|BEHAVIORAL|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
219203429|NCT06883760|COMBINATION_PRODUCT|Probiotic tablet candy group|40 volunteers were randomly divided into two groups (n=20): Group A (probiotic → washout → placebo) and Group B (placebo → washout → probiotic). Each group took 1g of tablets (0.5g/tablet, 2 tablets) twice daily for 1 week, followed by a 2-week washout, then switched interventions. Fecal samples were collected at baseline, Day 7, and Day 28. Alcohol tests were conducted on Days 7 and 28 after fasting; participants consumed alcohol (1 mL/kg, 40% v/v) with a standard meal. Serum and saliva were collected post-meal. Body weight was measured, and alcohol dosage was adjusted accordingly. Participants maintained their usual diet and avoided alcohol-detoxifying or liver-protecting drugs. Medication during alcohol tests: 2 pills before tolerance test (after lunch), 2 pills before drinking, and 2 pills after waking.
219203430|NCT06884774|PROCEDURE|Hemorrhoidectomy with lateral internal sphincterotomy|Patients undergoing Hemorrhoidectomy with lateral internal sphincterotomy.
219203431|NCT06884774|PROCEDURE|Hemorrhoidectomy|Patients undergoing Hemorrhoidectomy without lateral internal sphincterotomy.
219203432|NCT06552130|OTHER|Spiroergometer test with intranasal insulin spray|Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
219203433|NCT06552130|OTHER|Spiroergometer test with intranasal placebo spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
219203434|NCT06884982|DRUG|QL1706 Plus Lenvatinib|All enrolled subjects will receive QL1706 5 mg/kg intravenously plus lenvatinib 8/12mg on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
219203435|NCT06882291|OTHER|Intermittent fasting diet|Women in the first experimental group will follow an intermittent fasting diet, where they eat for 8 hours and fast for 16. They can skip breakfast or have an early dinner. Meals will include 500-800 calories of high-fiber and protein-rich foods. Participants can start with 2-3 fasts per week and increase gradually. They must drink 2-3L of water daily and can consume zero-calorie beverages. Weekly assessments will track progress.
219203436|NCT06882291|OTHER|Resistive exercise program|Women in the second experimental group will receive medical treatment and follow an 8-week resistive exercise program (30 min, 5 days/week). Exercises target the upper body, abdomen, and lower limbs, starting with a 10-min warm-up, followed by 30 min of resistance training (biceps curls, triceps exercises, chest press, plank, crunches, squats, lunges, hamstring, and quadriceps curls), and ending with a 10-min cool-down. Repetitions are logged weekly for assessment.
219203437|NCT06882291|DRUG|Medical treatment|Each woman in the three groups will receive medical treatment (metformin tablets) for eight weeks and the dose will prescribed by the gynecologist during the first visit. Patients will be asked to attend the clinic each month for routine monitoring.
219203438|NCT06884020|BEHAVIORAL|EMOTIONAL REGULATION PROGRAMME|"This programme works on early identification and implementation of strategies to improve self-awareness and facilitate children's emotions.~This intervention is designed to be delivered in the educational setting by the tutor in the form of a learning situation with 8 sessions plus 1 family session.~The topics covered are:~* Embarking on an emotional journey~* Recognising our emotions~* Emotions have a voice~* Identifying different emotions~* How do I make decisions?~* Emotion, action, and consequence~* Learning to self-regulate~* Celebrating our learning"
219203439|NCT06883682|OTHER|No intervention|No intervention is conducted in this study.
219203440|NCT06718634|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
219203441|NCT06710223|DRUG|SD-101|Toll-like receptor 9 (TLR9) agonist
218890489|NCT03418636|BEHAVIORAL|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
219033563|NCT00005833|DRUG|R115777|300mg P.O. BID.
219033564|NCT01380184|DRUG|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
219033565|NCT00016952|DRUG|fluorouracil|
219033566|NCT00016952|DRUG|irinotecan hydrochloride|
219033567|NCT00016952|DRUG|leucovorin calcium|
219033568|NCT04300972|DIAGNOSTIC_TEST|Body/weight adaption|contrast media dose is adapted to weight and body type
219033569|NCT04300972|DIAGNOSTIC_TEST|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
219033570|NCT00044343|DRUG|lapatinib|
219033571|NCT06968988|DRUG|Zanzalintinib|Zanzalintinib will be supplied by Exelixis, Inc.
219033572|NCT06968988|DRUG|Ipilimumab|Ipilimumab will be commercially sourced.
219033573|NCT06968988|DRUG|Nivolumab|Nivolumab will be commercially sourced.
219033574|NCT00719836|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
219033575|NCT03393156|BEHAVIORAL|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
219033576|NCT02180516|DRUG|Meloxicam|
219033577|NCT02180516|DRUG|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
219033578|NCT05028621|DIAGNOSTIC_TEST|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
219033579|NCT03532295|DRUG|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
219033580|NCT03532295|DRUG|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
219033581|NCT03532295|RADIATION|Radiation therapy|-The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.
219033582|NCT03532295|DRUG|Retifanlimab|-Will be supplied by Incyte
219203442|NCT06710223|DEVICE|Cryotherapy|Cryoablation of liver
219203443|NCT06710223|DRUG|Tremelimumab|Anti-CTLA4
219203444|NCT06710223|DRUG|Durvalumab|Anti-PDL1
219203445|NCT06709898|OTHER|Cognitive job accommodation|Job accommodation focused on the cognitive aspects at work
219203446|NCT06723665|DRUG|18F-PSMA-1007|18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
219203447|NCT06723665|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
219203448|NCT06885450|PROCEDURE|Perforator Pedicled Flaps|Perforator Pedicled V-Y Advanced Flaps
219203449|NCT06722417|DRUG|Icalcaprant|Oral capsules
218890490|NCT03335735|BEHAVIORAL|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
218890491|NCT03335735|BEHAVIORAL|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
218890492|NCT04707495|DEVICE|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
219033583|NCT03388190|DRUG|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
219033584|NCT03388190|DRUG|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
219033585|NCT05984823|OTHER|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
219033586|NCT05984823|OTHER|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
219033587|NCT06551701|OTHER|Pharmacist call|Pharmacists will call patients and their providers to discuss benefits of statin use
219033588|NCT03511976|BEHAVIORAL|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
219203450|NCT06885567|DRUG|BEY2153|Participants administer once daily, PO, 26 weeks
219203451|NCT06885567|DRUG|Placebo|Participants administer once daily, PO, 26 weeks
219203452|NCT06885944|DIETARY_SUPPLEMENT|Probiotic mix preparation|Bifidobacterium containing supplement with vitamin D will start after preterm infants reaches full enteral feeding
219203453|NCT06885944|DIETARY_SUPPLEMENT|Bifidobacteria|Rather than early period we will start probiotics after infant receive full enteral feedings
219203454|NCT06886243|PROCEDURE|Direct Posterior Composite Restoration|"Description: Composite restorations performed using Clearfil Majesty Posterior (Kuraray, Japan) and Clearfil Universal Bond Quick (Kuraray, Japan) in self-etch mode.~Inferior alveolar nerve block (IANB) administered with articaine hydrochloride with epinephrine (1:100,000) (Maxicaine)."
219203455|NCT06885138|DEVICE|active transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of active transcranial Direct Current Stimulation (tDCS) (anodal polarity). The active electrode (35 cm²) will be placed over the left dorsolateral prefrontal cortex (DLPFC), while the reference electrode (35 cm²) will be positioned over the contralateral area, with a stimulation intensity of 2mA.~Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
219203456|NCT06885138|DEVICE|sham transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of sham tDCS. The electrodes will be placed over the left DLPFC and the contralateral area, as in the active stimulation condition. However, the current will be delivered only for the first 5 seconds, preventing the participants from detecting the placebo condition while ensuring that no neuromodulation occurs in the underlying brain areas. Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
219203457|NCT06886334|OTHER|exercise|Ultrasound (4 minutes), TENS (100 Hz, 20 minutes), heat application (15 minutes), and home exercises will be applied. Treatment will be conducted three times a week for four weeks.
219203458|NCT06886334|OTHER|mobilization|In addition to heat application (15 minutes) and home exercises, the Cox technique will be used. The patient will be placed face down on a specialized table, and traction will be applied to the lumbar spine for 10 minutes.
219203459|NCT06885606|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. Active tDCS intervention increases excitability of neurons at the anode with 20-30% of the current going through the brain from anode to cathode so that both cortical and subcortical structures are stimulated. The procedure is very safe, convenient, and fast-acting with well-established parameters. It has the ability to modulate plasticity in specific brain areas and has established efficacy in human laboratory models of addictive motivation and has been shown to decrease craving for cigarettes when the anode is placed over the left dorsolateral prefrontal cortex (DLPFC).
218890493|NCT04707495|DEVICE|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
219203460|NCT06885606|DEVICE|Sham tDCS|Sham tDCS applies a 2mA current for the initial 30 seconds, followed by 0 mA for the remaining 19.5 minutes to simulate active tDCS stimulation. The cathode electrode is placed on the right dorsolateral prefrontal cortex (DLPFC), and the anode is positioned on the left DLPFC, aligned with the electrode placement used in active tDCS.
219203461|NCT06887699|OTHER|AI-ECG P4P program|The AI-ECG system will conduct a real-time analysis of the ECG. When the system identifies potential OMI cases, it will immediately send short message service notifications to the on-duty cardiologists. This will enable the cardiologists to promptly review and confirm the diagnosis.
219203462|NCT06887452|OTHER|Pharmacist-Led|Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
219203463|NCT06886906|BEHAVIORAL|Intermittent light walking|The participant will remain seated throughout the 1 hour experimental period. During this 1-hour period, participants will complete six bouts of 2.5-minutes of light intensity walking. Overall, the bouts will occur on six occasions, providing a total of 15 minutes of light intensity activity.
219203464|NCT06886906|BEHAVIORAL|uninterrupted sitting|The participant will remain seated throughout the experimental period and will be instructed to minimize excessive movement, only rising from the chair to void. This experimental condition is designed to mimic prolonged uninterrupted sedentary behavior.
219203465|NCT06885632|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
218890494|NCT02995317|OTHER|Number of falls based on an one year follow-up|
219203466|NCT06885632|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
219203467|NCT06887309|DIAGNOSTIC_TEST|MRI|MRI : anatomical (3DT1, 3D-FLAIR), functional (task-based and resting-state) and tractographic (multiband diffusion imaging) at three time points: one week, three months and twelve months after the spinal cord injury (SCI)
219203468|NCT06887309|BEHAVIORAL|Neuropsychological tests|The following tests will be performed: the Montreal Cognitive Assessment (MOCA), the Montgomery-Åsberg depression rating scale (MADRS), the Medical Outcome Study Short Form 36 (SF-36)
219203469|NCT06884059|BEHAVIORAL|Time Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
219203470|NCT06709495|DRUG|PEEL-224|Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.
219203471|NCT06709495|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.
219203472|NCT06709495|DRUG|Vincristine|Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.
219203473|NCT06709495|BIOLOGICAL|Pegfilgrastim|Myeloid growth factor administered per institutional standards.
219203474|NCT06709495|BIOLOGICAL|Filgrastim|Myeloid growth factor administered per institutional standards.
219203475|NCT06697223|DEVICE|INTERCEPT Blood System for Platelets with LED Illuminator|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.
219203476|NCT06711796|DEVICE|emg measurement in adductor pollucis|EMG measurement from adductor pollucis and dorsal interosseus muscles in supination and pronation using increasing stimulation current
219203477|NCT06711705|DRUG|Elranatamab|Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
219203478|NCT06713421|DRUG|Dimethicone+Pronase|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
219203479|NCT06713421|DRUG|Dimethicone|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
219203480|NCT06713421|BEHAVIORAL|with Postural Exercise|After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
218890495|NCT00016679|DRUG|1-Octanol|
218890496|NCT04859426|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
218890497|NCT03623763|DIAGNOSTIC_TEST|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
218890498|NCT00004893|BIOLOGICAL|recombinant interleukin-12|
219203481|NCT06713421|BEHAVIORAL|without Postural Exercise.|After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
219203482|NCT06713148|BIOLOGICAL|IDOV-SAFETM|Each patient received intratumoral injection on the first day, 14 days as a course of treatment, and the follow-up investigator decided whether to continue the second (D14) and third (D28) course of administration according to the comprehensive evaluation of the subjects' conditions
219203483|NCT05016895|DRUG|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
219203484|NCT06728631|DRUG|Candonilimab and ATRA|Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
219203485|NCT06728631|OTHER|other treatment or observation|other treatment other than Candonilimab/ATRA or observation
219203486|NCT05416697|DRUG|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
219033589|NCT03511976|BEHAVIORAL|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
219033590|NCT03511976|BEHAVIORAL|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
219203487|NCT05416697|DRUG|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
219203488|NCT06728228|OTHER|Amnioinfusion|A 20- or 22-gauge spinal needle (routinely used obstetrics and gynecology needle) will be used by an expert in fetal procedures with sterile technique to access the amniotic cavity under real-time ultrasound guidance to infuse isotonic fluid (Lactated Ringers with 1g/L of Oxacillin). This fluid will act as replacement amniotic fluid. Regular monitoring of fluid levels may suggest serial infusion, which will be completed as deemed necessary by the study doctor.
219203489|NCT06729164|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods guided by cognitive, sociocultural, and linguistic theories that are applied to interventions supporting sign language development among deaf children.
219203490|NCT06729164|BEHAVIORAL|Business-As-Usual Instruction|Teachers will teach business-as-usual without the inclusion of SISI.
219203491|NCT06729021|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
219203492|NCT06729021|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
219203493|NCT06727812|DRUG|HRS-6208|HRS-6208.
219203494|NCT06728020|OTHER|Active Comparator: Conventional rehabilitation (Group A)|The conventional group will undergo standard rehabilitation treatment according to the rehabilitation plan developed by the rehabilitation team. This group will undergo 3 hours of rehabilitation per day and will carry out face-to-face rehabilitation following an impairment-based approach aimed at the treatment of motor-cognitive functions.
219203495|NCT06728020|DEVICE|ROOMMATE 1st|In addition to Group A, this group will have the bedside multimedia monitor apparatus to access informative, rehabilitation, and entertainment content. Additionally, this group will have a digital and innovation coach to receive support in using the technology.
219203496|NCT06728020|DEVICE|ROOMMATE 2nd|Once the first RCT of the cmRCT is completed, a pilot RCT will be initiated, randomizing 60 cases between Group A and this group. In addition to conventional treatment, this group will have a version of the ROOMMATE system integrated with inertial sensors worn on the hands and fingers to guide the serious games on the platform.
219203497|NCT06729112|DIAGNOSTIC_TEST|pan immune inflammation value|Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
219203498|NCT06727513|PROCEDURE|A single-operator technique for GlideScope intubation.|A single-operator technique where the senior resident will insert the GlideScope and perform the endotracheal intubation using an angulated stylet.
219203499|NCT06727513|PROCEDURE|A double-operator technique for GlideScope intubation|A double-operator technique where the senior resident will insert the GlideScope until visualizing an optimal glottic view, then the attending physician will take over the GlideScope keeping it in the same fixed position, while the resident performs the endotracheal intubation using an angulated stylet.
218890499|NCT00622375|DRUG|mesalamine|encapsulated mesalamine granules
218890500|NCT02947646|DEVICE|BabyGentleStick™ ON|experimental intervention
218890501|NCT02947646|DEVICE|BabyGentleStick™ OFF|active comparator
218890502|NCT05583123|DEVICE|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
219203500|NCT04686799|DRUG|Doxycycline Hyclate 20 MG|Subjects will receive doxycycline 20 mg BID
219203501|NCT06884839|PROCEDURE|Therapeutic resection|Patients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival.
219203502|NCT06882616|OTHER|surgery|All patients will be perform laparoscopic sleeve gastrectomy. Carotid intima-media thickness will be analyzed preoperatively and at the end of the first postoperative year.
218890503|NCT05583123|DEVICE|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
218890504|NCT05258604|PROCEDURE|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
218890505|NCT05258604|PROCEDURE|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
219033591|NCT03511976|DRUG|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
219033592|NCT04964102|BEHAVIORAL|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
219033593|NCT03999710|RADIATION|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
219033594|NCT03999710|DRUG|Durvalumab|A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
219033595|NCT04960787|OTHER|Educational Intervention|Watch online educational videos
219033596|NCT04960787|BEHAVIORAL|Patient Navigation|Meet with CENTS counselor and PAF case manager
219033597|NCT04960787|OTHER|Quality-of-Life Assessment|Ancillary studies
219033598|NCT04960787|OTHER|Questionnaire Administration|Complete questionnaires
219033599|NCT06521567|DRUG|Cobolimab|Cobolimab will be administered
219033600|NCT06521567|DRUG|Dostarlimab|Dostarlimab will be administered
219033601|NCT05630859|BIOLOGICAL|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
219033602|NCT05630859|BIOLOGICAL|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
219033603|NCT05630859|BIOLOGICAL|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
219033604|NCT05630859|BIOLOGICAL|Placebo|Two doses of placebo, administered intramuscularly.
219033605|NCT05630859|BIOLOGICAL|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
219033606|NCT05630859|BIOLOGICAL|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
219033607|NCT00587886|BEHAVIORAL|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
219033608|NCT00587886|BEHAVIORAL|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
219033609|NCT01356654|DEVICE|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
219033610|NCT01356654|DEVICE|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
219033611|NCT03747874|DIAGNOSTIC_TEST|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
219033612|NCT03402009|BEHAVIORAL|Apps|Apps and weblinks to coach self-guided meditation.
219033613|NCT03402009|BEHAVIORAL|EEG neurofeedback|Device provides feedback based on EEG readings.
219033614|NCT06018883|DRUG|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
219033615|NCT06018883|DRUG|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
219033616|NCT06018883|DRUG|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
219033617|NCT02776917|DRUG|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
219033618|NCT06015503|DRUG|PLB1004|PLB1004 is a capsule in the form of 80mg and 40mg.
219033619|NCT06571175|DIAGNOSTIC_TEST|High frame rate echocardiography|Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
219203503|NCT06883721|BEHAVIORAL|Pilates|Participants in this group performed Pilates exercises twice a week for 8 weeks. The exercises included mat and equipment-based exercises, focusing on core stabilization, breathing control, and postural alignment. Exercise difficulty was progressively increased throughout the intervention period.
219203504|NCT06883721|BEHAVIORAL|Cervical stabilization exercise|Participants in this group performed cervical stabilization exercises at home twice daily for 8 weeks. The exercises included chin tucks, cervical extensions, shoulder elevations, and scapular retractions.
219203505|NCT06885866|BEHAVIORAL|Emotion regulation treatment|Emotion regulation intervention in two phases. Phase A focus on establishing normalised eating patterns, and in phase B the emotion regulation interventions are added. Participants will get access to treatment modules every third day over a time period of 8.5 weeks, each module consist of psychopedagogical material, excercises and home work.
219203506|NCT06886113|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs
219203507|NCT06886113|DEVICE|CorVad|Control group treated with Impella CP for a minimum of 48 hrs
219203508|NCT06879808|OTHER|Color therapy|In the experimental group, color therapy was applied 3 days a week for the first two weeks, while no intervention was performed in the third and fourth weeks. In the fifth and seventh weeks, color therapy was applied for 15 minutes each day, while no intervention was performed in the sixth week.
219203509|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer|MTT combined with Pucotenlimab, Sacituzumab Govitecan, Eribulin, and Gemcitabine
219203510|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Melanoma|MTT combined with Pucotenlimab, with other specific drugs determined based on first-line treatment regimen and classification.
219203511|NCT06890104|OTHER|Mouthrinse with Coconut oil pulling|Using mouth rinse with coconut oil for two weeks to treat halitosis
219203512|NCT06890104|OTHER|Mouthrinse with Chlorhexidine 0.12%|Using mouthrinse with 0.12% chlorhexidine for two weeks to treat halitosis
219203513|NCT06723301|BEHAVIORAL|Chatbot-base problem-solving skills training(PSST)|The intervention incorporates eight sessions: Session 1 involves rapport building, understanding relevant personal and medical history, and introducing the Chatbot-based program and worksheet; Session 2 focuses on maintaining brightness and optimism when faced with a specific obstacle; Sessions 3-7 involve the continued application of problem-solving skills training(PSST) to identify problems and the promotion of problem-solving strategies and skills in vivo, including (a) identifying the problem, (b) determining the options, (c) evaluating and choosing the best option, (d) acting according to the best option, and (e) seeing if it works; and Session 8 involves a review of PSST principles and termination.
219203514|NCT06888713|OTHER|Telemonitoring of ADL|Telemonitoring of ADL is based on smart environments sensors (non wearables) and gathers information about activity of daily living routines for a better understanding of homecare services needed.
219203515|NCT06888661|BIOLOGICAL|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
219203516|NCT06886633|BEHAVIORAL|Breathing exercise|"Patients participating in the breathing exercise group will be trained to apply the breathing exercise at least 1 hour before starting the debridement process. 5 minutes before starting the debridement procedure, the researcher will start breathing exercises in the patient's room. The exercise duration will be approximately 15-20 minutes, and the environment will be quiet, at room temperature and well ventilated during the exercise.~The gel part of the pressurized cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application. The cold gel pack removed from the freezer section of the refrigerator will be placed inside the pressurized cold therapy bandage before application. Pressurized cold will be applied to the patient 10 minutes before starting the debridement procedure."
218890506|NCT06122623|OTHER|Health Education|As previously mentioned, the intervention for this study will be a gaming education program that will be conducted once with each participant. Implementation of the program will occur at different times. Each performance will include a maximum of 60 participants who will be divided into small groups within the same room. Seven to 10 participants will comprise a small group, and each group will have one facilitator. The facilitator will be either a member of the research team or a Health lecturer who will be recruited and trained by the Japanese and Indonesian research teams.
219203517|NCT06886633|DEVICE|Experimental: Pressurized Cold Application Group|The gel part of the pressure cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application, and the cold gel pack taken from the freezer section of the refrigerator before application will be placed inside the pressure cold therapy bandage. Pressure cold will be applied to the patient 10 minutes before starting the debridement procedure. The patient will be assessed and recorded by a nurse independent of the research on the State Anxiety Scale before and after debridement, and the Visual Comparison Scale before, during and after debridement.
218890507|NCT03596203|DEVICE|TransCutaneous Magnetic Stimulator (TCMS)|TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
218890508|NCT06119113|OTHER|Evaluation of the wound infection at the 10th day post-op check-up among all groups|Discharge, redness, increased temperature, and dehiscence were accepted as wound infection.
219033620|NCT06571175|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
219033621|NCT06571175|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
219033622|NCT06571175|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
219033623|NCT06571175|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
219509467|NCT00283686|OTHER|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
219033624|NCT06563765|OTHER|FAP-targeting PET/CT imaging will be performed on the enrolled patients.|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
219509468|NCT00283686|OTHER|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
218890509|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 2nd month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
219033625|NCT06977737|DRUG|ATTR-01|Intravenous injection
218890510|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 6th month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
218890511|NCT00469703|DRUG|Thalidomide|
218890512|NCT01449435|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
219033626|NCT06135376|BEHAVIORAL|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
219033627|NCT06348524|DRUG|Ferumoxytol injection|ferumoxytol will assess patency of coronary arteries
219033628|NCT06476886|BEHAVIORAL|Intensive Crisis Intervention (ICI)|ICI is a brief (Average Length of Stay \[ALOS\]: M±SD=4.5±1.4 days), intensive family-centered, skills-based alternative to traditional inpatient psychiatric care. Adolescents participate in 2-3 individual sessions and 1-2 family sessions daily. Based on the cognitive-behavioral model of suicidality, ICI emphasizes that learned, maladaptive cognitive, behavioral, and affective responses to stressors contributing to suicidal behavior can be changed. Master's-level clinicians facilitate this process by engaging adolescents and their families in developing more effective coping skills when faced with potential triggers to suicidal crises.
219033629|NCT06476886|BEHAVIORAL|Adolescent Psychiatric Inpatient Unit (APIU)|APIU provides comprehensive assessment and treatment services to children and adolescents with significant psychiatric difficulties and to their families using a multidisciplinary approach. Symptoms and behaviors that led to admission are targeted through a milieu-based model of care and therapeutic group programming. The multidisciplinary treatment team includes a child and adolescent psychiatrist, often in collaboration with an advanced practice provider, psychologist, psychiatric nursing staff including trained mental health specialists, behavioral healthcare clinicians, care managers, rehabilitative care staff, teachers, and parent partners. Average length of stay is 9-11 days. An individualized treatment plan is developed by the entire treatment team, including the patient and caregivers, and includes initial planning for discharge with the primary treatment goal being stabilization of acute psychiatric symptoms. Programming is based on a trauma-informed biopsychosocial approach.
219033630|NCT06604039|DEVICE|Central venous catheter|Placement of a medical device to gain entry into the bloodstream, typically through a vein or artery, for the purpose of administering fluids, medications, blood products, or for hemodialysis
219033631|NCT05991557|PROCEDURE|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
219033632|NCT06987474|DEVICE|Unity DX and SMARTCataract DX (SCDX) Biometer|Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.
219033633|NCT06987474|DEVICE|IOLMaster 700 Biometer|The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.
219033634|NCT06987474|DEVICE|Argos with Alcon Image Guidance Biometer|The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.
219033635|NCT05431959|OTHER|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
219509469|NCT03892148|DRUG|Furosemide|Protocol for the use of diuretics
219509470|NCT03892148|DRUG|Hydrochlorothiazide|Protocol for the use of diuretics
218890513|NCT04838535|DIAGNOSTIC_TEST|Raman spectrum|The wavelength of the follicular fluids were scaned by Raman spectrum
218890514|NCT02859246|DRUG|Mucinex®|Mucinex®
219203518|NCT06731049|OTHER|Treadmill-based Training Group|The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.
219203519|NCT06731049|OTHER|Dual-Task Treadmill-based Training Group|In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.
219203520|NCT06873321|DRUG|rivaroxaban 2.5 mg bid + aspirin 100 mg|rivaroxaban 2.5 mg bid + aspirin
219203521|NCT06873321|DRUG|clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures|comparator
219203522|NCT06716203|DRUG|Drug: 5 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
219203523|NCT06716203|DRUG|Drug: : 10 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
219203524|NCT06716203|DRUG|Drug: Placebo Administered SC|Drug: Placebo Administered SC
219203525|NCT06710873|DEVICE|TYRX Absorbable Antibacterial Envelope|All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.
219203526|NCT06730360|PROCEDURE|MTA Pulpotomy without photobiomodulation|This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.
219203527|NCT06730360|PROCEDURE|MTA Pulpotomy with Photobiomodulation (LLLT)|This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
219203528|NCT06889649|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Radiation dose of 6-10 Gy per fraction, administered in 5 fractions for peripheral lesions. For lesions near organs at risk, partial-SABR will be used. If neither SABR nor partial-SABR is feasible, moderate hypofractionated radiotherapy (MHFRT) with curative doses will be applied.
219203529|NCT06889649|DRUG|TORIPALIMAB INJECTION(JS001 )|"Toripalimab (intravenous infusion):~Dosage: 240 mg intravenously every 3 weeks. Frequency: Administered every 3 weeks for the duration of the study, until progression or unacceptable toxicity occurs or reach 2 years."
219203530|NCT06889649|DRUG|Axitinib (VEGF-TKI)|"Axitinib (oral, tablet):~Dosage: 5 mg orally twice daily. Frequency: Daily, for the duration of the study, with continuation during progression or until intolerable side effects occur."
219509471|NCT06381726|DIAGNOSTIC_TEST|Resting State Functional Magnetic Resonance Imaging (rs-fMRI)|rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop
218890515|NCT02218684|DRUG|Telmisartan|
218890516|NCT02218684|DRUG|Lacidipine|
218890517|NCT02218684|DRUG|Placebo|
219509472|NCT06381726|BEHAVIORAL|Up-front Motor Rehabilitation|personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop
218890518|NCT01746368|OTHER|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
218890519|NCT01746368|OTHER|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
218890520|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
218890521|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
218890522|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
218890523|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
218890524|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
218890525|NCT05280717|BIOLOGICAL|sotrovimab|via IV injection
218890526|NCT05280717|BIOLOGICAL|sotrovimab|via IV infusion
218890527|NCT06246110|DRUG|EIK1001|EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
219203531|NCT06888518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|specially selected probiotic strains for the diatary treatment of Lactobacillus deficiencies in women
219203532|NCT06888518|DRUG|antibiotic|regular antibiotic treatment against bacterial vaginosis
219203533|NCT06882369|PROCEDURE|TAP Block|The transabdominal plane (TAP) block is a regional anesthesia technique used for postoperative pain management in abdominal wall procedures, providing somatic analgesia to the anterior and lateral abdominal walls
219509473|NCT06381726|DRUG|Up-front Chemotherapy|Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
219509474|NCT05555589|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
219509475|NCT05555589|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
218890528|NCT06246110|DRUG|Pembrolizumab|PD-1 inhibitor
218890529|NCT06246110|DRUG|Paclitaxel|Chemotherapy
218890530|NCT06246110|DRUG|Pemetrexed|Chemotherapy
218890531|NCT06246110|DRUG|Carboplatin|Chemotherapy
218890532|NCT01302028|DRUG|ASP1941|Oral
219509476|NCT05189561|OTHER|near-infrared scanner|"Tests to be administered: Near Infra-Red Scanning of the head at the bedside.~Time taken for testing: Two minutes~Biological samples collected: None~Frequency of testing/collection: Once~Risks for the participants while being tested: None"
218890533|NCT04602117|DRUG|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
219608501|NCT03885661|DRUG|Icosapent Ethyl 1000 MG [Vascepa]|Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
218890534|NCT03881111|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
218890535|NCT03881111|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
218890536|NCT03881111|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
218890537|NCT03881111|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
218890538|NCT00193921|DRUG|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
218890539|NCT00193921|RADIATION|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
218890540|NCT00193921|DRUG|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
218890541|NCT00193921|DRUG|Cisplatin|20mg/m2, IV, weekly
218890542|NCT00193921|RADIATION|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
218890543|NCT00089037|DRUG|methotrexate|
218890544|NCT00089037|DRUG|sirolimus|
218890545|NCT00089037|DRUG|tacrolimus|
218890546|NCT05337800|BEHAVIORAL|stress managment program|A four-session stress management program will be applied to the experimental group students.
218890547|NCT03654937|BIOLOGICAL|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB."
218890548|NCT01069965|DRUG|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
218890549|NCT01069965|DRUG|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
218890550|NCT01069965|DRUG|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
218890551|NCT01069965|DRUG|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
218890552|NCT01069965|DRUG|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
218890553|NCT01069965|DRUG|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
218890554|NCT06122974|DEVICE|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
218890555|NCT06122974|DEVICE|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
218890556|NCT06466460|OTHER|Motion based - Virtual cycling|To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment. (Intervention study)
218890557|NCT02233634|DRUG|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
218890558|NCT02233634|OTHER|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
218890559|NCT02233634|OTHER|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
218890560|NCT05143034|DIETARY_SUPPLEMENT|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
218890561|NCT05143034|DIETARY_SUPPLEMENT|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
218890562|NCT02766868|DRUG|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
218890563|NCT01588444|DEVICE|cortical FDBA|cortical mineralized freeze-dried bone allograft
218890564|NCT01588444|DEVICE|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
218890565|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
218890566|NCT05877144|OTHER|Medical Device Usage and Evaluation|Receive LiSWT
218890567|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
218890568|NCT05877144|OTHER|Survey Administration|Ancillary studies
219509477|NCT02628340|OTHER|Ex-vivo analysis|
219509478|NCT02625415|DEVICE|Vitamin B6 cream|Topical Vitamin B6 cream
219509479|NCT02625415|DEVICE|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
219509480|NCT00303992|BIOLOGICAL|trastuzumab|
219509481|NCT00303992|DRUG|irinotecan hydrochloride|
219608502|NCT01023009|PROCEDURE|vitrectomy|
219608503|NCT02054052|DRUG|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
219608504|NCT01893515|DRUG|PRC-4016|
219608505|NCT01893515|DRUG|Placebo|
219608506|NCT02607046|OTHER|Exercise training|The exercise program includes supervised and home-based walking and strength exercise.
219608507|NCT02607046|OTHER|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
218890569|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
219509482|NCT02970669|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
218890570|NCT05877144|PROCEDURE|Sham Intervention|Receive sham LiSWT
218890571|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
218890572|NCT05877144|OTHER|Survey Administration|Ancillary studies
218890573|NCT00335296|DEVICE|PFx catheter|
218890574|NCT03243357|PROCEDURE|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
218890575|NCT03243357|PROCEDURE|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
218890576|NCT06352749|BEHAVIORAL|Advice to increase physical activity and reduce sedentary behavior|After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations will be transmitted verbally and through written material.
218890577|NCT06352749|BEHAVIORAL|Online Physical Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised online by trained physiotherapists or sports physiologists."
218890578|NCT06352749|BEHAVIORAL|Face-to-Face Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists."
218890579|NCT05028452|OTHER|Internet based support|Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.
219608508|NCT05797610|DRUG|Sefaxersen (RO7434656)|Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified.
218890580|NCT06285396|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature.
219033636|NCT06402825|BEHAVIORAL|Fit-for-Fertility program|Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
219033637|NCT06861920|DRUG|Naproxen Sodium 550mg|Participants will receive Naproxen Sodium 550 mg oral tablet, administered twice daily for the first 48 hours of their menstrual period, for 1-year. Naproxen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation reduction. 550 mg naproxen sodium is the highest FDA-approved starting dosage, equivalent to 500 mg naproxen; the sodium formulation quickens absorption.
219033638|NCT06861920|DRUG|Placebo|Participants will receive a placebo oral tablet, identical in appearance to Drug X, administered twice daily for the first 48 hours of their menstrual period, for 1-year. The placebo contains inactive ingredients with no known therapeutic effect.
219203534|NCT06882369|DRUG|Intrathecal morphine injection|Intrathecal injection of morphine plus 20 mg hyperbaric bupivacaine in spinal anesthesia
219203535|NCT06882369|DRUG|spinal anesthesia|intrathecal injection of bupivacaine
219509483|NCT02970669|DRUG|enalapril|Enalapril tablet taken orally.
219509484|NCT02970669|DRUG|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
219509485|NCT02970669|DRUG|matching placebo enalapril|matching placebo enalapril tablet taken orally
219509486|NCT04253925|OTHER|Kegel exercises|global postural correction exercises
219509487|NCT04217668|DRUG|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
219608509|NCT05797610|DRUG|Placebo|Matching placebo will be administered as SC injection per schedule as specified.
219608510|NCT04206917|DEVICE|Multi Pulse Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
219608511|NCT05754749|DRUG|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
218890581|NCT06285396|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature.
218890582|NCT06285396|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature.
218890583|NCT06285396|DRUG|Oxytocin|Oxytocin, at applicable concentrations based on literature.
218890584|NCT06807580|DRUG|Placebo|The placebo will be nearly identical in size, color, and shape to micronized progesterone
218890585|NCT06807580|DRUG|Progesterone|Oral micronized progesterone 200 mg
218890586|NCT06391489|BEHAVIORAL|HOBSCOTCH-PACS|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
218890587|NCT00581906|RADIATION|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
218890588|NCT04923126|DRUG|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
218890589|NCT06580561|BEHAVIORAL|Personalized exercise coaching|"This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions)."
218890590|NCT06580561|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|"This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises."
218890591|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
218890592|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
218890593|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
218890594|NCT04954859|DRUG|Bepirovirsen|No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
218890595|NCT04954859|DRUG|Placebo|No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
218890596|NCT06982183|DRUG|Propranolol|An administration of a 40-mg propranolol capsule immediately after tarantula exposure
218890597|NCT06982183|DRUG|Hydrocortisone|An intramuscular administration of 62.5 mg/1 ml of hydrocortisone immediately after tarantula exposure
219033639|NCT06861920|DRUG|Extended Release Acetaminophen (650 mg)|Participants may take extended release acetaminophen 650mg oral tablet as needed for breakthrough menstrual pain. Participants will be instructed to take 1 dose of acetaminophen after 2 hours of taking a dose of either naproxen sodium or placebo, only if needed for pain relief. They are able to take an additional dose of acetaminophen after 2 more hours have elapsed for continued breakthrough symptoms. Use of rescue medication will be monitored and recorded.
219033640|NCT07006142|OTHER|Modified Fasting Guidelines|Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure
219033643|NCT07011810|BIOLOGICAL|Axatilimab|Given IV
219033644|NCT07011810|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219033645|NCT07011810|OTHER|Questionnaire Administration|Ancillary studies
219033646|NCT07011810|PROCEDURE|Skin Biopsy|Undergo optional skin biopsy
219033647|NCT07011810|PROCEDURE|Skin Measurement|Undergo optional skin flexibility assessment
218890598|NCT06982183|DRUG|Morphine|An intramuscular administration of 5 mg/1 ml of morphine immediately after tarantula exposure
218890599|NCT06982183|DRUG|Placebo (oral)|An administration of a placebo capsule after tarantula exposure
218890600|NCT06982183|DRUG|Placebo (IM)|An intramuscular administration of 1 ml of saline immediately after tarantula exposure
219033648|NCT06689566|DIETARY_SUPPLEMENT|genistein|the patients will receive genistein 250mg BID orally for complete 3 months. Afterwards, there will be 3 months washout period. Patients would then be followed for outcome measurement.
219203536|NCT06881069|BEHAVIORAL|Clinic Level: AAC - SDOH, AAC - Tobacco|Ask-Advise-Connect (AAC) is a health information technology (HIT) implementation strategy that consists of EHR-based point-of-care supports for the assessment of tobacco use and Social Drivers of Health (SDOH).
219203537|NCT06881069|BEHAVIORAL|Non-Bundled|All patient level strategies will address only the content of increasing reach of the Utah Tobacco Quit Services.
219203538|NCT06881069|BEHAVIORAL|Bundled|All patient level strategies will address the content of increasing reach of the Utah Tobacco Quit Services and SDOH.
219203539|NCT06881069|BEHAVIORAL|Dose 1|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 1 opportunity for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
219608512|NCT01400542|DEVICE|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
218890601|NCT04209205|DRUG|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
219203540|NCT06881069|BEHAVIORAL|Dose 3|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 3 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
219203541|NCT06881069|BEHAVIORAL|Dose 6|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 6 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
219203542|NCT06881069|BEHAVIORAL|Dose 9|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 9 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
218890602|NCT04209205|DRUG|Placebo|Matching placebo to AIN457 i.v. infusion
219203543|NCT06881069|BEHAVIORAL|Dose 12|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 12 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
219203544|NCT06881069|BEHAVIORAL|RPN|Reactive Patient Navigation Only (RPN): Patient can request to speak to a CHW, over 12 months following a patient's initial clinic visit, at any time.
219203545|NCT06881069|BEHAVIORAL|PPN|Proactive Patient Navigation (PPN): Patient is proactively called, over 12 months following a patient's initial clinic visit, by a CHW up to 4 times.
219203546|NCT06883708|BEHAVIORAL|iSupport-Malaysia Web-Based Intervention|"iSupport-Malaysia web-based intervention is a website version of the culturally adapted iSupport for Dementia into the Malaysia context (in local Malay language).~The 23 lessons is arranged under the 5 modules in the same way as the original iSupport manual. Each lesson is delivered in bite-sized knowledge, using engaging videos, interactive quizzes with feedback, and reflection exercises. Each lesson takes an average of 10-20 minutes to complete. At the end of each lesson, a completion batch is given. The lesson plan can be personalised by the caregivers themselves according to individual needs. Caregivers will also have the option to receive a course completion certificate if they completed all 23 lessons in the program. Additionally, in each lesson, participants are encouraged to post comments in response to the prompt questions, and also reply to others' comments."
219203547|NCT06883708|BEHAVIORAL|iSupport-Malaysia eBook|"iSupport-Malaysia eBook is the Malay-translated, culturally adapted version of the iSupport for Dementia manual in PDF format. This eBook is approximately 275 pages long, containing comprehensive text-based details for the 5 modules and 23 lessons. The modules and lessons are similar to the iSupport-Malaysia web-based program. The main lesson content is delivered in text-based format. Each lesson includes at least one case 1 scenario(s) presented in a quiz format. Some lessons offer additional worksheets for caregivers to reflect on their own caregiving experiences and apply the strategies learned to their caregiving journey. A completion batch is given at the end of each lesson. The lesson plan can be personalised by the caregivers themselves according to individual needs."
219203548|NCT06884683|DRUG|Metformin|"Drug: metformin tablet 500 mg, 1 tablet twice a day (total dose 1000 mg daily), administered orally continuously~\+~Biological: Nivolumab 240 mg via IV infusion every 14 days~Other Names:~Opdivo®"
219203549|NCT06716151|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
219203550|NCT06716151|DRUG|HB0034 matching placebo|HB0034 matching Palcebo
219608513|NCT01400542|DEVICE|No treatment|no treatment
219608514|NCT00144729|PROCEDURE|Bone marrow transplant|
219608515|NCT05669664|PROCEDURE|Biopsy Procedure|Undergo biopsy
219608516|NCT05669664|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218890603|NCT04209205|DRUG|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
218890604|NCT05244564|OTHER|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)|"Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy."
218890605|NCT06593496|BEHAVIORAL|Text Message Reminder|Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.
219033649|NCT07017972|DEVICE|AI evaluation of embryos|AI evaluation of embryos inside a time-lapse incubator.
219203551|NCT06889987|DRUG|Intramuscular quadratus lumborum block|Patients will receive bilateral ultrasound-guided intramuscular quadratus lumborum block with an injection of 0.4 ml/kg bupivacaine 0.25% after induction of general anesthesia
219608517|NCT05669664|PROCEDURE|Computed Tomography|Undergo CT
219608518|NCT05669664|DRUG|Darolutamide|Given PO
219608519|NCT05669664|DRUG|Leuprolide Acetate|Given IM
219509488|NCT03521999|BEHAVIORAL|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
219509489|NCT03521999|OTHER|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
218890606|NCT06595914|OTHER|Clinical implementation strategies|Clinical implementation strategies, selected based on ED clinician survey/interview findings from Aim 1 using the Implementing Promoting Action on Research Implementation in Health Services (i-PARIHS) implementation science framework
218890607|NCT03254940|BEHAVIORAL|Charge|Text messaging-based study to determine effect of different components on weight loss.
218890608|NCT03966872|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
219033650|NCT06681376|OTHER|Comfort menu and cart|"The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance."
219033651|NCT07015346|DRUG|Rotigexole 8 mg|Rotigotine 8 mg
219033652|NCT07015346|DRUG|Neupro ® 8 mg|Rotigotine 8 mg
219033653|NCT04057040|DRUG|PTG-300|Active
219033654|NCT04057040|DRUG|Placebo|Placebo
219033655|NCT06627452|OTHER|Dynamic Neuromuscular Stabilization Training|Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.
219033656|NCT06627452|OTHER|Pelvic Floor Muscle Training|Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
219033657|NCT06461351|OTHER|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection
219033658|NCT06714435|OTHER|Intermittent hypoxia|Intermittent hypoxia during 6 hours in daytime
219033659|NCT06714435|OTHER|Normoxia|Normoxia during 6 hours in daytime
219033660|NCT00849160|DRUG|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
219608520|NCT05669664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219608521|NCT00383253|BEHAVIORAL|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
218890609|NCT03966872|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
219033661|NCT07041918|DEVICE|The study is entirely designed to analyze product performance (analyze only results from whole blood and derived from the PRP tubes), and no interventions will be performed.|The study will evaluate and analyze only the results obtained from whole blood in the hemogram test and the results derived from the PRP tubes. The main objective is to measure the performance of the Vacusera PRP Tube and Vacusera PRP Tube with Gel in obtaining platelet-rich plasma. The study is entirely designed to analyze product performance, and no interventions will be performed.
219033662|NCT07042139|PROCEDURE|No reduction|No reduction
219033663|NCT07042139|PROCEDURE|Closed Reduction|Closed reduction
219509490|NCT00000372|DRUG|D-cycloserine|
219509491|NCT00000372|DRUG|Glycine|
219608522|NCT00383253|BEHAVIORAL|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
219033664|NCT07042139|OTHER|Casting|Dorsal cast
219033665|NCT07039656|DRUG|Toripalimab|Participants will receive Toripalimab (240 mg IV) Q3W for 17 cycles (cycle length=21 days).
219033666|NCT07039656|DRUG|Cisplatin-based chemotherapy|Cisplatin\[75 mg/m\^2 IV Q3W\]/carboplatin\[AUC 5 IV Q3W\]+paclitaxel\[260 mg/m\^2 IV Q3W\] or cisplatin\[75 mg/m\^2 IV Q3W)\]/carboplatin\[AUC 5 IV Q3W\]+ pemetrexed\[500 mg/m2 IV Q3W\],dependent on tumor histology. Participants will receive Chemotherapy for 3-4 cycles
219033667|NCT06732349|DIAGNOSTIC_TEST|Urinary tubular test panel|The urinary tubular test panel will be applied to urine samples that are collected as part of the routine outpatient follow-up. Its predictive power for CKD progression will be assessed. The results of the tubular test panel will not influence the treatment of the patients. They will remain under standard outpatient treatment throughout the study.
219509492|NCT00000372|DRUG|Clozapine|
219509493|NCT00000372|DRUG|Placebo|
219509494|NCT05030090|BEHAVIORAL|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
219608523|NCT00383253|BEHAVIORAL|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
219608524|NCT00383253|BEHAVIORAL|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
219203552|NCT06889987|DRUG|Lateral quadratus lumborum block|Patients will receive bilateral ultrasound-guided lateral quadratus lumborum with an injection of 0.4 ml/kg of bupivacaine 0.25 after induction of general anesthesia.
219203553|NCT06889987|DRUG|General anesthesia|Patients will receive only general anesthesia without any block.
219203554|NCT06732258|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle.
219203555|NCT06732258|DRUG|Tifcemalimab injection|100 mg or 200 mg q3w until disease progression or intolerable toxicity;
219203556|NCT06732258|DRUG|Toripalimab|240 mg q3w until disease progression or intolerable toxicity;
219203557|NCT06732258|DRUG|Cisplatin|75 mg/m2 q3w for 4-6 cycles;
219203558|NCT06732258|DRUG|Carboplatin|AUC = 5, q3w for 4-6 cycles;
219203559|NCT06732258|DRUG|Etoposide|100 mg/m2, d1, d2, d3, q3w for 4-6 cycles;
219203560|NCT06885437|OTHER|Pain and sedation assessment with the N-PASS scale by each nurse|After a painful procedure, the infant's N-PASS pain and sedation scores were assessed simultaneously by three observers (two researchers and the patients' head nurses) independently and blinded.
219203561|NCT06739772|BEHAVIORAL|HPV Self-Sampling and Behavior Intervention|Participants in the intervention group will receive HPV self sampling and behavioral intervention
219203562|NCT06739772|BEHAVIORAL|Participants in the intervention group will receive HPV self sampling and behavioral intervention|Received enhance standard care
219203563|NCT06883487|OTHER|No intervention|Observational study without intervention
219608525|NCT05624879|BEHAVIORAL|Accelerated Resolution Therapy|A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
219608526|NCT05624879|OTHER|Information and Support|4 sessions of a standardized social work intervention. Standard of care including education and active listening.
219608527|NCT05409729|BEHAVIORAL|retrospective charts reviewing|
219608528|NCT06972069|PROCEDURE|Combined Kidney/Bone Marrow Transplant|The conditioning regimen to be used in this protocol consists of an ordered series of procedures and treatments including thymic irradiation, low-dose cyclophosphamide, antibody administration (Siplizumab, rituximab and tegoprubart), and bone marrow cell infusion.
219608529|NCT06972069|PROCEDURE|Donation of Kidney / Bone Marrow|The donor will undergo nephrectomy and under general anesthesia. Donors will undergo bone marrow harvested under general anesthesia. Sufficient marrow will be obtained to provide at least 2 x 108 nucleated cells per kilogram weight of the recipient.
219033668|NCT06788834|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase.~Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effects. The duration of the program will be set at a minimum of three weeks."
219033669|NCT06469164|DRUG|BNT331|Vaginal insert
219033670|NCT06469164|OTHER|Placebo|Vaginal insert
219033671|NCT06745518|DRUG|TS-172|oral administration of TS-172 20\~60 mg/day
219033672|NCT06745518|DRUG|Placebo|oral administration of placebo
219033673|NCT06745531|DRUG|TS-172 20~60 mg/day|oral administration of TS-172 20\~60 mg/day
219203564|NCT06887075|BIOLOGICAL|Blood sample|"* Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence~* Serum inflammatory markers : CRP, IL-6, MCP-1, TNF, sTNFR1~* Single Molecule Array for IL1 and LUMINEX for IL18 in patient's sera~* RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells~* Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry"
219203565|NCT06887075|BEHAVIORAL|Geriatric assessment standardized|"* Exhaustion (2 standardized questions)~* Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ)~* 4-meters gait speed, with sex and height-specific cutoffs~* Handgrip strength, measured using a dynamometer, with sex and BMI-sp Comorbidity (CIRS-G score )~* Screening for intrinsic capacity decline (first step of ICOPE program, adapted to the study, )~* Physical performance (SPPB score )~* Cognitive functions (MoCA score ),~* Depression (GDS-15 score ),~* Nutrition (MNA score )~* Sensory functions (Snellen test for vision, HHIES questionnaire for hearing) -- Dependency in activities of daily living (ADL and IADL scores)"
219203566|NCT06885164|OTHER|Continuous monitroing|Continuous monitoring for 30 days with a small combined SCG and 1-lead ECG sensor
219203567|NCT06884085|DRUG|Co-administration of AD-227A and AD-227B|Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
219203568|NCT06884085|DRUG|Administration of AD-227|Administration of AD-227 1Tab., Per Oral
219203569|NCT06889363|DRUG|MTA|The indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above
219203570|NCT06889363|BIOLOGICAL|PRF|The indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above
219203571|NCT06736873|OTHER|Light intervention|Light intervention
219203572|NCT06885489|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) based psychoeducation program|This study implements an ACT-based psychological intervention designed to enhance psychological well-being and reduce depression, anxiety, and stress among university students. The intervention consists of structured sessions focusing on psychological flexibility, mindfulness, acceptance, and value-driven actions. Participants engage in experiential exercises, cognitive defusion techniques, and behavioral commitment strategies. The intervention is delivered over 8 weeks, with weekly sessions lasting approximately 40 minutes. The sessions are conducted in groups by trained professionals.
219608530|NCT06972069|DRUG|Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)|Recipients will receive a conditioning regimen that includes rituximab on study day -6 and -2, Siplizumab (0.6mg/kg) on day -6, -1, 0 and +1, cyclophosphamide (CP, 22.5mg/kg) on days -5 and -4. Tegoprubart (Fc-modified anti-CD154 mAB, Eledon Pharm) 20mg/kg will be administered on days 0, 2, 5, 12 and 19).
219033674|NCT06745531|DRUG|Placebo|oral administration of placebo
219033675|NCT07109479|DEVICE|Intravascular Lithotripsy|study group will receive the investigational devices (Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device) for calcified lesion pre-treatment.
219033676|NCT07109479|DEVICE|Rotational Atherectomy|control group will receive the control device (Coronary Rotational Atherectomy System)
219033677|NCT06896422|DRUG|Glutathione|Glutathione is administered as an adjunct intervention to the PD-1 inhibitor plus chemotherapy regimen.
219033678|NCT06896422|DRUG|PD1 Inhibitor|e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab
219033679|NCT06896422|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
219203573|NCT06584292|PROCEDURE|caudal block|Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
219203574|NCT06584292|PROCEDURE|Retrolaminar block|Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
219203575|NCT06881758|BEHAVIORAL|Exercise|The investigators will investigate the differences between high and low intensity training
219203576|NCT06739330|DEVICE|Fibroscan|Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
219203577|NCT06738563|OTHER|Collection breast milk|Collection of a milk sample taken as part of women's donation
219203578|NCT06889402|PROCEDURE|Neoadjuvant therapy with PD-L1 inhibitor|During neoadjuvant treatment, patients may receive neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, or neoadjuvant chemotherapy combined with immunotherapy during the perioperative period.
219203579|NCT06737692|OTHER|Exercise|"Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises."
219203580|NCT06737055|BEHAVIORAL|Education about behavioral strategies to improve sleep|In collaboration with direct care workers, the investigators are developing an intervention to help home visitors support clients who experience sleep difficulties in the perinatal period. The intervention consists of a series of educational videos about promoting healthy sleep and addressing sleep difficulties during pregnancy and the postpartum period.
219509495|NCT05030090|DIETARY_SUPPLEMENT|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
219509496|NCT05030090|COMBINATION_PRODUCT|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
219033680|NCT06227767|OTHER|spinal stabilization exercise|The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.
219509497|NCT00670475|DRUG|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
219509498|NCT00670475|DIETARY_SUPPLEMENT|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
219509499|NCT04711629|OTHER|Clinical Tests|Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
219509500|NCT02632656|OTHER|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
219033681|NCT06588738|DRUG|ESK-001|ESK-001
219033682|NCT06588738|DRUG|Placebo|Placebo
219033683|NCT06588738|DRUG|Apremilast|Apremilast
219033684|NCT05906537|DRUG|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
219033685|NCT05525156|DRUG|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
218890610|NCT06986642|OTHER|core stability exercises|"core stability exercises General Exercises~1. Brisk walking (30 minutes)~2. Squats (3 sets, 10-15 repetitions)~3. Lunges (3 sets, 10-15 repetitions per leg)~4. Push-ups (3 sets, 10-15 repetitions)~5. Seated row (3 sets, 10-15 repetitions)~1\. Brisk walking (30 minutes) 2. Squats (3 sets, 10-15 repetitions) 3. Lunges (3 sets, 10-15 repetitions per leg) 4. Push-ups (3 sets, 10-15 repetitions) 5. Seated row (3 sets, 10-15 repetitions)"
219203581|NCT06737731|DRUG|SHR-1681|SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
218890611|NCT06986642|OTHER|Genreal Exercises|Genreal Exercises
219033686|NCT07087626|OTHER|Arterial Blood Gas Analysis|Arterial blood gas analysis will be performed at predefined time points: at rest during the preoperative period, before induction and preoxygenation during the perioperative period, two minutes after induction but prior to intubation, within the first 30 minutes in the PACU during the postoperative period, and at the 72nd postoperative hour in the ward
218890612|NCT02784847|DRUG|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
218890613|NCT03310528|BEHAVIORAL|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
218890614|NCT03310528|PROCEDURE|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
218890615|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
218890616|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
218890617|NCT06996665|OTHER|High-flow device flow rate setting|To evaluate the feasibility of diaphragmatic speckle tracking, images acquired under three different high-flow settings (low, medium, and high) will be compared with those obtained under the clinically applied flow rate previously used for each patient.
219033687|NCT03889912|DRUG|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
219033688|NCT05703763|DIAGNOSTIC_TEST|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to superficial temporal artery"
219033689|NCT05703763|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
219033690|NCT05703763|DIAGNOSTIC_TEST|Repeat applanation tonometry (optional)|Repeat index test at month 6 and at disease relapse.
219608531|NCT01996930|DRUG|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
219033691|NCT05592678|OTHER|Donepezil|Donepezil is administered as a standard of care treatment by the subject's provider.
219033692|NCT07101679|DRUG|LICSBR|Participating patients will receive the GnP regimen every 21 days (nab-paclitaxel 125mg/m² ivgtt on days 1 and 8 + gemcitabine 1000mg/m² ivgtt on days 1 and 8, repeated every 21 days) combined with serplulimab (200mg ivgtt Q3W). In the second cycle, patients will receive SBRT targeting the primary tumor and/or retroperitoneal lymph nodes: 6.6Gy×5 fractions, 7Gy×5 fractions, or 8Gy×5 fractions, administered every other day with radiotherapy completed in 5 sessions (specific selection determined by investigators based on lesion size and organs at risk \[OAR\] assessment).
219203582|NCT06739252|COMBINATION_PRODUCT|Gemcitabine Oxaliplatin and 5FU|The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.
219203583|NCT06779461|DEVICE|Magnesium Microspheres|Biodegradable Magnesium Embolic Microspheres
219203584|NCT06779461|PROCEDURE|cTACE|cTACE
219203585|NCT01527188|DRUG|100 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
219608532|NCT01996930|DRUG|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
219608533|NCT06144944|DRUG|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
218890618|NCT06996665|OTHER|PEEP titration through different approaches|To investigate the clinical value of diaphragmatic speckle tracking, this study compares PEEP titrated by ultrasound-based assessment with PEEP determined by conventional P/F ratio tables, and analyzes differences in clinical outcomes between the two groups.
218890619|NCT06996210|DEVICE|Acupuncture|The needles will be inserted to 12.5-30 mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
219033693|NCT07104773|DEVICE|Control Lens (omafilcon A)|15 minutes of daily wear
219608534|NCT06144944|DRUG|Epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
219608535|NCT06211036|DRUG|Tarlatamab|Intravenous (IV) infusion
219608536|NCT06211036|DRUG|Durvalumab|IV infusion
219608537|NCT04699591|DRUG|Domperidone|Domperidone taken 4 times a day, dose based on body weight
219608538|NCT03740529|DRUG|Pirtobrutinib|Oral
219608539|NCT03740529|DRUG|Venetoclax|Oral
219608540|NCT03740529|DRUG|Rituximab|IV
219608541|NCT03907475|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219608542|NCT03907475|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219608543|NCT03907475|DRUG|Capecitabine|Given PO
219608544|NCT03907475|DRUG|Carboplatin|Given IV
219608545|NCT03907475|PROCEDURE|Computed Tomography|Undergo CT
219203586|NCT01527188|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
219203587|NCT01527188|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
219033694|NCT07104773|DEVICE|Test Lens (stenfilcon A)|15 minutes of daily wear
219033695|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
219203588|NCT01527188|DRUG|Placebo tablet|One sublingual tablet daily during 6 months
219203589|NCT06735391|DRUG|JMT101|JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
219203590|NCT06735391|DRUG|Osimertinib|EGFR TKI
218890620|NCT06996210|DEVICE|sham acupuncture|The needle will be inserted to 2-3mm in sham Baihui acupoint. For the remaining sham acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
218890621|NCT04742920|DEVICE|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
219203591|NCT06736236|OTHER|Inspiratory muscle warm-up|This study will use a respiratory muscle warm-up protocol set at 40% of the maximal inspiratory pressure (MIP) using the POWERbreath® device, as this intensity has been shown to optimally stimulate respiratory muscles. The protocol involves two sets of 30 breaths with a 60-second rest between sets, performed with participants sitting and using a nose clip. Participants will be trained in this technique during the familiarization session and monitored throughout the tests to ensure proper execution.
218890622|NCT04742920|PROCEDURE|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
218890623|NCT07022119|DRUG|VX-407|Suspension for oral administration.
219033696|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
219033697|NCT07102979|DRUG|Ursodeoxycholic Acid (URSO)|Ursodeoxycholic acid (UDCA) was administered orally at a dose of 10 mg/kg/day for 6 months.
219203592|NCT06736236|OTHER|General warm-up (Control)|The general warm-up (Control) protocol will include exercises such as running and dynamic, active, and passive movements tailored to the diverse sports disciplines in the study. These movements will follow the principles of elevation, activation, and mobilization, focusing on increasing mobility from the arms and shoulders to the lower back and legs. Each session will involve demonstrations emphasizing proper technique and speed, with participants completing a consistent number of repetitions. Researchers will monitor participants closely to ensure correct form and execution throughout the intervention.
219203593|NCT06736236|OTHER|Inspiratory muscle warm-up placebo (IMW %15)|The respiratory muscle warm-up protocol will be conducted at 15% of maximal inspiratory pressure (MIP) using the POWERbreath® device. This placebo protocol will involve two sets of 30 breaths, separated by a 60-second rest, with participants seated and wearing a nose clip. Training for the technique will occur during a familiarization session, and participants will be observed during tests to ensure proper execution. The purpose of this protocol is to serve as a placebo, masking the actual aim of the study to enhance data reliability.
219203594|NCT06736067|BEHAVIORAL|Exercise|Thirty minutes of exercise on a treadmill, including a 5-minute warm-up followed by increments in speed until reaching optimal moderate to high intensity (60-80% of age-predicted maximal heart rate), which will be maintained for 20 min, followed by a 5-minute cool-down. Age-predicted maximal HR will be defined as 220 beats-per-minute (BPM) minus age in years.
219203595|NCT06735274|DIAGNOSTIC_TEST|Cerebral Autoregulation (CAR)|Cerebral Autoregulation (CAR) is the mechanism capable of maintaining cerebral blood flow constant despite fluctuations in blood pressure. The evaluation of dynamic CAR (dCAR) with spontaneous blood pressure variations allows it to be applied in acute and non-collaborating patients
219203596|NCT06735274|DIAGNOSTIC_TEST|Neurovascular coupling (NVC)|Neurovascular coupling (NVC) is the relationship between neural activity and cerebral blood flow, allowing this activity to be evaluated in spatiotemporal terms .
219203597|NCT06735274|DIAGNOSTIC_TEST|Microembolic signals (MES)|Microembolic signals (MES)
219203598|NCT06735274|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Montreal Cognitive Assessment (MoCA)
218890624|NCT07022119|DRUG|Placebo|Suspension for oral administration.
218890625|NCT06697899|DRUG|TGRX-678|All participants are given TGRX-678 orally at 240 mg
219033698|NCT07102979|DRUG|Simvastatin|Simvastatin was administered orally at a dose of 40 mg/day for 6 months.
219203599|NCT06735274|DIAGNOSTIC_TEST|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
219203600|NCT06735274|DIAGNOSTIC_TEST|Instrumental Activities of Daily Living Scale (IADL)|Instrumental Activities of Daily Living Scale (IADL)
219203601|NCT06735274|DIAGNOSTIC_TEST|Modified Rankin Scale for Neurologic Disability (mRS)|Modified Rankin Scale for Neurologic Disability (mRS)
219608546|NCT03907475|BIOLOGICAL|Durvalumab|Given IV
219608547|NCT03907475|PROCEDURE|Echocardiography Test|Undergo ECHO
219608548|NCT03907475|DRUG|Gemcitabine Hydrochloride|Given IV
219608549|NCT03907475|DRUG|Nab-paclitaxel|Given IV
219608550|NCT03907475|DRUG|Paclitaxel|Given IV
219608551|NCT03907475|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219033699|NCT07101523|BEHAVIORAL|mHealth|"The intervention was carried out over a period of 8 consecutive weeks and was delivered through a mobile application specifically developed for this project, called IDHEApp, which incorporated gamification elements to enhance user engagement and motivation. Participants in the experimental group received a structured mHealth-based program aimed at promoting healthier behaviors in three primary domains: physical activity, sedentary behavior reduction, and dietary improvement. Objective data on physical activity and sedentary behavior were collected using a smartwatch device (Fitbit Versa 3), which was worn by all participants in both the experimental and control groups throughout the study. However, only participants in the experimental group received a daily personalized behavioral challenge targeting one of the following domains:~1. Increasing physical activity (e.g., Walk an additional 1,000 steps today);~2. Reducing sedentary behavior (e.g., Stand up and move for at least 5 minut"
219608552|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
218890626|NCT07029776|DRUG|teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance|teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
219033703|NCT06191315|DRUG|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219033704|NCT06191315|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219033705|NCT07109362|DRUG|mild sedation|In this experiment, all subjects were administered remimazolam via a TCI pump until they reached a state of mild sedation, as indicated by a MOAA/S score of 4.
219033706|NCT07109076|OTHER|skin-to-skin contact|Uninterrupted skin-to-skin contact between the neonate and the mother will be initiated immediately and maintained for at least 15 minutes following cesarean birth.
219033707|NCT07109076|OTHER|routine care|Current routine neonatal care following cesarean section includes delayed umbilical cord clamping. Afterward, the newborn is dried by a midwife, dressed, briefly shown to the mother, and then handed over to the father.
219033708|NCT07109687|OTHER|HIIT GROUP|Participants will perform a 31-minute protocol on a cycle ergometer consisting of 1-minute high-intensity intervals at 90% of peak workload (W peak) and low-intensity intervals at 30-40% of W peak, twice a week for 8 weeks.
219033709|NCT07109687|OTHER|MICT|Moderate intensity continous exercise
218890627|NCT07029776|PROCEDURE|melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy|Subjects who are MRD-positive (a threshold of 10\^5) will receive a single melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by a 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
218890628|NCT04770701|DRUG|Ahah Drug|"\- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
219033710|NCT07108452|OTHER|A mobile application that uses AI to deliver behavioral nudges that encourage healthy food choices.|As a mobile application for assessing dietary intake, the app provides a daily report of food intake- a core function that both the gamified and limited app versions have. The gamified version has the added functionality of delivering behavioral nudges that encourage healthy food selections.
219203602|NCT04549792|DRUG|Ustekinumab|Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
219203603|NCT02232386|DRUG|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
219203604|NCT02232386|DRUG|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
219203605|NCT03520114|DEVICE|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
219509501|NCT05293587|BEHAVIORAL|Physical Activity|Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
218890629|NCT04770701|DEVICE|Ahah Placebo|"\- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
218890630|NCT06883630|DRUG|RC148 plus Carboplatin and Paclitaxel/pemetrexed|RC148; Carboplatin; Paclitaxel; pemetrexed
218890631|NCT06883630|DRUG|RC148|RC148 Monotherapy
218890632|NCT06885424|OTHER|No additional intervention administered in this long term follow-up study|Safety follow-up for A2 Bio GT products administered in a previous interventional study
218890633|NCT06720090|BEHAVIORAL|Light therapy|5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
219033711|NCT07108452|OTHER|Limited app version for dietary assessment only|This app version provides a daily report of energy and nutrient intake- available to those randomized to the control group
219033712|NCT07109999|OTHER|None-placebo|This study is an observational study, and no interventions will be implemented.
219033713|NCT07108400|PROCEDURE|ultrasound-guided injections of hyaluronic acid plus high-power laser therapy|Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of active high-power laser therapy using a diode laser.
219033714|NCT07108400|PROCEDURE|"ultrasound-guided injections of hyaluronic acid plus sham high-power laser therapy"|"Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of sham high-power laser therapy using a diode laser, due to the presence of a light pointer and an acoustic signal of the device, which made it impossible to distinguish the active treatment from the sim-ulated one."
219033715|NCT07110259|OTHER|DeepGEM-guided Molecular Testing and Treatment|Artificial intelligence-based mutation prediction using DeepGEM to guide clinical decision-making for molecular testing and therapy selection.
219509502|NCT01538342|OTHER|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
219509503|NCT01538342|OTHER|2 biopsies|
218890634|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
218890635|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
218890636|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
218890637|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
219033716|NCT07110259|OTHER|Standard Diagnostic Pathway|DeepGEM is used for eligibility screening, but its results are withheld. Clinicians manage patients per standard diagnostic and treatment practices.
219033717|NCT07108829|DEVICE|Renal Artery Radiofrequency Ablation Clamp|This device is a clamp used during a laparoscopic surgical procedure. It is placed on the external surface (adventitia) of the renal artery and is connected to a radiofrequency generator. It delivers targeted radiofrequency energy to ablate the renal sympathetic nerves.
219033718|NCT07108673|DIAGNOSTIC_TEST|MRI|structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.
219033719|NCT07108582|DRUG|no NSAID|no NSAID but a placebo with identical galenic formulations to maintain blindness at all times during participation in the study
219033720|NCT07108582|DRUG|protocol for administering NSAIDs already used in routine care|"* 100 mg ketoprofen LP orally administered 30 minutes before surgery,~* 50 mg ketoprofen intravenously at the end of surgery~* then 100 mg ketoprofen LP PO twice a day for 7 days following surgery"
219033721|NCT07109973|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy (CA-CBT)|CA-CBT is an 8-week manualized therapy program based on core CBT principles, adapted for Arab and Asian adolescents in the UAE. Adaptations followed the Southampton Adaptation Framework (SAF-CaCBT) and the PEN-3 model, including culturally relevant metaphors, integration of religious/spiritual beliefs, family involvement, and emphasis on academic and familial stressors. Sessions were delivered weekly for 60 minutes by trained therapists, with support in English, Arabic, and Tagalog.
219203606|NCT03520114|DEVICE|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
219203607|NCT03769506|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
219509504|NCT01538342|OTHER|biopsy|1 biopsy ok healthy skin
219509505|NCT01842451|DRUG|VX-135|
219509506|NCT01842451|DRUG|Daclatasvir|
219608553|NCT06292013|DRUG|Placebo|Administered SC
219608554|NCT04569747|COMBINATION_PRODUCT|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
219608555|NCT04569747|DRUG|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
219608556|NCT06518447|DEVICE|Digital occlusal splints (CAD/CAM)|Consists of occlusal stabilization intra-oral splints fabricated using a fully digital workflow, involving intraoral scanning, virtual design, and 3D printing to ensure precise fit and comfort.
219608557|NCT06518447|DEVICE|Conventional occlusal splints|Consists of occlusal stabilization splints fabricated using traditional analog methods, including physical impressions, plaster models, and manual processing with heat-cured acrylic resin to achieve the desired occlusal arrangement.
219608558|NCT04563520|DRUG|Emicizumab|HEMLIBRA® is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
218890638|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
218890639|NCT06456580|BIOLOGICAL|Telitacicept|Subcutaneous injection
218890640|NCT06456580|DRUG|Placebo|Subcutaneous injection
219033722|NCT07109973|OTHER|Treatment-as-Usual (TAU)|Participants in the TAU group received standard care available within their community. This included optional access to school counselors, general practitioners, or local mental health clinics. No structured psychotherapy or manualized intervention was provided by the research team. This arm served as a pragmatic comparator to evaluate the added value of the Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) intervention.
219033723|NCT07108530|OTHER|Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML|This intervention is distinguished by its risk-adapted, time-compressed, and economically tiered design. It integrates two induction options-IAV (idarubicin + cytarabine + venetoclax) for patients with better economic resources and DAV (daunorubicin + cytarabine + venetoclax) for those with limited resources-followed by consolidation with either the MA regimen (liposomal mitoxantrone + intermediate-dose cytarabine) or intermediate-dose cytarabine alone. Eligible patients proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a FA-BuCy/ATG conditioning regimen and a novel GVHD prophylaxis strategy using anti-CD25 monoclonal antibody combined with delayed oral cyclosporine. The entire treatment is designed to be completed within four months from diagnosis. This protocol is unique in its combination of liposomal chemotherapy, venetoclax-based induction, and tailored transplant strategies.
219203608|NCT03769506|DRUG|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
219203609|NCT06742541|DEVICE|Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively|Planned surgery to receive a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
219203610|NCT06742437|DEVICE|Standard sperm preparation|Sperm samples in the control group will undergo traditional processing
219203611|NCT06742437|DEVICE|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing
219608559|NCT04563520|DRUG|FEIBA|"FEIBA™ is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.~The max dose allowed for aPCC will be 50 U/kg dose given at a single visit."
219033724|NCT07108530|DRUG|First Induction (IAV or DAV Regimen)|"* IAV Regimen:Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3 (total cumulative dose ≤ 40 mg)，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）~* DAV Regimen：Intravenous Daunorubicin (D): 60 mg/m²/day on days 1-3，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）"
219203612|NCT06742970|COMBINATION_PRODUCT|Telematic intervention|Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided
219203613|NCT06741631|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
219203614|NCT01220531|BIOLOGICAL|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
219203615|NCT06890572|DEVICE|HEPA + VOC collecting filter purifier|Subjects operate HEPA + VOC collecting filter purifier
219203616|NCT06890572|DEVICE|fake air purifier|Subjects operate fake air purifiers
219608560|NCT04563520|DRUG|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
219608561|NCT06975722|DRUG|SAR442970|Route of administration: Subcutaneous
219203617|NCT06892158|OTHER|Massage therapy|Participants in IA will receive a 20-30-minute massage five days per week for 21 days.
219608562|NCT06975722|DRUG|Placebo|Route of administration: Subcutaneous
219608563|NCT06307613|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
219608564|NCT06307613|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
219608565|NCT05249283|OTHER|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
219608566|NCT05685797|PROCEDURE|Herpes zoszter (acute)with inter vention|nerve block
219203618|NCT06892158|OTHER|Standard of care|Institutional standard of care treatment
219608567|NCT06575153|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
219509507|NCT01766674|BEHAVIORAL|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
219509508|NCT00739856|PROCEDURE|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
219608568|NCT03346954|OTHER|[11C]-Methionine PET/MRI|Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
219608569|NCT06574984|DRUG|Turoctocog alfa|Turoctocog alfa was administered intravenously.
219608570|NCT06284954|BIOLOGICAL|Empasiprubart IV|Intravenous infusion with Empasiprubart IV
219608571|NCT06284954|OTHER|Placebo IV|Intravenous infusion with Placebo IV
219608572|NCT04895709|DRUG|BMS-986340|Specified dose on specified days
219608573|NCT04895709|DRUG|BMS-936558-01|Specified dose on specified days
218890641|NCT07059663|OTHER|Schroth Method with Core Stabilization Exercises|The Schroth method will focus on postural correction techniques aimed at improving spinal alignment, reducing the curvature of the spine, and enhancing trunk control. Key exercises will include spinal elongation, de-rotation, and specific breathing techniques to help reduce the scoliotic curve. Core stabilization exercises will target the deep trunk muscles, such as the transversus abdominis and multifidus, to improve spinal stability. These exercises will involve bodyweight exercises, resistance bands, and stability balls, aimed at increasing muscle endurance and promoting better posture. The interventions will be performed three times a week for 10 weeks, with each session lasting 60 minutes
219033725|NCT07108530|DRUG|Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen|"* MA Regimen (Liposomal Mitoxantrone + Intermediate-Dose Cytarabine):Liposomal Mitoxantrone: 10 mg/m²/day on days 1-2.Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~* Intermediate-Dose Cytarabine Regimen:Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3)."
219033726|NCT07108530|OTHER|Subsequent Treatment Plan for Transplant-Eligible Patients|"Patients eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) should proceed directly to transplant after the above two treatment cycles（The requirement before transplantation is that minimal residual disease should be negative).~* Conditioning Regimen: FA + BuCy (Fludarabine + Busulfan + Cyclophosphamide). For haploidentical transplantation, ATG (antithymocyte globulin) is added.~* Donor Selection Priority:~  1. HLA-matched sibling donor (MSD)~ 2. Matched unrelated donor (MUD)~ 3. Haploidentical donor (Haplo) Selection should consider donor age, health status, and other clinical factors."
219033727|NCT07108530|OTHER|Allogeneic Stem Cell Transplantation Protocol|"Conditioning Regimen: FA-BuCy/ATG~* Fludarabine: 30 mg/m²/day on days -8 to -6~* Cytarabine: 1 g/m²/day on days -8 to -6~* Busulfan: 2.4 mg/kg/day on days -5 to -3~* Cyclophosphamide: 30 mg/kg/day on days -4 to -3~* ATG (Antithymocyte Globulin): 7.5 mg/kg total dose, administered from day -5 to -2"
219033728|NCT07108530|OTHER|GVHD Prophylaxis Regimen|"GVHD Prophylaxis~* Recombinant Humanized Anti-CD25 Monoclonal Antibody: 50 mg on days +1 and +4.~* The GVHD prophylaxis regimen consists of cyclosporine, mycophenolate mofetil (MMF), and short-course methotrexate (MTX).Cyclosporine (CsA):Initiated as a continuous 24-hour intravenous infusion at a dose of 2 mg/kg/day, starting from day -9 before transplantation.Once the patient can tolerate oral intake, cyclosporine is switched to oral administration at a dose of 3-5 mg/kg/day, divided into two daily doses.The target therapeutic trough concentration of cyclosporine should be maintained between 150-250 μg/L.~* Delayed Oral Cyclosporine Protocol:Continue IV infusion until day +20, even if GI symptoms resolve.Switch to oral only if no acute GVHD occurs.If grade II-IV acute GVHD develops, continue IV CsA."
219033729|NCT07108530|OTHER|Subsequent Consolidation Therapy for Transplant-Ineligible Patients|"1. Consolidation Therapy (Two Cycles)~   * Option A Intermediate-Dose Cytarabine-Based Regimen：Liposomal Mitoxantrone: 10 mg/day on days 1-2 (dose-reduced).Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~  * Option B VA Regimen (Venetoclax + Azacitidine)：Venetoclax (V): Dose-escalation starting at 100 mg on day 1, increasing to 400 mg/day by day 6, continued through day 14.Azacitidine (A): 75 mg/m²/day subcutaneously or intravenously on days 1-7.~  * Treatment Cycle:Each regimen is administered for two cycles with a 3-week interval between cycles, followed by maintenance therapy.~2. Maintenance Therapy After Two Consolidation Cycles~   * Pegylated Interferon α-2b (Long-acting Interferon): 180μg subcutaneously every two weeks.~Continued until disease progression or unacceptable toxicity occurs."
219033730|NCT07109622|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.
219033731|NCT07109622|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast for 12 Weeks
219033732|NCT07110701|OTHER|Retention of the fissure sealants evaluated|Following classification system was employed for the retention evaluation of the sealants: 1 = complete retention; 2 = partial loss; or 3 = complete loss.
219033733|NCT07110038|DRUG|Avelumab|Avelumab, 1,200 mg IV
219033734|NCT07110038|DRUG|enfortumab vedotin|Enfortumab vedotin, 1.25 mg/kg IV
219033735|NCT07108712|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
219033736|NCT07109908|BEHAVIORAL|Wiping Bath|"The babies in this group were given the first bath in the form of wiping baths. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes except the diaper are removed, the newborn is wrapped in a towel, the newborn's face and body are wiped clean with a skin cleanser and cotton cloth compatible with the baby's skin, the diaper is removed and the genital area is wiped, the baby's body is wiped with a cloth moistened with water (37-39 oc), the body is dried, the baby's body is wrapped in a dry towel, the baby's head is washed with a shampoo compatible with the baby's skin, the baby's head is dried and a hat is put on, The newborn was dressed in clothes."
219203619|NCT06891521|PROCEDURE|Electroacupuncture|"Patients received electroacupuncture on the day before and the first day of each ICIs treatment cycle. The electroacupuncture points selected Zusanli (ST36), Quchi (LI11), and Hegu (LI4). Patients will be positioned supine, and the acupuncturist will disinfect the local skin at the acupuncture points using 75% ethanol on cotton balls. A disposable acupuncture needle (0.3mm × 40mm) will be inserted using either a single-hand or double-hand needling technique, with rapid, direct insertion. Once the needle reaches a depth of approximately 0.5 cun, the technique of lifting, thrusting, twirling, and rotating will be applied. After obtaining de qi, the needles will be retained for 30 minutes. Needling will be performed once every 10 minutes, and the needling technique used will be a balanced reinforcing and reducing method. Electroacupuncture will be applied using a dense-wave form, with a frequency of 2 Hz and an intensity not exceeding 10 mA."
219203620|NCT06890949|OTHER|(Group A: Preformed Bioflx Crown)|"Crown Selection \& Tooth Preparation~Measure the mesiodistal width using calipers to select an appropriately sized crown.~If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach.~if crimping is necessary use Howe's pliers.~Tooth Preparation Perform 1-1.5 mm occlusal reduction using a tapered diamond bur. Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
219203621|NCT06890949|OTHER|(Group B: Preformed Zirconia crown)|"Crown Selection~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur. Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish. Perform a 1-2 mm subgingival preparation using a tapered fissure bur.~Crown Placement \& Passive Fit Check~Place the selected crown and check for passive fit.~Cementation of the Crown~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup~Remove excess cement using floss or an explorer. Verify fit, occlusion, and stability"
219509509|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
219033737|NCT07109908|BEHAVIORAL|Wrapping Bath|"The first bath of the babies in this group was in the form of a wrap-up bath, in which the baby was wrapped and placed in the bathtub. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes were removed, the newborn was wrapped in a towel, the newborn was slowly immersed in water wrapped in a towel in a bathtub with a maximum of 7 cm of water at the appropriate temperature (37-39 oC), the towel was gently opened and the baby's body was gently cleaned with a suitable cleansing product and a cotton swab, including the torso, legs and genital area, the baby's head was wetted and washed with a shampoo compatible with the baby's skin, the baby's head was rinsed by pouring water from the hairline, The baby's torso was gently removed from the bathtub and rinsed, the newborn baby was dried and then dressed in clothes."
219033738|NCT07109908|BEHAVIORAL|Showering Bath|"The first bath of the babies in this group was in the form of a shower bath. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes are removed, the newborn's body is soaked with water at the appropriate temperature (37-39 oC) under running water, the body is washed with the appropriate skin cleanser and cotton cloth, the head is washed with the appropriate shampoo for the baby's skin, the whole body is rinsed under running water, the whole body is dried with a towel and the clothes are dressed."
219509510|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
219509511|NCT05498285|BEHAVIORAL|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
219509512|NCT00006381|BIOLOGICAL|trastuzumab|
219509513|NCT00006381|DRUG|celecoxib|
219033739|NCT07110103|DRUG|golidocitinib with PD-1 inhibitors|"Dose escalation: 75/150mg golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy.~Dose expansion: Selected dose (75mg or 150mg) of golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy."
219509514|NCT02354378|DRUG|Dexmedetomidine|
219509515|NCT02354378|OTHER|Memory Test|
219509516|NCT02140450|DRUG|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
219509517|NCT02140450|DRUG|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
219509518|NCT02140450|DRUG|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
219509519|NCT02140450|DRUG|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
219509520|NCT02140450|DRUG|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
219509521|NCT00795561|PROCEDURE|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
219509522|NCT00795561|PROCEDURE|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
219509523|NCT02776761|BIOLOGICAL|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
219509524|NCT02776761|BIOLOGICAL|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
219509525|NCT02776761|BIOLOGICAL|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
219509526|NCT06048900|DEVICE|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
219608574|NCT04895709|DRUG|Docetaxel|Specified dose on specified days
219608575|NCT05272826|DRUG|Iberdomide|Available as formulated capsules and administered as oral medication
218890642|NCT07059663|OTHER|Schroth Method|The control group will receive the Schroth method alone, focusing solely on postural correction exercises. These exercises will aim to improve spinal alignment, reduce curvature, and enhance postural control through spinal elongation, de-rotation, and specific breathing techniques designed to address the scoliosis. The control group will not receive any core stabilization exercises in addition to the Schroth method. This intervention will also be performed three times a week for 10 weeks, with each session lasting 60 minutes
218890643|NCT04712097|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
218890644|NCT04712097|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
218890645|NCT04712097|DRUG|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
218890646|NCT04712097|DRUG|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
218890647|NCT07065916|BEHAVIORAL|Modified Constraint Induced Movement Therapy|Constraint Induced Movement Therapy and Bimanual Therapy
219203622|NCT04873232|BIOLOGICAL|Engensis|Injections with Engensis in study VMDN-003-2
219203623|NCT04873232|OTHER|Placebo|Injections with Placebo in study VMDN-003-2
219203624|NCT06890299|DRUG|BR3006|One tablet administered alone
219203625|NCT06890299|DRUG|BR3006A|One tablet administered alone
219203626|NCT06890299|DRUG|BR3006B|One tablet administered alone
219203627|NCT06890299|DRUG|BR3006C|One tablet administered alone
219203628|NCT06890806|OTHER|Foot Core Stabilization Exercise Group (FCSEG)|"Exercise Group (Foot Core Stabilization Exercises)~Exercise Group will perform foot core stabilization exercises under the supervision of a physiotherapist, three times a week for five weeks. The exercises will include:~Short foot exercise Towel curl exercise Big toe press exercise Toe splay exercise Calf raise to big toe press exercise Leg swings Backward tandem walking Each exercise will be performed in three sets of 15 repetitions."
219203629|NCT06890806|OTHER|Extracorporeal Shock Wave Therapy Group (ESWTG)|Extracorporeal Shock Wave Therapy Group (ESWTG) One group will receive Extracorporeal Shock Wave Therapy (ESWT) once a week for five weeks. The ESWT sessions will be performed using the Gymna Shockmaster 500 device at a frequency of 15 Hz and a pressure of 3 bar, delivering a total of 1800 pulses per session.
219203630|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
219509527|NCT01775761|DRUG|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
218890648|NCT07066696|BEHAVIORAL|Mindfulness and Compassion Program|"The CUIDA2 program is an adaptation of the manual The practice of compassion. Kindness with others and with oneself (2019) by Dr. Javier García Campayo. It comprises a total of 9 sessions of approximately 50 minutes (one class).~This program is structured in 3 modules: Module I mindfulness, module II compassion and module III convergence of the previous elements. Each module includes group dynamics, short meditation practices adapted to the trainees and the explanation of the main theoretical contents through exercises and stories."
218890649|NCT07066696|BEHAVIORAL|Relaxation|The active control group is composed of a relaxation program consisting of 9 sessions. The sessions will be given weekly (once a week) and have an estimated duration of 50 minutes. Different breathing practices and exercises and relaxation techniques such as visualization, Jacobson's progressive relaxation and Schultz's autogenic relaxation will be used.
219033740|NCT07110025|OTHER|designed physical therapy program|a one-hour physical therapy program, focusing on abdominal and back muscle activation and improving balance during standing. The program includes exercises like supine on wedges, prone on wedges, weight shifting, and balance training.
219033741|NCT07110025|OTHER|core stabilization exercise with neuromuscular electrical stimulation|The text describes various exercises for children to improve their physical abilities. These exercises include bridging, crab, plank, superhero, wheelbarrow walk, and kneeling on balls. The placement of electrodes on the gluteus maximus and rectus abdominis muscles is determined using anatomical landmarks. The electric current is generated using a biphasic symmetrical waveform with pulse width and intensity, and the stimulus frequency is adjusted to 35 Hz. The neuromuscular electric stimulation mode is used in a Synchronous mode.
219033742|NCT07103551|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma used during clear aligner therapy for acceleration of Orthodontic Tooth Movement
219033743|NCT07109921|BEHAVIORAL|Structured Early Rehabilitation Nursing Program|A protocolized, phased program. Phase 1 (unconscious): passive range of motion and repositioning. Phase 2 (awake/stable): respiratory training (deep breathing, incentive spirometry), bed mobility (bridging, rolling), and progressive mobilization (sitting at edge of bed). Phase 3 (active): in-place stepping and supervised ambulation. Psychological support was provided throughout. Safety criteria were monitored continuously.
219033744|NCT07109921|OTHER|Usual Care|Standard ICU management for SAP as directed by the primary ICU team. Rehabilitation was discretionary, typically limited to passive range of motion exercises by bedside nurses if deemed necessary.
219033745|NCT07109102|OTHER|Moderate-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
219203631|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
219203632|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
219203633|NCT06891638|DEVICE|Schedule of tDCS administration|This study evaluates the combined effects of Phono-Motor Treatment (PMT) and transcranial direct current stimulation (tDCS) for reading rehabilitation in post-stroke aphasia. Unlike standard speech therapy, this intervention integrates non-invasive brain stimulation to enhance language recovery by modulating neural activity in perilesional areas. We hypothesize that active tDCS will enhance PMT efficacy, leading to greater improvements in reading competence and phonological processing compared to sham tDCS. Through systematic testing across the 3 study arms, we expect to identify the most effective stimulation timing.
219203634|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Vanilla|flavour Vanilla
219608576|NCT05272826|DRUG|Bortezomib|Administered as subcutaneous injection
218890650|NCT07066618|BEHAVIORAL|Breakfast-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 50% of daily energy intake was provided at breakfast, 35% at lunch, and 15% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
218890651|NCT07066618|BEHAVIORAL|Dinner-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 15% of daily energy intake was provided at breakfast, 35% at lunch, and 50% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
218890652|NCT07066007|BEHAVIORAL|First Aid Education Programme|A six-module behavioral education program for parents, designed to improve first aid knowledge, application skills, and self-efficacy. Delivered face-to-face in three 120-minute sessions using theoretical lectures, demonstrations, and case-based simulations.
218890653|NCT07065760|DEVICE|Endovascular Aneurysm Repair with Physician Modified Endograft|The surgeon will make an incision to access the femoral artery and insert a thin wire to guide the catheter to the juxtarenal aortic aneurysm. The main graft will be modified by hand to match the participant's anatomy, then reloaded and guided through the artery to the aorta. Once in place, the graft will be deployed, and additional stents will be inserted into vital arteries that supply the kidneys and bowels. Two smaller grafts will be placed into the iliac arteries.This allows blood to flow to the target organs and legs, protecting the aneurysm from rupture. All catheters will then be removed, leaving the graft in place, and the incisions will be closed.
218890654|NCT07066748|PROCEDURE|group P:pressure support ventilation mode|Group P: Weaning trial will be done for patients using PSV 8 cmH2O without ATC
219033746|NCT07109102|OTHER|High-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 80% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (80%-100% PPO)."
219203635|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Cappuccino|flavour Cappuccino
219608577|NCT05272826|DRUG|Dexamethasone|Administered as oral medication
219608578|NCT05272826|DRUG|Isatuximab|Administered as subcutaneous injection
219608579|NCT03520647|DRUG|Cyclophosphamide|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
219608580|NCT03520647|OTHER|Peripheral Blood Stem Cells|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
219608581|NCT02470338|PROCEDURE|MBP plus arthroscopy (Group A)|
219608582|NCT02470338|PROCEDURE|MBP alone (Group B)|
219608583|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219608584|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
219608585|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
219608586|NCT06976268|DRUG|BHV-8000|BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily
219608587|NCT06976268|DRUG|BHV-8000|BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily
219608588|NCT06976268|DRUG|Placebo|Matching placebo taken once daily
219608589|NCT06285253|COMBINATION_PRODUCT|miroliverELAP treatment|Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
219608590|NCT05490446|DRUG|Tebapivat|Tebapivat Tablet
219608591|NCT04141826|DIETARY_SUPPLEMENT|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
219608592|NCT04141826|DIETARY_SUPPLEMENT|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
219608593|NCT04141826|DIETARY_SUPPLEMENT|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
219608594|NCT01404676|DRUG|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
219608595|NCT01404676|DRUG|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
219608596|NCT00866944|DRUG|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
219608597|NCT00866944|DRUG|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
219608598|NCT00866944|DRUG|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
219613346|NCT04394403|BEHAVIORAL|Internet-based guided self-help based on CBT principles|Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
218890655|NCT07066748|PROCEDURE|group A:automatic tube compensation (ATC).|Group A: Weaning trial will be done for patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).
218890656|NCT07065461|OTHER|200 g serving of white chocolate-based confection product|200 g serving of white chocolate-based confection product
218890657|NCT07065695|PROCEDURE|transposition surgery|Reconstructs spermatic vein drainage via end to side/end to end anastomosis with vessels (e.g., inferior epigastric vein) under 8-15× magnification, preserving testicular arteries/lymphatics.
219203636|NCT06736327|DRUG|SKB500|The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
219203637|NCT06745492|DRUG|Neostigmine + Glycopyrrolate|a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.
219203638|NCT06743984|OTHER|Polychromatic resin composite|Polychromatic layering resin composite (enamel and dentin shades).
219203639|NCT06743984|OTHER|Monochromatic resin composite|Monochromatic resin composite (opaquer and dentin shades)
219203640|NCT06743464|DRUG|Rifaximin 550 MG|Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7
219203641|NCT06743464|OTHER|SOC|SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.
219203642|NCT06744738|BEHAVIORAL|Pharmacist led behavioral change technique|"The intervention was developed based on the behavior change technique taxonomy (v1). This intervention was designed to improve adherence to all therapeutic aspects of hemodialysis patients, including the dialysis program, medications, diet, and fluids. Additionally, the effect of the pharmacist intervention on physiological indices (serum potassium, total calcium, phosphate, IDWG, and hemoglobin) was examined.~The program was explicitly created for implementation in an actual setting, ensuring that the time allocation for participants and facilitators (the party responsible for conducting the PL-BCT) remained reasonable in most contexts.~The BCT components were developed after the identification and coding of the BCTs from previous interventional studies that contain behavioral components and result in positive effects on one or more hemodialysis patients' adherence domains toward their therapeutic regimen (dialysis program, medications, diet, and fluid)."
219203643|NCT06744387|DIAGNOSTIC_TEST|clinical assessments and tissue oxygenation monitoring by Near Infrared Spectroscopy|Flap failure will be identified, based upon gold standard monitoring (flaps skin color, temperature, tissue turgor and capillary refill time) along with Doppler technique during a postoperative period of five days. In all patients Near Infrared Spectroscopy (NIRS) by FORE-SIGHT ELITE will be applied to obtain continuous tissue oxygenation measurements. NIRS values and trends from patients with flap failure (case group) will be compared to NIRS values and trends from patients with no flap failure(control group).
219509528|NCT01775761|DRUG|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
219509529|NCT01775761|DRUG|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
219509530|NCT00646152|DRUG|Poly-ICLC|
219613347|NCT01277783|DEVICE|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
219613348|NCT01715961|PROCEDURE|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
218890658|NCT07065695|PROCEDURE|microscopic simple ligation|Blocks venous reflux via double ligation and division of spermatic veins under microscopy, with identical surgical exposure and vascular protection.
218890659|NCT07066865|DEVICE|omniLenz|sutureless dehydrated amniotic membrane (omnigen) mounted on contact lens (omnilenz)
218890660|NCT07066163|DEVICE|Kinesia U|KinesiaU is a commercially available wearable technology, which includes a smart watch and a mobile application which can continuously monitor and quantify motor symptoms such as tremor, bradykinesia, dyskinesia, gait parameters throughout the day. The technology has been validated for motor symptoms and has high agreement with clinician ratings of motor severity. The motion sensor records data using KinesiaU smart watch and is then transmitted to a secure cloud database, where specialized algorithms analyze the information to detect motor symptoms and compute severity scores every 2 minutes. The results are then not only available to clinicians in the form of detailed reports for review but also for PwP in easily understandable format on the phone application . The validity of this device has been studied to assess tremor, bradykinesia and dyskinesia.
218890661|NCT07066163|OTHER|Standard of care treatment|Participants in the control group will receive standard of care, consisting of regular management of their motor symptoms and monitoring using motor dairy, interview by their neurologist, family physician, and other healthcare providers.
218890662|NCT07066605|DRUG|Group A (Dexmedetomidine Group)|patients will receive dexmedetomidine infusion starting at 0.2 mcg/kg/hr.
219509531|NCT01212783|BEHAVIORAL|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
219509532|NCT01212783|BEHAVIORAL|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
219613349|NCT04196283|DRUG|ABBV-368|Intravenous (IV) infusion
219613350|NCT04196283|DRUG|Tilsotolimod|Intratumoral (IT) injection
219613351|NCT04196283|DRUG|Nab-paclitaxel|Intravenous (IV) infusion
219613352|NCT04196283|DRUG|ABBV-181|Intravenous (IV) infusion
219613353|NCT04867005|BEHAVIORAL|Impact of a training program|Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
219613354|NCT03218020|OTHER|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
219613355|NCT02890173|DRUG|CS-3150|
219613356|NCT02890173|DRUG|Eplerenone|
219613357|NCT04200820|DIAGNOSTIC_TEST|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
219613358|NCT06211101|OTHER|Providing training on kangaroo care guide|Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
219613359|NCT01350882|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
218890663|NCT07066605|DRUG|Group B (Control Group)|patients will receive standard ICU sedation protocol without dexmedetomidine (e.g., fentanyl)
219509533|NCT05584527|OTHER|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
219203644|NCT06744179|DIAGNOSTIC_TEST|echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire|Participants from both exposed and non-exposed groups will be assessed using different standardized questionnaire and a number of investigations to identify any cardiac and pulmonary complications over time. Individuals will be matched for age and sex to ensure comparability. This study aims to evaluate these complications and analyze any significant differences between the groups over the defined follow-up period.
219203645|NCT06744309|BEHAVIORAL|Heat Literacy Intervention|The behavioral intervention aims to improve heat literacy among participants through an 8-12 week education and training program. It includes three main modules: enhancing community awareness of hot weather, recognizing and responding to heat-related illnesses, and teaching personal cooling strategies. Participants will use SwitchBot meters to monitor indoor temperature and humidity, access real-time weather information, and learn about heat wave warnings. They will receive educational materials, including infographics, videos, and one-to-one training from field staff. The content of intervention and delivery methods will be refined through co-design workshops with stakeholders and community members to ensure they are practical and culturally appropriate. The goal is to equip participants with the knowledge and skills to protect themselves from extreme heat, resulting in better heat adaptation behaviors and improved health outcomes.
219203646|NCT06744309|OTHER|Structural (Cool Roof) Intervention|The structural intervention in this study involves implementing cool roofs to reduce indoor temperature and mitigate the effects of extreme heat in rural Malaysian communities. Selected households will have their roofs painted with UV-resistant paint, which reflects direct sunlight and reduces thermal absorption. This intervention aims to decrease the amount of solar energy absorbed by the roof, thereby lowering indoor temperature and reducing the physiological heat strain on residents. By maintaining cooler indoor environment, the cool roof intervention seeks to alleviate the health risks associated with prolonged exposure to high temperature.
219509534|NCT05584527|OTHER|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
218890664|NCT06810778|DRUG|Duvelisib|15 and 25 mg BID
219509535|NCT05584527|OTHER|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
218890665|NCT06810778|DRUG|Venetoclax|200, 400, and 800 mg QD
218890666|NCT07065136|BIOLOGICAL|627|subcutaneous injection
219509536|NCT01735058|DRUG|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
219509537|NCT01735058|DRUG|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
219509538|NCT00989079|DRUG|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
219509539|NCT00989079|DRUG|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
219613360|NCT01350882|DRUG|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
219613361|NCT04617457|DRUG|nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)|preoperative chemotherapy
219613362|NCT00596791|DRUG|tafluprost|prostaglandine analoque
218890667|NCT07065136|OTHER|Placebo|Single subcutaneous injection
218890668|NCT07066111|DRUG|Tramadol|The control group routinely injected tramadol 100mg(Tramal) intramuscularly
218890669|NCT07066111|DRUG|bupivacaine liposome (ultrasound-guided high iliofascial space block)|the experimental group was given ultrasound-guided high iliofascial space block: High-frequency linear probe (5-13 MHZ, Sonosite, USA) was used to identify the iliac bone, iliac muscle and deep circumiliac artery. Then a short oblique puncture needle was used, with the intraplanar technique, and the needle was inserted from the outside. When the needle tip reached the surface of the iliac muscle (iliac fascia space), 20ml of bupivacaine liposome was injected. After the operation, electrocardiogram monitoring(Mindray) was performed for 1 hour to observe adverse reactions.
219033747|NCT07109102|OTHER|Moderate-intensity concentric cycling|"* This group will perform concentric cycling exercise twice per week for ten weeks using the Lode Excalibur sport ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
219033748|NCT07109232|OTHER|Position the patient|In addition, prior to the operation and throughout the PCNL procedure, hemodynamic measurements were obtained while patients were positioned in the supine, lithotomy, and prone positions, as necessitated by the surgical protocol.
219033749|NCT07109440|DIAGNOSTIC_TEST|FAPI PET/CT|Patient will undergo FAPI PET/CT Prior to surgery
219033750|NCT07110545|OTHER|Acupuncture|Application of acupuncture on specific acupoints
219033751|NCT07109258|DRUG|Dexamethasone (Decadron) 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction
219033752|NCT07109258|DRUG|Misoprostol 25 mcg|vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
219203647|NCT06745167|PROCEDURE|Pulsed field ablation|Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation.
219203648|NCT06745167|PROCEDURE|Radiofrequency ablation alone|Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation
219203649|NCT06743867|DRUG|Pressurized Intraperitoneal Aerosol Chemotherapy|"The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively."
219203650|NCT06743789|RADIATION|Radiation Therapy|"Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)"
219203651|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)
219203652|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)
219203653|NCT06743789|RADIATION|Radiation Therapy|Group 1 (3 participants) - will receive a dose of 12 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)
219203654|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 10 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)
219203655|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 8 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)
219509540|NCT01195571|BIOLOGICAL|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
219203656|NCT06744699|OTHER|Infants fed goat milk-based infant formula|Type of infant feeding during the age of 0-12 months
219203657|NCT06743607|BEHAVIORAL|Immediate Intervention|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.
219203658|NCT06743607|BEHAVIORAL|Waitlist control|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.
219203659|NCT06744036|OTHER|Therapeutic Exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.
219203660|NCT06744036|DEVICE|Interferential Current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The interferential current will be applied for 30 minutes.
219203661|NCT06744036|DEVICE|placebo interferential current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The device will only be turned on in the first minute
219509541|NCT00177112|PROCEDURE|clean patient preparation for cystoscopy|
219509542|NCT00177112|PROCEDURE|sterile patient preparation for cystoscopy|
219509543|NCT04738279|DEVICE|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
219509544|NCT04738279|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
219509545|NCT04324879|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
219509546|NCT01128647|DIETARY_SUPPLEMENT|Fructose:glucose drink|
219509547|NCT01128647|DIETARY_SUPPLEMENT|glucose drink|
219509548|NCT00467584|DRUG|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
219613363|NCT06399835|DRUG|Enavogliflozin|Enavogliflozin 0.3mg once daily
219613364|NCT06399835|DRUG|Pioglitazone|Pioglitazone 15mg once daily
219613365|NCT01320995|PROCEDURE|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
218890670|NCT07065019|OTHER|The Internalized Stigma Scale in Mental Illness (ISS)|The ISS consists of 29 items and is a self-report scale assessing internalized stigma. ISS includes 5 subscales: 1. Alienation (6 items), 2. Confirmation of Stereotypes (7 items), 3. Perceived Discrimination (5 items), 4. Social Withdrawal (6 items), 5. Resistance to Stigmatization (5 items). ISS is a Likert-type scale calculated as 'strongly disagree' (1 point), 'disagree' (2 points), 'agree' (3 points), 'strongly agree' (4 points). The items of the 'Resistance to stigmatization' subscale are reverse scored. High scores on this scale indicate how aggressive the person's internalized stigma is negatively. ISS has been adapted for many diseases other than mental illnesses in our country and its validity and reliability have been demonstrated.
218890671|NCT06771544|DRUG|Pembrolizumab|Given IV
218890672|NCT06771544|DRUG|Cyclophosphamide|Given PO
218890673|NCT07065591|DRUG|Metformin|The intervention group will receive metformin (max: 500mgx4=2000mg daily). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
219033753|NCT07109258|DRUG|Both Misoprostol 25 mcg & Dexamethasone 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
219033754|NCT05588843|DRUG|SAR443122|oral capsule
219033755|NCT05588843|DRUG|Placebo|oral capsule
219033756|NCT07110428|PROCEDURE|NCgroup|The patients in this group received oxygen therapy via nasal cannula at a flow rate of 5 L/min, with an oxygen concentration of 100%. An end-tidal carbon dioxide (ETCO2) monitoring catheter was placed at the nostril opening to monitor ETCO2, observe whether the waveform was regular, and record the values.
219033757|NCT07110428|PROCEDURE|SJOVgroup|Gently insert an appropriately sized WNJ tube into one nostril of the subject. Connect one port of the tube to a jet ventilator (Twinstream), with the following SJOV (Synchronized Jet Ventilation) parameters: Driving pressure (DP): 15 psi (1 bar ≈ 15 psi) Respiratory rate: 15 breaths per minute Inspiratory-to-expiratory ratio (I:E): 1:2 Fraction of inspired oxygen (FiO₂): 100% Connect the other port to an end-tidal carbon dioxide (ETCO₂) monitoring catheter to observe the ETCO₂ waveform for regularity and record the numerical values.
219033758|NCT07108374|OTHER|Implementation strategies to increase use of transfusion recommendations|Five implementation strategies will be employed in this study to enhance use of the blood transfusion recommendations. These include 1) building consensus, 2) provider education, 3) identifying and empowering champions ,4) use of computerized clinical decision support tools, and 5) provide quantitative metric-based feedback. Strategies 1-3 will occur prior to initiation of CCDS tools. All patients admitted to the PICU following the date of CCDS tool initiation will be considered to be part of the post-implementation phase. The investigators will collect data from the EHR on CCDS use and conduct provider surveys and interviews following CCDS tool initiation. Surveys and interviews will be both be conducted at 6 and 12 months post-CCDS tool initiation. Process and outcomes measures will be assessed before an after use of the implementation strategies.
219033759|NCT02890589|DEVICE|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
219509549|NCT00467584|DRUG|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
219509550|NCT00467584|DRUG|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
219509551|NCT01597895|DRUG|Maraviroc|Maraviroc 150 mg BID x 5 days with food
218890674|NCT07065591|OTHER|Placebo|The placebo group will receive placebo. The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
219033760|NCT02890589|DEVICE|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
219509552|NCT01597895|DRUG|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
219509553|NCT01597895|DRUG|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
219613366|NCT06578793|PROCEDURE|Catheter Ablation Combined with Marshall Vein Ethanol Ablation|This study involves two procedures. The first procedure is a combination of catheter ablation with ethanol ablation of the Marshall vein. The second procedure is catheter ablation alone. Both procedures involve standard techniques used to treat persistent atrial fibrillation, with the addition of Marshall vein ethanol ablation in the experimental group aimed at potentially improving outcomes by targeting additional arrhythmogenic substrates.
219033761|NCT06923098|PROCEDURE|PET-CT guided biopsy|PET-CT guided biopsy of lung lesions
219033762|NCT06923098|PROCEDURE|CT guided biopsy|CT guided biopsy of lung lesions
219033763|NCT06923969|OTHER|balneotherapy|
219033764|NCT07108517|BEHAVIORAL|IC-Growth ACT-Based Support Program|IC-Growth Psychosocial Group Intervention is a structured, manualized program designed to enhance post-traumatic growth (PTG) in adults diagnosed with breast, colorectal, or head and neck cancer. The intervention is delivered in small groups (8-10 participants) over 6-8 weeks, with weekly 90-minute sessions led by trained health psychologists. The program integrates evidence-based therapeutic approaches, including Acceptance and Commitment Therapy (ACT), mindfulness, cognitive restructuring, narrative exercises, and interpersonal support-building, with the goal of improving psychological flexibility, resilience, quality of life, and overall well-being.
219033765|NCT07108868|BIOLOGICAL|CAR-T cells targeting CD19 and CD22|"Using the 3+3 design, the following dose levels will be assessed:~Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg"
219033766|NCT07108946|OTHER|Black background|Changing the background color during scanning to evaluate its effect on scan quality .
219033767|NCT07108946|OTHER|White background|Changing the background color during scanning to evaluate its effect on scan quality .
219203662|NCT06743919|DRUG|Magnesium sulfate 50% - 1g/h|magnesium sulfate group 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
219203663|NCT06743919|DRUG|dexmedetomidine 0.5 µg/kg IV|dexmedetomidine group 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
219203664|NCT06743919|DRUG|Bupivacaine|20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
218890675|NCT03071393|DEVICE|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
218890676|NCT03071393|DEVICE|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
218890677|NCT05253443|BEHAVIORAL|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
218890678|NCT05253443|BEHAVIORAL|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
218890679|NCT07064668|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|TUDCA administered orally according to protocol-defined dosage.
218890680|NCT07064668|DRUG|Immune checkpoint inhibitor (ICI)|Administered intravenously according to standard practice or protocol.
219033768|NCT07108946|OTHER|Participant own skin as a background|Changing the background color during scanning to evaluate its effect on scan quality .
219033769|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
219033770|NCT05573555|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
219033771|NCT05573555|DRUG|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
218890681|NCT07065669|DEVICE|Dorsal medial Prefrontal Cortex intermittent theta burst stimulation|iTBS stimulation of the dmPFC is a FDA-approved treatment for adults with OCD
218890682|NCT07065669|DEVICE|cTBS to ROFC|continuous theta burst stimulation (cTBS) 1,800 pulses per session
218890683|NCT04866680|PROCEDURE|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
218890684|NCT06474845|DEVICE|T-Control® catheter|Patients will be catheterized with T-Control® for 4 weeks
218890685|NCT06474845|DEVICE|Foley-type catheter|Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
219033772|NCT04328207|OTHER|No Financial Incentive|Standard of care eye health education
219509554|NCT03831633|DRUG|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~\- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
219509555|NCT03831633|DRUG|Standard of Care|"* oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
218890686|NCT07065799|DEVICE|Group 1: NHF/LTOT|Patients assigned to this group will start NHF (Nasal High Flow) + oxygen therapy at home and undergo a preliminary trial with NHF to set the optimal flow using the MyAIRVO 3 (Fisher \& Paykel Healthcare, Auckland, New Zealand) with Optiflow+Duet interface. Patients assigned to this group will be required to use NHF for a minimum of 6 hours per night during sleep, while no restrictions will be set on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the control respiratory strategy (HMV+LTOT) will begin.
219033773|NCT04328207|BEHAVIORAL|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
219509556|NCT00494104|DIETARY_SUPPLEMENT|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
219509557|NCT01332110|DEVICE|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
219509558|NCT01636297|BEHAVIORAL|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
219608599|NCT03298217|DEVICE|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
219608600|NCT01340131|DRUG|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
219608601|NCT01340131|DRUG|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
219608602|NCT03858010|DIAGNOSTIC_TEST|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
219608603|NCT04927143|BEHAVIORAL|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
219608604|NCT04927143|BEHAVIORAL|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
219608605|NCT04265703|PROCEDURE|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
219509559|NCT01636297|BEHAVIORAL|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
219509560|NCT02081261|PROCEDURE|Coronary artery bypass surgery|coronary artery bypass surgery
219509561|NCT02549742|PROCEDURE|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
219509562|NCT02549742|DEVICE|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
219608606|NCT04265703|PROCEDURE|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
219608607|NCT04265703|PROCEDURE|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
219608608|NCT00173511|DEVICE|24 hr Holter monitor|
219608609|NCT05469334|BEHAVIORAL|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
219509563|NCT02549742|DRUG|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
219509564|NCT02353000|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
219509565|NCT02353000|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
218890687|NCT07065799|DEVICE|Group 2: HMV/LTOT|Patients assigned to this group will start home treatment with HMV (Home Mechanical Ventilation) + oxygen therapy and will be treated with HMV using a pressure support (PS) ventilator. HMV will be administered via nasal mask or full face mask according to patients' preference. Patients assigned to this group will be required to use HMV for a minimum of 6 hours per night in addition to daily home oxygen therapy for at least 15 hours. Moreover, no restrictions will be imposed on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the studied respiratory strategy (NHF+LTOT) will begin.
219203665|NCT06745713|OTHER|Turkish- Computer System Usability Questionnaire Short Version|Developed in 1995 by Lewis at IBM, the Computer System Usability Questionnaire (CSUQ) is one of the widely used questionnaires in the field of usability. The scale, which was adapted into Turkish by Erdinç in 2013, consists of 13 items in total. It has 4 sub-dimensions: system usefulness (items 1-6), information quality (items 7-9), interface quality (items 10-12) and general satisfaction (item 13). Each item is scored as 1 (Strongly agree) - 7 (Strongly disagree). The Cronbach α of the scale is \> .70 and the Cronbach α value for each sub-dimension varies between .73 and .92. A minimum score of 13 and a maximum score of 91 can be obtained from the scale. A low score is defined as good usability, and the higher the score, the lower the usability quality of the system (Erdinç \& Lewis, 2013).
218890688|NCT06916494|DRUG|Rutin|Rutin 40 mg tid. Treatment will be given for 2 cycles (21 days per cycle)
218890689|NCT06916494|DRUG|Gemcitabine, Cisplatin|Cisplatin 100 mg/m² D2 q3w, and Gemcitabine 1000 mg/m² D1, D8 q3w. Treatment will be given for 2 cycles (21 days per cycle)
219033774|NCT06941974|BEHAVIORAL|Patient Navigation Program|PATH navigation is an antenatal patient navigator program designed to reduce barriers to care, enhance access, improve self-efficacy and knowledge, and improve multiple perinatal health outcomes. PATH navigation is a flexible, multi-pronged, patient-centered program with the capacity to evolve with patient needs and preferences. Early in pregnancy, navigators will establish themselves as a non-medical resource and will introduce PATH as a program designed to help inform, support, and connect patients during pregnancy. Navigators will review screen and address supportive and adverse non-medical needs, facilitate communication, perform logistical support, provide advocacy and bridge communication with clinical teams, and perform health education. Navigation services will be tailored to individual medical, psychosocial, or logistical complexity.
219608610|NCT02819089|DRUG|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
219608611|NCT02819089|OTHER|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
219608612|NCT00478517|DRUG|Erythropoetin (rHuEPO, EPREX®)|
219033775|NCT06944002|DIETARY_SUPPLEMENT|Milk product|The participants will abstain from consumption of any dairy product for ten days and subsequently drink milk for seven consecutive days (700 ml per day), while concomitant consumption of other dairy products is also allowed.
219033776|NCT03190278|BIOLOGICAL|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
219033777|NCT05864053|DRUG|Ketamine|Ketamine will be administered over a 45-minute period.
219608613|NCT02765256|DRUG|Fluconazole|400mg orally once daily (Day 1-14)
219608614|NCT02765256|DRUG|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
218890690|NCT06916494|DRUG|Tislelizumab|Tislelizumab 200 mg D1 q3w Treatment will be given for 2 cycles (21 days per cycle)
218890691|NCT06915831|DEVICE|Continuous positive airway pressure (CPAP)|All-night CPAP will be applied with bedtimes 23:00h to 7:00h.
218890692|NCT02599779|DRUG|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
219033778|NCT05864053|DRUG|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
219033779|NCT05864053|DRUG|Saline|Saline will be administered over a 45-minute period.
219033780|NCT05254327|DRUG|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
219033781|NCT00857922|OTHER|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
219033782|NCT04439318|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219033783|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
219033784|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
219033785|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
219033786|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
219033787|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
219033788|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
219033789|NCT00126295|DEVICE|'What you need to know about stroke' education package|
219033790|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
219033791|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
219033792|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
219033793|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
219608615|NCT02765256|DRUG|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
219608616|NCT02765256|DRUG|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
218890693|NCT02599779|RADIATION|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
218890694|NCT06914440|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The prescribed dose of radiation is 24 Gy delivered in 3 fractions (8 Gy/fraction) using SBRT technique. Subjects received SBRT for the primary breast cancer lesion at 8Gy/Fraction each time for 3 consecutive days, 1 week before the start of systemic therapy. The first day of radiation is C1D1.
218890695|NCT06914440|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion every 3 weeks (q3w). The first dose is given on Cycle 2 Day 1 (C2D1), followed by dosing on the first day of each subsequent cycle for a total of 4 cycles. (Toripalimab×4 240mg D1 q3w)
218890696|NCT06914440|DRUG|Neoadjuvant Chemotherapy|Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day cycle) for 4 cycles.(T×4, Nab-Paclitaxel 125mg/m2，D1、D8、D15 q3w).
218890697|NCT06914440|PROCEDURE|Surgery|Surgery will be performed 2-6 weeks after completion of neoadjuvant therapy. The surgical approach will be determined by the investigator based on disease status and patient preference.
218890698|NCT06914440|DRUG|Adjuvant Chemotherapy|The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide (body surface area-adjusted 600 mg/m²). Both drugs were administered intravenously every 3 weeks, and then the first day of each course was administered for 4 cycles. (EC×4, Epirubicin 50 mg/m² or Liposomal Doxorubicin 30 mg/m², comined with Cyclophosphamide 600 mg/m², D1, q3w)
218890699|NCT06914440|RADIATION|Adjuvant Radiotherapy|Conventional radiotherapy will be delivered to the breast/chest wall and regional lymph nodes (investigator-selected technique), with explicit prohibition of tumor bed boost irradiation.
218890700|NCT06914440|DRUG|Endocrine therapy|Investigator-selected adjuvant endocrine therapy will be deterimend according to applicable guidelines, considering menopausal status, recurrence risk, treatment history, comorbidities as well as patient preference.
218890701|NCT03162471|DIAGNOSTIC_TEST|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
218890702|NCT06921057|OTHER|exergame|playing exergames
218890703|NCT06921681|DEVICE|Cryobiopsy of lymph nodes group 6 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
218890704|NCT06921681|DEVICE|Cryobiopsy lymphnode group 3 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
218890705|NCT06920836|DRUG|QR052107B 100 mg|QR052107B 100 mg QD
219608617|NCT02765256|DRUG|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
218890706|NCT06920836|DRUG|QR052107B 400 mg|QR052107B 400 mg QD
218890707|NCT06920836|DRUG|Placebo|placebo QD
219608618|NCT02765256|DRUG|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
218890708|NCT06921018|BEHAVIORAL|change in diet|the participants will either be assigned consumption of a vegan diet or their habitual average danish diet with a high intake of meat for the intervention period which is 4 weeks.
218890709|NCT06919315|BEHAVIORAL|CO-OP intervention|CO-OP intervention: Initial phase: Goalsetting is mandatory and based on the participant's prioritized ADL performance issues identified in their baseline COPM. Education phase: Individual education in the metacognitive Goal-Plan-Do-Check strategy. Training phase: CO-OP training that involves repetitive use of the Goal-Plan-Do-Check for problem solving and skill acquisition. The therapist employs dynamic performance analysis and guided discovery to help participants understand performance issues and formulate plans for achieving their goals. Participants then execute and evaluate these plans, with a focus on developing domain-specific cognitive strategies. The therapist actively encourages generalization and transfer of skills. Homework is mandatory.
219033794|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
219203666|NCT06745713|OTHER|Student Information Form|In the form developed by the researchers in line with the literature, a total of 12 questions were included to determine the socio-demographic characteristics of the students (such as age, gender, academic average, whether they provide care to patients with chest tubes, whether they receive training on chest tube care). All participants in the experimental and control groups were applied once as a pre-test.
219608619|NCT02765256|DRUG|Fluconazole placebo|Once daily
219608620|NCT02534389|DIETARY_SUPPLEMENT|omega-3 fish oil|2,4g of EPA + DHA
219608621|NCT04139824|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
219608622|NCT04139824|DRUG|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
219608623|NCT04662814|OTHER|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
219203667|NCT06745713|OTHER|Clinical Reasoning Readiness Scale for Nursing Students|It is a comprehensive assessment tool developed by Huang Huiman (2018) to determine the clinical reasoning readiness levels of nursing students in Taiwan (Ho et al., 2021; H.-M. Huang et al., 2018). 'Clinical Reasoning Readiness Scale for Nursing Students' consists of 4 sub-dimensions. These sub-dimensions are 'awareness of clinical clues' (4 items), 'verification of clinical problems' (4 items), 'action determination and implementation' (4 items) and 'evaluation and reflection' (4 items). Each sub-dimension contains four items to assess students' clinical reasoning readiness levels. The lowest score that can be obtained from the scale is 16 and the highest score is 80. Responses to the scale are evaluated on a 5-point Likert scale (5=strongly agree, 4=agree, 3=decided, 2=disagree, 1=strongly disagree). Cronbach's α ranged from 0.894 for the total and 0.78 to 0.89 for each sub-dimension. The corrected item-total correlation is between 0.627-0.728. Higher scores indicate higher levels
219203668|NCT06745713|OTHER|Self-directed Learning Scale|The original Self-Managed Learning Scale was used as a self-report scale by Lounsbury et. al. (2009). The Turkish adaptation and validity and reliability study of the scale, which shows the extent to which individuals learn autonomously with a one-dimensional structure, was conducted by Demircioğlu, Öge, Fuçular, Çevik, Nazlıgül, and Özçelik in 2018. The scale is 5-point Likert-type and consists of 10 items. For each item, participants are expected to respond according to 1 (Strongly disagree), 2 (Disagree), 3 (No opinion), 4 (Agree) and 5 (Strongly agree). Cronbach's alpha coefficient of the scale is 0.85. In line with the scores obtained from the scale, above average self-directed learning skill means high and below average self-directed learning skill means low (Demircioğlu et al., 2018). Both groups were applied as pre-test and post-test.
218890710|NCT06919315|BEHAVIORAL|Usual practice|Usual practice: Initial phase: Goalsetting is optional and may be based on previous assessment or on a conversation with the participant. Training phase: Different approaches may be taken such as observation and practice of activities or consultation about performance issues and how participants may deal with them. The therapist may guide the participant's performance verbally, physically or trough picture materials. Homework may be included.
219203669|NCT06745713|OTHER|Chest Tube Care Management Knowledge Test|It was created by the researchers in line with the evidence in the literature (Abuejheisheh et al., 2021; Basler, 2020; Bertrandt et al., 2019; Charnock \& Evans, 2001; El-Senousy, Mahrous, Abd-Al Salam, \& Zedan, 2020; Ho et al., 2021; Tarhan et al., 2016; Zisis et al., 2015). The 'Chest Tube Care Management Knowledge Test' was initially prepared as a total of 43 multiple-choice questions, including the headings and subheadings in each session (Abuejheisheh et al., 2021; Malone, 2015). Expert opinions were obtained from 5 faculty members with clinical experience and studies on chest tube care. The experts gave suitability scores to the knowledge test questions one by one on a 4-point Likert-type scale (1: The item is not suitable, 2: The item should be seriously revised, 3: Suitable should be slightly revised, 4: Suitable). In line with the suggestions from the experts, the questions were reorganised and 9 questions were removed. For the remaining 34 multiple-choice questions in the kno
219203670|NCT06743841|DIETARY_SUPPLEMENT|Nutritional supplement|60g of a nutritional supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
219203671|NCT06743841|DIETARY_SUPPLEMENT|Control supplement|60g of a placebo supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
219203672|NCT06744218|PROCEDURE|Standard Treatment|Patients who will be assigned to the control group and subjected to standard treatment (usual care at our clinic) will undergo a physiotherapy treatment of 8 in-person sessions for 4 post-operative weeks
219203673|NCT06744218|PROCEDURE|Experimental Treatment|patients who will be assigned to the experimental group and subjected to the experimental treatment will undergo a physiotherapy treatment of 8 sessions in telerehabilitation for 4 post-operative weeks
219203674|NCT06890325|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|The intervention will consist of a total of 3 sessions which will take place in different areas of the Faculty of Health and Welfare Sciences (FCSB) at the University of Vic - Central University of Catalonia. In Session 1, a comprehensive geriatric assessment (CGA) will be conducted to the users (by students supervised by health professionals).
219203675|NCT06890325|BEHAVIORAL|Health education|A report with the results of the CGA and health recommendations will be delivered to the users. They will receive health education including specific recommendations and community health resources based on their health status and CGGA.
218890711|NCT06921824|OTHER|Glucagon|A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)
218890712|NCT04148430|DRUG|Anakinra|100mg subcutaneous
219203676|NCT06891092|DEVICE|RayOne EMV|non-diffractive monofocal IOL
219203677|NCT06891092|DEVICE|Vivinex Impress|non-diffractive monofocal IOL
219613367|NCT04666948|DEVICE|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg\*h/L
219613368|NCT04666948|DRUG|Vancomycin|Vancomycin treatment
219613369|NCT01113372|DRUG|Clopidogrel|Clopidogrel 75mg daily.
219613370|NCT02507739|OTHER|no possibility to walk during labor|
219613371|NCT02507739|OTHER|possibility to walk during labor|
218890713|NCT06921174|DEVICE|"Use of the Crescendo 2 Intravaginal Device"|"Self-administered perineal massage at home with Crescendo device.~Three times per week, 10 minutes each session, over a 12-week period."
218890714|NCT06921174|PROCEDURE|Classical Perineal Massage Therapy|"Performed manually by a pelvic floor physiotherapist.~One 30-minute session per week for 12 weeks."
218890715|NCT06919133|DEVICE|The MENTINA app|A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.
218890716|NCT06919133|OTHER|Control|The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.
218890717|NCT06927115|OTHER|Maitland Mobilization|Provide maitland mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
218890718|NCT06927115|OTHER|Mulligan Mobilization|Provide mulligan mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
218890719|NCT06936176|DEVICE|Neurovascular Intravascular Shockwave Catheter|"Device:~Neurovascular Intravascular Shockwave Catheter (single-use, rapid-exchange balloon catheter with integrated shockwave emitters).~Intravascular Shockwave Therapy Device (IVL-HVG-N01, generates localized shockwaves to fracture calcifications).~Procedure:~Patients undergo standard CAS preparation with guidewire placement and cerebral protection.~If conventional balloon angioplasty fails (residual stenosis \>70%), the IVL catheter is advanced to the target lesion.~Shockwave therapy is applied at 6 atm, followed by low-pressure balloon dilation (8 atm) if needed.~Subsequent stent deployment is performed per standard practice."
218890720|NCT06937164|BEHAVIORAL|Isometric Exercise Training (IET)|Participants perform four repetitions of 90 degree bilateral isometric leg extensions on a dynamometer at 30% of their maximum voluntary contraction (MVC). Each contraction is held for 2 minutes, with 2-minute rest intervals between bouts. Sessions are performed three times per week for four weeks. This behavioral intervention is designed to investigate the acute and chronic effects of isometric exercise on blood pressure, heart rate variability, and muscle fatigue.
218890721|NCT06937164|BEHAVIORAL|Expectation-Enhancing Informational Framing|Participants receive a brief standardized presentation highlighting isometric exercise as an evidence-based intervention for lowering blood pressure. The presentation includes statements designed to enhance outcome expectations based on prior literature and expert framing.
218890722|NCT00924443|DRUG|clofarabine|
218890723|NCT06947824|BEHAVIORAL|Fasted Morning Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after a 12h overnight fast. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
219509566|NCT03697421|OTHER|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
218890724|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (6h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 6h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
218890725|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 12h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
218890726|NCT06947824|BEHAVIORAL|Fed Morning Exercise (12h AMEx-Fed)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after consuming a small pre-exercise snack (30 min before exercise). The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
218890727|NCT06750497|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
218890728|NCT06949644|COMBINATION_PRODUCT|Light and Citalopram|Participants will receive placebo or citalopram, followed by bright light exposure
218890729|NCT06951685|DEVICE|Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit|The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 33cm length and 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The XPAD conduit is in a straight configuration and may be implanted above the knee for elective femoral popliteal bypass surgery.
218890730|NCT02822261|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66\_R84-088)
218890731|NCT04676035|DRUG|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
219033795|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
219033796|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
219033797|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
219033798|NCT06200181|DRUG|Olanzapine|Given by PO
219509567|NCT03697421|OTHER|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
219509568|NCT01200472|DRUG|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
219509569|NCT01200472|DRUG|Placebo|Placebo capsules identical to apremilast
219509570|NCT00364403|BEHAVIORAL|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
219509571|NCT00364403|BEHAVIORAL|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
219613372|NCT00472563|DRUG|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
219613373|NCT00882518|DRUG|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
219613374|NCT00882518|DRUG|Chlorpromazine|50 mg, oral, double dose
219203678|NCT06890494|DRUG|BiTE-EV|Thi product organically combines extracellular vesicles with BiTEs, and enables stable expression of the bispecific antibody on the surface of mesenchymal stem cells. By collecting the culture supernatant, the bispecific vesicles BiTE-EV, which express both CD3 and CD19 antibodies on their surface, are enriched and isolated.
219203679|NCT06891014|OTHER|Combine Exercise|The participants in the exercise group will be individuals over the age of 65 who applied the same exercise programs 2-3 days a week for 8 weeks under the control of two different physiotherapists independent of the study. The exercise session will be applied for one hour, including a warm-up phase, a combined exercise program including strengthening, stretching, balance and proprioceptive exercises, and a cool-down phase.
219203680|NCT06891118|PROCEDURE|Stellate gangion blockade %1 5 mL|"SGB is performed under sterile conditions in the operating room, with the patient's intravenous line established, monitored during the procedure, and ultrasound guidance used simultaneously. The patient is positioned supine, with the neck slightly hyperextended and the head slightly turned to the opposite side. After the skin is cleaned with an antiseptic solution and the probe is sterilized, a linear ultrasound probe is placed transversely at the level of the sixth cervical vertebra (C6).~The relevant anatomical landmarks, including the internal carotid artery, internal jugular vein, thyroid tissue, longus colli muscle, prevertebral fascia, C6 transverse process (Chassaignac's tubercle), C6 nerve root, and vertebral artery, are visualized. Avoiding vascular structures and thyroid tissue, a 25-gauge 38 mm sterile needle is advanced with a lateral approach using the in-plane technique, ensuring the needle tip is just below the surface of the longus colli m"
219203681|NCT06733207|OTHER|Pupil examination|Pupil assessment : bilateral clinical examination of the patient's pupils, assessed in qualitative data : mydriasis, myosis, pupillary light reflex, anisocoria or isochoria.
219203682|NCT06737042|DRUG|GZR18|GLP-1
218890732|NCT01678612|OTHER|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
218890733|NCT00364091|DRUG|R89674 0.025% ophthalmic solution|
218890734|NCT03944291|PROCEDURE|Pudendal Nerve Block|Pudendal Nerve Block
218890735|NCT02711007|DRUG|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
218890736|NCT01210586|BEHAVIORAL|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
218890737|NCT01521663|DRUG|IPX159|
219033799|NCT06200181|DRUG|Olanzapine|Given by PO
219033800|NCT06200181|DRUG|Placebo|Given by PO
219203683|NCT06737042|DRUG|Tirzepatide|Active Comparator
219203684|NCT06741124|PROCEDURE|Channel Esophagogastrostomy|Channel Esophagogastrostomy
219203685|NCT06741124|PROCEDURE|Double Tract Reconstruction|Double Tract Reconstruction
218890738|NCT01521663|DRUG|Placebo|
218890739|NCT00874848|BIOLOGICAL|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
218890740|NCT00874848|BIOLOGICAL|Cetuximab|initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
218890741|NCT00874848|DRUG|Paclitaxel|200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
218890742|NCT00874848|DRUG|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
218890743|NCT01622387|PROCEDURE|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
218890744|NCT01622387|PROCEDURE|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
218890745|NCT01907763|DRUG|SOTB07 200mg|
219033801|NCT06529991|DEVICE|Occipivot suboccipital pillow self-myofascial release|"Subjects will be instructed in the use of the Occipivot suboccipital pillow and how it should feel. They will be supervised as it is placed. Once verbal verification is obtained regarding the feel and placement of the wedge, the treatment time will begin and continue for 5 minutes."
219033802|NCT06957860|OTHER|Piezotome|Four Intra-lift diamond tips were used for drilling the osteotomy, increasing diameters till a final diameter of 2.8 mm is reached for placement of 3.5 mm diameter and 10-12 mm length implant.
219033803|NCT06957860|OTHER|Densah burs|implant drilling procedures will be done using the surgical drills of the supplier kit of densah burs. Surgical drills of increasing diameters will be used till a final drill diameter of 3 mm for placement of a 3.5 mm diameter.
219033804|NCT06957834|DRUG|Eflornithine hydrochloride cream|Eflornithine hydrochloride cream at 11.5% applied twice daily
219033805|NCT06957834|DRUG|Hydroquinone cream|Hydroquinone 2% cream, applied twice daily
219033806|NCT04770896|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
219033807|NCT04770896|DRUG|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
219509572|NCT02729688|DEVICE|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
219509573|NCT02729688|DEVICE|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
219509574|NCT03083054|BIOLOGICAL|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
218890746|NCT01907763|DRUG|SOTB07 400mg|
218890747|NCT01907763|DRUG|SOTB 200mg placebo|Placebo of SOTB07 200mg
218890748|NCT01907763|DRUG|SOTB 400mg placebo|Placebo of SOTB07 400mg
218890749|NCT03559933|DEVICE|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
218890750|NCT01581060|DRUG|WX-554|Capsules of WX-554
218890751|NCT01037738|PROCEDURE|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
218890752|NCT00716846|DRUG|simvastatin|10mg, 2 weeks
219033808|NCT04770896|DRUG|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
219033809|NCT04542707|PROCEDURE|joint manipulation|Thrust manipulation to the spine, hand, and foot
219033810|NCT04542707|PROCEDURE|Exercise|Strength training, bike aerobic training, and yoga exercise
219033811|NCT04542707|DEVICE|Soft tissue massage|Graston tool
218890753|NCT00716846|DRUG|atorvastatin|10mg
218890754|NCT00716846|DRUG|pitavastatin|2mg
218890755|NCT05345301|DIAGNOSTIC_TEST|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
218890756|NCT02324816|DEVICE|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
218890757|NCT05169424|DEVICE|Trelegy Ellipta|Trelegy Ellipta
219033812|NCT04517552|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
219033813|NCT06333262|DRUG|Pirtobrutinib|"Initial treatment:~\- Pirtobrutinib 200 mg by mouth (PO) daily from Cycle 1 Day 1 until the end of Cycle 12. Each cycle is 28 days.~Re-treatment:~-Pirtobrutinib 200 mg PO daily continuously"
219033814|NCT06333262|DRUG|Obinutuzumab|"Obinutuzumab is given intravenously from Cycle 7 to Cycle 12, for total 6 cycles during initial treatment only.~Initial treatment:~\- Obinutuzumab intravenous (IV) following the standard schedule from Cycle 6 through Cycle 12 (total 6 cycles: 100 mg on Cycle 6 Day 1, 900 mg on Cycle 6 Day 2, 1000 mg on Cycle 6 Day 8 and Cycle 6 Day 15, 1000 mg on Day 1 of Cycle 7 through Cycle 12)."
219033815|NCT04409821|BEHAVIORAL|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
219033816|NCT05062629|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing
219033817|NCT06780969|BEHAVIORAL|Green Mother Training|Poster education
218890758|NCT05169424|DEVICE|Stiolto Respimat|Stiolto Respimat
218890759|NCT05169424|DRUG|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
218890760|NCT05169424|DRUG|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
218890761|NCT03748719|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
218890762|NCT03570359|DRUG|Interferon Beta-1A|Interferon Beta-1A via inhalation
218890763|NCT03570359|OTHER|Placebo|Placebo via inhalation
218890764|NCT00130611|OTHER|BNP measurement|
218890765|NCT00130611|OTHER|Clinical examination|
218890766|NCT01447186|BEHAVIORAL|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
218890767|NCT01447186|BEHAVIORAL|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
218890768|NCT01447186|BEHAVIORAL|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
219033818|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
219203686|NCT06738758|DRUG|PCSK9 inhibitor|The patient used PCSK9 inhibitor (with or without statins ± Ezetimibe/Hybutimibe) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference. PCSK9 inhibitors include Evolocumab, Alirocumab, Tafolecimab, Recaticimab, and Inclisiran, among others.
219203687|NCT06738758|DRUG|Statin+Ezetimibe/Hybutimibe compound|The patient used statins and Ezetimibe/Hybutimibe in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
219509575|NCT05499494|OTHER|Beautifil Flow Plus X F00 injectable composite|bioactive injectable composite
219203688|NCT06738758|DRUG|Statin|The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
219509576|NCT05499494|OTHER|Tetric N ceram resin composite|Nano hybrid resin composite
219203689|NCT06736717|DRUG|Onvansertib|"20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle."
219203690|NCT06736717|DRUG|NALIRIFOX|"Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle."
219509577|NCT01037166|DRUG|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
218890769|NCT03469713|DRUG|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
219203691|NCT06739889|DIAGNOSTIC_TEST|Elongation longitudinaux articular vertebral and columnar decoaption osteo-articulaire also known as ELDOA|ELDOA targtes cervical and upper thoracic spine. ELDOA exercises involves spicific postural holds that improve forward neck posture.The goal of ELDOA is to help reduce stress and increase space in the vertebral joints so that muscles can move freely. The benefits of these stretches include joint mobility, increased fluid absorption in the discs of the spine, flexibility, improved muscle tone, postural alignment, body-mind connection, and coordination. The tension and release created by these stretches helps normalize the posture.
219203692|NCT06739889|DIAGNOSTIC_TEST|upper thoracic mobilization|Upper thoracic mobilization, often known as joint mobilization, is a common technique in manual therapy. In order to preserve or restore joint mobility, this approach glides and uses distraction on the joint surfaces.
219203693|NCT06740045|BIOLOGICAL|Tezepelumab|10 patients will receive teszpire
219203694|NCT06741176|BEHAVIORAL|Experimental|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The mothers in the experimental group will be asked to write messages to their babies on the milk bags they bring in the mornings for 3 days. They will be asked to write on the paper attached to the milk bag what they want to tell their baby that the investigators will read the message to them and to return it every morning. The post-test of all surveys will be conducted at the end of the 3rd day.
219203695|NCT06741176|BEHAVIORAL|Control|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The post-tests will be conducted 3 days after the pre-test without any messages being requested from the mothers in the control group.
219509578|NCT03869749|BEHAVIORAL|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
219033819|NCT00393679|DRUG|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
219033820|NCT00393679|DRUG|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
219509579|NCT03869749|BEHAVIORAL|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
219509580|NCT04597762|DRUG|Cyclosporin|Cyclosporin eyedrops
219509581|NCT04597762|DRUG|Hydrocortisone|Hydrocortisone eyedrops
219509582|NCT02277873|BEHAVIORAL|pregnancy|Observational study in order to establish relationship between moon and births
219509583|NCT00016926|DRUG|capecitabine|
219509584|NCT01348295|OTHER|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
219509585|NCT05283239|OTHER|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
219033821|NCT00393679|DRUG|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
219509586|NCT02879721|DRUG|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
219509587|NCT02879721|DRUG|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
219509588|NCT02970643|DRUG|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
219509589|NCT02970643|DRUG|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
219608624|NCT04662814|OTHER|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
218890770|NCT02402140|OTHER|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
218890771|NCT02956317|DRUG|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
219203696|NCT06740266|BEHAVIORAL|Promoting First Relationships in Primary Care (PFR-PC)|"Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
219203697|NCT06737848|PROCEDURE|Single catheter adrenal vein sampling|The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.
219203698|NCT06737848|PROCEDURE|Double catheters adrenal vein sampling|The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.
219203699|NCT06741306|BEHAVIORAL|Group1|Current chemsex users Men who have sex with men, Aged 16-35 years (defined as last chemsex used within 3 months), Able to communicate in Thai fluently.
219203700|NCT06737237|PROCEDURE|cervical plexus block|local anesthetic (10ml of bupivacaine 5mg/ml)
219509590|NCT02292238|DRUG|Benfotiamine|"* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
219509591|NCT01251926|DRUG|EZN-2208|
219509592|NCT01251926|DRUG|Bevacizumab|
219509593|NCT03001609|DRUG|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
219509594|NCT01950988|DEVICE|Manual toothbrush reference|
219509595|NCT01950988|PROCEDURE|Measure of the dental plaque|
219509596|NCT01950988|DEVICE|Manual toothbrush Broscyl®|
219509597|NCT03149588|DRUG|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
219509598|NCT03149588|DRUG|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
218890772|NCT02956317|DRUG|Placebo|Normal Saline
218890773|NCT00942825|DRUG|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
219203701|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|local anesthetic (20ml of bupivacaine 2.5mg/ml)
219203702|NCT06737237|PROCEDURE|cervical plexus block|placebo (10ml of 0.9% sodium chloride)
219203703|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|placebo (20ml of 0.9% sodium chloride)
219203704|NCT06735287|PROCEDURE|bladder sparing set|after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered
219509599|NCT01789320|DRUG|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
219509600|NCT04935827|OTHER|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November"
219608625|NCT06188221|DRUG|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
219608626|NCT06188221|DRUG|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
219608627|NCT04588168|DRUG|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
219608628|NCT04588168|DIAGNOSTIC_TEST|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
219608629|NCT04588168|PROCEDURE|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
219608630|NCT04588168|DIAGNOSTIC_TEST|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
219509601|NCT04935827|OTHER|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
219509602|NCT01821027|DRUG|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
219509603|NCT01821027|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
219509604|NCT01080430|OTHER|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
219509605|NCT00494806|OTHER|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
219509606|NCT05841381|DRUG|Pyrotinib|pyrotinib: 400mg orally daily for 1 year
219509607|NCT05841381|DRUG|Trastuzumab|8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
219509608|NCT05841381|DRUG|Paclitaxel|80mg/m2 per week for a total of 12 weeks
219509609|NCT00667927|DRUG|Busulfan|See Detailed Description section for description of treatment plan.
219509610|NCT00667927|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
219509611|NCT00667927|DRUG|Mesna|See Detailed Description section for description of treatment plan.
219509612|NCT02948322|DEVICE|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
219509613|NCT02948322|DRUG|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
219509614|NCT02948322|PROCEDURE|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
219509615|NCT00497367|DEVICE|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
219608631|NCT04588168|DIAGNOSTIC_TEST|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
219608632|NCT00316758|DRUG|GK Activator (2)|Escalating doses bid
218890774|NCT00942825|DRUG|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
218890775|NCT01516463|DRUG|Collagenase Santyl|Applied topically (2 mm thickness once daily)
218890776|NCT01516463|BIOLOGICAL|Bacitracin|Applied topically (2 mm thickness) once daily
218890777|NCT00573014|OTHER|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
218890778|NCT03405818|DRUG|Tavaborole 5% Topical Solution|topical solution for application to toenails
219509616|NCT04347590|DEVICE|Unblinded - CGM (Medtronic Guardian)|Data from device will be readable and alarms on
219509617|NCT04347590|DEVICE|Blinded - CGM (Medtronic Guardian)|Data from device will be blinded and alarms off
219509618|NCT04890600|BEHAVIORAL|well-being assessment|exploration of emotional, cognitive and behavioural resources of healthcare professionals
219509619|NCT04318652|DRUG|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
219509620|NCT04579874|DIAGNOSTIC_TEST|LIVERFASt|blood draw
219509621|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
219608633|NCT00316758|DRUG|Metformin|As prescribed, in patients who were in study BM18249
219608634|NCT06492122|DRUG|[225Ac]Ac-FL-020|\[225Ac\]Ac-FL-020 injected intravenously
219608635|NCT06492122|DRUG|Blood samples for PK|Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
219608636|NCT06492122|DRUG|[111In]In-FL-020|A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
219608637|NCT06492122|PROCEDURE|Blood and urine samples collection|For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
219608638|NCT06492122|PROCEDURE|SPECT/CT images|For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
219608639|NCT04423952|OTHER|COMQ-12 questionnaire|Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.
219608640|NCT03714919|DRUG|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
219608641|NCT03714919|DRUG|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
219608642|NCT03714919|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
218890779|NCT02237755|DRUG|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
219203705|NCT06735287|PROCEDURE|RC|Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
219509622|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
219509623|NCT02235233|DRUG|Technetium Tc 99M Mebrofenin|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
219509624|NCT00491504|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
219509625|NCT00491504|OTHER|Placebo|Placebo: 2 sprays in each nostril
219509626|NCT00425737|BIOLOGICAL|Rotarix|
219509627|NCT04228341|OTHER|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
219509628|NCT04228341|OTHER|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
219509629|NCT04228341|OTHER|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
219509630|NCT04228341|OTHER|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
219509631|NCT04228341|OTHER|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
219509632|NCT04228341|OTHER|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
219509633|NCT04228341|OTHER|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
219509634|NCT04228341|OTHER|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
219509635|NCT04603963|DEVICE|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
219509636|NCT02529059|DRUG|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
219509637|NCT02044978|DEVICE|Zoledronate-coated dental implant|
219509638|NCT01129999|BEHAVIORAL|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
218890780|NCT02237755|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
219509639|NCT01129999|BEHAVIORAL|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
219509640|NCT03184454|DEVICE|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
219509641|NCT01103505|DIAGNOSTIC_TEST|ForeseeHome AMD Monitoring Device|Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
219509642|NCT05815381|OTHER|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
219509643|NCT01912105|DEVICE|Airway medix closed suction system|
219509644|NCT01912105|DEVICE|standard closed suctioning systems|
219509645|NCT00097019|DRUG|bevacizumab|
219509646|NCT02789111|DRUG|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
219509647|NCT02789111|DRUG|Placebo|Placebo twice daily up to 15 doses
219509648|NCT02262949|DEVICE|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
219509649|NCT06527989|DRUG|Ceftriaxone 2000 mg|antibiotic prophylaxis
219509650|NCT05678920|OTHER|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
219509651|NCT01166971|DEVICE|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
219509652|NCT01166971|DEVICE|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
219509653|NCT03417622|PROCEDURE|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
219608643|NCT03714919|DRUG|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
218890781|NCT02913950|OTHER|validation of pediatric stool scale|validation of pediatric stool scale
218890782|NCT03197376|BIOLOGICAL|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
218890783|NCT03197376|BIOLOGICAL|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
219203706|NCT06739681|OTHER|Routine Intervention|These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.
219509654|NCT03417622|DRUG|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
219509655|NCT03417622|PROCEDURE|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
219509656|NCT03417622|PROCEDURE|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
219608644|NCT06529471|OTHER|Massage group|The patient in the massage group will be visited by the practitioner 3 times at 10:00-14:00-20:00 on the first day after surgery and a back massage will be applied. The patient in the massage group will be placed in an orthopnea position during the application. The massage procedure lasts an average of 30 minutes and is applied to the cervical 3 and thoracic 12 vertebrae.
219608645|NCT03282916|DRUG|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
219608646|NCT03282916|DRUG|Placebo|Placebo sugar pill 500mg caplet
219608647|NCT06653153|DRUG|Remternetug|Administered SC
219608648|NCT06653153|DRUG|Placebo|Administered SC
218890784|NCT02864160|BEHAVIORAL|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
219608649|NCT06350578|PROCEDURE|Hall Crown Technique|The Hall technique (HT) involves cementing Stainless Steel Crowns SSC on carious primary teeth without using rotary instruments nor local anaesthesia, thus eliminating discomfort, and increasing child's behavior.
219608650|NCT06350578|PROCEDURE|Conventional SSC Technique|The conventional technique involves complete removal of the carious lesion using rotary instruments and local anesthesia, then restoring the tooth with Stainless Steel Crown SSC.
219608651|NCT06854224|DRUG|Suvorexant (dual orexin receptor antagonist)|Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.
219608652|NCT06813924|DRUG|Etavopivat|Participants will receive a daily dose of etavopivat orally.
219608653|NCT06813924|DRUG|Digoxin|Participants will receive a single dose of digoxin orally.
219608654|NCT06813924|DRUG|Pitavastatin|Participants will receive a single dose of pitavastatin orally.
219608655|NCT06813924|DRUG|Metformin|Participants will receive a single dose of metformin orally.
219608656|NCT06813924|DRUG|Midazolam|Participants will receive a single dose of midazolam orally.
219608657|NCT06813924|DRUG|Rosuvastatin|Participants will receive a single dose of rosuvastatin orally.
219608658|NCT06982859|DRUG|Retatrutide|Administered SC
219608659|NCT06982859|DRUG|Semaglutide|Administered SC
219608660|NCT06982859|DRUG|Placebo|Administered SC
219608661|NCT06814132|DRUG|MK-5684|Oral tablet
219608662|NCT06814132|DRUG|Prednisone|Oral tablet
219608663|NCT06814132|DRUG|Fludrocortisone acetate|Oral tablet
219608664|NCT06126315|DRUG|Acetyl-l-carnitine|Acetyl-l-carnitine
219608665|NCT06126315|DRUG|Placebo|placebo
219608667|NCT06655883|DRUG|Suvorexant|Oral Tablet
219608668|NCT06655883|DRUG|Placebo|Oral Tablet
219608669|NCT06649851|DRUG|Granulocyte Colony Stimulating Factor (G-CSF)|Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.
219608670|NCT06649851|RADIATION|Radiation Therapy + Temozolomide|Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.
219608671|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
219608672|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
219608673|NCT06481293|DEVICE|Diode laser therapy|Dual wavelength laser diode therapy device
219608674|NCT06481293|COMBINATION_PRODUCT|Alveogyl dressing|Alveogyl is a haemostatic-analgesic alveolar dressing
219608675|NCT03452774|OTHER|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
219608676|NCT05443295|OTHER|MoveUS Program|The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.
218890785|NCT02864160|BEHAVIORAL|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
218890786|NCT00718705|DRUG|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
218890787|NCT00718705|DRUG|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
218890788|NCT01239823|OTHER|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
218890789|NCT01239823|OTHER|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
219509657|NCT01861327|DRUG|CO2|carbon dioxide (CO2) as arterial contrast media
218890790|NCT02303028|DRUG|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
219509658|NCT01861327|DRUG|Iodine contrast media|Iodine as arterial contrast media
219509659|NCT05448716|DIAGNOSTIC_TEST|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
219509660|NCT05448716|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
219509661|NCT03954561|PROCEDURE|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
219509662|NCT03954561|PROCEDURE|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
219509663|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
219509664|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
219509665|NCT01562795|DRUG|corticosteroids|corticosteroids plus artificial tear substitute
219509666|NCT01562795|DRUG|artificial tear substitute|artificial tear substitute alone
219509667|NCT04215055|DEVICE|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
219509668|NCT00374413|DEVICE|Artificial disk|Implant
219509669|NCT00374413|DEVICE|Artificial disc|Implant
219509670|NCT00935987|DRUG|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
219509671|NCT05442333|PROCEDURE|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures."
219509672|NCT03974633|COMBINATION_PRODUCT|Injection|All information is included in the Arm/group descriptions
219509673|NCT01179633|DEVICE|OPLON active patch|
219509674|NCT01179633|DEVICE|Sham patch|
219509675|NCT00627718|DEVICE|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
218890791|NCT04836845|DEVICE|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
219509676|NCT01869322|DEVICE|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
218890792|NCT04836845|DEVICE|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
218890793|NCT04836845|DEVICE|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
218890794|NCT02606799|DEVICE|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
218890795|NCT05305963|RADIATION|Mammogram|mammogram
218890796|NCT03218176|DEVICE|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
218890797|NCT03218176|DEVICE|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
218890798|NCT03218176|DEVICE|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
218890799|NCT03218176|DEVICE|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
218890800|NCT03218176|DEVICE|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
218890801|NCT03218176|DEVICE|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
219509677|NCT01869322|DEVICE|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
219509678|NCT01483872|DRUG|NAC/Tigecycline/Heparin combination lock solution|
219509679|NCT01483872|DRUG|Standard anticoagulant (Heparin or Citrate)|
219509680|NCT05254366|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
219509681|NCT02353065|PROCEDURE|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
219509682|NCT02353065|RADIATION|Bedside x-ray|Portable x-ray of fracture post-reduction
218890802|NCT03218176|DEVICE|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
219509683|NCT00457522|BEHAVIORAL|Nurse/community health worker telephone intervention|
219509684|NCT04203407|BEHAVIORAL|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
218890803|NCT03218176|DEVICE|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
219509685|NCT04203407|BEHAVIORAL|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
219509686|NCT04046042|OTHER|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
219509687|NCT04046042|OTHER|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
219608677|NCT05443295|OTHER|Control intervention|The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
219608678|NCT06586515|DRUG|LY3962673|Administered orally.
219608679|NCT06586515|DRUG|Cetuximab|Administered intravenously.
219608680|NCT06586515|DRUG|Gemcitabine|Administered intravenously.
219608681|NCT06586515|DRUG|nab-paclitaxel|Administered intravenously.
219608682|NCT06586515|DRUG|Oxaliplatin|Administered intravenously.
219608683|NCT06586515|DRUG|leucovorin|Administered intravenously.
219608684|NCT06586515|DRUG|Irinotecan|Administered intravenously.
219608685|NCT06586515|DRUG|5-fluorouracil|Administered intravenously.
219608686|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
219509688|NCT00680875|BEHAVIORAL|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
219509689|NCT04043013|DEVICE|Mini-Taurus® (Rocky Mountain©) Brackets|
219509690|NCT04043013|DEVICE|Smart Clip® SL3 High Torque (3M Unitek©)|
219509691|NCT04043013|DEVICE|Tip-Edge Plus® (TP Orthodontics©)|
219608687|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
219608688|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
219608689|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
218890804|NCT00003199|DRUG|tamoxifen citrate|Given orally
218890805|NCT00003199|DRUG|busulfan|Given orally
219608690|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
219608691|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
219203707|NCT06739681|OTHER|Mental Imagery Intervention|Mental Imagination will be done with Recording Audio. An audio recording will last 5 minutes. The audio recording will be listened to 3 times in one session. The total visualization session will last 15 minutes in a dark and quiet room.
219509692|NCT04043013|DEVICE|Victory® (3M Unitek©)|
219509693|NCT03387033|DEVICE|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
219509694|NCT00601484|DRUG|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
219608692|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
219608693|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
219608694|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
219608695|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
219608696|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
219608697|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
218890806|NCT00003199|DRUG|thiotepa|Given IV
218890807|NCT00003199|DRUG|melphalan|Given IV
218890808|NCT00003199|BIOLOGICAL|aldesleukin|Given SC
218890809|NCT00003199|BIOLOGICAL|sargramostim|Given SC
218890810|NCT00003199|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
218890811|NCT00003199|RADIATION|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
218890812|NCT03888729|DRUG|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
218890813|NCT03888729|DRUG|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
219509695|NCT00601484|DRUG|Placebo|placebo IV, single dose
219608698|NCT05203328|DEVICE|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
219608699|NCT05203328|DEVICE|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
219608700|NCT04768686|DRUG|FLX475|tablet
219608701|NCT04768686|DRUG|Pembrolizumab|IV infusion
219608702|NCT06860243|DRUG|Opevesostat|Oral film-coated tablet
219608703|NCT06860243|DRUG|Prednisone|Oral tablet
219509696|NCT01197313|OTHER|Home-based exercise|
218890814|NCT00089466|DRUG|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
219509697|NCT03966170|DRUG|Citicoline|Citicoline as neuroprotector
219509698|NCT03966170|DRUG|Placebo oral tablet|placebo drug
218890815|NCT00586885|DRUG|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
218890816|NCT02229409|BEHAVIORAL|Walkadoo|Walkadoo is a MeYou Health, LLC product.
218890817|NCT02137096|DRUG|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
218890818|NCT02137096|DRUG|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
218890819|NCT02137096|DRUG|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
219033822|NCT00393679|DRUG|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
219608704|NCT06860243|DRUG|Fludrocortisone acetate|Oral tablet
219608705|NCT06683092|OTHER|RETRIAL-MH|Participants will complete: daily diaries for 6 weeks, from about 2 weeks prior to starting VTD to about 4 weeks after; biweekly surveys, from about 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo post-initiation of VTD).
219608706|NCT06683092|OTHER|RETRIAL-Liver|Participants may have a research liver function test done prior to starting VTD and 28 days after, if not done clinically.
219608707|NCT06683092|OTHER|RETRIAL-Neuro|participants will complete a neurocognitive assessment prior to starting VTD and 28 days after.
219608708|NCT04416282|DRUG|Terlipressin|Injection terlipressin 2 mg/24 hours infusion
219608709|NCT04416282|BIOLOGICAL|Albumin|i/v albumin 1g/Kg/day
219608710|NCT07021547|DRUG|LY3867070|Administered orally
219608711|NCT07021547|DRUG|Placebo|Administered orally
219608712|NCT03555292|DRUG|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
219608713|NCT04164290|DRUG|Jiashen Tablets|1 tablet
219608714|NCT04164290|DRUG|Jiashen Tablets|2 tablets
219608715|NCT04164290|DRUG|Jiashen Tablets|4 tablets
218890820|NCT02137096|PROCEDURE|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
218890821|NCT01223183|DRUG|hypertonic saline (7%)|single treatment by inhalation
219203708|NCT06739681|OTHER|Breathing Exercise Intervention|Participants participating in Pranayama training will practice in a comfortable position in a quiet room at a temperature of 25 ± 2°C. The slow pranayama technique chosen is alternate nasal breathing (Nadishodhana Pranayama).
219203709|NCT06720727|RADIATION|craniospinal irradiation|Delivering radiotherapy to brain, spinal cord and its covering membrane.
219203710|NCT06742242|PROCEDURE|lymphaticovenous anastomosis|supermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation
219509699|NCT00548288|DRUG|pamidronate|
219509700|NCT03294278|OTHER|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
219608716|NCT04164290|DRUG|Jiashen Tablets|6 tablets
219608717|NCT04164290|DRUG|Jiashen Tablets|8 tablets
219608718|NCT04164290|DRUG|Jiashen Tablets|9 tablets
219608719|NCT04164290|DRUG|Jiashen Tablets Placebo|1 tablet
219608720|NCT04164290|DRUG|Jiashen Tablets Placebo|2 tablets
219608721|NCT04164290|DRUG|Jiashen Tablets Placebo|4 tablets
219608722|NCT04164290|DRUG|Jiashen Tablets Placebo|6 tablets
218890822|NCT01223183|DRUG|isotonic saline|single treatment by inhalation
218890823|NCT06069635|OTHER|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
219608723|NCT04164290|DRUG|Jiashen Tablets Placebo|8 tablets
219608724|NCT04164290|DRUG|Jiashen Tablets Placebo|9 tablets
219608725|NCT06694389|BIOLOGICAL|mRNA-1083|Suspension for injection
219608726|NCT06694389|OTHER|Placebo|0.9% sodium chloride suspension for injection
219608727|NCT06694389|BIOLOGICAL|Licensed Influenza Vaccine|Aqueous injectable (SC) or suspension for injection (IM)
219608728|NCT06694389|BIOLOGICAL|SARS-CoV-2 Vaccine|Suspension for injection
219608729|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
219608730|NCT07032909|BEHAVIORAL|comfortable reading mode|Subjects are asked to read a terminal display device for 45 minutes, featuring texts with different reading mode treatments. Specifically, they will read the same text content for 45 minutes with different background and text color. The participants will complete a total of 4 sets of tests in a random order.
219608731|NCT07123480|BEHAVIORAL|Usual Care Group|Standard of care to encourage cardiac rehabilitation attendance.
219509701|NCT02864680|OTHER|Electroretinography|
219509702|NCT02864680|OTHER|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
219509703|NCT02864680|OTHER|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
219509704|NCT02864680|OTHER|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
219509705|NCT02864680|OTHER|CAST (cannabis abuse screening test)|
219509706|NCT02864680|OTHER|PANSS (Positive And Negative Symptoms Scale) test|
219509707|NCT02864680|OTHER|Delayed Matching to Sample (DMS) test|
219509708|NCT02864680|OTHER|Spatial Working Memory (SWM) test|
219509709|NCT02864680|OTHER|Rapid Visual Information Processing (RVP) test|
219509710|NCT02864680|OTHER|Test for attentional performance (TAP) / Divided Attention|
219509711|NCT02864680|OTHER|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
219509712|NCT06356376|DEVICE|Heat Stimulation|Heat stimulation at a painful, but to the subject tolerable level.
219509713|NCT00376779|BIOLOGICAL|Infanrix hexa Vaccine|
219509714|NCT00352079|BIOLOGICAL|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
219509715|NCT00352079|DRUG|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
219509716|NCT00352079|PROCEDURE|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
219509717|NCT04954456|DRUG|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
219509718|NCT03179475|DRUG|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
219509719|NCT06102629|PROCEDURE|laparoscopy / laparotomy|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
219509720|NCT06102629|OTHER|NO INTERVENTION|".We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3\. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
219509721|NCT02460848|OTHER|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
219509722|NCT02460848|OTHER|Outpatient therapeutic program and counseling|
219509723|NCT06091800|OTHER|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
219509724|NCT05469282|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701 (Ceragem Master V6)
219509725|NCT04901000|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
219509726|NCT04057053|DRUG|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
219033823|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
219509727|NCT03123822|DEVICE|Glasses|Glasses traditionally prescribed for refractive error
219509728|NCT02214927|DRUG|BI 11634 tablet|
219509729|NCT02214927|DRUG|BI 11634 drinking solution|
219509730|NCT00545337|DRUG|Insuline glulisine|
219509731|NCT00060957|DRUG|Botulinum toxin type A|
219509732|NCT06301633|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219509733|NCT06301633|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219509734|NCT06301633|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219509735|NCT01589003|OTHER|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
219509736|NCT01589003|OTHER|High GI growing up milk|High glycaemic index growing up milk
219509737|NCT03847883|DRUG|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
219509738|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II SC|
219509739|NCT01463683|BIOLOGICAL|1XP HEPTAVAX™-II SC|
219509740|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II IM|
219509741|NCT01816152|OTHER|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
219509742|NCT01816152|OTHER|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
219509743|NCT01423838|DRUG|Solifenacin|5 mg, oral, once in a day
219509744|NCT01423838|DRUG|Oxybutynin|5 mg, oral, three times in a day
219509745|NCT00008099|BIOLOGICAL|MUC1 antigen/SB AS-2|
219509746|NCT03383393|DRUG|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
219509747|NCT00918671|OTHER|No new specific intervention|No new specific intervention
219509748|NCT01873638|PROCEDURE|Cholecystectomy|
219509749|NCT05286099|OTHER|Imaging examination and/or blood test|Imaging examination and/or blood test will be performed at a certain time
219509750|NCT00775697|DRUG|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
219509751|NCT00775697|DRUG|Montelukast|montelukast 4 mg day for 4 weeks
219509752|NCT02346539|DRUG|Nicotine polacrilex|Single Acute dose
219608732|NCT07123480|BEHAVIORAL|More Support and Tools|More Support and Tools includes the following: monetary incentive, text messages, case management, and physical activity coaching. The investigators will start providing support and tools while patients are still in the hospital and continue this support weekly after discharge. Intervention participants will receive a monetary incentive both in the hospital and upon attending cardiac rehabilitation. The support (case management) and tools (physical activity coaching and text messages) will continue for up to 3 months or until the individual attends cardiac rehabilitation, whichever occurs first. Participants can decline any or all support or tools.
219509753|NCT06537518|DRUG|Dexamethasone injection|Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
218890824|NCT06069635|OTHER|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
219509754|NCT06537518|DRUG|Bupivacaine 0.375% Injectable Solution|Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
219509755|NCT06537518|DRUG|Bupivacaine 0.5% Injectable Solution|20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
219509756|NCT03058536|DEVICE|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
219509757|NCT03058536|DRUG|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
219509758|NCT03058536|OTHER|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
219509759|NCT01841606|DRUG|Ondansetron|4mg of IV ondansetron
219509760|NCT01841606|OTHER|Normal saline|10mL of IV normal saline
219033824|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
219509761|NCT02099266|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
219509762|NCT03152461|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219509763|NCT02371967|DRUG|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
219509764|NCT01260480|OTHER|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
219509765|NCT04133480|DRUG|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
219509766|NCT00785122|DRUG|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
219509767|NCT00785122|DRUG|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
219509768|NCT00508586|DRUG|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
219509769|NCT04345471|DRUG|Desvenlafaxine 100 mg|once daily dosing for 8 weeks
219509770|NCT04345471|DRUG|Desvenlafaxine 50 mg|once daily dosing for 8 weeks
219509771|NCT04345471|DRUG|Placebo|once daily dosing for 8 weeks
219509772|NCT02373475|OTHER|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
219509773|NCT02373475|OTHER|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
219509774|NCT05484271|PROCEDURE|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
219509775|NCT01672372|DIETARY_SUPPLEMENT|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
219509776|NCT01672372|DIETARY_SUPPLEMENT|Placebo Max Stress B|
219509777|NCT02525029|DRUG|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
219509778|NCT00200005|DEVICE|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
219509779|NCT05571085|OTHER|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
219509780|NCT05571085|OTHER|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
219509781|NCT03896490|BEHAVIORAL|Attention Control Training|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
219613375|NCT05596110|BEHAVIORAL|TENS and KT|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
219033825|NCT03135041|DIETARY_SUPPLEMENT|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
219033826|NCT03135041|DIETARY_SUPPLEMENT|Placebo|Effects of placebo supplement on weight loss during energy restriction
219033827|NCT02342340|OTHER|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
219509782|NCT03896490|BEHAVIORAL|Control|The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
219509783|NCT02394132|DRUG|Imiquimod|
219509784|NCT02394132|RADIATION|Radiotherapy|
219509785|NCT05232578|RADIATION|Early salvage radiotherapy (eSRT)|"eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
219509786|NCT05232578|RADIATION|Delayed Salvage radiotherapy (dSRT)|"dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
219033828|NCT02342340|OTHER|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
219509787|NCT02260765|DEVICE|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
219509788|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
219509789|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
219509790|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
219509791|NCT02688127|DRUG|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
219509792|NCT01352559|DRUG|responders|Antidepressants administration for 6 weeks under therapeutic dose
219509793|NCT01352559|DRUG|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
219509794|NCT06052371|DEVICE|VerioVue (Enhancements) blood glucose monitoring system|VerioVue meter with expanded haematocrit range
219509795|NCT03773328|BIOLOGICAL|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
219509796|NCT02277314|PROCEDURE|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
219509797|NCT03743428|DRUG|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
219509798|NCT03743428|DRUG|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
219509799|NCT06542042|DIAGNOSTIC_TEST|NAS, NGS and Laboratory tests|Using three diffrent detection methods and comparing their efficiency
219509800|NCT00122850|DRUG|Duloxetine|
219509801|NCT00122850|DRUG|venlafaxine|
219509802|NCT00122850|DRUG|placebo|
219509803|NCT00003782|DRUG|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
219509804|NCT00003782|DRUG|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
219509805|NCT00003782|DRUG|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
219033829|NCT02342340|OTHER|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
219033830|NCT02342340|OTHER|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
219033831|NCT02342340|OTHER|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
219033832|NCT02342340|OTHER|White Rice|One time consumption of 3/4 cup of cooked white rice.
219033833|NCT01166685|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
219033834|NCT01166685|DEVICE|Bare-metal stent|Bare metal stent
219033835|NCT01166685|DEVICE|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
219033836|NCT02220270|DEVICE|ASD and PDA closure|
219033837|NCT03509675|DRUG|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
219033838|NCT03509675|DRUG|Placebos|Placebo
219509806|NCT01204320|PROCEDURE|Paclitaxel-coated Balloon|POBA
219509807|NCT01204320|DEVICE|Paclitaxel-eluting Stent|Stenting
219509808|NCT00152321|BEHAVIORAL|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
219509809|NCT00152321|BEHAVIORAL|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
219509810|NCT00152321|OTHER|Usual Care|
219509811|NCT01890707|PROCEDURE|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
219509812|NCT01890707|PROCEDURE|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
219509813|NCT03017599|DEVICE|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
219509814|NCT03362151|OTHER|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
219509815|NCT03362151|OTHER|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
219509816|NCT03362151|OTHER|White rice|White rice (Approximately 43 grams carbohydrate per meal)
219509817|NCT00000614|DRUG|warfarin|
219509818|NCT01082107|OTHER|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (\> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
219509819|NCT00717977|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
218890825|NCT02536027|PROCEDURE|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
218890826|NCT04050059|DRUG|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
218890827|NCT04050059|DRUG|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
218890828|NCT00004652|DRUG|pimozide|
218890829|NCT02277600|DRUG|BMS-663068|BMS-663068
218890830|NCT02277600|DRUG|Darunavir|Darunavir
219033839|NCT01991119|DRUG|Propafenone|
219033840|NCT01991119|DRUG|Dronedarone|
219033841|NCT02515409|DEVICE|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
219033842|NCT02515409|DEVICE|CPAP|CPAP, as a first line treatment in OSAS.
219033843|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
219033844|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
219509820|NCT06002295|DRUG|Chlorhexidine Topical Cream|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
219509821|NCT06002295|DRUG|Methylated Spirit|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
219608733|NCT05518084|OTHER|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
219608734|NCT07035093|DRUG|Retatrutide|Administered SC
219608735|NCT07035093|DRUG|Placebo|Administered SC
219608736|NCT00766740|DEVICE|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
219608737|NCT00766740|DEVICE|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
219033845|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
219033846|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
219033847|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
219033848|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
218890831|NCT02277600|DRUG|Cobicistat|Cobicistat
218890832|NCT06422195|OTHER|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
218890833|NCT06422195|OTHER|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
218890834|NCT02999906|DRUG|Oral Treprostinil|Sustained release oral tablets for three times daily administration
218890835|NCT02999906|DRUG|Placebo|Placebo (sugar pill) for three times daily oral administration
218890836|NCT06340945|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
219033849|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
219033850|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
219033851|NCT03791866|OTHER|Nutrition|Enteral nutrition
219033852|NCT03095066|DRUG|Placebo|Administered as capsules
218890837|NCT05047861|PROCEDURE|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
219509822|NCT05378087|RADIATION|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
219509823|NCT05378087|PROCEDURE|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
219509824|NCT01056549|DRUG|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
219509825|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
219509826|NCT00386672|BEHAVIORAL|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
219509827|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
219509828|NCT03015090|DRUG|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
219509829|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
219509830|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
219509831|NCT03516747|DIAGNOSTIC_TEST|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
219509832|NCT03516747|DIAGNOSTIC_TEST|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
219509833|NCT03052166|DEVICE|QT Ultrasound scan|QT Ultrasound scan
219509834|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
218890838|NCT05047861|PROCEDURE|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
219033853|NCT03095066|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
219033854|NCT03095066|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
219033855|NCT06072547|OTHER|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
219509835|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
219509836|NCT06217133|DEVICE|CPAP|"Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage."
219608738|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
219608739|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
219608740|NCT06881992|DRUG|Placebo|Placebo (9mg/kg) + SOC
219608741|NCT06712082|DRUG|PF-07264660|PF-07264660 solution for injection (single use only)
219608742|NCT06712082|OTHER|Placebo|Placebo solution for injection (single use only)
218890839|NCT06408571|OTHER|etiology|As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
219203711|NCT06750614|DEVICE|intermittent theta-burst stimulation (iTBS)|In each visit, the intensity of the iTBS applied to the participant will be set at 70% of their individual resting motor threshold (rMT), with one session specifically targeting the left DLPFC.
219509837|NCT04541888|DRUG|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
219509838|NCT04541888|DRUG|Placebo|Placebo
219509839|NCT04541888|DRUG|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
219509840|NCT04932356|OTHER|Therapeutic education by phone|The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.
219509841|NCT04932356|OTHER|Therapeutical education traditional|The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
219509842|NCT01677559|DRUG|MLN8237|
219509843|NCT01677559|DRUG|nab-Paclitaxel|
219509844|NCT00514995|DRUG|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
219509845|NCT03004690|DEVICE|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
218890840|NCT02618265|PROCEDURE|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
218890841|NCT02618265|PROCEDURE|traditional management|aspirin or clopidogrel monotherapy or double treatment for
218890842|NCT02618265|PROCEDURE|website platform management|second prevention based on website platform management
218890843|NCT05927766|DEVICE|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
218890844|NCT06184607|OTHER|Distance from contact point to attachment level|A periodontal probe will be used to measure distance between contact point to attachment level in maxillary central incisors
218890845|NCT02300363|DRUG|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
218890846|NCT02300363|DRUG|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
218890847|NCT02300363|DRUG|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
218890848|NCT05519514|DRUG|Cortiment|Budesonide 9 mg prolonged release tablets
218890849|NCT05519514|DRUG|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
218890850|NCT01771978|DRUG|Placebo|Received 250 ml of a 5% dextrose solution as placebo
219203712|NCT06784518|OTHER|Clinical scores and functional MRI|Motor evoked potentials between Day 3-Day 7 of the stroke, for a equal distribution of patients into three prognostic groups according to the PREP2 algorithm (good, limited and poor). Longitudinal follow-up with clinical scores and functional MRI at Day 7-Day 10, Day 30, Month 3 and Month 6 of stroke.
219203713|NCT06767475|OTHER|Best Practice|Receive usual care
219509846|NCT03004690|DEVICE|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
219509847|NCT06093256|DEVICE|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
219509848|NCT03705351|DEVICE|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
219509849|NCT03705351|DRUG|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
219509850|NCT03705351|RADIATION|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
219509851|NCT00446498|DEVICE|CPAP and Non Invasive Ventilation|
219608743|NCT06887192|DRUG|ML-007C-MA|ML-007C-MA dosed as 105/1.5 mg (one tablet of 105/1.5 mg ML-007C-MA), or 210/3 mg (two tablets of 105/1.5 mg ML-007C-MA )
219608744|NCT06887192|DRUG|Placebo|Placebo Tablets
218890851|NCT01771978|DRUG|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
218890852|NCT01771978|DRUG|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
218890853|NCT01771978|DRUG|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~* bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~* 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
218890854|NCT00502671|DRUG|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
218890855|NCT06271044|OTHER|With radioiodine treatment|Postoperative radioiodine not given
219203714|NCT06767475|OTHER|Discussion|Attend a focus group
219203715|NCT06767475|OTHER|Health Promotion|Participate in group discussion with exercises and activities
219203716|NCT06767475|OTHER|Interview|Attend a one-on-one interview
219608745|NCT06551207|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
219608746|NCT06551207|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
219509852|NCT02780661|DEVICE|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
219509853|NCT02780661|DEVICE|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
219509854|NCT02780661|OTHER|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
219509855|NCT03321747|RADIATION|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
219509856|NCT05994456|DRUG|PD-1 inhibitor|240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
219509857|NCT00494975|DEVICE|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
219509858|NCT01806688|OTHER|gluten-free high protein snack #1|buckwheat groats 30g serving
219509859|NCT01806688|OTHER|gluten-free snack with similar energy density but 1/2 the protein as snack #1|32g serving of corn nuts
219509860|NCT01806688|OTHER|non-caloric control|water
219509861|NCT01806688|OTHER|gluten-free high protein and high fibre snack #2|buckwheat and pinto bean flour pita bread 50g serving
219509862|NCT01806688|OTHER|gluten-free snack with similar energy density, but less protein and fibre than snack #2|50g serving of rice bread
219509863|NCT05089994|PROCEDURE|US guided injection|using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
219509864|NCT03642574|PROCEDURE|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
218890856|NCT06271044|PROCEDURE|With postoperative radioiodine treatment|Postoperative radioiodine given
218890857|NCT03633344|DRUG|Carbowhite|
218890858|NCT03633344|DRUG|Carbowhite placebo|
218890859|NCT05191693|PROCEDURE|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
218890860|NCT01204177|DRUG|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
218890861|NCT00412893|DRUG|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
218890862|NCT00412893|DRUG|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
218890863|NCT04344223|DEVICE|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
218890864|NCT04344223|DEVICE|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
218890865|NCT05503849|BEHAVIORAL|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
218890866|NCT01776606|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
219509865|NCT04298164|BEHAVIORAL|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
219509866|NCT04298164|BEHAVIORAL|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
219509867|NCT04776551|PROCEDURE|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
219509868|NCT01717014|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
218890867|NCT01776606|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
218890868|NCT01199419|PROCEDURE|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
218890869|NCT01311336|DRUG|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
218890870|NCT01311336|DRUG|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
218890871|NCT01304602|DRUG|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
218890872|NCT01304602|DRUG|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
218890873|NCT00475566|DEVICE|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
219509869|NCT05436821|DEVICE|Auricular vagus nerve stimulation|Autonomic nerve system regulation
219509870|NCT05436821|DEVICE|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
219509871|NCT04741100|OTHER|Ex-vivo analysis|Ex-vivo analysis
219509872|NCT02240407|GENETIC|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10\^13 vg per TA muscle (range of 7.64 x 10\^11 vg/gm to 4.6 x 10\^11 vg/gm based on TA weight).
219509873|NCT02240407|DRUG|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
218890874|NCT00475566|DEVICE|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
219608747|NCT06551207|RADIATION|SBRT|SBRT:8-10Gy×5F, god, in 10 days
218890875|NCT04132310|OTHER|N/A This is an observational study.|This is an observational study.
218890876|NCT03235947|DRUG|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
219509874|NCT02240407|OTHER|saline|Same volume as rAAV9-DES-hGAA injection will be used.
219509875|NCT02240407|DRUG|Rituxan|Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
219509876|NCT02240407|DRUG|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
219509877|NCT02240407|DRUG|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
219509878|NCT02240407|DRUG|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
219509879|NCT02240407|DRUG|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
219509880|NCT03097393|DIAGNOSTIC_TEST|measure Serum procalcitonin level|measuring procalcitonin level
219509881|NCT03562299|DEVICE|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
219509882|NCT00322556|DRUG|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
219509883|NCT02729155|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
219509884|NCT02729155|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
219509885|NCT02729155|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
219509886|NCT02729155|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
219509887|NCT02070848|OTHER|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
219509888|NCT02070848|OTHER|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
219608748|NCT07038369|DRUG|ATV-1601|"Drug: ATV-1601~• Oral ATV-1601"
219608749|NCT07038369|COMBINATION_PRODUCT|ATV-1601 + Fulvestrant|"Drug: ATV-1601~* Oral ATV-1601 Drug: Fulvestrant~* Intramuscular Injection"
218890877|NCT03235947|DRUG|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
218890878|NCT03235947|DRUG|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
218890879|NCT05743088|BEHAVIORAL|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
219509889|NCT02070848|OTHER|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
219509890|NCT04352374|OTHER|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
219509891|NCT04352374|DEVICE|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
219509892|NCT02232074|OTHER|Patient navigation enhanced with legal support|
219509893|NCT00736320|DRUG|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
219509894|NCT00736320|RADIATION|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
219509895|NCT00536926|DEVICE|Home spirometry with data transfer via cell phone|home spirometry recording
219509896|NCT00536926|DEVICE|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
218890880|NCT05295875|DRUG|ALT-801|Injected subcutaneously (SC)
218890881|NCT05295875|OTHER|Placebo|Injected subcutaneously (SC)
219509897|NCT00536926|DEVICE|Home spirometer w/o BT|Standard home spirometry
219509898|NCT03843957|OTHER|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
219033856|NCT06072547|OTHER|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
219033857|NCT06072547|OTHER|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
219203717|NCT06767475|OTHER|Questionnaire Administration|Ancillary studies
219509899|NCT03843957|OTHER|mPATH-Checkin|The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
219608750|NCT06619769|BEHAVIORAL|eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
219608751|NCT06619769|BEHAVIORAL|Navigator support for eSense-Cancer|The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
219608752|NCT06619769|BEHAVIORAL|Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
218890882|NCT00997919|DRUG|MABT5102A|single SC dose
218890883|NCT00997919|DRUG|MABT5102A|single IV dose
219509900|NCT03843957|OTHER|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
219509901|NCT03843957|OTHER|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
218890884|NCT02967653|DRUG|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
219509902|NCT01871467|DRUG|Sargramostim|
219509903|NCT04480463|DRUG|SCD411|IVT (intravitreal) injection
219509904|NCT04480463|DRUG|Aflibercept|IVT injection
219509905|NCT02857881|PROCEDURE|De-epithelization and therapeutic photokeratectomy|
219509906|NCT00290121|DRUG|Olanzapine|
219509907|NCT05170555|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.
219509908|NCT05170555|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
219509909|NCT00704418|DRUG|Bromfenac|sterile ophthalmic solution
219509910|NCT00704418|DRUG|Placebo|sterile ophthalmic solution
219509911|NCT04690413|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
219509912|NCT00757913|DIETARY_SUPPLEMENT|n-3 enriched nutrition|
219509913|NCT02322879|DRUG|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
219509914|NCT02322879|OTHER|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
219509915|NCT02322879|DRUG|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
219509916|NCT02962011|DEVICE|Knotless barbed suture|uterine incision closure
218890885|NCT06507306|DRUG|KQB198|Oral KQB198
219509917|NCT02962011|DEVICE|polyglactin 910|uterine incision closure
219509918|NCT01541956|DRUG|Metformin|500 mg twice daily
219509919|NCT01541956|DRUG|vildagliptin|Vildagliptin 50 mg twice daily
219509920|NCT01957683|DEVICE|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
219509921|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
219509922|NCT01579474|DRUG|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
218890886|NCT06507306|DRUG|osimertinib|Oral osimertinib
219033858|NCT05398978|OTHER|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
219203718|NCT06791655|DEVICE|Stock Abutment Implant|Participants in this intervention group receive a two-piece dental implant that utilizes a stock abutment. The stock abutment is a prefabricated component that connects the implant to the prosthetic suprastructure. This intervention aims to evaluate the standard outcomes of using stock abutments in the restoration of teeth in esthetic zones after immediate implant placement.
219509923|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
219509924|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
219509925|NCT01066494|DRUG|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
219509926|NCT02637076|DRUG|Xyrem|single 3.0 gram dose
219509927|NCT00130520|DRUG|bevacizumab|10mg/kg every two weeks IV-bevacizumab
219509928|NCT00130520|DRUG|erlotinib|150mg daily by mouth-erlotinib
219509929|NCT05730140|OTHER|this study did not involve interventions; it only observational study|this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
219509930|NCT02112240|OTHER|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
219509931|NCT02112240|DRUG|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
219509932|NCT02112240|OTHER|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
219608753|NCT06628947|OTHER|Placebo (Sterile Saline or Balanced Salt Solution)|A control 50 μl injection of clear sterile saline or balanced salt solution (BSS) liquid.
219509933|NCT02112240|PROCEDURE|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
219509934|NCT02112240|RADIATION|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
219509935|NCT03107013|DRUG|[14C]-BTD-001|Carbon-14 labeled BTD-001
219509936|NCT01501695|DRUG|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
219509937|NCT01501695|DRUG|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
219509938|NCT01501695|DRUG|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
219509939|NCT00407849|DRUG|triamcinolone acetonide|Intravitreal injection
218890887|NCT04473963|DEVICE|Electrographic Flow™ guided ablation|"In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
218890888|NCT05897034|DRUG|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
218890889|NCT05897034|DRUG|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
218890890|NCT05897034|DRUG|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
219509940|NCT02506647|DRUG|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
219509941|NCT02506647|DRUG|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
219509942|NCT02219191|DRUG|puerarin tablet 50 mg|
219509943|NCT02219191|DRUG|Atorvastatin tablet 20 mg|Approval No.: H19990258
219509944|NCT03811041|OTHER|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
219509945|NCT03811041|OTHER|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
219509946|NCT03811041|OTHER|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
219509947|NCT02638831|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
219509948|NCT02638831|DRUG|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
219509949|NCT02346968|OTHER|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
219509950|NCT04170179|PROCEDURE|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
219509951|NCT04170179|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219509952|NCT04170179|DRUG|Toripalimab|240mg intravenously every 3 weeks
219509953|NCT01148290|PROCEDURE|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
219509954|NCT01148290|PROCEDURE|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
219509955|NCT03064412|BIOLOGICAL|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
219509956|NCT03064412|BIOLOGICAL|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
219509957|NCT04145908|PROCEDURE|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
218890891|NCT00410878|DRUG|OROS Hydromorphone HCI (slow release)|
218890892|NCT01404780|DEVICE|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
219509958|NCT00006291|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219509959|NCT00006291|DRUG|Aldesleukin|
219509960|NCT02494128|OTHER|Education|Education in group leadership
219509961|NCT02015091|BIOLOGICAL|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
219608754|NCT06628947|DRUG|100 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
219509962|NCT00291395|DRUG|PGI2|
219509963|NCT02497833|DIETARY_SUPPLEMENT|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
219509964|NCT02497833|OTHER|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
219509965|NCT02636127|OTHER|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~\- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
219509966|NCT02585882|OTHER|Fluoride table salt|
219509967|NCT04459546|BEHAVIORAL|patient education, training booklet, 3 months tele health|Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
219509968|NCT01953666|OTHER|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
218890893|NCT01404780|DEVICE|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
218890894|NCT01613677|DRUG|BKM120|
219509969|NCT01953666|OTHER|Self - Training at home|Only instructions for a self - training at home
218890895|NCT03701672|OTHER|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
218890896|NCT04935073|DRUG|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
218890897|NCT04935073|DRUG|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
219509970|NCT02771665|OTHER|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
219509971|NCT00544765|DRUG|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
219509972|NCT00544765|DRUG|NX|Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
219509973|NCT04709159|OTHER|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
219509974|NCT00810732|DRUG|Open|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
219509975|NCT00810732|DRUG|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
219509976|NCT00810732|DRUG|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
219509977|NCT00957983|DRUG|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
219509978|NCT03083483|DEVICE|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
219509979|NCT01800565|OTHER|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
219509980|NCT01800565|OTHER|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
219509981|NCT05474625|DEVICE|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
219509982|NCT05474625|DEVICE|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
219509983|NCT05474625|DEVICE|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
219509984|NCT05474625|OTHER|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
219509985|NCT02018146|OTHER|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
219509986|NCT02018146|OTHER|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
219509987|NCT06456203|DIAGNOSTIC_TEST|AI|Artificial intelligence triage and reporting system
219509988|NCT01760603|PROCEDURE|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
219509989|NCT02020603|DEVICE|epinephrine injection plus soft coagulation using hemostatic forceps|
219509990|NCT02020603|DEVICE|epinephrine injection plus argon plasma coagulation|
219608755|NCT06628947|DRUG|50 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
219608756|NCT04286711|DRUG|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
219608757|NCT07046923|DRUG|LY4175408|IV infusion
219608758|NCT03875547|DRUG|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
219509991|NCT04200508|OTHER|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
219509992|NCT00163384|DRUG|Ciclesonide|
218890898|NCT02423655|OTHER|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
219509993|NCT04106375|BEHAVIORAL|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
219509994|NCT04771000|DRUG|Ambrisentan|Endothelin receptor antagonist
219509995|NCT04771000|DRUG|Placebo|Placebo
219509996|NCT04485052|DRUG|IBI188|anti-CD47 Monoclonal antibody
219509997|NCT04485052|DRUG|Azacitidine|Demethylation drugs
218890899|NCT02423655|OTHER|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
219509998|NCT04485052|DRUG|Decitabine|Demethylation drugs
218890900|NCT04168229|DEVICE|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
218890901|NCT04168229|DEVICE|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
218890902|NCT06375174|PROCEDURE|Thrombectomy|All procedures correspond to standard care and clinical routine
219509999|NCT01373775|OTHER|Patient charts reviewing|Reviewing chart and identifying risk factors
218890903|NCT04451941|DEVICE|Experimental: RecoveriX with individual EEG calibration|RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
218890904|NCT04451941|DEVICE|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
218890905|NCT03469466|DIAGNOSTIC_TEST|bedside ultrasound|bedside ultrasound imaging of the lungs
218890906|NCT01908530|DEVICE|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
218890907|NCT02228317|DEVICE|Telemedicine consultation|Telemedicine consultation done by telephone or video
218890908|NCT01582620|PROCEDURE|Telestroke|remote videoconference consultations
218890909|NCT01941329|PROCEDURE|Panretinal Photocoagulation (PRP)|
218890910|NCT01941329|DRUG|Intravitreous injection of ranibizumab|
218890911|NCT04585204|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test
218890912|NCT04829149|OTHER|Observational|Statin therapy group and Rosuzet tablet group
218890913|NCT00242541|DRUG|Octreotide acetate|
219510000|NCT03430375|DEVICE|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
219510001|NCT03430375|DEVICE|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
219510002|NCT01803152|BIOLOGICAL|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
219510003|NCT01803152|BIOLOGICAL|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
219510004|NCT01803152|DRUG|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
219510005|NCT01803152|DRUG|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
219510006|NCT01803152|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
219510007|NCT02711956|DRUG|ZEN003694|
219510008|NCT02711956|DRUG|Enzalutamide|
219608759|NCT01650701|DRUG|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219608760|NCT01650701|DRUG|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
219510009|NCT03734237|BIOLOGICAL|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
219510010|NCT03734237|BIOLOGICAL|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
219510011|NCT03734237|BIOLOGICAL|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
218890914|NCT00165178|DRUG|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
218890915|NCT00165178|DRUG|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
218890916|NCT00165178|DRUG|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
218890917|NCT00165178|DRUG|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
218890918|NCT00165178|DRUG|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
218890919|NCT00165178|DRUG|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
218890920|NCT00165178|DRUG|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
218890921|NCT00165178|DRUG|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
218890922|NCT00165178|DRUG|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
218890923|NCT00165178|DRUG|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
218890924|NCT00587158|DRUG|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
218890925|NCT00587158|OTHER|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
218890926|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
218890927|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
218890928|NCT06436118|BEHAVIORAL|RELAX® glasses|Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use.
218890929|NCT03714724|DIAGNOSTIC_TEST|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
218890930|NCT02402582|OTHER|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
218890931|NCT02402582|OTHER|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
218890932|NCT02139072|DEVICE|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
218890933|NCT02139072|PROCEDURE|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
219510012|NCT01673009|DRUG|Gleevec|Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
219510013|NCT00555256|DRUG|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
219510014|NCT05059756|DEVICE|PTNS|PTNS and PFR
219510015|NCT05059756|DEVICE|Sham PTNS|Sham PTNS and PFR
219510016|NCT04774575|BIOLOGICAL|biomarker-guided strategy|Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
219510017|NCT00959959|DRUG|TOK-001|2 capsules (325 mg each), once per day
218890934|NCT00022802|DEVICE|Image-guided surgical system|
218890935|NCT04120415|BIOLOGICAL|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
219510018|NCT00959959|DRUG|TOK-001|4 capsules (325 mg each), once per day
219510019|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), once per day
219510020|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day
219510021|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day with supplement
219608761|NCT01650701|DRUG|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
219510022|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
219510023|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), once per day
219510024|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
219510025|NCT02442856|DEVICE|Thigh Cuff|
219510026|NCT05267756|DEVICE|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
219510027|NCT00979160|DRUG|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
219510028|NCT04472975|DRUG|Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS|Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
219510029|NCT02942251|OTHER|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
219510030|NCT02942251|OTHER|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
219608762|NCT01650701|DRUG|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
219608763|NCT01650701|DRUG|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
219608764|NCT07041203|DRUG|sodium oxybate|Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)
219608765|NCT06731907|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg IV Infusion.
219608766|NCT06731907|DRUG|Carboplatin|Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
219608767|NCT06731907|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion.
219608768|NCT06731907|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m\^2 IV infusion.
219608769|NCT06731907|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2 IV infusion.
219608770|NCT06731907|BIOLOGICAL|HER3-DXd|HER3-Dxd 5.6mg/kg IV infusion.
219608771|NCT05703269|RADIATION|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
219608772|NCT05703269|RADIATION|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
219608773|NCT07045740|OTHER|PT Navigator|Participants assigned to the intervention group will meet with the PT Navigator withing the first month of starting cancer treatment. Following a one-hour initial assessment, the PT Navigator will follow up every two-three weeks for a total of six sessions. The PT Navigator will administer outcome measures to screen for complications or side effects of treatment. If any complications or side-effects are identified, the PT Navigator will facilitate referrals to other health care practitioners, provide exercise and/or rehabilitation treatment, or provide education and continue monitoring.
218890936|NCT04120415|BIOLOGICAL|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
219510031|NCT02942251|OTHER|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
219510032|NCT02942251|OTHER|Laboratory abnormality|This group will be suggested to more safety antidepressants.
219510033|NCT02942251|OTHER|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
219510034|NCT02942251|OTHER|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
219510035|NCT02517190|OTHER|Parabolic flight|
219510036|NCT02517190|OTHER|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
219510037|NCT02517190|OTHER|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
219510038|NCT02517190|OTHER|cellular energy metabolism measurements|purines, lactate
219510039|NCT05008289|DEVICE|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
219608774|NCT07047326|DRUG|Urokinase thrombolysis|The intravenous thrombolysis group was administered urokinase dissolved in 100 mL of saline via continuous intravenous infusion for 30 min, and the treatment was given within 6 h of stroke onset. The dose escalation plan includes the following increments: 15,000 IU/kg (maximum dose: 1.5 million IU), 20,000 IU/kg (maximum dose: 2.0 million IU), and 25,000 IU/kg (maximum dose: 2.5 million IU).
219608775|NCT07046559|DRUG|LY4066708|Administered IV
219608776|NCT07046559|DRUG|Placebo|Administered IV
219608777|NCT07046559|DRUG|LY4066708|Administered SC
219608778|NCT07046559|DRUG|Placebo|Administered SC
219608779|NCT06740253|DEVICE|Placebo intravaginal ring (IVR)|Antibody-Based Nonhormonal Placebo Contraceptive Intravaginal Ring
219608780|NCT00489255|DRUG|Tigan®|Oral capsule, 300mg three times daily
219608781|NCT00489255|DRUG|Placebo|Oral capsule, three times daily
218890937|NCT04120415|BIOLOGICAL|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
218890938|NCT03570814|DRUG|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
218890939|NCT03570814|DRUG|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
218890940|NCT03570814|DRUG|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
218890941|NCT03570814|DRUG|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
218890942|NCT02114606|DEVICE|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
218890943|NCT02109991|DEVICE|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
218890944|NCT04280055|DRUG|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
218890945|NCT04355208|OTHER|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
218890946|NCT02822898|DRUG|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
218890947|NCT02822898|DRUG|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
218890948|NCT06334848|PROCEDURE|transobturator tape|Women with stress urinary incontinence are treated by transobturator tape versus mini sling
218890949|NCT02275663|DRUG|Azacytidine|
218890950|NCT02275663|DRUG|Fludarabine|
218890951|NCT02275663|DRUG|Cytarabine|
219510040|NCT05008289|DEVICE|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
218890952|NCT02275663|DRUG|Filgrastim|G-CSF
218890953|NCT02382445|DEVICE|Anesthesia depth monitor|
218890954|NCT02382445|DEVICE|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
218890955|NCT02382445|DRUG|propofol and sevoflurane|
218890956|NCT00981461|DEVICE|HairMax LaserComb|Device application 3 times week, for 26 weeks
218890957|NCT00981461|DEVICE|Control Device|Device application 3 times week, for 26 weeks
218890958|NCT03306992|BEHAVIORAL|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
219033859|NCT02980965|DRUG|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
218890959|NCT03187119|BEHAVIORAL|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
219510041|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
219510042|NCT02207621|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
219510043|NCT02207621|OTHER|Placebo|1 drop QD, AM, OU
219510044|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
219510045|NCT00534625|DRUG|zileuton|Single injection of zileuton 150 mg
219510046|NCT00534625|DRUG|placebo|Single injection of placebo
219510047|NCT00534625|DRUG|zileuton|Single injection of zileuton 300 mg
219510048|NCT03686709|DIAGNOSTIC_TEST|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
219608782|NCT01171261|BEHAVIORAL|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
219608783|NCT07055165|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
219608784|NCT07055165|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
219608785|NCT07054606|DRUG|Perfluorohexyloctane ophthalmic solution|Eligible subjects will receive Miebo up to 4 times bilaterally on Day 1/Visit 1 (1 drop instilled bilaterally by site staff in-clinic while wearing contact lenses and the rest self-administered throughout the remainder of the day while wearing contact lenses). Starting on Day 2, subjects will self-administer the first drop of Miebo bilaterally before inserting contact lenses for the day. Subjects will wait 30 minutes after the first dose of Miebo to insert their contact lenses and will then instill 3 additional drops of Miebo while wearing contact lenses approximately evenly spaced throughout the rest of the day. Subjects will continue to self-administer Miebo QID bilaterally following the dosing schedule from Day 2 for approximately 30 days. Subjects are expected to record daily VAS assessments throughout the study. The VAS assessments will be collected by the sites at Visits 2, 3, and 4.
219608786|NCT04652960|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219608787|NCT04652960|PROCEDURE|Computed Tomography|Undergo CT scan
218890960|NCT03187119|BEHAVIORAL|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
219510049|NCT02833415|DRUG|[U-13C3] glycerol|Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
219510050|NCT02833415|DRUG|Empagliflozin|Active drug
219608788|NCT04652960|DRUG|Duvelisib|Given PO
219608789|NCT04652960|BIOLOGICAL|Nivolumab|Given IV
219510051|NCT02833415|DRUG|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
219608790|NCT04652960|PROCEDURE|Positron Emission Tomography|Undergo PET
219608791|NCT04652960|PROCEDURE|Punch Biopsy|Undergo punch biopsies
219608792|NCT06719141|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
218890961|NCT05432752|DEVICE|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
218890962|NCT01999400|DRUG|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
219510052|NCT01363037|DRUG|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
219510053|NCT01363037|DRUG|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
219510054|NCT01363037|OTHER|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
219510055|NCT01363037|DRUG|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
219608793|NCT06719141|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
219608794|NCT07079735|DRUG|Letermovir|CMV prophylaxis
219608795|NCT07079735|DRUG|Valganciclovir|Standard therapy for CMV prophylaxis
219608796|NCT06682780|DRUG|LM-2417|Q2W/Q3W,Intravenous Drip
219608797|NCT06682780|DRUG|Docetaxel|Q3W,Intravenous Drip
219608798|NCT06682780|DRUG|Toripalimab/Tirelizumab|Q3W,Intravenous Drip
219608799|NCT06682780|DRUG|Carboplatin|Q3W,Intravenous Drip
219608800|NCT06682780|DRUG|Niraparib|QD,Oral Administration
218890963|NCT01999400|DRUG|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
219608801|NCT06682780|DRUG|Lenvatinib|QD,Oral Administration
218890964|NCT01999400|DRUG|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
218890965|NCT01999400|DRUG|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
218890966|NCT03708718|DRUG|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
218890967|NCT03708718|DRUG|Placebo oral capsule; From August 2020 'no additional treatment'|Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
219608802|NCT01739712|BEHAVIORAL|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
219608803|NCT01739712|BEHAVIORAL|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
219608804|NCT04639284|DRUG|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
219608805|NCT07086131|DEVICE|Powerbreathe|The breathing training will consist of using the PowerBreathe for 12 weeks. The PowerBreathe is an inspiratory pressure threshold trainer. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
219510056|NCT01477437|OTHER|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
219510057|NCT04383756|BIOLOGICAL|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
219203719|NCT06791655|DEVICE|Customized CAD CAM Titanium Milled Abutment Implant|Participants in this intervention group are treated with a two-piece dental implant that includes a customized CAD CAM titanium milled abutment. These abutments are tailor-made using computer-aided design and manufacturing to fit the specific contours and needs of the patient's dental structure. This customized approach is hypothesized to offer superior integration with the soft and hard tissues, leading to better aesthetic outcomes and tissue health around the implant area.
219510058|NCT04383756|BIOLOGICAL|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
219510059|NCT05367856|DRUG|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
219510060|NCT04806009|BEHAVIORAL|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
219510061|NCT04806009|BEHAVIORAL|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
219510062|NCT00141752|DEVICE|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
219510063|NCT01530815|DRUG|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
219510064|NCT04535609|DRUG|Mavodelpar|Once daily
219510065|NCT04535609|DRUG|Placebo|Once daily
219510066|NCT01977261|PROCEDURE|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
219510067|NCT01977261|PROCEDURE|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
219510068|NCT00963183|DRUG|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
219510069|NCT00963183|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
219510070|NCT05670054|DRUG|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
219510071|NCT02302573|DRUG|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
219510072|NCT04431986|OTHER|No intervention: secondary use of a database|Statistical analyses
219510073|NCT04319484|DRUG|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
219510074|NCT04319484|DRUG|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
219510075|NCT04000321|OTHER|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
219608806|NCT07083011|DRUG|68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)|68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
218890968|NCT01994616|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
218890969|NCT03361293|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
219203720|NCT06793995|DRUG|LY03017|single dose，administered orally for each period
218890970|NCT03361293|BEHAVIORAL|Cognitive training|BrainHQ Computerized cognitive training
219203721|NCT06793995|DRUG|LY03017|single dose，administered orally
219203722|NCT02325154|DEVICE|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
218890971|NCT03361293|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
218890972|NCT01466127|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
218890973|NCT01466127|DRUG|Placebo|Matched nasal spray placebo
218890974|NCT01910402|DRUG|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
218890975|NCT01910402|DRUG|Atazanavir|Atazanavir capsule 300 mg
218890976|NCT01910402|DRUG|Ritonavir|Ritonavir tablet 100 mg
218890977|NCT01910402|DRUG|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
219510076|NCT04000321|OTHER|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
219510077|NCT06543147|OTHER|breast cancer and breast self- examination education|The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
219510078|NCT06169098|PROCEDURE|Auricular acupressure on the left ear|Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
219510079|NCT06169098|PROCEDURE|Auricular acupressure on the right ear|Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
219510080|NCT06169098|PROCEDURE|Sham auricular acupressure|Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
219510081|NCT05053698|OTHER|Aqueous flare measurement|Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
219510082|NCT06117488|DEVICE|endoscopy|gastro duodenal endoscoe
219510083|NCT03788577|DIETARY_SUPPLEMENT|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
219510084|NCT03788577|DIETARY_SUPPLEMENT|Placebo|Placebo
219510085|NCT01712880|PROCEDURE|open debridement with modular exchange|
219510086|NCT01712880|PROCEDURE|one stage exchange|
219510087|NCT02123992|DEVICE|Elevate Apical and Posterior|
219608807|NCT06899750|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, and nurse working together with patients via a remote monitoring, educational hypertension phone app to overcome barriers to hypertension control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
219510088|NCT02123992|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
219510089|NCT01627873|DRUG|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
219510090|NCT01627873|DRUG|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
219608808|NCT06899750|BEHAVIORAL|E3 Self-Guided Hypertension Education Program|Patients will receive timed, mailed educational materials on hypertension self-monitoring, diet and lifestyle modifications to supplement usual clinic-based hypertension care with their primary care doctor. A research assistant will ensure patients have home blood pressure monitors on enrollment, and will remind patients to check their blood pressures and follow-up with their primary care doctors at 3 months and 6 months.
218890978|NCT01657175|OTHER|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
218890979|NCT03610841|DIAGNOSTIC_TEST|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
218890980|NCT03610841|DIAGNOSTIC_TEST|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
218890981|NCT05527444|DRUG|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
218890982|NCT05527444|DRUG|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
218890983|NCT05527444|DRUG|NSAID|stable dose
218890984|NCT05527444|DRUG|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
218890985|NCT00483405|BIOLOGICAL|cetuximab|250 mg/m2, intravenously, once per week
219608809|NCT02630628|DRUG|Tacrolimus|Dosage: start at 2mg twice a day, then titrated according to therapeutic drug level monitoring using 12-hour post-dose blood sampling
219608810|NCT02630628|DRUG|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
218890986|NCT00483405|DRUG|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
218890987|NCT00483405|DRUG|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
218890988|NCT06198387|RADIATION|hormone and RT|The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).
219033860|NCT02980965|DRUG|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
219033861|NCT01885091|OTHER|Kinerase|
219033862|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
219203723|NCT06835621|PROCEDURE|Restricted inverse kinematic alignment Total Knee Arthroplasty|Restricted inverse kinematic alignment (restricted iKA) total knee arthroplasty is an alignment technique of total knee replacement surgery, aim to maintain the native coronal alignment within a HKA angle safe zone of 177° to 183°. This technique aims to 'resurface' the femur maintaining the native femoral joint line obliquity, with the flexion and extension gaps balanced by adjusting the tibial resection first. It is considered a more personalized approach because it aims to replicate the knee's pre-arthritic alignment and movement, believing that each patient's knee has a unique alignment.
219510091|NCT03955679|GENETIC|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
219510092|NCT01773564|DEVICE|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
219510093|NCT01773564|DEVICE|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
219510094|NCT01769378|DRUG|Placebo|Administered SQ
219608811|NCT06336018|DRUG|Etavopivat|Participants will receive a single dose of etavopivat orally.
219033863|NCT02427867|OTHER|Remote ischemic preconditioning|
219608812|NCT04416568|DRUG|Nivolumab|"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"
219608813|NCT04416568|DRUG|Ipilimumab|Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
219608814|NCT05977218|OTHER|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when grocery shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
219613376|NCT05596110|BEHAVIORAL|TENS and sham taping|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
219033864|NCT02427867|OTHER|no ischemic preconditioning|
219033865|NCT00710320|PROCEDURE|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
219510095|NCT01769378|DRUG|Dulaglutide|Administered SQ
219510096|NCT01769378|DRUG|Glimepiride|Administered PO
219510097|NCT03558100|BEHAVIORAL|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
219510098|NCT05056142|PROCEDURE|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
218890989|NCT06198387|DRUG|ADT combined with abiraterone|The patients will receive a two-year course of ADT combined with abiraterone.
218890990|NCT00571038|BEHAVIORAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
218890991|NCT00571038|BEHAVIORAL|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
219033866|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
219510099|NCT05056142|PROCEDURE|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
219510100|NCT01386346|DRUG|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
218890992|NCT03261388|BEHAVIORAL|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
218890993|NCT01062152|DRUG|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
218890994|NCT01062152|DRUG|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
219033867|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
219033868|NCT03667352|PROCEDURE|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
219033869|NCT03667352|PROCEDURE|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
219033870|NCT03667352|DRUG|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
219033871|NCT03732053|OTHER|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
219203724|NCT06835621|PROCEDURE|Adjusted Mechanical alignment Total Knee Arthroplasty|The adjusted Mechanical Alignment (aMA) technique is an adaptation of the conventional MA technique but with undercorrection of constitutional coronal deformity, within a limit of ± 3°. The femoral resection is adjusted to preserve mild constitutional deformity and/or reduce more severe deformity while leaving the tibial component mechanically aligned. The tibial component was positioned with the aim to be perpendicular (90°) to the mechanical tibial axis.
219203725|NCT06829290|DIAGNOSTIC_TEST|Ultrasound|Sonographisch measurement of muscles Blood muscle markers
219203726|NCT06746909|OTHER|Multidomain cognitive training and physical training|"The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility."
219203727|NCT04245085|DRUG|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
219510101|NCT01386346|DRUG|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
219510102|NCT01386346|DRUG|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
219510103|NCT01386346|DRUG|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
219510104|NCT03475797|DEVICE|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
219510105|NCT03475797|OTHER|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
219510106|NCT05260645|BEHAVIORAL|Back School|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
219510107|NCT04305964|DEVICE|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
218890995|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
219033872|NCT05175599|OTHER|Water Birth|The water birth group will use a tub of a water to labor and give birth.
219510108|NCT04305964|DIAGNOSTIC_TEST|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
219510109|NCT00503620|DRUG|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
219510110|NCT00647582|PROCEDURE|adjuvant therapy|
219510111|NCT00647582|PROCEDURE|therapeutic conventional surgery|
219510112|NCT00647582|RADIATION|intraoperative radiation therapy|
219510113|NCT00647582|RADIATION|radiation therapy|
219510114|NCT06412562|DIAGNOSTIC_TEST|The Maudsley 3-item Visual Analogue Scale (M3VAS)|Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
219510115|NCT05305274|OTHER|screening|This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
219510116|NCT01621425|OTHER|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
219510117|NCT01621425|OTHER|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
219510118|NCT01621425|OTHER|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
218890996|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
218890997|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
218890998|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
218890999|NCT06319703|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) Videos|Text message-delivered video-based DSMES intervention.
218891000|NCT06319703|BEHAVIORAL|Community Health Worker Support (CHW)|Assess participants' SDOH barriers to Type 2 diabetes care and link them to available resources in the community.
219033873|NCT05537376|BEHAVIORAL|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
219033874|NCT06164587|DRUG|K8|sustained released bio-erodible intravitreal implants
219033875|NCT03754894|DEVICE|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
219033876|NCT03754894|PROCEDURE|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
219033877|NCT05749094|DIAGNOSTIC_TEST|Optic nerve sheath ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
219510119|NCT01349439|DRUG|Propranolol|1mg per Kg (participant weight)
219510120|NCT01349439|DRUG|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
219510121|NCT02324972|DRUG|AQX-1125|Synthetic SHIP1 activator
219510122|NCT02324972|DRUG|Placebo|
219510123|NCT04259840|OTHER|Observation|Soft tissue implant measurements
219510124|NCT00719784|DEVICE|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
219510125|NCT05089123|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
219510126|NCT05089123|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
219510127|NCT00006443|DRUG|Indinavir sulfate|
219510128|NCT00006443|DRUG|Nelfinavir mesylate|
219510129|NCT00006443|DRUG|Lamivudine|
219510130|NCT00006443|DRUG|Stavudine|
219510131|NCT03260764|DEVICE|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
218891001|NCT03325842|DIAGNOSTIC_TEST|ASKp|30 items questionnaire
218891002|NCT02362750|OTHER|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
218891003|NCT02362750|OTHER|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
218891004|NCT02362750|OTHER|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
218891005|NCT02362750|OTHER|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
218891006|NCT02362750|OTHER|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
218891007|NCT02362750|OTHER|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
219510132|NCT03260764|DEVICE|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
219510133|NCT03260764|DEVICE|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
219510134|NCT03260764|DEVICE|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
219510135|NCT01191021|DRUG|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
219510136|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
218891008|NCT02362750|OTHER|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
219510137|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
219510138|NCT00656500|BEHAVIORAL|Standard brief advice|Brief general assistance with smoking cessation
219510139|NCT00656500|BEHAVIORAL|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
219608815|NCT03935997|OTHER|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff."
219608816|NCT06958536|DRUG|SAR442970|Route of Administration: Subcutaneous
218891009|NCT02960607|DRUG|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
218891010|NCT01952236|BEHAVIORAL|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
218891011|NCT01952236|BEHAVIORAL|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
218891012|NCT00200720|BEHAVIORAL|Atkins diet (low carbohydrate diet)|
219510140|NCT00719342|DRUG|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
219510141|NCT00719342|OTHER|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
219510142|NCT06053099|OTHER|Plasma ctDNA|"* Plasma ctDNA before surgery (optional)~* Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~* Plasma ctDNA every 6 months~* Plasma ctDNA at relapse"
219510143|NCT06053099|OTHER|FFPE blocks|"* Surgery FFPE blocks~* FFPE blocks at relapse (optional)"
219510144|NCT01161654|DRUG|naratriptan hydrochoride|2.5 mg tablet
219510145|NCT00765700|DRUG|Topical Ketoprofen 10% Cream|Topical Administration
219608817|NCT06958536|DRUG|Placebo|Route of Administration: Subcutaneous
219608818|NCT03184571|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor
218891013|NCT00200720|BEHAVIORAL|DASH diet (high carbohydrate diet)|
218891014|NCT03636126|DEVICE|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
218891015|NCT02814942|DEVICE|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
219510146|NCT00765700|DRUG|Topical Placebo Cream|Topical Administration
219608819|NCT03184571|DRUG|Bemcentinib|Bemcentinib is a selective Axl kinase inhibitor;
218891016|NCT01550757|BEHAVIORAL|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
219510147|NCT04165681|OTHER|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
219510148|NCT02285127|PROCEDURE|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
219510149|NCT03352427|DRUG|Dasatinib|60 mg/m2 orally twice daily
219510150|NCT03352427|DRUG|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
219510151|NCT05285280|DIAGNOSTIC_TEST|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
219510152|NCT05339009|BIOLOGICAL|BioADM determination in plasma|BioADM determination in plasma
219608820|NCT05247580|OTHER|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
219608821|NCT03855111|OTHER|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
219608822|NCT03855111|OTHER|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
219608823|NCT06493383|DEVICE|Lotrafilcon B plano cosmetic contact lenses|Commercially approved colored contact lenses worn for cosmetic purposes to alter or enhance the apparent color of the eye
218891017|NCT02134717|DRUG|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
219510153|NCT03478059|BEHAVIORAL|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
219510154|NCT02737215|DEVICE|CPAP|patients will receive CPAP therapy with Auto-CPAP
219510155|NCT05361278|OTHER|Chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
219510156|NCT05361278|OTHER|Activated chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
219510157|NCT05361278|OTHER|Chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the gel after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
219608824|NCT03274492|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
219608825|NCT03274492|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
219608826|NCT03274492|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219608827|NCT03274492|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219608828|NCT03274492|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
218891018|NCT02134717|PROCEDURE|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
218891019|NCT02134717|PROCEDURE|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
218891020|NCT02134717|PROCEDURE|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
218891021|NCT04182841|DEVICE|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
219608829|NCT03274492|DRUG|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
218891022|NCT02665182|BEHAVIORAL|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
218891023|NCT01504022|OTHER|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
219608830|NCT03274492|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
218891024|NCT05532358|DRUG|anle138b (TEV-56286)|Anle138b (TEV-56286) as perpetrator
219608831|NCT03274492|DRUG|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
219608832|NCT06474182|PROCEDURE|Blood sampling|Blood sampling
219608833|NCT06474182|DRUG|Apixaban|Treatment by Apixaban
218891025|NCT05532358|DRUG|Fluvoxamine 100 mg QD for 5 days|Anle138b (TEV-56286) as victim
218891026|NCT05072938|DRUG|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
218891027|NCT05072938|DRUG|Axid Capsule 150mg|Nizatidine Monotherapy
218891028|NCT04098809|DEVICE|16 French urinary catheter|16 French urinary catheter
218891029|NCT04098809|DEVICE|20 French urinary catheter|20 French urinary catheter
219033878|NCT05749094|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assesment, blood test review, temporal/axillary artery ultrasound
218891030|NCT04840082|DIAGNOSTIC_TEST|Nasopharyngeal swab for COVID-19 testing|A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
219510158|NCT05361278|OTHER|Activated chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
219510159|NCT05361278|OTHER|Sodium hypochlorite solution|"* Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
219510160|NCT05415566|COMBINATION_PRODUCT|toy nebulizer and toy mask|The treatment was administered using therapeutic play.
219510161|NCT03148574|DRUG|Misoprostol|intrauterine tablets
219510162|NCT03148574|DRUG|Oxytocin|intravenous
219510163|NCT05272358|OTHER|NETSARC network|MDTB and/or surgery in NETSARC network
219510164|NCT02380846|OTHER|White rice|Control - white rice
219510165|NCT02380846|OTHER|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
219510166|NCT02380846|OTHER|Rice with fish|Treatment 2 - steamed white rice with steamed fish
219510167|NCT02380846|OTHER|Rice with egg white|Treatment 3 - steamed white rice with egg white
219510168|NCT02380846|OTHER|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
219510169|NCT06404411|OTHER|Assigned interventions|Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.
219510170|NCT06404411|OTHER|conventional rehabilitation|Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
219510171|NCT03166982|PROCEDURE|transvaginal approach|
219510172|NCT03166982|PROCEDURE|laparoscopic approach|
219510173|NCT01462565|DRUG|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
219510174|NCT01462565|DRUG|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
219033879|NCT05553054|OTHER|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
219203728|NCT04245085|DRUG|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
219203729|NCT04245085|DRUG|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
219510175|NCT02899130|DRUG|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
219510176|NCT02899130|DRUG|Placebo|Inactive compound that is similar looking as the intervention
219510177|NCT01238848|DRUG|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
219510178|NCT01238848|DRUG|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
219510179|NCT00576901|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
219510180|NCT00576901|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
219510181|NCT00576901|DRUG|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
218891031|NCT00203164|DRUG|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
218891032|NCT00193206|DRUG|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
219510182|NCT02004704|DRUG|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
219510183|NCT01755858|DRUG|Bendavia|
218891033|NCT00193206|DRUG|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
218891034|NCT00193206|DRUG|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
218891035|NCT03981679|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
218891036|NCT05336578|OTHER|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
218891037|NCT03009474|DRUG|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
219510184|NCT01755858|DRUG|Placebo|
219510185|NCT04714619|DRUG|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
219510186|NCT00241917|BEHAVIORAL|Hepatitis C educational video|
219510187|NCT00241917|OTHER|Video|Prevention education video about hepatitis C
218891038|NCT03009474|DRUG|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
219510188|NCT03466190|PROCEDURE|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
219510189|NCT03466190|PROCEDURE|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
219510190|NCT05247710|PROCEDURE|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
219510191|NCT02613923|BEHAVIORAL|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
218891039|NCT04560933|PROCEDURE|Blood sample collection|Blood sample collection
218891040|NCT04260789|DEVICE|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
218891041|NCT02741596|DRUG|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
219033880|NCT00826800|DRUG|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
219033881|NCT00976742|BEHAVIORAL|Endurance exercise training|
219033882|NCT03774953|DIETARY_SUPPLEMENT|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
219510192|NCT02613923|BEHAVIORAL|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
219510193|NCT02613923|PROCEDURE|Blood Draw|blood sample measured for stress and sleep markers
219510194|NCT02613923|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
219510195|NCT02613923|OTHER|Insomnia Severity Index (ISI)|
219510196|NCT02613923|OTHER|SF-12 quality of life survey|
219510197|NCT02586766|BEHAVIORAL|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
219510198|NCT01408966|DIETARY_SUPPLEMENT|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
219510199|NCT01408966|DIETARY_SUPPLEMENT|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
218891042|NCT02741596|DRUG|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
219510200|NCT02398188|DRUG|LIPO-202|
219510201|NCT02398188|DRUG|Placebo|
219510202|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219033883|NCT05039008|OTHER|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
219033884|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
219033885|NCT02269280|DRUG|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
219033886|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
219033887|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
219033888|NCT05820893|DRUG|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
219510203|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219510204|NCT00782509|DRUG|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
219510205|NCT01739283|OTHER|GIP|
219510206|NCT01739283|OTHER|GLP-1|
219510207|NCT01739283|OTHER|Saline|
219510208|NCT05857839|OTHER|Myofascial release|Patients will get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks
219510209|NCT05857839|OTHER|pelvic Support belt|The support belt will be worn for less than two to three hours at a time and it will be used 4 times a week
219510210|NCT05861726|BEHAVIORAL|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 \& 70% maximum heart rate
218891043|NCT02195570|OTHER|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
219510211|NCT05861726|OTHER|None (control group)|None (the control group)
218891044|NCT02195570|BEHAVIORAL|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
219510212|NCT04278469|DRUG|Chemotherapy Drugs, Cancer|Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
219510213|NCT05166265|DEVICE|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
219510214|NCT01653665|DRUG|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
219510215|NCT01653665|DRUG|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
219510216|NCT01443065|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
219510217|NCT01443065|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
219510218|NCT01443065|DRUG|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
219510219|NCT01443065|DRUG|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
219510220|NCT01443065|DRUG|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
219510221|NCT05896631|OTHER|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
219510222|NCT05896631|OTHER|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
219510223|NCT04318665|DIAGNOSTIC_TEST|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
218891045|NCT01426958|DRUG|afatinib|standard therapeutic dose
218891046|NCT01426958|DRUG|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
219510224|NCT01259869|DRUG|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
219510225|NCT00175019|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
219510226|NCT00175019|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
219510227|NCT00175019|DRUG|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
219510228|NCT01808664|BEHAVIORAL|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
219510229|NCT01808664|BEHAVIORAL|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
219510230|NCT03164603|DRUG|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
219510231|NCT03209570|OTHER|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
218891047|NCT01426958|DRUG|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
218891048|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
218891049|NCT02236468|BEHAVIORAL|WASH/malaria behavior change|WASH/malaria behavior change communication
218891050|NCT02236468|DIETARY_SUPPLEMENT|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
218891051|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
218891052|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
218891053|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
219510232|NCT03209570|OTHER|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
219510233|NCT06211985|DIAGNOSTIC_TEST|Copeptin level measurement|Throughout the study period, a total of 202 eligible patients were admitted to the hospital. Twenty-four patients were excluded due to lack of consent from their families, and an additional 103 patients were excluded based on the predefined exclusion criteria. In the control group, 72 individuals without chronic or acute diseases were initially eligible, but 46 of them were excluded due to lack of consent from their families. The study included patients who met the inclusion criteria and whose families provided consent, and it concluded upon reaching a total of 25 patients for each group. Additional blood samples were collected from each child within every group to assess copeptin levels, in conjunction with routine tests
219510234|NCT05991661|DRUG|XKH001 Injection|100mg/ml，1ml/vial
219510235|NCT05991661|DRUG|XKH001 Placebo Injection|1ml/vial
219608834|NCT06452407|OTHER|Implementation of elleFA smartphone application|Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 5-point Likert scale.
219510236|NCT00928083|DRUG|OZ439 50mg API capsules|
219033889|NCT05303753|OTHER|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
219510237|NCT00928083|DRUG|OZ439 200mg API capsules|
219510238|NCT00928083|DRUG|OZ439 400mg aqueous dispersion|
219510239|NCT00928083|DRUG|OZ439 800mg aqueous dispersion|
219510240|NCT00928083|DRUG|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
219510241|NCT00928083|DRUG|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
219510242|NCT00928083|DRUG|OZ439 1600mg aqueous dispersion|
219510243|NCT00928083|DRUG|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
219510244|NCT00928083|DRUG|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
219510245|NCT00928083|DRUG|Placebo|
219510246|NCT00928083|DRUG|OZ439 200mg aqueous dispersion|
219510247|NCT00118053|BIOLOGICAL|herceptin|
219608835|NCT05239468|DRUG|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
219608836|NCT05239468|DRUG|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
219510248|NCT00118053|DRUG|carboplatin|
219510249|NCT00118053|DRUG|docetaxel|
219608837|NCT05239468|DRUG|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
219608838|NCT05239468|DRUG|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
219608839|NCT05239468|DRUG|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
219608840|NCT04876781|DRUG|Tofacitinib XR|Tofacitinib XR 11mg
219608841|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
219510250|NCT00118053|PROCEDURE|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
219510251|NCT00118053|PROCEDURE|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
219033890|NCT06244615|DEVICE|Verum (WO 6607)|Mouth and throat rinse and gargle solution
219033891|NCT06244615|DEVICE|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
219510252|NCT01601197|BEHAVIORAL|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
219510253|NCT00128453|DRUG|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily
219510254|NCT00128453|DRUG|Placebo|placebo
219510255|NCT00028665|BIOLOGICAL|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
219510256|NCT00028665|BIOLOGICAL|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
219510257|NCT00028665|DRUG|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
219510258|NCT00028665|DRUG|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
219510259|NCT00028665|DRUG|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
219203730|NCT04245085|DRUG|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
219203731|NCT04245085|DRUG|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
219510260|NCT00028665|DRUG|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
219510261|NCT00028665|PROCEDURE|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
219510262|NCT00028665|PROCEDURE|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
219510263|NCT00028665|RADIATION|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
219510264|NCT04338867|RADIATION|Whole-brain radiotherapy|Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
219510265|NCT00220701|DRUG|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
219510266|NCT01176448|DEVICE|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
219510267|NCT01176448|DEVICE|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
219510268|NCT02910609|DEVICE|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
218891054|NCT03958058|DRUG|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
218891055|NCT03958058|OTHER|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
218891056|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
219510269|NCT01003132|OTHER|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
219510270|NCT01345032|OTHER|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
219510271|NCT01345032|OTHER|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
219510272|NCT04365751|PROCEDURE|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
219510273|NCT02171533|DRUG|dabigatran|
218891057|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
218891058|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
218891059|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
218891060|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
218891061|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
218891062|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
218891063|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
218891064|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
219510274|NCT02171533|DRUG|Verapamil|
219510275|NCT02171533|DRUG|Verapamil ER|
219510276|NCT00138905|DEVICE|UMTS mobile basestation radiation|
219510277|NCT01586247|DIETARY_SUPPLEMENT|Synbiotic|8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis
219510278|NCT01586247|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
219510279|NCT01586247|DIETARY_SUPPLEMENT|Prebiotic|8g/day galacto-oligosaccharide
219510280|NCT01586247|DIETARY_SUPPLEMENT|Probiotic|10\^9 CFU/day B.lactis
219510281|NCT01199757|DRUG|Fluticasone furoate|cohort of patients receiving fluticasone furate
219510282|NCT01199757|DRUG|mometasone furoate|cohort receiving mometasone furoate
219510283|NCT01199757|DRUG|fluticasone propionate|cohort of patients on fluticasone propionate
219510284|NCT05665582|OTHER|Family program|A 4-day psychoeducational family program.
219510285|NCT00755326|DRUG|HLXL|Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
219510286|NCT03062566|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
219510287|NCT01102465|DRUG|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
219510288|NCT02140957|BEHAVIORAL|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
219510289|NCT04574310|OTHER|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
219510290|NCT04932733|OTHER|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
219510291|NCT04932733|OTHER|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
219510292|NCT03256968|DRUG|Ataluren|ataluren
219510293|NCT04954131|BIOLOGICAL|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
219510294|NCT04954131|OTHER|Placebo|Saline solution (0.9%)
219510295|NCT02076477|RADIATION|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
219510296|NCT02076477|DRUG|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
219510297|NCT02076477|DRUG|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
219510298|NCT02076477|DRUG|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
219510299|NCT02946164|BEHAVIORAL|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
219510300|NCT04711525|BEHAVIORAL|Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
219510301|NCT04711525|BEHAVIORAL|Control Group: Standard health education|The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
219510302|NCT04686136|DRUG|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
219510303|NCT04035590|PROCEDURE|No drain|Mastectomy with flap fixation without low vacuum drainage
219510304|NCT04035590|PROCEDURE|With drain|Mastectomy with flap fixation with low vacuum drainage
219510305|NCT04122274|BEHAVIORAL|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
219510306|NCT04122274|BEHAVIORAL|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
219510307|NCT04122274|BEHAVIORAL|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
219510308|NCT03551249|DEVICE|Focused ultrasound (FUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
219510309|NCT05713500|OTHER|TCI|Temperament and character inventory
219510310|NCT05713500|OTHER|BPI|Brief Pain Inventory
218891065|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
218891066|NCT00109824|DRUG|decitabine|Given IV
219203732|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
219510311|NCT05713500|OTHER|CPAQ-8|Chronic Pain Acceptance Questionnaire-8
219510312|NCT05713500|OTHER|SF-MPQ|short-form McGill Pain Questionnaire
219510313|NCT05713500|OTHER|King's Parkinson's Disease Pain Scale (KPPS)|King's Parkinson's Disease Pain Scale
219510314|NCT05713500|OTHER|Hospital Anxiety and Depression scale (HAD) questionary|Hospital Anxiety and Depression scale
219510315|NCT05713500|OTHER|PCS|Pain Catastrophism Scale
219510316|NCT05713500|OTHER|ORT|Opioid Risk Tool
219510317|NCT05713500|OTHER|Social Support Questionnaire (SSQ6)|Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)
219510318|NCT05713500|OTHER|IPQ-R|Illness Perception Questionnaire Revised
219510319|NCT05713500|OTHER|WCC-R|Ways of Coping Checklist Revised
219510320|NCT01480531|DRUG|Clevidipine|"Clevidipine administration begins in the ER or ICU~* Clevidipine is again administered post op when blood pressure control is required.~* Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~* Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~* Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~* Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
219510321|NCT01205607|DEVICE|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
218891067|NCT00109824|DRUG|valproic acid|Given PO
219203733|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
219510322|NCT01205607|DEVICE|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
219510323|NCT01699581|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
218891068|NCT00109824|OTHER|pharmacological study|Correlative studies
218891069|NCT00109824|OTHER|laboratory biomarker analysis|Correlative studies
218891070|NCT00021749|DRUG|Oblimerson sodium, G3139|
219510324|NCT05417048|DIAGNOSTIC_TEST|Blood Sample|Up to 5mL of blood via venipuncture
219510325|NCT00148915|DRUG|ibandronate|
219510326|NCT00148915|DRUG|Placebo|matching placebo
219510327|NCT03291509|BEHAVIORAL|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
219510328|NCT03291509|BEHAVIORAL|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
219510329|NCT03291509|BEHAVIORAL|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
219608853|NCT04677569|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes
218891071|NCT02832934|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
219510330|NCT03291509|BEHAVIORAL|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
219510331|NCT00003078|DRUG|cisplatin|
218891072|NCT02832934|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
218891073|NCT04301466|DRUG|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
218891074|NCT04301466|DRUG|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
218891075|NCT06151444|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
218891076|NCT06151444|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
218891077|NCT06518044|DRUG|N Acetyl L Cysteine|For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
219203734|NCT06761508|BEHAVIORAL|Intervention study for Arm one using video|A 3 Arm randomized control trial, using video as the first Arm of intervention to assess the behaviour change of the community in hypertension prevention.
219203735|NCT06761508|BEHAVIORAL|intervention 2:using infographics|A 3 Arm randomized control trial,that involves the use of infographics in Arm to assess the behaviour change of the community in hypertension prevention.
219510332|NCT00003078|DRUG|fluorouracil|
219510333|NCT00003078|RADIATION|brachytherapy|
219203736|NCT06761508|BEHAVIORAL|intervention 3: use of pamphlet|A 3 Arm randomized control trial,that contains the use of pamphlet for the 3rd Arm which is the control group to assess the behaviour change of the community in hypertension prevention.
219510334|NCT00003078|RADIATION|radiation therapy|
219510335|NCT04719000|DRUG|rhFSH+rhLH|300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
219510336|NCT04719000|DRUG|rhFSH|300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
219510337|NCT04469608|BEHAVIORAL|acupuncture|Traditional Chinese medicine clinical daycare
219510338|NCT00240682|DRUG|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
219510339|NCT03344367|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
219510340|NCT04041570|BIOLOGICAL|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
219510341|NCT02980848|OTHER|Screening digital mammography|Screening with digital mammography alone
219510342|NCT02980848|OTHER|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
219510343|NCT02980848|OTHER|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
219510344|NCT02980848|OTHER|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
219510345|NCT02980848|OTHER|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
218891078|NCT04348266|DEVICE|Radiofrequency ablation (RFA)|Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
218891079|NCT05177497|DRUG|SHR-1701|SHR-1701 administered by iv
219510346|NCT01697722|DRUG|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
219510347|NCT01697722|DRUG|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
219510348|NCT02185612|BEHAVIORAL|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
219510349|NCT03060005|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
219608854|NCT04677569|DRUG|Azithromycin|Oral tablet
219510350|NCT03060005|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
219510351|NCT03122002|DRUG|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
219510352|NCT03122002|DIAGNOSTIC_TEST|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
219510353|NCT03122002|OTHER|Intravascular therapy|Intravascular therapy including thrombectomy
219608855|NCT04677569|DRUG|Ethambutol|Oral tablet
219608856|NCT04677569|DRUG|ELC (matching placebo for ALIS)|Inhalation via nebulization over approximately 6 to 15 minutes
219608857|NCT05849259|OTHER|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) six modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
219608858|NCT06199921|DRUG|Atorvastatin 20mg|Participants will receive oral atorvastatin 20mg daily for 16 weeks
219608859|NCT06199921|DRUG|Atorvastatin 40mg|Participants will receive oral atorvastatin 40mg daily for 16 weeks
219608860|NCT06199921|DRUG|Atorvastatin 60mg|Participants will receive oral atorvastatin 60 mg daily for 16 weeks
219608861|NCT06199921|DRUG|Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)|Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid
219608862|NCT05910840|OTHER|Support-t|Support-t plus usual diabetes care for 18 months
218891080|NCT03378817|PROCEDURE|HOPE|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
219608863|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
218891081|NCT03378817|OTHER|Conventional cold storage|No intervention
219033892|NCT04922320|BEHAVIORAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
219510354|NCT03122002|OTHER|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
219510355|NCT03122002|OTHER|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
219510356|NCT01054508|DRUG|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
219510357|NCT00774358|DRUG|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
219510358|NCT03758365|DRUG|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219608864|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
218891082|NCT04713280|PROCEDURE|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
218891083|NCT05855772|DEVICE|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
219510359|NCT03758365|DRUG|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219510360|NCT03758365|DRUG|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219510361|NCT03758365|DRUG|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219608865|NCT04007562|DRUG|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
219608866|NCT06549179|DIAGNOSTIC_TEST|AMSE|Evaluation of the performance of the French-language AMSE tool used by non-expert psychiatrists and psychologists, trained in the tool, in the identification of ASD in adults.
219608867|NCT06295367|OTHER|Best Practice|Receive PAF brochure describing financial navigation services
219608868|NCT06295367|OTHER|Financial Navigation|Receive CostCOM financial counseling
219608869|NCT06295367|OTHER|Interview|Participate in a 1 on 1 in-depth interview
219608870|NCT06295367|OTHER|Survey Administration|Ancillary studies
219510362|NCT03758365|DRUG|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219510363|NCT03758365|DRUG|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
218891084|NCT05855772|BEHAVIORAL|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
219510364|NCT03758365|DRUG|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
219510365|NCT05825053|BEHAVIORAL|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
219510366|NCT05825053|BEHAVIORAL|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
218891085|NCT04550637|DRUG|Oral apixaban|apixaban (5 mg bid) is given until 12 weeks after surgery
218891086|NCT05617781|BEHAVIORAL|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
219510367|NCT06543836|DRUG|Sintilimab|Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
219510368|NCT06543836|DRUG|Fruquintinib or Regorafenib|"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
219510369|NCT06543836|DRUG|Fruquintinib|Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
219510370|NCT00261729|DRUG|Paroxetine|paroxetine 20 mg
219510371|NCT00261729|DRUG|Prazosin|Prazosin
219510372|NCT00261729|DRUG|placebo|placebo capsules
219510373|NCT02621515|DRUG|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
219510374|NCT03840746|OTHER|Tomato, onion and lovage soup (TOL)|Soup
219510375|NCT03840746|OTHER|TOL soup with inulin|Soup
219510376|NCT00268710|DRUG|docetaxel|
219510377|NCT03588390|DRUG|BI 1323495|Low strength tablet
219510378|NCT03588390|DRUG|BI 1323495|Middle strength tablet
219510379|NCT03588390|DRUG|BI 1323495|High strength tablet
219510380|NCT03588390|DRUG|Placebo|Placebo to low strength tablet
219510381|NCT03588390|DRUG|Placebo|Placebo to middle strength tablet
219510382|NCT03588390|DRUG|Placebo|Placebo to high strength tablet
219510383|NCT03980379|DRUG|304 injection|Monoclonal antibodies, 100mg/10ml per injection
219510384|NCT03980379|DRUG|rituximab injection|100mg/10ml per injection ，manufactured by Roche
219510385|NCT00603343|DRUG|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
219510386|NCT00603343|DRUG|placebo|placebo corresponding to body weight
219510387|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
219510388|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
218891087|NCT00100789|DRUG|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
218891088|NCT00100789|DRUG|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
219510389|NCT00384033|DRUG|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
219510390|NCT00384033|DRUG|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
218891089|NCT00080301|DRUG|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
218891090|NCT00080301|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
218891091|NCT03934567|DRUG|Abexinostat|Abexinostat tablets
218891092|NCT02518971|DRUG|Tamsulosin|0.4 mg daily
219510391|NCT03849365|DRUG|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
219510392|NCT02010723|PROCEDURE|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
219510393|NCT02010723|DRUG|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
219510394|NCT05333250|DRUG|Modafinil|Modafinil
219510395|NCT05333250|OTHER|Placebo|Placebo
219608871|NCT06850805|DRUG|OPN-375|OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
219608872|NCT06850805|DRUG|Placebo|Placebo solution administered via exhalation delivery system (EDS).
219608873|NCT05269004|DRUG|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
219608874|NCT05144256|DRUG|Mitapivat|Tablets or granules
219608875|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
219608876|NCT02498613|OTHER|18F-Fluoromisonidazole|Correlative studies
219608877|NCT02498613|DRUG|Cediranib Maleate|Given PO
219608878|NCT02498613|OTHER|Laboratory Biomarker Analysis|Correlative studies
219510396|NCT06318650|BIOLOGICAL|Demineralized Dentin Matrix|"preparation of Allogenic Demineralized Dentin Matrix: Extracted teeth will be collected from the Departments of oral maxillofacial surgery and periodontics, Cairo university. Cleaning the teeth from any caries, Filings, cement, tartar, soft tissue debris and prosthetic components will be performed using a diamond bur under abundant irrigation with physiological water. Then it will be proceeded to the following steps~1\. (Washing with Distilled water ) 2. (Quick Freezing with liquid nitrogen, then Grinding to particle size of 300- 800 μm). 3.(Ultrasonic Cleaning cycles, 1st with Distilled water , 2nd with 5-7% Hydrogen Perioxide then 3rd with Distilled water for at 60-80 o) 4. (Defatting with Chloroform Methanol Solution1:0.5. 5. (Demineralization with0.5N HCL) 6. (Dehydration with Neutral Ethyl Alcohol then Defatting with Chloroform Methanol Solution 1:0.5 for ) 7. (Washing with Normal Saline \& Freeze Drying then Sterilization using Ethylene oxide gas)."
219608879|NCT02498613|DRUG|Olaparib|Given PO
219608880|NCT02498613|PROCEDURE|Positron Emission Tomography|Correlative studies
219608881|NCT05920356|DRUG|Sotorasib|Oral administration
218891093|NCT02518971|DRUG|Placebo|one capsule daily
218891094|NCT06130241|PROCEDURE|sentinle lymphnode biopsy|intraoperative sentinle lymphnode biopsy
218891095|NCT06534008|BEHAVIORAL|12-week home-based exercise intervention|All participants will be given the same 12-week distance-based exercise intervention.
218891096|NCT02011100|DIETARY_SUPPLEMENT|Carnosine|
218891097|NCT02336230|DRUG|remestemcel-L|Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
218891098|NCT02524171|BEHAVIORAL|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
218891099|NCT06316349|OTHER|Isolated Resistance Training Program|The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.
219510397|NCT06318650|BIOLOGICAL|Demineralized freeze-dried bone allograft (DFDBA)|combination allograft, is a particulate bone graft combining 70% mineralized ground cortical with 30% demineralized ground cortical Particle sizing: 250 - 1000um.
218891100|NCT06316349|OTHER|Neuromuscular electrical stimulation|For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
218891101|NCT00704886|OTHER|video|video of dementia
218891102|NCT02781675|OTHER|Dietary Intervention|3 wk dietary intervention with prescribed menus and \~50% foods provided.
218891103|NCT02463279|DEVICE|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
218891104|NCT02535455|BEHAVIORAL|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
219510398|NCT01675908|PROCEDURE|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
219608882|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
219608883|NCT05168202|DRUG|CC-95251|Specified dose on specified days
219608884|NCT05168202|DRUG|Azacitidine|Specified dose on specified days
219608885|NCT05168202|DRUG|Venetoclax|Specified dose on specified days
218891105|NCT01933490|OTHER|high carbohydrate test meal|
218891106|NCT01933490|OTHER|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
219608886|NCT04696731|GENETIC|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
219608887|NCT04696731|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
218891107|NCT01933490|OTHER|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
218891108|NCT02669459|DRUG|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
218891109|NCT02669459|PROCEDURE|LLETZ|surgical treatment for CIN, current gold standard
218891110|NCT01314131|BEHAVIORAL|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
218891111|NCT02316080|OTHER|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
218891112|NCT02316080|OTHER|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
218891113|NCT00940901|DRUG|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
218891114|NCT00940901|OTHER|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
218891115|NCT03491826|BIOLOGICAL|rupture of membrane|
218891116|NCT05676307|BEHAVIORAL|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
219510399|NCT01675908|PROCEDURE|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
219510400|NCT06400849|DEVICE|cryotherapy alone of the upper or lower limbs|Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
219510401|NCT06400849|DEVICE|cryotherapy and crompression of the upper or lower limbs|Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
219510402|NCT00976235|DEVICE|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
219510403|NCT00974883|PROCEDURE|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
219510404|NCT00974883|PROCEDURE|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
219510405|NCT00290745|DRUG|letrozole|
219510406|NCT00290745|DRUG|tamoxifen citrate|
219510407|NCT00290745|PROCEDURE|conventional surgery|
219510408|NCT00290745|PROCEDURE|neoadjuvant therapy|
218891117|NCT00757237|DRUG|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
219510409|NCT02750306|DRUG|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
219510410|NCT02750306|DRUG|Placebo|Placebo to suvorexant
219510411|NCT01115218|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin C
219510412|NCT00942461|PROCEDURE|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
219510413|NCT00942461|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
219510414|NCT03787485|BEHAVIORAL|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
219510415|NCT03381547|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
219510416|NCT03969459|BIOLOGICAL|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
219510417|NCT03969459|BIOLOGICAL|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
219510418|NCT03969459|BIOLOGICAL|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
219510419|NCT03969459|OTHER|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
219510420|NCT01032395|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
219510421|NCT01032395|BIOLOGICAL|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
219510422|NCT01032395|BIOLOGICAL|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
219510423|NCT03960697|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
219510424|NCT04750005|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
219510425|NCT04750005|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
219510426|NCT04750005|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
219510427|NCT04750005|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
219510428|NCT02701478|DRUG|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
219510429|NCT01953497|DRUG|URC102|
219510430|NCT01953497|DRUG|Placebo|
219510431|NCT00992069|DRUG|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
219510432|NCT00992069|DRUG|TMC207|Single oral dose of 400 mg in the morning
219510433|NCT02318121|PROCEDURE|Amniotomy first|rupture of membranes to augment labor
219510434|NCT02318121|PROCEDURE|Oxytocin first|Administration of oxytocin to augment labor
219510435|NCT02318121|PROCEDURE|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
219510436|NCT02318121|DRUG|Oxytocin|
219510437|NCT03713138|DIETARY_SUPPLEMENT|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
219510438|NCT03090984|DEVICE|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
219510439|NCT03090984|DEVICE|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
219510440|NCT03090984|DEVICE|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
219510441|NCT01502618|BEHAVIORAL|Focus Group|N/A. Protocol is the focus group
219203737|NCT06746844|DEVICE|ViewMind Atlas™|The intervention involves the use of ViewMind Atlas™, a novel digital tool for cognitive assessment, and traditional cognitive tests. The ViewMind Atlas™ device evaluates cognitive performance through eye-tracking technology and advanced analytics, providing objective measurements of cognitive function. Traditional cognitive tests are used as the standard comparator to validate the device's diagnostic performance
219510442|NCT01689259|DRUG|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
219510443|NCT01689259|DRUG|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
219510444|NCT01689259|DRUG|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
219510445|NCT01689259|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
219510446|NCT05753384|DRUG|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
219608888|NCT04696731|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219608889|NCT04696731|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219510447|NCT02737306|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
219510448|NCT02737306|DRUG|Placebo|Placebo in parenteral solution.
219510449|NCT02806349|DIETARY_SUPPLEMENT|American Ginseng|herb
219510450|NCT02806349|DIETARY_SUPPLEMENT|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
219510451|NCT02806349|DIETARY_SUPPLEMENT|Control|Fiber matched control for intervention (corn starch and wheat bran)
219510452|NCT00297271|OTHER|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
219510453|NCT01524042|PROCEDURE|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
219510454|NCT03635853|DRUG|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
219510455|NCT01857193|DRUG|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
219608890|NCT04760353|DIETARY_SUPPLEMENT|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),
219608891|NCT04760353|OTHER|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
219510456|NCT01857193|DRUG|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
219510457|NCT01857193|DRUG|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
219510458|NCT04232397|DRUG|Anlotinib|anlotinib 8mg qd po
219510459|NCT03361423|DEVICE|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
219608892|NCT05239780|PROCEDURE|Brain stimulation|Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
219608893|NCT04546971|BEHAVIORAL|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
219608894|NCT04546971|BEHAVIORAL|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
219608895|NCT04546971|BEHAVIORAL|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
219510460|NCT03361423|DEVICE|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
219510461|NCT03263481|PROCEDURE|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
219510462|NCT00464750|DEVICE|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
219510463|NCT03147196|DRUG|Bicalutamide|Given PO
219510464|NCT03147196|OTHER|Laboratory Biomarker Analysis|Correlative studies
219510465|NCT03147196|OTHER|Questionnaire Administration|Ancillary studies
219608896|NCT05057234|DIAGNOSTIC_TEST|FoundationOne liquid CDx|FoundationOne liquid CDx testing
219608897|NCT05057234|BEHAVIORAL|Quality of life questionnaires|Quality of life questionnaire - EQ5D
219608898|NCT06963112|DRUG|Midazolam|The intervention group patients were given 2mg midazolam injection (Jiangsu Enhua Pharmaceutical Co., Ltd.) during anesthesia induction
219608899|NCT06963112|DRUG|Saline|The control group patients were given 2 mL physiological saline.
219608900|NCT05109611|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
219608901|NCT05109611|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
218891118|NCT00757237|DRUG|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
218891119|NCT01534000|PROCEDURE|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
218891120|NCT03534102|DRUG|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
218891121|NCT03534102|BEHAVIORAL|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
218891122|NCT04977284|DEVICE|DS7R, Digitimer, UK|Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
219510466|NCT03147196|DRUG|Raloxifene Hydrochloride|Given PO
219510467|NCT04459195|BEHAVIORAL|2 Minute Static Stretching|Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
219510468|NCT04459195|BEHAVIORAL|5 Minute Static Stretching|Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
219510469|NCT01336894|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219510470|NCT01336894|RADIATION|iodine I 125|Undergo seed implant radiotherapy
219510471|NCT01336894|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
219510472|NCT03821220|BEHAVIORAL|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
219510473|NCT03821220|BEHAVIORAL|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
219608902|NCT02557438|PROCEDURE|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
219608903|NCT02557438|PROCEDURE|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
219608904|NCT05081024|PROCEDURE|Biopsy|Undergo biopsy
219608905|NCT05081024|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or tissue samples
219608906|NCT05081024|OTHER|Electronic Health Record Review|Medical records are reviewed
218891123|NCT03738488|DEVICE|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
219510474|NCT03821220|BEHAVIORAL|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
219510475|NCT04642573|OTHER|non interventional|non interventional
219510476|NCT01171066|DEVICE|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
219510477|NCT05673668|DEVICE|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
219510478|NCT00421096|DRUG|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
219510479|NCT00421096|PROCEDURE|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
219510480|NCT00421096|DRUG|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
219510481|NCT00622908|DRUG|ISV-403|0.6% TID, 5 days
219510482|NCT00622908|DRUG|Vehicle|Vehicle of ISV-403 TID, 5 days
219510483|NCT03937466|DEVICE|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
219510484|NCT01987622|PROCEDURE|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
219510485|NCT01987622|PROCEDURE|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
219510486|NCT03658135|DRUG|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
219510487|NCT03658135|OTHER|Placebo|Inactive ingredient
219510488|NCT05528458|DRUG|Osimertinib 80Mg Tab|Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
219510489|NCT06152913|BEHAVIORAL|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
219510490|NCT00113490|BIOLOGICAL|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
219510491|NCT00113490|BIOLOGICAL|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
219510492|NCT04837053|OTHER|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
219510493|NCT04837053|OTHER|Routine care|Care as usual within the included study sites.
219510494|NCT02310477|DRUG|regorafenib|regorafenib for all groups
219510495|NCT03982966|DIETARY_SUPPLEMENT|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
219510496|NCT01253720|BEHAVIORAL|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
219510497|NCT03915938|DRUG|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
219510498|NCT03915938|DRUG|Placebo|Administered in an identical way than ketamine.
219510499|NCT01776281|BEHAVIORAL|Kangaroo Mother Care|
219510500|NCT01776281|BEHAVIORAL|Standard Care|
219510501|NCT06109558|DRUG|LMV-12(HE003)|1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
219510502|NCT03467334|DIETARY_SUPPLEMENT|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
219510503|NCT03467334|DIETARY_SUPPLEMENT|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
219608907|NCT06389396|DEVICE|CP362 Test Catheter|The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
219608908|NCT01002495|BIOLOGICAL|VM202|Endocardial injections on Day 0.
219510504|NCT03467334|DRUG|Simethicone 20 MG|Standard treatment for infant colic
219510505|NCT06057519|DRUG|Optimised dose rifampicin|Optimized dose of rifampicin
219510506|NCT06057519|DRUG|Standard dose rifampicin|Standard dose rifampicin
219510507|NCT02162758|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules
219510508|NCT02162758|DRUG|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
219510509|NCT03336541|DRUG|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
219510510|NCT03336541|DRUG|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
219510511|NCT02462538|DRUG|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
219510512|NCT02462538|DRUG|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
219510513|NCT04471935|DEVICE|At home Speech Hero therapy app|Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
219510514|NCT03356613|OTHER|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
219608909|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
219608910|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
219608911|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
218891124|NCT03738488|OTHER|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
219510515|NCT03356613|OTHER|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
219510516|NCT06274606|OTHER|Exercise Group|Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
219510517|NCT02368613|DRUG|DW-3102|
219510518|NCT05040685|PROCEDURE|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
219510519|NCT05343156|DRUG|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
219510520|NCT04886115|OTHER|Neuromuscular evaluation|"Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump"
219510521|NCT04886115|OTHER|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~\- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
219608912|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
219608913|NCT06168578|DEVICE|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
219608914|NCT06195930|DRUG|Vericiguat (BAY1021189) 5 mg|Vericiguat (BAY1021189) will be taken as 5 mg tablet 1x daily over at least 14 days up to 18 days (+ 4 days time window allowed)
218891125|NCT02718729|PROCEDURE|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
219510522|NCT04886115|OTHER|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
219510523|NCT04886115|OTHER|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
219510524|NCT04886115|OTHER|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
219510525|NCT03065309|DRUG|Remifentanil|bolus dose
219510526|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)"
219510527|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient & soy protein supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)"
218891126|NCT04995575|PROCEDURE|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
218891127|NCT06175481|OTHER|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
218891128|NCT04579640|DIETARY_SUPPLEMENT|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
218891129|NCT06383806|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
218891130|NCT02058446|DRUG|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
219203738|NCT06757972|COMBINATION_PRODUCT|Tele Rehab|Tele rehabilitation intervention is 6 months standardized program aimed to provide special rehabilitation services to patients with mobility impairments in rural areas without the need for them to travel to healthcare facility in big cities. The program consists of standard exercises addressing key components of mobility impairments.
219608915|NCT05506683|OTHER|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
219608916|NCT06256588|DRUG|Dostarlimab|Dostarlimab will be administered as an intravenous (IV) infusion
218891131|NCT01646086|BEHAVIORAL|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
219033893|NCT04922320|OTHER|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
219033894|NCT02121483|DRUG|empagliflozin medium dose|
219033895|NCT02121483|DRUG|empagliflozin high dose|
219033896|NCT02121483|DRUG|empagliflozin low dose|
219203739|NCT06757972|DIAGNOSTIC_TEST|Formal Rehab|After formal rehabilitation is completed, some impaired mobility victims re-access services; no attempt will be made to stop the control group from accessing further care, in either a public or private setting. However, physical activity participation will be assured during monthly phone call by a blinded -research assistant. Participants in this group will undergo three assessments at baseline, 6 and 12 months
219608917|NCT06256588|DRUG|Placebo|Placebo will be administered as an IV infusion
219608918|NCT04995029|DRUG|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
219608919|NCT04995029|DRUG|Extended-release Buprenorphine|Administered by subcutaneous injection
219033897|NCT05292560|OTHER|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
219033898|NCT00385528|BEHAVIORAL|Multi-faceted psychiatric intervention|
219608920|NCT06075537|DRUG|tividenofusp alfa|Intravenous repeating dose
219033899|NCT04924036|DRUG|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
219033900|NCT04924036|DRUG|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
219033901|NCT05738941|PROCEDURE|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
219033902|NCT05738941|PROCEDURE|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~\- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
219033903|NCT05447364|DRUG|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
219033904|NCT05447364|DRUG|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
219510528|NCT02975089|DIETARY_SUPPLEMENT|Nutrition education on balanced diet & food supplement|"1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)"
219608921|NCT05453461|DIAGNOSTIC_TEST|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
219613377|NCT05596110|BEHAVIORAL|KT and sham TENS|KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
219613378|NCT05596110|BEHAVIORAL|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
219613379|NCT01723800|DRUG|PI3K inhibitor BKM120|Given PO
219613380|NCT01723800|DRUG|pemetrexed disodium|Given IV
219613381|NCT01723800|DRUG|carboplatin|Given IV
219613382|NCT01723800|OTHER|laboratory biomarker analysis|Correlative studies
219613383|NCT01723800|OTHER|pharmacological study|Correlative studies
219033905|NCT01816828|BEHAVIORAL|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
219033906|NCT01816828|OTHER|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
219510529|NCT02397070|PROCEDURE|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
219510530|NCT02397070|DEVICE|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
219510531|NCT06483659|DRUG|Oxytocin|Intravenous Oxytocin infusion
219510532|NCT06483659|DRUG|Placebo|0.9% Saline
219510533|NCT00526578|BEHAVIORAL|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
219510534|NCT02730715|DRUG|Basiliximab|Periodic blood collection to monitor Treg cells
219510535|NCT02730715|DRUG|Thymoglobulin|Periodic blood collection to monitor Treg cells
219510536|NCT05945199|DEVICE|tDCS|"* 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group"
219510537|NCT05945199|BEHAVIORAL|Assessment of risk behaviours|Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
219510538|NCT05945199|OTHER|Scales|EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
219608922|NCT03708302|PROCEDURE|Unilateral serratus plane block|Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
219033907|NCT04127916|DRUG|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
219608923|NCT03708302|PROCEDURE|Unilateral parasternal infrapectoral block|"Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration."
219608924|NCT05407636|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
219608925|NCT05407636|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
219033908|NCT01420289|DEVICE|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
219033909|NCT01420289|BEHAVIORAL|Excercise|Treadmill walking 45 minutes once daily
219033910|NCT01360658|DRUG|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
219033911|NCT05655611|OTHER|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
219510539|NCT01409044|OTHER|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
219510540|NCT01303562|OTHER|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
219510541|NCT02846948|OTHER|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
219510542|NCT02044172|PROCEDURE|Radical prostatectomy|radical prostatectomy
219510543|NCT02044172|RADIATION|Conformal radiation therapy|Conformal radiation therapy, external beam
219510544|NCT02044172|OTHER|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
219510545|NCT03213210|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
219510546|NCT04582396|PROCEDURE|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
219510547|NCT04582396|PROCEDURE|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
219510548|NCT04582396|BEHAVIORAL|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
219510549|NCT02510716|BEHAVIORAL|SGR|
219510550|NCT02510716|BEHAVIORAL|Support message only|
219510551|NCT02521441|BIOLOGICAL|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
219510552|NCT02521441|BIOLOGICAL|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
219510553|NCT01650324|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
219510554|NCT01650324|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
219510555|NCT01333241|BEHAVIORAL|Lifestyle behavior interventon grop|
219510556|NCT01333241|OTHER|Placebo Comparator: Control group|
219510557|NCT05042141|DIETARY_SUPPLEMENT|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
219510558|NCT05042141|DIETARY_SUPPLEMENT|Placebo oral capsule|Placebo
219510559|NCT00648518|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
219608926|NCT05407636|BIOLOGICAL|Aflibercept (EYLEA®)|2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections
219608927|NCT06276010|DRUG|nafamostat mesilate|Use nafamostat mesilate as an anticoagulant
219608928|NCT06276010|DRUG|unfractionated heparin group|Use unfractionated heparin as an anticoagulant
219608929|NCT03915652|BEHAVIORAL|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
219033912|NCT05655611|OTHER|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
219033913|NCT02089061|DRUG|BMS-919373|
219033914|NCT02089061|DRUG|Rosuvastatin|
219033915|NCT02089061|DRUG|Atorvastatin|
219510560|NCT00648518|DRUG|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
219510561|NCT02407379|PROCEDURE|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
219510562|NCT02407379|PROCEDURE|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
219510563|NCT01325207|RADIATION|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
219510564|NCT06090656|DRUG|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
219608930|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
219608931|NCT05478239|DRUG|ArtemiCoffee|3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
219613384|NCT01723800|PROCEDURE|quality-of-life assessment|Ancillary studies
219033916|NCT03790826|DEVICE|cystoscopy|Comparison of bladder mucosa via cystoscopy.
219033917|NCT05804383|DRUG|BMS-984923|Capsules
219033918|NCT05804383|DRUG|Placebo|Capsules
218891132|NCT05450094|BEHAVIORAL|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
218891133|NCT05450094|BEHAVIORAL|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically-based implementation supports, including training, coaching, and data-based feedback. Enhancement aim to increase school teams' awareness and understanding of students' mental health well-being and need for intervention. enhancements.
219033919|NCT02286193|BEHAVIORAL|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
219033920|NCT02204891|DIETARY_SUPPLEMENT|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
219510565|NCT06090656|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
219510566|NCT00181922|DRUG|ziprasidone (Geodon)|
219510567|NCT00708422|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
219510568|NCT00708422|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
219510569|NCT00336310|DRUG|Repaglinide|
219510570|NCT00915057|DRUG|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
219510571|NCT06485024|DEVICE|Modeling Resin|it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
219510572|NCT04626999|PROCEDURE|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
219510573|NCT04626999|PROCEDURE|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
219510574|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
219510575|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
219510576|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
219510577|NCT04212039|DRUG|Saline Solution|0.5 ml/kg saline
219510578|NCT04212039|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
219510579|NCT04998409|DEVICE|Monofocal lens|not applicable as patients are already implanted with the monofocal lens
219510580|NCT01254409|BIOLOGICAL|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
219510581|NCT01254409|OTHER|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
219510582|NCT03530956|DEVICE|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
219510583|NCT01775020|DIETARY_SUPPLEMENT|L-arginine|
219510584|NCT02241603|BEHAVIORAL|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
219510585|NCT02053532|PROCEDURE|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
219510586|NCT02297009|PROCEDURE|Buccal swab|Buccal swabs will be taken from the volunteers
219510587|NCT01654107|BEHAVIORAL|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
219510588|NCT01654107|BEHAVIORAL|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
219510589|NCT01654107|DRUG|Nicotine lozenge|12-weeks 4mg nicotine lozenge
219510590|NCT02744183|BEHAVIORAL|Exercise|Moderate intensity exercise
219033921|NCT02204891|DIETARY_SUPPLEMENT|Probiotics|One capsule twice daily for 30 days
219510591|NCT02744183|BEHAVIORAL|Breakfast|Breakfast consumption
219510592|NCT02744183|BEHAVIORAL|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
219510593|NCT04089709|BEHAVIORAL|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
219510594|NCT00299156|DRUG|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
219510595|NCT00427128|DRUG|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
219510596|NCT00427128|DRUG|placebo|Week 13-36.
219510597|NCT05307861|DEVICE|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
219510598|NCT05307861|DEVICE|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
218891134|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
218891135|NCT05889676|DIAGNOSTIC_TEST|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
219033922|NCT01041872|DRUG|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
219033923|NCT01041872|DRUG|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
219033924|NCT01041872|DRUG|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
219510599|NCT00493571|DRUG|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
219510600|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
219510601|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
219510602|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
219510603|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
219510604|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
219510605|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
219510606|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
219510607|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
219510608|NCT00638365|BIOLOGICAL|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
219510609|NCT00638365|OTHER|Placebo|Placebo single-dose administered intravenously
219510610|NCT06546215|DRUG|Digoxin|Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
219510611|NCT01491620|DEVICE|532 nm KTP laser|Laser treatment sessions on the neck and/or chest
219510612|NCT05538884|PROCEDURE|Intertransverse process block|The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
219608932|NCT04569734|PROCEDURE|WATCHMAN device implant procedure utilizing ICE probe|The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
219608933|NCT03196843|DRUG|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
219033925|NCT01041872|DRUG|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
219510613|NCT03749265|OTHER|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
219510614|NCT06485895|DIAGNOSTIC_TEST|test IGRA|BLOOD SAMPLES
219608934|NCT03196843|RADIATION|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
219510615|NCT06485895|DIAGNOSTIC_TEST|TEST QUATIFERON TB Gold Plus|BLOOD SAMPLES
219510616|NCT00946257|DRUG|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
219510617|NCT03516383|DEVICE|PWVi|
219510618|NCT00996671|DRUG|GSK2256098|focal adhesion kinase inhibitor given as a single dose
219510619|NCT00996671|DRUG|Placebo|Placebo to be used as comparator for GSK2256098
219510620|NCT01720082|PROCEDURE|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
219510621|NCT01720082|PROCEDURE|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
219510622|NCT02101632|DIETARY_SUPPLEMENT|Bee Venom Ointment|2 weeks
219510623|NCT02101632|OTHER|Vaseline Ointment|2 weeks
219608935|NCT04814095|BEHAVIORAL|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
219608936|NCT04814095|DIAGNOSTIC_TEST|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
218891136|NCT05150990|BEHAVIORAL|Virtual Reality|Older adults (residents of senior living communities) engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children participate remotely from their own homes.
219033926|NCT01041872|DRUG|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
219033927|NCT01041872|DRUG|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
219033928|NCT03881137|OTHER|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
219510624|NCT01505257|BEHAVIORAL|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
219033929|NCT02646579|PROCEDURE|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
219510625|NCT01575522|OTHER|Laboratory Biomarker Analysis|Correlative studies
219510626|NCT01575522|DRUG|Tivantinib|Given PO
219510627|NCT05894161|OTHER|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day."
219510628|NCT05933005|DEVICE|D-kit/EF1|"D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills."
219510629|NCT05933005|DEVICE|Sham group program|The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
219510630|NCT04132661|DRUG|Bisacodyl 5 milligram|one single dose
219510631|NCT04132661|DRUG|Placebo oral tablet|one single dose
219608937|NCT03767660|DRUG|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
219033930|NCT02646579|PROCEDURE|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
219033931|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
219033932|NCT02639481|BEHAVIORAL|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
219510632|NCT05129579|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
219510633|NCT05129579|OTHER|no intervention|No intervention will be made in the control group.
219510634|NCT03308019|DEVICE|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
219608938|NCT04279210|DEVICE|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
219608939|NCT00865761|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
219608940|NCT00865761|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
219608941|NCT04850339|BIOLOGICAL|ANXV|Intravenous infusion
219608942|NCT04850339|OTHER|Placebo|Intravenous infusion
219608943|NCT04314453|OTHER|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
219608944|NCT03649672|DEVICE|TOF Watch SX|Neuromuscular monitoring via the TOF Watch SX device
219033933|NCT02639481|DEVICE|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
219510635|NCT03308019|PROCEDURE|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
219510636|NCT04919928|DEVICE|Cochlear Implant and Hearing aid in bimodal solution|"Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear."
219510637|NCT04919928|DEVICE|Bilateral hearing aids|Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
219510638|NCT05300932|DRUG|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
219510639|NCT05300932|DRUG|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
219510640|NCT04172298|OTHER|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
219510641|NCT04172298|OTHER|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
219510642|NCT04172298|OTHER|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
219510643|NCT00143156|DRUG|pregabalin|
219510644|NCT04168476|OTHER|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
219510645|NCT04168476|OTHER|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
219510646|NCT03101943|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
219510647|NCT03101943|OTHER|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
219608945|NCT06383494|DEVICE|LMA supreme group|Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia
219608946|NCT06383494|DEVICE|I-gel group|Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia
219608947|NCT06383494|DEVICE|GMA-Tulip|Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
218891137|NCT05150990|BEHAVIORAL|Video Chat|Older adults (residents of senior living communities) engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children participate remotely from their own homes.
218891138|NCT05256966|OTHER|Sauna (steam)|Steam Sauna
218891139|NCT00466921|DRUG|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
218891140|NCT03940300|DIETARY_SUPPLEMENT|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
218891141|NCT05026359|DEVICE|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
218891142|NCT00644020|DRUG|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
218891143|NCT02773485|RADIATION|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
218891144|NCT02773485|DRUG|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
218891145|NCT05782062|DEVICE|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
218891146|NCT05782062|DEVICE|Balloon|Use of balloon for disrupting thrombus.
219510648|NCT03101943|OTHER|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
218891147|NCT05567250|BEHAVIORAL|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
218891148|NCT02698514|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
218891149|NCT02698514|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
218891150|NCT04007016|PROCEDURE|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
218891151|NCT01100320|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
218891152|NCT01100320|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
218891153|NCT04036981|DRUG|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
218891154|NCT01418430|DRUG|CHOP-daclizumab|
218891155|NCT05956899|DRUG|Palonosetron|IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia
218891156|NCT05956899|DRUG|Ondansetron|IV ondansetron 0.15mg/kg at the start of wound closure
218891157|NCT05993923|OTHER|GPOU|"Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report"
218891158|NCT03797586|OTHER|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
218891159|NCT03797586|OTHER|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
219033934|NCT02639481|DEVICE|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
219033935|NCT01492452|OTHER|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
219033936|NCT00003724|PROCEDURE|surgical procedure|
219033937|NCT02507414|OTHER|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
219033938|NCT02507414|OTHER|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
219033939|NCT02507414|OTHER|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
219033940|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
219510649|NCT01994603|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
218891160|NCT03028610|DEVICE|radiofrequency generator|
218891161|NCT06562127|BEHAVIORAL|TRAIN-Vets|The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in personalized risk factor reduction sessions based at SFVAHCS focused on other risk factors and symptoms.
218891162|NCT06562127|BEHAVIORAL|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and dementia risk factor reduction over 8 months, as well as regular contact with study staff.
218891163|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
218891164|NCT04678414|OTHER|Survey Administration|Complete survey
218891165|NCT03534193|OTHER|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
218891166|NCT03534193|OTHER|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
218891167|NCT04002947|DRUG|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
218891168|NCT04002947|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
219510650|NCT01994603|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
219510651|NCT01392898|DRUG|liraglutide|liraglutide 1.8 mg q.d.
219510652|NCT01392898|DRUG|Insulin|insulin dosed according titration scheme
219608948|NCT01323400|DRUG|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
219608949|NCT01323400|OTHER|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
219608950|NCT05089383|DRUG|Utrogestan|PROSPECTIVE STUDY
219608951|NCT03485560|COMBINATION_PRODUCT|ACE CSD|Topical application of the ACE CSD 4 times daily.
218891169|NCT04002947|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
218891170|NCT04002947|DRUG|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
218891171|NCT06493734|RADIATION|Stereotactic body radiation therapy|SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
218891172|NCT05708001|DEVICE|transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
219033941|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
219510653|NCT01564758|DRUG|Linezolid|"1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
219510654|NCT04383990|OTHER|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
219510655|NCT03935659|DEVICE|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
219510656|NCT03935659|PROCEDURE|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
219510657|NCT02588625|DRUG|BMS-986020|
219510658|NCT02588625|OTHER|Placebo|
219510659|NCT02424981|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
219510660|NCT01236833|DRUG|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
219510661|NCT05265195|OTHER|Mixed Methods study|Mixed Methods study
219608952|NCT05541081|DIAGNOSTIC_TEST|Point-of-care STI testing|"Testing for:~* Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~* Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~* HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~* Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)"
219608953|NCT01593774|DRUG|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
219608954|NCT01593774|DRUG|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
219608955|NCT06118801|DIETARY_SUPPLEMENT|Probiotic Product Supplement|Mothers of preterm babies who feed their babies only with breast milk will be given a probiotic product supplement once a day (80 ml probiotic product support containing the Actregularis (5×106 CFU\\mL) (lactobacillus bulgaricus, streptococcus thermophilus, lactococcus lactis and bifidobacterium lactis) strain)
219510662|NCT02482571|DEVICE|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
218891173|NCT05708001|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
219203740|NCT05002439|OTHER|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
219203741|NCT06748586|DEVICE|Hyperbaric Oxygen Therapy|The HBOT protocol is 90 minutes, 5 times/week, for at least 40 sessions, 100% oxygen at 2 ATA with five-minute air breaks every 20 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel.
219510663|NCT00685971|DIETARY_SUPPLEMENT|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
219510664|NCT00685971|DIETARY_SUPPLEMENT|placebo|5 drops once daily for 12 weeks
219510665|NCT00927121|DEVICE|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
219510666|NCT01599208|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
219510667|NCT04429451|BIOLOGICAL|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
219510668|NCT00065858|DRUG|BufferGel|
219510669|NCT01446913|DEVICE|Standard CPAP Intervention|
219510670|NCT01446913|BEHAVIORAL|Enhanced CPAP Intervention|
218891174|NCT05708001|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
218891175|NCT01884896|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
218891176|NCT01884896|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
219203742|NCT06759870|OTHER|Collection of saliva|An unstimulated saliva sample will be obtained for 1 minute before implant surgery and immediately after implant surgery.
219203743|NCT06759870|OTHER|Collection of gingival samples|Gingival samples will be obtained by punch biopsy 3 months after implant surgery.
219203744|NCT06759870|OTHER|ISQ registration|ISQ value will be record in placement dental implant.
219510671|NCT05744609|OTHER|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
219510672|NCT03772483|PROCEDURE|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
219613385|NCT04113161|OTHER|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
218891181|NCT02876107|DRUG|Carboplatin|Given IV
218891182|NCT02876107|OTHER|Laboratory Biomarker Analysis|Correlative studies
218891183|NCT02876107|DRUG|Paclitaxel|Given IV
218891184|NCT02876107|BIOLOGICAL|Panitumumab|Given IV
218891186|NCT05132218|DRUG|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
218891187|NCT04477577|BEHAVIORAL|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
218891188|NCT04477577|BEHAVIORAL|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
218891189|NCT00820469|DRUG|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
218891190|NCT00820469|DRUG|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
218891191|NCT04355546|OTHER|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
218891192|NCT05175586|DIAGNOSTIC_TEST|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
218891193|NCT05175586|PROCEDURE|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
219510673|NCT03772483|DEVICE|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
219510674|NCT04588428|DRUG|INO-4700|INO-4700 was administered ID.
219510675|NCT04588428|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
219510676|NCT04588428|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device was administered following ID drug administration
219510677|NCT03561506|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
219510678|NCT03561506|DRUG|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
219510679|NCT03708861|DRUG|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
219510680|NCT06102967|BEHAVIORAL|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
219510681|NCT02130206|OTHER|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
219510682|NCT02130206|OTHER|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
219510683|NCT02130206|OTHER|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
218891194|NCT05175586|OTHER|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
219203745|NCT06825013|DRUG|Bronchodilators inhalation|Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)
219203746|NCT06825013|DRUG|Placebo|Nebulized saline
219203747|NCT05758766|DIETARY_SUPPLEMENT|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
219203748|NCT06808438|DEVICE|Esophageal pressure catheter|Esophageal pressure was monitored with an esophageal pressure catheter
219203749|NCT06841744|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercises will be performed twice a day, completing 3 sets of 10 repetitions, 5 days a week for 6 weeks, as instructed by the researcher physiotherapist.
219510684|NCT02130206|OTHER|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
219510685|NCT05359432|DRUG|Empagliflozin|Receiving allocated drug dosage as per clinical needs
219510686|NCT05359432|DRUG|Vildagliptin|Receiving allocated drug dosage as per clinical needs
219510687|NCT00745251|DRUG|VI-0521|15 mg Phentermine and 92 mg Topiramate
219510688|NCT00745251|DRUG|placebo|placebo
219510689|NCT04523142|DRUG|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
219510690|NCT04780503|DIAGNOSTIC_TEST|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
219510691|NCT00162604|DRUG|Cefuroxime|
219510692|NCT02687477|PROCEDURE|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
219510693|NCT02687477|PROCEDURE|Sham procedure|patient in the sham group will receive sham procedure
219510694|NCT02382471|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
219510695|NCT02382471|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
219510696|NCT04890275|OTHER|Blood flow restricted resistance exercise (BFR)|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
219510697|NCT04890275|OTHER|Resistance exercise without blood flow restricted (NON-BFR)|Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
219033942|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
219033943|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
219033944|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
219033945|NCT05956769|DRUG|Placebo|Normal saline injection
219510698|NCT03246698|OTHER|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
219510699|NCT03246698|OTHER|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
219510700|NCT03246698|OTHER|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
219510701|NCT01618305|DRUG|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
219510702|NCT01618305|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
219510703|NCT01618305|DRUG|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
219608956|NCT02655913|DRUG|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
219608957|NCT02655913|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
219033946|NCT02781103|OTHER|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
219033947|NCT02781103|OTHER|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
219033948|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
219510704|NCT01106872|DRUG|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
219510705|NCT06057298|PROCEDURE|Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)|"Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model:~* Oxaliplatin 360 mg/mq for 30 min.~* Oxaliplatin 200 mg/mq for 120 min.~* Mitomycin-C 35mg/mq for 60 min.~* Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)"
219510706|NCT05494905|OTHER|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
219510707|NCT05494905|OTHER|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
219510708|NCT02708277|DEVICE|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
219608958|NCT02655913|OTHER|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
219608959|NCT05202314|DRUG|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
218891195|NCT01499966|PROCEDURE|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
218891196|NCT06427473|BEHAVIORAL|Dietary program|Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.
219510709|NCT02708277|DEVICE|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
219510710|NCT01960816|DEVICE|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
219510711|NCT00030173|DRUG|Epothilone D (KOS-862)|
219510712|NCT02730065|BEHAVIORAL|Structured Aerobic Dance Training Group|Systematic physical activity
219608960|NCT00077207|DRUG|carboplatin|Given IV
219608961|NCT00077207|DRUG|temozolomide|Given orally
219608962|NCT00077207|DRUG|vincristine sulfate|Given IV
219608963|NCT05809960|OTHER|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
219608964|NCT05809960|OTHER|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
219608965|NCT05128825|DRUG|azenosertib|Azenosertib (ZN-c3) will be administered orally.
219608966|NCT05067283|DRUG|MK-1084|Oral dose
219608967|NCT05067283|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
219608968|NCT05067283|DRUG|carboplatin|Per label
219608969|NCT05067283|DRUG|pemetrexed|Per label
219608970|NCT05067283|BIOLOGICAL|cetuximab|Per label
219033949|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
219608971|NCT05067283|DRUG|oxaliplatin|Per label
219608972|NCT05067283|DRUG|leucovorin|Per label
219608973|NCT05067283|DRUG|5-fluorouracil|Per label
219033950|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
219510713|NCT02730065|BEHAVIORAL|Stretching plus education|Weekly group based stretching with psychoeducation and health education
219608974|NCT06290934|DRUG|GS-1427|Administered orally
218891197|NCT06427473|BEHAVIORAL|Exercise program|Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.
218891198|NCT06427473|BEHAVIORAL|Mindfulness program|Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
218891199|NCT01147055|DRUG|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
219510714|NCT05660057|DEVICE|New computer monitor|The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.
219510715|NCT04895410|BIOLOGICAL|Lemzoparlimab|Intravenous (IV) infusion
219510716|NCT04895410|DRUG|Dexamethasone|Oral tablet or IV infusion/injection
219510717|NCT04895410|DRUG|Carfilzomib|IV infusion
219608975|NCT06290934|DRUG|Placebo-to-match GS-1427|Administered orally
219608976|NCT06383390|DRUG|Retatrutide|Administered SC
219608977|NCT06383390|DRUG|Placebo|Administered SC
219608978|NCT02562118|DRUG|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
219033951|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
219510718|NCT04895410|DRUG|Pomalidomide|Oral capsule
219510719|NCT04895410|BIOLOGICAL|Daratumumab|Subcutaneous (SC) injection
218891200|NCT01147055|DRUG|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
219510720|NCT01118728|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218891201|NCT01147055|DRUG|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
219510721|NCT00408733|OTHER|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
219510722|NCT01591031|DRUG|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
219510723|NCT01591031|DRUG|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
219510724|NCT01026688|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
219510725|NCT01026688|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
219510726|NCT02417090|DRUG|Insulin|Pregnant women who used insulin to treat gestational diabetes
219510727|NCT02417090|DRUG|Metformin|Pregnant women who used metformin to treat gestational diabetes
219510728|NCT04898985|DIAGNOSTIC_TEST|ImmunoSEQ|experiment assay
219510729|NCT03665571|DIAGNOSTIC_TEST|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
219510730|NCT05778149|DRUG|Aumolertinib,Anlotinib|Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
219608979|NCT03969329|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
219608980|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219608981|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
219608982|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
219608983|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
219608984|NCT05930496|OTHER|Interview|Ancillary studies
218891202|NCT02672462|DEVICE|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
218891203|NCT02848807|DIETARY_SUPPLEMENT|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
218891204|NCT05237323|DRUG|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
218891205|NCT05237323|DRUG|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
218891206|NCT06108128|OTHER|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
218891207|NCT00604630|DRUG|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
218891208|NCT00604630|DRUG|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
218891209|NCT05711121|PROCEDURE|Transforaminal epidural steroid injection|Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
218891210|NCT05711121|PROCEDURE|Caudal epidural steroid injection|Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
218891211|NCT04320784|OTHER|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
218891212|NCT04320784|OTHER|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
218891213|NCT02728453|DRUG|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
218891214|NCT02728453|DRUG|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
219510731|NCT00274209|PROCEDURE|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
219510732|NCT04083339|DRUG|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
219608985|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
219608986|NCT05806567|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
219608987|NCT05806567|DRUG|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
219608988|NCT05806567|DRUG|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
219608989|NCT05806567|DRUG|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
218891215|NCT02276703|DEVICE|Skin Conductance Monitor|monitors skin conductance values
218891216|NCT03015324|DRUG|Hydroxychloroquine|Hydroxychloroquine
219510733|NCT04083339|DRUG|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
219510734|NCT03336983|DRUG|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
219510735|NCT03336983|DRUG|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
219510736|NCT00385541|DRUG|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
219510737|NCT00385541|DRUG|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
219510738|NCT03414164|DIETARY_SUPPLEMENT|procyanidine|natural antioxidants
219510739|NCT00929708|DRUG|AZD3199|Dry powder for inhalation, o.d., 4 weeks
219510740|NCT00929708|DRUG|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
218891217|NCT06965725|DEVICE|Annuloplasy ring sizing device|A single time use of a novel sizing tool for mitral valve repair surgery (used ONLY in an observational capacity - this device does NOT influence decision-making during the conduct of the operation in any way).
218891218|NCT05943015|PROCEDURE|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
219033952|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
219033953|NCT02697162|DEVICE|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
219510741|NCT00929708|DRUG|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
219510742|NCT01893138|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
219033954|NCT02697162|DEVICE|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
219033955|NCT02697162|DRUG|Octenidine chloride|Antiseptic
219033956|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
219033957|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
219033958|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
219033959|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
219510743|NCT01893138|BIOLOGICAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
219510744|NCT00824460|DRUG|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
219510745|NCT00824460|DRUG|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
219510746|NCT00824460|DRUG|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
219510747|NCT00824460|DRUG|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
219510748|NCT00824460|DRUG|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
219510749|NCT00824460|DRUG|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
219510750|NCT03571308|DRUG|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
219510751|NCT06398769|DEVICE|SecuFix UM|All surgeries were performed using Secufix UM.
219510752|NCT06398769|DEVICE|VCare UM|All surgeries were performed using VCare UM.
219510753|NCT02012647|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
219510754|NCT02012647|PROCEDURE|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
219510755|NCT05016349|DRUG|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
218891219|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
218891220|NCT05943015|PROCEDURE|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
218891221|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
218891222|NCT05943015|PROCEDURE|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
219510756|NCT05016349|DRUG|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
218891223|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
218891224|NCT00128310|DRUG|Vinorelbine|
218891225|NCT00128310|DRUG|Gemcitabine|
218891226|NCT05725746|DIAGNOSTIC_TEST|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
218891227|NCT06975761|DRUG|Resin Based sealer|Post-operative pain after Root Canal Therapy by using resin based sealer
218891228|NCT06975761|DRUG|ZnO eugenol based sealers|Post-operative pain after Root Canal Therapy by using ZnO eugenol based sealer
218891229|NCT04596826|DRUG|Dronabinol 5 MG|oral administration
219510757|NCT05016349|DRUG|Mifepristone|Mifepristone 200mg capsules daily for 28 days
219510758|NCT05016349|DRUG|Cannabidiol|Liquid taken orally for daily for 28 days
218891230|NCT04596826|DRUG|Dronabinol 10 MG|oral administration
219033960|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
219203750|NCT06841744|OTHER|Information brochure|An information brochure on ergonomic strategies for managing low back pain during pregnancy will be provided.
219510759|NCT05016349|DRUG|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
219510760|NCT05016349|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
219510761|NCT05016349|DRUG|Standard therapy|Patients will receive the approved standard therapy tamoxifen
219510762|NCT05188521|DRUG|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
219510763|NCT05188521|DRUG|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 12 weeks
219033961|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
219510764|NCT01341639|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
218891231|NCT04596826|DRUG|Placebo|oral administration
218891232|NCT01890837|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
218891233|NCT01890837|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
219033962|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
219203751|NCT05706766|BEHAVIORAL|PARE|Aerobic and resistance exercise program via Zoom platform.
219510765|NCT01341639|BIOLOGICAL|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
219510766|NCT01341639|BIOLOGICAL|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
219510767|NCT01341639|BIOLOGICAL|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
219510768|NCT01341639|BIOLOGICAL|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
219510769|NCT04582266|DRUG|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
219510770|NCT01657539|DIETARY_SUPPLEMENT|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
219510771|NCT01657539|DIETARY_SUPPLEMENT|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
219510772|NCT02872649|DRUG|Dabigatran|
219203752|NCT05706766|BEHAVIORAL|Waitlist Control Group|Normal Activities.
219203753|NCT06481995|DRUG|Fibrogammin|Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
219510773|NCT02872649|DRUG|Phenprocoumon|
219510774|NCT06234800|PROCEDURE|Removal of failed dental implants|Removal (with various techniques) of failed dental implants.
219510775|NCT03879213|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
219510776|NCT03879213|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
219510777|NCT03741413|OTHER|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
219510778|NCT03741413|OTHER|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
219510779|NCT03741413|OTHER|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
219510780|NCT03262181|OTHER|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
219510781|NCT03262181|OTHER|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
219510782|NCT04643678|DRUG|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
219510783|NCT04643678|OTHER|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
219608990|NCT04859205|BEHAVIORAL|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
219510784|NCT01502345|BIOLOGICAL|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
219510785|NCT05679765|DRUG|Greater Occipital Nerve Block with dexamethasone and lidocaine|Ultrasound guided Greater occipital nerve block on the side of headache
219510786|NCT05679765|DRUG|Greater Occipital Nerve Block with 0.9% saline|Ultrasound guided Greater occipital nerve block on the side of headache
219510787|NCT01209052|DRUG|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
219510788|NCT01209052|OTHER|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
219510789|NCT03281499|OTHER|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
219510790|NCT00006470|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
219510791|NCT00006470|BIOLOGICAL|monoclonal antibody 3H1 anti-idiotype vaccine|
219510792|NCT00006470|RADIATION|radiation therapy|
219510793|NCT01241461|DRUG|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
219510794|NCT01143025|DRUG|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
219510795|NCT01143025|DRUG|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
219510796|NCT01143025|DRUG|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
219510797|NCT02036372|DRUG|Liraglutide|
219510798|NCT02036372|DRUG|Insulin bolus|
218891234|NCT04030520|BEHAVIORAL|POPPi|behavioral intervention with offer of HIV self test
218891235|NCT04030520|BEHAVIORAL|Comparison|standard of care
218891236|NCT03886168|OTHER|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
218891237|NCT03069131|DRUG|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
218891238|NCT03069131|OTHER|Placebo|twice daily administration of 1 rifaximin placebo tablet
218891239|NCT06696027|DIAGNOSTIC_TEST|Single nucleotide polymorphisms (SNP)|Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
218891240|NCT06696027|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
219510799|NCT02036372|DRUG|GIK infusion|continuous infusion
219510800|NCT01650922|PROCEDURE|phlebotomy|
219510801|NCT01650922|PROCEDURE|biopsy|
219510802|NCT04493450|OTHER|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
219608991|NCT03091374|DRUG|Somatotropin (Human)|
219510803|NCT06324136|DIAGNOSTIC_TEST|Implementation of the diagnostic algorithm|Patients will be selected based on specific clinical criteria and referred to the tertiary center for genetic testing. All selected patients will undergo genetic testing by whole-exome sequencing (WES), followed by in silico analysis for an extended panel of genes associated with kidney diseases. The results of genetic testing will be evaluated by a multidisciplinary team of experts to establish conclusive diagnosis.
219510804|NCT00675649|BIOLOGICAL|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
219510805|NCT00675649|BIOLOGICAL|placebo|placebo sc injection every 4 weeks from week 0 to week 20
219510806|NCT02565420|OTHER|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
219510807|NCT02565420|OTHER|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
219510808|NCT01368523|DRUG|nilotinib|
219510809|NCT00682305|PROCEDURE|Hematopoietic stem cell transplantation|"conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT"
219510810|NCT05789277|OTHER|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging"
219608992|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
218891241|NCT06696027|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array|Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
218891242|NCT06696027|DIAGNOSTIC_TEST|Flow Cytometry|Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
218891243|NCT06696027|DIAGNOSTIC_TEST|Laboratory assessment|Serum Chemistry
218891244|NCT06696027|DIAGNOSTIC_TEST|Assessment of Pulmonary Involvement|Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
218891245|NCT06877897|DIAGNOSTIC_TEST|Submental ultrasound criteria|According to the submental ultrasound criteria, a maximum hyoid bone displacement of ≥1.38 cm is required in the swallowing function assessment to qualify for the oral feeding diet and tube removal training protocol.
218891246|NCT06877897|DIAGNOSTIC_TEST|Routine swallowing function assessment of speech-language pathologist|The speech-language pathologist (SLP) assessment includes the evaluation of sensory and motor functions of the oral and facial muscles, phonation, swallowing motion, and other relevant factors.
218891247|NCT06886412|BEHAVIORAL|Maternal Holding Intervention Group|The infant is required to be held in the mother's arms before, during, and after the procedure. The maternal holding method will be shown or explained to the mother by the researchers.
218891248|NCT06886412|BEHAVIORAL|Breast Feeding Intervention Group|The infant's mother is instructed to begin breastfeeding 2 minutes before the procedure, continuing during and after the procedure. The breastfeeding position for the infant will be shown or explained to the mother by the researchers.
218891249|NCT06725316|BEHAVIORAL|4-7-8 breathing exercises|Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
219510811|NCT05789277|OTHER|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
219510812|NCT04326777|PROCEDURE|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
219510813|NCT03164395|PROCEDURE|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
219510814|NCT03164395|PROCEDURE|External Cardioversion|External Cardioversion per institutional protocol
219510815|NCT02788422|OTHER|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
219510816|NCT02788422|OTHER|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
219510817|NCT03703713|DRUG|Sodium chloride|Treatment with Sodium chloride
219510818|NCT01132118|DRUG|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
219608993|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
218891250|NCT06725966|PROCEDURE|Conventional Epley maneuver|Epley maneuver using a mechanized chair
218891251|NCT06725966|PROCEDURE|Personalized Epley maneuver|Personalized Epley maneuver, using a mechanized chair
218891252|NCT06725394|OTHER|Filling out the survey|Data were collected using an information form, the Smartphone Addiction Scale-Short Version (SAS-SV), the Perceived Stress Scale (PSS-10), and the Neck Disability Index (NDI).
218891253|NCT06726512|DEVICE|XEOS AURA 10|Surgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
218891254|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by packs|GROUP A: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by packs on non woven gauzes entirely covering the area. Eventually, if dried, gauzes are externally watered with additional sulphurous thermal water during the 20 minutes. After water application the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
219510819|NCT02619123|OTHER|Tailored screening according to breast density|Different interval of mammography screening according to breast density
218891255|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by limb full immersion|GROUP B: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by limb full immersion in a limb tub. After the immersion, the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
218891256|NCT06726278|DRUG|Misoprostol 400mcg Tab|Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
218891257|NCT06726278|DRUG|Placebo|participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
218891258|NCT06725992|DRUG|IY-NS250|Ilaprazole 20mg + Sodium bicarbonate 500mg
218891259|NCT06725992|DRUG|IY-NT-SR|Ilaprazole 10mg
219033963|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
219033964|NCT02644707|DIETARY_SUPPLEMENT|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
219510820|NCT02619123|OTHER|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
219510821|NCT01557491|PROCEDURE|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
219510822|NCT01557491|PROCEDURE|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
219510823|NCT04942379|OTHER|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
219510824|NCT04942379|OTHER|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
219033965|NCT02644707|OTHER|Placebo|The group will be randomized to receive placebo (control group) for 6 months
219033966|NCT03961542|OTHER|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
219033967|NCT02932904|DRUG|Vortioxetine|Vortioxetine Overencapsulated Tablet
219033968|NCT02932904|DRUG|Paroxetine|Paroxetine Overencapsulated Tablets.
219510825|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
219608994|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
219608995|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
219033969|NCT02932904|DRUG|Placebo|Vortioxetine Placebo-matching Capsules.
218891260|NCT06720155|BEHAVIORAL|Sleeper stretch|Participants will complete their regularly scheduled workout activities over 8 weeks, with the addition of the sleeper stretch into the dynamic warm-up. Participants will be instructed to lie side-lying with the dominant arm downward, the trunk rotated posteriorly 20 to 30°, the shoulder raised to 90°, the elbow flexed to 90°, and both knees semi-flexed to ensure stability. Participants will then be asked to use the opposite hand to grasp the dominant hand below the wrist and gradually internally rotate the forearm towards the floor; (i.e., the participant will perform passive internal rotation with the opposite arm). This stretch position will be completed on both sides. Participants will be instructed to complete 2 sets of 10 repetitions for each arm and hold the position for \~2 seconds.
218891261|NCT06720155|BEHAVIORAL|Standard workout|Participants will complete their regularly programmed dynamic warm-ups before scheduled workout for 8 weeks.
218891262|NCT06744621|OTHER|Fingerstick|fingersticks during their labor process
219510826|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
218891263|NCT07066579|BEHAVIORAL|Valsalva Maneuver|Patients are instructed to perform the Valsalva maneuver by blowing into a 10-cc syringe to generate approximately 20 mmHg pressure for 15-20 seconds before arteriovenous fistula cannulation during each dialysis session.
219510827|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
219510828|NCT03728842|OTHER|Blood collection for laboratory studies|Peripheral whole blood will be collected
219510829|NCT03728842|OTHER|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
219608996|NCT01295112|DRUG|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
219608997|NCT01295112|DRUG|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
218891264|NCT06907693|DIAGNOSTIC_TEST|CT Pulmonary Angiography Scan|Computed tomography (CT) pulmonary angiography scan of the chest with IV contrast
218891265|NCT06763991|PROCEDURE|Two-stage connection|Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.
218891266|NCT06763991|PROCEDURE|One-stage connection|One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.
218891267|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 18.5-24.99
218891268|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 25-39.99
218891269|NCT02583555|BEHAVIORAL|Interview followed by frequent telephone support|Interview followed by telephone support
218891270|NCT06939790|BEHAVIORAL|Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I)|The digital CBT-I (dCBT-I) is a self-guided online program replicating the structure and content of standard face-to-face CBT-I, aiming to offer a more accessible treatment for chronic insomnia. It includes video lessons, interactive exercises, and relaxation techniques, with core components such as sleep education, sleep restriction, stimulus control and cognitive restructuring. Supervision is provided through periodic check-ins.
218891271|NCT06939790|BEHAVIORAL|standard face-to-face group-based Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The control group will receive standard face-to-face group-based CBT-I, the current gold-standard treatment for chronic insomnia. Delivered by trained professionals, the intervention includes seven structured sessions covering core components such as sleep education, sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. Sessions last about 90 minutes and aim to improve sleep quality through evidence-based strategies.
218891272|NCT06537674|DRUG|Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection|Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
218891273|NCT03657849|DEVICE|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
219033970|NCT01881659|OTHER|HPV screening|Women who signed informed consent will be screened with HPV testing.
219510830|NCT00171782|DRUG|VALSARTAN+HYDROCHLOROTHIAZIDE|
219608998|NCT03071692|DRUG|K-877|0.2mg tablet
219608999|NCT03071692|DRUG|Placebo|K-877 matching placebo tablet
219609000|NCT04110730|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
218891274|NCT02621294|OTHER|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
218891275|NCT04208438|DIAGNOSTIC_TEST|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
218891276|NCT04208438|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
218891277|NCT01558050|DIETARY_SUPPLEMENT|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
219510831|NCT06051396|PROCEDURE|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
219510832|NCT00084539|RADIATION|Radiation therapy|
219510833|NCT04123041|OTHER|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
219609001|NCT04110730|BEHAVIORAL|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
219609002|NCT04520269|DRUG|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
218891278|NCT02033746|DEVICE|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
218891279|NCT03625336|DIAGNOSTIC_TEST|MRI|An MRI will be obtained utilizing 3 different MRI sequences
218891280|NCT02034838|DRUG|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
219033971|NCT05325567|PROCEDURE|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
219033972|NCT03976427|BEHAVIORAL|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
219033973|NCT00337103|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
219609003|NCT00108004|DRUG|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
219609004|NCT05516186|OTHER|Scapular-focused exercise protocol with EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback
219609005|NCT05516186|OTHER|Control Therapy|manual and exercise therapy
219609006|NCT05516186|OTHER|Scapular-focused exercise protocol without EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol
219609007|NCT01200173|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
219609008|NCT01200173|OTHER|2-Non fermented dairy product (control)|
219609009|NCT02413567|DEVICE|DMR Procedure (Fractyl)|Endoscopic procedure
219510834|NCT03818490|OTHER|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
219510835|NCT00850902|OTHER|High Humidity (HH)|High Humidity Level
218891281|NCT01053039|DRUG|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
218891282|NCT01053039|DRUG|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
218891283|NCT05613829|OTHER|Burn surgery|Patients underwent burn surgery
219033974|NCT00337103|DRUG|Capecitabine|Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
219033975|NCT05532943|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
219033976|NCT05532943|BIOLOGICAL|Control group|Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
219033977|NCT05197842|DRUG|BDB-001 injection|Intravenously administered
219033978|NCT05197842|DRUG|Cyclophosphamide|Intravenously administered
219033979|NCT05197842|DRUG|Glucocorticoids|Orally administered
219033980|NCT01577758|DRUG|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
219609010|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
219033981|NCT03981133|BEHAVIORAL|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
219033982|NCT03981133|BEHAVIORAL|no pacifier|not to offer a pacifier at 15 days of life
219033983|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
219033984|NCT05785065|DRUG|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
219510836|NCT00850902|OTHER|Moderate Humidity|Moderate Humidity Level
219510837|NCT02398318|DEVICE|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
218891284|NCT01088620|DRUG|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
218891285|NCT01088620|DRUG|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
219033985|NCT05785065|OTHER|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
219033986|NCT00702117|DRUG|flecainide|2 mg/kg iv in 10 minutes
219033987|NCT00702117|DRUG|ajmaline|1 mg/kg iv in 10 minutes
219033988|NCT00702117|DRUG|procainamide|10 mg/kg iv in 10 minutes
219033989|NCT00004804|DRUG|interferon alfa|
219033990|NCT01142310|DRUG|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
219510838|NCT02398318|DEVICE|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
219510839|NCT00281619|DRUG|CellCept (mycophenolate mofetil)|
219510840|NCT00281619|BEHAVIORAL|Dietary Monitoring|
219510841|NCT00281619|BEHAVIORAL|Drug Diary|
219510842|NCT00281619|PROCEDURE|Blood Sampling|
219609011|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
219609012|NCT00970593|DRUG|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
219609013|NCT00970593|DRUG|placebo comparator|Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
219609014|NCT00897182|GENETIC|microarray analysis|
219609015|NCT00897182|GENETIC|polymerase chain reaction|
219609016|NCT01935830|RADIATION|[11c] LAAM|intravenous administration of 15-20 mCi of \[11c\] LAAM.
218891286|NCT01088620|DRUG|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
218891287|NCT04022655|OTHER|ICU Care|No intervention
218891288|NCT02037217|DEVICE|ExAblate Transcranial MRgFUS System|
218891289|NCT00916019|OTHER|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
218891290|NCT00005818|DRUG|irinotecan hydrochloride|Given IV
218891291|NCT00005818|DRUG|semaxanib|Given IV
218891292|NCT00005818|OTHER|laboratory biomarker analysis|Correlative studies
218891293|NCT05297188|DEVICE|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
218891294|NCT01252030|DEVICE|physical activity monitors|physical activity monitors
218891295|NCT01252030|OTHER|No physical activity monitors|No physical activity monitors
218891296|NCT01870726|DRUG|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
218891297|NCT01870726|DRUG|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
219033991|NCT01142310|DRUG|Placebo|
219033992|NCT05662579|OTHER|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
219033993|NCT06099977|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
219033994|NCT06099977|PROCEDURE|Placebo|Only headphone without sound will be applied.
219510843|NCT00782002|BIOLOGICAL|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
219609017|NCT01935830|DRUG|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
219609018|NCT01935830|DRUG|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
219609019|NCT02180048|DIETARY_SUPPLEMENT|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
219609020|NCT02180048|DIETARY_SUPPLEMENT|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
219510844|NCT03867903|DEVICE|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
219609021|NCT02180048|DIETARY_SUPPLEMENT|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
219609022|NCT05966415|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
218891298|NCT01836926|PROCEDURE|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
218891299|NCT01836926|DEVICE|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
218891300|NCT01292096|OTHER|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
218891301|NCT03478735|PROCEDURE|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
219033995|NCT01865162|OTHER|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
219033996|NCT00203970|BEHAVIORAL|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
219033997|NCT03387813|DEVICE|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
219033998|NCT00963261|BEHAVIORAL|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
219033999|NCT04318496|OTHER|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
219034000|NCT04318496|OTHER|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
219510845|NCT03867903|OTHER|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
219510846|NCT01299038|DRUG|rosuvastatin|Taken orally once a day for 4 weeks
219510847|NCT05786807|DRUG|K-CAB|Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
219510848|NCT03591978|DIAGNOSTIC_TEST|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
219510849|NCT05151978|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
219609023|NCT05966415|OTHER|placebo|4 capsules once daily OR 2 capsules twice daily
219609024|NCT04402411|PROCEDURE|Quadratus lumborum block|The patient will be placed in a lateral position with the side to be blocked facing upwards. The ultrasound probe will be properly sterilized and with sterile covers. An 18-20 gauge blunt tipped block needle or a Tuohy needle is advanced under ultrasound guidance on the posterior aspect of the Quadratus Lumborum. The QL muscle is identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the QL muscle adherent to the apex of the transverse process, a well recognisable pattern of a shamrock with three leaves can be seen.
219034001|NCT06376253|DRUG|[68Ga]Ga-EVS459|Radioligand imaging agent
219034002|NCT06376253|DRUG|[177Lu]Lu-EVS459|Radioligand therapy
219510850|NCT05127083|RADIATION|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
219510851|NCT00832078|DEVICE|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
219510852|NCT00832078|DEVICE|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
219510853|NCT01226277|DRUG|GDC-0917|Oral repeating dose
218891302|NCT03478735|PROCEDURE|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
218891303|NCT00502008|DRUG|Coccinia Cordifolia (herbal extract)|
218891304|NCT02057159|BIOLOGICAL|NeuroVax|TCR peptides in IFA
218891305|NCT02057159|BIOLOGICAL|IFA Placebo|IFA Placebo
218891306|NCT01746225|DRUG|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
218891307|NCT06058325|OTHER|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
218891308|NCT03941626|BIOLOGICAL|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
218891309|NCT03933761|DRUG|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
219034003|NCT05820347|DEVICE|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
219034004|NCT01399242|DRUG|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
219510854|NCT01767597|OTHER|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
219510855|NCT01767597|OTHER|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
219510856|NCT03386097|OTHER|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
219510857|NCT05566665|DIAGNOSTIC_TEST|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
218891310|NCT02800083|DRUG|Pitolisant (BF2.649)|
218891311|NCT02800083|DRUG|Placebo|
218891312|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
218891313|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
218891314|NCT03704909|DRUG|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
218891315|NCT03704909|DRUG|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
218891316|NCT00249678|BEHAVIORAL|Behavior Therapy|
218891317|NCT03580226|OTHER|No intervention|No intervention
218891318|NCT02168218|OTHER|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
218891319|NCT03162419|DRUG|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
218891320|NCT03162419|BIOLOGICAL|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
218891321|NCT03162419|BIOLOGICAL|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
218891322|NCT01834352|DRUG|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
218891323|NCT01834352|DRUG|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
218891324|NCT02451514|BIOLOGICAL|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
218891325|NCT01238302|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
219034005|NCT04762134|DRUG|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
219034006|NCT02259361|DRUG|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
219034007|NCT02259361|DRUG|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
219510858|NCT02961920|DEVICE|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
218891326|NCT01238302|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
218891327|NCT05487911|DEVICE|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
218891328|NCT02240355|DRUG|RO6885247|oral solution
218891329|NCT02240355|DRUG|placebo|oral solution
218891330|NCT06508671|DRUG|DL-3-n-butylphthalide|Take butylphthalide soft capsules orally
218891331|NCT06508671|DRUG|Empty Medication Capsules|Take empty medication capsules orally
218891332|NCT04720677|OTHER|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
218891333|NCT01092910|DEVICE|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
218891334|NCT04601805|DEVICE|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
218891335|NCT02106520|DRUG|Bevacizumab|
218891336|NCT02106520|DRUG|placebo|
218891337|NCT00685113|DRUG|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
218891338|NCT00685113|DRUG|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
218891339|NCT00685113|DRUG|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
218891340|NCT00908804|PROCEDURE|open appendectomy|
218891341|NCT00908804|PROCEDURE|laparoscopic appendectomy|
218891342|NCT00258934|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
219510859|NCT02961920|DEVICE|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
219609025|NCT04402411|PROCEDURE|Transversus abdominis plane block|"The patient will be supine while performing the block and sterilization of the site of the ultrasound and needle entry will be performed.~The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest.~The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles."
218891343|NCT00258934|BIOLOGICAL|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
218891344|NCT06383260|BEHAVIORAL|Behavioral diagnostic|Diagnosing the behavioral pattern
218891345|NCT01622465|BEHAVIORAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
218891346|NCT01622465|BEHAVIORAL|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
218891347|NCT03481699|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
218891348|NCT03481699|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
218891349|NCT04357483|DRUG|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
219034008|NCT02578654|OTHER|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
219510860|NCT03417349|DEVICE|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
219510861|NCT00050921|DRUG|somatropin|
219510862|NCT00050921|BIOLOGICAL|Hepatitis A virus, inactivated|
219510863|NCT00050921|DRUG|Keyhole-Limpet Hemocyanin|
219510864|NCT05379543|OTHER|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
219609026|NCT04402411|DRUG|Intravenous opioid|Patients will receive morphine 0.1 mg/kg
219510865|NCT04653870|OTHER|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
218891350|NCT04357483|DRUG|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
218891351|NCT00032734|DRUG|satavaptan (SR121463B)|
218891352|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
218891353|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
219034009|NCT02479256|DRUG|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
219034010|NCT02479256|DRUG|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
219510866|NCT04653870|OTHER|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
218891354|NCT01680744|OTHER|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
218891355|NCT01288001|DRUG|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
218891356|NCT02059603|PROCEDURE|Electroacupuncture|
218891357|NCT02059603|PROCEDURE|Fast-track program|
218891358|NCT04325620|DRUG|HIP1601|HIP1601
219510867|NCT02990832|DEVICE|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
219510868|NCT02006485|DRUG|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
219510869|NCT02006485|DRUG|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
219510870|NCT02006485|DRUG|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
219510871|NCT00208156|DRUG|Mifepristone|
219510872|NCT03760393|BEHAVIORAL|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
219510873|NCT03639428|DRUG|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
219510874|NCT04951128|DRUG|Tranexamic acid injection|Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
218891359|NCT04325620|DRUG|HGP1805|Placebo of HIP1601
218891360|NCT00603122|BEHAVIORAL|ascent protocol|ascent protocol for the two groups has different acclimatization time
218891361|NCT05917054|OTHER|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
219034011|NCT02479256|DRUG|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
219034012|NCT02479256|DRUG|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
219034013|NCT00253383|OTHER|counseling intervention|
219034014|NCT00253383|OTHER|educational intervention|
219034015|NCT00253383|PROCEDURE|psychosocial assessment and care|
219034016|NCT00253383|PROCEDURE|quality-of-life assessment|
218891362|NCT01518842|BIOLOGICAL|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
218891363|NCT02384512|DRUG|Azilect®|AZILECT® 1mg Tablets
218891364|NCT03219346|OTHER|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
218891365|NCT05538143|OTHER|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
218891366|NCT01998308|DRUG|Crespine gel|50 Knees will have single injection of Crespine gel
218891367|NCT01998308|DRUG|Intragel|50 Knees will have single injection of 2 ampules of Intragel
218891368|NCT01998308|DRUG|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
218891369|NCT01998308|DRUG|Monovisc|50 Knees will have single injection of Monovisc
218891370|NCT05310331|COMBINATION_PRODUCT|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
218891371|NCT03945149|DIETARY_SUPPLEMENT|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
218891372|NCT03945149|DIETARY_SUPPLEMENT|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
218891373|NCT03691571|DEVICE|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
218891374|NCT03691571|DEVICE|Control|Standard of care involves standard temperature probe monitoring.
218891375|NCT02221388|DRUG|BI 671800 HEA, 200 mg tablets|
218891376|NCT02221388|DRUG|BI 671800 HEA EC, 200 mg tablets|
218891377|NCT02221388|DRUG|BI 671800 HEA, 50 mg tablets|
218891378|NCT02221388|DRUG|BI 671800 ED, 100 mg capsules|
218891379|NCT02221388|OTHER|Standard meal|
218891380|NCT03135938|PROCEDURE|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
218891381|NCT03135938|PROCEDURE|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
218891382|NCT02415270|OTHER|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
218891383|NCT02415270|OTHER|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
218891384|NCT02415270|OTHER|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
219510875|NCT04951128|OTHER|Local anesthetic control|Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).
219510876|NCT03055533|BEHAVIORAL|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
218891385|NCT02909374|OTHER|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
218891386|NCT02321345|OTHER|Palliative Care Support|Palliative care meetings Quality of Life Assessments
218891387|NCT02831517|DRUG|BIIB074|Administered as specified in the treatment arm
219510877|NCT00909077|DRUG|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
219510878|NCT00909077|DRUG|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
219510879|NCT05508451|PROCEDURE|Double jaw surgery|A type of orthognathic surgery
218891388|NCT02831517|DRUG|Placebo|Matched Placebo
219034017|NCT01642017|DRUG|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
219609027|NCT04177407|PROCEDURE|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
219609028|NCT03027960|DRUG|Empagliflozin|10mg empagliflozin for a 2-week period
219609029|NCT03027960|DRUG|Placebo Oral Capsule|10 mg placebo for a 2-week period
219609030|NCT00118326|BIOLOGICAL|filgrastim|
218891389|NCT03240094|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
218891390|NCT00121186|DRUG|fludarabine phosphate|30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).
218891391|NCT00121186|DRUG|melphalan|70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).
218891392|NCT00121186|DRUG|methotrexate|5 mg/m\^2 on days 1, 3, and 7 post-transplant.
218891393|NCT00121186|DRUG|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
218891394|NCT00121186|PROCEDURE|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
218891395|NCT00121186|PROCEDURE|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
218891396|NCT01258283|OTHER|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
219034018|NCT06038201|PROCEDURE|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
219034019|NCT06038201|PROCEDURE|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
219034020|NCT01289847|BIOLOGICAL|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
219034021|NCT05876273|DEVICE|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
218891397|NCT03004352|OTHER|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
218891398|NCT03004352|OTHER|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
218891399|NCT00825903|BEHAVIORAL|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
219034022|NCT05876273|DEVICE|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
219034023|NCT00908726|DRUG|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
219510880|NCT02770183|DEVICE|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
218891400|NCT01406977|DRUG|BPS804|
218891401|NCT01996085|DRUG|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"
218891402|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
219034024|NCT06470412|OTHER|Control group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
219510881|NCT01070641|DRUG|Carvedilol|Carvedilol 12.5mg QD
219510882|NCT01070641|PROCEDURE|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
219510883|NCT05349903|OTHER|Rice flour|Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219510884|NCT05349903|OTHER|Alternanoligosaccharide 15|Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219510885|NCT05349903|OTHER|Inulin|Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219510886|NCT05349903|OTHER|Waxy potato starch|Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219609031|NCT00118326|PROCEDURE|allogeneic bone marrow transplantation|
219609032|NCT01648530|OTHER|No Treatment|No Treatment
218891403|NCT01996085|DRUG|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"
218891404|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
218891405|NCT01996085|DRUG|Amlodipine|1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
218891406|NCT01996085|DRUG|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
219510887|NCT05349903|OTHER|Waxy potato starch + epigallocatechin gallate (EGCG)|A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219510888|NCT05349903|OTHER|Chickpea flour + epigallocatechin gallate (EGCG)|A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
219510889|NCT00649025|DRUG|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
219510890|NCT00649025|DRUG|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
219510891|NCT00649025|DRUG|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
219609033|NCT02591524|OTHER|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
218891407|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
218891408|NCT01996085|DRUG|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
218891409|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
218891410|NCT01996085|DRUG|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
218891411|NCT02197091|OTHER|questionnaire administration|Ancillary studies
218891412|NCT02197091|OTHER|medical chart review|Ancillary studies
219034025|NCT06470412|OTHER|AI-Guided Group|Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
219510892|NCT03621800|OTHER|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
219510893|NCT03544320|DEVICE|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
218891413|NCT06060054|DIAGNOSTIC_TEST|Device measurements|Overnight device measurements
218891414|NCT00186901|DRUG|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
218891415|NCT00186901|OTHER|Placebo|Placebo
218891416|NCT04079075|OTHER|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
219034026|NCT06373497|DIAGNOSTIC_TEST|18-F-NaF Cardiac PET/MRI and|All eligible subjects will receive 18-F-NaF Cardiac PET/MRI at baseline and 6 months after the completion of radiotherapy where the heart is in the treatment field
219034027|NCT06373497|DIAGNOSTIC_TEST|CT Angiogram|All eligible subjects will receive CT Angiogram at baselin
219034028|NCT04033601|BEHAVIORAL|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
219034029|NCT02051036|PROCEDURE|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
219034030|NCT05774834|OTHER|No intervention|No intervention
219034031|NCT04809324|PROCEDURE|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins \<7mm will be revised on table
219510894|NCT03544320|DEVICE|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
219510895|NCT03404076|DIAGNOSTIC_TEST|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
218891417|NCT04079075|BEHAVIORAL|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
219034032|NCT04809324|PROCEDURE|Frozen section|frozen section evaluation of the specimen by the pathologist
219510896|NCT01259427|BEHAVIORAL|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
219609034|NCT03225417|DRUG|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
219609035|NCT03225417|DRUG|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
219609036|NCT03225417|DRUG|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
219510897|NCT01259427|BEHAVIORAL|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
218891418|NCT04079075|BEHAVIORAL|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
218891419|NCT04079075|BEHAVIORAL|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
218891420|NCT04079075|DIAGNOSTIC_TEST|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
218891421|NCT03848936|OTHER|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
218891422|NCT02955537|OTHER|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
218891423|NCT00525005|DRUG|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
218891424|NCT02921490|DEVICE|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
218891425|NCT05130749|OTHER|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
218891426|NCT02776059|DRUG|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
218891427|NCT02776059|DRUG|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
218891428|NCT02771197|DRUG|Fludarabine|
218891429|NCT02771197|DRUG|Melphalan|
218891430|NCT02771197|DRUG|Pembrolizumab|
218891431|NCT05138627|OTHER|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
219510898|NCT01628120|BIOLOGICAL|Epoetin Hospira|Subcutaneous(SC) injection
219510899|NCT02924857|DEVICE|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
219510900|NCT02924857|DEVICE|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
219510901|NCT00108420|DRUG|Prazosin|
218891432|NCT01794260|DRUG|Cream from Zingiber cassumunar Roxb. extract|
218891433|NCT01794260|DRUG|Placebo cream|
218891434|NCT05179525|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
218891435|NCT05179525|DRUG|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
218891436|NCT01802710|BEHAVIORAL|Psychological support|
219034033|NCT03990896|DRUG|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
219034034|NCT03975647|DRUG|tucatinib|300mg given twice per day by mouth (orally)
219510902|NCT04612920|DRUG|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
218891437|NCT01802710|OTHER|No intervention|
218891438|NCT05158725|DEVICE|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
219510903|NCT04118231|OTHER|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
219510904|NCT01886274|DEVICE|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
219609037|NCT03225417|DRUG|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
219510905|NCT04741035|OTHER|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
218891439|NCT05158725|DEVICE|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
218891440|NCT05158725|DEVICE|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
218891441|NCT02682992|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
218891442|NCT00291486|DRUG|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
218891443|NCT00291486|DRUG|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
218891444|NCT03618862|BIOLOGICAL|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
218891445|NCT03323177|DIETARY_SUPPLEMENT|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
218891446|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
219510906|NCT04741035|OTHER|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
219510907|NCT00767117|DRUG|Etravirine; Lopinavir; Ritonavir|
219510908|NCT04799210|DEVICE|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
219510909|NCT05118321|DEVICE|Custom-made upper limb exosuit and hand exoskeleton|Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
219510910|NCT02890823|DRUG|Cholecalciferol|
219510911|NCT01748500|DRUG|Pantoprazole|
219510912|NCT06059170|BEHAVIORAL|LARS score/ EORTC QLQ C30|administering questionnaire
219510913|NCT02958956|DRUG|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
219510914|NCT04611659|BEHAVIORAL|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
219510915|NCT04840407|BEHAVIORAL|SHARP coach intervention|The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
219510916|NCT02044471|OTHER|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
219510917|NCT03752593|OTHER|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
219510918|NCT05304637|DEVICE|iTEAR100 treatment|Vibratory energy to the external nasal nerve
219510919|NCT03814109|DRUG|LENINGRADO association|1 coated sustained-release tablet, oral, once a day.
219510920|NCT03814109|DRUG|Indapamide SR 1.5 MG|1 coated sustained-release tablet, oral, once a day.
219510921|NCT03814109|DRUG|Levamlodipine 2.5/ 5 mg|1 tablet, oral, once a day.
219510922|NCT03814109|OTHER|Leningrado association Placebo|1 coated sustained-release tablet, oral, once a day.
219510923|NCT03814109|OTHER|Indapamide SR Placebo|1 coated sustained-release tablet, oral, once a day.
219510924|NCT03814109|OTHER|Levamlodipine placebo|1 tablet, oral, once a day.
219510925|NCT00202137|BEHAVIORAL|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
219510926|NCT00202137|BEHAVIORAL|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
219510927|NCT05939661|RADIATION|Radiation|Neoadjuvant radiation therapy : 5Gyx5
219510928|NCT05939661|DRUG|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
219510929|NCT05939661|PROCEDURE|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
219510930|NCT02588183|DEVICE|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
219510931|NCT04958083|DIAGNOSTIC_TEST|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
219609038|NCT01561716|DEVICE|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
219609039|NCT00629018|BIOLOGICAL|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
219510932|NCT00002583|DRUG|cisplatin|50 mg/m2 IV
219510933|NCT00002583|DRUG|vinorelbine ditartrate|25 mg/m2 IV
219510934|NCT00004498|GENETIC|Adenoviral Vector-Mediated Gene Transfer|
219510935|NCT06528483|DRUG|Sacituzumab Govitecan + Zimberelimab|"Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice."
219609040|NCT00629018|DRUG|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
218891447|NCT03274063|OTHER|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
218891448|NCT03274063|OTHER|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
218891449|NCT00881816|DRUG|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
218891450|NCT06054139|OTHER|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
218891451|NCT01246336|OTHER|collection of exhaled breath|no intervention
218891452|NCT03156283|BEHAVIORAL|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
219034035|NCT03975647|DRUG|placebo|Given twice per day orally
219034036|NCT03975647|DRUG|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
219510936|NCT02192905|BEHAVIORAL|Diabetes Prevention Program Lifestyle Intervention|
219510937|NCT06393101|DRUG|BRC-002|BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
219609041|NCT00629018|BIOLOGICAL|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
219510938|NCT06393101|DRUG|BRC-002 Placebo|Oral solution of mono-, di-, and triglycerides
219510939|NCT00003520|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219510940|NCT03376594|DRUG|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
219510941|NCT03376594|DRUG|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
219510942|NCT02173704|BIOLOGICAL|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
219609042|NCT04364776|DRUG|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
219609043|NCT06487169|DIAGNOSTIC_TEST|Urine analysis to determine the presence of hexafluoroisopropanol|analysis of sevoflurane metabolites in urine
219609044|NCT06404918|PROCEDURE|Erector spinae plane group|The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
219609045|NCT06404918|PROCEDURE|Serratus anterior plane group|Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
218891453|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
219510943|NCT02173704|BIOLOGICAL|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
219510944|NCT02551289|OTHER|Gluten free diet|Patients will follow a gluten free diet
219609046|NCT03749889|OTHER|100 g carbs|Participants will be assigned a diet of 100g carbs max for the day
219609047|NCT03749889|OTHER|MyPlate|40-65% of daily intake is from carbohydrates
219609048|NCT05389787|DEVICE|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
219609049|NCT02045446|RADIATION|Stereotactic Body Radiation Therapy|
219609050|NCT02045446|DRUG|Maintenance chemotherapy|Maintenance chemotherapy
219609051|NCT03937505|DRUG|IS-001|intravenous injection of IS-001 investigational drug
218891454|NCT05141461|PROCEDURE|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
218891455|NCT05141461|PROCEDURE|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
218891456|NCT01628055|BIOLOGICAL|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
219510945|NCT04088214|PROCEDURE|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
219609052|NCT03937505|DRUG|No treatment|no drug injection
219609053|NCT00567008|DRUG|varenicline|1.0 mg BID for 8 weeks
219609054|NCT00567008|DRUG|placebo|placebo BID for 8 weeks
219609055|NCT04090125|BEHAVIORAL|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
219510946|NCT05378906|DRUG|DRV/COBI FDC|Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
219510947|NCT05378906|DRUG|COBI|Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.
219510948|NCT05378906|DRUG|DRV|Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
219510949|NCT01989520|DRUG|Phase IIb formulation|Single oral dose 45mg AZD5069
219510950|NCT01989520|DRUG|Putative phase III formulation|Single oral dose 45mg AZD5069
218891457|NCT01628055|OTHER|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
218891458|NCT04918511|DRUG|OPD5|OPD5 solution for i.v. infusion
219609056|NCT04090125|BEHAVIORAL|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
219609057|NCT00634946|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
218891459|NCT04999345|OTHER|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
218891460|NCT04999345|OTHER|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
219510951|NCT01989520|DRUG|Slow dissolution variant 1|Single oral dose 45mg AZD5069
219510952|NCT01989520|DRUG|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
219510953|NCT01989520|DRUG|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
219510954|NCT03744416|OTHER|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
219510955|NCT00419926|DRUG|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
219510956|NCT00419926|DRUG|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
219510957|NCT00419926|DRUG|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
219510958|NCT06141915|OTHER|Aerobic training|"patients will be engaged in aerobic training using treadmill three times per week, for 12 weeks. The exercise intensity will be 50-70% of each patient's maximum heart rate. Each exercise session will consist of three phases; five-minutes warming up phase in form of stretching exercises and walking on the treadmill at the slowest speed, 20-minutes conditioning phase in form of walking on the treadmill at 50% of participants' maximum heart rate in the first two weeks then progressed gradually to reach the 70% of maximum heart rate by the 12th weeks, and five-minutes cool down phase that will be constant as warming up phase. During the training, the patient's blood pressure, heart rate, and breathing pattern will be frequently monitored"
219510959|NCT06141915|OTHER|diet protocol|diet protocol
219609058|NCT00634946|DRUG|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
219609059|NCT04549350|OTHER|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score \> 5 is indicative of poor sleep quality
219609060|NCT01482416|DRUG|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
219609061|NCT01482416|DRUG|Placebo|Placebo group will use placebo once/day during 30 days
219609062|NCT01134250|DRUG|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
219609063|NCT01342081|DRUG|DE-111 ophthalmic solution|
219609064|NCT01342081|DRUG|Tafluprost ophthalmic solution 0.0015%|
219609065|NCT01342081|DRUG|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
218891461|NCT04992845|DEVICE|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
218891462|NCT01590160|DRUG|Ganetespib|IV, Using dose from Phase I
218891463|NCT03314272|DEVICE|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
218891464|NCT01099397|OTHER|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
218891465|NCT00583037|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
218891466|NCT02656953|OTHER|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
218891467|NCT02656953|OTHER|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
218891468|NCT02121249|DEVICE|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
218891469|NCT02121249|PROCEDURE|free hand technique|"No specific device is necessary in the free hand technique"
218891470|NCT02709603|DRUG|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
218891471|NCT02709603|DRUG|placebo|oral placebo; 2 tablets 30 minutes before the procedure
219034037|NCT05788458|DRUG|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
219034038|NCT05957796|DEVICE|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
219034039|NCT05957796|OTHER|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
219034040|NCT05836402|DIETARY_SUPPLEMENT|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
219034041|NCT05446883|DRUG|QL1706|Intravenous Infusion
219034042|NCT05446883|DRUG|Placebo|Intravenous Infusion
219034043|NCT05446883|DRUG|Paclitaxel injection|Intravenous Infusion
219510960|NCT03515395|BEHAVIORAL|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
219510961|NCT01081561|DRUG|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
219510962|NCT03106870|DRUG|Insulin Mixtard|"Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
219510963|NCT03106870|DRUG|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
219510964|NCT02294656|DRUG|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
218891472|NCT02384018|BIOLOGICAL|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
218891473|NCT02717039|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
218891474|NCT05906459|DIAGNOSTIC_TEST|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
218891475|NCT00020124|DRUG|doxorubicin hydrochloride|
218891476|NCT02676934|DEVICE|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
218891477|NCT02331667|OTHER|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
218891478|NCT02331667|OTHER|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
218891479|NCT00959205|DEVICE|CARTO 3D|CARTO (3D Electroanatomic imaging)
218891480|NCT00959205|DEVICE|Angiography|Conventional fluoroscopically guided activation mapping
218891481|NCT02363959|DRUG|Hyperbaric Oxygen Therapy|2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
219034044|NCT05446883|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
219034045|NCT06278324|DEVICE|Nasal Spray HSV Treatment|Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
219034046|NCT02872116|DRUG|Nivolumab|Specified dose on specified days
219510965|NCT02294656|DRUG|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
219510966|NCT00533403|DRUG|MK0686|
219510967|NCT02764008|DRUG|Bupivacaine|20 ml %0,25 bupivacaine
219510968|NCT02764008|DEVICE|Ultrasound|
219510969|NCT01632787|OTHER|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
219510970|NCT00004381|DRUG|tin mesoporphyrin|
219510971|NCT01531465|OTHER|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
219510972|NCT01531465|OTHER|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
219510973|NCT06460974|OTHER|stress ball|A stress ball was applied to the patients in the during chemotherapy treatment.
219510974|NCT01695109|DRUG|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
219510975|NCT01695109|DRUG|Placebo|0.9% NaCl, 0.2 ml
218891482|NCT02363959|PROCEDURE|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
219034047|NCT02872116|DRUG|Ipilimumab|Specified dose on specified days
219510976|NCT03936400|BEHAVIORAL|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
219510977|NCT02287532|DEVICE|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
219510978|NCT01617577|DRUG|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
219510979|NCT01617577|DRUG|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
219510980|NCT02605109|OTHER|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
219510981|NCT06125613|BEHAVIORAL|Experimental|"In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total."
219510982|NCT04226911|BEHAVIORAL|S&SEs|"S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned."
219510983|NCT04226911|BEHAVIORAL|Sugar|"Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products."
219609066|NCT06042543|DIAGNOSTIC_TEST|Screening with HPV test|Women aged 25-49 yrs will be screened with a validated HPV test. They will also provide urine samples for HPV test. Women HPV positive in either sample will be referred to colposcopy for disease ascertainment.
218891483|NCT01958359|BEHAVIORAL|Short IVR|IVR-based alcohol diary with feedback
218891484|NCT01958359|BEHAVIORAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
218891485|NCT04168099|DRUG|Cefotaxime|Cefotaxime IV
219034048|NCT02872116|DRUG|Oxaliplatin|Specified dose on specified days
218891486|NCT04168099|DRUG|Gemifloxacin|Gemifloxacin oral
219034049|NCT02872116|DRUG|Capecitabine|Specified dose on specified days
219034050|NCT02872116|DRUG|Leucovorin|Specified dose on specified days
219034051|NCT02872116|DRUG|Fluorouracil|Specified dose on specified days
219034052|NCT02514837|DEVICE|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
219034053|NCT04663581|OTHER|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
219034054|NCT04663581|OTHER|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
219034055|NCT05004233|BIOLOGICAL|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
219034056|NCT05004233|BIOLOGICAL|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
218891487|NCT04422704|BEHAVIORAL|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
218891488|NCT01511016|DRUG|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
218891489|NCT01511016|DRUG|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
219034057|NCT01460433|PROCEDURE|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
219034058|NCT04420156|OTHER|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
219034059|NCT03588221|PROCEDURE|four sets of hand hygiene measurements per participant|"1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"
219510984|NCT04152928|DIAGNOSTIC_TEST|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
219510985|NCT02563509|BIOLOGICAL|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
219510986|NCT02374918|DEVICE|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
219510987|NCT02374918|DEVICE|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
219510988|NCT02374918|DEVICE|HC wavelength-1 bright light|30 minutes of light exposure
219510989|NCT02374918|DEVICE|HC wavelength-2 bright light|30 minutes of light exposure
219510990|NCT05899790|OTHER|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
219510991|NCT02243956|OTHER|Flavanol rich food product|polyphenol rich test product
219510992|NCT04026464|DRUG|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
219510993|NCT04026464|DRUG|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
219510994|NCT01968798|DRUG|Aspirin|100mg enteric-coated aspirin, taken daily
219609067|NCT03236090|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
219034060|NCT03226262|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
219510995|NCT01968798|DRUG|Placebo|100mg enteric-coated placebo, taken daily
219510996|NCT03342495|OTHER|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
219510997|NCT03342495|OTHER|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
219510998|NCT05751070|OTHER|Bowen Technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Bowen treatment will be 15 to 20 Bowen moves with 2 mins gap between each set for total of 20 mins."
219510999|NCT05751070|OTHER|Graston technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Graston treatment will be by using lubricant on the skin then a stainless steel instrument to relax the fascia and muscles. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute for total of 20 mins."
219511000|NCT04842487|DRUG|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
218891490|NCT01303198|DEVICE|APAP - Therapy|automatic positive pressure therapy
219034061|NCT03342742|BEHAVIORAL|Weight Loss|Weight loss behavioral intervention via one of two strategies.
219034062|NCT04839614|OTHER|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
219511001|NCT01180244|DEVICE|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
219511002|NCT01180244|DEVICE|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
219511003|NCT05713409|DIAGNOSTIC_TEST|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
219609068|NCT03432143|OTHER|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
219609069|NCT01228058|PROCEDURE|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
218891491|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
218891492|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
218891493|NCT00950248|DRUG|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
219034063|NCT03278964|PROCEDURE|Orbital decompression|
219034064|NCT00532285|DRUG|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
219034065|NCT06353503|PROCEDURE|autologous bone marrow aspirate concentrate|local knee joint injection of autologous bone marrow
219034066|NCT04839159|OTHER|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
219034067|NCT04839159|OTHER|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
219511004|NCT04801966|DRUG|Trametinib|2 mg per day, continuous
219511005|NCT04801966|DRUG|Cobimetinib|60 mg/day for 21 days of a 28 day cycle
219511006|NCT04801966|DRUG|Binimetinib|45 mg/twice a day, continuous
219511007|NCT04801966|DRUG|Alpelisib|300 mg/day, continuous
219511008|NCT04801966|DRUG|Vemurafenib|960 mg/twice per day, continuous
219511009|NCT04801966|DRUG|Dabrafenib|150 mg/twicce per day, continuous
219511010|NCT04801966|DRUG|Encorafenib|450 mg/day, continuous
219511011|NCT04801966|DRUG|Palbociclib|125 mg/day, day 1-21 of a 28 day cycle
219511012|NCT04801966|DRUG|Olaparib|300 mg/twice per day, continuous
219511013|NCT04801966|DRUG|Ribociclib|600 mg/day, on day 1 -21 of a 28 day cycle
219511014|NCT04801966|DRUG|Abemaciclib|150 mg twice/day, continuous
219511015|NCT04801966|DRUG|Talazoparib|1 mg/day, on day 1 -28 of each 28 day cycle
219511016|NCT04801966|DRUG|Nivolumab|240 mg IV once every 2 weeks
219511017|NCT04801966|DRUG|Atezolizumab|1200 mg IV on Day 1 of a 21 day cycle
219511018|NCT04801966|DRUG|Pembrolizumab|200 mg IV on day 1 of a 21 day cycle
219511019|NCT05221580|DRUG|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
219511020|NCT03353909|DEVICE|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
219511021|NCT01455753|OTHER|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
219511022|NCT01455753|OTHER|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
219511023|NCT00729859|DRUG|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
219511024|NCT00729859|DRUG|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
219511025|NCT00729859|DRUG|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
219511026|NCT01111110|DEVICE|anti-static then static|Albuterol using static chambers
219511027|NCT01111110|DEVICE|Static then anti-static chamber|albuterol with Static then anti-static chambers
219511028|NCT04646057|DEVICE|DuraSorb®|Monofilament Surgical Mesh
219511029|NCT03882164|DIAGNOSTIC_TEST|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
218891494|NCT00950248|OTHER|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
218891495|NCT02240511|DIETARY_SUPPLEMENT|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
219511030|NCT02623829|DRUG|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
219511031|NCT02623829|DRUG|Saline|1ml of normal saline will be administered
219511032|NCT04195295|PROCEDURE|Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane|"* In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane"
218891496|NCT02240511|OTHER|Resistance Exercise|
218891497|NCT06026878|DRUG|gemcitabine,nimotuzumab, toripalimab|same as before
218891498|NCT06026878|DRUG|gemcitabine, cisplatin|same as before
218891499|NCT00373178|DRUG|rosiglitazone|
218891500|NCT00373178|DRUG|metformin|
218891501|NCT00373178|DRUG|Anti-diabetic medications|
218891502|NCT05397249|BEHAVIORAL|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
218891503|NCT02578199|BEHAVIORAL|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
218891504|NCT04305847|OTHER|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
218891505|NCT06038422|DRUG|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
218891506|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
218891507|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
218891508|NCT01890564|OTHER|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
218891509|NCT01890564|OTHER|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
218891510|NCT01890564|OTHER|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
218891511|NCT00535119|DRUG|Carboplatin|Given IV
219609070|NCT05609513|OTHER|HTN-BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
219609071|NCT05609513|OTHER|HTN-PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
218891512|NCT00535119|OTHER|Laboratory Biomarker Analysis|Correlative studies
219034068|NCT00805974|BIOLOGICAL|Biological examinations (blood and urinary).|
218891513|NCT00535119|DRUG|Paclitaxel|Given IV
218891514|NCT00535119|OTHER|Pharmacological Study|Correlative studies
218891515|NCT00535119|DRUG|Veliparib|Given PO
219034069|NCT03552575|DRUG|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
219034070|NCT03552575|DRUG|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
218891516|NCT00230542|DRUG|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
218891517|NCT00230542|DRUG|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
218891518|NCT04600583|DEVICE|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
218891519|NCT02329899|OTHER|Second step of investigations|"Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia."
218891520|NCT03742453|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
218891521|NCT03742453|DIAGNOSTIC_TEST|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
218891522|NCT04667546|OTHER|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
218891523|NCT05400772|OTHER|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
218891524|NCT03151187|OTHER|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
219609072|NCT03864419|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219609073|NCT03864419|DRUG|Cyclophosphamide|Given IV
219609074|NCT03864419|DRUG|Vincristine|Given IV
219609075|NCT03864419|DRUG|Methotrexate|Given IV
219609076|NCT03864419|DRUG|Doxorubicin|Given IV
219511033|NCT04195295|PROCEDURE|Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material|Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.
218891525|NCT00148876|DRUG|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
219511034|NCT04195295|PROCEDURE|Open flap debridement procedure in intrabony defects.|full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
219511035|NCT03803566|OTHER|Pegboard practice|Practice of the grooved pegboard test
219609077|NCT03864419|DRUG|Doxorubicin Hydrochloride|Given IV
219609078|NCT03864419|DRUG|Prednisone|Given PO
219511036|NCT03803566|OTHER|Force control practice|Practice performing steady muscle contractions
219609079|NCT03864419|DRUG|Etoposide|Given IV
219609080|NCT03864419|BIOLOGICAL|Rituximab|Given IV
219609081|NCT03845205|BEHAVIORAL|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
219609082|NCT03379402|OTHER|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
219609083|NCT02041819|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
219609084|NCT03063008|DEVICE|PEEK|"Procedure/Surgery:~TLIF fusion with common PEEK cages."
219609085|NCT03063008|DEVICE|TiPEEK|"Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages."
219511037|NCT01082653|BIOLOGICAL|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
219511038|NCT02197728|DEVICE|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
219511039|NCT00479310|DRUG|Summers 5% L.A.|
219609086|NCT01221870|DRUG|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
219609087|NCT01221870|DRUG|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
219609088|NCT02611908|DRUG|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
218891526|NCT00148876|DRUG|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
218891527|NCT04791631|PROCEDURE|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
218891528|NCT01900652|DRUG|Emibetuzumab|Administered IV
219511040|NCT04115449|DRUG|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
219511041|NCT04115449|DRUG|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
219511042|NCT04546906|BIOLOGICAL|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
219511043|NCT01384695|DRUG|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
219609089|NCT02611908|DRUG|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
219609090|NCT05206123|OTHER|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
219609091|NCT01202175|DRUG|Nebivolol|Oral nebivolol 2.5-5mg once daily
218891529|NCT01900652|DRUG|Erlotinib|Administered Orally
218891530|NCT04629690|OTHER|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
218891531|NCT00863291|DRUG|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
219511044|NCT01384695|DRUG|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
219609092|NCT06086106|PROCEDURE|caudal block|The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
219609093|NCT06086106|PROCEDURE|Dorsal Penile Nerve Block DPNB|DPNB is A type of pain control post-operative, often performed as a circumferential infiltration of the root of the penis (ring block). Two skin wheals are raised at the dorsal base of the penis, one on each side just below and medial to the pubic spine. A 25-gauge, 37.5-mm needle is introduced on each side, and the bupivacaine (1 to 1.5 mL) maximum dose 2 ml concentration 0.25% for infants is injected superficially and deep along the lower border of the pubic ramus to anesthetize the dorsal nerve. For a complete ring of infiltration,
219609094|NCT06086106|DRUG|Systemic opioids|Systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
219511045|NCT03741608|BEHAVIORAL|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
219511046|NCT03741608|BEHAVIORAL|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
219511047|NCT03349333|DRUG|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
218891532|NCT00863291|DRUG|placebo|Placebo in a manner similar to the active comparator
218891533|NCT05175742|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
218891534|NCT05175742|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
218891535|NCT05175742|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
218891536|NCT04209933|DRUG|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
218891537|NCT04209933|DRUG|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
218891538|NCT04209933|DRUG|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
218891539|NCT04209933|DRUG|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
219511048|NCT03349333|DIETARY_SUPPLEMENT|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
219511049|NCT01961791|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
219511050|NCT01851161|PROCEDURE|computed tomography|Undergo conventional CT scan in both supine and prone positioning
219511051|NCT01851161|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
219511052|NCT01851161|RADIATION|radiation therapy|Undergo radiation therapy
219511053|NCT05955352|PROCEDURE|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
219609095|NCT01608100|DEVICE|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
218891540|NCT04109326|OTHER|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
218891541|NCT00576225|DRUG|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
218891542|NCT00576225|DRUG|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
218891543|NCT02267538|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
219034071|NCT01485562|DRUG|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
219511054|NCT03848585|DEVICE|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
219511055|NCT03848585|OTHER|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
219511056|NCT00783796|DEVICE|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
219511057|NCT00710203|DEVICE|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
219511058|NCT00710203|PROCEDURE|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
219511059|NCT00710203|PROCEDURE|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
219511060|NCT00710203|OTHER|No treatment|A fourth lesion will not be treated and will serve as a control.
219609096|NCT02790437|DRUG|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
219609097|NCT02790437|PROCEDURE|Kidney transplantation|Performed following IdeS treatment
218891544|NCT02267538|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery."
218891545|NCT00869518|DRUG|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
218891546|NCT00869518|DRUG|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
219511061|NCT02823899|BIOLOGICAL|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
219511062|NCT02823899|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
219511063|NCT02807142|BIOLOGICAL|NC 1 cell therapy|All patients will be treated with NC1
219511064|NCT01497483|DRUG|Pravastatin alone|Pravastatin 40 mg with placebo.
219511065|NCT01497483|DRUG|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
219511066|NCT03337178|BEHAVIORAL|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
219511067|NCT03337178|BEHAVIORAL|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
219034072|NCT01485562|OTHER|placebo|4 tablets, administered sublingually if the woman experiences a PPH
219511068|NCT01362933|PROCEDURE|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
219511069|NCT05152342|BEHAVIORAL|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
219511070|NCT05152342|BEHAVIORAL|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
219511071|NCT03081715|OTHER|PD-1 Knockout T Cells|Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
219511072|NCT01290393|OTHER|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
219511073|NCT03267264|DEVICE|BD Nano™ vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~2. subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
219034073|NCT06050551|PROCEDURE|uniportal VATS|"1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
219034074|NCT00729339|DRUG|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
219511074|NCT03267264|DEVICE|NovoFine® vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~2. subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
219511075|NCT03267264|DEVICE|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~2. subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
219609098|NCT04719442|BEHAVIORAL|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
219511076|NCT03267264|DEVICE|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~2. subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
219511077|NCT02559050|OTHER|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
219609099|NCT05314231|DRUG|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
218891547|NCT03413306|DRUG|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
218891548|NCT03413306|DRUG|IST (ATG + CsA)|
219034075|NCT00729339|DRUG|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
219034076|NCT02533336|DRUG|abamectin and fenpyroximate|
219203754|NCT05016791|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
219511078|NCT05329636|BIOLOGICAL|Fecal Microbial Transplant (FMT)|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
219511079|NCT05329636|OTHER|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
219511080|NCT05329636|BIOLOGICAL|Auto Fecal Microbial Transplant (FMT) via enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
219511081|NCT05911373|OTHER|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
219511082|NCT05911373|OTHER|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
219511083|NCT04210895|OTHER|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
219511084|NCT04210895|OTHER|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
219034077|NCT06219681|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.
219034078|NCT06219681|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
219511085|NCT01834521|OTHER|Web-based screening and tailored support|
219034079|NCT01720433|PROCEDURE|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
218891549|NCT01629277|DEVICE|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
218891550|NCT01629277|DEVICE|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
218891551|NCT01364025|PROCEDURE|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
219034080|NCT04648865|DRUG|LY3537031|Administered SC.
219034081|NCT04648865|DRUG|Placebo|Administered SC.
219203755|NCT06811207|DRUG|Vonoprazan|Vonoprazan (20 mg bid, for 14 days)
218891552|NCT03892239|BEHAVIORAL|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
218891553|NCT03892239|BEHAVIORAL|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
219034082|NCT05904717|DRUG|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
219034083|NCT05904717|DRUG|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
219511086|NCT02046421|DRUG|mifepristone|Given PO
219034084|NCT05319444|DEVICE|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
219511087|NCT02046421|DRUG|carboplatin|Given IV
219511088|NCT02046421|DRUG|gemcitabine hydrochloride|Given IV
219511089|NCT02046421|OTHER|laboratory biomarker analysis|Correlative studies
219511090|NCT02046421|OTHER|pharmacological study|Correlative studies
219511091|NCT04884581|DEVICE|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
219511092|NCT02476526|DRUG|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
219511093|NCT02476526|DRUG|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
219511094|NCT02476526|DRUG|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
219511095|NCT02476526|PROCEDURE|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
219511096|NCT05520424|DIETARY_SUPPLEMENT|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
219511097|NCT01766921|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
219511098|NCT06159062|DRUG|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
219511099|NCT06159062|DRUG|Placebo|Placebo do not consist any active ingredients.
219511100|NCT04832113|OTHER|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
219511101|NCT04832113|OTHER|conventional management|Dietary and hydratation advices according to the recommendations
219511102|NCT01807871|DRUG|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
219511103|NCT01807871|DRUG|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
219511104|NCT01659567|DRUG|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
219511105|NCT01659567|DRUG|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
219511106|NCT04232462|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
219511107|NCT03019965|DRUG|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
219511108|NCT03019965|DRUG|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
219511109|NCT03019965|DRUG|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
219511110|NCT03019965|DRUG|Extended Imipenem|Imipenem administered in 6 hours infusion.
219511111|NCT03019965|DRUG|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
219511112|NCT03019965|DRUG|Extended Meropenem|Meropenem administered in 8 hours infusion.
219511113|NCT01628081|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
219609100|NCT05544474|OTHER|Delphi questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of radical right colectomy. The Delphi questionnaire will be administered via www.surveymonkey.com.~In the first survey, panel members will agree on surgical steps, definition of surgical steps and nomenclature for radical right colectomy In subsequent surveys, panel expert will agree on a common definition, nomenclature and reporting for right colectomy. Multiple rounds will be conducted until consensus is reached. After each round, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 70% in the first round or need further explanation, additional rounds of the survey may be performed."
218891554|NCT06399250|OTHER|meal service|We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
218891555|NCT04556019|PROCEDURE|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
218891556|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
219511114|NCT01628081|DIETARY_SUPPLEMENT|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
219511115|NCT00219258|DRUG|Zoledronic acid|
219511116|NCT02796235|OTHER|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
219511117|NCT04857619|OTHER|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
219511118|NCT05131906|DEVICE|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
219609101|NCT01631760|GENETIC|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
219609102|NCT03727074|DRUG|5-FU Cream|topical cream twice a day
219609103|NCT03727074|DRUG|Efudex®|topical cream twice a day
219609104|NCT03727074|DRUG|Vehicle|topical cream twice a day
219609105|NCT05012046|OTHER|Orange juice|Matched for volume (240 mL/ 8 oz) of other test beverages. 100% orange juice.
219511119|NCT02720003|DEVICE|LTX DCB|Treatment with a drug-coated balloon
219511120|NCT01314690|OTHER|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
219511121|NCT00358384|DRUG|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
219511122|NCT00358384|DRUG|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
219511123|NCT00358384|DRUG|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
219511124|NCT00358384|DRUG|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
219511125|NCT01915732|DRUG|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
219511126|NCT01915732|DRUG|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
219511127|NCT00940056|PROCEDURE|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
219511128|NCT00940056|DRUG|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
218891557|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
218891558|NCT01587430|DRUG|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
218891559|NCT01587430|DRUG|standard dose ARA-C|
219511129|NCT02478307|OTHER|Cognitive Therapy|
219511130|NCT02478307|OTHER|Mindfulness Meditation|
219511131|NCT02478307|OTHER|Mindfulness-Based Cognitive Therapy|
219511132|NCT02832856|BEHAVIORAL|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
219511133|NCT02832856|BEHAVIORAL|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
219511134|NCT01684358|DEVICE|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
219609106|NCT05012046|OTHER|Orange flavoured drink|Matched for volume (240 mL/ 8 oz) of other test beverages. Orange flavoured drink
219609107|NCT05012046|OTHER|Water|Matched for volume (240 mL/ 8 oz) of other test beverages. Water control
218891560|NCT00947115|PROCEDURE|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
218891561|NCT00947115|PROCEDURE|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
218891562|NCT05768035|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
219609108|NCT00004667|DRUG|von Willebrand factor|
219609109|NCT04991246|OTHER|Antigenic tests (on saliva samples)|SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).
219511135|NCT04843163|BEHAVIORAL|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
219609110|NCT04991246|OTHER|Individual electronic sensor port|Individual electronic sensor recording contacts but not their location (in the form of a bracelet, a key ring or a badge) Contact data collection points (5 maximum, located at compulsory passage points for participants). When a sensor is close to one of these terminals, it discharges its contacts in seconds.
218891563|NCT01169935|DRUG|Administration of intra-dermal Endorem|single dose, intradermal
218891564|NCT01169935|BIOLOGICAL|Mantoux test|single dose, intradermal
219511136|NCT00244322|DRUG|LY450139 dihydrate|
219511137|NCT00244322|DRUG|placebo|
219511138|NCT04314739|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
219511139|NCT04314739|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
219511140|NCT00868309|BIOLOGICAL|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
219511141|NCT00868309|BIOLOGICAL|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
219511142|NCT05132309|COMBINATION_PRODUCT|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
219511143|NCT03567109|OTHER|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
219511144|NCT04621409|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
219609111|NCT04991246|OTHER|Atmospheric measurements of CO2|Atmospheric measurements of CO2 in the relevant closed places of the faculty (lectures / practical work / BU / refectory): battery operated sensors. When a sensor is installed in a place, the ventilation conditions (number of open windows, etc.) as well as the number of people present will be noted.
219609112|NCT00743925|DRUG|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
219609113|NCT03440840|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Application of a small electrical current (1-2 mA) across the head.
218891565|NCT01169935|BIOLOGICAL|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
219511145|NCT04621409|BIOLOGICAL|Placebo|IV infusion of saline, approximately 5 hours
219609114|NCT03440840|BEHAVIORAL|Computer-based Cognitive Training|Use of computer-delivered games or exercises with the goal of improving cognitive performance.
219609115|NCT03440840|BEHAVIORAL|Watching Educational Videos|Watching educational videos and answering questions about them
219609116|NCT05760963|OTHER|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line \>C) and caudally (line \<C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, \>C, \<C on the costiform processes were noted."
219609117|NCT00738179|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
219609118|NCT00738179|OTHER|Standard care|Standard care of cardiovascular risk factors
219609119|NCT02530502|OTHER|Laboratory Biomarker Analysis|Correlative studies
218891566|NCT01169935|DRUG|Administration of Endorem|single dose, intravenous
218891567|NCT01709656|BIOLOGICAL|MSC|"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
218891568|NCT01709656|DRUG|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
218891569|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
219511146|NCT04242771|BEHAVIORAL|Mindfulness|Subjects practice mindfulness before bedtime
219511147|NCT01569451|DRUG|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
219511148|NCT01569451|DRUG|Glatiramer Acetate|20 mg injected subcutaneously daily
219511149|NCT01569451|OTHER|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
219511150|NCT05743920|BEHAVIORAL|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
219609120|NCT02530502|BIOLOGICAL|Pembrolizumab|Given IV
219609121|NCT02530502|RADIATION|Radiation Therapy|Undergo focal RT
219609122|NCT02530502|DRUG|Temozolomide|Given PO
218891570|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
218891571|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
219609123|NCT02426502|DRUG|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
219609124|NCT02426502|DRUG|conversion of non-immunosuppressant drugs to once daily|"* Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
219609125|NCT02426502|DRUG|Conversion to once daily MPA|"* Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose."
218891572|NCT01481454|BIOLOGICAL|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
219609126|NCT03694509|OTHER|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
219609127|NCT03694509|OTHER|Water|Water 250ml.
218891573|NCT04483609|OTHER|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
218891574|NCT04483609|OTHER|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
219203756|NCT06811207|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg tid, for 14 days)
219511151|NCT04216069|OTHER|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
219609128|NCT05289505|DEVICE|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
219609129|NCT01146171|DRUG|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
218891575|NCT03058900|DRUG|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
218891576|NCT03058900|OTHER|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
219203757|NCT06811207|DRUG|Amoxicillin|Amoxicillin (750 mg qid, for 14 days)
219364709|NCT04285775|DEVICE|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
219511152|NCT04216069|OTHER|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
219511153|NCT01523964|OTHER|Testing with EIM|
219511154|NCT03871608|OTHER|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
219511155|NCT03871608|OTHER|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
219034085|NCT03464006|OTHER|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
219511156|NCT00747175|DRUG|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
219034086|NCT03464006|OTHER|Standard of Care|The normal care that patients receive at the institution.
219511157|NCT00747175|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
219511158|NCT05409677|OTHER|This was a retrospective study with no intervention other than normal treatment|This was a retrospective study with no intervention other than normal treatment
219511159|NCT00211159|DRUG|EPAX 1050TG|
219511160|NCT04025788|DEVICE|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
219034087|NCT02822989|DEVICE|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
219034088|NCT02822989|DEVICE|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
219511161|NCT02815878|BEHAVIORAL|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
219511162|NCT03614377|DIAGNOSTIC_TEST|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
219511163|NCT01507857|BIOLOGICAL|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
219511164|NCT01507857|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
219511165|NCT00963157|DRUG|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
219511166|NCT00963157|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
219034089|NCT02550496|DEVICE|Dermoscopy|
219034090|NCT04424238|BEHAVIORAL|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
219511167|NCT01166568|DEVICE|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
219511168|NCT04868526|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
219034091|NCT02984358|OTHER|Animal protein based diet|
219511169|NCT02520557|OTHER|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
219511170|NCT00233857|PROCEDURE|Auricular acupuncture|
219511171|NCT04415125|DIAGNOSTIC_TEST|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
219511172|NCT05805553|DRUG|Propranolol|2mg/kg/day in 3-4 dividd doses
219511173|NCT05805553|DRUG|Nandrolone Decanoate|1mg/kg weekly
219511174|NCT02647983|DRUG|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
219511175|NCT02230397|OTHER|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
219511176|NCT02230397|OTHER|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
219511177|NCT05097872|OTHER|Diet|Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
219511178|NCT06141070|OTHER|Standard systemic therapy + radiotherapy|Combined systemic therapy + radiation
219511179|NCT06141070|DRUG|Standard systemic therapy|Chemoimmunotherapy or immunotherapy
219511180|NCT02928913|OTHER|No intervention|
219511181|NCT01328275|DRUG|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
219511182|NCT01229085|DRUG|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
219511183|NCT02548507|OTHER|observational study, no intervention|
219511184|NCT01652365|BEHAVIORAL|RDT Training and Subsidy Offered|
219511185|NCT01652365|BEHAVIORAL|Information/Education Campaign|
219511186|NCT01654380|DRUG|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
219511187|NCT01654380|OTHER|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
219511188|NCT03432013|BEHAVIORAL|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
219511189|NCT03432013|BEHAVIORAL|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
219511190|NCT00347542|DRUG|Vitamin D|
219511191|NCT01923077|DRUG|Simvastatin|usual care with Simvastatin
219511192|NCT01923077|DRUG|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
219511193|NCT00684671|BIOLOGICAL|Twinrix|Intramuscular injection, single dose in left deltoid.
219511194|NCT00684671|BIOLOGICAL|Engerix-B|Intramuscular injection, single dose in left deltoid.
219511195|NCT00684671|BIOLOGICAL|Havrix|Intramuscular injection, single dose in right deltoid.
219511196|NCT00684671|BIOLOGICAL|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
219511197|NCT00684671|BIOLOGICAL|Vaqta|Intramuscular injection, single dose in right deltoid.
219511198|NCT03335371|DRUG|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
219511199|NCT03335371|DRUG|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
219511200|NCT03335371|DRUG|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
219511201|NCT00655577|BEHAVIORAL|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
219511202|NCT00802802|DRUG|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
219511203|NCT00802802|DRUG|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
219511204|NCT03155984|DRUG|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
219511205|NCT01323764|DEVICE|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
219511206|NCT04303338|PROCEDURE|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
219511207|NCT00638599|DEVICE|LMA®|LMA® is placed after anesthesia induction and removed after the operation
219511208|NCT00638599|DEVICE|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
219511209|NCT00003237|DRUG|cisplatin|
218891577|NCT03058900|DRUG|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
218891578|NCT01584362|DRUG|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
218891579|NCT01584362|DRUG|placebo|single oral dose of placebo
219511210|NCT00003237|DRUG|paclitaxel|
219511211|NCT00003237|PROCEDURE|surgical procedure|
219511212|NCT02582970|DRUG|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
219511213|NCT02582970|DRUG|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
219511214|NCT02582970|DRUG|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
219511215|NCT02582970|DRUG|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
219511216|NCT01759199|PROCEDURE|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
219511217|NCT01618799|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
219511218|NCT01618799|DRUG|Lamotrigine|2 x 25 mg tablet once a day
219511219|NCT04419337|DRUG|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
219511220|NCT00977288|DRUG|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
219511221|NCT00977288|DRUG|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
219511222|NCT00977288|DRUG|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
219511223|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
219511224|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
219511225|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
219511226|NCT05291078|DEVICE|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
219511227|NCT04033809|DIETARY_SUPPLEMENT|Multigrain powder (S)|A twice daily high fiber multigrain powder supplementation for 12 weeks
219609130|NCT05362071|OTHER|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
218891580|NCT01584362|DRUG|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
219511228|NCT01601678|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
219511229|NCT01601678|PROCEDURE|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
219511230|NCT03629093|DRUG|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
219511231|NCT05577793|OTHER|Mother's Voice|The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.
219511232|NCT05577793|OTHER|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
219511233|NCT05577793|OTHER|Mother's Voice +Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
219511234|NCT05577793|OTHER|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
219511235|NCT01964742|GENETIC|blood samples|
218891581|NCT01584362|DRUG|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
218891582|NCT01584362|DRUG|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
218891583|NCT01584362|DRUG|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
218891584|NCT01584362|DRUG|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
218891585|NCT05977062|OTHER|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
218891586|NCT05977062|OTHER|Phone call|Phone call at the beginning of the program and at the middle and at the end.
218891587|NCT05977062|OTHER|Online questionnaires|To be completed at week 1, 6, 12 and 24.
219511236|NCT01684553|BEHAVIORAL|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
219511237|NCT01684553|BEHAVIORAL|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
219511238|NCT04894747|DIETARY_SUPPLEMENT|Bolus ingestion of protein|Ingestion of 25g of protein
219511239|NCT01820039|OTHER|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
218891588|NCT00924339|DIETARY_SUPPLEMENT|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
218891589|NCT00924339|DIETARY_SUPPLEMENT|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
218891590|NCT00682526|DEVICE|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
218891591|NCT03063905|DRUG|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
218891592|NCT02087969|PROCEDURE|Dry Needling|
218891593|NCT02087969|PROCEDURE|Stretching|
218891594|NCT00509626|BEHAVIORAL|exercise intervention|
218891595|NCT00509626|OTHER|questionnaire administration|
218891596|NCT00509626|PROCEDURE|CAM exercise therapy|
218891597|NCT00509626|PROCEDURE|management of therapy complications|
218891598|NCT00509626|PROCEDURE|psychosocial assessment and care|
218891599|NCT00509626|PROCEDURE|quality-of-life assessment|
219034092|NCT02984358|OTHER|Low-nucleotide mycoprotein based diet|
218891600|NCT03893500|DEVICE|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
219511240|NCT06485375|DIAGNOSTIC_TEST|EMG|Disposable bipolar surface electrodes will be used. The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres. Doing so the position of the electrodes results as follows: Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
219511241|NCT03532685|PROCEDURE|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
219511242|NCT06303999|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219511243|NCT06303999|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219511244|NCT01042483|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
219511245|NCT01725451|DRUG|Testosterone|Administered topically to axillae
219511246|NCT01725451|OTHER|Deodorant Spray|Administered topically to axillae
219511247|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
219511248|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
219511249|NCT05300984|OTHER|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
219511250|NCT05300984|OTHER|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
219511251|NCT05300984|OTHER|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
219511252|NCT05485675|BEHAVIORAL|Stand & Move at Work|Web-based platform only.
219511253|NCT05485675|BEHAVIORAL|Stand & Move at Work+|Web-based platform and support from an expert facilitator
219511254|NCT04679870|DRUG|GB2064|GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
219511255|NCT00854009|DRUG|BLI-489|
219609131|NCT05362071|OTHER|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
219609132|NCT02711631|BEHAVIORAL|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
219609133|NCT04395820|DIAGNOSTIC_TEST|Lung function test|MBW
219609134|NCT04395820|DIAGNOSTIC_TEST|Imaging|MP-MRI
219609135|NCT03771092|DIETARY_SUPPLEMENT|SunActive®Fe|SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
218891601|NCT01228526|DEVICE|PriMatrix|
218891602|NCT01707901|DRUG|ONO-8539|Treatment
218891603|NCT01707901|OTHER|Placebo|Placebo
218891604|NCT03133351|DEVICE|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
218891605|NCT00662545|DRUG|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
218891606|NCT00662545|DRUG|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
218891607|NCT00653380|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
219511256|NCT00854009|DRUG|Placebo|
219511257|NCT02410512|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
219511258|NCT02410512|DRUG|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
219511259|NCT04385446|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
218891608|NCT00653380|DRUG|Monodox|Capsules, 100 mg, single-dose
218891609|NCT01571011|BEHAVIORAL|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
218891610|NCT03180125|DRUG|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
218891611|NCT03180125|DEVICE|ultrasound|ultrasound guided injection
218891612|NCT03180125|DRUG|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
218891613|NCT03180125|DRUG|Corticosteroid and 1%lidocain|injection in the carpal tunnel
219511260|NCT02167464|DRUG|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
219034093|NCT02984358|OTHER|High-nucleotide mycoprotein based diet|
219034094|NCT02404350|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
219034095|NCT05698966|OTHER|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
219034096|NCT01972672|DRUG|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
219511261|NCT02167464|OTHER|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
219511262|NCT02167464|DRUG|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
219511263|NCT02051881|OTHER|Taking intestinal biopsies|
219511264|NCT02903056|OTHER|Rett Syndrome|Diagnosis of Rett Syndrome
219511265|NCT05062850|OTHER|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
219511266|NCT03562806|DIAGNOSTIC_TEST|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
219609136|NCT03771092|DIETARY_SUPPLEMENT|Lipofer®|Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
219609137|NCT03771092|DIETARY_SUPPLEMENT|Intravenous ferric gluconate|Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
218891614|NCT02112292|DRUG|tetrahydrocannabinol|
218891615|NCT02112292|DRUG|cannabidiol|
218891616|NCT02112292|DRUG|Placebo|
218891617|NCT02745028|DIETARY_SUPPLEMENT|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
218891618|NCT05325021|DIAGNOSTIC_TEST|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
218891619|NCT05325021|DIAGNOSTIC_TEST|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
218891620|NCT02941224|DEVICE|SELUTION DCB (sirolimus coated balloon)|
219034097|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
219034098|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~1. Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~2. Behaviour change constructs"
219034099|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
219034100|NCT05844852|DEVICE|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
219034101|NCT03695731|PROCEDURE|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
219034102|NCT04692961|DEVICE|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
219034103|NCT02307006|DRUG|Ceftaroline|Surgical prophylaxis
219511267|NCT04536259|BEHAVIORAL|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
219609138|NCT06271148|OTHER|Interview|We made multiple interviews with randomly selected surgical candidates
218891621|NCT01112878|DRUG|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
218891622|NCT01112878|DRUG|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
218891623|NCT01112878|DRUG|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
218891624|NCT04479202|DRUG|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
219511268|NCT04536259|BEHAVIORAL|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
219511269|NCT04536259|BEHAVIORAL|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
219511270|NCT00341354|BEHAVIORAL|Prolonged Mechanical Ventilation|
219511271|NCT00091598|DRUG|Ambrisentan|
219511272|NCT00482547|DEVICE|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
219609139|NCT04174274|OTHER|ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
219609140|NCT04174274|OTHER|not ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
219609141|NCT02026401|BIOLOGICAL|NGM282|
219609142|NCT02026401|BIOLOGICAL|Placebo|
219609143|NCT05248737|DIETARY_SUPPLEMENT|DHA/EPA fortified chicken plus Placebo|For participants who received DHA/EPA fortified chicken
219609144|NCT05248737|DIETARY_SUPPLEMENT|non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement|Provided to participants in the group where they consumed non-fortified chicken/eggs
219609145|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced chicken plus supplement DHA Omega-3|Used in the crossover part of the study given to the group who did not received DHA bio-enhanced chicken
219609146|NCT05248737|DIETARY_SUPPLEMENT|25(OH)D bioenhanced chicken and eggs plus placebo|participants will receive 25(OH)D bioenhanced chicken and eggs plus a placebo as a dietary intervention
219511273|NCT00482547|DEVICE|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
219609147|NCT05248737|DIETARY_SUPPLEMENT|Dietary Supplement: DHA/EPA fortified eggs plus Placebo|For the participants who received DHA/EPA fortified eggs
219609148|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced eggs plus supplement DHA Omega-3|for the participants who received non-DHA bio-enhanced eggs plus supplement DHA Omega-3
219609149|NCT05248737|OTHER|non-25(OH)D fortified chicken/eggs plus placebo|Provided to participants in the group where they consumed non-fortified chicken/eggs + placebo pills
219609150|NCT02144714|BIOLOGICAL|SB5|
219511274|NCT01576978|BEHAVIORAL|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
219511275|NCT03857022|DEVICE|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
219609151|NCT02144714|BIOLOGICAL|EU sourced Humira®|
218891625|NCT04479202|DRUG|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
218891626|NCT00900029|BIOLOGICAL|No HP802 Treatment|
218891627|NCT00900029|OTHER|No HP802 Vehicle Treatment|
219609152|NCT02144714|BIOLOGICAL|US sourced Humira®|
218891628|NCT03047421|DIAGNOSTIC_TEST|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
218891629|NCT00822536|DRUG|Aspirin and Clopidogrel|Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
218891630|NCT00822536|DRUG|Aspirin|Aspirin : \<= 325 mg/j
218891631|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
218891632|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
218891633|NCT01487850|BIOLOGICAL|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
218891634|NCT03152591|DRUG|LIK066|LIK066 tablets for oral administration
218891635|NCT03152591|DRUG|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
218891636|NCT00163020|DRUG|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
219511276|NCT02015793|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
219511277|NCT02015793|BIOLOGICAL|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
219511278|NCT02777060|PROCEDURE|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
219511279|NCT02777060|PROCEDURE|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
219511280|NCT03295058|DRUG|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
219511281|NCT03295058|DRUG|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
219511282|NCT03295058|PROCEDURE|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
219511283|NCT03295058|DRUG|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
219511284|NCT00437281|DRUG|Placebo|Placebo
219511285|NCT00437281|DRUG|Pregabalin|Orally-administered pregabalin
219511286|NCT05890456|BEHAVIORAL|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
219511287|NCT05890456|BEHAVIORAL|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
219511288|NCT01685970|DRUG|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
219511289|NCT01685970|DRUG|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
219511290|NCT05084690|OTHER|Unilateral resistance training|Unilateral resistance training of the elbow flexors
219511291|NCT05084690|OTHER|Illusionary mirror visual feedback|Modified Ramachandran's mirror box
219511292|NCT05621486|BIOLOGICAL|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
219511293|NCT06482866|OTHER|Cottle's septoplasty and radiocoagulation conchoplasty|Cottle's septoplasty and radiocoagulation conchoplasty Study group - added nasal splits; Control group - nasal splits weren't used.
219511294|NCT03309891|DRUG|GX-H9|subcutaneous injection (weekly or twice-monthly)
219511295|NCT03309891|DRUG|Genotropin|subcutaneous injection (daily)
219511296|NCT01818570|DRUG|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
218891637|NCT00163020|DRUG|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
218891638|NCT06423131|PROCEDURE|TCRαβ Depleted haploidentical HCT|Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
218891639|NCT03772665|DRUG|Emixustat|Once daily oral tablet taken for 24 months
218891640|NCT03772665|DRUG|Placebo|Once daily oral tablet taken for 24 months
218891641|NCT00187473|PROCEDURE|liver biopsy|Liver biopsy every 5 years
218891642|NCT04657471|OTHER|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score \<2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
218891643|NCT06125366|DRUG|BAY1747846|Single dose; IV injection.
218891644|NCT06125366|DRUG|Matching placebo|Single dose; IV injection.
218891645|NCT05754853|DRUG|MRG002|Administrated intravenously
218891646|NCT05754853|DRUG|Docetaxel Injection|Administrated intravenously
218891647|NCT05754853|DRUG|Paclitaxel Injection|Administrated intravenously
218891648|NCT05754853|DRUG|Gemcitabine Hydrochloride for Injection|Administrated intravenously
219511297|NCT01818570|DRUG|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
219511298|NCT04853810|OTHER|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
219511299|NCT01682161|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
219511300|NCT00510549|PROCEDURE|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
219511301|NCT02848430|DIETARY_SUPPLEMENT|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
218891649|NCT05754853|DRUG|Pemetrexed Disodium Injection|Administrated intravenously
218891650|NCT05113511|DRUG|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
219511302|NCT03617484|DRUG|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
218891651|NCT05113511|DRUG|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
218891652|NCT00447226|DRUG|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
218891653|NCT04395807|DEVICE|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
219511303|NCT03617484|DRUG|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
219511304|NCT00525967|DRUG|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
219511305|NCT03939169|OTHER|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
219511306|NCT00601354|BEHAVIORAL|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
218891654|NCT04395807|DEVICE|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
218891655|NCT02986711|BEHAVIORAL|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
219511307|NCT00601354|DRUG|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
219609153|NCT01001650|BIOLOGICAL|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
218891656|NCT02986711|BEHAVIORAL|Control|Only survey questions about smoking status
218891657|NCT03969914|PROCEDURE|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
218891658|NCT03868254|DEVICE|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
219511308|NCT05868109|DRUG|inhaled nitric oxide (iNO)|In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
219511309|NCT05868109|DRUG|Sham|In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
218891659|NCT03868254|PROCEDURE|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
218891660|NCT04145882|PROCEDURE|additional osteotomies|varisation osteotomy, supination osteotomy or both
219511310|NCT02920411|OTHER|Pediatopic Treatment Cream|Applied twice a day minimum.
219511311|NCT02920411|OTHER|Pediatopic Body lotion|Applied at libitum.
219511312|NCT01519128|DRUG|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
219609154|NCT05027308|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
219609155|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
219609156|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
219609157|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
218891661|NCT02433886|PROCEDURE|Gamma Ventral Capsulotomy|
218891662|NCT04891016|DRUG|FLOT combined with toripalimab|Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
218891663|NCT02585362|BEHAVIORAL|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
219609158|NCT00718874|OTHER|Dietary|modification of macronutrient content
218891664|NCT02585362|BEHAVIORAL|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
218891665|NCT02585362|DIETARY_SUPPLEMENT|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
218891666|NCT06435377|PROCEDURE|Procedure: Cold EMR + APC|"* Initial submucosal injection of saline solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare~* Biopsy of the resection bed~* Ablation of the defect using argon plasma coagulation (APC)."
218891667|NCT00258492|BEHAVIORAL|Aerobic exercise|
218891668|NCT02848222|DEVICE|Bruder Moist Heat Compress|
218891669|NCT02848222|OTHER|Washcloth|
218891670|NCT06096649|OTHER|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Instructions: Apply to the entire face twice daily - morning and evening
219511313|NCT01519128|DRUG|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
219511314|NCT04592991|DIAGNOSTIC_TEST|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
218891671|NCT06096649|OTHER|Topical Vehicle|Instructions: Apply to the entire face twice daily - morning and evening
218891672|NCT05653414|OTHER|short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife|4 consultations with a psychologist over 2 months maximum
218891673|NCT05653414|OTHER|encouragement of early support consultation with generalist practitioner or midwife|encouragement of early support consultation with generalist practitioner or midwife
218891674|NCT02219646|DRUG|Vardenafil|Vardenafil 10 mg twice daily for six months
218891675|NCT02219646|DRUG|Placebo|Placebo two tablets daily for 6 months
219609159|NCT00683865|DRUG|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
219609160|NCT00683865|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
219609161|NCT01750801|DRUG|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
219034104|NCT02307006|DRUG|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
219511315|NCT04592991|DIAGNOSTIC_TEST|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
219609162|NCT01750801|DRUG|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
219609163|NCT03908125|DEVICE|Eversense® CGM System|Continuous Glucose monitoring device
219034105|NCT06030843|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG
219034106|NCT06030843|DRUG|Placebo|Matching placebo containing Lactose content (0.26 gram)
219034107|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
219034108|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
219609164|NCT04677335|DIETARY_SUPPLEMENT|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
219609165|NCT04677335|OTHER|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
218891676|NCT03814707|DRUG|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
218891677|NCT03814707|BIOLOGICAL|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
218891678|NCT04537975|DEVICE|C2Rx|Hemofiltration
218891679|NCT04537975|OTHER|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
218891680|NCT01145534|DRUG|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
218891681|NCT01145534|OTHER|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
218891682|NCT01803425|OTHER|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
218891683|NCT01916382|DRUG|Nitisinone|drug
218891684|NCT05941416|DIAGNOSTIC_TEST|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
218891685|NCT01436578|DRUG|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
218891686|NCT01606709|DRUG|GnRH agonist|GnRH agonist 1mg one dose
219034109|NCT01845285|DEVICE|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
219034110|NCT02086942|DRUG|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
219034111|NCT02086942|DRUG|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
219034112|NCT02086942|DRUG|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
219034113|NCT01514968|DRUG|cyclosporine|Single oral dose
219511316|NCT01643369|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
219511317|NCT01643369|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
219511318|NCT01643369|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
219511319|NCT01862328|DRUG|MLN4924|"MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle"
219511320|NCT01862328|DRUG|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle"
219511321|NCT01862328|DRUG|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
219511322|NCT01862328|DRUG|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~\- Docetaxel on Day 1 of each cycle"
218891687|NCT01606709|DRUG|hCG|5,000 IU one dose
219034114|NCT01514968|DRUG|danoprevir|Single oral dose
219511323|NCT01862328|DRUG|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~\- Carboplatin on Day 1 of each cycle"
219511324|NCT04748211|PROCEDURE|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
218891688|NCT06172686|DRUG|Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).|The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
218891689|NCT06172686|DRUG|Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
218891690|NCT04515212|OTHER|Optic Nerve Ultrasounds|Patients will have up to four ultrasounds of the optic nerve.
219034115|NCT01514968|DRUG|ritonavir|Single oral dose
219034116|NCT01991171|OTHER|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
219034117|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
218891691|NCT04977401|PROCEDURE|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
219034118|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
219034119|NCT01324388|BIOLOGICAL|LY2189265|Administered subcutaneously
219034120|NCT01324388|DRUG|Metoprolol|Administered orally
219034121|NCT01324388|DRUG|Lisinopril|Administered orally
219511325|NCT04748211|PROCEDURE|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
219034122|NCT01324388|DRUG|Placebo|Administered subcutaneously
219034123|NCT02086929|DRUG|Trazodone|
219511326|NCT05358873|DEVICE|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
219511327|NCT05358873|DEVICE|Placebo|Normal saline
219034124|NCT02086929|DRUG|Venlafaxine|
219034125|NCT06548191|BEHAVIORAL|Time-restricted eating|Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms
219034126|NCT05227794|BEHAVIORAL|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
219511328|NCT03436628|DEVICE|MyT1DHero|A mobile phone application
219511329|NCT02404740|DEVICE|Pulse oximetry|Pulse oximetry
219511330|NCT04766918|PROCEDURE|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
219511331|NCT04766918|PROCEDURE|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
218891692|NCT04977401|DEVICE|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
218891693|NCT04977401|DEVICE|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
218891694|NCT04295525|DIETARY_SUPPLEMENT|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
218891695|NCT04295525|DIETARY_SUPPLEMENT|placebo mucoadhesive oral tablet|placebo
218891696|NCT02722954|DRUG|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
218891697|NCT02722954|DRUG|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
218891698|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
218891699|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
219034127|NCT05227794|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
219034128|NCT00727753|DRUG|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
219034129|NCT00727753|DRUG|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
219034130|NCT00727753|OTHER|No treatment|No treatment
219511332|NCT01592799|PROCEDURE|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
219511333|NCT01592799|OTHER|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: \< 6 months; 6-23 months; 24-59 months; \> 5 years.
219511334|NCT04775784|DIAGNOSTIC_TEST|Determination of SARS-CoV2 presence in CNS|Brain tissue sampling
218891700|NCT03211494|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
218891701|NCT03211494|OTHER|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
218891702|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
219511335|NCT03158142|DRUG|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
218891703|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine|standart support
218891704|NCT01553903|DRUG|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
218891705|NCT01553903|DRUG|Exemestane|Exemestane 25mg/day during 5 years
218891706|NCT01553903|DRUG|Anastrozole|Anastrozole 1 mg/day during 5 years,
218891707|NCT01553903|DRUG|Letrozole|Letrozole 2.5 mg/day during 5 years,
218891708|NCT00330603|PROCEDURE|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
219034131|NCT04962646|PROCEDURE|Carbon dioxide flooding|Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
219034132|NCT04089787|OTHER|Intervention|Shortened antibiotic treatment of 5 days
219034133|NCT04089787|OTHER|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
219511336|NCT02027779|BIOLOGICAL|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
219609166|NCT00578591|DRUG|Rituximab|"Rituximab 375 mg/m\^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
218891709|NCT00996463|PROCEDURE|Electro-thermo-coagulation|Electro-thermo-coagulation
218891710|NCT00996463|DRUG|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
218891711|NCT00996463|DRUG|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
218891712|NCT00988013|RADIATION|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
218891713|NCT00988013|RADIATION|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
218891714|NCT00988013|RADIATION|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
218891715|NCT00988013|RADIATION|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
218891716|NCT00020917|BIOLOGICAL|cetuximab|
218891717|NCT00020917|DRUG|fluorouracil|
218891718|NCT00020917|DRUG|irinotecan hydrochloride|
218891719|NCT00020917|DRUG|leucovorin calcium|
219034134|NCT06131554|BIOLOGICAL|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
219034135|NCT06131554|BIOLOGICAL|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
219034136|NCT06131554|BIOLOGICAL|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
219511337|NCT02027779|BIOLOGICAL|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
219511338|NCT01656889|BIOLOGICAL|HP-802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
219511339|NCT01656889|BIOLOGICAL|Vehicle|(fibrinogen solution \& thrombin solution without cells)
218891720|NCT04410718|OTHER|Glycaemic levels|Glycaemic levels during admission for COVID-19
218891721|NCT05189912|DEVICE|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
218891722|NCT05189912|BEHAVIORAL|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
219511340|NCT04576767|OTHER|anaesthetic|different states of consciousness
219609167|NCT02242253|DRUG|Tiotropium|administered via HandiHaler®
219609168|NCT02242253|DRUG|Salmeterol|administered via metered dose inhaler (MDI)
219609169|NCT02242253|DRUG|Placebo-MDI|
219609170|NCT02242253|DRUG|Placebo HandiHaler®|
219609171|NCT05738733|DEVICE|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
219609172|NCT05738733|DEVICE|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
219609173|NCT05738733|DEVICE|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
219609174|NCT05738733|DEVICE|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
219609175|NCT00114140|DRUG|Temozolomide|"Concurrent chemoradiotherapy temozolomide given 75 mg/m\^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles."
219609176|NCT00114140|RADIATION|Radiation therapy|One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
219609177|NCT04150172|DRUG|Rebamipide SR 150mg|Test drug
219609178|NCT04150172|DRUG|Rebamipide IR 100mg|Reference Drug
219609179|NCT02261272|BEHAVIORAL|CBT for insomnia SHUTi|SHUTi
219609180|NCT02261272|BEHAVIORAL|passive patient education/sleep hygiene|
218891723|NCT02328248|PROCEDURE|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
218891724|NCT04377217|OTHER|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
218891725|NCT04303481|OTHER|normal diet|Control
218891726|NCT04303481|OTHER|weight loss program kit|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
218891727|NCT04303481|OTHER|weight loss program kit with A. muciniphila prebiotics|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
218891728|NCT05347836|DIAGNOSTIC_TEST|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
218891729|NCT04052308|BEHAVIORAL|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
218891730|NCT04052308|BEHAVIORAL|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
218891731|NCT04052308|BEHAVIORAL|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
218891732|NCT04052308|BEHAVIORAL|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
219511341|NCT03144856|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
219511342|NCT03586336|DEVICE|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
219511343|NCT03586336|DEVICE|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
219511344|NCT02153307|DEVICE|Implantable loop recorders system Reveal ICM LINQ®,|
219511345|NCT03857113|PROCEDURE|PSMA-radioguided surgery|PSMA-radioguided surgery
219511346|NCT05751681|OTHER|progestin primed ovarian stimulation protocol|progestin primed ovarian stimulation protocol
219511347|NCT05751681|DRUG|dydrogesterone (Duphaston, Abbott)|20 mg oral dose of dydrogesterone (Duphaston, Abbott)
218891733|NCT04052308|BEHAVIORAL|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
218891734|NCT04052308|BEHAVIORAL|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
218891735|NCT01209351|DRUG|Placebo|placebo
219511348|NCT05751681|DRUG|Cetrotide|0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
219511349|NCT06026982|DIETARY_SUPPLEMENT|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
219511350|NCT00003536|DRUG|antineoplaston A10|
218891736|NCT01209351|DRUG|teduglutide|teduglutide 4 mg
219511351|NCT00003536|DRUG|methotrexate|
219511352|NCT00003536|PROCEDURE|alternative product therapy|
219511353|NCT00003536|PROCEDURE|biological therapy|
218891737|NCT06185582|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
218891738|NCT04502641|DRUG|Docetaxel|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
218891739|NCT04502641|DRUG|5-fluorouracil|600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.
218891740|NCT04502641|DRUG|Cisplatin|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
218891741|NCT04502641|RADIATION|Intensity Modulated Radiation Therapy|The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.
219511354|NCT00003536|PROCEDURE|biologically based therapies|
219511355|NCT00003536|PROCEDURE|cancer prevention intervention|
219511356|NCT00003536|PROCEDURE|chemotherapy|
219511357|NCT00003536|PROCEDURE|complementary and alternative therapy|
219511358|NCT00003536|PROCEDURE|differentiation therapy|
218891742|NCT04502641|DRUG|Platinum|100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
219511359|NCT06464809|OTHER|kinesio taping (KT)|
219511360|NCT06428708|DIAGNOSTIC_TEST|[18F] PSMA-1007 PET/CT|\[18F\] PSMA-1007 PET/CT scan
218891743|NCT00228358|DRUG|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
218891744|NCT00228358|DRUG|cyclophosphamide|Given IV
218891745|NCT00228358|BIOLOGICAL|denileukin diftitox|Given IV
218891746|NCT00228358|OTHER|flow cytometry|Intracellular cytokine staining (correlative study)
218891747|NCT00228358|OTHER|immunoenzyme technique|ELIspot assay (correlative study)
218891748|NCT02348125|DRUG|Mitochondrial Cocktail|
218891749|NCT00613496|DRUG|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
218891750|NCT00613496|DRUG|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
219511361|NCT03149913|DEVICE|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
219511362|NCT03149913|DEVICE|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
219511363|NCT02942303|DRUG|Dysport|
219511364|NCT02942303|PROCEDURE|lateral orbicularis injection|
219511365|NCT02942303|PROCEDURE|Lateral orbicularis + corrugator injection|
219511366|NCT05980988|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
219511367|NCT05980988|DIETARY_SUPPLEMENT|Placebo|Placebo
219511368|NCT04432948|OTHER|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
219511369|NCT04432948|OTHER|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
219511370|NCT04432948|OTHER|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
219511371|NCT05299268|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
219511372|NCT05299268|BEHAVIORAL|No pain (Isotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
219511373|NCT04550949|DRUG|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
219511374|NCT04550949|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
219511375|NCT02521948|DEVICE|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
219511376|NCT02496026|DEVICE|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
219511377|NCT02496026|DEVICE|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
219511378|NCT02427607|DRUG|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
219511379|NCT05508100|BIOLOGICAL|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
219511380|NCT05508100|BIOLOGICAL|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
219511381|NCT05508100|BIOLOGICAL|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
219511382|NCT04469738|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
219511383|NCT04469738|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
219511384|NCT00756028|DRUG|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
219511385|NCT00756028|DRUG|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
219511386|NCT00423800|DRUG|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
219511387|NCT04164953|PROCEDURE|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
219511388|NCT04000009|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
219511389|NCT05699707|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Participants will consume a ketone monoester drink (0.75 k/kg body mass) with venous blood samples obtained before and after (30, 60 and 90 minutes) drink consumption.
219609181|NCT01878357|DRUG|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
218891751|NCT02871635|DRUG|BI 695501|
218891752|NCT02871635|DRUG|HUMIRA|
218891753|NCT00233766|DEVICE|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
218891754|NCT03530826|OTHER|No intervention|No Intervention
218891755|NCT04811066|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period."
218891756|NCT02420379|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
218891757|NCT06106048|OTHER|Closed kinetic chain exercises|"Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
218891758|NCT06106048|OTHER|Abdominal contraction exercises|"Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
218891759|NCT01768507|DIETARY_SUPPLEMENT|Resveratrol|5 g (10 capsules) as single oral dose on day 1
218891760|NCT02968368|DRUG|Ferric maltol|
218891761|NCT02968368|OTHER|Placebo|
219034137|NCT06131554|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
219034138|NCT00403247|DIETARY_SUPPLEMENT|Capsule with folate, Vitamin B12 & pyridoxine|
219034139|NCT00403247|OTHER|placebo|placebo capsule
219034140|NCT03887000|OTHER|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
219511390|NCT06334926|OTHER|no intervention, retrospective data analysis|not applicable, retrospective data analysis
219511391|NCT01181661|BEHAVIORAL|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
219511392|NCT01181661|BEHAVIORAL|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
219511393|NCT01576588|DRUG|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
219511394|NCT01576588|DRUG|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
219609182|NCT01878357|DRUG|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
219609183|NCT00600730|PROCEDURE|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
219609184|NCT00600730|PROCEDURE|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
219609185|NCT03618550|DRUG|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
219609186|NCT03618550|DRUG|gemcitabine|1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
219609187|NCT03618550|DRUG|vinorelbine|20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
219609188|NCT03618550|DRUG|liposomal doxorubicin|15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
219511395|NCT05214807|DEVICE|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
219609189|NCT03618550|PROCEDURE|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
219609190|NCT05485831|DRUG|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
219609191|NCT03321318|DRUG|AK-R215|Investigational product is prescribed to all ofrandomized subjects
218891762|NCT01966523|BEHAVIORAL|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
218891763|NCT01966523|OTHER|Control|
219609192|NCT03321318|DRUG|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
218891764|NCT01802008|PROCEDURE|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
219034141|NCT03887000|OTHER|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
219609193|NCT03321318|DRUG|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
219609194|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub A)|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
219609195|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
219609196|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub B)|Spatial Automation profile
219609197|NCT06100393|DEVICE|Investigational pre-processing algorithm (Sub D)|Microphone miscalibration profile with applied correction method
218891765|NCT01802008|PROCEDURE|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
218891766|NCT00940940|BIOLOGICAL|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
218891767|NCT00940940|BIOLOGICAL|Placebo vaccine|0.65 mL subcutaneous
219034142|NCT06171178|DRUG|ASP1012|Intravenous (IV) infusion
219034143|NCT06171178|DRUG|Pembrolizumab|IV infusion
219034144|NCT05481177|DRUG|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
219034145|NCT01075698|DRUG|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
219034146|NCT01075698|DRUG|ARB (Telmisartan)|Telmisartan 20-80 mg/day
219034147|NCT05316831|BIOLOGICAL|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
219609198|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Standard microphone calibration profile
219609199|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub C)|Spatial Automation profile and DNR algorithm
219609200|NCT03449732|DEVICE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
219609201|NCT02957383|OTHER|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
219609202|NCT02957383|OTHER|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
219609203|NCT00821561|DRUG|Nexagon®|
219609204|NCT00821561|DRUG|Nexagon® vehicle|
219609205|NCT00666328|DRUG|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
219034148|NCT05316831|BIOLOGICAL|PPSV23|Pneumococcal polysaccharides
218891768|NCT04164134|OTHER|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
218891769|NCT04585425|BEHAVIORAL|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
218891770|NCT04585425|BEHAVIORAL|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
219511396|NCT05214807|DEVICE|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
219511397|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
219511398|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
219511399|NCT02629549|DRUG|OTL38|Infusion of OTL38 prior to surgery
219511400|NCT03756753|DIAGNOSTIC_TEST|Results available to provider|Results of point of care testing are given to provider
219511401|NCT03406130|PROCEDURE|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
219511402|NCT03406130|PROCEDURE|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
219511403|NCT03935581|DEVICE|ExAblate|Auto Focusing (AF) echo imaging
219511404|NCT00679783|DRUG|AZD2281|PARP inhibitor Olaparib tablets, oral
218891771|NCT01811888|BEHAVIORAL|Quantitative sensory testing (QST)|
218891772|NCT05406336|OTHER|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
218891773|NCT04212598|DRUG|Sintilimab|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
219511405|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
219609206|NCT05064397|DRUG|Eptinezumab|Eptinezumab will be administered per schedule specified in the arm description.
219609207|NCT04820725|DIAGNOSTIC_TEST|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
219609208|NCT06300203|BIOLOGICAL|Interleukin-4 receptor responders|Interleukin-4 receptor was injected subcutaneously.
218891774|NCT01701206|BEHAVIORAL|HIV knowledge Intervention|
219034149|NCT01085097|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
219034150|NCT01085097|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
219609209|NCT06300203|OTHER|Placebo|Placebo was injected subcutaneously.
219609210|NCT06339008|DRUG|LY3650150|Administered SC
219609211|NCT06339008|DRUG|Placebo|Administered SC
219609212|NCT06339008|DRUG|Standard therapy for INCS|Administered as intranasal spray
219609213|NCT06388785|OTHER|No Intervention|This is a non-interventional study.
219609214|NCT06538116|DRUG|Mevidalen|Administered orally
219609215|NCT06538116|DRUG|Placebo|Administered orally
219609216|NCT06440239|DRUG|PMS-101|PMS-101
219609217|NCT06440239|OTHER|Standard treatment|Standard treatment according to physicians
218891775|NCT05361824|DRUG|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
219034151|NCT01085097|DRUG|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
219034152|NCT01085097|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
219609218|NCT04924075|DRUG|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
218891776|NCT05361824|DRUG|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
218891777|NCT05005481|OTHER|NIL intervention|NIL intervention will be performed on patients.
218891778|NCT04234867|DRUG|Dapagliflozin|once daily for 5 days
218891779|NCT04234867|DRUG|Placebo oral tablet|once daily for 5 days
218891780|NCT04234867|OTHER|Stress|single dose after last administration of experimental drug
218891781|NCT04234867|OTHER|Placebo Stress|single dose after last administration of experimental drug
219511406|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
219511407|NCT00996528|BEHAVIORAL|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
219511408|NCT06014437|DRUG|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
219511409|NCT06014437|DRUG|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
219511410|NCT05248932|DRUG|Norepinephrine bolus|5 microgram bolus therapy
219511411|NCT05248932|DEVICE|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
218891782|NCT04917484|DRUG|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
218891783|NCT05733156|RADIATION|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
218891784|NCT06433323|OTHER|Anti-aging cosmetic care product|"This is an intra-individual comparison study.~* frequency of application: Once a day (in the evening)~* modalities of application: Apply the cream on the tested area determined by the randomization~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)"
219034153|NCT01085097|DRUG|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
219511412|NCT05248932|DRUG|Norepinephrine infusion|2.5 microgram/min infusion
219511413|NCT05374863|DEVICE|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
219511414|NCT05374863|DEVICE|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
219511415|NCT05374863|DEVICE|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
219034154|NCT03149107|DRUG|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
219511416|NCT03908255|DRUG|Branch Chain Amino Acid|Nutritional supplementation
219511417|NCT03908255|OTHER|maltodextrin|Placebo
219511418|NCT01968733|DRUG|Solithromycin|
219511419|NCT01968733|DRUG|Moxifloxacin|
219609219|NCT05514470|OTHER|Skin biopsy|"A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond).~Culture of fibroblasts and immortalization."
219034155|NCT03149107|DRUG|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
219034156|NCT03149107|BEHAVIORAL|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
219034157|NCT03149107|BEHAVIORAL|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
219609220|NCT05270200|DRUG|Azacitidine|Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.
219609221|NCT05270200|DRUG|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
219511420|NCT00121654|DEVICE|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
219511421|NCT00756964|DRUG|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
219511422|NCT00756964|DRUG|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
219511423|NCT03960918|BEHAVIORAL|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
219511424|NCT01754259|DRUG|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
219511425|NCT01754259|DRUG|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
219511426|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
219511427|NCT04403100|DRUG|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
219511428|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
219511429|NCT04403100|DRUG|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
219609222|NCT06007716|OTHER|reflexology massage|5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
219609223|NCT06007716|OTHER|Placebo massage|Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
219511430|NCT05268978|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
219609224|NCT01795417|DEVICE|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
218891787|NCT00651716|OTHER|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
218891788|NCT00651716|OTHER|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
219034158|NCT05336474|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
219034159|NCT02570061|BEHAVIORAL|telephone|information given at the primary contact by phone, or at a scheduled later time
219511431|NCT05477329|DEVICE|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
219511432|NCT04813250|OTHER|ventilation mode setting|Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
219511433|NCT02363751|DRUG|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
219511434|NCT04938778|OTHER|PNF|PNF Participants will engage in 8 weeks of 14 hours per night fasting
219511435|NCT03664856|OTHER|interview|The patient will be asked to answer the questions that the interviewer will ask him.
219609225|NCT01795417|DEVICE|XP200 RF device|4 RF treatments of periorbital region on one side of the face
219034160|NCT02570061|BEHAVIORAL|consultation face-to-face|information given at a scheduled consultation at the hospital
218891789|NCT00651716|OTHER|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
219511436|NCT03849781|DEVICE|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
219511437|NCT05950724|DRUG|Etanercept Injection [Enbrel]|25 mg subcutaneous injection
219511438|NCT03171714|DEVICE|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
219511439|NCT03171714|DEVICE|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
219511440|NCT00638859|DRUG|Telithromycin (HMR3647)|
219511441|NCT03520283|OTHER|Interview|Ancillary studies
219511442|NCT03520283|OTHER|Questionnaire Administration|Ancillary studies
219511443|NCT03520283|BEHAVIORAL|System Support Mapping|Complete MAP
219511444|NCT04056143|DIAGNOSTIC_TEST|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
219511445|NCT06496919|DRUG|Recombinant Mutant Human Tumor Necrosis Factor|The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
219609226|NCT02665104|DEVICE|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
219609227|NCT06368011|BEHAVIORAL|acceptance and commitment therapy|Psychoeducation was delivered in 8 sessions lasting 90 minutes to two separate groups of 8-10 individuals in the experimental group.Group sessions were conducted once a week at the community mental health center under the leadership of the researcher.In total, the psychoeducation lasted 10 weeks, including make-up sessions.
219609228|NCT03996811|OTHER|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
219609229|NCT04632576|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
219609230|NCT06184945|BEHAVIORAL|Realtime audit and feedback|ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data
219609231|NCT06184945|BEHAVIORAL|RN Implementation Facilitator|ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation
218891790|NCT00697372|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
219364710|NCT03674021|OTHER|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
219364711|NCT04429126|BEHAVIORAL|Acupressure|Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
219364712|NCT00055666|DRUG|beclomethasone dipropionate|
219364713|NCT02154425|PROCEDURE|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
219364714|NCT02154425|BIOLOGICAL|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
219364715|NCT04934930|DRUG|Bendamustin|Chemotherapy
219364716|NCT04934930|DRUG|Obinutuzumab|Immunotherapy
218891791|NCT00697372|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
219364717|NCT06257914|DIAGNOSTIC_TEST|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
219364718|NCT03891550|DRUG|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
219364719|NCT00773279|DEVICE|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
219609232|NCT05881304|DEVICE|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
219609233|NCT05716737|RADIATION|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
219609234|NCT04772079|DRUG|Deucravacitinib|Specified dose on specified days
219609235|NCT04772079|OTHER|Placebo matching deucravacitinib|Specified dose on specified days
219609236|NCT00707473|DRUG|Carboplatin|Given IV
219609237|NCT00707473|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
219511446|NCT05476874|PROCEDURE|Open Mini-Laparotomy|A 5-cm paraumbilical skin is made, and the abdominal wall is incised in layers. The distal catheter tip is inserted into the peritoneal cavity in a craniocaudal direction, and the abdominal wound is sutured in layers.
219511447|NCT05476874|PROCEDURE|Abdominal Puncture|An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
219511448|NCT03197402|DIETARY_SUPPLEMENT|Leucine-enriched protein gel delivery system|Leucine enriched
219609238|NCT00707473|DRUG|Cisplatin|Given IV
218891792|NCT00991939|DRUG|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
218891793|NCT00991939|DRUG|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
219511449|NCT03197402|DIETARY_SUPPLEMENT|Milk protein gel delivery system|Non-leucine enriched
219511450|NCT01323881|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
219609239|NCT00707473|PROCEDURE|Definitive Surgical Resection|Undergo surgery
219609240|NCT00707473|DRUG|Docetaxel|Given IV
218891794|NCT01699165|DEVICE|Nasal filter|Active nasal filter
218891795|NCT01699165|DEVICE|Placebo nasal filter|Placebo nasal filter
218891796|NCT02234804|DEVICE|Xience Prime Stent|
218891797|NCT02234804|DEVICE|Medtronic Resolute Integrity stent|
218891798|NCT02234804|PROCEDURE|Angiography|
218891799|NCT02234804|PROCEDURE|OCT|
218891800|NCT03211975|OTHER|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
218891801|NCT04666896|OTHER|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
218891802|NCT04666896|OTHER|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
218891803|NCT04185675|DEVICE|The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.|All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
218891804|NCT00714415|DRUG|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219609241|NCT00707473|DRUG|Fluorouracil|Given IV
219609242|NCT00707473|PROCEDURE|Quality-of-Life Assessment|Correlative studies
219609243|NCT00707473|RADIATION|Radiation Therapy|Undergo radiation therapy
219609244|NCT03164538|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
218891805|NCT02278861|DRUG|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
218891806|NCT02278861|DRUG|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
218891807|NCT02278861|DRUG|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
218891808|NCT05465343|DRUG|Furmonertinib|Furmonertinib 160mg orally QD
218891809|NCT00307905|DRUG|Traumeel S|homeopathic remedy
218891810|NCT00307905|DRUG|Placebo remedy|identical size, shape and taste of treatment medication
218891811|NCT00123318|DRUG|epirubicin|50mg/m2 IV day 1
218891812|NCT00123318|DRUG|cisplatin|60mg/m2 IV day 1
219609245|NCT03164538|BEHAVIORAL|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
218891813|NCT00123318|DRUG|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
219511451|NCT04971057|OTHER|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
219511452|NCT05682495|DRUG|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
219511453|NCT05682495|DRUG|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
219511454|NCT05682495|DRUG|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
218891814|NCT00123318|RADIATION|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
219364720|NCT00773279|DEVICE|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
219511455|NCT05682495|DRUG|ARM D|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
219511456|NCT05682495|DRUG|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
218891815|NCT04270708|DRUG|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
218891816|NCT04270708|DRUG|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
219511457|NCT05682495|DRUG|ARM F|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
219609246|NCT00535405|DRUG|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
219609247|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
218891817|NCT06236685|DEVICE|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
218891818|NCT03165422|OTHER|Non-Interventional|Non-Interventional
218891819|NCT02766634|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
218891820|NCT02766634|BIOLOGICAL|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
218891821|NCT03315039|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
218891822|NCT00366691|DRUG|Acular LS|
218891823|NCT00366691|DRUG|Lotemax|
218891824|NCT06143267|OTHER|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
218891825|NCT01460758|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
218891826|NCT01460758|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
218891827|NCT01460758|DEVICE|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
218891828|NCT01576432|BEHAVIORAL|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
219364721|NCT01558063|DRUG|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
219364722|NCT01558063|DRUG|Saline|Single infusion of saline given intravenously over 40 minutes.
219364723|NCT01558063|PROCEDURE|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
219609248|NCT00535405|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
219609249|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
219609250|NCT00535405|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
219609251|NCT02671929|BEHAVIORAL|self-help program|Access to the internet-based self-help program
219511458|NCT00977002|OTHER|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
219511459|NCT00977002|OTHER|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
219511460|NCT03339037|DEVICE|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
219511461|NCT03339037|DEVICE|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
219511462|NCT05241821|PROCEDURE|Mechanical thrombectomy|Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
219511463|NCT05241821|DRUG|Thrombolytic Agent|Drug aimed to dissolve thrombus affecting the cerebral circulation
219511464|NCT00306748|DRUG|MD-1100 Acetate|
219511465|NCT00619385|DRUG|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
219511466|NCT02535819|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
219511467|NCT02535819|PROCEDURE|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
219511468|NCT02190461|PROCEDURE|Early Respiratory Rehabilitation Program|
219511469|NCT02190461|PROCEDURE|Conventional Respiratory Rehabilitation Program|
219511470|NCT05869942|DIAGNOSTIC_TEST|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
219511471|NCT05869942|DIAGNOSTIC_TEST|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
219511472|NCT01577511|BIOLOGICAL|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
218891829|NCT01103427|DEVICE|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
218891830|NCT01103427|DEVICE|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
218891831|NCT01103427|DEVICE|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
219511473|NCT02114307|DEVICE|REVITIVE IX|neuromuscular electrical stimulation device
218891832|NCT01103427|DEVICE|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
218891833|NCT02258646|BEHAVIORAL|Exercise training at home|
218891834|NCT02258646|BEHAVIORAL|Telemonitoring and education/self-management|
218891835|NCT05659368|DRUG|Tirzepatide|tirzepatide once weekly
219511474|NCT01543100|OTHER|blood and bone marrow samples|"Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
219511475|NCT03788499|OTHER|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
219511476|NCT03160677|OTHER|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
219511477|NCT03160677|OTHER|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
219511478|NCT00332761|DRUG|Caduet|
219511479|NCT05933096|DIAGNOSTIC_TEST|Contrast-enhanced multispectral optoacoustic tomography|Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
218891836|NCT04851054|PROCEDURE|Surgery for colon cancer with intention to cure|Surgery by open or laparoscopic approach
218891837|NCT05467384|DRUG|Amlodipine|5mg/day in two divided doses
218891838|NCT03236077|BEHAVIORAL|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
218891839|NCT01210898|BIOLOGICAL|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
219511480|NCT03674008|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
219511481|NCT03674008|DRUG|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
219511482|NCT01672346|PROCEDURE|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
219511483|NCT02264951|DIETARY_SUPPLEMENT|Tributyrin|a triglyceride containing three C4-acids
219609252|NCT02671929|BEHAVIORAL|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
219609253|NCT00327756|DRUG|Coenzyme Q10|
219511484|NCT02264951|DIETARY_SUPPLEMENT|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
219511485|NCT02264951|DIETARY_SUPPLEMENT|Olive oil|a triglyceride containing mostly three oleic acids
219511486|NCT02264951|DIETARY_SUPPLEMENT|Carrot|mainly water and glucose
219511487|NCT03678961|BEHAVIORAL|external rotation of leg|external rotation of leg by 45 degrees
219511488|NCT03678961|BEHAVIORAL|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
219511489|NCT02523456|BEHAVIORAL|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
219511490|NCT02523456|BEHAVIORAL|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
219511491|NCT00334490|DRUG|Sildenafil|12.5 mg Sildenafil once with optional second dose
219511492|NCT00334490|DRUG|Sildenafil|12.5 mg orally once with optional second dose
219511493|NCT00334490|DRUG|Placebo|Oral Placebo in 5 mls distilled water
219511494|NCT01388023|DIETARY_SUPPLEMENT|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
219511495|NCT01232673|PROCEDURE|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
219511496|NCT03845946|BEHAVIORAL|angioedema|electronic tracking book
219609254|NCT03875924|OTHER|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
218891840|NCT04233203|DRUG|Insulin Faster Aspart|Currently receiving Faster Aspart during 3 or more months.
218891841|NCT04233203|DEVICE|Insulin pump|Currently receiving CSII therapy during 6 or more months.
218891842|NCT03187444|PROCEDURE|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
218891843|NCT00740584|DRUG|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
218891844|NCT02754531|DEVICE|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
219511497|NCT02041702|DIAGNOSTIC_TEST|Non-Diagnostic Cardiac MRI scan|
219609255|NCT03404674|BIOLOGICAL|CssBA|Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B
219609256|NCT03404674|BIOLOGICAL|dmLT|Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
218891845|NCT02754531|OTHER|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
219511498|NCT02809092|BIOLOGICAL|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
219511499|NCT01484405|PROCEDURE|posterior approach|Surgical approach for Total Hip Arthroplasty
219511500|NCT01484405|PROCEDURE|anterolateral approach|anterolateral surgical approach
219609257|NCT06359912|DRUG|EPCs|IV
219609258|NCT06359912|BEHAVIORAL|Clinical standard treatment (CST)|Clinical standard treatment
219609259|NCT00264901|DRUG|insulin detemir|
219609260|NCT02012270|PROCEDURE|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
219609261|NCT02012270|PROCEDURE|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
219609262|NCT01832571|DRUG|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
219609263|NCT05855824|OTHER|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
219609264|NCT05855824|OTHER|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
219609265|NCT03091179|DEVICE|THRIVE|active nasal oxygen delivery system
219609266|NCT03091179|DEVICE|Endotracheal tube|a plastic tube for mechanical ventilation
219609267|NCT01311323|PROCEDURE|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
219609268|NCT01311323|PROCEDURE|CABG|Coronary Artery Bypass Graft
218891846|NCT04516109|DEVICE|Modified hip capsule side fixed slotted cannula|Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
219511501|NCT04958980|BEHAVIORAL|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
219511502|NCT02975466|DEVICE|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
219511503|NCT02975466|DEVICE|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
219511504|NCT02975466|DEVICE|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
219511505|NCT00349505|PROCEDURE|hyper thermic chemo + surgery|
219511506|NCT03109366|BEHAVIORAL|Online patient-provider communication service|
219511507|NCT02499549|DRUG|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
219511508|NCT05668871|DRUG|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
219511509|NCT05928728|DRUG|Colchicine|Colchicine 0.5 mg once daily
219511510|NCT05928728|DRUG|Placebo|Placebo once daily
218891847|NCT04516109|DEVICE|Modified bone graft delivery tool set|Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
219511511|NCT00134888|DRUG|Buprenorphine/naloxone|
219511512|NCT01965561|DEVICE|CRoC|Use of Combat Ready Clamp (CRoC)
219609269|NCT04459741|DIETARY_SUPPLEMENT|Dietary salt (Sodium chloride)|Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
218891848|NCT02951494|OTHER|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
218891849|NCT04789876|OTHER|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
218891850|NCT04789876|BEHAVIORAL|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
219511513|NCT01965561|DEVICE|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
219511514|NCT01965561|DEVICE|JETT|Use of Junctional Emergency Treatment Tool (JETT)
219511515|NCT01965561|DEVICE|SJT|Use of SAM Junctional Tourniquet (SJT)
219511516|NCT05709106|DRUG|Rimegepant 75 MG|Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
219511517|NCT00717756|DRUG|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
219511518|NCT00306384|DRUG|Alogliptin|Alogliptin tablets.
219511519|NCT04867161|DIAGNOSTIC_TEST|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
219511520|NCT03753854|DIAGNOSTIC_TEST|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
219511521|NCT03753854|BIOLOGICAL|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
219511522|NCT03753854|BIOLOGICAL|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
219511523|NCT03753854|OTHER|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
219511524|NCT03753854|OTHER|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
219511525|NCT06190847|OTHER|regular chemoradiotherapy|regular chemoradiotherapy
219511526|NCT04217226|DEVICE|Perfusion index derived parameters|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time."
218891851|NCT04397744|BEHAVIORAL|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
219203758|NCT06881134|DEVICE|SCS+EXS|Eligible participants will undergo implantation of the spinal cord stimulation (SCS) system. Intraoperative electrophysiological monitoring will be used to adjust stimulation parameters. SCS will be tested postoperatively to assess the patient's tolerance to stimulation and its therapeutic effects. Parameters designed to improve sensory function and bladder/bowel control will be established. All parameters will be integrated into a sequential stimulation protocol. Additionally, the simultaneous activation of the SCS and the robotic exoskeleton will be tested to ensure smooth integration. Exoskeleton-assisted training will be conducted for no less than 1 hour per day (divided into two 30-minute sessions). Other rehabilitation interventions will be provided for at least 3 hours per day. Follow-ups will be conducted at 1, 2, 3, 6, and 12 months postoperatively.
219203759|NCT04912596|DRUG|Albuterol Sulfate inhalation aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
219511527|NCT05263219|PROCEDURE|dTACE-HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination."
219511528|NCT05263219|PROCEDURE|HAIC|"HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles."
219511529|NCT05263219|DRUG|dTACE-HAIC protocol|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h."
219511530|NCT05263219|DRUG|HAIC protocol|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
219511531|NCT04125004|DEVICE|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
219511532|NCT04995978|DRUG|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
219511533|NCT04995978|DRUG|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
219511534|NCT02156648|OTHER|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
219609270|NCT06429293|BEHAVIORAL|Cognitive processing therapy|The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
219609271|NCT03904290|OTHER|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
219511535|NCT00169533|DRUG|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
219511536|NCT02941809|BEHAVIORAL|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
219511537|NCT05348109|OTHER|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
219609272|NCT00523939|DRUG|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
219609273|NCT01915030|OTHER|High protein diet|controlled feeding trail. Both arms are caloric restricted
219609274|NCT01915030|OTHER|standard protein diet|
219609275|NCT02969044|DRUG|Placebo|
219609276|NCT02969044|DRUG|PF-06651600|200mg pill every day (QD) for 8 weeks
219609277|NCT04728802|DRUG|Proxalutamide|Proxalutamide 300mg q.d
219609278|NCT04728802|DRUG|Placebo|Placebo pill
219609279|NCT00717717|BEHAVIORAL|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
219609280|NCT06488287|DEVICE|Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
218891852|NCT05434390|BEHAVIORAL|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
218891853|NCT05434390|BEHAVIORAL|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
218891854|NCT06324292|PROCEDURE|complete denture, CG|fabrication of conventional complete denture followed by a digital denture
219511538|NCT05296915|DEVICE|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
219511539|NCT05296915|DEVICE|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
219511540|NCT05296915|BEHAVIORAL|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
219511541|NCT04786652|DEVICE|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
219511542|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
219511543|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2\) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
219511544|NCT04390854|BIOLOGICAL|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
218891855|NCT06324292|PROCEDURE|complete denture, DG|fabrication of digital complete denture followed by a conventional one
218891856|NCT00950313|OTHER|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
218891857|NCT00950313|OTHER|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
218891858|NCT03000855|PROCEDURE|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
218891859|NCT03000855|PROCEDURE|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
218891860|NCT03786536|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
218891861|NCT04249817|OTHER|Video Conferencing with Exteneded Role Practitioner (VC-ERP)|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
218891862|NCT05674019|OTHER|MRI exam|Brain MRI Morphometric exam
219203760|NCT04912596|DRUG|Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
219203761|NCT04912596|OTHER|Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo|MDI
218891863|NCT01582139|DEVICE|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
219511545|NCT04390854|BIOLOGICAL|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
218891864|NCT01693536|BEHAVIORAL|Lifestyle counselling|as in Arm Description
218891865|NCT00060632|DRUG|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
218891866|NCT06440941|OTHER|chatbot-based mindfulness-based stress reduction|During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
218891867|NCT00123123|DRUG|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
218891868|NCT00123123|DRUG|placebo|
218891869|NCT03101501|DRUG|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
218891870|NCT03101501|DEVICE|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
218891871|NCT02794766|DRUG|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
219203762|NCT04912596|OTHER|Albuterol Sulfate inhalation Placebo|MDI
219203763|NCT04912596|OTHER|Methacholine|Methacholine 100 mg/vial
219203764|NCT06816771|DRUG|pazopanib|Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.
219203765|NCT06816771|DRUG|TGI chemotherapy|TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)
219203766|NCT06816771|DRUG|CIV chemotherapy|CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)
219203767|NCT06881316|OTHER|Caffeine|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCAFF (1.2% w/v caffeine solution, Nature's Supreme). An MRI was performed before the LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The caffeine solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
219203768|NCT06881316|OTHER|CHO|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCHO (6% w/ v glucose solution, Protein Ocean, Turkey) An MRI was performed prior to LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
219203769|NCT06881316|OTHER|Control|For the control condition, no supplements were taken and only exercise was performed.
219203770|NCT06679803|BEHAVIORAL|Physical Activity Chats after Stroke (PA-ChatS)|"PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety."
219034161|NCT05889598|OTHER|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
219034162|NCT05889598|OTHER|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
218891872|NCT02794766|DRUG|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
218891873|NCT02794766|DRUG|Placebo|Placebo 1 gum each 12 hours for 10 days
219034163|NCT00035854|DRUG|Zyvox® / Linezolid|
219034164|NCT01066988|OTHER|ORB Ocular Emulsion|lubricant eye drop
219034165|NCT01066988|OTHER|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
219034166|NCT06140095|DRUG|Evolocumab|See arm description
219034167|NCT00324064|PROCEDURE|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
218891874|NCT04402879|PROCEDURE|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements."
219034168|NCT04391790|PROCEDURE|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
219034169|NCT04391790|PROCEDURE|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
219034170|NCT05078853|DEVICE|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
219034171|NCT03676881|DEVICE|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
219203771|NCT06878339|BEHAVIORAL|A social robot KaKa-assisted intervention|A social robot KaKa-assisted intervention (SRAI) to provide auditory rehabilitation and physical activity program
219511546|NCT00202449|DRUG|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
219511547|NCT00202449|DRUG|paroxetine|20 mg taken at 10a for duration of the study
219511548|NCT00202449|DRUG|Placebo|Placebo
219511549|NCT03500848|DRUG|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
219511550|NCT03500848|DRUG|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
219034172|NCT03676881|DEVICE|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
219034173|NCT03062956|DRUG|MYK-491 or placebo|Oral suspension
219034174|NCT01900028|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
219034175|NCT01900028|DRUG|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
219034176|NCT01900028|DRUG|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
219034177|NCT04028245|DRUG|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
219034178|NCT04028245|DRUG|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
219034179|NCT01498640|BIOLOGICAL|Collagenase clostridium histolyticum|up to three 0.58 mg injections
219609281|NCT06488287|DEVICE|sham Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
219609282|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
219609283|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
219609284|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
219609285|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
219034180|NCT02037542|BEHAVIORAL|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
219034181|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - carbon fibers-based implants|Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
219034182|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - titanium implants|Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
219034183|NCT06293157|RADIATION|Stereotactic body radiotherapy|Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
219034184|NCT04253288|OTHER|Morbidity Mortality Review (MMR)|"* Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
219034185|NCT06558474|BEHAVIORAL|Liberal post-dilatation strategy during PCI|"A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons"
219034186|NCT03178747|DIAGNOSTIC_TEST|Methylene blue|working solution methylene blue
219034187|NCT03178747|DIAGNOSTIC_TEST|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
219034188|NCT02635516|DEVICE|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
219609286|NCT02770378|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
219609287|NCT02770378|DRUG|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
219609288|NCT02770378|DRUG|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
219609289|NCT02770378|DRUG|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
219609290|NCT02770378|DRUG|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
218891875|NCT03038295|DRUG|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
218891876|NCT03038295|DRUG|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
218891877|NCT00829842|OTHER|oral hygiene|oral hygiene with 0.12% chlorexidine
218891878|NCT00829842|OTHER|placebo|oral hygiene placebo
218891879|NCT03071887|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
218891880|NCT02073682|DRUG|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
218891881|NCT02073682|DRUG|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
218891882|NCT02073682|DRUG|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
218891883|NCT03461146|DRUG|MT-6548|Oral tablet
218891884|NCT04841616|PROCEDURE|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
219034189|NCT00415233|BIOLOGICAL|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
219034190|NCT00415233|RADIATION|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
219034191|NCT06003010|BEHAVIORAL|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
219034192|NCT01514695|DRUG|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
219034193|NCT01514695|DRUG|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
219034194|NCT01514695|OTHER|Placebo|One dose of saline (2ml)
219034195|NCT05434520|PROCEDURE|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
219511551|NCT03500848|DRUG|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
219511552|NCT03500848|DRUG|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
219511553|NCT01604681|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
219511554|NCT01604681|DIETARY_SUPPLEMENT|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
219511555|NCT05861648|DRUG|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
219511556|NCT05861648|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement: Placebo
219511557|NCT04809181|DRUG|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
219511558|NCT00002965|BIOLOGICAL|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
219511559|NCT04743258|PROCEDURE|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.
219511560|NCT04743258|PROCEDURE|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
219511561|NCT05993338|DIAGNOSTIC_TEST|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
219609291|NCT02770378|DRUG|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
219609292|NCT02770378|DRUG|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
218891885|NCT04841616|PROCEDURE|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
218891886|NCT06144879|PROCEDURE|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
218891887|NCT06144879|PROCEDURE|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
218891888|NCT06144879|PROCEDURE|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
219511562|NCT03825458|OTHER|Blood sampling|Blood sampling at each clinical follow-up visit.
218891889|NCT04392843|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
218891890|NCT04392843|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
218891891|NCT05193162|OTHER|No any intervention|have no any intervention
218891892|NCT01086774|OTHER|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
218891893|NCT00181766|DRUG|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
218891894|NCT00270309|BEHAVIORAL|Self-management|
219034196|NCT06220708|OTHER|dance movement therapy|Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
219034197|NCT06220708|OTHER|yoga training|The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
219511563|NCT05777538|OTHER|hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days.
219511564|NCT05777538|OTHER|foot exercises|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each.
219511565|NCT01379781|BEHAVIORAL|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
219511566|NCT05782790|BEHAVIORAL|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
219511567|NCT05782790|BEHAVIORAL|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
219034198|NCT02578927|DIETARY_SUPPLEMENT|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
218891895|NCT05336747|BEHAVIORAL|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
218891896|NCT00987311|DIETARY_SUPPLEMENT|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
218891897|NCT00987311|DIETARY_SUPPLEMENT|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
218891898|NCT00987311|DIETARY_SUPPLEMENT|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
218891899|NCT03353480|DRUG|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
218891900|NCT03353480|DRUG|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
218891901|NCT05586984|PROCEDURE|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
219511568|NCT01045590|DRUG|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
219511569|NCT01045590|DRUG|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
219511570|NCT02586103|DEVICE|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
219511571|NCT03041766|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
219609293|NCT02770378|DRUG|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
218891902|NCT05586984|PROCEDURE|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
219034199|NCT02578927|DIETARY_SUPPLEMENT|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
219034200|NCT02578927|DIETARY_SUPPLEMENT|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
219034201|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
219034202|NCT06385145|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
219034203|NCT06385145|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
219034204|NCT04430010|BEHAVIORAL|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
219034205|NCT04017936|DRUG|Anakinra|Active Treatment
219034206|NCT01161992|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
219511572|NCT03041766|DRUG|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
219511573|NCT01586858|OTHER|Observational|Observational study of subjects previously enrolled in the RAVE trial
219511574|NCT02689908|RADIATION|computed tomography|low dose protocol of thorax ct
219511575|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
219511576|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
219511577|NCT05228314|OTHER|Squalene based adjuvant|Squalene based adjuvant
219511578|NCT05228314|OTHER|CpG/alum adjuvant|CpG/alum adjuvant
219609294|NCT02770378|DRUG|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
219034207|NCT02438202|DEVICE|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
219034208|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
219034209|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
219034210|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
219034211|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
219034212|NCT00870571|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
219034213|NCT00870571|DRUG|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
219034214|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 24%|transfusion
219034215|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 28%|transfusion
219034216|NCT01524692|DRUG|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
219034217|NCT01970111|DRUG|KPS-0373, High dose|
219034218|NCT01970111|DRUG|KPS-0373, Low dose|
219609295|NCT02770378|DRUG|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
218891903|NCT02742220|OTHER|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
218891904|NCT02742220|OTHER|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
218891905|NCT05498168|GENETIC|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
218891906|NCT01968330|BEHAVIORAL|Go!®to sleep|
218891907|NCT00402870|DEVICE|ProSeal LMA|ProSeal LMA vs Tracheal Tube
218891908|NCT00402870|DEVICE|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
218891909|NCT00855816|BEHAVIORAL|Breathing training|relaxation training
218891910|NCT04496856|DIETARY_SUPPLEMENT|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
218891911|NCT03393494|DRUG|Adapalene and Benzoyl Peroxide Topical Gel|Test product
218891912|NCT03393494|DRUG|Epiduo Topical Product|RLD product
218891913|NCT03393494|DRUG|Placebo|Placebo gel
218891914|NCT03530943|BEHAVIORAL|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
219609296|NCT01176513|DRUG|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
218891915|NCT03530943|BEHAVIORAL|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
218891916|NCT00536237|DRUG|Comparator: niacin / Duration of Treatment: 17 Weeks|
218891917|NCT00536237|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
218891918|NCT00536237|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
218891919|NCT03222687|DRUG|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
218891920|NCT03222687|DRUG|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
218891921|NCT00002404|DRUG|Valacyclovir hydrochloride|
218891922|NCT02096016|PROCEDURE|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
219609297|NCT03164616|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
219609298|NCT03164616|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
219609299|NCT03164616|DRUG|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
219609300|NCT03164616|DRUG|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
218891923|NCT00378781|DRUG|Heparin|Heparin flush solution into CVC once daily.
218891924|NCT00378781|DRUG|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
218891925|NCT03337334|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
218891926|NCT01965704|DRUG|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
218891927|NCT01965704|DRUG|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
219034219|NCT03984591|DRUG|Eplerenone|Eplerenone according to guidelines
219034220|NCT03984591|DRUG|Spironolactone|Spironolactone according to guidelines
219609301|NCT03164616|DRUG|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
218891928|NCT00061893|DRUG|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
218891929|NCT00061893|DRUG|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
218891930|NCT00061893|DRUG|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
218891931|NCT00061893|DRUG|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
218891932|NCT00061893|DRUG|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
218891933|NCT00061893|DRUG|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. \[Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.\]
218891934|NCT00061893|DRUG|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
219364229|NCT05038683|BEHAVIORAL|Conventional Obesity Treatment|"Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
219511579|NCT04983121|DRUG|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
219511580|NCT01526538|DRUG|d-cycloserine|50 mg d-cycloserine
219511581|NCT01526538|DRUG|sugar pill|placebo
219511582|NCT03296475|PROCEDURE|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
219609302|NCT03164616|DRUG|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
219609303|NCT03164616|DRUG|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
219609304|NCT06817590|DRUG|deoxycytidine|Oral administration, in combination with deoxythymidine
219609305|NCT06817590|DRUG|deoxythymidine|Oral administration, in combination with deoxycytidine
219609306|NCT06991205|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 on-demand sessions, each \~30 minutes long, that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
219511583|NCT05129852|OTHER|Sage oil group|Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
219511584|NCT05129852|BEHAVIORAL|Reiki group|Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
218891935|NCT00061893|PROCEDURE|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
218891936|NCT00061893|RADIATION|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
219511585|NCT01880970|OTHER|starter infant formula with pro and prebiotics|
219511586|NCT01880970|OTHER|Placebo comparator|
219511587|NCT03604419|DRUG|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
219511588|NCT03604419|DRUG|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
219511589|NCT03604419|DRUG|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
219511590|NCT03604419|DRUG|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
219511591|NCT03237819|DRUG|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
219511592|NCT03237819|DRUG|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
219511593|NCT02377336|DRUG|GS-6615|GS-6615 tablets administered orally
219511594|NCT02377336|DRUG|Placebo|Placebo to match GS-6615 tablets administered orally
219511595|NCT03329027|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
219511596|NCT03329027|DEVICE|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
219511597|NCT01802502|DRUG|Rifampicin intravenous|
219511598|NCT01802502|DRUG|Oral rifampicin|
219511599|NCT01775592|DRUG|Arterakin (DHA-PPQ)|
219511600|NCT04089982|DRUG|Varenicline|Chantix
219511601|NCT04089982|DRUG|Placebo oral tablet|Placebo
219511602|NCT02730078|BEHAVIORAL|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
219511603|NCT02730078|BEHAVIORAL|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
219511604|NCT03889756|DRUG|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
219511605|NCT03889756|DRUG|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
219511606|NCT04107974|DEVICE|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
219511607|NCT04107974|PROCEDURE|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
219609307|NCT06991205|OTHER|Web-MEUC|An educational information web-based pamphlet, containing brief, summarized information tailored for the respective patient population that follows topics including the trajectory of pain and adaptation after non-traumatic painful upper extremity conditions, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living.
219034221|NCT06532513|OTHER|Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
219034222|NCT04533373|PROCEDURE|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
219511608|NCT01535326|PROCEDURE|air insufflation|insufflate air during the insertion of colonoscopy
219511609|NCT01535326|PROCEDURE|water immersion|infuse water during insertion, aspirate water during withdrawal
219511610|NCT01535326|PROCEDURE|water exchange|infuse and remove water during insertion phase of colonoscopy
218891937|NCT00061893|DRUG|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
218891938|NCT00061893|DRUG|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
218891939|NCT01526213|DRUG|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
219364230|NCT05839210|BEHAVIORAL|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
218891940|NCT04526912|DRUG|VIB7734|Single subcutaneous dose
218891941|NCT04526912|DRUG|Placebo|Intravenous single dose matched to VIB7734.
218891942|NCT00687804|DRUG|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
218891943|NCT00687804|PROCEDURE|Laser|Laser photocoagulation treatment
218891944|NCT00687804|PROCEDURE|Sham laser|Sham to laser procedure.
218891945|NCT00687804|DRUG|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
219364231|NCT05839210|BEHAVIORAL|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
219511611|NCT05048303|PROCEDURE|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
218891946|NCT02870153|DRUG|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
218891947|NCT02870153|DRUG|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
218891948|NCT02837458|DEVICE|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
218891949|NCT02837458|DEVICE|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
218891950|NCT04992663|DEVICE|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~* Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~* Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~* Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~* Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~* Counseling video (cesarean section, epidural anesthesia)"
218891951|NCT00006343|BIOLOGICAL|recombinant interferon alfa|
218891952|NCT00006343|DRUG|cytarabine|
218891953|NCT00006343|DRUG|imatinib mesylate|
218891954|NCT02686918|OTHER|Advanced Practice Nurse consultation|
218891955|NCT05377424|DRUG|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
218891956|NCT05377424|OTHER|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
219511612|NCT03444116|DIAGNOSTIC_TEST|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
219511613|NCT03444116|DIAGNOSTIC_TEST|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
218891957|NCT05377424|DRUG|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
218891958|NCT05377424|OTHER|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
218891959|NCT04390243|DRUG|Binimetinib|Given PO
218891960|NCT04390243|DRUG|Encorafenib|Given PO
219511614|NCT03444116|BEHAVIORAL|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
219511615|NCT00929500|BEHAVIORAL|MAST program|MAST program: twice a week for 4 months
219511616|NCT01104207|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
219511617|NCT01104207|DEVICE|placebo rTMS|placebo rTMS
219511618|NCT05543148|OTHER|Questionnaire|Evaluate hearing loss and communication and conversation disabilities
219511619|NCT02268422|DRUG|Buprenorphine|7 day patch
219511620|NCT00020345|DRUG|fluorouracil|
219511621|NCT00020345|DRUG|gemcitabine|
219511622|NCT00003390|DRUG|irofulven|
219511623|NCT01312610|DIETARY_SUPPLEMENT|High flavanone orange juice|High flavonone orange juice drink.
219511624|NCT01312610|DIETARY_SUPPLEMENT|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
219511625|NCT03940313|PROCEDURE|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
219511626|NCT04186390|OTHER|Simulation training in small bowel capsule endoscopy|Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
219511627|NCT02516566|OTHER|PEEP|Mechanical ventilation with PEEP 8 cmH2O
219511628|NCT02742090|DRUG|Umbralisib|Umbralisib was administered as a tablet(s), orally once daily.
219511629|NCT05057156|BEHAVIORAL|cognitive rehabilitation|patients have to use an app with cognitive games
219511630|NCT05954715|OTHER|Ischaemic Preconditioning|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
219511631|NCT05954715|OTHER|Sham|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
219511632|NCT02916173|DRUG|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
219511633|NCT02916173|DRUG|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
219511634|NCT00836927|DRUG|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
219609308|NCT04323943|DEVICE|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
219609309|NCT02419534|DRUG|Polyethylene glycol|Laxative to treat constipation
219609310|NCT02419534|DRUG|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
219609311|NCT01954862|OTHER|Air Insufflation method.|Air Insufflation method.
218891961|NCT01769963|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
218891962|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
218891963|NCT04142801|DEVICE|MeMo web application|The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
218891964|NCT04142801|OTHER|Control group|the patient have the classical follow up at the memory center (consultation)
218891965|NCT04851912|OTHER|Winterlight Apps|Longitudinal speech recordings
219609312|NCT01954862|OTHER|CO2 insufflation|CO2 insufflation.
219609313|NCT01954862|OTHER|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
219609314|NCT01954862|OTHER|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
218891966|NCT00004936|DRUG|iodinated contrast dye|
218891967|NCT00004936|PROCEDURE|computed tomography|
218891968|NCT00004936|PROCEDURE|magnetic resonance imaging|
218891969|NCT00004936|RADIATION|gadopentetate dimeglumine|
219511635|NCT00836927|DRUG|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
219511636|NCT00631176|BEHAVIORAL|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
219511637|NCT02243020|DEVICE|Vagus Nerve Stimulation (VNS)|
219511638|NCT00001074|DRUG|Hydroxyurea|
219511639|NCT00001074|DRUG|Didanosine|
219511640|NCT00004776|DRUG|topiramate|
219511641|NCT05711030|PROCEDURE|Thoracic paravertebral block multiple (3) injections|already described in arm description
219511642|NCT05711030|PROCEDURE|Thoracic paravertebral block single injection|already described in arm description
219511643|NCT02267096|BEHAVIORAL|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
219511644|NCT02267096|BEHAVIORAL|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
218891970|NCT05682339|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
218891971|NCT05682339|OTHER|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
218891972|NCT05682339|OTHER|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
218891973|NCT05682339|OTHER|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
218891974|NCT04104607|DRUG|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
219034223|NCT03993678|DRUG|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
219034224|NCT03993678|DEVICE|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
219511645|NCT02708290|OTHER|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
219511646|NCT00000464|DRUG|amiodarone|
219511647|NCT00000464|DRUG|imipramine|
219609315|NCT01954862|OTHER|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
219609316|NCT01954862|OTHER|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
218891975|NCT04800250|PROCEDURE|Treatment of gingival recessions|Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
218891976|NCT04572763|DRUG|Copanlisib|Intravenous infusion
218891977|NCT04572763|DRUG|Venetoclax|Tablet taken orally
218891978|NCT06091735|DRUG|OSS|experimental
218891979|NCT06091735|DRUG|OSS+Linzess|experimental
218891980|NCT06091735|DRUG|PEG-Interferon Alfa|Placebo Comparator
219034225|NCT04770012|DRUG|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
219034226|NCT04770012|DRUG|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
219034227|NCT04770012|DRUG|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
219034228|NCT05306418|DRUG|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
219034229|NCT00457782|DRUG|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
219034230|NCT05749575|DRUG|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
219034231|NCT03922451|DRUG|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
219034232|NCT03922451|DRUG|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
219034233|NCT00369512|DRUG|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
219511648|NCT00000464|DRUG|mexiletine|
219511649|NCT00000464|DRUG|procainamide|
219511650|NCT00000464|DRUG|propafenone|
219511651|NCT00000464|DRUG|quinidine|
219511652|NCT00000464|DRUG|sotalol|
219511653|NCT03229252|DRUG|Placebo Inhalation Solution|Normal Saline Inhalation Solution
219511654|NCT03229252|DRUG|SPX-101|SPX-101 Inhalation Solution
219511655|NCT05170256|DRUG|Trastuzumab|Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
219511656|NCT00221390|DRUG|Ropinirole (+ physical therapy)|
219511657|NCT00221390|DRUG|(vs.) Placebo + physical therapy|
219609317|NCT06989424|DEVICE|Magnetic Flexible Endoscope (MFE)|The Magnetic Flexible Endoscope (MFE) is a single-use endoscope intended to integrate with other commercially available devices for visualization of the human colon in order to eliminate the need for passage of the much stiffer, non-intuitive, risk prone standard colonoscope. The MFE will be introduced into the colon and traverse from the rectum to the cecum.
219609318|NCT03522025|DEVICE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
219609319|NCT06606106|DRUG|LY3537031|Administered SC
219609320|NCT06606106|DRUG|Placebo|Administered SC
219511658|NCT05819008|DIAGNOSTIC_TEST|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995)."
219511659|NCT05304299|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
218891981|NCT03826069|OTHER|Augmented reality-based curriculum|Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
219034234|NCT04007523|BEHAVIORAL|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
219511660|NCT03164954|DIAGNOSTIC_TEST|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
219609321|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
219609322|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
219609323|NCT06860542|DRUG|Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care|Budesonide (Pulmicort® Turbuhaler®) 800ug inhaled twice daily (BID) will be taken in addition to usual care for 36 weeks.
219609324|NCT06860542|OTHER|Arm 1- Usual care|The comparison arm will be usual care (UC) for Checkpoint inhibitor pneumonitis (CIP) (steroids).
219034235|NCT04007523|BEHAVIORAL|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
219034236|NCT02608554|BEHAVIORAL|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
219034237|NCT02608554|BEHAVIORAL|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
219609325|NCT06997497|DRUG|MK-1084|Oral tablet
218891982|NCT03826069|OTHER|Conventional Simulation Curriculum|Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
218891983|NCT03754517|DIAGNOSTIC_TEST|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
218891984|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010; placebo|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
219609326|NCT06997497|DRUG|Oxaliplatin|Per label
219609327|NCT06997497|DRUG|Leucovorin/levofolinate calcium|Per label
219609328|NCT06997497|DRUG|5-Fluorouracil|Per label
219609329|NCT06997497|BIOLOGICAL|Cetuximab|Per label
219609330|NCT06997497|DRUG|Bevacizumab|Per label
219609331|NCT05934396|BEHAVIORAL|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
219609332|NCT05934396|BEHAVIORAL|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
218891985|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
218891986|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
218891987|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
218891988|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
219511661|NCT04884659|OTHER|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
219511662|NCT04884659|OTHER|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
219511663|NCT05083650|PROCEDURE|Macular hole closure with amniotic membrane with/without internal limiting membrane peeling|Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
219511664|NCT05688930|OTHER|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
219511665|NCT05688930|OTHER|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
219511666|NCT00132002|DRUG|vorinostat|Given PO
219511667|NCT00132002|OTHER|laboratory biomarker analysis|Correlative studies
219511668|NCT05824312|DRUG|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
219511669|NCT00888810|DRUG|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
219511670|NCT00888810|DRUG|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
219511671|NCT01568008|DRUG|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
219511672|NCT05832255|DRUG|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
219511673|NCT00003213|DRUG|dexamethasone|4 mg Dexamethasone in the morning
219511674|NCT00003213|DRUG|granisetron hydrochloride|1 mg Granisetron in the morning
219511675|NCT00003213|DRUG|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
219511676|NCT02688400|DRUG|Diacerein|
219511677|NCT02688400|DRUG|Celecoxib|
219609333|NCT05934396|BEHAVIORAL|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
219609334|NCT05934396|BEHAVIORAL|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
218891989|NCT04200092|OTHER|Placebo|Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.
219511678|NCT02688400|DRUG|Placebo|
219511679|NCT04886375|PROCEDURE|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
219511680|NCT04886375|PROCEDURE|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
219511681|NCT05073575|PROCEDURE|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
218891990|NCT06463262|DIAGNOSTIC_TEST|ctDNA|the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA
218891991|NCT05986214|OTHER|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
218891992|NCT06848699|DRUG|HLX43 dose 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219034238|NCT01821534|OTHER|No Intervention|No treatment (intervention) was administered.
219511682|NCT05073575|PROCEDURE|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
219511683|NCT05460442|PROCEDURE|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
219511684|NCT05460442|PROCEDURE|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
219511685|NCT05460442|PROCEDURE|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
219511686|NCT02259842|DRUG|BI 34021 FU2 solution|
219511687|NCT02259842|DRUG|BI 34021 FU2 tablet|dose group 4 only
219511688|NCT02259842|DRUG|Placebo|
219511689|NCT02259842|OTHER|High fat, high calorie breakfast|only for dose groups 3 and 5
219511690|NCT01103037|DRUG|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
219511691|NCT01103037|DRUG|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
219511692|NCT00232115|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
219511693|NCT00232115|DRUG|Placebo|Vehicle cream (placebo)
219511694|NCT02465411|DEVICE|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
219511695|NCT03467477|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
219511696|NCT03467477|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
218891993|NCT06848699|DRUG|HLX43 dose 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
218891994|NCT06848699|DRUG|HLX43 dose 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
218891995|NCT06848699|DRUG|HLX43 dose 4|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
218891996|NCT06848699|DRUG|HLX43 dose 5|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219034239|NCT04652479|DRUG|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
219511697|NCT03853577|OTHER|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
219511698|NCT06332547|OTHER|Restrictive Transfusion Strategy|Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
219511699|NCT06332547|OTHER|Liberal Transfusion Strategy|Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
219511700|NCT01497236|DIETARY_SUPPLEMENT|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
219511701|NCT04659733|DRUG|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
219609335|NCT05934396|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
218891997|NCT06848699|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
219034240|NCT04879004|DRUG|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
219034241|NCT03872089|OTHER|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
219511702|NCT05393947|OTHER|patient education|It is planned to provide education to patients about the side effects of chemotherapy.
219511703|NCT02497677|BEHAVIORAL|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
219609336|NCT06993792|DRUG|Orforglipron|Administered orally
219609337|NCT06993792|DRUG|Placebo|Administered orally
219609338|NCT06541379|OTHER|No intervention|
219609339|NCT06004050|DRUG|Delgocitinib|Topical administration
219609340|NCT06004050|OTHER|Vehicle cream|Topical administration
218891998|NCT00196664|DRUG|Paroxetine|
218891999|NCT06845488|BEHAVIORAL|CBT|"Participants will receive will receive 12 weeks of weekly CBT for Social Anxiety, including an intervention to improve conversational skills. The CBT for Social Anxiety will include imaginal exposure, which is a way of using the imagination to work with situations that produce anxiety. Participants will also receive a mindfulness intervention."
219609341|NCT03740841|BEHAVIORAL|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
219609342|NCT03869957|DIETARY_SUPPLEMENT|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
219609343|NCT05027204|DRUG|Docetaxel|Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
219609344|NCT05027204|DRUG|Nivolumab|Nivolumab, Q3W, i.v. 30 min
219609345|NCT04687969|DRUG|[18F]DCFPyL|will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
219609346|NCT04687969|RADIATION|PET/MRI scanner|PET/MRI Scan with \[18F\]DCFPyL as directed by protocol
218892000|NCT06845488|DEVICE|VR|The VR software, the Virtual Communicator (VC) consists of a highly realistic avatar that interacts with the client in one of several situations. The therapist controls its gestures, facial expressions, body movements, and speech and builds and saves modular combinations of gestures and facial expressions that can be assembled in any order to create a conversational interaction. The software has two adult avatars of ambiguous race/ethnicity, male and female. The VC is delivered without a headset interactively over the internet, on a secure, password-protected connection that increase access by not requiring headsets and not requiring the client to come to the office. The VC can be done in English, or in Spanish where appropriate. Treatment will be done for 12 sessions. The VR software is used to provide CBT exposures to reduce anxiety and also to practice social interactions.
218892001|NCT06256445|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
218892002|NCT06256445|DRUG|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
218892003|NCT06419036|DEVICE|Pneumowave DC|Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
219034242|NCT03389009|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
219034243|NCT03784885|BIOLOGICAL|AD07010|A protein based adjuvant
219034244|NCT03784885|BIOLOGICAL|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
219034245|NCT03906045|DRUG|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
219034246|NCT02197806|DRUG|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
219034247|NCT02197806|DRUG|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
218892004|NCT05671380|BEHAVIORAL|Longitudinal Proactive Outreach (LPO).|All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.
218892005|NCT05671380|BEHAVIORAL|Ask-Advice-Connect (AAC)|Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
218892006|NCT04945642|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR-BT
219511704|NCT02497677|BEHAVIORAL|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
218892007|NCT04945642|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219511705|NCT04354194|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
219511706|NCT04354194|PROCEDURE|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
218892008|NCT05262270|DRUG|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
218892009|NCT05262270|DRUG|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
219034248|NCT02197806|DRUG|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
219034249|NCT03352323|DRUG|Oxymetazoline|RLD
219034250|NCT02547610|DEVICE|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
219511707|NCT02295774|PROCEDURE|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
219511708|NCT02295774|DRUG|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
219511709|NCT01053273|PROCEDURE|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
219511710|NCT01053273|PROCEDURE|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
219511711|NCT01075763|DRUG|Interferon beta-1a|Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
219511712|NCT01075763|DRUG|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
219511713|NCT00586521|DRUG|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
219511714|NCT02337179|PROCEDURE|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
219511715|NCT03182179|DRUG|Ondansetron 4 MG|Ondansetron is taken orally BD
219511716|NCT03182179|DRUG|Placebo|Placebo is taken orally BD
219511717|NCT03517852|DEVICE|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
219511718|NCT03145532|OTHER|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
219511719|NCT02841306|DRUG|Ursodeoxycholic Acid|
219511720|NCT00619632|BEHAVIORAL|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
219609347|NCT06607185|DRUG|LY4066434.|Administered orally.
219609348|NCT06607185|DRUG|Cetuximab|Administered intravenously.
219609349|NCT06607185|DRUG|Nab paclitaxel|Administered intravenously.
219609350|NCT06607185|DRUG|Gemcitabine|Administered intravenously.
219609351|NCT06607185|DRUG|Oxaliplatin|Administered intravenously.
219609352|NCT06607185|DRUG|Leucovorin|Administered intravenously.
219609353|NCT06607185|DRUG|Irinotecan|Administered intravenously.
219609354|NCT06607185|DRUG|5Fluorouracil|Administered intravenously.
219609355|NCT06607185|DRUG|Carboplatin|Administered intravenously.
219609356|NCT06607185|DRUG|Cisplatin|Administered intravenously.
219609357|NCT06607185|DRUG|Pemetrexed|Administered intravenously.
219511721|NCT00619632|BEHAVIORAL|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
219511722|NCT00619632|BEHAVIORAL|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
219511723|NCT01022788|BEHAVIORAL|Home-based counselling|
218892010|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-NTX|3 doses of intramuscular injections (Week 0, 3, 6)
218892011|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-BUP|2 doses of subcutaneous injections (Week 0, 4)
218892012|NCT06122584|DRUG|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
218892013|NCT04024696|DRUG|Abexinostat|Abexinostat Tosylate Tablets
218892014|NCT03869008|DEVICE|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
218892015|NCT03869008|DEVICE|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
218892016|NCT05630001|DRUG|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
219034251|NCT03487861|DIAGNOSTIC_TEST|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
219034252|NCT03477227|DEVICE|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
219511724|NCT02103088|BEHAVIORAL|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
219511725|NCT03654456|BIOLOGICAL|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
219511726|NCT03584737|DIAGNOSTIC_TEST|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
219511727|NCT03584737|DIAGNOSTIC_TEST|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
219609358|NCT06607185|DRUG|Pembrolizumab|Administered intravenously.
219609359|NCT06598943|DRUG|Eltrekibart|Administered
219609360|NCT06598943|DRUG|Mirikizumab|Administered
219034253|NCT03477227|DEVICE|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
219034254|NCT02283047|BEHAVIORAL|DIET|Lifestyle intervention through hypocaloric diet
219609361|NCT06598943|DRUG|Placebo|Administered
219609362|NCT06528314|DRUG|Efruxifermin|Administered by subcutaneous injection
218892017|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
218892018|NCT05683184|DRUG|[11C]OMAR|For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
219034255|NCT02283047|BEHAVIORAL|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
219034256|NCT02283047|BEHAVIORAL|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
219511728|NCT03584737|DIAGNOSTIC_TEST|PCR assay|Semiquantitative real-time PCR assay
219511729|NCT02352883|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219511730|NCT02352883|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy
219511731|NCT02352883|PROCEDURE|Therapeutic Surgical Procedure|Undergo wide local excision
219511732|NCT02352883|RADIATION|Radiation Therapy|Undergo radiation therapy
219511733|NCT02352883|DRUG|Endocrine Therapy|Undergo endocrine therapy
219511734|NCT02352883|OTHER|Quality-of-Life Assessment|Ancillary studies
219511735|NCT02352883|OTHER|Laboratory Biomarker Analysis|Correlative studies
219511736|NCT02352883|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219511737|NCT03845309|BEHAVIORAL|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
219511738|NCT02261428|DEVICE|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
219609363|NCT06528314|DRUG|Placebo|Administered by subcutaneous injection
219609364|NCT06614946|BEHAVIORAL|Electronic Safety Plan (ESP)|Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.
219609365|NCT06614946|BEHAVIORAL|Text support|Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
219511739|NCT02261428|DEVICE|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
219511740|NCT05702177|DRUG|Daridorexant 25 mg|A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
219511741|NCT05702177|DRUG|Daridorexant 50 mg|A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
219511742|NCT05702177|DRUG|Placebo|A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
219511743|NCT06057883|DIETARY_SUPPLEMENT|Probiotic|A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
219511744|NCT03480711|PROCEDURE|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
219511745|NCT03480711|PROCEDURE|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
219511746|NCT01095003|DRUG|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
219511747|NCT01095003|DRUG|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
219511748|NCT03493126|DRUG|Estradiol|17β-estradiol vaginal cream
219511749|NCT03493126|OTHER|Placebo|Compounded placebo cream
219511750|NCT05531266|OTHER|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10\^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
219511751|NCT05531266|OTHER|glucocorticoids|Participants were treated with glucocorticoids only.
218892019|NCT05564754|DEVICE|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
218892020|NCT05564754|OTHER|High MAP|A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.
218892021|NCT05564754|OTHER|Deep sedation|Deep sedation for at least 36h
219511752|NCT05414474|OTHER|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
219511753|NCT05414474|OTHER|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
219511754|NCT05414474|OTHER|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
219511755|NCT05414474|OTHER|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
219511756|NCT05414474|OTHER|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
219511757|NCT05414474|OTHER|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
219511758|NCT04809870|PROCEDURE|surgery|retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
219511759|NCT05326022|DEVICE|Microcurrent therapy|Microcurrent therapy
219609366|NCT06998498|BEHAVIORAL|Ready for Recovery|The Ready for Recovery program is a 6-week, multicomponent, tailored, prehabilitation intervention to promote the optimization of medical and psychological status prior to surgery. Its key components include education, enhancement of beneficial health behaviors, reduction of negative psychological symptoms, and the promotion of social support. Following an initial session, the team will develop a customized prehabilitation plan for each participant. Participants will work towards goals each week and will discuss progress with their study trainer via weekly phone sessions, which will continue until the scheduled surgical procedure.
218892022|NCT05564754|OTHER|Fever control without a device|Management of fever in the ICU without a device
219511760|NCT05326022|DEVICE|Low Level Laser Therapy|Laser therapy
219511761|NCT05326022|OTHER|Medical therapy|Medical therapy
218892023|NCT05564754|OTHER|Low MAP|A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.
218892024|NCT05564754|OTHER|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
219511762|NCT05518942|BEHAVIORAL|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
218892025|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
219511763|NCT03731182|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
219511764|NCT03731182|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
219511765|NCT02007148|DRUG|capecitabine|twice a day
219511766|NCT02007148|DRUG|Docetaxel|cycles repeated every 3 weeks
218892026|NCT04559893|BEHAVIORAL|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
218892027|NCT04700098|BEHAVIORAL|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
218892028|NCT04700098|BEHAVIORAL|Online insomnia patient education|Online insomnia patient education
218892029|NCT05774717|DRUG|Tranexamic acid|1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
218892030|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
218892031|NCT05297786|DRUG|Placebo|Placebo injection
219034257|NCT02283047|BEHAVIORAL|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
219034258|NCT00448474|BEHAVIORAL|Mailed Arthritis Self-Management Education|
219034259|NCT05544786|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
219034260|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
219034261|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
219034262|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
219034263|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
219034264|NCT02306629|BIOLOGICAL|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
218892032|NCT06434012|OTHER|registry|This is registry for Infective Endocarditis
218892033|NCT06275412|BEHAVIORAL|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
219034265|NCT02306629|BIOLOGICAL|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
219034266|NCT03065244|DRUG|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
219511767|NCT01440530|BEHAVIORAL|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
219511768|NCT01440530|OTHER|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
218892034|NCT06275412|BEHAVIORAL|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
218892035|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
218892036|NCT05314998|DRUG|Oxaliplatin|85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
218892037|NCT05314998|DRUG|Irinotecan|150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
218892038|NCT05314998|DRUG|Folinic acid|400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
218892039|NCT05314998|DRUG|5-fluorouracil|2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
219034267|NCT03065244|DRUG|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
219034268|NCT01907672|PROCEDURE|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
219034269|NCT00187460|BEHAVIORAL|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
219034270|NCT03163082|OTHER|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
219034271|NCT03163082|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
219034272|NCT03163082|OTHER|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
219511769|NCT00311779|DRUG|Spinosad Creme Rinse|
219511770|NCT02883790|DIETARY_SUPPLEMENT|Somnage|Melatonin 1mg, Zinc, Magnesium
219511771|NCT02883790|OTHER|Placebo|Placebo
218892040|NCT05314998|DRUG|Gemcitabine|1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
218892041|NCT05314998|DRUG|Capecitabine|1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
218892042|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
218892043|NCT06800274|DRUG|NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL|80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
218892044|NCT06800274|DRUG|azelastine hydrochloride 0.05%|54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
218892045|NCT06113211|DRUG|Narcotic pain medication|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
218892046|NCT06113211|DRUG|Nonnarcotic pain medications|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
218892047|NCT05528341|BIOLOGICAL|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
218892048|NCT06260670|DEVICE|Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter|"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."
218892049|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
218892050|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
218892051|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
218892052|NCT05939999|OTHER|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
218892053|NCT05939999|OTHER|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
218892054|NCT00206336|DRUG|Topiramate (drug)|Topiramate 25 mg to 200 mg
218892055|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
218892056|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
218892057|NCT04639024|DRUG|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
218892058|NCT01196026|BIOLOGICAL|Fluarix™|One or two intramuscular injections
218892059|NCT01196026|BIOLOGICAL|Havrix™ Junior|Two intramuscular injections
218892060|NCT01687296|DRUG|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
218892061|NCT01687296|DRUG|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
218892062|NCT01687296|DRUG|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
218892063|NCT01687296|DRUG|placebo tablet|placebo soluble tablet, oral ,once daily
218892064|NCT01687296|DRUG|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
219034273|NCT03163082|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
219511772|NCT02006706|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
218892065|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
218892066|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
218892067|NCT01471834|DEVICE|BAROSTIM NEO System|
218892068|NCT01471834|DRUG|Medical Management|
218892069|NCT05152108|DEVICE|BCI feasibility test|Testing the feasibility of BCI device by determining the accuracy of BCI control
218892070|NCT05326633|COMBINATION_PRODUCT|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
219034274|NCT02755324|BIOLOGICAL|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
219511773|NCT02006706|DRUG|methotrexate|10 - 25 mg/week
218892071|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.5 mg/kg
218892072|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.25 mg/kg
218892073|NCT04912583|DEVICE|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
219034275|NCT05259007|DIETARY_SUPPLEMENT|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
219511774|NCT02006706|DRUG|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
218892074|NCT04912583|DEVICE|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
218892075|NCT04300101|OTHER|Prospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
218892076|NCT04300101|OTHER|Retrospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
218892077|NCT06551168|OTHER|Heat exposure|Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.
218892078|NCT06551168|OTHER|Control group|Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
218892079|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game (Psycho-education Tool) Design|"The narrative-based medication intervention game Healing Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
218892080|NCT00752479|BIOLOGICAL|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
218892081|NCT00752479|DRUG|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
218892082|NCT00213265|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
218892083|NCT00213265|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
218892084|NCT02072265|DEVICE|Infrared thermal images|
218892085|NCT04979650|DRUG|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
218892086|NCT04979650|DRUG|Normal saline|500 g of normal saline without methylprednisolone succinate
218892087|NCT01568840|OTHER|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
218892088|NCT01568840|OTHER|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
218892089|NCT05088057|DRUG|Camrelizumab|200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
219511775|NCT02145975|DRUG|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
219609367|NCT06069583|BEHAVIORAL|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
218892090|NCT05088057|DRUG|Doxorubicin|60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
218892091|NCT05088057|DRUG|Cyclophosphamide|600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
218892092|NCT05088057|DRUG|Docetaxel|75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
218892093|NCT04131946|OTHER|Community-Based (Intervention Arm)|Community dispensed FIT
219034276|NCT05259007|DRUG|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
218892094|NCT02378324|OTHER|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
218892095|NCT01463241|BEHAVIORAL|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
219034277|NCT05259007|OTHER|IV saline 0.9%|Physiological serum solution is given as a placebo
219034278|NCT05259007|OTHER|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
219511776|NCT02145975|DRUG|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
219511777|NCT00582036|DRUG|Regular Insulin|Use of sliding scale insulin as per Appendix 1
219511778|NCT00582036|DEVICE|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
219511779|NCT03354247|BEHAVIORAL|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
219511780|NCT04147754|PROCEDURE|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
219511781|NCT04147754|PROCEDURE|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
219511782|NCT04147754|PROCEDURE|Erector spinae block|Preoperative erector spinae block at physician discretion
219511783|NCT02873390|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
219511784|NCT05492591|DRUG|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
219511785|NCT05492591|DRUG|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
219511786|NCT05492591|DRUG|Valacyclovir|Valacyclovir is a positive control drug.
219511787|NCT03141489|DIETARY_SUPPLEMENT|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
218892096|NCT02486016|DRUG|Duragesic reference fentanyl TDS|25 µg/hour
218892097|NCT02486016|DRUG|Apotex generic fentanyl TDS|25 µg/hour
218892098|NCT02486016|DRUG|Mylan generic fentanyl TDS|25 µg/hour
218892099|NCT00056979|DRUG|CAMPATH-1H|
218892100|NCT00056979|DRUG|Anti-CD45|
218892101|NCT00056979|DRUG|FK506|
218892102|NCT00056979|DRUG|Fludarabine|
218892103|NCT05865522|OTHER|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
218892104|NCT05865522|OTHER|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
218892105|NCT05747183|PROCEDURE|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
218892106|NCT05747183|PROCEDURE|ProTaper Gold|Root canal preparation using ProTaper Gold files.
219034279|NCT05275647|DRUG|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
219034280|NCT05275647|DRUG|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
219034281|NCT05486221|OTHER|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
219034282|NCT03717480|DEVICE|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
219034283|NCT03603444|OTHER|No intervention are provided|
219034284|NCT03647865|PROCEDURE|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
219034285|NCT00199355|DRUG|Istradefylline (KW-6002)|
219034286|NCT04448405|BEHAVIORAL|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
218892107|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
218892108|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
218892109|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
218892110|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
218892111|NCT01552863|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
218892112|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
218892113|NCT02957734|PROCEDURE|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
218892114|NCT03672292|DRUG|SCY-078|Oral tablets of SCY-078
218892115|NCT03672292|DRUG|Voriconazole|Voriconazole IV vials or oral tablets
218892116|NCT03672292|OTHER|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
218892117|NCT05730309|BEHAVIORAL|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
218892118|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
218892119|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
218892120|NCT01035671|DRUG|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
218892121|NCT00799903|DRUG|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
218892122|NCT00799903|DRUG|Placebo|Placebo administered in addition to standard therapy
218892123|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
218892124|NCT01216813|OTHER|informational intervention|
218892125|NCT01216813|PROCEDURE|assessment of therapy complications|
219034287|NCT06243887|OTHER|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
219034288|NCT06243887|OTHER|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
219034289|NCT02190812|DEVICE|Forearm supporter|The forearm supporter be use in tennis elbow.
219034290|NCT02190812|DEVICE|Grip ball|
219034291|NCT04573595|DEVICE|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
218892126|NCT01216813|PROCEDURE|psychosocial assessment and care|
218892127|NCT05395325|OTHER|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
218892128|NCT05395325|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
218892129|NCT05395325|OTHER|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
218892130|NCT02864901|DRUG|KSL-W|Antimicrobial KSL-W Plaque reducing chewing gum
219034292|NCT02782533|DEVICE|Deep Brain Stimulation V3|
219034293|NCT01894152|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
219034294|NCT03891420|DRUG|Galidesivir|Galidesivir IV infusion
219034295|NCT03891420|DRUG|Placebo|Placebo IV infusion
219034296|NCT05533047|PROCEDURE|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
219034297|NCT02401880|DRUG|Linagliptin|22 subjects will receive Linagliptin for 30 days
219034298|NCT02401880|OTHER|Placebo|22 subjects will receive Placebo for 30 days
219034299|NCT02401880|DRUG|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
219034300|NCT00641407|DRUG|NPL insulin|Starting dose 10 IU bedtime and then titration
219034301|NCT00641407|DRUG|Insulin glargine|10 IU bedtime and then titration
218892131|NCT04905745|PROCEDURE|Korean integrative medicine|"Any kind of Korean integrative medicine will be applicable and the treatment will be entirely determined by experienced clinicians. On the premise of the above, the following examples are the treatments applicable to the subject of this observational study.~* Chuna: Chuna therapy is performed on the face and cervical spine to induce decompression of the captured facial nerve. In addition, SJS Non-Resistance Technique-Facial palsy (SJS NRT-F), a technique of Chuna, can be performed to stimulate the intrinsic receptive sensation of the facial muscles to promote the neuromuscular response.~* Acupuncture: acupuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Pharmacopuncture: pharmacopuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Herbal medicine: It is prescribed according to clinical judgment according to the patient's symptoms and disease status."
218892132|NCT04777331|DRUG|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
218892133|NCT04777331|DRUG|Placebo|Prasinezumab placebo will be administered to participants.
219034302|NCT03444922|OTHER|Placebo|Ingestion of Placebo
219034303|NCT03444922|OTHER|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
219034304|NCT03444922|OTHER|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
219511788|NCT04401566|OTHER|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
219511789|NCT04401566|OTHER|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
219511790|NCT04401566|OTHER|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
219511791|NCT03108365|DEVICE|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
219511792|NCT03108365|DEVICE|Cotton Gauze|Size: 1 x 1 cm
219511793|NCT04403048|PROCEDURE|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
219511794|NCT04403048|PROCEDURE|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
219609368|NCT05016739|DEVICE|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
219609369|NCT06672549|DRUG|Orforglipron|Administered orally. ISA specific interventions will be listed in the ISA.
219609370|NCT06672549|DRUG|Placebo|Administered orally. ISA specific interventions will be listed in the ISA.
219609371|NCT06593860|BEHAVIORAL|Remote speech rehabilitation|Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
218892134|NCT05730387|OTHER|Observational only|This is a non-interventional study
218892135|NCT04823442|DRUG|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
218892136|NCT04823442|DRUG|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
218892137|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
219034305|NCT04680689|DIAGNOSTIC_TEST|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
219034306|NCT04680689|DIAGNOSTIC_TEST|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
219034307|NCT04680689|DIAGNOSTIC_TEST|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
219034308|NCT04459312|DIAGNOSTIC_TEST|Antibody test (SARS-CoV2)|Antibody test
219034309|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)"
219034310|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
219034311|NCT02641769|BIOLOGICAL|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
219034312|NCT04395209|OTHER|assesment|muscle strength assessment in stroke individuals
218892138|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
219511795|NCT05755425|DEVICE|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
218892139|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
219034313|NCT04563169|OTHER|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
219034314|NCT00962507|DRUG|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
219034315|NCT00962507|DRUG|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
219034316|NCT00962507|OTHER|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
219034317|NCT00962507|OTHER|pharmacological study|Pre-study, day 1 and day 26
219511796|NCT05755425|DEVICE|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
219511797|NCT01790022|DRUG|Methylprednisolone|
219511798|NCT04161144|DRUG|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
219511799|NCT04161144|DRUG|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
219511800|NCT04645095|DEVICE|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
219609372|NCT07007442|OTHER|Instrument assisted soft tissue mobilization|for application of IASTM. the patient will sit on chair in comfortable position, apply lubricant material on treated area (trapezius muscle). Apply IASTM in 30-60 angle for 40 to 120 sec until hyperemia occur for each side+ conventional therapy
219609373|NCT07007442|OTHER|dry cupping|the dry cupping will be aplied by using plastic cups that are placed over localized areas of skin. A vacuum suction is achieved with a manual handheld pump device to create a negative pressure, drawing localized skin and soft tissue structures into the cup+ conventional therapy
219609374|NCT07007442|OTHER|conventional therapy|the patients will receive Isometric strengthening exercises for cervical Extensors, Flexors, bilateral side Flexors and Rotators (resistance was about 50% of the patient's maximum strength, hold for 10 seconds, for 10 repetitions.Stretching of the upper fibers of trapezius (stretching was held for 30 seconds and repeated 3 times). postural correction exercises in the form of ; 1) Chin tucks exercise is quick and easy to do and it helps strengthening upper thoracic extensors, the muscles that align head over shoulders.2)Corner stretch: provides a deep stretch of the chest and shoulders, which can help maintain good posture.
219609375|NCT07127159|BEHAVIORAL|Intentional Music Listening|Participants will receive an iPad with Spotify (for music listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will listen to music for one hour per session, without multitasking (e.g., no chores or cooking), and will be encouraged to listen attentively. The investigators will collaborate with each participant to co-create a personalized playlist composed of self-selected, culturally relevant songs. This playlist can be updated at any time by the participant, either independently or with assistance from the team. During the music-listening session, participants will be on FaceTime with a team member, who will be available to provide support as needed. A custom Python script will continuously track the songs played by participants through Spotify, logging playback activity for research purposes.
219609376|NCT07127159|BEHAVIORAL|Audiobook Listening|Participants will be provided with an iPad equipped with a Spotify (for audiobook listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will be asked to listen to an audiobook of their choice for one hour per session, without engaging in other activities such as chores or cooking. Participants will be instructed to listen attentively and avoid multitasking during the session. A team member will connect with each participant via FaceTime to offer support. Participants may update or change their audiobook selections at any time, either independently or with help from the team. A custom Python script will be used to continuously track audiobook playback activity for research and analysis.
219609377|NCT07005284|DRUG|LY3981314|Administered SC
219609378|NCT07005284|DRUG|Placebo|Administered SC
219034318|NCT00768144|DRUG|Sunitinib|
219034319|NCT02378363|OTHER|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
219034320|NCT04432311|BEHAVIORAL|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
219034321|NCT04432311|BEHAVIORAL|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
219034322|NCT00744627|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
219034323|NCT00744627|DRUG|Placebo|Vortioxetine placebo-matching capsules
219034324|NCT02268786|OTHER|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
219034325|NCT00366600|DRUG|neratinib|HKI-272
219034326|NCT04251221|DRUG|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
219511801|NCT04645095|DEVICE|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
219511802|NCT04954014|DRUG|Bevacizumab|Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
219511803|NCT04954014|DRUG|BAT|Patients will receive best available treatment for COVID-19.
219511804|NCT04703946|OTHER|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~1. Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~2. Association or not of the AG with sex.~3. Association or not of the AG with gestational age.~4. Association or not of the AG with other minor and major malformations."
219511805|NCT04759508|DIETARY_SUPPLEMENT|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
219511806|NCT04759508|DIETARY_SUPPLEMENT|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
219511807|NCT04473508|DRUG|Local administration of ropivacaine|Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery
219511808|NCT04473508|DRUG|Local administration of placebo (saline solution)|injection of saline solution in addition with conventional anesthesia for spine surgery
219511809|NCT05936879|OTHER|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
219609379|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Ketone Supplement|Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.
219609380|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Placebo|Participants (n=25) will receive three doses of a placebo drink for seven days.
219609381|NCT05314010|DRUG|MIL62|"Phase 1b: Participants will receive intravenous (IV) infusions of MIL62 at doses of 500 mg or 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, W79D1, W105D1, W131D1, W157D1, W183D1, and W209D1. Participants initially assigned to the 500 mg dose group who exhibit good tolerance may be escalated to the 1000 mg dose starting from W25D1.~Phase 3 (Randomised Controlled Period \[RCP\]): Participants will receive IV MIL62 1000 mg or placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1. The administration protocol for placebo is identical to that of MIL62.~Phase 3 (Open-Label Period \[OLP\]): Participants who enter the OLP will receive IV MIL62 1000 mg on W1D1, W27D1, W53D1, W79D1, W105D1, and W131D1, along with matching placebo on W3D1."
219609382|NCT05314010|OTHER|Placebo|"Phase 3 (RCP): Participants will receive IV placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1.~Phase 3 (OLP): Participants entering the OLP will receive IV MIL62 1000 mg on W1D1, W3D1, W27D1, W53D1, W79D1, W105D1, and W131D1."
219034327|NCT06427356|BEHAVIORAL|PREVAIL Interdisciplinary Team|Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
219034328|NCT04725760|DEVICE|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
219034329|NCT00632255|DRUG|Imatinib|Conventional therapy with imatinib
219034330|NCT05719805|DRUG|Mavacamten|Specified dose on specified days
219034331|NCT01797289|OTHER|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
219034332|NCT02171260|DRUG|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
219034333|NCT00145873|DRUG|nesiritide, continuous infusion|
219511810|NCT05936879|OTHER|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
219511811|NCT06542159|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.
219511812|NCT06542159|RADIATION|Conventional SBRT|SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
219511813|NCT03267342|BEHAVIORAL|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
219511814|NCT03267342|BEHAVIORAL|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
219609383|NCT06252649|DRUG|FOLFIRI Regimen|Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.
219609384|NCT06252649|DRUG|Sotorasib|Immediate-release solid dosage form administered orally.
219609385|NCT06252649|DRUG|Panitumumab|Administered via IV infusion Q2W.
219609386|NCT06252649|DRUG|Bevacizumab-awwb|Administered via IV infusion Q2W.
219609387|NCT06987201|DEVICE|DigiVibe Vibration Anesthesia|DigiVibe Vibration Anesthesia
219609388|NCT06465069|DRUG|LY4052031|Intravenous
219609389|NCT04417465|DRUG|ABBV-CLS-579|Oral Capsule
218892140|NCT01219985|OTHER|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
218892141|NCT06314607|GENETIC|Prospective Biological Collection|"All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)"
218892142|NCT06314607|GENETIC|Retrospective Biological Collection|Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
219511815|NCT03267342|BEHAVIORAL|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
218892143|NCT05157126|DRUG|Gentamicin|Liquid gentamicin administered at the open fracture site
218892144|NCT05157126|DRUG|normal Saline|Normal saline administered at the open fracture site
219511816|NCT03267342|BEHAVIORAL|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
219511817|NCT06424899|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
219511818|NCT06424899|RADIATION|radical chemoradiotherapy|The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
219511819|NCT06424899|DRUG|Platinum based chemotherapy|Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
219511820|NCT00000909|DRUG|Aldesleukin|
219511821|NCT01769209|DRUG|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
219511822|NCT01769209|DRUG|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
219511823|NCT01769209|DRUG|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
219511824|NCT01769209|DRUG|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
219609390|NCT04417465|DRUG|PD-1 inhibitor|Intravenous (IV) infusion
219609391|NCT04417465|DRUG|VEGFR TKI|Oral Tablet
219511825|NCT01769209|DRUG|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
219609392|NCT06671236|BIOLOGICAL|Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)|Regulatory T cell therapy, intrathecal injection
219609393|NCT07005128|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
219609394|NCT07005128|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
219609395|NCT07005128|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
219609396|NCT07005128|DRUG|Etoposide|Etoposide will be administered as an IV infusion.
219609397|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
219609398|NCT07017712|PROCEDURE|Complex esophageal surgery for carcinoma|Appropriate combination of ICD-10 code (C15, C16.0) and medical procedure code (5-423, 5-424, 5-425, 5-426, 5-427.0, 5-427.1, 5-438.0, 5-438.1, 5-438.x)
219609399|NCT07017712|PROCEDURE|Rectum resection for carcinoma|Appropriate combination of ICD-10 code (C19, C20, C218, D011, D012) and medical procedure code (5-484, 5-485)
218892145|NCT05556759|PROCEDURE|control|patient will be operated under general anesthesia
218892146|NCT05556759|PROCEDURE|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
218892147|NCT05556759|PROCEDURE|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
218892148|NCT05379465|OTHER|No intervention|No intervention was done.
218892149|NCT00442728|DEVICE|ELECTRICAL STIMULATION|
218892150|NCT00812773|DRUG|GSK2190915|Investigational Product
218892151|NCT01317251|OTHER|Dietary intervention (without dairy products)|Control diet without dairy products
218892152|NCT01317251|OTHER|Dietary intervention (high milk content)|Diet with a high content of milk (\~1200 mg Ca/d from milk)
218892153|NCT01317251|OTHER|Dietary intervention (high cheese content)|Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
218892154|NCT00264199|DRUG|GLP-1|iv. by weight (1.0 pmol/kg/min )
218892155|NCT00264199|DRUG|placebo|same rate of infusion as GLP-1
219511826|NCT01769209|DRUG|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
219511827|NCT01769209|DRUG|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
219511828|NCT00958256|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
219511829|NCT00958256|DRUG|Rituximab|375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
219511830|NCT00958256|DRUG|Cyclophosphamide|300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
219511831|NCT00958256|DRUG|Mesna|600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
219511832|NCT00958256|DRUG|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
219511833|NCT03777670|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
219511834|NCT02266836|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
219511835|NCT03842943|DRUG|Pembrolizumab|Preoperative infusions
219511836|NCT03842943|DRUG|Talimogene Laherparepvec|Preoperative intralesional injection
219609400|NCT07017712|PROCEDURE|Colon resection for carcinoma|Appropriate combination of ICD-10 code (C18, D01.0) and medical procedure code (5-455, 5-456, 5-458)
219609401|NCT07017712|PROCEDURE|Pancreatic resection for carcinoma|Appropriate combination of ICD-10 code (C25, C24.1) and medical procedure code (5-524, 5-525.0, 5-525.1, 5-525.2, 5-525.x, 5-525.y, 5-528)
219609402|NCT07017712|PROCEDURE|Gastric resection for carcinoma|Appropriate combination of ICD-10 code (C16) and medical procedure code (5-436, 5-437, 5-438)
218892156|NCT00209352|DRUG|Acyclovir|
218892157|NCT00596752|DRUG|Alprostadil|"* Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
218892158|NCT00596752|OTHER|Placebo|"* Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
218892159|NCT02842294|DRUG|Bevacizumab|
219511837|NCT00967642|DRUG|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
219511838|NCT00049036|BIOLOGICAL|rituximab|Given IV
219511839|NCT00049036|DRUG|etoposide|Given IV
219511840|NCT00049036|DRUG|doxorubicin hydrochloride|Given IV
219511841|NCT00049036|DRUG|vincristine sulfate|Given IV
219511842|NCT00049036|DRUG|prednisone|Given orally
219609403|NCT07016711|BEHAVIORAL|Lifestyle and Nutrition Promotion|Adherence to the Mediterranean diet
219609408|NCT06713837|DRUG|High intensity therapies|"* High and intermediate dose Cytarabine~* Mitoxantrone - Etoposide - Cytarabine (MEC)~* fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA)~* cladribine - high dose cytarabine (2CDA+HDAraC)~* mitoxantrone - intermediate dose cytarabine (MiDAC)~* fludarabine - amsacrine - cytarabine (FLAMSA)~* Mitoxantrone - Intermediate-dose Cytarabine (HAM)~* 3+7 (cytarabine and daunorubicine or idarubicine)"
219609409|NCT06713837|DRUG|Low intensity therapies|"* Venetoclax+hypomethylating agent (decitabine, azacitidine)~* Venetoclax+low dose cytarabine~* Gilteritinib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* 2CDA 5mg/sqm + low dose cytarabine~* Glasdegib+low dose cytarabine~* Ivosidenib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* Single agent Gemtuzumab or Gemtuzumab in combination with alone or in combination with low dose hypomethylating agent or low dose cytarabine"
219609410|NCT07030127|DRUG|LY3985863|Administered SC
219609411|NCT07030127|DRUG|Placebo|Administered SC
219609412|NCT06400030|PROCEDURE|Root canal treatment with AH Plus sealer|\- AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
218892160|NCT04716946|DRUG|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
218892161|NCT04716946|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
219511843|NCT00049036|DRUG|cyclophosphamide|Given IV
219511844|NCT00049036|OTHER|laboratory biomarker analysis|Correlative studies
219511845|NCT02696811|DIETARY_SUPPLEMENT|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
219511846|NCT02696811|DIETARY_SUPPLEMENT|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
219511847|NCT03029533|DRUG|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
219511848|NCT03029533|DRUG|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
219511849|NCT05602922|COMBINATION_PRODUCT|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
218892162|NCT04770220|DRUG|Experimental: ALZ-801|ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
218892163|NCT04770220|DRUG|Placebo Comparator: Placebo|Placebo tablet BID
218892164|NCT00760955|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
218892165|NCT00760955|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
218892166|NCT00760955|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
218892167|NCT00760955|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
218892168|NCT04797780|DRUG|Tamibarotene|Administered as specified in the treatment arm
218892169|NCT04797780|DRUG|Placebo|Administered as specified in the treatment arm
218892170|NCT04797780|DRUG|Azacitidine|Administered as specified in the treatment arm
218892171|NCT06223685|DRUG|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
218892172|NCT06223685|DIETARY_SUPPLEMENT|Probiotic|2x1 capsules per day. 12 weeks.
218892173|NCT05690984|DRUG|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
219511850|NCT05602922|OTHER|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
218892174|NCT05690984|DRUG|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
218892175|NCT05690984|DRUG|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
218892176|NCT04669301|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
218892177|NCT04669301|BEHAVIORAL|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
218892178|NCT05009069|RADIATION|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
218892179|NCT05009069|DRUG|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
218892180|NCT05009069|DRUG|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
218892181|NCT05009069|DRUG|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
218892182|NCT05009069|DRUG|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
218892183|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
218892184|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
218892185|NCT02940496|DRUG|Elbasvir/Grazoprevir|Given PO
218892186|NCT02940496|OTHER|Laboratory Biomarker Analysis|Correlative studies
218892187|NCT02940496|BIOLOGICAL|Pembrolizumab|Given IV
218892188|NCT02940496|DRUG|Ribavirin|Given PO
218892189|NCT05973006|BIOLOGICAL|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
219511851|NCT05303922|DIAGNOSTIC_TEST|Dual-energy CT|Dual-energy CT
219511852|NCT05303922|DIAGNOSTIC_TEST|MRI|MRI
219511853|NCT05287139|OTHER|Quality of Life|Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
219511854|NCT03036579|DEVICE|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
219511855|NCT01645800|DRUG|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
219511856|NCT01645800|DRUG|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
218892190|NCT05973006|BIOLOGICAL|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
218892191|NCT03637569|OTHER|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
218892192|NCT01970267|PROCEDURE|Laser Ablation of Floaters|
218892193|NCT01970267|PROCEDURE|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
218892194|NCT02652351|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
218892195|NCT02489292|BIOLOGICAL|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
218892196|NCT03318016|DRUG|Cyclophosphamide 500 MG|ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
218892197|NCT03318016|DRUG|Cyclophosphamide 1000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
218892198|NCT03318016|DRUG|Cyclophosphamide 2000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
218892199|NCT03318016|DRUG|Cyclophosphamide 3000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
218892200|NCT03318016|DRUG|Cyclophosphamide 4000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
218892201|NCT04305171|PROCEDURE|non-surgical periodontal treatment|scaling and root planing, home care instruction
219034334|NCT03571542|OTHER|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
219511857|NCT01758302|BEHAVIORAL|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
218892202|NCT00132808|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous
218892203|NCT00132808|DRUG|Placebo|Physiologic 0.9% normal saline
218892204|NCT06369389|OTHER|Patients eligible for CAR-T treatment|Patients eligible for CAR-T treatment for their hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
218892205|NCT02225093|DRUG|Caffeine|Oral
218892206|NCT02225093|DRUG|Dextromethorphan|Oral /.L
218892207|NCT02225093|DRUG|Enzalutamide|Oral
218892208|NCT02225093|DRUG|Enzalutamide Placebo to Match (PTM)|Oral
218892209|NCT04215640|DEVICE|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
218892210|NCT04215640|DEVICE|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
218892211|NCT05585840|DEVICE|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
219034335|NCT01527279|DRUG|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
219034336|NCT01527279|DRUG|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
219034337|NCT00399009|DEVICE|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
219034338|NCT00323492|DRUG|Truvada|Truvada + NNRTI or PI.
219034339|NCT00323492|DRUG|Current HAART regimen|Maintain baseline regimen
219034340|NCT00152750|DRUG|APO-clonidine|
219034341|NCT02824250|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
219034342|NCT01092533|DRUG|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
219034343|NCT01092533|DRUG|Decortin|Maintenance dose 5 mg/d
219034344|NCT04116138|DIETARY_SUPPLEMENT|Salovum|Egg yolk powder enriched for anti secretory factor
219034345|NCT02788968|OTHER|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
219511858|NCT01758302|BEHAVIORAL|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
219511859|NCT01758302|OTHER|Cookies|Participants are asked to taste test chocolate chip cookies
219511860|NCT01758302|OTHER|Vegetables|Participants are asked to taste test raw celery or radishes
219511861|NCT01758302|BEHAVIORAL|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
219511862|NCT03604120|DEVICE|Preoxygenation with high flow therapy by nasal cannula|Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
218892212|NCT03785379|BEHAVIORAL|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
219511863|NCT03604120|DEVICE|Preoxygenation by standard Facial mask|"* For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation."
219511864|NCT01518491|DRUG|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
219511865|NCT01518491|OTHER|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
219511866|NCT02375126|PROCEDURE|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
219511867|NCT05372081|OTHER|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
219511868|NCT02337933|DRUG|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
219511869|NCT02337933|DRUG|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
218892213|NCT03785379|BEHAVIORAL|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
218892214|NCT01714765|DRUG|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
218892215|NCT01714765|DRUG|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
218892216|NCT04661046|DRUG|Traditional Chinese Medicine|Chinese medicine prescription
218892217|NCT04721210|OTHER|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
218892218|NCT02954393|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
218892219|NCT02954393|DRUG|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
218892220|NCT02954393|DRUG|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
218892221|NCT02954393|DRUG|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
218892222|NCT02954393|DRUG|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
218892223|NCT02954393|DRUG|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
218892224|NCT02954393|DRUG|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
219511870|NCT01790165|DRUG|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
219511871|NCT04572100|OTHER|Transoral Robotic Surgery (TORS) or Radiotherapy|Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
219511872|NCT04572100|OTHER|Chemotherapy and Low-Dose Radiotherapy|Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
219511873|NCT04572100|OTHER|Chemotherapy and High-Dose Radiotherapy|Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
219511874|NCT04572100|DRUG|Paclitaxel|This drug will be combined with carboplatin during induction therapy for 9 weeks.
219511875|NCT04572100|DRUG|Carboplatin|This drug will be combined with paclitaxel during induction therapy for 9 weeks.
218892225|NCT05276817|DEVICE|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
218892226|NCT05276817|DRUG|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
218892227|NCT05276817|DEVICE|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
219511876|NCT00992407|DRUG|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
219609413|NCT06400030|PROCEDURE|Root canal treatment with BioCeramic sealer|\- BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
219609414|NCT07053917|DRUG|Psilocybin (Usona Institute)|Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.
219609415|NCT06578728|DRUG|Methotrexate|25mg/mL intralesional injection into nail bed/nail matrix
219609416|NCT06578728|DRUG|Triamcinolone Acetonide 10mg/mL|10mg/mL intralesional injection into nail bed/nail matrix
219609417|NCT06578728|DRUG|Saline|saline intralesional injection into nail bed/nail matrix
218892228|NCT02898402|PROCEDURE|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
219034346|NCT05049070|DIAGNOSTIC_TEST|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
219034347|NCT05049070|DIAGNOSTIC_TEST|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
219511877|NCT00992407|DRUG|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
219511878|NCT04204577|DRUG|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
219609418|NCT07058974|DRUG|lamivudine|Lamivudine (Epivir) is a drug used typically to treat HIV and Hepatitis B Virus (HBV). It has not been studied when given in combination with spermidine.
219609419|NCT07058974|DRUG|rapamycin|Rapamycin (Rapamune, Sirolimus) is an FDA-approved drug and indicated for use as an immune modulator.
219609420|NCT07058974|BEHAVIORAL|Exercise Regimen|All experimental groups will receive an exercise regimen combining high-intensity interval training (HIIT) (targeting aerobic fitness) and resistance training (targeting strength and skeletal muscle mass preservation). The HIIT exercise component will consist of 2 sessions per week totaling 20 minutes per session. The resistance training component will consist of 3 sessions per week totaling 40 minutes per session.
219609421|NCT07058974|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. Participants will take an oral dosage of 2mg/day for 180 days.
219609422|NCT03258580|DEVICE|Medoc thermal stimulator|Heat pain stimulation for substudy 1
219609423|NCT03258580|DEVICE|Electric shock stimulator|Electric pain stimulation for substudy 1
219609424|NCT03258580|DEVICE|Cold water bath|Cold pain stimulation for substudy 1
219609425|NCT03258580|BEHAVIORAL|Pain assessment performance feedback|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
219511879|NCT02462824|BEHAVIORAL|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
219511880|NCT00513968|GENETIC|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
219511881|NCT00513968|DRUG|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
219511882|NCT04653220|OTHER|Control 1|25g glucose dissolve in 250ml of water
219511883|NCT04653220|OTHER|Control 2|25g glucose dissolve in 250ml of water
218892229|NCT04903535|DEVICE|Alonefire SV003 10W 365nm UV Flashlight|Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
218892230|NCT02403999|OTHER|Test shampoo|Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
218892231|NCT02403999|OTHER|Test bath foam|Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
218892232|NCT02403999|OTHER|Test head to toe wash|Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
219034348|NCT05114135|DEVICE|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
219034349|NCT02486042|DRUG|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
219511884|NCT04653220|OTHER|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
219511885|NCT04653220|OTHER|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
219511886|NCT04653220|OTHER|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
219511887|NCT04653220|OTHER|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
219511888|NCT04653220|OTHER|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
219511889|NCT04653220|OTHER|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
219034350|NCT02486042|DIETARY_SUPPLEMENT|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
219034351|NCT02441933|DRUG|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
219511890|NCT02072759|DIETARY_SUPPLEMENT|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)"
219511891|NCT02072759|DIETARY_SUPPLEMENT|Placebo|
219511892|NCT00006075|DRUG|Chlorhexidine gluconate|
219511893|NCT04868448|BIOLOGICAL|Covid-19 vaccines|Observation of individuals who received one or more doses of covid-19 vaccines.
219511894|NCT04835948|DRUG|single dose of Anti-thymocyte globulin|Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
219511895|NCT05313204|OTHER|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
219511896|NCT05969470|DEVICE|Internal fixation with short intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
219511897|NCT05969470|DEVICE|Internal fixation with long intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
219511898|NCT06373575|PROCEDURE|Lung and inferior vena cava ultrasound guidance|The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.
219511899|NCT06373575|PROCEDURE|Conventional protocol guidance|Fluid removal using conventional protocol including blood pressure and physical examination
219511900|NCT03615937|BEHAVIORAL|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
219511901|NCT03615937|BEHAVIORAL|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
219511902|NCT03615937|BEHAVIORAL|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
219511903|NCT03615937|OTHER|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
219609426|NCT06370611|DEVICE|Early mobile health intervention supplemented by weekly calls from a physiotherapist|"Six-week home-based rehabilitation program using the ICURA app and sensor-based technology (ICURA ApS, Copenhagen, Denmark). During the hospital stay patients in the intervention group are introduced to the app's usage, and an individualized training plan is collaboratively created and subsequently tailored by a physiotherapist.~The comprehensive mobile health intervention includes customized training programs, activity tracking, visualization of exercises with videos, and a password-protected webpage for physiotherapists to customize training programs and track patient activity.~The patients will receive two calls from a physiotherapist per week for the first two weeks and as required the following four weeks."
219609427|NCT03231111|OTHER|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
219609428|NCT06748976|OTHER|Positive sham neurofeedback|Participants receive simulated positive reinforcement feedback designed to mimic successful modulation of EEG alpha rhythms, despite the feedback not being directly based on their actual neural activity. This condition aims to create the perception of improved attentional control.
219609429|NCT06748976|OTHER|Negative sham neurofeedback|Participants receive simulated negative reinforcement feedback that mimics unsuccessful modulation of EEG alpha rhythms, regardless of their actual neural activity. This condition is intended to simulate reduced attentional control.
219609430|NCT06748976|OTHER|Control|Participants perform the same attentional task but without receiving any feedback. This condition serves as a baseline to evaluate the effects of the sham neurofeedback interventions on EEG alpha rhythm modulation.
219609431|NCT02398266|DRUG|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
219609432|NCT01328184|DRUG|levonorgestrel|multiple doses
219609433|NCT01328184|DRUG|levonorgestrel|multiple doses
219609434|NCT01328184|DRUG|Ethinylestradiol|multiple doses
218892233|NCT04118387|DRUG|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
219609435|NCT01328184|DRUG|Microgynon + BI 10773|multiple doses BI 10773
218892234|NCT04118387|DRUG|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
218892235|NCT04118387|DRUG|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
219034352|NCT02441933|DRUG|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses"
219034353|NCT03905460|DIAGNOSTIC_TEST|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
219609436|NCT01328184|DRUG|Ethinylestradiol|multiple doses
218892236|NCT06538922|BEHAVIORAL|Single Session Family Intervention|A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
219609437|NCT06890403|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover human papillomavirus (HPV) disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
218892237|NCT06553495|OTHER|Nerve block|Analgesic effect of different nerve blocks
218892238|NCT04383782|BEHAVIORAL|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
218892239|NCT04383782|BEHAVIORAL|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
218892240|NCT04383782|BEHAVIORAL|Control|Neutral reading condition (see description in study arms).
218892241|NCT03553524|OTHER|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
218892242|NCT03553524|OTHER|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
218892243|NCT01930942|RADIATION|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
218892244|NCT03728010|DIAGNOSTIC_TEST|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
218892245|NCT06184594|OTHER|eNav|The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).
218892246|NCT06184594|OTHER|Standard of Care|Standard of care procedures for selecting their CRC screening test.
218892247|NCT06383598|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
218892248|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
218892249|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
218892250|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
218892251|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
218892252|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
219034354|NCT04241497|BEHAVIORAL|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
219034355|NCT01470742|DRUG|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
219203772|NCT06815705|PROCEDURE|Vascularized lymphatic transplantation|"Preoperative ultrasonography was performed to check the distribution, quantity and size of axillary lymph nodes. During the operation, methylene blue was injected subcutaneously into the elbow fossa to make the axillary lymph nodes in area B and D chromogenic, and avoid damage to the arm drainage lymph nodes.~Adjusting the flap design according to the size of the defect. The perforating branches of lymphoid tissue in areas A and C of grade I were located about 3-5cm above the perforating branches of the skin, and moved towards the thoracic side to the lymphatic adipose tissue. Finally, the pedicle of the thoracic dorsal artery was separated, and the blood transport of the flap and the lymphatic adipose tissue was examined by fluorescence imaging and other methods. The lymphoid adipose tissue was placed in the neck area I and II, and fixed by suture. The arteriovenous microvessels in the thoracic dorsal were anastomosed to the vessels in the receiving area of neck."
218892253|NCT06290687|DRUG|Neoadjuvant Chemotherapy|"Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)"
219034356|NCT01470742|DRUG|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
219034357|NCT02530450|DEVICE|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
219034358|NCT04982055|DRUG|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
218892254|NCT06290687|PROCEDURE|Partial cystectomy with Extended pelvic lymph node dissection|Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.
218892255|NCT06290687|DRUG|Adjuvant systemic therapy|Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
219609438|NCT06890403|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
218892256|NCT00108771|DRUG|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
218892257|NCT00108771|DRUG|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
218892258|NCT03275805|OTHER|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
218892259|NCT03275805|OTHER|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
218892260|NCT07020988|DRUG|Staccato Alprazolam|Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.
218892261|NCT07020988|DRUG|Midazolam|Study participants will receive single dose of IV Midazolam at pre-specified time points.
218892262|NCT07020988|DRUG|Diazepam|Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.
218892263|NCT07021274|BEHAVIORAL|DBT skills training adjusted to autistic needs|Adjustments to fit the specific learning style of people with autism. Simplified skills - fewer words, ,more pictures, autism relevant examples. Hands- on training using props and role play. adjustments so sensory sensitivities.
218892264|NCT06700525|BEHAVIORAL|Non-Sedentary Behavior Habit Formation|"Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time."
218892265|NCT06700525|BEHAVIORAL|Sedentary Screen Time Reduction Smartphone App|The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
218892266|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
219609439|NCT06758310|OTHER|Individualized Exercise|Each participant will be prescribed an individualized exercise program related to their fitness testing results and personal interests.
218892267|NCT06702553|DRUG|Nitric Oxide Gas|Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
218892268|NCT06702553|DRUG|Standard Care Arm|Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
219203773|NCT06814483|BEHAVIORAL|Experimental: A computer-based multimodal mind and body approach (cbMMBA)|cbMMBA will include three modules: BDJ, acupressure, and relaxation techniques including deep breathing, guided imagery, and progressive muscle relaxation.
219203774|NCT06814483|BEHAVIORAL|A standard cognitive training group|The program uses paper puzzles (Sudoku, crosswords, word-search, etc.) to engage subjects
219203775|NCT06888401|PROCEDURE|ERCP|
219609440|NCT03807570|DIETARY_SUPPLEMENT|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
219609441|NCT03807570|DIETARY_SUPPLEMENT|Placebo|Placebo 30 ml/day for 12 weeks.
219609442|NCT06766747|OTHER|Intermittent Fasting|Participants in the alternate-day fasting group will receive biweekly telecounseling to ensure adherence to the prescribed dietary plan and to monitor for potential adverse events. During the 12-week weight loss phase, patients are instructed to restrict calories to 75% of usual intake 2 days per week. A daily intake of at least 2 liters of low-energy beverages (water, caffeine- and sugar-free beverages) is generally recommended on fasting days. Usual physical activity is encourage
218892269|NCT07036120|DEVICE|orthosis|(1) one pair of two orthoses, regardless of the right and left sides; (2) loosen the two Velcro straps, put the large Velcro strap into the arch of the foot, and put the small Velcro strap on the thumb; (3) place the rigid plastic fixation plate along the medial edge of the foot and align the axis of rotation with the 1st metatarsalphalangeal joint; (4) tighten the Velcro straps as much as possible to prevent dislocation of the orthoses, without interfering with sleep; (5) tighten the Velcro straps to prevent dislocation of the orthoses, and to prevent the orthoses from moving out of position. Tighten the Velcro straps as much as possible without disturbing sleep to prevent the orthosis from shifting and to position the phalanx correctly in the outer table. Contact the laboratory staff for a new pair of orthotics if the adhesive tape is not sufficiently sticky to maintain positional fixation during sleep.
218892270|NCT07036120|BEHAVIORAL|foot exercises|"1. Warm-up: 30 seconds per movement~   1. Joint loosening~  2. Plantar relaxation~2. Toe spreading: 10 reps/set, 3 sets/day~3. Toe grasping towel: 10 times/set, 3 sets/day~4. Standing Heel Raise: 10 times/group, 3 groups/day~5. Short Foot Exercise: 10 times/sets, 3 sets/day~6. Relax the soles of the feet again at the end of all exercises."
219034359|NCT04982055|DRUG|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
219034360|NCT05602987|PROCEDURE|enema|receiving enema at the night before anal surgery
219034361|NCT05602987|PROCEDURE|no enema|no enema before anal surgery
219511904|NCT03615937|OTHER|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
219511905|NCT05012345|PROCEDURE|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
219511906|NCT01827007|OTHER|Volume expansion with gelofusine|
219511907|NCT05398822|DIAGNOSTIC_TEST|MRI|Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
219511908|NCT01153048|OTHER|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
219511909|NCT01902680|RADIATION|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
219609443|NCT06766747|OTHER|Continuous calorie restriction|Participants in the continuous calorie restriction group will receive biweekly nutritional counseling via Telecoaching to ensure adherence to the prescribed dietary plan. Based on weekly caloric intake obtained from the 7-day log, a model menu will be prescribed with a 25% daily calorie restriction divided among 3 meals every day consisting of macronutrient intake, with 20% of energy as fat, 40 to 50% as carbohydrate, and 20 to 30% as protein. They will be instructed to continue their usual physical activity.
219034362|NCT06086028|OTHER|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
219034363|NCT06078033|BIOLOGICAL|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
219034364|NCT06078033|BIOLOGICAL|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
219511910|NCT03286582|DRUG|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
219511911|NCT03286582|DRUG|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
219511912|NCT02918162|DRUG|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
219511913|NCT02918162|DRUG|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
219034365|NCT00907985|DRUG|Placebo|Single dose of placebo will be provided.
219034366|NCT00907985|DRUG|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
219034367|NCT00907985|DRUG|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
219034368|NCT04010123|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
219511914|NCT00395226|DRUG|zinc sulfate|zinc sulfate 220 mg bis for 90 days
219511915|NCT00395226|DRUG|placebo|placebo bid for 90 days
219511916|NCT04245566|PROCEDURE|Prostatic Artery Embolization (PAE)|Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
219511917|NCT04245566|DRUG|Pharmacotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
218892271|NCT06722872|OTHER|Laughter therapy|Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.
219511918|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
219511919|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
218892272|NCT06726486|DIETARY_SUPPLEMENT|Atémpero|A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.
218892273|NCT06726486|DIETARY_SUPPLEMENT|Control (Standard treatment)|A complete high-protein and high-calorie diet with mixed fibre was administered.
219203776|NCT06887946|OTHER|Medical couching and traditional|"The control group received traditional OHI using the tell-show-do method, which was personalized based on the individual PCR and GBI. The recommendations were tailored to each participant, based on personalized instructions to improve plaque control, decrease of gingival inflammation and facilitate optimal patient compliance, contributing to oral hygiene performance.~The intervention group was actively engaged in an iterative, collaborative process, based on the following steps:~Definition of the goals of oral hygiene and lifestyle styles according to the SMART model (Specific, Measurable, Achievable, Realistic, Timely):"
219511920|NCT00295958|BIOLOGICAL|LMB-2 immunotoxin|
219511921|NCT00295958|BIOLOGICAL|MART-1 antigen|
219511922|NCT00295958|BIOLOGICAL|gp100 antigen|
219511923|NCT00295958|BIOLOGICAL|incomplete Freund's adjuvant|
219511924|NCT04842058|OTHER|Mobilisation procedure|A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.
219203777|NCT06862947|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath block performed under ultrasound guidance using 15 ml of 0.4% ropivacaine on each side
219511925|NCT04172363|DRUG|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
219511926|NCT00096395|DRUG|gemcitabine hydrochloride|Given IV
218892274|NCT06725524|BIOLOGICAL|JMT601|intravenous infusion on day 1 once a week
219511927|NCT00096395|DRUG|sorafenib tosylate|Given orally
219511928|NCT00096395|OTHER|laboratory biomarker analysis|Correlative studies
219511929|NCT01396681|DRUG|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4\~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
219511930|NCT03190746|DIAGNOSTIC_TEST|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
218892275|NCT07046689|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two cycles of Trop2-ADC therapy.
218892276|NCT06725056|OTHER|DS-MCE and EGD examinations|sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
218892277|NCT06726538|BIOLOGICAL|Intravenous administration of Autologous, adipose-derived mesenchymal stem cells|"Patients in group A will receive two infusions of autologous, adipose-derived mesenchymal stem cells at day 0 and day 90 ± 14 at a dose of 10\^6 cells/kg.~Autologous, adipose-derived mesenchymal stem cells used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5%. For clinical use, cells at passage 3 will be harvested in 100 mL Ringer's lactate. Therapeutic ASC products must pass the following releasing criteria: (1) negative for bacteria, fungi and mycoplasma; (2) more than 90% viability; (3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and (4) endotoxin \<5 EU/kg. The patient will be infused with 1x106 cells/kg body weight within 60 minutes via the intravenous route."
219511931|NCT05451459|OTHER|12-week FMS Intervention|4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
219511932|NCT05451459|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
219511933|NCT00263809|DEVICE|Pathogen Reduction Technology|
218892278|NCT06919562|PROCEDURE|Percutaneous coronary intervention with protocolized implantation of a second generation thin-strut bioresorbable scaffold guided by intracoronary imaging|Percutaneous coronary intervention (PCI) with implantation of the MeRes100 thin-strut BRS with protocolized PSP (predilatation, sizing, postdilatation) method and intracoronary imaging guidance.
218892279|NCT06725940|DEVICE|68Ga-GZMB PET/CT|68Ga-GZMB PET/CT
218892280|NCT07053956|OTHER|Chewing Gum|Patients admitted to our outpatient clinic for bronchial asthma undergo regular FeNO measurements. If the value is ≥ 25 ppb (elevated), the patients are randomized into two groups after obtaining their consent. In the control group, a FeNO measurement is performed again after 15 minutes. In the second group, the FeNO measurement is measured again after 15 minutes of consuming sugar-free, antioxidant-containing chewing gum. The following data are then collected and documented from the patients: age, gender, height, weight, smoking status, current medication, other illnesses, whole body lung function test, and laboratory tests (eosinophils, IgE). Participation in the study will not change the course of the patient's stay in our clinic.
218892281|NCT07060859|DRUG|Topical Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate|A topical combination of dexamethasone (anti-inflammatory), ascorbic acid (antioxidant), and β-sodium glycerophosphate (mineralization support) was applied directly to the implant site during surgery. The intervention aimed to enhance early osseointegration by modulating local biological responses.
218892282|NCT07066540|DRUG|Reamberin® solution for infusion, 1.5 %|Reamberin® in daily dose 10 mL/kg
218892283|NCT07064811|PROCEDURE|Exercise Intervention Protocol|Subjects participated in the supervised exercise program twice weekly (with a 48-72-hour interval between sessions) for 24 weeks, totaling 48 supervised sessions. The progressive resistance training program used velocity-based training principles \[24-26\], a novel approach in exercise oncology that allows for precise load management and indi-vidualization based on daily performance capacity
219203778|NCT06862947|PROCEDURE|Placebo|Injection of 15 ml of 0.9% saline as a placebo under the same conditions as the experimental group.
219203779|NCT06792292|OTHER|conventional colonoscopy procedure|Study subjects in this interventional arm will undergo conventional colonoscopy.
219203780|NCT06792292|OTHER|artificial intelligence-assisted colonoscopy procedure|Study subjects in this interventional arm will undergo colonoscopy done with a commercially-available module that uses artificial intelligence to highlight suspected polyps on the screen during colonoscopy. This module also attempts to characterize the detected polyp as adenomatous or not. The detection and characterization of polyps is in real time, during the procedure.
219511934|NCT03665909|OTHER|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
219203781|NCT06749639|GENETIC|PUMCH-E101 Injection（Low dose）|Single intravitreal injection
219203782|NCT06749639|GENETIC|PUMCH-E101 Injection（High dose）|Single intravitreal injection
219203783|NCT04750551|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
219203784|NCT04750551|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
219203785|NCT06763965|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.
219511935|NCT00207337|DEVICE|Exhale Drug-Eluting Stent|
219511936|NCT02873988|OTHER|bronchial epithelial cell culture|
219511937|NCT06496737|BEHAVIORAL|Moderate-Intensity Interval Training (MIIT)|Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches, three times a week for 12 weeks
219511938|NCT06496737|BEHAVIORAL|High-Intensity Interval Training (HIIT)|High-Intensity Interval Training (HIIT) is developed by university badminton coaches, three times a week for 12 weeks
219511939|NCT04800653|PROCEDURE|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
219511940|NCT02142244|PROCEDURE|Near infra red sentinel node biopsy|Explicated in the protocol arm
219511941|NCT02142244|DRUG|Indocyanine green|Explicated in the protocol arm
219511942|NCT02142244|DEVICE|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
219511943|NCT05733247|OTHER|Copenhagen adductor exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
218892284|NCT07064811|PROCEDURE|SPoRT-Control Intervention|structured written instructions for a personalized home-based resistance training program. The protocol was designed to prioritize safety, progressive adaptation, and individualization based on each participant's functional capacity and available resources at home. The program was intended to be performed two to three times per week on non-consecutive days, focusing exclusively on lower-body training through a single primary movement. Each session consisted of three effective sets of 12 repetitions, which served as the standard training volume for the main exercise.
218892285|NCT07066995|BIOLOGICAL|Mesothelin and Claudin 18.2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, Mesothelin and Claudin 18.2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial Mesothelin and Claudin 18.2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
218892286|NCT07065487|DEVICE|Intraoral Scanner - Standard Protocol|A full-arch digital impression is obtained using a high-precision intraoral scanner. Scan bodies are placed on multi-unit abutments and scanned without the use of external reference markers or geometric aids. The scan follows the manufacturer-recommended scanning path to capture the complete arch. This serves as a baseline digital technique for comparison with geometric pattern-assisted scanning.
218892287|NCT07065487|DEVICE|Intraoral Scanner with Geometric Reference Pattern|The same intraoral scanner is used, but with an additional geometric reference pattern introduced in the scanning field to improve stitching accuracy and alignment of the digital scan.
218892288|NCT07065487|PROCEDURE|Conventional Splinted Impression Technique|A physical impression is taken using open-tray impression copings splinted with DuraLay resin and polyvinyl siloxane (PVS) material in a custom tray, according to conventional protocols for full-arch implant prostheses.
218892289|NCT07066683|OTHER|CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION|"Tip: Ensure that this name matches the name used in the associated Arm Description.~CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION):~* Perceived fatigue~* Mental functions~* Sensory functions and pain~* Neuromusculoskeletal and movement-related functions~* Functions of the cardiovascular and respiratory systems~  o Exercise stress test~* Fatigability (neuromuscular fatigue)~  * Lower limbs~ * Maximum voluntary strength and power~ * Study of the central and peripheral components of fatigue~ACTIVITIES AND PARTICIPATION~* Mobility~  * Clinical standard tests for balance and walking~ * Quantified motion analysis~* Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls"
218892290|NCT06753448|DRUG|Diosmin and Hesperidin Combination|Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
218892291|NCT06241170|PROCEDURE|mesentery-guided resection margin|Mesentery-guided resection margin where the mesentery adjacent to the intestine completely transitions from abnormal to normal upon palpation and transillumination, compared to the proximal normal mesentery. Open, laparoscopic, hand-assisted, or robotic mobilization are all acceptable, but extracorporeal resection and anastomosis are required. After intestinal mobilization , the diseased intestinal segment is exteriorized from the abdominal cavity.
218892292|NCT06241170|PROCEDURE|traditional resection margin|"2 cm proximal to the site where gross lesions disappear. After transecting the bowel, re-examine the mucosal condition; if mucosal ulcers or obvious scars are present, extend the incision until reaching the site with normal mucosa. Definition of gross lesions: Evaluation from the outer intestinal wall: The site where the tough texture, thickening, or contracture at the mesenteric edge of the intestinal wall disappears; evaluation from the intestinal lumen: The site where mucosal ulcers, fissures, or obvious scars disappear. Mucosa appearing seemingly abnormal is considered normal."
219034369|NCT04868279|BEHAVIORAL|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
219034370|NCT02320500|BEHAVIORAL|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
219511944|NCT05733247|OTHER|The adduction and abduction partner exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
219511945|NCT00001776|DEVICE|Cadwell Rapid Rate Magnetic Stimulator|
219511946|NCT00628823|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten containing foods removed from diet
219511947|NCT04502069|DRUG|Opaganib|500 mg Q12 hours orally
219511948|NCT02642666|BEHAVIORAL|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
219609444|NCT07067398|BEHAVIORAL|Peer Coaching Delivered Life's Essential 8 Program|This intervention includes structured bi-weekly peer coach (PC) Zoom or telephone sessions and a cardiovascular health curriculum including links to AHA resources. During the 1:1 session, PCs will elicit participants' challenges and successes from the previous week, track progress, and set goals (behavioral targets). PCs will use cognitive training techniques to teach participants how to manage negative thinking and replace it with positive thinking and goal setting. They will be encouraged to work towards these goals and monitor their progress (i.e. getting more physical activity on the job).
219609445|NCT07066176|DRUG|Aspirin|Aspirin 650mg prior mixed meal beverage
219609446|NCT07066176|DIETARY_SUPPLEMENT|Mixed meal beverage|Mixed meal beverage
219609447|NCT06786637|DRUG|Nociceptin Receptor Antagonist (LY-2940094)|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist LY-2940094. Peak concentrations are achieved 2-4 hours post-administration.
219609448|NCT06786637|DEVICE|DS8R Biphasic Constant Current Stimulator|As part of the fear conditioning task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). This model has been safely implemented in studies within McLean Hospital and Massachusetts General Hospital.
219609449|NCT07072585|PROCEDURE|Biopsy Procedure|Undergo biopsy
219609450|NCT07072585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219609451|NCT07072585|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219609452|NCT07072585|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219609453|NCT07072585|PROCEDURE|Bone Scan|Undergo bone scan
219609454|NCT07072585|DRUG|Bortezomib|Given IV or SC
219609455|NCT07072585|DRUG|Calaspargase Pegol|Given IV
219609456|NCT07072585|PROCEDURE|Computed Tomography|Undergo CT
219609457|NCT07072585|DRUG|Cyclophosphamide|Given IV
219609458|NCT07072585|DRUG|Cytarabine|Given IT or IV or SC
219511949|NCT06020885|RADIATION|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
219609459|NCT07072585|BIOLOGICAL|Daratumumab|Given IV
219511950|NCT06020885|DRUG|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
219511951|NCT06020885|DRUG|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
219609460|NCT07072585|DRUG|Daunorubicin Hydrochloride|Given IV
219609461|NCT07072585|DRUG|Dexamethasone|Given PO or IV
219609462|NCT07072585|DRUG|Doxorubicin Hydrochloride|Given IV
219034371|NCT02320500|OTHER|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
219511952|NCT06367569|DIAGNOSTIC_TEST|Screening for trilateral retinoblastoma with MRI|The diagnostic accuracy of the screening program, baseline screening with MRI followed by follow-up of suspicious pineal glands in heritable retinoblastoma patients.
219511953|NCT05075603|DRUG|Efineptakin alfa|NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
219609463|NCT07072585|PROCEDURE|Echocardiography Test|Undergo ECHO
219609464|NCT07072585|PROCEDURE|Lumbar Puncture|Under lumbar puncture
219034372|NCT02437955|OTHER|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
219034373|NCT02437955|OTHER|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
219034374|NCT02437955|OTHER|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
219034375|NCT02437955|OTHER|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
219034376|NCT03013556|DRUG|Group A, TDF|TDF for 96 weeks
219511954|NCT05075603|DRUG|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
219511955|NCT05075603|DRUG|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
219609465|NCT07072585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219609466|NCT07072585|DRUG|Mercaptopurine Oral Suspension|Given PO
219609467|NCT07072585|DRUG|Methotrexate|Given IT or IV or PO
219609468|NCT07072585|DRUG|Methylprednisolone|Given IV
219609469|NCT07072585|DRUG|Nelarabine|Given IV
219609470|NCT07072585|DRUG|Pegaspargase|Given IV or IM
219609471|NCT07072585|PROCEDURE|Positron Emission Tomography|Undergo PET or PET-CT
219609472|NCT07072585|DRUG|Prednisolone|Given PO or IV
219609473|NCT07072585|DRUG|Prednisone|Given PO or IV
219609474|NCT07072585|OTHER|Questionnaire Administration|Ancillary studies
219609475|NCT07072585|RADIATION|Radiation Therapy|Undergo radiation therapy
219609476|NCT07072585|DRUG|Therapeutic Hydrocortisone|Given IT
219609477|NCT07072585|DRUG|Thioguanine|Given PO
219609478|NCT07072585|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219609479|NCT07072585|DRUG|Vincristine Sulfate|Given IV
219609480|NCT04537871|PROCEDURE|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
219609481|NCT04537871|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219609482|NCT04537871|PROCEDURE|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
219609483|NCT04537871|PROCEDURE|Echocardiography|Undergo echocardiogram
219609484|NCT04537871|PROCEDURE|Physical Performance Testing|Undergo physical function tests
219609485|NCT04537871|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
219511956|NCT05075603|DRUG|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
219511957|NCT05229757|OTHER|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
219511958|NCT05229757|OTHER|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
219511959|NCT06201273|BEHAVIORAL|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
219609486|NCT04537871|OTHER|Questionnaire Administration|Ancillary studies
218892293|NCT07065110|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Blood draw for testing of metabolics.
218892294|NCT07065110|DIETARY_SUPPLEMENT|Skin test panel|Testing of improving the skin hydration and other skin-related parameters.
218892295|NCT07065110|DIETARY_SUPPLEMENT|HA gel|Participants obtained altogether 3 flasks with 500ml of SH60, SH 120 solution. They tooj 15 ml of the SH60 or SH120 aupplements (experimental group) once daily in the morning before breakfast for 3 months.
218892296|NCT07065110|DIETARY_SUPPLEMENT|Xanthan gum|Participants obtained altogether 3 flasks of placebo solution. They took 15 mL of placebo solution (control group) once daily in the morning before breakfast for 3 months.
219511960|NCT06201273|BEHAVIORAL|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
219511961|NCT06374030|PROCEDURE|Endotracheal intubation|All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
219511962|NCT04071600|DRUG|Neuropeptide Y|Intranasal
219511963|NCT04071600|OTHER|Placebo|intranasal
219511964|NCT03736109|GENETIC|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
219511965|NCT02456532|DRUG|placebo|six months of nightly placebo
219511966|NCT02456532|DRUG|Zolpidem CR|six months of nightly zolpidem
219511967|NCT02456532|DRUG|Eszopiclone|
219511968|NCT00455052|DRUG|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
219511969|NCT01000337|DRUG|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
219609487|NCT04537871|PROCEDURE|Ultrasound|Undergo musculoskeletal ultrasound
219609488|NCT06830746|DEVICE|LBBAP Implant with a CSP ICD Lead|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
219609489|NCT04729959|BIOLOGICAL|Atezolizumab|Given IV
218892297|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
218892298|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
219609490|NCT04729959|PROCEDURE|Biospecimen Collection|Undergo blood sample and tumor tissue collection
219609491|NCT04729959|PROCEDURE|Conventional Surgery|Undergo surgery
219609492|NCT04729959|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
219609493|NCT04729959|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218892299|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
219511970|NCT01000337|DRUG|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
219511971|NCT03235778|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
219511972|NCT03235778|DRUG|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
219511973|NCT02475083|OTHER|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
219511974|NCT02475083|OTHER|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
219609494|NCT04729959|BIOLOGICAL|Tocilizumab|Given IV
219511975|NCT03602326|OTHER|Neurodevelopmental Therapy-Bobath group|Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
219511976|NCT03602326|OTHER|Standart Rehabilitation Group (SR group)|Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
219511977|NCT01610466|PROCEDURE|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
219511978|NCT03799666|OTHER|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
219511979|NCT03799666|OTHER|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
219511980|NCT01612000|BIOLOGICAL|PanBlok|Intramuscular injection
219609495|NCT06811545|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Children with CP can have trouble with daily tasks such as walking. This raises their risk of disability as they age into their teens. Current treatments are not very effective. In this study, children with CP will walk on a treadmill while receiving NMES on their lower limb muscles, using surface electrodes, while their gait dynamics are assessed. Our proposed study aims to gather preliminary evidence to support the potential efficacy of NMES assistance to muscles across all lower limb joints during walking, i.e., multi-joint NMES assistance. Additionally, the investigators aim to investigate the optimal level of intensity.
219609496|NCT06018129|BIOLOGICAL|GEN3017|Subcutaneous injection
219609497|NCT06782087|DRUG|nano chitosan|nano chitosan
218892300|NCT06926855|OTHER|CHC-level cluster randomized control trial|"CHW (with clinic champion support) outreach to eligible patients, verbally consent patients, confirm eligibility, conduct social needs screening, make service or resource referrals, plan and support referral completion as needed, follow-up with patients to assess referral completion and outcomes~Implementation supports: financial support for CHW, clinic champion, and CHC administration of trial activities; 12 weeks of preparatory CHW training and coaching; practice coaching and technical support for data collection at all sites; additional support for sites without existing research data infrastructure; CHW Learning Collaborative through intervention and follow-up period for implementation support and cross-training control sites."
218892301|NCT06710860|BEHAVIORAL|The intelligent voice-interactive tailored communication system-based intervention|Participants in intervention group will receive the ScreenTalk intervention consisting of 3 modules:(1) a measurement module, (2) an algorithmic tailoring module, and (3) an open di-alogue module. All participants will be required to complete 3 modules within 1 month. If the intervention group does not undergo CRC screening at the follow-up time point, the system will repeatedly provide tailored communication intervention to further enhance the CRC risk perception of FDRs based on the current evaluation results. The primary outcome (uptake of CRC screening) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), 9 months post-intervention (T3) and 12 months post-intervention (T4).
219034377|NCT03013556|DRUG|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
219034378|NCT03013556|DRUG|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
219609498|NCT06928662|DRUG|Decitabine|Given IV
219609499|NCT06928662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsies
219034379|NCT01599273|DRUG|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
219609500|NCT06928662|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsies
219609501|NCT06928662|PROCEDURE|Chest Radiography|Undergo chest X-rays
219609502|NCT06928662|DRUG|Cytarabine|Given IV
219609503|NCT06928662|PROCEDURE|Echocardiography Test|Undergo ECHO
219609504|NCT06928662|BIOLOGICAL|Filgrastim|Given SC
219609505|NCT06928662|DRUG|Fludarabine|Given IV
219609506|NCT06928662|PROCEDURE|Hematopoietic Cell Transplantation|Given via infusion
219034380|NCT02265055|PROCEDURE|transfer early cleavage embryos|transfer early cleavage embryos
219034381|NCT02265055|PROCEDURE|transfer non early cleavage embryo|
219609507|NCT06928662|DRUG|Idarubicin|Given IV
219609508|NCT06928662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219609509|NCT06928662|PROCEDURE|Pheresis|Undergo apheresis
218892302|NCT06902181|BEHAVIORAL|Experimental Group - 100% CXMCI-01 Essential Oil|Participants in the experimental group will inhale 100% CXMCI-01 essential oil twice(CXMCI-01-M in morning, CXMCI-01-N in night) daily for 28 days using an aroma necklace. Each session involves placing 2 drops of the essential oil on a cotton pad inside the necklace. Inhale near the nose for 5 minutes, then wear the aroma necklace and continue inhalation for 60 minutes.
218892303|NCT06902181|BEHAVIORAL|Control Group - 0.1% CXMCI-01 Essential Oil (placebo)|Participants in the placebo group will inhale a 0.1% CXMCI-01 essential oil dilution twice (CXMCI-01-M in morning, CXMCI-01-N in night) ) daily for 28 days. The protocol mirrors the experimental group: inhalation near the nose for 5 minutes, followed by wearing an aroma necklace infused with the diluted essential oil for 60 minutes. This group serves as a placebo comparator to evaluate the effectiveness of the experimental intervention.
218892304|NCT06911840|OTHER|No Intervention: Observational Cohort|No intervention
218892305|NCT06927167|OTHER|Chin Tuck Exercise|Chin Tuck Exercises and Cervical Extension Exercises on Forward Head Posture
218892306|NCT06927167|OTHER|Seated cervical extension exercises|Perform seated cervical extension exercises focusing on activating posterior neck muscles
218892307|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
218892308|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
218892309|NCT06920706|DEVICE|RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (200 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
219511981|NCT01612000|BIOLOGICAL|rHA adjuvant|Intramuscular injection
219511982|NCT01798459|DRUG|Methylphenidate|
219511983|NCT05142436|OTHER|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
219511984|NCT05142436|OTHER|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
219511985|NCT05142436|OTHER|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
219511986|NCT05142436|OTHER|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
219511987|NCT05142436|OTHER|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
219511988|NCT00377052|DRUG|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
219511989|NCT00377052|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
219609510|NCT06928662|RADIATION|Total-Body Irradiation|Undergo TBI
218892310|NCT06920706|DEVICE|Sham-RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (60 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
218892311|NCT06921395|DRUG|Fang Le Shu (Follitrope)|rFSH 150 IU, 225 IU, 300 IU per syringe
218892312|NCT06921395|DRUG|Guo Na Fen (Gonal-F)|rFSH 450 IU per pen
218892313|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
218892314|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
219034382|NCT01808430|PROCEDURE|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
219034383|NCT03921697|DEVICE|Werable sensors|Parkinson Disease Patients monitored by werable sensors
219511990|NCT00751946|BEHAVIORAL|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
219511991|NCT00751946|BEHAVIORAL|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
219511992|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
219609511|NCT06928662|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219609512|NCT07074886|DRUG|Ocrelizumab Test Formulation|Ocrelizumab test formulation will be administered as per the schedule specified in the respective arm.
219609513|NCT07074886|DRUG|Ocrelizumab Reference Formulation|Ocrelizumab reference formulation will be administered as per the schedule specified in the respective arm.
219609514|NCT05196984|DEVICE|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
218892316|NCT06935058|OTHER|Chocolade milk|Participants will drink 400 ml of chocolate milk after exercise.
218892317|NCT06935058|OTHER|Water (Placebo)|Participants will drink 400 ml of water after exercise.
218892318|NCT00979927|DRUG|SPC3649|5 weekly doses
218892319|NCT00979927|DRUG|saline|5 weekly doses
218892320|NCT06940609|DEVICE|accelerated intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS), a FDA-approved form of noninvasive neuromodulation, can reduce neuropsychiatric symptoms and modulate inflammation in the thalamus as detected using dMRS, suggesting a potentially effective and efficient treatment approach with a pathophysiological component that is readily quantifiable.
219034384|NCT03829748|PROCEDURE|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
219511993|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
219511994|NCT05092490|PROCEDURE|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
219511995|NCT05092490|PROCEDURE|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
219034385|NCT02903186|BEHAVIORAL|SMS|This is an intervention using short mobile messages (SMS)
219034386|NCT03745144|DRUG|Cladribine|Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
219034387|NCT03745144|DRUG|Placebo|Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
219034388|NCT03745144|DRUG|Microgynon®|Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
219034389|NCT02609334|DRUG|CRD007|One single dose given 3 hours prior to Mannitol challenge
219034390|NCT02609334|OTHER|Placebo|One single dose given 3 hours prior to Mannitol challenge
219034391|NCT01542385|PROCEDURE|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
219511996|NCT03891719|PROCEDURE|Unilateral cleft lip rhinoplasty|"* Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
219511997|NCT03309449|DEVICE|Syringe and needle|Intramuscular administration of simulated naloxone
219511998|NCT03309449|DEVICE|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
219511999|NCT03309449|DEVICE|Nasal spray|Nasal spray administration of simulated naloxone
219512000|NCT01616732|DRUG|Testosterone|TU im
219512001|NCT01616732|DRUG|placebo|placebo im
219512002|NCT05567380|OTHER|Observation|Observation of Rheumatoid arthritis disease response to JAK inhibitors and TNF inhibitors after definite timepoints from the initialization of treatment in comparison to the current standard of care of therapy with conventional DMARDs.
219034392|NCT03125434|OTHER|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
219034393|NCT03295708|DIETARY_SUPPLEMENT|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
219034394|NCT03295708|DIETARY_SUPPLEMENT|soybean oil capsule|placebo capsule
219034395|NCT00896337|DEVICE|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
218892321|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
219512003|NCT01450709|DIETARY_SUPPLEMENT|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
218892322|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
218892323|NCT02640495|DRUG|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
218892324|NCT05275036|DEVICE|early detection test|Blood collection and early detection testing
218892325|NCT06348667|OTHER|Specific ankle stability exercises|Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
219512004|NCT00208988|PROCEDURE|Educational handout about prostate cancer screening|
219609515|NCT05196984|DEVICE|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
218892326|NCT06348667|OTHER|Conventional physiotherapy exercises program|Conventional exercise program performed in the center twice a week, of which all participants are part.
218892327|NCT03834831|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10
218892328|NCT03834831|DIETARY_SUPPLEMENT|Selenium|Selenium
218892329|NCT03057275|DEVICE|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
218892330|NCT05020210|DRUG|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
219512005|NCT00208988|PROCEDURE|Simple cue for patient to talk to doctor|
218892331|NCT02671097|DRUG|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
219609516|NCT06930638|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, non-affected thigh and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
218892332|NCT02671097|DRUG|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
218892333|NCT02471222|DRUG|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
218892334|NCT02471222|OTHER|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
218892335|NCT01242605|DRUG|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
218892336|NCT01242605|DRUG|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
218892337|NCT01242605|DRUG|cisplatin|cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
219512006|NCT02473211|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
219512007|NCT02473211|DRUG|Daclatasvir|Daclatasvir 60mg tablet administered once daily
219512008|NCT02175797|DEVICE|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
219512009|NCT04652453|OTHER|Geriatrics Bundle|Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
218892338|NCT00308854|PROCEDURE|Photodynamic Therapy|
218892339|NCT02736344|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent|
219512010|NCT03061409|DIETARY_SUPPLEMENT|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
219512011|NCT03061409|DIETARY_SUPPLEMENT|Placebo|served as placebo
219512012|NCT03806036|DRUG|Vitamin D|300.000 I.U single dose of VIT D IM injection
219609517|NCT06930638|DIETARY_SUPPLEMENT|Antioxidant Supplement|MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. As MitoQ reaches peak concentrations at \~40 to 60 minutes after ingestion, we will wait 45 minutes (time matched to Ischemic conditioning).
219609518|NCT07086248|DEVICE|Radiesse|Radiesse injections diluted 1:2 with sterile saline.
219609519|NCT06805773|OTHER|Educational videos|Participants will be provided with four educational videos in clinic prior to their initial medical oncology consult.
218892340|NCT00003763|PROCEDURE|radionuclide imaging|
218892341|NCT00003763|RADIATION|indium In 111 folic acid|
219609520|NCT06805773|OTHER|Standard of Care|Participants in the control arm will be provided with the educational videos after their consult with the medical oncologist.
218892342|NCT05879497|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
218892343|NCT03511157|OTHER|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
218892344|NCT03511157|OTHER|Control Group|See Control group description
218892345|NCT00548145|DRUG|Pitavastatin|2 mg by orally/day Duration: 12 months
218892346|NCT00548145|DRUG|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
219512013|NCT03806036|DRUG|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
218892347|NCT03223376|COMBINATION_PRODUCT|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
218892348|NCT03223376|COMBINATION_PRODUCT|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
219034396|NCT00896337|DRUG|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
219512014|NCT04433390|DRUG|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
219512015|NCT04433390|DRUG|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
219512016|NCT03820583|PROCEDURE|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
219512017|NCT04079907|DIETARY_SUPPLEMENT|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
219609521|NCT03630380|OTHER|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
219609522|NCT03630380|OTHER|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
219609523|NCT03630380|OTHER|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
219609524|NCT03630380|OTHER|Lung Ultrasound|We will perform lung ultrasound on all patients.
219609525|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
219609526|NCT04729114|DRUG|prednisone|Oral dose
219609527|NCT04729114|DRUG|dexamethasone|Oral dose
218892349|NCT02377648|DEVICE|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
218892350|NCT03325595|DRUG|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
219034397|NCT00896337|DRUG|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
219609528|NCT04729114|DRUG|enzalutamide|Oral capsule
219034398|NCT01793727|DEVICE|Glidescope videolaryngoscope|
219512018|NCT04079907|DIETARY_SUPPLEMENT|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
219512019|NCT00343980|DRUG|rosiglitazone|Tablets, 4 mg once or twice a day.
219609529|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV Infusion
219512020|NCT00343980|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
218892351|NCT03325595|DRUG|Placebo|Matching capsule placebo
218892352|NCT01918280|PROCEDURE|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
218892353|NCT02800980|PROCEDURE|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
218892354|NCT02800980|PROCEDURE|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
219034399|NCT04083807|BIOLOGICAL|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
219512021|NCT00343980|DRUG|glimepiride|Tablets, 4 mg/day.
219512022|NCT03465566|DIAGNOSTIC_TEST|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
219512023|NCT04740021|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
219512024|NCT04740021|DRUG|Carboplatin|AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
219512025|NCT04740021|DRUG|Etoposide|100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
219512026|NCT05079009|DEVICE|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
219512027|NCT03284775|DEVICE|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
219512028|NCT05137080|DRUG|Dexamethasone|24mg dexamethasone
219512029|NCT05137080|DRUG|Isotonic saline|Isotonic saline
219512030|NCT05889871|DRUG|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
219512031|NCT02314377|DRUG|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
219512032|NCT04997343|OTHER|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
219512033|NCT04997343|OTHER|clinical assessment|"Clinical evaluation, performed at each time point, will include:~* The assessment of clinical disability using EDSS score~* The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk \[T25FW\]), upper limbs (nine-hole peg test \[9HPT\]) and cognitive (three-second paced auditory serial addition test \[PASAT3\]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
219512034|NCT02978326|DRUG|SAGE-217 15/20 mg Oral Solution|SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
219512035|NCT02978326|DRUG|Placebo|SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
219512036|NCT02978326|DRUG|SAGE 217 30 mg Capsules|SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
219512037|NCT00617526|DRUG|RDEA806 400 mg|
219609530|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
219609531|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
219609532|NCT07084818|DEVICE|Reia System pessary self-care management|The Reia-System pessary is an FDA-cleared device to manage pelvic organ prolapse which is collapsible and intended to be more easily removed, with less discomfort.
219609533|NCT07084818|DEVICE|Standard pessary office-based management|These subjects will continue with the current pessary they are using to manage their prolapse, with office-based care.
219609534|NCT06538740|PROCEDURE|Ventilating the patient with lower (40 or 70%) oxygen concentration during the wash out phase, before extubation|The investigated intervention is the application of 70% inspired oxygen compared to 100% inspired oxygen during the anesthetic washout, right before extubation of the patient for the first 24 enrolled patients, and 40% inspired oxygen compared to 100% inspired oxygen for the subsequently enrolled 24 patients. Before and after the intervention EIT measurements are performed at designated time points to assess lung aeration and calculate the center of ventilation. This information allows assumptions on atelectasis formation in the patients' lung.
219609535|NCT01959295|DRUG|ASP2151|200 mg once daily
218892355|NCT03089541|BEHAVIORAL|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
218892356|NCT03348176|OTHER|Vegetable exposure|Repeated exposure to variety of vegetables
218892357|NCT03348176|BEHAVIORAL|VIPP-Feeding Infants|Promoting responsive feeding practices
218892358|NCT03348176|OTHER|Control|Phone calls with mother about development of child, no advice on complementary feeding
218892359|NCT02119663|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
219034400|NCT04083807|PROCEDURE|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
219512038|NCT00617526|DRUG|Placebo|Placebo
219512039|NCT00617526|DRUG|RDEA806 1000 mg|
219609536|NCT01959295|DRUG|ASP2151 placebo|once daily
219609537|NCT07089485|OTHER|effects of sound|The surgical trainees will perform four 15-minute surgical sequences in a controlled environment, with varying sound levels (64, 67, 73, and 75 dB(A)) randomized across the sequences to assess the surgeons' responses.
219609538|NCT02698033|DRUG|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
219609539|NCT02698033|OTHER|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
219609540|NCT03008759|OTHER|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
218892360|NCT02119663|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
219609541|NCT03008759|OTHER|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
218892361|NCT02119663|DRUG|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
218892362|NCT01227863|DRUG|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
218892363|NCT01227863|DRUG|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
218892364|NCT02022163|BIOLOGICAL|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
218892365|NCT02022163|BIOLOGICAL|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
218892366|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
218892367|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
219512040|NCT00617526|DRUG|RDEA806 600 mg|
219512041|NCT00617526|DRUG|RDEA806 800 mg|
219512042|NCT03588325|DIAGNOSTIC_TEST|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
219512043|NCT04449159|DIETARY_SUPPLEMENT|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
219512044|NCT04449159|DIETARY_SUPPLEMENT|Placebo|Placebo
219512045|NCT03607006|PROCEDURE|Patient specific PEEK sheets|Computer aided sheet design
219512046|NCT03607006|PROCEDURE|Autogenous bone shell|autogenous retromolar/chin bone graft
219512047|NCT03074526|OTHER|Amniotic Fluid|Amniotic Fluid
219512048|NCT03074526|OTHER|Saline Placebo|Saline Placebo
219512049|NCT03994445|BEHAVIORAL|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
219609542|NCT03008759|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
219609543|NCT04917861|BIOLOGICAL|mRNA-1893|Solution for injection
219609544|NCT04917861|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
219609545|NCT06901505|DRUG|Erythropoiesis-Stimulating Agent (ESA)|Administered by intra-venous (IV) infusion.
218892368|NCT02022163|BIOLOGICAL|Placebo|Placebo, 2 doses given 21 days apart
218892369|NCT04093440|OTHER|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
218892370|NCT05854979|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
218892371|NCT04355793|DRUG|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
218892372|NCT02863328|DRUG|semaglutide|Oral administration once-daily.
218892373|NCT02863328|DRUG|empagliflozin|Oral administration once-daily.
218892374|NCT00699660|BEHAVIORAL|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
218892375|NCT00699660|BEHAVIORAL|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
218892376|NCT00398320|DRUG|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
218892377|NCT00398320|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
218892378|NCT00398320|DRUG|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
218892379|NCT02682082|PROCEDURE|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
218892380|NCT02682082|DRUG|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
219609546|NCT06901505|DRUG|Vadadustat|300mg, oral tablets
219609547|NCT06906601|PROCEDURE|magnetic clip localization|magnetic clip localization for preoperative localization for breast cancer surgery
219609548|NCT06906601|PROCEDURE|metallic wire localization.|metallic wire localization for preoperative localization for breast cancer surgery
219609549|NCT06906601|PROCEDURE|Breast cancer surgery|Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure
219609550|NCT07091851|BEHAVIORAL|Group medical visits and home blood pressure monitoring|This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.
219512050|NCT03360201|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
219512051|NCT05753657|DRUG|Pioglitazone|hyperinsulinemia and hyperglycemia
219512052|NCT02763111|DRUG|BCD-085|
219512053|NCT02763111|OTHER|Placebo|
219512054|NCT01344408|PROCEDURE|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
219512055|NCT04648293|DEVICE|Starling|Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
219512056|NCT00947427|DRUG|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
219512057|NCT00947427|DRUG|Placebo|Placebo subcutaneous injections
219512058|NCT02703077|PROCEDURE|Spyglass|Endoscopic direct view of the bile ducts
219512059|NCT02703077|PROCEDURE|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
219512060|NCT02703077|PROCEDURE|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
219512061|NCT02703077|PROCEDURE|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
219512062|NCT00951288|DIETARY_SUPPLEMENT|Saffron|Saffron 20 mg/day supplementation
219512063|NCT00951288|DIETARY_SUPPLEMENT|Placebo|Placebo
219512064|NCT02597543|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
219609551|NCT06887569|BEHAVIORAL|Rewards|Financial rewards for attending therapy
219609552|NCT06887569|BEHAVIORAL|Screening|Information about screening for depression and anxiety
219609553|NCT06389487|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.
219512065|NCT02597543|DRUG|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
219609554|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
219609555|NCT06908304|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
219609556|NCT06908304|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
219609557|NCT06908304|DRUG|Docetaxel|Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.
218892381|NCT01586221|OTHER|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
219512066|NCT02597543|PROCEDURE|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
219512067|NCT04104568|BEHAVIORAL|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
219609558|NCT06908304|DRUG|Vinorelbine|Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.
219609559|NCT06908304|DRUG|Gemcitabine alone|Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.
219609560|NCT07105878|PROCEDURE|Epidural Electrical Stimulation|Epidural Electrical Stimulation (EES) is a medical technology that involves delivering controlled electrical impulses to the spinal cord through electrodes implanted in the epidural space-the area between the outermost membrane of the spinal cord (dura mater) and the vertebrae. This technique aims to modulate the activity of spinal neural networks, thereby regulating neurological functions and promoting functional recovery, particularly in individuals with spinal cord injuries or certain neurological disorders.
219609561|NCT07105878|PROCEDURE|Standard Rehabilitation Therapy|A structured, multidisciplinary rehabilitation program designed to improve motor function, mobility, and independence in participants with paralysis. The therapy typically includes physical Therapy and occupational Therapy.
218892382|NCT00064792|DRUG|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
219512068|NCT04104568|OTHER|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
219512069|NCT02832609|OTHER|Supine|measurements after 30 minutes in complete supine position
219512070|NCT00593879|DRUG|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
219609562|NCT07105878|RADIATION|positron emission tomography-computed tomography (PET-CT)|PET-CT is an advanced hybrid imaging modality that combines metabolic information from positron emission tomography with anatomical details from computed tomography.
218892383|NCT00064792|DRUG|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
218892384|NCT00002458|BIOLOGICAL|monoclonal antibody 3F8|
218892385|NCT04218539|DRUG|Psilocybin|10mg Psilocybin
218892386|NCT04218539|DRUG|Placebo|25mg Diphenhydramine
218892387|NCT03507010|RADIATION|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
218892388|NCT03507010|OTHER|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
219034401|NCT01296256|DRUG|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
219034402|NCT03854422|DEVICE|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
219034403|NCT03854422|DEVICE|left supine position|Colonoscopy in the Left supine position
219034404|NCT03854422|DEVICE|dynamic position|Colonoscopy in the Dynamic position
219512071|NCT02959905|BIOLOGICAL|TSA-CTL|Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
219512072|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
219512073|NCT02959905|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.
219512074|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
219609563|NCT07105878|RADIATION|Diffusion Tensor Imaging (DTI)|DTI is an advanced MRI technique that maps white matter tracts by measuring the directionality (anisotropy) and magnitude of water molecule diffusion in neural tissues. It provides quantitative metrics of fibers.
219609564|NCT07105878|PROCEDURE|Somatosensory Evoked Potentials (SEPs)|SEPs are electrophysiological responses recorded from the central or peripheral nervous system following electrical stimulation of sensory nerves. They assess the functional integrity of somatosensory pathways.
219609565|NCT07105878|PROCEDURE|Motor Evoked Potentials (MEPs)|MEPs are electrophysiological responses elicited by transcranial magnetic stimulation or electrical stimulation of the motor cortex, recorded from peripheral muscles or the spinal cord. They evaluate the integrity of corticospinal tracts.
219609566|NCT06923306|BEHAVIORAL|Virtual reality exposure|This is a single case design and there is only one intervention. In the no-treatment arm, participants will only have assessment but no virtual reality exposure therapy.
218892389|NCT03301350|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
218892390|NCT03301350|DRUG|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
219034405|NCT01673035|BEHAVIORAL|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
219034406|NCT01673035|BEHAVIORAL|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
219034407|NCT00864747|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
219034408|NCT00864747|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
219034409|NCT06418503|OTHER|Balance Training|Participants will complete 16 sessions of balance training (30 min. each) over one month.
219034410|NCT06418503|OTHER|EMG-Biofeedback Training|Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
219034411|NCT01089439|DRUG|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
219034412|NCT01089439|DRUG|Placebo|placebo
219512075|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
218892391|NCT03301350|DRUG|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
219034413|NCT06528522|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."
219034414|NCT01249612|OTHER|Thermotherapy|Knee joint icing
219512076|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
219512077|NCT01937364|DRUG|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
219512078|NCT01937364|DRUG|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
219512079|NCT01099384|BEHAVIORAL|Written self-help materials|Written materials to help adolescents stop tobacco use
219512080|NCT01099384|BEHAVIORAL|Group behavioral counseling|group behavioral counseling (2 day weekend program)
219512081|NCT00936975|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
219512082|NCT01443806|DRUG|Oseltamivir|75 mg, one time
219512083|NCT01832805|OTHER|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
219512084|NCT01790620|OTHER|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
219512085|NCT01790620|OTHER|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
219512086|NCT04104646|DRUG|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
219512087|NCT04104646|DRUG|Morphine|Oral morphine administration at starting dose of 0.07 mg/kg q4
219512088|NCT04104646|DRUG|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
219512089|NCT04104646|DRUG|Morphine matched placebo|Oral morphine matched placebo administration
219512090|NCT00858000|OTHER|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
219512091|NCT02405507|DIETARY_SUPPLEMENT|wheat bread with wheat germ|
219512092|NCT02405507|DIETARY_SUPPLEMENT|wheat bread without wheat germ|
219512093|NCT00284297|PROCEDURE|History taken and clinical examination|History is taken and clinical examination is followed
218892392|NCT03301350|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
219034415|NCT01249612|OTHER|Thermotherapy|Elbow joint icing
219034416|NCT01883427|DRUG|Placebo|placebo containing saline+glucose
219034417|NCT01883427|DRUG|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
219512094|NCT03742531|DRUG|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
219512095|NCT01108900|DRUG|sildenafil|tables, 25,50,100 mg, on demand, 1 month
219512096|NCT02933593|DRUG|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
219512097|NCT02933593|DRUG|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
219512098|NCT02933593|DRUG|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
218892393|NCT03301350|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
219512099|NCT03002649|DRUG|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
219512100|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
219512101|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Placebo|
219512102|NCT03932266|DRUG|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
219512103|NCT03932266|DRUG|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
219512104|NCT03932266|DRUG|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
219512105|NCT03932266|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
219512106|NCT04170699|PROCEDURE|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
219512107|NCT02184273|DRUG|Magnesium metamizol|
219512108|NCT02184273|DRUG|Placebo|
219512109|NCT03919201|OTHER|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
219512110|NCT03919201|OTHER|No exercise intervention group|Control group: no exercise intervention
219512111|NCT00317161|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
219512112|NCT00805298|DRUG|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
219512113|NCT00805298|DRUG|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
219512114|NCT00805298|DRUG|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
219512115|NCT00805298|DRUG|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
219512116|NCT04784195|BEHAVIORAL|Observation|Verification of morfology and functionality of neck muscles
219512117|NCT04936997|BIOLOGICAL|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
219512118|NCT01127009|DRUG|bortezomib|Given IV
219512119|NCT01127009|DRUG|mitoxantrone hydrochloride|Given IV
219512120|NCT01127009|DRUG|etoposide|Given IV
219512121|NCT01127009|DRUG|cytarabine|Given IV
219609567|NCT06926699|PROCEDURE|Medial Patellofemoral Ligament Reconstruction|An initial evaluation with a diagnostic knee arthroscopy is done to ensure there are no loose bodies or osteochondral lesions missed on MRI that require removal or fixation. Graft harvest and preparation is done using either an autograft or allograft tendon as per a shared decision-making approach between the surgeon and patient. A 2cm longitudinal incision is made over the anteromedial aspect of the patella and dissection done between the second and third layers. Fixation (variable depending on surgeon preference) is performed over the proximal half of the patella. Another skin incision is then made over the medial femoral epicondyle with a guide pin passed through Schottle's point. The proximal femoral cortex is then drilled overtop of the guide pin to a diameter equal to the graft diameter with the remainder of the femoral tunnel drilled to 4.5mm.The graft ends are tied to the patellar fixation and shuttled through the second and third layers and fixed to the femur.
219609568|NCT06926699|OTHER|Rehabilitation|Patients will be initially placed in a patellar stabilizing brace and told to remain non weight-bearing for the first two weeks. Subjects will be permitted to perform gentle ROM exercises while in the knee brace with progressive weight-bearing as tolerated permitted at the 2-week mark. Formal physiotherapy commences at 2-weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
219609569|NCT06932250|OTHER|Leg heating|Participants will perform home-based leg heating using a portable sauna blanket set at different temperature.
219034418|NCT04697693|DRUG|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
219609570|NCT07140679|PROCEDURE|Biopsy Procedure|Undergo biopsy
219034419|NCT04697693|DRUG|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
219034420|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
219034421|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
219034422|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
219512122|NCT01127009|OTHER|flow cytometry|Correlative studies
219512123|NCT01851070|DRUG|Allogeneic Mesenchymal Precursor Cells|
219512124|NCT01851070|DRUG|Normal Saline|
219512125|NCT02177955|DRUG|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
219512126|NCT02177955|DRUG|10 mg diazepam|10 mg midazolam 45 minutes before surgery
219512127|NCT02034331|DRUG|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
219512128|NCT02034331|DRUG|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
219512129|NCT02034331|DRUG|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
219512130|NCT02034331|OTHER|Heat application|For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
219512131|NCT04088578|OTHER|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
219512132|NCT04088578|OTHER|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
219512133|NCT04088578|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
219512134|NCT04740684|OTHER|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
219512135|NCT03455179|OTHER|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
219512136|NCT03455179|OTHER|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
219512137|NCT03455179|OTHER|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
219512138|NCT02592694|DRUG|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
219512139|NCT02592694|DEVICE|thrombus aspiration|manual thrombus aspiration
219512140|NCT04405934|OTHER|Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures|Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
219512141|NCT03277183|DRUG|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
219512142|NCT03277183|DRUG|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
219512143|NCT01561183|PROCEDURE|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
219512144|NCT01561183|PROCEDURE|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
219512145|NCT01561183|PROCEDURE|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
219512146|NCT01561183|PROCEDURE|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
219512147|NCT03271528|DRUG|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
219609571|NCT07140679|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219609572|NCT07140679|PROCEDURE|Colonoscopy|Undergo colonoscopy
219609573|NCT07140679|PROCEDURE|Computed Tomography|Undergo CT
219512148|NCT03271528|DRUG|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
219512149|NCT04184310|OTHER|Modified perineal linear stapler resection for external rectal prolapse|After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
219512150|NCT06546579|DIAGNOSTIC_TEST|Skin sampling|All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
219512151|NCT00625690|OTHER|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
219609574|NCT07140679|OTHER|Questionnaire Administration|Ancillary studies
219609575|NCT07140679|DRUG|Toripalimab|Given IV
219512152|NCT00625690|PROCEDURE|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
219512153|NCT00625690|PROCEDURE|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
219512154|NCT00625690|PROCEDURE|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
219512155|NCT03818958|OTHER|blood sampling|blood sampling
219512156|NCT06483958|BEHAVIORAL|palliative care protocol|"1. Symptom management~2. Respect for patient and family autonomy.~3. Respectful management of clinical information.~4. Provision of holistic care and support."
219512157|NCT00026104|DRUG|gemcitabine hydrochloride|Given IV
219512158|NCT00026104|DRUG|paclitaxel|Given IV
219512159|NCT00026104|DRUG|tipifarnib|Given orally
219609576|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
219609577|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
219609578|NCT04872985|DRUG|Pyrotinib|400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
219609579|NCT04872985|DRUG|Epirubicin|100 mg/m2,q3W\*4
219609580|NCT04872985|DRUG|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w\*4
218892394|NCT03301350|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
218892395|NCT03137225|DEVICE|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
218892396|NCT03137225|DEVICE|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
219034423|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
219034424|NCT02733536|DEVICE|Standard endotracheal tube|1\) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
219034425|NCT02733536|DEVICE|C-MAC|C-MAC introduced with a h size 3 blade.
219034426|NCT01541137|DRUG|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
219034427|NCT01541137|DRUG|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
219034428|NCT01541137|DEVICE|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
219034429|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
219512160|NCT00026104|RADIATION|radiation therapy|Undergo radiation therapy
219512161|NCT01873859|DRUG|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
219512162|NCT01144884|OTHER|Procedure (education and exercise)|education/exercise
219609581|NCT04872985|DRUG|Cyclophosphamide|600 mg/m2, q3w\*4
219609582|NCT04872985|DRUG|Docetaxel|100 mg/m2, q3w\*4
219609583|NCT04872985|DRUG|Nab paclitaxel|120mg/m2 qw\*12 or 260mg/m2 q3w\*4
218892397|NCT01487889|OTHER|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
218892398|NCT00390650|DRUG|Saredutant|
218892399|NCT01248949|DRUG|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
218892400|NCT01248949|DRUG|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
218892401|NCT01248949|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
219512163|NCT04258241|PROCEDURE|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
219512164|NCT04258241|PROCEDURE|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
218892402|NCT01248949|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
219609584|NCT04872985|DRUG|Placebo|400 mg orally once per day
218892403|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
218892404|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
218892405|NCT00286429|DRUG|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
218892406|NCT01973413|DEVICE|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
218892407|NCT01973413|DEVICE|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
218892408|NCT01973413|DEVICE|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
218892409|NCT00816192|PROCEDURE|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
218892410|NCT03851198|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
218892411|NCT01882530|DRUG|Paracetamol|
218892412|NCT01882530|DRUG|Nefopam|
218892413|NCT01882530|DRUG|Ketoprofen|
219034430|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
219034431|NCT04851899|DIETARY_SUPPLEMENT|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
219034432|NCT04620083|OTHER|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
219034433|NCT03156478|BEHAVIORAL|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
219609585|NCT06938399|DEVICE|Silicone gel-filled breast implants - Motiva Implants®|Breast Surgery
219609586|NCT06938399|OTHER|Aesthetic Surgery|Aesthetic procedure other than breast implant surgery
219609587|NCT07144293|DRUG|Dasatinib|Dasatinib will be administered as one 100 mg capsule.
219609588|NCT07144293|DRUG|Quercetin|Quercetin will be administered as five 250 mg capsules.
219609589|NCT07144293|OTHER|Placebo - Dasatinib|Matching Placebo for Dasatinib will be administered as one 100 mg capsule.
219609590|NCT07144293|OTHER|Placebo - Quercetin|Matching Placebo for Quercetin will be administered as five 250 mg capsules.
218892414|NCT01882530|DRUG|Morphine|
218892415|NCT03915470|DRUG|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
218892416|NCT03915470|DRUG|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
218892417|NCT02150915|OTHER|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
219609591|NCT07148024|DEVICE|ETT cuff pressure 0 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 0 mmHg during cardiopulmonary bypass (CPB)
219609592|NCT07148024|DEVICE|ETT cuff pressure 20-30 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 20-30 mmHg during cardiopulmonary bypass (CPB)
219609593|NCT06954948|BEHAVIORAL|pulmonary rehabilitation (PR)|PR is an exercise and education programme designed for people with lung disease who experience symptoms of breathlessness.
219609594|NCT06953453|DRUG|Inhaled Fentanyl Aerosol|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg Fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg Fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
218892418|NCT01772732|DRUG|Simotinib Hydrochloride|
218892419|NCT03160898|DRUG|Reldesemtiv|Oral tablet
218892420|NCT03160898|DRUG|Placebo|Oral tablet
218892421|NCT00078247|DRUG|Abacavir|300 mg tablet taken orally twice daily
218892422|NCT00078247|DRUG|Lamivudine|300 mg tablet taken orally daily
218892423|NCT00078247|DRUG|Zidovudine|300 mg tablet taken orally twice daily
218892424|NCT00078247|DRUG|Tuberculosis treatment|Tuberculosis treatment
218892425|NCT02508909|PROCEDURE|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
218892426|NCT00862056|PROCEDURE|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
219512165|NCT04258241|DEVICE|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
219512166|NCT04258241|DRUG|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
219512167|NCT04258241|DRUG|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
218892427|NCT06021509|DEVICE|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
219512168|NCT05493696|DEVICE|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
219512169|NCT05493696|OTHER|Traditional physical therapy program|applied 3 times/week for 12 weeks
219512170|NCT03358459|OTHER|non|non
219512171|NCT03977584|DRUG|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
219512172|NCT03977584|DRUG|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
219512173|NCT03977584|OTHER|[^18F]GTP1|IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
219512174|NCT03232203|DRUG|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
219512175|NCT02634060|DEVICE|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
219512176|NCT02172248|DRUG|BI 10773|
219609595|NCT06953453|DRUG|Fentanyl Citrate Injection|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
219609596|NCT07157930|BEHAVIORAL|The Beighton Scoring system|The Beighton Scoring System is widely used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring System consists of: • Passive dorsiflexion of the fifth metacarpophalangeal joint • Passive hyperextension of the elbow • Passive hyperextension of the knee joint • Passive placement of the thumb on the flexor side of the forearm • Forward flexion of the trunk In adults up to 50 years of age, a score of ≥5 out of 9 indicates joint hypermobility, while in adults over 50, a score of ≥4 out of 9 is considered positive for joint hypermobility.
219609597|NCT07157930|BEHAVIORAL|2D:4D Digit Ratio|The lengths of the second (2D) and fourth (4D) digits will be measured separately on both hands. Measurements will be taken with the participants' hands placed on a flat surface with the palms facing upward. Digit length will be defined as the distance from the midpoint of the proximal crease at the base of the finger to the distal tip of the finger. A digital caliper with a precision of 0.01 mm will be used, and two separate measurements will be obtained for each finger, with the mean value recorded. Based on these measurements, the 2D:4D digit ratio will be calculated for each hand by dividing the length of the second digit by that of the fourth digit. To enhance reliability, assessments will be performed independently by two different researchers, and inter-rater agreement will be evaluated.
218892428|NCT04205734|DIAGNOSTIC_TEST|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
218892429|NCT02601833|DEVICE|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
219034434|NCT03156478|BEHAVIORAL|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
219034435|NCT02719132|DRUG|Dapagliflozin|Dapagliflozin, 10 mg
219512177|NCT02172248|DRUG|Metformin|
219512178|NCT01042366|BIOLOGICAL|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
219512179|NCT02220465|BEHAVIORAL|PA+ Smoking Cessation (LMPA)|
219512180|NCT02220465|BEHAVIORAL|Standard Care Smoking Counseling (SCC)|
219512181|NCT06094374|BEHAVIORAL|observation of physical activity behavior|"An observational study will be conducted to gather data on multiple levels aiming to identify diverse digital phenotypes related to PA behavior among community-dwelling older adults.~A hybrid approach will be employed, combining both cross-sectional and longitudinal data collection methods. The overall aim is to employ data analysis to identify patterns of PA - behavior (referred to as phenotypes) and to pinpoint prognostic factors that affect PA outcomes.~This integrated strategy will be complemented by four distinct measurement approaches, ensuring a comprehensive assessment of the research objectives. These measurement approaches include:self-reporting, clinical, ecological momentary and time series assessment."
219512182|NCT05346549|BEHAVIORAL|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
219512183|NCT05346549|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
219512184|NCT02277457|RADIATION|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
219512185|NCT02277457|DRUG|Erlotinib|150 mg once daily
219512186|NCT02277457|DRUG|Crizotinib|250 mg twice daily
219512187|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
219512188|NCT00990613|DRUG|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
219512189|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
219512190|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
219512191|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
219512192|NCT00002174|DRUG|Thalidomide|
219512193|NCT06265935|BEHAVIORAL|Experimental Group|It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
219512194|NCT05925790|DIAGNOSTIC_TEST|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described \[Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527\].
219512195|NCT05925790|DIAGNOSTIC_TEST|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
219512196|NCT00496184|DRUG|Nifedipine cream topical application|
219512197|NCT06085482|DRUG|LY3502970|Administered orally
219512198|NCT06085482|DRUG|[14C]-LY3502970|Administered IV
219609598|NCT07157930|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a one-month period. The measure consists of 19 items divided into 7 components that produce a single overall score and takes 5-10 minutes to complete. Component scores are as follows: • Subjective sleep quality • Sleep latency (time to fall asleep) • Sleep duration • Habitual sleep efficiency (percentage of time spent in bed) • Sleep disturbances • Use of sleeping pills • Daytime dysfunction Each item is scored on a 0-3 scale. The seven component scores are then summed to create an overall score ranging from 0-21, with lower scores indicating better sleep quality
219609599|NCT07160257|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
219034436|NCT02719132|DRUG|Metformin|Metformin, up to 2500 mg
219512199|NCT01933828|PROCEDURE|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
219512200|NCT01933828|PROCEDURE|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
219512201|NCT01933828|DEVICE|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
219512202|NCT06178679|DRUG|ST-100 (vezocolmitide)|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
219512203|NCT06178679|DRUG|Vehicle|Vehicle Ophthalmic Solution
219512204|NCT03504852|DRUG|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
219512205|NCT00727454|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
219512206|NCT00727454|DEVICE|No treatment|No treatment
219512207|NCT01066052|DRUG|r-hGH|Subcutaneous administration.
219512208|NCT03350022|PROCEDURE|Sham Feeding|Sham feeding will be offered to participants.
219512209|NCT02442479|BEHAVIORAL|resistance training|
219512210|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
219609600|NCT07160257|DRUG|Placebo|Placebo will be administered SC.
219609601|NCT07165041|PROCEDURE|SPSIP Block|Ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block performed prior to cardiac implantable electronic device (CIED) implantation. A total of 30 mL of 0.25% bupivacaine will be injected into the interfascial plane between the rhomboid major and serratus posterior superior muscles under sterile conditions.
219034437|NCT02028988|DRUG|Enzalutamide|
219512211|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
219512212|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
219512213|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
219512214|NCT01475656|DRUG|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
219512215|NCT01097356|DIETARY_SUPPLEMENT|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
219512216|NCT03419663|DIETARY_SUPPLEMENT|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
219512217|NCT03262298|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
218892430|NCT02601833|PROCEDURE|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
218892431|NCT03245775|BEHAVIORAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
218892432|NCT03245775|BEHAVIORAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
218892433|NCT06433089|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block was performed before surgery
218892434|NCT02401451|DEVICE|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
219512218|NCT01680679|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine (TIV)|
218892435|NCT02713828|DRUG|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
219512219|NCT01680679|BIOLOGICAL|Inactivated poliovirus vaccine (IPV), trivalent|
219512220|NCT02452645|BEHAVIORAL|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
219512221|NCT02452645|BEHAVIORAL|Comparison Group|Written materials, videos, books, and telephone counseling.
219512222|NCT00046709|DRUG|Smoked Marijuana|
219512223|NCT02677909|DEVICE|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
219512224|NCT01027442|DEVICE|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
219512225|NCT01027442|DEVICE|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
219512226|NCT01027442|DEVICE|Dental Implants|Dental implants placed via conventional free-hand method
219512227|NCT04883736|DRUG|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219512228|NCT04883736|DRUG|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
218892436|NCT02713828|DRUG|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
218892437|NCT04686383|DRUG|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
218892438|NCT00003968|DRUG|bryostatin 1|
218892439|NCT04611828|DEVICE|Philips SmartSleep|closed-loop auditory stimulation
219034438|NCT02028988|RADIATION|External Beam Radiation|
219034439|NCT06219460|OTHER|Ventilation using two types of face masks|ventilation using two types of face mask
219512229|NCT04883736|DRUG|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219512230|NCT00907309|BEHAVIORAL|iMET|Participants will receive the iMET intervention
219512231|NCT00907309|BEHAVIORAL|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
219512232|NCT02928848|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
219512233|NCT02426619|DEVICE|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
219512234|NCT02426619|DEVICE|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
219512235|NCT05178355|DRUG|KVD824|Active
219512236|NCT05178355|DRUG|Placebo to KVD824|Placebo
219512237|NCT03850509|DRUG|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
219512238|NCT03850509|DRUG|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
219512239|NCT00015106|DRUG|Lamotrigine|
219609602|NCT07165041|PROCEDURE|Sham procedure|Sham procedure with 1 mL saline injection at the same anatomical site, without administration of local anesthetic, prior to CIED implantation.
219609603|NCT07171125|DRUG|Liposomal bupivacaine (local infiltration)|"Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg bupivacaine hydrochloride (10 mL total volume). The drug will be injected bilateral into the paraspinal muscles and subcutaneous tissues prior to wound closure. This provides both immediate (bupivacaine HCl) and prolonged (liposomal) analgesia."
219609604|NCT07171125|DRUG|ropivacaine (local infiltration)|Patients will receive 120 mg ropivacaine diluted to 30 mL (single-level) or 40 mL (two-level) with normal saline. The solution will be infiltrated bilateral into the paraspinal muscles and subcutaneous tissues using the same technique as the experimental arm, ensuring consistent injection depth and distribution.
218892440|NCT03565614|BEHAVIORAL|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
218892441|NCT03565614|BEHAVIORAL|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
219034440|NCT06151587|DRUG|QLM3004 Concentration 1|"Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
219512240|NCT06262711|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).
219512241|NCT06262711|DIETARY_SUPPLEMENT|Placebo|Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
219512242|NCT03147170|DIAGNOSTIC_TEST|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
219512243|NCT02880072|DIETARY_SUPPLEMENT|phosphate orally|4 different preparations of phosphate
219512244|NCT00969332|DRUG|Omegaven|0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
219512245|NCT06545136|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
219512246|NCT02038478|BIOLOGICAL|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
219512247|NCT05837364|OTHER|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
219512248|NCT02437799|OTHER|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
219512249|NCT01532245|OTHER|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
219512250|NCT01532245|OTHER|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
218892442|NCT03910088|DRUG|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
218892443|NCT03910088|DRUG|Hydrocortisone|Giving drug to relieve post-dural puncture headache
218892444|NCT03910088|DRUG|Acetaminophen|giving a drug to relieve post-dural puncture headache
219512251|NCT01532245|OTHER|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
218892445|NCT03910088|OTHER|oral fluids|giving oral fluids to maintain good hydration
218892446|NCT03910088|DRUG|Caffeine|giving a drug to relieve post-dural puncture headache
218892447|NCT03910088|DRUG|Diclofenac|giving a drug to relieve post-dural puncture headache
219512252|NCT00630565|BIOLOGICAL|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
219512253|NCT00630565|DRUG|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
219512254|NCT00630565|DRUG|cyclophosphamide|4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
219512255|NCT00630565|DRUG|dexamethasone|20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
219512256|NCT00630565|DRUG|etoposide|300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
218892448|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (600 IU)|Daily oral dose for 12 months
219512257|NCT00630565|PROCEDURE|bone marrow transplantation|Day 0 infusion of bone marrow cells
219512258|NCT00630565|PROCEDURE|hematopoietic stem cell transplantation|Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)
219512259|NCT00630565|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
219609605|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 350 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
219034441|NCT06151587|DRUG|QLM3004 Concentration 2|"Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
219034442|NCT06151587|DRUG|QLM3004 Concentration 3|"High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
219034443|NCT06151587|OTHER|Placebo|Vehicle
219034444|NCT04445428|BIOLOGICAL|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
219034445|NCT04445428|BEHAVIORAL|Information|Advice regarding how to protect oneself from COVID-19
219034446|NCT01453283|DRUG|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
219512260|NCT00630565|RADIATION|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
219512261|NCT01835145|DRUG|Cabozantinib S-malate|Given PO
219512262|NCT01835145|DRUG|Dacarbazine|Given IV
219512263|NCT01835145|OTHER|Laboratory Biomarker Analysis|Correlative studies
219512264|NCT01835145|DRUG|Temozolomide|Given PO
218892449|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (2000 IU)|Daily oral dose for 12 months
219512265|NCT02729896|DRUG|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
219512266|NCT02729896|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
219512267|NCT02729896|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
219512268|NCT02729896|DRUG|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
219512269|NCT05997056|DRUG|nab-sirolimus|Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion
219512270|NCT00582309|PROCEDURE|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
219512271|NCT00582309|PROCEDURE|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving \>80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
218892450|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (4000 IU)|Daily oral dose for 12 months
218892451|NCT01992263|OTHER|Placebo|Daily oral dose for 12 months
218892452|NCT02486393|PROCEDURE|Parotid surgery|Surgery of the parotid gland tumours
219034447|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
219512272|NCT00582309|PROCEDURE|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
219512273|NCT03497533|BIOLOGICAL|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
218892453|NCT01110031|BIOLOGICAL|Ofatumumab|Anti-CD20 monoclonal antibody
218892454|NCT02888288|BEHAVIORAL|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
218892455|NCT02888288|BEHAVIORAL|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
218892456|NCT01002183|DRUG|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
218892457|NCT04314583|BEHAVIORAL|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
218892458|NCT04314583|BEHAVIORAL|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
219034448|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
218892459|NCT02155920|DRUG|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
218892460|NCT02085109|DIETARY_SUPPLEMENT|Fat milkshake|
218892461|NCT02085109|DIETARY_SUPPLEMENT|Theobromine|
218892462|NCT00681733|DRUG|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
218892463|NCT00681733|DRUG|Pioglitazone|30 mg OD
218892464|NCT00681733|DRUG|Pentoxifylline|1200 mg/d
218892465|NCT01732016|OTHER|Normobaric hypoxia chamber|
219034449|NCT03832374|OTHER|Descriptive|
218892466|NCT05463523|DEVICE|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
218892467|NCT03421106|BEHAVIORAL|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
219512274|NCT02335970|OTHER|Training group|"After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
219512275|NCT01261520|BEHAVIORAL|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
219512276|NCT01101009|DRUG|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
219512277|NCT01101009|DRUG|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
219512278|NCT05152641|DRUG|BGE-117, 4mg|BGE-117, 4mg Capsules
219512279|NCT05152641|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous Sulfate, 325mg Tablets
219512280|NCT05152641|OTHER|Matching Placebo|Matching Placebo to BGE-117 Capsules
219512281|NCT05152641|DRUG|BGE-117, 12mg|BGE-117, 12mg Capsules
219512282|NCT03724110|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
219512283|NCT03846921|DIAGNOSTIC_TEST|Laboratory blood test|Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
219512284|NCT01391182|OTHER|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
219512285|NCT01391182|OTHER|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
219512286|NCT05692921|OTHER|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
219512287|NCT05692921|OTHER|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
219512288|NCT02431403|DRUG|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
219512289|NCT02177097|BIOLOGICAL|Blood samples|4 x 10 ml blood samples.
218892468|NCT03421106|OTHER|Control Food Pantries|Normal food pantry use
218892469|NCT03027349|OTHER|No intervention are provided|
218892470|NCT03767751|BIOLOGICAL|Dual Specificity CD38 and bcma CAR-T Cells|1\) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
219512290|NCT04987177|OTHER|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
219512291|NCT06234852|BEHAVIORAL|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
219512292|NCT06234852|BEHAVIORAL|Glucocorticoid maintenance group|Daily 5-mg prednisolone over 24 weeks
219512293|NCT03120702|DEVICE|Investigational Rainbow SpHb sensor|Investigational Rainbow SpHb sensor
219512294|NCT02066584|OTHER|Sibling oocyte incubation|
218892471|NCT02774148|DRUG|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
218892472|NCT02774148|DRUG|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
218892473|NCT02151890|BIOLOGICAL|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
219512295|NCT02494245|OTHER|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
219512296|NCT02212405|DEVICE|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
218892474|NCT05356585|GENETIC|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
218892475|NCT02663622|DRUG|Efprezimod alfa|Acute GVHD prophylaxis
218892476|NCT02663622|DRUG|Methotrexate|Acute GVHD prophylaxis
218892477|NCT02663622|DRUG|Tacrolimus|Acute GVHD prophylaxis
219203786|NCT06734221|DEVICE|Paclitaxel Coated Peripheral Angioplasty Balloon Catheter|"Paclitaxel coated peripheral angioplasty balloon catheters are catheters of over the wire (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty."
219203787|NCT06788392|OTHER|reminiscence therapy|Reminiscence Therapy is a supportive care model that has been used in recent years and increases life comfort.
219512297|NCT02212405|OTHER|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
219512298|NCT01816698|DRUG|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
219512299|NCT01816698|DRUG|Placebo|Placebo: 1 package once a day after meals, 12 weeks
219512300|NCT01565083|DRUG|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
219203788|NCT03105336|BIOLOGICAL|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
219512301|NCT01565083|DRUG|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
219512302|NCT01565083|DRUG|Vinorelbine|A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
218892478|NCT02663622|DRUG|Placebo|100 ml saline IV infusion.
218892479|NCT01588600|OTHER|Dietary Fiber|Fiber added to breakfast
218892480|NCT01659684|BIOLOGICAL|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
219203789|NCT03105336|DRUG|Cyclophosphamide|Administered intravenously
219203790|NCT03105336|DRUG|Fludarabine|Administered intravenously
219512303|NCT05297747|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
219512304|NCT05297747|DIAGNOSTIC_TEST|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
219512305|NCT04753736|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
219512306|NCT01058421|PROCEDURE|intensive physical therapy|four week course of daily intensive physical therapy
219512307|NCT01058421|PROCEDURE|control group|four weeks of routine physical therapy
219512308|NCT00902083|DRUG|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
218892481|NCT03469687|DEVICE|Symax uncemented hip stem|
218892482|NCT04813887|OTHER|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
218892483|NCT06457711|DIETARY_SUPPLEMENT|Free diet Group (FDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
218892484|NCT06457711|DIETARY_SUPPLEMENT|Very low Calorie Ketogenic Diet Group (VLCKDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
218892485|NCT06457711|DIETARY_SUPPLEMENT|Intermittent Fasting Group (IFG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
218892486|NCT02430857|OTHER|OMT|Manuel osteopathic treatment of the spine
218892487|NCT04869969|PROCEDURE|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
218892488|NCT04869969|PROCEDURE|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
218892489|NCT02865902|DEVICE|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
219512309|NCT00902083|PROCEDURE|surgery|remove tumor surgery
219512310|NCT00902083|DRUG|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
219512311|NCT00902083|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
219512312|NCT00798551|BEHAVIORAL|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
218892490|NCT04308629|OTHER|Transcranial direct current stimulation|
218892491|NCT04266054|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
218892492|NCT04933487|DEVICE|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
219512313|NCT03279679|PROCEDURE|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
219512314|NCT03279679|PROCEDURE|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
219512315|NCT03279679|DEVICE|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
219512316|NCT03279679|DRUG|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
218892493|NCT00050947|DRUG|oxcarbazepine|
218892494|NCT02744638|OTHER|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
218892495|NCT02744638|OTHER|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
218892496|NCT02744638|DRUG|Arilin|2 tablets Arilin 500mg for 7 days
218892497|NCT02177682|DRUG|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
218892498|NCT04375345|DEVICE|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
218892499|NCT02587819|DRUG|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
218892500|NCT04649814|OTHER|Questionnaire|Questionnaire for all, interview for part of the respondents.
218892501|NCT02820675|OTHER|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
218892502|NCT02820675|OTHER|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
218892503|NCT01311882|DRUG|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
218892504|NCT01311882|DRUG|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
218892505|NCT01311882|DRUG|Zopiclone|1 x 7.5 mg Zopiclone tablet
218892506|NCT01311882|DRUG|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
219512317|NCT00028353|DRUG|GTX-006 (Acapodene)|
219512318|NCT00367588|BEHAVIORAL|Low bacterial diet|
219512319|NCT00042497|BIOLOGICAL|autologous dexosomes loaded with tumor-specific peptides|
219512320|NCT05729633|OTHER|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
218892507|NCT01311882|DRUG|Matching Placebo for MK-4305|Matching Placebo for MK-4305
218892508|NCT01522326|DRUG|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
218892509|NCT01522326|DRUG|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
218892510|NCT03027622|BEHAVIORAL|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
218892511|NCT03947710|OTHER|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
218892512|NCT03947710|OTHER|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
218892513|NCT03947710|OTHER|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
218892514|NCT02222610|DRUG|0.5 mg ranibizumab|
218892515|NCT02222610|PROCEDURE|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
218892516|NCT02936635|DRUG|tirasemtiv|Oral
218892517|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
218892518|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
218892519|NCT06263374|BEHAVIORAL|Motor imagery of the jaw|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the experimental group, which involves practicing motor imagery in addition to a self-rehabilitation program and physiotherapy. Patients will be guided to visualize three sets of jaw movements three times a day. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers as the study is multicentric.
219034450|NCT00338910|DRUG|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
219512321|NCT00748007|DRUG|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
219512322|NCT06294171|DEVICE|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
219512323|NCT05434403|DEVICE|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
219512324|NCT05434403|DEVICE|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
219512325|NCT05071547|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
219512326|NCT05071547|OTHER|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
219512327|NCT04771819|DEVICE|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
219512328|NCT01104857|PROCEDURE|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
219512329|NCT01104857|PROCEDURE|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
219512330|NCT03750474|DIAGNOSTIC_TEST|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
219512331|NCT00004812|BEHAVIORAL|Exercise|
219512332|NCT05269654|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
219512333|NCT05269654|OTHER|Normal Saline|Sham Comparator
219512334|NCT05164809|DEVICE|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
219512335|NCT03405285|DEVICE|Connected Catheter|The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
219512336|NCT00698425|OTHER|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
219512337|NCT00698425|DRUG|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
219512338|NCT01050231|DEVICE|Functional/ Multi-joints activities|Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
219609606|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 500 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by another 5 min of infusion at the original rate.
219512339|NCT01050231|DEVICE|Individual Joint Training|Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
219512340|NCT03859609|PROCEDURE|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
218892520|NCT06263374|BEHAVIORAL|Control task (Sudoku or Crossword puzzle)|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the control group, which involves practicing a control task (completion of Sudoku or crossword puzzles) in addition to a self-rehabilitation program and physiotherapy. Patients will be instructed to engage in the task for approximately 10 minutes per day, equivalent to the duration of motor imagery practice in the group 1. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers, as the study is multicentric.
218892521|NCT00741975|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
218892522|NCT00741975|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
219203791|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Preservation|Group 1 (Round Ligament Preservation): Patients will undergo laparoscopic TAPP surgery with the round ligament preserved. The preservation will be achieved using a longitudinal incision technique in the peritoneum.
219203792|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Cutting|Group 2 (Round Ligament Cutting): Patients will undergo laparoscopic TAPP surgery with the round ligament cut close to the peritoneum using an energy device.
219512341|NCT02286518|DRUG|TAK-114 10 mg capsule|
219512342|NCT02286518|DRUG|TAK-114 matched placebo|
219512343|NCT01824251|DRUG|NPB-01|
219512344|NCT05770258|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
218892523|NCT05904561|RADIATION|low level laser therapy|"comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest"
218892524|NCT03686735|OTHER|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
218892525|NCT03686735|OTHER|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
219512345|NCT03650933|BIOLOGICAL|G-CHOP|6 cycles(each cycle is 3 weeks)
219512346|NCT03650933|BIOLOGICAL|R-CHOP|6 cycles(each cycle is 3 weeks)
219512347|NCT00588393|DRUG|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
219512348|NCT06121869|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
219512349|NCT06121869|DIETARY_SUPPLEMENT|Leucine|Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
218892526|NCT03686735|OTHER|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
218892527|NCT03686735|OTHER|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
218892528|NCT03553758|DRUG|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
218892529|NCT00487357|BEHAVIORAL|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
218892530|NCT02205671|BEHAVIORAL|Building Better Caregivers Small-group Workshop|
219512350|NCT06121869|DIETARY_SUPPLEMENT|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
219512351|NCT01983020|DRUG|Lidocaine|
219512352|NCT01983020|DRUG|Ketamine|
219512353|NCT01983020|OTHER|Saline|
219512354|NCT01309919|DEVICE|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
219512355|NCT01309919|OTHER|Diary|Subjects will keep a bleeding diary for three months
219512356|NCT01018888|DEVICE|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
219512357|NCT06347497|DRUG|Zonisamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219512358|NCT06347497|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219512359|NCT04875234|DEVICE|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
219512360|NCT00319449|DRUG|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
219203793|NCT06922214|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT ( 25 Gy single fractions at isodose 80%) on the area responsible of ventricular tachicardia
219512361|NCT00319449|DRUG|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
219512362|NCT00319449|DRUG|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
219512363|NCT02102490|DRUG|Abemaciclib|Administered orally
219609607|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 650 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by intermittent infusion at the original rate for another 5 min twice. The interval between two times is also 5 min.
219512364|NCT00618969|OTHER|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
219512365|NCT00897442|OTHER|Laboratory Biomarker Analysis|Correlative studies
219609608|NCT07163845|BIOLOGICAL|Live-attenuated CHIKV vaccine VLA1553|Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.
219609609|NCT07176559|BEHAVIORAL|Chaplain Intervention Group|Eligible and consented participants that are randomized to the Chaplain Intervention Group will receive a total of 4 visits with a board-certified or board-eligible chaplain. These visits will occur weekly for approximately 4 weeks either in person, by telephone, or through a HIPAA compliant video platform. The visits will last an average of 30 minutes each.
219609610|NCT07173361|DRUG|Micronized progesterone (oral capsules)|Two doses of 400 mg total micronized progesterone, administered as 2 × 200 mg capsules \~34 hours and \~10 hours prior to infusion trial, taken with a standardized nutritional drink.
219609611|NCT07173361|DRUG|placebo capsule|Matched oral placebo capsules administered on the same schedule (\~34 and \~10 hours prior to infusion trial) with a standardized nutritional drink.
218892531|NCT04206735|OTHER|Interprofessional Education (IPE)|We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.
218892532|NCT04206735|OTHER|Usual care|Usual care of patients hospitalized with severe COPD exacerbation
218892533|NCT04388761|DRUG|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
218892534|NCT00670904|OTHER|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
219034451|NCT04574804|OTHER|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
219034452|NCT04720196|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
219034453|NCT04720196|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
219034454|NCT05016388|OTHER|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
219512366|NCT02289924|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
219512367|NCT00062309|RADIATION|radiation therapy|
219512368|NCT01346410|RADIATION|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
219512369|NCT04485247|PROCEDURE|Transumbilical Laparoscopic-Assisted Appendectomy|appendectomy performed extracorporeally through umbilical port
219034455|NCT05016388|OTHER|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
219203794|NCT06736002|OTHER|Vitamin D|Vitamin D
219512370|NCT04485247|PROCEDURE|3-port laparoscopic appendectomy|appendectomy performed intracorporeally with 3-port
219609612|NCT07170891|DEVICE|Morning Running and IMT|Inspiratory muscle training was performed in addition to morning running
219609613|NCT07170891|DEVICE|Inspiratory muscle training and evening running|Inspiratory muscle training was performed in addition to evening running
219609614|NCT07170891|OTHER|Control|non-exercise group
219609615|NCT07176286|DRUG|18F-MFBG|Intravenous injection of 222-370 MBq (6-10 mCi) 18F-mFBG followed by whole body PET imaging.
219512371|NCT06369337|DIAGNOSTIC_TEST|Ultrasound|The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
219512372|NCT05994781|DEVICE|EasyDew MD regen cram|No intervention
219512373|NCT00211783|PROCEDURE|fMRI|there is no intervention
219512374|NCT03542136|DEVICE|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
219512375|NCT02669680|DRUG|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
219512376|NCT02669680|OTHER|Standard therapy|
219512377|NCT01094444|OTHER|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
219512378|NCT03449043|OTHER|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
219512379|NCT02154529|DRUG|Tesevatinib|
219512380|NCT02154529|DRUG|Trastuzumab|
219512381|NCT00468533|DRUG|Aripiprazole|
219512382|NCT01412671|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
219512383|NCT03248856|DRUG|Triamcinolone Acetonide|Intratympanic administration
219512384|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
219512385|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
219512386|NCT06464328|BEHAVIORAL|Tai Chi Combined with Music Therapy Intervention|Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for twelve weeks
219512387|NCT06464328|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for twelve weeks
219512388|NCT06464328|BEHAVIORAL|Tai Chi intervention only|Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice; twice a week for twelve weeks
219512389|NCT01026961|DRUG|Phenylephrine HCL|Phenylephrine HCL 10mg
219512390|NCT01026961|DRUG|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
219512391|NCT02010047|DEVICE|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
219609616|NCT07179523|COMBINATION_PRODUCT|Hemostatic gelatin sponge|Colisorb® exhibits optimal pore structure, number and size, which results in its structure being highly porous with low density. In addition, Colisorb® possesses optimal mechanical integrity allowing it to swell to its maximal absorption capacity while maintaining mechanical stability. The sponge can absorb fluids in the blood resulting in prompt recruitment of clotting factors, hence accelerating the body's natural blood clotting cascade. Colisorb® was configured in a way to imitate natural adhesive mechanism without the use of co-agulants, it provides a safer and a more efficient alternative for minimizing post-operative complications and enhancing recovery. Upon performing the tooth extraction, oral surgeon instantly applied the sponge. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery.
219512392|NCT01625156|OTHER|Laboratory Biomarker Analysis|Correlative studies
219512393|NCT01625156|OTHER|Pharmacological Study|Correlative studies
219512394|NCT01625156|DRUG|Temsirolimus|Given IV
219203795|NCT06736002|OTHER|Placebo|Placebo oral solution
219512395|NCT01625156|DRUG|Tivantinib|Given PO
219512396|NCT02178709|DRUG|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
219512397|NCT06378983|DRUG|Oral isotretinoin|Oral isotretinoin
219512398|NCT06378983|OTHER|Oral isotretinoin combined with microneedle radiofrequency therapy|Oral isotretinoin combined with microneedle radiofrequency therapy
219512399|NCT02492490|OTHER|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
219512400|NCT02492490|DRUG|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
219512401|NCT01824758|DRUG|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
219512402|NCT01824758|DRUG|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
219512403|NCT01824758|DRUG|rocuronium|0.05 mg/kg rocuronium
219512404|NCT01824758|DRUG|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
219512405|NCT00704795|OTHER|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
218892535|NCT00670904|OTHER|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
218892536|NCT02892526|OTHER|Abdominoplasty with exeresis of cutaneous tissue|
219512406|NCT00704795|OTHER|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
218892537|NCT02892526|OTHER|Collection of cutaneous tissue|
218892538|NCT04804683|GENETIC|Genetic dissection of Fibromuscular Dysplasia|Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
218892539|NCT04804683|OTHER|Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia|Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
218892540|NCT05577338|BEHAVIORAL|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
218892541|NCT05577338|BEHAVIORAL|health education|disease-related health knowledge
219034456|NCT05492669|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
219034457|NCT05492669|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
219034458|NCT04745403|DRUG|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
219203796|NCT06861309|DEVICE|ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS)|All study participants, regardless of arm, will receive a combine ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) research exam with the Verasonics Vantage 256 (Verasonics, Inc, Kirkland, WA) every three weeks from their routine growth ultrasound until delivery.
219512407|NCT00386464|DEVICE|noninvasive positive pressure ventilation|
219512408|NCT04849988|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
219512409|NCT04849988|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
219512410|NCT03185065|DRUG|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
219512411|NCT03185065|DRUG|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
219512412|NCT03185065|DRUG|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
219512413|NCT03185065|DRUG|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
219512414|NCT00826930|DRUG|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
219512415|NCT04055402|OTHER|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
219512416|NCT04055402|OTHER|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
219512417|NCT05533502|DIETARY_SUPPLEMENT|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
219512418|NCT05533502|DIETARY_SUPPLEMENT|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
219512419|NCT01052116|DRUG|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
219512420|NCT01052116|DRUG|Placebo|Placebo
219512421|NCT05701371|OTHER|Biological samples collection|blood drawing + feces collection in a dedicated device
219512422|NCT02146430|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
219512423|NCT02146430|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
219512424|NCT02146430|DRUG|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
219512425|NCT02146430|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
219512426|NCT05284890|DRUG|CC-99677|Specified dose on specified days
219512427|NCT01894711|DRUG|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
219512428|NCT01893905|DRUG|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
219512429|NCT01893905|DRUG|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
219512430|NCT01768858|DRUG|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
219512431|NCT03985670|DRUG|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
219512432|NCT03985670|DRUG|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
219512433|NCT01539915|DRUG|BCT194|Topically applied BCT194 cream (0.5%)
219512434|NCT02541526|DRUG|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
219512435|NCT02541526|DRUG|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
219512436|NCT01424839|RADIATION|craniospinal irradiation|"* Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~* Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
219512437|NCT01424839|DRUG|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
218892542|NCT03210207|PROCEDURE|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
218892543|NCT06106126|DRUG|GST-HG171 Tablets|150mg GST-HG171 100mg Tablets and ritonavir
218892544|NCT00497445|PROCEDURE|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
219512438|NCT01424839|RADIATION|ventricular irradiation|"* Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
219512439|NCT01424839|DRUG|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
219512440|NCT01424839|DRUG|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
219512441|NCT01424839|RADIATION|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
219512442|NCT03346395|BEHAVIORAL|Problem solving based intervention|Problem solving based intervention
219512443|NCT03346395|BEHAVIORAL|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
219512444|NCT02792413|DRUG|Denosumab|Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
219512445|NCT02792413|DRUG|NaCl (placebo)|Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
219512446|NCT01927536|DEVICE|White LED Flashlight|white light setting
219512447|NCT01927536|DEVICE|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
218892545|NCT00497445|PROCEDURE|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
218892546|NCT00597402|DRUG|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
218892547|NCT00597402|DRUG|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
218892548|NCT00597402|RADIATION|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
219203797|NCT06760013|BEHAVIORAL|Su Jok Therapy|The researcher, who has a Su-Jok practitioner certificate, applied pressure for 1-2 minutes on the active point on the meridian (the area between the 3rd and 4th fingers pointing to the uterus) that provides energy flow in the palm in 20-minute periods, with the help of a diagnostic probe (diagnostic stick). The point will be determined. Once this point is detected, a massage will be performed on the point. The massage will be applied with a 10-minute rest period between each two periods.
219512448|NCT01132599|DIETARY_SUPPLEMENT|C-11 choline|
219512449|NCT01132599|RADIATION|18F-fluoromethylcholine|
219512450|NCT04341740|PROCEDURE|Bone Marrow Aspirate|bone marrow aspiration
219609617|NCT07179523|COMBINATION_PRODUCT|Hemostatic Agent|"Gelatin sponge that may be soaked with sterile physiological solution. Biocompatible and easy to use for 5 to 10 minute bleeding control rate.~Upon performing the tooth extraction, oral surgeon instantly applied the sponge in the socket where the tooth was extracted to facilitate hemostasis. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery."
218892549|NCT00597402|DRUG|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
218892550|NCT03059316|COMBINATION_PRODUCT|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
218892551|NCT03059316|DRUG|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
219512451|NCT01289509|DRUG|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
219512452|NCT01289509|DRUG|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
219034459|NCT00511693|BEHAVIORAL|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
219034460|NCT00511693|BEHAVIORAL|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
219034461|NCT05629832|PROCEDURE|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
219203798|NCT06819423|DEVICE|AI fundus photography|In the dark room, Canon CR-2AF automatic mydria-free fundus camera was used to collect images of both eyes of the patients, and one fundus photo was taken with macula as the center of each eye
218892552|NCT03059316|DRUG|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
218892553|NCT00687180|DRUG|Treatment with mycophenolat mofetil|
218892554|NCT00687180|DRUG|Treatment with azathioprin|
219203799|NCT06879444|OTHER|Core Muscle testing and patient reported outcome measures|These are the situation evaluation parameters. It presents the data of the participants at the time of evaluation.
219512453|NCT00996554|PROCEDURE|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
219512454|NCT00996554|PROCEDURE|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
219512455|NCT03923179|DRUG|Pyrotinib|Pyrotinib, 400mg qd
219512456|NCT03923179|DRUG|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
219512457|NCT03362437|DRUG|BMS-986177|Form A
219512458|NCT03362437|DRUG|BMS-986177|Form B
219512459|NCT02643901|BIOLOGICAL|GW003|single SC injection
219512460|NCT01201746|PROCEDURE|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
219512461|NCT01201746|PROCEDURE|Periodontal therapy|Scaling, root planning and oral hygiene instructions
219512462|NCT04064229|DEVICE|ivWatch Model 400 with SmartTouch Sensor|The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
219512463|NCT04064229|DEVICE|ivWatch Model 400 with Fiber Optic Sensor|The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
219512464|NCT04193631|DRUG|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
219512465|NCT01992289|DRUG|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
219512466|NCT02518230|DEVICE|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
219512467|NCT02518230|DEVICE|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
219512468|NCT05943925|OTHER|No intervention|no intervention
219512469|NCT05943925|DIETARY_SUPPLEMENT|Probiotic supplement|A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.
219512470|NCT01548781|BEHAVIORAL|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
218892555|NCT02620969|OTHER|Blood and dialysate sampling|Blood and dialysate sampling
219512471|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
219512472|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
219512473|NCT00614055|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
219512474|NCT00614055|DRUG|metformin|Tablets, 1500-2000 mg/day
218892556|NCT06040411|OTHER|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
218892557|NCT02921672|OTHER|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
218892558|NCT05042700|DRUG|Melatonin|Enema with 25 mg melatonin
218892559|NCT05042700|DRUG|Placebo|Enema without melatonin
219203800|NCT06952985|DIETARY_SUPPLEMENT|Sugar free chew gum|Chew gum has a role in ERAS protocol which is significant in early post operative recovery as compared to normal routine care methods
219512475|NCT04138849|DRUG|BBT-877 single dose|Oral capsule, single dose.
219512476|NCT04138849|DRUG|Placebo single dose|Oral capsule, single dose.
219609618|NCT07183826|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 6-week (42 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
219609619|NCT07183826|BEHAVIORAL|No intervention|Participants in this arm received no active intervention during the 6-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered to take part in the online MBCT program.
219609620|NCT07184229|BEHAVIORAL|motivational interviewing-based family planning counseling|This intervention consists of motivational interviewing-based family planning counseling aimed at women currently using traditional contraceptive methods. The counseling sessions are designed to enhance participants' motivation and readiness to adopt modern contraceptive methods by addressing their concerns, increasing knowledge, and resolving ambivalence. The comparator group will receive only standard family planning counseling.
219609621|NCT07184229|BEHAVIORAL|standard family planning counseling.|The comparator group will receive only standard family planning counseling.
218892560|NCT02320006|OTHER|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
219203801|NCT06952985|OTHER|Nil Per Oral|According to classic protocols patient were kept nil per oral till bowel sounds were audible
219203802|NCT06744452|BEHAVIORAL|harmony|Use of the app-based digital self-help intervention harmony over a 12-week-period. The app was designed for stress management and the preventive promotion of mental health. Harmony provides users with access to a wide range of psychological self-help content, including video episodes, audio sessions, texts, and downloadable materials. Utilizing artificial intelligence, Harmony offers personalized content suggestions tailored to the user's individual situation and preferences, ensuring the content remains relevant and updated. Content is delivered through a combination of psychoeducation, guided exercises, relaxation techniques, meditations, practical tasks, self-reflection activities, and everyday application tasks.
219203803|NCT05598957|DIAGNOSTIC_TEST|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
219203804|NCT02790853|PROCEDURE|Biopsy|Undergo brush biopsy and incisional biopsy
219203805|NCT02790853|PROCEDURE|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
219203806|NCT02790853|PROCEDURE|High-Resolution Microendoscopy|Undergo HRME imaging
219512477|NCT06539364|DIAGNOSTIC_TEST|Quality of life surveys were conducted|Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
219512478|NCT00208390|DEVICE|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
219609622|NCT07180212|DIAGNOSTIC_TEST|utDNA testing + Urine Cytology|Participants undergo urine tumor DNA (utDNA) testing and urine cytology every 3 months, and cystoscopy once per year. If either utDNA or urine cytology is positive, an additional cystoscopy will be performed. If urine cytology is positive but cystoscopy is negative, or if two consecutive utDNA tests are positive while cystoscopy remains negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
219609623|NCT07180212|DIAGNOSTIC_TEST|Cystoscopy + Urine Cytology|Participants undergo cystoscopy and urine cytology every 3 months as per standard high-risk NMIBC surveillance. If urine cytology is positive but cystoscopy is negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
219512479|NCT05157321|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
219512480|NCT05157321|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
219512481|NCT02072356|RADIATION|yttrium Y 90 glass microspheres|Given Interartrial
219512482|NCT02072356|OTHER|laboratory biomarker analysis|Alpha-fetoprotein assay
219512483|NCT02072356|DRUG|TheraSphere|TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
219512484|NCT01001897|DRUG|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
219512485|NCT01001897|DRUG|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
218892561|NCT03086096|DEVICE|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
218892562|NCT01860287|DRUG|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
219034462|NCT03904238|BEHAVIORAL|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
219512486|NCT03417128|BEHAVIORAL|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
219512487|NCT06015373|DRUG|supress the night dose of carvedilol|already described
219512488|NCT03972982|DRUG|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
218892563|NCT01860287|DRUG|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
218892564|NCT01860287|DRUG|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
219034463|NCT01342510|DRUG|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
219034464|NCT01342510|DRUG|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
219034465|NCT01342510|DRUG|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
219034466|NCT01342510|DRUG|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
219034467|NCT03526419|DRUG|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
219512489|NCT03972982|DRUG|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
219512490|NCT01501799|DRUG|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
219512491|NCT01501799|DRUG|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
219512492|NCT01501799|DRUG|Placebo (Vehicle Gel)|Vehicle Gel
219512493|NCT02132299|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
219512494|NCT02132299|BIOLOGICAL|Normal Saline (Placebo)|
219512495|NCT02132299|BIOLOGICAL|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
219512496|NCT01797471|RADIATION|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
219203807|NCT02790853|DRUG|Proflavine Hemisulfate|Applied on mucosa
219203808|NCT01612351|DRUG|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
219512497|NCT00332293|DRUG|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
219512498|NCT00332293|DRUG|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
219512499|NCT02303561|BEHAVIORAL|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
219512500|NCT02303561|BEHAVIORAL|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
219512501|NCT01419106|DEVICE|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
219512502|NCT01959256|BEHAVIORAL|Visual perceptual learning|24 times of training for visual perceptual learning
219512503|NCT01558141|OTHER|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
219512504|NCT01558141|OTHER|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
219609624|NCT07183436|DRUG|Intra-articular Hyaluronic Acid and Ketorolac|Single intra-articular injection containing 2 mL moderate-molecular-weight hyaluronic acid (20 mg/2 mL), 1 mL ketorolac (30 mg/mL), and 2 mL lidocaine (10 mg/mL), total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
219512505|NCT04023565|DRUG|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
219512506|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
218892565|NCT05413408|OTHER|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
219034468|NCT05694728|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
219034469|NCT05694728|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
219034470|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate and Ipratropium Bromide|
219034471|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate|
219034472|NCT03496142|PROCEDURE|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
219512507|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
219512508|NCT05694325|OTHER|peripheral blood and bone marrow withdrawal|samples evaluation
219512509|NCT02463617|OTHER|magnetic resonance imaging|
219203809|NCT01612351|DRUG|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
219512510|NCT03749655|BEHAVIORAL|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
219512511|NCT00268502|OTHER|study of socioeconomic and demographic variables|
219512512|NCT00268502|PROCEDURE|fatigue assessment and management|
219512513|NCT00268502|PROCEDURE|management of therapy complications|
219512514|NCT00268502|PROCEDURE|psychosocial assessment and care|
219512515|NCT00268502|PROCEDURE|quality-of-life assessment|
219512516|NCT01537484|PROCEDURE|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
219512517|NCT01998321|OTHER|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production
219512518|NCT01998321|OTHER|conventional technique for TKA|
219512519|NCT01693484|DRUG|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
219512520|NCT06543264|DEVICE|Cryotherapy|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
219512521|NCT05602090|DRUG|4 IU of recombinant GH (Somatotropin )|4 IU of recombinant GH
219512522|NCT02435979|OTHER|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
219609625|NCT07183436|DRUG|Intra-articular Ketorolac|single intra-articular injection containing 1 mL ketorolac (30 mg/mL), 2 mL lidocaine (10 mg/mL), and 2 mL normal saline, total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
219609626|NCT07180849|PROCEDURE|Fluoride varnish|Group A will receive conventional fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
219203810|NCT01612351|DRUG|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
219203811|NCT01612351|DRUG|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
219512523|NCT02435979|OTHER|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
219512524|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
219512525|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
219512526|NCT04583579|DEVICE|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
219512527|NCT04583579|DEVICE|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
219512528|NCT04583579|DEVICE|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
219609627|NCT07180849|PROCEDURE|Novel titania nanoparticle infused fluoride varnish|Group B will receive topical application of titania nanoparticle infused fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
219609628|NCT07181668|DEVICE|Low-Level Light Therapy|The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Marketing S.p.A., Italy), which delivers low-level monochromatic red light (633 ± 10 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after femtosecond laser-assisted in situ keratomileusis (Femto-LASIK). The treatment is designed to stimulate meibomian gland activity, improve tear film stability, and reduce ocular surface inflammation. This protocol is unique compared to standard post-refractive surgery care because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications.
219609629|NCT07181668|DEVICE|Sham (No Treatment)|Participants in the Control group underwent the same procedural setup as the LLLT group, using the Eye-light® device (Espansione Marketing S.p.A., Italy). Instead of delivering therapeutic light energy, the device operated in demo mode, emitting less than 30% of the full treatment power. This configuration mimicked the visual and sensory aspects of a low-level light therapy session without producing biologically effective photobiomodulation. Sham treatment consisted of two 15-minute sessions, one 7 days before and one 7 days after Femto-LASIK. This design ensured masking of participants and investigators while preventing active therapeutic exposure in the control group.
218892566|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
218892567|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|
219512529|NCT01691859|DRUG|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
219512530|NCT04820842|DRUG|TAK-994|TAK-994 tablets.
219512531|NCT04820842|DRUG|Placebo|Placebo-matching tablets.
219512532|NCT00928837|DIETARY_SUPPLEMENT|Flavocoxid 500 mg|flavonoid mixture
218892568|NCT02372526|OTHER|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
218892569|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
218892570|NCT02372526|OTHER|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
218892571|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
218892572|NCT05229393|OTHER|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
218892573|NCT05229393|OTHER|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
218892574|NCT05229393|OTHER|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
218892575|NCT02857673|BEHAVIORAL|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
219512533|NCT00928837|DRUG|Naproxen|non-steroidal anti-inflammatory drug
219609630|NCT07181148|DRUG|MSP01-R|Total 20 tablets, split-dose administration over 2 days: 14 tablets the day before colonoscopy, 14 tablets on the morning of colonoscopy, oral intake.
219609631|NCT07181148|DRUG|MSP01-T|Total 20 tablets, split-dose administration over 2 days: 10 tablets the day before colonoscopy, 10 tablets on the morning of colonoscopy, oral intake.
219609632|NCT07186530|OTHER|Best Practice|Receive usual care
219512534|NCT00928837|OTHER|Placebo|Placebo
219512535|NCT00928837|OTHER|flavocoxid 250 mg|Medical food product
219609633|NCT07186530|OTHER|Communication Intervention|Receive portal message
219609634|NCT07186530|OTHER|Electronic Health Record Review|EHR reviewed to assess whether recommended follow-up was completed, if follow-up was indicated.
219609635|NCT07186530|PROCEDURE|HPV Self-Collection|Complete HPV self-collection
218892576|NCT02857673|BEHAVIORAL|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
219512536|NCT06366256|BEHAVIORAL|Traditional ultrasound biofeedback|"Participants use a B-mode ultrasound device to view their tongue movement on a screen. The participant sees the ultrasound image of their tongue moving in sagittal plane on the screen. The speech-language pathologist working with the participant also views participant's tongue movement and provides verbal instruction on how the participant should move their tongue to produce a perceptually correct r sound in simple syllables (CV, VC), as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
219512537|NCT06366256|BEHAVIORAL|Simplified ultrasound biofeedback|"Participants use a B-mode ultrasound device that captures the movement of their tongue and software that transforms the movement of their tongue into gamified objects on a screen. The participant sees a game object (a character) move on the screen towards goals; the movement of the game object represents the movement of the tongue and the goals are representative of tongue movements that correlate with an acoustic percept of accuracy. The speech-language pathologist working with the participant views the movement of the game object and provides verbal instruction on how the participant should move the game character in order to reach the goals when saying simple syllable words (CV, VC) as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
219512538|NCT01917409|DEVICE|conventional laryngoscopy|the device is to assist nasotracheal intubation
219512539|NCT01917409|DEVICE|video-stylet|the device is to guide the nasotracheal tube into trachea
219512540|NCT01073306|BIOLOGICAL|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
219512541|NCT01073306|OTHER|Placebo|Subcutaneous injection of placebo
219512542|NCT00071552|DRUG|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
219512543|NCT00071552|DRUG|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
219512544|NCT03561259|DRUG|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
219512545|NCT03561259|DRUG|131-MIBG + Vorinostat|Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
219512546|NCT05492071|DEVICE|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
219512547|NCT05492071|OTHER|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
219512548|NCT02110771|BEHAVIORAL|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
219512549|NCT02110771|BEHAVIORAL|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
218892577|NCT00397384|DRUG|cetuximab|Given IV
219034473|NCT03496142|PROCEDURE|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
219512550|NCT01296932|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
219609636|NCT07186530|PROCEDURE|Standard Follow-Up Care|Receive standard follow-up care
218892578|NCT00397384|DRUG|erlotinib hydrochloride|Given PO
218892579|NCT00397384|OTHER|laboratory biomarker analysis|Correlative studies
218892580|NCT01708512|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219034474|NCT04750837|PROCEDURE|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
219034475|NCT04750837|BIOLOGICAL|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
219512551|NCT00974493|DRUG|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
219512552|NCT01468051|BIOLOGICAL|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
219512553|NCT01468051|BIOLOGICAL|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
218892581|NCT04360746|OTHER|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
218892582|NCT04360746|OTHER|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
218892583|NCT02734745|DEVICE|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
218892584|NCT03308006|BIOLOGICAL|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
218892585|NCT04915443|DEVICE|Periotome|"Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth."
218892586|NCT04915443|DEVICE|Piezotome|"Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL."
218892587|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
219034476|NCT04750837|PROCEDURE|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
219034477|NCT05608876|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
219034478|NCT01936116|DEVICE|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
219512554|NCT06543654|OTHER|Omnichroma|Each participants had two kinds of veneers
219512555|NCT06543654|OTHER|Ceram. X Spectra|Ceram. X Spectra
219512556|NCT02796027|OTHER|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
218892588|NCT06035705|OTHER|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
218892589|NCT03264365|BEHAVIORAL|Intervention|"Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed"
219034479|NCT01936116|DEVICE|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
219034480|NCT02282956|DRUG|Ropivacaine 0,75%|Ropivacaine injection
219034481|NCT02282956|PROCEDURE|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
219034482|NCT02282956|DRUG|morphine and droperidol|i.v PCA
219034483|NCT01538862|DRUG|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
219034484|NCT04470999|OTHER|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
219203812|NCT01612351|DRUG|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
218892590|NCT01599663|OTHER|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
218892591|NCT03348839|DEVICE|NeLLY service|Telesurveillance and therapeutic support
218892592|NCT03217955|BEHAVIORAL|CBT-SA|Info has been included in arm description
218892593|NCT03217955|BEHAVIORAL|Standard Treatment|Info has been included in arm description
218892594|NCT00028847|DRUG|cytarabine|
219034485|NCT02978742|BEHAVIORAL|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
219034486|NCT02978742|BEHAVIORAL|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
219512557|NCT05945394|OTHER|No intervention|This is an obvertional study, and there is no intervention.
219512558|NCT04464694|DRUG|Ranibizumab|Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3\~7 days before vitrectomy.
219512559|NCT04464694|OTHER|Sham injection|Patients will receive single sham injection 3\~7 days before vitrectomy.
219512560|NCT04464694|PROCEDURE|Pars plana vitrectomy|Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
219512561|NCT01493765|OTHER|Simulator training with expert scoring|Residents will be trained using surgical simulation
219512562|NCT02174939|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
219512563|NCT02174939|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
219512564|NCT00093964|DRUG|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
219512565|NCT00093964|DRUG|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
219512566|NCT02725944|DEVICE|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
218892595|NCT00028847|DRUG|imatinib mesylate|
218892596|NCT05851833|BEHAVIORAL|Early Mobilization|The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
218892597|NCT04593108|DEVICE|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
218892598|NCT04593108|DRUG|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
219034487|NCT01400516|DRUG|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
219034488|NCT01400516|DRUG|calcium citrate|1000 mg of calcium citrate
219034489|NCT01400516|DRUG|Vitamin D|800 IU of Vitamin D
219034490|NCT01400516|DRUG|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
219034491|NCT01412866|BEHAVIORAL|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
219512567|NCT01005836|BEHAVIORAL|Cognitive behavioral therapy for youth anxiety|
219512568|NCT01005836|OTHER|Usual clinic care|
219512569|NCT01005836|BEHAVIORAL|Cognitive behavioral treatment for youth depression|
219512570|NCT01915056|OTHER|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
219512571|NCT03949556|OTHER|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
219512572|NCT02935959|DRUG|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
219512573|NCT02935959|DRUG|nebulized Dexmedetomidine|
219512574|NCT02935959|DRUG|nebulized midazolam|
219512575|NCT03651115|DIAGNOSTIC_TEST|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
219512576|NCT00968383|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
219512577|NCT00968383|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
219512578|NCT00968383|DRUG|Statins|Participants will receive statins.
219512579|NCT00968383|DRUG|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
219512580|NCT00968383|PROCEDURE|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
219512581|NCT03076177|OTHER|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
219512582|NCT00423761|DRUG|midazolam|
218892599|NCT00235586|PROCEDURE|10 vit. D deficient subjects take vit. D for 3 months.|
218892600|NCT03795116|DEVICE|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
219512583|NCT00423761|DRUG|GW876008|
219609637|NCT07185308|DIETARY_SUPPLEMENT|Postbiotics, 2.5 g per dose, three times per day|Postbiotics oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
219609638|NCT07185308|DIETARY_SUPPLEMENT|Placebo, 2.5 g per dose, three times per day|Placebo made of cyclodextrine, oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
219609639|NCT07186465|DRUG|Nitrofurantoin|Nightly oral nitrofurantoin 100 mg for 6 months as prophylaxis for recurrent UTI in postmenopausal women. If symptomatic UTI occurs, treat per standard care and, once resolved, continue assigned prophylaxis to complete 6 months. Monitoring per protocol: baseline and month-6 visits with urinalysis, urine culture, urinary microbiome, and kidney function; twice-weekly phone/Line check-ins for adherence, symptoms, and adverse events.
219609640|NCT07186465|DRUG|Gynoflor|Vaginal tablet containing Lactobacillus with ultra-low-dose estriol. Insert 1 tablet nightly for 14 days, then twice weekly through month 6 as prophylaxis against recurrent urinary tract infection. If a symptomatic UTI occurs, treat per standard of care; after resolution, continue assigned prophylaxis to complete 6 months. Monitoring identical to comparator.
218892601|NCT03795116|DEVICE|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
219512584|NCT01167920|OTHER|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
219512585|NCT04001608|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
219512586|NCT04001608|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
219512587|NCT06195670|DRUG|Experimental|SCRT: 5\*5Gy for 5 days, after a one-week rest, with fruquintinib plus sintilimab followed; Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w; Sintilimab: intravenous infusion, 200mg, on day 1, q3w.
219512588|NCT06195670|DRUG|Active Comparator|Capecitabine: bid po, 1000mg/m², on days 1-14, q3w; Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.
219512589|NCT01442909|DRUG|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
219512590|NCT04253561|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.
218892602|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/rilpivirine|
218892603|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/efavirenz|
219512591|NCT04253561|DRUG|Trastuzumab|600 mg every 3 weeks
219512592|NCT04253561|DRUG|Pertuzumab|420 mg every 3 weeks
219512593|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
218892604|NCT02620592|DRUG|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
218892605|NCT02620592|DRUG|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
218892606|NCT02041507|OTHER|Air insufflation method.|Air insufflation colonoscopy.
218892607|NCT02041507|OTHER|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
218892608|NCT02041507|OTHER|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
218892609|NCT00977171|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
218892610|NCT01051687|DRUG|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
219512594|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
219512595|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
219512596|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
219512597|NCT03778047|DRUG|Enzalutamide|oral
219512598|NCT03778047|DRUG|HC1119|oral
219512599|NCT01903486|DRUG|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
219512600|NCT04641429|BEHAVIORAL|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
219512601|NCT04641429|BEHAVIORAL|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
219609641|NCT07181031|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants in the HIIT group engaged in a 12-week resistance-based high intensity interval training program, designed to target both aerobic and anaerobic energy systems. Training sessions were conducted twice per week in addition to the athletes' regular volleyball practice schedule. Each session commenced with a standardized 10-minute warm-up involving low-intensity jogging and dynamic stretching, and concluded with a 5-minute cool-down of light jogging and static stretching to promote recovery. The main training component consisted of short, repeated high intensity bouts (30 s) of multi-modal exercises-including sprint drills, plyometric movements, functional bodyweight resistance exercises, multi-joint strength movements, agility drills, and aerobic conditioning-performed at 85-95% of maximal heart rate (HRmax) \[28,13\]. Each bout was followed by 30 s of active recovery (e.g., walking or light movement).
218892611|NCT03540108|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
218892612|NCT03540108|DIETARY_SUPPLEMENT|Placebo Comparator: Maltodextrin|Please see intervention description above.
218892613|NCT04365712|DEVICE|Piezoelectric tool|
218892614|NCT04365712|DEVICE|Oscillating Saw|
218892615|NCT01934491|BEHAVIORAL|Cognitive Training A|
218892616|NCT01934491|BEHAVIORAL|Cognitive Training B|
218892617|NCT01473732|DRUG|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
218892618|NCT01473732|DRUG|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
218892619|NCT01473732|DRUG|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
219512602|NCT00720486|BEHAVIORAL|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
218892620|NCT00005961|DRUG|O6-benzylguanine|
218892621|NCT00005961|DRUG|carmustine|
218892622|NCT03087695|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
218892623|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
218892624|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
219512603|NCT00720486|BEHAVIORAL|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
219512604|NCT04110028|DRUG|Nicotinamide riboside|Nicotinamide riboside in different doses
219512605|NCT04110028|DRUG|Placebo|Placebo
219512606|NCT02304120|OTHER|Proprioceptive postural training|
219512607|NCT02304120|OTHER|Treadmill training|
219034492|NCT01412866|BEHAVIORAL|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
219512608|NCT02304120|OTHER|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
219512609|NCT00993057|DRUG|Insulin|Adjustable insulin infusion scale with loading doses
219512610|NCT01836848|PROCEDURE|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
219512611|NCT06124430|OTHER|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
219512612|NCT02503579|BEHAVIORAL|physical training|physical activity program, 30 minutes
219609642|NCT07181031|BEHAVIORAL|High-Intensity Functional Training (HIFT)|Participants completed a 12-week high intensity functional training program aimed at developing aerobic capacity, anaerobic power, muscular strength, and agility. Training sessions were performed twice weekly in addition to regular volleyball practices. Each training session followed a standardized structure, beginning with a 10-minute warm-up of light jogging and dynamic mobility exercises, followed by a main training phase consisting of circuit-style functional workouts that combined sprint drills, plyometric exercises, bodyweight resistance movements, multi-joint strength exercises, agility drills, and aerobic activities; each exercise was performed for 30 seconds at maximal effort with no fixed rest between exercises (≤10 seconds transition allowed), and participants completed 4-6 sets per session with 1-2 minutes of rest between sets, while emphasizing maximal movement speed and explosive execution of all repetitions, and concluding with a 5-minute cool-down of low-intensity joggi
219609643|NCT07186205|DIAGNOSTIC_TEST|Standard blood test|Blood test will measure haemoglobin and other parameters
219609644|NCT07186205|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected to develop algorithms to estimate iron status
219609645|NCT07178782|OTHER|Dual-Task Training Program|the participant will receive dual task program in form of balance and hand function program
219609646|NCT07178782|OTHER|rehabilitation program|designed rehabilitation program
218892625|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
218892626|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
218892627|NCT04766463|DRUG|Placebo|Saline Solution
218892628|NCT04766463|DRUG|Morphine|Morphine
218892629|NCT04811742|OTHER|bathing|immerson bathing and showering
218892630|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
218892631|NCT03271424|DIAGNOSTIC_TEST|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
219203813|NCT01612351|RADIATION|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
218892632|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
219512613|NCT03106090|OTHER|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
219512614|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fasted state.
219512615|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fed state.
219512616|NCT06302231|BEHAVIORAL|Dietary Approach|Intermittent fasting plus energy restriction without aerobic exercise training.
219512617|NCT06544317|BEHAVIORAL|physical training|All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
219512618|NCT02848599|DRUG|morphine|
219512619|NCT02848599|DRUG|levobupivacaine|
219512620|NCT01775033|OTHER|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
219512621|NCT02352337|DRUG|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
219512622|NCT02352337|DRUG|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
218892633|NCT01165983|DRUG|Placebo|0mg tablet, taken orally for 12 weeks daily
218892634|NCT01165983|DRUG|Aliskiren|150mg tablet, taken orally for 12 weeks daily
218892635|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
218892636|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
219512623|NCT02352337|DRUG|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
219512624|NCT02352337|DRUG|Gemcitabine|Gemcitabine perfusion
219512625|NCT05624164|PROCEDURE|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
219512626|NCT05973227|DEVICE|use of the TRIDENT system|usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
219512627|NCT06322927|OTHER|Patient Interview|Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
219512628|NCT05873894|DEVICE|EEG|EEG recordings and analysis. Sensory evoked potentials analysis Motor evoked potentials studies
219512629|NCT01090765|DRUG|TRC105|
219512630|NCT01001065|PROCEDURE|Vascular ultrasound|RI ist predictive for arteriosclerosis
219609647|NCT07192328|DEVICE|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally).|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally. rTMS delivered with 250 pulses via the same double-cone coil used for the neurophysiological study, at either 1 Hz or 5 Hz. For rTLSMS (lumbar and sacral), 2400 pulses (600 per hotspot) were applied at 1 Hz, 5 Hz, or 10 Hz using a 70mm refrigerated air film coil (Magstim, UK). Each dose and stimulation site (cortical or peripheral) were tested in separate sessions.
218892637|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
218892638|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
218892639|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
218892640|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
218892641|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
218892642|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
219512631|NCT00589095|OTHER|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
219512632|NCT04700995|PROCEDURE|NiTi instruments|Root canal filling removal
219512633|NCT05785455|OTHER|COGMO Intervention|Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy
219512634|NCT05785455|OTHER|Usual Care|Usual Primary Care health education and treatment for patients with chronic neck pain
219512635|NCT02401542|DRUG|Vofatamab|
219512636|NCT02401542|DRUG|Docetaxel|
219512637|NCT02401542|DRUG|Placebo|
219512638|NCT02623959|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
219512639|NCT02623959|DRUG|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
219512640|NCT02623959|DRUG|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
219512641|NCT02623959|OTHER|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
219512642|NCT02623959|DRUG|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
218892643|NCT01217944|DRUG|Ranibizumab|0.5 mg ranibizumab intravitreal injection
218892644|NCT01217944|DRUG|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
218892645|NCT01217944|DRUG|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
218892646|NCT01217944|DRUG|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
218892647|NCT02246595|BIOLOGICAL|CaCP29|
219034493|NCT02280135|BIOLOGICAL|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
219034494|NCT02280135|OTHER|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
219034495|NCT01500642|BIOLOGICAL|Slit One|slit one sublingual immunotherapy 200 stu
219034496|NCT01500642|BIOLOGICAL|Slit One|slit one vestibular immunotherapy 200 stu
219034497|NCT01500642|BIOLOGICAL|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
219034498|NCT02204748|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|
219034499|NCT03007758|PROCEDURE|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
219034500|NCT03007758|PROCEDURE|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
219034501|NCT05151263|DRUG|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
219203814|NCT01612351|RADIATION|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
219203815|NCT01612351|PROCEDURE|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
219203816|NCT03512301|DEVICE|CAMCI|CAMCI is a computerized screening tool for the assessment of cognitive status. CAMCI accurately assesses cognitive performance using standard neuropsychological tests of memory, attention, and executive ability modified for computer administration, and an innovative Virtual Environment task, testing domains such as incidental memory, not easily assessed using paper-pencil tests. Computer-administered tasks ensure standard administration and scoring, avoiding inter-site and inter-examiner variability. The CAMCI battery consists of tasks testing multiple aspects of cognitive function, and a series of self-report questions administered via tablet computer. Using touchscreen technology for response input, CAMCI takes approximately 15-20 minutes to complete.
219512643|NCT02623959|BEHAVIORAL|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
219512644|NCT03057899|DRUG|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
219512645|NCT03057899|DRUG|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
218892648|NCT02246595|BIOLOGICAL|Placebo|
218892649|NCT03579940|DRUG|Lasmiditan|Administered orally.
218892650|NCT03579940|DRUG|Placebo|Administered orally.
218892651|NCT03524482|BEHAVIORAL|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
219512646|NCT00421174|DRUG|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
219609648|NCT07192640|DRUG|After induction of anaesthesia tranexamic acid will be administered at the start of surgery to reduce intraoperative bleeding. loading dose of 10 mg/kg for high BMI patients who are undergoing bariatr|This intervention will be applied for High-risk patients, with obesity, BMI more than 45, Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.
219609649|NCT07192224|DEVICE|Hypothermia|This study involves the comparison of 2 groups, one receiving warm fluids while the other group receiving room temperature fluids during surgeries.
219609650|NCT07192224|DEVICE|Hotline|Used as a fluid warmer.
219609651|NCT07192991|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
218892652|NCT03524482|BEHAVIORAL|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
218892653|NCT00257426|DRUG|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
218892654|NCT00671034|DRUG|Calaspargase Pegol-mknl|Given IV
218892655|NCT00671034|DRUG|Cyclophosphamide|Given IV
218892656|NCT00671034|DRUG|Cytarabine|Given IV, IT, PO, or SC
218892657|NCT00671034|DRUG|Daunorubicin Hydrochloride|Given IV
218892658|NCT00671034|DRUG|Dexamethasone|Given PO or IV
218892659|NCT00671034|DRUG|Doxorubicin Hydrochloride|Given IV
218892660|NCT00671034|OTHER|Laboratory Biomarker Analysis|Correlative studies
218892661|NCT00671034|DRUG|Mercaptopurine|Given PO
218892662|NCT00671034|DRUG|Methotrexate|Given IV, IT, or PO
218892663|NCT00671034|DRUG|Pegaspargase|Given IV
218892664|NCT00671034|OTHER|Pharmacological Study|Correlative studies
218892665|NCT00671034|DRUG|Prednisone|Given IV or PO
218892666|NCT00671034|RADIATION|Radiation Therapy|Some patients undergo RT
219034502|NCT05151263|DIAGNOSTIC_TEST|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
219034503|NCT06372353|OTHER|Baduanjin Exercise|Baduanjin exercise training program was applied to the subjects in the exercise group, 3 days a week, 5 minutes each with warm-up and cool-down exercises, for a total of 24 sessions, 60 minutes each, under supervision, online, via the ZOOM application, for 8 weeks. In addition, the patients did the exercises unsupervised at home once a week. The patients' first sessions were held in the hospital
219034504|NCT02313753|BEHAVIORAL|CLASP|
219034505|NCT02313753|BEHAVIORAL|SAFE|
219609652|NCT07192120|DRUG|MHB048C for Injection|IV administration of MHB048C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219609653|NCT07193017|DEVICE|BIPAP|After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods
218892667|NCT00671034|DRUG|Thioguanine|Given PO
218892668|NCT00671034|DRUG|Vincristine Sulfate|Given IV
218892669|NCT03609086|OTHER|Melatonin analysis|Measurement of 6-hydroxymelatonin
218892670|NCT04044469|BEHAVIORAL|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
218892671|NCT04044469|BEHAVIORAL|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
218892672|NCT04044469|BEHAVIORAL|Control group|This group receives no further information after watching the videotaped doctor's report.
218892673|NCT01301313|DRUG|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
218892674|NCT01301313|DRUG|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
218892675|NCT00853151|DRUG|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
218892676|NCT00853151|DRUG|TT223|subcutaneous injection once a day for 4 weeks
218892677|NCT00853151|DRUG|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
218892678|NCT00853151|DRUG|Placebo for TT223|subcutaneous injection once a day for 4 weeks
218892679|NCT02376868|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
218892680|NCT02376868|DEVICE|iVue|OCT machines used for diagnostic purposes
218892681|NCT04053166|DEVICE|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
218892682|NCT04053166|OTHER|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
219512647|NCT00421174|DRUG|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
219512648|NCT02939274|DRUG|Verteporfin|
219512649|NCT02939274|DEVICE|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
219512650|NCT01986036|DIETARY_SUPPLEMENT|Protein|Milk-Protein
219512651|NCT01986036|DIETARY_SUPPLEMENT|Calcium|Soluble calcium powder.
218892683|NCT04053166|BIOLOGICAL|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
218892684|NCT04053166|OTHER|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
218892685|NCT04053166|OTHER|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
218892686|NCT04830579|DRUG|Etoricoxib film-coated tablet 120 mg|Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
219034506|NCT04289116|BEHAVIORAL|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
219034507|NCT04289116|BEHAVIORAL|IHTC|Individual HIV Testing and Counseling
219034508|NCT03034993|BEHAVIORAL|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
219512652|NCT01986036|DIETARY_SUPPLEMENT|Porridge-based breakfast.|Oats and water.
219512653|NCT01829464|DRUG|Placebo|TAK-875 placebo-matching tablets
219512654|NCT01829464|DRUG|TAK-875|TAK-875 tablets
219512655|NCT01829464|DRUG|TAK-875|TAK-875 tablets
219512656|NCT02743702|OTHER|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~* supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~* lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~* sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~* diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~* in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~* exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
219512657|NCT02743702|OTHER|USUAL THERAPIES|
219512658|NCT02229890|DRUG|alteplase|
219512659|NCT00274703|DRUG|mepolizumab|
219512660|NCT02295709|PROCEDURE|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
219512661|NCT02295709|PROCEDURE|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
219512662|NCT02295709|DRUG|Dexamethasone|One of the most efficient steroids
219609654|NCT07193108|DEVICE|Inspiratory Muscle Warm-Up|Inspiratory Muscle Warm-Up (IWU) The POWERbreathe® device (IMT Technologies Ltd., Birmingham, UK) was used for the inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe® device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Yılmaz et al., 2025).
218892687|NCT04830579|DRUG|Arcoxia® film-coated tablet 120 mg|Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
218892688|NCT02656355|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
218892689|NCT02656355|OTHER|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
218892690|NCT00200603|DEVICE|calcium phosphate macroporous bioceramics|
218892691|NCT00269919|DRUG|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
218892692|NCT01789684|OTHER|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
219609655|NCT07193108|DEVICE|Control|Inspiratory Muscle Warm-Up Non-treated group, Control
219609656|NCT07193251|OTHER|Core Stabilization Exercises|Participants will receive supervised core stabilization exercises twice weekly for 8 weeks (≈50 min: 10 min warm-up, 30 min stabilization, 10 min cool-down), progressing from basic trunk activation and bridging to plank and ball-assisted tasks. A daily 60-min home program with illustrated handouts will be prescribed.
219512663|NCT02295709|DEVICE|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
219512664|NCT02295709|RADIATION|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
219512665|NCT04872907|DEVICE|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
219512666|NCT04872907|DEVICE|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
219512667|NCT04872907|DRUG|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
219512668|NCT01904500|DRUG|Pre-operative cefazolin|
219512669|NCT01947777|DRUG|IPI-145|25 mg oral capsule
219512670|NCT01947777|DRUG|Rifampin|2x 300 mg oral capsule
219512671|NCT02207309|DRUG|Pazopanib|
219512672|NCT02207309|DRUG|Placebo (for Pazopanib)|
219512673|NCT00898482|OTHER|This is a non-intervention study for all groups.|This is a non-intervention study.
219512674|NCT00898482|OTHER|study of socioeconomic and demographic variables|Non-intervention study.
219609657|NCT07193251|OTHER|Connective tissue massage|each supervised session will include 20 min of connective tissue massage (CTM) applied bilaterally to lumbar and lower thoracic regions using oblique and transverse pulls at connective tissue reflex zones. CTM will be performed in seated or prone position depending on patient comfort
219609658|NCT07192016|DRUG|fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg|The investigational drug is a single Ellipta inhaler containing 100 ug fluticasone furoate(inhaled corticosteroid), 62.5 ug umeclidinium(long-acting muscarinic antagonist) and 25 ug vilanterol(long-acting β2-adrenergic agonist). The drug is delivered in an Ellipta inhaler in a single dose once daily.
219609659|NCT07192159|DEVICE|Quantitative ultrasound (DeepUSFF)|"\*\*Novel Quantitative Ultrasound Technology Assessment\*\*~This study evaluates Samsung Medison's proprietary DeepUSFF (Deep Learning-based Ultrasound Fat Fraction) technology, a next-generation quantitative ultrasound method for liver fat assessment that differs from conventional ultrasound approaches in several key aspects: advanced RF data analysis, proprietary technology, standardized protocol, direct MRI-PDFF correlation, specific MSALD poopulation and multicenter design."
219609660|NCT07184554|PROCEDURE|us-guided espb|Hemodynamic monitoring is provided. The lumbar region where the procedure will be performed is cleaned with povidone iodine. Sterile draping is provided. For the lumbar erector spinae plane block application, a 5 Hz convex ultrasound probe is first placed sagittally over the desired level of the lumbar vertebra. After the spinous processes are visualized, the ultrasound probe is laterally shifted in the sagittal plane, first visualizing the laminae, then the facet joints, and finally the transverse processes. The erector spinae muscles are visualized over the transverse processes. The skin and subcutaneous tissue are then anesthetized with 2 cc of 2% lidocaine. A spinal needle is inserted from the anesthetized area in the same plane as the ultrasound probe (in plane) and contacts the relevant transverse process. Thanks to the real-time imaging advantage of ultrasound, a certain distance is maintained from the nerves and vascular structures. Once the appropriate location is reached, a m
218892693|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
218892694|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
218892695|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
218892696|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
218892697|NCT00797277|DRUG|IM olanzapine|10mg olanzapine IM
218892698|NCT00797277|DRUG|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
218892699|NCT00659113|DRUG|cisplatin|
218892700|NCT00659113|DRUG|tegafur-gimeracil-oteracil potassium|
218892701|NCT00659113|OTHER|cytology specimen collection procedure|
218892702|NCT00659113|PROCEDURE|endoscopic biopsy|
218892703|NCT01751984|DRUG|ETC-1002|Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
218892704|NCT01751984|DRUG|Placebo|Placebo once daily for 8 weeks
218892705|NCT01119469|BEHAVIORAL|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
218892706|NCT02911870|DRUG|SNAC|Oral administration
218892707|NCT02911870|DRUG|Placebo|Oral administration
218892708|NCT02911870|DRUG|Moxifloxacin|Oral administration
219512675|NCT03473782|OTHER|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
219512676|NCT03473782|OTHER|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
219512677|NCT01204580|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
219512678|NCT05271474|DEVICE|ANNE ONE Platform|ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
219512679|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
219512680|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
219512681|NCT00617448|PROCEDURE|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
219512682|NCT00617448|PROCEDURE|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
219512683|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
219512684|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
219512685|NCT03763110|DEVICE|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
219512686|NCT03763110|DRUG|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
219512687|NCT00043836|DRUG|ALT-711|
219512688|NCT00035087|DRUG|epothilone b|
219512689|NCT03377400|DRUG|Durvalumab|concurrent radiotherapy
219512690|NCT04648475|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
219512691|NCT05927285|DIAGNOSTIC_TEST|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
219512692|NCT05927285|OTHER|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
219512693|NCT02336737|DEVICE|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
219512694|NCT02336737|DRUG|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
219512695|NCT02336737|DRUG|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
219512696|NCT03476720|DEVICE|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
218892709|NCT01689142|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
218892710|NCT01689142|DRUG|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
218892711|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (10 mg QD) for 17 weeks
218892712|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg QD\] + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (30 mg QD) for 17 weeks
218892713|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
219512697|NCT03665103|OTHER|Laser-assisted ICSI|Laser opening of the zona pellucida.
219512698|NCT00200122|DEVICE|Spinal Cord Stimulation|
219512699|NCT05744973|OTHER|No intervention|This is an observational study
219512700|NCT05394168|BIOLOGICAL|HLX53|There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.
219512701|NCT02517801|DIETARY_SUPPLEMENT|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
219512702|NCT02517801|DIETARY_SUPPLEMENT|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
219512703|NCT03656796|OTHER|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
219512704|NCT03656796|OTHER|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
219512705|NCT03931863|DRUG|Ondansetron 4mg|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
219512706|NCT03931863|DRUG|Ondansetron 8mg|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
219512707|NCT03931863|DRUG|100ml normal saline 0.9 percent|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
219512708|NCT04302779|BEHAVIORAL|Solid Model|Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
219512709|NCT04302779|BEHAVIORAL|Liquid Model|To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
219512710|NCT05637281|DRUG|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
218892714|NCT05221502|DRUG|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
219512711|NCT05637281|OTHER|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
219512712|NCT05583812|DRUG|FB2001 for inhalation|FB2001 once or twice daily inhalation
219512713|NCT05583812|DRUG|FB2001 for inhalation placebo|FB2001 placebo once or twice daily inhalation
219512714|NCT02396381|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
219512715|NCT02396381|OTHER|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
219512716|NCT04605510|OTHER|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
219512717|NCT01925755|OTHER|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
219512718|NCT06461208|DRUG|Encapsulated FMT|Encapsulated Faecal Microbiota Transplant
219512719|NCT06461208|OTHER|Placebo|The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
219512720|NCT02934750|BEHAVIORAL|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~1. Breathe in through your nose (as if you are smelling something) for about 2 seconds.~2. Pucker your lips like you're getting ready to blow out candles on a birthday cake.~3. Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~4. Repeat."
219512721|NCT03197064|DRUG|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
219512722|NCT05549284|DRUG|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
219512723|NCT00509964|DRUG|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
219512724|NCT00509964|DRUG|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
219512725|NCT05632848|DRUG|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
218892715|NCT04869839|OTHER|oral examination|examination done by dentist
219512726|NCT02470559|BIOLOGICAL|Aldesleukin|Given SC
219512727|NCT02470559|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV and IP
219512728|NCT02470559|OTHER|Laboratory Biomarker Analysis|Correlative studies
219512729|NCT02470559|BIOLOGICAL|Sargramostim|Given SC
219512730|NCT00356200|DRUG|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
219512731|NCT00356200|DRUG|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
219512732|NCT00344552|DRUG|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
219512733|NCT04072588|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
218892716|NCT03984214|DRUG|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
219034509|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
219034510|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
219512734|NCT00635778|DRUG|dalotuzumab|Administered as an IV infusion over one to two hours
219512735|NCT02012309|BIOLOGICAL|PCV-13|
219512736|NCT02012309|BIOLOGICAL|PPSV-23|
219512737|NCT00519337|DRUG|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
219512738|NCT00519337|DRUG|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
219512739|NCT01625637|BEHAVIORAL|AAT-experiment|This AAT condition trains kids to avoid cigarettes
218892717|NCT03984214|DRUG|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
218892718|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
218892719|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
219034511|NCT05009810|DIETARY_SUPPLEMENT|Placebo|They will take placebo 1 capsule once daily for 2 months.
219512740|NCT01625637|BEHAVIORAL|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
219512741|NCT04120428|OTHER|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
219512742|NCT05780879|DRUG|Venetoclax|Venetoclax administered orally once daily on days 3-16.
219512743|NCT05780879|DRUG|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
219512744|NCT02679677|DEVICE|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
219512745|NCT00812253|DRUG|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
219512746|NCT00812253|DRUG|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
219512747|NCT04289545|DIETARY_SUPPLEMENT|Functional bread|Postprandial effects of bread containing galactomannan
219609661|NCT07184554|PROCEDURE|fl-guided Ilesi|For lumbar interlaminar epidural steroid injection, the anterior view of the desired level is obtained under fluoroscopy to visualize the relevant interlaminar epidural space. The skin and subcutaneous tissue are anesthetized with a local anesthetic. A paramedian approach is used to enter the target interlaminar space with an epidural needle using a negative pressure injector. The lateral view is checked using fluoroscopy. 2 cc of opaque material is administered, and its presence in the epidural space is confirmed from the lateral and anterior-posterior views. A mixture of steroid and local anesthetic (8 mg dexamethasone, 3 cc 5mg/ml bupivacaine, and SF for a total of 10 cc) is injected. The needle is removed in a controlled manner and the needle site is closed. After the procedure, patients are monitored in the recovery unit for 60 minutes and then transferred to the ward for follow-up. Patients who have completed their 1-hour follow-up in the ward are discharged.
219609662|NCT07193394|DRUG|Tucatinib (ONT-380)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
218892720|NCT01157247|PROCEDURE|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
218892721|NCT01699230|DIETARY_SUPPLEMENT|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
218892722|NCT03697642|PROCEDURE|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
218892723|NCT03697642|PROCEDURE|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
219034512|NCT01796197|DRUG|Trastuzumab|
219034513|NCT01796197|DRUG|Pertuzumab|
219609663|NCT07193394|DRUG|Trastuzumab (Herceptin)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
219609664|NCT07192302|PROCEDURE|Arthroscopy|Early Surgical Intervention in Patients with Partial Rotator Cuff Tears and Concomitant Shoulder Stiffness.
219609665|NCT07192302|DRUG|Drugs administration|Oral Medication for Conservative Management of Partial Rotator Cuff Tears with Concomitant Shoulder Stiffness.
219609666|NCT07191587|DIETARY_SUPPLEMENT|Vitamin B Complex|Vitamin B complex given as prophylaxis in prophylactic arm and as treatment in non-prophylactic arm.
219034514|NCT01796197|DRUG|Paclitaxel|
219034515|NCT01796197|DRUG|Doxorubicin|
219034516|NCT01796197|DRUG|Cyclophosphamide|
219034517|NCT01796197|PROCEDURE|Mastectomy|
219034518|NCT01796197|RADIATION|Radiation Therapy|
219034519|NCT05721248|OTHER|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
219034520|NCT01660828|OTHER|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
219512748|NCT04073147|DRUG|Venetoclax|Venetoclax per os
219512749|NCT04073147|DRUG|Obinutuzumab|ObintuzumabIV
219512750|NCT02035709|DRUG|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
218892724|NCT04494906|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
218892725|NCT04494906|OTHER|Square stepping exercise|Square stepping exercise
218892726|NCT04914065|OTHER|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~1. Inspiratory muscles: diaphragm~2. Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~1. Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~2. Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
218892727|NCT04486651|DRUG|Irinotecan Hydrochloride Injection|160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
218892728|NCT04486651|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
218892729|NCT04486651|DRUG|Placebo|Administered as IV infusion on Day 1 of each 21-day cycle.
218892730|NCT00545090|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
218892731|NCT04110782|OTHER|Radium223|55 kBq/ Kg
218892732|NCT01388907|OTHER|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
218892733|NCT01388907|DEVICE|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
219512751|NCT05773183|DRUG|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
219512752|NCT05773183|DRUG|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
219512753|NCT01884025|BEHAVIORAL|Get Moving and Get Well|Walking Class
219512754|NCT01884025|BEHAVIORAL|Health and Humor Class|Class about the role of humor in health
219512755|NCT05883176|DRUG|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
219203817|NCT03512301|DIAGNOSTIC_TEST|MoCA|"The Montreal Cognitive Assessment (MoCA) is a rapid screening tool used to detect mild cognitive impairment (MCI), assessing cognitive domains (visuospatial skills, executive function, memory, attention, language, and orientation). Individual test scores are summed into a total score from 0 (worst) to 30 (best). Individuals may achieve any score within that range. Individual test scores are not reported.~Scores:~26-30 considered Normal; 19-25 may suggest Mild Cognitive Impairment (MCI); 10-18 can suggest moderate impairment; \< 10 may indicate severe impairment"
219203818|NCT03512301|DIAGNOSTIC_TEST|Clinical Adjudication|"Cognitive status assessed by traditional neuropsychological tests measuring visuospatial skills, executive function, memory, attention, language, orientation. Results compared to age-adjusted norms, reviewed by expert neuropsychologists for consensus classification, per Univ of Pittsburgh Alzheimers Disease Research Ctr and Ntl Alzheimers Coordinating Ctr, and Alzheimer's Assoc criteria. Final classification adjusted per clinical judgment.~Impaired: ≥3 scores ≥2SD below norms Indeterminate: ≤2 scores \>1SD below norms Normal: Neither criteria met. Total and domain scores not reported."
219203819|NCT06957730|DEVICE|Phonak Audeo Infinio Hearing Aid|Commercially available receiver-in-canal (RIC) style hearing aid manufactured by Sonova.
219512756|NCT05176977|BEHAVIORAL|Peer Support-Whole Health Coaching|Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
219512757|NCT00215462|DRUG|Vinorelbine|
218892734|NCT05092945|OTHER|Cold exposure|The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
218892735|NCT05092945|DRUG|Oral Nicotinic acid|A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
218892736|NCT05460988|PROCEDURE|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
219034521|NCT04243538|BEHAVIORAL|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
219034522|NCT05386108|DRUG|Elacestrant|300 mg, 400 mg
219034523|NCT05386108|DRUG|Abemaciclib|100 mg, 150 mg
219512758|NCT03146091|OTHER|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
219609667|NCT07193134|DRUG|Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)|Wound debridement will be performed, followed by the application of temporary allogeneic skin grafts for 3-5 days. The allografts will then be removed, and the GMEB-SASS grafts will be applied.
219609668|NCT07192848|DRUG|Adebrelimab + Apatinib|"Adebrelimab: A fixed dose of 1200 mg is administered as an intravenous infusion over 30 minutes (not less than 20 minutes and not more than 60 minutes, including the flushing phase), once every 3 weeks (Q3W). The interval between two administrations should not be less than 12 days.~The maximum treatment duration is 6 courses.~Apatinib: 250 mg, once daily (QD), taken orally within half an hour after a meal, continuously, with a 3 - week (21 - day) cycle.~The maximum treatment duration is 6 courses."
218892737|NCT05460988|PROCEDURE|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
219034524|NCT05429892|BEHAVIORAL|Smoking cessation counseling and food delivery|"The community health workers will delivery three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with food boxes or grocery store gift card at 1,3, and 6 months. Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials at 1, 3, and 6 months."
219034525|NCT05429892|BEHAVIORAL|Smoking cessation counseling|"The community health workers will deliver three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials at 1, 3, and 6 months."
219512759|NCT03146091|OTHER|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
219609669|NCT07193277|DRUG|Butylphthalide|Butylphthalide soft capsules (0.1g per capsule) manufactured by CSPC NBP Pharmaceutical Co., Ltd. Participants take 2 capsules (0.2g total) orally three times daily, 15-30 minutes before meals, for 48 weeks. This represents off-label use for cognitive impairment comorbid with epilepsy, as the drug is currently approved in China only for acute ischemic stroke treatment.
219609670|NCT07193277|DRUG|Placebo|Matching placebo capsules identical in appearance, weight, and odor to butylphthalide soft capsules, manufactured by the same company following GMP standards. Participants take 2 capsules orally three times daily, 15-30 minutes before meals, for 48 weeks. Placebo contains starch and appropriate excipients.
219609671|NCT07192835|DIETARY_SUPPLEMENT|Juice from untreated control fruits|Participants will consume 300 g of juice prepared from untreated fruits (lemon, blood orange, or sweet cherry) under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
219609672|NCT07192835|DIETARY_SUPPLEMENT|Juice from melatonin-treated fruits|Participants will consume 300 g of juice prepared from fruits (lemon, blood orange, or sweet cherry) treated preharvest with melatonin (0.1, 0.3, or 0.5 mM). Juice will be consumed under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
219034526|NCT05429892|BEHAVIORAL|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with food boxes or grocery store gift card at 1, 3, and 6 months Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
219203820|NCT06953791|DIETARY_SUPPLEMENT|aCDED + Modulen|"Unique diet + partial enteral nutrition (PEN): This group will receive as follows:~* Weeks 1-6: 50% of dietary needs from PEN (Modulen, ModuLife phase I) and 50% from a limited whole food diet~* Weeks 7-12: 25% of dietary needs from PEN (Modulen, ModuLife phase II) and 75% from a limited whole food diet~* Weeks 12-48: liberal diet and Modulen as needed"
219512760|NCT04060368|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
219512761|NCT04060368|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
219512762|NCT00314938|DRUG|PHA-794428|
218892738|NCT05650021|DEVICE|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
219203821|NCT06953791|DRUG|Prednisolone|1 mg/kg, tapering scheme
219203822|NCT06952634|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
219512763|NCT02382666|DRUG|Rolapitant|
219512764|NCT00414531|DRUG|Atorvastatin|20 to 80 mg per day
218892739|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
218892740|NCT05904795|OTHER|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
219609673|NCT07191782|BEHAVIORAL|Universal, classroom-based, Bullying and Aggression Prevention Program|PRAISE is a universal, classroom-based aggression and bullying prevention program that addresses all forms (physical, verbal, relational, cyber), with a strong focus on the relational and reactive behaviors. All emotional and social skills taught focus on applying and practicing the skills within peer relationships. This program has gone through iterative development and adaptations using a community-based participatory approach whereby the elementary students and staff were active partners with researchers in refining the program. Specific attention was paid to ensuring that the program is feasible for schools to implement and sustain while also being relevant and relatable for students from a variety of backgrounds and school communities (e.g., under-resourced, higher levels of community violence). This updated PRAISE includes \~14 sessions (amounts can vary by grade) and training and coaching for school-based facilitators of the program.
219609674|NCT07192900|BIOLOGICAL|locally manufactured adoptive cellular therapy (ACT) product|Single dose, intrapleural delivery (via indwelling pleural catheter) of adoptive cellular therapy (ACT) product derived from autologous pleural infiltrating T-cells.
219609675|NCT07192900|DRUG|Interleukin-2|Low dose Interleukin-2 (IL-2) will also be administered intrapleural at the dose of 20 milliliters (mL) at 1 x 10⁵ International Units (IU)/mL starting approximately 2 hours after ACT infusion and every 8 to 16 hours thereafter, as tolerated, for up to 4 doses (total 8 x 10⁶ IU).
219609676|NCT07193420|DRUG|Cyclophosphamide 35mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the experimental dose (70 mg/kg, divided into two doses of 35 mg/kg/day on days +3 and +4).
219609677|NCT07193420|DRUG|Cyclophosphamide 50mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the standard dose (100 mg/kg, divided into two doses of 50 mg/kg/day on days +3 and +4).
219512765|NCT05105373|BEHAVIORAL|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~1. Poor parental bonding and child attachment;~2. Harsh parenting~3. Inequitable socialisation by gender~4. Parental conflict."
219512766|NCT04613830|DRUG|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
219512767|NCT04613830|DRUG|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
219512768|NCT01365429|DEVICE|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
219512769|NCT00361322|DRUG|clindamycin phosphate|
219512770|NCT00361322|DRUG|salicylic acid|
218892741|NCT05904795|OTHER|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
218892742|NCT04575571|OTHER|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
218892743|NCT02502045|DEVICE|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
219512771|NCT05103722|OTHER|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
219609678|NCT07191548|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
219609679|NCT07192185|DRUG|FOLFOX|oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W
219609680|NCT07192185|DRUG|Atezolizumab & Bevacizumab|Atezolizumab 1200mg iv.drip + Bevacizumab 15mg/kg iv.drip Q3w
219609681|NCT07192263|DRUG|IN-B00009|Test drug
219609682|NCT07192263|DRUG|Placebo|Placebo drug
219609683|NCT07192692|DIETARY_SUPPLEMENT|fast|fast state
219609684|NCT07192692|DIETARY_SUPPLEMENT|low fat meal|take HSK47388 with low fat meal
219609685|NCT07192692|DIETARY_SUPPLEMENT|take meal after HSK47388 administration|take meal after HSK47388 administration at specific time
218892744|NCT02502045|DEVICE|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
218892745|NCT03263624|DEVICE|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
218892746|NCT03263624|DRUG|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
219034527|NCT06684379|DRUG|Placebo comparator|A single dose of saline solution 0.9% for infusion
219512772|NCT05822401|BEHAVIORAL|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
218892747|NCT03187132|DEVICE|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
218892748|NCT03187132|DEVICE|Active Control|An active control TENS unit used to reduce acute localized pain.
218892749|NCT01797263|OTHER|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
218892750|NCT01797263|OTHER|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
219512773|NCT05822401|BEHAVIORAL|Usual care (control)|Will continue their work as usual
219512774|NCT00280267|DRUG|Testosterone gel|
219512775|NCT02384616|OTHER|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
219512776|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
219512777|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
219512778|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
219512779|NCT04682041|DIETARY_SUPPLEMENT|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
218892751|NCT02045095|DRUG|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
219034528|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose A) for infusion
219034529|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose B) for infusion.
219034530|NCT07016035|OTHER|mPCOSQ-F and SF-36|Questionnaires
219034531|NCT07015762|DRUG|IBI3002|Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.
219034532|NCT07015762|DRUG|Placebo|Participants with AD will receive placebo at the corresponding volume and dosing interval.
219034533|NCT06626048|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
219512780|NCT04682041|OTHER|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
219512781|NCT00095381|DRUG|forodesine hydrochloride (BCX-1777)|
219512782|NCT03082781|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
219512783|NCT03082781|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
219512784|NCT03651323|DEVICE|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
219512785|NCT05779449|DIETARY_SUPPLEMENT|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~1. packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~   From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~2. capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
219512786|NCT05779449|DIETARY_SUPPLEMENT|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
219512787|NCT05779449|PROCEDURE|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
219512788|NCT05779449|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
219512789|NCT02324465|DEVICE|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
219512790|NCT02324465|DEVICE|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
219512791|NCT02059993|DEVICE|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
219512792|NCT01580878|DRUG|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
219512793|NCT01580878|DRUG|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
219609686|NCT07191691|DIAGNOSTIC_TEST|Bayley Scales of Infant and toddler Development, fourth edition (BSID-4)|"The BSID-4 is a test that evaluates three areas of child's development, divided into three scales:~* The Motor Scale, which includes the fine motor and gross motor subtests;~* The Cognitive Scale, which consists of items assessing sensorimotor development, object exploration and manipulation, concept formation, memory, and other primary functions from which the child's reasoning abilities emerge;~* The Language Scale, which includes the receptive communication and expressive communication subtests.~The administration of the BSID-4 involves the standardized delivery of items. The BSID-4 standardization does not specify a fixed order for administering the scales: depending on the child's temperament and spontaneous interest, the examiner adapts the order in which the motor, language, and cognitive scales are administered."
219609687|NCT07193368|BIOLOGICAL|Polyacrylamide hydrogel 2.5% intra-articular injection|A single intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (iPAAG), composed of 2.5% polyacrylamide and 97.5% non-pyrogenic water. The product (Arthrosamid®, Contura, Denmark) was administered under ultrasound guidance into the knee joint. Patients were followed retrospectively for 12 months to evaluate safety and effectiveness in reducing pain (VAS) and improving function (WOMAC).
219609688|NCT07192497|OTHER|DRY NEEDLING|Myofacial trigger point dry needling used to treat taught bands superficial or deep inside of muscles .
219609689|NCT07192497|OTHER|Acupressure|Acupressure therapy based on traditional Chinese principles
219609690|NCT07192497|OTHER|Dry needling and Acupressure therapy|combination of dry needling and acupressure therapy on cervical trigger points
219512794|NCT01580878|DRUG|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
219609691|NCT07192497|OTHER|Hot Pack|Hot fermentation will be applied on cervical pain area
219609692|NCT07191925|BEHAVIORAL|Community Co-designed Physical Activity and Diet Intervention Package|A package of 4-6 diet and physical activity interventions selected from a long-list of potential interventions and adapted to the unique school and neighborhood context via consultation with community stakeholders. Intervention packages are multi-level (i.e. targeting at least two of individual, external and structural environments), target elements of both diet and physical activity, and are health equity oriented in terms of both access and improvement. Long-list potential interventions include items related to school intramural programming, active transport, health education, community recreational programming, and structural/public space design improvements.
219609693|NCT07192003|DEVICE|Floss Band Group (FBG)|Participants in this arm will perform the standardized Floss Band (FBG) protocol. While seated with the shoulder at 90° abduction, the researcher will apply a compressive elastic band made of 100% polymer gel (T.P.E), measuring 210 cm in length, 5 cm in width, and 1.3 mm in thickness. The first anchor is placed two fingers medial to the acromion, and the band is wrapped around the shoulder until the second anchor at the end of the band is fixed. After the application, the participant will perform sport-specific movements (spike and serve) for 2 minutes. Following the completion of the compression period, the band will be removed. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
218892752|NCT03594773|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
218892753|NCT03594773|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
218892754|NCT00918177|DRUG|AP09004|
219512795|NCT05159609|DEVICE|Closed loop auditory stimulus|50ms of low volume pink noise delivered during slow wave sleep
218892755|NCT00918177|DRUG|Carbidopa/Levodopa, immediate release|
218892756|NCT03618420|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
218892757|NCT03618420|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
218892758|NCT04879693|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
218892759|NCT01243723|DRUG|Eductyl suppository|One suppository every morning during 21 days
218892760|NCT01243723|DRUG|Placebo suppository|One suppository every morning during 21 days
219512796|NCT01226056|DRUG|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
219512797|NCT03868137|DRUG|Ibuprofen|3 doses of Ibuprofen 800 mg
219512798|NCT03868137|DRUG|Placebos|Placebo
219512799|NCT02655237|DRUG|Relugolix|Relugolix tablets
219512800|NCT02655237|DRUG|Relugolix Placebo|Relugolix placebo-matching tablets
219512801|NCT02655237|DRUG|Leuprorelin|Leuprorelin injection
219512802|NCT02655237|DRUG|Leuprorelin Placebo|Leuprorelin placebo-matching injections
219512803|NCT00153283|DRUG|Gabapentin|
219512804|NCT00039611|DRUG|FOLFOX regimen|
219512805|NCT00039611|DRUG|fluorouracil|
218892761|NCT04640649|OTHER|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
219512806|NCT00039611|DRUG|leucovorin calcium|
219512807|NCT00039611|DRUG|oxaliplatin|
219512808|NCT00928954|DRUG|gabapentin|increasing to 1200 mg/day
218892762|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
219609694|NCT07192003|OTHER|Mobilization with Movement (MWM) Group|Participants in this arm will perform the standardized Mobilization with Movement (MWM) protocol. While seated in a chair with back support and hips, knees, and ankles at 90° flexion, the researcher will stabilize the scapula with one hand and apply a posterolateral glide to the anterior humeral head with the other hand during active shoulder elevation in the scapular plane. The intervention consists of 3 sets of 10 repetitions, with a 1-minute rest interval between sets. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
219512809|NCT00928954|DRUG|memantine|increasing to 40 mg/day
219512810|NCT01911494|BEHAVIORAL|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
219512811|NCT01911494|DEVICE|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
219512812|NCT01911494|DRUG|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
219512813|NCT01911494|DRUG|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
218892763|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
219609695|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds|Removal of deposits above and below the gum line using hand or ultrasonic tools to reduce the inflammatory parameters
218892764|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
218892765|NCT04320017|DIAGNOSTIC_TEST|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"* 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
218892766|NCT00202761|BEHAVIORAL|PIH|Intensified training
219034534|NCT06626048|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
219034535|NCT05425524|PROCEDURE|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
219034536|NCT05084768|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|As mentioned previously
219034537|NCT06887465|DEVICE|Non-invasive Blood Pressure Monitor|Application of the VeriTrack non-invasive blood pressure monitor
219512814|NCT01241968|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
219512815|NCT01241968|DEVICE|Placebo|Placebo
219512816|NCT06436196|DEVICE|Video Laryngoscope|Use of Video laryngoscope to secure airway
219512817|NCT06436196|DEVICE|Direct laryngoscope|Macintosh or Miller's laryngoscopes used to secure paediatric airways
219512818|NCT01906541|GENETIC|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
219512819|NCT03679741|DEVICE|CONTROL Lens|Acuvue OASYS
219512820|NCT03679741|DEVICE|TEST Lens|senofilcon A
219512821|NCT01117610|DRUG|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
219512822|NCT01117610|DRUG|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
219512823|NCT03935269|DEVICE|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
218892767|NCT02318966|DIETARY_SUPPLEMENT|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
219512824|NCT03935269|PROCEDURE|Stress management therapy|Undergo Cereset research office intervention
219512825|NCT03935269|OTHER|Questionnaire administration|Ancillary studies
219512826|NCT03935269|OTHER|Quality of Life Assessment|Ancillary studies
219512827|NCT05380635|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
219512828|NCT03711409|OTHER|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
219512829|NCT03711409|OTHER|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
219512830|NCT00726700|BIOLOGICAL|pegfilgrastim|Given subcutaneously
219512831|NCT00726700|BIOLOGICAL|rituximab|Given IV
219034538|NCT06736522|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
219512832|NCT00726700|DRUG|cyclophosphamide|Given IV
219512833|NCT00726700|DRUG|doxorubicin hydrochloride|Given IV
219609696|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds + aPDT (antimicrobial photodynamic therapy)|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light and oxygen to generate reactive oxygen species (ROS) that kill bacteria
218892768|NCT01544725|DRUG|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
219034539|NCT06736522|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
219034540|NCT07044843|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
219034541|NCT07044843|OTHER|Standard ambiant air will be breathed during endurance training.|ambiant air
219034542|NCT02152254|DRUG|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.
219034543|NCT02152254|DRUG|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
219034544|NCT06687980|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
219034545|NCT06687980|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
219512834|NCT00726700|DRUG|prednisone|Given orally
219512835|NCT00726700|DRUG|vincristine sulfate|Given IV
219512836|NCT02842697|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
219512837|NCT02842697|PROCEDURE|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
219512838|NCT02842697|PROCEDURE|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
219512839|NCT04834245|PROCEDURE|Hydrogel/nano silver-based dressing|compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
219512840|NCT06101654|DEVICE|Pulse oximeter|Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
219512841|NCT06496763|DEVICE|Vision-700|OCT machines used for diagnostic purposes
219609698|NCT07192718|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
219609699|NCT07192718|OTHER|Education|Educational content: Participants view videos online focusing on specific areas of postpartum recovery (Sleep, Mental Health, Physical Therapy, Obstetric care).
219609700|NCT07193459|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily
219609701|NCT07193459|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily
219609702|NCT07193459|DRUG|Placebo|Placebo tablets, once daily
219512842|NCT05832463|DIETARY_SUPPLEMENT|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
219512843|NCT05832463|DIETARY_SUPPLEMENT|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
219512844|NCT01860976|DRUG|Abatacept|
219512845|NCT01860976|DRUG|Placebo|
219609703|NCT07193433|OTHER|CSNAT-I|CSNAT-I will be conducted in five stages, including an introduction of the CSNAT, family caregivers' consideration of needs, prioritize needs, a shared care plan, and a shared review for effectiveness and subsequent actions .
219609704|NCT07192965|RADIATION|Non-ECG-gated computed tomography|Scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus.
219609705|NCT07191873|DRUG|Tirzepatide|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
219609706|NCT07191873|DRUG|Tirzepatide Placebo|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
219609707|NCT07193121|DEVICE|Inspiratory Muscle Warm-Up|The POWERbreathe device (IMT Technologies Ltd., Birmingham, UK) was used for inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Koizumi \& Ohya, 2023).
219609708|NCT07193121|DEVICE|Control|No intervention
218892769|NCT01544725|DRUG|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
218892770|NCT03430778|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
218892771|NCT03430778|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
218892772|NCT02246959|BEHAVIORAL|Process Incentive|Daily sweepstake conditional on daily medication adherence
218892773|NCT02246959|BEHAVIORAL|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
218892774|NCT01900158|DRUG|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
218892775|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
218892776|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules containing 9000 FCC of acid lactase
218892777|NCT01593631|DIETARY_SUPPLEMENT|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
218892778|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
219034546|NCT06754904|PROCEDURE|Omitting TLND|Omitting TLND in patients who achieve an MPR in the index node following neoadjuvant ipilimumab and nivolumab.
218892779|NCT01593631|DIETARY_SUPPLEMENT|Placebo|Capsules containing di-calcium-phosphate
218892780|NCT01302717|DEVICE|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
218892781|NCT01302717|DEVICE|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
218892782|NCT01057849|DRUG|risperidone|3-6 mg per day
219034547|NCT06754904|PROCEDURE|Index node procedure|Index node procedure
219512846|NCT06269276|BEHAVIORAL|Caregiver Contribution to Self-Care in Ostomy Patient Index|This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.
219512847|NCT02227862|DRUG|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
218892783|NCT01057849|DRUG|olanzapine|5-20 mg per day
218892784|NCT01057849|DRUG|Aripiprazole|10-30 mg per day
219512848|NCT02227862|DRUG|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
219512849|NCT06220292|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
218892785|NCT03658005|OTHER|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).
218892786|NCT05962866|OTHER|I and II. Performing Leopold Maneuvers by the pregnant|24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
218892787|NCT03349788|PROCEDURE|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
218892788|NCT03349788|PROCEDURE|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
218892789|NCT03423316|BEHAVIORAL|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
218892790|NCT04389723|DIETARY_SUPPLEMENT|Qualia Mind|Multi-ingredient Dietary supplement
218892791|NCT04389723|DIETARY_SUPPLEMENT|Placebo|Multi-ingredient Placebo
218892792|NCT01574235|BIOLOGICAL|Nivestim®|
218892793|NCT02481739|OTHER|retrospective study|
219034548|NCT07063836|PROCEDURE|VST|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth.Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone and an immediate implant is placed using a surgical guide. the augmentation is done using A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~A special 0.6 mm thick membrane is inserted through the access incision. the vestibular incision is then sutured and the provisional is inserted."
219034549|NCT07063836|PROCEDURE|contour augmentation and early implant placement|"Teeth extraction : minimally invasive adjacent teeth extraction under anesthesia using periotome and forceps.~the empty sockets will be filled with a special collagen material (BioPlug) to aid healing for 4 to 8 weeks.~flap elevation : a full-thickness flap will be carefully raised using a crestal incision extended one tooth mesial and distal to the extraction location, then connected with two vertical incisions extended through the sulcus forming a trapezoid flap.~Implants Insertion: The two implant is then placed into the prepared sockets using surgical guide.~Bone Grafting: Any bone deficiencies are addressed by grafting. This involves placing a layer of (autogenous bone) directly on the two implants' surface, followed by a layer of a bone-grafting material (Demineralized Bone Matrix).~Membrane Placement: A double-layered collagen membrane is used to cover the grafted area.~Flap Closure: The previously lifted flap is repositioned and sutured back in place."
219512850|NCT06220292|DEVICE|Intermittent Oral-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219609709|NCT07192783|OTHER|Lavender|Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.
218892794|NCT01631994|DRUG|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
218892795|NCT00724672|DRUG|etanercept|etanercept 50 mg subcutaneously once weekly
218892796|NCT00724672|DRUG|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
218892797|NCT00724672|DRUG|adalimumab|adalimumab 40 mg subcutaneously biweekly
218892798|NCT06153368|DRUG|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
218892799|NCT03769038|DEVICE|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
218892800|NCT00558116|DEVICE|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
218892801|NCT02694302|DEVICE|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
218892802|NCT02694302|DEVICE|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
218892803|NCT03029910|OTHER|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
218892804|NCT03029910|OTHER|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
219512851|NCT06220292|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
218892805|NCT03070535|OTHER|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
219512852|NCT02457429|DEVICE|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
218892806|NCT00612755|DRUG|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
218892807|NCT05766176|DIAGNOSTIC_TEST|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
218892808|NCT01764555|DRUG|acetaminophen 2 g|
219034550|NCT07064135|BEHAVIORAL|Prompt Medication Adjustment and Intensive Follow-up|Participants receive prompt adjustment of lipid-lowering therapy perioperatively and 6-8 weeks after carotid endarterectomy to achieve guideline-recommended LDL-C targets, combined with intensive follow-up visits and laboratory monitoring. Intensive follow-up visits and laboratory monitoring of lipid parameters are performed at 6-8 weeks and again at 12-16 weeks postoperatively to optimize lipid management.
219034551|NCT07064135|OTHER|Standard Care|Participants receive standard postoperative care according to guidelines, including lipid management and routine follow-up without additional early intervention or intensive monitoring. Lipid parameters are assessed only once at 12-16 weeks postoperatively.
219034552|NCT06776731|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
219034553|NCT06776731|OTHER|Room Air (placebo)|Room air (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
219512853|NCT02457429|OTHER|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
219609710|NCT07193212|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a hands-on approach where a trained physician uses techniques such as gentle pressure, stretching, and guided movements to improve mobility, reduce pain, and support the body's natural healing. It focuses on the interconnectedness of muscles, joints, and fascia to restore balance and function.
219609711|NCT07192094|BEHAVIORAL|Mindfulness Sessions - 8 Week Program|A culturally, and developmentally adapted Mindfulness-Based Stress Reduction (MBSR) program for Hispanic (self-identified) emerging adult (EA) participants (ages 18-25 years old) over 8 weeks (1.5 hours/week).
218892809|NCT01594229|DRUG|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
218892810|NCT01594229|DRUG|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
218892811|NCT01594229|DRUG|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
218892812|NCT05060770|GENETIC|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
219034554|NCT06813742|DRUG|18F-MFBG|Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
219034555|NCT04586699|DEVICE|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
219034556|NCT04586699|DEVICE|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
219034557|NCT06591780|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and a 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
218892813|NCT03093337|OTHER|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
219512854|NCT02457429|OTHER|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
219512855|NCT01774474|DRUG|Bromfenac|
219512856|NCT01774474|DRUG|Dexamethasone|
219512857|NCT01774474|DRUG|Bevacizumab|
219512858|NCT01774474|DRUG|Triamcinolone Acetonide|
219512859|NCT00964626|DRUG|cisplatin|
219512860|NCT00964626|DRUG|paclitaxel|
219512861|NCT05770726|DIETARY_SUPPLEMENT|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
219512862|NCT00719966|DRUG|anastrozole|Patients receive aromatase inhibition therapy.
219512863|NCT00719966|DRUG|exemestane|Patients receive aromatase inhibition therapy.
219512864|NCT00719966|DRUG|letrozole|Patients receive aromatase inhibition therapy.
219512865|NCT00719966|PROCEDURE|assessment of therapy complications|Endothelial function is measured
219512866|NCT05994222|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
218892814|NCT02068625|DRUG|Rasagiline|Rasagiline 1mg daily orally for 7 days
218892815|NCT02068625|DRUG|Placebo|Oral treatment with placebo for 7 days
219512867|NCT06371248|BEHAVIORAL|Steady Feet|Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.
218892816|NCT00277550|DRUG|Tegaserod and Placebo|
219203823|NCT06061939|OTHER|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
219512868|NCT06371248|OTHER|Usual care for fall prevention|CGH's usual care for fall prevention, which include fall prevention materials and advice.
219512869|NCT05331222|DRUG|JT-1|JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
219512870|NCT01263158|OTHER|Expectancy of standard oxytocin treatment|
219512871|NCT00310258|BEHAVIORAL|Drug use prevention intervention|
219512872|NCT03847376|DRUG|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter \[mL\] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
219512873|NCT01336829|DRUG|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
219512874|NCT01336829|DRUG|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
219512875|NCT01336829|DRUG|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
219512876|NCT01336829|DRUG|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
219512877|NCT01390363|OTHER|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
219609715|NCT07191951|OTHER|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
218892817|NCT05740943|DRUG|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
218892818|NCT04472234|OTHER|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
218892819|NCT01461707|BEHAVIORAL|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
219034558|NCT06591780|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target
219203824|NCT06953895|PROCEDURE|Mulligan's Mobilization With Movement|The Mulligan's MWM group received mobilization with movement in the glenohumeral joint, as described by Mulligan. The participant was seated, and the physiotherapist was placed on the opposite side to the affected shoulder with the thenar eminence of one hand over the anterior aspect of the humeral head, and the other hand over the spine of the scapula posteriorly of the affected shoulder. The hand over the humeral head performed a posterolateral glide, while the other hand stabilized the scapula. This maneuver was sustained while the participant asked to raise the arm in scapular plan (as explained above) without pain. The physiotherapist previously determined the amount of posterolateral pressure which was the best to abolish the pain during shoulder scaption for each participant. The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes.
219203825|NCT06953895|PROCEDURE|Active Mobilization|"In the Placebo group, no effective intervention was performed, the participant was asked to raise the affected arm in scapular plane without pain, while the physiotherapist placed their hands-on shoulder, with the same manual contacts described in Mulligan's MWM group, but without performing any pressure.~The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes."
219203826|NCT04823247|DRUG|Tildrakizumab|As provided in real world clinical practice.
219203827|NCT06952569|OTHER|IKE System|Age-gate the access and activation of a device to authorized users of legal age
219203828|NCT06952764|OTHER|Seizure risk forecast|Participants are provided with daily risk estimates about upcoming seizure likelihood.
219203829|NCT06952764|OTHER|Control seizure risk forecast|Participant receive uninformative control forecast
219609716|NCT07193160|DRUG|Sacituzumab Tirumotecan|fixed dosage 4mg/kg iv, D1, D15, each 4 weeks one cycle. Drug reduction will be implemented according to the research plan.
219609717|NCT07193160|DRUG|Furmonertinib|160mg QD or 80mg QD, each 4 weeks one cycle, according to the safety run-in phase, until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terrminate treatment, or other treatment termination criteria specified in the protocol. Drug reduction will be implemented according to the research plan.
219609718|NCT07192445|OTHER|Reading of Mental Health Graphic Novels|Participants read carefully selected excerpts from graphic novels focused on mental health. These excerpts integrate written narratives with visual storytelling to illustrate daily life challenges, symptoms, interpersonal relationships, and treatment experiences in mental health contexts. The intervention is conducted individually in a supervised classroom environment. Along with the graphic novel, a guide is provided with questions designed to encourage focused and reflective reading.
219609719|NCT07191626|PROCEDURE|PFA - PV + SVCI|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins AND the superior vena cava.
219609720|NCT07191626|PROCEDURE|PFA - PVI only|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins only. No ablation is performed in the superior vena cava.
218892820|NCT01461707|BEHAVIORAL|Activity monitor|Participants will receive an activity monitor
219609721|NCT07191535|DRUG|linvemastat|Matrix Metalloproteinase-12 inhibitor
219609722|NCT07191535|DRUG|Placebo|Placebo
218892821|NCT00075621|DRUG|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
218892822|NCT00075621|DRUG|melphalan|200 mg/kg over 2 days
218892823|NCT00075621|PROCEDURE|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
218892824|NCT03513276|DRUG|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
218892825|NCT03513276|DRUG|Saline Solution|Multimodal analgesia + Saline solution
218892826|NCT03513276|DRUG|Adrenaline 10mcg/ml|
218892827|NCT03158194|BEHAVIORAL|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
218892828|NCT01450761|BIOLOGICAL|Ipilimumab|
218892829|NCT01450761|BIOLOGICAL|Placebo matching Ipilimumab|
219609723|NCT07191847|BIOLOGICAL|eye drops|apply 2 drops 3 times daily for 12 weeks
219609724|NCT07191808|OTHER|Low Level Laser Therapy|cluster method
218892830|NCT01450761|DRUG|Etoposide|
218892831|NCT01450761|DRUG|Cisplatin|
218892832|NCT01450761|DRUG|Carboplatin|
218892833|NCT00672919|DRUG|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
218892834|NCT00535002|DRUG|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
218892835|NCT00535002|DRUG|Placebo|
218892836|NCT01327677|DRUG|Fentanyl|25-50 mcg every 20 minutes
219034559|NCT06591780|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant\&#39;s immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
218892837|NCT01327677|DRUG|Fentanyl|20mcg/demand dose with an 8 minute lock out
218892838|NCT00970112|PROCEDURE|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
218892839|NCT04668768|DRUG|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
218892840|NCT01220739|DEVICE|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
218892841|NCT03018899|PROCEDURE|paravertebral block|Ultrasound guided two-segment paravertebral block
219034560|NCT06734234|DRUG|GSK4771261|GSK4771261 will be administered.
219034561|NCT06734234|DRUG|Placebo matching GSK4771261|Placebo matching GSK4771261 will be administered.
219034562|NCT07080905|GENETIC|CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)|Administered as a single IV infusion.
219034563|NCT07083050|DEVICE|Volume stable collagen matrix|Volume stable collagen matrix obtained from porcine collagen after proprietary cross-linking by device manufacturer
219034564|NCT07083050|PROCEDURE|Autologous Connective Tissue Graft from the Hard Palate|Autologous connective tissue surgically harvested from the hard palate and transplanted in the area of gingival recession
219034565|NCT07084064|BEHAVIORAL|Families Moving Together|The Families Moving Together intervention was co-designed with community leaders and caregivers to address these barriers and promote physical activity co-participation among families. This evidence-based curriculum consists of six progressive lessons aimed at helping families learn, practice, and sustain an active lifestyle. The goals of this study are to increase community awareness of the importance of physical activity, create changes in parent and child physical activity, and increase parent physical activity knowledge and self-efficacy for promoting family physical activity.
219203830|NCT06953518|DIETARY_SUPPLEMENT|Qualia Senolytic|Qualia Senolytic manufactured by Qualia Life Science
219203831|NCT06744777|DRUG|Ribavirin|Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.
219609725|NCT07191509|DEVICE|Speaking Valve ，Tracheostomy Tube Occlusion ，Tracheostomy Tube Ventilation|"Speaking Valve:~Participants are assessed while breathing through a one-way speaking valve attached to the tracheostomy tube. The valve directs exhaled air through the upper airway, restoring phonation and more closely simulating post-decannulation airflow. The assessment is performed for up to 4 hours to evaluate tolerance and respiratory function prior to tracheostomy tube removal.~Tracheostomy Tube Occlusion:~Participants undergo a capping trial, in which the tracheostomy tube is completely occluded. During this intervention, patients must breathe entirely through their natural upper airway, which increases airway resistance and tests their ability to tolerate decannulation. The capping trial is conducted for 24-48 hours, with monitoring for signs of intolerance.~Tracheostomy Tube Ventilation:~This intervention involves assessment of respiratory function while the participant breathes directly through the open tracheostomy tube, representing the baseline state prior to any decannu"
218892842|NCT03018899|PROCEDURE|epidural anesthesia|thoracic epidural anesthesia
218892843|NCT03741504|PROCEDURE|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
218892844|NCT01076530|DRUG|vorinostat|
219609726|NCT07191717|DRUG|Abemaciclib|Given PO
219609727|NCT07191717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219609728|NCT07191717|DRUG|Imlunestrant|Given PO
219609729|NCT07191717|OTHER|Questionnaire Administration|Ancillary studies
219609730|NCT07191717|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic scans
219609731|NCT07193316|OTHER|no intervention|no intervention
219609732|NCT07192107|DRUG|MHB042C for Injection|IV administration of MHB042C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219609733|NCT07192211|BIOLOGICAL|Mesenchymal stem cell|ADR-002K administration
219609734|NCT07192211|BIOLOGICAL|Placebo|Placebo
219609735|NCT07193225|DEVICE|Ultrasound localization microscopy, circle of Willis|Ultrasound localization microscopy sequences coupled with SonoVue® injection of the circle of Willis before carotid endarterectomy
219609736|NCT07193225|DEVICE|Ultrasound localization microscopy, coronary arteries|ultrasound localization microscopy sequences coupled with SonoVue® injection of coronary arteries before carotid endarterectomy
219609737|NCT07192289|PROCEDURE|Using advanced platelet-rich fibrin (A-PRF+) or injectable platelet-rich fibrin (i-PRF) in regenerative endodontic treatment in mature permanent teeth.|"After obtaining informed consent, the study will be conducted over 2 appointments, 2-4 weeks apart.~The first appointment will focus on infection control and inflammation reduction. The canal will be instrumented with a single-file system. The canal will be then irrigated sequentially with 3% sodium hypochlorite (NaOCl), saline, and 17% ethylenediaminetetraacetic Acid (EDTA) to ensure thorough disinfection. Finally, a temporary filling of Glass Ionomer Cement will be placed over an intracanal dressing of calcium hydroxide.~At the second appointment, the final treatment will be performed based on the patient's group:~Control Group - Blood clot method for regenerative endodontics. Experimental Group 1 - Regenerative endodontics using advanced platelet-rich fibrin (A-PRF+).~Experimental Group 2 - Regenerative endodontics using injectable platelet-rich fibrin (i-PRF).~All three groups will be then sealed with mineral trioxide aggregate (MTA) and a final composite resin filling."
219609738|NCT07193303|OTHER|mental imagination|The Nine-Hole Peg Test (9 DPT) will be performed with a mental chronometer.the duration between actually physically performing the movement and mentally imagining the same movement will be recorded.
219609740|NCT07191483|DRUG|KYN-5356 low dose|oral tablet
219609741|NCT07191483|OTHER|Placebo|Oral tablet
219609742|NCT07191483|DRUG|KYN-5356 Medium Dose|oral tablet
219609743|NCT07191483|DRUG|KYN-5356 High Dose|oral tablet
219609744|NCT07192081|DRUG|Labetalol|Labetalol 0.25 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
218892845|NCT01076530|DRUG|temozolomide|
219609745|NCT07192081|DRUG|Lignocaine|Lignocaine 1.5 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
219609746|NCT07192796|BEHAVIORAL|Pilates Exercise Program|A 6-week supervised Pilates exercise program, with 18 sessions. Exercises focused on core stabilization, posture, and lower limb alignment using mat-based and resistance band movements.
218892846|NCT01076530|OTHER|diagnostic laboratory biomarker analysis|
218892847|NCT01076530|OTHER|pharmacological study|
218892848|NCT05732675|BEHAVIORAL|"Vina-STEAM (Skills to Empower Affirmative Men)"|The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
218892849|NCT00813189|DEVICE|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
218892850|NCT03531086|DRUG|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
218892851|NCT02636205|DEVICE|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
218892852|NCT00096434|DRUG|sorafenib tosylate|Given orally
218892853|NCT00096434|OTHER|laboratory biomarker analysis|Correlative studies
218892854|NCT02753426|DRUG|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
219034566|NCT06268340|PROCEDURE|ECochG monitored CI surgery incl. corrective action guide|Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide
219609747|NCT07192796|BEHAVIORAL|Neuromuscular Exercise Program|A 6-week supervised neuromuscular training program, 18 sessions . Training emphasized balance, proprioception, dynamic stability, and strengthening of lower extremity muscles.
218892855|NCT02753426|DRUG|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
218892856|NCT00337207|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
219034567|NCT06268340|PROCEDURE|Routine CI surgery without ECochG monitoring|Routine CI surgery with access to ECochG monitoring by surgeon
219034568|NCT04088071|DEVICE|Catheter ablation|Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
219609748|NCT07192484|BEHAVIORAL|KT group|Receiving additional KT
219609749|NCT07192484|BEHAVIORAL|Conventional group|Conventional physical therapy
219609750|NCT07191938|PROCEDURE|Ultrasound guided penile block|The penile block is performed supine. After skin disinfection, the Buck's fascia is sonographically located, and the local anesthetic is injected close to the dorsal nerve of the penis in the plane after a negative aspiration test (16). The recommended dose is 0.1 ml/kg per side of ropivacaine 2 mg/ml (8). Injection is performed bilaterally. A subcutaneous injection of 1ml ropivacaine 2mg/ml (i.e. 2mg) is made at the base of the penis to ensure blockage of the perineal fibers.
218892857|NCT05669547|DEVICE|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
219609751|NCT07191938|PROCEDURE|Neurostimulation guided pudendal block|The pudendal block is performed in the supine position, with the legs flexed. After skin disinfection and palpation of the ischial tuberosity, the neurostimulator needle, set at 0.5 mA, is inserted 1 cm medial to the tuberosity. Contraction of the anal sphincter enables the proximity of the pudendal nerve, originating from the S2, S3 and S4 roots, to be identified. Once contraction has been obtained, local anaesthetic is injected using ropivacaine 2 mg/ml at a dose of 0.2 ml/kg per side, in the absence of blood reflux.
219609752|NCT07192367|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants receive structured Virtual Reality Exposure Therapy sessions using a VR headset. The intervention provides simulated social situations (e.g., public speaking, group interactions) to gradually expose participants to anxiety-provoking scenarios. The sessions are guided and standardized to target symptoms of social anxiety disorder.
218892858|NCT05627232|DRUG|Tazemetostat|Given PO
218892859|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
218892860|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
218892861|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218892862|NCT05627232|DRUG|Palbociclib|Given PO
219512878|NCT01390363|OTHER|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
219512879|NCT05814081|PROCEDURE|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
219512880|NCT00012714|BEHAVIORAL|Case management services|
219512881|NCT03745625|DRUG|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
219512882|NCT03745625|DRUG|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
219512883|NCT05629949|DRUG|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
219512884|NCT05629949|DRUG|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
219609753|NCT07192367|DRUG|Sertraline (Oral Antidepressant)|Participants receive pharmacological treatment with Sertraline, a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for social anxiety disorder. Dosage and administration will follow clinical guidelines and physician judgment.
219609754|NCT07192809|OTHER|Stabilisation exercise, resistance exercise and distraction task|The 8-week exercise intervention consists of 25 minutes non supervised training while distracting their attention with a knowledge based application
219609755|NCT07192809|OTHER|stabilisation exercise and resistance exercises|The 8-week exercise intervention consists of 25 minutes non supervised training without distracting their attention with a knowledge based application
219609756|NCT07193043|BEHAVIORAL|Body Image Program (BIP)|The Body Image Program (BIP) is a culturally adapted, dissonance-based group intervention derived from the Body Project. It is delivered in two weekly sessions of 120 minutes each, in small groups of 7-10 participants, by trained health professionals with experience in eating disorders. Activities include verbal, written, and behavioral exercises to critique sociocultural appearance ideals, reduce thin-ideal internalization, and promote more adaptive body image. Each session ends with homework: after Session 1, tasks include a behavioral challenge and reflective writing; after Session 2, a commitment activity (e.g., self-affirmation or body activism) is completed within one week and submitted by email. Participants in the waitlist control arm complete the same assessments but receive the BIP between weeks 6 and 8, after the final follow-up.
219609757|NCT07192757|DEVICE|transcutaneous auricular vagus nerve stimulation|active electrical stimulation applied to the cymba conchae of the left ear
218892863|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
218892864|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
218892865|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
218892866|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
218892867|NCT01732276|DRUG|gefitinib|
218892868|NCT00904735|DRUG|hydroxyurea|Given orally
218892869|NCT00904735|DRUG|imatinib mesylate|Given orally
218892870|NCT04869540|OTHER|Usual care|Evidence based care for transition-aged youth (TAY) with ASD.
218892871|NCT04869540|OTHER|'Got Transition' toolkit and resources|Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.
218892872|NCT04869540|BEHAVIORAL|PSE intervention|A family-based problem solving education (PSE) intervention.
218892873|NCT03655041|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
218892874|NCT03655041|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
218892875|NCT02691559|DEVICE|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
219512885|NCT05629949|DRUG|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
219512886|NCT00904020|DRUG|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
219512887|NCT02030184|DRUG|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
218892876|NCT01450865|DRUG|flupirtine|Potassium channel opener (SNEPCO)
218892877|NCT01669486|OTHER|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
219512888|NCT00231868|DRUG|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
219512889|NCT00231868|PROCEDURE|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
219512890|NCT00231868|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
219512891|NCT02892500|DRUG|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
219512892|NCT02892500|DRUG|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
219512893|NCT02863302|OTHER|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
219512894|NCT00346086|DRUG|AIC (Amb a 1 Immunostimulatory Conjugate)|
219512895|NCT05253560|DIAGNOSTIC_TEST|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
219512896|NCT02115906|OTHER|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
219512897|NCT02115906|OTHER|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
219512898|NCT02115906|OTHER|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
218892878|NCT02738749|DEVICE|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
218892879|NCT00166829|DRUG|sirolimus, tacrolimus, mycophenolate mofetil|
219512899|NCT03988270|OTHER|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
219512900|NCT00575406|DRUG|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
219512901|NCT00575406|DRUG|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
219512902|NCT00575406|DRUG|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
219609758|NCT07192757|DEVICE|Sham Control|electrical stimulation applied to a location on the ear not innervated by the auricular vagus
219609759|NCT07192471|DRUG|KK2223|Intravenous infusion
218892880|NCT01204749|DRUG|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
218892881|NCT01204749|DRUG|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
218892882|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
218892883|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
218892884|NCT02650765|OTHER|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
218892885|NCT04775563|OTHER|COVID-19 vaccine hesitancy scale in rheumatic diseases|The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
218892886|NCT04775563|OTHER|COVID-19 vaccine hesitancy associated factors|The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
219609760|NCT07191977|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
219609761|NCT07191977|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
218892887|NCT02996149|PROCEDURE|Endoscopic lung volume reduction coil treatment|
218892888|NCT06264739|DRUG|esp Dexmedetomidine (dekstomid)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
219512903|NCT00575406|DRUG|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
219512904|NCT00575406|DRUG|Vincristin|i.v., 2mg, d1 of each treatment cycle
219512905|NCT00575406|DRUG|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
219512906|NCT05412407|OTHER|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
218892889|NCT06264739|DRUG|esp remifentanyl (ultiva)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
218892890|NCT01185015|DRUG|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
219034569|NCT05086887|DIAGNOSTIC_TEST|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
219034570|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
219034571|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
219034572|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
219034573|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
219512907|NCT05102279|DIETARY_SUPPLEMENT|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
219034574|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
219512908|NCT02490488|DRUG|Masitinib|
219512909|NCT02490488|DRUG|Gemcitabine|
219512910|NCT02490488|DRUG|Placebo|
219512911|NCT00747188|BEHAVIORAL|PBL|
219034575|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
219034576|NCT00694759|DRUG|pioglitazone|30 mg for 2 weeks, then 45 mg daily
219034577|NCT00694759|DRUG|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
219034578|NCT00694759|DRUG|placebo|capsule twice daily
219512912|NCT01261078|DRUG|Placebo|intrathecal 8 mg of bupivacaine only
219512913|NCT01261078|DRUG|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
219512914|NCT01261078|DRUG|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
219512915|NCT01261078|DRUG|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
219512916|NCT01261078|DRUG|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
219512917|NCT01645306|DRUG|Revacept|single intravenous injection
219512918|NCT01645306|DRUG|Placebo|single intravenous injection
219512919|NCT03445195|DRUG|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
219512920|NCT03445195|DRUG|Placebo|Matching 1g IV solution.
219512921|NCT03445195|DRUG|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
218892891|NCT01440088|DRUG|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
219512922|NCT05241236|DEVICE|Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer|Subjects diagnosed by a transperineal fusion or random transperineal or random transrectal prostate biopsy. Laser treatment plan generated by biopsy results +/- MRI is uploaded into the device. In procedure suite, a transperineal anesthetic block is conducted following by Bianco - USPTO PCT/US18/24404. On lithotomy a transrectal ultrasound probe is advanced, the prostate scanned. The images are acquired by fusion device. Co-registration is performed by surgeon delimiting boundaries of prostate. Medical device delivers real-time fusion guidance outlining prostate contours, ablation goals and laser introduce location. Surgeon executes plan or adjust as needed. Surgeon activates laser device, performs ablation monitored by medical device in real-time. The fusion device will deliver great perspective between the ablation areas and critical anatomical landmarks such as: NVB, membranous urethra, etc. Patient is dismissed to the recovery room and discharged afterwards
219512923|NCT05709509|DRUG|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
219512924|NCT05709509|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
219512925|NCT05709509|OTHER|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
219512926|NCT01134081|BIOLOGICAL|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
219512927|NCT01134081|PROCEDURE|Free Gingival Graft|Harvested tissue from palate
219512928|NCT05180006|DRUG|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
219512929|NCT05180006|DRUG|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
219512930|NCT05180006|DRUG|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
219512931|NCT05180006|DRUG|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
219512932|NCT04982146|DRUG|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
219512933|NCT04982146|DRUG|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
219512934|NCT01447264|PROCEDURE|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
219512935|NCT01447264|PROCEDURE|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
219512936|NCT02204371|DRUG|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
219512937|NCT02204371|DRUG|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
218892892|NCT01440088|DRUG|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
218892893|NCT02470520|PROCEDURE|CRRT|continuous renal replacement therapy
218892894|NCT05505344|DEVICE|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
219203832|NCT06744777|OTHER|Standard Treatment|"The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol."
219203833|NCT05927649|DRUG|Omaveloxolone|Omaveloxolone capsules
219203834|NCT05927649|DRUG|Moxifloxacin|Moxifloxacin capsules
219512938|NCT00425815|DRUG|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
219512939|NCT00425815|OTHER|Placebo|Placebo comparison
219512940|NCT02419313|DRUG|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
219512941|NCT02419313|DRUG|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
219512942|NCT03097042|PROCEDURE|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
219512943|NCT03097042|PROCEDURE|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
219512944|NCT05150509|DIAGNOSTIC_TEST|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
218892895|NCT02316418|DEVICE|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
219512945|NCT05705713|RADIATION|chest computed tomography (CT)|Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
219609762|NCT07193238|OTHER|The Ethics and Moral Course based on the Ashridge training model|Based on the three-stage characteristics of the Ashridge training model, the developed the content of this ethics course. (1) Discrete stage (within 3 months of employment): This stage aims to initially cultivate the professional identity of new nurses, stimulating humanistic awareness. It primarily involves self-study, supplemented by instructor supervision and implicit positive guidance. (2) Integrated stage (4-6 months of employment): This stage combines professional identity with actual work, enhancing humanistic care abilities in practice. It emphasizes mutual sharing between instructors and new nurses, utilizing diverse training methods to promote experience and reflection. (3) Cumulative stage (7-12 months of employment): This stage develops critical thinking and ethical problem-solving abilities. It focuses on assessing comprehensive abilities in complex nursing situations, providing feedback on the teaching plan, and evaluating training effectiveness.
219609763|NCT07191795|OTHER|Gait analysis|Participants with unilateral amputations and a control group will undergo a comprehensive walking analysis. In a lab setting (on a treadmill or floor), their gait will be recorded using inertial sensors, EMG, force plates, and motion capture, while an EEG cap and a NASA-TLX questionnaire will assess cognitive load. Capable participants will also perform a walking test on a real-world outdoor course with varied terrain. The data will be analyzed to compare walking patterns between groups (amputees vs. controls, and amputees with vs. without phantom limbs). Finally, participants will describe any interactions they perceived between their phantom sensations and walking during the tests.
219609764|NCT07191795|OTHER|Mapping of referred sensations.|Participants reporting referred sensations in gait analysis phase will undergo further testing. The study will investigate whether prosthesis pressure or a specific socket interaction causes these sensations. A 3x3 cm grid will be drawn on the residual limb to systematically map referred sensations using various stimuli (brush, pressure tip, electrical stimulation). Participants will rate the intensity and describe the location of any resulting phantom sensations. This mapping will be repeated after 6 months to assess the stability of these sensations over time, with the ultimate goal of potentially using them to provide sensory feedback for prosthesis users. The session will last approximately 2 hours.
219609765|NCT07191795|OTHER|Exploration of the areas of the brain activated during referred sensations|Unilateral transfemoral amputees with detailed referred sensation maps will have their brain activity recorded using a 64-electrode EEG cap. Non-invasive stimuli will be applied to four specific sites: an area on the residual limb that elicits a referred sensation, the corresponding location on the intact foot, a neutral area on the residual limb, and its corresponding location on the intact thigh. This process, involving 400 total stimulations, will be repeated after 6 months to track cortical changes. Non-amputee participants will also be tested as a control group to check for symmetry in brain responses to thigh stimulation. Each session lasts about 2 hours.
219609766|NCT07191795|OTHER|Evaluation of the effects of socket modifications on phantom sensations and walking|This phase will evaluate how socket modifications affect phantom sensations and walking in 10 transfemoral amputees. First, the best material to comfortably induce referred sensations will be determined in a small sub-study. Then, each participant will be tested under four conditions: their usual socket and a socket with different rigidity, both with and without a specific local pressure point added inside. The location of this pressure point is based on the user's sensation map. Participants' walking will be analyzed in both lab and real-world environments for each condition, and they will provide feedback on their sensations and which setup they find most helpful. The evaluation involves 4 sessions over 2-3 months
219609767|NCT07191795|OTHER|Phantom limb interview|A semi-structured interview will be conducted to ask participants to describe their phantom limb sensations (type, location, intensity) under three conditions: without their prosthesis, while standing with it, and while walking with it. This aims to identify factors influencing these sensations. Additionally, a brief physical examination of the residual limb will be performed to see if touch in specific areas triggers any referred sensations.
219609768|NCT07193147|DRUG|GZR4|GZR4 s.c., single-dose
218892896|NCT04308941|DIAGNOSTIC_TEST|Intraocular pressure|The intraocular pressure will be measured using one of three devices
218892897|NCT01366326|DRUG|Methylnaltrexone bromide|Subcutaneous MNTX
218892898|NCT05437523|OTHER|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
218892899|NCT05437523|OTHER|Standard of care without constipation action plan|Standard of care without constipation action plan
218892900|NCT06369974|DRUG|Antisense oligonucleotide treatment (ASO)|Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
218892901|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
219512946|NCT03972566|DRUG|INOMAX|INOMAX + PBM
219512947|NCT04351009|PROCEDURE|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
219512948|NCT04581005|BEHAVIORAL|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
219512949|NCT03196999|BEHAVIORAL|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
218892902|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
218892903|NCT02332174|DRUG|rufinamide|comparison of different doses, sex and medication conditions
218892904|NCT00195949|PROCEDURE|Laparoscopic pyloromyotomy|
218892905|NCT03133507|BEHAVIORAL|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
218892906|NCT03133507|BEHAVIORAL|Reassurance Condition|Children will be reassured by the experimenter .
219034579|NCT05328492|DEVICE|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
219034580|NCT05328492|DEVICE|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
219512950|NCT03196999|BEHAVIORAL|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
219512951|NCT03196999|BEHAVIORAL|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
219609769|NCT07186699|OTHER|Non-Interventional Study|Non-interventional study
219609770|NCT07192744|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
219609771|NCT07192029|PROCEDURE|Balloon guide catheter combined with conventional thrombectomy treatment|The experimental group will use balloon guide catheter combined with conventional thrombectomy treatment.
219609772|NCT07192029|PROCEDURE|Standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment|use standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment
218892907|NCT03133507|BEHAVIORAL|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
218892908|NCT05282771|DRUG|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
218892909|NCT05282771|DRUG|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
219034581|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
218892910|NCT05282771|DRUG|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
218892911|NCT04252131|DRUG|cassia seed tablet|traditional Chinese herbs
218892912|NCT03645733|PROCEDURE|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
218892913|NCT01207258|BEHAVIORAL|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
218892914|NCT04438395|DEVICE|Cardiac ablation via catheter|Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
218892915|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
218892916|NCT03862183|OTHER|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
218892917|NCT02114463|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
219034582|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
219034583|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
219203835|NCT03520374|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
219512952|NCT05638503|OTHER|Left ventricular hypertrophy|Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
219512953|NCT05638503|OTHER|Left ventricular non-hypertrophy|Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
219512954|NCT00120900|DRUG|GW406381|
218892918|NCT02114463|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
218892919|NCT02114463|DRUG|ropivacaine|0.2% ropivacaine
218892920|NCT02114463|DRUG|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
218892921|NCT02625792|DRUG|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
218892922|NCT00366951|PROCEDURE|Foley catheter only|
218892923|NCT00366951|PROCEDURE|Extraamniotic saline infusion|
218892924|NCT04626375|DRUG|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
219512955|NCT01093209|DEVICE|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
219512956|NCT03706989|PROCEDURE|EEG|EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
219512957|NCT03706989|GENETIC|Apolipoprotein genotype|APOE genotyping will be performed for each patient
219512958|NCT03706989|BIOLOGICAL|Serum NfL measurements|5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
219512959|NCT03706989|OTHER|Preoperative neurocognitive evaluation|Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
219512960|NCT01159548|DRUG|Promethazine|
219512961|NCT01159548|DRUG|Promethazine|
219512962|NCT03072680|BEHAVIORAL|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
219512963|NCT03072680|BEHAVIORAL|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
219512964|NCT03072680|BEHAVIORAL|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
219512965|NCT00906425|DEVICE|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
219512966|NCT02339766|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
219512967|NCT02339766|PROCEDURE|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
219512968|NCT02339766|DRUG|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
219512969|NCT02339766|DRUG|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
219512970|NCT06078163|OTHER|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
218892925|NCT04626375|DRUG|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
219034584|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
219034585|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
219034586|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
219034587|NCT04124172|DEVICE|Sham rTMS|See arm description
219034588|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
219512971|NCT06078163|OTHER|rehabilitation|rehabilitation protocol lasting 20 sessions.
219512972|NCT05559996|DEVICE|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
219512973|NCT00725439|DRUG|Talarozole|Oral Dose 1.0 mg once daily
219512974|NCT00620763|OTHER|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
219512975|NCT00620763|OTHER|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
219512976|NCT03797664|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
219512977|NCT03797664|DRUG|Placebo|Phosphate Buffer Diluent oral solution
219512978|NCT00325533|BEHAVIORAL|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
219512979|NCT00325533|OTHER|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
219512980|NCT04602104|BIOLOGICAL|low dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
218892926|NCT05520632|DIAGNOSTIC_TEST|Brainstem Auditory Evoked Potentials|Performing Brainstem Auditory Evoked Potentials under sedation
218892927|NCT01562080|DIETARY_SUPPLEMENT|Armolipid Plus|one tablet per day during 12 weeks
218892928|NCT01562080|DIETARY_SUPPLEMENT|placebo|one tablet per day during 12 weeks
218892929|NCT04830930|DRUG|CKD-381|single-dose, oral administration of CKD-381 1 tablet
218892930|NCT05865626|OTHER|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
218892931|NCT01721863|OTHER|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
218892932|NCT03351517|DRUG|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
218892933|NCT03351517|DRUG|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
218892934|NCT01338818|DRUG|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
218892935|NCT05695807|DEVICE|Carboxytherapy|Device generating CO2 gas
219203836|NCT03496181|BEHAVIORAL|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
218892936|NCT04508426|DRUG|[14C]AR882|Single dose of \[14C\]AR882
218892937|NCT03391661|BEHAVIORAL|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
218892938|NCT03391661|BEHAVIORAL|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
218892939|NCT00740207|DRUG|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
218892940|NCT00740207|DRUG|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
218892941|NCT02507388|DRUG|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
218892942|NCT02507388|DRUG|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
218892943|NCT02980471|DEVICE|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
218892944|NCT03943641|OTHER|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
219034589|NCT06486571|OTHER|Electromyography recording with HD-sEMG|Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
219203837|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
218892945|NCT05423314|PROCEDURE|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
219034590|NCT06486571|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
219034591|NCT00132340|DEVICE|Electrodes|
219034592|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
218892946|NCT00855244|OTHER|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
218892947|NCT04982939|DRUG|Sintilimab|Sintilimab, 200mg IV d1 Q3W
218892948|NCT04982939|DRUG|S-1|S-1, 40-60mg BID d1-14 Q3W
218892949|NCT04982939|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
218892950|NCT00102128|DRUG|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
218892951|NCT04499495|OTHER|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
218892952|NCT03274908|OTHER|regular medical treatment|regular medical treatment
218892953|NCT04410094|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
218892954|NCT04410094|DRUG|Itraconazole|Itraconazole capsules will be administered orally.
218892955|NCT04410094|DRUG|Rifampin|Rifampin capsules will be administered orally.
218892956|NCT05254106|DEVICE|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
218892957|NCT01380795|BIOLOGICAL|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
219512981|NCT04602104|BIOLOGICAL|medium dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
219512982|NCT04602104|BIOLOGICAL|high dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
218892958|NCT06579963|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
218892959|NCT01257516|DRUG|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
218892960|NCT01257516|DRUG|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
218892961|NCT02929030|DEVICE|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
218892962|NCT01522716|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
218892963|NCT03349658|OTHER|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
218892964|NCT03349658|OTHER|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
219034593|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
219512983|NCT04602104|BIOLOGICAL|Dosage 1of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
219512984|NCT04602104|BIOLOGICAL|Dosage 2 of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
219512985|NCT04602104|BIOLOGICAL|No hMSC-derived exosomes|basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
219512986|NCT01141725|DRUG|bendamustine hydrochloride|Given IV
219512987|NCT01141725|DRUG|idarubicin|Given IV
219512988|NCT04682275|OTHER|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
219512989|NCT03855475|BEHAVIORAL|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
219512990|NCT03855475|BEHAVIORAL|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
219512991|NCT00368966|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
219512992|NCT00368966|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|
219512993|NCT02866175|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
219512994|NCT02866175|DRUG|Clopidogrel|Clopidogrel 75 mg once-daily
219512995|NCT02866175|DRUG|Prasugrel|prasugrel 5mg or 10 mg once-daily
219512996|NCT02866175|DRUG|Ticagrelor|ticagrelor 90 mg twice-daily
219512997|NCT02866175|DRUG|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
219512998|NCT02490709|PROCEDURE|Local excision|Local excision for rectal cancer with good response
219512999|NCT06460714|OTHER|Shock wave therapy, stretching and orthosis|Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
219513000|NCT06460714|OTHER|Stretching, strengthening and orthosis|In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
219513001|NCT00004096|DRUG|carboplatin|
219513002|NCT00004096|DRUG|vinorelbine ditartrate|
219513003|NCT02907203|DEVICE|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
219513004|NCT05095909|DEVICE|Cryo-compression|Programmable intermittent compression with integrated cryo-therapy.
219513005|NCT05095909|OTHER|Cryo-therapy|Subjects are fitted with gel ice packs and wraps.
219513006|NCT05023213|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
219513007|NCT00748293|OTHER|Low-residue diet|Commercialized (not yet marketed)low-residue diet
219513008|NCT00760383|DIETARY_SUPPLEMENT|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
219513009|NCT00760383|DIETARY_SUPPLEMENT|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
219513010|NCT03943251|DRUG|HEC113995PA•H2O tablet|2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
219513011|NCT03943251|DRUG|Placebo tablet|2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
219513012|NCT00897897|DEVICE|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
219513013|NCT06099314|DRUG|Fruquintinib+PD-1 inhibitors|Third-line treatment with fruquintinib combined with PD-1 inhibitors. Fruquintinib: 5mg,Oral once daily,2 weeks on/1 week off,Q3W； PD-1 inhibitor：for example, Sintilimab,iv,200mg, Q3W.
218892965|NCT03232996|OTHER|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
219513014|NCT06099314|DRUG|Fruquintinib+TAS-102|Fourth-line treatment with fruquintinib combined with TAS-102 . Fruquintinib: 3-5mg(Depending on the patient's physical condition), Oral once daily,3 weeks on/1 week off,Q4W； TAS-102:orally, 35mg/m2 twice daily (maximum dose 80mg in a single dose) for days 1-5, repeated every 14 days.
219513015|NCT01490281|BEHAVIORAL|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
218892966|NCT03062514|DEVICE|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
219034594|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
219034595|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
219034596|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
219513016|NCT01490281|BEHAVIORAL|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
219513017|NCT00186914|BIOLOGICAL|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
219513018|NCT06154863|DRUG|RAI|Radioactive iodine
219513019|NCT01816477|DEVICE|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
219513020|NCT01816477|DRUG|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
219513021|NCT00819247|DRUG|Degarelix|Given as a subcutaneous injection.
219513022|NCT05017584|DRUG|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
219513023|NCT00282256|DRUG|tacrolimus modified release (MR)|Oral
219513024|NCT00282256|DRUG|tacrolimus|Oral
219513025|NCT05100758|DIETARY_SUPPLEMENT|Active Hexoses Correlated Compound|Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
219513026|NCT05530356|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
219513027|NCT05530356|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
219513028|NCT05530356|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
219513029|NCT05530356|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
219513030|NCT05530356|RADIATION|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
219513031|NCT02879019|OTHER|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
219513032|NCT02879019|OTHER|Walking training group|Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
219034597|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
219034598|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
219513033|NCT04484337|DRUG|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
219513034|NCT04484337|DRUG|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
218892967|NCT05144100|PROCEDURE|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
218892968|NCT05144100|RADIATION|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
219513035|NCT04484337|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
219513036|NCT04484337|DRUG|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
219513037|NCT04484337|DRUG|Topical steroid|Steroid will be available for topical application
219513038|NCT04484337|DRUG|Placebo creams/gels|Placebo creams/gels will be available for topical application
219513039|NCT04484337|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
219513040|NCT06046027|DEVICE|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
219513041|NCT01621464|DEVICE|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
219513042|NCT02540356|BIOLOGICAL|BAX69 Single-Route Arm|Intraperitoneal (IP) only
219513043|NCT02540356|BIOLOGICAL|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
219609773|NCT07192198|DRUG|Methoxyflurane|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
219609774|NCT07192198|OTHER|Control|This intervention will be the control group, only receiving local infiltration.
218892969|NCT05144100|DRUG|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
218892970|NCT05212558|OTHER|Placebo respiratory muscle training|Unloaded respiratory muscle training plus conventional respiratory exercises
218892971|NCT05212558|OTHER|Inspiratory muscle training|Inspiratory muscle training plus conventional respiratory exercises
218892972|NCT05212558|OTHER|Combined inspiratory and expiratory muscle training|Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
218892973|NCT04976686|OTHER|Diet modification|Participants will reduce their carbohydrate consumption to 80g daily
218892974|NCT00556998|DRUG|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
218892975|NCT04314986|DRUG|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
218892976|NCT04314986|DRUG|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
219034599|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
219034600|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
219513044|NCT01513148|DEVICE|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
219513045|NCT03056274|DRUG|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
219513046|NCT03056274|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
219513047|NCT02833038|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
219513048|NCT02833038|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
219513049|NCT03252470|PROCEDURE|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
219513050|NCT00585780|DRUG|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
219513051|NCT00585780|DRUG|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
218892977|NCT04314986|DRUG|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
218892978|NCT04314986|DRUG|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
218892979|NCT00947271|BEHAVIORAL|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health
218892980|NCT00947271|BEHAVIORAL|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
218892981|NCT03314701|DEVICE|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
218892982|NCT03314701|DEVICE|Airway Pressure Release Ventilation (APRV)|"* high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second"
219203838|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms\* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
219513052|NCT03050593|DIAGNOSTIC_TEST|MRI scan, Echo scan|
219513053|NCT06138379|OTHER|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
219513054|NCT06138379|OTHER|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
219513055|NCT04769466|OTHER|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
219513056|NCT00967538|DRUG|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
219513057|NCT02901899|DRUG|Guadecitabine|Given SC
219513058|NCT02901899|OTHER|Laboratory Biomarker Analysis|Correlative studies
219609775|NCT07191600|BEHAVIORAL|Talking Pen Audio-Interactive Oral Frailty Care Program|Participants in the intervention group will receive a structured oral frailty delay care program integrated with talking pen audio-interactive technology. The program includes bilingual (Mandarin and Taiwanese) teaching materials with audio support to enhance comprehension and engagement. Training sessions will focus on oral frailty prevention, oral function exercises, and related health education. The intervention is delivered over 3 to 6 months, with outcomes measured at baseline, 3 months, and 6 months.
219609776|NCT07189845|DIAGNOSTIC_TEST|BIS GROUP|In the BIS group, monitoring will be visible and anesthesia depth will be maintained within a BIS value range of 40-60.
219609777|NCT07189845|DIAGNOSTIC_TEST|CONTROL GROUP|In the control group, the BIS monitor will be applied with the screen concealed from the investigator, and anesthesia depth will be guided solely by clinical parameters.
218892983|NCT02838758|DEVICE|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
218892984|NCT02838758|DRUG|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
218892985|NCT02838758|DRUG|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
219513059|NCT02901899|BIOLOGICAL|Pembrolizumab|Given IV
219513060|NCT04844177|OTHER|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
219513061|NCT00855842|DEVICE|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
219513062|NCT03317613|DRUG|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
219513063|NCT03196947|DRUG|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
219513064|NCT06159270|OTHER|Blood sample|Venuous blood sampling
219513065|NCT03920137|BEHAVIORAL|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
219513066|NCT03920137|BEHAVIORAL|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
219513067|NCT03920137|DEVICE|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
219609778|NCT07192562|BEHAVIORAL|Virtual Reality-Based Exercise Program|"Participants in the VR Exercise Group received a virtual reality-based physical activity intervention using the Meta Quest 2 headset. Two exergames, Beat Saber and PowerBeatsVR, were implemented twice a week for six weeks, totalling 12 exercise sessions. Each session lasted 30-35 minutes and was conducted individually during work hours. Beat Saber provided rhythm-based tasks involving block slicing and obstacle dodging, while PowerBeatsVR included high-intensity punching, squatting, and side-stepping movements. Game difficulty increased weekly."
219609779|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
218892986|NCT05887557|OTHER|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
219513068|NCT05710978|OTHER|Work Protocol|Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
219609780|NCT05995899|DRUG|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
219609781|NCT06431269|OTHER|Screening for neurodevelopmental disorders by an advanced practice nurse|Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
218892987|NCT05887557|OTHER|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
219034601|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
219513069|NCT03239132|BEHAVIORAL|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
219034602|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
219034603|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
219034604|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
219513070|NCT03239132|BEHAVIORAL|Meditation educational materials|Meditation educational materials
219513071|NCT01048437|BEHAVIORAL|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
219609782|NCT00595491|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
219609783|NCT04956640|DRUG|LY3537982|Oral
219609784|NCT04956640|DRUG|Pembrolizumab|Intravenous
219609785|NCT04956640|DRUG|Cetuximab|Intravenous
219609786|NCT04956640|DRUG|Pemetrexed|Intravenous
219609787|NCT04956640|DRUG|Cisplatin|Intravenous
219513072|NCT01048437|BEHAVIORAL|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
219609788|NCT04956640|DRUG|Carboplatin|Intravenous
219609789|NCT03922724|DRUG|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
219609790|NCT03922724|DRUG|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
219609791|NCT03922724|PROCEDURE|allo HCT|Stem cell transplant
219609792|NCT03922724|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
219609793|NCT03922724|DRUG|GVHD prophylaxis|"High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25."
219609794|NCT03922724|DRUG|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
219609795|NCT05357170|OTHER|Human feces collection|Oral swab and saliva, human feces collection and blood sampling
219609796|NCT06544499|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
219609797|NCT06544499|OTHER|Placebo IV|Intravenous infusion of placebo
219609798|NCT06392386|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injections
219034605|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
219609799|NCT04599647|BIOLOGICAL|PVSRIPO|PVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
218892988|NCT05887557|OTHER|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
218892989|NCT05887557|OTHER|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
218892990|NCT05887557|OTHER|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
218892991|NCT05887557|OTHER|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
218892992|NCT05887557|OTHER|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
218892993|NCT05887557|OTHER|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
218892994|NCT05887557|OTHER|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
218892995|NCT05887557|OTHER|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
218892996|NCT05887557|OTHER|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
218892997|NCT05887557|OTHER|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
218892998|NCT03707301|OTHER|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
218892999|NCT00490269|DRUG|Placebo|
218893000|NCT00490269|DRUG|Dronabinol|
219034606|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
219609800|NCT04225156|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
219609801|NCT06353373|OTHER|Application of the modified DeVTEcare system|The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024.
219609802|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
218893001|NCT02864121|OTHER|all patients included in IDAHO study|
218893002|NCT02320916|PROCEDURE|23Gauge|Arterial puncture will be made using a 23Gauge needle
218893003|NCT02320916|PROCEDURE|25Gauge|Arterial puncture will be made using a 25Gauge needle
218893004|NCT04694690|OTHER|Self adhesive resin cement|Self adhesive resin cement
218893005|NCT04694690|OTHER|Resin cement|Resin Cement system used after surface treatment
219034607|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
219034608|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
219609803|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
219609804|NCT05394909|DRUG|Tocilizumab 162Mg/0.9Ml Autoinjector|Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
219609805|NCT05790213|DRUG|Androgen Deprivation Therapy (ADT)|ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.
219609806|NCT05790213|PROCEDURE|Focal prostate ablation (focal therapy)|Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.
219609807|NCT04528680|DEVICE|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
219513073|NCT04730505|DEVICE|MyHOPE™ for Multiple Myeloma|The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.
218893006|NCT04400058|BIOLOGICAL|Octagam 10%|Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
218893007|NCT04400058|OTHER|Saline Solution|Placebo
218893008|NCT04941495|OTHER|conventional physiotherapy|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying."
218893009|NCT04941495|OTHER|Cervical proprioceptive training|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted."
218893010|NCT04064749|BEHAVIORAL|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
218893011|NCT00216671|DRUG|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
218893012|NCT00216671|DRUG|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
218893013|NCT01142882|BEHAVIORAL|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
218893014|NCT01142882|BEHAVIORAL|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
218893015|NCT03214354|DRUG|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
218893016|NCT03214354|RADIATION|Total Body Irradiation|TBI 300 cGy on Day -2
219609808|NCT04528680|DRUG|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
219609809|NCT04528680|DRUG|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
218893017|NCT03214354|DRUG|Sirolimus|Sirolimus is used for GVHD prophylaxis
218893018|NCT05938075|BIOLOGICAL|VXCO-100|Sterile suspension for injection
218893019|NCT05938075|BIOLOGICAL|COVID-19 mRNA vaccine|Sterile suspension for injection
218893020|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
218893021|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
219609810|NCT03593590|DRUG|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
219609811|NCT06639828|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
218893022|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
219513074|NCT04730505|DEVICE|MyHope HCP Portal|Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
219513075|NCT04894994|DRUG|FLX475|Tablet
219513076|NCT04894994|DRUG|Ipilimumab|IV infusion
219609812|NCT06525246|DRUG|ONO-7475|Specified dose, once daily
219609813|NCT06525246|DRUG|Osimertinib Mesylate|Specified dose, once daily
219609814|NCT05327894|DRUG|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
219609815|NCT05327894|DRUG|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
219609816|NCT05061134|DRUG|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
219609817|NCT05061134|BIOLOGICAL|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
218893023|NCT03605108|DIETARY_SUPPLEMENT|Probiotic|"• Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
218893024|NCT03605108|OTHER|Placebo|Rice flour only
218893025|NCT04683003|BIOLOGICAL|TAK-755|TAK-755 IV infusion
218893026|NCT06215261|DRUG|Methylone|Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)
218893027|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of quadrivalent hemagglutinin nanoparticle influenza vaccine(qNIV2), SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
219513077|NCT02566135|DEVICE|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
219609818|NCT05961527|DRUG|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
219609819|NCT05961527|BEHAVIORAL|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
218893028|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
218893029|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
218893030|NCT00664885|OTHER|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
218893031|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
218893032|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
218893033|NCT04192266|BEHAVIORAL|Prolonged Exposure (PE) therapy|There will be an introductory Prolonged Exposure (PE) therapy session, followed by 5 imaginal exposure sessions, such that there will be 2 sessions per week conducted for a total of 6 sessions over 3 weeks. The PE sessions are 60 minutes long and consist of imaginal exposure. Specifically, the patient is instructed to imagine the trauma and recount it aloud for about 25-30 minutes. In the following 15 minutes, the patient processes her reactions to revisiting the traumatic event by discussing related thoughts and feelings. The session ends with in vivo exposure homework to be completed that same day as the session. In the last session, imaginal exposure is conducted one last time for the same duration as previous sessions. The therapist and patient review treatment progress and discuss applications of treatment principles to daily life.
218893034|NCT00851279|DEVICE|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
218893035|NCT01843023|DRUG|Extended Release Naltrexone|naltrexone for extended release injectable suspension
218893036|NCT01843023|BEHAVIORAL|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
218893037|NCT01843023|DRUG|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
218893038|NCT00003967|DRUG|etoposide|
218893039|NCT00003967|DRUG|topotecan hydrochloride|
218893040|NCT05381363|DRUG|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
219034609|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
219034610|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
219609820|NCT04640259|OTHER|Online Survey|Epidemiological Survey (approx 200 questions)
219609821|NCT06154239|DEVICE|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
218893041|NCT05381363|OTHER|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
218893042|NCT03305770|DEVICE|verofilcon A contact lenses|Daily disposable soft contact lenses
218893043|NCT03305770|DEVICE|delefilcon A contact lenses|Daily disposable soft contact lenses
218893044|NCT00748371|DRUG|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
218893045|NCT00748371|DRUG|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
218893046|NCT00748371|DRUG|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
219034611|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
219034612|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
219034613|NCT05224492|OTHER|Placebo|Placebo
219034614|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
219034615|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
219034616|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
219513078|NCT02566135|DEVICE|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
218893047|NCT03539601|DRUG|Crisaborole ointment, 2%|Applied twice a day (BID)
218893048|NCT03539601|DRUG|Hydrocortisone butyrate cream, 0.1%|Applied BID
219034617|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
219034618|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
219034619|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
219034620|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
219034621|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
219034622|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
219034623|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
219034624|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
219034625|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
219034626|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
219513079|NCT03945565|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
219609822|NCT06154239|DIAGNOSTIC_TEST|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
219609823|NCT06154239|DIAGNOSTIC_TEST|Clinician vaginal swab|"A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.~The clinician swab is not taken in sub-study participants."
219609824|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
219609825|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
218893049|NCT03539601|DRUG|Pimecrolimus cream, 1%|Applied BID
218893050|NCT03539601|DRUG|Crisaborole Vehicle|Applied BID
218893051|NCT06062329|DEVICE|Symphony Thrombectomy System|The Symphony Thrombectomy System will be used to restore blood flow to the pulmonary arteries by removing thrombus/embolus/clot using aspiration and mechanical clot engagement.
218893052|NCT04875091|BEHAVIORAL|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
218893053|NCT05433025|DEVICE|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
219034627|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
219034628|NCT02041130|DEVICE|Renal Denervation|
219034629|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
219034630|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
219034631|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
219034632|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
219203839|NCT04660526|OTHER|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
219609826|NCT04865107|BIOLOGICAL|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
219609827|NCT04865107|BIOLOGICAL|Placebo|PlasmaLyte A and 5% Human Albumin
219034633|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219513080|NCT02454270|DRUG|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
218893054|NCT01970306|DEVICE|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
218893055|NCT01005498|DIETARY_SUPPLEMENT|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
218893056|NCT01005498|DIETARY_SUPPLEMENT|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
218893057|NCT01444885|DRUG|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
218893058|NCT01819155|BIOLOGICAL|Adjuvanted seasonal trivalent inactivated influenza vaccine|
218893059|NCT01819155|BIOLOGICAL|Seasonal trivalent inactivated influenza vaccine|
218893060|NCT01819155|BIOLOGICAL|Saline (bacteriostatic 0.9% sodium chloride for injection)|
218893061|NCT00226811|DRUG|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
218893062|NCT01470456|DRUG|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
218893063|NCT01470456|DRUG|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
218893064|NCT03136289|BEHAVIORAL|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
218893065|NCT06465004|DIETARY_SUPPLEMENT|Consumption of protein - rich drink|The participants will drink on of three protein - rich drinks
218893066|NCT06498206|OTHER|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
218893067|NCT06498206|OTHER|Patching|Conventional patching therapy.
218893068|NCT04728386|OTHER|curcumin solution|2 % curcumin solution as root canal irrigant
219513081|NCT02454270|DRUG|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
219513082|NCT03539315|BEHAVIORAL|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
219513083|NCT06022133|BEHAVIORAL|Dietary sodium restriction|Selfemployed dietary sodium restriction
219513084|NCT02509000|OTHER|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
219513085|NCT00092859|DRUG|MK0557|
219513086|NCT00151294|DRUG|escitalopram oxalate antidepressant|
219513087|NCT03841032|DRUG|Coppertone, BAY1183345|Lotion, for 4 weeks
218893069|NCT04728386|OTHER|sodium hypochlorite|2.5% sodium hypochlorite solution as root canal irrigant
218893070|NCT00550017|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
219034634|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
218893071|NCT00745537|OTHER|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
219034635|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219034636|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
219513088|NCT04217408|DEVICE|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
219513089|NCT03050632|BEHAVIORAL|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
219513090|NCT03050632|BEHAVIORAL|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
218893072|NCT02426736|DRUG|Dexamethasone|
218893073|NCT02426736|DRUG|Bupivacaine|
218893074|NCT02426736|PROCEDURE|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
218893075|NCT02951078|PROCEDURE|Thulium Laser en Bloc Resection of bladder tumor|
218893076|NCT02951078|PROCEDURE|Electrical transurethral resection of bladder tumor|
218893077|NCT04811846|DEVICE|Bipolar transurethral resection of bladder tumor (TURBT)|Standard resection in piecemeal technique with standard bipolar cutting loop. (Storz medical, 27040 GP1)
219034637|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
219513091|NCT06428448|COMBINATION_PRODUCT|REMEDY Spectrum IM Spacer Nail|"The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.~The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools."
219513092|NCT02752945|OTHER|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
219034638|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
219034639|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
219034640|NCT02059928|DEVICE|Intraosseous Device|
219034641|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
219034642|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
219513093|NCT02752945|OTHER|Usual care|Usual care afforded by local CAMHS services
219513094|NCT01411995|DRUG|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
219513095|NCT01411995|DRUG|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
219513096|NCT04685421|DRUG|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
219513097|NCT03715270|DEVICE|Image surgical area|Image surgical area
219513098|NCT02003495|BIOLOGICAL|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
219513099|NCT02003495|BIOLOGICAL|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
219513100|NCT02003495|BIOLOGICAL|MPV-A Vaccine Group|0.5ml, intramuscular
219513101|NCT02003495|BIOLOGICAL|MCV-AC Vaccine Group|0.5ml, intramuscular
219609828|NCT01013077|OTHER|Optive, Soothe, New Emulsion|One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the New Emulsion use a minimum of 2 drops per day for 1 month.
219609829|NCT01013077|OTHER|Soothe, New Emulsion, Optive|One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Optive use a minimum of 2 drops per day for 1 month.
219609830|NCT01013077|OTHER|New Emulsion, Optive, Soothe|One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Soothe use a minimum of 2 drops per day for 1 month.
218893078|NCT04811846|DEVICE|Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)|Vaporization of bladder tumor with standard bipolar vaporization electrode. (Storz medical, 27040 NB)
218893079|NCT04783909|PROCEDURE|Phacoemulsification cataract surgery|All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
219034643|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
219034644|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
218893080|NCT00652795|DRUG|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
218893081|NCT00652795|DRUG|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
218893082|NCT06056661|BEHAVIORAL|WMR|Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
219513102|NCT02003495|BIOLOGICAL|Hib Vaccine Group|0.5ml, intramuscular
219513103|NCT05058742|DEVICE|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
219513104|NCT00803842|DRUG|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
219513105|NCT03133442|DEVICE|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
219513106|NCT04570566|PROCEDURE|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
219513107|NCT02974153|BIOLOGICAL|ALD403 (Eptinezumab)|
219513108|NCT02974153|BIOLOGICAL|Placebo|
219513109|NCT05330507|OTHER|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
219513110|NCT02089490|DEVICE|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
219513111|NCT01919879|DRUG|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
219513112|NCT01919879|DRUG|Cetuximab|Cetuximab administered intravenously
219513113|NCT02277769|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
219513114|NCT02277769|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
219513115|NCT06328283|OTHER|measure of Glutamine synthetase and BCLFAF1|compare Glutamine synthetase and BCLFAF1 in cases and controls
219513116|NCT03841383|DIAGNOSTIC_TEST|Echo stress dipyridamole|Echo stress dipyridamole
219513117|NCT06469879|DRUG|TQB2450+Anlotinib|"TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week."
219513118|NCT06469879|DRUG|TQB2450 placebo + Anlotinib placebo|No drug substance is contained
219513119|NCT03556371|DRUG|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
219609831|NCT05989841|BEHAVIORAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
219609832|NCT05989841|BEHAVIORAL|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
219609833|NCT06520449|DRUG|68Ga-NTA-476|The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
219609834|NCT01894802|DEVICE|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
219609835|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
219609836|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
219609837|NCT05144685|DEVICE|OTX-202|Experimental Pscyhoeducation and Intervention App
219609838|NCT05144685|DEVICE|OTX-000|Other Pscyhoeducation App
219609839|NCT05144685|BEHAVIORAL|Treatment as Usual|Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.
219609840|NCT05432284|DRUG|Placebo|Placebo (ambient air)
219609841|NCT05432284|DRUG|THC|Pure THC vapor
219609842|NCT05432284|DRUG|Beta-Myrcene|Pure beta-myrcene vapor
219609843|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
219609844|NCT06407323|DIAGNOSTIC_TEST|Personalized vibration therapy powered by AI|A target frequency of either 20 Hz or 25 Hz, and amplitude 2-4 mm The whole treatment session will be around 20 minutes along with hot pack as a baseline treatment, consisted of 6 sessions per week for total 8 weeks of duration
219609845|NCT06407323|OTHER|Physical therapy treatment|A selected physical therapy treatment program for spastic diplegic CP.
218893083|NCT04988529|BEHAVIORAL|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
219034645|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
219034646|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
219034647|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
219513120|NCT03556371|DRUG|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
219513121|NCT00581620|BIOLOGICAL|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
219513122|NCT00391690|DRUG|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
219513123|NCT04458077|BEHAVIORAL|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
219513124|NCT04529642|DIAGNOSTIC_TEST|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
219513125|NCT00000359|BEHAVIORAL|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
219513126|NCT00000359|BEHAVIORAL|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
219513127|NCT00000359|BEHAVIORAL|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
219513128|NCT00000359|BEHAVIORAL|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
219513129|NCT00000359|BEHAVIORAL|ShamManeuver|Passive movement of the head
219513130|NCT00134836|BEHAVIORAL|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
219513131|NCT06396520|OTHER|No intervention, observational|No intervention, observational
219513132|NCT02255513|DRUG|HLD200|
219513133|NCT02255513|DRUG|Placebo|
219513134|NCT04810923|PROCEDURE|i-PRF|intra-articular i-PRF injection after arthrocentesis
219513135|NCT04810923|PROCEDURE|Arthrocentesis|Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
219513136|NCT00203307|DRUG|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
219513137|NCT00203307|DRUG|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
218893084|NCT02770989|PROCEDURE|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
219034648|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
219513138|NCT05462288|DEVICE|Entia Liberty|Home monitoring blood analyser
219513139|NCT03730103|OTHER|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
219513140|NCT04645290|BEHAVIORAL|"Intervention group: Educational Intervention KARER"|"Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~* Module 0: the introduction~* Module 1: called Identifying my role as a caregiver~* Module 2: called Strategies to strengthen care~* Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~\- One season of practices abilities of 4 hours."
219513141|NCT04387110|DRUG|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
219513142|NCT01488578|DRUG|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
219513143|NCT00672828|BEHAVIORAL|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
219513144|NCT00672828|BEHAVIORAL|Interactive computer intervention|
219513145|NCT02308111|DRUG|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
219513146|NCT02308111|DRUG|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
219513147|NCT01342679|DRUG|dasatinib|100mg QD
219513148|NCT00873210|DRUG|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
219513149|NCT00929357|DRUG|DMARDs or Biologics|
219513150|NCT05914519|PROCEDURE|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
219513151|NCT05914519|PROCEDURE|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
219513152|NCT02957279|DRUG|Antibiotics|In the sepsis group, antibiotics were used when needed.
219513153|NCT00870909|PROCEDURE|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
219513154|NCT00870909|PROCEDURE|sham tDCS|sham condition as delivered by the stimulator
219513155|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test|Skin Prick Testing with inhalant allergens
219203840|NCT04660526|OTHER|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
219513156|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
219513157|NCT03013933|DRUG|Brentuximab Vedotin|Given IV
219513158|NCT03013933|DRUG|Cyclosporine|Given PO
219513159|NCT03013933|OTHER|Pharmacokinetic Study|Correlative studies
219513160|NCT03013933|DRUG|Verapamil|Given PO
219203841|NCT04660526|OTHER|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
219513161|NCT03013933|DRUG|Verapamil Hydrochloride|Given PO
219513162|NCT01305083|DRUG|Udenafil|Placebo-control
219513163|NCT01305083|DRUG|Placebo|Placebo
219513164|NCT02779816|DEVICE|Pen device|Adaptive pen device
219513165|NCT03885102|BEHAVIORAL|Intradialytic exercise intervention|50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
219513166|NCT03885102|BEHAVIORAL|Usual Care|Usual care with no exercise intervention or health literacy counselling
219513167|NCT03812068|BEHAVIORAL|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
219513168|NCT03812068|BEHAVIORAL|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
219513169|NCT05657093|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
219513170|NCT05657093|COMBINATION_PRODUCT|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
219513171|NCT05128188|OTHER|No intervention will be given in this study|No intervention will be given in this study
219513172|NCT05705583|OTHER|Other: Blood and Urine Collection|Blood and Urine Collection
219513173|NCT00215982|DRUG|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
219513174|NCT00215982|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
219513175|NCT00215982|DRUG|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
219513176|NCT02304575|OTHER|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
218893085|NCT00421057|BEHAVIORAL|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
219513177|NCT02304575|OTHER|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
219513178|NCT00455533|DRUG|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
218893086|NCT00421057|BEHAVIORAL|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
218893087|NCT02003092|DRUG|RX-5902|escalating doses (mg)
218893088|NCT05990634|DEVICE|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
218893089|NCT04708093|DEVICE|whole body vibration training|Oscillating platform
218893090|NCT02733523|BEHAVIORAL|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
218893091|NCT03670563|OTHER|Short foot exercise protocol|Exercises that target intrinsic foot muscles
218893092|NCT03670563|OTHER|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
218893093|NCT01523418|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
218893094|NCT03081884|DRUG|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
219203842|NCT04660526|OTHER|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
219513179|NCT00455533|DRUG|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
219513180|NCT00455533|DRUG|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
219513181|NCT00455533|DRUG|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
219513182|NCT03594877|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
219513183|NCT00129779|BEHAVIORAL|Intermediate care package|
219513184|NCT00901368|DRUG|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
219513185|NCT00901368|DRUG|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
219513186|NCT02785172|DRUG|IDP-118 Vehicle Lotion|Vehicle
219513187|NCT02785172|DRUG|IDP-118 Vehicle Cream|Vehicle
219513188|NCT02785172|DRUG|IDP-118 Lotion|Lotion
219513189|NCT02785172|DRUG|Ultravate Cream|Cream
219513190|NCT05077852|DIAGNOSTIC_TEST|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
219513191|NCT00800059|RADIATION|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
219513192|NCT06528262|DRUG|Enavogliflozin|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
218893095|NCT01696370|DRUG|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
218893096|NCT01696370|OTHER|Placebo capsule|one capsule three times per day for 3 months
218893097|NCT04223713|PROCEDURE|TriRec|Trileaflet Reconstruction of the Aortic Valve
218893098|NCT04223713|PROCEDURE|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
218893099|NCT03676972|DEVICE|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
218893100|NCT02552134|OTHER|exercise training|
219513193|NCT06528262|DRUG|Placebo|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
219513194|NCT06527963|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
219513195|NCT04638985|BIOLOGICAL|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
218893101|NCT02552134|OTHER|recommendation to be active|
218893102|NCT03948334|DRUG|ZPL389 30mg|30mg of ZPL389; once daily
218893103|NCT03948334|DRUG|ZPL389 50mg|50mg of ZPL389; once daily
218893104|NCT03948334|DRUG|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
218893105|NCT06312202|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
218893106|NCT06006195|OTHER|patients with dysphagia symptoms|patients with dysphagia symptoms examined by high resolution impedance manometry
218893107|NCT06006195|OTHER|patients without dysphagia symptoms|patients without dysphagia symptoms examined by high resolution impedance manometry
218893108|NCT05717816|DEVICE|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
219513196|NCT04638985|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
219609846|NCT04233138|OTHER|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
219609847|NCT00194402|DRUG|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
219609848|NCT05012371|DRUG|Cabozantinib|Given PO
219609849|NCT05012371|DRUG|Everolimus|Given PO
219609850|NCT05012371|DRUG|Lenvatinib|Given PO
219609851|NCT05012371|OTHER|Questionnaire Administration|Ancillary studies
219609852|NCT01122485|OTHER|PG201|two tablets
219609853|NCT01122485|OTHER|Placebo|two tablets
219609854|NCT06280703|DRUG|LY3938577|Administered Intravenously (IV)
219609855|NCT06280703|DRUG|Placebo|Administered Intravenously (IV)
219609856|NCT06280703|DRUG|Insulin Degludec|Administered Intravenously (IV)
219609857|NCT06280703|DRUG|Insulin Lispro|Administered Intravenously (IV)
219609858|NCT06280703|DRUG|LY3938577|Administered subcutaneously (SC)
219609859|NCT06280703|DRUG|Placebo|Administered subcutaneously (SC)
219609860|NCT06280703|DRUG|insulin degludec|Administered SC
219609861|NCT05839626|DRUG|SAR445514|Powder for solution for injection. Sub Cutaneous administration.
219609862|NCT06297603|DRUG|Retatrutide|Administered SC
219609863|NCT06297603|DRUG|Placebo|Administered SC
219609864|NCT03056170|DEVICE|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
219609865|NCT04479852|DRUG|SP-624|Oral capsule
219609866|NCT04479852|DRUG|Placebo|Oral capsule
219609867|NCT06475703|DEVICE|Isla wound prioritisation module|The intervention group will use the artificial intelligence enabled platform with the new wound prioritisation module for 30 days after surgery in addition to standard post-operative wound follow-up care for 60 days after surgery.
219609868|NCT06475703|OTHER|Standard follow-up|Standard care, mapped during the economic scoping exercise may include; out-patient appointments, advised to contact GP, or no follow-up.
219609869|NCT00001521|DRUG|Fludrocortisone|Mineralocorticoid needed to replace aldosterone deficiency. Patients will continue to receive an optimal fludrocortisone dose
219609870|NCT00001521|DRUG|Hydrocortisone|Glucocorticoid needed to replace cortisol deficiency. Reduced hydrocortisone dose might normalize the growth and adult stature of children with congenital adrenal hyperplasia
219609871|NCT00001521|DRUG|Letrozole|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
219609872|NCT00001521|DRUG|Flutamide|Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
219609873|NCT00001521|DRUG|Testolactone|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
218893109|NCT04339829|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
218893110|NCT02169986|BEHAVIORAL|electronic reminders|
219513197|NCT04638985|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
219513198|NCT04638985|BIOLOGICAL|MMR|MMR at the age of 18 month old
219513199|NCT00979628|DRUG|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
219513200|NCT00979628|DRUG|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
219513201|NCT00979628|DRUG|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
219513202|NCT00912418|BIOLOGICAL|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
219513203|NCT06529198|DEVICE|NeuroGyn Genital Neuromodulation System|Genital Neuromodulation
219513204|NCT06526845|OTHER|Video-Conference based rehabilitation|"All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
219513205|NCT06526845|OTHER|Home-Based rehabilitation|"Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
219513206|NCT04224090|DIAGNOSTIC_TEST|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
219513207|NCT02768142|OTHER|Natural cesarean delivery|Natural cesarean delivery
219513208|NCT02768142|OTHER|Standard cesarean delivery|Standard cesarean delivery
219513209|NCT02758366|DRUG|Doxorubicin|
218893111|NCT00598936|DEVICE|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
218893112|NCT00497757|BIOLOGICAL|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
218893113|NCT05897229|OTHER|Analysis of costs with patient care during hospitalization|Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
218893114|NCT03843086|DEVICE|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
218893115|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
218893116|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
218893117|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
218893118|NCT01128426|OTHER|No Intervention|No Intervention
218893119|NCT04104737|DEVICE|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
218893120|NCT03087136|DIAGNOSTIC_TEST|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
219034649|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
219034650|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
219034651|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
219034652|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
219034653|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
218893121|NCT03087136|DIAGNOSTIC_TEST|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
218893122|NCT02120066|PROCEDURE|Vitrectomy for submacular hemorrhage|
218893123|NCT02120066|DRUG|subretinal injection of tissue-plasminogen activator|
218893124|NCT03796065|BEHAVIORAL|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
218893125|NCT02442024|BEHAVIORAL|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
218893126|NCT02442024|BEHAVIORAL|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
218893127|NCT04483726|PROCEDURE|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
218893128|NCT04483726|PROCEDURE|open distal pancreatectomy|open distal pancreatectomy
218893129|NCT04807933|BEHAVIORAL|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
218893130|NCT00775996|DRUG|Clorazepate Dipotassium 15mg Tablets|
218893131|NCT02472574|DEVICE|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
218893132|NCT02472574|DRUG|rt-PA|Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
218893133|NCT00818792|DEVICE|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
218893134|NCT01592071|OTHER|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
218893135|NCT00869752|BIOLOGICAL|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
218893136|NCT00869752|DRUG|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
218893137|NCT00869752|DRUG|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
218893138|NCT04448977|DRUG|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
218893139|NCT03976388|DEVICE|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
218893140|NCT03976388|OTHER|Small-Group Discussion|Small group discussion led by a physician.
218893141|NCT01104896|DRUG|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
218893142|NCT01104896|DRUG|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
219513210|NCT04119661|DEVICE|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
219513211|NCT04119661|DEVICE|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
219513212|NCT02702206|DRUG|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
219513213|NCT02702206|DRUG|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
219513214|NCT02702206|DRUG|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
219513215|NCT02938494|DRUG|IDP-123 Lotion|Lotion
219513216|NCT02938494|DRUG|Tazorac Cream|Cream
219513217|NCT02938494|DRUG|Vehicle Lotion|Lotion
219513218|NCT02938494|DRUG|Vehicle Cream|Cream
219513219|NCT04330300|DRUG|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
219513220|NCT04330300|DRUG|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
219513221|NCT04330300|DRUG|ACE inhibitor|Anti-hypertensive (Control Arm)
219034654|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
219034655|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
219034656|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
219513222|NCT04330300|DRUG|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
219513223|NCT06113796|OTHER|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
219513224|NCT02676219|OTHER|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
219513225|NCT02676219|OTHER|Water|
218893143|NCT02214641|BEHAVIORAL|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
218893144|NCT02214641|BEHAVIORAL|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
218893145|NCT01027715|OTHER|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
219034657|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
219034658|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
219513226|NCT03281421|OTHER|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
219034659|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
219513227|NCT02495597|OTHER|no intervention - just observational|
219513228|NCT04730557|BEHAVIORAL|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
219513229|NCT01314755|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
219513230|NCT01314755|DIETARY_SUPPLEMENT|An iso-caloric, iso-nitrogenous control feed|
219513231|NCT02201498|PROCEDURE|Pulpotomies with Formocresol/OZE and Biodentine|
219513232|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
219513233|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
219513234|NCT05147051|DRUG|Meglumine Sodium Succinate|500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
219513235|NCT05147051|DRUG|Placebo|Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
219609874|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
219609875|NCT02487966|BEHAVIORAL|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
219609876|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
219609877|NCT02487966|BEHAVIORAL|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
219609878|NCT03089710|OTHER|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
219609879|NCT06336434|DRUG|CAB LA 600mg|600mg (3mL) IM Injection
219609880|NCT06336434|DRUG|RPV LA 900mg|900mg (3mL) IM Injection
219609881|NCT06336434|DRUG|CAB LA 400mg|400mg (2mL) IM Injection
219609882|NCT06336434|DRUG|RPV LA 600mg|600mg (2mL) IM injection
219609883|NCT03582462|DRUG|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
219609884|NCT03582462|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
219609885|NCT00834509|DEVICE|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
218893146|NCT01698385|OTHER|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
218893147|NCT00550953|DRUG|telmisartan+amlodipine|
218893148|NCT00550953|DRUG|telmisartan|
218893149|NCT01936714|PROCEDURE|cataract surgery|
218893150|NCT06262100|DEVICE|Carragelose|Application of Carragelose containing eye drops
218893151|NCT04005261|DIAGNOSTIC_TEST|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
218893152|NCT03890237|BEHAVIORAL|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
218893153|NCT03890237|BEHAVIORAL|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
218893154|NCT03890237|BEHAVIORAL|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
218893155|NCT03890237|BEHAVIORAL|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
218893156|NCT06137586|OTHER|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
219513236|NCT02331537|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
219513237|NCT04578743|DEVICE|Graded Exercise Therapy: ClearPlay(TM)|ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
219513238|NCT03801161|BIOLOGICAL|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP \>5 mg/L in infants within 24 hours of immunization.
219513239|NCT04143113|OTHER|Decision Aid|Shared decision making tool
219513240|NCT03562442|BEHAVIORAL|Smoking cessation|Smoking cessation with or without professional / medical support
219513241|NCT02224456|DRUG|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
219513242|NCT04059601|DIAGNOSTIC_TEST|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
219609886|NCT02632266|DIETARY_SUPPLEMENT|Powder HMF|powder human milk fortifier
219609887|NCT02632266|DIETARY_SUPPLEMENT|Liquid HMF|Liquid human milk fortifier
219034660|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
219034661|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
219034662|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
219609888|NCT04885881|PROCEDURE|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
219513243|NCT04059601|DIAGNOSTIC_TEST|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
219513244|NCT00966225|DIETARY_SUPPLEMENT|LIP-01|comparison of different dosages of natural health product
219513245|NCT05411770|DEVICE|Thoracic kyphosis and lumbar lordosis angle assessment|Thoracic kyphosis and lumbar lordosis angle assessment was performed with the reliable Baseline Bubble Inclinometer®.
219513246|NCT05411770|DEVICE|Temporomandibular range of motion|TMJ range of motion, maximum mouth opening amount (MAAM), right and left lateral movements of the mandible (laterotrusion), anterior movement of the mandible (protrusion), and backward movement of the mandible (retrusion) were measured with a millimetric ruler, while the adolescent was seated on a chair.
219609889|NCT04885881|PROCEDURE|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
219609890|NCT04487613|DRUG|Moringa oleifera leaf|450 mg capsule
218893157|NCT05398094|DRUG|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
219034663|NCT00002794|DRUG|carboplatin|
219034664|NCT00002794|DRUG|vincristine sulfate|
219034665|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
219609891|NCT04487613|DRUG|Placebo|placebo capsule
218893158|NCT04980612|BEHAVIORAL|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
218893159|NCT04980612|BEHAVIORAL|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
218893160|NCT04015206|OTHER|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
218893161|NCT02446717|DRUG|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
218893162|NCT02446717|DRUG|ribavirin (RBV)|Tablet
218893163|NCT02446717|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
218893164|NCT04589442|BIOLOGICAL|Split thickness skin graft|standard of care graft
218893165|NCT04589442|BIOLOGICAL|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
218893166|NCT02527590|OTHER|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
218893167|NCT02527590|OTHER|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
218893168|NCT02527590|OTHER|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
218893169|NCT02527590|OTHER|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
218893170|NCT02527590|OTHER|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
218893171|NCT05357716|DEVICE|HeartWatch|The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
218893172|NCT05357716|DEVICE|Event Recorder|A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
219513247|NCT05411770|DEVICE|Measuring the cervical joint range of motion|Cervical joint flexion, extension, lateral flexion and rotation ranges of motion were measured with a universal goniometer while the adolescent was sitting in a chair.
219513248|NCT05411770|DEVICE|Craniovertebral angle measurement|Head posture of the adolescent was evaluated by craniovertebral angle (CVA) method. Adolescents sat on a chair with back support in an upright position and turned sideways to the worker. The pivot point was accepted as the seventh cervical vertebra, and the angle between the head (tragus) and the horizontal plane was measured with a goniometer and recorded in degrees.
219513249|NCT05411770|DEVICE|Tragus-to-wall distance measurement|Tragus-to-wall distance was measured using a tape measure and recorded in cm.
219513250|NCT05411770|DEVICE|Scoliosis angle assessment|Scoliosis angle assessment was done with a scoliometer.
219513251|NCT00178581|DRUG|Glutamine|
219609892|NCT06069219|DRUG|Epidural administration of sufentanil|The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
218893173|NCT05357716|DEVICE|Holter Monitor|A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
218893174|NCT00006474|DRUG|O6-benzylguanine|
218893175|NCT00006474|DRUG|temozolomide|
219513252|NCT03665181|OTHER|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
219513253|NCT02815969|OTHER|vena punction|vena punction and urine collection
218893176|NCT00006474|PROCEDURE|conventional surgery|
218893177|NCT05820659|BEHAVIORAL|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
219034666|NCT05694650|BEHAVIORAL|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
219034667|NCT05694650|BEHAVIORAL|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
219034668|NCT06193746|DEVICE|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
219513254|NCT01644890|DRUG|NK105|IV, Weekly
218893178|NCT05275595|OTHER|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
218893179|NCT05275595|OTHER|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
218893180|NCT01629173|PROCEDURE|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
218893181|NCT01629173|PROCEDURE|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
218893182|NCT01629173|PROCEDURE|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
218893183|NCT01629173|PROCEDURE|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
218893184|NCT01327599|DRUG|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
218893185|NCT01187485|DRUG|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
218893186|NCT01187485|DRUG|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
218893187|NCT01187485|DRUG|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
218893188|NCT05816083|BEHAVIORAL|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
218893189|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
218893190|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
218893191|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
218893192|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
218893193|NCT00310596|DRUG|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
218893194|NCT00310596|DRUG|Placebo|0,9% saline at 0,6mL/kg at bolus rate
218893195|NCT04260646|DEVICE|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
218893196|NCT04260646|DEVICE|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
218893197|NCT06110806|BEHAVIORAL|MBIE|MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
219364232|NCT05839210|BEHAVIORAL|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
219609893|NCT03200990|DEVICE|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
219609894|NCT04347577|DRUG|duloxetine|open-label study
219609895|NCT01666626|PROCEDURE|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
219609896|NCT05295225|DEVICE|Green Light Emitting Diode|GLED exposure for two hours
219609897|NCT05295225|DEVICE|White Light Emitting Diode|WLED exposure for two hours
219609898|NCT04134533|OTHER|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
219609899|NCT01158235|DRUG|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
219609900|NCT06521060|PROCEDURE|tru cut biopsy|Proving that preoperative TCB could provide accurate information about the histological nature of the tumor would have great impact for setting an adequate, tailored, oncologically safe treatment approach.
219513255|NCT01644890|DRUG|Paclitaxel|IV, Weekly
219609901|NCT03482518|OTHER|custom slippers with perforated synthetic leather cover.|the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
218893200|NCT04903028|DEVICE|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
218893201|NCT04903028|DEVICE|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
218893202|NCT06437964|OTHER|No use of prophylactic antibiotics|In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
218893203|NCT06437964|DRUG|Prophylactic Antibiotics|Intravenous infusion of 2.0g ceftriaxone before endoscopic therapy
218893204|NCT06059989|DRUG|Infliximab subcutaneous|Mono and combination therapy group
218893205|NCT06059989|DRUG|Immunosuppressive Agents|Combination group only
218893206|NCT02989753|DIETARY_SUPPLEMENT|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
219513256|NCT00214279|DRUG|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
219513257|NCT00238069|DEVICE|CPAP machine as a result of sleep study|
219513258|NCT03482063|DIETARY_SUPPLEMENT|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
219513259|NCT03482063|OTHER|Placebo|riboflavin (2.2mg)
219513260|NCT05889338|DRUG|adalimumab and methotrexate|Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
219609902|NCT05430243|DRUG|Empagliflozin 10 MG|once daily empagliflozin 10mg+/- diuretics
219609903|NCT05430243|DRUG|Diuretics|diuretics as clinically indicated
219609904|NCT05459246|OTHER|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
219609905|NCT01356823|BIOLOGICAL|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
219609906|NCT01356823|BIOLOGICAL|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
219609907|NCT01356823|BIOLOGICAL|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
219609908|NCT01356823|BIOLOGICAL|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
219609909|NCT03098719|BEHAVIORAL|Active Mobility|see detailed discription
219609910|NCT03973736|OTHER|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
219609911|NCT01159808|DRUG|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
219609912|NCT01159808|DRUG|Placebo|matching placebo capsules, oral administration, single dose
219609913|NCT05389137|BIOLOGICAL|Inavtivated Quadrivalent Influenza Virus Split Vaccine|Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
218893207|NCT02989753|DIETARY_SUPPLEMENT|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
218893208|NCT02989753|DIETARY_SUPPLEMENT|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
218893209|NCT02193295|BEHAVIORAL|Caloric Restriction|Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
218893210|NCT05697341|PROCEDURE|Ultra-Mini-PCNL|treatment to extract or disintegrate renal stones
219513261|NCT01462214|DRUG|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
219513262|NCT05780541|DRUG|PF-07304814|PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
219513263|NCT05780541|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
218893211|NCT05697341|PROCEDURE|Stented SWL|treatment to disintegrate renal stones in the presence of a JJ
218893212|NCT00921778|DEVICE|Lapcone|Use of Lapcone during LSH
218893213|NCT00921778|PROCEDURE|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
219034669|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
219034670|NCT02710604|DRUG|CMX157|tablet
219513264|NCT05780541|BIOLOGICAL|Remdesivir|Antiviral agent
219513265|NCT06162923|BEHAVIORAL|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
218893214|NCT06613802|OTHER|Time|This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023
218893215|NCT06523868|OTHER|GRAIL Galleri|A multi-cancer early detection (MCED) blood test.
219034671|NCT02710604|DRUG|TDF|300mg tablet
219034672|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
219034673|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
219513266|NCT06162923|BEHAVIORAL|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
219513267|NCT00252980|BEHAVIORAL|Psychotherapy|
219513268|NCT00620490|DRUG|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
219513269|NCT00620490|OTHER|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
219513270|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
219513271|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
219513272|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
219513273|NCT01418157|DRUG|Acetazolamide|125 mg twice daily until 4380 meters altitude
219513274|NCT01418157|DRUG|Placebo|Twice daily
219513275|NCT01806922|BEHAVIORAL|Yoga|
219513276|NCT02761980|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
219513277|NCT02761980|DRUG|Ibuprofen 250 mg|Ibuprofen 250 mg
219513278|NCT02761980|DRUG|Acetaminophen 500 mg|1 APAP 500 mg caplet
218893216|NCT00242996|BIOLOGICAL|filgrastim|
218893217|NCT00242996|BIOLOGICAL|rituximab|
219034674|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
219034675|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
219513279|NCT02761980|DRUG|Placebo|Placebo tablet
219513280|NCT03400930|OTHER|Severe Acute Malnutrition|
219513281|NCT05404035|BEHAVIORAL|Family Connections for relatives of people with eating disorders and personality disorders|"The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment."
219513282|NCT05404035|BEHAVIORAL|Optimized Treatment As Usual|"Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs."
219513283|NCT05891990|PROCEDURE|immediate implant augmented with sticky tooth|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~* Finally, the flap will be repositioned and sutured."
219513284|NCT05891990|PROCEDURE|immediate implant augmented with autogenous tooth graft|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~* Finally, the flap will be repositioned and sutured."
219513285|NCT04820803|OTHER|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
219513286|NCT04820803|OTHER|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
219513287|NCT04640103|OTHER|No interventions|No interventions
219513288|NCT04303988|DRUG|SHR-1316|IV
219513289|NCT04303988|DRUG|Bevacizumab|IV
219513290|NCT04303988|DRUG|Cisplatin/Carboplatin|IV
219513291|NCT00613470|DRUG|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5."
218893218|NCT00242996|BIOLOGICAL|sargramostim|
218893219|NCT00242996|DRUG|carmustine|
218893220|NCT00242996|DRUG|cyclophosphamide|
218893221|NCT00242996|DRUG|etoposide|
218893222|NCT00242996|PROCEDURE|adjuvant therapy|
218893223|NCT00242996|PROCEDURE|bone marrow ablation with stem cell support|
218893224|NCT00242996|PROCEDURE|peripheral blood stem cell transplantation|
218893225|NCT00892775|BIOLOGICAL|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
218893226|NCT00892775|BIOLOGICAL|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
218893227|NCT00769912|DRUG|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
218893228|NCT00769912|DRUG|Placebo (air)|Placebo administration during the intervention
218893229|NCT06294340|OTHER|Exposure to loud pre-recorded road traffic noise|Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
218893230|NCT02762214|DEVICE|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
218893231|NCT02762214|OTHER|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
219513292|NCT03976713|DRUG|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
219513293|NCT03976713|DRUG|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
218893232|NCT01578122|DEVICE|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
218893233|NCT01578122|DEVICE|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
218893234|NCT00145132|PROCEDURE|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
219034676|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
219034677|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
219034678|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
219034679|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
219513294|NCT03976713|DRUG|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
218893235|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
218893236|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
218893237|NCT01589393|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
218893238|NCT01589393|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
219034680|NCT03709264|DRUG|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
219034681|NCT03709264|DRUG|Placebos|Placebo: standard treatment
219034682|NCT00741884|DRUG|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
219034683|NCT00741884|DRUG|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
219034684|NCT00741884|DRUG|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
219034685|NCT00741884|DRUG|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
219034686|NCT00741884|DRUG|Placebo|Placebo BID for 7 weeks
219034687|NCT00178659|OTHER|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
219034688|NCT00423306|DRUG|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
219034689|NCT00003256|DRUG|alvocidib|
219034690|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
219034691|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
219034692|NCT02218333|DIETARY_SUPPLEMENT|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
219034693|NCT02218333|DIETARY_SUPPLEMENT|Placebo|
219513295|NCT01130688|DRUG|Zileuton|Imatinib combined with Zileuton
219513296|NCT02427685|DEVICE|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
219513297|NCT00101582|DRUG|Placebo|
219513298|NCT00101582|DRUG|palifermin|
219513299|NCT00101582|DRUG|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
219513300|NCT00101582|RADIATION|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
219513301|NCT03370068|OTHER|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
219609914|NCT00815932|DEVICE|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
219609915|NCT02366689|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
219609916|NCT02366689|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
219609917|NCT02366689|DRUG|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
219609918|NCT02366689|DRUG|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
218893239|NCT00434109|DRUG|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
219513302|NCT03370068|OTHER|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
218893240|NCT00434109|PROCEDURE|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
218893241|NCT02406105|RADIATION|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
219513303|NCT00056160|DRUG|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
219513304|NCT00056160|DRUG|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
219513305|NCT06486480|PROCEDURE|Using robot assisted endoscopy to clear intraventricular hemorrhage|More advanced surgical auxiliary instruments are used to improve surgical accuracy
219513306|NCT04898296|OTHER|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
219513307|NCT04898296|OTHER|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
219513308|NCT01551095|DEVICE|PEGJ tube|The self-propelled PEGJ feeding tube
219609919|NCT02366689|DRUG|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
219609920|NCT03535792|DRUG|Fentanyl/Hyperbaric bupivacaine|Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
219609921|NCT03535792|DRUG|Nalbuphine/Hyperbaric bupivacaine|Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
219609922|NCT06013475|DRUG|Apalutamide|Decision by the treating physician
219609923|NCT06013475|DRUG|Darolutamide (BAY 1841788)|Decision by the treating physician
219609924|NCT06013475|DRUG|Enzalutamide|Decision by treating physician
219609925|NCT06338501|OTHER|Specifical Functional Training Exercises|"Strength Training: Include compound exercises like squats, deadlifts, lunges, and bench presses to build overall strength and muscle mass. Focus on functional movements that mimic the actions used in Muay Thai.~Core Stability Exercises: A strong core is essential for generating power and maintaining balance during strikes and defensive maneuvers.~Plyometric Training: Jumping exercises such as box jumps, squat jumps, and split jumps help improve explosive power and enhance muscular endurance, crucial for delivering swift and powerful strikes.~Flexibility and Mobility Training: Incorporate stretching exercises to improve flexibility, joint range of motion, and prevent injuries.~Interval Training: Perform high-intensity interval training (HIIT) sessions that combine cardiovascular exercises."
219609926|NCT06172712|OTHER|Variations in daily life activity signals detected by unobtrusive sensors|Patients will be equipped with unobtrusive devices for a duration of 12 months. Throughout this period, they will attend scheduled visits every three months following the baseline visit. These assessments will focus on determining the frequency of exacerbations, evaluating exercise capacity, measuring the severity of dyspnea, and assessing health-related quality of life. The data gathered from the sensors embedded in these unobtrusive devices will be instrumental in developing AI-based models. These models aim to accurately predict COPD exacerbations and effectively estimate the progression of the previously mentioned health outcome.
219609927|NCT06578221|OTHER|Kegel Pelvic Floor Muscle Exercise Group|After the surgery, the patients will be taken to the clinic room in a supine position and the researcher will perform the Kegel pelvic floor muscle exercises three times at the 1st, 4th and 7th hours within the first 8 hours after the patients are taken to the clinic room.
219609928|NCT01576679|DRUG|Cathflo (Alteplase)|
219609929|NCT01576679|DRUG|Saline|
219609930|NCT03283566|DRUG|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
219609931|NCT03283566|DRUG|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
218893242|NCT02406105|DRUG|CyberKnife|
218893243|NCT02321553|OTHER|Brown rice|brown rice cake
218893244|NCT02321553|OTHER|White rice|white rice cake
219513309|NCT05436002|DEVICE|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
219609932|NCT02934672|OTHER|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
219034694|NCT03650010|PROCEDURE|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
219034695|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
219034696|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
219513310|NCT02199548|OTHER|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
219513311|NCT03382002|DIAGNOSTIC_TEST|TCL|evaluation of oxidative status
219609933|NCT01231646|OTHER|No intervention|No intervention. This is a cross-sectional study.
218893245|NCT06241053|OTHER|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
218893246|NCT06241053|OTHER|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
219513312|NCT05268432|PROCEDURE|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
219513313|NCT04882332|OTHER|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
219513314|NCT04882332|OTHER|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
219513315|NCT01436032|DRUG|N1539|IV
219513316|NCT01436032|DRUG|N1539|IV
219513317|NCT01436032|DRUG|N1539|IV
219513318|NCT01436032|DRUG|Ketorolac Tromethamine|IV
219513319|NCT01436032|DRUG|Placebo|IV
219513320|NCT05532332|DRUG|Fluoxetine 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
219513321|NCT05532332|DRUG|Prozac® 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
219513322|NCT03528200|OTHER|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
219513323|NCT03519828|OTHER|No intervention has been conducted|It is an observational study, and no intervention has been conducted
219513324|NCT02441972|DRUG|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
219609934|NCT00023413|DRUG|Rifabutin|
219609935|NCT00023413|DRUG|Efavirenz|
219609936|NCT05846035|DIAGNOSTIC_TEST|Triphasic C.T abdomen and pelvis|for cirrhotic patients to ensure hepatocellular carcinoma
219609937|NCT05596656|DIAGNOSTIC_TEST|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
219513325|NCT03207581|BEHAVIORAL|Professional Coaching|Professional, individualized coaching
219609938|NCT00814476|OTHER|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
219513326|NCT03312530|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
219609939|NCT00814476|OTHER|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
219609940|NCT01917682|PROCEDURE|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
219609941|NCT02706444|DEVICE|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
219513327|NCT03312530|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
218893247|NCT05590507|BEHAVIORAL|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
218893248|NCT02420236|BEHAVIORAL|High-intensity resistance training|
218893249|NCT02420236|BEHAVIORAL|General physical activity|
218893250|NCT02420236|BEHAVIORAL|Multidisciplinary rehabilitation program|
218893251|NCT04374240|GENETIC|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"
218893252|NCT01773187|DRUG|Pacritinib|
218893253|NCT01773187|DRUG|Best Available Therapy|
219513328|NCT03312530|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
219513329|NCT04329208|DEVICE|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
218893254|NCT05486611|DEVICE|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
218893255|NCT05486611|DEVICE|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
218893256|NCT06060587|DRUG|Docetaxel|75 mg/m2 via IV
218893257|NCT06060587|DRUG|ADT|Prior to randomization as part of standard of care.
218893258|NCT06060587|DRUG|Abiraterone|1000 mg by mouth
218893259|NCT00704860|OTHER|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
218893260|NCT02978833|BIOLOGICAL|PRP|
218893261|NCT02978833|BIOLOGICAL|Whole Blood|
218893262|NCT02978833|DEVICE|Ultrasound|
218893263|NCT00015795|DEVICE|airway interruption test|
219034697|NCT03132051|DRUG|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
219034698|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
219513330|NCT00868400|DIETARY_SUPPLEMENT|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
219513331|NCT00868400|DIETARY_SUPPLEMENT|flavored water|will be given in doses equal to those of high-carbohydrate beverage
219513332|NCT00909493|OTHER|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
219513333|NCT06451861|DRUG|Chidamide|Induction Therapy
218893264|NCT02436538|OTHER|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
218893265|NCT03644667|BIOLOGICAL|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
218893266|NCT03644667|BIOLOGICAL|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
218893267|NCT03644667|DRUG|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
218893268|NCT05476016|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
219034699|NCT04654533|OTHER|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
219034700|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
219513334|NCT06451861|DRUG|Venetoclax|Induction Therapy
219513335|NCT06451861|DRUG|azacitidine|Induction Therapy
219513336|NCT06451861|DRUG|Anthracyclines or anthraquinones|Induction Therapy
219513337|NCT06451861|DRUG|cytarabine|Induction Therapy
219513338|NCT01452451|DRUG|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
218893269|NCT04688229|DEVICE|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
219513339|NCT01452451|DRUG|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
219513340|NCT04505033|DRUG|HB0017|HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
218893270|NCT04688229|OTHER|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
218893271|NCT06428370|PROCEDURE|Damage Control Surgery|Simple resection, drop, and open abdomen in case of Hinchey III-IV
218893272|NCT03410303|DIAGNOSTIC_TEST|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
218893273|NCT00103740|DRUG|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
218893274|NCT00103740|DRUG|placebo to zoledronic acid|5 mL of sterile water for infusion
218893275|NCT00103740|DRUG|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
218893276|NCT00103740|DRUG|Placebo to risedronate|oral capsules
218893277|NCT00103740|DRUG|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
218893278|NCT04224961|DEVICE|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
219034701|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
219513341|NCT04505033|DRUG|placebo|A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
219513342|NCT04347746|BEHAVIORAL|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
219609942|NCT02706444|DEVICE|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
219609943|NCT01806194|BEHAVIORAL|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
219609944|NCT01806194|BEHAVIORAL|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
219609945|NCT05506670|OTHER|Diagnostic test and phone call|Viral diagnostic test will be performed at inclusion. In case of RSV positive results, follow up phone calls will be scheduled at day 14 and day 30 to collect data.
219609946|NCT05506670|DIAGNOSTIC_TEST|Diagnostic test|Viral diagnostic test will be performed at inclusion. In case of RSV negative result, no more intervention will be required.
218893279|NCT01863329|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
219034702|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
219609947|NCT04882241|BIOLOGICAL|Pembrolizumab|IV infusion
219609948|NCT04882241|DRUG|Placebo|IV infusion
219609949|NCT04882241|DRUG|Cisplatin|IV infusion
219609950|NCT04882241|DRUG|Capecitabine|Oral tablets
219034703|NCT05010928|COMBINATION_PRODUCT|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
219034704|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
219034705|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
219034706|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
219609951|NCT04882241|DRUG|5-fluorouracil|IV infusion
219609952|NCT04882241|DRUG|Docetaxel|IV infusion
219609953|NCT04882241|DRUG|Oxaliplatin|IV infusion
219609954|NCT04882241|DRUG|Leucovorin|IV infusion
219609955|NCT04553393|DRUG|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
219609956|NCT04553393|DRUG|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
219609957|NCT04553393|DRUG|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
219513343|NCT04347746|BEHAVIORAL|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
219513344|NCT03093324|DRUG|ALKS 8700|Administered as specified in the treatment arm.
219513345|NCT03093324|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
219513346|NCT05367388|DRUG|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
219513347|NCT05367388|DRUG|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
219513348|NCT05064462|OTHER|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
219513349|NCT04629404|DRUG|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
219513350|NCT04629404|DRUG|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
219513351|NCT03343522|BEHAVIORAL|Exercise|A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
219513352|NCT01139255|BEHAVIORAL|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
219513353|NCT04579328|BEHAVIORAL|Exposure to Growth Mats|see arm/group descriptions for description of intervention
219513354|NCT04119349|BEHAVIORAL|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
219513355|NCT00278200|BIOLOGICAL|Inactivated EBV-infected vaccine|
219513356|NCT03968471|BEHAVIORAL|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
219513357|NCT01142037|DIETARY_SUPPLEMENT|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
219034707|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
219513358|NCT02505854|DIETARY_SUPPLEMENT|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
219513359|NCT02505854|DIETARY_SUPPLEMENT|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
219513360|NCT02505854|DIETARY_SUPPLEMENT|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
219513361|NCT00976664|DEVICE|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
219513362|NCT00976664|DEVICE|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
219513363|NCT04330248|DRUG|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
219513364|NCT04330248|DRUG|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
219513365|NCT00759447|DEVICE|Genesis and Gemini|3 dimensional breast mammography system
219034708|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
219034709|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
219034710|NCT06358456|DRUG|Artificial tear|Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
219034711|NCT06358456|OTHER|No artificial tears|Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
219034712|NCT03010787|DRUG|V565|single ascending dose of V565
219513366|NCT00759447|DEVICE|Investigational 3D Mammography system|3 dimensional breast mammography system
218893280|NCT02503150|BIOLOGICAL|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
218893281|NCT02503150|DRUG|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
218893282|NCT02434042|DIETARY_SUPPLEMENT|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
218893283|NCT02434042|OTHER|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
218893284|NCT05460143|OTHER|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
218893285|NCT05460143|OTHER|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
218893286|NCT00461084|DRUG|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
218893287|NCT00461084|DRUG|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
218893288|NCT00815893|DRUG|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
218893289|NCT00815893|DRUG|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
218893290|NCT00815893|DRUG|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
218893291|NCT02982057|DEVICE|the ABSORB:bioresorbable vascular scaffold|
218893292|NCT02982057|DRUG|O.M.T|
218893293|NCT01643824|RADIATION|Proton Beam Therapy|"\- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~\- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
219034713|NCT03010787|DRUG|V565|Multiple dose
219034714|NCT03010787|DRUG|Placebo|Single and multiple dose
219513367|NCT03407859|BIOLOGICAL|Sequential Treatment With different CART|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
219513368|NCT06041464|OTHER|cell culture|isolation of cell culture
219513369|NCT04100499|DEVICE|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
218893294|NCT01336153|DRUG|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
218893295|NCT01336153|DRUG|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
219034715|NCT03010787|DRUG|V565|Open-label single dose
219034716|NCT03010787|DRUG|V565|Open-label single ascending dose
219034717|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
219034718|NCT03412916|BEHAVIORAL|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
219034719|NCT03412916|BEHAVIORAL|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
219513370|NCT06036758|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14 Test|Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
219513371|NCT03085446|BEHAVIORAL|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
219609958|NCT04553393|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
218893296|NCT04511858|OTHER|maximum effort test on a cycloergometer|5 h test on cycloergometer
218893297|NCT04511858|OTHER|maximum effort test on a treadmill|5 h test on treadmill
218893298|NCT00546949|PROCEDURE|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
218893299|NCT00546949|PROCEDURE|Interspinous Process Decompression (IPD)|Interspinous device
218893300|NCT01920308|DEVICE|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
218893301|NCT01023724|DRUG|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
218893302|NCT01023724|DRUG|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
218893303|NCT03314311|BEHAVIORAL|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
218893304|NCT02424175|BIOLOGICAL|Fecal Microbiota Transplantation|
218893305|NCT03722394|BEHAVIORAL|Pain Neuroscience Education|15 minute verbal one-on-one education session
218893306|NCT00258167|BEHAVIORAL|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
218893307|NCT02021630|OTHER|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
218893308|NCT04787978|OTHER|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
218893309|NCT06414447|DIAGNOSTIC_TEST|Huxley Medical|diagnostic
218893310|NCT01583842|DRUG|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."
218893311|NCT01583842|DRUG|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."
218893312|NCT01583842|PROCEDURE|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
218893313|NCT04309708|DEVICE|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
218893314|NCT06527326|DIETARY_SUPPLEMENT|Live Combined Bifidobacterium|the Bifidobacterium genus supplement
218893315|NCT06527326|DIETARY_SUPPLEMENT|Placebo|Placebo
218893316|NCT04071197|DEVICE|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
218893317|NCT04071197|DEVICE|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
218893318|NCT01594931|DRUG|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
219513372|NCT03085446|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
219513373|NCT03513393|DRUG|velpatasvir|Test 1
219513374|NCT03513393|DRUG|velpatasvir|Test 2
219513375|NCT03513393|DRUG|velpatasvir|Reference
219513376|NCT04592354|DIETARY_SUPPLEMENT|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
219513377|NCT02512354|OTHER|Sample of a fragment of fetal tissue|
218893319|NCT01555372|DEVICE|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
219034720|NCT06483971|DIAGNOSTIC_TEST|Oral Isotretinoin|20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily
219513378|NCT02512354|OTHER|Parent's blood samples|
219513379|NCT02616692|DRUG|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
219513380|NCT04963348|OTHER|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
219513381|NCT05063461|DEVICE|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
219513382|NCT05063461|PROCEDURE|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
219513383|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
219513384|NCT01309009|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
219513385|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
219513386|NCT03519256|BIOLOGICAL|Nivolumab|Specified dose on specified days
219513387|NCT03519256|BIOLOGICAL|BCG|Specified dose on specified days
219513388|NCT03519256|DRUG|BMS-986205|Specified dose on specified days
218893320|NCT01555372|DEVICE|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
219513389|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
219513390|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
219513391|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
219513392|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
219513393|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
219513394|NCT04828161|DRUG|ensovibep|IV on day 1 only.
219513395|NCT04828161|DRUG|Placebo|IV on day 1 only.
219034721|NCT06483971|COMBINATION_PRODUCT|Antibiotics|250 mg on laternate day/3 months Frequency: Once or twice daily
218893321|NCT01310465|DRUG|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
218893322|NCT01310465|DRUG|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
218893323|NCT00430105|DRUG|cyclophosphamide|
218893324|NCT05090735|PROCEDURE|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
218893325|NCT05090735|PROCEDURE|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
218893326|NCT03678311|DEVICE|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.
218893327|NCT01372059|OTHER|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
218893328|NCT01372059|OTHER|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
218893329|NCT01372059|OTHER|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
218893330|NCT06543901|PROCEDURE|Submuscular plating|the patient was fixed with a submuscular plate
218893331|NCT06543901|PROCEDURE|Traction and casting|the patient was placed on a traction with a thomas splint and then was casted with a hip spica
218893332|NCT01064115|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
218893333|NCT01260714|DRUG|Azacitidine|Given SC
218893334|NCT01260714|DRUG|Etoposide|Given IV
219034722|NCT05140577|OTHER|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
219034723|NCT02558790|DRUG|L-Threonic Acid Magnesium Salt (L-TAMS)|
218893335|NCT01260714|OTHER|Laboratory Biomarker Analysis|Correlative studies
219034724|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
218893336|NCT01260714|DRUG|Mitoxantrone Hydrochloride|Given IV
218893337|NCT02135055|OTHER|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
219034725|NCT05111132|DIAGNOSTIC_TEST|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
219034726|NCT03424837|BEHAVIORAL|ASCENT|"ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care"
219034727|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
219034728|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
219034729|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
219609959|NCT04766645|DEVICE|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
219609960|NCT04766645|GENETIC|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
219609961|NCT04766645|DIAGNOSTIC_TEST|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
219609962|NCT05436730|DEVICE|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
219609963|NCT05436730|DEVICE|Sphygmocor|Assessment of the arterial stiffness
219609964|NCT05436730|DEVICE|VaSera-VS|Assessment of the arterial stiffness
219609965|NCT05436730|DEVICE|Somnocheck|Assessment of the sleep breath disturbances
219609966|NCT01436955|DRUG|Placebo|multiple oral doses
219609967|NCT01436955|DRUG|RG1662|Cohorts receiving multiple oral doses
218893338|NCT02135055|DRUG|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
218893339|NCT02135055|DRUG|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
218893340|NCT02135055|PROCEDURE|Sedation interruption|Sedation interruption is performed at 8 am every morning.
218893341|NCT04085549|DEVICE|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
218893342|NCT04085549|OTHER|Reference Cream|Commercial refence cream not containing berry and plant oils.
218893343|NCT02744092|DRUG|Rivaroxaban|Anticoagulation therapy.
218893344|NCT02744092|DRUG|Apixaban|Anticoagulation therapy.
218893345|NCT02744092|DRUG|Edoxaban|Anticoagulation therapy.
218893346|NCT02744092|DRUG|Dabigatran|Anticoagulation therapy.
218893347|NCT02744092|DRUG|Warfarin|Anticoagulation therapy.
218893348|NCT02744092|DRUG|Dalteparin|Anticoagulation therapy.
219034730|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
219034731|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
219034732|NCT03898765|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
219034733|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
219034734|NCT05228470|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219513396|NCT05480397|OTHER|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~* Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~* Group (3): Will receive (cryotherapy and conventional physical therapy )"
219513397|NCT03250533|DEVICE|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
219513398|NCT03250533|DEVICE|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
219513399|NCT04488575|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbe
218893349|NCT02744092|DRUG|Enoxaparin|Anticoagulation therapy.
218893350|NCT02744092|DRUG|Fondaparinux|Anticoagulation therapy.
218893351|NCT01885221|BEHAVIORAL|Multimedia Support Intervention|
218893352|NCT01365286|DRUG|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
218893353|NCT01365286|DRUG|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
218893354|NCT01633788|DRUG|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
218893355|NCT01633788|DRUG|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
218893356|NCT01633788|DRUG|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
219034735|NCT02795390|DRUG|Chinese herbal medicine|
219034736|NCT02795390|DRUG|Placebo|
219513400|NCT04488575|DRUG|Placebo|Placebo oral capsule
218893357|NCT01633788|DRUG|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
218893358|NCT03536585|DEVICE|Vulvovaginal treatment|"* Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
218893359|NCT03536585|DEVICE|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
218893360|NCT00310011|DRUG|cisplatin|
218893361|NCT00310011|DRUG|gemcitabine hydrochloride|
218893362|NCT00310011|DRUG|paclitaxel|
218893363|NCT00310011|PROCEDURE|conventional surgery|
218893364|NCT00215111|BEHAVIORAL|Low carbohydrate, reduced glycemic load, and a control diet|
218893365|NCT01929226|BIOLOGICAL|ETI-204|Monoclonal Antibody
218893366|NCT01929226|OTHER|Placebo|Placebo for ETI-204
219034737|NCT00842660|DRUG|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
219034738|NCT02311439|DRUG|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
219513401|NCT01224132|DRUG|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
219513402|NCT01274416|BEHAVIORAL|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
219513403|NCT01274416|BEHAVIORAL|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
219513404|NCT04194866|OTHER|receiving operation during the day or at night|120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
219513405|NCT03386422|BEHAVIORAL|MSC|Mindfulness and Self-Compassion training
219513406|NCT03386422|BEHAVIORAL|CBT|Cognitive-behavioural techniques training
219513407|NCT02458638|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
219513408|NCT01908127|BEHAVIORAL|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
219513409|NCT01908127|BEHAVIORAL|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
219513410|NCT01908127|DRUG|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
219513411|NCT01908127|PROCEDURE|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
219513412|NCT04617665|OTHER|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
219513413|NCT04617665|OTHER|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
219513414|NCT05116020|OTHER|Usual chiropractic care|Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
219513415|NCT02296580|DEVICE|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
219513416|NCT02215694|DIETARY_SUPPLEMENT|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
219513417|NCT02215694|DIETARY_SUPPLEMENT|placebo|2g of powder daily without probiotics
219513418|NCT03408366|PROCEDURE|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
219513419|NCT03408366|OTHER|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
219513420|NCT03408366|OTHER|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
219513421|NCT03495648|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
219513422|NCT04409665|DRUG|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
219513423|NCT04409665|DRUG|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
219513424|NCT01290939|BIOLOGICAL|bevacizumab|
219513425|NCT01290939|DRUG|lomustine|
219513426|NCT01290939|GENETIC|DNA methylation analysis|
219513427|NCT01290939|OTHER|laboratory biomarker analysis|
219513428|NCT01290939|PROCEDURE|cognitive assessment|
219513429|NCT01290939|PROCEDURE|quality-of-life assessment|
219034739|NCT05929092|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
219034740|NCT02117375|DEVICE|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
219034741|NCT02117375|OTHER|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
219034742|NCT02117375|OTHER|brain MRI follow-up|
219034743|NCT03725189|DEVICE|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
219034744|NCT04445558|DIETARY_SUPPLEMENT|oral nutritional supplementation|Adjunction of oral nutritional supplementation
219034745|NCT04445558|DIETARY_SUPPLEMENT|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
219034746|NCT02985632|DRUG|BMS-986141|
219034747|NCT00661076|DRUG|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
219034748|NCT00661076|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
219034749|NCT05413252|OTHER|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
219034750|NCT01301872|OTHER|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
219034751|NCT02449239|BIOLOGICAL|Vicinium|Intravesical administration
219513430|NCT04177264|PROCEDURE|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
219034752|NCT02479152|DEVICE|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
219513431|NCT04177264|PROCEDURE|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
219609968|NCT02262455|DRUG|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
219609969|NCT02262455|DRUG|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
219034753|NCT03821558|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
219034754|NCT03244865|DEVICE|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
219034755|NCT04898751|DRUG|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
219034756|NCT03222843|DRUG|Hetrombopag Olamine|once daily
219034757|NCT03222843|DRUG|matching placebo|once daily
219034758|NCT04628312|OTHER|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
219513432|NCT04177264|PROCEDURE|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
219609970|NCT00442208|DRUG|PN 200|
219609971|NCT00074308|DRUG|imatinib mesylate|Given orally
219609972|NCT00074308|BIOLOGICAL|bevacizumab|Given IV
219609973|NCT00074308|OTHER|pharmacological study|Correlative studies
219609974|NCT00074308|OTHER|laboratory biomarker analysis|Correlative studies
219609975|NCT01910818|DEVICE|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
219609976|NCT01910818|OTHER|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
219609977|NCT03595956|OTHER|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
218893367|NCT05802589|PROCEDURE|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
219513433|NCT04177264|PROCEDURE|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
219513434|NCT04177264|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
219513435|NCT04177264|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
219609978|NCT04068493|BEHAVIORAL|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
219609979|NCT00614640|BIOLOGICAL|DermaVir patch|DNA Vaccine
219609980|NCT00614640|BIOLOGICAL|Placebo patch|10% dextrose (D-glucose) solution
219609981|NCT02543944|DRUG|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
218893368|NCT05802589|PROCEDURE|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
218893369|NCT05802589|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
218893370|NCT04734886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 + vitamin D|1 \* 10\^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
218893371|NCT04734886|DIETARY_SUPPLEMENT|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
218893372|NCT03164811|PROCEDURE|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
218893373|NCT03164811|OTHER|Controlled|standard fluid treatment by an anesthesiologist
218893374|NCT02492178|DRUG|Intrarectal artesunate|
218893375|NCT02492178|DRUG|Intravenous artesunate|
218893376|NCT02492178|DRUG|Intravenous quinine|
218893377|NCT04248699|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
218893378|NCT01552070|BEHAVIORAL|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
218893379|NCT01552070|OTHER|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
218893380|NCT00881738|DRUG|Clarithromycin 250 mg Tablets (Geneva, USA)|
218893381|NCT00881738|DRUG|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
218893382|NCT03793348|DEVICE|MCD|Micro coring skin removal with automated coring device
218893383|NCT04265014|OTHER|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
218893384|NCT04265014|OTHER|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
218893385|NCT03667755|PROCEDURE|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
218893386|NCT01454791|DRUG|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
219034759|NCT05620576|DRUG|LY3857210|Administered orally
219034760|NCT05620576|DRUG|Placebo|Administered orally
219034761|NCT00165490|DRUG|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
218893387|NCT01454791|OTHER|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
218893388|NCT04934371|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
219034762|NCT00165490|DRUG|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
219034763|NCT00165490|DRUG|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
219034764|NCT00165490|DEVICE|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
219513436|NCT06141096|DRUG|MB07133|Evaluate the effectiveness and safety of different doses of MB07133
219513437|NCT00600795|OTHER|CSF collection|CSF collection at time of VPS insertion
219513438|NCT05197712|BIOLOGICAL|25 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
219513439|NCT05197712|BIOLOGICAL|50 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
219513440|NCT01479881|DRUG|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
218893389|NCT04934371|DEVICE|Sham TDCS|Sham control will be administered to the same area as active TDCS
219034765|NCT00165490|PROCEDURE|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
219513441|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
219513442|NCT01479881|DRUG|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
219513443|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
219513444|NCT05056181|OTHER|Physical Activity|Physical activity
219513445|NCT00390312|DRUG|Intranasal Placebo|Intranasal placebo
219513446|NCT00390312|DRUG|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
219513447|NCT00390312|DRUG|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
219513448|NCT00390312|DRUG|Intravenous morphine|Intravenous morphine 7.5 mg
219513449|NCT00390312|DRUG|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
219513450|NCT00390312|DRUG|Oral placebo|Oral placebo
219513451|NCT00390312|DRUG|Intravenous placebo|Intravenous placebo
219513452|NCT00648323|DRUG|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
219513453|NCT05209646|DIETARY_SUPPLEMENT|Bee honey|patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
219513454|NCT03528408|DRUG|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
219034766|NCT04702087|DIETARY_SUPPLEMENT|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
219034767|NCT04702087|COMBINATION_PRODUCT|Placebo|Isocaloric formula
219034768|NCT03817619|DRUG|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
219034769|NCT03817619|DRUG|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
219034770|NCT03367143|DRUG|Lenalidomide|
219513455|NCT03528408|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
219513456|NCT03711955|OTHER|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
219609982|NCT02543944|DRUG|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
219609983|NCT02543944|DRUG|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
219609984|NCT02543944|DRUG|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
219609985|NCT02543944|DRUG|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
219609986|NCT02543944|DRUG|Placebo|Microcrystalline cellulose
219609987|NCT00172029|DRUG|Zoledronic acid|
219609988|NCT01612065|DRUG|Misoprostol|200 ug
219609989|NCT01612065|DRUG|Misoprostol|Misoprostol vaginally, 400 ug
219609990|NCT04555434|DIETARY_SUPPLEMENT|Probiotics|"* Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose"
218893390|NCT06371105|OTHER|10-week water-based aerobic training|The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
218893391|NCT01467505|DRUG|Telaprevir|Tablet
218893392|NCT01467505|DRUG|Ribavirin|Tablet
218893393|NCT01467505|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
219034771|NCT03367143|DRUG|Ifosfamide|
219034772|NCT03367143|DRUG|Carboplatin|
219034773|NCT03367143|DRUG|Etoposide|
219034774|NCT02464202|OTHER|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
219034775|NCT02721316|OTHER|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
219034776|NCT01510119|DRUG|Hydroxychloroquine|
219513457|NCT05760664|OTHER|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
219513458|NCT05760664|OTHER|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
219609991|NCT03266796|BEHAVIORAL|goal setting process|goal setting process during the first consultation
219609992|NCT06191588|PROCEDURE|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
219609993|NCT04163965|DEVICE|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
219609994|NCT00149474|BEHAVIORAL|Peak Flow Monitoring|
219609995|NCT03347201|DEVICE|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
219609996|NCT02766114|PROCEDURE|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
219609997|NCT04001036|DRUG|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
219609998|NCT04001036|DRUG|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
219609999|NCT05924321|DRUG|Carbetocin|Single infusion of Carbetocin
218893394|NCT01467505|DRUG|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
218893395|NCT01229189|DIETARY_SUPPLEMENT|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
219513459|NCT05760664|OTHER|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
219513460|NCT02236338|PROCEDURE|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
219513461|NCT02236338|DEVICE|ClosureFAST radiofrequency catheter|
219513462|NCT02236338|DEVICE|EVLT 980nm diode laser system|
219513463|NCT05095064|DRUG|Onivyde® + 5-FULV|Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
219513464|NCT01645384|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
219513465|NCT02966379|DEVICE|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point"
219513466|NCT02577159|DRUG|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
219513467|NCT01202006|OTHER|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
219513468|NCT03169959|DRUG|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
219513469|NCT03169959|DRUG|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
219513470|NCT03169959|DRUG|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
219513471|NCT03169959|DRUG|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
218893396|NCT01229189|DIETARY_SUPPLEMENT|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
218893397|NCT02102295|DRUG|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
219610000|NCT05924321|DRUG|Placebo|Single IV infusion of matching placebo
219610001|NCT05924321|DRUG|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
218893398|NCT02102295|DRUG|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
218893399|NCT03870295|DIAGNOSTIC_TEST|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
218893400|NCT06027203|PROCEDURE|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
218893401|NCT03826121|DIETARY_SUPPLEMENT|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
218893402|NCT03826121|DIETARY_SUPPLEMENT|placebo|placebo for 12 weeks.
218893403|NCT06261177|DEVICE|Functional Electrical Stimulation (FES)|45 mins per day for the duration of 4 weeks (20 sessions).
218893404|NCT06261177|DEVICE|Sham FES|Sham FES
218893405|NCT00972192|BEHAVIORAL|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
219034777|NCT01510119|DRUG|RAD001|
218893406|NCT00972192|BEHAVIORAL|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
219034778|NCT02262481|DRUG|dydrogesterone|
219034779|NCT02262481|DRUG|placebo|
219034780|NCT02769416|OTHER|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
218893407|NCT00792012|RADIATION|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
219513472|NCT03169959|DRUG|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
219610002|NCT00200902|DRUG|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
218893408|NCT00792012|DRUG|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
218893409|NCT03449758|DRUG|SARILUMAB|Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
219610003|NCT00200902|OTHER|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
219610004|NCT00200902|BEHAVIORAL|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
219610005|NCT00470535|DRUG|erlotinib hydrochloride|Oral
219610006|NCT00470535|OTHER|immunohistochemistry staining method|Correlative Study
219610007|NCT00470535|OTHER|laboratory biomarker analysis|Correlative Study
218893410|NCT03449758|DRUG|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
218893411|NCT03449758|DRUG|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
218893412|NCT03449758|DRUG|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
218893413|NCT03449758|DRUG|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
219034781|NCT02029651|DEVICE|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
218893414|NCT03449758|DRUG|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
218893415|NCT03449758|DRUG|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
218893416|NCT03601260|DRUG|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
219034782|NCT02029651|PROCEDURE|Conventional occupational therapy|conventional occupational therapy
219034783|NCT02811939|DRUG|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
219034784|NCT02811939|DRUG|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
218893417|NCT03864939|DRUG|dHAM|A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
218893418|NCT03864939|DRUG|No dHAM|A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
218893419|NCT05036174|DRUG|Diphenhydramine 5%|Diphenhydramine 5% ointment
218893420|NCT05036174|DRUG|Placebo|Placebo matched to diphenhydramine 5% ointment
218893421|NCT06344728|DRUG|Brensocatib Oral Solution|Brensocatib solution
219034785|NCT02811939|DRUG|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
219034786|NCT02811939|DRUG|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
219034787|NCT01855295|DIETARY_SUPPLEMENT|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
218893422|NCT06344728|DRUG|Brensocatib Oral Tablet|Brensocatib tablet
218893423|NCT05062005|DRUG|Induction Chemotherapy|Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
218893424|NCT05062005|DRUG|Concurrent Chemotherapy|Cisplatin 100 mg/m², Q3w.
218893425|NCT05062005|RADIATION|Definitive Radiotherapy|For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
219513473|NCT03169959|DRUG|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
219513474|NCT02659852|PROCEDURE|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
219513475|NCT02659852|PROCEDURE|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
219513476|NCT01521442|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
219513477|NCT01521442|BEHAVIORAL|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
219513478|NCT00949299|DRUG|buprenorphine|intradermal injection
219513479|NCT06454006|DEVICE|Placebo PBMT-sMF|Placebo, without therapeutic dose.
219513480|NCT06454006|DEVICE|Active PBMT-sMF|Active with a dose of 31.50 J per site.
219513481|NCT00006052|DRUG|imatinib mesylate|
219513482|NCT04184037|BEHAVIORAL|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR\_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
219513483|NCT00135707|DRUG|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
219513484|NCT00135707|DRUG|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
219513485|NCT01918878|DRUG|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
219513486|NCT03129477|PROCEDURE|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
218893426|NCT06056492|BEHAVIORAL|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
218893427|NCT06138769|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day
218893428|NCT00001499|DRUG|paclitaxel|
218893429|NCT00001499|DRUG|cisplatin|
218893430|NCT00001499|PROCEDURE|chest radiotherapy|
218893431|NCT04084717|DRUG|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
218893432|NCT04391114|PROCEDURE|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
219034788|NCT02622828|BEHAVIORAL|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
219034789|NCT00983554|DRUG|Anastrazole|Arimidex 1mg daily
219513487|NCT03093454|DRUG|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
219513488|NCT00278694|DRUG|Oxaliplatin|
219513489|NCT00278694|DRUG|Chemoradiation|
219513490|NCT00278694|DRUG|5-FU|
219513491|NCT00278694|RADIATION|Preoperative chemoradiation|
219513492|NCT00278694|PROCEDURE|Pelvic surgery|
219513493|NCT00278694|DRUG|Neoadjuvant oxaliplatin|
218893433|NCT04391114|PROCEDURE|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
218893434|NCT02196935|OTHER|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
219034790|NCT00983554|DRUG|Testosterone|Testim 10g daily
219034791|NCT00983554|DRUG|Dutasteride|Avodart 2.5mg daily
219513494|NCT05522010|PROCEDURE|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
219513495|NCT02353130|DRUG|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
219034792|NCT00983554|DRUG|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
219034793|NCT03303833|OTHER|No intervention, observational study.|
219513496|NCT00100165|DRUG|Placebo|Placebo by mouth twice a day for 4 weeks
219610008|NCT06382532|DIAGNOSTIC_TEST|Niacin skin reaction test|Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
218893435|NCT01387841|BEHAVIORAL|yoga|Postures,relaxation techniques
218893436|NCT01387841|BEHAVIORAL|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
218893437|NCT02619474|OTHER|Whiteboard|"1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
218893438|NCT00254319|DRUG|Avastin, Alimta|
218893439|NCT04510649|DRUG|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
218893440|NCT04510649|DRUG|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
218893441|NCT04722874|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
218893442|NCT04722874|DEVICE|RLRL|RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
218893443|NCT00524277|BIOLOGICAL|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
218893444|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
218893445|NCT00524277|BIOLOGICAL|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
218893446|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
218893447|NCT02788344|OTHER|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
218893448|NCT03973216|BEHAVIORAL|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
218893449|NCT01322100|DEVICE|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
218893450|NCT01322100|DRUG|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
219034794|NCT04760158|OTHER|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
219034795|NCT01735656|DEVICE|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
219034796|NCT03171454|PROCEDURE|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
218893451|NCT04844736|PROCEDURE|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
219513497|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
219513498|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 75 mg|3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
219513499|NCT04540497|DRUG|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
219513500|NCT04540497|OTHER|Placebo|Placebo
219513501|NCT06547580|OTHER|Group-based PFMT|Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.
219513502|NCT06547580|OTHER|Individualized PFMT|Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
219513503|NCT02042391|DRUG|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
219513504|NCT02042391|DRUG|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
219513505|NCT02042391|DRUG|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
219513506|NCT02042391|DRUG|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
219513507|NCT02850068|DEVICE|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
219513508|NCT02287168|PROCEDURE|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
219513509|NCT02287168|PROCEDURE|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
219513510|NCT02287168|PROCEDURE|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
219610009|NCT04648787|BEHAVIORAL|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
219610010|NCT04648787|BEHAVIORAL|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
218893452|NCT00610402|OTHER|blood sample tear drop sample|blood sample tear drop sample
218893453|NCT05539885|PROCEDURE|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
219034797|NCT03171454|PROCEDURE|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
219034798|NCT03592433|BEHAVIORAL|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
219034799|NCT02189564|BEHAVIORAL|Feedback about good performance|
219034800|NCT02189564|BEHAVIORAL|Feedback about good performance + money|
219034801|NCT02189564|BEHAVIORAL|Feedback about average performance|
219034802|NCT06197594|OTHER|Proprioceptive neuromuscular facilitation techniques|Proprioceptive neuromuscular facilitation techniques
218893454|NCT05539885|PROCEDURE|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
218893455|NCT00003575|BIOLOGICAL|filgrastim|
218893456|NCT00003575|BIOLOGICAL|recombinant interleukin-12|
219034803|NCT06197594|OTHER|Rebound Therapy|Rebound Therapy
219034804|NCT06163248|OTHER|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
219513511|NCT04325074|OTHER|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
219513512|NCT04325074|OTHER|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
219513513|NCT04325074|OTHER|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
219513514|NCT03688230|DRUG|abituzumab|1000 mg IV
219513515|NCT03688230|COMBINATION_PRODUCT|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
219513516|NCT05166330|DRUG|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
219513517|NCT05166330|DRUG|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
219513518|NCT01681030|BIOLOGICAL|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
219513519|NCT01681030|BIOLOGICAL|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
219513520|NCT01681030|OTHER|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
219513521|NCT05263648|OTHER|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
219610011|NCT06392529|DRUG|Voriconazole Powder|The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
219610012|NCT02531529|DRUG|dexmedetomedine|intraoperative infusion
219610013|NCT02531529|DRUG|Fentanyl|
219610014|NCT06551792|OTHER|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection
219610015|NCT01299012|DRUG|Liraglutide|Liraglutide s/c 0.6mg once daily.
218893457|NCT00003575|DRUG|etoposide|
218893458|NCT00003575|DRUG|ifosfamide|
219610016|NCT05688917|DIETARY_SUPPLEMENT|Green coffee been extract|supportive treatment
219610017|NCT05688917|OTHER|Placebo|Placebo capsule
219610018|NCT04463758|OTHER|An auto-questionnaire comprising three psychometric scales|"three psychometric scales validated in French: \_depression (Edinburgh Postpartum Depression Scale (EPDS)), anxiety (State-Trait Anxiety Inventory (STAI)~\- and Impact of Event Scale (Revised) (IES-R)"
219610019|NCT03348332|BEHAVIORAL|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
219610020|NCT00308178|DRUG|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
218893459|NCT05120427|DIETARY_SUPPLEMENT|Lipid based nutrient Supplements (LNS):|LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
219034805|NCT06163248|OTHER|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
219034806|NCT04460222|PROCEDURE|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
219513522|NCT03845920|COMBINATION_PRODUCT|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
219513523|NCT00760058|DEVICE|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
218893460|NCT05120427|DEVICE|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
219513524|NCT00760058|DEVICE|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
218893461|NCT04773119|PROCEDURE|PVI only|Patients in this group receive PVI only
218893462|NCT04773119|PROCEDURE|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
218893463|NCT00948753|DRUG|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
218893464|NCT00948753|DRUG|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
218893465|NCT00948753|DRUG|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
219034807|NCT04460222|PROCEDURE|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
219513525|NCT00760058|DEVICE|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
219513526|NCT00000563|DRUG|dexamethasone|
219513527|NCT00003696|DRUG|carboplatin|
218893466|NCT00799682|DRUG|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
219034808|NCT01723163|BEHAVIORAL|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
219034809|NCT01723163|BEHAVIORAL|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
219513528|NCT00003696|DRUG|cyclophosphamide|
219513529|NCT00003696|DRUG|doxorubicin hydrochloride|
219513530|NCT00003696|DRUG|etoposide|
219513531|NCT00003696|DRUG|paclitaxel|
219513532|NCT04566835|OTHER|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
219513533|NCT04566835|BEHAVIORAL|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
218893467|NCT00799682|DRUG|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
218893468|NCT02727218|PROCEDURE|Chest tube removal|chest tube removal post thoracoscopic surgery
219034810|NCT00779012|BIOLOGICAL|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
219034811|NCT03549702|DRUG|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
219513534|NCT02524379|DRUG|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
218893469|NCT00731419|DEVICE|SEMS|Comparing plastic and metal stents
218893470|NCT00269971|DRUG|epoetin alfa|
218893471|NCT04473209|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
218893472|NCT00893958|DRUG|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
218893473|NCT01867749|BEHAVIORAL|Group Interpersonal Psychotherapy (IPT-G)|
218893474|NCT01867749|BEHAVIORAL|Coping with Depression (CWD)|
219513535|NCT03996603|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
219513536|NCT00003584|DRUG|estramustine phosphate sodium|
219513537|NCT00003584|DRUG|prednisone|
219513538|NCT00003584|DRUG|vinorelbine tartrate|
219513539|NCT01269970|OTHER|18-FDG-PET-CT|
219513540|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 1472 mcg, single dose
219513541|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 736 mcg, single dose
219513542|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 368 mcg, single dose
219513543|NCT00783406|DRUG|Placebo|Placebo
219513544|NCT00197275|BIOLOGICAL|Hib-MenAC mixed with Tritanrix™-HepB|
218893475|NCT03464747|DEVICE|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
219513545|NCT02270788|DRUG|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
219513546|NCT02270788|DRUG|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
219513547|NCT02270788|DRUG|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
219513548|NCT02046928|DRUG|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
219513549|NCT01390883|DRUG|Fondaparinux Sodium|
219513550|NCT04172389|PROCEDURE|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
219610021|NCT04658134|DIETARY_SUPPLEMENT|Glycine|Oral glycine tablets (100 mg/kg/day) in divided doses
219610022|NCT00186732|PROCEDURE|Subcuticular Suture|
219610023|NCT00186732|PROCEDURE|Surgical Staples|
219610024|NCT05262387|DRUG|Lyumjev with 50% basal rate reduction|Administered SC.
218893476|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
219513551|NCT01855724|DRUG|Gemcitabine-Pazopanib|
219513552|NCT04954950|OTHER|no intervention|no intervention
219513553|NCT01290263|DRUG|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
219513554|NCT01290263|DRUG|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
219513555|NCT05273619|DRUG|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
219513556|NCT05273619|DRUG|Placebo|4 tablets twice a day
219513557|NCT02707536|PROCEDURE|Socket grafting with PRF|Extraction with socket grafting using PRF.
219513558|NCT02707536|PROCEDURE|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
219513559|NCT04448665|DIAGNOSTIC_TEST|microbiological investigation|a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
219610025|NCT05262387|DRUG|Humalog with 50% basal rate reduction|Administered SC.
219610026|NCT05262387|DRUG|Humalog with 100% basal rate reduction|Administered SC.
218893477|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
219513560|NCT04700449|DRUG|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
219513561|NCT04700449|DRUG|Double-Blind Placebo|Placebo capsule oral administration
219513562|NCT04700449|DRUG|Open-label CBP-307|0.2 mg capsule oral administration
219610027|NCT05262387|DRUG|Lyumjev with 100% basal rate reduction|Administered SC.
219610028|NCT01669187|OTHER|Education brochure|
219610029|NCT01669187|OTHER|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
219610030|NCT02941471|DEVICE|Interferential Stimulation|Transabdominal interferential electrcial stimulation
218893478|NCT04208308|DIETARY_SUPPLEMENT|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
219513563|NCT04700449|DRUG|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
219513564|NCT03738332|DEVICE|Low-Level Laser|Low-level laser therapy
219513565|NCT01521559|PROCEDURE|Macular Laser Photocoagulation|
219513566|NCT01521559|DRUG|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
219513567|NCT03543956|BEHAVIORAL|Questionnaire|Questionnaire
219513568|NCT00027807|BIOLOGICAL|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
219513569|NCT00027807|BIOLOGICAL|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
219513570|NCT00027807|BIOLOGICAL|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
219610031|NCT02941471|DEVICE|TENS stimulation|Transabdominal standard electrical stimulation
219610032|NCT06128161|DEVICE|Hearing Aid|Contralateral Hearing Aid to Cochlear Implant
219610033|NCT01437293|DRUG|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
219610034|NCT02070965|DRUG|DFD01 Spray|
219610035|NCT02070965|DRUG|Comp01 Lotion|
218893479|NCT04208308|DIETARY_SUPPLEMENT|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
218893480|NCT04201665|DRUG|Carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
218893481|NCT04201665|DRUG|Oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
218893482|NCT03279029|BIOLOGICAL|blood samples|blood samples
219034812|NCT05677620|RADIATION|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
218893483|NCT03279029|BIOLOGICAL|biopsy|biopsy of aortic valve
218893484|NCT04183374|OTHER|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
218893485|NCT00313417|DIETARY_SUPPLEMENT|Creatine monohydrate|Up to 10 grams
219513571|NCT06408909|BEHAVIORAL|Clinical Pharmacist Intervention Group|Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
219513572|NCT03558477|DRUG|YYD601 1|YYD601 1
219513573|NCT03558477|DRUG|YYD601 2|YYD601 2
219513574|NCT03558477|DRUG|YYD601 3|YYD601 3
219513575|NCT03558477|DRUG|Nexium|Nexium
219513576|NCT06483945|DEVICE|Dexcom CGM G6/G6 Pro/G7|Dexcom CGM G6/G6 Pro/G7 device
219513577|NCT00356798|BIOLOGICAL|an inactivated whole virion H5N1 vaccine, adjuvanted|
219513578|NCT01190969|DIETARY_SUPPLEMENT|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
219513579|NCT06003920|BEHAVIORAL|Process group|The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
219513580|NCT04447638|PROCEDURE|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
219513581|NCT03312062|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
219610036|NCT00055731|DRUG|bicalutamide|
219610037|NCT00055731|DRUG|Goserelin Acetate|
219610038|NCT00055731|DRUG|docetaxel|
219610039|NCT00055731|DRUG|Estramustine phosphate sodium|
219610040|NCT00055731|DRUG|acetylsalicylic acid|
219610041|NCT00055731|PROCEDURE|conventional surgery|
219610042|NCT00055731|RADIATION|radiation therapy|
218893486|NCT00313417|OTHER|Placebo|Placebo will be given in the same way and appearance as the active treatment
218893487|NCT05751746|DRUG|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
218893488|NCT04327102|BEHAVIORAL|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
219034813|NCT05677620|DRUG|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
219513582|NCT02228382|DRUG|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
219513583|NCT00315874|DRUG|Buprenorphine transdermal delivery system|
219513584|NCT04360031|DRUG|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
219513585|NCT02337465|DEVICE|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
219513586|NCT02337465|RADIATION|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
219513587|NCT04154748|DEVICE|Argon Plasma Coagulation 90W power|
219513588|NCT04154748|DEVICE|Argon Plasma Coagulation 60W power|
219513589|NCT04154748|DRUG|Omeprazole 120 mg|
219513590|NCT04154748|DRUG|Omeprazole 40 mg|
219513591|NCT02407444|OTHER|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
219513592|NCT02407444|OTHER|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
219513593|NCT03996486|DRUG|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
219513594|NCT03726463|PROCEDURE|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
219513595|NCT05883410|OTHER|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
219513596|NCT05883410|OTHER|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
219513597|NCT05883410|OTHER|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
219513598|NCT02531984|DRUG|Azithromycin|
219513599|NCT06236737|OTHER|Sensorimotor Exercise|The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.
219513600|NCT06236737|OTHER|Yoga Exercise|A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
219513601|NCT00099528|DRUG|REN-1654|
219513602|NCT02132247|DRUG|Diclofenac hydroxyethylpyrrolidine|
219513603|NCT02932254|DRUG|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
219513604|NCT02932254|DRUG|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
219513605|NCT00658398|BEHAVIORAL|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
219513606|NCT01189825|BEHAVIORAL|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
219034814|NCT05677620|DEVICE|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
219034815|NCT00751816|DRUG|systemic chemotherapy|
219034816|NCT00751816|OTHER|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
219513607|NCT06109103|PROCEDURE|telerehabilitation-based motor imagery training|"Motor imagery is defined as the mental thinking of a movement without actual movement being revealed. Many of the currently available physiotherapy and rehabilitation approaches are designed to stimulate damaged motor neural connections through neuroplasticity.~based on real movements. Studies have shown that similar brain regions are activated during motor imagery and real movement. By repeatedly visualizing the same movement, people can improve their motor activity skills such as lifting weights, playing the piano or performing surgery. These findings suggest that motor imagery provides motor learning by strengthening synaptic connections depending on activity."
219513608|NCT06109103|PROCEDURE|telerehabilitation-based physiotheraphy training|The telerehabilitation application will be carried out by video conference method, one of the image-based telerehabilitation technologies. The telerehabilitation-based physiotherapy program will be administered to both Group 1 and Group 2 children by a physiotherapist experienced in the physiotherapy of neuromuscular diseases, excluding the researchers who performed the randomization and evaluations.
219513609|NCT00437242|DRUG|Odiparcil|
219513610|NCT02404948|OTHER|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
219513611|NCT04736992|OTHER|No intervention involved|No intervention involved
219513612|NCT00359086|DRUG|MGCD0103|MGCD0103 given orally three times per week
219513613|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
219513614|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
219513615|NCT00348010|DRUG|Tramadol HCl ER|
219513616|NCT05111821|PROCEDURE|Magnetic Resonance Imaging (MRI)|Quantification of iron will be performed through Magnetic Resonance Imaging
219513617|NCT05111821|DRUG|Deferiprone treatment|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
219513618|NCT01913990|DRUG|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
219513619|NCT01913990|OTHER|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
219513620|NCT04910490|OTHER|No interventions - retrospective data collection|No new/additional patients will be enrolled within this project.
219513621|NCT04858100|PROCEDURE|Surgical excision of the lesion|"The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case."
219513622|NCT04858100|OTHER|Wait and see approach|"The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression."
219513623|NCT04332978|DRUG|Fluticasone Propionate|
219610043|NCT03256604|DIAGNOSTIC_TEST|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
219034817|NCT00751816|PROCEDURE|adjuvant therapy|
219513624|NCT04596956|DRUG|sodium bicarbonate Ringer injection|Used in surgery
219513625|NCT04596956|DRUG|Lactated Ringer's solution|Used in surgery
219513626|NCT01079637|PROCEDURE|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
219513627|NCT01079637|PROCEDURE|Cast treatment|Cast treatment
219513628|NCT02750761|DRUG|Tedizolid Phosphate (IV)|200 mg/vial powder for injection
219513629|NCT02750761|DRUG|Tedizolid Phosphate (oral suspension)|Powder for oral suspension 20 mg/mL following reconstitution
219513630|NCT02715947|DRUG|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
219034818|NCT00751816|PROCEDURE|management of therapy complications|
219034819|NCT00751816|PROCEDURE|musculoskeletal complications management/prevention|
219034820|NCT00751816|PROCEDURE|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
219034821|NCT00751816|RADIATION|radiation therapy|
219034822|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
219034823|NCT03430804|OTHER|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
219034824|NCT04111094|DIAGNOSTIC_TEST|No intervention|No intervention
219034825|NCT05547321|DRUG|OMTX705|The investigational product is OMTX705 administered as monotherapy.
219034826|NCT05547321|DRUG|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
219610044|NCT05523115|DIETARY_SUPPLEMENT|Heights Smart Supplement|"The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate"
219513631|NCT01451853|DRUG|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
219513632|NCT01451853|DRUG|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
219513633|NCT01451853|DRUG|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
219513634|NCT01451853|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
219513635|NCT05875818|DIAGNOSTIC_TEST|In-clinic Rehabilitation|Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
219513636|NCT05875818|DIAGNOSTIC_TEST|Tele-rehabilitation|Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
219513637|NCT02498548|BEHAVIORAL|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
219513638|NCT00795665|DRUG|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
219513639|NCT00795665|DRUG|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
219513640|NCT01270750|DRUG|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
219513641|NCT05184049|DRUG|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
219513642|NCT05184049|DRUG|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
219513643|NCT04908566|DRUG|PD-1 antibody combined with FOLFIRINOX regimen|Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
219513644|NCT04908566|DRUG|PD-1 antibody combined with SOX program|"Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles."
219513645|NCT03627936|DRUG|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
219513646|NCT03627936|DRUG|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
219513647|NCT03256799|DRUG|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
219513648|NCT00279721|PROCEDURE|IMRT|
219513649|NCT02354586|DRUG|Niraparib|
219513650|NCT05004428|OTHER|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
219513651|NCT02627742|DEVICE|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
219513652|NCT04981899|DRUG|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
219610045|NCT03693417|DEVICE|Heated circuit on|Heated circuit will be turned on.
219610046|NCT03693417|DEVICE|Heated circuit off|Heated circuit will be turned off.
219610047|NCT04756947|PROCEDURE|surgical treatment according to standard indication criteria|internal fixation according to standard indication criteria
219034827|NCT00382811|DRUG|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
219034828|NCT00382811|DRUG|carboplatin|AUC=2 weekly in 28 day cycles
219034829|NCT00382811|DRUG|placebo|every 8 hours daily in 28 day cycles
219034830|NCT00802022|DEVICE|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
219034831|NCT01963390|DRUG|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
219034832|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
218893489|NCT05217160|DRUG|KeraStat® Gel with Morphine application|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes."
218893490|NCT05217160|DRUG|KeraStat® Gel application|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes."
218893491|NCT00922623|DEVICE|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
218893492|NCT00723307|DRUG|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
218893493|NCT00723307|DRUG|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
218893494|NCT04424667|OTHER|donor milk|pasteurized donor milk
218893495|NCT04709042|PROCEDURE|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
218893496|NCT04709042|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
219610048|NCT04756947|PROCEDURE|conservative treatment according to standard indication criteria|conservative therapy according to standard indication criteria
219610049|NCT00771498|DRUG|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
218893497|NCT01088334|OTHER|screening|CT-Chest/abdomen and mammography in women
219034833|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
219034834|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
219034835|NCT05455983|BIOLOGICAL|covid19 vaccines|different types of (COVID-19) vaccination
219034836|NCT05526872|OTHER|Best Practice|Receive usual care
219034837|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
219034838|NCT05526872|OTHER|Interview|Ancillary studies
219513653|NCT04981899|DRUG|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
219513654|NCT04981899|DRUG|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
219034839|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
219513655|NCT04981899|DRUG|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
219513656|NCT01208558|BEHAVIORAL|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
219610050|NCT02515331|DRUG|LHW090|Capsule - oral dose
219610051|NCT02515331|DRUG|Placebo|Capsule - oral dose
219610052|NCT06551597|PROCEDURE|Extremely low frequency electromagnetic fields stimulation|"* In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation."
219610053|NCT00124748|DRUG|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
219610054|NCT03942601|DRUG|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
219610055|NCT03942601|DRUG|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
219610056|NCT05125640|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Orally, with 240 mL of water at dosing in sitting position
219513657|NCT01208558|BEHAVIORAL|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
218893498|NCT01402817|DRUG|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
218893499|NCT00314639|DRUG|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
219610057|NCT05125640|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Orally, with 240 mL of water at dosing in sitting position
219610058|NCT03684850|OTHER|Home-based exercise|Home-based exercises three times per week.
219610059|NCT03684850|DEVICE|Knee brace|Progressive use of knee brace each day during activities of daily living.
218893500|NCT01179581|DRUG|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
218893501|NCT01179581|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
218893502|NCT01179581|DRUG|GLPG0634|multiple dose, capsule, 10 days
218893503|NCT01179581|DRUG|placebo|multiple dose, capsule, 10 days
219513658|NCT01208558|BEHAVIORAL|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
219610060|NCT03684850|DEVICE|Biomechanical footwear device|Progressive use of footwear each day during activities of daily living.
219610061|NCT04069650|PROCEDURE|Free flap|Free flap reconstruction of the oral cavity
219610062|NCT02801123|BEHAVIORAL|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
219610063|NCT02801123|BEHAVIORAL|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
219610064|NCT04582032|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
219610065|NCT04582032|DRUG|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
218893504|NCT03708107|DEVICE|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
218893505|NCT03708107|OTHER|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
219034840|NCT05526872|OTHER|Survey Administration|Ancillary studies
219034841|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
219034842|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
219610066|NCT06195137|DIETARY_SUPPLEMENT|Caffeine|caffeine supplementation
219610067|NCT06195137|DRUG|Alpha Lipoic Acid|600-800 mg ALA
219610068|NCT01186237|PROCEDURE|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
218893506|NCT03056417|BEHAVIORAL|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
218893507|NCT05640440|DIAGNOSTIC_TEST|Executive function testing|Assessment of executive function subdivision
218893508|NCT01907464|OTHER|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
219513659|NCT04207281|DIETARY_SUPPLEMENT|Raw Honey|Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
219513660|NCT04207281|DIETARY_SUPPLEMENT|Comparator|Honey comparator(1.5 tablespoons) administered for 7 days
219513661|NCT00634907|GENETIC|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
219610069|NCT06583252|DEVICE|multimodal monitoring cluster management|All patients will be monitored for baseline TCD at admission and at least once a day during treatment to assess changes in cerebral blood flow dynamics. Brain Oxygen Monitoring, Equipment \&amp;amp; Frequency: Continuous monitoring of partial pressure of oxygen (PbtO2) in brain tissue using near-infrared spectroscopy (NIRS). qEEG monitoring，Frequency and timing of monitoring. Baseline monitoring: All patients will undergo a baseline qEEG test at the time of admission. Continuous monitoring: In the ICU, for critically ill patients, qEEG will be performed continuously to monitor changes in EEG activity in real time. Monitoring brain activity: qEEG is able to detect subtle changes in brain waves that can be used to assess brain functional status, such as EEG quiescence, abnormal electrical discharges (e.g., epileptiform activity), etc. Abnormal parameters: focus on abnormal rhythms (e.g., high-amplitude slow-wave activity), acute asymmetric activity, and epileptiform discharge.
219610070|NCT05079048|OTHER|PEEK retentive elements|received implant-supported mandibular overdenture retained by PEEK retentive element and housings
218893509|NCT01907464|OTHER|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
218893510|NCT01907464|OTHER|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
218893511|NCT01907464|OTHER|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
218893512|NCT00086047|BEHAVIORAL|Coping Skills Training|8 weekly sessions of behavioral treatment
218893513|NCT00086047|BEHAVIORAL|Education|8 weekly sessions of fibromyalgia education
218893514|NCT00096421|BEHAVIORAL|Tight control of blood glucose levels|
219610071|NCT05626842|OTHER|Total Diet Replacement (800kcal/day)|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
219610072|NCT00379392|BEHAVIORAL|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
219610073|NCT00379392|PROCEDURE|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
219610074|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
219610075|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
219610076|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
219610077|NCT03889886|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
219610078|NCT06227039|OTHER|Vibroacoustic stimulation on|Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.
218893515|NCT00096421|BEHAVIORAL|Conventional control of glucose levels|
218893516|NCT01798966|DEVICE|SENSIMED Triggerfish|
218893517|NCT03558542|OTHER|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
218893518|NCT02471014|DRUG|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
218893519|NCT02471014|OTHER|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
218893520|NCT02471014|OTHER|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
218893521|NCT06095219|OTHER|Non- contrast Magnetic Resonance Imaging (MRI) of the hip|Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.
218893522|NCT06095219|OTHER|Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent|The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
218893523|NCT04551118|DEVICE|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
219513662|NCT00634907|OTHER|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
219513663|NCT06157307|DEVICE|Aortic compression|Aortic compression with four different methods on each participants
219513664|NCT02584140|BEHAVIORAL|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
219513665|NCT02584140|BEHAVIORAL|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
219513666|NCT02584140|DRUG|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
219513667|NCT01243554|BEHAVIORAL|Exercise|Exercise training at the hospital
219513668|NCT01787136|DRUG|Dextromethorphan|added on therapy
219513669|NCT04259177|OTHER|Scale|This test is divided into 3 sections: neurological examination, developmental motor boundary stones and behavioral status, and consists of a total of 37 items. The first part consists of 26 items such as cranial nerve functions, posture, quality, amount of movements, muscle tone, reflex and reactions. The second part evaluates motor development boundary stones consisting of 8 items. The third part refers to the behavioral condition consisting of 3 items. These items can be easily scored. It can be rated as optimal or inadequate. Each item is scored separately (as 0, 1, 2, 3) and the final total score is calculated. The total score ranges from 0-78. The total score shows the global optimal scores.
219513670|NCT06227975|DRUG|[14C]-BMS-986368|Specified dose on specified days
219513671|NCT01158365|DRUG|LACTIC ACID (Dermacid)|Route of administration: local
219513672|NCT01158365|DRUG|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
218893524|NCT04551118|DEVICE|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
218893525|NCT04551118|DEVICE|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
218893526|NCT05234047|PROCEDURE|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
218893527|NCT05234047|PROCEDURE|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
219610079|NCT06227039|OTHER|Augmented Reality on|Visual stimulus is provided through augmented reality glasses in the form of a game.
218893528|NCT06394986|PROCEDURE|Hemodialysis session|Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
218893529|NCT03321084|OTHER|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
218893530|NCT03321084|OTHER|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
218893531|NCT02098798|PROCEDURE|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
218893532|NCT02098798|PROCEDURE|HD Colonoscopy + iSCAN|
218893533|NCT02098798|PROCEDURE|HD Colonoscopy + dye spray|
219513673|NCT03439163|DEVICE|MRI scan|All participants underwent the MRI scan
219513674|NCT02309125|PROCEDURE|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
218893534|NCT02568761|PROCEDURE|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
218893535|NCT02568761|OTHER|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
218893536|NCT01914263|BIOLOGICAL|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
218893537|NCT03468244|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
218893538|NCT04809571|OTHER|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
219513675|NCT02309125|PROCEDURE|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
219513676|NCT02031848|OTHER|Diet Intervention|
219513677|NCT02031848|OTHER|Assessments and Diet Intake|
219610080|NCT06227039|OTHER|Vibroacoustic stimulation off|Vibroacoustic device is worn but turned off.
219610081|NCT06227039|OTHER|Augmented reality off|Augmented reality glasses are worn but turned off.
218893539|NCT03368365|DEVICE|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
218893540|NCT03767946|DIAGNOSTIC_TEST|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
219513678|NCT03256110|BEHAVIORAL|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
219513679|NCT01747603|OTHER|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
219610082|NCT05334030|DEVICE|High Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
219610083|NCT05334030|DEVICE|Neutral Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
219610084|NCT05334030|DEVICE|High Swing Resistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
219610085|NCT05334030|DEVICE|Max Trajectory Control|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - Bilateral;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
219610086|NCT03572686|DRUG|Ropivacaine 0.5% 20mL|In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.
219610087|NCT03572686|DRUG|Ropivacaine 0.25% 20ml|In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.
219610088|NCT03572686|DRUG|Ropivacaine 0.25% 20ml + dexamethasone 8mg|In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
219610089|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
219610090|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
219610091|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
219610092|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
219610093|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
219610094|NCT04176250|DRUG|HRZE|Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
219610095|NCT05175105|DRUG|Mitapivat|Tablets or granules
219610096|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
219610097|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
219610098|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
219513680|NCT00752323|DRUG|aminolevulinic acid|Given orally
219513681|NCT00752323|PROCEDURE|Surgical Resection|Surgical resection - 6 biopsies from 3 fluorescent regions
219513682|NCT05852548|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
218893541|NCT01172535|DRUG|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
218893542|NCT05487222|DEVICE|ICON|hemodynamics variability in response to different fluid regiemens
219034843|NCT02927028|OTHER|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
219034844|NCT02646696|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
219034845|NCT04377607|OTHER|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
219034846|NCT01421784|OTHER|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
219034847|NCT01277939|BEHAVIORAL|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
219513683|NCT01694485|BIOLOGICAL|Abrilumab|Administered by subcutaneous injection.
219513684|NCT01694485|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
219513685|NCT05608356|BIOLOGICAL|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
218893543|NCT04157777|OTHER|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
219513686|NCT05608356|DRUG|Sham Injection|Sham injection as a placebo injection
219513687|NCT01595009|DRUG|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
219513688|NCT03987152|DRUG|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
219513689|NCT04956666|DRUG|Lyophilized S95014|"Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015."
219513690|NCT00506909|DRUG|Oxytocin|20 IU BID or 40 IU BID
219513691|NCT00506909|DRUG|Placebo|20 IU BID or 40 IU BID
219513692|NCT03486977|PROCEDURE|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
219034848|NCT01277939|BEHAVIORAL|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
219513693|NCT03129269|PROCEDURE|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
219513694|NCT02724683|DEVICE|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
219513695|NCT02724683|BEHAVIORAL|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
219513696|NCT02724683|BEHAVIORAL|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
219513697|NCT02724683|DEVICE|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
219513698|NCT02724683|OTHER|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
219513699|NCT00436358|OTHER|Not applicable: none|Please refer to the detailed description section
219513700|NCT03172780|DRUG|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
219513701|NCT03172780|DRUG|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
219513702|NCT03172780|DRUG|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
219513703|NCT00662025|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
219513704|NCT00662025|DRUG|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
219513705|NCT01919632|BEHAVIORAL|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
219513706|NCT00029679|DRUG|Gingko biloba|
219513707|NCT00029679|DRUG|Borage oil|
219513708|NCT00355628|DRUG|KW-2246 (fentanyl citrate)|KW-2246
219513709|NCT00528242|DRUG|SLx-2101|
219513710|NCT00528242|DRUG|Placebo|
219513711|NCT00000391|DRUG|Peptide T|
219513712|NCT02010762|DRUG|Vitamin D|25.000 IU oral drops
219513713|NCT02010762|DRUG|Placebo|placebo oral drops
219513714|NCT05400876|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
219513715|NCT05400876|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
219513716|NCT06367400|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire|Questionnaire with 22 questions of symptoms of OSDB
219513717|NCT04631770|PROCEDURE|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
219513718|NCT04631770|PROCEDURE|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
219513719|NCT02780570|PROCEDURE|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
219513720|NCT01165671|RADIATION|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
219513721|NCT01165671|RADIATION|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
219513722|NCT00930488|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
219513723|NCT03179345|DRUG|Gabapentin|
219513724|NCT03179345|DRUG|Pregabalin|
219513725|NCT03179345|OTHER|Placebo|
219513726|NCT05521750|PROCEDURE|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
219513727|NCT02925065|OTHER|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
219513728|NCT00820625|PROCEDURE|pulmonary vein isolation|common pulmonary vein isolation procedure
219513729|NCT00820625|PROCEDURE|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
219513730|NCT05575414|BEHAVIORAL|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
219513731|NCT05575414|BEHAVIORAL|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
219513732|NCT00095290|DRUG|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
219513733|NCT00095290|DRUG|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
219513734|NCT04873674|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
219513735|NCT04873674|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219513736|NCT03824522|BIOLOGICAL|ADYNOVATE|Pegylated recombinant human factor VIII
219513737|NCT00418483|BIOLOGICAL|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513738|NCT00418483|BIOLOGICAL|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513739|NCT00418483|BIOLOGICAL|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513740|NCT00418483|BIOLOGICAL|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
219513741|NCT00418483|BIOLOGICAL|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513742|NCT00418483|BIOLOGICAL|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513743|NCT00418483|BIOLOGICAL|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
219513744|NCT06449079|OTHER|Machine learning|Analysis of data with machine learning methods
219513745|NCT02623790|OTHER|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
219513746|NCT02623790|OTHER|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
219513747|NCT02623790|OTHER|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
219513748|NCT02300025|DRUG|cobimetinib|single oral 10-mg dose of cobimetinib
219513749|NCT00626925|DRUG|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
219513750|NCT00626925|DRUG|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
218893544|NCT04371575|DRUG|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
218893545|NCT03008161|DRUG|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
218893546|NCT03008161|DRUG|Placebo|Placebo
218893547|NCT05800223|DRUG|Almonertinib|The dosage is 110 mg/day (2 tablets/day) orally once a day
218893548|NCT05800223|RADIATION|SBRT|SRT, 27Gy-40Gy/3-5f
218893549|NCT06006650|DRUG|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
218893550|NCT04977440|DIETARY_SUPPLEMENT|Whey protein|"Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given"
218893551|NCT05754723|BEHAVIORAL|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
218893552|NCT01683799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
218893553|NCT04256824|DRUG|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
219610099|NCT03277443|PROCEDURE|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
218893554|NCT04256824|DRUG|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
218893555|NCT00988598|DRUG|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
218893556|NCT00988598|DRUG|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
218893557|NCT04591938|DEVICE|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
218893558|NCT02347397|DEVICE|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem
218893559|NCT02347397|DEVICE|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
218893560|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR)|Imagery rescripting (IR) is a technique where the individual is instructed to imagine a negative memory or image as vividly as possible, and to change it in a direction that he/she desires. IR seems particularly efficient because it is based on the experienced emotions during perceptual information processing, thereby eliciting stronger emotional responses than verbal processing.
219513751|NCT05921058|DRUG|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
219513752|NCT05921058|DRUG|Placebo|NaCl 0,9% infusion
219513753|NCT01000740|GENETIC|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
219513754|NCT01000740|GENETIC|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
219513755|NCT01142843|DRUG|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
219513756|NCT02320357|DRUG|Treatment by clopidogrel|Peripheral blood will be obtained during the study
219513757|NCT01606566|DRUG|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
219513758|NCT00780026|DRUG|insulin|bolus or infusion 80 to 110 mg/dl
219513759|NCT05067257|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
219513760|NCT05067257|DRUG|Placebo|Vehicle solution
219513761|NCT04665076|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
219513762|NCT04665076|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
219513763|NCT04665076|PROCEDURE|Leukapheresis|Leukapheresis
218893561|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR) and Targeted Memory Reactivation (TMR) during sleep|Targeted Memory Reactivation (TMR) is a technique used to strengthen a memory trace during sleep. TMR is used to modify memory formation through the application of cues during sleep. In this TMR protocol, an olfactory cue is associated with the imagery rescripting (IR) during the day, and then administered during sleep. In that way, the replay of the associated memory and its corresponding neural representation in memory networks are artificially promoted, a procedure which usually strengthens memory consolidation. Previous studies have shown that TMR in sleep reduces emotional arousal, making it a promising technique for insomnia.
218893562|NCT06335784|BEHAVIORAL|Sleep Hygiene|Sleep hygiene education includes modifications in the behavior (e.g., exercise, coffee, alcohol intake) and environment (e.g., light, noise, temperature conditions) that offer to the individual the foundation for healthy sleep. Sleep hygiene is an important component in treating ID, but insufficient and less effective than CBT-I when offered alone.
218893563|NCT06335784|BEHAVIORAL|Sleep Hygiene + Odor|Sleep hygiene instructions will be applied in the presence of an odor, which will be also used during the night.
219513764|NCT00102362|BEHAVIORAL|Behavior Therapy|
219513765|NCT01696591|BIOLOGICAL|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
219513766|NCT01076803|DRUG|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
219513767|NCT02959775|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
218893564|NCT06335784|OTHER|"Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention"|Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.
218893565|NCT03974386|DEVICE|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
218893566|NCT03315572|OTHER|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
218893567|NCT03315572|OTHER|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
218893568|NCT03315572|OTHER|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
218893569|NCT05195658|DEVICE|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
219513768|NCT02959775|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
219513769|NCT01215942|DRUG|LY2127399|Administered Subcutaneously
219513770|NCT01966042|PROCEDURE|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
219513771|NCT01966042|PROCEDURE|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
219513772|NCT01966042|PROCEDURE|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
219513773|NCT01966042|BIOLOGICAL|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
219513774|NCT02678910|PROCEDURE|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
219513775|NCT06087874|DIETARY_SUPPLEMENT|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
218893570|NCT02167516|DRUG|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
218893571|NCT02167516|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
218893572|NCT04585282|BEHAVIORAL|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
218893573|NCT04585282|BEHAVIORAL|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
218893574|NCT01598467|PROCEDURE|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
218893575|NCT02233972|DRUG|Midazolam|
218893576|NCT02233972|DRUG|Ginkgolides Meglumine Injection|
218893577|NCT02233972|DRUG|placebo|
218893578|NCT04316559|OTHER|Placebo|Placebo capsule
218893579|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
218893580|NCT06504316|DEVICE|CRRT filter|The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
218893581|NCT02938208|DEVICE|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
218893582|NCT02150447|DRUG|Proton pump inhibitor|Lansoprazole 30 mg, daily
218893583|NCT02150447|DRUG|Placebo|Placebo, daily
218893584|NCT02393937|DRUG|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
218893585|NCT02393937|DRUG|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
218893586|NCT02393937|DRUG|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
218893587|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
219513776|NCT06087874|DIETARY_SUPPLEMENT|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
219513777|NCT01220349|DEVICE|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
219513778|NCT02625831|OTHER|Biological analysis|"Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies"
219513779|NCT03960320|OTHER|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
219513780|NCT01798069|BEHAVIORAL|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
219513781|NCT01798069|BEHAVIORAL|reading medical publication workshops|
218893588|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
218893589|NCT02682368|DIAGNOSTIC_TEST|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
218893590|NCT02682368|DIAGNOSTIC_TEST|Radiology report|Radiologist report compared to the point of care ultrasound impression.
218893591|NCT02682368|PROCEDURE|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
218893592|NCT06493058|OTHER|Prone positioning|The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
218893593|NCT04393402|PROCEDURE|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
219034849|NCT03225612|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
219610100|NCT03277443|PROCEDURE|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
218893594|NCT03859271|BEHAVIORAL|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
218893595|NCT03859271|BEHAVIORAL|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
218893596|NCT03257124|DRUG|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
218893597|NCT00038064|DRUG|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
218893598|NCT00038064|DRUG|rHuEPO|150 IU/kg TIW
218893599|NCT00659074|DRUG|Ondansetron|ODT, single-dose, fasting
218893600|NCT00659074|DRUG|Zofran|ODT, single-dose, fasting
218893601|NCT06434181|DIETARY_SUPPLEMENT|Beetroot Juice|Beet-It Sports Shot, 70mL, containing 6.5 mmol nitric oxide (taking two shots per day in active group)
218893602|NCT06434181|DIETARY_SUPPLEMENT|Placebo Control|Beet-It Placebo Shot, 70mL (taking two shots per day in placebo group)
218893603|NCT04792021|DRUG|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
218893604|NCT00171171|DRUG|deferasirox|
218893605|NCT01329237|OTHER|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
219034850|NCT02555995|DEVICE|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
218893606|NCT02256566|BEHAVIORAL|emotional memory training exercise|
219034851|NCT03666169|OTHER|Survey|Survey
219513782|NCT03522948|BEHAVIORAL|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
219513783|NCT03866850|BEHAVIORAL|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
219513784|NCT00930865|DRUG|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
219513785|NCT00930865|DRUG|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
218893607|NCT02256566|BEHAVIORAL|memory training exercise|
218893608|NCT05236608|DRUG|Nivolumab|Administered together with ADG106 via intravenous infusion.
218893609|NCT05236608|DRUG|ADG106|Administered as an intravenous infusion over 90 minutes.
218893610|NCT04934501|DIAGNOSTIC_TEST|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
219034852|NCT02752191|DRUG|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
219034853|NCT02752191|DRUG|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
219034854|NCT05973916|OTHER|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
219513786|NCT03305055|DRUG|ketamine|Information included in arm descriptions
218893611|NCT04934501|DIAGNOSTIC_TEST|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
218893612|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
218893613|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
218893614|NCT04880096|OTHER|eDOL|e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
219034855|NCT02965443|DRUG|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
219034856|NCT02965443|DRUG|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
219513787|NCT03305055|DRUG|Fentanyl|Information included in arm descriptions
219610101|NCT03277443|DEVICE|2D cephalometric radiograph|2D cephalometric radiograph
219610102|NCT03277443|DEVICE|3D computerized tomography|3D computerized tomography
219610103|NCT03495375|DIETARY_SUPPLEMENT|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
219610104|NCT03495375|OTHER|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
218893615|NCT02442440|DRUG|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
218893616|NCT06139744|DRUG|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
218893617|NCT06139744|DRUG|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
218893618|NCT04800601|OTHER|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
219034857|NCT01536496|BIOLOGICAL|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
219034858|NCT01536496|BIOLOGICAL|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
219203843|NCT04050280|DRUG|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
219203844|NCT06237270|PROCEDURE|Nerve transfer surgery for elbow flexion|A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
219513788|NCT04181450|OTHER|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., \& Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
219513789|NCT03198013|DRUG|Prednisolone|Specified dose on specified days
219513790|NCT03198013|DRUG|BMS-791826|Specified dose on specified days
219513791|NCT03198013|DRUG|Placebo|Specified dose on specified days
219034859|NCT06106971|DRUG|Sodium tetradecyl sulfate|Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.
219203845|NCT06548009|DIAGNOSTIC_TEST|Metabolomics and other blood samples|Blood samples taken with the objective of identifying a diagnostic test
219203846|NCT05134142|OTHER|Electronic Health Record Review|Undergo medical record review
219513792|NCT01802879|DRUG|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
219513793|NCT02829671|OTHER|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
219513794|NCT05572411|OTHER|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
219610105|NCT03304145|OTHER|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
219610106|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
219034860|NCT06106971|DRUG|Cyanoacrylate|Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
219034861|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
219513795|NCT04845061|DRUG|Nebivolol Tablets|cardio selective beta-1 blocker
219610107|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
219034862|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
219034863|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
219203847|NCT05134142|OTHER|Physical Performance Testing|Undergo physical performance testing
219610108|NCT01144611|DRUG|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
219610109|NCT01144611|DRUG|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
219610110|NCT05641298|DRUG|Sodium Fusidate|Tablets
219610111|NCT05641298|DRUG|Placebo|Tablets
218893619|NCT04800601|OTHER|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
218893620|NCT00688584|BEHAVIORAL|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
219513796|NCT04384172|DEVICE|Tibial e-stim|For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
219513797|NCT04384172|DEVICE|Genital e-stim|For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
219513798|NCT01105650|DRUG|Fludarabine|Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
219610112|NCT03304405|DIAGNOSTIC_TEST|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
218893621|NCT00688584|BEHAVIORAL|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
218893622|NCT05755139|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
219610113|NCT00633997|DRUG|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
219610114|NCT00633997|DRUG|Vildagliptin|
218893623|NCT03573323|DRUG|Ixekizumab|Administered SC
218893624|NCT03573323|DRUG|Guselkumab|Administered SC
218893625|NCT03573323|DRUG|Placebo|Administered SC
218893626|NCT04354662|DRUG|Toripalimab|240mg d1
218893627|NCT04354662|DRUG|Docetaxel|50mg/m2, d1;
218893628|NCT04354662|DRUG|Fluorouracil|2600 mg/m², d1
218893629|NCT04354662|DRUG|Leucovorin|200 mg/m², d1
218893630|NCT04354662|DRUG|Oxaliplatin|85 mg/m², d1
218893631|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
218893632|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
219513799|NCT01105650|DRUG|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
218893633|NCT03209531|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
218893634|NCT03209531|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
219513800|NCT01105650|DRUG|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
219513801|NCT01105650|BIOLOGICAL|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.
219513802|NCT01105650|DRUG|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
219513803|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
219513804|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
219513805|NCT01105650|DRUG|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
219513806|NCT00263107|PROCEDURE|telerounding versus bedside rounding|
219513807|NCT02180308|DEVICE|PET/MRI|Simultaneous PET/MRI (3T system)
219610115|NCT05217576|DEVICE|NBM-200|Finger Prick and Venipuncture
219610116|NCT04406077|DEVICE|Ligasure|Using ligasure to treat hydrocele
219610117|NCT03241992|BEHAVIORAL|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
219610118|NCT03983980|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
219610119|NCT03983980|DRUG|Vehicle Cream|Vehicle cream applied once daily
219610120|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
219610121|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
219610122|NCT02074150|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
218893635|NCT03209531|DEVICE|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
218893636|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
218893637|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
219203848|NCT05134142|OTHER|Quality-of-Life Assessment|Complete assessments
219203849|NCT05134142|OTHER|Questionnaire Administration|Complete questionnaire
218893638|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
218893639|NCT05981547|DEVICE|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
218893640|NCT05585710|OTHER|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
218893641|NCT05585710|PROCEDURE|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
218893642|NCT05585710|PROCEDURE|Bilateral or unilateral mastectomy|Standard of care
218893643|NCT05585710|DEVICE|Tissue expander|Standard of care
218893644|NCT05585710|OTHER|Acellular dermal matrix|Standard of care
218893645|NCT04502290|DEVICE|Combined Non-invasive brain stimulation and functional electrical hand stimulation|Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
218893646|NCT01138488|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
218893647|NCT00837213|DRUG|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
218893648|NCT00837213|DRUG|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
218893649|NCT02303249|OTHER|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
218893650|NCT02545218|PROCEDURE|Perineorraphy|Surgery for improperly healed perineal tear
219513808|NCT00193778|PROCEDURE|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
219513809|NCT00193778|OTHER|No Loco-regional treatment|This group will not receive any loco-regional treatment
219513810|NCT01047345|BIOLOGICAL|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
218893651|NCT02545218|OTHER|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
218893652|NCT00835250|PROCEDURE|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
218893653|NCT00835250|PROCEDURE|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
218893654|NCT02293798|DEVICE|silk surgical scaffold|surgical implant
219513811|NCT01047345|BIOLOGICAL|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
219513812|NCT01948505|DRUG|Intravenous acetaminophen|
219513813|NCT01948505|DRUG|Placebo for IV acetaminophen|
219513814|NCT02368847|DEVICE|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
219513815|NCT02368847|DEVICE|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
219610123|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610124|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
218893655|NCT06226038|OTHER|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
218893656|NCT06226038|OTHER|Stainless steel|For control
218893657|NCT01004926|DEVICE|Echelon foot|One Echelon foot for each subject, for a period of a month.
218893658|NCT01944124|BEHAVIORAL|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
218893659|NCT01944124|BEHAVIORAL|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
218893660|NCT01558947|DRUG|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
218893661|NCT01558947|DRUG|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
219513816|NCT03299153|OTHER|barberry juice|
219513817|NCT00865553|BEHAVIORAL|computer-assisted smoking cessation intervention|
219513818|NCT00865553|OTHER|cancer prevention|
219513819|NCT00865553|OTHER|educational intervention|
219513820|NCT00865553|OTHER|survey administration|
219610125|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
218893662|NCT02396706|DRUG|Ivy Leaves Cough Liquid|
218893663|NCT02396706|DRUG|Placebo|
218893664|NCT01931306|DRUG|Afatinib|BIBW2992 low to medium dose once daily
219513821|NCT02520271|BEHAVIORAL|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
219513822|NCT02520271|BEHAVIORAL|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
219513823|NCT03565809|OTHER|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
219513824|NCT01415466|DRUG|Cresto|tablet, 20mg
219513825|NCT01415466|DRUG|Olmetec|tablet, 40mg
219513826|NCT01415466|DRUG|Cresto, Olmetec|tablet, 20mg and 40mg
219513827|NCT00376571|PROCEDURE|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
219513828|NCT00698685|DRUG|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
219513829|NCT00698685|BIOLOGICAL|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
219513830|NCT00698685|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
218893665|NCT03202563|DRUG|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
218893666|NCT03202563|DRUG|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
219513831|NCT00600626|DRUG|biphasic insulin aspart|
219513832|NCT00600626|DRUG|insulin NPH|
219513833|NCT00600626|DRUG|insulin aspart|
219513834|NCT06528717|PROCEDURE|Carotid graft interposition|In patients with extensive atherosclerotic carotid disease, when endarterectomy isn't feasible, replacement of the carotid artery with a graft is needed. Graft interposition can be performed either by end-to-end proximal and distal anastomoses in the undiseased common and internal carotid artery with ligation of the external carotid artery, or by side-to-end proximal anastomosis on the origin of the internal carotid artery and end-to-end distal anastomosis on the internal carotid artery with flow preservation in the external carotid artery.
219513835|NCT02576990|BIOLOGICAL|Pembrolizumab|IV infusion
219513836|NCT05017233|DEVICE|Spectral CT|Using Spectral CT to scan Breast
219610126|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610127|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610128|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610129|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610130|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
218893667|NCT03202563|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
218893668|NCT03202563|DEVICE|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
218893669|NCT03202563|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
218893670|NCT01865227|BEHAVIORAL|Group Counseling|
218893671|NCT00825201|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
218893672|NCT00825201|OTHER|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
218893673|NCT00825201|OTHER|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
218893674|NCT00825201|OTHER|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
218893675|NCT00825201|OTHER|laboratory biomarker analysis|Correlative studies
218893676|NCT06363734|DRUG|Osimertinib plus Dalpiciclib|osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
218893677|NCT05543902|BEHAVIORAL|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
219513837|NCT04621942|OTHER|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
219513838|NCT04621942|OTHER|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
219513839|NCT04450290|DEVICE|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
219610131|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
218893678|NCT06117241|BEHAVIORAL|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
219610132|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
219610133|NCT02074150|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219610134|NCT02074150|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219610135|NCT05580250|DRUG|LY3526318|Administered orally.
219610136|NCT05580250|DRUG|Placebo|Administered orally.
219610137|NCT05580250|DRUG|Iohexol|Administered intravenously (IV).
218893679|NCT05646537|BEHAVIORAL|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
218893680|NCT02432417|DRUG|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
219610138|NCT05580250|DRUG|Simvastatin|Administered orally.
219610139|NCT05580250|DRUG|Metformin|Administered orally.
219610140|NCT04827823|OTHER|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
219610141|NCT00354913|DRUG|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
218893681|NCT05802446|OTHER|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
218893682|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
219203850|NCT04773834|OTHER|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
218893683|NCT03508934|DEVICE|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
218893684|NCT03508934|OTHER|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
218893685|NCT05566769|DEVICE|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
218893686|NCT00133042|DRUG|omalizumab|
218893687|NCT05303623|OTHER|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
219034864|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
219034865|NCT02533271|RADIATION|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
219034866|NCT02533271|RADIATION|Long-term chemoradiotherapy|Standard chemoradiotherapy
219034867|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
219034868|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
219034869|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
219034870|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
219034871|NCT02850536|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells
219034872|NCT06212102|DRUG|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
219034873|NCT06212102|DRUG|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
219034874|NCT03751215|PROCEDURE|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
219034875|NCT06377293|OTHER|Dialysis-specific therapeutic diet|A healthy diet for dialysis patients
219034876|NCT01847391|DRUG|GS-6615|GS-6615 tablet(s) administered orally once daily
219034877|NCT01847391|DRUG|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
219034878|NCT00950534|DRUG|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
219034879|NCT00950534|DRUG|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
219034880|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
219034881|NCT04700748|RADIATION|Brain metastases radiation|Brain metastases radiation according to clinical practice.
219034882|NCT05125939|OTHER|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
219034883|NCT03893799|DRUG|RBT-1|Single intravenous administration
219034884|NCT01991158|DRUG|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
219034885|NCT01991158|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
219034886|NCT01991158|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
219034887|NCT01991158|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
219034888|NCT01742338|DRUG|Low Dose Corticosteroids|
219034889|NCT01742338|DRUG|High Dose Corticosteroids|
219034890|NCT03249779|DEVICE|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
219513840|NCT04650100|PROCEDURE|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
219513841|NCT00762671|DRUG|Ebselen|150 mg BID for 2 weeks
219513842|NCT00762671|DRUG|Placebo|Placebo 1 po BID for 2 weeks
219513843|NCT02907008|OTHER|Polysomnography|
219513844|NCT01881399|DEVICE|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
219513845|NCT01881399|OTHER|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
219513846|NCT01881399|PROCEDURE|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
219513847|NCT05728632|DRUG|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
219513848|NCT05728632|DRUG|Placebo|Placebo, capsule, once daily, for 12 months
219513849|NCT02484820|DEVICE|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
219610142|NCT00354913|DRUG|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
219610143|NCT03879785|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
219610144|NCT03530683|DRUG|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
219610145|NCT03530683|DRUG|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
219610146|NCT03530683|DRUG|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
219610147|NCT03530683|DRUG|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
219610148|NCT03530683|DRUG|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
219610149|NCT03530683|DRUG|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
219610150|NCT03530683|DRUG|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
219610151|NCT01091194|OTHER|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
219610152|NCT02802410|DEVICE|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
219034891|NCT05410327|OTHER|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
219034892|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
219034893|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
219513850|NCT00911859|DRUG|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
219513851|NCT00911859|DRUG|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
219513852|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
219513853|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
219513854|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
219513855|NCT00911859|DRUG|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
219513856|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
219513857|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
218893688|NCT05303623|OTHER|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
218893689|NCT05303623|OTHER|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
219034894|NCT01442363|DRUG|placebo|topical ointment
219034895|NCT06146036|BEHAVIORAL|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
219034896|NCT06146036|BEHAVIORAL|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
219034897|NCT06146036|OTHER|Control|No exercise, sedentary.
219034898|NCT06530654|BEHAVIORAL|Distraction by dentist|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
219034899|NCT06530654|BEHAVIORAL|Distraction by cartoon movie|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
219203851|NCT04773834|OTHER|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
219610153|NCT02802410|DEVICE|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
219610154|NCT02802410|OTHER|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
219610155|NCT06345729|DRUG|MK-1084|Oral tablets
219034900|NCT06530654|BEHAVIORAL|AG-active distraction group|The active distraction group is treated and interacting with the designed application
219203852|NCT05896163|DRUG|maplirpacept (PF-07901801)|Intravenous infusion
219203853|NCT05896163|DRUG|Glofitamab|Intravenous infusion
219203854|NCT05896163|DRUG|Obinutuzumab|Intravenous infusion
219203855|NCT06166563|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
219203856|NCT05805436|DRUG|Polyethylene Glycol 3350|Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
219203857|NCT04665908|OTHER|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
219203858|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
219203859|NCT05714384|DEVICE|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
219610156|NCT06345729|OTHER|Placebo|Oral tablets
219610157|NCT06345729|BIOLOGICAL|Pembrolizumab|IV infusion
219610158|NCT02497586|RADIATION|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
218893690|NCT04555460|PROCEDURE|Hemicraniectomy|Large hemicraniectomy and duraplasty
218893691|NCT04555460|OTHER|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
218893692|NCT01910415|DRUG|Lumacaftor|
219034901|NCT05372276|OTHER|Assessment 1|Mental Toughness Questionnaire in Sport
219203860|NCT01825226|OTHER|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
219513858|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
219513859|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
219034902|NCT05372276|OTHER|Assessment 2|Sport Imagery Questionnaire
219034903|NCT05372276|OTHER|Assessment 3|The Pittsburgh Sleep Quality Index
219034904|NCT05372276|OTHER|Assessment 4|The Perceived Stress Scale (PSS)
219034905|NCT05829759|BEHAVIORAL|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
219203861|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
219203862|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
219203863|NCT02611687|DRUG|pitolisant|Tablet
219203864|NCT02611687|DRUG|Placebo|Tablet
219203865|NCT04848974|DRUG|Cladribine|Given IV
219203866|NCT04848974|DRUG|Cytarabine|Given SC
219203867|NCT04848974|DRUG|Uproleselan|Given IV
219203868|NCT01057628|DRUG|ipragliflozin|oral
219203869|NCT01057628|DRUG|placebo|oral
219203870|NCT00262717|DIAGNOSTIC_TEST|Blood test: genotype testing|
219203871|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
219203872|NCT06800833|OTHER|Low fat cookies|To determine the effects of low fat cookie consumption on physiological indicators of sexual, mental, skin, and gut health
219513860|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
219513861|NCT00021502|DRUG|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
219513862|NCT01396044|OTHER|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
218893693|NCT01910415|DRUG|Lumacaftor Placebo|
218893694|NCT01910415|DRUG|Ivacaftor|
218893695|NCT01910415|DRUG|Ivacaftor Placebo|
218893696|NCT01910415|DRUG|moxifloxacin hydrochloride|
218893697|NCT02545608|DEVICE|Restylane Vital|
219513863|NCT01396044|OTHER|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
218893698|NCT02698826|OTHER|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
219513864|NCT01048333|DRUG|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
219513865|NCT01048333|DRUG|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
219513866|NCT01048333|DRUG|Placebo|Placebo Diskus and Placebo Turbuhaler
219513867|NCT01403883|BEHAVIORAL|Standard Care|Psychological \& enterostomal therapy clinics on demand only
219513868|NCT01403883|BEHAVIORAL|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
219513869|NCT04784117|OTHER|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
219513870|NCT04582227|DEVICE|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
219513871|NCT01962883|OTHER|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
219513872|NCT00003860|BIOLOGICAL|filgrastim|
218893699|NCT02526602|PROCEDURE|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
218893700|NCT02526602|PROCEDURE|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
218893701|NCT01540357|BEHAVIORAL|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
218893702|NCT01540357|BEHAVIORAL|Treatment after waiting time|Treatment was performed after completion of the active arm.
218893703|NCT00490958|DRUG|telmisartan|
218893704|NCT03311165|OTHER|no intervention|no intervention was given
218893705|NCT00934765|BEHAVIORAL|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
218893706|NCT01034930|PROCEDURE|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
218893707|NCT02916901|DRUG|CKD-519 200mg|
218893708|NCT02916901|DRUG|Placebo|
219513873|NCT00003860|DRUG|carboplatin|
219513874|NCT00003860|DRUG|etoposide|
219513875|NCT00003860|DRUG|ifosfamide|
219610159|NCT02283723|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
219610160|NCT02283723|OTHER|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
218893709|NCT04774263|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
218893710|NCT05947864|BIOLOGICAL|Biological samples (blood and oral fluid)|"For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)"
219513876|NCT00003860|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219513877|NCT05892757|DRUG|Atogepant|Oral Tablet
219513878|NCT05892757|DRUG|Ubrogepant|Oral Tablet
219513879|NCT04571723|BEHAVIORAL|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
219513880|NCT04571723|BEHAVIORAL|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
219513881|NCT00851045|DRUG|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
219513882|NCT00851045|DRUG|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
219513883|NCT00851045|DRUG|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
219513884|NCT00851045|DRUG|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
218893711|NCT05783336|BEHAVIORAL|Stepping Stones and Creating Futures Plus (SSCF+)|Group-based intervention delivered to small friendship networks, by a facilitator.
218893712|NCT01436786|OTHER|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
218893713|NCT04161937|BEHAVIORAL|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
218893714|NCT05594407|DRUG|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
218893715|NCT05594407|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
219034906|NCT05829759|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
219610161|NCT02016534|DRUG|AMG 337|AMG 337 300mg orally daily.
219034907|NCT06579144|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
219034908|NCT04747340|BEHAVIORAL|Training for Awareness Resilience and Action (TARA)|See arm-description
219513885|NCT00851045|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
219513886|NCT00851045|DRUG|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
219513887|NCT00851045|DRUG|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
219610162|NCT01582035|DRUG|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
219610163|NCT01582035|DRUG|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
218893716|NCT05565703|OTHER|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
218893717|NCT05565703|OTHER|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
218893718|NCT02949999|DRUG|Voclosporin|
219034909|NCT04747340|OTHER|Standard treatment|See arm-description
219034910|NCT04296006|BEHAVIORAL|Money|Three money values offered as alternatives to cocaine.
219034911|NCT04296006|DRUG|Cocaine HCl|3 mg/70 kg is available as an alternative to money.
219034912|NCT03314584|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
219034913|NCT03314584|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
219034914|NCT03314584|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
219034915|NCT06134817|DEVICE|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
219034916|NCT05098132|DRUG|STK-012|pegylated alpha/beta-biased engineered interleukin-2
219034917|NCT05098132|DRUG|pembrolizumab|anti-PD-1 humanized monoclonal antibody
219034918|NCT05098132|DRUG|pemetrexed|antifolate chemotherapy
219034919|NCT05098132|DRUG|carboplatin|platinum chemotherapy
219513888|NCT00359229|DRUG|Zolpidem|Administration of Zolpidem 5mg
219513889|NCT00101972|BIOLOGICAL|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
219513890|NCT01880099|DRUG|placebo|placebo compared to 8mg of Galantamine
219513891|NCT01880099|DRUG|Galantamine 8mg|8mg of galantamine compared to placebo
219513892|NCT01880099|DRUG|Galantamine 16mg|16mg of galantamine compared to placebo
219513893|NCT00711503|DRUG|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
219513894|NCT00711503|DRUG|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
219513895|NCT00955747|DRUG|Tagatose|powder; 15 grams three times daily; one year
219513896|NCT00955747|DRUG|Sugar Substitute Splenda|1.5 g powder tid
219513897|NCT05647083|OTHER|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
219610164|NCT01582035|DRUG|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
218893719|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
218893720|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
218893721|NCT00452868|DRUG|Donepezil|Donepezil 5 milligrams a day for 6 weeks
218893722|NCT00137514|DRUG|chloroquine|
218893723|NCT00137514|DRUG|amodiaquine|
218893724|NCT03610191|DIAGNOSTIC_TEST|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
218893725|NCT03610191|BEHAVIORAL|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
218893726|NCT03610191|PROCEDURE|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
218893727|NCT05375227|OTHER|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
218893728|NCT01567111|PROCEDURE|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
218893729|NCT03641040|DIAGNOSTIC_TEST|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
218893730|NCT03641040|DIAGNOSTIC_TEST|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
218893731|NCT01828229|BEHAVIORAL|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
218893732|NCT01828229|BEHAVIORAL|inactivity|inactivity for 2 weeks
218893733|NCT01828229|BEHAVIORAL|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
218893734|NCT01828229|BEHAVIORAL|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
219034920|NCT04435015|DRUG|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
219034921|NCT04435015|DRUG|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
219034922|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
219203873|NCT06800833|OTHER|Mango|To determine the effects of mango consumption on physiological indicators of sexual, mental, skin, and gut health
219513898|NCT02610049|BEHAVIORAL|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson \& Chard (11/2010)
219513899|NCT02610049|BEHAVIORAL|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson \& Chard (11/2010)
219513900|NCT02610049|BEHAVIORAL|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson \& Chard (1/2010) CPT + Art Therapy of mixed individual techniques
219513901|NCT03623256|DRUG|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
219513902|NCT03623256|DRUG|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
219513903|NCT03623256|DRUG|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
218893735|NCT01828229|BEHAVIORAL|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
218893736|NCT04764513|BIOLOGICAL|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10\^6、 1×10\^7 and 5×10\^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
218893737|NCT01618669|DRUG|Regadenoson|Administered as an intravenous (IV) bolus
218893738|NCT01618669|PROCEDURE|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
218893739|NCT00238979|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
218893740|NCT01964417|DRUG|Colonoscopy after bowel cleansing|
218893741|NCT05988879|DRUG|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
218893742|NCT02577692|OTHER|Oxygen|breathing oxygen
218893743|NCT02577692|OTHER|Ambient|breathing ambient air
218893744|NCT04818970|DEVICE|Narrow Band ultraviolet B-Band Light|Daily doses of NB-UVB for 8 consecutive days.
218893745|NCT04818970|DEVICE|non Narrow Band ultraviolet B-Band Light|Daily doses of non-NB-UVB for 8 consecutive days.
218893746|NCT02641431|PROCEDURE|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
218893747|NCT02641431|DRUG|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
218893748|NCT02641431|PROCEDURE|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
218893749|NCT02641431|PROCEDURE|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
218893750|NCT02203695|DRUG|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
218893751|NCT02203695|RADIATION|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
218893752|NCT04317040|DRUG|Efprezimod alfa|Efprezimod alfa is given on Day 1.
218893753|NCT04317040|DRUG|Placebo|Placebo is given on Day 1.
219513904|NCT03623256|DRUG|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
219513905|NCT01909583|OTHER|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
219513906|NCT00539539|OTHER|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
219513907|NCT03349606|DRUG|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
219513908|NCT03349606|RADIATION|[C-11]FLB 457|PET radiotracer
219513909|NCT03562403|DEVICE|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
219513910|NCT00634179|DRUG|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
219610165|NCT01582035|DRUG|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
218893754|NCT05711134|BEHAVIORAL|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
219203874|NCT06435260|DRUG|Camrelizumab+chemotherapy|"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."
219203875|NCT06435260|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),
219513911|NCT00634179|BIOLOGICAL|Rituximab|Rituximab 375 mg/m²
219513912|NCT00634179|DRUG|Doxorubicin|Doxorubicin 50 mg/m²
219513913|NCT00634179|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m²
219513914|NCT00634179|DRUG|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
219513915|NCT00634179|DRUG|Prednisone|Prednisone 100 mg/day given orally on days 1-5
219610166|NCT01582035|DRUG|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
219610167|NCT01582035|DRUG|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
219610168|NCT01582035|DRUG|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
218893755|NCT03896321|DRUG|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
218893756|NCT03896321|DRUG|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
218893757|NCT05617144|OTHER|Aromatherapy treatment|60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
218893758|NCT02241148|DRUG|Acetaminophen 500mg|500 mg, tablets every 8 hours
218893759|NCT02241148|DEVICE|Kinesio taping|Taping will be changed every week.
219513916|NCT04288596|OTHER|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
219513917|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.
219513918|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic spoon grasper|Hysteroscopic endometrial biopsy performed through the spoon grasper.
219513919|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic alligator grasper|Hysteroscopic endometrial biopsy performed through the alligator grasper.
219513920|NCT04784481|DRUG|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
219513921|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
219513922|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
219513923|NCT02231320|DRUG|Berodual® Respimat® - inhaler|
219513924|NCT05571709|OTHER|Exercise training|Resistance training of the lower limbs
219513925|NCT05571709|BEHAVIORAL|Questionnaire|Physical activity questionnaire
219513926|NCT05571709|PROCEDURE|Percutaneous muscle biopsy|Muscle biopsy of the vastus lateralis (m. quadriceps)
219610169|NCT00750425|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
219610170|NCT04467502|OTHER|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
219610171|NCT04467502|OTHER|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
219610172|NCT04467502|OTHER|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
219610173|NCT03349021|DEVICE|Bougiecap|Treatment of esophagel Stenosis by Bougiecap
219610174|NCT01706406|BEHAVIORAL|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
219034923|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
219513927|NCT05571709|PROCEDURE|Blood sample|Venous blood sample
219513928|NCT01858714|BEHAVIORAL|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
219513929|NCT01858714|BEHAVIORAL|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
219513930|NCT01858714|BEHAVIORAL|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
219513931|NCT03419195|OTHER|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
219513932|NCT04654403|DRUG|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
219513933|NCT02627027|DRUG|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
219610175|NCT02633007|DRUG|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
219610176|NCT02633007|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
219610177|NCT02633007|OTHER|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
219610178|NCT04654793|DEVICE|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
219610179|NCT04654793|DEVICE|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
219610180|NCT01522911|DEVICE|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
219610181|NCT01942993|DRUG|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
219610182|NCT01350271|DRUG|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
219610183|NCT01350271|DRUG|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
219610184|NCT01350271|DRUG|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
219610185|NCT01349192|DRUG|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: \<40kg : 15mg/kg daily for 14 days divided every 12 hours.
219610186|NCT01349192|DRUG|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: \<40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
219610187|NCT01349192|DRUG|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
219610188|NCT01349192|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
219610189|NCT01349192|DRUG|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
219610190|NCT01349192|DRUG|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
219610191|NCT01349192|BEHAVIORAL|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
219203876|NCT04700800|OTHER|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
219203877|NCT04700800|OTHER|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
219203878|NCT06003153|DRUG|oral semaglutide|Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
219513934|NCT02627027|DRUG|CKD-395 0.25/750mg|oral administration
219610192|NCT03364101|DIETARY_SUPPLEMENT|Placebo Capsule|Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
218893760|NCT06531486|OTHER|XS-02 capsules|Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.
218893761|NCT00004092|BIOLOGICAL|filgrastim|Given IV or subcutaneously
218893762|NCT00004092|DRUG|carboplatin|Given IV
218893763|NCT00004092|DRUG|cyclophosphamide|Given IV
218893764|NCT00004092|DRUG|doxorubicin hydrochloride|Given IV
218893765|NCT00004092|DRUG|paclitaxel|Given IV
218893766|NCT00004092|DRUG|thiotepa|Given IV
218893767|NCT00004092|PROCEDURE|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
218893768|NCT02509923|DRUG|Z-215 10mg|Z-215 10mg, capsules
218893769|NCT02509923|DRUG|Z-215 20mg|Z-215 20mg, capsules
218893770|NCT02509923|DRUG|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
218893771|NCT02509923|DRUG|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
218893772|NCT03918421|OTHER|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
218893773|NCT01177007|DEVICE|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
218893774|NCT05083533|BEHAVIORAL|tele-rehabilitation exercise|"Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Treatment program planned to stretch the muscles of individuals with short hamstring muscle group.~Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions."
218893775|NCT05083533|BEHAVIORAL|Home exercise|All participants received home exercise for 8 weeks. The exercise program includes stretching exercises Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.
219203879|NCT06003153|OTHER|Mixed Meal Tolerance Test (MMTT)|The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
219203880|NCT06382844|DIAGNOSTIC_TEST|Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).|Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
219513935|NCT03441542|BEHAVIORAL|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
219513936|NCT03441542|BEHAVIORAL|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
219513937|NCT03800069|DEVICE|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
219513938|NCT04503798|BEHAVIORAL|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
219513939|NCT00767325|DRUG|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
219513940|NCT00767325|DRUG|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
219513941|NCT04464044|DEVICE|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
219513942|NCT01987804|DRUG|Oxytocin 100 i.u.|
219513943|NCT01987804|DRUG|Oxytocin 400 i.u.|
219513944|NCT01987804|DRUG|Placebo|
219610193|NCT03364101|DIETARY_SUPPLEMENT|POWEROFF Capsule|blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
219513945|NCT03538756|DEVICE|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
219513946|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
219513947|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
219513948|NCT02002156|BIOLOGICAL|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
219513949|NCT03982758|OTHER|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
219513950|NCT03982758|OTHER|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
219513951|NCT02542306|DRUG|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
219513952|NCT03136692|BEHAVIORAL|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
219513953|NCT03064633|DRUG|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
219513954|NCT03064633|DRUG|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
219513955|NCT03064633|DRUG|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
219610194|NCT05474014|PROCEDURE|superior trunk block|Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
219610195|NCT05474014|DRUG|intravenous patient-controlled analgesia|Analgesics will be given using a patient-controlled analgesia device.
219610196|NCT01354210|BEHAVIORAL|SMS Text Message Reminder|Daily
219610197|NCT04406428|PROCEDURE|NKI followed by EBD|Needle-knife incision therapy followed by endoscopic bougie dilation
219610198|NCT04881474|DRUG|Ibuprofen 800 mg|30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
219610199|NCT03365362|DRUG|Long-Term Varenicline|Varenicline tablet x 24 weeks
218893776|NCT04226508|OTHER|Physical exercise|"The patients can choose between three modality of EX:~1. Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~2. Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~3. Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
218893777|NCT05802043|BEHAVIORAL|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
219513956|NCT00752856|DRUG|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
219513957|NCT00752856|DRUG|Atripla|Atripla 1 tab once a day
219513958|NCT06175702|DRUG|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
219513959|NCT06175702|DRUG|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
219513960|NCT06175702|DRUG|Imatinib|600 mg per day from 1 to up to 5 years
219513961|NCT06175702|DRUG|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
219513962|NCT06175702|DRUG|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
219513963|NCT06175702|DRUG|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
219513964|NCT06175702|DRUG|Ponatinib|15 mg per day from consolidation start up to 5 years
219513965|NCT06175702|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
219513966|NCT06175702|PROCEDURE|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
219513967|NCT06175702|DRUG|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
219513968|NCT06175702|DRUG|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
219513969|NCT04973956|OTHER|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
219513970|NCT04973956|OTHER|Control|No intervention
219513971|NCT06016855|PROCEDURE|Tumor Debulking|Undergo surgical debulking
219513972|NCT06016855|DRUG|Lutetium Lu 177 Dotatate|Given by IV
219513973|NCT06016855|PROCEDURE|Computed Tomography|Undergo Computed Tomography
218893778|NCT00059345|PROCEDURE|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
218893779|NCT00059345|PROCEDURE|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
218893780|NCT00059345|OTHER|Usual Care|Usual care for knee osteoarthritis
218893781|NCT01961271|DRUG|Buprenorphine transdermal patch|Please see Arm Description.
218893782|NCT01951560|DRUG|Valproic Acid|By infusion over 1 hour
218893783|NCT01951560|DRUG|Isotonic saline solution|By infusion over 1 hour
219513974|NCT06016855|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
219513975|NCT06016855|DRUG|Copper Cu 64 Dotatate|Given by IV
219513976|NCT06016855|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
219513977|NCT03131999|DRUG|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
219513978|NCT03131999|DRUG|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
219513979|NCT02402868|DRUG|Ketamine and saline|Ketamine intravenous and intranasal
218893784|NCT00002043|DRUG|Dapsone|
219513980|NCT02260492|DRUG|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
219513981|NCT02260492|DRUG|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
219513982|NCT02260492|DRUG|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
219513983|NCT01898910|PROCEDURE|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
219610200|NCT03365362|DRUG|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
219610201|NCT03365362|BEHAVIORAL|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
218893785|NCT05010980|OTHER|CMR|clinical indication
218893786|NCT05010980|OTHER|scintigraphy|clinical indication
218893787|NCT05376631|PROCEDURE|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
219513984|NCT01898910|PROCEDURE|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
219610202|NCT03365362|BEHAVIORAL|Self Administered Therapy|Varenicline doses are self-administered
218893788|NCT05376631|PROCEDURE|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
218893789|NCT02518386|OTHER|No intervention|No intervention is planned
218893790|NCT02186574|DRUG|Tenofovir disoproxil|
218893791|NCT02186574|DRUG|Placebo Oral Tablet|
218893792|NCT04603261|DIAGNOSTIC_TEST|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
218893793|NCT00226486|OTHER|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
218893794|NCT00226486|OTHER|Usual care|No intervention, but ususal care after an accidental fall.
218893795|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
219513985|NCT01898910|DRUG|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
219513986|NCT01323998|DRUG|5ARI|Dutasteride or Finasteride
219513987|NCT01323998|DRUG|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
219513988|NCT04366479|BEHAVIORAL|Multistage Fitness Test|Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
218893796|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
218893797|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
218893798|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
218893799|NCT04800458|BIOLOGICAL|Blood samples|"* Thrombopoietin : 7 ml whole blood.~* Anti-platelet antibodies free : 14 ml whole blood.~* Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
218893800|NCT01300312|DRUG|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
218893801|NCT01300312|DRUG|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
218893802|NCT02962167|BIOLOGICAL|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
218893803|NCT02962167|BIOLOGICAL|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
218893804|NCT04914026|OTHER|Biomarker analysis|Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
218893805|NCT02186613|BEHAVIORAL|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
218893806|NCT03782233|DRUG|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
219034924|NCT04302389|BEHAVIORAL|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
219034925|NCT05987423|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
219034926|NCT05987423|DRUG|Placebo|Placebo will be administered by SC injection
219034927|NCT03250026|BEHAVIORAL|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
219034928|NCT03250026|BEHAVIORAL|Care Manager|Regular contact Care Manager during around 12 weeks
218893807|NCT03782233|DRUG|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
218893808|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
218893809|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 1 tablet of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
218893810|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 2 tablets of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
218893811|NCT01680666|PROCEDURE|central line placement|central line placement
218893812|NCT01680666|DEVICE|Ultrasound|Ultrasound guided central venous access
219034929|NCT02855437|DEVICE|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
219513989|NCT06547593|BEHAVIORAL|multifaceted nutrition intervention|"In this group, a 3-month multifaceted nutrition intervention will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: WeChat groups will be established to record the dietary status of the research subjects. The research subjects will be asked to keep a dietary diary and take photos of their diet daily. Trained researchers will record their daily diet and provide timely feedback to the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks. The content will include basic knowledge of frailty, prevention and treatment guidance, health outcomes, medication management, and healthy behaviors."
219513990|NCT06547593|BEHAVIORAL|Nutritional and Exercise Combined Intervention|To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
219513991|NCT06547593|BEHAVIORAL|Control Group|The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.
219513992|NCT04295395|DEVICE|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
219513993|NCT05937113|BIOLOGICAL|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
218893813|NCT04917965|OTHER|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
218893814|NCT01954641|OTHER|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
218893815|NCT01954641|OTHER|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
218893816|NCT02179411|OTHER|tilt test|
218893817|NCT04351217|BEHAVIORAL|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
218893818|NCT04351217|BEHAVIORAL|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
218893819|NCT00003619|BIOLOGICAL|filgrastim|
218893820|NCT00003619|DIETARY_SUPPLEMENT|vitamin E|
218893821|NCT00003619|DRUG|busulfan|
218893822|NCT00003619|DRUG|cytarabine|
218893823|NCT00003619|DRUG|etoposide|
219513994|NCT06544577|DRUG|ELacestrant|345 mg/day once daily oral dosing
219513995|NCT00197756|DIETARY_SUPPLEMENT|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
219513996|NCT00197756|DIETARY_SUPPLEMENT|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
219513997|NCT00197756|DIETARY_SUPPLEMENT|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
219513998|NCT00197756|OTHER|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
219513999|NCT02550756|DRUG|CTNX-4975|
219514000|NCT00102869|DRUG|levodopa|100mg levodopa per day over 10 days/ treatment phase
219514001|NCT00894907|OTHER|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI \>12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP\>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP\>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP\>65mmHg (MAP: Mean Arterial Pressure); IAPP \>60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
218893824|NCT00003619|DRUG|fludarabine phosphate|
218893825|NCT00003619|DRUG|isotretinoin|
218893826|NCT00003619|DRUG|topotecan hydrochloride|
218893827|NCT00003619|PROCEDURE|bone marrow ablation with stem cell support|
218893828|NCT00003619|PROCEDURE|peripheral blood stem cell transplantation|
218893829|NCT03259087|DRUG|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
218893830|NCT00755495|DRUG|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
218893831|NCT00755495|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
218893832|NCT00755495|DRUG|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
218893833|NCT00755495|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
218893834|NCT00335400|DRUG|Anesthetic Dilating Gel|
218893835|NCT00356044|PROCEDURE|Coronary angioplasty|
218893836|NCT03097965|DIETARY_SUPPLEMENT|PROGRAM|
218893837|NCT03097965|OTHER|DIET|
218893838|NCT00311935|PROCEDURE|method of hernia repair|
218893839|NCT04333368|BIOLOGICAL|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
218893840|NCT04333368|OTHER|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
218893841|NCT05066386|OTHER|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
218893842|NCT04043559|OTHER|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
218893843|NCT04043559|OTHER|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
219034930|NCT02855437|DEVICE|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
219034931|NCT05262556|DRUG|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
219034932|NCT05262556|DRUG|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
218893844|NCT04950465|OTHER|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste containing 0.454% SnF2.
218893845|NCT04950465|OTHER|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.
219034933|NCT05262556|DRUG|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
219034934|NCT00602147|OTHER|laboratory biomarker analysis|Blood or cheek cells wil be collected.
219034935|NCT01984775|DRUG|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
219514002|NCT00894907|OTHER|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP \>65mmHg;IAPP \>60mmHg"
219514003|NCT02989142|BEHAVIORAL|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
219514004|NCT00838877|DRUG|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
218893846|NCT04950465|OTHER|Sensodyne Repair and Protect|Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
218893847|NCT01978496|DRUG|Placebo|matching placebo
218893848|NCT01978496|DRUG|Eletriptan 20 mg|20mg oral
218893849|NCT01978496|DRUG|Eletriptan 40 mg|40mg oral
218893850|NCT01978496|DRUG|Eletriptan 80 mg|80mg oral
218893851|NCT00006252|DRUG|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
218893852|NCT00006252|DRUG|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
218893853|NCT00006252|BIOLOGICAL|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
218893854|NCT00006252|DRUG|G-CSF|5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5
218893855|NCT00006252|BIOLOGICAL|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
218893856|NCT01231919|DRUG|Akt inhibitor MK2206|Given PO
218893857|NCT01231919|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
218893858|NCT01231919|OTHER|pharmacological study|Correlative studies
219034936|NCT01984775|DRUG|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
219034937|NCT01984775|DRUG|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
219034938|NCT01984775|DRUG|Negative control|Negative control contains petrolatum.
219514005|NCT00838877|DRUG|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
219514006|NCT05653713|DRUG|CSL324|Single intravenous (IV) dose of CSL324
219514007|NCT05653713|DRUG|Placebo|IV dose of 0.9% saline
219514008|NCT01503723|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
219514009|NCT06357026|DEVICE|Percutaneous Ventricular Assist System（Phigine Medical）|Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.
218893859|NCT03263273|DRUG|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
218893860|NCT03263273|DRUG|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
218893861|NCT03263273|OTHER|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
218893862|NCT05277376|DRUG|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
218893863|NCT02883803|BIOLOGICAL|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
219610203|NCT01275846|DEVICE|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
219610204|NCT02262325|RADIATION|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
219610205|NCT02262325|DRUG|cisplatin|Given IV
219034939|NCT03264287|PROCEDURE|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
219034940|NCT03264287|PROCEDURE|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
219610206|NCT02262325|DRUG|etoposide|Given IV
219610207|NCT02262325|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
219610208|NCT02262325|OTHER|laboratory biomarker analysis|Correlative studies
218893864|NCT02883803|BIOLOGICAL|Injection of albumin alone|Injection of albumin alone
218893865|NCT00483691|BEHAVIORAL|Home Visit|Homw visits scheduled weekly for one year.
218893866|NCT01854970|DRUG|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
218893867|NCT02133898|OTHER|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
218893868|NCT03703544|OTHER|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
218893869|NCT03703544|OTHER|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
218893870|NCT00207311|DRUG|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
218893871|NCT00207311|BEHAVIORAL|Xenicare Program|Xenicare program for 36 weeks.
218893872|NCT02134860|OTHER|Bed rest|8 days of full bed rest
218893873|NCT02134860|OTHER|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
218893874|NCT02134860|OTHER|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
218893875|NCT02134860|OTHER|Cognitive testing|Daily testing of memory and concentration using standardized tests
218893876|NCT02134860|OTHER|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
218893877|NCT02134860|OTHER|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
218893878|NCT02134860|OTHER|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
218893879|NCT02072863|DRUG|Oprozomib|Study subjects will receive oprozomib administered orally.
218893880|NCT02072863|DRUG|Melphalan|Study subjects will receive melphalan 9 mg/m2.
218893881|NCT02072863|DRUG|Prednisone|Study subjects will receive prednisone 60 mg/m2.
219034941|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
219034942|NCT04613024|DRUG|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
219034943|NCT04613024|DRUG|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
219034944|NCT05289323|DRUG|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
219034945|NCT05289323|DRUG|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
218893882|NCT05416866|PROCEDURE|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
219034946|NCT02306512|PROCEDURE|H&E|Sample will be stained with H\&E according to standard procedures
219034947|NCT02306512|PROCEDURE|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
219034948|NCT02306512|PROCEDURE|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
219610209|NCT01695616|DRUG|Placebo|
219610210|NCT01695616|DRUG|Active drug|
219610211|NCT06494475|DRUG|GBS-NN/NN2 vaccine|Intramuscular injection.
219610212|NCT06494475|DRUG|Tdap vaccine|Intramuscular injection.
219514010|NCT06357026|DEVICE|intra-aortic balloon pump (IABP)|IABP provides intraoperative circulatory support during high-risk PCI.
219514011|NCT05809674|DEVICE|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
219514012|NCT04085081|OTHER|E-mail|Receive brief motivational text or email messages
219514013|NCT04085081|BEHAVIORAL|Exercise Intervention|Receive personalized walking program plus strength exercises
219514014|NCT04085081|OTHER|Quality-of-Life Assessment|Ancillary studies
219514015|NCT04085081|OTHER|Questionnaire Administration|Ancillary studies
219514016|NCT04085081|BEHAVIORAL|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
219514017|NCT04085081|OTHER|Text Message|Receive brief motivational text or email messages
219514018|NCT00996736|DRUG|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
219514019|NCT00996736|DRUG|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
219514020|NCT03577236|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
219514021|NCT02688608|DRUG|Pembrolizumab|200 mg IV once every 3 weeks
219514022|NCT01412138|OTHER|genetic analysis|"1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
219514023|NCT01729702|OTHER|blood sample collection|
219514024|NCT03863275|DEVICE|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
219514025|NCT03863275|OTHER|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
219514026|NCT01629875|DRUG|Generic equivalent of Clostridium Botulinum A Toxin|
219610213|NCT06494475|DRUG|Placebo|Intramuscular injection.
219610214|NCT04507399|BEHAVIORAL|Liquid Model|"To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages."
219610215|NCT05834556|BEHAVIORAL|Prehabilitation|Everyone will participate in a home-based prehab program with individual video sessions with a physiotherapist at 4 time points over a period of 3 weeks. The initial session will take an hour and consist of a subjective and physical assessment followed by an individualized exercise program demonstration and education. Patients will be instructed to complete the exercises independently 3x/week. The second and third sessions will be 30 minutes in duration and will check in on activity progress, the presence of abnormal responses to exercise, review exercise technique, address barriers and facilitators to activity completion as well as provide support and encouragement for the current level of activity. The final session will take 30 minutes and will review exercise progress, presence of abnormal responses to exercise followed by a reassessment of physical function.
219610216|NCT06550999|PROCEDURE|Laceration repair with adhesive strips|Repair of the patient's facial laceration with adhesive strips
219514027|NCT01629875|DRUG|Botox (Clostridium Botulinum A Toxin)|
219514028|NCT04065893|PROCEDURE|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
219514029|NCT04065893|DRUG|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
219514030|NCT02456909|DEVICE|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
219514031|NCT02456909|DEVICE|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
219610217|NCT06550999|PROCEDURE|Laceration repair with sutures|Repair of the patient's facial laceration with sutures
219610218|NCT01296087|DRUG|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
219610219|NCT01296087|DRUG|Placebo|Matching placebo capsule given once daily on Days 1 to 28
219610220|NCT00795899|DRUG|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
219034949|NCT02306512|PROCEDURE|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
218893883|NCT05416866|PROCEDURE|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
218893884|NCT05416866|PROCEDURE|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
218893885|NCT06021639|DIETARY_SUPPLEMENT|The last 24 hours will consume low fiber food.|White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
218893886|NCT06271434|DIETARY_SUPPLEMENT|THYROX (Atlantic krill oil|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
218893887|NCT06271434|DIETARY_SUPPLEMENT|Placebo|The control capsules will be made of olive oil of equal size and color.
218893888|NCT02172638|PROCEDURE|Fast-Track Protocol|
218893889|NCT02172638|PROCEDURE|Usual management|
218893890|NCT02059226|BEHAVIORAL|cognitive behavioural therapy|Internet-based CBT
218893891|NCT02059226|OTHER|Internet-based resource page|Static webpage
218893892|NCT03740659|DRUG|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
218893893|NCT03740659|DRUG|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
219514032|NCT02456909|DRUG|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
219514033|NCT01250158|DEVICE|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
219514034|NCT04604639|DIAGNOSTIC_TEST|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
219514035|NCT04464135|OTHER|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
219514036|NCT04464135|OTHER|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
219514037|NCT04203680|DRUG|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
219514038|NCT04203680|DRUG|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
219610221|NCT05435027|DRUG|GRT-R912, samRNA-Spikebeta-TCE11|IM injection of GRT-R912. Doses will be decided after safety review of Part A.
219610222|NCT05435027|DRUG|GRT-R914, samRNA-Spikebeta-TCE9|"Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A."
219610223|NCT05435027|DRUG|GRT-R918, samRNA-SpikeOmicron-N-TCE11|IM injection of GRT-R918. Doses will be decided after safety review of Part A.
219610224|NCT02623062|DRUG|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
219610225|NCT02623062|DRUG|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
218893894|NCT03740659|DRUG|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
218893895|NCT06502548|PROCEDURE|Endometriosis|"Anatomopathology waste will be recovered, i.e. the remainder of the endometriosis lesions and the remainder of the endometrial biopsy.~A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up."
218893896|NCT06502548|PROCEDURE|Tubal ligation or Hysterectomy|During surgery, an endometrial biopsy will be taken for research purposes. A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.
219610226|NCT01499264|DEVICE|MySkin patch|Hydrogel and polyurethane film
219610227|NCT01499264|DEVICE|Traditional Dressing|Gauze and Patch
219610228|NCT04110015|DEVICE|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
219610229|NCT03074578|BEHAVIORAL|Watching Video-clip 1|Video -clip 1 contains violent images and text
219610230|NCT03074578|BEHAVIORAL|Watching Video-clip 2|Video -clip 2 contains neutral images and text
218893897|NCT00548600|PROCEDURE|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
218893898|NCT00548600|RADIATION|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
218893899|NCT00671424|DRUG|Hydrochlorothiazide (HCTZ)|
218893900|NCT00671424|DRUG|Remogliflozin etabonate (GSK189075)|
218893901|NCT00671424|DRUG|Furosemide|
218893902|NCT04579341|DIETARY_SUPPLEMENT|probiotics|probiotics administration
218893903|NCT00931931|BIOLOGICAL|HSV1716|
219514039|NCT06354244|DEVICE|Electroacupuncture of 2 sessions per week|Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.
219514040|NCT06354244|DEVICE|Electroacupuncture of 3 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
219514041|NCT06354244|DEVICE|Electroacupuncture of 4 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
218893904|NCT05497089|DRUG|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
219514042|NCT02367495|DEVICE|PCB|PCB with Citrate-based excipient
219514043|NCT03923595|OTHER|Adherence intervention research|dedicated management
219514044|NCT03482713|DRUG|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
219514045|NCT03482713|DRUG|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
219514046|NCT06087809|BEHAVIORAL|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
219514047|NCT06087809|BEHAVIORAL|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
219610231|NCT01071915|DRUG|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
218893905|NCT05497089|DRUG|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
218893906|NCT05649007|DEVICE|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
218893907|NCT03869554|DIAGNOSTIC_TEST|Detection of Fabry disease|Systematic detection of Fabry disease
218893908|NCT05458206|OTHER|mulligan snag mobilization and diaphragmatic release|"The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement"
218893909|NCT01153126|BEHAVIORAL|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
218893910|NCT02366195|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
218893911|NCT01599000|DRUG|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
218893912|NCT02988778|DRUG|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
218893913|NCT02988778|DRUG|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
218893914|NCT02921659|DIETARY_SUPPLEMENT|Niagen™|nicotinamide riboside chloride, 250mg capsules
218893915|NCT02921659|DIETARY_SUPPLEMENT|Placebo|silicified microcrystalline cellulose, vegetarian capsule
218893916|NCT03485066|BEHAVIORAL|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
218893917|NCT03692039|PROCEDURE|M-pro files in rotating motion|An endodontic file that has controlled memory properties
218893918|NCT03692039|PROCEDURE|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
218893919|NCT00202007|DRUG|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
218893920|NCT00202007|DRUG|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
218893921|NCT01527968|DRUG|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
218893922|NCT01527968|DRUG|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
218893923|NCT01527968|DRUG|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
218893924|NCT04663503|OTHER|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
218893925|NCT01388569|OTHER|flow cytometry|
218893926|NCT01388569|OTHER|immunologic technique|
218893927|NCT01388569|OTHER|laboratory biomarker analysis|
218893928|NCT02107066|BEHAVIORAL|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
218893929|NCT04445142|PROCEDURE|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
218893930|NCT04946890|DRUG|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
218893931|NCT01434173|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
218893932|NCT01434173|DRUG|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
218893933|NCT00158717|DRUG|Hepsera|
218893934|NCT02348996|OTHER|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
218893935|NCT02348996|OTHER|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
218893936|NCT05747742|DEVICE|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
218893937|NCT02741635|DEVICE|New Nasal Pillows Mask|Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
218893938|NCT01427933|BIOLOGICAL|Ramucirumab (IMC-1121B)|Administered intravenously
218893939|NCT01427933|DRUG|Eribulin|Administered intravenously
219514048|NCT06463964|DIAGNOSTIC_TEST|Serum Creatinine|Laborataries for prediction of AKi in patients with ADHF
218893940|NCT00982826|DRUG|ABT-072|See Arms information for a detailed description.
218893941|NCT00982826|DRUG|Placebo|See Arms information for a detailed description.
218893942|NCT01643382|DRUG|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
218893943|NCT01643382|DRUG|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
218893944|NCT01633541|DRUG|AT-101|Patients will receive AT-101 40 mg orally two times a day.
218893945|NCT01633541|DRUG|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
218893946|NCT01633541|DRUG|Cisplatin|Cisplatin 100 mg/m2
218893947|NCT01633541|DRUG|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
218893948|NCT00491127|DRUG|gemcitabine|
218893949|NCT00491127|DRUG|cisplatin|
218893950|NCT00491127|DRUG|dexamethasone|
218893951|NCT00806039|OTHER|Early Renal Involvement|Renal Consultation
218893952|NCT06453967|DIAGNOSTIC_TEST|blood glucose levels|measurement of blood glucose level at admission ,during ICU admission and at discharge for patients with acute decompensated heart failure
218893953|NCT03472326|DRUG|GS-9131|Tablet(s) administered orally once daily
218893954|NCT03472326|DRUG|BIC|Tablet(s) administered orally once daily
218893955|NCT03472326|DRUG|TAF|Tablet(s) administered orally once daily
218893956|NCT03472326|DRUG|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
218893957|NCT03472326|DRUG|DRV|Tablet(s) administered orally once daily
218893958|NCT03472326|DRUG|RTV|Tablet(s) administered orally once daily
218893959|NCT01010971|DRUG|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
218893960|NCT01010971|DRUG|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
218893961|NCT01010971|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily
219514049|NCT01497938|DEVICE|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
219514050|NCT01497938|DEVICE|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
219514051|NCT02210403|DEVICE|transcranial direct current stimulation (tDCS)|
218893962|NCT03507205|DEVICE|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
218893963|NCT03507205|DEVICE|Xience Prime|Durable polymer-coated everolimus-eluting stents
219514052|NCT01823003|RADIATION|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall \> 1 cm, tumour size \< 2 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
219514053|NCT01823003|RADIATION|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall \> 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
219514054|NCT01823003|RADIATION|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
219610232|NCT05576688|OTHER|Balance|Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.
219610233|NCT05576688|OTHER|Trunk control|Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.
218893964|NCT03507205|DEVICE|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
218893965|NCT03507205|DEVICE|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
218893966|NCT03507205|DEVICE|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
218893967|NCT03994666|BIOLOGICAL|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
218893968|NCT03994666|BIOLOGICAL|Placebo (NaCl)|Placebo injection
218893969|NCT03826238|DIAGNOSTIC_TEST|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
218893970|NCT03360643|DIAGNOSTIC_TEST|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
218893971|NCT03360643|DIAGNOSTIC_TEST|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
218893972|NCT01011543|PROCEDURE|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
218893973|NCT03386721|DRUG|simlukafusp alfa|simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
218893974|NCT03386721|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
218893975|NCT03386721|DRUG|Gemcitabine|Single-agent treatment administered as per approved protocol.
218893976|NCT03386721|DRUG|Vinorelbine|Single-agent treatment administered as per approved protocol.
218893977|NCT05114473|OTHER|Workshops|Several face-to-face workshops given by a researcher
218893978|NCT05114473|OTHER|Online-accessed material|Access to a website containing the educational program
218893979|NCT04515758|OTHER|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
219034950|NCT06639126|DIETARY_SUPPLEMENT|Wild thyme extract|All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
219034951|NCT06639126|OTHER|Placebo|600 mg/day microcrystalline cellulose
219514055|NCT01823003|RADIATION|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
218893980|NCT04515758|OTHER|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
218893981|NCT04311255|PROCEDURE|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
219034952|NCT06038799|BEHAVIORAL|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
219514056|NCT00024453|BIOLOGICAL|teicoplanin|
219514057|NCT04546607|OTHER|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
219514058|NCT05895253|DEVICE|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
219514059|NCT04810819|DRUG|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
219514060|NCT04810819|DRUG|Placebo|Placebo
219610234|NCT05576688|OTHER|Gait|Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
219610235|NCT05576688|OTHER|Functional mobility|Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.
219610236|NCT05576688|OTHER|Fear of falling|Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
218893982|NCT03948841|OTHER|magnetic resonance imaging|
218893983|NCT01951651|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
218893984|NCT01951651|DRUG|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
218893985|NCT06164834|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
218893986|NCT06164834|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
218893987|NCT06164834|DRUG|Esomeprazole 20mg|Esomeprazole 20 mg tablet
218893988|NCT06182969|DRUG|APG-2575|Take orally once daily (QD) for 12 weeks.
218893989|NCT06182969|OTHER|Placebo|Take orally once daily (QD) for 12 weeks.
218893990|NCT01383226|PROCEDURE|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
219034954|NCT06356883|DRUG|IA Carboplatin + IA Caelyx|Intraarterial infusion of carboplatin combined with liposomal doxorubicin
219034955|NCT06356883|DRUG|IA Carboplatin + IA Etoposide Phosphate|Intraarterial infusion of carboplatin combined with etoposide phosphate
219034956|NCT04214288|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
219034957|NCT04214288|DRUG|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
219610237|NCT02094482|DEVICE|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
219610238|NCT01510951|DRUG|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
219610239|NCT04298944|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
219610240|NCT04298944|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep
219610241|NCT04298944|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
219514061|NCT00365352|DRUG|XP13512 600MG|XP13512 600MG ONCE DAILY
219514062|NCT00365352|DRUG|XP13512 1200MG|XP13512 1200MG ONCE DAILY
219514063|NCT00365352|DRUG|PLACEBO|PLACEBO ONCE DAILY
218893991|NCT01922141|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
219514064|NCT04258670|OTHER|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)
219514065|NCT00235859|DRUG|adalimumab|
219514066|NCT00235859|DRUG|methotrexate|
218893992|NCT01922141|DRUG|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
218893993|NCT01922141|DRUG|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
218893994|NCT01922141|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
218893995|NCT03314064|DRUG|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
218893996|NCT04528719|BIOLOGICAL|mRNA-1345|Formulation for injection
218893997|NCT04528719|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
218893998|NCT03088488|DIAGNOSTIC_TEST|fasting venous blood samples|
218893999|NCT02905266|BIOLOGICAL|Nivolumab|-Specified dose on specified days
218894000|NCT02905266|BIOLOGICAL|Ipilimumab|-Specified dose on specified days
218894001|NCT04871425|DRUG|Ketamine|IV ketamine
218894002|NCT04871425|DRUG|Fentanyl|IV fentanyl
218894003|NCT03149172|DEVICE|Equimatrix®|Ridge preservation bone grafting after tooth extraction
218894004|NCT03149172|DEVICE|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
219610242|NCT04298944|BEHAVIORAL|Emotional/ Behavioural assessments|Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
218894005|NCT03149172|DEVICE|Endobon®|Ridge preservation bone grafting after tooth extraction
218894006|NCT05801666|OTHER|Acupuncture|Acupuncture 5 points
218894007|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
218894008|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
219514067|NCT05895084|BEHAVIORAL|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
219514068|NCT01914315|BEHAVIORAL|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
219514069|NCT01914315|OTHER|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
218894009|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
219034958|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
219514070|NCT00190554|DRUG|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
219610243|NCT03327701|DRUG|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
219514071|NCT00190554|DRUG|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
218894010|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
219514072|NCT04371978|DRUG|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
219514073|NCT02546908|OTHER|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
219514074|NCT02368405|BEHAVIORAL|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
219514075|NCT02368405|BEHAVIORAL|Eat Smart, Live Better|Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
219610244|NCT03866889|OTHER|Strength|"In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight."
219610245|NCT03866889|OTHER|Normal activity|The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
218894011|NCT06251310|DRUG|SW-682|SW-682 tablet administered orally
218894012|NCT06251310|DRUG|Combination Therapy|Appropriate combination therapy
219203881|NCT01917942|DEVICE|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
218894015|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
219034959|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
219034960|NCT04327999|DRUG|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
219034961|NCT03792672|DRUG|TAK-653|TAK-653 tablets.
219034962|NCT03792672|DRUG|Placebo|TAK-653 placebo-matching tablets.
219034963|NCT03792672|DRUG|Ketamine|Ketamine intravenous infusion.
218894016|NCT03884790|DEVICE|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
218894017|NCT03382990|DEVICE|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
218894018|NCT04378270|DEVICE|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
218894019|NCT02726724|OTHER|5 observers|
218894020|NCT02726724|OTHER|1 observer|
218894021|NCT04944849|DIAGNOSTIC_TEST|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
218894022|NCT03399630|OTHER|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
218894023|NCT03399630|OTHER|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
218894024|NCT04584437|OTHER|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
218894025|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
218894026|NCT01132313|DRUG|BI 201335|40 weeks, QD
218894027|NCT01132313|DRUG|BI 207127|4 weeks, low dose TID
218894028|NCT01132313|DRUG|BI 201335|24 weeks, QD
219034964|NCT01408121|OTHER|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
219034965|NCT04606979|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
219034966|NCT01271868|BIOLOGICAL|IB1001|
219034967|NCT00125866|BEHAVIORAL|Flavonoid rich or flavonoid depleted chocolate drink|
219034968|NCT05424536|OTHER|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
219514076|NCT01680185|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
219034969|NCT02562651|DRUG|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
219034970|NCT02562651|OTHER|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
219514077|NCT01680185|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
219514078|NCT01680185|OTHER|Standard of care|all covered above
219034971|NCT05400616|PROCEDURE|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
219034972|NCT05400616|PROCEDURE|Placebo|Normal saline.
219514079|NCT01983956|BEHAVIORAL|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
219514080|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
219514081|NCT02081326|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
219514082|NCT02081326|BIOLOGICAL|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
218894029|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
218894030|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
218894031|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
218894032|NCT01132313|DRUG|BI 207127|40 weeks, high dose, TID
218894033|NCT01132313|DRUG|BI 207127|24 weeks, very high dose, BID
218894034|NCT01132313|DRUG|BI 207127|16 weeks, standard dose, BID
218894035|NCT01132313|DRUG|BI 201335|24 weeks, QD
218894036|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
219514083|NCT02322528|DRUG|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
219514084|NCT03712657|COMBINATION_PRODUCT|ERAS|"1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging."
218894037|NCT01132313|DRUG|Ribavirin|40 weeks, according to label
218894038|NCT01132313|DRUG|BI 207127|16 weeks, high dose, TID
218894039|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
218894040|NCT01132313|DRUG|BI 201335|28 weeks, QD
218894041|NCT01132313|DRUG|BI 201335|16 weeks, QD
218894042|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
218894043|NCT01132313|DRUG|BI 201335|24 weeks, QD
218894044|NCT01132313|DRUG|BI 201335|28 weeks, QD
218894045|NCT01132313|DRUG|BI 207127|24 weeks, standard dose, BID
218894046|NCT01132313|DRUG|BI 201335|24 weeks, QD
218894047|NCT01132313|DRUG|BI 201335|16 weeks, QD
218894048|NCT01132313|DRUG|BI 207127|16 weeks, high dose, BID
218894049|NCT01132313|DRUG|BI 201335|24 weeks, QD
218894050|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
219514085|NCT02957656|BIOLOGICAL|H7N9 pLAIV|10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
219514086|NCT02957656|BIOLOGICAL|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
218894051|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
219514087|NCT02957656|BIOLOGICAL|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
218894052|NCT01132313|DRUG|BI 207217|28 weeks, high dose BID
218894053|NCT01132313|DRUG|BI 201335|16 weeks, QD
218894054|NCT01132313|DRUG|BI 207127|24 weeks, high dose, TID
218894055|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
218894056|NCT01132313|DRUG|BI 207127|4 weeks, high dose, TID
218894057|NCT01132313|DRUG|BI 201335|28 weeks, QD
219514088|NCT01813656|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
218894058|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
218894059|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
218894060|NCT00747084|PROCEDURE|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
218894061|NCT06359613|DIETARY_SUPPLEMENT|nutrient rich food product|Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
218894062|NCT06359613|DIETARY_SUPPLEMENT|food product|Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
218894063|NCT04041934|DIETARY_SUPPLEMENT|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
218894064|NCT01678378|BEHAVIORAL|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
218894065|NCT04078347|PROCEDURE|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
218894066|NCT04452019|DEVICE|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
218894067|NCT04452019|DEVICE|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
218894068|NCT05113446|DIAGNOSTIC_TEST|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
218894069|NCT03830359|OTHER|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
218894070|NCT02715609|DRUG|Disulfiram|
218894071|NCT02715609|DRUG|Copper Gluconate|
218894072|NCT02715609|PROCEDURE|Surgery|
218894073|NCT02715609|RADIATION|Radiation|
218894074|NCT02715609|DRUG|Temozolomide|
218894075|NCT06966440|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)-based MRD|MRD testing will be performed before the start of the first treatment cycle, and at weeks 8 and 11 of each subsequent cycle. MinerVa Prime is a tumor-informed MRD assay based on a fixed panel spanning 769 cancer-related genes.
219514089|NCT01813656|DRUG|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
219514090|NCT03070249|BEHAVIORAL|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
219514091|NCT05123456|PROCEDURE|Radiography|Comparative X-ray of the single knee at 30 ° flexion.
219514092|NCT02946385|BIOLOGICAL|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY\_ 0\_2 Group, ABCWY\_ 0\_2\_6 Group and ABCWY\_ 0\_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
218894076|NCT06966440|DRUG|adjuvant chemotherapy regimens|Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1 monotherapy/adjustable S-1 monotherapy, fluorouracil monotherapy/adjustable fluorouracil monotherapy, GEM plus CAP regimen/adjustable GEM plus CAP regimen, mFOLFIRINOX regimen, GEM plus nab-paclitaxel regimen/adjustable GEM plus nab-paclitaxel regimen.
218894077|NCT04457232|PROCEDURE|Computed Tomography|Undergo PET/CT imaging
218894078|NCT04457232|OTHER|Gallium Ga 68 FAPi-46|Given IV
218894079|NCT04457232|PROCEDURE|Positron Emission Tomography|Undergo PET/CT imaging
219514093|NCT02946385|BIOLOGICAL|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B\_0\_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
218894080|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (low dose)|Participants are administered 25 µg of vilanterol + fluticasone furoate
218894081|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (high dose)|Participants are administered 100 µg of vilanterol + fluticasone furoate
219514094|NCT02206204|DRUG|selexipag|
218894082|NCT06066606|DRUG|Placebo|Participants are administered placebo
218894083|NCT02612922|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
218894084|NCT02612922|DRUG|Placebo|Placebo administered orally twice daily for five days
218894085|NCT02657304|BEHAVIORAL|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
218894086|NCT02657304|OTHER|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
219034973|NCT05526326|DEVICE|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
219034974|NCT05372120|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
219514095|NCT02206204|DRUG|placebo for selexipag|
219514096|NCT02206204|DRUG|moxifloxacin|
219514097|NCT02206204|DRUG|moxifloxacin-matching placebo|
219514098|NCT05108623|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
219514099|NCT05108623|DRUG|Approved ICIs|Nivolumab and pembrolizumab
219514100|NCT03839706|DEVICE|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
218894087|NCT06458452|OTHER|Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support|Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
218894088|NCT00310089|BIOLOGICAL|filgrastim|
218894089|NCT00310089|BIOLOGICAL|pegfilgrastim|
218894090|NCT00310089|DRUG|cediranib maleate|
218894091|NCT00310089|DRUG|cyclophosphamide|
218894092|NCT00310089|DRUG|docetaxel|
218894093|NCT00310089|DRUG|doxorubicin hydrochloride|
218894094|NCT00310089|OTHER|laboratory biomarker analysis|
218894095|NCT00310089|PROCEDURE|conventional surgery|
218894096|NCT00310089|PROCEDURE|neoadjuvant therapy|
218894097|NCT02240641|DRUG|Lacidipine|
218894098|NCT02240641|DRUG|Diuretics|
218894099|NCT02240641|DRUG|antihypertensive drugs|
218894100|NCT02240641|DRUG|alpha blockers|
218894101|NCT02240641|DRUG|Angiotensin-Converting Enzyme Inhibitors|
218894102|NCT02240641|DRUG|beta blockers|
218894103|NCT03201419|DRUG|FE 201836|Oral solution for daily intake
218894104|NCT03201419|DRUG|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
218894105|NCT03201419|DRUG|Placebo oral solution|Manufactured to mimic experimental drug
218894106|NCT03201419|DRUG|Placebo ODT|Manufactured to mimic experimental drug
218894107|NCT01123616|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
218894108|NCT01307436|BIOLOGICAL|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
218894109|NCT01307436|BIOLOGICAL|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
219034975|NCT01185873|DRUG|danoprevir|Repeated oral doses
219034976|NCT01185873|DRUG|ritonavir|Repeated oral doses
219034977|NCT01379742|DEVICE|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
219034978|NCT01379742|DEVICE|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
219034979|NCT03387449|DEVICE|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
219514101|NCT00439790|PROCEDURE|Microneurography|Microneurography
219514102|NCT01583777|DRUG|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
219514103|NCT00006250|DRUG|chlorambucil|
219514104|NCT00006250|DRUG|dexamethasone|
219514105|NCT00006250|DRUG|fludarabine phosphate|
219514106|NCT00006250|DRUG|mitoxantrone hydrochloride|
219610246|NCT03632369|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
218894110|NCT05280353|OTHER|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
218894111|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
218894112|NCT06047145|DIETARY_SUPPLEMENT|soy isoflavones|1 capsule daily for 84 days
218894113|NCT06047145|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 84 days
218894114|NCT06261905|DRUG|[11C]-PHNO|PHNO is used as a tracer for in-vivo imaging.
218894115|NCT06261905|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.
218894116|NCT06261905|OTHER|Placebo Control|A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.
218894117|NCT06261905|PROCEDURE|PET Scan|A high resolution PET Scan performed using a NeurExplorer CT scanner.
218894118|NCT06263829|OTHER|Use of Tappt App|Use of Tappt, a novel digital medication companion solution
218894119|NCT05073471|BEHAVIORAL|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
218894120|NCT05073471|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
219514107|NCT01060670|DEVICE|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
219514108|NCT01060670|OTHER|Conventional Wound Therapy|Conventional Wound Therapy
219514109|NCT02596503|DRUG|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
219514110|NCT02596503|DRUG|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
219514111|NCT02596503|OTHER|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
219514112|NCT04442776|BEHAVIORAL|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
219514113|NCT04714658|OTHER|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~1. st group collective workshop : allow the patient to better understand autoimmune~2. nd workshop : fatigue and techniques that enable its best management.~3. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
219514114|NCT05942703|OTHER|saliva samples|Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
219514115|NCT01366508|OTHER|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
219514116|NCT01366508|OTHER|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
219514117|NCT02062047|PROCEDURE|FMSRP|FMSRP in a maximum of 24 hours.
219610247|NCT00608101|DRUG|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
219610248|NCT00608101|DRUG|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
219610249|NCT04899154|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
218894121|NCT06324630|OTHER|Produce Prescription Delivery|Fruit and vegetable box delivery
219514118|NCT02062047|DRUG|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
219514119|NCT02062047|PROCEDURE|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
219514120|NCT02062047|OTHER|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
219514121|NCT01190683|DRUG|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
219514122|NCT01190683|DRUG|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
219514123|NCT01190683|DRUG|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
219514124|NCT01190683|OTHER|lactose placebo|similar number of granules and tablets as active group
219514125|NCT01190683|OTHER|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
219514126|NCT04584268|BEHAVIORAL|mindfulness|in person and smart phone application mindfulness practice
219514127|NCT04584268|OTHER|standard medical education|standard medical education / control
218894122|NCT06324630|OTHER|Healthy Meal Kit Delivery|Ingredients to cook healthy meals delivered to home
219034980|NCT02772562|BIOLOGICAL|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
219514128|NCT01319656|BEHAVIORAL|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
219514129|NCT02105376|DEVICE|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
219514130|NCT00487344|PROCEDURE|Non-Personalized Meal Planning|
219610250|NCT04899154|OTHER|stool sampling|Participants will provide one stool sample at inclusion
219610251|NCT06147193|OTHER|with baseline intervention and power training interventions|"Group A (with power training ) was treated with~* squats jump,~* change of direction speed,~* countermovement jump,~* bench press,~* Romanian deadlift~* barbell squats,~* resistance band sprints,~* stair sprints~* weighted sled pulls"
219610252|NCT06147193|OTHER|baseline interventions and without power training interventions|"Group B (without power training) was treated with~* squats jump~* change of direction speed~* countermovement jump~* barbell squats~* resistance band sprints~* stair sprints~* Weighted sled pulls."
219610253|NCT03885986|RADIATION|Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee
218894123|NCT06324630|OTHER|Produce Prescription Mobile Market|Voucher to purchase fruits and vegetables at a mobile market
219514131|NCT00487344|PROCEDURE|Personalized Meal Planning and Dietetic Consultation|
219514132|NCT05210023|OTHER|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
219514133|NCT05210023|OTHER|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
219514134|NCT00133770|DRUG|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
219514135|NCT06029036|DRUG|Darolutamide+ADT|"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"
219514136|NCT00154024|DRUG|atorvastatin|
219610254|NCT00387335|DRUG|sunitinib malate|Given orally
219610255|NCT05583461|PROCEDURE|Positive end-expiratory pressure titration|Positive end-expiratory pressure level
219034981|NCT06306456|DRUG|GH21|Oral, 15mg BIW/6mg QD
219034982|NCT06306456|DRUG|Tagrisso|Oral, 80mg QD
219034983|NCT03095456|DRUG|Revefenacin|Revefenacin administered via nebulization.
219610256|NCT05434988|PROCEDURE|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
219610257|NCT01831661|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
219034984|NCT03095456|COMBINATION_PRODUCT|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
219034985|NCT03095456|DRUG|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
219514137|NCT00154024|DRUG|irbesartan|
219514138|NCT06126081|DEVICE|LBBP+GDMT|LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
218894124|NCT03838978|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
219034986|NCT03095456|DRUG|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
219610258|NCT01831661|DRUG|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
219610259|NCT04085237|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
219610260|NCT04085237|OTHER|Sham|Saline will be used at the same amounts as the ropivacaine arm.
219610261|NCT01269918|DRUG|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
219034987|NCT02768675|DEVICE|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
219034988|NCT00265824|DRUG|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
218894125|NCT06813417|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. Following infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance3.
218894126|NCT06599593|DIETARY_SUPPLEMENT|SQ-LNS|CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories).
219034989|NCT00265824|DRUG|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
219034990|NCT03243812|BIOLOGICAL|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
219034991|NCT03243812|OTHER|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
219034992|NCT03243812|OTHER|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
219034993|NCT03243812|OTHER|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
219034994|NCT00855088|DRUG|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
219034995|NCT00855088|DRUG|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
219034996|NCT00855088|DRUG|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
219034997|NCT04534764|DEVICE|etafilcon A with cosmetic pattern|TEST
219034998|NCT04534764|DEVICE|1-Day Acuvue DEFINE Vivid Style|CONTROL
219034999|NCT00164242|DRUG|Galantamine|
219035000|NCT03583996|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
219035001|NCT00189748|DRUG|Tacrolimus|
219035002|NCT04796246|OTHER|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
219035003|NCT04796246|OTHER|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
219035004|NCT03161483|DRUG|CC-220|CC-220
219514139|NCT06126081|DRUG|GDMT|GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
219514140|NCT00185523|PROCEDURE|Allogeneic hematopoietic cell transplantation|
219514141|NCT00399113|DRUG|188Re-PTI-6D2|monoclonal antibody
219514142|NCT01456182|DRUG|AFX-2|Dose level 1
219514143|NCT01456182|DRUG|AFX-2|Dose level 2
219514144|NCT01456182|DRUG|AFX-2|Dose level 3
219514145|NCT01456182|DRUG|AFX-2|Dose level 4
219514146|NCT01456182|DRUG|AFX-2|Dose level 5
219514147|NCT04241159|BIOLOGICAL|Allogeneic Young Plasma|"The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks."
219514148|NCT04826510|DRUG|Perospirone hydrochloride tablets|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
219514149|NCT04826510|DRUG|Lithium carbonate + perospirone hydrochloride|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
219514150|NCT04826510|DRUG|Lithium Carbonate Pill|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
219514151|NCT01521195|DEVICE|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
219514152|NCT03382366|DIAGNOSTIC_TEST|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
219610262|NCT01269918|DRUG|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
219610263|NCT02481206|DEVICE|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
219610264|NCT05001893|DEVICE|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
219610265|NCT04990453|OTHER|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
219610266|NCT03797170|OTHER|Gut microbiota samples|Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy
218894127|NCT06599593|OTHER|Integrated Nutritional Screening|In conjunction with SMC administration, CHWs screen children for MUAC. CHW refers children with MUAC \&lt;12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.
218894128|NCT06859476|DRUG|Manzanilla Sophia®|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
218894129|NCT06859476|DRUG|Meticel Ofteno® 0.5%|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
218894130|NCT06672042|DEVICE|CHAMP App|"CHAMP® App is a proprietary, downloadable, mobile Software Application and software platform designed and developed by the Children's Mercy Hospital of Kansas City (CMH), that permits parents and caregivers to transmit to the care team data to permit remote monitoring of the patient's condition. The parent or caregiver enters into the CHAMP App data including vital signs, intake and output, video, and images of patients (collectively, CHAMP® Data), which operates on computers, mobile devices, and handheld computers. The CHAMP® App is intended to be used in the clinical care of pediatric patients in the home setting that are followed by specialty health care teams to improve patient self-management through the use of asynchronous data. Videos and data related to the patient are entered by the parent and sent electronically to the Clinical Care Team as recommended by the clinical team."
218894131|NCT05508087|DIAGNOSTIC_TEST|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
218894132|NCT03384641|DRUG|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
219035005|NCT03161483|OTHER|Placebo|Placebo QD PO
219035006|NCT05766306|DIETARY_SUPPLEMENT|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
219035007|NCT05766306|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
219035008|NCT01523548|DRUG|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
219035009|NCT03818165|BIOLOGICAL|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
219035010|NCT03224702|DRUG|M6495|Subjects will receive M6495 on Day 1
219035011|NCT03224702|DRUG|Placebo|Subjects will receive placebo matched to M6495 on Day 1
219514153|NCT00275002|DRUG|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
219514154|NCT00275002|DRUG|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
219514155|NCT04749602|DRUG|Nivolumab|40 mg of the nivolumab will be used intrapleurally (once).
219514156|NCT01627275|BIOLOGICAL|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
219514157|NCT01819636|OTHER|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
219514158|NCT06123507|BEHAVIORAL|Student practitioner perspective-taking intervention|This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
219514159|NCT05198804|DRUG|ZN-c3|ZN-c3 will be administered.
219514160|NCT05198804|DRUG|Niraparib|Niraparib will be administered.
219610267|NCT02088762|PROCEDURE|surgical excision|comparison of safety margin 1 versus 2 cm
219610268|NCT04681716|OTHER|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
218894133|NCT03265236|DIAGNOSTIC_TEST|Anti - modified citrullinate vimentin|patients with early and late RA
218894134|NCT06998563|OTHER|Rotational Profile- Hip Internal and External Rotation Measurement|Hip internal and external rotation angles measurement, hip range of motion evaluations will be performed. Measurements will be performed using a universal goniometer. The children will be positioned in the prone position with their knees flexed 90° and placed on the edge of the bed. The tuberositas tibia will be chosen as the pivot point of the goniometer, and the movable arm will be aligned with the tibial crista. The fixed arm will be placed perpendicular to the floor and the movable arm will be guided by the tibial crista. During hip rotation, it will be ensured that the hip remains stable and the movement occurs only in the hip joint.
219035012|NCT04128683|DRUG|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
219035013|NCT04128683|DRUG|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
219035014|NCT04128683|DRUG|Placebo|Placebo pill with no active drug ingredients
219035015|NCT05984355|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
219035016|NCT03608488|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
219035017|NCT03608488|OTHER|Exercise|Core stability, balance exercises
218894135|NCT06998563|OTHER|Rotational Profile- Craig's Test Measurement|The Craig's (Ryder) test, also known as the 'Trochanteric Prominence Angle Test', will be performed on the children included in the study according to the following protocol. The children will be placed in a prone position. The physiotherapist stood on the opposite side of the hip to be tested. The hips of the children will be placed in the extension position and the knee on the side to be tested will be held in the 90° flexion position. The physiotherapist palpated the trochanter major with the left hand and internal rotated the hip with the right hand. At the point where the trochanteric process will be most prominent, the angle between the tibia and the vertical plane will be measured using a goniometer and the femoral anteversion angle will be recorded.
218894136|NCT06998563|OTHER|Rotational Profile- Foot/Thigh Angle Measurement|Foot/thigh angle assessment will be performed by measuring the angle between the long axis of the femur bone and the foot with a goniometer in the prone position. One arm of the goniometer will be placed parallel to the long axis of the femur, while the other arm will be placed so that it passes through the 2nd and 3rd metatarsals. Normally, the thigh-foot angle should be in external rotation between 10-15°. In young children, this angle can be considered normal up to 30°. A decrease in the thigh-foot angle will indicate internal tibial torsion (expressed as a negative value), which is the internal rotation of the tibia. In this case, there is an abnormal internal rotation of the tibia. If the measured foot-thigh angle exceeds 30°, it is considered to be external tibial torsion (external rotation of the tibia).
218894137|NCT06998563|OTHER|Rotational Profile- Heel Bisector Line Measurement|The heel bisector line test is an evaluation method that helps diagnose metatarsus adductus. During the test, the child will be placed in the prone position with the heel between the physiotherapist's fingers. Then, the midpoint of the lines drawn from the malleoli will be determined. From this point, a perpendicular line will be drawn from the heel to the toes along the foot axis with the help of a goniometer. Normally, this line should end between the 1st and 2nd toes. If the line ends at the 3rd, 4th or 5th toes, this may indicate the presence of metatarsus adductus.
219514161|NCT03408379|OTHER|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~* A Tissue sample will be taken during the surgery~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
219514162|NCT04567602|DRUG|PAH medication|There will be no specific interventions.
219514163|NCT06250595|OTHER|Collection of clinical and laboratory data from EHR.|Observational sutdy
218894138|NCT06998563|OTHER|Rotational Profile- Q Angle Measurement|The Q-angle is defined as the angle formed between an imaginary line connecting the anterior superior iliac spine of the pelvis to the midpoint of the patella and the proximal projection of the line from the tibial tubercle to the center of the patella. The child will first be placed in a supine position with legs extended and muscles relaxed, and the midpoint of the patella will be marked with a colored pencil. Then, the goniometer will be placed at the midpoint of the patella and care will be taken to fix the movable arm so that it points to the anterior superior iliac spine and the fixed arm so that it follows the tibia and the angle between the two will be recorded. The measurement will be recorded in two different positions, lying and standing. Q angle between 10-15° in boys and 15-20° in girls will be considered normal.
218894139|NCT06998563|OTHER|Rotational Profile- Navicular Drop Test Measurement|The navicular drop test is commonly used in clinics to assess pes planus. It will begin with the child sitting, feet flat on the floor, and no weight bearing. The navicular tubercle will be palpated and marked first, then the distance from the tubercle to the floor will be measured. The child will then stand with equal weight on both feet and the distance will be measured again. Measurements will be taken bilaterally and recorded in millimeters. The difference between the weighted and unweighted measurements will indicate foot posture: 5-9 millimeters is normal (neutral), 10 millimeters or more will indicate pronation (inward rotation), and 4 millimeters or less will indicate supination (outward rotation). This test is important for assessing the degree of pes planus.
219035018|NCT01544530|OTHER|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
219035019|NCT04448899|DRUG|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
219035020|NCT04448899|DRUG|Blacebo plus standard treatment|Blacebo plus standard treatment
219035021|NCT00881946|DRUG|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
219035022|NCT03998553|PROCEDURE|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
219035023|NCT02127632|DEVICE|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
219514164|NCT05431881|PROCEDURE|Binaural beat|Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.
219514165|NCT05431881|PROCEDURE|Silent|Apply a wave file which is created in silence.
219514166|NCT02494765|DEVICE|I-gel TM|Airway management with I-gel
219514167|NCT02494765|DEVICE|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
219514168|NCT02909140|DRUG|Topical phenylephrine 2.5%|
219514169|NCT02909140|DRUG|Topical cyclopentolate 1%|
219514170|NCT02909140|DRUG|Intracameral Lidocaine 1%|
219514171|NCT02909140|DRUG|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
218894140|NCT06998563|OTHER|Rotational Profile- Foot Progression Angle Measurement|The foot progression angle will be used as an important parameter in determining potential disorders and alignment errors in the child's walking pattern by reflecting the rotational relationships between the femur, tibia and foot. For this measurement, two chairs will first be placed opposite each other with a distance of 2 m between them. Then, the child will be asked to sit on the chair. In the sitting position, the middle of the heel and the second toe will be marked with colored paint. After the marking, the child will be asked to walk naturally on a flat surface to the chair opposite. The child will stand up from the sitting position and walk approximately 5-6 steps on a flat surface to the chair opposite. Then, the child will be asked to sit on the chair opposite and clean the paint off his foot. This colored marking will be made in a way that will create the child's walking traces. When the child finishes walking, these traces will be measured in degrees using a goniometer.
218894141|NCT06998563|OTHER|Muscle Shortness/Flexibility- Thomas Test Measurement|The Thomas test will be performed to evaluate shortness/tightness in the hip flexor muscle group, especially in the iliopsoas muscle. The child will be placed in the supine position, the lumbar spine will be fixed and the assessment will begin. During the test, while the assessed hip is in knee extension, the opposite hip and knee will be passively flexed by the physiotherapist, and the hip movement of the assessed side will be observed during this time. The Thomas test will be recorded as negative if no flexion movement is observed in the assessed hip. In the presence of shortness/tightness, the assessed hip is seen to be flexed, and in this case, the Thomas test will be recorded as positive.
218894142|NCT06998563|OTHER|Muscle Shortness/Flexibility- Popliteal Angle Measurement|The popliteal angle test will be used to evaluate shortness or tightness of the hamstring muscles. The hip and knee will be placed in a 90° flexion position while the child is in the supine position. While the physiotherapist passively moves the knee joint towards extension, the popliteal angle will be measured using a goniometer. While one arm of the goniometer is placed parallel to the lateral surface of the femur, the other arm is held parallel to the fibula head and the angle will be measured. The knee joint will be extended until it encounters resistance and the angle between the tibia and the vertical plane will be recorded as the popliteal angle.
219035024|NCT02127632|DEVICE|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
219035025|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
219035026|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
219035027|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
219035028|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
219035029|NCT04345952|BEHAVIORAL|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
219035030|NCT01222975|DRUG|Risperidone|orally disintegrating tablets
219035031|NCT04238728|DEVICE|Silverlon|silver nylon dressing will be applied daily
219514172|NCT02580630|BEHAVIORAL|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
219514173|NCT02580630|OTHER|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
219514174|NCT02580630|DRUG|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
219514175|NCT02580630|DRUG|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
219514176|NCT01964664|BEHAVIORAL|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
219514177|NCT01964664|BEHAVIORAL|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
219610269|NCT04681716|OTHER|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
219035032|NCT00793338|DRUG|Sildenafil|Sildenafil 20mg three times a day for 3 months.
219610270|NCT05900778|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
219610271|NCT05900778|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
219610272|NCT00769379|OTHER|Laboratory Biomarker Analysis|Correlative studies
219610273|NCT00769379|BIOLOGICAL|Trastuzumab|Given IV
218894143|NCT06998563|OTHER|Muscle Shortness/Flexibility- Silfverskiöld Test Measurement|Gastrocnemius assessment will be evaluated with the Silfverskiold test for all children participating in the study. The assessment will be performed bilaterally in supine positions where the child does not bear weight on their feet. The knee joint will be in full extension and 90° flexion, the subtalar joint will be in a neutral position, and the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles will be recorded in degrees (°). Passive ankle dorsiflexion of ≤ 10° with the knee extended and a minimum of 10° increase in dorsiflexion with the knee flexed will be considered as isolated gastrocnemius muscle shortness.
218894144|NCT06998563|OTHER|Muscle Shortness/flexibility- Ober Test Measurement|The Ober test will be performed to measure the length of the iliotibial band. Both the Ober test and the modified Ober test are widely used and accepted tests to assess iliotibial band length. During the test, the child will be placed in a supine position with the lower leg slightly bent at the hip and knee. The upper leg will be in 90° flexion of the knee. Once positioning is complete, the physiotherapist will hold the ankle of the upper leg with one hand and stabilize the hip with the other hand. The leg will then be abducted and the knee extended and the leg moved until the femur is in line with the body. Finally, the thigh will be allowed to fall towards the surface in this plane and the result of the test will be judged by the amount of adduction of the hip. If the knee hangs in the air, the test is positive. If the knee falls, the test is negative
219514178|NCT03318692|PROCEDURE|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
219514179|NCT03318692|PROCEDURE|CT|CT of operated area is performed within 7 days of surgery
219514180|NCT05557786|DEVICE|Transcranial Alternating Current Stimulation|Cerebellar Transcranial Alternating Current Stimulation（tACS）
219514181|NCT04607239|PROCEDURE|Telemonitoring|"* A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check."
218894145|NCT06998563|OTHER|Muscle Shortnes/flexibility- Duncan-Ely Test Measurement|The Duncan-Ely test will be used to evaluate the shortness and tightness of the rectus femoris muscle. While the child is lying in the prone position, the hip will be fixed with one hand by the physiotherapist and the hip and knee will be kept in extension. In this position, the knee joint will be passively flexed in order to stretch the rectus femoris muscle on the tested side. If no shortness or tightness is observed in the rectus femoris muscle on the same side during the test and hip extension is maintained, the Duncan-Ely test will be recorded as negative. However, when the knee is flexed and a flexion movement is observed in the hip, the test will be recorded as positive.
219035033|NCT02901951|BIOLOGICAL|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
219035034|NCT05727254|BEHAVIORAL|Agility training|Multi-component (strength, balance, cognition) exercise training.
219035035|NCT05727254|BEHAVIORAL|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
219035036|NCT05727254|BEHAVIORAL|Exercise diary|Participants are instructed to write down their physical activity and exercises.
219035037|NCT05389657|BEHAVIORAL|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
219035038|NCT05389657|BEHAVIORAL|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
219035039|NCT05228275|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219035040|NCT05228275|OTHER|Survey Administration|Complete survey
219035041|NCT01907828|DEVICE|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
219035042|NCT01907828|DEVICE|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
219203882|NCT01917942|OTHER|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
219203883|NCT05755711|DEVICE|Shockwave Medical Coronary IVL System|Coronary Intravascular Lithotripsy (IVL)
219514182|NCT04607239|PROCEDURE|Usual Care without Telemonitoring|"* Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
219514183|NCT04790084|OTHER|no intervention|no intervention
219514184|NCT03363295|DRUG|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
219514185|NCT02624843|DRUG|Benzyl Alcohol Lotion 5%|White topical lotion
219514186|NCT02624843|DRUG|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
219514187|NCT02624843|DRUG|Placebo|White topical lotion
219610274|NCT00769379|RADIATION|Whole Breast Irradiation|Undergo standard whole breast irradiation
219514188|NCT00576381|DRUG|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
219610275|NCT05021835|DRUG|Ziltivekimab B|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
219610276|NCT05021835|DRUG|Ziltivekimab C|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
219610277|NCT05021835|DRUG|Placebo (Ziltivekimab B)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
219610278|NCT05021835|DRUG|Placebo (Ziltivekimab C)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
219610279|NCT01928472|BIOLOGICAL|H7N9c low dose with adjuvant|
219610280|NCT01928472|BIOLOGICAL|H7N9c medium dose with adjuvant|
219610281|NCT01928472|BIOLOGICAL|H7N9c high dose with adjuvant|
219610282|NCT01928472|BIOLOGICAL|H7N9c high dose without adjuvant|
218894146|NCT06998563|OTHER|Muscle Shortness/Flexibility- Sit-Reach Test Measurement|The Sit-Reach test will be used to evaluate the flexibility of the hamstring and lower back muscle groups. The S\&R Sit and Reach® table will be used for this test. The child will sit in front of the table with dimensions of 55 centimeters long, 35 centimeters wide, and 30 centimeters high, and his/her feet will be positioned on the foot surface of the table. The child will be asked to place his/her hands on top of each other and stretch forward in a slow and controlled manner, bringing the ruler on the table forward. He/she will be asked to wait 1-2 seconds at the farthest point without stretching forward or backward. Scoring will be done according to the ruler on the table. (On this table, the child's ability to bring the ruler to the tips of his/her toes corresponds to 23 centimeters). The test will be repeated three times for each child to ensure reliability, and the highest value will be recorded in centimeters.
218894147|NCT06998563|OTHER|Postural Control Assessment with Biodex Balance System (BBS)|Postural stability, limits of stability, and sensory integration of balance will be assessed using the Biodex Balance System®. Biodex Balance System is a validated and reliable device used to evaluate postural stability, limits of stability, and fall risk. It consists of a balance platform, arm supports, a screen, and a printer. The platform can be set to static or dynamic mode (12 levels; level 12 = most stable, level 1 = least stable with up to 20° movement in all directions). Prior to testing, children will be informed about the procedures. The heel and toe positions will be recorded based on medial-lateral (B-J), anterior, and posterior (1-21) axes. Arm support and screen height will be individually adjusted. Child-specific posture and identification data will be entered into the system. Three tests will be performed: postural stability, limits of stability, and sensory integration of balance.
218894148|NCT06998563|OTHER|Muscle Strength Assessment with Micro-FET2|Muscle tests will be performed using the MicroFET 2 digital hand dynamometer according to the device manual. The measurement will be performed in supine, prone, side-lying and sitting positions by preventing compensatory movements. During the test, the arms will be positioned so that they will not receive power from anywhere on/to the side of the body. Measurements will be performed bilaterally. While the child to whom the test is applied is expected to perform the requested movement with all his/her strength, the evaluating physiotherapist will apply resistance in the opposite direction in proportion to the strength. During the evaluation of the same muscle, a 30-second break will be given between repetitions, and a five-minute rest will be given before moving on to the test for a different muscle. Isometric muscle strength of the Iliopsoas, Gluteus Maximus, Gluteus Medius, Quadriceps, Hamstring, Tibialis Anterior, and Gastrosoleus muscles will be evaluated.
219203884|NCT06099665|BEHAVIORAL|Automated alert|Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
219514189|NCT00972881|BIOLOGICAL|cetuximab|
219203885|NCT06463314|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
219514190|NCT00972881|DRUG|capecitabine|
219514191|NCT00972881|DRUG|irinotecan hydrochloride|
219203886|NCT04239157|BIOLOGICAL|Canakinumab|Given SC
219203887|NCT05765851|DRUG|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
219514192|NCT00972881|PROCEDURE|neoadjuvant therapy|
219514193|NCT00972881|PROCEDURE|therapeutic conventional surgery|
219514194|NCT00972881|RADIATION|radiation therapy|
219514195|NCT01747850|BEHAVIORAL|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
219514196|NCT01747850|DRUG|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
219514197|NCT01747850|DRUG|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
219514198|NCT04357275|OTHER|ICU treatment|ICU treatment according to standard of care
219514199|NCT05123937|OTHER|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
219610283|NCT04117438|OTHER|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
219610284|NCT02301013|PROCEDURE|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
219610285|NCT02301013|DRUG|300 cc saline|
219610286|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
219610287|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
219610288|NCT06174766|DRUG|HGP2102-1|Test drug
219610289|NCT06174766|DRUG|HGP2102-2|Test drug
219610290|NCT06174766|DRUG|RLD2209-1|Control drug
219610291|NCT06174766|DRUG|RLD2209-2|Control drug
218894149|NCT06998563|OTHER|Functional Capacity Assessmnet with 6 Minute Walk Test Measurement|"The 6MWT will be done on a flat 30-meter track marked every 3 meters, with clear start and finish lines. Before the test, the child rests 15 minutes while contraindications will be checked. If none, blood pressure, oxygen saturation, pulse, and Borg scale scores for dyspnea and fatigue will be recorded. Medications taken will be noted. The child will be instructed to walk at their own pace for 6 minutes, allowed to stop or rest, and continue until test is over is announced. The test will start with test is started and end with test is over. The timer will run continuously even if paused. The test ends if chest pain, severe breathlessness, cramps, unsteadiness, sweating, pallor, or oxygen saturation \<85% occurs. Afterward, the child will be sits and post-test vitals and Borg scores will be recorded. Distance walked and any complaints during the test will be noted."
219203888|NCT05765851|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
219610292|NCT04111731|PROCEDURE|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
219610293|NCT04111731|PROCEDURE|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
219610294|NCT04111731|PROCEDURE|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
219610295|NCT04111731|PROCEDURE|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
219203889|NCT06032988|DIETARY_SUPPLEMENT|LactoLevure|Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
219203890|NCT05373537|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
219610296|NCT05809479|OTHER|No intervention|No intervention
219610297|NCT01308424|DRUG|BTL TML HSV|Sublingual micro-dosing for 7 days
219610298|NCT01308424|DRUG|Matching placebo|sublingual dosing for 7 days
219610299|NCT00713037|PROCEDURE|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
219610300|NCT05355376|PROCEDURE|Bundle of measures to decreased SSI|
219610301|NCT04215887|DEVICE|Contactless Portable Respiratory rate Monitor|Novel hand-held respiratory rate monitor
219610302|NCT04877522|DRUG|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
219610303|NCT04877522|DRUG|Imatinib|Taken orally, once daily, in the morning with low-fat meal
219610304|NCT04877522|DRUG|Nilotinib|Taken orally, twice daily, on an empty stomach
219610305|NCT04877522|DRUG|Bosutinib|Taken orally, once daily, with food
219610306|NCT04877522|DRUG|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
218894150|NCT06998563|OTHER|Lower Extremity Functional Scale|The Lower Extremity Functional Scale will be used to evaluate the functional ability of the entire lower extremity in individuals with musculoskeletal disorders. This scale will question the difficulty experienced in various daily activities due to the problem in the lower extremity with 20 items. Each item will be scored between 0-4 on a Likert scale (0=extremely difficult/too difficult to do the activity; 4=not difficult at all). The total score varies between 0-80 and the higher the score, the higher the functional level. A validity and reliability study has been conducted for the Turkish version of the scale to be used in evaluating lower extremity functions.
218894151|NCT06998563|OTHER|Pain Assessment with Viusal Analog Scale|"The Visual Analog Scale is a simple and reliable tool that is widely used to assess subjective experiences such as pain. It consists of a 10 cm horizontal line with one end indicating no pain and the other end indicating worst pain imaginable. Individuals will mark the point that reflects their perception of intensity, which will then be measured in millimeters or centimeters to obtain a numerical score. Higher values will indicate greater severity. The Visual Analog scale is valid and reliable in a variety of populations and conditions, including musculoskeletal pain."
218894152|NCT06998563|OTHER|Demographic Information Form|All children's gender, age, body weight, height and dominant side information will be recorded before clinical evaluations. The body mass index (kilogram/meter2) of the child will be calculated and recorded with the recorded body weight (kilogram) and height (meter) values.
218894153|NCT06998563|OTHER|Ankle Joint Dorsiflexion Range of Motion Measurement|Dorsiflexion range of motion with the knee joint in full extension and 90° flexion, the subtalar joint in a neutral position, the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles were recorded in degrees (°). Measurements will be made bilaterally.
218894154|NCT06998563|OTHER|Leg Length Measurement|Leg Length Measurement, the child will be placed in a supine position. The legs will be positioned in extension and the muscles will be relaxed. The physiotherapist will measure and record the child's right leg length from the SIAS bone to the medial malleola with a flexible metal tape measure. Measurements will be made bilaterally.
219610307|NCT04877522|DRUG|Asciminib single agent pediatric formulation|Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.
218894155|NCT05907395|DRUG|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
218894156|NCT05907395|DRUG|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
218894157|NCT04544956|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
218894158|NCT04544956|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
218894159|NCT04342429|RADIATION|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
218894160|NCT06683599|PROCEDURE|Apneic oxygenation|1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
219035043|NCT06065826|OTHER|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
219610308|NCT02770482|BIOLOGICAL|spinal fluid collection|
219035044|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
219035045|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
219035046|NCT06471426|OTHER|Osteopathic Manipulative Treatment|The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
219610309|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
219610310|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)|Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
219610311|NCT00095446|DRUG|insulin aspart|
219610312|NCT03970577|DRUG|Rituximab|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
219610313|NCT03970577|DRUG|Prednisone|exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
219610314|NCT04757974|DRUG|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
219610315|NCT04757974|DRUG|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
219610316|NCT00399126|DRUG|Perifosine|Perifosine oral dose
219610317|NCT00399126|DRUG|Paclitaxel|Paclitaxel IV
219514200|NCT05123937|OTHER|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
219035047|NCT04237428|BIOLOGICAL|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg."
219514201|NCT01031537|BIOLOGICAL|FSME-IMMUN 0.5ml Baxter|Vaccine
219514202|NCT03784664|DIAGNOSTIC_TEST|Arterial blood gas|arterial blood sample with puncture of the radial artery
219035048|NCT06227507|BEHAVIORAL|Front-of-package label|Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
219035049|NCT01959152|DEVICE|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
219514203|NCT03784664|DIAGNOSTIC_TEST|Veinous blood gas|veinous blood sample using peripheral venepuncture
219514204|NCT00633282|BEHAVIORAL|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
219514205|NCT00633282|DRUG|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
219514206|NCT00633282|DRUG|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
219514207|NCT00442910|DRUG|3% SPL7013 Gel (VivaGel)|3% vaginal gel
219514208|NCT00442910|DRUG|Placebo Gel|Placebo for SPL7013 gel
219610318|NCT02007525|BEHAVIORAL|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
219610319|NCT06297590|DRUG|LY3954068|Administered IT
219610320|NCT06297590|DRUG|Placebo|Administered IT
219610321|NCT06297590|DRUG|Flortaucipir F18|Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
219610322|NCT01253902|DRUG|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
219035050|NCT00464828|PROCEDURE|Internal jugular vein cannulation|
219035051|NCT00464828|DEVICE|ultrasound|
219035052|NCT00906191|DRUG|SAM-531|
219514209|NCT00442910|DRUG|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
219514210|NCT03499938|DEVICE|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
219514211|NCT02439398|BIOLOGICAL|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
219514212|NCT02439398|OTHER|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
219514213|NCT04963426|BEHAVIORAL|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
219514214|NCT04963426|OTHER|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
219514215|NCT00623103|DRUG|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
219514216|NCT00623103|DRUG|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
219514217|NCT04784000|DRUG|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
219514218|NCT04784000|DRUG|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
219514219|NCT04784000|DRUG|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
219514220|NCT04784000|DRUG|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
219514221|NCT02401282|BEHAVIORAL|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
219514222|NCT02401282|BEHAVIORAL|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
219514223|NCT00063206|DRUG|DVS-233 SR|
219514224|NCT03653195|OTHER|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
219514225|NCT05586425|BEHAVIORAL|Emotion Regulation Skills + Treatment as Usual|ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.
219514226|NCT05586425|BEHAVIORAL|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
219514227|NCT00536900|BEHAVIORAL|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
219514228|NCT00536900|BEHAVIORAL|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
219514229|NCT06046664|DIAGNOSTIC_TEST|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
219514230|NCT00766207|OTHER|Clinical decision support|multi-faceted decision support
219610323|NCT01253902|DRUG|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
219610324|NCT01253902|DRUG|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
219610325|NCT02412553|OTHER|Specific carbohydrate diet|
219610326|NCT02412553|OTHER|Elemental diet|
219610327|NCT05842603|BEHAVIORAL|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
219610328|NCT03202940|DRUG|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
219610329|NCT03202940|DRUG|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
219610330|NCT04053088|DEVICE|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
218894161|NCT07013136|DRUG|Folic Acid 5 MG|In this study, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen. In a rat model of AKI with ischaemia-reperfusion, intraperitoneal injection of 5-methyltetrahydrofolate (5-MTHF) at 3 μg/kg body weight twice (30 min before ischaemia and 3 h after reperfusion) improved kidney function and alleviated oxidative stress within 24 hours. The average body weight is around 60 kg for Chinese. Considering the oral route often requires larger doses than injection to produce the same effect, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen to test its effect on AKI. Depending on the clinical condition, the therapeutic dose of folic acid varies. For foetal support during pregnancy, daily doses of 1 mg of folic acid are recommended; for lowering homocysteine, up to 5 mg daily are generally used.
219610331|NCT06196879|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) formulated solution
218894162|NCT05393661|OTHER|inpatient physical therapy poststroke|routine care
219514231|NCT00766207|OTHER|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
219514232|NCT01495377|DRUG|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
219514233|NCT01495377|DRUG|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
219514234|NCT01495377|DRUG|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
219514235|NCT01495377|DEVICE|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
219514236|NCT04779619|OTHER|Online self-report questionnaire completion|After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
219514237|NCT02083315|DRUG|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
219514238|NCT02083315|DRUG|TRV130 3 mg|TRV130 3 mg IV x 1 dose
219610332|NCT06196879|DRUG|Placebo|Verekitug (UPB-101) matching placebo
219610333|NCT06973291|DRUG|Zasocitinib|Zasocitinib tablets.
219610334|NCT06973291|DRUG|Deucravacitinib|Deucravacitinib capsules.
219610335|NCT06973291|DRUG|Placebo to match zasocitinib|Zasocitinib matching placebo tablets.
219514239|NCT02083315|DRUG|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
219514240|NCT02083315|DRUG|Morphine 10 mg|Morphine 10 mg IV x 1 dose
219514241|NCT02083315|DRUG|Placebo|Dextrose 5% in water IV x 1 dose
219610336|NCT06973291|DRUG|Placebo to match deucravacitinib|Deucravacitinib matching placebo capsules.
219610337|NCT05989711|DRUG|Pemvidutide|Administered by subcutaneous injection
219610338|NCT05989711|DRUG|Placebo|Administered by subcutaneous injection
219610339|NCT04154683|DEVICE|Cellvizio®|use of the Cellvizio® optical biopsy
219514242|NCT01024738|DRUG|Fluoride|Brush half mouth twice daily for four days.
218894163|NCT07029724|DEVICE|TrueCPR Multisensory Feedback Device|TrueCPR (Physio-Control, Inc., Redmond, WA, USA) is a real-time CPR feedback device that provides both visual and auditory cues to support the delivery of high-quality chest compressions. The system consists of two pads (chest and back) that measure compression depth using electromagnetic signal transmission. The device offers auditory rate guidance via a metronome and visual feedback through a color display indicating the adequacy of compression depth and recoil. Performance data-including compression depth, rate, ratio, and the percentage of compressions that are too shallow or too deep-are recorded and analyzed using dedicated software. TrueCPR delivers multisensory feedback (auditory and visual) for both professional rescuers and trainees.
218894164|NCT07029724|DEVICE|Ambu Smartman ALS Pro+ (AW301) Simulation Manikin|The Ambu SmartMan ALS Pro+ (AW301) is an advanced simulation manikin designed to support training in both Basic and Advanced Life Support (BLS and ACLS). It features multiple operational modes, including feedback, skills, code, and application modules, with or without manikin dependency. The manikin provides real-time auditory feedback through an integrated metronome and allows online monitoring by instructors. It records performance metrics such as compression depth and rate, compression-to-decompression ratio, hand position accuracy, and number of compressions with leaning.
218894165|NCT07029724|DEVICE|Metronome|The Ambu SmartMan ALS Pro+ (AW301), which is an advanced simulation manikin, offers real-time auditory feedback via an integrated metronome function. Devices that provide only a fixed auditory tempo-such as a metronome-are generally classified as coaching devices, because they do not measure or analyze the user's actions during CPR.
218894166|NCT02728154|OTHER|Blood Sample|One tablespoon of blood will be drawn once during the study.
219514243|NCT01024738|DRUG|Triclosan, fluoride|Brush twice daily
219514244|NCT01024738|DRUG|Chlorhexidine Gluconate|Rinse mouth twice a day
219514245|NCT05641597|OTHER|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
219514246|NCT05641597|OTHER|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
219514247|NCT05641597|OTHER|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
219514248|NCT05641597|OTHER|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
219514249|NCT00118105|BIOLOGICAL|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
219514250|NCT00118105|DRUG|capecitabine|Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
219514251|NCT00118105|DRUG|oxaliplatin|130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4
219514252|NCT00118105|PROCEDURE|conventional surgery|Resection
219514253|NCT01506947|DRUG|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
219514254|NCT01506947|DRUG|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
219514255|NCT00677196|DEVICE|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
219514256|NCT00677196|DEVICE|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
219514257|NCT05865639|BEHAVIORAL|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
219514258|NCT05865639|BEHAVIORAL|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
219514259|NCT03791749|OTHER|Breastfeeding Support|12-minute simple technique
219610340|NCT04471428|DRUG|Cabozantinib|Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.
218894167|NCT02728154|OTHER|Stool Sample|One stool sample will be collected.
218894168|NCT06726031|DEVICE|wearing VR glass|The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
219514260|NCT01421706|DRUG|Sibutramine-clopidogrel|Sibutramine-clopidogrel
219514261|NCT01421706|DRUG|sibutramine-Clarithromycin|sibutramine-Clarithromycin
219514262|NCT04179045|DEVICE|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
219514263|NCT02820922|PROCEDURE|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
219514264|NCT02551497|DRUG|CNV1014802|
219514265|NCT02503943|DRUG|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
219514266|NCT02503943|DRUG|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
219514267|NCT02503943|DRUG|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
219514268|NCT05717153|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219514269|NCT05717153|PROCEDURE|Computed Tomography|Undergo CT
219514270|NCT05717153|DRUG|Eflornithine|Given PO
219514271|NCT05717153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219514272|NCT05717153|DRUG|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Given PO
219514273|NCT05717153|PROCEDURE|Resection|Undergo surgical resection
219514274|NCT05717153|DEVICE|Microdialysis|Undergo Microdialysis
219514275|NCT05717153|PROCEDURE|Placement|Undergo placement of catheters
219514276|NCT05364827|DIAGNOSTIC_TEST|CTCA|CTCA performed in intervention arm patients prior to CTO PCI
218894169|NCT06725251|BEHAVIORAL|Art Therapy|Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
218894170|NCT06725563|PROCEDURE|Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures|We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \&lt;6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.
219514277|NCT03131180|OTHER|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
219514278|NCT04782648|PROCEDURE|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
219514279|NCT04540640|DEVICE|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
219610341|NCT04471428|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
218894171|NCT06725485|DRUG|Low-Dose Lidocaine|Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
218894172|NCT06727149|OTHER|Control Group|No intervention was performed to reduce pain, fear and anxiety in the control group
218894173|NCT06727149|OTHER|Virtual Reality Group|The children in the VR group were informed about the virtual reality glasses and told that they could remove the glasses at any time if they felt uncomfortable during the procedure
218894174|NCT06726252|DEVICE|FFR measurement and intravascular imaging|Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement, and intravascular imaging, including IVUS and integrated OCT-IVUS using a single cathete to assess the accurary of OUFR, using wire-based FFR measurement as the gold standard.
218894175|NCT07049432|DRUG|N803|N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles.
218894176|NCT07048483|BEHAVIORAL|Nutrition Education|This intervention uses curated audio-visual messages through videos and films to engage participants in learning about healthy eating behaviors, followed by structured, brief discussions designed to reflect on the content and relate it to personal dietary habits. The intervention leverages narrative-based media to increase self-efficacy for healthy eating.
218894177|NCT07048483|OTHER|control group|Educational materials about food and healthy in the form of handouts will be provided to participants to review.
218894178|NCT05283564|OTHER|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
219203891|NCT04933474|BEHAVIORAL|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
219514280|NCT00496444|DRUG|Azacitidine|Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
219514281|NCT00496444|DRUG|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
219514282|NCT01648010|DEVICE|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
219514283|NCT01648010|DEVICE|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
219610342|NCT04471428|DRUG|Docetaxel|Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
219610343|NCT01654172|DIETARY_SUPPLEMENT|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is \~900mg
219610344|NCT01654172|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|
219514284|NCT00257712|DRUG|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
219514285|NCT03282838|DRUG|DFN-15 (fasted)|DFN-15 administered to fasted subjects
219514286|NCT03282838|DRUG|DFN-15 (fed)|DFN-15 administered to fed subjects
219514287|NCT03282838|DRUG|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
219514288|NCT01700621|BIOLOGICAL|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
219514289|NCT01700621|BIOLOGICAL|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
219514290|NCT05389943|DRUG|Oral administration of vitamin D3|the effect of oral supplement in postmenopausal women.
219514291|NCT05389943|DRUG|Vitamin D3 50000 UNT Oral Capsule|In postmenopausal women with BMD less than 32 ng/ml
219514292|NCT05389943|DIETARY_SUPPLEMENT|milk, Dietary and life style modifications.|Postmenopausal women with BMD greater than 32 ng/ml
219610345|NCT06243848|PROCEDURE|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
219610346|NCT06243848|PROCEDURE|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
218894179|NCT07056946|OTHER|Fascia Iliaca Nerve Block|With the patient in the proper position, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. After a skin wheal is made, the needle is inserted in-plane
218894180|NCT07056946|OTHER|Caudal Block Anesthesia|The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view, two hyperechoic lines will appear between the sacral cornu the superficial line is the sacrococcygeal ligament
218894181|NCT07064941|BEHAVIORAL|Exercise|Exercise for 30 min a day 5x a week with a choice between Aerobic or strength training. Subjects will choose an aerobic activity to perform 3x/week (e.g. brisk walking, hiking, jogging). They will start at 15-20 min/day depending on fitness level and build up by 5 min intervals/week as tolerated to 50 min/day or 150 min/week by 12 weeks. Subjects will choose strength exercises to perform 2x/week, on days separate from aerobic activity. They will start with 1-2 exercises (e.g. squats, lunges, planks with and without resistance) and gradually add exercises to include all muscle groups (arms, legs, chest, back, abdomen). Start with 2 sets of 10 reps, and work up to 3 sets of 15 reps of given exercises.
219514293|NCT03923764|DIETARY_SUPPLEMENT|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
219514294|NCT03923764|OTHER|Habitual Diet|Patients continue their usual diet
219514295|NCT03487055|BIOLOGICAL|TK006|Subcutaneous injection in the upper arm
219514296|NCT02499666|PROCEDURE|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
219514297|NCT02499666|DEVICE|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
219514298|NCT02499666|DRUG|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
219514299|NCT05770752|PROCEDURE|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
219514300|NCT02210715|DRUG|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
219035053|NCT05933161|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor (CGM)|Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
219514301|NCT02210715|OTHER|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
219514302|NCT05757011|PROCEDURE|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
219514303|NCT03332693|OTHER|Exercise|Leg weight raising
219610347|NCT05184881|OTHER|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
219514304|NCT03332693|OTHER|No exercise|Volunteers will not participate in exercise
219514305|NCT02166697|DRUG|candesartan cilexetil|candesartan cilexetil tablets
219514306|NCT04566809|OTHER|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
219514307|NCT04566809|OTHER|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
219514308|NCT00939653|DRUG|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
219514309|NCT00939653|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
219514310|NCT00939653|DRUG|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
219514311|NCT00939653|DRUG|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.
219514312|NCT00939653|DRUG|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age"
218894182|NCT07066956|DEVICE|ATLAS 2030 Exoskeleton|They underwent intensive training with 4 weekly sessions during 6 weeks with the ATLAS 2030 exoskeleton, a wearable device that provides gait assistance through eight degrees of freedom, four for each leg, including hip, knee, and ankle rotations. During training sessions, participants were fitted with the exoskeleton and performed 25 minutes of automatic forward walking, 15 minutes of active forward walking, 15 minutes of automatic forward walking, 5 minutes of automatic backward walking, 5 minutes of active backward walking, and exoskeleton removal. During the walk, therapeutic activities based on therapeutic objectives were carried out according to the participants' abilities.
219035054|NCT01256593|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
219514313|NCT00515645|OTHER|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
219514314|NCT00569062|DRUG|GW856553X|GW856553X 7.5mg BID for 6 weeks
219514315|NCT00569062|OTHER|Placebo|Placebo to match GW856553X
219514316|NCT06837311|DEVICE|Ecological Momentary Assessment (EMA)|Daily ecological momentary assessment (EMA), in addition to treatment as usual (TAU) using apTeleCare eHealth device. Daily surveys includes questions reflecting all Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 symptom criteria for Depression, Generalized Anxiety Disorder, Post-Traumatic Symptom Disorder, evaluations of substance use (including dietary items at risk) as well as of two symptoms predictive of relapse (craving and loss of control), medication compliance and physical activity
219514317|NCT06837311|BIOLOGICAL|Biological assessment|Routine Biological assessment and of substance use
219514318|NCT06837311|BEHAVIORAL|Psychological examination and Substance Use symptomatology|Substance use symptomatology ; Neuropsychiatric symptomatology ; Functional outcomes ; Neurologic and Cardiovascular outcomes
219610348|NCT05184881|OTHER|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
219610349|NCT04856046|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
218894183|NCT07065708|DIAGNOSTIC_TEST|Visual biofeedback using transperineal ultrasound|Transperineal ultrasound with visual biofeedback
219514319|NCT06837311|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU)
218894184|NCT07065708|DIAGNOSTIC_TEST|Transperineal ultrasound without visual biofeedback|Transperineal ultrasound without visual biofeedback
218894185|NCT07065123|OTHER|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery
219035055|NCT06355427|DRUG|[18F]F-FAPI PET-CT|\[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
219035056|NCT06559111|DEVICE|2-week casting followed by 4-week bracing|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
219610350|NCT04856046|OTHER|Electronic Health Record Review|Review of medical records
219610351|NCT05167097|OTHER|ASSIST-linked Brief Intervention|WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)
219610352|NCT05167097|OTHER|Mindset Intervention|Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
219514320|NCT06837311|DIAGNOSTIC_TEST|Expired carbon monoxide (CO)|Expired carbon monoxide (CO) measurement
219514321|NCT03319420|DRUG|LO2A eye drops|Sodium hyaluronate
219514322|NCT03319420|DRUG|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
219514323|NCT04955262|BIOLOGICAL|Bempegaldesleukin (NKTR-214)|Specified dose on specified days
219514324|NCT04955262|BIOLOGICAL|Nivolumab|Specified dose on specified days
219514325|NCT04955262|DRUG|⁸⁹Zr-Df-IAB22M2C|Specified dose on specified days
219610353|NCT00226096|DRUG|Labetalol Hydrochloride|
219610354|NCT00226096|DRUG|Metoprolol tartrate|
219610355|NCT00226096|DRUG|Hydralazine Hydrochloride|
219610356|NCT00226096|DRUG|Glycerol Trinitrate|
219610357|NCT00226096|DRUG|Phentolamine mesylate|
219610358|NCT00226096|DRUG|Nicardipine|
219610359|NCT00226096|DRUG|Urapidil|
219610360|NCT00226096|DRUG|Esmolol|
219610361|NCT00226096|DRUG|Clonidine|
219610362|NCT00226096|DRUG|Enalaprilat|
219610363|NCT00226096|DRUG|Nitroprusside|
219610364|NCT05037825|DRUG|Checkpoint Inhibitor, Immune|anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
218894186|NCT07065955|OTHER|Longevity diet alone or in combination with fasting mimicking diet|The longevity diet generally consists of three isocaloric meals and one snack (for normal-weight individuals) or slightly hypocaloric meals (in the case of overweight or obesity). The diet consists of 50-60% of calories from complex carbohydrates, 30-35% of calories from mostly unsaturated fats, and 10-11% of calories from proteins, primarily from plant sources and fish, and occasionally from eggs, dairy, and meat, especially for those over 65. The diet is formulated to provide all necessary nutrients, including vitamins and minerals. The fasting-mimicking diet is a dietary intervention in which normal food is replaced with a standardized, highly hypocaloric vegan diet for a limited period of 5 consecutive days. This diet is designed to stimulate the same processes normally activated during fasting while minimizing the side effects of total food deprivation.
218894187|NCT04896593|BEHAVIORAL|Smartphone App|Smartphone app teaching suicide prevention skills.
219035057|NCT06559111|DEVICE|6-week casting|Participants in the casting group had a cast for 6 weeks after the surgery.
219035058|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
219514326|NCT06497322|OTHER|Exercise intervention - High intensity interval training on a cycle-ergometer|The experimental group starts with 5 minutes of unloaded cycling, followed by 3 × 3-minute HIIT training sequences alternating between: i) 30 seconds at 90% of maximal PO (70 rpm for 30 seconds) and ii) 30 seconds of light pedaling at 20% of PO). Recent work suggests that this high-intensity approach to aerobic exercise is feasible and safe, even during acute oncology treatment. The HIIT sequences are interspersed with two 3-minute cycling sessions at moderate intensity. The training session will be concluded with a 5-minute cool-down by cycling (light pedaling) and stretching. This protocol will be performed twice a week throughout the study, and all patients who reach an 80% adherence threshold for the exercise intervention will be included in the final analysis.
219514327|NCT01311804|PROCEDURE|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
219514328|NCT01311804|PROCEDURE|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
219514329|NCT03622658|BIOLOGICAL|Placebo|Placebo solution for subcutaneous injection.
219514330|NCT03622658|BIOLOGICAL|Namilumab|Namilumab solution for subcutaneous injection
219514331|NCT01208012|DRUG|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
219514332|NCT02720510|DRUG|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
219514333|NCT02720510|DRUG|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
219035059|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
219035060|NCT03924830|PROCEDURE|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
219514334|NCT02720510|DRUG|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
219514335|NCT02720510|DRUG|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
219514336|NCT00983710|BEHAVIORAL|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
219514337|NCT00983710|BEHAVIORAL|Usual care|Booklet on coping with localized prostate cancer
219514338|NCT05585996|BIOLOGICAL|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
219514339|NCT02869646|PROCEDURE|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
219514340|NCT02869646|PROCEDURE|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
219514341|NCT01992055|BEHAVIORAL|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
219514342|NCT01992055|BEHAVIORAL|Education & relaxation training|The Education \& Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
219514343|NCT02063295|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
219514344|NCT02063295|DRUG|ZGN-440 for injectable suspension|
219610365|NCT03591042|DIAGNOSTIC_TEST|cervical length screening|transvaginal ultrasound cervical length
219610366|NCT01289145|BEHAVIORAL|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
219610367|NCT01289145|BEHAVIORAL|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
219610368|NCT01289145|BEHAVIORAL|Active Control|Participants receive a quiz on physical activity and sports.
218894188|NCT03718897|DIAGNOSTIC_TEST|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
218894189|NCT01376414|OTHER|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
218894190|NCT02777827|DRUG|Abediterol 0.156 μg|Dry powder for inhalation
218894191|NCT02777827|DRUG|Abediterol 2.5 μg|Dry powder for inhalation
218894192|NCT02777827|DRUG|Abediterol 0.05 μg|Pressurised metered-dose inhaler
218894193|NCT02777827|DRUG|Abediterol 0.156 μg|Pressurised metered-dose inhaler
218894194|NCT02777827|DRUG|Abediterol 2.5 μg|Pressurised metered-dose inhaler
219514345|NCT02780336|OTHER|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
219514346|NCT03003338|DRUG|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
219514347|NCT03003338|DRUG|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
219514348|NCT05045118|OTHER|Digital Structured Patient Education Material|Participants of home-based Cardiac Rehabilitation Program that are included in this research will be provided with a digital Structured Patient Education Material at the beginning of the program, and will be followed up for 12 weeks duration
219514349|NCT05043636|DEVICE|Vagus|Cardiovascular autonomic neuropathy (Vagus) both resting heart rate variability and cardiovascular reflex tests The examination consists of 4 measures, all aimed at measuring heart rate. Measurements are taken for 5 minutes rest, change of position from lying to standing position, during deep breathing and by Valsalva (by breathing in a mouthpiece with a 40 mmHg resistance).
219514350|NCT05043636|DEVICE|HeartsTrends|• Cardiovascular autonomic neuropathy (HeartTrends®) measurers 60-minutes heart rate variability via a chest belt electrode (a Holter monitor) and an external data acquisition device.
219514351|NCT05043636|DEVICE|Sudoscan|Peripheral small-fiber sympathetic function (Sudoscan), measuring sudomotor function by electrochemical skin conductance in hands and feet
219514352|NCT05043636|DEVICE|UllMeter|• Pressure pain sensitivity of the chest bone is recorded (with a device which has the size and shape as a pen)during rest as a measure for sympathetic autonomic activity of the brain (UllMeter®) (www.stressmeter.org)
219514353|NCT05043636|DEVICE|DPN-check|Nerve conduction velocity and amplitude of the Sural nerves by DPN-check
219514354|NCT05043636|DEVICE|Rolltemp|Cold and warm sense of foot and lower leg
219514355|NCT05043636|DEVICE|Dexcom G6 Device|"Insertion of continuous glucose monitor ( The Dexcom G6 Device)~After 10 days in the study the patient will return the glucose monitor and diary by prepaid mail.~Glycemic variability and hypoglycemia duration will be calculated from CGM data. Glycemic variability will be assessed by standard deviation (SD) and Coefficient of Variance (CV). We define normo-glycemic range as sensor glucose between 4.0 and 10.0 mmol/L. Hypoglycemia will be defined in two ranges as SG ≤3.9 mmol/L or SG ≤3.0 mmol/L). An episode of hypoglycemia will be defined as at least 15 minutes with SG below 3.9 mmol/L or 3.0 mmol/L, respectively. CGM recordings with less than 72 hours of data will be excluded from analysis."
219610369|NCT03788343|DIETARY_SUPPLEMENT|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
219610370|NCT03788343|DRUG|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
219610371|NCT06372210|DRUG|Placebo IEM tablet|Oral placebo-embedded IEM tablet.
219610372|NCT06372210|DRUG|Abilify MyCite®|Oral aripiprazole-embedded IEM tablet.
219610373|NCT06372210|DEVICE|D-Tect Patch|The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
218894195|NCT02777827|OTHER|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
218894196|NCT06941415|DRUG|Bumetanide|Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
219514356|NCT04005664|DRUG|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
219610374|NCT00129545|DEVICE|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
219610375|NCT00129545|DRUG|Warfarin|Subjects receive warfarin
219610376|NCT03315078|BIOLOGICAL|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
218894197|NCT06941415|DRUG|Furosemide|Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders
218894198|NCT06169111|BIOLOGICAL|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
219514357|NCT03886090|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
219514358|NCT03886090|BEHAVIORAL|rest|Seated rest following motor skill practice
219610377|NCT03315078|DRUG|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
219610378|NCT03315078|DRUG|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
219514359|NCT03886090|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
219514360|NCT01719406|BEHAVIORAL|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
219514361|NCT04216043|DIETARY_SUPPLEMENT|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
219514362|NCT04216043|DIETARY_SUPPLEMENT|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
219514363|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
219514364|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
219514365|NCT02834000|DEVICE|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
219514366|NCT03140007|DEVICE|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
219514367|NCT03140007|DEVICE|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
219514368|NCT05944107|OTHER|Activated Clotting Time measurements combined with heparin concentration monitoring|In the HC group, the initial heparin dose is calculated using the HepCon HMS Plus . Except for ACT, heparin concentration is measured to maintain target heparin levels during CPB. The protamine dose for reversal is computed based on actual measured heparin levels using the device. ACT is also performed in all instances.
219514369|NCT05944107|OTHER|Activated Clotting Time|The target ACT for procedures other than Coronary Artery Bypass Grafting (CABG) is 400s when Minimally Invasive Extracorporeal Circulation is used. A bolus of 300 International Units(IU)/kg heparin are administered to reach this target and initiate cardiopulmonary bypass (CPB). Repeated ACT measurements guide further heparin dose to maintain adequate anticoagulation. Then, at the end of the CPB, 0.75 mg of protamine are administered for every 100IU of the initial heparin bolus.
219514370|NCT00189709|DRUG|Micafungin|IV
219514371|NCT00189709|DRUG|fluconazole|IV
219514372|NCT01504737|OTHER|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
219514373|NCT01504737|OTHER|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
219514374|NCT02841826|OTHER|IUD|
219514375|NCT02841826|OTHER|Uterine sounding|
219514376|NCT02841826|RADIATION|Transvaginal ultrasound|
219514377|NCT02585700|BIOLOGICAL|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
219514378|NCT02585700|OTHER|Placebo|0.5 mL of phosphate buffered saline
219514379|NCT05685979|PROCEDURE|Robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
219514380|NCT04155983|DRUG|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
219514381|NCT03104205|BEHAVIORAL|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
219514382|NCT01618266|DRUG|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
219514383|NCT02985151|DEVICE|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
219514384|NCT00838318|BEHAVIORAL|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
219514385|NCT02226796|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
219514386|NCT04735419|OTHER|No intervention|No intervention
219514387|NCT00195299|DRUG|Temsirolimus|
219514388|NCT04693065|OTHER|ponseti|Standard of care, treatment by ponseti method
219514389|NCT00450996|DRUG|Topical Steroids|
219514390|NCT05391009|DIAGNOSTIC_TEST|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
219514391|NCT05391009|DIAGNOSTIC_TEST|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
219514392|NCT04902274|OTHER|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
219514393|NCT04902274|OTHER|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
219514394|NCT04902274|OTHER|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
219610379|NCT05528978|BEHAVIORAL|Shambhavi Kriya|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
219610380|NCT02922920|OTHER|Tart cherry juice|16 fl. oz of tart cherry juice
219610381|NCT02922920|OTHER|Placebo|16 fl. oz of placebo
219610382|NCT05712499|BEHAVIORAL|mindfulness-based psychoeducation program|Mindful awareness is a mind and body practice that involves increasing attention to what is happening at the moment and accepting what is perceived without judgment. Mindfulness includes awareness and attention; Awareness is the mechanism that constantly controls the of the state of consciousness. Mindfulness-based cognitive therapies are evidence-based psychoeducation. Psychoeducation was organized in 2 consecutive sessions once a week for 8 weeks, and each session was 60 minutes, in total 16 sessions. The content of the psychoeducation program was explained in detail, and techniques such as presentation and question-answer narrative techniques, video, audio recording, mindfulness assignments for the next session were used in the training.
219610383|NCT05712499|BEHAVIORAL|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
219610384|NCT02401269|DRUG|Aspirin|
219610385|NCT02401269|DRUG|Placebo|
219514395|NCT04104958|GENETIC|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
219514396|NCT03613350|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
219514397|NCT03341065|DEVICE|exoskeleton type robot|
219514398|NCT03341065|DEVICE|end-effector type robot|
219514399|NCT04744740|DEVICE|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
219514400|NCT04669665|DRUG|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
219610386|NCT05878457|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
218894199|NCT04424342|OTHER|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
219514401|NCT04669665|DRUG|Placebo|Intranasal placebo
219514402|NCT04669665|OTHER|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
219610387|NCT05590364|DEVICE|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
218894200|NCT04424342|OTHER|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
218894201|NCT04638426|DRUG|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
218894202|NCT04638426|DRUG|Placebo of HL237 tablet|Placebo of HL237, twice a day
218894203|NCT04178720|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
218894204|NCT04178720|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
218894205|NCT04178720|DEVICE|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
218894206|NCT01792115|DRUG|Vitamin E 200 IU/d|Supplement-low dose
219514403|NCT04669665|DEVICE|Intranasal device|Device to deliver intranasal solution
219514404|NCT05396820|OTHER|Experimental pain|Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
219514405|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
219610388|NCT05702944|DRUG|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
219610389|NCT01897805|DRUG|Heart-protecting Musk Pill|
219610390|NCT01897805|DRUG|Placebo|
219610391|NCT01308801|DEVICE|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
219610392|NCT01308801|DEVICE|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
219610393|NCT02308124|DRUG|Midodrine|
219610394|NCT02308124|DRUG|Pyridostigmine Bromide|
218894207|NCT01792115|DRUG|Vitamin E 400 IU/d|Supplement-intermediate dose
218894208|NCT01792115|DRUG|Vitamin E 800 IU/d|Supplement High Dose
219610395|NCT02308124|DRUG|Midodrine + pyridostigmine|
219610396|NCT03020771|BIOLOGICAL|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
218894209|NCT01792115|BEHAVIORAL|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
218894210|NCT04988750|DEVICE|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
218894211|NCT00008229|BIOLOGICAL|filgrastim|
218894212|NCT00008229|DRUG|melphalan|
218894213|NCT00008229|PROCEDURE|peripheral blood stem cell transplantation|
218894214|NCT00008229|RADIATION|holmium Ho 166 DOTMP|
219610397|NCT03020771|OTHER|Placebo|
219610398|NCT01679652|DRUG|Nebivolol|Tablet i blinded in capsula
219610399|NCT01679652|DRUG|placebo|
219610400|NCT00455156|DRUG|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
219610401|NCT03716856|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
219610402|NCT03716856|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219610403|NCT03716856|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion
219610404|NCT03567928|DEVICE|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
219610405|NCT03567928|DRUG|Propofol|Target controlled infusion (TCI) with propofol
219610406|NCT01029743|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
219610407|NCT01029743|DRUG|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
219514406|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
219514407|NCT00762957|DRUG|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
219514408|NCT02780557|BEHAVIORAL|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
219514409|NCT02780557|BEHAVIORAL|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
219514410|NCT03422926|BEHAVIORAL|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
219514411|NCT02598102|DRUG|Diclofenac sodium|Diclofenac for pain relief
219514412|NCT02598102|DRUG|Placebo|Placebo for comparison
219514413|NCT01164943|PROCEDURE|Stimulation with human FSH|Human FSH
219514414|NCT01164943|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
219514415|NCT06375590|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid stenosis with the Navitor platform
219514416|NCT05220670|OTHER|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
219514417|NCT05220670|OTHER|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
219514418|NCT05214742|OTHER|Diagnostic Test|Molecular diagnosis carried out in the context of care
219514419|NCT04664842|OTHER|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
219514420|NCT04664842|OTHER|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
219610408|NCT03674398|BEHAVIORAL|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
219610409|NCT03674398|BEHAVIORAL|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
219610410|NCT04499469|PROCEDURE|Spreader Graft|To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
219610411|NCT06810726|DEVICE|Platelet Rich Plasma|Tropocells(R) Autologous Platelet-Rich Fibrin
219610412|NCT06841770|BIOLOGICAL|OPC1|One injection of 10 million LCTOPC1 cells will be delivered to the target injection site of the damaged spinal tissue.
219610413|NCT06588439|OTHER|Cognitive-motor training|Cognitive-motor training is that cognitive tasks incorporated into motor tasks.
219610414|NCT06588439|OTHER|Conventional physiotherapy|Conventional physiotherapy includes stretching, ROM exercise, strengthening exercise, and eye-hand coordination.
219514421|NCT02583542|DRUG|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
219514422|NCT02583542|DRUG|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
219514423|NCT00317499|OTHER|Placebo|Placebo
219514424|NCT00317499|DRUG|Etanercept|Etanercept
219514425|NCT00002315|DRUG|Netivudine|
219514426|NCT00002315|DRUG|Acyclovir|
219514427|NCT01474278|DRUG|Placebo|Single dose
219514428|NCT01474278|DRUG|RO5028442|Single dose
219514429|NCT00625807|BEHAVIORAL|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
219514430|NCT00625807|BEHAVIORAL|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
219514431|NCT00007878|DRUG|bortezomib|Given IV
219514432|NCT00007878|DRUG|fluorouracil|Given IV
219610415|NCT04806516|DEVICE|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
219610416|NCT04806516|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
219514433|NCT00007878|DRUG|leucovorin calcium|Given IV
219514434|NCT00007878|OTHER|pharmacological study|Correlative studies
219514435|NCT00007878|OTHER|laboratory biomarker analysis|Correlative studies
219514436|NCT02473978|DEVICE|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
219514437|NCT05252481|DEVICE|Active tDCS|Eight sessions of transcranial current direct stimulation
219514438|NCT05252481|DEVICE|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
219514439|NCT01346423|BEHAVIORAL|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
219514440|NCT01346423|BEHAVIORAL|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
219610417|NCT01447043|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
219610418|NCT04077580|DRUG|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
219514441|NCT02259712|OTHER|Hypopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
219514442|NCT02259712|BEHAVIORAL|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
219610419|NCT02074007|DRUG|AR01|drops administered as needed for pain
219610420|NCT02074007|DRUG|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
219514443|NCT02259712|OTHER|Pelvic-perineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
219514444|NCT02259712|OTHER|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
219514445|NCT04550195|DRUG|BMS-986337|Specified Dose on Specified Days
219514446|NCT04550195|OTHER|BMS-986337 Placebo|Specified Dose on Specified Days
219514447|NCT04550195|BIOLOGICAL|Famotidine|Specified Dose on Specified Days
218894215|NCT03658824|OTHER|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
218894216|NCT04883866|BEHAVIORAL|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
218894217|NCT04883866|BEHAVIORAL|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
218894218|NCT01225094|DRUG|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
218894219|NCT01225094|OTHER|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
218894220|NCT01770574|DEVICE|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
218894221|NCT01770574|PROCEDURE|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
218894222|NCT03191630|BEHAVIORAL|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
219035061|NCT03924830|PROCEDURE|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
219514448|NCT02022813|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
219514449|NCT00116935|DRUG|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
219514450|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
219514451|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
219514452|NCT03997747|OTHER|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
219514453|NCT02870712|PROCEDURE|Suture of perineum|suture of the tear to obtain hemostasis
219514454|NCT02870712|PROCEDURE|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
219514455|NCT02224391|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
219514456|NCT02224391|OTHER|Laboratory Biomarker Analysis|Correlative studies
219514457|NCT02224391|DRUG|Nicotine Patch|Given via transdermal patch
219514458|NCT02224391|OTHER|Questionnaire Administration|Ancillary studies
219514459|NCT02224391|OTHER|Sham Intervention|Undergo sham training
219514460|NCT04879420|DRUG|Teriparatide|Teriparatide dispensing claim is used as the reference group.
219514461|NCT04879420|DRUG|Risedronate|Risedronate dispensing claim is used as the exposure group.
219514462|NCT00379457|BIOLOGICAL|dactinomycin|
219514463|NCT00379457|DRUG|carboplatin|
219514464|NCT00379457|DRUG|cyclophosphamide|
219514465|NCT00379457|DRUG|doxorubicin hydrochloride|
219514466|NCT00379457|DRUG|etoposide|
219514467|NCT00379457|DRUG|ifosfamide|
219514468|NCT00379457|DRUG|topotecan hydrochloride|
219514469|NCT00379457|DRUG|vincristine sulfate|
219514470|NCT00379457|DRUG|vinorelbine tartrate|
219514471|NCT00379457|PROCEDURE|conventional surgery|
219514472|NCT00379457|RADIATION|radiation therapy|
219514473|NCT04400526|BEHAVIORAL|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
219514474|NCT04400526|BEHAVIORAL|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
219514475|NCT04400526|BEHAVIORAL|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
219514476|NCT03718455|DEVICE|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
219514477|NCT05743218|OTHER|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
219514478|NCT00084084|DRUG|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
219514479|NCT05498246|PROCEDURE|laparoscopic partial nephrectomy|Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
219514480|NCT06484946|OTHER|aquatic occupational therapy|Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
219514481|NCT01784042|DRUG|Placebo|placebo
219514482|NCT01784042|DRUG|Lovaza|
219514483|NCT01784042|OTHER|Dietary energy restriction|
219514484|NCT04861545|OTHER|Soy|"Isolated soy protein food sources are foods that include isolated soy protein in different forms and matrix (e.g. soy beverage and meat analogue).~Non-isolated soy protein food sources of soy protein are foods made with soy (e.g. Tofu, tempeh, edamame)."
219514485|NCT05265182|PROCEDURE|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
219514486|NCT04716660|OTHER|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
219514487|NCT04702620|DEVICE|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
219514488|NCT04708795|DRUG|AP701|Preparation of Cannabis flowers (Cannabis flos)
219514489|NCT00108732|DRUG|Bicalutamide|Given orally
219514490|NCT00108732|DRUG|Goserelin Acetate|Given SC
219610421|NCT05082974|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
219610422|NCT05082974|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray \[control\]
219514491|NCT00108732|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
219514492|NCT00108732|BIOLOGICAL|Recombinant Vaccinia-TRICOM Vaccine|Given SC
219514493|NCT00108732|BIOLOGICAL|Sargramostim|Given SC
219514494|NCT02187042|OTHER|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
219514495|NCT02187042|OTHER|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
219514496|NCT00670956|DRUG|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
219514497|NCT00670956|DRUG|Placebo|PLACEBO: IM x 2 doses 24 hours apart
219514498|NCT05029583|OTHER|routine screening|routine screening for advanced NASH
219610423|NCT01627678|DRUG|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
219610424|NCT01627678|DRUG|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
219514499|NCT05029583|OTHER|physician-driven screening|physician-driven screening for advanced NASH
219514500|NCT04965571|GENETIC|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
219514501|NCT02779309|PROCEDURE|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
219514502|NCT00820456|OTHER|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
219514503|NCT04084756|BEHAVIORAL|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
219514504|NCT04084756|BEHAVIORAL|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
218894223|NCT03191630|BEHAVIORAL|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
218894224|NCT02707146|BEHAVIORAL|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
218894225|NCT02707146|OTHER|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
218894226|NCT02707146|DEVICE|iPad|
218894227|NCT05829954|OTHER|questionnaire|All questionnaire were obtained via online survey system.
219514505|NCT01601509|DRUG|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
219514506|NCT01601509|DRUG|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
219514507|NCT02116803|DRUG|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
219514508|NCT02116803|DRUG|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
219514509|NCT01060592|DEVICE|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
219514510|NCT04256265|DRUG|Risdiplam|Risdiplam will be administered orally once daily
219514511|NCT00280436|DRUG|GW679769|
219610425|NCT01258309|DRUG|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
219610426|NCT01258309|DRUG|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
219610427|NCT00028977|DRUG|herba scutellaria barbata|
219610428|NCT00028977|OTHER|herba scutellaria Barbatae (HSB)|
218894228|NCT00724178|DIETARY_SUPPLEMENT|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
218894229|NCT02884388|PROCEDURE|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
218894230|NCT02884388|PROCEDURE|general anesthesia|Patients in this group were assigned to receive general anesthesia.
219610429|NCT01050439|PROCEDURE|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
219610430|NCT01050439|OTHER|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
218894231|NCT03573141|OTHER|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
218894232|NCT01468740|DRUG|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
219035062|NCT03924830|PROCEDURE|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
219035063|NCT03719313|DRUG|Lonafarnib|Lonafarnib (LNF) 50 mg BID
219035064|NCT03719313|DRUG|Ritonavir|Ritonavir (RTV) 100 mg BID
219514512|NCT02354300|DEVICE|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
219514513|NCT05613699|BEHAVIORAL|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
219610431|NCT03081780|BIOLOGICAL|FATE-NK100|"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
219610432|NCT02642172|DIETARY_SUPPLEMENT|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
219514514|NCT05613699|BEHAVIORAL|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
219610433|NCT02642172|DIETARY_SUPPLEMENT|Placebo|Participants will consume 16 g/day maltodextrin
219610434|NCT00255554|BEHAVIORAL|Dialectical Behavioral Therapy|
219610435|NCT00255554|DRUG|Escitalopram|
219610436|NCT02176265|DEVICE|Qvanteq bioactive coronary stent|PCI
219610437|NCT01974973|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
219610438|NCT02881684|DEVICE|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
219610439|NCT02881684|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
219610440|NCT04032015|DEVICE|TMS|Device used to administer electromagnetic fields to the brain to alter connectivity patterns
219610441|NCT05361590|DEVICE|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
219610442|NCT01506388|DEVICE|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
219610443|NCT01506388|DRUG|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
219610444|NCT01506388|DRUG|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
219610445|NCT02961998|DRUG|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
219610446|NCT02961998|DRUG|Sorafenib|Each group will receive sorafenib as basic treatment.
219610447|NCT01564043|BEHAVIORAL|website and pedometer|use of pedometer and website
219610448|NCT04722497|OTHER|Sound Education|All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
219610449|NCT06079892|PROCEDURE|radiofrequency|haemorrhoidal removal using radiofrequency
218894233|NCT01468740|DRUG|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
218894234|NCT01468740|DRUG|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
218894235|NCT01468740|DRUG|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
219035065|NCT03719313|DRUG|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
219514515|NCT05613699|BEHAVIORAL|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
219514516|NCT00322478|BEHAVIORAL|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
219514517|NCT00322478|BEHAVIORAL|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
219514518|NCT00322478|BEHAVIORAL|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
219514519|NCT00991588|PROCEDURE|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
219514520|NCT01938118|BEHAVIORAL|Obesity Prevention Group|
219514521|NCT01938118|BEHAVIORAL|Injury Prevention Group|
219514522|NCT03112057|DIAGNOSTIC_TEST|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
219514523|NCT04040010|DIETARY_SUPPLEMENT|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
219514524|NCT00041509|DRUG|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
219514525|NCT00041509|DRUG|Placebo|matching placebo, oral, BID for 28 days
219514526|NCT06158321|DEVICE|M1 or DLPFC sham stimulation|Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.
219514527|NCT06158321|DEVICE|M1 rTMS|The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.
219514528|NCT06158321|DEVICE|DLPFC rTMS|The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
219514529|NCT01974895|BIOLOGICAL|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
219514530|NCT01974895|BIOLOGICAL|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
219514531|NCT02805803|OTHER|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
219514532|NCT04324008|DEVICE|Constic|Flowable resin composite
219514533|NCT04324008|DEVICE|G-ænial Universal Flo|Flowable resin composite
219514534|NCT04324008|DEVICE|Tetric N-Flow (self-etch)|Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
219514535|NCT04324008|DEVICE|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Tetric N-Bond Universal, etch\&rinse mode)
219035066|NCT03719313|DRUG|Placebo Lonafarnib|Placebo
219035067|NCT03719313|DRUG|Placebo Ritonavir|Placebo
218894236|NCT01468740|DRUG|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
218894237|NCT01468740|DRUG|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
219035068|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
219035069|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
219514536|NCT02811809|DRUG|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
219514537|NCT02811809|DRUG|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
219514538|NCT01566071|OTHER|Assessment of drive abilities|
219514539|NCT01566318|BEHAVIORAL|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
219514540|NCT02779036|PROCEDURE|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
219514541|NCT02779036|PROCEDURE|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
219514542|NCT02217865|BEHAVIORAL|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
219514543|NCT02217865|BEHAVIORAL|Questionnaire|Questionnaire completion asking general health and demographic questions.
219514544|NCT02217865|BEHAVIORAL|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
219514545|NCT02217865|BEHAVIORAL|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
219514546|NCT04809246|OTHER|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
219035070|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
219035071|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
219035072|NCT06114784|DIAGNOSTIC_TEST|Metagenomics|Clinical metagenomics is used to evaluate pathogens
219035073|NCT03376672|DRUG|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
219514547|NCT00699504|DRUG|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
219514548|NCT00699504|DRUG|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
219514549|NCT00699504|DRUG|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
219514550|NCT00699504|DRUG|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
219514551|NCT00699504|DRUG|placebo|placebo IV and oral
219514552|NCT02763722|OTHER|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
219514553|NCT01072942|DRUG|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
219514554|NCT01072942|DRUG|Placebo|Placebo TID for 10 days
219610450|NCT05308433|DEVICE|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
219610451|NCT05308433|OTHER|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
219610452|NCT05308433|OTHER|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
219610453|NCT04810715|OTHER|Patients with Ankylosing Spondylitis|Observational study, not applicable
219035074|NCT03376672|DRUG|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
219035075|NCT03376672|DRUG|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
219035076|NCT05835479|DRUG|Co-Trimoxazole|Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
219035077|NCT05835479|DRUG|Rezafungin Acetate / Co Trimoxazole|"Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication"
219035078|NCT04301414|DRUG|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
219035079|NCT04301414|DRUG|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
219035080|NCT02934906|PROCEDURE|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
219514555|NCT00160212|DRUG|Daglutril|
219514556|NCT01984242|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
218894238|NCT01468740|DRUG|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
218894239|NCT01468740|DRUG|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
218894240|NCT01468740|DRUG|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
218894241|NCT05206812|DRUG|durvalumab|"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
219203892|NCT04933474|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
219514557|NCT01984242|DRUG|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
218894242|NCT02459119|DRUG|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
218894243|NCT02649140|DIETARY_SUPPLEMENT|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
219514558|NCT01984242|DRUG|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
218894244|NCT04353245|OTHER|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
218894245|NCT00763646|DRUG|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
218894246|NCT05665010|OTHER|Genetic susceptibility|Genetic susceptibility increases the risk of ovarian injury
218894247|NCT05572866|OTHER|COVID-19 pandemic|To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
219514559|NCT05531409|BEHAVIORAL|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
219514560|NCT01357603|BIOLOGICAL|Glargine|dosage form: Subcutaneous injection
219514561|NCT01346852|DRUG|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
218894248|NCT05282069|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
218894249|NCT05282069|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
218894250|NCT05282069|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
218894251|NCT05282069|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
218894252|NCT05282069|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
218894253|NCT02148523|BEHAVIORAL|Comparison to peers|
219514562|NCT02070185|BEHAVIORAL|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
219514563|NCT02070185|BEHAVIORAL|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
219514564|NCT02983708|BIOLOGICAL|Peripheral blood mononuclear cells (mPBMC)|
219514565|NCT02983708|DRUG|G-CSF|
219514566|NCT02983708|DRUG|Placebo|
219203893|NCT05451043|BIOLOGICAL|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
219514567|NCT03712553|BEHAVIORAL|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
218894254|NCT02148523|BEHAVIORAL|Adherence feedback|
218894255|NCT02148523|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
218894256|NCT05103826|DRUG|SHR6390、Famitinib|SHR6390, oral;Famitinib, oral.
219514568|NCT03712553|BEHAVIORAL|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
218894257|NCT03170700|BEHAVIORAL|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
219514569|NCT03712553|BEHAVIORAL|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
219514570|NCT03712553|BEHAVIORAL|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
219514571|NCT06346210|PROCEDURE|Tracheostomy|Surgery for tracheostomy
218894258|NCT03170700|BEHAVIORAL|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
218894259|NCT02054585|OTHER|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
218894260|NCT02054585|OTHER|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
219514572|NCT04543136|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
219514573|NCT04543136|DEVICE|New intermittent Variant 1 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
219514574|NCT04543136|DEVICE|New intermittent Variant 2 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
218894261|NCT04589871|OTHER|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
219203894|NCT05451043|DRUG|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
219203895|NCT05451043|DRUG|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
218894262|NCT04589871|OTHER|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
218894263|NCT06383832|DRUG|Dapagliflozin|Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
218894264|NCT01367834|DRUG|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
218894265|NCT02917135|DEVICE|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
219203896|NCT05451043|BIOLOGICAL|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
219203897|NCT05451043|DRUG|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
219514575|NCT03219398|PROCEDURE|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
219514576|NCT00424658|PROCEDURE|SAHS diagnosis|
219514577|NCT00794183|DEVICE|CRT device settings|Comparision of A-V delay settings
219514578|NCT02259556|BIOLOGICAL|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
219514579|NCT02573909|DRUG|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
219514580|NCT02573909|DRUG|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
219514581|NCT03785236|RADIATION|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
219514582|NCT02991547|OTHER|Observational|
219514583|NCT03682952|DRUG|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
219514584|NCT03682952|DRUG|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
219610454|NCT02553772|DRUG|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
219514585|NCT05713591|BEHAVIORAL|Transition care model|The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
219514586|NCT03466957|OTHER|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
218894266|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
218894267|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
218894268|NCT00240461|OTHER|Placebo|crystalline substance 200 mg twice daily for 6 months
218894269|NCT04021095|DEVICE|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
218894270|NCT02939365|DRUG|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
218894271|NCT05851196|OTHER|Proprioceptive training|A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
218894272|NCT05413668|DRUG|RVP-001|Intravenous administration of RVP-001
218894273|NCT05413668|DRUG|Placebo|Intravenous administration of saline placebo
218894274|NCT03498950|OTHER|laser therapy|laser irradiation on the taste papillae
218894275|NCT04706949|DRUG|Pyrotinib combined with pemetrexed plus carboplatin|"1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min."
218894276|NCT02152176|DEVICE|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
218894277|NCT06091150|PROCEDURE|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
219514587|NCT01626079|DEVICE|MitraClip System|Percutaneous mitral valve repair using MitraClip System
219514588|NCT04229849|DRUG|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
219514589|NCT04229849|DRUG|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
219514590|NCT01215448|DIETARY_SUPPLEMENT|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
219610455|NCT02553772|DRUG|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
219610456|NCT00028171|DRUG|Tacrolimus|
219610457|NCT00033085|DRUG|Ondansetron|
219610458|NCT01295398|DEVICE|nebulisations|
219610459|NCT07128342|DEVICE|CGM Group|This group of patients will receive a CGM device to monitor their blood glucoses
219610460|NCT07128342|DEVICE|FSBG group|This group of patients will receive a fingerstick blood glucose (FSBG) device for glucose monitoring
219610461|NCT06865664|DRUG|fludarabine|30 mg/m2 per day IV on days -5, -4, -3, -2
219610462|NCT06865664|DRUG|cyclophosphamide|500 mg/m2 per day IV on days -4, -3, -2
219610463|NCT06865664|DRUG|cetuximab|"Participants Age \>=18 years, based on FDA approved dosing: Loading dose of 400 mg/m2 IV, followed by 250 mg/m2 IV weekly for a total of 4 doses.~Participants Age \<18 years, based on phase I data of cetuximab in children: Dose of 250 mg/m2 IV administered over 1 hour weekly for a total of 4 doses."
219610464|NCT06865664|BIOLOGICAL|FGFR4-CAR T Cells|Single intravenous (IV) infusion on Day 0
219035081|NCT03641144|DEVICE|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
219035082|NCT03641144|DEVICE|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
219514591|NCT02010411|DRUG|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
219610465|NCT07006792|DRUG|Lebrikizumab|Administered SC
219610466|NCT07008768|PROCEDURE|Cataract surgery and refractive lens exchange surgery|Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
219610467|NCT07008768|DEVICE|TRIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal
219610468|NCT07008768|DEVICE|EROV IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)
219610469|NCT07008768|DEVICE|BIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition
219610470|NCT07008768|DEVICE|MONOFOCAL IOL|Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL
219610471|NCT05552118|PROCEDURE|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
219610472|NCT05552118|PROCEDURE|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
219514592|NCT06165900|DRUG|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
219610473|NCT05552118|DEVICE|Compatible Implant Series and Compatible Sound Processors|Individuals who are implanted with a compatible cochlear implant series and compatible sound processor are eligible to participate.
219610474|NCT03752697|BEHAVIORAL|metacognitive performance|Paper and pencil/computerized tests of metacognition
219610475|NCT07011680|DIETARY_SUPPLEMENT|Phospholipid-rich dairy milk extract|Dietary phospholipid-rich dairy milk extract 500 mg/day for 12 weeks
218894278|NCT01588561|DRUG|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
219514593|NCT06165900|DRUG|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
219514594|NCT00006264|BIOLOGICAL|aldesleukin|
218894279|NCT01588561|OTHER|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
218894280|NCT04837573|BEHAVIORAL|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
219035083|NCT00914862|DRUG|Ramelteon|Ramelteon tablets, orally for one day only.
219514595|NCT00006264|DRUG|ganciclovir|
219514596|NCT00006264|DRUG|zidovudine|
219514597|NCT06355739|DEVICE|CAR T cell injection|intravenous injection
219514598|NCT04468256|OTHER|COVID-19 experience surveys|Serial online surveys recording experiences of the COVID-19 pandemic.
219514599|NCT06452810|DIETARY_SUPPLEMENT|Experimental: Sahajan Golden Glow Balm|Participants will apply the Sahajan Golden Glow Balm twice daily (morning and night) to the periorbital area following the specified instructions.
219514600|NCT01372787|PROCEDURE|Assessment of Therapy Complications|Ancillary studies
219514601|NCT01372787|OTHER|Medical Chart Review|Ancillary studies
219514602|NCT01372787|OTHER|Quality-of-Life Assessment|Ancillary studies
219610476|NCT07011680|DIETARY_SUPPLEMENT|Placebo|Placebo (Grape seed oil) 500 mg/day for 12 weeks
219610477|NCT07018414|BEHAVIORAL|Abdominal Massage|Non-pharmacological intervention involving manual massage of the abdomen to support gastric motility and reduce gastric residual volume and abdominal distension in enterally fed surgical ICU patients.
219610478|NCT07022678|OTHER|Best Practice|Given standard chemotherapy
219610479|NCT07022678|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
219610480|NCT07022678|DRUG|Cytarabine|Given IV
219610481|NCT07022678|OTHER|Electronic Health Record Review|Ancillary studies
219610482|NCT07022678|DRUG|Placebo Administration|Given intraorally
219610483|NCT07022678|OTHER|Xylitol-containing Oral Wipe|Given intraorally
219610484|NCT07031336|DEVICE|Photon-counting CT|The participants will receive a photon-counting CT scan as part of this protocol.
219610485|NCT07031336|DEVICE|Energy-integrating CT|The participants will receive an energy-integrating CT scan as part of the main study (NCT00608764).
219610486|NCT07037433|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
219610487|NCT07037433|DRUG|Placebo|Placebo will be administered SC.
219514603|NCT01372787|OTHER|Questionnaire Administration|Ancillary studies
219203898|NCT05451043|DRUG|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
219514604|NCT02958657|OTHER|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
219514605|NCT04059666|OTHER|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
219514606|NCT04059666|OTHER|Control|Cow's milk-based Infant Formula
219514607|NCT00865709|DRUG|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
219514608|NCT00865709|DRUG|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
219514609|NCT00429923|DRUG|Difluprednate|
219514610|NCT00429923|DRUG|Difluprednate|
219514611|NCT00429923|DRUG|Placebo|
219514612|NCT00365261|DRUG|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
219514613|NCT00365261|DRUG|Placebo|placebo 2 to 3 mg po at bedtime
219514614|NCT05024461|DIAGNOSTIC_TEST|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~* Pre-analytical particularities and analytical particularities~* Cycle threeshold~* Demographic variables~* Clinical variables~* Clinical criteria~* Questionnaire on the perception of the 2 sampling methods"
219514615|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
219514616|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
219514617|NCT00697775|BIOLOGICAL|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
219514618|NCT04292106|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
219610488|NCT07035288|DEVICE|EAM based Pulmonary Vein Isolation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to EAM by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
219610489|NCT07035288|DEVICE|Fluoro based pulmonary vein ablation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to Fluoroscopy by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
219610490|NCT06884462|RADIATION|High-intensity laser (HIL)|The wavelength measured 1064 nm, accompanied by a power output of 5.00 W. The frequency employed was 25 Hz
219035084|NCT02319031|DRUG|Daclatasvir|
219035085|NCT02319031|DRUG|Sofosbuvir|
219514619|NCT04292106|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
219514620|NCT03963570|BEHAVIORAL|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
219514621|NCT03963570|BEHAVIORAL|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
219514622|NCT00991198|DRUG|Topical oxygen|0.5% concentration of Topical oxygen
219514623|NCT00991198|DRUG|Topical oxygen|0.25% concentration topical oxygen
219514624|NCT00991198|DRUG|placebo|no O2
219514625|NCT01041781|DRUG|carboplatin|Given IV
219035086|NCT02319031|DRUG|Ribavirin|
219035087|NCT02168010|DRUG|Analgecine|Analgesic drug under test
219035088|NCT02168010|DRUG|Neurotropin|Analgesic drug as positive control
219035089|NCT02168010|DRUG|Placebo|Blank tablet as placebo.
219035090|NCT00591942|DEVICE|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
219035091|NCT05583396|DIAGNOSTIC_TEST|Acute exercise|The measurement will be repeated within one to seven days.
219035092|NCT02356692|DEVICE|enfilcon A|Test lens
219035093|NCT02356692|DEVICE|senofilcon A|Control lens
218894281|NCT05318404|DIETARY_SUPPLEMENT|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
218894282|NCT01634776|DIETARY_SUPPLEMENT|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
219514626|NCT01041781|DRUG|celecoxib|Given orally
219514627|NCT01041781|DRUG|gemcitabine hydrochloride|Given IV
218894283|NCT01634776|DIETARY_SUPPLEMENT|corn oil|
218894284|NCT01818596|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
218894285|NCT04197349|BIOLOGICAL|ALD1910|Single Dose IV infusion
218894286|NCT04197349|BIOLOGICAL|Sumatriptan|Single dose subcutaneous injection
218894287|NCT04197349|BIOLOGICAL|ALD1910|Single dose subcutaneous injection
218894288|NCT01366482|DEVICE|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
219610491|NCT06884462|PROCEDURE|moderate-intensity aerobic exercise|walking on a treadmill at a speed of 3-4 miles per hour on a flat surface (0% incline) for 40 minutes, 3 times weekly over eight weeks
219610492|NCT06924970|DRUG|Tebapivat|Oral tablets.
219610493|NCT06924970|DRUG|Tebapivat Matched Placebo|Oral tablets.
219610494|NCT06732440|BEHAVIORAL|Subthreshold Vestibular Conditioning|The subthreshold vestibular conditioning protocols will be performed while seated on a motion platform in a dark room. A 0.5Hz whole-body tilt conditioning stimulus will be delivered. The stimulus will consist of whole-body sinusoidal motions (similar to those used when measuring tilt perceptual thresholds) delivered at 57.4% of the measured baseline threshold (e.g., 0.574°/s for a 1 °/s threshold); the frequency (0.5Hz) was chosen to match the baseline threshold tasks. The participants and experimenter will be blinded to the nature of the condition and will be informed that while the chair may vibrate or move slightly, the motion will not occur in any particular direction. Music, audiobooks, or podcasts of the subject's choosing will be played to further discourage attention to the conditioning stimulus.
218894289|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
218894290|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
218894291|NCT02050009|DRUG|metformin hydrochloride|Given PO
218894292|NCT02050009|DRUG|carboplatin|Given IV
218894293|NCT02050009|DRUG|paclitaxel|Given IV
218894294|NCT02050009|OTHER|laboratory biomarker analysis|Correlative studies
218894295|NCT00268840|DRUG|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
218894296|NCT00268840|DRUG|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
218894297|NCT03801174|BEHAVIORAL|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
218894298|NCT03801174|BEHAVIORAL|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
218894299|NCT01740414|DRUG|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
218894300|NCT01740414|DRUG|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
218894301|NCT01337336|DRUG|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
218894302|NCT01337336|DRUG|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
218894303|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
218894304|NCT03954067|BIOLOGICAL|ASP9801|Administered by intratumoral injection
218894305|NCT03954067|COMBINATION_PRODUCT|Pembrolizumab|Administered by Intravenous Infusion
219514628|NCT01041781|DRUG|pemetrexed disodium|Given IV
219514629|NCT01041781|OTHER|placebo|Given orally
219514630|NCT04516850|GENETIC|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
219514631|NCT04516850|GENETIC|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
219514632|NCT01456611|DRUG|Diclofenac|Diclofenac Sodium Gel 1%
219514633|NCT01456611|DRUG|Placebo|Placebo Topical Gel
219514634|NCT01978678|DRUG|Pulmicort|ACQ and FeNO
219514635|NCT00257296|OTHER|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
218894306|NCT05817565|DEVICE|Ultrasound (Phyaction 190 I); with a frequency of 3 MHz was used|Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position.
219514636|NCT00257296|OTHER|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
219514637|NCT02276677|DRUG|Oxytocin|Single dose, intranasal
219514638|NCT02276677|DRUG|Placebo|Single dose, intranasal
219514639|NCT05237596|DRUG|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
219514640|NCT02204969|DIETARY_SUPPLEMENT|Lithia water|"* Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
219514641|NCT02204969|DEVICE|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
219514642|NCT03025607|DEVICE|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
219514643|NCT01448083|OTHER|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
219514644|NCT03644095|DRUG|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
219514645|NCT03644095|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
219514646|NCT03902275|OTHER|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
219610495|NCT06732440|BEHAVIORAL|Balance Training|Balance training will consist of progressive exposure to continuous pseudorandom platform perturbations delivered using a 6DoF motion platform. Participants will stand on a MOOG hexapod motion platform and will be secured using a safety harness tethered to the ceiling and a full enclosure of safety rails. Balance training will be progressed by (a) gradually increasing the number of degrees of freedom (e.g., 1DOF to 6DOF) in the perturbation, (b) removing visual cues, (c) narrowing the base of support, and (d) increasing the amplitude, velocity, and/or acceleration of the platform motion. In the event that subject experiences a loss of balance, the level of difficulty will be modified accordingly. Each balance training block will include 5 minutes of perturbations followed by 3 minutes of rest, repeated 5 times for a total of 40 minutes of training.
219610496|NCT06919809|DEVICE|A microsurfaced ADM (acellular dermal matrix)|X A-DERM™ ADM has been resurfaced (Microsurfaced) instead of currently utilized smooth surface reconstructive grafts. Microsurfacing of regenerative tissue grafts increases the surface area at the graft-to-host interface and results in quicker absorption of blood into the graft, greater cellular infiltration, improved seal and wound bed preparedness.
219610497|NCT04932057|OTHER|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
219610498|NCT04932057|OTHER|Action Practice|Participants perform an upper extremity functionality test a couple of times.
219610499|NCT04932057|OTHER|Observation|Participants will watch a slide show of landscape
219610500|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
218894307|NCT02915263|DRUG|IGIV-C|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
218894308|NCT02915263|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
219035094|NCT03435965|DIAGNOSTIC_TEST|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
219514647|NCT03902275|OTHER|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
219514648|NCT03640156|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
219514649|NCT03640156|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
219514650|NCT00119613|DRUG|placebo|placebo
219514651|NCT00119613|DRUG|darbepoetin alfa|darbepoetin alfa
219514652|NCT02534779|OTHER|Placebo Vaginal Insert|Placebo insert
219514653|NCT04509609|OTHER|Exon 3 truncating mutation|Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
219610501|NCT03609320|BEHAVIORAL|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
219610502|NCT05275920|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
219035095|NCT05819164|DEVICE|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
219514654|NCT04509609|OTHER|Any other mutation in SGBC gene|Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
219514655|NCT04332302|OTHER|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
219514656|NCT04153253|DRUG|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
219514657|NCT04153253|PROCEDURE|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
219514658|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
219514659|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
219514660|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
219514661|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
219610503|NCT05275920|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
219610504|NCT06738628|PROCEDURE|(Esophageal or Gastric) Per-Oral Endoscopic Myotomy|Performing Per-Oral Endoscopic Myotomy for the treatment of either achalasia of the esophagus, or gastroparesis of the stomach.
219610505|NCT00596076|BEHAVIORAL|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
218894309|NCT01939847|OTHER|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
218894310|NCT00673582|DRUG|Rosuvastatin|10 mg/day rosuvastatin
218894311|NCT00673582|DRUG|Placebo|Placebo, 10 mg a day for 96 weeks
218894312|NCT02289313|BEHAVIORAL|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
218894313|NCT01310764|PROCEDURE|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
218894314|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration|After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
218894315|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration|After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
218894316|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
218894317|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
218894318|NCT01474941|DRUG|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
218894319|NCT01879683|DRUG|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
218894320|NCT03820882|DEVICE|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
219035096|NCT05819164|DEVICE|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
219514662|NCT02133755|DRUG|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
219514663|NCT00896818|GENETIC|DNA analysis|
219514664|NCT00896818|GENETIC|genetic linkage analysis|
219514665|NCT00896818|GENETIC|loss of heterozygosity analysis|
219514666|NCT00896818|GENETIC|polymorphism analysis|
218894321|NCT03820882|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
218894322|NCT03356275|BEHAVIORAL|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
218894323|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
218894324|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
218894325|NCT01544426|PROCEDURE|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
218894326|NCT01544426|PROCEDURE|Office hysteroscopy|Office hysteroscopy
219514667|NCT00896818|OTHER|laboratory biomarker analysis|
219514668|NCT00896818|OTHER|medical chart review|
219514669|NCT00896818|OTHER|questionnaire administration|
219514670|NCT03158337|BEHAVIORAL|Aerobic exercise|
219035097|NCT05819164|DEVICE|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
219514671|NCT02701075|DEVICE|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
219514672|NCT02701075|DEVICE|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
219514673|NCT00545558|DRUG|Efavirenz|600 mg tablet taken orally daily
219514674|NCT00545558|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
219514675|NCT02687009|DRUG|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
219514676|NCT02629874|DRUG|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
219610506|NCT00950131|OTHER|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
219514677|NCT02629874|DRUG|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
219514678|NCT02629874|DRUG|Placebo|
219610507|NCT03958292|DEVICE|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
219610508|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
218894327|NCT01788566|DRUG|Necitumumab|Administered IV
219610509|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
219610510|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
218894328|NCT01788566|DRUG|Gemcitabine|Administered IV
218894329|NCT01788566|DRUG|Cisplatin|Administered IV
218894330|NCT06281535|DEVICE|Implant loading|Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
219035098|NCT01725191|OTHER|Laboratory Biomarker Analysis|Correlative studies
219035099|NCT01725191|OTHER|Pharmacological Study|Correlative studies
219035100|NCT01725191|DRUG|Tivantinib|Given PO
219035101|NCT06244069|DIAGNOSTIC_TEST|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
219514679|NCT03345316|DRUG|FFI-1010|Intravenous single dosing
219514680|NCT00662129|BIOLOGICAL|bevacizumab|
219514681|NCT00662129|DRUG|gemcitabine hydrochloride|
219514682|NCT00662129|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219514683|NCT03643419|PROCEDURE|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
219514684|NCT03643419|DEVICE|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
219514685|NCT05854758|OTHER|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
219610511|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
219610512|NCT03656588|DRUG|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
218894331|NCT06332066|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
219514686|NCT05854758|OTHER|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
218894332|NCT00329888|PROCEDURE|Endoscopic papillary balloon dilatation|
218894333|NCT00329888|PROCEDURE|Endoscopic sphincterotomy|
218894334|NCT05142605|BEHAVIORAL|Meaning-Centered Grief Therapy|Meaning-Centered Grief Therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in participants' life after participants' loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
218894335|NCT05142605|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy will help participants cope with participants' loss by giving them a place to express participants' feelings and providing participants with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
218894336|NCT05142605|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of participants' standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
218894337|NCT01379183|DRUG|Erythromycin|200 mg suspension
219514687|NCT02248077|DEVICE|AutoloGel|
219514688|NCT02248077|OTHER|Usual and Customary Care (UCC)|
219514689|NCT04534647|DIAGNOSTIC_TEST|different serum and urine biomarkers|urine exosomes and serum biomarkers
219514690|NCT03325647|DRUG|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
219514691|NCT03325647|DRUG|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
219514692|NCT02520115|DRUG|Dexamethasone|Given PO
218894338|NCT01379183|DRUG|Placebo|200 mg suspension
218894339|NCT01379183|PROCEDURE|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
219514693|NCT02520115|OTHER|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
219514694|NCT02520115|DRUG|Valproic Acid|Given PO
219514695|NCT00880282|BIOLOGICAL|cixutumumab|Given IV
219514696|NCT00880282|DRUG|temsirolimus|Given IV
219610513|NCT03656588|DRUG|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
219610514|NCT03452878|BEHAVIORAL|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
219610515|NCT00736437|DRUG|ME-609|Cream applied topically 6 times daily over the UVR exposed area
219610516|NCT00736437|DRUG|Vehicle|Treatment applied 6 times daily over the UVR exposed area
219610517|NCT01761760|BEHAVIORAL|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
219610518|NCT04060290|OTHER|Observational study|Observational study of this study, no interventions involved
219610519|NCT01213277|OTHER|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
219610520|NCT01213277|OTHER|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
219610521|NCT03785327|DEVICE|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
218894340|NCT01379183|OTHER|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
218894341|NCT02591940|PROCEDURE|Surgery or Treatment by Heart Catheter|
218894342|NCT04726683|PROCEDURE|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
218894343|NCT04726683|PROCEDURE|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
218894344|NCT04726683|PROCEDURE|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
218894345|NCT04726683|PROCEDURE|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
218894346|NCT00259714|DRUG|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
219514697|NCT00880282|OTHER|pharmacological study|Correlative studies
219514698|NCT00880282|OTHER|laboratory biomarker analysis|Correlative studies
219514699|NCT02494726|OTHER|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
219514700|NCT03348709|DIETARY_SUPPLEMENT|Isoosmolar|48 hours, 800 ml per 24 hours
219514701|NCT03348709|DIETARY_SUPPLEMENT|Hyperosmolar|48 hours, 800 ml per 24 hours
219514702|NCT01091025|OTHER|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
219514703|NCT02153736|BEHAVIORAL|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
219514704|NCT00767507|DRUG|cangrelor|
219514705|NCT00767507|OTHER|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
219610522|NCT03785327|BEHAVIORAL|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
219514706|NCT02848703|DEVICE|Magnetic Resonance Imaging (MRI)|
219610523|NCT04233073|DRUG|andexanet alfa|Andexanet is a recombinant version of human FXa
219610524|NCT04935229|DRUG|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
219610525|NCT04935229|BIOLOGICAL|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
219610526|NCT04935229|BIOLOGICAL|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
218894347|NCT00259714|DRUG|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
218894348|NCT05973734|BIOLOGICAL|Infusion of recipient T regulatory cell|Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
218894349|NCT05973734|BIOLOGICAL|Infusion of concomitant Donor Derived Vertebral Bone Marrow|The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
218894350|NCT03116711|OTHER|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
219514707|NCT02848703|DEVICE|phosphorus-31 Magnetic Resonance Spectroscopy|
219514708|NCT02848703|DEVICE|sodium-23 MRI|
219610527|NCT04935229|BIOLOGICAL|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
219610528|NCT04980989|DEVICE|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
219610529|NCT00143390|DRUG|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
219610530|NCT00143390|DRUG|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
219610531|NCT00041132|BIOLOGICAL|filgrastim|5 ug/kg
219610532|NCT00041132|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 of cycles 1-6
219610533|NCT00041132|DRUG|cyclophosphamide|300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
219610534|NCT00041132|DRUG|cytarabine|12 g/m\^2 over days 3-4 of cycles 2,4,6,8
219610535|NCT00041132|DRUG|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
219610536|NCT00041132|DRUG|doxorubicin|16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
219610537|NCT00041132|DRUG|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
219610538|NCT00041132|DRUG|methotrexate|1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
219514709|NCT05566093|PROCEDURE|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
218894351|NCT03116711|OTHER|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
218894352|NCT03116711|OTHER|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
218894353|NCT03116711|OTHER|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
218894354|NCT04416048|DRUG|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
219514710|NCT05566093|PROCEDURE|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
219514711|NCT02799602|DRUG|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
219514712|NCT02799602|DRUG|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
219514713|NCT02799602|DRUG|Docetaxel|As prescribed by the treating physician.
219514714|NCT02799602|DRUG|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
219514715|NCT01000896|DRUG|AZD0530|film coated tablet, PO, daily
219514716|NCT01000896|DRUG|Carboplatin|intravenous, 3 weeks
219514717|NCT01000896|DRUG|paclitaxel|intravenous, 3 weeks
219514718|NCT04452578|PROCEDURE|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
219514719|NCT02771015|DEVICE|Mepilex Border®|randomization
219514720|NCT02771015|DEVICE|Cosmopor steril®|randomization
219610539|NCT00041132|DRUG|vincristine|1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
219514721|NCT03455166|DIAGNOSTIC_TEST|Serum Markers|Serum Markers
219514722|NCT02626949|BEHAVIORAL|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
219514723|NCT02626949|BEHAVIORAL|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
219514724|NCT00899964|BEHAVIORAL|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
219610540|NCT03848494|PROCEDURE|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
219610541|NCT03417687|DRUG|129Xe MRI|Evaluation of pulmonary function
219610542|NCT03417687|DRUG|133 Xe scintigraphy|Evaluation of pulmonary function
219610543|NCT03620045|BEHAVIORAL|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
219610544|NCT04684472|BIOLOGICAL|Modified anti-CD19 CAR T cells|intravenous infusion
219610545|NCT05133674|DRUG|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
219610546|NCT00288730|DRUG|nesiritide|
219610547|NCT06582667|PROCEDURE|PENG block|US guided PENG block in hip fracture without anti thrombotic therapy
218894355|NCT04416048|OTHER|Standard Of Care (SOC)|Standard of care treatment
218894356|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
218894357|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
219514725|NCT02940743|BEHAVIORAL|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
219514726|NCT02940743|BEHAVIORAL|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
219610548|NCT01828801|DEVICE|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
219610549|NCT04597697|DRUG|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
219610550|NCT03219827|OTHER|Human biological samples|Blood samples collection
219610551|NCT02471040|DRUG|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
219610552|NCT02471040|OTHER|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
219610553|NCT06746883|OTHER|Non-interventional|Non-interventional
219610554|NCT03832205|DEVICE|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
219610555|NCT01548105|OTHER|Blood draw for the study participants|"These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels"
218894358|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
218894359|NCT01620086|DEVICE|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
218894360|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
218894361|NCT00738335|DRUG|erlotinib hydrochloride|
218894362|NCT00738335|OTHER|immunoenzyme technique|
218894363|NCT00738335|OTHER|laboratory biomarker analysis|
218894364|NCT00738335|OTHER|liquid chromatography|
218894365|NCT00738335|OTHER|mass spectrometry|
218894366|NCT00738335|OTHER|pharmacological study|
218894367|NCT00738335|RADIATION|stereotactic radiosurgery|
218894368|NCT00952458|DEVICE|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
218894369|NCT02633670|DEVICE|Hemopatch|
218894370|NCT02633670|DEVICE|No Hemopatch|
218894371|NCT01695135|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
218894372|NCT01695135|DRUG|Placebo|Placebo (4 tablets) taken orally once daily
218894373|NCT01695135|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
219610556|NCT05250297|OTHER|no intervention|standard prenatal care
219610557|NCT01605747|DIETARY_SUPPLEMENT|Culturelle|one capsule 2x per day per feeding tube
219610558|NCT01605747|DIETARY_SUPPLEMENT|Placebo|one placebo 2x per day per feeding tube
219610559|NCT04447560|PROCEDURE|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
219610560|NCT00932672|BEHAVIORAL|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
219514727|NCT02940743|BEHAVIORAL|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
219514728|NCT05638425|RADIATION|Radiotherapy combined with PD-1 inhibitors|Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
219514729|NCT03744260|DIAGNOSTIC_TEST|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
219514730|NCT01097161|BEHAVIORAL|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
218894374|NCT02576223|DRUG|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
218894375|NCT02576223|DRUG|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
218894376|NCT02576223|DRUG|PCA-pump|"PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes."
218894377|NCT04664374|OTHER|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
219514731|NCT04559295|BIOLOGICAL|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
219514732|NCT05436158|OTHER|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
219514733|NCT03580343|DRUG|tofacitinib|tofacitinib extended release, 11mg, daily, oral
219514734|NCT01117883|OTHER|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
219514735|NCT04473079|DIETARY_SUPPLEMENT|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
219514736|NCT04473079|DIETARY_SUPPLEMENT|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
219610561|NCT03289819|DRUG|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
219610562|NCT03289819|DRUG|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
219610563|NCT03289819|DRUG|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
219610564|NCT03289819|DRUG|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
219610565|NCT01050959|DEVICE|bion|
219610566|NCT00866359|DRUG|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
218894378|NCT01488526|DRUG|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
218894379|NCT03067428|DIETARY_SUPPLEMENT|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
219610567|NCT00866359|DRUG|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
218894380|NCT03067428|DIETARY_SUPPLEMENT|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
218894381|NCT02696265|PROCEDURE|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
218894382|NCT02696265|PROCEDURE|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
218894383|NCT03775798|DRUG|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
218894384|NCT02166892|OTHER|Specially designed plates|
218894385|NCT01844453|PROCEDURE|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
218894386|NCT02562716|DRUG|Fluorouracil|Given IV
218894387|NCT02562716|DRUG|Gemcitabine Hydrochloride|Given IV
218894388|NCT02562716|DRUG|Irinotecan Hydrochloride|Given IV
218894389|NCT02562716|DRUG|Oxaliplatin|Given IV
219514737|NCT01839084|DRUG|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
219514738|NCT01839084|DRUG|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
219514739|NCT02099461|DRUG|Denosumab|Single sucutaneous dose
219514740|NCT02099461|PROCEDURE|Percutaneous core needle breast biopsy|
219514741|NCT00663910|DRUG|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
219514742|NCT00663910|PROCEDURE|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
219514743|NCT00663910|PROCEDURE|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
219514744|NCT00663910|PROCEDURE|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
219514745|NCT04255459|OTHER|Moist Snuff|Moist Snuff product
219514746|NCT04255459|OTHER|Camel Snus|Camel Snus product
219514747|NCT04255459|OTHER|Cigarettes|Cigarette product
219514748|NCT04255459|OTHER|No tobacco usage|No tobacco usage
219514749|NCT03511352|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
219514750|NCT03511352|BEHAVIORAL|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
219514751|NCT00809809|DRUG|Zicam (Ionic zinc)|33mmol/l of ionic zinc
219514752|NCT00809809|DRUG|placebo|placebo swab
219514753|NCT04253548|BEHAVIORAL|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
219610568|NCT01790087|DRUG|ANX-188 Therapeutic Dose|
219610569|NCT01790087|DRUG|ANX-188 Supratherapeutic dose|
219610570|NCT01790087|DRUG|Saline|
219610571|NCT01790087|DRUG|Moxifloxacin|
218894390|NCT02562716|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
218894391|NCT02562716|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
218894392|NCT04064658|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
218894393|NCT04064658|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
218894394|NCT04064658|PROCEDURE|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
218894395|NCT00684996|DRUG|etaracizumab|Given IV
219514754|NCT02849925|DRUG|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
219514755|NCT01854788|OTHER|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
219514756|NCT01854788|OTHER|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
219514757|NCT01854788|OTHER|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
219514758|NCT04712435|DRUG|N-acetylcysteine|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
219514759|NCT04712435|DRUG|Placebo|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
219514760|NCT03730324|DIAGNOSTIC_TEST|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
219514761|NCT03730324|DIAGNOSTIC_TEST|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
219514762|NCT03503357|OTHER|IFT Testing1|Command List A
219514763|NCT03503357|OTHER|IFT Testing 2|Command List B
219514764|NCT03503357|OTHER|IFT Testing 3|Command List C
219514765|NCT03503357|OTHER|IFT Testing 4|Command List D
219514766|NCT01555619|DEVICE|CRT-D System|Implantation of a CRT-D System
219514767|NCT01123486|DRUG|hydromorphone|hydromorphone 0.02 mg/kg
219610572|NCT02245087|DRUG|Atorvastatin|20 mg of atorvastatin daily
218894396|NCT00684996|BIOLOGICAL|bevacizumab|Given IV
218894397|NCT06217848|DRUG|Saxenda|Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide\_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
218894398|NCT01775371|DEVICE|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
219514768|NCT05612386|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
218894399|NCT01775371|OTHER|Usual Care|Usual opioid analgesia determined by the provider
218894400|NCT00651339|DRUG|botox|botox injection
218894401|NCT03015168|RADIATION|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
218894402|NCT01145846|DRUG|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
219514769|NCT01533168|GENETIC|cytogenetic analysis|
219514770|NCT01533168|GENETIC|nucleic acid sequencing|
219514771|NCT01533168|OTHER|diagnostic laboratory biomarker analysis|
219514772|NCT01533168|OTHER|laboratory biomarker analysis|
219514773|NCT01533168|OTHER|medical chart review|
219514774|NCT04906603|DEVICE|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
219514775|NCT05912686|DRUG|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
219514776|NCT05912686|DRUG|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
219514777|NCT04317625|DIAGNOSTIC_TEST|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
219514778|NCT05987046|BEHAVIORAL|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
219514779|NCT00720122|DRUG|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
219610573|NCT01747954|OTHER|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
218894403|NCT05416216|BEHAVIORAL|WELL|The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
218894404|NCT04468581|BEHAVIORAL|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
219514780|NCT02202018|OTHER|Active KT intervention|"1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
218894405|NCT03030417|DRUG|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
218894406|NCT03030417|OTHER|Ondansetron|Anti-emetic for nausea or vomiting.
218894407|NCT03030417|OTHER|Olanzapine|Persistent nausea or vomiting.
218894408|NCT03030417|OTHER|Lorazepam|Persistent nausea or vomiting.
218894409|NCT03030417|OTHER|Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate|Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.
218894410|NCT03030417|OTHER|Loperamide|Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.
218894411|NCT03030417|OTHER|Diphenhydramine|Diphenhydramine 50 mg intravenous (IV) for allergic reaction.
219514781|NCT04976959|DRUG|High Fiber supplement|The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
219514782|NCT03862599|DEVICE|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
218894412|NCT03030417|OTHER|Steroid|For allergic reaction at discretion of principal investigator.
218894413|NCT03030417|OTHER|Epinephrine|For allergic reaction at discretion of principal investigator.
219514783|NCT03862599|OTHER|Standard care|Cialis and vacuum pump
219514784|NCT00907842|DEVICE|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
219514785|NCT05731154|OTHER|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
219514786|NCT03112356|DRUG|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
218894414|NCT03843892|DRUG|OFEV|twice daily
218894415|NCT01423968|BIOLOGICAL|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
219203899|NCT06476496|PROCEDURE|Acupuncture|A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
219514787|NCT05420428|DEVICE|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
218894416|NCT01423968|OTHER|saline|
218894417|NCT01166841|PROCEDURE|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
218894418|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
218894419|NCT04247230|DRUG|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
219203900|NCT05419856|DRUG|4P-004|single intraarticular administration in the knee joint
219203901|NCT05419856|DRUG|Placebo|single intraarticular administration in the knee joint
219203902|NCT06677879|RADIATION|Proton radiotherapy|"Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week."
219514788|NCT05420428|DEVICE|endotracheal intubation|under general anesthesia, patients received endotracheal intubation
219514789|NCT03805828|OTHER|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
219203903|NCT06677879|RADIATION|Photon radiotherapy|"Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week."
219203904|NCT06635486|BEHAVIORAL|Adapted cognitive-behavioral (CBT) intervention|The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
219610574|NCT01747954|OTHER|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
219610575|NCT00295997|BIOLOGICAL|anti-thymocyte globulin|
219514790|NCT06412133|BEHAVIORAL|photography|This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
219514791|NCT00793845|DRUG|Cyclophosphamide|First HDCT
218894420|NCT04247230|OTHER|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
219203905|NCT04793750|DIAGNOSTIC_TEST|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
219203906|NCT04793750|DIAGNOSTIC_TEST|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
219514792|NCT00793845|DRUG|Etoposide|First HDCT
219514793|NCT00793845|DRUG|Carboplatin|First HDCT
219514794|NCT00793845|DRUG|Thiotepa|Second HDCT
219514795|NCT00793845|DRUG|Melphalan|Second HDCT
219514796|NCT00793845|RADIATION|Total body irradiation|Second HDCT
219514797|NCT00050661|DRUG|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
219514798|NCT00050661|DEVICE|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
219514799|NCT03641898|PROCEDURE|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.
219514800|NCT03641898|DIAGNOSTIC_TEST|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
219203907|NCT04793750|DIAGNOSTIC_TEST|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
219610576|NCT00295997|BIOLOGICAL|filgrastim|
219610577|NCT00295997|BIOLOGICAL|graft-versus-tumor induction therapy|
219203908|NCT03358446|OTHER|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
219610578|NCT00295997|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219610579|NCT00295997|DRUG|busulfan|
219610580|NCT00295997|DRUG|cyclophosphamide|
218894421|NCT04247230|DRUG|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
218894422|NCT02239159|OTHER|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
218894423|NCT06290596|DRUG|Vasopressin|Hemostatic drug.
218894424|NCT06290596|DRUG|Tranexamic acid|Hemostatic drug.
218894425|NCT06290596|OTHER|Saline|Placebo
218894426|NCT04787107|DEVICE|Mechanical Chair Massage|Healthcare staff will be placed into either massage or break intervention
218894427|NCT02385851|DRUG|CHS-1701|
218894428|NCT02385851|DRUG|Pegfilgrastim|
219610581|NCT00295997|DRUG|fludarabine phosphate|
218894429|NCT02446184|PROCEDURE|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
218894430|NCT02446184|PROCEDURE|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
218894431|NCT04376307|PROCEDURE|minimal flow anesthesia|Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
218894432|NCT02729220|OTHER|Bronchoscopy|Sampling of airways
218894433|NCT03790722|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
218894434|NCT03790722|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
219035102|NCT06244069|DIAGNOSTIC_TEST|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
219035103|NCT06244069|DIAGNOSTIC_TEST|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,…). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
219035104|NCT04483024|DIETARY_SUPPLEMENT|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
219035105|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
219514801|NCT03917628|DRUG|SCT630|SCT630 single s.c. injection
219514802|NCT03917628|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
219514803|NCT00822198|DEVICE|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
219514804|NCT01371578|DRUG|GS-5885 tablet|30 mg active tablet
219514805|NCT01371578|DRUG|GS-9451 tablet|two active 100 mg tablets
219514806|NCT01371578|BIOLOGICAL|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
219514807|NCT01371578|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
219610582|NCT00295997|DRUG|methotrexate|
219610583|NCT00295997|DRUG|mycophenolate mofetil|
219610584|NCT00295997|DRUG|tacrolimus|
219610585|NCT00295997|PROCEDURE|allogeneic bone marrow transplantation|
219610586|NCT00295997|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219610587|NCT00295997|PROCEDURE|peripheral blood stem cell transplantation|
219610588|NCT02046811|BEHAVIORAL|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
219610589|NCT02046811|BEHAVIORAL|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
219035106|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
219610590|NCT02046811|BEHAVIORAL|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
219610591|NCT02431377|OTHER|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
218894435|NCT03090477|BEHAVIORAL|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
218894436|NCT01078441|DRUG|liposomal doxorubicin|Given IV
219514808|NCT04476082|OTHER|No intervention - observational study only|No intervention - observational study only
219514809|NCT06399770|DEVICE|Muscle ultrasound|Role of muscle ultrasound in LGMD
219514810|NCT04038970|BIOLOGICAL|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
219514811|NCT04038970|BIOLOGICAL|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
219610592|NCT00136227|BEHAVIORAL|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
219610593|NCT02163057|BIOLOGICAL|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
219610594|NCT02163057|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
219610595|NCT01625091|DRUG|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
219610596|NCT01625091|DRUG|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
219610597|NCT00768248|DRUG|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
219035107|NCT02979743|BEHAVIORAL|Occupational therapy|
219610598|NCT00768248|DRUG|normal saline (placebo)|the basal rate will be set at 7 mL/h
219610599|NCT03051672|DRUG|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
219610600|NCT03051672|RADIATION|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
219610601|NCT03126448|DIAGNOSTIC_TEST|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
218894437|NCT01078441|DRUG|bortezomib|Given subcutaneously.
218894438|NCT01078441|DRUG|dexamethasone|Given orally
218894439|NCT01078441|DRUG|cyclophosphamide|Given IV
219035108|NCT02979743|OTHER|Occupational therapy puls acupuncture and massage methods|
219035109|NCT06277934|DRUG|RGT001-075|Administered orally
219035110|NCT06277934|DRUG|Placebo|Administered orally
219035111|NCT01219725|BEHAVIORAL|Exercise training|6 months of moderate intensity exercise training 3 times per week
219035112|NCT05564793|DEVICE|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
219035113|NCT05564793|DEVICE|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
219035114|NCT06135168|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
219035115|NCT06135168|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
219035116|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
219035117|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
219514812|NCT04038970|BIOLOGICAL|Placebo|Solution, intravenous, Placebo
219514813|NCT04038970|COMBINATION_PRODUCT|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
219514814|NCT06179966|OTHER|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
219514815|NCT06179966|OTHER|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
219514816|NCT04275687|RADIATION|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost."
219514817|NCT04275687|DRUG|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
219514818|NCT00329602|DRUG|Placebo|Matching Placebo
219514819|NCT00329602|DRUG|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
218894440|NCT03402334|BEHAVIORAL|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
218894441|NCT01068522|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
218894442|NCT01068522|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
218894443|NCT05917613|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
218894444|NCT01425801|DRUG|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
218894445|NCT01425801|DRUG|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
218894446|NCT01425801|DRUG|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
218894447|NCT01425801|DRUG|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
218894448|NCT01425801|DRUG|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
219203909|NCT03358446|OTHER|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
219203910|NCT05900557|DIAGNOSTIC_TEST|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
219203911|NCT05325437|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
219514820|NCT04683822|OTHER|Telerehabilitation|Patients will attend telerehabilitation sessions
219610602|NCT06280339|BEHAVIORAL|Test two food cravings strategies during dietary weight loss|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
219514821|NCT04436692|BEHAVIORAL|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
219514822|NCT02275364|DEVICE|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
219514823|NCT02275364|DEVICE|Placebo strip|Placebo strip
219514824|NCT02275364|OTHER|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
218894449|NCT01425801|DRUG|Salbutamol placebo|Pressurized inhalation, once-daily
218894450|NCT01425801|DRUG|LAS100977 placebo|Dry powder inhalation, once-daily
218894451|NCT02868554|DEVICE|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
218894452|NCT02868554|DEVICE|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
218894453|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Squamous NSCLC
218894454|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Non-Squamous NSCLC
218894455|NCT06434896|OTHER|ctDNA analysis after surgery|ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
218894456|NCT02553057|DEVICE|mechanical ventilation|
218894457|NCT02864693|DEVICE|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
218894458|NCT02864693|DEVICE|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
218894459|NCT01031719|BIOLOGICAL|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
218894460|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
218894461|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
218894462|NCT02491983|DRUG|Palbociclib|
218894463|NCT02491983|DRUG|Fulvestrant|
218894464|NCT02491983|DRUG|Letrozole|
218894465|NCT03546946|BEHAVIORAL|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
219514825|NCT06544343|OTHER|Remote Monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
219514826|NCT06544343|OTHER|On site monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
218894466|NCT03546946|BEHAVIORAL|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
218894467|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
218894468|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
218894469|NCT02714569|DRUG|LY3202328|Administered orally
218894470|NCT02714569|DRUG|Placebo|Administered orally
218894471|NCT02714569|DRUG|Atorvastatin|Administered orally
219514827|NCT06544434|DEVICE|Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)|MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
219610603|NCT06280339|BEHAVIORAL|Dietary weight loss program +Food cravings strategies|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
219610604|NCT00469924|PROCEDURE|Real Time Clinical Alerting|
219610605|NCT02962986|DRUG|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
219610606|NCT02962986|DRUG|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
219610607|NCT05806892|OTHER|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
218894472|NCT02714569|DRUG|Simvastatin|Administered orally
218894473|NCT05225129|OTHER|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
218894474|NCT05546034|DIAGNOSTIC_TEST|Standard nutrition screening tools to be compared with routine blood tests|None other than completion of questionnaires one of which would be done in routine practice
219035118|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
219035119|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
218894475|NCT00001944|DRUG|Vinorelbine|
218894476|NCT00001944|DRUG|XR9576|
218894477|NCT05001035|OTHER|Time of assessment|Immediate and after one month and after two months
219035120|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
218894478|NCT02950909|PROCEDURE|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
218894479|NCT02950909|PROCEDURE|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
218894480|NCT02950909|PROCEDURE|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
218894481|NCT02950909|PROCEDURE|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
219035121|NCT06283797|DEVICE|OmniPod 5|Participants will be trained to use OmniPod 5 to treat type 1 diabetes for 1 year
219035122|NCT06283797|DEVICE|Dexcom G6|Participants will use Dexcom G6 for continuous glucose monitoring
219035123|NCT06283797|OTHER|PAID questionnaires|At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
219035124|NCT00299013|DRUG|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
219035125|NCT00299013|DRUG|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
219035126|NCT02087527|DRUG|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
219514828|NCT06544434|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
219514829|NCT03177603|DRUG|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
219514830|NCT05882474|DEVICE|PaCO2|Level of partial pressure of carbon dioxide
219514831|NCT05070156|BIOLOGICAL|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
218894482|NCT06322888|BEHAVIORAL|Exercise Training Program|A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
218894483|NCT04724915|PROCEDURE|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
218894484|NCT04724915|PROCEDURE|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
218894485|NCT04915729|DRUG|tenecteplase|tenecteplase
218894486|NCT04915729|DRUG|alteplase|alteplase
218894487|NCT03301493|OTHER|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
218894488|NCT05335876|BIOLOGICAL|onasemnogene abeparvovec|Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
218894489|NCT01960582|BEHAVIORAL|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
218894490|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
218894491|NCT06138626|BEHAVIORAL|Alert|An alert that appears when anesthetic fresh gas flow is excessive
218894492|NCT05919823|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
218894493|NCT05919823|DRUG|Placebo|Placebo Capsules
218894494|NCT01684202|DRUG|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
218894495|NCT00191308|DRUG|pemetrexed|500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
218894496|NCT00191308|DRUG|cisplatin|75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
218894497|NCT00191308|PROCEDURE|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
218894498|NCT06583629|BEHAVIORAL|Emotional Freedom Technique|EFT is a self-help technique that incorporates conscious awareness of thoughts and feelings with a gentle touch involving tapping with fingertips on acupuncture/acupressure points on the face, hands, and body. EFT also helps relieve primary physical and emotional symptoms. Gary Craig created EFT, which involved lightly tapping on the body on 12 acupressure sites (also known as acupoints). This acupoints are situated along the body's meridians, or virtual energy channels
218894499|NCT05651906|PROCEDURE|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
219035127|NCT02087527|DRUG|Normal Saline|IV normal saline every 6 hours for 48 hours
219514832|NCT05070156|BIOLOGICAL|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
219514833|NCT05070156|BIOLOGICAL|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
219514834|NCT06544876|BEHAVIORAL|sit-to-stand|test for balance during movement from sitting to standing
218894500|NCT00779025|DEVICE|PD-F-5254|Female Personal Lubricant (MINE)
218894501|NCT00779025|DEVICE|10855-096|Male Personal Lubricant (YOURS)
218894502|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
218894503|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
218894504|NCT02376972|DRUG|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
218894505|NCT02376972|DRUG|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
218894506|NCT03008694|DEVICE|PET/CT|pet/ct is used as radiotherapy simulation
218894507|NCT04146350|PROCEDURE|PPV+/-Cat|pars plana vitrectomy+/-cataract
218894508|NCT04146350|PROCEDURE|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
218894509|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
219203912|NCT06128356|DRUG|Dexmedetomidine Sublingual|Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
219203913|NCT05255926|DRUG|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
219203914|NCT05255926|DEVICE|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
219514835|NCT06544876|BEHAVIORAL|stand to sit|test for balance during movement from standing to sitting
219514836|NCT06544876|BEHAVIORAL|standing perturbation|test for balance recovery following perturbation
219514837|NCT06544876|OTHER|MRI of sciatic nerve|measure of peripheral nerve diameter
219514838|NCT05265325|DRUG|AND017 capsules TIW|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
219514839|NCT05265325|DRUG|AND017 capsules QW|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
219514840|NCT05265325|DRUG|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
219514841|NCT01361126|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX\_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
219610608|NCT04092140|DEVICE|ultrasound|easy new non invasive tool
219610609|NCT04006002|OTHER|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
218894510|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
218894511|NCT04146350|PROCEDURE|PSR|posterior scleral reinforcement
218894512|NCT04146350|PROCEDURE|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
219035128|NCT00956904|DEVICE|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
219035129|NCT00396045|DRUG|Revlimid (CC-5013)|
219035130|NCT05137561|PROCEDURE|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
219035131|NCT05137561|PROCEDURE|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
219035132|NCT04012944|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)."
219514842|NCT00940368|DIETARY_SUPPLEMENT|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
219514843|NCT02447900|DEVICE|BioXmark|
219514844|NCT00624481|DRUG|Teriparatide|20ug subcutaneous injection daily for 24 weeks
219035133|NCT00155337|PROCEDURE|photodynamic therapy|
219035134|NCT02832310|PROCEDURE|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
219035135|NCT01456104|BIOLOGICAL|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
219035136|NCT06159725|DRUG|CMTX-101|CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
219514845|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
219514846|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
219514847|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
219514848|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
219514849|NCT02593981|DIETARY_SUPPLEMENT|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
219514850|NCT02593981|DIETARY_SUPPLEMENT|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
219514851|NCT03834675|DIAGNOSTIC_TEST|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
219514852|NCT00663871|DIETARY_SUPPLEMENT|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
219514853|NCT00663871|DIETARY_SUPPLEMENT|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
219514854|NCT03303638|BEHAVIORAL|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
218894513|NCT04146350|PROCEDURE|Gas|gas tamponade alone
218894514|NCT02067936|DRUG|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
218894515|NCT02067936|DRUG|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
218894516|NCT02067936|DRUG|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
219035137|NCT06159725|DRUG|Placebo|Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
219035138|NCT03519971|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219035139|NCT03519971|OTHER|Placebo|Placebo IV (intravenous infusion)
219035140|NCT03519971|DRUG|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
219035141|NCT03519971|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
219035142|NCT03519971|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
219035143|NCT03519971|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
219514855|NCT05655936|BEHAVIORAL|Heart Health Doula Intervention Program|The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
219514856|NCT05655936|BEHAVIORAL|Usual Care|Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
219514857|NCT04094870|DRUG|Sertraline|daily SSRI (Sertraline 25mg)
219514858|NCT04094870|BEHAVIORAL|Interpersonal therapy|11 sessions over a 24-week period
219514859|NCT00669578|DRUG|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
219514860|NCT01798745|DRUG|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
219514861|NCT01798745|OTHER|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
219514862|NCT03480828|DIAGNOSTIC_TEST|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
219514863|NCT01484821|DEVICE|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
219610610|NCT04530643|DRUG|HY209 0.3%|25 subjects will be assigned to drug (HY209 0.3% gel).
219610611|NCT04530643|DRUG|HY209 0.5%|25 subjects will be assigned to drug (HY209 0.5% gel).
219610612|NCT04530643|DRUG|Placebo|25 subjects will be assigned to drug (Placebo).
219610613|NCT01547390|DRUG|Aspirin|
219610614|NCT01547390|DRUG|placebo|
219610615|NCT03406754|BEHAVIORAL|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
219610616|NCT01459783|BEHAVIORAL|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
219610617|NCT03248427|DRUG|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
218894517|NCT02067936|DRUG|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
218894518|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
219035144|NCT03519971|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
219035145|NCT05800470|OTHER|fNIRS-based neurofeedback with motor imagery|A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the cortical activity in SMA. The HbO concentration will be processed and displayed as a visual feedback during MI training.
219203915|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
219203916|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
219514864|NCT04695405|GENETIC|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
219514865|NCT05960851|DRUG|LY3871801|Administered orally.
219514866|NCT05960851|DRUG|Placebo|Administered orally.
219514867|NCT02646345|PROCEDURE|Surgical checklist|Use of the World Health Organization Surgical checklist
219514868|NCT01394458|OTHER|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
219514869|NCT01394458|DRUG|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
219514870|NCT01721525|DRUG|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects \> 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
219514871|NCT02992405|BEHAVIORAL|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
219514872|NCT02992405|BEHAVIORAL|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
219610618|NCT03248427|DRUG|Letrozole 2.5mg|Daily continuous
219610619|NCT03248427|DRUG|Doxorubicin|60 mg/m2 as a continuous IV perfusion
219610620|NCT03248427|DRUG|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
219610621|NCT03248427|DRUG|Paclitaxel|80 mg/m2, in one hour IV infusion
219610622|NCT00488189|DRUG|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
219610623|NCT00479986|DRUG|pioglitazone|
219610624|NCT00479986|DRUG|placebo|
218894519|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
219514873|NCT01877759|BIOLOGICAL|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
219514874|NCT02742181|DRUG|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
219514875|NCT02742181|OTHER|Control Group|Standard postoperative care
219514876|NCT00654485|DRUG|Rosuvastatin|
219514877|NCT00654485|DRUG|Atorvastatin|
219514878|NCT01351142|OTHER|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
219514879|NCT05764889|OTHER|wrapped with the Flexible Sleeve Penis Protection Device|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
219514880|NCT05764889|OTHER|wrapped with traditional gauze|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
219514881|NCT05391399|DEVICE|Interlocking detachable coils system|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
219514882|NCT05391399|DEVICE|Interlock Fibered IDC Occlusion System|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
219203917|NCT03529019|DRUG|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
219514883|NCT04648059|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
219514884|NCT06364800|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
219514885|NCT06364800|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
219514886|NCT06364800|DRUG|targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
219514887|NCT05548933|PROCEDURE|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
219514888|NCT02739984|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection with an automated mini doser
219514889|NCT02739984|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
219514890|NCT02419638|DRUG|Rebif (IFN β-1a subcutaneous three times per week)|
219514891|NCT02419638|DRUG|Tecifdera (dimethyl fumarate)|
219514892|NCT05213078|OTHER|Educational Intervention|Receive teaching intervention
219514893|NCT05213078|OTHER|Quality-of-Life Assessment|Ancillary studies
219514894|NCT05213078|OTHER|Questionnaire Administration|Ancillary studies
219514895|NCT06375928|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
219514896|NCT06375928|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
219610635|NCT07064707|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
219610636|NCT07064707|DRUG|Rupatadine|Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions
219610637|NCT06589986|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
219610638|NCT06589986|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
219610639|NCT07075640|DRUG|AG-236|Subcutaneous (SC) Injection
219610640|NCT07075640|DRUG|Placebo|SC Injection
219610641|NCT07104838|PROCEDURE|Non-intubated spontaneous ventilation anesthesia|Non-intubated spontaneous ventilation anesthesia
219610642|NCT06908096|BIOLOGICAL|EBV gp350-ferritin vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
219610643|NCT06908096|BIOLOGICAL|EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
219610644|NCT07107737|BEHAVIORAL|Physician Consultation|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Physician Consultation, direct communication between the patient and a designated physician by phone will be implemented when a patient refuses transport in cases where the EMS clinician feels that physician consultation is warranted for further guidance. The physician will attempt to address patient concerns and provide additional medical advice.
218894520|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
219514897|NCT06375928|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
219514898|NCT04147728|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
219514899|NCT04147728|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
219514900|NCT02233790|DRUG|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
219514901|NCT02233790|DRUG|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
219514902|NCT01760122|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
219610645|NCT07107737|BEHAVIORAL|Standard of Care|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Standard of Care, physician intervention will not be provided. For safety reasons, if physicians or EMS MEDIC clinicians feel that speaking with the patient is important to provide additional clinical benefit, they may do so without hesitation and can override the designated intervention month.
219610646|NCT07143604|DRUG|AZD0901|Participants will receive AZD0901 IV, Q3W
219610647|NCT06946056|OTHER|biofiller prp|Ten ml of the patient's blood was drawn in a syringe pre-filled with 1 mLacid citrate dextrose(anticoagulant). It wascentrifuged firstat 3500 rotations per minute (RPM)for 15 min and thenat 1500 RPM for 5 min. The upper part,i.e.,platelet-poor plasma (PPP) waswithdrawn in a 5 mL syringe. PPP wasincubated in hot water at 100a °C for 5 min and then cooled in a refrigerator for 5 min.The PRP injection was performed in a standardized manner and injected into the IA surface of the affected knee joint
219610648|NCT01942421|PROCEDURE|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
219610649|NCT07143838|DEVICE|Transcranial Electrical Stimulation (TES)|Using the Sleep WISP device, transcranial electrical stimulation will be delivered during sleep as 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
219610650|NCT07142252|DRUG|Rezpegaldesleukin|Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.
219610651|NCT07142252|DRUG|Placebo|Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.
219610652|NCT07149350|BEHAVIORAL|FAVORes Workshop|The FAVORes (Food Access, Value, and Optimization of Resources) Workshop is a 4-week, in-person group coaching program for caregivers of children in food-insecure households. The intervention focuses on financial and nutrition literacy, community resource navigation, healthy eating habits, and setting family goals.
219610653|NCT07152132|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin c application
219610654|NCT07152132|PROCEDURE|Slow coagulation trans-scleral cyclophotocoagulation|Slow coagulation trans-scleral cyclophotocoagulation
219610655|NCT07161960|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the definite treatment for acute cholecystitis. According to Tokyo Guideline 2018, the proper timing of delay LC remains unclear due to lack to proper evidence.
219610656|NCT07193186|DRUG|Anlotinib and Benmelstobart|Patients will receive Benmelstobart (1200mg, d1, q3w) in combination with Anlotinib (12mg, qd, d1-14, q3w). Treatment will continue until disease progression, voluntary withdrawal of informed consent, intolerable toxicity, or until the investigator determines that the patient no longer benefits.
219610657|NCT07192523|OTHER|Restrictive fluid therapy|Group Restrictive (Group R) received 3ml/kg/hr, crystalloid (Ringer Lactate).
219610658|NCT07192523|OTHER|Liberal fluid therapy|Group Restrictive liberal received 8ml/kg/hr, crystalloid (Ringer Lactate).
219514903|NCT01760122|DRUG|Pegasys|sc, qw, 48 weeks.
219514904|NCT05024071|DEVICE|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
219514905|NCT05024071|DEVICE|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
219514906|NCT04900233|OTHER|surgery|emergency surgery
219514907|NCT02415959|DRUG|Creon IR|
219514908|NCT02415959|DRUG|Creon® (DR/GR)|
219514909|NCT04433481|DRUG|Dabigatran|T. Dabigatran 150 mg twice a day
219514910|NCT04433481|OTHER|Placebo|placebo
219610659|NCT07192055|BEHAVIORAL|Self-sampling|Self-sampling instructions will be provided to participants who will insert the swab into the anus to collect cells. Then the participant will put the swab in a vial of transport fluid for assessment at a laboratory.
219610660|NCT07192055|OTHER|Nylon-flocked Swab|At the cytology appointment, participants may receive self-sampling or clinician sampling with 1 of 2 kinds of swabs. The nylon-flocked swab is the intervention and will be assessed on patient acceptability and patient and clinician ability to collect an adequate sample.
218894521|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
218894522|NCT01522300|OTHER|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
219514911|NCT03342703|DIAGNOSTIC_TEST|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
219514912|NCT00200031|DEVICE|Interstim therapy|
219514913|NCT03880279|BIOLOGICAL|TAC01-CD19|Dose-escalating cohorts plus expansion groups
219514914|NCT05781659|PROCEDURE|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
218894523|NCT01522300|OTHER|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
218894524|NCT05932472|DRUG|Aspirin|Aspirin at currently prescribed dose
218894525|NCT04332718|DEVICE|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
219514915|NCT05781659|PROCEDURE|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
219514916|NCT05652621|DIETARY_SUPPLEMENT|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
219514917|NCT00564174|DRUG|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
219514918|NCT00564174|DRUG|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
219514919|NCT00317954|DRUG|Spironolactone|
219514920|NCT03731481|BEHAVIORAL|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
219514921|NCT05370521|DRUG|Tildacerfont|Oral tablet formulation taken once daily.
219514922|NCT05370521|DRUG|Placebo|Non-active dosage form taken once daily.
219514923|NCT01152203|DRUG|Bendamustine|Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
219514924|NCT01152203|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
218894526|NCT00587678|DRUG|Simvastatin|40mg each night
218894527|NCT00587678|DRUG|Ezetimibe|10mg daily
218894528|NCT00587678|DRUG|Simvastatin/Ezetimibe|40mg/10mg each night
218894529|NCT03710642|DRUG|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
218894530|NCT03710642|DRUG|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
218894531|NCT02240771|PROCEDURE|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
219203918|NCT03529019|DRUG|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
219514925|NCT04165538|PROCEDURE|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of \> 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
219514926|NCT04511390|DEVICE|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
219514927|NCT05153122|DEVICE|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
218894532|NCT02240771|DRUG|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days"
218894533|NCT05282927|OTHER|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
218894534|NCT05282927|OTHER|Implementation Strategy: Enhanced REP (enREP)|The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
218894535|NCT04633928|BIOLOGICAL|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
218894536|NCT02289638|DEVICE|Intubrite|Video-Laryngoscopy
218894537|NCT02289638|DEVICE|MIL|Direct-Laryngoscopy
218894538|NCT02727907|DRUG|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
218894539|NCT02727907|DRUG|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
218894540|NCT02727907|DRUG|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
218894541|NCT06140706|BEHAVIORAL|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
218894542|NCT00530738|DRUG|Lipoplus|i.v. fat emulsion for parenteral nutrition
218894543|NCT00530738|DRUG|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
218894544|NCT05034419|DEVICE|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
218894545|NCT05034419|DEVICE|Sham stimulation|Sham stimulation
218894546|NCT02992574|RADIATION|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
218894547|NCT06154707|DRUG|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
218894548|NCT06154707|OTHER|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
218894549|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
218894550|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
218894551|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
218894552|NCT04649515|OTHER|0.9% saline|Placebo
219514928|NCT02893748|DEVICE|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
218894553|NCT01079416|DEVICE|Capsule endoscopy, Esophagogastroduodenoscopy|
219514929|NCT02893748|PROCEDURE|Colonoscopy|Screening colonoscopy as per standard of care.
219514930|NCT02893748|DRUG|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
218894554|NCT00782717|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
218894555|NCT00782717|OTHER|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
218894556|NCT00782717|DRUG|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
218894557|NCT03016065|DIETARY_SUPPLEMENT|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
218894558|NCT03016065|DIETARY_SUPPLEMENT|Control|Baked goods (2 snacks) without added fiber
219514931|NCT01575678|DRUG|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
219514932|NCT01575678|DRUG|Lactose|blinded capsule 1/day, oral use, for 4 weeks
219514933|NCT04659109|DRUG|glenzocimab|IV administration as a sterile product
219514934|NCT04659109|DRUG|Placebo|IV administration
219514935|NCT05443243|PROCEDURE|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
219514936|NCT00097695|DRUG|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
219514937|NCT00097695|DRUG|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
219610661|NCT07192510|OTHER|Pancake oral immunotherapy|The baked egg tolerant group underwent a 4-dose initial escalation (at intervals of 20-30 minutes) with pancakes in hospital (37.5 mg, 75 mg, 150 mg, 300 mg egg protein) to determine the home starting dose of pancake. The dose tolerated was one which resulted in no more than mild transient (not lasting more than 20 minutes) symptoms (e.g. itchy mouth) - transient Grade 1 symptoms. The home starting dose (taken daily at home) was one step below the tolerated dose, to minimise risk of allergic reactions at home, particularly as the presence of co-factors might decrease reaction threshold. Those reacting at 37.5 mg or 75 mg would not begin OIT with pancakes but instead began with cookies. Updosing visits were performed in the hospital at approximately 4 weekly intervals. Participants were kept at the pancake daily maintenance dose (2500 mg) for a minimum of 16 weeks, or total OIT duration of 18 months, whichever earlier
219610662|NCT07193485|OTHER|Buteyko breathing|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.
219610663|NCT07193485|OTHER|usual care|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.
219610664|NCT07193446|BEHAVIORAL|D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.|Enhanced Usual Care intervention aims to train health care professionals to detect and prevent, and manage diabetes distress in routine diabetes care, in the UK NHS. The REDUCE programme aims to prevent and manage elevated diabetes distress.
219610665|NCT07191912|DRUG|Govorestat|Govorestat will be provided as a liquid suspension (200mg/mL) for weight-based administration and administered orally at 20 mg/kg QD (every 24 hours)
219610666|NCT07191912|DRUG|Placebo Control|Placebo will also be provided as a matching liquid suspension to be taken orally QD
218894559|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
219514938|NCT06211426|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
218894560|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
218894561|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
218894562|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
218894563|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
219514939|NCT06211426|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219514940|NCT00428415|DRUG|Tesofensine|
219514941|NCT02109133|PROCEDURE|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
219610667|NCT07191665|OTHER|Acute nutrition intervention|The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.
219610668|NCT07192601|BEHAVIORAL|E-cigarette Cessation Manual|E-cigarette cessation manual development. Empirically supported treatment content. We anticipate grounding the intervention in an empirically supported psychosocial smoking cessation program (i.e., Cognitive Behavior Therapy; CBT), which has been found to be effective with both adults and adolescents to quit cigarette smoking (Vinci, 2020). We anticipate including sessions that teach CBT skills to help adolescents quit e-cigarette use. These CBT skills and format will be adapted from prior manualized CBT smoking cessation interventions for adolescent smoking cessation and manualized CBT e-cigarette intervention for adolescents and young adults that are currently ongoing (e.g., Kong et al., 2017; Kong et al., 2021; Bold et al., 2022). The structure and content of the e-cigarette cessation manual will be further informed by themes and sub-themes from the focus group data analysis relating to both surface and deep structure cultural modifications.
218894564|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
218894565|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
218894566|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
218894567|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
218894568|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
218894569|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
218894570|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
218894571|NCT01669317|OTHER|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
218894572|NCT01669317|OTHER|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
218894573|NCT00241722|DRUG|Alvimopan|
218894574|NCT00241722|DRUG|Placebo|
218894575|NCT06312657|BEHAVIORAL|Drug Cue|Individualized drug cues paired with choice options reinforced by $0.25
218894576|NCT06312657|BEHAVIORAL|Money|Two money values will be tested ($0.25 and $4.00)
218894577|NCT06312657|DRUG|Withdrawal|Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
219514942|NCT02109133|PROCEDURE|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
219514943|NCT02109133|DRUG|Rocuronium|
219514944|NCT02109133|DRUG|Sugammadex|
219514945|NCT02109133|DRUG|Atracurium|
219514946|NCT02109133|DRUG|Neostigmine|
219514947|NCT03363581|BEHAVIORAL|Food Preference|Buffet meal to assess food preference
219514948|NCT00409578|DRUG|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
219514949|NCT00409578|DRUG|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
219610669|NCT07185841|DRUG|HX9428 tablet|Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..
219610670|NCT07192549|DRUG|Sevoflurane group|Patients fasted for 6 hours and abstained from clear fluids for 3 hours preoperatively. Upon entering the operating room, oxygen was administered via an appropriately sized face mask at a flow rate of 6-8 L/min. Anesthesia was induced by sequential intravenous injection of remimazolam, sufentanil, and rocuronium. A laryngeal mask was inserted after the disappearance of the eyelash reflex. Anesthesia was maintained with sevoflurane (Inhalation Sevoflurane, Brand: Kaiteli, Specification: 120 mL, Approval Number: National Drug Approval H20070172, Manufacturer: Shanghai Hengrui Pharmaceutical) combined with continuous intravenous infusion of remifentanil. During surgery, vital signs and body movement responses were closely monitored, and the inhaled concentration of sevoflurane was adjusted as needed (maintained at 1%-3%). Administration of anesthetics was discontinued 5 minutes before the end of surgery.
218894578|NCT03291483|OTHER|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
218894579|NCT03291483|OTHER|plyometric training|Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
218894580|NCT03796117|DEVICE|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
219203919|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
219514950|NCT00409578|DRUG|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
219514951|NCT00409578|DRUG|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
219514952|NCT05200858|DEVICE|TENS - high-dose|Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
219514953|NCT05200858|DEVICE|TENS - low-dose|Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
219514954|NCT01737177|DRUG|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~\- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
219514955|NCT07036991|DRUG|Evolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe|PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe
219514956|NCT07036991|DRUG|Rosuvastatin/Atorvastatin ± Ezetimibe|Rosuvastatin/atorvastatin ± ezetimibe
219514957|NCT06394102|OTHER|The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.|A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
219514958|NCT05241535|DRUG|MT-7117|oral
219514959|NCT05241535|DRUG|moxifloxacin|oral
219514960|NCT05241535|DRUG|Placebo|oral
219514961|NCT04054024|DRUG|Erenumab|140 mg Erenumab
219514962|NCT04054024|DRUG|Placebos|Saline
219610671|NCT07192549|DRUG|Propofol group|Preoperative preparation was identical to that of the Sevoflurane Group. Anesthesia induction was performed using the same sequence of intravenous injections of remimazolam, sufentanil, and rocuronium, followed by laryngeal mask insertion after the disappearance of the eyelash reflex. Anesthesia was maintained with remifentanil combined with continuous intravenous infusion of propofol at a maintenance dose of 0.5 mg/(kg·h). The infusion rate was dynamically adjusted based on intraoperative vital signs. Administration of anesthetics was stopped 5 minutes before the end of surgery.
219610672|NCT07191769|PROCEDURE|general anaesthesia|Patients undergoing general anaesthesia
219610673|NCT07191769|PROCEDURE|regional anaesthesia|Patients undergoing regional anaesthesia
219610674|NCT07193095|BEHAVIORAL|Brief Mindfulness Oriented Recovery Enhancement|B-MORE is a 2-hour, single session adaptation of the traditional MORE program.
219610675|NCT07193095|BEHAVIORAL|Empowered Relief|ER is an evidence-based 2-hour single session intervention for chronic pain.
219610676|NCT07193095|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE is an 8-week evidence-based treatment for chronic pain.
218894581|NCT03796117|DEVICE|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
218894582|NCT02292719|DRUG|OBV/PTV/r|Tablet
218894583|NCT02292719|DRUG|Sofosbuvir|Tablet
218894584|NCT02292719|DRUG|Ribavirin (RBV)|Tablet
219035146|NCT05800470|OTHER|Kinesthetic motor imagery|Prior to each task, participants will watch a video of a person executing balance tasks and walking tasks. The balance tasks will include static and dynamic standing tasks such as sit-to-stand, tandem stance, standing on a balance board, reaching out to different directions and single leg stance. The walking tasks consists of tandem walking, crossing obstacles, sideward walking, backward walking, and turning. The participants will be asked to kinesthetically imagine movements in the first-person perspective, and the researcher will give the explicit instruction encouraging them to focus on the feeling (i.e. tactile, proprioceptive and kinesthetic sensations). Each MI session consists of 10-min of balance tasks and 10-min of walking tasks.
219035147|NCT05800470|OTHER|Motor training|The tasks for balance and gait training are similar to those during the MI training. The difficulty of the tasks will be modified individually for each participant. The researcher will ensure the safety.
219035148|NCT06024603|DIAGNOSTIC_TEST|Drug Sensitivity Test (DST)|Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
219035149|NCT05852431|DRUG|Pegozafermin|Subcutaneous injection
219035150|NCT05852431|DRUG|Placebo|Subcutaneous injection
219035151|NCT05331378|DEVICE|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
219514963|NCT01147120|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
219514964|NCT01147120|PROCEDURE|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
219514965|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
219610677|NCT07185828|BEHAVIORAL|Contact your PCP|Text messages will be sent and discharge paperwork will be modified to encourage contacting a primary care provider.
219610678|NCT07185828|BEHAVIORAL|Use Intelligent Triage|Text messages will be sent and discharge paperwork will be modified to encourage using Intelligent Triage.
219610679|NCT07191613|BEHAVIORAL|HAPPY GO GO Somatosensory Game|"Participants in the intervention group will engage in the HAPPY GO GO somatosensory exergame program. The intervention consists of structured game-based physical activity sessions, conducted once per week for a total duration of 12 weeks. Each session includes interactive, movement-based tasks designed to promote physical health, and mental well-being among community-dwelling older adults."
219035152|NCT05331378|DEVICE|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
219035153|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
219035154|NCT04242615|OTHER|Prognostic score|
219035155|NCT01828047|DEVICE|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
219035156|NCT00210054|DRUG|denufosol tetrasodium (INS37217)|
219035157|NCT01591876|OTHER|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
219035158|NCT01591876|OTHER|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
219035159|NCT01147705|DRUG|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
219035160|NCT01147705|DRUG|Placebo|Same appearance/dosing as active drug.
219035161|NCT02245074|OTHER|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
219035162|NCT01066754|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
219035163|NCT03168152|RADIATION|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
218894585|NCT02538042|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
218894586|NCT02538042|DRUG|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
218894587|NCT02538042|BEHAVIORAL|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
218894588|NCT02538042|BEHAVIORAL|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
218894589|NCT04936061|DEVICE|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
218894590|NCT04936061|DEVICE|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
218894591|NCT03026881|DRUG|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
218894592|NCT03026881|DRUG|Apatinib|Oral
218894593|NCT03026881|DRUG|Paclitaxel|Intravenous injection
218894594|NCT00034294|DRUG|GT160-246|
218894595|NCT04676620|PROCEDURE|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
218894596|NCT01187628|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
218894597|NCT01059734|GENETIC|DNA analysis|
218894598|NCT01059734|GENETIC|RNA analysis|
218894599|NCT01059734|GENETIC|mutation analysis|
218894600|NCT01059734|GENETIC|polymerase chain reaction|
218894601|NCT01059734|GENETIC|polymorphism analysis|
218894602|NCT01059734|OTHER|laboratory biomarker analysis|
218894603|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
219514966|NCT02218359|DRUG|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
219514967|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
218894604|NCT03136016|BEHAVIORAL|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
219035164|NCT03168152|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
219514968|NCT04017013|PROCEDURE|Epidural Analgesia|"The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
219514969|NCT04017013|DRUG|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
219514970|NCT00287027|DRUG|Risperdal Long Acting Injectable Antipsychotic Medication|
219514971|NCT06033066|BEHAVIORAL|Financial Incentives|Small financial incentive or prize incentive
218894605|NCT03136016|BEHAVIORAL|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
218894606|NCT03136016|BEHAVIORAL|nudging + educational activities|Group 4 will receive both interventions
218894607|NCT04931069|OTHER|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
218894608|NCT02220829|DRUG|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
218894609|NCT02220829|DRUG|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
219514972|NCT06033066|BEHAVIORAL|Message|Message inviting participant to enroll
219514973|NCT00974142|DRUG|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
219514974|NCT00974142|DRUG|Placebo|Fifteen patients will receive will receive placebo.
219514975|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
218894610|NCT03575728|OTHER|MyChart-MHT|All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
218894611|NCT06821607|BEHAVIORAL|In-Clinic Physical Therapy|Patients in this group will receive all PT sessions in-clinic with a trained physical therapist. Treatment provided for this group will be consistent with evidence-based guidelines that recommend patient education, exercise instruction, manual therapy interventions, and psychosocial interventions. Specific interventions to be provided within each of these categories: Education, Exercise, Manual Therapy, and Psychosocial interventions. Components of the intervention will be determined by the treating therapist based on patients' symptoms, examination findings, and patients' preferences and goals.
218894612|NCT06821607|BEHAVIORAL|Telehealth Physical Therapy (Telerehabilitation)|Those randomized to telerehabilitation will receive all PT care, including the initial evaluation and 7 follow-up sessions, via real-time video conferencing technology. Like the interventions provided to those receiving in-clinic PT, treatments provided in the telerehabilitation group will be consistent with evidence-based guidelines, adapted for delivery via real-time video visits. Consistent with the in-clinic group, specific interventions will be selected by the treating physical therapist based on patients' symptoms, examination findings, and preferences and goals. There will be an emphasis: Open-ended questions to allow patients to describe the participant's impairments and limitations; Review patient-reported measures of disability and pain intensity to help identify functional impairments; and Clinical examination of spinal movements and impairments in strength, flexibility, and joint mobility.
218894613|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
219035165|NCT02861703|BEHAVIORAL|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
219035166|NCT00277433|OTHER|Buccal Swab|collection of buccal swab
219035167|NCT01337219|DRUG|Tobramycin|
219035168|NCT01774786|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
219035169|NCT01774786|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
219035170|NCT01774786|DRUG|Cisplatin|Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
219035171|NCT01774786|DRUG|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
219035172|NCT01774786|DRUG|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
219035173|NCT01774786|DRUG|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
219035174|NCT02385084|DRUG|LY2409021|Administered orally
219035175|NCT01920919|DRUG|Dexamethasone|
219035176|NCT01920919|DRUG|Placebo|
219514976|NCT01463540|DEVICE|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
219514977|NCT01463540|DEVICE|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
219514978|NCT02259751|DRUG|KUC 7483 CL|
219514979|NCT02259751|DRUG|Placebo|
219514980|NCT00944970|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
219514981|NCT00944970|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
219514982|NCT06148909|OTHER|Small Talk Motivational Interviewing|Combining small talks and skills on Motivational Interviewing in the smoking cessation services
219514983|NCT05111470|OTHER|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
219514984|NCT00002387|DRUG|Indinavir sulfate|
219514985|NCT00002387|DRUG|Efavirenz|
218894614|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
218894615|NCT06367257|PROCEDURE|App Usage|Conducting patient surveys with app
218894616|NCT06367257|OTHER|Standard of Care|supportive care during and after radio(chemo)therapy according to hospial standards
218894617|NCT05842070|PROCEDURE|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
218894618|NCT05842070|PROCEDURE|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
218894619|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
218894620|NCT02586727|DRUG|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
218894621|NCT04382885|DRUG|Cariprazine|Oral Solution
219035177|NCT04357015|DRUG|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
219035178|NCT04357015|DRUG|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
219035179|NCT04357015|DRUG|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
219035180|NCT05113615|DRUG|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
219035181|NCT05113615|DRUG|Matching placebo|matching placebo Respimat inhaler
219514986|NCT00564525|DRUG|Amitriptyline|Medication taken for 4 weeks
219514987|NCT00564525|DRUG|Placebo|Medication taken for 4 weeks
219514988|NCT03810430|BEHAVIORAL|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
219514989|NCT02717247|DEVICE|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
219514990|NCT02717247|DEVICE|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
219514991|NCT00110968|DRUG|Itopride hydrochloride|
219514992|NCT05216536|OTHER|No intervention|No intervention
219514993|NCT01643837|OTHER|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
218894622|NCT03784677|DRUG|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
218894623|NCT00096980|DRUG|Raptiva (efalizumab)|
218894624|NCT01648972|DRUG|Gastrografin|
218894625|NCT01648972|DRUG|Placebo|
219514994|NCT01643837|OTHER|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
219514995|NCT05172375|BEHAVIORAL|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
219514996|NCT02333370|DRUG|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
219035182|NCT03099447|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
219514997|NCT02333370|DRUG|Letrozole|25mg
219514998|NCT02333370|DRUG|Tamoxifen|20 mg
218894626|NCT04311762|DRUG|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
218894627|NCT03554928|DIAGNOSTIC_TEST|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
218894628|NCT03822767|BIOLOGICAL|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
219514999|NCT02333370|DRUG|Fulvestrant|500 mg
219515000|NCT02333370|DRUG|goserelin|
218894629|NCT03822767|BIOLOGICAL|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
218894630|NCT04514822|DIAGNOSTIC_TEST|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
218894631|NCT03203083|OTHER|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
218894632|NCT04417608|PROCEDURE|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
218894633|NCT04090411|DRUG|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
219035183|NCT03099447|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
219515001|NCT05769530|DRUG|Nalbuphine，dexmedetomidine|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
219515002|NCT02929979|BEHAVIORAL|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
219515003|NCT02929979|BEHAVIORAL|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
219515004|NCT04762056|OTHER|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
219515005|NCT00488748|DEVICE|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
219515006|NCT00488748|DEVICE|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
219515007|NCT05833386|PROCEDURE|Ureteral access sheath placement during flexible ureteroscope for renal stones|Ureteral access sheath placement during flexible ureteroscope
219515008|NCT00805558|DRUG|moxifloxacin|400 mg moxifloxacin once daily for 7 days
219515009|NCT00805558|DRUG|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
219515010|NCT00160407|DRUG|Orlistat (Xenical)|
219515011|NCT00160407|BEHAVIORAL|1400 kcal diet (30% fat)|
219515012|NCT01581970|DRUG|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
219515013|NCT01581970|DRUG|Cetuximab|The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
219515014|NCT00584298|DRUG|SMS995|
219515015|NCT00584298|DRUG|Placebo|
218894634|NCT04090411|DRUG|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
218894635|NCT04090411|DRUG|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
218894636|NCT04090411|OTHER|Induction- Placebo SC Q4W|0 mg Placebo
218894637|NCT04090411|DRUG|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
218894638|NCT04090411|DRUG|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
218894639|NCT04090411|DRUG|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
218894640|NCT00756418|DRUG|montelukast|montelukast 5 mg QD 4-weeks.
218894641|NCT00756418|DRUG|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
218894642|NCT01849406|DRUG|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
218894643|NCT01849406|DRUG|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
218894644|NCT02699320|OTHER|Complications|Not involved
219610680|NCT07192731|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
219610681|NCT07186634|DRUG|Liberal inspired oxygen|The concentration of Oxygen will differ according to the randomisation
219610682|NCT07186634|DRUG|Conservative inspired oxygen|Conservative inspired oxygen
219610683|NCT07186634|DRUG|Intermediate inspired oxygen|Intermediate inspired oxygen
219610684|NCT07192315|OTHER|Bloodsampling|Blood will be sampled At Visit 1, 2, 3 and 4. For patients presenting immuno-induced adverse events (iRAEs), an additionnal visit V tox will be planned will a blood sampling.
219610685|NCT07192315|OTHER|Pharyngeal swab sampling|Pharyngeal swab will be sampled at visit 4 for patients without immuno-induced adverse events (iRAEs) Pharyngeal swab will be sampled at visit Tox for patients presenting immuno-induced adverse events (iRAEs)
219610686|NCT07192315|OTHER|Cuteanous swab sampling|"Cuteanous swab will be sampled at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Cuteanous swab will be sampled at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
219610687|NCT07192315|OTHER|Stools sample collection|"Stools sample will be collected at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Stools sample will be collected at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
218894645|NCT04370613|BEHAVIORAL|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
218894646|NCT03612336|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219515016|NCT05067361|PROCEDURE|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
219515017|NCT05067361|PROCEDURE|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
219515018|NCT01361802|DRUG|Ambroxol Spray|low dose Ambroxol Spray
219515019|NCT01361802|DRUG|Ambroxol Spray|medium dose Ambroxol Spray
219610688|NCT07193290|OTHER|Lifestyle Questionnaire|All subjects will complete the lifestyle questionnaire
219610689|NCT07193290|OTHER|Self-portrait image (Face and Hair)|All subjects will take one self-portrait image of their face and hair
219610690|NCT07193290|DIAGNOSTIC_TEST|Skin microbiome collection|Subjects randomly assigned in the skin microbiome subset will complete the skin microbiome collection
219610691|NCT07192250|PROCEDURE|short segment TPF|short segment transpedicular screw fixation with one or two screws in fractured vertebra
219610692|NCT07192250|PROCEDURE|conservative management|brace and bed rest with mobilization as tolerated
219610693|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; High dose
218894647|NCT03612336|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218894648|NCT00798525|DRUG|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
219035184|NCT03099447|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
219515020|NCT01361802|DRUG|Ambroxol Spray|high dose Ambroxol Spray
219515021|NCT01361802|DRUG|Placebo Spray|Placebo Spray
219515022|NCT01691508|DRUG|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
219515023|NCT01691508|DRUG|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
219515024|NCT01691508|DRUG|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
219610694|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; Low dose
219610695|NCT07192939|DRUG|HRS-9813 capsule mimetic|HRS-9813 capsule mimetic
219610696|NCT07192536|DEVICE|Transcranial magnetic stimulation|Intermittent theta burst stimulation (iTBS) will be delivered via the Magstim Horizon 3.0 Transcranial Magnetic Stimulation device. This device has been authorized by Health Canada (License No.: 111334, Type: System, Device class: 3 Device first issue date 2024-06-04, License name: HORIZON 3.0 TMS THERAPY SYSTEM) and is indicated for use in treating mild depressive disorder. The device will be used off-label as a potential treatment for Post-Traumatic Stress Disorder (PTSD) and chronic pain in this Investigator-Initiated study. rTMS will be delivered using modified intermittent theta burst accelerated bilateral treatments (MITAB), combining low frequency 1HZ to the right dorsolateral prefrontal cortex (dlPFC) with high frequency intermittent theta burst to the left dlPFC, up to 6 times per day for 5 days.
218894649|NCT00798525|DRUG|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
218894650|NCT00365924|DRUG|Forteo|Open label single arm study with Forteo as an intervention
218894651|NCT03117855|DRUG|Capecitabine|Given PO
219035185|NCT04903249|BEHAVIORAL|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
219035186|NCT03556579|DEVICE|senofilcon A with new UV blocker|Test Lens
218894652|NCT03117855|OTHER|Laboratory Biomarker Analysis|Correlative studies
219035187|NCT03556579|DEVICE|senofilcon A|Control Lens
219035188|NCT02965703|DRUG|Aspirin|Given PO
219035189|NCT02965703|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
219035190|NCT02965703|OTHER|Placebo Administration|Given PO
219035191|NCT02965703|OTHER|Questionnaire Administration|Ancillary studies
219035192|NCT02965703|PROCEDURE|Rectal Biopsy|Undergo rectal biopsy
219035193|NCT03893604|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
219035194|NCT05180214|DRUG|Bupivacain|analgesic
219035195|NCT05180214|DRUG|Ketorolac|analgesia
219203920|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
218894653|NCT03117855|RADIATION|Radioembolization|Undergo yttrium Y-90 radioembolization
218894654|NCT03915314|DIAGNOSTIC_TEST|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
218894655|NCT04791618|BEHAVIORAL|Health360x plus health coach|Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
219035196|NCT02574130|DRUG|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
219035197|NCT02574130|DRUG|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
219035198|NCT00188019|PROCEDURE|diagnosis methods|
219035199|NCT05225142|PROCEDURE|Modified minimally invasive surgery|Surgical intervention alone
219035200|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
219035201|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
219035202|NCT02488603|BEHAVIORAL|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
219035203|NCT02488603|DRUG|tamoxifen|
219035204|NCT05492565|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
219035205|NCT02918149|OTHER|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
219035206|NCT02918149|DEVICE|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
219203921|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
219203922|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
219203923|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
218894656|NCT04791618|BEHAVIORAL|Health360x only (High tech)|All participants will have access to Helath360x with reminders generated for goal setting.
218894657|NCT05799131|DEVICE|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
218894658|NCT00731679|DRUG|Rifaximin|
218894659|NCT00731679|DRUG|Placebo|
218894660|NCT00330122|PROCEDURE|fore locked plate|
218894661|NCT00330122|PROCEDURE|external radiocarpal fixer|
218894662|NCT04671264|DEVICE|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
218894663|NCT01598922|BEHAVIORAL|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
218894664|NCT00292019|PROCEDURE|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
218894665|NCT01940835|PROCEDURE|Upper endoscopy with small bowel biopsies and brushings.|
219515025|NCT03432247|BEHAVIORAL|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
219515026|NCT03432247|BEHAVIORAL|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
219515027|NCT03700944|OTHER|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
219515028|NCT00159302|PROCEDURE|Induced Sputum|
219515029|NCT00159302|PROCEDURE|Exhaled Nitric Oxide|
219515030|NCT00159302|PROCEDURE|Nasal Nitric Oxide|
219515031|NCT00159302|PROCEDURE|Blood Tests|
219515032|NCT00159302|PROCEDURE|24hr Urine Samples|
219515033|NCT00159302|PROCEDURE|Exhaled Breath Condensate|
219515034|NCT00159302|PROCEDURE|Spirometry|
219515035|NCT01016028|BEHAVIORAL|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
219515036|NCT01016028|BEHAVIORAL|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
219610697|NCT07192172|DEVICE|Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes|"Device: Twin Internally Cooled-Perfusion (TICP) Electrodes~Two 17-gauge internally cooled-perfusion electrodes Multichannel RF generator (RF Medical Co., Seoul, Korea) Bipolar mode application Saline perfusion rate: approximately 1 cc/min"
218894666|NCT01940835|OTHER|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
218894667|NCT01940835|OTHER|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
218894668|NCT03724929|PROCEDURE|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
218894669|NCT03724929|DEVICE|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
218894670|NCT02488005|DEVICE|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
218894671|NCT02964000|DEVICE|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
218894672|NCT02964000|DEVICE|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
218894673|NCT02964000|DEVICE|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
219610698|NCT07192354|OTHER|Questionnaire and Physical Exam|Participants will be administered the Cyberchondria Severity Scale Short Form (CSS-12), Health Perception Scale, and State and Trait Anxiety Scale online via Google form.
219610699|NCT07192952|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 270±7 days.
219610700|NCT07191899|DRUG|KN060|The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks
218894674|NCT03286452|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
218894675|NCT00079560|DRUG|dronabinol|dronabinol to prevent development of marijuana withdrawal
218894676|NCT02478099|DRUG|MPDL3280A|Anti-PD-L1 antibody
218894677|NCT01377662|DRUG|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
218894678|NCT01377662|OTHER|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
218894679|NCT02481297|DRUG|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
218894680|NCT02481297|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
218894681|NCT00180388|PROCEDURE|endoscopic vein harvesting|
218894682|NCT00180388|PROCEDURE|open vein harvesting|
218894683|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
218894684|NCT01593553|OTHER|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
218894685|NCT00834262|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218894686|NCT00834262|DRUG|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218894687|NCT00834262|DRUG|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218894688|NCT03967054|DRUG|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
218894689|NCT03967054|DRUG|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
218894690|NCT05980585|DEVICE|CPM Device|Daily use of the CPM wearable device
218894691|NCT05431478|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
218894692|NCT05431478|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
218894693|NCT05431478|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
219515037|NCT01016028|BEHAVIORAL|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
219515038|NCT02915679|OTHER|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling"
219515039|NCT02472678|OTHER|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
219515040|NCT02472678|OTHER|Standard care|The control group will receive standard care.
219515041|NCT05344183|DEVICE|Low-level laser|A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
219515042|NCT01584661|BEHAVIORAL|Dietary recommendations|
219515043|NCT00275483|DEVICE|Vital-band (R)|
219610701|NCT07191899|DRUG|0.9% Sodium Chloride Injection|0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks
219610702|NCT01191450|DRUG|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
219610703|NCT01191450|DRUG|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
219610704|NCT02598050|OTHER|No Interventions as this is a observational study|
218894694|NCT03127293|DIAGNOSTIC_TEST|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
218894695|NCT02326597|OTHER|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
218894696|NCT02326597|OTHER|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
218894697|NCT05192993|OTHER|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
219515044|NCT01752348|OTHER|Endotoxin, US standard reference E.coli|
219515045|NCT04125628|BEHAVIORAL|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
219515046|NCT04125628|BEHAVIORAL|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
219610705|NCT05191277|DRUG|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
219610706|NCT05191277|DRUG|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
219610707|NCT05191277|BEHAVIORAL|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
219515047|NCT01827722|DRUG|Ozurdex|Intravitreal injection of Ozurdex
219515048|NCT01827722|DRUG|Ranibizumab|Intravitreal Injection of Ranibizumab
218894698|NCT05192993|OTHER|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
218894699|NCT05192993|OTHER|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
218894700|NCT02286921|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
219515049|NCT01827722|DRUG|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
219515050|NCT05639842|OTHER|Pain in competitive athletes with physical disabilities. Techniques for its management, support received and perceived difficulties.|A total of 413 athletes with physical disabilities participated in the study, 157 Spanish athletes and 260 Latin American athletes. The athletes were contacted through different sports federations, Paralympic Committees and sports teams of people with disabilities.For the distribution of the questionnaire, the researcher made an initial telephone contact with the Spanish Paralympic Committee and the Spanish Sports Federation for People with Physical Disabilities, to explain the objectives of the study and ask for their collaboration in the dissemination. Subsequently, the information was officially sent to them by email.
219515051|NCT05022836|DIAGNOSTIC_TEST|four-limb blood pressure measurements|Four-limb blood pressures were measured by certificated nurses at admission.
219515052|NCT01812421|OTHER|Hypertension Health Education Protocol (HHEP)|
219515053|NCT01183000|PROCEDURE|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
219515054|NCT00721877|DRUG|resveratrol|Given orally
219515055|NCT00721877|OTHER|pharmacological study|Correlative studies
219515056|NCT00721877|OTHER|laboratory biomarker analysis|Correlative studies
219515057|NCT01596647|DRUG|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
219515058|NCT01596647|DRUG|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
219515059|NCT01596647|DRUG|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
219515060|NCT01596647|DRUG|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
219610708|NCT05191277|BEHAVIORAL|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
219610709|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
219610710|NCT05156970|DRUG|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
219515061|NCT01596647|DRUG|TKI258|dovitinib, 5 days on / 2 days off dose schedule
218894701|NCT02286921|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
218894702|NCT02286921|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
218894703|NCT02369913|OTHER|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
218894704|NCT01158781|BEHAVIORAL|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
218894705|NCT01815827|DRUG|inclacumab|single intravenous doses
218894706|NCT04345562|PROCEDURE|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
219035207|NCT05864911|DEVICE|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
219035208|NCT03895983|PROCEDURE|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
219035209|NCT00642668|DRUG|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
219035210|NCT00665977|DRUG|Thermosmart & placebo|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
219515062|NCT01350063|DRUG|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
219515063|NCT01350063|DEVICE|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
219515064|NCT01350063|OTHER|No intervention|
219515065|NCT02574052|BEHAVIORAL|participants' food choices|just recorded the participants' food choices in the school cafeteria
219515066|NCT02574052|BEHAVIORAL|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
219515067|NCT02574052|BEHAVIORAL|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
219515068|NCT04126356|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
219515069|NCT01636856|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
219610711|NCT05156970|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
219610712|NCT05156970|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
219610713|NCT05156970|DRUG|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
219610714|NCT05156970|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
219610715|NCT06404099|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
219610716|NCT06404099|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
219515070|NCT01636856|BEHAVIORAL|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
219515071|NCT00003145|DRUG|Fludarabine Phosphate|Given IV
219515072|NCT00003145|RADIATION|Total-Body Irradiation|Undergo TBI
219515073|NCT00003145|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
219515074|NCT00003145|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219515075|NCT00003145|DRUG|Cyclosporine|Given PO or IV
219515076|NCT00003145|DRUG|Mycophenolate Mofetil|Given PO or IV
219515077|NCT00003145|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
219515078|NCT00003145|OTHER|Laboratory Biomarker Analysis|Correlative studies
219515079|NCT03185897|OTHER|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
219610717|NCT06404099|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
218894707|NCT05661279|PROCEDURE|general anesthesia|general anesthesia
219035211|NCT00665977|DRUG|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
219203924|NCT06966362|DRUG|Motivation-Phase Varenicline|Varenicline reduction dosing will start when participants initiate Motivation-phase treatment: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the duration of the 12-week reduction regimen.
219610718|NCT06404099|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
219203925|NCT06966362|DRUG|Motivation-Phase Nicotine Mini-Lozenge|NRT mini-lozenge reduction dosing will start when participants initiate Motivation-phase treatment: 2-mg mini-lozenges in place of cigarettes (5-15/day).
219515080|NCT04222036|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
219515081|NCT04222036|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
219515082|NCT04222036|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
219515083|NCT06205719|DRUG|ciprofol|sedation
219515084|NCT06205719|DRUG|Remazolam|sedation
219610719|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
219203926|NCT06966362|DRUG|Cessation-Phase Combination Nicotine Replacement Therapy (NRT)|Combination NRT (nicotine patch + nicotine mini-lozenge) cessation dosing will begin on the target quit day: if smoking \>10 cigarettes/day = 8 weeks of 21-mg, 2 weeks of 14-mg, and 2 weeks of 7-mg nicotine patches; if smoking 10 cigarettes/day = 10 weeks of 14-mg and 2 weeks of 7-mg nicotine patches. All participants will receive 2 or 4 mg mini-lozenge for the 12-week cessation period (9/day, 1 piece every 1-2/hours).
219203927|NCT06966362|DRUG|Cessation-Phase Varenicline|Varenicline cessation dosing will start one week prior to their TQD: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the remainder of the 12-week cessation regimen.
219610720|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
218894708|NCT05661279|PROCEDURE|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
219515085|NCT06205719|DRUG|Flumazenil|antagonism
219515086|NCT06205719|DRUG|Remifentanil|2ug/kg Remifentanil
219515087|NCT03491449|PROCEDURE|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
219515088|NCT03491449|PROCEDURE|Group B|Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
219515089|NCT00836836|OTHER|Modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
219515090|NCT06009913|OTHER|online teaching|teaching of subject was done using online system only
218894709|NCT05661279|PROCEDURE|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
219035212|NCT00665977|DEVICE|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
219035213|NCT06386835|PROCEDURE|Collagen Paste|Collagen paste injection
219515091|NCT06009913|OTHER|In class teaching|subjects were explained in normal class room
219515092|NCT01246375|DEVICE|Dual energy X-ray absorptiometry|Device which measures bone density
219515093|NCT02234609|DEVICE|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
219515094|NCT04316273|OTHER|colonic surgery|resection of duplicated colon
219515095|NCT00175357|DRUG|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
219610721|NCT05536258|OTHER|Fluid|The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
219610722|NCT06789731|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a loving kindness meditation adapted to apply to college communities and designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
219610723|NCT06789731|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to creating connections with campus community and managing anxiety and/or depression through a presentation. They will also receive information on resources for connecting with their community and treating anxiety and/or depression.
219610724|NCT06790017|OTHER|body temperature|Body temperature measurement will be performed in the preoperative and intraoperative periods.
219610725|NCT05277168|DRUG|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
219610726|NCT05108831|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
219035214|NCT06386835|PROCEDURE|Mucosal advancement|Mucosal advancement flap
219035215|NCT03686410|BEHAVIORAL|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
219515096|NCT00175357|DRUG|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
219515097|NCT04496635|OTHER|Implementation of a bundle of care|
219515098|NCT06153121|OTHER|Physical performance test - Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST)|The test is performed in a pushup position with the hands placed 91.4 cm apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
219515099|NCT06153121|OTHER|Physical performance test - modified Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a pushup position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
219515100|NCT06153121|OTHER|Physical performance test - Seated Seated Single Arm Shot Put Test (SSASPT)|Set up requires that the subject is placed in a seated position with their back against the wall, and a 2kg medicine ball held in a shot put position. When ready, the subject will perform a shot put motion to project the medicine ball as far as possible. The average of three trials is recorded for each arm.
219610727|NCT04574089|DRUG|Experimental: Baofukang Suppository 7 days|Experimental: Baofukang Suppository 7 days
219610728|NCT04574089|DRUG|Experimental: Baofukang Suppository 14 days|Experimental: Baofukang Suppository 14 days
219610729|NCT06378996|DIAGNOSTIC_TEST|14-day rhythm monitoring|Eligible patients will be monitored during 14 days using the Byteflies patch ambulatory rhythm monitor.
218894710|NCT03642652|BEHAVIORAL|SMS|Text reminders to mobile telephone
218894711|NCT00203489|DEVICE|KERLIX A.M.D. Gauze|
218894712|NCT05937061|BIOLOGICAL|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
219515101|NCT06153121|OTHER|Physical performance test - Upper Limb Rotation Test (ULRT)|Participants starts in a modified (on elbows) push-up position. Participants are positioned next to a wall in order to allow the shoulder, the elbow epicondyle, the greater trochanter and the lateral malleolus of the ankle to touch the wall. Participants are asked to perform a trunk rotation, coupled with an external rotation of the shoulder in a 90°-90° position (90° abduction, 90° external rotation) touching the tape placed vertically on the wall as quickly as possible for 15 s. Finally, three 15-s test trials were performed, with 45 s rest between each trial.
219515102|NCT06153121|OTHER|Physical performance test - Shoulder endurance test (SET)|Participants were instructed to stand up straight with their back against a wall. The tested arm was placed in a 90°forward flexion holding a 1-m long thera-band® fixed at shoulder height on a graduated stick. Participants were asked to pull the thera-band® from the starting position 90°forward flexion-to a 90° external rotation and 90° abduction (90°90°position) at an alternated cadence given by a metronome. Males are asked to pull a green thera-band (2.1 kg) and females a red thera-band (1.7 kg). Repetitions are performed until the participant is fatigued.
219515103|NCT06153121|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm perpendicular to the floor. A bar on a stick is adjusted for each patient and fixed at the point that the participant's shoulder reaches 90° of horizontal abduction, the point at which the participant was to hold the arm at the top of the arc of motion for 1 second. The participant held a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg). Starting with the arm perpendicular to the floor, the participant horizontally abducted his arm to 90 degrees at a cadence of 30 beats per minute. Repetitions are performed until the participant is fatigued.
219515104|NCT06153121|OTHER|Analytical test - Shoulder Strength|shoulder external rotation and internal rotation measured with a hand held dynanometer
219515105|NCT06153121|OTHER|Analytical test - Hand Grip Strength|Hand grip strength measured with a JAMAR Hand Dynamometer
219515106|NCT06153121|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
219515107|NCT06153121|OTHER|PROM - Kerlan-Jobe Orthopedic Clinic Shoulder and Elbow Score (KJOC-SES)|The KJOC-SES survey is composed of ten 10-point questions to evaluate specifically the performance of overhead athletes, with the highest performance score of 100.
219515108|NCT06153121|OTHER|PROM - Competitive State Anxiety Inventory-2 (CSAI-2)|The Competitive State Anxiety Inventory scale contains 27 items. It a psychometric scale that asks the volunteer to rate, on a 4-point Likert scale, their coping skills for sports performance.
219515109|NCT06153121|OTHER|PROM - General elf-efficacy scale (GSES).|The GSES measures (10 statements) how a person deals with stressors/difficult situations in life. The scale is about a person's self-confidence that his or her actions are responsible for successful outcomes or, in other words, that one has control over challenging demands imposed by the environment.
219515110|NCT04516525|DEVICE|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
219515111|NCT04928261|DRUG|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
219515112|NCT03020121|PROCEDURE|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
219515113|NCT00326079|DEVICE|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
219515114|NCT02258256|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
219515115|NCT02369809|DRUG|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
219515116|NCT04489407|DEVICE|Remote Photoplethysmography (rPPG) vital sign acquisition|Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
219515117|NCT00409994|DRUG|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
219515118|NCT01150487|PROCEDURE|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
219515119|NCT01150487|PROCEDURE|lymph node collection|An Iliac lymph node collection.
219515120|NCT05326464|DRUG|Tofacitinib 10mg|10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
219515121|NCT05005949|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter System|Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
219515122|NCT03462940|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
219515123|NCT02276196|DRUG|Lixisenatide|GLP-1 receptor agonist
219515124|NCT02276196|DRUG|Insulin glulisine|Insulin analogue
219515125|NCT03735602|BEHAVIORAL|perceptual training|orientation discrimination task
219515126|NCT00998699|DRUG|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
219515127|NCT00998699|DRUG|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
219515128|NCT00698906|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
219515129|NCT00698906|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
218894713|NCT05937061|OTHER|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
218894714|NCT05937061|RADIATION|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
218894715|NCT05937061|OTHER|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
219515130|NCT02889185|DEVICE|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
219515131|NCT05231109|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
219515132|NCT02375009|PROCEDURE|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
219515133|NCT02586259|DRUG|budesonide MMX®|
219515134|NCT00995137|BIOLOGICAL|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
219515135|NCT01315145|PROCEDURE|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
219515136|NCT01315145|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
219610730|NCT06397950|OTHER|Assessment of potential fatigue factors|"3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk."
219610731|NCT05650476|DRUG|Talazoparib|capsules
219610732|NCT04595773|OTHER|Aerobic Exercise Training|Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
219610733|NCT04595773|OTHER|Education|Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
219610734|NCT06514547|BIOLOGICAL|Conjugate Pneumococcal Vaccine 20 (PCV20)|Vaccine
219610735|NCT06415058|DEVICE|HemoIV|A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.
219610736|NCT05351164|DRUG|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
219610737|NCT03568266|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
219610738|NCT05854498|DRUG|Liposomal irinotecan|50mg/m2 IV on days 1 and 15
219515137|NCT02933281|BIOLOGICAL|MTBVAC|Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU
219515138|NCT02933281|BIOLOGICAL|BCG|BCG 5 x 10\^5 CFU
219515139|NCT02675543|DEVICE|Vitreous Tamponade with Silicone Oil|
219515140|NCT04601584|BIOLOGICAL|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219515141|NCT04601584|BIOLOGICAL|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219515142|NCT04601584|BIOLOGICAL|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219515143|NCT04601584|BIOLOGICAL|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219515144|NCT04601584|BIOLOGICAL|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219035216|NCT03686410|OTHER|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
219035217|NCT04662801|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will receive twelve weeks of BWL treatment.
219035218|NCT04662801|BEHAVIORAL|Early Responder: BWL continued|Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
219515145|NCT04601584|BIOLOGICAL|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
219515146|NCT03211559|OTHER|Exercise|clinical pilates on mat
219515147|NCT04815642|RADIATION|radiotherapy|Hypofractionated radiotherapy concomitantly with weekly boost
219515148|NCT02309099|DEVICE|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
218894716|NCT04089761|DEVICE|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
218894717|NCT01553019|RADIATION|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
218894718|NCT01553019|DRUG|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
218894719|NCT06245733|OTHER|Compassion-Based Education Program Adapted for Adults|Training will be given once a week. This training will last 10 weeks in total.
218894720|NCT04747899|OTHER|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
219515149|NCT06115005|BIOLOGICAL|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
219515150|NCT06291688|BEHAVIORAL|Mobile healthcare education game|Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.
219515151|NCT06291688|BEHAVIORAL|Mobile healthcare education application|Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
219515152|NCT04788680|OTHER|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
219515153|NCT04788680|OTHER|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
219515154|NCT04788680|OTHER|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
219515155|NCT04788680|OTHER|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
219515156|NCT04524065|OTHER|Early rehabilitation protocol for children hospitalized in the PICU|The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
219610739|NCT05854498|DRUG|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
219610740|NCT05854498|DRUG|Bevacizumab|5mg/kg IV on days 1 and 15
219610741|NCT03493685|DRUG|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
219610742|NCT03493685|DRUG|Irbesartan|target dose of 300 mg daily
219610743|NCT05969821|OTHER|observational cohort study|observational cohort study
219610744|NCT05814627|DRUG|Upadacitinib|Oral Tablets
219610745|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
219610746|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
219610747|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
218894721|NCT04747899|OTHER|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
219515157|NCT00392639|PROCEDURE|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
219515158|NCT01496040|DRUG|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
219515159|NCT02786238|BEHAVIORAL|Standard Behavioral Treatment (SBT)|See description of treatment arm.
219515160|NCT02786238|BEHAVIORAL|Acceptance-Based Treatment (ABT)|See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
219515161|NCT02815852|OTHER|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women \<40 years the typical imaging presentation pattern of malignancies observed in women\> 40 years are confirmed.
219610748|NCT04000880|BEHAVIORAL|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
219610749|NCT04000880|OTHER|Diet-Exercise|Diet-Exercise
219610750|NCT04000880|OTHER|Exercise-Diet|Exercise-Diet
219610751|NCT04000880|OTHER|Combined Diet and Exercise|Combined Diet and Exercise
219610752|NCT04223518|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of \>90% protein which consists primarily of immunoglobulins (\>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
219610753|NCT04223518|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed Collagen
218894722|NCT02316496|DRUG|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
218894723|NCT02316496|DRUG|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
218894724|NCT05747703|COMBINATION_PRODUCT|Ria Treatment Platform|combined medication, coaching, education, and monitoring
218894725|NCT00899756|GENETIC|molecular diagnostic method|
218894726|NCT00899756|GENETIC|mutation analysis|
218894727|NCT01112397|DRUG|AZD1480|continuous daily oral capsule
218894728|NCT06308419|DRUG|Gemcitabine|Given by IV
218894729|NCT06308419|DRUG|Nab-Sirolimus|Given by IV
218894730|NCT04346329|DRUG|Hydroxychloroquine|Treated group
218894731|NCT04346329|DRUG|Placebo oral tablet|Placebo Group
218894732|NCT03410524|DRUG|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
218894733|NCT03410524|DRUG|Water|3 mL of water as placebo added to the bowel preparation
218894734|NCT04628780|BIOLOGICAL|PF-07209960|PD-1 targeted IL-15 mutein
218894735|NCT02732964|OTHER|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
218894736|NCT02732964|OTHER|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
218894737|NCT05315479|DRUG|N1539|Once daily
218894738|NCT00773162|DRUG|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
218894739|NCT00773162|DRUG|Sugar Pill|Sugar pill to match seroquel
218894740|NCT00273273|PROCEDURE|blood draw|
219515162|NCT05366959|OTHER|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
218894741|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 6 hours|catheter placement for 6 hours beginning in the morning at around 8 a.m.
218894742|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 12 hours|catheter placement for 12 hours in the evening at around 8 p.m.
219515163|NCT05366959|OTHER|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
219515164|NCT05366959|OTHER|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
218894743|NCT04323059|DIETARY_SUPPLEMENT|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
218894744|NCT02977858|OTHER|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
218894745|NCT02977858|OTHER|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
218894746|NCT00858624|DRUG|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
218894747|NCT02934165|BEHAVIORAL|Family Safety 123|Theoretically-based injury prevention videos for families
218894748|NCT02934165|BEHAVIORAL|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
218894749|NCT04415814|PROCEDURE|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
218894750|NCT04415814|PROCEDURE|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
218894751|NCT03622814|BEHAVIORAL|Partners at Meals|The focus of the intervention was to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals. Families recorded three meals including behavior at home each month.
218894752|NCT03622814|BEHAVIORAL|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites received training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month.
219035219|NCT04662801|COMBINATION_PRODUCT|Early Non-responder: BWL continued with medication added|Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
219610754|NCT04452669|DRUG|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
219610755|NCT03300817|OTHER|Laboratory Biomarker Analysis|Correlative studies
219610756|NCT03300817|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
219610757|NCT05117476|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
219610758|NCT05117476|DRUG|Pembrolizumab|Keytruda
218894753|NCT06242301|OTHER|The collective person-centered dialogue intervention|"* Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
218894754|NCT05306587|DRUG|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
219610759|NCT05117476|DRUG|Paclitaxel|Taxane
219610760|NCT05117476|DRUG|Carboplatin AUC 6|Platinum compound
218894755|NCT02907151|OTHER|Survey|Complete a survey prior to the consultation and a questionnaire after
218894756|NCT01867762|DRUG|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
218894757|NCT01867762|DRUG|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
218894758|NCT01862536|DRUG|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
218894759|NCT01862536|DRUG|placebo|Daily use in double blind study.
218894760|NCT00503269|PROCEDURE|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
218894761|NCT00503269|PROCEDURE|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
218894762|NCT00921349|PROCEDURE|Ligation of varices|all varices are ligated until obliteration
218894763|NCT00921349|DRUG|Nadolol|Nadolol (beta-blocker)
218894764|NCT01156714|BEHAVIORAL|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
219515165|NCT05366959|OTHER|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
219515166|NCT00861809|DRUG|GSK962040 25 mg|25 mg
219610761|NCT05117476|DRUG|pemetrexed|antifolate
219610762|NCT05117476|DRUG|Datopotamab deruxtecan-dlnk (Dato-DXd)|TROP-2 antibody-drug conjugate (ADC)
219610763|NCT04838730|DEVICE|Surgical procedure|Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
218894765|NCT01156714|BEHAVIORAL|Memory training with computerized memory program|memory testing and training on computer program
218894766|NCT01156714|BEHAVIORAL|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
219515167|NCT00861809|DRUG|Placebo|placebo comparator
219515168|NCT00861809|DRUG|GSK962040 50 mg|50 mg
219515169|NCT00861809|DRUG|GSK962040 1250 mg|125 mg
219515170|NCT00583700|DRUG|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
219515171|NCT00583700|DRUG|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
219610764|NCT06437015|DIAGNOSTIC_TEST|Constraint-Induced Movement Therapy|patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.
219610765|NCT06437015|OTHER|Mirror Therapy|In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
219610766|NCT01159730|DRUG|VB-201 or Placebo|
219610767|NCT04430959|DRUG|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
219610768|NCT04430959|DRUG|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
219610769|NCT03847467|DRUG|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
219610770|NCT03847467|OTHER|Placebo|Dextrose
219610771|NCT06021405|PROCEDURE|Tape stripping|a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
219610772|NCT03122730|COMBINATION_PRODUCT|VentaProst|epoprostenol for inhalation via custom drug delivery system
219610773|NCT04135677|DRUG|Rivaroxaban|Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
219610774|NCT04135677|DRUG|DAPT|Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
218894767|NCT05932797|OTHER|Multimodal intervention in Long Covid19|The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
218894768|NCT02052752|DRUG|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
219515172|NCT03338361|BEHAVIORAL|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
219515173|NCT03338361|BEHAVIORAL|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
219515174|NCT03338361|BEHAVIORAL|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
219515175|NCT03338361|BEHAVIORAL|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
219515176|NCT00890877|DRUG|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
219515177|NCT03238677|BEHAVIORAL|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
219515178|NCT03238677|BEHAVIORAL|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
219515179|NCT03238677|BEHAVIORAL|Distributed Practice|2 sessions per week for 10 weeks
219515180|NCT03238677|BEHAVIORAL|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
219515181|NCT00011297|DRUG|gabapentin (Neurontin)|
219515182|NCT00011297|DRUG|lorazepam (Ativan)|
219515183|NCT03834805|OTHER|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
219515184|NCT04217720|DRUG|SNS-301|SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
219515185|NCT00724568|DRUG|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
219515186|NCT00724568|DRUG|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
219515187|NCT00724568|DRUG|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
219515188|NCT00724568|DRUG|Doxil|Patients will be treated with Doxil on day 4.
219515189|NCT00066131|PROCEDURE|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
219610775|NCT05798182|DIAGNOSTIC_TEST|Ultrasound measurement|Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
219610776|NCT01437436|PROCEDURE|ventilation tube|ventilation tube insertion
219515190|NCT00066131|PROCEDURE|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
219515191|NCT05700591|DRUG|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
219515192|NCT05700591|DRUG|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
219515193|NCT01242280|DEVICE|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
219515194|NCT01242280|DEVICE|Tamponade|Sengstaken-Blakemore tube
219515195|NCT00073294|BEHAVIORAL|diet|
219515196|NCT01456481|DRUG|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
219515197|NCT01456481|DRUG|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
219610777|NCT05642897|BEHAVIORAL|Mind|ACT, mindfulness, and compassion-based intervention
219610778|NCT05642897|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.
219610779|NCT06404398|OTHER|OMNICHROMA, Ceram. x spectra|Each patient had two types of veneers.
219610780|NCT01861223|DRUG|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
219610781|NCT01581437|PROCEDURE|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
219610782|NCT04203342|DRUG|Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
218894769|NCT02052752|DRUG|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
218894770|NCT02052752|DRUG|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
218894771|NCT03609996|DEVICE|Panretinal Photocoagulation|Laser treatment for PDR
218894772|NCT03609996|DRUG|Lucentis|Intraviteral injection
218894773|NCT02114229|DRUG|alisertib|Alisertib will be administered orally at 80 mg/m\^2 per day for enteric coated tablet formulation and 60 mg/m\^2 per day for oral solution formulation.
218894774|NCT02114229|DRUG|methotrexate|Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
218894775|NCT02114229|DRUG|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m\^2 IV infusion.
219203928|NCT06966362|BEHAVIORAL|Motivation-Phase Counseling|All participants receive motivation-phase counseling. Motivation-phase counseling involves 5, 10-15-minute counseling calls. The counselor will work with participants on smoking control skills selected by the participant, such as avoidance of smoking cues, reducing smoking heaviness/contexts, developing urge coping skills, or finding support from friends and family. Counseling will emphasize setting realistic and achievable smoking control goals. Counseling will also emphasize competence and self-efficacy, which will be linked to success in smoking control.
219203929|NCT06966362|BEHAVIORAL|Cessation-Phase Counseling|All participants who enter cessation treatment will be offered 4, 10-15-minute counseling calls. The first counseling session involves pre-quit preparation, and can occur any time before the target quit day. The other 3 counseling calls will be scheduled for 1 day, 1 week, and 4 weeks after the target quit date. Cessation counseling will be based on treatment guidelines and will review instructions for when to start cessation medication, the timing of the quit day (relative to medication start), and medication adherence. Counseling will involve problem solving and skill development.
218894776|NCT02114229|DRUG|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
218894777|NCT02114229|DRUG|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
218894778|NCT02114229|DRUG|etoposide|"Etoposide will be given 100 mg/m\^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
218894779|NCT02114229|DRUG|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL\*hr.
219203930|NCT06965179|OTHER|Jenga game|In the Jenga game group, participants will complete the Elderly Information Form and Mini-Mental State Examination (MMSE) before the intervention. As pre-tests, the Life Satisfaction Scale (LSS) and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) will also be administered. Participants will play Jenga in pairs for at least 30 minutes once a week over four weeks. Grouping will consider participant preferences and promote social interaction. After the intervention, the same scales (LSS and WEMWBS) will be re-administered as post-tests to evaluate changes in life satisfaction and mental well-being.
219610783|NCT04203342|DRUG|Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
219610784|NCT04203342|DRUG|Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)|Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
219610785|NCT03729596|BIOLOGICAL|vobramitamab duocarmazine|Anti-B7H3 antibody drug conjugate
219610786|NCT03713593|DRUG|lenvatinib|Administered orally once a day
218894780|NCT02114229|DRUG|vincristine|Vincristine will be given 1 mg/m\^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
218894781|NCT02114229|PROCEDURE|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
218894782|NCT02114229|RADIATION|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age \> 36 months.
218894783|NCT04854694|DEVICE|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
218894784|NCT04854694|DEVICE|conventional surgical N95 respirator|standard N95 respirator
218894785|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
218894786|NCT05199545|DIETARY_SUPPLEMENT|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
218894787|NCT05199545|OTHER|Placebo|Placebo of the dietary supplement
219610787|NCT03713593|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
219610788|NCT03713593|DRUG|saline placebo|Administered as an IV infusion on Day 1 Q3W
219515198|NCT03824626|DIAGNOSTIC_TEST|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
219610789|NCT04704453|DRUG|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
219610790|NCT04704453|DRUG|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
218894788|NCT06999330|DEVICE|Theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 90%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Session length: 10 min; Time between sessions: 50 minutes.
218894789|NCT06999330|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
218894790|NCT07009509|BEHAVIORAL|YES-CAN! program|Youth Engaged Strategies to Change Adolescent Norms
218894791|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
218894792|NCT04664634|DEVICE|Aria Sensor|The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.
218894793|NCT06726421|RADIATION|Stereotactic body radiotherapy (SBRT)|The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.
218894794|NCT06726421|DRUG|axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib|Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
218894795|NCT06477419|DRUG|Sacituzumab govitecan-hziy|After enrollment, participants will receive SG until disease progression or intolerable toxicity.
218894796|NCT00293618|DEVICE|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
218894797|NCT00293618|OTHER|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
218894798|NCT00293618|OTHER|Feedback|Feedback about the physician's personal performance on prevention of PONV
219515199|NCT05539820|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
219515200|NCT05153265|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
219515201|NCT05471674|DRUG|Nivolumab|3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
219515202|NCT05471674|PROCEDURE|Hepatectomy|Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
219515203|NCT02433665|DRUG|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
219610791|NCT04467840|DRUG|Opaganib|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
218894799|NCT00369577|DRUG|Inhaled Placebo|Inhaled Placebo, single dose
219610792|NCT04467840|DRUG|Placebo|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
219610793|NCT05749055|DRUG|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
219610794|NCT05749055|DRUG|Placebo|Placebo
219610795|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib: 150 mg orally once daily
219610796|NCT04961515|DRUG|Sintilimab|Sintilimab: 200 mg intravenously every 3 weeks
218894800|NCT00369577|DRUG|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
218894801|NCT00369577|DRUG|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
218894802|NCT03471780|DIAGNOSTIC_TEST|ultrasound|Transperineal us are made to pregnant ladies in labour
219610797|NCT04961515|DRUG|Temozolomide (TMZ)|Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
219610798|NCT06625177|DRUG|TEV-53408|TEV-53408 injection administered subcutaneously
219610799|NCT06556199|DRUG|Selinexor|Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
219610800|NCT06556199|DRUG|Temozolomide|Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
218894803|NCT02850380|OTHER|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
219515204|NCT02433665|DEVICE|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
218894804|NCT05761002|BIOLOGICAL|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
219515205|NCT05948748|PROCEDURE|foot surgery|minimally invasive osteoarticular foot surgery
219515206|NCT01868841|DRUG|AdreView|10 millicurie of AdreView (123I-mIBG)
219515207|NCT01868841|OTHER|Single Photon Emission Computed Tomography|
219515208|NCT03702621|DRUG|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
219515209|NCT03702621|DRUG|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
218894805|NCT00352430|DRUG|Nitric Oxide/INP Pulse Delivery|
219515210|NCT00527423|DRUG|VEGF Trap Eye|Intravitreal injection
219515211|NCT04322175|DRUG|Meloxicam|Meloxicam Eye Drops
219515212|NCT01079442|OTHER|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
219515213|NCT01079442|OTHER|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
219610801|NCT06556199|DRUG|Anti-PD-1 monoclonal antibody|The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
219610802|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
219515214|NCT04112485|PROCEDURE|Microdiscectomy|
219515215|NCT02192736|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
219515216|NCT04774432|OTHER|GM-CSF group|GM-CSF added to CAPA and maturation medium
219515217|NCT04774432|OTHER|Control group|GM-CSF will not be added to CAPA and maturation medium
219515218|NCT05707000|OTHER|group A concentric muscle training|"One set of each of the following exercises will completed during each session:~* leg press,~* knee flexion,~* knee extension,~* Quad drills For each set, 12 repetitions will be performed at a resistance load of 60% of the one-repetition maximum (1RM) for that exercise. The exercises will be performed 2 times a week for 6 weeks."
219515219|NCT05707000|OTHER|Group B fascilitatory kinesiotaping|Kinesiotaping is applied on the anterior thigh (quadriceps) region starting at 1/5 of the distance between anterosuperior iliac spine (ASIS) and tibia tuberosity. The tape is applied with 20% tension of the tape. The tape was tensioned from proximal region of mid quadriceps down to tibia tuberosity and, once it reached the knee, the tape was divided in the middle allowing it to circle the joint
219610803|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
219610804|NCT04025905|BEHAVIORAL|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
218894806|NCT00352430|DRUG|Nitric Oxide/INO Pulse Delivery|
218894807|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
218894808|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
219515220|NCT05592509|DIETARY_SUPPLEMENT|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
219515221|NCT00436007|BIOLOGICAL|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
219515222|NCT00436007|BIOLOGICAL|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
219515223|NCT00436007|BIOLOGICAL|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
219515224|NCT00436007|BIOLOGICAL|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
219515225|NCT00436007|BIOLOGICAL|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
219610805|NCT04025905|BEHAVIORAL|Informations|informations about work environment, social environment, stress management, sleep management, treatments
219610806|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|The first and final sessions will include clinical assessments and acquisition of MRI and EEG data. To minimize variability, each patient will undergo tDCS at a consistent time in the afternoon or evening and will remain lying in bed with eyes closed throughout stimulation. Stimulation will be delivered using the GTEN 200 system (Magstim EGI, Oregon, USA), which also enables simultaneous EEG recording. The stimulation current will be limited to 1.5 mA, with a maximum of 0.15 mA per electrode (up to 20 electrodes). Electrode placement and current intensity will be individualized to achieve the targeted electric field strength (0.1 or 0.2 V/m at SMHC;). Each session will include 5 min of resting-state EEG immediately before and after stimulation to assess tDCS-induced changes in brain dynamics. Current onset and offset will be gradual, with 2-s ramp-up and ramp-down periods.
219515226|NCT04927533|OTHER|Ronnie Gardiner Method|"The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants."
219610807|NCT04408183|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
219515227|NCT03104322|OTHER|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
219515228|NCT03104322|OTHER|usual care|usual care
219515229|NCT01957488|DEVICE|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
219515230|NCT01957488|DEVICE|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
219515231|NCT01957488|DEVICE|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
219515232|NCT03405207|DRUG|Vitamin D3 50000 UNT Oral Capsule|Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
219515233|NCT03405207|DRUG|Placebo oral capsule|identical as active drug providing by pharmaceutical company unless it is placebo
219610808|NCT04408183|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
219610809|NCT04987229|DRUG|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
218894809|NCT05551611|OTHER|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
219515234|NCT01439165|BIOLOGICAL|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
219515235|NCT01439165|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
218894810|NCT05551611|OTHER|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
218894811|NCT03192761|PROCEDURE|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
218894812|NCT03192761|PROCEDURE|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
219515236|NCT05233280|OTHER|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
219515237|NCT01223807|OTHER|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
219515238|NCT02101541|PROCEDURE|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
219515239|NCT00810368|DRUG|Carnosine|500mg Carnosine x2 daily
219610810|NCT06261970|BEHAVIORAL|Connect|Community level enhancements
219610811|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
219515240|NCT00810368|DRUG|Placebo|Microcrystalline cellulose placebo tablets x2 daily
219515241|NCT06291948|BIOLOGICAL|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose
219610812|NCT05419492|DRUG|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
219515242|NCT06291948|BIOLOGICAL|Adalimumab Richmond [Test Product]|A single subcutaneous dose
219515243|NCT02274298|BEHAVIORAL|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
218894813|NCT03192761|PROCEDURE|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
219515244|NCT04021069|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
219515245|NCT02468739|DRUG|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
219515246|NCT02468739|DRUG|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
219515247|NCT01138072|DRUG|GSK2248761|200mg once daily
219515248|NCT01138072|DRUG|Simvastatin|20 mg Simvastatin single dose
219515249|NCT01138072|DRUG|Atorvastatin|20 mg atorvastatin single dose
219515250|NCT01138072|DRUG|Rosuvastatin|10 mg rosuvastatin single dose
219515251|NCT01985802|OTHER|Pacing|
219515252|NCT02096419|DRUG|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
219515253|NCT03272139|DRUG|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
219515254|NCT03272139|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
219515255|NCT05423808|OTHER|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
219515256|NCT05423808|DEVICE|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
219515257|NCT03694990|OTHER|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
219515258|NCT05867355|PROCEDURE|surgical fixation|compare implant removal rates between surgical fixation techniques.
219515259|NCT01568164|DEVICE|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
219515260|NCT05936749|GENETIC|Pre-implantation genetic testing|
219610813|NCT05265273|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
219610814|NCT04765514|OTHER|Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)|Temozolomide or Radiotherapy
219610815|NCT04765514|COMBINATION_PRODUCT|Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.|Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
219610816|NCT05841862|DEVICE|2C-QD|Quantum Dot
219610817|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
219610818|NCT04436757|BEHAVIORAL|IPS program : Self-image and body representation|"The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network"
219610819|NCT04436757|BEHAVIORAL|TAU|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
218894814|NCT03250208|DIETARY_SUPPLEMENT|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
218894815|NCT03250208|OTHER|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
218894816|NCT04441255|DRUG|TAK-788|TAK-788 Capsule.
218894817|NCT01839812|DRUG|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
218894818|NCT02210260|PROCEDURE|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
218894819|NCT02210260|PROCEDURE|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
218894820|NCT02210260|DRUG|Bupivacaine|
219610820|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
219610821|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
218894821|NCT02210260|DRUG|Diamorphine|500mcg
219610822|NCT05513001|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
219610823|NCT05513001|DRUG|Placebo|Placebo
219610824|NCT05513001|DRUG|LOU064 (open label)|LOU064 (open-label) active treatment
218894822|NCT02210260|DEVICE|A Painbuster® catheter|
218894823|NCT02210260|DEVICE|25G Whitacre needle|
218894824|NCT00543777|DIAGNOSTIC_TEST|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
218894825|NCT00543777|DIAGNOSTIC_TEST|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
218894826|NCT04239651|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
218894827|NCT04239651|OTHER|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
219035220|NCT03266120|OTHER|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
218894828|NCT03388047|DEVICE|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
218894829|NCT00848783|DRUG|Irinotecan|
218894830|NCT00848783|DRUG|Cisplatin|
219610825|NCT05616793|BIOLOGICAL|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
219610826|NCT02555579|BEHAVIORAL|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
219610827|NCT04049591|DRUG|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
219610828|NCT04049591|DRUG|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
219610829|NCT06481033|BEHAVIORAL|Real Time fMRI Neurofeedback|The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
219610830|NCT04209218|DRUG|Dexamethasone|Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
219610831|NCT04209218|OTHER|Targeted blood pressure management|Blood pressure is maintained within ±10% from baseline.
218894831|NCT00848783|PROCEDURE|Surgery|
218894832|NCT00848783|DRUG|Floxuridine|
218894833|NCT00848783|DRUG|Capecitabine|
218894834|NCT01205971|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
218894835|NCT01205971|BEHAVIORAL|Dental Preventive Services|Written oral health educational materials
218894836|NCT04239690|OTHER|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
218894837|NCT04840212|OTHER|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
218894838|NCT02937558|DRUG|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
218894839|NCT02937558|OTHER|Placebo|Isotonic saline
218894840|NCT00745043|DRUG|bronchodilator response|
218894841|NCT04160663|DIAGNOSTIC_TEST|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
218894842|NCT01668225|PROCEDURE|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
219610832|NCT04209218|DRUG|Placebo|Placebo (2 ml normal saline) is administered before anesthesia induction.
219610833|NCT04209218|OTHER|Routine blood presure management|Blood pressure is maintained according to routine practice.
219610834|NCT06034405|DIAGNOSTIC_TEST|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
219610835|NCT05781399|DRUG|JNT-517 Suspension|JNT-517 in on-site compounded suspension
219610836|NCT05781399|DRUG|Placebo Suspension|On-site compounded placebo suspension
219610837|NCT05781399|DRUG|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
219610838|NCT05781399|DRUG|Placebo Tablet|Matching film-coated placebo tablet
218894843|NCT06444815|DRUG|VET3-TGI|Oncolytic vaccinia virus engineered with immunomodulatory transgenes
218894844|NCT06444815|DRUG|Pembrolizumab|anti-pd1 antibody
219515261|NCT03955536|OTHER|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
219515262|NCT03955536|OTHER|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
219515263|NCT03955536|OTHER|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~\- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
219515264|NCT05201690|DRUG|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
219515265|NCT05201690|DRUG|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
219515266|NCT05201690|DRUG|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
219515267|NCT00008736|DRUG|metoclopramide|
219515268|NCT01449266|DRUG|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
219515269|NCT00732290|DRUG|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
219515270|NCT00732290|DRUG|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
219515271|NCT00776503|DRUG|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
219515272|NCT03273244|DEVICE|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
219515273|NCT04690270|DRUG|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
219515274|NCT01375881|DRUG|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
219515275|NCT00343759|DRUG|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
219515276|NCT03165552|OTHER|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
219610839|NCT06384885|DIAGNOSTIC_TEST|Ultrasound|Lung ultrasound
218894845|NCT04280731|DIETARY_SUPPLEMENT|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
218894846|NCT02755220|DEVICE|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
218894847|NCT01429181|DRUG|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
219515277|NCT04277533|DIAGNOSTIC_TEST|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
218894848|NCT02769221|DEVICE|Rigid video stylet|
218894849|NCT02769221|DEVICE|Video laryngoscope|
219610840|NCT05126693|OTHER|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
219610841|NCT04483583|DRUG|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
218894850|NCT05846373|DRUG|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
218894851|NCT05846373|DRUG|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
218894852|NCT05846373|OTHER|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
218894853|NCT00516256|BEHAVIORAL|CHESS System|Internet-based computer program for 6 months.
218894854|NCT00516256|BEHAVIORAL|Cancer Information Mentor|Phone calls to the patient for 6 months.
218894855|NCT01188304|DRUG|aleglitazar|repeated daily doses
218894856|NCT01188304|DRUG|aspirin|repeated daily doses
218894857|NCT01188304|DRUG|placebo|repeated daily doses
218894858|NCT04527367|PROCEDURE|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
218894859|NCT03316703|PROCEDURE|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
218894860|NCT03316703|PROCEDURE|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
218894861|NCT05019534|DRUG|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
218894862|NCT05019534|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
218894863|NCT05019534|DRUG|Camrelizumab|Camrelizumab 200mg Q2W
218894864|NCT03539575|OTHER|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
218894865|NCT01059318|DRUG|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
218894866|NCT02700828|DRUG|Hydrocortisone|4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
218894867|NCT02700828|DRUG|Placebo|4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
218894868|NCT01557907|DEVICE|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
219035221|NCT03266120|OTHER|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
219035222|NCT01004588|DIETARY_SUPPLEMENT|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
219035223|NCT01004588|DIETARY_SUPPLEMENT|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
219035224|NCT06404151|DEVICE|monitoring|rc02, ORI , spO2
219035225|NCT03602469|DRUG|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
218894869|NCT01557907|DEVICE|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
218894870|NCT03419988|BEHAVIORAL|Exercise Intervention|24 sessions of aerobic exercise
218894871|NCT04352023|PROCEDURE|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
218894872|NCT04880369|DIETARY_SUPPLEMENT|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
218894873|NCT04880369|DIETARY_SUPPLEMENT|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
218894874|NCT04880369|DIETARY_SUPPLEMENT|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
219035226|NCT03602469|DRUG|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
219035227|NCT03602469|DRUG|Propofol|Using propofol 1.5-2.5 mg/kg
219035228|NCT03602469|DEVICE|Ultrasound|Ultrasound-guided suprascapular nerve block
219035229|NCT03602469|DRUG|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
219035230|NCT03602469|DRUG|Rocuronium|Rocuronium 0.6 mg/kg
219035231|NCT06256042|PROCEDURE|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
219035232|NCT06256042|PROCEDURE|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
219035233|NCT06202742|BEHAVIORAL|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
218894875|NCT04131075|PROCEDURE|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
218894876|NCT05254483|BEHAVIORAL|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
218894877|NCT05254483|BEHAVIORAL|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
218894878|NCT05254483|DEVICE|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
218894879|NCT02989883|OTHER|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
218894880|NCT05994027|BEHAVIORAL|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
218894881|NCT01149915|DRUG|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
218894882|NCT06029569|PROCEDURE|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
218894883|NCT06029569|PROCEDURE|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
218894884|NCT00474214|BEHAVIORAL|Early hospital discharge facilitated by close nurse practitioner follow-up|
218894885|NCT00970229|DRUG|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
218894886|NCT04705506|DRUG|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
218894887|NCT03024125|OTHER|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
218894888|NCT03024125|OTHER|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
218894889|NCT03024125|OTHER|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
218894890|NCT03141632|DRUG|Dulaglutide|Evaluation visit with assessment of fluid intake
219515278|NCT02047266|PROCEDURE|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
219610842|NCT04483583|DRUG|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
218894891|NCT03141632|OTHER|Placebo|Evaluation visit with assessment of fluid intake
219610843|NCT04011722|DEVICE|Portico™ NG (Navitor) Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
219610844|NCT04011722|DEVICE|Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
219610845|NCT06030804|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
218894892|NCT02800525|DEVICE|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
218894893|NCT02800525|DEVICE|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
218894894|NCT00761826|DEVICE|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
219515279|NCT02047266|PROCEDURE|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time\>250seconds).
219515280|NCT02047266|PROCEDURE|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time\>450seconds).
219515281|NCT02047266|DEVICE|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
219610846|NCT06030804|DRUG|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
219610847|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
219610848|NCT05478720|DRUG|Placebo|Single intravenous dose of saline
219610849|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
219610850|NCT05844449|DRUG|VNZ/TEZ/D-IVA|Fixed-dose combination tablets or granules for oral administration.
219610851|NCT06082843|DRUG|Placebo|Placebo-matching Avenciguat
219610852|NCT06082843|DRUG|Avenciguat|1 millligram (mg), 2 mg, or 3 mg film-coated tablet
219610853|NCT06220513|PROCEDURE|erector spinae plane block (ESP)|patients will receive Ultrasound-guided erector spinae plane block (ESP) block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
219610854|NCT06220513|PROCEDURE|transversus abdominis plane block(TAP)|patients will receive Ultrasound-guided transversus abdominis plane block(TAP) Block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
219610855|NCT03326791|DRUG|Acetylsalicylic acid|Trombyl 160 mg once daily
219610856|NCT03326791|DRUG|Placebo Oral Tablet|Placebo one tablet daily
219610857|NCT00765687|DRUG|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
218894895|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
218894896|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
218894897|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
218894898|NCT01270815|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
218894899|NCT03858374|DEVICE|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
218894900|NCT03858374|DEVICE|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
218894901|NCT03858374|DEVICE|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
218894902|NCT00176462|DRUG|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
218894903|NCT00176462|DRUG|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
219035234|NCT06202742|BEHAVIORAL|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
219610858|NCT05473182|OTHER|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
219610859|NCT06577935|DRUG|AGA2118|Subcutaneous injection
218894904|NCT00176462|DRUG|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
218894905|NCT00176462|DRUG|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
218894906|NCT00176462|DRUG|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
219203931|NCT06965179|OTHER|Bocce game|In the Bocce game group, participants will first complete the Elderly Information Form and Mini-Mental State Examination (MMSE), followed by pre-tests including the SF-36, Life Satisfaction Scale (LSS), and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). Bocce sessions will take place once a week for four weeks, with each session lasting at least 30 minutes. Games will be played in pairs to enhance social interaction and psychomotor skills. Participants will be randomly assigned to six groups of two, considering individual preferences. Pairings will rotate weekly based on game outcomes to encourage diverse interaction. After the final week, the LSS and WEMWBS will be re-administered as post-tests by the researcher.
219515282|NCT02047266|DEVICE|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
219515283|NCT03951337|DRUG|64Cu-ATSM|64 Cu-ATSM PET/CT scan
219515284|NCT05435001|DEVICE|Holter ECG Monitoring|Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
219515285|NCT02433678|DRUG|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
219515286|NCT02433678|DRUG|Placebo|
219515287|NCT02152878|DEVICE|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
219610860|NCT06577935|OTHER|Placebo|Subcutaneous injection
219610861|NCT06437054|DRUG|Dexamethasone|Dexamethasone 5mg/ml
219610862|NCT06437054|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
219610863|NCT06437054|OTHER|Indocyanine green(ICG)|ICG 25mg
219610864|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
219610865|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
218894907|NCT00176462|DRUG|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
218894908|NCT00176462|DRUG|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
218894909|NCT00176462|DRUG|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
219515288|NCT02152878|DEVICE|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
218894910|NCT00176462|DRUG|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
219610866|NCT06078137|OTHER|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
219610867|NCT06377241|DEVICE|ScentAware|ScentAware is a smell test
219610868|NCT06377241|DEVICE|UPSIT|UPSIT is a smell test
219610869|NCT05327530|DRUG|Avelumab|Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
218894911|NCT00176462|DRUG|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
219515289|NCT00631033|DRUG|Placebo|
219515290|NCT00631033|DRUG|Diazoxide|
219515291|NCT00631033|DRUG|Metformin + Diazoxide|
219515292|NCT00277745|DEVICE|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
219515293|NCT06189378|OTHER|Inclusion of patient-provided pictures into blood pressure diaries|Patient-provided pictures with positive meaning were included into blood pressure diaries
219515294|NCT06189378|OTHER|Conventional blood pressure diary|Conventional blood pressure diary
219515295|NCT04076501|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
219515296|NCT04076501|PROCEDURE|Sham room air|Room air applied via mask
219515297|NCT04103177|OTHER|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
219515298|NCT05108038|DRUG|CKD-382, D860, D027|QD, PO for 7days
219515299|NCT03209882|DEVICE|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
219515300|NCT03209882|DEVICE|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
219515301|NCT05252130|DEVICE|NoaScope|Smart digital stethoscope
219515302|NCT04855981|OTHER|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
219515303|NCT04855981|OTHER|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
219515304|NCT04855981|OTHER|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
219515305|NCT03393650|OTHER|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
219515306|NCT03393650|OTHER|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
219515307|NCT03970564|DIAGNOSTIC_TEST|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
219515308|NCT03365375|BEHAVIORAL|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
219515309|NCT03365375|OTHER|Usual Care Referral|Referral to PCP or Psychiatry
219515310|NCT03683407|OTHER|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
219515311|NCT05532085|OTHER|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
219515312|NCT05532085|OTHER|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
219515313|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
218894912|NCT00176462|DRUG|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
218894913|NCT00176462|DRUG|Leucovorin|
218894914|NCT01600079|BIOLOGICAL|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
218894915|NCT06064383|DEVICE|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
218894916|NCT04486872|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
218894917|NCT05168228|PROCEDURE|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
218894918|NCT01797913|DRUG|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
218894919|NCT00002913|DRUG|paclitaxel|Given IV
218894920|NCT00002913|DRUG|cisplatin|Given IV
218894921|NCT00002913|DRUG|topotecan hydrochloride|Given IV
218894922|NCT00002913|BIOLOGICAL|filgrastim|Given SC
218894923|NCT01725594|DRUG|CAT 2003|
218894924|NCT01725594|DRUG|Placebo|
218894925|NCT04010591|DEVICE|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
218894926|NCT01640444|DRUG|FOLFIRI + bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
219035235|NCT01449526|DEVICE|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
219610870|NCT05327530|DRUG|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
219610871|NCT05327530|DRUG|M6223|Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
218894927|NCT01640444|DRUG|FOLFIRI + cetuximab|"* Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
218894928|NCT05581069|BEHAVIORAL|STEPS|STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
218894929|NCT00003917|DRUG|topotecan hydrochloride|
218894930|NCT05745519|OTHER|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
218894931|NCT05745519|DEVICE|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
219035236|NCT01449526|DEVICE|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
218894932|NCT04284475|DIAGNOSTIC_TEST|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
218894933|NCT04284475|DIAGNOSTIC_TEST|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
218894934|NCT04284475|DIAGNOSTIC_TEST|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
218894935|NCT03452709|BEHAVIORAL|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
218894936|NCT03452709|DEVICE|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
218894937|NCT00185575|DRUG|duloxetine|
219035237|NCT04350151|BEHAVIORAL|no intervention|no intervention
219035238|NCT03005821|OTHER|Chinese pediatric massage therapy + usual care|
219035239|NCT03005821|OTHER|Sham massage therapy + usual care|
219035240|NCT06284785|PROCEDURE|Bariatric surgery|Patients included in our obese patient group are all scheduled to undergo bariatric surgery
219035241|NCT00363454|DRUG|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
219035242|NCT00199290|DRUG|Trafermin (genetical recombination)|
218894938|NCT05465291|PROCEDURE|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
218894939|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation group|"* Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
219515314|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
219515315|NCT05896956|OTHER|no interventions|no interventions
219515316|NCT02317237|PROCEDURE|Local anesthesia|Conscious sedation
219515317|NCT05332015|OTHER|Hypotonic (distilled) water|orally given daily two liters of distilled water
219515318|NCT05332015|OTHER|Normal water|orally given daily two liters of normal water
219515319|NCT06301698|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
219515320|NCT06301698|PROCEDURE|Injection|the patients in the observation group were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219610872|NCT05327530|DRUG|NKTR-255|Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
219610873|NCT05859490|BIOLOGICAL|17D|Vaccine administration in subjects previously vaccinated with 17D.
219610874|NCT02732730|DRUG|Truvada|400 women who accept to initiate PrEP
218894940|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
219035243|NCT05471050|DRUG|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
219035244|NCT05471050|DRUG|Danazol|Danazol is given at 200mg bid for 12 weeks.
219610875|NCT02732730|BEHAVIORAL|Drug level counseling at Weeks 8 and 13|Women who are randomized to enhanced counselling will have adherence monitoring based on plasma TFV levels obtained 4 and 8 weeks after PrEP acceptance
219610876|NCT02769520|DRUG|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
219610877|NCT06430086|OTHER|Walnut consumption|Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
219610878|NCT06430086|OTHER|HCHS consumption|"Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality."
219610879|NCT05699200|OTHER|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
219035245|NCT02190799|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
219610880|NCT05699200|DIAGNOSTIC_TEST|Echocardiogram|We will collect limited ultrasound images of the heart.
219610881|NCT05699200|DIAGNOSTIC_TEST|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
219610882|NCT05699200|DIAGNOSTIC_TEST|Elastography|We will measure the elastic properties of the arteries using elastography.
219610883|NCT05699200|OTHER|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
219610884|NCT05699200|OTHER|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
219515321|NCT06301698|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219610885|NCT05342675|PROCEDURE|Rapid Rollover|Repositioning of the participant post biopsy
219610886|NCT03407820|PROCEDURE|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
219610887|NCT03407820|PROCEDURE|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
219610888|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
219610889|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
219610890|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
219610891|NCT03441074|BEHAVIORAL|Odor Enrichment|Patients in intervention group will get odor enrichment during perioperative period (3 days before the surgery and 7 days after the surgery). Odor-enriched participants were exposed daily for 24 hours to different aromatic fragrances (phenyl ethyl alcohol - rose; eucalyptol - eucalyptus; citronellal - lemon; eugenol - cloves) referred to previous studies. Odors were changed for each subject after 24 hours. According to previous studies, 10 drops of the 100% essential oil (0.5 ml) were dropped on a fabric which was placed in tea bags hanging at the hospital bedside.
219610892|NCT03176134|DRUG|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
219610893|NCT03176134|DRUG|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
219610894|NCT02498912|PROCEDURE|Production of Genetically-modified T cells|
219610895|NCT02498912|DRUG|Cyclophosphamide|
219610896|NCT02498912|DEVICE|IP Catheter Insertion|
218894941|NCT03840954|OTHER|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
218894942|NCT03108417|DEVICE|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
219610897|NCT02498912|GENETIC|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
219610898|NCT02498912|DRUG|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
218894943|NCT01250041|PROCEDURE|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
218894944|NCT01250041|PROCEDURE|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
218894945|NCT03360799|OTHER|Questionnaire Administration|Complete questionnaires
219610899|NCT00293787|DRUG|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219610900|NCT00293787|OTHER|Timolol Vehicle|Placebo
219610901|NCT00293787|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
219610902|NCT00293787|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
219610903|NCT01368497|DRUG|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
219610904|NCT02729298|DRUG|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
219610905|NCT00218933|BEHAVIORAL|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
219610906|NCT00218933|BEHAVIORAL|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
219610907|NCT00459563|DRUG|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
219610908|NCT00459563|DRUG|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
218894946|NCT05268172|DRUG|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
218894947|NCT01408459|DIETARY_SUPPLEMENT|Tomato Product|Motivational Telephone Counseling weekly
218894948|NCT01408459|DIETARY_SUPPLEMENT|Control|No Motivational telephone Counseling
218894949|NCT00915707|OTHER|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
218894950|NCT00915707|OTHER|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
218894951|NCT00915707|OTHER|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
218894952|NCT03801226|DRUG|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
218894953|NCT03801226|DRUG|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
218894954|NCT00289926|DRUG|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
218894955|NCT00289926|DRUG|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
218894956|NCT02696759|OTHER|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
218894957|NCT02632357|OTHER|Spinal Manipulation|
218894958|NCT01994044|PROCEDURE|Cervical fusion|
218894959|NCT00930878|DEVICE|Cardiac Stenting|Drug Eluting stent
218894960|NCT03064971|BEHAVIORAL|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
219515322|NCT02747745|BEHAVIORAL|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
219515323|NCT06440564|PROCEDURE|Er:YAG Laser irradiation|The presented DALIR procedure differs in so far from a standard treatment that after exposure all accessible metal implant surfaces and the adjacent soft tissue is irradiated manually with the Er:YAG laser all over line-by-line with an intended overlap of approximately 10% at constant spot diameter.
219515324|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
218894961|NCT03064971|BEHAVIORAL|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
218894962|NCT03064971|BEHAVIORAL|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
218894963|NCT04166097|OTHER|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
218894964|NCT04842383|DRUG|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
219515325|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
219515326|NCT05786573|OTHER|Placebo|Placebo
218894965|NCT02499705|DIETARY_SUPPLEMENT|Sucralose|2 packets
218894966|NCT02499705|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
218894967|NCT02499705|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
218894968|NCT03658447|DRUG|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
218894969|NCT03658447|DRUG|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
218894970|NCT01939184|DRUG|WC3055|12.5, 25, 50 or 75 mg dose
218894971|NCT01939184|OTHER|Placebo|Placebo
218894972|NCT02870608|OTHER|lung and liver elastography measurement of fetus|
219035246|NCT01132495|OTHER|Stenting plus OMT|FFR guided PCI, plus OMT
219035247|NCT01132495|OTHER|OMT|OMT alone
219035248|NCT01132495|OTHER|Standard of care|FFR \> 0.80; treatment according to local practice
219515327|NCT05060627|DRUG|Belantamab mafodotin|"In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
219515328|NCT05060627|DRUG|Carfilzomib|"In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
219515329|NCT05060627|DRUG|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
219515330|NCT06229925|DEVICE|Experimental Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.
219515331|NCT06229925|DEVICE|Sham Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
219515332|NCT03879239|DEVICE|Vibrating capsule|Vibrating Capsule administered 5 times per week
219515333|NCT04342923|OTHER|No intervention|Blood analysis
219515334|NCT01875575|DIETARY_SUPPLEMENT|Placebo|
219515335|NCT01875575|DIETARY_SUPPLEMENT|Glucose 25g|
219515336|NCT01875575|DIETARY_SUPPLEMENT|Glucose 10g|
219515337|NCT00404274|DRUG|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
219515338|NCT00404274|DRUG|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
219515339|NCT02586831|DRUG|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
219515340|NCT02586831|DRUG|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
219515341|NCT02586831|DRUG|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
219515342|NCT02586831|DRUG|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
219515343|NCT02586831|OTHER|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
219515344|NCT02586831|OTHER|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
219515345|NCT02586831|OTHER|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
219515346|NCT02586831|OTHER|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
219515347|NCT03707873|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
219515348|NCT02617108|DEVICE|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
219515349|NCT00266409|DRUG|Niravam|
219515350|NCT00266409|DRUG|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
219515351|NCT01933295|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
219515352|NCT01933295|BEHAVIORAL|Sleep Education|
219515353|NCT01933295|BEHAVIORAL|Sleep Restriction Therapy|
219610909|NCT00459563|DRUG|Placebo|Placebo once a week for 3 weeks
219610910|NCT05335824|OTHER|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
219610911|NCT05335824|OTHER|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
219610912|NCT05335824|DEVICE|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019\*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
219610913|NCT01383720|DEVICE|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
219610914|NCT03397030|OTHER|Home-Based Exercise Program|The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
219610915|NCT00270946|DEVICE|Bilayered Cellular Matrix (OrCel)|
219610916|NCT04378972|OTHER|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
219610917|NCT04378972|OTHER|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
219610918|NCT01435850|PROCEDURE|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
219203932|NCT02760537|BEHAVIORAL|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
219203933|NCT02760537|BEHAVIORAL|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
219203934|NCT05772533|PROCEDURE|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
219203935|NCT05772533|PROCEDURE|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
219203936|NCT06973460|DEVICE|Hunova Robotic-Assisted System|Hunova Movendo Robotic System
219203937|NCT06973460|OTHER|Balance and Mobility Exercise|Balance and Mobility Exercise derived from the Otago Exercise Programme
219203938|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
219203939|NCT03549442|COMBINATION_PRODUCT|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
219203940|NCT03549442|COMBINATION_PRODUCT|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
219515354|NCT04041765|DRUG|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
219515355|NCT02044783|BEHAVIORAL|Behavioral Counseling|
219515356|NCT01876862|OTHER|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
219515357|NCT04842110|DEVICE|Experimental: eonTM FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
219515358|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
219515359|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
219515360|NCT01801670|PROCEDURE|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
219515361|NCT01801670|PROCEDURE|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
219515362|NCT05412498|BEHAVIORAL|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
219515363|NCT05412498|BEHAVIORAL|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
219515364|NCT00331890|DRUG|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
218894973|NCT04119232|BEHAVIORAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
218894974|NCT00839644|DEVICE|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
219515365|NCT00331890|DRUG|Placebo|As active drug
219515366|NCT04491409|OTHER|Best Practice|Undergo standard of care
219515367|NCT04491409|OTHER|Medical Chart Review|Medical charts reviewed
218894975|NCT00839644|DEVICE|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
218894976|NCT00839644|OTHER|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
218894977|NCT01657292|DRUG|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
219515368|NCT05704556|DRUG|VX-548|Tablets for oral administration.
219515369|NCT00783666|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
219515370|NCT02327000|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
219515371|NCT02327000|DRUG|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
219515372|NCT00635154|BIOLOGICAL|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
219515373|NCT00635154|DRUG|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
218894978|NCT01657292|DEVICE|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
218894979|NCT02519205|OTHER|Survey|
218894980|NCT05658705|PROCEDURE|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
219515374|NCT04159909|DEVICE|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
219515375|NCT04159909|DEVICE|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
219610919|NCT04335890|BIOLOGICAL|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
219610920|NCT03523741|DRUG|Clozapine|Clozapine is administered orally according to individual prescribed dosing regimens.
219610921|NCT04937413|DRUG|Evolocumab|Evolocumab subcutaneous injection
219610922|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention was administered intramuscularly to HSVTI\_F1 Group.
219610923|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention was administered intramuscularly to HSVTI\_F2 Group.
218894981|NCT05658705|PROCEDURE|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
219515376|NCT02563756|PROCEDURE|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
219515377|NCT02563756|PROCEDURE|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
219515378|NCT04390828|BEHAVIORAL|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
219515379|NCT06403865|DRUG|Cabotegravir, Rilpivirine Drug Combination|Treatment switch to CAB+RPV LA
219515380|NCT04122430|OTHER|Review of Health Information|
219610924|NCT05989672|BIOLOGICAL|Placebo|This intervention was administered intramuscularly to Placebo group.
219610925|NCT00254787|DRUG|IR (Immediate-Release) quetiapine fumarate (drug)|
219610926|NCT00443729|DRUG|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
219610927|NCT00443729|DRUG|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
219610928|NCT00443729|DRUG|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
219610929|NCT00443729|DRUG|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
219610930|NCT04182178|OTHER|10 years follow up|Questionnaires
219610931|NCT03526328|OTHER|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
219610932|NCT06353464|OTHER|Ensure and Water|Ensure, a liquid meal with 9 grams of protein in 8 ounces consumed 20 minutes before eating pizza; and water, 8 ounces consumed 20 minutes before eating pizza
218894982|NCT00931775|DRUG|Pindolol|Pill orally administered. 15 mg/day t.i.d.
218894983|NCT01996280|BEHAVIORAL|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
218894984|NCT01996280|BEHAVIORAL|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
219610933|NCT01582490|DRUG|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
219515381|NCT04908826|PROCEDURE|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
219515382|NCT01399736|PROCEDURE|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
219515383|NCT01399736|PROCEDURE|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
219515384|NCT05399264|BEHAVIORAL|Auditory-working memory training program|"The AT-WMT program is comprised of 1,200 daily used sentences either created or selected from newspapers, books, TV programs and magazines by the research assistants. The sentences are political-, cultural-, and religious-neutral sentences. Each of them contains 10 words. Noise was recorded from the upper and lower decks of a bus, in a café, a Chinese restaurant, an MTR (the Mass Transit Railway) carriage, and from a street.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
219515385|NCT05399264|BEHAVIORAL|Auditory training program|During the training, an adaptive speech-in-noise perception task will be administered. Specifically, the sentences in a sentence set will be presented binaurally using a headphone at a level the listeners felt is comfortable. The trainees are expected to immediately repeat each noise-masked sentence after hearing it. If they cannot repeat the sentence, then the sound intensity of the noise will be automatically decreased (step size = 2 dB) until the sentence can be correctly repeated. If the sentence can be repeated at the first attempt, then the intensity of the noise will be automatically increased by 2 dB in the next sentence. To provide feedback, the targeted sentence will be replaced by an asterisk and only shown after clicking the sentence.
219515386|NCT05399264|BEHAVIORAL|Mindfulness training program|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training.
219515387|NCT05701202|DIETARY_SUPPLEMENT|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
219515388|NCT05701202|DIETARY_SUPPLEMENT|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
219515389|NCT03500484|DRUG|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
219515390|NCT04509479|PROCEDURE|Valve replacement|Description of valve replacements
219515391|NCT01046123|RADIATION|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
219515392|NCT04750187|OTHER|Hypo-pressive abdominal exercise intervention|An 8-week hypo-pressive abdominal exercise program
219515393|NCT05449977|DIAGNOSTIC_TEST|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
219515394|NCT02502253|DRUG|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
219610934|NCT01582490|DRUG|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
219610935|NCT04311372|BEHAVIORAL|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
219515395|NCT04888910|OTHER|observational|observation of biomarkers in different asthma groups
219515396|NCT03729310|DEVICE|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
219515397|NCT03729310|DRUG|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
219515398|NCT03729310|DEVICE|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
219515399|NCT00620009|BEHAVIORAL|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
219515400|NCT00046267|DRUG|Niacin|
219610936|NCT04311372|BEHAVIORAL|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
219610937|NCT02673736|DRUG|PLX73086|
219610938|NCT04485442|OTHER|data collection by questionnaires|psychological well-being in patients evaluated by Patient Reported Outcomes (PRO)
219610939|NCT04485442|OTHER|data collection (photos of the patients' tumors)|photos of the patients' tumors will be taken at baseline and at follow-up after the surgery
219610940|NCT03244761|PROCEDURE|The modified HFT|The HFT was modified by increasing the expiratory resistance.
219610941|NCT02708628|DRUG|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
219610942|NCT02708628|PROCEDURE|Scar excision|Scar excision in second c-section
219610943|NCT02332629|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
219610944|NCT02332629|DRUG|Isotonic Sodium Chloride|Placebo
219610945|NCT04146792|BEHAVIORAL|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
219610946|NCT04146792|BEHAVIORAL|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
218894985|NCT01559051|PROCEDURE|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
219515401|NCT01048320|DRUG|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
219515402|NCT01048320|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
219515403|NCT01048320|DRUG|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
219515404|NCT04570904|BIOLOGICAL|Influenza vaccination at different time points|All HCWs will receive the seasonal influenza vaccine but at two different time points.
219515405|NCT04887142|OTHER|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
219515406|NCT03265080|BIOLOGICAL|ADXS-NEO|Intravenous infusion
219515407|NCT03265080|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219515408|NCT01762085|PROCEDURE|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
219515409|NCT04265365|DEVICE|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219610947|NCT02363218|RADIATION|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
219610948|NCT03718832|OTHER|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
219610949|NCT03190525|OTHER|Quality of life questionnaires|QLQ-C30
219610950|NCT04140305|DRUG|RPC-1063|Oral capsule
219610951|NCT05492643|BIOLOGICAL|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
218894986|NCT01696890|DEVICE|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
218894987|NCT01696890|DEVICE|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
218894988|NCT04269876|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
219610952|NCT05492643|OTHER|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
219610953|NCT05492643|OTHER|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
219610954|NCT05492643|OTHER|Safety|all the 500 participants enrolled will undergo safety observation
219610955|NCT04126538|DRUG|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
218894989|NCT04269876|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
218894990|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
218894991|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
218894992|NCT00650845|DRUG|Dotarem®-enhanced MRI|Single IV administration before MRI exam
219610956|NCT04126538|DRUG|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
219610957|NCT03503669|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
218894993|NCT00650845|OTHER|non-enhanced MRI|non injected MRI
218894994|NCT05112003|DEVICE|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
218894995|NCT04371601|DRUG|Oseltamivir|Oseltamivir capsules
218894996|NCT04371601|DRUG|hormones|a moderate amount of hormone
219515410|NCT04265365|DEVICE|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219515411|NCT04265365|DEVICE|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219515412|NCT04265365|DEVICE|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219515413|NCT04265365|DEVICE|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219515414|NCT04265365|DEVICE|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
219515415|NCT04265365|DEVICE|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219515416|NCT04265365|DEVICE|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
219515417|NCT01709760|DRUG|Methotrexate|Methotrexate 15-25 mg/week
219515418|NCT01709760|DRUG|ENIA11|ENIA11 25 mg, sc twice weekly
219515419|NCT01709760|DRUG|Placebo|Placebo, sc twice weekly
219515420|NCT00481780|DEVICE|plain balloon angioplasty|
219515421|NCT00481780|DEVICE|cutting balloon angioplasty|
219515422|NCT05540509|BEHAVIORAL|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
219515423|NCT05540509|BEHAVIORAL|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
219515424|NCT04012697|BEHAVIORAL|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
219515425|NCT00536575|DRUG|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
219515426|NCT00536575|DRUG|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
219515427|NCT00261196|DRUG|Collagenase|Anterior shoulder capsule injection
219515428|NCT02193438|OTHER|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
219515429|NCT02193438|OTHER|Placebo|Tomato juice intake
218894997|NCT04371601|DEVICE|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
218894998|NCT04371601|PROCEDURE|mesenchymal stem cells|mesenchymal stem cells
218894999|NCT01003652|PROCEDURE|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
218895000|NCT00917839|DRUG|lamotrigine|100 mg, once daily, 12 months
218895001|NCT06130592|DIAGNOSTIC_TEST|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
218895002|NCT01698723|DRUG|Ribavirin|
218895003|NCT01698723|DRUG|Placebo|
218895004|NCT05482841|DIAGNOSTIC_TEST|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
218895005|NCT01301833|DRUG|teneligliptin|
218895006|NCT01301833|DRUG|glinide|
218895007|NCT01301833|DRUG|biguanide|
219515430|NCT02844153|OTHER|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
219515431|NCT02026453|OTHER|Pharmacist obtains admission medication history|
219515432|NCT02026453|OTHER|Pharmacy technician obtains admission medication history|
219515433|NCT00554151|DEVICE|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
219515434|NCT04971551|DRUG|Jaktinib Hydrochloride Tablets|Oral on an empty stomach
219515435|NCT05276284|COMBINATION_PRODUCT|Atezolizumab, 6-mercaptopurine, 6-thioguanine|Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
219515436|NCT03784261|DRUG|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
219515437|NCT03784261|DRUG|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
219515438|NCT03784261|DRUG|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
219515439|NCT02334059|DRUG|Ketamine|Ketamine infusion plus placebo infusion of normal saline
219515440|NCT02334059|DRUG|Ketamine plus magnesium|Ketamine plus magnesium infusion
219515441|NCT02334059|OTHER|Placebo|2 placebo infusions
219515442|NCT01520948|BEHAVIORAL|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
219515443|NCT01520948|BEHAVIORAL|Behavioral control|Mirrored star drawing
219515444|NCT06321081|DRUG|irinotecan, cetuximab, envafolimab|rechallenge treatment
219515445|NCT00546390|DEVICE|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
219515446|NCT04287881|GENETIC|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
219610958|NCT03503669|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
219610959|NCT04793711|DEVICE|EpiCeram|protective emollient
219610960|NCT04837040|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
219610961|NCT04837040|DRUG|Placebo|Placebo, tablets, once daily by mouth
219610962|NCT04038463|BEHAVIORAL|EFP|This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
219610963|NCT04038463|BEHAVIORAL|LFP|The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
218895008|NCT01301833|DRUG|alpha-glucosidase inhibitor|
218895009|NCT01813448|DRUG|Fidaxomicin|oral
218895010|NCT01813448|DRUG|Placebo|oral
218895011|NCT03922620|DRUG|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
218895012|NCT03922620|DRUG|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
218895013|NCT04797351|BEHAVIORAL|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
218895014|NCT00983385|DRUG|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
219515447|NCT03648944|OTHER|Accelerated Rehabillitation|
219515448|NCT03648944|OTHER|Non-Accelerated Rehabillitation|
219515449|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
219515450|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
219515451|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
219515452|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
219515453|NCT00559481|DRUG|dexamethasone|
219515454|NCT00559481|DRUG|ketoconazole|
219515455|NCT00559481|DRUG|therapeutic hydrocortisone|
219515456|NCT00559481|PROCEDURE|pharmacological study|
219515457|NCT02519413|DRUG|dimethyl fumarate|delayed release capsules
219515458|NCT05602688|DIETARY_SUPPLEMENT|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
219515459|NCT05602688|DIETARY_SUPPLEMENT|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
219515460|NCT01709032|DRUG|Deferasirox and deferiprone|
219515461|NCT01457053|DRUG|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
219610964|NCT04038463|BEHAVIORAL|ELP|The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
219610965|NCT04038463|BEHAVIORAL|LLP|The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
219610966|NCT04968834|GENETIC|Genomic profiling|Genomic profiling using CLIA assay
219610967|NCT03288714|DEVICE|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
219610968|NCT03288714|DEVICE|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
219610969|NCT03689465|DRUG|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
219610970|NCT03689465|DRUG|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
219610971|NCT03689465|DRUG|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
219610972|NCT03689465|DRUG|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
219610973|NCT03689465|DRUG|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
219515462|NCT01457053|OTHER|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
219515463|NCT03734497|OTHER|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
219515464|NCT03734497|OTHER|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
219515465|NCT03734497|OTHER|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
219515466|NCT02253797|DRUG|14C-Tipranavir|
219515467|NCT02253797|DRUG|Tipranavir|
219610974|NCT01169792|DRUG|tamoxifen|
219610975|NCT01027325|OTHER|Dietary Intervention|Starch digestibility and carbohydrate quantity
219610976|NCT03530839|PROCEDURE|Arthrodesis|see study group description
219610977|NCT03530839|PROCEDURE|Resection arthroplasty|see study group description
219610978|NCT04213495|OTHER|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
219610979|NCT03590210|DRUG|Trabectedin|Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
219610980|NCT03590210|DRUG|Nivolumab|Cycle 2 to 16 240 mg IV over 30 minutes, q3w
219610981|NCT05669235|DIAGNOSTIC_TEST|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
218895015|NCT00983385|OTHER|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
218895016|NCT00983385|DRUG|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
218895017|NCT00724204|DIETARY_SUPPLEMENT|follow on formula without probiotics|A follow on formula without probiotics
219515468|NCT02253797|DRUG|Ritonavir|
219515469|NCT01713309|DRUG|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
219515470|NCT03982433|BEHAVIORAL|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
219515471|NCT04488640|PROCEDURE|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
219515472|NCT00642538|DRUG|MKC253 Inhalation Powder|Inhalation Powder, prandial
219515473|NCT00642538|DRUG|Technosphere Inhalation Powder|Inhalation Powder, prandial
219515474|NCT00642538|DRUG|subcutaneous injection|10µg Exenatide, prandial
219610982|NCT02521415|DRUG|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
219610983|NCT02521415|DRUG|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
219610984|NCT02521415|DRUG|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
219515475|NCT03080181|DRUG|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
219515476|NCT02398877|OTHER|stress|
219610985|NCT05963724|DEVICE|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
219610986|NCT05963724|PROCEDURE|Stanford Colonoscopy|This involves white-light colonoscopy
219610987|NCT01117974|PROCEDURE|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
219610988|NCT01108614|BEHAVIORAL|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
219610989|NCT01951924|DRUG|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
219610990|NCT01951924|DRUG|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
218895018|NCT00724204|DIETARY_SUPPLEMENT|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
218895019|NCT03209856|DRUG|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
218895020|NCT04689789|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
218895021|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
218895022|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
218895023|NCT03145259|DRUG|Diclofenac Epolamine Patch|patch
218895024|NCT03145259|DRUG|diclofenac sodium solution|solution
218895025|NCT03690895|OTHER|Retrospective survival analysis|Kaplan-Meier model
218895026|NCT00781833|DEVICE|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
218895027|NCT02966561|BEHAVIORAL|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
218895028|NCT02966561|BEHAVIORAL|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
218895029|NCT02966561|OTHER|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
218895030|NCT04270539|BEHAVIORAL|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
218895031|NCT04301544|BEHAVIORAL|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
218895032|NCT04301544|BEHAVIORAL|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
218895033|NCT04301544|BEHAVIORAL|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
219203941|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
219203942|NCT05862545|DRUG|BGF (budesonide/glycopyrrolate/formoterol fumarate)|BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
219203943|NCT04098276|BEHAVIORAL|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
219203944|NCT04846790|BEHAVIORAL|Nature Only|See above for description.
218895034|NCT04177212|DEVICE|MRZF111|MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
218895035|NCT00648557|DRUG|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
218895036|NCT00648557|DRUG|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
218895037|NCT00278746|DRUG|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
218895038|NCT00278746|DRUG|ORS only|Promoted routine management of diarrhea in underfive with ORS
219515477|NCT01147952|BEHAVIORAL|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
219515478|NCT01065103|PROCEDURE|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
219515479|NCT06495814|DRUG|1/bag of Jinlida granules, 3 times/day, taken with hot water.|All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.
219515480|NCT04799158|DRUG|Vonoprazan|Orally via capsules
219515481|NCT04799158|DRUG|Placebo|Orally via capsules
219515482|NCT03772639|OTHER|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
219515483|NCT04928651|DRUG|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
219515484|NCT03922477|DRUG|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
219515485|NCT03922477|DRUG|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
219610991|NCT04016519|OTHER|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
218895039|NCT02361008|DEVICE|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
218895040|NCT02361008|PROCEDURE|Surgery repair with CBP|Traditional surgery repair under the CBP.
218895041|NCT00897455|GENETIC|DNA analysis|
218895042|NCT00897455|GENETIC|mutation analysis|
218895043|NCT00897455|GENETIC|polymorphism analysis|
219203945|NCT04846790|BEHAVIORAL|Nature+Mindfulness|See above for description.
219203946|NCT02954809|DEVICE|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
219515486|NCT03357783|OTHER|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
219515487|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
219610992|NCT05778461|DRUG|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
219610993|NCT05778461|DRUG|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
219203947|NCT02954809|DEVICE|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
219203948|NCT02295891|DEVICE|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
218895044|NCT00897455|OTHER|laboratory biomarker analysis|
218895045|NCT00897455|PROCEDURE|evaluation of cancer risk factors|
218895046|NCT05686291|BEHAVIORAL|Hybrid volunteer training programme|The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
218895047|NCT00946543|RADIATION|hypofractionated radiation therapy|
218895048|NCT00946543|RADIATION|intensity-modulated radiation therapy|
218895049|NCT00554047|OTHER|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
218895050|NCT00554047|OTHER|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
218895051|NCT00718692|DRUG|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
218895052|NCT04979611|DRUG|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
218895053|NCT04725500|DEVICE|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
218895054|NCT01412788|PROCEDURE|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
218895055|NCT01412788|PROCEDURE|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
218895056|NCT00857857|DRUG|GW870086X|Investigational product
218895057|NCT00857857|DRUG|FP|Positive control
218895058|NCT00857857|DRUG|Placebo|Placebo control
218895059|NCT02333786|OTHER|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
219035249|NCT00128921|DRUG|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
219035250|NCT05145829|DIAGNOSTIC_TEST|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
219035251|NCT05210686|OTHER|subgingival re-instrumentation|subgingival re-instrumentation (control)
219035252|NCT00918021|DRUG|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
219035253|NCT00918021|DRUG|placebo|placebo
219035254|NCT00082433|DRUG|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
219203949|NCT06490601|DRUG|thalidomide and hydroxyurea|"Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity."
219515488|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
219515489|NCT06544993|DRUG|Meso-botox|Micro-Botox, is a highly diluted Botulinum toxin type A
219515490|NCT01698996|PROCEDURE|Packing vs No Packing|
219515491|NCT00440596|BEHAVIORAL|Mindfulness based stress reduction|8 weeks group MBSR
219515492|NCT00440596|BEHAVIORAL|Progressive Muscle Relaxation|8 weeks PMR in group format
219515493|NCT06484101|PROCEDURE|Exercise|3 x 30 seconds of supramaximal exercise
219515494|NCT01004770|DRUG|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
219515495|NCT01004770|DRUG|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
218895060|NCT02333786|OTHER|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
218895061|NCT03163901|OTHER|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
218895062|NCT05675501|DRUG|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
218895063|NCT02023684|DRUG|control saline|Surgical bed irrigation with saline 40ml
218895064|NCT02023684|DRUG|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
218895065|NCT02023684|DRUG|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
218895066|NCT00277784|PROCEDURE|Ultrasound examination|one ultrasound examination
218895067|NCT02797392|BEHAVIORAL|Lifestyle intervention|1\) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
218895068|NCT04618744|DRUG|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
218895069|NCT04618744|OTHER|Placebo|Matching Placebo
218895070|NCT00930930|DRUG|cisplatin|Given IV
218895071|NCT00930930|DRUG|everolimus|Given orally
218895072|NCT00930930|DRUG|paclitaxel|Given IV
218895073|NCT00930930|OTHER|placebo|Given orally
219610994|NCT05620446|PROCEDURE|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
219610995|NCT04898699|DEVICE|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
219610996|NCT04898699|DEVICE|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
219610997|NCT04898699|DRUG|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
219610998|NCT04898699|BEHAVIORAL|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
219610999|NCT04898699|BEHAVIORAL|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
219611000|NCT04671589|DRUG|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
219515496|NCT01441271|PROCEDURE|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.
219515497|NCT01441271|PROCEDURE|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
219515498|NCT02277652|DEVICE|The Miller Laryngoscope|Direct laryngoscopy
219515499|NCT02277652|DEVICE|The Bonfils intubation fibrescope|Optical laryngoscopy
219515500|NCT02277652|DEVICE|The GlideScope Ranger|Videolaryngoscopy
219515501|NCT02277652|DEVICE|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
218895074|NCT00930930|PROCEDURE|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
218895075|NCT01505816|DEVICE|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
218895076|NCT05311930|DRUG|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
218895077|NCT02647424|DRUG|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
218895078|NCT02647424|DRUG|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
218895079|NCT02709330|DRUG|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
218895080|NCT02709330|OTHER|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
218895081|NCT01918956|BIOLOGICAL|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
218895082|NCT05269108|PROCEDURE|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
218895083|NCT05269108|PROCEDURE|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
219035255|NCT00082433|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
219035256|NCT00443586|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
218895084|NCT01411956|OTHER|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
218895085|NCT01411956|OTHER|Placebo video|The control group watched a 25-minute patient education video on depression.
219515502|NCT05662553|PROCEDURE|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
219515503|NCT05662553|PROCEDURE|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
219515504|NCT01380028|DRUG|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
219515505|NCT01380028|DRUG|placebo|placebo
219515506|NCT00001564|DRUG|EF-1 Peptide|
219515507|NCT00001564|DRUG|EF-2 Peptide|
219515508|NCT00001564|DRUG|PXFK Peptide|
219515509|NCT00001564|DRUG|E7 Peptide|
219515510|NCT00001564|DRUG|IL-2|
219515511|NCT00001564|DRUG|IL-4|
219515512|NCT00001564|DRUG|GM-CSF|
219611001|NCT03701893|DIETARY_SUPPLEMENT|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1\*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
219611002|NCT00758524|DRUG|LCI699|LCI699 oral capsules
219611003|NCT00758524|DRUG|Eplerenone|Eplerenone oral capsules
219515513|NCT00001564|DRUG|CD40 Ligand|
219515514|NCT00788957|DRUG|Panitumumab|Panitumumab for intravenous infusion
219515515|NCT00788957|DRUG|Ganitumab|Ganitumab for intravenous infusion
219515516|NCT00788957|DRUG|Rilotumumab|Rilotumumab for intravenous infusion
219515517|NCT00788957|DRUG|Placebo|Placebo intravenous infusion
219515518|NCT05555459|PROCEDURE|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
219611004|NCT00758524|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
218895086|NCT01356446|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
218895087|NCT01279681|BIOLOGICAL|bevacizumab|Given IV
218895088|NCT01279681|DRUG|capecitabine|Given PO
218895089|NCT01279681|DRUG|fluorouracil|Given IV
218895090|NCT01279681|DRUG|leucovorin calcium|Given IV
218895091|NCT01279681|DRUG|oxaliplatin|Given IV
218895092|NCT00125320|DRUG|RSD1235|
218895093|NCT04948853|BEHAVIORAL|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
218895094|NCT00195936|DRUG|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
218895095|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
218895096|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
218895097|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
218895098|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
218895099|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
219515519|NCT06111456|OTHER|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
219515520|NCT06111456|OTHER|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
219515521|NCT01938976|BEHAVIORAL|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
219515522|NCT03028272|OTHER|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
219515523|NCT03028272|OTHER|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
219515524|NCT03105609|DEVICE|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
219515525|NCT06301802|PROCEDURE|CIC|clean intermittent catheterization
219515526|NCT06301802|DRUG|Anticholinergic|antimuscarinic once daily
219515527|NCT03246542|DIAGNOSTIC_TEST|shistocytes percentage|
219515528|NCT02272868|BIOLOGICAL|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
219515529|NCT02272868|DRUG|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
219515530|NCT02272868|DRUG|rifaximin+omeprazole+miralax|
219515531|NCT01820871|OTHER|Self-Management Using Smartphone Application for Type2 DM|
218895100|NCT02807623|DRUG|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
218895101|NCT02807623|BEHAVIORAL|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
219035257|NCT00443586|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
219035258|NCT00443586|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
219035259|NCT00443586|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
219035260|NCT03733171|DRUG|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
219515532|NCT01820871|OTHER|self-management using booklet for management type 2 DM|
219515533|NCT03387098|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
219515534|NCT03387098|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219515535|NCT03387098|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219611005|NCT00758524|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
219611006|NCT04801992|DEVICE|MINI WELL Ready (SIFI SpA, Italy)|Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.
218895102|NCT02807623|DRUG|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
218895103|NCT00425724|DRUG|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
218895104|NCT00239239|DRUG|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
219515536|NCT03387098|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
219515537|NCT03387098|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
219515538|NCT03387098|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
219515539|NCT03387098|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
219611007|NCT01121250|BEHAVIORAL|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
219611008|NCT01121250|BEHAVIORAL|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
219515540|NCT03387098|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219515541|NCT03387098|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219515542|NCT03387098|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219515543|NCT03387098|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219611009|NCT00004012|DRUG|capecitabine|
219611010|NCT00348725|DRUG|fenofibrate and metformin fixed combination (drug)|
219611011|NCT03901313|DRUG|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
219515544|NCT03387098|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219515545|NCT03387098|DRUG|lovaza|Omega-3-acid ethyl esters
219611012|NCT03901313|DRUG|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
218895105|NCT02213835|OTHER|Specific Carbohydrate diet (SCD)|
218895106|NCT04092686|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
218895107|NCT04092686|DRUG|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
218895108|NCT04092686|DRUG|Placebo|Placebo tablet dosed once daily
219515546|NCT03387098|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219515547|NCT03387098|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
219515548|NCT03795103|DEVICE|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
219515549|NCT03795103|OTHER|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
219515550|NCT03795103|OTHER|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
219515551|NCT04736264|OTHER|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
219611013|NCT03901313|DRUG|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
219611014|NCT04747470|DRUG|GS-3583|Administered as an intravenous (IV) infusion
219611015|NCT04747470|DRUG|Zimberelimab|Administered as an IV infusion
219611016|NCT04747470|DRUG|Cisplatin|Administered as an IV infusion
219611017|NCT04747470|DRUG|Carboplatin|Administered as an IV infusion
219611018|NCT04747470|DRUG|5-Fluorouracil|Administered as an IV infusion
218895109|NCT02953522|OTHER|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
218895110|NCT02953522|OTHER|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
218895111|NCT01835821|DEVICE|prosthetic crowns|prosthetic crowns
219515552|NCT04736264|OTHER|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
219515553|NCT04736264|OTHER|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
219611019|NCT04747470|DRUG|Docetaxel|Administered as an IV infusion
219611020|NCT04089449|DRUG|PRT811|PRT811 will be administered orally
219611021|NCT06155201|BEHAVIORAL|functional training|Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
219611022|NCT06155201|OTHER|Observation|Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
219515554|NCT02309749|OTHER|CAP|
219515555|NCT05618171|DIAGNOSTIC_TEST|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
219515556|NCT05067049|DEVICE|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
219515557|NCT05067049|DEVICE|Unconnected arm|Follow-up visits with the pysicians as usual
218895112|NCT04639544|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
218895113|NCT04639544|DIETARY_SUPPLEMENT|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
218895114|NCT02326285|DRUG|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
218895115|NCT02326285|DRUG|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
219035261|NCT03733171|DRUG|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
218895116|NCT02326285|DRUG|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
219035262|NCT03733171|DEVICE|hemoclips|diluted epinephrine was injected followed by application of hemoclips
219035263|NCT01076907|OTHER|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
218895117|NCT02326285|PROCEDURE|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
218895118|NCT06233188|PROCEDURE|orthogantic surgery|surgery that correcting the maxilla and mandible related with each other
219035264|NCT01076907|OTHER|Control|Air will be used instead of warm water for unsedated colonoscopy.
219035265|NCT06333327|DEVICE|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter
219035266|NCT04097821|DRUG|Ruxolitinib|5 mg tablets for oral use
219515558|NCT03317236|DRUG|Quetiapine|A fixed 50 mg exteded release formulation.
219515559|NCT03276975|DRUG|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
219515560|NCT01811043|BEHAVIORAL|Guided Meditation|
218895119|NCT02942758|DRUG|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
218895120|NCT02942758|DRUG|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
219515561|NCT01811043|BEHAVIORAL|Music|
219515562|NCT01811043|BEHAVIORAL|Supportive Dialogue|
219515563|NCT01349556|DRUG|Tretinoin|tretinoin 0.025% cream
218895121|NCT02942758|DRUG|ATRA|ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
219035267|NCT04097821|DRUG|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
219035268|NCT04097821|DRUG|Crizanlizumab|100 mg/10 mL concentrate for infusion for intravenous use
219035269|NCT04097821|DRUG|Sabatolimab|100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
219515564|NCT00040378|DRUG|alphatocopherol|400 IU daily
219035270|NCT04097821|DRUG|Rineterkib|100 mg capsule for oral use
219515565|NCT00040378|DRUG|Selenium|200mcg daily
219515566|NCT00040378|DRUG|Placebo replacement for vitamin E|1 placebo pill daily
219515567|NCT00040378|DRUG|Placebo replacement for Selenium|1 placebo pill daily
219515568|NCT03845933|PROCEDURE|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
218895122|NCT02942758|DRUG|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
218895123|NCT00215358|DRUG|Formoterol Fumarate|
218895124|NCT00028483|DRUG|cBR96-doxorubicin immunoconjugate|
218895125|NCT00028483|DRUG|docetaxel|
218895126|NCT05599308|DEVICE|OMRON blood pressure monitor with AFib screening feature|Blood pressure measurement by an oscillometric blood pressure monitor
218895127|NCT05599308|DEVICE|Microlife WatchBP Home A|Blood pressure measurement by an oscillometric blood pressure monitor
218895128|NCT04820244|OTHER|No intervention|No intervention
218895129|NCT05272371|COMBINATION_PRODUCT|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
219035271|NCT04097821|DRUG|NIS793|700 mg/7 mL concentrate for infusion for intravenous use
219035272|NCT03688763|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
219035273|NCT03510117|BEHAVIORAL|Mindfulness|Mindfulness
219035274|NCT03159728|BEHAVIORAL|Educative intervention:|"* In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
219515569|NCT06348836|OTHER|Exercise|Description of exercises are noted in the arms/groups descriptions
219515570|NCT05197166|OTHER|Acute Clinical Settings|Acute clinical settings, like hospitals, where students are exposed to normal daily shift activities, involving prolonged walking and standing positions.
219515571|NCT04498923|DRUG|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
219515572|NCT02029209|DRUG|Anlotinib|Anlotinib QD
219515573|NCT02029209|DRUG|Placebo Capsule|Placebo capsule QD
219515574|NCT01282996|OTHER|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
219611023|NCT02329509|PROCEDURE|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
219611024|NCT02329509|PROCEDURE|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
219611025|NCT04332315|PROCEDURE|Vaginally assisted laparoscopic sacrocolpopexy|"The VALS procedure consists of two steps. First, vaginal hysterectomy or laparoscopically assisted vaginal hysterectomy performed, anterior vaginal wall dissected up to bladder neck starting from initial vaginal incision, posterior vaginal wall dissected from rectum starting from initial vaginal incision up to distal third of posterior vaginal wall.The free arms of fixed meshes are introduced to the peritoneal cavity and the vaginal vault is closed with absorbable polyglactin suture. laparoscopy phase was performed with one intraumbilical (10 mm), 3 lateral abdominal (5 mm) trocars. Two mesh strips fixated to anterior longitudinal ligament of the sacrum with two separate no: 1 polypropylene sutures without tension.~AS was performed via Pfannenstiel incision after total or subtotal abdominal hysterectomy"
219611026|NCT00806429|PROCEDURE|transvaginal appendectomy|patient undergoes transvaginal appendectomy
218895130|NCT00003425|BIOLOGICAL|filgrastim|
218895131|NCT00003425|DRUG|amifostine trihydrate|
218895132|NCT00003425|DRUG|cyclophosphamide|
218895133|NCT00003425|DRUG|melphalan|
218895134|NCT00003425|PROCEDURE|peripheral blood stem cell transplantation|
218895135|NCT00181363|DEVICE|Mamma board|use of mamma board during radiotherapy
218895136|NCT03310723|DEVICE|Face Mask preoxygenation|Standard face mask preoxygenation.
218895137|NCT03310723|DEVICE|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
218895138|NCT06071949|DRUG|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
218895139|NCT06071949|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
218895140|NCT01599975|DRUG|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
218895141|NCT01599975|DRUG|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
219515575|NCT06285721|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
219611027|NCT02317003|BEHAVIORAL|Intervention PPIL|
219611028|NCT02317003|BEHAVIORAL|Control OR|
219611029|NCT04720053|DEVICE|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
219611030|NCT05362604|PROCEDURE|scheduled delivery at a tertiary center|Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
218895142|NCT01599975|DRUG|Matched placebo|2 tablets of matched placebo daily by mouth
218895143|NCT06115616|BEHAVIORAL|Morning exercise|Exercise before noon in the morning
218895144|NCT06115616|BEHAVIORAL|Afternoon exercise|Exercise in the late after noon
218895145|NCT02098746|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
218895146|NCT05087771|DRUG|injectable naltrexone|360 mg dose to be given prior to hospital discharge
218895147|NCT05087771|DRUG|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
218895148|NCT03816735|DEVICE|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
219203950|NCT06490601|DRUG|Thalidomide|"Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile."
218895149|NCT03816735|DEVICE|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
218895150|NCT04062110|DEVICE|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
218895151|NCT01410890|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
218895152|NCT05777044|BEHAVIORAL|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
218895153|NCT01467141|DRUG|insulin aspart|Injected s.c. (under the skin) three times a day
218895154|NCT01467141|DRUG|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
218895155|NCT01467141|DRUG|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
218895156|NCT05001334|BEHAVIORAL|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
218895157|NCT00247403|DRUG|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
218895158|NCT00938184|DRUG|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
219611031|NCT04818125|OTHER|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~* at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~* at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
219611032|NCT05494996|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
219611033|NCT01495299|DEVICE|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
219611034|NCT05471999|PROCEDURE|surgery|interventional or surgical treatment
219611035|NCT04931693|DRUG|paracetamol|iv post operative analgesia
219611036|NCT04931693|PROCEDURE|modifiedPECs block|sonar guided pectoral nerve block
218895159|NCT00938184|DRUG|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
218895160|NCT00938184|DRUG|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
218895161|NCT04699565|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Evaluate the predictive value of myocardial viability measured with cardiac magnetic resonance for the identification of LV REM 6 months after STEMI
218895162|NCT01889823|OTHER|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
219035275|NCT01730183|OTHER|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
219611037|NCT03258411|DEVICE|Rapid Expansion of palatal suture|
219611038|NCT02716961|DRUG|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
219611039|NCT02764593|DRUG|Nivolumab|Anti-PD-1 targeted immunotherapy
219611040|NCT02764593|DRUG|Cisplatin|Anti-cancer alkylating agent
219611041|NCT02764593|DRUG|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
219611042|NCT02764593|RADIATION|IMRT|High-precision radiotherapy
219611043|NCT02143128|OTHER|Efficacy Safety Score|Evaluation using the score for postoperative patients
219611044|NCT02143128|OTHER|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
218895163|NCT01889823|OTHER|Hyperoxia|Subjects will be breathing 100% oxygen
218895164|NCT01033539|OTHER|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
218895165|NCT01230463|DRUG|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
218895166|NCT01230463|DRUG|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
218895167|NCT03749759|PROCEDURE|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
219611045|NCT00977093|OTHER|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
219611046|NCT00977093|OTHER|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
219611047|NCT02906670|DRUG|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
218895168|NCT04053257|OTHER|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
219035276|NCT06974968|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of spinal cord injury (SCI) and represents a novel approach in regenerative medicine."
219035277|NCT06974968|OTHER|Placebo|Standard rehabilitation protocols
218895169|NCT04126694|BEHAVIORAL|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
218895170|NCT00217425|BIOLOGICAL|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
218895171|NCT00217425|DRUG|cyclophosphamide|IV infusion per institutional guidelines.
219515576|NCT06285721|DEVICE|Sham transcranial alternating current stimulation (tACS)|Sham-tACS is a form of non-effective stimulation which can mimic the subjective sensation of active tACS treatment. During sham-tACS, the device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.The sham-tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
219515577|NCT00719290|PROCEDURE|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
219515578|NCT00719290|PROCEDURE|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
219515579|NCT00918567|DRUG|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
219515580|NCT00918567|BEHAVIORAL|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
219515581|NCT06482463|BIOLOGICAL|CSF sample|an additional CSF sample of 1 ml is taken from the external ventriculostomy
219515582|NCT06352320|BIOLOGICAL|Diagnosis of HCM|Hypertrophic cardiomyopathy (HCM) is defined as the presence of increased LV wall thickness (with or without RV hypertrophy) or mass that is not solely explained by abnormal loading conditions.
219515583|NCT06352320|BIOLOGICAL|Diagnosis of DCM|Dilated cardiomyopathy (DCM) is defined as the presence of LV dilatation and global or regional systolic dysfunction unexplained solely by abnormal loading conditions (e.g. hypertension, valve disease, CHD) or CAD.Very rarely, LV dilatation can occur with normal ejection fraction (EF) in the absence of athletic remodelling or other environmental factors; this is not in itself a cardiomyopathy, but may represent an early manifestation of DCM. The preferred term for this is isolated left ventricular dilatation. Right ventricular dilatation and dysfunction may be present but are not necessary for the diagnosis.
219515584|NCT06352320|BIOLOGICAL|Diagnosis of ARVC|Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined as the presence of predominantly RV dilatation and/or dysfunction in the presence of histological involvement and/or electrocardiographic abnormalities in accordance with published criteria.
219611048|NCT05092789|OTHER|Kinesio taping group|"Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions."
219611049|NCT05092789|OTHER|Cervical thrust manipulation group|"Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up."
219203951|NCT03565913|DRUG|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
219203952|NCT03565913|OTHER|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
219203953|NCT02863107|PROCEDURE|Biospecimen Collection|Undergo collection of blood or saliva samples
219515585|NCT06352320|BIOLOGICAL|Diagnosis of NDLVC|The NDLVC phenotype is defined as the presence of non-ischaemic LV scarring or fatty replacement regardless of the presence of global or regional wall motion abnormalities (RWMAs), or isolated global LV hypokinesia without scarring.
218895172|NCT00217425|DRUG|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
218895173|NCT00217425|DRUG|prednisone|Prednisone is taken orally.
218895174|NCT00217425|DRUG|vincristine|IV push using extravasation precautions.
218895175|NCT04608721|OTHER|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
218895176|NCT01121146|DEVICE|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
218895177|NCT02589054|OTHER|Monitoring|
218895178|NCT03273673|OTHER|Biofeedback Intervention|Visual and Tactile Biofeedback
219203954|NCT02863107|OTHER|Medical Chart Review|Review of medical charts
219203955|NCT02863107|OTHER|Quality-of-Life Assessment|Ancillary studies
219203956|NCT02863107|OTHER|Questionnaire Administration|Complete questionnaires
219203957|NCT03242915|DRUG|Pembrolizumab|200mg IV every 3 weeks
219203958|NCT03242915|DRUG|Carboplatin|AUC 5 IV every 3 weeks
219203959|NCT03242915|DRUG|Pemetrexed|500 mg/m\^2 IV every 3 weeks
218895179|NCT01499615|DEVICE|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
218895180|NCT05887921|PROCEDURE|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
218895181|NCT02724098|DRUG|Dexmedetomidine|
218895182|NCT00330759|BIOLOGICAL|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
218895183|NCT00330759|DRUG|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
218895184|NCT00997035|DRUG|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
218895185|NCT00997035|DRUG|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
218895186|NCT02375035|DEVICE|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
218895187|NCT04045379|PROCEDURE|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
218895188|NCT04045379|PROCEDURE|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
218895189|NCT04045379|DRUG|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
218895190|NCT03110471|BEHAVIORAL|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
218895191|NCT03110471|BEHAVIORAL|usual care|usual care
218895192|NCT00089596|PROCEDURE|Expansion of umbilical cord stem cells|
218895193|NCT01067378|OTHER|Peer-led debriefing|
218895194|NCT01067378|OTHER|Expert instructor debriefing|
218895195|NCT00468026|DEVICE|ProstaPlant Stent|
218895196|NCT03654690|DIAGNOSTIC_TEST|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
218895197|NCT03654690|BEHAVIORAL|Counseling|Post-Test HIV Risk ReductionCounseling
218895198|NCT06295861|OTHER|no different intervention between the two cohort.|no different intervention between the two cohort.
218895199|NCT06284850|DRUG|Empagliflozin10Mg Tab|TB JARDIANCE 10MG
218895200|NCT00390767|BIOLOGICAL|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
218895201|NCT03285269|DIAGNOSTIC_TEST|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
218895202|NCT03285269|DEVICE|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
218895203|NCT03285269|PROCEDURE|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
218895204|NCT02335307|GENETIC|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
219035278|NCT06617975|OTHER|Balneotherapy program in rheumatology indication|"At least 4 balneotherapy sessions per day, 6 days a week during 3 consecutive weeks that may include: 1 whirlpool bath per day, 1 poultice application per day, 1 bath with immersion showers in a pool per day, a local jet shower every other day, a penetrating shower every other day.~Alternative treatments may replace penetrating shower or local jet shower, or other care, e.g., collective jet shower or steam bath. 10-minute air diffusion baths are taken in individual tubs at 37°C. Mud is applied 10 minutes as a poultice to both knees (minimum 2 per knee, 52°C), if necessary, to other painful osteoarthritis areas. 10-minute collective pool bathing takes place in a thermal pool equipped with jet stations immersed in water at 32°C. 3-minute local jet shower is applied to the predefined area using thermal water at 37°C. 10-minute penetrating showers are delivered by an affusion ramp on the patient lying down and directed on the area defined, using thermal water at 37°C."
219035279|NCT05500378|OTHER|Head extension and rotation movement|Active exercise of the head
219035280|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
218895205|NCT02335307|OTHER|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
218895206|NCT02335307|OTHER|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
218895207|NCT00249509|DRUG|Nefazodone|
218895208|NCT00249509|DRUG|Bupropion|
218895209|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
219515586|NCT06352320|BIOLOGICAL|Diagnosis of RCM|Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness.Restrictive cardiomyopathy commonly presents as biatrial enlargement. Left ventricular systolic function can be preserved, but it is rare for contractility to be completely normal. Restrictive pathophysiology may not be present throughout the natural history, but only at an initial stage (with an evolution towards a hypokinetic-dilated phase). Restrictive physiology can also occur in patients with end-stage hypertrophic and dilated cardiomyopathy; the preferred terms are 'hypertrophic' or 'dilated cardiomyopathy with restrictive physiology'. Restrictive ventricular physiology can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic function
218895210|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
218895211|NCT04526626|DEVICE|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
219515587|NCT06352320|BIOLOGICAL|Diagnosis of LVNC|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickerendocardial layer. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope. Left ventricular non-compaction has also been used to describe an acquired and sometimes transient phenomenon of excessive LV trabeculation (e.g. in athletes, during pregnancy, or following vigorous activity)that must reflect increased prominence of an otherwise normal myocardial architecture, given that cardiomyocytes are terminally differentiated and the formation of new cardiac structures is impossible.The Task Force does not consider LVNC to be a cardiomyopathy in the general sense.
219515588|NCT00021658|PROCEDURE|Pesticide application procedures|
219515589|NCT00508560|BEHAVIORAL|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
218895212|NCT06100679|BEHAVIORAL|Responsible Engaged and Loving (REAL) Fathers Initiative|REAL Fathers is a multilevel norms-shifting intervention among: young fathers (ages 16-25 whose oldest child is under the age of 3); couple dyads (fathers and wives); mentoring dyads and groups; and communities. Respected men in the community are identified by participating young fathers, their partners and community members to become mentors. Mentors participate in a training and mentor young fathers through home and group sessions on conflict resolution, non-violent discipline, family planning, and couple communication. Mentoring is supplemented with a monthly poster campaign designed to reinforce messages from the home and group mentoring sessions and a community celebration. REAL Fathers aims to build positive partnerships and parenting practices among young fathers to: 1) reduce incidence of intimate partner violence; 2) reduce harsh physical punishment of children; 3) improve early childhood development; 4) decrease unmet need for family planning.
218895213|NCT05569447|PROCEDURE|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
218895214|NCT03477396|DRUG|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
218895215|NCT03477396|OTHER|Laboratory Biomarker Analysis|Correlative studies
218895216|NCT03477396|OTHER|Pharmacokinetic Study|Correlative studies
218895217|NCT03477396|OTHER|Questionnaire Administration|Ancillary studies
218895218|NCT03477396|DRUG|Ribociclib|Given PO
218895219|NCT01391624|DRUG|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
218895220|NCT01391624|DRUG|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
218895221|NCT03852017|BEHAVIORAL|Audio Program|
218895222|NCT02544503|DEVICE|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
218895223|NCT02544503|DEVICE|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
218895224|NCT02544503|DEVICE|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
218895225|NCT02544503|DEVICE|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
218895226|NCT00068341|BIOLOGICAL|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
219035281|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
219203960|NCT03019263|DIETARY_SUPPLEMENT|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
219515590|NCT00508560|BEHAVIORAL|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
219515591|NCT00858195|DRUG|Indomethacin 75mg Extended-Release Capsules, Sandoz|
219515592|NCT00858195|DRUG|Indocin 75mg SR Capsules|
219515593|NCT05596708|DRUG|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
219515594|NCT00653536|DEVICE|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
219515595|NCT03411005|DIETARY_SUPPLEMENT|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
219515596|NCT02294071|DRUG|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
219515597|NCT02294071|DRUG|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
219515598|NCT00738166|OTHER|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
219515599|NCT00738166|OTHER|Diet (organic or conventional)|organic or conventional diet
219515600|NCT01017783|BEHAVIORAL|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
219515601|NCT01017783|BEHAVIORAL|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
219515602|NCT01017783|BEHAVIORAL|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
219515603|NCT01055223|DRUG|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
219515604|NCT01055223|DRUG|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
219515605|NCT01055223|DRUG|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
219515606|NCT02568384|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
219515607|NCT03475784|DRUG|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
219515608|NCT03475784|DRUG|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
219611050|NCT05092789|OTHER|Conventional therapy group|"Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up."
219611051|NCT03749330|BEHAVIORAL|CICU Team And Loved Ones Communicating (CICU TALC)|When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
219515609|NCT01485536|DRUG|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
219515610|NCT01131858|DRUG|Vigantol|Vigantol 4000IU/day
219515611|NCT01131858|DRUG|Placebo|Placebo
219515612|NCT00950157|OTHER|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
219035282|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
219035283|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
219203961|NCT03019263|OTHER|Control|Nutritional counseling
219203962|NCT02780024|DRUG|Metformin|Metformin,
219203963|NCT05497024|BEHAVIORAL|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
219203964|NCT05497024|BEHAVIORAL|Surveys|Participants may answer questions that are sensitive in nature.
219203965|NCT03068819|DRUG|CIML NK Cell Infusion|-Day 0
219515613|NCT02381977|OTHER|No intervention|
219515614|NCT04812106|OTHER|No Intervention|No Intervention
219515615|NCT00796510|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
219515616|NCT00796510|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
219515617|NCT01093937|DRUG|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
219515618|NCT06266988|DRUG|Sacubitril and Valsartan Tablets 97mg/103mg|Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
219515619|NCT06266988|DRUG|Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)|Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
218895227|NCT00068341|DRUG|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
219611052|NCT04383548|OTHER|hyper immunoglobulins containing anti-Corona VS2 immunoglobulin|Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
219611053|NCT03566030|DRUG|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
219611054|NCT03566030|DRUG|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
219611055|NCT01973439|OTHER|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
218895228|NCT00068341|DRUG|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
218895229|NCT00068341|BIOLOGICAL|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
218895230|NCT06528236|DIAGNOSTIC_TEST|Artificial intelligence model|Using the artificial intelligence model to diagnosis benign, borderline, and malignant ovarian masses.
218895231|NCT05237349|DRUG|Envafolimab|300mg,sc,d1,Q3W
218895232|NCT05237349|DRUG|Oxaliplatin|130mg/m2, iv,d1,Q3W
218895233|NCT05237349|DRUG|S1|40mg/m2, op,bid,d1-14,Q3W
218895234|NCT01513408|OTHER|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
218895235|NCT00458380|PROCEDURE|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
218895236|NCT03512171|DRUG|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
218895237|NCT03512171|DRUG|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
219515620|NCT04111744|OTHER|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
219515621|NCT04111744|OTHER|Optimal medical therapy|Standard medication for stable CAD
219515622|NCT00859664|OTHER|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
219515623|NCT01291303|PROCEDURE|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
219515624|NCT01291303|PROCEDURE|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
219515625|NCT03619031|OTHER|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
219515626|NCT03619031|OTHER|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
219515627|NCT03619031|OTHER|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
219515628|NCT04359641|DEVICE|CoMET Display|Display and presentation of predictive monitoring score CoMET
219515629|NCT00744809|DRUG|TMC278; Moxifloxacin; Efavirenz|
219515630|NCT02651441|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
219515631|NCT02651441|DRUG|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
219515632|NCT02651441|BIOLOGICAL|D-CIK|8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
219515633|NCT01968252|OTHER|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
219611056|NCT01973439|OTHER|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
218895238|NCT03512171|DIAGNOSTIC_TEST|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
218895239|NCT03512171|DIAGNOSTIC_TEST|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
218895240|NCT04645446|DRUG|Pro-ocular gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
218895241|NCT04645446|DRUG|Placebo gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
218895242|NCT00202514|DRUG|divalproex sodium extended release|
218895243|NCT05923879|DRUG|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
218895244|NCT01072188|DEVICE|Arginine/Calcium Carbonate|One time treatment
218895245|NCT01072188|DEVICE|Nupro - Fluoride Free|Brush twice daily
219515634|NCT01938950|OTHER|Aerobic Exercise|
219515635|NCT01938950|OTHER|Resistance Exercise|
219515636|NCT01938950|OTHER|Aerobic and Resistance Exercise|
219515637|NCT04105881|DIETARY_SUPPLEMENT|Investigation|Cross sectional intervention
219515638|NCT03532321|OTHER|NA : non interventional study|NA : non interventional study
219515639|NCT03918798|DRUG|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
219611057|NCT05577559|PROCEDURE|intermediate cervical plexus block|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
219611058|NCT05577559|PROCEDURE|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
219611059|NCT01472861|PROCEDURE|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
219611060|NCT01472861|OTHER|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
219611061|NCT05839444|OTHER|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
219611062|NCT05839444|OTHER|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
219611063|NCT05302960|DEVICE|Fitbit|The use of Fitbit sensors to see if activity levels can be improved to track recovery from COVID
218895246|NCT04908085|BEHAVIORAL|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
218895247|NCT00725777|DRUG|artemether-lumefantrine|Standard artemether-lumefantrine treatment
218895248|NCT05404243|DRUG|phenolization|In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
219515640|NCT03918798|DRUG|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
219515641|NCT04351295|DRUG|Favipiravir|Favipiravir
219515642|NCT04351295|DRUG|Chloroquine|chloroquine oral tablets
219515643|NCT06166472|DRUG|AK132|IV infusion, specified dose on specified days.
219611064|NCT04748640|PROCEDURE|Gamma Knife VIM thalamotomy|Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
218895249|NCT05404243|PROCEDURE|Conventional surgery|In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
218895250|NCT03922581|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
218895251|NCT00168441|DRUG|Botulinum Toxin Type A|
219515644|NCT05998213|OTHER|Fecal microbiota transplant|Frozen FMT via duodenal tube (2 times) and enemas (4 times)
219611065|NCT02352701|DRUG|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
219611066|NCT02352701|DRUG|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
219515645|NCT01161641|DRUG|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
219515646|NCT01161641|DRUG|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
219611067|NCT02352701|DRUG|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
219611068|NCT02815995|DRUG|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
218895252|NCT04472611|DRUG|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
218895253|NCT00566423|OTHER|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
218895254|NCT04419831|DIAGNOSTIC_TEST|Yale Stress Pain Test (YSPT)|Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
218895255|NCT05757752|BEHAVIORAL|Problem Solving Therapy and Integrated Care|The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
219515647|NCT01161641|DRUG|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
219515648|NCT01729936|BEHAVIORAL|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
219515649|NCT00673491|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
219515650|NCT03231839|BEHAVIORAL|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
219515651|NCT03231839|BEHAVIORAL|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
219611069|NCT02815995|DRUG|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
219611070|NCT03571828|DRUG|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
219611071|NCT01901640|DRUG|DA-8159 (Udenafil)|
219613386|NCT04113161|OTHER|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
219613387|NCT03330561|DRUG|PRS-343|PRS-343
219611072|NCT06443229|BEHAVIORAL|Graded Activity based in exercises and educational approach|"Exercises for warming up, strengthening, and relaxation, along with informational sessions incorporating an educational approach for low back pain using Telerehabilitation platform. Participants will be randomized into two groups: the Experimental Group (EG), which will receive graded activity along with the educational approach, three times a week, over 12 sessions, totaling 4 weeks.~The intervention will involve adapting a protocol from an exercise program based on gradual activity with progressively increasing exercise intensity using web applications from Physitrack® Ltd., LDN, United Kingdom (used by the physiotherapist/researcher) and Physiapp® (used by the participant). Participants will be provided with (i) a welcome letter outlining the intervention/group components they are allocated to; (ii) instructions on how to use the Physiapp® web application (web browser, Android or iOS app) at home."
219611073|NCT06443229|OTHER|Educational Approach|Educational approach for low back pain using Telerehabilitation platform. Participants will receive educational materials with an isolated educational approach, with the delivery of the materials occurring three times a week.
219611074|NCT01841593|DRUG|Raltegravir|Isentress 400mg tablet taken twice daily
219611075|NCT01841593|DRUG|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
218895256|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
219611076|NCT04584411|DIAGNOSTIC_TEST|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~* Cine imaging using SSFP sequence for cardiac structure and function.~* Tissue characterization imaging, T1 and T2.~* Myocardial perfusion imaging.~* Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities\[5\]"
218895257|NCT04685798|DEVICE|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
218895258|NCT04685798|DEVICE|FDG PET/CT|Standard of care
219035284|NCT04134923|DRUG|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
219515652|NCT03231839|BEHAVIORAL|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
219515653|NCT03776032|DRUG|Darbepoetin alfa|Administered by subcutaneous injection once a week
219515654|NCT03776032|DRUG|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
219515655|NCT01604421|PROCEDURE|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
219515656|NCT01604421|PROCEDURE|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
219515657|NCT02564913|OTHER|clinical evaluation|
219515658|NCT01485913|OTHER|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
219611077|NCT03561649|DRUG|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
219611078|NCT00548613|BIOLOGICAL|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
218895259|NCT05480683|DIAGNOSTIC_TEST|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
219203966|NCT03068819|PROCEDURE|CD3+ T Cell Product Infusion|-Day -1
218895260|NCT00028704|PROCEDURE|conventional surgery|
218895261|NCT00028704|RADIATION|radiation therapy|
218895262|NCT06427031|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
219203967|NCT05802602|DEVICE|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
219203968|NCT05802602|DEVICE|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
218895263|NCT06427031|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
218895264|NCT06065618|OTHER|Without intervention|Without intervention
219035285|NCT06095141|DRUG|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
218895265|NCT03205124|PROCEDURE|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
218895266|NCT03205124|PROCEDURE|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
219515659|NCT02579096|DRUG|allopurinol capsule, 100-800 mg by mouth once daily|Patients will be up-titrated up to the dose required to reach target uric acid levels.
219515660|NCT02579096|DRUG|febuxostat tablet 40-120 mg by mouth once daily|Patients will be up-titrated to the dose required to reach target uric acid levels.
219515661|NCT02579096|DRUG|Placebo, vehicle control (febuxostat-shaped)|Placebo tablets resembling febuxostat will be given with allopurinol.
219515662|NCT02579096|DRUG|Placebo, vehicle control (allopurinol-shaped)|Placebo capsules resembling allopurinol will be given with febuxostat.
219515663|NCT05151835|DEVICE|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console \[SGC\], a Patient Side Robot \[PSR\], and a Vision Cart \[VCT\], and is used with an endoscope, Surgical Instruments \[SGI\], and Accessories \[ACC\]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
219515664|NCT01781039|DEVICE|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (\> 50% of the time), and 100 persons reporting little difficulty HIN (\< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
219515665|NCT05854654|DIAGNOSTIC_TEST|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
219515666|NCT01876186|DRUG|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
219515667|NCT01876186|DRUG|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
219515668|NCT05132413|DRUG|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
219515669|NCT05132413|DRUG|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
219515670|NCT05132413|DRUG|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
219515671|NCT05977257|DEVICE|VitaFlow® Transcatheter Aortic Valve Replacement System|This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
218895267|NCT06521710|PROCEDURE|Intraoperative Somatic-Autonomic Nerve Grafting|A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
218895268|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
218895269|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
219035286|NCT03490513|DRUG|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
219515672|NCT02898649|DEVICE|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
219515673|NCT02097121|BIOLOGICAL|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
219035287|NCT03490513|DRUG|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
219035288|NCT05829928|DIAGNOSTIC_TEST|Infectious Disease Testing|Participants will undergo infectious disease testing.
219035289|NCT05829928|PROCEDURE|Gonadal Tissue Removal|Removal of gonadal tissue will be done through a surgical procedure.
218895270|NCT01409876|RADIATION|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
218895271|NCT00002306|DRUG|Fluconazole|
218895272|NCT03030469|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
218895273|NCT04867746|OTHER|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
219515674|NCT03066999|PROCEDURE|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
219515675|NCT03066999|DEVICE|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
219515676|NCT00661999|BIOLOGICAL|darbepoetin alfa|Given by injection
219515677|NCT00661999|DIETARY_SUPPLEMENT|ferrous sulfate|Given by mouth
219515678|NCT00661999|DRUG|sodium ferric gluconate complex in sucrose|Given by IV
219515679|NCT00661999|OTHER|placebo|Given by mouth
219515680|NCT06015048|DRUG|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
218895274|NCT04867746|OTHER|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
218895275|NCT04867746|OTHER|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 \* 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
218895276|NCT04867746|OTHER|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
218895277|NCT04867746|OTHER|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
218895278|NCT03316144|BIOLOGICAL|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
219203969|NCT05190211|OTHER|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
219515681|NCT06015048|DRUG|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
219515682|NCT01157390|OTHER|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage \& frequency: Fed as need Duration: at least 3 months
219515683|NCT01157390|OTHER|Breast feeding|Breast feeding
218895279|NCT04198480|DRUG|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
218895280|NCT03956550|DRUG|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
218895281|NCT03956550|DRUG|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
218895282|NCT00150267|DRUG|Xalacom|
219515684|NCT00510510|DRUG|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
219515685|NCT00510510|DRUG|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
219515686|NCT00510510|DRUG|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
219515687|NCT01938482|DRUG|0.3% GSK1940029 gel|Will be supplied as gel for topical application
218895283|NCT00006591|DRUG|Ritonavir|
218895284|NCT00006591|DRUG|Amprenavir|
218895285|NCT02776111|OTHER|Blood Sample|A one time blood sample will be provided.
219515688|NCT01938482|DRUG|1% GSK1940029 gel|Will be supplied as gel for topical application
219515689|NCT01938482|DRUG|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
219515690|NCT02294812|BEHAVIORAL|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
219515691|NCT03595657|BIOLOGICAL|CS1001|monoclonal antibody
219515692|NCT00654264|PROCEDURE|Water immersion|Subjects will sit in tub for four hours.
219515693|NCT04790851|BIOLOGICAL|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
219515694|NCT04790851|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
219515695|NCT04790851|BIOLOGICAL|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
219515696|NCT00939445|PROCEDURE|Online HDF|Online HDF
219515697|NCT00939445|PROCEDURE|Short Daily Hemodialysis|Short Daily Hemodialysis
219515698|NCT06380946|BIOLOGICAL|iPRF|iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
219611079|NCT00548613|BIOLOGICAL|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
218895286|NCT01574508|DRUG|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
218895287|NCT01574508|DRUG|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
218895288|NCT01372969|DRUG|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
218895289|NCT00984308|PROCEDURE|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
218895290|NCT05768412|PROCEDURE|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
218895291|NCT00172263|PROCEDURE|blood sampling|
218895292|NCT03965494|DRUG|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
218895293|NCT03965494|DRUG|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
218895294|NCT00592904|DRUG|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
218895295|NCT04881617|BEHAVIORAL|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
218895296|NCT04881617|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
218895297|NCT02089594|DRUG|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
218895298|NCT02089594|DRUG|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
218895299|NCT02686385|DRUG|Prednisolone|
218895300|NCT02686385|DRUG|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
218895301|NCT04012580|BEHAVIORAL|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
218895302|NCT06149455|OTHER|Duration of antibiotics|Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
218895303|NCT03706443|OTHER|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
218895304|NCT03706443|OTHER|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
219515699|NCT06318858|DIETARY_SUPPLEMENT|Iron supplement|Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
219515700|NCT05478993|DRUG|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
219035290|NCT05409118|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
219035291|NCT05409118|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
219515701|NCT04263870|DRUG|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
219515702|NCT03384745|DRUG|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
219515703|NCT03384745|DRUG|Placebo|Placebo contains no active drug.
219515704|NCT03384745|DRUG|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
219515705|NCT01924390|DEVICE|Mineralized freeze-dried bone allograft alone|
219515706|NCT01924390|DEVICE|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
219515707|NCT02984683|DRUG|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
219515708|NCT04050488|DRUG|Zinc Sulfate|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
218895305|NCT02056795|DEVICE|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
219515709|NCT04050488|DRUG|Placebos|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
219515710|NCT04240483|OTHER|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
219515711|NCT04240483|OTHER|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
219515712|NCT04950283|DIAGNOSTIC_TEST|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
219515713|NCT01499121|DRUG|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop \> grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
219515714|NCT01847183|BEHAVIORAL|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
219515715|NCT01015430|DRUG|Placebo (for RO4917523 ascending doses)|Placebo daily po
219611080|NCT00307086|DRUG|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
219611081|NCT00307086|DRUG|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
219611082|NCT00307086|PROCEDURE|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
219515716|NCT01015430|DRUG|Placebo (for RO4917523 fixed dose)|Placebo daily po
219515717|NCT01015430|DRUG|RO4917523|RO4917523 ascending doses daily po
219515718|NCT01015430|DRUG|RO4917523|RO4917523 fixed dose daily po
219611083|NCT06354517|OTHER|SENSE group|Parents of babies in this group will be given SENSE program training. After the training, parents will care for their babies within the scope of the SENSE program. These babies will receive care from their parents with positive sensory exposures within the scope of the SENSE program from admission to the clinic until discharge. Data collection forms will be administered to babies and their parents.
219611084|NCT02263963|DRUG|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
219611085|NCT02263963|PROCEDURE|TAP Block|no intervention will be done to this arm.
219611086|NCT00327418|DRUG|Atorvastatin|
219611087|NCT00890617|PROCEDURE|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
219611088|NCT00890617|DRUG|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
219035292|NCT03369210|DRUG|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
219035293|NCT02722447|DRUG|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
219035294|NCT02722447|DRUG|Placebo|Placebo for 6 weeks
219035295|NCT06610448|DEVICE|ABPMPro|This is an upper arm, cuff-based intermittent ambulatory BP device. This device has an internal activity and body position sensor which gathers information about sleep-wake estimation.
219035296|NCT06610448|DEVICE|Spacelabs Ambulatory Blood Pressure Monitoring|This is an upper arm cuff-based device with tubing for continuous ambulatory BP monitoring with a unique activity sensor that correlate with patient movement activity with blood pressure changes.
219515719|NCT05169164|OTHER|No intervention, observational|No intervention, observational
219515720|NCT03008460|DRUG|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
219515721|NCT03008460|DRUG|Klean-Prep®|Oral solution taken the evening before the colonoscopy
219611089|NCT04943133|DEVICE|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
218895306|NCT02056795|DEVICE|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
218895307|NCT01860833|DRUG|Ibuprofen|time of treatment 14 days
218895308|NCT01860833|DRUG|Celecoxib|time of treatment 14 days
218895309|NCT01860833|DRUG|Diclofenac|time of treatment 14 days
218895310|NCT02939586|PROCEDURE|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
218895311|NCT02939586|PROCEDURE|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
218895312|NCT06106802|DRUG|Lazertinib|Lazertinib 240mg/day
219515722|NCT04479657|DRUG|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
219515723|NCT04479657|DRUG|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
219515724|NCT04555525|DRUG|sarecycline|sarecycline tablet
219515725|NCT04555525|DIETARY_SUPPLEMENT|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
218895313|NCT06106802|DRUG|Tepotinib|Tepotinib 500mg/day
218895314|NCT04688749|DIAGNOSTIC_TEST|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
218895315|NCT00302341|DRUG|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
218895316|NCT00302341|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
218895317|NCT05912764|OTHER|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
218895318|NCT06129279|OTHER|EFT group|"Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed."
219035297|NCT06610448|DEVICE|Aktiia Blood Pressure|This is a wrist cuff-based device which uses an optical sensor (photoplethysmography sensor) to gather data from the arteries under the skin surface. Aktiia has an upper arm cuff device which is used for calibration once every month to provide a baseline blood pressure reading.
219035298|NCT06610448|DEVICE|LiveMetric|This is a wrist cuff-based applanation tonometry continuous ambulatory BP device. This device has automatic self-calibration and comes in various sizes.
219035299|NCT06610448|DEVICE|Bpro|This is a wrist cuff-based wireless oscillometric, continuous ambulatory BP device. It has applanation tonometry at the wrist with Pulse wave analysis. This device needs calibration with a brachial cuff BP measurement.
219515726|NCT06382181|BEHAVIORAL|Music therapy for community-dwelling individuals with unwanted loneliness|Music therapy workshops were implemented. The enjoyment and expression of feelings were encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. There was one session per week. Total 12 sessions.
219515727|NCT06382181|BEHAVIORAL|Health education for community-dwelling individuals with unwanted loneliness|Twelve health education workshops were carried out. They included group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others.
218895319|NCT04168658|COMBINATION_PRODUCT|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
218895320|NCT04168658|BEHAVIORAL|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
218895321|NCT01361646|DRUG|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
218895322|NCT05291793|DRUG|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
218895323|NCT05291793|DRUG|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
218895324|NCT05291793|DRUG|Saline|2ml sterile saline administered intraarticularly
219611090|NCT04943133|DEVICE|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
219611091|NCT04943133|DEVICE|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
219611092|NCT01870778|DRUG|RLX030|1 mg/mL solution in 6 mL vials
219611093|NCT01870778|DRUG|Placebo|Matching placebo solution to serelaxin
219611094|NCT05782777|DRUG|ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
218895325|NCT02408133|OTHER|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
218895326|NCT03992079|PROCEDURE|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
218895327|NCT02339753|DRUG|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
218895328|NCT01433016|DRUG|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
219035300|NCT06991296|DIETARY_SUPPLEMENT|SPM Active®|Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).
219515728|NCT06382181|BEHAVIORAL|Physical exercise for community-dwelling individuals with unwanted loneliness|This intervention was implemented with 2 group sessions each week for 13 weeks. It included physical exercise adapted to the physical conditions of each participant.
219611095|NCT05782777|DRUG|high-intensity statin monotherapy (atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
219611096|NCT01304056|DEVICE|Ventilatory therapy|
219611097|NCT03809689|OTHER|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
219611098|NCT03809689|DIAGNOSTIC_TEST|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
218895329|NCT03369418|DEVICE|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
218895330|NCT03369418|DEVICE|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
218895331|NCT01094678|DEVICE|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
219611099|NCT00258726|BIOLOGICAL|MMR-II|
219611100|NCT00258726|BIOLOGICAL|Pro-Quad|
219611101|NCT00258726|BIOLOGICAL|Varivax|
219611102|NCT03881293|DRUG|lidocaine 2% gel|Transurethral instillation of 5 ml lidocaine 2% gel
218895332|NCT01485094|DRUG|GRT6010|Oral solution given once daily.
218895333|NCT01485094|DRUG|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
218895334|NCT01485094|DRUG|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
218895335|NCT02702466|OTHER|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
218895336|NCT04955457|OTHER|Healthy women active teachers|The neuropsychological testing data, psychometric measure, demographic, clinical and lifestyle information and blood samples were collected at similar time points. This group not received any intervention.
219515729|NCT04986696|DEVICE|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
219515730|NCT02153047|BEHAVIORAL|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
219515731|NCT04947579|DRUG|CC-99677|Oral
219515732|NCT04947579|OTHER|Placebo|Oral
219611103|NCT03881293|DRUG|water soluble lubricant|Transurethral instillation of 5 ml water soluble lubricant
219611104|NCT03308214|DRUG|Imipenem|Imipenem 1.0 q 8h
219611105|NCT00312338|DRUG|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
219611106|NCT02292693|DEVICE|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
219611107|NCT02292693|DEVICE|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
219611108|NCT02292693|DEVICE|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
219611109|NCT02960009|DEVICE|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
219611110|NCT04968613|DRUG|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
219611111|NCT04968613|DRUG|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
219611112|NCT04968613|DRUG|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
219611113|NCT00262028|BIOLOGICAL|MenACWY-CRM Vaccine|
219611114|NCT00262028|BIOLOGICAL|MenACWY-PS Vaccine|
219611115|NCT05148221|OTHER|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
219611116|NCT05148221|OTHER|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
219611117|NCT04708704|DIETARY_SUPPLEMENT|Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
219611118|NCT04708704|DIETARY_SUPPLEMENT|SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
219611119|NCT04708704|DIETARY_SUPPLEMENT|Iodine, prepared in drinking water 0.075 mg/kg bw/day)|Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
219515733|NCT05720533|DRUG|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
219515734|NCT02381509|DEVICE|IVC Filter|
219515735|NCT04223050|DRUG|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
219515736|NCT00046813|DRUG|Nicotine patch|
219515737|NCT04272021|DRUG|Methylphenidate|standard therapy for ADHD
219515738|NCT05796609|OTHER|Driving under the influence of alcohol|"Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
219611120|NCT01679990|BIOLOGICAL|PLX-PAD Low dose|
219611121|NCT01679990|BIOLOGICAL|PLX-PAD high doses|
219611122|NCT01679990|BIOLOGICAL|Double Placebo|
219611123|NCT01679990|BIOLOGICAL|high dose +Placebo|
219611124|NCT00564512|BIOLOGICAL|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
219611125|NCT00564512|BIOLOGICAL|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
219611126|NCT00564512|DRUG|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
219611127|NCT00564512|DRUG|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
219611128|NCT02248987|OTHER|patients treated with antipsychotics|
219515739|NCT05796609|OTHER|Driving under the influence of a placebo|"Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
219515740|NCT03769480|OTHER|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
219515741|NCT04915807|DRUG|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
219515742|NCT04915807|DRUG|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
219515743|NCT01575054|BIOLOGICAL|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
219515744|NCT01575054|DRUG|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
219515745|NCT01566409|DRUG|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
219515746|NCT01566409|OTHER|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
219515747|NCT05777213|BIOLOGICAL|Secretome|The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
219203970|NCT05190211|OTHER|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
219515748|NCT04897698|DIETARY_SUPPLEMENT|LB001|Probiotics
219515749|NCT04666766|DEVICE|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
219515750|NCT00395707|DRUG|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
219515751|NCT00395707|DRUG|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
219515752|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
219515753|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.5mg/0.05 ml
219515754|NCT02958215|DRUG|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
219515755|NCT02958215|OTHER|Placebo|5 ml normal saline will be given before spinal anesthesia
219515756|NCT04689074|OTHER|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
219515757|NCT04689074|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219515758|NCT04689074|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
219515759|NCT04474938|DRUG|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
219515760|NCT04474938|DRUG|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
219515761|NCT04474938|DRUG|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
219515762|NCT00764309|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
219515763|NCT03502642|DEVICE|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
219515764|NCT03502642|PROCEDURE|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
219515765|NCT03502642|DRUG|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
219515766|NCT03502642|DRUG|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
219515767|NCT03502642|DRUG|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
219203971|NCT06972771|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Clinical specimens will be incubated with TTP-ICG with different concentrations and times.
219515768|NCT01179490|DRUG|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
219515769|NCT01179490|DRUG|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
219515770|NCT00001683|DRUG|COL-3|
219515771|NCT02676154|DRUG|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
219515772|NCT00462982|DRUG|sunitinib malate|
219515773|NCT03958825|PROCEDURE|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
219611129|NCT06367985|OTHER|Air Oxygen Concentration CAPA-IVM culture|"* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
219611130|NCT06367985|OTHER|Low Oxygen Concentration CAPA-IVM culture|"* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
219611131|NCT03354715|DEVICE|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
218895337|NCT05048173|PROCEDURE|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
218895338|NCT05048173|PROCEDURE|Lymphadenectomy|Conventional lymphadenectomy
218895339|NCT03064646|OTHER|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
218895340|NCT02564133|DEVICE|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
218895341|NCT01064934|PROCEDURE|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
219515774|NCT03958825|PROCEDURE|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
218895342|NCT01064934|OTHER|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
218895343|NCT05491408|DEVICE|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure \[4,5\].
218895344|NCT04899622|BEHAVIORAL|MBSR|Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
218895345|NCT04899622|BEHAVIORAL|Exercise|"Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises."
218895346|NCT04899622|BEHAVIORAL|Online Self-Management Guide|Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
218895347|NCT05045261|DRUG|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
218895348|NCT05045261|DRUG|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
219515775|NCT00004584|DRUG|Atazanavir|
219611132|NCT03354715|DEVICE|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
219611133|NCT06357585|OTHER|Web based education|Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
219611134|NCT06357585|OTHER|inactive group|Parents in the control group will continue to receive routine care and treatment.
219611135|NCT00207519|BEHAVIORAL|weekly behavioral modification group|
219611136|NCT00207519|BEHAVIORAL|liquid meal replacements|
219611137|NCT03333434|DEVICE|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
219611138|NCT03333434|DEVICE|Hinged AFO|
219611139|NCT04350411|DEVICE|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
218895349|NCT03445884|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
219515776|NCT00004584|DRUG|Ritonavir|
219515777|NCT00004584|DRUG|Saquinavir|
219515778|NCT03604887|DIAGNOSTIC_TEST|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
219515779|NCT07076056|DRUG|DW1026C1|Sitagliptin 100mg+Empagliflozin 10mg
219611140|NCT04350411|DEVICE|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
219515780|NCT07076056|DRUG|DW1026C2|Sitagliptin 100mg+Empagliflozin 25mg
219515781|NCT07076056|DRUG|DW1026S|Sitagliptin 100mg
219515782|NCT00002637|BIOLOGICAL|aldesleukin|
219515783|NCT00002637|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
219515784|NCT00002637|BIOLOGICAL|recombinant interferon gamma|
219515785|NCT02683187|DRUG|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
219515786|NCT02683187|DRUG|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
219515787|NCT00770315|BIOLOGICAL|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
219515788|NCT00770315|BIOLOGICAL|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
219515789|NCT02585258|DRUG|Prednisolone|1 capsule containing a tablet of 5 mg prednisolone/ day
219515790|NCT02585258|DRUG|Placebo|1 capsule containing a placebo tablet / day
219515791|NCT02398461|DRUG|rHIgM22|Administered via IV infusion
219515792|NCT02398461|DRUG|Placebo|
219515793|NCT03735758|DRUG|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
219515794|NCT01919190|DRUG|EXPAREL|TAP with EXPAREL
219515795|NCT01919190|DRUG|Placebo|Placebo
219515796|NCT00026936|PROCEDURE|Radiotherapy|
219515797|NCT02322047|DRUG|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
219515798|NCT02322047|DRUG|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
219515799|NCT02322047|DRUG|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
219515800|NCT02322047|DRUG|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
219515801|NCT02213796|DRUG|Meropenem|
219515802|NCT03830645|BIOLOGICAL|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
219515803|NCT02207231|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
219515804|NCT02207231|DRUG|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
219515805|NCT02207231|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
219515806|NCT02207231|DRUG|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
219515807|NCT02954757|PROCEDURE|HIFU treatment|High intensity focused ultrasound
219515808|NCT01897974|OTHER|Survey|Families complete survey to measure medication compliance.
219515809|NCT03990675|PROCEDURE|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
219515810|NCT03937063|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
219515811|NCT04637997|DEVICE|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
219515812|NCT04637997|DEVICE|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
219515813|NCT04957108|OTHER|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
219515814|NCT05054868|DRUG|Oxycodone|Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).
219515815|NCT05054868|DRUG|Ketorolac|Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
219515816|NCT04808089|OTHER|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
219515817|NCT04808089|OTHER|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
219515818|NCT03803410|PROCEDURE|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
219515819|NCT05497414|BEHAVIORAL|Sleep deprivation|Overnight sleep deprivation.
219515820|NCT04879810|PROCEDURE|Sigmoidoscopy and biopsy, blood work|Flexible tube up lower colon, blood draws, quality of life questionnaires
218895350|NCT05104307|DEVICE|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
218895351|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
219515821|NCT05102175|OTHER|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
219515822|NCT03501875|RADIATION|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
219515823|NCT01083875|DRUG|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
219515824|NCT01083875|DRUG|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
219515825|NCT03492359|DEVICE|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
219515826|NCT03492359|DEVICE|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
219515827|NCT03492359|DEVICE|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
219515828|NCT05224895|PROCEDURE|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
219515829|NCT04518774|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
219515830|NCT06409962|OTHER|Technological combination|The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
219515831|NCT03392974|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
219515832|NCT01963039|DEVICE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
219515833|NCT01963039|PROCEDURE|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
219515834|NCT05140096|DRUG|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
219515835|NCT05140096|DRUG|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
219611141|NCT06861478|DRUG|Omeprazol 40 mg IV|Daily until discharge
219515836|NCT05140096|DRUG|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
219515837|NCT03006016|DRUG|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
219611142|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
219611143|NCT03622424|DEVICE|Gelesis200|Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)
219611144|NCT03622424|DEVICE|Placebo|Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)
218895352|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
218895353|NCT00556907|RADIATION|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
218895354|NCT00556907|DEVICE|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
218895355|NCT01284517|DRUG|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
218895356|NCT01284517|DRUG|Placebo|Equivalent to Lurasidone dosing
218895357|NCT03626792|OTHER|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
218895358|NCT03626792|OTHER|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
218895359|NCT01677325|DRUG|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
219515838|NCT03006016|OTHER|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
219515839|NCT02879279|DEVICE|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
219611145|NCT03622424|DEVICE|Gelesis200 and Placebo|Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
219611146|NCT05510284|OTHER|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
219611147|NCT01738451|DRUG|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
219611148|NCT01738451|DRUG|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
219611149|NCT00530205|OTHER|physiologic testing|
219611150|NCT00530205|OTHER|questionnaire administration|
219611151|NCT00530205|PROCEDURE|management of therapy complications|
219203972|NCT05988398|BEHAVIORAL|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
219515840|NCT02879279|OTHER|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
219515841|NCT00996190|DRUG|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
219515842|NCT04535908|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
219611152|NCT00530205|RADIATION|radiation therapy|
218895360|NCT04504981|BEHAVIORAL|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
218895361|NCT03686904|DRUG|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
218895362|NCT03686904|OTHER|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
218895363|NCT03686904|PROCEDURE|Debridement|Removing dead tissue from infected wound (in clinic)
219611153|NCT04201197|DRUG|Inje cocktail|Acute drug exposure
219611154|NCT04201197|DRUG|THC Cannabis extract|Acute drug exposure
218895364|NCT03686904|DRUG|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
218895365|NCT03686904|OTHER|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
218895366|NCT04457765|DRUG|Povidone-Iodine (PVP-I)|1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
218895367|NCT00040443|DRUG|CX516|
218895368|NCT00040443|DRUG|Placebo|
218895369|NCT01759043|PROCEDURE|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
219611155|NCT04201197|DRUG|THC/CBD Cannabis Extract|Acute drug exposure
219611156|NCT06530797|DRUG|First-line Adebrelimab regiment for advanced stage ES-SCLC|First-line Adebrelimab in any regiment for advanced stage ES-SCLC
219611157|NCT06530797|DRUG|Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC|Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
219611158|NCT00786409|BIOLOGICAL|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
219611159|NCT00031148|DRUG|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
219611160|NCT00610129|DRUG|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
219611161|NCT02216097|DRUG|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
219611162|NCT02216097|DRUG|Placebo|Matching placebo tablet taken once daily for 7 days.
219515843|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
219515844|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
219515845|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
219515846|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
219515847|NCT05014308|PROCEDURE|Piezoelectric Alveolar Decortication, fibrotomy|
219515848|NCT03942523|BEHAVIORAL|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
219611163|NCT02449278|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
219611164|NCT02449278|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
219611165|NCT02449278|DRUG|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
219611166|NCT02449278|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
219611167|NCT02449278|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy
219611168|NCT02449278|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy
219611169|NCT07007702|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-Acetyl Aspartyl Glutamic Acid
219611170|NCT07011121|BEHAVIORAL|CenteringPregnancy|. CenteringPregnancy, a group prenatal care model, is a promising alternative that challenges the standard model of one-on-one prenatal counseling. Previous research has documented that group prenatal care is associated with a lower prevalence of preterm birth and low birth weight infants. 18,39 Group prenatal care also has been associated with improved maternal mental health, breastfeeding, optimal pregnancy weight gain, improved postpartum weight loss, better birth spacing, and higher patient satisfaction. 18,39 All participants will attend routine one-on-one prenatal appointments prior to the intervention. The sessions occur from week 14 of pregnancy through birth with women of similar gestational age, following the same schedule as standard care. Once the groups of women are formed (5 per group), the participants attend all appointments together for the duration of their pregnancies. Mobile health clinic located at FBOs will provide a location for providers to provide brief one-on-
219611171|NCT04400539|DEVICE|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
219611172|NCT04400539|DRUG|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
219515849|NCT03365323|OTHER|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
219515850|NCT03365323|OTHER|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
219515851|NCT03643666|DRUG|dexamethasone|before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
219515852|NCT03643666|DRUG|magnesium sulphate|patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
219515853|NCT03643666|DRUG|Placebo (saline)|before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
219515854|NCT01751152|DRUG|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
219515855|NCT01751152|DRUG|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
219515856|NCT00655642|DRUG|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
219515857|NCT00655642|DRUG|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
219515858|NCT00655642|DRUG|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
219515859|NCT00655642|DRUG|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
218895370|NCT01759043|PROCEDURE|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
219035301|NCT06340737|DRUG|CD22CART Infusion|Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
219035302|NCT04449432|BEHAVIORAL|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
219035303|NCT04449432|BEHAVIORAL|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
219035304|NCT04477304|BEHAVIORAL|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
219035305|NCT04477304|BEHAVIORAL|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
219035306|NCT04477304|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
219035307|NCT06995430|BIOLOGICAL|rMenB+OMV NZ vaccine|1 dose in the Primed group or 2 doses in the Naive group.
219035308|NCT02795195|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (51GyE, 54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. And the started dose level will be 54GyE. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study.
219035309|NCT07004686|DEVICE|MGRNOX index-guided analgesia|After anesthesia induction, the remifentanil plasma target concentration was adjusted intraoperatively to maintain the MGRNOX index between 30 and 50,but MAP and HR also were considered .In case the MGRNOX index was below 30 for more than 1 minute, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml , whereas in case of a value greater than 50 for more than 1 minute, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.
219035310|NCT07004686|DEVICE|Standard Clinical Care|After anesthesia induction, if hypertension (MAP \> 100 mmHg) or tachycardia (heart rate \> 90 bpm) persists for more than 2 minutes, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.If there is no response to remifentanil or the MAP and HR exceed a certain threshold, then urapidil or esmolol will be administered.For hypotension (50 mmHg \< MAP ≤ 60 mmHg) persisting for more than 2 minutes, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml (lowest target plasma concentration that was allowed is 1 ng/ml), and 4μg of norepinephrine were given. If MAP ≤ 50 mmHg, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml(lowest target plasma concentration that was allowed is 1 ng/ml), and 8μg of norepinephrine were given.
219035311|NCT07108608|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings. Further, the investigators have adapted WET for this setting based on stakeholder and expert feedback.
219515860|NCT02016300|DEVICE|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
219515861|NCT02016300|DEVICE|Non-Bracing|Microfracture performed with no post-operative unloader bracing
219515862|NCT05495542|OTHER|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects \[5\]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered \[6\]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory \[7\]
218895371|NCT00170872|DRUG|Lumiracoxib|
218895372|NCT03129867|DRUG|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
219515863|NCT04396028|OTHER|data collection|retrospective data collection
219515864|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA fingerstick point of care assay|Xpert® HBV DNA point of care assay from finger-stick whole blood
219515865|NCT04289428|DIAGNOSTIC_TEST|Point of Care ALT|Point of Care ALT from finger-stick whole blood
219515866|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA point of care assay from dried blood spot|Xpert® HBV DNA point of care assay from dried blood spot
218895373|NCT01020786|DRUG|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
218895374|NCT01020786|DRUG|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
219515867|NCT02103283|DRUG|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
218895375|NCT00269672|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
218895376|NCT06185517|DIAGNOSTIC_TEST|Questionnaire translation and validation|Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
218895377|NCT02366351|DRUG|SHR3824|Once daily, 12 weeks
218895378|NCT02366351|DRUG|Placebo|Once daily, 12 weeks
218895379|NCT02058953|PROCEDURE|Craniotomy scheduled|Resection of affected brain tissue
218895380|NCT02058953|PROCEDURE|Collection for non-craniotomy|CSF, Blood, biopsy
219515868|NCT00665041|DRUG|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
219515869|NCT06165744|DEVICE|UNITY Vitreoretinal Cataract System|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY TOTAL PLUS Combined Procedure Pak, and additional devices as needed to complete surgery
219515870|NCT06165744|PROCEDURE|Posterior segment surgery in the operating room with or without simultaneous cataract surgery|Posterior segment surgery involves removal of the vitreous (i.e., vitrectomy) followed by additional interventions as needed. Cataract surgery involves removal of the crystalline lens (which is often cloudy).
219515871|NCT06211491|OTHER|Urodynamic test|Urodynamic testing is performed using saline solution at the same temperature as body temperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min, respectively.
219515872|NCT01096927|DRUG|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
219515873|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose
219515874|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
219515875|NCT01056874|DRUG|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
218895381|NCT05189548|BIOLOGICAL|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
218895382|NCT02959593|DEVICE|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
218895383|NCT05792813|DRUG|LGYY|LGYY = Linggui Yangyuan paste
219515876|NCT04997694|PROCEDURE|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
218895384|NCT05792813|DRUG|LGYY mimetic|LGYY = Linggui Yangyuan paste
218895385|NCT05792813|DRUG|WZYZ|WZYZ= Wuzi Yanzong oral solution
218895386|NCT05792813|DRUG|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
219035312|NCT07108608|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
219035313|NCT07109310|DIAGNOSTIC_TEST|RTImodel001|This model was developed through transcriptome sequencing combined with machine learning to predict the risk of disease progression and clinical outcomes of respiratory tract infections
219035314|NCT07109323|DRUG|BCMA CART|Bcma-cart was reinfused at a dose of 1.0-2.0 × 10 \^ 6 / kg on day +3 (± 1 day) after autologous hematopoietic stem cell reinfusion.
219035315|NCT06867484|RADIATION|Intensity modulated radiation therapy (IMRT)|40 Gy total in 15 consecutive weekday sessions to the partial breast
219611173|NCT00707616|OTHER|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
218895387|NCT00115440|RADIATION|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
218895388|NCT05470335|PROCEDURE|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
218895389|NCT00000526|DRUG|encainide|
218895390|NCT00000526|DRUG|flecainide|
218895391|NCT00000526|DRUG|moricizine|
218895392|NCT02537249|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
218895393|NCT02537249|DRUG|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
218895394|NCT05616923|DRUG|Trametinib|Topical cream containing 0.1 mg/g trametinib
219035316|NCT04866771|OTHER|Transcranial Direct Current Stimulation (tDCS)|Noninvasive brain stimulation
219515877|NCT03244774|DRUG|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
219515878|NCT03244774|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
219515879|NCT05456529|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
219515880|NCT02687048|BEHAVIORAL|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
219611174|NCT04640415|DEVICE|Active Alarms|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
218895395|NCT01165541|DRUG|Mirtazapine|mirtazapine (7.5-45mg)
218895396|NCT01165541|DRUG|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
219035317|NCT04866771|OTHER|Sham tDCS + anodal tDCS|Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
218895397|NCT06217107|BEHAVIORAL|Micro-learning content|This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
218895398|NCT06217107|BEHAVIORAL|Health360x app|The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
218895399|NCT06217107|BEHAVIORAL|Culturally congruent coaching|The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
218895400|NCT02289664|DEVICE|MAC|Direct-Laryngoscopy
219515881|NCT02687048|BEHAVIORAL|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
219515882|NCT00797108|DRUG|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
219515883|NCT00797108|DRUG|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
219515884|NCT00797108|DRUG|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
219515885|NCT03901014|OTHER|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
219515886|NCT03901014|OTHER|Very low carbohydrate diet|Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
219515887|NCT02518113|DRUG|LY3039478|Administered orally
219515888|NCT02518113|DRUG|Dexamethasone|Administered orally
219515889|NCT02518113|DRUG|Placebo|Administered orally
219515890|NCT04384549|BIOLOGICAL|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
219515891|NCT04384549|OTHER|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
219515892|NCT01785836|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
219515893|NCT01785836|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
219515894|NCT01785836|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
219515895|NCT01785836|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
218895401|NCT02289664|DEVICE|Coopdech|Video-Laryngoscopy -1
218895402|NCT02289664|DEVICE|CoPilot|Video-Laryngoscopy -2
218895403|NCT02289664|DEVICE|Intubrite|Video-Laryngoscopy -3
218895404|NCT05404087|DEVICE|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
218895405|NCT04072913|OTHER|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
218895406|NCT00138593|DRUG|vildagliptin|
218895407|NCT00130858|DRUG|Topotecan|
218895408|NCT00130858|DRUG|Carboplatin|
218895409|NCT03705052|OTHER|Questionnaire|Patients and caregivers were asked to complete a questionnaire
219035318|NCT07009951|DEVICE|Virtual reality|VR headset provides an immersive environment, such as natural landscapes accompanied by relaxing music. The use of VR will begin at least five minutes before the start of the procedure to allow the patient to acclimate. The headset will remain in use throughout the entire procedure, unless complications arise (e.g., nausea or significant discomfort).
219515896|NCT02349165|PROCEDURE|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
219515897|NCT02349165|DRUG|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
219515898|NCT02349165|DRUG|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
219515899|NCT02270736|DRUG|NT 201 Placebo|NT 201 placebo matching injection.
219515900|NCT02270736|DRUG|NT 201|NT 201 injection.
219515901|NCT03622866|DEVICE|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
219515902|NCT03622866|DEVICE|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
219515903|NCT04726202|OTHER|Standard procedure|Coding of cases follows the standard procedures established at the hospital
219515904|NCT04726202|OTHER|precoding|"Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report."
219515905|NCT01631864|DRUG|LCZ696|LCZ696 was provided as 400 mg tablets.
219611175|NCT07017920|DIAGNOSTIC_TEST|Vitamin D Levels measurement|Patient will have a vitamin D level drawn with their other prenatal labs during an OB visit. If vitamin D insufficiency (less than 30 ng/mL) or deficiency (less than 20 ng/mL) is detected, the patient will be prescribed and provided a supplementation of 2000 IU of vitamin D daily for the remainder of the pregnancy.
219611176|NCT07018427|DRUG|Sacituzumab Govitecan Monotherapy or Combination Therapy|The interventions in this study comprised either Sacituzumab Govitecan monotherapy or combination therapy. The specific combination regimens were determined based on real - world clinical practice patterns.
219611177|NCT07017738|OTHER|Corrective exercises|The corrective exercise program will include various positions: in standing, scapular retraction and arms overhead; in sitting, chin tuck and thoracic extension; in supine, arms in a W shape and horizontal abduction with external rotation; in side-lying, forward flexion starting with arms parallel to the body; and in prone, scapular retraction and depression in a T shape, extension from 90° forward flexion, and horizontal abduction at 90° with external rotation. Exercises will start with three repetitions held for 10 seconds and progress to six repetitions held for 25 seconds, based on overload principles and individual needs. Participants experiencing pain may stop and rest until symptoms subside.
218895410|NCT03512834|DRUG|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
218895411|NCT03512834|DRUG|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
219515906|NCT01631864|DRUG|amlodipine|amlodipine was provided as 5 mg tablets.
219515907|NCT01631864|DRUG|Placebo|Matching placebo to LCZ696 and amlodipine.
219515908|NCT03130764|DRUG|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
219515909|NCT03130764|DRUG|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
219515910|NCT00265733|DRUG|capecitabine|
219515911|NCT00265733|DRUG|paclitaxel poliglumex|
218895412|NCT02745171|OTHER|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
218895413|NCT03912012|DRUG|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
219035319|NCT07023978|OTHER|Some movements in the qigong study called Ba Duan Jin, which will be applied to pregnant women, will be arranged for pregnant women and explained in detail. These are very slow, movements|Ba Duan Jin Qigong
219515912|NCT05625256|DEVICE|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
219515913|NCT02134756|DRUG|NutraStem Active|
219515914|NCT02134756|DRUG|NutraStem Placebo|
219515915|NCT03443778|DRUG|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
219515916|NCT03443778|DRUG|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
219515917|NCT03443778|DRUG|Nacl 0,9 %|Injectable Solution
219515918|NCT04066309|DEVICE|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
219515919|NCT04066309|DEVICE|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
219515920|NCT04066309|DEVICE|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
219515921|NCT04066309|DEVICE|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
218895414|NCT03912012|DEVICE|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
219515922|NCT00952783|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
219515923|NCT03650777|OTHER|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
219515924|NCT02792205|OTHER|Non interventional study|no intervention
219515925|NCT03602768|BEHAVIORAL|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
219515926|NCT03602768|BEHAVIORAL|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
219515927|NCT03602768|BEHAVIORAL|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
219515928|NCT02841774|DRUG|Pravastatin|40mg daily (Weeks 2 - 14)
219515929|NCT02841774|DRUG|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
218895415|NCT03912012|DEVICE|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
218895416|NCT03912012|BIOLOGICAL|Blood sampling|37 mL of blood sample will be performed at Day 1
218895417|NCT03912012|BIOLOGICAL|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
218895418|NCT03912012|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
219035320|NCT07022041|DIAGNOSTIC_TEST|conductivity and dieletric constant|collecting blood samples and directly measuring plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring.
218895419|NCT03912012|RADIATION|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
218895420|NCT02095470|DEVICE|video laryngoscope|newly developed innovatory device
219515930|NCT01434966|OTHER|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
219515931|NCT01434966|OTHER|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
219611178|NCT07017738|OTHER|Neural mobilization|Median nerve mobilization will be performed with the patient in a supine position, shoulder abducted to 90°, elbow flexed at 90°, and both wrist and head in a neutral position. The therapist will mobilize the nerve by extending the elbow to 45°, while the patient performs ipsilateral cervical lateral flexion to unload the nervous system.
219611179|NCT07012668|PROCEDURE|Interventional or surgical treatment|Simultaneous interventional or surgical treatment/staged interventional or surgical treatment
219611180|NCT07012668|PROCEDURE|Interventional or surgical treatment|Interventional or surgical treatment
219611181|NCT07018687|OTHER|day hospital|This multidisciplinary day hospital consists of 3 information workshops focused on balanced nutrition, oral nutritional supplements and enrichments as well as artificial feeding. During this day hospital, patients will meet with an endocrinologist nutritionist, a dietitian, and a teacher in adapted physical activity.
219611182|NCT07018687|OTHER|dietician consultation|dietician consultation
219611183|NCT07016737|DRUG|Sintilimab Combined With Docetaxel Monotherapy|79 patients will receive treatment with a PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w) combined with monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w) for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy (45-50.4 Gy/25-28/F/5-5.5 weeks) in conjunction with a dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw) for 5 cycles.
218895421|NCT02095470|DEVICE|traditional laryngoscope|traditional way for intubation
218895422|NCT06421584|DEVICE|Surgical telementoring|The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
218895423|NCT03787550|DRUG|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
219035321|NCT07027644|DEVICE|Dry Cupping Therapy|The patients receive dry cupping therapy for 10 min on the marked trigger point using a plastic set with a hand vacuum pump
219035322|NCT07027644|OTHER|Integrated Neuromuscular Inhibition Technique|The patients receive the Integrated Neuromuscular Inhibition Technique, which consists of ischemic compression, strain-counterstrain, and muscle energy techniques.
219035323|NCT07027644|OTHER|stretching and strengthening exercises|The patients receive stretching and strengthening exercises
219035324|NCT07027644|OTHER|combined integrated neuromuscular inhibition, dry cupping and stretching and strengthening exercises|the patients recive all the three interventions
219035325|NCT06687967|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
219035326|NCT06687967|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
219035327|NCT06007547|DRUG|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
219035328|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
219035329|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
219035330|NCT05142358|OTHER|Free Breath|Regular breathing
218895424|NCT05356832|DIAGNOSTIC_TEST|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
218895425|NCT05292716|DEVICE|MitraClip|MitraClip
219515932|NCT01434966|OTHER|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
218895426|NCT04637737|DEVICE|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
218895427|NCT04637737|BEHAVIORAL|Conventional therapy|The control group received the usual gait training.
218895428|NCT06263894|OTHER|Experimental group|Alexander technique will be applied to the experimental group.
219515933|NCT03305029|DRUG|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
219515934|NCT03409757|DRUG|Velphoro|4 weeks
218895429|NCT02598440|DRUG|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
218895430|NCT02598440|DRUG|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
219515935|NCT03409757|OTHER|saliva collection|2 samples
219515936|NCT03409757|OTHER|Supragingival biofilm collection|2 samples
219515937|NCT03409757|OTHER|stool collection|2 samples
219515938|NCT03409757|OTHER|blood collection|2 samples
218895431|NCT01314001|DRUG|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
218895432|NCT01314001|DRUG|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
218895433|NCT01314001|DRUG|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
218895434|NCT02485561|BEHAVIORAL|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
219035331|NCT06742736|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
219035332|NCT07058324|DIETARY_SUPPLEMENT|Prebiotic fiber|Chicory root-derived prebiotic fiber
218895435|NCT02485561|BEHAVIORAL|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
218895436|NCT04347863|OTHER|Group swallowing disorder diet preparation program|This program included food properties, select food, type of cooking, using thickener and tasting
219035333|NCT07058324|DIETARY_SUPPLEMENT|Placebo control|Maltodextrin
219035334|NCT01515527|DRUG|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
219035335|NCT01515527|DRUG|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
219515939|NCT05390346|BEHAVIORAL|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
219515940|NCT05364957|DEVICE|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
219515941|NCT05364957|PROCEDURE|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
219515942|NCT05364957|PROCEDURE|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
219515943|NCT04908748|DRUG|Esflurbiprofen Hydrogel Patch|Esflurbiprofen is a cyclooxygenase (COX) inhibitor
219515944|NCT03165448|DIAGNOSTIC_TEST|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
219515945|NCT03165448|DIAGNOSTIC_TEST|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
219515946|NCT03165448|DIAGNOSTIC_TEST|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
219515947|NCT03165448|DIAGNOSTIC_TEST|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
219515948|NCT04654104|OTHER|check immune check points|we will evaluate the expression of immune check points
219515949|NCT00757601|DRUG|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
218895437|NCT00082498|DRUG|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
218895438|NCT00082498|DRUG|Placebo|Patients in Group 1 will receive placebo.
218895439|NCT05694039|DEVICE|Hearing Aids|The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
218895440|NCT04048486|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
218895441|NCT04048486|OTHER|Physical development and General Health|Physical development and General health examination
218895442|NCT04048486|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
218895443|NCT01969006|DRUG|Marcaine ½%|
218895444|NCT01969006|PROCEDURE|Needle prick|
218895445|NCT01403493|BEHAVIORAL|Patient education|
218895446|NCT05184517|DRUG|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
218895447|NCT05184517|DRUG|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
219035336|NCT01515527|DRUG|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
219035337|NCT06682754|OTHER|Stress|All participants will perform a baseline test in which they will first be asked to visualize low-arousal IAPS images for three minutes while seated in a chair, and then get up, walk to a table with two bottles, transfer liquid from one bottle to the other, return to the starting chair and sit down again. Subsequently, they will perform an experimental test, where they will repeat the same movements as in the baseline test after visualizing high-arousal IAPS images for three minutes. In addition, IAPS images will continue to be projected in the background while participants perform the described motor tasks.
219515950|NCT00757601|DRUG|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
219515951|NCT01552096|DRUG|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
219515952|NCT04121390|BEHAVIORAL|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
219515953|NCT04639596|BEHAVIORAL|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
219515954|NCT00999869|DRUG|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
218895448|NCT03986203|DEVICE|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
218895449|NCT00671489|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
218895450|NCT01295593|DRUG|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
218895451|NCT02309008|DRUG|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
219035338|NCT07086235|DRUG|self-assembling peptide|According to the instructions of the manufacturer, the lesion will be treated with etch solution (Super Etch, SDI Ltd, Bayswater, Victoria, Australia) for 30 seconds to open up the pores to the subsurface lesion and subsequently will be washed and dried. Curodont Repair Fluoride Plus brush will be rehydrated with 0.05 ml of sterile water and a single drop of the resulting solution will be immediately applied to the lesion surface. Moisture control will be ensured until the Curodont Repair Fluoride Plus solution will be no longer visible (approximately two minutes).
219035339|NCT07086235|DRUG|S-PRG Barrier Coat|According to the instructions of the manufacturer, after mixing one drop of activator with base, a thin film coating will be applied to the WSL area then will be left undistributed for 3 seconds and finally will be light cured for 10 seconds using LED light-curing unit.
218895452|NCT02309008|OTHER|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
218895453|NCT03962179|DEVICE|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
219515955|NCT00999869|DRUG|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
219515956|NCT00102908|DRUG|Zoledronate|Zoledronate infusion
219515957|NCT00102908|DRUG|Zoledronate placebo|Zoledronate placebo infusion
219515958|NCT04359238|BEHAVIORAL|Individualized excercise|The participants in the intervention group carry out regularly endurance and strength exercises.
219515959|NCT06440655|DEVICE|Platelet rich plasma|Subjects were treated by Platelet rich plasma in each side of head (Left or right)
219515960|NCT06440655|DEVICE|Platelet rich fibrin|Subjects were treated by Platelet rich fibrin in each side of head (Left or right)
219515961|NCT02422823|DRUG|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
218895454|NCT02602522|DRUG|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
219515962|NCT02422823|DRUG|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
218895455|NCT02602522|DRUG|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
218895456|NCT06097663|DRUG|MAS825|Active MAS825 single dose
218895457|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
218895458|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
218895459|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
218895460|NCT02526277|DEVICE|MMF07 Foot Massager|
218895461|NCT02526277|DEVICE|Heat Therapy|
218895462|NCT02753946|DRUG|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
218895463|NCT02753946|DRUG|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
218895464|NCT00016497|PROCEDURE|bilateral myringotomy|
218895465|NCT00016497|PROCEDURE|bilateral myringotomy and tubes|
219515963|NCT02422823|DRUG|Epinephrine|
219515964|NCT00650936|DEVICE|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
219515965|NCT02464566|BEHAVIORAL|Intensive lifestyle intervention|
219515966|NCT02464566|OTHER|Health Education|
219515967|NCT03194464|OTHER|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
218895466|NCT00016497|PROCEDURE|adenoidectomy|
218895467|NCT06039709|COMBINATION_PRODUCT|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given \~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
218895468|NCT03074565|DEVICE|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
218895469|NCT03074565|DEVICE|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
218895470|NCT02519439|DRUG|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
218895471|NCT05054998|RADIATION|Fludeoxyglucose F-18|Given IV
219515968|NCT01764438|PROCEDURE|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
219515969|NCT01055964|DRUG|Tacrolimus|
219515970|NCT02791100|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
219515971|NCT03103100|DRUG|1% Lidocaine|10 mL of 1% lidocaine
218895472|NCT05054998|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
218895473|NCT05054998|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
218895474|NCT01126723|OTHER|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
218895475|NCT01126723|OTHER|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
219035340|NCT06902740|DRUG|Recaticimab and Statin|Recaticimab (450mg every 12 weeks subcutaneously) combined with rosuvastatin 10mg qn or atorvastatin 20mg qn
219515972|NCT03103100|DRUG|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
218895476|NCT04369313|PROCEDURE|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
218895477|NCT04369313|PROCEDURE|early cord clamping|umbilical cord clamping within 15 seconds after birth
218895478|NCT00837200|DRUG|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
218895479|NCT05897008|BIOLOGICAL|CMAB007|for subcutaneous injection only
218895480|NCT05897008|BIOLOGICAL|Xolair|for subcutaneous injection only
218895481|NCT05402514|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with subacromial shoulder pain consist of two daily distributed and progressively adaptable exercises there are delivered through the app as videos with subtitles. Patient education is provided 2-3 times per week as short lessons in the app with a quiz following the text to ensure that the information is properly understood by the patients. An individual physical therapist is assigned to each patient with compulsory telephone or video consultations at the start of the treatment, at 6 weeks and at 3 months. An asynchronous chat function with the physical therapist is available during the treatment period as well as a peer support chat.
219035341|NCT06902740|DRUG|Statin|Rosuvastatin 10mg qn or atorvastatin 20mg qn
219035342|NCT00209677|DRUG|Gemcitabine|
219035343|NCT00209677|DRUG|S-1|
219515973|NCT03103100|DRUG|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
219515974|NCT00842842|PROCEDURE|tack fixation of mesh|tack fixation of mesh
219515975|NCT00842842|PROCEDURE|glue fixation of mesh|glue fixation of mesh
219515976|NCT06330870|PROCEDURE|WGS/TME evaluation|WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
219515977|NCT00003399|DRUG|carmustine|
219515978|NCT00003399|DRUG|cisplatin|
219515979|NCT00003399|DRUG|cyclophosphamide|
219515980|NCT00003399|DRUG|dexamethasone|
219515981|NCT00003399|DRUG|etoposide|
219515982|NCT00003399|DRUG|melphalan|
219515983|NCT00003399|DRUG|paclitaxel|
219515984|NCT00003399|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219515985|NCT04502342|COMBINATION_PRODUCT|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
219515986|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
219515987|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
219515988|NCT05219227|OTHER|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~1. Static abdominal exercises:~2. Dynamic abdominal exercises:~   * Hip shrugging exercise from crook lying position:~  * Lateral flexion of the trunk from crook lying position:~  * Antero-posterior flexion of the trunk from crook lying position:"
219611184|NCT07016893|OTHER|Healthy aging interventions|In our study workshop activities conducted for eight weeks and included an Exercise Workshop (Music-Based Exercise Workshop, Exercise Training with Active Video Games (Exergaming), Clinical Pilates Training Workshop, Cognitive Exercise Therapy Approach Workshop, Nordic walking, dance therapy), Skill-Oriented Art Workshop (Systemic Calligraphy Therapy Workshop, soap-candle making workshop, culinary arts workshop), and Disease Awareness Studies (disease awareness information and education, the process from diagnosis to acceptance, experiences of patients and relatives, use of daily life technologies, home adjustments against falls, introduction of municipal services for the elderly).
219611185|NCT07018115|OTHER|Basic Preoperative Information|Participants receive a brief, non-detailed explanation of the surgical procedure.
219611186|NCT07018115|OTHER|Detailed Verbal Preoperative Information|Participants receive a detailed verbal explanation covering the surgical procedure, including anesthesia, incision, bone removal, tooth sectioning, and suturing.
219611187|NCT07018115|OTHER|Visual Preoperative Information (2D Animation)|Participants receive a 2D animated video illustrating the surgical procedure in addition to the detailed verbal explanation.
219611188|NCT07018115|DRUG|Articaine 4% with epinephrine 1:100,000|A local anesthetic solution (Ultracain D-S; Aventis) administered in a dose of 2 ml for all patients. The anesthetic was injected to achieve regional nerve block anesthesia (inferior alveolar, lingual, and buccal nerves) prior to the surgical extraction of impacted mandibular third molars. The solution contains epinephrine as a vasoconstrictor to prolong anesthetic effect and minimize intraoperative bleeding.
219611189|NCT07018115|PROCEDURE|Surgical extraction of impacted mandibular third molar|A standardized surgical protocol was followed for the removal of impacted mandibular third molars. All procedures were performed under local anesthesia using a mucoperiosteal flap approach. The surgery included a linear or triangular incision, elevation of the mucoperiosteal flap, ostectomy using rotary instruments as needed, and tooth sectioning in cases of difficult extraction. The socket was irrigated with sterile saline solution, and hemostasis was achieved. Wound closure was performed with 4.0 silk sutures. All surgeries were conducted by experienced oral and maxillofacial surgeons without sedation or premedication. The entire procedure was monitored for hemodynamic parameters including heart rate, blood pressure, and oxygen saturation.
219611190|NCT07018115|DEVICE|Multiparameter patient monitor|A hospital-grade multiparameter monitor was used to measure and record patients' vital signs at five defined surgical stages: before surgery, after information delivery, after local anesthesia, during tooth extraction, and postoperatively. The monitor continuously recorded heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), and peripheral oxygen saturation (SpO₂). The collected data were used to evaluate physiological responses associated with anxiety and surgical stress.
219611191|NCT07018388|DEVICE|NervioX-2400|To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling.
219611192|NCT07018388|DEVICE|NervioX-2400|To design the individualized GPi-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data is used to determine the GPi-tTIS montage and stimulation settings via computational modeling.
219611193|NCT05836051|OTHER|Flavor|E-liquid flavor chemicals
219611194|NCT04153019|OTHER|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
219611195|NCT07017348|OTHER|Clinical assessments|dermatitis atopic scores will be evaluated on the entire body and on target areas by the investigator
219611196|NCT07017348|OTHER|Biometrological measurements|Measurements will be performed on the target areas
219611197|NCT07017348|OTHER|Biological sampling|Skin and faecal samples will be performed
219611198|NCT07017348|OTHER|Questionnaires|dietary habits, health and lifestyle, and digestive health
218895482|NCT03107260|OTHER|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
218895483|NCT05318261|PROCEDURE|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
219515989|NCT00552331|DEVICE|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
219515990|NCT00552331|DEVICE|LISS|treatment of distal femur fractures with less invasive stabilization systems
218895484|NCT01539759|DEVICE|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
219515991|NCT02715869|DRUG|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
218895485|NCT01541046|BIOLOGICAL|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
219515992|NCT02715869|PROCEDURE|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
219515993|NCT06411366|GENETIC|Follistatin plasmid|Follistatin-344 plasmid
218895486|NCT01541046|BIOLOGICAL|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
218895487|NCT03805802|OTHER|active product|Once daily consumption over the period of the study
219515994|NCT02907996|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
219515995|NCT03735446|DRUG|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
219611199|NCT07017101|OTHER|PILATES BASED EXERCISE TRAINING WITH REFORMER|"Participants will only be given training on pilates-based exercises with reformers. Breathing, which are the 5 key elements of clinical pilates exercises after the first evaluation to individuals,~Focus, rib cage placement, shoulder placement, head and neck placement will be taught. Whole~Participants will be informed about the reformer instrument and work schedule. Exercises 2 days a week, 6~Will be applied throughout the week."
219611200|NCT07017101|OTHER|NEUROPHYSIOLOGICAL FASCILITATION TECHNIQUES|"In addition to reformer-based pilates training, participants will be given Neurophysiological facilitation techniques training. Neurophysiological facilitation techniques are non-invasive, easy to apply, the physiotherapist is active~It consists of exercises made with guidance and active participation of the patient. These techniques are any~Does not contain an electrotherapy current. In this study, the neurophysiological~Facilitation techniques, perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, medium~Graded manual pressure and abdominal co-contraction techniques and each technique for 15 seconds~Will be applied. Neurophysiological facilitation techniques are used to repeat 10 sessions each session throughout the treatment.~It will be done."
219611201|NCT07017426|DRUG|Fuzheng Huayu tablets|Fuzheng Huayu Tablets are composed of various medicinal ingredients such as Salvia miltiorrhiza, Prunus persica seed, Gynostemma pentaphyllum, pine pollen, Cordyceps sinensis, and Schisandra chinensis. They have the functions of promoting blood circulation and removing blood stasis, nourishing the liver and enriching essence, and can be used to treat chronic liver diseases, anti-fibrosis, and patients with liver cirrhosis.
218895488|NCT03805802|OTHER|reference product|Once daily consumption over the period of the study
218895489|NCT04894032|PROCEDURE|Combination of Laparoscopic Uterosacral Ligament and Round Ligament Plication.|Laparoscopic Uterosacral Ligament Plication, Fixation of PVC fascia and the combination with round ligament plication
219515996|NCT03735446|DRUG|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
219515997|NCT03735446|DRUG|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
219515998|NCT03735446|DRUG|Cytarabine|Standard chemotherapy (anti-metabolite)
219515999|NCT06001632|DIETARY_SUPPLEMENT|krill oil (SuperbaBoostTM)|4 g/day of Krill oil supplements (LC n-3 PUFAs) (1g capsule containing 191mg EPA, 94mg DHA and 78mg choline).
219516000|NCT06001632|DIETARY_SUPPLEMENT|4g/day of mixed vegetable oil|vegetable oil capsules (mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
218895490|NCT03901144|DRUG|2% urea/20% glycerol cream|Moisturizing cream for topical application
218895491|NCT03901144|DRUG|Miniderm® 20% cream|Moisturizing cream for topical application
218895492|NCT03901144|DRUG|Diprobase® cream|Emollient cream for topical application
218895493|NCT05724407|OTHER|Diagnostic assistance tool|"Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months."
219516001|NCT02606500|DRUG|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years."
219516002|NCT00623207|DRUG|Atropine|I.V Atropine 0.5mg up to 2 mg
218895494|NCT01864343|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
218895495|NCT03552497|DIAGNOSTIC_TEST|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
218895496|NCT02085018|DRUG|Omeprazole|Drug
219516003|NCT02470507|OTHER|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
218895497|NCT02085018|DRUG|Matched placebo|Matched placebo
218895498|NCT03413124|DRUG|MGL-3196 Tablet|MGL-3196 in Tablet form
218895499|NCT03413124|DRUG|MGL-3196 Capsule|MGL-3196 in Capsule form
219516004|NCT02153398|DRUG|D961H sachet 10 mg|
219516005|NCT02153398|DRUG|D961H capsule 10mg|
219516006|NCT02153398|DRUG|D961H capsule 20 mg|
219516007|NCT04508998|DIAGNOSTIC_TEST|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
219611202|NCT07017426|OTHER|Placebo Comparator|placebo combined with conventional antiviral therapy
219516008|NCT04508998|DIAGNOSTIC_TEST|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
219516009|NCT04552613|DRUG|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
219611203|NCT07017517|DEVICE|Motomed Letto® servo-assisted cycling + standard physiotherapy|Servo-assisted cycling using the Motomed Letto® device with a cadence target of 30 revolutions per minute (rpm), performed for 60 minutes twice daily for 7 days. This intervention is administered in addition to standard ICU physiotherapy to critically ill patients at risk of critical illness myopathy (CIM).
219611204|NCT07017517|BEHAVIORAL|Standard physiotherapy|Standard physiotherapy including mobilization and passive/active range-of-motion exercises, delivered during routine ICU care for 7 days.
219611205|NCT07018154|OTHER|Musculoskeletal Assessment|Patients underwent a musculoskeletal Assessment.
219611206|NCT07016828|DEVICE|guided surgery technique|"* Clinical examination will be performed and preoperative CBCT will be taken for all the patients prior to the surgery to evaluate the posterior maxilla for the placement of the pterygoid implants.~* Ideal pterygoid implant placement will be planned using the BlueSky Bio software (USA) which will be mostly to emerge from the third molar position and to engage the dense pillar of bone formed by the pyramidal process and pterygoid process of sphenoid bone.~* surgical guide will be fabricated which will be either soft tissue without flap elevation."
219611207|NCT07016828|PROCEDURE|Free hand technique|the surgery will be done without the use of the surgical guides depending on the anatomical landmarks.
219611208|NCT07018622|DRUG|Dapagliflozin 10 MG Oral Tablet|Participants in this arm will receive oral dapagliflozin 10 mg daily starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. The intervention aims to assess the potential nephroprotective effect of SGLT2 inhibition. Standard supportive care including hydration and magnesium supplementation will be provided to all participants.
219611209|NCT07018622|DRUG|Placebo Oral Tablet|Participants in this arm will receive a matched oral placebo starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. Standard supportive care including hydration and magnesium supplementation will also be provided. Investigators and participants will remain blinded to the group assignments.
219611210|NCT07024173|DRUG|HRS-8080 Tablet|HRS-8080 tablet orally administered.
219611211|NCT07024173|DRUG|Fulvestrant injection|Fulvestrant injection.
219611212|NCT07024173|DRUG|Exemestane tablets|Exemestane tablets orally administered.
218895500|NCT00458120|BIOLOGICAL|rDEN1delta30|Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
218895501|NCT00458120|BIOLOGICAL|rDEN2/4delta30(ME)|Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
218895502|NCT00458120|BIOLOGICAL|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
218895503|NCT00721240|DRUG|montelukast|5mg montelukast once daily for 12 weeks
218895504|NCT03923894|DIETARY_SUPPLEMENT|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
219611213|NCT07024173|DRUG|Everolimus Tablets|Everolimus tablets orally administered.
218895505|NCT03923894|DIETARY_SUPPLEMENT|Placebo|Placebo 2.07 g/day for 8 weeks.
218895506|NCT04891380|DEVICE|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
218895507|NCT04891380|OTHER|Hypotension|measurement of physiological parameters
218895508|NCT04891380|OTHER|Intensive care transport|Measurement of physiological parameters
219035344|NCT06622759|PROCEDURE|CTG|Connective Tissue Graft has been widely used around implants to increase either the thickness of the soft tissues or the width of keratinized tissues. It is considered the gold standard for soft tissue grafting. The main drawbacks are the donor morbidity and the limit amount of intraoral donor sites. In this study it will be used in the test 1 group in order to compare its clinical results with the other groups.
219516010|NCT04552613|DRUG|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
219516011|NCT04450745|BEHAVIORAL|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
219516012|NCT04450745|BEHAVIORAL|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
219516013|NCT03528668|DEVICE|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
218895509|NCT04311684|DEVICE|hybrid Brillouin-Raman spectroscopy|Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
218895510|NCT04827888|PROCEDURE|Orthopaedic surgery|One of the 25 most common orthopedic surgeries reported in the database which are the following as per surgical types: spine surgery (CPT codes 63030, 63047, 22612, 22551 or 22558), trauma (CPT codes 27236, 27125, 27244, 27814, or 27792), sports medicine injuries (CPT codes 29881, 29827, 29880, 29888, 29826, 29877, 29807, or 23412), or joint arthroplasty (CPT codes 27447, 27130, 23472, 27487, 27134, 27446, or 27486).
218895511|NCT05210491|OTHER|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
219516014|NCT03923036|DRUG|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
219516015|NCT01073995|DRUG|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
219516016|NCT02402166|DRUG|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
219516017|NCT06433453|DRUG|Indomethacin 50 MG|The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
219516018|NCT06433453|PROCEDURE|Transvaginal ultrasound scans|Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
219516019|NCT06433453|DIAGNOSTIC_TEST|Finger prick blood test|Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
219516020|NCT06433453|DIAGNOSTIC_TEST|Urine test|Early morning urine tests to assay reproductive hormones
219516021|NCT05190263|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
219516022|NCT03931642|DRUG|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
219516023|NCT03931642|DRUG|Blinatumomab|Blinatumomab by continuous vein infusion
219516024|NCT01536626|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
219516025|NCT04293666|DIETARY_SUPPLEMENT|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
219516026|NCT04293666|DIETARY_SUPPLEMENT|placebo|Maltodextrin, same calorie as kefir, 200ml/day
219516027|NCT03331042|DRUG|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
219516028|NCT03331042|DRUG|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
219516029|NCT03331042|DRUG|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
219516030|NCT03331042|DRUG|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
219516031|NCT01690936|DIETARY_SUPPLEMENT|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
219611214|NCT06691984|DRUG|Xaluritamig|Short-term IV infusion
219611215|NCT06691984|DRUG|Abiraterone|Oral tablets
219611216|NCT06691984|DRUG|Enzalutamide|Oral tablets
219611217|NCT06691984|DRUG|Cabazitaxel|IV infusion
218895512|NCT03564613|DRUG|DTG|Subjects with DTG exposure during any trimester will be included
218895513|NCT05771766|OTHER|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
218895514|NCT05771766|OTHER|Postural Drainage|Postural Drainage
218895515|NCT02904733|OTHER|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
218895516|NCT03575403|DRUG|Alcohol|In each arm and during sessions, subjects will receive doses of alcohol designed to raise breath alcohol levels (BAL) to 0.03 g/dl.
218895517|NCT03575403|DRUG|Placebos|Subjects will receive oral placebo capsules.
218895518|NCT03575403|DRUG|Duloxetine (60 MG)|Subjects will receive 60-mg of oral duloxetine capsules.
218895519|NCT03575403|DRUG|Methylphenidate|Subjects will receive methylphenidate capsules.
218895520|NCT03575403|DRUG|Duloxetine (30 MG)|Subjects will receive 30-mg of oral duloxetine capsules.
218895521|NCT05326711|BEHAVIORAL|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
218895522|NCT01223729|DRUG|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
218895523|NCT01223729|OTHER|placebo|placebo twice per day
218895524|NCT06276426|OTHER|Soy foods|Soy milk, soy yogurt, tofu, tempeh, soy nuts, edamame, soy protein bar, and soy-based frozen meat substitutes.
218895525|NCT06276426|OTHER|Non-Soy Plant-Based Foods|Pea milk, almond milk yogurt, chickpeas, chickpea chips, lentil chips, non-soy protein bar, and non-soy based frozen meat substitutes.
218895526|NCT01683539|BEHAVIORAL|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
218895527|NCT01683539|BEHAVIORAL|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
218895528|NCT01094535|DRUG|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
218895529|NCT01509235|PROCEDURE|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
218895530|NCT02330055|PROCEDURE|Forty-five degrees elevated upper body position|
218895531|NCT02330055|PROCEDURE|non-elevated upper body position|
218895532|NCT02330055|DEVICE|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
218895533|NCT02330055|OTHER|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
218895534|NCT02330055|OTHER|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
218895535|NCT02330055|OTHER|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
219035345|NCT06622759|PROCEDURE|Collagen Matrix|Collagen matrix has been used in several studies in order to evaluate its clinical properties over the last years. In this study, the graft will be placed buccally at the time of implant placement in the aesthetic zone in order to assess its clinical and radiographic properties in terms of buccal bone resorption and soft tissue augmentation. Histological assessment and Patient Reported outcomes will also be evaluated.
219035346|NCT06622759|PROCEDURE|Control group|In the control group, the implant will be placed without any kind of soft tissue graft in order to compare this treatment modality that many clinicians apply at the clinical practice.
219035347|NCT05756790|BEHAVIORAL|Motivational Interviewing|Counseling
219035348|NCT05756790|BEHAVIORAL|Motivational Interviewing plus Breathalyzer|Counseling plus mobile breathalyzer/ app
219516032|NCT00825227|DRUG|Armodafinil 150 mg/day|"* 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
219516033|NCT00825227|DRUG|Placebo,|"* placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
219516034|NCT00376948|DIETARY_SUPPLEMENT|genistein|
219516035|NCT00376948|DRUG|erlotinib hydrochloride|
219516036|NCT00376948|DRUG|gemcitabine hydrochloride|
219611218|NCT04567420|DRUG|Palbociclib|4 week cycles
219611219|NCT04567420|DRUG|Fulvestrant|4 week cycles
219611220|NCT04567420|DRUG|Adjuvant Therapy|Standard of Care
219611221|NCT06702969|DEVICE|Intra oral scanner|Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner
219035349|NCT07087860|OTHER|Best Practice|Receive standard of care
219035350|NCT07087860|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219035351|NCT07087860|PROCEDURE|Central Venous Cannula Insertion|Undergo central line placement
219035352|NCT07087860|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219035353|NCT07087860|DRUG|Enfortumab Vedotin|Given IV
219516037|NCT03236857|DRUG|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
219516038|NCT03236857|DRUG|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
219516039|NCT05586022|PROCEDURE|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
219611222|NCT06702969|DEVICE|impression analog|Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
219611223|NCT06728423|OTHER|Temporary target during an anaerobic training session|Temporary target during an anaerobic training session
218895536|NCT02330055|OTHER|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
218895537|NCT02976935|OTHER|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
218895538|NCT05607524|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and twice a day
218895539|NCT05607524|DIETARY_SUPPLEMENT|placebo|Eat a capsule for once, and twice a day
218895540|NCT00746616|DEVICE|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
218895541|NCT02151188|DIETARY_SUPPLEMENT|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
218895542|NCT02151188|DEVICE|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
219035354|NCT07087860|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219035355|NCT07087860|BIOLOGICAL|Pembrolizumab|Given IV
219611224|NCT06728423|OTHER|SmartGuard during an anaerobic training session|SmartGuard during an anaerobic training session
219035356|NCT07087860|PROCEDURE|Plasmapheresis|Undergo TPE
219035357|NCT07087860|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219611225|NCT03173209|BEHAVIORAL|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
219611226|NCT06730633|BEHAVIORAL|Heart Matters|Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.
219611227|NCT01329900|DRUG|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
219611228|NCT01329900|DRUG|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
219611229|NCT01329900|DRUG|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
218895543|NCT00963391|OTHER|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
218895544|NCT00540072|DRUG|daptomycin|
218895545|NCT03903419|DIAGNOSTIC_TEST|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
219516040|NCT06364722|OTHER|Acupuncture treatment|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
219516041|NCT06364722|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
219516042|NCT00688064|DRUG|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
219516043|NCT00688064|DRUG|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
219516044|NCT00919308|OTHER|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
219516045|NCT02524223|OTHER|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
219516046|NCT02524223|OTHER|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
219516047|NCT02524223|OTHER|systematic HPV Status in newborns in case of pregnancy|
219516048|NCT02276313|DEVICE|Passeo-18 Lux|Endovascular Therapy
219516049|NCT00605449|DRUG|GSK376501|
219516050|NCT00001849|DRUG|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
219516051|NCT00001849|DRUG|18F-DOPA|18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
219516052|NCT00001849|DEVICE|CT scan|CT scan of chest, abdomen, neck and /or pelvis
219516053|NCT00001849|DEVICE|MRI|MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis
219516054|NCT00001849|DRUG|18-FDG|FDG PET scan of body
219611230|NCT01329900|DRUG|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
219611231|NCT01329900|DRUG|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
219611232|NCT01329900|PROCEDURE|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
218895546|NCT03763019|PROCEDURE|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
218895547|NCT03763019|PROCEDURE|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
218895548|NCT03407755|PROCEDURE|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
219516055|NCT01297049|BEHAVIORAL|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
219516056|NCT02428699|OTHER|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
219516057|NCT02428699|OTHER|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
219516058|NCT01690442|BEHAVIORAL|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
219516059|NCT01690442|BEHAVIORAL|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
219611233|NCT06634173|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
218895549|NCT02946034|DRUG|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
218895550|NCT02946034|DRUG|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
218895551|NCT00500188|DRUG|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
218895552|NCT04661436|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
219035358|NCT07087860|OTHER|Questionnaire Administration|Ancillary studies
219516060|NCT03231475|DRUG|SPH1188-11|qd.po
219516061|NCT04173013|BIOLOGICAL|Uromune|2 sprays of solution once daily for a total of 3 months.
219611234|NCT00424229|DRUG|LENALIDOMIDE|
219611235|NCT04810065|OTHER|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
219516062|NCT03459937|BEHAVIORAL|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
219516063|NCT03459937|BEHAVIORAL|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
219516064|NCT02295397|OTHER|food|food provocation, skin testing, blood sampling
219516065|NCT05898568|DEVICE|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
219516066|NCT05898568|BEHAVIORAL|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
219516067|NCT00252356|DRUG|SR58611A|
219516068|NCT02697903|DIETARY_SUPPLEMENT|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
219516069|NCT02697903|DIETARY_SUPPLEMENT|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
219516070|NCT05266248|OTHER|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
219516071|NCT02922868|DEVICE|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
219516072|NCT02922868|DEVICE|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
219516073|NCT01781286|BEHAVIORAL|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
219516074|NCT01781286|BEHAVIORAL|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
219516075|NCT04123210|DIETARY_SUPPLEMENT|Vitamin A supplement|
219516076|NCT04123210|DIETARY_SUPPLEMENT|Placebo|
219516077|NCT03594123|DRUG|Brexpiprazole|2 or 3 mg tablet
219516078|NCT03594123|DRUG|Brexpiprazole|0.5 to 3 mg tablet
219516079|NCT02415023|DRUG|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
219516080|NCT00146523|DRUG|Mifepristone|
218895553|NCT02728089|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
218895554|NCT05432713|DRUG|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
219516081|NCT00146523|DRUG|placebo|
219516082|NCT04240938|PROCEDURE|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
218895555|NCT05432713|DRUG|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
219516083|NCT01144936|DRUG|VX-985 or matching placebo|low dose
219516084|NCT01144936|DRUG|VX-985 or matching placebo|high dose
219516085|NCT01144936|DRUG|VX-985 or matching placebo|dose TBD
219516086|NCT06179238|OTHER|Education|Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.
219516087|NCT06179238|OTHER|without patient education|without patient education
219516088|NCT00093990|DRUG|Tipifarnib;Zarnestra; R115777|
219516089|NCT00864864|DRUG|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
219516090|NCT03597490|COMBINATION_PRODUCT|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
218895556|NCT04544358|BEHAVIORAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
218895557|NCT02521922|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
218895558|NCT02521922|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
219516091|NCT05681208|BEHAVIORAL|Motivational interview|"Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week."
219516092|NCT02483975|DRUG|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
218895559|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
218895560|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
218895561|NCT03233113|BEHAVIORAL|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
219516093|NCT02483975|DRUG|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
219516094|NCT02483975|DRUG|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
219516095|NCT02483975|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
219611236|NCT04880473|DEVICE|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
218895562|NCT03359174|DRUG|All-trans retinoic acid|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
218895563|NCT01180686|DEVICE|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
218895564|NCT01180686|DEVICE|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
218895565|NCT04889183|DRUG|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
218895566|NCT04889183|DRUG|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
218895567|NCT02591108|DEVICE|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
219516096|NCT00508170|BEHAVIORAL|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
219516097|NCT04912349|PROCEDURE|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
219516098|NCT04912349|PROCEDURE|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
219516099|NCT02716870|OTHER|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
219516100|NCT04172870|DIAGNOSTIC_TEST|Molecular analysis|RT- PCR
219516101|NCT05554770|DIAGNOSTIC_TEST|Examinations in a TRV chair|Positional tests (Dix-Hallpike and SRT) traditionally used to diagnose BPPV uwith a TRV chair.
219516102|NCT00442806|DRUG|Injection of ADRC's|ADRC's are injected
219516103|NCT00442806|OTHER|Injection of Placebo|Placebo is injected
218895568|NCT02591108|DEVICE|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
219516104|NCT01578837|DIETARY_SUPPLEMENT|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
219611237|NCT04357548|DEVICE|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
218895569|NCT00239733|DRUG|Anti-D|30-minute infusion administered in an outpatient setting
218895570|NCT03715803|DEVICE|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
219611238|NCT02307773|DRUG|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
219611239|NCT01534130|DEVICE|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
219611240|NCT01534130|DEVICE|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
218895571|NCT03715803|DEVICE|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
218895572|NCT04714164|BEHAVIORAL|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
218895573|NCT06024486|DIAGNOSTIC_TEST|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
218895574|NCT03055117|BEHAVIORAL|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
218895575|NCT03055117|BEHAVIORAL|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
218895576|NCT03055117|BEHAVIORAL|Home exercise|Supervised home exercise
218895577|NCT06301451|DEVICE|General dietary guidance and hydrogen water prepared by portable hydrogen rich water machine|The trial group drink the hydrogen water prepared by the experimental equipment on the basis of receiving general dietary guidance.
218895578|NCT06527118|OTHER|ACTIVITIES TO LEARN SELF CARE SKILLS|This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
218895579|NCT00420862|PROCEDURE|Spiral Computed Tomography|
219035359|NCT07084077|OTHER|Narratology education module|At RCSI Dublin, mentioned by James Joyce in Dubliners, a one-week student-choice module Narrative Medicine: lessons from Irish writers and storytellers was offered to those in the second of our five-year undergraduate medical degree program, i.e., students were 18-months into the curriculum, had limited communication skills training, and no real-world clinical exposure. The module used close reading, group viewing, small-group workshops, and whole-group discussions to foster narrative competence. A medically-trained narratology-expert facilitated students' interrogation of classic and award-winning non-healthcare themed works by Irish writers and storytellers, i.e., directors and/or producers.
219035360|NCT07087366|PROCEDURE|ERAS protocol|Procedure: ERAS protocol
219516105|NCT01578837|DIETARY_SUPPLEMENT|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
219516106|NCT04138732|BEHAVIORAL|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
219516107|NCT02381171|DEVICE|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
219516108|NCT02381171|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
219516109|NCT02381171|DEVICE|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
219516110|NCT02381171|DEVICE|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
219516111|NCT05641909|DRUG|Remifentanil|Remifentanil
219516112|NCT05641909|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
219611241|NCT02198963|DRUG|Hypochlorous acid solution 106 mg/L|test product
219611242|NCT02198963|DRUG|0.1% (w/v) Sodium Lauryl Sulfate|positive control
219611243|NCT02198963|DRUG|0.9% Physiological Saline, USP|negative control
218895580|NCT05570266|DIAGNOSTIC_TEST|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
218895581|NCT02416739|DRUG|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
218895582|NCT03678701|DIETARY_SUPPLEMENT|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
219516113|NCT01556009|DRUG|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
219516114|NCT01556009|DRUG|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
219516115|NCT01485965|DRUG|SEN0014196|100 mg, immediate release tablets, once daily administration
219516116|NCT06182020|DEVICE|Peripheral functional magnetic stimulation (ISKRA MEDICAL TESLA Former prestige Magneto therapy)|The peripheral functional magnetic stimulation will be conducted 30 minutes a session, 2 sessions per week, for consecutive 8 weeks. The stimulation will be placed over bilateral forearm flexor muscles and bilateral thighs over rectus femoris muscles.
219516117|NCT06182020|DIETARY_SUPPLEMENT|Nutritional supplementation (ENSURE HIGH CALCIUM)|"The nutritional supplementation includes 7 cans of ENSURE HIGH CALCIUM per week for 8 consecutive weeks."
219516118|NCT06182020|BEHAVIORAL|Education|The education includes a DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
219516119|NCT02758665|DRUG|ibrutinib|
219516120|NCT02758665|DRUG|obinutuzumab|
219516121|NCT02758665|DRUG|venetoclax|
218895583|NCT06212557|DEVICE|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
219516122|NCT03942965|DEVICE|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
219516123|NCT01505530|DRUG|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
219516124|NCT01505530|DRUG|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
219516125|NCT01505530|DRUG|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
219611244|NCT03982992|DRUG|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
219516126|NCT04475965|OTHER|Isometric exercise for shoulder external rotators|The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
219516127|NCT00973700|BIOLOGICAL|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
219611245|NCT06632119|DEVICE|high-intensity laser therapy|high-intensity laser therapy (HILT) machine, ASA laser
219611246|NCT06632119|DEVICE|Sham-HILT|Sham-HILT, HILT machine without laser release
219516128|NCT00973700|BIOLOGICAL|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
219516129|NCT06038357|BEHAVIORAL|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
219516130|NCT06038357|OTHER|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
219611247|NCT03997851|DRUG|Acetaminophen|Topical acetaminophen gel
219611248|NCT03997851|DRUG|Carbomer 980|Topical vehicle gel
218895584|NCT06212557|BEHAVIORAL|KIOS App education|Educational tools provided to participants with opioid use disorder
218895585|NCT06212557|BEHAVIORAL|Treatment as usual|Behavioral counseling in clinic
218895586|NCT00424944|BIOLOGICAL|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
218895587|NCT00424944|BIOLOGICAL|GMZ2 malaria vaccine|100 micrograms of GMZ2
218895588|NCT00424944|BIOLOGICAL|Verorab vaccine|Anti-rabies vaccine
219035361|NCT07090681|DEVICE|Active Control Placebo|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received a high frequency temporal interference stimulation with an overlapping sinusoidal wave at 2KHz, without any interferent pattern.
219611249|NCT06403254|PROCEDURE|There isn't an intervention name because the study is observational and has only one group.|Follow-up after surgey
219611250|NCT03350607|OTHER|Non interventional study|Non interventional study (collect of data)
219611251|NCT04053127|DEVICE|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
219611252|NCT00146276|DRUG|gemcitabine|
219035362|NCT07090681|DEVICE|tTIS|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
219611253|NCT04252339|DRUG|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
219611254|NCT00681031|BIOLOGICAL|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
219611255|NCT04957030|DIAGNOSTIC_TEST|ULDCT group|underwent ultralow-dose chest CT
219611256|NCT02210624|BIOLOGICAL|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
219611257|NCT01476514|OTHER|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
218895589|NCT04154046|PROCEDURE|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
219516131|NCT04043845|DRUG|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
219516132|NCT04043845|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
219516133|NCT03420066|OTHER|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
219516134|NCT03887195|OTHER|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
219516135|NCT02492958|BIOLOGICAL|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
219516136|NCT02492958|BIOLOGICAL|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
219516137|NCT03086772|BEHAVIORAL|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
219611258|NCT02300155|DRUG|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
219611259|NCT02300155|DRUG|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
219611260|NCT00396643|DRUG|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
219611261|NCT05019950|DRUG|NIM-1324|Once daily oral tablet
219611262|NCT05019950|DRUG|Placebo|Once daily oral tablet
219611263|NCT02457923|OTHER|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
219611264|NCT05329259|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
218895590|NCT02677935|OTHER|Community education programs|
218895591|NCT05986786|DEVICE|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
218895592|NCT06368258|DIETARY_SUPPLEMENT|Red yeast rice|Red yeast rice 160 mg (total monacolins 2.8 mg)
218895593|NCT06368258|OTHER|Placebo|Placebo
218895594|NCT04868955|OTHER|Oral screen training|Oral screen training (IQoro®) during 13 weeks.
218895595|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
218895596|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
218895597|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
218895598|NCT01611038|DIETARY_SUPPLEMENT|Methylselenocysteine|Methylselenocysteine capsule given daily
218895599|NCT01611038|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given daily
218895600|NCT02677168|DEVICE|cNEP|continuous negative external pressure
218895601|NCT03568240|DIAGNOSTIC_TEST|Patients suffering from Sleep apnea|PSG test
218895602|NCT01332994|DRUG|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
218895603|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
218895604|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
218895605|NCT00354380|DRUG|Methylene blue|
218895606|NCT00354380|DRUG|Artesunate|
218895607|NCT00354380|DRUG|Amodiaquine|
218895608|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
218895609|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)|Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
219203973|NCT06432725|BEHAVIORAL|JUNTOS|HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
219516138|NCT03086772|BEHAVIORAL|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
219516139|NCT01193608|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
219611265|NCT06265259|DRUG|Initiation of vasopressine as a first vasoconstrictive drug|The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
219611266|NCT06265259|DRUG|Initiation of noradrenaline as a first vasoconstrictive drug|ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
219611267|NCT01290159|OTHER|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
219611268|NCT00695305|DRUG|rilapladib|250 mg oral dose once daily
219611269|NCT00695305|DRUG|placebo|placebo
218895610|NCT03360123|DRUG|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
219516140|NCT01193608|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
219516141|NCT01193608|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
219516142|NCT01193608|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
219516143|NCT01193608|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
219516144|NCT01193608|OTHER|Placebo|Placebo, IV
219516145|NCT04924309|OTHER|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
219516146|NCT02637193|DRUG|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
219611270|NCT00695305|OTHER|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
219611271|NCT03180645|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
219611272|NCT03180645|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
218895611|NCT03360123|DRUG|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
219516147|NCT02637193|DRUG|Moxifloxacin|400 mg single dose moxifloxacin
219516148|NCT02637193|DRUG|Drug - placebo|Placebo administered for 16 days
219516149|NCT05976971|OTHER|7T MRI|Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
219611273|NCT03180645|OTHER|No treatment|No treatment
218895612|NCT04651868|OTHER|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
219516150|NCT03168074|DRUG|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
219516151|NCT05050786|DEVICE|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
219516152|NCT05050786|OTHER|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
219516153|NCT03317197|DRUG|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
219611274|NCT05607745|OTHER|FMT and placebo|Similar healthy diet counseling is given to all participants in both FMT and placebo group. FMT to placebo is given in 2:1.
219611275|NCT02914860|DEVICE|Cardiac CT|"* Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map."
218895613|NCT04651868|OTHER|Placebo|A 210 mins intravenous infusion with isotonic NaCl
218895614|NCT04651868|OTHER|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)
218895615|NCT04651868|OTHER|Placebo|A 180 mins intravenous infusion with isotonic NaCl
218895616|NCT06470997|BIOLOGICAL|Blood sample collection|6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)
218895617|NCT06470997|PROCEDURE|Liver biopsy|1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.
218895618|NCT06061081|DRUG|VH3739937|VH3739937 will be administered.
218895619|NCT06061081|DRUG|Placebo|Placebo will be administered.
219035363|NCT07090681|DEVICE|tTIS + TMS|In this intervention, participants underwent cerebellar magnetic stimulation at the level of a predefined individual point in the inferior left cerebellar hemisphere with a TMS coil, receiving a total of 600 pulses organised in an intermittent theta-burst pattern. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
219035364|NCT07084493|DEVICE|CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm OR double-pigtail stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
219035365|NCT07084493|DEVICE|biliary stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
219516154|NCT03317197|DRUG|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
219516155|NCT03317197|DRUG|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
219516156|NCT03317197|DRUG|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
219516157|NCT05813587|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
219516158|NCT05813587|OTHER|Normal saline|Normal saline
219516159|NCT04122105|DRUG|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
219611276|NCT02914860|PROCEDURE|Ablation Procedure|"1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
219611277|NCT02914860|DEVICE|D-SPECT|
219611278|NCT05052112|OTHER|E-PR-01|Active arm
219611279|NCT05052112|OTHER|E- PR-02|Placebo arm
219611280|NCT01892280|BEHAVIORAL|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
219611281|NCT01892280|BEHAVIORAL|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
219611282|NCT05243446|DRUG|Losartan|losartan treatment
219611283|NCT01028482|DRUG|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
219611284|NCT01028482|DRUG|placebo|placebo
219611285|NCT01028482|OTHER|psychotherapy|psychotherapy
218895620|NCT05496296|DEVICE|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
218895621|NCT04255589|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
218895622|NCT04255589|DRUG|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
218895623|NCT04255589|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
218895624|NCT04255589|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
218895625|NCT05528393|DIAGNOSTIC_TEST|Blood sampling|blood sampling
219035366|NCT07095959|PROCEDURE|vein of Marshall ethanol infusion|After PFA, the coronary sinus venography will be acquired in search of VOM ostium. Then an over-the-wire balloon will be sent into the VOM and deflated with 4-6 atm. Selective VOM venography will be performed, followed by injection of 10ml 95% ethanol into the VOM.
219035367|NCT07095959|PROCEDURE|PVI using pulsed field ablation|Bilateral pulmonary vein antrum ablation using a pulsed field ablation
219035368|NCT06906341|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
219516160|NCT05128357|OTHER|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
219611286|NCT00858182|DRUG|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
218895626|NCT04428229|OTHER|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
219516161|NCT04510701|OTHER|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
219516162|NCT03849599|BIOLOGICAL|PRV-300|Treatment
219611287|NCT00858182|DRUG|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
219611288|NCT00508131|OTHER|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
219611289|NCT00247780|PROCEDURE|Pulmonary vein isolation and cavotricuspid ishtmusblock|
218895627|NCT05733052|OTHER|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
218895628|NCT02309801|DIETARY_SUPPLEMENT|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
218895629|NCT02309801|DIETARY_SUPPLEMENT|Alcohol|Alcohol single oral dose
219035369|NCT06906341|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
219035370|NCT06906341|DRUG|Bevacizumab 10 mg/kg|Bevacizumab is administered as IV infusion on Days 1 and 15 of each 28-day cycle.
219035371|NCT07098559|BEHAVIORAL|Creative drama|This intervention is unique in its integration of the Bystander Intervention Model with creative drama techniques to enhance empathy, self-efficacy, and active intervention behaviors among middle school students witnessing peer bullying. Unlike traditional anti-bullying programs that rely on lectures or cognitive-based approaches, this study uses experiential learning and role-playing scenarios to simulate real-life bullying situations and encourage emotional engagement and behavioral change.
219035372|NCT07108478|DEVICE|Transcatheter aortic valve and recyclable delivery system|In this study, the transcatheter aortic valve and its recycling delivery system were VitaFlow Liberty®, a TAVR product independently developed by Shanghai Minimally Invasive Cardiovascular Treatment Co., Ltd. (approved and marketed by NMPA). This product is equipment/consumables routinely purchased by hospitals. For routine clinical use, it is designed for transcatheter aortic valve implantation. The valve is delivered to the intended implantation site via the peripheral artery by retrograde flow through the delivery system, realizing the delivery, positioning and release of the valve. Under the supervision of medical imaging equipment, the valve is delivered to the lesion site of the aortic valve, and marked by the diseased aortic annulus, to release the valve and relieve the stenosis at the lesion site, thereby ensuring smooth aortic flow, improving cardiac function and achieving therapeutic purposes.
219035373|NCT07108569|OTHER|Lutetia|Lutetia is an AI-based training plattform
219035374|NCT07109947|DRUG|Letrozole 2.5mg|to determine the effect of Letrozole as a premedication before misoprostol treatment used to induce missed miscarriage.
219035375|NCT07109128|BEHAVIORAL|The T1D Talks: A Virtual Group for Teens and Tweens with T1D|The T1D Talks intervention is an 11 session, virtual (online), group intervention. The T1D Talks intervention teaches developmentally appropriate emotion regulation (ER) skills and facilitates practicing these skills via role-plays and in-session experiences that are meant to elicit strong emotions. The investigators adapted the content and situations of an established intervention to be relevant for youth with T1D (e.g., practicing ER skills while role playing situations like telling parents about high blood glucose numbers or telling a coach about needing to take a time out from a game because of a low blood glucose level). The intervention also provides basic diabetes education about risky situations (e.g., how physical activity can affect blood glucose).
219516163|NCT03849599|BIOLOGICAL|Placebo|Control
219516164|NCT06545383|OTHER|Dynamic Neuromuscular Stabilization Exercises|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally DNS exercises will be performed in 40-minute sessions, 2 days a week for 6 weeks.
219516165|NCT06545383|OTHER|Exercise|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally, the control group will be asked to walk at moderate intensity for 40 minutes, 2 days a week, for 6 weeks.
219516166|NCT00314171|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
219516167|NCT00314171|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
219611290|NCT01808573|DRUG|neratinib|
219611291|NCT01808573|DRUG|capecitabine|
219611292|NCT01808573|DRUG|lapatinib|
219611293|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
218895630|NCT00279916|DRUG|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
218895631|NCT00279916|DRUG|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
218895632|NCT01068574|OTHER|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
218895633|NCT03055520|OTHER|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
218895634|NCT03055520|OTHER|placebo|nonspecific recreation including befriending and free simple activities.
218895635|NCT01451385|DRUG|COV795|COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
218895636|NCT02717494|BIOLOGICAL|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
218895637|NCT02717494|BIOLOGICAL|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
218895638|NCT02717494|OTHER|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
218895639|NCT01833559|DIETARY_SUPPLEMENT|Dietary control|
219516168|NCT00009711|PROCEDURE|management of therapy complications|
219516169|NCT05427097|DEVICE|Helical® patches|Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
219516170|NCT05795491|DEVICE|Blue Light Emitting Diode Therapy|Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
218895640|NCT01833559|DRUG|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
218895641|NCT02053636|DRUG|lucitanib|
218895642|NCT00214981|DRUG|Modafinil|
219516171|NCT05795491|DRUG|Azole Antifungal|Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
218895643|NCT00217217|DEVICE|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
218895644|NCT01374633|DRUG|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
218895645|NCT05721521|OTHER|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
218895646|NCT05721521|OTHER|Control|30 minute completing seated activities (e.g., wordsearches)
219035376|NCT07110649|DEVICE|Virtual Reality Rehabilitation Group|Conducted in three progressive stages using VR games: improving ROM, strengthening shoulder muscles, and simulating game scenarios.
219035377|NCT07110649|OTHER|Traditional Rehabilitation Group|Used conventional physical therapy methods based on established rehabilitation programs.
219035378|NCT07108972|PROCEDURE|Transabdominal pre-peritoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through transabdominal approach
219035379|NCT07108972|PROCEDURE|Totally extraperitoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through extraperitoneal approach
219035380|NCT07110454|DEVICE|Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry until that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
219203974|NCT06432725|BEHAVIORAL|Referral Sheet|HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
219203975|NCT06525376|DIAGNOSTIC_TEST|smartphone inclinometer application|an instrument for measuring angles of slope (or tilt), elevation, or depression of an object with respect to gravity.
219516172|NCT00584766|PROCEDURE|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
219516173|NCT03576391|BEHAVIORAL|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
219516174|NCT03576391|BEHAVIORAL|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
219516175|NCT03576391|BEHAVIORAL|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
219516176|NCT03576391|BEHAVIORAL|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
219516177|NCT04549064|DIAGNOSTIC_TEST|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
219516178|NCT04919421|DRUG|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
218895647|NCT03467711|OTHER|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
218895648|NCT03467711|OTHER|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
219516179|NCT04919421|DEVICE|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
219516180|NCT01346332|DEVICE|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
219516181|NCT00197951|DRUG|Treatment of psychiatric symptoms associated to alcoholism|
219516182|NCT01781065|DEVICE|transcranial direct current stimulation|
218895649|NCT04485546|DRUG|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
218895650|NCT06303596|OTHER|Hippotherapy|Hippotherapy: Hippotherapy in psychiatry is not concerned only about the patient sitting on a horse and the horseback movement influencing the physical condition of the patient and his functional and postural disorders. This therapy is concerned with positive effects on a patient's mental state and use mainly contact with the horse, work with the horse from the ground and riding on horseback. It aims for enjoyment, social communication, and the development of cognitive and executive functions.
218895651|NCT06303596|OTHER|Standard psychiatric treatment|Standard psychiatric treatment: Standard psychiatric treatment includes medication and routine activities provided by the Community Mental Health Center.
218895652|NCT04366661|DIAGNOSTIC_TEST|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
219611294|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
219611295|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
219611296|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
219516183|NCT01474226|DIETARY_SUPPLEMENT|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
219516184|NCT01474226|DIETARY_SUPPLEMENT|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
219516185|NCT03947138|BIOLOGICAL|GC3107|BCG Vaccine
219611297|NCT06432816|DIETARY_SUPPLEMENT|NANO-PSO|NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
219516186|NCT03947138|BIOLOGICAL|Intradermal BCG SSI inj.|BCG Vaccine
219516187|NCT02639949|BEHAVIORAL|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
218895653|NCT01817439|DRUG|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
218895654|NCT00099138|BEHAVIORAL|Caloric Restriction (CR)|
218895655|NCT00099138|BEHAVIORAL|Exercise|
218895656|NCT00895115|DIETARY_SUPPLEMENT|vitamin E|Given once daily
218895657|NCT00895115|PROCEDURE|sham intervention|No supplementation
219516188|NCT02639949|BEHAVIORAL|Standard Care|
219035381|NCT07110337|DEVICE|Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry unit that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
219611298|NCT06432816|OTHER|PLACEBO|"Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg."
218895658|NCT03036020|RADIATION|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
218895659|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
218895660|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
219203976|NCT05441683|PROCEDURE|horizontal extending incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the initial incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
219516189|NCT02795104|BEHAVIORAL|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
219516190|NCT02795104|BEHAVIORAL|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
219611299|NCT03420521|DRUG|Nivolumab|240mg IV over 60 minutes Q2W
219611300|NCT03420521|DRUG|Ipilimumab|1mg/kg IV over 30 minutes Q6W
219611301|NCT03414476|OTHER|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
219611302|NCT05186792|OTHER|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
219611303|NCT03885583|PROCEDURE|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
219611304|NCT03885583|PROCEDURE|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
219611305|NCT02404480|DRUG|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
218895661|NCT04739436|DEVICE|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
218895662|NCT06162026|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
218895663|NCT00676013|PROCEDURE|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
219035382|NCT06924593|DEVICE|Trans-Carotid Artery Occlusion Shunt System|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System for Carotid Artery Revascularization during Endovascular Treatment
219035383|NCT06923280|DRUG|Pegylated Interferon-alpha (IFN)|pegylated interferon-alpha 180 μg once weekly for 24 weeks
219035384|NCT06924255|DRUG|Xanomeline and Trospium Chloride|accelerated titration of Xanomeline and Trospium Chloride
219035385|NCT06924255|DRUG|Xanomeline and Trospium Chloride|slow titration of Xanomeline and Trospium Chloride
219516191|NCT02795104|BEHAVIORAL|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
219611306|NCT01774162|DEVICE|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
219611307|NCT01774162|DEVICE|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
219613388|NCT03976271|PROCEDURE|hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp|For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
218895664|NCT00676013|PROCEDURE|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
218895665|NCT00676013|PROCEDURE|Homograft|Grafting using homograft as a skin substitute
219516192|NCT02128048|DEVICE|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
219613389|NCT04395456|DRUG|AMY-101|C3 complement inhibitor
218895666|NCT00676013|PROCEDURE|Autograft|grafting using patients own skin from a separate donor site
218895667|NCT06056583|DRUG|Cimetidine 200 MG|Cimetidine will serve as the probe drug
218895668|NCT01926834|DRUG|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
218895669|NCT01926834|DRUG|placebo|normal saline, 500ml,i.v.,qd, for 7 days
218895670|NCT00428948|DRUG|Tolvaptan|Tolvaptan was supplied as tablets.
218895671|NCT00428948|DRUG|Placebo|Placebo was supplied as tablets.
218895672|NCT01288989|BIOLOGICAL|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
218895673|NCT03602365|DEVICE|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
218895674|NCT03104179|DEVICE|Cytosorb Adsorber|Cytokine adsorption during CPB
219035386|NCT06923254|OTHER|7.0T MRI-Scan|7.0T MRI-Scan
219516193|NCT05946148|DRUG|Empagliflozin|Empagliflozin 10mg daily, as add-on to previous treatment regimen.
218895675|NCT04203836|DRUG|LEO 152020 Tablet|film-coated tablet
218895676|NCT03946748|DRUG|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
219516194|NCT05946148|DRUG|Dulaglutide|Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
219516195|NCT05946148|DRUG|Control Rx|Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
218895677|NCT00178568|BEHAVIORAL|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
218895678|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
218895679|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
219035387|NCT06928337|DEVICE|AI evaluation of oocytes.|AI evaluation of oocytes inside a time-lapse incubator.
219035388|NCT07108322|OTHER|Intraoral scanning|Adigital impression with intraoral scanning
218895682|NCT05950698|DEVICE|Holter Faros 360° EKG (Bittium Corporation)|Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.
218895683|NCT05950698|DIAGNOSTIC_TEST|Beck Depression Inventory (BDI)|The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
218895684|NCT05950698|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scales - HADS|The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
219035389|NCT07108426|BEHAVIORAL|Educational Intervention via Telemedicine|A structured educational program delivered remotely through WhatsApp®, including a 30-minute online lecture and daily dissemination of educational content (videos, texts, and practical guidance) on hospital hyperglycemia and glycemic management strategies.
219035390|NCT02988791|DIETARY_SUPPLEMENT|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
219035391|NCT02988791|DIETARY_SUPPLEMENT|Placebo|Placebo
219035392|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
218895685|NCT05950698|DIAGNOSTIC_TEST|Three Factor Eating Questionnaire-R21 - TFEQ-R21|The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
219035393|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
219035394|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
219035395|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
219516196|NCT04677062|DRUG|GV-328|Patients with GV-328 treatment
219516197|NCT01255475|DRUG|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
219516198|NCT01255475|DRUG|Placebo|Patients will receive placebo
219516199|NCT04547946|DRUG|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
219516200|NCT03763500|OTHER|Internet-based education|A six-step Internet-based patient education.
219516201|NCT00948675|DRUG|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
219516202|NCT00948675|DRUG|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
219516203|NCT00948675|DRUG|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
218895686|NCT05950698|DIAGNOSTIC_TEST|hort-Form Health Survey-36 itens - SF-36|he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
219203977|NCT05441683|PROCEDURE|vertical releasing incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the initial incision before a full-thickness flap is lifted. The incision formed an oblique trapezoidal flap with a wider base.
219203978|NCT06501495|OTHER|video polysomnography|video polysomnography during 2 nights
219203979|NCT06501495|OTHER|Attention task|Attention task : SART Test (Sustained Attention to Response Task)
219516204|NCT00948675|BIOLOGICAL|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
219516205|NCT02296775|BIOLOGICAL|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219516206|NCT02296775|BIOLOGICAL|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219516207|NCT02296775|BIOLOGICAL|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
219516208|NCT04465942|DRUG|(chemo)immunotherapy|Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
219516209|NCT04634448|PROCEDURE|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
219516210|NCT04634448|DIAGNOSTIC_TEST|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
218895687|NCT03449719|RADIATION|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
219203980|NCT04658693|DEVICE|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
219203981|NCT05109871|OTHER|KForce Link|Traction (pull-type) dynamometer
219203982|NCT05826860|BEHAVIORAL|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
219203983|NCT05826860|BEHAVIORAL|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
219516211|NCT02090829|DRUG|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
219516212|NCT02090829|OTHER|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
219516213|NCT04751110|OTHER|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
219516214|NCT00866242|BIOLOGICAL|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
219516215|NCT01788956|DEVICE|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
219611308|NCT04277962|DEVICE|Triton L and D system for estimation of blood loss at time of vaginal delivery|The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
219611309|NCT04273191|DRUG|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
218895688|NCT03449719|DRUG|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
219611310|NCT00773474|DRUG|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
219611311|NCT00626457|BEHAVIORAL|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
219611312|NCT00971373|OTHER|Vestagen scrubs|antimicrobial impregnated textile
218895689|NCT04219241|BIOLOGICAL|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
218895690|NCT02784171|DRUG|Cisplatin|
218895691|NCT02784171|DRUG|Pemetrexed|
218895692|NCT02784171|DRUG|Pembrolizumab|
218895695|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
218895696|NCT03842033|BEHAVIORAL|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
218895697|NCT03842033|BEHAVIORAL|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
218895698|NCT03842033|BEHAVIORAL|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
218895699|NCT04290897|DRUG|Anhydrous Enol-oxaloacetate|Given PO
218895700|NCT04290897|OTHER|Questionnaire Administration|Ancillary studies
218895701|NCT06431633|DRUG|Zimberelimab|"Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells.~Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL.~No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle."
218895702|NCT06431633|DRUG|Sacituzumab govitecan|"Sacituzumab govitecan (SG) is an ADC composed of the following 3 components:~o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers.~o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38.~Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer."
219516216|NCT01788956|DEVICE|Co-Oximeter|
219516217|NCT03372538|PROCEDURE|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
219516218|NCT03106584|DIETARY_SUPPLEMENT|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
219516219|NCT03106584|DIETARY_SUPPLEMENT|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
219516220|NCT03843203|DEVICE|Transcranial Direct Current Stimulation - tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
219516221|NCT01166542|BIOLOGICAL|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
219516222|NCT01166542|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
219516223|NCT01166542|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
218895703|NCT06431633|DRUG|Cisplatin|"Cisplatin-based adjuvant chemotherapy~Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation."
219203984|NCT06576271|DRUG|GSK4527363|GSK4527363 will be administered to participants.
219203985|NCT06576271|DRUG|Placebo matching GSK4527363|Placebo matching GSK4527363 will be administered to participants.
219203986|NCT06576271|DRUG|Belimumab|Belimumab will be administered to participants.
219516224|NCT01166542|DRUG|Placebo|Placebo
219516225|NCT04892979|OTHER|Cardiopulmonary exercise (centre-based)|Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale \[10\], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
219516226|NCT04892979|OTHER|Cardiopulmonary exercise (online-based)|Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
219516227|NCT00001052|BIOLOGICAL|Aluminum hydroxide|
219516228|NCT00001052|BIOLOGICAL|QS-21|
219516229|NCT00001052|BIOLOGICAL|rgp120/HIV-1MN|
219516230|NCT05063409|OTHER|Treatment|Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
219516231|NCT01856088|DEVICE|Inspiron Stent|stent implantation
219516232|NCT01856088|DEVICE|Biomatrix Flex Stent|stent implantation
219203987|NCT05436652|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
219516233|NCT03044548|OTHER|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
219516234|NCT02625948|DRUG|Tranexamic Acid|
219516235|NCT01932840|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
219516236|NCT04462263|DRUG|HTL0014242|Solid suspension capsule
219516237|NCT02497456|BEHAVIORAL|Follow-up counselling|
219516238|NCT05310370|GENETIC|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
219516239|NCT00394056|DRUG|Vestipitant|NK1 receptor antagonist
219516240|NCT00394056|DRUG|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
218895704|NCT06431633|DRUG|Carboplatin|Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02
218895705|NCT00539162|BEHAVIORAL|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
218895706|NCT06308666|DEVICE|Delefilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
218895707|NCT01748097|DRUG|sodium bicarbonate 4.2%|
219516241|NCT00394056|OTHER|Placebo|Placebo
219516242|NCT00109109|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
218895708|NCT06624163|BEHAVIORAL|OHWL Clinic Activities (Standard of Care)|Following a directed history and physical at the initial visit, the OHWL Care provider (OCP) develops a medical and weight management plan, which includes laboratory testing (such as for Hemoglobin A1C (HbA1c), consultant referrals (e.g. sleep, heart failure clinics) and referral to nutritionists and physical therapy (PT). The OCP begins the process of establishing patient goals, which will be followed up by the coach. The OCP reviews patient progress with the goals during face-to-face visits (some by telehealth) at two, four and six months. As part of the standard initial clinic evaluation, a medical assistant evaluates grip strength (using a hand dynamometer) the timed up and go mobility test; these are repeated at the 6-month visit.
219516243|NCT03392298|DRUG|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
218895709|NCT06624163|BEHAVIORAL|Coach Activities|A patient coach follows patients outside of clinic to ensure adherence with referral appointments and use of recommended community services. The coach assesses the participant at baseline, 3 months, and 6 months using the Patient-Specific Functional Scale and follows up with patients via phone over 6 months. The coach utilizes S.M.A.R.T. (Specific, Measurable, Achievable, Relevant, Time-bound) goals to facilitate, for example, transportation, barriers to scheduling, etc. The coach follows up on specialist referral recommendations, physical therapy, and nutrition program, as well as social work recommendations. Barriers and facilitators to program adherence are identified and addressed.
218895710|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in DDP
218895711|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in HT
218895712|NCT03546972|OTHER|Questionnaire Administration|Ancillary studies
218895713|NCT04965688|DRUG|Biopsy-Guided Therapy Selection|"All enrolled participants will undergo a tumor biopsy, which will be analyzed for genomic and transcriptomic alterations using FoundationOne (DNA) and Fulgent (RNA). Based on the genomic findings, participants will receive one of the following therapy standard-of-care treatment options:~PI3K inhibitor + anti-estrogen therapy ( alpelisib + fulvestrant)~MTOR inhibitor + anti-estrogen therapy (everolimus + exemestane)~Anti-estrogen therapy alone (fulvestrant monotherapy)~Cytotoxic chemotherapy (capecitabine)"
219035396|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
219035397|NCT00956410|BIOLOGICAL|CAD106|
219035398|NCT00003739|BIOLOGICAL|filgrastim|
219035399|NCT04076644|DEVICE|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
219035400|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
219516244|NCT01431924|DRUG|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
219516245|NCT01431924|DRUG|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
219035401|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
219203988|NCT05436652|DRUG|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
219516246|NCT01562496|BEHAVIORAL|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
219516247|NCT03333226|PROCEDURE|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
219516248|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months.
219516249|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
219516250|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months
219516251|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
219516252|NCT01722981|PROCEDURE|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
219611313|NCT05847348|DRUG|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
219611314|NCT05847348|OTHER|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
219611315|NCT06633874|DIAGNOSTIC_TEST|TD Playing the Serious Game APSOU|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then, the child may interact with the Serious Game. Typically developed (TD) children engage under the clinician's face-to-face supervision with the serious game APSOU, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for TD children to play the whole game is estimated to be 45 minutes.
219611316|NCT06633874|DIAGNOSTIC_TEST|Non-TD Playing Serious Game|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then the child may interact with the serious game. Non-typically developed (non-TD) children engage under the clinician's face-to-face supervision with the serious game Apsou, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for non-TD children to play the whole game is estimated to be over an hour.
219611317|NCT04469504|OTHER|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
219611318|NCT04469504|DIETARY_SUPPLEMENT|Oral Impact|perioperative immunonutrition by ORAL IMPACT
219611319|NCT05282563|PROCEDURE|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
219516253|NCT00770510|DRUG|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
219516254|NCT00770510|DRUG|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
218895714|NCT05864586|BEHAVIORAL|Vaping study EC A|Vaping two puffs using the study EC device
218895715|NCT05864586|BEHAVIORAL|Vaping study EC B|Vaping two puffs using the study EC device
218895716|NCT05864586|BEHAVIORAL|Vaping study EC C|Vaping two puffs using the study EC device
219035402|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
219516255|NCT00770510|DRUG|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
219516256|NCT00770510|DRUG|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
219611320|NCT02459938|DRUG|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
219611321|NCT02459938|DRUG|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
219611322|NCT01912261|DRUG|Placebo|one capsule orally daily times 84 days
219611323|NCT01912261|DRUG|Polysaccharide iron complex|150 mg daily orally times 84 days
219611324|NCT04615351|DRUG|Metformin|Medication
219611325|NCT04359797|OTHER|Prone|Provider-recommended guidance on prone positioning of patients
219611326|NCT04359797|OTHER|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
218895717|NCT05864586|BEHAVIORAL|Vaping study EC D|Vaping two puffs using the study EC device
218895718|NCT05864586|BEHAVIORAL|Vaping study EC E|Vaping two puffs using the study EC device
218895719|NCT05864586|BEHAVIORAL|Vaping study EC F|Vaping two puffs using the study EC device
218895720|NCT05864586|BEHAVIORAL|Vaping study EC G|Vaping two puffs using the study EC device
218895721|NCT05864586|BEHAVIORAL|Vaping study EC H|Vaping two puffs using the study EC device
218895722|NCT05864586|BEHAVIORAL|Vaping study EC I|Vaping two puffs using the study EC device
218895723|NCT05864586|BEHAVIORAL|Vaping study EC J|Vaping two puffs using the study EC device
218895724|NCT04215809|DRUG|Lisaftoclax|Lisaftoclax investigation drug in ramp up dosing
218895725|NCT06848348|DRUG|Halneuron|Halneuron for Subcutaneous Injection
218895726|NCT06848348|DRUG|Placebo|Placebo for Subcutaneous Injection
219035403|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
219035404|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
219035405|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
219035406|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
219035407|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
219035408|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
219516257|NCT00770510|DRUG|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
219611327|NCT01609205|BIOLOGICAL|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
219516258|NCT03150602|DRUG|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
219516259|NCT04188821|PROCEDURE|breast drain removal|"Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care."
219516260|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
219516261|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
219516262|NCT00571428|DRUG|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
219611328|NCT01108627|DRUG|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
218895727|NCT05044962|DRUG|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
219611329|NCT01108627|DRUG|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
218895728|NCT05044962|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
218895729|NCT05044962|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
218895730|NCT05044962|DRUG|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
218895731|NCT05044962|DRUG|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
218895732|NCT03151733|PROCEDURE|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
219035409|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
219516263|NCT02192346|DRUG|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
219611330|NCT01108627|DRUG|foradil|open-labeled inhaled corticosteroids (ICS); foradil
219611331|NCT03691727|DRUG|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
219611332|NCT03691727|DIAGNOSTIC_TEST|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
219516264|NCT02192346|DRUG|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
219516265|NCT02192346|DRUG|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
219516266|NCT02192346|DRUG|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
218895733|NCT03151733|PROCEDURE|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
218895734|NCT06156735|OTHER|Passive Music Therapy (P)|Music Therapy Intervention
218895735|NCT06156735|OTHER|Active Music Therapy (A)|Music Therapy Intervention
218895736|NCT06156735|OTHER|Standard Care Control Condition (C)|Without any intervention
218895737|NCT05421013|DRUG|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
218895738|NCT03671226|OTHER|Questionnaire Administration|Given questionnaire
218895739|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
218895740|NCT06725355|DRUG|IN-R00002|Single administration of IN-R00002 60mg
219035410|NCT05771428|DRUG|ABBV-552|Oral Capsule
219035411|NCT05771428|DRUG|Placebo for ABBV-552|Oral Capsule
219035412|NCT06270459|DEVICE|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
219035413|NCT06196671|DRUG|H101|H101 15x10\^11vp intratumorally injection starts at day 1.
219203989|NCT05436652|DRUG|Prednisolone 10mg|Standard of care prednisolone
219035414|NCT06196671|DRUG|Camrelizumab|Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
219516267|NCT02192346|DRUG|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
219516268|NCT02192346|DRUG|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
219516269|NCT02192346|DRUG|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
219516270|NCT02192346|DRUG|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
219516271|NCT02192346|DRUG|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
219516272|NCT04087395|DEVICE|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
219516273|NCT04087395|DEVICE|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
218895741|NCT06725355|DRUG|IN-G00002|Single administration of IN-G00002 60mg
218895742|NCT07065513|DIAGNOSTIC_TEST|Normal diet|Normal diet (control group, 20 participants: 10 boys and 10 girls).
219516274|NCT05127577|OTHER|Abdominal massage|Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
218895743|NCT07065513|COMBINATION_PRODUCT|Normal diet plus nutritional protein-based bar|: Normal diet plus nutritional protein-based bar (intervention group, 20 participants: 10 boys and 10 girls). The participants will consume 3 servings of 14g each per day, providing 6.8g protein and 283 kcal
218895744|NCT06748001|DRUG|Avapritinib|Avapritinib will be administered in accordance with the parent study protocol.
219516275|NCT02864758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
219035415|NCT04576117|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219516276|NCT02864758|DRUG|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
219516277|NCT02864758|DRUG|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
219516278|NCT03057249|OTHER|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
219516279|NCT00025896|DRUG|recombinant human acid alpha-glucosidase (rhGAA)|
219516280|NCT06486116|BEHAVIORAL|Task Specific Physical Therapy Home Program|Home exercise program based on specific findings from physical therapy evaluations.
219516281|NCT02840409|DRUG|Vinblastine|
218895745|NCT07066150|OTHER|Apply a cream containing 0.05% marula oil-derived ceramide NPs|The participants were requested to apply a cream containing 0.05% marula oil-derived ceramide NPs on their faces twice daily for 28 consecutive days.
218895746|NCT06921694|BEHAVIORAL|Runner group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (running), a schedule of gradually intensifying strengthening exercises and flexibility exercises
219035416|NCT04576117|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219516282|NCT02840409|DRUG|Bevacizumab|
219516283|NCT05427656|RADIATION|[18F] TRACK|We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.
219611333|NCT03691727|DIAGNOSTIC_TEST|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
219611334|NCT03691727|BEHAVIORAL|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
219611335|NCT03691727|DIAGNOSTIC_TEST|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
219611336|NCT03691727|OTHER|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
219611337|NCT05522127|OTHER|Colonoscopy|Colonoscopy
219611338|NCT05522127|OTHER|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
219613390|NCT04395456|OTHER|WFI 5% glucose|Placebo
219035417|NCT04576117|OTHER|Quality-of-Life Assessment|Ancillary studies
219035418|NCT04576117|OTHER|Questionnaire Administration|Ancillary studies
219035419|NCT04576117|DRUG|Selumetinib Sulfate|Given PO
219035420|NCT04576117|DRUG|Vinblastine Sulfate|Given IV
219035421|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
219035422|NCT05630235|DRUG|CBD/CBD-A|Participants will be administered a one-time dose of 204.6 mg of CBD/CBD-A orally.
219035423|NCT05630235|OTHER|Placebo|The placebo equivalent of the CBD/CBD-A dose administered orally.
219203990|NCT05436652|DRUG|Additional prednisolone|Over encapsulated prednisolone
219203991|NCT05436652|DRUG|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
219203992|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
219516284|NCT05427656|DEVICE|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
219516285|NCT03174756|DRUG|Hypochlorous Acid|Mouthwashes of antiplaque agents
219516286|NCT03174756|DRUG|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
219516287|NCT03174756|OTHER|Placebo|Sterile water as placebo
219516288|NCT05823207|OTHER|sage essential oil|It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
219516289|NCT03463278|DIAGNOSTIC_TEST|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
219516290|NCT05007288|OTHER|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
219516291|NCT05007288|OTHER|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
219516292|NCT00998023|DEVICE|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
219516293|NCT00998023|DEVICE|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
219516294|NCT00711464|DRUG|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
219516295|NCT02309827|DRUG|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
219516296|NCT00594347|BIOLOGICAL|Pneumo 23|Vaccine (Pneumo 23)
219516297|NCT00594347|BIOLOGICAL|Prevnar|Vaccine (Prevnar)
219516298|NCT05380271|DRUG|sequential DEB-BACE and Arotinib and Tirelizumab|DEB-BACE+Arotinib + Tirelizumab
219516299|NCT05380271|DRUG|DEB-BACE alone|DEB-BACE alone
219516300|NCT00757809|DRUG|neratinib|HKI-272
219611339|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with ALL plasty|ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
219611340|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with modified Lemaire's LET|ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
219611341|NCT02083627|DRUG|rosuvastatin|Oral
219611342|NCT02083627|DRUG|fidaxomicin|Oral
219611343|NCT00006760|BIOLOGICAL|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
219611344|NCT00006760|DRUG|ifosfamide|V over 24 hours on days 1-4
219611345|NCT00006760|DRUG|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
219611346|NCT02110784|DRUG|Eurartesim tablets|dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
218895747|NCT06921694|BEHAVIORAL|Swim/Cycle Group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (swim/cycle), a schedule of gradually intensitfing strengthening exercises and flexibility exercises
219203993|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
219516301|NCT03397862|DRUG|Donepezil TDS|Donepezil patch
219516302|NCT03397862|DRUG|Vehicle TDS|Placebo patch
219516303|NCT03553160|OTHER|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
219516304|NCT04963192|DEVICE|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
219516305|NCT04963192|DEVICE|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
219611347|NCT03200717|DRUG|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
219611348|NCT01807312|DEVICE|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
218895748|NCT06920810|DRUG|viscum album|"Active Ingredient: Viscum album Excipients: Ascorbic acid, disodium phosphate dihydrate, monosodium phosphate monohydrate Formulation: Injectable solution contained in a colorless ampoule; the solution is colorless to pale yellow and clear.~Manufacturer: LB Abnoba Co., Ltd. Dosage and Administration: Administered subcutaneously three times per week, with dose escalation according to the following protocol."
218895749|NCT00564213|DRUG|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
218895750|NCT03739346|BEHAVIORAL|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
219516306|NCT04963192|OTHER|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
219516307|NCT04963192|DEVICE|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
219611349|NCT01807312|DEVICE|Placebo|
218895751|NCT03739346|BEHAVIORAL|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
219516308|NCT04963192|DEVICE|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
219516309|NCT04963192|DEVICE|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
219516310|NCT04963192|DEVICE|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
219516311|NCT04963192|DEVICE|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
219516312|NCT04963192|OTHER|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
219516313|NCT04963192|OTHER|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
219516314|NCT04963192|OTHER|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
219516315|NCT04963192|OTHER|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
219516316|NCT04963192|OTHER|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
219516317|NCT01089647|DRUG|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
219516318|NCT01089647|DRUG|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
219516319|NCT00995553|BEHAVIORAL|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
219516320|NCT00995553|BEHAVIORAL|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
219516321|NCT06277193|DIAGNOSTIC_TEST|valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
219516322|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
219516323|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
218895752|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
218895753|NCT06103994|OTHER|Placebo|Placebo
218895754|NCT04845763|OTHER|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
218895755|NCT04254601|DEVICE|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
218895756|NCT04254601|DRUG|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
218895757|NCT03213834|PROCEDURE|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
219516324|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
219516325|NCT05892978|OTHER|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
219516326|NCT03840057|DRUG|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
219516327|NCT03840057|DRUG|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
218895758|NCT03213834|PROCEDURE|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
218895759|NCT03213834|DRUG|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
218895760|NCT03213834|DRUG|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
218895761|NCT00791908|PROCEDURE|Electrodessication|Treatment applied to a third of the torso at each study visit.
218895762|NCT00791908|PROCEDURE|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
218895763|NCT00791908|PROCEDURE|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
218895764|NCT06330259|DIAGNOSTIC_TEST|menstrual cycle monitoring|frequent serum sampling and 3D ultrasound
218895765|NCT04742114|DEVICE|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
218895766|NCT04742114|DEVICE|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
219035424|NCT06001346|BEHAVIORAL|ActiveCBT|Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
219203994|NCT03528447|OTHER|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
218895767|NCT03205176|DRUG|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
218895768|NCT03205176|DRUG|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
218895769|NCT02410239|BIOLOGICAL|Mesenchymal Stem Cells|
218895770|NCT00319254|DRUG|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
218895771|NCT03075358|DRUG|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
218895772|NCT03075358|OTHER|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
218895773|NCT01505374|PROCEDURE|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
218895774|NCT01505374|PROCEDURE|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
218895775|NCT02360228|DEVICE|tACS (alpha)|
219035425|NCT06001346|BEHAVIORAL|CalmCBT|Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
219035426|NCT05400278|OTHER|No intervention|No intervention
219035427|NCT00003217|BIOLOGICAL|filgrastim|
219203995|NCT06649266|DRUG|RBD1016|RBD1016, active drug.
218895776|NCT02360228|DEVICE|tDCS|
218895777|NCT03809494|DEVICE|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
218895778|NCT03809494|OTHER|Saline|Normal (0.9%) saline
218895779|NCT04177979|BEHAVIORAL|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
218895780|NCT02095080|DIETARY_SUPPLEMENT|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
219035428|NCT00003217|DRUG|cyclophosphamide|
219035429|NCT00003217|DRUG|cytarabine|
219035430|NCT00003217|DRUG|dexamethasone|
219035431|NCT00003217|DRUG|doxorubicin hydrochloride|
219203996|NCT06649266|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
219516328|NCT03840057|DRUG|Sodium chloride 0.9%|Normal saline is used as a placebo control.
219516329|NCT02652026|PROCEDURE|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
219516330|NCT02652026|PROCEDURE|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
219516331|NCT00927810|DRUG|Canakinumab|
219516332|NCT03920657|DRUG|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
219516333|NCT00314691|GENETIC|Blood samples|
219516334|NCT00006156|OTHER|Control|No injection of FSH
219516335|NCT00006156|DRUG|Drug: FSH|FSH Stimulation Test
219516336|NCT00198029|DEVICE|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
219516337|NCT04820868|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
218895781|NCT03308994|OTHER|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
219035432|NCT00003217|DRUG|methotrexate|
219035433|NCT00003217|DRUG|vincristine sulfate|
219035434|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
219035435|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
219035436|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
219516338|NCT01961908|DRUG|Proellex|
219516339|NCT04774081|DEVICE|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
219203997|NCT05456698|DRUG|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
219516340|NCT04337996|DIAGNOSTIC_TEST|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
219516341|NCT04716738|DIAGNOSTIC_TEST|Blood analyses and coprological|We will take a blood and stool sample
219516342|NCT03695926|DRUG|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
219516343|NCT04947956|DRUG|Camrelizumab|The camrelizumab-based treatment will be determined by the investigator.
219516344|NCT01589536|OTHER|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
219516345|NCT05083598|OTHER|6 Minute walking test|The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
219516346|NCT05083598|OTHER|Frailty questionaires|Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
219516347|NCT00790959|BEHAVIORAL|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
219516348|NCT00790959|OTHER|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
219516349|NCT00448578|DRUG|Quetiapine Fumarate|
219516350|NCT00448578|DRUG|Lithium|
219516351|NCT01184196|DRUG|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
219516352|NCT01184196|DRUG|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
219516353|NCT00814463|BEHAVIORAL|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
219516354|NCT00814463|BEHAVIORAL|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
219516355|NCT00814463|PROCEDURE|MRI|MRI done every 3 months for the length of the study.
219516356|NCT00814463|RADIATION|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
219516357|NCT00624871|DRUG|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
219516358|NCT00624871|DRUG|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
219516359|NCT00624871|DRUG|Placebo|
219516360|NCT04832230|OTHER|Hearing test|"The hearing test is composed of several examinations:~* pure tone audiogram~* otoscopy~* tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
219516361|NCT04832230|OTHER|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
219516362|NCT04832230|OTHER|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
219516363|NCT04832230|OTHER|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
218895782|NCT03308994|OTHER|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
218895783|NCT02452424|DRUG|PLX3397|PLX3397 capsules, 200 mg
218895784|NCT02452424|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 200 mg, IV
218895785|NCT03977766|PROCEDURE|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
218895786|NCT05650281|OTHER|NO INTERVENTION|NO INTERVENTION
218895787|NCT02082600|OTHER|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
218895788|NCT02082600|OTHER|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
218895789|NCT04266925|BEHAVIORAL|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
218895790|NCT04266925|OTHER|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
218895791|NCT00048698|PROCEDURE|TMS|
219516364|NCT04832230|OTHER|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
219516365|NCT04832230|OTHER|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
218895792|NCT00048698|PROCEDURE|EEG|
219516366|NCT04832230|OTHER|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
219516367|NCT04832230|BIOLOGICAL|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
219516368|NCT02686216|DRUG|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
219516369|NCT01548872|DRUG|HTK solution|50 ml/kg bolus in 2 minutes
219516370|NCT01548872|DRUG|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
219516371|NCT05964634|DIAGNOSTIC_TEST|OCT imaging|Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy.
218895793|NCT06327828|DEVICE|Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)|Semi-automated computer-aided treatment based on a mathematical model
218895794|NCT06327828|PROCEDURE|Usual care|Guiding methimazole therapy based on the treating physician's decision
219516372|NCT00098709|DEVICE|Fetal pulse oximeter|
218895795|NCT05594628|OTHER|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
218895796|NCT00559221|DRUG|FLAG+IDA|Fludarabine, cytarabine, G-CSF
218895797|NCT04205721|BEHAVIORAL|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
218895798|NCT04186871|DRUG|branebrutinib|Specified dose on specified days
218895799|NCT04186871|DRUG|abatacept|Specified dose on specified days
218895800|NCT04186871|DRUG|branebrutinib placebo|Specified dose on specified days
219516373|NCT02369042|DEVICE|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
219516374|NCT02532010|DRUG|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
219611350|NCT03254264|BEHAVIORAL|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
218895801|NCT01013857|BEHAVIORAL|Health coaching|Calling patients every week to discuss medication adherence
218895802|NCT01013857|BEHAVIORAL|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
218895803|NCT02444325|BEHAVIORAL|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
218895804|NCT02464410|BEHAVIORAL|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
219035437|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
219035438|NCT00353743|DRUG|placebo|placebo
219516375|NCT02532010|DRUG|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
219611351|NCT03254264|BEHAVIORAL|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
219035439|NCT00353743|DRUG|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
219035440|NCT01195805|DRUG|Spironolactone|1 tablet twice a day for 28 days
219035441|NCT01195805|OTHER|Placebo|1 tablet twice a day for 28 days
219611352|NCT01590303|DRUG|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
219035442|NCT01195805|DRUG|Amiloride|1 tablet twice a day for 28 days
219035443|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
219035444|NCT02498093|BEHAVIORAL|Maximal strength training|
219035445|NCT02498093|BEHAVIORAL|conventional rehabilitation|
219035446|NCT03026257|DEVICE|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
219035447|NCT03026257|DEVICE|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
219035448|NCT03026257|DEVICE|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
219035449|NCT03026257|DEVICE|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
219035450|NCT03026257|DEVICE|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
219516376|NCT02532010|DRUG|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
219516377|NCT00439764|BEHAVIORAL|General health talk|Routine clinical practice and talk on general health
219611353|NCT01590303|DRUG|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
219611354|NCT05446259|OTHER|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
219611355|NCT05225779|DIAGNOSTIC_TEST|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
218895805|NCT02464410|BEHAVIORAL|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
218895806|NCT02464410|OTHER|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
218895807|NCT04891354|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
219035451|NCT03026257|DEVICE|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
219516378|NCT00439764|BEHAVIORAL|Handout of The Back Book|Talk on health of the back and handout of The Back Book
219516379|NCT00439764|BEHAVIORAL|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
219516380|NCT04373577|PROCEDURE|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
219516381|NCT04373577|PROCEDURE|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
219516382|NCT00368277|DRUG|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
219516383|NCT00368277|DRUG|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
219516384|NCT00368277|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
219516385|NCT00368277|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
219516386|NCT01951846|DRUG|BIBF 1120|
219516387|NCT01072110|PROCEDURE|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
219516388|NCT01072110|PROCEDURE|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
219516389|NCT00984295|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
219516390|NCT00984295|BIOLOGICAL|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
219516391|NCT00984295|BIOLOGICAL|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
219516392|NCT00984295|BIOLOGICAL|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
219516393|NCT00984295|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
219516394|NCT04137822|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
219516395|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
219516396|NCT04137679|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
219516397|NCT04137679|PROCEDURE|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
219516398|NCT03075137|DEVICE|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
219516399|NCT00879242|DRUG|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
219611356|NCT00034008|BEHAVIORAL|Healing Touch|
219611357|NCT01884038|DRUG|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
219611358|NCT01884038|DRUG|Placebo|
218895808|NCT04891354|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
218895809|NCT04386642|DRUG|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
218895810|NCT04386642|DRUG|Placebo|normal saline solution in a clear 50-ml syringe
218895811|NCT01971385|DRUG|Squaric Acid solution|
218895812|NCT01971385|DRUG|Placebo solution|
219035452|NCT03026257|DEVICE|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
219035453|NCT03026257|DEVICE|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
218895813|NCT01810718|DRUG|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
218895814|NCT04342117|DRUG|duvelisib|25 mg BID, 15 mg BID
219516400|NCT03318770|DRUG|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
219516401|NCT00809042|DRUG|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
219516402|NCT00809042|DRUG|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
219516403|NCT00809042|DRUG|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
219516404|NCT00809042|DRUG|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
219516405|NCT03117673|OTHER|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
219516406|NCT02762097|PROCEDURE|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
219516407|NCT02762097|PROCEDURE|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
219516408|NCT02762097|DRUG|normal saline|Normal saline would be injected into uterine cavity to delineate defects
219516409|NCT03978403|DRUG|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
219516410|NCT03978403|DRUG|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
219516411|NCT03978403|DRUG|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
219516412|NCT03978403|DRUG|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose
219516413|NCT02581800|OTHER|App group|
219516414|NCT00857636|BEHAVIORAL|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
219516415|NCT02524990|BEHAVIORAL|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
219516416|NCT00128557|DIETARY_SUPPLEMENT|vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)|Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
219516417|NCT02697409|BEHAVIORAL|Education Against Tobacco intervention|
219516418|NCT02746952|BIOLOGICAL|UCART19|
219611359|NCT03714243|DEVICE|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
219611360|NCT03132233|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
219611361|NCT03132233|OTHER|placebo powder|matched placebo powder to the IMP.
219611362|NCT01461538|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
218895815|NCT04342117|DRUG|PI3K inhibitor|FDA approved PI3K inhibitors
218895816|NCT05209373|BEHAVIORAL|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
219035454|NCT01530971|DRUG|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
219611363|NCT01461538|DRUG|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
219611364|NCT01461538|DRUG|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
219611365|NCT00141778|DRUG|Placebo|Matching placebo taken once a day
219611366|NCT00141778|DRUG|Ramipril|Taken orally, once a day
219611367|NCT00141778|DRUG|Spironolactone|Taken orally, once a day
219611368|NCT01723475|BIOLOGICAL|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
219516419|NCT00143819|DRUG|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
219516420|NCT00143819|DRUG|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
219516421|NCT00000406|PROCEDURE|Progressive resistance exercise|
219516422|NCT03587207|BIOLOGICAL|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
219516423|NCT03587207|BIOLOGICAL|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group, rMenBOMV+ACWY\_D Group and rMenBOMV Group
219516424|NCT03587207|BIOLOGICAL|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group and rMenBOMV+ACWY\_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
219516425|NCT01473966|DIETARY_SUPPLEMENT|coffee|patients will receive a cup of coffee at room temperature orally twice daily
219516426|NCT01473966|DIETARY_SUPPLEMENT|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
219516427|NCT03416595|DIETARY_SUPPLEMENT|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
219516428|NCT03416595|DIETARY_SUPPLEMENT|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
219516429|NCT00966953|DRUG|Fluoride|Brush twice daily
219516430|NCT00966953|DRUG|Triclosan/Fluoride toothpaste|Brush twice daily
219516431|NCT00966953|DRUG|Fluoride|Brush twice daily
219516432|NCT00966953|DRUG|Fluoride|Brush twice daily
219516433|NCT00966953|OTHER|antibacterial plant extract|Brush twice daily
219516434|NCT06496269|OTHER|No intervention|No intervention
219516435|NCT03283709|DEVICE|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
218895817|NCT05209373|BEHAVIORAL|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
219516436|NCT03283709|DEVICE|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
219516437|NCT05345132|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
219516438|NCT05345132|DRUG|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
219516439|NCT02359604|DRUG|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
219516440|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
218895818|NCT03209466|DRUG|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
218895819|NCT03209466|DRUG|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
219516441|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
219516442|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
219516443|NCT05011500|RADIATION|Radiotherapy with Closed Mask|Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.
218895820|NCT01100359|DRUG|carboplatin|
218895821|NCT01100359|DRUG|liposome-encapsulated doxorubicin citrate|
218895822|NCT01100359|OTHER|laboratory biomarker analysis|
218895823|NCT01100359|PROCEDURE|quality-of-life assessment|
218895824|NCT01142622|DRUG|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
218895825|NCT01142622|DRUG|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
219516444|NCT05011500|RADIATION|Radiotherapy with Open Mask and Surface Scanning|Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
219516445|NCT05011500|RADIATION|Radiotherapy with No Mask|Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
219516446|NCT01734772|DRUG|dabigatran etexilate|multiple doses of dabigatran
219516447|NCT01734772|DRUG|dabigatran etexilate|medium dose dabigatran
219516448|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
219516449|NCT01734772|DRUG|ticagrelor|multiple doses of ticagrelor
219516450|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
219516451|NCT01734772|DRUG|dabigatran etexilate|single dose of dabigatran
219516452|NCT02535507|DRUG|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
218895826|NCT01568294|DRUG|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
218895827|NCT03094533|DRUG|TIVA|total intravenous anesthesia with propofol
218895828|NCT03094533|DRUG|VIMA|volatile induction and maintenance anesthesia with sevoflurane
219035455|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
219516453|NCT02627911|DEVICE|Diabeloop System|Insulin delivery
219516454|NCT02627911|DEVICE|Continuous Glucose Monitoring|
219516455|NCT02627911|DEVICE|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
219516456|NCT02627911|DIETARY_SUPPLEMENT|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
219516457|NCT02556242|OTHER|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
219516458|NCT02556242|OTHER|Generalised Indoor residual spraying|IRS is carried out as normally practiced
219516459|NCT00914667|DRUG|warfarin|Single Dose Warfarin 25 mg on Day 1
219516460|NCT00914667|DRUG|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
219516461|NCT06309706|OTHER|No intervention|Just observation
219516462|NCT02281578|BEHAVIORAL|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
219516463|NCT02281578|BEHAVIORAL|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
219516464|NCT04984018|DRUG|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
219516465|NCT02217722|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
219516466|NCT02217722|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
219516467|NCT03680170|BEHAVIORAL|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
219516468|NCT03680170|BEHAVIORAL|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
219516469|NCT01600495|OTHER|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
219516470|NCT00569426|DEVICE|NovoFine® needle 6 mm|
219516471|NCT00569426|DEVICE|NovoFine® needle 8 mm|
219516472|NCT04297852|DIETARY_SUPPLEMENT|Vegan drink|Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
219516473|NCT04297852|DIETARY_SUPPLEMENT|Control|Placebo drink Dose: 500 mL a day
219516474|NCT03425864|PROCEDURE|connective tissue graft|patient will receive immediate implant and connective tissue graft
218895829|NCT05313087|BIOLOGICAL|COVID-19 vaccine|assess response to vaccine
218895830|NCT03963648|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
219035456|NCT04489030|OTHER|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
219516475|NCT03425864|DEVICE|immediate implant|patient will receive immediate implant with connective tissue graft.
219516476|NCT01298856|PROCEDURE|hydrotherapy|hydrotherapy and ankle taping and land-based
219516477|NCT00766688|DRUG|AVE5530|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
219516478|NCT00766688|DRUG|Placebo|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
219516479|NCT00186706|DRUG|Selenium|
218895831|NCT04408040|BIOLOGICAL|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
218895832|NCT06356051|DEVICE|Echocardiography|cardiovascular evaluation
219035457|NCT02366832|PROCEDURE|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
219516480|NCT00219830|BEHAVIORAL|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
219516481|NCT01790568|DRUG|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
219516482|NCT01790568|DRUG|Tacrolimus|
219516483|NCT01790568|DRUG|Methotrexate|
219516484|NCT03958890|DRUG|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
219516485|NCT03958890|DRUG|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
219516486|NCT00210548|DRUG|paliperidone palmitate|
219516487|NCT02994056|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
219516488|NCT02994056|DRUG|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
219516489|NCT01701284|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
219516490|NCT04107493|DEVICE|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
219516491|NCT04107493|DEVICE|Mobi|ResMed's variant of POC
219516492|NCT01197963|PROCEDURE|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
219611369|NCT01723475|BIOLOGICAL|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
219611370|NCT05209607|OTHER|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
219203998|NCT02971046|OTHER|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
219203999|NCT06815029|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219611371|NCT05209607|OTHER|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
219204000|NCT06815029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially
219204001|NCT06815029|PROCEDURE|Echocardiography|Undergo echocardiography
219516493|NCT01197963|DIETARY_SUPPLEMENT|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
219611372|NCT02729909|DRUG|Lubiprostone|Lubiprostone capsules
219611373|NCT02729909|DRUG|Placebo|Lubiprostone placebo-matching capsules
219611374|NCT00003183|BIOLOGICAL|filgrastim|
219611375|NCT00003183|DRUG|mitoxantrone hydrochloride|
219611376|NCT04763954|OTHER|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
219611377|NCT03220854|RADIATION|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
219611378|NCT03220854|OTHER|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
219611379|NCT03220854|OTHER|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
219611380|NCT00082277|DRUG|Anastrozole|1mg/Day Oral
219611381|NCT00082277|DRUG|Risedronate Sodium|35mg/week, oral
219611382|NCT02660905|DRUG|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
219204002|NCT06815029|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
219204003|NCT06815029|PROCEDURE|Intracranial Catheter Placement|Undergo placement of Rickham catheter
219204004|NCT06815029|PROCEDURE|Leukapheresis|Undergo leukapheresis
219611383|NCT02660905|DRUG|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
219611384|NCT06353698|DIETARY_SUPPLEMENT|fasting mimicking diet|Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
219611385|NCT00368797|DRUG|XRP0038 (NV1FGF)|
219611386|NCT01321827|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
219611387|NCT01321827|DRUG|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
219611388|NCT03580473|DRUG|SATURNO II association|opthalmic solution, 4 times a day
219611389|NCT03580473|DRUG|Vigadexa®|opthalmic solution, 4 times a day
219611390|NCT03660176|DRUG|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
219611391|NCT03660176|OTHER|routine management|the colonic irrigations
219611392|NCT03657225|DEVICE|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
219611393|NCT03657225|DRUG|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
219611394|NCT00922740|DRUG|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
219611395|NCT00922740|DRUG|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
219611396|NCT00079430|PROCEDURE|adjuvant therapy|
219204005|NCT06815029|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219204006|NCT06815029|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
219204007|NCT06815029|PROCEDURE|Resection|Undergo surgical resection
219204008|NCT03267498|DRUG|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
219204009|NCT03267498|DRUG|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
219204010|NCT03267498|RADIATION|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
219204011|NCT03614533|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
219611397|NCT00079430|DRUG|paclitaxel|Given IV
219611398|NCT00079430|DRUG|carboplatin|Given intraperitoneally
219611399|NCT00079430|BIOLOGICAL|bevacizumab|Given IV
218895833|NCT04966949|PROCEDURE|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
219516494|NCT02686840|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219035458|NCT02366832|DEVICE|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
219516495|NCT02686840|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
219611400|NCT04663230|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
219611401|NCT06090201|OTHER|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
219611402|NCT03959969|OTHER|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
219611403|NCT03959969|OTHER|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
219611404|NCT03959969|DRUG|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
219611405|NCT03959969|DRUG|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
219611406|NCT02258763|DRUG|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
219611407|NCT02258763|DRUG|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
219611408|NCT02730663|DEVICE|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
219611409|NCT05919615|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
219611410|NCT05919615|DRUG|Normal saline|0.9% sodium chloride normal saline
219611411|NCT05843747|OTHER|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
219611412|NCT06471374|BEHAVIORAL|Circadian rhythm assessment|Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
219611413|NCT06471374|BEHAVIORAL|Light sensitivity assessment|Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
218895834|NCT02154841|BEHAVIORAL|Questionnaire, taste test, visual food test|
218895835|NCT00543387|DRUG|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
218895836|NCT00543387|DRUG|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
219035459|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
219611414|NCT05851027|DRUG|QL0911|Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
218895837|NCT03611673|OTHER|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
219035460|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
219035461|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
219035462|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
219035463|NCT00232908|DRUG|ARV regimen|As prescribed
219035464|NCT00232908|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
219035465|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
219611415|NCT03768362|PROCEDURE|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
219611416|NCT03768362|PROCEDURE|Resection strabismus surgery|resection strabismus surgery
219611417|NCT02058329|OTHER|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
219516496|NCT05793736|DEVICE|Biofeedback training|The intervention lasts 5 weeks, twice a week, each session lasts 45 minutes in which HRV (Heart Rate Variability) is detected, through plethysmographic sensors placed on the finger or earlobe during assigned tasks. During tasks that involve progressively more complex phases, they allow the person to receive immediate feedback on the video screen.
219516497|NCT05793736|DRUG|Treatment as usual|The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
219516498|NCT01925313|DRUG|CJ-30044|20.51mg a day,PO,QD
219516499|NCT01925313|DRUG|TALION TAB. 10mg|10mg a day,PO,BID
219611418|NCT05347329|DIETARY_SUPPLEMENT|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
219516500|NCT04025034|PROCEDURE|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
219611419|NCT03623191|OTHER|Clinical examination|
219035466|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
219204012|NCT03614533|BIOLOGICAL|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
219516501|NCT03294356|OTHER|FT210771|An electronic cigarette
219516502|NCT03294356|OTHER|FT210751|An electronic cigarette
219516503|NCT03294356|OTHER|6T30134157764|An electronic cigarette
219516504|NCT03294356|OTHER|G41A7C071|An electronic cigarette
219516505|NCT03294356|OTHER|M011161212|An electronic cigarette
219516506|NCT03294356|OTHER|FT21002|A combustible cigarette
219516507|NCT03758833|DIAGNOSTIC_TEST|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
219516508|NCT03758833|PROCEDURE|Single embryo transfer|Transfer of single embryo
219516509|NCT03758833|PROCEDURE|Double embryo tranfer|Transfer of two embryos
219611420|NCT05873790|DRUG|Serplulimab plus chemotherapy|"Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles."
219611421|NCT00767403|BEHAVIORAL|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
219611422|NCT00767403|BEHAVIORAL|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
219611423|NCT00767403|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
219611424|NCT00006038|DRUG|cisplatin|
219611425|NCT00006038|DRUG|docetaxel|
219516510|NCT05875688|OTHER|Cementation Technique A|"* Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration."
219516511|NCT05875688|OTHER|Cementation Technique B|"* Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place."
219035467|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
219035468|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
219516512|NCT05875688|OTHER|Cementation Technique C|"* The utilisation of an appropriate quantity of cement.~* The mitigation of cement waste.~* Prolonged retention of dental crowns."
219611426|NCT00006038|DRUG|floxuridine|
219516513|NCT00414947|DRUG|Vildagliptin (LAF237)|
219611427|NCT00006038|DRUG|fluorouracil|
219035469|NCT05932186|PROCEDURE|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
219035470|NCT05932186|PROCEDURE|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
219035471|NCT01387321|DRUG|BYL719|
219035472|NCT05501106|OTHER|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
219516514|NCT03992287|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
219516515|NCT03992287|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219611428|NCT00006038|DRUG|leucovorin calcium|
219204013|NCT05511649|DEVICE|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
219204014|NCT06845631|DEVICE|PNS device, observational study, no intervention during study|PNS device, observational study, no intervention during study
219204015|NCT06985784|OTHER|Interview|Ancillary studies
219204016|NCT06985784|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
219204017|NCT06985784|OTHER|Questionnaire Administration|Ancillary studies
219516516|NCT02113306|DEVICE|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
219611429|NCT00006038|PROCEDURE|conventional surgery|
219611430|NCT06398379|OTHER|Fecal Virome Transplantation|The primary steps of the production of fecal virome transplantation capsules is the same as when producing fecal microbiota transplantation capsules. Through an subsequent proces of filtering bacterial parts of the material are removed. The material, now called fecal virome transplanation material, has then been moved to capsules and stored in -80c untill use.
219611431|NCT06398379|OTHER|Fecal microbiota Transplantation|Donor fecal material is mixed with cryoprotectant and NaCl. Following processing the material transfered to capsules and is stored at -80c prior to use.
219611432|NCT01245283|OTHER|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
219611433|NCT01245283|OTHER|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
219611434|NCT01245283|OTHER|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
219516517|NCT02113306|DEVICE|sham stimulation|electrodes will be put upside down
219516518|NCT02739542|DRUG|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
219516519|NCT02739542|DRUG|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
219516520|NCT01775215|RADIATION|Cardiac I123-MIBG Scintigraphy|
219516521|NCT01775215|OTHER|Cardiac MRI|
219611435|NCT00091611|DRUG|IL-2 (interleukin-2)|
219611436|NCT00091611|DRUG|OKT3|
219611437|NCT00091611|DRUG|Cyclophosphamide|
219611438|NCT00091611|DRUG|Fludarabine|
219611439|NCT00091611|DRUG|Mesna|
219611440|NCT03672227|BEHAVIORAL|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
219516522|NCT01775215|OTHER|Stress and rest Echocardiogram|
219516523|NCT01775215|OTHER|High Sensitivity Troponin I|
219516524|NCT01775215|OTHER|Brain Natriuretic Peptide|
219516525|NCT02042911|DRUG|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
218895838|NCT04532775|DRUG|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
218895839|NCT04532775|DRUG|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
218895840|NCT04532775|DRUG|Bupivacaine Hydrochloride|local anesthetic drug
218895841|NCT04532775|DRUG|saline 0.9%|solution for intravenous and epidural injection
218895842|NCT04532905|OTHER|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
218895843|NCT00083005|DRUG|docetaxel|
218895844|NCT00083005|DRUG|estramustine phosphate sodium|
218895845|NCT00083005|DRUG|thalidomide|
218895846|NCT05109923|DIETARY_SUPPLEMENT|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
218895847|NCT05109923|DIETARY_SUPPLEMENT|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
218895848|NCT02742545|BEHAVIORAL|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
218895849|NCT05429398|DRUG|Linperlisib Tablet|"1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
219516526|NCT04765033|DRUG|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
219516527|NCT05038813|DRUG|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
219516528|NCT04656977|OTHER|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
218895850|NCT04520399|OTHER|none intervention|there is no intervention in this study
218895851|NCT01904045|OTHER|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
218895852|NCT01904045|OTHER|tacrolimus Prograf|intake of Prograf twice daily for 3 months
218895853|NCT00169156|DRUG|Rituximab|375 mg/m2 D1
218895854|NCT00169156|DRUG|Prednisone|40 mg/m2 D1 to D5
218895855|NCT00169156|DRUG|Doxorubicine|50 mg/m2 D1
218895856|NCT00169156|DRUG|Cyclophosphamide|750 mg/m2 D1
218895857|NCT00169156|DRUG|Vincristine|1,4 mg/m2 D1
218895858|NCT00940498|DRUG|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
218895859|NCT03932760|BEHAVIORAL|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
218895860|NCT03932760|BEHAVIORAL|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
219516529|NCT04656977|OTHER|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
218895861|NCT02373774|DEVICE|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
218895862|NCT00513435|DRUG|saracatinib|Given PO
218895863|NCT00513435|OTHER|laboratory biomarker analysis|Correlative studies
218895864|NCT06337708|BEHAVIORAL|Smart Walk|Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
218895865|NCT06337708|BEHAVIORAL|Fitbit|This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.
218895866|NCT03707470|DEVICE|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
218895867|NCT03707470|DEVICE|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
218895868|NCT03707470|PROCEDURE|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
218895869|NCT01695356|DRUG|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
218895870|NCT01695356|DRUG|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
219516530|NCT01547195|PROCEDURE|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
218895871|NCT01825967|OTHER|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
219516531|NCT01547195|PROCEDURE|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
219516532|NCT03714295|OTHER|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
219516533|NCT02202174|DEVICE|Supraglottic Airway Device|
219516534|NCT04322071|OTHER|Interview|Qualitative interviews only
219516535|NCT03481309|DEVICE|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
219516536|NCT03481309|DEVICE|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
219516537|NCT03481309|DEVICE|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
219516538|NCT03501680|DRUG|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
219516539|NCT03501680|DEVICE|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
219516540|NCT05013671|OTHER|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
219516541|NCT05013671|OTHER|balance|compare the balance of residents with BPPV with residents without BPPV
219516542|NCT00721058|OTHER|CT-scan|A pre-operative CT-scan will be made
218895872|NCT04523883|RADIATION|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
219516543|NCT04935775|OTHER|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
219516544|NCT03951948|OTHER|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
219516545|NCT04516148|DRUG|Cefazolin|Dosing per hospital policy
219516546|NCT04516148|DRUG|Clindamycin|Dosing per hospital policy
219516547|NCT02946099|PROCEDURE|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
219611441|NCT07057557|OTHER|Aloe Vera Gel Dressing|Participants in this arm will receive Aloe Vera gel applied directly to the split-thickness skin graft (STSG) donor site immediately after graft harvesting. The Aloe Vera gel will be applied in a sterile manner, followed by secondary dressing with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
218895873|NCT04523883|DRUG|JS001|JS001 240mg every three week
218895874|NCT01646606|PROCEDURE|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
218895875|NCT01646606|PROCEDURE|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
218895876|NCT00000706|DRUG|Quinine sulfate|
219204018|NCT06985784|OTHER|Virtual Technology Intervention|Receive 3D mindfulness VR headset
219204019|NCT06985784|OTHER|Virtual Technology Intervention|Receive 2D non-immersive VR headset
219516548|NCT02946099|PROCEDURE|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
218895877|NCT00000706|DRUG|Probenecid|
219516549|NCT00570271|OTHER|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
219516550|NCT00570271|OTHER|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
219516551|NCT00570271|OTHER|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
219516552|NCT00570271|OTHER|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
219516553|NCT00570271|OTHER|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
219516554|NCT00570271|OTHER|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
219516555|NCT01693783|BIOLOGICAL|Ipilimumab|Given IV
219516556|NCT01693783|OTHER|Laboratory Biomarker Analysis|Correlative studies
219516557|NCT04267666|DEVICE|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
219516558|NCT04267666|OTHER|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
219516559|NCT03400306|DRUG|Veliparib, capsule|capsule; 50 mg or 100 mg
219516560|NCT03400306|DRUG|Veliparib, tablet|tablet; 400 mg
219516561|NCT03400306|DRUG|Carboplatin|Intravenous
219516562|NCT03400306|DRUG|Paclitaxel|Intravenous
219516563|NCT01729130|PROCEDURE|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
219516564|NCT04758936|DRUG|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
219516565|NCT04758936|DRUG|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
219516566|NCT02346201|DRUG|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
219611442|NCT07057557|OTHER|Paraffin-Based Tulle Dressing|Participants in this arm will receive a conventional paraffin-based tulle dressing impregnated with chlorhexidine applied to the STSG donor site. The dressing will be followed by secondary coverage with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
219516567|NCT02346201|DRUG|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
219516568|NCT00698100|BIOLOGICAL|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
219516569|NCT00698100|BIOLOGICAL|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
219516570|NCT04951388|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
219516571|NCT04951388|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
219516572|NCT02557607|DEVICE|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
219516573|NCT03832465|DRUG|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
219516574|NCT03832465|DRUG|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
219611443|NCT01610492|DRUG|belimumab|10mg/kg administered intravenously
219611444|NCT01982955|DRUG|Tepotinib|Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
218895878|NCT00000706|DRUG|Zidovudine|
218895879|NCT00672906|BEHAVIORAL|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
218895880|NCT00672906|BEHAVIORAL|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
218895881|NCT01050244|DIETARY_SUPPLEMENT|Whole soybean soymilk powder|
218895882|NCT01050244|DIETARY_SUPPLEMENT|Whole milk powder|
218895883|NCT00443417|DRUG|SK-PC-B70M|dosage, frequency
218895884|NCT03833024|DRUG|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
219516575|NCT03504111|PROCEDURE|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
219516576|NCT03504111|PROCEDURE|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
218895885|NCT03833024|DRUG|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
218895886|NCT01794988|BEHAVIORAL|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
218895887|NCT01794988|BEHAVIORAL|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
218895888|NCT01794988|BEHAVIORAL|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
218895889|NCT01794988|BEHAVIORAL|NO TIVR|Control - no intervention
218895890|NCT02599363|DRUG|Ribociclib (LEE011)|
219516577|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
219516578|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
219516579|NCT01836419|PROCEDURE|classic LMA insertion|
219516580|NCT01975805|OTHER|Chlorhexidine Gluconate|
219611445|NCT01982955|DRUG|Gefitinib|Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
218895891|NCT02599363|DRUG|Paclitaxel|
218895892|NCT00956917|DEVICE|Akern USA EFG|Impedance measurement device
219516581|NCT01975805|OTHER|Povidone Iodine|
219611446|NCT01982955|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
219611447|NCT01982955|DRUG|Cisplatin|Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
218895893|NCT00956917|DEVICE|RJL Impedance analyzer|Impedance analyzer
218895894|NCT01174407|OTHER|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
218895895|NCT00859547|BIOLOGICAL|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
218895896|NCT01480960|OTHER|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
218895897|NCT02944214|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
218895898|NCT02944214|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
218895899|NCT01727596|OTHER|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
218895900|NCT01919944|DRUG|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
218895901|NCT01919944|DRUG|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
218895902|NCT02431988|PROCEDURE|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
218895903|NCT02431988|DRUG|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
219516582|NCT03708211|DRUG|TAK-931 PIC|TAK-931 PICs.
219516583|NCT03708211|DRUG|TAK-931 Tablet|TAK-931 Tablets.
219611448|NCT01982955|DRUG|Carboplatin|Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
219611449|NCT02449850|OTHER|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
219611450|NCT02449850|OTHER|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
218895904|NCT02431988|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
219516584|NCT03708211|DRUG|Esomeprazole|Esomeprazole Tablets.
219516585|NCT04986228|OTHER|Digital aftercare|The intervention group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge. These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.
218895905|NCT02431988|BIOLOGICAL|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg"
219516586|NCT04986228|OTHER|TAU|The control group will receive the regular follow-up consultations in the clinic (treatment-as-usual, TAU). This includes at least one consultation with the case-leading therapist from the previous inpatient stay about 6 weeks after discharge. The assessment consisting of questionnaires at multiple time points about different topics is the same as in the intervention group.
218895906|NCT02960516|DEVICE|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
218895907|NCT05449184|PROCEDURE|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
218895908|NCT05449184|PROCEDURE|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
218895909|NCT01102088|RADIATION|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
218895910|NCT03685630|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection"
219035473|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
219035474|NCT05371600|DRUG|Midazolam|midazolam IV at 0.04 mg/kg
219035475|NCT05371600|OTHER|Saline|an equal volume of saline IV
219035476|NCT05687240|BEHAVIORAL|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
219035477|NCT05687240|BEHAVIORAL|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
219035478|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
219035479|NCT04453917|BIOLOGICAL|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
219516587|NCT01508936|DRUG|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
219516588|NCT01508936|DRUG|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
219516589|NCT01134523|DRUG|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
219516590|NCT01134523|DRUG|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
219516591|NCT04876898|OTHER|prospective cohort in high body mass index patient with covid 19|A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels
219516592|NCT02401126|DIETARY_SUPPLEMENT|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
219516593|NCT02401126|DIETARY_SUPPLEMENT|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
219516594|NCT03164148|DEVICE|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
219611451|NCT06753955|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
219611452|NCT06753955|DRUG|Intravenous immunoglobulin (IVIG)|Administered as background treatment prior to the investigational product
218895911|NCT05563610|DRUG|Amoxicillin 500mg|Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
218895912|NCT04562181|OTHER|Bispectral index and qCON/qNOX monitoring|This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
218895913|NCT00000801|DRUG|Filgrastim|
219516595|NCT05707299|PROCEDURE|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
219516596|NCT00679367|DRUG|dexamethasone|40 mg once weekly
219516597|NCT00679367|DRUG|lenalidomide|10 mg/day D1-21
219516598|NCT00679367|DRUG|melphalan|5 mg/m2 D1-4
219516599|NCT01180595|DEVICE|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
219516600|NCT01180595|DEVICE|Trabecular Metal Monoblock Tibial Total Knee Component|
219516601|NCT00905125|BIOLOGICAL|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
219516602|NCT00905125|BIOLOGICAL|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
219516603|NCT01192646|BEHAVIORAL|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
219516604|NCT04843670|PROCEDURE|duodenopancreatectomy|resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
219516605|NCT06871176|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be administered intravenously using the recommended activity for adults which is up to 150 MBq (4 mCi) fixed dose. There is no weight adaption recommended in the literature.
219516606|NCT04603937|DRUG|KSI-301|Intravitreal Injection
219516607|NCT04603937|DRUG|Aflibercept|Intravitreal Injection
219516608|NCT04603937|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
219516609|NCT01932034|DEVICE|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
218895914|NCT00000801|DRUG|Vincristine sulfate|
219035480|NCT04453917|BIOLOGICAL|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
219516610|NCT00436878|BEHAVIORAL|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
219516611|NCT02249884|DRUG|Urea Dose A|Urea cream for topical use.
219516612|NCT02249884|DRUG|Urea Dose B|Urea cream for topical use.
219516613|NCT02249884|DRUG|Urea Dose C|Urea cream for topical use.
218895915|NCT00000801|DRUG|Doxorubicin hydrochloride|
219516614|NCT02249884|DRUG|Chamomile Dose A|Chamomile gel for topical use.
218895916|NCT00000801|DRUG|Cyclophosphamide|
218895917|NCT00000801|DRUG|Cytarabine|
218895918|NCT00000801|DRUG|Dexamethasone|
218895919|NCT01317758|DRUG|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
218895920|NCT01317758|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
218895921|NCT01317758|BIOLOGICAL|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
218895922|NCT03689023|OTHER|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
219035481|NCT04453917|DIAGNOSTIC_TEST|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
219035482|NCT04453917|BIOLOGICAL|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
219035483|NCT05897879|BIOLOGICAL|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
219516615|NCT02249884|DRUG|Chamomile Dose B|Chamomile gel for topical use.
219516616|NCT02249884|DRUG|Chamomile Dose C|Chamomile gel for topical use.
219516617|NCT01922349|DRUG|BI 113608|Medium dose (Multiple dosing)
219516618|NCT01922349|DRUG|Placebo|Placebo (Multiple dosing)
219516619|NCT01922349|DRUG|BI 113608|Low dose (Multiple dosing)
219516620|NCT01922349|DRUG|Placebo|Placebo (Single dosing)
219516621|NCT01922349|DRUG|BI 113608|High dose (Single dosing)
218895923|NCT00669214|DRUG|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
218895924|NCT00669214|DRUG|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
218895925|NCT04643626|DEVICE|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
218895926|NCT05331560|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
218895927|NCT00075712|DRUG|carboplatin|
219035484|NCT05897879|BIOLOGICAL|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
219035485|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
219035486|NCT06958432|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive node-sparing modified short-course radiotherapy, followed by six cycles of CAPOX chemotherapy combined with a PD-1 inhibitor. After neoadjuvant treatment, patients will either undergo total mesorectal excision (TME) surgery or enter a watch-and-wait strategy based on clinical assessment.
219035487|NCT06958432|COMBINATION_PRODUCT|Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive conventional-target short-course radiotherapy, followed by six cycles of CAPOX chemotherapy. After neoadjuvant treatment, patients will either undergo TME surgery or enter a watch-and-wait strategy based on clinical assessment.
219516622|NCT01922349|DRUG|BI 113608|Medium dose (Single dosing)
219516623|NCT01922349|DRUG|BI 113608|Low dose (Single dosing)
219516624|NCT01922349|DRUG|BI 113608|High dose (Multiple dosing)
219035488|NCT06232525|PROCEDURE|transobturator tape operation (TOT)|TOT surgery: With an 18 French Foley urinary catheter, the sling passes through the skin in the groin, the obturator foramen, the back of the adductor longus tendon, and the midurethral vaginal incision; extends 1 cm below the midpoint of the urethra, the tape is held in place without sutures by its interface with the patient's tissue. After the mesh is placed, the incision in the suburethral midline is closed.
219204020|NCT06980259|RADIATION|Spatially Fractionated Radiotherapy|SFRT builds on CRT, administered at 3.0 Gy per fraction for 15-20 fractions, with the addition of weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions. It employs Intensity-Modulated Radiation Therapy (IMRT), Intensity-Modulated Proton Therapy (IMPT), or Volumetric Modulated Arc Therapy (VMAT) to create a grid-like pattern of alternating high- and low-dose regions. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
219516625|NCT00922779|DRUG|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
219516626|NCT00922779|DRUG|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
219516627|NCT02448771|DRUG|Palbociclib|
219611453|NCT06054321|DRUG|stepwise pharmacotherapy|In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
219516628|NCT02448771|DRUG|Bazedoxifene|
219516629|NCT03136783|OTHER|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
219516630|NCT01907009|DRUG|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
219516631|NCT01907009|DRUG|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
219516632|NCT01572766|OTHER|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
219516633|NCT07076147|OTHER|Non-Interventional Study|Non-interventional study
219516634|NCT07076108|DRUG|Normal regimen of treatment of anemia|Patients were on normal regimen of treatment of anemia.
219516635|NCT07076108|DRUG|Vitamin C|Patients were on 250 mg oral vitamin C daily for 3 months.
219516636|NCT07076108|DRUG|Vitamin C|Patients were on 500 mg oral vitamin C daily for 3 months.
219516637|NCT07076095|DRUG|IBB0979|bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor
219611454|NCT06054321|DRUG|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
218895928|NCT00075712|DRUG|paclitaxel|
218895929|NCT00075712|PROCEDURE|adjuvant therapy|
218895930|NCT00075712|PROCEDURE|conventional surgery|
218895931|NCT00075712|PROCEDURE|neoadjuvant therapy|
218895932|NCT02063204|DRUG|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
218895933|NCT06601062|DEVICE|Tele-BE|Clinicians and their patients use the newly developed telehealth tool to support their use of CBT during session
219611455|NCT04996979|DRUG|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
219611456|NCT04996979|DRUG|Placebo|Standard care
219611457|NCT02719275|BEHAVIORAL|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
219611458|NCT04599075|DRUG|Insulin|IV Insulin Infusion
219611459|NCT04599075|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion (Pump)
218895934|NCT03453905|DIAGNOSTIC_TEST|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
218895935|NCT03453905|OTHER|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
218895936|NCT00837915|DRUG|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
218895937|NCT02362321|DRUG|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
218895938|NCT02362321|OTHER|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
218895939|NCT00754377|OTHER|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
218895940|NCT05487521|DRUG|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
218895941|NCT03636217|OTHER|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
219035489|NCT06232525|PROCEDURE|urethral ligament plication|Urethral ligament plication: With an 18 French Foley urinary catheter, a vertical incision of approximately 3 cm is made in the anterior-lateral wall sulcus of the vagina on the right and left lines, 2 cm laterally from the midline, with the urethral meatus remaining in the midline, and external urethral ligaments on both sides inferolateral to the urethra, sutured in the midline by using 2-0 or 3-0 polyester sutures on both sides separately. The incised anterior vaginal tissue is closed one by one with 2-0 rapid Vicryl.
219035490|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
219035491|NCT05083442|DEVICE|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
219035492|NCT05083442|OTHER|Sham (placebo)|Use of sham (placebo) option
219035493|NCT06376019|PROCEDURE|solitary Implant loading with ball attachment|ball attachment will be attached to the dental implant on the day of implant placement
219516638|NCT07076095|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
219516639|NCT03618979|BIOLOGICAL|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
219516640|NCT03618979|BIOLOGICAL|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
219611460|NCT04834609|PROCEDURE|Injection of autologous adipose tissue in anal fistula|
219611461|NCT02951754|DRUG|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
219611462|NCT06581679|DRUG|Triptorelin|GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
219611463|NCT06581679|DEVICE|levonorgestrel-releasing intrauterine system|The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
218895942|NCT03636217|OTHER|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
218895943|NCT03636217|OTHER|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
218895944|NCT04957446|DEVICE|Sculptra Aesthetic|Injectable implant containing microparticles of poly-L-lactic acid (PLLA)
218895945|NCT04957446|OTHER|Placebo|Saline solution
218895946|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
218895947|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
218895948|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
218895949|NCT04257201|OTHER|Yellow Oyster -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
218895950|NCT04257201|OTHER|Yellow Oyster -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
218895951|NCT04257201|OTHER|White button -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
219035494|NCT06376019|PROCEDURE|splinted Implant loading with intra oral welding|Titanium bar will be welded to the dental implant on the day of implant placement
219035495|NCT06376019|PROCEDURE|complete denture|Mucosa supported conventional complete denture will be fabricated without supporting implants
218895952|NCT04257201|OTHER|White button -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
218895953|NCT04257201|OTHER|Control|Participants will consume the standardized test day salad only
218895954|NCT02075112|DRUG|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
218895955|NCT02075112|RADIATION|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
218895956|NCT02075112|DRUG|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
218895957|NCT04026321|DRUG|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
218895958|NCT04026321|DRUG|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
219516641|NCT03618979|BIOLOGICAL|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
219516642|NCT06078488|OTHER|Individualized and Protocolized Nutritional Care Bundle|"Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks."
219516643|NCT06078488|OTHER|Optimized Standard Care|Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
219516644|NCT04637438|OTHER|Fecal Microbiota Transplantation|FMT via colonoscopy
219516645|NCT04637438|OTHER|Placebo|Water infusion via colonoscopy
219516646|NCT04740385|DIAGNOSTIC_TEST|Lung auscultation|auscultation of air entry through chest wal
219516647|NCT04740385|DEVICE|Fiberoptic bronchoscopy|Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
219516648|NCT04740385|DEVICE|Lung Ultrasound|real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
219516649|NCT00213811|BEHAVIORAL|clinical, biological, and radiological|
219516650|NCT00212095|DRUG|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
219516651|NCT02474264|OTHER|Endothelial function assessment|reactive hyperemia index
218895959|NCT04026321|DRUG|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
219516652|NCT02474264|OTHER|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
218895960|NCT04026321|DRUG|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
218895961|NCT04026321|DRUG|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
218895962|NCT04058444|COMBINATION_PRODUCT|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
218895963|NCT06111417|OTHER|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire"
218895964|NCT06111417|OTHER|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
218895965|NCT01276639|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
218895966|NCT01276639|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
219516653|NCT02474264|OTHER|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
218895967|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
218895968|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
219035496|NCT03878316|DRUG|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
219035497|NCT00943228|DRUG|mycophenolate mofetil|High dose 4gms daily
219035498|NCT03292081|DEVICE|OFDI|PCI under OFDI guidance
219035499|NCT03292081|DEVICE|IVUS|PCI under IVUS guidance
219035500|NCT02888847|DEVICE|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
219035501|NCT02888847|DEVICE|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
219035502|NCT01515800|BEHAVIORAL|Text message reminder|Receive text message
219516654|NCT04713059|GENETIC|FGFR2|Mutation of FGFR2
219516655|NCT00262600|DRUG|warfarin|once a day
219035503|NCT00762398|DEVICE|Masimo hemoglobin-meter|Placing a probe on the finger
219516656|NCT00262600|DRUG|Dabigatran dose 1|twice daily
219516657|NCT00262600|DRUG|Dabigatran dose 2|twice a day
218895969|NCT05271916|DRUG|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
218895970|NCT05271916|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
218895971|NCT05590052|DEVICE|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
218895972|NCT05590052|DEVICE|Thermocautery|achievement of hemostasis using thermocautery
218895973|NCT03833869|PROCEDURE|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
219516658|NCT05473052|BEHAVIORAL|Preoperative home-based exercise training|"1\) Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity:Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week~2\) Weekly telephone supervision: A physical therapist carried out weekly telephone calls with all participants to monitor adverse events, give positive reinforcement and recommend strategies to overcome barriers that arise during the exercise program."
218895974|NCT02987465|DRUG|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
218895975|NCT02987465|DRUG|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
218895976|NCT02987465|DRUG|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
218895977|NCT02987465|DRUG|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
218895978|NCT03464409|OTHER|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
219516659|NCT05395000|BEHAVIORAL|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
219516660|NCT05395000|BEHAVIORAL|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
219516661|NCT05395000|BEHAVIORAL|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
219516662|NCT03423888|DEVICE|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
219516663|NCT02188797|BEHAVIORAL|Group MI risk reduction program|
219516664|NCT05588856|OTHER|In depth Interview|In depth Interviews
219516665|NCT02320942|OTHER|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
219516666|NCT02280629|DRUG|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
219516667|NCT02280629|DRUG|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
219516668|NCT02280629|DRUG|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
219516669|NCT06120127|RADIATION|SBRT|postoperative SBRT of liver lesions
219516670|NCT06120127|DRUG|Chemotherapy|XELOX/FOLFOX/FOLFIRI
219516671|NCT06120127|DRUG|PD-1 antibody|Sintilimab (200mg d1，q3w)
219516672|NCT03233620|OTHER|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
219035504|NCT00762398|BIOLOGICAL|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
219035505|NCT04695938|DIAGNOSTIC_TEST|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
219035506|NCT00136084|DRUG|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
219611464|NCT06581679|PROCEDURE|frozen embryo transfer|"Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur."
219611465|NCT04190121|DIETARY_SUPPLEMENT|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
218895979|NCT03464409|OTHER|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
218895980|NCT03464409|OTHER|SF-36|A health-related quality of life (QoL) self-reported survey.
218895981|NCT05156788|DRUG|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
219516673|NCT00376220|DRUG|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
219516674|NCT00376220|OTHER|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
219516675|NCT04347291|BEHAVIORAL|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
219516676|NCT04347291|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
219516677|NCT03238066|RADIATION|Brachytherapy|HDR/PDR brachytherapy
219516678|NCT03238066|OTHER|Hyperthermia|Interstitial hyperthermia
219516679|NCT00269048|DRUG|SB-480848|SB-480848
219516680|NCT00269048|DRUG|placebo|placebo
219516681|NCT03747822|PROCEDURE|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
219516682|NCT03089112|DRUG|HGP1607|Take it once per period
219516683|NCT03089112|DRUG|HGP1501|Take it once per period
219516684|NCT03089112|DRUG|HGP1607+HGP1501|Take it once per period
219516685|NCT03196024|BEHAVIORAL|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
219516686|NCT03196024|BEHAVIORAL|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
219516687|NCT01640496|DRUG|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
219516688|NCT01640496|OTHER|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
219516689|NCT00003123|DRUG|amifostine trihydrate|
219516690|NCT00988923|OTHER|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
219516691|NCT00988923|OTHER|No intervention|the intervention tool was switched in off, only bolus was activated
219516692|NCT00067236|DRUG|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
219516693|NCT00067236|DRUG|Placebo tablet|placebo tablet, twice a day for 90 days
219611466|NCT06582108|GENETIC|DNA, RNA, ctDNA, metabolomics|The use of specific assays or global molecular profiling to identify novel biomarkers based on DNA, RNA, protein, lipids, or metabolites obtained from tumor tissue or body fluids
219611467|NCT03087500|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
218895982|NCT05488639|OTHER|Registration of football exposure and occurrence of injuries and illnesses only|"Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
218895983|NCT03723369|DEVICE|accupuncture|accupuncture
218895984|NCT05899140|DRUG|Clindamycin|Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
218895985|NCT05899140|OTHER|Standard of care|Standard of care
218895986|NCT01227980|DRUG|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
218895987|NCT01227980|DRUG|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
218895988|NCT00263874|DRUG|UK-500,001|
218895989|NCT03818750|DEVICE|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
218895990|NCT03818750|BEHAVIORAL|Alcohol Use Disorders Identification Test|Questionnaire
218895991|NCT02398240|DRUG|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
218895992|NCT02398240|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
218895993|NCT02398240|DRUG|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
218895994|NCT02398240|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
218895995|NCT00001002|DRUG|Zidovudine|
218895996|NCT00001002|DRUG|Foscarnet sodium|
218895997|NCT02454023|DEVICE|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
218895998|NCT02454023|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
218895999|NCT00329368|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
218896000|NCT00329368|BIOLOGICAL|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
219516694|NCT04167566|COMBINATION_PRODUCT|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
219516695|NCT00919464|DEVICE|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
219516696|NCT00919464|DEVICE|Compartmental fracture pressure monitoring|
218896001|NCT00329368|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
218896002|NCT00329368|DRUG|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
218896003|NCT00329368|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
218896004|NCT04440878|BEHAVIORAL|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
218896005|NCT04440878|BEHAVIORAL|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
218896006|NCT00974753|DRUG|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
218896007|NCT00974753|OTHER|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
218896008|NCT00809900|DIETARY_SUPPLEMENT|Experimental|Administration of of 480 mL cranberry juice
218896009|NCT00155493|PROCEDURE|obtain surgical specimen for analysis|
218896010|NCT00003279|BIOLOGICAL|BCG vaccine|
218896011|NCT00003279|BIOLOGICAL|monoclonal antibody BEC2|
218896012|NCT01487135|DRUG|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
218896013|NCT01487135|DRUG|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
218896014|NCT01487135|DRUG|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
218896015|NCT03868033|DRUG|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
218896016|NCT03868033|DRUG|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
218896017|NCT03976258|DRUG|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
218896018|NCT03976258|DRUG|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
218896019|NCT03976258|DRUG|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
218896020|NCT03976258|DRUG|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
218896021|NCT03780335|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
218896022|NCT00989001|DRUG|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
219516697|NCT00919464|DEVICE|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
219516698|NCT01672190|OTHER|Yoga Therapy Program|
219516699|NCT00682084|PROCEDURE|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
219516700|NCT05251103|OTHER|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
219516701|NCT02313103|DRUG|lofexidine HCl|400 micrograms
219516702|NCT05560464|DRUG|VX-548|Tablets for oral administration.
218896023|NCT00989001|DRUG|Placebo|Injection
218896024|NCT02919644|BIOLOGICAL|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate
218896025|NCT02919644|DRUG|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
218896026|NCT03726489|DEVICE|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
218896027|NCT03726489|DEVICE|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
219204021|NCT06980259|RADIATION|Conventional Radiotherapy|CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions, utilizing Intensity-Modulated Radiation Therapy (IMRT) or Intensity-Modulated Proton Therapy (IMPT) techniques, ensuring a target volume dose coverage of at least 90%. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
219516703|NCT01098721|DRUG|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
219516704|NCT00000775|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
219516705|NCT04511559|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.
219516706|NCT04511559|DIAGNOSTIC_TEST|tissue DNA Methylation Sequencing|Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
219516707|NCT05865600|OTHER|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.
219516708|NCT05865600|DIAGNOSTIC_TEST|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
219516709|NCT05865600|DIAGNOSTIC_TEST|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
219516710|NCT05865600|OTHER|Standard of care|Standard of care
218896028|NCT03744949|DRUG|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
218896029|NCT03744949|DRUG|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
218896030|NCT03744949|DRUG|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
218896031|NCT03744949|DRUG|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
218896032|NCT00242671|PROCEDURE|Isocapnic Hyperponea|
218896033|NCT01380769|DRUG|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
218896034|NCT01380769|OTHER|Best Supportive Care|best supportive care
218896035|NCT00203229|DRUG|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
218896036|NCT00203229|DRUG|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
218896037|NCT04229628|OTHER|No special intervention|No special intervention
218896038|NCT03754348|RADIATION|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
219516711|NCT03427970|BEHAVIORAL|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
219516712|NCT03427970|BEHAVIORAL|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
219516713|NCT03304600|DEVICE|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
219516714|NCT03304600|DEVICE|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
219516715|NCT00531206|DRUG|Tipranavir|
219516716|NCT00531206|DRUG|Ritonavir|low dose
219516717|NCT01574170|OTHER|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
219611468|NCT06583200|DIAGNOSTIC_TEST|End Expiratory Occlusion Test|All studied mechanically ventilated patients under post operative sedation. EEO test will be applied to predict probable responder and probable non-responder according to pulse pressure variation in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of 5% or more
218896039|NCT06105840|PROCEDURE|Acupressure and Standardized Curcuminoid from Turmeric Extract|capsules containing curcuminoid from Tumeric Extract three times a day for 3 weeks and acupressure massage at points provide comfort for knee pain twice a week for 3 weeks
218896040|NCT06105840|PROCEDURE|Sham Acupressure and Placebo|capsules containing starch three times a day for 3 weeks and acupressure massage at points that are not to provide comfort for knee pain twice a week for 3 weeks
218896041|NCT03647657|DRUG|177Lu-PP-F11N|Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
218896042|NCT03647657|DRUG|Sacuitril|Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
218896043|NCT00091091|OTHER|medical chart review|
218896044|NCT00091091|OTHER|questionnaire administration|
218896045|NCT00091091|PROCEDURE|management of therapy complications|
218896046|NCT00117299|DRUG|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
218896047|NCT00742183|DEVICE|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
218896048|NCT00742183|DEVICE|Silvadene|Silvadene - dressing changes every day, more frequently if needed
218896049|NCT04057807|DRUG|LPS|LPS (0.4 ng/kg)
218896050|NCT04095182|DRUG|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
218896051|NCT04095182|DRUG|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
219516718|NCT05976399|OTHER|Connective Tissue Massage|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
219516719|NCT05976399|OTHER|Manual Lymph Drainage|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
219516720|NCT01878370|OTHER|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
219611469|NCT06583200|DIAGNOSTIC_TEST|Passive Leg Raising Test|All studied mechanically ventilated patients under post operative sedation.Passive leg raising test will be applied to predict probable responder and probable non-responder according to the PPV in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of at least 10%
219611470|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
219611471|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
219611472|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
219611473|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
219611474|NCT00810147|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
218896052|NCT04095182|DRUG|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)
219611475|NCT03950154|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab injection
219611476|NCT03950154|DRUG|Oxaliplatin|Oxaliplatin injection
219611477|NCT03950154|DRUG|Capecitabine|Capecitabine oral agent
219611478|NCT03950154|BIOLOGICAL|PD1-T cells|PD1-T cells injection
218896053|NCT04095182|DRUG|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
218896054|NCT04095182|DRUG|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
219611479|NCT03309098|DIAGNOSTIC_TEST|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
218896055|NCT04095182|DRUG|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
218896056|NCT00972335|DRUG|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
218896057|NCT00972335|DRUG|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
218896058|NCT05575362|OTHER|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
218896059|NCT05575362|OTHER|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
218896060|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
218896061|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
218896062|NCT01988675|RADIATION|Whole Brain Irradiation|
218896063|NCT01988675|RADIATION|Partial Brain Irradiation|
218896064|NCT01988675|BEHAVIORAL|Neuropsychological Testing|
218896065|NCT01988675|BEHAVIORAL|Quality of Life Questionnaire|
218896066|NCT01988675|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
218896067|NCT04041271|OTHER|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
218896068|NCT04041271|OTHER|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
218896069|NCT04041271|OTHER|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
218896070|NCT04041271|OTHER|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
218896071|NCT04041271|OTHER|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
218896072|NCT05960981|BEHAVIORAL|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
218896073|NCT00726648|DRUG|CDP323|50mg capsules, 100mg bid for 4 weeks
219035507|NCT00136084|DRUG|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
219516721|NCT01878370|OTHER|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
219516722|NCT05420506|DEVICE|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
219516723|NCT00926406|DRUG|lead chelation therapy|Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
219516724|NCT02635100|OTHER|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
219516725|NCT02301247|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
218896074|NCT00726648|DRUG|CDP323|250mg capsules, 500mg bid for 4 weeks
219035508|NCT00102232|PROCEDURE|supplementation with phosphatidylcholine|
219035509|NCT02531412|DRUG|Spironolactone|After a major surgery event a time 0, 24h and 48h
219035510|NCT02531412|DRUG|Placebo|After a major surgery event a time 0, 24h and 48h
219035511|NCT03427359|DRUG|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
219204022|NCT06985277|DIAGNOSTIC_TEST|Urgent endoscopy strategy|Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately
219516726|NCT02301247|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219611480|NCT03487289|PROCEDURE|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
219611481|NCT01395927|DRUG|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
219611482|NCT01395927|DRUG|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
218896075|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg bid for 4 weeks
218896076|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg daily for 4 weeks
218896077|NCT00726648|DRUG|Placebo|placebo capsules for 4 weeks
219035512|NCT06231303|GENETIC|DNA extraction and PCR amplification|"Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR."
219035513|NCT00703547|DRUG|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
219516727|NCT05422547|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
219516728|NCT00802451|DRUG|Mesalamine|
219516729|NCT02397733|RADIATION|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
219516730|NCT02397733|RADIATION|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
219516731|NCT02798484|DEVICE|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
219516732|NCT05042856|PROCEDURE|PanOptix IOL implantation|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
219516733|NCT02886078|PROCEDURE|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
219516734|NCT02886078|PROCEDURE|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
219516735|NCT03770923|DRUG|Rupatadine|Rupatadine 10 mg daily
219516736|NCT03770923|DRUG|Montelukast|Montelukast 10 mg daily
219516737|NCT01234636|DIETARY_SUPPLEMENT|Placebo oil|Placebo oil of 4g/day
219516738|NCT00721409|DRUG|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
218896078|NCT01080807|DRUG|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
219516739|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
219516740|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
218896079|NCT01080807|DRUG|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
218896080|NCT01219309|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|3 capsules bid orally
219516741|NCT00216398|DRUG|Lanreotide (Autogel formulation)|
219516742|NCT02972398|DRUG|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
219516743|NCT02972398|DRUG|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
219516744|NCT04844840|DRUG|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
219516745|NCT04844840|OTHER|Placebo|Saline
219611483|NCT04386382|PROCEDURE|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~1. Proper dental and medical history.~2. Scaling and oral hygiene measurements.~3. Clinical examination.~4. Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~1. Optical scanning of the dental casts was done using Ceramill map 400~2. surgical stent was designed using Mimics Innovation Suite 19 ™ software.~3. Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
219611484|NCT00317629|DRUG|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
219611485|NCT00317629|DRUG|meglumine antimoniate|20mg/kg daily during 20 days
218896081|NCT01219309|DIETARY_SUPPLEMENT|Placebo (olive oil)|3 capsules bid orally
218896082|NCT03637777|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
218896083|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
218896084|NCT02430090|DRUG|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
218896085|NCT02430090|DRUG|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
218896086|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
218896087|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
218896088|NCT01425502|BEHAVIORAL|DQIP Intervention|"The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives"
218896089|NCT03253042|OTHER|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
218896090|NCT03253042|OTHER|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
218896091|NCT00254137|DRUG|capecitabine|
218896092|NCT00254137|DRUG|irinotecan|
218896093|NCT00254137|DRUG|oxaliplatin|
218896094|NCT00254137|DRUG|cetuximab|
219035514|NCT00703547|DRUG|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
219516746|NCT05420051|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.
218896095|NCT04955171|DRUG|BEOVU intravitreal injection|BEOVU intravitreal injection
218896096|NCT03917849|BEHAVIORAL|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
218896097|NCT04093713|PROCEDURE|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
218896098|NCT05706922|OTHER|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
218896099|NCT02223715|OTHER|CDI Pts|
218896100|NCT03056677|DIETARY_SUPPLEMENT|Control|200mls water will be given prior to a mixed carbohydrate meal
218896101|NCT03056677|DIETARY_SUPPLEMENT|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
218896102|NCT03056677|DIETARY_SUPPLEMENT|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
218896103|NCT02405156|DRUG|Letrozole|
218896104|NCT02405156|DRUG|Placebo|
218896105|NCT02405156|DRUG|Misoprostol|
218896106|NCT03901131|DRUG|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
218896107|NCT01620229|DRUG|brentuximab vedotin|Given IV
219035515|NCT00703547|DRUG|Placebo|Placebo tablets and capsules will be provided to subjects.
219035516|NCT02755376|BIOLOGICAL|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
219035517|NCT02755376|BIOLOGICAL|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
219035518|NCT02755376|PROCEDURE|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
219035519|NCT00355186|PROCEDURE|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
218896108|NCT01620229|OTHER|laboratory biomarker analysis|Correlative studies
218896109|NCT01620229|OTHER|pharmacological study|Correlative studies
218896110|NCT01011374|DRUG|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
218896111|NCT06166966|OTHER|Flipped Education Model|The effect of the Inside Out Education Model on the course success of nursing students.
218896112|NCT05005663|OTHER|surgical management of incisional hernia|surgical repair of the incisional hernia
218896113|NCT00605124|OTHER|Knee muscle exercises|Home exercises three times a week, control every three months
218896114|NCT02635607|DRUG|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
218896115|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
218896116|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.
218896117|NCT02635607|DRUG|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
218896118|NCT02635607|DRUG|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
218896119|NCT04331717|DEVICE|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
219516747|NCT05420051|BEHAVIORAL|Motivational Interviewing|The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
218896120|NCT04331717|BEHAVIORAL|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
218896121|NCT04331717|DRUG|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
218896122|NCT01745367|DRUG|Tivozanib Hydrochloride|
219035520|NCT03721419|DEVICE|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
219035521|NCT03721419|DEVICE|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
219035522|NCT04055688|DEVICE|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
219035523|NCT04055688|DRUG|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
219035524|NCT03476083|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
218896123|NCT01745367|DRUG|paclitaxel|
218896124|NCT01745367|DRUG|Placebo|
219035525|NCT02476968|DRUG|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
219516748|NCT03174119|DEVICE|Light therapy - active|Active light will be used for one week, as compared to placebo light.
219516749|NCT03174119|DEVICE|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
219516750|NCT01138683|PROCEDURE|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
219516751|NCT01138683|DRUG|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
219516752|NCT00789425|DIETARY_SUPPLEMENT|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
219516753|NCT00789425|DIETARY_SUPPLEMENT|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
219516754|NCT02635243|DRUG|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
219516755|NCT02635243|DRUG|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
219516756|NCT02635243|DRUG|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
219516757|NCT02136095|PROCEDURE|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
219611486|NCT05311189|DRUG|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
219611487|NCT04211831|DRUG|URO-902|intradetrusor injection
219611488|NCT04211831|DRUG|Placebo|intradetrusor injection
219516758|NCT04014322|OTHER|E-cigarette|"All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)"
218896125|NCT03648294|OTHER|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
218896126|NCT03520985|DRUG|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
219035526|NCT04855643|DEVICE|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
219035527|NCT04855643|DEVICE|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
219035528|NCT03015051|DRUG|Oxygen|
219035529|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
219035530|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
219035531|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
219035532|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
219516759|NCT03510559|DRUG|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
219035533|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
219516760|NCT03510559|DRUG|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
219516761|NCT01989728|PROCEDURE|psychiatric examination and feedback|
219516762|NCT05137756|OTHER|no intervention|no intervention
219516763|NCT05984771|DIETARY_SUPPLEMENT|Epineuron|Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)
219611489|NCT00898287|DRUG|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
219611490|NCT00898287|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
218896127|NCT03520985|DRUG|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients \> 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
218896128|NCT05220085|DRUG|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
219035534|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
219204023|NCT06985277|DIAGNOSTIC_TEST|Standard colonoscopy with standard VCE group|Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies
219516764|NCT05984771|OTHER|Placebo group|Usual care
219516765|NCT02984436|PROCEDURE|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
218896129|NCT00287222|DRUG|Bevacizumab|15 mg/KG I.V. every 21 days
218896130|NCT00287222|DRUG|Erlotinib|150 mg orally every day
218896131|NCT05514600|PROCEDURE|closure of parastomal hernia fascial defect|For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
219035535|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
219035536|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
219035537|NCT00002882|BIOLOGICAL|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
219516766|NCT02984436|BEHAVIORAL|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
219516767|NCT03614195|DEVICE|MCDTT|The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.
219516768|NCT03614195|DEVICE|MDTT|The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.
219516769|NCT03614195|DEVICE|CDTT|The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
219516770|NCT05333523|RADIATION|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~1. Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~2. Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~3. Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
219516771|NCT05333523|RADIATION|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
219516772|NCT00487227|DRUG|caffeine|
219516773|NCT00487227|DRUG|Placebo|
219611491|NCT03697031|DRUG|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
218896132|NCT02919774|DRUG|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
218896133|NCT02919774|DRUG|placebo|matching placebo tablets
218896134|NCT06238440|OTHER|Splint and taping methods|"In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape"
218896135|NCT06344299|OTHER|potential predictors|Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
218896136|NCT01392131|DIETARY_SUPPLEMENT|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
218896137|NCT01392131|OTHER|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
219035538|NCT00002882|BIOLOGICAL|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
219035539|NCT00002882|DRUG|Cisplatin|IV Days 1-4
219516774|NCT05137678|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
219516775|NCT02068482|DRUG|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
218896138|NCT00824473|DRUG|Placebo|Placebo
218896139|NCT00824473|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
218896140|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
218896141|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
218896142|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
218896143|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
218896144|NCT05576922|OTHER|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
218896145|NCT05576922|OTHER|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
219035540|NCT00002882|DRUG|Dacarbazine|IVPB on day 1
219035541|NCT00002882|DRUG|Vinblastine|IVPB on days 1-4
219035542|NCT00002882|PROCEDURE|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
219516776|NCT02445664|BEHAVIORAL|Educational video|Video: Information on osteoporosis and alendronate treatment.
219516777|NCT05140447|OTHER|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
218896146|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
218896147|NCT06462183|DRUG|RGT-61159|Oral MYB inhibitor
218896148|NCT01359904|OTHER|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
218896149|NCT04372420|DRUG|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
218896150|NCT04372420|PROCEDURE|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
218896151|NCT05534399|PROCEDURE|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
218896152|NCT01934257|OTHER|Marketed milk-based lactose-containing infant formula|
218896153|NCT01934257|OTHER|Marketed milk-based lactose-free infant formula|
219516778|NCT03767088|DEVICE|WB-EMS|whole body electromyostimulation
219516779|NCT03767088|OTHER|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
219516780|NCT05608512|OTHER|interview|The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
219516781|NCT02329756|DRUG|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
219516782|NCT02329756|DRUG|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
219611492|NCT05717569|DRUG|Vitamin D|o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
219611493|NCT02833337|RADIATION|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
219611494|NCT00397514|PROCEDURE|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
218896154|NCT01934257|OTHER|Marketed soy-based lactose-free infant formula|
218896155|NCT01944540|PROCEDURE|Optimized ESD with snaring|
219035543|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
218896156|NCT01944540|PROCEDURE|Conventional ESD|
218896157|NCT01396213|DRUG|Larazotide Acetate|gelatin capsule
218896158|NCT01396213|DRUG|placebo|gelatin capsule
218896159|NCT03539718|DRUG|Taurolidine heparin|Taurolock-hep 500 at end of session
218896160|NCT03539718|DRUG|Heparin Sodium|Heparin sodium 5000 at end of session
218896161|NCT04601012|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
218896162|NCT04268108|BIOLOGICAL|liquid tumor infiltrating lymphocytes|Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
218896163|NCT01576289|OTHER|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
218896164|NCT02525588|DEVICE|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
219035544|NCT02256891|DEVICE|PRFM|
219035545|NCT02256891|PROCEDURE|Double Row|
219035546|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
218896165|NCT01156220|DRUG|Furosemide|Injection, 40 mg, single dose over 5 min
218896166|NCT01156220|DRUG|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
218896167|NCT03073239|GENETIC|ALS patients genetic characterization|Genetic findings in ALS patients
218896168|NCT03073239|OTHER|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
218896169|NCT00184795|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
219035547|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
219035548|NCT01344447|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
219035549|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
219035550|NCT00724516|DEVICE|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
219035551|NCT03094754|PROCEDURE|nevi excision|After general anesthesia, nevi excision in children is performed.
219035552|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
219516783|NCT06167538|OTHER|Decannulation|From the 1st of September 2021, the investigators started to perform decannulation earlier after admission to the Department of Brain Injury. Before attempting to decannulate a patient, several factors were considered and assessed by the patient's treating team: patient's level of consciousness, hemodynamical stability, need for and frequency of salivary aspiration, cough strength and respiration frequency. Patients could not be under treatment for pneumonia and simultaneously have respiratory instability at the time of decannulation.
219516784|NCT03270007|DRUG|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
218896170|NCT00184795|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
218896171|NCT00184795|DRUG|placebo|Placebo tablets for 24 weeks
218896172|NCT05712070|BEHAVIORAL|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
218896173|NCT05712070|BEHAVIORAL|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
218896174|NCT02478463|DRUG|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
218896175|NCT02478463|DRUG|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
218896176|NCT02731495|DIETARY_SUPPLEMENT|EGCG|EGCG (Epigallocatechin -3-gallate)
218896177|NCT02731495|DIETARY_SUPPLEMENT|Placebo (deionized water)|
218896178|NCT06279455|OTHER|Pelvic Floor Muscle Exercise|A 12-week pelvic floor muscle exercise program was applied to pregnant women.
218896179|NCT01290614|OTHER|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
219035553|NCT05044806|OTHER|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
219516785|NCT02550223|PROCEDURE|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
219516786|NCT01567930|DRUG|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
219516787|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
219516788|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
219516789|NCT01879280|PROCEDURE|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
219611495|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
219035554|NCT05044806|OTHER|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
218896180|NCT01290614|OTHER|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
218896181|NCT02036047|DEVICE|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
218896182|NCT02036047|DEVICE|Regular polypectomy snare (Snare Master, SD-210U-10)|
218896183|NCT01358825|PROCEDURE|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
218896184|NCT04079595|DEVICE|Head immobilization mask|Immobilization
218896185|NCT01479868|DRUG|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
218896186|NCT01479868|DRUG|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
218896187|NCT01479868|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
219611496|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
219611497|NCT05536063|PROCEDURE|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
219611498|NCT01256879|DRUG|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
219611499|NCT01259479|DRUG|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
219611500|NCT00366795|DRUG|Satavaptan|oral administration once daily
219611501|NCT00366795|DRUG|placebo|oral administration once daily
219611502|NCT06181773|BEHAVIORAL|EPO Feeding Program|The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
219611503|NCT07067229|DEVICE|Personalized rTMS|Personalized repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
219611504|NCT07067229|DEVICE|Standard rTMS|Standard repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
218896188|NCT00354146|DRUG|tipifarnib (R115777)|
218896189|NCT02081157|DEVICE|GalaFlex Mesh|
218896190|NCT01508169|DEVICE|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
218896191|NCT01825187|DEVICE|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
218896192|NCT01825187|DEVICE|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
218896193|NCT01825187|OTHER|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
218896194|NCT02364141|OTHER|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
218896195|NCT02364141|OTHER|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
218896196|NCT06155461|PROCEDURE|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
218896197|NCT02558855|OTHER|Thrust Joint Manipulation of the Lumbar Spine|
219611505|NCT07067229|DEVICE|Sham rTMS|Sham rTMS together with mixed-reality (MR) exercise
218896198|NCT02558855|OTHER|Non-thrust Joint Manipulation of the Lumbar Spine|
218896199|NCT04035252|DIAGNOSTIC_TEST|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
218896200|NCT03501472|BEHAVIORAL|text-only PWL|
219035555|NCT05044806|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
219035556|NCT03087370|OTHER|No intervention|No intervention
219035557|NCT04094701|OTHER|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
219035558|NCT04094701|OTHER|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
219035559|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
219035560|NCT05217849|BEHAVIORAL|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
219035561|NCT05217849|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
219035562|NCT05217849|BEHAVIORAL|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
219516790|NCT01879280|PROCEDURE|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
219516791|NCT01608581|OTHER|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
219516792|NCT04518176|PROCEDURE|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
219516793|NCT04518176|DRUG|Oxytocin|20 units by slow intravenous drip injection
218896201|NCT03501472|BEHAVIORAL|low-emot PWL|
218896202|NCT03501472|BEHAVIORAL|high-emot PWL|
219035563|NCT04434768|BIOLOGICAL|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
219035564|NCT06790173|BEHAVIORAL|Strategy training for physical activity|STPA is a home-based rehabilitation that guides stroke participants to implement strategy training for addressing barriers to physical activity engagements. Participants learn and practice meta-cognitive strategies (to set a goal, to make a plan, to do the plan, to check the performance of the plan) throughout the intervention period.
219035565|NCT06790173|BEHAVIORAL|Physical activity|PA program consists of a warm-up for 5 minutes, an aerobic exercise program for 30-40 minutes, a multicomponent exercise program (resistance and balance training) for 10-20 minutes, and finally, a cooling down program for 5 minutes.
219035566|NCT06790173|OTHER|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
219035567|NCT03932409|DRUG|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
219516794|NCT00602329|BIOLOGICAL|bevacizumab|Given IV
219516795|NCT00602329|DRUG|fluorouracil|Given IV
219516796|NCT00602329|DRUG|leucovorin calcium|Given IV
218896203|NCT03501472|BEHAVIORAL|immed posttest|
218896204|NCT03501472|BEHAVIORAL|delay posttest|
218896205|NCT03266133|BEHAVIORAL|Sleep Education for Pregnancy|Sleep education specific to pregnancy
218896206|NCT03865082|DRUG|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
218896207|NCT03865082|DRUG|Nivolumab|Specified dose on specified days.
218896208|NCT03865082|DRUG|Ipilimumab|Specified dose on specified days.
218896209|NCT00962637|DRUG|Androxal|12.5 mg once daily
218896210|NCT00962637|DRUG|Androxal|25 mg once daily
219516797|NCT00602329|DRUG|oxaliplatin|Given IV
219611506|NCT04927845|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
219611507|NCT07100106|DRUG|GDC-4198|GDC-4198 will be administered orally.
219611508|NCT07100106|DRUG|Giredestrant|Giredestrant will be administered orally.
218896211|NCT00962637|DRUG|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
219611509|NCT07100106|DRUG|Abemaciclib|Abemaciclib will be administered orally.
219611510|NCT07101328|DRUG|LY4152199 - IV|Administered by IV infusion
219611511|NCT07101328|DRUG|LY4152199 - SC|Administered by SC injection
218896212|NCT00962637|DRUG|Placebo|1 capsule daily
218896213|NCT01749969|DRUG|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
218896214|NCT01749969|DRUG|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
218896215|NCT01749969|DRUG|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
218896216|NCT05233592|DEVICE|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
218896217|NCT00814450|DEVICE|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
218896218|NCT01749306|BIOLOGICAL|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
218896219|NCT01749306|OTHER|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
218896220|NCT03653858|DEVICE|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
218896221|NCT04161742|DEVICE|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
218896222|NCT00195039|DRUG|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
218896223|NCT03742973|DRUG|Baricitinib|Administered orally.
218896224|NCT03742973|DRUG|Placebo|Administered orally.
218896225|NCT01814527|DIETARY_SUPPLEMENT|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
218896226|NCT01814527|DRUG|Placebo|5 capsules that are identical to the treatment.
218896227|NCT04524858|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
218896228|NCT03479086|DRUG|Topiramate|200mg/day 100mg b.i.d
218896229|NCT03479086|DRUG|Naltrexone|50mg/day
219035568|NCT03932409|RADIATION|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
219035569|NCT03932409|DRUG|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
219516798|NCT00060866|DRUG|Propranolol|
219516799|NCT00826774|BEHAVIORAL|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
219516800|NCT00826774|BEHAVIORAL|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
219611512|NCT02698111|DRUG|Donafenib|donafenib 200mg，bid
219611513|NCT06747949|DRUG|Dazodalibep|Dazodalibep will be given intravenously (IV).
219611514|NCT05026827|OTHER|Iyengar Yoga|Participation in Iyengar Yoga classes
219611515|NCT05026827|OTHER|Socialization Control|Participation in socialization control group sessions
219611516|NCT05409976|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
218896230|NCT06423469|DEVICE|Noninvasive ICP monitoring|The brain4care system is a FDA approved noninvasive device for surrogate intracranial pressure monitoring. Serial monitoring sessions were performed in included patients. Information recorded was for study purposes only and did not affect any therapy planned for the attending teams.
218896231|NCT02109640|DRUG|Targinact|Post-operative analgesia
218896232|NCT02109640|DRUG|Oxycodone|Postoperative analgesia
219035570|NCT03932409|DRUG|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
219035571|NCT06364553|DEVICE|Esophageal self-expandable metal stent|The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
219035572|NCT04415606|DEVICE|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
219035573|NCT05002127|DRUG|Evorpacept (ALX148)|IV Q2W
219516801|NCT00826774|BEHAVIORAL|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
219516802|NCT05473169|DEVICE|Videofluoroscopy|Swallowing assessment
219516803|NCT00322491|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
219516804|NCT04418726|OTHER|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
219516805|NCT05003648|DRUG|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
219516806|NCT05003648|DRUG|Placebo|Matching placebo
219516807|NCT04503330|PROCEDURE|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
218896233|NCT02109640|PROCEDURE|Laparoscopic segmental colectomy|
218896234|NCT03155126|OTHER|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
218896235|NCT02461654|OTHER|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
218896236|NCT01363700|DRUG|DE-114 ophthalmic solution|
218896237|NCT01363700|DRUG|Placebo ophthalmic solution|
219035574|NCT05002127|DRUG|Trastuzumab|IV Q2W
219035575|NCT05002127|DRUG|Ramucirumab|IV Q2W
219516808|NCT03239522|DRUG|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
219516809|NCT03239522|DRUG|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
219516810|NCT03239522|DRUG|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
219516811|NCT01362725|DEVICE|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
219516812|NCT00846625|DRUG|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
218896238|NCT01363700|DRUG|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
218896239|NCT02230566|DRUG|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
218896240|NCT02230566|OTHER|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
218896241|NCT03904212|PROCEDURE|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
218896242|NCT03904212|PROCEDURE|saline|injection with saline
218896243|NCT00804700|BEHAVIORAL|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
219035576|NCT05002127|DRUG|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
219035577|NCT05379478|DIAGNOSTIC_TEST|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
219516813|NCT00846625|DRUG|ranibizumab|Intravitreal injection, 0.5 mg
219516814|NCT00929539|DRUG|JTT-130|Tablets
219516815|NCT00929539|DRUG|JTT-130 Placebo|Tablets
219516816|NCT05425667|OTHER|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
218896244|NCT03563820|BEHAVIORAL|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
218896245|NCT06020157|OTHER|Simple Suture Technique|The half of the full arch flap will be closed by the simple suture technique.
218896246|NCT06020157|OTHER|Continuous Suture Technique|The half of the full arch flap will be closed by the continuous suture technique.
218896247|NCT00531258|DEVICE|rTMS|Bilateral rTMS
218896248|NCT00531258|DEVICE|Sham rTMS|sham rTMS
218896249|NCT01274026|DRUG|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
218896250|NCT00113841|DRUG|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
218896251|NCT00113841|DRUG|Bioperine|5 mg (Tablets) orally twice daily
218896252|NCT03507036|DEVICE|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
218896253|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
219516817|NCT05385068|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
219516818|NCT03652701|OTHER|Hair Up|Herbal topical
219516819|NCT03652701|OTHER|Placebo|Placebo
219516820|NCT05258864|BEHAVIORAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
219516821|NCT03228095|DIAGNOSTIC_TEST|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
218896254|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
218896255|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
218896256|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
218896257|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
218896258|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
218896259|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
218896260|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
218896261|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
218896262|NCT02296567|OTHER|Control Group|Control group Subjects will no previous anti-VEGF treatment
218896263|NCT04283305|OTHER|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
218896264|NCT04283305|OTHER|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
219516822|NCT03228095|DIAGNOSTIC_TEST|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
219516823|NCT03228095|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
219516824|NCT03228095|PROCEDURE|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
219611517|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
219516825|NCT03228095|PROCEDURE|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
219516826|NCT03228095|DIAGNOSTIC_TEST|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
218896265|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
218896266|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
218896267|NCT05362123|OTHER|non interventional|Online google form questioner
219035578|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
219035579|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
219035580|NCT03581240|DRUG|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
219035581|NCT05989607|OTHER|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
219035582|NCT05989607|OTHER|Plain Water|Commercially available bottled, spring water.
219035583|NCT05530096|DIAGNOSTIC_TEST|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
219516827|NCT03228095|PROCEDURE|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
219516828|NCT03228095|DIAGNOSTIC_TEST|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
219516829|NCT04913896|DRUG|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
219611518|NCT06667700|DRUG|Molnupiravir|Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
219035584|NCT06104124|DRUG|Dazodalibep|IV infusion
219611519|NCT06667700|DRUG|Placebo|Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
219611520|NCT06917222|PROCEDURE|Slide tracheoplasty|Management of tracheal stenosis by slide tracheoplasty
218896268|NCT06342908|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
218896269|NCT06342908|BIOLOGICAL|Dendritic Cell Therapy|Given PpDC vaccine ID
218896270|NCT06342908|PROCEDURE|Leukapheresis|Undergo leukapheresis
219035585|NCT06104124|DRUG|Placebo|IV infusion
219035586|NCT05421897|DRUG|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
219035587|NCT04471844|DEVICE|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression."
219035588|NCT06448403|DEVICE|MRI Scanning|MRI scanning with volumetric, resting and activity-based sequences.
219035589|NCT06448403|DEVICE|64-channel EEG|EEG to quantifiy electric activity.
219035590|NCT06448403|DEVICE|Polysomnography|A randomized group will undergo polysomnography.
219035591|NCT06448403|BIOLOGICAL|Blood samples|Analysis of specific blood biomarkers.
219035592|NCT06448403|BIOLOGICAL|Fecal samples|Analysis of bacterial composition.
219035593|NCT06448403|BEHAVIORAL|Cognitive tests|Interview-based cognitive tests for assesment of cognitive levels.
219035594|NCT01794806|PROCEDURE|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
219035595|NCT01794806|PROCEDURE|Tooth extraction|Minimally traumatic single-rooted tooth extraction
218896271|NCT06342908|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218896272|NCT06342908|DRUG|Poly ICLC|Given IM
218896273|NCT02412228|DRUG|Ixazomib|"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
218896274|NCT02412228|DRUG|Cyclophosphamide|"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"
219035596|NCT01171131|OTHER|Blood/saliva sampling|one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
219035597|NCT04884685|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
219516830|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
218896275|NCT02412228|DRUG|Dexamethasone|"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
219516831|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
219516832|NCT01052090|DRUG|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
219516833|NCT04940455|OTHER|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
218896276|NCT02703298|DRUG|TRX-818 capsules|
218896277|NCT05183945|DEVICE|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
218896278|NCT05183945|DEVICE|Coil|A coil which is used for preoperative localization of lung nodules.
218896279|NCT04112966|PROCEDURE|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
218896280|NCT04112966|OTHER|the health education|The health education for lymphedema prevention.
218896281|NCT01365728|PROCEDURE|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
218896282|NCT05568628|DEVICE|ultrasound|screening of breast lesions by ultrasonography
218896283|NCT04143685|DRUG|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
218896284|NCT04143685|DRUG|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
219035598|NCT04884685|BIOLOGICAL|Placebo|aluminium hydroxide solution only
219035599|NCT04896658|DRUG|Belantamab Mafodotin, Cyclophosphamide and Dexamethasone|Study drug
219035600|NCT02902510|OTHER|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
219035601|NCT05087056|COMBINATION_PRODUCT|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
219035602|NCT05087056|COMBINATION_PRODUCT|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
219035603|NCT06074380|DRUG|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
219035604|NCT06537882|DIETARY_SUPPLEMENT|G-NiiB synbiotics formula (SLP07)|SLP07 consists of a blend of food-grade Bifidobacterium and Lactobacillus as active probiotics, omega 3, and vitamin E.
219035605|NCT06537882|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 2mg of vitamin C with corn starch filler
219035607|NCT06433596|OTHER|Platelet-rich plasma|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
219035608|NCT06433596|OTHER|Shock waves therapy|6 sessions of focal shock waves, 1 per week
219035609|NCT06433596|OTHER|Placebo PRP|3 injections of 10 cc of saline solution, weeks 1, 5 and 9
219035610|NCT06433596|OTHER|Sham shock waves therapy|6 sessions of sham shock waves, 1 per week
219035611|NCT05914779|OTHER|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
219035612|NCT05914779|OTHER|with antibiotics treatment|with antibiotics treatment
219035613|NCT02225522|OTHER|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
219035614|NCT02706509|DRUG|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
219611521|NCT06917222|PROCEDURE|Tracheal resection anastomosis|Management of tracheal stenosis by tracheal resection anastomosis
218896285|NCT04358302|BEHAVIORAL|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
218896286|NCT05032482|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
218896287|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
218896288|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
218896289|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
219035615|NCT02706509|BEHAVIORAL|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
219035616|NCT02706509|DEVICE|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
219035617|NCT06223074|OTHER|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
219035618|NCT06223074|DRUG|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
219035619|NCT03806166|OTHER|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
219035620|NCT03806166|OTHER|Standard treatment|Standard duration of systemic antibiotic treatment
219035621|NCT05642416|DRUG|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
219516834|NCT00720096|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
219516835|NCT00720096|DRUG|Topotecan|"1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
219204024|NCT06985745|OTHER|Standard Cleanser, Investigational emulsion, Standard moisturizer, Standard Sunscreen|"Products Application and Usage Instruction:~Wash out: T-2W \~ T0~Frequency:~AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: All the products should be applied to full face. No any other skincare or facial make up products are used except provide products.~b. Mode of application : 4-week Treatment T0 \~ T4W~Frequency:~AM: Standard cleanser + test emulsion (FLA#2039180 68) + standard sunscreen PM: Standard cleanser + test emulsion (FLA#2039180 68) Caution: All the products should be applied to full face. No other skincare or facial make up products are used except provide products.~c. Mode of application : 2-week relapse T4W \~ T6W AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer~Usage Instruction： Test emulsion (FLA#2039180 68): Self-application 0.6 ml for full face by hand every day (2x/day)."
219516836|NCT05334849|DEVICE|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
219204025|NCT02347254|DEVICE|Transcranial ExAblate|Transcranial ExAblate MRgFUS
219516837|NCT00442936|DRUG|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
219516838|NCT00442936|DRUG|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
219516839|NCT00442936|DRUG|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
219516840|NCT00442936|DRUG|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
219516841|NCT00442936|DRUG|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
219516842|NCT00442936|DRUG|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
219516843|NCT00442936|DRUG|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
218896290|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
218896291|NCT01739036|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
218896292|NCT03668002|PROCEDURE|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
218896293|NCT03668002|PROCEDURE|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
218896294|NCT06108154|BEHAVIORAL|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
218896295|NCT05163262|OTHER|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
218896296|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
219516844|NCT02512666|DEVICE|AM4113-N5UT Dino-Lite|
218896297|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
218896298|NCT03532126|DEVICE|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
218896299|NCT05275374|DRUG|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
218896300|NCT05275374|DRUG|Trametinib|Trametinib will be administered 2mg orally once a day.
219516845|NCT00005938|DRUG|exatecan mesylate|
219516846|NCT05524103|DRUG|ALMB-0166|A single dose of ALMB-0166 injection.
219516847|NCT03400384|OTHER|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
218896301|NCT04383457|DEVICE|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
218896302|NCT04690530|PROCEDURE|mechanical ventilation|mechanical vantilation will be performed
218896303|NCT04690530|DRUG|Sedation|sedation wil be performed
218896304|NCT02451995|DEVICE|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
219516848|NCT04494659|DRUG|Famitinib capsule|single dose and co-administrated with Rifampicin capsule
219516849|NCT04494659|DRUG|Rifampicin capsule|repeated doses of Rifampicin capsule
218896305|NCT02451995|DEVICE|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
218896306|NCT03292068|COMBINATION_PRODUCT|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
218896307|NCT03292068|DIETARY_SUPPLEMENT|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
218896308|NCT03292068|OTHER|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
218896309|NCT00190723|DRUG|Enzastaurin|
218896310|NCT01361893|OTHER|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
219035622|NCT05642416|DRUG|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
219035623|NCT06322836|PROCEDURE|Duble current electro cardioversion|Instead of the regular clinical treatment, in this study direct-current electrical cardioversion (DC-ECV) will be performed at the patient's home and will be carried out by well-trained and certified advanced practice providers (APP) on site, i.e. nurse practitioner or physician assistant, supported by an EMS ambulance team containing an ambulance nurse and ambulance driver, both trained advanced life-support (ALS) professionals.
219516850|NCT06850688|DEVICE|Remote monitoring platform|"EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training.~Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge"
219516851|NCT01292109|DRUG|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
219516852|NCT00524459|DRUG|docetaxel|
219611522|NCT07106658|OTHER|TEAS + Urgent Endoscopy|Participants receive real Transcutaneous Electrical Acupoint Stimulation (TEAS) delivered via surface electrodes bilaterally at four predefined acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]). Stimulation (dense-disperse wave, 2/100Hz frequency, intensity 5-15mA based on tolerance) begins 30 minutes before urgent endoscopy and continues throughout the procedure. All participants receive standard medical management and urgent endoscopy.
218896311|NCT01915043|OTHER|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
218896312|NCT04736381|DRUG|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
218896313|NCT06333379|OTHER|Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF|Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.
218896314|NCT03468361|OTHER|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
218896315|NCT03468361|OTHER|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
218896316|NCT05370131|OTHER|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
219035624|NCT05863676|PROCEDURE|Oophorectomy|Ovary will be removed for fertility preservation.
219035625|NCT05863676|DIAGNOSTIC_TEST|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
218896317|NCT00104650|GENETIC|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
218896318|NCT00104650|DRUG|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
218896319|NCT00104650|GENETIC|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
219204026|NCT02765854|DRUG|Dexamethasone|Given PO
219204027|NCT02765854|DRUG|Ixazomib|Given PO
219204028|NCT02765854|DRUG|Lenalidomide|Given PO
218896320|NCT03390465|DRUG|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
218896321|NCT05820854|OTHER|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
219035626|NCT01650207|PROCEDURE|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
219204029|NCT06986603|DRUG|Glucagon for Injection (Fresenius Kabi USA)|We are assessing response to glucose, including incremental glucose values as well as changes in endogenous glucose production, insulin secretion, and glucagon levels.
219516853|NCT00524459|DRUG|pegylated liposomal doxorubicin hydrochloride|
219516854|NCT00524459|PROCEDURE|conventional surgery|
219516855|NCT00524459|PROCEDURE|neoadjuvant therapy|
219516856|NCT04039542|OTHER|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
219516857|NCT04371250|OTHER|Survey and Questionnaire|Resilience and Loneliness questionnaires
218896322|NCT00990743|DRUG|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
218896323|NCT00135317|DRUG|darbepoetin alfa|
218896324|NCT06393075|BEHAVIORAL|combined care guidance|Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
218896325|NCT06393075|BEHAVIORAL|general care guidance|general care guidance
218896326|NCT03353805|BEHAVIORAL|questionnaire|questionnaire
218896327|NCT01431781|DRUG|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
218896328|NCT01431781|OTHER|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
219035627|NCT01650207|PROCEDURE|TENS|
219204030|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
219516858|NCT06101836|OTHER|Training intervention|Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
219516859|NCT06278142|OTHER|Internet Based Intervention - GUIDED|In the expert-supported application, each participant will be sent a folder to be shared by the user and the guide via Google Drive, and the user is expected to perform the application in the folder. A module is added to the folder every Monday and the participant is asked to complete the relevant module until Friday of the same week. In the following two days, a feedback message is provided by the expert, taking into account the user's responses.
218896329|NCT04800146|PROCEDURE|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
218896330|NCT06500637|DRUG|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
219035628|NCT01650207|PROCEDURE|sham acupuncture|
219035629|NCT03890549|DIAGNOSTIC_TEST|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
219035630|NCT03149692|OTHER|Penile allograft transplantation|Proof of concept of surgical procedure
219035631|NCT01990495|OTHER|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
219035632|NCT01990495|OTHER|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
219035633|NCT01747109|DEVICE|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
218896331|NCT04958889|OTHER|No intervention|(observational study)
218896332|NCT02294058|DRUG|Ozanimod|Capsules for oral administration once a day
218896333|NCT02294058|DRUG|Interferon beta-1a|Administered by intramuscular injection once a week
218896334|NCT02294058|DRUG|Placebo to ozanimod|Matching placebo capsules administered orally once a day
218896335|NCT02294058|DRUG|Placebo to interferon beta-1a|Placebo intramuscular injection once a week
218896336|NCT04932239|OTHER|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
218896337|NCT02111330|DRUG|PBF-509|
218896338|NCT02111330|DRUG|Placebo|
218896339|NCT04617067|DRUG|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
218896340|NCT04617067|DRUG|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
218896341|NCT04470635|DIAGNOSTIC_TEST|ELISA|Saliva sample collection
218896342|NCT00298974|DRUG|hydrocodone / acetaminophen extended release|2 tablets twice daily
218896343|NCT00298974|DRUG|Placebo|2 tablets twice daily
218896344|NCT05357027|BIOLOGICAL|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
218896345|NCT05357027|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
218896346|NCT05357027|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
218896347|NCT05357027|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
218896348|NCT00250341|DRUG|QVAR|480 mcg
218896349|NCT00250341|DRUG|Advair|250/50 mcg
218896350|NCT00250341|DRUG|Servent Diskus|50 mcg
218896351|NCT03934606|BEHAVIORAL|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
218896352|NCT05006261|DEVICE|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
218896353|NCT00189839|DRUG|tacrolimus|Immunosuppression
218896354|NCT00657644|DRUG|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
218896355|NCT02722226|OTHER|Simulation|High fidelity simulation based sedation learning program
218896356|NCT02722226|DEVICE|Airway management|Workshop on using airway management and oxygenation devices.
218896357|NCT02722226|BEHAVIORAL|Crisis resource management|Learning crisis resource management principles
218896358|NCT04642391|DRUG|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
218896359|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
219516860|NCT06278142|OTHER|Internet Based Intervention - WİTHOUT GUİDANCE|The developed implementation plan is communicated to the participants without expert support and their participation is ensured. A common folder will be created with the participants accepted to the study and in the group without expert support, and the process is managed by transmitting the module to the user via the folder every Monday.
219516861|NCT00539877|DRUG|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
219516862|NCT03672110|DRUG|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
219516863|NCT06434285|OTHER|Questionnaire development|Cognitive interviewing group will be run to inform questionnaire development.
219611523|NCT07106658|OTHER|Sham TEAS + Urgent Endoscopy|Participants receive placebo TEAS. Electrodes are placed identically to the Active TEAS Group at the same four acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]) using the same device, but no electrical current is delivered. The device appears active to maintain blinding. All participants receive standard medical management and urgent endoscopy.
219611524|NCT07106658|OTHER|Urgent Endoscopy Only|Participants receive standard urgent endoscopy care only, with no TEAS electrodes or device applied. They receive identical standard medical management and urgent endoscopy as the other groups.
219611525|NCT07112742|DEVICE|High-Intensity Laser Therapy and Exercise|High-intensity laser therapy will be applied to the painful and affected joint of the participants. A Class IV high-intensity laser device will be used. The parameters to be applied have been determined based on the relevant guidelines: average power 3 W, in analgesic mode, wavelength of 1064 nm, frequency of 2 Hz, energy dose of 75 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The total treatment duration will be 160 seconds. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
218896360|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
218896361|NCT01154868|PROCEDURE|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
218896362|NCT03863756|RADIATION|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
219516864|NCT00530010|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
219516865|NCT05754047|DIAGNOSTIC_TEST|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
218896363|NCT00994526|OTHER|Ham|Ham : 180 g per day during 4 days
218896364|NCT00994526|OTHER|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
219516866|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
219516867|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
219516868|NCT03203915|DIETARY_SUPPLEMENT|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
219516869|NCT03689790|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
218896365|NCT00994526|OTHER|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
218896366|NCT02531724|DRUG|Levosimendan|
219516870|NCT03689790|PROCEDURE|gastric bypass|gastric bypass
219516871|NCT04611698|DEVICE|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
218896367|NCT02531724|DRUG|Placebo|Sodium chloride
219516872|NCT05019066|DIETARY_SUPPLEMENT|Herbal Supplementation|A proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa.
219516873|NCT03325530|BEHAVIORAL|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
219516874|NCT05318651|DEVICE|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
218896368|NCT03565536|DRUG|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
218896369|NCT03565536|PROCEDURE|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
218896370|NCT03565536|RADIATION|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
218896371|NCT01807598|DRUG|Brentuximab vedotin|
218896372|NCT01895595|BEHAVIORAL|Guided Imagery|
218896373|NCT01895595|BEHAVIORAL|Digital Storytelling|
218896374|NCT05581459|OTHER|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
218896375|NCT05581459|OTHER|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
218896376|NCT05581459|OTHER|Sham vibration|Handheld device was applied to the participants without any vibrations.
218896377|NCT04298437|BEHAVIORAL|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
218896378|NCT01887184|DRUG|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranasally
218896379|NCT01887184|DRUG|Placebo|Intranasal saline was given
219516875|NCT05223582|DRUG|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
219516876|NCT05223582|DRUG|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
219516877|NCT05223582|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
219516878|NCT05223582|DRUG|Androgen deprivation therapy|Patients would get medical castration.
219516879|NCT05223582|PROCEDURE|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
219516880|NCT03388320|DEVICE|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
218896380|NCT03960112|DEVICE|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
218896381|NCT00056004|DRUG|zileuton|
218896382|NCT00209859|DRUG|Methotrexate|
218896383|NCT00209859|DRUG|Intraarticular betamethasone|
218896384|NCT00209859|DRUG|Cyclosporine/placebo-cyclosporine|
218896385|NCT00531635|DRUG|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
219516881|NCT04663360|OTHER|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
219516882|NCT01151748|PROCEDURE|Intra-arterial infusion of chemotherapy|
219516883|NCT05901948|OTHER|Classification|Novel Asherman Scoring Classification
219516884|NCT00004825|DRUG|recombinant human insulin-like growth factor I|
219516885|NCT03637582|DRUG|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
219516886|NCT03637582|OTHER|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
219516887|NCT01574248|DRUG|icatibant|Subcutaneous at time 0 and 6 hours
218896386|NCT05348200|DRUG|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
218896387|NCT05348200|DRUG|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
218896388|NCT05348200|DRUG|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
218896389|NCT05348200|DRUG|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
218896390|NCT05348200|DRUG|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
218896391|NCT01550809|OTHER|iBolus|Insulin bolus calculated from data obtained through CGM
218896392|NCT01550809|OTHER|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
218896393|NCT01736371|DRUG|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
218896394|NCT01736371|DRUG|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
218896395|NCT01736371|DRUG|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
218896396|NCT02386449|DRUG|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
218896397|NCT02386449|DRUG|mannitol|
218896398|NCT02386449|DRUG|Bisacodyl|
218896399|NCT04740697|OTHER|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
219516888|NCT01574248|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
219516889|NCT01424722|DEVICE|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
219035634|NCT01747109|PROCEDURE|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
219516890|NCT05428722|BEHAVIORAL|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
219035635|NCT02912026|DRUG|IV F901318|Metabolic profile AUC 0 to infinity
219516891|NCT00493272|DRUG|Fibrinogen|Fibrinogen behandling
219035636|NCT02912026|DRUG|Oral F901318|Metabolic profile AUC 0 to infinity
219516892|NCT04647604|DRUG|Omegaven®|A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
219516893|NCT04647604|DRUG|Sodium chloride|intravenously administered 2 mL/kg/day
219611526|NCT07112742|DEVICE|High-Intensity Laser Therapy at a Non-Therapeutic Dose Combined With Exercise|Participants will receive high-intensity laser therapy at an ineffective dose to the painful and affected joint. Due to the absence of a placebo mode in the laser device used in hospital, the lowest possible parameters will be applied to simulate an ineffective dose. For the ineffective dose, the device parameters will be set as follows: average power 0.5 W, in analgesic mode, wavelength of 1064 nm, frequency of 1 Hz, energy dose of 12 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The treatment duration will be the same as that of the intervention group. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
219611527|NCT07114601|DRUG|LY4257496|Administered IV
219611528|NCT07114601|DRUG|Standard of Care Anticancer Therapies|Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib
219611529|NCT07128368|OTHER|Resistance Exercise Training|Participants will undergo resistance exercise training 3 days a week for approximately 1 hour each day for 8 weeks.
219611530|NCT07193342|PROCEDURE|computer controlled automatic injection (Star pen® system)|local anesthesia will be administered using computer controlled automatic injection(Star pen® system ) to provide slow and consistent anesthetic flow, aiming to reduce pain and anxiety during pediatric dental treatment.
219611531|NCT07193342|PROCEDURE|conventional anesthetic syringe|local anesthesia will be administered using a standard manual dental syringe , following conventional injection techniques for pediatric dental patients.
219611532|NCT07192627|PROCEDURE|Endoscopic mucosal dissection|Removal of lesions extending down to submucosa
219611533|NCT07192666|DRUG|Exosome Preparation|Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.
219611534|NCT07192068|DRUG|Zanidatamab|"Single arm study where the experimental regimen used for all patients will be zanidatamab, administered intravenously every 3 weeks :~* Patients \<70 kg: 1800 mg IV Q3W on Day 1 of each 21-day cycle~* Patients ≥70 kg: 2400 mg IV Q3W on Day 1 of each 21-day cycle."
219611535|NCT07191860|COMBINATION_PRODUCT|The Airiver Pulmonary drug-coated balloon (DCB) dilation|drug coated balloon dilation
219611536|NCT07191860|DEVICE|Commercial airway balloon dilation|uncoated airway balloon dilation
219611537|NCT07192588|DRUG|GR1014-CG 2.4%|Topical gel formulation of amifostine thiol (GR1014) at 25 mg/mL
219611538|NCT07192588|DRUG|Vehicle Gel|The same topical formulation as GR1014-CG without the active ingredient amifostine thiol
219611539|NCT07192588|RADIATION|Radiation Therapy|Ultra hypofractionated RT, 26 Gy in 5 daily fractions (5.2 Gy) given over 1 week on the whole breast
219611540|NCT07192588|DRUG|GR1014-CG 4.7%|Topical gel formulation of amifostine thiol (GR1014) at 50 mg/mL
219611541|NCT07191990|PROCEDURE|Final irrigation by cryotreated NaOcl.|Final irrigation by cryotreated NaOcl (2.6%) at 2-4 °C for 1 min
219611542|NCT07191990|PROCEDURE|Final irrigation by preheated NaOcl|Final irrigation by preheated 60°C(15) NaOcl (2.6%) for 1 min.
219611543|NCT07191990|PROCEDURE|Final irrigation with ultrasonic activation of NaOcl|Final irrigation with ultrasonic activation of NaOcl(2.6%) for 1 min
219611544|NCT07191990|PROCEDURE|Final irrigation by NaOcl at room temperature|Final irrigation by NaOcl (2.6%) at room temperature 24 °C for 1 min
219611545|NCT03258502|DRUG|RV521|RV521 drug in capsules
219611546|NCT03258502|DRUG|Placebo|Placebo in capsules
219035637|NCT03601221|OTHER|Sample collection|Collection of one sampling pouch from each blood donor
219035638|NCT01928862|DRUG|Prepopik® ½ Sachet x 2 (9-12 years)|
219035639|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (9-12 years)|
219035640|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
219611547|NCT05954988|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
219611548|NCT05954988|DRUG|Placebo|Matching placebo
219611549|NCT06263179|BEHAVIORAL|Target Heartrate Aerobic Exercise|Exercise program
219611550|NCT03528642|OTHER|Questionnaire Administration|Ancillary studies
219611551|NCT03528642|RADIATION|Radiation Therapy|Undergo RT
219611552|NCT03528642|DRUG|Telaglenastat Hydrochloride|Given PO
219611553|NCT03528642|DRUG|Temozolomide|Given PO
219611554|NCT06288282|OTHER|No Intervention|No intervention will be used.
219611555|NCT04059952|DEVICE|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
218896400|NCT06315946|DEVICE|Pixie® skin tag|The skin tag is treated by treatment with the cryogenic device. To protect the surrounding skin, a protective foam plaster is applied before the device is used on the skin tag. The skin tag is treated for 20 seconds after loading the device for 2 seconds.
219035641|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (13-16 years)|
219516894|NCT06200701|BEHAVIORAL|Job Crafting program|The training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
219516895|NCT05885139|DEVICE|Exopulse Mollii Suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
219611556|NCT06290765|DRUG|Ropeginterferon alfa-2b|"Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value."
219611557|NCT06290765|PROCEDURE|Phlebotomy and aspirin|Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
219516896|NCT05885139|DEVICE|Sham Exopulse Mollii Suit|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
219516897|NCT00082563|DRUG|Azithromycin/Chloroquine|
219516898|NCT00082563|DRUG|Chloroquine|
219516899|NCT00995410|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
219516900|NCT01029938|PROCEDURE|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
219611558|NCT03829540|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
219611559|NCT00265759|DRUG|anastrozole|Given PO
219611560|NCT00265759|DRUG|exemestane|Given PO
219611561|NCT00265759|DRUG|letrozole|Given PO
219611562|NCT00265759|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
219611563|NCT03802526|DRUG|NVP-1805-R1|1 tablet, multiple oral dosing
219611564|NCT03802526|DRUG|NVP-1805-R2|1 tablet, multiple oral dosing
218896401|NCT06315946|DEVICE|Wortie® Skin Tag Remover|The skin tag is treated by treatment with the cryogenic device. The frozen metal nib is applied on the skin tag for 40 seconds.
218896402|NCT00003811|BIOLOGICAL|bleomycin sulfate|
219611565|NCT03802526|DRUG|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
218896403|NCT00003811|DRUG|amifostine trihydrate|
218896404|NCT00003811|DRUG|cisplatin|
218896405|NCT00003811|DRUG|etoposide|
218896406|NCT00003811|PROCEDURE|conventional surgery|
219035642|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
219035643|NCT02290288|PROCEDURE|vaginal surgery|
219035644|NCT02290288|PROCEDURE|laparoscopic surgery|
219035645|NCT01478321|DRUG|Temozolomide|Given PO
219035646|NCT01478321|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
219035647|NCT01478321|BIOLOGICAL|bevacizumab|Given IV
219035648|NCT01478321|OTHER|questionnaire administration|Ancillary studies
219035649|NCT00145665|PROCEDURE|FLT-PET scan|PET scan using FLT
218896407|NCT01440855|OTHER|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
218896408|NCT01440855|OTHER|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
218896409|NCT00018967|DRUG|glucarpidase|
219035650|NCT02888548|PROCEDURE|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
219516901|NCT01029938|PROCEDURE|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
218896410|NCT04334993|DRUG|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
218896411|NCT03893032|DRUG|Modafinil 200mg|single 200 mg dose
219035651|NCT02888548|PROCEDURE|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
219035652|NCT00983268|DRUG|capecitabine|1000 mg taken by mouth on the days of radiation only.
219516902|NCT05993156|DEVICE|modified Fixed twinblock|modified fixed twin block functional appliance, with cemented bands on the first molars
219516903|NCT05993156|DEVICE|removable twin block|Conventional Removable Clark twin block myofunctional appliance
219516904|NCT02230007|DRUG|MEOPA|3 sessions of reeducation using MEOPA
219516905|NCT03943056|DRUG|BIIB091|Administered as specified in the treatment arm.
219516906|NCT03943056|DRUG|Placebo|Administered as specified in the treatment arm.
219516907|NCT00818883|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
218896412|NCT03893032|DRUG|mixed amphetamine salts|single 10 mg dose
218896413|NCT03893032|DRUG|Placebo|single oral-administration placebo tablet
219035653|NCT00983268|DRUG|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg"
219035654|NCT00983268|RADIATION|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
219035655|NCT00983268|PROCEDURE|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
219035656|NCT01731522|BEHAVIORAL|EF condition|
219035657|NCT03168464|DRUG|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
219516908|NCT00818883|DRUG|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
218896414|NCT01428908|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
218896415|NCT01428908|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
219516909|NCT03992196|DRUG|Rotigotine 1 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).
219516910|NCT03992196|DRUG|Rotigotine 2 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).
219516911|NCT03992196|DRUG|Rotigotine 3 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
219516912|NCT00048048|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
219516913|NCT02684578|DRUG|Metformin|
219516914|NCT05283044|BIOLOGICAL|biopsy liquid|Patient performs a blood test at treatment baseline
218896416|NCT01428908|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
218896417|NCT01428908|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
218896418|NCT02209701|DRUG|Porfiromycin|
218896419|NCT04702841|DRUG|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
218896420|NCT04603118|PROCEDURE|Optic ultrasonography|
218896421|NCT04603118|PROCEDURE|Lumbar puncture|
219035658|NCT03168464|DRUG|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
219516915|NCT05919966|OTHER|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
219516916|NCT04569682|DEVICE|LifePort transrenal artery perfusion|transrenal artery perfusion group
219516917|NCT04569682|DEVICE|LifePort transrenal vein perfusion|transrenal vein perfusion group
219516918|NCT06056869|DRUG|hyoscine butylbromide|will be given during first stage of labor intravenously
219516919|NCT06056869|OTHER|normal saline|placebo
218896422|NCT03607942|DIETARY_SUPPLEMENT|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
218896423|NCT03607942|DIETARY_SUPPLEMENT|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
218896424|NCT03117985|OTHER|no drug|Stopping antiretroviral therapy
218896425|NCT02690350|DRUG|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
218896426|NCT00917761|DRUG|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
218896427|NCT00917761|DRUG|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
218896428|NCT00917761|DRUG|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
218896429|NCT01758913|DRUG|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
218896430|NCT06149208|BEHAVIORAL|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
218896431|NCT03374540|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
219035659|NCT03168464|RADIATION|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
219035660|NCT04649164|BEHAVIORAL|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
219035661|NCT04649164|OTHER|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
219035662|NCT02053753|DRUG|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
219035663|NCT02053753|DRUG|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
219035664|NCT03433664|DEVICE|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
218896432|NCT03374540|DRUG|Vitamin K antagonist (VKA)|Individually adjusted dose
218896433|NCT05922371|DIAGNOSTIC_TEST|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
218896434|NCT01668849|DIETARY_SUPPLEMENT|Grape extract|Grape extract self-administered by mouth daily for 35 days
219035665|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
219035666|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
219035667|NCT04722796|DEVICE|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
218896435|NCT01668849|DRUG|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
218896436|NCT03384940|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
219035668|NCT04722796|DEVICE|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
219035669|NCT01969812|DEVICE|Evie Slow-release Insemination Device|
219035670|NCT01969812|OTHER|Traditional Intrauterine Insemination|
219035671|NCT05210166|DEVICE|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
219035672|NCT05210166|DEVICE|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
219611566|NCT04009759|DRUG|Morphine|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
219611567|NCT04009759|DRUG|Ketamine Injectable Solution|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
218896437|NCT05206149|DRUG|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
218896438|NCT05206149|DRUG|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
218896439|NCT02497183|DEVICE|ultrasound|A repeat ultrasound exam following oral contrast material consumption
218896440|NCT02497183|OTHER|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
218896441|NCT03308708|DRUG|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
218896442|NCT05682742|DEVICE|Robotic-assisted Surgery|Subjects scheduled to undergo robotic-assisted surgery
218896443|NCT05211427|PROCEDURE|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
218896444|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
218896445|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
218896446|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
219035673|NCT03183414|OTHER|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
219516920|NCT03795363|DRUG|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
218896447|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218896448|NCT01242592|DRUG|Anti-Tuberculosis Treatment|
218896449|NCT04981379|DRUG|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
218896450|NCT04981379|DRUG|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
218896451|NCT04981379|DRUG|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
218896452|NCT04981379|DRUG|Placebo|Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
219035674|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
219035675|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
219204031|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
219516921|NCT05130892|DRUG|Colchicine|1 tablet (0.5mg) / time, once a day
219516922|NCT05130892|DRUG|Tranilast|1 capsule (0.1g) / time, 3 times a day
219516923|NCT05130892|DRUG|Oridonin|2 tablets (0.5g) / time, 3 times a day;
219611568|NCT04009759|DRUG|Saline 0.9%|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
218896453|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI|
219516924|NCT00405314|DEVICE|Continuous positive airway pressure ventilation mask|
219516925|NCT05293990|RADIATION|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
219516926|NCT04630938|DRUG|Morphine Sulfate|intrathecal morphine will be added to anaesthetics
219516927|NCT04630938|DRUG|morphine+lidocaine|local anesthetic will be infused intravenously
219516928|NCT04630938|DRUG|Saline|intravenous saline infusion
218896454|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 1|
218896455|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 2|
218896456|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI replicate|
218896457|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
218896458|NCT04184297|DRUG|Tiotropium and Olodaterol (Tio+Olo)|drug
218896459|NCT04184297|DRUG|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
218896460|NCT00786318|DRUG|ziprasidone|ziprasidone 20mg IM
218896461|NCT00786318|DRUG|Standard therapy|Haldol 5mg/ Ativan 2mg IM
218896462|NCT02732548|OTHER|Negative Pressure Wound Therapy (NPWT)|
218896463|NCT02732548|OTHER|MIRODERM Application(s)|
218896464|NCT02732548|OTHER|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
218896465|NCT03078894|DIAGNOSTIC_TEST|Zika|Zika Diagnostic test
219035676|NCT00499096|BEHAVIORAL|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
219035677|NCT03507712|PROCEDURE|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
219035678|NCT03507712|PROCEDURE|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
219035679|NCT01203072|DRUG|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
219035680|NCT01203072|DRUG|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
219611569|NCT06794658|DEVICE|software|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to diabetes.
219611570|NCT02593565|OTHER|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
219611571|NCT06447103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219611572|NCT06447103|PROCEDURE|Bone Scan|Undergo bone scan
219611573|NCT06447103|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and CT of the brain
218896466|NCT03078894|DIAGNOSTIC_TEST|Chikagunya|Chikagunya Diagnostic test
219035681|NCT01203072|DRUG|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
219035682|NCT01203072|DRUG|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
219035683|NCT01203072|DRUG|Placebo|Matching placebo oral tablets, once daily for 2 weeks
219035684|NCT01067768|OTHER|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
219035685|NCT02153944|DRUG|Propranolol|Propranolol 40 mg was given orally during study visit
219035686|NCT02153944|DRUG|Methylphenidate|Methylphenidate 20mg was given orally during study visit
219611574|NCT06447103|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of the brain
218896467|NCT03078894|DIAGNOSTIC_TEST|Dengue|Dengue Diagnostic test
218896468|NCT06281093|OTHER|questionary|Parental questionnaire on pregnancy history and environmental exposure
218896469|NCT06281093|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (1 week) by positioning a dosimeter close to the incubator
218896470|NCT06281093|OTHER|Follow-up of daily infants clinical parameters|Follow-up of daily infants clinical parameters
218896471|NCT06281093|OTHER|recording of cerebral (EEG)|recording of cerebral (EEG)
218896472|NCT06281093|OTHER|autonomic nervous (ECG) activity|autonomic nervous (ECG) activity
218896473|NCT02412098|DRUG|Eleclazine|Eleclazine tablets administered orally
218896474|NCT03089580|DEVICE|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
218896475|NCT03089580|PROCEDURE|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
218896476|NCT03764644|BEHAVIORAL|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
218896477|NCT03764644|BEHAVIORAL|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
218896478|NCT00977626|DRUG|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
218896479|NCT00977626|DRUG|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
219035687|NCT02153944|DRUG|Placebo|Placebo was given orally during study visit
219035688|NCT06096714|DRUG|Nicotine|Nicotine will be infused using a pump.
219035689|NCT06096714|OTHER|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
219035690|NCT04037020|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
219204032|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
219611575|NCT06447103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219204033|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
219204034|NCT05800717|BEHAVIORAL|SCI Self-Management for AIS D|An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
219611576|NCT06447103|OTHER|Questionnaire Administration|Ancillary studies
219611577|NCT06447103|DRUG|Zirconium Zr 89 Girentuximab|Given IV
219611578|NCT05732064|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
219611579|NCT05732064|DRUG|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
219611580|NCT05732064|DRUG|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
218896480|NCT00977626|DRUG|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
218896481|NCT03871699|DRUG|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
218896482|NCT03087513|DRUG|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
219035691|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
219035692|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
219516929|NCT04051970|DRUG|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
218896483|NCT03087513|DRUG|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
218896484|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
218896485|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
218896486|NCT05529693|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
218896487|NCT06346015|PROCEDURE|Gamma Entrainment Stimulation|"Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）"
218896488|NCT05590975|BEHAVIORAL|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
218896489|NCT00083525|DRUG|WX-UK1 in combination with Capecitabine|
219611581|NCT06482749|DEVICE|Repetitive transcranial magnetic stimulation|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
219611582|NCT06482749|DEVICE|Sham stimulation|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
219611583|NCT04213625|OTHER|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care"
219035693|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
219035694|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
219035695|NCT00579111|DRUG|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
219035696|NCT00579111|DRUG|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
219035697|NCT00579111|DRUG|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
219035698|NCT00579111|PROCEDURE|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
219035699|NCT00579111|DRUG|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
219035700|NCT03943563|DIAGNOSTIC_TEST|Dixon sequences acquisition|Dixon sequences acquisition
219035701|NCT04828668|DIETARY_SUPPLEMENT|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
219035702|NCT05578781|BEHAVIORAL|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
219035703|NCT05578781|BEHAVIORAL|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
219035704|NCT05578781|BEHAVIORAL|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
219035705|NCT06042036|OTHER|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
219611584|NCT04204798|DRUG|Dexmedetomidine|"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
219611585|NCT04204798|DRUG|Placebo|"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."
219611586|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
218896490|NCT01462240|DEVICE|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
218896491|NCT02739399|DRUG|Phenylephrine|Intravenous administration
218896492|NCT00770601|DRUG|Canakinumab|
218896493|NCT06169553|OTHER|Holistic injection-related injection treatment|Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
218896494|NCT03779698|OTHER|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
219516930|NCT01661452|OTHER|Referral to counseling services if desired|
219035706|NCT02389504|OTHER|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
219035707|NCT02389504|OTHER|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
219035708|NCT03437785|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
219035709|NCT03437785|DRUG|CKD-495 150mg|CKD-495 150mg Tab.
219035710|NCT03437785|DRUG|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
219035711|NCT03437785|DRUG|Rebamipide 100mg|Rebamipide 100mg Tab.
219516931|NCT01232270|DRUG|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
219516932|NCT06367452|DRUG|Sodium alginate + sodium bicarbonate + magaldrate + simeticone|Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
219516933|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
219516934|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
219516935|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
219516936|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
219516937|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
219516938|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
219516939|NCT02288832|OTHER|-self-collected vaginal samples|
219516940|NCT02288832|DRUG|zithromax|
219516941|NCT02288832|OTHER|usual practices|
219516942|NCT02412215|PROCEDURE|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
219516943|NCT02412215|DEVICE|NanoFlex toric Intraocular Lens|
219516944|NCT05518487|BIOLOGICAL|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
219516945|NCT04352361|DRUG|TVB-2640|TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
219516946|NCT04352361|DRUG|Placebo|Oral, matching number of placebo Tablets with active arm.
219516947|NCT02802371|BEHAVIORAL|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
219611587|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
218896495|NCT03779698|DRUG|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
219035712|NCT03437785|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
218896496|NCT00878748|DRUG|Effexor XR|
219035713|NCT03437785|DRUG|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
219035714|NCT03437785|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
219035715|NCT03437785|DRUG|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
218896497|NCT00878748|OTHER|Effexor XR discontinue|
219035716|NCT05261984|PROCEDURE|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
219516948|NCT02802371|OTHER|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
219516949|NCT04270305|OTHER|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
219516950|NCT04270305|OTHER|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
219516951|NCT01931033|DRUG|Intranasal Oxytocin|
219516952|NCT05956197|OTHER|No intervention|No intervention. This is a cohort study
218896498|NCT04693559|PROCEDURE|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
218896499|NCT04693559|PROCEDURE|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
218896500|NCT04693559|PROCEDURE|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
218896501|NCT04119674|DRUG|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
219516953|NCT02052609|DRUG|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
219516954|NCT02052609|DRUG|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
218896502|NCT04119674|DRUG|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
218896503|NCT04119674|RADIATION|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
219516955|NCT02752776|DRUG|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
219516956|NCT00194740|DRUG|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
219516957|NCT00194740|DRUG|Vinorelbine|27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
219516958|NCT00194740|DRUG|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
219516959|NCT02419677|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
219516960|NCT02419677|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
219516961|NCT05577585|DRUG|Ketamine 50 MG/ML Blinded|See also Arm description
219516962|NCT05577585|DRUG|Midazolam|See also Arm description
219516963|NCT05577585|DRUG|Ketamine 50 MG/ML Open Label|Open Label Follow Up (up to 8 Infusions)
219516964|NCT05577585|OTHER|Treatment as Usual (TAU)|Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.
219516965|NCT04209972|DEVICE|Precision Ultra-High-Resolution CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
218896504|NCT00181662|DRUG|Curcumin|
218896505|NCT06141863|OTHER|questionnaire|Neck Disability Index, The Fonseca Anamnestic Index (FAI) and Visual Analogue Scale (VAS)
218896506|NCT02569684|DIETARY_SUPPLEMENT|Prebiotic fibers: oligofructose and inulin|
218896507|NCT02569684|DIETARY_SUPPLEMENT|Maltodextrin|
218896508|NCT02094651|DRUG|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
218896509|NCT02094651|OTHER|Placebo|The placebo is an inactive substance that looks like the active drug.
219516966|NCT04209972|DEVICE|Genesis high-end CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
219516967|NCT04282538|DEVICE|Active rTMS|4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
219516968|NCT04282538|DEVICE|Sham rTMS|4-week (5 days per week) sham rTMS
219516969|NCT04282538|DEVICE|Active tDCS|4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
219516970|NCT04282538|DEVICE|Sham tDCS|4-week (5 days per week) sham tDCS
219516971|NCT04282538|OTHER|Walking training|4-week (5 days per week) walking training
219516972|NCT04282538|OTHER|Cognition training|4-week (5 days per week) cognition training
219516973|NCT00712010|OTHER|Whey protein native|Whey protein native against the 6 other arms
218896510|NCT03441087|DEVICE|Transvaginal ultrasound|
218896511|NCT03441087|DEVICE|Hysteroscopy|
218896512|NCT02160652|PROCEDURE|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
218896513|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
218896514|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
219516974|NCT00712010|OTHER|Whey protein microgels|Whey protein microgels versus the six other arms
219516975|NCT00712010|OTHER|Hydrolyzed whey protein|versus the six other arms
219516976|NCT00712010|OTHER|Casein native|versus the six other arms
219516977|NCT00712010|OTHER|Hydrolyzed casein|versus the six other arms
219516978|NCT00712010|OTHER|Total milk protein native|versus the six other arms
219516979|NCT00712010|OTHER|Hydrolyzed milk protein|versus the six other arms
219516980|NCT02238223|DRUG|Alesion®|
219516981|NCT00409019|DRUG|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
219516982|NCT00409019|DRUG|Adefovir|
219516983|NCT00409019|DRUG|Tenofovir|
219516984|NCT04956419|DRUG|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
218896515|NCT05373849|DIETARY_SUPPLEMENT|essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
219516985|NCT04956419|DRUG|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
219516986|NCT01399164|OTHER|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
218896516|NCT05373849|DIETARY_SUPPLEMENT|no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
219035717|NCT05261984|DIETARY_SUPPLEMENT|Oral protein supplementation|24 grams of hydrolyzed whey protein.
219035718|NCT01746212|PROCEDURE|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
219035719|NCT01746212|BIOLOGICAL|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
219035720|NCT01746212|DEVICE|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
219035721|NCT00165412|PROCEDURE|breast MRI|Repeated once a year for three years
218896517|NCT03387865|PROCEDURE|tissue biopsies|additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.
219035722|NCT00165412|PROCEDURE|Mammogram|Repeated once a year for three years
219035723|NCT00006478|BIOLOGICAL|autologous tumor cell vaccine|
219611588|NCT05537155|PROCEDURE|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
219611589|NCT05537155|OTHER|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
219611590|NCT05793151|BEHAVIORAL|ENDURE|ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
218896518|NCT03387865|PROCEDURE|blood sampling|additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)
218896519|NCT03387865|GENETIC|DNA banking|constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation
218896520|NCT03761186|BEHAVIORAL|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
218896521|NCT03761186|BEHAVIORAL|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
219035724|NCT00006478|BIOLOGICAL|keyhole limpet hemocyanin|
219035725|NCT00006478|BIOLOGICAL|sargramostim|
219035726|NCT00006478|PROCEDURE|adjuvant therapy|
218896522|NCT03761186|BEHAVIORAL|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
218896523|NCT02862873|PROCEDURE|Spinal anaesthesia|
218896524|NCT02862873|DRUG|Ondansetron|
218896525|NCT02862873|OTHER|saline solution|
218896526|NCT05659771|BEHAVIORAL|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
219516987|NCT03724006|BEHAVIORAL|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
218896527|NCT00854880|DRUG|PDC339|
218896528|NCT00854880|DRUG|Placebo|
219516988|NCT03967249|DRUG|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
218896529|NCT02506634|DRUG|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
219516989|NCT03967249|DRUG|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
219516990|NCT03714100|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
219516991|NCT05234437|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
219516992|NCT05664256|OTHER|Build capacity of canteen|"The investigators will conduct 1 day orientation training to the school nurse, principal and canteen managers of the facilities.~Different sessions on basic nutrition concept, healthy eating, healthy cooking practices including purchasing and serving will be conducted.~The investigators will develop training manuals: training curriculum, facilitators guide, and participants guide, aligning with policy contents."
219516993|NCT05664256|OTHER|Information, Education and Communication materials|Posters showing healthy plate model will be displayed on the canteen walls. The fact sheet on healthy eating will be distributed to all the public facilities and make it available at the entrance/ gate of the canteen.
218896530|NCT00943930|DRUG|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
218896531|NCT03899298|BIOLOGICAL|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
219035727|NCT06493552|DRUG|SEphB4-HSA|A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
219035728|NCT06493552|DRUG|Pembrolizumab|Antibody to human PD-1.
219035729|NCT06493552|DRUG|Gemcitabine|A chemotherapy drug used to treat various types of cancer.
219516994|NCT05664256|OTHER|Monitoring visit|A monitoring team from each municipality will be formed. The monitoring plan will be prepared with the team. At least one monitoring visit from the municipality government with onsite feedback will be done.
219611591|NCT02205047|DRUG|Cisplatin|
218896532|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
219035730|NCT06493552|DRUG|Cisplatin|A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
219516995|NCT05295771|PROCEDURE|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
219516996|NCT01946165|DRUG|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
219516997|NCT01946165|DRUG|Prednisone|5 mg by mouth once daily for each 28 day cycle.
219516998|NCT01946165|DRUG|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
219516999|NCT01946165|DRUG|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
219611592|NCT02205047|DRUG|5-fluorouracil or Capecitabine|
219611593|NCT02205047|DRUG|Trastuzumab|
219611594|NCT02205047|DRUG|Pertuzumab|
219611595|NCT02205047|PROCEDURE|gastrectomy|D2 gastrectomy
219611596|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
219611597|NCT05730283|DRUG|ORC-13661|High-dose intervention (30mg daily)
219611598|NCT05730283|DRUG|ORC-13661|Low-dose intervention (12mg daily)
219035731|NCT06493552|DRUG|Enfortumab vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate.
219035732|NCT05369858|DRUG|[14C] SKLB1028|A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
219035733|NCT02767427|DEVICE|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
219035734|NCT02767427|OTHER|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
219035735|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
219035736|NCT04081948|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219611599|NCT05730283|DRUG|Placebo|Placebo intervention
219611600|NCT05079568|DEVICE|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
219611601|NCT05079568|DEVICE|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
219517000|NCT03978884|DRUG|Losartan 50Mg Tab|Take 1 tab daily
218896533|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
219035737|NCT04081948|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219035738|NCT05102188|COMBINATION_PRODUCT|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
219035739|NCT02000375|DRUG|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
219035740|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
219035741|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
219035742|NCT03142880|COMBINATION_PRODUCT|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
219035743|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
218896534|NCT04892082|BEHAVIORAL|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
218896535|NCT04892082|OTHER|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
219035744|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
219517001|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
219517002|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
219517003|NCT03978884|DRUG|Amlodipine 5mg|Take 1 tablet daily
219517004|NCT01901055|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
219035745|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
219035746|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
219035747|NCT02151448|BIOLOGICAL|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
219035748|NCT02151448|DRUG|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
219517005|NCT01901055|DEVICE|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
219517006|NCT01901055|BEHAVIORAL|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
219517007|NCT05226910|DEVICE|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
219517008|NCT05226910|DEVICE|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
219517009|NCT04113343|DRUG|Remimazolam|Remimazolam via oral administration
219517010|NCT04113343|OTHER|Alcohol|Alcohol
218896536|NCT00776971|OTHER|Sugar-sweetened soft drink|500mL as a preload drink
218896537|NCT00776971|OTHER|Aspartame-sweetened soft drink|500mL as a preload drink
219517011|NCT00731159|BIOLOGICAL|sperm capacitation|sperm capacitation measured at Bar Ilan University
219517012|NCT00731159|OTHER|biologic|sperm synthesis of G-actine to F-actine
219517013|NCT00731159|OTHER|sperm capacitation|sperm synthesis of G-actine to F-actine
219517014|NCT01127542|DRUG|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
219517015|NCT00816959|DRUG|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
218896538|NCT00776971|OTHER|Semi-skimmed milk|500mL as a preload drink
218896539|NCT00776971|OTHER|Water|500mL as a preload drink
218896540|NCT00063778|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
218896541|NCT00063778|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
218896542|NCT02132819|OTHER|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
218896543|NCT02132819|OTHER|feeding during transfusion|The feeding process will be continued during the transfusion
218896544|NCT05940701|COMBINATION_PRODUCT|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
218896545|NCT05940701|OTHER|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
218896546|NCT06087484|BEHAVIORAL|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
218896547|NCT00762047|DEVICE|Durasphere FI|Durasphere Injection
218896548|NCT00762047|DEVICE|Sham|Sham injection with anesthesia
218896549|NCT04321070|DRUG|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
218896550|NCT04321070|DRUG|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
218896551|NCT04321070|DRUG|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
218896552|NCT05065788|OTHER|data collection|data collection
218896553|NCT04706481|PROCEDURE|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
218896554|NCT00546546|DRUG|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
218896555|NCT04712370|PROCEDURE|Conventional caudal block|Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
218896556|NCT04712370|PROCEDURE|Ultrasound-guided caudal block|Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
219517016|NCT00816959|DRUG|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
218896557|NCT04712370|PROCEDURE|Ultrasound guided erector spinae plane Block|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
218896558|NCT06189924|DIAGNOSTIC_TEST|Proteomic analysis of exhaled breath condensate|Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.
218896559|NCT06357039|DEVICE|Sleep tracking device|In addition to polysomnography, a device containing EEG+PPG sensors for sleep classification was placed on the forehead, and another device containing PPG and accelerometer sensors was placed on the wrist. The wrist to which the device is attached is randomly assigned.
218896560|NCT00679835|DRUG|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
218896561|NCT04924595|BEHAVIORAL|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
219035749|NCT02151448|DRUG|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
219035750|NCT02151448|BIOLOGICAL|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
219035751|NCT02245243|DRUG|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
219517017|NCT03138070|DRUG|BYL719|BYL719 400 mg daily by mouth continue for 14 days
219517018|NCT03879200|OTHER|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
218896562|NCT00991653|PROCEDURE|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
218896563|NCT06310616|DRUG|VH4524184|VH4524184 will be administered.
218896564|NCT06310616|DRUG|Loestrin|Loestrin will be administered.
218896565|NCT00213499|PROCEDURE|non invasive ventilation|
218896566|NCT05112562|BEHAVIORAL|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
219035752|NCT01139528|PROCEDURE|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
219035753|NCT00886431|OTHER|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
219035754|NCT05656924|DEVICE|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
219035755|NCT05155228|BEHAVIORAL|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
219035756|NCT05155228|BEHAVIORAL|Treatment as usual|Supportive psychotherapy
219517019|NCT02141100|DRUG|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
219517020|NCT02824900|DEVICE|Vibration stimuli to neck muscles|
219517021|NCT02824900|DEVICE|Vibration stimuli to hand|
219517022|NCT02824900|BEHAVIORAL|conventional physiotherapy|
219035757|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
219035758|NCT04848935|DEVICE|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
219517023|NCT03864588|DRUG|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
219035759|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
219035760|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
219035761|NCT02119065|PROCEDURE|positron emission tomography|Undergo PET/CT scan
219035762|NCT02119065|PROCEDURE|computed tomography|Undergo PET/CT scan
219035763|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
219517024|NCT04620174|OTHER|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
219517025|NCT04620174|OTHER|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
219517026|NCT00140257|DRUG|Escitalopram|
219517027|NCT02983448|DEVICE|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
219517028|NCT05909267|DRUG|L-dopa/Carbidopa|Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
219517029|NCT05909267|DRUG|Placebo|Patients and healthy controls will receive one time administration of Placebo.
218896567|NCT05112562|BEHAVIORAL|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
218896568|NCT00306085|GENETIC|Autologous bone marrow cells|
218896569|NCT00306553|BIOLOGICAL|CYT004-MelQbG10|
219035764|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
219035765|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
219035766|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
219035767|NCT03880721|PROCEDURE|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
219035768|NCT01161199|PROCEDURE|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
219517030|NCT04059796|DEVICE|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
218896570|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
218896571|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
219517031|NCT04059796|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
219517032|NCT01179919|DRUG|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
219517033|NCT01586741|PROCEDURE|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
219517034|NCT04787302|DRUG|CVL-231|Cohort 1: 30mg dose of CVL-231
219517035|NCT04787302|DRUG|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
219517036|NCT04787302|DRUG|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
219517037|NCT00806156|DRUG|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
219517038|NCT00806156|DRUG|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
218896572|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
218896573|NCT06454383|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218896574|NCT06454383|DRUG|Cholestyramine|Given PO
218896575|NCT06454383|PROCEDURE|Computed Tomography|Undergo CT
218896576|NCT06454383|PROCEDURE|Diagnostic Imaging|Undergo imaging scans
218896577|NCT06454383|DRUG|Gemcitabine|Given IV
218896578|NCT06454383|DRUG|Leflunomide|Given PO
218896579|NCT06454383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219517039|NCT04487210|BIOLOGICAL|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
219517040|NCT00417690|DRUG|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
219517041|NCT00417690|DRUG|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
219517042|NCT05292742|DRUG|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
219517043|NCT05292742|DRUG|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
219517044|NCT00479622|DRUG|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
219517045|NCT03202225|DEVICE|constrained polyethylene|constrained polyethylene insert
219517046|NCT02106065|BEHAVIORAL|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
218896580|NCT02053090|BEHAVIORAL|Group Education and Stretching|
219517047|NCT02106065|OTHER|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
219517048|NCT03186066|DEVICE|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
218896581|NCT02053090|PROCEDURE|Group Acupuncture|
218896582|NCT06823908|OTHER|Reuse of surgical waste|Heathly donnors will be received in the plastic surgery department as part of routine care. They will be informed of the study and their surgical waste (adipose tissue) will be recovered specifically for this research.
218896583|NCT06823908|OTHER|Reuse of biological samples|Patients included in the cellcordes 2 trial who have given their consent for the re-use of their biological samples (Stromal Vascular Fraction) in other clinical research projects, and who have been informed of the cellcordes bio study.
218896584|NCT06122506|PROCEDURE|Laparoscopic cerclage|Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
218896585|NCT06122506|PROCEDURE|Vaginal cerclage|Transvaginal cerclage in pregnant women.
218896586|NCT06281925|DEVICE|Cryotherapy Gloves|All patients in the intervention group will receive cryotherapy with cold packs enclosed in a fabric envelope (gloves). The fabric envelope (gloves) will be patient specific.
219035769|NCT01073865|DRUG|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
219035770|NCT01073865|DRUG|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
219035771|NCT01839448|BIOLOGICAL|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
219035772|NCT05477563|BIOLOGICAL|CTX001|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan
219035773|NCT06267235|OTHER|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
219517049|NCT03186066|PROCEDURE|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
219517050|NCT00525590|DRUG|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
218896587|NCT00466531|BIOLOGICAL|therapeutic autologous lymphocytes|
218896588|NCT00466531|DRUG|cyclophosphamide|
219517051|NCT04111770|DEVICE|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
219517052|NCT04111770|DEVICE|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
219517053|NCT05278806|OTHER|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
219517054|NCT05278806|OTHER|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
218896589|NCT05721170|DRUG|Beta blocker|Investigation on beta-blockers in TAVI and brief post-TAVI period.
218896590|NCT05628103|DRUG|SEP-363856|SEP-363856 will be flexibly dosed for 8 weeks.
218896591|NCT05769023|BEHAVIORAL|Intervention test|behavioral sessions to promote vaccines
218896592|NCT05003674|DEVICE|Focused stimulation strategy|Investigational focused stimulation strategy
218896593|NCT05003674|DEVICE|ACE stimulation strategy|Standard of care stimulation strategy
218896594|NCT02313584|DRUG|dabigatran|
218896595|NCT02313584|DRUG|placebo|
218896596|NCT01458483|DEVICE|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
218896597|NCT01564563|DRUG|standard therapy|Standard treatment of bleeding
218896598|NCT01564563|DRUG|placebo|Placebo
218896599|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
218896600|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
218896601|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
218896602|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
218896603|NCT04000061|OTHER|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
218896604|NCT04000061|OTHER|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
218896605|NCT04485416|DRUG|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
218896606|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
218896607|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
218896608|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
218896609|NCT06662058|OTHER|Interview|Ancillary studies
218896610|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
218896611|NCT06991010|DEVICE|Suction-Activated Patent Hemostasis (SAPH) Device|A compression device intended to achieve patient hemostasis of the radial artery
218896612|NCT04927650|DIAGNOSTIC_TEST|HPV testing|Undergo collection of cervical samples for HPV testing
218896613|NCT04927650|OTHER|Questionnaire Administration|Complete questionnaires
218896614|NCT06174987|DRUG|T-DXd|T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
218896615|NCT06610214|OTHER|IMPACT-care intervention|1, Training of Healthcare Staff; 2, Development of Medication Summary; 3, Information Package for Patient and/or Caregiver; 4, Discharge Coaching; 5, Post-Discharge follow-Up call
218896616|NCT03191266|DEVICE|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
218896617|NCT03191266|DEVICE|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
219517055|NCT00622609|DRUG|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
219517056|NCT00622609|DRUG|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
219517057|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
218896618|NCT06920771|BIOLOGICAL|PURETHAL Mites 50,000 AUeq/ml|"Biological/Vaccine: Placebo~Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals"
218896619|NCT06920771|BIOLOGICAL|Biological/Vaccine: Placebo|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
218896620|NCT06922071|OTHER|REMINDER4Care|"REMINDER4Care was an adapted version of the original REMINDER program, tailored to the characteristics, needs, and interests of older adults in RDF.~The REMINDER4Care intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). Social support and emotion regulation strategies (like attention management, positive cognitive reappraisal, and reframing speech) were included to address psychosocial risk factors like stress, social isolation, and depression."
218896621|NCT07009015|OTHER|The oral health education intervention program|The intervention program will be designed to improve oral health knowledge, attitudes, and behaviors among students over a one-month school term, carefully scheduled to avoid disrupting regular academic activities. The program consists of initial sessions focused on building students' understanding and appreciation of oral health and healthy eating habits, followed by sessions aimed at developing practical behavioral skills. The effectiveness of the program will be evaluated at three points-before the intervention, two months after, and four months post-intervention-using a closed-ended questionnaire to assess changes in knowledge, attitudes, and practices.
218896622|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
218896623|NCT05481359|DEVICE|Electrographic Flow™ (EGF) mapping and ablation|"Electrographic Flow™ (EGF) mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF algorithm (Ablamap® Software). Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity levels exceeding the recommended threshold are deemed significant and are targeted for ablation. The success of the ablation is confirmed through an EGF remap, where elimination of the source is defined as reduction of EGF source activity below the threshold."
218896624|NCT06870422|DRUG|Esflurbiprofen Topical System|TK-254RX will be applied for one day
218896625|NCT07015125|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Use of TENS device for 1 hour during each migraine episode.
218896626|NCT06689878|BEHAVIORAL|Mobile Cognitive Behavioral App|"A mobile cognitive behavioral therapy (CBT) app called Maya that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke."
218896627|NCT04904536|DRUG|Atorvastatin|40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
218896628|NCT04904536|OTHER|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
218896629|NCT07022262|BEHAVIORAL|Progressive resistance training plus impact loading|The structure of the exercise sessions will be: 1) warm up; 2) progressive resistance training plus impact loading; 3) cool down. Briefly, the warm-ups will be based on RAMP methodology (i.e., raise, activate, mobilise and potentiate) in order to maximize middle-term performance of the main exercises. Exercises focused on the brace, squat, lunge or jump patterns will be included in the first part of the session. The main part of the session will consist of 9 sets of 10-12 jumps, 9 sets of 10-12 repetitions of lower body resistance exercise and 3 sets of 10-12 repetitions of upper resistance exercise. Each set will be performed with approximately 15-30 seconds of rest for jumps and 2-3 minutes of rest for resistance exercises. Finally, participants will perform a cool down including guided static stretching and relaxing exercises.
219035774|NCT00805766|DRUG|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
219035775|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
219035776|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
219035777|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
219035778|NCT00621218|DRUG|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
219517058|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
219517059|NCT00599209|OTHER|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
218896630|NCT06719804|DRUG|Propranolol|Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
218896631|NCT06722677|DEVICE|VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
219611602|NCT05527041|DEVICE|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~* Gaze coordinates~* Pupil sizes~* Accelerometer data~* Gyroscopic data~* Rotation data~* Blink data"
219611603|NCT06540196|DIAGNOSTIC_TEST|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
219611604|NCT06540196|DIAGNOSTIC_TEST|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
219517060|NCT03934073|OTHER|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
219517061|NCT03934073|OTHER|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
219517062|NCT03934073|OTHER|CONTROLE|Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
219517063|NCT01609764|BEHAVIORAL|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
219611605|NCT06095986|DRUG|Aramchol meglumine|Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
219611606|NCT06418529|DRUG|tofacitinib|New index treatment of tofacitinib
219611607|NCT06418529|DRUG|tumor necrosis factor inhibitors (TNFi)|New index treatment of TNFi
219611608|NCT06418529|DRUG|abatacept|New index treatment of abatacept
219611609|NCT06418529|DRUG|tocilizumab or sarilumab|New index treatment of tocilizumab or sarilumab
219611610|NCT04537741|PROCEDURE|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
219611611|NCT04537741|PROCEDURE|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
219611612|NCT05758506|DEVICE|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
218896632|NCT06722677|DEVICE|Sham VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
218896633|NCT06722677|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke.
218896634|NCT06460142|DIAGNOSTIC_TEST|Aortic/ cardiac magnetic resonance imaging|MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
218896635|NCT06460142|DIAGNOSTIC_TEST|Vascular ultrasound|Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
219035779|NCT00621218|DRUG|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
219035780|NCT00600756|DRUG|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
219035781|NCT00600756|DRUG|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
219035782|NCT00343057|OTHER|Patients' questionnaire|
218896636|NCT06460142|DIAGNOSTIC_TEST|Transorbital Ultrasound|Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
218896637|NCT06460142|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
218896638|NCT06460142|DIAGNOSTIC_TEST|Optical coherence tomography angiography|OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
218896639|NCT06460142|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
218896640|NCT06460142|DIAGNOSTIC_TEST|Fundus autofluorescence|This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
218896641|NCT06460142|DIAGNOSTIC_TEST|Color Fundus Photography|Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
218896642|NCT06460142|DIAGNOSTIC_TEST|Cell-based ex-vivo assay with high-content analysis|This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
218896643|NCT06460142|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
218896644|NCT06460142|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
218896645|NCT06460142|DIAGNOSTIC_TEST|Flow cytometry|Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
218896646|NCT06460142|DIAGNOSTIC_TEST|Laboratory assessment:|Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
218896647|NCT06460142|DIAGNOSTIC_TEST|Immunohistochemistry of Temporal Artery Biopsies|Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
218896648|NCT06460142|DIAGNOSTIC_TEST|Functional assessment questionnaires|The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
218896649|NCT06726330|PROCEDURE|Fimbriectomy Followed by Delayed Oophorectomy (F-DO)|"This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis"
219035783|NCT03827278|DRUG|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
219035784|NCT04760717|DRUG|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
219035785|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
219035786|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
219517064|NCT02806921|DEVICE|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
219517065|NCT01493479|DRUG|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
219517066|NCT01493479|DRUG|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial."
219517067|NCT02663596|DRUG|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
219517068|NCT04330937|DIETARY_SUPPLEMENT|dietetics|90 days of consumption
219517069|NCT05362448|DEVICE|Frequency|First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
219517070|NCT03922438|PROCEDURE|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
219517071|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP|"1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0"
219035787|NCT00180024|DRUG|irbesartan (drug)|
219204035|NCT05708443|OTHER|LL group|"The program will include daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 60 minutes on a stationary bike for the lower limbs (2 sessions per day of 30 minutes) at moderate-high intensity;~2. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
219517072|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP; MVA ME-TRAP|"1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)"
219517073|NCT01286038|DRUG|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
219517074|NCT04344418|DEVICE|Nurse-performed Focused cardiac ultrasound (FoCUS)|A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
218896650|NCT06726330|PROCEDURE|Bilateral Salpingo-Oophorectomy|This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
218896651|NCT06506942|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
218896652|NCT05503862|DEVICE|YoSperm|The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
218896653|NCT06725641|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
218896654|NCT06725641|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）|Cholinergic agonists
218896655|NCT06921265|BEHAVIORAL|Training with Speech Language Therapy|"The SLT will consist of an online intervention performed through a web-based platform.~The SLT training of the SLT group will consist of 2 cycles of training lasting 1 (rest) + 5 (training) weeks, 3 times per week, 1 hour each session, separated by a 12-week washout period."
218896656|NCT06921265|DEVICE|Standard rTMS|Stimulation of DLPFC; rTMS will be administered as high-frequency (20Hz) in 2 second trains (40 pulses per train) with an inter-train interval of 22 seconds for a total of 50 trains (2000 pulses per session) at 120% of the patient's resting motor threshold. Patients will undergo an induction with 20-minutes rTMS protocol for 5 consecutive days, then they will start a maintenance phase where rTMS will be performed 3 days a week per 20 minutes preceding the SLT session, for a total of 20 sessions (of whom 15 combined with SLT).
218896657|NCT06921265|DEVICE|Targeted rTMS|The protocol will be the same as standard STIM. The site of stimulation will be defined using EEG/fMRI recordings of language tasks (syntax production for nfvPPA; silent naming for svPPA and lvPPA) to evidence the areas of higher activation/connectivity of the language network. We will define the area of higher fMRI activation; then, we will use fMRI-EEG connectivity and spectral activity to select the site of stimulation, among the areas with the highest fMRI activation and the highest Beta/Gamma frequencies.
218896658|NCT06921265|DEVICE|Standard rTMS (first cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will firstly undergo the standard rTMS in the first 6 week of training after the baseline visit
218896659|NCT06921265|DEVICE|Standard rTMS (second cycle)|Patients of the SLT + STIM (targeted rTMS + standard rTMS) will secondly undergo the standard rTMS after 12 week washout period
218896660|NCT06921265|DEVICE|Targeted rTMS (first cycle)|Patients of the SLT + STIM (targeted rTMS + standardTMS) will firstly undergo the targeted rTMS in the first 6 weeks of training after the baseline visit
218896661|NCT06921265|DEVICE|Targeted rTMS (second cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will secondly undergo the targeted rTMS after 12 week washout period
218896662|NCT06920875|BEHAVIORAL|Imagery and Breathing Exercises|Participants performed daily imagery and breathing exercises before bedtime for 10 weeks. The protocol involved a 4-second inhale through the nose and a 4-second exhale through the mouth while visualizing a 200-meter freestyle swim with detailed attention to technique and performance. A 6-day training period was provided to teach the techniques, and participants received daily reminders and feedback via a WhatsApp group.
219035788|NCT01767922|DIETARY_SUPPLEMENT|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
219035789|NCT01767922|DIETARY_SUPPLEMENT|Placebo - Excipient only|
219035790|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
219035791|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
219035792|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
219035793|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
219035794|NCT00757835|DRUG|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
219035795|NCT00757835|DRUG|latanoprost/timolol fixed combination drops|once in the evening
219517075|NCT04344418|OTHER|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
219517076|NCT01952249|DRUG|Demcizumab|administered intravenously
219517077|NCT01952249|DRUG|Taxol|administered intravenously
219517078|NCT04662892|DRUG|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
219517079|NCT00717457|DRUG|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
219517080|NCT00717457|DRUG|taspoglutide|10mg once weekly
218896663|NCT06921564|OTHER|Combined training|During the 6-week intervention period, the combined training group performed 2 sessions per week of lower-body strength training and 2 sessions per week of small-sided games training in different formats. The strength training was performed on Tuesdays and Thursdays. This training was finished at least one hour before the team's technical and tactical soccer training. The strength training program is designed to include movements for bilateral hip dominant, bilateral knee dominant, unilateral hip dominant, unilateral knee dominant and calf muscles. The exercises were selected to allow players to perform them on the field with minimal equipment, without the need for machines. In addition, small field games training was practiced two days a week. Repetitions in reserve and resistance training-specific ratings of the perceived exertion scale were used to determine training intensity and load.
218896664|NCT06921564|OTHER|Small-sided games alone|The small-sided games group performed 2 sessions per week of small-sided games training program in different formats, without participating in any strength training. The small-sided games training was conducted twice a week on Wednesdays and Fridays (8:00-10:00 p.m.) for 6 weeks. These training sessions started before the team's technical and tactical training. Extra balls are placed at the goals and along the field boundary lines, allowing play to restart immediately after the ball leaves the field. During the games, the offside rule was not applied. The game started with the foot when the ball left edge of the field. Other rules in the games were kept similar to those of official soccer. During the games, the coaches encouraged the players to exert maximum effort. The number of defenders, midfielders, and attackers in the teams was kept as equal as possible.
218896665|NCT06921226|OTHER|Psychological Processes|"* The sense of thwarted belonging and perceived burden will be measured using the Interpersonal Needs Questionnaire (INQ; Van Orden et al., 2012). The back-translated French version by Landrault et al. (2019) will be used. This scale is based on a seven-point Likert scale, ranging from 1 (not at all true for me) to 7 (very true for me).~* To assess impulsivity, we will use the short version of the UPPS validated in French by Billieux and colleagues (2012). It comprises 20 items divided into 5 dimensions (negative urgency, positive urgency, lack of premeditation, lack of perseverance and sensation seeking). Participants were asked to respond on a Likert scale from 1 (I strongly agree) to 4 (I strongly disagree).~* We will use the French version of the SRS (Suicidal Rumination Scale, Rogers et al., 2022), back-translated for this study. This eight-item scale assesses suicidal ruminations."
219035796|NCT02735083|BIOLOGICAL|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
219517081|NCT00717457|DRUG|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
219517082|NCT00414401|BEHAVIORAL|Clinical Reminder|
219517083|NCT00469625|DRUG|paricalcitol (initial dose 1 mcg orally per day)|
219517084|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
219517085|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
219517086|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
219611613|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
219611614|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
219517087|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
219517088|NCT05458609|DRUG|Lemborexant 10 mg|10 mg of Lemborexant
219517089|NCT05458609|DRUG|Naltrexone|50 mg of Naltrexone
219517090|NCT00593281|DRUG|Hylenex|Add Hylenex to SC injection of Morphine
219517091|NCT01634906|DRUG|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
219517092|NCT04884893|DRUG|Nitrous Oxide|50% nitrous oxide
219517093|NCT04555928|OTHER|No intervention|This is a prospective cohort (survey) study. It has no intervention.
219517094|NCT01969357|DRUG|Placebo|Tablets(n=4),once daily for 84 days
219517095|NCT01969357|DRUG|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
219517096|NCT01969357|DRUG|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
218896666|NCT06921226|OTHER|Risk-taking variables|"* One of the behavioral tasks based on a real-life model of risky decision-making is BART (Lejuez et al., 2002, 2007). It is based on a conceptual framework of balance between reward and loss potential (Leigh, 1999; Lejuez et al., 2002).~* We will measure one of the cognitive aspects of risk-taking behavior, especially the general cognitive decision-making styles (GDMS, from Scott and Bruce, 1995; Gerard et al., 2016).~* We will measure negative (NRTB , Duell et al., 2020) and positive (PRTB, Fryts et al., 2024) self-reported risk-taking behaviour."
218896667|NCT06921226|OTHER|Suicidal ideation and behavior|"Suicidal ideation and behavior were measured using the screening grid, the Columbia Suicide Severity Rating Scale (C-SSRS screen version, Posner, Brown, Stanley et al., 2011). It is composed of 6 questions, which take into account the potential method of suicide, the presence of suicidal intent and/or ideation with a plan or intention. This scale has high reliability and validity in general paediatric emergencies (Scudder et al., 2023) and psychiatric samples (Campos et al., 2023).~It classifies people as being at low or high risk of suicide, based on the presence or absence of significant active suicidal ideation in the last three months."
218896668|NCT06937437|OTHER|Teletherapy|A teletherapy patient presenting with stammering (stuttering) is a person receiving speech therapy remotely, using technology like video conferencing, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
218896669|NCT06937437|OTHER|Traditionally speech therapy|This type of intervention is traditional speech therapy that will be given to stammering adults, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
218896670|NCT03577678|PROCEDURE|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
218896671|NCT01902121|DRUG|Technosphere® Insulin 10U + 20U|Inhaled Insulin
218896672|NCT01902121|DRUG|Technosphere® Insulin 30U|Inhaled Insulin
219517097|NCT01969357|DRUG|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
219517098|NCT01969357|DRUG|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
219517099|NCT02636400|OTHER|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
219517100|NCT00449150|DRUG|Cetrorelix 78 mg + 78 mg|
219517101|NCT00449150|DRUG|Cetrorelix 78 mg + 52 mg|
219517102|NCT00449150|DRUG|Placebo|
218896673|NCT05901402|BEHAVIORAL|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
218896674|NCT00685789|DEVICE|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
218896675|NCT00685789|DEVICE|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
218896676|NCT02812927|DEVICE|Edelvaiss Multiline-8|Optimised infusion line
218896677|NCT02812927|DEVICE|Standard infusion line|
218896678|NCT06525142|BEHAVIORAL|Audiovisual Intervention|"【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person."
218896679|NCT01712204|DRUG|Placebo|Placebo Capsule BID for 16 Weeks
219517103|NCT03312257|COMBINATION_PRODUCT|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
219517104|NCT02776709|PROCEDURE|ERCP with cholangioscopy|
219517105|NCT04182971|OTHER|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
219517106|NCT04182971|OTHER|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
219517107|NCT04182971|OTHER|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
218896680|NCT01712204|DRUG|AC-201|AC-201 50mg Capsule BID for 16 Weeks
218896681|NCT01712204|DRUG|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
219517108|NCT00600925|DRUG|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
219517109|NCT01651702|DEVICE|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
219517110|NCT01651702|DEVICE|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
219517111|NCT03830164|DRUG|Atorvastatin|Given PO
219517112|NCT03830164|DRUG|Pentoxifylline|Given PO
219517113|NCT03830164|DIETARY_SUPPLEMENT|Vitamin E Compound|Given PO
219517114|NCT05655832|DEVICE|Vivalink wearable device|a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
219517115|NCT02192099|DRUG|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
219517116|NCT00628199|PROCEDURE|Improving the scientific process of human cell reprogramming|
219517117|NCT02348385|DRUG|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
219517118|NCT00379756|DRUG|LEVITRA (vardenafil)|active comparator
219517119|NCT00379756|DRUG|placebo|placebo comparator
219611615|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
219517120|NCT01170286|BIOLOGICAL|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
219517121|NCT01170286|BIOLOGICAL|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
219611616|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
218896682|NCT04374045|OTHER|ECG-Holter|Patient will have a ECG-Holter recording during all their hospitalization.
218896683|NCT01192308|DRUG|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
218896684|NCT01079494|OTHER|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
218896685|NCT02315534|DRUG|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
219611617|NCT03492944|DRUG|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
218896686|NCT02315534|DRUG|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
218896687|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
218896688|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
218896689|NCT06267222|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
218896690|NCT01647776|OTHER|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
218896691|NCT01647776|PROCEDURE|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
218896692|NCT01647776|OTHER|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
218896693|NCT01463306|DRUG|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
218896694|NCT06061835|OTHER|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
219517122|NCT04330807|OTHER|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
219517123|NCT04330807|OTHER|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
219517124|NCT01432977|DRUG|paracetamol /droperidol|
219517125|NCT01432977|DRUG|paracetamol / ondansetron|
219517126|NCT02796664|DIETARY_SUPPLEMENT|Ginseng|Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
219517127|NCT02796664|DIETARY_SUPPLEMENT|Placebo|Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
219517128|NCT03388307|PROCEDURE|unilateral laminotomy|minimally invasive technique
219517129|NCT03388307|PROCEDURE|decompressive laminectomy|classic surgery
219517130|NCT01305070|DEVICE|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
219517131|NCT01305070|DEVICE|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
219611618|NCT03492944|DEVICE|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
219611619|NCT04027647|DRUG|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
219611620|NCT06297265|OTHER|Lymphedema Management|Undergo MLD breast massage
219611621|NCT06297265|OTHER|Questionnaire Administration|Ancillary studies
219611622|NCT06297265|RADIATION|Adjuvant breast radiation therapy|Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.
218896695|NCT06061835|OTHER|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
218896696|NCT01903629|DEVICE|MCE|MCE first, followed by standard gastroscopy
218896697|NCT01903629|DEVICE|Standard gastroscopy|
218896698|NCT00345618|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
218896699|NCT00345618|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
218896700|NCT00345618|DRUG|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
218896701|NCT00345618|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
218896702|NCT00345618|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
218896703|NCT00345618|DRUG|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
218896704|NCT04679974|BEHAVIORAL|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
219035797|NCT03162601|PROCEDURE|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
219035798|NCT06068569|BIOLOGICAL|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
219035799|NCT04223882|BEHAVIORAL|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
219035800|NCT04223882|OTHER|Usual care|outpatient medical appointments
219035801|NCT00838227|DRUG|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
219611623|NCT04653454|DEVICE|Continuous Glucose Monitor (CGM)|CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
219035802|NCT04503564|DEVICE|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
219035803|NCT06001658|DRUG|Gemcitabine|Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
219035804|NCT06001658|DRUG|Cisplatin|Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
219035805|NCT06001658|DRUG|Pembrolizumab|Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
219035806|NCT05850936|DRUG|Assigned Interventions: IOP-lowering eye drops|IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.
219517132|NCT02679001|DRUG|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
219517133|NCT02246478|DRUG|TAS-205|"* Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
219517134|NCT02246478|DRUG|Placebo|"* Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
218896705|NCT04921228|BEHAVIORAL|Heart rate variability biofeedback|"* 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
218896706|NCT05042583|PROCEDURE|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
218896707|NCT04713956|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
218896708|NCT04713956|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
218896709|NCT04713956|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
218896710|NCT04713956|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
218896711|NCT04713956|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
218896712|NCT02110095|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
218896713|NCT03580681|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
218896714|NCT03580681|DIETARY_SUPPLEMENT|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
218896715|NCT04360837|PROCEDURE|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
218896716|NCT00386243|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
218896717|NCT00386243|BEHAVIORAL|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
218896718|NCT00386243|DRUG|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
218896719|NCT00386243|DRUG|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
218896720|NCT02781610|DRUG|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
218896721|NCT03143504|DIAGNOSTIC_TEST|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
219035807|NCT02781870|PROCEDURE|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
219035808|NCT02781870|PROCEDURE|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
219035809|NCT05368987|DEVICE|Transcranial magnetic stimulation (TMS)|Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
219204036|NCT05708443|OTHER|L+UL group|"These patients will attend a rehabilitation program with daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 30 minutes on a stationary bike for the lower limbs (1 session of 30 minutes per day) at moderate-high intensity;~2. 30 minutes with arm-ergometer (1 daily session of 30 minutes) at moderate-high intensity;~3. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
219204037|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose)|Inject 1 dose of low-dose vaccine
219204038|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose)|Inject 1 dose of low-dose placebo
219204039|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose)|Inject 1 dose of high-dose vaccine
219204040|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose)|Inject 1 dose of high-dose placebo
218896722|NCT03878680|OTHER|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis."
218896723|NCT03478033|DRUG|Rifampicin|Rifampicin capsules, 150mg
218896724|NCT03478033|DRUG|Rifabutin|Rifabutin capsules, 150mg
218896725|NCT03658733|DRUG|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
218896726|NCT03658733|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
218896727|NCT02679287|DEVICE|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
219035810|NCT05368987|BEHAVIORAL|Fear Conditioning and Extinction Paradigm|"Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.~On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.~On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day."
219035811|NCT04180761|DRUG|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
219035812|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
218896728|NCT02956187|BEHAVIORAL|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
219035813|NCT00145925|DRUG|Perindopril-indapamide|
219035814|NCT00145925|DRUG|Gliclazide MR-based glucose lowering|
218896729|NCT02956187|DIETARY_SUPPLEMENT|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
219611624|NCT04500119|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
219035815|NCT04941950|BEHAVIORAL|PlaySmart|PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.
219035816|NCT04941950|OTHER|Video Game Control|Participants in the control group will play another video game with no intended effect similar to PlaySmart.
219035817|NCT06563401|OTHER|prognosis of adult-onset t1d|We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people
219035818|NCT04227236|OTHER|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
219035819|NCT04227236|OTHER|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
219204041|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|Inject 1 dose of positive control vaccine
219517135|NCT06250010|DIAGNOSTIC_TEST|tissue samples (healthy and tumor taken from the same patient) and tissue samples (decidualized endometrium and trophoblast taken from it patient)|Correlation between the immuno-score results of each patient with his prognosis, in terms disease-free survival, overall survival, relapse-free survival, disease-specific survival cancer, distant and/or local free survival, to validate their potential role independent in the progression of endometrial cancer; later, for a better characterization of the various ones risk classes, we will combine our immuno-score with the already known risk factors, included in the ESMO-ESGO-ESTRO classification and in the biomolecular classification of endometrial cancer, to investigate whether the Microenvironmental immunological factors in endometrial cancer could allow better stratification of patients in risk classes.
219517136|NCT04645615|DEVICE|Cardioblate surgical ablation system|This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
218896730|NCT01840345|DRUG|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
219517137|NCT04645615|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
218896731|NCT04793113|OTHER|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
218896732|NCT02699710|DRUG|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
218896733|NCT02699710|DRUG|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
218896734|NCT02699710|DRUG|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
218896735|NCT02699710|DRUG|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
219517138|NCT01096420|PROCEDURE|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
219517139|NCT01096420|DRUG|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
219517140|NCT01375322|DRUG|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
219517141|NCT01375322|DRUG|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
219517142|NCT03453125|BEHAVIORAL|Spanish modified Story Memory Technique (mSMT)|
219517143|NCT05207280|COMBINATION_PRODUCT|Noradrenaline plus Terlipressin|Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
219517144|NCT04671641|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
219517145|NCT02090608|DRUG|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
219611625|NCT03620708|BEHAVIORAL|Motivational Interviewing|Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
219517146|NCT05475353|BEHAVIORAL|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
219517147|NCT05475353|PROCEDURE|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
219517148|NCT02805322|DEVICE|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
219517149|NCT02805322|DEVICE|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
219517150|NCT02805322|DEVICE|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
219611626|NCT03620708|DRUG|Nicotine Replacement Therapy Sampling|Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
218896736|NCT00374933|DRUG|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
218896737|NCT00374933|DRUG|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
218896738|NCT00374933|DRUG|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
218896739|NCT02628353|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
218896740|NCT02628353|DIETARY_SUPPLEMENT|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
218896741|NCT05481489|DRUG|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
218896742|NCT02679170|DRUG|Crizotinib|Treatment with crizotinib following routine clinical practice
218896743|NCT05331586|BEHAVIORAL|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
218896744|NCT00992459|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
218896745|NCT00992459|DRUG|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
218896746|NCT01166204|RADIATION|Radiotherapy|Radiotherapy
218896747|NCT04219904|OTHER|Fludeoxyglucose F-18|Given IV
218896748|NCT04219904|DRUG|Gadobutrol|Given IV
218896749|NCT04219904|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
218896750|NCT04219904|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
218896751|NCT04627207|DRUG|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
218896752|NCT04627207|DRUG|CKD-333 1 Tab|Other names: Test
218896753|NCT04201613|DEVICE|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
218896754|NCT04201613|BEHAVIORAL|Usual Care|This group will receive standard care with no additional therapy.
218896755|NCT02903498|DRUG|UFT|UFT 360mg/m2 qd po d1-14, q3w
218896756|NCT00158041|DRUG|Amifostine administered subcutaneously|
218896757|NCT00927212|DRUG|AS101 ointment|Twice daily topical application
218896758|NCT01453010|OTHER|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
218896759|NCT03320720|OTHER|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
218896760|NCT03320720|OTHER|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
218896761|NCT01081899|OTHER|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
218896762|NCT01043991|DRUG|Darbepoetin alfa|
218896763|NCT01043991|DRUG|Placebo|
218896764|NCT04019899|DIETARY_SUPPLEMENT|control group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
219517151|NCT02115646|DEVICE|fractionated carbon dioxide laser|patients will have serial laser treatments
219517152|NCT04112030|DIAGNOSTIC_TEST|Digital image analysis|
219517153|NCT02079753|DEVICE|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
219517154|NCT02079753|DEVICE|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
219517155|NCT01531205|DRUG|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
219517156|NCT01531205|DRUG|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m\^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
219517157|NCT01531205|DRUG|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
219517158|NCT01531205|DRUG|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
219611627|NCT03620708|BEHAVIORAL|Referral Only|Participants are provided with a written referral for tobacco dependence treatment.
219611628|NCT06191796|DRUG|zanzalintinib|Specified doses on specified days
219611629|NCT06191796|DRUG|AB521|Specified doses on specified days
219611630|NCT06191796|BIOLOGICAL|Nivolumab|Specified doses on specified days
218896765|NCT04019899|DIETARY_SUPPLEMENT|study group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
218896766|NCT01361971|PROCEDURE|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
218896767|NCT02302365|DEVICE|Spectra Optia® Apheresis System|White Blood Cell Depletion
218896768|NCT00227721|DRUG|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
218896769|NCT00227721|DRUG|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
218896770|NCT01848665|DRUG|Indomethacin|
218896771|NCT01848665|DRUG|Placebo|
218896772|NCT00431561|DRUG|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
218896773|NCT00431561|DRUG|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
218896774|NCT00431561|DRUG|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
218896775|NCT00431561|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
218896776|NCT00431561|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
218896777|NCT02608658|OTHER|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test"
219517159|NCT01531205|DRUG|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m\^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
219035820|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
219035821|NCT03762096|DIETARY_SUPPLEMENT|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
219035822|NCT03762096|DIETARY_SUPPLEMENT|Placebo|Placebo
219035823|NCT02747836|OTHER|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
219035824|NCT06367348|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention. Sessions consist of incentivized savings accounts, financial literacy training, and relationships skills building, including couple communication.
219517160|NCT02632136|DRUG|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
219035826|NCT05407623|BEHAVIORAL|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
219035827|NCT05407623|BEHAVIORAL|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
219517161|NCT02632136|DRUG|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
219517162|NCT02800798|OTHER|Preeclampsia positive|
219517163|NCT05316675|DRUG|Isotretinoin|isotretinoin 13-cis-retinoic acid), derived from vitamin A
219517164|NCT02252731|DRUG|Warfarin|Oral
219517165|NCT02252731|DRUG|FG-4592|Oral
219517166|NCT05277727|DIETARY_SUPPLEMENT|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
219517167|NCT05277727|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily with food (morning and evening).
219517168|NCT04345978|BEHAVIORAL|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
219517169|NCT02081521|BEHAVIORAL|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
219517170|NCT05742581|OTHER|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
218896778|NCT05699850|OTHER|ARTIFICIAL INTELLIGENCE (AI)|ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINE
219517171|NCT05042336|DRUG|camrelizumab/lenvatinib combined with TACE|"Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w"
218896779|NCT05324111|DEVICE|Kardia 6L|The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
218896780|NCT02568735|DRUG|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
218896781|NCT02568735|DRUG|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
218896782|NCT04974255|OTHER|Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples|Examination of pathology specimen and laboratory measuring
218896783|NCT05298202|BIOLOGICAL|Capsaicin|application of capsaicin gel from shoulder to wrist and mid thigh to ankle
218896784|NCT05298202|BIOLOGICAL|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
218896785|NCT05298202|OTHER|Exercise|treadmill walking 3.5 mph at 5% grade
218896786|NCT05298202|OTHER|Hot environment|38°C, 60% relative humidity
218896787|NCT06053853|BIOLOGICAL|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~1. Perform sensitivity tests, and desensitization if necessary.~2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~3. The recommended DAT treatment dosage ranges (pediatric and adult) are:~   * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~  * Nasopharyngeal disease 40,000 - 60,000 unit~  * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~  * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
218896788|NCT03190395|PROCEDURE|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
218896789|NCT03190395|PROCEDURE|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
218896790|NCT04862325|OTHER|Multimodal Prehabilitation|"1. High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~2. Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~3. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
218896791|NCT01875159|DRUG|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
218896792|NCT03943615|DRUG|Voxelotor|
218896793|NCT01029184|OTHER|commercialized complete cereals|complete cereals suitable for the weaning period
218896794|NCT01029184|OTHER|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
218896795|NCT03462108|BIOLOGICAL|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
219517172|NCT03629158|BEHAVIORAL|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
219517173|NCT00013546|DRUG|TMTDS|
219517174|NCT00174642|DRUG|Insulin Glargine|One daily injection in the evening. 100 U/ml
219517175|NCT00174642|DRUG|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
219517176|NCT00174642|DRUG|Metformin|At same dosages as the previous treatment
219517177|NCT00174642|DRUG|insulin secretagogue|sulfonylurea or glinide
219517178|NCT00669630|BEHAVIORAL|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
218896796|NCT03462108|OTHER|Placebo|Placebo contains 30% sucrose in DMEM
218896797|NCT02575755|DRUG|Azithromycin plus piperaquine phosphate|
218896798|NCT02575755|DRUG|Sulfadoxine-pyrimethamine|
218896799|NCT06525415|DIAGNOSTIC_TEST|DCE MRI|the recruited patients should complete pre- and post-operative DCE MRI workshops
218896800|NCT00361192|PROCEDURE|biopsy of temporal artery|
218896801|NCT00408122|PROCEDURE|PET/CT scan and EUS|
219517179|NCT03629574|PROCEDURE|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
219517180|NCT04905342|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
219517181|NCT04905342|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
219517182|NCT03463356|BEHAVIORAL|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
219517183|NCT00339768|DRUG|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
219517184|NCT02001558|DRUG|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
219517185|NCT02001558|OTHER|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
219517186|NCT02483637|DEVICE|RejuvenAir|Device: RejuvenAir
219517187|NCT00531375|DEVICE|Silicone hydrogel contact lens|
219517188|NCT04128007|DRUG|Roflumilast foam 0.3%|experimental
218896802|NCT03840863|DIETARY_SUPPLEMENT|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
218896803|NCT01253642|PROCEDURE|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
218896804|NCT01253642|DRUG|Docetaxel|Given IV
218896805|NCT01253642|OTHER|Laboratory Biomarker Analysis|Correlative studies
218896806|NCT01253642|DRUG|Phenelzine Sulfate|Given PO
218896807|NCT02498301|DRUG|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
218896808|NCT02498301|DRUG|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
218896809|NCT01412164|DEVICE|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
218896810|NCT04480840|DRUG|PLN-74809|PLN-74809
218896811|NCT04480840|DRUG|Placebo|Placebo
218896812|NCT06086509|OTHER|Music|Children were played music during computerized tomography.
218896813|NCT01456286|DRUG|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
218896814|NCT01916135|RADIATION|[18F]-SKI-249380|
218896815|NCT01916135|PROCEDURE|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
218896816|NCT01916135|OTHER|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic \& metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
218896817|NCT01389882|PROCEDURE|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
219035828|NCT05407623|BEHAVIORAL|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
219035829|NCT06024668|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
219035830|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.
219035831|NCT01510678|BEHAVIORAL|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
219035832|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
219517189|NCT04128007|DRUG|Vehicle foam|experimental
219517190|NCT00136201|DRUG|tigecycline|
219517191|NCT02371525|BEHAVIORAL|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
218896818|NCT03923257|DRUG|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
218896819|NCT03923257|PROCEDURE|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
218896820|NCT00436995|DRUG|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
218896821|NCT03014739|OTHER|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
218896822|NCT00567450|DRUG|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
218896823|NCT00567450|DRUG|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
218896824|NCT03095079|DRUG|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
218896825|NCT03074409|DRUG|oxytocin|self-administration of oxytocin (nasal spray)
218896826|NCT03074409|DRUG|placebo|self-administration of placebo (nasal spray)
218896827|NCT03685955|BIOLOGICAL|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
218896828|NCT04640233|BIOLOGICAL|Gam-COVID-Vac|Vaccine for intramuscular injection
218896829|NCT04640233|OTHER|Placebo|Placebo comparator
218896830|NCT00107692|BEHAVIORAL|Physical activity and diet|
218896831|NCT05532865|OTHER|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
218896832|NCT05532865|OTHER|Stool samples|A stool sample for collection of digestive microbiota at inclusion
218896833|NCT05532865|OTHER|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
218896834|NCT05532865|OTHER|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
219517192|NCT05152719|BEHAVIORAL|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
218896835|NCT05532865|OTHER|Skin biopsies|At inclusion and 18 months
218896836|NCT06151548|DRUG|THYROX (Atlantic krill oil).|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
218896837|NCT06151548|DRUG|Placebo|The control capsules will be made of olive oil of equal size and color.
218896838|NCT02654886|OTHER|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
218896839|NCT01863381|DEVICE|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
218896840|NCT01863381|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
218896841|NCT03042117|OTHER|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
218896842|NCT00754702|DRUG|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
218896843|NCT00754702|DRUG|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
219035833|NCT02049242|PROCEDURE|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
219611631|NCT04673175|DRUG|Ceftolozane / Tazobactam Injection|Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
218896844|NCT01120366|DRUG|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
218896845|NCT01120366|DRUG|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
218896846|NCT00769886|DRUG|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
218896847|NCT00769886|DRUG|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
218896848|NCT00769886|DRUG|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
218896849|NCT00769886|DRUG|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
218896850|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
218896851|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
218896852|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
218896853|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
218896854|NCT04581486|OTHER|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
218896855|NCT04581486|OTHER|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
218896856|NCT05219331|PROCEDURE|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
218896857|NCT03871062|PROCEDURE|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
219611632|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
219611633|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
218896858|NCT03871062|PROCEDURE|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
218896859|NCT03306940|DRUG|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
218896860|NCT02343393|DRUG|Hydralazine|
218896861|NCT02343393|DRUG|Isosorbide Dinitrate|
218896862|NCT01841905|OTHER|Observational Study|Observational Study
218896863|NCT05620095|DEVICE|drug-coated balloon|To evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.
218896864|NCT04796363|PROCEDURE|Erector Spinae Plane Block with Bubivacaine|Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
218896865|NCT04796363|PROCEDURE|Standard General Anaesthesia|Standard General Anaesthesia without ESPB
218896866|NCT04662359|DIAGNOSTIC_TEST|Ultrasound Assessment|Patients will undergo an ultrasound scan to assess the severity of their rheumatoid arthritis.
218896867|NCT06134219|OTHER|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
218896868|NCT06134219|OTHER|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
218896869|NCT04601935|BIOLOGICAL|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
218896870|NCT04738981|DRUG|UC-MSC|UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
218896871|NCT04738981|DRUG|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
219517193|NCT01106963|PROCEDURE|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
218896872|NCT04513756|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
218896873|NCT00381004|DRUG|Cyclophosphamide|Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
218896874|NCT00381004|DRUG|Fludarabine|Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
218896875|NCT00381004|DRUG|Sargramostim|Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10
218896876|NCT00381004|DRUG|Rituximab|Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
218896877|NCT05414890|DIAGNOSTIC_TEST|CBA-TSA|Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
219035834|NCT02049242|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
219035835|NCT00231348|DRUG|Nefazodone|
219035836|NCT03611868|DRUG|Phase 1b: APG-115+pembrolizumab|"dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.~Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone."
219035837|NCT04203381|DEVICE|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
219035838|NCT05368545|DRUG|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
219035839|NCT06473480|DEVICE|Abbott FreeStyle Libre System 2 Plus|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
219035840|NCT06473480|DEVICE|Abbott Freestyle Libre Pro|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
219035841|NCT05740787|OTHER|No intervention|Observation only
219035842|NCT04598035|DIAGNOSTIC_TEST|Diagnostic Tests|"1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain"
219517194|NCT03651674|DEVICE|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
219517195|NCT03651674|DRUG|Drug treatment|Patients only have antipsychotic drugs
219611634|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
218896878|NCT03973359|BEHAVIORAL|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
218896879|NCT02966808|BEHAVIORAL|cognitive and behavioural questionnaires|
218896880|NCT00637065|DRUG|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
218896881|NCT00637065|DRUG|Placebo|Placebo tables - identical to active drug but without the active ingredient -
218896882|NCT04903782|DIAGNOSTIC_TEST|Family-based whole genome sequencing|"1. Germline whole-genome family-based sequencing and variant identification.~2. Multidisciplinary Meeting case discussion.~3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling.~4. Psychosocial study to analyse the impact of germline sequencing on families."
218896883|NCT03036410|DEVICE|standard telephone setting|without streaming function
218896884|NCT03036410|DEVICE|DECT|cordless telephone (streaming to both hearing devices)
218896885|NCT03036410|DEVICE|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
218896886|NCT03036410|DEVICE|DuoPhone|streaming function, which provides the speech signal to both ears
218896887|NCT02620982|DEVICE|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
218896888|NCT06514872|OTHER|prevalance and determinants of home accidents|home accidents among Turkish older
218896889|NCT02329470|PROCEDURE|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
218896890|NCT04839016|DRUG|SHR-1314|SHR-1314
218896891|NCT04839016|DRUG|Placebo|Placebo
219517196|NCT00322907|DRUG|Cotrifazid vs mefloquine or quinine+SP|
219035843|NCT05222932|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
219035844|NCT05222932|DRUG|Avelumab|Anti-PDL1 antibody
219035845|NCT03396614|DIAGNOSTIC_TEST|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
219517197|NCT04117607|OTHER|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
219517198|NCT04117607|DRUG|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
218896892|NCT01579435|DEVICE|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
218896893|NCT01116401|DRUG|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
218896894|NCT02893241|DRUG|Cafedrine/theodrenaline|
218896895|NCT02893241|DRUG|Ephedrine|
218896896|NCT01560286|BIOLOGICAL|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
218896897|NCT01957878|BIOLOGICAL|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
218896898|NCT01957878|BIOLOGICAL|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
218896899|NCT01521026|BEHAVIORAL|Cognitive Training|12-week compensatory cognitive training in group format
219035846|NCT02375191|DRUG|fentanyl|
219035847|NCT02375191|DRUG|dexmedetomidine|
219035848|NCT02375191|DRUG|Ropivacaine|
219035849|NCT02662127|DEVICE|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
219035850|NCT03261947|DRUG|TAK-931|TAK-931 hard gelatin capsules
219517199|NCT04117607|DRUG|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
218896900|NCT01545726|DRUG|QAW039|QAW039 was supplied as capsules for oral administration.
218896901|NCT01545726|DRUG|Placebo|Placebo was supplied as capsules for oral administration.
218896902|NCT05313035|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
218896903|NCT05313035|BIOLOGICAL|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
218896904|NCT03654183|DIAGNOSTIC_TEST|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
219517200|NCT00532337|DRUG|ONO-5334|Placebo - 24/mos.
219517201|NCT00532337|DRUG|ONO-5334|100mg QD /24 months
218896905|NCT02171221|DRUG|Oral DFP-11207|
218896906|NCT03967145|BEHAVIORAL|Determining quality of life|Quality of Life
218896907|NCT00746070|OTHER|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
218896908|NCT06317571|BEHAVIORAL|fertility support education|In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
218896909|NCT03955835|DEVICE|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
218896910|NCT03255135|DEVICE|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
218896911|NCT05842759|PROCEDURE|Monitoring|Continuous blood pressure monitoring
218896912|NCT05842759|PROCEDURE|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
218896913|NCT05842759|PROCEDURE|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
218896914|NCT05842759|PROCEDURE|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
218896915|NCT05842759|PROCEDURE|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
218896916|NCT02416843|OTHER|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
218896917|NCT05275816|OTHER|Comparing the appropriateness of our practice and the usability of the AUC through comparing the actual management provided at our institution with that recommended by the AUC.|"The AUC application for carpal tunnel syndrome management requires four patients' variables to generate appropriateness ratings for six different treatment options. Each procedure is rated as appropriate, maybe appropriate, or rarely appropriate. The six procedures include splint, steroid injection, carpal tunnel release, oral steroids or Ketoprofen phonophoresis, investigation of alternative diagnoses, and further investigation using an electro-diagnostic study.~To judge the usability of the AUC for the management of carpal tunnel syndrome, the required parameters of each patient were collected and entered into the AUC application by two independent authors to generate the appropriateness rating of the provided treatment for each patient. Afterwards, the agreement between the AUC recommendations and the actual treatment that was provided at our institution was assessed."
218896918|NCT05661812|DIAGNOSTIC_TEST|Quationnaires and symptom registration|Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
219517202|NCT00532337|DRUG|ONO-5334|50mg BID /24 mos.
219517203|NCT00532337|DRUG|ONO-5334|300mg QD /24 mos.
219517204|NCT00532337|DRUG|ONO-5334|Alendronate 70mg once weekly / 24 mos
219517205|NCT02493244|OTHER|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
219517206|NCT03538236|DEVICE|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
219517207|NCT03538236|BEHAVIORAL|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
219517208|NCT02200900|OTHER|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
219517209|NCT02200900|OTHER|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
219611635|NCT05755932|DRUG|HFO-1234ze(E)|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
219517210|NCT02200900|OTHER|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
219517211|NCT02200900|OTHER|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
219611636|NCT05755932|DRUG|HFA-134a|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
219611637|NCT03172897|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
218896919|NCT05661812|DIAGNOSTIC_TEST|PNIF and spirometry|To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
219611638|NCT03172897|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
219611639|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
219611640|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
219611641|NCT06454734|DEVICE|Extracorporeal shock wave therapy by radial device|Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
219611642|NCT06454734|DEVICE|Placebo extracorporeal shock wave therapy by radial device|Patients will receive treatment sham extracorporeal shock waves.
219611643|NCT06454734|OTHER|DLT|Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
219611644|NCT06451003|BEHAVIORAL|Exposure to clinical decision support system and education|"Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge."
218896920|NCT05661812|DIAGNOSTIC_TEST|SPT, spesific IgE, pBAT and NPT|To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
218896921|NCT05448339|COMBINATION_PRODUCT|PVHA or TACE|PVHA or TACE
218896922|NCT00359996|BEHAVIORAL|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
218896923|NCT00359996|OTHER|No additional educational sessions|
218896924|NCT01302483|DRUG|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
218896925|NCT01302483|DRUG|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
218896926|NCT01364584|DRUG|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
218896927|NCT01364584|DRUG|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
218896928|NCT05162183|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference group.
219517212|NCT02250560|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
219517213|NCT04252469|OTHER|Oral care|oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
219517214|NCT00537147|BIOLOGICAL|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
219517215|NCT00537147|BIOLOGICAL|Placebo|Placebo for WN/DEN4delta30 vaccine
219517216|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
219611645|NCT04556188|PROCEDURE|Cardiac surgery|
219517217|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
219517218|NCT03605043|OTHER|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
219517219|NCT00257153|DEVICE|Coronary thrombus aspiration catheter|
219517220|NCT02594462|DRUG|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
218896929|NCT05162183|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
218896930|NCT01758809|PROCEDURE|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
218896931|NCT01758809|PROCEDURE|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
218896932|NCT05460455|DRUG|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
218896933|NCT01161186|DRUG|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
218896934|NCT00491465|BEHAVIORAL|Intensive Physical activity|
218896935|NCT00491465|BEHAVIORAL|Control- regular physical activity|
218896936|NCT03919539|DIAGNOSTIC_TEST|5hmc testing|NGS
219517221|NCT02852564|DRUG|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
219517222|NCT05928780|DRUG|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
219517223|NCT05928780|DRUG|A2:SG|SG 10mg/kg d1, 8
219517224|NCT05928780|DRUG|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
219517225|NCT05928780|DRUG|B2:SG|SG 10mg/kg， d1, 8
219517226|NCT05928780|DRUG|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
219517227|NCT05928780|DRUG|C2:SG|SG 10mg/kg d1, 8
218896937|NCT01773486|DRUG|Hesperidin|Citrus polyphenol, hesperidin
218896938|NCT01773486|DRUG|Placebo|Placebo matching hesperidin
218896939|NCT01729286|DEVICE|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
218896940|NCT01729286|OTHER|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
218896941|NCT05710055|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
218896942|NCT05710055|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
218896943|NCT05710055|DIETARY_SUPPLEMENT|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
218896944|NCT05710055|DIETARY_SUPPLEMENT|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
218896945|NCT04220216|OTHER|H4H fitness program|4 weekly, 1 hour exercise sessions
218896946|NCT05161416|BEHAVIORAL|Bubble Blowing|Active Distraction Methods
218896947|NCT05161416|BEHAVIORAL|Cartoon Watching|Passive Distraction Methods
218896948|NCT04675385|DRUG|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
219517228|NCT05928780|DRUG|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
219517229|NCT05928780|DRUG|D2:SG|SG 10mg/kg d1, 8
218896949|NCT04890379|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
218896950|NCT04890379|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
218896951|NCT00210717|DRUG|paliperidone palmitate|
218896952|NCT06528951|OTHER|Control Phase ( 6Weeks)|The participants will perform a control phase of six weeks of resistance training using the same volume for the upper (160 repetitions) and lower limbs (230 repetitions), with relative intensities ranging from 40% to 70% of 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 5-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 5-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 6-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 5-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
219517230|NCT03491436|DEVICE|iHealth Align|remote monitor glucometer
219517231|NCT04506242|DRUG|SHR-1210|PD-1
219517232|NCT04506242|DRUG|Apatinib|VEGFR2
219517233|NCT00459888|DEVICE|PolarCath Peripheral Dilatation System (Boston Scientific)|
219517234|NCT02024087|DRUG|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
219517235|NCT03536338|OTHER|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
219517236|NCT03536338|OTHER|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
219517237|NCT01550211|DEVICE|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
219517238|NCT00007436|DRUG|Tenofovir disoproxil fumarate|
219517239|NCT02236507|DEVICE|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
219517240|NCT01861366|OTHER|A one year multifaceted implementation strategy|
219517241|NCT01861366|OTHER|A three hour lecture about the guidelines|
219517242|NCT03195985|OTHER|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
219517243|NCT03195985|OTHER|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
219517244|NCT03083171|DRUG|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
219517245|NCT03083171|DRUG|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
219517246|NCT03083171|DRUG|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
218896953|NCT06528951|OTHER|15% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 15% (upper limbs - 184 repetitions; lower limbs - 268 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 4-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 3-8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
219035851|NCT05938751|BEHAVIORAL|TEAm_YOUNG ADULTS program|The TEAm\_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
219035852|NCT03969992|DRUG|AeroFact|Aerosolized SF-RI 1
219035853|NCT03969992|OTHER|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
219035854|NCT01841151|BEHAVIORAL|SCP training|
219517247|NCT00950807|DRUG|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
219517248|NCT00950807|DRUG|Placebo|Inactive/ excipients only
219517249|NCT00950807|DRUG|GSK573179|GSK573179 investigational drug
219517250|NCT01587222|DRUG|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
218896954|NCT06528951|OTHER|30% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
219517251|NCT01587222|DRUG|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
219035855|NCT01841151|BEHAVIORAL|Live Z-score training|
219517252|NCT01587222|DRUG|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
219517253|NCT05960864|DRUG|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
219517254|NCT05432011|PROCEDURE|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
219517255|NCT05432011|PROCEDURE|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
219517256|NCT05432011|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
219517257|NCT04933825|BIOLOGICAL|ET-02|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
219517258|NCT03652077|DRUG|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
219517259|NCT00337077|DRUG|eribulin mesylate|Given IV
219517260|NCT01460797|OTHER|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
219035856|NCT01841151|BEHAVIORAL|WM training|
219035857|NCT03967392|DRUG|Xylocaine|TREATMENT
219035858|NCT06110429|DRUG|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
219035859|NCT06110429|DRUG|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
219035860|NCT04462809|DRUG|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
219035861|NCT04244513|DEVICE|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
219517261|NCT05413603|PROCEDURE|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
219035862|NCT01141881|DRUG|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
219035863|NCT05907096|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
219035864|NCT05907096|OTHER|Placebo|Intravenous administration of placebo
219035865|NCT00929682|DRUG|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
218896955|NCT06528951|OTHER|One group that performed 15% more volume and increased to 30% (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed a 15% volume will now increase more by 15% and perform 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
218896956|NCT06528951|OTHER|One group that performed 30% more volume and increased to 45% (10 Weeks).|The participants will perform 10 weeks of resistance training. The group that performed a 30% volume will now increase more by 15% and perform 45% (upper limbs - 232 repetitions; lower limbs - 334 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 2-3 sets of 8 repetitions in the sit-to-stand exercise, v) 2-3 sets of 8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
218896957|NCT06528951|OTHER|Control group ( 29 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
218896958|NCT04933071|BEHAVIORAL|Podcast|A list of podcasts that are specified for each rotation
218896959|NCT01742195|PROCEDURE|Oral EBUS insertion|
218896960|NCT01742195|PROCEDURE|Nasal EBUS insertion|
218896961|NCT05338034|DRUG|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
218896962|NCT05338034|DRUG|Placebo|Capsule
218896963|NCT05107895|BEHAVIORAL|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
218896964|NCT04702412|OTHER|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
218896965|NCT04585724|DRUG|Abemaciclib|Given PO
218896966|NCT04585724|DRUG|Palbociclib|Given PO
218896967|NCT04585724|OTHER|Quality-of-Life Assessment|Ancillary studies
219035866|NCT03521258|DEVICE|Dehydrated Human Amnion/Chorion Membrane|
219035867|NCT03521258|PROCEDURE|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
219204042|NCT06015191|BEHAVIORAL|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
219517262|NCT05413603|PROCEDURE|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
219517263|NCT02129348|DRUG|Lithium|
219517264|NCT02129348|DRUG|Placebo|
218896968|NCT04585724|DRUG|Ribociclib|Given PO
218896969|NCT02863614|DRUG|Ibuprofen 600 mg|
218896970|NCT02863614|DRUG|Lorazepam 1 mg|
218896971|NCT02863614|DRUG|Placebo|
218896972|NCT04493996|BEHAVIORAL|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
218896973|NCT06014346|OTHER|Psychological strategy|"* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* then realization accompanied by a training of these exercises"
219035868|NCT03960151|DRUG|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
219035869|NCT03960151|DRUG|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
219035870|NCT03960151|DRUG|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
219035871|NCT03960151|DRUG|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
219035872|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
219035873|NCT03317171|DIETARY_SUPPLEMENT|Flavonoids, DHA, EPA|oral administration
219035874|NCT03317171|DIETARY_SUPPLEMENT|placebo compound|oral administration
219035875|NCT06003530|BIOLOGICAL|hOMSC200|Human Oral Mucosal Stem Cells
219517265|NCT03395106|BEHAVIORAL|Parent source|Having a parent feature prominently in a news story
219517266|NCT03395106|BEHAVIORAL|Doctor source|Having a doctor feature prominently in a news story
219517267|NCT03395106|BEHAVIORAL|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
219517268|NCT03395106|BEHAVIORAL|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
218896974|NCT06014346|OTHER|Physiological strategy|\- ingesting a salty snack
218896975|NCT00930891|DRUG|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
218896976|NCT00930891|DRUG|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
218896977|NCT00930891|DRUG|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
218896978|NCT05555303|DRUG|Amikacin|"In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration."
219517269|NCT01033162|BEHAVIORAL|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~* Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~* Reduce patients' negative affect and increase their emotional well being~* Improve patients' sense of social support~* Improve patients' health self-efficacy~* Improve patients' ratings of experience with cancer specialty care services~* Improve patients' health related quality of life (HRQL)~* Improve clinicians' ratings of quality of patient contacts~* Reduce healthcare utilization and costs (obtained via the EMR)"
219517270|NCT00154180|DRUG|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
218896979|NCT04049708|OTHER|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
218896980|NCT04546035|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
218896981|NCT05020509|PROCEDURE|medial branch block|lumbar medial branch block
218896982|NCT02655029|DRUG|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
218896983|NCT01466608|DRUG|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
218896984|NCT06458790|BEHAVIORAL|AARC|This intervention will adapt an already-existing evidence-based Centering Parenting program addressing topics that are specific to African American families. There will be 7 90 min sessions via zoom. Group education topics include (parenting goals, infant feeding and sleep, self-care). Participants will complete surveys and interviews at various times to evaluate the program. The survey topics will include: parent stress, parent confidence and thoughts about the intervention. Surveys will be completed independently by participants online via redcap at a time that is convenient to them; if requested, the coordinator may complete the survey with the participant directly by phone /zoom. Interviews will be completed with a coordinator via zoom/phone.
218896985|NCT05876507|BEHAVIORAL|Progressive relaxation exercise|Progressive relaxation exercises will take 25-30 minutes of patients daily.
218896986|NCT04039958|DRUG|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218896987|NCT04039958|DRUG|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218896988|NCT04039958|DRUG|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218896989|NCT06042634|BEHAVIORAL|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
218896990|NCT06042634|BEHAVIORAL|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
218896991|NCT01751100|BEHAVIORAL|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
218896992|NCT01751100|BEHAVIORAL|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
218896993|NCT03172312|PROCEDURE|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
218896994|NCT00047515|DRUG|Alcon Investigational Agent|
218896995|NCT03166241|DIAGNOSTIC_TEST|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
218896996|NCT03166241|DIAGNOSTIC_TEST|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
218896997|NCT03166241|DIAGNOSTIC_TEST|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
219035876|NCT06003530|OTHER|Placebo|Animal component-free, defined cryopreservation medium with 5% DMSO
219035877|NCT02759666|DRUG|SHR3162|SHR3162 capsule(s) is administered orally QD.
219035878|NCT00062582|DRUG|Roflumilast|
219035879|NCT03897790|OTHER|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
219035880|NCT00656006|DRUG|Albuferon|
219035881|NCT00656006|DRUG|Ribavirin|
219035882|NCT04499586|COMBINATION_PRODUCT|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
218896998|NCT03166241|DIAGNOSTIC_TEST|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
218896999|NCT03166241|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
219035883|NCT00439556|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
219035884|NCT00439556|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219035885|NCT00439556|DRUG|Bortezomib|Given IV
219035886|NCT00439556|DRUG|Carmustine|Given IV
219035887|NCT00439556|DRUG|Cytarabine|Given IV
219035888|NCT00439556|DRUG|Etoposide|Given IV
219035889|NCT00439556|BIOLOGICAL|Filgrastim|Given SC
219035890|NCT00439556|DRUG|Melphalan|Given IV
219035891|NCT00439556|DRUG|Methotrexate|Given IV
219517271|NCT00154180|DRUG|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
219035892|NCT00439556|BIOLOGICAL|Rituximab|Given IV
219035893|NCT00439556|DRUG|Tacrolimus|Given IV and PO
219035894|NCT02871739|BEHAVIORAL|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
219035895|NCT02871739|BEHAVIORAL|DA viewing|Participants will receive 3 decisions aids to review.
219035896|NCT02871739|BEHAVIORAL|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
219035897|NCT03769272|PROCEDURE|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
219035898|NCT02438748|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
219035899|NCT02189421|DEVICE|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
219035900|NCT00849966|DRUG|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
219035901|NCT00849966|DRUG|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
219517272|NCT00154180|DRUG|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
219035902|NCT03818516|OTHER|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
219035903|NCT04330742|DRUG|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
219517273|NCT00154180|DRUG|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
219517274|NCT00154180|DRUG|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
219517275|NCT02327195|DRUG|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
219517276|NCT02327195|DRUG|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
219517277|NCT01775319|DIETARY_SUPPLEMENT|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
219517278|NCT01775319|DIETARY_SUPPLEMENT|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
219517279|NCT01775319|DIETARY_SUPPLEMENT|Placebo|
219517280|NCT01264224|DRUG|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
218897000|NCT03166241|DIAGNOSTIC_TEST|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
218897001|NCT03953833|BIOLOGICAL|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
219035904|NCT03321669|PROCEDURE|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
219035905|NCT03166280|DRUG|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
219035906|NCT03166280|DRUG|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
219035907|NCT01944995|DEVICE|glasses broadband|
219517281|NCT04351204|RADIATION|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
219517282|NCT04312906|OTHER|no intervention|No intervention
219517283|NCT04195997|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.
219517284|NCT04195997|DRUG|Heparin|heparin during left atrial appendage occlusion.
219611646|NCT05645003|DEVICE|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
218897002|NCT05561023|DRUG|Hawthorn red pigment|"For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme"
218897003|NCT02464436|DRUG|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
218897004|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
218897005|NCT01971541|BEHAVIORAL|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
218897006|NCT01971541|BEHAVIORAL|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
218897007|NCT04001348|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897008|NCT04001348|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897009|NCT04001348|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897010|NCT04001348|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897011|NCT04001348|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897012|NCT04001348|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897013|NCT04001348|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897014|NCT04001348|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897015|NCT04001348|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897016|NCT04001348|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897017|NCT04001348|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
219035908|NCT01944995|DEVICE|nasal CPAP|
219035909|NCT01642238|DRUG|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
219035910|NCT01642238|DRUG|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
219611647|NCT05645003|DEVICE|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
218897018|NCT04001348|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
219517285|NCT03509103|OTHER|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
218897019|NCT04001348|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897020|NCT04001348|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897021|NCT04001348|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897022|NCT04001348|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
218897023|NCT06423313|PROCEDURE|maintenance of anesthesia|Types used to maintain anesthesia
218897024|NCT03845647|PROCEDURE|contralateral central lymph node dissection|contralateral central lymph node dissection
219035911|NCT02181062|BEHAVIORAL|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
219035912|NCT02371707|DRUG|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
219035913|NCT02371707|DRUG|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
219035914|NCT05751330|PROCEDURE|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~* Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~* Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
219517286|NCT05554822|DRUG|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
219517287|NCT05554822|DRUG|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
218897025|NCT02660853|DIAGNOSTIC_TEST|FEV1|Participants have FEV1 test
218897026|NCT01837277|DRUG|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
218897027|NCT01837277|DRUG|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
219035915|NCT04372602|DRUG|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
219035916|NCT04372602|PROCEDURE|Peripheral blood draw|"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
219035917|NCT04372602|DRUG|Placebo|-Provided by Verastem
219517288|NCT05657496|DRUG|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
219611648|NCT05969041|DRUG|MT-302 (A)|MT-302 is an investigational drug
219611649|NCT06478251|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
219611650|NCT06478251|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
219611651|NCT06022822|PROCEDURE|Biopsy Procedure|Undergo biopsy
219611652|NCT06022822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219611653|NCT06022822|DRUG|Placebo Administration|Given PO
219611654|NCT06022822|DIETARY_SUPPLEMENT|Urolithin A Supplement|Given PO
219611655|NCT05525520|DRUG|EP547|Once daily
219611656|NCT05525520|DRUG|Placebo|Once daily
219611657|NCT05574868|DEVICE|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
219035918|NCT04065789|DRUG|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
218897028|NCT03018691|DRUG|OPA-15406|
218897029|NCT03018691|DRUG|Placebos|
218897030|NCT00358397|DRUG|Clostridium novyi-NT spores|
218897031|NCT03487991|BEHAVIORAL|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
218897032|NCT03415282|DRUG|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
218897033|NCT00952029|BIOLOGICAL|bevacizumab|
218897034|NCT00952029|DRUG|FOLFIRI regimen|
218897035|NCT00952029|DRUG|fluorouracil|
219517289|NCT05657496|BIOLOGICAL|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
219611658|NCT05806138|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.
218897036|NCT00952029|DRUG|irinotecan hydrochloride|
218897037|NCT00952029|DRUG|leucovorin calcium|
219035919|NCT04065789|DRUG|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
219035920|NCT04065789|DRUG|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
219035921|NCT04065789|DRUG|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
219517290|NCT00665730|DEVICE|Sepraspray|
219517291|NCT04339465|BEHAVIORAL|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
219611659|NCT05806138|OTHER|Optimal medical therapy|All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
218897038|NCT01495286|DEVICE|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
218897039|NCT05892601|OTHER|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
218897040|NCT02218645|DRUG|WE 941 OD tablets|
218897041|NCT02218645|DRUG|Brotizolam|
218897042|NCT00796666|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
218897043|NCT00796666|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
218897044|NCT02576639|DRUG|CNP520|
218897045|NCT02576639|DRUG|Placebo|Matching placebo to CNP520 was supplied in capsules.
218897046|NCT05701007|DRUG|abiraterone|mCRPC
218897047|NCT05701007|DRUG|enzalutamide|mCRPC
218897048|NCT05701007|DRUG|docetaxel|mCRPC
218897049|NCT05701007|DRUG|apalutamide|mCRPC
219035922|NCT03305510|DIAGNOSTIC_TEST|vitamin D is below 20ng/ml|
218897050|NCT05701007|DRUG|cabazitaxel|mCRPC
218897051|NCT05701007|DRUG|Radium-223|mCRPC
218897052|NCT05701007|DRUG|Lutetium-177|mCRPC
218897053|NCT05701007|DRUG|degarelix|mCSPC
218897054|NCT05701007|DRUG|goserelin|mCSPC
218897055|NCT05701007|DRUG|leuprorelin|mCSPC
218897056|NCT05701007|DRUG|triptorelin|mCSPC
218897057|NCT06129643|DRUG|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
218897058|NCT06129643|DEVICE|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
218897059|NCT06129643|COMBINATION_PRODUCT|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
218897060|NCT02125084|DRUG|Everolimus|
218897061|NCT02125084|DRUG|Enzalutamide|
218897062|NCT01880658|DRUG|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
218897063|NCT03174366|DRUG|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
218897064|NCT00638534|DRUG|Telithromycin (HMR3647)|
218897065|NCT05502913|DRUG|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
218897066|NCT05502913|OTHER|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
218897067|NCT03169166|DRUG|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
218897068|NCT06328673|DRUG|DM919|Anti-MICA/MICB monoclonal antibody
218897069|NCT06328673|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
218897070|NCT02882594|BEHAVIORAL|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
218897071|NCT03959059|DEVICE|Mixed Reality technology|combine image with real body
218897072|NCT00670280|BEHAVIORAL|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
218897073|NCT00670280|BEHAVIORAL|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
218897074|NCT00670280|BEHAVIORAL|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
218897075|NCT05003375|BEHAVIORAL|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures"
218897076|NCT06032169|OTHER|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
218897077|NCT01380223|DRUG|placebo|I.V. infusion of placebo for 8 hr
218897078|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
218897079|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
218897080|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
218897081|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
218897082|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
218897083|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
218897084|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
218897085|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
218897086|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
218897087|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
218897088|NCT01503008|DEVICE|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
218897089|NCT01503008|DRUG|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
218897090|NCT02418039|DIETARY_SUPPLEMENT|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
218897091|NCT02418039|DIETARY_SUPPLEMENT|Normal protein|A normal protein diet will be administrated in patients with MHE.
218897092|NCT01226225|BEHAVIORAL|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
218897093|NCT01226225|BEHAVIORAL|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
218897094|NCT03871426|PROCEDURE|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
219035923|NCT05464004|OTHER|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
219035924|NCT04966676|DIAGNOSTIC_TEST|cfDNA blood test|Blood sample will be taken for cfDNA testing
218897095|NCT02845817|OTHER|Qualitative research|Semi-structured interviews
218897096|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
219035925|NCT04966676|DRUG|Nivolumab|Antineoplastic agent
219035926|NCT04966676|DRUG|Ipilimumab|Antineoplastic agent
219035927|NCT04966676|COMBINATION_PRODUCT|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
219035928|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
219035929|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
219035930|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
219035931|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
219035932|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
219035933|NCT03063996|PROCEDURE|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
219035934|NCT03063996|PROCEDURE|Peripheral IJ access procedure|standard of care guided IV access into IJ
219517292|NCT04339465|BEHAVIORAL|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
218897097|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
218897098|NCT04934566|OTHER|ECMO flow|Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
218897099|NCT02894671|OTHER|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
218897100|NCT04205526|DEVICE|Active rTMS|Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
218897101|NCT04205526|DEVICE|Sham TMS|For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
218897102|NCT00002963|DRUG|aminolevulinic acid hydrochloride|
219035935|NCT02907359|DRUG|Guadecitabine|
219035936|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
219517293|NCT00540501|DRUG|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
219517294|NCT01433666|DRUG|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
219517295|NCT01433666|DRUG|Placebo|Acute intervention: single administration, capsulated form.
219517296|NCT01433666|DRUG|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
218897103|NCT00002963|PROCEDURE|conventional surgery|
218897104|NCT00057863|DRUG|Paclitaxel|Given IV
218897105|NCT00057863|DRUG|Oxaliplatin|Given IV
219517297|NCT02019940|DRUG|Riluzole|
219517298|NCT01434121|DRUG|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
219611660|NCT06117332|DEVICE|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
218897106|NCT02316561|RADIATION|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
218897107|NCT00367939|DRUG|valsartan + amlodipine|
218897108|NCT02461381|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
218897109|NCT03188107|OTHER|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
218897110|NCT00182039|DRUG|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
218897111|NCT00182039|DRUG|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
218897112|NCT04610047|DRUG|Norketotifen|Oral capsule
218897113|NCT04610047|DRUG|Placebo|Oral capsule
218897114|NCT03228771|DRUG|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
218897115|NCT03228771|DRUG|ATV gel|Atorvastatin loaded in methyl cellulose gel
218897116|NCT01521507|DEVICE|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
218897117|NCT01521507|DEVICE|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
218897118|NCT03074071|BEHAVIORAL|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
218897119|NCT03531671|DEVICE|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
218897120|NCT02093507|OTHER|parents manipulation|parents perform manipulation the child foot to correct the deformity
218897121|NCT02079038|DEVICE|Totalis|
218897122|NCT02079038|PROCEDURE|Comparator Surgical Procedure|
219517299|NCT01434121|DRUG|Placebo|
219517300|NCT01598701|DRUG|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
218897123|NCT05605626|OTHER|the better retaining of skills|identify which teaching program has the better retaining of skills
218897124|NCT05424016|DRUG|Propranolol|120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
219517301|NCT01598701|DRUG|Placebo|100 mL 0.9% Sodium Chloride
219517302|NCT06547944|DRUG|Zanubrutinib|160mg bid/d, from C1 to CR and MRD-negative or C24
219517303|NCT06547944|DRUG|Lenalidomide|From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
219517304|NCT06547944|DRUG|Obinutuzumab|1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
219517305|NCT01409486|OTHER|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
219517306|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
219517307|NCT00074906|DRUG|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
219517308|NCT02989688|DIETARY_SUPPLEMENT|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
219517309|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
219517310|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
219517311|NCT02223000|DRUG|BIBV 308 SE solution|
219517312|NCT02223000|DRUG|BIBV 308 SE capsule 1|
219517313|NCT02223000|DRUG|BIBV 308 SE capsule 2|
219517314|NCT02349893|DEVICE|RFA treatment|RFA treatment using CelonProSleep plus system
219517315|NCT04944537|OTHER|No Intervention|No Intervention
219517316|NCT01459328|RADIATION|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days"
218897125|NCT05424016|OTHER|follow-up|routine follow-up (neurosurgical consultation and an MRI every six months)
218897126|NCT06117735|DEVICE|Transjugular Intrahepatic Portosystemic shunt|The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
218897127|NCT05206175|OTHER|Affect Treatment Program for Methamphetamine Use Disorder|Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
218897128|NCT04764474|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
218897129|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
218897130|NCT05597033|BEHAVIORAL|Control|seated rest
218897131|NCT03171337|DEVICE|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
218897132|NCT03171337|DEVICE|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
218897133|NCT03171337|DEVICE|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
218897134|NCT00669890|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
218897135|NCT00669890|DRUG|Busulfan|Conditioning Regimen
218897136|NCT00669890|DRUG|Cyclophosphamide|Conditioning Regimen
218897137|NCT00669890|DRUG|Thymoglobulin|(Unrelated Donors only)
219035937|NCT05918991|BEHAVIORAL|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
219035938|NCT05918991|OTHER|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
218897138|NCT00669890|DRUG|Tacrolimus|GVHD Prophylaxis
218897139|NCT00669890|DRUG|Mycophenolate Mofetil|GVHD Prophylaxis
218897140|NCT00669890|DRUG|Methotrexate|GVHD Prophylaxis
219611661|NCT06404034|DRUG|Gallium Maltolate|GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed
218897141|NCT03746626|BEHAVIORAL|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
218897142|NCT01809821|BEHAVIORAL|Online Sleep Education|
218897143|NCT03167333|DRUG|platelet rich plasma|The amount of PPR was about 4-5 cc
218897144|NCT03167333|DRUG|Hyaluronic acid|HA was 2.5cc
218897145|NCT03178383|BEHAVIORAL|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
218897146|NCT03178383|BEHAVIORAL|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
218897147|NCT02749539|DEVICE|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
218897148|NCT02749539|PROCEDURE|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
219611662|NCT06529068|BEHAVIORAL|Isometric handgrip exercise|The participants will perform isometric handgrip exercises without blood flow restriction.
218897149|NCT05003037|DRUG|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
218897150|NCT05065905|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
218897151|NCT02867735|DRUG|LKA651|Interventional
218897152|NCT02867735|OTHER|Sham Comparator|
218897153|NCT04731389|BEHAVIORAL|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
219517317|NCT01459328|RADIATION|Radiotherapy|"Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
219517318|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 0cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
218897154|NCT04731389|BEHAVIORAL|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
218897155|NCT05505448|DRUG|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
218897156|NCT05505448|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
218897157|NCT02414308|DRUG|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
218897158|NCT01933308|OTHER|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
218897159|NCT01933308|OTHER|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
218897160|NCT01933308|OTHER|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
218897161|NCT02789059|OTHER|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
218897162|NCT00580723|OTHER|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
218897163|NCT00230646|BEHAVIORAL|Exercise counseling|
218897164|NCT03223402|OTHER|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
218897165|NCT06350188|OTHER|experimental|15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month
219204043|NCT06015191|BEHAVIORAL|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
219517319|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 40cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
219611663|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a narrow-elastic band|The participants will perform isometric handgrip exercises with blood flow restriction using a narrow-elastic band.
219611664|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a wide-rigid cuff|The participants will perform isometric handgrip exercises with blood flow restriction using a wide-rigid cuff.
219611665|NCT04603625|OTHER|postural management|postural management in sitting position
219611666|NCT06041880|DEVICE|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
219611667|NCT06424184|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|"The rTMS protocol implemented in this study will include approximately 10-minute long sessions of intermittent theta burst stimulation (iTBS) with at least 50 minutes in between iTBS sessions.~Study participants will receive the rTMS intervention for up to 50 sessions across a three-week period. The total of 50 sessions will be administered as up to 4 sessions each day, up to 5 days per week over an up to 3-week-long period."
219611668|NCT05957848|DRUG|Guanfacine Extended Release Oral Tablet|Target dose 4 mg daily
219204044|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
218897166|NCT06350188|OTHER|traditional|15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
218897167|NCT03258307|OTHER|Preoperative level|Blood sample
218897168|NCT00148759|DRUG|LPV/r|LPV/r 800/200 mg once daily
218897169|NCT03408197|DEVICE|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
218897170|NCT03408197|DEVICE|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
218897171|NCT05202418|BEHAVIORAL|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
218897172|NCT04230317|DIAGNOSTIC_TEST|Chest CT|Low dose CT taken with three different protocols
218897173|NCT01557426|OTHER|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
218897174|NCT03776695|BIOLOGICAL|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
218897175|NCT03776695|OTHER|Placebo|0.9% Saline
218897176|NCT01454596|BIOLOGICAL|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
218897177|NCT01454596|DRUG|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
218897178|NCT01454596|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
218897179|NCT01454596|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
219517320|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 60cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
219517321|NCT06114251|DIAGNOSTIC_TEST|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
218897180|NCT03997526|DEVICE|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
218897181|NCT01671163|PROCEDURE|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
218897182|NCT06023940|DIETARY_SUPPLEMENT|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
219517322|NCT05283005|PROCEDURE|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
219517323|NCT01415778|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
219035939|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
219035940|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
219611669|NCT05957848|BEHAVIORAL|Residential withdrawal|4-14 days in residential withdrawal treatment
219611670|NCT05957848|BEHAVIORAL|Engagement with alcohol and other drug services|Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
219611671|NCT05957848|DRUG|Placebo|Placebo capsule taken daily
219611672|NCT04541082|DRUG|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
218897183|NCT05038865|OTHER|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
219517324|NCT01415778|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
219517325|NCT06257745|OTHER|Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019|Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
218897184|NCT04221724|OTHER|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
218897185|NCT04735874|OTHER|Evaluate vascular disease risk factors in children with Down Syndrome|We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw \[lipid panel with subfractions (NMR), insulin, glucose, and CRP\].
218897186|NCT04735874|OTHER|Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome|We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
218897187|NCT05035758|OTHER|Transcendental Meditation|"In the beginning, the patients from group B will receive an introductory lecture about transcendental meditation (TM) which includes general information, the procedure itself and other techniques of relaxation and personal development.~In this first session the method is learned by practice, in the following 3 meetings additional instructions are given about the correct practice of the TM technique; TM is practiced twice a day for 20 minutes. The method is easy to learn and effortless. To guarantee the right performance of TM by the patients, there will be two group meetings per week and one individual personal meeting with the TM teacher.After discharge from the rehabilitation program (after 4 weeks) there will be meetings offered according to the patients need. This will then be arranged individually."
218897188|NCT05035758|OTHER|Yoga|"In addition to the standard rehabilitation exercise training, the patients in this group will receive a 20-minute workshop where they learn how to do the yoga exercise. The initial yoga workshop will be held by Dr. Gilda Wüst who is a yoga expert with a lot of experience based in St. Radegund.~After this, yoga sessions will be included (additionally to the regular/standard exercise) into their daily timetable. Two yoga sessions will be done every day, one in the morning (6:30-6:50) and one in the evening (16:30-16:50) and will last for about 20 minutes."
218897189|NCT00488488|DRUG|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
218897190|NCT04924335|PROCEDURE|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
219035941|NCT04360018|OTHER|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
219035942|NCT04360018|OTHER|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
219035943|NCT01758380|DRUG|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
219035944|NCT01758380|DRUG|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
219517326|NCT01743157|DRUG|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
219517327|NCT01888081|DRUG|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
219517328|NCT01888081|RADIATION|Ionizing Radiation|
219517329|NCT02665143|DRUG|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
219517330|NCT05754008|BEHAVIORAL|AURORA Care Strategy|Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
219517331|NCT02430870|DRUG|TAK-648|TAK-648 solution
219517332|NCT02430870|DRUG|Placebo|TAK-648 placebo-matching solution
219517333|NCT04170309|DRUG|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
219517334|NCT01958463|PROCEDURE|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
219517335|NCT04697511|DRUG|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
219517336|NCT04697511|DRUG|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
218897191|NCT04173806|OTHER|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
218897192|NCT04173806|OTHER|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
218897193|NCT02721875|DRUG|Volasertib|
218897194|NCT02721875|DRUG|Volasertib|
218897195|NCT02721875|DRUG|Azacitidine|
218897196|NCT01207375|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
218897197|NCT01207375|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
218897198|NCT01485159|PROCEDURE|Spirometry|assessment of lung function by spirometry
218897199|NCT06473220|BEHAVIORAL|Narrative nursing|Narrative nursing is an intervention mode of psychological nursing.
218897200|NCT00240058|DRUG|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
218897201|NCT02426515|DEVICE|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
218897202|NCT02376764|PROCEDURE|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
218897203|NCT00376129|DRUG|Alefacept|15 mg i.m. once weekly for 12 weeks
218897204|NCT02647307|DRUG|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
218897205|NCT03154385|DRUG|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
218897206|NCT00895284|PROCEDURE|Robotic hysterectomy|Robotic hysterectomy.
218897207|NCT00895284|PROCEDURE|Standard Hysterectomy|Standard hysterectomy.
218897208|NCT05716074|OTHER|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
218897209|NCT05716074|OTHER|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
218897210|NCT05770817|OTHER|N/A: SKyRoCKeT is an observational study|None; this is an observational study
218897211|NCT06116734|DRUG|Grastofil®|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
218897212|NCT06116734|DRUG|Lapelga|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
218897213|NCT06396234|DEVICE|Safe VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
219517337|NCT02175706|DEVICE|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
219517338|NCT02175706|DEVICE|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
219517339|NCT03973983|PROCEDURE|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
219517340|NCT03973983|PROCEDURE|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
218897214|NCT06396234|PROCEDURE|Endotracheal intubation using video laryngoscope|Endotracheal intubation (size 7.0 mm) using video laryngoscope
218897215|NCT06396234|DEVICE|SaCo VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
218897216|NCT00430716|DRUG|Sildenafil citrate|oral, 20 mg, tid
218897217|NCT00430716|DRUG|Sildenafil citrate|oral 1 mg, tid
218897218|NCT00430716|DRUG|Sildenafil citrate|oral 5 mg, tid
218897219|NCT00430716|DRUG|Sildenafil citrate|oral 20 mg, tid
218897220|NCT00006000|DRUG|cisplatin|
218897221|NCT00006000|DRUG|irinotecan hydrochloride|
218897222|NCT00006000|DRUG|semaxanib|
218897223|NCT02483806|PROCEDURE|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0-\>5-\>10, 0-\>10-\>5, 5-\>10-\>0, 5-\>0-\>10, 10-\>5-\>0, 10-\>0-\>5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
219035945|NCT01758380|DRUG|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
219035946|NCT01758380|DRUG|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
219035947|NCT01758380|DRUG|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
219035948|NCT01405963|DRUG|Placebo|Administered in a 1-hour intravenous infusion
219035949|NCT01405963|BIOLOGICAL|Tezepelumab|Administered in a 1-hour intravenous infusion
218897224|NCT04507243|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
218897225|NCT04507243|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
219517341|NCT04945876|BEHAVIORAL|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
218897226|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
218897227|NCT05663203|OTHER|Interview|Complete interview
218897228|NCT05663203|OTHER|Survey Administration|Complete survey
218897229|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
218897230|NCT02949609|OTHER|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
218897231|NCT02949609|OTHER|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
218897232|NCT03482622|DIAGNOSTIC_TEST|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
218897233|NCT05309902|DRUG|Soticlestat|Soticlestat tablet.
218897234|NCT05309902|DRUG|Placebo|Soticlestat placebo-matching tablet.
218897235|NCT05309902|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
218897236|NCT05309902|DRUG|Placebo|Moxifloxacin placebo-matching capsule.
218897237|NCT00804726|DEVICE|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
218897238|NCT03855696|BIOLOGICAL|MG1113|MG1113
218897239|NCT03855696|OTHER|Placebo of MG1113|Placebo of MG1113
218897240|NCT05339360|PROCEDURE|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
218897241|NCT03803189|BEHAVIORAL|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
219035950|NCT03139149|PROCEDURE|Adhesiolysis|"Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
219517342|NCT01265784|DRUG|TP-434|
219517343|NCT01265784|DRUG|Ertapenem|
219517344|NCT01265784|DRUG|Placebo|Administered IV to maintain the blind.
219517345|NCT01619826|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
219517346|NCT01619826|BEHAVIORAL|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
218897242|NCT05918185|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218897243|NCT05918185|OTHER|Comprehensive Geriatric Assessment|Undergo cGA
218897244|NCT05918185|OTHER|Electronic Health Record Review|Medical records are reviewed
218897245|NCT05918185|OTHER|Survey Administration|Complete surveys
218897246|NCT01335776|BEHAVIORAL|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
219035951|NCT03139149|RADIATION|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
219035952|NCT03139149|RADIATION|Computer tomography|Computer tomography of abdomen with iv contrast
219035953|NCT03139149|PROCEDURE|Ultrasound|Ultrasound of the abdomen (2 times)
219035954|NCT03139149|OTHER|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
219035955|NCT00624676|DRUG|Lipo Hydroxy Acid|Twice a day
218897247|NCT01335776|BEHAVIORAL|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
219035956|NCT00624676|DRUG|5% benzoyl peroxide gel|Once a day
219035957|NCT01805024|DRUG|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
219035958|NCT00400647|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219035959|NCT00400647|DRUG|Mycophenolate mofetil|
219611673|NCT05636020|BEHAVIORAL|ICARE Treatment|The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
218897248|NCT00675909|DRUG|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
218897249|NCT00675909|DRUG|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
218897250|NCT00675909|DRUG|Oral midazolam|oral midazolam 0.5mg/kg
218897251|NCT01329978|DRUG|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
218897252|NCT01329978|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
218897253|NCT01329978|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
218897254|NCT04950244|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
218897255|NCT02677194|DEVICE|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
218897256|NCT02677194|OTHER|Control device|Device without any LED exposition
218897257|NCT02952365|DRUG|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
219035960|NCT03519568|BIOLOGICAL|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
219035961|NCT03615807|PROCEDURE|Surgical debridement (if needed)|Surgical debridement
219035962|NCT03615807|DIAGNOSTIC_TEST|Microbiological sampling|Microbiological sampling
219035963|NCT03615807|PROCEDURE|Revascularisation (if needed).|Revascularisation (if needed).
219035964|NCT03615807|DEVICE|Off-loading|Off-loading by Special shoes
219035965|NCT03615807|BEHAVIORAL|Patient's education and instructions|Patient's education and instructions by specialized nurses
218897258|NCT03324802|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218897259|NCT03324802|OTHER|Quality-of-Life Assessment|Ancillary studies
218897260|NCT03324802|RADIATION|Radiation Therapy|hypofractionated radiation therapy
218897261|NCT01887132|DRUG|Donepezil|
218897262|NCT01887132|DRUG|Placebo|
218897263|NCT05984043|BEHAVIORAL|Biofeedback|Heart-rate Variability Biofeedback
218897264|NCT05984043|OTHER|Waitlist|Waitlist control group
218897265|NCT02598206|DRUG|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
218897266|NCT03293030|DRUG|Dupilumab|Dupilumab treatment
218897267|NCT00821496|DRUG|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
218897268|NCT03579706|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
218897269|NCT03579706|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
218897270|NCT03015636|BEHAVIORAL|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
218897271|NCT03015636|OTHER|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
218897272|NCT00351754|DRUG|Isovue|
218897273|NCT01214005|BEHAVIORAL|smoking abstinence|3 days of biologically-confirmed smoking abstinence
219035966|NCT03615807|PROCEDURE|Wound debridement|Regular wound debridement by specialized nurses
219035967|NCT03615807|DRUG|Antibiotic duration|Systemic antibiotic duration according to the study arms
219035968|NCT00554437|BEHAVIORAL|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
218897274|NCT04394065|DEVICE|ultrasensitive positron emission tomography|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
218897275|NCT00393211|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
218897276|NCT00393211|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
218897277|NCT00773513|DRUG|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
218897278|NCT00773513|DRUG|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
218897279|NCT00773513|DRUG|Epoetin Beta|Epoetin beta will be administered as per approved label.
218897280|NCT00773513|DRUG|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
218897281|NCT00991991|GENETIC|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
218897282|NCT00991991|GENETIC|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
218897283|NCT00991991|GENETIC|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
218897284|NCT00991991|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
218897285|NCT00991991|OTHER|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
218897286|NCT05864222|OTHER|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
218897287|NCT04789915|DRUG|Memantine|Add on treatment with memantine to aripiprazole.
219035969|NCT06372288|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)
219517347|NCT03777137|BEHAVIORAL|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
219517348|NCT03846713|PROCEDURE|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
219517349|NCT03846713|PROCEDURE|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
219611674|NCT06306300|DRUG|Specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.
218897288|NCT04789915|DRUG|Placebo|Placebo add on to aripiprazole
218897289|NCT02436616|DEVICE|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
218897290|NCT00804466|DEVICE|OncoE6|HPV oncoprotein assay
218897291|NCT00804466|DEVICE|EVA System|low-cost colposcope
218897292|NCT02573766|PROCEDURE|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
219035970|NCT06372288|DEVICE|Sham Transcranial Magnetic Stimulation|Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
219035971|NCT05167162|DIAGNOSTIC_TEST|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always"
219035972|NCT05167162|DIAGNOSTIC_TEST|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable"
219035973|NCT05167162|DIAGNOSTIC_TEST|Motor coordination tests|"The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns"
219611675|NCT06306300|DRUG|Non- specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
219611676|NCT02621866|DEVICE|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
218897293|NCT02573766|PROCEDURE|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
218897294|NCT02573766|BEHAVIORAL|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
218897295|NCT02573766|BEHAVIORAL|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
218897296|NCT02021669|DRUG|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
218897297|NCT02021669|DRUG|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
218897298|NCT05300776|DIAGNOSTIC_TEST|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
218897299|NCT05244746|PROCEDURE|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
218897300|NCT04593524|DIETARY_SUPPLEMENT|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
218897301|NCT04593524|OTHER|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
218897302|NCT04170543|DRUG|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
219517350|NCT06203275|DRUG|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
218897303|NCT04170543|DRUG|Placebo|Placebo
219517351|NCT06203275|DRUG|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
219517352|NCT05694091|OTHER|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
219517353|NCT06207409|BEHAVIORAL|PARTS-SUD|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
218897304|NCT04170543|DRUG|Dapagliflozin|Dapagliflozin 10 mg
219517354|NCT02624570|DRUG|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
219517355|NCT05240677|PROCEDURE|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
219517356|NCT01809613|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
218897305|NCT00041379|DRUG|beta alethine|
218897306|NCT02518763|DRUG|Vitamin D3, 100 000 IU weekly, 4 times|
218897307|NCT02518763|BIOLOGICAL|25 OH vitamin D serum concentration measurements|
218897308|NCT05267886|DRUG|Dobutamine|Dobutamine administered according to its clinical dose stage for cardiogenic shock
218897309|NCT05267886|DRUG|Milrinone|Milrinone administered according to its clinical dose stage for cardiogenic shock
218897310|NCT05267886|DRUG|Normal Saline|Normal saline running at a standardized rate
218897311|NCT03593057|OTHER|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
218897312|NCT03593057|OTHER|Control group|Advice on self-care and body awareness.
219517357|NCT01867242|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
219611677|NCT02621866|DEVICE|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of \<500nm, but permits visible light to pass.
219517358|NCT01867242|OTHER|Snus|Winterchill or Robust flavors
219517359|NCT03139968|DEVICE|(sham) radiation absorbing drape (RADPAD®)|
219611678|NCT00000525|DRUG|hydrochlorothiazide|
219611679|NCT00000525|BEHAVIORAL|diet, potassium supplementation|
219611680|NCT00000525|BEHAVIORAL|diet, magnesium supplementation|
219611681|NCT00000525|DRUG|triamterene|
219611682|NCT00000525|DRUG|chlorthalidone|
218897313|NCT03627871|BEHAVIORAL|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
218897314|NCT03627871|BEHAVIORAL|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
219611683|NCT03657797|DRUG|NCX 470|NCX 470 Ophthalmic Solution
219611684|NCT03657797|DRUG|Latanoprost 0.005%|Latanoprost 0.005% Ophthalmic Solution
219611685|NCT05981235|BIOLOGICAL|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
219611686|NCT00118157|OTHER|Laboratory Biomarker Analysis|Correlative studies
219611687|NCT00118157|DRUG|Lapatinib Ditosylate|Given PO
219611688|NCT00118157|DRUG|Tamoxifen Citrate|Given PO
219517360|NCT05521763|BEHAVIORAL|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
218897315|NCT03627871|BEHAVIORAL|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
218897316|NCT03627871|BEHAVIORAL|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
218897317|NCT03627871|BEHAVIORAL|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
218897318|NCT04385186|DRUG|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
218897319|NCT04385186|DRUG|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
219517361|NCT03339349|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
219611689|NCT03685916|OTHER|Control|Plain rice with plain water
219611690|NCT03685916|OTHER|Cumin Rice|Cumin rice with plain water
218897320|NCT00599066|DEVICE|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
218897321|NCT03635749|DRUG|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
219035974|NCT05167162|PROCEDURE|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
219035975|NCT05167162|OTHER|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
218897322|NCT03635749|DRUG|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
218897323|NCT03635749|DRUG|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
218897324|NCT03635749|DRUG|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
218897325|NCT00592488|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
219035976|NCT05957783|OTHER|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
219517362|NCT00218179|OTHER|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
219517363|NCT02324998|DRUG|Olaparib|PARP Inhibitor
219517364|NCT02324998|DRUG|Degarelix|Gonadotrophin releasing hormone blocker
219517365|NCT00034125|DRUG|LY353381|
219517366|NCT00034125|DRUG|tamoxifen|
219611691|NCT03685916|OTHER|Cumin Drink|Cumin drink with plain rice
219611692|NCT03685916|OTHER|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
219611693|NCT03685916|OTHER|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
219611694|NCT03685916|OTHER|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
219611695|NCT03685916|OTHER|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
218897326|NCT01952886|DRUG|Granisetron|
218897327|NCT01952886|DRUG|Ondansetron|
218897328|NCT05809609|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
219035977|NCT03471533|DIETARY_SUPPLEMENT|nutraceutical: experimental product|84 days of consumption
219035978|NCT03471533|DIETARY_SUPPLEMENT|placebo|84 days of consumption
219035979|NCT05264155|BEHAVIORAL|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
219517367|NCT05525195|PROCEDURE|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
219611696|NCT03685916|OTHER|Tamarind Rice|Tamarind rice with plain water
219611697|NCT03685916|OTHER|Tamarind Drink|Tamarind drink with plain rice
219611698|NCT01308203|DRUG|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
218897329|NCT05809609|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
218897330|NCT05367570|BEHAVIORAL|Cross-sectional observational study|The first work package of this project is an explanatory cross-sectional study with no intervention.
218897331|NCT06342817|BEHAVIORAL|online mindfulness based meditation program|Participants in the intervention group will attend 8 weekly online meetings lasting approximately 60 minutes each (generally structured in an initial 10 minutes for questions about the practices, 15-20 minutes of exposition on the central theme of the meeting, 5-10 minutes for class practice, 10-15 minutes for post-practice inquiry, 5 minutes for explanation of the week's informal practice and audios for daily practice). Audio in mp3 of the practice carried out at each meeting will be provided to maintain daily individual practice during the week. An online questionnaire related to weekly practices will also be left at the beginning of each meeting.
219517368|NCT03094910|DIAGNOSTIC_TEST|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
219517369|NCT03094910|DIAGNOSTIC_TEST|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
219517370|NCT03094910|DIAGNOSTIC_TEST|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
219611699|NCT01308203|DRUG|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
218897332|NCT02745834|OTHER|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
218897333|NCT02645292|DEVICE|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
218897334|NCT02645292|DEVICE|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
218897335|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
218897336|NCT05246371|DRUG|Propofol, dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
218897337|NCT05246371|DRUG|Desflurane|Patients will receive maintenance of general anesthesia by desflurane.
218897338|NCT04751318|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
218897339|NCT04751318|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
218897340|NCT00110500|GENETIC|hVEGF-A|
218897341|NCT00774293|DRUG|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
218897342|NCT00774293|DRUG|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
218897343|NCT03890588|OTHER|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
218897344|NCT04648319|DRUG|BMS-936558|BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
218897345|NCT05557344|DRUG|Acetaminophen IV|An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
218897346|NCT05557344|DRUG|Acetaminophen|A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
218897347|NCT04662008|BEHAVIORAL|Tele-coaching|This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
218897348|NCT04662008|BEHAVIORAL|Website|This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
219035980|NCT04544293|DRUG|Molgramostim|Molgramostim 300 µg nebulizer solution
219517371|NCT03094910|DIAGNOSTIC_TEST|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
219035981|NCT04544293|DRUG|Placebo|Matching placebo nebulizer solution
219035982|NCT04544293|DRUG|Molgramostim Open-label|Molgramostim 300 µg nebulizer solution
219035983|NCT05337592|DRUG|BI 1815368 formulation 1|BI 1815368 formulation 1
219035984|NCT05337592|DRUG|Placebo|Placebo
219035985|NCT05337592|DRUG|BI 1815368 formulation 2|BI 1815368 formulation 2
219035986|NCT00329407|DRUG|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
218897349|NCT05122728|OTHER|Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment|"Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)"
218897350|NCT05774938|PROCEDURE|Standard Endovascular aneurysm repair (sEVAR)|Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).
218897351|NCT05774938|PROCEDURE|Complex Endovascular Aneurysm Repair (cEVAR)|Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
218897352|NCT04502563|OTHER|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
218897353|NCT04502563|OTHER|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
218897354|NCT04699383|DRUG|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
218897355|NCT06552650|BEHAVIORAL|Exercise|Four supervised exercise interventions after surgery: One exercise education session per week from postoperative day 5 through 1 month Subsequent home-based exercise: Home-based exercise recommendations from 1 month to 3 months post-surgery
218897356|NCT06552650|OTHER|Usual Care|The full spectrum of patient care practices in which clinicians have the opportunity (which is not necessarily seized) to individualize care
218897357|NCT03642509|DEVICE|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
218897358|NCT03642509|DRUG|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
218897359|NCT04991662|DRUG|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
219517372|NCT03094910|DIAGNOSTIC_TEST|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
219517373|NCT03094910|DIAGNOSTIC_TEST|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
219611700|NCT03262428|OTHER|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
219611701|NCT00929968|BIOLOGICAL|Placebo|
219611702|NCT00929968|BIOLOGICAL|VAK694|
219611703|NCT00929968|DRUG|Fluticasone|
219611704|NCT01224405|DRUG|Docetaxel + LH-RH analogues|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration."
219611705|NCT01224405|DRUG|Docetaxel|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues."
219611706|NCT01224405|DRUG|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced \>50%. Docetaxel treatment will be resumed when the serum PSA will rise by \>50% from the lowest PSA level recorded and will be \>10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
219611707|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
219611708|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
219611709|NCT01090778|DRUG|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
219611710|NCT03920514|DRUG|hCG|Women will be given hCG before or with IUI
219611711|NCT02363543|DEVICE|Hyalomatrix|
219611712|NCT02363543|DEVICE|Integra|
218897360|NCT04991662|DRUG|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
218897361|NCT04991662|DRUG|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
218897362|NCT00214539|PROCEDURE|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
218897363|NCT00214539|DRUG|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
218897364|NCT04494620|DIAGNOSTIC_TEST|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
218897365|NCT02033434|DRUG|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
218897366|NCT05873608|OTHER|Educational video|Testing an educational video
218897367|NCT05873608|OTHER|Interview|Participate in interview
218897368|NCT05873608|OTHER|Observation|Undergo observation
218897369|NCT02306798|DRUG|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
218897370|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
218897371|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
219035987|NCT02374645|DRUG|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219035988|NCT02374645|DRUG|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219035989|NCT00493584|PROCEDURE|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
219611713|NCT04047667|PROCEDURE|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
218897372|NCT01826656|PROCEDURE|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
218897373|NCT01826656|RADIATION|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
218897374|NCT01826656|RADIATION|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
218897375|NCT01826656|RADIATION|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
218897376|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
218897377|NCT05938894|OTHER|online games with various food images|Participant will play a series of online games with various food images.
218897378|NCT05938894|OTHER|online games with images of flowers and songbirds|Participant will play a series of online games with images of flowers and songbirds.
218897379|NCT05684276|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
218897380|NCT05684276|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
218897381|NCT05684276|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
218897382|NCT06665828|DRUG|REGN9533|Administered per the protocol
219035990|NCT00493584|PROCEDURE|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
219035991|NCT03560531|DRUG|ZN-c5|ZN-c5 is a study drug
218897383|NCT06665828|DRUG|Matching Placebo|Administered per the protocol.
219035992|NCT03560531|DRUG|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
219035993|NCT06182644|DIAGNOSTIC_TEST|FAPI PET/CT|The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
219035994|NCT04297137|DIETARY_SUPPLEMENT|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
219035995|NCT01751386|DRUG|Baclofen|
219035996|NCT01751386|OTHER|Placebo|
219035997|NCT00012142|DRUG|temsirolimus|
219035998|NCT05766930|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
219035999|NCT00067678|DRUG|soy protein|
219036000|NCT03543592|DIAGNOSTIC_TEST|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
219036001|NCT01200797|DRUG|SJG-136|Given IV
219036002|NCT01200797|OTHER|laboratory biomarker analysis|Correlative studies
219036003|NCT03048656|OTHER|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
218897384|NCT00748345|DRUG|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
218897385|NCT06805331|BEHAVIORAL|Intervention group(Pelvic Floor Muscle Exercise Training)|The intervention will involve educating participants on pelvic floor muscle exercises, using the health belief model. The goal is to evaluate improvements in incontinence severity, quality of life, and pelvic floor muscle exercise self-efficacy
218897386|NCT06805331|OTHER|control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
218897387|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
219036004|NCT04174911|DRUG|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
219036005|NCT04174911|DRUG|Placebo|sublingual drops
219036006|NCT04681482|DRUG|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
219517374|NCT04068142|OTHER|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
219517375|NCT03301675|OTHER|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
219517376|NCT05736081|DRUG|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
218897388|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
218897389|NCT04659317|DRUG|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
218897390|NCT04659317|DRUG|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
218897391|NCT04674722|DRUG|Injection of 99mTc-NM-02|A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
218897392|NCT04674722|DRUG|Injection of 188Re-NM-02|A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
218897393|NCT05846815|DEVICE|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
218897394|NCT05846815|OTHER|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
218897395|NCT06420323|DEVICE|Treatment with NovoX® Cup|NovoX® Cup treatment
218897396|NCT06420323|DEVICE|Treatment with Omnistrip®|Omnistrip® treatment
218897397|NCT06009094|DRUG|VC005|VC005 group with Local topical application
218897398|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
218897399|NCT03116685|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
218897400|NCT03116685|OTHER|Placebo|Placebo
218897401|NCT01200303|PROCEDURE|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
218897402|NCT02173106|DRUG|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
219036007|NCT03608774|DRUG|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
218897403|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
218897404|NCT06654882|DRUG|TNFi (Tumor Necrosis Factor inhibitor) medication|"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"
218897405|NCT06654882|DRUG|Abatacept|"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"
218897406|NCT06654882|DRUG|Tocilizumab|"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"
218897407|NCT06654882|DRUG|Tofacitinib|"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"
218897408|NCT04166071|DRUG|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
218897409|NCT04166071|DRUG|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
218897410|NCT04232241|DRUG|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
218897411|NCT06611527|DEVICE|PS+PEEP group|Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%
218897412|NCT06611527|DEVICE|CPAP group|Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.
218897413|NCT05404048|OTHER|89Zr-atezolizumab PET-imaging|89Zr-atezolizumab tracer injection + PET/CT-scan
218897414|NCT06623890|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
218897415|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2
218897416|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2
218897417|NCT06431243|DRUG|A group Purinostat Mesylate 6mg/m2|Purinostat Mesylate 6mg/m2 + FS 500mg
218897418|NCT06431243|DRUG|A group Purinostat Mesylate 8.4mg/m2|Purinostat Mesylate 8.4mg/m2 + FS 500mg
218897419|NCT06431243|DRUG|A group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + FS 500mg
218897420|NCT06431243|DRUG|A group Purinostat Mesylate 15 mg/m2|Purinostat Mesylate 15 mg/m2 + FS 500mg
218897421|NCT06431243|DRUG|B group Purinostat Mesylate 6 mg/m2|Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg
218897422|NCT06431243|DRUG|B group Purinostat Mesylate 8.4 mg/m2|Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
218897423|NCT06431243|DRUG|B group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
218897424|NCT06431243|DRUG|B group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg
218897425|NCT02617654|DRUG|Liraglutide|Treatment with liraglutide for 52 weeks
218897426|NCT02617654|DRUG|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
218897427|NCT01857297|BIOLOGICAL|Enzira® vaccine|
218897428|NCT04323072|PROCEDURE|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
218897429|NCT04323072|PROCEDURE|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
218897430|NCT03731091|DRUG|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
218897431|NCT03731091|DRUG|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
218897432|NCT03731091|OTHER|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
218897433|NCT00452790|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
218897434|NCT00452790|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
218897435|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
218897436|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
218897437|NCT02517697|DRUG|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
218897438|NCT02517697|DRUG|Placebo|oral formulation of matching placebo three times daily for 12 weeks
218897439|NCT00882960|DRUG|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
218897440|NCT00882960|DRUG|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
218897441|NCT03492125|DRUG|MS-553|Oral, multiple dose levels
218897442|NCT03492125|DRUG|MS-553|Oral recommended phase 2 dose of MS-553
219611714|NCT06490848|PROCEDURE|Diagnostic cerebral angiography|In transradial access, no preprocedural upper extremity collateral blood supply testing was completed. When the radial access is unsuccessful, it is shifted to ulnar or femoral access. All right arms were secured in the fully supine position to allow access to both radial and ulnar arteries. At the conclusion of radial access procedures, a TR band was applied to close the access. Neurological exams as well as radial artery pulse and pulse oximeter of the right first finger were assessed during and on discharge by trained recovery nurses. Femoral access was performed in a standard manner. After the access (femoral or radial), a cerebral angiogram was performed in a standard manner using appropriate catheters (vertebral, bern, Simmons 2 or 3) according to the access. For the radial access, the patient was slightly sedated.
219611715|NCT01961219|PROCEDURE|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
218897443|NCT03492125|DRUG|acalabrutinib|Oral
218897444|NCT03492125|DRUG|venetoclax|Oral
218897445|NCT03492125|DRUG|Rituximab|IV
218897446|NCT03492125|DRUG|obinutuzumab|IV
218897447|NCT02918357|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
218897448|NCT05075590|DIAGNOSTIC_TEST|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
218897449|NCT05080530|DRUG|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
218897450|NCT03046030|OTHER|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
218897451|NCT03046030|OTHER|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
218897452|NCT03046030|OTHER|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
218897453|NCT03046030|OTHER|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
218897454|NCT01679873|OTHER|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
218897455|NCT06040944|DRUG|antipsychotic drugs inducing hyperprolactinemia|not exposed
218897456|NCT05639257|DRUG|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
218897457|NCT05639257|DRUG|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
218897458|NCT05525650|DRUG|House Dust Mite Extract, Dermatophagoides Farinae|"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
218897459|NCT04231604|BEHAVIORAL|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
218897460|NCT04231604|BEHAVIORAL|Waiting list control|Control group placed on a twelve-week waiting list.
218897461|NCT05371912|DEVICE|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
219611716|NCT01961219|PROCEDURE|Arthroscopic capsular release|Arthroscopic capsular release
219517377|NCT00264810|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
219517378|NCT00264810|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
219517379|NCT06192251|BEHAVIORAL|Lifestyle Medicine|Education and support for lifestyle modification to improve health conditions
219517380|NCT01206842|OTHER|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
219517381|NCT05991739|BEHAVIORAL|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
219517382|NCT05717699|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
219611717|NCT01365819|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
219611718|NCT01365819|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
219611719|NCT00288535|PROCEDURE|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
219517383|NCT05778409|BIOLOGICAL|Cordyceps cicadae extract|500mg/ day for one month
219611720|NCT02453932|DRUG|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
219611721|NCT02453932|DRUG|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
219611722|NCT02453932|DRUG|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
219611723|NCT03045211|DEVICE|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
219611724|NCT03721861|DEVICE|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
218897462|NCT04887753|OTHER|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
218897463|NCT05533424|OTHER|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
219517384|NCT04052867|DRUG|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
218897464|NCT05533424|OTHER|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
218897465|NCT01756404|DRUG|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
218897466|NCT01756404|DRUG|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
218897467|NCT01405612|DRUG|Midazolam|Single oral administration on Day 1 or Day 5
218897468|NCT01405612|DRUG|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
218897469|NCT05396144|DRUG|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
218897470|NCT01060852|BEHAVIORAL|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
218897471|NCT00120965|DEVICE|AutoPulse|Standard device settings
218897472|NCT00120965|OTHER|Manual CPR|Manual CPR
218897473|NCT04505332|PROCEDURE|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
218897474|NCT04393168|COMBINATION_PRODUCT|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
219517385|NCT04052867|DRUG|Normal saline|An equivalent volume of normal saline is given
219517386|NCT02199509|DRUG|Levetiracetam|Anticonvulsant
219611725|NCT03452761|DIETARY_SUPPLEMENT|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
218897475|NCT00079573|BEHAVIORAL|Atkins diet (extremely low carbohydrate)|
218897476|NCT00079573|BEHAVIORAL|Zone diet (low carbohydrate, high protein)|
218897477|NCT00079573|BEHAVIORAL|Ornish diet (very low fat)|
218897478|NCT04623840|OTHER|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
218897479|NCT04623840|DRUG|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
218897480|NCT03867643|BIOLOGICAL|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
218897481|NCT02669992|PROCEDURE|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
218897482|NCT02669992|PROCEDURE|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
218897483|NCT03062293|DEVICE|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
219517387|NCT04018625|BEHAVIORAL|SMART Mom|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
219517388|NCT04018625|BEHAVIORAL|Mama Support|Participants will be enrolled in an 8-week time and attention matched, process-based support group.
219517389|NCT06173245|PROCEDURE|Intravitreal injection of ranibizumab|"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."
219517390|NCT01231061|RADIATION|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
218897484|NCT01284023|OTHER|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
218897485|NCT06407245|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
219517391|NCT01231061|RADIATION|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
219517392|NCT04098536|BEHAVIORAL|Diesel exhaust|Exposure to diesel exhaust fumes
219517393|NCT06313047|DRUG|Doxorubicin|each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
218897486|NCT06407245|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
218897487|NCT01045694|DRUG|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
218897488|NCT01045694|DRUG|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
218897489|NCT01045694|DRUG|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
219517394|NCT00044226|DRUG|ML-04A|
219611726|NCT01629628|DRUG|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
219611727|NCT01629628|DRUG|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~\--------------------------------------------------------------------------------"
219611728|NCT00564642|DRUG|N Acetylcysteine|1200 mg, BD, 2weeks
219611729|NCT06549842|DRUG|Heparin|The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
218897490|NCT02226887|PROCEDURE|MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit."
219036008|NCT03608774|DRUG|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
219036009|NCT03608774|OTHER|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
219036010|NCT03390881|OTHER|Fasting condition|Subjects will fast over the whole experimental period (480 min)
219036011|NCT03390881|OTHER|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
219036012|NCT03390881|OTHER|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
219036013|NCT01177540|DRUG|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
219036014|NCT01177540|DRUG|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
219036015|NCT00360464|DRUG|Azithromycin SR|
219036016|NCT01112852|DRUG|pantoloc 40 mg|pantoloc iv. infusion per day
219036017|NCT01112852|DRUG|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
219036018|NCT06456333|DEVICE|High-density surface electromyography|Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
219036019|NCT00196079|DEVICE|Coronary stent|
219036020|NCT05697887|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
219517395|NCT02093689|DRUG|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
219517396|NCT02093689|DRUG|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
219517397|NCT02093689|DRUG|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
219517398|NCT04094194|OTHER|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
219517399|NCT03309956|DEVICE|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
218897491|NCT02226887|PROCEDURE|NO MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~\- Hospital discharge after verification of normal digestive transit"
218897492|NCT02226887|RADIATION|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
218897493|NCT02226887|RADIATION|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
218897494|NCT02226887|OTHER|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
218897495|NCT03051308|COMBINATION_PRODUCT|NPT and UW Solution|Tissue preservation solutions for transplantation
218897496|NCT03015935|PROCEDURE|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
219517400|NCT03309956|DEVICE|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
219517401|NCT02768298|DRUG|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
219517402|NCT02768298|DRUG|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
219517403|NCT02768298|DRUG|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
219517404|NCT02768298|DRUG|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
219517405|NCT04634409|DRUG|Bamlanivimab|Administered IV.
218897497|NCT03015935|PROCEDURE|Veress entry|First trocar entry will be performed with Veress
218897498|NCT04718493|PROCEDURE|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
219517406|NCT04634409|DRUG|Etesevimab|Administered IV.
219517407|NCT04634409|DRUG|Placebo|Administered IV.
219517408|NCT04634409|DRUG|VIR-7831|Administered IV.
219517409|NCT04634409|DRUG|Bebtelovimab|Administered IV.
219517410|NCT04059211|DIAGNOSTIC_TEST|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
219517411|NCT00260780|BEHAVIORAL|The MISTERS Intervention for Post Jail Release Men|
218897499|NCT04718493|PROCEDURE|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
219036021|NCT01113762|DEVICE|articular surface replacement ASR, DePuy|posterolateral incision
219036022|NCT01113762|DEVICE|ReCap/Magnum modular head, Biomet|posterolateral incision
219517412|NCT01168505|DRUG|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
219517413|NCT01779622|OTHER|Mixed meal|Ingestion of mixed meal
219517414|NCT02078063|DRUG|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
219517415|NCT02078063|DRUG|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
219517416|NCT02929693|DRUG|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
219517417|NCT02929693|DRUG|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
219517418|NCT02929693|DRUG|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
219517419|NCT02518685|DEVICE|TransPyloric Shuttle|
219517420|NCT02518685|DEVICE|Sham procedure|
219036023|NCT01113762|DEVICE|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
219036024|NCT01113762|DEVICE|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
219036025|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
219036026|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
219036027|NCT01880112|DRUG|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
219517421|NCT02518685|BEHAVIORAL|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
219517422|NCT04823000|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
219517423|NCT01611090|DRUG|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
219517424|NCT01611090|DRUG|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
219517425|NCT01611090|DRUG|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
219517426|NCT01611090|DRUG|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
218897500|NCT00284219|DEVICE|Transcranial Magnetic Stimulation 10Hz|3\. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
219036028|NCT02323854|DEVICE|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
219517427|NCT07036250|DRUG|U32 CAR-T|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
219517428|NCT02328781|DEVICE|Drug-eluting stent|
219517429|NCT03559764|BIOLOGICAL|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
219517430|NCT07056036|DEVICE|ActiveTreatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
219517431|NCT07056036|DEVICE|Sham Treatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will se to 5% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
219517432|NCT01640769|PROCEDURE|4D Model guided delivery of cardiac pacing leads|4D model-guided placement of LV and RV leads to optimal myocardial targets, as derived from pre-procedural Cardiac MRI
219517433|NCT01640769|PROCEDURE|Standard CRT lead delivery|Standard lead delivery
219517434|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
219611730|NCT06549842|DEVICE|Terumo Radial Band|Group 1 will receive TR band post cardiac catheterization for radial hemostasis.
219611731|NCT06549842|DEVICE|Vaosband|Group 2 will receive Vasoband post cardiac catheterization for radial hemostasis.
219611732|NCT06381206|DRUG|Silodosin|Selective Alpha Blocker drug
219611733|NCT01858844|OTHER|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
219611734|NCT02989220|OTHER|Positive Reappraisal Coping Intervention|
219611735|NCT00902772|DRUG|Lorazepam|mg, oral dose
219611736|NCT00902772|DRUG|AZD7325|mg, oral dose
218897501|NCT00284219|DEVICE|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
218897502|NCT06399237|DEVICE|Foot Orthoses|Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
218897503|NCT04190732|BEHAVIORAL|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
218897504|NCT05701696|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
218897505|NCT05701696|DIAGNOSTIC_TEST|Widespread pain index|Total the number of painful body areas
218897506|NCT05701696|DIAGNOSTIC_TEST|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
218897507|NCT05701696|OTHER|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
218897508|NCT05701696|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
218897509|NCT05701696|DIAGNOSTIC_TEST|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
218897510|NCT04740216|BEHAVIORAL|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
218897511|NCT04740216|BEHAVIORAL|exercise therapy|the control group performed 20-minute stretching exercises each time.
219036029|NCT02323854|PROCEDURE|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
219036030|NCT01999595|DEVICE|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
219517435|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
219517436|NCT04476732|OTHER|Paraben-free skincare product|Paraben-free lotion will be applied twice a day for one week.
219517437|NCT04476732|OTHER|Paraben-containing skincare product|Paraben-containing lotion will be applied twice a day for one week.
219611737|NCT00902772|DRUG|Placebo|
219611738|NCT03227081|BEHAVIORAL|Sleep Deprivation|Sleep Deprivation
219611739|NCT02223962|BEHAVIORAL|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
219611740|NCT03863782|OTHER|No intervention|No specific intervention. Collection of clinical data
219611741|NCT05342350|OTHER|GALAD Score|GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)
219517438|NCT02358980|DEVICE|KIDNEY therapy|
218897512|NCT05276921|OTHER|ultrasound|Quadriceps and abdominal muscle ultrasonography
218897513|NCT01150097|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
218897514|NCT01150097|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
218897515|NCT01150097|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
218897516|NCT01150097|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
219517439|NCT03457909|DEVICE|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
219517440|NCT00161278|DRUG|Carboplatin|
219517441|NCT00161278|DRUG|Paclitaxel|
219517442|NCT00161278|PROCEDURE|Gene expression profiling (analysis) of tumor samples|
219517443|NCT06776003|PROCEDURE|Vertebroplasty|Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy
218897517|NCT01150097|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
218897518|NCT01150097|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
218897519|NCT02815423|BIOLOGICAL|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
218897520|NCT02815423|BIOLOGICAL|Percutaneous|Percutaneous injection
218897521|NCT03383510|OTHER|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
218897522|NCT03383510|OTHER|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
218897523|NCT03383510|OTHER|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
218897524|NCT03383510|OTHER|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
218897525|NCT04872699|DIAGNOSTIC_TEST|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
219036031|NCT01999595|DEVICE|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
219036032|NCT01999595|DEVICE|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
219036033|NCT01999595|DEVICE|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
219517444|NCT06776003|PROCEDURE|Sham Vertebroplasty|A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
219517445|NCT01298570|DRUG|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
219517446|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
219517447|NCT01298570|DRUG|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
219517448|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
219517449|NCT06178081|OTHER|Periodontal Healthy|Non surgical periodontal therapy
219517450|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 low dose
219517451|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
219517452|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
219517453|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
219517454|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
219517455|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
219517456|NCT01056796|DEVICE|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
219517457|NCT06202716|DRUG|Cadonilimab plus CapeOX chemotherapy|Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
219517458|NCT03633890|DRUG|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
219517459|NCT03633890|DRUG|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
219517460|NCT03111043|DIAGNOSTIC_TEST|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
219517461|NCT03371290|OTHER|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
219517462|NCT03371290|OTHER|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
219517463|NCT01739790|DRUG|N-Acetylcysteine|1800 mg twice daily for 8 weeks
219517464|NCT01739790|DRUG|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
218897526|NCT03483493|BEHAVIORAL|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
218897527|NCT03483493|OTHER|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
218897528|NCT01966913|DRUG|Bevacizumab|
218897529|NCT01966913|DRUG|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
218897530|NCT05238545|OTHER|gluten-free diet|Diet excluding foods containing gluten.
218897531|NCT02919072|DRUG|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
218897532|NCT02919072|DRUG|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
218897533|NCT05286502|DEVICE|fundus photography|color fundus photography
218897534|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
219517465|NCT04354532|PROCEDURE|Laparoscopic Banded Sleeve Gastrectomy|The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
219517466|NCT02122796|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
219517467|NCT03830125|DRUG|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
219517468|NCT03830125|DRUG|Placebo group|Placebo matched to BBT-877, oral capsule
219517469|NCT03830125|DRUG|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
218897535|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
219036034|NCT01999595|DEVICE|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
219517470|NCT01393678|DRUG|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
219517471|NCT01393678|DRUG|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
218897536|NCT04826939|DEVICE|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
219036035|NCT01999595|DEVICE|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
219036036|NCT01969903|DRUG|Precedex injection|
219611742|NCT05440123|OTHER|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
219611743|NCT05481853|PROCEDURE|One Anastomosis Gastric Bypass|
218897537|NCT00256802|DEVICE|MR-angiography, GTN|
218897538|NCT03683953|OTHER|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
218897539|NCT03683953|DRUG|0.9% sodium chloride|0.9% sodium chloride in control group
218897540|NCT06400953|OTHER|Kinetic Brain Exercises and Core Stabilization Exercises|Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.
219036037|NCT04714996|DRUG|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
219036038|NCT04714996|DRUG|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
219517472|NCT04511273|DRUG|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
219517473|NCT00590395|DRUG|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
219517474|NCT02279797|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
219517475|NCT01451762|DRUG|.9 normal saline|.9 normal saline administered before surgery.
219517476|NCT01451762|DRUG|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
219517477|NCT01451762|DRUG|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
219517478|NCT02346097|DEVICE|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
219517479|NCT03986177|BEHAVIORAL|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager"
219517480|NCT01921920|DRUG|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
219036039|NCT04714996|DRUG|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
219036040|NCT02299557|DRUG|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
219036041|NCT02299557|DRUG|Placebo gel|Placebo gel applied intra-anally once daily
219036042|NCT00787774|DRUG|resume raltegravir|resume raltegravir after 16 weeks of stopping
219036043|NCT02820012|OTHER|Scoliosis|Questionnaires, radiography
219036044|NCT01083095|BIOLOGICAL|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
219036045|NCT03193411|DEVICE|Visumax femtosecond laser|
219036046|NCT03193411|DEVICE|Moria M2 microkeratome (MK)|
219036047|NCT02191228|DRUG|Linagliptin - single dose|
219036048|NCT02191228|DRUG|Linagliptin - Multiple dose|
219517481|NCT00907998|DRUG|APL180|
219517482|NCT00907998|DRUG|APL180|
219517483|NCT00907998|DRUG|Placebo|
219517484|NCT01544361|OTHER|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
218897541|NCT06400953|OTHER|Core Stabilization Exercises|Core Stabilization Exercise Program in groups of 8-10 people, for 40 minutes, 2 days a week, for 8 weeks.These exercises included a 5-minute active warm-up, a 30-minute Core Stabilization exercise that included upper and lower extremity movements, and immediately followed by a 5-minute cool-down exercise.The exercises are pilates-based and in the first stage of the program. Movements were performed in standing and sitting positions.Movements were started with 6-8 repetitions, increased by 1-2 repetitions each week, and in the last week, 12-15 repetitions were performed, with contraction times increasing from 5 seconds to 10 seconds. As the exercises progressed from easy to difficult, from simple movements to complex movements, the movements were continued by adding an elastic band and 0.5 kg weight.While advancing the exercise program, the exercises were personalized by taking into account the individual's strain levels.
218897542|NCT02457676|BEHAVIORAL|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
218897543|NCT00549445|DRUG|Azithromycin|250 mg daily
218897544|NCT00549445|DRUG|Placebo|Daily
218897545|NCT02425059|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
218897546|NCT02425059|DEVICE|NanoKnife|
218897547|NCT00748423|DRUG|Nitric Oxide|NO in inhalation for 3 days
218897548|NCT00748423|DRUG|Placebo|Placebo in inhalation for 3 days
218897549|NCT03589027|DRUG|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
218897550|NCT03589027|DRUG|Rilpivirine|Oral ripilvirine 25mg once daily
218897551|NCT03589027|DRUG|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
218897552|NCT03019094|DEVICE|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
218897553|NCT06379776|OTHER|Education through a 3D model|Training through a 3D model of the spine fractures
218897554|NCT06379776|OTHER|Education through a traditional pedagogical support|Training through a traditional pedagogical support
218897555|NCT01047982|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
218897556|NCT01047982|OTHER|folic acid 400 mcg|2 pills a day
218897557|NCT02761382|OTHER|Mindfulness-based psychological treatment|
218897558|NCT02761382|OTHER|Non-specific psychological treatment|
218897559|NCT04958174|DEVICE|web-application|web application for monitoring children's development
218897560|NCT03160820|BIOLOGICAL|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
218897561|NCT03963843|BEHAVIORAL|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
218897562|NCT03963843|OTHER|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
218897563|NCT00791752|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
218897564|NCT00791752|DRUG|Placebo|Placebo
218897565|NCT02458833|BEHAVIORAL|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
218897566|NCT03944512|DRUG|Pravastatin|20 mg Pravastatin taken daily
218897567|NCT03944512|OTHER|Placebo|Identical appearing placebo pill
219517485|NCT01544361|BIOLOGICAL|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
219517486|NCT01544361|BIOLOGICAL|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
219611744|NCT03983525|DIETARY_SUPPLEMENT|Goji berry|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
218897568|NCT04499625|PROCEDURE|Sinus floor elevation|
218897569|NCT04499625|DEVICE|Sinus floor elevation using an ultrasonic device|
218897570|NCT02865655|PROCEDURE|Hysteroscopic|
218897571|NCT02748395|DRUG|Triamcinolone|
218897572|NCT02748395|OTHER|Placebo|
218897573|NCT02748395|DRUG|Lidocaine|
218897574|NCT03053843|DIETARY_SUPPLEMENT|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
219517487|NCT01544361|BIOLOGICAL|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
219517488|NCT01544361|BIOLOGICAL|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
218897575|NCT02380911|OTHER|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
218897576|NCT00890110|BIOLOGICAL|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
218897577|NCT00559247|DRUG|BMS-650032 or Placebo|Oral, Once daily, Single Dose
218897578|NCT01091012|DRUG|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
218897579|NCT01925547|DIETARY_SUPPLEMENT|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
218897580|NCT01925547|DIETARY_SUPPLEMENT|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
218897581|NCT04489472|DIETARY_SUPPLEMENT|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
218897582|NCT04436172|PROCEDURE|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
218897583|NCT03212534|OTHER|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
218897584|NCT01943591|DEVICE|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
218897585|NCT02829580|PROCEDURE|Echocardiography|Measures by Doppler and study of endothelial function
218897586|NCT05641636|DIAGNOSTIC_TEST|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
218897587|NCT05830175|OTHER|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
219036049|NCT03984786|BEHAVIORAL|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
219517489|NCT06008457|DEVICE|Labcorp COVID-19+Flu+RSV Test Home Collection Kit|The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
219517490|NCT02058056|RADIATION|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
219517491|NCT05699356|OTHER|Non Surgical treatment|Non Surgical
219517492|NCT05699356|PROCEDURE|laparoscopic drilling|Surgical intervension
219517493|NCT05699356|BEHAVIORAL|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
219517494|NCT05699356|PROCEDURE|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
219517495|NCT02980887|OTHER|No Intervention|There is no intervention in this observational study
219517496|NCT05387902|DEVICE|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
219517497|NCT05719870|BEHAVIORAL|Educational training|The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
219517498|NCT03378700|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
219517499|NCT03378700|OTHER|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
219517500|NCT02495324|DRUG|Placebo|2 weeks of placebo PO daily
219517501|NCT02495324|DRUG|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
219517502|NCT02495324|DRUG|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
219517503|NCT02495324|DRUG|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
219517504|NCT03467568|DIETARY_SUPPLEMENT|Sodium Chloride|300mg sodium chloride will be provided in a capsule
219517505|NCT03467568|OTHER|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
219517506|NCT03467568|DIETARY_SUPPLEMENT|Water|Twice during the morning a drink of 150ml of water will be consumed
219517507|NCT03467568|BIOLOGICAL|No water consumed|No water will be consumed during the monring
219611745|NCT03983525|DIETARY_SUPPLEMENT|Lutein + zeaxanthin supplementation|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
219611746|NCT04948346|OTHER|diagnosed with ALS|diagnosed with ALS
219611747|NCT05526638|RADIATION|ultraviolet phototherapy|thrice weekly sessions of ultraviolet phototherapy
218897588|NCT05830175|OTHER|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
218897589|NCT03662594|OTHER|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
218897590|NCT02566694|PROCEDURE|Implant|orthopaedic implant
218897591|NCT02168114|OTHER|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
218897592|NCT02168114|PROCEDURE|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
218897593|NCT04957797|PROCEDURE|round tunnel|reamed with round tunnel
218897594|NCT04957797|PROCEDURE|flat tunnel|reamed with flat tunnel
219036050|NCT03984786|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
219036051|NCT03984786|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
219036052|NCT04052542|BEHAVIORAL|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
219517508|NCT00139321|DEVICE|Force platform and electromyography|
219517509|NCT03913000|DRUG|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
219611748|NCT00100672|DRUG|LErafAON-ETU|
219611749|NCT02760004|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"* Access to MCPAP for Moms~* PRogram In Support of Moms Toolkit with Stepped Care Algorithms~* Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~* Customization of depression screening for each practice~* Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~* Employ psychoeducation and Motivational Interviewing to engage patients with depression~* medical assistant champion and psychiatrist contact bi-weekly to review cases~* Stepped care treatment to depression screening/assessment"
219517510|NCT00502775|DRUG|fluticasone furoate, fexofenadine|
219517511|NCT06237075|DEVICE|transcranial direct current stimulation|2-milliamp stimulation for 5\~15 min
219517512|NCT02127606|DEVICE|Vibration with tilt-table standing|
219517513|NCT06444074|BEHAVIORAL|Patient Activation through Conversations (PACT) Program|Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
219517514|NCT06444074|BEHAVIORAL|Usual Care|Routine Chronic Disease care
219517515|NCT04483700|DRUG|Filgotinib|Tablets administered orally once daily
219517516|NCT04483700|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
219517517|NCT05611034|DRUG|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
219517518|NCT03012477|DRUG|Cisplatin|chemotherapy
219517519|NCT03012477|DRUG|AZD1775|Wee1 tyrosine kinase inhibitor
219517520|NCT05450770|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
219517521|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
219517522|NCT01208480|DRUG|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
218897595|NCT04437485|BEHAVIORAL|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
218897596|NCT04437485|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
218897597|NCT04437485|DRUG|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
218897598|NCT04437485|OTHER|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
218897599|NCT04049487|OTHER|Exercise|Both groups will participate in group exercise as previously described
218897600|NCT02954107|OTHER|MRI|
218897601|NCT02954107|OTHER|24h-EEG + video|
218897602|NCT02954107|OTHER|Neuropsychological tests|
218897603|NCT04533724|DRUG|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
218897604|NCT03303326|BEHAVIORAL|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
218897605|NCT02182323|DRUG|BI 201335 NA|
218897606|NCT02182323|DRUG|Placebo solution|
218897607|NCT04260893|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
218897608|NCT00428766|DRUG|MORAb-003|
218897609|NCT02289495|DRUG|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
218897610|NCT02289495|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
218897611|NCT02289495|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
218897612|NCT05244616|OTHER|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
218897613|NCT02719171|DRUG|risankizumab|Risankizumab administered by SC injection
218897614|NCT02719171|DRUG|placebo for risankizumab|Placebo for risankizumab administered by SC injection
218897615|NCT02614729|OTHER|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
218897616|NCT02614729|OTHER|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
218897617|NCT02614729|OTHER|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
219517523|NCT06370663|RADIATION|Radiotherapy|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
219517524|NCT06370663|DRUG|HAIC (GEMOX)|Hepatic Arterial Infusion Chemotherapy (GEMOX)
218897618|NCT02614729|OTHER|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
219517525|NCT06370663|DRUG|Chemotherapy|Chemotherapy (Gesitabine)
219517526|NCT00287118|DRUG|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
219611750|NCT02760004|BEHAVIORAL|MCPAP for Moms|"* 30-60 minute presentation on perinatal depression~* Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~* Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~* Access to assessment and treatment protocols in Provider Toolkit~* Resource provision/referrals"
219611751|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
218897619|NCT05822882|PROCEDURE|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
219517527|NCT06799117|OTHER|EMBED CDS|"EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.~Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)"
219611752|NCT06961864|BEHAVIORAL|Visual Adaptation|Presentation of visual stimuli to quantify the appearance of visual snow or its effects in the visual system of the brain.
219611753|NCT06961864|BEHAVIORAL|Assessments and Questionnaires|Administration of clinical assessments and questionnaires to gather information about visual and mental symptoms, cognitive, and sensory function.
219611754|NCT06961864|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|7 tesla fMRI data will be acquired during visual paradigms designed to measure neural responses with and without adaptation.
219611755|NCT06961864|DEVICE|Magnetic Resonance Imaging (MRS)|7 tesla MRS data will be acquired to quantify the concentrations of different brain chemicals in brain regions including visual cortex.
219611756|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
218897620|NCT02963454|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
218897621|NCT02963454|DRUG|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
218897622|NCT02963454|DRUG|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
218897623|NCT05927038|OTHER|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
218897624|NCT05927038|OTHER|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
218897625|NCT01013129|GENETIC|DNA analysis|saliva samples will be collected from men (probands) who join the study.
218897626|NCT01013129|GENETIC|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
218897627|NCT01013129|OTHER|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
218897628|NCT01013129|OTHER|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
218897629|NCT01013129|OTHER|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
218897630|NCT01013129|PROCEDURE|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
218897631|NCT01013129|PROCEDURE|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
218897632|NCT06133335|OTHER|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
219611757|NCT00128401|DRUG|D-Cycloserine|
218897633|NCT00333021|DRUG|Fondaparinux sodium|
218897634|NCT00333021|DRUG|GSK576428|
218897635|NCT02828371|DEVICE|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
218897636|NCT02828371|OTHER|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
218897637|NCT00908453|DRUG|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
218897638|NCT06079385|OTHER|Acupuncture treatment|Acupuncture treatment with needles
218897639|NCT03921827|DEVICE|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
218897640|NCT02796677|DRUG|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
219611758|NCT00128401|DRUG|Placebo|
219611759|NCT05193955|OTHER|Laughter Yoga|Laughter yoga is one of the methods that is among the complementary therapy and supportive care practices in the world and is used increasingly. Laughter yoga is a non-invasive and non-pharmacological method that combines unconditional laughter with yoga breathing techniques. In laughter yoga, one can laugh without being humorous, joking, or funny. Laughter is simulated by starting out as a physical exercise and making eye contact with other members of the group and playing games with them. The body cannot distinguish between real and unreal laughter and laughter begins.
218897641|NCT02796677|DRUG|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
218897642|NCT02796677|DRUG|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
219517528|NCT06799117|OTHER|Nurse prompt to complete COWS|Nurse prompt to complete COWS
219517529|NCT06799117|OTHER|Provider Prompt|Provider Prompt to use EMBED: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community. Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)
219517530|NCT06799117|OTHER|Patient facing materials|Provider prompt to give patient customized discharge instructions directing patient to resources matched to their needs.
218897643|NCT02796677|OTHER|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
218897644|NCT02796677|DRUG|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
219517531|NCT06799117|OTHER|Optimized EMBED|CDS following Optimization Phase, Stage 2: Rapid serialized testing
219611760|NCT04464850|DRUG|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose"
219611761|NCT04464850|DRUG|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate"
218897645|NCT02796677|OTHER|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
218897646|NCT04921566|DRUG|Torasemide tablet 10 mg|Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.
219611762|NCT00544635|DEVICE|no intervention|no intervention
219611763|NCT00544635|DEVICE|light|scars will be treated with light
219611764|NCT05944471|OTHER|Providing breastfeeding support with Telehealth|After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
219611765|NCT00276484|DRUG|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
219611766|NCT00276484|DRUG|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
218897647|NCT04921566|DRUG|Toradiur® tablet 10 mg|Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
218897648|NCT01103765|PROCEDURE|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
218897649|NCT01103765|PROCEDURE|stent deployment without post-dilatation|stent deployment without systematic post dilatation
218897650|NCT01532947|PROCEDURE|post placement|placement of an endocanalar post
218897651|NCT03372785|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
219517532|NCT06799117|OTHER|Name of Intervention|Intervention to be informed by results during Evaluation Phase, Stage 1 and will involve refinement of user interface and workflows for the EMBED CDS: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.
219517533|NCT03958032|OTHER|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
219517534|NCT00098488|DRUG|tanespimycin|Given IV
219517535|NCT00098488|BIOLOGICAL|rituximab|Given IV
219517536|NCT04471207|DEVICE|Therapist Guided Prolonged Exposure with BioWare Device|"Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
219517537|NCT04471207|DEVICE|Record Only Prolonged Exposure with BioWare Device|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
219517538|NCT01817556|DRUG|Stillen Tab.|
219517539|NCT01817556|DRUG|Mucosta Tab.|
219517540|NCT05334771|DEVICE|Dual band pure tune audiometer|Orbiter 922 Tympanometry
219517541|NCT06327815|DRUG|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets|10 mg Dapagliflozin/1000 mg Metformin HCl extended-release
219517542|NCT06327815|DRUG|Dapagliflozin tablets and Metformin HCl extended-release tablets|Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
219517543|NCT02222428|DRUG|BI 1744 CL/BI 54903 XX FDC|
219517544|NCT02222428|DRUG|BI 54903 XX|
219517545|NCT02222428|DRUG|BI 1744 CL|
219517546|NCT06365645|BEHAVIORAL|M.Bapp|Please see experimental group description.
219517547|NCT06365645|BEHAVIORAL|App-based parenting education|Please see active comparator group description.
219611767|NCT00276484|DRUG|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
219611768|NCT03333993|OTHER|Pilates Exercise|The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.
219611769|NCT03333993|OTHER|Home exercises|Exercises for upper limbs according to the institutional routine.
219611770|NCT06025071|DRUG|colchicine|Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
219611771|NCT05990829|DRUG|Ozurdex|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
218897652|NCT03372785|DEVICE|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
218897653|NCT00515151|DRUG|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
218897654|NCT00515151|DRUG|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
219517548|NCT02538445|OTHER|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
219517549|NCT02538445|OTHER|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
219517550|NCT02538445|OTHER|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
219517551|NCT02538445|OTHER|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
219517552|NCT03230851|DRUG|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
219517553|NCT03230851|DRUG|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
219517554|NCT03230851|DRUG|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
219517555|NCT03230851|DRUG|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
219517556|NCT03230851|DRUG|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
219517557|NCT03230851|DRUG|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
219517558|NCT03230851|DRUG|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
219517559|NCT01667783|PROCEDURE|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
218897655|NCT04147689|DEVICE|DESIRIAL® PLUS|"DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study."
218897656|NCT01319669|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
218897657|NCT00961181|DEVICE|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
218897658|NCT01045967|DRUG|Lansoprazole|30 mg delayed-release Capsule
219517560|NCT01667783|BEHAVIORAL|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
218897659|NCT01045967|DRUG|Prevacid®|30 mg delayed-release Capsule
218897660|NCT04914780|BEHAVIORAL|Education|Education intervention with mobile application for 4 weeks
218897661|NCT01525836|DRUG|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 29th day)
218897662|NCT01525836|DRUG|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
218897663|NCT03314493|DRUG|Spironolactone 25Mg Tablet|Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
218897664|NCT05582486|BEHAVIORAL|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
218897665|NCT01804478|BEHAVIORAL|Mild pneumatic compression|
218897666|NCT01248195|DRUG|Amisulpride open label|4-week open label amisulpride treatment
218897667|NCT01248195|DRUG|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
218897668|NCT01248195|DRUG|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
218897669|NCT01248195|DRUG|12-week clozapine open-label treatment|12-week clozapine open-label treatment
218897670|NCT01248195|BEHAVIORAL|Psychosocial intervention|Psychosocial intervention
218897671|NCT04541407|DRUG|Temozolomide plus Osimertinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
218897672|NCT04541407|DRUG|Temozolomide plus Lorlatinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
218897673|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
218897674|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
218897675|NCT04412577|DRUG|TQB3473|TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
219517561|NCT01667783|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
219611772|NCT05990829|DRUG|Aflibercept|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
219611773|NCT00190762|DRUG|Pemetrexed|
219611774|NCT06282939|DEVICE|OPTIMA and OPTIMAX Coils manufactured by Balt USA|\*Percentage from protocol
218897676|NCT01138423|DRUG|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
219517562|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
219517563|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluzone)|
219517564|NCT00769106|BIOLOGICAL|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
219517565|NCT00561730|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
219517566|NCT01210729|DEVICE|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
219517567|NCT05733572|DRUG|CHF6467|drug eyedrops
219517568|NCT05733572|DRUG|Placebo|placebo eyedrops
219517569|NCT05663281|DIAGNOSTIC_TEST|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
219517570|NCT00678366|PROCEDURE|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
219517571|NCT00678366|PROCEDURE|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
219517572|NCT06172842|DIAGNOSTIC_TEST|Echocardiography|Multi-modality echocardiography
219517573|NCT05975970|DEVICE|MyoTrain AR|MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.
219517574|NCT05975970|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
218897677|NCT01138423|DRUG|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
218897678|NCT01138423|DRUG|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
218897679|NCT01138423|DRUG|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
219517575|NCT00253032|DEVICE|PRIMA|
219517576|NCT04799600|OTHER|BRESCİA-COVİD Respiratory Severity Scale|KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
219517577|NCT01385033|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
219517578|NCT05209945|PROCEDURE|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
219611775|NCT00974116|BEHAVIORAL|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
219611776|NCT00974116|BEHAVIORAL|Control Group|No intervention
219611777|NCT05293119|DRUG|JAK-2 inhibitor|In this trial, one group will receive the tofacitinib 5 mg twice daily
219517579|NCT02659722|DEVICE|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
218897680|NCT01138423|DRUG|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
218897681|NCT05348902|OTHER|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
218897682|NCT03189186|DRUG|Pembrolizumab Injection [Keytruda]|Same as arm description
219517580|NCT02906709|DRUG|Omarigliptin|Omarigliptin, 25 mg orally once weekly
219517581|NCT02906709|DRUG|Placebo|Placebo to omarigliptin orally once weekly
219517582|NCT02906709|BIOLOGICAL|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
219517583|NCT00017784|DRUG|Valganciclovir|
219611778|NCT05293119|DRUG|Topical corticosteroid|Mometasone furoate 0.1% ointment once daily
219611779|NCT05032300|DEVICE|Focused shockwave|Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
219611780|NCT05032300|OTHER|Home therapy|Stretching and ice massage
219611781|NCT02659423|BEHAVIORAL|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
218897683|NCT03189186|PROCEDURE|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
218897684|NCT03189186|PROCEDURE|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
218897685|NCT03327909|BEHAVIORAL|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
218897686|NCT02875379|PROCEDURE|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
218897687|NCT01414894|OTHER|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
218897688|NCT01414894|OTHER|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
218897689|NCT04895254|DEVICE|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
218897690|NCT04895254|PROCEDURE|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
218897691|NCT00481819|DRUG|FK506MR|oral
218897692|NCT00481819|DRUG|Prograf|oral
218897693|NCT00481819|DRUG|Mycophenolate Mofetil|oral
218897694|NCT00481819|DRUG|Methylprednisolone|oral
218897695|NCT00481819|DRUG|Prednisolone|oral
218897696|NCT05077930|BIOLOGICAL|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
218897697|NCT05077930|DRUG|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
218897698|NCT01379716|OTHER|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
218897699|NCT00963963|BEHAVIORAL|Healthy Futures parent education|Multi-year audio CD parent education
218897700|NCT01982734|DIETARY_SUPPLEMENT|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
218897701|NCT04929535|DRUG|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
218897702|NCT04059510|PROCEDURE|rectovaginal swab|Self taken rectal and vaginal swab
218897703|NCT04059510|PROCEDURE|pregnancy test|Urine pregnancy test
218897704|NCT04059510|PROCEDURE|Menstrual cup|Menstrual cup vaginal fluid collection
218897705|NCT04059510|PROCEDURE|Blood test|Venous blood sample
218897706|NCT04059510|OTHER|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
218897707|NCT06527898|DRUG|hypofractionated radiotherapy with immunotherapy|hypofractionated radiotherapy with Adebrelimab consolidation
218897708|NCT03471247|DEVICE|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
218897709|NCT03471247|OTHER|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
218897710|NCT00035789|DRUG|Entecavir|
218897711|NCT02700308|DEVICE|Kyphoplasty|Placement and inflation of balloon prior to cement injection
218897712|NCT02700308|DEVICE|Conventional vertebroplasty|Conventional vertebroplasty
218897713|NCT02372877|DEVICE|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
218897714|NCT03018444|DRUG|Atorvastatin|Atorvastatin tablet
218897715|NCT03018444|OTHER|Placebo|Placebo tablet
218897716|NCT01982123|DIAGNOSTIC_TEST|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
218897717|NCT01982123|PROCEDURE|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
218897718|NCT01982123|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
218897719|NCT01982123|DRUG|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
218897720|NCT02046707|OTHER|initial evaluation|
218897721|NCT02046707|OTHER|Period of cardiac rehabilitation|
218897722|NCT02046707|OTHER|final evaluation|
218897723|NCT02046707|OTHER|Concentric and eccentric exercise sessions|
218897724|NCT00760682|PROCEDURE|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
218897725|NCT00183131|BEHAVIORAL|Brief Personalized Feedback|
218897726|NCT04363879|PROCEDURE|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
219517584|NCT04765709|COMBINATION_PRODUCT|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
219517585|NCT04765709|COMBINATION_PRODUCT|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
219517586|NCT04765709|BIOLOGICAL|durvalumab|Consolidation treatment with durvalumab
219517587|NCT06066502|OTHER|Precision ventilation|The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.
218897727|NCT04363879|PROCEDURE|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
218897728|NCT03138421|DRUG|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
218897729|NCT03138421|DRUG|Placebo|Matching placebo
218897730|NCT01822197|DEVICE|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
218897731|NCT01896024|BEHAVIORAL|Psychiatric Management|
218897732|NCT01896024|BEHAVIORAL|Motive-oriented therapeutic relationship/Plan Analysis|
218897733|NCT03999515|DRUG|Abiraterone Acetate|Given PO
219517588|NCT06066502|OTHER|Guided usual care ventilation|The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
218897734|NCT03999515|DRUG|Enzalutamide|Given PO
219517589|NCT05649176|OTHER|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
219517590|NCT05649176|OTHER|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
219517591|NCT00726960|DRUG|aprepitant|Oral, 125 mg once daily for one week
219517592|NCT00726960|DRUG|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
219517593|NCT00000880|DRUG|Cyclosporine|
219517594|NCT05897580|BEHAVIORAL|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
219611782|NCT02659423|BEHAVIORAL|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
219611783|NCT02659423|BEHAVIORAL|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
219611784|NCT03926299|DEVICE|FotonaSmooth SP® Spectro laser device|dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
219611785|NCT03926299|DRUG|Clobetasol propionate 0.05% ointment|6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
219611786|NCT03923140|DRUG|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
219611787|NCT06346301|BEHAVIORAL|Imagery rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 90 minutes.
219611788|NCT06582069|DEVICE|Bleaching|Bleaching
219611789|NCT00995917|OTHER|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
219611790|NCT00995917|OTHER|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
219611791|NCT04136314|BEHAVIORAL|Decision-Framed Survey|Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.
219611792|NCT01626690|DEVICE|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
219611793|NCT01626690|DEVICE|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
219611794|NCT04688671|DRUG|ETX-018810|Study Drug
219611795|NCT04688671|DRUG|Placebo|Matching Placebo
219611796|NCT01807403|PROCEDURE|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
219611797|NCT00202371|PROCEDURE|Red Blood Cell transfusion|
219611798|NCT02969252|DRUG|Rifamycin SV-MMX® 600|
219611799|NCT02251093|DRUG|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
219611800|NCT02251093|DRUG|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
219611801|NCT06551532|OTHER|Multicomponent program|Lumbopelvic training (foam rolling, manual therapy, mobility, posture, and strength training) and sprint technique program.
219611802|NCT01605851|DEVICE|Closure, Foramen Ovale|
219611803|NCT02009189|DRUG|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
219611804|NCT02009189|DRUG|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
219611805|NCT04055740|DEVICE|IVUS Imaging|IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.
219611806|NCT01525329|DRUG|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
219611807|NCT05957601|OTHER|No intervention was made as it was a descriptive epidemiological study.|No intervention was made as it was a descriptive epidemiological study.
218897735|NCT03999515|DRUG|Erdafitinib|Given PO
218897736|NCT05448040|PROCEDURE|Socket preservation|Tooth extraction and preservation with a biomaterial
218897737|NCT01963195|DRUG|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
219611808|NCT01708577|DEVICE|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
218897738|NCT00175513|DRUG|Valacyclovir (Valtrex)|
219517595|NCT05897580|BEHAVIORAL|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
219517596|NCT05057715|BIOLOGICAL|VCN-01|Intravenous administration of VCN-01
219517597|NCT05057715|BIOLOGICAL|huCART-meso Cells|Intravenous administration of huCART-meso cells
219517598|NCT05478226|OTHER|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
219517599|NCT05227820|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
219517600|NCT06173336|PROCEDURE|gastric per-oral endoscopic myotomy (G-POEM)|Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
219517601|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
219517602|NCT03714165|DIAGNOSTIC_TEST|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
219517603|NCT04860492|DIETARY_SUPPLEMENT|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
219517604|NCT03818048|DRUG|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
219517605|NCT03818048|DRUG|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
219517606|NCT06254248|DRUG|Systemic therapy|"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."
219517607|NCT00763022|DRUG|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
219517608|NCT00763022|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
219517609|NCT00763022|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
218897739|NCT01132807|BIOLOGICAL|Bleomycin Sulfate|Given IV
218897740|NCT01132807|DRUG|Doxorubicin Hydrochloride|Given IV
219517610|NCT00012857|DRUG|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
219517611|NCT03273322|DRUG|Rivaroxaban 10 mg qd|10mg qd
219517612|NCT03273322|DRUG|Rivaroxaban 15 mg qd|15mg qd
218897741|NCT01132807|DRUG|Procarbazine Hydrochloride|Given PO
218897742|NCT01132807|DRUG|Vinblastine Sulfate|Given IV
218897743|NCT01132807|DRUG|Dacarbazine|Given IV
218897744|NCT01132807|DRUG|Cyclophosphamide|Given IV
218897745|NCT01132807|DRUG|Etoposide phosphate|Given IV
218897746|NCT01132807|DRUG|prednisone|Given PO
218897747|NCT01132807|DRUG|Radiation Therapy|Undergo radiation therapy
218897748|NCT01132807|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
218897749|NCT01132807|PROCEDURE|computed tomography|Undergo FDG PET/CT
218897750|NCT01132807|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
218897751|NCT03326804|DEVICE|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
218897752|NCT05408962|OTHER|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
218897753|NCT00955214|DEVICE|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
218897754|NCT05625984|DEVICE|Fascigel|The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
219517613|NCT03273322|DRUG|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
219517614|NCT00920140|DRUG|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
219517615|NCT00920140|DRUG|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
219517616|NCT04428567|BEHAVIORAL|Dual-Task Treadmill exercise + Cognitive Training|The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
219517617|NCT00048646|DRUG|IV Progesterone|
219517618|NCT00825708|DEVICE|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
219517619|NCT00825708|DEVICE|shamTMS|sham TMS session
219517620|NCT03215108|DEVICE|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
219517621|NCT05368623|DIAGNOSTIC_TEST|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
219517622|NCT05368623|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
218897755|NCT02134223|BEHAVIORAL|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
218897756|NCT02134223|OTHER|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
218897757|NCT04985929|DRUG|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
219517623|NCT05368623|DRUG|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
219517624|NCT03876613|BEHAVIORAL|Different music types|the type of music that reduces anxiety best and most effectively.
219036053|NCT04052542|BEHAVIORAL|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
219036054|NCT04052542|BEHAVIORAL|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
219517625|NCT06484218|PROCEDURE|conventional endodontic treatment|The conventional access cavity was prepared under the microscope through the incisal edge as this approach facilitates straight-line access. A high-speed contra-angle handpiece, associated with a long surgical bur 010 (Meisinger, CO, USA), was used until the dentin was exposed, which is in general 3 to 4 millimeters from the incisal edge. Then, the ultrasonic tip ED5 (woodpecker-DTE, Guilin, China) was marked with a stopper according to the calcification level viewed on the preoperative CBCT and then used gently at the stopper level until the canal was found.
219611809|NCT00150605|DRUG|Extended-release carbamazepine|
218897758|NCT04985929|DRUG|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
219036055|NCT02956733|PROCEDURE|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
219036056|NCT02956733|PROCEDURE|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
219036057|NCT02665416|DRUG|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
219036058|NCT02665416|DRUG|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
219036059|NCT02665416|DRUG|Bevacizumab|Bevacizumab will be administered via IV infusion.
219036060|NCT04785274|DEVICE|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
219036061|NCT02071524|DRUG|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
219036062|NCT02071524|DRUG|Cristalloid administration|Only Ringer Lactate administration
219036063|NCT06215963|DEVICE|App for Independence-O (A4i-O)|A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
219036064|NCT03718442|DEVICE|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
219611810|NCT05383183|DRUG|Choline Alfoscerate 400mg|Oral administration
219611811|NCT05383183|DRUG|Placebo|Oral administration
218897759|NCT00178477|PROCEDURE|MRI with breath-holding|Breath holding for diminished tumor motion.
218897760|NCT06381934|OTHER|Standard Care|Standard diagnosis and therapy procedures at physician's discretion.
219611812|NCT06035692|DRUG|Ropivacaine|According to the results of the preliminary experiment, the BPB group was given ultrasound-guided BPB with 0.15% ropivacaine 20ml.The ropivacaine concentration was the 90% minimum effective concentration(MEC90) for preventing vasospasm during operation.
219611813|NCT02038010|DRUG|PI3K inhibitor BYL719|Given PO
219611814|NCT02038010|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
219611815|NCT02038010|OTHER|pharmacological study|Correlative studies
219611816|NCT02038010|OTHER|laboratory biomarker analysis|Optional correlative studies
219611817|NCT02000726|DRUG|Placebo|
219611818|NCT02000726|DRUG|Citalopram|
219611819|NCT02000726|DRUG|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
219611820|NCT01856725|PROCEDURE|Hemodynamic measurements for CRT device programming|
219611821|NCT01856725|DEVICE|CRT device implant with MultiPoint Pacing|
219517626|NCT06484218|PROCEDURE|Guided endodontic treatment|In all cases, digital and clinical protocols were followed according to the method reported by Zehnder et al. and Connert et al. The guide was replaced, and the access cavity precisely drilled using the EG6 drill, mounted on a low-speed contra-angle handpiece. With every 3 mm of progression, the cavity was rinsed, and the head of the bur was cleaned until reaching the canal. The irrigation was done to avoid overheating the dentine and the accumulation of dentine debris
219036065|NCT01802658|DRUG|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
219036066|NCT01802658|DRUG|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
219036067|NCT01886807|DEVICE|TrueView PCD Video Laryngoscope|
218897761|NCT06381934|OTHER|aSID/ChU Guided Therapy|"Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization."
218897762|NCT05583487|OTHER|Nurse-led progressive mobility protocol|The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.
218897763|NCT05583487|OTHER|Standard of Care|For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
218897764|NCT06173583|DIAGNOSTIC_TEST|Detection/screening|Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
219204045|NCT06988254|OTHER|Animation-based breathing therapy|The animation-based breathing therapy includes breathing exercises for children, such as lion, crab, and rainbow breathing. The intervention will continue for six weeks (two sessions per day, five days per week).
219517627|NCT01124149|DRUG|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
219517628|NCT06256536|DRUG|GZR18|0.6 mg-30 mg
219517629|NCT06256536|OTHER|Placebo|administered the same volume as GZR18
219517630|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
218897765|NCT02471235|BEHAVIORAL|Physiotherapy|Pulmonary rehabilitation
218897766|NCT03373929|DEVICE|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
218897767|NCT03373929|DEVICE|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
219517631|NCT00977106|DRUG|placebo|single iv infusion
219517632|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
219036068|NCT01623596|DRUG|Fingolimod|
219036069|NCT01623596|DRUG|Disease Modifying therapy|
219036070|NCT03119415|BEHAVIORAL|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
219036071|NCT01070316|DRUG|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
219204046|NCT06990360|DIAGNOSTIC_TEST|CBCT Scanning|The Styrofoam mandibles were scanned using CBCT, which was performed for each mandible pre-operatively, the raw DICOM data set obtained from the CBCT scanning were imported to a special third-party software\* for secondary reconstruction.
219204047|NCT04242992|BEHAVIORAL|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
219517633|NCT03913806|DRUG|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
219517634|NCT01278849|DRUG|ASA404|
219611822|NCT02414958|DRUG|Empagliflozin|
219611823|NCT02414958|DRUG|Empagliflozin|
219611824|NCT02414958|DRUG|Placebo|
218897768|NCT04467086|DRUG|Propranolol Hydrochloride|"Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min."
219611825|NCT03524443|BEHAVIORAL|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
218897769|NCT02602093|PROCEDURE|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
218897770|NCT02602093|PROCEDURE|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
218897771|NCT00896298|DRUG|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
218897772|NCT00896298|DRUG|Placebo|Sugar pill
218897773|NCT01544920|BIOLOGICAL|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
219204048|NCT04242992|OTHER|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
218897774|NCT01544920|DRUG|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
218897775|NCT01544920|DRUG|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
218897776|NCT01454986|DRUG|ALXN1007|Single dose, IV
218897777|NCT01454986|OTHER|Placebo|Single dose, IV
218897778|NCT00466440|DRUG|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
218897779|NCT00466440|DRUG|placebo|Loading dose, then po QD until unblinding
218897780|NCT00466440|DRUG|docetaxel|75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
218897781|NCT00466440|DRUG|prednisone|5 mg po BID, six 21-day cycles
219204049|NCT06989177|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
219204050|NCT06989177|BEHAVIORAL|Energy-restricted nutritional and lifestyle intervention|Participants will receive dietary advice, behavioral guidance and nutritional and lifestyle education by dietitian and physicians. App-connected wearable devices will be utilized to monitor their dietary intakes and App-connected scale will be used to monitor their weight changes during interventions.
219204051|NCT06989177|DIETARY_SUPPLEMENT|Placebo|Participants will receive one bag (2 g; 1 × 10¹² CFU) daily of LC-19.
219204052|NCT06989177|DIETARY_SUPPLEMENT|Probiotic|participants will receive daily one bag of LC-19 (10\^12 cfu/bag).
219611826|NCT03786588|OTHER|Observation|The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
219611827|NCT00923741|DRUG|Talactoferrin|
219611828|NCT00923741|PROCEDURE|Apheresis|
218897782|NCT02935530|DRUG|s-LMWH|2125KU, subcutaneous injection of 5-10 days
218897783|NCT02935530|DRUG|LMWH|4250KU, subcutaneous injection of 5-10 days
218897784|NCT02935530|DRUG|Argatroban|20mg, injection for 5-10 days
218897785|NCT06262308|BEHAVIORAL|Psychological intervention along Cognitive Behavioural Therapy principles|Women who have PPROM will be offered a series of 6 sessions with a Clinical Psychologist
219204053|NCT06989177|DRUG|semaglutide|Participants will receive prescibed semaglutide therapy
219204054|NCT06990919|OTHER|Saliva collection|Pre-operative saliva collected before the full mouth treatment under general anesthesia while, post-operative saliva collected at 1-month follow-up after general anesthesia.
219204055|NCT06021769|OTHER|Observational only|No intervention
219204056|NCT06782035|DEVICE|Ora-Aid-Oral Wound Dressing|Intended as a physical barrier for temporary protection of oral mucosal tissue and to provide pain relief. This product is a non-eugenol protective material applied to intraoral wounds. Ora-Aid is a new concept of pasting intra-oral patch to protect the affected area such as post implant, extraction, orthodontic, and ulcers. This new concept of pasting intra-oral wound dressing is designed to protect the affected area and aid natural healing.
219204057|NCT06782035|BIOLOGICAL|Platelet rich fibrin|"It has been reported that the use of Platelet-Rich Fibrin (PRF) to cover palatal wounds accelerates healing and reduces postoperative morbidity. Studies have demonstrated that PRF supports key processes in wound healing, such as immunity, angiogenesis, and cellular proliferation. Its use has garnered significant interest, particularly in non-healing wounds and areas left to heal by secondary intention after surgery. Leukocyte and Platelet-Rich Fibrin (L-PRF) is frequently used in periodontal surgical applications. The platelets and growth factors it contains accelerate the healing process and facilitate tissue repair."
219204058|NCT06782035|DEVICE|Palatal Stent|Palatal stents help prevent complications such as infection or excessive discomfort. These plates are typically customized to fit the patient's palate by taking impressions before the surgery. Once placed, they serve as a barrier, especially during the early stages of healing. Additionally, they may reduce the need for postoperative interventions, such as the use of strong painkillers.
218897786|NCT03029468|BEHAVIORAL|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
218897787|NCT03029468|BEHAVIORAL|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
218897788|NCT00997958|DRUG|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
218897789|NCT00001716|DRUG|Nitric Oxide|
218897790|NCT00001716|DRUG|Nitroglycerin|
218897791|NCT05913830|OTHER|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
218897792|NCT03586713|DIAGNOSTIC_TEST|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
218897793|NCT00882232|DEVICE|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
218897794|NCT02817126|PROCEDURE|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
218897795|NCT02817126|PROCEDURE|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
218897796|NCT03656029|DRUG|Cannabis|Participants will smoke as much of the cigarette as they wish
218897797|NCT03656029|DRUG|Placebo|Participants will smoke a placebo cigarette
218897798|NCT04762732|DEVICE|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
218897799|NCT04762732|DEVICE|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
218897800|NCT00834665|BIOLOGICAL|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
218897801|NCT00834665|BIOLOGICAL|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
218897802|NCT00998465|OTHER|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
218897803|NCT00998465|OTHER|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
218897804|NCT00998465|OTHER|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
218897805|NCT00998465|RADIATION|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
218897806|NCT00998465|RADIATION|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
218897807|NCT00998465|RADIATION|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
218897808|NCT00998465|OTHER|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
218897809|NCT00998465|OTHER|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
218897810|NCT00998465|DIETARY_SUPPLEMENT|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
218897811|NCT04581265|DRUG|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
219613391|NCT04861753|OTHER|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
218897812|NCT06166940|OTHER|ROTEM Guided Management|ROTEM guided management of hemostasis after CPB
218897813|NCT03335410|OTHER|Non- interventional|Non- interventional
218897814|NCT03153514|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
218897815|NCT04067934|BEHAVIORAL|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
218897816|NCT02506712|DEVICE|SmartDrive assisting device|oxygen consumption
218897817|NCT02506712|DEVICE|Standard manuel wheelchair|oxygen consumption
218897818|NCT03433963|DIETARY_SUPPLEMENT|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
218897819|NCT03433963|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
218897820|NCT00585117|PROCEDURE|PET-imaging with CuATSM|imaging with CuATSM
218897821|NCT00585117|PROCEDURE|PET Imaging|Imaging with CuATSM
218897822|NCT00585117|PROCEDURE|PET CuATSM|Imaging with CuATSM
218897823|NCT00585117|PROCEDURE|PET imaging|imaging with CuATSM
218897824|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
218897825|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
218897826|NCT02398305|DEVICE|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
218897827|NCT02398305|DEVICE|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
218897828|NCT00965081|DRUG|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
218897829|NCT00965081|DRUG|Placebo|QD po at the same time each day for 12 weeks
218897830|NCT00176774|DRUG|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
218897831|NCT00176774|DRUG|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
218897832|NCT00176774|DRUG|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
218897833|NCT00176774|DRUG|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
218897834|NCT01263964|PROCEDURE|coronary angiogram|coronary angiogram
218897835|NCT02060435|OTHER|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
218897836|NCT00350571|BEHAVIORAL|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
218897837|NCT00350571|BEHAVIORAL|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
218897838|NCT00350571|BEHAVIORAL|standard care follow up|routine counselor phone calls and letters
218897839|NCT02736058|DEVICE|Trans- abdominal sonography|
218897840|NCT02736058|DEVICE|Trans-vaginal sonography|
218897841|NCT02736058|PROCEDURE|post-operative pathological specimen examination|
218897842|NCT02497924|DRUG|GBT440|GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
218897843|NCT01246427|DRUG|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
218897844|NCT01246427|DRUG|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
218897845|NCT02961959|PROCEDURE|Surgery|Arthrodesis of SI-joints, Physiotherapy
218897846|NCT02961959|OTHER|Non-surgery|Physiotherapy
219036072|NCT04225169|OTHER|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
219036073|NCT01243359|DRUG|sunitinib malate|Given PO
219036074|NCT01243359|BIOLOGICAL|bevacizumab|Given IV
219036075|NCT01243359|OTHER|pharmacological study|Correlative studies
219036076|NCT01243359|OTHER|laboratory biomarker analysis|Correlative studies
219036077|NCT01243359|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
219036078|NCT01243359|PROCEDURE|positron emission tomography|Undergo FLT PET/CT
219036079|NCT01243359|PROCEDURE|computed tomography|Undergo FLT PET/CT
219036080|NCT02531321|DRUG|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
218897847|NCT03687788|BEHAVIORAL|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
219517635|NCT04669236|BEHAVIORAL|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
218897848|NCT02727829|DEVICE|pefusion index measurement|perfusion index measurement using massimo radical 7 device
219036081|NCT00748215|DRUG|calcium aluminosilicate anti-diarrheal|Given orally
219036082|NCT00748215|OTHER|placebo|Given orally
219036083|NCT00543764|OTHER|pathway|Comparison of pre and post pathway
219036084|NCT01561352|DRUG|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
219517636|NCT03875157|BIOLOGICAL|IBI318|0.3 mg intravenous infusion, C1D1 and afterwards Q2W
219611829|NCT01106079|DRUG|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
219517637|NCT03875157|BIOLOGICAL|IBI318|1 mg intravenous infusion, C1D1 and afterwards Q2W
219517638|NCT03875157|BIOLOGICAL|IBI318|3 mg intravenous infusion, C1D1 and afterwards Q2W
219517639|NCT03875157|BIOLOGICAL|IBI318|10 mg intravenous infusion, C1D1 and afterwards Q2W
219611830|NCT01106079|DRUG|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
219611831|NCT04442464|DEVICE|Scleral Lens|15.0 mm diagnostic spherical rigid contact lens
219517640|NCT03875157|BIOLOGICAL|IBI318|30 mg intravenous infusion, C1D1 and afterwards Q2W
219517641|NCT03875157|BIOLOGICAL|IBI318|100 mg intravenous infusion, C1D1 and afterwards Q2W
219517642|NCT03875157|BIOLOGICAL|IBI318|300 mg intravenous infusion, C1D1 and afterwards Q2W
219517643|NCT03875157|BIOLOGICAL|IBI318|600 mg intravenous infusion, C1D1 and afterwards Q2W
219517644|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
219517645|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
219517646|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion Q3W
219517647|NCT04375254|OTHER|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
219517648|NCT05680233|DRUG|OA-235i (4 mg)|3 participants will receive 4 mg as a single subcutaneous dose
219517649|NCT05680233|DRUG|OA-235i (8 mg)|3 participants will receive 8 mg as a single subcutaneous dose
219517650|NCT05680233|DRUG|OA-235i (16 mg)|3 participants will receive 16 mg as a single subcutaneous dose
219517651|NCT05680233|DRUG|OA-235i (30 mg)|3 participants will receive 30 mg as a single subcutaneous dose
219517652|NCT05680233|DRUG|OA-235i (40 mg)|3 participants will receive 40 mg as a single subcutaneous dose
219517653|NCT05680233|DRUG|OA-235i or placebo|9 participants will receive a daily subcutaneous dose of OA-235i or placebo for 7 consecutive days
218897849|NCT05665894|DEVICE|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
218897850|NCT02541812|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
218897851|NCT05555966|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
218897852|NCT04555395|OTHER|survival rates|survival rates
219517654|NCT00796900|DRUG|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
219517655|NCT00796900|DRUG|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
219517656|NCT04911959|DRUG|Lenvatinib|Lenvatinib is taken orally.
219517657|NCT04911959|PROCEDURE|TACE|TACE treatment once.
219517658|NCT00059852|DRUG|erlotinib hydrochloride|
219517659|NCT00059852|DRUG|gemcitabine hydrochloride|
219517660|NCT01644500|DRUG|Dulaglutide|Administered SC
219517661|NCT01644500|DRUG|Glimepiride|Administered orally
218897853|NCT03116516|DRUG|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
218897854|NCT03116516|DRUG|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
219204059|NCT05374109|BEHAVIORAL|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
219204060|NCT06996041|OTHER|Chocking first aid management program|Power point presentation , Video demonstration, and Practical demonstration of chocking first aid management
219517662|NCT01644500|DRUG|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
219517663|NCT01644500|DRUG|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
218897855|NCT03211468|BEHAVIORAL|Clinical intervention program to prevent eating disorders|See previous
218897856|NCT05180695|DRUG|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
219204061|NCT06997237|BEHAVIORAL|Music Listening Intervention|Participants listened to a playlist of 5-6 music tracks they personally selected before surgery. The music was played continuously for 30 minutes through Bluetooth headphones during liver transplantation. Volume was kept at 65 decibels.
219204062|NCT06997237|BEHAVIORAL|Silence with Headphones|Participants wore Bluetooth headphones during the surgery, but no audio was played. This intervention was designed to control for the effect of wearing headphones and isolating ambient operating room sounds.
219204063|NCT06996587|PROCEDURE|Robotic-Assisted Flexible Ureteroscopy|Use of the ILY® robotic system to perform flexible ureteroscopy.
219204064|NCT06996587|PROCEDURE|Manual Flexible Ureteroscopy|Conventional flexible ureteroscopy performed manually by the surgeon.
219517664|NCT02773836|OTHER|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
219517665|NCT00891475|PROCEDURE|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
219611832|NCT05477784|OTHER|Educational Intervention|Receive EC-PC program
219611833|NCT05477784|OTHER|Informational Intervention|Receive education booklet
219611834|NCT05477784|OTHER|Questionnaire Administration|Ancillary studies
218897857|NCT05180695|DRUG|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
218897858|NCT00984984|DRUG|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
218897859|NCT00984984|DRUG|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
218897860|NCT06104085|DIAGNOSTIC_TEST|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
218897861|NCT02800616|OTHER|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
218897862|NCT02800616|BEHAVIORAL|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
218897863|NCT02928315|DRUG|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
218897864|NCT02928315|OTHER|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
218897865|NCT06375213|DIAGNOSTIC_TEST|Plasma tau phosphorylated at Thr217|Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.
218897866|NCT06375213|OTHER|Neurocognitive examination|Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.
218897867|NCT01303939|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
218897868|NCT03334032|OTHER|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
218897869|NCT02037139|OTHER|Screening|Standard care screening
218897870|NCT02037139|OTHER|Brochure|Participants are given an illustrated educational brochure
219204065|NCT06996054|BEHAVIORAL|Multifaceted School-Based Mental Health and Suicide Prevention Program|Pupils will receive a four-session psychoeducational programme, delivered weekly by trained psychologists during school hours, covering mental health literacy, emotion regulation, identification of suicide risk, and help-seeking skills. Concurrently, parents and teachers will access a digital co-intervention through a custom-designed platform with four multimedia modules.
219517666|NCT00891475|PROCEDURE|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
219517667|NCT00891475|DRUG|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
219517668|NCT06206356|DEVICE|PNS Injectrode F1|The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
219517669|NCT01573065|BEHAVIORAL|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
219517670|NCT06139237|OTHER|High-protein supplement|High protein supplement 200 mL
219204066|NCT06997653|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
219517671|NCT06139237|OTHER|Balanced supplement|Balanced supplement 200 mL
219517672|NCT02334371|RADIATION|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
219517673|NCT03505853|DRUG|Givosiran|single dose of givosiran by subcutaneous (sc) injection
219611835|NCT06970652|DEVICE|virtual reality|Participants in the intervention group received access to the MR smartphone application and a smartphone-compatible VR headset, both developed by MindCo Health.32 The application contained a stress reduction program that comprised a structured sequence of 77 modules designed to be completed over the course of 8 weeks. Each module was designed to be completed in approximately 7 minutes, and each module needed to be completed before progressing to the next module. Forty modules used VR, and for these modules, participants placed their personal smartphones running the MR application in the VR headset, and the smartphone provided all audiovisual content. All other modules used smartphones without the VR headset.
218897871|NCT02037139|BEHAVIORAL|Education|Participants undergo a in-person educational intervention
218897872|NCT00614679|DRUG|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
218897873|NCT01083823|OTHER|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
218897874|NCT02668458|PROCEDURE|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
218897875|NCT02668458|PROCEDURE|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
218897876|NCT00623324|DRUG|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
218897877|NCT00623324|DRUG|Placebo|Placebo tablets to match the number of active tablets
218897878|NCT06009367|PROCEDURE|Fascial Manipulation by Stecco method|Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
218897879|NCT02254473|OTHER|Wedge Insert|
218897880|NCT02254473|OTHER|Flat Insert|
218897881|NCT00256724|DEVICE|Impedance Threshold Device|Active impedance threshold device
218897882|NCT00256724|DEVICE|sham ITD|sham impedance threshold device
219036085|NCT03561493|OTHER|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
219036086|NCT05175066|DRUG|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
218897883|NCT01018277|OTHER|Mobilization (walking)|25 meters twice
218897884|NCT03955614|OTHER|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
218897885|NCT03955614|OTHER|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
218897886|NCT03955614|OTHER|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
218897887|NCT03159559|DRUG|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
219036087|NCT05175066|DRUG|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
218897888|NCT01217463|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
219036088|NCT00592566|DRUG|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
219036089|NCT02330796|DRUG|Bucillamine|Bucillamine Tablets
219036090|NCT02330796|DRUG|Colchicine|
219517674|NCT03505853|DRUG|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
219517675|NCT03828045|DRUG|Apremilast|Apremilast
219517676|NCT00006106|DRUG|cisplatin|
219517677|NCT00006106|DRUG|fluorouracil|
219517678|NCT00006106|DRUG|ONYX-015|
219517679|NCT00002899|PROCEDURE|adjuvant therapy|
219517680|NCT00002899|RADIATION|radiation therapy|
219517681|NCT00002899|RADIATION|stereotactic radiosurgery|
219517682|NCT00418470|PROCEDURE|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
219517683|NCT00418470|PROCEDURE|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
218897889|NCT02241564|OTHER|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
218897890|NCT02241564|DRUG|Switch from calcineurin inhibitor to an mTOR inhibitor|
218897891|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
219517684|NCT01239251|OTHER|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
219611836|NCT05767905|DRUG|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
219611837|NCT05767905|DRUG|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
219611838|NCT05767905|DRUG|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
219611839|NCT05767905|DRUG|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
219611840|NCT05767905|DRUG|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
219611841|NCT05767905|DRUG|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
219611842|NCT03762239|OTHER|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
219611843|NCT03762239|OTHER|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
218897892|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
218897893|NCT04619615|OTHER|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
218897894|NCT04619615|OTHER|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
219036091|NCT04944901|DRUG|SB-121|SB-121 is a formulation of L. reuteri
219611844|NCT06183983|DIAGNOSTIC_TEST|Extended or additional MRI-scan (with contrast) prior to radiotherapy|The MRI-protocol before radiotherapy is extended with 20 minutes. Patients who would not have received an MRI-scan prior to radiotherapy, will get an extra MRI-scan when participating.
219611845|NCT06122363|DEVICE|hysteroscopy|uterine hysteroscopy right after Novasure endometrial ablation
219611846|NCT05357846|DRUG|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
219611847|NCT05357846|RADIATION|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
219611848|NCT05357846|DRUG|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
219611849|NCT05357846|DRUG|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
219611850|NCT05357846|PROCEDURE|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
219611851|NCT05195801|DEVICE|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
218897895|NCT05724992|GENETIC|Saliva swab testing|41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
218897896|NCT01285817|DRUG|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
218897897|NCT03725631|DIAGNOSTIC_TEST|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
218897898|NCT06192849|DRUG|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
218897899|NCT04262726|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
219036092|NCT04944901|DRUG|Placebo|Placebo oral formulation
219036093|NCT05284838|OTHER|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
219036094|NCT05284838|OTHER|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
219036095|NCT05284838|OTHER|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
219204067|NCT06996405|OTHER|Access to dietary treatment|Dietary treatment using current nutrition guidelines, dialogic communication and Nutrition Care Process repeatedly by weekly access to a dietitian for four month.
219611852|NCT03645863|DRUG|MT-6548|Oral tablet
219611853|NCT03645863|DRUG|Iron supplement A|Oral tablet
219611854|NCT03645863|DRUG|Iron supplement B|Oral tablet
219611855|NCT03645863|DRUG|Iron supplement C|Oral tablet
219611856|NCT03645863|DRUG|Iron supplement D|Oral tablet
219611857|NCT04756115|PROCEDURE|Vascular Surgery.|Open Vascular, endovascular or hybrid procedures.
219611858|NCT05321004|OTHER|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
218897900|NCT04262726|BEHAVIORAL|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
219517685|NCT04915092|DEVICE|CoSIE app|"The app is a mobile phone application compatible with both iOS and Android operating system. Parents are able to register their children and to keep track of their weight status and activities. The app include five themes: child development, physical activity, healthy food, critical situations, BMI.~Push notification on healthy behaviours, on important event taking place in the province of Reggio Emilia, on food advices based on seasonality and on party tips are constantly delivered by the app."
219517686|NCT01879839|DIETARY_SUPPLEMENT|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
218897901|NCT01685775|PROCEDURE|Transvaginal/transumbilical|
218897902|NCT01685775|PROCEDURE|Needlescopic with 3 trocars|
218897903|NCT05371925|DRUG|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
218897904|NCT03836768|DRUG|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
218897905|NCT06375070|PROCEDURE|PFO closure|PFO closure
218897906|NCT06375070|DRUG|anticoagulant|rivaroxaban
219517687|NCT00902876|DEVICE|Mucograft|Collagen Matrix for soft tissue regeneration
219611859|NCT02171195|DRUG|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
219517688|NCT00902876|PROCEDURE|Coronally advanced flap (CAF)|
219517689|NCT03204526|DEVICE|deep brain stimulation|
219517690|NCT04848948|BEHAVIORAL|Calory Restriction (F.X. Mayr & VLCD)|"VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution."
219517691|NCT04848948|BEHAVIORAL|Biofeedback|Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
219611860|NCT02171195|DRUG|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
219611861|NCT02143544|DEVICE|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
219611862|NCT03624192|DEVICE|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
218897907|NCT00706446|DRUG|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
218897908|NCT00706446|DRUG|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
218897909|NCT00706446|DRUG|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
218897910|NCT00706446|DRUG|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
218897911|NCT00706446|DRUG|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
218897912|NCT02956343|DEVICE|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
218897913|NCT01569841|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
218897914|NCT01569841|DRUG|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
218897915|NCT01908686|BEHAVIORAL|Pivotal Response Training|Behavioral intervention for autism
218897916|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
218897917|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
218897918|NCT04004910|DRUG|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
218897919|NCT00005674|DRUG|Creatine|
218897920|NCT02028442|BIOLOGICAL|Enadenotucirev|Oncolytic virus
219517692|NCT01400425|DRUG|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
219517693|NCT00521170|DRUG|Levocetirizine|
219517694|NCT00925314|BIOLOGICAL|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
219611863|NCT03624192|OTHER|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
219611864|NCT04660331|OTHER|Communication Intervention|Undergo communication strategy intervention
219611865|NCT04660331|OTHER|Communication Skills Training|Undergo communication training sessions
219611866|NCT04660331|BEHAVIORAL|Healthcare Activity|Participate in interview
219517695|NCT02295956|BEHAVIORAL|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
219517696|NCT02295956|OTHER|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
219036096|NCT05393557|OTHER|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
219036097|NCT03200899|BEHAVIORAL|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
219036098|NCT03200899|OTHER|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
219036099|NCT04646499|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
219036100|NCT06167018|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
219517697|NCT02295956|OTHER|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
219517698|NCT02295956|BEHAVIORAL|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
219517699|NCT02295956|OTHER|Booklet|Exercise instructional booklet given to all participants describing all exercises.
219517700|NCT03437083|DRUG|Eribulin mesylate|intravenous infusion
219517701|NCT04023409|OTHER|NA: no intervention|NA: no intervention
219517702|NCT03313609|BEHAVIORAL|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
219517703|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
219517704|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
219517705|NCT02388763|DEVICE|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
219517706|NCT02388763|DEVICE|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
219517707|NCT00309972|DRUG|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
219611867|NCT04660331|BEHAVIORAL|Healthcare Activity|Undergo environmental scan
219611868|NCT04660331|OTHER|Survey Administration|Complete survey
219611869|NCT05814731|DRUG|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
219036101|NCT00837707|DRUG|aripiprazole|Flexible dose: 5-30 mg/day
219036102|NCT00012558|DRUG|lithium|
219036103|NCT00012558|DRUG|valproate|
219036104|NCT00012558|DRUG|bupropion|
219036105|NCT00012558|DRUG|paroxetine|
219036106|NCT00012558|DRUG|lamotrigine|
219036107|NCT00012558|DRUG|risperidone|
219517708|NCT00309972|DRUG|Experimental arm (CON):|concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
219517709|NCT01434108|DRUG|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
219517710|NCT03916952|DIAGNOSTIC_TEST|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
219611870|NCT05814731|DRUG|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
219611871|NCT03112473|BEHAVIORAL|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
218897921|NCT04821258|DIETARY_SUPPLEMENT|MICODIGEST 2.0 supplement|MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes
218897922|NCT04821258|DIETARY_SUPPLEMENT|Placebo supplement|Placebo
218897923|NCT01505959|DEVICE|CPAP treatment|Usual CPAP treatment
218897924|NCT01505959|DEVICE|CPAP treatment|CPAP treatment with telemedicine system
218897925|NCT03515525|DIAGNOSTIC_TEST|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
218897926|NCT00876161|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
218897927|NCT00876161|DRUG|Lactose|
218897928|NCT01082692|BIOLOGICAL|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
218897929|NCT02327676|DRUG|Emtricitabine|emtricitabine were given to each patients for 48 weeks
219517711|NCT05375175|OTHER|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
219611872|NCT03112473|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
219611873|NCT03112473|DEVICE|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
219611874|NCT01491451|DEVICE|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
219611875|NCT01491451|DEVICE|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
219611876|NCT04952350|DRUG|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
219611877|NCT04952350|OTHER|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
218897930|NCT05783206|DRUG|MIR 19 ®|"MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs."
218897931|NCT05783206|COMBINATION_PRODUCT|Standard therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
218897932|NCT03777761|DRUG|tucatinib|300mg oral dose
219611878|NCT00000714|DRUG|Trimetrexate glucuronate|
219611879|NCT00000714|DRUG|Leucovorin calcium|
218897933|NCT03777761|DRUG|placebo|Matching placebo for tucatinib
218897934|NCT03777761|DRUG|moxifloxacin|400mg single oral dose
218897935|NCT05010096|DRUG|Copanlisib|Given IV
218897936|NCT05010096|DRUG|Elimusertib|Given PO
218897937|NCT00172211|DRUG|Physioneal|
218897938|NCT06051669|DEVICE|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
218897939|NCT06051669|DEVICE|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
218897940|NCT01818102|DEVICE|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
218897941|NCT01818102|DEVICE|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
218897942|NCT03728543|DRUG|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
218897943|NCT04188938|OTHER|Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma|
218897944|NCT02907762|DEVICE|Endovascular aneurysm repair EVAR|
218897945|NCT03543761|DEVICE|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
218897946|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
219611880|NCT02635984|DRUG|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
219611881|NCT02635984|DRUG|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
219611882|NCT06581744|OTHER|[18F]AlF-NOTA-Pentixather|inject 185\~370MBq \[18F\]AlF-NOTA-Pentixather
219611883|NCT04020523|OTHER|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
219613392|NCT00777387|PROCEDURE|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
219613393|NCT00777387|PROCEDURE|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
219613394|NCT02343653|BEHAVIORAL|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
218897947|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
218897948|NCT03787186|DRUG|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
218897949|NCT03787186|DRUG|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1690
218897950|NCT03787186|DRUG|[14C]-GLPG1690 capsules|single oral dose of \[14C\]-GLPG1690
218897951|NCT04474678|OTHER|"My Logbook! - I know my way around!"|"Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment."
219036108|NCT00012558|DRUG|inositol|
219036109|NCT00012558|DRUG|tranylcypromine|
219517712|NCT05375175|OTHER|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
219517713|NCT05339100|DRUG|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
219517714|NCT05339100|DEVICE|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
219517715|NCT05339100|DEVICE|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
219517716|NCT04035642|RADIATION|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
219517717|NCT04035642|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
219517718|NCT04035642|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
218897952|NCT04479826|DEVICE|Advanced hybrid closed loop system|Free living follow-up of meal handelling
218897953|NCT04486534|OTHER|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
219036110|NCT00012558|BEHAVIORAL|Cognitive Behavioral Therapy|
219036111|NCT00012558|BEHAVIORAL|Family-focused Therapy|
219036112|NCT00012558|BEHAVIORAL|Interpersonal and Social Rhythms Therapy|
219036113|NCT05165212|DRUG|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
219036114|NCT02202733|OTHER|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
219036115|NCT04151290|DIAGNOSTIC_TEST|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
219036116|NCT03214809|DIAGNOSTIC_TEST|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
219036117|NCT02051530|DIETARY_SUPPLEMENT|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
219036118|NCT05252039|BEHAVIORAL|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
219036119|NCT01302912|PROCEDURE|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
219517719|NCT04035642|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
219517720|NCT03561142|RADIATION|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
219517721|NCT03561142|DRUG|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
219517722|NCT03561142|OTHER|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
218897954|NCT00764361|DRUG|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
218897955|NCT00764361|DRUG|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
219517723|NCT05749133|BIOLOGICAL|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based."
218897956|NCT05238389|DEVICE|AI-based upper limb robotic therapy|"Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years)."
218897957|NCT03393234|RADIATION|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
218897958|NCT02090426|OTHER|Link2Care|
218897959|NCT02462148|DRUG|Dexamethasone|Used in nerve block mixture
218897960|NCT02462148|DRUG|Bupivacaine|Used in nerve block mixture
219036120|NCT05834517|DRUG|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
219517724|NCT02268032|DRUG|DHEA|DHEA 2.2 g in vaginal ring
219613395|NCT02343653|BEHAVIORAL|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
219613396|NCT03383965|BIOLOGICAL|ICAR30 T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
219613397|NCT02137252|DRUG|Naltrexone|
219613398|NCT02137252|DRUG|Sugar Pill|
219613399|NCT03224728|DEVICE|intraocular lens|
219613400|NCT05112081|DRUG|Botulinum toxin type A|The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
218897961|NCT02462148|DRUG|Epinephrine|Used in nerve block mixture
218897962|NCT02462148|PROCEDURE|Saphenous Peripheral Nerve Block|Peripheral nerve block.
218897963|NCT03471273|PROCEDURE|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
218897964|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
218897965|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
218897966|NCT05923814|DRUG|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
218897967|NCT00106314|DRUG|Dehydroepiandrosterone [DHEA]|
218897968|NCT04521322|DRUG|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
218897969|NCT04143867|DEVICE|Nolix Device|For temporary management of SUI
218897970|NCT03882892|DRUG|Ezetimibe|Ezetimibe 10 mg tablets
218897971|NCT03882892|DRUG|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
218897972|NCT03882892|DRUG|Placebo|Placebo tablets matched to ezetimibe
218897973|NCT05771649|BEHAVIORAL|Mindfulness-based intervention|A mindfulness instructor will guide focused attention meditations that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
219036121|NCT05834517|PROCEDURE|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
219036122|NCT02727920|DIETARY_SUPPLEMENT|Energy drink|
219613401|NCT05112081|OTHER|Sterile saline|The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
219613402|NCT04283630|DIETARY_SUPPLEMENT|Dietary nitrate in the form of beetroot juice for all participnats|participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
219036123|NCT02727920|OTHER|Placebo|placebo drink
219036124|NCT03978364|DRUG|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
219036125|NCT03978364|DRUG|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
219036126|NCT01530321|OTHER|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
219517725|NCT02268032|DRUG|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
219517726|NCT02268032|DRUG|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
219517727|NCT06253676|BEHAVIORAL|Problem Management Plus (PM+)|Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
219517728|NCT06374615|DIAGNOSTIC_TEST|IgG and IgM search for specific Tick-Borne Patogens|"Ticks will be classified based on morphological characteristics by microscopy observation.~For TBP detection by molecular test, Nucleic acid extraction will be performed on ticks lysate or blood using kits MagMAX TM Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific) on MagEX STARlet platform from Hamilton. Species identification by molecular method will be performed by Sanger sequencing for Rickettsiae and Babesia, and Multi-Locus Sequence Typing will be used to characterize Borrelia.~Serum samples collected throughout the study will be tested to assess any seroconversions during the follow-up period.~Samples will be tested for the presence of specific IgG and IgM for the following TBPs: TBEV, R. typhi. R. conorii, Borrelia spp, Anaplasma, Ehrlichia and Babesia."
218897974|NCT05771649|BEHAVIORAL|Physical exercise|An instructor will guide to running with mental association strategies that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
218897975|NCT06457061|OTHER|Survey Study|"Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers."
218897976|NCT03986996|DRUG|amoxicillin, metronidazole and doxycycline|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
218897977|NCT03986996|DRUG|amoxicillin and doxycyclin|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
218897978|NCT05201508|PROCEDURE|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
218897979|NCT05201508|PROCEDURE|Sutures only|Traditional hiatal closure with non-absorbable sutures.
218897980|NCT01952132|DRUG|OMS643762|
218897981|NCT01952132|DRUG|Placebo|
218897982|NCT01141712|PROCEDURE|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
218897983|NCT01141712|DRUG|BCNU|Participants will receive BCNU 300 mg/m\^2 Day -6
218897984|NCT01141712|DRUG|Etoposide|Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
219517729|NCT04519437|DRUG|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
219517730|NCT04519437|DRUG|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
219611884|NCT05729490|RADIATION|Coronary computed tomography angiography|"All patients will be subjected to:~Two CT scans (coronary calcium scoring and angiography) using 128 or 160-row scanners with a slice thickness of 0.5 mm (Revolution Evo 128, GE Health care, Chicago, Illinois, USA) or (Aquilion 160, Canon Medical Systems, Tochigi, Japan). Calcium scoring will be performed with the use of prospective electrocardiographic gating with 400-ms gantry rotation, 120-kV tube voltage, and 300-mA tube current. For CTA, retrospective electrocardiographic gating will be used, with heart rate adjusted gantry rotations of 350 ms to 500 ms to enable adaptive multisegmented reconstruction.~Iopromide (Ultravist 370, Bayer AG, Berlin, Germany) is the intravenous contrast medium that will be used for CTA. Beta-blockers will be given if the resting heart rate is 70 beats/min."
219611885|NCT06152432|DEVICE|Maxillary implant overdenture|Patients with an edentulous maxilla and problems with their conventional denture are treated with an implant overdenture either retained by bars or Locators
218897985|NCT01141712|DRUG|Cytarabine|Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
218897986|NCT01141712|DRUG|Melphalan|Participants will receive Melphalan 140 mg/m\^2 Day -1
218897987|NCT01308736|DRUG|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
218897988|NCT01308736|DRUG|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
218897989|NCT06409910|RADIATION|Radiotherapy|Non-institutional-standard radiotherapy
218897990|NCT05698680|DRUG|Prednisolone 30 mg Tablet|"See treatment arm Prednisolone"
218897991|NCT05698680|DRUG|Colchicine 0.5 mg Oral Tablet|"See treatment arm Colchicine"
218897992|NCT03841422|PROCEDURE|video-assisted nasal self-packing|video-assisted nasal self-packing
218897993|NCT06161597|BEHAVIORAL|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
219036127|NCT01530321|OTHER|Light Massage|5 minutes of light pressure massage to the neck and upper back
219036128|NCT05798416|DRUG|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
219036129|NCT05798416|OTHER|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
219036130|NCT00969553|DRUG|BI 6727|Dose level 1
219036131|NCT03173716|PROCEDURE|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
219036132|NCT01719185|DRUG|Phentermine and B12|
219036133|NCT01719185|DRUG|Phentermine|
219517731|NCT01449071|BIOLOGICAL|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
219517732|NCT01449071|BIOLOGICAL|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
219517733|NCT01449071|BIOLOGICAL|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
218897994|NCT03269149|OTHER|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
218897995|NCT03269149|BEHAVIORAL|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
218897996|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
218897997|NCT06138548|DEVICE|Ossiofiber® Trimmable Fixation Nail|OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*
218897998|NCT05258136|DRUG|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
218897999|NCT04404231|RADIATION|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
218898000|NCT04404231|OTHER|No Infrared treatment|This is sham treatment. No light is actually given.
218898001|NCT01867736|DEVICE|Passeo-18 Lux DRB|
218898002|NCT01867736|DEVICE|Standard PTA (POBA)|
218898003|NCT01175863|DEVICE|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
218898004|NCT01175863|DEVICE|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
219204068|NCT06997666|PROCEDURE|Prone Position|Patients assigned to the Prone Position Group were placed in the prone position (lying face down) for 30 minutes once daily over two consecutive days while hospitalized in the ICU for COVID-19-induced ARDS. The intervention was performed between 12:30 and 13:00 under nurse supervision. Oxygen saturation, blood gas parameters (SaO₂, PO₂, PCO₂, pH, lactate, sodium), and respiratory rate were measured before and after each prone positioning session. The procedure was standardized across patients and no additional treatments were introduced during the intervention period.
219517734|NCT01449071|BIOLOGICAL|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
219517735|NCT01449071|BIOLOGICAL|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
219517736|NCT02003053|DEVICE|Inspiratory Muscle Trainer|
219517737|NCT02603783|OTHER|Capsaicin|capsaicin 1,5 mg
219517738|NCT02603783|OTHER|Placebo|0,9% saline 75 ml
219517739|NCT05126056|OTHER|Plant stanol ester|Product with active ingredient vs product without active ingredient
219517740|NCT05126056|OTHER|Placebo|Placebo
219517741|NCT04084483|DRUG|K-161|K-161 alternate dosage
219517742|NCT04084483|OTHER|Placebo (Vehicle)|Placebo solution
219611886|NCT00291317|DEVICE|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
219611887|NCT01640249|DRUG|Placebo|Capsules administered orally
219611888|NCT01640249|DRUG|LY3006072|Capsules administered orally
219517743|NCT05884853|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
219517744|NCT03831451|BEHAVIORAL|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
219517745|NCT03831451|BEHAVIORAL|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
219517746|NCT05887297|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
219517747|NCT01458405|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
219517748|NCT01458405|DRUG|Placebo|Single, blinded, intracoronary infusion of a placebo solution
219517749|NCT02194998|DRUG|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
219517750|NCT02194998|DRUG|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
219517751|NCT02194998|DRUG|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
219517752|NCT00305045|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
219517753|NCT05402852|DRUG|EuBone ® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
219517754|NCT05402852|DRUG|placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
218898005|NCT05754294|DIAGNOSTIC_TEST|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
218898006|NCT04561895|GENETIC|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
218898007|NCT02055326|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
219517755|NCT02029105|BIOLOGICAL|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
219517756|NCT01362998|DRUG|Preservative free morphine|3mg given epidurally during the Cesarean section.
219517757|NCT01362998|DRUG|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
218898008|NCT02055326|BEHAVIORAL|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
218898009|NCT02055326|BEHAVIORAL|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
218898010|NCT00634439|DRUG|atomoxetine|
218898011|NCT00634439|DRUG|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
218898012|NCT00634439|OTHER|No intervention (general population)|
218898013|NCT00296816|DRUG|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
218898014|NCT00296816|DRUG|Docetaxel (Taxotere®)|75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
218898015|NCT00296816|DRUG|Oxaliplatin (Eloxatin®)|85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
218898016|NCT05369663|DEVICE|mask use|face mask use
218898017|NCT02104453|PROCEDURE|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
219036134|NCT04563091|DEVICE|Hemodialysis with online HFR|"1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
219517758|NCT00000941|DRUG|Pravastatin sodium|
218898018|NCT01556451|BIOLOGICAL|Zoster Vaccine Live|Zoster vaccine live
219036135|NCT05410470|DRUG|Ruxolitinib|
219611889|NCT06030375|DRUG|KAND567|Continuous intravenous infusion for 6 hours
218898019|NCT06420947|OTHER|atomizer|Participants received 2% lidocaine by atomizer.
219611890|NCT06030375|OTHER|Placebo|Continuous intravenous infusion for 6 hours
219611891|NCT01776632|BEHAVIORAL|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
219611892|NCT01776632|BEHAVIORAL|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
219611893|NCT01683396|DRUG|Placebo|Solution for subcutaneous injection
219611894|NCT01683396|DRUG|gevokizumab|Solution for subcutaneous injection
218898020|NCT02624440|DRUG|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
218898021|NCT02624440|DRUG|Clarithromycin|P.o. clarithromycin 250 mg twice daily
218898022|NCT02624440|DRUG|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
218898023|NCT02624440|DRUG|Observation|Observation without prophylactic antibiotic
219517759|NCT00000941|DRUG|Simvastatin|
219517760|NCT00000941|DRUG|Atorvastatin calcium|
219517761|NCT00000941|DRUG|Ritonavir|
219517762|NCT00000941|DRUG|Nelfinavir mesylate|
219517763|NCT00000941|DRUG|Saquinavir|
219517764|NCT01454466|PROCEDURE|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
219517765|NCT01190748|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
218898024|NCT02152709|BIOLOGICAL|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
218898025|NCT02152709|BIOLOGICAL|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
218898026|NCT03030001|BIOLOGICAL|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
218898027|NCT00945282|DRUG|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
218898028|NCT00945282|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
218898029|NCT00945282|DRUG|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
218898030|NCT00945282|DRUG|Placebo|Placebo is a capsule with no drug in it.
219036136|NCT02131402|DEVICE|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
219036137|NCT02131402|DEVICE|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
219036138|NCT02131402|DEVICE|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
219036139|NCT05705063|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
219036140|NCT05400174|DIAGNOSTIC_TEST|Tilt table (upright position)|Different versions of cognitive assessments will be administered in the supine and upright positions.
219036141|NCT06249321|DRUG|mFOLFIRINOX plus IMRT|Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
219036142|NCT07099170|BEHAVIORAL|Brochure-Based Pelvic Floor Muscle Training|Brochure-based pelvic floor muscle training will be conducted by providing participants with a brochure containing information about the anatomy, functions, and importance of the pelvic floor, as well as instructions on how to contract the pelvic floor muscles. All educational content will be delivered solely through the brochure, and no additional verbal or written information will be provided to the participants. The brochure will include detailed explanations of pelvic floor muscle contractions and imagery techniques. Participants will be given 30 minutes to review the brochure and apply the training independently.
219036143|NCT07099170|BEHAVIORAL|Verbal Instruction-Based Pelvic Floor Muscle Training|Verbal instruction-based pelvic floor muscle training involves providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as instruction on how to correctly contract the pelvic floor muscles. All explanations will be delivered verbally, and no additional equipment or visual aids will be used. During the training, imagery techniques based on verbal cues will be employed. Commonly used metaphors such as a hammock, a faucet, an elevator, or a ship will be utilized to facilitate imagery. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be informed about the potential effects of these contractions during the session.
219517766|NCT01190748|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
219517767|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
219517768|NCT03873701|DIAGNOSTIC_TEST|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
219611895|NCT02321059|DEVICE|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
219611896|NCT02190370|BEHAVIORAL|Resources activation|
219611897|NCT02315911|PROCEDURE|ATE|surgical removal of adenoids and tonsils
219611898|NCT02315911|PROCEDURE|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
219611899|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
219611900|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
219611901|NCT01363193|DRUG|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = \[9270 x weight (kg)\] / \[6680+216 x BMI\] Female = \[9270 x weight (kg)\] / \[8780+244 x BMI\]"
219611902|NCT05712083|DRUG|BCMA CAR-T cells|Each subject receive BCMA CAR T-cells by intravenous infusion
219611903|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
218898031|NCT00945282|DRUG|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
218898032|NCT03494920|OTHER|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
218898033|NCT03494920|OTHER|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
218898034|NCT00808093|DRUG|GSK256073|GSK256073 100 mg study drug
218898035|NCT00941408|PROCEDURE|Diagnostic tumor core biopsy|
218898036|NCT00854230|DRUG|Naltrexone|Naltrexone dose 25-100mg
218898037|NCT02018081|DRUG|Levofloxacin|8 blood sampling by patients between the 48th and 60th
218898038|NCT03694717|DRUG|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
218898039|NCT02744365|OTHER|Observational|"All women of the biobank have provided:~1. blood samples (plasma, serum and Buffy-coat)~2. urine samples~3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~4. mean arterial blood pressure~5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
218898040|NCT05364463|PROCEDURE|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
218898041|NCT01729299|DRUG|Exendin (9-39)|
218898042|NCT01729299|DRUG|acyl ghrelin|
218898043|NCT01729299|DRUG|saline|
218898044|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
218898045|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
218898046|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
219611904|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
219611905|NCT01215136|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
219611906|NCT02851628|DEVICE|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
218898047|NCT02333357|BEHAVIORAL|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
218898048|NCT02333357|BEHAVIORAL|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
218898049|NCT02486536|DRUG|polyethylene glycol|
218898050|NCT02486536|DEVICE|capsule endoscopy|
218898051|NCT05064371|DRUG|Eptinezumab|Concentrate for solution for IV infusion
218898052|NCT04872192|OTHER|transversus thoracic muscle plane block|transversus thoracic muscle plane block by injection of 15 ml of bupivacaine 0.25% on each side combined with general anaesthesia
218898053|NCT04872192|OTHER|general anaesthesia|transversus thoracic muscle plane block by injection of 15 ml of saline on each side combined with general anaesthesia
218898054|NCT04113317|DRUG|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
218898055|NCT00423839|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
218898056|NCT01410513|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
218898057|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
218898058|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
218898059|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
218898060|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
219611907|NCT02851628|DEVICE|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
219611908|NCT01644851|BEHAVIORAL|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
219517769|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
219517770|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
219611909|NCT06421766|DEVICE|BAHS|Implantation of a percutaneous bone-anchored hearing system
218898061|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
218898062|NCT01594320|BIOLOGICAL|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 \& Day 21
218898063|NCT02345473|GENETIC|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
218898064|NCT01153737|OTHER|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
218898065|NCT01153737|OTHER|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
218898066|NCT05944406|OTHER|Educational training of ER Nurses|educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
219036144|NCT07099170|BEHAVIORAL|Visual-Aided Pelvic Floor Muscle Training|Visual-aided pelvic floor muscle training includes providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as training on how to properly contract the pelvic floor muscles. The training will be conducted using anatomical models, visual materials, and videos. Following the explanation of pelvic floor anatomy with models and visual aids, the function and importance of the pelvic floor will be presented through video demonstrations. During the session, the pelvic floor will be visually represented using common metaphors such as a hammock, a faucet, an elevator, or a ship, and these visuals will support the use of imagery techniques. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be provided with information about the expected effects of the contractions.
219036145|NCT07099170|BEHAVIORAL|External Palpation-Aided Pelvic Floor Muscle Training|External Palpation-Aided Pelvic Floor Muscle Training This training involves educating participants on the pelvic floor's anatomy, function, and importance, along with instructions on proper muscle contraction. After an educational session using anatomical models, visuals, and videos, external palpation is used to guide correct muscle activation. In a hook-lying position and fully clothed, participants receive light, transverse pressure from a physiotherapist on key pelvic floor muscles (ischiocavernosus, bulbospongiosus/bulbocavernosus, or perineum). The therapist observes real-time muscle response, provides feedback, and offers verbal cues. Imagery techniques (e.g., hammock, faucet, elevator, ship) may be used to support motor learning and awareness.
219611910|NCT03862924|DEVICE|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
219611911|NCT03438019|DEVICE|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
219611912|NCT03438019|DEVICE|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
219611913|NCT05748951|DEVICE|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
219611914|NCT00708110|DRUG|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
219611915|NCT00708110|DRUG|Placebo|Placebo is a tablet with no drug in it.
219611916|NCT01910428|DRUG|L-asparaginase encapsulated in RBC|"* 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV"
219611917|NCT01573104|OTHER|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
218898067|NCT00985465|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
218898068|NCT03101566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV
219611918|NCT01573104|OTHER|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
218898069|NCT03101566|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV
219036146|NCT06910839|DRUG|PF-07976016|PF-07976016 oral tablets
219036147|NCT06910839|DRUG|PF-06882961|PF-06882961 oral tablets
218898070|NCT03101566|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV
218898071|NCT03101566|DRUG|Nivolumab|Nivolumab 360 mg or 240 mg IV
218898072|NCT00509470|DRUG|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
218898073|NCT00509470|DEVICE|Amlodipine|
218898074|NCT04390126|OTHER|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
219036148|NCT07095621|PROCEDURE|3 days discharge|"Patients scheduled for elective minimally invasive DP, eligible for the study and willing to participate will be asked to sign the consent form in person during the preoperative counseling session.~Participants will receive comprehensive preoperative education and will be enrolled in an ERAS protocol that includes urinary catheter removal, initiation of a solid food diet, cessation of intravenous infusions, and oral pain management starting on postoperative day (POD 1). Following discharge on POD3, patients will receive a daily telephonic follow-up by a nurse navigator for the first 7 days after surgery (POD 7)."
219036149|NCT06826430|DRUG|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection, the autologous 2nd generation CD19-directed CAR-T cells, will be administered by vein. Before CAR-T infusion，patients will get a 3-4 days lymphodepletion therapy with fludarabine and cyclophosphamide.
219036150|NCT06586112|DRUG|ESK-001|ESK-001
219036151|NCT06586112|DRUG|Apremilast|Apremilast
219036152|NCT06586112|DRUG|Placebo|Placebo
219036153|NCT07110194|DRUG|TQB2825 Injection (Subcutaneous Injection)|TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.
219036154|NCT07110662|DRUG|DARATUMUMAB (DARZALEX®)|A single injection of DARZALEX 16 mg/kg body weight administered by intravenous infusion (day 1) in addition to standard symptomatic treatment of NET until re-epidermalization.
219204069|NCT06995976|DRUG|68Ga-dPNE|Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
219204070|NCT06995976|DRUG|18F-FDG|Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.
219517771|NCT03130205|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
219517772|NCT03130205|RADIATION|Computed Tomography|Computed Tomography
219611919|NCT01573104|OTHER|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
219611920|NCT01163864|BEHAVIORAL|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
219611921|NCT01163864|BEHAVIORAL|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
219611922|NCT04640870|DRUG|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
218898075|NCT04390126|OTHER|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
218898076|NCT00152893|DRUG|chromium nicotinate|
218898077|NCT00152893|DRUG|Placebo|
218898078|NCT05775016|BEHAVIORAL|Exercise|12 week resistance and cardiovascular exercise program
218898079|NCT02397304|OTHER|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
218898080|NCT04703426|DRUG|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
218898081|NCT04703426|DRUG|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
218898082|NCT05375591|OTHER|Non-Interventional Study|First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
218898083|NCT02150278|BEHAVIORAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
219204071|NCT06997549|DEVICE|Patients treated with NeuroStar TMS|non-invasive brain stimulation device
219611923|NCT01595685|DRUG|Telbivudine|Telbivudine 600 mg Daily Oral
219204072|NCT06997549|DRUG|Patients treated with Esketamine|nasal spray for treating depression
219204073|NCT06996236|DRUG|Treatment with brimonidine eye drops 0.025%|Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.
219517773|NCT03130205|RADIATION|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
219517774|NCT03130205|PROCEDURE|Phlebotomy|3 EDTA tubes drawn from peripheral vein
219517775|NCT03130205|GENETIC|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
219517776|NCT03479736|DRUG|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
219517777|NCT03479736|DRUG|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
219611924|NCT01595685|DRUG|Entecavir|Entecavir 0.5 mg Daily Oral
219611925|NCT02251899|BEHAVIORAL|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
218898084|NCT04592588|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
218898085|NCT04592588|BEHAVIORAL|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
218898086|NCT00986843|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
218898087|NCT05373446|DRUG|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
218898088|NCT05373446|DRUG|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
219036155|NCT07108491|BIOLOGICAL|Balance Training with Stroboscopic Glasses|"The difficulty level of intermittent visual occlusion was structured from Level 1 to Level 8 based on frequency. As the flicker speed of the lenses decreased and the frequency lowered, the difficulty increased. For example, a setting of 6 Hz means the lenses flicker six times per second, whereas 1 Hz indicates one flicker per second.~Levels 1 to 5 are suitable for dynamic movements such as catching or hitting a ball, while Levels 3 to 8 are appropriate for balance and proprioceptive training.~In this study, participants wore stroboscopic glasses (Senaptec Strobe, Senaptec, USA, 2016) and began at Level 1 (6 Hz). The difficulty was gradually increased each week, with the setting adjusted to Level 3 (4 Hz) in Week 2, Level 4 (3 Hz) in Week 3, and Level 5 (2.25 Hz) in Week 4 (see Table 5).~The training was conducted using the standard Mode A, in which both lenses flicker simultaneously."
219036156|NCT07108491|BIOLOGICAL|Balance Training without Glasses|The exercise program consisted of six types of exercises and was conducted in a 30-minute circuit training format repeated twice per session. Participants took part in two sessions per week for four weeks, totaling eight sessions. The six exercises were completed as a circuit, repeated twice per session. A 30-second rest was provided between exercises and a 2-minute rest between circuits. All exercises were conducted by a licensed physical therapist to ensure safety.
219036157|NCT07109180|PROCEDURE|Robot-assisted lateral pancreaticojejunostomy|Robot-assisted
219517778|NCT03479736|OTHER|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
219517779|NCT02497781|DRUG|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
219517780|NCT02497781|DRUG|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
219517781|NCT01910766|DRUG|Coenzyme Q10|no more details
219517782|NCT01910766|DRUG|clomiphene citrate|
219517783|NCT04568681|DEVICE|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
219517784|NCT03259581|COMBINATION_PRODUCT|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
219517785|NCT04524039|DEVICE|intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.
218898089|NCT05373446|DRUG|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
218898090|NCT02564458|BEHAVIORAL|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
218898091|NCT05441631|DRUG|Insulin|"* Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)"
218898092|NCT05441631|DRUG|Subcutaneous Insulin|"* Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine"
218898093|NCT00828230|DRUG|budesonide|One application of 2mg budesonide once daily for 8 weeks
218898094|NCT00828230|DRUG|Placebo foam|One application of placebo foam once daily for 8 weeks
218898095|NCT03406637|DEVICE|BPK-S Integration|primary total knee endoprosthesis
218898096|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
218898097|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
218898098|NCT03744767|DRUG|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
218898099|NCT01225614|DEVICE|Bilevel pressure ventilator|Nocturnal home ventilation
219036158|NCT07109180|PROCEDURE|Open lateral pancreaticojejunostomy|Open surgery
219036159|NCT07109141|PROCEDURE|PFA ablation procedure of atrial arrythmia|PFA ablation procedure of atrial arrythmia accroding to the particular patients needs
218898100|NCT04117204|OTHER|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
218898101|NCT04832932|BIOLOGICAL|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
218898102|NCT00756431|DEVICE|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
219036160|NCT07108634|OTHER|RenalGuard Therapy|The RenalGuard Therapy® is comprised of a console, a single-use sterile IV infusion set, urine collection set and a cart. The console is a microcontroller device that has a means for measuring urine output and automatically controls the hydration infusion pump based on the measured urine output and clinician settings. The system is designed for infusion of hydration solutions only. The patient is connected to the console by the IV Infusion set connected to the patient's peripheral IV cannula and the urine collection set connected to the patient's indwelling Foley urinary catheter. The console continuously monitors urine production by measuring the weight of urine in the collection set, converts the urine weight to volume and then, automatically infuses the pre-set volume of hydration fluid to compensate for this output.
219036161|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-0.75mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day
219036162|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-1.5mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day
219036163|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler Simulant|HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily
219036164|NCT07108959|PROCEDURE|Erector spinae plane block (Group E)|The ultra sound probe will be placed on the paravertebral region in a Sagittal plane about 3 cm lateral to the T5 spinous process on the operating side to locate erector spinae muscle, rhomboid major and trapezius from inward (To reach T5, we used C7 as an anatomical landmark, which is the most prominent vertebrae in the back and count downwards to reach T5. To locate C7, we will use palpation or ultrasound guidance if there is difficulty in palpation). Following visualization of these muscles and the transverse process of T5, the skin will be infiltrated with 5 ml of 2% lidocaine, and then 30 ml bupivacaine 0.25% will be injected in the plane between the erector spinae muscle and transverse process using a 22-G 10-cm nerve block needle.
219204074|NCT06996509|DEVICE|Non-Invasive Ventilation (NIV)|Bi-Level NIV delivers two preset pressure levels-Inspiratory Positive Airway Pressure (IPAP) and Expiratory Positive Airway Pressure (EPAP)-via a tightly fitting mask interface
219204075|NCT06996509|DEVICE|High Velocity Nasal Insufflation|High-Velocity Nasal Cannula therapy delivers heated, humidified gas at flow rates exceeding patients' peak inspiratory demands (35-60 L/min), with precise FiO₂ control up to 100 %
219204076|NCT06996223|DRUG|The Group A received PCSK9 inhibitor plus statin therapy|Subjects randomized to the Group A will be treated with a lipid-lowering regimen based on PCSK9 inhibitors (subcutaneous injection, twice a week) + statins (maximum tolerated dose).
219204077|NCT06997692|DIAGNOSTIC_TEST|Gong's Mobilization with NMES|Gong's Mobilization Technique: The participant will be positioned in a side-lying posture on a height-adjustable bed, with the affected side upward and the head supported by a pillow The therapist will apply an antero-posterior glide to the humeral head while stabilizing the scapula with the other hand. The participant will perform quick, powerful shoulder abduction in the coronal plane without external rotation or elbow flexion while the therapist maintains the mobilization force.
219517786|NCT04524039|DEVICE|sham intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
219517787|NCT00386113|BIOLOGICAL|Fluarix and adjuvanted influenza vaccine|
219517788|NCT02709356|DIETARY_SUPPLEMENT|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
218898103|NCT00756431|DEVICE|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
218898104|NCT00314743|DRUG|Ondansetron|
218898105|NCT00314743|DRUG|Dexamethasone|
219036165|NCT07108959|PROCEDURE|Lidocaine (drug)|Patients in group L will receive an initial bolus of lidocaine 1.5mg /kg over 10 minutes immediately before the induction of general anaesthesia then 1.5mg/kg/hr lidocaine infusion in a 50cc syringe pump intra operatively that will be stopped at the end of surgery.
219036166|NCT07109752|BEHAVIORAL|eHealth cardiac rehabilitation|A face-to-face interview for goal setting and action planning, as well as learning the use of CR website and accelerometer.
219036167|NCT07108933|BIOLOGICAL|Autologous platelet-rich plasma|Guided injection of PRP in bony cavities of maxilla after surgical excision of non-malignant tumors.
219517789|NCT02709356|DIETARY_SUPPLEMENT|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
219517790|NCT03162666|DEVICE|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
219517791|NCT02236130|PROCEDURE|Regional block|Single shot peripheral nerve block
219517792|NCT02236130|PROCEDURE|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
219517793|NCT02236130|DRUG|Local Anesthetic Ropivacaine|0.5% Ropivacaine
219517794|NCT02236130|DRUG|Opioids Morphine|Morphine
219517795|NCT02236130|DRUG|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
219517796|NCT00981786|DRUG|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
219517797|NCT00981786|DRUG|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
219611926|NCT05466045|OTHER|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
219611927|NCT05466045|OTHER|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
218898106|NCT00314743|DRUG|Aprepitant|
218898107|NCT04701333|DRUG|Cabergoline 1 MG|Dopamine agonist
218898108|NCT04701333|DRUG|Placebo|Placebo
219517798|NCT05127993|DEVICE|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
219517799|NCT00780520|DIETARY_SUPPLEMENT|alanine-glutamine infusion|
218898109|NCT01012258|BIOLOGICAL|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
218898110|NCT01292187|DRUG|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
218898111|NCT01292187|DRUG|Oral placebo at dinnertime|Oral placebo at dinnertime.
218898112|NCT01292187|DRUG|Oral calcitonin at bedtime|Oral calcitonin at bedtime
218898113|NCT01292187|DRUG|Oral placebo at bedtime|Oral placebo at bedtime
218898114|NCT05266612|DRUG|VG2025|"1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15"
218898115|NCT05266612|DRUG|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
218898116|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
219517800|NCT06227065|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
219517801|NCT06227065|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
219517802|NCT06227065|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
218898117|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
218898118|NCT01725490|DRUG|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
218898119|NCT03457376|DIAGNOSTIC_TEST|Hand Grip Force|Hand Grip Force
218898120|NCT03457376|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
218898121|NCT03457376|DIAGNOSTIC_TEST|Maximal Expiratory Pressure|Maximal Expiratory Pressure
219517803|NCT06227065|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
219517804|NCT01697020|DRUG|Mercaptopurine 20mg/ml oral suspension|50mg
219517805|NCT01697020|DRUG|Mercaptopurine 50mg tablet|50mg
219517806|NCT03082274|DIAGNOSTIC_TEST|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
218898122|NCT00076414|DRUG|Acetylcholine|
218898123|NCT00076414|DRUG|L-NMMA|
218898124|NCT02116881|PROCEDURE|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
218898125|NCT02952599|DRUG|Edoxaban|Prescribed according to approved label
218898126|NCT01584310|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
218898127|NCT01584310|OTHER|No STAMP using|No intervention
218898128|NCT01533506|DRUG|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
218898129|NCT03600740|DEVICE|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
218898130|NCT04440748|DEVICE|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
219036168|NCT07108842|PROCEDURE|Conventional Needle Irrigation|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
218898131|NCT04440748|OTHER|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
218898132|NCT03062020|DEVICE|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
218898133|NCT03921034|DRUG|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
218898134|NCT03921034|DRUG|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
218898135|NCT00141674|PROCEDURE|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
218898136|NCT02414685|DRUG|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
219611928|NCT01097512|DRUG|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
218898137|NCT02414685|DRUG|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
218898138|NCT02414685|DRUG|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
218898139|NCT03571204|BIOLOGICAL|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
218898140|NCT03571204|BIOLOGICAL|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
219036169|NCT07108842|DEVICE|Conventional Needle Irrigation (Control Group)|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
219036170|NCT07108842|DEVICE|endoactivator|in group 2 irrigation done with endoactivator
219517807|NCT03082274|DIAGNOSTIC_TEST|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
219517808|NCT02177084|DEVICE|PTNS|
219517809|NCT03812081|DEVICE|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
219517810|NCT03812081|DEVICE|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
219517811|NCT00454636|DRUG|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
219517812|NCT00454636|DRUG|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
219611929|NCT01097512|DRUG|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
219517813|NCT00454636|DRUG|Epirubicin|50 mg/m2/day, IV, every 3 weeks
219517814|NCT00454636|DRUG|Cisplatin|60 mg/m2/day, IV, every 3 weeks
218898141|NCT06522789|PROCEDURE|corneal cross-linking procedure|Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
219036171|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with disposable syringe
219036172|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with endoactivator
219036173|NCT07108842|DEVICE|Sonic Irrigation with EndoActivator (Experimental Group)|Patients in this arm will receive sonic activation of the irrigant using the EndoActivator device during root canal treatment. After initial instrumentation and irrigation with 2.5% sodium hypochlorite, the irrigant will be activated using a medium-sized (25/04) EndoActivator tip for 30 seconds per canal at a sonic frequency (\~6000 cycles/min), to enhance cleaning and irrigant penetration.
219611930|NCT05001646|DEVICE|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
219611931|NCT05721911|GENETIC|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
219611932|NCT00481117|DRUG|LY2405319|
219611933|NCT00481117|DRUG|Placebo|
219611934|NCT04762004|BEHAVIORAL|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
218898142|NCT02996630|PROCEDURE|Sonography|Fetal Ultrasound exploration
218898143|NCT02996630|DEVICE|Magnetic Resonance Imaging|Fetal MRI for brain study
218898144|NCT02996630|OTHER|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
218898145|NCT02996630|PROCEDURE|Surgical intervention|Congenital Heart Disease repair
218898146|NCT02996630|PROCEDURE|Brain monitoring|EEG and continuous brain oximetry before surgery.
218898147|NCT02996630|PROCEDURE|cord blood sample|Cord blood samples will be taken after birth in both groups.
218898148|NCT02396212|BIOLOGICAL|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
218898149|NCT01623115|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
219036174|NCT07110506|OTHER|Arterial pressure monitoring|Arterial pressure is monitored and obtained
219036175|NCT07108270|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219036176|NCT07108270|DRUG|Carboplatin|Carboplatin will be administered.
218898150|NCT01623115|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
218898151|NCT01623115|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
218898152|NCT03980249|DRUG|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
218898153|NCT05932108|BEHAVIORAL|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
218898154|NCT05932108|OTHER|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
219036177|NCT07108270|DRUG|Paclitaxel|Paclitaxel will be administered.
219036178|NCT07109037|OTHER|Conventional exercise therapy|"Conventional exercise therapy includes four exercises: the little swallow flying exercise, the hip bridge exercise, back muscle stretching, and relaxation. It is performed once a day, 45 minutes ."
219036179|NCT07109037|OTHER|Suspension training and conventional exercise therapy|Suspension training alternates with conventional exercise therapy. It is conducted every other day, 45 minutes each time, 2-3 times a week for four consecutive weeks. Elastic ropes for suspension training are chosen based on patients' body mass: single - strand for those with body mass ≤ 30 kg and double - strand for those with body mass \> 30 kg. Suspension slings are placed on the head, lower back, and pelvis, and non-elastic rope slings on the ankles. Lower the lifting bed so that the vertical distance from the ankles to the bed surface is about 25-30 cm.
219036180|NCT07109375|DRUG|pegunigalsidase alfa|Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
219611935|NCT04762004|BEHAVIORAL|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
218898155|NCT04612166|BEHAVIORAL|Medication Action Plan and Patient Empowerment (MAP-PE )|"Intervention patients (after consenting) will meet with a study health coach for an in-person meeting where the health coach will review the pharmacists Medication Action Plan (MAP) for deprescription of high-risk medication. The MAP will have previously been approved by both the patient and the patient's primary care physician. If the patient is on more than one high risk medication, the medication that puts them at the highest risk will be deprescribed first and only one medication will be decreased at a time. During this initial meeting, the health coach will use motivational interviewing and distribute materials to empower and support the patient in the reduction of the medication as outlined on their MAP. The health coach will then follow up with the patient on a schedule determined~by the type and dosage of medication being reduced. Follow ups will decrease in frequency over time (starting with at least once a week). The patients will be followed for up to 12 months."
218898156|NCT00114816|DRUG|capecitabine|
218898157|NCT00114816|DRUG|docetaxel|
218898158|NCT03061357|BEHAVIORAL|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
218898159|NCT01155336|DRUG|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
218898160|NCT01155336|DRUG|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
218898161|NCT06106113|DRUG|GST-HG171 Tablets|150mg GST-HG171 Tablets
218898162|NCT03449966|DEVICE|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
218898163|NCT03449966|DEVICE|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
218898164|NCT04539600|DRUG|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
218898165|NCT04361734|OTHER|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
218898166|NCT00348985|DRUG|belinostat|
219517815|NCT00454636|DRUG|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
218898167|NCT00348985|DRUG|bortezomib|
218898168|NCT00348985|OTHER|pharmacological study|
219036181|NCT07110493|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single-pulse TMS is applied to specific areas of the visual cortex to non-invasively induce the perception of phosphenes (brief flashes of light). Stimulation is delivered using a TMS device, with the operator controlling the intensity and frequency parameters to a level equal to the phosphene-evoking threshold. During stimulation, participants are seated comfortably and asked to report the location of perceived phosphenes on a monitor and a physical grid, helping to map the cortical visual field.
219036182|NCT07110493|DEVICE|Electroencephalography (EEG)|Continuous brain electrical activity is recorded using a 128-channel gel-based EEG system (Skoltech). The EEG cap is fitted to the participant's head to capture neural responses with high temporal resolution throughout the session. The collected data is used to analyze brain activity changes, including the P300 component and other event-related potentials, to identify neural correlates of phosphene perception and the effects of TMS.
219204078|NCT06997692|COMBINATION_PRODUCT|Comprehensive Conservative Physical Therapy|Thermal Modality Application: Participants will receive either a cold or hot pack (based on individual preference and clinical presentation) applied to the affected shoulder for 10-15 minutes. Cold packs will be wrapped in a thin towel and applied to
218898169|NCT03788174|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
218898170|NCT03788174|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
218898171|NCT02119871|PROCEDURE|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
218898172|NCT02119871|PROCEDURE|Right Pleura Open|Right pleura open Left ventricular apical drainage
218898173|NCT03790566|DRUG|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
219517816|NCT00454636|DRUG|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
218898174|NCT03214107|OTHER|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
218898175|NCT03214107|OTHER|Snack|Full snack or Distributed snack
218898176|NCT03170726|DRUG|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
218898177|NCT03170726|DRUG|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
219036183|NCT07110493|DEVICE|Eye-Tracking|Eye movements are continuously monitored using a Tobii Defusion 2 eye-tracker (Skoltech) operating at 60 Hz. This device provides high-accuracy measurements of gaze fixation and saccades. Participants are instructed to fixate their gaze on one of five predetermined points on a screen (center, top, bottom, left, right), with the fixation point being determined randomly for each trial. The eye-tracking data is analyzed to assess the influence of gaze position on phosphene localization and to study any stimulation-induced changes in eye movement patterns.
219036184|NCT07109583|BEHAVIORAL|Early dinner|Consume dinner between 17:30 and 19:00 for a week
219036185|NCT07109583|BEHAVIORAL|Delayed dinner|Consume dinner between 20:30 and 22:00 for a week
219204079|NCT06996106|OTHER|Effect of Platelet Rich Fibrin on Septoplasty|it is a randomized trial of usage of platelet rich fibrin in septoplasty
219517817|NCT00454636|DRUG|Docetaxel|60 mg/m2/day, IV, every 3 weeks
219517818|NCT00454636|DRUG|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
219517819|NCT01400113|DRUG|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
219517820|NCT01400113|DRUG|Placebo|Placebo Sublingual Tablet, single-dose
219611936|NCT04762004|BEHAVIORAL|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
219611937|NCT01748201|PROCEDURE|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
218898178|NCT03170726|OTHER|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
218898179|NCT04494035|DEVICE|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
218898180|NCT02530021|OTHER|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
218898181|NCT06461663|DEVICE|Breast Cancer Locator Guided Breast Conserving Surgery|Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
218898182|NCT00857285|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
219517821|NCT01437865|DRUG|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
219517822|NCT03554096|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
219517823|NCT04175496|OTHER|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
219517824|NCT04175496|OTHER|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
218898183|NCT00857285|DRUG|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
218898184|NCT02146417|PROCEDURE|Low pressure pneumoperitoneum|
219517825|NCT04175496|OTHER|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
219517826|NCT04175496|OTHER|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
218898185|NCT02146417|PROCEDURE|Normal pressure pneumoperitoneum (12 mmHg)|
218898186|NCT02146417|PROCEDURE|Deep neuromuscular block|
218898187|NCT04392817|BEHAVIORAL|Arabic Articulatory Error Remediation software program|A speech therapy computerized intervention
219517827|NCT04175496|OTHER|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
219517828|NCT04076358|BEHAVIORAL|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
219517829|NCT00209118|DRUG|paroxetine|
219611938|NCT04368338|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
218898188|NCT03811444|DEVICE|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
218898189|NCT03811444|DEVICE|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
218898190|NCT03811444|DEVICE|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
218898191|NCT01433172|BIOLOGICAL|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
218898192|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
219517830|NCT00003096|GENETIC|DNA ploidy analysis|
219517831|NCT00003096|GENETIC|comparative genomic hybridization|
219517832|NCT00003096|GENETIC|cytogenetic analysis|
219517833|NCT00003096|GENETIC|fluorescence in situ hybridization|
219517834|NCT01095510|BIOLOGICAL|CINRYZE|
219517835|NCT05376046|BIOLOGICAL|Erythrocytic parameters and thrombin generation assay measurement|Erythrocytic parameters and thrombin generation assay measurement
219517836|NCT05483322|DRUG|LAM-002A|25mg capsules
219611939|NCT04368338|PROCEDURE|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
219611940|NCT00006464|DRUG|7-hydroxystaurosporine|
219611941|NCT00006464|DRUG|cisplatin|
218898193|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
218898194|NCT02782286|DRUG|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
218898195|NCT02782286|DRUG|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
218898196|NCT00924248|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
218898197|NCT00287716|DRUG|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
218898198|NCT00287716|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
218898199|NCT05277558|OTHER|Observational|Investigators are observing brain health over time (21 months) in these groups
218898200|NCT00900055|GENETIC|microarray analysis|
218898201|NCT00900055|GENETIC|polyacrylamide gel electrophoresis|
218898202|NCT00900055|GENETIC|polymerase chain reaction|
218898203|NCT00900055|GENETIC|protein expression analysis|
218898204|NCT00900055|GENETIC|reverse transcriptase-polymerase chain reaction|
218898205|NCT00900055|GENETIC|western blotting|
218898206|NCT00900055|OTHER|chromatography|
218898207|NCT00900055|OTHER|high performance liquid chromatography|
218898208|NCT00900055|OTHER|immunoenzyme technique|
218898209|NCT01950403|DRUG|linaclotide acetate|Given PO
218898210|NCT01950403|OTHER|placebo|Given PO
218898211|NCT01950403|OTHER|pharmacological study|Correlative studies
218898212|NCT01950403|OTHER|laboratory biomarker analysis|Correlative studies
218898213|NCT02864563|PROCEDURE|Blood sampling|"* Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
218898214|NCT04725253|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide, 1,5 gr per day for 7 days.
218898215|NCT04725253|OTHER|Placebo tablets|Placebo tablets, 1 per day for 7 days.
218898216|NCT01824550|OTHER|home-based exercise training condition|Home based endurance exercise training
218898217|NCT03219502|OTHER|Best Practice|Receive standard of care
219517837|NCT01025037|DEVICE|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
218898218|NCT03219502|OTHER|Quality-of-Life Assessment|Ancillary studies
218898219|NCT03219502|OTHER|Questionnaire Administration|Ancillary studies
218898220|NCT03219502|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
218898221|NCT03219502|PROCEDURE|Sham Intervention|Undergo sham rTMS
218898222|NCT05668910|GENETIC|whole genomic methylation and fragmentation profile analysis of cfDNA|The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
218898223|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Resource Energy|Carbohydrate Supplement
218898224|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
218898225|NCT03115762|BIOLOGICAL|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
218898226|NCT03115762|BIOLOGICAL|ASKB1202|
218898227|NCT01987102|DRUG|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
218898228|NCT01987102|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
218898229|NCT00643968|DRUG|EFV+TDF|
218898230|NCT00643968|DRUG|EFV+3TC+TDF|
218898231|NCT00419731|DRUG|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
218898232|NCT00419731|DRUG|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
219036186|NCT07109401|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Neoadjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide; Adjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.
219517838|NCT04371809|OTHER|DNA methylome|Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
219517839|NCT00414297|DEVICE|ECP Therapy|application of ECP Therapy to CAD Patients
218898233|NCT01236521|DRUG|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
219517840|NCT00337571|DRUG|Aripiprazole|Tablets, Oral, once daily, 8 weeks
218898234|NCT01236521|BEHAVIORAL|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
218898235|NCT05524779|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
218898236|NCT05910216|OTHER|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
218898237|NCT05910216|OTHER|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
218898238|NCT02238119|DRUG|Tiotropium + formoterol combination|
218898239|NCT02238119|DRUG|Tiotropium|
218898240|NCT02238119|DRUG|Formoterol|
218898241|NCT00893061|DRUG|anastrozole|Given orally
218898242|NCT00893061|DRUG|exemestane|Given orally
218898243|NCT00893061|DRUG|letrozole|Given orally
218898244|NCT00893061|DRUG|tamoxifen citrate|Given orally
218898245|NCT06096636|OTHER|Study participants|Participants will complete study survey and dietary assessment.
218898246|NCT06654440|DRUG|SHR-A2102 for injection|SHR-A2102 for injection
218898247|NCT06603558|DRUG|Atogepant|Oral Tablet
218898248|NCT06824051|DRUG|Orforglipron|Administered orally
218898249|NCT06824051|DRUG|Placebo|Administered orally
218898250|NCT02472717|DRUG|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
218898251|NCT02472717|OTHER|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
219517841|NCT00337571|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
219517842|NCT02356471|DEVICE|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
219517843|NCT02356471|OTHER|Questionnaire Administration|Ancillary studies
219517844|NCT02356471|OTHER|Quality-of-Life Assessment|Ancillary studies
219517845|NCT04078451|PROCEDURE|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
219517846|NCT01890915|OTHER|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
218898252|NCT03446313|BEHAVIORAL|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
218898253|NCT06538662|DRUG|FID 123320 Ophthalmic Solution|Investigational sterile aqueous solution
218898254|NCT06538662|DRUG|Vehicle|FID 123320 Ophthalmic Solution inactive ingredients
218898255|NCT04183205|DIAGNOSTIC_TEST|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
218898256|NCT04183205|DRUG|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
218898257|NCT04183205|DRUG|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
218898258|NCT06699602|DRUG|Cemiplimab|cemiplimab IV flat
218898259|NCT06699602|DRUG|Fianlimab|fianilmab IV flat
218898260|NCT06304207|COMBINATION_PRODUCT|Onsite Maintenance Exercise Training|Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.
219517847|NCT03856970|DRUG|Microgestin®|30 μg/1500 μg tablets for oral administration
219517848|NCT03856970|DRUG|Levothyroxine|600 μg tablets for oral administration
219517849|NCT03856970|DRUG|Glyburide|5 mg tablets for oral administration
219517850|NCT03856970|DRUG|Digoxin|0.25 mg tablets for oral administration
219517851|NCT03856970|DRUG|IW-3718|500-mg film-coated tablets for oral administration
219517852|NCT03363074|DEVICE|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
219517853|NCT03363074|DEVICE|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
219517854|NCT04191564|PROCEDURE|low perfusion state|reduce SAP below 100 mmHg
219517855|NCT04191564|PROCEDURE|normal perfusion state|maintain SAP above 100 mmHg
219517856|NCT02895529|DRUG|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
218898261|NCT06304207|COMBINATION_PRODUCT|Telehealth Maintenance Exercise|Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
218898262|NCT05516953|DRUG|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
219517857|NCT02895529|DRUG|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
218898263|NCT03066063|DEVICE|iCare|The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.
218898264|NCT03066063|BEHAVIORAL|Amblyopia standard of Care|The amblyopia standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily
218898265|NCT03066063|BEHAVIORAL|CI standard of Care|A dosage-matched CI standard of Care group will be prescribed pencil pushups for 20 minutes per day, five days per week.
218898266|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
218898267|NCT06631183|BEHAVIORAL|Self-help information based on principles of behavioral activation|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on behavioral activation and physical activity.
218898268|NCT06631183|BEHAVIORAL|Self-help information based on principles of cognitive restructuring|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on cognitive restructuring.
218898269|NCT06693089|OTHER|MIT-ED|The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
218898270|NCT06720857|DIAGNOSTIC_TEST|Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium|Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
219036187|NCT07109167|DRUG|Benmelstobart combined with gemcitabine and cisplatin|Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8;Cisplatin 25mg/m², intravenous infusion on Day 1 and Day 8. Maintenance dose of study medication: Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8
219611942|NCT02060812|PROCEDURE|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
219036188|NCT07110467|PROCEDURE|blinking exercises|The study group was instructed to instill artificial tears and perform blinking exercises three- five times a day for 4 weeks.
219036189|NCT07109765|DRUG|Secukinumab|secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
219036190|NCT07109089|OTHER|Race Pace-based training|Participants complete one week of endurance training based on race pace zones individually determined from a 5-km time trial performance. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
219517858|NCT05431868|OTHER|AT LISA tri 839MP (Carl Zeiss Meditec AG)|This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
219611943|NCT02060812|PROCEDURE|Group II, SSNB alone|This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
219611944|NCT06462755|OTHER|No intervention|no intervention
219611945|NCT03171012|OTHER|Lower limbs CRT|cycle ergometer for lower limbs
219611946|NCT03171012|OTHER|Upper limbs CRT|cycle ergometer for upper limbs
219611947|NCT03171012|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
219517859|NCT05815069|DIAGNOSTIC_TEST|[18F]AlF-NOTA-pentixather PET/CT|The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
218898271|NCT06725043|DEVICE|Therapeutic ultrasound|Pulsed therapeutic ultrasound (1 MHz , 50% duty cycle and intensity gradually increased till the patient felt a deqi sensation).Each point was stimulated by ultrasound for 5 minutes at bilateral acupuncture points of PC6, PC7, BL60 and KI1(3 times / week for 4 weeks).
218898272|NCT06725043|DEVICE|Placebo therapeutic ultrasound|patients were received placebo therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI.
218898273|NCT06725043|OTHER|Traditional physical therapy program|Strengthing exercise, balance training, stretching exercises and home exercise program and education
219611948|NCT03171012|OTHER|respiration|respiration
218898274|NCT06726603|PROCEDURE|Assisted Reproductive Technology|Assisted Reproductive Technology for the purposes of this study include IVF and IVF+ICSI. Ovulation induction methods are not considered Assisted Reproductive Technology
218898275|NCT06726798|PROCEDURE|Endoscopic submucosal dissection with EndoRobotics traction device|All patients received robotic ESD under general anesthesia or monitored anaesthetic care at the endoscopy center of Prince of Wales Hospital. The targeted lesion would first be localized and pre-injected using a mixture of normal saline, indigocarmine, epinephrine and sodium hyaluronate. The robotic endoscopic traction device was then inserted to reach the target. Mucosal incision first started from the anal side followed by lifting with the grasper\[Figure 1; Video 1\]. Vio 3 diathermy system (ERBE, Germany) was used with endocut Q effect 3 and forced coagulation effect 3. Further submucosal dissection would be performed by electrocautery knife with traction achieved via EndoRobotics traction. Upon completion, the specimen would be retrieved upon withdrawal of the whole system.
218898276|NCT06725498|DRUG|Tislelizumab-jsgr|200mg, Q3W
218898277|NCT06725498|DRUG|Cisplatin|60-75 mg/㎡, Q3W
218898278|NCT06725498|DRUG|Albumin-Bound Paclitaxel|260 mg/㎡, Q3W
218898279|NCT06725498|RADIATION|Radiotherapy|Radical Radiotherapy or adjuvant Radiotherapy per guidelines.
218898280|NCT06922513|DEVICE|digital health (Application and Smart Measuring Tape)|For lymphedema management, we use a smart measuring tape to measure arm circumference and provide analysis results along with self-management strategies.
218898281|NCT06921122|DEVICE|IOWA ORAL PERFORMANCE INSTRUMENT|"In the first session all protocols and assessments will be carried out as a way of observing the responses and previous measures of all participants. The group in this study must appear weekly for six weeks to verify if necessary, reinsufflate the bulb, carry out force measurement and lingual press with the IOPI, as well as receive or reinforce the guidance provided at the beginning of the treatment.~The participants in the group will study that will have a mobile phone and an instant message application will receive weekly, on scheduled days, a letter containing the following text message: Here is the day of performing the last exercise by the Speech Pathologist. Participants who do not have a mobile phone will be notified through a telephone connection or contact with a responsible family member/caregiver.~After the end of the sixth week of training, patients will be subjected to the last set of data on the two protocols and evaluations proposed in this study."
218898282|NCT06921122|DEVICE|Placebo Group - Without Treatment|"The group in study, without treatment, supported by the same schedule of the patients treated, will represent the natural progression of failure disorders in PD. A decision was made not to include a false treatment, in order to adhere to the principle of balance and not to place an undue burden of time and effort on patients who receive a treatment with low therapeutic potential. Furthermore, the researchers considered that given the questions regarding the adequacy of simulations as comparators of treatment in behavioral studies, research in this work between the group in the study and the placebo group (without treatment) can provide more useful contrasts than a group with therapeutic simulation.~If the intervention clearly aims to provide direct benefits to the participants, this group will be contacted to carry out the same intervention later."
218898283|NCT06921109|BEHAVIORAL|Experimental: Relaxation training with VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment integrated into various virtual environments. Homework exercises will be assigned to them after each session.
218898284|NCT06921109|BEHAVIORAL|Experimental: Relaxation training without VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment displayed on a computer screen. Homework exercises will be assigned to them after each session.
218898285|NCT06921109|BEHAVIORAL|No Intervention: Control group|This group will benefit from 8 psychoeducation sessions delivered through video modules sent to their homes.
218898286|NCT06921187|BEHAVIORAL|Psychoacoustic test|Natural sounds will be presented at different decibels (dB), and the subject will be asked to rate the pleasantness/unpleasantness of the sound heard on a visual analogue scale, as well as the loudness (subjective intensity) of the sound heard.
218898287|NCT06921187|OTHER|semi-structured interviews|interview, designed under the supervision of a psychologist and using the methodology of micro-phenomenological interviews the aim of these interviews is to gain access to the participants' experiences, as they describe them in the first person, during misophonic episodes
219036191|NCT07109089|OTHER|Heart Rate-Based Training|Participants complete one week of endurance training based on heart rate zones individually determined from ventilatory threshold assessments. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
219036192|NCT07110480|DIETARY_SUPPLEMENT|Supplement|The enrolled patient was advised to take 1 to 2 tablets daily at any time, preferably with a sip of water, as directed by the pharmaceutical company. In detail, starting with the distribution of Assonal®️PEA (T0) by the principal investigator, patients took 2 tablets per day (1 in the morning and 1 in the evening) for the first 15 days of treatment (T1). Treatment continued with 1 tablet per day until the end of the clinical study (T3).
219517860|NCT05528016|PROCEDURE|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
218898288|NCT06921187|OTHER|Exposure to unpleasant sounds|"Home exposure is a practice whereby participants voluntarily subject themselves to SMs in a controlled environment.~Participants will be asked to complete two tasks: firstly, they will have to expose themselves to all 10 sounds at least twice a week; secondly, they will have to record the annoyance felt for each sound and the subjective loudness (loudness) of each SM using VAS."
218898289|NCT06921161|DEVICE|TongueFit|"TongueFit is a newly orofacial manometer. This device is specifically developed for children to measure and improve tongue strength and endurance which includes a complementary application. Participants will do a series of tongue exercise therapy using TongueFit. The exercise therapy will be performed once per day, three times a week, for eight weeks."
219036193|NCT07108556|BEHAVIORAL|Mindfulness VR-Typical|Participants first experience mindfulness exercise with virtual reality incorporated, then another mindfulness exercise with only audio-guidance as typically delivered without the technology
219036194|NCT07108556|BEHAVIORAL|Mindfulness Typical-VR|Participants first experience mindfulness exercise with only audio-guidance, then another mindfulness exercise with virtual reality incorporated
219036195|NCT07109115|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Subjects will be supplemented with the following vitamin C doses: 0mg, 200mg, 500mg, 1000mg.
219036196|NCT07109934|DEVICE|deep breathing exercises, chest mobilization:|The patients were instructed to engage in deep and gentle inspired breathing, maintain it for 3 seconds, and then exhale gently via the mouth while seated in a semi-sitting posture. During expiration, the patients were instructed to cough twice with maximum efficiency (patients were instructed to maintain a cushion in the incision area during coughing). Thereafter, the patient was provided with an incentive spirometer to be utilized 5 to 10 times daily at intervals of 2 hours. The chest mobilization was conducted five times each set, with three sets assigned to each session Individual participants independently performed chest mobilization under the guidance of a physiotherapist for the first time. The chest mobilization technique involves pulling the arms upwards to their maximum extent while inhaling appropriately during arm movement.
219036197|NCT07100496|COMBINATION_PRODUCT|MIG-SPRAY|"MIG-SPRAY® is a film-forming liquid dressing designed for the preventive treatment of migraine.~Key Features:~* Administration:~  * Applied as 2 sprays per nostril, 3 times daily.~ * Treatment duration: 3 months.~* Mechanism: Forms a protective film on the nasal mucosa, potentially modulating local triggers of migraine.~* Use Case: Prophylactic (preventive) therapy for migraine, intended to reduce attack frequency and severity.~Additional Notes:~* Non-systemic (local action).~* CE-marked as a Class I medical device (under EU Directive 93/42/EEC)."
219036198|NCT07107152|BEHAVIORAL|single GPT generated message|Participants receive a single \~640-word message generated by GPT-4.1. The message is tailored to participants' self-reported demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). The message provides persuasive content encouraging colorectal cancer screening, emphasizing stool and colonoscopy screening options. Participants are required to read the message for a minimum of 3 minutes.
219036199|NCT07107152|BEHAVIORAL|AI Chatbot|Participants engage in a multi-turn conversation with a GPT-4.1 chatbot trained to emulate motivational interviewing techniques. The chatbot personalizes its conversation based on each participant's demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). Conversations last at least 3 minutes and aim to increase participant motivation to complete colorectal cancer screening.
218898290|NCT06921161|OTHER|OSMS|Patients will receive OSMS therapy, conducted for 15 minutes per session, three times a week, over a duration of eight weeks.
219036200|NCT07107152|BEHAVIORAL|Expert-Written Patient Materials|Participants read a 642-word expert-written educational summary from the Journal of the American Medical Association's Patient Page on colorectal cancer screening. The material is designed to provide objective information about screening options and guidelines recommended by the US Preventive Services Task Force. Participants are required to read the material for at least 3 minutes.
219204080|NCT06059378|DEVICE|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
219204081|NCT06747663|PROCEDURE|Needle Depth Measurement Using MRI, Ultrasound, and Fluoroscopy|This intervention involves cervical epidural steroid injection (CESI) for patients with chronic neck and radicular pain. Needle depth is measured pre-procedurally using MRI and ultrasound to predict the ideal needle placement. Fluoroscopy is used during the procedure to confirm and compare these measurements, aiming to evaluate the accuracy of imaging techniques and minimize radiation exposure.
219204082|NCT06996470|OTHER|- Cervical Vestibular-Evoked Myogenic Potential (cVEMP) along the Sternocleidomastoid|Endurance time during gazing
219517861|NCT05043233|DRUG|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
218898291|NCT06922045|DRUG|STSP-0601 for Injection|Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors
218898292|NCT02466932|DEVICE|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
219204083|NCT05292222|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
219517862|NCT00927147|RADIATION|BNCT|Boronophenylalanine infusion followed by neutron irradiation
219517863|NCT00927147|DRUG|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
219517864|NCT00861445|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
219517865|NCT00861445|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
219517866|NCT02386033|DRUG|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
218898293|NCT06726083|BEHAVIORAL|Nutrition Intervention|Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
218898294|NCT06726083|BEHAVIORAL|Contact Control|Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
218898295|NCT00451971|DRUG|LEFLUNOMIDE|
218898296|NCT06726629|OTHER|Version Of The New Knee Society Knee Scoring System|All patients will be subjected to the same clinical and radiographic checks, the data of which will be collected in the different centres
218898297|NCT06725550|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
218898298|NCT06725550|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
218898299|NCT06725368|DRUG|PCC|"PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death."
218898300|NCT05648188|BIOLOGICAL|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
218898301|NCT06897202|DRUG|MET097 Injection|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
219036201|NCT07109674|DEVICE|adjustable compression device (type circaid® reduction kit, Medi-Bayreuth)|inelastic compression during intensive phase of physical therapy
219611949|NCT02063750|OTHER|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
219611950|NCT02063750|OTHER|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
218898302|NCT06897202|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
218898303|NCT07064980|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Performed under intravenous anesthesia. A duodenoscope was advanced to the major duodenal papilla. After cannulation and cholangiography, purulent bile was aspirated. Biliary sphincterotomy was performed in most patients (95.2%), followed by stone extraction using a balloon catheter or basket. A 7-10 Fr nasobiliary tube was placed for drainage in all patients. Prophylactic rectal indomethacin (100mg) was also administered.
218898304|NCT07064980|PROCEDURE|Percutaneous Transhepatic Biliary Drainage|Performed under general anesthesia with endotracheal intubation and ultrasound guidance. An 18G needle was used to puncture a dilated intrahepatic bile duct. After guidewire placement, an 8-10 Fr drainage catheter was inserted for either internal-external drainage (if the guidewire could pass into the duodenum) or purely external biliary drainage.
218898305|NCT07066969|GENETIC|Sophia DDM|Germline panel for patients with tumoral BRCA alteration in EC
219036202|NCT07109674|DEVICE|Comparison of inelastic compression efficiency|The effect of compression on volume reduction, physical functioning, disease-related symptoms and comfort
219036203|NCT07108881|DRUG|C|isotonic saline solution infusion (fluid preloading) to achieve correction of hypovolemia before spinal anesthesia using cardiac ultrasoud guidance by measurment of VTI variation after a 250ml saline solution loading, with a maximum of 4 challenges, until hypovolemia complete correction
219036204|NCT07108881|DRUG|T|"isotonic saline solution coloading after spinal anesthesia associated with recsue boluses of Ephedrine would be the standard of care in this arm. No correction of hypovolemia is done before spinal anesthesia. parturients receive a cristalloid coloading with saline isotonic solution with rescue boluses of ephedrine if hypotesion happens after spinal anesthesia"
219204084|NCT05966766|OTHER|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
219204085|NCT05966766|OTHER|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
219204086|NCT05522517|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
219204087|NCT05522517|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
219611951|NCT03359408|BEHAVIORAL|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
218898306|NCT06795490|BEHAVIORAL|Online program|Families in Balance Online is a 6-week online program that includes 6 weekly group discussions and 3 individual support sessions, all held over Zoom. Program activities will focus on improving parent and child self-regulation as a means to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
219036205|NCT07109986|DRUG|UB-VV410|Treatment with single dose of UB-VV410, intravenous injection at Day 1. Note: Subjects may receive retreatment with UB-VV410 if there are preliminary findings suggesting incomplete improvement and acceptable safety.
218898307|NCT06795490|BEHAVIORAL|Control Condition|Families in Balance is an asynchronous program in which participants will be sent materials weekly over 6 weeks to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
218898308|NCT06901583|OTHER|Mindfulness-oriented psycho-education|The program, consisting of six sessions and developed by evaluating studies in the literature, covers topics such as mindfulness, anger, and interpersonal relationships
218898309|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
218898310|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
218898311|NCT06915246|DRUG|VI-0609|Carmustine with Propylene Glycol
219036206|NCT07108647|OTHER|Progressive Hip Strengthening Program|"This 12-week, in-season exercise intervention is designed for athletes with FAI syndrome and consists of three progressive phases.~Phase 1 (Weeks 1-4): Focus on neuromuscular re-education and motor control using low-load exercises to improve hip and core activation, alignment, and stability.~Phase 2 (Weeks 5-8): Targeted strengthening with increased load and movement complexity, emphasizing single-leg control, endurance, and pelvic stability.~Phase 3 (Weeks 9-12): Integration of dynamic control, proprioception, and sport-specific movement patterns to support return to performance.~Exercises target gluteus medius, gluteus maximus, core musculature, and functional movement systems. Participants complete the program \>=3 times per week. Weekly questionnaires will monitor symptoms, adherence, and other management (e.g., physiotherapy)."
219036207|NCT07108647|OTHER|Progressive Muscle Relaxation|Participants in the time and attention control group will complete a 12-week, three-phase progressive muscle relaxation (PMR) program based on the Jacobson method. Phase 1 introduces isolated muscle tensing and relaxing to build awareness of muscle tension and promote body-mind connection. Phase 2 focuses on sequential relaxation of muscle groups, enhancing control and reducing stress. Phase 3 transitions to full-body relaxation through guided breathing and visualization techniques. Sessions are practiced 2-3 times per week using audio guides, with weekly check-ins from study staff. Symptom response, adherence, and participant experience are tracked throughout the season.
218898312|NCT06915246|DRUG|BiCNU|Carmustine with Ethanol
219036208|NCT07108413|BEHAVIORAL|Activ4Brain Program|The Activ4Brain Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session is divided in four blocks. Each block consists of 5 min aerobic exercises and 5 min of cognitive training. Participants are instructed to keep moving, marching in place, while performing the cognitive training tasks to maintain the increased heart rate. Each group class is composed of four participants with as must as possible a narrow age range given the participants' schedule convenience.
219517867|NCT02386033|DRUG|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
219517868|NCT03361371|DEVICE|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
218898313|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218898314|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
218898315|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
218898316|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
218898317|NCT06917755|OTHER|Virtual Reality Training in Thyroid Surgery|Participants will use an application in an Immersive Virtual Reality environment. In this module, the participant will be the chief surgeon and will be guided to accomplise the first steps of thyroidectomy: from neck incision until continious neuromonitoring device placement in vagus nerve.
218898318|NCT06917755|OTHER|Convetional Training|This intervation consists of traditional methods of training. Participants will read specific chapters of a technical book specialised in Endocrine Surgery (Atlas of Thyroid Surgery- Alexander Shifrin). Also, they will be provided with videos of the clinic's archive which will support them with specific surgical steps : neck incision up to Continious Neuromonitoring Device placement on Vagus nerve.
218898319|NCT06922422|BEHAVIORAL|Sensory-Motor Integration Exercises|A structured sensory-motor integration program based on sensory play activities designed to enhance sensory processing and balance. Each session lasted 45 minutes, conducted four times per week, for a total of 64 sessions over 16 weeks. Activities targeted multiple sensory modalities, including tactile, proprioceptive, and vestibular inputs.
218898320|NCT06922422|BEHAVIORAL|Conventional therapy group|Conventional therapy sessions consisting of Applied Behavior Analysis (ABA) and massage therapy without specific sensory-motor integration activities. Each session lasted 45 minutes, conducted four times weekly, for a total of 64 sessions over 16 weeks.
218898321|NCT06921044|DRUG|R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone|Rituximab ：375 mg/m2，ivgtt，d0； Mitoxantrone Liposome ： The first dose level: 6mg/m2, ivgtt, d1; The second dose level: 8mg/m2, ivgtt, d1; The third dose level: 10mg/m2, ivgtt, d1; Cyclophosphamide :400 mg/m2，ivgtt，d1； Vincristine :1mg（，ivgtt，d1； Prednisone:40 mg/m2，po.，d1-5； Q3W
218898322|NCT06920758|DIETARY_SUPPLEMENT|USPlus DERM Bioactive Fatty Acids 160 mg Softgels|"USPlus® DERM Bioactive Fatty Acids (160 mg) Ingredient List (Per Softgel)~Active: 100% Concentrated Lipidosterolic Extract of Saw Palmetto (Serenoa repens).~Shell: Bovine Gelatin, Glycerin, Water"
218898323|NCT06920758|OTHER|Placebo softgel|"Placebo Ingredient List:~Palm oil Gelatin Glycerin Water Caramel color"
219517869|NCT03361371|DEVICE|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
218898324|NCT06920966|OTHER|Cold Water Immersion (CWI)|Participants undergo five intermittent immersions of 2 minutes each in cold water (11°C), with 2-minute rest periods in between.
218898325|NCT06920966|OTHER|Hot water immersion (HWI)|Participants undergo a continuous immersion of 18 minutes in hot water (38°C)
218898326|NCT06920966|OTHER|Thermography-Guided Immersion (TI)|Based on thermographic assessments, participants with a hypothermic profile (decreased temperature) receive hot water immersion, while those with a hyperthermic profile (increased temperature) receive cold water immersion.
218898327|NCT06922136|DEVICE|Hyalo Gyn Vaginal Gel|Hyalo Gyn® is uniquely formulated with Hydeal-D®, a proprietary HA derivative component manufactured by Fidia Farmaceutici S.p.A.
218898328|NCT06922136|OTHER|Placebo|Placebo
218898329|NCT06921096|OTHER|Tai Chi|The Tai chi group practiced 24-form simplified Tai Chi for 12 weeks, 3 times/week, 60 minutes/session (including 5-minute warm-up and 5-minute cool-down) at our university's track, under professional coaching, from 8:00-9:10 AM. The first 4 weeks were for learning, and the next 8 for consolidation.
219204088|NCT06613828|BEHAVIORAL|Mnemonic-Based Educational Training for Stroke Symptom Recognition|"This is a Culturally Adapted Mnemonic-Based Educational Strategies for Rapid Stroke Symptom Recognition in the Spanish-Speaking Population.~It uses five distinct mnemonic strategies (RAPIDO, CORRE, DALE, CAMALEON, ICTUS 911), each specifically tailored for a Spanish-speaking audience.~Aims to improve the recognition of early cerebrovascular disease symptoms, differentiating it from other clinical studies that might focus on different health conditions or target populations.~Emphasizes its focus on rapid action by educating participants about stroke symptoms and the importance of contacting emergency services (911)."
219204089|NCT06526520|DRUG|Exposure to progesterone or HRT medication|to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
219204090|NCT04908930|BEHAVIORAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
219204091|NCT06677320|OTHER|Exercise|Patients with rotator cuff disease will receive exercise treatment for two months.
219204092|NCT06854380|DRUG|Intralesional injection of steroids (betamethasone), (Betafos®) and hyaluronidase (enzyme), (Hynidase®) into benign vocal fold lesions by a naso-fiberscope with a side working channel(Storz 11001UD1)|that this intervention is intralesional injection of glucocorticoid (betamethasone) and enzyme (hyaluronidase) via flexible fiberscope
218898330|NCT06922084|DEVICE|Clareon PanOptix|Bilateral Clareon PanOptix IOL implantation
218898331|NCT06922084|DRUG|Clareon PanOptix PRO|Bilateral Clareon PanOptix PRO IOL implantation
218898332|NCT06922084|DRUG|Mix-and-Match PanOptix/Vivity|Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye
218898333|NCT06921421|DIAGNOSTIC_TEST|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging captures at specific timepoints.
219036209|NCT07108413|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session consists of a sequence of four different 5 min blocks of aerobic exercise repeated twice. Each block consists of a combination of three different rhythmic movements. Each group class is composed of four participants.
218898334|NCT06921902|DEVICE|FreeStyle Libre 3|Abbott Sensor Based Glucose Monitoring System (FreeStyle Libre 3 System)
219036210|NCT07110233|DEVICE|TheraSphere® Yttrium-90 microspheres|Administered intra-arterially
219036211|NCT07110233|OTHER|Health Related Quality of Life Questionnaires (HRQOL)|Surveys administered
219036212|NCT06912802|OTHER|Non-Intervention|Non-Intervention study
219036213|NCT06008288|DRUG|JAB-21822|800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
219036214|NCT02813343|DEVICE|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
219036215|NCT04262895|DRUG|TTI-0102|TTI-0102 is a cysteamine precursor.
219036216|NCT04262895|DRUG|Placebo|Placebo
219036217|NCT06228430|DRUG|Acyclovir 800 mg Tablet|Acyclovir 800 mg Tablet (Test Drug)
219036218|NCT06228430|DRUG|Zovirax™ 800 mg Tablet|Zovirax™ 800 mg Tablet (Reference Drug)
219036219|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
219036220|NCT01879566|OTHER|No intervention will be done. The study is observational|
219036221|NCT05905484|DRUG|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
219036222|NCT05905484|DRUG|Placebo|A single dose of matching placebo will be administered.
219036223|NCT05905484|DRUG|Moxifloxacin|A single dose of Moxifloxacin will be administered.
219517870|NCT00756288|PROCEDURE|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
219611952|NCT01875978|DIETARY_SUPPLEMENT|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
218898335|NCT06921343|DRUG|Iron (III) Hydroxide Polymaltose (50 mg/5 mL)|"Participants randomized to the intervention group will receive oral iron supplementation in addition to a gluten-free diet. The specific iron formulation used in this study is Iron (III) Hydroxide Polymaltose (50 mg/5 mL) at a dosage of 6 mg/kg/day, up to a maximum of 100 mg/day, for 3 months.~The iron supplement will be given once daily, preferably on an empty stomach or with vitamin C-containing foods to enhance absorption. Parents/caregivers will be instructed on proper administration, and adherence will be monitored through weekly self-reported intake logs and pharmacy dispensing records.~This intervention is specifically targeted at children with newly diagnosed celiac disease and iron deficiency without anemia.~The study follows a non-inferiority design, comparing the effect of iron supplementation versus a gluten-free diet alone on ferritin levels."
218898336|NCT06921343|OTHER|Gluten-free diet|Participants in the control group will follow a strict gluten-free diet, the standard-of-care treatment for celiac disease. No iron supplementation will be given. Compliance will be monitored through self-reported adherence and TTG antibody levels at follow-up.
218898337|NCT06920979|OTHER|(semi)continue monitoring of patients at risk for sepsis at home|(semi)continue monitoring of patients at risk for sepsis at home
218898338|NCT06922487|PROCEDURE|Karolinska Sleepiness Scale, KSS|Assessment of sleepiness during resection using KSS
218898339|NCT06921291|DRUG|Salbutamol (Ventolin®)|Randomized controlled trials
218898340|NCT06920823|PROCEDURE|antegrade (proximal entry) fixation|In the antegrade headless cannulated screw fixation technique, a small incision was made on the extensor aspect of the fractured metacarpal at the level of the carpometacarpal joint.
218898341|NCT06920823|PROCEDURE|retrograde (distal entry) fixation|In the fixation technique with retrograde headless cannulated screw, a small incision was made on the extensor side of the fractured metacarpal at the level of the metacarpophalangeal joint.
218898342|NCT06921798|OTHER|mHealth|This mHealth intervention is designed to provide health education, and to notify study participants when their result is ready and it is time for them to return to the healthcare clinic for follow up.
218898343|NCT06921642|DEVICE|Echocardiography images|Addition of a recording loop during routine ultrasound, during which the patient is in simplified standardized ventilation
218898344|NCT06920862|BEHAVIORAL|Multi-Modal Digital Intervention|"Participants in this group will receive a multi-modal digital intervention designed to enhance healthy weight control behaviors among overweight and obese adolescents.~1. The intervention integrates AI-driven coaching, interactive platforms, gamified applications, and real-time feedback mechanisms.~2. Participants will complete biweekly intervention sessions (2 hours each) over a 3-month period.~3. The intervention is grounded in the Theory of Planned Behavior (TPB) to target attitudes, subjective norms, and perceived behavioral control regarding weight control behaviors.~4. Participants will have access to the Virti platform, where they will receive personalized guidance and feedback."
218898345|NCT06939712|BEHAVIORAL|Online Positive Psychology Intervention|A 6-week online psychological support program, held once a week, primarily organized by a facilitator, with patient-led discussions and communication.
218898346|NCT06939712|OTHER|Routine Care|A 6-week program of health education provided by IBD specialists and nurses during patient follow-ups, tailored to individual patient circumstances and needs. Topics include IBD disease knowledge, medication management, diet, exercise, lifestyle, psychological support, and follow-up care. Patients in this group will also join a control group WeChat group for study-related communication.
218898347|NCT01603485|DRUG|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
218898348|NCT01603485|DRUG|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
218898349|NCT01603485|DRUG|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
219611953|NCT05662176|OTHER|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
218898350|NCT01603485|DRUG|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
219204093|NCT07007013|OTHER|Humor therapy|The intervention consists of a cycle of 8 group sessions (one per week) led by trained professionals specialized in humor ('clown doctors'). Each session will last approximately 90 to 120 minutes
219517871|NCT00756288|PROCEDURE|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
219517872|NCT05329805|BEHAVIORAL|job crafting intervention|the participated nurses will receive session about job crafting followed by activity related to job crafting
219517873|NCT05701683|DRUG|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
219517874|NCT02114697|DRUG|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
219611954|NCT05662176|OTHER|Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
219611955|NCT02436343|OTHER|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
219611956|NCT03561038|DEVICE|Franseen Needle|Comparing 2 needles designed for tissue acquisition
219611957|NCT03561038|DEVICE|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
219517875|NCT02114697|BEHAVIORAL|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
219517876|NCT02632877|DRUG|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
218898351|NCT01603485|DRUG|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
218898352|NCT02154256|BEHAVIORAL|Increasing incentives|Offer incentives that increase over time.
218898353|NCT02154256|BEHAVIORAL|Decreasing incentives|offer incentives that decrease over time
218898354|NCT02154256|BEHAVIORAL|stable incentives|offer incentives that are stable over time, but higher than usual care
218898355|NCT06937658|DEVICE|Alert-based care|Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators
218898356|NCT06937658|DEVICE|Guideline-based care|Guideline-based care is the current typical standard for longitudinal management of patients with wireless pacemakers and implantable defibrillators
218898357|NCT04491136|DRUG|ACEI/ARB|Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
218898358|NCT04491136|DRUG|ARNI|Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
218898359|NCT00587717|DRUG|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
218898360|NCT00587717|DRUG|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
218898361|NCT03929107|BIOLOGICAL|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
219204094|NCT06670911|DRUG|Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)|Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
219517877|NCT02632877|DRUG|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
219517878|NCT00991848|DRUG|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
219517879|NCT05903365|OTHER|Blood sampling|Additional blood samples at J100, M6, M12, M24
219517880|NCT01624519|PROCEDURE|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
218898362|NCT01611194|DRUG|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
218898363|NCT01611194|DRUG|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
218898364|NCT04346992|OTHER|no intervention|no intervention
218898365|NCT03999060|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
219036224|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
219036225|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
219204095|NCT06863129|PROCEDURE|Internal Fixation|Internal Fixation
219517881|NCT04897802|DRUG|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
218898366|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
218898367|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
218898368|NCT02756572|DRUG|Cladribine|Given IV
218898369|NCT02756572|DRUG|Cyclosporine|Given PO
218898370|NCT02756572|DRUG|Cytarabine|Given IV
218898371|NCT02756572|BIOLOGICAL|Filgrastim|Given SC
218898372|NCT02756572|DRUG|Fludarabine Phosphate|
218898373|NCT02756572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
218898374|NCT02756572|OTHER|Laboratory Biomarker Analysis|Correlative studies
218898375|NCT02756572|DRUG|Melphalan|Given IV
219036226|NCT03155009|DRUG|Alectinib|600 mg orally BID with food
219036227|NCT00909948|OTHER|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
219517882|NCT04897802|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
219517883|NCT00006864|BIOLOGICAL|aldesleukin|
219517884|NCT05842538|DEVICE|Triathlon|Total knee arthroplasty
219611958|NCT04311294|DRUG|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
218898376|NCT02756572|DRUG|Mitoxantrone Hydrochloride|Given IV
218898377|NCT02756572|DRUG|Mycophenolate Mofetil|Given PO
218898378|NCT02756572|OTHER|Questionnaire Administration|Ancillary studies
218898379|NCT02756572|DRUG|Sirolimus|Given PO
219036228|NCT00909948|RADIATION|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
219036229|NCT02780804|DRUG|Entinostat|Given PO
219036230|NCT02780804|OTHER|Laboratory Biomarker Analysis|Correlative studies
219036231|NCT02780804|OTHER|Pharmacological Study|Correlative studies
219036232|NCT03126994|DEVICE|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
219036233|NCT03126994|DEVICE|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
219036234|NCT03126994|DEVICE|Detecto SOLO|Measurement of Body Weight and BMI
219517885|NCT05981625|OTHER|Giomer varnish containing surface pre-reacted glass fillers|"Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity"
219036235|NCT02130063|DRUG|iron isomaltoside 1000 (Monofer®)|
219036236|NCT02130063|DRUG|iron sucrose (Venofer®)|
219036237|NCT01039896|DRUG|Period I : SLM0807, Period II : HKB0701 and SLM0807|
219036238|NCT01039896|DRUG|Period I : HKB0710 and SLM0807, Period II : SLM0807|
219036239|NCT06221228|BEHAVIORAL|Audio-visual assisted Flipped Classroom (FC) CAPD Training Programme|"FC CAPD programme is a one-week individual intervention, which consists of five sessions (8-hours each).~Pre-class audio-visual tutorials will be provided for self-study prior to face-to-face (F2F) sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace.~Participants will be asked to take note of any issues or difficulties they encounter while watching the video.~A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session.~Take-home exercises will allow participants to revise the materials covered in the videos and consolidate their learning."
219036240|NCT04914728|PROCEDURE|mini-invasive lumbar arthrodesis|"* The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
219036241|NCT00820001|BEHAVIORAL|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
219204096|NCT06863129|PROCEDURE|Resection and reconstruction|Resection and reconstruction
219036242|NCT00820001|BEHAVIORAL|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
219036243|NCT00820001|OTHER|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
219517886|NCT05478148|DEVICE|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
218898380|NCT02756572|RADIATION|Total-Body Irradiation|Undergo TBI
218898381|NCT02756572|DRUG|Melphalan Hydrochloride|Given IV
218898382|NCT00293995|PROCEDURE|Repair of unilateral inguinal hernia|
218898383|NCT04359485|PROCEDURE|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
218898384|NCT04359485|OTHER|Saline|Sodium chloride
218898385|NCT01579890|DRUG|Diclofenac|diclofenac topical lotion
219036244|NCT00820001|OTHER|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
219204097|NCT06870565|DRUG|paclitaxel and platinum|After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin \[Area Under Curve (AUC) = 4-5\], Q3W (every 3 weeks is a dosing cycle), administered on the first day of each cycle, for a total of 4 cycles. Adjuvant chemotherapy started 4 weeks after the end of external irradiation therapy, and chemotherapy-related adverse reactions dropped to grade 2 or below before chemotherapy began. If not met, it can be postponed for 2 weeks.
219204098|NCT06870565|DRUG|platinum|During EBRT, cisplatin (40 mg/m2) or carboplatin (AUC = 2) was used for concurrent chemotherapy once a week for a total of 5 times. On the day of cisplatin infusion, radiotherapy should be performed after cisplatin or carboplatin.
219517887|NCT05438797|DRUG|Adoptive TIL-TCM transfer therapy|Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
219517888|NCT02471469|DRUG|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
218898386|NCT05890469|COMBINATION_PRODUCT|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
219036245|NCT01064895|DEVICE|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
219036246|NCT03837548|OTHER|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
219036247|NCT03837548|OTHER|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
219036248|NCT05522465|DRUG|Prednisone|Prednisone 4mg/kg.d, d1-4
219036249|NCT05522465|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
219036250|NCT04133493|DEVICE|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
219611959|NCT04311294|DRUG|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
219611960|NCT04311294|DRUG|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
218898387|NCT05890469|COMBINATION_PRODUCT|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
219036251|NCT04133493|DEVICE|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
219036252|NCT00624962|DIETARY_SUPPLEMENT|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
219036253|NCT00624962|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
219036254|NCT05718635|DIAGNOSTIC_TEST|coloured duplex|colored duplex to locate numbers sites and size of perforators.
219036255|NCT05718635|PROCEDURE|supra facial dissection|flap raising in supra facial plane
219036256|NCT05274256|PROCEDURE|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
219036257|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
219036258|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
219036259|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
219036260|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
219036261|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
219517889|NCT02060006|DRUG|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
219517890|NCT05561400|DEVICE|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
219517891|NCT05561400|OTHER|Placebo|sham tDCS to the right cerebellum
219517892|NCT04085770|DRUG|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
219517893|NCT04670432|DRUG|Hydroxyethylrutoside|500 mg film-coated tablet
219517894|NCT03732170|DEVICE|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
218898388|NCT06267534|DEVICE|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
218898389|NCT02345213|DRUG|E2020|E2020 tablets will be orally administered once daily after breakfast
218898390|NCT02345213|DRUG|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
218898391|NCT02051322|DEVICE|Jet Nebulizer|
218898392|NCT02051322|DEVICE|Trunk Mask Nebulizer|
218898393|NCT02051322|DEVICE|Aerobika Nebulizer|
218898394|NCT01290744|DRUG|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
218898395|NCT01290744|DRUG|Placebo|Daily for 12 months
218898396|NCT03833414|PROCEDURE|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
219036262|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
219036263|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
219036264|NCT00358202|DRUG|cefepime|cefepime hydrochloride 1gm IM q24h
219036265|NCT00358202|DRUG|ceftriaxone|ceftriaxone 1 gm IM q24h
219036266|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
219036267|NCT01859507|DRUG|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
219036268|NCT00275158|DRUG|L-Arginine Supplementation|
219036269|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
218898397|NCT01166425|DRUG|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
219036270|NCT03621228|DEVICE|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
219036271|NCT01715818|DRUG|Placebo|matching aleglitazar placebo tablet orally daily
219036272|NCT01715818|DRUG|aleglitazar|150 mcg orally daily
218898398|NCT01166425|DRUG|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
218898399|NCT02404818|PROCEDURE|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
218898400|NCT02404818|PROCEDURE|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
218898401|NCT05633888|DEVICE|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
219036273|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
219036274|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
219036275|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
219036276|NCT04476030|DRUG|SAGE-217|Oral capsules
219036277|NCT04476030|DRUG|Matching Placebo|Oral capsules
219036278|NCT04476030|DRUG|Sertraline|Oral tablets
219036279|NCT04476030|DRUG|Escitalopram|Oral tablets
219036280|NCT04476030|DRUG|Citalopram|Oral tablets
219036281|NCT04476030|DRUG|Duloxetine|Oral capsules
219036282|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
219517895|NCT03732170|DEVICE|AH plus® sealer|The participant will be treated with AH plus® sealer.
218898402|NCT03009799|DRUG|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
219036283|NCT03395366|OTHER|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
219036284|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
219036285|NCT05159245|DRUG|Alectinib|ALK
219036286|NCT05159245|DRUG|Cobimetinib|MEK1, MEK2
219036287|NCT05159245|DRUG|Vismodegib|Hedgehog
219036288|NCT05159245|DRUG|Trastuzumab+Pertuzumab|HER2
219036289|NCT05159245|DRUG|Entrectinib|NTRK/ ROS1, ALK
219036290|NCT05159245|DRUG|Atezolizumab|PD-L1
219036291|NCT05159245|DRUG|Vemurafenib|BRAF V600
219036292|NCT05159245|DRUG|Regorafenib|KIT/BRAF, RET
219036293|NCT05159245|DRUG|Apalutamide|AR
219517896|NCT00079170|DIETARY_SUPPLEMENT|garlic|
219517897|NCT00079170|DRUG|docetaxel|
219517898|NCT02714309|DIETARY_SUPPLEMENT|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
219517899|NCT02714309|OTHER|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
219517900|NCT02714309|OTHER|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
219517901|NCT02714309|OTHER|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
219036294|NCT05159245|DRUG|Abemaciclib|CDK4/6
219517902|NCT02521207|DRUG|Ibuprofen|
219036295|NCT05159245|DRUG|Tepotinib|MET ex14
219036296|NCT05159245|DRUG|Dabrafenib|RAF
219036297|NCT05159245|DRUG|Trametinib|MEK1, MEK2
219204100|NCT06771284|BEHAVIORAL|Function-based assessment and intervention|This intervention will be implemented by the caregiver. The intervention will consist of teaching the child an alternative, appropriate skill (usually communication) to replace the problem behavior. The caregiver will provide reinforcement for the appropriate skill and no reinforcement (i.e., extinction) following problem behavior. The caregiver will also learn and use general strategies for teaching social-emotional skills (e.g., setting appropriate rules) as part of the intervention.
219517903|NCT04238156|OTHER|Hypopressive abdominal exercises|Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
219036298|NCT05159245|DRUG|Dabrafenib+Trametinib|RAF, MEK1, MEK2
219036299|NCT05159245|DRUG|Pemigatinib|FGFR2
219036300|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
219204101|NCT06867042|DRUG|Tacrolimus Lipid Suspension for enema|Tacrolimus Lipid Suspension for enema 4 mg/vial
219517904|NCT00424489|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
219517905|NCT00424489|DRUG|Cyclophosphamide|
219517906|NCT00424489|DRUG|ATG (rabbit)|
219517907|NCT00424489|DRUG|Mesna|
219517908|NCT00424489|DRUG|Methylprednisolone|
218898403|NCT03009799|DRUG|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
218898404|NCT03583970|DEVICE|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
218898405|NCT06288074|DIAGNOSTIC_TEST|Multi-omics tests|Biological sample collection for Multi-omics tests
218898406|NCT05858372|DIETARY_SUPPLEMENT|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
219036301|NCT00445510|DRUG|GSK256066|
219036302|NCT01653522|DRUG|Triptan|
219517909|NCT00424489|DRUG|G-CSF|
219517910|NCT04108325|DRUG|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
219036303|NCT01653522|DRUG|Doxycycline|
219036304|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
219036305|NCT02243150|DRUG|Placebo|
219036306|NCT02404311|BIOLOGICAL|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
219036307|NCT02404311|BIOLOGICAL|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
219517911|NCT00345410|DRUG|AVE1625 B|
219517912|NCT05028842|OTHER|No intervention|None.This is an observational study
219517913|NCT06149936|DEVICE|excimer light|Excimer laser using high-dose monochromatic UV radiation
219517914|NCT03614520|OTHER|Administration of olive oil|25 mL of extra virgin olive oil
219517915|NCT03614520|OTHER|Administration of red wine|150 mL or Red Wine
219204102|NCT06867042|DRUG|Identical Tacrolimus-free Lipid Suspension for Enema|Identical Tacrolimus-free Lipid Suspension for Enema
219517916|NCT03614520|OTHER|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
219517917|NCT03614520|OTHER|Water|Mineral water will be given as placebo
219611961|NCT02574182|RADIATION|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
219517918|NCT03614520|OTHER|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
218898407|NCT05858372|OTHER|Placebo|Placebo
218898408|NCT02648568|BEHAVIORAL|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
218898409|NCT02648568|BEHAVIORAL|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
218898410|NCT03928795|PROCEDURE|elective caesarean section|elective caesarean section
218898411|NCT04057521|OTHER|Care Coordination|Comprehensive care coordination.
218898412|NCT04277065|PROCEDURE|BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection|Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
218898413|NCT04277065|PROCEDURE|cotton tourniquet|cotton tourniquet
218898414|NCT04371965|DRUG|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
218898415|NCT01065038|DRUG|Anagrelide|
218898416|NCT01065038|DRUG|Hydroxyurea|
218898417|NCT02602535|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
218898418|NCT02602535|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
218898419|NCT04324671|DEVICE|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP\*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
218898420|NCT03222635|PROCEDURE|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
218898421|NCT00110539|BEHAVIORAL|Complementary and alternative medicine education|
218898422|NCT03984110|DRUG|Ozurdex|Intravitreal injection
218898423|NCT03984110|DRUG|Eylea|Intravitreal injection
219517919|NCT03614520|OTHER|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
219517920|NCT03614520|OTHER|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
219517921|NCT01632709|DRUG|Bupivacaine|one injection of 10ml of .25%
219611962|NCT06213376|BEHAVIORAL|Melodic Intonation Therapy|Melodic Intonation Therapy uses intonation and melody to aid individuals with aphasia with producing words.
219611963|NCT06213376|BEHAVIORAL|Video Feedback Performance Review|Participant will view recording to judge correct and incorrect productions of trained words and to identify motor techniques increasing intelligibility
218898424|NCT04510714|DEVICE|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
218898425|NCT04456634|DRUG|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
218898426|NCT04456634|OTHER|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
218898427|NCT05588349|OTHER|Dry needling|Dry needling + stretching exercise
218898428|NCT05588349|OTHER|Stretching exercise|Stretching exercise only
219517922|NCT01632709|DRUG|Placebo|Dry needling
219517923|NCT03783208|DRUG|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
219517924|NCT03783208|OTHER|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
219517925|NCT02554864|DRUG|lidocaine|Local anesthetic
219517926|NCT02554864|DRUG|ropivacaine|Local anesthetic
219611964|NCT01669291|DRUG|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
219611965|NCT01669291|DRUG|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
219611966|NCT01669291|DRUG|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
219517927|NCT05941221|PROCEDURE|pericapsular nerve group (PENG) block|patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
219517928|NCT02045121|DEVICE|Indwelling Pleural Catheter|
218898429|NCT06139549|OTHER|Gross motor development group session|Group session for gross motor development
218898430|NCT01848158|DEVICE|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
218898431|NCT01848158|DEVICE|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
219204103|NCT07016789|DEVICE|Near-infrared spectroscopy monitoring (NIRS) INVOS 5100C|Continuous bilateral cerebral oxygen saturation monitoring using near-infrared spectroscopy (NIRS) during TAVI. Sensors are placed on the forehead to record rSO₂ values at predefined timepoints. Device used: INVOS 5100C (Medtronic/Covidien).
219517929|NCT02045121|PROCEDURE|Talc Pleurodesis|
219517930|NCT01767064|OTHER|Posted commitment letter|
219517931|NCT00321542|OTHER|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
219517932|NCT03825809|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
219517933|NCT03825809|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
219517934|NCT03825809|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
218898432|NCT03790111|DRUG|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
218898433|NCT01432405|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
218898434|NCT01432405|DRUG|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
218898435|NCT02467179|DEVICE|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
218898436|NCT02467179|DEVICE|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
219036308|NCT02404311|BIOLOGICAL|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
219036309|NCT02404311|BIOLOGICAL|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
219204104|NCT06681389|DRUG|NP-201 acetate injection (Part A)|Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
219204105|NCT06681389|DRUG|Placebo|Matching placebo administered across Part A and Part B
219204106|NCT01992913|BEHAVIORAL|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
219036310|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
219204107|NCT01992913|OTHER|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
219517935|NCT03825809|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
219517936|NCT03825809|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
219517937|NCT03825809|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
219517938|NCT02351726|DEVICE|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
219517939|NCT03552757|DRUG|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
219517940|NCT03552757|DRUG|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
219517941|NCT03552757|DRUG|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
219517942|NCT03552757|DRUG|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
219517943|NCT02674334|DEVICE|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
219517944|NCT02674334|DEVICE|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
219036311|NCT04552938|OTHER|pre-LVA|Venous serum samples were collected from patients before LVA.
219036312|NCT04552938|OTHER|post-LVA|Venous serum samples were collected from patients one-month after LVA.
219036313|NCT00218296|DRUG|Usual Care Group|Nicotine replacement therapy
219036314|NCT00218296|OTHER|Reduction Group|Subject selects preferred method for reduction.
219036315|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
219517945|NCT01673958|OTHER|Exercise|Comparison between stair descending and stair ascending training
219517946|NCT06111911|DIAGNOSTIC_TEST|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
219517947|NCT05621265|BEHAVIORAL|Automated Text messaging|daily text message
219517948|NCT05921890|DRUG|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
219611967|NCT03738072|DIAGNOSTIC_TEST|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
219036316|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
219036317|NCT00634088|DRUG|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
219517949|NCT03765632|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
219517950|NCT03765632|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
219517951|NCT03765632|DRUG|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
219517952|NCT04905433|BEHAVIORAL|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
219517953|NCT04905433|BEHAVIORAL|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
219517954|NCT04558554|OTHER|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
219517955|NCT04655599|DRUG|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
219611968|NCT04876638|DRUG|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
219611969|NCT04840381|BEHAVIORAL|Questionnaire administrations|Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
219611970|NCT00047450|DRUG|Citalopram (Celexa)|Citalopram for 3 months
219611971|NCT00047450|DRUG|Placebo|Placebo for 3 months
219611972|NCT04429945|DEVICE|Virtual Reality|Virtual Reality Headset with Virtual Reality Applications
219517956|NCT04655599|DRUG|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
219517957|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
218898437|NCT02494960|BEHAVIORAL|The brief smoking cessation AWARD model|"* Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
219517958|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
218898438|NCT02494960|BEHAVIORAL|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
218898439|NCT03798717|DIAGNOSTIC_TEST|Heating|Warm water immersion
219204108|NCT01992913|BEHAVIORAL|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
219517959|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219517960|NCT04362397|BEHAVIORAL|FoCo|This is an attention, care and self-care training.
219517961|NCT04362397|BEHAVIORAL|No intervention|This is a waiting list
219517962|NCT00543478|DRUG|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
219517963|NCT00543478|DRUG|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
219517964|NCT01307098|DRUG|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
219611973|NCT06577233|DRUG|Bupivacaine Hydrochloride|10cc of 0.25% Bupivacaine Hydrochloride will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
219611974|NCT06577233|DRUG|Normal saline|10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
219611975|NCT06821100|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases. Ta1 has been shown to provide increased response to vaccines.
219611976|NCT03367195|DRUG|Omeprazole|1 Omeprazole 20 mg capsules twice daily
219611977|NCT03367195|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
219611978|NCT03367195|DRUG|Placebo capsule of Omeprazole|1 placebo capsule of omeprazole, twice daily
219611979|NCT03367195|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
219611980|NCT03354598|DRUG|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
219611981|NCT03354598|DRUG|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
219517965|NCT01307098|DRUG|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
219517966|NCT01307098|DRUG|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
219611982|NCT05475197|DEVICE|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
219611983|NCT04870710|DEVICE|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
219611984|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
219611985|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
218898440|NCT00942903|DEVICE|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
218898441|NCT02752880|DRUG|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
218898442|NCT02752880|DRUG|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
218898443|NCT01686334|BIOLOGICAL|DC vaccine|Autologous WT1 mRNA-electroporated DCs
219204109|NCT05029726|DRUG|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
219204110|NCT05029726|DRUG|normal saline|normal saline in 30cc syringes administered using ESPB technique
219517967|NCT00005842|BIOLOGICAL|trastuzumab|
219517968|NCT00005842|DRUG|tipifarnib|
219517969|NCT02660242|DRUG|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
219517970|NCT02660242|OTHER|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
219611986|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
219611987|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
219517971|NCT02660242|OTHER|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
218898444|NCT06142539|RADIATION|CT Radiation Doses|Obtaining Low CT Radiation Doses by Adjusting Dose Levels
218898445|NCT05314868|DEVICE|PhotoFix|Surgical repair with patch.
218898446|NCT01777308|BIOLOGICAL|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
218898447|NCT01799707|BEHAVIORAL|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
218898448|NCT01799707|BEHAVIORAL|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
218898449|NCT04381858|DRUG|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction."
219204111|NCT06201403|DIAGNOSTIC_TEST|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
219517972|NCT01282151|DRUG|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
219517973|NCT01282151|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
218898450|NCT04381858|DRUG|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
218898451|NCT03410628|DEVICE|gammaCore|Non-invasive vagal nerve stimulator
219517974|NCT03977051|BEHAVIORAL|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
219517975|NCT02921477|DRUG|bosutinib|
219517976|NCT01856153|DIETARY_SUPPLEMENT|Before meal|
219517977|NCT01856153|DIETARY_SUPPLEMENT|With Meal|
219517978|NCT01856153|DIETARY_SUPPLEMENT|After meal|
219517979|NCT01124851|DRUG|ABT-652|See arm description for details
219517980|NCT01124851|DRUG|Placebo|See arm description for details
219517981|NCT00982553|DRUG|Ribavirin|800mg once daily
219517982|NCT00982553|DRUG|Raltegravir|400mg twice daily
219517983|NCT03194581|DEVICE|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
219517984|NCT01432795|DEVICE|Gliding aids for medical compression stockings|"Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)"
218898452|NCT03212326|DRUG|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
219517985|NCT03236181|OTHER|SFA|High saturated fatty acid/SFA oil source
219517986|NCT03236181|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
218898453|NCT02942212|BEHAVIORAL|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
218898454|NCT02942212|BEHAVIORAL|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
218898455|NCT02942212|OTHER|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
218898456|NCT02942212|DRUG|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke \>10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
219517987|NCT03236181|OTHER|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
219517988|NCT03236181|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
219517989|NCT03056781|BEHAVIORAL|social interaction|Participants will engage in a social interaction with another person
219517990|NCT03056781|BEHAVIORAL|food consumption|Participants will be offered food stuffs to eat/drink
219517991|NCT02064595|PROCEDURE|External fixator|Treatment with external fixation
219517992|NCT02064595|PROCEDURE|Intramedullary nail|Fracture treated with intramedullary nail
219517993|NCT01345019|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
219517994|NCT01345019|DRUG|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
219517995|NCT01345019|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
218898457|NCT02942212|BEHAVIORAL|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
219517996|NCT01345019|DRUG|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
218898458|NCT02942212|BEHAVIORAL|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
218898459|NCT02942212|BEHAVIORAL|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
218898460|NCT03533673|BIOLOGICAL|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
218898461|NCT04333914|DRUG|Autophagy inhibitor (GNS651)|Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
218898462|NCT04333914|OTHER|Standard of care|"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest."
219204112|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
219517997|NCT01345019|DRUG|Denosumab (for the open-label treatment phase)|Administered by subcutaneous injection once every 4 weeks.
219517998|NCT05718778|DRUG|Piamprimab (AK105)|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
219517999|NCT00971893|DRUG|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
219518000|NCT01706471|DRUG|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
219518001|NCT01706471|DRUG|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
219518002|NCT02992171|BEHAVIORAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
219518003|NCT02834611|DRUG|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
219518004|NCT05556109|DIAGNOSTIC_TEST|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
219518005|NCT01818856|DRUG|Ritonavir withdrawal, atazanavir 200 mg/12h|
219518006|NCT01818856|DRUG|Telaprevir interactions|
219518007|NCT00235456|PROCEDURE|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
219518008|NCT00235456|PROCEDURE|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
219518009|NCT03816371|OTHER|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
219518010|NCT04558307|DIAGNOSTIC_TEST|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
219518011|NCT04558307|OTHER|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
219518012|NCT00114426|DEVICE|non-invasive mechanical ventilation|
219518013|NCT00925626|PROCEDURE|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
219518014|NCT00925626|PROCEDURE|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
219518015|NCT05960526|DRUG|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
219518016|NCT05960526|DRUG|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
219518017|NCT01252069|DRUG|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
219518018|NCT01252069|DRUG|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
219611988|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
218898463|NCT04333914|DRUG|Avdoralimab|Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
218898464|NCT04333914|DRUG|Monalizumab|Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
218898465|NCT03430791|DRUG|Nivolumab 240 mg IV|Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
219204113|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
219518019|NCT00526968|DRUG|EVT 101|8 mg capsule, single oral dose
219518020|NCT00526968|DRUG|EVT 101|15 mg capsule, single oral dose
219611989|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
218898466|NCT03430791|DRUG|Nivolumab 3 mg/kg|Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
219036318|NCT00634088|DRUG|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
219036319|NCT05360563|OTHER|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
219036320|NCT01578928|DRUG|SOM230|
219036321|NCT03951246|OTHER|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo …..~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
219036322|NCT00151814|DRUG|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
219518021|NCT00526968|DRUG|placebo|Placebo capsule, single oral dose
219518022|NCT03996512|OTHER|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
219518023|NCT05530681|DIAGNOSTIC_TEST|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
219518024|NCT05530681|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
219036323|NCT06366399|BEHAVIORAL|Resistance Exercise Timing|1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
219518025|NCT00072124|DRUG|cisplatin|
219518026|NCT00072124|DRUG|dacarbazine|
219518027|NCT00072124|PROCEDURE|conventional surgery|
219518028|NCT02778919|DRUG|KLH-2109|
219518029|NCT02778919|DRUG|Placebo|
219036324|NCT03891654|DIAGNOSTIC_TEST|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
219036325|NCT01120613|DRUG|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
219036326|NCT05548660|OTHER|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
219204114|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
219518030|NCT02778919|DRUG|Leuprorelin acetate|
219518031|NCT05834283|OTHER|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
219518032|NCT05834283|OTHER|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
219611990|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
219611991|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
218898467|NCT03430791|DRUG|Ipilimumab 1 mg/kg|Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
218898468|NCT03430791|DEVICE|NovoTTF200A (Optune)|A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
218898469|NCT02016976|DRUG|EMLA Analgesic Cream|
218898470|NCT02016976|DRUG|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
218898471|NCT05581602|DEVICE|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
219611992|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
219611993|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
218898472|NCT02918617|DRUG|Control toothpaste containing Novamin® technology|
218898473|NCT02918617|DRUG|Control toothpaste containing 1500 ppm fluoride as MFP|
218898474|NCT02918617|DRUG|Test toothpaste with nano-HAP (high concentration)|
218898475|NCT02918617|DRUG|Test toothpaste with nano-HAP (low concentration)|
218898476|NCT02918617|DRUG|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
218898477|NCT02918617|DRUG|Control toothpaste without nano-HAP|
218898478|NCT02918617|DRUG|Test toothpaste with nano-HAP (medium concentration)|
218898479|NCT02918617|DRUG|Test cream with nano-HAP (higher concentration)|
218898480|NCT02918617|DRUG|Control cream without nano-HAP|
218898481|NCT00791063|OTHER|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
218898482|NCT05390372|OTHER|human milk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
218898483|NCT05390372|OTHER|Routine care group|cream applied as part of hospital routine practice
218898484|NCT04456023|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of 0.6 - 6.0×10\^8 CAR positive viable T cells.
218898485|NCT05441826|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
218898486|NCT03840317|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
218898487|NCT02964221|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
218898488|NCT05118646|DEVICE|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
218898489|NCT05118646|DEVICE|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
218898490|NCT05062122|OTHER|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
218898491|NCT05062122|OTHER|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
218898492|NCT05062122|OTHER|control group|Manual dexterity was assessed before and after traditional physiotherapy.
218898493|NCT05317104|OTHER|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
218898494|NCT02937337|DEVICE|Laryngeal mask insertion with videostylet guided technique|
218898495|NCT02937337|DEVICE|Laryngeal mask insertion with standard blind technique|
218898496|NCT06453408|PROCEDURE|Punción seca con aguja retráctil|"The placebo dry needling protocol will be performed in the same position, with identical antiseptic measures and the same number of simulated incisions as the real dry needling protocol, using DONGBANG AcuPrime® 0.30 x 30mm blunt-tipped placebo needles with a retractable handle. These needles simulate the sensation of needle contact without penetrating the skin. The therapist will hold the needle and guide tube, pressing the tube against the skin and simulating needle manipulation. Changes in pressure direction will mimic the real technique. The protocol will end with compression using an alcohol swab and an upper trapezius stretch.~Participants in both groups will receive the same information about the sensations of the dry needling procedure. At the beginning, they will be informed that they may or may not feel the needle insertion. They will also be told that the physiotherapist will manually manipulate the needle multiple times during the procedure."
218898497|NCT06453408|PROCEDURE|Punción seca con aguja normativa.|To perform the actual SP, patients shall be asked to lie prone with arms close to the body. The dry needling shall be performed with a 0,30 × 30 mm DN needle (APS Regular Agupunt) with a guide tube. The therapist shall first clean the area with alcohol. The trapezius muscle is then firmly grasped with a clamp between the thumb and index finger, so that the needle is directed deep into the index finger until the tip of the needle is felt to be approaching (33). This procedure involves an approximate insertion of the needle to a depth of 30 mm and ensures the intramuscular penetration necessary for dry needling. Puncture of the PGM shall be performed using the Hong technique (34), performing up to 12 inlets and outlets, at a frequency of 1 Hz. When the needle is withdrawn, the area is firmly compressed with cotton wool for 60 seconds. Finally, the upper trapezius muscle is stretched, following the technique originally described by Simons (35).
218898498|NCT02754973|BEHAVIORAL|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
219611994|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
218898499|NCT02754973|BEHAVIORAL|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
218898500|NCT04471519|BIOLOGICAL|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
218898501|NCT04471519|BIOLOGICAL|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
218898502|NCT04471519|BIOLOGICAL|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
218898503|NCT04471519|BIOLOGICAL|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
218898504|NCT04471519|BIOLOGICAL|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
218898505|NCT04471519|BIOLOGICAL|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
218898506|NCT00291616|DRUG|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
219518033|NCT04999553|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
219518034|NCT04999553|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
219518035|NCT04999553|DEVICE|Low Frequency Right (LFR)|Low Frequency Right (LFR)
219518036|NCT00921193|DEVICE|Radiation Therapy Positioning System (RTPS)|
219518037|NCT03716141|OTHER|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
219518038|NCT03716141|OTHER|Conventional Saline dressing|saline dressing of diabetic wounds will be done
219518039|NCT05830019|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
219518040|NCT03151018|DEVICE|Resolute Onyx|
219518041|NCT04462458|DEVICE|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
219518042|NCT01718639|DEVICE|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
219518043|NCT01718639|DEVICE|IQP-LH-101 liquid|Oral medical device in the form of a liquid
218898507|NCT00291616|DRUG|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
218898508|NCT04849208|OTHER|Presentation of fast and slow trials|"In each task trial participants will solve a reasoning problem. Half of the trials will be traditional Slow trials in which participants get ample time to deliberate (i.e., 20 s). The other half of the trials will be Fast trials in which people do not get sufficient time to deliberate (i.e., 4 s deadline) and need to rely on intuitive processing"
218898509|NCT03111303|DEVICE|mechanical ventilation|Connection to mechanical ventilator
218898510|NCT02763306|DEVICE|Dermal Cooling System|Treatment with dermal cooling system.
218898511|NCT04154436|OTHER|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
218898512|NCT04154436|OTHER|Water (H2o)|Alkaline Solution
219518044|NCT01718639|OTHER|Placebo|
219611995|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
218898513|NCT06182878|BEHAVIORAL|Tender loving care intervention|Receiving weekly prenatal care counseling messages
218898514|NCT03910504|DRUG|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.
218898515|NCT03910504|DRUG|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
218898516|NCT00032669|DRUG|HAART|
218898517|NCT02582528|BEHAVIORAL|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
218898518|NCT02582528|BEHAVIORAL|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
218898519|NCT04839510|DRUG|MRG002|Administrated intravenously
218898520|NCT06244004|DRUG|Antiandrogen Therapy|Undergo SOC ADT
218898521|NCT06244004|PROCEDURE|Bone Scan|Undergo bone scan
218898522|NCT06244004|PROCEDURE|Computed Tomography|Undergo CT
219518045|NCT00000462|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219518046|NCT00000462|PROCEDURE|coronary artery bypass|
219518047|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
219518048|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
219518049|NCT00674999|DRUG|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
219518050|NCT05261685|PROCEDURE|Single-step transepithelial PRK|Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
219518051|NCT03382756|DIETARY_SUPPLEMENT|High fat diet|A diet consisting of more than 900kcal and 35% of fat
219518052|NCT03382756|DRUG|CKD-337|Test Drug
219611996|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
219611997|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
218898523|NCT06244004|DRUG|Cytotoxic Chemotherapy|Receive SOC cytotoxic chemotherapy
218898524|NCT06244004|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
218898525|NCT06244004|RADIATION|Radiation Therapy|Undergo MDRT
219518053|NCT05867576|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
219518054|NCT03931876|DRUG|Placebos|Single ascending dose administration
219518055|NCT03931876|DRUG|AV-006|Single ascending dose administration
218898526|NCT04239001|DRUG|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
218898527|NCT04921202|OTHER|Metabolic syndrome and meniscus injuries|Metabolic syndrome
219518056|NCT00388180|DRUG|GW501516|
218898528|NCT00051870|DEVICE|Magstim Rapid Magnetic Stimulator|
219518057|NCT00388180|DRUG|GW590735|
219518058|NCT00394108|PROCEDURE|Determination of neuropsychological status|
218898529|NCT03588663|DEVICE|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
218898530|NCT03588663|OTHER|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
218898531|NCT03588663|OTHER|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
219036327|NCT05548660|OTHER|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
219036328|NCT05548660|OTHER|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
219036329|NCT04958057|BEHAVIORAL|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
219036330|NCT00006181|BEHAVIORAL|Team-based intervention|
219036331|NCT00006181|BEHAVIORAL|One-on-one intervention|
219036332|NCT01293240|DEVICE|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
219036333|NCT00422032|DRUG|Clofarabine|"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"
219036334|NCT03903354|OTHER|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
219518059|NCT00386009|DRUG|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
219518060|NCT00386009|DRUG|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
219518061|NCT00010647|PROCEDURE|Acupuncture|
218898532|NCT03588663|OTHER|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
218898533|NCT00058396|BIOLOGICAL|lumiliximab|
218898534|NCT00985673|BIOLOGICAL|GSK2340274A|Two intramuscular injections
218898535|NCT00985673|BIOLOGICAL|GSK2340273A|Two intramuscular injections
219036335|NCT03666078|PROCEDURE|cesarean delivery|women delivered by cesarean section
219036336|NCT03594383|DEVICE|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
219204115|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
219518062|NCT00537225|BEHAVIORAL|exercise|tailored multifactor CVD risk reduction
219518063|NCT05493176|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
219518064|NCT01013025|PROCEDURE|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
218898536|NCT00985673|BIOLOGICAL|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
218898537|NCT00985673|BIOLOGICAL|Saline placebo|Single intramuscular injection
218898538|NCT04760756|OTHER|Fragility Fracture Integrated Rehabilitation Management|"* At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)"
219518065|NCT01901666|DRUG|Growth Hormone|"All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
219518066|NCT04230083|DRUG|Dienogest 2.0 mg Test Drug|Bioequivalence
219518067|NCT04230083|DRUG|Dienogest 2.0 mg Reference Product|Bioequivalence
219518068|NCT04705142|DRUG|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
219518069|NCT04031300|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
219518070|NCT00194103|BEHAVIORAL|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
219518071|NCT00194103|BEHAVIORAL|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
219518072|NCT01637038|OTHER|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
219611998|NCT06662968|OTHER|Lollipop group|In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.
219611999|NCT06662968|OTHER|Control group|In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
219612000|NCT02245607|BEHAVIORAL|Compensatory Cognitive Training|
219518073|NCT05003011|DEVICE|Cardiospire|Non-invasive hemodynamic monitoring
219518074|NCT05488197|OTHER|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
219518075|NCT05169554|DRUG|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
219612001|NCT02245607|BEHAVIORAL|Recreational Therapy|
219612002|NCT00248872|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
219612003|NCT00710268|DRUG|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
219612004|NCT00710268|DRUG|Bevacizumab|IV administration10 mg/kg every 14 days
219612005|NCT05012020|DEVICE|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
219612006|NCT03616457|DEVICE|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
219612007|NCT00561119|DRUG|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
219612008|NCT03357185|PROCEDURE|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
219612009|NCT02502032|DRUG|Cisatracurium|Different groups received different pretreatments of cisatracurium.
219612010|NCT03443349|DEVICE|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
219612011|NCT00302653|DRUG|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
219612012|NCT03123068|DRUG|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
219612013|NCT03123068|OTHER|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
219612014|NCT04680572|PROCEDURE|arthroplasty|arthroplasty for fracture neck of femur
219612015|NCT03035188|DRUG|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
219612016|NCT00002422|DRUG|HE2000|
219612017|NCT06998069|DRUG|Arm I Carboplatin, Paclitaxel, Pembrolizumab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
218898539|NCT04519736|DEVICE|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
218898540|NCT02252146|DRUG|IMO-8400|MO-8400 given subcutaneously twice weekly
218898541|NCT04034368|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
219518076|NCT05169554|DRUG|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
219612018|NCT06998069|DRUG|Arm II Carboplatin, Paclitaxel, Cetuximab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Cetuximab 400 mg/m2, day 1 of the first cycle and then 250 mg/m2 days 1, 8, 15 every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
219612019|NCT06998069|DRUG|Arm III Pembrolizumab|Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
219612020|NCT05724589|DRUG|Epidermal Growth Factor|Apply facial twice daily.
219612021|NCT04493164|DRUG|Ivosidenib|Given PO
219612022|NCT04493164|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219612023|NCT04480242|DRUG|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
219612024|NCT04480242|DRUG|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
219612025|NCT04480242|DRUG|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
219612026|NCT04480242|DRUG|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
219612027|NCT04480242|BEHAVIORAL|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
219612028|NCT06254456|DIAGNOSTIC_TEST|End expiratory occlusion test|Fluid responsiveness test
218898542|NCT03715517|PROCEDURE|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
218898543|NCT03715517|PROCEDURE|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
218898544|NCT03715517|DRUG|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
218898545|NCT03715517|DRUG|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
219518077|NCT06801093|BEHAVIORAL|Digital psychosocial tool|Wysa is a digital psychosocial tool that provides AI conversational chatbot support. The conversational agent acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT), mindfulness, and motivational intervention. Participants can progressively work through learning different skills and practice them in their daily life. The app also provides a repository of tools to manage problems and SOS resources for high distress.
218898546|NCT03715517|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
218898547|NCT03715517|DRUG|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
218898548|NCT03715517|DRUG|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
218898549|NCT05736874|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
218898550|NCT05736874|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219036337|NCT01764568|BEHAVIORAL|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
219036338|NCT01764568|BEHAVIORAL|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
219036339|NCT03394768|OTHER|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
219036340|NCT06026865|DIETARY_SUPPLEMENT|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
219518078|NCT04026126|BEHAVIORAL|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
219612029|NCT01765335|DEVICE|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
219612030|NCT01970137|DRUG|KPS-0373, High dose|
219612031|NCT01970137|DRUG|KPS-0373, Low dose|
219612032|NCT01427699|DRUG|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
219612033|NCT02329015|BEHAVIORAL|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
218898551|NCT03065322|OTHER|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
218898552|NCT04314908|PROCEDURE|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
218898553|NCT04314908|PROCEDURE|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
218898554|NCT04314908|PROCEDURE|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
218898555|NCT04314908|PROCEDURE|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
218898556|NCT00531284|DRUG|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
218898557|NCT00531284|DRUG|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
218898558|NCT00433641|DRUG|sibutramine|placebo
218898559|NCT00433641|DRUG|sibutramine|oral 15 mg sibutramine once per day
218898560|NCT00433641|DRUG|sibutramine|oral sibutramine 10 mg once per day
218898561|NCT05904158|BIOLOGICAL|Platelet-Rich Fibrin during Standard ACL reconstruction surgery|Plateleth-rich fibrin was obtained from patients own blood (40 cc) and applied to the tunnels which were drilled for ACL graft
218898562|NCT05904158|OTHER|Standard ACL reconstruction surgery|This was a control group where patients received Standard ACL reconstruction surgery
218898563|NCT02805686|DEVICE|spectral domain optical coherence tomography|
218898564|NCT02805686|DEVICE|multifocal electroretinogram|
219036341|NCT06026865|OTHER|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
219036342|NCT05346263|DEVICE|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
219036343|NCT05346263|DEVICE|Usual ventilation|NIV
219036344|NCT01023646|OTHER|Carbohydrate + Protein|Light Tuna Packed in water.
219036345|NCT01023646|OTHER|Carbohydrate + Fat|Butter
219036346|NCT01023646|OTHER|Fiber|Unrefined Carbohydrate
219036347|NCT01023646|OTHER|Carbohydrate load|Carbohydrate
219036348|NCT01108536|DEVICE|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
219518079|NCT04761731|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
219612034|NCT02329015|BEHAVIORAL|Physical Education Class|Standard physical education
218898565|NCT00291135|DRUG|letrozole|Letrozole 2.5 mg daily
218898566|NCT02219464|DEVICE|Nasopharyngeal catheter|
219518080|NCT04548453|DEVICE|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
218898567|NCT02219464|DEVICE|Nasal Cannula|
218898568|NCT02219464|PROCEDURE|Oxygen Supplementation|Initially set at 3 liters/minute
218898569|NCT02219464|PROCEDURE|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
218898570|NCT01909895|OTHER|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
218898571|NCT01909895|OTHER|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
218898572|NCT01909895|OTHER|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
218898573|NCT01909895|OTHER|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
218898574|NCT03194906|DRUG|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
219036349|NCT05528237|DEVICE|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
219036350|NCT04227847|DRUG|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
219036351|NCT04227847|DRUG|azacitidine|75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
218898575|NCT03194906|OTHER|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
218898576|NCT03194906|OTHER|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
219518081|NCT04929626|DRUG|Magnesium Sulfate 500 mg/ml+ ventolin|3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
219518082|NCT04929626|DRUG|Ventolin|it will be given to control group in nebulized form after every 20 min in 1st hour
218898577|NCT03695224|DIAGNOSTIC_TEST|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
218898578|NCT04834180|DIETARY_SUPPLEMENT|Hypocaloric diet plan|The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
218898579|NCT04834180|OTHER|Auricular Acupuncture|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
218898580|NCT04834180|OTHER|Acupressure|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
218898581|NCT00984256|DRUG|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
219036352|NCT04227847|DRUG|Venetoclax|400 mg /day PO, continuously; administered with ramping
219036353|NCT00129363|DRUG|Carvedilol|
219036354|NCT00733863|BIOLOGICAL|Placebo|
219518083|NCT03748082|DRUG|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
219518084|NCT03748082|DIAGNOSTIC_TEST|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
219518085|NCT03748082|PROCEDURE|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
219518086|NCT02502110|DRUG|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
219518087|NCT03328780|DEVICE|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
218898582|NCT00984256|OTHER|Procedure - malaria challenge|2\) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
218898583|NCT00002682|DRUG|Amoxicillin|
218898584|NCT00002682|DRUG|Bismuth Subsalicylate|
218898585|NCT00002682|DRUG|Clarithromycin|
218898586|NCT00002682|DRUG|Metronidazole Hydrochloride|
218898587|NCT00002682|DRUG|Omeprazole|
218898588|NCT00002682|DRUG|Tetracycline Hydrochloride|
219036355|NCT00733863|BIOLOGICAL|CAD106|
219036356|NCT03591237|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
219518088|NCT02305823|DRUG|Aripiprazole|
219518089|NCT02305823|DRUG|Quetiapine|
219518090|NCT02305823|DRUG|Ziprasidone|
219612035|NCT06919432|DEVICE|Active-tACS|Participants were comfortably positioned on a lounge chair and received alternating current stimulation using an FDA-approved tACS device (Nexalin Technology, Inc., Houston, TX, USA). Electrodes were evenly placed across the forehead and mastoid regions. Trained nurses administered the tACS according to standardized protocols.
219612036|NCT06919432|DEVICE|Sham-tACS|The sham tACS device will resemble the active stimulation device in appearance, weight, size, color, and odor, ensuring indistinguishability for the patients. Throughout the entire intervention period, each participant will be allocated to the same tACS device, regardless of whether it delivers active or sham stimulation.
218898589|NCT01500590|DRUG|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
219036357|NCT04659278|DIETARY_SUPPLEMENT|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
219036358|NCT04659278|DIETARY_SUPPLEMENT|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
219518091|NCT01097408|DRUG|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
219518092|NCT01097408|DRUG|Placebo comparator|Placebo capsules
219518093|NCT05873023|OTHER|Chewing gum|chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
219518094|NCT02107690|PROCEDURE|Low temperature lidocaine injection|4 °C
219518095|NCT02107690|PROCEDURE|Room temperature lidocaine injection|20 °C
218898590|NCT01500590|DRUG|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
218898591|NCT05525377|BEHAVIORAL|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
218898592|NCT01493193|OTHER|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
218898593|NCT01493193|OTHER|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
218898594|NCT01493193|OTHER|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
218898595|NCT03057496|DEVICE|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
218898596|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
218898597|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
218898598|NCT02040623|OTHER|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
218898599|NCT00259545|DRUG|Retarded Release Phosphatidylcholine (rPC)|
218898600|NCT05245435|DIAGNOSTIC_TEST|FDHT-PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
218898601|NCT05245435|DIAGNOSTIC_TEST|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
218898602|NCT00786383|BIOLOGICAL|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
218898603|NCT00786383|BIOLOGICAL|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
218898604|NCT00786383|BIOLOGICAL|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
218898605|NCT00786383|BIOLOGICAL|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
218898606|NCT00786383|BIOLOGICAL|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
218898607|NCT01512134|DEVICE|Deep Brain Stimulation Device|Deep brain stimulation surgery
218898608|NCT03033277|BIOLOGICAL|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
218898609|NCT03033277|BIOLOGICAL|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
218898610|NCT02383563|DRUG|metformin extended release|
218898611|NCT01447654|DRUG|Losartan|100 mg for 12 months.
218898612|NCT01447654|DRUG|Placebo|100 mg for 12 months.
218898613|NCT01033981|DRUG|Sunitinib|Treatment for mRCC as indication approved and physician criterium
218898614|NCT01925885|PROCEDURE|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
218898615|NCT01925885|PROCEDURE|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
219204116|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
219518096|NCT02107690|PROCEDURE|Body temperature lidocaine injection|37 °C
218898616|NCT05254665|DRUG|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
218898617|NCT02136979|DRUG|Propofol|group of patients with propofol-based anesthesia
218898618|NCT02136979|DRUG|Sevoflurane|group of patients with sevoflurane-based anesthesia
218898619|NCT03270943|BEHAVIORAL|MFY|Mindful Self-Compassion course for teens
218898620|NCT03270943|BEHAVIORAL|HLG|Healthy Lifestyles course for teens
218898621|NCT05980728|OTHER|No Intervention|No Intervention
218898622|NCT06136364|BIOLOGICAL|CAR-T|CAR-T immunotherapy targeting CD7+
218898623|NCT02981368|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
218898624|NCT02981368|DIAGNOSTIC_TEST|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
218898625|NCT00280917|DRUG|CF101|
218898626|NCT06059235|OTHER|pharmaceutical care|"consultation with a pharmacist performing advanced pharmaceutical care : Package of clinical pharmacy activities including :~Medication history (during assessment consultation) Medication review and consultation with the geriatrician Therapeutic education (during results consultation) Shared decision (at results consultation) One-week follow-up call + usual care"
218898627|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
218898628|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
219204117|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
219204118|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
218898629|NCT01459588|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
218898630|NCT01459588|DRUG|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
218898631|NCT02264275|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
218898632|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
218898633|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
218898634|NCT00860873|DIETARY_SUPPLEMENT|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
218898635|NCT00860873|DIETARY_SUPPLEMENT|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
218898636|NCT03684616|DRUG|Statin|continuous statin treatment for 3 months prior to cardiac arrest
219518097|NCT05629884|OTHER|COPERIA-REHAB|"After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week)."
219612037|NCT06546826|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
218898637|NCT02544321|DRUG|Bromocriptine|
218898638|NCT02544321|OTHER|Placebo|
219204119|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
219612038|NCT06546826|PROCEDURE|simple tooth extraction|tooth extraction without grafting procedure.
219518098|NCT02780687|DRUG|Afatinib|
219612039|NCT06546826|PROCEDURE|tooth root and PRF|Autogenous roots derived from the extracted hopeless tooth and stabilized with osteosynthesis screws to reconstruct the missing buccal wall of the socket. The defect was then filled with PRF.
219612040|NCT06546826|PROCEDURE|Ice cream cone technique|xenogeneic granules and a resorbable collagen membrane
219612041|NCT07128316|DEVICE|Contoura Topolyzer with Phorcides|LASIK calculated ablation using Contoura Topolyzer with Phorcides
219612042|NCT07128316|DEVICE|iDesign|LASIK calculated ablation using iDesign Refractive Studio 2.0
219612043|NCT03972761|DEVICE|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
219612044|NCT02984371|PROCEDURE|Coronary artery bypass grafting|
218898639|NCT01584232|DRUG|LY2189265|
219612045|NCT02984371|PROCEDURE|Epicardial ganglionated plexi ablation|
219612046|NCT02984371|PROCEDURE|implantable loop recorder|
219612047|NCT00004263|DRUG|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
218898640|NCT01584232|DRUG|Insulin glargine|
218898641|NCT01584232|DRUG|Sulfonylureas (SU)|
218898642|NCT01584232|DRUG|Biguanide (BG)|
218898643|NCT04554420|BEHAVIORAL|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
218898644|NCT02099240|DRUG|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
218898645|NCT02099240|PROCEDURE|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
218898646|NCT03991312|DRUG|itraconazole|Participants will receive an oral solution as described in the arm description.
218898647|NCT03991312|DRUG|rifampin|Participants will receive oral capsule(s) as described in the arm description.
218898648|NCT03991312|DRUG|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
219612048|NCT00004263|DRUG|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
219612049|NCT07003724|OTHER|Questionaire|Questionnaire evaluating level of awareness of patients towards using AI in dentistry
218898649|NCT04557540|BEHAVIORAL|Lifestyle Therapy|Receive The WORD lifestyle CER weight loss intervention
218898650|NCT04557540|OTHER|Quality-of-Life Assessment|Ancillary studies
218898651|NCT04557540|OTHER|Questionnaire Administration|Ancillary studies
218898652|NCT04557540|OTHER|Short-Term Fasting|Receive Fasting WORD intermittent fasting weight loss intervention
218898653|NCT03789916|DRUG|Ticagrelor|90 mg bis in die
218898654|NCT03789916|DRUG|acetylsalicylic acid|100 mg die
219612050|NCT07011927|DEVICE|Cochlear Implant|Eligible Cochlear Americas devices eligible for inclusion in this study include any Cochlear Americas device that has two ground electrodes.
219612051|NCT07011927|DEVICE|Modified Implant Procedure|Implant procedure will be modified to place ground electrode (ECE1) near Arnold's nerve.
219612052|NCT04508738|OTHER|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
218898655|NCT05915845|OTHER|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
219204120|NCT06875063|DRUG|GB5005 CART|Included patients will receive GB5005 chimeric antigen receptor T-cell injection: A sterile syringe will be used to draw the assigned dose volume (calculated based on the patient's weight and converted to volume). The cells will be slowly infused intravenously at a rate of about 10 mL/min.
218898656|NCT05915845|OTHER|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
218898657|NCT04296656|BEHAVIORAL|The 5 S's infant calming intervention|5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
218898658|NCT02768766|DRUG|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
218898659|NCT02768766|DRUG|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
218898660|NCT02768766|DRUG|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
219204121|NCT06872021|OTHER|Early IABP use|Patients receive IABP for left ventricular unloading within 6 hours after VA-ECMO initiation.
219204122|NCT06872021|OTHER|Conventional approach|Patients do not receive mechanical unloading within 6 hours after VA-ECMO initiation.
219204123|NCT06871423|BEHAVIORAL|distraction|"distraction via virtual reality game named Waltz of the Wizards aka magic bowl."
219612053|NCT04508738|OTHER|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1\) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
219612054|NCT07018440|DIETARY_SUPPLEMENT|Low-Volume Oral Carbohydrate Loading (200 mL of 12.5% solution)|Patients were given Low Volume Oral Carbohydrate feeding (200 mL 12.5% solution) in the preoperative period.
219612055|NCT07016867|DRUG|l-carnitine|to compare the efficacy of medical treatment (l-carnitine and antioxidants) versus surgical treatment (varicocelectomy) versus surgical treatment and medical treatment (varicocelectomy with adjuvant medications) on pregnancy rate on varicocele related subfertility patients with isolated teratozoospermia.
218898661|NCT02768766|DRUG|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
219204124|NCT06697015|OTHER|Pendulum Exercises|In this group, 18 participants will perform pendulum exercises, which involve leaning forward and allowing the affected arm to hang down, swinging it gently in small circular or side-to-side motions. This exercise is designed to enhance shoulder mobility and promote relaxation of the rotator cuff muscles without straining the shoulder joint. The pendulum movement helps improve circulation and relieve tension in the shoulder area, making it a suitable intervention for individuals experiencing rotator cuff pain.
219204125|NCT06697015|OTHER|Serratus Punch Exercises|In this group, 18 participants will engage in serratus punch exercises, focusing on strengthening the serratus anterior muscle. Participants will perform a punching motion by extending the arm forward while maintaining shoulder stability. This exercise activates the shoulder muscles to enhance scapular control, supporting the rotator cuff and improving overall shoulder function. The goal is to build strength in the stabilizing muscles, which can help alleviate pain and enhance mobility in participants suffering from rotator cuff issues.
219364233|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
218898662|NCT02768766|DRUG|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
218898663|NCT02768766|DRUG|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
218898664|NCT02564666|OTHER|telephone counseling|regular telephone counseling for compliance and advese event
218898665|NCT01912066|DRUG|Stillen|
218898666|NCT01912066|DRUG|Cytotec (reference drug)|
219036359|NCT04659278|OTHER|Placebo|Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
219036360|NCT04659278|DIETARY_SUPPLEMENT|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
219036361|NCT04167007|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
219036362|NCT04167007|DRUG|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
219364234|NCT01781221|DEVICE|Alpha-Bio's GRAFT Natural Bovine Bone|
219364235|NCT01781221|DEVICE|Bio-Oss xenograft|
219518099|NCT03038737|OTHER|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
219518100|NCT03038737|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
219518101|NCT05182489|DEVICE|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
219518102|NCT05182489|DEVICE|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
219518103|NCT02165228|BEHAVIORAL|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
218898667|NCT01912066|DRUG|NSAID (Aceclofenac)|
219036363|NCT03735667|DEVICE|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
219036364|NCT03735667|DEVICE|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
219364236|NCT04609878|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
219364237|NCT04609878|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
219364238|NCT04609878|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
219364239|NCT04609878|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
219364240|NCT02312024|DEVICE|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
219518104|NCT02165228|BEHAVIORAL|Nutrition Enhancement|Nutrition education class and behavioral intervention
219518105|NCT05881096|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
218898668|NCT00262496|DRUG|Botox|
218898669|NCT00569712|DRUG|budesonide/formoterol fumarate dihydrate inhalation aerosol|
218898670|NCT00569712|GENETIC|DNA methylation analysis|
218898671|NCT00569712|GENETIC|comparative genomic hybridization|
218898672|NCT00569712|GENETIC|microarray analysis|
218898673|NCT00569712|OTHER|bronchoalveolar lavage|
218898674|NCT00569712|OTHER|immunoenzyme technique|
218898675|NCT00569712|OTHER|laboratory biomarker analysis|
218898676|NCT00569712|PROCEDURE|bronchoscopy|
218898677|NCT00500916|DEVICE|ProSeal LMA|GEB vs digital vs introducer tool
218898678|NCT05346120|BIOLOGICAL|allogeneic marrow stromal cells (MSCs)|stem cell infusion
218898679|NCT05638932|DRUG|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
219036365|NCT03735667|DEVICE|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
219036366|NCT03735667|DEVICE|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
219036367|NCT06564584|DRUG|TLC-2716 Dose 1|Capsules administered orally
219036368|NCT06564584|DRUG|TLC-2716 Dose 2|Capsules administered orally
219036369|NCT06564584|DRUG|Placebo|Capsules administered orally
219036370|NCT05114421|DRUG|Lenvatinib|Given PO
219036371|NCT05114421|BIOLOGICAL|Pembrolizumab|Given IV
219036372|NCT06114758|DRUG|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
219036373|NCT06114758|DRUG|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
218898680|NCT01866371|PROCEDURE|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
218898681|NCT02436525|DEVICE|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
218898682|NCT02436525|DEVICE|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
218898683|NCT02436525|DEVICE|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
218898684|NCT00763412|DRUG|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
219364241|NCT01583179|DRUG|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
219364242|NCT01246206|DRUG|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
219364243|NCT01211912|DRUG|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
219364244|NCT01211912|DRUG|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
218898685|NCT00763412|DRUG|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
218898686|NCT00314730|DEVICE|handheld Personal Digital Assistant (PDA)|
218898687|NCT03908333|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
218898688|NCT03908333|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
218898689|NCT03908333|DRUG|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
219364245|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
219364246|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
219364247|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
219364248|NCT05630963|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
219364249|NCT05630963|DRUG|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
219364250|NCT04660643|DRUG|Tirzepatide|Administered SC
219364251|NCT04660643|OTHER|Placebo|Administered SC
219364252|NCT03988907|DRUG|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
218898690|NCT03908333|DRUG|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
219518106|NCT05881096|OTHER|Sham Control|Practice of movement task without START
218898691|NCT00509184|DRUG|Rituximab|375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap
218898692|NCT03909893|RADIATION|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
218898693|NCT01198197|DRUG|NOP-1A|
218898694|NCT05681650|BIOLOGICAL|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D
218898695|NCT05681650|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
219518107|NCT05722509|PROCEDURE|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
219518108|NCT05722509|PROCEDURE|"Only Exodontia Group"|Third molar exodontia without associated surgery.
219518109|NCT03825900|DEVICE|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
219518110|NCT01820377|BEHAVIORAL|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
219518111|NCT00519142|DRUG|placebo for mitiglinide|three times a day with meals
219518112|NCT00519142|DRUG|mitiglinide|three times a day with meals
219518113|NCT00519142|DRUG|mitiglinide|two times a day with meals
219612056|NCT07017881|BEHAVIORAL|Psychosocial Skills Training|The 24-person intervention group was divided into three separate groups of 8 people (Group 1, Group 2, Group 3). Group 1 and Group 2 attended sessions on Tuesdays at different times, while Group 3 attended sessions on Thursdays. Psychosocial Skills Training consisted of eleven sessions in total, one session per week. Sessions lasted an average of 60 minutes for each group. In each session, 5-10 minute breaks were given for rest and eating and drinking, considering the attention span and fatigue of the patients. Psychosocial Skills Training was applied two days a week (Group 1-2: Tuesday, Group 3: Thursday) in order to ensure that the patients could get more benefit from the application.
219612057|NCT07018609|BEHAVIORAL|Zen Den Experience|The Zen Den is a dedicated safe space for healthcare staff to decompress and recharge during shifts, addressing the growing issue of workplace stress. It has soft warm lighting, sound machines and aroma therapy, relaxing furnishings centered around a faux fireplace to create a stress-free environment.
218898696|NCT05681650|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
218898697|NCT05681650|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
218898698|NCT01731912|DRUG|Degarelix|Given SC
218898699|NCT01731912|RADIATION|External Beam Radiation Therapy|Undergo standard EBRT
218898700|NCT01731912|OTHER|Laboratory Biomarker Analysis|Correlative studies
218898701|NCT04213300|OTHER|Low carbohydrate diet|"Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) ."
218898702|NCT02757144|DRUG|DWP14012|DWP14012 tablets
218898703|NCT02757144|DRUG|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
218898704|NCT02757144|DRUG|Esomeprazole|Nexium®
218898705|NCT01624116|DRUG|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
218898706|NCT01624116|OTHER|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
218898707|NCT01624116|DRUG|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
218898708|NCT01624116|DRUG|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
218898709|NCT01624116|DRUG|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
218898710|NCT02043938|DEVICE|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
218898711|NCT03646877|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
219518114|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
218898712|NCT03646877|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
218898713|NCT04507607|DRUG|Tenofovir Alafenamide 25 MG|TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
218898714|NCT03202407|DRUG|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
218898715|NCT02339311|OTHER|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
218898716|NCT01107951|DRUG|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)"
218898717|NCT06000124|OTHER|Plyometric exercises|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
218898718|NCT06000124|OTHER|Regulation Exercises Program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
218898719|NCT03200119|BEHAVIORAL|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
218898720|NCT02222558|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
219036374|NCT04770584|BEHAVIORAL|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color.
218898721|NCT00127023|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
218898722|NCT03400852|DRUG|MNK-1411|MNK-1411 (1 mg/mL suspension) for subcutaneous injection
218898723|NCT03400852|OTHER|Placebo|Placebo suspension for subcutaneous injection
218898724|NCT06144463|DIAGNOSTIC_TEST|lung ultrasound-guided fluid resuscitation|For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion
218898725|NCT05134558|RADIATION|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
218898726|NCT04690140|PROCEDURE|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
218898727|NCT04690140|PROCEDURE|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
219036375|NCT04770584|OTHER|Avoidance conditioning|Via button pressing. Only one stimulus-CS will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock.
219036376|NCT04770584|OTHER|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding appears with no button to press and no shock is administered.
219036377|NCT04770584|OTHER|Willingness to pay to avoid shock|On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. This and all previously described experimental phases noted above will occur inside of the fMRI scanner.
219036378|NCT00980395|DRUG|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
218898728|NCT02528708|DRUG|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
218898729|NCT02528708|DRUG|Placebo|0.9% saline solution
218898730|NCT06268054|DRUG|DEH113|Tablets
218898731|NCT06268054|DRUG|Placebo Comparator|Tablets
218898732|NCT06288555|DIAGNOSTIC_TEST|Ipswich touch test|"Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses."
219036379|NCT00980395|DRUG|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
219036380|NCT00980395|DRUG|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
219036381|NCT01464658|PROCEDURE|panniculectomy|surgery
218898733|NCT03421522|OTHER|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
218898734|NCT05551858|DRUG|Proglumide|(CAS: 6620-60-6.)
218898735|NCT05551858|DRUG|Placebo|Avicel fiber filled capsule taken by mouth three times daily
219518115|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
218898736|NCT01762553|BEHAVIORAL|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
218898737|NCT03493555|BEHAVIORAL|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
218898738|NCT01169948|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
218898739|NCT02759757|OTHER|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
218898740|NCT02759757|OTHER|Placebo|A micropore tape will be used as placebo
218898741|NCT02621112|BIOLOGICAL|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
218898742|NCT02621112|BIOLOGICAL|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
218898743|NCT02621112|BIOLOGICAL|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
218898744|NCT05724940|OTHER|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~1. Thorough medical history of the patients~2. Full clinical examination including:~   1. General examination and vital signs.~  2. Complete rheumatological examination.~  3. SLE disease activity index SLEDAI (ref).~  4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~4. Renal investigations:~   1. Kidney functions~  2. Urine analysis~  3. 24 hours protein in urine and/or A/C ratio~  4. Renal biopsy if indicated.~5. ANA (Antinuclear Antibodies)test.~6. ANA profile for the most common 19 autoantibodies by immunoblot."
218898745|NCT00974649|BEHAVIORAL|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
218898746|NCT04033744|PROCEDURE|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
218898747|NCT00502554|PROCEDURE|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
219518116|NCT01584921|DRUG|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
218898748|NCT04019353|GENETIC|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
218898749|NCT02436018|DEVICE|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
218898750|NCT02436018|DEVICE|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
218898751|NCT05977400|DRUG|Ampicillin|Intravenous Ampicillin
218898752|NCT05977400|DRUG|Gentamicin|Intravenous Gentamicin
218898753|NCT05977400|DRUG|Placebo|Intravenous Normal Saline
219036382|NCT03984422|OTHER|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
219036383|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
219036384|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
219518117|NCT04955379|DEVICE|EQ103|Ophthalmic Refractometer with a measurement and background channel
219518118|NCT05607914|PROCEDURE|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
219518119|NCT05607914|PROCEDURE|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
218898754|NCT05874284|DRUG|Gelofusin|In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
218898755|NCT04945187|OTHER|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
219612058|NCT07018609|BEHAVIORAL|Music Therapy Experience|The music therapy experience will consist of either Music Minutes which have music therapists available on specific units and circulating amongst staff across flexible shift times. Intervention choices will include relaxation songs, motivation songs, music, mindfulness, breathing to music, dance-a-minute, and brief song rewrites. Notes for Resilience will be scheduled group sessions that follow a more structured format and are 30 to 60 minutes in length. Involvement and coping will be emphasized through active forms of music participation, including drum circles, unit playlist creation, song writing, jam sessions, and song discussion.
218898756|NCT00936702|DRUG|carboplatin|Given IV
218898757|NCT00936702|DRUG|everolimus|Given PO
218898758|NCT00936702|DRUG|paclitaxel|Given IV
218898759|NCT01636635|OTHER|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
218898760|NCT02532465|DEVICE|Air-Q|
219612059|NCT07017504|DEVICE|proprioception-enhancing assistive orthosis|A wearable device that provides mechanical vibration to the tendons around the knee and ankle to enhance proprioceptive feedback. Vibration intensity and timing are controlled automatically based on body tilt measured by an IMU sensor. The device is applied during balance and joint sense assessments conducted across three visits.
218898761|NCT02532465|DEVICE|i-gel|
218898762|NCT00793858|DRUG|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
218898763|NCT03915171|DIAGNOSTIC_TEST|Next generation sequencing|NGS can provide genetic and MSI test for patients
218898764|NCT04567641|DIETARY_SUPPLEMENT|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
218898765|NCT00790192|DRUG|Lurasidone|Lurasidone 80 mg tablets
219612060|NCT07018544|OTHER|semaglutide|Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
219612061|NCT07018674|DIETARY_SUPPLEMENT|Experimental|Brain Edge, a cognition supporting supplement beverage formulated from herbs, vitamins, and amino acids.
219612062|NCT07018674|OTHER|Placebo|A sensory-matched placebo beverage formulated from flavors, colors, fillers, and excipients.
219612063|NCT07018674|OTHER|Water|Bottled Water
219612064|NCT07018219|DEVICE|X ray device|X ray macjine : shimadzo corporation ( japan)
219612065|NCT07017036|DRUG|IVIG-VImmune|V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
219036385|NCT01094548|DRUG|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
219612066|NCT07017036|DRUG|IVIG-Immuglo|Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
218898766|NCT00790192|DRUG|Lurasidone|Lurasidone 4 40 mg tablets
219612067|NCT07016841|DEVICE|pHA130 hemoperfusion device|HP once every 2 weeks.
218898767|NCT00790192|DRUG|Quetiapine XR|Quetiapine XR 600mg
218898768|NCT00790192|DRUG|Placebo|Matching Placebo to Lurasidone or Quetiapine
218898769|NCT04115384|DRUG|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
218898770|NCT00354679|BIOLOGICAL|bevacizumab|
218898771|NCT00354679|DRUG|cisplatin|
218898772|NCT00354679|DRUG|irinotecan hydrochloride|
218898773|NCT00354679|GENETIC|proteomic profiling|
218898774|NCT00354679|OTHER|diagnostic laboratory biomarker analysis|
219036386|NCT01094548|DRUG|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
219612068|NCT07016841|DEVICE|HD/HDF|HD twice weekly, HDF once weekly, with each session lasting 4 hours.
219612069|NCT07016841|DEVICE|HA130 hemoperfusion device|HP once every 2 weeks.
218898775|NCT00354679|OTHER|mass spectrometry|
218898776|NCT00354679|PROCEDURE|adjuvant therapy|
218898777|NCT00354679|PROCEDURE|neoadjuvant therapy|
218898778|NCT00354679|PROCEDURE|therapeutic conventional surgery|
218898779|NCT00354679|RADIATION|radiation therapy|
218898780|NCT02089919|BIOLOGICAL|cancer stem cell vaccine|
218898781|NCT02938195|RADIATION|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
218898782|NCT02938195|PROCEDURE|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
218898783|NCT02019732|OTHER|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
218898784|NCT06421038|OTHER|Thyme honey|Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days
218898785|NCT06421038|DRUG|Kenalog|kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)
218898786|NCT05527665|PROCEDURE|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
218898787|NCT05315102|OTHER|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
218898788|NCT05315102|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
218898789|NCT05315102|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
218898790|NCT03678064|DEVICE|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
218898791|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
218898792|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
219036387|NCT00790439|DRUG|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
219036388|NCT00790439|DRUG|Heparin|Anticoagulant
219036389|NCT00790439|DRUG|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
219036390|NCT00790439|DRUG|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
219036391|NCT00790439|DRUG|Tacrolimus|Calcineurin inhibitor
219364253|NCT03988907|DRUG|Midazolam|single dose administration of 2 mg midazolam
218898793|NCT05870891|OTHER|Food|Food
218898794|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
218898795|NCT03938896|OTHER|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
218898796|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
219036392|NCT00790439|DRUG|Cyclosporine|Calcineurin inhibitor, immunosuppressant
219036393|NCT00790439|DRUG|Daclizumab|Monoclonal IL-2 receptor blocker
219036394|NCT00790439|DRUG|Basiliximab|Monoclonal IL-2 receptor blocker
219036395|NCT00790439|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|
219364254|NCT06434311|DIAGNOSTIC_TEST|3 meter Backward Test|evaluation
219036396|NCT05278078|OTHER|psychological support|psychological support will be given to the patients in the experimental group.
219036397|NCT05278078|OTHER|nutritional education|nutritional education will be given to the patients in the experimental group.
219036398|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
219036399|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
219036400|NCT01466946|BEHAVIORAL|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
219036401|NCT05804266|PROCEDURE|Coventional coagulation|In the conventional group, the haemostasis of vessels will be performed with the conventional coagulation technique under CO2 insufflation. First, submucosal fibres surrounding a blood vessel will be dissected and the vessel will be isolated. After, both sides of the isolated vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until the blood vessel turns white and can be finally cut.
219036402|NCT05804266|PROCEDURE|Underwater coagulation|In the treatment group, the prophylactic haemostasis of vessels will be accomplished by the underwater coagulation technique. First, physiological solution will be instilled until there is no more air around the blood vessel. Then, the vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until it turns white and, after the removal of all the physiological solution, can be finally cut.
219364255|NCT02810964|DRUG|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
219364256|NCT02810964|DRUG|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
219518120|NCT00980603|DRUG|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
218898797|NCT03566706|BEHAVIORAL|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
218898798|NCT03566706|BEHAVIORAL|Discussion Tool: Marijuana Use|Parent Discussion Tools
218898799|NCT03566706|BEHAVIORAL|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
218898800|NCT00622505|DRUG|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
218898801|NCT04294602|OTHER|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
218898802|NCT04294602|OTHER|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
218898803|NCT04294602|OTHER|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
218898804|NCT04294602|OTHER|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
218898805|NCT00056693|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
218898806|NCT04322188|OTHER||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
218898807|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
218898808|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
218898809|NCT00933322|DIETARY_SUPPLEMENT|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
218898810|NCT01135615|DRUG|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
218898811|NCT01135615|DRUG|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
218898812|NCT00250237|DRUG|Haloperidol|Haloperidol 1mg twice daily during 72hours
219518121|NCT00980603|DRUG|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
219518122|NCT00980603|DRUG|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
219518123|NCT02583503|RADIATION|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
219518124|NCT02933866|DRUG|DSXS topical|topical treatment
219518125|NCT02933866|DRUG|Vehicle topical|topical treatment
219518126|NCT00446732|DEVICE|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
219518127|NCT05342857|DRUG|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T\&E criteria in Taiwan local consensus
219518128|NCT02603952|DRUG|Oseltamivir|75 mg capsules orally BID from Day 1 to Day 5.
218898813|NCT00250237|DRUG|placebo|Placebo 1mg twice daily during 72hours
219518129|NCT02603952|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
219518130|NCT02603952|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
218898814|NCT01839058|OTHER|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
218898815|NCT06189326|PROCEDURE|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
219036403|NCT05996107|DRUG|Ribociclib|400 mg daily with a possibly dose reduction to 200 mg daily if required
219036404|NCT05996107|RADIATION|Postoperative Radiation Therapy|50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
219036405|NCT04732975|DEVICE|CardioFlux|Non-invasive screening for ACS
219036406|NCT00212953|PROCEDURE|Advanced Life Support|
219518131|NCT06452160|DRUG|BGC515|Capsules for oral administration
219518132|NCT01887626|DRUG|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
219518133|NCT01887626|DRUG|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
219518134|NCT01887626|DRUG|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
219518135|NCT05564832|DRUG|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
218898816|NCT06189326|PROCEDURE|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
218898817|NCT04979676|BEHAVIORAL|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
218898818|NCT04979676|BEHAVIORAL|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
218898819|NCT04979676|BEHAVIORAL|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
219036407|NCT06291714|DEVICE|GDT-based hemodynamic management based on Clearsight device|Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
219036408|NCT04426617|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
219036409|NCT00806884|OTHER|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
219036410|NCT00806884|OTHER|Control group measurements|None other than control group measurements
219036411|NCT00461695|BIOLOGICAL|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
219036412|NCT00918515|DRUG|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
219036413|NCT05302375|OTHER|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
219036414|NCT05318144|OTHER||
219036415|NCT03062475|BEHAVIORAL|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
219036416|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
219036417|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
219036418|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
219036419|NCT01973101|RADIATION|Radiotherapy|45 Gy
219036420|NCT01973101|RADIATION|Brachytherapy|80 Gy
219036421|NCT02271191|DRUG|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
219036422|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
219036423|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
219036424|NCT00981006|PROCEDURE|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
219036425|NCT02547129|DEVICE|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
219364257|NCT06434831|DEVICE|Medical device for SNM: Interstim II, Interstim micro|ANI will be used during the SNM (2 hours)
218898820|NCT01395576|DEVICE|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
219036426|NCT02547129|DEVICE|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
219036427|NCT02944318|BEHAVIORAL|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
219036428|NCT00005770|DEVICE|Acupuncture|
218898821|NCT00414141|BIOLOGICAL|Grass MATA MPL|4 subcutaneous injections
218898822|NCT00414141|BIOLOGICAL|Placebo|4 subcutaneous injections
219036429|NCT00144586|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
219036430|NCT00138983|DRUG|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
219036431|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
219036432|NCT01914484|DRUG|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
219036433|NCT01914484|DRUG|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
219036434|NCT02170610|DRUG|BIBR 1048 MS|
219036435|NCT02170610|DRUG|Pantoprazole|
219364258|NCT06530433|DEVICE|CPRCard + TCPR Link App and Web|Application that allows responder to perform CPR with two-way audio communication and one-way video streaming to SCDF Dispatcher
219364259|NCT06530433|DEVICE|CPRCard Only|Control arm with standard care of procedure that Bystander using CPRCard only
219518136|NCT00429806|DRUG|DHEA|DHEA
219518137|NCT00429806|DRUG|Placebo|Placebo
219518138|NCT04127409|OTHER|Control Chicken-meat|
219518139|NCT04127409|OTHER|Control Eggs|
219518140|NCT04127409|OTHER|Omega-3-PUFA Enriched Chicken-meat|
219518141|NCT04127409|OTHER|Omega-3PUFA Enriched Eggs|
218898823|NCT05734755|BEHAVIORAL|The Individualized Dietary Behavioural Change Programme (IDBC)|The first three weekly face-to-face sessions will be during the 'goal initiation' and 'planning' phases. The remaining seven face-to-face sessions will be offered once to twice per month between weeks 4 and 24 during the program at the 'action execution' phase. Family members will be encouraged to join the dietary consultations. Strategies will be discussed with the family members to facilitate the participant's adherence to the recommended diet regimen.Phase I Goal Initiation is aimed at motivating the participants to actively manage their sarcopenic obesity. Phase II Plan Formulation is aimed at guiding the participants in transforming their (sub-) goals into detailed individualized action plans.Phase III Action Execution is aimed at encouraging the participants to continually execute the action plan. The IDBC guidebook will be given to the participants to guide them on how to gradually adopt our dietary recommendations in their daily life.
218898824|NCT05734755|BEHAVIORAL|The Exercise Training|The group size will be \< 10. They will be used in the resistance exercise in this study to improve muscle strength (20 mins). Brisk walking (20 mins) will be employed in the aerobic exercise in this study. Each session will include 10 minutes of warm-up and cool-down exercises at the beginning and at the end. A YouTube video and a pamphlet describing the different types of exercises used in this programme will be disseminated to all participants to encourage them to continually practise their exercises at home for 30 minutes at least 5 times per week.
218898825|NCT02361333|BEHAVIORAL|Teaching Intervention|Patients will be taught how to install and use a remote monitor
218898826|NCT00980356|DRUG|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
218898827|NCT04105049|OTHER|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
219036436|NCT00259090|DRUG|Fulvestrant|500 mg intramuscular injection
219036437|NCT00259090|DRUG|Anastrazole|oral tablet
219036438|NCT00094965|DRUG|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
219036439|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
219036440|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
219036441|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
219612070|NCT07017049|BEHAVIORAL|Integrative Neuromuscular Training|Participants will receive a 12-week Integrative Neuromuscular Training (INT) program, conducted 3 times per week, each session lasting 1 hour. The intervention includes progressive exercises targeting balance, strength, plyometrics, speed, agility, and coordination. Training intensity increases from 55-65% HRmax in weeks 1-2, to 65-75% HRmax in weeks 3-5, and 70-85% HRmax in weeks 6-12. Exercises include single-leg balance, BOSU balance, box jumps (30-50 cm), lateral jumps, squats, Nordic hamstring exercises, sprints (20-30m), shuttle runs, and agility drills. Rest between sets is 30-60 seconds.
218898828|NCT02420093|DEVICE|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
219036442|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
219036443|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
219036444|NCT06485700|OTHER|Peer Delivery of Medications|Door-to-door peer delivery of medications within patients' communities will be implemented.
219036445|NCT06485700|OTHER|Health Information Technology (HIT) Platform|The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
219204126|NCT06697158|OTHER|Physiotherapy and rehabilitation|"Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions.~Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour."
219364260|NCT05588635|OTHER|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
219364261|NCT02013843|BEHAVIORAL|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
218898829|NCT03292224|DIAGNOSTIC_TEST|- Microscopic examination and culture of collected specimens|"1. Unstained wet mount with 10%-20% KOH.~2. Wet mounts stained with:~   * Lactophenol cotton blue.~  * India ink~  * Gram stain Culturing on Sabouraud´s dextrose agar ."
218898830|NCT00819936|PROCEDURE|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
218898831|NCT00819936|PROCEDURE|backward walking|physiotherapy with use a backward walking type of physiotherapy
219613403|NCT04283630|DIETARY_SUPPLEMENT|Nature Made vitamin c 1000 mg|vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
218898832|NCT00411749|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
218898833|NCT00411749|BIOLOGICAL|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
218898834|NCT00651781|DRUG|Bortezomib|2 times per week of Velcade administration.
218898835|NCT02768493|DRUG|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
218898836|NCT02768493|DRUG|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
218898837|NCT01648634|DRUG|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
219036446|NCT04933266|PROCEDURE|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
219036447|NCT04933266|PROCEDURE|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
219204127|NCT06699303|OTHER|Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care|In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
219613404|NCT04283630|DIETARY_SUPPLEMENT|Placebo|Vitamin C matched Placebo capsules that made from starch.
219613405|NCT00751062|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
218898838|NCT01648634|DRUG|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
218898839|NCT01645254|DRUG|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
218898840|NCT02373488|OTHER|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
218898841|NCT02373488|OTHER|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
218898842|NCT02373488|OTHER|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
219036448|NCT02530983|OTHER|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
218898843|NCT02820454|DRUG|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
218898844|NCT02820454|RADIATION|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
218898845|NCT02088450|DRUG|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
218898846|NCT05963620|OTHER|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
218898847|NCT04006093|DRUG|Apixaban Oral|one Tablet 5mg
218898848|NCT03560336|DRUG|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
218898849|NCT04499937|BEHAVIORAL|Streak incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
218898850|NCT04499937|BEHAVIORAL|Loss-based incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
218898851|NCT04499937|BEHAVIORAL|Flat-fee control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
218898852|NCT04499937|BEHAVIORAL|Flat-Fitbit control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
218898853|NCT05762497|OTHER|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
218898854|NCT01509755|DRUG|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
218898855|NCT01509755|DRUG|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
218898856|NCT01509755|DRUG|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
218898857|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years"
218898858|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years"
218898859|NCT01809522|PROCEDURE|Posterior reconstruction of the rhabdosphincter|
218898860|NCT06273150|OTHER|Positive genetic test for pathological expansion in ATN1|Positive genetic test for pathological expansion in ATN1
218898861|NCT04869865|DIETARY_SUPPLEMENT|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
218898862|NCT02426463|DRUG|propofol|
218898863|NCT02426463|DRUG|oxycodone|
218898864|NCT03444493|OTHER|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
219036449|NCT02530983|OTHER|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1"
219036450|NCT05862766|DRUG|Isatuximab|The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.
219036451|NCT05862766|PROCEDURE|bone marrow biopsy|Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
219613406|NCT00751062|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
219613407|NCT00981812|PROCEDURE|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
219613408|NCT04933695|DRUG|Sotorasib|Oral tablet
218898865|NCT02532608|OTHER|Acute sleep deprivation|Participants will stay awake for 36 hours
218898866|NCT03287999|DIAGNOSTIC_TEST|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
218898867|NCT03287999|DIAGNOSTIC_TEST|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
218898868|NCT00295191|PROCEDURE|high-flux membrane|high-flux dialyser
218898869|NCT00295191|PROCEDURE|low-flux membrane|low-flux dialyser
218898870|NCT00295191|PROCEDURE|conventional dialysate|conventional dialysate
218898871|NCT00295191|PROCEDURE|ultrapure dialysate|ultrapure dialysate
219204128|NCT06702293|BEHAVIORAL|Digital psychotherapeutic intervention|Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.
219613409|NCT02465905|OTHER|raw milk|
219613410|NCT02465905|OTHER|Heated milk|
219613411|NCT02418884|DRUG|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
219613412|NCT04620746|DRUG|Penicillin Major Determinant (PrePen) Skin Testing|Skin testing followed by oral challenge with amoxicillin 250 mg single dose
218898872|NCT01865760|DIETARY_SUPPLEMENT|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
218898873|NCT01865760|DIETARY_SUPPLEMENT|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
219036452|NCT05383768|OTHER|preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C|"Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020)."
219036453|NCT02596594|DEVICE|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
219036454|NCT01952756|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
219036455|NCT01952756|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
219036456|NCT05601206|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
219036457|NCT05601206|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
219036458|NCT02059850|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
219036459|NCT02059850|DRUG|Cyclophosphamide|Given IV
219036460|NCT02059850|OTHER|Laboratory Biomarker Analysis|Correlative studies
219036461|NCT00289809|DRUG|combination of TLC D-99 and Ifosfamide|"* TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
219036462|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
219036463|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
219036464|NCT00228917|BIOLOGICAL|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
218898874|NCT01865760|DRUG|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
218898875|NCT03244917|BEHAVIORAL|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
218898876|NCT05888675|DRUG|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
219036465|NCT00716911|DRUG|ganciclovir|
219036466|NCT00716911|GENETIC|polymerase chain reaction|
219036467|NCT00716911|OTHER|flow cytometry|
219036468|NCT00716911|OTHER|immunologic technique|
219036469|NCT00716911|PROCEDURE|allogeneic bone marrow transplantation|
218898877|NCT00964496|DRUG|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
219036470|NCT00716911|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219036471|NCT00716911|PROCEDURE|assessment of therapy complications|
219036472|NCT00716911|PROCEDURE|peripheral blood stem cell transplantation|
219036473|NCT03857984|OTHER|Blood sampling|blood sample before and after a single HD
219036474|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Other Week dosing
219036475|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
219036476|NCT04025996|DIAGNOSTIC_TEST|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master"
219036477|NCT02487238|BIOLOGICAL|Fecal Microbiota Enema|Active intervention.
219036478|NCT02487238|BIOLOGICAL|Normal Saline Enema|Placebo comparator.
219204129|NCT06702293|BEHAVIORAL|Healthy365|Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
218898878|NCT00964496|DRUG|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
218898879|NCT00896766|GENETIC|loss of heterozygosity analysis|
219518142|NCT05480722|OTHER|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
218898880|NCT00896766|GENETIC|microarray analysis|
219613413|NCT04620746|DRUG|Direct Oral challenge|Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
219613414|NCT01559077|DRUG|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
218898881|NCT00896766|GENETIC|polymorphism analysis|
218898882|NCT00896766|GENETIC|tumor replication error analysis|
218898883|NCT05878834|DIETARY_SUPPLEMENT|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
218898884|NCT05878834|DIETARY_SUPPLEMENT|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
219036479|NCT05951530|OTHER|traditional physical therapy|this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
219036480|NCT05951530|OTHER|mobile app-based cognitive training|This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
219518143|NCT05480722|OTHER|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
219518144|NCT01701726|OTHER|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
219518145|NCT01701726|OTHER|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
219518146|NCT00005910|PROCEDURE|Intraoperative ultrasound|
219518147|NCT02512913|BEHAVIORAL|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
219518148|NCT01870661|DEVICE|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
219518149|NCT01870661|DEVICE|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
218898885|NCT02159066|DRUG|LGX818|Combination of LGX818 and MEK162 (Part I)
218898886|NCT02159066|DRUG|MEK162|Combination of LGX818 and MEK162 (Part I)
218898887|NCT02159066|DRUG|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
218898888|NCT02159066|DRUG|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
218898889|NCT02159066|DRUG|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
218898890|NCT02159066|DRUG|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
218898891|NCT01147666|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arms.
218898892|NCT01147666|DRUG|Epoetin Alfa|Epoetin Alfa will be administered per dose and schedule specified in the arms.
218898893|NCT01147666|OTHER|Placebo|Placebo matching to roxadustat will be administered per schedule specified in the arm.
219036481|NCT00525668|DRUG|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
219036482|NCT00525668|DRUG|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
219036483|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
219036484|NCT02758392|DRUG|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
219036485|NCT02758392|DRUG|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
219036486|NCT02758392|DRUG|Placebo|Participants will receive placebo on Day 1.
219518150|NCT01911975|DRUG|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
219518151|NCT01911975|DRUG|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
219518152|NCT02698800|DEVICE|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
219613415|NCT01559077|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219613416|NCT03411863|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
219613417|NCT03411863|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
218898894|NCT02750774|BEHAVIORAL|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
218898895|NCT02750774|OTHER|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
218898896|NCT05220878|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
219036487|NCT01883687|PROCEDURE|Septoplasty|
219036488|NCT02319005|DRUG|Revusiran (ALN-TTRSC)|
219036489|NCT02319005|DRUG|Sterile Normal Saline (0.9% NaCl)|
219036490|NCT02063737|BEHAVIORAL|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
219036491|NCT02063737|BEHAVIORAL|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
219036492|NCT01152463|PROCEDURE|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
219036493|NCT00902642|BEHAVIORAL|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
219036494|NCT05464654|DRUG|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
219036495|NCT05464654|DRUG|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
219036496|NCT06522191|OTHER|Physiotherapy Training (PT)|Both groups received the same therapist-led standardized PT for 5 days a week including 2 days of RR plus 3 days of conventional rehabilitation (CR) for 5 weeks. RR training will be given 40 min per session using an intelligent feedback robotic system. The system allows patients to move a cursor to targets on a monitor using a unilateral exoskeleton robotic arm and handle, which supports shoulder, elbow, forearm, and optionally multi-joint movements. The system provides visual and auditory feedback, offering exergame training with 1Dimension (D), 2D, and 3D options adjustable to three levels (low to high). Exergames and their parameters will be customized based on each patient's capacity. The CR protocol consists of joint range-of-motion, correct movement, stretching and balance exercises, gait training (walking on level surfaces, stairs), strengthening of antagonist muscle pattern will be provided. Each CR session will last 45 min of active treatment.
219036497|NCT06522191|DEVICE|Cross-Education Intervention|Participants in the CE group will have the less affected upper extremity undergo game-based, unilateral, repetitive movement training using RR to enhance the effectiveness of the training to be provided to the affected side. Similar therapeutic games (exergames) planned for the more affected upper extremity will be selected through the unilateral exoskeleton RR device. As described in the PT section, upper extremity movements will be performed using the robotic arm and handle during the games. The difficulty level will be adjusted by the supervisor physiotherapist based on the grip threshold on the robotic handle, the game's difficulty level (low to high), workspace arrangement before each session, and suspension level according to the patient's needs. An approximately 20-minute program will be implemented, consisting of 8 games, each lasting about 2.5 minutes, tailored to the patient's capacity.
219518153|NCT02698800|DEVICE|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
219518154|NCT04646109|DRUG|Ivermectin|"Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions."
219518155|NCT01679821|OTHER|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
219518156|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
219518157|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
219518158|NCT00577460|DRUG|Pramipexole|Pramipexole ER 0.375 -4.5 mg
219518159|NCT00577460|DRUG|Placebo|Placebo tablets identical to Pramipexole ER tablets
218898897|NCT05220878|BIOLOGICAL|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
219518160|NCT06286969|PROCEDURE|acupuncture|The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.
219518161|NCT04066166|DIAGNOSTIC_TEST|Palpation|All healthy subjects palpated
219518162|NCT01607645|DRUG|decitabine|Given IV
219518163|NCT01607645|DRUG|idarubicin|Given IV
219518164|NCT01607645|DRUG|cytarabine|Given IV
219518165|NCT01610258|OTHER|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
218898898|NCT00217932|DRUG|Divalproex Sodium (Depakote)|
218898899|NCT00462007|DRUG|Stalevo|Oral 3-4 daily doses for 6 weeks
218898900|NCT02869399|DIETARY_SUPPLEMENT|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
219036498|NCT06522191|OTHER|Control Intervention|The exercises to be administered in the control intervention will be selected based on the patient's level of impairment but will be planned without progression or intensity increase, and the involvement of the upper extremity will be kept to a minimum. The exercises will include lower limb joint range of motion exercises, weight bearing, weight shifting, and gait training.
219036499|NCT03373383|DRUG|Padsevonil|Padsevonil in different dosages.
219036500|NCT03373383|OTHER|Placebo|Placebo will be provided matching Padsevonil.
219036501|NCT02689258|DRUG|HTX-011B|HTX- 011B (bupivacaine/meloxicam) via injection
219036502|NCT02689258|DRUG|Placebo|Saline placebo via injection
219036503|NCT02689258|DRUG|HTX-011A|HTX- 011A (bupivacaine/meloxicam) via injection
219036504|NCT02689258|DRUG|HTX-002|HTX-002 via combination
219036505|NCT02689258|DRUG|Bupivicaine HCl|Bupivacaine HCl via injection
219518166|NCT04641481|BIOLOGICAL|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
219518167|NCT04641481|BIOLOGICAL|Placebo|Placebo (PBS+Alum, without antigen)
219518168|NCT05894863|DEVICE|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
219518169|NCT01683617|BEHAVIORAL|Coping skills and relaxation training with new technologies|
219518170|NCT01683617|BEHAVIORAL|Traditional coping skills and relaxation training|
218898901|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
219518171|NCT02133339|DRUG|TRN-157|
219518172|NCT02133339|DRUG|Placebo|
218898902|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
218898903|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
219036506|NCT03657355|DRUG|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
218898904|NCT04266808|DEVICE|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
219036507|NCT03657355|DRUG|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
219036508|NCT03657355|DRUG|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
219036509|NCT03657355|DRUG|Placebo|Matching-placebo will be used.
219036510|NCT03317431|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
219036511|NCT00210704|DRUG|Dapoxetine|
219036512|NCT02261376|DRUG|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
219036513|NCT05251376|DRUG|Levomethadone HCl|One dose given orally on Day 8 of the study.
219036514|NCT05251376|DRUG|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
219036515|NCT05251376|DRUG|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
219036516|NCT05251376|DIAGNOSTIC_TEST|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
219518173|NCT02494713|DRUG|Degarelix|Subcutaneous injection, once/month for 4 months
219518174|NCT02494713|DRUG|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
219518175|NCT02494713|DRUG|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
219518176|NCT02494713|DRUG|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
219518177|NCT02494713|DRUG|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
219518178|NCT03475927|OTHER|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
219518179|NCT03777033|DRUG|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
219518180|NCT01107002|PROCEDURE|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
219518181|NCT00615784|DRUG|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
219518182|NCT04554654|DIAGNOSTIC_TEST|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
218898905|NCT04266808|BEHAVIORAL|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
218898906|NCT05768100|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
218898907|NCT05768100|DIETARY_SUPPLEMENT|Placebo|Isovolumic placebo
218898908|NCT01203735|DRUG|Valproic acid|800mg per day for entire period of RT
219036517|NCT05251376|DIAGNOSTIC_TEST|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
219036518|NCT04649775|DEVICE|AirFLO2|Mask device
218898909|NCT00130169|DRUG|E7974|Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
218898910|NCT02299726|DRUG|Spironolactone|
219036519|NCT04262037|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
219036520|NCT02479737|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
219036521|NCT03184181|OTHER|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
219036522|NCT03184181|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
219036523|NCT05437978|OTHER|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
219036524|NCT01540058|OTHER|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
219036525|NCT01540058|OTHER|No test Empiric strategy|Empiric strategy
219036526|NCT04753164|DRUG|ACT-539313|ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
219036527|NCT04753164|DRUG|Placebo|Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
219036528|NCT01050985|DRUG|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
219204130|NCT07030985|RADIATION|CTP scan|Patients with diagnosed aSAH and no evidence of early radiologic vasospasm will receive a CTP scan within 48 hours of aSAH symptom onset.
219518183|NCT00159965|DRUG|sertraline|flexible dose sertraline
219518184|NCT00159965|DRUG|placebo|flexible dose placebo
218898911|NCT02299726|OTHER|Placebo|Matching placebo
218898912|NCT02531217|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
218898913|NCT05716061|PROCEDURE|Sacral ESPB|Cadaver study
218898914|NCT01744249|DRUG|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
218898915|NCT01744249|DRUG|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
219518185|NCT06132646|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
218898916|NCT01744249|DRUG|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
218898917|NCT01712126|DRUG|Irbesartan and Hydrochlorothiazide|
218898918|NCT01712126|DRUG|Avalide|
218898919|NCT01630915|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
218898920|NCT00301626|BEHAVIORAL|smoking reduction intervention (including NRT)|
218898921|NCT01658007|DRUG|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
218898922|NCT03145740|OTHER|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
218898923|NCT03145740|OTHER|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
218898924|NCT06015386|OTHER|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
218898925|NCT06015386|OTHER|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
218898926|NCT02171507|DRUG|Dabigatran etexilate|
218898927|NCT02171507|DRUG|Diclofenac|
219518186|NCT01434836|OTHER|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
218898928|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
218898929|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
218898930|NCT00474955|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
218898931|NCT00282139|DRUG|Aripiprazole|
218898932|NCT01135134|DRUG|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
218898933|NCT01135134|DRUG|Placebo|"MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
218898934|NCT05490862|BEHAVIORAL|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
218898935|NCT05490862|BEHAVIORAL|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
218898936|NCT01496235|DIETARY_SUPPLEMENT|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
218898937|NCT01496235|DIETARY_SUPPLEMENT|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
218898938|NCT06018948|DRUG|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
219036529|NCT03616288|DIETARY_SUPPLEMENT|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
219036530|NCT03774940|DIAGNOSTIC_TEST|peripheric blood count|preoperative peripheric blood count
219036531|NCT04602858|DEVICE|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
219036532|NCT04602858|OTHER|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
219036533|NCT00694369|DRUG|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
219036534|NCT00694369|DRUG|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
219036535|NCT00694369|DRUG|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
219036536|NCT00694369|DRUG|Comparator: placebo|matching placebo over three Days
218898939|NCT06018948|DRUG|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
218898940|NCT06018948|DRUG|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
218898941|NCT02174991|DRUG|Rho-Kinase Inhibitor (AR-12286)|
218898942|NCT04163029|PROCEDURE|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
219036537|NCT01250587|DRUG|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
219036538|NCT05019924|DIETARY_SUPPLEMENT|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
219036539|NCT03823248|DRUG|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
219036540|NCT03823248|DRUG|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
219036541|NCT03823248|DRUG|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
219036542|NCT03823248|DRUG|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
219036543|NCT03823248|DRUG|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
219036544|NCT03823248|DRUG|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
219036545|NCT05336058|OTHER|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
218898943|NCT02255916|OTHER|Music|live sound-bed music intervention
218898944|NCT02289677|DEVICE|ATMOS Scope|Video-laryngoscopy 1
218898945|NCT02289677|DEVICE|COOPDECH|Video-laryngoscopy-1
219612071|NCT07017049|BEHAVIORAL|Routine training intervention|"Participants in the control group will follow the standard physical training program of the school over a 12-week period, with sessions conducted 3 times per week, each lasting approximately 50 minutes (including warm-up and cool-down). The training intensity will progressively increase from 55%-65% HRmax in weeks 1-3, 65%-75% HRmax in weeks 4-8, and 75%-85% HRmax in weeks 9-12.~Each session includes:~Warm-up (10 minutes): Movement of hands and legs, small-sided games, ball handling, and stretching exercises.~Intervention (30 minutes):~Weeks 1-3: Barbell back squat, barbell deadlift, bench press, continuous broad jumps, continuous burpee jumps, frontal plank (60 sec), 50m sprinting (5 reps), 2 sets of each exercise with 30-60 seconds rest.~Weeks 4-5: Similar structure with increased repetitions (barbell exercises 6-10 reps, plank 70 sec).~Weeks 6-8: Barbell back squat, deadlift, bench press, broad jumps, each for 3 sets, 30-60 sec rest.~Weeks 9-12: Higher load with 8-12 reps per"
219036546|NCT06821854|DEVICE|PN20 (Plinest)|"PN20 (Plinest) is a single-use viscoelastic, and sterile gel for intradermal use. PN20 contains polynucleotides (20 mg/ml- 2%), water, sodium chloride, sodium phosphate and disodium phosphate.~PN20 is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques, such as linear threading, serial punctures, crosslinked, radial fanning or mixed, can be used. The injection site must consist of healthy skin. PN20 can also be administered by means of modern non-invasive techniques (electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application.~PN20, thanks to its versatility and manageability, can be used in any skin area; in the current clinical investigation the face, neck or décolleté will be treated."
219036547|NCT01015586|DRUG|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
219036548|NCT01015586|DRUG|Placebo|Placebo once daily for 12 weeks
219036549|NCT03152539|RADIATION|MRI|
219036550|NCT03152539|DEVICE|EEG|
219036551|NCT03152539|DEVICE|NIRS|
218898946|NCT02289677|DEVICE|AirTraq|Optical-laryngoscopy
218898947|NCT04013607|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
219036552|NCT00819988|DRUG|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
219036553|NCT00819988|OTHER|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
219036554|NCT00907374|DRUG|benazepril|benazepril 10 mg orally once daily
219036555|NCT00907374|DRUG|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
219036556|NCT00314236|DEVICE|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
219036557|NCT00314236|PROCEDURE|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
219036558|NCT02457403|DEVICE|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
219036559|NCT02457403|OTHER|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
219612072|NCT07017699|DRUG|Deucravacitinib|According to product label
219612073|NCT07017699|DRUG|Other systemic treatments for PsO|According to product label
218898948|NCT00631358|DRUG|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
218898949|NCT00631358|OTHER|No treatment|Healthy normal control group receiving no treatment
218898950|NCT00802516|DIETARY_SUPPLEMENT|stanol ester|enriched margarine
218898951|NCT00802516|DIETARY_SUPPLEMENT|sterol ester|enriched margarine
218898952|NCT00802516|DIETARY_SUPPLEMENT|No intervention|placebo margarine
218898953|NCT05951946|DRUG|BR3006-1|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
218898954|NCT05951946|DRUG|BR3006-2|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
218898955|NCT05951946|DRUG|BR3006-3|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
218898956|NCT05646134|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
219036560|NCT01060033|DEVICE|MR Spectroscopy|
219036561|NCT01060033|DEVICE|Fat-Saturation and Diffusion-Weighted Imaging|
219036562|NCT01060033|DEVICE|Dynamic Contrast Enhancement MRI (MR-DCE)|
219036563|NCT01060033|DEVICE|Diffusion Tensor Imaging (DTI)|
219036564|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
218898957|NCT05646134|DEVICE|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
218898958|NCT01915160|BEHAVIORAL|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
218898959|NCT01915160|BEHAVIORAL|TF-CBT|Treatment as usual.
218898960|NCT00407186|DRUG|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
218898961|NCT00407186|RADIATION|radiotherapy|45 Gy in 25 fracions (5 days/week)
218898962|NCT00407186|DRUG|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
218898963|NCT05283551|DRUG|Famciclovir|Famciclovir (500mg BD)
219036565|NCT06582485|DRUG|iCM012 solution 2 mg/mL|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
218898964|NCT00067184|DEVICE|Toitu 320/325|Fetal monitor
219036566|NCT06582485|DRUG|Placebo|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
219036567|NCT04820790|OTHER|Mobile applications|Monitoring of patients with home oxygen through a mobile application
219036568|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
219036569|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
219036570|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
219036571|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
219204131|NCT07030985|DIAGNOSTIC_TEST|Neurological and neuropsychological testing|All enrolled patients will receive neurological and neuropsychological assessment at 12 months after aSAH.
218898965|NCT01877512|DRUG|Change in daily dosage of Growth Hormone|
219036572|NCT03023085|DRUG|BLI4700|BLI4700 bowel preparation
219036573|NCT00884299|DIETARY_SUPPLEMENT|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
219036574|NCT05828251|PROCEDURE|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
219204132|NCT06878820|BEHAVIORAL|Function Focused Care|FFCiH is an effective nursing approach and focuses on stimulating nurses to promote patients' self-reliance in daily functioning, encouraging the patients' engagement in daily activities and helping patients to attain and maintain their highest level of function and to increase time spent in physical activity.
219204133|NCT06877689|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
219364262|NCT05933538|DRUG|Cariprazine|The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.
218898966|NCT02386046|OTHER|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
218898967|NCT01122602|DRUG|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
218898968|NCT01122602|DRUG|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
218898969|NCT01122602|DRUG|Placebo|Two placebo tablets
218898970|NCT01007357|DEVICE|Body MR imaging|Body MR imaging will be performed to optimize sequences
218898971|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
218898972|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
218898973|NCT05703750|PROCEDURE|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
218898974|NCT02513121|OTHER|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
218898975|NCT00889135|DRUG|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
218898976|NCT04692623|DRUG|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
218898977|NCT04692623|DRUG|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
218898978|NCT06376630|DRUG|Esmolol Hcl 10Mg/Ml Inj|"the loading dose of 500 mkg/kg for 1 minute, followed by the initial rate of 50 mkg/kg/min. Individual titration depending on the desired hemodynamical effect (to the heart rate of 60 bpm or to the maximum tolerated dose maintaining stable hemodynamics) every 5-15 minutes (the maximum allowed rate of administration is 300 mkg/kg/min) for 6 hours.~Thereafter patients in both treatment arms - the IV esmolol arm and the placebo arm, will be administered oral β-adrenergic blockers, if decided so by the treating physician and unless contraindicated."
218898979|NCT02609308|OTHER|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
218898980|NCT02609308|PROCEDURE|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
218898981|NCT00304174|BEHAVIORAL|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
218898982|NCT00105911|BEHAVIORAL|Cognitive Behavioral Therapy|
218898983|NCT03326778|PROCEDURE|AVR and CABG|Combined AVR with CABG
218898984|NCT02451085|BEHAVIORAL|training with video therapy|training with video therapy
218898985|NCT02451085|BEHAVIORAL|conventional exercise|training in conventional way
219612074|NCT07018726|BEHAVIORAL|Resilient Together-YOD|This is a 6 session dyadic (patient and spousal care-partner) intervention that teaches resiliency and interpersonal communication skills early after YOD diagnoses. It aims to decrease heightened symptoms of depression and anxiety among dyads to help them engage in important decisions around long term care-planning and optimize adjustment. The goal is to equip dyads with the necessary skills to cope and engage in meaningful, challenging conversations around care-planning, symptom deterioration, work/family planning to improve well-being in both members of the dyad.
218898986|NCT00815217|PROCEDURE|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
218898987|NCT00815217|OTHER|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
218898988|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
218898989|NCT02610582|DRUG|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
219036575|NCT05828251|PROCEDURE|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
219036576|NCT05828251|PROCEDURE|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
219036577|NCT02599753|DRUG|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
219036578|NCT05111977|DEVICE|Vibrant capsule|A capsule delivering mechanical vibrations
219364263|NCT05933538|COMBINATION_PRODUCT|Treatment as usual|Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
219364264|NCT00469950|BEHAVIORAL|exercise training|Exercise training in groups
219364265|NCT02633683|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
219364266|NCT01276171|PROCEDURE|Ultrasound|Participants will place arterial line using ultrasound technique
219364267|NCT01276171|PROCEDURE|Doppler|Participants will place arterial line using doppler technique
219364268|NCT01276171|PROCEDURE|Palpation|Participants will place arterial line using Palpation technique
219364269|NCT06099782|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
219364270|NCT06099782|BIOLOGICAL|Pembrolizumab|Administered via IV infusion
219364271|NCT02273583|DRUG|continuous oral cyclophosphamide and methotrexate|
219364272|NCT03020862|DIETARY_SUPPLEMENT|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
219364273|NCT06399926|DRUG|Pemetrexed injection|Group 1（20mg）:induction stage is 20 mg per 24 hours for 72 hours, every 2 weeks; consolidation stage is 20mg per 24 hours for 72 hours, every 3 weeks.
218898990|NCT03148366|DRUG|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
218898991|NCT03148366|DRUG|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
218898992|NCT06437262|DRUG|0.20% CHX gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
218898993|NCT06437262|DRUG|0.20% CHX and Cymenol gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
218898994|NCT06437262|DRUG|0.20% CHX gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
218898995|NCT06437262|DRUG|0.20% CHX and Cymenol gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
218898996|NCT02041481|DRUG|MEK inhibitor MEK162|Given PO
218898997|NCT02041481|DRUG|leucovorin calcium|Given IV
218898998|NCT02041481|DRUG|fluorouracil|Given IV
218898999|NCT02041481|DRUG|oxaliplatin|Given IV
218899000|NCT02041481|OTHER|pharmacological study|Correlative studies
218899001|NCT02041481|OTHER|Laboratory Biomarker Analysis|Correlative Studies
218899002|NCT02539641|RADIATION|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
218899003|NCT02539641|OTHER|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
218899004|NCT06097065|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Grouping based on detected oral glucose tolerance test results without any other intervention.
218899005|NCT00644046|BEHAVIORAL|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
218899006|NCT00293917|DRUG|Tacrolimus Cream|
218899007|NCT01859923|DRUG|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
218899008|NCT01859923|DRUG|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
218899009|NCT01859923|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
218899010|NCT03544021|BIOLOGICAL|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
218899011|NCT03148613|DEVICE|Carbon Monoxide Breath Sensor System (COBSS)|Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
219036579|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
219036580|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
218899012|NCT03148613|DEVICE|Bedfont - Micro+™ Smokerlyzer®|Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
218899013|NCT00429949|DRUG|Dasatinib|
219612075|NCT07018726|BEHAVIORAL|Health Enhancement Program-YOD|This is a 6 session program that will deliver educational information to dyads and will mimic the dose and duration of Resilient Together. The program will not teach any individual and dyadic interpersonal skills, but will contain education on psychological distress and healthy behaviors. Sessions will also be delivered virtually.
219612076|NCT07018453|DRUG|SHR-3167|SHR-3167 Injection.
219612077|NCT07018453|DRUG|Insulin Degludec|Insulin Degludec Injection.
218899014|NCT05222828|DRUG|Carbocaine Injectable Product|One injection per patient
218899015|NCT00226928|BEHAVIORAL|Supportive-Expressive Group Therapy plus education|
218899016|NCT00226928|BEHAVIORAL|Education|
218899017|NCT00547651|DRUG|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
218899018|NCT00547651|DRUG|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
218899019|NCT03572452|BEHAVIORAL|McKenzie Method|Treatment according to the Mechanical Diagnosis and Therapy Approach
219364274|NCT06399926|DRUG|Pemetrexed|Group 2（30mg）:induction stage is 30 mg D1，every week.Consolidation stage is 30 mg D1,every 3 weeks.
219364275|NCT02277717|DRUG|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
219612078|NCT07016659|DRUG|0.12% Chlorhexidine Mouthwash ( Hexitol )|About 10 ml will be administered, and participants will be asked to swish mouthwash for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks.
219612079|NCT07016659|DRUG|Triphila mouthwash|The participant will be instructed to administer 15 ml of the mouthwash and swish it for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks
219036581|NCT01871363|RADIATION|chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
219036582|NCT02189057|OTHER|AssureRx GeneSight genotyping results|
219204134|NCT06876844|DRUG|combination of Surufatinib and Envolizumab|envolizumab: 300 mg subcutaneously every 3 weeks (Q3W); Surufatinib : 200 mg orally within 1 hour after breakfast, once daily continuously every 3 weeks as a treatment cycle until intolerable toxicity or disease progression. If any ≥ Grade 2 treatment-related adverse event occurs during treatment, the dose may be adjusted to 100 mg according to the investigator 's clinical assessment.
218899020|NCT03572452|BEHAVIORAL|Advice to saty active|Physiotherapy councelling advicing to stay normally active
218899021|NCT02456155|PROCEDURE|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
218899022|NCT02456155|PROCEDURE|placing nasal jejunal tube endoscopically|
218899023|NCT04503746|DRUG|ALH-L1005 600mg/day|ALH-L1005 300mg 2 tablet and placebo 2 tablet
218899024|NCT04503746|DRUG|ALH-L1005 1,200mg/day|ALH-L1005 300mg 4 tablet
218899025|NCT04503746|DRUG|Placebo|Placebo 4 tablet
218899026|NCT02719496|DRUG|IBEROGAST|
218899027|NCT03096340|DRUG|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
218899028|NCT03634085|DRUG|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
218899029|NCT06386523|DIAGNOSTIC_TEST|Passage of olfactory tests|test TODA2 and Sniffin Stick Test
218899030|NCT03246789|BEHAVIORAL|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
218899031|NCT03246789|BEHAVIORAL|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
218899032|NCT00006107|DRUG|Taxotere|
218899033|NCT00006107|PROCEDURE|Surgery|
218899034|NCT00006107|RADIATION|radiation therapy|
218899035|NCT03025646|OTHER|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~1. Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~   Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~2. Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
218899036|NCT01889875|DRUG|"ALK Grazax 75,000 SQ-T Phleum pratense"|
218899037|NCT01889875|DRUG|"ALK AluTard 225 Phleum pratense"|
218899038|NCT05922189|OTHER|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
218899039|NCT05922189|OTHER|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
219036583|NCT02189057|OTHER|Treatment as usual|
219204135|NCT06877767|OTHER|Graston Technique|"Following the conventional treatment, this technique will be carried out through Graston tool called GT-1 The special Graston Emollient or lubricant will be applied to the hamstrings of the subject then the tool used to find adhesions and break them up for 2.5 minutes per leg. First, the subject will lay prone and bent the knee joint to around 30° to 60°.The Graston instrument will be rubbed on each subject 30 times for 60 seconds from the gluteal line to the popliteal fossa. This treatment technique will be applied twice a week"
219204136|NCT06877767|OTHER|Active Release Technique|Following the conventional treatment, subject received single session of ART on each side. There are 3 steps to perform ART. Step 1:Subject lies supine on the plinth and gentle tension was applied to the hamstring muscle along the entire length while stretching the leg in different positions to better work the muscle. Step 2: Gentle tension will be applied at the origin and insertion of the hamstring muscle. Step 3: The therapist will place tension on the bellies of hamstrings longitudinally at a specific tension \& ask the patient to extend his knee as per ART protocol.• This is done for 2.5 minutes on each leg. • This treatment technique will be applied twice a week.
219612080|NCT07017075|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in traditional CPR location and the better position
219612081|NCT07018375|DRUG|Oliceridine|postoperative patient-controlled analgesia (PCA)
219612082|NCT07018375|DRUG|Sufentanil|Sufentanil
219612083|NCT02008812|DEVICE|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
219612084|NCT02577991|DRUG|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
219612085|NCT02577991|DRUG|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
218899040|NCT04648813|DRUG|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
218899041|NCT04648813|DRUG|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
218899042|NCT01897363|OTHER|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
218899043|NCT00806910|DRUG|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
218899044|NCT00806910|OTHER|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
218899045|NCT01999296|DEVICE|Use of Thunderbeat (TM) in laparoscopic surgery|
218899046|NCT01187940|BEHAVIORAL|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
218899047|NCT02360826|DRUG|Pravastatin|
219204137|NCT06876181|OTHER|Pharmacokinetics of Intra-Articularly Administered TXA: Postoperative Concentration Dynamics in Periarticular Hematoma|As part of the standard total knee arthroplasty procedure, participants receive a 2 g dose of tranexamic acid into the joint space after suturing the joint capsule. Before closing the joint capsule, a silicone drain is inserted into the joint space, through which periarticular hematoma samples are collected aseptically at 0.5, 1.5, 3, 6, and 9 hours post-application.
218899048|NCT02360826|DRUG|Simvastatin|
219204138|NCT07028008|BIOLOGICAL|tumor-infiltrating lymphocyte (TIL)|tumor-infiltrating lymphocyte (TIL): CT-SP 1\~100 x10 9 cells
219364276|NCT01125280|PROCEDURE|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
219364277|NCT02975843|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
219364278|NCT00002559|BIOLOGICAL|filgrastim|
219364279|NCT00002559|DRUG|cisplatin|
219364280|NCT00002559|DRUG|ifosfamide|
219364281|NCT00002559|DRUG|paclitaxel|
219364282|NCT01688024|DRUG|Mitomycin C|
219364283|NCT01688024|DRUG|Normal saline|
219364284|NCT05588570|BEHAVIORAL|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
219364285|NCT03363633|DRUG|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
219364286|NCT03363633|DEVICE|Compression|20-30 mmHg compression stockings
219364287|NCT04691583|OTHER|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
219364288|NCT03723187|OTHER|normal saline|experimental group use normal saline sealing tube
219364289|NCT03723187|OTHER|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
219364290|NCT01042080|DEVICE|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
219364291|NCT01042080|OTHER|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
219364292|NCT05167773|DEVICE|tonometer|A subject undergoes intraocular pressure measurement with tonometer
219364293|NCT03674151|DEVICE|Silver Nylon dressing|Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
219364294|NCT03674151|DEVICE|Manuka-Honey|Manuka-Honey dressing on split-skin grafted third-degree burn wound
219364295|NCT03674151|DEVICE|Povidone-Iod (PVP-Iod)|Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
219364296|NCT03674151|DEVICE|Hydrogel|Hydrogel dressing on split-skin grafted third-degree burn wound
219364297|NCT02441790|BEHAVIORAL|Early Active Range of Motion|3-9 days
219364298|NCT02441790|BEHAVIORAL|Standard Immobilization|21-27 days
218899049|NCT00898963|GENETIC|gene expression analysis|
218899050|NCT00898963|GENETIC|microarray analysis|
218899051|NCT00898963|GENETIC|polymorphism analysis|
219612086|NCT02513862|DEVICE|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
219612087|NCT00115076|DRUG|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
219612088|NCT03618251|DIAGNOSTIC_TEST|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
218899052|NCT00898963|OTHER|diagnostic laboratory biomarker analysis|
218899053|NCT00898963|OTHER|immunohistochemistry staining method|
218899054|NCT00898963|OTHER|immunologic technique|
218899055|NCT03833739|DEVICE|Fixed appliance|
218899056|NCT00504088|PROCEDURE|Bypass|
218899057|NCT00504088|PROCEDURE|Silverhawk Plaque Excision|
218899058|NCT02670486|OTHER|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
218899059|NCT01473290|DIETARY_SUPPLEMENT|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
219036584|NCT04915391|DIAGNOSTIC_TEST|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
219612089|NCT05164692|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
219612090|NCT05164692|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
219612091|NCT07016997|DRUG|CBA-1535|Dosing is increased from 0.1 µg/body until DLT or disease progression occurs.
218899060|NCT01473290|OTHER|placebo|Given PO
218899061|NCT06150950|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.
218899062|NCT06150950|OTHER|Usual care|For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.
218899063|NCT01335139|BIOLOGICAL|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
218899064|NCT01335139|BIOLOGICAL|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
218899065|NCT01335139|OTHER|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
218899066|NCT01645072|OTHER|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI \>55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
218899067|NCT01645072|OTHER|Control group|The ongoing anti epileptic drug treatment will be continued without change.
218899068|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (Moderate Risk)|Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.
218899069|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (High Risk)|Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
219036585|NCT04371380|DRUG|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
219036586|NCT04371380|DRUG|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
219036587|NCT04371380|DRUG|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
219364299|NCT04714515|DRUG|Montelukast|An FDA approved medicine to treat asthmatic patients
219364300|NCT04714515|DRUG|Hydroxychloroquine|An FDA approved antiarthritis drug
219364301|NCT04714515|DRUG|Ivermectin|An FDA approved anti-parasitic medicine
219364302|NCT00325078|DRUG|Infliximab|
219364303|NCT05234580|DRUG|PA9159 nasal spray solution, 10 μg once daily for 14 days|PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
219364304|NCT05234580|DRUG|PA9159 nasal spray solution, 20 μg once daily for 14 days|PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
218899070|NCT05706311|OTHER|Standard of Care|Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
219612092|NCT07016997|DRUG|CBA-1535+Pembrolizumab|"Drug：CBA-1535 First Dosing will be determined by Part 1. And dosing will be increased until DLT or disease progression occurs.~Drug：Pembrolizumab 200 mg/body"
219612093|NCT07016698|DEVICE|Rotarex(TM) Rotational Excisional Atherectomy System|Subjects treated with Rotarex(TM) Rotational Excisional Atherectomy System
218899071|NCT06063863|DIAGNOSTIC_TEST|Nurse led screening with Optos ultra-widefield retinal-imaging device|The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
218899072|NCT01216202|RADIATION|Preoperative radiotherapy|"Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes."
218899073|NCT05028192|OTHER|no intervention|no intervention
218899074|NCT04564664|DRUG|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
218899075|NCT04968158|DRUG|Etoricoxib 90 mg / Tramadol 50 mg|One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
218899076|NCT04968158|DRUG|Acetaminophen 325 mg / Tramadol 37.5 mg|One tablet, every 8 hours of 325 mg/ 37.5 m
218899077|NCT05055544|DRUG|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
218899078|NCT05055544|DRUG|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
218899079|NCT03196544|BEHAVIORAL|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
218899080|NCT03196544|BEHAVIORAL|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
218899081|NCT06379165|DRUG|Meloxicam Nanocrystal Injection|30 mg (1 mL), once daily, by intravenous infusion
218899082|NCT06379165|DRUG|Placebo|1 mL Placebo, once daily, by intravenous infusion
219036588|NCT04371380|DRUG|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
219036589|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
219036590|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is greater than 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.
219036591|NCT05270434|DRUG|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
219518187|NCT01434836|OTHER|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
219518188|NCT01661270|DRUG|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
219518189|NCT01661270|DRUG|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
219518190|NCT04811768|PROCEDURE|Maxillary sinus augmentation|The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
219518191|NCT03184441|DEVICE|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
219518192|NCT04652570|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
219612094|NCT07017283|DEVICE|Tracheal intubation general anesthesia|Endotracheal intubation with general anesthesia was administered to the patient during the ERCP procedure.
219612095|NCT07017283|DEVICE|Nasopharyngeal airway ventilation|Nasopharyngeal airway-assisted anesthesia was employed for the patient during the ERCP procedure.
219612096|NCT04699240|DRUG|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
219612097|NCT04699240|DRUG|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
219036592|NCT02444247|OTHER|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
219518193|NCT05496075|DRUG|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
218899083|NCT04836585|OTHER|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~1. Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~2. PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~3. Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
218899084|NCT04506541|OTHER|Kangaroo Care|Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
218899085|NCT05806463|BEHAVIORAL|Mother's Time|Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
218899086|NCT03287401|DEVICE|Electroencephalography|Patients electroencephalogram will be recorded
218899087|NCT04724408|DEVICE|VieScope|see above
218899088|NCT04724408|DEVICE|Conventional|see above
218899089|NCT03982641|PROCEDURE|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
218899090|NCT04757493|DRUG|Prucalopride 2mg|Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
218899091|NCT06059365|BEHAVIORAL|Hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward
218899092|NCT06059365|BEHAVIORAL|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
218899093|NCT00061659|DRUG|ABT-510 - Thrombospondin-1 mimetic|
218899094|NCT05109780|DEVICE|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
219518194|NCT05496075|DRUG|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
219518195|NCT00968370|OTHER|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
219518196|NCT00968370|OTHER|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
218899095|NCT00271375|BEHAVIORAL|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
218899096|NCT00271375|BEHAVIORAL|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
218899097|NCT00271375|BEHAVIORAL|Control|Control group usual care
218899098|NCT02161796|DRUG|FG-4592|Oral
218899099|NCT02161796|DRUG|Placebo|Oral
219518197|NCT02986009|BEHAVIORAL|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
218899100|NCT04618146|DRUG|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
218899101|NCT04618146|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
219036593|NCT02444247|OTHER|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
219036594|NCT02444247|OTHER|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
219036595|NCT02444247|OTHER|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
219036596|NCT05711732|DIAGNOSTIC_TEST|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
219036597|NCT06088433|DRUG|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
219036598|NCT06088433|DRUG|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
218899102|NCT05861596|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
218899103|NCT05861596|DEVICE|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
219518198|NCT02986009|BEHAVIORAL|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
219518199|NCT01482156|DRUG|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
219612098|NCT05106192|DEVICE|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
219612099|NCT05106192|DRUG|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
218899104|NCT05052034|OTHER|Music|Through headphones, the patients would listen to different types of music during the intervention.
218899105|NCT00165880|DRUG|E7070|
218899106|NCT03913858|PROCEDURE|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
218899107|NCT03913858|PROCEDURE|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
218899108|NCT00017602|BIOLOGICAL|oblimersen sodium|
218899109|NCT00017602|DRUG|dexamethasone|
218899110|NCT05853146|DEVICE|Oxitone 1000M|World's First FDA-cleared Wrist-Sensor Pulse Oximetry Monitor
218899111|NCT00930696|PROCEDURE|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
218899112|NCT00930696|PROCEDURE|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
218899113|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
218899114|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
219612100|NCT05106192|DRUG|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
219612101|NCT05106192|DRUG|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
219612102|NCT05106192|DEVICE|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
218899115|NCT05612308|OTHER|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
218899116|NCT03476135|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
218899117|NCT00071227|DRUG|Triamcinolone Acetonide (TAC-PF)|
219204139|NCT06880185|OTHER|Connective Tissue Graft|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The group were divided into CTG , and 10 patients were randomly assigned to group.
218899118|NCT00694616|DEVICE|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
218899119|NCT00694616|DEVICE|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
218899120|NCT04363203|DRUG|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.
218899121|NCT04363203|DRUG|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
218899122|NCT04363203|DRUG|Placebo oral tablet|Placebo in pill packs identical to study drugs
218899123|NCT05854355|OTHER|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
218899124|NCT04703088|DRUG|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
219036599|NCT06088433|DRUG|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
219036600|NCT00928928|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
219036601|NCT00928928|PROCEDURE|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
219036602|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
219036603|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
219036604|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
219612103|NCT02435524|BEHAVIORAL|A&T infant and young child feeding intervention|"1. Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~   * Increase mother's knowledge about optimal breastfeeding and its benefits~  * Increase mother's self-efficacy related to breastfeeding~  * Improve mother's perceptions about social norms relating to breastfeeding~2. Community mobilisation activities to:~   \- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~3. Enhanced training of government health workers in infant and young child feeding to:~   * Improve their ability to support mothers and provide timely information about infant feeding"
219036605|NCT03928951|OTHER|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
219036606|NCT05309109|OTHER|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
219036607|NCT05256667|COMBINATION_PRODUCT|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
219036608|NCT05256667|OTHER|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
219036609|NCT05256667|OTHER|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
219036610|NCT05603416|DIETARY_SUPPLEMENT|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
219036611|NCT05603416|DIETARY_SUPPLEMENT|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
219036612|NCT01113632|DRUG|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
219612104|NCT01042093|DRUG|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
218899125|NCT04703088|DRUG|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
219036613|NCT04654117|OTHER|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
219036614|NCT05183737|DIETARY_SUPPLEMENT|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
219036615|NCT00386867|DRUG|800 mcg misoprostol via oral or buccal administration|
219036616|NCT03040635|DRUG|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
219036617|NCT03040635|DRUG|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
219036618|NCT03330938|BEHAVIORAL|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
219036619|NCT03330938|BEHAVIORAL|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
219036620|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
219036621|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
219036622|NCT05644704|OTHER|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
219036623|NCT05363735|OTHER|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
219364305|NCT05234580|DRUG|PA9159 nasal spray solution, 40 μg once daily for 14 days|PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
219364306|NCT05234580|DRUG|Placebo nasal spray solution without PA9159, once daily for 14 days|Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
219612105|NCT01042093|DRUG|Toradol|Toradol 30mg/ml (1 ml)
218899126|NCT05515731|BIOLOGICAL|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
218899127|NCT05150184|OTHER|Non-interventional|observational study, thus no different arm/groups
218899128|NCT01101399|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
218899129|NCT06214975|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on stroke related symptoms."
218899130|NCT04035733|DRUG|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
218899131|NCT04602403|PROCEDURE|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
218899132|NCT05003947|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219036624|NCT00738972|DRUG|valsartan|80 mg valsartan. Duration: 12 months. Tablets
219036625|NCT00738972|DRUG|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
219036626|NCT00738972|DRUG|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
219036627|NCT00738972|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
219204140|NCT06880185|OTHER|Ribose Cross-Linked Thick Collagen Membrane|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The groups were divided into RCCM, and 10 patients were randomly assigned to group.
219204141|NCT06879509|DIAGNOSTIC_TEST|Thromboelastography|All participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.
219518200|NCT05202704|PROCEDURE|Procedure/Surgery: Experimental: Hidden conditioning + Positive Expectation|Patients will be submitted to quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectations about the treatment by means of a workshop. Immediately after the first session of manipulative therapy, participants will be submitted again to the QST but now the heat pain threshold of the hidden conditioning group will be surreptitiously downgraded (the intense noxious stimulus will be downgraded to the moderate stimulus - individually obtained during the QST) as a mean to conditioning patients to believe that spinal manipulative therapy promoted pain relief. Patients will be invited to report the pain intensity perceived just after the QST (second test - conditioning procedure). The objective of questioning the pain intensity after the conditioning test is a procedure check to ensure that the conditioning procedure worked.
219612106|NCT01042093|DRUG|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
219612107|NCT01042093|DRUG|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
219612108|NCT02273388|DRUG|BI 6727|BI 6727
219612109|NCT05860738|OTHER|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
218899133|NCT05696249|DEVICE|OhmTrak device.|All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
218899134|NCT05696249|OTHER|Outpatient Physiotherapy|All probands will undergo six-week outpatient therapy once a week for an hour
218899135|NCT04045327|DRUG|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
218899136|NCT04045327|DRUG|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
219036628|NCT04988347|COMBINATION_PRODUCT|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
219036629|NCT04988347|OTHER|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
219036630|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
219036631|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
219612110|NCT04854161|BEHAVIORAL|Empathic Attunement to Affect Training|"Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence"
219612111|NCT04854161|BEHAVIORAL|Compassion Training|Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other
218899137|NCT01587144|DRUG|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
218899138|NCT01587144|DRUG|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
218899139|NCT01587144|RADIATION|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
218899140|NCT01587144|DRUG|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
218899141|NCT02426840|DIETARY_SUPPLEMENT|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
218899142|NCT02426840|DIETARY_SUPPLEMENT|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
218899143|NCT01398371|DRUG|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
218899144|NCT01398371|DRUG|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
218899145|NCT00431626|DRUG|Dutasteride (Avodart)|
218899146|NCT00431626|DRUG|Placebo|Placebo before and after treatment of TURP
218899147|NCT02673918|OTHER|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
218899148|NCT00485017|DRUG|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
218899149|NCT00485017|DRUG|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
218899150|NCT05706948|OTHER|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
218899151|NCT05706948|OTHER|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
218899152|NCT05533996|DIAGNOSTIC_TEST|ultrasound|Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
218899153|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
218899154|NCT01862913|OTHER|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
218899155|NCT01862913|OTHER|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
218899156|NCT05005975|DRUG|MT-7117|MT-7117
218899157|NCT02738554|OTHER|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
218899158|NCT03374579|DIAGNOSTIC_TEST|Fluid challenge|Fluid challenge and measure change in co2 gap
218899159|NCT02927392|DRUG|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
218899160|NCT00278733|BEHAVIORAL|Brief intervention (physician advice)|
218899161|NCT04287621|DRUG|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
219612112|NCT04854161|BEHAVIORAL|Focusing Oriented Therapy Training|Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
219036632|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
219036633|NCT05399524|OTHER|Standard of Care|Neuronavigation and intraoperative 5-ALA
219612113|NCT00489632|BEHAVIORAL|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
218899162|NCT03708978|DIAGNOSTIC_TEST|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
218899163|NCT05187078|PROCEDURE|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
219036634|NCT05399524|OTHER|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
219036635|NCT04418596|RADIATION|bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
219036636|NCT05171972|DRUG|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
219036637|NCT06122636|DIETARY_SUPPLEMENT|The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory|Each patient should take 1 sachet per day, dissolve it in a glass of water, hold in the mouth for 2-3 minutes and then swallow, for a period of 30 days.
219036638|NCT06122636|OTHER|Placebo|The placebo will be administered in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention.
219036639|NCT06779318|DRUG|S-1|Tegafur, Gimeracil, and Oteracil Potassium (S-1) 40-60 mg per dose, orally (p.o.), twice daily (BID), from Day 1 to Day 28, with a 6-week cycle, for a total of 8 cycles; or from Day 1 to Day 14, with a 3-week cycle, for a total of 16 cycles.
219036640|NCT06060665|DRUG|Seladelpar 10 mg|Administered orally
219036641|NCT06060665|DRUG|Placebo|Administered orally
219036642|NCT06970353|DRUG|Tunlametinib|Locally advanced or metastatic radioactive iodine refractory NRAS mutant differentiated thyroid cancer
219036643|NCT06970353|DRUG|Tunlametinib+PD-1 mAb|Locally advanced or metastatic NRAS mutant poor-differentiated, undifferentiated thyroid cancer
219036644|NCT06685042|BIOLOGICAL|CAR T cell|"The investigational medicinal product (IMP) CD19-CAR\_Lenti consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis product and processed by using the CliniMACS Prodigy® device (Miltenyi Biotec). CD19-CAR\_Lenti is a suspension of fresh CD4/CD8-enriched CD3+ T cells that have been genemodified with a self-inactivating (SIN) lentiviral vector expressing a CAR directed against human CD19. The SIN lentiviral vector is derived from clinically validated viral vectors described in the literature with a fully characterized sequence."
219036645|NCT04477811|DRUG|Vitamin K1|vitamin k1 tablets
219036646|NCT04477811|DRUG|Vitamin k2|vitamin k2 45 ug tablets twice daily
219036647|NCT04477811|OTHER|placebo|placebo tablets
219036648|NCT03403816|BEHAVIORAL|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
219036649|NCT02921048|DIETARY_SUPPLEMENT|omega-3 fatty acids|
219036650|NCT01256112|BEHAVIORAL|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
219036651|NCT01256112|BEHAVIORAL|Nutrition/Activity Education (NAE)|
219036652|NCT04217473|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
219036653|NCT04946292|BEHAVIORAL|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
219204142|NCT06878378|OTHER|Investigation of Factors Influencing Bowel Preparation Quality|Observed parameters include BMI, history of abdominal surgery, history of diabetes, history of diarrhea and constipation, stool characteristics, and specific bowel preparation protocols.
218899164|NCT05187078|PROCEDURE|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
218899165|NCT06303921|DRUG|11C-M503 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
218899166|NCT06303921|DIAGNOSTIC_TEST|Brain MRI|MRI scan of brain.
218899167|NCT06303921|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB
218899168|NCT06303921|BEHAVIORAL|Neurological assessments|Neurological assessments, including a video interview.
218899169|NCT06731088|DRUG|Midazolam|Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
218899170|NCT06731088|DRUG|Remazolam besylate|Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
218899171|NCT06581653|BEHAVIORAL|Phone-based PERT education intervention|Participants who allocate to the intervention group will receive regular phone-based PERT education intervention by professional team.
218899172|NCT04532034|BEHAVIORAL|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
218899173|NCT02733445|DRUG|dasatinib|
218899174|NCT02733445|DRUG|nilotinib|
218899175|NCT06361589|DRUG|Lorlatinib|lolatinib 100mg qd po
218899176|NCT01152528|DEVICE|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
218899177|NCT04303559|DRUG|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
218899178|NCT04303559|DRUG|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
218899179|NCT00421681|BEHAVIORAL|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
219036654|NCT04946292|BEHAVIORAL|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
219036655|NCT03498378|DRUG|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
219036656|NCT03498378|DRUG|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
219036657|NCT03498378|DRUG|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
219036658|NCT00732147|DRUG|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
219036659|NCT00732147|DRUG|Placebo|120 micrograms given subcutaneously before each meal x 3.
219036660|NCT03625245|OTHER|Control Yogurt|125 g/day
219036661|NCT03625245|OTHER|Yogurt Variety 1|125 g/day
218899180|NCT02534363|DRUG|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
218899181|NCT02534363|DRUG|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
218899182|NCT02534363|DRUG|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
218899183|NCT02534363|BEHAVIORAL|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
218899184|NCT05355064|DRUG|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
218899185|NCT03904121|PROCEDURE|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
218899186|NCT00398658|DRUG|gentamycin and clindamycin|
218899187|NCT02408588|OTHER|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
218899188|NCT05279287|OTHER|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
218899189|NCT05730582|BEHAVIORAL|Parkland Diabetes Detection Program (PDDP) Screening Invitation|"The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days."
219036662|NCT03625245|OTHER|Yogurt Variety 2|125 g/day
218899190|NCT04655573|PROCEDURE|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
218899191|NCT04140630|OTHER|No intervention|No intervention; 1 week observational study
218899192|NCT04807686|DEVICE|Auditory simulation|Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.
218899193|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
218899194|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
218899195|NCT04037891|DRUG|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.
218899196|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
219036663|NCT00927433|BEHAVIORAL|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
219036664|NCT06427018|OTHER|No intervention.|Observational study with no intervention.
219036665|NCT01228357|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
219036666|NCT01228357|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
219036667|NCT04641611|OTHER|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
219036668|NCT04641611|OTHER|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
219036669|NCT03318354|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
219036670|NCT03318354|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
219518201|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Positive Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate whether the positive instructions will show any effect.
219518202|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Neutral Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce neutral expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate/confirm the effect of neutral instructions.
218899197|NCT04037891|DRUG|rVA576|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
218899198|NCT05441267|DRUG|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
218899199|NCT05441267|DRUG|Placebo oral tablet|Placebo oral semaglutide
218899200|NCT05974098|OTHER|Observational study|This study intends to use correlation analysis and mediation analyses to assess the mediating effects of self-efficacy, coping, depression and anxiety on the quality of life of patients with paroxysmal atrial fibrillation.
218899201|NCT04947696|DIAGNOSTIC_TEST|Blood sampling|Blood sampling preoperatively and sequentially up to 30 days post op
219036671|NCT04377477|RADIATION|Single fraction whole lung radiotherapy|Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
219036672|NCT01982851|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
219036673|NCT01982851|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
219036674|NCT01420445|DRUG|YHD001 dose level 1|three times daily / 7 days
219036675|NCT01420445|DRUG|YHD001 dose level 2|three times daily / 7 days
219036676|NCT01420445|DRUG|Pelargonium sidoides extract|6-9mL three times daily / 7 days
219036677|NCT01420445|DRUG|placebo|three times daily / 7 days
218899202|NCT06598475|OTHER|Facilitator-driven provider- and practice-level implementation strategies for influencing provider recommendations and practice-level HPV vaccination rates|"The practice facilitator (UTHealth research staff) will implement the following 4 strategies with providers and immunization navigators at each practice:~* Facilitator-driven provider education: The practice facilitator will conduct one provider education module (5 total modules) over three months with health care providers using a booklet and resource binder.~* Facilitator-driven clinical practice plan: The practice facilitator will assist the implementation team in creating their clinical practice in two additional modules and encourage providers to identify strategies to increase HPV vaccination.~* Training and education for staff (Immunization Navigators): The facilitator will train immunization navigators to implement the plan, and practice immunization navigators will implement the plan.~* Technical assistance plus assessment and feedback: During implementation of the plan, the facilitator will provide technical assistance, ongoing assessment and feedback, and booster trainings."
218899203|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
218899204|NCT06817031|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
218899205|NCT06817031|DRUG|Placebo|Enteric Capsules filled with approximately 400mg of Microcrystalline Cellulose (bulking agent)
218899206|NCT06817031|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
218899207|NCT05274958|BEHAVIORAL|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
218899208|NCT06670755|BIOLOGICAL|ID93/GLA-SE|"ID93/GLA-SE is a protein-adjuvant vaccine which has been purposefully designed to elicit a diverse immune response against M.tb bacterial antigens, improve treatment outcomes and prevent TB disease in people already infected with M.tb.~ID93/GLA-SE will be administered intramuscularly."
218899209|NCT06670755|BIOLOGICAL|BCG Danish|"BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.~For the challenge, aerosol BCG will be administered via nebulizer."
218899210|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
218899211|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
219036678|NCT01037387|DRUG|Control|Current treatment according to the ATS/ERS guidelines
219036679|NCT01037387|DEVICE|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
219204143|NCT06880133|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Screening|"This intervention involves the use of SCG/GCG diagnostic testing, a radiation-free, non-invasive technique for assessing cardiac function. SCG/GCG utilizes high-precision accelerometers and gyroscopes to record and analyze cardiac-induced microvibrations on the chest.~Participants will undergo SCG/GCG testing before their scheduled coronary artery calcium computed tomography (CAC-CT) or coronary computed tomography angiography (CCTA). The study aims to evaluate the diagnostic performance of SCG/GCG in identifying CAD, particularly in hypertensive patients and those with mild CAD.~Data collected from SCG/GCG will be compared with CAC-CT and CCTA findings to determine its predictive value for CAD severity and coronary artery stenosis."
219612114|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
219612115|NCT07016984|OTHER|standard phototherapy eye patches|Following the mydriasis procedure performed prior to ROP examination, the eyes were covered with these patches.
218899212|NCT05118139|OTHER|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
218899213|NCT05118139|OTHER|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
218899214|NCT05118139|OTHER|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
218899215|NCT05118139|OTHER|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
218899216|NCT05118139|OTHER|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
218899217|NCT05118139|OTHER|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
218899218|NCT05118139|OTHER|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
218899219|NCT05118139|OTHER|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
218899220|NCT05118139|OTHER|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
219036680|NCT02112669|DEVICE|VasQ|
219036681|NCT02796040|DEVICE|MRI|
219036682|NCT04576611|OTHER|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
219036683|NCT04576611|OTHER|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
219036684|NCT00426582|DRUG|Patupilone|
219036685|NCT03175328|PROCEDURE|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
219612116|NCT04331808|DRUG|Tocilizumab|Tocilizumab 8mg/kg on day 1 and if no response (no decrease of oxygen requirement) a second injection at day 3 (fixed dose of 400 mg)
218899221|NCT05118139|OTHER|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
218899222|NCT05118139|OTHER|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
219612117|NCT05290727|OTHER|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
219612118|NCT05290727|OTHER|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
218899223|NCT05118139|OTHER|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
218899224|NCT05118139|OTHER|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
218899225|NCT05118139|OTHER|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
218899226|NCT05118139|OTHER|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
218899227|NCT05118139|OTHER|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
218899228|NCT04588116|BEHAVIORAL|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
218899229|NCT03189537|DRUG|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
218899230|NCT03189537|DRUG|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
218899231|NCT04757116|DEVICE|iTind|The iTind is implemented for 5-7 days
218899232|NCT04757116|PROCEDURE|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
218899233|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~\- TDF/3TC/DOR)"
218899234|NCT06695546|OTHER|VExUS evaluation ultrasound|"VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity."
218899235|NCT06419062|DEVICE|Frontier X2|Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
218899236|NCT06713330|DEVICE|BioFLX crown|Device: BioFLX crown
218899237|NCT06713330|DEVICE|3M Stainless Steel Crown|3M Stainless Steel Crown
218899238|NCT06706141|BEHAVIORAL|PowerPoint presentation.|The training included topics such as breast anatomy; breast cancer incidence in Somalia, mortality, morbidity rates; breast cancer risk factors, importance of screening methods; The messages on breast self-examination, health belief models, breast cancer awareness, confidence for BSE, and perceived barriers/benefits for BSE were presented in a PowerPoint presentation. The procedure for performing breast self-examination was described using the English edition of Bristol-Myers Squibb Oncology. In the movie, BSE was made simpler with schematics showing the breast area that needed to be covered. Simple directions on which fingers to use and how to move them over the breast were provided. After the film, the emphasis shifted to helping students gain more self-assurance in their ability to accurately complete each BSE step. Students were encouraged to use proper palpation technique to find lumps by performing a breast examination on a silicone breast model.
218899239|NCT06727422|DRUG|rifaximin 66mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
218899240|NCT06727422|DRUG|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
218899241|NCT06727422|DRUG|Placebo|placebo three times daily
218899242|NCT06725914|BEHAVIORAL|kangaroo care|Transport practice with paternal kangaroo care in preterm infants
218899243|NCT06727201|DRUG|Ondansetron (Zofran)|Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.
218899244|NCT06727201|DRUG|Saline (NaCl 0,9 %) (placebo)|normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia
218899245|NCT06725407|BEHAVIORAL|Cesarean section|In the study, the participants' postoperative hypothermia development status was monitored.
219612119|NCT06054165|OTHER|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
219612120|NCT04851873|GENETIC|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
218899246|NCT06725745|OTHER|Survey|Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
219036686|NCT00581568|OTHER|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
219036687|NCT01951157|DRUG|Docetaxel|Powder for solution for infusion
219036688|NCT01951157|DRUG|Gemcitabine|Powder for solution for infusion
218899247|NCT06725758|DRUG|ODM-212|ODM-212 5mg and/or 40mg tablets
218899248|NCT06727383|PROCEDURE|peripheral blood collection|standard blood test procedures
219036689|NCT01951157|DRUG|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
219036690|NCT01200654|DRUG|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
219036691|NCT04645407|DRUG|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
219612121|NCT06634290|DEVICE|intramedullary nailing augmentation|Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement
218899249|NCT06727383|PROCEDURE|leukapheresis|"Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma."
219036692|NCT05125328|DRUG|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
219518203|NCT05202704|PROCEDURE|Spinal Manipulative Therapy|All the groups recruited in the study will receive five sessions of Spinal Manipulative Therapy. The intervention will be performed with the patient in the supine position. The clinician-researcher will passively lean over the patient to the side to be manipulated and ask the patient to place their hands behind their head. The researcher will then passively rotate the patient on the side to be manipulated and perform a posterior and inferior thrust on the opposite anterosuperior spine. The patients will receive 4 maneuvers (twice towards right side and twice towards left side).
218899250|NCT06725511|BEHAVIORAL|Opt-out framing|Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.
218899251|NCT06725511|BEHAVIORAL|Opt-in framing|Eligible participants are invited to enroll
218899252|NCT05587816|DEVICE|Validation of the PortionSize app|The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
219036693|NCT03864315|DEVICE|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
219036694|NCT03398031|DRUG|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
219036695|NCT03398031|DRUG|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
219204144|NCT06876961|OTHER|Arm cycling exercise|The study involves a 20-minute arm cycling exercise twice daily for five days, starting with a warming-up and ending with a cooling-down. The workload is gradually increased to 60-70% of maximal heart rate, with patients sitting on a back support chair with 20 degrees backward inclination.
219204145|NCT06876961|OTHER|The traditional physical therapy program|The patient undergoes 10 minutes of deep diaphragmatic breathing exercises, 10 minutes of spirometer training, 3-set ankle pump and heel slide exercises, 10-minute sitting on the bed edge, 5 minutes of walking in the intensive care unit, and 3-set active free range of motion exercises.
219204146|NCT06757868|DRUG|Amobarbital|Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
219036696|NCT04809220|DRUG|Dulaglutide|Administered SC
219036697|NCT04809220|DRUG|Oral antihyperglycemics|Administered orally
219036698|NCT05416983|PROCEDURE|Discussion|Attend discussion
219036699|NCT05416983|OTHER|Questionnaire Administration|Complete questionnaire
219036700|NCT01683981|DRUG|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
219036701|NCT06558240|DEVICE|HERADERM Hydrogel Wound Dressing (Sterile)|HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
219036702|NCT05894876|OTHER|No treatment is given|No treatment is provided to the participants as part of this study.
219612122|NCT06634290|DEVICE|intramedullary nailing|Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
219612123|NCT06235827|DIETARY_SUPPLEMENT|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
219204147|NCT06757868|DRUG|Midazolam|midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
219204148|NCT06874309|DEVICE|home-based tDCS stimulation|stimulation parameters: 20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), 2 mA intensity, 20 min duration (30 s fade in/fade out)
218899253|NCT06440473|DRUG|Roflumilast|Roflumilast 0.3% cream
218899254|NCT06440473|OTHER|Vehicle (Roflumilast 0.3% vehicle cream)|Vehicle (Roflumilast 0.3% vehicle cream)
219036703|NCT05218018|DIETARY_SUPPLEMENT|Lipid drink|100 mls of heavy cream
219036704|NCT01429272|DRUG|Minocycline|100 mg po bid for 6 weeks
219036705|NCT01429272|DRUG|Aspirin|81 mg po bid for 6 weeks
219036706|NCT01429272|DRUG|placebo|placebo for minocycline and/or aspirin
219036707|NCT03418909|PROCEDURE|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
219518204|NCT00863525|DRUG|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
219518205|NCT00863525|DRUG|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
219518206|NCT00783757|DEVICE|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
218899255|NCT06074848|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
218899256|NCT06074848|BEHAVIORAL|Motor Training|Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
218899257|NCT06074848|BEHAVIORAL|Cognitive Training|an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
218899258|NCT03342586|DIAGNOSTIC_TEST|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
218899259|NCT03342586|OTHER|Auditory Attention and Executive Functions Test|"* Trail Making Test (Parts A \& B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~* Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~* Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
218899260|NCT03342586|OTHER|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
218899261|NCT03342586|OTHER|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
218899262|NCT03342586|OTHER|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
218899263|NCT01517750|DEVICE|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
219036708|NCT03418909|RADIATION|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
219518207|NCT01512381|DEVICE|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
219518208|NCT01512381|DEVICE|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
219518209|NCT00182091|DRUG|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
219518210|NCT00182091|DRUG|Saline|To maintain study-subject blinding, doses were sham adjusted.
219518211|NCT04872322|DRUG|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
219036709|NCT01062555|DRUG|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
219036710|NCT01062555|DRUG|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
219518212|NCT04872322|DRUG|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
219518213|NCT04872322|DRUG|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
219036711|NCT01062555|DRUG|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
219518214|NCT04872322|DRUG|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
219518215|NCT04872322|PROCEDURE|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
219518216|NCT03349671|PROCEDURE|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
219518217|NCT02289768|DRUG|5-fluorouracil/salicylic acid|
219518218|NCT02289768|DRUG|Vehicle|
219518219|NCT00169936|DEVICE|Magnetocardiograph|
219518220|NCT01264952|PROCEDURE|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
219518221|NCT05324735|DRUG|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
219518222|NCT05324735|DRUG|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
218899264|NCT01517750|DEVICE|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
218899265|NCT01810484|DEVICE|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
218899266|NCT01810484|DEVICE|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
218899267|NCT01810484|DEVICE|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
218899268|NCT01307319|DRUG|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
219518223|NCT04131361|OTHER|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
218899269|NCT01307319|DRUG|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
218899270|NCT03689582|DRUG|68Ga-PSMA|"Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
218899271|NCT05308992|DEVICE|HydroGlyde Condom|The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
219036712|NCT01062555|DRUG|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
219518224|NCT03726190|PROCEDURE|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
218899272|NCT02038816|DRUG|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
218899273|NCT02038816|DRUG|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
219518225|NCT01002690|DRUG|Etoricoxib|90 mg/day orally for 10-13 days
219518226|NCT00145938|DRUG|sildenafil|
219518227|NCT01487733|GENETIC|gene expression analysis|
219518228|NCT01487733|GENETIC|in situ hybridization|
219612124|NCT06235827|DIETARY_SUPPLEMENT|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
219612125|NCT00240565|DRUG|Tositumomab 450 mg|Unlabeled TST
219612126|NCT00240565|DRUG|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
219612127|NCT03590769|DRUG|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
219612128|NCT02644473|DRUG|Tranexamic Acid|
219612129|NCT02644473|DRUG|Normal saline|Control
219612130|NCT00484640|DRUG|Coumadin|
219036713|NCT00005955|DRUG|temozolomide|
219612131|NCT02628886|BIOLOGICAL|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
219612132|NCT02628886|BIOLOGICAL|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
219612133|NCT02628886|OTHER|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
219612134|NCT03240263|PROCEDURE|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
219612135|NCT03240263|PROCEDURE|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
219612136|NCT03860324|PROCEDURE|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
218899274|NCT01913951|DRUG|vosaroxin|Given IV over 10 minutes on Day 1 and 4
218899275|NCT01913951|DRUG|Azacitidine|Given SC or IV over 15 minutes on days 1-7
218899276|NCT00333008|DRUG|Doxil|
219036714|NCT02346084|DRUG|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
219036715|NCT03234660|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
219036716|NCT03234660|OTHER|control|0.9% normal saline continuous infusion
219036717|NCT03035955|DRUG|Azelaic acid|15% gel twice daily for four weeks to one side of face
219518229|NCT01487733|OTHER|immunohistochemistry staining method|
218899277|NCT00333008|DRUG|Cyclophosphamide|
218899278|NCT00333008|DRUG|Vincristine|
218899279|NCT00333008|DRUG|Prednisone|
218899280|NCT00333008|DRUG|Rituximab|
219518230|NCT01487733|OTHER|laboratory biomarker analysis|
218899281|NCT00333008|DRUG|Pegfilgrastim|
218899282|NCT05401162|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
218899283|NCT05261555|DEVICE|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
218899284|NCT03347123|DRUG|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
218899285|NCT03347123|DRUG|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
218899286|NCT03347123|DRUG|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
218899287|NCT03347123|DRUG|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
218899288|NCT04197830|PROCEDURE|Thrombectomy for stroke|Patients who have had thrombectomy for acute stroke.
218899289|NCT00072007|BIOLOGICAL|filgrastim|filgrastim
218899290|NCT00072007|BIOLOGICAL|rituximab|rituximab
219036718|NCT04404647|PROCEDURE|Irreversible electroporation|The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
219518231|NCT00543686|DRUG|Montelukast|Intake of Montelukast
219518232|NCT00543686|DRUG|Fluticasone|Intake of Fluticasone
219518233|NCT01079676|DRUG|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
219518234|NCT01079676|DRUG|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
219518235|NCT02525328|OTHER|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
219518236|NCT04455659|DEVICE|Trans-cutaneous Electrical Nerve Stimulation|TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
219518237|NCT04455659|PROCEDURE|Conventional physical therapy exercise|physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
218899291|NCT00072007|DRUG|CHOP regimen|CHOP regimen
218899292|NCT00072007|DRUG|cladribine|cladribine
219518238|NCT00801190|OTHER|HES (130/0.4)|33 ml/kg i.v. during surgery
219518239|NCT00801190|OTHER|Ringer's Lactate|33 ml/kg i.v.
219612137|NCT03860324|PROCEDURE|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
219612138|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL ECT)|
219612139|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL LAP ECT)|
218899293|NCT00072007|DRUG|cyclophosphamide|cyclophosphamide
219036719|NCT00937872|DRUG|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
219036720|NCT00937872|DRUG|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
219036721|NCT05732649|BEHAVIORAL|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
219518240|NCT06683508|DRUG|LY3549492|Administered orally
218899294|NCT00072007|DRUG|doxorubicin hydrochloride|doxorubicin hydrochloride
219518241|NCT06683508|DRUG|Placebo|Administered orally
218899295|NCT00072007|DRUG|prednisone|prednisone
218899296|NCT00072007|DRUG|vincristine sulfate|vincristine sulfate
218899297|NCT04569877|DRUG|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
218899298|NCT04569877|OTHER|Placebo nebuliser solution|Placebo nebulised seven times within 7 days via rapid nebuliser system
218899299|NCT02803736|DEVICE|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
218899300|NCT02484066|DEVICE|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
219036722|NCT05732649|BEHAVIORAL|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
219518242|NCT00231296|DEVICE|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
219518243|NCT00231296|DRUG|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
218899301|NCT02484066|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
218899302|NCT02484066|DEVICE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
218899303|NCT03941496|DRUG|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay"
218899304|NCT05117736|DRUG|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
218899305|NCT05117736|DRUG|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
218899306|NCT00248495|DRUG|cisplatin|Given IV
219518244|NCT01261884|BEHAVIORAL|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
218899307|NCT00248495|DRUG|pemetrexed disodium|Given IV
218899308|NCT00248495|PROCEDURE|adjuvant therapy|Metastasis prevention/control
218899309|NCT00248495|PROCEDURE|conventional surgery|Undergoing tissue removal
218899310|NCT00248495|PROCEDURE|neoadjuvant therapy|Tumor Reduction
219036723|NCT05732649|BEHAVIORAL|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
219036724|NCT05732649|BEHAVIORAL|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
219036725|NCT00116441|BIOLOGICAL|Therapeutic Cellular Vaccine, GM-CSF Producing|
219204149|NCT06874309|DEVICE|home-based tDCS stimulation - sham|20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), the electric current will flow for only 15 s, with similar fade in/fade out, at the beginning and at the end of 20 min, to mimic the subjective sensations that occur during active tDCS.
219518245|NCT01261884|BEHAVIORAL|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
219518246|NCT05263232|OTHER|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
219518247|NCT06130358|OTHER|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
219518248|NCT06130358|OTHER|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
219518249|NCT03176550|DEVICE|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
218899311|NCT03617952|BEHAVIORAL|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
218899312|NCT03065777|DEVICE|ONE ENDO|single file rotary system
218899313|NCT03065777|DEVICE|F6 SKYTaper|single file rotary system
218899314|NCT03065777|DEVICE|ProTaper Universal|multi-file rotary system
218899315|NCT03812380|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
218899316|NCT03812380|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
218899317|NCT00308477|DRUG|dexamethasone|
218899318|NCT03662958|DRUG|Lutrate|a novel leuprolide acetate 3.75mg depot
218899319|NCT03662958|DRUG|Enantone|market reference leuprolide acetate 3.75 mg depot
219204150|NCT06874309|PROCEDURE|Bariatric surgery|The operation itself is not a study-related procedure and thus the indicated patients would undergo the surgery regardless of their participation in this study. The operating surgeons will perform either Roux-en-Y or gastric sleeve resection.
219204151|NCT06877039|OTHER|Observational studies did not involve any interventions|
219518250|NCT07064746|DIAGNOSTIC_TEST|¹²³I-MIBG SPECT/CT|Patients take Lugol's iodine 2 days and on the day of injection for thyroid blockade. ¹²³I-MIBG (3-5 MBq/kg; max 370 MBq) is given IV. Whole-body planar imaging is performed 24 h post-injection, then focused SPECT/CT of any suspicious areas with low-dose CT; children are sedated only if motion control is required.
219518251|NCT07064746|DIAGNOSTIC_TEST|SSTR PET|Patients receive an intravenous bolus of 68Ga-DOTA-TATE (1.8-2.2 MBq/kg, max 200 MBq). After a 45-60 min uptake phase, a low-dose whole-body PET/CT or PET/MRI (skull base-mid-thigh) is acquired for \~20 min; MRI or CT provides attenuation correction. Sedation used when required.
218899320|NCT03318835|DRUG|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
218899321|NCT03318835|DRUG|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
218899322|NCT01683708|DIETARY_SUPPLEMENT|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
218899323|NCT04319367|DRUG|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
218899324|NCT00481702|DRUG|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
218899325|NCT00481702|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
218899326|NCT00481702|DRUG|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
218899327|NCT00992758|BIOLOGICAL|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
218899328|NCT03432507|OTHER|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
218899329|NCT05876481|DRUG|Psilocybin|Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
218899330|NCT05230940|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
218899331|NCT05230940|BIOLOGICAL|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
218899332|NCT01285401|DRUG|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
218899333|NCT01285401|DRUG|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
218899334|NCT01285401|BIOLOGICAL|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
218899335|NCT02648204|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
218899336|NCT02648204|DRUG|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
218899337|NCT02925897|BEHAVIORAL|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
218899338|NCT03354949|OTHER|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
218899339|NCT06159088|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
219036726|NCT03143699|OTHER|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
219518252|NCT04125654|DEVICE|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
219518253|NCT00993616|DRUG|belinostat|Given IV
219518254|NCT00993616|DRUG|carboplatin|Given IV
219518255|NCT06899646|DEVICE|Treatment with BTL-699-2|Four transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 5 to 10 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
218899340|NCT06159088|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
218899341|NCT06159088|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
219036727|NCT00978068|DRUG|Lopinavir/Ritonavir (LPV/r)|
219036728|NCT00978068|DRUG|Nevirapine (NVP)|NVP will be used for children \< 3 years of age
219036729|NCT00978068|DRUG|Efavirenz (EFV)|EFV for children ≥3 years of age
218899342|NCT00659802|DRUG|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
218899343|NCT00659802|DRUG|Placebo|Matching dose of Placebo
218899344|NCT00659802|DRUG|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
218899345|NCT05625698|DRUG|MagTrace only|see information in arm descriptions
218899346|NCT05625698|COMBINATION_PRODUCT|MagTrace and Magseed|see information in arm descriptions
218899347|NCT01512199|DRUG|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
218899348|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
218899349|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
218899350|NCT01512199|DRUG|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
218899351|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
218899352|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
218899353|NCT01512199|DRUG|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
219036730|NCT00978068|DRUG|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
219518256|NCT05600374|DEVICE|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
219518257|NCT04611035|DEVICE|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
219518258|NCT06481800|OTHER|Progressive muscle relaxation (PMR)|patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
218899354|NCT02161835|OTHER|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
219204152|NCT06880614|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
219518259|NCT06481800|OTHER|cnotrol group|Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests
219518260|NCT06481800|OTHER|Manual lymphatic drainage (MLD)|Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
219518261|NCT06504472|DIETARY_SUPPLEMENT|ProstaThrive™ Supplement|Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.
219518262|NCT06504472|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
219518263|NCT03533946|DRUG|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.
218899355|NCT01909999|PROCEDURE|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
218899356|NCT01909999|PROCEDURE|Clinical parameters evaluation|"The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
218899357|NCT01909999|PROCEDURE|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
218899358|NCT01909999|PROCEDURE|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
218899359|NCT01909999|PROCEDURE|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
218899360|NCT01909999|DRUG|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
218899361|NCT00494585|DRUG|CEP-701|80 mg orally twice a day for 30 days
218899362|NCT01359345|DRUG|gadollinum|use of on injection gadollinum Iv for imaging
218899363|NCT04557800|DRUG|DNL151|oral dose(s)
218899364|NCT04557800|DRUG|Placebo|oral dose(s)
218899365|NCT00112372|DRUG|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
218899366|NCT02248805|DRUG|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
218899367|NCT01578681|PROCEDURE|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
218899368|NCT01578681|PROCEDURE|Stretching|Patient will be instructed to do muscle stretching of the thorax
219036731|NCT05847075|OTHER|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
219036732|NCT05847075|OTHER|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last \~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
219204153|NCT06880614|DIETARY_SUPPLEMENT|Whey|Supplemented with whey protein isolate masked with a chicken-flavored soup
219518264|NCT05293223|BIOLOGICAL|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
219518265|NCT04702425|DRUG|VOB560|Powder for concentrate for solution for infusion
219518266|NCT04702425|DRUG|MIK665|Concentrate for solution for infusion
219518267|NCT05826925|OTHER|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
219518268|NCT06779981|OTHER|Nasopharyngeal swabs|Completion of an electronic Diary (eDiary) and collection of nasopharyngeal swabs in case the subject experiences ILI symptoms
219518269|NCT04104126|OTHER|Standard of Care Physical Therapy|Will receive standard of care physical therapy
219518270|NCT04104126|OTHER|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
219518271|NCT05820737|DIETARY_SUPPLEMENT|EF2001|One capsule to be consumed once a day
219518272|NCT05820737|DIETARY_SUPPLEMENT|beLP1|One capsule to be consumed once a day
219518273|NCT05820737|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed once a day
219518274|NCT01639508|DRUG|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
219518275|NCT06186037|DRUG|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
219518276|NCT06186037|DRUG|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
219518277|NCT06784648|BIOLOGICAL|pembrolizumab (KEYTRUDA®)|fixed dose 200mg
219518278|NCT06784648|BIOLOGICAL|BI-1607|Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles
219518279|NCT06784648|BIOLOGICAL|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles
219518280|NCT03317847|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
219036733|NCT05847075|OTHER|Sedentary Control|Participants will not receive any intervention during 12 weeks.
219036734|NCT03010111|OTHER|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
219036735|NCT02017314|DRUG|Morphine|
219036736|NCT04153500|OTHER|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
219036737|NCT04996459|DRUG|Tislelizumab|Tislelizumab 200mg iv q3w
219204154|NCT06880614|DIETARY_SUPPLEMENT|House cricket|Supplemented with house cricket powder masked with chicken-flavored soup
219204155|NCT06880614|DIETARY_SUPPLEMENT|Placebo|Placebo consists of chicken-flavored soup without any supplement inside
219204156|NCT06879132|DRUG|BR3409|One tablet administered alone
219204157|NCT06879132|DRUG|BR3409-1|One tablet administered alone
219204158|NCT06879132|DRUG|BR3409-2|One tablet administered alone
219518281|NCT03317847|DRUG|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
218899369|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
218899370|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|"ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL"
218899371|NCT04402424|DIAGNOSTIC_TEST|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
219036738|NCT04964128|DEVICE|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
219036739|NCT01677975|PROCEDURE|FNA (fine needle aspiration)|
219036740|NCT01471379|DRUG|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
219036741|NCT01471379|DRUG|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
219036742|NCT01471379|DRUG|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
219204159|NCT06880432|OTHER|Collection of fluid samples|\- Blood sampling, urine sampling and tissue sampling
219204160|NCT06880484|DEVICE|Far-Infrared Radiation (FIR) Socks|Participants in the experimental group will receive two pairs of Far-Infrared Radiation (FIR) emitting socks, designed to be worn for at least 8 hours per day over a 3-month period. These socks utilize FIR technology, which is hypothesized to improve circulation, reduce neuropathic pain, and enhance quality of life in patients with diabetic peripheral neuropathy (DPN). Participants will be educated on the proper use of the socks, provided with a usage protocol, and monitored for adherence via three follow-up phone calls assessing compliance and comfort using the Visual Analog Scale (VAS). At the end of the study, participants will undergo a follow-up Electroneuromyography (ENMG) evaluation, and pain and quality of life will be reassessed using the LANSS Scale and NePIQoL forms.
219518282|NCT03815942|BIOLOGICAL|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
219518283|NCT03815942|DRUG|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
219518284|NCT05094180|OTHER|Face-to-face appointment|Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).
219612140|NCT00939016|OTHER|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
219036743|NCT01471379|DRUG|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
219036744|NCT02120794|DEVICE|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
219612141|NCT03555110|BEHAVIORAL|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
219036745|NCT04444609|OTHER|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
219036746|NCT00644293|DRUG|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
219036747|NCT00644293|DRUG|placebo|placebo
219036748|NCT00644293|DRUG|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
219036749|NCT00644293|DRUG|placebo|placebo
219036750|NCT00411164|DRUG|OROS hydromorphone HCI (slow release)|
219036751|NCT04863755|BEHAVIORAL|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
219036752|NCT04863755|BEHAVIORAL|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
219036753|NCT03550703|BIOLOGICAL|V3-Myoma|Once daily oral pill of V3-Myoma
219036754|NCT03777293|DEVICE|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
219518285|NCT05094180|OTHER|Remote consultation (telephone or video consultation mode)|"Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment.~In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. .~In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference."
218899372|NCT01507688|BEHAVIORAL|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
218899373|NCT02534415|DRUG|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
219036755|NCT05296785|PROCEDURE|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
219036756|NCT00819468|DRUG|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
219518286|NCT04249154|DRUG|Eligard|Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
219518287|NCT02602184|DRUG|AR/101|
218899374|NCT02534415|DRUG|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
218899375|NCT02534415|DRUG|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
218899376|NCT01333228|OTHER|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
219518288|NCT02602184|DRUG|Placebo|
219518289|NCT00295178|DRUG|Daptomycin|
219518290|NCT00295178|DRUG|Vancomycin|
219518291|NCT00442845|DRUG|Atorvastatin (Lipitor)|
219518292|NCT00311961|DRUG|Intravenous prednisolone|
219518293|NCT00311961|DRUG|Oral prednisolone|
218899377|NCT05178199|BEHAVIORAL|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
218899378|NCT05178199|BEHAVIORAL|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
219518294|NCT05147077|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group."
219518295|NCT02785913|OTHER|Laboratory Biomarker Analysis|Correlative studies
218899379|NCT01514019|DRUG|Acebutolol|Acebutolol
218899380|NCT01514019|DRUG|Placebo|Placebo capsule(Capsules filled up with lactose)
218899381|NCT04966260|OTHER|Standardized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
218899382|NCT04966260|OTHER|Control|This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
219036757|NCT06250062|DRUG|Recombinant humanized IL-17A Monoclonal Antibody（JS005）|Injection
219036758|NCT06250062|DRUG|Placebo（JS005）|Injection
219518296|NCT02785913|DRUG|Taselisib|Given PO
219036759|NCT04657133|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
219036760|NCT04657133|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
219036761|NCT04657133|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
219036762|NCT00271349|DRUG|Budesonide|
219518297|NCT03745859|DEVICE|Fraxinus VBN system|Open source planning tool for bronchoscopy
218899383|NCT04966260|OTHER|Personalized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
219518298|NCT03717064|DRUG|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
219518299|NCT03717064|DRUG|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
218899384|NCT02341235|BEHAVIORAL|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
218899385|NCT02341235|BEHAVIORAL|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
218899386|NCT02163824|DRUG|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
219518300|NCT03852706|OTHER|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
219518301|NCT03852706|OTHER|Treatment as usual|Treatment-as-usual
218899387|NCT02163824|DRUG|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
219036763|NCT02818777|DRUG|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
219036764|NCT00559520|DIETARY_SUPPLEMENT|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
219518302|NCT03787459|DRUG|Arbidol|Oseltamivir plus Arbidol will be administrated from Days 1-7.
219518303|NCT03787459|DRUG|Placebos|Oseltamivir plus placebos will be administrated from Days 1-7.
219518304|NCT02841709|DRUG|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
219036765|NCT00559520|DIETARY_SUPPLEMENT|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
219518305|NCT02841709|DRUG|Placebo|Capsules for oral administration matching the ACT-541468 capsules
219518306|NCT01929109|DRUG|LY2409021|Administered orally
219518307|NCT01292161|DRUG|Silymarin|Tab 210 mg, 630 mg, daily, six months.
219612142|NCT03555110|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
218899388|NCT02163824|DRUG|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
219518308|NCT03508713|DRUG|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
219518309|NCT02354742|OTHER|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
219518310|NCT02354742|OTHER|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
219518311|NCT02391064|BEHAVIORAL|Cognitive evaluation|"* Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test"
219518312|NCT02391064|BEHAVIORAL|Expanded Disability Status Scale (EDSS) score|\- EDSS score
219518313|NCT00076102|DRUG|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
219518314|NCT02702960|PROCEDURE|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for \>3 wks
219518315|NCT02702960|RADIATION|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
219518316|NCT02702960|PROCEDURE|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
219518317|NCT02702960|DRUG|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
219518318|NCT02702960|DRUG|Mesna|administered on Days 3 and 4 with PTCy
219518319|NCT02702960|DRUG|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
219518320|NCT02702960|DRUG|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
219518321|NCT02702960|DRUG|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
219518322|NCT02702960|DRUG|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
219518323|NCT02702960|DRUG|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
219518324|NCT02702960|DRUG|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
219518325|NCT06369805|OTHER|there is no intervention|there is no intervention
219518326|NCT03920007|DRUG|ATSN-101|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
219518327|NCT03920007|DRUG|ATSN-101 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
219518328|NCT03920007|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
219612143|NCT00736632|DRUG|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
219612144|NCT00736632|DRUG|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
219036766|NCT05683119|OTHER|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
219036767|NCT05230212|OTHER|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
219036768|NCT05230212|OTHER|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
219518329|NCT03920007|DRUG|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
219518330|NCT03920007|DRUG|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
219518331|NCT03920007|DRUG|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
219518332|NCT05510648|OTHER|high-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
219518333|NCT05510648|OTHER|sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
219518334|NCT02528760|DRUG|Metaclopramide|23\. Metoclopromide to be given 10mg iv 8 hourly
219518335|NCT02528760|DRUG|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
219518336|NCT02528760|OTHER|Placebo|
219518337|NCT01621022|DRUG|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
219518338|NCT01621022|DRUG|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
219518339|NCT01621022|DRUG|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
219518340|NCT02515422|DRUG|Ketamine|Subcutaneous infiltration of ketamine
219518341|NCT02515422|DRUG|Bupivacaine|Subcutaneous infiltration of bupivacaine
219518342|NCT02515422|DRUG|Placebo (0.9% saline solution)|
219518343|NCT01076972|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
219518344|NCT02154308|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
219612145|NCT03065946|OTHER|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
219612146|NCT00797589|DRUG|HES|20ml/kg as prime fluid
219612147|NCT00797589|DRUG|Ringer lactate|
219612148|NCT04746144|PROCEDURE|Total knee arthroplasty|
219612149|NCT00281957|DRUG|sorafenib tosylate|Given orally
219612150|NCT00281957|DRUG|tipifarnib|Given orally
219612151|NCT00281957|DRUG|temsirolimus|Given IV
219612152|NCT02871544|OTHER|BNP and NGAL|
219612153|NCT03103516|PROCEDURE|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
219612154|NCT03103516|PROCEDURE|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
219612155|NCT01693510|BEHAVIORAL|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
218899389|NCT02163824|DRUG|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
218899390|NCT04110912|OTHER|This is a registry and no interventions are taking place.|
218899391|NCT03470480|DEVICE|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
218899392|NCT03470480|DEVICE|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
218899393|NCT03470480|BEHAVIORAL|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
218899394|NCT03470480|BEHAVIORAL|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
218899395|NCT02366312|DRUG|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
218899396|NCT04254224|PROCEDURE|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
218899397|NCT04222296|DEVICE|Fitting strategy of cohlear implant of hearing aid|To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
218899398|NCT05147376|DRUG|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
218899399|NCT05147376|DRUG|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
218899400|NCT02581306|OTHER|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
219036769|NCT04595864|OTHER|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
219612156|NCT01876446|OTHER|Laboratory Biomarker Analysis|Correlative studies
219612157|NCT01876446|DRUG|Pegylated Irinotecan|Given IV
219612158|NCT01876446|OTHER|Pharmacological Study|Correlative studies
218899401|NCT06357702|BEHAVIORAL|Physical Self Regulation Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.
218899402|NCT06357702|BEHAVIORAL|Psycho-education Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
218899403|NCT05651945|OTHER|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
218899404|NCT05682326|DRUG|Daprodustat|Daprodustat will be administered up to Week 52.
218899405|NCT03719131|DRUG|Nivolumab|Receive standard of care nivolumab therapy
218899406|NCT03719131|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV or SC
218899407|NCT03719131|DRUG|Ipilimumab|Receive standard of care ipilimumab therapy
219036770|NCT02234921|DRUG|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
219036771|NCT02234921|BIOLOGICAL|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
219036772|NCT02234921|BIOLOGICAL|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
219036773|NCT02234921|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
218899408|NCT05555329|DRUG|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
219518345|NCT00424203|DRUG|AC regimen|
219518346|NCT00424203|DRUG|cyclophosphamide|
219518347|NCT00424203|DRUG|doxorubicin hydrochloride|
219518348|NCT00424203|PROCEDURE|adjuvant therapy|
218899409|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
218899410|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
218899411|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
218899412|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
218899413|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
218899414|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
218899415|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
218899416|NCT04748614|OTHER|Cost|ICU cost
218899417|NCT04192955|DRUG|Acetyl Salicylate|Tablets
218899418|NCT00637078|OTHER|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
218899419|NCT03494296|DRUG|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
218899420|NCT01412528|OTHER|Allergen extracts|
218899421|NCT05663021|DIAGNOSTIC_TEST|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
219036774|NCT06484608|DRUG|Isotonic Saline with Dextrose|This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
219518349|NCT00424203|PROCEDURE|cognitive assessment|
219518350|NCT00424203|PROCEDURE|management of therapy complications|
219518351|NCT00424203|PROCEDURE|psychosocial assessment and care|
219518352|NCT00424203|PROCEDURE|quality-of-life assessment|
219518353|NCT05567614|RADIATION|Liver Fibroscan|Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
219518354|NCT00664781|DRUG|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
218899422|NCT03294590|OTHER|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
218899423|NCT03294590|OTHER|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
219518355|NCT00664781|GENETIC|protein expression analysis|
219518356|NCT00664781|GENETIC|western blotting|
218899424|NCT01844388|DRUG|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
218899425|NCT01844388|DRUG|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
218899426|NCT06396819|DRUG|collagen-povidone solution|Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
218899427|NCT05580822|DRUG|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
219518357|NCT00664781|OTHER|immunohistochemistry staining method|
219518358|NCT00664781|OTHER|liquid chromatography|
219518359|NCT00664781|OTHER|mass spectrometry|
219518360|NCT00664781|OTHER|pharmacological study|
219518361|NCT04002700|DRUG|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
219518362|NCT04002700|DRUG|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
219518363|NCT04002700|DRUG|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
219518364|NCT01402908|DRUG|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
219518365|NCT01402908|OTHER|Placebo|Lactose lyophilized powder
218899428|NCT05580822|DRUG|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
218899429|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
218899430|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
218899431|NCT01061970|DRUG|Fispemifene|once daily for 4 weeks
218899432|NCT02304900|OTHER|white implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
218899433|NCT02304900|OTHER|yellow implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
218899434|NCT01030029|DEVICE|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
219036775|NCT04401696|DEVICE|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
219036776|NCT04401696|OTHER|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
219518366|NCT00872079|DEVICE|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
219518367|NCT04251390|DEVICE|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
218899435|NCT01030029|DEVICE|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
219036777|NCT00000514|DRUG|chlorthalidone|
219036778|NCT00000514|DRUG|atenolol|
219518368|NCT02328690|OTHER|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
219612159|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
218899436|NCT02525653|DRUG|albumin-bound paclitaxel|
218899437|NCT02525653|DRUG|gemcitabine|
218899438|NCT01272232|DRUG|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
218899439|NCT01272232|DRUG|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
218899440|NCT01272232|DRUG|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
218899441|NCT04852861|DIAGNOSTIC_TEST|immunogenicity after first and second dose|Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
218899442|NCT04291846|DRUG|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
218899443|NCT04291846|DRUG|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
218899444|NCT04140396|DRUG|Saline infusion|Normal saline infusion at 10mL/hour
219036779|NCT00000514|DRUG|reserpine|
219036780|NCT00150046|DRUG|Everolimus|
219036781|NCT04339699|DEVICE|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
218899445|NCT04140396|DRUG|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
218899446|NCT04713488|BIOLOGICAL|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
218899447|NCT05616468|BIOLOGICAL|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
218899448|NCT05616468|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
219036782|NCT04339699|DEVICE|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
218899449|NCT05616468|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
218899450|NCT05936489|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
219036783|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Discontinued IST
219036784|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Continued IST
219036785|NCT03483675|OTHER|Survey Administration|Ancillary studies
219036786|NCT05016232|BEHAVIORAL|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
219036787|NCT05016232|BEHAVIORAL|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
219036788|NCT00656630|DRUG|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
219036789|NCT00656630|DRUG|Naltrexone|50mg capsule, Once daily, 1 week duration
219036790|NCT00656630|DRUG|Placebo|Matched placebo capsule, 1 week duration
219036791|NCT01340092|OTHER|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them."
219036792|NCT00682188|BEHAVIORAL|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
219036793|NCT00682188|BEHAVIORAL|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
219036794|NCT02621814|DIETARY_SUPPLEMENT|Low glycation formula feeding|Formula feeding on demand for 3 months
219036795|NCT02621814|DIETARY_SUPPLEMENT|Commercially common formula feeding|Formula feeding on demand for 3 months
219036796|NCT02374879|DEVICE|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
219518369|NCT06240390|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
219518370|NCT06240390|DRUG|pharmacological treatment by Opioids|Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
218899451|NCT05936489|DRUG|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
219518371|NCT06111703|BEHAVIORAL|Knowledge assessment|Knowledge, Attitude and Practice Survey
218899452|NCT01936571|OTHER|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
218899453|NCT01881516|DEVICE|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
218899454|NCT01881516|DEVICE|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
218899455|NCT00628030|BEHAVIORAL|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
219036797|NCT00181961|DRUG|Maca Root|
219036798|NCT05718232|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
219036799|NCT05718232|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
219036800|NCT05718232|RADIATION|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
219036801|NCT01770561|DEVICE|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
219036802|NCT01889316|DEVICE|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
219036803|NCT01889316|DEVICE|AN24|
219036804|NCT04860102|PROCEDURE|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
219036805|NCT05200754|OTHER|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
219036806|NCT03951922|BEHAVIORAL|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
219036807|NCT00799578|DRUG|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
219036808|NCT01667978|DRUG|Norethindrone acetate|
219036809|NCT00856908|DRUG|AZD1656|Tolerable dose given twice daily
219036810|NCT00856908|DRUG|Placebo|Tolerable dose given twice daily
219518372|NCT04790448|DRUG|Cetuximab|Route of administration: Intravenous
219518373|NCT04790448|DRUG|Irinotecan|Route of administration: Intravenous
218899456|NCT00628030|OTHER|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
218899457|NCT02394535|DRUG|Capecitabine|Given PO
219518374|NCT04790448|DRUG|Vemurafenib|Route of administration: Oral
218899458|NCT02394535|OTHER|Laboratory Biomarker Analysis|Correlative studies
218899459|NCT02394535|DRUG|Nab-paclitaxel|Given IV
218899460|NCT02394535|OTHER|Questionnaire Administration|Ancillary studies
218899461|NCT02394535|RADIATION|Radiation Therapy|Undergo radiation therapy
218899462|NCT03392935|DEVICE|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
218899463|NCT02486575|OTHER|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
218899464|NCT02486575|OTHER|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
218899465|NCT03568981|RADIATION|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
218899466|NCT03568981|RADIATION|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
218899467|NCT01536717|DRUG|Articaine hydrochloride 2% solution|"* 4 ml/h periosteal wound infusion~* duration of 72 h"
218899468|NCT01536717|DRUG|Sodium Chloride|Placebo Sodium chloride 0,9%
218899469|NCT01732744|OTHER|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
218899470|NCT01732744|OTHER|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
218899471|NCT01732744|OTHER|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
218899472|NCT01732744|OTHER|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
218899473|NCT01235013|DRUG|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
218899474|NCT01156480|DRUG|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
218899475|NCT01156480|DRUG|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
218899476|NCT03997461|DEVICE|BPro|BPro and Oscar 2 comparison for 24 hours
219204161|NCT06880484|DEVICE|Placebo Socks|Participants in the placebo group will receive two pairs of non-FIR socks, which are visually identical to the FIR socks but lack FIR-emitting properties. They will follow the same 8-hour daily usage protocol for 3 months and receive the same education on sock usage. Compliance and comfort will be monitored through three follow-up phone calls, and assessments will be conducted using the VAS, LANSS Scale, and NePIQoL forms. At the end of the study, participants will undergo a final ENMG evaluation.This study aims to determine the effect of FIR socks on neuropathic pain, nerve conduction, and quality of life, using both subjective (pain scales) and objective (ENMG) measures.
219204162|NCT06877832|OTHER|Static Stretching (SS)|For the SS, participants will be instructed to stand and place their dominant foot on a wedge with a 35° incline, stretching the plantar flexor muscles.
219518375|NCT04000217|BEHAVIORAL|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
219518376|NCT04000217|BEHAVIORAL|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
219036811|NCT06176950|OTHER|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
219518377|NCT04578158|DRUG|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
219518378|NCT04578158|DIETARY_SUPPLEMENT|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
219518379|NCT02315690|DRUG|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
219518380|NCT02315690|PROCEDURE|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
218899477|NCT04816084|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|"Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age,~* known risk-factor for Covid-19~* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays"
218899478|NCT01726894|DEVICE|Irreversible Electroporation|
218899479|NCT03301883|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
218899480|NCT03301883|DRUG|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
218899481|NCT03301883|DRUG|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
218899482|NCT03301883|DRUG|MTX|Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
219518381|NCT02592161|DRUG|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
218899483|NCT06159452|DRUG|SAR153191-P3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
218899484|NCT06159452|DRUG|SAR153191-P2 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
218899485|NCT06159452|DRUG|SAR153191-C1F3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
219518382|NCT00316745|DRUG|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
219518383|NCT00316745|DRUG|TS-1|S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)
219518384|NCT00316745|DRUG|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
219518385|NCT00316745|DRUG|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
218899486|NCT06457724|DIETARY_SUPPLEMENT|Levilactobacillus brevis CNCM I-5566|Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
219036812|NCT01452464|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
219036813|NCT04407130|DRUG|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
219518386|NCT00316745|DRUG|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
219518387|NCT02581345|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
218899487|NCT06457724|DIETARY_SUPPLEMENT|Placebo|Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
218899488|NCT02470221|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
218899489|NCT02470221|OTHER|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
218899490|NCT03268785|DIAGNOSTIC_TEST|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
219036814|NCT04407130|DRUG|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
219036815|NCT04407130|DRUG|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
219036816|NCT00896558|DRUG|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
219036817|NCT00896558|DRUG|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
219036818|NCT06021951|DRUG|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
219518388|NCT02581345|BIOLOGICAL|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
219518389|NCT02101346|DIETARY_SUPPLEMENT|Mixed High Fat Diet|Healthy, Round 1
219518390|NCT02101346|DIETARY_SUPPLEMENT|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
219518391|NCT02101346|DIETARY_SUPPLEMENT|Monounsaturated fat diet|Healthy, Round 1
219518392|NCT02101346|DIETARY_SUPPLEMENT|Polyunsaturated fat diet|Healthy, Round 1
219518393|NCT02101346|DIETARY_SUPPLEMENT|Triolein 13C|Healthy, Round 2
219518394|NCT02101346|DIETARY_SUPPLEMENT|Low fat|Healthy, Round 1
218899491|NCT02271464|DRUG|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~\- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
218899492|NCT02271464|DRUG|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
218899493|NCT05034913|OTHER|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
218899494|NCT03367858|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
218899495|NCT03367858|BEHAVIORAL|Brief Adolescent Mindfulness (BAM)|Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
218899496|NCT00232622|DRUG|Streptokinase|Accelerated infusion of streptokinase
218899497|NCT00232622|DRUG|Streptokinase|Standard dose streptokinase
218899498|NCT01119053|DEVICE|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
218899499|NCT01119053|DEVICE|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
218899500|NCT03006146|DRUG|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
218899501|NCT05377853|BEHAVIORAL|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
218899502|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
218899503|NCT01250366|DRUG|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
218899504|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
218899505|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
218899506|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
218899507|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
218899508|NCT01250366|DRUG|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
218899509|NCT01250366|DRUG|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
218899510|NCT01250366|DRUG|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
218899511|NCT03363516|DIAGNOSTIC_TEST|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
218899512|NCT02197117|DEVICE|Remote ischemic conditioning|
218899513|NCT02197117|DEVICE|Control|
218899514|NCT04075344|OTHER|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
218899515|NCT00508326|DRUG|Paclitaxel|Starting dose 150 mg/m\^2 HAI once every 4 weeks
218899516|NCT00596986|DRUG|Duloxetine|Duloxetine 30mg up to 120mg per day.
218899517|NCT00596986|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
218899518|NCT00377793|DRUG|Levitra (Vardenafil, BAY38-9456)|
218899519|NCT00377793|DRUG|Placebo|
218899520|NCT03493295|DRUG|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
219204163|NCT06877832|OTHER|Foam Rolling (FR)|For the FR, participants will be instructed to position the muscle belly of the PF on the roller. Thirty rolls (15 proximal and 15 distal) will be performed on the muscle belly while maintaining compression on the muscle.
219204164|NCT06877832|OTHER|Foam rolling with dynamic movement (FR-DM)|The FR-DM will involve positioning the muscle belly of the PF on the roller and, without moving the roller, performing 15 plantar flexions and 15 dorsiflexions of the ankle for a period of 30 seconds while compressing the dominant leg with the contralateral leg.
219204165|NCT06185595|OTHER|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
219518395|NCT00003422|DRUG|fluorouracil|
219518396|NCT00003422|DRUG|leucovorin calcium|
219518397|NCT00003422|PROCEDURE|adjuvant therapy|
219518398|NCT00003422|PROCEDURE|conventional surgery|
219518399|NCT00003422|PROCEDURE|neoadjuvant therapy|
219518400|NCT00003422|RADIATION|radiation therapy|
219518401|NCT00041808|DRUG|MTC-DOX for Injection|
219518402|NCT00041808|PROCEDURE|Chemotherapy|
219518403|NCT00969800|DEVICE|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
219518404|NCT00969800|DEVICE|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
219518405|NCT05285085|DRUG|Statin|Statin use
219518406|NCT02445456|DRUG|Sienna+ injection|Endoscopic injection of magnetic tracer
219518407|NCT02445456|OTHER|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
218899521|NCT04276233|DRUG|Mepolizumab|Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
218899522|NCT04276233|DRUG|Salbutamol|Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
218899523|NCT02251626|DIETARY_SUPPLEMENT|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
218899524|NCT02251626|DIETARY_SUPPLEMENT|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
218899525|NCT01946139|PROCEDURE|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
218899526|NCT01946139|OTHER|laboratory biomarker analysis|Correlative studies
218899527|NCT01946139|OTHER|questionnaire administration|Ancillary studies
218899528|NCT01946139|PROCEDURE|quality-of-life assessment|Ancillary studies
218899529|NCT01191723|DRUG|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
218899530|NCT01191723|DRUG|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
218899531|NCT01191723|DRUG|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
218899532|NCT01191723|DRUG|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
218899533|NCT03117816|DRUG|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
218899534|NCT03117816|OTHER|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
218899535|NCT01676987|DRUG|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
218899536|NCT01676987|DRUG|Budesonide|Delivered dry powder inhaler for 12 weeks.
218899537|NCT03275740|DRUG|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
218899538|NCT03275740|DRUG|Placebo intravenous healthy participant|Placebo comparator
218899539|NCT03275740|DRUG|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
218899540|NCT03275740|DRUG|Placebo subcutaneous healthy participant|placebo comparator
218899541|NCT03275740|DRUG|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
218899542|NCT00486369|DRUG|Oral salmon calcitonin|
219204166|NCT07033520|BEHAVIORAL|Online Mindfulness-Based Cognitive Therapy|The intervention consists of an 8-week Online Mindfulness-Based Cognitive Therapy (MBCT) program for adults with chronic migraine and adverse childhood experiences. Participants attend one 90-minute virtual group session per week via video conferencing, led by a trained therapist. Daily home practice is encouraged, including 20-30 minutes of guided mindfulness exercises provided as audio files. The program includes cognitive restructuring, body scans, breathing awareness, and acceptance-based techniques. The intervention is fully remote and requires no in-person contact.
219518408|NCT02445456|PROCEDURE|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
219518409|NCT02445456|DEVICE|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
219518410|NCT06144671|DRUG|GT201|Autologous tumor infiltrating lymphocyte injection
219518411|NCT01408199|DRUG|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
219518412|NCT03025594|DRUG|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
218899543|NCT01388517|DRUG|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
219036819|NCT06021951|DRUG|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
219036820|NCT00006481|DRUG|Biafine cream|
219518413|NCT03025594|DRUG|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
219518414|NCT04768179|DRUG|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
219518415|NCT00881556|DRUG|Palifermin|60 mcg/kg/day for 6 days
219518416|NCT00881556|DRUG|Fludarabine|30 mg/m2 IV x 1 for 6 days
219518417|NCT00881556|DRUG|Busulfan|4 mg/kg/day IV divided BID for 4 days
219518418|NCT00881556|DRUG|Lorazepam|0.02-0.05 mg/kg for 5 days
219518419|NCT00881556|DRUG|Alemtuzumab|20 mg/m2 IV for 5 days
219518420|NCT00881556|DRUG|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
219518421|NCT00077948|DRUG|Enoximone|Enoximone administered orally
219518422|NCT00077948|DRUG|Metoprolol succinate|Metoprolol succinate administered orally
219518423|NCT00077948|DRUG|Placebo to match enoximone|Placebo to match match enoximone administered orally
219518424|NCT00077948|DRUG|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
219518425|NCT02885077|DEVICE|High-intensity IMT + combined exercise|
219518426|NCT04761965|DIAGNOSTIC_TEST|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
219518427|NCT03272048|BEHAVIORAL|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, \& Rudd, 2011; Jin, Khazem, \& Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, \& Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
219036821|NCT00006481|PROCEDURE|quality-of-life assessment|
219036822|NCT00006481|RADIATION|radiation therapy|
219036823|NCT01162382|DEVICE|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
219036824|NCT02029534|DRUG|Atorvastatin 20 mg|
219036825|NCT02029534|DRUG|Atorvastatin 80 mg|
219036826|NCT06371742|OTHER|Liquid ingestion during labour|An assessment of the volume capacity of the water glasses was carried out using duly certified 50mL syringes in order to calibrate and control the correct measurement of the amount of water ingested. Water is measured using a graduated cup, which is pre-existing in the BP service, since its water intake policy is governed by the formula 1ml/kg/h of clear liquids (water or tea).
219036827|NCT04988217|DRUG|Interferon-Alpha2B|Nebulized interferon alpha 2B
219518428|NCT01244126|DRUG|Intranasal fentanyl|2mcg/kg fentanyl IN
219518429|NCT01244126|DRUG|morphine IM|0.1 mg/kg morphine IM for postop pain
219518430|NCT01244126|DRUG|IV morphine|0.1 mg/kg morphine IV
219518431|NCT03354026|DRUG|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
219518432|NCT03354026|DRUG|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
219518433|NCT03354026|DRUG|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
219518434|NCT02853279|BEHAVIORAL|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗\_peak- 〖WR〗\_LT )+ 〖WR〗\_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
218899544|NCT01388517|DRUG|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
218899545|NCT01388517|DRUG|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
218899546|NCT03880058|DRUG|SLI-F06|Active treatment
218899547|NCT03880058|DRUG|Formulation buffer|Placebo treatment
218899548|NCT00750724|DRUG|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
218899549|NCT00750724|DRUG|normal saline,2 ml., intraarticular weekly for 5 weeks|
218899550|NCT00002164|DRUG|Nelfinavir mesylate|
219036828|NCT04988217|DRUG|Placebo|Nebulized placebo
219036829|NCT04353011|OTHER|questionnaire assesment|questionnaire assesment
219036830|NCT04347382|DRUG|Honey|1gm/Kg/Day
219036831|NCT04347382|DRUG|Nigella Sativa / Black Cumin|80mg/Kg/day
219036832|NCT04347382|DRUG|Placebos|Empty capsule with 250ml of distilled water
219036833|NCT01324349|DEVICE|Veriset Hemostatic Patch|Topical hemostat
218899551|NCT04179006|DIETARY_SUPPLEMENT|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
218899552|NCT03639363|DRUG|4% chlorhexidine gluconate soap-like solution|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
218899553|NCT03639363|OTHER|standard soap|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
218899554|NCT03178435|OTHER|Measures to prevent AKI among critically ill patients|"1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary"
218899555|NCT02604446|DRUG|Tapentadol|
218899556|NCT02604446|DRUG|Oxycodone|
218899557|NCT02604446|DRUG|Placebo|
218899558|NCT02604446|DRUG|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
218899559|NCT02977000|DRUG|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
218899560|NCT06410898|DEVICE|Punch Biopsy 5mm|Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
218899561|NCT03827655|DRUG|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
218899562|NCT03827655|DRUG|TAK-954|TAK-954 intravenous infusion.
219612160|NCT02376816|BIOLOGICAL|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
219612161|NCT04226521|PROCEDURE|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
219612162|NCT03277755|DRUG|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
219612163|NCT03277755|DRUG|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
219612164|NCT03277755|DRUG|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
218899563|NCT04781166|BEHAVIORAL|Calm program|7 online modules designed to teach cognitive behavioral skills
218899564|NCT06124365|OTHER|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
218899565|NCT06124365|OTHER|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
218899566|NCT03168620|PROCEDURE|Restoration|
218899567|NCT05543954|DRUG|68Ga-FAPI-RGD|Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
218899568|NCT05543954|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
218899569|NCT05543954|DRUG|68Ga-FAPI|Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
218899570|NCT05543954|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
218899571|NCT00778778|DRUG|cefprozil 500mg tablets|
218899572|NCT02544568|OTHER|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
218899573|NCT04903210|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide supplied as 400mg capsule|NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
218899574|NCT04903210|BEHAVIORAL|Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
218899575|NCT02318563|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
218899576|NCT02318563|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol
218899577|NCT02336607|DRUG|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
218899578|NCT02336607|DRUG|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
219036834|NCT01324349|DEVICE|Fibrin Sealant (TachoSil®)|Topical hemostat
219036835|NCT05972538|DEVICE|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
218899579|NCT02336607|DRUG|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
218899580|NCT02336607|DRUG|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
219518435|NCT02853279|BEHAVIORAL|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
219518436|NCT02445300|OTHER|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
219518437|NCT02445300|OTHER|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
219518438|NCT06799260|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|500 mg/kg body weight of the KME supplement
219518439|NCT06799260|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo drink
219518440|NCT06799260|DEVICE|iTBS|iTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
219518441|NCT06799260|DEVICE|cTBS|cTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
219518442|NCT01491009|DRUG|Remifentanil|IV infusion
219518443|NCT01491009|DRUG|Midazolam|IV infusion
219518444|NCT01273337|BIOLOGICAL|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
219518445|NCT01273337|PROCEDURE|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
219518446|NCT02139553|PROCEDURE|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
219518447|NCT04978649|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
219518448|NCT04978649|DRUG|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
219518449|NCT00245609|DRUG|Pregabalin|
218899581|NCT02587741|DRUG|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
218899582|NCT02587741|DRUG|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
219518450|NCT00245609|DRUG|Alprazolam|
219518451|NCT00245609|DRUG|Placebo|
219518452|NCT02696070|DEVICE|Provant Therapy System|
218899583|NCT02587741|DRUG|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
218899584|NCT04748666|BEHAVIORAL|Problem Solving Training|Problem Solving Training (PST) is a metacognitive strategy training approach, grounded in self-management theory, that teaches a simple, systematic method for evaluating problems, generating and selecting solutions, developing specific goals and action plans, and evaluating and revising plans as needed.
218899585|NCT01180335|DRUG|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
219612165|NCT02308995|PROCEDURE|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
218899586|NCT01180335|DRUG|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
218899587|NCT00339586|DRUG|Erlotinib|
218899588|NCT03744728|DIAGNOSTIC_TEST|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
218899589|NCT03744728|DIAGNOSTIC_TEST|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
218899590|NCT04203511|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
218899591|NCT04203511|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
218899592|NCT04203511|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
218899593|NCT04203511|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
218899594|NCT04203511|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
218899595|NCT04203511|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
219518453|NCT01771965|BEHAVIORAL|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
219518454|NCT03146247|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
219518455|NCT00951925|OTHER|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
218899596|NCT04203511|DRUG|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
218899597|NCT04203511|RADIATION|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
218899598|NCT04590807|DEVICE|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
218899599|NCT04590807|DEVICE|Anterior vertebral body tethering|Vertebral screws and cable
218899600|NCT04139226|DRUG|CC-11050|CC-11050
219518456|NCT02435225|BEHAVIORAL|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
219518457|NCT04697498|PROCEDURE|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
218899601|NCT02763423|PROCEDURE|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
218899602|NCT02552966|DEVICE|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
218899603|NCT02643459|BEHAVIORAL|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
219518458|NCT04697498|PROCEDURE|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
219518459|NCT01653626|OTHER|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
218899604|NCT02232217|BEHAVIORAL|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
218899605|NCT02232217|OTHER|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
218899606|NCT04983966|DRUG|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
218899607|NCT04983966|DRUG|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
218899608|NCT05022186|DRUG|Cannabidiol Oil|Patients will use it with specific instructions and they will be monitored at least one time in a month
218899609|NCT05022186|DRUG|Homotaurine|Patients will use it with specific instructions and they will be monitored at least one time in a month
218899610|NCT04370158|OTHER|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
218899611|NCT00961311|PROCEDURE|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
218899612|NCT00961311|DEVICE|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
218899613|NCT02489071|BEHAVIORAL|Brain Training Program|
218899614|NCT02489071|BEHAVIORAL|Brain Health Program|
218899615|NCT04959747|OTHER|acupuncture|"Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
218899616|NCT01495208|DRUG|Aflibercept|intravitreal aflibercept injection 2mg
218899617|NCT03075618|BEHAVIORAL|Questionnaires|Questionnaires
218899618|NCT01167803|DRUG|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
219518460|NCT00863746|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
219518461|NCT00863746|DRUG|Placebo|Placebo - 2 tablets twice daily (BID)
219518462|NCT04461808|DIAGNOSTIC_TEST|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
219518463|NCT04461808|DIAGNOSTIC_TEST|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
219518464|NCT05589896|OTHER|Ossium HPC Marrow, Bone Marrow Transplant|Hematopoetic Cell Transplantation
219518465|NCT05589896|OTHER|Pre-transplant conditioning - Myeloablative (MAC)|Regimen A or Regimen B
218899619|NCT01167803|DRUG|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
218899620|NCT00744926|DRUG|placebo|sc, once weekly
218899621|NCT00744926|DRUG|taspoglutide|10mg sc, once weekly
218899622|NCT00744926|DRUG|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
218899623|NCT00005952|BIOLOGICAL|filgrastim|
218899624|NCT00005952|DRUG|temozolomide|
218899625|NCT00005952|PROCEDURE|peripheral blood stem cell transplantation|
218899626|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
218899627|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
218899628|NCT03930693|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice shot (70mL containing 400mg inorganic nitrate)
218899629|NCT04079426|OTHER|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
218899630|NCT03780049|PROCEDURE|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
218899631|NCT03780049|DRUG|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
218899632|NCT03780049|DRUG|Placebos|Patients receive normal saline 10ml in each session of HAIC
218899633|NCT01721161|BIOLOGICAL|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
218899634|NCT01721161|DRUG|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
218899635|NCT05262257|DRUG|Metformin|Take it regularly for 12 weeks
218899636|NCT05262257|DRUG|Dapagliflozin|Take it regularly for 12 weeks
218899637|NCT05262257|BEHAVIORAL|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
218899638|NCT05716555|DEVICE|Deep brain stimulation|Electrical stimulation of lateral habenula
218899639|NCT01338337|DRUG|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
218899640|NCT01658748|DEVICE|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
218899641|NCT01658748|DEVICE|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
218899642|NCT02464618|BEHAVIORAL|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
218899643|NCT04107714|BEHAVIORAL|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure."
218899644|NCT03226717|DRUG|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
218899645|NCT06187259|DEVICE|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
218899646|NCT06187259|DEVICE|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
218899647|NCT03093896|DIETARY_SUPPLEMENT|snack mix|commercial cereal mix with bits of beef jerky and coconut
218899648|NCT03093896|DIETARY_SUPPLEMENT|almonds, 1.5 oz|almonds, 1.5 oz/day
218899649|NCT03093896|DIETARY_SUPPLEMENT|almonds, 3 oz|almonds, 3.0 oz/day
218899650|NCT06034288|DRUG|Xeomin 100 UNT Injection|intravesical injection
218899651|NCT06034288|DRUG|Botox 100 UNT Injection|intravesical injection
218899652|NCT02091817|DRUG|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
219036836|NCT05972538|DEVICE|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
219036837|NCT05972538|OTHER|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
219612166|NCT02308995|PROCEDURE|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
219036838|NCT01165866|DRUG|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
219612167|NCT02308995|DEVICE|V-Loc (Covidien, Mansfield, MA)|
219612168|NCT02308995|DEVICE|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
218899653|NCT02091817|DRUG|Placebo|Placebo will be given to control group and experimental group as well.
219036839|NCT01165866|DRUG|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
219036840|NCT03408015|DRUG|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
219036841|NCT02196792|DEVICE|E-Poly liner|E-Poly liner with a titanium cup
219036842|NCT02196792|DEVICE|ArComXL liner|ArComXL liner with a titanium cup
218899654|NCT04247386|DRUG|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
218899655|NCT04247386|DRUG|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
218899656|NCT05642585|DRUG|MY008211A tablets|Single oral
218899657|NCT05642585|DRUG|Placebo|Single oral
218899658|NCT04404868|OTHER|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
218899659|NCT02191371|DRUG|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
218899660|NCT02191371|DRUG|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
218899661|NCT02828735|DEVICE|respiration assessment|Respiration Breathing Exercise
218899662|NCT00230126|DRUG|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
218899663|NCT00434226|DRUG|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
218899664|NCT00434226|DRUG|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
218899665|NCT00434226|DRUG|carboplatin|On the first day of each cycle for 4 cycles
219036843|NCT02196792|DEVICE|32 mm femoral head|Stem with a 32 mm CoCr femoral head
219036844|NCT02196792|DEVICE|36 mm femoral head|Stem with a 36 mm CoCr femoral head
219204167|NCT06705153|OTHER|laughter yoga|Patients who come to the outpatient clinic will be met, informed about the study and written informed consent will be obtained from patients who agree to participate in the study. Patient information form will be applied, baseline measurements will be made (IBS-SSS, DAS-42, PSQI and IBS-QOL) and IBS type will be determined according to Bristol stool scale. Type 1-2 constipation, Type 6-7 diarrhea, Type 1 or Type 2 at the same time with Type 6 or Type 7 will be considered as mixed type IBS and those who do not fit any of the scales will be considered as unclassifiable IBS. A total of 8 sessions will be held with the patients in the intervention group in the form of meetings via zoom with the help of a smart cell phone/computer (2 weekly sessions). The meetings will be in 3 groups.
219204168|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to healthy controls|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain
219204169|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
219518466|NCT05589896|OTHER|Pre-transplant conditioning - Reduced Intensity (RIC)|Regimen C or Regimen D
219518467|NCT05589896|OTHER|Post-transplant treatment|Post-transplant treatment
218899666|NCT00434226|DRUG|paclitaxel|On the first day of each cycle for 4 cycles
218899667|NCT03767647|BEHAVIORAL|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
218899668|NCT01679496|OTHER|Food items|Food items with different fatty acid composition
218899669|NCT02394314|DRUG|MEDI0382|MEDI0382 administered subcutaneously
218899670|NCT02394314|DRUG|Placebo|Placebo administered subcutaneously
218899671|NCT03827135|OTHER|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
218899672|NCT03827135|OTHER|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
218899673|NCT00115505|OTHER|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
218899674|NCT00115505|OTHER|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
218899675|NCT05136508|DRUG|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
218899676|NCT05136508|DRUG|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
219036845|NCT02086669|PROCEDURE|Pneumatic dilatation|
219036846|NCT02086669|PROCEDURE|Laparoscopic myotomy|
219036847|NCT03673163|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
219036848|NCT03673163|DRUG|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
219036849|NCT01024712|DRUG|carboplatin|
219036850|NCT01024712|DRUG|gefitinib|
219036851|NCT01024712|DRUG|paclitaxel|
219036852|NCT01024712|PROCEDURE|quality-of-life assessment|
219518468|NCT02048111|BIOLOGICAL|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
219518469|NCT00323349|PROCEDURE|Oral Glucose Tolerance Testing|
219518470|NCT00323349|BEHAVIORAL|Education tailored to learning style preferences|
219518471|NCT06309901|OTHER|Exercise|"Home exercises were applied in 3 progressive phases.~1st phase: postoperative 0-4. week, 2nd phase: 5-12. week, 3rd phase 12-15. week.~In the 1st phase, ice application, strengthening for the hip, knee and ankle, and walking exercises were applied. 90 degrees knee flexion range of movement (ROM) was targeted.~In the 2nd phase, the resistance of the strengthening exercises was increased and closed kinetic chain exercises were added. Weight bearing, step climbing and balance exercises were performed. Full ROM targeted in the knee.~In the 3rd phase, pain-free full ROM was targeted, and progressive strengthening, balance and agility exercises for sports and recreational activities were applied."
219518472|NCT06309901|OTHER|Fascial Distortion Model|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of FDM technique were applied.~In this study, trigger band technique was chosen to apply around the knee. Interventions were made directly to the skin in the form of medial, lateral, anterior, posterior techniques of the knee and posterior and lateral techniques of the thigh. The techniques was made after the exercises."
219518473|NCT06309901|OTHER|Instrument Assisted Soft Tissue Mobilisation|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of IASTM technique were applied.~In this study, the Graston technique was chosen to apply IASTM around the knee. Technique was applied with using stainless steel and ultrasound gel to around the knee, m. quadriceps, m. hamstring, iliotibial band and medial thigh. The technique was performed for at least 2 minutes in each region."
219518474|NCT01475448|OTHER|Long distance training|Long distance training during four months, 3 times per week
219518475|NCT01475448|OTHER|Walking training|Walking training during four months, three times per week
218899677|NCT04502537|DRUG|Roxadustat|Oral
218899678|NCT04502537|DRUG|erythropoietin|injection
218899679|NCT01091675|DRUG|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
218899680|NCT00408850|DRUG|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
218899681|NCT00408850|DRUG|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
218899682|NCT02223780|OTHER|early palliative care|the patients will benefit from an early palliative care consultation
218899683|NCT04113850|DEVICE|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
218899684|NCT04103359|OTHER|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
218899685|NCT00614380|DRUG|telmisartan/amlodipine 40/5 mg fixed combination|
218899686|NCT00614380|DRUG|telmisartan/amlodipine 80/5 mg fixed combination|
218899687|NCT03483896|OTHER|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
218899688|NCT05312593|OTHER|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
218899689|NCT05312593|OTHER|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
218899690|NCT02888106|DRUG|Myrcludex B|Lyophilised powder for solution for subcutaneous injection
218899691|NCT02888106|DRUG|PEG IFN alfa-2a|solution for subcutaneous injection, once per week
218899692|NCT02888106|DRUG|Tenofovir|Film-coated tablets, 300 mg, per os, once daily
218899693|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 12 g polydextrose|12 g polydextrose
218899694|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
218899695|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
218899696|NCT02314936|DIETARY_SUPPLEMENT|Placebo|12 g Maltodextrin
218899697|NCT04001712|DRUG|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
218899698|NCT01577017|DRUG|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
218899699|NCT03287921|DRUG|mono bronchodilatation|within indication according to current GOLD recommendation
218899700|NCT03287921|DRUG|dual bronchodilatation|within indication according to current GOLD recommendation
218899701|NCT01528059|PROCEDURE|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
218899702|NCT04471077|PROCEDURE|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
218899703|NCT03572179|DEVICE|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
218899704|NCT04653480|DRUG|Surufatinib|250mg per oral, once daily
218899705|NCT04653480|DRUG|Toripalimab|3mg/kg IV, once every 2 weeks
218899706|NCT04653480|DRUG|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
218899707|NCT03782519|OTHER|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
218899708|NCT03782519|OTHER|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
218899709|NCT03853330|DEVICE|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
218899710|NCT03853330|DRUG|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
218899711|NCT03853330|DRUG|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
219518476|NCT05004194|PROCEDURE|Vestibular Caloric Stimulation|Irrigation of the right external ear canal
219518477|NCT06213844|DRUG|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
219518478|NCT06213844|DRUG|Placebo|Single dose of Placebo, administered subcutaneously on Day 1
218899712|NCT03435185|PROCEDURE|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
219036853|NCT01575184|OTHER|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
219036854|NCT01575184|OTHER|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
219036855|NCT02886390|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
219036856|NCT05796674|DEVICE|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
219036857|NCT05796674|DEVICE|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
219204170|NCT06705140|BIOLOGICAL|Low Dose (LD) RSVt vaccine|"Pharmaceutical form:~Liquid for nasal spray~Route of administration: Intranasal"
219204171|NCT06705140|BIOLOGICAL|Standard Dose (SD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
219204172|NCT06705140|BIOLOGICAL|High Dose (HD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
219204173|NCT06705140|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
219518479|NCT05165381|DEVICE|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
219518480|NCT02400047|DRUG|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
219612169|NCT05999487|DRUG|Dobutamine|"Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment."
218899713|NCT03435185|PROCEDURE|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
218899714|NCT03592316|OTHER|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
218899715|NCT05007522|DRUG|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
218899716|NCT05007522|DRUG|Placebo|Matching placebo tablet
218899717|NCT02307708|DEVICE|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
218899718|NCT02307708|OTHER|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
219518481|NCT02400047|DRUG|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
219518482|NCT02400047|DRUG|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
219518483|NCT00453362|OTHER|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
219518484|NCT00453362|OTHER|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
219518485|NCT00453362|DRUG|erlotinib HCl|Tablets taken orally 150 mg/day.
219612170|NCT02852577|DRUG|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
218899719|NCT00867230|DRUG|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
218899720|NCT01813916|OTHER|proteomic analysis|
218899721|NCT00790946|DRUG|Valsartan|Valsartan 80 to 160 mg
219036858|NCT05796674|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
219036859|NCT03995212|DRUG|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
218899722|NCT02885688|DIETARY_SUPPLEMENT|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
218899723|NCT02885688|PROCEDURE|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
218899724|NCT02643108|PROCEDURE|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
218899725|NCT03865446|DRUG|Dacomitinib|anti-cancer agent
218899726|NCT00069446|DRUG|rhuMAb VEGF (telbermin)|
218899727|NCT02995356|OTHER|Collecting cervical liquid and sera samples|
218899728|NCT01244685|DEVICE|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
218899729|NCT04033562|DRUG|Lidocaine patch|Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
218899730|NCT04033562|DEVICE|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
218899731|NCT01774032|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
218899732|NCT03262220|RADIATION|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
218899733|NCT06239740|PROCEDURE|Electroacupuncture group|The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.
218899734|NCT06239740|PROCEDURE|Sham acupuncture|participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
218899735|NCT04265196|OTHER|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
218899736|NCT04265196|OTHER|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
218899737|NCT00006269|DRUG|irinotecan hydrochloride|
218899738|NCT00006269|DRUG|octreotide acetate|
218899739|NCT01069432|OTHER|No Intervention|No Intervention
218899740|NCT00498459|BEHAVIORAL|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
218899741|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
218899742|NCT01847963|DRUG|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
218899743|NCT01847963|DRUG|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
218899744|NCT00860730|DEVICE|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
218899745|NCT00334217|BEHAVIORAL|Cognitive Remediation|PSS Cogrehab
218899746|NCT01188772|DRUG|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
218899747|NCT01188772|DRUG|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
218899748|NCT01188772|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
218899749|NCT01188772|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
218899750|NCT00128895|DRUG|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
218899751|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
218899752|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
218899753|NCT01125982|DRUG|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
218899754|NCT01125982|DRUG|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
218899755|NCT00055835|DRUG|carboplatin|\*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
218899756|NCT00055835|DRUG|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
218899757|NCT00055835|DRUG|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 \& 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
218899758|NCT00055835|DRUG|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
218899759|NCT00055835|PROCEDURE|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
218899760|NCT00055835|RADIATION|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
218899761|NCT01894607|PROCEDURE|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
219036860|NCT03995212|DRUG|Placebo|Oral Placebo administered twice daily
219036861|NCT03863028|OTHER|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
219612171|NCT02852577|DRUG|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
219518486|NCT05281822|OTHER|The stress management training|The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
219518487|NCT03065582|OTHER|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
219518488|NCT03065582|OTHER|Topical Product B|topical application of product A without topical antioxidants
219518489|NCT03065582|OTHER|Topical Product C|Topical application of antioxidants only
219518490|NCT03065582|OTHER|Control|No product applied
219518491|NCT04885296|DEVICE|TRP-200|JJVC Investigational Contact Lens
219612172|NCT02336646|DRUG|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
219612173|NCT02336646|DRUG|Normal saline|
218899762|NCT01894607|DRUG|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
218899763|NCT01894607|BEHAVIORAL|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
218899764|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
218899765|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
219036862|NCT03913091|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
219036863|NCT03913091|DRUG|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
219036864|NCT03146442|BEHAVIORAL|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
219204174|NCT06000254|DEVICE|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
219518492|NCT04885296|DEVICE|JJVC Marketed Contact Lens|ACUVUE Oasys 1-Day
219036865|NCT01894269|DRUG|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
219036866|NCT06287073|DRUG|JARDIANCE®|JARDIANCE®
219036867|NCT01726738|DRUG|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
219518493|NCT00862979|DRUG|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
219518494|NCT00862979|DRUG|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
219518495|NCT00862979|DRUG|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
219518496|NCT00862979|DRUG|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
219518497|NCT00862979|DRUG|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
219518498|NCT00862979|DRUG|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
219518499|NCT00283699|DRUG|albendazole|Active drug or placebo dosed bid p o for 8days
219518500|NCT00283699|OTHER|placebo|an inactive substance
219518501|NCT03718234|DRUG|Subcutaneous hydrocortisone|Pulsatile subcutaneous hydrocortisone administered in 8 doses per day via SQ infusion pump for 6 weeks
219612174|NCT00619060|DRUG|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
219612175|NCT00619060|DRUG|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
219612176|NCT03016273|PROCEDURE|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
219612177|NCT05327231|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
219612178|NCT05327231|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
219612179|NCT00178282|PROCEDURE|Pelvic Floor Muscle exercises|
218899766|NCT04579471|DIAGNOSTIC_TEST|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
218899767|NCT05586919|PROCEDURE|Direct Puncture Repair / Ethanol|Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
218899768|NCT05586919|PROCEDURE|Direct Puncture Repair / Polidocanol|Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
218899769|NCT04388254|DRUG|Simufilam 100 mg oral tablet|Simufilam 100 mg oral tablet for b.i.d. administration
218899770|NCT04388254|DRUG|Placebo|Matching placebo oral tablets
218899771|NCT00881114|DRUG|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
219518502|NCT05395533|DRUG|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection|The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.
218899772|NCT00881114|DRUG|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
219036868|NCT05588102|DRUG|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
219518503|NCT01188707|DRUG|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
219518504|NCT00218530|DRUG|Lofexidine|
219518505|NCT00384852|DRUG|rhBMP-2/CPM|
219612180|NCT02892929|BEHAVIORAL|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
219612181|NCT02892929|BEHAVIORAL|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
218899773|NCT05189470|PROCEDURE|Inforatio technique|Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
218899774|NCT05189470|OTHER|Usual care of the respective outpatient clinics|Usual care of the DFUs includes local wound care and offloading treatment.
218899775|NCT05287828|OTHER|Surgeons CT scan analysis|Surgeons extract indicators using standard methods of analysis
218899776|NCT05287828|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed using PRAEVAorta Suite which is composed of the software PRAEVAorta 2 and PRAEVAorta Web. Indicators extraction is fully automatic.
218899777|NCT04998955|BEHAVIORAL|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
218899778|NCT00512876|DRUG|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
218899779|NCT06410014|OTHER|No intervention is performed|The study is observational
218899780|NCT03455738|OTHER|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a \>10% decrease in mean arterial pressure (MAP).
218899781|NCT03674632|BEHAVIORAL|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
218899782|NCT04083365|DRUG|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
218899783|NCT04083365|DRUG|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
219518506|NCT06327022|OTHER|Social media-based electronic bibliotherapy|Eight weekly sessions of bibliotherapy are delivered via their daily social media.
219518507|NCT06327022|OTHER|Usual care|The routine services provided by community centers
219518508|NCT02357732|DRUG|Nivolumab|
219518509|NCT02357732|DRUG|Trametinib|
219518510|NCT02357732|DRUG|Dabrafenib|
219518511|NCT00679640|DRUG|Candesartan|Oral tablets
219518512|NCT04272632|DRUG|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
219518513|NCT04272632|DRUG|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
219518514|NCT04272632|DRUG|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
219518515|NCT06162793|BEHAVIORAL|RehaPlus+|24-week eHealth intervention
219518516|NCT04079088|DRUG|Placebo|Administered as specified in the treatment arm.
219518517|NCT04079088|DRUG|BIIB061|Administered as specified in the treatment arm.
219518518|NCT04079088|BIOLOGICAL|Interferon-beta1|Stable dose as prescribed by the physician.
219518519|NCT04079088|DRUG|Glatiramer acetate|Stable dose as prescribed by the physician.
218899784|NCT04083365|DRUG|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
218899785|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
218899786|NCT03342417|BIOLOGICAL|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
218899787|NCT03342417|BIOLOGICAL|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
218899788|NCT06164574|OTHER|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
218899789|NCT01708317|BEHAVIORAL|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
218899790|NCT02493686|DIAGNOSTIC_TEST|audiogram|hearing test
218899791|NCT02401347|DRUG|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
218899792|NCT05037474|PROCEDURE|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
218899793|NCT02936674|DEVICE|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
218899794|NCT02936674|DEVICE|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
218899795|NCT00363636|DRUG|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
218899796|NCT00363636|DRUG|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
219518520|NCT05673642|OTHER|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
219518521|NCT01382433|PROCEDURE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
219518522|NCT01382433|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
219518523|NCT01382433|BEHAVIORAL|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
219518524|NCT05863949|DIETARY_SUPPLEMENT|vitamin D +/- calcium|vitamin D 1000iU daily +/- calcium 500mg BID daily
219518525|NCT05863949|OTHER|Placebo|placebo pill x3 daily
219518526|NCT03129919|DEVICE|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
219518527|NCT03129919|DEVICE|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
219518528|NCT00248638|DRUG|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
219518529|NCT00248638|DRUG|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
218899797|NCT04104386|OTHER|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
218899798|NCT02660164|DEVICE|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
218899799|NCT00957879|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
218899800|NCT00957879|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
219518530|NCT05037123|DRUG|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
218899801|NCT01111695|DEVICE|ApisSept|honey and ionic silver based dressing
218899802|NCT02354534|DRUG|Artesunate Suppositories|
218899803|NCT00174902|DRUG|inderal (drug), acetylsalicylic acid (drug)|
219518531|NCT05037123|DRUG|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
218899804|NCT00374439|BEHAVIORAL|Cognitive-behavioral|Cognitive-behavioral approach
218899805|NCT00374439|BEHAVIORAL|Interpersonal Therapy|Interpersonal therapy approach
218899806|NCT03169335|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
219518532|NCT05037123|OTHER|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
219036869|NCT05987865|BEHAVIORAL|Neurofeedback training|Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
219036870|NCT03488979|OTHER|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
218899807|NCT03169335|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
218899808|NCT03169335|DRUG|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
218899809|NCT03169335|DRUG|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
218899810|NCT03458312|BEHAVIORAL|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
218899811|NCT06526416|OTHER|Anterior segment optical coherence tomography|Imaging of the anterior segment of the eye using optical coherence tomography
218899812|NCT04469972|OTHER|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
218899813|NCT02972203|BEHAVIORAL|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
218899814|NCT02972203|BEHAVIORAL|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
218899815|NCT03259555|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
218899816|NCT03259555|DRUG|Placebo|Administered orally daily for 3 weeks.
218899817|NCT03965013|DRUG|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
218899818|NCT03965013|DRUG|Placebo|A single dose of placebo given in Part 1
218899819|NCT03965013|DRUG|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
218899820|NCT05057663|DRUG|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
218899821|NCT00000346|BEHAVIORAL|counseling|
218899822|NCT03850860|OTHER|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
218899823|NCT01363089|DRUG|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
218899824|NCT01363089|DRUG|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
218899825|NCT05894785|PROCEDURE|External cephalic version|An ECV attempt is made on the study group
219036871|NCT01385475|BEHAVIORAL|RT|8 week RT Intervention
219204175|NCT06000254|OTHER|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
219518533|NCT00663559|DRUG|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
219612182|NCT03216863|OTHER|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
219612183|NCT03680612|DRUG|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
218899826|NCT02194595|DRUG|Basal insulin and exenatide|
219036872|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
219036873|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
219036874|NCT01672476|DRUG|Placebo|Placebo
219036875|NCT01672476|DRUG|Valsartan|Valsartan 80mg
219036876|NCT01672476|DRUG|Fimasartan|Fimasartan 30mg
219036877|NCT04382248|OTHER|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
219036878|NCT04382248|BEHAVIORAL|Tailored education|in-person coaching
219518534|NCT05084742|DEVICE|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
218899827|NCT02194595|DRUG|Basal insulin only|
218899828|NCT02194595|DRUG|Basal insulin and bolus insulin|
219036879|NCT05354128|DRUG|Thrombolytic|Standard intravenous thrombolysis.
219204176|NCT06000254|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
219204177|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
219518535|NCT05561413|BEHAVIORAL|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
219518536|NCT05561413|BEHAVIORAL|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
219518537|NCT03928782|RADIATION|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
219204178|NCT06707623|OTHER|Respiratory Physiotherapy|Physiotherapy will include: Progressive breathing retraining, neurosensory training, nose breathing training, activity modification, inhalation-exhalation ratio training, dynamic respiratory control training and instructions for continuing all of the above training at home. Total 5 sessions in 9 weeks time.
219204179|NCT06707623|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation will be completed in 16 sessions (2 times a week for 8 weeks). It will combine exercise with breathing retraining guided by CPET findings regarding erratic breathing pattern and/or hyperventilation.
219518538|NCT05118906|DRUG|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
219518539|NCT05118906|DRUG|Placebo|2 tablets of placebo per day
219518540|NCT05426720|OTHER|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
219612184|NCT03680612|DRUG|cefepime 1 g or cefepime 2 g|cefepime monotherapy
219612185|NCT00036192|DRUG|FK614|
219612186|NCT00822692|DRUG|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
219612187|NCT00822692|DRUG|placebo|matched placebo 2 pills PO BID x 7 days
219612188|NCT02513212|DEVICE|Potassium Oxalate|Professionally applied liquid
218899829|NCT05943886|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
218899830|NCT05943886|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen.
219036880|NCT05354128|PROCEDURE|percutaneous coronary stenting|Percutaneous coronary stenting
219036881|NCT01885312|BEHAVIORAL|Adaptive Tailored Intervention|Adaptive
219204180|NCT06704217|DIAGNOSTIC_TEST|Six Spot Step Test|The Six-Spot Step Test (SSST), which evaluates balance and functional ambulation, will be performed in an area 5 meters long and 1 meter wide. Five wooden cylinders will be arranged in a zig-zag pattern within this space, with the last cylinder positioned at the centerline. The participant will be asked to strike the wooden cylinders with the medial or lateral side of the same foot and push them outward. The test will be repeated twice with the dominant foot and twice with the non-dominant foot. A trial will be conducted before the test to familiarize participants with the procedure. A two-minute rest period between the test and trials will be provided to minimize fatigue effects. The test's inter-rater reliability will be assessed by two physiotherapists with more than 5 years of clinical experience, who will administer the test twice at 5-minute intervals.
219204181|NCT06704217|DIAGNOSTIC_TEST|Oxford Hip Score|The Oxford Hip Score will be used for functional level assessment.
219612189|NCT02513212|DRUG|Stannous fluoride paste|SnF2 Paste
219612190|NCT02513212|DEVICE|Manual toothbrush|Marketed manual toothbrush
219612191|NCT02513212|DEVICE|Power toothbrush|Marketed power toothbrush
219612192|NCT05863169|DEVICE|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
218899831|NCT02552030|DEVICE|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
218899832|NCT02552030|DEVICE|iPhone 4s|
219036882|NCT01885312|BEHAVIORAL|Consequence-based Intervention|Loss Framed
219036883|NCT01885312|BEHAVIORAL|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
219036884|NCT01885312|OTHER|Assessment only|EMA only
219036885|NCT02248090|DRUG|AZD9496|AZD9496
219036886|NCT02248090|DRUG|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
219036887|NCT01153412|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
219036888|NCT02196324|DRUG|serlopitant|NK1 receptor antagonist
219036889|NCT02196324|DRUG|Placebo|Placebo
219036890|NCT01542216|BEHAVIORAL|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
219036891|NCT01542216|BEHAVIORAL|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
219036892|NCT05111691|PROCEDURE|Dry needling|Dry needling
219518541|NCT01578174|DRUG|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
219518542|NCT01578174|DRUG|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
219518543|NCT04055363|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
219518544|NCT01367275|DRUG|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
219518545|NCT01367275|DRUG|Irinotecan|180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
218899833|NCT02147756|DEVICE|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
218899834|NCT02147756|DEVICE|Repair|
218899835|NCT04339816|DRUG|Azithromycin|orally or into nasogastric tube for 5 days
218899836|NCT04339816|DRUG|Hydroxychloroquine|orally or into nasogastric tube for 5 days
218899837|NCT04339816|DRUG|Placebo|orally or into nasogastric tube for 5 days
218899838|NCT03420872|OTHER|Nutrient mixtures|consumption of a mixture of beneficial nutrients
218899839|NCT00148148|DRUG|caspofungin|
218899840|NCT00148148|DRUG|liposomal amphotericin B|
218899841|NCT01190501|DEVICE|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
218899842|NCT05137964|DIAGNOSTIC_TEST|Vitamin D|Serum Biochemical routine lab workup and gynaecological ultra sound AFC
218899843|NCT03392220|PROCEDURE|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
219204182|NCT06704217|DIAGNOSTIC_TEST|Berg Balance Scale|The Berg Balance Scale (BBS) will be used to assess dynamic balance, which is reliable and commonly used within the orthopedic setting.
219204183|NCT06708260|DRUG|ENN0403, low dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
219518546|NCT03852199|OTHER|Test protocol for proprioceptive force sense in case group|"* The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~* Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
219518547|NCT00750659|DRUG|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
219518548|NCT06376032|DEVICE|EndeavorOTC®|EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
219518549|NCT00449878|DRUG|Liprotamase|Administered orally
219518550|NCT00449878|DRUG|Placebo|Administered orally
218899844|NCT03392220|PROCEDURE|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
218899845|NCT03406273|RADIATION|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
218899846|NCT03406273|RADIATION|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
218899847|NCT04393493|DRUG|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
218899848|NCT04393493|DRUG|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
218899849|NCT04393493|DRUG|Spironolactone|One 50 mg pill administrated every 24 hours in group B
218899850|NCT02654548|OTHER|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
218899851|NCT01125800|DRUG|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
218899852|NCT01492205|DRUG|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
218899853|NCT04885335|OTHER|PAS (Pediatric Appendicitis Score) survey|Score ≤ 5: appendicitis unlikely. Score ≥ 6: probable appendicitis. core ≥ 7: very probable appendicitis
218899854|NCT02625805|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
219204184|NCT06708260|DRUG|ENN0403, high dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
219518551|NCT02237183|DRUG|Iloprost|Given via inhalation
219518552|NCT02237183|OTHER|Placebo Administration|Given via inhalation
219518553|NCT02237183|OTHER|Quality-of-Life Assessment|Ancillary studies
219518554|NCT02237183|OTHER|Questionnaire Administration|Ancillary studies
219518555|NCT01751347|DRUG|Bupivacaine|Local anesthetics
219518556|NCT01751347|DRUG|Lidocaine|Local anesthetics
219518557|NCT03631524|DEVICE|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
219518558|NCT05346055|BEHAVIORAL|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
218899855|NCT02625805|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
218899856|NCT02625805|DRUG|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
219036893|NCT01615471|BEHAVIORAL|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
219036894|NCT00454168|BIOLOGICAL|PR1 leukemia peptide vaccine|Given subcutaneously
219036895|NCT00454168|BIOLOGICAL|sargramostim|Given subcutaneously
219036896|NCT00454168|OTHER|placebo|Given subcutaneously
219204185|NCT06708026|BEHAVIORAL|Action Observation and Motor Imagery (AOMI) training|Participants will watch home-based exercise videos and simultaneously imagine themselves performing these exercises in their minds by following verbal instructions in the videos, without actual execution.
219204186|NCT06708026|BEHAVIORAL|Basic wheelchair exercises|A set of low-intensity warm-up wheelchair exercises developed specifically for survivors with spinal cord injury
219204187|NCT06708026|BEHAVIORAL|Watch landscape videos|A set of landscape videos
219204188|NCT06303037|DRUG|Remimazolam besylate and low-dose Esketamine|Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
219518559|NCT05262621|OTHER|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
219518560|NCT05262621|OTHER|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
219518561|NCT00090038|DRUG|rituximab|Dose, schedule,and duration specified in protocol
219518562|NCT03403764|OTHER|Wellness Intention|
219518563|NCT04933513|BEHAVIORAL|pre DBS patients responding to the DBS-PS scale|we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
219518564|NCT04236765|OTHER|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
219518565|NCT01059500|DEVICE|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP \>5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP\>20% consider empiric anticoagulation with heparin if no contraindications.
219518566|NCT01545076|BIOLOGICAL|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
219036897|NCT00885547|DRUG|tripterygium wilfordii (TW)|90 mg/d for 6 months
219518567|NCT01545076|BIOLOGICAL|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
219518568|NCT01545076|BIOLOGICAL|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
219036898|NCT04400903|DEVICE|Activity Monitor|Undergo HRV monitoring via WHOOP device
219036899|NCT04400903|OTHER|Quality-of-Life Assessment|Ancillary studies
219036900|NCT04400903|OTHER|Questionnaire Administration|Complete questionnaires
219036901|NCT05960396|BEHAVIORAL|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
219036902|NCT01385124|DRUG|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
219036903|NCT04384302|OTHER|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
219036904|NCT01940926|DRUG|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
219204189|NCT06303037|DRUG|Remimazolam besylate and Medium dose Esketamine|Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
219204190|NCT06708156|DRUG|Atropine sulfate eye drops 0.01%|Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
219204191|NCT06708156|DRUG|Atropine sulfate eye drops 0.02%|Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
219036905|NCT00690963|PROCEDURE|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
218899857|NCT02687464|OTHER|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
218899858|NCT02687464|PROCEDURE|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
218899859|NCT00055692|BIOLOGICAL|bevacizumab|Given orally
218899860|NCT01876355|DRUG|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
218899861|NCT01876355|DRUG|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
218899862|NCT00966615|OTHER|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
218899863|NCT00966615|OTHER|glucose-based dialysis solution|2-L exchange; three times a day
218899864|NCT01168726|BEHAVIORAL|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
218899865|NCT01168726|BEHAVIORAL|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
218899866|NCT01168726|BEHAVIORAL|Alcohol Education|Educational information about harms associated with heavy drinking.
218899867|NCT01908452|DRUG|Pyridoxine|1200 mg/d during 12 weeks
218899868|NCT03823183|BEHAVIORAL|Cognitive training|Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
218899869|NCT03823183|BEHAVIORAL|Physical training|Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
218899870|NCT03823183|BEHAVIORAL|Cognitive control|Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
218899871|NCT03823183|BEHAVIORAL|Physical control|Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
219036906|NCT00692770|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
219204192|NCT06708156|DRUG|Placebo eye drops|Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
219204193|NCT06753864|DRUG|Test (T)|Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
219204194|NCT06753864|DRUG|Reference (R)|Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.
218899872|NCT02840708|DRUG|Sargramostim|
218899873|NCT01212861|DEVICE|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
218899874|NCT02883231|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
219612193|NCT03353012|DRUG|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
219612194|NCT03353012|DRUG|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
218899875|NCT06062654|OTHER|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
218899876|NCT06062654|OTHER|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
218899877|NCT03370718|DRUG|Cabozantinib|Given PO
219612195|NCT06318312|OTHER|Hypoxia|Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
218899878|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
218899879|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
218899880|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
219036907|NCT00692770|DRUG|Placebo|Placebo 2 tablets twice daily (BID)
219036908|NCT00397800|BIOLOGICAL|rituximab|
219036909|NCT00397800|DRUG|cyclophosphamide|
219036910|NCT00397800|DRUG|fludarabine phosphate|
219036911|NCT00397800|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219036912|NCT06355895|DIETARY_SUPPLEMENT|Standardized high-carbohydrate meal|8 ounces of Ensure® nutritional protein shake or a similar meal
219612196|NCT00004212|BIOLOGICAL|filgrastim|
219612197|NCT00004212|DRUG|exatecan mesylate|
218899881|NCT04354324|DRUG|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
218899882|NCT01670721|DRUG|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
218899883|NCT01670721|DRUG|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
218899884|NCT01670721|DRUG|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
218899885|NCT01670721|DRUG|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
218899886|NCT05301517|DRUG|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
218899887|NCT05301517|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
218899888|NCT04106609|OTHER|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
218899889|NCT04106609|OTHER|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
218899890|NCT04665271|BEHAVIORAL|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
218899891|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
218899892|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
219036913|NCT05637437|BEHAVIORAL|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants."
219518569|NCT01545076|BIOLOGICAL|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
219518570|NCT05671484|OTHER|Transversalis Fascial Plane Block|Patients will receive ultrasound-guided transversalis fascial plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
219518571|NCT05671484|OTHER|Quadratus Lumborum Plane Block|Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
219518572|NCT05848986|OTHER|Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
219612198|NCT04524195|DRUG|[18F]F-AraG Injection|Single dose of 5 mCi+/- \[18F\]F-AraG IV injection followed by the PET/CT scan. A baseline \[18F\]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second \[18F\]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
219612199|NCT04934046|OTHER|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
219612200|NCT03709212|OTHER|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
219612201|NCT03245866|OTHER|Observational/ no intervention|
218899893|NCT03971461|DRUG|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
218899894|NCT02912715|DEVICE|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
218899895|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
218899896|NCT03095248|DRUG|Selumetinib|Continuous twice daily dosing; oral agent
218899897|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by ICG|Use of ICG during the targeted axillary dissection (TAD)
218899898|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by Blue patent|Use of Blue patent during the targeted axillary dissection (TAD)
218899899|NCT01572480|DRUG|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
218899900|NCT01572480|DRUG|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
218899901|NCT01572480|DRUG|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
218899902|NCT06128304|OTHER|Core Implementation strategies|"Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants"
219036914|NCT05637437|OTHER|Usual care|Participants in the control group will receive the usual care of the hospital.
219036915|NCT00654160|DRUG|fluorouracil|
219036916|NCT00654160|DRUG|irinotecan hydrochloride|
219036917|NCT00654160|DRUG|leucovorin calcium|
219518573|NCT05241184|DIAGNOSTIC_TEST|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
219518574|NCT01398384|DRUG|Nitric Oxide|MI size at 48-72 hours
218899903|NCT06128304|OTHER|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5\. Community engagement using Health Beginning Initiative Model~6\. Smart Cards to facilitate patient engagement"
218899904|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
218899905|NCT06172348|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
218899906|NCT01006759|OTHER|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
218899907|NCT05171192|BEHAVIORAL|CMAP Plus LTP|The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
218899908|NCT06468995|OTHER|Surveys completion|Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
218899909|NCT06468995|DRUG|Home administration of CAB+RPV|Drug treatment and follow-up at home (home arm).
218899910|NCT06468995|DRUG|Hospital administration of CAB+RPV|Drug treatment and follow-up in hospital (hospital arm)
218899911|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
218899912|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
218899913|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
218899914|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
218899915|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
218899916|NCT06533280|DRUG|Part A, C and D: VH3739937 500 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions
218899917|NCT06533280|DRUG|Part A: VH3739937 100 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
218899918|NCT06533280|DRUG|Part A and C: Placebo|Oral administration of Placebo in moderate fat/moderate calorie conditions
218899919|NCT06533280|DRUG|Part B: Treatment A|VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
218899920|NCT06533280|DRUG|Part B: Treatment B|VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
219036918|NCT00654160|OTHER|pharmacogenomic studies|
219036919|NCT00654160|OTHER|pharmacological study|
219036920|NCT02241499|RADIATION|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
218899921|NCT06533280|DRUG|Part B: Treatment C|VH3739937, 500 mg single tablet administered under fasted conditions.
218899922|NCT06533280|DRUG|Part B: Treatment D|VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
218899923|NCT06533280|DRUG|Part B: Treatment E|VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
218899924|NCT06533280|DRUG|Part D: Probe cocktail|Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
218899925|NCT04837833|DIAGNOSTIC_TEST|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
218899926|NCT02378545|DRUG|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
218899927|NCT03458949|OTHER|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
218899928|NCT02825615|PROCEDURE|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
219036921|NCT02241499|DRUG|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
219036922|NCT00287664|DRUG|terlipressin|
219036923|NCT04277754|OTHER|Observational|To Observe and describe motor and visual development
219036924|NCT04268420|DRUG|FMP013|Falciparum Malaria Protein-13
219036925|NCT04268420|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
219036926|NCT05463302|DEVICE|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
219036927|NCT05463302|DEVICE|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
219036928|NCT03904888|PROCEDURE|r-TAPP|Robot-assisted repair
219036929|NCT03904888|PROCEDURE|l-TAPP|Laporoscopic repair
219036930|NCT03904888|PROCEDURE|local anesthetics|local anesthetics will be administred
219036931|NCT02437851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
219036932|NCT04231877|DRUG|Polatuzumab Vedotin|Given IV
219036933|NCT04231877|BIOLOGICAL|Rituximab|Given IV
219036934|NCT04231877|DRUG|Prednisone|Given PO
218899929|NCT00191334|DRUG|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
218899930|NCT00191334|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
218899931|NCT02747810|DEVICE|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
218899932|NCT01817504|PROCEDURE|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
219036935|NCT04231877|DRUG|Etoposide|Given IV
219036936|NCT04231877|DRUG|Doxorubicin|Given IV
219036937|NCT04231877|DRUG|Cyclophosphamide|Given IV
219036938|NCT04231877|BIOLOGICAL|Glofitamab|Given IV
219036939|NCT04231877|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219036940|NCT04231877|PROCEDURE|Echocardiography|Undergo echocardiography
219036941|NCT04231877|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET scan
219036942|NCT04231877|PROCEDURE|Computed Tomography|Undergo CT scan
219036943|NCT04231877|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219518575|NCT01398384|DRUG|MI size at 48-72 hours|Placebo gas
219518576|NCT02745977|OTHER|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
219518577|NCT00000949|DRUG|Aldesleukin|
219518578|NCT01860248|DRUG|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
219518579|NCT01860248|DRUG|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
219612202|NCT05273450|BEHAVIORAL|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
219612203|NCT01256502|DEVICE|SERI® Surgical Scaffold|Breast reconstruction surgery
219612204|NCT05904002|DRUG|pulmicort inhaler|Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
219036944|NCT04231877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219036945|NCT04231877|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219036946|NCT05622045|BEHAVIORAL|Voice data|Recorded response to a question about their participation in a weight loss study.
219036947|NCT06571110|PROCEDURE|Traditional Acupuncture|Acupuncture is a type of treatment where thin needles are gently inserted into specific parts of your body. It's often used to help with things like pain, headaches, stress, and anxiety.
219036948|NCT06571110|PROCEDURE|Sham Acupuncture|Sham acupuncture in this trial involves the insertion superficially to mimic the procedure of true acupuncture without providing any therapeutic effect. The needles will be similar to those used in the true acupuncture group but will not be stimulated, ensuring blinding and controlling for placebo effects.
219036949|NCT06810076|BEHAVIORAL|Machine Learning-Based Clinical Decision Support: Overdose Prevention Alert (OPA) Intervention|In this study, researchers will pilot test an interruptive, ML CDS tool for opioid overdose risk across thirteen primary care clinics at the UF Health in Gainesville, FL. When a patient is identified by the ML algorithm as having an elevated overdose risk and a PCP signs an opioid prescription for the patient, an Opioid Prevention Alert (OPA) will be triggered. The alert will include the rationale for the patient's elevated risk status and provide three risk mitigation recommendations: optimizing pain treatment and mental health support, reviewing and discussing risks with the patient, and offering naloxone annually if no prior naloxone order is found in the patient's record. PCPs can also select an override reason, such as the patient already has naloxone, declined the intervention, is not present/it is not the right time, or the alert is not relevant/other comments, when appropriate.
219204195|NCT04717102|DRUG|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
219204196|NCT04717102|DRUG|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
219518580|NCT02019810|DRUG|Norepinephrine|
219518581|NCT02019810|DRUG|Dobutamine and norepinephrine|
219518582|NCT01195714|DRUG|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
219518583|NCT02973893|BIOLOGICAL|Placebo|Placebo
219518584|NCT02973893|BIOLOGICAL|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
219518585|NCT02973893|BIOLOGICAL|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
219518586|NCT04022148|BIOLOGICAL|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
219518587|NCT05456074|OTHER|Data collection|Retrospective data collection
219518588|NCT05904808|DRUG|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
219612205|NCT05904002|DEVICE|Incentive spirometer treatment|Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
218899933|NCT01817504|PROCEDURE|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
219204197|NCT04717102|DRUG|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
219204198|NCT06697782|DRUG|Ondansetron 8mg|Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
219518589|NCT05904808|DRUG|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
219518590|NCT05904808|DRUG|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
219518591|NCT01626664|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
219518592|NCT01626664|DRUG|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
219518593|NCT01626664|DRUG|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
219518594|NCT01626664|DRUG|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
219518595|NCT02304588|BIOLOGICAL|Mesenchymal stem cells|10-20 x 10\^6 cells/20mL
219518596|NCT02747615|OTHER|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
219518597|NCT02747615|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
219518598|NCT02747615|OTHER|transfused only allogeneic blood.|
219518599|NCT02252562|DEVICE|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
219518600|NCT02310165|PROCEDURE|Z-tract Insertion Technique|
218899934|NCT04266132|PROCEDURE|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
218899935|NCT04266132|PROCEDURE|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
218899936|NCT04266132|PROCEDURE|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
218899937|NCT04266132|DRUG|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
218899938|NCT05957965|DEVICE|Wii fit|Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
218899939|NCT05957965|OTHER|Strengthening, proprioceptive exercises.|"-Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board"
218899940|NCT05396300|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
218899941|NCT02551341|PROCEDURE|higher PEEP ventilation|
218899942|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
218899943|NCT00597688|DRUG|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
218899944|NCT00597688|DRUG|Placebo gel|Oral mucosal application of placebo gel
219204199|NCT06697782|DRUG|Aprepitant 125 mg|Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
219204200|NCT06713226|DEVICE|Hativ P30 and 12-lead ECG comparator device|"The purpose of this study is to compare the clinical equivalence and diagnostic ability of the Hativ P30 against the 12-lead ECG comparator device.~Electrocardiograms of all participants will be obtained using both the Hativ P30 and a 12-lead ECG comparator. That is, all participants will get the same intervention."
219204201|NCT06876675|DRUG|Lorlatinib|To study hyperlipidemia frequency, levels, impact on cardiovascular events after use of Lorlatinib in NSCLC patients.
219518601|NCT02310165|PROCEDURE|Coaxial Insertion Technique|
219518602|NCT06261229|BEHAVIORAL|Intermittent fasting|The participant will consume food about/ within 8-hour per day
219518603|NCT06261229|BEHAVIORAL|Intermittent fasting + Behavioral economic|The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week
219518604|NCT06261229|BEHAVIORAL|Intensive Lifestyle Modification|Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
219518605|NCT05803746|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
219518606|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D3|a single oral dose of vitamin D3
219612206|NCT01523002|DRUG|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
219612207|NCT01523002|DRUG|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
218899947|NCT05414292|DRUG|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
219518607|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D2|a single oral dose of vitamin D2
218899948|NCT05414292|BEHAVIORAL|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
218899949|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
218899950|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
218899951|NCT01001247|DRUG|TMC278; Omeprazole|
218899952|NCT06216938|BIOLOGICAL|Vusolimogene oderparepvec (RP1)|Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
219036950|NCT05660824|DEVICE|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
219036951|NCT05660824|PROCEDURE|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 1500 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
219036952|NCT06653166|DEVICE|bougie (S Guide)|bougie (S Guide)
219204202|NCT06882148|DRUG|target therapies (biological drug, small molecules)|describe the drug sruvival rate of the different approved drugs
219518608|NCT01675557|DIETARY_SUPPLEMENT|Placebo|a single oral dose of placebo
219518609|NCT06369948|PROCEDURE|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed with the patient in the supine position. A linear high-frequency ultrasound probe (GE LOGIQ/P7 ultrasound, korea/ L6-12RS probe) is initially placed in a transverse plane over the anterior inferior iliac spine (AIIS); the probe is turned slightly medial until the hyperechoic continuous shadow of the iliopubic eminence (IPE). The target will be the plane between the psoas tendon and pubic ramus. The skin puncture site will be anesthetized using lidocaine 2% after skin disinfection and draping. A 22-gauge, 100 mm echogenic needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, 25 mL of the local anesthetic solution (bupivacaine 0.5%) was injected in 5 mL increments while observing for adequate fluid spread in this plane.
219612208|NCT05927597|DRUG|INS1007|Oral tablets.
219612209|NCT05927597|DRUG|Placebo|Oral tablets.
219612210|NCT05348447|DEVICE|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
219612211|NCT05348447|OTHER|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
219036953|NCT06653166|DEVICE|videolaryngoscopy|videolaryngoscopy hyperangulated or Macintosh
219204203|NCT06882473|OTHER|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day.
219612212|NCT05709197|PROCEDURE|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
218899953|NCT06726317|BEHAVIORAL|Early palliative care integration|The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
218899954|NCT06725654|OTHER|Diagnostic Procedures|To evaluation the oral and dental health of orphaned children, DMFT, deft, GI, PI and CPITN indices were used to assess dental caries experience, gingival inflammation, the amount of plaque on the tooth surface and periodontal status, respectively.
219036954|NCT02818218|PROCEDURE|Liver Transplant|liver transplant recipient surgery
219036955|NCT05377905|DRUG|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
219518610|NCT06369948|PROCEDURE|elective hip hemiarthroplasty without receiving a PENG block.|elective hip hemiarthroplasty without receiving a PENG block.
219518611|NCT06369948|DRUG|bupivacaine 0.5% injection|bupivacaine 0.5% injection
219518612|NCT04797130|DEVICE|Hospital Fit 2.0|HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
219518613|NCT04709848|OTHER|None - standard of care|Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
219518614|NCT00751465|BEHAVIORAL|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
219036956|NCT06535802|OTHER|Focus group|Attend a focus group session
219036957|NCT06535802|OTHER|Clinician Interviews|Participate in clinician interviews
219036958|NCT06535802|OTHER|Intervention testing|Test the virtual health intervention
219036959|NCT06535802|OTHER|Survey|Complete a follow-up survey
219518615|NCT00751465|BEHAVIORAL|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
219518616|NCT04223440|OTHER|MRI|MRI on both shoulder
219518617|NCT04223440|OTHER|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
219518618|NCT00001221|DRUG|Growth Hormone (Humatrope)|
219612213|NCT05709197|PROCEDURE|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
219036960|NCT06535802|OTHER|Follow-up Interview|Participate in a follow-up interview
219036961|NCT06535802|OTHER|Virtual Health Intervention|Participate in the virtual health intervention
219036962|NCT06982885|DIAGNOSTIC_TEST|artificial intelligence|Artificial intelligence assisted diagnostic system was used to diagnose colorectal lesions
219036963|NCT04473053|DRUG|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
219204204|NCT06880926|DRUG|Krill oil|Antarctic krill oil was used for intervention in the experimental group.
219518619|NCT03026270|OTHER|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
219518620|NCT06389409|OTHER|Observation of testicular cancer patients|Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
219612214|NCT02797197|PROCEDURE|handgrip strength test|
219612215|NCT02797197|DRUG|chemotherapy|
219612216|NCT03437473|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
219612217|NCT03377101|DRUG|Copanlisib|Given IV
219036964|NCT04473053|DRUG|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
219036965|NCT04473053|OTHER|Standard care|Patients will receive standard care.
219612218|NCT03377101|DRUG|Fulvestrant|Given IM
219612219|NCT03377101|OTHER|Laboratory Biomarker Analysis|Correlative studies
219036966|NCT04473053|BIOLOGICAL|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
219036967|NCT06985498|COMBINATION_PRODUCT|Sandwich stratergy|The patients received blinatumoab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed after blinatumomab. Auto-HSCT was proceeded after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after stem cell reinfusion.
219204205|NCT06880926|DIETARY_SUPPLEMENT|Olive Oil|Olive oil was used for intervention in the placebo group.
219612220|NCT03377101|DRUG|Palbociclib|Given PO
219612221|NCT00269984|DRUG|Epoetin alfa|
219612222|NCT01593046|DRUG|GSK1265744 Oral|30mg tablet
219612223|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
219036968|NCT06587451|DRUG|JPB898 (Induction and Maintenance)|Induction and Maintenance: Intravenous (IV)
219036969|NCT06587451|DRUG|Opdivo-EU (Induction)|Induction: Intravenous (IV)
219036970|NCT06587451|DRUG|Opdivo-US (Induction)|Induction: Intravenous (IV)
219036971|NCT06587451|DRUG|Yervoy-EU (Induction)|Induction: Intravenous (IV)
219036972|NCT06587451|DRUG|Opdivo-EU (Maintenance)|Maintenance: Intravenous (IV)
219612224|NCT01593046|DRUG|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
219518621|NCT03500861|OTHER|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
219518622|NCT03618953|BIOLOGICAL|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
218899955|NCT06725342|GENETIC|Combined DNA/RNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.|"Dual extractions (DNA/RNA) will be carried out from macrodissected thick unstained FFPE sections; samples will be measured for adequate quality / quantity; libraries will be constructed separately with each panel and samples will be sequenced in the same chip in an Ion Torrent Proton System, according to the manufacturer's instructions.~Sequencing results will be called with the Variant Caller for each panel and submitted for initial analysis and annotation to the Ion Reporter pipeline with each DNA and RNA panel"
218899956|NCT06727175|BEHAVIORAL|non-invasive neuromodulation therapy|Patients with subjective tinnitus were treated using non-invasive neuroregulation therapy. That is, to generate personalized, non-invasive acoustically stimulated neuroregulation regimens for six montns. Each participant was treated three times a day (morning, noon and bedtime) for 30 minutes each time.
218899957|NCT06727175|OTHER|before any intervention|before any intervention
219518623|NCT03618953|BIOLOGICAL|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
218899958|NCT06921447|OTHER|Clinical Cases|Seven clinical cases that have to be analysed
218899959|NCT06756490|DRUG|HY-2003 (10 mg/ml), BELKYRA and placebo|Participants received HY-2003 (10 mg/ml), or BELKYRA, or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments.
219518624|NCT03618953|BIOLOGICAL|Atezolizumab|monoclonal antibody; checkpoint inhibitor
219518625|NCT00264797|DRUG|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
219518626|NCT00264797|DRUG|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
219518627|NCT06196060|BEHAVIORAL|Visual perspective taking training|Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.
219518628|NCT06196060|BEHAVIORAL|Block building training|Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.
219518629|NCT06196060|BEHAVIORAL|Thought-bubble training|Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.
219518630|NCT06196060|BEHAVIORAL|Treatment as usual|Participants will continue to receive treatment as usual during the trial.
219518631|NCT05692999|DRUG|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
219036973|NCT06653894|PROCEDURE|PENG block with 0.25% bupivacaine.|In the PENG group, patients were placed in the supine position. A convex ultrasound probe was positioned under sterile conditions on the operated side, aligned with the iliac bone below the anterior superior iliac spine (ASIS). The anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas muscle, and its tendon were identified. Using an in-plane technique, a 22G 100-mm peripheral block needle was advanced toward the IPE, targeting the space between the iliopsoas muscle tendon and the IPE. Proper placement was confirmed via hydrodissection. Subsequently, 20 mL of 0.25% bupivacaine was administered slowly, with aspiration performed every 5 mL to avoid intravascular injection. The correct spread of the local anesthetic was verified via ultrasound, confirming elevation of the iliopsoas tendon.
219204206|NCT06881680|DEVICE|virtual reality (VR) head mounted display|This group of subjects received immersive and interactive VR training, which combined rich immersive VR scenes with specific interactive tasks, including two VR scenes. Task selection was based on the subjects' upper limb functional performance, and experienced therapists provided guidance and monitoring, and adjusted the tasks when necessary.
219518632|NCT05692999|DRUG|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m\^2 Q3W
219518633|NCT05692999|DRUG|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
219518634|NCT03533465|BEHAVIORAL|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
219612225|NCT01593046|DRUG|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
219612226|NCT01593046|DRUG|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
219612227|NCT01593046|DRUG|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
219612228|NCT01593046|DRUG|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
218899960|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (5 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
218899961|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.
218899962|NCT06752239|RADIATION|Modified delineation|Modified delineation (MD) of cervical lymphatic drainage areas, sparing the common carotid artery within the clinical target volume (CTV)
218899963|NCT06752239|RADIATION|Standard delineation|Standard delineation
218899964|NCT05657990|DRUG|Tamsulosin|Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
219204207|NCT06882200|OTHER|A combined mindfulness and therapeutic scuba-diving protocol|The Bathysmed program is a unique scuba diving program that combines scuba immersion with techniques from mindfulness meditation, psychology and sports mental preparation. The program includes 30 different exercises over ten scuba-diving sessions with mindfulness training, twice a week for five weeks.
218899965|NCT06906978|PROCEDURE|blood sampling|Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.
218899966|NCT05524220|DEVICE|Standard care with a facemask.|The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
218899967|NCT05524220|DEVICE|SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)|The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
219204208|NCT06882200|OTHER|Control group regular follow up in primary care|Standard care includes regular appointments and health education with their general practitioner and monthly appointments with the dietician and psychotherapist at the primary care centre in Montpellier, France throughout the study. This care includes monthly sessions on diet, exercise and general stress management with a registered dietician.
219518635|NCT02359331|PROCEDURE|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
219612229|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
218899968|NCT04088006|DEVICE|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
218899969|NCT00434187|DRUG|ERB-041|
218899970|NCT06910748|BEHAVIORAL|E-training for Medical Professionals On Wellbeing and Effective Resolutions (E.M.P.O.W.E.R.)|The EMPOWER programme aims to help participants acquire problem-solving skills adapted into the context of MPs' workplace and daily life to address their work-related, personal, and interpersonal problems, including self-neglect, work-life imbalance, patient communication problems, as well as stress during emerging public health crises. The session elements include video introduction, metaphors, daily examples, and narrative stories with prototype MP characters depicting the targeted problems to demonstrate how the taught problem-solving skills could be applied in a variety of situations. Brief exercise and homework will be assigned after each session and personalized written feedback will be provided.
218899971|NCT06910748|OTHER|Education Materials|The waitlist control receive education materials covering (1) introduction of mental health problems; (2) signs, symptoms, causes, and consequences of anxiety and depression, and (3) treatment approaches and available community resources.
218899972|NCT06319898|BEHAVIORAL|Lavender aromatherapy sticker|Lavender aromatherapy during procedure, music and dim lighting
218899973|NCT06914544|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
218899974|NCT05321927|DEVICE|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 7 pulses per burst for the last 5 minutes.
218899975|NCT05321927|OTHER|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
218899976|NCT05321927|DEVICE|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
218899977|NCT06914947|BEHAVIORAL|Brain Health Together|Each week, the program included a 1-hour group brain health education class, a 1-hour group Moving Together class, and a 30-minute individual brain health coaching session (total: 2.5 hours/week). Before the first session, participants were asked to complete a brief online survey about lifestyle behaviors and medical conditions related to dementia risk. The first 4 brain health education classes focused on general content to introduce and reinforce the concept that healthy lifestyle behaviors and management of chronic medical conditions can improve cognitive function, delay cognitive decline, and potentially prevent dementia. Another goal was to introduce participants to health coaching and to help participants each set specific, measurable, achievable, realistic, time-limited (SMART) goals to improve brain health. The remaining 8 weeks were adjusted to accommodate participant feedback in the early portion of the pilot study.
218899978|NCT04894669|DEVICE|INVSENSOR00045|Noninvasive sensor will be fitted to the subject's hand, foot, or toe to measure oxygen saturation and pulse rate.
218899979|NCT06911736|OTHER|Trendelenburg position|In addition to the management described above, the postoperative position was modified in the intervention group (trendelenburg). After admission to the hospital unit (general ward, special care, or intensive care unit), the patient's position was adjusted with a 30° leg elevation and a 10° downward head tilt. Proper positioning was verified with a goniometer. This position was maintained until the drains were removed, and the patient was then positioned according to usual care. If the patient decided to get out of bed, the nurse occluded the drains and reopened them when the patient returned to the position described for each group.
218899980|NCT06922565|DEVICE|acupuncture|Subjects in the acupuncture group received traditional acupuncture. The needles were inserted to induce a sense of 'getting qi' and left in place for 30 minutes.
218899981|NCT06922565|DEVICE|sham acupuncture|Sterile disposable retractable needles and a fake placebo acupuncture device are used for sham acupuncture. The acupuncturist attached the base of the sham acupuncture device to the acupoints, and then inserted sterile disposable blunt-tipped retractable needles into the tubes; when the blunt tips touched the skin, the needles retracted into the handles, and there was no sensation of getting qi.
218899982|NCT06920849|BIOLOGICAL|SRP+iPRF|SRP (scaling and root planing) with iPRF (injectable platelet-rich fibrin)
218899983|NCT06920849|PROCEDURE|SRP|SRP (scaling and root planing)
218899984|NCT06918366|DRUG|Part A - single rising dose 1|Inhaled XQ-001
218899985|NCT06918366|DRUG|Part A - single rising dose 2|Inhaled XQ-001 or Placebo
218899986|NCT06918366|DRUG|Part A - single rising dose 3|Inhaled XQ-001 or Placebo
218899987|NCT06918366|DRUG|Part A - single rising dose 4|Inhaled XQ-001 or Placebo
219036974|NCT06653894|PROCEDURE|anterior quadratus lumborum block|"The quadratus lumborum and psoas major muscles, along with the transverse process of the L4 vertebra, were visualized in the midaxillary line using an in-plane technique. A 22G, 100-mm peripheral block needle (Stimuplex® Ultra; B. Braun Melsungen AG, Melsungen, Germany) was advanced into the subfascial plane between the quadratus lumborum and psoas major muscles, and 1-2 mL of 0.9% saline was injected to confirm correct placement via hydrodissection.~Following this, 20 mL of 0.25% bupivacaine (Buvasin® 0.5%, VEM, Tekirdağ, Turkey) was injected incrementally, with aspiration performed every 5 mL. Proper spread of the local anesthetic was confirmed by ultrasound visualization of a hypoechoic distribution between the fascial planes."
219036975|NCT02620046|DRUG|Vedolizumab SC|Vedolizumab SC 108 mg injection
219518636|NCT02359331|DRUG|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
219518637|NCT02359331|DRUG|Metronidazole|
219518638|NCT02359331|DRUG|Tetracycline|
219036976|NCT06826196|DRUG|ALD-102|Treatment every 4 weeks for total of 8-week treatment period.
219036977|NCT06826196|DRUG|Placebo|Treatment every 4 weeks for 8-week treatment period
219518639|NCT02359331|DRUG|tripotassium dicitrate bismuthate|
219518640|NCT02359331|DRUG|7 days tailored therapy Proton Pump Inhibitor|
219518641|NCT02359331|DRUG|Moxifloxacin|
219518642|NCT02359331|DRUG|Amoxicillin|
219518643|NCT02314338|OTHER|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
219518644|NCT02402348|DRUG|Metformin|
219518645|NCT02931474|DRUG|Tesamorelin|Growth Hormone-Releasing
218899988|NCT06918366|DRUG|Part A - single rising dose 5|Inhaled XQ-001 or Placebo
218899989|NCT06918366|DRUG|Part A - single rising dose 6|Inhaled XQ-001 or Placebo
218899990|NCT06918366|DRUG|Part B - mutiple rising dose 1|Inhaled XQ-001 or Placebo
218899991|NCT06918366|DRUG|Part B - mutiple rising dose 2|Inhaled XQ-001 or Placebo
218899992|NCT06922773|DIAGNOSTIC_TEST|Completion of questionnaires; child psychiatric screening; faecal sample analysis|"Completion of questionnaires:~* FFQ (Food Frequency Questionnaire) - completed by child~* KIDSCREEN-10 - completed by child~* CRIES-13 (Child Revised Impact of Events Scale) - completed by parents/guardian and child~* CTES (Childhood Trust Events Survey) - completed by parents/guardian~* RCADS-25 (Revised Children's Anxiety and Depression Scale) - completed by parents/guardian and child~Child psychiatric screening using SCID-5-Junior - semi-structured interview conducted with child and parent(s)/guardian~Faecal sample analysis:~* Beta-diversity (UniFrac and Bray-Curtis distance index)~* Firmicutes/Bacteroidetes ratio~* Abundance of Prevotella, Lactobacillaceae, Bifidobacteriacae and Lachnospiraceae~* Short-chain fatty acid metabolites"
218899993|NCT06922682|BEHAVIORAL|Training with Sudden Infant Death Syndrome Training Booklet|Sudden Infant Death Syndrome Training Booklet was prepared. Prgenant women who agreed to participate were provided a face-to-face training on the risk factors triggering sudden infant death syndrome through the booklet. Following the educational session, they received the safe sleep handout to use at home and were informed that the researcher would call them two months later to check on their adherence to safe sleep practices. Following the training, participants were re-administered the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire and the training booklet was given to them as a gift. Two months after the training, the pregnant women were contacted via phone and they were required to fill out the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire once again.
219518646|NCT02931474|OTHER|Placebo|
219518647|NCT02268669|OTHER|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
219518648|NCT04260204|PROCEDURE|Pediatric cardiac surgery|
219518649|NCT04271722|OTHER|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
219612230|NCT03905616|DEVICE|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
219612231|NCT03953612|DRUG|Pregnenolone (PREG)|2 doses of PREG (300 or 500 mg/day)
219612232|NCT03953612|DRUG|Placebos|placebo
219612233|NCT00641446|DRUG|budesonide|
219518650|NCT03727568|PROCEDURE|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
218899994|NCT06922500|DEVICE|depth of anesthesia|Time spent within recommended pEEG-levels
218899995|NCT06921252|DRUG|chemotherapy agents|Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
218899996|NCT05688696|DRUG|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
218899997|NCT05688696|DRUG|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
218899998|NCT05688696|DRUG|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
218899999|NCT06921889|PROCEDURE|Autologous Chondrocyte Implantation (ACI)|ACI is a two-stage process that utilises the patient's own chondrocytes to repair damaged chondral tissue. After a harvesting procedure to obtain the cells, the chondrocytes are cultured and expanded in a specialised laboratory. A second procedure is then performed to implant the cells into the defect to replace and regenerate the injured cartilage. ACI allows the knee to generate durable and hyaline-like repair tissue.
218900000|NCT06920927|OTHER|Decision aid|Decision aid for use by physicians and patients with CKD when deciding upon an invasive vs a conservative approach to management of coronary artery disease.
219036978|NCT05462340|DRUG|[18F]ASEM|\[18F\]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. \[18F\]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
219036979|NCT05462340|DRUG|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
219204209|NCT06694714|DRUG|0.5 ml lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
219204210|NCT06694714|DRUG|1.0 ml lidocaine + epinephrine 1:100,000|1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
219204211|NCT06718621|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
219518651|NCT04219501|OTHER|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
219518652|NCT05505812|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
219518653|NCT05360316|DEVICE|ESWT|extracorporeal shock wave therapy
219518654|NCT04277910|DRUG|MT2004|MT2004 oral capsules
219518655|NCT04277910|DRUG|Placebo|Placebo oral capsules
219518656|NCT06357338|OTHER|no intervention|No intervention
219612234|NCT00641446|DRUG|varicella zoster virus|
218900001|NCT06922201|OTHER|SmartCoach|Participants will receive a tailored life-skills training program over four months, which includes 2-4 personalized messages per week via Whatsapp. These messages, in the form of microdialogues generated by an automated system, will focus on self-management skills, social skills and substance use resistance skills. The program will use interactive elements such as quiz questions, behavioural plans, message contests and multimedia content (audio testimonials, motivational podcasts, videos, images and links to relevant websites).
218900002|NCT06919601|BEHAVIORAL|Grief-Informed Healing Circles|Eight one-hour sessions delivered in a group setting
218900003|NCT06921629|OTHER|Menstruatie Educatie Kalender (Menstrution Education Calendar) application (MEK-app)|The MEK-APP is a mHealth application to evaluate menstrual complaints like heavy menstrual blood loss and dysmenorrhea. The MEK-APP is a calendar and facilitates daily monitoring of pain intensity using a Visual Analogue Scale (VAS), the amount of blood loss through a pictorial blood loss assessment chart (PBAC), and the impact of these complaints on daily life. The MEK-APP followed the waterfall methodology for software development and the usability was evaluated by both adults and adolescents(4). Furthermore, the MEK app has been approved by the privacy and security officers of Amsterdam UMC
219612235|NCT02317029|DEVICE|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
219612236|NCT02317029|PROCEDURE|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
219612237|NCT02317029|DEVICE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
218900004|NCT06921629|OTHER|Questionnaires|"After registration for this study via www.mijnmenstruatie.nl (which has also been approved by the privacy and security officers of Amsterdam UMC), participants received the first digital questionnaire. This questionnaire consisted of a baseline questionnaire, the electronic self bleeding assessment tool (e-self-BATH) and the Menstrual Health Literacy questionnaire.~After using the MEK-app for at least one month, participants received an e-mail with the second questionnaire. This questionnaire consisted of the Menstrual Bleeding Questionnaire; Period ImPact and Pain Assesment; Pelvic Pain Impact Questionnaire; ENDOPAIN-4D; Endometriosis Health Profile 5 and iMTA Productivity Cost Questionnaire."
218900005|NCT06922253|DRUG|Sacubitril and Valsartan-Test product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
218900006|NCT06922253|DRUG|Sacubitril and Valsartan-Reference product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
218900007|NCT06920732|PROCEDURE|VLNT（Vascularized Lymph Node Transfer）|VLNT is a physiologic surgical procedure in which vascularized lymph nodes are harvested from a donor site (e.g., groin or submental region) and transplanted to the affected limb to restore lymphatic drainage. The transferred lymph nodes are anastomosed to recipient vessels to ensure perfusion, aiming to reconstruct lymphatic flow and reduce lymphedema-related swelling and fibrosis.
218900008|NCT06920732|PROCEDURE|LVA（Lymphaticovenular Anastomosis）|LVA is a supermicrosurgical technique designed to improve lymphatic drainage by creating anastomoses between functional lymphatic vessels and nearby venules. Under high magnification, lymphatic vessels (typically \<0.8 mm) are identified and connected to subdermal venules to bypass obstructed lymphatic pathways, facilitating improved lymph flow and symptom relief in patients with early-stage lymphedema.
218900009|NCT06920732|PROCEDURE|LS（Liposuction）|LS is a volume-reduction procedure used in the management of advanced lymphedema characterized by fibroadipose tissue hypertrophy. Tumescent liposuction is performed to remove excess subcutaneous adipose tissue, thereby reducing limb volume and improving limb contour. This procedure is often combined with physiologic surgical techniques for optimal long-term outcomes.
219612238|NCT02317029|PROCEDURE|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
219036980|NCT06666491|DRUG|Tafenoquine|A single dose of TQ will be administered orally on Day 1 or Day 2.
219036981|NCT06666491|DRUG|Primaquine|A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
219036982|NCT06666491|DRUG|Chloroquine|A single dose of CQ will be administered orally, daily, on Days 1 to 3.
219036983|NCT02814786|RADIATION|MRI scanner|"This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
219036984|NCT02814786|OTHER|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
219036985|NCT05365672|BIOLOGICAL|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
219036986|NCT05365672|OTHER|Standard of Care|No application of the investigational medicinal product MIC
219036987|NCT05969314|DRUG|Cannabis capsules|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
219036988|NCT06149689|COMBINATION_PRODUCT|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
219036989|NCT03974750|DEVICE|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
219036990|NCT06607718|OTHER|Resistance Training|Resistance training for elderly patients in the acute care unit.
219612239|NCT02028676|OTHER|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
219036991|NCT06607718|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.
219036992|NCT06607718|OTHER|Control Group|No intervention
219036993|NCT06586281|DRUG|Guselkumab|This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
219036994|NCT06598124|OTHER|Investigational Product (IP)|1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
219518657|NCT05323864|BIOLOGICAL|Hypoxia|Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
218900012|NCT06921369|OTHER|Compassionate Care Education Level|Compassionate Care Education Level
218900013|NCT06921369|OTHER|Question Form Created for Nurses' Compassionate Care Attitudes|Question Form Created for Nurses' Compassionate Care Attitudes
218900014|NCT06921369|OTHER|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model
218900015|NCT05579977|DRUG|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
218900016|NCT05579977|OTHER|Placebo|No drug
218900017|NCT05579977|DRUG|Rybelsus|Oral Semaglutide
218900018|NCT06939296|DRUG|VCT220|A small molecule GLP-1R drug, film coated tablet
218900019|NCT06939296|DRUG|Placebo|Placebo tablets
218900020|NCT06937216|DEVICE|Volara therapy|Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
218900021|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:|In this approach, patients who were treated with rTMS five days per week during their acute episode receive less frequent treatments during a taper period (for example treatment three days per week followed by two sessions per week) with a gradual transition into a maintenance schedule. For example, the maintenance schedule might begin with a single weekly session for one or two months and then the intensity is reduced to one session every two weeks (and possibly then one session every three or four weeks).
218900022|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:|Clustered maintenance rTMS typically involves around 4 TMS sessions applied over 2 days, at 1-month intervals. Our team initially developed this approach based upon preclinical TMS studies (for example (Maeda et al. 2000)) suggesting that rTMS treatment effects may accumulate when applied over multiple sessions in a shorter period of time (Maeda et al. 2000).
218900023|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS|Sham treatment will be administered as either standard or clustered maintenance rTMS for 6 months period using a sham coil. The intervention target will be located via a Brainsight TMS Navigator (Brainsight, Montreal, Canada). For safety reasons, the individual TMS intensity will be limited to 130% of the individual resting motor threshold.
218900024|NCT06939205|DIAGNOSTIC_TEST|Assessment of body surface area and assessment ventricular dilatation prevalence|Estimation of body surface area and quantification of absolute and relative values of echocardiographic variables
219036995|NCT06598124|OTHER|Comparator Product (CP)|1 single dose of CP consisting in 400 mL of milk with lactose
219036996|NCT04287738|BEHAVIORAL|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
219036997|NCT00593671|PROCEDURE|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
219036998|NCT01184547|BEHAVIORAL|Combex|12 weeks of exercise with a trainer post discharge.
219036999|NCT01184547|BEHAVIORAL|Standard of Care|No exercise training received.
219037000|NCT01909349|BEHAVIORAL|self-regulation|Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
219037001|NCT05659628|COMBINATION_PRODUCT|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
219037002|NCT04754347|DEVICE|Computer Aided Detection device|The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
219037003|NCT07109336|DEVICE|Heterogeneous Treatment Effect-Based Decision Model|Heterogeneous Treatment Effect-Based Decision Model
219037004|NCT06770322|PROCEDURE|Conventional|According to the clinician's own practice, the cuff of the endotracheal intubation tube will be manually inflated with the help of a syringe and the pressure will be measured with manometry and a note will be taken.
219037005|NCT06770322|PROCEDURE|manometer|The cuff pressure will be measured by manometry and the cuff of the endotracheal intubation tube will be inflated with 25-30 cmH2O.
219037006|NCT07091279|DRUG|Propranolol|Propranolol, oral, titrated in weekly increments from 10 mg TID to a maximum of 200 mg TID (total daily dose: 30 mg to 600 mg at 8 weeks), based on tolerability. Participants will continue at the highest tolerated dose for additional 4 weeks. Target doses: 10 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg TID.
219037007|NCT07091279|DRUG|Placebo|Placebo for Propranolol
219518658|NCT02305966|PROCEDURE|surgery|All patients will receive a Delta XTEND reverse shoulder implant
218900025|NCT00964652|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
218900026|NCT06939192|OTHER|Intervention Group (APP)|Combination of app-based information and diagnostic screening for parents of premature babies.
218900027|NCT06939192|OTHER|Treatment as usual-Group (TAU)|No intervention. Treatment in the form of usual aftercare service is possible.
218900028|NCT06938789|OTHER|Blood Transfusion|Blood transfusion is given without delay (within 4 hours) in case of hemoglobin below our threshold.
218900029|NCT06938789|OTHER|Standard care|These patients recieve our standard care including blood transfusion as usual. Vital parameters and delirium screening are collected three times a day.
218900030|NCT06938321|DRUG|AK112|Following a predefined dose and date.
218900031|NCT06938321|DRUG|AK130|Following a predefined dose and date.
218900032|NCT06937736|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
219037008|NCT07099911|BEHAVIORAL|NMES|Acute bout of neuromuscular electrical stimulation during a 3-h OGTT.
219037009|NCT07099911|BEHAVIORAL|Sham (No Treatment)|Sham stimulation during a 3-h OGTT.
219037010|NCT07099300|DIAGNOSTIC_TEST|Abdominal Radiography|Obtain plain film radiographs 3 times after adminstration of WSC
218900033|NCT06937671|PROCEDURE|Cold EMR|Cold EMR with cold forceps (regular or jumbo forceps) removal of any visible neoplasia that cannot be ensnared.
219518659|NCT02305966|DEVICE|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
219518660|NCT01153984|DRUG|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
218900034|NCT06937671|PROCEDURE|Hybrid EMR|Cold EMR with hot avulsion of any visible residual neoplasia within the resection bed, in addition to precise APC of the fibrotic bands that may harbor invisible neoplasia within the resection bed.
218900035|NCT06937151|PROCEDURE|Rocabado approach exercise program 6×6 and manibulation .|Rocabado's approach (Rocabado's 6 × 6 Exercises and manipulation). This program included 6 exercises to be performed 6 times a day, repeated 6 times, and three gliding exercises.
218900036|NCT06937151|PROCEDURE|Arthrocentesis|"Participants in the Control Group underwent arthrocentesis of the affected temporomandibular joint. The procedure was performed as follows:~Anesthesia: Local anesthesia was administered to the area surrounding the TMJ.~Needle Insertion: A 20-gauge needle was inserted into the upper joint space approximately 10 mm anterior to the tragus.~Lavage: The joint was lavaged with lactated Ringer's solution to reduce inflammation and remove debris. The joint was irrigated with lactated Ringer's solution."
218900037|NCT06231979|DRUG|Dexmedetomidine|1 μg/kg Dexmedetomidine per side in erector spinae block
218900038|NCT06231979|DRUG|Bupivacain|18 mL of bupivacaine 0.25 % per side in erector spinae block
218900039|NCT06231979|DRUG|Normal saline|2 ml normal saline 0.9% per side in erector spinae block
218900040|NCT02623621|DRUG|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
219037011|NCT07096544|DEVICE|CardioMEMS Device|The CardioMEMS device will be implanted during a right heart catheterization procedure. The device will be positioned in the pulmonary artery and calibrated using a Swan-Ganz catheter. After implantation, PAP measurements will be taken daily using the home monitoring system provided to the patient. These readings will be transmitted wirelessly to the clinical team, who will review the data at least once per week. Adjustments to the patient's medical therapy and LVAD speed settings will be made based on the hemodynamic data provided by the CardioMEMS device.
219037012|NCT07101406|OTHER|Türkiye Nutrition Guideline Diet|A diet structured according to the Türkiye Nutrition Guideline (TÜBER) for pregnant women, consisting of 45-60% carbohydrates, 12-20% protein (minimum 70 g), and 20-35% fat. Diets were tailored weekly based on blood glucose levels and individual dietary intake records.
219037013|NCT07101406|OTHER|DASH Diet|A dietary plan based on DASH guidelines: 45-60% carbohydrates (≥175 g), 12-20% protein (≥70 g), 20-35% fat (≤6% saturated), ≤2300 mg sodium, ≥4700 mg potassium, ≥1250 mg calcium, ≥500 mg magnesium. Includes low-fat dairy, lean meats, fruits/vegetables, and nuts/seeds.
218900041|NCT03628976|OTHER|tVNS|Intervention
218900042|NCT03628976|OTHER|Motor training|Same finger training for both arms
218900043|NCT05235542|DRUG|AK104|IV infusion,Specified dose on specified days
219037014|NCT07101289|BEHAVIORAL|Personal health planning and nutritional coaching|Behavioral support will be offed by ZealCare, an evidence-based, virtual coaching behavioral support program for patients with chronic conditions.
219037015|NCT07101289|OTHER|Prescription Produce|Eat Well is a prescription produce program that provides a reloadable, restricted use debit card to participants to purchase fresh, frozen, or canned fruits, vegetables, and legumes at grocery stores.
219037016|NCT07100119|DRUG|LY4256984|Administered IT
219037017|NCT07100119|DRUG|Placebo|Administered IT
219037018|NCT06025513|DEVICE|Embrace Patch|Tension offloading skin patch
219037019|NCT07104825|PROCEDURE|Intraoperative autonomic neural blockade (ANB)|Local anesthetic block of the neurovascular tissue along the lesser curve of the stomach and celiac trunk during sleeve gastrectomy or gastric bypass surgery.
219037020|NCT07104825|PROCEDURE|Laparoscopic Standard of Care Abdominal Wall Block|Administration of local anesthetic to abdominal incisions (standard of care)
218900044|NCT05235542|DRUG|AK117|IV infusion,Specified dose on specified days
218900045|NCT05235542|DRUG|Capecitabine tablets|Oral,Specified dose on specified days
218900046|NCT05235542|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
218900047|NCT05235542|DRUG|Cisplatin|IV infusion,Specified dose on specified days
218900048|NCT05235542|DRUG|Paclitaxel|IV infusion,Specified dose on specified days
218900049|NCT05235542|DRUG|Irinotecan|IV infusion,Specified dose on specified days
218900050|NCT05235542|DRUG|Docetaxel|IV infusion,Specified dose on specified days
218900051|NCT05235542|DRUG|5-FU|IV infusion,Specified dose on specified days
218900052|NCT01612130|DRUG|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
218900053|NCT01612130|DRUG|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
219037021|NCT07109960|OTHER|Isometric exercise and hand reflexology|"Each participant in the isometric exercise group receives included ankle exercises, knee workouts, head exercises, static abdominis exercises, and sustained hand grip exercises. Every contraction lasted for 10 seconds, 10 repetitions, two IE sessions over a period of three days. Each IE session lasted between 25 and 35 minutes.~Each participant in the hand reflexology group underwent two the sessions of hand reflexology. Each session had a duration of 15 minutes, which was then followed by a five-minute period of rest.~While isometric exercise- hand reflexology experimental group was given for the participant, the same intervention of isometric exercise and hand reflexology groups Furthermore, no interventions were done for the control group (received routine care only)."
219518661|NCT02460159|DRUG|EZ 10 mg/Atorva 20 mg FDC|
219518662|NCT02460159|DRUG|EZ 10 mg/Atorva 10 mg FDC|
219518663|NCT05522270|PROCEDURE|revitalization by concentrated growth factor|modified platelet concentrate
219612240|NCT02028676|OTHER|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
219518664|NCT03489759|DEVICE|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
218900054|NCT04340453|OTHER|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
218900055|NCT04340453|OTHER|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
218900056|NCT04340453|OTHER|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
218900057|NCT04730856|DRUG|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
219518665|NCT03489759|DEVICE|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
219518666|NCT00650000|DRUG|Modafinil Tablets 200 mg|200mg, single dose fasting
219518667|NCT00650000|DRUG|Provigil® Tablets 200 mg|200mg, single dose fasting
219518668|NCT01474564|OTHER|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
219518669|NCT02000856|DIETARY_SUPPLEMENT|Beetroot juice|
219518670|NCT03027661|DRUG|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
219518671|NCT03027661|DRUG|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
219518672|NCT01520051|DRUG|Mepolizumab|3 monthly intravenous infusions of 750 mg
219518673|NCT01520051|DRUG|Placebo|3 monthly intravenous infusions with saline
219518674|NCT05369871|DEVICE|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
219518675|NCT05369871|DEVICE|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
219518676|NCT02636907|DRUG|BI 695501 Autoinjector|
219518677|NCT02636907|DRUG|BI 695501 Prefilled syringe|
219518678|NCT00003666|DRUG|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
219518679|NCT04315857|OTHER|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
219518680|NCT00000866|BIOLOGICAL|MN rgp120/HIV-1|
219518681|NCT00000866|BIOLOGICAL|TBC-3B Vaccine|
219518682|NCT02596334|DRUG|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
219518683|NCT02596334|DRUG|dolutegravir|
219612241|NCT02028676|DRUG|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
219612242|NCT02028676|DRUG|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
219518684|NCT06193395|OTHER|Questionnaire|No intervention, only clinical testing of questionnaire
218900058|NCT00788788|DRUG|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
218900059|NCT00475189|DRUG|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
218900060|NCT00475189|DRUG|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
218900061|NCT04368780|OTHER|Effect of Progressive Muscle Relaxation Combined With Music|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
218900062|NCT02416154|PROCEDURE|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
218900063|NCT01755871|DRUG|Fingolimod|0,5mg Fingolimod once a day
218900064|NCT00350844|DRUG|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
218900065|NCT04247737|OTHER|gluten free diet|Participants keep a gluten free diet for six weeks
218900066|NCT04957121|OTHER|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
218900067|NCT04957121|OTHER|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
218900068|NCT03004235|DEVICE|Observational data collection|Observational data collection
218900069|NCT00005644|DRUG|gemcitabine hydrochloride|
218900070|NCT00005644|DRUG|paclitaxel|
218900071|NCT01420926|DRUG|Bortezomib|Given SC
218900072|NCT01420926|DRUG|Decitabine|Given IV
218900073|NCT01420926|OTHER|Laboratory Biomarker Analysis|Correlative studies
218900074|NCT01420926|OTHER|Pharmacological Study|Correlative studies
219037022|NCT07108816|DRUG|Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab|"Patients will receive 4 cycles of neoadjuvant treatment with preoperative Sacituzumab tirumotecan in combination with tagitanlimab, followed by surgery.~After surgery, patients will receive up to 13 cycles of adjuvant tagitanlimab."
219037023|NCT07109544|OTHER|Breathing Therapy|The patients in the control group will be receiving breathing therapy by a certificated clinical nurse
219037024|NCT07108998|DRUG|Epcoritamab|Epcoritamab is the investigational product under study in combination with SOC drugs in this protocol. During C1, epcoritamab will be initiated using step-up dosing (SUD) C1D1 .16mg, C1D8 .8mg, C1D15 3 mg, C1D22 24 mg vs 48 mg (full dose) during safety lead in to determine the RP2D. On Cycles 2-3 the RP2D (24mg vs 48 mg) will be administered on Days 1, 8, 15, 22. Then Cycles 4-9 RP2D will be administered on Days 1 \& 15. Then Cycle 10-12 RP2D on Day 1 of each cycle. Epcoritamab is administered subcutaneously. The SOC BTKi are oral medications administered daily during the trial period.
219037025|NCT07110415|DRUG|Yangxinshi tablet|"Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs)) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Yangxinshi tablet, 3 tablets/3 times a day, taken orally"
219037026|NCT07110415|DRUG|Blank control|"Basic treatment: All patients received a conventional treatment regimen, including prognosis-improving drugs (aspirin, β-blockers, statins, and ACEIs) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Blank control"
219037027|NCT07108985|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg, taken once daily for 24 weeks.
219037028|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
219518685|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
218900075|NCT01420926|OTHER|Quality-of-Life Assessment|Ancillary studies
218900076|NCT01420926|OTHER|Questionnaire Administration|Ancillary studies
218900077|NCT02285387|PROCEDURE|Rhythm control|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
218900078|NCT02285387|PROCEDURE|Rate control|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
218900079|NCT00932321|DRUG|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
218900080|NCT00932321|DRUG|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
218900081|NCT05152771|OTHER|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
218900082|NCT02860104|DEVICE|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
218900083|NCT00158288|BEHAVIORAL|LAAM|
218900084|NCT01792037|DRUG|Etomidate|
219037029|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
219518686|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
218900085|NCT01792037|DRUG|Midazolam|
219518687|NCT05154721|DEVICE|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
218900086|NCT01792037|DRUG|methylprednisolone|
218900087|NCT02606331|PROCEDURE|Piezosurgery|Corticotomy cuts will be performed by this technique.
218900088|NCT02606331|RADIATION|ER:YAG laser|Corticotomy cuts will be performed by this technique.
219037030|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg, taken once daily for 24 weeks.
218900089|NCT02775916|DRUG|CDZ173|
218900090|NCT02775916|DRUG|Placebo|
218900091|NCT02698150|DEVICE|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
218900092|NCT04027894|DRUG|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
218900093|NCT04027894|DRUG|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
218900094|NCT00294294|BIOLOGICAL|Prevenar|
218900095|NCT00294294|BIOLOGICAL|Infanrix hexa|
218900096|NCT03727815|OTHER|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
218900097|NCT03727815|OTHER|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
218900098|NCT01151488|OTHER|Resistance Training|RT 3x/wk for 4 months
218900099|NCT00034775|DRUG|risperidone|
218900100|NCT06153134|DRUG|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
218900101|NCT06153134|DRUG|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
218900102|NCT03710148|OTHER|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet \& drinking water, and of excessive iodine intake from drinking water
218900103|NCT05489848|DRUG|Paclitaxel|Paclitaxel: paclitaxel dose of 135\~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
218900104|NCT05489848|DRUG|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
218900105|NCT05489848|DRUG|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
218900106|NCT05489848|RADIATION|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
218900107|NCT05489848|RADIATION|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
219037031|NCT07108309|BIOLOGICAL|BCD-236|as an intravenous infusion
219037032|NCT07108309|DRUG|Chemotherapy|CHT (at the investigator's discretion):
219037033|NCT07109466|OTHER|Mulit-modality Balance Intervention|Participants will attend a virtual group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
219037034|NCT07109466|OTHER|Gerofit|Participation in a virtual wellness program that consists of a warm up, aerobic training, and general strength training 3-times per week for up to 12 months
219037035|NCT07109804|DEVICE|Deep Brain Stimulation (DBS)|The DBS system delivers electrical current into deep areas of the brain. In this study, the electrical current will be delivered continuously during the study duration to an area of the brain called the cuneiform nucleus (CnF). Stimulation frequencies are anticipated to be between 20 and 50 Hertz. Participants may choose to continue stimulation following study termination. This area of the brain is associated with the body's ability to start a movement.
219037036|NCT07109804|PROCEDURE|Deep Brain Stimulation (DBS) Device Implant Procedure|Participants will undergo a one-time implantation of Cartesia DBS electrodes (bilateral) including the Vercise pulse generator in a single surgery (up to approximately 6 hours) to implant bilateral directional DBS leads in the cuneiform nucleus.
219037037|NCT07109804|OTHER|Training Sessions|Training sessions occurs 3 times/week at the study center to condition the subjects before DBS implantation and after DBS implantation. Each session may last up to 60 minutes. Training sessions include joint mobility (passive stretching), volitional neuromuscular activation (active hip mobility), task isolation (weight shifting), task integration (stepping), and activity rehearsal (walking).
219518688|NCT05154721|DEVICE|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
219518689|NCT03375593|DRUG|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
219518690|NCT03375593|DRUG|Acetaminophen 500Mg Tab|tablet
219518691|NCT03375593|DRUG|Ibuprofen 600 mg tab|tablet
219518692|NCT00866593|DRUG|Generic Escitalopram|10mg/d or 20mg/d
219518693|NCT00866593|DRUG|Innovator Escitalopram|10mg/d or 20mg/d
219518694|NCT04308577|OTHER|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
219518695|NCT04931667|DRUG|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
219518696|NCT00043381|DRUG|decitabine (5-aza-2'deoxycytidine)|
218900108|NCT00602212|BEHAVIORAL|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
218900109|NCT00602212|BEHAVIORAL|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
218900110|NCT02264158|DRUG|Telmisartan high|
218900111|NCT02264158|DRUG|Telmisartan low|
219037038|NCT07109648|BEHAVIORAL|Access to app|"The intervention is offering a free subscription to a mental health app that combines self-guided digital tools with AI-powered support. The app features functions such as an emotional diary and structured courses on topics including managing anxiety and stress regulation. A personalized chatbot, powered by large language models (LLMs) and trained on content grounded in cognitive behavioral therapy, delivers evidence-based strategies such as cognitive restructuring, behavioral activation, and emotion regulation. The chatbot also guides users through these resources using natural, supportive conversations.~Participants were randomly assigned to one of two groups:~A treatment group offered free access to the app for three months, or A control group, which will receive free access to the app for one month at the end of the study"
219037039|NCT07108504|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m², d1, 8, 15, q4 week
219037040|NCT07108504|DRUG|LM-302|LM-302, 1.8 mg/kg, d1, q2 week
219037041|NCT07108348|GENETIC|Adenosine deaminase acting on RNA1|Previous studies have demonstrated that increased ADAR1 expression is associated with poor survival in gastric and metastatic colon cancer. In rectal cancer, however, the relationship between ADAR1 levels and TNT response in locally advanced disease has not been investigated. Another point is that ADAR1 can also be studied using immunohistochemistry; however, its sensitivity and specificity are low, so in our study, RNA will be isolated and analyzed using real-time PCR.
219037042|NCT07109830|DIAGNOSTIC_TEST|Cognitive assessment|Cognitive assessment using BCI-game
219037043|NCT07109830|DIAGNOSTIC_TEST|NEPSY-II|Standardized cognitive assessment
219204212|NCT06706960|DIAGNOSTIC_TEST|measurement of IJV-height|"Protocol 1: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is smaller than CCA throughout the whole respiratory cycle.~Protocol 2: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is completely collapsed throughout the whole respiratory cycle.~Protocol 3: IJV tapering portion is portrayed in a longitudinal view. With a skin marker, the IJV height at the end of expiration is marked and measured at the following two positions:~1. Measurement 1: at the very end of the tapering portion (collapsing point / top of pulsation).~2. Measurement 2: at the beginning of the tapering portion (taper point)."
219204213|NCT06714708|RADIATION|Experimental|Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
219518697|NCT00708019|BEHAVIORAL|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls \[total time 12.3 hours\]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls \[8.0 hours\]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
219518698|NCT00000619|PROCEDURE|catheterization, Swan-Ganz|
219518699|NCT00719316|DRUG|Aliskiren|Aliskiren 300mg per day for 6 weeks
219518700|NCT01215890|DRUG|risedronate|
218900112|NCT02264158|DRUG|Lacidipine high|
218900113|NCT02264158|DRUG|Lacidipine low|
218900114|NCT02264158|DRUG|Placebo|
219518701|NCT01215890|DRUG|placebo|
219518702|NCT02272764|DRUG|Itraconazole|Administered orally in a crossover design
218900115|NCT04393675|DRUG|LT5001|Administered twice daily
218900116|NCT04393675|DRUG|Placebo|Administered twice daily
218900117|NCT05429216|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
218900118|NCT05429216|PROCEDURE|ESD procedure|ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
218900119|NCT06413602|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
219518703|NCT02272764|DRUG|ALKS 5461|Administered sublingually in a crossover design
218900120|NCT06413602|OTHER|Neuromuscular Electrical Stimulation|During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
218900121|NCT01232868|BIOLOGICAL|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
218900122|NCT00025597|DRUG|carboplatin|
218900123|NCT00025597|DRUG|cyclophosphamide|
218900124|NCT00025597|DRUG|doxorubicin hydrochloride|
218900125|NCT00025597|DRUG|etoposide|
218900126|NCT00025597|DRUG|vincristine sulfate|
218900127|NCT00025597|PROCEDURE|conventional surgery|
218900128|NCT01538069|OTHER|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
218900129|NCT01538069|OTHER|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
218900130|NCT01538069|OTHER|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
218900131|NCT04575194|DRUG|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
218900132|NCT04575194|DRUG|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
218900133|NCT00981097|GENETIC|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
219037044|NCT07108764|DRUG|Lidocaine|Patients will receive an IV bolus (50 ml) of lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. This will be followed by intraoperative lidocaine infusion in a dose of 1.5mg /kg/hr till the end of surgery.
218900134|NCT00981097|OTHER|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
218900135|NCT00867516|BIOLOGICAL|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
218900136|NCT00867516|BIOLOGICAL|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
219037045|NCT07108764|DRUG|Dexmedetomidine|Patients will receive an IV bolus (50 ml) of dexmedetomidine in dose 0.5 μg/kg over 10 min before induction of anesthesia. This will be followed by intraoperative dexmedetomidine infusion in a dose of 0.3 μg/kg/hr till the end of surgery.
219037046|NCT07110402|PROCEDURE|Autogenous transplant of fragmented adipose tissue taken from abdominal integuments|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of autogenous graft of fragmented adipose tissue taken from the abdominal wall.
219518704|NCT00639990|OTHER|PEEP|Application of positive end expiratory pressure
218900137|NCT02619760|DRUG|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
219518705|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
219518706|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
218900138|NCT02619760|DRUG|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
218900139|NCT00774761|DRUG|fluticasone propionate/formoterol fumarate|inhalation suspension
218900140|NCT00774761|DRUG|fluticasone propionate|inhalation suspension
218900141|NCT00774761|DRUG|formoterol fumarate|inhalation solution
218900142|NCT03128515|DRUG|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
218900143|NCT05644314|DEVICE|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
218900144|NCT01316016|DIETARY_SUPPLEMENT|Rose hip|40 g of rose hip powder daily for 6 weeks.
218900145|NCT04589858|OTHER|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
218900146|NCT04589858|OTHER|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
218900147|NCT03880539|DRUG|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
218900148|NCT03880539|DRUG|Vancomycin Oral|SOC vancomycin pulse/taper
219037047|NCT07110402|PROCEDURE|PRP GF (platelet-rich plasma with growth factors)|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of PRP GF (platelet-rich plasma with growth factors)
219518707|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
219518708|NCT02232100|BEHAVIORAL|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
218900149|NCT03564717|OTHER|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
218900150|NCT04532268|DRUG|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
218900151|NCT05872685|DRUG|S1|S-1 orally intake as perioperative chemotherapy
218900152|NCT05872685|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
218900153|NCT05872685|DRUG|Serplulimab|Perioperative serplulimab, 300 mg IV infusion
218900154|NCT05872685|DRUG|Placebo|Perioperative placebo, 300 mg IV infusion
218900155|NCT02539797|DEVICE|tDCS|comparing anodal, cathodal, and sham tDCS
218900156|NCT02762695|OTHER|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
219612243|NCT02028676|DRUG|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
218900157|NCT02762695|OTHER|Usual Care|Usual Care at Primary Health Care Center
218900158|NCT05721495|OTHER|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
219612244|NCT02028676|DRUG|Once-daily ABC+3TC|
219612245|NCT02028676|DRUG|Twice-daily ABC+3TC|
218900159|NCT05721495|OTHER|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
218900160|NCT05651100|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
218900161|NCT01475877|DRUG|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
218900162|NCT06129526|DIETARY_SUPPLEMENT|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
218900163|NCT06129526|DIETARY_SUPPLEMENT|Corn Oil|Corn Oil
218900164|NCT02335619|BEHAVIORAL|Early palliative care|
218900165|NCT02742831|BEHAVIORAL|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan."
218900166|NCT02742831|OTHER|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
219204214|NCT06714708|DRUG|Active comparator|Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
218900167|NCT02495129|DRUG|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
218900168|NCT02495129|DRUG|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
219204215|NCT06719427|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.
218900169|NCT03741153|DEVICE|slit lamp|"1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma."
218900170|NCT06327698|DRUG|Cadonilimab|Injectable solution
218900171|NCT06327698|DRUG|anlotinib|capsule
218900172|NCT01775644|DRUG|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
218900173|NCT00455299|PROCEDURE|Laparoscopic ventral hernia repair|
218900174|NCT05051748|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
218900175|NCT05051748|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
218900176|NCT05051748|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
219612246|NCT02028676|DRUG|Continued cotrimoxazole prophylaxis|
219612247|NCT02028676|OTHER|Stopped cotrimoxazole prophylaxis|
219612248|NCT03008174|OTHER|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
219612249|NCT02748148|OTHER|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
219612250|NCT02720848|DEVICE|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
219518709|NCT02232100|BEHAVIORAL|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
219518710|NCT00710229|DRUG|Ranibizumab|intravitreal injection
218900177|NCT01139814|DEVICE|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
218900178|NCT05091658|DEVICE|LH Urine Test|Test for qualitative detection of LH in urine
218900179|NCT04002960|DEVICE|INVSENSOR00036|Noninvasive regional oximeter
219037048|NCT07110402|PROCEDURE|Mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest|Treatment of cartilage chondromalacia in the knee joint by arthroscopic technique using mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest
219037049|NCT07110402|PROCEDURE|Hyaluronic acid - low molecular weight|Treatment of chondromalacia of the cartilage in the knee joint with the use of Hyaluronic Acid - low molecular weight
219037050|NCT07110402|PROCEDURE|Hyaluronic acid - cross-linked|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of cross-linked Hyaluronic Acid Arti Aid Plus, Synovial, Durolain, StavOn, Collagenu
219037051|NCT07109284|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W
219037052|NCT07109284|BIOLOGICAL|Tagitanlimab|Tagitanlimab 900mg, intravenously (iv), Q2W
219037053|NCT07100678|PROCEDURE|Porcelain-Fused-to-Metal Fixed Dental Prosthesis|This prosthesis consists of a metal substructure for strength and a porcelain coating for improved aesthetics. The treatment will be planned and delivered by prosthodontic specialist. The intervention is non-surgical
219037054|NCT07108738|PROCEDURE|Pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline will be performed by sterile #330 high speed bur using water spray. Caries will be removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber will be removed by low speed round bur. Haemostasis will be obtained by applying pressure with a moist cotton pellet with saline. Then the test materials will be applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material, then the tooth will be restored with a preformed stainless steel crown
219037055|NCT07108738|PROCEDURE|Radiation|Radiographic evaluation will be performed immediately after teeth restoration (baseline radiograph), then after three, six, and twelve months for the furcation radiolucency area and bone radiodensity. A photo-simulated phosphorus plate sensor was used to take direct standardized digital radiographs. The parallel periapical technique was obtained by Rinn, which is attached to the X-ray tube with its arm fastened to the film holder that contained a coated PSP (photo-stimulated phosphorus plate). To ensure standardization during radiographic film retakes, condensation rubber base impression material will be positioned on the outside of the film holder, and the child is told to bite on it while the material is set. The sensor wil exposed to an X-ray machine (Planmeca ProX, Helsinki, Finland) with a central ray perpendicular to the sensor at 70 kVp, 6 mA, and 0.8 s. Radio-densitometric and radiometric analysis of the radiographs will be performed by RadiAnt software.
219037056|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
219037057|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
219037058|NCT07109245|DRUG|Haloperidol|The oral investigational agent haloperidol (Generic Brand: TEVA-HALOPERIDOL) will be self-administered, at night, over 7 days. Haloperidol will be titrated up to 2 mg.
219037059|NCT07109245|DRUG|Placebo|Oral placebo, encapsulated and to be taken at an equivalent titration schedule to Haloperidol.
219204216|NCT06705218|BEHAVIORAL|MINDSET|2.5-hour mHealth intervention consisting of three modules containing brief films and corresponding interactive reflection activities aimed to improves whole patient health (physical, social, emotional, and functional quality of life as measured by the FACT-G) in patients undergoing systemic treatment for cancer with curative intent. Films feature interviews with people living with cancer describing their experience with diagnosis, treatment, and recovery, and the importance of their mindsets during their experience. The films also feature Stanford faculty with expertise in oncology, psychiatry, and psychology who offer a scientific framework for the importance of mindsets during cancer treatment and provide examples from their clinical practices. The reflection exercises that follow the films are designed to help patients craft a personalized strategy (a) for changing maladaptive mindsets and maintaining adaptive ones and (b) for translating ideas from the film into actionable behavior
219204217|NCT06705218|BEHAVIORAL|Digital Information Series for Cancer|This behavioral intervention provides educational information on coping strategies for individuals undergoing cancer treatment through a hybrid of videos and corresponding questions.
219518711|NCT00710229|DRUG|Bevacizumab|intravitreal injection
219518712|NCT01189123|BIOLOGICAL|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
219518713|NCT01189123|BIOLOGICAL|fluzone by sanofi pasteur|standard dose fluzone
218900180|NCT02529540|OTHER|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
218900181|NCT02529540|OTHER|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
218900182|NCT02529540|OTHER|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
218900183|NCT01250106|DIETARY_SUPPLEMENT|Lactobacillus reuteri|twice daily
218900184|NCT03958175|OTHER|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
219518714|NCT05801263|DIAGNOSTIC_TEST|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
218900185|NCT06274463|BEHAVIORAL|Exercise therapy including a trunk stabilization exercise program|All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
218900186|NCT04965142|BEHAVIORAL|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
218900187|NCT04595552|OTHER|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
218900188|NCT00379665|DRUG|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
218900189|NCT02962258|DRUG|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
218900190|NCT02962258|DRUG|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
218900191|NCT06112574|BEHAVIORAL|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
218900192|NCT01815944|DRUG|0.75% Ropivacaine|
219518715|NCT01076452|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
219518716|NCT00860405|DRUG|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
219518717|NCT00860405|DRUG|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
219518718|NCT00005006|DRUG|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
219518719|NCT00005006|DRUG|Alendronate|Alendronate 70mg/week
219518720|NCT00005006|DRUG|Teriparatide|Teriparatide 20mcg/day
219518721|NCT01141465|DRUG|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
219518722|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
219518723|NCT01141465|DRUG|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
219518724|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
219518725|NCT01141465|DRUG|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
219518726|NCT01141465|DRUG|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
219518727|NCT04320173|DRUG|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
219518728|NCT04320173|DRUG|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
218900193|NCT01815944|DRUG|Normal saline|
218900194|NCT01815944|DRUG|Dextrose 5%|
218900195|NCT01649895|DRUG|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
218900196|NCT01649895|DRUG|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
218900197|NCT01609348|DRUG|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
218900198|NCT01609348|DRUG|Venlafaxine|225 mg daily for 12 weeks
218900199|NCT01879917|DRUG|Liraglutide|
218900200|NCT01879917|DRUG|Placebo|Saline
218900201|NCT02620501|DRUG|Lidocaine|topical lidocaine
218900202|NCT02620501|DRUG|Placebo|0.45% Normal Saline
218900203|NCT00865345|DEVICE|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
219518729|NCT04320173|DRUG|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
219518730|NCT01282359|OTHER|Clinical practice group|Clinical practice group will not receive any specific education
219518731|NCT01282359|OTHER|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
219518732|NCT01282359|OTHER|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
219518733|NCT04854148|OTHER|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
219518734|NCT02465567|DRUG|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
219518735|NCT02465567|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
219518736|NCT02465567|DRUG|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
219518737|NCT02465567|DRUG|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
219518738|NCT06356675|DRUG|Tislelizumab|200mg iv D1 Q3W
219518739|NCT06356675|DRUG|Anlotinib|Anlotinib 12mg D1-12 Q3W
219518740|NCT02651636|DRUG|myo-inositol,alpha-lipoic acid and folic acid|
219518741|NCT04553575|BIOLOGICAL|serology|biological blood samples withdrawn at 6, 12 and 24 months
219518742|NCT05101174|BEHAVIORAL|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
219518743|NCT05101174|BEHAVIORAL|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
218900204|NCT00383786|DRUG|NK1 Antagoist (GR205171)|
218900205|NCT00383786|PROCEDURE|Psychophysiology (Trauma Script)|
219037060|NCT07109245|DRUG|Insulin Lispro|A total of 160 IU of intransal insulin (=1.6 mL) will be administered on MRI scanning visits (80 IU = 0.8 mL delivered per nostril). Humalog; Eli Lilly Canada
219037061|NCT07109245|OTHER|Saline|A total of 1.6 mL of intranasal saline will be administered on each MRI scanning visit (0.8 mL delivered per nostril).
219037062|NCT07109882|DRUG|Chlorzoxazone|This group will receive Chlorzoxazone twice daily for two weeks
219518744|NCT05020548|OTHER|peak inspiratory pressure 10 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 10 cmH2O
219612251|NCT02720848|DEVICE|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
219612252|NCT02565940|OTHER|biopsy|
219612253|NCT04727801|DEVICE|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
219612254|NCT00973063|BEHAVIORAL|Routine sterile gloving|routinely new sterile gloving just before sampling
219518745|NCT05020548|OTHER|peak inspiratory pressure 15 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 15 cmH2O
219518746|NCT05020548|OTHER|peak inspiratory pressure 20 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 20 cmH2O
219518747|NCT02234466|DRUG|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
219518748|NCT02234466|DRUG|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
219518749|NCT02234466|OTHER|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
219612255|NCT01244503|DRUG|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
219612256|NCT03529201|PROCEDURE|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
219612257|NCT03529201|DEVICE|PCA|Patient-controlled analgesia
218900206|NCT00383786|PROCEDURE|Psychophysiology (Verbal Threat)|
219612258|NCT03529201|PROCEDURE|GA|General anesthesia
219612259|NCT03529201|DRUG|Oxycodone|administered by PCA
218900207|NCT00383786|PROCEDURE|Psychophysiology (Fear Conditioning)|
218900208|NCT00383786|PROCEDURE|Psychophysiology (Affective Modulation)|
218900209|NCT00383786|PROCEDURE|Psychophysiology (Heart rate variability)|
218900210|NCT00383786|PROCEDURE|Lumbar Puncture|
218900211|NCT00383786|PROCEDURE|24-hour plasma sampling|
218900212|NCT00383786|PROCEDURE|MRI|
218900213|NCT00894140|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
219037063|NCT07109882|DRUG|Orphenadrine Citrate|This group will receive Orphenadrine Citrate twice daily for two weeks.
219037064|NCT07108855|DRUG|Indocyanine Green (IC-Green)|Systemic administration of indocyanine green during the endoscopic procedure.
219518750|NCT04527809|DEVICE|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
219612260|NCT03529201|DRUG|Sevoflurane|Inhalational anesthetic during GA
218900214|NCT01722019|DEVICE|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
218900215|NCT01722019|DEVICE|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
218900216|NCT00317551|DEVICE|Aberration controlled contact lens|
218900217|NCT00317551|BEHAVIORAL|Vision training|
218900218|NCT03813888|OTHER|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
218900219|NCT03813888|OTHER|Usual Activity group|Usual after school activities at home.
218900220|NCT06525428|DRUG|standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab|"First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT"
218900221|NCT00246519|DRUG|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
219037065|NCT07108855|DIAGNOSTIC_TEST|Fluorescence guided identification using indocyanine green|Near-infrared quantified fluorescence molecular endoscopy (qFME) will be used during the endoscopic procedure.
219037066|NCT07110246|DRUG|Dabrafenib|Given orally (PO)
219037067|NCT07110246|DRUG|Trametinib|Given PO
219037068|NCT07110246|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo imaging by MRI
219037069|NCT07110246|PROCEDURE|Specimen Collection|Under collection of blood and optional CSF samples
219037070|NCT07110246|PROCEDURE|Optional Lumbar puncture|Undergo optional lumbar puncture
219612261|NCT03529201|DRUG|Fentanyl|painkiller during GA
219612262|NCT03529201|DRUG|Rocuronium|muscle relaxant during GA
219612263|NCT01308502|DEVICE|Dx-pH probe|Dx-pH probe with 24 hour recording
219612264|NCT00016081|DRUG|ribavirin|
219612265|NCT04580264|BEHAVIORAL|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
219612266|NCT02829645|OTHER|Clinical assessment|Clinical assessment with questionnaires
219612267|NCT03204448|DEVICE|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
218900222|NCT00246519|DRUG|Atenolol|atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
218900223|NCT05720650|OTHER|No intervention|No intervention
218900224|NCT04978896|DEVICE|Self-guided program on stress coping|This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.
218900225|NCT04978896|DEVICE|Self-guided program on cooperation|The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
218900226|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
218900227|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
219037071|NCT02090127|DRUG|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
219037072|NCT07109531|DRUG|ASKC202+ Limertinib|ASKC202 orally once per day (QD) combined with Limertinib orally BID for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
219037073|NCT07109531|DRUG|Pemetrexed + Cisplatin /Carboplatin|The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed on Day 1of 21 day cycles for 4\~6 cycles (every 3 weeks).
219037074|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
219037075|NCT03087201|DRUG|placebo|analogous to experimental intervention
219037076|NCT02283814|DRUG|BIA 2-093|
219037077|NCT02283814|DRUG|Topamax|
219037078|NCT04633408|BEHAVIORAL|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
219037079|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
219037080|NCT06442137|DRUG|Chazhu Xiaozhi decoction|Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
219037081|NCT06442137|DRUG|Control placebo|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
219037082|NCT05169658|BIOLOGICAL|Mosunetuzumab|Given SC
219518751|NCT04527809|DEVICE|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
219612268|NCT06628804|DIETARY_SUPPLEMENT|Artemisia and green tea extracts|Artemisia and green tea extracts 700 mg/day for 8 weeks
219518752|NCT01900509|DRUG|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
219518753|NCT01900509|DRUG|Clofarabine|Route of administration: IV days 1-5.
219518754|NCT01900509|DRUG|Etoposide|Route of administration: IV days 1-5.
218900228|NCT02583919|DRUG|Placebo|once weekly dosing for 26 weeks
218900229|NCT00675181|DRUG|Melatonin|5mg per os
218900230|NCT00675181|DRUG|Placebo|per os
218900231|NCT01298479|OTHER|Uniject|single use container
218900232|NCT00001572|DRUG|Id-KLH Vaccine|
218900233|NCT00001572|DRUG|QS-21 (Stimulation-QS-21) Drug|
218900234|NCT05549895|DRUG|Dexamethasone|8 mg intrathecally
218900235|NCT05549895|DRUG|Bupivacaine Hydrochloride|0.5 % intrathecally
218900236|NCT04813588|OTHER|Pantomiming|Pantomiming with fluency shaping techniques
218900237|NCT04813588|OTHER|Easy onset|Easy onset method with breathing exercises
218900238|NCT02204930|DRUG|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
219037083|NCT05169658|BIOLOGICAL|Obinutuzumab|Given IV
219037084|NCT05169658|DRUG|Polatuzumab Vedotin|Given IV
219037085|NCT05169658|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET and FDG-PET/CT
219518755|NCT01900509|DRUG|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
219518756|NCT01900509|DRUG|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
219518757|NCT04556214|PROCEDURE|Liver Transplant|Liver Transplant
219518758|NCT05037149|DRUG|STP707|STP707 Powder for Injection
219518759|NCT03531021|BEHAVIORAL|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
219612269|NCT06628804|DIETARY_SUPPLEMENT|Placebo|Placebo 700 mg/day for 8 weeks
218900239|NCT01476059|OTHER|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
218900240|NCT01476059|OTHER|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
218900241|NCT04123886|DRUG|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
218900242|NCT02735239|DRUG|Durvalumab|Anti PD-L1 antibody
218900243|NCT02735239|DRUG|Tremelimumab|Anti CTLA-4 antibody
218900244|NCT02735239|DRUG|Oxaliplatin|IV administered chemotherapy
218900245|NCT02735239|DRUG|Capecitabine|orally-administered chemotherapy
218900246|NCT02735239|RADIATION|Radiotherapy|
218900247|NCT02735239|DRUG|Paclitaxel|IV administered chemotherapy
218900248|NCT02735239|DRUG|Carboplatin|IV administered Chemotherapy
218900249|NCT02735239|DRUG|5-fluorouracil (5-FU)|IV administered chemotherapy
218900250|NCT02735239|DRUG|Leucovorin|chemo-protective agent
219037086|NCT05169658|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
219037087|NCT05169658|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and FDG-PET/CT
219037088|NCT05169658|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219037089|NCT05169658|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219518760|NCT03629925|DRUG|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
219037090|NCT05169658|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219204218|NCT06733753|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
219518761|NCT03629925|DRUG|Gemcitabine|1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
219518762|NCT03629925|DRUG|Cisplatin|75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
219518763|NCT03629925|DRUG|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
219518764|NCT03629925|DRUG|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
219612270|NCT01288404|DRUG|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
219612271|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
219612272|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
219612273|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
218900251|NCT02735239|DRUG|Docetaxel|IV administered chemotherapy
218900252|NCT00048412|DRUG|FLUDARABINE|
218900253|NCT00048412|DRUG|CAMPATH 1H|
218900254|NCT00048412|DRUG|FK50|
218900255|NCT00048412|PROCEDURE|Stem Cell Collection and Infusion|
218900256|NCT05647135|OTHER|Medical food|enteral formulas with different protein composition
218900257|NCT01626924|DRUG|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
218900258|NCT02723773|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
218900259|NCT02682381|DRUG|Teduglutide 0.05mg/kg|0.05 mg/kg
218900260|NCT02682381|DRUG|Teduglutide 0.025 mg/kg|0.025 mg/kg
218900261|NCT02682381|OTHER|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
219037091|NCT06338345|DIAGNOSTIC_TEST|Therapeutic drug monitoring of beta-lactam|During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
219612274|NCT01649986|BEHAVIORAL|Non-pharmacologic intervention|Diet and physical exercise
219612275|NCT01649986|DRUG|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
219612276|NCT05114733|BEHAVIORAL|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
219612277|NCT04217954|DRUG|OXA, 5-FU and bevacizumab plus Toripalimab|"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
218900262|NCT06343246|DEVICE|Inspiratory muscle training with device|: A randomized, controlled three-arm study. Forty-five patients with HT randomized three group: Group 1 will receive IMT (7 days/8 weeks) with function and POWERbreathe® Classic LR device, group 2 will reviece only IMT with 50 % maximal inspiratory pressure (MIP), n: 15) and control group will recieve breathing exercises(7 days/8 weeks).
218900263|NCT02300792|DIETARY_SUPPLEMENT|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
218900264|NCT02300792|DIETARY_SUPPLEMENT|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
218900265|NCT00387881|DRUG|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
218900266|NCT00387881|DRUG|Placebo|Placebo to match Treximet tablets
218900267|NCT05490017|DRUG|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
219204219|NCT06721143|BIOLOGICAL|AION-301|AION-301 Infusion
219204220|NCT06721143|DRUG|Placebo|Placebo Infusion
219204221|NCT06720350|DRUG|Romosozumab and Denosumab Combination Therapy|Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied
219204222|NCT06720350|DRUG|Romosozumab Prefilled Syringe [Evenity]|Romosozumab 210mg subcutaneously per month
219204223|NCT06720350|DRUG|Denosumab (Prolia)|Denosumab 60 mg subcutaneously per 6 months
218900268|NCT05490017|DRUG|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
218900269|NCT01275352|DRUG|Eplerenone|Eplerenone 50 mg/day
218900270|NCT01275352|DRUG|placebo|placebo
218900271|NCT00003994|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
218900272|NCT00003994|DRUG|cisplatin|Given IV
218900273|NCT00003994|DRUG|vincristine sulfate|Given IV
218900274|NCT00003994|DRUG|fluorouracil|Given IV
219037092|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
219037093|NCT03592615|PROCEDURE|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
219518765|NCT05177627|OTHER|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~* educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~* drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~* classroom lessons on philosophies and theories on communication and trust~* small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
219612278|NCT04718454|DEVICE|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
219612279|NCT04970628|OTHER|Medical records collection|Patient's medical records before and after surgery.
219612280|NCT06187805|DEVICE|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
219612281|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
219612282|NCT01370031|DRUG|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
219612283|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
219612284|NCT01370031|DRUG|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
219612285|NCT04379427|DEVICE|Sanmina Biosensor|non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
219612286|NCT02345876|OTHER|no intervention|
218900275|NCT00003994|DRUG|amifostine trihydrate|Given IV
218900276|NCT00003994|DRUG|carboplatin|Given IV
218900277|NCT03629886|BIOLOGICAL|HPV (Types 16, 18) Vaccine, Adsorbed|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
218900278|NCT00461617|DRUG|Mitiglinide|10mg tablet, 10mg TID
218900279|NCT04558177|DEVICE|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
218900280|NCT06217965|OTHER|survey|The study will involve patients completing a questionnaire on a secure online platform (such as RedCap)
218900281|NCT02831621|BEHAVIORAL|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
218900282|NCT06523335|OTHER|Neuromuscular coordination-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
218900283|NCT06523335|OTHER|Force strengthening-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
218900284|NCT01179724|DRUG|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
218900285|NCT01179724|DRUG|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
218900286|NCT02155634|DRUG|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
218900287|NCT05228665|BEHAVIORAL|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
218900288|NCT00463255|BEHAVIORAL|diet|
218900289|NCT02018341|OTHER|homeopathic remedy in 30C potency|
218900290|NCT02018341|OTHER|Placebo|
218900291|NCT00942565|DRUG|tramadol/acetaminophen|
218900292|NCT00942565|DRUG|acetaminophen|
218900293|NCT05133024|DIETARY_SUPPLEMENT|concentrated beetroot juice|Nitrate supplementation; natural source of dietary nitrate
218900294|NCT04098523|DIAGNOSTIC_TEST|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
218900295|NCT01772966|PROCEDURE|Spinal manipulation|
218900296|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-01|1 capsule after breakfast once a day
218900297|NCT05952232|DIETARY_SUPPLEMENT|MK-GH-04|1 capsule after breakfast once a day
218900298|NCT05952232|DIETARY_SUPPLEMENT|TSH-GH-03|1 capsule after breakfast once a day
218900299|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-02|1 capsule after breakfast once a day
218900300|NCT03985241|DIAGNOSTIC_TEST|Functional Assessment of Myocardial Ischemia by icECG|
218900301|NCT02472860|BEHAVIORAL|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
218900302|NCT02472860|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition
218900303|NCT01288755|DRUG|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
218900304|NCT01288755|DRUG|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
218900305|NCT01757314|BEHAVIORAL|ultrasound technique|instruction in the ultrasound technique
218900306|NCT01757314|OTHER|palpation technique|placement of a line via palpation technique
218900307|NCT04497649|DRUG|Sofosbuvir|Sofosbuvir once daily
218900308|NCT04497649|DRUG|Daclatasvir|daclatasuvir once daily
219037094|NCT03592615|PROCEDURE|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
219037095|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
219037096|NCT05692661|RADIATION|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
219037097|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
219612287|NCT06048276|DRUG|Herbal medicines (e.g., Yunkang granules, Duzhong granules)|Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
219204224|NCT06719635|PROCEDURE|Laparoscopic Presacral Neurectomy|Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.
219612288|NCT03263676|DEVICE|Icon resuable underwear|Reusable incontinence underwear
219612289|NCT03263676|DEVICE|Disposable pad|Standard market disposable pad
219612290|NCT02557763|DEVICE|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
219612291|NCT03437408|DEVICE|Mapping and ablation|High density substrate map. Data collection during ablation
219612292|NCT02183779|PROCEDURE|post-occlusive hyperemia|
219612293|NCT02183779|PROCEDURE|cooling box|
219612294|NCT02183779|DRUG|L-NMMA and Fluconazole dermic injection|
218900309|NCT02313259|OTHER|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
218900310|NCT02313259|BEHAVIORAL|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
218900311|NCT04057066|BEHAVIORAL|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
219037098|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
219037099|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
219612295|NCT01834833|OTHER|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
219612296|NCT02891668|DRUG|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
219612297|NCT02649712|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
219613418|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
218900312|NCT04057066|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
218900313|NCT04354792|DIAGNOSTIC_TEST|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
218900314|NCT04956536|OTHER|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
218900315|NCT01573546|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression \> 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
218900316|NCT01573546|BEHAVIORAL|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
218900317|NCT01573546|OTHER|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
219037100|NCT02787252|DEVICE|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
218900318|NCT03088891|OTHER|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
218900319|NCT03088891|OTHER|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
218900320|NCT01050634|DRUG|Aromasin (exemestane)|25mg oral tablet, daily, for \>1yr
219037101|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
219037102|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
219518766|NCT05177627|OTHER|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~\- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
219612298|NCT05325827|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
219612299|NCT07097701|DRUG|Granular powder in unit dose foil-lined sachet Mexiletine (PR)|Mexiletine (PR)
219612300|NCT07097701|DRUG|Oral Capsule Mexiletine (IR)|Mexiletine (IR)
219612301|NCT07097259|COMBINATION_PRODUCT|Test: Follitropin alfa|It is a solution for injection in prefilled pen. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of at least 23 days will be maintained between period 1 and 2.
219612302|NCT07097259|DRUG|Reference: Follitropin alfa|It is a powder and diluent for solution for injection in multidose vial. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of 23 days will be maintained between period 1 and 2.
219612303|NCT07097259|DRUG|Zoladex|It is a auxiliary medicinal product. Participants will receive Zoladex injection on Day -11 in down regulation period, and on Day 17 prior to the start of Period 2.
219612304|NCT06345807|OTHER|Individuals activity programs|activity program will be adjusted every week by practitioner for each patient following data coming from the wearable device ( connected whatch and bellt for 12 months)
219037103|NCT06080152|DEVICE|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
218900321|NCT05947188|OTHER|prostate cancer diagnosis|prostate cancer diagnosis
218900322|NCT01840007|DRUG|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
218900323|NCT00900510|PROCEDURE|Incision and drainage|
218900324|NCT00900510|DRUG|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
218900325|NCT00900510|DRUG|Placebo|
219518767|NCT05177627|OTHER|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~\- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~* attendance of clinical internship~* analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
218900326|NCT01089686|PROCEDURE|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
219037104|NCT06958419|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by 8 cycles of FOLFOX chemotherapy combined with bevacizumab and a PD-1 inhibitor. After induction therapy, patients will continue with maintenance therapy using bevacizumab, PD-1 inhibitor, and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
219037105|NCT06958419|COMBINATION_PRODUCT|First-line treatment|Patients will receive 8 cycles of FOLFOX chemotherapy combined with bevacizumab, followed by maintenance therapy with bevacizumab and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
219037106|NCT05151744|DRUG|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
219037107|NCT05151744|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
219037108|NCT05151744|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
219037109|NCT04403139|DRUG|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
219518768|NCT03712722|OTHER|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
219518769|NCT03141203|DRUG|Romidepsin|10mg vial for Injection
219518770|NCT03141203|DRUG|Carfilzomib|60mg vial for injection
219518771|NCT00497796|DRUG|maribavir|100mg twice a day for 14 weeks.
219518772|NCT00497796|DRUG|ganciclovir|1000mg three times per day for 14 weeks.
219518773|NCT02184130|OTHER|transcranial magnetic stimulation and motion stimuli|
219518774|NCT04284488|DRUG|APG-1387 for Injection|APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.
219518775|NCT04284488|DRUG|Toripalimab|240 mg toripalimab IV on Day 1 of each 21-Day Cycle
219518776|NCT01807637|DEVICE|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
219518777|NCT05203393|DEVICE|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
219518778|NCT02771548|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
219037110|NCT06135155|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
219037111|NCT06135155|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
219037112|NCT03711162|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
219037113|NCT03711162|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
219037114|NCT05161130|PROCEDURE|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
219037115|NCT05609955|DRUG|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
219037116|NCT03034954|DEVICE|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
219037117|NCT03034954|DEVICE|Sham HD-tDCS|Participants will receive sham HD-tDCS
219037118|NCT04727658|RADIATION|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
219518779|NCT01238237|DRUG|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
219613419|NCT05015816|DIAGNOSTIC_TEST|Total body photography|3 monthly TBP imaging
219613420|NCT03535740|DRUG|Brigatinib|Brigatinib Tablets
219613421|NCT04894734|DEVICE|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
218900327|NCT01089686|PROCEDURE|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
218900328|NCT02356445|OTHER|Cytotoxic drug|Observe patients versus treatment type
218900329|NCT05982990|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
218900330|NCT05982990|DRUG|ADVAIR DISKUS® 250/50|2 inhalations in one study period
218900331|NCT01239069|DRUG|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
218900332|NCT01239069|DRUG|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
218900333|NCT01239069|OTHER|Placebo|DE-110 ophthalmic suspension vehicle;QID
218900334|NCT05884086|OTHER||no intervention is necessary. Clinical observation and clinical examination only.
218900335|NCT03880292|PROCEDURE|Document intraoperative Maneuvers|Monitoring procedure during surgery
218900336|NCT00496015|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
219518780|NCT06145815|PROCEDURE|Arthroscopic rotator cuff repair|Patients underwent an arthroscopic repair for rotator cuff lesions
219518781|NCT05575271|PROCEDURE|Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network|The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
219518782|NCT04418388|DRUG|PBK-1801|Administered orally
219518783|NCT04418388|DRUG|PBK-1801|Administered orally
219518784|NCT04418388|DRUG|PBK-1801|Administered orally
219518785|NCT02292745|RADIATION|stereotactic radiotherapy|
219518786|NCT04338126|DRUG|Tranexamic acid|previously described
219518787|NCT04338126|DRUG|Placebo oral tablet|previously described
219518788|NCT00004579|BIOLOGICAL|gp160 MN/LAI-2|
219518789|NCT00004579|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
218900337|NCT00496015|BIOLOGICAL|Infanrix hexa.|1 intramuscular injection.
218900338|NCT00496015|BIOLOGICAL|Meningococcal vaccine GSK134612.|1 intramuscular injection.
218900339|NCT00496015|DRUG|Paracetamol.|Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
218900340|NCT02632292|DEVICE|Absorb GT1|Bioresorbable vascular scaffold
218900341|NCT02632292|DEVICE|Promus|Everolimus-eluting stent
219037119|NCT02684643|OTHER|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
218900342|NCT00675402|OTHER|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
218900343|NCT03004729|OTHER|CoMiSS questionnaire|
218900344|NCT00190437|DRUG|Amoxicillin-clavulanic|Amoxicillin-clavulanic
218900345|NCT04792736|DIAGNOSTIC_TEST|Blood lactate level|Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
218900346|NCT00043719|DRUG|Nitroglycerin ointment|
218900347|NCT00043719|DRUG|Calcium supplement with vitamin D|
218900348|NCT00527735|DRUG|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
218900349|NCT00527735|DRUG|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
218900350|NCT00527735|DRUG|Paclitaxel|175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
218900351|NCT00527735|DRUG|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
219518790|NCT03773848|PROCEDURE|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
219518791|NCT06487676|PROCEDURE|Toe transfer|Toe-to-hand transfer
219518792|NCT06487676|PROCEDURE|Replantation|Finger or thumb replantation after amputation
219612305|NCT06345807|OTHER|activity program|pre established program without adjustement. The patient has connected whatch and bellt for 12 months
219612306|NCT06345807|OTHER|no Physical Activity program|no Physical Activity (PA)program but just PA recommendations.PA is carried out independently (common practice).The patient has connected whatch and bellt for 12 months
219612307|NCT06765070|DEVICE|EXPLORER|Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
219612308|NCT06819254|DRUG|Fisetin followed by Placebo|Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over placebo-controlled dosing regimen to be taken twice daily on two consecutive days for two consecutive weeks.
219612309|NCT06819254|DRUG|Placebo followed by Fisetin|Placebo twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks.
218900352|NCT01911611|DRUG|RO6870868|Single ascending doses
218900353|NCT01911611|DRUG|placebo|Single ascending doses
218900354|NCT00472225|DRUG|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
218900355|NCT04851626|OTHER|Hypnotic intervention for persistent pelvic pain.|Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
218900356|NCT04851626|OTHER|Control group persistent pelvic pain no intervention.|Control group no hypnotic intervention. Waitlist control.
218900357|NCT02916966|OTHER|Patient Registry|Patient Registry
218900358|NCT04759235|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Anatomical (T2W) and functional MRI (DWI) at a 3.0T Siemens or Philips scanner Three MRI scan series (before, during, after nCRT) Measurements: change in apparent diffusion coefficient (ADC)
218900359|NCT04759235|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT)|PET-CT scan at diagnosis and 4-6 weeks after nCRT before operation Measurements: change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value)，MTV（Metabolic tumor volume）
218900360|NCT04759235|DIAGNOSTIC_TEST|Blood and urine metabolic biomarker|Blood and urine specimens are collected before radiotherapy, the third week of radiotherapy, and at the end of radiotherapy.
218900361|NCT01535807|DEVICE|CorMatrix extra cellular matrix (ECM)|"* Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
218900362|NCT01590979|DRUG|Ranolazine|1000mg, two times a day, 12 hour intervals
218900363|NCT01590979|DRUG|Placebo|two times a day, 12 hour intervals
218900364|NCT00138749|DRUG|SS-RBX|
219518793|NCT02361047|BEHAVIORAL|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
219518794|NCT04860219|DIETARY_SUPPLEMENT|Lactoferrin|7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
219518795|NCT00973193|DRUG|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
219518796|NCT00219323|DRUG|Omalizumab|
219518797|NCT03043924|DRUG|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
219612310|NCT06849713|DRUG|Zanubrutinib|Bruton's Tyrosine Kinase (BTK) inhibitor
218900365|NCT05198817|DRUG|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
218900366|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
218900367|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
218900368|NCT02533414|DEVICE|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
218900369|NCT02533414|DEVICE|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
218900370|NCT02730728|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
218900371|NCT02730728|DRUG|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
218900372|NCT02730728|DRUG|5ml bolus of 0.5% ropivicaine|Local anesthetic
218900373|NCT03354117|DRUG|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
218900374|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
218900375|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
219037120|NCT02684643|OTHER|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
219037121|NCT02684643|OTHER|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
219037122|NCT03729336|DEVICE|Midstream urine collection device|Non-invasive midstream urine collection device
219037123|NCT03729336|DEVICE|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
219037124|NCT06343844|DIAGNOSTIC_TEST|cardiac imaging to assess left ventricular volumes and function|non-invasive cardiac imaging (echocardiography and MRI)
219037125|NCT02340299|DEVICE|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
219518798|NCT03043924|DRUG|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
219612311|NCT06849713|DRUG|Sonrotoclax|B-cell lymphoma 2 (BCL2) protein inhibitor
219612312|NCT06849713|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
219613422|NCT04894734|DEVICE|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
219518799|NCT01184560|DRUG|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
219518800|NCT01184560|DRUG|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
219518801|NCT04842045|DRUG|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
219612313|NCT07077447|PROCEDURE|Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma|"This is an observational cohort study with no direct intervention assigned by the investigators. The study compares two groups of patients in our cohort diagnosed with high-risk pTa upper tract urothelial carcinoma (UTUC), as defined by the European Association of Urology (EAU) guidelines. The experimental group includes patients who, due to imperative indications (e.g., solitary kidney, impaired renal function, or comorbidities), undergo kidney-sparing surgery. These patients are compared to a reference group treated with radical nephroureterectomy, which is considered standard of care."
219612314|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
218900376|NCT03614117|DIETARY_SUPPLEMENT|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
218900377|NCT04531761|BEHAVIORAL|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
218900378|NCT03148535|DRUG|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
218900379|NCT03148535|DRUG|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
218900380|NCT01153165|DRUG|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
218900381|NCT01153165|DRUG|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
218900382|NCT01548274|DRUG|Sarpogrelate|Sarpogrelate 300mg/day
218900383|NCT01855412|OTHER|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
218900384|NCT01293825|DRUG|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
218900385|NCT05004831|DRUG|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
218900386|NCT06340022|OTHER|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.
218900387|NCT06340022|OTHER|Face Image Scale (FIS) scoring system|Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.
218900388|NCT06340022|OTHER|Visual Analogue Scale (VAS)|In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.
218900389|NCT06340022|OTHER|pulse rate|Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
219037126|NCT02340299|DEVICE|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
219037127|NCT02283112|OTHER|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
219037128|NCT05235191|DRUG|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
218900390|NCT00665665|DRUG|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
218900391|NCT00665665|DRUG|placebo|Placebo for s.c. injection
218900392|NCT00665665|DRUG|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
218900393|NCT00665665|DRUG|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
219037129|NCT05235191|DRUG|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
219037130|NCT05595993|DRUG|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
219037131|NCT05595993|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
219037132|NCT05489315|DEVICE|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
219037133|NCT05489315|OTHER|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
219037134|NCT02235779|OTHER|Transbronchial lung cryobiopsy|
219037135|NCT00394212|DEVICE|Transoral Suturing|suturing of anastomosis
219037136|NCT00394212|OTHER|Sham Endoscopy|suturing not performed
219037137|NCT01902446|DRUG|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
219037138|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
219037139|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
219037140|NCT00117858|PROCEDURE|Anodal DC polarization of left prefrontal cortex|
219037141|NCT03323528|DRUG|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
219037142|NCT03323528|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
219037143|NCT00588445|DRUG|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
219204225|NCT06719635|PROCEDURE|Fluoroscopically guided Superior Hypogastric Plexus Neurolysis|The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
219037144|NCT03924258|DIAGNOSTIC_TEST|Iron status testing|Blood sample for iron status testing
219037145|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
219037146|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
219037147|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
219037148|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
219612315|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
219612316|NCT07095504|BEHAVIORAL|Virtual World-based Cardiac Rehabilitation (VWCR) program|36 Virtual World-based Cardiac Rehabilitation sessions over the course of 12 weeks (3 sessions/week)
219612317|NCT03576079|DEVICE|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
218900394|NCT00665665|DRUG|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
218900395|NCT02932137|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
218900396|NCT03068871|OTHER|ACT|Psycho-educational group
218900397|NCT03068871|OTHER|CET|Psycho-educational group
218900398|NCT02122679|DRUG|Tranexamic Acid|
218900399|NCT02122679|DRUG|placebo|
218900400|NCT00911248|DRUG|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
218900401|NCT01292941|DEVICE|Intermittent catheterisation|Speedicath, Intermittent catheterisation
218900402|NCT01292941|DEVICE|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
218900403|NCT01292941|DEVICE|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
219037149|NCT03240133|DRUG|BCX7353|oral liquid formulation
219037150|NCT03240133|DRUG|Placebo|oral liquid formulation to match BCX7353
219037151|NCT03146234|GENETIC|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
218900404|NCT01292941|DEVICE|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
218900405|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
218900406|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
218900407|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
218900408|NCT00404651|BIOLOGICAL|DTaP-HBV-IPV vaccine|0.5 mL, IM
218900409|NCT02723812|BIOLOGICAL|GCFLU® Influenza vaccine (Split virion, Inactivated)|
218900410|NCT02785185|DRUG|IDP-122 Vehicle Lotion|Vehicle
218900411|NCT02785185|DRUG|IDP-122 Vehicle Cream|Vehicle
218900412|NCT02785185|DRUG|IDP-122 Lotion|Lotion
218900413|NCT02785185|DRUG|Ultravate Cream|Cream
218900414|NCT02028377|PROCEDURE|PET/MRI|PET/MRI
218900415|NCT04458155|DEVICE|Siemens® Point-of-care high sensitive troponin I analyzer|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
218900416|NCT00420485|DRUG|gimatecan|
218900417|NCT02539771|OTHER|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
218900418|NCT03041948|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
218900419|NCT03041948|PROCEDURE|Caudal-epidural nerve block|See arm description
218900420|NCT03041948|DRUG|Acetaminophen|See arm description
218900421|NCT03041948|DRUG|Sevoflurane|See arm description
218900422|NCT03041948|DRUG|Remifentanil|See arm description
218900423|NCT03041948|DRUG|Propofol|See arm description
219518802|NCT02301676|BEHAVIORAL|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
219518803|NCT02301676|DRUG|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
219612318|NCT03576079|DEVICE|anterior re-positioning splint|hard acrylic anterior re-positioning splint
218900424|NCT03041948|DRUG|Morphine|See arm description
218900425|NCT03041948|DRUG|Ondansetron|See arm description
218900426|NCT03041948|DRUG|Dexamethasone|See arm description
218900427|NCT03041948|DRUG|Ketorolac|See arm description
218900428|NCT02495701|PROCEDURE|Hip arthroscopic surgery|Hip arthroscopic surgery
218900429|NCT04535635|OTHER|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
218900430|NCT04535635|OTHER|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
219518804|NCT02301676|DRUG|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
219612319|NCT03576079|DEVICE|inactive Laser therapy|sham Laser, with inactive beam
218900431|NCT00666666|DRUG|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
218900432|NCT00666666|DRUG|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
218900433|NCT00666666|OTHER|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
218900434|NCT04004897|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
218900435|NCT04998071|DRUG|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
218900436|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
218900437|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
218900438|NCT00934635|OTHER|PET Scan|PET Scan
218900439|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
218900440|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
218900441|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
218900442|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
218900443|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
218900444|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
219612320|NCT05608473|OTHER|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
219612321|NCT01611779|DEVICE|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
218900445|NCT00793195|DRUG|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
218900446|NCT00793195|DRUG|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
219037152|NCT05771259|OTHER|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
219037153|NCT03278990|BEHAVIORAL|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
219518805|NCT02301676|DEVICE|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
219518806|NCT01127022|DIETARY_SUPPLEMENT|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
219518807|NCT01127022|DIETARY_SUPPLEMENT|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
219518808|NCT02116712|DRUG|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
219518809|NCT00946803|BEHAVIORAL|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
219518810|NCT01492400|DRUG|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
219518811|NCT01492400|DRUG|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
219518812|NCT00604500|DRUG|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
219612322|NCT01004744|DRUG|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
219518813|NCT00628888|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
219518814|NCT02648607|DEVICE|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
219518815|NCT00804661|DEVICE|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
219518816|NCT00821028|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
219612323|NCT00262665|DRUG|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
219612324|NCT00262665|DRUG|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
219612325|NCT03791684|DEVICE|Cross linking|Cross linking strategy either standard or accelerated
219612326|NCT02644915|DRUG|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
219518817|NCT05899478|DEVICE|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
219518818|NCT05899478|DEVICE|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
219518819|NCT00201305|DRUG|Gemcitabine+5FU+Leucovorin|
219518820|NCT00878397|DEVICE|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
218900447|NCT03104296|DIAGNOSTIC_TEST|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
218900448|NCT00952302|DRUG|Iron sucrose|Single intravenous infusion of iron 200 mg
218900449|NCT00952302|DRUG|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
218900450|NCT00952302|PROCEDURE|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
218900451|NCT00952302|DRUG|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
218900452|NCT00952302|DRUG|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
218900453|NCT02463916|OTHER|Exercise|8 week structured exercise programme
218900454|NCT03300401|DRUG|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
218900455|NCT03300401|DRUG|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
218900456|NCT03300401|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
218900457|NCT03300401|DEVICE|Positron Emission Tomography|Undergo PET/CT
219037154|NCT03278990|BEHAVIORAL|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
219037155|NCT01598792|BIOLOGICAL|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
219037156|NCT04055597|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
219037157|NCT04055597|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
219518821|NCT00113347|DRUG|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
219518822|NCT00113347|DRUG|Docetaxel|15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
219518823|NCT00113347|RADIATION|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
219518824|NCT01622998|DRUG|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
219518825|NCT01622998|DRUG|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
219612327|NCT02644915|DRUG|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg"
219612328|NCT03475992|DEVICE|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
219612329|NCT06932263|DRUG|Tozorakimab|The drug will be administered subcutaneously.
219612330|NCT06932263|DRUG|Placebo|Placebo will be administered subcutaneously.
219612331|NCT06942910|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
218900458|NCT03300401|DEVICE|Computed Tomography|Undergo CT scan
218900459|NCT03300401|BIOLOGICAL|Yttrium-90 (90Y)|Given IV
218900460|NCT04214223|OTHER|Pre-Anesthesic Consultation|Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
219612332|NCT06942910|DRUG|Dapagliflozin|Participants will receive dapagliflozin in fixed-dose combination as per the arms they are randomized to
218900461|NCT04214223|OTHER|Pre-Anesthesic Numerical Evaluation|Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
218900462|NCT03624673|PROCEDURE|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
218900463|NCT03624673|PROCEDURE|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
218900464|NCT06143358|DRUG|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
218900465|NCT06143358|OTHER|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
218900466|NCT01755364|BIOLOGICAL|AdimFlu-V|
218900467|NCT05332600|OTHER|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
218900468|NCT02126722|PROCEDURE|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
218900469|NCT02126722|DEVICE|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
219518826|NCT00320112|BEHAVIORAL|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
219518827|NCT00320112|BEHAVIORAL|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
219612333|NCT06942078|PROCEDURE|Cryoneurolysis|Targeting of specific nerves related to surgical procedure using very low temperatures
219612334|NCT07139314|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within 4 weeks after symptom onset.
218900470|NCT02126722|OTHER|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
218900471|NCT02126722|OTHER|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
218900472|NCT02343146|BEHAVIORAL|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
218900473|NCT00182169|DRUG|Human recombinant growth hormone|
218900474|NCT04243694|BEHAVIORAL|Mindfulness training|Participants of the intervention group will receive 6-weeks of mindfulness training.
218900475|NCT04662567|DRUG|acetaminophen|compare the postoperative pain 1 hour and \~24h post surgery
218900476|NCT01668459|DRUG|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
218900477|NCT01668459|OTHER|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
218900478|NCT00170508|BIOLOGICAL|Fluzone®|
218900479|NCT01702974|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
218900480|NCT01702974|DRUG|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
218900481|NCT04300985|DRUG|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
218900482|NCT04300985|DRUG|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
218900483|NCT04300985|DRUG|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
218900484|NCT04895449|BIOLOGICAL|MVA-SARS-2-ST|i.m. vaccine administration
218900485|NCT03446755|DEVICE|intra uterine Cook balloon|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
219518828|NCT00320112|BEHAVIORAL|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
219612335|NCT07139314|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 4-8 weeks after symptom onset.
219612336|NCT07146581|BEHAVIORAL|SIRENS|The SIRENS intervention is a technology intervention designed specifically for caregivers of those with dementia, providing them with easy access to expert-reviewed information and helpful resources. The content includes take-home messages summarizing the main points discussed and a goal-setting feature that encourages the care givers to establish small, actionable goals.
219612337|NCT04207307|BEHAVIORAL|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
218900486|NCT00917930|BEHAVIORAL|physical training|intensive cardiac rehabilitation program
218900487|NCT03752138|DRUG|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
218900488|NCT03752138|DRUG|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
218900489|NCT03752138|DRUG|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
218900490|NCT03752138|DRUG|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
218900491|NCT03752138|DRUG|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
218900492|NCT03752138|DRUG|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
218900493|NCT03752138|DRUG|Part 2: TK216|Recommended dose from Part 1.
218900494|NCT01702844|DRUG|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
218900495|NCT05979948|DRUG|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
218900496|NCT05979948|DRUG|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
218900497|NCT05979948|DRUG|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
218900498|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
218900499|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
218900500|NCT01062750|BIOLOGICAL|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
218900501|NCT00721006|BIOLOGICAL|MESENDO|40 subcutaneous injections of biological product
219612338|NCT04207307|BEHAVIORAL|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
219612339|NCT00251121|OTHER|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
219612340|NCT00251121|OTHER|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
218900502|NCT00721006|BIOLOGICAL|Placebo|40 subcutaneous injections of placebo
218900503|NCT00702858|DRUG|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
218900504|NCT00702858|DRUG|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
218900505|NCT04118465|PROCEDURE|external cephalic version|external cephalic version
218900506|NCT02123134|DRUG|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
218900507|NCT02123134|DRUG|Placebo|Phosphate buffered saline placebo for injection
218900508|NCT02458716|PROCEDURE|Robotic Assisted Radical Prostatectomy|Undergo RARP
218900509|NCT02458716|PROCEDURE|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
219518829|NCT05767385|PROCEDURE|Single Arm|"* Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
218900510|NCT02458716|OTHER|Laboratory Biomarker Analysis|Correlative studies
219518830|NCT05767385|PROCEDURE|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
219518831|NCT02045927|OTHER|sedation monitoring with RASS score|
219518832|NCT02045927|OTHER|sedation monitoring with BIS-Guided monitoring|
219612341|NCT07192575|BEHAVIORAL|Perioperative Pulmonary Physiotherapy in Laparoscopic Liver Surgery|The intervention includes pulmonary physiotherapy training 7 days prior to surgery and 7 days postoperatively. Patients receive physiotherapy education in a single session preoperatively or via an educational video, to guide pulmonary training at home. The pulmonary training includes deep breathing, and coughing, pursed lip breathing and positive expiratory pressure (PEP) therapy. The exercise session (10min) is to be performed two times daily for a total of 14 days.
218900511|NCT02458716|OTHER|Quality-of-Life Assessment|Ancillary studies
218900512|NCT02458716|DRUG|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
218900513|NCT05574023|DEVICE|Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|"Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
218900514|NCT05574023|DEVICE|Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia|"in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
218900515|NCT04761601|DRUG|UCT-01-097|Orally available kinase inhibitor
218900516|NCT04761601|DRUG|Gemcitabine|Gemcitabine injection for intravenous use.
218900517|NCT04761601|DRUG|Paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
218900518|NCT03431441|DEVICE|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
218900519|NCT00346216|DRUG|celecoxib|100 to 200 mg twice daily, taken by mouth
218900520|NCT00346216|DRUG|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
218900521|NCT00346216|DRUG|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
218900522|NCT02166099|PROCEDURE|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
218900523|NCT02448277|DEVICE|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
218900524|NCT02448277|DEVICE|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
218900525|NCT02448277|DEVICE|Glidescope|the device is to assist the nasotracheal tube into trachea
218900526|NCT00904813|RADIATION|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
218900527|NCT00904813|RADIATION|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
218900528|NCT00024336|DRUG|tamoxifen citrate|
219518833|NCT01674582|OTHER|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
219518834|NCT02844803|DRUG|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
219612342|NCT07192653|PROCEDURE|nonanatomical anastomosis|In Period 1 (2016-2019, n=41), nonanatomical anastomosis was performed if portal flow was insufficient.
218900529|NCT00024336|RADIATION|radiation therapy|
219518835|NCT02844803|DRUG|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
218900530|NCT01475435|PROCEDURE|non- surgical periodontal treatment|scaling and root planning
219518836|NCT02899338|DRUG|BI695501 Prefilled syringe|
219518837|NCT02899338|DRUG|BI695501Autoinjector|
219518838|NCT06370221|BEHAVIORAL|The effect of psoriatic Arthritis|to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.
219518839|NCT04296149|DRUG|Y90-DOTA-Tyr3-Octreotide|Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
219518840|NCT06495905|PROCEDURE|transbronchoscopic interventional debridement|"1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement"
219518841|NCT03006445|DRUG|FYU-981|
219518842|NCT00822874|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
219518843|NCT01543880|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
219518844|NCT00811668|DEVICE|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
219518845|NCT00811668|DEVICE|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
219518846|NCT04980001|BEHAVIORAL|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
219612343|NCT07192653|PROCEDURE|LTH-based EVT|In Period 2 (2019-2024, n=34), patients with persistent hypoperfusion underwent additional LTH-based EVT (stenting or shunt occlusion)
218900531|NCT01475435|PROCEDURE|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
218900532|NCT00914186|DRUG|TS022|Lotion
218900533|NCT00914186|DRUG|Vehicle|Lotion
218900534|NCT00505557|PROCEDURE|Transaxillary dual plane technique|
218900535|NCT02568514|DEVICE|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
218900536|NCT02271698|DRUG|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
218900537|NCT02271698|OTHER|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
218900538|NCT01038141|PROCEDURE|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
219518847|NCT05233163|DRUG|Empagliflozin|Empagliflozin 10 mg oral daily for 12 weeks
219612344|NCT07192913|DEVICE|Transcranial Magnetic Stimulation|"TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.~Device: Transcranial Magnetic Stimulation (Sham)~TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used."
219612345|NCT07191756|DRUG|Amphotericin B|This is a retrospective observational study. Patients in this cohort received various formulations of amphotericin B as part of their standard medical care.
218900539|NCT05182788|DIETARY_SUPPLEMENT|Placebo pressed candy|consume 2 tablets per day for 8 weeks
218900540|NCT05182788|DIETARY_SUPPLEMENT|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
218900541|NCT02834481|DEVICE|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
218900542|NCT00764699|DRUG|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
218900543|NCT05098028|DRUG|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
218900544|NCT05098028|DRUG|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
219518848|NCT06192134|DEVICE|CPM device|CPM brace
218900545|NCT05098028|DRUG|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
219518849|NCT03131310|OTHER|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
219518850|NCT04439396|DRUG|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
219518851|NCT04439396|OTHER|Saline|saline fluid injection
218900546|NCT05098028|DRUG|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
218900547|NCT05098028|DRUG|Placebo|Placebo Twice Daily
218900548|NCT06415318|DRUG|Paclitaxel + Ifosfamide + Cisplatin & Toripalimab|Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
219037158|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
219612346|NCT07191756|DRUG|Isavuconazole|This is a retrospective observational study. Patients in this cohort received isavuconazole as part of their standard medical care.
218900549|NCT03788057|OTHER|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
218900550|NCT03985761|BEHAVIORAL|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
218900551|NCT03301558|DRUG|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
218900552|NCT03301558|DRUG|High dose sodium bicarbonate|3000 mg sodium bicarbonate
218900553|NCT01755234|DRUG|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
218900554|NCT01755234|DRUG|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
218900555|NCT01865422|OTHER|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
218900556|NCT01320189|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
218900557|NCT00151385|PROCEDURE|single blood draw|
218900558|NCT05905094|OTHER|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
219037159|NCT02259933|DRUG|KUC 7483 CL|
219037160|NCT02259933|DRUG|Placebo|
219037161|NCT02511470|OTHER|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
219518852|NCT00138060|DRUG|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
219612347|NCT07192380|DEVICE|Electroencephalogram|EEG measurement to assess attentional state
218900559|NCT03011281|DRUG|Tofacitinib|
218900560|NCT05580523|DRUG|75 mg acetylsalicylic acid|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
218900561|NCT05580523|DRUG|1.5g Metformin|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g
218900562|NCT05580523|DRUG|150 mg acetylsalicylic acid|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
218900563|NCT05580523|DRUG|Placebo of acetylsalicylic acid and Metformin|Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
219037162|NCT02511470|OTHER|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
219037163|NCT00462319|BEHAVIORAL|Education, weight reduction and physical exercise|
219612348|NCT07192380|DEVICE|Actigraphy|Evaluation of sleep-wake phases 24 hours prior to eye tracking measurement
218900564|NCT00303823|DRUG|placebo|Given orally
218900565|NCT00303823|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
219037164|NCT04871295|BEHAVIORAL|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
219037165|NCT05935579|DRUG|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
218900566|NCT00303823|OTHER|laboratory biomarker analysis|Correlative studies
219037166|NCT05935579|DRUG|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
219037167|NCT05935579|DRUG|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
219037168|NCT05729334|DEVICE|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator."
219037169|NCT03033017|OTHER|Blood Testing|
219037170|NCT04366622|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
219037171|NCT05385419|DIAGNOSTIC_TEST|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
219518853|NCT00138060|DRUG|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
219518854|NCT05586009|DRUG|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
219612349|NCT07192380|DEVICE|Eye Tracking|"Assessment of ocular parameters during controlled eye tracking: guided saccade task followed by analysis of chest scans to detect pulmonary embolism. Measurement of ocular saccade parameters (distance, velocity), fixation time and pupil diameter.~Measurements performed twice: after a night on call and after a night of rest."
219518855|NCT04055337|PROCEDURE|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
219612350|NCT07192380|OTHER|Questionnaires|"Measurements of sleepiness (Karolinska Sleep Scale KSS, Epworth Sleep Scale ESS), mental fatigue (EVA Scale), insomnia (Insomnia Severity Index, ISI) and chronotype (Morningness Eveningness Questionnaire, MEQ)~* Inclusion visit: MEQ~* Before the first evaluation: ISI, KSS, ESS, EVA~* Before the second evaluation: ISI, KSS, ESS, EVA"
219612351|NCT07193355|OTHER|Mental Imagery Application Protocol|"Before the GYKO test, the patient will be asked to perform mental imagery to visualize a 3-meter distance for five cycles, and the time will be recorded. The TKYT will be administered according to standard protocols.~Mental Imagery Application Protocol:~1. Awareness:~   The therapist will show a video of a typical normal gait for an adult male or female without pathology and compare it with a video of the patient's own gait.~2. Problem Identification/Explanation In the EG, subjects will identify gait problems and compare their gait with their typical gait. They will then use the comparative information for feedback.~3. Progressive Relaxation~4. Mental Imagery of Gait~5. Physıcal Performance Of The gait This protocol will be implemented the day after the initial assessment and will be conducted in 12 training sessions of no more than 90 minutes, three times per week for 4 weeks."
219612352|NCT07192822|BEHAVIORAL|Virtual Reality distraction|Participants goes into an immersive virtual reality during a brief painful stimulus
218900567|NCT01572181|DRUG|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"* IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
219612353|NCT07192822|BEHAVIORAL|No Virtual Reality|Participant receives a brief thermal stimulus during no treatment
219037172|NCT05676957|DEVICE|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
219612354|NCT07192822|BEHAVIORAL|One brief pain stimulus|patient receives one brief pain stimulus with no simultaneous second stimulus
219612355|NCT07192822|BEHAVIORAL|Two simultaneous brief thermal stimuli|Participants receive two brief thermal stimuli at the same time
219612356|NCT07191639|OTHER|completion of the QOL-HHT questionnaire|filling in the QOL-HHT questionnaire when they come for consultation
219518856|NCT00137397|DRUG|Tolterodine ER|
219518857|NCT00137397|DRUG|Placebo|
219518858|NCT02729376|DRUG|galeterone|
219518859|NCT01028469|DEVICE|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
219612357|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
219612358|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
219612359|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
219612360|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
219612361|NCT05837845|DRUG|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
218900568|NCT02322281|DRUG|Rociletinib|
218900569|NCT02322281|DRUG|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
218900570|NCT01418144|PROCEDURE|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
218900571|NCT01418144|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
219037173|NCT06310512|BEHAVIORAL|Structured drug therapy management|Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
219037174|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
219037175|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
219037176|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
219037177|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
219037178|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
219037179|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
218900572|NCT01826396|DRUG|Irinotecan|Comparison of standard and high dose irinotecan
218900573|NCT03497065|PROCEDURE|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
218900574|NCT03002441|DEVICE|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D\&E procedure
218900575|NCT03002441|DEVICE|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D\&E procedure
218900576|NCT05925946|DIETARY_SUPPLEMENT|CURE-DM|"1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
218900577|NCT05432492|DRUG|AK112|IV infusion, specified dose on specified days
218900578|NCT00721448|DRUG|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
218900579|NCT00721448|DRUG|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
218900580|NCT01220167|DRUG|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
219037180|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
219518860|NCT02770963|PROCEDURE|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
219037181|NCT00116831|DRUG|Glipizide|oral anti-diabetic medication
219037182|NCT00116831|DRUG|rosiglitazone maleate|oral antidiabetic medication
219037183|NCT01040585|DRUG|Linezolid|Treatment for VAP as indication approved and as physician criterium.
219037184|NCT00380393|BIOLOGICAL|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
219037185|NCT00380393|BIOLOGICAL|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
219037186|NCT01933048|DRUG|FluMist|FluMist Intranasal Vaccine
219518861|NCT02770963|PROCEDURE|Sham acupuncture|"Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
219518862|NCT04551638|OTHER|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
219518863|NCT04180345|OTHER|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
219518864|NCT00896285|OTHER|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
219518865|NCT00896285|OTHER|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
219518866|NCT00896285|OTHER|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
219518867|NCT00896285|OTHER|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
219518868|NCT03806777|DRUG|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
219518869|NCT02353169|DRUG|Dexmedetomidine|
219518870|NCT02353169|DRUG|Saline|
219518871|NCT01790204|DIETARY_SUPPLEMENT|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
219518872|NCT00442390|DRUG|hydrocortisone substitution therapy versus withdrawal|
219612362|NCT05837845|BEHAVIORAL|Cognitive Processing Therapy|Participants will receive 8-15 (average of 12) sessions of Cognitive Processing Therapy
219612363|NCT05837845|BEHAVIORAL|MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)|Participants assigned to MDMA-aCPT will undergo a therapeutic approach administered by trained therapists. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. MDMA can elicit feelings of empathy, love, and deep appreciation, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present. A combined treatment of MDMA and therapy may be especially useful for treating PTSD because MDMA can attenuate the fear response of a perceived threat to one's emotional integrity and decrease defensiveness without blocking access to memories or preventing a deep and genuine experience of emotion.
219612364|NCT05287230|BEHAVIORAL|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
219612365|NCT05287230|BEHAVIORAL|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
219037187|NCT01790334|OTHER|Ultrasonography|
219037188|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
219037189|NCT04941508|BEHAVIORAL|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
219037190|NCT04941508|DRUG|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
219037191|NCT04941508|OTHER|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
219037192|NCT02353767|PROCEDURE|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
219037193|NCT02478138|PROCEDURE|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
219037194|NCT02478138|DRUG|Indocyanine Green (ICG)|
219037195|NCT02478138|DEVICE|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
219037196|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
219037197|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
219037198|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
219518873|NCT03194412|DIETARY_SUPPLEMENT|Diet /nutritional|"• Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
219612366|NCT05733416|DIAGNOSTIC_TEST|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
219612367|NCT05733416|DIAGNOSTIC_TEST|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
219613423|NCT06120153|DIAGNOSTIC_TEST|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
219613424|NCT06974760|DEVICE|IVUS|The Participants will receive IVUS examinations from Pulse and Boston
219037199|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
219037200|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
219037201|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
219037202|NCT03001570|DRUG|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
219037203|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
219037204|NCT03865329|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
219037205|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
219037206|NCT00526058|DEVICE|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
219037207|NCT00526058|DEVICE|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
219037208|NCT01746784|DRUG|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
218900581|NCT01220167|DRUG|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
218900582|NCT01220167|DRUG|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
218900583|NCT02071199|DRUG|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
218900584|NCT02071199|DRUG|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
218900585|NCT02071199|DRUG|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
219037209|NCT01746784|DRUG|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
219037210|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219037211|NCT05147896|DRUG|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
219037212|NCT04335721|DRUG|Voxelotor|Voxelotor 1500mg once a day
219037213|NCT05960747|OTHER|Simulation group|Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
219037214|NCT05915767|DIETARY_SUPPLEMENT|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
219037215|NCT05351424|OTHER|Audiovisual Intervention- Radiation Therapy Education|A video with educational information will be shown regarding radiation therapy.
219204226|NCT06721611|DEVICE|Optical Blood Pressure Monitoring Device (Aktiia G1)|"Non-hypertensive Nucor employees that accept to wear an optical blood pressure monitoring device (Aktiia 24/7 device) to screen for and identify potential undiagnosed hypertension.~100 participants. Each participant will wear the device continuously for 28 days."
219518874|NCT03194412|BEHAVIORAL|Physical activity|"* Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises."
219518875|NCT03194412|COMBINATION_PRODUCT|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
219518876|NCT03194412|BEHAVIORAL|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
218900586|NCT04674007|OTHER|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
218900587|NCT00580736|DEVICE|Optical Clearing|Optical Clearing
218900588|NCT03987477|BEHAVIORAL|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
218900589|NCT03987477|BEHAVIORAL|Waiting list|Waiting list procedure for the control group.
218900590|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
218900591|NCT02726763|BEHAVIORAL|Questionnaires|
218900592|NCT01028417|DEVICE|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
219037216|NCT05351424|OTHER|ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|Brochure with written information will be given to the subject regarding radiation therapy.
219037217|NCT05351424|OTHER|Audiovisual Intervention- Cancer Clinical Trials Education|A video with educational information will be shown regarding cancer clinical trials.
219037218|NCT05351424|OTHER|NCI Taking Part in Cancer Research Studies Brochure|Brochure with written information will be given to the subject regarding cancer clinical trials.
219037219|NCT06505525|PROCEDURE|Extra-articular reconstruction with the Anterolateral Ligament|Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
219037220|NCT01226381|DRUG|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
219037221|NCT00003679|DRUG|cyclophosphamide|
219037222|NCT00003679|DRUG|docetaxel|
219037223|NCT00003679|DRUG|doxorubicin hydrochloride|
219037224|NCT00003679|DRUG|tamoxifen citrate|
219037225|NCT00003679|PROCEDURE|conventional surgery|
219037226|NCT00003679|RADIATION|radiation therapy|
219037227|NCT05133999|BIOLOGICAL|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
219204227|NCT06882967|DEVICE|Thoracic Endovascular Aortic Repair|Placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
219204228|NCT06883786|DEVICE|Virtual reality hypnosis|Virtual reality hypnosis
219518877|NCT00679965|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
218900593|NCT03518294|BEHAVIORAL|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
218900594|NCT03324243|DRUG|Crenolanib|66.7 mg/m2 three times a day (TID)
218900595|NCT03324243|DRUG|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
218900596|NCT03324243|DRUG|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
218900597|NCT02043158|BEHAVIORAL|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
218900598|NCT02043158|BEHAVIORAL|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
218900599|NCT05200143|DRUG|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
218900600|NCT05200143|DRUG|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
218900601|NCT05200143|DRUG|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
219037228|NCT05133999|OTHER|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
219037229|NCT01283126|PROCEDURE|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
219037230|NCT01781442|DRUG|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
219037231|NCT06089486|DIAGNOSTIC_TEST|ICA|Patients will undergo annual CAV surveillance with ICA
219037232|NCT06089486|DIAGNOSTIC_TEST|PET|Patients will undergo annual CAV surveillance with PET
219037233|NCT00097721|DRUG|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
219037234|NCT03869450|DEVICE|Restylane Volyme|Hyaluronic based filler
219518878|NCT00679965|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
219518879|NCT00679965|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
219518880|NCT00679965|DRUG|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
219612368|NCT06146361|BEHAVIORAL|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
219612369|NCT06146361|BEHAVIORAL|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
219037235|NCT03869450|DEVICE|Restylane Defyne|Hyaluronic based filler
219037236|NCT03869450|DEVICE|Restylane Lyft Lidocaine|Hyaluronic based filler
219037237|NCT04927936|BIOLOGICAL|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
219037238|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
219518881|NCT02274129|DEVICE|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
219037239|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
219037240|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
219037241|NCT00030563|DRUG|irinotecan hydrochloride|
219037242|NCT00030563|PROCEDURE|adjuvant therapy|
219518882|NCT04978766|BEHAVIORAL|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
218900602|NCT05599750|PROCEDURE|Incisional hernia repair|Participants will undergo incisional hernia repair
218900603|NCT04811703|DRUG|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
218900604|NCT03077191|OTHER|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
218900605|NCT05789745|DRUG|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
218900606|NCT05789745|OTHER|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
218900607|NCT04493138|DRUG|Azacitidine|Given SC or IV
218900608|NCT04493138|DRUG|Quizartinib|Given PO
218900609|NCT05400655|DRUG|L9LS|Administered subcutaneously.
219037243|NCT00030563|PROCEDURE|conventional surgery|
219037244|NCT00030563|PROCEDURE|radiofrequency ablation|
219037245|NCT01752855|BIOLOGICAL|New formulation adalimumab|New formulation adalimumab 40 mg every other week
219037246|NCT00014365|DRUG|MKC-1|
219037247|NCT00181207|DEVICE|pneumatic vest|
219037248|NCT00181207|OTHER|placebo pneumatic vest|
219037249|NCT02203487|DRUG|BIIF 1149 BS - single rising dose|
219037250|NCT02203487|DRUG|Placebo|
219518883|NCT03635359|DIAGNOSTIC_TEST|blood test|analysis of cell-free DNA in maternal plasma
219037251|NCT01110421|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
219518884|NCT01021150|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
219612370|NCT06146361|BEHAVIORAL|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
219612371|NCT04150783|PROCEDURE|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
218900610|NCT05400655|OTHER|Normal Saline|Administered subcutaneously.
218900611|NCT05257278|DEVICE|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
218900612|NCT05992064|OTHER|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~* Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~* Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
218900613|NCT03777943|PROCEDURE|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
218900614|NCT03203252|OTHER|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
219037252|NCT01110421|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
219037253|NCT01110421|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
219037254|NCT01110421|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
219037255|NCT01110421|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
219037256|NCT01733914|PROCEDURE|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
219037257|NCT01733914|OTHER|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
219037258|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
219518885|NCT01021150|DRUG|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
219518886|NCT06325579|DEVICE|Immersive Virtual Reality for Dysphagia Treatment|Patients wore a VR headset while undergoing their rehabilitation session
218900615|NCT03203252|OTHER|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
218900616|NCT03203252|OTHER|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
218900617|NCT00619515|OTHER|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
218900618|NCT00619515|PROCEDURE|implanted fiducial-based imaging|Undergo fiducial placement imaging
218900619|NCT00619515|RADIATION|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
218900620|NCT04533919|PROCEDURE|Biospecimen Collection|Undergo collection of dorsal root ganglia
218900621|NCT04410172|DIAGNOSTIC_TEST|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
219037259|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
219037260|NCT03283020|DRUG|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
219037261|NCT03283020|DRUG|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
219037262|NCT02434835|DRUG|[14C]KWA-0711|
219037263|NCT06351683|DRUG|MitoQ (mitoquinol mesylate)|MitoQ is an antioxidant molecule designed to target cell stress
219037264|NCT06351683|OTHER|Placebo|Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
219037265|NCT03726008|BEHAVIORAL|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
219037266|NCT00382538|DRUG|Addition of mifepristone 200 mg 24 hours before induction|
219037267|NCT04916730|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
219037268|NCT04916730|BEHAVIORAL|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
219037269|NCT02846207|DRUG|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
219037270|NCT02846207|DRUG|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
219037271|NCT02846207|DRUG|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
219037272|NCT02846207|DRUG|placebo|Dextrin,oral administration, twice one day, for 12weeks.
219037273|NCT02812758|DEVICE|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
219518887|NCT02767193|BIOLOGICAL|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
219037274|NCT01257958|DRUG|19 nor vitamin d|
218900622|NCT03140397|DIETARY_SUPPLEMENT|Placebo|
218900623|NCT03140397|DIETARY_SUPPLEMENT|6-prenylnaringenin|
218900624|NCT03140397|DIETARY_SUPPLEMENT|8-prenylnaringenin|
218900625|NCT03482531|OTHER|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
218900626|NCT03242694|DIAGNOSTIC_TEST|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
219037275|NCT05514158|DRUG|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
219518888|NCT02767193|BIOLOGICAL|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG\_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
219518889|NCT02767193|BIOLOGICAL|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
219518890|NCT02767193|BIOLOGICAL|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG\_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
219518891|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
219518892|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
219518893|NCT02508961|BEHAVIORAL|Exercise|web-based physio exercise programme
219518894|NCT02560350|OTHER|no intervention|no intervention
219518895|NCT05951569|DEVICE|Community-Derived Open-Source Automated Insulin Delivery Loop System|The Loop System consists of an insulin pump and a Dexcom CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
219518896|NCT00796822|DRUG|Pentoxifylline|400 mg three times a day for 8 weeks
219518897|NCT00796822|DRUG|Placebo|One pill three times a day for 8 weeks
219518898|NCT04182009|DEVICE|Omron NE-U17 Ultrasonic nebuliser|The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.
219518899|NCT04182009|DEVICE|Akita Jet Inhalation System|The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
218900627|NCT03242694|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
218900628|NCT04034823|BIOLOGICAL|KN035|KN035 5 mg/kg s.c. Q3W
218900629|NCT04034823|BIOLOGICAL|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
218900630|NCT04034823|DRUG|Docetaxel|100 mg/m2 Q3W IV
218900631|NCT04100382|DEVICE|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
218900632|NCT02493036|DRUG|SYN-010|
218900633|NCT03232346|DRUG|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
218900634|NCT03232346|DRUG|Buprenorphine|5-week buprenorphine taper
218900635|NCT01095432|PROCEDURE|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
218900636|NCT00327106|DRUG|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
218900637|NCT00327106|DRUG|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
219518900|NCT02028936|OTHER|Grape juice R@isol|
219518901|NCT02028936|OTHER|Commercially-available grape juice|
219518902|NCT00002595|DRUG|toremifene|
219612372|NCT03328884|DRUG|Irinotecan (CPT-11) liposome|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered 50 mg/m2 on D1 of a 14-day cycle in monotherapy."
219612373|NCT02360215|RADIATION|Whole brain radiation therapy with hippocampal avoidance|Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
218900638|NCT00088140|DRUG|IDN-6556|
218900639|NCT00088140|DRUG|Placebo|
218900640|NCT04862065|DEVICE|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
218900641|NCT05098730|BEHAVIORAL|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
218900642|NCT05674058|OTHER|No intervention|According to clinical practice.
218900643|NCT06299449|PROCEDURE|free-hand socket shield|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
218900644|NCT06299449|PROCEDURE|AI/guided socket shield|"The patient specific guides will be placed at the pre-planned positions at the labial buccal mucosa.~using artificial intelligence the socket shield approach will be planned to keep the buccal shield and using surgical guide the shield will be preciesly prepared followed by guided implant placement and whole tooth grafting of the jumping gap"
218900645|NCT00139074|DRUG|Quetiapine fumarate|oral variable dose
218900646|NCT00139074|DRUG|sodium valproate|oral
218900647|NCT00218504|DRUG|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
218900648|NCT03371472|DEVICE|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
218900649|NCT03103126|BEHAVIORAL|Combined resistance exercise and walking|Combined resistance exercise and walking
218900650|NCT00878956|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
219037276|NCT05514158|DRUG|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
219037277|NCT02501980|BIOLOGICAL|Biomarker testing and Ultrasonography|
219518903|NCT00002595|PROCEDURE|conventional surgery|
219518904|NCT00290056|DRUG|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
219518905|NCT02923947|DRUG|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
219518906|NCT02070237|DRUG|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
219518907|NCT02183064|DRUG|Meloxicam|
219518908|NCT02183064|DRUG|NSAID|
219518909|NCT00597194|PROCEDURE|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
219612374|NCT02360215|DRUG|Memantine|Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
218900651|NCT00878956|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
218900652|NCT04380389|DIAGNOSTIC_TEST|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
218900653|NCT05459467|OTHER|Exercise|12 weeks high intensity exercise programme
218900654|NCT01507922|DRUG|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
218900655|NCT01507922|DRUG|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
218900656|NCT02634333|PROCEDURE|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
218900657|NCT02634333|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
218900658|NCT02634333|PROCEDURE|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
218900659|NCT02634333|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
218900660|NCT04365621|OTHER|we enrolled ultra-high risk of psychosis (UHR) patient to describe|there is no intervention because we study only the prevalence of patients meeting UHR criteria
218900661|NCT03170661|DRUG|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
218900662|NCT03846050|BEHAVIORAL|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
218900663|NCT03846050|BEHAVIORAL|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
218900664|NCT02884024|OTHER|no intervention|there is no intervention in this study
219037278|NCT02791620|DEVICE|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
219037279|NCT05358275|DEVICE|surgical cutting guide with piezo|3D planned lid surgery
219037280|NCT05358275|OTHER|control|ordinary cyst enucleation
218900665|NCT00639470|OTHER|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
219037281|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
219037282|NCT00983216|DRUG|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
219037283|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
219037284|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
219037285|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
218900666|NCT00269308|PROCEDURE|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
218900667|NCT00269308|PROCEDURE|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
218900668|NCT00269308|BEHAVIORAL|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
218900669|NCT03001557|DRUG|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
218900670|NCT03001557|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablets
218900671|NCT03001557|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablets
218900672|NCT03001557|DRUG|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
218900673|NCT03001557|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
218900674|NCT01794000|DRUG|Prasugrel|Administered orally
218900675|NCT01794000|DRUG|Placebo|Administered orally
219037286|NCT00378066|DRUG|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
219037287|NCT02394080|DEVICE|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
219518910|NCT00158119|BEHAVIORAL|InVEST (Increased Velocity Exercise Specific to Task)|
219612375|NCT02360215|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
219612376|NCT05394519|DRUG|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
219612377|NCT05394519|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
219612378|NCT05394519|DRUG|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
218900676|NCT02646631|OTHER|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
218900677|NCT02646631|BEHAVIORAL|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
218900678|NCT02646631|BEHAVIORAL|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
218900679|NCT02646631|OTHER|Educational Materials|Printed educational materials on the management of epilepsy
219037288|NCT05874180|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition"
219037289|NCT04067284|BEHAVIORAL|Nutrition education|"Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding"
219037290|NCT04067284|DIETARY_SUPPLEMENT|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
219612379|NCT05394519|DRUG|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
219037291|NCT04067284|OTHER|Usual care|No intervention/ control group
219037292|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
219518911|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
219518912|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
219518913|NCT00978900|DIETARY_SUPPLEMENT|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
219518914|NCT00978900|DIETARY_SUPPLEMENT|Water|
219612380|NCT05878015|DRUG|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
219612381|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
219612382|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
219612383|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
219612384|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
218900680|NCT00754585|DEVICE|Logic Back Grahl Duo Back Model DB11-01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
218900681|NCT04718207|DEVICE|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
218900682|NCT02915666|DRUG|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
218900683|NCT02915666|DRUG|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
218900684|NCT02915666|DRUG|Trametinib|trametinib 2 mg PO daily for 8-week cycles
218900685|NCT03360435|DIETARY_SUPPLEMENT|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
218900686|NCT04122326|BEHAVIORAL|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
219518915|NCT01570465|OTHER|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
219518916|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
219518917|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
218900687|NCT01227798|DRUG|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
219037293|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
219037294|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
219037295|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
219037296|NCT02351869|DRUG|Nitrous Oxide|
219037297|NCT02351869|DRUG|Midazolam|
219037298|NCT01378793|BEHAVIORAL|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
219037299|NCT01378793|BEHAVIORAL|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
219037300|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
219037301|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
219037302|NCT03215134|OTHER|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
219037303|NCT05581316|DIAGNOSTIC_TEST|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
219037304|NCT02479711|OTHER|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
219037305|NCT02479711|OTHER|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
219037306|NCT06163508|DRUG|Q-Cells®|Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
219037307|NCT06466096|OTHER|no intervention|this is an observation study, no intervention
219037308|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
219037309|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
219037310|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
219037311|NCT02410720|OTHER|Picoprep solution|
219037312|NCT01504724|DRUG|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
219037313|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
219037314|NCT00367068|DRUG|baclofen, intrathecal|
219037315|NCT00367068|DEVICE|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
219037316|NCT03925324|BIOLOGICAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
219037317|NCT03925324|OTHER|Placebo|1.5 mL/kg Lactated Ringer's Solution
219037318|NCT06262841|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
219518918|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
219518919|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
219518920|NCT05718609|DRUG|Rabeprazole|proton-pump inhibitor (PPI)
218900688|NCT01227798|DRUG|Placebo|Normal Saline
218900689|NCT01546558|DRUG|Metformin|Metformin 1000 mg bid on Days 1-10
218900690|NCT01546558|DRUG|Ranolazine|Ranolazine 500 mg bid on Days 6-10
218900691|NCT03898726|BIOLOGICAL|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
219037319|NCT06262841|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
219037320|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
219037321|NCT00753116|DEVICE|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
219518921|NCT05718609|DRUG|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
219518922|NCT05718609|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219037322|NCT04923971|OTHER|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
219037323|NCT00628433|DRUG|Placebo|Placebo
219037324|NCT00628433|DRUG|HE3286|daily for 28 days
219037325|NCT03873389|DRUG|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
219037326|NCT03830554|OTHER|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
219037327|NCT05106855|RADIATION|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
219037328|NCT05106855|OTHER|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
219037329|NCT05106855|RADIATION|Low Laser Radiation off|This group will receive laser application off.
219037330|NCT05106855|PROCEDURE|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
219037331|NCT05106855|PROCEDURE|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
219037332|NCT00459836|DRUG|PR-104|
219612385|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
219612386|NCT05471856|DRUG|BI 1703880|BI 1703880
219037333|NCT00459836|DRUG|docetaxel|
219037334|NCT00459836|DRUG|gemcitabine hydrochloride|
219037335|NCT00459836|OTHER|laboratory biomarker analysis|
219037336|NCT00459836|OTHER|pharmacological study|
219037337|NCT04515342|DIAGNOSTIC_TEST|DXA|Each participant will undergo one DXA scan
219037338|NCT04515342|OTHER|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
219037339|NCT04515342|OTHER|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
219037340|NCT03917420|DRUG|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
219037341|NCT03917420|DRUG|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
219037342|NCT03282292|PROCEDURE|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
219037343|NCT01144507|PROCEDURE|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
219037344|NCT01144507|OTHER|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
219037345|NCT02293070|OTHER|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
219037346|NCT02293070|PROCEDURE|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
219037347|NCT00641095|BIOLOGICAL|rituximab|concentrate for solution for infusion
219037348|NCT00641095|DRUG|Cyclophosphamide|Tablets
219612387|NCT05471856|DRUG|Ezabenlimab|Ezabenlimab
219612388|NCT04797039|PROCEDURE|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
219037349|NCT00641095|DRUG|Fludarabine|Film coated tablet
219037350|NCT00669812|DRUG|carmustine|
219037351|NCT00669812|DRUG|cyclophosphamide|
219037352|NCT00669812|DRUG|cytarabine|
219037353|NCT00669812|DRUG|doxorubicin hydrochloride|
219037354|NCT00669812|DRUG|epirubicin hydrochloride|
219037355|NCT00669812|DRUG|etoposide|
219037356|NCT00669812|DRUG|ifosfamide|
219037357|NCT00669812|DRUG|melphalan|
219037358|NCT00669812|DRUG|methotrexate|
219037359|NCT00669812|DRUG|prednisolone|
219037360|NCT00669812|DRUG|vincristine sulfate|
219037361|NCT00669812|PROCEDURE|autologous hematopoietic stem cell transplantation|
219037362|NCT00669812|PROCEDURE|biopsy|
219037363|NCT00669812|PROCEDURE|peripheral blood stem cell transplantation|
219037364|NCT03957512|PROCEDURE|Heart surgery|All invasive procedures
219204229|NCT06883734|BEHAVIORAL|Illness Management Skills Training|In this study, in addition to routine outpatient clinic check-ups, 12 sessions of Illness Management Skills Training were applied to the intervention group of 25 patients, each in four separate groups of 6+6+6+7 patients (Group 1, Group 2, Group 3, Group 4), once a week, for 60 minutes each. The training consisted of 1) Introduction-Getting Acquainted, 2) Recovery Goals, 3) Understanding Schizophrenia-1, 4) Understanding Schizophrenia-2, 5) Stress Vulnerability Model and Coping with Stress-1, 6) Stress Vulnerability Model and Coping with Stress-2, 7) Learning About Medication, 8) Using Medication Effectively and Monitoring Treatment, 9) Coping with Persistent Symptoms, 10) Recognizing and Monitoring Warning Signs, 11) Warning Signs My Emergency Plan, and 12) Termination sessions.
219037365|NCT00897065|GENETIC|microarray analysis|
219037366|NCT00897065|GENETIC|polymerase chain reaction|
219037367|NCT00897065|GENETIC|protein expression analysis|
219037368|NCT00897065|OTHER|diagnostic laboratory biomarker analysis|
219037369|NCT00897065|OTHER|fluorescent antibody technique|
219037370|NCT00897065|OTHER|immunohistochemistry staining method|
219037371|NCT00897065|OTHER|immunologic technique|
218900692|NCT03041571|BEHAVIORAL|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
218900693|NCT03041571|BEHAVIORAL|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
218900694|NCT00134303|DRUG|Metformin|Metformin is used.
218900695|NCT00677404|BIOLOGICAL|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
218900696|NCT00425646|BIOLOGICAL|bevacizumab|
219037372|NCT06352450|DIAGNOSTIC_TEST|Active isolated stretching (AIS)|Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
219037373|NCT06352450|DIAGNOSTIC_TEST|Myofascial release (MFR)|Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
219037374|NCT05401955|OTHER|Physical exercise|An adapted physical exercise protocol
219037375|NCT02159521|DEVICE|EkoSonic® Endovascular System|
219037376|NCT02159521|BIOLOGICAL|Alteplase|Recombinant tissue plasminogen activator
219037377|NCT02221310|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
219037378|NCT04504383|DRUG|PN-943|Administered by the oral route BID for the duration of the study.
219037379|NCT04504383|DRUG|Placebo|Administered by the oral route BID for 12 weeks.
219037380|NCT00916175|DIETARY_SUPPLEMENT|P1&P2|"* First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
219037381|NCT00916175|DIETARY_SUPPLEMENT|P1&CC|"* First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
219037382|NCT00916175|DIETARY_SUPPLEMENT|AG&P2|"* First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
219037383|NCT00916175|DIETARY_SUPPLEMENT|AG&CC|"* First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
219037384|NCT00916175|DIETARY_SUPPLEMENT|TA (concentrated 5:1 aloe vera gel)|"* First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
219518923|NCT05718609|DRUG|Furazolidone|Antibiotic for H. pylori eradication
219037385|NCT00916175|DIETARY_SUPPLEMENT|P3|"* First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
219037386|NCT04892238|DIAGNOSTIC_TEST|13-C urea breath test|"Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive."
219518924|NCT05718609|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
219037387|NCT06031974|BEHAVIORAL|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
219518925|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
219518926|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
218900697|NCT00425646|DRUG|imatinib mesylate|
219518927|NCT05504603|DRUG|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
219518928|NCT05504603|DRUG|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
219518929|NCT01206257|DRUG|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
219518930|NCT06115265|BEHAVIORAL|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
219518931|NCT06115265|BEHAVIORAL|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
218900698|NCT03650088|BEHAVIORAL|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
218900699|NCT04353128|DRUG|Melatonin 2mg|2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
218900700|NCT04353128|DRUG|Placebo oral tablet|Identically looking placebo tablets P.O. before bedtime for 12 weeks
218900701|NCT05114408|OTHER|4 week trimodal prehabilitation course|"trimodal prehabilitation in mixed: stationary and at-home structure"
218900702|NCT05753488|DIAGNOSTIC_TEST|graft function|renal transplantation
218900703|NCT03076762|DRUG|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
218900704|NCT03111836|BEHAVIORAL|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
218900705|NCT03111836|BEHAVIORAL|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
219037388|NCT03712410|BEHAVIORAL|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
219037389|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
219518932|NCT05065879|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
219518933|NCT03752541|BIOLOGICAL|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
218900706|NCT03111836|BEHAVIORAL|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
218900707|NCT05313789|DEVICE|Analgesia Nociception Index (ANI)|Monitorization of Analgesia Nociception Index in Intensive Care Patients
218900708|NCT01730521|BEHAVIORAL|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
218900709|NCT06216067|DEVICE|CALLISTO eye|Cataract toric lens placement tool
218900710|NCT06216067|DEVICE|Wavetec AnalyzOR|Cataract toric lens placement tool
218900711|NCT01425034|OTHER|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
218900712|NCT01425034|OTHER|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
218900713|NCT03679065|DRUG|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
218900714|NCT03679065|DRUG|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
218900715|NCT03679065|DRUG|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
219037390|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
219037391|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
219037392|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
219204230|NCT06879379|DRUG|KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation|After post-transplant randomization, patients will receive either KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation then maintenance or no consolidation and maintenance.
219518934|NCT05557565|DRUG|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
219518935|NCT05287984|DRUG|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
219037393|NCT01573780|OTHER|pharmacological study|Correlative studies
219037394|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
219037395|NCT02048020|DRUG|paclitaxel|Given IV
219037396|NCT02048020|DRUG|carboplatin|Given IV
219037397|NCT02048020|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219037398|NCT02048020|PROCEDURE|quality-of-life assessment|Ancillary studies
219037399|NCT02717481|DEVICE|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
219518936|NCT05287984|DRUG|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
219518937|NCT01302314|BEHAVIORAL|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
219518938|NCT06543524|OTHER|Care of premature infants|No intervention was performed
219518939|NCT00284102|PROCEDURE|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
219518940|NCT04016636|OTHER|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
219518941|NCT03051685|DRUG|DFN-15 Dose 1|
219518942|NCT03051685|DRUG|DFN-15 Dose 2|
219518943|NCT03051685|DRUG|DFN-15 Dose 3|
219518944|NCT03051685|DRUG|Active Comparator|
219037400|NCT04360577|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
219037401|NCT04401917|DRUG|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
219037402|NCT05723016|OTHER|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
219037403|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
219037404|NCT05407246|DRUG|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
219037405|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
219037406|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
219037407|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
219037408|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
219037409|NCT00594464|DRUG|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
219037410|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
219037411|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
218900716|NCT03439501|DRUG|avelumab|"* Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
219518945|NCT04591626|DRUG|Dulaglutide|Administered SC
218900717|NCT01931423|BEHAVIORAL|Placental cord drainage|
218900718|NCT04696081|OTHER|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
218900719|NCT01900795|DRUG|V117957|V117957 4.5 mg suspension taken orally after surgery.
218900720|NCT01900795|DRUG|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
218900721|NCT01900795|DRUG|Placebo|Placebo taken orally after surgery.
218900722|NCT01344902|DRUG|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
218900723|NCT04122365|OTHER|Chest Wall Mobilization Program|Soft tissue therapy and joints mobilization
218900724|NCT04122365|OTHER|Control|Routine limbs exercises and education
218900725|NCT02368665|DRUG|Amlodipine 5mg|\- Daily oral administration for 8 weeks
219037412|NCT01728025|DRUG|Ranolazine|
219518946|NCT04591626|DRUG|Placebo|Administered SC
219518947|NCT04591626|DRUG|Insulin Glargine|Administered SC
219518948|NCT02672553|DEVICE|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
219518949|NCT02672553|DEVICE|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
219518950|NCT03203148|DIAGNOSTIC_TEST|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
219518951|NCT00870922|PROCEDURE|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
218900726|NCT02368665|DRUG|Amlodipine 5mg, Candesartan cilexetil 16mg|\- Daily oral administration Amlodipine 5mg for 8 weeks
219518952|NCT04232150|DRUG|single-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
219612389|NCT06297941|DRUG|REM-422|"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"
219612390|NCT02603146|DRUG|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
218900727|NCT02368665|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|\- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
218900728|NCT01295359|OTHER|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
218900729|NCT00887302|PROCEDURE|Gastric Band|Places a band over the upper portion of the stomach.
218900730|NCT00887302|PROCEDURE|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
218900731|NCT00887302|PROCEDURE|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
218900732|NCT04562454|OTHER|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
218900733|NCT04598022|OTHER|cross-sectional observation|observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester
218900734|NCT04598022|OTHER|cross-sectional follow-up observation|follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
218900735|NCT06256172|DEVICE|Medlink|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
218900736|NCT00510159|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
218900737|NCT00510159|DRUG|Praziquantel|
218900738|NCT06136429|PROCEDURE|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
218900739|NCT01775774|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
218900740|NCT01054105|DRUG|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
218900741|NCT02365649|DRUG|Placebo|Oral Dosing
218900742|NCT02365649|DRUG|ABT-494|Oral Dosing
218900743|NCT03591926|DRUG|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
219037413|NCT04264468|COMBINATION_PRODUCT|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
219037414|NCT03876314|BEHAVIORAL|Physical Activity Condition|Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
219037415|NCT06063148|DEVICE|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
219037416|NCT03594162|DRUG|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
219518953|NCT04232150|DRUG|Double-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
219518954|NCT04232150|PROCEDURE|spinal anesthesia with no sedation.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
218900744|NCT04142034|BEHAVIORAL|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
218900745|NCT04142034|BEHAVIORAL|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
218900746|NCT04142034|OTHER|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
219037417|NCT03594162|DRUG|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
219037418|NCT03594162|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
219518955|NCT03137563|OTHER|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
219612391|NCT02603146|DRUG|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
219037419|NCT03594162|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
219037420|NCT01327352|DRUG|Oshadi D|oral administration
219612392|NCT05343260|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
219612393|NCT05343260|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
218900747|NCT04142034|OTHER|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
219518956|NCT02761096|DEVICE|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
219518957|NCT02761096|OTHER|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
219518958|NCT01353300|GENETIC|DNA analysis|
218900748|NCT04024488|BEHAVIORAL|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
218900749|NCT04024488|BEHAVIORAL|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
218900750|NCT06491602|DIAGNOSTIC_TEST|renal biobsy|analsis of renal biobsy and decide grade of renal affection
219037421|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
219037422|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
219037423|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
219037424|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
219037425|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
219037426|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
218900751|NCT01324661|BEHAVIORAL|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
219037427|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
219037428|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
219037429|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
219037430|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
219037431|NCT06442735|OTHER|intrapartum ultrasound|In IPUS group, the patient's labor was observed by intrapartum ultrasound.
219037432|NCT06442735|OTHER|vaginal examination|In VE group, the patient's labor was observed by vaginal examination.
219518959|NCT01353300|GENETIC|cytogenetic analysis|
219518960|NCT01353300|GENETIC|gene expression analysis|
219518961|NCT01353300|GENETIC|gene rearrangement analysis|
219518962|NCT01353300|GENETIC|mutation analysis|
219518963|NCT01353300|GENETIC|polymerase chain reaction|
219518964|NCT01353300|GENETIC|polymorphism analysis|
219037433|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
219037434|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
219037435|NCT01304745|BEHAVIORAL|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
219037436|NCT01304745|BEHAVIORAL|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
219037437|NCT03131440|BEHAVIORAL|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
219037438|NCT03131440|BEHAVIORAL|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
219037439|NCT03131440|BEHAVIORAL|App+|"Participants will receive deluxe version of smartphone app with additional features."
219037440|NCT03131440|BEHAVIORAL|Online gym|Participants will receive access to online exercise videos.
219037441|NCT03131440|BEHAVIORAL|App notifications|Participants will receive motivational app notifications
219037442|NCT03131440|BEHAVIORAL|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
219037443|NCT03710421|PROCEDURE|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
219037444|NCT03710421|DRUG|Cyclophosphamide|Given IV
219037445|NCT03710421|DRUG|Fludarabine|Given IV
219037446|NCT03710421|PROCEDURE|Leukapheresis|Undergo leukapheresis
219518965|NCT01353300|OTHER|laboratory biomarker analysis|
219518966|NCT01353300|OTHER|medical chart review|
219518967|NCT02740608|DEVICE|OrganOx metra|Normothermic Machine Liver Perfusion
219518968|NCT05290181|OTHER|A support program with pilates exercise and whatsapp text message|Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
218900752|NCT01366001|DRUG|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
218900753|NCT01366001|DRUG|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
218900754|NCT01366001|DRUG|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
218900755|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
218900756|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
218900757|NCT03824041|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
218900758|NCT03546582|DRUG|Pembrolizumab|Anti-PD-1 targeted immunotherapy
218900759|NCT03546582|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
218900760|NCT05184530|DRUG|Evolocumab 140 MG/ML|140 mg per two weeks, subcutaneous injection
218900761|NCT02843906|PROCEDURE|Lombar Punction|cerebrospinal fluid testing at screening and M36
218900762|NCT02843906|RADIATION|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
218900763|NCT02843906|RADIATION|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
218900764|NCT02843906|OTHER|Psychiatric tests|
218900765|NCT02843906|OTHER|Neuropsychological Tests|done at screening, M12, M24 and M36
218900766|NCT02843906|GENETIC|Apolipoprotein (ApoE) detection|ApoE detection done at screening
218900767|NCT05772624|DRUG|low dose nivolumab in combination with AVD|Nivolumab as an standard dose of 40mg in combination with AVD.
218900768|NCT00583336|DEVICE|ShuntCheck|Thermal dilution test for CSF flow
218900769|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (active treatment)|
218900770|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (placebo treatment)|
218900771|NCT03631342|OTHER|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
219037447|NCT03892460|DEVICE|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
219518969|NCT04641936|OTHER|No intervention required|No intervention required
219518970|NCT03314025|DRUG|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
219518971|NCT03314025|DRUG|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
218900772|NCT03631342|OTHER|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
218900773|NCT03631342|OTHER|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
218900774|NCT03631342|OTHER|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
218900775|NCT03631342|OTHER|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
218900776|NCT05041335|OTHER|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
218900777|NCT05041335|OTHER|Microsieve|A microsieve used for tissue preparation
219518972|NCT03314025|DEVICE|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
218900778|NCT05041335|OTHER|No heparin flush|The needle not prepped
218900779|NCT05041335|OTHER|No microsieve|The tissue is placed into formalin
218900780|NCT01603589|PROCEDURE|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
218900781|NCT01603589|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
219037448|NCT01750008|PROCEDURE|Global Fibroid Ablation|
219037449|NCT01750008|PROCEDURE|Myomectomy|
219037450|NCT06541288|DIAGNOSTIC_TEST|AI Prediction Model|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
218900782|NCT03887013|DRUG|Trimetazidine|Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
218900783|NCT00778115|DRUG|Loperamide HCl 2 mg and simethicone 125 mg tablets|
219037451|NCT06541288|DIAGNOSTIC_TEST|Conventional Imageing Assessment|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
219037452|NCT03517527|BEHAVIORAL|Exercise|
219037453|NCT00746941|DRUG|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
219037454|NCT03229824|DEVICE|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
219037455|NCT01011842|PROCEDURE|Radiotherapy|Standard of care
219037456|NCT01011842|PROCEDURE|Align RT|Standard of care
219037457|NCT03316885|DEVICE|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
219037458|NCT03316885|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with unilateral IOL implantation
219037459|NCT00230698|DRUG|topiramate|
219037460|NCT03606954|COMBINATION_PRODUCT|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
219037461|NCT04209309|DEVICE|repetitive transcranial magnetic stimulation|
219037462|NCT02574871|OTHER|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
219037463|NCT05898295|OTHER|no intervention|No intervention: only observation of the child behavior
219518973|NCT01512043|BEHAVIORAL|Breathing control|Practice of device guided breathing control twice a day for four weeks.
219518974|NCT01310049|DRUG|LEO 32731|"* Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days"
219518975|NCT06298656|OTHER|No intervention|It is an observational study.
219518976|NCT03676803|OTHER|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
218900784|NCT00376792|DRUG|docetaxel|
218900785|NCT00376792|OTHER|active surveillance|
218900786|NCT00376792|PROCEDURE|adjuvant therapy|
218900787|NCT02910466|DRUG|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
218900788|NCT04037865|DRUG|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
218900789|NCT05416905|DEVICE|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
218900790|NCT05416905|DEVICE|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
218900791|NCT05177614|DIETARY_SUPPLEMENT|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
219037464|NCT04079478|OTHER|AI|Artificial intellignece colonoscopy
219037465|NCT01102413|DRUG|Monofer|Infusion or injections
219037466|NCT01102413|DRUG|Iron Sulphate|Oral intake
219037467|NCT05923892|DRUG|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
219037468|NCT05923892|DRUG|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
219037469|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
219037470|NCT05257538|OTHER|placebo enema|colored water enema
219037471|NCT05239273|OTHER|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
219037472|NCT05239273|OTHER|Control|No intervention
219037473|NCT03904407|OTHER|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96"
219037474|NCT03904407|OTHER|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
219037475|NCT00262509|DEVICE|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
219037476|NCT04090554|DEVICE|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
219037477|NCT01820455|DRUG|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
219037478|NCT01820455|DRUG|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
219518977|NCT03676803|OTHER|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
219518978|NCT00055783|BIOLOGICAL|apolizumab|
218900792|NCT05177614|DIETARY_SUPPLEMENT|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
218900793|NCT05177614|DIETARY_SUPPLEMENT|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
218900794|NCT00965250|DRUG|IMC-12|20 mg/kg intravenously once every three weeks
218900795|NCT04387513|PROCEDURE|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
218900796|NCT04528160|OTHER|Pain neuroscience education and exercise|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
218900797|NCT04528160|OTHER|Usual Care|Usual care delivered at primary care for older adults with pain.
219037479|NCT02245789|PROCEDURE|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
219037480|NCT02245789|DRUG|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
219037481|NCT02180412|BIOLOGICAL|Panhematin|Glucose loading
219037482|NCT02180412|OTHER|Glucose|Glucose is administered to both groups as routine care.
219204231|NCT06884046|OTHER|Personalized support project|"1. Presence of a child nurse at the consultation of the anesthesiologist-resuscitator.~2. Antenatal paramedical consultation conducted by a child nurse composed of a semi-structured interview and an evaluation of Parental Stress by the ISP-4 self-questionnaire.~3. Implementation of the personalized support project~4. Self-assessment of parental stress using the ISP-4 self-questionnaire (child admitted to intensive care or resuscitation unit)~5. Application of the personalised support project~6. Self-assessment of parental stress using the ISP-4 self-questionnaire (child discharged from intensive care)~7. Paramedical follow-up consultation with parents (semi-directive interview, ISP-4 self-questionnaire) and assessment of the child's psychomotor development in the child's 6th month of life"
218900798|NCT00549315|DEVICE|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
218900799|NCT02221869|DRUG|Xyrem|
218900800|NCT00066677|DRUG|rhuMAB-VEGF|
218900801|NCT00066677|DRUG|docetaxel|
218900802|NCT05774301|BEHAVIORAL|simulation-based training|the training will include a theoretical \& practical parts
218900803|NCT04332107|DRUG|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
218900804|NCT04332107|DRUG|Placebos|Participants will be shipped a dose of matching placebo
218900805|NCT02348593|DRUG|JZP-110|
218900806|NCT02348593|DRUG|Placebo oral tablet|
219204232|NCT06703632|DIAGNOSTIC_TEST|blood sampling|PreveCol test based on blood sampling
219204233|NCT06703632|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
219518979|NCT01849042|DRUG|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
219518980|NCT01849042|DRUG|donepezil|
219518981|NCT02537756|BEHAVIORAL|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
218900807|NCT00879385|DRUG|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
218900808|NCT00879385|DRUG|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
218900809|NCT05775770|DRUG|Insulin|insulin therapy
218900810|NCT05217277|DIAGNOSTIC_TEST|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
218900811|NCT01808196|DRUG|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
218900812|NCT05676112|DRUG|nintedanib|nintedanib
218900813|NCT05676112|DRUG|pirfenidone|pirfenidone
218900814|NCT05297591|OTHER|assessment of UL function and prognostic factors|clinical assessments and questionnaires
219037483|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
219037484|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|"Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells"
219037485|NCT04618120|OTHER|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
219037486|NCT04618120|OTHER|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
219037487|NCT03200678|OTHER|isokinetic assessment|muscle torque assessement
219518982|NCT02253979|DEVICE|Standard double lumen tube|Endotracheal left side double lumen tube
219518983|NCT02253979|DEVICE|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
219518984|NCT00841100|DRUG|Kuvan|20mg/kg by mouth once daily
219518985|NCT00841100|OTHER|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
219518986|NCT01355081|DRUG|Vortioxetine|Vortioxetine tablets
219518987|NCT01355081|DRUG|Placebo|Vortioxetine placebo
219518988|NCT03365726|DIAGNOSTIC_TEST|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
219518989|NCT04807270|OTHER|Intra-articular T-LAB / PRP KIT injection|Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
218900815|NCT02290015|OTHER|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
218900816|NCT03035799|OTHER|Paleolithic diet|Paleolithic diet
218900817|NCT03035799|OTHER|General Healthful Diet|General Healthful Diet
219037488|NCT06045039|OTHER|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
219518990|NCT04807270|OTHER|Intra-articular T-LAB / PRP INJECTION SYRINGE injection|Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
219518991|NCT04807270|OTHER|Intra-articular SALINE injection|Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
219518992|NCT02968888|OTHER|Strength training|
219518993|NCT02968888|DIETARY_SUPPLEMENT|Milk 1%|
218900818|NCT01366989|DEVICE|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
218900819|NCT04187495|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
219037489|NCT04154228|DIAGNOSTIC_TEST|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
219518994|NCT02968888|DIETARY_SUPPLEMENT|Whey protein concentrate 80|
219518995|NCT02968888|DIETARY_SUPPLEMENT|Native whey|
219518996|NCT06033482|PROCEDURE|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
219518997|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
219518998|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
219518999|NCT01475474|DEVICE|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
219519000|NCT01333527|PROCEDURE|No Sling|Early range of motion
218900820|NCT03216408|DRUG|Neuronox|
218900821|NCT03216408|DRUG|Botox|
218900822|NCT00271102|PROCEDURE|anterior vaginal repair (colporrhaphy)|vaginal repair
218900823|NCT00271102|PROCEDURE|abdominal paravaginal defect repair|abdominal repair
218900824|NCT00479713|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
219037490|NCT06390228|PROCEDURE|Major hepatectomy|the extent of liver resection
219037491|NCT01335958|DRUG|DMUC5754A|Escalating intravenous dose
219037492|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
219519001|NCT01333527|PROCEDURE|Sling|Patients will use the sling for 6 weeks, as per usual care
218900825|NCT00479713|DRUG|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
218900826|NCT00479713|DRUG|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
218900827|NCT00479713|DRUG|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
218900828|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
218900829|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
218900830|NCT02664662|OTHER|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
219037493|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
219037494|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
219519002|NCT06081647|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
219519003|NCT06081647|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
218900831|NCT02226718|OTHER|Administration of questionnaire|
218900832|NCT00200330|BEHAVIORAL|Behavioral weight loss treatment|
218900833|NCT00200330|BEHAVIORAL|Behavioral and home environment weight loss treatment|
218900834|NCT02952885|DRUG|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
218900835|NCT00141102|DRUG|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
218900836|NCT00141102|DRUG|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
218900837|NCT03863509|BEHAVIORAL|Cigarettes|smokes daily
218900838|NCT03863509|BEHAVIORAL|E-Cigarettes|E-cigarette usage \>/= 5 days/week
218900839|NCT03549221|DRUG|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
218900840|NCT05455476|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
219037495|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
219519004|NCT01868009|DEVICE|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
219519005|NCT01868009|DEVICE|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
219037496|NCT00184262|BEHAVIORAL|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
219037497|NCT00184262|BEHAVIORAL|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
219037498|NCT02739269|OTHER|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
218900841|NCT05455476|BEHAVIORAL|CBT for Chronic Pain|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
218900842|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
219037499|NCT02739269|OTHER|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
219037500|NCT02237846|BIOLOGICAL|Human umbilical cord tissue-derived mesenchymal stem cells|
219037501|NCT01914224|BEHAVIORAL|dietary education of low sodium and high potassium consumption|
218900843|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
218900844|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
218900845|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
219037502|NCT01914224|BEHAVIORAL|dietary education of low sodium consumption only|
219037503|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
219037504|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
219037505|NCT04766242|OTHER|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
219037506|NCT04766242|OTHER|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
219519006|NCT01276782|DRUG|Levothyroxine|It is FDA approved drug for thyroid disease
219519007|NCT06004609|DEVICE|Low-level laser therapy (LLLT)|Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
219519008|NCT06004609|OTHER|Conventional physical therapy|Conventional physical therapy will be applied three time each week, for 12 weeks
218900846|NCT04508049|DEVICE|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
218900847|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
218900848|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
218900849|NCT04186767|DIETARY_SUPPLEMENT|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
218900850|NCT05676502|DEVICE|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
218900851|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
218900852|NCT06666088|OTHER|Cognitive stimulation and Strength training|"The experimental group will participate in a 12-week program to enhance cognitive functions and physical strength through twice-weekly sessions of 45 minutes to 1 hour. Cognitive stimulation activities will improve memory, attention, processing speed, and executive functions through memory games, recall exercises, and tasks that promote focus and quick thinking. Each session will be led by a neuropsychology or occupational therapy professional who will tailor activities to individual needs.~Strength training will also occur twice a week, focusing on exercises that strengthen major muscle groups, improve balance, and enhance coordination. Participants will use light weights, resistance bands, and bodyweight exercises, with modifications based on their physical levels. A specialized trainer will supervise the program, progressively adjusting exercise intensity to ensure safety and optimize benefits."
218900853|NCT06577597|DRUG|GSK3923868|Participants will receive single dose of GSK3923868.
218900854|NCT06577597|DRUG|Placebo|Participants will receive single dose of Placebo.
218900855|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
218900856|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
218900857|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
218900858|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
218900859|NCT03254199|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
218900860|NCT03254199|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
219037507|NCT03216850|DEVICE|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
219037508|NCT01391481|DRUG|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
219037509|NCT01391481|DRUG|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
219037510|NCT02948491|OTHER|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
219519009|NCT00165399|DRUG|Docetaxel|Given intravenously on day 2 of four three-week cycles
218900861|NCT06579950|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
219037511|NCT02347748|BEHAVIORAL|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
219037512|NCT02347748|BEHAVIORAL|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
219037513|NCT02347748|BEHAVIORAL|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
219037514|NCT00228345|PROCEDURE|Optical coherence tomography,Fluorescein angiography|
219037515|NCT05926167|DIAGNOSTIC_TEST|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
219204234|NCT06703632|OTHER|Survey using a questionnaire.|PREMs for colorectal cancer screening programme
219519010|NCT00165399|DRUG|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
219519011|NCT00165399|DRUG|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
219519012|NCT00165399|DRUG|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
218900862|NCT04315233|DRUG|Ribociclib|Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28
219519013|NCT00001805|DRUG|Rituximab|
219519014|NCT03493100|DIETARY_SUPPLEMENT|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
218900863|NCT04315233|DRUG|Belinostat|"Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules."
218900864|NCT06665438|DRUG|Normal Saline (Placebo)|the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
218900865|NCT06665438|DRUG|Bupivacaine 0.25%|the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
218900866|NCT06665438|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
218900867|NCT06151522|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
218900868|NCT06151522|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
218900869|NCT06939348|DEVICE|The Brainsonix BX Pulsar 1002 was designed to deliver low-intensity focused ultrasound pulsations (LIFUP) to the human brain.|The BX Pulsar 1002 consists of two main elements: the transducer and the ultrasound console. The transducer itself and the housing for it went through several iterations in order to be compatible with an MRI environment. Currently, the transducer and its housing are deemed MR-conditional at 3T with SAR ≤ 2W/kg. The design includes a solid acoustic coupling gel pad attached to the front of the transducer to provide good acoustic transmission into the scalp. An outer housing was designed to attach the transducer firmly to the head above the temporal window, and to allow it to be moved side to side to accurately target intended structures.
219037516|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
219037517|NCT06165835|DEVICE|breathing training|Breathing training for six weeks.
218900870|NCT06938334|GENETIC|Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA|The intervention is intended for newly diagnosed T1D patients with residual beta-cell function, who can receive the Drug Product (DP) within 180 days from the first insulin administration. Mobilized autologous HSPCs, collected by leukapheresis, are ex vivo transduced with a LVV encoding for hPD-L1 and formulated in a cryopreservation medium containing DMSO (DP). After release, the DP is thawed and administered to the patient at a dose ranging between 5 and 20 million of cells per kilogram of body weight. The intervention plans for a single DP injection.
218900871|NCT06939452|DRUG|anlotinib +TQB2450 + Oxaliplatin+S-1|"Anlotinib: 10mg, po, d1-14,q3w,until disease progression or unacceptable toxicity.~TQB2450: 1200mg, iv, d1, q3w,until disease progression or unacceptable toxicity. Oxaliplatin: 130mg/㎡, iv, d1,6 cycles.~S-1:40mg, po, bid, d1\~14,6 cycles."
218900872|NCT06937697|DRUG|Test toothpaste|A commercially available fluoride toothpaste
218900873|NCT06937697|DRUG|Control toothpaste|A commercially available fluoride toothpaste
218900874|NCT06938958|OTHER|Video and Motion Analysis|"1. Measurements of joint angle, body segment position, static and dynamic postures and posture duration.~2. Video of Surgeon and Procedure."
218900875|NCT06939270|BIOLOGICAL|CD73/AXL.HypoSti.CAR-T cells|Dose escalation: Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg); Dose expansion: RP2D.
218900876|NCT06939270|DRUG|Albumin-Bound Paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5 .
218900877|NCT06939270|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2 .
218900878|NCT06939270|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2.
218900879|NCT06937684|BEHAVIORAL|Early Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 1 hour after anesthesia.
218900880|NCT06937684|BEHAVIORAL|Traditional Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 2 hours after anesthesia.
218900881|NCT06937554|OTHER|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters
219037518|NCT03190889|OTHER|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
219037519|NCT03190889|OTHER|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
219037520|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
219037521|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
219037522|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
219519015|NCT03493100|OTHER|Usual care|The control group will receive treatment according to usual care.
219519016|NCT04895111|DIAGNOSTIC_TEST|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
219519017|NCT00205049|DRUG|pentoxifylline|daily dosing
219519018|NCT04770961|PROCEDURE|Erector spinae plane catheter with 0.5% Ropivacaine|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.
219612394|NCT06476730|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased
219612395|NCT06476730|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
218900882|NCT06200753|PROCEDURE|Mechanical Thrombectomy|"Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury."
219612396|NCT01546818|BIOLOGICAL|SAV001-H|A whole-killed HIV
219612397|NCT00944099|BEHAVIORAL|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
219612398|NCT02670616|DRUG|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
218900883|NCT06937489|DEVICE|Hydrogel conventional toric lenses with -10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
218900884|NCT06937489|DEVICE|Hydrogel conventional toric lenses with +10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
218900885|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 0.5 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
218900886|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 1.0 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
218900887|NCT06938087|DEVICE|3D printed prosthesis foot|Energy storage and restoration 3D printed prosthesis foot
218900888|NCT06938087|DEVICE|Current prosthesis foot|Energy storage and restitution prosthesis foot made in carbon fibers blades
219037523|NCT02306135|OTHER|n/a- this is an observational study|
219037524|NCT00405548|DRUG|BNP (nesiritide)|
219037525|NCT00405548|DRUG|Placebo|
219037526|NCT03554291|DRUG|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
219612399|NCT02670616|DRUG|Rituximab|375 mg/m2 IV, day 1
219612400|NCT02670616|DRUG|Cyclophosphamide|750 mg/m2 IV day 1
219612401|NCT02670616|DRUG|Doxorubicin|50 mg/m2 IV day 1
219612402|NCT02670616|DRUG|vincristine|1.4 mg/m2 IV on day 1
219612403|NCT02670616|DRUG|Prednisolone|100mg per day on day 1-5
219612404|NCT00102219|DRUG|Pemetrexed|
219612405|NCT00102219|DRUG|Doxorubicin|
219612406|NCT01813617|DRUG|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
219612407|NCT00696423|BIOLOGICAL|Infanrix™|Intramuscular injection, one dose
219612408|NCT00696423|BIOLOGICAL|Hiberix™|Intramuscular injection, one dose
219612409|NCT03075371|OTHER|Glucose|75 g of glucose dissolved in 300 ml of water
219612410|NCT03075371|OTHER|Placebo|300 ml of tap water
219612411|NCT02897778|DRUG|Entinostat|Single, supratherapeutic dose of entinostat given orally.
219612412|NCT02897778|DRUG|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
219613425|NCT04481035|DRUG|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
219612413|NCT03444311|DIETARY_SUPPLEMENT|A: 1 dosis|"1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
219612414|NCT03444311|DIETARY_SUPPLEMENT|B: 2 dosis|"1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
219612415|NCT02069639|OTHER|no treatment|
218900889|NCT06938178|OTHER|Mindfulness treatment|The Mindfulness treatment will consist of a series of 8 weekly meetings in small groups . An experienced therapist will guide patients and during the sessions they will be encouraged to close their eyes, assume a relaxed posture, focus on breathing and the present moment in order to improve awareness of mental and bodily sensations. Patients will also be encouraged to add a regular, practice at home of about 10 minutes to the group treatment. If necessary, patients in both groups can take the medication they normally take for acute events. These occurrences will be reported in the headache diary given to each subject. Before conducting the study protocol, the investigator will explain the study to each participant and collect a signed copy of the written informed consent. All participants will undergo a clinical, neurophysiological and neuropsychological evaluation before the first session and after the last. In both groups, the usual drug therapies in case of crisis will be allowed.
218900890|NCT06937515|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
218900891|NCT06938711|DRUG|Elacestrant|Elacestrant 200mg once daily oral dosing in cycles of 28 days.
218900892|NCT06938711|DRUG|Onapristone|Onapristone 40mg twice daily oral dosing in cycles of 28 days.
218900893|NCT06938815|OTHER|Pigment Balancing Peel|Chemical Peel
218900894|NCT06938815|OTHER|Discoloration Defense Serum|Dark spot correcting serum
218900895|NCT06938815|OTHER|LHA Cleansing Gel|exfoliating gel facial cleanser
218900896|NCT06938815|OTHER|Hydrating B5 Gel|Vitamin B5 serum with hyaluronic acid
218900897|NCT06938815|OTHER|Daily Brightening Sunscreen|daily moisturizing sunscreen SPF 30
218900898|NCT00866814|DEVICE|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
218900899|NCT06938360|PROCEDURE|breast-conserving surgery combined with radiotherapy|The experimental group received breast-conserving surgery combined with radiotherapy
218900900|NCT06939387|OTHER|Observational study, no intervention|Observational study, no intervention
218900901|NCT06937567|BIOLOGICAL|CDH17 CAR-T|The initial dose of cell therapy in this clinical study was set at 1.0×106/Kg and the maximum dose was set at 6.0×106/Kg.
218900902|NCT03842670|BEHAVIORAL|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
218900903|NCT03842670|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
218900904|NCT00765804|DRUG|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
218900905|NCT00765804|DRUG|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
219612416|NCT03989102|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
218900906|NCT02001935|DRUG|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
219204235|NCT06880094|GENETIC|blood withdrawal|blood withdrawal for genetic testing
218900907|NCT00001146|DRUG|Ethyl Eicosapentaenoic Acid|
218900908|NCT00001146|DRUG|OmegaBrite|
219204236|NCT06881238|OTHER|History of IBD course and outcome in HBV patients|"Full history taking including:~* Personal history (name, age, sex, occupation, residence, and marital state).~* Complaint.~* Age at diagnosis of IBD.~* Medication history.~* History of hospital admissions and disease flares.~* Disease extent, location, and behavior. (Montreal classification, Truelove-Witts severity index).~* Surgical history (intestinal resection in CD patients and total proctocolectomy in UC patients).~* Follow up duration and mortality.~* Data of endoscopic examination~* Data of laboratory investigations (complete blood picture, HBV serology, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP))."
219519019|NCT04770961|PROCEDURE|Erector spinae plane catheter with saline|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
219519020|NCT05847699|OTHER|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
219612417|NCT03989102|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
219612418|NCT03642262|DRUG|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
219612419|NCT00000520|DRUG|immunoglobulins, intravenous|
219612420|NCT00000520|DRUG|aspirin|
219612421|NCT06150586|OTHER|Skin Conductance (SC) Measurement|SC will be measured using a specific monitor and three self-adhesive electrodes on one foot of the infant (one plantar and two on the ankles). Peaks per second (the rate of firing in the sympathetic nerves), average amplitude (mean peaks) and area under curve (forcefulness of sympathetic nerve firing) will be automatically analyzed. Corresponding data will be transferred to a separate tablet computer via bluetooth.
218900909|NCT02145117|BEHAVIORAL|MBSR|Behavioral
218900910|NCT01663012|DRUG|Etirinotecan pegol|
218900911|NCT01202630|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
218900912|NCT01202630|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
218900913|NCT05030168|DRUG|Ketosteril|ketoanalogues of essential amino acid
218900914|NCT04767503|DRUG|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
218900915|NCT04767503|DRUG|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
218900916|NCT01154777|BEHAVIORAL|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
218900917|NCT01385657|DRUG|Placebo|A total of 4 doses were administered.
219519021|NCT03319498|OTHER|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
219612422|NCT06150586|OTHER|Video Recording|The video recording for later N-PASS assessment will be done by a camera fixed above the incubator / resuscitation unit, not interfering with the LISA procedure. The video will show the full body of the newborn as well as the hands / forearms of the treating clinical team with the awareness and oral consent of the treating team.
218900918|NCT01385657|DRUG|Dupilumab|A total of 4 doses were administered.
218900919|NCT01385657|OTHER|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
218900920|NCT00556816|BEHAVIORAL|on demand clinic|Outpatient on demand clinic
218900921|NCT00556816|BEHAVIORAL|Control|conventional outpatient clinic
218900922|NCT05899374|BEHAVIORAL|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
218900923|NCT03787797|DIAGNOSTIC_TEST|Echocardiography|Assessment of epicardial adipose tissue thickness
218900924|NCT05958849|DRUG|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
218900925|NCT01630291|DEVICE|Electrode device|Lacrimal gland stimulation
218900926|NCT06422013|DIETARY_SUPPLEMENT|GTB1|oral administration of GTB1 powder packet once daily
219519022|NCT03319498|OTHER|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
219519023|NCT04803357|DEVICE|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
219519024|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
218900927|NCT06422013|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo powder packet once daily
218900928|NCT01063153|DRUG|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
218900929|NCT05708456|OTHER|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
218900930|NCT04304872|BEHAVIORAL|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
219037527|NCT03554291|OTHER|Placebo|Placebo capsule taken daily for 24 weeks.
219519025|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
219519026|NCT05209841|DRUG|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
218900931|NCT04304872|BEHAVIORAL|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
219519027|NCT05209841|DRUG|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
218900932|NCT00411255|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
218900933|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
218900934|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
219519028|NCT02608853|OTHER|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
218900935|NCT05154253|OTHER|Standard gait training|Standard gait training without a device.
218900936|NCT05154253|DEVICE|Ankle foot orthosis|Standard ankle foot orthosis
219519029|NCT05197907|PROCEDURE|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
219519030|NCT05197907|PROCEDURE|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
218900937|NCT05154253|OTHER|Standard physical therapy|Physical therapy without a device.
218900938|NCT05154253|OTHER|Standard walking|Walking without a device
218900939|NCT02607943|DRUG|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
218900940|NCT02607943|DRUG|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
218900941|NCT06262724|PROCEDURE|Breast auto-augmentation|Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
218900942|NCT02753166|DRUG|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
219519031|NCT03246295|OTHER|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
218900943|NCT03974048|DIAGNOSTIC_TEST|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
218900944|NCT01773681|DRUG|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
218900945|NCT01773681|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
218900946|NCT01773681|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
218900947|NCT00585481|PROCEDURE|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
219037528|NCT03465618|DRUG|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
218900948|NCT00585481|PROCEDURE|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
218900949|NCT02741622|BEHAVIORAL|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
219519032|NCT03526965|OTHER|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
219519033|NCT03526965|DRUG|Usual care|Intervention included pain medications and exercise movements for neck.
218900950|NCT02741622|BEHAVIORAL|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
219519034|NCT00315549|DRUG|Telithromycin|
219519035|NCT00315549|DRUG|Penicillin|
219612423|NCT04142736|OTHER|Prone Position|The best-fitting and most-tolerated oxygen interface will be used in the prone position--this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV). The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation. After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.
219612424|NCT00242138|BEHAVIORAL|Erectile Dysfunction|
219612425|NCT01783990|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
219612426|NCT00001041|BIOLOGICAL|rgp120/HIV-1MN|
219612427|NCT03063788|DRUG|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
219612428|NCT05285423|PROCEDURE|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
219612429|NCT02203357|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
218900951|NCT02836912|OTHER|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
218900952|NCT00670553|DRUG|panobinostat|
218900953|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
218900954|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
218900955|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
218900956|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
219037529|NCT03465618|OTHER|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
219519036|NCT04782609|DRUG|Icapamespib|to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.
219519037|NCT04930081|BEHAVIORAL|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
219519038|NCT04323670|DEVICE|"Selectra 3D guiding catheter"|His lead measurements
219519039|NCT00372788|DRUG|AZD6244|oral vial
219519040|NCT00372788|DRUG|Pemetrexed|oral
219519041|NCT02914795|OTHER|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
219519042|NCT03301909|DEVICE|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
219612430|NCT04696536|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
219612431|NCT04696536|OTHER|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
219612432|NCT04696536|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
218900957|NCT04481243|BIOLOGICAL|Pneumovax 23- pneumococcal polysaccharide|PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
219519043|NCT03301909|DRUG|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
218900958|NCT04481243|PROCEDURE|Blood draw|6 ml blood draw at baseline and 6 months post immunization
218900959|NCT05669859|PROCEDURE|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
218900960|NCT01131988|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
218900961|NCT04434079|OTHER|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
218900962|NCT00786292|OTHER|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
218900963|NCT02191462|DIETARY_SUPPLEMENT|Niagen 100mg|
218900964|NCT02191462|DIETARY_SUPPLEMENT|Niagen 300mg|
218900965|NCT02191462|DIETARY_SUPPLEMENT|Niagen 1000mg|
218900966|NCT02831764|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
218900967|NCT02831764|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
219037530|NCT01394679|DRUG|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
219519044|NCT03438448|OTHER|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
219519045|NCT04353908|PROCEDURE|Rehabilitation|The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks
218900968|NCT02831764|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
219037531|NCT01394679|DRUG|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
219037532|NCT01452607|DRUG|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
219037533|NCT01452607|DRUG|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
219612433|NCT04696536|OTHER|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
219612434|NCT04696536|OTHER|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
219612435|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
219612436|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
219612437|NCT06581315|DRUG|Donafenib|Donafenib 100 mg twice daily (BID)
219612438|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single low dose on day 1 following protocol requirements.
219612439|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single high dose on day 1 following protocol requirements.
218900969|NCT00004858|BIOLOGICAL|B43-genistein immunoconjugate|
218900970|NCT05360927|DRUG|BDB-001 injection|Intravenous injection
218900971|NCT05360927|DRUG|Placebo|Intravenous injection
218900972|NCT01638455|DEVICE|Noninvasive device|Noninvasive device
218900973|NCT04564846|DRUG|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
218900974|NCT04564846|OTHER|Placebo|Placebo capsule (Fish Oil)
218900975|NCT06136780|OTHER|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
218900976|NCT00157885|DRUG|Amodiaquine plus artesunate; Artekin|
219519046|NCT04353908|PROCEDURE|Collagen Injection|With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
219612440|NCT03182426|DRUG|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
219612441|NCT03182426|DRUG|Alemtuzumab|T-cell depletion
219612442|NCT03182426|DRUG|Anakinra|Anti-inflammatory
219612443|NCT03182426|DRUG|Etanercept|Anti-inflammatory
219612444|NCT03182426|DRUG|Liraglutide|Beta-cell regeneration
219612445|NCT01050530|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
219612446|NCT01050530|DRUG|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
219612447|NCT02288312|DRUG|BIA 2-093|
218900977|NCT04745364|BEHAVIORAL|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
218900978|NCT02933788|DRUG|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
218900979|NCT02933788|DRUG|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
218900980|NCT00471692|DRUG|Ropivicaine|
218900981|NCT03306667|DRUG|FYU-981|Oral single dosing
219519047|NCT01046253|DRUG|Lansoprazole|30 mg Delayed-Release Capsules
219612448|NCT03965195|BIOLOGICAL|Recombinant Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
219612449|NCT03965195|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
219612450|NCT01276041|DRUG|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
219612451|NCT01366118|DRUG|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
219612452|NCT05087225|BIOLOGICAL|polyethelyene glycol|the excipients at covid-19 vaccines
218900982|NCT04967976|PROCEDURE|TiLoop Bra mesh in expander-implant breast reconstrution|The tissue expander is inserted with TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral.
218900983|NCT04967976|PROCEDURE|sub-pectoral expander-implant breast reconstruction|The tissue expander is inserted without TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
218900984|NCT04633668|BEHAVIORAL|CBT for parasomnias (CBT-p)|Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
218900985|NCT04633668|BEHAVIORAL|Self-Monitoring|Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
218900986|NCT06237582|PROCEDURE|epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
218900987|NCT02574403|DRUG|eculizumab|eculizumab discontinuation
218900988|NCT04277559|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
218900989|NCT04277559|OTHER|Classical music|Patients will listen to classical music through headphones before surgery.
218900990|NCT04277559|OTHER|No music|Patients will not listen to music.
219519048|NCT01046253|DRUG|Prevacid®|30 mg Delayed-Release Capsule
219519049|NCT04081480|DRUG|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
219612453|NCT01950221|DIETARY_SUPPLEMENT|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
219612454|NCT01950221|OTHER|Placebo|
219612455|NCT03888846|DRUG|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
219612456|NCT03888846|DRUG|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
219612457|NCT03843060|DRUG|AZD9977|Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
219612458|NCT03843060|DRUG|Itraconazole|Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
219612459|NCT00461916|DRUG|Half-Dose Depot Triptorelin|
219612460|NCT00461916|DRUG|Reduced-Dose Daily Buserelin|
219612461|NCT06294717|OTHER|Progressive relaxation exercises will be applied.|Progressive relaxation exercises will be not applied.
218900991|NCT02216669|DRUG|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
218900992|NCT00027170|DEVICE|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
218900993|NCT05195229|DEVICE|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
218900994|NCT03111563|OTHER|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
218900995|NCT00831961|PROCEDURE|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
218900996|NCT00708292|DRUG|AUY922|
218900997|NCT00708292|DRUG|Bortezomib|
219519050|NCT06101121|DEVICE|Lubri-Cream|Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
219519051|NCT01271439|DRUG|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
219519052|NCT05131126|PROCEDURE|Latarjet method|This operation consists of fixing a bone graft
219519053|NCT05131126|OTHER|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
219519054|NCT03703063|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
219519055|NCT03703063|DRUG|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
219519056|NCT03703063|DRUG|Onivyde|Administered by intravenous infusion over 90 minutes.
219519057|NCT03703063|DRUG|Leucovorin|Administered by intravenous infusion over 30 minutes.
219519058|NCT03703063|DRUG|5-fu|Administered by intravenous infusion over 46 hours.
219519059|NCT02339909|BEHAVIORAL|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
219519060|NCT02339909|BEHAVIORAL|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
219519061|NCT02339909|BEHAVIORAL|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
218900998|NCT00708292|DRUG|Dexamethasone|
218900999|NCT00884364|OTHER|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
218901000|NCT00884364|BEHAVIORAL|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
218901001|NCT04380506|PROCEDURE|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
218901002|NCT00908986|DRUG|Rituximab|375mg/m2 q week x 4; repeated in 6 months
218901003|NCT04277949|DEVICE|Erbium:YAG|Treatment with Erbium:YAG laser
218901004|NCT04277949|DRUG|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
218901005|NCT02454790|RADIATION|Radiotherapy|
218901006|NCT02908022|DEVICE|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
219037534|NCT02473354|DRUG|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
219519062|NCT02703610|DRUG|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
219519063|NCT02703610|DRUG|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
219519064|NCT00855283|DRUG|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
218901007|NCT02908022|DEVICE|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
218901008|NCT01647165|DRUG|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
218901009|NCT01647165|DRUG|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
219519065|NCT00855283|DRUG|IN NEO|40 mg Neostigmine via intranasal administration
218901010|NCT01647165|DRUG|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
219037535|NCT02473354|DRUG|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
219519066|NCT00855283|DRUG|IN NEO|60 mg Neostigmine via intranasal administration
219519067|NCT00855283|DRUG|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
219519068|NCT00855283|DRUG|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
219519069|NCT00981305|DRUG|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
219519070|NCT00981305|DRUG|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
219519071|NCT03086356|DRUG|Dabigatran etexilate|Days 1-4 and Day 8-11
219519072|NCT03086356|DRUG|Idarucizumab|Day 11
219519073|NCT03536624|BEHAVIORAL|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
219519074|NCT05112328|DRUG|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
219519075|NCT05112328|DRUG|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
219519076|NCT06597149|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
219612462|NCT01776710|BEHAVIORAL|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
219612463|NCT04989543|DIAGNOSTIC_TEST|vaginal swabs|"Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab"
219612464|NCT03936036|DRUG|Linagliptin|Linagliptin dispensing claim is used as the exposure
219612465|NCT03936036|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
218901011|NCT02893566|BEHAVIORAL|Mi Band Step Challenge|
219612466|NCT01332487|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
219612467|NCT03469232|DRUG|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
218901012|NCT02718079|BIOLOGICAL|Plasma Exchange|
218901013|NCT02718079|OTHER|Management of cerebral edema/intracranial hypertension:|
218901014|NCT02718079|OTHER|Transfer to Intensive Care Unit|
218901015|NCT02718079|DRUG|Prophylactic Antibiotics|
218901016|NCT02718079|OTHER|Intubation of trachea|
218901017|NCT02718079|OTHER|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
219037536|NCT02473354|DRUG|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
219037537|NCT00680901|DRUG|Lapatinib|5 pills at 250mg each once daily
219037538|NCT00680901|DRUG|Placebo|5 pills once daily
219037539|NCT00680901|DRUG|Capecitabine|1700mg/m2/day in two daily doses
219519077|NCT03194035|BIOLOGICAL|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
218901018|NCT02718079|OTHER|Volume Replacement|
218901019|NCT02718079|OTHER|Pressor Support|
218901020|NCT02718079|DRUG|N-acetyl-L-cysteine|
218901021|NCT02718079|OTHER|Correction of metabolic parameters|
219037540|NCT00680901|DRUG|Oxaliplatin|130mg/m2 on day 1
219037541|NCT05020392|DRUG|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
218901022|NCT02718079|DIETARY_SUPPLEMENT|Correction of nutrition|
218901023|NCT06211439|DEVICE|real transcranial alternating current stimulation|The alternating current was non-invasively delivered using an M×N five-channel high-definition transcranial electrical current stimulator (Soterix Medical). A BrainCap (Brain Vision) embedded with high-definition plastic holders consisted of five 12-mm-diameter Ag/AgCl ring electrodes, filled with conductive gel. During real HD-tACS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
218901024|NCT06211439|DEVICE|sham transcranial alternating current stimulation|For the sham condition(sham HD-tACS), the same electrode placement was used as in the stimulation condition, but the current was only applied during the first and last 30 seconds of the entire 20-minute stimulation period.
218901025|NCT05359172|DRUG|Tranexamic acid|preoperative intravenous infusion
218901026|NCT03900494|DEVICE|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
218901027|NCT03900494|DEVICE|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
218901028|NCT04822675|PROCEDURE|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
218901029|NCT04822675|PROCEDURE|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
218901030|NCT01100866|DIETARY_SUPPLEMENT|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
218901031|NCT01100866|OTHER|Placebo|placebo capsules
218901032|NCT01279434|DRUG|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
218901033|NCT01279434|DRUG|Vitamin E|Vitamin E 400 mg BD daily for 12 months
218901034|NCT03737123|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
218901035|NCT03737123|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
219037542|NCT05020392|DRUG|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
219037543|NCT06095323|DEVICE|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
219037544|NCT00974012|DRUG|Divalproex Sodium|500 mg ER Tablet
219519078|NCT03202758|DRUG|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
219519079|NCT01365962|GENETIC|gene expression analysis|
219612468|NCT00738387|DRUG|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
219612469|NCT00738387|DRUG|Placebo|Placebo i.v. on day 1 of each 21 day cycle
219612470|NCT00738387|DRUG|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
218901036|NCT03737123|DRUG|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
218901037|NCT03737123|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
218901038|NCT00633971|OTHER|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
219037545|NCT00974012|DRUG|Depakote®|500 mg ER Tablet
219037546|NCT01408979|DRUG|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
219037547|NCT01408979|DRUG|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
219037548|NCT00725218|DRUG|Saline|Saline 5 ml injection 10 min prior to propofol administration.
219519080|NCT01365962|OTHER|immunohistochemistry staining method|
219612471|NCT03593837|DRUG|Huang qi gui zhi wu wu granule|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
219612472|NCT03593837|DRUG|Huang qi gui zhi wu wu granule placebo|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
219612473|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
218901039|NCT01715181|OTHER|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
218901040|NCT05385666|OTHER|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
218901041|NCT05914948|DEVICE|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
219037549|NCT00725218|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
219037550|NCT03559140|PROCEDURE|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
219037551|NCT03559140|PROCEDURE|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
219519081|NCT01365962|OTHER|laboratory biomarker analysis|
219519082|NCT01365962|OTHER|mass spectrometry|
219519083|NCT01994525|BIOLOGICAL|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
219519084|NCT01994525|BIOLOGICAL|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
219519085|NCT01994525|OTHER|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
219519086|NCT00060905|DRUG|Divalproex Sodium (Depakote ER)|
219519087|NCT04183231|DRUG|Anti-caries varnish|topical tooth varnish
218901042|NCT00500617|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
218901043|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
218901044|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
218901045|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
219037552|NCT03559140|PROCEDURE|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
219037553|NCT02251951|DRUG|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
219037554|NCT00923559|OTHER|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
219037555|NCT00923559|OTHER|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
219037556|NCT03189615|DRUG|Lu AF35700|Single oral dose of 10 mg Lu AF35700
219037557|NCT00494832|DRUG|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
219037558|NCT00494832|DRUG|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
219037559|NCT02436421|OTHER|Best Practice Alert based in the Electronic Medical Record|
219037560|NCT00430560|BEHAVIORAL|cognitive rehabilitation|computer training
219037561|NCT00430560|PROCEDURE|work therapy|opportunity to work in carefully supervised hospital job
218901046|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
218901047|NCT02386020|DRUG|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
218901048|NCT02386020|DRUG|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
218901049|NCT04607486|DIAGNOSTIC_TEST|3DfUS and IPSA of leg muscles|"1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
218901050|NCT03460886|DEVICE|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
218901051|NCT03460886|DEVICE|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
219037562|NCT00430560|BEHAVIORAL|work therapy|work therapy
219037563|NCT04530006|DIAGNOSTIC_TEST|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
219519088|NCT00860028|DRUG|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
219519089|NCT00860028|DRUG|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
218901052|NCT03460886|OTHER|Walking on treadmill|walking on treadmill for 10 minutes
218901053|NCT00273338|DRUG|calcitriol|
218901054|NCT00273338|DRUG|docetaxel|
218901055|NCT02173769|DRUG|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
218901056|NCT02173769|DRUG|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
218901057|NCT03382886|DRUG|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
219037564|NCT01625455|DRUG|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
219037565|NCT01625455|DRUG|Placebo|Placebo will be given orally for a total of 7 days.
218901058|NCT03382886|DRUG|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
219037566|NCT02034461|DEVICE|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
219037567|NCT02120976|DRUG|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
219037568|NCT02120976|DRUG|JTT-252|Subjects will receive JTT-252
218901059|NCT04388111|DRUG|Morphine|10mg of Morphine delivered Intraosseously
218901060|NCT02490436|DRUG|Cetuximab|Randomized cross-over between cetuximab and placebo
218901061|NCT02490436|DRUG|Placebo|Randomized cross-over between cetuximab and placebo
218901062|NCT03534609|DEVICE|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
219037569|NCT04926532|DRUG|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
219037570|NCT04926532|DRUG|Sorafenib|Sorafenib is a multi-kinase inhibitor
218901063|NCT02832544|DRUG|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
219037571|NCT01148511|DRUG|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
219037572|NCT00002627|BIOLOGICAL|filgrastim|
219037573|NCT00002627|DRUG|carboplatin|
219037574|NCT00002627|DRUG|cyclophosphamide|
219037575|NCT00002627|DRUG|mesna|
219037576|NCT00002627|DRUG|paclitaxel|
219037577|NCT00002627|PROCEDURE|peripheral blood stem cell transplantation|
219037578|NCT02963337|DRUG|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
219612474|NCT00485264|DRUG|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
219612475|NCT00485264|DRUG|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
219612476|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
219612477|NCT01324778|DEVICE|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
218901064|NCT02832544|DRUG|Vitamin K antagonists (VKA)|
218901065|NCT00132574|BEHAVIORAL|Minimization of milk and dairy products in the diet|
218901066|NCT00915954|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
219037579|NCT02963337|DRUG|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
219037580|NCT04121260|DRUG|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
219037581|NCT00772499|DRUG|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
219037582|NCT00772499|DRUG|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
219037583|NCT05282719|DRUG|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
219037584|NCT06083350|DIETARY_SUPPLEMENT|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
219037585|NCT06083350|DIETARY_SUPPLEMENT|Starch|Produced by Angel Yeast Co., LTD
219037586|NCT03170973|OTHER|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
219037587|NCT05699083|OTHER|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
219037588|NCT02858245|OTHER|No intervention - registry|
219037589|NCT04258605|DEVICE|ASHCOM Shoulder System|Reverse Shoulder Arthroplasty
219037590|NCT03684018|BIOLOGICAL|IgPro10|Normal human immunoglobulin G administered intravenously
219037591|NCT04328831|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
219037592|NCT00648596|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
219037593|NCT00648596|DRUG|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
219037594|NCT01442870|DRUG|Metformin|Metformin
219612478|NCT01324778|DEVICE|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
218901067|NCT00915954|DIAGNOSTIC_TEST|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
218901068|NCT00915954|DIAGNOSTIC_TEST|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
218901069|NCT05723224|PROCEDURE|elective endoscopic gallbladder treatment|Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
218901070|NCT03112681|DRUG|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
218901071|NCT03112681|DRUG|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
218901072|NCT03112681|DRUG|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
219037595|NCT00265512|BEHAVIORAL|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
219037596|NCT00265512|BEHAVIORAL|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
219037597|NCT04717375|DRUG|SAR444881|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219037598|NCT04717375|DRUG|Pembrolizumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219519090|NCT00677911|BEHAVIORAL|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
218901073|NCT06552273|BEHAVIORAL|Emotional Reasoning bias correction training|Emotional Reasoning Bias correction training involves 12 daily self-applied sessions focusing on psychoeducation about emotions and identifying ER biases and their impact on behaviour.
218901074|NCT06552273|BEHAVIORAL|Module of Mindfulness of the Transdiagnostic treatment|Module based on mindfulness using techniques for training in awareness and acceptance of experiences, observing experiences as they arise without judgment.
218901075|NCT02041325|DRUG|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
218901076|NCT02041325|DRUG|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
218901077|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
219037599|NCT04717375|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219037600|NCT04717375|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
219037601|NCT04717375|DRUG|Pemetrexed|Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
219037602|NCT04249258|DRUG|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
219037603|NCT02881645|BEHAVIORAL|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
219037604|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
219519091|NCT06347757|PROCEDURE|Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy|laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).
219519092|NCT05803915|DRUG|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
219037605|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
219519093|NCT03029520|OTHER|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
219519094|NCT03029520|OTHER|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
219519095|NCT02687256|DEVICE|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
219519096|NCT02687256|DEVICE|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
219519097|NCT02687256|DRUG|Heparin|
219037606|NCT00208936|DRUG|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
219037607|NCT05021367|DRUG|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
219037608|NCT05121883|DRUG|Edaravone Dexborneol|Edaravone dexborneol (Jiangsu Simcere Pharmaceutical, Co, Ltd) will be initiated within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days (maximum: 14 days)
219519098|NCT00483496|DRUG|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
219519099|NCT00483496|DRUG|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
219519100|NCT00483496|DRUG|bisoctrizole 10% alone (formula RV3131A-MV1237)|
219519101|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
219519102|NCT00483496|DRUG|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
219519103|NCT00483496|DRUG|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
219519104|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
219519105|NCT00483496|DRUG|V0096 CR vehicle (formula RV3131A-MV1197)|
219519106|NCT02559583|OTHER|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
219519107|NCT02559583|OTHER|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
219519108|NCT02559583|OTHER|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
219519109|NCT03389386|DIAGNOSTIC_TEST|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
219519110|NCT03389386|OTHER|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
219519111|NCT03389386|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
219519112|NCT06056388|DEVICE|Straumann BLX implant|Implant system with a deep fixture thread depth.
219519113|NCT06056388|DEVICE|Straumann BLT implant|Implant system with a regular fixture thread depth.
219519114|NCT02159105|DEVICE|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
218901078|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
218901079|NCT00318084|DRUG|Esomeprazole|
219519115|NCT01658943|DRUG|Akt Inhibitor MK2206|Given PO
219519116|NCT01658943|DRUG|Fluorouracil|Given IV
219519117|NCT01658943|DRUG|Oxaliplatin|Given IV
219519118|NCT01658943|DRUG|Selumetinib|Given PO
219519119|NCT06455020|PROCEDURE|Catheter ablation|Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission
219519120|NCT06455020|PROCEDURE|Stepped-care strategies|Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
219519121|NCT06824701|DRUG|Tazemetostat|Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.
219519122|NCT06824701|DRUG|Zanubrutinib|Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
219519123|NCT06824701|DRUG|Rituximab|Rituximab or a biosimilar will be administered intravenously per standard of care.
219519124|NCT06824701|DRUG|Obinutuzumab|Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.
219519125|NCT02625545|DEVICE|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
219519126|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
219519127|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
219519128|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
218901080|NCT00318084|PROCEDURE|Ambulatory 24-hour esophageal pH-monitoring|
218901081|NCT03388034|PROCEDURE|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
218901082|NCT03388034|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
218901083|NCT02701517|DRUG|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
218901084|NCT02701517|DRUG|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
218901085|NCT05227456|DRUG|Etonogestrel 68mg implant|Implant will be inserted
218901086|NCT05227456|DEVICE|Etonogestrel 68mg implant|Implant will be inserted
218901087|NCT00436150|BEHAVIORAL|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
218901088|NCT00436150|BEHAVIORAL|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
218901089|NCT05301985|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
218901090|NCT00659412|DRUG|Alefacept|Intramuscular
218901091|NCT00659412|DRUG|Methotrexate|Oral
219519129|NCT03630718|BEHAVIORAL|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
219519130|NCT03630718|BEHAVIORAL|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
218901092|NCT00659412|DRUG|Placebo|Intramuscular
219519131|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
219519132|NCT06784973|DRUG|Obeldesivir|Administered orally
218901093|NCT00453154|DRUG|Carboplatin|Given IV
219613426|NCT04481035|OTHER|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
218901094|NCT00453154|DRUG|Cisplatin|Given IV
218901095|NCT00453154|DRUG|Etoposide|Given IV
218901096|NCT00453154|OTHER|Laboratory Biomarker Analysis|Correlative studies
218901097|NCT00453154|OTHER|Placebo Administration|Given PO
218901098|NCT00453154|DRUG|Sunitinib Malate|Given PO
218901099|NCT02719535|OTHER|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
218901100|NCT01790594|BIOLOGICAL|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
218901101|NCT01790594|DRUG|methylprednisolone|
218901102|NCT01790594|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|
218901103|NCT01790594|DRUG|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
219519133|NCT06784973|DRUG|Obeldesivir Placebo|Administered orally
218901104|NCT01790594|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
219519134|NCT06132113|DRUG|BI 764532|BI 764532
219613427|NCT06536465|DRUG|REC-3964|REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h
218901105|NCT04578275|OTHER|diagnostic strategy using ECGI|"Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.~ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure."
218901106|NCT03011008|DRUG|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
218901107|NCT03011008|DRUG|Insulin|Receive insulin following clinician's instruction.
218901108|NCT02907034|PROCEDURE|Virtual reality experimentation sequency (VR)|
218901109|NCT02907034|PROCEDURE|Classical narrative approach (CN)|
218901110|NCT01772446|BEHAVIORAL|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
218901111|NCT01473771|BEHAVIORAL|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
218901112|NCT05528705|BIOLOGICAL|LAENNEC|Subacromial spatial administration
218901113|NCT05528705|OTHER|0.9% normal saline|Subacromial spatial administration
218901114|NCT00445081|DRUG|Prednisolone|
218901115|NCT00445081|DRUG|Ciclosporine A|
218901116|NCT02823509|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68\_R84-089)
218901117|NCT02439697|OTHER|Darbepoetin alfa|Conversion from Aranesp® to NESP®
218901118|NCT03291067|DRUG|MT-8554 1mg|MT-8554 1mg QD, oral, 12 weeks
218901119|NCT03291067|DRUG|MT-8554 5mg|MT-8554 5mg QD, oral, 12 weeks
218901120|NCT03291067|DRUG|MT-8554 10mg|MT-8554 10mg QD, oral, 12 weeks
218901121|NCT03291067|DRUG|Placebo|Placebo QD, oral, 12 weeks
218901122|NCT02038153|OTHER|Laboratory Biomarker Analysis|Correlative studies
218901123|NCT02038153|DRUG|Lenalidomide|Given PO
218901124|NCT04796597|DEVICE|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
218901125|NCT03016312|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
218901126|NCT03016312|DRUG|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
219037609|NCT05071885|OTHER|games based exercise|Range of motion and strengthening exercises
219519135|NCT06132113|DRUG|Carboplatin|Standard of care
218901127|NCT04319952|DEVICE|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
218901128|NCT04072926|DRUG|BioRoot|Influence of biomaterial BioRoot on periapical healing
219519136|NCT06132113|DRUG|Etoposide|Standard of care
219037610|NCT05392361|DRUG|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
218901129|NCT03921749|DEVICE|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
219612479|NCT03977948|OTHER|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
219612480|NCT03738046|BEHAVIORAL|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
218901130|NCT06528366|DIETARY_SUPPLEMENT|Chlorella pyrenoidosa|Functional food, organically pressed into tablets (Registration with Anvisa/MS/Brazil: 6.7273.000)
219037611|NCT05392361|DRUG|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
219037612|NCT02506504|DEVICE|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
219037613|NCT02506504|DEVICE|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
219037614|NCT01500707|DRUG|SCH 900800|SCH 900800, one 20 mg tablet, orally
219037615|NCT01712256|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
219037616|NCT02194868|BIOLOGICAL|Recipients|"1. Adult recipient:~   * collected 20 ml pre-transplant~  * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~  * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~   * collected residual blood pre-transplant~  * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~  * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
219519137|NCT06132113|DRUG|Cisplatin|Standard of care
219519138|NCT06830785|BEHAVIORAL|rhythmic auditory stimulation incorporated in upper-limb movement training|Rhythmic auditory stimulation will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
219519139|NCT06830785|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
219519140|NCT02704351|PROCEDURE|Surgery|Sugammadex to reverse neuromuscular blockade
219612481|NCT05447104|BEHAVIORAL|Mastication|Chewing sugar-free gum for 20 min
219612482|NCT04185155|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
219612483|NCT04185155|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
218901131|NCT06528366|DEVICE|High Definition Transcranial Direct Current Stimulation|Neuromodulation Technics, non invasive, target and safety
218901132|NCT05241262|DRUG|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
219037617|NCT02194868|BIOLOGICAL|Donors|"1. Adult donors :~   * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~  * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~   * collected residual blood~  * 2ml of bone marrow (bottom of tube)"
219612484|NCT03575208|BIOLOGICAL|hepatitis B immune globulin (HBIg)|HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
219612485|NCT03575208|DRUG|Pegylated interferon alfa (pegIFN)|peginterferon alfa-2a 180 mcg weekly for 24 weeks
219037618|NCT00962104|DRUG|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
219037619|NCT00962104|DRUG|Placebo|Taken by mouth, once daily for 10 weeks.
219519141|NCT06955715|OTHER|Pasteurized Donor Human Milk|This is a single arm study in which all participants will receive pasteurized donor human milk sourced from the Norther Star Mother's Milk Bank (Calgary, AB, Canada)
219519142|NCT04894513|OTHER|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
218901133|NCT04744675|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
218901134|NCT04744675|DRUG|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
219037620|NCT06044376|COMBINATION_PRODUCT|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving).
219037621|NCT06044376|OTHER|Formula milk|Formula milk without any addition of probiotic strain
219037622|NCT01933867|PROCEDURE|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
219037623|NCT01933867|PROCEDURE|Air insufflation insertion|
218901135|NCT04744675|DRUG|Bupivacaine|Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
218901136|NCT02050113|DEVICE|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
219037624|NCT02013167|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
219037625|NCT02013167|DRUG|Standard of Care Chemotherapy|"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
219037626|NCT02220244|DRUG|MD1003 100mg capsule|
219519143|NCT04894513|OTHER|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
219519144|NCT00482521|DRUG|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
219519145|NCT01669538|DRUG|Galantamine|
218901137|NCT06296589|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Behavioral therapy for trauma related guilt and shame
219519146|NCT01669538|DRUG|Placebo|
219612486|NCT02441010|DEVICE|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
219612487|NCT02441010|OTHER|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
219612488|NCT02441010|DEVICE|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
218901138|NCT06296589|BEHAVIORAL|Prolonged Exposure Therapy|Behavioral exposure therapy for PTSD
218901139|NCT05191394|DIAGNOSTIC_TEST|Evolution of antibodies titre|For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.
218901140|NCT04148534|DRUG|Rocroniom, Non Depolarizing Muscle Relaxant|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
219612489|NCT04004481|DRUG|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
218901141|NCT03604211|RADIATION|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
219037627|NCT02146638|DRUG|Morphine|
219037628|NCT02146638|DRUG|Fentanyl|
219037629|NCT02098577|OTHER|Crossover|Crossover cycle
219037630|NCT02098577|OTHER|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
219037631|NCT05066971|COMBINATION_PRODUCT|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
219037632|NCT01069133|DRUG|Rifaximin|550mg BID open-label
219519147|NCT00148681|DRUG|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
219612490|NCT04527510|DIAGNOSTIC_TEST|Conventional-reading|Two radiologists interpret at least three views of each breast without AI independently.
219612491|NCT04527510|DIAGNOSTIC_TEST|Second-reading|One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.
219519148|NCT00148681|DRUG|Navelbine|Intravenously every week for 12 weeks
219519149|NCT00148681|DRUG|Doxorubicin|Every 3 weeks for 12 weeks
219519150|NCT00148681|DRUG|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
219519151|NCT00148681|DRUG|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
218901142|NCT02246049|BIOLOGICAL|Bevacizumab|Given IV
218901143|NCT02246049|DRUG|5-fluorouracil|Given IV
218901144|NCT02246049|DRUG|Irinotecan hydrochloride|Given IV
218901145|NCT02246049|DRUG|Leucovorin calcium|Given IV
218901146|NCT02246049|DRUG|Oxaliplatin|Given IV
218901147|NCT05510063|DRUG|Humira (Adalimumab)|Subcutaneous (SC) injection
218901148|NCT05510063|DRUG|SB5 (Adalimumab Biosimilar)|Subcutaneous (SC) injection
218901149|NCT02520817|DIETARY_SUPPLEMENT|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
218901150|NCT02520817|DIETARY_SUPPLEMENT|Lactulose|
218901151|NCT02818868|DRUG|apixisaban|
219037633|NCT01069133|DRUG|rifaximin|550mg PO BID
219037634|NCT04977258|OTHER|Treadmill aerobic exercise without water intake|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
219519152|NCT03228693|PROCEDURE|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
218901152|NCT04078802|PROCEDURE|VNOTES/VH|same as above
219037635|NCT04977258|OTHER|Treadmill aerobic exercise with water intake of a predetermined amount.|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
219037636|NCT04977258|OTHER|Treadmill aerobic exercise with water intake according to the desire to drink|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
219037637|NCT04558931|DRUG|CellProtect|In vitro expanded and activated autologous NK cells
219519153|NCT03228693|PROCEDURE|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
219519154|NCT01465477|BIOLOGICAL|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
219612492|NCT04527510|DIAGNOSTIC_TEST|Concurrent-reading|One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.
219612493|NCT04527510|DIAGNOSTIC_TEST|Tow views-reading|Two radiologists interpret only two views of each breast without AI independently.
218901153|NCT01884077|DEVICE|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
218901154|NCT01884077|DEVICE|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
218901155|NCT01052155|OTHER|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
218901156|NCT04508881|DEVICE|Ahmed Glaucoma Valve|To compare the prevalence of postoperative hypotony between the 2 arms
218901157|NCT00981149|DRUG|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
218901158|NCT00981149|DRUG|Placebo|Placebo match duloxetine for 6 week period.
218901159|NCT06135961|DEVICE|eCTG monitoring with the NFMS|Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
218901160|NCT04722900|OTHER|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
218901161|NCT01492790|PROCEDURE|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
218901162|NCT01492790|PROCEDURE|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
218901163|NCT05757648|DRUG|Non-buffered Anesthetic|non-buffered LA, 2% lidocaine with epinephrine 1:100,000
218901164|NCT05757648|DRUG|Buffered Anesthetic|A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
218901165|NCT05757648|DEVICE|Onset|"The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge."
218901166|NCT02249936|DRUG|AZD1722|
218901167|NCT02249936|DRUG|Omeprazole|
218901168|NCT00395655|DRUG|Hydralazine and magnesium valproate administration|
219037638|NCT04558931|DRUG|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
219037639|NCT03221803|OTHER|OT Vertical attachment|new extra coronal castable attachment
219037640|NCT03221803|OTHER|OT cap attachment|standard extra coronal attachment
219037641|NCT03200925|OTHER|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
219037642|NCT00965822|OTHER|North American ginseng|3 day, once daily, dosing
218901169|NCT00395655|PROCEDURE|Core-needle biopsy of the breast|
218901170|NCT05513339|DEVICE|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
218901171|NCT04087980|DEVICE|Poseidon System|Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
219037643|NCT00965822|OTHER|Placebo|3 day, once daily dosing
219037644|NCT04484324|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
219519155|NCT01465477|BIOLOGICAL|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
219519156|NCT03769285|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
219519157|NCT03769285|DRUG|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
218901172|NCT02748863|DRUG|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
218901173|NCT02748863|DRUG|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
218901174|NCT02748863|DRUG|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
219037645|NCT03349216|PROCEDURE|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
219037646|NCT03349216|DRUG|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
219519158|NCT06387186|DRUG|Leucine-Enriched Essential Amino Acid powder|Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
219519159|NCT05594472|DRUG|Ozonated olive oil|Topical treatment will be applied for 5 consecutive days on the erosions.
219519160|NCT05594472|DRUG|Topical garamycin cream|Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
219519161|NCT06245265|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|In this study, 15 periodontitis patients with RA, 15 healthy individuals with RA, 15 systemic healthy periodontitis patients and 15 systemic periodontally healthy individuals will be included. ANGPTL-4 biomarker and other biomarkers (MMP-13, TNF-α, IL-6) that have not been previously analysed in the serum and saliva of both RA and periodontitis patients will be evaluated before and 3 months after COPT. Clinical parameters (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), biochemical evaluations of serum, saliva and gingival samples will be performed and correlated with clinical parameters at baseline and 3 months after COPT in all individuals with periodontitis included in the study.
219519162|NCT00890981|PROCEDURE|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
219519163|NCT00890981|PROCEDURE|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
219519164|NCT00890981|BIOLOGICAL|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
219519165|NCT00890981|DRUG|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
219519166|NCT06630676|BEHAVIORAL|Control|Brief 4-slide presentation without a separate session for questions and answers
219519167|NCT06630676|BEHAVIORAL|Education|Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
219519168|NCT02203448|DEVICE|Facet Wedge spinal system|
219519169|NCT01027143|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
218901175|NCT04258878|PROCEDURE|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
219037647|NCT04152512|BEHAVIORAL|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
219037648|NCT00764270|DIETARY_SUPPLEMENT|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
219037649|NCT03468881|OTHER|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
219037650|NCT05820971|OTHER|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)"
219519170|NCT01027143|DRUG|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
219519171|NCT03730597|DEVICE|reverse shoulder arthroplasty|prosthesis implantation
218901176|NCT02140515|DRUG|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
218901177|NCT02140515|DRUG|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
219037651|NCT01113879|BEHAVIORAL|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
219037652|NCT01113879|BEHAVIORAL|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
219037653|NCT03080558|DRUG|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
219519172|NCT06451445|DEVICE|Irreversible Electroporation (NanoKnife)|Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
219519173|NCT05942612|DRUG|SHR-2001|Subcutaneous injection, single dose or multiple doses.
219519174|NCT05942612|DRUG|Placebo|Subcutaneous injection, single dose or multiple doses.
219519175|NCT03149861|PROCEDURE|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
219037654|NCT02603835|DEVICE|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
219204237|NCT06880705|BEHAVIORAL|The TLC Program|Participants randomized to the TLC Program will receive TAU plus the telehealth, peer-delivered group intervention. The TLC Program was adapted from Acceptance and Commitment Therapy (ACT) - an acceptance and mindfulness-based third wave cognitive behavioral therapy. The intervention will be delivered in a group format with peer facilitators via telehealth using videoconferencing. The protocol covers all six ACT core concepts (i.e., contact with the present, acceptance, defusion, self-as-context, values, and committed action) with tailored examples and exercises focused on gender affirmation, internalized stigma, and substance use. Additional sessions are included defining stigma, how stigma affects physical and sexual health and engagement with healthcare, and values-driven self-care goals of substance use reduction and healthcare engagement. Sessions are approximately 1.5 hours each and are delivered over 12 weeks.
218901178|NCT06264011|BEHAVIORAL|Salaat|While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
218901179|NCT06264011|OTHER|Sham comparator|Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
218901180|NCT05711043|DEVICE|Endoscopic sutured gastroplasty with endomina|"Subjects in the intervention group will be treated with an ESG with the endomina ® and TAPES devices (Endo Tools Therapeutics S.A.), both CE-marked for endoscopic gastroplasty. The endomina is a device that can be attached to an endoscope and allows remote actuation of the device during a peroral intervention. Thanks to a therapeutic channel that can be angled perpendicularly to the axis of vision of the endoscope, it allows the possibilities of making transoral full thickness tissue apposition and performing, via a transoral route, large plications with tight serosa to serosa apposition in the stomach. This suturing will be done from the incisura to the upper body of the stomach, along the great curvature with TAPES, a single use needle preloaded with suture.~In addition to the endomina device, any other required endoscopic accessories can be used during the procedure (e.g., grasping forceps, loop cutter)."
218901181|NCT03361085|PROCEDURE|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
218901182|NCT03308916|DIAGNOSTIC_TEST|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
218901183|NCT03308916|DIAGNOSTIC_TEST|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
218901184|NCT03308916|DIAGNOSTIC_TEST|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
218901185|NCT03308916|DIAGNOSTIC_TEST|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
218901186|NCT03308916|DIAGNOSTIC_TEST|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
218901187|NCT03308916|DIAGNOSTIC_TEST|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
219037655|NCT04210752|DRUG|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
219519176|NCT03149861|PROCEDURE|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
219519177|NCT04438356|COMBINATION_PRODUCT|M-Health|The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
219612494|NCT04527510|DIAGNOSTIC_TEST|Handheld US-screening|One radiologist screens the breast cancer using Handheld US and interprets images immediately.
218901188|NCT03308916|DIAGNOSTIC_TEST|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
218901189|NCT04236102|DIAGNOSTIC_TEST|Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples|Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
218901190|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
218901191|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
218901192|NCT01960140|DRUG|Baricitinib|Administered orally
218901193|NCT01960140|DRUG|Simvastatin|Administered orally
219037656|NCT04210752|DRUG|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
219037657|NCT04210752|DRUG|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
219612495|NCT00654095|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
218901194|NCT06270069|OTHER|Excercise-based therapy|An individual 60-min motor training sessions twice a week for eight-week outpatient program, that included exercises aimed at improving postural control, strengthening and stabilizing the back muscles, and stretching
218901195|NCT00732823|DEVICE|Placebo - No device worn|
218901196|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218901197|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218901198|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218901199|NCT01353404|DRUG|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
218901200|NCT01353404|DRUG|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
218901201|NCT01353404|DRUG|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
218901202|NCT01353404|DRUG|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
218901203|NCT01353404|DRUG|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
218901204|NCT01353404|DRUG|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
218901205|NCT06171958|DRUG|Iodine-containing Contrast Media|Patients will receive or not receive ICM depending on their medical need.
218901206|NCT03571139|DEVICE|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
218901207|NCT04537793|DRUG|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
218901208|NCT04537793|DRUG|IVA|Granules for oral administration.
218901209|NCT02414815|DEVICE|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
218901210|NCT02976337|DRUG|Naloxone|active drug infusion
218901211|NCT02976337|DRUG|Normal Saline|placebo comparator
218901212|NCT05470387|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
218901213|NCT05470387|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
218901214|NCT01255423|DRUG|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
218901215|NCT01255423|DRUG|Placebo|Placebo, 4 times daily
218901216|NCT00006275|DRUG|calcitriol|
218901217|NCT04826172|DRUG|IMB-1018972|Modified release (MR) oral tablet
219612496|NCT00654095|DRUG|atorvastatin|atorvastatin 20 mg once daily
218901218|NCT04826172|DRUG|Placebo|Matching oral tablet
218901219|NCT05794035|OTHER|Surgery with additional moderate hypofractionation RT (15 fractions)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed."
218901220|NCT05794035|OTHER|Surgery alone, without radiation post surgery|Arm A: Surgery alone followed by surveillance
218901221|NCT05794035|RADIATION|Surgery with extreme hypo fractionation treatment (HF)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed."
218901222|NCT03567772|DEVICE|Wiifit Nintendo video game|
218901223|NCT03567772|OTHER|Pulmonary rehabilitation program|
218901224|NCT03022877|DRUG|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
218901225|NCT02638766|DRUG|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
218901226|NCT00543257|OTHER|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
218901227|NCT00543257|OTHER|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
218901228|NCT06313983|DRUG|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
219612497|NCT01977495|BEHAVIORAL|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
218901229|NCT06313983|DRUG|Lapatinib+Capecitabine|Take the pills according to the instructions
218901230|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
219612498|NCT04353635|DEVICE|dolphin 3d|software
219612499|NCT05236335|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
219612500|NCT05236335|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
218901231|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
218901232|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
218901233|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
218901234|NCT03890068|DRUG|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
218901235|NCT01994642|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
218901236|NCT01994642|DRUG|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
218901237|NCT01994642|DRUG|Placebo Sterile Otic Suspension|
218901238|NCT00363844|DRUG|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
218901239|NCT02308956|BEHAVIORAL|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
218901240|NCT02308956|BEHAVIORAL|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
218901241|NCT04684264|OTHER|Heart Failure Prevention Clinic|Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
219037658|NCT04210752|DRUG|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
219037659|NCT04210752|DRUG|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
219037660|NCT00258076|DRUG|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
219037661|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
219037662|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
219037663|NCT01499888|PROCEDURE|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
218901242|NCT01612975|DRUG|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
218901243|NCT01612975|DRUG|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
219037664|NCT01499888|DRUG|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
218901244|NCT00574808|OTHER|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
218901245|NCT03831477|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
218901246|NCT03309566|DRUG|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
219037665|NCT01499888|DRUG|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
219037666|NCT00891137|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
219037667|NCT05813158|DRUG|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
218901247|NCT00690729|BEHAVIORAL|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
219037668|NCT05813158|DRUG|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
219037669|NCT00133874|DRUG|SB-275833 ointment, 1%|
219037670|NCT02572466|OTHER|Hemodialysis|ESRD group received long-term hemodialysis
219519178|NCT03820921|DIAGNOSTIC_TEST|EUS-FNB|"EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA)."
218901248|NCT00690729|BEHAVIORAL|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
218901249|NCT00429559|DRUG|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
218901250|NCT00429559|DRUG|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
218901251|NCT06316908|DRUG|Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.
218901252|NCT06316908|DRUG|Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
218901253|NCT05948241|OTHER|Online psychological support group|"1. st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~2. nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments"
218901254|NCT05948241|OTHER|Standard multidisciplinary care|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
218901255|NCT03407898|OTHER|intubation time|intubation attempt number and intubation time
218901256|NCT00657046|DRUG|Droxidopa|Capsules containing 200 mg droxidopa
218901257|NCT00657046|DRUG|Placebo|Capsules with mannitol substituted for droxidopa
218901258|NCT05353595|DIETARY_SUPPLEMENT|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
218901259|NCT05353595|BEHAVIORAL|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
218901260|NCT00546624|DRUG|MK0777|
218901261|NCT00027625|DRUG|gefitinib|
218901262|NCT00027625|DRUG|temozolomide|
218901263|NCT01022021|DRUG|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
218901264|NCT01022021|DRUG|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
218901265|NCT04138303|OTHER|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
219037671|NCT03864874|DIAGNOSTIC_TEST|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
219037672|NCT04248595|DRUG|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
219037673|NCT04248595|DRUG|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
219037674|NCT05817019|DRUG|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period
219037675|NCT05817019|DRUG|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
219037676|NCT03098342|PROCEDURE|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
219037677|NCT03098342|DRUG|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
219037678|NCT02472938|DRUG|dimethyl fumarate|dimethyl fumarate 120 mg capsules
219612501|NCT02440464|PROCEDURE|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
219519179|NCT03820921|OTHER|Immunohistochemistry|IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
219519180|NCT03882320|PROCEDURE|Patient Controlled Analgesia (PCA)|Patient Controlled Analgesia (PCA)
219519181|NCT02564263|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
219519182|NCT02564263|DRUG|paclitaxel|80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
219519183|NCT02564263|DRUG|docetaxel|75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle
219519184|NCT02564263|DRUG|irinotecan|180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
219519185|NCT00676871|DRUG|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
219519186|NCT00676871|DRUG|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
219519187|NCT00676871|DRUG|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
219519188|NCT00676871|DRUG|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
219519189|NCT00676871|DRUG|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
219519190|NCT00676871|DRUG|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
219519191|NCT00676871|DRUG|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
219519192|NCT00689013|OTHER|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
219519193|NCT00689013|OTHER|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
219519194|NCT00689013|OTHER|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
219519195|NCT03577509|DRUG|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
219519196|NCT03190577|GENETIC|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
219519197|NCT01949194|DRUG|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
219519198|NCT02319148|DRUG|itraconazole|itraconazole dosed at 200 mg
219519199|NCT02319148|DRUG|diltiazem|diltiazem dosed at 240 mg
219519200|NCT02319148|DRUG|SR verapamil|SR verapamil dosed at 240 mg
219519201|NCT02319148|DRUG|PF-00489791|PF-00489791 20 mg single dose administration
219519202|NCT05106166|BEHAVIORAL|Occupational Therapy|occupational therapy sessions are based on the joint attention
219519203|NCT02735174|DEVICE|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
219519204|NCT02735174|OTHER|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
219519205|NCT02735174|BEHAVIORAL|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
219612502|NCT02440464|DRUG|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
219612503|NCT02440464|DRUG|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
219612504|NCT02440464|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
219037679|NCT02472938|OTHER|Placebo|Placebo for BG00012
219612505|NCT02440464|DRUG|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
218901266|NCT04138303|OTHER|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
219519206|NCT02735174|OTHER|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
219519207|NCT06399822|DIAGNOSTIC_TEST|Nail capillaroscopy|"The intervention studied as part of the project is capillaroscopy. This examination consists of visualizing the capillaries located at the base of the nail using a device called a capillaroscope. This device magnifies the image of the capillaries to clearly visualize them. Capillaries are the smallest blood vessels, which allow the passage of only one red blood cell at a time. At the nail bed, they form a network of loops and are aligned next to each other. This alignment allows them to be viewed over their entire length. Researchers have described abnormalities in capillaries that are associated with certain diseases involving microvascular damage.~The results of capillaroscopy will be reported qualitatively, for all eight long fingers examined."
218901267|NCT04138303|OTHER|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
218901268|NCT00430469|DRUG|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
218901269|NCT04210674|OTHER|The traditional medicinal product of Argan spinosa oil|All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
218901270|NCT05775068|RADIATION|Radiotherapy|Radiotherapy
219519208|NCT02048865|DRUG|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
219519209|NCT02048865|DRUG|Placebo drug|placebo drug 2.5mg BID for 6 months
219519210|NCT02583204|DEVICE|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
218901271|NCT04386369|OTHER|Airway pressure release ventilation|Ventilator management strategy
219037680|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
219519211|NCT02583204|OTHER|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
219612506|NCT02440464|DRUG|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
219612507|NCT03158103|DRUG|MEK162|MEK162 at 30mg twice daily
219612508|NCT03158103|DRUG|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
219612509|NCT00871208|DRUG|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
218901272|NCT02278926|OTHER|Ultrasound|Ultrasound measurements
219037681|NCT00615056|DRUG|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
219037682|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
218901273|NCT02278926|OTHER|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
218901274|NCT03625284|DIETARY_SUPPLEMENT|Placebo|Edible oil
218901275|NCT03625284|DIETARY_SUPPLEMENT|FucoVital|Microalgae oil extract
218901276|NCT05594719|DEVICE|Shorter-wavelength dominant light|Shorter-wavelength dominant light
218901277|NCT05594719|DEVICE|Light similar to the solar spectrum proportion|Light similar to the solar spectrum proportion with no specific wavelength dominant
218901278|NCT05594719|DEVICE|Longer-wavelength dominant light|Longer-wavelength dominant light
218901279|NCT05745311|DRUG|The KPCXM18 injection|Intravenous infusion
218901280|NCT05745311|DRUG|Placebo|Intravenous infusion
218901281|NCT01176058|DRUG|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
219519212|NCT01087970|DRUG|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
219612510|NCT00871208|DRUG|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
219612511|NCT00965887|DRUG|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
218901282|NCT01212562|PROCEDURE|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
219612512|NCT00965887|DRUG|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
218901283|NCT03762031|DRUG|GC4711 30mg|single dose given via a 15 minute intravenous infusion
218901284|NCT03762031|DRUG|GC4711 60mg|single dose given via a 15 minute intravenous infusion
218901285|NCT03762031|DRUG|GC4711 90mg|single dose given via a 15 minute intravenous infusion
219037683|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
219037684|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
219612513|NCT00290017|DRUG|talabostat|
219519213|NCT01087970|DRUG|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
219519214|NCT01087970|DRUG|Carboplatin|Administered intravenously, for a maximum of 6 cycles
219612514|NCT00290017|DRUG|pemetrexed|
219612515|NCT02504528|OTHER|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
219612516|NCT03726060|OTHER|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
218901286|NCT03762031|DRUG|GC4711 120mg|single dose given via a 15 minute intravenous infusion
218901287|NCT03762031|DRUG|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
218901288|NCT03762031|DRUG|GC4711 75mg|single dose given via a 15 minute intravenous infusion
218901289|NCT03762031|DRUG|GC4711 105mg|single dose given via a 15 minute intravenous infusion
218901290|NCT06248606|DRUG|Adagrasib|Adagrasib 600mg orally
218901291|NCT06248606|RADIATION|Stereotactic Radiosurgery|Delivered as per standard of care
218901292|NCT02528825|DRUG|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
218901293|NCT06079333|DRUG|dabrafenib/trametinib|braf/mek-inhibition
218901294|NCT02757989|OTHER|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
218901295|NCT05220306|DEVICE|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
218901296|NCT04540965|DRUG|Telaglenastat|Glutaminase inhibitor
218901297|NCT04540965|DRUG|Famotidine|Histamine-H2 Receptor Antagonist
218901298|NCT04540965|DRUG|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
218901299|NCT01858363|DEVICE|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
218901300|NCT01858363|DEVICE|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
218901301|NCT03004365|DRUG|C16G2 Varnish|Antimicrobial Peptide
219037685|NCT00615056|DRUG|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
219519215|NCT01087970|DRUG|Cisplatin|Administered intravenously, for a maximum of 6 cycles
219519216|NCT01689480|OTHER|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
219519217|NCT05485909|OTHER|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
219519218|NCT05485909|DRUG|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
218901302|NCT03004365|DRUG|Placebo Varnish|Placebo
219519219|NCT03756857|PROCEDURE|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
219519220|NCT03756857|PROCEDURE|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
219519221|NCT05640453|DRUG|Pregabalin|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
219612517|NCT03726060|OTHER|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
218901303|NCT00491413|DRUG|epoetin|
218901304|NCT05418322|BEHAVIORAL|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
218901305|NCT02579213|OTHER|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
219612518|NCT04800081|DRUG|Sacubitril/Valsartan|Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
219612519|NCT04800081|DRUG|Valsartan|Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
218901306|NCT01619839|DRUG|NKTR-181|
219612520|NCT00002019|DRUG|Amphotericin B, Lipid-based|
219612521|NCT00002019|DRUG|Amphotericin B|
218901307|NCT01619839|DRUG|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
218901308|NCT00003815|BIOLOGICAL|bleomycin sulfate|
218901309|NCT00003815|DRUG|carmustine|
219204238|NCT06883838|BEHAVIORAL|Survivorship care delivery intervention|"Guided by the Practical, Robust Implementation and Sustainability Model (PRISM), the intervention includes three evidence-based components:~1. Training: This will include provider-to-provider tele-mentoring using Enhancing Community Health Outcomes (ECHO).~2. Tracking: This includes systematically assessing cancer history and monitoring survivors' care to plan and organize subsequent care.~3. Coordinating care for cancer survivors. Each clinic leader will designate a staff member (or members) as the care coordinator champion after exploring current clinic staff, skills, and capacity of various staff roles."
219204239|NCT06884150|OTHER|Exercise|Participating in schroth exercises for 45 minutes, 2 days a week after receiving the relevant diagnosis
219519222|NCT05640453|DRUG|Dexmedetomidine|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
219519223|NCT03048162|DRUG|sodium chloride|500 ml of 0.9% isotonic sodium chloride
219519224|NCT03048162|DRUG|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
219519225|NCT03048162|DRUG|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
219519226|NCT00762086|DEVICE|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
218901310|NCT00003815|DRUG|cyclophosphamide|
218901311|NCT00003815|DRUG|cytarabine|
218901312|NCT00003815|DRUG|doxorubicin hydrochloride|
218901313|NCT00003815|DRUG|etoposide|
219519227|NCT00762086|OTHER|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
219519228|NCT05909124|DEVICE|MCE|underwent MCE examination
219519229|NCT03902171|DEVICE|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
219519230|NCT06447883|BEHAVIORAL|Lifestyle modification program|The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
219519231|NCT04791553|DRUG|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
219612522|NCT04335513|OTHER|Early CGM-guided education and initiation of insulin therapy.|Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
219612523|NCT04335513|OTHER|Usual care: glucometer surveillance and basic education.|"* Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~* Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes."
218901314|NCT00003815|DRUG|melphalan|
218901315|NCT00003815|DRUG|prednisolone|
218901316|NCT00003815|DRUG|vincristine sulfate|
218901317|NCT00003815|PROCEDURE|autologous bone marrow transplantation|
218901318|NCT00003815|RADIATION|radiation therapy|
218901319|NCT03992352|DIAGNOSTIC_TEST|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
218901320|NCT00006326|DRUG|Indinavir sulfate|
218901321|NCT00006326|DRUG|Ritonavir|
218901322|NCT00006326|DRUG|Delavirdine mesylate|
218901323|NCT03480152|BIOLOGICAL|National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine|Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
218901324|NCT04166812|DIAGNOSTIC_TEST|oscillometry|assessment of peripheral airway resistance using oscillometry
218901325|NCT04166812|DIAGNOSTIC_TEST|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
218901326|NCT04166812|DIAGNOSTIC_TEST|spirometry|assessment of lung function using spirometry
218901327|NCT04166812|DIAGNOSTIC_TEST|body plethysmography|assessment of lung function using body plethysmography
218901328|NCT04166812|DIAGNOSTIC_TEST|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
218901329|NCT04166812|DIAGNOSTIC_TEST|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
218901330|NCT04166812|DIAGNOSTIC_TEST|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])
218901331|NCT04166812|DIAGNOSTIC_TEST|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
218901332|NCT04166812|DIAGNOSTIC_TEST|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
219519232|NCT06441435|DIETARY_SUPPLEMENT|Low protein diet with AC-134|Low protein diet combined with AC-134 Dosage: 2 capsules,three times/day
219519233|NCT06441435|OTHER|Standard treatment|Low protein diet
219519234|NCT04856345|OTHER|Walking with music with synchronisation|Walking with music than one can synch to
219519235|NCT04856345|OTHER|Walking with music without synchronisation|Walking with music than one cannot synch to
219612524|NCT01431079|BEHAVIORAL|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
219612525|NCT03617666|DRUG|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
219612526|NCT02851784|BIOLOGICAL|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
219612527|NCT02851784|PROCEDURE|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
219612528|NCT05857683|PROCEDURE|cextension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
219519236|NCT04856345|OTHER|walking without music|Walking without music
219519237|NCT01135641|DRUG|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
219519238|NCT01135641|DRUG|Ciclosporine|
218901336|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
218901337|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
218901338|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
218901339|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
218901340|NCT06306170|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
218901341|NCT06634875|DRUG|isunakinra|Isunakinra is a potent IL1R1 inhibitor
218901342|NCT05777603|DRUG|aerosolized aztreonam|antibiotic with gram-negative bacteria coverage
218901343|NCT05777603|DRUG|aerosolized vancomycin|antibiotic with gram-positive bacteria coverage
218901344|NCT05777603|DRUG|pembrolizumab|standard of care therapy/monoclonal antibody for patients with advanced NSCLC
218901345|NCT00970918|PROCEDURE|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
218901346|NCT00970918|BIOLOGICAL|Blood sample testing for hs-CRP|one time, blood sample taking
219519239|NCT01135641|DRUG|Corticosteroids|
219519240|NCT00526786|DEVICE|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
219519241|NCT03598439|BIOLOGICAL|Standard IIV4|Standard inactivated influenza vaccine
219519242|NCT03598439|BIOLOGICAL|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
219519243|NCT03598439|BIOLOGICAL|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
219519244|NCT03928197|BEHAVIORAL|Tilt Test|Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
219519245|NCT03928197|DEVICE|Inbody S10|Bio-electrical impedance measurement every 5 minutes
219612529|NCT05857683|PROCEDURE|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
219612530|NCT02771873|BEHAVIORAL|Integrated cardiovascular disease risk management.|Health promotion intervention
219612531|NCT04762667|PROCEDURE|reverse shoulder arthroplasty|"In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique."
219612532|NCT05902507|DIAGNOSTIC_TEST|Magnetic Resonance Imaging Simulation|Radiographic Image Simulation
218901347|NCT02110563|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
218901348|NCT05024435|DEVICE|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
218901349|NCT00101686|DRUG|Modified Bolus 5-FU/LV with Irinotecan|Day 1 \& 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID \[two times a day\] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
218901350|NCT00101686|DRUG|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID \[two times a day\] oral Every 2 weeks"
218901351|NCT00101686|DRUG|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV \*over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID \[two times a day\] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID \[two times a day\] continues daily without interruption Every 3 weeks
218901352|NCT00101686|DRUG|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID \[two times a day\](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
218901353|NCT00101686|DRUG|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
218901354|NCT03599206|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
218901355|NCT03599206|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
218901356|NCT00348439|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
218901357|NCT00348439|DRUG|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
219037686|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
219037687|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
219037688|NCT02231346|DRUG|Berodual® Respimat® - inhaler|
219519246|NCT03928197|DEVICE|Tape measurements|Every 5 minutes, circumference of every leg is measured using a tape measure
219519247|NCT03928197|DEVICE|SOMNOtouchTMNIBP, Vivisol, Belgium|Continous measurement of blood pressure, heart rate and saturation
219519248|NCT00242346|DRUG|candesartan cilexetil|
219519249|NCT03378466|DRUG|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
219519250|NCT03378466|OTHER|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
219519251|NCT01074554|DRUG|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
219519252|NCT01074554|DRUG|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
219519253|NCT03056248|DRUG|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
219519254|NCT03056248|DRUG|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
219519255|NCT01282047|DRUG|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
219519256|NCT04614961|OTHER|Lifestyle therapy - individual|Individual therapy
219519257|NCT04614961|OTHER|Lifestyle therapy - group|Group therapy
219519258|NCT04614961|OTHER|Medical therapy|Medical therapy
219612533|NCT03076840|OTHER|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
218901358|NCT05923840|DIAGNOSTIC_TEST|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
218901359|NCT05923840|DIAGNOSTIC_TEST|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
218901360|NCT05923840|DIAGNOSTIC_TEST|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
218901361|NCT02525471|DRUG|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
218901362|NCT05904197|OTHER|Gamified Cards about Nephrotic Syndrome|"* The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication…etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child."
218901363|NCT02907424|DIETARY_SUPPLEMENT|2 months of treatment|standard 2 months of treatment
218901364|NCT01722539|DRUG|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
219037689|NCT05096936|OTHER|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
219037690|NCT05096936|OTHER|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
219519259|NCT04614961|PROCEDURE|Bariatric surgery|Surgical and endoscopic therapy
219519260|NCT02645526|OTHER|Woolen cap|
219519261|NCT04276883|DRUG|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
219519262|NCT04276883|DRUG|Placebo Film|Placebo Film for BXCL501
219519263|NCT02918994|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
219519264|NCT04038060|BEHAVIORAL|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
219519265|NCT04038060|BEHAVIORAL|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
219519266|NCT04038060|BEHAVIORAL|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
219519267|NCT04038060|BEHAVIORAL|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
219519268|NCT04133376|OTHER|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
219519269|NCT04133376|OTHER|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
219519270|NCT02366780|PROCEDURE|Pump|Breast milk expression using manually or using an electric pump
219519271|NCT02556944|DEVICE|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
219519272|NCT02707848|OTHER|No intervention|
219612534|NCT02344667|RADIATION|Stereotactic Body Radiotherapy|
219612535|NCT04998565|OTHER|Routine care|Reverse pressure applied to the areola
219612536|NCT04998565|PROCEDURE|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
219612537|NCT04998565|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
219612538|NCT02042157|BEHAVIORAL|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
219612539|NCT02042157|OTHER|Regular toileting|Patients in the control arm will toilet as usual.
218901365|NCT01722539|DRUG|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
218901366|NCT01722539|DRUG|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
218901367|NCT01722539|DRUG|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
218901368|NCT03044366|OTHER|general anesthesia management of preterm infants|general anesthesia management of preterm infants
218901369|NCT02354274|RADIATION|Escalated: Inhomogeneous dose plan|
218901370|NCT02354274|RADIATION|Standard: Homogeneous dose plan|
218901371|NCT02183857|DEVICE|Ultrasound|
219037691|NCT05040633|DEVICE|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
219037692|NCT05040633|OTHER|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
219037693|NCT06208436|OTHER|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
219519273|NCT05251025|OTHER|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
219519274|NCT05251025|OTHER|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
219519275|NCT05999669|OTHER|GLASS staging|use the Global Limb Anatomic Staging System (GLASS) to evaluate its correlation with clinical outcomes after revascularization
219519276|NCT01876706|DEVICE|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
219519277|NCT03178500|DRUG|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
218901372|NCT02183857|OTHER|Landmark|
218901373|NCT05806437|DIETARY_SUPPLEMENT|sideremil vita cp|assunzione per 30 giorni dell'integratore
218901374|NCT00890825|DRUG|AZD6244|oral capsules, 75mg twice daily
218901375|NCT00890825|DRUG|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
218901376|NCT00890825|DRUG|Placebo|placebo
218901377|NCT01054456|DRUG|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
219037694|NCT02876965|PROCEDURE|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
219037695|NCT02876965|PROCEDURE|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
219037696|NCT05677542|DRUG|secukinumab|all patients who received secukinumab
219037697|NCT05040581|BEHAVIORAL|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
218901378|NCT03018236|DRUG|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
218901379|NCT03018236|DRUG|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
218901380|NCT03018236|DRUG|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
218901381|NCT03018236|DRUG|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
218901382|NCT03142529|DRUG|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
218901383|NCT02498288|DRUG|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
218901384|NCT02498288|DRUG|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
219612540|NCT04138901|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
219612541|NCT04138901|DRUG|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
219037698|NCT01137942|DRUG|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
219519278|NCT01743378|PROCEDURE|TAP Block Ropivacaine 0,75 %|
219519279|NCT01743378|PROCEDURE|TAP Block Saline 0,9 %|
219519280|NCT04211493|BEHAVIORAL|whole-body-workout|20 minutes whole-body-workout
219519281|NCT04211493|DEVICE|EMS|Electromyostimulation-intensity 5 (muscle stimulation)
219519282|NCT04211493|DEVICE|EMS-Placebo|Electromyostimulation-intensity 1 (no muscle stimulation)
219612542|NCT04138901|DEVICE|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
219612543|NCT01108172|OTHER|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
218901385|NCT02498288|DRUG|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
219037699|NCT03439969|DEVICE|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
219037700|NCT03439969|DEVICE|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
219037701|NCT02276612|DRUG|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
219037702|NCT03026465|DEVICE|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
219519283|NCT05498805|RADIATION|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
219519284|NCT06497153|PROCEDURE|lung ultrasound|lung ultrasound repeated according to protocol during the stay in the paediatric intensive care unit
219519285|NCT02597998|DRUG|14C-BI 409306|
219519286|NCT01351688|DRUG|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
219612544|NCT01108172|OTHER|Usual care|The usual care provided to patients after discharge from hospital
219612545|NCT04868825|DEVICE|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
218901386|NCT05413746|DEVICE|Reoxcare antioxidant dressing|After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
219519287|NCT01825993|DRUG|L-BUPIVACAINE ; MORPHINE|
219519288|NCT01825993|DRUG|MORPHINE|
219519289|NCT04590378|OTHER|intensive care unit admission ratio|intensive care unit admission ratio
219519290|NCT01509300|BIOLOGICAL|anti-thymocyte globulin|On days -10 to -9
219519291|NCT01509300|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
219519292|NCT01509300|RADIATION|Total body irradiation|2Gy D-6 to D-4
219519293|NCT01509300|DRUG|Fludarabine|30mg/M2 once daily IV on days -8 to -4
219519294|NCT01509300|DRUG|cyclophosphamide|60 mg/kg IV on day-3 and -2
219519295|NCT01509300|DRUG|Tacrolimus|begin on 0
219519296|NCT01509300|DRUG|Mycophenolate mofetil|begin on 0
219519297|NCT01509300|DRUG|Rituximab|375mg/m2 on day +21
219519298|NCT02936856|DEVICE|Hepatic Arteriography|
219519299|NCT05711771|BEHAVIORAL|medication therapy management|Patients receive medication therapy management within the primary care office
219519300|NCT02293083|DRUG|trigger point injection|
219519301|NCT06295653|PROCEDURE|implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane|assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
219519302|NCT04326998|PROCEDURE|solvent|using solvent (GuttaClear) in procedure
219519303|NCT04326998|PROCEDURE|non-solvent|non-solvent
219612546|NCT04868825|DEVICE|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
219612547|NCT04166786|DRUG|Testosterone gel|Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
219612548|NCT04166786|DRUG|Ethanol Solution|Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
219037703|NCT03026465|DEVICE|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
219037704|NCT05071703|DRUG|Trilaciclib|"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"
219037705|NCT04124107|DEVICE|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
219037706|NCT04124107|PROCEDURE|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
218901387|NCT00687401|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
218901388|NCT05806320|OTHER|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
218901389|NCT05806320|OTHER|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
219037707|NCT01846975|DRUG|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
219037708|NCT02806050|DRUG|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
219037709|NCT02806050|DEVICE|FES PET|all patients will have a FES PET at baseline
219519304|NCT02339233|DEVICE|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
219037710|NCT02806050|DRUG|Letrozole|all patients will be treated with Letrozole daily until progression
219037711|NCT01306370|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
219037712|NCT01306370|DRUG|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
219037713|NCT01306370|BIOLOGICAL|Fibrin glue|Topical administration, before to close the surgical wound.
219037714|NCT01306370|OTHER|Habitual haemostasis|The surgical habitual haemostasis.
219037715|NCT00832403|OTHER|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
219037716|NCT03250468|BEHAVIORAL|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
219037717|NCT04327986|DRUG|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
219519305|NCT02962297|DRUG|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
219519306|NCT02962297|DRUG|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
219519307|NCT02550574|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
219037718|NCT04327986|DRUG|M9241|Subcutaneous injection on Day 1 of every cycle
219037719|NCT04327986|RADIATION|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
219037720|NCT01998451|DRUG|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
219037721|NCT04248816|BEHAVIORAL|Usual care|Subjects will receive outreach through their providers as is standard of care.
219037722|NCT04248816|BEHAVIORAL|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
219037723|NCT04248816|BEHAVIORAL|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
219037724|NCT04413084|OTHER|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
219519308|NCT02550574|PROCEDURE|Wound Closure with 5-0 Vicryl Sutures|
219519309|NCT02347501|DRUG|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
219612549|NCT04166786|DRUG|Testosterone placebo (vaseline)|Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
219612550|NCT04166786|DRUG|Ethanol placebo (lemon-flavoured water)|Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
219612551|NCT01589458|DRUG|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
218901390|NCT04711785|BEHAVIORAL|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
218901391|NCT02920892|DRUG|AFQ056|12.5 mg - 100 mg oral suspension (liquid)
218901392|NCT02920892|DRUG|Placebo|Placebo oral suspension (liquid)
218901393|NCT02920892|OTHER|Language Intervention|"All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children."
218901394|NCT03306966|DEVICE|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
219037725|NCT04413084|OTHER|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center."
219037726|NCT03325686|DIETARY_SUPPLEMENT|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
219037727|NCT03325686|OTHER|Placebo|placebo
219037728|NCT00175890|DRUG|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
219519310|NCT01541280|DRUG|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
219037729|NCT00175890|OTHER|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
219037730|NCT00262067|DRUG|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
219037731|NCT00262067|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
219037732|NCT00262067|DRUG|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle"
219519311|NCT01541280|OTHER|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of \>grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
219519312|NCT02157220|DEVICE|Fixed bearing prosthesis|
218901395|NCT02474563|DRUG|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
218901396|NCT02474563|DRUG|Melphalan|Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.
218901397|NCT02474563|DRUG|Prednisone|Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
218901398|NCT05016466|OTHER|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
218901399|NCT05016466|OTHER|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
219037733|NCT01522066|PROCEDURE|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
219519313|NCT02157220|DEVICE|Mobile bearing prosthesis|
219519314|NCT00765648|DRUG|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
219519315|NCT00765648|DRUG|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
218901400|NCT05591092|PROCEDURE|Computed Tomography|Undergo a SPECT/CT scan
218901401|NCT05591092|RADIATION|Iodine I-123|Given PO
218901402|NCT05591092|PROCEDURE|Planar Imaging|Undergo planar imaging
219519316|NCT02401386|BEHAVIORAL|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
218901403|NCT05591092|PROCEDURE|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
218901404|NCT04486235|BEHAVIORAL|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
218901405|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
218901406|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
218901407|NCT00451672|DRUG|bromocriptine|
218901408|NCT01715168|DRUG|DOXIL/CAELYX|
218901409|NCT01715168|DRUG|ATI-0918|
218901410|NCT02124733|PROCEDURE|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
218901411|NCT00495729|DRUG|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
218901412|NCT00495729|DRUG|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
218901413|NCT00495729|DRUG|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
218901414|NCT00881517|DRUG|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
218901415|NCT00881517|DRUG|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
219519317|NCT03165968|DEVICE|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
219519318|NCT06354504|PROCEDURE|Non-surgical periodontal treatment|Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
219519319|NCT04364568|RADIATION|Magnetic Resonance Imaging|IRM Sequences T1, T2, FLAIR, T2\*, Cerebral Blood Flow (CBF) et mean diffusivity (MD)
219519320|NCT03597334|BEHAVIORAL|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
218901416|NCT01622621|PROCEDURE|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
218901417|NCT01622621|RADIATION|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
218901418|NCT00213512|DRUG|Mabthera|
218901419|NCT01009658|DIETARY_SUPPLEMENT|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
218901420|NCT01009658|DIETARY_SUPPLEMENT|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
219037734|NCT01522066|PROCEDURE|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
219037735|NCT00655564|DRUG|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
219037736|NCT05504629|BEHAVIORAL|Concurrent training order 1|atag
219037737|NCT05504629|BEHAVIORAL|RT+ET|aetaer
219037738|NCT00134212|DRUG|Dopexamine and norepinephrine|
218901421|NCT04641845|OTHER|Cork inlay wedge|
218901422|NCT00343265|DRUG|Vaginal progesterone gel|Vaginal gel once daily
218901423|NCT00343265|DRUG|Placebo gel|once daily
218901424|NCT03935126|DIAGNOSTIC_TEST|Diagnostics|Diagnostics
218901425|NCT02604381|DIETARY_SUPPLEMENT|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
218901426|NCT02604381|OTHER|Placebo|
218901427|NCT05058807|OTHER|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
219037739|NCT00134212|DRUG|Epinephrine|
219037740|NCT00343733|DRUG|OraVescent Fentanyl|
219037741|NCT03811795|OTHER|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
218901428|NCT05058807|OTHER|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
218901429|NCT03649217|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
218901430|NCT01092728|DRUG|Dasatinib|100 mg daily.
218901431|NCT01092728|PROCEDURE|Surgical Resection|Complete surgical resection of tumor(s).
218901432|NCT02520726|DRUG|Sertraline|\< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
218901433|NCT02520726|DRUG|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
218901434|NCT00646685|PROCEDURE|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
218901435|NCT00646685|PROCEDURE|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
219519321|NCT04745546|DEVICE|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
219519322|NCT01282606|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
219519323|NCT01370408|DRUG|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
218901436|NCT00734435|DRUG|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
218901437|NCT00734435|DRUG|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
219037742|NCT02964858|RADIATION|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
219519324|NCT01370408|DRUG|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
219519325|NCT01370408|DRUG|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
219519326|NCT02601495|BEHAVIORAL|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
219519327|NCT02931318|BEHAVIORAL|Nevsehir|The data of the study were collected with the questionnaire
218901438|NCT00721396|BIOLOGICAL|rMenB+OMV NZ|
218901439|NCT00721396|BIOLOGICAL|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
218901440|NCT00721396|BIOLOGICAL|Pneumococcal vaccine|
219519328|NCT00239421|DRUG|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
219519329|NCT00239421|DRUG|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
219519330|NCT06021821|OTHER|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
218901441|NCT04827108|OTHER|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
218901442|NCT02205996|DRUG|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
218901443|NCT02205996|DEVICE|Euglycaemic Hypoglycaemic Insulin clamp|
219519331|NCT06021821|OTHER|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
219519332|NCT02120443|DEVICE|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
219037743|NCT02964858|RADIATION|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
219037744|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
219037745|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
218901444|NCT01521130|DRUG|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
218901445|NCT03546621|DRUG|Myrcludex B|2 mg, once daily, subcutaneously
218901446|NCT03546621|DRUG|Myrcludex-B|5 mg, once daily, subcutaneously
218901447|NCT03546621|DRUG|Myrcludex-B|10 mg, once daily, subcutaneously
218901448|NCT03546621|DRUG|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
218901449|NCT02253225|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
218901450|NCT01096836|OTHER|macronutrient and energy manipulation|
218901451|NCT00226590|DRUG|Gemcitabine|Induction Chemotherapy.
218901452|NCT00226590|DRUG|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
218901453|NCT00226590|DRUG|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
218901454|NCT00226590|PROCEDURE|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
218901455|NCT05384340|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|On the first day, an acute test will be carried out with beet juice rich in nitrate, in which two units of juice will be provided, totaling 140 ml (800 mg of nitrate) for each protocol. That is, each participant will receive 2 units of juice bottles. From the second to the seventh day, participants will receive 6 units of vials of the juice corresponding to the first intervention on the first visit to the laboratory and will drink one vial a day for a week. Of the 8 units (100%), six bottles (75%) will be provided for the participants to take home. On the seventh day of the intervention, the participants will return to the laboratory for the consumption of the seventh and last bottle of juice. Between one protocol and another, a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
218901456|NCT02714192|OTHER|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
218901457|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
218901458|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
219037746|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
219037747|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
219364307|NCT03072693|PROCEDURE|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
219519333|NCT00803803|DRUG|Pilocarpine Concentration|Varying concentration 0.5 to 8%
218901459|NCT03938935|PROCEDURE|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
218901460|NCT03111238|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
218901461|NCT03111238|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
218901462|NCT01562808|DRUG|Aripiprazole|single oral administration of aripiprazole
218901463|NCT02304744|OTHER|Observational study, no intervention.|Observational study, no intervention.
218901464|NCT04508946|DRUG|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
218901465|NCT05195307|OTHER|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
218901466|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
218901467|NCT01145742|BEHAVIORAL|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
219519334|NCT00803803|DRUG|Pilocarpine Frequency|1 to 4 times daily
219519335|NCT06006364|OTHER|Survey|"The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire"
219613428|NCT05437198|OTHER|collection of human exhalation|"the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device"
218901468|NCT00111514|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
218901469|NCT01207635|PROCEDURE|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
218901470|NCT00292240|BEHAVIORAL|Brief motivational substance use intervention|
218901471|NCT03523884|OTHER|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
218901472|NCT03523884|OTHER|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
218901473|NCT03434730|RADIATION|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
219037748|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
219037749|NCT05196906|PROCEDURE|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
219037750|NCT05537623|BEHAVIORAL|Safe Alternatives for Teens and Youths (SAFETY)|Please see description of experimental arm (arm one)
219037751|NCT05537623|BEHAVIORAL|Supportive Therapy|Please see description of active comparator arm (arm two)
219037752|NCT05855330|DRUG|Arginine Hydrochloride|Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
219364308|NCT03072693|PROCEDURE|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
219364309|NCT04444232|OTHER|Media Intervention|View an educational video
219364310|NCT04444232|OTHER|Survey Administration|Complete survey
219519336|NCT00188864|DRUG|dexamethasone|
219519337|NCT00605709|DRUG|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
219519338|NCT02958709|DRUG|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
219519339|NCT02958709|DRUG|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
219519340|NCT02958709|DRUG|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
219613429|NCT05807828|PROCEDURE|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup or stem implantation before actual implantation.
219613430|NCT06975683|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|On the day of the ovarian puncture of the 1st IVF cycle, intraovarian instillation of plasma rich in growth factors will be performed.
218901474|NCT03434730|DRUG|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
218901475|NCT03434730|DRUG|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
218901476|NCT03434730|DRUG|Tocilizumab|For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
218901477|NCT03434730|DRUG|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
218901478|NCT05646498|PROCEDURE|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
218901479|NCT05646498|DEVICE|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
218901480|NCT00461006|DRUG|Actos|45mg po daily
218901481|NCT00461006|DRUG|aleglitazar|0.6mg po daily
218901482|NCT00139230|DRUG|Taxotere|
218901483|NCT00139230|DRUG|Cisplatin|
218901484|NCT00139230|DRUG|5-Fluorouracil|
218901485|NCT00139230|DRUG|Leucovorin|
218901486|NCT00139230|DRUG|G-CSF|
219037753|NCT06093100|DEVICE|wearable technology|Three wearable devices
219037754|NCT04965636|DRUG|Mepolizumab|Mepolizumab will be provided in pre-filled safety syringe
218901487|NCT00139230|DRUG|Ciprofloxacin|
218901488|NCT04067323|DIETARY_SUPPLEMENT|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
218901489|NCT04067323|DIETARY_SUPPLEMENT|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
218901490|NCT06012682|DRUG|Metformin Hydrochloride|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
218901491|NCT06012682|DRUG|Placebo|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
218901492|NCT04362436|RADIATION|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
218901493|NCT05640323|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
219037755|NCT06311461|PROCEDURE|Acupuncture|The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).
219037756|NCT06311461|OTHER|Attention control|Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
219037757|NCT06501235|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.
219037758|NCT06501235|BEHAVIORAL|Virtue-Based Intervention (VBI)|A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
219037759|NCT04429217|OTHER|immediate post-operative complete weight-bearing after surgery|"Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement."
219364311|NCT06170996|BEHAVIORAL|Internet-based behavioral parent training (I-BPT)|Internet-based behavioural parent training in a group format, 8 sessions over 2 months, delivered by a systematically trained and supervised therapist.
218901494|NCT05474352|DEVICE|Allon System|Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
218901495|NCT05532644|OTHER|AD drugs|AD drugs
218901496|NCT04894721|DRUG|Ivermectin|0,6mg/kg of weight orally on days 1 and 7
219364312|NCT00176293|DRUG|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, \& 5 of each 28-day cycle
219364313|NCT00176293|DRUG|doxorubicin|Doxorubicin 50mg/m\^2 I.V. on day 5
219364314|NCT00926692|OTHER|Blood draw|Subject will have blood draw.
219364315|NCT04620486|OTHER|Epic Best Practice Alert|This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
219364316|NCT03194984|DRUG|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
218901497|NCT04894721|OTHER|Placebo|A substance with similar physical characteristics as ivermectin, without the active drug ingredient
218901498|NCT02021565|BEHAVIORAL|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
218901499|NCT02021565|OTHER|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
219612552|NCT05653557|OTHER|Shen Que Moxibustion|Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of previous menstrual cycle day 2 until oocyte retrieval. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
218901500|NCT01944137|OTHER|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
218901501|NCT01307826|OTHER|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
218901502|NCT01307826|OTHER|massage|classical massage (Swedish massage)
219037760|NCT04429217|OTHER|delayed weight-bearing for 6 weeks after surgery|"Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED)."
219612553|NCT00110396|BIOLOGICAL|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
219612554|NCT04305132|DEVICE|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
218901503|NCT03318549|DIAGNOSTIC_TEST|Visual Performance tests|Participants came to the clinic in person for 2 hours for visual performance tests once every 6 months for up to 5 years. These tests included virtual reality tests and tests on a computer screen to investigate performance during simulated daily life activities, such as driving, situations of low contrast and glare.
219037761|NCT01653496|PROCEDURE|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
219037762|NCT03594097|OTHER|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
219037763|NCT03594097|OTHER|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
219037764|NCT06987695|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
219037765|NCT06987695|DRUG|Placebo|Placebo will be administered SC.
219037766|NCT06854653|DRUG|PTX-100|Peptidomimetic inhibitor of GGTase 1
219037767|NCT03244124|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219037768|NCT03244124|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219364317|NCT03194984|DRUG|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
219364318|NCT02266680|BEHAVIORAL|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
219364319|NCT00872950|DRUG|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
219612555|NCT00300807|DRUG|XTL 6865|
219612556|NCT00446693|DEVICE|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
219519341|NCT03202576|DEVICE|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
219519342|NCT02285738|DRUG|Aspirin|81mg/day for 4 weeks
219519343|NCT02285738|DRUG|Simvastatin|Daily dose of Simvastatin for 4 weeks
219519344|NCT02285738|OTHER|Observation|participants will be observed for thrombotic evens for 4 weeks
219519345|NCT01909076|BEHAVIORAL|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
219519346|NCT01909076|BEHAVIORAL|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
219037769|NCT03244124|OTHER|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219519347|NCT01909076|BEHAVIORAL|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
219519348|NCT01909076|BEHAVIORAL|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
219519349|NCT01909076|BEHAVIORAL|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
219519350|NCT04963491|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
219519351|NCT04963491|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
219519352|NCT05546359|DRUG|Amisulpride Injection|Dose finding treatment for continuation to phase 3
219519353|NCT05546359|DRUG|Dexamethasone|Standard of care treatment
219519354|NCT00119886|DRUG|Botulinum toxin|
219364320|NCT02569060|OTHER|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
219519355|NCT04448223|DRUG|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
219519356|NCT04448223|DRUG|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
218901504|NCT03318549|DEVICE|Brain-computer interface|The brain-computer interface (BCI) consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle. The test is done in person and may take up to 30 minutes, once every 6 months for up to 5 years.
218901505|NCT04415372|DIAGNOSTIC_TEST|MRI|The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
219364321|NCT02569060|OTHER|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
219364322|NCT02569060|OTHER|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
218901506|NCT04415372|DIAGNOSTIC_TEST|Neuropsychological Testing|A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
218901507|NCT05924945|DEVICE|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
219037770|NCT03244124|OTHER|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219037771|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
219037772|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
219037773|NCT06329453|PROCEDURE|Colon Tissue Biopsy|Colonoscopy and colon tissue biopsy.
219037774|NCT03176186|COMBINATION_PRODUCT|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
219364323|NCT02569060|BEHAVIORAL|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
218901508|NCT05924945|DEVICE|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
219364324|NCT03932799|OTHER|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
219519357|NCT04283084|DEVICE|Virtual Reality Based Balance and Coordination Exercises|With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
219519358|NCT01062256|DRUG|Placebo|One placebo tablet administered orally as a single dose
218901509|NCT04320355|OTHER|Soft tissue manual therapy|The intervention is a type of massage.
218901510|NCT04138641|DRUG|Cangrelor|Cangrelor intravenous
218901511|NCT00997802|DEVICE|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
218901512|NCT03797846|PROCEDURE|combined glaucoma surgery|combined procedure with trabeculectomy and cataract removal
219519359|NCT01062256|DRUG|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
219519360|NCT01062256|OTHER|Buckwheat Honey|10 mL administered orally as a single dose
219519361|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
218901513|NCT04970875|OTHER|Questionnaire|QoL questionnaire
218901514|NCT02202239|DRUG|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
218901515|NCT02202239|DRUG|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
218901516|NCT02202239|DRUG|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
218901517|NCT02202239|DRUG|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
218901518|NCT02202239|DRUG|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
218901519|NCT02202239|DRUG|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
218901520|NCT02202239|DRUG|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
218901521|NCT02202239|DRUG|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
218901522|NCT03309423|DIAGNOSTIC_TEST|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
218901523|NCT02303093|BIOLOGICAL|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
218901524|NCT02303093|BIOLOGICAL|Panzyga|Panzyga
218901525|NCT02021942|DRUG|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
218901526|NCT02798250|OTHER|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
218901527|NCT02798250|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
218901528|NCT02798250|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
219519362|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
219519363|NCT03246100|BEHAVIORAL|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
219519364|NCT03049488|BIOLOGICAL|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
219519365|NCT03049488|OTHER|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
219519366|NCT03157856|OTHER|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
219519367|NCT05723822|DEVICE|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
219519368|NCT06544018|GENETIC|Genetic analysis of NLRP3|Blood test for genetic analysis of NLRP3
219519369|NCT06544018|DEVICE|Circadian rhythm measurement|Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
219612557|NCT03239093|OTHER|No intervention|Observational study using official data from the Federal Office of Statistics
219612558|NCT02764671|BIOLOGICAL|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
218901529|NCT02798250|DEVICE|Dexcom G4 Platinum glucose sensor|
218901530|NCT02798250|DEVICE|Accu Chek Combo insulin pump|
218901531|NCT01490775|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
218901532|NCT01490775|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
218901533|NCT00510835|PROCEDURE|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
218901534|NCT00510835|PROCEDURE|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
218901535|NCT00510835|PROCEDURE|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
218901536|NCT05061511|OTHER|Analysis of inflammasome expression|RNA isolation, spectrophotometric quantification, reverse transcription to cDNA and relative quantification of gene expression using a quantitative reverse transcription polymerase chain reaction (qRT-PCR). Specific inflammasome-related transcripts will be investigated, including ASC, caspase-1, IL-1beta, IL-18, NLRP3, NLRP2, AIM2, POP1, POP2, CARD16, CARD18, TRIM16, and TRIM20. A qRT-PCR System (e.g. StepOne Plus, Applied Biosystems) will be used for the amplification and analysis of the PCR products. Expression data will be reported as the ratio between each investigated target gene and GAPDH (used as housekeeping endogenous control).
218901537|NCT05061511|OTHER|Histological analysis|"gingival tissue samples will be prepared for paraffin inclusion and different stains will be used to evaluate the histological features of the tissues, distribution of inflammatory cells and alignment of collagen fibers.~Moreover, a trained examiner will assess semi-quantitatively the inflammatory infiltrate under light microscopy.~The expression of inflammatory/immune-related proteins such as NLRP3, ASC-2, IL-1beta and IL-18 protein expressions will be compared among the three groups by immunodetection methods"
218901538|NCT02870283|DRUG|Lithium|
218901539|NCT02870283|DRUG|Valproic Acid|
218901540|NCT02870283|DRUG|Carbamazepine|
219037775|NCT06275165|OTHER|acupressure|In the experimental group, routine nursing care and acupressure (Neiguan and Zusanli points) were performed from the 1st to the 5th day after the postoperative transfer from the ward to the hospital room. Twice a day, 3 minutes each time, 12 minutes in total.
219037776|NCT05863637|OTHER|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
219037777|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
219037778|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
219037779|NCT02417051|BEHAVIORAL|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
219519370|NCT06544018|BIOLOGICAL|Saliva sampling|Saliva sampling for salivary melatonin determination
219612559|NCT03246451|DRUG|Placebo Oral Tablet|2-4 tablets in 14 days
219612560|NCT03246451|DRUG|Metformin|1000-2000 mg in 14 days
219612561|NCT03246451|DRUG|Saline|9 mg/ml saline infusion during experimental days
219612562|NCT03246451|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
219612563|NCT04655560|OTHER|no intervention|qualitative study
218901541|NCT06483724|PROCEDURE|cervical tourniquet|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-An assistant slides a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix 4-The bladder peritoneum is isolated from the uterus 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
218901542|NCT06483724|PROCEDURE|uterine artery ligation|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-The bladder peritoneum is isolated from the uterus 4-The uterine vessels were ligated in continuity at the level of the utero-vesical fold on each side 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
218901543|NCT03123666|DRUG|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
218901544|NCT03123666|OTHER|Placebo|Placebo identical to GMCSF will be given
218901545|NCT00323141|DEVICE|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
218901546|NCT05839171|BEHAVIORAL|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
218901547|NCT06028997|BEHAVIORAL|Behavioral and Sleep Hygiene Education with Mindfulness Intervention|Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
218901548|NCT04808817|DIAGNOSTIC_TEST|calorimetry, impedance measurement at baseline and after 3 months of treatment|biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
218901549|NCT06426472|OTHER|Web-based support program|Web-based support program for infertile women with failed IVF experience
218901550|NCT00607087|DRUG|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
218901551|NCT00607087|DRUG|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
218901552|NCT00607087|DRUG|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
218901553|NCT02173080|OTHER|PLD-Q|polycystic liver disease questionnaire
218901554|NCT05455528|DIAGNOSTIC_TEST|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
218901555|NCT03499093|OTHER|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
218901556|NCT04451499|OTHER|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
218901557|NCT01597336|PROCEDURE|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
218901558|NCT01597336|PROCEDURE|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
218901559|NCT02647437|DRUG|Levetiracetam|
218901560|NCT02647437|DRUG|Placebo|
218901561|NCT04423055|DRUG|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
219364325|NCT03932799|OTHER|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
219364326|NCT03404466|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
219364724|NCT05953792|PROCEDURE|Select the vertebra above sagittal stable vertebra as the distal fusion level|The surgeries were performed by the same surgical team. Multi-level Ponte osteotomies were performed across the apex of the kyphosis after complete exposure of the spine, with resection of supra- and inter-spinous ligaments, ligamentum flavum, and the whole facet joints. After placement of the pedicle screws at the expected fusion levels, pre-contoured rods were attached to the screws followed by segmental compression. During rod placement, two to three rounds of compression in the area with Ponte osteotomies were employed to enhance kyphosis correction. Satellite rods were routinely added to long rods and implanted with duet screws. The final tightening was performed, and the posterior fusion was completed with a mixture of local and allogeneic bone. Due attention was given to preserving the posterior ligamentous structures at the upper and lower junctional areas.
218901562|NCT01673997|DRUG|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
218901563|NCT00650767|DRUG|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
218901564|NCT00650767|DRUG|Placebo; oral|matching placebo
218901565|NCT01302353|DRUG|Emulsified Isoflurane|
219037780|NCT04476537|DEVICE|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
219037781|NCT06663605|DRUG|PALI-2108|Oral dose
219037782|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
219037783|NCT05283538|DIAGNOSTIC_TEST|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
219037784|NCT04116853|BEHAVIORAL|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
219037785|NCT04116853|BEHAVIORAL|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
219037786|NCT06863766|DIETARY_SUPPLEMENT|fortified formula milk powder group|Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.
219037787|NCT06863766|DIETARY_SUPPLEMENT|regular milk powder group|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
219037788|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
219037789|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
219037790|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
219037791|NCT05277311|DRUG|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
219037792|NCT05277311|DRUG|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
219037793|NCT00157378|DRUG|Risperidone, Haloperidol|
218901566|NCT05396053|OTHER|Physical therapy exercises|Three times a week for 12 weeks.
218901567|NCT05396053|OTHER|Mirror therapy|Three times a week for 12 weeks.
218901568|NCT05396053|OTHER|Constraint Induced Movement Therapy|Three times a week for 12 weeks.
218901569|NCT02273661|DRUG|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
219364725|NCT02015169|DRUG|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
219519371|NCT06544018|OTHER|Questionnaire|Questionnaire to determine chronotype
219519372|NCT06544018|OTHER|AIDAI score|Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
218901570|NCT02273661|DRUG|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
218901571|NCT05944679|RADIATION|No Xray|Just one Xray 12 months after the intervention
218901572|NCT05944679|RADIATION|Xray|Xray at 1, 3, 6 and 12 months after intervention
218901573|NCT00387296|DEVICE|functional microarray|functional microarray application
218901574|NCT02548208|DEVICE|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
218901575|NCT02548208|DEVICE|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
218901576|NCT01774799|BEHAVIORAL|Advance care planning intervention|
218901577|NCT01774799|OTHER|Control group|
218901578|NCT04761133|DRUG|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
218901579|NCT01111617|PROCEDURE|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
218901580|NCT05647590|PROCEDURE|Chemotherapy|3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
219037794|NCT04141995|DRUG|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
219037795|NCT04141995|DRUG|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
219037796|NCT04141995|DRUG|Calcium Leucovorin|IV injection over 90 minutes
219037797|NCT04141995|DRUG|Irinotecan|IV administration over 90 minutes
219037798|NCT04141995|DRUG|Oxaliplatin|IV administration
219037799|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
219037800|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
219037801|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
219037802|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
219037803|NCT07110350|PROCEDURE|Laparotomy refers to a definitive single-stage exploratory abdominal surgery. Damage Control Surgery refers to a staged surgical approach including initial abbreviated laparotomy followed by planned.|This intervention involves exploratory laparotomy performed for abdominal trauma at a single tertiary care trauma center in Taiwan between 2013 and 2024. Patients are stratified based on whether they received a single definitive laparotomy or staged damage control surgery. Staged surgery is defined as an abbreviated initial laparotomy followed by planned reoperation(s), regardless of whether physiological indications were strictly met. This study specifically investigates the discrepancy between guideline-based indications and actual surgical practice.
218901581|NCT05647590|PROCEDURE|Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)|"* RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks … maintenance"
218901582|NCT05647590|PROCEDURE|Maintenance chemotherapy|Maintenance chemotherapy will follow 3-6 weeks after RT.
219037804|NCT07110181|BEHAVIORAL|a blended version of the Unified Protocol for Adolescents (UP-A)|The blended UP-A includes 8 weekly modules, 6 of which (Modules 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (Module 8), each with an expected duration of 90 minutes.
219037805|NCT07110181|DRUG|Standard psychiatric treatment|Participants in the control group will receive treatment as usual, including pharmacotherapy and routine clinical follow-up, as determined by their treating psychiatrists.
219037806|NCT05717777|OTHER|There is no intervention, only observational study|There is no intervention, only observational study
219037807|NCT06118346|BEHAVIORAL|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
219037808|NCT06118346|BEHAVIORAL|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
219037809|NCT06676657|DEVICE|iPancreas automated insulin delivery system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The MPC has a new feature called hyperglycemia pattern detection and dosing algorithm that will analyze problem patterns associated with high blood sugar and automatically calculate and deliver a correction dose.
219364726|NCT03484715|BEHAVIORAL|Physical Activity Intervention|A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
219364727|NCT03447626|DEVICE|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
219519373|NCT06544018|BIOLOGICAL|Blood sampling|"1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways"
219519374|NCT00208026|DRUG|Pimecrolimus 1% Cream|Open label single arm
219519375|NCT03967730|COMBINATION_PRODUCT|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
219612564|NCT00815880|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
219612565|NCT01375062|OTHER|analyse and proliferate the cells|"1. Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~2. Digestion of the biopsies through controlled enzymes~3. Replication of the cells~4. Selection undifferentiated cells~5. Expansion of the purification cells population~6. Characterization of the cell population~7. Assessment of pluripotent and germinal cell potential.~8. Possible maturation of the cells."
219612566|NCT00246818|PROCEDURE|Tai Chi Chuan|
219612567|NCT01601418|DRUG|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
219612568|NCT01601418|DRUG|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
218901583|NCT01640782|DRUG|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"* Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
218901584|NCT01640782|DRUG|Leucovorin, 5-Fluorouracil|"* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
218901585|NCT02386982|DRUG|HMS5552|
218901586|NCT06005181|BEHAVIORAL|Music listening|Daily music listening
218901587|NCT06005181|BEHAVIORAL|Piano training|Daily piano practice
218901588|NCT04014283|DIETARY_SUPPLEMENT|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
218901589|NCT04014283|OTHER|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
218901590|NCT04014283|OTHER|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
218901591|NCT00295542|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
218901592|NCT00295542|PROCEDURE|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
218901593|NCT00295542|DRUG|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
218901594|NCT00295542|DRUG|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
218901595|NCT00295542|DRUG|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
219037810|NCT05794789|BEHAVIORAL|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
219037811|NCT05165615|DEVICE|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
219364728|NCT00155480|PROCEDURE|computed tomography|
219612569|NCT04688437|RADIATION|standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination|Routine examination
219612570|NCT02101944|DRUG|Carfilzomib|Given IV
218901596|NCT00295542|DRUG|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
218901597|NCT00295542|PROCEDURE|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
218901598|NCT02504489|DRUG|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
218901599|NCT02504489|DRUG|Docetaxel (D)|Docetaxel 75 mg/m2 IV
218901600|NCT04364828|GENETIC|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
218901601|NCT04364828|GENETIC|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
218901602|NCT04364828|GENETIC|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
218901603|NCT04852939|OTHER|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
218901604|NCT04852939|OTHER|Conventional physical therapy|"* Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
219037812|NCT06303115|OTHER|Nicotine Pouch P1312914, 4 mg nicotine|P1312914 pouch product
219037813|NCT06303115|OTHER|Nicotine Pouch P1312915, 8 mg nicotine|P1312915 pouch product
219037814|NCT06303115|OTHER|Nicotine Pouch P1013215, 8 mg nicotine|P1013215 pouch product
219037815|NCT06303115|OTHER|Nicotine Pouch P1013218, 10 mg nicotine|P1013218 pouch product
219037816|NCT06303115|OTHER|Nicotine Pouch P1012919, 12 mg nicotine|P1012919 pouch product
219037817|NCT06303115|OTHER|Smoking Abstinence|No tobacco/nicotine
219037818|NCT06303115|OTHER|Continued UB cigarette smoking|Usual Brand Cigarette
219037819|NCT00560950|BIOLOGICAL|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
219364729|NCT01390792|DRUG|Zanamivir hydrate|
219364730|NCT00067704|BEHAVIORAL|Trauma writing|
219364731|NCT00067704|BEHAVIORAL|Writing about daily events|
219364732|NCT04052581|PROCEDURE|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
219364733|NCT03588377|DEVICE|Pulse Oximetry|"Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under \<5 children with symptoms of cough or difficulty breathing~Case definition:~1. Birth - 6 days: Fast breathing +/- Low oxygen in blood \<92% (Hypoxemia)~2. 7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood \<92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor."
219364734|NCT04285333|PROCEDURE|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
219364735|NCT04285333|PROCEDURE|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
219612571|NCT02101944|DRUG|Dexamethasone|Given IV
219612572|NCT02101944|OTHER|Laboratory Biomarker Analysis|Correlative studies
219612573|NCT02101944|BIOLOGICAL|Pelareorep|Given IV
218901605|NCT02418052|PROCEDURE|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
218901606|NCT02586623|DRUG|Droxidopa capsules|100, 200 or 300 mg
218901607|NCT02586623|DRUG|Placebo capsules|
218901608|NCT06278792|PROCEDURE|Diuretic protocol|Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result
218901609|NCT06278792|PROCEDURE|Standard of Care|Diuretic therapy at the discretion of the physician
219364736|NCT05242770|OTHER|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
219519376|NCT03027830|DEVICE|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
219519377|NCT03027830|DEVICE|Conventional|Other diagnostic devices (including FFR and angiography)
219612574|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
219612575|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
219612576|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
218901610|NCT00704366|DRUG|AZD0530|oral, tablet, once daily, dose will be variable
218901611|NCT03624842|DRUG|Trappsol (R) Cyclo (TM)|
218901612|NCT02338544|DRUG|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
218901613|NCT01788917|DIETARY_SUPPLEMENT|Linseed oil|Dietary supplement: 10 mL linseed oil per day
218901614|NCT05705466|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
218901615|NCT05705466|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
218901616|NCT05705466|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
219519378|NCT02221765|DRUG|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
219519379|NCT02221765|DRUG|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
218901617|NCT04487106|DRUG|Azacitidine|Given IV or SC
218901618|NCT04487106|DRUG|Trametinib|Given PO
218901619|NCT04487106|DRUG|Venetoclax|Given PO
218901620|NCT00003419|PROCEDURE|antiviral therapy|
218901621|NCT00391300|PROCEDURE|bioelectric field imaging|
218901622|NCT00391300|PROCEDURE|biopsy|
218901623|NCT00391300|PROCEDURE|histopathologic examination|
218901624|NCT04816474|BEHAVIORAL|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
219519380|NCT02067364|DEVICE|Fit & Function test|
219519381|NCT01666470|OTHER|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
219519382|NCT00891293|DRUG|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
218901625|NCT04154475|DIETARY_SUPPLEMENT|yogurt diet|500 g yogurt/day
218901626|NCT04154475|DIETARY_SUPPLEMENT|dairy diet|500 g non-yogurt dairy products
218901627|NCT04154475|DIETARY_SUPPLEMENT|standard diet|500 g soya-yogurt
218901628|NCT04184570|OTHER|Observational Trial|Observational Trial
218901629|NCT01163526|PROCEDURE|CT perfusion|
218901630|NCT02108249|DEVICE|Annex™ Adjacent Level System|
218901631|NCT00001118|DRUG|Enfuvirtide|
218901632|NCT04608565|DEVICE|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
218901633|NCT05742477|DRUG|Antibiotic|role of antibiotics in treatment of neonatal sepsis
219364737|NCT05242770|OTHER|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
219519383|NCT01271530|OTHER|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
219519384|NCT00500474|PROCEDURE|endolymphatic sac drainage with steroids|
219612577|NCT02150226|DEVICE|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
219612578|NCT03671161|DEVICE|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
219519385|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
219519386|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine|
219519387|NCT01815073|BIOLOGICAL|live attenuated JE vaccine|
219519388|NCT06360627|RADIATION|Computed Tomography|Computed Tomography CHEST
219519389|NCT06115889|BEHAVIORAL|Smart Taiko Drumming|Participants will play drumming with the developed Smart Taiko Drumming System for 30-45 minutes three times per week for 16 weeks, in addition to usual care.
218901634|NCT03952013|OTHER|To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure|All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
218901635|NCT00871871|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
218901636|NCT00871871|DRUG|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
218901637|NCT00871871|DRUG|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
218901638|NCT00871871|DRUG|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
218901639|NCT02093793|DEVICE|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
218901640|NCT04657874|OTHER|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
218901641|NCT04657874|OTHER|Placebo|Oral tablet without the active principle
218901642|NCT05100615|PROCEDURE|surgery|applying the graft inside bony defect after surgery
219037820|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fasting)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally after at least 10 hours overnight fast
219037821|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fed)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that is preceded by at least 10 hours overnight fast
219519390|NCT05732766|BIOLOGICAL|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
219519391|NCT05890157|OTHER|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
219519392|NCT05512026|DEVICE|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
219519393|NCT01448057|DRUG|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
219519394|NCT01448057|DRUG|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
219519395|NCT05013112|DRUG|SGLT2 inhibitor|Empagliflozin 20mg once daily from discharge
219519396|NCT05013112|DRUG|Metformin|Metformin 500mg twice daily from discharge
219519397|NCT05013112|OTHER|Placebo|Placebo group
219519398|NCT05335408|DEVICE|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
219519399|NCT05335408|DEVICE|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
218901643|NCT03067246|DEVICE|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
218901644|NCT03067246|DEVICE|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
219037822|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (US RS/RLD)|Single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) will be administered orally after at least 10 hours overnight fast
219037823|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (EU product)|Single dose of 5 mg Apixaban Oral Tablet (EU product) will be administered orally after at least 10 hours overnight fast
219037824|NCT06869135|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects will undergo assessments and saliva sampling at enrollment time (T0) and one year after (T12).
219519400|NCT03124966|DEVICE|Pulse Oximeter sensor|
219519401|NCT03354221|DEVICE|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
218901645|NCT06807151|PROCEDURE|Extracorporeal Treatment|Extracorporeal treatments in our study included hemoperfusion and continuous veno-venous hemodiafiltration.
218901646|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
218901647|NCT06311292|DEVICE|Volara System|Intrapulmonary percussive ventilation for mobilizing mucus.
218901648|NCT06347978|DEVICE|Deep Brain Stimulation|"Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks."
218901649|NCT05247086|DEVICE|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
218901650|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
218901651|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
218901652|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
218901653|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
218901654|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
219364738|NCT05242770|OTHER|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
219364739|NCT05242770|OTHER|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
219364740|NCT05242770|OTHER|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
219364741|NCT02908516|DRUG|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
219364742|NCT02908516|DRUG|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
219364743|NCT03143803|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
219364744|NCT03143803|DRUG|Placebo|Similar looking inactive powder
219364745|NCT02251912|DRUG|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
219364746|NCT02251912|DRUG|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
219364747|NCT06388902|DRUG|BR115 for injection|BR115 for injection will be administered by subcutaneous injection, two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data.
219364748|NCT01645267|PROCEDURE|Hydroxyapatite|Use of artifical bonegraft material
219364749|NCT04171739|DRUG|Itraconazole oral solution|200 mg once daily on Days 6 to 15
219364750|NCT04171739|DRUG|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
219519402|NCT03354221|OTHER|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
218901655|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
218901656|NCT03009851|BEHAVIORAL|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
218901657|NCT04726722|BEHAVIORAL|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
218901658|NCT05626530|DRUG|Letermovir|Open label 480 mg given daily for 60 days
218901659|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
218901660|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
219037825|NCT03114462|RADIATION|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
219204240|NCT06884709|OTHER|Mirror Therapy|"During mirror therapy, participants will sit in an arm chair with a mirror placed in their mid-sagittal plane so that their non-paretic lower limb is reflected and their paretic lower limb is hidden. They will be asked to complete activity-based exercises with their non-paretic limb whilst watching the reflection in the mirror and imagining the reflection is their paretic limb.~The activity-based exercises consist of rocker board dorsi/plantarflexion, rocker board in/eversion, step ups, wiping floor (or ball rolling) in/external hip rotation, wiping floor ab/adduction, ball kicking, and picking up marbles with the toes. Participants will do these exercises for 15 minutes, three days per week for four weeks.~Participants will also receive 45 to 60 minutes of usual personalized conventional physiotherapy such as neurodevelopmental facilitation, sensory motor re-education, active/active-assisted exercises, and balance/gait training, five days per week."
219204241|NCT06724523|BEHAVIORAL|Business-as-usual instruction|Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
219204242|NCT06878482|DRUG|Botulinum toxin A|subcutaneous injection of Botulinum toxin A
218901661|NCT05233033|DRUG|KT-413|KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
218901662|NCT03400475|DRUG|Simvastatin|One topical application in peri-implant gingival crevice
218901663|NCT03400475|OTHER|Placebo|One topical application in peri-implant gingival crevice
218901664|NCT00966511|PROCEDURE|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
218901665|NCT06915207|DIETARY_SUPPLEMENT|Counselling, behavioural, nutrition|integrative medical care delivered by one physician and referral to other health professionals as appropriate
218901666|NCT06867289|DEVICE|EEG|EEG monitoring will be performed in addition to the usual practice, before DEX administration and for 20 minutes before NMRI, to enable calculation of the PSI sedation score (at 0, 10, 20 minutes). Sedation will also be assessed by the PSSS clinical score at 0, 10, 20 minutes after DEX administration, as well as at 150 minutes after DEX.
218901667|NCT06613724|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
219037826|NCT03114462|BEHAVIORAL|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
219037827|NCT05695495|DRUG|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
219037828|NCT05695495|DRUG|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
219037829|NCT05695495|DRUG|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
219037830|NCT05695495|DRUG|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
219037831|NCT05695495|DRUG|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
219037832|NCT05695495|DRUG|Placebo (saline)|Intravenous bolus application over 45 seconds
219364751|NCT04171739|DRUG|Olorofim|Single oral dose on Days 1 and 11
219364752|NCT03790592|DEVICE|trifocal IOL|intraocular lens
219364753|NCT00643630|DEVICE|Tetrix|Twice daily topical application
219364754|NCT00643630|DEVICE|Tetrix|Twice daily topical application
219364755|NCT05176912|OTHER|Exercise|Reformer Pilates exercises will given for 8 weeks, 3 days in a week
219364756|NCT00838591|DRUG|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
219364757|NCT00838591|DRUG|Placebo|
219364758|NCT01694043|OTHER|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
219364759|NCT01694043|OTHER|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
219364760|NCT01107444|DRUG|Docetaxel|Administered intravenously
219364761|NCT01107444|DRUG|LY2181308|Administered intravenously
219519403|NCT03354221|OTHER|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
219519404|NCT03354221|OTHER|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
218901668|NCT01347528|BEHAVIORAL|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
219519405|NCT05210738|DEVICE|Single incision sling|Single incision sling is used to treat occult SUI
218901669|NCT06692140|DEVICE|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)|Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
218901670|NCT06692140|DEVICE|PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
218901671|NCT06727435|DRUG|non-sedation strategy|Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
218901672|NCT06726564|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
218901673|NCT06726967|DIAGNOSTIC_TEST|vitamin D 25(OH)D|Thyroid functions (thyroid-stimulating hormone (TSH), serbest triiodothyronine (fT3), serbest thyroxine (fT4)); Thyroid antibodies (Anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG))
218901674|NCT06725628|DIAGNOSTIC_TEST|Thy_CLNM_multi_omics|Surgery
218901675|NCT06726005|DEVICE|functional appliance twin block|3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
219037833|NCT06875024|BEHAVIORAL|Intelligent intervention programs|The intervention involves a structured exercise program, with participants in the experimental group engaging in cycling exercises three times per week, each session lasting 30 minutes during hospitalization. After discharge, they will follow a walking program, increasing their daily step count by 1,000 steps above the average recorded during hospitalization, for a total of 12 weeks. Structured questionnaires and medical records will be used for data collection at four time points: the first week of enrollment (T0), hospital discharge (T1), the eighth week post-enrollment (T2), and the twelfth week post-enrollment (T3). Additionally, a tri-axial accelerometer-equipped smart wristband will be used to monitor and record participants' heart rate, respiration, blood pressure, daily step count, and sleep quality.
219037834|NCT07027631|DEVICE|Magnesium Sulfate Iontophoresis|Magnesium Sulfate iontophoresis utilizing an iontophoretic drug delivery system
219204243|NCT04000763|DEVICE|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
219519406|NCT05210738|DRUG|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
219519407|NCT01822600|DRUG|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
219612579|NCT01958437|DEVICE|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
218901676|NCT06725381|DRUG|SKB571|SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
219037835|NCT07027631|DEVICE|Shock Wave Therapy|using Shock Wave Therapy Device
219037836|NCT07027631|OTHER|stretching and strengthening|stretching and strengthening exercises
219037837|NCT04846673|DRUG|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
219037838|NCT04846673|DRUG|Pregabalin 150mg|pregabalin qd
219612580|NCT03469635|OTHER|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
219037839|NCT04846673|DRUG|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
219037840|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
218901677|NCT06725836|PROCEDURE|Implantation of electrodes into the epidural space for spinal cord stimulation|Under X-ray guidance and with neurophysiological supervision, the electrode is implanted. The stimulator is surgically placed in a pocket formed in the iliac crest area on the left side, where it is secured. The generator is connected to an electrode array positioned on the dorsal epidural surface of the spinal cord at the appropriate level (sacral-lumbar/cervical region), as confirmed by intraoperative fluoroscopy.
218901678|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for spastic syndrome suppression|During the selection of the optimal stimulation program for spasticity suppression, spinal cord stimulation (SCS) is performed at various sites on the electrode array. Stimulation is initiated at a specific site with a frequency of 60 Hz, and the intensity is gradually increased until the spasticity is alleviated (i.e., the limb can flex and extend without restriction). If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is again adjusted from 0 to comfortable values. Stimulation is sequentially applied at different sites, and those sites where muscle spasticity is most effectively suppressed are selected.
218901679|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for volitional motor control|Over the course of two weeks, the configuration of the electrodes and the intensity of the stimulation are adjusted to ensure optimal voluntary muscle control. A systematic approach is used to determine the most suitable settings. First, the anodes and cathodes on the electrode array are identified. The desired frequency range is 20-40 Hz. The pulse width is determined empirically. The adjustment begins at 20 Hz, with the stimulation intensity gradually increased. If unpleasant sensations (such as muscle spasms or pain) occur, the intensity is reduced to comfortable values. If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is adjusted again from 0 to comfortable levels. Stimulation is sequentially applied at different sites, with the sites that provide the most effective voluntary muscle control being selected.
219037841|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
219037842|NCT06884267|OTHER|standard hyperkalemia management implementation|The interventions include HK disease management and quality audits for health care professionals (HCPs) and patients (Figure 1). The main contents of HK disease management in CKD include a standardized clinical pathway based on guideline adoption and medical trainings to educate HCPs and patients.
219204244|NCT06882681|DIETARY_SUPPLEMENT|LipoMicel Milk Thistle|A maximum single dose of approx. 140 mg silymarin (in soft gel capsule)
219204245|NCT06882681|DIETARY_SUPPLEMENT|Unformulated Milk Thistle Extract|A maximum single dose of approx. 130 mg silymarin (in hard gel capsules)
219204246|NCT06882252|OTHER|Low glycemic index diet|Replacement of typical meal/snack with lean pork containing meal/snack
219204247|NCT06887374|DRUG|Probiotic Bacillus Clausii|Patients were given 2 billion spores of probiotic (Bacillus clausii) every12 hours, contained in a small bottle.
219204248|NCT06885060|DEVICE|BGaze ADHD Diagnostic Test|The BGaze Clinic ADHD diagnostic test will be administered to all participants. This involves a computer-based task, where an eye-tracker will be recording their eye-movements.
219204249|NCT06885060|DEVICE|Oddball/Alerting Computer Task|Oddball/Alerting Computer Task will be completed by all participants while an eye-tracker records their eye movements.
219204250|NCT06885060|DEVICE|Facical Emotion Computer Task|The Facial Emotion Computer Task will also be completed by all participants while their eye movements are recorded using an eye-tracker.
219519408|NCT01822600|DRUG|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
219204251|NCT06886815|PROCEDURE|Popliteal Nerve Block|Popliteal sciatic nerve blocks will be performed with the patient in prone position, with the popliteal fossa of the surgical leg marked and sterilized. A high-frequency 10-12 MHz linear array ultrasound transducer will be positioned transversely at the level of the popliteal crease and moved proximally to identify the bifurcation of the sciatic nerve into the tibial and common peroneal nerves. Under ultrasound guidance, a 22-gauge, 80-mm echogenic needle will be inserted using an in-plane lateral-to-medial approach. 15 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine will be deposited between tibial and common peroneal nerves within the paraneural sheath. Adequate spread of local anesthetic will be confirmed by visualization of paraneural spread.
219204252|NCT06886815|PROCEDURE|Sham Block|Sham blocks will be performed using a 25G needle to inject 1 mL of saline subcutaneously in the popliteus of the surgical knee. Sterilization and ultrasound scanning will mirror that of a popliteal nerve block. The ultrasound screen will be blinded from the patient's vision for all patients in the trial to prevent unblinding by patients with knowledge of the technique.
219519409|NCT00002132|DRUG|Itraconazole|
219519410|NCT00002132|DRUG|Fluconazole|
219519411|NCT00183807|DRUG|irinotecan, cisplatin, celecoxib|
219519412|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
219519413|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
218901680|NCT06725836|DIAGNOSTIC_TEST|Resting electroencephalography for identifying neurocorrelates of spinal cord stimulation.|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. Initially, the participant is recorded in a resting state before the implantation of the stimulator for 20 minutes (5 minutes with eyes open, followed by 5 minutes with eyes closed). After the surgery, the participant is recorded in the same manner before the first activation of the stimulator. After selecting the programs, the participant is recorded without stimulation (eyes open, then closed), followed by recordings with the spinal cord stimulator (SCS) activated (eyes open, then closed). The stimulation is then turned off again, and recording is conducted with eyes open and closed. Before discharge, the participant is recorded in a resting state for 20 minutes with the stimulation program active.
218901681|NCT06725836|DIAGNOSTIC_TEST|Electroencephalography within the motor imagery paradigm|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. During the experiment, with the stimulator turned off, the participant views a fixation cross on a computer screen. Then, they hear an auditory signal and see a sign indicating a specific movement (complete flexion and extension of the left arm, complete flexion and extension of the right arm, complete flexion and extension of the left leg, complete flexion and extension of the right leg). The participant imagines the movements according to the auditory and visual signals on the screen. Subsequently, the participant performs the same movements in the same order. The motor control stimulation program is then activated, and the entire sequence is repeated (first imagining the movement, then performing the imagined movements). The timing of the command presentations is recorded with marker placements.
218901682|NCT06705543|GENETIC|multi-omics genetic analyses included exome|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit. These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study.~* Trio exome study (parents-fetus)."
218901683|NCT06705543|GENETIC|multi-omics genetic analyses|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit; These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study."
218901684|NCT05776251|DEVICE|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
218901685|NCT06718543|DRUG|AK112 with SCRT and CapeOX|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally).
218901686|NCT06718543|DRUG|AK112 with SCRT|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion).
218901687|NCT06727019|DEVICE|low-level red-light|650-nm low-level red-light
218901688|NCT06727019|DRUG|Atropine (0.01%)|Atropine eye drops at concentration of 0.01%
218901689|NCT06727461|OTHER|Home-based Feeding EnhancEment in Dementia (Feed@home)|"The FEED@home program is an 8-week initiative led by a speech therapist (ST) and nurse team through teleconsultations and home visits:~* Within 3 days after discharge, a nurse teleconsultation with the family caregiver to assess the patient's mealtime behaviors and provide feeding strategy recommendations and educational materials.~* Two to three home visits by STs during mealtime (depending on the mastery of feeding techniques) to assess swallowing and cognitive feeding issues, providing tailored interventions and proper training of feeding techniques.~* Two teleconsultations by nurses to assess the caregiver's techniques and provide additional training.~* One additional home visit during mealtime by a nurse to assess the caregiver's mastery of the feeding techniques through observation.~* The program lasts 8 weeks, regardless of readmissions, unless the patient converts to tube feeding, moves to a care home, passes away, or withdraws from study."
218901690|NCT06726525|DEVICE|HPMC+GlicoPro eyedrops|HPMC+GlicoPro eyedrops, artificial tears for dry eye disease
218901691|NCT06726525|DEVICE|Hydroxypropyl-methylcellulose|Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease
218901692|NCT00004164|BIOLOGICAL|filgrastim|
218901693|NCT00004164|DRUG|cisplatin|
218901694|NCT00004164|DRUG|docetaxel|
218901695|NCT00004164|DRUG|fluorouracil|
218901696|NCT00004164|DRUG|leucovorin calcium|
219204253|NCT06885242|DEVICE|Microdrop instillation of cyclopentolate 1%|1 drop administered through the Nanodropper device adapted to the commercially available multi-dose dropper bottle
219204254|NCT06885242|DEVICE|Standard drop instillation of cyclopentolate 1%|1 drop administered directly through the commercially available multi-dose dropper bottle
218901697|NCT00004164|RADIATION|radiation therapy|
218901698|NCT05935592|BEHAVIORAL|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
218901699|NCT05935592|BEHAVIORAL|Didactic health information|Web-based newsletters (for child and parent) by email and/or text
219204255|NCT06726369|DRUG|MK-6204 (SKB535) for Injection|MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
219204256|NCT06427447|COMBINATION_PRODUCT|Adjuvant chemoradiotherapy|Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
219204257|NCT06427447|DRUG|Adjuvant chemotherapy|Chemotherapy (gemcitabine plus capecitabine)
218901700|NCT06885879|RADIATION|Temporal change of fragmentomics of Circulating tumour DNA undergoing Stereotactic Body Radiation Therapy investigation|"Patients will have blood taking for Circulating tumour DNA (ctDNA) (20cc each) at Week 0 (before radiotherapy), Week 1 (during radiotherapy), Week 2 (after radiotherapy), Week 12 and Week 24.~Radiological assessment will be performed before radiotherapy, Week 12 (approximately 3 months post treatment) and Week 24-26 (approximately 6 months post treatment)."
218901701|NCT06755281|OTHER|Direct Oral challenge|Patients will receive a 1-step or 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be instructed to contact the hospital after the drug provocation test to inquire delayed allergic reactions.
218901702|NCT06755281|OTHER|standard of care|The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.
218901703|NCT03064490|DRUG|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
218901704|NCT06777784|OTHER|Product A|Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette
218901705|NCT06777784|OTHER|Product B|Modern Nicotine Oral Product Cool Mint 6 mg Nicotine
218901706|NCT06777784|OTHER|Product C|Modern Nicotine Oral Product Cool Mint 12 mg Nicotine
218901707|NCT06777784|OTHER|Product D|Modern Nicotine Oral Product Cool Mint 15 mg Nicotine
219037843|NCT06886295|DEVICE|Prosthetic controller|The intervention includes an upper limb prosthesis composed at the minimum by skin-surface electrodes for myoelectric signals, a vibrotactile actuator, a multi-articulated and instrumented hand prosthesis and a centralized control system. The centralized prosthetic controller processes the myoelectric signals acquired at the residual limb to enable the movements on the multi-articulated prosthesis.
219037844|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
219204258|NCT06726889|BEHAVIORAL|Standard care|Patient will not receive any additional interventions
218901708|NCT06777784|OTHER|Product E|Modern Nicotine Oral Product Smooth 6 mg Nicotine
218901709|NCT06777784|OTHER|Product F|Modern Nicotine Oral Product Wintergreen 6 mg Nicotine
218901710|NCT06777784|OTHER|Product G|Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine
218901711|NCT06777784|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
218901712|NCT06188767|DRUG|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
218901713|NCT06607523|DIETARY_SUPPLEMENT|Inulin|Inulin, 4g twice daily for 42 days
218901714|NCT06770023|DEVICE|Protek Solo Transseptal Cannula|The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.
218901715|NCT04846387|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
218901716|NCT04846387|DIAGNOSTIC_TEST|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
218901717|NCT04846387|DIAGNOSTIC_TEST|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
218901718|NCT04846387|BEHAVIORAL|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
218901719|NCT02647723|DIETARY_SUPPLEMENT|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
218901720|NCT02647723|DIETARY_SUPPLEMENT|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
218901721|NCT03929159|PROCEDURE|Biospecimen Collection|Undergo blood biospecimen collection
218901722|NCT06760364|DRUG|CHT102|CHT 102 : MSLN UCAR-T.
218901723|NCT01806142|OTHER|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
219037845|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
219037846|NCT06728072|DRUG|Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin|Metronidazole, ciprofloxacin, aspirin is initiated Cycle 1 Day 1 of chemotherapy. May be initiated any time from 7 days before Cycle 1 Day 1 up to and including Cycle 1 Day 3
219037847|NCT07044180|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
218901724|NCT01806142|OTHER|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
218901725|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
218901726|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
218901727|NCT06908044|DRUG|Bryophyllum|Bryophyllum Pinnatum - tablets, for 6 Months
218901728|NCT06911216|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution once daily (QD) (9AM ± 60 min), one drop for each eye
218901729|NCT06921525|DRUG|Tea Tree Oil Topical Application Oil|Tea tree oil (TTO), derived from the leaves of Melaleuca alternifolia,
218901730|NCT06921525|DRUG|Azithromycin Ophthalmic Solution|Azithromycin has demonstrated efficacy in improving meibomian gland function and reducing inflammation and improving symptoms of dryness of the eye
218901731|NCT06922396|OTHER|Parameters on admission|"A: Parameters on admission:~* Age.~* Sex.~* Comorbidities (DM, HTN, CKD, IHD, Liver Disease)~* Mode of trauma.~* Laboratory data (RBS, INR, AST, ALT, Urea, Creatinine, WBC ,HB, CK, Myoglobin).~* Ct brain findings.~* Scoring system (GCS, RTS, APACHE II).~B: Parameters after 2 weeks:~* Days on Mechanical Ventilation.~* Medical or surgical management.~* Complications (Pneumonia, DVT, septic shock, Pulmonary embolism, ARDS)."
218901732|NCT06922721|OTHER|Focus group|"The Well-Being Coffee Group intervention is implemented in two formats: in person and others via videoconference, all facilitated by the same psychologist throughout the study. Across all formats, participation is voluntary and follows an information phase and the signing of an informed consent form. Participants will complete standardized evaluation questionnaires at multiple time points. The discussion groups are designed to create a supportive and open environment that encourages free expression. Their goal is to provide participants with a space to share their thoughts, emotions, and personal experiences, as well as to reflect on those emerging from group discussions. Topics explored include identity, substance use, migratory experiences, and mental health, fostering meaningful dialogue and mutual support."
218901733|NCT06921577|COMBINATION_PRODUCT|antimicrobial agent|Adding nanoparticles to 3Dprinted denture base resin improve the properties of the material
218901734|NCT06921005|OTHER|Exercise|Recovery with vascular occlusion or active recovery in soccer players.
218901735|NCT06914011|DRUG|Tislelizumab|"* Participants who underwent upfront surgery without prior neoadjuvant therapy:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for one cycle~ * Concurrent radiotherapy (25 fractions of 1.8 Gy each, with 5 fractions per week) with Tislelizumab 200 mg iv D1, D22, Paclitaxel 50 mg/m2 iv D1, 8, 15, 22, 29, and Carboplatin AUC 2 mg/mL/min D1, 8, 15, 22, 29~ * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for 1 cycle~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles~* For participants who underwent neoadjuvant chemoradiotherapy followed by surgery will receive adjuvant chemoimmunotherapy in the following sequence:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for four cycles~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles"
218901736|NCT06922370|DIAGNOSTIC_TEST|conventional radiograph or computed tomography|patients with gitelman syndrome evaluated with conventional radiograph or computed tomography
218901737|NCT06922058|DEVICE|Virtual Reality Glasses|Virtual reality glasses haven\&#39;t used in orthodontics in another clinical study.
218901738|NCT06920589|BEHAVIORAL|"Safe and Protected Sex intervention targeting HPV"|"This study used the Safe and Protected Sex intervention (Báez et al., 2019), adapted and validated from an HIV prevention program to focus on HPV. The intervention consists of a single module with two stages aimed at increasing HPV knowledge by enhancing personal (self-determination) and social (controlled behavior) motivation.~Module 1: Nursing Consultation on HPV This structured, planned process follows Corona and Kaltmeier's (2012) horizontal methodology, promoting self-care through social support and trust in nurse-patient dialogue. The goal is to provide counseling on HPV prevention and responsible sexual behavior while acknowledging participants' prior knowledge.~Stage 1: A 4.21-minute educational video, HPV Fun Facts, uses persuasive narrative to explain HPV transmission, symptoms, complications, and prevention.~Stage 2: A 45-minute Friendly Educational Guidance session uses open-ended questions to explore participants' experiences."
218901739|NCT06920589|BEHAVIORAL|Diptych of the Secretary of Health in Mexico|a brochure is provided with general information about the human papilloma virus in men, including the form of contagion, diagnosis, treatment and the use of condoms for prevention.
218901740|NCT01446627|OTHER|There is no intervention for this study|None, no intervention made.
218901741|NCT05929625|DEVICE|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
218901742|NCT05929625|DEVICE|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
218901743|NCT04886713|DIAGNOSTIC_TEST|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
218901744|NCT04886713|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and \> 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume"
219037848|NCT07044180|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
218901745|NCT04886713|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
218901746|NCT00862693|DRUG|Calcitriol|0.5ug/Biw
218901747|NCT00002609|BIOLOGICAL|lintuzumab|
218901748|NCT00002609|DRUG|cytarabine|
218901749|NCT00002609|DRUG|idarubicin|
218901750|NCT00751803|DRUG|BI 44370 TA Low Dose|
218901751|NCT00751803|DRUG|Eletriptan|
219037849|NCT06740344|PROCEDURE|Two-handed facemask hold|Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver PIP via the T-piece.
219037850|NCT06740344|PROCEDURE|Control: One-handed facemask hold|One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering PPV via the T-piece.
219037851|NCT07047612|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
219519414|NCT04836000|OTHER|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
219519415|NCT02921737|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
219519416|NCT05723809|DEVICE|Percussive Therapy Device|Same as group description
219519417|NCT05723809|BEHAVIORAL|Physical Therapy|Same as group description
219519418|NCT04164745|DRUG|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
219519419|NCT04164745|BIOLOGICAL|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
219519420|NCT01826383|BEHAVIORAL|Active-Video|This group will watch an active-video with pain management strategies for parents
219519421|NCT01826383|BEHAVIORAL|Placebo Video|This group will watch a placebo-video describing immunization generally.
219519422|NCT00422747|DRUG|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
219519423|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
218901752|NCT00751803|DRUG|Placebo|
218901753|NCT00751803|DRUG|BI 44370 TA Medium Dose|
218901754|NCT02135510|DRUG|metoclopramide|
219037852|NCT07047612|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
219037853|NCT06891300|DRUG|ketamine hydrochloride|Participants will undergo intravenous (IV) ketamine infusions (0.5 mg/kg infused over 40 minutes) under medical supervision. Treatments will be administered twice weekly for two weeks, for a total of four infusions.
218901755|NCT02135510|DRUG|dexamethason|
218901756|NCT02135510|DRUG|palonosetron|
218901757|NCT03177928|DEVICE|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
218901758|NCT03186027|DIETARY_SUPPLEMENT|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
218901759|NCT03186027|DIETARY_SUPPLEMENT|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
218901760|NCT00206843|DEVICE|Triage BNP Test|
218901761|NCT01667653|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule once daily
218901762|NCT01667653|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
218901763|NCT00519051|OTHER|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
218901764|NCT03374033|DIETARY_SUPPLEMENT|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
218901765|NCT03374033|BEHAVIORAL|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
218901766|NCT00880295|PROCEDURE|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
218901767|NCT00880295|PROCEDURE|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
219037854|NCT00366990|BEHAVIORAL|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
219037855|NCT00366990|BEHAVIORAL|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
219204259|NCT06726889|BEHAVIORAL|Decision Support System (DSS)|DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link
218901768|NCT06546046|DEVICE|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
218901769|NCT06482541|COMBINATION_PRODUCT|5 billion exosomes and saline solution microneedling|Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
218901770|NCT06482541|COMBINATION_PRODUCT|50 billion exosomes and saline solution microneedling|Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
218901771|NCT03226925|DIAGNOSTIC_TEST|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
218901772|NCT03226925|DIAGNOSTIC_TEST|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
218901773|NCT03226925|DIAGNOSTIC_TEST|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
218901774|NCT02360891|OTHER|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
218901775|NCT00282763|DRUG|MK0686|
218901776|NCT04931940|DIETARY_SUPPLEMENT|Usual Care|Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU
218901777|NCT04931940|DIETARY_SUPPLEMENT|Higher Protein/Amino Acid Group|Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
218901778|NCT01218334|DEVICE|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
218901779|NCT04032067|DRUG|GV1001 placebo|0.9 % Normal Saline
218901780|NCT04032067|DRUG|Proscar placebo|PO
218901781|NCT02861612|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
218901782|NCT01017484|OTHER|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
218901783|NCT03237793|PROCEDURE|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
218901784|NCT03237793|PROCEDURE|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
218901785|NCT05111860|DRUG|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
218901786|NCT02152306|DRUG|Fimasartan and Amlodipine|
218901787|NCT02152306|DRUG|Fimasartan|
218901788|NCT05481775|DRUG|Anlotinib|Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
218901789|NCT05481775|DRUG|Chemotherapy|Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
218901790|NCT05481775|RADIATION|Radiotherapy|Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
218901791|NCT05481775|DRUG|Immunotherapy|consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
218901792|NCT02217163|DRUG|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
218901793|NCT02153593|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
218901794|NCT02153593|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
218901795|NCT02153593|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
218901796|NCT03622008|DRUG|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
218901797|NCT03622008|OTHER|Placebo|Placebo IV
218901798|NCT02321241|DRUG|Aflibercept (EYLEA, BAY-86-5321)|"1. st year: 3 monthly injections followed by 1 injection every two months~2. nd year and following: injection according the visual and anatomical results observed the 1st year"
219519424|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (40 mg/ml) with needles|Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
219519425|NCT00986297|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
219519426|NCT03472365|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
219519427|NCT03472365|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
219519428|NCT03472365|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
219519429|NCT03472365|DRUG|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
219519430|NCT03593980|DIETARY_SUPPLEMENT|Cranberry juice|400ml cranberry juice
219519431|NCT05332925|DRUG|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
218901799|NCT02413918|DRUG|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
218901800|NCT05697783|DRUG|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
218901801|NCT04985526|OTHER|Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)|Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
218901802|NCT04309292|DIETARY_SUPPLEMENT|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
218901803|NCT04309292|DIETARY_SUPPLEMENT|Protein supplement|commercially available protein supplementation with high leucine content
218901804|NCT04309292|DIETARY_SUPPLEMENT|Maltrodextrin (placebo)|Starchy substance
219519432|NCT06341322|BEHAVIORAL|Standard letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, based on the current invite letter.
218901805|NCT01147042|DRUG|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
218901806|NCT03338777|BIOLOGICAL|Suicide plus immunogene therapy|"1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
219037856|NCT07109661|BEHAVIORAL|Rational Positive Parenting Program (rPPP)|The Rational Positive Parenting Program (rPPP) is a structured cognitive-behavioral group intervention based on Rational Emotive Behavior Therapy (REBT). It comprises 8-10 weekly sessions focused on addressing irrational parenting beliefs, improving emotion regulation, and teaching positive behavior management strategies for children with disruptive behaviors. Participants in the control group will not receive the intervention during the active phase, but will be offered the rPPP after final assessment to ensure ethical treatment.
219519433|NCT06341322|BEHAVIORAL|Behaviorally informed letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, with incorporates severally behaviorally informed components, including an active choice prompt, social norm, call to action, chunking and simplification.
219519434|NCT06341322|BEHAVIORAL|Home testing colorectal cancer kit|The home testing kit is included with the reminder letter, instead of the usual process of responding to the letter to order the kit
219519435|NCT01728922|DIETARY_SUPPLEMENT|5000IU vitamin D|Vigantol Oil
218901807|NCT04233801|DRUG|Empagliflozin|Empagliflozin
219519436|NCT01728922|DIETARY_SUPPLEMENT|10000IU vitamin D|Vigantol Oil
218901808|NCT04233801|DRUG|Placebo|Placebo
218901809|NCT00434538|DEVICE|BST-DermOn|
218901810|NCT00761475|PROCEDURE|mesh supported closure|onlay mesh supported closure midline laparotomy
218901811|NCT00761475|PROCEDURE|primary closure|primary closure of the midline
218901812|NCT00761475|PROCEDURE|mesh supported closure|sublay mesh supported closure midline laparotomy
218901813|NCT06032065|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
218901814|NCT06032065|BEHAVIORAL|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
219519437|NCT01728922|OTHER|Placebo|Placebo Oil
219519438|NCT06427057|DRUG|Cadonilimab plus chemotherapy|AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）
219519439|NCT06427057|DRUG|Cadonilimab plus TKI|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)
219519440|NCT03769844|DRUG|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
219519441|NCT01944267|PROCEDURE|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
218901815|NCT06032065|DIETARY_SUPPLEMENT|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
218901816|NCT04397510|DRUG|Heparin|Nebulized Heparin
218901817|NCT04397510|DRUG|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
218901818|NCT01860664|DRUG|hydrocortisone ophthalmic ointment 0.5%|"* Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
218901819|NCT01860664|DRUG|placebo|Mineral oil and white petrolatum
218901820|NCT06428110|OTHER||
218901821|NCT04772872|OTHER|Assessment by Brazelton neonatal behavior for group A,Band C|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
219037857|NCT07108543|PROCEDURE|Antegrade versus retrograde cross k-wire|\> Closed reduction of distal radius fracture followed by percutaneous insertion of two or more K-wires in an antegrade direction (from proximal to distal), crossing the fracture site under fluoroscopic guidance. The wires are introduced from the radial metaphysis and directed distally to stabilize the fracture.
219612581|NCT04408729|OTHER|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
218901822|NCT04848675|OTHER|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
219204260|NCT06726889|BEHAVIORAL|Reminders|Personalized reminders will be delivered to patients through a common messaging application (WhatsApp)
218901823|NCT04848675|OTHER|Brisk walking|Participants will perform brisk walking.
218901824|NCT03118414|OTHER|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
218901825|NCT03118414|OTHER|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
219204261|NCT06726889|BEHAVIORAL|Feedback|Feedback message will be delivered by physician to patients, through WhatsApp, after medication diary revision
219519442|NCT01944267|PROCEDURE|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
218901826|NCT03118414|OTHER|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
218901827|NCT05959044|DRUG|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
218901828|NCT05959044|OTHER|Placebo|orally 5mg two times daily for 8weeks
218901829|NCT01026545|DRUG|PF-04287881|500 mg once daily for 10 days
218901830|NCT01026545|DRUG|Placebo|To match 500 mg dose once daily for 10 days
218901831|NCT01026545|DRUG|PF-04287881|750 mg once daily for 10 days
218901832|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
218901833|NCT01026545|DRUG|PF-04287881|1100 mg once daily for 10 days
218901834|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
218901835|NCT01026545|DRUG|PF-04287881|Optional cohort with dose not greater than 1100 mg
218901836|NCT01026545|DRUG|Placebo|Optional cohort to match dose not greater than 1100 mg
218901837|NCT01026545|DRUG|PF-04287881|750 mg dose once daily for 10 days
219519443|NCT01944267|PROCEDURE|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
219612582|NCT05048901|DRUG|Cabozantinib|Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
218901838|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
218901839|NCT01026545|DRUG|PF-04287881|1100 mg dose once daily for 10 days
218901840|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
218901841|NCT00928486|DRUG|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
218901842|NCT00928486|DRUG|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
218901843|NCT00008008|BIOLOGICAL|filgrastim|
218901844|NCT00008008|BIOLOGICAL|sargramostim|
218901845|NCT00008008|DRUG|cyclophosphamide|
218901846|NCT00008008|DRUG|thiotepa|
218901847|NCT00008008|PROCEDURE|autologous bone marrow transplantation|
218901848|NCT00008008|PROCEDURE|bone marrow ablation with stem cell support|
218901849|NCT00008008|PROCEDURE|peripheral blood stem cell transplantation|
218901850|NCT02660177|DRUG|Metamizole|metamizole IV administration
219612583|NCT05048901|DRUG|Lanreotide|Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
219612584|NCT06273319|DRUG|OXYGEN THERAPY|15 AND 30 LT OXYGEN TREATMENT
218901851|NCT04715620|DRUG|Niraparib|Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
218901852|NCT00173407|PROCEDURE|immunohistochemical, methylation, gene transfection|
218901853|NCT03478540|DRUG|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
218901854|NCT01342913|DRUG|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
218901855|NCT01342913|DRUG|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
218901856|NCT01447589|DRUG|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
218901857|NCT01447589|RADIATION|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
218901858|NCT02122835|BEHAVIORAL|aerobic exercise training|12 weeks of supervised aerobic exercise training
218901859|NCT02474797|DEVICE|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7)."
218901860|NCT00923923|BEHAVIORAL|stress|compare levels of stress
218901861|NCT04024891|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
218901862|NCT04024891|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
218901863|NCT03832348|DEVICE|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
219037858|NCT06895811|BIOLOGICAL|PSMA-UCAR T (BRL-302)|"Three patients will be firstly enrolled at a dose level (DL) of 5.0 × 10\^6cells/kg in the DL1 group, following lymphodepleting chemotherapy which will be given under instruction of protocol and investigators' assessment;~Based on preliminary safety data, efficacy information, and PK/PD parameters obtained at DL1 cohort, the investigator may enroll another three patients in a decreased dose level group of DL-2: 3 × 10\^6 cells/kg or DL-1:1 × 10\^6 cells/ kg, after thorough discussions between the investigators."
219037859|NCT06776965|OTHER|Dietary Questionnaire|Self administered dietary questionnaire at baseline, 6 and 12 months.
218901864|NCT05295849|BEHAVIORAL|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
219037860|NCT06776965|OTHER|Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)|Self administered questionnaire of disease activity at baseline, 6 and 12 months.
219037861|NCT06844331|DEVICE|Thoracic ultrasound|The investigators want to investigate that TUS/US can use to identify and to monitir the disease progression in the patients with F-ILD
218901865|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
218901866|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy combined with the local treatment of FES-negative lesions|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
218901867|NCT06195709|COMBINATION_PRODUCT|Chemotherapy|Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
219204262|NCT06705712|BEHAVIORAL|Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.|"All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing."
219204263|NCT06883968|BEHAVIORAL|Therapeutic exercise during hemodialysis session|"Participants in the intervention group will receive a therapeutic exercise program during hemodialysis sessions at the hospital. The physiotherapist, after assessing the participant, will plan a program with the sets and number of repetitions for the prescribed exercises based on the participant's condition.~In this exercise program, the lower and upper extremities will be worked on with the aim of improving strength, balance, as well as contributing to the improvement of the participant's quality of life and mood."
219519444|NCT01787058|OTHER|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
219519445|NCT03006419|DRUG|Basiliximab|Standard induction therapy
219519446|NCT03006419|DRUG|Thymoglobulin|Induction therapy
219519447|NCT03883906|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
219519448|NCT03063814|BEHAVIORAL|APP|See arm description
219519449|NCT03063814|BEHAVIORAL|PHY|see arm description
219519450|NCT02367638|BIOLOGICAL|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
219519451|NCT02367638|BIOLOGICAL|VARIVAX|VARIVAX is administered by subcutaneous injection
219519452|NCT03237364|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
219519453|NCT00242021|BEHAVIORAL|Fatty acid composition of a margarine (spread)|
219519454|NCT04659421|DRUG|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
219519455|NCT03239509|PROCEDURE|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
219519456|NCT03239509|PROCEDURE|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
219519457|NCT00660647|DRUG|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
219519458|NCT00660647|DRUG|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
219519459|NCT01197339|BEHAVIORAL|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
219519460|NCT01197339|BEHAVIORAL|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
219519461|NCT01197339|BEHAVIORAL|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
219519462|NCT01197339|BEHAVIORAL|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
219519463|NCT01197339|BEHAVIORAL|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
219612585|NCT04886596|BIOLOGICAL|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.
219612586|NCT04886596|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.
219612587|NCT03702127|DEVICE|Transcranial magnetic stimulation|NIBS is applied to the brain.
218901868|NCT01474317|DEVICE|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
218901869|NCT01105910|OTHER|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
218901870|NCT01105910|OTHER|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
218901871|NCT04283617|BEHAVIORAL|Intensification of insulin regimen/Nutrition|The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
218901872|NCT04013386|DRUG|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
218901873|NCT04013386|DRUG|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
218901874|NCT04013386|DRUG|Dexamethasone|Dexamethasone 8 mg IVI
218901875|NCT03481894|DRUG|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
218901876|NCT03481894|DRUG|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
218901877|NCT04066439|OTHER|specimen|Immunohistochemistry analysis
218901878|NCT02946437|DRUG|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
219037862|NCT06898658|BEHAVIORAL|Mindfulness Intervention|"Hybrid MAPs course will be delivered by a Spanish-speaking Latina certified mindfulness instructor, with a blend of in-person instruction, online instruction and asynchronous (audio-recorded) content instruction over 6-wks. There will be three live-2hr classes (2 in-person, 1 online) and three 3 weeks of 1-hr self-guided audio/week asynchronous content (1hr/wk). Additionally, the instructor will invite the intervention group to join optional weekly via Zoom 1x/wk for 30-min sessions for time to encourage questions, dialogue, and brief group mindfulness practice opportunities.~Class attendance and engagement with audio-recorded materials will be tracked. The study team will call or text participants weekly to maintain engagement, remind about any upcoming scheduled classes, and answer any questions. Participant attendance in classes (in-person and zoom) will be monitored."
219037863|NCT07064577|DRUG|ROS-scavenging Nanoenzymes|ROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.
219204264|NCT06879119|PROCEDURE|Localized scalp thread embedding|Volunteers who met the inclusion criteria were enrolled in the trial. All participants underwent treatment intervention in the vertex alopecic area via vertex alopecic area scalp thread embedding. A single thread embedding session was performed upon enrollment, with monthly follow-ups conducted over a total period of 6 months. Operative procedure: After fully exposing and disinfecting the treatment area, threads were inserted into the scalp at an approximately 15-degree oblique angle, with needle tips reaching the subgaleal space at a depth of 2-4 mm. Threads were spaced 1 cm apart. Upon completion, the treated area was disinfected and applied with erythromycin ointment.
219612588|NCT00948155|DRUG|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
219037864|NCT07064577|BEHAVIORAL|Standard of care|Standard of care
219037865|NCT06874452|DRUG|Xanax|The patients will each receive a single tablet of 0.5mg XANAX 30 minutes before surgery. Patients older than 65 years or with liver disease will receive a reduced dose of 0.25 mg rather than 0.5 mg of oral XANAX 30 minutes before surgery.
219037866|NCT06874452|OTHER|Placebo Tablets|The patients will each receive a single tablet of placebo 30 minutes before surgery.
219612589|NCT06345911|BEHAVIORAL|Experimental group|The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer. The child and their parents were taken to the blood collection room. During the bloodletting procedure, the child was asked to focus on the animal character they had chosen.
219612590|NCT04610190|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
218901879|NCT02946437|DRUG|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
218901880|NCT02946437|DRUG|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
218901881|NCT02946437|DEVICE|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
218901882|NCT00282035|RADIATION|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
218901883|NCT00282035|RADIATION|Whole breast irradiation|Whole breast irradiation
218901884|NCT02423850|DEVICE|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
219037867|NCT05535777|BEHAVIORAL|Enhanced texts with Callback by a Person|"Enhanced texts - Callback by a person: Patient randomized to this study arm will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
219519464|NCT02307734|BEHAVIORAL|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
219612591|NCT02406690|OTHER|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
219612592|NCT03473925|DRUG|Navarixin|Oral capsules
219612593|NCT03473925|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219612594|NCT02614326|BEHAVIORAL|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
219612595|NCT02614326|BEHAVIORAL|Psychoeducation|As in experimental arm description
218901885|NCT00060645|DRUG|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
218901886|NCT01314196|OTHER|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
218901887|NCT01314196|OTHER|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
218901888|NCT03392103|DRUG|Raltitrexed|concurrent chemotherapy
218901889|NCT03392103|RADIATION|postoperative radiotherapy|concurrent postoperative radiation therapy
219612596|NCT06823349|DRUG|Dexmedetomidine|5 mic dexmedetomidine will be given intrathecally added to 2.5 mg bupivacaine
219612597|NCT06823349|DRUG|fentanyl|25 mic of fentanyl will be given intrathecally added to 2.5 mg bupivacaine
219612598|NCT06823349|DRUG|Saline 0.9%|0.5 ml of saline 0.9% will be given intrathecally added to 2.5 mg of bupivacaine
219612599|NCT02691234|DEVICE|Extracorporeal Shockwave Therapy and debridement|
218901890|NCT03636659|DRUG|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
218901891|NCT03636659|DRUG|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
218901892|NCT06305702|DRUG|inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
218901893|NCT04803383|OTHER|Tele-yoga|Tele-yoga training 3 days a week for 8 weeks
218901894|NCT00617786|PROCEDURE|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
218901895|NCT04842903|OTHER|Therapeutic Touch|Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
219037868|NCT05535777|BEHAVIORAL|Enhanced Bidirectional Texts|"Patients randomized to this study arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient."
219037869|NCT06841692|DIAGNOSTIC_TEST|Diuretic Testing|The administration of hydrochlorothiazide and bumetanide is used to stimulate and assess tubular function.
219612600|NCT02691234|OTHER|debridement and cleaning|
218901896|NCT03758781|DRUG|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
218901897|NCT03758781|DRUG|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
218901898|NCT02680522|OTHER|Exercise|exercise training with virtual reality in videogame
218901899|NCT00121563|DRUG|Thalidomide, Ibuprofen or Diazepam|
218901900|NCT02598401|OTHER|observation|Observational study with no intervention
218901901|NCT02107417|DEVICE|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
218901902|NCT02107417|DEVICE|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
218901903|NCT00197314|BEHAVIORAL|circular muscle exercises versus pelvic floor exercises|
218901904|NCT04796714|DRUG|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
218901905|NCT04796714|DRUG|Aspirin|One sachet of aspirin 160 mg per day during 3 months
218901906|NCT04796714|DEVICE|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
218901907|NCT04796714|OTHER|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
218901908|NCT05270668|DRUG|Tulisokibart|Tulisokibart administered at timepoints as directed by the protocol
218901909|NCT05270668|DIAGNOSTIC_TEST|Companion diagnostic ( CDx)|CDx+ or CDx-
218901910|NCT05270668|DRUG|Placebo|Placebo
218901911|NCT05844891|BEHAVIORAL|Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)|TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (when possible), featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
218901912|NCT05844891|BEHAVIORAL|Enhanced Care (EC)|Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
218901913|NCT05747443|OTHER|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
218901914|NCT05747443|OTHER|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
218901915|NCT05730725|DRUG|BMS-986322|Specified dose on specified days
219519465|NCT02307734|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
218901916|NCT05730725|OTHER|Placebo|Specified dose on specified days
218901917|NCT04275323|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
218901918|NCT04275323|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
218901919|NCT05861466|DRUG|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
218901920|NCT05861466|PROCEDURE|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
218901921|NCT02152631|DRUG|Abemaciclib|Administered orally
219519466|NCT01155986|DRUG|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
219519467|NCT01155986|DRUG|Placebo topical plaster|Topical hydrogel plaster
219519468|NCT04057144|BEHAVIORAL|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
219519469|NCT04057144|BEHAVIORAL|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
218901922|NCT02152631|DRUG|Erlotinib|Administered orally
218901923|NCT05473026|BEHAVIORAL|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
218901924|NCT05672329|OTHER|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
218901925|NCT05672329|OTHER|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
218901926|NCT05672329|OTHER|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
218901927|NCT05672329|OTHER|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
218901928|NCT05624476|DIAGNOSTIC_TEST|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
218901929|NCT00359463|DRUG|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
218901930|NCT03006380|DRUG|oxytocin|Ecbolic used to reduce blood loss
219612601|NCT06492109|BEHAVIORAL|Sleep manipulation|"This study will collect the MMSE results as a supplement to the MoCA. The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS).~Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether experimentally induced (controlled) or naturally occurring (passive), along with assessment scales including anxiety and depression assessments.~For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments.~Experimentally induced sleep deprivation takes place under controlled laboratory conditions, whereas passive sleep deprivation arises from external factors such as aging or shift work."
219612602|NCT04584502|BEHAVIORAL|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
218901931|NCT03776747|DRUG|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
218901932|NCT03776747|DRUG|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
219612603|NCT04852406|DRUG|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
218901933|NCT03776747|DIAGNOSTIC_TEST|Vitals|
218901934|NCT03776747|DIAGNOSTIC_TEST|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
218901935|NCT03776747|DIAGNOSTIC_TEST|Initial protocol MRI scan|Initial scan to determine placement
218901936|NCT02071966|DRUG|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
218901937|NCT02071966|DRUG|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
218901938|NCT05327179|OTHER|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
218901939|NCT05327179|OTHER|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
218901940|NCT03487731|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
218901941|NCT03487731|DRUG|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
218901942|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
218901943|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
218901944|NCT04909489|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
218901945|NCT05686785|DIAGNOSTIC_TEST|Transient elastography|Transient elastography measures liver stiffness in kPa
218901946|NCT05877755|DEVICE|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
218901947|NCT00905450|DRUG|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
219612604|NCT04852406|DRUG|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
219612605|NCT02777372|DRUG|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
218901948|NCT00905450|DRUG|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
218901949|NCT05084313|OTHER|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
218901950|NCT05084313|OTHER|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
218901951|NCT05084313|OTHER|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
218901952|NCT06330740|OTHER|Clinical Decision Support|Upon ordering antibiotics the provider will be prompted to utilize an indication-based order set which guides the clinician to the appropriate empiric antibiotic choice.
218901953|NCT01529073|DRUG|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
218901954|NCT03683173|BEHAVIORAL|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
219037870|NCT06803797|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
219037871|NCT06832137|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 2 weeks of CMTS4520 daily for chronic constipation.
219037872|NCT06832137|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
219037873|NCT04009655|OTHER|music|music selected by musician
219037874|NCT03642691|BIOLOGICAL|Ryplazim|Plasminogen IV replacement therapy
219037875|NCT07108790|OTHER|Concentrated growth factors, collagen membrane and xenograft bone graft|Ten sites were treated by concentrated growth factors (CGF), collagen membrane, and xenograft bone graft.
219037876|NCT07108790|OTHER|Collagen membrane and xenograft bone graft|Ten sites were treated with a collagen membrane and a xenograft bone graft.
219037877|NCT07101471|DRUG|Tofacitinib|Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.
219519470|NCT04057144|BEHAVIORAL|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
219519471|NCT02134080|DRUG|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
218901955|NCT01494948|OTHER|allergen challenge|nasal challenges with antigen to which they are sensitive to
218901956|NCT04149249|OTHER|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
218901957|NCT04149249|OTHER|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
218901958|NCT04258930|OTHER|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
218901959|NCT04258930|DEVICE|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
218901960|NCT04258930|DEVICE|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
218901961|NCT05279352|DRUG|FBR-002|Administration on D1 and D3
219037878|NCT07110077|OTHER|Young First Aiders Traing of Early Secondry School children|Training Young First Aiders in Early Secondary School Children with a pre-, immediate post- and final post-tests to determine knowledge change.
219037879|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 2D imaging device|participants will undergo colonoscopy examination using 2D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
219037880|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 3D imaging device|participants will undergo colonoscopy examination using 3D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
219519472|NCT02134080|DRUG|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
219519473|NCT06302374|BIOLOGICAL|GR2001|intramuscular injection
219519474|NCT06302374|BIOLOGICAL|Placebo|intramuscular injection
219519475|NCT06302374|BIOLOGICAL|HTIG|intramuscular injection
219037881|NCT06923371|BEHAVIORAL|Direct Cash Support for Maternal and Infant Health (High fee)|The high fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, alleviate financial strain, and facilitate healthier lifestyle choices. This group will receive a higher level of financial support compared to the low fee group, with the aim of examining how larger amounts of financial assistance affect maternal and infant health, healthcare access, and well-being.
219037882|NCT06923371|BEHAVIORAL|Behavioral: Direct Cash Support for Maternal and Infant Health (Low fee)|The low fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, reduce financial strain, and support healthier lifestyle choices. This group will receive a lower level of financial support compared to the high fee group, allowing us to compare the effects of varying levels of financial assistance on maternal and infant health outcomes.
218901962|NCT05279352|DRUG|Placebo|Administration on D1 and D3
218901963|NCT03567031|PROCEDURE|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
218901964|NCT00363532|DRUG|infusion of calcitonin gene related peptide (CGRP)|
219037883|NCT07108595|DRUG|T- Dxd|T-DXd based therapy
219037884|NCT06923228|DRUG|CGB-500 Ointment with 1% tofacitinib|experimental drug
219037885|NCT06923228|DRUG|Ruxolitinib 1.5% Cream QD|topical cream
219037886|NCT03921710|DRUG|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
219037887|NCT03921710|DRUG|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
219204265|NCT06882239|OTHER|SPINEPASS Physical Therapy|SPINEPASS consists of a core set of three daily exercises integrated into daily activities to improve/restore overall spinal and dural mobility and or stability. It also provides training in the use of specific tools to be used as needed to address symptoms as they occur. Treatment can also include spinal manual therapy and other exercises to enhance the tools, but the emphasis is on self-management.
219204266|NCT06882239|OTHER|Standard Physical Therapy|The cervical therapy for standard Physical Therapy will be based on impairments found but could include cervical and or thoracic manual therapy, exercises to improve segmental range of motion, exercises for cervical and axioscapular neuromotor retraining, and specific cervical related sensorimotor control exercises such as proprioceptive retraining. A home program of exercises tailored for the individual will be provided.
219204267|NCT06880952|OTHER|Chlorhexidine Digluconate Mouthwash without Alcohol|In the rinsing group, the patients received a bottle of 0,2% chlorhexidine
218901965|NCT01934959|DRUG|Bifico|
218901966|NCT02647281|DRUG|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
218901967|NCT02647281|DRUG|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
218901968|NCT05801991|DEVICE|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
218901969|NCT05801991|DEVICE|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
218901970|NCT00972101|RADIATION|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
218901971|NCT00972101|DRUG|Melphalan|140 mg/m\^2 by vein over 30 minutes as a single dose on Day -8
218901972|NCT00972101|DRUG|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
218901973|NCT00972101|DRUG|Fludarabine|40 mg/m\^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
218901974|NCT00972101|DRUG|Rituximab|"Regimen 1:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
218901975|NCT00972101|DRUG|Etoposide|60 mg/m\^2 by vein over 1-2 hours as a single dose on Day -3.
218901976|NCT00972101|DRUG|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
219037888|NCT03561857|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone."
219037889|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
219037890|NCT00752583|PROCEDURE|Peritoneal dialysis|Blood, urine and dialysate sampling
219037891|NCT00752583|PROCEDURE|Haemodialysis|Blood, urine and dialysate sampling
219037892|NCT05742880|DIAGNOSTIC_TEST|6 Minute Walking Test|6 Minute walking test
219037893|NCT05742880|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analyisis
219037894|NCT05742880|PROCEDURE|Wearing a Surgical Facemask|Wearing a Surgical Facemask
219037895|NCT05742880|PROCEDURE|Wearing a FFP2- Facemask|Wearing a FFP2- Facemask
219037896|NCT05742880|PROCEDURE|Wearing no Mask|Wearing no Mask
219037897|NCT02181556|DRUG|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
219204268|NCT06881407|DEVICE|Robot|This robot will serve as a cheerleader and coach to provide encouragement and feedback.
218901977|NCT00972101|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
218901978|NCT00972101|DRUG|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
219037898|NCT02181556|DRUG|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
219037899|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
219037900|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
219204269|NCT06881407|DEVICE|Virtual Reality|Our developed Super Pop VR system will be used to provide virtual reality intervention.
219204270|NCT06884475|PROCEDURE|Implantoplasty|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, surgical access will be performed for debridement and implantoplasty of the affected dental implant.
219519476|NCT06302374|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
219037901|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
219037902|NCT02550327|DRUG|Nab-paclitaxel|125 mg/m2
219037903|NCT02550327|DRUG|Gemcitabine|1000 mg/m2
219037904|NCT02550327|DRUG|Cisplatin|25 mg/m2
219037905|NCT02550327|DRUG|Anakinra|100 mg
219037906|NCT02317302|DEVICE|FDG-PET/MR|
219037907|NCT02317302|DEVICE|FDG-PET/CT|
219037908|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
219037909|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
219037910|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
219037911|NCT00363974|DRUG|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
219037912|NCT05371314|DIAGNOSTIC_TEST|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
219037913|NCT00427635|DRUG|Esomeprazole|
219037914|NCT03277846|DEVICE|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
219037915|NCT01088646|DEVICE|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
218901979|NCT00972101|PROCEDURE|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
218901980|NCT00972101|DRUG|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is \> 2.5 x 10e\^9/L.
218901981|NCT00972101|PROCEDURE|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e\^5 T cells/kg on Day 14+.
219612606|NCT06262204|PROCEDURE|Hallux Valgus Treatment with Shark Screw®|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
218901982|NCT05019690|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
218901983|NCT05019690|DRUG|Albumin-Bound Paclitaxel|Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
218901984|NCT01057953|GENETIC|Blood drawn|Blood drawn for patient
218901985|NCT00547274|DRUG|MK0767|
218901986|NCT03684174|DEVICE|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
218901987|NCT00276510|DRUG|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
218901988|NCT00276510|OTHER|Placebo|1 tablet twice a day, oral route, during 5 years.
218901989|NCT05661786|OTHER|Observation|Monitor every 6 months
218901990|NCT05661786|OTHER|Antiviral treatment|Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
218901991|NCT01320475|DRUG|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
218901992|NCT01320475|DRUG|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
218901993|NCT05631561|DEVICE|Endovascular denervation System (Generator and Catheter )|All patients receive endovascular denervation (EDN) treatment
218901994|NCT02210000|DRUG|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
219612607|NCT06262204|PROCEDURE|Hallux Valgus Treatment with metal screw|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
218901995|NCT02210000|DRUG|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
218901996|NCT01378988|DRUG|Dexmedetomidine|For sedation according to protocol
218901997|NCT01329263|OTHER|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
218901998|NCT02773186|OTHER|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
218901999|NCT03959163|DIAGNOSTIC_TEST|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
218902000|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
218902001|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
218902002|NCT05343858|DIETARY_SUPPLEMENT|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
218902003|NCT02790996|DRUG|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
219037916|NCT01572038|DRUG|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
219037917|NCT01572038|DRUG|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
219037918|NCT01572038|DRUG|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
219037919|NCT01572038|DRUG|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
218902004|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
218902005|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
218902006|NCT04369378|BEHAVIORAL|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
218902007|NCT02372578|DRUG|ASP3662|oral
218902008|NCT02372578|DRUG|pregabalin|oral
218902009|NCT02372578|DRUG|ASP3662 placebo|oral
218902010|NCT02372578|DRUG|pregabalin placebo|oral
219037920|NCT01572038|DRUG|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
219037921|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
219037922|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
219037923|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
219612608|NCT04661150|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
218902011|NCT05655663|OTHER|Vascular investigation|Measure of of carotid stiffness
218902012|NCT05626166|DRUG|Placebo|placebo tablets twice daily
218902013|NCT05626166|DRUG|Diosmin|diosmin 600 mg twice daily
218902014|NCT02076607|PROCEDURE|Arthrodesis|Posterior approach to toracolumbar spine fusion.
218902015|NCT02076607|DEVICE|Brace|Toracolumbar imobilization
218902016|NCT05412147|DIETARY_SUPPLEMENT|RECO-18|4 pills daily, oral
219612609|NCT04661150|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
219612610|NCT04661150|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
219612611|NCT04661150|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
218902017|NCT05412147|DIETARY_SUPPLEMENT|Multi-vitamins|one tablet daily, oral
218902018|NCT01421017|RADIATION|Radiation|
218902019|NCT01421017|DRUG|Imiquimod|
218902020|NCT01421017|DRUG|Cyclophosphamide|
218902021|NCT00308139|DRUG|exenatide, long acting release|
218902022|NCT00308139|DRUG|exenatide|
218902023|NCT05439044|OTHER|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
218902024|NCT02152826|DEVICE|Potassium oxalate|Professional application
218902025|NCT04051398|OTHER|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
218902026|NCT03960216|PROCEDURE|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
219037924|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
219037925|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
219037926|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
219037927|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
219037928|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
218902027|NCT03960216|PROCEDURE|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
219519477|NCT04617327|RADIATION|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is \<3 mm in any dimension, or rotation is \<3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
219519478|NCT04483102|DEVICE|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
218902028|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
218902029|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
218902030|NCT02093884|OTHER|Text Messaging Intervention|
218902031|NCT02093884|OTHER|Standard Referral|
218902032|NCT00833040|DRUG|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
218902033|NCT02313766|OTHER|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
218902034|NCT02313766|OTHER|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
218902035|NCT04739826|DRUG|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
218902036|NCT04739826|DRUG|Nilotinib Pill|Nilotinib Capsules 300mg bid
218902037|NCT03723148|DRUG|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
219612612|NCT06362421|GENETIC|Pre-Radiation Dental Evaluation/Sample Collection|Collection of saliva samples and mouth swabs and pre-cancer dental evaluation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
219612613|NCT06362421|OTHER|Pre-Study Visit|Collection of vital signs, medical history and current medications
219612614|NCT06362421|GENETIC|Oral Medicine Consultation Visit/Sample Collection|Collection of saliva samples and mouth swab, complete oral medicine consultation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
218902038|NCT06079788|DRUG|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion."
218902039|NCT06079788|DRUG|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
218902040|NCT02849379|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
218902041|NCT02849379|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
218902042|NCT03573934|OTHER|GLP-2|GLP-2
218902043|NCT03573934|OTHER|GIP|GIP
218902044|NCT03573934|OTHER|GLP-2+GIP|GLP-2+GIP
218902045|NCT03573934|OTHER|Placebo|Placebo
218902046|NCT04674891|OTHER|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
218902047|NCT04674891|OTHER|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
218902048|NCT01972581|OTHER|Reaction Time Training|
219037929|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
219037930|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
219037931|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
219037932|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
219037933|NCT04152447|DEVICE|VR device|Patients use a VR device
218902049|NCT03932877|OTHER|MMP-14 and s-ENG levels|Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
218902050|NCT05572008|BEHAVIORAL|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
218902051|NCT03489863|DRUG|Prasugrel|Maintenance dose will be maintained for 10±3 days.
218902052|NCT03489863|DRUG|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
218902053|NCT01893801|DRUG|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
218902054|NCT01893801|DRUG|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
218902055|NCT01893801|DRUG|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
218902056|NCT05917912|DRUG|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
218902057|NCT05917912|DRUG|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
219037934|NCT00065533|DRUG|pemetrexed|
219612615|NCT04157595|OTHER|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
219612616|NCT06045689|DRUG|Luspatercept|Specified dose on specified days.
219612617|NCT06304883|DRUG|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally.
218902058|NCT03422029|DRUG|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
218902059|NCT04907734|OTHER|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
218902060|NCT01045486|DRUG|ATP mixed probiotics|\- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
218902061|NCT01045486|DRUG|Placebo|\- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
218902062|NCT02984488|PROCEDURE|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
218902063|NCT02984488|PROCEDURE|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
218902064|NCT01290107|GENETIC|DNA analysis|
219037935|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
219037936|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
219037937|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
219612618|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
219612619|NCT06004674|DRUG|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
219612620|NCT04416581|DRUG|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
219612621|NCT04416581|DRUG|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
219612622|NCT04175041|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
219612623|NCT05198518|DEVICE|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
219612624|NCT05198518|DEVICE|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
219612625|NCT05024825|DRUG|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
219519479|NCT04483102|PROCEDURE|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
219519480|NCT00741871|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
219519481|NCT02370407|DEVICE|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
219519482|NCT02370407|DEVICE|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
219519483|NCT04574193|DEVICE|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
219519484|NCT04574193|OTHER|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
219519485|NCT04996238|PROCEDURE|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
219519486|NCT00718679|DRUG|IVN201|Intralymphativ injection of the study drug
219519487|NCT00718679|DRUG|Placebo|
218902065|NCT01290107|GENETIC|gene rearrangement analysis|
218902066|NCT01290107|GENETIC|microarray analysis|
218902067|NCT01290107|GENETIC|polymerase chain reaction|
218902068|NCT01290107|OTHER|immunological diagnostic method|
218902069|NCT01290107|OTHER|laboratory biomarker analysis|
219519488|NCT04260503|OTHER|Monitoring of the gut-microbiome and ultrasound elasticity.|The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
219519489|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome before and after operation.
219519490|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome along with the disease progress.
219519491|NCT04260503|OTHER|Monitoring of the gut-microbiome.|The investigator will investigate the alteration of gut-microbiome according to the normal development.
219519492|NCT02602379|OTHER|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
219519493|NCT03670238|DEVICE|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
219519494|NCT03670238|DEVICE|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
219519495|NCT02623088|OTHER|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
219612626|NCT05024825|DRUG|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
219612627|NCT03427515|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10\^9 CFU/day
219612628|NCT03427515|DIETARY_SUPPLEMENT|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10\^9 CFU/day
218902070|NCT02718521|PROCEDURE|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
218902071|NCT02718521|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
218902072|NCT02718521|DRUG|0.9% sodium chloride ﬂuid administration|
219612629|NCT03427515|DIETARY_SUPPLEMENT|Placebo|30 days of supplementation
218902073|NCT02718521|DRUG|isosorbide dinitrate|
218902074|NCT03255239|PROCEDURE|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
218902075|NCT04273607|DRUG|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
218902076|NCT04636281|OTHER|Active and passive static stretching exercises|Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
218902077|NCT03598179|BIOLOGICAL|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10\^6 Acute lymphocytic leukemia 2×10\^6 Chronic lymphocytic leukemia 10×10\^6
218902078|NCT03167385|DRUG|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
218902079|NCT02193776|DRUG|PA-824|oral
218902080|NCT02193776|DRUG|bedaquiline|oral
218902081|NCT02193776|DRUG|moxifloxacin|oral
218902082|NCT02193776|DRUG|pyrazinamide|oral
218902083|NCT02193776|DRUG|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
218902084|NCT02211053|DRUG|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
219037938|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
219037939|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
219037940|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
219037941|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
219519496|NCT03186911|BEHAVIORAL|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
219519497|NCT05274711|OTHER|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
218902085|NCT02211053|DRUG|placebo|
218902086|NCT05193214|DRUG|Recombinant anti-PD-1 humanized monoclonal antibody injection|Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
218902087|NCT02754570|DRUG|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
218902088|NCT00530413|DRUG|Phenobarbital|Phenobarbital will be given based on weight range
218902089|NCT00530413|OTHER|Placebo|Placebo group
218902090|NCT00182130|PROCEDURE|Quality Initiative in Rectal Cancer (QIRC) strategy|
218902091|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
218902092|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
218902093|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
218902094|NCT03467321|OTHER|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
219037942|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
219612630|NCT02068313|RADIATION|Toxicity and outcome measures of IMRT|
218902095|NCT03447002|DIAGNOSTIC_TEST|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
218902096|NCT00703456|BEHAVIORAL|Balance Training|balance training three days per week for 4 weeks during single limb standing
218902097|NCT00737113|DRUG|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
218902098|NCT00629226|BIOLOGICAL|cetuximab|Given IV
219612631|NCT02521649|DRUG|G17DT|
218902099|NCT00629226|DRUG|bortezomib|Given IV
218902100|NCT00629226|DRUG|cisplatin|Given IV
218902101|NCT00629226|RADIATION|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
218902102|NCT00454714|DRUG|single dose Sildenafil|Application of a single dose Sildenafil
218902103|NCT00454714|DRUG|Single dose placebo|Application of a single dose placebo
218902104|NCT02971423|DRUG|ETX2514|
218902105|NCT02971423|DRUG|Placebo|matching placebo infusion
218902106|NCT02971423|DRUG|Sulbactam|
218902107|NCT02971423|DRUG|Imipenem/Cilastatin|
218902108|NCT00962208|DEVICE|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
218902109|NCT00962208|DEVICE|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
218902110|NCT03936114|BEHAVIORAL|SMART|SMART program mindfulness training program
218902111|NCT01139502|BEHAVIORAL|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
218902112|NCT01139502|BEHAVIORAL|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
219037943|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
219037944|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
219037945|NCT02208791|DRUG|No intervention|
219037946|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
219037947|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
219037948|NCT02595736|DRUG|Placebo (SC)|Administered SC
219037949|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
219037950|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
219037951|NCT02595736|DRUG|Placebo (IV)|Administered IV
219037952|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
219037953|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
219037954|NCT03998124|OTHER|Usual care|Staff-led social activity
219037955|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
218902113|NCT03729648|BEHAVIORAL|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
218902114|NCT00285896|DRUG|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
219037956|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
218902115|NCT00285896|DRUG|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
219037957|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
219037958|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
219037959|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
219037960|NCT00001720|DRUG|Alendronate|
219204271|NCT06884475|PROCEDURE|Surgical access|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, only surgical access will be performed for debridement without implantoplasty of the affected dental implant.
219204272|NCT06879821|OTHER|high intensity functional training|The pillar of rehabilitation will be based on high intensity functional training. 45-minute sessions divided into 5 minutes of warm-up, 35 minutes of functional exercises, and 5 minutes of going back to bed and cooling down. The 35 minutes of exercises were divided into 3 categories: lower extremity exercises, upper extremity exercises, and static and dynamic coordination and balance exercises. Each category will consist of 3 exercises per session, performing 2-3 series with a maximum of repetitions of 10-RM. The progression of the load will be progressively increased in weeks 3, 5 and 8 between 40-60% of the 1-RM.
219204273|NCT06887127|DRUG|TLL-018|TLL-018 20 mg BID for 78 weeks
219204274|NCT06886074|DRUG|Short course of blinatumomab|"Patients will receive 175 mcg of blinatumomab trough out seven days in a 24-hours infusion.~Blinatumomab therapy will be assigned 17.5 mcg per day for the first 2 days. Then blinatumomab 28 mcg per day for 5 days (completing 7 days). A single intravenous 20 mg dose of dexamethasone will be applied one hour before starting dose."
219037961|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
219037962|NCT04250064|DRUG|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
219037963|NCT04250064|RADIATION|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
219037964|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
219037965|NCT03662100|DRUG|LY3074828|Administered SC
219037966|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
219037967|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
219037968|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
219037969|NCT02159547|OTHER|Normal Saline|50 ml normal saline
219037970|NCT04445545|DEVICE|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
219204275|NCT06872567|DEVICE|genicular artery embolization|genicular artery embolization
219204276|NCT06872567|DRUG|Corticosteroid Injection|Corticosteroid Injection
219204277|NCT06885541|DIAGNOSTIC_TEST|Detection of objective internal tremors|head-mounted motion sensors
219364762|NCT03851692|OTHER|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
219364763|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
219364764|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
219364765|NCT05949307|DEVICE|acupuncture|acupuncture
219364766|NCT05949307|DEVICE|laser acupuncture|laser acupuncture
219364767|NCT05949307|DEVICE|Sham-laser acupuncture|Sham-laser acupuncture
219364768|NCT06213428|BIOLOGICAL|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
219364769|NCT06213428|OTHER|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
219364770|NCT00737451|BEHAVIORAL|blood sampling|blood sampling 10ml from the study subjects
218902116|NCT02867267|DRUG|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
218902117|NCT02867267|OTHER|Placebo|Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
218902118|NCT00935181|BEHAVIORAL|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
218902119|NCT00888693|DRUG|ABT-288|See Arm Description for details.
218902120|NCT00888693|DRUG|Placebo|See Arm Description for details.
218902121|NCT06733467|OTHER|Stimulus properties: remembered feature|The feature used to determine which stimulus feature to remember to will be varied across trials using a letter cue (M = remember-motion; C = remember-color; 0 = remember nothing)
218902122|NCT02904798|DRUG|Polypodium Leucotomos|\- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
218902123|NCT01635231|OTHER|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
218902124|NCT00791388|DRUG|Placebo|oral capsule, 2x/day for 14 days
219037971|NCT04445545|DEVICE|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
219037972|NCT04445545|PROCEDURE|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
219037973|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
218902125|NCT00791388|DRUG|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
218902126|NCT00791388|DRUG|PG-760564|oral capsule, 100mg, 2x/day for 14 days
218902127|NCT00791388|DRUG|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
218902128|NCT00791388|DRUG|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
218902129|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Acute DVT
218902130|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Chronic DVT
218902131|NCT02324946|OTHER|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
218902132|NCT05084040|OTHER|90 days interval between catheter maintenance|Length of time between catheter maintenances extended from 60 days to 90 days
218902133|NCT03930836|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
218902134|NCT03930836|BEHAVIORAL|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
218902135|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
218902136|NCT00498914|DRUG|YM155|Continuous IV infusion
218902137|NCT03090308|OTHER|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for \> 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
218902138|NCT04375917|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
218902139|NCT03902691|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
218902140|NCT03902691|DRUG|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
218902141|NCT04133558|OTHER|tracheal aspirate during routine care|tracheal aspirate during routine care
218902142|NCT00379847|DRUG|conivaptan|IV
218902143|NCT03290443|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
219037974|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
219364790|NCT05740228|DEVICE|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
219364791|NCT05740228|DEVICE|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
219364792|NCT03969888|DRUG|ABBV-3067|Tablet taken orally.
219364793|NCT03969888|DRUG|Placebo ABBV-3067|Tablet taken orally.
219364794|NCT03969888|DRUG|ABBV-2222|Capsule taken orally.
219364795|NCT03969888|DRUG|Placebo ABBV-2222|Capsule taken orally.
219364796|NCT03875950|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
218902144|NCT06028919|DEVICE|Temperature controlled DiamondTemp (DT) ablation catheter|The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
218902145|NCT06028919|DEVICE|Tacticath/Tactiflex (TF) ablation catheter|The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
218902146|NCT02064946|DIETARY_SUPPLEMENT|vitamin D|50,000IU/week of vitamin D3
218902147|NCT02064946|DIETARY_SUPPLEMENT|Placebo|
218902148|NCT02602769|DIAGNOSTIC_TEST|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
218902149|NCT04718623|DIAGNOSTIC_TEST|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
218902150|NCT01458639|DRUG|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
218902151|NCT01458639|DRUG|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
218902152|NCT01169129|OTHER|surgery|resection of brain metastases
219519498|NCT05274711|OTHER|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
219519499|NCT06343948|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
218902153|NCT01169129|RADIATION|radiosurgery|radiosurgery to brain metastases
218902154|NCT02870998|OTHER|Active learning|1-day continuing education activity consisting of a lecture on patient education.
218902155|NCT02870998|OTHER|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
219037975|NCT05602415|DRUG|Anlotinib|Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
219037976|NCT05602415|RADIATION|Radiotherapy|Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
219037977|NCT05602415|PROCEDURE|Surgery|Surgery
219519500|NCT06343948|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
219519501|NCT06343948|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
219519502|NCT06343948|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
219519503|NCT06343948|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
219519504|NCT04442906|DRUG|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
219519505|NCT04442906|DRUG|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
219037978|NCT02431754|DRUG|Tadalafil|Administered orally
219037979|NCT02431754|DRUG|Placebo|Administered orally
219037980|NCT02431754|DRUG|Alpha1 Blocker|Administered orally
219037981|NCT02009410|DRUG|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
219037982|NCT02009410|DRUG|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
219519506|NCT04442906|DRUG|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
218902156|NCT03900507|PROCEDURE|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
218902157|NCT00317993|DRUG|ezetimibe|
218902158|NCT00317993|DRUG|simvastatin|
218902159|NCT00317993|DRUG|ezetimibe plus simvastatin|
219037983|NCT02904057|DEVICE|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
219037984|NCT01275066|DRUG|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
219519507|NCT00906347|DRUG|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
219519508|NCT00906347|DRUG|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
219519509|NCT01326403|DRUG|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
219612632|NCT04364178|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
218902160|NCT02946281|BEHAVIORAL|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
218902161|NCT01262807|OTHER|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
218902162|NCT06381804|OTHER|shotblocker|shotblocker device
218902163|NCT06381804|OTHER|palm stimulator|palm stimulator
218902164|NCT04622111|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
218902165|NCT04622111|DRUG|Placebo|matching placebo tablet
219519510|NCT05742529|PROCEDURE|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
218902166|NCT04622111|DRUG|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
218902167|NCT05101447|DRUG|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
218902168|NCT06304961|BIOLOGICAL|Tozorakimab|Tozorakimab will be administered as a single SC dose on Day 1.
218902169|NCT05416138|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be performed at either peaks or troughs of ongoing prefrontal theta oscillations (3-7 Hz) concurrently with the cognitive test at the beginning of every test trial. Theta oscillations will be monitored in real-time at the left dorsolateral prefrontal cortex using electroencephalography (EEG).
218902170|NCT02016196|DRUG|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~\--------------------------------------------------------------------------------"
218902171|NCT02016196|DRUG|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
218902172|NCT03776799|DEVICE|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
218902173|NCT03776799|DEVICE|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
218902174|NCT05154084|BEHAVIORAL|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
218902175|NCT04390451|BEHAVIORAL|Whole Health STEPS|A peer-delivered package of Whole Health services.
218902176|NCT00867165|DRUG|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
218902177|NCT00867165|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
218902178|NCT04138992|DRUG|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
218902179|NCT04138992|DRUG|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
218902180|NCT04138992|DRUG|Docetaxel|used in neoadjuvant chemotherapy
218902181|NCT04138992|RADIATION|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
218902182|NCT04125043|DIAGNOSTIC_TEST|Direct ophthalmoscope|Red reflex test
218902183|NCT04441411|DEVICE|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
218902184|NCT00611689|DRUG|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in \< 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
218902185|NCT03781661|OTHER|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
218902186|NCT00017511|DRUG|cevimeline hydrochloride|
218902187|NCT04283071|DEVICE|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
219037985|NCT01275066|DRUG|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
219037986|NCT01275066|DRUG|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
219037987|NCT04175093|DIAGNOSTIC_TEST|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
219037988|NCT01581463|DRUG|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
219037989|NCT06438042|DEVICE|Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies|Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
218902188|NCT00586859|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
218902189|NCT03741465|PROCEDURE|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
218902190|NCT03741465|PROCEDURE|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
218902191|NCT04337424|DIAGNOSTIC_TEST|Sampling salivary|Collection of 1 to 2 ml of saliva
218902192|NCT03298802|DRUG|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
218902193|NCT03298802|DRUG|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
218902194|NCT05355103|OTHER|Educational tool about epidural analgesia|See arm description
218902195|NCT02313701|OTHER|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
218902196|NCT00646646|DRUG|propofol|sedative
218902197|NCT00646646|DRUG|dexmedetomidine|Sedative
218902198|NCT00646646|DRUG|Midazolam|sedative
218902199|NCT00646646|DRUG|saline placebo|saline placebo
218902200|NCT04907981|DIAGNOSTIC_TEST|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
218902201|NCT00128739|DRUG|Budesonide|
218902202|NCT03901495|OTHER|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
218902203|NCT00377520|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
218902204|NCT01944007|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
218902205|NCT02111447|DRUG|Propofol|Propofol infusion with nasal oxygen
218902206|NCT02111447|DRUG|Propofol|Propofol infusion with an LMA
218902207|NCT02111447|DRUG|Sevoflurane|Sevoflurane with an LMA
218902208|NCT02111447|DRUG|Isoflurane|Isoflurane with an LMA
218902209|NCT03476200|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
218902210|NCT01111708|PROCEDURE|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
218902211|NCT06045312|OTHER|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
218902212|NCT04139655|DRUG|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
218902213|NCT04139655|DRUG|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
218902214|NCT00521287|OTHER|Immune profiling and DC vaccine|"1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression."
218902215|NCT01506271|DRUG|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
218902216|NCT01506271|DRUG|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
218902217|NCT01506271|DRUG|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
218902218|NCT01506271|DRUG|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
218902219|NCT06304116|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
218902220|NCT06304116|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218902221|NCT06304116|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218902222|NCT04169958|OTHER|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
218902223|NCT01746303|DIETARY_SUPPLEMENT|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
218902224|NCT01746303|DIETARY_SUPPLEMENT|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
218902225|NCT01746303|OTHER|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
218902226|NCT01746303|OTHER|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
218902227|NCT00407771|DRUG|Tirofiban|
218902228|NCT04002076|BEHAVIORAL|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
218902229|NCT04002076|BEHAVIORAL|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
218902230|NCT06185465|DEVICE|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
218902231|NCT06185465|DEVICE|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
218902232|NCT05081895|DEVICE|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
218902233|NCT05081895|OTHER|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
218902234|NCT03291938|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
218902235|NCT03291938|OTHER|Pharmacodynamic Study|Correlative studies
218902236|NCT03291938|OTHER|Pharmacokinetic Study|Correlative studies
218902237|NCT04802330|OTHER|Questionnaire|Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
218902238|NCT04389359|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
218902239|NCT05444556|DRUG|Imlunestrant|Administered orally.
218902240|NCT05444556|DRUG|Repaglinide|Administered orally.
218902241|NCT05444556|DRUG|Omeprazole|Administered orally.
218902242|NCT05444556|DRUG|Dextromethorphan|Administered orally.
218902243|NCT05444556|DRUG|Quinidine|Administered orally.
218902244|NCT05444556|DRUG|Rosuvastatin|Administered orally.
218902245|NCT05444556|DRUG|Digoxin|Administered orally.
218902246|NCT06110663|DRUG|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
218902247|NCT06110663|DRUG|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
218902248|NCT01847352|DRUG|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
218902249|NCT01847352|OTHER|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
218902250|NCT02922530|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|
218902251|NCT02922530|OTHER|Commercially available computerized training|
218902252|NCT04771832|PROCEDURE|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
218902253|NCT04410185|BEHAVIORAL|Meditation|Meditation sessions will take place over 12 weekly sessions of 1.5 hours
218902254|NCT01043172|DRUG|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
218902255|NCT00258141|DRUG|Rupatadine|
218902256|NCT00258141|DRUG|Placebo|
218902257|NCT02570503|DRUG|Ropivacaine|Ropivacaine (5mg/ml)-50ml
218902258|NCT02570503|DRUG|Ketorolac|ketorolac (30mg/ml)- 1 ml
218902259|NCT02570503|DRUG|Clonidine|clonidine (0.1mg/ml)- 0.8ml
218902260|NCT02570503|DRUG|Epinephrine|epinephrine (1mg/ml)-1ml
218902261|NCT02570503|DRUG|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
218902262|NCT03040141|DRUG|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
218902263|NCT03040141|DRUG|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
218902264|NCT03040141|DRUG|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
218902265|NCT04345341|DRUG|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
218902266|NCT01464086|OTHER|whole body MRI|whole body MRI at inclusion, one and two years
218902267|NCT04296760|DIAGNOSTIC_TEST|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
218902268|NCT04296760|DIAGNOSTIC_TEST|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
218902269|NCT02823769|DEVICE|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
218902270|NCT02823769|DEVICE|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
218902271|NCT03826940|DRUG|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
218902272|NCT03826940|DRUG|Placebos|60 MG Placebo per day for 3 consecutive days
218902273|NCT06141707|OTHER|Arabic pediatric sleep questionnaire|Pediatric Sleep Questionnaire (PSQ) developed and validated by chervil et al. (2000) is a 22 item questionnaire which had been shown to have a sensitivity of 81% and specificity of 87% for SRBD.These scales for childhood SRBDs, snoring, sleepiness, and behavior are valid and reliable instruments that can be used to identify SRBDs or associated symptom-constructs in clinical research when polysomnography is not feasible.
218902274|NCT05093439|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
218902275|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
218902276|NCT06114186|DEVICE|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
218902277|NCT06114186|OTHER|standard of care|self reported HbA1C or GMI
218902278|NCT02692937|PROCEDURE|Neurolysis|
218902279|NCT02692937|OTHER|Traditional neck-specific exercise program|
218902280|NCT06073808|DEVICE|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
218902281|NCT06073808|DEVICE|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
218902282|NCT03612778|BEHAVIORAL|Plant-based diet|Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
218902283|NCT03612778|BEHAVIORAL|Mediterranean diet|Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
218902284|NCT01391663|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
218902285|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
218902286|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
218902287|NCT00462306|PROCEDURE|Survey: Berlin questionnaire|Completion of questionnaire
218902288|NCT04236674|DEVICE|Buzzy thermomechanical device|Buzzy thermomechanical device placed near intervention site.
218902289|NCT04236674|BEHAVIORAL|Music Selection|Patient specified procedural music
218902290|NCT02721602|BEHAVIORAL|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
218902291|NCT01693549|DRUG|Cabazitaxel|
218902292|NCT03515824|BIOLOGICAL|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
218902293|NCT01623479|DRUG|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
218902294|NCT01451489|DRUG|FK506|FK506:0.05-0.1mg/kg/d
218902295|NCT01451489|DRUG|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
219037990|NCT02579746|BEHAVIORAL|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
219037991|NCT02579746|BEHAVIORAL|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
219037992|NCT02310178|PROCEDURE|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
218902296|NCT02650089|OTHER|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
219037993|NCT03856437|BEHAVIORAL|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
219037994|NCT01404091|DRUG|LY2940094|Administered orally
219037995|NCT05092555|DIAGNOSTIC_TEST|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
219037996|NCT00816699|OTHER|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
219037997|NCT01147991|BIOLOGICAL|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
219037998|NCT01147991|OTHER|laboratory biomarker analysis|
219037999|NCT01147991|OTHER|pharmacological study|
219204278|NCT06883136|DRUG|Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine|"1. Sintilimab, 200mg, intravenous infusion on day 1 of each cycle, every 3 weeks as a cycle (Q3W), until disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or termination of treatment for other reasons specified in the protocol; The longest treatment time of sintilimab was 24 months.~2. Chemotherapy regimen:~1\) Pemetrexed combined with platinum regimen (non-squamous cell carcinoma) : pemetrexed 500mg/m2, intravenous infusion on day 1 of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for a total of 4-6 cycles.~2\) Gemcitabine plus platinum regimen (squamous cell carcinoma) : gemcitabine 1000mg/m2 intravenously on days 1 and 8 of each cycle, cisplatin 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for 4-6 cycles."
219519511|NCT05742529|PROCEDURE|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
219519512|NCT04259229|OTHER|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
218902297|NCT02650089|OTHER|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
218902298|NCT02650089|OTHER|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
218902299|NCT01384734|DRUG|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
219038000|NCT01290848|BEHAVIORAL|Take TIME Health Campaign|"1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
219038001|NCT01308190|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
219038002|NCT01308190|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
219038003|NCT01308190|PROCEDURE|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
219038004|NCT01308190|PROCEDURE|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
219038005|NCT00554671|OTHER|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
219038006|NCT00554671|BEHAVIORAL|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
219038007|NCT00554671|BEHAVIORAL|Group support|Peer support are provided in the group setting
219038008|NCT00554671|BEHAVIORAL|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
219038009|NCT04200248|DRUG|RBM-007 Injectable Solution|RBM-007 Injectable Solution
219038010|NCT04200248|DRUG|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
219038011|NCT04200248|DRUG|Sham|Sham intravitreal injection
219038012|NCT04761068|DEVICE|VEST|Venous External Support for vein grafts in CABG
219038013|NCT00743912|DRUG|rifaximin|550 mg TID
219038014|NCT01200875|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
219038015|NCT01200875|PROCEDURE|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
218902300|NCT01384734|DRUG|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
218902301|NCT01384734|DRUG|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
218902302|NCT01384734|DRUG|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
218902303|NCT01384734|DRUG|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
218902304|NCT01384734|DRUG|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
218902305|NCT01384734|DRUG|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
219038016|NCT05909371|OTHER|exercise|Application of two different exercises to liver transplant individuals.
219038017|NCT02155335|DRUG|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
219038018|NCT02155335|DRUG|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
219038019|NCT06432530|OTHER|C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.|Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
219038020|NCT00934544|DRUG|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
219038021|NCT00934544|DRUG|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
219038022|NCT00482495|BIOLOGICAL|bevacizumab|
218902306|NCT01384734|DRUG|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
219038023|NCT00482495|GENETIC|gene expression analysis|
219038024|NCT00482495|GENETIC|protein expression analysis|
219038025|NCT00482495|OTHER|laboratory biomarker analysis|
218902307|NCT00920855|DRUG|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
218902308|NCT00920855|DRUG|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
219038026|NCT02781636|DEVICE|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
219038027|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
219038028|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
219038029|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
219038030|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
219038031|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
219038032|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
219038033|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
219038034|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
219038035|NCT04033003|BEHAVIORAL|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
219038036|NCT01023165|PROCEDURE|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
219038037|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
219038038|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
219038039|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
219038040|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
219038041|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
219038042|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
219364797|NCT06175858|DIAGNOSTIC_TEST|CMR|We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
218902309|NCT01484210|DRUG|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
218902310|NCT03070080|PROCEDURE|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
218902311|NCT03070080|PROCEDURE|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
218902312|NCT04480268|DRUG|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~* nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~* cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~* capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~* gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
218902313|NCT00102765|DRUG|fluticasone propionate/salmeterol powder|
218902314|NCT00102765|DRUG|fluticasone propionate powder|
218902315|NCT00186225|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
218902316|NCT02634385|PROCEDURE|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
218902317|NCT02634385|PROCEDURE|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
219038043|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
219038044|NCT00515307|PROCEDURE|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
219038045|NCT03377946|BIOLOGICAL|probiotics|the probiotics group was taking probiotics 4 packets a day
219038046|NCT03377946|BIOLOGICAL|placebo|the placebo group was taking placebo 4 packets a day
219038047|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
219038048|NCT01435291|DRUG|Advagraf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
219038049|NCT01435291|DRUG|Prograf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
219038050|NCT03516669|DRUG|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
219612633|NCT04364178|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
219038051|NCT03516669|DRUG|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
219038052|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
219204279|NCT06886724|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
219204280|NCT06886724|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
218902318|NCT02991638|DRUG|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
218902319|NCT00346125|BIOLOGICAL|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
218902320|NCT00346125|DRUG|doxorubicin hydrochloride|65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
218902321|NCT00346125|DRUG|ifosfamide|9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
218902322|NCT00346125|DRUG|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
218902323|NCT00346125|PROCEDURE|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
218902324|NCT00346125|RADIATION|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
218902325|NCT04871659|OTHER|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
219038053|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
219038054|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
219038055|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
219038056|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
219038057|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
219038058|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
219038059|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
219038060|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
219612634|NCT02608411|DRUG|ARQ197|
219612635|NCT05228678|DIAGNOSTIC_TEST|cardiopulmonary exercise tests|"Spirometry~* forced expiratory volume in 1 second (FEV1) % predicted,~* forced vital capacity (FVC)% predicted,~* forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC"
219038061|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
218902326|NCT04428346|BEHAVIORAL|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
218902327|NCT00539994|DRUG|retapamulin|200mg BID retapamulin 3 days
219038062|NCT01323075|PROCEDURE|Truncal block|Patients will have a truncal block during hand or wrist surgery.
218902328|NCT00539994|DRUG|Retapamulin|200mg BID retapamulin 5 days
218902329|NCT00539994|DRUG|Placebo|200mg BID placebo 5 days
219204281|NCT06888934|DEVICE|Intervention with Lync device.|Treatment of arthritis and/or correction of bone alignement default in the toes (mallet toes, claw toes, hammer toes) with Lync device.
218902330|NCT02763839|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
218902331|NCT02763839|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
218902332|NCT02763839|DRUG|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
218902333|NCT03071263|DRUG|Patiromer|2 packets/day starting dose, administered orally
218902334|NCT03071263|DRUG|Placebo|2 packets/day starting dose, administered orally
218902335|NCT03071263|DRUG|Spironolactone|25 mg tablet/day starting dose, administered orally
219038063|NCT04883632|COMBINATION_PRODUCT|Saypha Volume Lidocaine|"correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma.~The amount injected depended on the size of the area to be corrected and the desired level of soft tissue augmentation. It was estimated that a maximum volume of 4 mL per treatment was needed but should not have exceeded 10 mL in total per treatment or 20 mL per year. and use in respective indications. The investigational device was administered to eligible subjects on investigation Day 0. A touchup treatment at Week 2 was optional at the investigator's discretion if full correction was"
219038064|NCT06498284|DRUG|HM-002-1005|HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets
219204282|NCT06888440|PROCEDURE|scaling and zinc stents|this group will receive scaling and zinc containing stents
219204283|NCT06888440|PROCEDURE|scaling and placebo stents|this group will receive scaling and placebo stents
218902336|NCT05549011|OTHER|PENG Block|PENG block for analgesic purposes performed before hip surgery
218902337|NCT05549011|OTHER|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
218902338|NCT05549011|DIAGNOSTIC_TEST|Numeric Rating Scale|Self-reported pain intensity score between 0-10
218902339|NCT05549011|DIAGNOSTIC_TEST|Angle of sitting|Measurement of sitting angle in degrees with a protractor
218902340|NCT05569902|DEVICE|active tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
219364798|NCT01260454|DRUG|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
219364799|NCT05776849|OTHER|flipped classroom|Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.
219364800|NCT04747925|OTHER|Mulligan two leg rotation core muscle strengthning exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
219364801|NCT04747925|OTHER|mulligan bent leg raise technique, core muscle strengthning exercises|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
219364802|NCT01357369|PROCEDURE|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
219364803|NCT02899143|DRUG|Antibiotic|Targeted antimicrobial therapy
219364804|NCT05505266|OTHER|observational|observational
219364805|NCT02530931|DRUG|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
219364806|NCT01121380|DRUG|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
219364807|NCT01121380|DRUG|1021|1021
219364808|NCT06539546|OTHER|Yttria stabilized multilayered (YML) zirconia restorations|Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties
219364809|NCT06539546|OTHER|Lithium disilicate restorations|Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
219364810|NCT02570269|PROCEDURE|AuraGain|Fiberoptic Intubation
219364811|NCT02570269|PROCEDURE|Slotted Guedeltubus|Fiberoptic Intubation
218902341|NCT05569902|DEVICE|sham tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
218902342|NCT00002781|DRUG|boronophenylalanine-fructose complex|
218902343|NCT05839574|DRUG|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
219038065|NCT05793944|BEHAVIORAL|SmartMom text messaging|SmartMom is a mobile health program delivered via text messaging that guides participants through each week of pregnancy. Participants receive three messages per week with links to content focused on improving knowledge, providing information about prenatal assessments and screening, and encouraging the adoption of behaviours to support healthy pregnancy and physiologic birth. Messages are consistent with current professional guidelines and peer reviewed prenatal education curricula. SmartMom provides optional supplemental streams for individuals who wish to have additional messages addressing topics such as reducing use of tobacco, alcohol or illicit drugs, depression, obesity, and maternal age over 35.
219038066|NCT05793944|BEHAVIORAL|Control text messaging|Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
219519513|NCT04259229|OTHER|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
219038067|NCT04164901|DRUG|Vorasidenib|Vorasidenib oral film-coated tablets
219038068|NCT04164901|DRUG|Matching Placebo|Matching Placebo oral tablets
219038069|NCT05097833|BEHAVIORAL|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
219038070|NCT05097833|BEHAVIORAL|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
219038071|NCT06414174|DEVICE|Split septum needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
219364812|NCT06438081|COMBINATION_PRODUCT|Cook double-balloon catheter|To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
219364813|NCT02629562|BIOLOGICAL|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
219519514|NCT03743480|OTHER|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
219519515|NCT05946993|OTHER|Physiotherapy|participant will have 2 x 1h exercise classes per week with a physiotherapist, who will develop individualized plans based on medical history and scan reviews. Participants will be progressively guided through the programme, incrementally increasing in intensity or with modifications based on symptomatic presentation. This will be based on their baseline strength and cardiovascular fitness testing and grounded on evidence-based protocols previously demonstrating an effect in this patient population. Individualised tailored exercise programme which includes strength and conditioning.
219364814|NCT00116766|DEVICE|anti-mosquito plant use|
219364815|NCT03775876|PROCEDURE|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
219612636|NCT04942678|BEHAVIORAL|10-minute visit with therapy dog and child life specialist handler|A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.
219612637|NCT05545189|DIAGNOSTIC_TEST|colonoscopy,polypectomy|polyp removal during colonoscopy
219612638|NCT02740192|PROCEDURE|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
219612639|NCT02740192|PROCEDURE|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
219364816|NCT03775876|PROCEDURE|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
219612640|NCT02740192|DRUG|Ropivacaine|Ropivacaine was used for the periarticular injection
219612641|NCT02740192|DRUG|Bupivacaine|Bupivacaine was used for the periarticular injection
219612642|NCT03125798|DEVICE|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
219612643|NCT03125798|DEVICE|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
218902344|NCT05839574|DRUG|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
218902345|NCT04840446|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Sensor
218902346|NCT01437280|BIOLOGICAL|CGTG-102|"VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
218902347|NCT04163575|BIOLOGICAL|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
219038072|NCT06414174|DEVICE|Mechanical valve needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
219038073|NCT02638298|DEVICE|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
219038074|NCT02638298|OTHER|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
219038075|NCT06398990|OTHER|Cognitive Exercise Therapy Approach|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
219204284|NCT06890169|BEHAVIORAL|OneSTOP program|The OneSTOP program will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription and calorie restriction will be tailored to each subject's individual needs as in the F2F structured weight management program in the control group. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions curated by their doctors and dieticians.
219038076|NCT06398990|OTHER|Yoga|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
219038077|NCT06398990|OTHER|Routine Medical Treatment|Assessments of individuals in this group will be made face-to-face in the relevant clinic.
219038078|NCT06548061|DEVICE|Visualase Thermal Therapy System|Spine laser interstitial therapy used instead of open decompression followed by spine stereotactic radiosurgery (SSRS).
219038079|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
219038080|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
219038081|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
219038082|NCT05780671|OTHER|oxygen|inhaled oxygen 10L/min with face mask for 1 hour
219204285|NCT06890169|BEHAVIORAL|Standard of care weight management program|The standard face-to-face weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury.
219612644|NCT06365528|PROCEDURE|Subcutaneous tunnelling|The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
218902348|NCT03084796|DRUG|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
218902349|NCT03084796|DRUG|Placebo|Placebo Control
219038083|NCT03855995|PROCEDURE|Whole blood sample|Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
218902350|NCT03084796|DRUG|Tiotropium Bromide 18 µg Inhalation Capsule|Active Control
218902351|NCT00154856|BEHAVIORAL|Detect the variation of limb lengthening|
219038084|NCT06833229|PROCEDURE|FDG-PET|PET scan are performed within 28 days before the start of immunotherapy, then at week 6 and week 12 of follow-up. Various metabolic parameters extracted from the standard PET image (ΔSUVmax, ΔTLG, appearance of new visceral lesion(s)), parametric (metabolic glucose rate (Ki), volume of distribution (VD)) and tumor response based on PERCIST criteria (adapted to immunotherapy) are assessed.
219364817|NCT03775876|DRUG|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
219364818|NCT03775876|DRUG|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
219038085|NCT04570085|DRUG|Caffeine|100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
219038086|NCT04570085|DRUG|Placebo|Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
219038087|NCT02046148|BIOLOGICAL|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
219038088|NCT02046148|BIOLOGICAL|Placebo|Intramuscular injection - Normal saline
219038089|NCT06007183|BIOLOGICAL|CHIKV VLP vaccine booster|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
219038090|NCT06007183|BIOLOGICAL|Placebo booster|Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
219038091|NCT04998136|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
219038092|NCT04998136|DRUG|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
219038093|NCT01012011|DRUG|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
219038094|NCT05932095|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
218902352|NCT02266355|DRUG|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
218902353|NCT05470985|DRUG|Ozanimod|Specific dose on specific days
218902354|NCT03651037|BEHAVIORAL|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
218902355|NCT02640638|BEHAVIORAL|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
218902356|NCT03487926|RADIATION|[18F]FEPPA|up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI
218902357|NCT02374151|DEVICE|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
218902358|NCT02741245|DRUG|Ezetimibe 10 mg|
219038095|NCT05932095|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
219038096|NCT05083988|DEVICE|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
219038097|NCT05083988|DEVICE|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
219204286|NCT06889051|PROCEDURE|Flexible & Navigable Suction Ureteral Access Sheath (FANS)|The Flexible \& Navigable Suction Ureteral Access Sheath (FANS) is used during retrograde flexible ureteroscopy (FURS) for renal stones (1.5-2 cm). It allows continuous active suctioning, improving stone fragment evacuation, reducing operative time, lowering intrarenal pressure, and optimizing stone-free rates (SFR). The procedure involves inserting the Navigator 10F, 55 cm YIGAOMED FANS over a guidewire, followed by flexible ureteroscopy with PUSEN® 9.2 Fr ureteroscope and laser lithotripsy using Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W).
219204287|NCT06889051|PROCEDURE|Antegrade Suction via Percutaneous Nephrostomy|This technique involves antegrade suction from the kidney during flexible ureteroscopy (FURS) without the use of a ureteral access sheath. A percutaneous nephrostomy (PCN) tract is created using an 18G needle, and a 6F renal dilator is placed and fixed to the skin, allowing for direct suctioning from the collecting system. Following this, retrograde flexible ureteroscopy (FURS) is performed using the PUSEN® 9.2 Fr ureteroscope and Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W) for stone fragmentation. This technique aims to improve stone clearance while minimizing ureteral trauma associated with access sheaths.
219204288|NCT06731166|BEHAVIORAL|self-care|Videomonitoring provide by cardiovascular nurses
219612645|NCT06365528|PROCEDURE|Non-tunnelling|The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
219612646|NCT06196489|BEHAVIORAL|adapted vaping cessation intervention|Behavioral intervention for vaping cessation
218902359|NCT02741245|DRUG|Rosuvastatin 2.5 mg|
218902360|NCT02741245|DRUG|Placebo for Ezetimibe|
218902361|NCT02741245|DRUG|Placebo for Rosuvastatin|
218902362|NCT01685567|DEVICE|MICHI NPS+f|Cerebral protection with carotid flow reversal
218902363|NCT00700440|DRUG|C225 (cetuximab)|one week before and then weekly during radiotherapy
218902364|NCT00154297|DRUG|Everolimus (RAD001)|
219038098|NCT04176094|OTHER|16h overnight duty|schedule observed by participating ICUs.
219038099|NCT04176094|OTHER|24h overnight duty|schedule observed by participating ICUs.
219612647|NCT05593744|OTHER|no intervention|This is an observational study so not involved intervention
218902365|NCT06544174|OTHER|Percutaneous Coronary Intervention of CTO|CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
218902366|NCT01619371|DEVICE|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
218902367|NCT05397769|DRUG|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
218902368|NCT06262893|PROCEDURE|Shoulder arthroscopy blocks|Effect of dexamethasone adjuvant in combined supraclavicular block and suprascapular block versus Interscalene block in patients undergoing shoulder arthroscopy.
218902369|NCT04477161|DIETARY_SUPPLEMENT|Ketone Ester Elite endurance Nutrition Drink|Subjects will take one bottle four times daily for four weeks
218902370|NCT04477161|OTHER|Stool Sample|Subjects will provide a stool sample at 2 timepoints.
218902371|NCT06155422|DRUG|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
218902372|NCT00967317|DRUG|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
219519516|NCT05946993|OTHER|Dietitian Support|The main goal of the nutritional intervention is to improve the diet quality of each patient using a standardized nutrition assessment, offering evidence-based diet group education and developing personalized nutrition goals. Participants will be progressively guided through the nutrition education programme; with modifications to the individual's usual diet, thereby recognizing personal eating patterns and preferences, which form the basis for individualized dietary counselling. The dietary counselling identifies the type, amount, and frequency of feeding and specifies the caloric/protein level to attain, together with any restrictions and limited or increased individual dietary components.
219519517|NCT05946993|OTHER|Nursing and Psychosocial|Nursing, Psycho-oncology, pastoral care and social work-led sessions to inform participants on items including diagnosis shock, acceptance, coping with relationship changes with their partner and their roles, fear of uncertainty and the future, medication management, masculinity (male values being strong, capable, independent), practical management of bills, and household tasks. There will be an inclusion of practical information sessions including health systems information and managing side effects such as urinary symptoms, hot flushes, penile shortening, and loss of body hair.
219519518|NCT02099500|PROCEDURE|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
219519519|NCT02099500|OTHER|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
219613431|NCT06103045|OTHER|unilateral and bilateral mirror therapy|The mirror box is placed on a table in the sagittal plane of the participant. The affected upper extremity of the participant is hidden in the morror box and the unaffected upper extremity is placed symmetrically. During the unilateral or bilateral mirror therapy, the participant is requested to execute a serial of movements and tasks and pay attention on observing the reflection of the unaffected side in the mirror simultaneously. In the bilateral mirror therapy, the participant also has to move the affected upper extremity simultaneously; while in the unilateral mirror therapy, the participant only keeps the affected side relaxed.
218902373|NCT00967317|DRUG|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
218902374|NCT05430958|DRUG|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
218902375|NCT05430958|DRUG|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
218902376|NCT05430958|DEVICE|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
218902377|NCT01205100|BEHAVIORAL|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
218902378|NCT01205100|DRUG|Placebo|
218902379|NCT00798616|DRUG|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
218902380|NCT00798616|DRUG|placebo|oral or IV placebo
219204289|NCT06731556|DRUG|Intravenous paracetamol|Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.
219204290|NCT06731556|DRUG|Intranasal Paracetamol|Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.
219519520|NCT04552704|BIOLOGICAL|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
219519521|NCT04552704|DRUG|Placebo Administration|Given IV
219519522|NCT03441581|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
219519523|NCT00680121|DRUG|Benfotiamine|Benfotiamine 600 mg
219519524|NCT00680121|DRUG|Placebo|Placebo
219519525|NCT02809183|DRUG|Placebo|oral suspension
219519526|NCT02809183|DRUG|TRC101|oral suspension
219519527|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
219519528|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
219519529|NCT02942966|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
219519530|NCT00858910|OTHER|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
219519531|NCT00858910|OTHER|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home."
219519532|NCT03118466|DRUG|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
219519533|NCT03118466|DRUG|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
219519534|NCT03118466|DRUG|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
219519535|NCT03118466|DRUG|Mitoxantrone|It interfere with cell reproduction
218902381|NCT02356913|DRUG|Nicotine gum|
218902382|NCT02107833|DRUG|OPRX-106|
218902383|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
218902384|NCT02872246|DRUG|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
218902385|NCT02872246|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
218902386|NCT00012103|OTHER|bronchoalveolar lavage|
218902387|NCT00012103|OTHER|screening questionnaire administration|
218902388|NCT00012103|OTHER|sputum cytology|
218902389|NCT00012103|PROCEDURE|bronchoscopic and lung imaging studies|
218902390|NCT00012103|PROCEDURE|bronchoscopy|
218902391|NCT00012103|PROCEDURE|computed tomography|
218902392|NCT00012103|PROCEDURE|study of high risk factors|
218902393|NCT05054140|DRUG|IMU-838|IMU-838 tablets
218902394|NCT05054140|DRUG|Placebo matching IMU-838|Placebo matching IMU-838 tablets
218902395|NCT01381393|DRUG|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
218902396|NCT05662085|OTHER|No intervention|According to clinical practice.
218902397|NCT00116012|DRUG|rNAPc2|
218902398|NCT05990192|DRUG|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
218902399|NCT05990192|RADIATION|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
218902400|NCT04849130|PROCEDURE|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
218902401|NCT04849130|PROCEDURE|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
218902402|NCT04744961|OTHER|SCAR-Q survey|Telephone survey
218902403|NCT05609942|DRUG|BLU-263|BLU-263 Oral Tablets
218902404|NCT05609942|DRUG|Azacitidine|Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
218902405|NCT06542133|DEVICE|AVEIR remote care system|In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
218902406|NCT00990106|DRUG|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
218902407|NCT00990106|DRUG|placebo|placebo
219613432|NCT04659369|DRUG|CMAB819|for injection only
219613433|NCT04659369|DRUG|Nivolumab|for injection only
219613434|NCT06021418|DEVICE|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
218902408|NCT05577923|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
218902409|NCT05577923|DRUG|pyrotinib|Pyrotinib 320mg, PO daily, continuously
218902410|NCT05577923|DRUG|Dalpiciclib|Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
218902411|NCT05577923|DRUG|fulvestrant|Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
218902412|NCT05152459|DRUG|Tazemetostat|Given PO
218902413|NCT05152459|BIOLOGICAL|Ublituximab|Given IV
218902414|NCT05152459|DRUG|Umbralisib|Given PO
218902415|NCT02511379|OTHER|Propylene Glycol 0.6% eye drops|
218902416|NCT06067503|DRUG|18F-fluorofuranylnorprogesterone|The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
218902417|NCT06067503|DEVICE|Liquid Biopsy|20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
218902418|NCT06067503|DEVICE|Positron Emission Tomography/Computed Tomography|FFNP drug in combination with PET/CT scans to image participant
218902419|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
218902420|NCT00052585|DRUG|irinotecan hydrochloride|Given IV
218902421|NCT00052585|DRUG|gefitinib|Given orally
218902422|NCT00052585|DRUG|leucovorin calcium|Given IV
218902423|NCT00052585|DRUG|fluorouracil|Given IV
218902424|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
218902425|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
219204291|NCT06731556|DRUG|Intranasal Diclofenac Sodium|Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
219613435|NCT05856851|DRUG|Alteplase|See arm/group descriptions.
218902426|NCT06763055|DRUG|Colchicine 0.5 mg|The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.
218902427|NCT06763055|DRUG|Deferoxamine Mesylate|The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
218902428|NCT06763055|OTHER|Control (Standard treatment)|The group will not receive deferoxamine mesylate or colchicine
218902429|NCT00410956|BIOLOGICAL|bevacizumab|
218902430|NCT00410956|DRUG|dexamethasone|
218902431|NCT00410956|DRUG|floxuridine|
218902432|NCT00410956|GENETIC|protein expression analysis|
218902433|NCT00410956|OTHER|flow cytometry|
218902434|NCT00410956|OTHER|immunoenzyme technique|
218902435|NCT00410956|OTHER|immunohistochemistry staining method|
218902436|NCT00410956|OTHER|immunologic technique|
218902437|NCT00410956|OTHER|laboratory biomarker analysis|
218902438|NCT00410956|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
218902439|NCT01194037|DRUG|recombinant variant of interferon-alpha 2b|SC, Weekly
218902440|NCT01194037|DRUG|Peginterferon alfa-2a|SC Weekly
218902441|NCT01194037|DRUG|Ribavirin|Oral administration (The daily dose of ribavirin(RBV) was 1000mg for subjects weighing \< 75 kg or 1200 mg for subjects weighing ≥ 75 kg)
218902442|NCT04418258|DEVICE|Capillary Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter\[#CSL2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
218902443|NCT04418258|DEVICE|Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter\[#2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
218902444|NCT06920888|BEHAVIORAL|Cognitive restructuring|CR drawn from classic CBT
218902445|NCT06920888|BEHAVIORAL|Attention allocation|AA drawn from contemporary CBTs
218902446|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
218902447|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
218902448|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
218902449|NCT02783196|DRUG|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
218902450|NCT02783196|DRUG|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
219038100|NCT04176094|OTHER|Handover training|Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
219519536|NCT05802966|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
219519537|NCT02534948|BEHAVIORAL|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
219519538|NCT03401710|DRUG|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
219519539|NCT05090657|COMBINATION_PRODUCT|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
218902451|NCT06703671|DEVICE|electroacupuncture group|"According to the acupuncture prescription, the acupuncture doctor carried out acupuncture and lifting and twisting, and qi appeared under the needle. Select waist Jiaji point and Shenshu point on the same side to connect a set of electronic needle therapy instrument, the positive pole (red clip) connected to Shenshu point, the negative pole (white clip) connected to waist Jiaji point, after confirming that the electric current intensity of the electric needle instrument returns to zero, open the electronic needle therapy instrument, select continuous wave, 2Hz, current intensity 2mA. During the process of needle retention, the other points were injected every 15 minutes and retained for 30 minutes.The investigators have developed detailed acupoint positioning and operation rules."
219038101|NCT05457569|OTHER|Focus group (FC) - WP1|"3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk"
219038102|NCT05457569|OTHER|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
219038103|NCT05457569|OTHER|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
218902452|NCT06703671|DEVICE|sham-acupuncture group|The investigators fixed the foam pad with one hand and inserted a comfort needle with the other, making sure the needle only touched the surface of the skin and did not penetrate the point. After the completion of all acupoint operations, the operator selected the simulated needle insertion points of Jiaji point on the waist and Shenshu point on the same side. An electroacupuncture treatment device designed to connect a circuit interrupt treatment is operated with the electroacupuncture group, a process that ensures that the participant does not experience any perceptible stimulation
218902453|NCT06726226|OTHER|Standard care for preterm infants|Standard care for preterm infants according to the institutional protocol
218902454|NCT06726356|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
218902455|NCT04388683|DRUG|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
218902456|NCT06725472|PROCEDURE|Open Heart Surgery|This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.
218902457|NCT06725771|DRUG|Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline|Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
218902458|NCT06725771|DRUG|Sertraline Hydrochloride Tablets|Sertraline are given to patients simultaneously
218902459|NCT06726642|DIAGNOSTIC_TEST|Cell-free DNA analysis|Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).
218902460|NCT06921135|DIETARY_SUPPLEMENT|supplementation, food|Supplementation of fresh foods
218902461|NCT06921811|OTHER|Intact chickpeas|Salad meal containing intact chickpeas
218902462|NCT06921811|OTHER|Broken chickpeas|Burger meal containing chickpea flour
218902463|NCT06922578|PROCEDURE|NeoPUTTY MTA pulpotomy|Neoputty MTA pulpotomy performed in vital primary molars with symptomatic irreversible pulpitis
218902464|NCT06922578|PROCEDURE|Endoflas pulpectomy|Endoflas pulpectomy in vital primary molars with symptomatic irreversible pulpitis
218902465|NCT03741088|DEVICE|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
218902466|NCT00880698|BIOLOGICAL|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose
219613436|NCT02927470|DEVICE|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
218902467|NCT00880698|BIOLOGICAL|Placebo|2 mL solution
218902468|NCT06726980|DRUG|dextrose 5%|patients will receive 5 % dextrose infusion
218902469|NCT06726980|DRUG|Dextrose 10%|patients will receive 10 % dextrose infusion (25gm/ 250 mL)
218902470|NCT06726980|DRUG|0.9% saline|patients will receive infused IV 0.9 % saline
218902471|NCT06727162|PROCEDURE|Contrast-Enhanced Ultrasound|"Participants are scanned in a supine position with the neck fully exposed. A routine ultrasound examination is first performed to assess the cervical lymph nodes. Assessment includes: number, size, location (zones I-VII), structure, echogenicity, margin, shape, hilum, calcification, and vascular distribution.~After the routine ultrasound scan, the ultrasound system is switched to dual contrast-enhanced ultrasound mode. Sonazoid (GE Healthcare) is then administered intravenously through the antecubital vein at a dose of 0.015 mL/kg, followed by an injection of 5 mL of physiological saline. A timer is started after the injection, and video recording is made during the vascular phase from 5 to 60 seconds."
218902472|NCT06727188|DIAGNOSTIC_TEST|Laboratory as cbc crp|Using laboratory and imaging investigations to help in diagnosis and follow up the cases
219038104|NCT05457569|OTHER|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
219519540|NCT03955770|COMBINATION_PRODUCT|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).
219038105|NCT05457569|OTHER|4 Focus Group (FC) - WP2|"* Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice"
219038106|NCT01213979|DRUG|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
219038107|NCT01213979|DRUG|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
219038108|NCT04938232|DRUG|Nivolumab|Intravenous infusion
219038109|NCT04938232|DRUG|Ipilimumab|Intravenous infusion
219519541|NCT03955770|COMBINATION_PRODUCT|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
219519542|NCT04366609|DRUG|Methylphenidate|Treatment with methylphenidate through dose escalation
219519543|NCT05282888|OTHER|blood sample|in order to develop a diagnostic assay using an innovative technology by imaging flow cytometry to identify red blood cell morphological anomalies in the diagnosis flowchart of anemia.
219519544|NCT03319056|OTHER|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
219519545|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
218902473|NCT06705075|DRUG|Perfluten|Use of UCA Definity to evaluate uterine fibroids by contrast-enhanced ultrasound (CEUS) and subharmonic-aided pressure estimation (SHAPE) pre and post-uterine artery embolization (UAE).
218902474|NCT06726291|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
219613437|NCT02927470|DEVICE|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
218902475|NCT06890702|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including urine, feces, cerebrospinal fluid, blood, plaques, emboli, drainage fluid, bone marrow, lymph nodes and brain tissue etc al) of ischemic cerebrovascular disease
218902476|NCT06576934|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
218902477|NCT06785207|DEVICE|3D-printed scoliosis brace|"Scoliosis brace will be 3D printed using a Filament Innovations Icarus printer and the material CPX. There will be corrugations where extra strength is needed. The brace will be made using the same shape as the participant's current brace to minimize variables at play.~According to Sec. 890.3490 of the Code of Federal Regulations Title 21, scoliosis braces are Class I devices, requiring only general controls. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records and § 820.198, regarding complaint files."
218902478|NCT05107908|BEHAVIORAL|Active Implicit Priming|Approximately 10-minute behavioral intervention
218902479|NCT05107908|BEHAVIORAL|Control Implicit Priming|Approximately 10-minute behavioral intervention
218902480|NCT05107908|BEHAVIORAL|Food Exposure Task|Approximately 10-30 minute behavioral intervention
218902481|NCT06912698|RADIATION|Reduced dose radiation|Reduced dose group would receive 61.48Gy radiation.
218902482|NCT06912698|RADIATION|Standard dose radiation|Standard dose group would receive 69.96Gy radiation.
218902483|NCT06920784|DEVICE|PRISMATIC ADAPTATION|"The experimental treatment includes a session of prismatic adaptation, in which patients, wearing priasmatic lenses, performs pointing exercises using an 11'' tablet. The visual target is represented by a black squares randomly presented in one of three spatial positions of the tablet's screen (in the centre of the screen or at 21° to the right or to the left space). Taking into account the type of lesion resulting from traumatic brain injury, the prismatic deviation induced by the lenses will be changed alternately from right to left. Then patients will wear rightward prism lenses for 5 days and leftward prism lenses for other 5 days. The prismatic deviation will be randomized.~Following these prismatic adaptation, lasting 10 minutes, cognitive training with serious games will be performed, for the remaining 30 minutes."
218902484|NCT06920784|DEVICE|Serious games|patients receiving the same serious games for 10 days over a span of 2 weeks, withouth prismatic adaptation session.
218902485|NCT06913166|OTHER|Online quiz competition|Students in the intervention and control arm will participate in an online quiz game on tobacco or diet related topics respectively. Each day, students could answer a maximum of 10 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 5 days.
218902486|NCT06939231|BEHAVIORAL|Living Lab approach to improve sustainable and healthy dietary behaviours|Living Lab baseline data collection measures, plus invitations to Study 1-3 and events/ activities (optional), and LL endpoint data collection measures.
218902487|NCT06939179|OTHER|Class III Malocclusion|Class III malocclusion treatment
218902488|NCT06939179|OTHER|Class III Malocclusion|non treated Class III malocclusion
218902489|NCT06937905|DRUG|Standard of Care Chemotherapy|Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX, FOLFIRI or alkylating-based chemotherapy in primary digestive tumors.
218902490|NCT06937905|DRUG|Tarlatamab|Tarlatamab 10 mg every 2 weeks
218902491|NCT06938919|DEVICE|routine care without electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%.
218902492|NCT06938919|DEVICE|routine care with electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%; and refer to the following electronic breath sound abnormalities to maintain sedation depth: Maintain respiratory rate (RR) at 12-20 bpm; avoid partial airway obstruction
218902493|NCT02907684|DIETARY_SUPPLEMENT|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
218902494|NCT02907684|DIETARY_SUPPLEMENT|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
218902495|NCT00932581|OTHER|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
218902496|NCT00932581|OTHER|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
219038110|NCT04653779|DRUG|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
219038111|NCT01115595|BIOLOGICAL|Intervention|Dermatophagoides pteronyssinus from ALK company
219038112|NCT01115595|OTHER|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
219038113|NCT01289769|DRUG|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
219038114|NCT01289769|DRUG|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
219038115|NCT02581696|DRUG|Lafutidine|Lafutidine 10mg, 1 tablet, bid
218902497|NCT05954000|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
218902498|NCT02458053|BEHAVIORAL|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
218902499|NCT02458053|BEHAVIORAL|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
218902500|NCT02458053|BEHAVIORAL|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
218902501|NCT02458053|BEHAVIORAL|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
218902502|NCT02458053|OTHER|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
218902503|NCT02458053|BEHAVIORAL|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
218902504|NCT00006133|DRUG|estradiol|
218902505|NCT00006133|DRUG|ethinyl estradiol|
218902506|NCT00006133|DRUG|medroxyprogesterone|
218902507|NCT00006133|DRUG|norethindrone|
218902508|NCT01344083|DRUG|T1210|2 drops T1210 once a day
218902509|NCT01344083|DRUG|Olopatadine hydrochloride|2 drops once a day Olopatadine
218902510|NCT04480658|DRUG|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
218902511|NCT04384055|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
218902512|NCT02756117|DRUG|L-Lysine|
218902513|NCT02756117|DRUG|Normal (0.9%) Saline|
218902514|NCT03607955|DRUG|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
219204292|NCT06731556|DRUG|Intranasal Ibuprofen|Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
219204293|NCT06730399|DEVICE|Computed-assisted-cryotherapy|cryotherapy device
219612648|NCT03869944|DRUG|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
218902515|NCT03607955|DRUG|Paclitaxel|Commercially available
218902516|NCT03607955|DRUG|Carboplatin|Commercially available
218902517|NCT03607955|PROCEDURE|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
219038116|NCT02581696|DRUG|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
219038117|NCT03194451|OTHER|non-interventional study|teeth collection
219038118|NCT06092515|DIETARY_SUPPLEMENT|Fermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
219038119|NCT06092515|DIETARY_SUPPLEMENT|Unfermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
218902518|NCT03607955|PROCEDURE|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
218902519|NCT03607955|PROCEDURE|Interval Debulking|"* Standard of Care~* Research tissue samples will be collected"
218902520|NCT03607955|PROCEDURE|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
218902521|NCT03607955|PROCEDURE|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
218902522|NCT02817243|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
218902523|NCT02817243|DRUG|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
218902524|NCT01582399|DRUG|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
219204294|NCT06730906|DEVICE|PACTAID App|The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
219364819|NCT03775876|DIAGNOSTIC_TEST|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
219519546|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
218902525|NCT05842018|DRUG|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
218902526|NCT01041820|BEHAVIORAL|Exercise|Children will be exposed to a 10-week exercise intervention
218902527|NCT01855360|DRUG|Tauroursodeoxycholic Acid and Doxycycline|
218902528|NCT06449495|DEVICE|NIRVANA|"NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection."
218902529|NCT02947737|OTHER|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
218902530|NCT02947737|OTHER|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
218902531|NCT03703089|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
219519547|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
219519548|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
219519549|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
219519550|NCT01623622|DRUG|HC-58|once or more / week
219519551|NCT01623622|DRUG|Placebo|once or more / week
219519552|NCT06004102|OTHER|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
219519553|NCT06272409|DRUG|DEP114|DEP114 oral solution
219519554|NCT06272409|DRUG|Desloratadine 0.5 MG/ML|Desloratadine oral solution
219519555|NCT00265304|DRUG|Ketoprofen|
219519556|NCT03472729|OTHER|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
219519557|NCT02572310|DEVICE|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
218902532|NCT03703089|DRUG|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
219519558|NCT01402037|DRUG|Glucose|Glucose 20% intravenous
218902533|NCT04168671|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
218902534|NCT00955396|DRUG|GSK1014802|Tablets
218902535|NCT00955396|DRUG|Placebo|Tablets
218902536|NCT01060696|DRUG|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
219038120|NCT06092515|DIETARY_SUPPLEMENT|Post-Harvest Fortified Whole Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months."
219038121|NCT06092515|DIETARY_SUPPLEMENT|Low Zinc Whole Wheat Flour Flatbread (Control Group)|"* Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months."
219038122|NCT06423547|OTHER|no intervention|this is an observation study,no intervention
219038123|NCT00203528|DRUG|divalproex sodium ER|
219038124|NCT00203528|DRUG|risperidone|
219038125|NCT00892567|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
218902537|NCT01252706|BEHAVIORAL|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
218902538|NCT04631848|DEVICE|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
218902539|NCT05354271|OTHER|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
218902540|NCT05354271|OTHER|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
218902541|NCT00502788|DRUG|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
218902542|NCT00502788|DRUG|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
218902543|NCT04158583|DRUG|RO7296682|RO7296682 will be administered by the schedules specified in the respective arms.
218902544|NCT05545683|BIOLOGICAL|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
218902545|NCT01871519|DEVICE|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
218902546|NCT05160896|DRUG|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
218902547|NCT05160896|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
218902548|NCT05160896|DRUG|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
219612649|NCT05211648|DEVICE|Aktiia Bracelet|Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
219612650|NCT03412331|DEVICE|Ultrasonic|Cavitron® BOBCAT® Pro, Dentsply International, USA
219612651|NCT03412331|DEVICE|Hand Instruments|Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
219612652|NCT03412331|DEVICE|LED Source|LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
218902549|NCT05160896|DRUG|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
218902550|NCT00044473|DRUG|levofloxacin|
218902551|NCT02779647|BEHAVIORAL|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
218902552|NCT03232866|OTHER|Pilates exercise|Pilates methods exercises
218902553|NCT00320515|DRUG|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
218902554|NCT00320515|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
219612653|NCT01470092|DRUG|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
218902555|NCT06154356|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
219038126|NCT01250470|OTHER|Laboratory Biomarker Analysis|Correlative studies
219038127|NCT01250470|DRUG|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
219038128|NCT01250470|BIOLOGICAL|Sargramostim|Given SC
219364820|NCT00769119|DRUG|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
219364821|NCT00769119|DRUG|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
219364822|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel|
219364823|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel (Reference)|
219364824|NCT02525549|DRUG|Placebo gel|
219364825|NCT05642910|DRUG|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
219364826|NCT05642910|DRUG|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
219364827|NCT04167475|DIETARY_SUPPLEMENT|Probiotic capsule|Each probiotic capsule contains 1 x 10\^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
219364828|NCT04167475|DIETARY_SUPPLEMENT|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
218902556|NCT06154356|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
218902557|NCT04221646|DEVICE|BTL-899|Treatment with study device.
218902558|NCT00056953|BEHAVIORAL|Peer mentoring program|
218902559|NCT00794950|DRUG|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
218902560|NCT02717052|DRUG|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
218902561|NCT02717052|DRUG|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
218902562|NCT02717052|DRUG|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
218902563|NCT02717052|DRUG|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
218902564|NCT02717052|OTHER|PILOT Study II: PET1|\[11C\]DASB PET
218902565|NCT02717052|OTHER|PILOT Study II: PET2|\[11C\]DASB PET
218902566|NCT02717052|OTHER|Main Study: PET1|\[11C\]DASB PET
218902567|NCT02717052|OTHER|Main Study: PET2|\[11C\]DASB PET
218902568|NCT02717052|OTHER|PILOT Study I: PET1|\[11C\]DASB PET
219038129|NCT01627938|DRUG|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
219613438|NCT02927470|DEVICE|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
218902569|NCT02717052|OTHER|PILOT Study I: PET2|\[11C\]DASB PET
218902570|NCT02717052|DRUG|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
218902571|NCT02717052|DRUG|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
218902572|NCT02717052|OTHER|PILOT Study III: PET1|\[11C\]DASB PET
218902573|NCT02717052|OTHER|PILOT Study III: PET2|\[11C\]DASB PET
218902574|NCT02485704|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
218902575|NCT02485704|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
219038130|NCT01627938|DRUG|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
219038131|NCT04682821|OTHER|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
219038132|NCT00006890|DRUG|prednisone|Prednisone 50mg on alternate days
219038133|NCT00006890|DRUG|thalidomide|THALIDOMIDE 200 mg qhs
219038134|NCT01849211|DRUG|rocuronium|
219038135|NCT02882321|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
219038136|NCT02882321|OTHER|Pharmacological Study|Correlative studies
219364829|NCT01961115|DRUG|Epacadostat|Given PO
219364830|NCT01961115|BIOLOGICAL|MELITAC 12.1 Peptide Vaccine|Given ID/SC
218902576|NCT02187068|DRUG|Dexmedetomidine|Dexmedetomidine administered intravenously
218902577|NCT01777776|DRUG|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
218902578|NCT01777776|DRUG|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
218902579|NCT00851786|BIOLOGICAL|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
218902580|NCT00851786|BIOLOGICAL|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
218902581|NCT02806453|DIETARY_SUPPLEMENT|thickened formula|
218902582|NCT02806453|DIETARY_SUPPLEMENT|Mg alginate|
218902583|NCT02806453|BEHAVIORAL|reassurance with lifestyle changes|
218902584|NCT06225687|OTHER|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
218902585|NCT05065151|OTHER|Stimulation on|Stimulation from Percept DBS will be on while the patient is playing a decision-making game on a computer-based application.
218902586|NCT05065151|OTHER|Stimulation off|Stimulation from Percept DBS will be off while the patient is playing a decision-making game on a computer-based application.
218902587|NCT05065151|BEHAVIORAL|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
218902588|NCT01524146|PROCEDURE|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
218902589|NCT00902460|DRUG|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
219038137|NCT00096512|DRUG|sorafenib tosylate|Given orally
219038138|NCT00096512|OTHER|laboratory biomarker analysis|Correlative studies
219038139|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
219038140|NCT01389180|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
219038141|NCT01389180|BEHAVIORAL|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
219038142|NCT01389180|BEHAVIORAL|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
219038143|NCT04055857|OTHER||There is no Intervention.
219519559|NCT01402037|DEVICE|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
219519560|NCT04826809|DEVICE|N95 mask|Standard 1870 N95 one time use mask
219519561|NCT04826809|DEVICE|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
219519562|NCT04826809|DEVICE|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
219519563|NCT05047406|DIETARY_SUPPLEMENT|Bacillus clausii Probiotic liquid|mini bottles for oral administration containing 2 million spores of Bacillus clausii
219038144|NCT04050111|BIOLOGICAL|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
219038145|NCT03764722|DRUG|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
219204295|NCT06731036|BIOLOGICAL|CD34+ cell enriched stem cell graft|Patients will receive a peripheral blood stem cell graft that has been CD34+ cell enriched using the Miltenyi CliniMACS Prodigy® system.
219519564|NCT04154033|DRUG|Naltrexone|Topical naltrexone cream (1%)
219519565|NCT04154033|OTHER|Placebo Cream|Topical placebo cream
219613439|NCT03168022|DRUG|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
219613440|NCT03168022|DRUG|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
219519566|NCT04195165|BEHAVIORAL|SIT|For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.
219519567|NCT04195165|BEHAVIORAL|ACTIVE|For the ACTIVE+EX condition, the subject will be asked to take \>10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.
219519568|NCT04195165|BEHAVIORAL|EX|The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
219613441|NCT03214783|OTHER|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
218902590|NCT00902460|DRUG|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
219204296|NCT06716216|DRUG|Drug: 5 mg BGM0504 Administered SC|Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
219038146|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
219204297|NCT06716216|DRUG|Drug:10 mg BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
219204298|NCT06716216|DRUG|Drug: Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
218902591|NCT01706523|DRUG|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
218902592|NCT04737018|OTHER|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
218902593|NCT04737018|OTHER|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
219204299|NCT06715488|DIAGNOSTIC_TEST|AI assisted smartphone diagnosis|Patients will examination and clinical photographs for convolutional networks to diagnose inflammatory arthritis
219519569|NCT04835922|PROCEDURE|Intercostal Nerve Block|: Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)
219519570|NCT04835922|PROCEDURE|Peritract Infiltration|At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
219519571|NCT04528420|OTHER|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
219519572|NCT01820026|DRUG|Imipenem|second line therapy
219519573|NCT01820026|DRUG|Vancomycin|Second line therapy
219519574|NCT01820026|DRUG|azithromycin|Second line therapy
219519575|NCT01820026|DRUG|Cefotaxime|Standard antibiotic therapy
219519576|NCT01820026|DRUG|Amoxicillin|Standard therapy
219519577|NCT04407819|RADIATION|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
219519578|NCT04173754|PROCEDURE|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
219519579|NCT00003313|BIOLOGICAL|filgrastim|
219613442|NCT02677350|DRUG|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
219519580|NCT00003313|DRUG|amifostine trihydrate|
219613443|NCT05209789|BEHAVIORAL|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
219613444|NCT05209789|BEHAVIORAL|Playtime|Very little intervention from the therapists
219613445|NCT02188810|BIOLOGICAL|PAL|Single dose administered intramuscularly.
219364831|NCT00003063|BIOLOGICAL|recombinant interferon alfa|
219613446|NCT02188810|BIOLOGICAL|TIV|Single dose administered intramuscularly .
218902594|NCT04737018|OTHER|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
218902595|NCT04737018|OTHER|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
218902596|NCT04737018|OTHER|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
218902597|NCT04737018|OTHER|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
218902598|NCT04737018|DEVICE|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
218902599|NCT04737018|OTHER|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
218902600|NCT04737018|OTHER|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
219038147|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
219038148|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
219038149|NCT06469255|OTHER|Diet Treatment|4 weeks low calorie diet treatment
219038150|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
219364832|NCT00003063|DRUG|fluorouracil|
219364833|NCT00003063|DRUG|leucovorin calcium|
219364834|NCT00003063|DRUG|levamisole hydrochloride|
219364835|NCT02670603|DRUG|EVONAIL® solution|
219364836|NCT05112510|OTHER|Observing whether developing distant metastasis or recurrence|The study is a observational study and has no intervention.
219364837|NCT02315924|OTHER|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
219364838|NCT02315924|OTHER|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
219364839|NCT03987204|DRUG|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
218902601|NCT06128577|COMBINATION_PRODUCT|3-month intensive intervention|"Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week."
218902602|NCT03488277|OTHER|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
218902603|NCT03698123|OTHER|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
218902604|NCT04936633|OTHER|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~\- Intervention contents~1. Diet, exercise pattern~2. Causes of hypoglycemia~3. Causes of hyperglycemia~4. Causes of glycemic variability~5. Counseling for improvement plans for the cause~6. Counseling to strengthen lifestyle modification~7. Counseling for insulin administration~8. Counseling for Insulin dose adjustment (adjusted dose)~9. Counseling for how to use a FSGM"
219519581|NCT00003313|DRUG|carboplatin|
219519582|NCT00003313|DRUG|paclitaxel|
219519583|NCT00003313|RADIATION|radiation therapy|
219519584|NCT01211548|OTHER|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
219519585|NCT04480411|BEHAVIORAL|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
219519586|NCT02789033|DRUG|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
218902605|NCT04776512|PROCEDURE|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
218902606|NCT04776512|PROCEDURE|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
218902607|NCT05144139|BIOLOGICAL|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
218902608|NCT03522792|OTHER|Neurotensin|Intravenous infusion of neurotensin
218902609|NCT03522792|OTHER|Saline|Intravenous infusion of saline
218902610|NCT03522792|OTHER|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
218902611|NCT03522792|OTHER|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
218902612|NCT00727792|PROCEDURE|MRI -Clinical|MRI done is standard of care
218902613|NCT00727792|PROCEDURE|MRI-Research|MRI includes extra sequences
218902614|NCT05309148|BEHAVIORAL|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
218902615|NCT05309148|BEHAVIORAL|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
218902616|NCT05309148|BEHAVIORAL|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
218902617|NCT04382742|BEHAVIORAL|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
218902618|NCT02171442|DRUG|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
218902619|NCT02171442|DRUG|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
218902620|NCT06009055|DRUG|Remimazolam|0.3mg/kg，injection completed in 30 seconds
218902621|NCT06009055|DRUG|Propofol|2mg/kg，injection completed in 30 seconds
218902622|NCT02987270|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
218902623|NCT03603483|PROCEDURE|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
218902624|NCT01743443|OTHER|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
218902625|NCT00284700|DRUG|Iron|
219519587|NCT02789033|DRUG|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
219519588|NCT02789033|DRUG|Placebo|placebo
219519589|NCT03437356|OTHER|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm
219519590|NCT03437356|DRUG|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, \>70kg, except 80 mg OD if female \>70 years or Cr \>1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
219204300|NCT06726954|DEVICE|High-frequency real-time rTMS DLPF cortex protocol|It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
219519591|NCT05328713|DIAGNOSTIC_TEST|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
219519592|NCT04028453|OTHER|Survey|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
219519593|NCT04504513|DRUG|Trilaciclib|"Trilaciclib is a highly potent, selective, and reversible cyclin-dependent kinase 4/6 inhibitor administered intravenously prior to chemotherapy for chemotherapy-induced myelosuppression (CIM).~In patients being treated for SCLC, trilaciclib transiently maintains G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thus protecting the cells from damage by cytotoxic chemotherapy (myelopreservation). This can reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions."
218902626|NCT02649556|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
218902627|NCT02649556|OTHER|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
218902628|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
218902629|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
218902630|NCT02866227|DRUG|TOL-463|TOL-463 vaginal gel
218902631|NCT02866227|DRUG|TOL-463|TOL-463 vaginal insert
218902632|NCT03095729|OTHER|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
218902633|NCT01209429|DRUG|GH hormone infusion|Norditropin 30 ng/kg/min
218902634|NCT01209429|BEHAVIORAL|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
218902635|NCT01209429|BEHAVIORAL|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
218902636|NCT03656991|OTHER|Bicycle intervention|
218902637|NCT05914090|PROCEDURE|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
218902638|NCT02707627|DEVICE|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
218902639|NCT01102686|DRUG|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
218902640|NCT01102686|DRUG|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
218902641|NCT03250637|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
218902642|NCT04290039|DRUG|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
218902643|NCT04290039|DRUG|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
218902644|NCT01411826|BEHAVIORAL|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
218902645|NCT01411826|BEHAVIORAL|Information Only|Information from CDC website on colon cancer screening.
218902646|NCT06411717|DEVICE|Microstructure lens A|Subjects randomized to Trial Group A will be required to wear microstructural lens A (microstructural design type with low defocus ratio) for 12 months
218902647|NCT06411717|DEVICE|Microstructure lens B|Subjects randomized to Trial B will be required to wear microstructural lens B (high defocus ratio microstructural design type) for 12 months
218902648|NCT06411717|OTHER|Control group|Subjects randomized to the control group will be required to wear aspherical single-light lenses for 12 months
218902649|NCT00825292|PROCEDURE|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
218902650|NCT00825292|PROCEDURE|colon polyp removal|identify and remove polyp
219364840|NCT03894345|DRUG|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
219364841|NCT05965674|PROCEDURE|Sacral Erector Spinae Plane Block|The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
219519594|NCT00006166|PROCEDURE|Transjugular intrahepatic portasystemic shunts (TIPS)|
218902651|NCT00825292|PROCEDURE|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
218902652|NCT03439280|DRUG|Mezagitamab|Mezagitamab subcutaneously.
218902653|NCT03439280|DRUG|Pomalidomide|Pomalidomide orally.
218902654|NCT03439280|DRUG|Dexamethasone|Dexamethasone orally.
218902655|NCT00055302|DRUG|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
218902656|NCT02598726|DRUG|Curcumin|Given PO
218902657|NCT02598726|OTHER|Laboratory Biomarker Analysis|Correlative studies
218902658|NCT02598726|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
218902659|NCT02598726|OTHER|Quality-of-Life Assessment|Ancillary studies
218902660|NCT02149914|DEVICE|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
218902661|NCT02149914|DEVICE|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
218902662|NCT02149914|DEVICE|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
218902663|NCT02149914|OTHER|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
218902664|NCT02149914|DRUG|PPI|
218902665|NCT04634097|OTHER|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
218902666|NCT04634097|OTHER|standrad group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
218902667|NCT02397577|OTHER|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
218902668|NCT04046328|DRUG|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
218902669|NCT04046328|DRUG|Placebo|Enteric-Coated Delayed Release Placebo Capsules
218902670|NCT02172430|DRUG|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
218902671|NCT02172430|DRUG|Tersigan®|2 puffs of oxitropium three times daily via MDI
218902672|NCT01816217|DEVICE|Intubation with The McGrath Mac videolaryngoscope|
218902673|NCT02374697|DEVICE|During tele-expertise|
218902674|NCT03858049|DRUG|Crinone|Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
218902675|NCT03858049|DRUG|Duphaston|Participants received 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoign pregnancy was confirmed up to Day 63.
218902676|NCT02429323|DRUG|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
218902677|NCT02167308|DEVICE|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
218902678|NCT04617782|COMBINATION_PRODUCT|Donepezil TDS|Transdermal Delivery System
218902679|NCT04617782|DRUG|Aricept|Oral
218902680|NCT04104256|BEHAVIORAL|Nudge #1: Alert highlighting the safety/potential harms to patients of undergoing pre-op tests|"Nudge 1:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-op tests do NOT increase patient safety and go AGAINST local and national guidelines Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
218902681|NCT04104256|BEHAVIORAL|Nudge #2: Alert highlighting the financial harms to the patient experiencing pre-op tests|"Nudge #2:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can increase the patient's out-of-pocket costs without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Nudge includes hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
218902682|NCT04104256|BEHAVIORAL|Nudge #3: Alert highlighting potential psychological harms to the patient of experiencing pre-op tests|"Nudge 3:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can cause aggravation and psychological stress for the patient without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
218902683|NCT04104256|OTHER|Usual Care|Patients will receive usual care from their physicians.
218902684|NCT03080857|OTHER|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
219038151|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
219519595|NCT00006166|PROCEDURE|Total paracentecis (TP)|
219519596|NCT00301756|DRUG|Belinostat|Given IV
219519597|NCT00301756|OTHER|Laboratory Biomarker Analysis|Correlative studies
218902685|NCT03080857|DEVICE|AliveCor Heart Monitor|A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
218902686|NCT01650298|OTHER|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
219519598|NCT06158269|DRUG|DVRd|The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
218902687|NCT00699036|DRUG|avandia|4 mg twice daily
218902688|NCT00699036|DRUG|metformin|500 mg twice daily for 48 weeks
219612654|NCT02023931|DRUG|Broccoli Sprout Extract (BSE)|"1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
218902689|NCT00699036|DRUG|losartan|losartan 50 mg once daily
218902690|NCT00490087|DEVICE|Levonorgestrel intrauterine device (IUD)|
218902691|NCT00579774|OTHER|Low AGE Diet|Diet
218902692|NCT00579774|OTHER|Regular Diet|Diet
218902693|NCT00251524|DRUG|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
218902694|NCT04752267|PROCEDURE|Computed Tomography|Undergo PET/CT
218902695|NCT04752267|DRUG|18F-FMAU|Given IV
218902696|NCT04752267|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
218902697|NCT04752267|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218902698|NCT03441438|DIETARY_SUPPLEMENT|Water|Serum and urine markers will be obtained after drinking 5 oz of water
218902699|NCT03441438|DIETARY_SUPPLEMENT|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
218902700|NCT03441438|DIETARY_SUPPLEMENT|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
218902701|NCT06409806|OTHER|ECOG Array|"The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment.~Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference.~Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain."
218902702|NCT01690052|DRUG|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
218902703|NCT01690052|DRUG|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
218902704|NCT05477615|DRUG|Lazertinib|\- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
218902705|NCT05477615|DRUG|Pemetrexed|\- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
218902706|NCT05477615|DRUG|Carboplatin|\- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
218902707|NCT03872375|DIETARY_SUPPLEMENT|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
219519599|NCT04304963|OTHER|NO intervention - observational study|NO intervention - observational study
219519600|NCT03558308|BEHAVIORAL|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
219519601|NCT03558308|OTHER|Sham computerized gaming|Sham training with generally stimulating computer-games
219612655|NCT02463773|DEVICE|Ultrasound|Diaphragmatic excursion ultrasound assessment
219612656|NCT02688738|DRUG|Doxycycline|
219612657|NCT00399048|DRUG|OROS hydromorphone HCL ; OxyContin|
219612658|NCT00401661|DRUG|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
218902708|NCT03872375|BEHAVIORAL|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
219038152|NCT04212585|DIAGNOSTIC_TEST|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
219038153|NCT01828034|DRUG|Gemcitabine|
219038154|NCT01828034|DRUG|Cisplatin|
218902709|NCT06183580|OTHER|neurofeedback training involving dACC|"Participants are pseudorandomized to the dACC group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the dACC. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase dACC neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
218902710|NCT06183580|OTHER|neurofeedback training involving amygdala|"Participants are pseudorandomized to the rAMY group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the rAMY. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase rAMY neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
218902711|NCT06048302|DRUG|Obicetrapib|1 single dose of obicetrapib
218902712|NCT02537613|DRUG|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
218902713|NCT02537613|DRUG|Ibrutinib|Ibrutinib given once daily by mouth
218902714|NCT03397264|BIOLOGICAL|Aflibercept|Intravitreal injection
218902715|NCT03397264|BIOLOGICAL|OPT-302|Intravitreal Injection
218902716|NCT03397264|OTHER|Sham intravitreal injection|Sham (mock) intravitreal injection
218902717|NCT05621330|DRUG|QL0911|The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
218902718|NCT05621330|DRUG|Placebo comparator|The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
218902719|NCT03665636|DRUG|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
218902720|NCT06295159|DRUG|Nivolumab|Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
218902721|NCT06295159|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
218902722|NCT06295159|DRUG|Ipilimumab|Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
218902723|NCT05470140|BIOLOGICAL|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
218902724|NCT05867979|DIAGNOSTIC_TEST|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
218902725|NCT06333665|OTHER|Whether there is type 2 diabetes mellitus before surgery|Patients were grouped according to whether they had type 2 diabetes mellitus before surgery
219519602|NCT06970613|BEHAVIORAL|Watching cartoons|While watching the cartoons, local anesthesia will be applied and restorative treatments will be completed.
219519603|NCT06970613|BEHAVIORAL|Robot cat|Local anesthesia will be applied with the robot cat in their lap during the treatment and their restorative treatments will be completed.
219519604|NCT03199157|DRUG|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
219519605|NCT02206659|DRUG|Telmisartan|
219519606|NCT02206659|DRUG|Placebo|
219519607|NCT04871737|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
219519608|NCT05559268|DRUG|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
218902726|NCT05403034|PROCEDURE|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
218902727|NCT04189367|DRUG|Traditional Chinese Medicine|"One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks."
218902728|NCT04189367|DRUG|Western medicine|"Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks"
219519609|NCT05559268|DRUG|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
218902730|NCT03416855|DRUG|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
218902731|NCT05718973|OTHER|short, animated storytelling video (intervention video)|Participants in the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital.
218902732|NCT05718973|OTHER|short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
218902733|NCT02995980|DEVICE|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
218902734|NCT02995980|DEVICE|digital mammography|routine digital mammography
218902735|NCT01173016|DRUG|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
219519610|NCT05524688|DIETARY_SUPPLEMENT|Beta-glucan|2, 250 mg capsules of beta-glucan per day
218902736|NCT03274323|DEVICE|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
218902737|NCT03274323|PROCEDURE|Trabeculectomy|Standard trabeculectomy
218902738|NCT02719548|DEVICE|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield"
218902739|NCT02719548|DEVICE|Modified PF breast shield - Soft edge oval - Hard oval|"1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield"
218902740|NCT02719548|DEVICE|Hard oval - Soft edge oval - Modified PF breast shield|"1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield"
218902741|NCT02291146|BEHAVIORAL|LA Sprouts intervention|see arm 1 description
218902742|NCT04277728|DIAGNOSTIC_TEST|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
218902743|NCT04441359|OTHER|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
218902744|NCT04441359|OTHER|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
218902745|NCT00657540|DRUG|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
218902746|NCT00657540|DRUG|Saline|50 mL of saline infused over 10 minutes
218902747|NCT03714178|DEVICE|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
218902748|NCT03296917|DRUG|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
219612659|NCT05446558|PROCEDURE|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
218902749|NCT03296917|DRUG|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
218902750|NCT00555412|DRUG|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
219519611|NCT05524688|DIETARY_SUPPLEMENT|Placebo|2, 250 mg capsules of cellulose
219519612|NCT00249275|DEVICE|spectacles|
219519613|NCT01539109|BEHAVIORAL|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
219612660|NCT05446558|PROCEDURE|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
218902751|NCT00555412|DRUG|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
218902752|NCT00555412|DRUG|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
218902753|NCT00555412|DRUG|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
218902754|NCT04781010|DEVICE|MRI|MRI pattern in children with Leukodystrophy
218902755|NCT05979740|DRUG|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection \[2.0 mg/kg, Q2W, iv\] and Toripalimab injection \[3mg/kg, Q2W, iv\] for 1\~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
218902756|NCT01169103|DRUG|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
218902757|NCT01169103|DRUG|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
218902758|NCT05440877|BEHAVIORAL|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
218902759|NCT05440877|BEHAVIORAL|Tutorial guide|A tutorial guide including description of the smokers' cases
218902760|NCT03852602|DRUG|Preemptive Analgesics|Analgesic application15 minutes before the treatment
218902761|NCT03852602|DRUG|Control|Analgesic application15 minutes before the end of the treatment
218902762|NCT03536156|OTHER|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
219038155|NCT01828034|DRUG|MEK162|
219038156|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
219038157|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
218902763|NCT05495932|DIAGNOSTIC_TEST|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
218902764|NCT03010527|DRUG|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
218902765|NCT03010527|OTHER|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
218902766|NCT04458506|PROCEDURE|Maxillary expansion|Correction of the unilateral posterior cross bite in children
218902767|NCT02838069|BIOLOGICAL|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
218902768|NCT02838069|BIOLOGICAL|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
218902769|NCT02838069|OTHER|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
219038158|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
219204301|NCT06726954|DEVICE|High-frequency real-time rTMS M1 motor cortex protocol|It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
218902770|NCT03092583|OTHER|Blood sample|35 mL, 7 tubes
219038159|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
219204302|NCT06726954|DEVICE|Sham rTMS Protocol|It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
219204303|NCT06727045|OTHER|Mandala Coloring|"A literature review was conducted to determine the frequency and number of mandalas to be applied to the patients in the intervention group, and the average of the number of mandala sessions applied to different patient groups was obtained, and mandala application was performed during a total of eight hemodialysis sessions, every other day. Mandala painting was performed approximately 30 minutes after the start of HD treatment, considering the art therapist's recommendation and the symptoms that may develop during HD. Each mandala painting was performed with a structured and different mandala pattern. Since it was stated that the use of round patterns instead of square patterns was effective in increasing the comfort level, the booklet called Mandala Booklet, consisting of 8 structured mandala patterns with round shapes and containing general information about mandala, was used in the study. The group was informed about the content of the booklet face to face. Dry pencils were prefer"
219519614|NCT01539109|PROCEDURE|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
219519615|NCT01539109|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
218902771|NCT01793428|OTHER|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
219038160|NCT00253565|DRUG|capecitabine|
219038161|NCT00253565|DRUG|imatinib mesylate|
219038162|NCT01296516|BEHAVIORAL|Non-intervention group|A pedometer and written material on a healthy lifestyle.
219038163|NCT01296516|BEHAVIORAL|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
219038164|NCT01296516|BEHAVIORAL|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
219038165|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
219038166|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
219038167|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
219038168|NCT02233010|OTHER|The level of NGAL after pre op,post op 4hr, post op 12hr|
219038169|NCT05190042|DEVICE|Cotinuous suture|Cotinuous suture using surgery thread
219038170|NCT05190042|DEVICE|Clips|Hemostatic clips
219038171|NCT04122482|BEHAVIORAL|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
218902772|NCT06269224|OTHER|Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.|The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
218902773|NCT02656017|DRUG|Metformin|Monitoring of tolerability and symptoms.
218902774|NCT02656017|OTHER|Placebo|Monitoring of tolerability and symptoms.
218902775|NCT00823862|DRUG|SD-101|Intramuscular (IM)
218902776|NCT00823862|DRUG|ribavirin|oral, 2 times per day, for 2 months
218902777|NCT00400777|DRUG|Valsartan, hydrochlorothiazide and amlodipine|
218902778|NCT06169319|BIOLOGICAL|Collagenase Clostridium Histolyticum (CCH)|Biologic: Intrafascial injection
219612661|NCT03472781|OTHER|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
218902779|NCT06169319|BIOLOGICAL|Placebo|Intrafascial injection
218902780|NCT05656339|DIETARY_SUPPLEMENT|CHO+WP|Oral supplement containing carbohydrates plus whey protein
218902781|NCT05656339|DIETARY_SUPPLEMENT|CHO|Oral supplement containing carbohydrates
218902782|NCT05656339|DIETARY_SUPPLEMENT|Fast|Fast condition of 12 hours
219038172|NCT02108821|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
219038173|NCT02128295|DEVICE|Electric breast pump - A|
219038174|NCT02128295|DEVICE|Electric breast pump - B|
219204304|NCT06725459|DEVICE|Prophylactic ciNPWT|The prophylactic closed incision negative pressure wound therapy (ciNPWT) will be applied to one breast for up to 7 days postoperatively to promote wound healing and prevent complications.
219612662|NCT00332670|PROCEDURE|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
219612663|NCT00332670|PROCEDURE|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
219612664|NCT03135015|OTHER|Placebo capsules|250ml water with 16 x 250mg placebo capsules
218902783|NCT05400135|BEHAVIORAL|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
218902784|NCT02153957|BEHAVIORAL|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
218902785|NCT04552522|OTHER|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
219038175|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
219038176|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
219519616|NCT00431548|DRUG|100% O2|
219519617|NCT03879356|DRUG|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
219519618|NCT01208064|DRUG|pazopanib hydrochloride|
219519619|NCT01208064|OTHER|laboratory biomarker analysis|
219519620|NCT01208064|OTHER|pharmacogenomic studies|
219519621|NCT01208064|OTHER|pharmacological study|
219519622|NCT01208064|PROCEDURE|quality-of-life assessment|
219519623|NCT06134778|OTHER|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
219519624|NCT01840371|DRUG|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation"
219519625|NCT01840371|DRUG|Experimental sedation|"Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation"
219519626|NCT06032351|OTHER|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
219519627|NCT06032351|OTHER|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
219519628|NCT04870190|DRUG|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
219519629|NCT04870190|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
219519630|NCT04770623|DRUG|Docetaxel|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
219612665|NCT03135015|OTHER|2g capsules|250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules
219612666|NCT03135015|OTHER|4g capsules|250ml water with 16 x 250mg capsules containing Axulin powder
219612667|NCT03135015|OTHER|Water Control|250ml water
218902786|NCT05262855|DRUG|[68Ga]FAPI-46|\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
218902787|NCT06145373|DRUG|Fitusiran (SAR439774)|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
218902788|NCT06145373|BIOLOGICAL|Clotting factor concentrates (CFC) or bypassing agents (BPA)|Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
218902789|NCT06145373|BIOLOGICAL|Antithrombin concentrate (ATIIIC)|Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
218902790|NCT06145373|BIOLOGICAL|Emicizumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
218902791|NCT03770390|PROCEDURE|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
218902792|NCT06800261|BIOLOGICAL|Sinovac PCV24|Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.
218902793|NCT06800261|BIOLOGICAL|Prevnar®|Prevnar® (0.5 mL) is administered intramuscularly according to different immunization schedules.
218902794|NCT03650621|DEVICE|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
218902795|NCT03650621|DEVICE|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
218902796|NCT06065488|DEVICE|ankle kinesio tap|Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
218902797|NCT05952349|DRUG|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
218902798|NCT05952349|DRUG|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
218902799|NCT05406414|BEHAVIORAL|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems"
218902800|NCT05406414|BEHAVIORAL|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
218902801|NCT06792708|DRUG|LUMRYZ|Prescribed for narcolepsy in accordance with product label.
218902802|NCT05957679|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
218902803|NCT05957679|PROCEDURE|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
218902804|NCT06840002|DRUG|SHR-A1811|SHR-A1811.
218902805|NCT06840002|DRUG|Carboplatin|Carboplatin.
218902806|NCT06840002|DRUG|Bevacizumab|Bevacizumab.
218902807|NCT06840002|DRUG|Oxaliplatin for Injection|Oxaliplatin for injection.
218902808|NCT06840002|DRUG|Paclitaxel injection|Paclitaxel injection.
218902809|NCT06840002|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injetction.
218902810|NCT06840002|DRUG|Adebrelimab Injection|Adebrelimab injection.
218902811|NCT06958835|DRUG|Linezolid 600 mg|linezolid 600 mg tablets (twice a day for 5 days)
218902812|NCT06958835|DRUG|Placebo|Placebo tablets (twice a day for 5 days)
218902813|NCT06840015|DEVICE|Airpod Pro as hearing assistive technology|All participants will use and evaluate four types of assistive technology: hearing aids, Airpod pro 2nd and 3rd generation, dedicated wireless remote microphones, and Smartphone wireless remote microphone.
218902814|NCT05968274|DEVICE|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
218902815|NCT05968274|DEVICE|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
218902816|NCT06130254|DRUG|Adagrasib|Given by PO BID
218902817|NCT06130254|DRUG|Olaparib|Given by PO BID
218902818|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
219519631|NCT04770623|DRUG|Irinotecan|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
218902819|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
218902820|NCT04935957|DEVICE|GLUCUBE device|device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
218902821|NCT04705662|DIAGNOSTIC_TEST|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
218902822|NCT04705662|OTHER|Stool sample|Participants will provide a stool sample pre and post iron supplementation
218902823|NCT04705662|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
219519632|NCT02014181|DIETARY_SUPPLEMENT|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
218902824|NCT04705662|OTHER|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
218902825|NCT04705662|DIETARY_SUPPLEMENT|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
218902826|NCT05518643|PROCEDURE|ERAS protocol|ERAS protocol as described above
218902827|NCT04608617|DEVICE|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
218902828|NCT04608617|OTHER|Baseline Effectiveness Cohort|No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
218902829|NCT04125563|DRUG|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
219519633|NCT03415906|COMBINATION_PRODUCT|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
218902830|NCT04125563|DRUG|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
218902831|NCT05963672|DEVICE|EEG-guided sleep protection|"The tablet will display a specific picture prioritize sleep or prioritize care depending on the patient status determined by the algorithm. When the picture favor/prioritize sleep is displayed, all caregivers and visiting family are asked to follow the sleep protection rules: refrain to enter the room for not urgent reasons, switch off television, reduced light in the room/corridor, reduce noise in front of the door, close curtain (if any), and delay non urgent care…etc; if caregivers have to enter the room, headlight and/or additional light will be favored. All these rules will be established collegially by nurses and doctors. Obviously, urgent care and reactions to alarms are maintained.~When the picture favor/prioritize care is displayed, all caregivers and visiting family are invited to perform non urgent care, cleaning, restocking perfusion needles, comfort care, visiting."
218902832|NCT05963672|OTHER|Control condition|the recording device will be placed on the patient to record sleep but the tablet will be masked and placed face down on the bench in the room, invisible from the door.
218902833|NCT04755816|BEHAVIORAL|Sodium intervention|The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.
218902834|NCT04755816|BEHAVIORAL|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
218902835|NCT04755816|BEHAVIORAL|Educational content|Standard heart failure educational information and a daily symptom survey.
218902836|NCT03093922|DRUG|Atezolizumab|1200 mg/m\^2
218902837|NCT03093922|DRUG|Gemcitabine|1000 mg/m\^2
218902838|NCT03093922|DRUG|Cisplatin|70 mg/m\^2
218902839|NCT04467073|BEHAVIORAL|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
218902840|NCT05072418|BEHAVIORAL|Eye-opened and Eye-closed|The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
218902841|NCT04736888|OTHER|extended-reality CPR training|extended-reality technologies based CPR training module
218902842|NCT04736888|OTHER|conventional CPR training|conventional CPR training with video
218902843|NCT04306614|PROCEDURE|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
218902844|NCT03049761|DEVICE|Water Flosser|Power interdental cleaner
218902845|NCT03049761|DEVICE|String Floss|Mechanical interdental cleaner
218902846|NCT03049761|DEVICE|Manual Toothbrush|ADA standard soft bristle toothbrush
218902847|NCT02792231|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
218902848|NCT02792231|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
218902849|NCT02792231|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
218902850|NCT02792231|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
218902851|NCT03895333|OTHER|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
218902852|NCT05196828|DEVICE|NTX100 Neuromodulation System|Active Noninvasive peripheral nerve stimulation device programmed to active mode
219038177|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
219519634|NCT03415906|DRUG|valsartan|Angiotensin receptor inhibition alone
219519635|NCT00004109|DRUG|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
218902853|NCT02005367|BEHAVIORAL|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
218902854|NCT02005367|BEHAVIORAL|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
218902855|NCT03866655|DEVICE|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
218902856|NCT02469623|DEVICE|Dipole Density Mapping with AcQMap followed by ablation|
218902857|NCT04073186|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
218902858|NCT03309878|BIOLOGICAL|Mogamulizumab|Given IV
218902859|NCT03309878|BIOLOGICAL|Pembrolizumab|Given IV
218902860|NCT01270178|DRUG|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
218902861|NCT01096316|BEHAVIORAL|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
218902862|NCT02763644|DRUG|LFG316 active drug|LFG316
218902863|NCT02763644|OTHER|Standard of care treatment|SoC (site specific)
218902864|NCT02461667|DRUG|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
218902865|NCT02461667|DRUG|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
218902866|NCT02461667|DRUG|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
218902867|NCT01028989|DIETARY_SUPPLEMENT|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories"
218902868|NCT01028989|DIETARY_SUPPLEMENT|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories"
219612668|NCT03135015|OTHER|2g tablets|250ml water with 2 x 1g tablets containing Axulin powder
219612669|NCT03135015|OTHER|4g tablets|250ml water with 4 x 1g tablets containing Axulin powder
218902869|NCT01719796|PROCEDURE|Regional analgesia infusion|
218902870|NCT01772628|BEHAVIORAL|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
219038178|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
219038179|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
219038180|NCT04054687|DRUG|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
218902871|NCT01772628|BEHAVIORAL|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
218902872|NCT01772628|BEHAVIORAL|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
219038181|NCT04054687|OTHER|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
219038182|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
219612670|NCT03153358|DRUG|Icotinib|icotinib 125 milligram three times a day
219612671|NCT03153358|RADIATION|SBRT|given radiation for the primary lesion
219612672|NCT05560490|DEVICE|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
219612673|NCT01172041|DEVICE|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
219612674|NCT01172041|DEVICE|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
219612675|NCT01172041|DRUG|18-FDG|15mCi
218902873|NCT01772628|BEHAVIORAL|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
218902874|NCT02836652|DEVICE|HeartMate II (HMII)|Left Ventricular Assist Device
218902875|NCT02836652|DRUG|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
218902876|NCT02836652|DRUG|acetylsalicylic acid (ASA) therapy|(81mg/day)
219038183|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
219038184|NCT00534235|PROCEDURE|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
219038185|NCT00534235|DEVICE|Posterolateral Fusion and Implantation of Pedicle Screws|
219038186|NCT00534235|DEVICE|Implantation of coflex Interlaminar Technology|
219519636|NCT00004109|RADIATION|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
219519637|NCT03510364|BEHAVIORAL|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
219519638|NCT06355245|DIAGNOSTIC_TEST|Blood sampling|Collection of blood samples
219519639|NCT01891292|DRUG|Enalapril|0.25-0.35 mg/kg/day
219519640|NCT01891292|DRUG|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
219519641|NCT01226797|DRUG|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
219519642|NCT01226797|DRUG|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
219519643|NCT04917978|DIAGNOSTIC_TEST|Hematological Phenotype Analysis|Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio- Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).
219519644|NCT03320304|DEVICE|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
219519645|NCT05921214|BEHAVIORAL|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
219612676|NCT04488588|OTHER|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
219612677|NCT04658966|OTHER|administration of a self-questionnaire|Women will have to fill in an online self questionnaire on pre-eclampsia
219612678|NCT03855982|DRUG|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
219612679|NCT05883124|DRUG|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
219612680|NCT05883124|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
219612681|NCT05481671|OTHER|Questionnaires|Participants will be asked to respond to the Demographic Information Sheet, Tampa Scale for Kinesiophobia, Numeric Rating Scale, Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Resilience Scale , Pain Self-efficacy Questionnaires and Functional Exercise Compliance Scale for Orthopaedic Patients.
219519646|NCT04141033|DIAGNOSTIC_TEST|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
219519647|NCT05455073|DIETARY_SUPPLEMENT|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
219519648|NCT05455073|COMBINATION_PRODUCT|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
219519649|NCT05455073|COMBINATION_PRODUCT|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
219612682|NCT01174693|DRUG|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
219612683|NCT01174693|DRUG|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
219612684|NCT06581445|BEHAVIORAL|Birdsongs|The participants listened to a clip of birdsongs from laughing thrushes.
219612685|NCT06581445|BEHAVIORAL|Music|The participants listened to a cheerful Cuckoo Waltz music.
219612686|NCT05681598|DRUG|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
219612687|NCT03817645|OTHER|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
218902877|NCT01474525|DEVICE|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
218902878|NCT00473434|DRUG|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
218902879|NCT03536013|OTHER|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
218902880|NCT06474624|OTHER|Cardio Rehabilitation program|A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.
218902881|NCT06474624|OTHER|Cycling for 20-30 minutes|Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.
218902882|NCT06474624|OTHER|Cycling a total of 4 cycles|Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
218902883|NCT02349633|DRUG|PF-06747775|
218902884|NCT02349633|DRUG|Palbociclib|
218902885|NCT02349633|DRUG|Avelumab|
218902886|NCT03679975|DRUG|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
218902887|NCT03647930|DEVICE|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
218902888|NCT00558246|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
218902889|NCT00558246|DEVICE|Suture|Topical Suturing
218902890|NCT00038753|PROCEDURE|Vision Screening|
218902891|NCT06366178|DEVICE|BONFIX system|"The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide."
218902892|NCT05478421|PROCEDURE|Collagen sponge|The bone cavity will be filled with collagen sponge.
218902893|NCT05478421|PROCEDURE|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
218902894|NCT05478421|PROCEDURE|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
218902895|NCT01160276|DRUG|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
218902896|NCT01160276|DRUG|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
218902897|NCT04870658|PROCEDURE|Dental implant treatment|Patients who receive one o more dental implant treatment to restore oral function.
218902898|NCT03820609|BEHAVIORAL|Digital Intervention|This digital application for sexual assault prevention can be completed on a tablet computer.
218902899|NCT02760940|DRUG|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
218902900|NCT05233865|BEHAVIORAL|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
218902901|NCT05233865|BEHAVIORAL|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
218902902|NCT06359158|DEVICE|Digital stethoscope use|In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
218902903|NCT05548517|BEHAVIORAL|Time Restricted Eating (TRE)|9-hour eating window
218902904|NCT05548517|BEHAVIORAL|Calorie Restriction|daily calorie restriction
219038187|NCT05001243|DRUG|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
219038188|NCT05001243|DRUG|Pilocarpine Hydrochloride|Apply in the fellow eye
219038189|NCT05001243|DRUG|Brimonidine Tartrate|Apply in the fellow eye
218902905|NCT06034210|DEVICE|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
219519650|NCT05455073|BEHAVIORAL|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
219519651|NCT05455073|BEHAVIORAL|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
219519652|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
219519653|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
219519654|NCT01318499|OTHER|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
219519655|NCT00352261|DRUG|Esomeprazole|
219519656|NCT00352261|DRUG|Lansoprazole|
218902906|NCT03315520|DRUG|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
218902907|NCT06085599|BEHAVIORAL|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
218902908|NCT01008943|BIOLOGICAL|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
218902909|NCT06007534|OTHER|Samples|Blood samples, urine samples and oropharyngeal swabs before taking 200mg of doxycycline and then 2h, 24h, 48h, 7 days, 14 days, 60 days and 90 days after the single dose of doxycycline Hair samples: at the time of doxycycline administration, 1 month and 3 months after the single dose of doxycycline
219038190|NCT04619056|DRUG|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
219038191|NCT02187302|DRUG|CRLX101|
219038192|NCT02187302|DRUG|Bevacizumab|
219038193|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
219038194|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
219038195|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
219038196|NCT05072353|DEVICE|SEFFICARE|"The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
219038197|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
219519657|NCT03905486|DRUG|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
219519658|NCT03905486|DRUG|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
219519659|NCT06230081|DRUG|Ropivacain 5 mg/ml + Clonidine|Drug used in the block
219519660|NCT04117841|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
219519661|NCT00849459|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
219519662|NCT01988922|DRUG|ketamine|0.4 mg/kg oral racemic ketamine
219519663|NCT00208286|DEVICE|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
219519664|NCT00208286|DEVICE|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
219519665|NCT03938922|DRUG|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
219519666|NCT05161611|DRUG|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
219519667|NCT05161611|OTHER|Placebo|10 mg of normal saline will be given to neonates per day
219519668|NCT05161611|OTHER|Phototherapy|Neonates will be put under phototherapy
218902910|NCT05590481|DEVICE|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
218902911|NCT05590481|BEHAVIORAL|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
218902912|NCT06518824|DEVICE|DBS On|The DBS device will be turned on while the patient undergoes the working memory task.
218902913|NCT06518824|DEVICE|DBS Off|The DBS device will be turned off while the patient undergoes the working memory task.
218902914|NCT05685043|DEVICE|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients \> 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
218902915|NCT05428332|DEVICE|Tri-Compartment Unloader Brace|Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
218902916|NCT06532643|GENETIC|anti-CD20/CD30-CAR-T cells|"Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed."
218902917|NCT06532643|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
218902918|NCT06532643|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
218902919|NCT01725906|DRUG|empirical therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
219612688|NCT02226211|DEVICE|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
218902920|NCT01725906|DRUG|Genotypic resistance guided therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
219038198|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
219519669|NCT05328141|OTHER|Bread and butter|A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
219519670|NCT05328141|OTHER|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
219519671|NCT05328141|OTHER|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
219519672|NCT02219945|OTHER|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
219519673|NCT01780415|OTHER|blastocoele aspiration|
219519674|NCT01128686|OTHER|No intervention|This study is retrospective chart review
219519675|NCT05935098|DRUG|BGB-A3055|Administered intravenously
218902921|NCT02370329|OTHER|Laboratory Biomarker Analysis|Correlative studies
218902922|NCT02370329|OTHER|Quality-of-Life Assessment|Ancillary studies
218902923|NCT02370329|BIOLOGICAL|Ropeginterferon Alfa-2B|Given SC
218902924|NCT06580587|DRUG|MK-8527|Oral administration
218902925|NCT04244253|DRUG|OPC-64005 20 mg , Once-daily|Active, High Dose
219038199|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
219038200|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
219519676|NCT05935098|DRUG|Tislelizumab|Administered intravenously
219519677|NCT05935098|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219519678|NCT00715442|DRUG|Sunitinib|50 mg by mouth daily for 28 consecutive days
219519679|NCT00715442|PROCEDURE|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
219612689|NCT02226211|DEVICE|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (\> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT."
219612690|NCT04356989|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
218902926|NCT04244253|DRUG|OPC-64005 10 mg , Once-daily|Active, Low Dose
218902927|NCT04244253|DRUG|Placebo, Once-daily|Placebo
218902928|NCT05222958|DEVICE|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
218902929|NCT04663321|DRUG|MK-1942|MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
218902930|NCT04663321|DRUG|Placebo|Dose matched placebo capsules BID orally over 4 weeks.
218902931|NCT04327206|DRUG|BCG Vaccine|"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection"
218902932|NCT04327206|DRUG|0.9%NaCl|0.9% Sodium Chloride Injection
218902933|NCT02181309|DRUG|Meloxicam, low dose|
218902934|NCT02181309|DRUG|Meloxicam, medium dose|
218902935|NCT02181309|DRUG|Meloxicam, high dose|
218902936|NCT00571155|DRUG|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
218902937|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
218902938|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
218902939|NCT01453140|DRUG|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
218902940|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
218902941|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
218902942|NCT01453140|DRUG|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
218902943|NCT00641004|DRUG|Rebamipide and Esomeprazole|"1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
218902944|NCT05734599|DEVICE|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
218902945|NCT01003158|DRUG|AZD8931|Tablet Oral bid
218902946|NCT01003158|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off
218902947|NCT05788055|DIAGNOSTIC_TEST|Stool Analysis|Stool Analysis to detect H.Pylori Antigen in Stool
218902948|NCT06403462|PROCEDURE|transversalis fascial plane block|ultrasound guidance transversalis fascial plane block after iliac bone graft
218902949|NCT06403462|PROCEDURE|transversus abdominis plane block|ultrasound guidance lateral transversus abdominis plane block after iliac bone graft
218902950|NCT00005992|BIOLOGICAL|PSA prostate cancer vaccine|
218902951|NCT00005992|BIOLOGICAL|therapeutic autologous dendritic cells|
218902952|NCT03214861|OTHER|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
218902953|NCT04379063|OTHER|COVID-19 pandemic|Currently practicing during the COVID-19 pandemic
218902954|NCT01332123|DEVICE|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
218902955|NCT05850949|DIETARY_SUPPLEMENT|Konjac Grain|Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
218902956|NCT05289843|OTHER|Rosmarinus Officinallis|Root canal Irrigants
218902957|NCT02795117|DRUG|Ivermectin|
218902958|NCT02795117|DRUG|Ivermectin (reference)|
219612691|NCT02735109|OTHER|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
219612692|NCT02735109|PROCEDURE|biopsy normal area|biopsy done to compare with abnormal area
218902959|NCT02795117|DRUG|Placebo|
218902960|NCT01059409|PROCEDURE|Meniscal Allograft|Meniscal Allograft
218902961|NCT02653326|DEVICE|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
218902962|NCT02653326|PROCEDURE|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
218902963|NCT02653326|BEHAVIORAL|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
218902964|NCT02653326|OTHER|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
218902965|NCT02653326|DRUG|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
218902966|NCT02422498|RADIATION|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
218902967|NCT02422498|DRUG|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
218902968|NCT02422498|PROCEDURE|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
218902969|NCT05507307|BEHAVIORAL|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
218902970|NCT02305030|DRUG|BIA 9-1067|
218902971|NCT02305030|DRUG|Warfarin|
218902972|NCT03206216|DIAGNOSTIC_TEST|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
218902973|NCT04958824|DIAGNOSTIC_TEST|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
218902974|NCT03438617|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
218902975|NCT06279858|DIETARY_SUPPLEMENT|Probiotics|Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
218902976|NCT04394923|PROCEDURE|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
218902977|NCT04394923|PROCEDURE|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
218902978|NCT05655884|OTHER|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
218902979|NCT05655884|OTHER|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
218902980|NCT04177706|DRUG|Ketamine Hydrochloride|Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
218902981|NCT04177706|DRUG|Placebo|Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
218902982|NCT01387217|DRUG|GSK2018682|GSK2018682
218902983|NCT01387217|DRUG|Placebo|Matched Placebo
218902984|NCT00217958|BEHAVIORAL|SHS reduction intervention based on social cognitive learning theory|
219038201|NCT00202618|DRUG|Valsartan|
219038202|NCT00202618|DRUG|Amlodipine|
218902985|NCT03243695|OTHER|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
218902986|NCT03243695|OTHER|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
218902987|NCT03642977|DIAGNOSTIC_TEST|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
218902988|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
218902989|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
218902990|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
218902991|NCT00388986|DRUG|GK Activator (2)|100mg po bid
218902992|NCT00388986|DRUG|Glyburide|10-20mg po daily
218902993|NCT01415271|OTHER|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
218902994|NCT05537220|DRUG|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
218902995|NCT05537220|DRUG|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
218902996|NCT06417814|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
218902997|NCT06417814|DRUG|Osimertinib|Osimertinib will be administered orally.
218902998|NCT06417814|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
218902999|NCT06417814|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
219519680|NCT04656353|BEHAVIORAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
219519681|NCT04656353|BEHAVIORAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
219519682|NCT04977336|DRUG|VX-548|Tablets for oral administration.
219519683|NCT04977336|DRUG|HB/APAP|Capsules for oral administration.
218903000|NCT06417814|DRUG|Cisplatin|Cisplatin will be administered as IV infusion.
218903001|NCT04534205|BIOLOGICAL|BNT113|IV injection
219038203|NCT03137693|OTHER|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
219519684|NCT04977336|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
219038204|NCT03137693|PROCEDURE|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
219038205|NCT03914560|OTHER|Burn injury|minor burn injury
219038206|NCT00422331|DRUG|Lithium Carbonate Capsule|
219038207|NCT00591448|OTHER|Virtual Reality (VR)|See above
219038208|NCT03249285|DRUG|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
219038209|NCT03249285|DRUG|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
219519685|NCT04977336|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
219519686|NCT05344898|PROCEDURE|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
219519687|NCT05344898|PROCEDURE|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
219519688|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
219519689|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
219519690|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
218903002|NCT04534205|BIOLOGICAL|Pembrolizumab|IV infusion
218903003|NCT04727307|DRUG|Atezolizumab (neoadjuvant)|Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
218903004|NCT04727307|PROCEDURE|Percutaneous Radiofrequency|Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
218903005|NCT04727307|DRUG|Bevacizumab (adjuvant)|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
218903006|NCT04727307|DRUG|Atezolizumab (adjuvant)|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
218903007|NCT06952816|DEVICE|Emily.AI|EMILY.AI is composed of an O2 regulating valve together with an intelligent system, EDGE computing, which allows the automation in the regulation of O2 and its customization.
218903008|NCT06961084|DRUG|Iodine-124|Given Orally
218903009|NCT06961084|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Combination of PET and CT imaging
218903010|NCT00060541|PROCEDURE|Laboratory tests|
219519691|NCT01347710|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
218903011|NCT00060541|PROCEDURE|Radiological exams|
218903012|NCT05528809|OTHER|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
218903013|NCT06588556|BEHAVIORAL|ICUconnect|ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.
218903014|NCT06588556|OTHER|Usual care|Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
219204305|NCT06725459|OTHER|Standard Adhesive Dressing|The standard adhesive strip dressing will be applied to one breast immediately after surgery. It provides a protective covering for the wound during the initial healing phase and is the standard of care for incision management.
218903016|NCT05767021|DRUG|Mirikizumab|Administered IV
218903017|NCT05767021|DRUG|Mirikizumab|Administered Subcutaneously (SC)
218903018|NCT02423057|DRUG|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
218903019|NCT03181867|DRUG|18F-DCFPyL|Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
218903020|NCT03181867|DRUG|18F-FDG|Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.
218903021|NCT03181867|DRUG|PSMA-11|For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
219038210|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
219038211|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
219038212|NCT01071928|DRUG|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
219038213|NCT01071928|DRUG|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
219038214|NCT00649896|DRUG|Mylan Estradiol Transdermal System 0.025 mg/day|
219038215|NCT00649896|DRUG|Climara® Transdermal System 0.025 mg/day|
219038216|NCT04930887|DRUG|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
219038217|NCT04930887|DRUG|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
219038218|NCT02712944|DRUG|Testosterone|Testosterone
219038219|NCT02712944|DRUG|Saline|Placebo
219038220|NCT06225726|PROCEDURE|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
219038221|NCT03121326|DIAGNOSTIC_TEST|blood and urine sampling|Ten mL blood and 15mL urine are collected.
219519692|NCT01347710|DRUG|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
218903022|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
218903023|NCT06237335|OTHER|Placebo|Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
218903024|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
218903025|NCT06237335|DRUG|RCT2100|RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
218903026|NCT06072131|DRUG|Belinostat Injection|Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
218903027|NCT06072131|DRUG|Pralatrexate Injection|Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
218903028|NCT06072131|DRUG|CHOP|CHOP is the comparator arm
218903029|NCT06072131|DRUG|COP|COP is given in combination with Pralatrexate
218903030|NCT06412510|OTHER|Prehabilitation|"Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy"
218903031|NCT03822897|RADIATION|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
218903032|NCT03822897|DRUG|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
218903033|NCT00875849|BIOLOGICAL|cetuximab|
218903034|NCT00875849|DRUG|cisplatin|
218903035|NCT00875849|RADIATION|radiation therapy|
218903036|NCT04325425|DRUG|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
219038222|NCT05863897|BEHAVIORAL|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
218903037|NCT04325425|DRUG|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
218903038|NCT01936675|OTHER|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
218903039|NCT04772703|DIAGNOSTIC_TEST|COMET ASSAY|The description in the detailed description of the study
218903040|NCT02251015|PROCEDURE|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
219038223|NCT04079985|OTHER|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
219038224|NCT03829371|DRUG|Velcade|Subcutaneous use
219038225|NCT03829371|DRUG|Melphalan|Oral use
219038226|NCT03829371|DRUG|Prednisone|Oral use
219038227|NCT03829371|DRUG|Lenalidomide|Oral use
218903041|NCT02251015|PROCEDURE|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
218903042|NCT01467544|OTHER|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
219038228|NCT03829371|DRUG|Dexamethasone|Oral use
219038229|NCT03829371|DRUG|Daratumumab|Subcutaneous Injection
219038230|NCT06571981|DEVICE|TUP ultraportable US with teleradiology capacities|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
219038231|NCT06571981|DEVICE|CUS conventional ultrasound|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
219038232|NCT03539835|OTHER|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
218903043|NCT06561295|OTHER|Later Morning Timing of Spontaneous Breathing Trials|Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
218903044|NCT05220722|DRUG|SD-101|SD-101 doses will be delivered via HAI using the PEDD method of administration.
218903045|NCT05220722|BIOLOGICAL|Pembrolizumab|During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
218903046|NCT05220722|BIOLOGICAL|Nivolumab|During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
218903047|NCT05220722|BIOLOGICAL|Ipilimumab|During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
218903048|NCT06146257|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
218903049|NCT06850415|DEVICE|Siriraj gastrointestinal transit capsule|The Siriraj gastrointestinal transit capsule is a local made colonic transit capsule. Each capsule contains 6 circular-shaped radiopaque markers.
218903050|NCT06850415|DEVICE|Sitz-Markers|The standard Sitzmark colonic capsule containing 24 ring-shaped radiopaque markers.
218903051|NCT06272812|BIOLOGICAL|MTBVAC|Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
218903052|NCT06272812|BIOLOGICAL|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
218903053|NCT04211818|BEHAVIORAL|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
218903054|NCT04211818|BIOLOGICAL|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
218903055|NCT03496805|DRUG|MGE|The patients will take 4 capsules by mouth BID (twice daily).
218903056|NCT03496805|OTHER|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
218903057|NCT03496805|OTHER|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
218903058|NCT04347603|PROCEDURE|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
218903059|NCT04058431|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
218903060|NCT04058431|OTHER|Control- No Intervention|This group will refrain from getting OMT while in the study.
218903061|NCT05852509|BEHAVIORAL|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
219204306|NCT06705595|DRUG|Tracheo-Spray|Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
218903062|NCT05852509|BEHAVIORAL|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
218903063|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
218903064|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
218903065|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
218903066|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
218903067|NCT00876200|DRUG|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
218903068|NCT00876200|DRUG|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
218903069|NCT01368588|RADIATION|radiation therapy|Undergo RT using IMRT or 3D-CRT
218903070|NCT01368588|RADIATION|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
218903071|NCT04154943|DRUG|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
218903072|NCT00872625|DRUG|cyclophosphamide|
218903073|NCT00872625|DRUG|docetaxel|
218903074|NCT00872625|DRUG|epirubicin hydrochloride|
218903075|NCT00872625|DRUG|fluorouracil|
218903076|NCT00872625|PROCEDURE|neoadjuvant therapy|
219204307|NCT06705595|DRUG|Lidocaine Spray on DLT|Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).
218903077|NCT00872625|PROCEDURE|therapeutic conventional surgery|
218903078|NCT00872625|RADIATION|hypofractionated radiation therapy|
218903079|NCT00872625|RADIATION|image-guided radiation therapy|
218903080|NCT00872625|RADIATION|radiation therapy|
218903081|NCT00872625|RADIATION|stereotactic radiosurgery|
219204308|NCT06705595|DRUG|Saline (Placebo)|Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
219204309|NCT06705881|OTHER|Eccentric exercise program (EEP)|All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.
218903084|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody.
218903085|NCT06960577|DRUG|Methotrexate|Chemotherapy agent.
218903086|NCT06960577|DRUG|Vinblastine|Chemotherapy agent
218903087|NCT06960577|DRUG|Doxorubicin|Chemotherapy agent
218903088|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
218903089|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody
218903090|NCT06960577|DRUG|Gemcitabine|Chemotherapy agent
218903091|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
218903092|NCT05800665|DRUG|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
219519693|NCT04512768|BEHAVIORAL|Transdiagnostic Internet-delivered Cognitive Behaviour Therapy|All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
219612693|NCT00065156|DRUG|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
219612694|NCT00613171|DRUG|STI571|STI571 tablets taken orally once a day
219612695|NCT04801511|DRUG|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
219612696|NCT00929851|DRUG|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
218903097|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
218903098|NCT05717647|OTHER|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
218903099|NCT06518798|BEHAVIORAL|Fasting Mimicking Diet|Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
218903100|NCT06240780|OTHER|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
218903101|NCT06240780|OTHER|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
218903102|NCT05570851|BEHAVIORAL|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
218903103|NCT05570851|BEHAVIORAL|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
218903104|NCT06337188|DEVICE|Experimental AAC|Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
218903105|NCT06337188|DEVICE|Generic AAC|Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
218903106|NCT04782063|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
218903107|NCT03281928|DIETARY_SUPPLEMENT|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
218903108|NCT03281928|DIETARY_SUPPLEMENT|Placebo|Sodium without Potassium Citrate
218903109|NCT02008123|DRUG|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
218903110|NCT02659930|DRUG|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
218903111|NCT02659930|DRUG|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
218903112|NCT06823141|DEVICE|Virtual reality immersion|The study intervention, defined by the use of a virtual reality, exclusively takes place during the pre-oxygenation period where the patient is exposed to a virtual reality immersion scenario.
218903113|NCT05578092|DRUG|MRTX0902|SOS1 inhibitor
218903114|NCT05578092|DRUG|MRTX849|KRAS G12C inhibitor
219519694|NCT04512768|BEHAVIORAL|Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia|A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
219519695|NCT06379009|OTHER|Training|12 week home-based training program
219519696|NCT03262974|DIAGNOSTIC_TEST|PCR|PCR
219519697|NCT03262974|DIAGNOSTIC_TEST|HPLC-UV|HPLC-UV
219519698|NCT03385746|OTHER|polyamide|metal reinforced polyamide denture base material
219519699|NCT03385746|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
219519700|NCT03089203|BIOLOGICAL|CART-PSMA-TGFβRDN cells|autologous CAR T cells
219519701|NCT03089203|DRUG|Cyclophosphamide|300 mg/m2/day given over 3 days
219519702|NCT03089203|DRUG|Fludarabine|30 mg/m2/day given over 3 days
219519703|NCT04538040|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
219519704|NCT02215174|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
219519705|NCT03541681|PROCEDURE|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
218903115|NCT00391482|BEHAVIORAL|Peer Mentoring Intervention for HCV-Infected IDUs|
218903116|NCT02351765|DRUG|Acelarin|First-in-class nucleotide analogue
218903117|NCT02351765|DRUG|Cisplatin|Platinum-compound chemotherapy drug
218903118|NCT02243592|OTHER|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
218903119|NCT05246774|BIOLOGICAL|Biological sample collection|"The following biological samples will be collected on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* fecal sample~* urinary sample~* blood sample (22 ml at each occasion)"
219038233|NCT03539835|BEHAVIORAL|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
218903120|NCT05246774|OTHER|Questionnaires|"The following questionnaires will be filled by the patients on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* CTCAE Radiation Adverse Event Questionnaire~* Lower Urinary Tract Disorders Questionnaire (IPSS Score)~* Quality of Life Questionnaire (FACT-P)~* Physical Activity Questionnaire (IPAQ)"
218903121|NCT03273335|DEVICE|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
219519706|NCT03541681|PROCEDURE|Anesthetic Injections|0,5 ml Bupivacain
219519707|NCT05150236|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.
219519708|NCT05150236|DRUG|Ipilimumab|Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.
219519709|NCT05150236|DRUG|Nivolumab|Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
219519710|NCT04812587|BEHAVIORAL|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
219519711|NCT02161874|DEVICE|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
219519712|NCT02161874|DEVICE|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
219519713|NCT01376128|DRUG|Paroxetine|
219612697|NCT00929851|DRUG|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
219612698|NCT00036153|DRUG|Tacrolimus (Prograf®)|
219612699|NCT00036153|DRUG|Methotrexate|
219612700|NCT01197911|DRUG|aleglitazar|single oral dose
219612701|NCT00220389|DRUG|SPM 907|
218903122|NCT04428736|BEHAVIORAL|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
218903123|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures|All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
218903124|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures|All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding…
218903125|NCT04354376|DRUG|Loop diuretics, thiazides, dihydropyridines|Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
218903126|NCT04354376|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
218903127|NCT05120414|OTHER|balanace exercises|Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
218903128|NCT05120414|OTHER|Balance Exercises plus Ankle strategy|ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
218903129|NCT05852080|BEHAVIORAL|multilevel system intervention based on information platform|"1. Standardized templates of medical record~2. Continuous medical quality control and feedback system: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the percentage of stroke of undetermined cause.~3. Team collaboration based on video conferencing: hospitals will receive corresponding suggestions for their improvement from experts online.~4. Enhanced feedback incentives"
218903130|NCT06802406|OTHER|Food Bags|Participants will receive bags of shelf-stable food for 2-3 days for one individual twice a week in clinic. They will also receive recipes, handouts, and videos to help with education and food preparation.
219204310|NCT06705881|OTHER|ESWT (Extracorporeal Shock Wave Therapy)|ESWT is a therapy method routinely used in private and public hospitals. Tendinopathy therapy parameters approved by the International Society for Medical Shock Wave Therapy (ISMST) for focused ESWT treatment are: 0.10-0.25 mJ/mm (dosing appropriate to pain), up to a maximum of 5 Hz, 1500-2500 pulses per session, 1-2 weeks apart. Accordingly, in our study, the focused ESWT dosage of the ESWT group will be applied as; 0.10-0.25 mJ/mm (dosing appropriate to pain), 4 Hz, 2000 pulses, 1 session per week for 3 weeks. No exercise will be done on the day of ESWT.
219519714|NCT00023283|DRUG|Buprenorphine|"1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
218903133|NCT00003239|BIOLOGICAL|Recombinant Interferon Alfa|Daily by subcutaneous injection.
218903134|NCT00003239|DRUG|Cytarabine|Daily by subcutaneous injection.
218903135|NCT00003239|DRUG|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
218903136|NCT03212118|BEHAVIORAL|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
219519715|NCT04018261|DRUG|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
219519716|NCT00551005|DRUG|celecoxib|
219519717|NCT00551005|DRUG|etoposide|
219519718|NCT00551005|OTHER|immunoenzyme technique|
219519719|NCT00551005|OTHER|laboratory biomarker analysis|
219519720|NCT04089683|OTHER|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
219519721|NCT01004172|DRUG|carboplatin|
219519722|NCT01004172|DRUG|bevacizumab|
219519723|NCT01004172|DRUG|herceptin|
218903137|NCT03212118|BEHAVIORAL|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
218903138|NCT03212118|BEHAVIORAL|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
218903139|NCT00290173|DRUG|efficacy of oral ritodrine in maintaining uterine quiescence|
219519724|NCT01946347|OTHER|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
219519725|NCT01946347|OTHER|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
219519726|NCT03623048|OTHER|chlorhexidine|antibacterial and anti-inflammatory mouthwash
219519727|NCT03623048|OTHER|saline|anti-inflammatory cleansing mouthwash
219519728|NCT03623048|OTHER|Propolis extract|antibacterial mouthwash
219519729|NCT03623048|OTHER|pomegranate extract|antibacterial mouthwash
219519730|NCT03979248|DRUG|BMS-986165|Specified dose on specified days.
219519731|NCT03979248|DRUG|Rabeprazole|Specified dose on specified days.
219519732|NCT01606306|DRUG|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
219519733|NCT01606306|DRUG|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
219519734|NCT01606306|DRUG|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
219519735|NCT06249399|OTHER|Aerobic Exercise|Aerobic Exercise training will be provided three days a week, 45 minutes a day, for 12 weeks. Patients will be subjected to submaximal aerobic exercise with rhythmic movements without equipment via video conference accompanied by a physiotherapist.
218903140|NCT05513352|DEVICE|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
218903141|NCT05513352|DEVICE|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
218903142|NCT05513352|DEVICE|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
218903143|NCT00507169|DRUG|SVT-40776|
218903144|NCT04438694|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
219038234|NCT06482008|DRUG|Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib|HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
219038235|NCT01052545|BEHAVIORAL|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
218903145|NCT04438694|DRUG|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
218903146|NCT05555875|BEHAVIORAL|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
218903147|NCT04951830|DIAGNOSTIC_TEST|MRI|MRI of TMJ
219038236|NCT05137873|OTHER|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
218903148|NCT02738008|DRUG|ARC-520 Injection|IV injection
219038237|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
219038238|NCT04226482|DEVICE|New Device|Laparoscopic appendectomy using new ultrasonic shears.
219038239|NCT04226482|DEVICE|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
219038240|NCT00453999|DRUG|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
219038241|NCT00453999|DRUG|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
219038242|NCT00453999|DRUG|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
219038243|NCT00802412|DRUG|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
219038244|NCT00802412|DRUG|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
219038245|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
219038246|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
219038247|NCT01391728|BEHAVIORAL|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
219519736|NCT06249399|BEHAVIORAL|Behavioral Treatment Program|Behavioral Treatment Program will be completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.
218903149|NCT02738008|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
218903150|NCT02738008|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
218903151|NCT02738008|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
218903152|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
218903153|NCT00004925|BIOLOGICAL|trastuzumab|
218903154|NCT00004925|DRUG|pegylated liposomal doxorubicin hydrochloride|
218903155|NCT03143530|PROCEDURE|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
218903156|NCT03143530|DRUG|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
218903157|NCT03143530|DRUG|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
218903158|NCT01735448|OTHER|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
218903159|NCT01735448|OTHER|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
218903160|NCT01735448|OTHER|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
218903161|NCT04912778|OTHER|Filling in an online survey|Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
218903162|NCT03145311|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|
218903163|NCT03550378|DRUG|MEDI0382|Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
218903164|NCT03550378|DRUG|Placebo|Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
218903165|NCT04129502|DRUG|TAK-788|TAK-788 capsule
218903166|NCT04129502|DRUG|Pemetrexed|Pemetrexed IV infusion
218903167|NCT04129502|DRUG|Cisplatin|Cisplatin IV infusion
218903168|NCT04129502|DRUG|Carboplatin|Carboplatin IV infusion
218903169|NCT02519023|DRUG|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
219038248|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
219204311|NCT03872466|DEVICE|GRASP HEP|The GRASP system comprises a sensor package and therapy game software that works with a commercial glove orthosis to enable virtual world-based practice of activities of daily living (ADLs) involving the hand.
219612702|NCT05712174|DRUG|[18]F-PSMA-1007|\[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
218903170|NCT02519023|DRUG|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
218903171|NCT02519023|DEVICE|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
218903172|NCT02519023|DRUG|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
218903173|NCT02519023|DRUG|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
219038249|NCT06105385|OTHER|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
219038250|NCT05930665|DRUG|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
219038251|NCT04307628|OTHER|Walnut|Study participants will eat 2 ounces of walnuts each day.
219038252|NCT04307628|OTHER|Nut-Free|Study participants will not eat nuts.
219038253|NCT04185233|OTHER|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
219038254|NCT04185233|DRUG|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
219038255|NCT02550457|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
219038256|NCT02550457|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
219519737|NCT01506830|PROCEDURE|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
219612703|NCT06972810|OTHER|A/Texas/71/2017, clade 3C3a H3N2 influenza virus|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device. Participants will be admitted into an inpatient facility prior to the administration of the flu virus. Following inoculation, they will be quarantined for a minimum of 8 days prior to discharge. Participants will receive supportive care and PCR positive participants will receive an effective antiviral medication. Participants will be followed for a total of 6 months.
218903174|NCT02519023|DRUG|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
218903175|NCT02519023|DRUG|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
219612704|NCT06649344|DRUG|HRS9531 Injection|HRS9531 injected subcutaneously once weekly.
219612705|NCT06649344|DRUG|Semaglutide Injection|Semaglutide injected subcutaneously once weekly.
218903176|NCT05196607|OTHER|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
218903177|NCT04916574|OTHER|Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum|Concentration of active substance on nasal mucosal surface in time
218903178|NCT04590014|DEVICE|Conventional Precision Flow|Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
218903179|NCT04590014|DEVICE|HVNI HVT2.0 Device|Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
218903180|NCT00468299|DRUG|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
218903181|NCT00468299|DRUG|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
218903182|NCT01667289|RADIATION|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
218903183|NCT01667289|DRUG|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
218903184|NCT05931757|DRUG|Olverembatinib|Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
218903185|NCT05841368|DIAGNOSTIC_TEST|CAM-ICU|Delirium in adult patients will be screened according to CAM-ICU
218903186|NCT05841368|DIAGNOSTIC_TEST|pCAM-ICU|Delirium in adult patients will be screened according to pCAM-ICU
218903187|NCT00799201|DRUG|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
219038257|NCT02550457|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
219038258|NCT00594061|DEVICE|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
219038259|NCT01971853|DRUG|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
219038260|NCT01971853|DRUG|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
219519738|NCT01506830|PROCEDURE|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
219612706|NCT06319560|DRUG|Hydroxychloroquine Oral Tablet|200mg daily
219519739|NCT01904786|DRUG|Melatonin|
219519740|NCT01904786|DRUG|placebo|
219519741|NCT01107236|DRUG|IW-6118|Single dose
219519742|NCT01107236|DRUG|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
219519743|NCT01107236|DRUG|Naproxen Sodium|Single dose
219038261|NCT00987116|DRUG|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
219038262|NCT03522181|OTHER|saline|saline
219038263|NCT03522181|OTHER|Insulin|
219038264|NCT03688672|DEVICE|Apioc Contact Lens Design|Novel soft contact lens design.
218903188|NCT01071681|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
218903189|NCT01290523|DEVICE|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
219519744|NCT06364670|PROCEDURE|acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
219519745|NCT01434342|DRUG|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
218903190|NCT05101434|DIAGNOSTIC_TEST|Periodontal Probing|with the help Michigan probe, periodontal pocket measurement was done.
218903191|NCT01665469|DIETARY_SUPPLEMENT|Tomato extracted lycopene|
218903192|NCT01665469|DIETARY_SUPPLEMENT|Placebo|
218903193|NCT02854046|OTHER|Calcific Uremic Arteriolopathy|
218903194|NCT01917747|BEHAVIORAL|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
218903195|NCT01917747|BEHAVIORAL|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
218903196|NCT04492410|OTHER|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
218903197|NCT00603330|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
218903198|NCT03692559|OTHER|full aseptic dressing|Replacement of the central venous catheters in the dressing process
218903199|NCT00093210|DRUG|rFIX|
218903200|NCT00093210|DRUG|rFIX-R|
219519746|NCT02898623|OTHER|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
219519747|NCT03874130|DRUG|Scopolamine|IV Scopolamine
219519748|NCT00408902|DRUG|tandutinib|Given orally, 500 mg bid daily
219519749|NCT00408902|OTHER|laboratory biomarker analysis|Correlative studies
219519750|NCT03696381|OTHER|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
219519751|NCT03696381|OTHER|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
219612707|NCT04548440|DRUG|Sintilimab|Route of administration: Intravenous
219612708|NCT04548440|DRUG|Nab paclitaxel|Route of administration: Intravenously over 30min
218903201|NCT02976714|OTHER|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
218903202|NCT02997501|PROCEDURE|T790M+ Testing|The patient will need to have T790M+ testing
218903203|NCT02997501|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
218903204|NCT02997501|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
218903205|NCT02997501|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
218903206|NCT02997501|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
219038265|NCT04869072|DRUG|Convalescent plasma|"Convalescent plasma will be delivered as FFP. Three units of 200ml CP/FFP harvested from one donor will be transfused to one recipient, i.e. there will be a match between donor and recipient and each recipient will receive CP/FFP only from one donor.~CP/FFP will be administered intravenously at the infusion rate of 100ml/hour, starting from day 0, with a new transfusion every 24 hours, for a total of 3 transfusions (see scheme)."
218903207|NCT02997501|PROCEDURE|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
218903208|NCT05057481|DRUG|Mycophenolate Mofetil 500mg|MMF 2gram/day orally for 12 weeks
218903209|NCT05057481|DRUG|Rituximab|375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
218903210|NCT00415285|DRUG|Docetaxel|
219519752|NCT00970281|DRUG|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
219519753|NCT00970281|DRUG|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
219519754|NCT04500522|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
219519755|NCT04500522|DRUG|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
219519756|NCT05151406|OTHER|educational program|The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
218903211|NCT00415285|DRUG|Capecitabine|
218903212|NCT00415285|DRUG|Docetaxel/Capecitabine|
218903213|NCT03712514|OTHER|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
218903214|NCT03195283|OTHER|Meal service|The type of meal service in the hospital (usual care)
218903215|NCT02023307|DEVICE|V-Loc Suture|
218903216|NCT06341712|DRUG|Cabozantinib|Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
218903217|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
218903218|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
218903219|NCT00415948|DEVICE|Biomarkers|
218903220|NCT02429635|BEHAVIORAL|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
218903221|NCT04632888|OTHER|Telephone support for breastfeeding follow-up|The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
218903222|NCT00152503|DRUG|Seletracetam (UCB44212)|"* Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration"
218903223|NCT01173354|DIETARY_SUPPLEMENT|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
218903224|NCT01173354|DIETARY_SUPPLEMENT|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
218903225|NCT03375034|DRUG|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
218903226|NCT03375034|DRUG|NDMC60mg|Oral administration of three NDMC 20mg capsules
218903227|NCT03375034|DRUG|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
218903228|NCT03375034|DRUG|Placebo|Oral administration of three Placebo capsules
218903229|NCT04361435|PROCEDURE|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
218903230|NCT00874146|GENETIC|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
218903231|NCT02922725|DRUG|5-hydroxytryptophan and Creatine|
218903232|NCT02922725|OTHER|Placebo control|
218903233|NCT01300234|DRUG|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
218903234|NCT01300234|DRUG|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
218903235|NCT04140968|DRUG|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
218903236|NCT03994510|OTHER|Clinical and biological assessments - a 5 Years follow-up|During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
218903237|NCT03253679|DRUG|Adavosertib|Given PO
218903238|NCT02944409|DEVICE|total knee prothesis VEGA System|total knee replacement
219038266|NCT06159972|DEVICE|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
219038267|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
219038268|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
219038269|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
218903239|NCT06622161|DEVICE|automated oxygen vs manual oxygen|Patient characteristics, ventilator, and blood gas parameters at the time of study will be shown in Tabular form. At the start of the study, half of the babies will be randomly assigned to a manual 12-hour period where a bedside nurse will adjust the FiO2 of the baby according to SpO2 levels, and half of the babies to an automated 12-hour period where Oxygenie will adjust FiO2 according to target SpO2 levels. After 12 hours, they will be shifted to contralateral intervention. The ventilator parameters (peak inspiratory pressure, positive end expiratory pressure, and rate) will be compared between the automated and manual 12-hour periods. The amount of time spent within different ranges of SpO2 will also be measured and shown in tabular form.
218903240|NCT00895635|BEHAVIORAL|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
218903241|NCT00895635|BEHAVIORAL|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
218903242|NCT00895635|BEHAVIORAL|Usual Care|Usual care for PAD
218903243|NCT02584179|DEVICE|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
218903244|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
218903245|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
218903246|NCT06038331|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
218903247|NCT03269422|RADIATION|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
218903248|NCT03190057|DEVICE|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
218903249|NCT05660772|DEVICE|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
218903250|NCT05660772|DRUG|Corticosteroid|intra-articular knee injection of corticosteroid
219519757|NCT02003183|RADIATION|[F-18]FDDNP|Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
219519758|NCT01406678|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
219519759|NCT01406678|PROCEDURE|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
219519760|NCT01406678|DRUG|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
219519761|NCT06497387|BIOLOGICAL|PRG-1801|PRG-1801 (BCMA-targeting CAR-T Cells)
218903252|NCT06027099|DRUG|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
218903253|NCT06027099|BEHAVIORAL|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
218903254|NCT06027099|DRUG|Placebo|1 tablet three times a day for 5 weeks after surgery
218903255|NCT06027099|BEHAVIORAL|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
218903256|NCT03863119|DRUG|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
219038270|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
219038271|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
219038272|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
219038273|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
219038274|NCT00615563|BEHAVIORAL|NO BI Drug administered|
219519762|NCT01581957|OTHER|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
218903257|NCT03692702|BEHAVIORAL|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
218903258|NCT03902314|DRUG|Lidocaine Iv|Intravenous infusion
218903259|NCT03902314|DRUG|Saline Solution|Intravenous infusion
218903260|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
219519763|NCT01581957|OTHER|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
218903261|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
218903262|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
218903263|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
218903264|NCT04816214|DRUG|Capmatinib|Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).
218903265|NCT04816214|DRUG|Osimertinib|Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)
218903266|NCT04816214|DRUG|Pemetrexed|Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
218903267|NCT04816214|DRUG|Cisplatin|Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.
218903268|NCT04816214|DRUG|Carboplatin|Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
218903269|NCT00625079|DRUG|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
218903270|NCT00550407|DRUG|lamotrigine|lamotrigine 100mg/day or 200mg/day
218903271|NCT00550407|DRUG|Placebo|placebo once daily
218903272|NCT00930085|OTHER|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
218903273|NCT05546775|DIAGNOSTIC_TEST|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~* To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~* To assess the growth parameters in patients with CGD."
218903274|NCT06296485|BEHAVIORAL|SAGE Group Sessions|Participants enroll in 3 educational group sessions and receive CGMs
218903275|NCT06296485|OTHER|Usual Care|Participants continue to receive usual care (Control Arm)
218903276|NCT02151669|BEHAVIORAL|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
218903277|NCT00584415|DEVICE|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
219204312|NCT03872466|BEHAVIORAL|Usual Care Treatment (UCT)|Participants in the control group will continue to receive any previously prescribed therapy services. These patients will not receive any treatment services through the study as UCT group participants.
219204313|NCT06707259|BIOLOGICAL|anti-CD19 IL10 CAR-NK|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19-IL10 CAR
219204314|NCT06710249|DIETARY_SUPPLEMENT|Salovum/SPC flakes|Egg yolk powder and specially processed cereals
219519764|NCT00878995|DRUG|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
219519765|NCT00878995|DRUG|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
219519766|NCT02968485|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
219519767|NCT04586621|DEVICE|Atoldys/ Lexilens - SHAM|Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
219519768|NCT04586621|DEVICE|SHAM- Atoldys/ Lexilens|SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
219519769|NCT02291900|PROCEDURE|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
219519770|NCT00191932|DRUG|Duloxetine|
219519771|NCT03338972|BIOLOGICAL|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Given IV
218903278|NCT03741686|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)
218903279|NCT03741686|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
219519772|NCT03338972|DRUG|Cyclophosphamide|Given IV
219519773|NCT03338972|DRUG|Fludarabine|Given IV
219519774|NCT03338972|PROCEDURE|Leukapheresis|Undergo leukapheresis
218903280|NCT02935647|DRUG|Diprivan|
218903281|NCT02650180|DEVICE|Soberlink Cellular Device|Alcohol Breath Analyzer
218903282|NCT00187863|BEHAVIORAL|pain perception|pain perception
218903283|NCT06374953|DIAGNOSTIC_TEST|Ultrasound-based viscoelastic hemostasis analysis|Adding recombinant tissue plasminogen activator (rtPA) and/or Tranexamic acid （TXA）to blood in vitro, and fibrinolysis capacity is assessed using ultrasound-guided viscoelastic coagulation testing.
218903284|NCT05051579|DRUG|LY3502970|Administered orally
218903285|NCT05051579|DRUG|Placebo|Administered orally
218903286|NCT02447614|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy
219038275|NCT05128175|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
219038276|NCT01772641|OTHER|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
219038277|NCT01772641|OTHER|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
219038278|NCT01772641|OTHER|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
219038279|NCT01772641|OTHER|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
219038280|NCT05410626|DRUG|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
219038281|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
219038282|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
219204315|NCT06728592|DEVICE|Portable Magnetic Resonance Imaging|0.23T Low-field Magnetic Resonance Imaging
219204316|NCT06727864|DRUG|4-month regimen (2HERZ/2HRE)|4-month (2HERZ/2HRE)
219204317|NCT06727864|DRUG|6-month (2HERZ/4HRE)|2 months of HREZ followed by 4 months of HR/HRE
219519775|NCT02480764|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
219519776|NCT02480764|DRUG|Valsartan|Valsartan 80 mg capsules
219519777|NCT02480764|DRUG|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
219519778|NCT02480764|DRUG|Valsartan Placebo|Valsartan placebo-matching capsules
219519779|NCT03629249|DRUG|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
219519780|NCT03629249|DRUG|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
219519781|NCT03629249|DRUG|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
219519782|NCT02385396|DIETARY_SUPPLEMENT|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
219519783|NCT05084001|DRUG|silver diamine fluoride|topical application of the agent on tooth surface
219519784|NCT05084001|DRUG|sodium fluoride varnish|topical application of the agent on tooth surface
219519785|NCT05084001|OTHER|tonic water|topical application of tonic water on tooth surface
219519786|NCT05128981|BEHAVIORAL|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
219519787|NCT02767310|DRUG|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
219519788|NCT02767310|DRUG|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
219519789|NCT06139224|DIETARY_SUPPLEMENT|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
219519790|NCT05483153|BEHAVIORAL|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
219612709|NCT04548440|DRUG|Cisplatin|Route of administration: Intravenous
219612710|NCT05441592|DRUG|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
219612711|NCT05441592|OTHER|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
219612712|NCT02212314|BEHAVIORAL|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
218903287|NCT02447614|OTHER|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
218903288|NCT02447614|OTHER|no treatment|just regular follow-up
218903289|NCT05055024|DRUG|Mazindol|Drug: NLS-2
218903290|NCT01271556|DRUG|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
218903291|NCT01271556|PROCEDURE|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
218903292|NCT01271556|OTHER|Placebo|placebo, inhalatory (MDI) once
219038283|NCT03356249|DIAGNOSTIC_TEST|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
219038284|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
219364842|NCT02858427|BEHAVIORAL|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
219519791|NCT03963206|DRUG|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
219519792|NCT03931239|BIOLOGICAL|Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval|An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
219519793|NCT01853553|DRUG|Spironolactone|Blood pressure medication.
219519794|NCT01853553|DRUG|Sugar pill|Placebo.
218903293|NCT06389578|DRUG|Teprotumumab|SC administration and IV infusion
218903294|NCT03333707|BEHAVIORAL|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
219519795|NCT05432193|DRUG|[Ga-68]-PNT6555|\[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
218903295|NCT00717249|DEVICE|galyifilcon A control lens|Marketed daily wear contact lens
218903296|NCT00717249|DEVICE|galyfilcon A with a silver additive|Investigational daily wear contact lens
218903297|NCT00876616|DRUG|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
218903298|NCT00876616|DRUG|Cyclophosphamide|CTX 0.75g/m2 BSA
218903299|NCT00360412|DRUG|E2007|
218903300|NCT00043043|DRUG|celecoxib|
218903301|NCT03318588|PROCEDURE|Vitrectomy|Pars plana vitrectomy
218903302|NCT04874935|DRUG|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
218903303|NCT04874935|DRUG|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
218903304|NCT05094726|RADIATION|photobiomodulation|Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.
218903305|NCT05094726|OTHER|placebo intervention by photobiomodulation device|placebo intervention while the photobiomodulation device is on the off mode
218903306|NCT03082248|OTHER|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
218903307|NCT03082248|PROCEDURE|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
219038285|NCT01853033|BIOLOGICAL|ABT-122|Injection
219038286|NCT01853033|BIOLOGICAL|Placebo|Placebo Injection
219038287|NCT03444974|OTHER|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
219038288|NCT03913481|PROCEDURE|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
219038289|NCT03913481|PROCEDURE|Standard care|Best available treatment without ANH
219038290|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
219038291|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
219038292|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
219038293|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
219038294|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
219204318|NCT06888336|BEHAVIORAL|Yoga nidra (full)|"The intervention consists of remotely delivered audio recordings (\~30 minute length) of iRest yoga nidra meditation instructions that participants will be asked to listen to daily for 8 weeks, for a total listening time of about 3.5 hours each week. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (\~2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more often but are instructed to listen to the recordings at least once per day."
219364843|NCT02858427|BEHAVIORAL|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
219364844|NCT02858427|BEHAVIORAL|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
219364845|NCT02858427|BEHAVIORAL|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
219364846|NCT03845387|DRUG|KDT-3594|oral administration, dose titration
219364847|NCT03845387|DRUG|Pramipexole|ER formulation, oral administration, dose titration
219364848|NCT05526027|DIAGNOSTIC_TEST|CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement|cf supra
218903308|NCT04065139|DRUG|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
218903309|NCT04065139|DRUG|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
218903310|NCT01568489|DRUG|HL-009 Liposomal Gel|Topical adenosylcobalamin gel
218903311|NCT01568489|DRUG|Placebo|Placebo gel
218903312|NCT01041313|DRUG|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
218903313|NCT01041313|DRUG|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
218903314|NCT00001114|DRUG|Interferon alfa-2b|
218903315|NCT00001114|DRUG|Didanosine|
219038295|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
219038296|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
219038297|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
219364849|NCT03828487|DEVICE|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
219038298|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
219038299|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
219038300|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
219038301|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
219364850|NCT03828487|DEVICE|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
219364851|NCT05792514|OTHER|stong,stamp,pyms|STRONG(screening tool for risk of nutritional status and growth) STAMP(screening tool assessment of malnutrition in pediatrics) PYMS
219364852|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
219364853|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
219364854|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
219364855|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
218903316|NCT03075917|OTHER|Self Questionnaire|self questionnaire for allergic rhinitis control
218903317|NCT06974201|DEVICE|Diabetes M bolus calculator|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
218903318|NCT06974201|DEVICE|Diabetes M app|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
218903319|NCT06972381|BEHAVIORAL|Navigator|Participants in the navigator condition will meet with their counselor for sessions twice in month 1, once in month 2, once in month 4, and once in month 8. Three additional sessions may scheduled if desired by the participant. Navigators will assess treatment preferences, provide information about evidence-based treatment options for weight loss, aid in decision making, and facilitate action during the intervention initiation process. Following initiation of a weight loss treatment, navigators will also assess adherence to and acceptability of the selected weight loss intervention, and engage in problem solving and motivational enhancement to facilitate persistence with the original intervention or provide the support necessary for switching to an alternative intervention option. Additional intervention contact will include monthly emails over the 12 month period. Navigators will receive resource guides to help them tailor sessions to the individual participant.
219612713|NCT05248204|DEVICE|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
218903320|NCT06366464|DRUG|Pitolisant tablet|Pitolisant tablet
218903321|NCT06366464|OTHER|Placebo tablet|Placebo tablet
218903322|NCT05809908|DRUG|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 2-4 weeks."
218903323|NCT05809908|DRUG|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of placebo; 80 ml total daily dose of placebo, over the course of 2-4 weeks."
219519796|NCT05432193|DRUG|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
219519797|NCT02068248|DIETARY_SUPPLEMENT|Soluble Fibre|
219519798|NCT05326659|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
219519799|NCT05326659|DRUG|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
219519800|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
219519801|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
219519802|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
219612714|NCT05248204|DEVICE|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
219519803|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
219519804|NCT01674556|DRUG|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
219519805|NCT01150747|DRUG|ceftriaxone|250mg IM once
219519806|NCT01150747|DRUG|Azithromycin|1 gm once
219519807|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
219519808|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
219519809|NCT04426409|DRUG|tarivid ointment|Vaseline ointment is applied to both noses.
219519810|NCT01242865|BEHAVIORAL|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
219519811|NCT00234429|DRUG|Gefitinib, raltitrexed|
219519812|NCT01030965|DRUG|GSK573719 125mcg|125mcg once-daily
219519813|NCT01030965|DRUG|GSK573719 250mcg|250mcg once-daily
219519814|NCT01030965|DRUG|GSK573719 500mcg|500mcg once-daily
219519815|NCT01030965|DRUG|Placebo|once-daily
219519816|NCT05563909|OTHER|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
219519817|NCT05563909|OTHER|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
219612715|NCT06987513|DRUG|Pemvidutide|Pemvidutide 2.4mg
219612716|NCT06987513|OTHER|Placebo|Subcutaneous injection
219612717|NCT00951496|BIOLOGICAL|Bevacizumab|Given IV
219612718|NCT00951496|DRUG|Carboplatin|Given IV
219612719|NCT00951496|DRUG|Carboplatin|Given IP
219612720|NCT00951496|DRUG|Cisplatin|Given IP
219612721|NCT00951496|OTHER|Laboratory Biomarker Analysis|Correlative studies
219364856|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
219519818|NCT05563909|OTHER|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
219519819|NCT02029937|DRUG|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
219519820|NCT06121037|PROCEDURE|proximal ultrasound-guided GON radiofrequency ablation|proximal GON radiofrequency
219519821|NCT06121037|PROCEDURE|distal ultrasound-guided GON radiofrequency ablation|distal GON radiofrequency
219519822|NCT02097290|DEVICE|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
219519823|NCT00156949|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
219519824|NCT02467621|DRUG|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
219519825|NCT02467621|OTHER|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
219612722|NCT00951496|DRUG|Paclitaxel|Given IV
219612723|NCT00951496|DRUG|Paclitaxel|Given IP
219612724|NCT00951496|OTHER|Quality-of-Life Assessment|Ancillary studies
219612725|NCT04628091|OTHER|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
219612726|NCT03575377|OTHER|Disposal Aid|Deterra® drug deactivation system
219612727|NCT02791451|DEVICE|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
219612728|NCT00808951|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
219612729|NCT00808951|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
218903324|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
218903325|NCT05746520|OTHER|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
218903326|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
218903327|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
218903328|NCT05148234|DRUG|BMS-986253|Intravenous (IV) infusion, 200 mg/Vial (20 mg/mL) or 1000 mg/vial (100mg/mL). Abbreviated Title: Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) in Myelodysplastic Syndromes 34 Version Date: 9/08/2021 outlined in Food and Drug Administration (FDA) product label.
218903329|NCT05148234|PROCEDURE|Bone Marrow Biopsy|"Bone marrow biopsy: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
218903330|NCT05148234|PROCEDURE|Bone Marrow Aspiration|"Bone marrow aspiration: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
218903331|NCT05148234|PROCEDURE|ECG|12-lead electrocardiogram (ECGs) will be performed at baseline only for safety.
218903332|NCT03061201|BIOLOGICAL|SB-525 (PF-07055480)|Single dose of investigational product SB-525 (PF-07055480)
218903333|NCT05797441|BEHAVIORAL|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
218903334|NCT05797441|OTHER|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
218903335|NCT06373458|DRUG|Ritlecitinib|Ritlecitinib 50mg QD for 36 weeks starting at Day 1
218903336|NCT06432985|BEHAVIORAL|Focus Group|In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
219038302|NCT05935241|BEHAVIORAL|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
219038303|NCT05935241|OTHER|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
219038304|NCT03452592|DRUG|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
218903337|NCT06432985|BEHAVIORAL|Contingency Management|Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
219038305|NCT05432310|COMBINATION_PRODUCT|A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme|Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
219038306|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
219038307|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
219038308|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
219038309|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
219038310|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
219038311|NCT05575141|PROCEDURE|incisional hernia repair|Incisional hernia repair for the treatment of wide ventral incisional hernias.
219038312|NCT02771496|OTHER|Other: observational only- no intervention|Other: observational only- no intervention
219038313|NCT06145971|BEHAVIORAL|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
219519826|NCT02449876|OTHER|Neuroscience Education|"The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
219612730|NCT02020278|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
219612731|NCT01486225|DEVICE|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
219612732|NCT01486225|OTHER|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
219612733|NCT00920491|BIOLOGICAL|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
219038314|NCT02979145|OTHER|No intervention involved|
218903338|NCT06432985|BEHAVIORAL|Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
218903339|NCT06432985|BEHAVIORAL|TUD Treatment as Usual (TAU)|Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
218903340|NCT03412877|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
219364857|NCT06909435|OTHER|PEEK dental bar|"the master stone cast is scanned with external desktop scanner to produce an STL (Standard Tesellation Language) file for a virtual model using the CAD/CAM software (Medit 500i.). The design of the multiunit abutment and bar (Rhein Bar )was selected from the library of the CAD software. The bar dimensions were selected according to the study bar design .~After the data acquisition, the STL file was imported to the CAM part of the CAD/CAM system to mill PEEK bar from biological high-performance polymer (Bio-HPP) (BreCAM. BioHPP, Bredent GmbH \& Co.KG, Senden, Germany) block PEEK type. Multi-unit abutments were screwed to the implants and the PEEK bar was screwed to the abutments ."
219612734|NCT00546663|DRUG|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
219612735|NCT04880486|OTHER|Education|Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
219612736|NCT04880486|OTHER|Supervision upper limb weight training exercise with VR|Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
219612737|NCT01526057|BIOLOGICAL|PF-05280586|1000 mg, IV on days 1 and 15
219612738|NCT01526057|BIOLOGICAL|MabThera|1000 mg, IV on days 1 and 15
219612739|NCT01526057|BIOLOGICAL|Rituxan|1000 mg, IV on days 1 and 15
219612740|NCT06401135|OTHER|Inspiratory muscle training|IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
219612741|NCT06207721|DRUG|Polyethylene Glycols|Polyethylene Glycols syrup (0.7 g/kg daily)
219612742|NCT06207721|OTHER|Physical therapy program|The physical therapy program includes exercises and massage
219612743|NCT02108184|DRUG|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
219612744|NCT02108184|DRUG|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
219612745|NCT02108184|DRUG|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
218903341|NCT03412877|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
218903342|NCT03412877|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
219612746|NCT02108184|DRUG|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
219612747|NCT00584324|COMBINATION_PRODUCT|BIS 40|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
218903343|NCT03412877|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
218903344|NCT03412877|DRUG|Pembrolizumab (KEYTRUDA(R))|Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
218903345|NCT05698316|DIAGNOSTIC_TEST|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
218903346|NCT03062358|BIOLOGICAL|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
218903347|NCT03062358|DRUG|placebo|Normal saline solution administered as an IV infusion Q3W
218903348|NCT03062358|OTHER|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
218903349|NCT04628663|DRUG|Dexmedetomidine|Administration
218903350|NCT04628663|OTHER|Normal Saline|Administration
218903351|NCT05051527|DRUG|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
219364858|NCT06909435|OTHER|Metal bar attachment|Co-Cr metal bar group, in the master cast , the multiunit abutment were attached to the implant analogues and plastic abutments were adjusted , prepared and then wax pattern coping was customized on each abutment and was connected to a preformed castable bar 2.4mm Height, (Rhein 83) The bar was placed to be away from the anterior ridge by about 2-3 mm for proper hygiene measures. The wax pattern was then sprued and casted into cobalt- chromium alloy.
218903352|NCT05358808|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
218903353|NCT05831111|BIOLOGICAL|mRNA-1195.1|Sterile liquid for injection
218903354|NCT05831111|BIOLOGICAL|mRNA-1195.2|Sterile liquid for injection
218903355|NCT05831111|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
218903356|NCT05831111|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219519827|NCT05159635|DEVICE|Active Living programme and wearable technical aids|attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
219519828|NCT05159635|DEVICE|Wearable technical aids|apply wearable technical aids for 8 weeks.
219519829|NCT03190486|OTHER|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
219519830|NCT01911195|DRUG|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
219519831|NCT01911195|OTHER|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
219519832|NCT00663221|DIETARY_SUPPLEMENT|Anthocyans, Calcium and Vitamin D|
219519833|NCT00663221|DIETARY_SUPPLEMENT|placebo|
219519834|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
219519835|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
219519836|NCT05312125|PROCEDURE|backward downhill walking|Children in the intervention group will take backward downhill walking program plus to routine physiotherapy.
219519837|NCT05312125|PROCEDURE|routine physiotherapy|Children in one of the groups will take routine physiotherapy programme
219612748|NCT00584324|COMBINATION_PRODUCT|BIS 60|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
219612749|NCT03660995|BEHAVIORAL|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
219612750|NCT04386850|DRUG|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
219612751|NCT00571324|DRUG|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
218903357|NCT05831111|BIOLOGICAL|mRNA-1195|Sterile liquid for injection
218903358|NCT03861273|BIOLOGICAL|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
218903359|NCT05012410|BEHAVIORAL|Immediate treatment group with High-Intensity Prompts|Caregivers in the immediate treatment group with high-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive telephone and email prompts to use the tool.
218903360|NCT05012410|BEHAVIORAL|Immediate treatment group with Low-Intensity Prompts|Caregivers in the immediate treatment group with low-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive email prompts to use the tool.
219364859|NCT06912217|DEVICE|robotic rehabilitation|It is planned to provide a robotic rehabilitation program for patients in the robotic group, in addition to conventional rehabilitation for 4 weeks, with 30 minutes, 3 days a week, focusing only on their dominant upper extremities.
219519838|NCT03673059|DRUG|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
219612752|NCT00571324|OTHER|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
219612753|NCT01719614|DRUG|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
218903361|NCT05012410|BEHAVIORAL|Waitlist Control after three months with High-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive telephone and email prompts. Once the caregiver receives the WeCareAdvisor tool, they will receive a weekly automated email as well as a weekly telephone call from study staff to prompt them to use the tool.
219612754|NCT01719614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
219612755|NCT03328975|DRUG|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
219612756|NCT03328975|OTHER|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
219612757|NCT06632821|OTHER|No intervention will be used.|University students' health literacy, physical activity, back pain and posture habits will be evaluated.
218903362|NCT05012410|BEHAVIORAL|Waitlist Control after three months with Low-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive email prompts.
218903363|NCT06304168|OTHER|Non-Interventional Study|Non-interventional study
218903364|NCT00001987|DEVICE|HR-pQCT scan|HR-pQCT is a non-invasive, low-dose three-dimensional imaging method used to evaluate volumetric bone mineral density and bone microarchitecture of peripheral skeletal sites, including distal radius and distal tibia. HR-pQCT has an ability to differentiate between cortical and trabecular bone compartments providing density and structure parameters.
218903365|NCT06827795|DEVICE|A burr used in spine surgery|A burr used in spine surgery
218903366|NCT04038138|DIAGNOSTIC_TEST|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
218903367|NCT06528769|DRUG|all-trans retinoic acid|Given orally
218903368|NCT06528769|DRUG|Cemiplimab|Given intravenously (IV)
219038315|NCT06304090|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
218903369|NCT06528769|PROCEDURE|Computed Tomography|Undergo CT
219038316|NCT06304090|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219038317|NCT06304090|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219038318|NCT03504696|OTHER|Non-interventional|Non-interventional
219038319|NCT00149747|BEHAVIORAL|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
219519839|NCT03673059|OTHER|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
219519840|NCT03392571|DRUG|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
219519841|NCT05487833|BIOLOGICAL|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
219038320|NCT00149747|BEHAVIORAL|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
219038321|NCT00217360|BEHAVIORAL|a customised multifactorial falls prevention program|
219519842|NCT05487833|OTHER|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
219519843|NCT04437693|DRUG|Hydroxychloroquine|The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
219519844|NCT03144687|DRUG|Itacitinib|Itacitinib self-administered orally once daily .
219612758|NCT05080153|DIETARY_SUPPLEMENT|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
219612759|NCT01555697|DRUG|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
218903370|NCT06528769|PROCEDURE|Magnetic resonance imaging|Undergo MRI
218903371|NCT06528769|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218903372|NCT06284317|DRUG|Adjuvant durvalumab|Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
218903373|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
219519845|NCT03144687|DRUG|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
219519846|NCT01395953|DRUG|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
219519847|NCT01395953|DRUG|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
219519848|NCT00743197|DRUG|Aspirin|Aspirin 81 mg daily
219519849|NCT00743197|DRUG|Lisinopril|Lisinopril 10 mg every night
219519850|NCT00743197|DRUG|Simvastatin|Simvastatin 20 mg every night
219612760|NCT01555697|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
219612761|NCT05727098|DRUG|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
219612762|NCT05727098|DRUG|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
219612763|NCT05727098|DRUG|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
219612764|NCT05939765|DRUG|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
218903374|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
218903375|NCT05353530|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
218903376|NCT05357443|PROCEDURE|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
218903377|NCT05357443|PROCEDURE|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
218903378|NCT05889117|DEVICE|Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)|3-10 minute sessions of brain stimulation applied to the left dorsolateral prefrontal cortex, up to 10 sessions a day, 30 sessions in total, planned within 2 weeks.
218903379|NCT06227091|DIETARY_SUPPLEMENT|Beetroot juice|acute dose of beetroot juice
218903380|NCT06227091|DIETARY_SUPPLEMENT|Placebo|depleted nitrate beetroot juice
218903381|NCT02873533|OTHER|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
218903382|NCT04216472|DRUG|Alpelisib|Given PO
219038322|NCT02452151|DRUG|Infliximab-Biosimilar|
219038323|NCT02452151|DRUG|Infliximab-Innovator|
219038324|NCT05920434|OTHER|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
218903383|NCT04216472|DRUG|Nab-paclitaxel|Given IV
218903384|NCT06576856|OTHER|This is an observational study, no intervention is anticipated.|There is no intervention. This is an observational study.
219519851|NCT00743197|DRUG|Lovaza|Lovaza 1 gram daily
219519852|NCT00743197|BEHAVIORAL|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
219519853|NCT01564433|PROCEDURE|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
219519854|NCT01564433|PROCEDURE|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
219612765|NCT02587091|BEHAVIORAL|Portable obstetric ultrasound|This intervention was advertised at the cluster level
219612766|NCT06552182|DRUG|HUC2-344|per oral
219612767|NCT06552182|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
219612768|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
219612769|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
219612770|NCT03198676|DRUG|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
218903385|NCT05311956|DEVICE|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
218903386|NCT05311956|DEVICE|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
219038325|NCT05157932|BEHAVIORAL|Talk test prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
219038326|NCT05157932|BEHAVIORAL|CPET prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
219038327|NCT01667640|RADIATION|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
219038328|NCT01667640|RADIATION|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
219038329|NCT04130243|OTHER|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
219038330|NCT00736801|DRUG|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
219038331|NCT02205593|BEHAVIORAL|Control|Regular follow-up and treatment WITHOUT behavioural intervention
219038332|NCT00111969|DEVICE|Celacade™ system|
219038333|NCT05625035|DRUG|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
219038334|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
219364860|NCT06912217|DEVICE|Functional Electrical Stimulation|In the FES group, an upper extremity FES bicycle program (ADI) will be applied to the dominant upper extremity and hand, three days a week for 4 weeks.
219612771|NCT03198676|DRUG|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
218903387|NCT06307054|DRUG|anti-CLL-1 CAR NK cells|Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
218903388|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
219038335|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
219612772|NCT01331993|DRUG|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
219612773|NCT01331993|DRUG|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
219612774|NCT01331993|DRUG|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
219612775|NCT02012426|BEHAVIORAL|Weight management program|
219612776|NCT01232933|DEVICE|VPS System|Use of the navigational VPS system during catheter placement
219612777|NCT06997900|DRUG|Combination therapy : Follitropin delta and HP-hMG|Follitropin delta dose will be determined by age. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight.
219038336|NCT03458130|DRUG|AG10|TTR stabilizer
219038337|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
219038338|NCT00122343|DRUG|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
219038339|NCT05193474|BEHAVIORAL|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
219038340|NCT00706836|DRUG|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
219038341|NCT00706836|DRUG|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
219038342|NCT00706836|DRUG|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
219364861|NCT06912217|OTHER|occupational therapy|In the occupational therapy group, patients will receive the planned treatment in addition to conventional rehabilitation for 4 weeks, three days a week, for 30 minutes.
219364862|NCT00874211|PROCEDURE|assessment of therapy complications|By dental and medical assessments.
219364863|NCT02514512|DEVICE|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
219364864|NCT03883516|OTHER|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
219364865|NCT03883516|OTHER|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
219612778|NCT07005921|BEHAVIORAL|qEEG-neurofeedback|The participants will be submitted to a qEEG-neurofeedback intervention in order to verifify its feasibility to enhance cognition. The theta/beta ratio reduction protocol at electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4 will be performed, with 10 sessions of qEEG-neurofeedback training, 2 sessions for pre and post test, and 1 session for follow-up after 30 days of intervention. Each session will last approximately 1 hour. The Psychological Battery of Attention 2 (BPA-2) and Digit Span Test will be employed to measure attention and working memory levels. The Montreal Cognitive Assessment (Moca) will be used for neurological and cognitive assessment. Participants will receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
218903389|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
218903390|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
218903391|NCT02960022|DRUG|Leuprolide acetate|Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily
218903392|NCT06192576|DRUG|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
219038343|NCT06378086|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
219038344|NCT06378086|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
219038345|NCT04974671|RADIATION|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
219038346|NCT01094691|PROCEDURE|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
219038347|NCT03432806|OTHER|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
219519855|NCT03970772|DRUG|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
219519856|NCT03970772|OTHER|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
219519857|NCT01966081|OTHER|Blood sample|
219519858|NCT01966081|OTHER|tissue samples from abdominal subcutaneous adipose|
219519859|NCT00475020|DRUG|Busulfan|Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days
219519860|NCT00475020|DRUG|Fludarabine|40 mg/m\^2 by vein daily over 1 hour x 4 days
219519861|NCT00475020|DRUG|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
219519862|NCT03218592|DRUG|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
219519863|NCT03218592|DRUG|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
219519864|NCT03218592|DRUG|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
219519865|NCT02514174|DRUG|Afatinib|afatinib starting at 30 mg daily dose
219612779|NCT07005921|BEHAVIORAL|SHAM qEEG-neurofeedback|The participant will be submitted to an inactive qEEG-neurofeedback that appears to be the same as a functional procedure or device. Participants will not receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
219519866|NCT01255371|DRUG|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
219519867|NCT01255371|DRUG|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
219519868|NCT01627366|OTHER|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
219612780|NCT03578302|DEVICE|BI Anterior Segment Mode|Single eye measurement in Anterior Segment Mode
218903393|NCT04927416|DRUG|68-Gallium-DOTATATE-PET/CT|68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.
218903394|NCT01116648|PROCEDURE|Biopsy Procedure|Undergo optional tissue biopsy
218903395|NCT01116648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218903396|NCT01116648|DRUG|Cediranib Maleate|Given PO
218903397|NCT01116648|PROCEDURE|Computed Tomography|Undergo CT
218903398|NCT01116648|PROCEDURE|Echocardiography Test|Undergo ECHO
218903399|NCT01116648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219519869|NCT01669109|BEHAVIORAL|Hatha yoga|
219519870|NCT01649622|DRUG|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
218903400|NCT01116648|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218903401|NCT01116648|DRUG|Olaparib|Given PO
218903402|NCT01172314|DIETARY_SUPPLEMENT|EAA+LEU vs total AA|15 g as a bolus
218903403|NCT01172314|DIETARY_SUPPLEMENT|Total AA vs EAA+LEU|15 g as a bolus
218903404|NCT04133506|DRUG|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
218903405|NCT04539938|DRUG|tucatinib|300 mg orally twice daily
218903406|NCT04539938|DRUG|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
218903407|NCT06312579|BEHAVIORAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
218903408|NCT06312579|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
218903409|NCT00285909|BEHAVIORAL|Alcohol: 25 gday (white wine)|
219038348|NCT03432806|PROCEDURE|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
219038349|NCT03432806|DIAGNOSTIC_TEST|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
219038350|NCT02669368|DRUG|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
219364866|NCT03883516|OTHER|No Pre-briefing|no instruction of the study participants prior to the simulation training
219519871|NCT06073249|OTHER|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
219519872|NCT06073249|OTHER|Tibial Nerve Stimulation|The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
219519873|NCT05654909|PROCEDURE|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
219519874|NCT02130466|BIOLOGICAL|Pembrolizumab|IV infusion
219519875|NCT02130466|DRUG|Dabrafenib|oral capsule
219519876|NCT02130466|DRUG|Trametinib|oral tablet
219612781|NCT03578302|DEVICE|BI Anterior Segment and IOL Biometry Mode|Eye measurement 3 times with and without dilation in IOL biometry and Anterior Segment mode
219519877|NCT02130466|DRUG|Placebo|IV infusion
219038351|NCT02669368|DRUG|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
219038352|NCT02669368|DRUG|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
219038353|NCT02669368|DRUG|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
219364867|NCT06912074|DRUG|Induction chemoimmunotherapy|All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.
219519878|NCT01963364|DIETARY_SUPPLEMENT|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
219519879|NCT01963364|DIETARY_SUPPLEMENT|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
219519880|NCT02924480|PROCEDURE|Cystectomy|
219519881|NCT02924480|DRUG|Lidocaine|Patients will receive lidocaine infusion during surgery
219519882|NCT02924480|DRUG|Saline|Patients will receive saline infusion during surgery
219612782|NCT06668987|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
219612783|NCT07005765|BEHAVIORAL|Video-Based Stabilization Exercise Program|Participants will follow a 6-week home exercise program focusing on stabilization exercises. The instructions and demonstrations will be delivered through video format, which participants can watch at their convenience. The program aims to improve pain, functionality, exercise adherence, kinesiophobia, and quality of life.
218903410|NCT06604130|DIAGNOSTIC_TEST|Prostate cancer screening decision|The subjects would receive serum PSA test.
218903411|NCT06868511|PROCEDURE|Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase|Neuronavigation-assisted stereotactic minimally invasive puncture will enhances catheter placement precision, reducing complications and improving hematoma evacuation and neurological outcomes. TNK, a third-generation thrombolytic will offers advantages over alteplase (rt-PA), including a longer half-life for rapid bolus administration and effective thrombolytic effects to dissolve clots and promote hematoma clearance.
218903412|NCT06868511|DRUG|Standard medical treatment|The standard medical treatment for this group of patients will be provided according to the optimal care standards defined by the American Heart Association (AHA) guidelines for intracerebral hemorrhage management
218903413|NCT05937399|BEHAVIORAL|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
218903414|NCT05937399|BEHAVIORAL|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
218903415|NCT06703567|BEHAVIORAL|Standard Policy|Patients will receive information about the GEP test by clinical teams
218903416|NCT06703567|BEHAVIORAL|Standard Policy + GEP Information Film|Patients will receive information about the GEP test by clinical teams and, after consultation with physician, they will be sent a link to view the film regarding OncotypeDX
218903417|NCT06726382|DRUG|Esketamine Nasal Spray|1 x 28 mg dose
218903418|NCT06726382|DRUG|Esketamine 28 mg|1 x 5,6 ml p.o.
218903419|NCT06726382|DRUG|Cobicistat 150 MG|1 x 150 mg tablet
218903420|NCT06725875|OTHER|White Noise Group|During the procedure, a mobile white noise (WN) application called Noise: White, Pink, Brown will be played via over-the-ear headphones to provide the individual with a sense of comfort. The intensity of the white noise will be determined using sound samples for patient comfort. The mobile WN application will be played to the patient by selecting white from among the color options. The sound level will be adjusted below 50 dB using a measuring device to prevent possible hearing damage (12). At the end of the procedure, the listening process will be terminated and the headphones will be removed. At the end of the procedure, the outer and inner surfaces of the headphones will be cleaned with disposable disinfectant wipes to prevent decontamination when used by another patient.
218903421|NCT06725875|OTHER|Earplug group|2\. Earplug group: An earplug that prevents patients from hearing outside sounds will be used during the procedure. Features: Smooth, dirt-resistant surface provides better hygiene. Earplugs are easy to roll for quick and easy insertion. Conical design fits comfortably in ear canals. Soft polyurethane foam is hypoallergenic. Similar earplugs were used in a previous study
218903422|NCT03288571|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
219612784|NCT07005765|BEHAVIORAL|Brochure-Based Stabilization Exercise Program|Participants will follow the same 6-week home exercise program using illustrated printed brochures that provide step-by-step instructions for stabilization exercises. This format allows participants to perform exercises independently. The program's effects on pain, functionality, exercise adherence, kinesiophobia, and quality of life will be evaluated.
218903423|NCT01810770|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
218903424|NCT06705634|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the multifidus of the C5-C6 cervical muscles. Once the needle has been inserted, the needle will be pistoned in an up and down motion within the multifidus muscle at approximately 1Hz for 10 seconds and then left in-situ for 5 minutes.
218903425|NCT06922331|DRUG|Upadacitinib|A selective Janus kinase (JAK) 1 inhibitor used for the treatment of refractory inflammatory bowel disease.
218903426|NCT06932861|BIOLOGICAL|mRNA Tumor Vaccine Therapy|personalized mRNA vaccines
218903427|NCT06938165|OTHER|Fecal Microbiota Transplant (FMT)|FMT in patients with refractory GVHD
218903428|NCT06937450|DEVICE|CLR Irrigator|All enrolled patients will have their hemothorax treated with a CLR device that allows for easy suction and irrigation through indwelling catheters,
218903429|NCT06937450|PROCEDURE|Serial Lavage and Drainage|The current protocol is to do a singular lavage and drainage, this study will investigate the benefits of daily lavage.
218903430|NCT06937450|DEVICE|28 Fr Open Chest Tube|Patients will have a standard 28 Fr open chest tube or a percutaneous 14Fr chest tube placed.
218903431|NCT06937450|DEVICE|Percutaneous 14Fr Chest Tube|Patients will have a standard 28 Fr open chest tube, or a percutaneous 14Fr chest tube placed.
218903432|NCT06938126|DIETARY_SUPPLEMENT|L-Arginine and Citrulline-Malate Supplementation|L-Arginine and Citrulline Malate supplementation was consumed as a liquid one single time to examine the acute effects on sport performance
218903433|NCT06938126|DIETARY_SUPPLEMENT|Placebo consumption|Consumption of placebo as a liquid
218903434|NCT06938490|PROCEDURE|Anterior rectal resection with D3-lymphatic dissection|"This study aims to determine the incidence of anastomosis failure in the group with first SA and LCA preservation in order to identify the feasibility of manipulation.~The study is unique in that there is only one study in the world that evaluates the incidence of anastomosis failure with preservation of the first sigmoid and there is no study comparing the groups described in this study."
219612785|NCT05024773|DRUG|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
218903435|NCT06937411|DRUG|LY4100511|Administered orally
218903436|NCT06938256|OTHER|Suboccipital Muscle Inhibition|With the patient in the supine position and the eyes closed, the therapist sits behind the subject's head and place the palms of his/her hands beneath it, resting the pads of his/her fingers on the projection of the posterior arch of the atlas. Pressure is exerted upward and toward the therapist. The pressure is maintained for 2 minutes until tissue relaxation had been achieved. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
218903437|NCT06938256|OTHER|Rocabado 6x6 Exercises|"Rocabado created 6X6 program for the management of CGH which includes 6 fundamental components, one session under supervision and remaining five sessions by the subject at home.~These components are:~* Rest position of the tongue~* Control of TMJ rotation~* Rhythmic stabilization technique~* Stabilized head flexion~* Axial extension of the neck~* Shoulder posture"
219038354|NCT04231786|PROCEDURE|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
219038355|NCT02474095|OTHER|Quality-of-Life Assessment|Ancillary studies
219038356|NCT02474095|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
219038357|NCT04209179|DRUG|PCO371|PCO371 capsule
219038358|NCT04209179|DRUG|Placebo|Placebo capsule
219038359|NCT06528392|BIOLOGICAL|Efgartigimod|Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
219038360|NCT00195247|DRUG|TTI-237|
219038361|NCT06300333|DRUG|Methotrexate|use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
218903438|NCT01800591|BEHAVIORAL|Financial incentive|
218903439|NCT05692544|PROCEDURE|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
218903440|NCT01332383|DRUG|Naratriptan|
218903441|NCT01456065|BIOLOGICAL|Procure|The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
218903442|NCT01456065|BIOLOGICAL|Procure|The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
218903443|NCT02843841|OTHER|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
218903444|NCT02459444|DEVICE|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
218903445|NCT02459444|OTHER|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
218903446|NCT04561440|DIAGNOSTIC_TEST|molecular karyotyping|performed by NGS or CMA chip
218903447|NCT01928927|DRUG|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
219038362|NCT01820754|DRUG|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
219038363|NCT01820754|DRUG|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
219038364|NCT01589081|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
218903448|NCT06284083|DIAGNOSTIC_TEST|taking a blood sample|Blood samples collected from patienst, only 7 mL
218903449|NCT03369977|DEVICE|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
218903450|NCT03369977|OTHER|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
219038365|NCT01589081|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
218903451|NCT01756196|DRUG|Spinal Steroid Injection|Steroid Injection
218903452|NCT02557737|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
218903453|NCT03043885|DEVICE|FDBA|Graft material used to graft extraction socket
218903454|NCT03043885|DEVICE|PRF|Autologous blood product used to graft extraction socket
218903455|NCT03043885|PROCEDURE|Blood Clot|Surgical treatment of extraction socket without addition of graft material
219038366|NCT01262482|DRUG|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
219038367|NCT01262482|DRUG|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
219038368|NCT01391065|RADIATION|MR PET Guided Brachytherapy|
219519883|NCT05612438|DEVICE|RADIX 2 Stent|RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis \> 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.
219519884|NCT05155800|DEVICE|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
218903456|NCT01063647|DRUG|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
218903457|NCT01063647|DRUG|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
218903458|NCT01063647|DRUG|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
218903459|NCT04291573|DEVICE|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
218903460|NCT04291573|DEVICE|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
218903461|NCT04810052|BEHAVIORAL|Behavioral Intervention|Perform 1 nice thing
218903462|NCT04810052|BEHAVIORAL|Behavioral Intervention|Write a letter or note of gratitude
218903463|NCT04810052|BEHAVIORAL|Behavioral Intervention|Track daily activities
218903464|NCT04810052|OTHER|Interview|Ancillary studies
218903465|NCT04810052|OTHER|Quality-of-Life Assessment|Ancillary studies
218903466|NCT04810052|OTHER|Questionnaire Administration|Ancillary studies
218903467|NCT06176365|DRUG|Survodutide|once weekly subcutaneous injection
218903468|NCT06176365|DRUG|Placebo matching survodutide|once weekly subcutaneous injection
218903469|NCT04446468|BEHAVIORAL|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
218903470|NCT04446468|OTHER|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
218903471|NCT04986670|BEHAVIORAL|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
218903472|NCT04986670|OTHER|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
218903473|NCT04986670|BEHAVIORAL|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
218903474|NCT04986670|OTHER|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
218903475|NCT04986670|BEHAVIORAL|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
218903476|NCT04986670|BEHAVIORAL|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
218903477|NCT06007846|DRUG|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
218903478|NCT02082418|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
218903479|NCT02082418|DIETARY_SUPPLEMENT|Whey|commercially available whey protein
218903480|NCT02082418|DIETARY_SUPPLEMENT|Casein|commercially available casein protein
218903481|NCT05691517|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218903482|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218903483|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
218903484|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
218903485|NCT06501586|DRUG|SGB-3908|SGB-3908 for sc injection
218903486|NCT06501586|OTHER|SGB-3908-Matching placebo|Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
218903487|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
219038369|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
219038370|NCT05387317|BIOLOGICAL|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
219038371|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
219038372|NCT05387317|BIOLOGICAL|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
219038373|NCT05387317|BIOLOGICAL|Moderna Standard dose|Standard dose (50ug in 0.25ml)
218903488|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
218903489|NCT02079740|PROCEDURE|Biopsy Procedure|Undergo biopsy
218903490|NCT02079740|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218903491|NCT02079740|PROCEDURE|Computed Tomography|Undergo conventional CT or PET/CT
218903492|NCT02079740|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218903493|NCT02079740|BIOLOGICAL|Navitoclax|Given PO
218903494|NCT02079740|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218903495|NCT02079740|DRUG|Trametinib|Given PO
218903496|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
218903497|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
218903498|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
218903499|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
218903500|NCT01734473|DIETARY_SUPPLEMENT|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
218903501|NCT03723551|DRUG|Afabicin|Administered intravenously and orally.
218903502|NCT03723551|DRUG|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
218903503|NCT04939051|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219038374|NCT05387317|BIOLOGICAL|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
219038375|NCT04344873|OTHER|Placebo|Placebo injection at day one and day fourteen.
218903504|NCT04939051|PROCEDURE|Esophageal Biopsy|Undergo esophageal biopsy, brushings and gastric aspirate
219038376|NCT04344873|DRUG|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
219038377|NCT00765310|DIETARY_SUPPLEMENT|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
219038378|NCT00765310|DIETARY_SUPPLEMENT|Placebo|two capsules once daily in morning on empty stomach
219519885|NCT00458900|DRUG|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
218903505|NCT04939051|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
218903506|NCT04939051|PROCEDURE|Liver Ultrasonographic Elastography|Undergo liver ultrasound with elastography
218903507|NCT04939051|BIOLOGICAL|Obeticholic Acid|Given PO
218903508|NCT04939051|DRUG|Placebo Administration|Given PO
218903509|NCT04939051|OTHER|Questionnaire Administration|Ancillary study
218903510|NCT03493945|BIOLOGICAL|M7824|1,200 mg intravenous (IV) once every 2 weeks.
218903511|NCT03493945|DRUG|N-803|8-15 mcg/kg subcutaneous every 2 weeks.
218903512|NCT03493945|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
218903513|NCT03493945|BIOLOGICAL|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of modified vaccinia Ankara (MVA)-Bavarian Nordic (BN)-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 months.
218903514|NCT03493945|DRUG|Epacadostat|600 mg orally twice daily (1200 MG total).
218903515|NCT03493945|DRUG|Acetaminophen|Antipyretic medication, orally, prior to infusion, up to 650mg.
218903516|NCT03493945|DRUG|Ibuprofen|Antipyretic medication, orally, prior to infusion, up to 600mg.
218903517|NCT03493945|DRUG|Naproxen|Antipyretic medication, orally, prior to infusion, up to 500mg.
218903518|NCT03493945|OTHER|Benadryl|50mg orally prior to infusion.
218903519|NCT03493945|DIAGNOSTIC_TEST|EKG|Baseline and principal investigator discretion.
218903520|NCT03493945|DIAGNOSTIC_TEST|Bone scan|Restaging every 12 weeks.
218903521|NCT03493945|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Every 12 weeks after start of therapy.
218903522|NCT03493945|DIAGNOSTIC_TEST|MRI|If clinically indicated.
219038379|NCT06049043|OTHER|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
219038380|NCT06049043|OTHER|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
219038381|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
219038382|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
219038383|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
219038384|NCT03217747|DRUG|Avelumab|Given IV
219038385|NCT03217747|BIOLOGICAL|Ivuxolimab|Given IV
219038386|NCT03217747|RADIATION|Radiation Therapy|Undergo radiation therapy
219038387|NCT03217747|BIOLOGICAL|Utomilumab|Given IV
219612786|NCT00324220|DRUG|MGCD0103|MGCD0103 Oral administration 3 times per week.
218903523|NCT03477942|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10\^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
218903524|NCT05152823|BIOLOGICAL|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
218903525|NCT06785272|DRUG|magnesium sulfate|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
218903526|NCT06785272|DRUG|Normal Saline|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
218903527|NCT06335303|DRUG|BI 1819479|BI 1819479
218903528|NCT06335303|DRUG|Placebo matching BI 1819479|Placebo matching BI 1819479
218903529|NCT06528093|DRUG|BI 765883|BI 765883
218903530|NCT06528093|DRUG|gemcitabine|gemcitabine
218903531|NCT06528093|DRUG|nab-paclitaxel|nab-paclitaxel
219519886|NCT05337709|OTHER|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
219519887|NCT03287700|OTHER|No intervention|No intervention will be administered to any group in this observational study.
219612787|NCT05248347|DEVICE|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
219612788|NCT05248347|DEVICE|The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
219612789|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
219612790|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
219612791|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
219612792|NCT02297997|DRUG|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
219612793|NCT02297997|DRUG|Placebo|Control group takes the placebo for the same period.
218903532|NCT04889846|PROCEDURE|SAFE early intervention approach|SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
219612794|NCT01652547|DRUG|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
218903533|NCT03415321|DEVICE|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
218903534|NCT01589796|PROCEDURE|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
218903535|NCT01722305|DRUG|Dexamethasone|Given PO
218903536|NCT01722305|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218903537|NCT01722305|OTHER|Pharmacological Study|Optional correlative studies
218903538|NCT01722305|DRUG|Pomalidomide|Given PO
218903539|NCT04175249|OTHER|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
218903540|NCT00005984|DRUG|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
218903541|NCT00005984|DRUG|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
219038388|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
219038389|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
219038390|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
219038391|NCT06247514|BEHAVIORAL|The BEET Diabetes Program|The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
219038392|NCT06247514|BEHAVIORAL|Cognitive Behavioral Therapy Guided Self-Help|"6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert."
219038393|NCT06029699|DEVICE|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
219038394|NCT06029699|DEVICE|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
219038395|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
219038396|NCT00233051|DRUG|Salmeterol or Salmeterol/Fluticasone|
219038397|NCT04685564|DRUG|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
219038398|NCT04685564|DRUG|Placebo|the same as RBD1016
219038399|NCT05907850|DRUG|Riboflavin|Commercially available source of riboflavin capsules
219038400|NCT05907850|DRUG|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
219038401|NCT01425879|DRUG|Akt Inhibitor MK2206|Given PO
219038402|NCT01425879|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219038403|NCT01425879|OTHER|Pharmacological Study|Correlative studies
219038404|NCT06086080|OTHER|Standard care|Bracing and physical therapy
219038405|NCT06086080|OTHER|Taping|The patient is treated with tape in special configuration (McConell modified) for the patella + standard care
219038406|NCT06086080|DEVICE|Sham taping|Taping with no treatment disposition
219519888|NCT03307239|OTHER|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
219612795|NCT01652547|DRUG|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
219612796|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
219038407|NCT02361255|OTHER|no intervention|
219038408|NCT04352751|OTHER|convalescent plasma|"* Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks"
219038409|NCT02679859|OTHER|BNP guided medical therapy optimisation|
219038410|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
219038411|NCT01354496|DRUG|LY2409021 Reference Form|Administered orally
219038412|NCT01354496|DRUG|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
219038413|NCT01354496|DRUG|LY2409021 Test-High Formulation (high particle size)|Administered orally
219038414|NCT01354496|DRUG|LY2409021 Test-Low Formulation (low particle size)|Administered orally
219038415|NCT06446947|OTHER|blood sampling|Blood sampling (6ml) on admission and a second on discharge from intensive care.
219038416|NCT03327610|OTHER|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
219519889|NCT03307239|OTHER|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
219519890|NCT02419352|DRUG|Sugammadex|
219519891|NCT02419352|DRUG|Neostigmine/atropine|
218903542|NCT00005984|DRUG|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
218903543|NCT00005984|PROCEDURE|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
218903544|NCT00005984|PROCEDURE|radiation therapy|total body irradiation twice a day on days -4 through -1
219038417|NCT03327610|OTHER|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
219038418|NCT03327610|OTHER|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
219038419|NCT03327610|OTHER|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
218903545|NCT05821985|PROCEDURE|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
218903546|NCT05821985|PROCEDURE|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
218903547|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
219038420|NCT03327610|OTHER|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
219038421|NCT03327610|OTHER|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
219038422|NCT01814735|OTHER|Brown rice|
219038423|NCT01814735|OTHER|White rice|
218903548|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.6cm circles, attached to a digitimer.
219038424|NCT01100411|DEVICE|Air Optix Aqua|Contact lens material: Lotrafilcon A
219038425|NCT01100411|DEVICE|Biofinity|Contact lens material: Comfilcon A
219038426|NCT01100411|DEVICE|Proclear|Contact lens material: Omafilcon A
219038427|NCT01100411|DEVICE|Acuvue Oasys|Contact lens material: Senofilcon A
219038428|NCT01100411|DEVICE|Acuvue 2|Contact lens material: Etafilcon A
219038429|NCT01100411|DEVICE|Purevision|Contact lens material: Balafilcon A
219038430|NCT02386696|OTHER|Ultrasound|Lung ultrasound examination on healthy volunteers
219038431|NCT03042858|OTHER|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
219612797|NCT07005414|DRUG|Bumetanide|Participants will receive bumetanide (0.5mg bid) for a period of three months.
219612798|NCT07005414|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
219612799|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
219038432|NCT03042858|OTHER|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
219038433|NCT05568472|OTHER|Best Practice|Standard of care hormone therapy and standard visit with clinician
219612800|NCT07006077|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
219038434|NCT05568472|PROCEDURE|Biospecimen Collection|Undergo correlative studies
219038435|NCT05568472|PROCEDURE|Endocrine Drug Therapy|Undergo endocrine therapy
219038436|NCT05568472|BEHAVIORAL|Health Education|Receive list of websites
219038437|NCT05568472|OTHER|Questionnaire Administration|Ancillary studies
219038438|NCT05568472|OTHER|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
219038439|NCT04307212|OTHER|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
219038440|NCT04307212|OTHER|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
219612801|NCT06866288|BEHAVIORAL|Meditation|Each person will participate in seated meditation, then walking meditation, then return to seated meditation.
219612802|NCT06866288|BEHAVIORAL|Yoga|Each person will participate in a yoga sessions.
219038441|NCT04307212|OTHER|Control no exercise|Trained and untrained participants will have a no exercise control day
219038442|NCT03628612|BIOLOGICAL|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
219038443|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
219038444|NCT05079204|OTHER|No intervention|No intervention
219038445|NCT03518385|DIAGNOSTIC_TEST|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
219038446|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
219038447|NCT01228747|DRUG|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
219038448|NCT01228747|DRUG|Placebo|Matching oral placebo tablets twice daily for 28 weeks
219519892|NCT05320263|PROCEDURE|Contact aspiration Thrombectomy|"The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature."
219519893|NCT05320263|PROCEDURE|Stent retriever thrombectomy|The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
219519894|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 1|TEST
219519895|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 2|CONTROL
219612803|NCT04813276|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
219612804|NCT04813276|BEHAVIORAL|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
219612805|NCT07012967|OTHER|Kinesiology Taping|"For thoracic kinesiology taping (KT), a 5 cm wide, 100% cotton, latex-free elastic tape will be used. Application sites will follow the technique and principles described by Kase. Participants will sit upright in an armless chair with knees at 90° flexion, feet flat on the floor, and arms relaxed.~The tape will be applied to the front and back of the body to facilitate respiratory muscles, primarily the diaphragm. On the anterior side, an I-shaped strip will be applied with 50-75% tension at the xiphoid process along the linea alba, and the tails will be laid over the subcostal area without tension. Posteriorly, another I-shaped strip will be applied from the projection of the 12th thoracic vertebra with 50-75% tension, and the ends placed toward the ribs without tension. Additionally, two more strips will be applied to the upper trapezius region between the neck and acromion bilaterally."
219038449|NCT05567289|PROCEDURE|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
219038450|NCT05567289|PROCEDURE|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
219038451|NCT02036502|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
219038452|NCT02036502|DRUG|Lenalidomide|Oral capsule
219038453|NCT02036502|DRUG|Dexamethasone|Oral tablet IV infusion
219038454|NCT02036502|DRUG|Carfilzomib|IV infusion
219038455|NCT06056050|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
219038456|NCT06056050|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
218903549|NCT06343831|PROCEDURE|2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)|The study participant will be requested to stand upright with hands comfortably behind their back and turn 45 degrees and 90 degrees in either direction for standard anteroposterior (AP), oblique and lateral photos. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers. The photographs will be acquired using a commercially available camera or study iPad device.
218903550|NCT06343831|PROCEDURE|3-Dimensional (3-D) Photographs (Visit 1- 6)|3-Dimensional surface scans of the participant's torso will be acquired using a commercially available handheld camera scanning device that offers texture, geometry, and color acquisition from any complex surface using white light technology, which is safe for exposure to skin and eyes. Prior to imaging, a pattern of lines and dots will be marked on the patient's breasts using a washable marker. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member moves around their torso with the handheld scanner. The exam room table will then be reclined to a lay-flat position such that the patient is laying supine, and breast imaging will be repeated. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers.
218903551|NCT06343831|PROCEDURE|Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)|The images will be acquired using a commercially available handheld ultrasound scanning device. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member obtains images of the specific area of the breast of chest wall to be grafted (V1) and that which was grafted (V4-6). Images usually take 5-10 minutes to acquire depending on the number of areas grafted.
218903552|NCT06343831|PROCEDURE|Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)|An MRI of the breast will be obtained around visit 1 and visits 4-6 timepoints. The images will be acquired in collaboration with the Breast Imaging Core and the Magnetic Resonance Research Imaging Center. Dr. Abe (co-investigator, radiology) will review the images to assess volume of the overall breast, the specific areas of the breasts that were grafted.
219038457|NCT06056050|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
219038458|NCT00546611|DRUG|PEP005|
219038459|NCT04416087|OTHER|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
219038460|NCT02074995|BIOLOGICAL|BVS857|Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
219038461|NCT02074995|OTHER|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
219038462|NCT00844363|PROCEDURE|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
219038463|NCT00500292|DRUG|Vandetanib|once daily oral tablet two dose strengths
219038464|NCT00500292|DRUG|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
219038465|NCT03551912|PROCEDURE|Surgery|All patients coming for elective surgery
219519896|NCT04523649|DEVICE|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
219519897|NCT01834053|BIOLOGICAL|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
219519898|NCT04302948|OTHER|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
219038466|NCT02741700|BEHAVIORAL|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
219038467|NCT00811577|DRUG|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
219038468|NCT00811577|DRUG|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
219038469|NCT03359642|OTHER|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219038470|NCT03359642|OTHER|stool samples|Study of the fecal microbiota
219519899|NCT05544448|OTHER|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
219519900|NCT01567956|DRUG|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
219519901|NCT01567956|DRUG|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
219519902|NCT00605748|PROCEDURE|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
219519903|NCT00605748|PROCEDURE|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
219519904|NCT00001765|DEVICE|Nexell Isolex with T-cell Depletion|
219519905|NCT00001765|DEVICE|Baxter isolex 300i|
219519906|NCT03059862|DIETARY_SUPPLEMENT|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
218903553|NCT06343831|PROCEDURE|BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)|"The BREAST-QTM measures three satisfaction domains and three quality of life (QoL) domains.6 For BREAST-QTM, each domain has a score range from 0 - 100. A difference in score, either positive or negative, of 10 points is considered clinically important; a difference of 20 points is considered clinically very important. This survey will be administered to participants via iPad during visit 1 and visits 4-6 and takes approximately 10-20 minutes to complete."
219038471|NCT03359642|OTHER|food questionnaire|food questionnaire on the seven days before the collection
219038472|NCT03359642|OTHER|colonoscopy|Only for patients with ulcerative colitis (in routine care)
219038473|NCT03359642|OTHER|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
219038474|NCT04244188|OTHER|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
219038475|NCT06496009|DRUG|PD-1 Inhibitors|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
219038476|NCT03254186|DRUG|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
219038477|NCT03254186|DRUG|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
219519907|NCT03059862|DIETARY_SUPPLEMENT|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
219519908|NCT02170688|DRUG|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
219519909|NCT02170688|OTHER|Weight calculation|
219519910|NCT02725307|DEVICE|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
219519911|NCT06345248|PROCEDURE|US-TAP|regional block team under ultrasound guidance
219519912|NCT06345248|PROCEDURE|LAPTAP|performed TAP block under direct visualization with the laparoscope
219519913|NCT01894178|DEVICE|Parker Flex-Tip® tracheal tube|
219519914|NCT01894178|DEVICE|Portex® Tracheal Tube|
219519915|NCT06344338|DEVICE|tDCS stimulation|In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation
219519916|NCT06344338|DEVICE|TDCS sham-stimulation|TDCS sham-stimulation
218903554|NCT05016882|DRUG|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
218903555|NCT05016882|DRUG|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
219038478|NCT01068509|BIOLOGICAL|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
219038479|NCT01822080|DRUG|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
219038480|NCT01822080|DRUG|Placebo|Matching placebo once daily by mouth
219519917|NCT04426799|OTHER|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
219519918|NCT06312371|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
219519919|NCT06312371|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
218903556|NCT05016882|DRUG|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
218903557|NCT05016882|DRUG|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
218903558|NCT05016882|DRUG|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
219038481|NCT01653080|PROCEDURE|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
219038482|NCT00921180|DRUG|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
219519920|NCT05481307|DRUG|RLD2202|Take it once a day per period
219519921|NCT05481307|DRUG|RLD2203|Take it once a day per period
219519922|NCT01217086|DRUG|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
219519923|NCT04029675|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
219519924|NCT02405195|PROCEDURE|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
218903559|NCT05016882|DRUG|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
219519925|NCT07027657|DEVICE|Treatment with BTL-699-2|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
219519926|NCT07027657|DEVICE|Treatment with BTL-699-2 (sham)|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.
218903560|NCT05607810|GENETIC|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
218903561|NCT04355754|DEVICE|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
218903562|NCT01419795|DRUG|lenalidomide|Given PO
218903563|NCT01419795|BIOLOGICAL|rituximab|Given IV
218903564|NCT01419795|OTHER|pharmacological study|Correlative studies
218903565|NCT01419795|OTHER|laboratory biomarker analysis|Correlative studies
218903566|NCT00367250|DRUG|Cetuximab|weekly i.v.
218903567|NCT00367250|DRUG|Trastuzumab|weekly i.v.
219612806|NCT07012967|OTHER|Diaphragmatic Breathing Exercises|Participants in the control group will receive diaphragmatic breathing exercises. Exercises will be taught and supervised by a physiotherapist. Sessions will be conducted twice weekly for four weeks, and participants will be instructed to continue home practice between sessions.
218903568|NCT01391364|DEVICE|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
218903569|NCT01391364|DEVICE|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
218903570|NCT06391099|OTHER|Best Practice|Undergo standard of care diet
218903571|NCT06391099|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
218903572|NCT06391099|PROCEDURE|Computed Tomography|Under CT
218903573|NCT06391099|OTHER|Dietary Intervention|Undergo ketogenic diet
218903574|NCT06391099|OTHER|Educational Activity|Receive coaching support
218903575|NCT06391099|OTHER|Glucose Measurement|Undergo blood glucose testing
218903576|NCT06391099|OTHER|Ketone Measurement|Undergo ketone measurement
218903577|NCT06391099|OTHER|Questionnaire Administration|Ancillary studies
218903578|NCT02421172|BIOLOGICAL|CJM112|CJM112 Fully human IgG1 monoclonal antibody
218903579|NCT02421172|DRUG|Placebo|
218903580|NCT06218914|BIOLOGICAL|NT-112: Autologous, engineered T Cells targeting KRAS G12D|NT-112 targets KRAS G12D in the context of HLA-C\*08:02
218903581|NCT06218914|BIOLOGICAL|AZD0240: Autologous, engineered T Cells targeting KRAS G12D|AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02
218903582|NCT04128137|DRUG|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
218903583|NCT04128137|OTHER|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
219038483|NCT00921180|DRUG|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
218903584|NCT06196385|DEVICE|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
218903585|NCT02426333|OTHER|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
218903586|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
218903587|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
218903588|NCT00683878|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
218903589|NCT00683878|DRUG|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
218903590|NCT06445543|BEHAVIORAL|MFeast ENHANCED|The intervention group will initially receive 10 weekly prepared heart-healthy meals from MFeast; Lactation nutritional snack bundles to boost milk supply + structural support for breastfeeding/ pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (medically tailored via study team-crafted virtual grocery store) for 16 more weeks.
218903591|NCT06445543|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive 10 weekly prepared heart-healthy meals from MFeast."
218903592|NCT02757638|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
218903593|NCT02869633|DRUG|Ibrutinib|Given by mouth
218903594|NCT02869633|OTHER|Laboratory Biomarker Analysis|Correlative studies
219038484|NCT04935411|OTHER|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
219038485|NCT03733821|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
218903595|NCT02003235|DEVICE|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
219038486|NCT05465382|DEVICE|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
219519927|NCT04962685|OTHER|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
218903596|NCT04355234|DIAGNOSTIC_TEST|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
218903597|NCT04355234|BIOLOGICAL|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
218903598|NCT00599872|BIOLOGICAL|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
218903599|NCT00599872|BIOLOGICAL|Placebo|Placebo, sublingual oral
218903600|NCT02137863|DRUG|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
218903601|NCT02137863|DRUG|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
218903602|NCT02137863|DRUG|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
218903603|NCT04319198|DRUG|Sacituzumab Govitecan-hiy|Administered intravenously
218903604|NCT04206319|DRUG|Radium-223|an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
219038487|NCT05465382|OTHER|No intra-articular saline lavage|Subjects in group 2 will not undergo normal saline lavage.
219038488|NCT05465382|DRUG|Lidocaine - intra-articular injection|Intra-articular injection of 10cc of 1% lidocaine without epinephrine via the existing anteromedial 16-gauge needle.
219038489|NCT05465382|OTHER|Synovial Fluid Aspiration|Aspiration of ankle joint via standard anteromedial approach. Performed using sterile technique using 16-guage needle attached to 10cc syringe.
219038490|NCT03836196|RADIATION|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
219038491|NCT02442778|DRUG|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
219038492|NCT02442778|DRUG|Placebo|Administered as capsules.
219519928|NCT01615081|OTHER|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
218903605|NCT04206319|DRUG|18F Sodium Fluoride|18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
218903606|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
218903607|NCT01693029|DRUG|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
218903608|NCT01693029|DRUG|US-licensed epoetin alfa|Solution for subcutaneous injection.
218903609|NCT05005403|DRUG|Azirkitug|Intravenous (IV) Infusion
218903610|NCT05005403|DRUG|Budigalimab|Intravenous (IV) Infusion
218903611|NCT05005403|DRUG|Bevacizumab|Intravenous (IV) Infusion
218903612|NCT06492174|DEVICE|AGENT DCB 40 mm|Drug coated PTCA balloon catheter 40 mm size
219519929|NCT02607319|DRUG|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
219038493|NCT02442778|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
219038494|NCT02442778|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
219519930|NCT03746353|PROCEDURE|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
219519931|NCT02507375|DRUG|Erlotinib|Erlotinib will be administered as oral tablets.
219519932|NCT02507375|DRUG|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
219519933|NCT07037550|BEHAVIORAL|Strength-based intervention|"The Strength-based intervention incorporates 8-week Ambassador-led strength-based intervention including:~1. a strength-based assessment to the patient-participant and caregiver done by the Social Worker,~2. Ambassador-assisted preparation of the strength-based biography,~3. four Ambassador-led workshops, the workshop will be delivered in group of 6-8 participants by at least 2 Ambassadors, and~4. one Social Worker-led zoom video conference delivered to the caregivers."
219519934|NCT00565305|BEHAVIORAL|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
219519935|NCT00565305|RADIATION|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
219519936|NCT07035756|DEVICE|Arterial Pressure Monitoring Set Fixation Device|A newly developed fixation device designed to securely stabilize the arterial pressure monitoring set, improving patient comfort and reducing device displacement during the postoperative period in patients undergoing coronary artery bypass graft surgery.
218903615|NCT05889182|DRUG|Upadacitinib|Oral Tablets
218903616|NCT05889182|DRUG|Placebo|Oral Tablets
219519937|NCT04595136|DRUG|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
218903618|NCT05668949|DRUG|TTI-101|Given by PO
218903619|NCT05668949|DRUG|Pembrolizumab|Given by IV (vein)
218903620|NCT06558552|OTHER|transcutaneous pulsed radiofrequency|Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.
219038495|NCT02860715|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
219038496|NCT02860715|DRUG|Placebo|This is the placebo of GX-I7 described above.
219038497|NCT02482025|OTHER|SMMRT|Includes My HealtheVet registration and enrollment
219038498|NCT01165138|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
219038499|NCT01165138|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
219519938|NCT04595136|DRUG|normal saline|0.9% NS via nebulization
219519939|NCT02765321|BEHAVIORAL|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
218903621|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)'|A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
218903622|NCT04634578|DRUG|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
218903623|NCT02639273|DRUG|Nalmefene|Active Drug
218903624|NCT02639273|OTHER|Placebo|Single Dose Placebo
218903625|NCT06168799|DRUG|Ilofotase alfa|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
218903626|NCT06168799|DRUG|Placebo|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
218903627|NCT06255782|GENETIC|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
218903628|NCT06363383|BIOLOGICAL|MB-001|Oral, delayed release formulation of a biologic drug
218903629|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
218903630|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
218903631|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
218903632|NCT05181592|DRUG|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
219038500|NCT01165138|DRUG|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
219038501|NCT02641379|DRUG|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
219038502|NCT02641379|DRUG|Ribavirin|Ribavirin is available as 200 mg tablets
219038503|NCT03498742|OTHER|NO Intervention|Routine clinical data; asthma control test and spirometry
219519940|NCT06884943|BEHAVIORAL|AI-guided maintenance training with visual-acoustic biofeedback|"Participants will complete AI-guided practice in the home setting in which they will interact with a web interface of the staRt web-based software for speech practice. The staRt software will present words to practice and show a real-time visual display of the acoustic signal of speech (biofeedback). On select trials, feedback will be provided by a classifier for children's r sounds, PERCEPT. Research assistants will join sessions to facilitate but will not provide direct clinical guidance to participants."
219519941|NCT06884943|BEHAVIORAL|Treatment as Usual (TAU)|Participants will return to their regular community-based care. This may consist of treatment in the school setting or by a private SLP; participants who were not previously receiving treatment may return to a no-treatment condition. Data will be collected from parents/guardians to determine the frequency of treatment, if any, received during this phase.
218903643|NCT06768671|DRUG|Sonelokimab|Open label
218903644|NCT03760523|DRUG|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
218903645|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
218903646|NCT04512144|BEHAVIORAL|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
219519942|NCT06266377|OTHER|Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder|"The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0)."
219519943|NCT06266377|OTHER|Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder|A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
218903647|NCT04554277|BIOLOGICAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
218903648|NCT02843165|DRUG|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
218903649|NCT02843165|RADIATION|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
218903652|NCT06202144|DEVICE|Noninvasive support|Noninvasive respiratory support delivered through a helmet
218903653|NCT04984356|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
218903654|NCT04926818|DRUG|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
218903655|NCT04926818|DRUG|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
218903656|NCT04926818|DRUG|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
218903657|NCT04926818|OTHER|Fingolimod placebo|Fingolimod matching placebo capsule
218903658|NCT04926818|OTHER|Siponimod placebo|Siponimod matching placebo tablet
218903659|NCT04926818|OTHER|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
219038504|NCT05849103|OTHER|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
218903660|NCT06797089|DEVICE|Oral appliance therapy plus scaling and root planing on left or right of mouth|This device opens the upper airway by bringing the mandible forward to improve breathing during sleep. The mouth shield minimizes mouth breathing to optimize salivary function. Scaling and root planing (deep cleaning of all teeth requiring it).
218903661|NCT06287463|DRUG|DCC-3084|Administered orally
218903662|NCT06840171|OTHER|Mandala coloring|Mandala group will participate in 8 sessions of mandala application. Mandala Coloring Application will be applied to the Intervention group 2-3 times a week for 3 weeks. Mandala application will be done by the researcher and feedback about the mandala will be received from the patients at the end of each session. Data collection forms will be applied before the mandala painting application starts and after the mandala painting application ends (after the 8th session).
218903663|NCT06039579|DRUG|VH4004280|VH4004280 was administered as tablets orally at Day 1.
219038505|NCT05849103|OTHER|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
219038506|NCT04910009|OTHER|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
218903664|NCT06039579|DRUG|VH4011499|VH4011499 was administered as tablets orally at Day 1 and Day 6.
218903665|NCT06039579|DRUG|VH4004280 Matching Placebo|VH4004280 Matching Placebo was administered as tablets orally at Day 1.
218903666|NCT06039579|DRUG|VH4011499 Matching Placebo|VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
218903667|NCT06039579|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
218903668|NCT04699890|OTHER|Blood sampling, questionnaires and specific exams|Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
218903669|NCT02362438|GENETIC|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
218903670|NCT04663997|DRUG|177Lu-PSMA-617|IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
218903671|NCT04663997|DRUG|Docetaxel|75mg/m2 IV every 3 weeks maximum 12 cycles
218903672|NCT06102902|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
218903673|NCT06102902|PROCEDURE|Biopsy Procedure|Undergo biopsy
218903674|NCT06102902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218903675|NCT06102902|BIOLOGICAL|Cetuximab|Given IV
218903676|NCT06102902|PROCEDURE|Computed Tomography|Undergo CT
218903677|NCT06102902|PROCEDURE|Echocardiography Test|Undergo ECHO
218903678|NCT06102902|DRUG|Encorafenib|Given PO
218903679|NCT06102902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218903680|NCT06102902|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219038507|NCT02508025|OTHER|Functional Capacity Evaluation|Assessment of work related physical capacity
218903681|NCT06014684|BEHAVIORAL|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
218903682|NCT05304351|BIOLOGICAL|Amezosvatein Antigen High Dose Arm A|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
219038508|NCT00586183|PROCEDURE|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
219038509|NCT00721786|BEHAVIORAL|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
218903683|NCT05304351|BIOLOGICAL|Amezosvatein Antigen Low Dose Arm B|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903684|NCT05304351|BIOLOGICAL|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903685|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm D|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903686|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm F|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903687|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm H|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903688|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm J|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903689|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm L|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
218903690|NCT01273168|DRUG|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
218903691|NCT01631617|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
218903692|NCT01631617|DRUG|Cephalexin|500 mg orally every 8 hours for 14 days
218903693|NCT01631617|DRUG|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
218903694|NCT01631617|OTHER|Sodium hypochlorite|6 % dilute bleach
218903695|NCT01631617|OTHER|Placebo capsules|Capsule orally every 8 hours daily for 14 days
218903696|NCT01631617|OTHER|Placebo Sodium hypochlorite|Three times a week for 14 days
218903697|NCT05382494|DRUG|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
218903698|NCT05382494|DRUG|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
218903699|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
219038510|NCT00384800|DRUG|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
219519944|NCT00522457|DRUG|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
218903700|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
218903701|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
218903702|NCT04493372|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
218903703|NCT05412927|DEVICE|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
218903704|NCT02443077|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
218903705|NCT02443077|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
218903706|NCT02443077|DRUG|Carmustine|Given IV
218903707|NCT02443077|DRUG|Cyclophosphamide|Given IV
218903708|NCT02443077|DRUG|Cytarabine|Given IV
218903709|NCT02443077|DRUG|Etoposide|Given IV
218903710|NCT02443077|DRUG|Ibrutinib|Given PO
219038511|NCT04982250|BEHAVIORAL|Enhanced peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
218903711|NCT02443077|OTHER|Laboratory Biomarker Analysis|Correlative studies
219038512|NCT02283710|DRUG|Pentoxifylline|Pentoxifylline 600 mg BD
219038513|NCT02283710|BEHAVIORAL|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
219038514|NCT00176553|DRUG|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
218903712|NCT02443077|DRUG|Melphalan|Given IV
218903713|NCT02443077|OTHER|Pharmacogenomic Study|Correlative studies
218903714|NCT02443077|OTHER|Placebo Administration|Given PO
218903715|NCT06846320|DRUG|ABBV-932|Oral Capsule
218903716|NCT06846320|DRUG|Placebo for ABBV-932|Oral Capsule
218903717|NCT06846320|DRUG|Antidepressant Therapy (ADT)|Standard of care
218903718|NCT06553456|DRUG|Recombinant Human Serum Albumin|The experimental drug was administered at a dose of 20 g/ day for 7 days.
218903719|NCT06553456|DRUG|Human Serum Albumin|The positive control drug was administered at a dose of 20 g/ day for 7 days.
218903720|NCT06846541|DRUG|Open-Label ESK-001|Open-Label ESK-001
218903721|NCT06846541|DRUG|Blinded ESK-001|Blinded ESK-001 during Randomized Treatment Withdrawal Period
218903722|NCT06846541|DRUG|Placebo|Placebo during Randomized Treatment Withdrawal Period
218903723|NCT05726396|DRUG|RMT|A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
219038515|NCT01048723|DRUG|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
219038516|NCT05518968|BEHAVIORAL|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
219038517|NCT01080898|OTHER|tests|color photographs, FLUORESCEIN angiography and OCT
219038518|NCT03365700|PROCEDURE|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
218903724|NCT05726396|DRUG|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
218903725|NCT05013736|DEVICE|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
218903726|NCT05013736|BEHAVIORAL|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
218903727|NCT05013736|DEVICE|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
218903728|NCT05552027|DEVICE|CCS System- Prototype|Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
218903729|NCT05552027|DEVICE|CCS System- Control|The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
218903730|NCT04471961|GENETIC|Exome sequencing in pediatrics cancers|This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
218903731|NCT05512377|DRUG|brigimadlin|brigimadlin
219038519|NCT03365700|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
219038520|NCT02885961|DRUG|Dabigatran|Anti-coagulant
219038521|NCT02885961|RADIATION|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
219038522|NCT02283515|DRUG|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
219038523|NCT06190431|OTHER|Learning the use of an in-exsufflation device with the guidance of a physiotherapist|Learning to use an in-exsufflation device with the guidance of a physiotherapist
219038524|NCT06190431|OTHER|Using the coaching mode|Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
219038525|NCT05033639|DRUG|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
219038526|NCT05033639|OTHER|Breast Milk|Naturally occurring milk from the mother of the infant.
219038527|NCT00527930|DRUG|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
218903732|NCT02356159|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m\^2 intravenous (IV) day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
218903733|NCT02356159|DRUG|Conditioning chemotherapy|Fludarabine:30 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m\^2 per day IV infusion over 2 hours on Days 6, -5, -4, -3. Mesna: 1200 mg/m\^2 per day IV infusion, daily on days 6, -5, -4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3.
219038528|NCT06376240|DIETARY_SUPPLEMENT|Pyridoxamine 300mg per day|oral supplement
219038529|NCT06376240|OTHER|Placebo 300mg placebo per day|oral supplement
219038530|NCT00446147|DRUG|Pyridoxine|100mg BID/daily, Per oral
219038531|NCT00446147|DRUG|Placebo|placebo 100mg BID/daily, Per oral
219038532|NCT04695132|BEHAVIORAL|Illness Management and Recovery treatment programme|The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
219038533|NCT05211128|PROCEDURE|Robotic Surgery|Surgical procedure using robotic technologies.
219038534|NCT05211128|PROCEDURE|Open Surgery|Surgical procedure using a large, open cut in the skin.
219038535|NCT05211128|PROCEDURE|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
219038536|NCT01315704|DRUG|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
218903734|NCT02356159|DRUG|TMS|Tacrolimus: 0.02 mg/kg, start day 3. Continue intravenous (IV) or by mouth (PO). Taper will begin at day +60 if no acute graft-versus-host disease (GVHD) then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m\^2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
218903735|NCT02356159|DRUG|FLAG|Fludarabine: 25 mg/m\^2 per day intravenous (IV) over 30 minutes, daily on days 1-5 Cytarabine: 2,000 mg/m\^2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy.
218903736|NCT02356159|DRUG|EPOCH-F|"Fludarabine: 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days 1-4. Etoposide: 50 mg/m\^2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin: 10 mg/m\^2/day continuous intravenous (CIV), days 1-4. Vincristine: 0.4 mg/m\^2 per day continuous IV infusion over 24 hours daily on days 1-4.~Cyclophosphamide: 750 mg/m\^2 IV infusion over 30 minutes on day 5. Prednisone: 60 mg/m\^2 per day by mouth (PO) daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV."
218903737|NCT02356159|PROCEDURE|Hematopoietic stem cell transplant|Hematopoietic stem cell transplant
218903738|NCT02356159|DRUG|Palifermin|Escalating doses of palifermin given during transplant phase.
218903739|NCT02356159|DRUG|Acetaminophen|Before each infusion of rituximab as indicated.
218903740|NCT02356159|DRUG|Diphenhydramine|Before each infusion of rituximab as indicated.
218903741|NCT02356159|DRUG|Prednisone|For engraftment syndrome.
218903742|NCT02356159|DRUG|Epinephrine|Emergency medication as indicated.
218903743|NCT02356159|OTHER|IV Saline|Before each infusion of rituximab as indicated.
218903744|NCT02356159|DIAGNOSTIC_TEST|ECG|As indicated.
218903745|NCT02356159|DIAGNOSTIC_TEST|ECHO|As indicated.
218903746|NCT02356159|DIAGNOSTIC_TEST|MUGA|As indicated.
218903747|NCT02356159|DIAGNOSTIC_TEST|DEXA|As indicated.
219038537|NCT02251795|DRUG|Tipranavir|
219038538|NCT02251795|DRUG|Ritonavir|
218903748|NCT02356159|DIAGNOSTIC_TEST|CT chest|As indicated.
218903749|NCT02356159|DIAGNOSTIC_TEST|PET|As indicated.
218903750|NCT02356159|DIAGNOSTIC_TEST|MRI|As indicated.
218903751|NCT02356159|PROCEDURE|BM aspirate|As indicated.
218903752|NCT02356159|PROCEDURE|BM biopsy|As indicated.
218903753|NCT02356159|PROCEDURE|Lumbar puncture|As indicated.
218903754|NCT06525220|DRUG|Petosemtamab|MCLA-158
218903755|NCT06525220|DRUG|Pembrolizumab|Humanized Antibody
218903756|NCT05443126|DRUG|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
218903757|NCT00861705|BIOLOGICAL|Bevacizumab|Given IV
218903758|NCT00861705|DRUG|Carboplatin|Given IV
218903759|NCT00861705|DRUG|Cyclophosphamide|Given IV
218903760|NCT00861705|DRUG|Doxorubicin Hydrochloride|Given IV
218903761|NCT00861705|OTHER|Laboratory Biomarker Analysis|Correlative studies
218903762|NCT00861705|DRUG|Paclitaxel|Given IV
218903763|NCT05423977|DRUG|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
218903764|NCT06418152|BEHAVIORAL|Multi-modal treatment|Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
218903765|NCT03190941|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
218903766|NCT03190941|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
218903767|NCT03190941|BIOLOGICAL|Anti-KRAS G12V mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
218903768|NCT03190941|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
218903769|NCT02729519|PROCEDURE|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
218903770|NCT05840302|DEVICE|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
218903771|NCT05840302|OTHER|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
218903772|NCT02455245|DRUG|Carboplatin and Vincristine|Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
218903773|NCT02455245|DRUG|Carboplatin|Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
218903774|NCT04218968|DRUG|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
218903775|NCT02781922|GENETIC|Autologous cardiac stem cells (JRM-001)|3x 10\^5 cells/kg, single treatment
218903776|NCT04498221|PROCEDURE|Imaging procedure|During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
218903777|NCT04498221|PROCEDURE|Surgical procedure|Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
219038539|NCT02251795|DRUG|Darunavir|
219038540|NCT02251795|DRUG|Aspirin|single dose on day 2
219038541|NCT02213211|DRUG|Artemether lumefantrine|
219038542|NCT02177279|OTHER|Visit A high wheat bran|
219038543|NCT02177279|OTHER|Visit B normal wheat bran|
219038544|NCT02177279|OTHER|Follow up normal (8days) and high (1day) bran consumption|
219519945|NCT01691248|DRUG|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
219519946|NCT01691248|DRUG|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
218903778|NCT00497380|DIETARY_SUPPLEMENT|Arginine|Oral nutritional supplement
218903779|NCT06413108|DRUG|TB31F|transmission-blocking monoclonal antibody TB31F
218903780|NCT06413108|OTHER|Normal saline|normal saline as control (placebo)
218903781|NCT04765371|DRUG|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
218903782|NCT04765371|DRUG|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
218903783|NCT06183359|OTHER|SIP|compare the SIP group versus the ACT group
218903784|NCT02839551|PROCEDURE|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
219038545|NCT01644175|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
219038546|NCT01644175|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
219038547|NCT01644175|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
219038548|NCT01261182|OTHER|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
219038549|NCT01261182|OTHER|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
219038550|NCT05046041|DRUG|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
219038551|NCT01025427|DRUG|Raltegravir, tenofovir/emtricitabine|16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
219038552|NCT05860283|DEVICE|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
218903785|NCT05533385|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
219038553|NCT05860283|PROCEDURE|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
219038554|NCT04694677|DRUG|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
219038555|NCT04694677|DRUG|women receiving misoprostol|women receiving misoprostol in myomectomy
219038556|NCT04819555|GENETIC|Blood|a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
219519947|NCT01740700|DEVICE|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
218903786|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
218903787|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
218903788|NCT04643457|DRUG|UCB9741|\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
218903789|NCT04643457|DRUG|Intravenous Placebo|\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
218903790|NCT04643457|DRUG|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
218903791|NCT00667628|DRUG|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
218903792|NCT00667628|DRUG|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
218903793|NCT03327974|OTHER|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~\- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
218903794|NCT06580496|BEHAVIORAL|Mightier|Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
218903795|NCT03838562|OTHER|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
218903796|NCT03838562|OTHER|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
218903797|NCT05894434|BEHAVIORAL|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
219038557|NCT04716127|BEHAVIORAL|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"* Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear."
219038558|NCT03532620|DRUG|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
219038559|NCT03532620|DRUG|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
219038560|NCT01169506|DEVICE|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
219204319|NCT06888336|BEHAVIORAL|Yoga nidra (brief)|"The intervention will consist of remotely delivered audio recordings of yoga nidra meditation instructions. Participants will be asked to listen to one \~30-minute practice and six \~10-minute practices per week (total listening time of \~1.5 hours each week) for 8 weeks. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more than once a day but are instructed to listen to the 30-minute recording once per week and the 10-minute meditations the other 6 days of the week."
219038561|NCT04109664|PROCEDURE|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
218903798|NCT05894434|BEHAVIORAL|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
218903799|NCT04014920|DEVICE|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
218903800|NCT04014920|DEVICE|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
218903801|NCT06509659|DIAGNOSTIC_TEST|Methacholine Challenge Test|MCT with IOS alone versus MCT IOS and FEV1 combined
219519948|NCT02962128|DIETARY_SUPPLEMENT|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high \[10% energy\] LA-containing diet for 12 weeks.
219519949|NCT02962128|DIETARY_SUPPLEMENT|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low \[2.5% energy\] LA-containing diet for 12 weeks.
219519950|NCT05308043|DIAGNOSTIC_TEST|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
219519951|NCT04738747|BEHAVIORAL|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
219519952|NCT02863575|DRUG|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
218903809|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
218903810|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
218903811|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
219038562|NCT01553006|DRUG|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
219519953|NCT02863575|DRUG|Ibuprofen|Ibuprofen capsule
218903812|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
218903813|NCT04079387|DEVICE|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
218903814|NCT04079387|DEVICE|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
218903815|NCT02946346|OTHER|vaginal sampling|
218903816|NCT06634901|OTHER|Health Literacy Educational Session- Comparator|During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
218903817|NCT06634901|BEHAVIORAL|Health Literacy Educational Session|The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
218903818|NCT06247215|OTHER|Religious leaders|Religious leaders who have experience providing pastoral or spiritual care to Chinese Americans living in Chicago
218903819|NCT06247215|OTHER|Chinese Americans|Chinese Americans living in Chicago.
218903820|NCT06247215|OTHER|Chinese Americans with end-of-life care discussions|Chinese Americans who have experience discussing end-of-life care decisions with others.
219038563|NCT03462238|PROCEDURE|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
219038564|NCT03462238|RADIATION|CT Scan|A scanner will be performed
219519954|NCT02863575|DRUG|Placebo|Placebo treatment
219519955|NCT07076082|DRUG|Clopidogrel (Plavix) Pharmacogenetic Test Reagents|Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
219519956|NCT05687058|DRUG|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session at home.
218903821|NCT06247215|OTHER|Chinese Americans with chronic diseases|Chinese Americans who are diagnosed with cancer, hypertension, or heart disease and their family caregivers
218903822|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
218903823|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
218903824|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
218903825|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
219038565|NCT00828191|DRUG|Progesterone|25 mg, once a day, SC
219519957|NCT05687058|DRUG|Empagliflozin 10 mg daily dosing|Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
219519958|NCT05026866|DRUG|Donanemab|Administered intravenously
219519959|NCT05026866|DRUG|Placebo|Administered intravenously
218903826|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
218903827|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
218903828|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
219038566|NCT00828191|DRUG|Progesterone|100 mg, twice a day, vaginally
219519960|NCT06497101|BEHAVIORAL|Temperament Based Therapy with Support (TBT-S)|Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
219519961|NCT05370183|PROCEDURE|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
219519962|NCT05370183|PROCEDURE|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
219612807|NCT07010627|PROCEDURE|Auriculotherapy for chronic pain treatment with laser stimulation of acupoints using red light|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine region in elderly individuals, using the application of laser acupuncture with low-power laser and red light on acupoints of Auriculotherapy.~As a criterion for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be used. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)."
219038567|NCT02402985|OTHER|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
219038568|NCT02402985|OTHER|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
219519963|NCT03577964|DIAGNOSTIC_TEST|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
219519964|NCT04696419|OTHER|Different intensities of contact to dogs|Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
219519965|NCT03893539|DEVICE|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
219519966|NCT04480788|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
219519967|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
219519968|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
218903829|NCT05046834|OTHER|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
219038569|NCT06538272|DRUG|ONO-2910|ONO-2910 Tablet will be orally administered once daily.
219038570|NCT06538272|DRUG|Placebo|Placebo Tablet will be orally administered once daily.
219038571|NCT04227106|BIOLOGICAL|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
219038572|NCT03627819|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
219038573|NCT03627819|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
219038574|NCT03627819|DIETARY_SUPPLEMENT|Control margarine|Margarine without any addition
219038575|NCT02459028|BEHAVIORAL|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
218903830|NCT05046834|OTHER|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
218903831|NCT06275815|OTHER|Sit Together and Read (STAR)|Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.
218903832|NCT06275815|BEHAVIORAL|Monetary Reward|Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).
218903833|NCT06275815|BEHAVIORAL|Text Encouragement|Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
218903834|NCT03774238|OTHER|FMD analysis|Blood sample and vascular exploration.
218903835|NCT05641896|DRUG|[18F]FAPI-74 PET/CT|\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
218903836|NCT02867423|DEVICE|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
218903837|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
218903838|NCT04665843|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
218903839|NCT04665843|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
218903840|NCT04665843|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
218903841|NCT02508012|OTHER|Immuno monitoring|treatment optimization
218903842|NCT06016686|OTHER|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
218903843|NCT06016686|OTHER|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
219038576|NCT02459028|BEHAVIORAL|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
219038577|NCT01511575|GENETIC|RNA analysis|
219038578|NCT01511575|GENETIC|reverse transcriptase-polymerase chain reaction|
219038579|NCT01511575|OTHER|laboratory biomarker analysis|
219038580|NCT01386736|DRUG|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
219519969|NCT01674530|DRUG|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
219519970|NCT00788125|DRUG|carboplatin|
218903844|NCT02879604|OTHER|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
218903845|NCT02879604|OTHER|Usual|Usual care
218903846|NCT05256901|DRUG|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or more.
218903847|NCT05256901|DRUG|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
218903848|NCT02908425|OTHER|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
218903849|NCT06461897|DRUG|Upadacitinib|Oral Tablet or Oral Solution
219038581|NCT01386736|DRUG|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
219038582|NCT03920631|DRUG|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
219038583|NCT03920631|BIOLOGICAL|Microtransplantation|HLA-mismatched peripheral blood stem cells
218903850|NCT06461897|DRUG|Dupilumab|Subcutaneous Injection
218903851|NCT00781612|DRUG|Docetaxel|Docetaxel will be administered as per local prescribing information.
218903852|NCT00781612|DRUG|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
219519971|NCT00788125|DRUG|dasatinib|
219519972|NCT00788125|DRUG|etoposide phosphate|
219519973|NCT00788125|DRUG|ifosfamide|
219519974|NCT00788125|GENETIC|microarray analysis|
219519975|NCT00788125|GENETIC|western blotting|
219519976|NCT00788125|OTHER|immunohistochemistry staining method|
219519977|NCT00788125|OTHER|laboratory biomarker analysis|
219519978|NCT00788125|PROCEDURE|therapeutic conventional surgery|
219204320|NCT06888167|OTHER|Study setting|"The subjects in the study will undergo two days of visits, in random order.~1. Following a fasting period of at least 4 hours, the study participants will undergo a PET-CT examination with Ga-exadin-4. Fasting will reduce the endogenous secretion of GLP-1 by the small intestine, which can otherwise compete with exendin-4 for binding to GLP-1R. Blood glucose will be measured before the injection of the tracer and monitored at each time point.~2. On a fasting basis, the anthropometric data of the enrolled subjects will be collected and they will undergo a short interview on their lifestyle. Subsequently, at time 0, the subjects will ingest a standard mixed meal consisting of 2 commercially available ABC Parmareggio snacks. Venous blood samples will be taken at specific time intervals (from -20 to 300 minutes) to measure glucose, C-peptide, insulin, glucagon, GLP-1 and glucose-dependent insulinotropic (GIP) curves. An additional blood sample will be taken at time -10 in order to isolate"
219519979|NCT00788125|RADIATION|radiation therapy|
219519980|NCT04667078|DRUG|Cangrelor|administration of cangrolor by iv befor thrombectomy
219519981|NCT04667078|OTHER|best medical management|used yhe best medical management
218903853|NCT00781612|DRUG|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
218903854|NCT00781612|DRUG|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
219519982|NCT03093506|DRUG|Low-dose rhEpo|60IU/kg/week
219519983|NCT03093506|DRUG|Micro-dose rhEpo|20IU/kg/week
219519984|NCT03093506|OTHER|Placebo Control|Saline
219519985|NCT03724149|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
219519986|NCT03724149|DRUG|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
219519987|NCT00163449|DRUG|Ciclesonide|Efficacy and Safety of Ciclesonide
219519988|NCT00163449|DRUG|Placebo|Placebo
219519989|NCT01677078|DEVICE|Neuronavigation system|Neuronavigation
219519990|NCT01677078|DEVICE|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
219519991|NCT03581448|BEHAVIORAL|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
219519992|NCT03157622|BEHAVIORAL|Exposure in vivo|10 sessions based on an individualized fear hierarchy
219519993|NCT03157622|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
219519994|NCT01279525|DEVICE|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
219519995|NCT01284439|DRUG|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
219519996|NCT01284439|DRUG|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
219519997|NCT05787639|DRUG|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
219519998|NCT01718938|DRUG|velusetrag dose 1|
219519999|NCT01718938|DRUG|velusetrag dose 2|
219520000|NCT01718938|DRUG|velusetrag dose 3|
219520001|NCT01718938|DRUG|placebo|
219520002|NCT04807621|BIOLOGICAL|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
219520003|NCT04807621|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
219520004|NCT02300090|DEVICE|Test Group|Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
219520005|NCT02300090|OTHER|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
219520006|NCT03611894|OTHER|radiological comparison|comparison between clinical and radiological characteristics
219520007|NCT01490944|DRUG|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
219520008|NCT01490944|DRUG|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
219520009|NCT00411866|DRUG|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
219520010|NCT00411866|DRUG|Ketoconazole|Ketoconazole will be available as 200mg tablets.
219520011|NCT02673580|OTHER|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
219520012|NCT02673580|OTHER|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
219520013|NCT03102580|OTHER|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
219520014|NCT05829148|DRUG|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
219520015|NCT05829148|DRUG|Melatonin|Melatonin
219520016|NCT05829148|DRUG|Pregabalin|Pregabalin
219520017|NCT05829148|DRUG|Placebo|Placebo
219520018|NCT01936922|DEVICE|GaitAid®|Provides visual and auditory cues for walking.
218903855|NCT00781612|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
218903856|NCT00781612|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
219520019|NCT04947748|OTHER|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
218903857|NCT06798402|DRUG|Ciprofloxacin (BAYO9867)|Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).
218903858|NCT06798402|DRUG|sodium stibogluconate (Pentostam)|Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
218903859|NCT02674347|DRUG|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
218903860|NCT02674347|DRUG|Placebo|IV matching the Investigational drug
218903861|NCT06229691|BEHAVIORAL|30 minute treadmill walk|"Participants will walk on a treadmill at their preferred speed for 30 minutes. One minute challenge periods will occur at minutes 7, 17, and 27, when the treadmill speed will increase by 50%. This walk will induce a magnitude of muscle fatigue corresponding to an individual participant's fatigability."
218903862|NCT05727878|DRUG|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
218903863|NCT05727878|DRUG|KPI-012 Vehicle|KPI-012 formulation with no active drug
218903864|NCT04960969|OTHER|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
218903865|NCT06388941|DRUG|Iptacopan|LNP023 administered orally
218903866|NCT06388941|DRUG|Placebo|Matching placebo administered orally
219038584|NCT02246803|PROCEDURE|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
219038585|NCT02246803|PROCEDURE|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
219038586|NCT00752882|DRUG|ceftazidime|
219520020|NCT00005939|RADIATION|brachytherapy|
219520021|NCT00005939|RADIATION|phosphorus P32|
218903867|NCT06388941|DRUG|Rituximab|Standard of care
218903868|NCT04599088|OTHER|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
218903869|NCT04198792|OTHER|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
219520022|NCT03413046|DIAGNOSTIC_TEST|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
219520023|NCT05395858|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
219520024|NCT05240196|OTHER|music|playing binaural or non-binaural music
219520025|NCT03165058|DIAGNOSTIC_TEST|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
219520026|NCT03900624|DRUG|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
219520027|NCT01130623|DRUG|Pazopanib (GW786034)|
219520028|NCT01075581|DRUG|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
219520029|NCT01075581|DRUG|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
218903870|NCT04824469|OTHER|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
218903871|NCT05223270|OTHER|wound dressing under the NIMV mask|wound dressing under the NIMV mask
218903872|NCT00925262|BEHAVIORAL|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
218903873|NCT00925262|BEHAVIORAL|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
218903874|NCT00925262|BEHAVIORAL|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
219038587|NCT01418937|BIOLOGICAL|CervarixTM (GSK580299)|Three intramuscular injections
219038588|NCT06221033|DEVICE|manual hyperinflation|Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
218903875|NCT02147743|BEHAVIORAL|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
218903876|NCT02147743|BEHAVIORAL|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
218903877|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) lecture|OHEM via lecture will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
218903878|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) exhibition|OHEM via exhibition will be delivered to the mothers who will be instructed to teach their children.
218903879|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) demonstration|OHEM via demonstration will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
218903880|NCT00557921|DRUG|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
218903881|NCT00557921|DRUG|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
218903882|NCT05268640|PROCEDURE|Double-level cervical cerclage|two cervical sutures + regimen of antibiotics + indomethacin + progesterone
218903883|NCT05268640|PROCEDURE|Single-level cervical cerclage|single cervical suture + regimen of antibiotics + indomethacin + progesterone
218903884|NCT02750189|OTHER|Direct cost|Money spent to treat COPD in medical institute based on HIRA
218903885|NCT02750189|OTHER|Indirect cost|extra-expanses excluding hospital fees
218903886|NCT00325715|DRUG|AGN 201904|
218903887|NCT00325715|DRUG|esomeprazole|
218903888|NCT03003052|PROCEDURE|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
218903889|NCT02383875|BEHAVIORAL|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
218903890|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
218903891|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
218903892|NCT03936608|DEVICE|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
218903893|NCT03936608|DEVICE|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
218903894|NCT00730977|DRUG|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
218903895|NCT00423657|DRUG|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
218903896|NCT00423657|DRUG|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
218903897|NCT00423657|DRUG|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
218903898|NCT04538937|OTHER|no intervention|no intervention
219520030|NCT03252964|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
219520031|NCT03252964|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
219520032|NCT03252964|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
218903899|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
218903900|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
218903901|NCT03700801|DRUG|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
218903902|NCT03700801|DRUG|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
218903903|NCT03972865|OTHER|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
218903904|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
218903905|NCT04918186|DRUG|BA3011|IV
218903906|NCT04918186|DRUG|BA3021|IV
218903907|NCT04918186|DRUG|ENB003|IV
218903908|NCT04918186|DRUG|Toripalimab|IV
218903909|NCT06209619|PROCEDURE|Biopsy|Undergo biopsy
218903910|NCT06209619|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218903911|NCT06209619|PROCEDURE|Computed Tomography|Undergo PET/CT
218903912|NCT06209619|DRUG|Golcadomide|Given PO
218903913|NCT06209619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218903914|NCT06209619|BIOLOGICAL|Rituximab|Given IV
218903915|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
218903916|NCT04504422|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
218903917|NCT05109936|DRUG|Adenuric|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
218903918|NCT05671835|DRUG|TTI-101|Orally via a tablet.
218903919|NCT05671835|DRUG|Placebo|Orally via a tablet.
218903920|NCT04822181|DRUG|Semaglutide|Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
218903921|NCT04822181|DRUG|Placebo|Placebo administrated subcutaneously (under the skin) once weekly.
218903922|NCT06644768|DRUG|valemetostat tosylate|Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
218903923|NCT06644768|DRUG|pembrolizumab|One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
218903924|NCT06643611|BEHAVIORAL|Continuous Glucose Monitor|Patient will be provided a continuous glucose monitor. Pharmacist will provide information regarding how to best manage type 2 diabetes.
218903925|NCT06643611|BEHAVIORAL|Usual Care|Routine physician office visits and hemoglobinA1c every 3 for those with HbA1c outside goal and every 6 months for those with HbA1c within goal. Medication regimens managed by physicians, nurse practitioners, and physician assistants. Patients are sent reminders on the phone prior to their visits or when they are due for a visit or any physical examination.
218903926|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
218903927|NCT03755297|OTHER|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
218903928|NCT04517799|DRUG|Epidiolex|"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
219038589|NCT06221033|OTHER|Diaphragmatic proprioceptive neuromuscular facilitation technique|"Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath"
219038590|NCT06221033|OTHER|traditional physiotherapy|This group will receive the traditional medical treatment and chest physiotherapy only.
219038591|NCT04045678|DRUG|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
219520033|NCT05261464|DRUG|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
219520034|NCT05261464|DRUG|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
219520035|NCT05261464|DRUG|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
218903929|NCT04517799|DRUG|placebo oral solution|"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
218903930|NCT06801899|PROCEDURE|Total pancreatectomy (TP)|The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head.
218903931|NCT06801899|PROCEDURE|Partial pancreaticoduodenectomy (PD)|The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
218903932|NCT06009926|DRUG|Acetaminophen|Given PO
218903933|NCT06009926|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218903934|NCT06009926|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
218903935|NCT06009926|DRUG|Placebo Administration|Given PO
218903936|NCT06009926|OTHER|Questionnaire Administration|Ancillary studies
218903937|NCT06009926|OTHER|Training|Undergo flashover training
218903938|NCT04046536|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
218903939|NCT04046536|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
218903940|NCT06229353|BIOLOGICAL|Gardasil 9|Prevent HPV-associated diseases and cancers
218903941|NCT05251948|DRUG|Atezolizumab|Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
218903942|NCT05251948|DRUG|Capecitabine|Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
218903943|NCT05251948|DRUG|Oxaliplatin|Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
218903944|NCT05251948|DRUG|Tiragolumab|Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
218903945|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
218903946|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)/RIV|Combination of BNT162b2 (Omi XBB.1.5) and RIV
218903947|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|Licensed COVID-19 vaccine
218903948|NCT06237049|BIOLOGICAL|RIV|Licensed recombinant influenza vaccine
218903949|NCT06237049|OTHER|Normal saline placebo|Normal saline (solution for injection)
218903950|NCT04941573|COMBINATION_PRODUCT|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
218903951|NCT03005925|DEVICE|Smartphone|Smartphone application coupled with a hand dynamometer
218903952|NCT03005925|OTHER|physical follow up|regular visits with the specialist
219520036|NCT01843608|OTHER|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
218903953|NCT06799533|DRUG|PF-08046031|Given into the vein (IV; intravenous)
218903954|NCT03826043|DIAGNOSTIC_TEST|Blood sample analysis|Thrombophilia, blood count and coagulation count
218903955|NCT05159427|DRUG|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
218903956|NCT05159427|DRUG|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
218903957|NCT05159427|DRUG|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
218903958|NCT05159427|DRUG|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
218903959|NCT05054790|BIOLOGICAL|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
219038592|NCT04045678|DRUG|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
219520037|NCT03171155|DEVICE|XPro System|Implantation of the XPro System
219520038|NCT00583258|DRUG|Alfuzosin (Xatral)|10 mg PO once a day
219520039|NCT00583258|DRUG|Placebo Alfuzosin|10 mg PO once a day
218903960|NCT04069091|BEHAVIORAL|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
218903961|NCT04835805|DRUG|Belvarafenib|Twice daily (BID), continuous dosing
218903962|NCT04835805|DRUG|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
218903963|NCT04835805|DRUG|Nivolumab|Once every 4 weeks (Q4W)
218903964|NCT04459156|DIETARY_SUPPLEMENT|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
218903965|NCT04459156|DIETARY_SUPPLEMENT|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
218903966|NCT06085833|DIAGNOSTIC_TEST|Nanomechanical Phenotype Test|The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
218903967|NCT04551469|BEHAVIORAL|music|Music intervention for 30 minutes
218903968|NCT00885066|DRUG|capecitabine|
218903969|NCT00885066|DRUG|erlotinib hydrochloride|
218903970|NCT00885066|DRUG|gemcitabine hydrochloride|
219038593|NCT01485211|DRUG|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
219038594|NCT01869283|OTHER|Kinesiotherapy|
219038595|NCT01869283|OTHER|Ultrasound|
219038596|NCT01869283|OTHER|Diadynamic currents|
219038597|NCT05832957|BEHAVIORAL|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
219520040|NCT05039502|OTHER|Protaper Universal Retreatment|D1-D2-D3 Retreatment files were used in 500 rpm and 3 Ncm with X-Smart endomotor
219520041|NCT05039502|OTHER|Reciproc|R25 retratment files were used with X-Smart endomotor in reciprocal motion
219520042|NCT05039502|OTHER|XP-Endo finisher R|XP-Endo finisher r file were used in 1000 rpm 1 Ncm with X-Smart endomotor
219520043|NCT00444145|DRUG|Prevacid|30 mg bid for 3 months
219520044|NCT00444145|PROCEDURE|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
219520045|NCT04814745|DRUG|intrathecal infusion|morphine 150 mcg will be used by intrathecal administration
219520046|NCT04814745|DRUG|Intravenous Infusion|tramadol administration
219520047|NCT04814745|DRUG|Ropivacaine injection|bilateral transversus abdominis plane block by using ropivacaine 80 mg
219520048|NCT01195298|DRUG|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
219520049|NCT05046548|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
219520050|NCT05046548|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
219520051|NCT01374919|DRUG|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
219520052|NCT03968549|DIETARY_SUPPLEMENT|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
218903971|NCT03650673|DIAGNOSTIC_TEST|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
218903972|NCT03535350|DRUG|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
218903973|NCT03535350|RADIATION|Radiation|2Gy x 30minutes for 6 weeks.
218903974|NCT03535350|DRUG|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
218903975|NCT06804057|OTHER|Blood Collection|Blood will be collected for the subjects who are willing to participate in the optional biorepository
218903976|NCT03396666|OTHER|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
218903977|NCT06565390|DEVICE|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
219038598|NCT05832957|BEHAVIORAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
218903978|NCT05707962|DRUG|Magnesium sulfate|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
218903979|NCT03025386|OTHER|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
218903980|NCT03025386|OTHER|Electroencephalography|Mesure of the mismatch negativity wave
219038599|NCT05832957|OTHER|No intervention|one-time short guidance on safe driving at the end of the study.
219520053|NCT03968549|OTHER|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
219520054|NCT05289713|PROCEDURE|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
219520055|NCT05390437|DIETARY_SUPPLEMENT|Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination|4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
219520056|NCT05390437|DIETARY_SUPPLEMENT|Ready to use theraputic food (RUTF) and Starch (placebo)|Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
219520057|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
219520058|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
219612808|NCT07010627|PROCEDURE|"Auriculotherapy for chronic pain treatment with stimulation of acupoints using mustard seeds."|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine regions in elderly individuals, utilizing the application of mustard seeds on Auriculotherapy acupoints.~As criteria for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be utilized. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)"
219204321|NCT06883955|COMBINATION_PRODUCT|Disease education, pharmacological treatment, Non-pharmacological treatment|"Disease education: Provide patients with education on knowledge related to primary headache, including the causes, pathogenesis, symptoms, treatment methods, and preventive measures of headache, etc., to help patients better understand their own diseases and improve their self-management ability.~Non-pharmacological treatment: Although specific non-pharmacological treatment methods are not elaborated in detail in the research protocol, they may include psychotherapy, physical therapy, etc. For example, biofeedback therapy, relaxation training, transcranial magnetic stimulation, etc. These can all be recorded as possible intervention measures.~Pharmacological treatment: Record the medications used for the treatment of acute episodes and preventive treatment by patients during the research process, including the types of medications, dosages, frequency of use, etc. For instance, non-steroidal anti-inflammatory drugs and triptan drugs used during acute episodes, and β-blockers."
219038600|NCT01770288|OTHER|Anaerobic wingate test|
219038601|NCT00842348|DRUG|lanreotide (Autogel formulation)|Autogel 120 mg
219038602|NCT06072937|DEVICE|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
219520059|NCT03022773|OTHER|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
219520060|NCT02700464|DEVICE|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
219520061|NCT02700464|PROCEDURE|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
219520062|NCT03189888|DEVICE|apheresis|
219204322|NCT06882941|DIETARY_SUPPLEMENT|Fermented Black Soybean and Adlay Supplement|The preparation of the fermented black soybean and adlay supplement involves autoclaved black soybean and dehulled adlay, which are inoculated with Bacillus subtilis natto (1.3 × 10⁶ CFU/g) and incubated for 43 hours at 28°C. Participants assigned to the experimental group will take the Fermented Black Soybean and Adlay Supplement daily for 12 weeks.
219204323|NCT06882941|DIETARY_SUPPLEMENT|non-fermented black soybean and adlay supplement|The placebo product was prepared using uninoculated autoclaved black soybean and dehulled adlay. The samples were provided as frozen food and required microwaving for 30 seconds before serving. Participants assigned to the placebo group will take the non-fermented black soybean and adlay supplement daily for 12 weeks.
219520063|NCT04949620|BEHAVIORAL|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
219038603|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
219038604|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
219520064|NCT04949620|BEHAVIORAL|Online parenting program|The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
219520065|NCT05901857|DIAGNOSTIC_TEST|convolutional neural network|A deep learning model for dental age classification from panoramic images
219520066|NCT03339856|DEVICE|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
219038605|NCT01536431|DRUG|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
219038606|NCT03467087|DEVICE|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
219038607|NCT01616485|DRUG|TA-1790|2 TA-1790 100 mg capsules
219038608|NCT01616485|DRUG|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
219520067|NCT05701670|BEHAVIORAL|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
219520068|NCT00186290|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
219520069|NCT00236457|DRUG|risperidone|
218903988|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
218903989|NCT03731832|DRUG|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
219038609|NCT01616485|DRUG|Placebo|2 placebo capsules for TA-1790 100 mg capsules
219038610|NCT01616485|DRUG|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
219038611|NCT01299922|DRUG|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
219038612|NCT01299922|DRUG|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
219038613|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
219038614|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
219038615|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
219520070|NCT01494506|DRUG|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"
219038616|NCT06133309|BEHAVIORAL|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
219038617|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
219038618|NCT00456716|DRUG|sorafenib|400mg po bid
218903990|NCT03731832|DRUG|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
219038619|NCT01787578|DRUG|Sobetirome|50 mcg or 100 mcg once-daily oral
219038620|NCT03323658|DRUG|Bexarotene|Given topically
219038621|NCT03323658|OTHER|Questionnaire Administration|Ancillary studies
219038622|NCT06108505|OTHER|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
219038623|NCT06108505|OTHER|Plain oats|Subjects will receive 7.5 gr of plain oats
219038624|NCT03080259|BEHAVIORAL|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
218903991|NCT03731832|DRUG|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
218903992|NCT03731832|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
218903993|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
218903994|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
218903995|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
219038625|NCT03073590|COMBINATION_PRODUCT|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
218903996|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
218903997|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
219038626|NCT03073590|COMBINATION_PRODUCT|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
219038627|NCT03073590|COMBINATION_PRODUCT|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
219038628|NCT03073590|BEHAVIORAL|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
219520071|NCT01494506|DRUG|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
219520072|NCT01494506|DRUG|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
219520073|NCT01979341|PROCEDURE|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
218903998|NCT05970172|DRUG|Roxadustat|Oral
218903999|NCT03190954|DRUG|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
219038629|NCT02849548|DRUG|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
219038630|NCT02849548|OTHER|placebo|Pill with inactive ingredients
219038631|NCT01317238|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
219038632|NCT03195959|OTHER|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
219038633|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
219038634|NCT06272877|OTHER|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
219038635|NCT06272877|OTHER|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
219038636|NCT06055023|DRUG|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038637|NCT06055023|DRUG|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038638|NCT06055023|DRUG|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038639|NCT06055023|DRUG|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038640|NCT06055023|DRUG|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038641|NCT06055023|DRUG|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
218904000|NCT03190954|DRUG|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
218904001|NCT03190954|DRUG|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
218904002|NCT05779423|DRUG|Ipilimumab|Monoclonal antibody administered through intravenous infusion
218904003|NCT05779423|DRUG|Nivolumab|Monoclonal antibody administered through intravenous infusion
218904004|NCT05779423|PROCEDURE|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
218904005|NCT05159960|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
218904006|NCT00690560|BIOLOGICAL|rituximab|
218904007|NCT00690560|DRUG|cyclophosphamide|
218904008|NCT00690560|DRUG|doxorubicin hydrochloride|
218904009|NCT00690560|DRUG|prednisone|
218904010|NCT00690560|DRUG|vincristine sulfate|
218904011|NCT00690560|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
218904012|NCT04614129|DIAGNOSTIC_TEST|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
218904013|NCT05984979|OTHER|Standardized meal|The participants will receive a standardized meal for breakfast
219520074|NCT04500470|DRUG|Ketoprofen + INH|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
218904014|NCT03290846|DRUG|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
218904015|NCT03290846|DRUG|Saline Solution|Randomized, single-blinded saline infusion.
218904016|NCT03290846|OTHER|Cold exposure|All subjects will undergo a cold exposure PET scan.
218904017|NCT06340958|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
218904018|NCT06340958|DRUG|Placebo|1 tablet of placebo administered once daily
218904019|NCT05534217|BIOLOGICAL|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
219038642|NCT06055023|DRUG|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
218904020|NCT04908397|DIETARY_SUPPLEMENT|L-carnitine|supplement provided twice a day for 2 weeks
218904021|NCT04264442|DRUG|Losmapimod|Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
218904022|NCT03744429|OTHER|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
218904023|NCT03644615|OTHER|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
218904024|NCT03644615|OTHER|Usual care|No intervention on the patients
218904025|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
218904026|NCT06028022|DRUG|Placebo Administration|Given PO
218904027|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
218904028|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
218904029|NCT05756751|DEVICE|Device: Impella 5.5 with SmartAssist|Patients who are deemed high-risk due to low preoperative ejection fraction undergoing cardiac surgery with cardiopulmonary bypass (CPB) which will be supported by the Impella 5.5 System.
218904030|NCT04979806|DRUG|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
219038643|NCT06055023|DRUG|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219520075|NCT04500470|DRUG|Ketoprofen + placebo|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
218904031|NCT04979806|DRUG|Meropenem|1 g IV q8h
218904032|NCT04061720|BEHAVIORAL|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
218904033|NCT04061720|BEHAVIORAL|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
219520076|NCT03596190|DIAGNOSTIC_TEST|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
219520077|NCT00075543|DRUG|docetaxel|
219612809|NCT07011537|BEHAVIORAL|Digital Musculoskeletal (MSK) Program|"Hinge Health is a digital MSK program to help participants manage chronic MSK pain through offering exercise therapy sessions, educational articles, and personal health coaching. Hinge Health delivers exercise therapy sessions and education through playlists accessed through the program app. Each playlist consists of three to seven exercises specific to the body region(s) the participant experiences pain in. Animations and videos, while paired with sensors and computer vision, demonstrate how to perform exercises, the number of repetitions for each exercise, and how long to hold positions. Playlists present more challenging exercises and/or more repetitions as participants progress further along in the program. After participants complete the exercises, the playlist delivers educational articles and resources focused on MSK pain-related topics, including lifestyle changes, pain neuroscience, and social support."
219612810|NCT07011537|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The Enso is a strong complement/enhancement to the Hinge Health program, as it helps users to better manage their pain in order to work through their exercise sessions in the program. The Enso device is not intended to be a stand-alone solution; it provides pain relief, but exercise therapy provides important long-term benefits. Participants will use the digital MSK program (Hinge Health) in combination with a pain management device (Enso).
218904034|NCT00713492|DRUG|Alcohol|human laboratory alcohol consumption.
218904035|NCT06049654|DEVICE|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
218904036|NCT06049654|DEVICE|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
218904037|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
218904038|NCT05237401|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|participants will receive local anaesthesia, then thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes.
218904039|NCT05237401|PROCEDURE|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|Patients will receive local anaesthesia and intrasulcular incisions will be made on the buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using diamond coated inserts, sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Osteoplasty (removal of non-supporting bone) may be carried out, as judged by the operator. The surgical site will be closed with resorbable or non-resorbable sutures.
218904040|NCT05920122|DRUG|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
219038644|NCT06055023|DRUG|zL-82 placebo 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038645|NCT06055023|DRUG|ZL-82 placebo 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038646|NCT06055023|DRUG|ZL-82 placebo 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038647|NCT06055023|DRUG|ZL-82 placebo 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038648|NCT06055023|DRUG|ZL-82 placebo 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038649|NCT06055023|DRUG|ZL-82 placebo 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7. Edit
219038650|NCT06055023|DRUG|ZL-82 placebo 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038651|NCT06055023|DRUG|ZL-82 placebo 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
219038652|NCT05460494|BEHAVIORAL|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
219038653|NCT04171856|DEVICE|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
219520078|NCT00075543|DRUG|oxaliplatin|
219520079|NCT02627209|OTHER|spectrophotometric assay|measurement of enzyme activity in the serum
219520080|NCT02627209|OTHER|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
219520081|NCT03659656|BEHAVIORAL|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
219520082|NCT03659656|DEVICE|Fitbit usage|The participants will have a Fitbit to use for 3 months.
219520083|NCT02019056|DRUG|Placebo /bid P.O|
219520084|NCT02019056|DRUG|MG-1|
219520085|NCT02019056|DRUG|MG-2 : MG1000mg, Placebo /bid P.O|
219520086|NCT02019056|DRUG|metadoxine|
219520087|NCT02303548|DRUG|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
219520088|NCT02303548|DRUG|Normal saline|Placebo
219520089|NCT02359981|BEHAVIORAL|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
218904041|NCT05920122|DRUG|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
218904042|NCT05180448|BEHAVIORAL|Coach Share On|If an index participant is randomized to have Coach Share ON, the coach will have continuous access to objective, real-time, detailed device data, and address data directly in all individual interactions with index participants (groups, individual weigh-ins, phone calls, texts), conveying that they are closely monitoring progress.
218904043|NCT05180448|BEHAVIORAL|Group Share On|If Group Share is ON, participants in a given LM group will view and respond to aspects of each other's self-monitoring device data in their small-group text messages. Each small group participant's data will be highlighted one day of the month, and content from the Group Share Off message library also will be sent.
218904044|NCT05180448|BEHAVIORAL|Friend/Family Share On|Index participants who are randomized to have Friend/Family Share ON will give their friend or family member access to their self-monitoring data. Text messages sent by the program bot, which includes the index participant and friend/family member, will use a similar format as described in Group Share ON. The friend or family member will be trained to respond to data in ways that enhance the participant's motivation and self-regulation.
218904045|NCT05180448|BEHAVIORAL|Coach Share Off|Among index participants who are randomized to have Coach Share OFF, the coach will have no access to their device data. Index participants will be explicitly told their coach does not have data access. During groups and phone calls, the participant will self-report progress, and goal setting will be based on that self-report. Text messages from the coach will be personalized in the OFF condition, as they are when coach data sharing is ON, though these messages will not be informed by device data. Instead, text messages will provide a reminder of key goals and strategies discussed in the previous phone call and provide encouragement for participant efforts.
218904046|NCT05180448|BEHAVIORAL|Group Share Off|Among index participants randomized to have Group Share OFF, supportive accountability will not be the target of participant interactions and no data will be shared with LM program peers. Instead, once weekly prompts for small group text exchanges will encourage index participants to provide social support (primarily of the informational type) to each other. Index participants will be explicitly told that they should not include information on goal progress such as weight change or minutes of PA.
218904047|NCT05180448|BEHAVIORAL|Friend/Family Share Off|If an index participant is randomized to Friend/Family Share OFF, the text messages from the bot will prompt the participant and friend/family member to communicate about the LM program; those messages will be standardized, except for names, and will not be tailored to index participant progress. Index participants will be instructed to refrain from sharing any device data with friends or family members.
218904048|NCT05180448|BEHAVIORAL|Behavioral Weight Loss Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
218904049|NCT03650114|BIOLOGICAL|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
218904050|NCT03650114|BIOLOGICAL|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
218904051|NCT03650114|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
218904052|NCT03650114|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
218904053|NCT03650114|BIOLOGICAL|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
218904054|NCT03650114|BIOLOGICAL|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
218904055|NCT06584513|OTHER|Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements|The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
218904056|NCT01871350|DIETARY_SUPPLEMENT|Daily intake for 10 weeks (+/- 2 weeks)|
218904057|NCT03173924|DRUG|18F-NaF|Baseline IV followed by PET/CT IMAGING
218904058|NCT03173924|DRUG|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
218904059|NCT03173924|DRUG|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
218904060|NCT05797168|DRUG|AZD5335|IV Antibody-drug conjugate
218904061|NCT05797168|DRUG|Saruparib (AZD5305)|Oral PARP inhibitor
218904062|NCT05797168|DRUG|Bevacizumab|IV Monoclonal antibody
218904063|NCT05797168|DRUG|Carboplatin|IV Alkylating agent
218904064|NCT05797168|DRUG|AZD9574|Oral PARP inhibitor
218904065|NCT03997669|OTHER|Collection of pleural effusion|Detection of pleural effusion
218904066|NCT01528930|DRUG|Amikacin|500 mg, once daily for 2 years
218904067|NCT04215536|DRUG|Empagliflozin|Empagliflozin dispensing claim is exposure
218904068|NCT04215536|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
218904069|NCT00811525|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
218904070|NCT00567853|DEVICE|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
218904071|NCT02371824|OTHER|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
218904072|NCT06205537|OTHER|Control Liquid Supplement|Ready to drink supplement.
218904073|NCT06205537|OTHER|Experimental Liquid Supplement|Ready to drink supplement.
218904074|NCT05388214|BEHAVIORAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
218904075|NCT04257448|DRUG|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
218904076|NCT04257448|DRUG|Azacitidine|Powder for suspension for injection; Subcutaneous use
218904077|NCT04257448|DRUG|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
218904078|NCT04257448|DRUG|Gemcitabine|Powder for solution for infusion; Intravenous use
218904079|NCT04257448|DRUG|Durvalumab|Concentrate for solution for infusion; Intravenous use
218904080|NCT04257448|DRUG|Lenalidomide capsule|Hard capsule for oral use
218904081|NCT03545256|PROCEDURE|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~\- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
218904082|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
218904083|NCT05710315|DEVICE|RELiZORB™|RELiZORB cartridges will be used with routine enteral feedings for 5 days for randomized participants
218904084|NCT05710315|OTHER|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants
218904085|NCT05626478|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
218904086|NCT05626478|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
218904087|NCT05626478|DRUG|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
218904088|NCT05654532|DRUG|AC699|Participants will receive AC699 orally daily in 28-day cycles.
218904089|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
218904090|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
218904091|NCT03743935|OTHER|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
218904092|NCT05668988|DRUG|sunvozertinib|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
218904093|NCT05668988|DRUG|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
218904094|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
218904095|NCT05858034|OTHER|Customized activity plan|Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
218904096|NCT05858034|OTHER|Customized nutrition plan|Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
218904097|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
218904098|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
219038654|NCT06346782|BEHAVIORAL|Internet-Based Parent-Child Interaction Therapy|I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
219038655|NCT05673408|DEVICE|Philips IntelliVue X3 Patient Monitor|All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
218904099|NCT06451965|OTHER|Timeline Intervention|"The proposed intervention consists of six sessions. In Session One, the focus is on building rapport, assessing individual difficulties, setting client-focused goals, and introducing the timeline. Participants complete timeline examples during the session and as homework.~In Session Two, psychoeducation is provided regarding the impact of stroke, addressing changes in identity and associated feelings of grievance.~Session Three onwards introduces active change methods, encouraging reflection on complex life events. The aim is to promote resilience, meaning, self-compassion, and self-acceptance by exploring past coping strategies and finding significance in events of regret. This framework aims to enhance research on complex interventions, considering efficacy, effectiveness, theory-based approaches, and systems perspectives."
218904100|NCT03858153|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
218904101|NCT03858153|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
218904102|NCT06481670|OTHER|Carbohydrate drink|The \>50 g carbohydrate drink will be consumed up to 2 hours prior to surgery.
218904103|NCT03327597|OTHER|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
218904104|NCT03327597|OTHER|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
218904105|NCT03327597|OTHER|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
218904106|NCT03327597|OTHER|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
218904107|NCT03327597|OTHER|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
218904108|NCT03327597|OTHER|Clinical follow-up control|Control clinical visit
218904109|NCT04232566|PROCEDURE|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
218904110|NCT06204549|OTHER|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
218904111|NCT06800066|BEHAVIORAL|Purchase Behavior - (Non-CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
218904112|NCT06800066|BEHAVIORAL|Purchase Behavior - (CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
218904113|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
218904114|NCT02923206|DEVICE|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
218904115|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
218904116|NCT05686070|DRUG|Asundexian (BAY2433334)|Once daily, oral
218904117|NCT05686070|DRUG|Placebo|Placebo to asundexian, once daily, oral
218904118|NCT06168669|DIAGNOSTIC_TEST|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
218904119|NCT06058650|PROCEDURE|Biopsy of Breast|Undergo biopsy of breast
218904120|NCT06058650|OTHER|Medical Device Usage and Evaluation|Utilization of the Stereo Navigator accessory
218904121|NCT06058650|RADIATION|Scintimammography|Undergo MBI
218904122|NCT06058650|OTHER|Technetium Tc-99m Sestamibi|Given IV
218904123|NCT05851586|PROCEDURE|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
218904124|NCT05851586|PROCEDURE|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
218904125|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
218904126|NCT04879628|DRUG|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
218904127|NCT04879628|DRUG|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
218904128|NCT04879628|DRUG|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
218904129|NCT04879628|DRUG|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
218904130|NCT04879628|DRUG|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
218904131|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
218904132|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
218904133|NCT03167437|DRUG|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
218904134|NCT03167437|DRUG|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
219612811|NCT07011537|OTHER|Standard of Care (SOC)|The control group will continue to receive the access to traditional medical care for their MSK needs through their healthcare provider. Upon study completion, control group members who complete all follow-up surveys will receive Hinge Health membership and an Enso device for free for 12 months, starting at the conclusion of their participation in the study.
219612812|NCT07013071|DRUG|2% Mepivacaine with 1:100,000 epinephrine|A standard vasoconstrictor-containing local anesthetic used in dental procedures to minimize bleeding and prolong anesthetic effect.
218904137|NCT01419561|DRUG|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
218904138|NCT01419561|DRUG|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
218904139|NCT01419561|DRUG|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
218904140|NCT01419561|DRUG|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
218904141|NCT01419561|OTHER|Standard Therapies|Standard of Care drugs
218904142|NCT01419561|OTHER|Cohort 1|Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
218904143|NCT06489873|DIETARY_SUPPLEMENT|Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)|Each participant will be assigned to t a LZF supplement daily for six months
218904144|NCT06489873|DIETARY_SUPPLEMENT|Placebo Comparator|Each participant will be assigned to take a placebo supplement daily for six months
218904145|NCT06014762|BIOLOGICAL|P-CD19CD20-ALLO1|Single weight-based IV administration
218904146|NCT06014762|DRUG|Rimiducid|Single weight-based IV administration
218904147|NCT06383403|DRUG|Elafibranor|Round and orange film coated tablet of 80 mg.
218904148|NCT06383403|OTHER|Placebo|Round and orange film coated tablet of placebo
218904149|NCT01174121|DRUG|Pembrolizumab (Keytruda)|"Arm 3 or 5: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment~evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks)."
218904150|NCT01174121|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
218904151|NCT01174121|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
218904152|NCT01174121|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
218904153|NCT01174121|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
218904154|NCT06330064|DRUG|Ifinatamab deruxtecan|Intravenous administration
218904155|NCT03937830|DRUG|durvalumab|1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
218904156|NCT03937830|DRUG|Doxorubicin-Eluting Beads|used for TACE (only in patients with HCC BCLC stage B)
218904157|NCT03937830|PROCEDURE|TACE|TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.
218904158|NCT03937830|DRUG|bevacizumab|7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
218904159|NCT03937830|DRUG|Tremelimumab|300, 150 or 75 mg once on day 1 of cycle 1
218904160|NCT03642197|BEHAVIORAL|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
218904161|NCT04036331|BEHAVIORAL|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
218904162|NCT04036331|BEHAVIORAL|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories\*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories\*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
218904163|NCT04036331|BEHAVIORAL|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
218904164|NCT05322460|OTHER|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
219038656|NCT06446713|RADIATION|Image guided hybrid hyper-fractioned dose escalation with proton therapy|"Radiation: Image-guided hybrid hyper-fractioned dose escalation with proton therapy~The investigational radiation regime will be administered in a two-part schedule:~* The first 4 weeks (i.e. first 20 fractions) of the radiation treatment of the pathological tumor will be according to the conventional clinical standard with proton therapy: 20x 2 Gy to the CTV70 and 20 x 1.55 Gy to the CTV54.~* In week 4 (\~ fraction 16) GTV80 will be determined on conventional weekly CT and additional MR imaging (conventional clinical protocol). Only this adapted tumor volume, the so-called GTV80, will receive the dose escalation (i.e., 80.5 Gy).~* In the last 3 weeks (last 15 fractions) patients will be radiated twice per day (i.e. hyperfractionation). The GTV80, CTV70 and CTV54 will receive 1.55 Gy in the morning, and the GTV80 and CTV70 will receive additional dose in the afternoon."
219520090|NCT02359981|BEHAVIORAL|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
219038657|NCT06550700|PROCEDURE|laparoscopic hybrid surgery (LHS)|First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
219038658|NCT06326424|DEVICE|Empatica EmbracePlus|wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
219520091|NCT02359981|DEVICE|Smartphone|An Android Smartphone with operating system version higher than 2.2
218904165|NCT04604730|PROCEDURE|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
219038659|NCT06239844|OTHER|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
219038660|NCT05370287|OTHER|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
219038661|NCT05370287|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
219038662|NCT05527080|OTHER|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
219038663|NCT05527080|DEVICE|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
219038664|NCT01732523|DIAGNOSTIC_TEST|Contrast enhanced carotid ultrasound|
219038665|NCT06466083|OTHER|no intervention|this is an observation study,no intervention
219520092|NCT05216081|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
219520093|NCT05526950|DEVICE|Device: CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
219520094|NCT01311908|PROCEDURE|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
219520095|NCT02576353|DRUG|Fentanyl|Fentanyl Sublingual Spray (FSS)
219520096|NCT02576353|DRUG|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
218904166|NCT04604730|PROCEDURE|Anastomosis with protective stoma|Anastomosis with protective stoma
218904167|NCT05089370|COMBINATION_PRODUCT|Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab|Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells (MDSCs, Tregs) (1-4), increasing the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit mucosal melanoma patients.
218904168|NCT06392074|DRUG|MB04|Subcutaneous injection
218904169|NCT06392074|DRUG|US License Enbrel|Subcutaneous injection
219038666|NCT04731987|BEHAVIORAL|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
219520097|NCT04172454|BIOLOGICAL|AK104|AK104, 6mg/kg, Q2W
219520098|NCT05525026|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
219520099|NCT05034653|OTHER|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
219520100|NCT05034653|OTHER|Healthy Plate|Quarter-quarter-half meal concept
219520101|NCT00715065|PROCEDURE|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
219520102|NCT02393482|DRUG|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
219520103|NCT02393482|DRUG|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
219520104|NCT02393482|DRUG|Add back therapy 1 (tibolone)|tibolone 5 mg/die
219612813|NCT07013071|DRUG|2% Mepivacaine with 1:55,000 Epinephrine Bitartrate|An alternative formulation of vasoconstrictor-containing local anesthetic evaluated for its safety and analgesic effectiveness in dental extractions.
219612814|NCT03888963|PROCEDURE|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
219612815|NCT03888963|PROCEDURE|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
218904170|NCT06392074|DRUG|EU Source Enbrel|Subcutaneous injection
218904171|NCT03329313|DRUG|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
218904172|NCT03329313|DRUG|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
219038667|NCT01785979|DRUG|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
219038668|NCT01785979|DRUG|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
219038669|NCT04478357|DRUG|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
219038670|NCT04478357|DRUG|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
219038671|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
218904173|NCT06973395|BEHAVIORAL|Nursing interventions, education, and follow-up will be provided to Type 2 diabetes patients for blood glucose variability.|Implementation of individual nursing interventions and provision of trainingIndividual nursing interventions will be applied to individuals with Type 2 diabetes regarding the risk of variability in blood glucose, and education and follow-up will be provided.
219520105|NCT02393482|DRUG|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
219520106|NCT01149629|DRUG|Droxidopa|One capsule containing 300 mg droxidopa, given once
219612816|NCT05117346|DRUG|CARDIX-101A, CARDIX-101B, CARDIX-101C|Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
218904174|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
218904175|NCT06444867|DRUG|LEO 158968|SC injection
218904176|NCT06618118|DRUG|Fosigotifator|Oral Use
218904177|NCT06618118|DRUG|Placebo|Oral Use
219038672|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
219038673|NCT01271088|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
219038674|NCT00196560|DEVICE|Immobilization in External Rotation|
219038675|NCT02357147|DRUG|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
219038676|NCT02357147|DRUG|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
219038677|NCT02357147|DRUG|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
219038678|NCT02357147|DRUG|Cisplatin|Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
218904178|NCT07008586|DIETARY_SUPPLEMENT|OliPhenolia®|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass.
218904179|NCT07008586|DIETARY_SUPPLEMENT|Taste and appearance matched placebo|Equal parts prune juice (Sunsweet California Prune Juice, Yuba City, CA, USA), diet cola (Tesco Cola, Tesco, UK) and tonic water (Tesco low calorie Indian tonic water, Tesco, UK).
218904180|NCT05872295|DRUG|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
218904181|NCT00765440|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Given orally
218904182|NCT00765440|OTHER|placebo|Given orally
218904183|NCT06625411|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
218904184|NCT06625411|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
219038679|NCT01220258|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
219038680|NCT04656067|DRUG|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
219038681|NCT04829487|DRUG|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
219612817|NCT04328090|OTHER|Computer based Antimicrobial stewardship (AMS) intervention system|"1. Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~2. Re-evaluation alerts and decision support for the choice of antimicrobial.~3. Quality control audit and feedback."
218904185|NCT06625060|BIOLOGICAL|IPN10200|Lyophilised powder
218904186|NCT06625060|OTHER|Placebo|Excipients without active substance, Lyophilised powder
218904187|NCT06625060|BIOLOGICAL|IPN10200 dose A|Lyophilised powder
219520107|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
219520108|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
219520109|NCT01845363|DRUG|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
218904188|NCT06625060|BIOLOGICAL|IPN10200 dose B|Lyophilised powder
218904189|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
218904190|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
218904191|NCT07019727|PROCEDURE|ESSKA/ESMA 'ACL Prevention for All' methodology|A workshop led by a trained physiotherapist/strength and conditioning coach and conducted under medical supervision. Based on the ESSKA/ESMA 'ACL Prevention for All' methodology, a total of 12 exercise units lasting 5 minutes each will be included.
218904192|NCT06312644|DRUG|Ultomiris|Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.
218904193|NCT07024745|BEHAVIORAL|Intervention Group|The Intervention is 1) interact with the Us\*Now mHealth app for 1 month; 2) participate in 4 weekly sessions with other group members and led by a Female Facilitator. Each week will cover a different topic - Week 1: Intersectional Stigma, Week 2: Sexual Health, Week 3: HIV Prevention, Week 4: Engagement in PrEP Care.
219038682|NCT04829487|DRUG|Placebo|Placebo capsules
219038683|NCT02925546|DRUG|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
219038684|NCT02925546|DRUG|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
219038685|NCT02925546|DRUG|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
219038686|NCT01179971|DIETARY_SUPPLEMENT|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
219038687|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
219038688|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
219038689|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
219038690|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
219038691|NCT06200532|OTHER|FOOTSAK (FOOTwear self-assessment kit)|FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
219038692|NCT05512507|BEHAVIORAL|Physical Therapy Program|Physical Therapy Program
219038693|NCT03962543|DRUG|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
219520110|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab."
219520111|NCT02321384|DRUG|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
219520112|NCT02321384|DRUG|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
219520113|NCT02321384|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
219520114|NCT02321384|DRUG|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
219612818|NCT07017374|OTHER|Proteomic analysis, targeted temperature management|Biobank serum samples from patients that were included in the TTM trial will be used for proteomic analysis. TTM trial randomised patients to targeted temperature management of 33 °C or 36 °C.
218904194|NCT07024745|BEHAVIORAL|Control (Standard treatment)|The Control group will be asked to interact with the Us\*Now mHealth app for 1 month.
219612819|NCT07018076|DIAGNOSTIC_TEST|RS ratio|We will evaluate the non-culture, sputum-based assay RS ratio, which measures ongoing Mycobacterium tuberculosis activity by quantifying the abundance of precursor rRNA relative to mature rRNA (an indicator of active rRNA synthesis).
218904195|NCT05561634|RADIATION|Radiotherapy|Irradiation of the tumoral bed.
218904196|NCT05561634|OTHER|Observation|Patients will be followed up in consultation every 3 months.
219520115|NCT06000280|PROCEDURE|Trabeculectomy surgery|The Trabeculectomy aims to create a permanent drainage outflow channel for the aqueous humor, connecting the anterior chamber to the sub-Tenon's space, using mitomycin C consisted of opening the conjunctival base of the fornix and applying mitomycin C 0.4 mg/ml for 2 minutes. The trabeculectomy techniques require controlled outflow of aqueous humor through a sclerostomy and a partial-thickness scleral flap to form a subconjunctival bleb. The protected strength of the flap, with or without sutures, and the strength of the episcleral tissue determine the final IOP.
219520116|NCT02472522|DRUG|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
219520117|NCT02472522|OTHER|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
218904197|NCT05561634|DRUG|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
218904198|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1|MP0533 is administered by intravenous infusion
218904199|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A|"* MP0533 is administered by intravenous infusion~* Obinutuzumab pretreatment administered"
218904200|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
218904201|NCT05673057|DRUG|MP0533 with Obinutuzumab pretreatment|"* MP0533 is administered by intravenous infusion at densified dosing schedule~* Obinutuzumab pretreatment administered"
219038694|NCT05627492|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
219520118|NCT02777528|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
219520119|NCT02777528|PROCEDURE|Revascularization Procedure|Revascularization procedure of the great vessel
219520120|NCT05035355|PROCEDURE|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
219520121|NCT01785368|OTHER|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
219520122|NCT01785368|OTHER|Baseline observation|During this period of the study, baseline data will be collected.
218904202|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
218904203|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
218904204|NCT07030972|OTHER|Exercise|Individuals in the control and intervention groups will be included in a routine exercise program. For this exercise program; shoulder joint range of motion exercises, finger ladder, Codman and stick exercises will be given to protect functional range of motion in the early stages and to increase it in the later stages. Isometric exercises will be performed on the scapular muscles in the early stages to preserve muscle strength. In the later stages, rotator cuff, scapula stabilizers and deltoid strengthening exercises will be shown and applied, initially with low-resistance therabants for strengthening. In addition, neuromuscular control exercises and proprioceptive exercises will be included in the treatment to increase joint stabilization and coordination. Exercises will be performed for 6 weeks, 3 days a week, with 10-30 repetitions.
218904205|NCT07030972|OTHER|Deep friction massage|Individuals in the intervention group will receive a deep friction massage to the biceps tendon after the exercise program. The individual will be placed in a long sitting position with their back supported. While the patient's shoulder is next to the body and the elbow is flexed at 90 degrees, the therapist's thumb will be placed on the painful area on the extension of the biceps tendon fibers and a deep friction massage will be applied to the point where the tendonitis occurs in a transverse direction for 3-10 minutes.
218904206|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
218904207|NCT06712784|BEHAVIORAL|Treatment Package (for both simulation and procedure sessions|Treatment Package for both simulation and procedure sessions will include visit priming (contingency specifying stimuli in the form of social stories and YouTube videos) and differential reinforcement of alternative behavior (DRA).
218904208|NCT07037277|DRUG|Bemnifosbuvir-Ruzasvir|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
219520123|NCT05172622|DRUG|JP-2266|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
219520124|NCT05172622|DRUG|JP-2266 Placebo|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
219520125|NCT03359434|DEVICE|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
218904209|NCT07037277|DRUG|Sofosbuvir-Velpatasvir|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
218904210|NCT07122687|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
218904211|NCT07122687|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
218904212|NCT07122687|DRUG|IBI363|1.5 mg/kg D1 IV Q3W
218904213|NCT07122687|DRUG|Carboplatin|AUC 5 mg/ml/min D1 IV Q3W
218904214|NCT07122687|DRUG|Keytruda|200mg D1 IV Q3W
219038695|NCT06917378|PROCEDURE|Percutaneous coronary intervention of coronary chronic total occlusion|Coronary CTO was identified by coronary angiography, and its revascularization was attempted by either antegrade, retrograde or both approach.
219038696|NCT06866548|DRUG|anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)|"Drug: Teprotumumab/IBI311 Given by IV infusion Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks.~Drug: Tislelizumab Given by IV infusion 200 mg every 3 weeks"
219038697|NCT06869837|OTHER|Group EOİPB|Bilateral external oblique intercostal plane block under USG guidance will be applied 45 minutes before cholecystectomy surgery.
219038698|NCT06165861|OTHER|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
218904215|NCT06686446|BEHAVIORAL|Enhanced Education Package|"Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~Education Toolkit - contains links to websites of key organisations including the National Allergy Council (NAC), Allergy \& Anaphylaxis Australia (A\&AA), Australasian Society of Clinical Immunology and Allergy (ASCIA), National Asthma Council Australia (NACA) and AusPollen which include educational videos and other resources."
218904216|NCT07046143|DEVICE|tSCS|The experimental group received noninvasive spinal cord electrical stimulation treatment, requiring patients to take the prone position or sitting position, the anode was placed in the patient's bilateral anterior superior iliac spines, the cathode was placed in the nerve root outlets corresponding to the upper and lower spinal segments of the spinous processes, the stimulation frequency was adjusted to 10,000 Hz, the treatment frequency was 30Hz, the pulse width was 1ms, the waveform was a square wave, and the length of a single session of the treatment was 20min, and the amplitude of current was adjusted to the sensory threshold below the threshold value for 20min twice a day for 2 weeks.The duration of a single treatment was 20 min, and the amplitude of the current was adjusted to below the sensory threshold, each time 20 min, twice a day for 2 weeks of noninvasive spinal cord electrical stimulation.
219038699|NCT04927390|DRUG|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
219612820|NCT07018076|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate blood-based assays measuring host immune response parameters for predicting mycobacterial activity.
219612821|NCT07017491|OTHER|Orange candy melon (Cucumis melo)|Participants will consume a portion of melon A containing 50g of available carbohydrates to evaluate postprandial glycemic response.
218904217|NCT07046078|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
218904218|NCT07046078|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218904219|NCT07046078|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
218904220|NCT07046078|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
218904221|NCT07046078|DRUG|Cytarabine|Given IV
218904222|NCT07046078|PROCEDURE|Echocardiography Test|Undergo ECHO
219038700|NCT06022185|DIAGNOSTIC_TEST|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
219520126|NCT03359434|DEVICE|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
219520127|NCT01421030|PROCEDURE|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
218904223|NCT07046078|DRUG|Fludarabine|Given IV
218904224|NCT07046078|DRUG|Idarubicin|Given IV
218904225|NCT07046078|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218904226|NCT07046078|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
218904227|NCT07046078|OTHER|Questionnaire Administration|Ancillary studies
218904228|NCT07046078|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
218904229|NCT07046078|RADIATION|Total-Body Irradiation|Undergo TBI
219612822|NCT07017491|OTHER|Rock melon ( Cucumis melo var.cantalupensis)|Participants will consume a portion of melon B containing 50g of available carbohydrates to evaluate postprandial glycemic response.
219612823|NCT07017491|OTHER|honey dew (cucumis melo L.)|Participants will consume a portion of melon C containing 50g of available carbohydrates to evaluate postprandial glycemic response.
218904230|NCT07044336|DRUG|Puxitatug Samrotecan|2.4 mg/kg on Day 1 Q3W Route of administration: IV infusion
218904231|NCT07044336|DRUG|Doxorubicin|60 mg/m2 on Day 1 Q3W Route of administration: IV
218904232|NCT07044336|DRUG|Paclitaxel|80 mg/m2 on Days 1, 8, and 15 in 28-day cycles Route of Administration: IV
218904233|NCT07042594|DRUG|RBD1119|Subcutaneously Administered RBD1119 in Healthy Subjects.
218904234|NCT07042594|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subject.
219520128|NCT05941403|BEHAVIORAL|Enhanced Produce Prescription Implementation|Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
218904235|NCT06723795|OTHER|Cardiologist evaluation|The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.
218904236|NCT06723795|OTHER|Pulmonologist evaluation|optimize basic treatment, and recommend continued follow-up as needed.
218904237|NCT07045181|DIAGNOSTIC_TEST|XGBoost machine learning|XGBoost is a powerful machine learning algorithm known for its efficiency and performance. It is an optimized gradient boosting library designed to be highly efficient, flexible, and portable. XGBoost works by combining multiple weak prediction models, typically decision trees, to produce a strong predictive model. It supports various objective functions and evaluation metrics, making it suitable for a wide range of tasks, including classification and regression. XGBoost also includes features like regularization to prevent overfitting and can handle missing data effectively.
218904238|NCT06730061|DRUG|Elafibranor|Tablet of 80 mg
218904239|NCT06926660|DRUG|Vicadrostat|Vicadrostat
218904240|NCT06926660|DRUG|Empagliflozin|Empagliflozin
218904241|NCT06926660|DRUG|Placebo matching vicadrostat|Placebo matching vicadrostat
218904242|NCT06732427|DRUG|fospropofol Disodium for injection|Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)
218904243|NCT06732427|DRUG|Propofol|Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
218904244|NCT01624792|DIETARY_SUPPLEMENT|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
219520129|NCT04916652|RADIATION|MRI|MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).
219520130|NCT05467683|BEHAVIORAL|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
219520131|NCT05193279|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
219520132|NCT03100903|DRUG|BI 655130|single dose
219520133|NCT06834230|DRUG|Dotinurad|Start at 0.5 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (2 mg once daily).
218904245|NCT01624792|DIETARY_SUPPLEMENT|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
218904246|NCT01624792|DIETARY_SUPPLEMENT|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
218904247|NCT07049640|OTHER|Acupressure Group|Effects of Acupressure Interventions
218904248|NCT07049640|OTHER|Cold Application to Acupressure Points Group|Effects of Cold Application to Acupressure Points Interventions
218904249|NCT06732596|OTHER|Embodied conversational agent (ECA)|The app with the ECA will be provided.
218904250|NCT06732596|OTHER|Technical support|Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.
218904251|NCT06732596|OTHER|Additional ECA messages|Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.
218904252|NCT06732596|OTHER|Additional incentives|Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
218904253|NCT03273023|DEVICE|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
218904254|NCT06745284|DRUG|Survodutide|Survodutide
218904255|NCT06745284|DRUG|Semaglutide|Semaglutide
218904256|NCT06880510|DEVICE|t-VNS transcutaneous auricular vagus nerve stimulator|An investigator will clip the the transcutaneous auricular vagus nerve stimulator (taVNS) to the outer ear, and apply electrical current to modulate the activity of the vagus nerve. During this process, the investigator will monitor pupil size and heart rate to determine whether either of these variables is affected by vagus nerve stimulation.
218904257|NCT06727214|DRUG|Chemotherapy with platine|medical records that patients received neoadjuvant systemic chemotherapy platine based
218904258|NCT06727305|DRUG|Sirolimus 0.5 Mg Oral Tablet|Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
219038701|NCT03027869|DEVICE|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
219038702|NCT00003055|DRUG|cisplatin|
219038703|NCT00003055|DRUG|irinotecan hydrochloride|
219038704|NCT06629311|DEVICE|Autotransfusion device|Standard cardiac surgery using I-SEP and SAME™ autotransfusion device
218904259|NCT06727305|DRUG|Sirolimus 1Mg Oral Tablet|Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
218904260|NCT06727305|DRUG|Sirolimus 2 MG Oral Tablet|Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
218904261|NCT06727305|DRUG|Everolimus 0.5 MG Oral Tablet|Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
218904262|NCT06727305|DRUG|Everolimus 1 MG Oral Tablet|Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
218904263|NCT06727305|DRUG|Everolimus 2 MG Oral Tablet|Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
218904264|NCT06785415|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218904265|NCT06785415|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218904266|NCT06785415|PROCEDURE|Bone Scan|Undergo bone scan
218904267|NCT06785415|PROCEDURE|Chest Radiography|Undergo chest x-ray
218904268|NCT06785415|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219038705|NCT03521986|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
219038706|NCT03521986|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
219038707|NCT06696690|DEVICE|MNS|The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
219038708|NCT06696690|DEVICE|Sham stimulation|The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
219038709|NCT06701513|DRUG|Deucravacitinib|As prescribed by treating clinician
219038710|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
219520134|NCT06834230|DRUG|Febuxostat|Start at 10 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (40 mg once daily).
219038711|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
219038712|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
219038713|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
219038714|NCT06703125|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
219038715|NCT04629417|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
219038716|NCT06736808|OTHER|Handout Written at Below a Sixth Grade Reading Level|Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.
219038717|NCT06736808|OTHER|Handout Written at Above a Sixth Grade Reading Level|Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
219038718|NCT06904599|DRUG|Human chorionic gonadotropin (hCG)|2500 IU intramuscular on days 1, 3, and 5 of the protocol. Patients who have at least a partial response by day 7 will receive 3 weekly doses for an additional 4 weeks.
219038719|NCT06904599|DRUG|Prednisone|Oral prednisone 1 mg/kg/day for 14 days
219038720|NCT06904599|DRUG|Dexamethasone|IV dexamethasone 0.15 mg/kg/day for 14 days
219038721|NCT01090726|DEVICE|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
218904269|NCT06785415|BIOLOGICAL|Daratumumab|Given SC
218904270|NCT06785415|DRUG|Dexamethasone|Given PO
218904271|NCT06785415|BIOLOGICAL|Elotuzumab|Given IV
218904272|NCT06785415|DRUG|Iberdomide|Given PO
218904273|NCT06785415|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218904274|NCT06785415|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218904275|NCT04111718|BIOLOGICAL|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
218904276|NCT04111718|BEHAVIORAL|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
218904277|NCT06743347|OTHER|MRI Contrast|Pass a Phase Contrast MRI. No injection required.
219038722|NCT01090726|DEVICE|Airtraq|Airtraq being used for the actual intubation
219520135|NCT04788836|OTHER|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
219038723|NCT04634084|PROCEDURE|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
219038724|NCT04634084|PROCEDURE|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
219038725|NCT00224211|BEHAVIORAL|Music|
219038726|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
219520136|NCT04788836|OTHER|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
218904278|NCT06895057|OTHER|Exercise|Individuals who voluntarily accept to participate in the study will be divided into two groups as telerehabilitation and clinical practice groups by randomization. Exercises will be applied face to face to the clinical practice group and online to the telerehabilitation group via tablet. Individuals who will participate in the study will be applied twice a week for 8 weeks, each session lasting 50 minutes. Pain, quality of life, endurance, functionality, and flexibility assessments will be taken face to face for both groups before and after the application. Treatment satisfaction scale (PGIC) will be taken from both groups in the 4th and 8th weeks. All assessments will be evaluated twice before and after the training by the same therapist in the clinic, face to face.
218904279|NCT07059429|DRUG|Ketamine|Ketamine administered intravenously at 0.15 mg/kg/h via PCA with 1 mg boluses, 5-minute lockout, maximum 500 mg per 24 hours after knee arthroplasty.
218904280|NCT07059429|DRUG|Standard Analgesia|Standard analgesia includes ketoprofen 100 mg twice daily and paracetamol 1000 mg every 8 hours for 24 hours after knee arthroplasty; morphine 10 mg IM as needed for rescue therapy.
219612824|NCT07017127|BEHAVIORAL|Mediterranean diet|Exclusion of highly processed food products and beverages, introduction of a diet according to the modern pyramid of the Mediterranean diet (44). Subjects will be recommended to reduce as much as possible the use of plastic food and drinks containers. The nutritionist will create personalized nutritional recommendation, with a moderate reduction in caloric intake (quantified by calculating the basal metabolism and ideal body mass of each subject, and the whole day's energy consumption). The goal of this part of the intervention is to achieve a weight loss of at least 0.5 kg every week, by reducing caloric intake by 300-500 kcal. The nutritionist will create sample menus throughout the day, for 30 days, to make it easier for subjects to follow this part of the intervention. In addition, each subject of the experimental group will receive a total of six liters of extra virgin olive oil (one liter per month for 6 months).
219038727|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
219520137|NCT04888221|DRUG|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
219520138|NCT04888221|DRUG|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
219520139|NCT00433147|DRUG|Afegostat tartrate|
219038728|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
219038729|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
219038730|NCT00301405|DRUG|Thalidomide|Open label drug
219612825|NCT07017127|BEHAVIORAL|Physical activity intervention|Participants will be involved in aerobic activities expertly guided by kinesiologist (Nordic walking) every day for 45-60 minutes, spent in nature or indoors in case of unfavorable weather. Along with Nordic walking, participants will be involved in organized muscle strength and endurance exercises twice a week for 60 minutes with the use of external loads (elastic bands, small weights), and mobility, balance and coordination will also be developed. All training programs will be conducted by trained kinesiologists who will instruct, monitor and correct participants in order to perform the exercises correctly and get the maximum effect on the targeted motor skills. Nordic walking, resistance exercise, and a combination of aerobic activity and resistance exercise have been shown to be effective in improving cardiometabolic parameters, physical fitness, and quality of life in people with DM2.
219038731|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
218904281|NCT07060963|BEHAVIORAL|Motivational interviews within the context of a health promotion-based diabetes self-management program|The researcher provided counseling services to pregnant women to provide Diabetes Self-Management Group training based on Pender's Health Promotion Model. A group was formed consisting of at least 10 people. The training was completed face-to-face and practically, in 1 day (160 minutes), in 4 sessions, each session being 40 minutes. Motivational interviews were conducted by the researcher within the scope of the health promotion-based diabetes self-management program. A second motivational interview was planned according to the determined need and the interviews were provided. Each interview lasted approximately 40 minutes. In order to ensure continuity for the pregnant women who obtained positive behavioral outcomes, reinforcement was provided by telephone interviews and the counseling process was completed.
218904282|NCT05616338|OTHER|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
218904283|NCT06685718|DRUG|BG-60366|Administered orally
218904284|NCT06750562|BEHAVIORAL|interactive game|Interactive game supported sleep hygiene will be prepared by researchers. The game will be shared after each sleep hygiene training. The intervention is planned as 4 trainings and 4 games in total.
218904285|NCT06570889|DIETARY_SUPPLEMENT|Cholecalciferol D3|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
218904286|NCT06570889|OTHER|Olive oil|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
218904287|NCT02483429|DEVICE|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
218904288|NCT06826105|DRUG|Zenpep|two capsules (each containing 15000 USP units of lipase) together with nutritional supplements
218904289|NCT06826105|DRUG|Placebo|two capsules (containing placebo) together with nutritional supplements
218904290|NCT06896916|DRUG|Etentamig|Intravenous (IV) Infusion
219038732|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
219520140|NCT00517647|DRUG|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
219520141|NCT02821247|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
219520142|NCT00002166|DRUG|Nevirapine|
219520143|NCT01609322|BEHAVIORAL|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
219520144|NCT01609322|BEHAVIORAL|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
219520145|NCT06203522|PROCEDURE|Data collection of successful completion of MRI|age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
219520146|NCT02405325|BEHAVIORAL|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
219612826|NCT07017127|BEHAVIORAL|Psychological intervention|Support group meetings discussing mental health topics and encouraging change through the adoption of healthy lifestyle habits. Psycho-educational component, stimulating group environment for sharing personal experiences, motivation and becoming aware of emotions and resistance. The specific topics of individual group meetings will be: stress and stress management, relaxation techniques (breathing techniques, autogenic training, progressive muscle relaxation techniques and guided fantasies), emotion management (recognition of negative beliefs and thought patterns, awareness and management of emotional reactions), interpersonal skills in the function of self-care (awareness and communication of one's own needs through assertive communication techniques), self-care through the adoption of healthy habits (motivation, adoption of habits and planning), conscious eating and the alike, creating a list of SMART goals (45).
219612827|NCT07017062|OTHER|hybrid ceramic occlusal veneers|occlusal veneers cemented with self adhesive resin cements
218904291|NCT06896916|DRUG|Iberdomide|Oral Capsule
218904292|NCT07058519|DRUG|Osimertinib-based adaptive treatment|Participants in Cohort 1 will receive Osimertinib-based adaptive treatment (either Osimertinib monotherapy or Osimertinib plus chemotherapy) depending on ctDNA EGFRm clearance or relapse by ctDNA EGFRm dynamic monitoring, until radiological disease progression (PD) as per RECIST v1.1 or other withdrawal criteria are met.
218904293|NCT07058519|DRUG|Osimertinib 80 MG|Participants in Cohort 2 will receive Osimertinib 80 mg once daily (QD) plus pemetrexed maintenance every 3 weeks (Q3W) until radiological PD as per RECIST v1.1 or other withdrawal criteria are met.
219520147|NCT04681703|BEHAVIORAL|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
219520148|NCT02493270|BEHAVIORAL|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
219520149|NCT02493270|PROCEDURE|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
219520150|NCT04344847|PROCEDURE|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
219612828|NCT07012083|OTHER|survey|"This cross-sectional survey study will be conducted on a consecutive sample of physicians who treat patients with animal bites potentially requiring post-exposure anti-rabies prophylaxis. The sample will include emergency physicians, general practice or family physicians, and surgeons of both sexes, with varying degrees of experience and post-graduate clinical training.~All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire will include introductory personal, academic, and work experience data about the physicians as gender, age, specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience. Candidates will be asked to reflect on their pre and postgraduate education/training quality and their confidence level in prescribing anti-rabies post-exposure prophylaxis treatment. (as a linear scale)."
218904294|NCT07055451|DRUG|B/F/TAF|Tablet for oral suspension administered
219204490|NCT06761391|DIAGNOSTIC_TEST|Balance Error Scoring|"Balance performance will be assessed using the Balance Error Scoring System (BESS), known in Turkish as DHPS. Subjects must maintain test positions for 20 seconds under 6 conditions with eyes closed and no support: 2 surfaces (flat and foam) and 3 stance positions (double-foot, single-foot, tandem). A laboratory floor will serve as the flat surface, and an exercise mat will serve as the foam surface. All subjects will perform the conditions in this sequence: double-foot flat, single-foot flat, tandem flat, double-foot foam, single-foot foam, tandem foam, both pre-test and post-test. Each 20-second period will be timed with a stopwatch, and each error within this period will count as 1 point. Each test condition has a maximum error score of 10. Errors include:~1. Lifting hands above the iliac crest,~2. Opening eyes,~3. Taking a step,staggering, falling,~4. Flexing or abducting the hip joint beyond 30°,~5. Lifting the forefoot or heel off the ground,~6. Leaving the test position"
219520151|NCT02146261|DRUG|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
219520152|NCT02146261|DRUG|Placebo|Subcutaneous administration of placebo
218904298|NCT06827990|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
218904299|NCT07063498|BEHAVIORAL|Coughing Maneuver|1\. Voluntary Coughing Maneuver (Hileli Öksürük): Patients in this group were instructed to perform a voluntary coughing maneuver immediately prior to the percutaneous biopsy procedure. The maneuver was demonstrated by the clinician, and patients were asked to perform 2-3 forceful coughs while in the biopsy position, 30 seconds before needle insertion, to reduce anxiety and procedural pain perception.
219520153|NCT03399526|DRUG|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
219038733|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
219038734|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
219038735|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
219520154|NCT03399526|DRUG|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
219520155|NCT03399526|DRUG|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
219520156|NCT03399526|DRUG|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
219612829|NCT07017296|OTHER|Placebo|150 mL of water during the breakfast
219612830|NCT07017296|DRUG|Positive control|Normal antihypertensive in 150 ml of water during the breakfast
219612831|NCT07017296|DIETARY_SUPPLEMENT|Active comparator|20 g microencapsulated pomegranate juice in 150 mL water
219612832|NCT07017296|DIETARY_SUPPLEMENT|Control|150 mL fresh pomegranate juice
219612833|NCT07017114|DRUG|Gel PKB171|"Subjects received a single dose of pentoxifylline PKB171 gel or placebo, in a one-dose form with an applicator device that allowed for vaginal administration following the randomisation list:~* First dose level: 2% (100 mg)~* Second dose level: 3% (150 mg)~* Third dose level: 4% (200 mg) The treatment was provided by a member of the investigator's staff and self-administered by volunteers under clinical supervision.~The dose-escalation process enabled to determine MTD or the highest dose that was safe to administer in later studies was determined. The results of this study helped to define the recommended doses to be used in the multiple-dose extension."
219612834|NCT07017114|DRUG|Gel PKB171 placebo|PKB vaginal gel at the MTD or placebo once every 24 hours for two consecutive days
218904300|NCT07063498|BEHAVIORAL|Stress ball|2\. Stress Ball Intervention: Patients were given a standard-sized rubber stress ball to hold and repeatedly squeeze during the entire percutaneous biopsy procedure. The intervention began 1 minute before needle insertion and continued until the procedure was completed. The aim was to provide a behavioral distraction to alleviate anxiety and pain.
219520157|NCT03399526|DRUG|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
219520158|NCT03413631|BEHAVIORAL|Prenatal mentalization intervention|
219520159|NCT03413631|OTHER|Prenatal obstetric treatment as usual|
219520160|NCT04760067|OTHER|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
219520161|NCT02439008|PROCEDURE|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~* Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
219612835|NCT07016958|BEHAVIORAL|Carbohydrate Counting Training|Advanced Carbohydrate Counting Training is a meal planning training where individuals can calculate the amount of carbohydrates in foods based on their portion sizes, and the insulin doses they need to take based on their plasma glucose levels and the amount of carbohydrates they consume.
219520162|NCT02439008|PROCEDURE|Blood samples collection during radiotherapy|"* Sample T1: within 15 minutes after the administration of the first fraction,~* Sample T2: within 15 minutes after the administration of the second fraction,~* Sample T3: within 15 minutes after the administration of the third fraction"
219520163|NCT02439008|PROCEDURE|Blood samples collection after radiotherapy|"* Sample T4: one week after the end of the radiotherapy,~* Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
219520164|NCT02439008|RADIATION|Radiotherapy|
219520165|NCT04638166|OTHER|Mineral water|Drinking mineral water for 12 weeks
219520166|NCT04638166|OTHER|Plain water|Drinking plain water for 12 weeks
219520167|NCT01492361|DRUG|AMR101|Parallel Assignment
219612836|NCT07017855|RADIATION|Stereotactic Arrhythmia Radioablation (STAR)|"Radiotherapy Implementation: During treatment on a TrueBeam™ linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), a planned radiation dose of 25 Gy will be delivered to the defined planning target volume (PTV) using highly conformal stereotactic techniques. Image-guided radiotherapy (IGRT), respiratory gating, and Triggered Tracking will be utilized, targeting the previously delineated defibrillation lead of the implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), with position verification every 15 degrees of gantry rotation.~Patient positioning will be performed using kV-kV imaging, based on pre-determined fiducial markers on the ICD/CRT-D defibrillation lead, followed by verification using gated cone-beam computed tomography (CBCT). Continuous ECG monitoring will be conducted throughout the treatment, and the patient will remain under cardiologist supervision."
219612837|NCT07017855|PROCEDURE|Catheter Ablation|CA will be conducted in an electrophysiology laboratory and will routinely follow diagnostic procedures, including an electrophysiological study (EPS) and three-dimensional electroanatomical mapping (3D-EAM). Once sufficient data on the nature and location of the arrhythmic substrate have been obtained from the three primary mapping modules-voltage, activation, and propagation-spatial 3D-EAM maps will be integrated with a 3D left ventricular reconstruction from multislice computed tomography (MSCT) or cardiac magnetic resonance (CMR). Subsequently, ablation will be performed by delivering energy to predefined target sites identified as the arrhythmia source to close the sVT isthmus or eliminate late potentials (LPs) and/or low-amplitude ventricular activities (LAVAs). Following CA, a repeat induction attempt of sVT using programmed ventricular pacing (VP) will be conducted to verify procedural efficacy.
219612838|NCT07016724|COMBINATION_PRODUCT|cadonilizumab combined with neoadjuvant radiochemotherapy|Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.
219612839|NCT07016724|COMBINATION_PRODUCT|neoadjuvant radiochemotherapy|Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.
219612840|NCT07018505|DIAGNOSTIC_TEST|SERS detection|"Incubation: A mixture of 20 μL (0.5 mg/mL) magnetic beads (MB@RB20115UD), 40 μL SERS nanotags (Au-IR808@RB20115UC), and prepared sample is incubated for 5 min.~Washing: The supernatant is removed after magnetic separation (30 s), followed by washing with PBST (pH 7.4, 0.05% Tween-20).~Detection: The separated pellet is resuspended in 10 μL ultrapure water. Then 2 μL solution is spotted onto a 2.5 mm × 2.5 mm gold substrate for air-drying. Raman spectra are acquired using a portable spectrometer (785 nm laser, 500 mW power, 5 s acquisition time, triplicate measurements). Peak areas within 540-570 cm-1 are quantified."
219612841|NCT07017205|DEVICE|Application of oropharyngeal dye and tracheal aspirate collection|After intubation, 2 mL of blue dye will be applied to the oropharyngeal mucosa. Once hemodynamically stable (MAP \>65 mmHg), the first tracheal aspirate will be collected within 10 minutes by a blinded investigator for analysis.
219612842|NCT07016854|PROCEDURE|Endovascular treatment|Endovascular treatment could be performed with any recanalization strategy, such as thrombectomy with aspiration or stent and angioplasty with balloon dilation or stent implantation, depending on the operator's choice and anatomical and radiological circumstances. In the setting of emergency stenting, the use of antiplatelet agents will depend on operator preference, anatomy, and bleeding risk.
219612843|NCT07016854|DRUG|The best medical treatment|Medical treatment includes intravenous thrombolysis, anticoagulant or antiplatelet drugs, etc. which is determined by the attending physician according to the Chinese guidelines or expert consensus.
219612844|NCT07016945|BEHAVIORAL|Stress and Mindfulness Intervention|Participants will be randomized to either the race-related stress condition or the non-race-related stress condition and the experimental group (7-minute pre-recorded audio file of a guided mindfulness practice) or the control group (7-minute pre-recorded neutral audio file). Thus there are four conditions total (RRS/Control Audio, RRS/Mindfulness Audio, Control Stress/Control Audio, Control Stress/Mindfulness Audio)
219612845|NCT07018479|DIETARY_SUPPLEMENT|FemmeBalance Supplement Group|Participants will take two capsules daily of the FemmeBalance supplement with their evening meal for four menstrual cycles
218904301|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
218904302|NCT05417594|DRUG|AZD9574|Participants will receive AZD9574 orally.
218904303|NCT05417594|DRUG|Temozolomide (TMZ)|Participants will receive temozolomide orally.
218904304|NCT05417594|DRUG|[11C]AZ1419 3391|Participants will receive \[11C\]AZ1419 3391 intravenously.
218904305|NCT05417594|DRUG|Trastuzumab Deruxtecan (T-DXd)|Participants will receive T-DXd intravenously.
218904306|NCT05417594|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Participants will receive Dato-DXd intravenously.
218904307|NCT07065227|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
218904308|NCT07065227|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
218904309|NCT06172478|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
218904310|NCT06935890|OTHER|Jack Jumper Ant Venom Immunotherapy|Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-\<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial.
218904311|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
218904312|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
218904313|NCT07145996|OTHER|AI Based Exercises|This intervention combines structured exercise therapy with artificial intelligence-powered movement analysis using Google MediaPipe Pose technology. Participants perform prescribed exercises (flexibility, core stability, functional strength) while a computer vision system analyzes their movements through standard webcam or smartphone cameras. The AI provides real-time feedback on exercise form, automatically counts repetitions, measures hold times, and flags technique errors. Physiotherapists review AI-generated performance data and provide personalized corrective guidance through scheduled video consultations. The platform delivers 8-week progressive exercise programs specifically designed for chronic non-specific low back pain, integrating objective movement monitoring with human therapeutic oversight to optimize adherence and clinical outcomes.
218904314|NCT07145996|OTHER|Standard Telerehabilitation|This intervention delivers structured exercise therapy through pre-recorded video instructions without AI monitoring or automated feedback. Participants receive the same exercise components as the AI-enhanced group (flexibility, core stability, functional strength) but rely on video demonstrations and written instructions for proper technique. Physiotherapists conduct periodic consultations via video conferencing to monitor progress, provide guidance, and adjust exercise programs based on visual observation and participant self-reports. The 8-week progressive program represents current standard telerehabilitation practice for chronic non-specific low back pain, serving as an active comparator to isolate the specific effects of AI-enhanced movement analysis and real-time feedback systems.
218904315|NCT07147634|BEHAVIORAL|Outdoor science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks in an outdoor setting
218904316|NCT07147634|BEHAVIORAL|Indoor classroom-based science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks inside the classroom
218904317|NCT06954909|BEHAVIORAL|Hydration education and self-assessment|Hydration education is a 25-minute session based on the theory of planned behavior, including the instructions how to use a worksheet for hydration self-assessment and materials.
218904318|NCT06953960|DRUG|ABBV-453|Oral Tablet
218904319|NCT06953960|DRUG|Daratumumab|Subcutaneous (SC) Injection
218904320|NCT06953960|DRUG|Dexamethasone|Oral Tablet
218904321|NCT06953960|DRUG|Pomalidomide|Oral Capsule
218904322|NCT07149376|DEVICE|TOMs of Maine Sensitive SLS Free Xtra Fresh|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for one (1) minute each time.~For investigational use only by the study participant. Not for Sale."
218904323|NCT07149376|DRUG|Colgate Cavity protection toothpaste|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for (2) two minutes each time.~For investigational use only by the study participant."
219520168|NCT01492361|DRUG|Placebo|Parallel Assignment
219520169|NCT01492361|DRUG|Statin therapy|Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
218904326|NCT04172532|PROCEDURE|Biopsy Procedure|Undergo tissue collection
218904327|NCT04172532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218904328|NCT04172532|PROCEDURE|Computed Tomography|Undergo CT
218904329|NCT04172532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218904330|NCT04172532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218904331|NCT04172532|DRUG|Peposertib|Given PO
218904332|NCT04172532|OTHER|Placebo Administration|Given PO
218904333|NCT06092333|DRUG|VIR-2218 and peginterferon alfa-2a|(VIR-2218) administered as a lead-in followed by combination with peginterferon alfa-2a
218904334|NCT07157254|OTHER|No intervention|During the no treatment period participants do not receive any study drug
218904335|NCT07157254|DRUG|GTX-102|antisense oligonucleotide
218904336|NCT07153887|DRUG|Vebreltinib|"Vebreltinib： Oral capsule formulation, specification: 100 mg/capsule. Subjects will start medication after enrollment, 200 mg bid po, until disease progression, intolerable toxicity, or death.~If disease progression is observed in the first evaluation (2 months after the first administration), if the investigator deems it possible to continue benefiting from targeted therapy, targeted therapy combined with best supportive care can be continued until the second evaluation (4 months)."
218904337|NCT07153887|OTHER|Standard medical treatment|standard treatment like chemotherapy, PD1, Anlotinib……
218904338|NCT07160829|OTHER|No treatment given|No treatment given
218904340|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage RSV vaccine uptake.
218904341|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the RSV vaccine to encourage vaccine uptake, but do not receive the counseling intervention
218904342|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage discussion of RSV vaccine uptake among older adults in their social networks
218904343|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the vaccine to encourage discussion of RSV vaccine uptake among older adults in their social networks, but do not receive the counseling intervention
218904344|NCT07170878|DIETARY_SUPPLEMENT|Blueberry Supplementation|The research group (Control Group (CG) (n:12): soccer training group; Supplementation Group (EG) (n:12): group given blueberry supplement in addition to soccer training; Reinforcement+Exercise (SEG) (n:12): the group who was given additional blueberry supplement in soccer training and 20 minutes of resistance band exercise) consisted of 36 male athletes in the football branch and regularly participating.
218904345|NCT07170878|DIETARY_SUPPLEMENT|Supplementation Group|Supplementation + Exercise
218904346|NCT07186049|BEHAVIORAL|Thesis Sessions|Thesis Sessions
218904347|NCT07186049|BEHAVIORAL|General Health Guidelines|General Health Guidelines
218904348|NCT07186049|BEHAVIORAL|Thesis and Exercises|Thesis and Exercises
218904349|NCT07185256|GENETIC|OPGx-BEST1|Experimental Genetic Therapy
218904350|NCT07194837|DEVICE|diode laser|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each.
218904351|NCT07194837|OTHER|Calcium Hydroxide (Ca(OH)2)|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
218904352|NCT07192341|DRUG|Sacubitril/Valsartan|Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].
218904353|NCT07192341|DRUG|Conventional anti-heart failure therapy|Patients will be treated only with conventional anti-heart failure therapy as a control group.
218904354|NCT07193199|DEVICE|Revanesse Sculpt+|Revanesse Sculpt+ is approved and commercially available for use in Canada and is manufactured by Prollenium Technologies Inc. All study participants will receive Revanesse Sculpt+ for the treatment of mild to severe chin retrusion.
218904355|NCT07190339|PROCEDURE|ultrasound-guided femoral and obturator nerve articular branches pulsed radiofrequency|"Hemodynamic monitoring is provided. The hip joint where the procedure will be performed is cleaned with povidone-iodine. Sterile draping is performed. For PRF application to the articular branches of the femoral nerve, a convex ultrasound probe is first used to locate the articular branches of the femoral nerve in the groin area, followed by the articular branches of the obturator nerve. The radiofrequency cannula is inserted sequentially into the target points and sensory feedback is obtained. Then, a pulsed radiofrequency current, which has therapeutic properties for chronic pain and does not damage tissues by exceeding a temperature of 42 degrees, is applied to the relevant nerve root for 240 seconds. Subsequently, an injectate consisting of 2 cc of 5% bupivacaine, 4 mg of dexamethasone, and 2 cc of physiological saline is administered to the same nerve.~Translated with DeepL.com (free version)"
218904356|NCT07193004|BEHAVIORAL|Quality of Life|"Measures - We will use the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to assess QoL, Mini-Montreal Cognitive Assessment (Mini-MoCA) to assess cognitive function, the Clinical Frailty Scale (CFS) to assess frailty status, and life expectancy estimation by the heart team to categorize patients as having: 1-2 years expected survival or more than 2 years expected survival (This will allow for an analysis of how life expectancy correlates with QoL improvements after TAVI).~Assessment Timeline - Patients will be assessed at four key time points: at time of referral (baseline assessment), pre-procedure (to assess impact of delay on the patient), 30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVI (longer-term follow-up to evaluate sustained QoL changes). At each time point, the KCCQ-12, Mini-MoCA, and Clinical Frailty Scale (CFS) will be administered."
218904357|NCT07200141|RADIATION|GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant long course radiotherapy using VMAT or IMAT with daily image guided.~Gross tumor volume (GTV): A total dose of 58.75Gy delivered in 25 fractions using a simultaneous integrated boost approach; CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f ; Lateral lymph node（GTVnd2）：60Gy/25f;"
218904358|NCT07200141|RADIATION|GTV 50 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant radiotherapy with GTV 50 Gy in 25 fractions , delivered with IMRT or VMAT technique.~CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f; Lateral lymph node（GTVnd2）"
218904359|NCT07200141|DRUG|Concurrent Chemotherapy|Concurrent administration of capecitabine (825 mg/m² twice daily, 5 days per week) or XELOX regimen during radiotherapy.
218904360|NCT07200141|PROCEDURE|Total mesorectal excision (TME) surgery or non-operative management|"After treatment, patients will undergo restaging and proceed to total mesorectal excision (TME) or non-operative management (watch-and-wait) depending on response and clinical assessment."
219038736|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
219038737|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
218904361|NCT07200154|DRUG|Adebrelimab with concurrent chemoradiotherapy|Adebrelimab combined with chemotherapy and concurrent radiotherapy, followed by maintenance therapy with Adebrelimab until disease progression or intolerable toxicity, for up to 2 years.
218904362|NCT07199192|DRUG|Corticosteroid|systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge
218904363|NCT07199049|OTHER|Neuro-Mimic Observation Protocol|Observation of eyelid reflex, eye movements, and pupil responses at three standardized intraoperative time points (after induction, during skin incision, and mid-surgery). Parameters will be recorded alongside BIS values without any intervention, device application, or additional risk to patients.
218904364|NCT07199036|DEVICE|TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation)|Per session 20 min, twice daily; 5 days/week; up to 28 days or until successful weaning.
218904365|NCT07199036|DEVICE|abFES (Functional Electrical Stimulation of Abdominal Muscles)|Per session 20 min, twice daily
218904366|NCT07199036|DEVICE|Sham TEDS|Position/time matched; 2 Hz low-intensity sensation only; no visible contraction.
219038738|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
219038739|NCT00794872|OTHER|blood sampling|
219038740|NCT02020668|OTHER|Physiotherapy|
219038741|NCT02020668|OTHER|Wait list control|
219038742|NCT03264404|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
219038743|NCT03264404|DRUG|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
219520170|NCT03460197|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
219520171|NCT00093925|DRUG|clevidipine|
219520172|NCT00093925|DRUG|nicardipine|
219520173|NCT05912322|DIETARY_SUPPLEMENT|Black chokeberry juice|100ml black chokeberry juice/day
219520174|NCT01034319|BEHAVIORAL|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
219038744|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
219520175|NCT01034319|BEHAVIORAL|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
219520176|NCT00125424|DRUG|AQUAVAN® (fospropofol disodium) Injection|
219520177|NCT00125424|DRUG|Midazolam HCl|
219520178|NCT03444038|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219204491|NCT06761391|DIAGNOSTIC_TEST|Cervical Joint Position Sense|The sense of joint position in the cervical region will be evaluated in four positions: flexion, extension, right rotation, and left rotation, using a goniometer. Participants will sit upright with arms at their sides, looking ahead. The physiotherapist will passively move the participant's head to 65% of the maximum joint range of motion, previously determined, minimizing vestibular function effects. After holding the head in position for three seconds, participants will be asked to remember the position. Subsequently, they will be instructed to return their head to the neutral position and then actively move it to the previously determined point. The degree of error between the target and achieved positions will be measured.
218904367|NCT07199036|DEVICE|Sham abFES|Position/time matched; sensation only; no visible contraction.
218904368|NCT07198464|DRUG|Relmacabtagene autoleucel and transplantation|This study enrolled patients with primary central nervous system lymphoma, from whom mononuclear cells and hematopoietic stem cells were collected. Participants receive infusions of hematopoietic stem cells and CAR-T cells, followed by maintenance therapy with orelabrutinib and sintilimab starting on day 15 post-transplantation, for a median duration of up to 6 months and 1 year, respectively.
219520179|NCT02523105|DEVICE|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
219520180|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
219520181|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
219520182|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
219520183|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
219520184|NCT01752257|DRUG|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
219038745|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
219520185|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy|"the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
218904369|NCT07198919|DRUG|Chlorhexidine gel|0.12% Chlorhexidine gel (Consepsis Ultradent)
218904370|NCT07198919|DRUG|Nitrofurantoin 100 MG|Nitrofurantoin Tablets 100mg
218904371|NCT07200011|OTHER|Observational: Serum Vitamin D Levels|Participants' serum vitamin D levels will be measured from existing laboratory records, and radiographic images of mandibular implant overdentures will be analyzed to assess marginal bone loss. No active treatment or experimental intervention will be administered
218904372|NCT07198269|DEVICE|Intelligent emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
218904373|NCT07198269|DEVICE|high-performance emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
218904375|NCT07199153|DEVICE|D Printed Custom Registration Marker for Dynamic Navigation|A patient-specific, 3D printed registration marker designed for use with the Mininavident dynamic navigation system. The marker is fabricated based on CBCT and intraoral scans, enabling accurate registration between virtual planning and clinical implant placement in the esthetic zone. Accuracy of placement is assessed through postoperative CBCT superimposition.
218904376|NCT07199400|BEHAVIORAL|physical activity program|Received eight sessions of technology-assisted exercise courses, covering 26 movements in the shoulders, neck, chest, upper limbs and lower limbs, with demonstrations and real-time feedback on movement performance through high-end monitors
218904377|NCT07200102|DRUG|Selinexor|Selinexor will be provided by Karyopharm Therapeutics, Inc.
218904378|NCT07200024|OTHER|Virtual functional- based treadmill training|rehabilitation technique that combines virtual reality (VR) with treadmill training to improve gait, balance, and functional mobility for individuals with conditions like stroke
218904379|NCT07200024|OTHER|gait training|a specialized form of physical therapy focused on improving a person's walking ability, balance, and coordination after an injury, stroke, neurological condition, or other illness.
218904380|NCT07198061|DEVICE|Cold Atmospheric Plasma (CAP)|CAP-activated gas treatment developed by Xi'an Jiaotong University (Chinese patent No. ZL202110209052.X); administered once daily for 10 days, 25 minutes per session.
218904381|NCT07198061|DEVICE|Sham CAP Therapy|Identical equipment without plasma activation; simulates treatment environment (sound, airflow) for participant blinding.
218904382|NCT07198061|PROCEDURE|Infrapopliteal Endovascular Revascularisation|Balloon angioplasty is performed on infrapopliteal arteries with significant stenosis or occlusion. Technical success is defined as \<30% residual stenosis, confirmed intraoperatively by digital subtraction angiography (DSA). Only patients with successful revascularisation are eligible for randomisation.
218904383|NCT07198061|OTHER|Guideline-Based Standard DFU Care|All participants will receive diabetic foot ulcer (DFU) care according to current international and Chinese clinical guidelines
218904384|NCT07199023|DIETARY_SUPPLEMENT|Amino Acid Formula (AAF)|A formula composed of 100% free amino acids with no intact cow's milk protein. Participants will be fed AAF ad libitum according to their nutritional needs. Daily intake and symptoms will be recorded through an electronic diary (eCOA).
218904385|NCT07199023|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Formula (eHF)|A formula in which cow's milk proteins are broken down into small peptides through enzymatic hydrolysis, reducing allergenicity. Participants will be fed eHF ad libitum based on their nutritional needs. Intake and symptoms will be tracked through an electronic diary (eCOA).
218904386|NCT07199725|COMBINATION_PRODUCT|immediate dental implant|control group: 8 teeth were extracted then 8 immediate implants were placed without bone grafting
218904387|NCT07199725|COMBINATION_PRODUCT|immediate dental implant, natural bovine bone substitute material|study group: 8 teeth were extracted then received 8 immediate implants followed by grafting with natural bovine bone substitute material with hyaluronic acid
219204324|NCT06889376|DRUG|Intranasal midazolam administration via the DART™ intranasal atomization device along with routine comfort care.|"Intervention: Intranasal midazolam (0.2 mg/kg) administered 10 minutes before ROP screening via the DART™ intranasal atomization device.~Comfort Measures:~* 1 ml of 20% glucose solution orally with a pacifier, 5 min before screening.~* Swaddling and placement under the radiant warmer.~Monitoring:~* Vital Signs (heart rate, respiratory rate, blood pressure, oxygen saturation monitoring before drug administration until 2 hours after).~* Pain assessment (PIPP scale) conducted before, during, and 10 and 30 min post-procedure.~* Modified N-PASS to assess the level of sedation conducted before, during, 10, 30 minutes 1 hour and 2 hours post-procedure~Observations for signs of:~* Respiratory Distress (apnoea, desaturation, increased work of breathing)~* Cardiovascular Instability (Bradycardia, tachycardia, hypotension)~* Neurological Symptoms (Lethargy, seizures, abnormal tone)~* Gastrointestinal Issues (Feeding intolerance, NEC-like symptoms)"
219204325|NCT06725433|PROCEDURE|Nissen fundoplication|Hiatal hernia repair and Nissen fundoplication
219204326|NCT06725433|PROCEDURE|Dor fundoplication|Hiatal hernia repair and Dor fundoplication
219038746|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
219038747|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
219038748|NCT05939739|BIOLOGICAL|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
219038749|NCT05939739|OTHER|Consultation for results delivery|at 4 months
219038750|NCT05939739|OTHER|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
219038751|NCT04569123|DEVICE|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
219038752|NCT04569123|DEVICE|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
219038753|NCT05898646|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219038754|NCT05898646|BIOLOGICAL|Daratumumab|Given SC
219038755|NCT05898646|PROCEDURE|Echocardiography Test|Undergo echocardiography
219038756|NCT05898646|OTHER|Questionnaire Administration|Ancillary studies
219038757|NCT05898646|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219038758|NCT05898646|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219038759|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
219038760|NCT05195489|OTHER|Family Connectors|The Family Connectors Program is a manualized program that uses a time-limited parent-to parent (i.e. peer parent) support and education program delivered by phone to families of youth with serious mental health difficulties, assisting family members in becoming fully engaged with provider teams who coordinate and provide care. Family Connectors is delivered weekly by phone over the course of between three and six months.
219038761|NCT04902495|OTHER|MTA Pro Root|pulp therapy
219038762|NCT04902495|OTHER|MTA HP Repair|pulp therapy
219038763|NCT04902495|OTHER|Biodentine|pulp therapy
219038764|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
219038765|NCT02534792|OTHER|Revalvulation|
219038766|NCT00849368|DRUG|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
219038767|NCT04655716|DRUG|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
219038768|NCT02886377|BIOLOGICAL|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
219204327|NCT06704763|DRUG|Orforglipron|Administered orally
219204328|NCT06704763|DRUG|Midazolam|Administered orally
219204329|NCT06704763|DRUG|Quinidine|Administered orally
218904391|NCT07198763|OTHER|Conventional pulmonary rehabilitation|After completing the assessments, participants will be randomly divided into two groups: Group 1, which will perform PR exercises and the Group 2, which will perform PR through dance. Both groups will have the interventions of pulmonary rehabilitation during approximately 50 minutes, for 8 weeks. The group 1 will perform five different exercises with resistance bands, with 3 sets of 1 minute each. Exercises will always begin with the lightest resistance band, and if more than 30 repetitions are observed in 1 minute, the resistance band will be replaced with one of the next highest resistance. The Group 2 will perform rehabilitation through dance using 2 different playlists. The music will be from nationally and internationally known artists. The steps will be based on the exercises performed in group 1 and will be incremented throughout each song and playlist. At the end of 8 weeks of intervention, the evaluative tests will be applied again.
218904392|NCT07198529|DRUG|Short DAPT|Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.
218904393|NCT07198529|DRUG|Standard DAPT|Patients with high bleeding risk will receive aspirin and clopidogrel for 6 months after PCI (unoptimization confirmed in OCT), followed by single antiplatelet therapy thereafter.
219520186|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel|"The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
219520187|NCT01465295|DEVICE|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
219520188|NCT04048148|DEVICE|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
219520189|NCT01220830|DEVICE|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
219612846|NCT07017543|OTHER|Psychotherapy Process-Outcome Study in Group Therapy|A manualized group dynamic psychotherapy conducted at the University Hospital in Kraków, focused on monitoring and enhancing therapeutic alliance and insight development. The intervention targeted patients diagnosed with neurotic and personality disorders. Psychological assessments were conducted at weeks 1, 4, 8, and 12 to track changes in symptoms, resilience, alliance, and insight. The psychotherapy emphasized the interplay between trait-like and state-like components of alliance and insight and their relationship to therapeutic outcomes (symptom reduction and resilience enhancement).
218904394|NCT07198529|DRUG|Extended DAPT|Patients (with stet unoptimazation results in OCT imaging) receive aspirin and clopidogrel for 12 months after PCI.
218904395|NCT07198529|DEVICE|OCT-guided PCI|All patients undergo percutaneous coronary intervention with mandatory intravascular imaging using optical coherence tomography to assess stent optimization (expansion, apposition, dissection).
218904396|NCT07199114|BEHAVIORAL|Adapted CrossFit Program (12 weeks)|Supervised sessions focused on functional, multi-joint movements adapted for older adults; emphasis on safety and progressive overload.
218904397|NCT07200128|DRUG|Ritlecitinib|As provided in real world practice
218904398|NCT07198412|PROCEDURE|Ultrasound-guided spinal anesthesia|Spinal anesthesia performed under real-time ultrasound guidance using a curvilinear ultrasound probe and 25-27G pencil-point spinal needle. Intrathecal injection of bupivacaine 0.5% hyperbaric (12-15 mg) following local infiltration with lidocaine 1% (2-3 mL).
218904399|NCT07198412|DRUG|Midazolam plus ultrasound-guided spinal anesthesia|Patients will receive midazolam (0.02-0.05 mg/kg IV; max 5 mg) 5-10 minutes prior to spinal anesthesia. Ultrasound guidance used for spinal needle placement. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration. Oxygen supplementation at 2 L/min and standard monitoring.
218904400|NCT07198412|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia performed using the traditional landmark palpation technique without ultrasound guidance or sedation. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration, using a 25-27G pencil-point spinal needle.
218904401|NCT07199738|DEVICE|Cemented CoCr|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (CoCr) Femoral component
218904402|NCT07199738|DEVICE|Cemented Oxinium|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (Ox) Femoral component
218904403|NCT07199738|DEVICE|Cementless|Primary TKA performed using the LEGION MS with CONCELOC Tibia with LEGION CR porous (without HA) Femoral component
218904404|NCT07199530|OTHER|Blood Product|blood sample for d dimer
218904405|NCT07199894|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis
218904406|NCT07199894|DRUG|Desmopressin (DDAVP)|ADH analogue in treatment of mono-symptomatic nocturnal enuresis
218904407|NCT07199127|DIAGNOSTIC_TEST|DRACO|A novel endoscopic classification to predict the risk of duodenal and ampullary high-grade dysplasia and cancer from baseline esophagogastroduodenoscopy (EGD)
218904408|NCT07199790|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
218904409|NCT07199790|OTHER|Therapeutic exercise|The therapeutic exercise program aimed at improving balance and preventing falls will be carried out three times per week (Monday, Wednesday, and Friday), with each session lasting 30-45 minutes. Each session will be structured into three blocks: a warm-up of 5-10 minutes, a main block focused on balance and strength lasting 20-25 minutes, and a cool-down of 5-10 minutes.
219038769|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
219038770|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
218904410|NCT07199699|PROCEDURE|Subxiphoid Minimally Invasive Resection of Giant Mediastinal Teratoma Assisted by Double Sternal Elevation|All patients underwent minimally invasive mediastinal tumor resection using a double hook technique via the subxiphoid approach. The procedure was as follows: A 3-4 cm longitudinal incision was made below the xiphoid, and subcutaneous tissue was dissected to reach the anterior rectus sheath. The retroxiphoid space was bluntly dissected, and a thoracoscopic lens was inserted. A double-retractor system was placed in the subxiphoid and suprasternal regions, and retractor height was adjusted to aid in separating tumor adhesions from residual thymic tissue. Blunt dissection was used to separate the tumor from the innominate vein and phrenic nerve. After full tumor mobilization, it was placed into a sterile specimen bag and removed through the incision. The surgical area was rinsed and a mediastinal drainage tube was inserted, and the incision was closed layer by layer.
218904411|NCT07198295|DEVICE|TEAVR with false lumen embolization|The procedure involves two key steps: first, deploying a stent-graft in the true lumen to seal the proximal entry tear; second, selectively catheterizing the false lumen to place 1-3 vascular plugs at critical locations-below the distal end of the stent-graft, at the celiac trunk level, and at the distal re-entry tear in the infrarenal aorta-to occlude distal outflow and induce complete false lumen thrombosis.
219520190|NCT03156764|OTHER|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
219612847|NCT07017309|BEHAVIORAL|Telerehabilitation Protocol for Diastasis Recti|12-week telerehabilitation program combining synchronous (live, supervised by physiotherapists) and asynchronous (video -recorded) therapeutic exercise sessions focused on progressive inner core exercises (i.e. transversus abdominis, pelvic floor muscle retraining), outer core strengthening, and functional retraining.
219612848|NCT07017088|DIETARY_SUPPLEMENT|Leuconostoc mesenteroides|Control vs Experiment
218904412|NCT07199101|RADIATION|Low dose CT|Participants will undergo a low dose CT adopting the pediatric low-dose CT protocol established based on low dose simulation technique.
218904413|NCT07197931|PROCEDURE|Additional extra-pulmonary vein trigger ablation group|"1. Circumferential PVI is performed in all patients.~2. After PVI, isoproterenol is infused starting at 5 μg/min, increased every 3-5 min to 10 and 20 μg/min (max 30 μg/min) to reach 85% of predicted heart rate for ≥10 min.~   2-1) If AF persists, internal cardioversion (5-30 J) is performed using catheters in the right atrium and coronary sinus.~   2-2) If sinus rhythm is present, a 15-beat drive train (10 mA, 2 ms) is delivered at 250 ms, shortened by 10 ms to 180 ms or until capture fails, up to three times, to induce AF or AT. Isoproterenol continues for 2 min. If arrhythmia occurs, cardioversion is repeated.~3. After cardioversion, isoproterenol is stopped and the patient is observed for 10 min.~4. Sustained or reproducible arrhythmias are defined as non-PV triggers.~5. These are localized with activation mapping, P-wave analysis, and high-density mapping.~6. Ablation is performed with the same catheter.~7. Reassessment is done with the same protocol."
218904414|NCT07197931|PROCEDURE|Empirical pulmonary vein isolation group|"1. Circumferential pulmonary vein isolation (PVI) is performed in all patients.~2. After PVI, a waiting period of at least 20 minutes is observed, followed by reassessment of pulmonary vein isolation before concluding the procedure.~3. Additional linear ablation or CFAE ablation not specified in the study protocol should be avoided whenever possible.~4. In cases where typical atrial flutter has been documented prior to the procedure or is induced during the procedure, cavo-tricuspid isthmus (CTI) ablation is performed. At the operator's discretion, CTI ablation may also be permitted even in patients without a prior history or inducibility.~5. If atypical atrial flutter involving these pathways is induced during the procedure, additional linear ablation (e.g., roof line, posterior-inferior line, left lateral isthmus, or anterior line) may be performed."
218904415|NCT07198737|DEVICE|VR and VNS|Participants will have Vagus nerve stimulation at the same time as a relaxing VR experience
218904416|NCT07198776|PROCEDURE|Percutaneous Vertebroplasty|Injection of PMMA cement into fractured vertebra under fluoroscopic guidance.
219038771|NCT06183684|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
219038772|NCT06284096|BEHAVIORAL|Psychoeducation|The study is planned to consist of 7 sessions, occurring once a week, with approximately 60-70 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
219038773|NCT04167774|DRUG|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
219038774|NCT04167774|DRUG|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
219038775|NCT06132607|DEVICE|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
219038776|NCT05572619|DEVICE|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
219038777|NCT05572619|DEVICE|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
219038778|NCT01427088|DEVICE|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
219520191|NCT05353764|OTHER|scalp nerve block combined with intercostal nerve block using 0.5% ropivacaine|Participants randomized to the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine, which was performed exclusively by an attending anesthesiologist.An attending anesthesiologist will select the site of SNB based on the surgical incision site. Scalp nerve was blocked including greater occipital nerve (2-3ml), superficial temporal nerve (2-3ml), trochlear nerve (2-3ml) and supraorbital nerve (2-3ml). The total volume in scalp nerve block will not exceed 10 ml.Ultrasound-guided unilateral ICNB will be performed at the level of T4-T5 next to the sternum.10-15ml of 0.5% ropivacaine will be injected into the intercostal spaces where incision locates after negative aspiration.
219520192|NCT02015000|PROCEDURE|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
219520193|NCT02171052|DRUG|Dabigatran etexilate|
218904417|NCT07198438|DEVICE|Deep Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a double-cone coil (90BFVT-LQC) to target the anterior cingulate cortex (ACC). The resting motor threshold (rMT) is determined from the tibialis anterior muscle. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
218904418|NCT07198438|DEVICE|Standard Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a planar coil (70BF-LQC) to target the left dorsolateral prefrontal cortex (DLPFC). The resting motor threshold (rMT) is determined from the abductor pollicis brevis muscle. The DLPFC is localized 5.5 cm anterior to the motor hotspot. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
218904419|NCT07200050|OTHER|Home-based Exercise Program|Participants follow a 12-week home-based exercise program including aerobic, strengthening, and flexibility exercises. Assessments are done at baseline and after 12 weeks.
218904420|NCT07198048|BEHAVIORAL|Music-Based Therapy for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to randomized selections from the playlist that meets their needs that day (i.e., energizing or relaxing). Participants will listen to their music selections on shuffle for 30 minutes per day for 8 weeks using the strategies provided by the music therapist. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after music listening. The music therapist will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the music therapist will update the music playlists and help submit their logs.
219520194|NCT02171052|DRUG|Digoxin|
219520195|NCT01220206|DRUG|Placebo|2 placebo capsules daily
219520196|NCT01220206|DRUG|One POMx capsule daily|One POMx capsule, one placebo capsule daily
219520197|NCT01220206|DRUG|2 POMx Capsules|2 POMx Capsules daily
219520198|NCT03919942|OTHER|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
219520199|NCT03919942|OTHER|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
219520200|NCT03919942|OTHER|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
219520201|NCT00728949|BIOLOGICAL|IMC-A12 (cixutumumab)|10 mg/kg I.V.
218904421|NCT07198048|BEHAVIORAL|Audiobook Intervention for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to an audiobook selected with a speech-language pathologist (SLP). Participants will listen to their audiobook for 30 minutes per day for 8 weeks using the strategies provided by the SLP. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after audiobook listening. The SLP will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the SLP will update the audiobook library and help submit their logs.
218904422|NCT07199998|OTHER|Samples collection (whole blood, urine, vaginal and cervical cells)|During the clinical visit, samples will be collected from participants, including blood, urine, and vaginal and cervical cells. These samples will be used for a range of analyses, including determination of the vaginal microbiota composition and sequencing, cytokine profiling, and assessment of local immunity through flow cytometry using CyTOF technology. Urine samples will be analyzed for pollutants such as phthalates and bisphenol, while blood samples will be used for blood cell counts.
219204330|NCT06728241|BEHAVIORAL|RecoVRy|A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
219204331|NCT06728241|BEHAVIORAL|VR Games|Patients randomized to this condition will receive a total of ten sessions of VR games.
219520202|NCT00728949|DRUG|tamoxifen|Daily 20 mg, oral
219520203|NCT00728949|DRUG|Anastrozole|Daily 1 mg, oral
219520204|NCT00728949|DRUG|Letrozole|Daily 2.5 mg, oral
219520205|NCT00728949|DRUG|Exemestane|Daily 25 mg, oral
219520206|NCT00728949|DRUG|Fulvestrant|Monthly 250 mg, intramuscularly
219520207|NCT05527756|OTHER|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
219520208|NCT05527756|OTHER|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
218904424|NCT07198880|DEVICE|BiPAP device (non invasive ventilation)|"BiPAP initiated 2-4 weeks post-discharge; IPAP 16 cmH₂O (titrate), EPAP 4 cmH₂O; supplemental O₂ as needed monitor SpO₂, ABG, vitals; target ≥20% PaCO₂ reduction, improved pH, reduced work of breathing; adherence ≥4 hrs/nigh~Scheduled monitoring of SpO₂, symptoms, and adherence; outpatient follow-up at 2-4 weeks and after 1, 3, 6 ,12 month intervals"
218904425|NCT07198880|DRUG|Optimal Medical Management ( long acting beta agonist , long acting muscarinic antagonist and inhaled corticosteroids)|Patients will continue on standard COPD management: inhaled bronchodilators, inhaled corticosteroids, LTOT when required, but without NIV
218904426|NCT07198594|OTHER|rTMS|individualized rTMS target the IFC with symptom provocation
218904427|NCT07200063|OTHER|nano silver mouthwash|nano silver mouthwash will reduce the side effect of chlorhexidine and increase acceptance of the mouthwash to patients
218904428|NCT07200063|OTHER|Chlorhexidine mouthwash (0.12%)|the concentration of chlorhexidine
219520209|NCT01346085|DRUG|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
218904429|NCT07200063|OTHER|Chlorhexidine mouthwash (0.2%)|chlorhexidine mouthwash 0.2% (orovex )
219520210|NCT03658837|PROCEDURE|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
218904437|NCT03992053|OTHER|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
219520211|NCT01550588|DEVICE|Device closure|PFO Amplatzer device closure
218904438|NCT03608319|DRUG|A4250|9.6 mg
218904439|NCT05471544|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
218904440|NCT05471544|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
218904441|NCT05188586|OTHER|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
218904442|NCT01874197|DEVICE|B-TEVAR device|Implantation of the Branched Thorcoabdominal aortic anerysm device
218904443|NCT02982902|BIOLOGICAL|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
218904444|NCT03121508|BEHAVIORAL|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
218904445|NCT01962441|DRUG|SOF|400 mg tablet administered orally once daily
218904446|NCT01962441|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218904447|NCT01962441|DRUG|Peg-IFN|180 µg administered via subcutaneous injection once weekly
218904448|NCT02055898|DRUG|Sodium Oxybate|
218904449|NCT02055898|OTHER|placebo (fresh potable water)|
218904450|NCT03802578|BEHAVIORAL|HAND EXERCISE|
218904451|NCT05072392|DEVICE|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
218904452|NCT00103168|DRUG|imatinib mesylate|400 mg/day for 2 years
218904453|NCT01441843|DRUG|Lorazepam|Once 1mg \<75kg body weight, 1.5mg 75kg and \>75kg body weight, IV, before surgery
218904454|NCT01441843|DRUG|NaCl 0.9% (Sodium Chloride)|Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
218904455|NCT01500772|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
219520212|NCT01550588|DRUG|Standard medical treatment|Standard Medical management using anti-coagulant therapy
219520213|NCT02695732|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
219520214|NCT02695732|DEVICE|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
219520215|NCT01513083|DRUG|trastuzumab emtansine|Multiple intravenous doses
219520216|NCT06234670|OTHER|No intervertion|This study is a retrospective observational study without intervention.
219520217|NCT01624376|DRUG|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
218904456|NCT01500772|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
218904457|NCT01500772|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
218904458|NCT02040649|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
218904459|NCT02040649|OTHER|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
218904460|NCT06468098|DRUG|IBI363 + chemotherapy|In this group, patients will receive IBI363 and chemotherapy
218904461|NCT06468098|DRUG|IBI363 + Investigator's Choice SOC|In this group, patients will receive IBI363 and Investigator's Choice SOC
218904462|NCT00466232|DRUG|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
218904463|NCT00466232|DRUG|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
218904464|NCT02338635|DRUG|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
218904465|NCT04926649|PROCEDURE|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
218904466|NCT02432326|DRUG|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
218904467|NCT02432326|DRUG|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
219038779|NCT03093675|DEVICE|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
219520218|NCT01624376|DRUG|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
219520219|NCT06526962|DEVICE|5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser|Outpatient hysteroscopic polypectomy
218904468|NCT04688658|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
218904469|NCT04688658|DRUG|Duvelisib|Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
218904470|NCT01028105|OTHER|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
218904471|NCT00956735|OTHER|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
218904472|NCT00743002|DRUG|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
218904473|NCT00743002|DRUG|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
218904474|NCT04522453|OTHER|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
218904475|NCT04522453|OTHER|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
218904476|NCT00367575|PROCEDURE|Internet personalized alcohol feedback (PAF)|
218904477|NCT05976516|DIAGNOSTIC_TEST|CXCL2/CXCL8|Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
219038780|NCT04780386|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
219038781|NCT04780386|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
219038782|NCT01041716|OTHER|None - Observational study|None - Observational study
219520220|NCT00263965|DRUG|Tesaglitazar|
219520221|NCT00263965|DRUG|Metformin|
219520222|NCT00263965|BEHAVIORAL|Dietary and lifestyle modification counseling|
219520223|NCT05886426|DIAGNOSTIC_TEST|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
219520224|NCT02084004|DRUG|Bifidobacterium viable pharmaceutics|
219520225|NCT02084004|DRUG|Berberine Hydrochloride|
219520226|NCT00543309|DRUG|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
219520227|NCT00543309|DRUG|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
219520228|NCT00543309|DRUG|placebo|Placebo bolus on CPB, then placebo infusion
219520229|NCT01524653|DRUG|Rosuvastatin|20 mg po od
219520230|NCT01524653|DRUG|Placebo|20 mg po od
219520231|NCT04541719|DRUG|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
219520232|NCT04541719|DRUG|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
219520233|NCT01249664|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
219520234|NCT01249664|PROCEDURE|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
219520235|NCT06437431|DRUG|glenzocimab|Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.
219520236|NCT06437431|DRUG|placebo|Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
219520237|NCT00349947|BEHAVIORAL|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
218904478|NCT03153774|DIAGNOSTIC_TEST|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
218904479|NCT00354016|BIOLOGICAL|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
218904480|NCT02787928|DRUG|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
218904481|NCT03573414|OTHER|raspberry powder, milled flaxseed and soy milk|"* The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples"
218904482|NCT05308875|BIOLOGICAL|PD1-BCMA-CART|Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
218904483|NCT05650008|DRUG|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
218904484|NCT02190136|OTHER|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
218904485|NCT02190136|OTHER|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
218904486|NCT02190136|OTHER|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
218904487|NCT02053012|DEVICE|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
218904488|NCT01615250|BIOLOGICAL|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
218904489|NCT02928068|BEHAVIORAL|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
219038783|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
218904490|NCT02780843|OTHER|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
218904491|NCT02780843|OTHER|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
218904492|NCT05225038|OTHER|Exercise|Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.
218904493|NCT05225038|DIETARY_SUPPLEMENT|Nutritional|Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.
218904494|NCT05225038|BEHAVIORAL|Behavioral Medicine|"Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support."
218904495|NCT05225038|BEHAVIORAL|Smoking Cessation|Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
218904496|NCT05961267|BEHAVIORAL|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
218904497|NCT05256680|OTHER|Gardening Activities|"In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home."
218904498|NCT06094920|DRUG|Empagliflozin 10 MG|Oral administration
219038784|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
219038785|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
218904499|NCT06094920|DRUG|Finerenone|"Oral administration.~Finerenone treatment may be initiated if serum potassium levels are ≤5.0 mmol/L. Conversely, if serum potassium levels are \>5.0 mmol/L, the initiation of finerenone treatment should be avoided. In such cases, a second serum potassium measurement will be performed two days later. If serum potassium levels are ≤5.0 mmol/L, these patients can still be considered for inclusion. However, if serum potassium levels are \>5.0 mmol/L again, these patients will be excluded, and an assessment of the underlying cause(s) of hyperkalaemia will be conducted.~The recommended initial dose of finerenone is determined based on eGFR, which will be assessed prior to the commencement of the trial. If eGFR is ≥60 mL/min/1.73m2, the dose will be set at 20 mg once daily. If eGFR is ≥25 to \<60, the dose will be set at 10 mg once daily. Participants with an eGFR \<25 are not advised to undergo finerenone treatment and will be excluded from the study."
218904500|NCT06094920|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 40 days. Three consecutive measurements are taken."
218904501|NCT06094920|DEVICE|Withings Body|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 49 days."
218904502|NCT06094920|DIAGNOSTIC_TEST|PeeSpot Urine Collection Device|Biochemical urine data will be collected using first-morning void urine samples. Participants will obtain urine samples with the PeeSpot device, a validated tool designed for the collection and preservation of small urine volumes. This device comprises a urine absorption pad, a holder, a tube, and a lid. Patients can void directly onto the absorption pad while it is placed in the holder. Following voiding, the pad and holder are inserted into the tube, sealed with the lid, and stored in a refrigerator until they are sent to the laboratory using a biological materials envelope (PolyMed, DaklaPack, Europe). Through the incorporation of an inert hygroscopic polymer, the pad efficiently absorbs 1.2 mL of urine, and with the addition of various preservatives, the urine remains stable for up to four days. The investigators will employ the PeeSpot to determine the first-morning void levels of albumin, creatinine, sodium, potassium, glucose, urea, and osmolality once daily on 28 days.
218904503|NCT06094920|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 17 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, potassium, hsCRP, haematocrit, cystatin C, and fasting plasma glucose.
218904504|NCT06094920|BEHAVIORAL|Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies|Participant perspectives regarding the feasibility of participating in a home-based trial will be evaluated using a digital questionnaire. This questionnaire includes inquiries adapted from the validated Telehealth Usability Questionnaire, supplemented with additional questions employed in prior studies that assessed the feasibility of decentralized clinical trials. The web application Research Electronic Data Capture 10.0.23 (REDCap - www.projectredcap.org) will facilitate the administration of these digital questionnaires. Participants will receive a link to access the digital questionnaires via email. Weekly telephone calls will be conducted to evaluate adherence to study procedures and monitor the occurrence of adverse events.
218904505|NCT00483613|BEHAVIORAL|Cognitive-behavioral therapy of Meichenbaum|
218904506|NCT03688815|DIAGNOSTIC_TEST|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
218904507|NCT02181465|BIOLOGICAL|G17DT|
218904508|NCT03654794|BIOLOGICAL|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
219038786|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
219038787|NCT00963573|DRUG|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
219038788|NCT00963573|DRUG|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
219038789|NCT00222456|BEHAVIORAL|Sensitizing parents|
219038790|NCT00072150|DRUG|bortezomib|Given IV
219038791|NCT04441333|DEVICE|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
219038792|NCT03227887|OTHER|Two samples of saliva|"1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
219038793|NCT03227887|OTHER|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
219038794|NCT03227887|OTHER|Study of the food bolus|"2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually"
218904509|NCT00088530|DRUG|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
218904510|NCT00088530|DRUG|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
218904511|NCT04864249|DEVICE|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
218904512|NCT04864249|OTHER|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
219038795|NCT03227887|OTHER|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
219520238|NCT02148302|DEVICE|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
219520239|NCT03281109|DIAGNOSTIC_TEST|diagnosis|diagnosis with ELISA
219520240|NCT03937453|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
219520241|NCT02947009|BEHAVIORAL|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
219520242|NCT04107870|BEHAVIORAL|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
219520243|NCT04107870|BEHAVIORAL|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
219520244|NCT03582332|DRUG|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
218904513|NCT02928575|DRUG|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
218904514|NCT02928575|DRUG|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
218904515|NCT02928575|RADIATION|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
218904516|NCT02911974|DEVICE|Acquire EUS Biopsy Device|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
218904517|NCT02911974|DEVICE|Expect EUS Aspiration Needle|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
219038796|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
219038797|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
219520245|NCT03582332|DRUG|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
219520246|NCT03582332|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
219038798|NCT01454726|OTHER|drug|the Western medical treatment alone.
219612849|NCT07017257|DEVICE|Active taVNS|Patients will receive active taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will range from 1 to 3 mA, adjusted to the patient's pain threshold, with a pulse width of 250 μsec and a frequency of 25Hz.
218904518|NCT03649074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
218904519|NCT01943812|DRUG|Estradiol and progeterone|Estradiol and progesterone
218904520|NCT03292380|OTHER|No intervention was included|
219204332|NCT06729437|OTHER|tDCS + Therapeutic eccentric exercise|A direct current of 1.5 mA will be applied for 20 minutes to the primary motor cortex (M1) during each session of eccentric exercises.
219204333|NCT06729437|OTHER|Sham tDCS + Therapeutic eccentric exercise|The current will be interrupted after 30 seconds.
219520247|NCT03582332|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
219520248|NCT01737671|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
219520249|NCT01737671|DRUG|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
219520250|NCT01737671|DRUG|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
219520251|NCT03107468|OTHER|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
218904521|NCT00775099|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
218904522|NCT00775099|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
218904523|NCT05864417|OTHER|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
218904524|NCT05864417|OTHER|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
218904525|NCT00556894|DRUG|CF101|orally q12h
219038799|NCT01784783|BEHAVIORAL|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
219038800|NCT01784783|BEHAVIORAL|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
219038801|NCT05022758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
219038802|NCT05022758|DRUG|Warfarin|One of OAC (Oral anticoagulation therapy)
219038803|NCT01661712|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
219520252|NCT03107468|OTHER|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
219520253|NCT02116049|BEHAVIORAL|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
219612850|NCT07017257|DEVICE|Sham taVNS|Patients will receive sham taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will be fixed at 100 µA, with a pulse width of 250 μsec and a frequency of 25 Hz.
219612851|NCT07017530|OTHER|Cognitive training|Combined Intervention of Cognitive Training and Supervised Physical Exercise
219038804|NCT01661712|DEVICE|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
219038805|NCT04763499|OTHER|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
219038806|NCT00189046|BEHAVIORAL|driving and laboratory tests|
219038807|NCT00283439|BIOLOGICAL|AMG 531|"Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose"
218904526|NCT00556894|DRUG|Placebo|orally q12h
218904527|NCT02331186|PROCEDURE|bariatric surgery|bariatric surgery for obese women
218904528|NCT01189474|DEVICE|Blephasteam|Eye lid warming goggles
218904529|NCT06070792|OTHER|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
218904530|NCT06070792|OTHER|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
218904531|NCT05092672|BEHAVIORAL|Exercise|Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
218904532|NCT00361881|DRUG|ME-609|Cream, dose 5 times daily during 5 days.
218904533|NCT00361881|DRUG|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
218904534|NCT00361881|DRUG|Vehicle|Dose 5 times daily for 5 days
218904535|NCT02341352|DRUG|fluoride varnish|Sodium fluoride 50mg/ml
218904536|NCT02341352|BIOLOGICAL|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
218904537|NCT02341352|DIETARY_SUPPLEMENT|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
218904538|NCT01603303|BEHAVIORAL|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
219038808|NCT02042924|RADIATION|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
219612852|NCT07017530|OTHER|Psychoeducational therapy|According to standard clinical practice
219520254|NCT02116049|BEHAVIORAL|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
219520255|NCT01272752|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
219520256|NCT01272752|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
219520257|NCT00637390|DRUG|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
219520258|NCT00369590|BIOLOGICAL|ziv-aflibercept|Given IV
219612853|NCT07018011|PROCEDURE|Conventional open CTR|Conventional open CTR involved making a longitudinal incision in the wrist, typically along the median palmar crease, to access and release the transverse carpal ligament.
219612854|NCT07018011|PROCEDURE|Transverse mini-incision technique|Mini-incision CTR involved a smaller incision than traditional CTR procedures, aiming to minimize scarring and improve recovery time.
218904539|NCT01603303|OTHER|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
218904540|NCT01603303|OTHER|Luvena|Use vaginally 2 or 3 times a week.
218904541|NCT01603303|OTHER|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
218904542|NCT01603303|OTHER|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
218904543|NCT01603303|BEHAVIORAL|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
218904544|NCT01603303|BEHAVIORAL|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
218904545|NCT00569140|DRUG|E10030|Intravitreal injection
218904546|NCT03477045|DIETARY_SUPPLEMENT|Single dose fish oil|Fish oil consumed within a single high fat test meal
219038809|NCT02042924|DEVICE|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
219038810|NCT02183441|DRUG|BI 1356|
219038811|NCT02183441|DRUG|Ritonavir|
219038812|NCT06096415|DRUG|ABX-101 1mg|ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
219520259|NCT00369590|OTHER|pharmacological study|correlative studies
219520260|NCT00369590|OTHER|laboratory biomarker analysis|correlative studies
219520261|NCT00460304|DRUG|pramlintide|
219520262|NCT00460304|PROCEDURE|continuous glucose monitoring|
219520263|NCT03409601|OTHER|100% Portion Size|Meal portion size at baseline
219520264|NCT03409601|OTHER|125% Portion Size|Meal portion size 125% of baseline
219612855|NCT07017452|DRUG|Methoxyflurane - Penthrox|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
219612856|NCT07017452|OTHER|Control|This intervention will be the control group only, receiving deep IV sedation.
219612857|NCT07017452|DRUG|Percocet Pill|Percocet will be given in conjunction with methoxyfluorane and lorazepam
218904547|NCT03477045|DIETARY_SUPPLEMENT|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
218904548|NCT03477045|DIETARY_SUPPLEMENT|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
218904549|NCT03477045|DIETARY_SUPPLEMENT|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
218904550|NCT02537717|DEVICE|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
218904551|NCT02537717|DEVICE|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
218904552|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|"For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis."
218904553|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers|For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
218904554|NCT05675046|DEVICE|Carpal Tunnel Release with Ultrasound Guidance using the UltraGuideCTR device|Participants who were treated with the Carpal Tunnel Release with Ultrasound Guidance procedure using the UltraGuideCTR device in the ROBUST Study.
218904555|NCT03133247|DRUG|SHR-1316|PD-L1
218904556|NCT01014130|RADIATION|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
219038813|NCT06096415|DRUG|ABX-101 2mg|ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
219520265|NCT03409601|OTHER|150% Portion Size|Meal portion size 150% of baseline
219612858|NCT07017452|DRUG|Lorazepam (drug)|Lorazepam will be given in conjunction with penthrox and percocet.
219612859|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
219612860|NCT04861623|OTHER|Placebo juice (SunnyD)|SunnyD beverage will be purchased commercially.
219038814|NCT05498558|OTHER|No intervention.|No intervention.
219038815|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
219038816|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
219038817|NCT03702478|OTHER|Questionnaire|No intervention only observational
219038818|NCT03038464|DIAGNOSTIC_TEST|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
219038819|NCT04858958|DRUG|Furmonertinib 160mg|randomized to 160mg QD
219038820|NCT04858958|DRUG|Furmonertinib 240mg|randomized to 240mg QD
219038821|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
219612861|NCT06153199|BEHAVIORAL|Self-management videos|Short video modules on self-management of back pain without medication and ergonomic adjustments for limiting back pain in nursery and landscape work
219612862|NCT06153199|BEHAVIORAL|Check lists for ergonomic options|Guidance on ergonomic choices appropriate for work tasks not currently being used that are the most difficult due to back pain, using a checklist
218904557|NCT01014130|RADIATION|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
218904558|NCT00005617|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
219038822|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
219038823|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
219204334|NCT06818903|DRUG|Misopristol|Foley catheter with Misopristol local application
219520266|NCT03409601|OTHER|175% Portion Size|Meal portion size 175% of baseline
219520267|NCT02220868|DRUG|Sofosbuvir, Ribavirin, and Stribild|
219038824|NCT01457495|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
219038825|NCT01457495|BIOLOGICAL|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
219038826|NCT01457495|BIOLOGICAL|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
219038827|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
219038828|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
219038829|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
219038830|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
219038831|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
219038832|NCT01034410|DRUG|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
219038833|NCT01034410|DRUG|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
219038834|NCT02825069|OTHER|Early introduction of solid foods|Early introduction of solid foods
219038835|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
219038836|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
219038837|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
219204335|NCT06818903|DEVICE|Foley catheter|Foley catheter alone
219204336|NCT06735079|DRUG|REL1017 (esmethadone HCI) (active drug)|REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.
219520268|NCT05198050|DRUG|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
219520269|NCT05198050|DRUG|Misoprostol Tabets|a synthetic prostaglandin medication
219520270|NCT05198050|DRUG|Placebo tablets|Placebo tables with a similar appearance to letrozole
219520271|NCT01828996|DEVICE|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
219520272|NCT01828996|DEVICE|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
219612863|NCT06153199|BEHAVIORAL|Text reminders|Reminders to implement choices using graphics and gifs as well as motivational messages
218904559|NCT00005617|PROCEDURE|leukapheresis|Patients require a single leukapheresis to obtain 2x10\^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
218904560|NCT03159390|OTHER|phenylacetate salt of ornithine|
218904561|NCT05195567|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
218904562|NCT05195567|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
218904563|NCT00064363|DRUG|talampanel|
218904564|NCT00251459|DRUG|rhuFab V2 (ranibizumab)|
218904565|NCT03584334|RADIATION|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
218904566|NCT03293667|OTHER|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
218904567|NCT05692596|OTHER|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
218904568|NCT06319807|BEHAVIORAL|Digital Health Intervention|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
218904569|NCT06319807|BEHAVIORAL|Safety Control|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
218904570|NCT03388606|BEHAVIORAL|Growth Mindset|30 Minute interactive video
218904571|NCT02867462|OTHER|Standard care|standard care
218904572|NCT02867462|OTHER|manipulator consultation radiotherapy added to standard care|
218904573|NCT05552469|DRUG|DFV890|DFV890 Single Agent
219520273|NCT03542422|DRUG|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
219520274|NCT04132856|OTHER|Psychosocial Navigator|Services of psychosocial navigator
219520275|NCT04132856|OTHER|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
219520276|NCT04500509|DRUG|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
219520277|NCT04500509|DRUG|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
219520278|NCT04744909|DEVICE|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
219520279|NCT00023309|DRUG|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
219520280|NCT00023309|DRUG|Adefovir alone|Adefovir (10 mg/day)
219520281|NCT01215409|DRUG|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
219520282|NCT03974256|OTHER|Training in the use of the automaton|2 days training on automaton use
219520283|NCT06348693|OTHER|cell isolation from tumor biopsies and biomarker investigation|cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
219520284|NCT03289156|BEHAVIORAL|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
219520285|NCT03289156|BEHAVIORAL|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
218904574|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
218904575|NCT06191640|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
219520286|NCT05457101|OTHER|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
218904576|NCT05190120|PROCEDURE|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
218904577|NCT05190120|PROCEDURE|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
218904578|NCT05190120|DRUG|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
218904579|NCT05190120|DRUG|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
218904580|NCT06305247|DRUG|IPN01194|"IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision."
218904581|NCT06305247|DRUG|IPN01194|"All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision"
218904582|NCT06128278|DRUG|S-equol|Oral supplementation of S-equol
219520287|NCT01246830|RADIATION|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
219612864|NCT06153199|BEHAVIORAL|Video review|Participants will review videos of their movement during their most difficult work tasks to help problem solving to adjust ergonomic adjustments
218904583|NCT06128278|OTHER|Placebo|Oral supplementation of placebo
219612865|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
219612866|NCT06103578|DIAGNOSTIC_TEST|GCF and saliva analysis|ELISA
218904584|NCT05300724|OTHER|No intervention|No intervention will be administered in this study.
218904585|NCT02664129|OTHER|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
219612867|NCT00702988|DRUG|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
218904586|NCT02664129|OTHER|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
219038838|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
219038839|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
219038840|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
219038841|NCT02227485|DRUG|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
219038842|NCT02227485|DRUG|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
219038843|NCT02227485|PROCEDURE|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
219520288|NCT01246830|RADIATION|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
219520289|NCT03247556|DRUG|Placebo|Placebo was administered once daily
219520290|NCT03247556|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to Placebo
219612868|NCT00702988|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
219612869|NCT06274866|OTHER|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
219612870|NCT06274866|OTHER|control group|Individuals in the control group were followed up with an exercise training brochure.
218904587|NCT06001801|BEHAVIORAL|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
218904588|NCT06001801|BEHAVIORAL|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
218904589|NCT03471312|DRUG|Magnesium|magnesium therapy
218904590|NCT02515734|DRUG|fluorouracil|
218904591|NCT02515734|DRUG|Leucovorin|
218904592|NCT02515734|DRUG|irinotecan|
218904593|NCT02515734|DRUG|oxaliplatin|
218904594|NCT02515734|BIOLOGICAL|bevacizumab|
218904595|NCT02515734|BIOLOGICAL|cetuximab|
219520291|NCT03247556|DRUG|600mg SPN-812|600mg SPN-812 was administered once daily and compared to Placebo
219520292|NCT00845156|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
219612871|NCT07030231|RADIATION|Intraoperative|Intraoperative radiotherapy with any device after conservative surgery in early breast cancer
219612872|NCT06208137|BEHAVIORAL|Health monitoring and regular return follow-up reminders|Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
219612873|NCT06882980|OTHER|Ciprofol group|In the Ciprofol group,children were given Ciprofol 0.6-0.8 mg/kg during anesthesia induction,and ciprofol 1.2-2 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
219612874|NCT06882980|OTHER|Propofol group|In the Propofol group,children were given Propofol 2.5-3.5 mg/kg during anesthesia induction,and propofol 6-10 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
219612875|NCT02189837|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219612876|NCT02189837|DRUG|Atorvastatin|Administered by mouth
219612877|NCT02189837|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
219520293|NCT02946762|OTHER|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
219520294|NCT04493723|PROCEDURE|Surgery|To collect tumour tissue
219520295|NCT04493723|PROCEDURE|Venepuncture|To collect blood samples
218904596|NCT01259180|PROCEDURE|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
218904597|NCT01259180|PROCEDURE|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
218904598|NCT04000529|DRUG|TNO155|Capsule
218904599|NCT04000529|DRUG|Spartalizumab|Concentrate for solution for infusion
218904600|NCT04000529|DRUG|Ribociclib|Capsule and tablet
218904601|NCT05036252|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
218904602|NCT05036252|DIAGNOSTIC_TEST|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
218904603|NCT05036252|DIAGNOSTIC_TEST|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
218904604|NCT00951366|OTHER|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
218904605|NCT03416140|OTHER|Therapeutic Exercise|30 minutes per day of therapeutic exercise
218904606|NCT06458075|BEHAVIORAL|CO-LEAD|The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
218904607|NCT03923270|DRUG|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
218904608|NCT03923270|DRUG|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
218904609|NCT03923270|DRUG|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
219520296|NCT06143722|RADIATION|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
219520297|NCT06143722|RADIATION|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
219520298|NCT06316921|PROCEDURE|Epidural patient-controlled analgesia|Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery
218904610|NCT03923270|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
218904611|NCT03923270|DRUG|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
218904612|NCT06087276|DRUG|60 mg ulixacaltamide|Once daily oral treatment with titration
218904613|NCT06087276|DRUG|Placebo|Once daily oral treatment
218904614|NCT03069352|DRUG|Placebo|tablet
219038844|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
219038845|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
218904615|NCT03069352|DRUG|Venetoclax|tablet
218904616|NCT03069352|DRUG|Cytarabine|Subcutaneous injection
218904617|NCT02621424|DEVICE|RTMS|stimulation of the brain with magnetic pulses
219520299|NCT06316921|PROCEDURE|Standard postoperative pain management|Standard of care for postoperative pain after lumber spine surgery
219520300|NCT00843323|OTHER|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
219520301|NCT01203878|DRUG|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
219520302|NCT01203878|DRUG|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
218904618|NCT02621424|DEVICE|sham|sham noise to block the sound of stimulation
218904619|NCT06752694|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218904620|NCT06752694|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219520303|NCT00795015|DRUG|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
219520304|NCT00795015|DRUG|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
219520305|NCT01652001|DRUG|Malic Acid|Oral spray for application into the oral cavity
219520306|NCT01652001|OTHER|Placebo|Oral spray for application into the oral cavity
218904621|NCT06752694|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
218904622|NCT06752694|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
218904623|NCT06752694|PROCEDURE|Computed Tomography|Undergo CT
218904624|NCT06752694|DRUG|Cyclosporine|Given PO
218904625|NCT06752694|DRUG|Fludarabine|Given IV
218904626|NCT06752694|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
218904627|NCT06752694|DRUG|Mycophenolate Mofetil|Given PO
218904628|NCT06752694|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
218904629|NCT06752694|DRUG|Ruxolitinib|Given PO
218904630|NCT06752694|DRUG|Sirolimus|Given PO
218904631|NCT06752694|RADIATION|Total-Body Irradiation|Undergo TBI
218904632|NCT06752694|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218904633|NCT06752694|PROCEDURE|Echocardiography|Undergo ECHO
218904634|NCT06659640|DRUG|ALN-6400|ALN-6400 will be administered subcutaneously (SC)
218904635|NCT06659640|DRUG|Placebo|Placebo will be administered subcutaneously (SC)
218904636|NCT06560255|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
218904637|NCT06560255|OTHER|Rape seed oil|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
218904638|NCT06118255|DRUG|fenfluramine|The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
218904639|NCT05766488|DEVICE|Continuous Glucose Monitor (CGM)|A Freestyle Libre 2 continuous glucose monitor (CGM) will be provided in the experimental arm of this study for 6 months.
218904640|NCT05766488|DEVICE|Self-monitoring Blood Glucose (SMBG)|A traditional glucometer device will be assigned in the active comparitor arm of this study for 6 months.
219520307|NCT01682083|DRUG|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
219520308|NCT01682083|DRUG|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
219520309|NCT01682083|DRUG|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
219520310|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
219520311|NCT03701256|PROCEDURE|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
219520312|NCT03701256|DRUG|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
218904641|NCT05626673|BEHAVIORAL|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
218904642|NCT03663725|DRUG|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
218904643|NCT03663725|DRUG|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
218904644|NCT05433961|DRUG|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
218904645|NCT03327181|DIETARY_SUPPLEMENT|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
219520313|NCT05537051|DRUG|PM1021, PM8001|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
218904647|NCT06560398|BEHAVIORAL|Continuing Medical Education Events (CME)|An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.
218904648|NCT06560398|BEHAVIORAL|Trial Connect Portal|A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.
218904649|NCT06560398|BEHAVIORAL|Clinical Trial Newsletters|Electronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail.
218904650|NCT06560398|BEHAVIORAL|Implicit Bias Training|A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.
218904651|NCT06560398|BEHAVIORAL|Recruitment Dashboard|A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.
218904652|NCT06560398|BEHAVIORAL|Portfolio Profiler|An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment.
218904653|NCT06560398|BEHAVIORAL|Eligibility Calculator|A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.
218904654|NCT06560398|BEHAVIORAL|Clinical Trial Education Sessions (Community Residents Only)|An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.
219612878|NCT02189837|DRUG|Placebo to Atorvastatin|Administered by mouth
218904655|NCT06560398|BEHAVIORAL|ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)|A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.
219612879|NCT02966977|OTHER|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
219612880|NCT02966977|OTHER|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
218904656|NCT06560398|BEHAVIORAL|New Patient Information (Moffitt Patients Only)|Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.
218904657|NCT06560398|OTHER|No Intervention|Control group with no intervention.
218904658|NCT05009277|DEVICE|Device|LINDA thermal device
218904659|NCT04074746|BIOLOGICAL|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
218904660|NCT04074746|DRUG|Cyclophosphamide|Given IV
218904661|NCT04074746|DRUG|Fludarabine|Given IV
218904662|NCT04074746|DRUG|Fludarabine Phosphate|Given IV
218904663|NCT04074746|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
218904664|NCT05719441|BIOLOGICAL|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
218904665|NCT05719441|BIOLOGICAL|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
218904666|NCT05719441|OTHER|Placebo|Sodium Chloride for Injection USP, 0.9%
218904667|NCT05719441|DRUG|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
218904668|NCT06098690|BEHAVIORAL|Culturally Tailored Multimedia Psychoeducational HPV Intervention|The culturally tailored multimedia psychoeducational intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
218904669|NCT06098690|BEHAVIORAL|General HPV Multimedia Psychoeducational Control Group|The general/publicly available multimedia intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
218904670|NCT03835429|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
219520314|NCT06179056|DIAGNOSTIC_TEST|assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.|"Microbiological samples were collected from all patients for:~1. Isolation of C. acnes~2. Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~3. Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine"
219520315|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
219520316|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
219520317|NCT01071122|DRUG|Valsartan|Valsartan 160mg, Once daily
219520318|NCT04331665|DRUG|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
219520319|NCT04813705|RADIATION|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
219612881|NCT04900181|PROCEDURE|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
219612882|NCT02421055|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
219612883|NCT02421055|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
219612884|NCT04991207|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
219612885|NCT04991207|DRUG|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
219612886|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; first study group: 10E7\_TCID50
219038846|NCT02312232|DRUG|levodopa, carbidopa, ODM-104|
219038847|NCT00846118|DRUG|Pitavastatin|1-4mg/day
219038848|NCT00882531|DRUG|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
219038849|NCT00882531|DRUG|placebo|
219038850|NCT02848976|OTHER|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
219038851|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
219038852|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
219038853|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
219038854|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
218904673|NCT00968500|BEHAVIORAL|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
218904674|NCT03396081|BEHAVIORAL|PRADO-IC|"1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
218904675|NCT03396081|BEHAVIORAL|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
218904676|NCT06210386|DEVICE|Noninvasive ventilation|noninvasive ventilation
218904677|NCT06366282|BEHAVIORAL|Caregiver Counseling for Childhood Traumatic Injury|Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
218904678|NCT06366282|BEHAVIORAL|Standard of Care for Childhood Traumatic Injury|Control group receives the current standard of care provided by the counseling team
218904679|NCT02963272|OTHER|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
218904680|NCT02963272|OTHER|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
218904681|NCT01673828|DRUG|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
218904682|NCT01673828|DRUG|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
218904683|NCT05395390|BEHAVIORAL|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
218904684|NCT06587386|DRUG|First patient Bupivacaine liposome and next patient Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome dose depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a dose of 66.5mg (15ml). Subsequently, if motor function was preserved, the next patient received a higher dose (increased by 6.65mg) with a probability of b=0.11; or the same dose with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower dose (decreased by 6.65mg).
218904685|NCT04750642|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
218904686|NCT04750642|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
218904687|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
218904688|NCT06532084|DRUG|Sorafenib|Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
218904689|NCT01800097|DRUG|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
218904690|NCT01800097|DRUG|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
218904691|NCT04440826|OTHER|Whole Food Meal|Whole foods meal
218904692|NCT04440826|OTHER|Processed Food Meal|Processed food meal
218904693|NCT04440826|OTHER|Gluten-free and lactose-free|Gluten-free and lactose-free food meal
218904694|NCT05049928|OTHER|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects"
218904695|NCT05147792|DEVICE|CLAAS|CLAAS
218904696|NCT05147792|DEVICE|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
218904697|NCT03840447|BEHAVIORAL|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
218904698|NCT04334889|OTHER|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
219038855|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
219612887|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; second study group: 10E8\_TCID50
218904699|NCT04012073|DEVICE|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH\>7.30 and PaCO2\<50 mmHg and FiO2 will be set to achieve a SpO2\>88-95%.~In case of hypercapnia with Ph\<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
218904700|NCT04012073|DRUG|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
218904701|NCT04012073|PROCEDURE|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
218904702|NCT04012073|PROCEDURE|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2\<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but \<15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
218904703|NCT04012073|PROCEDURE|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
218904704|NCT04012073|PROCEDURE|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio\>150 mm Hg and FIO2\<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
218904705|NCT04012073|PROCEDURE|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
218904706|NCT04012073|PROCEDURE|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
218904707|NCT06483984|DEVICE|Noninvasive ventilation|Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
219038856|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
219038857|NCT03930316|DEVICE|NOX T3|portable sleep study device
219038858|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
219038859|NCT00909636|DRUG|ABT-333|See arm description for more information
219038860|NCT00909636|DRUG|Placebo|See arm description for more information
219038861|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
219038862|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
219038863|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
219038864|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
219612888|NCT00701961|DRUG|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
218904708|NCT00092222|DRUG|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
218904709|NCT00092222|DRUG|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
218904710|NCT00092222|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
218904711|NCT00092222|DRUG|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
218904712|NCT00092222|DRUG|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
218904713|NCT00092222|DRUG|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
219038865|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
218904714|NCT00092222|DRUG|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
218904715|NCT00092222|DRUG|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
218904716|NCT00092222|DRUG|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
218904717|NCT00092222|DRUG|Cyclophosphamide|Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
218904718|NCT00092222|DRUG|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
218904719|NCT00092222|DRUG|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
218904720|NCT00092222|DRUG|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
218904721|NCT00092222|OTHER|Observation Only|Observation of symptoms
218904722|NCT06811727|DRUG|Continuos ceftazidime/avibactam infusion|Continuous infusion will include a loading dose of 2 g/0.5 g administered over 2 hours, followed by continuous infusion of 6 g/1.5 g over 24 hours, equivalent to 0.25 g of ceftazidime per hour. The drug reconstitution and dilution process are shown in Figure 2. The final volume of solution of CZA will be 50 mL, which gives concentration of ceftazidime of 40 mg/mL, with 4:1 concentration ratio for avibactam (10 mg/mL). The solution will be administered via an infusion syringe, with an infusion rate of 6.25 mL/h. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula
218904723|NCT06811727|DRUG|Intermitent dosing as per SMPC|Intermittent dosing, as outlined in the SmPC, consists of 2 g/0.5 g administered by prolonged infusion over 2 hours every 8 hours. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula.
218904724|NCT03932370|PROCEDURE|Flexible ureteroscopy|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water.
218904725|NCT03932370|PROCEDURE|mini-Percutaneus nephrolithotomy|The procedure is done in the prone position under fluoroscopy guidance with a semi-rigid 12Fr. Nephroscope
218904726|NCT06980376|OTHER|a2 UHT milk|Pregnant women in this arm will drink a2 UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
219038866|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
219038867|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
219038868|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
219038869|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
218904727|NCT06980376|OTHER|Conventional UHT Milk|Pregnant women in this arm will drink conventional UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
219038870|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
219038871|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
219038872|NCT02884089|DRUG|Abemaciclib|Administered orally
219038873|NCT02884089|DRUG|Metformin|Administered orally
219038874|NCT02884089|DRUG|Iohexol|Administered intravenously (IV)
219038875|NCT02884089|DRUG|Placebo|Administered orally
219038876|NCT03123159|DIAGNOSTIC_TEST|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
219038877|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
219038878|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
218904728|NCT01730560|OTHER|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
218904729|NCT01730560|OTHER|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
218904730|NCT06784349|DRUG|ALN-APOC3|Administered as per the protocol
218904731|NCT06784349|DRUG|Matching Placebo|Administered as per the protocol
218904732|NCT02733120|OTHER|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
218904733|NCT06806332|DEVICE|Nanodropper|The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.
218904734|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Volnewmer|Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
218904735|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Thermage CPT|Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
218904736|NCT04420624|DRUG|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
218904737|NCT06672978|DRUG|Meropenem-Vaborbactam|Administered as specified in the treatment arm
218904738|NCT06672978|DRUG|Antibiotics|Administered as prescribed by the study physician in accordance with the local marketing authorizations
218904739|NCT04201470|OTHER|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
218904740|NCT04201470|OTHER|MRI|Cervical and cerebral MRI without contrast injection
218904741|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
218904742|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
218904743|NCT06522737|DRUG|Duvelisib|oral capsules
218904744|NCT06522737|DRUG|Gemcitabine|solution for intravenous infusion
218904745|NCT06522737|DRUG|Bendamustine|solution for intravenous infusion
218904746|NCT06605079|BEHAVIORAL|Complex intervention|"A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed."
218904747|NCT06605079|OTHER|Routine treatment|No complex intervention is established, just routine procedures.
218904748|NCT06600711|DRUG|Nitazoxanide|5 mL suspension (100 mg), 2x/day for 3 days
218904749|NCT06600711|DRUG|Placebo|identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
218904750|NCT06596005|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
218904751|NCT06596005|DRUG|Placebo|Capsule, Once Daily
218904752|NCT06595953|BEHAVIORAL|Gaze-Contingent Music Reward Therapy|All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
218904753|NCT06588777|PROCEDURE|Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)|transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
219038879|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
219520320|NCT04813705|RADIATION|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
219520321|NCT04813705|DRUG|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
219520322|NCT03952143|DRUG|LY900014|Administered SC
219520323|NCT03952143|DRUG|Insulin Lispro|Administered SC
219520324|NCT03952143|DRUG|Insulin Glargine|Administered SC
218904754|NCT06588777|PROCEDURE|Quadratus lumborum block|"using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle"
219520325|NCT03952143|DRUG|Insulin Degludec|Administered SC
219520326|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
219520327|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
218904755|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
219612889|NCT01674218|DRUG|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
219612890|NCT01674218|DRUG|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
218904756|NCT06654778|OTHER|PEEP|Patients will be ventilated with PEEP of 8 cm H2O and fluid management: 500 ml of Ringer's lactate in the recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery.
218904757|NCT06654778|OTHER|PEEP/RM|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and fluid management: 500 ml of Ringer's lactate in recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery
218904758|NCT06654778|OTHER|PEEP/RM/RF|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and restrictive fluid management (RF). Ringer's lactate at a rate of 3 mL/kg/hour from the beginning to the end of the surgery
218904759|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
218904760|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
218904761|NCT06819865|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).
218904762|NCT06641908|DRUG|M3554|M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
219520328|NCT01476085|RADIATION|ML10|\[18F\]ML10 radioligand apoptosis biomarker
219520329|NCT00431600|OTHER|100% Oxygen|100% Oxygen- breathing over 30 minutes
219520330|NCT03968796|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
219520331|NCT03968796|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
219520332|NCT03968796|OTHER|Kinesio Taping|
219520333|NCT03968796|OTHER|Sham Kinesio Taping|
219520334|NCT04615793|OTHER|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
218904763|NCT06986863|OTHER|Always Uniquely Me mobile phone application|The app will allow the user to organize their healthcare information and personal needs which can help improve communication with doctors, clinicians and first responders.
218904764|NCT06987968|DRUG|VS-01 on top of SOC (Active Treatment Group)|Patients will received VS-01 intraperitoneally up to four consecutive days on top of SOC
218904765|NCT06987968|DRUG|SOC|Patients will received SOC
218904766|NCT06987643|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
218904767|NCT06987643|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
218904768|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
218904769|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
218904770|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
218904771|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
218904772|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
218904773|NCT05202353|DRUG|BI 456906|BI 456906
218904774|NCT05202353|DRUG|Semaglutide|Semaglutide
218904775|NCT05592990|DRUG|NGI226|NGI226 MP
218904776|NCT05592990|DRUG|Placebo|Placebo MP
218904777|NCT06985953|OTHER|TrialTalk™|TrialTalk™ is a communication tool that focuses on making the options visible and accessible while involving patients in the discussion.
218904778|NCT06854549|BEHAVIORAL|Parental Reading Picture-book|"In addition to receiving routine care, the experimental group will be given the Reading Picture Books from Scratch educational booklet once the preterm infant is removed from the incubator, the group assignment is confirmed, and participation in the study is verified. They will then undergo the Picture Book Reading Intervention. This intervention targets the preterm infant and one of the parents. It involves reading picture books from the second to the fourth day after the infant is removed from the incubator, during the visiting period from 14:10 to 14:20."
219038880|NCT04254614|DEVICE|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
218904779|NCT04716231|BIOLOGICAL|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
218904780|NCT04716231|OTHER|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
218904781|NCT04039464|DRUG|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
218904782|NCT04039464|DRUG|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
218904783|NCT05975905|BIOLOGICAL|Dose A KER-012|Dose A KER-012 (Q4W);
218904784|NCT05975905|BIOLOGICAL|Dose B KER-012|Dose B KER-012 (Q4W);
218904785|NCT05975905|BIOLOGICAL|Dose C KER-012|Dose C KER-012 (Q4W);
218904786|NCT05975905|BIOLOGICAL|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
218904787|NCT04012411|PROCEDURE|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
218904788|NCT04012411|PROCEDURE|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
218904789|NCT04012411|GENETIC|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
218904790|NCT04012411|OTHER|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
218904791|NCT05089695|DEVICE|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
218904792|NCT06592001|DEVICE|Atala™ lead|Subjects will receive the Atala™ lead being evaluated in the study.
218904793|NCT06993610|BIOLOGICAL|Tibulizumab Dose A|Anti BAFF/IL-17 antibody. ZB-106
218904794|NCT06993610|BIOLOGICAL|Tibulizumab Dose B|Anti BAFF/IL-17 antibody. ZB-106
218904795|NCT06993610|OTHER|Placebo|ZB-106 Placebo
218904796|NCT06668870|BEHAVIORAL|Supplemental Text Messaging|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. Supplemental text messages will be sent to engage patients and deliver personalized reminders to complete monitoring tasks.
218904797|NCT06668870|BEHAVIORAL|Education and Training for Patient-Generated Data|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information.
218904798|NCT06409130|DRUG|NNC0194-0499|Administered subcutaneously.
218904799|NCT06409130|DRUG|Semaglutide|Administered subcutaneously.
218904800|NCT06409130|DRUG|NNC0194-0499 placebo|Administered subcutaneously.
219038881|NCT04571112|DEVICE|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
219520335|NCT03606278|OTHER|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
219520336|NCT03606278|OTHER|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
218904801|NCT06409130|DRUG|Semaglutide placebo (Group A)|Administered subcutaneously.
218904802|NCT06409130|DRUG|Cagrilintide + semaglutide|Administered subcutaneously.
218904803|NCT06409130|DRUG|Cagrilintide|Administered subcutaneously.
219520337|NCT03653260|DRUG|Lidocaine (Zingo)|0.5 mg lidocaine, 20 bar pressure
219520338|NCT03653260|DRUG|Placebo|Placebo injector, 20 Bar pressure, empty injector
219520339|NCT01019603|DRUG|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
219520340|NCT01019603|DRUG|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
219612891|NCT01674218|OTHER|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
219612892|NCT00950365|DRUG|Erlotinib Hydrochloride|Given PO
218904804|NCT06409130|DRUG|Cagrilintide placebo|Administered subcutaneously.
218904805|NCT06409130|DRUG|Semaglutide placebo (Group B)|Administered subcutaneously.
218904806|NCT00874458|PROCEDURE|magnetic resonance imaging|
218904807|NCT00874458|PROCEDURE|radiomammography|
218904808|NCT00874458|PROCEDURE|ultrasound imaging|
218904809|NCT03771144|PROCEDURE|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
218904810|NCT06865105|DRUG|Lutikizumab|Subcutaneous (SC) Injection
218904811|NCT06865105|DRUG|Risankizumab|Subcutaneous (SC) Injection
218904812|NCT06671782|OTHER|Kegel exercises|Kegel exercises without any formal training
219612893|NCT00950365|OTHER|Laboratory Biomarker Analysis|Correlative studies
219612894|NCT00950365|DRUG|Pemetrexed Disodium|Given IV
219612895|NCT00408746|BEHAVIORAL|palatal development|Impressions of preterm and term palates.
219612896|NCT01164696|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
219612897|NCT03597659|GENETIC|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
219612900|NCT01769560|BEHAVIORAL|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
219612901|NCT04589663|DRUG|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
219612902|NCT04589663|DRUG|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
219612903|NCT04589663|DRUG|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
219520341|NCT06562413|DRUG|MAbs|Monthly or quarterly mAbs administration
218904813|NCT06671782|OTHER|Pelvic Floor Muscle Exercise Program with biofeedback|Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
218904814|NCT06671782|OTHER|Questionnaires|All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
218904815|NCT06671782|OTHER|Interviews|A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
218904816|NCT06673017|DRUG|PTM-101|PTM-101, an absorbable drug product containing paclitaxel
218904817|NCT05668741|DRUG|VX-522 mRNA therapy|Oral inhalation using nebulizer.
218904818|NCT05668741|DRUG|IVA|Tablet for oral administration.
218904819|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
218904820|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
218904821|NCT03100149|DRUG|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
218904822|NCT06666348|DRUG|Mirdametinib|Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
219520342|NCT01866319|BIOLOGICAL|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
219520343|NCT01866319|BIOLOGICAL|Ipilimumab|3 mg/kg IV Q3W.
219520344|NCT05053165|DRUG|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
219520345|NCT05053165|DRUG|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
219520346|NCT05053165|DRUG|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
219520347|NCT04684901|OTHER|AlloWrap® Amniotic Membrane|AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
219520348|NCT03433430|DEVICE|truSculpt|Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
219520349|NCT00056134|BIOLOGICAL|Dendritic cell vaccine plus denileukin difitox|
218904823|NCT06611748|DEVICE|Key Grip|KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing
218904824|NCT06611748|DEVICE|Implanted Key Grip Electrodes|"The KeyGrip System uses modified implanted wires (called electrodes) that deliver stimulation to the muscles. These electrodes are also investigational."
218904825|NCT06859346|DIETARY_SUPPLEMENT|Arm 1: TisinaTM complex|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
218904826|NCT06859346|DIETARY_SUPPLEMENT|Arm 2: Placebo (Microcrystalline Cellulose)|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
218904827|NCT06998329|OTHER|There will be no intervention|There will be no intervention
219520350|NCT01661114|DRUG|Gemcitabine|
219520351|NCT01661114|DRUG|5-FU|
219520352|NCT01661114|DRUG|Cisplatin|
219520353|NCT00661596|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
219520354|NCT00661596|DRUG|Placebo|Matching placebo
219520355|NCT06495983|DEVICE|dynamic microdialysis sampling|Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
219520356|NCT04421508|COMBINATION_PRODUCT|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
219520357|NCT04421508|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
219520358|NCT03141099|OTHER|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
219520359|NCT03141099|OTHER|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
219520360|NCT03141099|OTHER|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
219520361|NCT03141099|OTHER|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
219612904|NCT00275119|DRUG|fluorouracil|
219612905|NCT00275119|DRUG|gemcitabine hydrochloride|
219520362|NCT03980483|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
219520363|NCT03980483|DRUG|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
219520364|NCT03980483|DRUG|Placebo|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
219520365|NCT03980483|DRUG|Placebo|Placebo cap (containing lactose) to be administered orally.
219520366|NCT04559607|DRUG|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
219612906|NCT00275119|DRUG|oxaliplatin|
219612907|NCT00275119|RADIATION|radiation therapy|
219520367|NCT04559607|DEVICE|TACE|TACE if necessary
218904828|NCT07002203|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine|This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The intervention aims to induce T-cell responses against tumor-specific neoantigens. Vaccinations are given during priming and booster phases, with long-term follow-up and immune monitoring.
218904829|NCT07001475|DRUG|BI 3031185|BI 3031185
218904830|NCT07001475|DRUG|Placebo|Placebo matching BI 3031185
218904831|NCT01697397|DEVICE|Recording of Myoelectric Signals|Obtain recordings of the electrical signals of the gut.
218904832|NCT04737720|DRUG|Recombinant LCAT|iv infusion
218904833|NCT06678984|PROCEDURE|with treated umbilical vein allograft|Surgical treatment of female stress urinary incontinence using a treated allogeneic umbilical vein sling
218904834|NCT06678984|PROCEDURE|with autologous fascial pubovaginal sling|Surgical treatment of female stress urinary incontinence using a autologous fascial pubovaginal sling
218904835|NCT07007637|DRUG|Sonelokimab|Sonelokimab
218904836|NCT07006480|DEVICE|Real time CGM data monitoring|CGM data will be monitored in real time during daytime in the hospital. Alerts about high and low glucose levels will be communicated to patient's nurse and treating providers.
218904837|NCT07006480|DEVICE|Insulin dose adjustment based on glucometer and CGM glucose data trends|Insulin dose will be modulate based on glucometer values and previous day glucose trends as recorded on CGM.
218904838|NCT07006480|DEVICE|Share CGM data on admission and on discharge from the hospital|Record 14 days' worth of CGM data prior to admission and all CGM data recorded during the hospitalization at the time of discharge from the hospital
218904839|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
218904840|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
218904841|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
218904842|NCT06604663|BEHAVIORAL|Activation of the CDSS system|Activation of the CDSS system, whereby outreach workers and clinicians have access to and ability to act upon lists of patients who are at highest risk of missing their upcoming clinical appointment.
218904843|NCT05863702|BEHAVIORAL|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
218904844|NCT06625398|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
219612908|NCT04769531|OTHER|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
219612909|NCT04769531|OTHER|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
218904845|NCT06625398|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
219520368|NCT04559607|DRUG|Apatinib|Apatinib: 250m, po, QD
219612910|NCT04769531|OTHER|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
219612911|NCT04243031|DEVICE|QFT Access|Measure of Interferon Gamma
218904846|NCT07011147|DEVICE|Bionic Pancreas|The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
218904847|NCT07011147|OTHER|Routine Care|Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.
218904848|NCT07011576|DRUG|fruquintinib|Participants will receive oral fruquintinib, with or without food, for the first 21 days of each 28-day cycle.
219520369|NCT06343168|OTHER|prevalence of frailty|determine the prevalence of frailty
219520370|NCT04433910|DRUG|Convalesscent Plasma|Transfusion
219520371|NCT04922424|DRUG|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
219520372|NCT04922424|OTHER|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
219520373|NCT01164813|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
219520374|NCT01164813|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
219520375|NCT06222749|DRUG|Intranasal oxytocin administration|24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
219520376|NCT06222749|DRUG|Intranasal placebo administration|Nasal spray solution; Placebo will be administered as the placebo controlled condition.
219612912|NCT02137876|PROCEDURE|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
218904849|NCT07011576|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|Participants will receive FOLFIRI once every 2 weeks on day 1 of every 28-day cycle (twice in each cycle). The FOLFIRI regimen consists of irinotecan given 180 mg/m2 intravenous infusion (IV), leucovorin 400 mg/m2 (or 200 mg/m2 levoleucovorin) IV, followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus injection and 5-FU continuous IV infusion of 2400 mg/m2 over 46 to 48 hours.
218904850|NCT03712527|OTHER|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
218904851|NCT03712527|OTHER|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
218904852|NCT06625242|DRUG|Filgotinib Maleate|Administered as oral tablets.
218904853|NCT06626074|DEVICE|Quantitative MRI sequences|additional sequences during MRI
218904854|NCT07023029|DRUG|Etavopivat|Etavopivat will be administered orally.
218904855|NCT07023029|DRUG|Moxifloxacin|Moxifloxacin will be administered orally.
218904856|NCT07023029|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
218904857|NCT06686849|BEHAVIORAL|Low-touch: texting|Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.
219038882|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
219038883|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
219038884|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
219612913|NCT03009773|OTHER|rehabilitation multitasking walking.|rehabilitation multitasking walking.
219612914|NCT03009773|OTHER|Traditional walking rehabilitation|Traditional walking rehabilitation
218904858|NCT06686849|BEHAVIORAL|High-touch: Community health worker outreach|Community health worker (CHW) outreach: Within approximately one week of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
218904859|NCT06347718|DRUG|anti-CD19 CAR T cell therapy|Single-dose
218904860|NCT06462053|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
218904861|NCT06462053|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg d1 q3w
218904862|NCT06462053|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
218904863|NCT06462053|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
218904864|NCT06462053|DRUG|Capecitabine|Xeloda
218904865|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
219038885|NCT00556855|OTHER|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
219038886|NCT00556855|OTHER|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
218904866|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
218904867|NCT02867475|OTHER|Physical activity motivation|Physical activity motivation
218904868|NCT07030998|DEVICE|Wearable Device|"Wearable device to collect the following health metrics directly from participants for the duration of the study (4 weeks). Health metrics are collected every 15 minutes, except for the ECG which will be collected once per week.~Data points:~* ECG data (Once per week)~* Exercise time~* Body Temperature~* Heart Rate~* Irregular Heart Rhythm~* Blood Oxygen Saturation~* Respiratory Rate"
218904869|NCT06710483|BEHAVIORAL|Pre-Dental Telehealth (PDT)|The PDT will be a scripted telehealth interview 3-7 days before the scheduled dental visit to review medical and dental history, to evaluate the participants' needs for the dental visit, and to set an agreed goal for the dental visit using shared decision making. The goal wlll be one of the following: Goal 1: exam cleaning only, Goal 2: exam and cleaning, Goal 3: exam, radiographs, and cleaning.
218904870|NCT06714591|DRUG|BL-M11D1|"The study includes 2 parts:~Part 1 Dose escalation and Dose Finding"
218904871|NCT06713239|DEVICE|Cleerly Labs and Cleerly ISCHEMIA|Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
218904872|NCT06880744|DRUG|Risankizumab|Intravenous (IV) Infusion
218904873|NCT06880744|DRUG|Risankizumab|Subcutaneous (SC) injection
218904874|NCT06880744|DRUG|Vedolizumab|Intravenous (IV) infusion
219038887|NCT00392613|PROCEDURE|Strict versus lenient rate control|
219038888|NCT02487394|PROCEDURE|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
219204337|NCT06735079|DRUG|Placebo|"The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD)."
219612915|NCT01153373|BEHAVIORAL|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
219612916|NCT01153373|BEHAVIORAL|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
219612917|NCT05176873|DRUG|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
219612918|NCT05176873|DRUG|Placebo|A single oral dose of placebo will be given.
219612919|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
219612920|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
219612921|NCT02443740|DRUG|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
218904875|NCT05148546|DRUG|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
218904876|NCT05148546|DRUG|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
218904877|NCT05148546|DRUG|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
218904878|NCT07042165|DRUG|Atorvastatin|Participants will be orally administering one tablet daily of 40 mg Atorvastatin for two weeks followed by two tablets daily for two weeks (totalling 80 mg daily).
218904879|NCT07042165|DRUG|Placebo|Placebo tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the IMP except with the active ingredient (atorvastatin) omitted. Participants will be orally administering one tablet daily for two weeks followed by two tablets daily for two weeks.
218904881|NCT06727071|PROCEDURE|Hyperglycemic clamp|A continuous infusion of 20% dextrose will be maintained throughout the procedure, while a variable rate of insulin infusion will be used to control participants blood glucose level.
218904882|NCT06925503|BEHAVIORAL|Mind-Body Conditioning Course|Evidence-based mindfulness intervention curated to the physical and emotional needs of University Dance students
218904883|NCT06592261|DRUG|Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)|Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
218904884|NCT06592261|DRUG|Insulin regular, 32 mU/m2/min (hyperinsulinemia)|Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
218904885|NCT06592261|DRUG|Octreotide Acetate, 6-45 ng/kg/min|Suppression of endogenous insulin secretion
219038889|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
219038890|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
219038891|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
219038892|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
218904886|NCT06592261|DRUG|Dextrose 20 % in Water|Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
218904887|NCT06592261|DRUG|Glucagon, 0-0.5 ng/kg/min|Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
218904888|NCT06892275|BEHAVIORAL|Enhanced Usual Care|Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC)
218904889|NCT06892275|BEHAVIORAL|Decision Support|The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits.
218904890|NCT05371964|DRUG|Imetelstat sodium|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
218904891|NCT05371964|DRUG|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) in cohort B as the standard of care per local prescribing guidelines.
218904892|NCT05371964|DRUG|Pacritinib|Pacritinib will be administered once daily (QD) or BID in cohort B as the standard of care per local prescribing guidelines.
218904893|NCT05371964|DRUG|Momelotinib|Momelotinib will be administered once daily QD in cohort B as the standard of care per local prescribing guidelines.
218904894|NCT05371964|DRUG|Fedratinib|Fedratinib will be administered QD in cohort B as the standard of care per local prescribing guidelines.
218904895|NCT06742853|DRUG|AZD0780|AZD0780 tablet will be administered orally.
218904896|NCT06742853|DRUG|Ezetimibe|Ezetimibe tablet will be administered orally.
218904897|NCT06742853|DRUG|Rosuvastatin|Rosuvastatin tablet will be administered orally.
218904898|NCT06742853|DRUG|Bempedoic Acid|Bempedoic Acid tablet will be administered orally.
218904899|NCT06742853|DRUG|Placebo|Placebo will be administered orally.
218904900|NCT04782258|DRUG|Tolvaptan Suspension|Syrup
218904901|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
218904902|NCT06861855|OTHER|Observation|observation of METTL-14 prognosis
218904903|NCT06861855|BEHAVIORAL|IHC|IHC of METTL-14
218904904|NCT06747351|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
218904905|NCT06747351|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
218904906|NCT06747351|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881/HYQVIA to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
218904907|NCT06424522|DIETARY_SUPPLEMENT|Dietary Fiber|Receive dietary fiber
218904908|NCT06424522|PROCEDURE|Enema Administration|Undergo RRE
218904909|NCT06424522|DRUG|Loperamide Hydrochloride|Receive loperamide hydrochloride
218904910|NCT06424522|PROCEDURE|Physical Therapy|Undergo pelvic floor physical therapy
218904911|NCT06424522|OTHER|Questionnaire Administration|Ancillary studies
218904912|NCT06424522|PROCEDURE|X-Ray Imaging|Undergo abdominal film x-ray
218904913|NCT06428409|BIOLOGICAL|Sacituzumab tirumotecan|Given by IV infusion.
218904914|NCT06428409|DRUG|Fluorouracil (5-FU)|5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks.
218904915|NCT06428409|DRUG|Leucovorin (LV) or levoleucovorin|LV or levoleucovorin is administered by IV infusion every 2 weeks.
218904916|NCT06428409|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
218904917|NCT06428409|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
218904918|NCT06428409|DRUG|Cisplatin|Given by IV infusion.
218904919|NCT06428409|BIOLOGICAL|Pembrolizumab|Given by IV infusion.
218904920|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
218904921|NCT06740305|OTHER|Altitude|"Subjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA (space walks)."
218904922|NCT06740305|DRUG|100% Oxygen|Oxygen pre-breathing prior to altitude or simulated high altitude exposure is routinely used by the Air Force, NASA and organizations such as Duke Medical Center to prevent and treat decompression sickness as well as for treatment of patients. Oxygen used for this study is medical grade.
218904923|NCT07065929|DIETARY_SUPPLEMENT|Early nutritional management|"The food ingested by patients is collected until the day 7 of the stroke so that dieticians can calculate their needs and provide a suitable diet. If this is not sufficient, a reinforced nutrition strategy (meal enrichment) is implemented.~On day 5 of the stroke, if energy intake is less than 2/3 of the energy objectives, the strategy is switched to level 2, unless it is possible to increase intake within 48 hours."
218904924|NCT06886126|DRUG|HDM1005 injection or placebo|HDM1005 injection subcutaneous injection QW for 22weeks
219038893|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
219038894|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
219038895|NCT02567396|OTHER|Pharmacological Study|Correlative studies
219038896|NCT02567396|DRUG|Talazoparib|Given PO
219038897|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
219038898|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
219038899|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
219520377|NCT04495049|DEVICE|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
218904925|NCT03948529|DRUG|eltrombopag|eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
218904926|NCT06559891|DEVICE|TIVUS™ Renal Denervation System|Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
218904927|NCT06559891|OTHER|Sham|For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
218904928|NCT06056024|DRUG|BI 3706674|BI 3706674
218904929|NCT04972162|DEVICE|Web App Strategy Fitting|Web App Strategy fitting of hearing aids
218904930|NCT04972162|DEVICE|Standard-of-care Fitting|Standard-of-care fitting of hearing aids
218904931|NCT07071519|DRUG|Risankizumab|Risankizumab intravenous (IV) infusion
218904932|NCT07071519|DRUG|Risankizumab|Risankizumab subcutaneous (SC) injection
218904933|NCT06335979|DRUG|PIT565|In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
218904934|NCT00044304|DRUG|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
218904935|NCT00044304|DRUG|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
218904936|NCT05189925|BIOLOGICAL|gp91 Grans|Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
219204338|NCT06735547|DEVICE|Telerehabilitation|Patients in the Telerehabilitation group will perform an average of three therapy sessions per week, with data collected and monitored by TRAK's physiotherapists. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
219204339|NCT06735547|OTHER|Conventional therapy group|Patients in the conventional group will be assessed by a professional physiotherapist, scheduling appointments according to their own preferences and disponibility. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
218904939|NCT07134231|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
218904940|NCT07134231|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
219204340|NCT06735508|DRUG|mRNA Neoantigen Vaccine|mRNA Neoantigen Vaccine
218904941|NCT07134231|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
218904942|NCT07134231|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
218904943|NCT06928571|BEHAVIORAL|Connect4Health Engage|Intervention focused on motivating and guiding patients to use empirically supported, freely available online tools for weight loss.
218904944|NCT06928571|BEHAVIORAL|Connect4Health Discover|Educational control - information about healthy eating and physical activity
218904945|NCT07077070|DEVICE|Standard Electrical Categorical Loudness Scaling task (Standard-ELS)|The Standard-ELS task is conducted using the Mobile Research Application within the Nexus Research system. It is completed in two phases: the first phase identifies the lower and upper bounds of the loudness range based on participant ratings, while the second phase collects data from stimulations delivered within the established range.
219204341|NCT06735508|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
219520378|NCT02612636|OTHER|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
219520379|NCT02612636|OTHER|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
218904946|NCT07077070|DEVICE|Fast Electrical Categorical Loudness Scaling task (Fast-ELS)|The Fast-ELS task employs an algorithm to estimate the lower and upper bounds of the loudness range using a limited number of samples. This range is then refined by collecting additional samples across various loudness categories for comprehensive coverage.
218904947|NCT07080320|DEVICE|MoCap|"For each subject, the displacement of markers, the deformation of regions between markers, and the evolution of angles formed by the markers during facial expressions and vertical movements will be analyzed with MoCap. These will be compared between the two age groups (18-33 years vs. 50-65 years) using a MANOVA model. The reference values for marker displacement will be defined by the interval between the 2.5% and 97.5% percentiles of the values for each marker. If the distribution is Gaussian, the percentiles will be derived from the standard normal distribution; otherwise, the non-parametric method will be used.~The intervention will be Interventions :~* Recruitment of healthy and pathological subjects.~* Full-face and macro images of the periorbital region~* Measurement of periorbital skin properties using MoCap and standard reference tools.~* Application of a tightening product (aloe vera) and periorbital massage.~* Measurement of skin response to a vertical jump."
218904948|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
219520380|NCT00784849|DRUG|Methylene blue|1 mC1
219520381|NCT00322933|PROCEDURE|renal replacement therapy (intermittent or continuous)|
219520382|NCT01009398|OTHER|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
219520383|NCT06114706|BEHAVIORAL|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
219520384|NCT06114706|BEHAVIORAL|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
219038900|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
219520385|NCT06114706|BEHAVIORAL|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
219038901|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
219520386|NCT04622709|DRUG|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
219520387|NCT00760266|DRUG|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
219520388|NCT00760266|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
219520389|NCT02066675|DRUG|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
219520390|NCT00216437|DRUG|Capecitabine (Xeloda)|
219520391|NCT02684552|DEVICE|Non invasive ventilation|Training on treadmill with Non invasive ventilation
218904949|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
218904950|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
218904951|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
219520392|NCT02684552|DEVICE|Oxygen|Training on treadmill with oxygen
219520393|NCT00001025|DRUG|Zidovudine|
219612922|NCT05411341|DEVICE|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
219612923|NCT05411341|DEVICE|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
219612924|NCT02741414|DEVICE|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
218904952|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
218904953|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
218904954|NCT06139328|DRUG|BI 765845|BI 765845
218904955|NCT06139328|DRUG|Placebo matching BI 765845|Placebo matching BI 765845
218904956|NCT06801587|DRUG|Triamcinolone acetonide plus ropivacaine|The local infiltration solution in the triamcinolone acetonide plus ropivacaine group will consist of ropivacaine and triamcinolone acetonide. For local infiltration, a total of 30mL solution will be prepared for each group, 1 ml of triamcinolone acetonide (40mg per 1ml) plus 15 ml of 1% ropivacaine diluted to 30 ml with saline as the test drug in the triamcinolone acetonide group. The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
219038902|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
219038903|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
219520394|NCT00001025|DRUG|Didanosine|
219520395|NCT03249064|DIAGNOSTIC_TEST|CD 91 levels|
219520396|NCT03249064|DIAGNOSTIC_TEST|Tregs|
219520397|NCT03080090|BEHAVIORAL|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
219520398|NCT03080090|BEHAVIORAL|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
219520399|NCT03316729|DRUG|DS-9231|DS-9231 in saline solution for intravenous infusion
219520400|NCT03316729|DRUG|Placebo|Placebo is matching saline solution for intravenous infusion
219520401|NCT01625026|DRUG|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
219520402|NCT01625026|DRUG|Placebo|Placebo to obeticholic acid
219038904|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
219038905|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
219038906|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
219038907|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
219038908|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
218904957|NCT06801587|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 15ml of ropivacaine added to 15mL of saline for ropivacaine group . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
218904958|NCT05800964|DRUG|AMG 305|Short-term intravenous (IV) infusion
218904959|NCT07087054|DRUG|Paltusotine|Experimental Drug: Randomized
218904960|NCT07087054|DRUG|Placebo|Matching Placebo Drug: Randomized
218904961|NCT06270875|BEHAVIORAL|ADAPT HF|ADAPT is a multicomponent, lay palliative care coach-led or self-led supportive care intervention designed to improve pain of life in individuals with advanced heart failure. Participants will complete weekly sessions of the educational programs. This program includes the following modules: pain psychoeducation, self-care and relaxation tips, social support and communication, and spirituality and meaning coping. The sessions will either be self-guided or completed with a lay coach navigator.
218904962|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
218904963|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
218904964|NCT06930157|DRUG|Shenling Baizhu granules (TCM patent medicine)|Shenling Baizhu granules is a traditional Chinese medicine preparation in granular form. Participants in the experimental group will take 6 grams orally three times daily, before or with meals, for 6 months each year over a 2-year period. The granules contain multiple Chinese herbs including Ginseng, Poria, Atractylodes macrocephala, and other traditional ingredients. This formulation is standardized according to Chinese pharmacopoeia standards and is manufactured under GMP conditions. This intervention is being tested for its ability to prevent the recurrence of low-risk colorectal adenomas after endoscopic resection.
218904965|NCT06928051|DRUG|S-892216|S-892216 will be administered orally as a tablet.
218904966|NCT06928051|DRUG|Placebo|Placebo will be administered orally as a tablet.
218904967|NCT07083960|DRUG|OM336|OM336 is an engineered bispecific antibody directed against BCMA and CD3
218904968|NCT06788002|OTHER|Low-dose radiotherapy combine with chemoimmunotherapy|Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)
218904969|NCT00336024|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
218904970|NCT00336024|DRUG|Carboplatin|Given IV
218904971|NCT00336024|DRUG|Cisplatin|Given IV
218904972|NCT00336024|DRUG|Cyclophosphamide|Given IV
219038909|NCT00003589|DRUG|cisplatin|
219038910|NCT00003589|DRUG|gemcitabine hydrochloride|
219520403|NCT04251611|OTHER|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
219612925|NCT02741414|DEVICE|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
218904973|NCT00336024|DRUG|Etoposide|Given IV
219038911|NCT00003589|DRUG|paclitaxel|
219038912|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
218904974|NCT00336024|BIOLOGICAL|Filgrastim|Given IV or SC
218904975|NCT00336024|OTHER|Laboratory Biomarker Analysis|Correlative studies
218904976|NCT00336024|DRUG|Leucovorin Calcium|Given IV or orally
218904977|NCT00336024|DRUG|Methotrexate|Given IV
218904978|NCT00336024|OTHER|Quality-of-Life Assessment|Ancillary studies
218904979|NCT00336024|DRUG|Thiotepa|Given IV
218904980|NCT00336024|DRUG|Vincristine Sulfate|Given IV
218904981|NCT07088406|BEHAVIORAL|Physical Activity Promotion|The Conmigo Physical Activity intervention involves the delivery of ten weekly sessions led by YMCA Facilitators supported by Drs. Arredondo and Ayala, Project Manager and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in ten in-person 2-hour sessions on topics such as PA parenting, communication, goal setting, etc. Mothers and daughters participate together in most activities, with small group breakouts where just mothers or just daughters have separate activities during some sessions. Each session includes didactic teaching, skill building (e.g. role plays), interactive discussions, 30 minutes of group PA, and goal-setting/review of previous goals. Overall, the activities are designed to promote increased physical activity and mediators to PA (family communication, parenting strategies, etc.). Each cohort will include 12-15 mother-daughter dyads.
219038913|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
219038914|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
219038915|NCT00654381|DRUG|BI 1356|5 mg/daily
219038916|NCT00654381|DRUG|BI 1356|10 mg/daily
219038917|NCT00654381|DRUG|voglibose placebo|three times daily
219038918|NCT00654381|DRUG|BI 1356 placebo|once daily
219038919|NCT00654381|DRUG|voglibose|0.6 mg/daily
219038920|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
219038921|NCT01782781|DRUG|Placebo|Placebo group
219038922|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
219038923|NCT02607514|BEHAVIORAL|hyperthermic yoga|heated yoga, 90-minutes
219038924|NCT00141063|DRUG|Focalin XR|
218904982|NCT07088406|BEHAVIORAL|Healthy Eating|The Healthy Eating intervention involves the delivery of 10 sessions by YMCA facilitators supported by Drs. Arredondo and Ayala, the Project Manager, and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in 10 2-hour in-person sessions that include both large and small group activities. Overall, the activities are designed to promote engagement in dietary behavioral strategies and parenting strategies across contexts and settings to promote fruit, vegetable and fiber consumption. Large and small groups activities include goal setting, implementation planning, homework activities, and focused discussion on mediators (e.g., family communication, parenting strategies) and moderators (e.g. acculturation). Each cohort will include 12-15 mother-daughter dyads.
219520404|NCT04346706|DEVICE|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
219612926|NCT02741414|DEVICE|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
219612927|NCT01736969|DEVICE|RD047-023|Experimental hydrogel
219612928|NCT01736969|DEVICE|Predicate Device|
218904983|NCT06907199|PROCEDURE|Electrofulguration (EF)|Nitrofurantoin (NF) daily antibiotic prophylaxis for 6 months plus Electrofulguration.
218904984|NCT06907199|DRUG|Nitrofurantoin (NF)|Nitrofurantoin (NF) daily antibiotic prophylaxis given daily for 6 months.
218904985|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
218904986|NCT07090226|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
218904987|NCT06797544|DRUG|Levofloxacin 0.5%|"Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously."
218904988|NCT06648460|OTHER|Effort-based Decision-Making Task|"Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive."
218904989|NCT07093814|DRUG|VRT106|VRT106,intravenous
218904990|NCT06904833|DEVICE|locomotion formats|two different types of popular locomotion methods in golf (i.e., walking 18 holes and using a buggy)
218904991|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
218904992|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
218904993|NCT06908824|PROCEDURE|Conventional surgery|Pars plana vitrectomy (PPV) with temporal internal limiting membrane (ILM) flap would be performed. Perfluorocarbon liquid (PFCL) or viscoelastic may be used as an adjunct. Air/Fluid exchange would be performed at the end of surgery, further exchange of air with 8-14% octafluoropropane (C3F8) would be performed based on operating surgeon's discretion. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Patients with visually significant cataract may undergo concomitant phacoemulsification and intraocular lens implantation or deferred to post-operative month 6-12. Patients would be instructed to adopt a face-down posturing in the first 5 days following operation.
219038925|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
219038926|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
218904994|NCT06908824|PROCEDURE|ILM flap with no gas tamponade|Pars plana vitrectomy with temporal internal limiting membrane (ILM) flap would be performed. The ILM flap would be stabilised over the macular hole using perfluorocarbon liquid (PFCL) followed by sub-PFCL dispersive viscoelastic injection. The PFCL would be removed towards the end of surgery. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Concomitant phacoemulsification and intraocular lens implantation would be performed in patients with visually significant cataract or deferred to post-operative month 6-12. Patients will be instructed to avoid excessive movement and adopt a face forward/ supine position for first 24 hours. Afterwards, there would be no restriction on post-operative posturing.
218904995|NCT07092566|DRUG|Ropivacaine HCL|123 mg, intramuscular
219520405|NCT04346706|DEVICE|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
219520406|NCT04815902|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
219520407|NCT04815902|DRUG|Losartan|12.5 mg oral Losartan taken for 30 days total.
219520408|NCT04815902|DRUG|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
219520409|NCT04815902|DRUG|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
219520410|NCT01715038|DIETARY_SUPPLEMENT|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
218904996|NCT07092566|DRUG|Exparel|100 mL total dose - Intramuscular (IM), intraoperatively
218904997|NCT07092566|DRUG|Epinephrine|0.25 mg, intramuscular
218904998|NCT07092566|DRUG|Clonidine HCL|0.04 mg, intramuscular
218904999|NCT07092566|DRUG|Ketorolac|15 mg, intramuscular
218905000|NCT06905158|DEVICE|White noise device|"* Product name: TinniSoothe white noise-non-invasive tinnitus device~* Usage: Worn around the neck during the daytime and docked to a stand at night~* Duration: At least one-month of use"
218905001|NCT06911502|DRUG|Golcadomide|Specified dose on specified days
218905002|NCT06911502|DRUG|Rituximab|Specified dose on specified days
218905003|NCT06911502|DRUG|Lenalidomide|Specified dose on specified days
218905004|NCT06911502|DRUG|Cyclophosphamide|Specified dose on specified days
218905005|NCT06911502|DRUG|Doxorubicin|Specified dose on specified days
218905006|NCT06911502|DRUG|Vincristine|Specified dose on specified days
218905007|NCT06911502|DRUG|Prednisone/Prednisolone|Specified dose on specified days
218905008|NCT06911502|DRUG|Bendamustine|Specified dose on specified days
218905009|NCT07098338|DRUG|Rilvegostomig|Rilvegostomig will be administered as IV infusion.
219520411|NCT01715038|DIETARY_SUPPLEMENT|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
218905010|NCT07098338|DRUG|Ramucirumab|Ramucirumab will be administered as IV infusion.
218905011|NCT07098338|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
218905012|NCT07095140|OTHER|Ecological Momentary Assessment|Complete EMAs
218905013|NCT07095140|OTHER|Monitoring|Wear alcohol monitoring wristband
218905014|NCT07095140|DRUG|Nicotine Oral Pouch|Receive ONPs
218905015|NCT07095140|OTHER|Survey Administration|Ancillary studies
218905016|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
218905017|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
218905018|NCT06911320|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination|A single dose of BEM/RZR will be administered
218905019|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
218905020|NCT06118333|DRUG|BL-B01D1|Administration by intravenous infusion
219520412|NCT01715038|DIETARY_SUPPLEMENT|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
219520413|NCT01715038|DIETARY_SUPPLEMENT|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
218905021|NCT06118333|DRUG|capecitabine|Oral administration
218905022|NCT06118333|DRUG|gemcitabine|Administration by intravenous infusion
218905023|NCT06118333|DRUG|docetaxel|Administration by intravenous infusion
219204342|NCT06404827|OTHER|Horseback riding simulator|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.
219204343|NCT06404827|OTHER|Routine Physiotherapy and Rehabilitation|Routine Physiotherapy and Rehabilitation within a spesific programme
218905024|NCT06821022|OTHER|Pain Neuroscience Education|The intervention group will receive a lecture of 70min duration on pain neuroscience. The objective of this educational session is to educate students that pain can be overprotective, and that nociceptive transmission can be heavily influenced by central sensitisation (sensitivity of the central nervous system) as well as the thoughts and beliefs of the individual. The session used drawings, stories and metaphors to depict the underlying neuroscience of pain, and current pain theory.
218905025|NCT06821022|OTHER|Red Flags Education|The control group received an education session of red flags. Red flags form part of routine subjective practice for therapists as a process of screening serious or potentially sinister pathologies. Sign and symptoms for such pathologies include history of cancer, systemic symptoms such as fever or unexplained weight loss, and saddle analgesia. The red flag session will not include the neuroscience of pain.
218905026|NCT05296070|DRUG|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
218905027|NCT05296070|DRUG|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
218905028|NCT06914908|DRUG|lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
218905029|NCT06914908|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Intranasal spray Route of administration: intranasal
218905030|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used overnight for 14 days post-SRP
218905031|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used 2x/day for 30 minutes use
218905032|NCT06806592|DRUG|Nerandomilast|Nerandomilast
218905033|NCT06806592|DRUG|Placebo matching nerandomilast|Placebo matching nerandomilast
219038927|NCT06574230|OTHER|TRAINING PROGRAM|Each training session included a structured set of exercises aimed at enhancing these skills. For example, participants practiced precision drills to target specific areas of the dartboard, endurance drills to build stamina for longer games, and competitive exercises to simulate real-game conditions. This combination of theoretical knowledge, practical skill development, and strategic gameplay was designed to comprehensively improve the participants\&#39; dart-throwing abilities over the course of the program. A 12-week dart training program, with sessions conducted three times per week, each lasting 90 minutes. In the first week, participants received comprehensive theoretical and practical instruction covering the rules of the game, proper breathing techniques, and throwing mechanics. This initial phase was designed to ensure a solid understanding of the fundamentals before progressing to more advanced training.
219038928|NCT02514356|BEHAVIORAL|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
219038929|NCT02514356|BEHAVIORAL|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
219038930|NCT05148481|DRUG|BIIB104|Administered as specified in the treatment arm
219038931|NCT05148481|DRUG|Placebo|Administered as specified in the treatment arm
219520414|NCT01132976|BEHAVIORAL|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
219520415|NCT01132976|BEHAVIORAL|Treatment as usual|No specific motivational interview
219520416|NCT01976130|PROCEDURE|Bronchoscopy|
219520417|NCT01997203|DRUG|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
219520418|NCT02590861|PROCEDURE|Dental implant|All participants will receive the same intervention, this is a single group study.
218905034|NCT07107256|DRUG|TQC2731 injection|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
219520419|NCT02283775|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
219520420|NCT02283775|DRUG|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
219520421|NCT02283775|DRUG|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
219520422|NCT06090149|DEVICE|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
219520423|NCT06090149|DEVICE|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
219520424|NCT02396875|PROCEDURE|Blood sampling and exercise protocol pre and post CRT implant|
219520425|NCT02396875|PROCEDURE|Peripheral blood sampling|
218905035|NCT07107256|DRUG|Placebo of TQC2731|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
219520426|NCT02396875|PROCEDURE|Central blood sampling pre and post CRT implant|
219520427|NCT02396875|PROCEDURE|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
219520428|NCT01697878|PROCEDURE|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
219520429|NCT01697878|PROCEDURE|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
219520430|NCT00150007|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219520431|NCT01050647|DRUG|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
219520432|NCT01050647|OTHER|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
219520433|NCT00220337|DRUG|Lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
219520434|NCT02799797|PROCEDURE|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
219520435|NCT02799797|PROCEDURE|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
219520436|NCT02799797|DEVICE|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
218905047|NCT07020936|DEVICE|Normal Glycemia Goal|Participants will use the normal AIDANET system aggressivity adjustment to achieve target glucose for both the hotel and AIDANET at home periods.
218905048|NCT07020936|DEVICE|Tight Glycemia Goal|Participants will have the AIDANET system controller target set to have higher aggressivity adjustment to maintain target glucose for both the hotel and AIDANET at home periods.
218905049|NCT05603104|DRUG|Clozapine|See arm description
219520437|NCT02799797|DEVICE|PAJUNK Contiplex S Catheter|
218905050|NCT05603104|DRUG|Esketamine Nasal Product|See arm description
218905051|NCT05603104|DRUG|Escitalopram|See arm description
218905052|NCT05603104|DRUG|Sertraline|See arm description
218905053|NCT05603104|DRUG|Venlafaxine|See arm description
218905054|NCT05603104|DRUG|Lithium|See arm description
218905055|NCT05603104|DRUG|Valproate acid|See arm description
218905056|NCT05603104|DRUG|Quetiapine|See arm description
218905057|NCT05603104|DRUG|Second-line Antidepressants|See arm description
218905058|NCT05603104|DRUG|Second-line Antipsychotics|See arm description
218905059|NCT05603104|DRUG|Ketamine Hydrochloride|See arm description
218905060|NCT05603104|DRUG|Esketamine hydrochloride|See arm description
218905061|NCT05603104|DRUG|Bupropion|See arm description
218905062|NCT06638307|DRUG|MEN2312|MEN2312 administered as oral tablets.
218905063|NCT06638307|DRUG|Elacestrant|Elacestrant administered as oral tablets.
218905070|NCT07106762|DRUG|Iza-bren|Specified dose on specified days
218905071|NCT07106762|DRUG|Cisplatin|Specified dose on specified days
218905072|NCT07106762|DRUG|Gemcitabine|Specified dose on specified days
218905073|NCT07106762|DRUG|Carboplatin|Specified dose on specified days
218905074|NCT06920199|BIOLOGICAL|Donor-derived Treg cell injection combined with interleukin 2|Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.
218905075|NCT01403623|PROCEDURE|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
218905076|NCT01403623|PROCEDURE|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
218905077|NCT05063565|DEVICE|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
219038932|NCT05010889|PROCEDURE|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
219038933|NCT02623803|DRUG|Lidocaine|
219038934|NCT02623803|DRUG|Placebo D5W|
219038935|NCT02413827|DRUG|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
219038936|NCT02413827|DRUG|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
219038937|NCT01919658|PROCEDURE|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
219038938|NCT01909661|OTHER|Damira/Celia peptide hydrolyzed casein|
219038939|NCT01909661|OTHER|Picot riz/Celia rice/Sanutri arroz|
219038940|NCT02750891|DRUG|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
219038941|NCT02852096|OTHER|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
219038942|NCT02852096|OTHER|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
218905078|NCT05063565|DRUG|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
218905079|NCT05063565|DRUG|Tremelimumab immunotherapy|300 mg, single administration
218905080|NCT07115875|OTHER|Digital Outreach|Digital outreach interventions through focus groups. The study is based on narrative interventions that highlights culturally sensitive and values among Native American communities.
218905081|NCT07115875|OTHER|In Person consultation|In-Person Consultation will receive standard of care at IHS Lawton Hospital. Consultation includes a colonoscopy risk assessment (i.e., current medication use, risk of perforation and bleeding, ability to complete bowel prep).
218905082|NCT06062238|BIOLOGICAL|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
218905083|NCT06062238|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent \[%\] sodium chloride \[NaCl\]), on Day 1 and Day 29.
218905084|NCT06924606|DRUG|JS207 injection +docetaxel|Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
219038943|NCT03741764|DEVICE|Vivosorb|Resorbable implant device
219038944|NCT02984384|DRUG|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
219038945|NCT02984384|DRUG|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
219038946|NCT00542750|DRUG|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
219520438|NCT02799797|DRUG|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
218905085|NCT06924606|DRUG|JS207 injection +JS004 injection|Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
218905086|NCT06924606|DRUG|JS207 injection|Patients receive JS207 10mg/kg or other dosage.
218905087|NCT06918067|DEVICE|Coloplast Micro Zone Luja Female Catheter|clean self-catheterization with 14 Fr Coloplast micro zone Luja female urinary catheter
218905088|NCT06918067|DEVICE|Coloplast SpeediCath Female Catheter|clean self-catheterization with 14 Fr two eyelet Coloplast SpeediCath female urinary catheter
218905089|NCT07114614|OTHER|Specimen #1|Specimen 1 will be collected in a 10 ml SST (serum separator tube).
218905090|NCT07114614|OTHER|Specimen #2|Specimen #2 will be collected in a 10 ml SST (serum separator tube)
218905091|NCT07118371|OTHER|Clamshell exercise|The clamshell starts with lying on the side, with legs stacked and knees bent at a 45-degree angle. Rest the head on the lower arm and use the top arm to steady the frame. Hipbones are stacked on top of one another, as there is a tendency for the top hip to rock backward. Engage the abdominals by pulling your belly button in, as this will help to stabilize the spine and pelvis. Keeping the feet touching, raise the upper knee as high as they can without shifting the hips or pelvis. They don't move their lower leg off the floor. Pause, and then return the upper leg to the starting position on the ground. 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set.
219038947|NCT00688480|DRUG|Placebo|1 capsule, orally for 9 months
219038948|NCT00688480|DRUG|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
219038949|NCT05763888|OTHER|No drug will given|No intervention will be given to the subject
219038950|NCT01188408|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
219204344|NCT06081127|OTHER|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
219520439|NCT02799797|DRUG|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
219520440|NCT05163951|PROCEDURE|Trabeculectomy|trabeculectomy
219520441|NCT05163951|PROCEDURE|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
219520442|NCT00003797|BIOLOGICAL|trastuzumab|
218905092|NCT07118371|OTHER|Frog pump exercises|"The Frog pump exercise will start with lying on your back, arms by sides, palms facing down. Alternatively, make fists with your hands, rest the elbows on the floor, and lift the fists so that your forearms are perpendicular to the floor. Then bend the knees and press the soles of the feet together so that the legs create a frog legs or butterfly shape. Pressing the outer edges of the feet against the floor, engage the core, and use the glutes to lift the hips. Make sure the shoulders and upper back remain anchored to the floor. Pause, then slowly lower the hips to the floor. . 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set."
219038951|NCT00323973|DRUG|Bisoprolol|10 mg qd
219038952|NCT01554566|DIETARY_SUPPLEMENT|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
219038953|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
219520443|NCT00003797|DRUG|gemcitabine hydrochloride|
219038954|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
219520444|NCT03358849|BIOLOGICAL|Natural killer cell|Patients who received natural killer cell injection
218905093|NCT06925555|DRUG|BV+R-CHP|Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5
218905094|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Open Label Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Adaptations targeting those in JHOME will be made on a per-client basis as part of the open-label pilot. The investigators will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain those perspectives of the acceptability and feasibility of implementing the CAPABLE Care + Connect intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
218905095|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
218905096|NCT07125209|OTHER|Patient Reported Outcomes Assessment|Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes.
218905097|NCT07125209|OTHER|Cognitive and General Health Assessments|"* Rey Verbal Learning Test~* Trail Making Test~* Patient Health Questionnaire (PHQ-2)~* Mini Mental State Exam (MMSE)~* Controlled Oral Word Association Test of the Multilingual Aphasia Examination"
218905098|NCT07129694|DEVICE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
218905099|NCT07129694|PROCEDURE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
218905100|NCT07137247|PROCEDURE|Venipuncture|"For adults (including those who are 18 years old): During the routine follow-up visits, an extra 30 milliliters of peripheral blood will be drawn.~For minors (under 18 years old): During the routine follow-up visits, an extra 6 milliliters of peripheral blood will be drawn.~Follow-ups will be conducted every six months, with a minimum of six visit points."
218905101|NCT06937606|BEHAVIORAL|Self-compassion training|Online group intervention: led by a certified mindfulness teacher for mindful self-compassion and additional qualification in self-compassion in healthcare communities (duration: 6 weekly appointments of 90 min each);
218905102|NCT06938880|BIOLOGICAL|ZGGS18 for Injection|Intravenous infusion
218905103|NCT06938880|BIOLOGICAL|ZG005 for Injection|Intravenous infusion
218905104|NCT06939218|BEHAVIORAL|Countermovement Jump (CMJ)|Participants perform a vertical jump starting from a standing position, bending their knees to 90 degrees, and then jumping as high as possible. The height of the jump is measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
218905105|NCT06939218|BEHAVIORAL|Repeated Jump Test|Participants perform repeated vertical jumps for 20 seconds, with the height of each jump measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
218905106|NCT06939218|BEHAVIORAL|Repeated Sprint Ability (RSA) Test|articipants perform six 30-meter sprints with 20 seconds of rest between each sprint. Sprint times are measured using photocell timing gates (RaceTime, Microgate, Bolzano, Italy).
218905107|NCT06939218|BEHAVIORAL|Maximum Sprint Test|Participants perform three maximum effort sprints over 40 meters. Sprint times and speeds are measured using 1080 motion analysis
218905108|NCT06939218|BEHAVIORAL|Change of Direction (COD) Test|Participants perform a sprint with a change of direction, running 5 meters in one direction and then 5 meters at a 90-degree angle. The time to complete the test is measured.
218905109|NCT06939218|BEHAVIORAL|Shooting Test|Participants perform a shooting test, aiming to hit a target with maximum speed. The speed of the shot is measured using radar.
218905110|NCT06939218|BEHAVIORAL|Small side game test|Participants engage in a 5v5 small-sided game on a 600 m² field to simulate match conditions and assess performance in a game-like scenario.
218905111|NCT06939218|BEHAVIORAL|Performance and Comfort Perception Questionnaire|Participants complete a questionnaire to assess their perception of performance and comfort on the surface, using a Visual Analogue Scale (VAS).
218905112|NCT06939218|BEHAVIORAL|Perceived Exertion Questionnaire|Participants complete a questionnaire to assess their perceived exertion during the tests, using the Borg scale
218905113|NCT06943833|BIOLOGICAL|Volrustomig|IV infusion
218905114|NCT07141238|OTHER|Environmental microplastic exposure|Exposure to environmental microplastics measured by their presence in intestinal tissue, blood, urine, and stool using Raman spectroscopy. This study does not assign any exposure or treatment; it investigates the existing presence of microplastics as an environmental factor of interest.
218905115|NCT06954675|DIETARY_SUPPLEMENT|Exogenous ketone ester|25g Bis-octanoyl-(R)-1,3-butanediol (C8)
219038955|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
219520445|NCT02238145|DRUG|Atrovent® Inhaletten|
219520446|NCT00186108|DRUG|Oral Triamcinalone|
219520447|NCT02566824|BEHAVIORAL|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q\&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
218905116|NCT06954402|BEHAVIORAL|Acute Stress Intervention (MAST-based)|This intervention uses the Maastricht Acute Stress Test (MAST) to induce an acute stress response. Participants are exposed to standardized stress tasks while performing laboratory-based assessments of cognitive, emotional, and control aspects of resilience.
219520448|NCT02566824|BEHAVIORAL|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
218905117|NCT06954402|BEHAVIORAL|Non-Stress Intervention (NST-based)|In this control intervention, participants complete the same battery of laboratory tasks without exposure to the acute stressor.
218905118|NCT06951217|COMBINATION_PRODUCT|AP01|AP01 will be administered open-label via the eFlow Nebulizer System
218905119|NCT06954597|DRUG|TOP-N53|TOP-N53 solution (IMP) containing 80 µg/ml TOP-N53 is applied topically directly to the digital ulcer of patients with systemic sclerosis. The dose if defined by volume and exposure time of the IMP.
219038956|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
219204345|NCT06081127|OTHER|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral"
219520449|NCT02566824|OTHER|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
219520450|NCT02566824|DRUG|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
219520451|NCT04876378|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218905120|NCT06954597|DRUG|Sildenafil|Parallel treatment with Sildenafil 20 mg 3-times per day is permitted if patient has been on a stable dose for 2 weeks prior to screening.
218905121|NCT06954597|DRUG|TOP-N53 vehicle|TOP-N53 vehicle solution will be topically applied to digital ulcers of systemic sclerosis patients.
219520452|NCT04876378|OTHER|Questionnaire Administration|Complete questionnaires
219520453|NCT02754401|OTHER|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
218905122|NCT07150494|DEVICE|Phototherapy|Phototherapy used to decrease high billirubin level in neonatal jaundice
218905123|NCT07156201|DRUG|ABS-1230|ABS-1230
218905124|NCT07156201|DRUG|Placebo|Placebo
219038957|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
219038958|NCT04891848|OTHER|inflammation|inflammatory values in complete blood count (CBC)
219038959|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
219204346|NCT06883864|PROCEDURE|Catheter ablation plus medication|All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.
219038960|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
219038961|NCT00749983|DIETARY_SUPPLEMENT|Creatine supplementation|
218905127|NCT07156188|OTHER|Permanent Suture|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed in a standardized manner. In the control group, a permanent 0-0 polypropylene suture will be used to close the hernia defect in a transverse or vertical interrupted fashion using either the simple interrupted or the figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
219038962|NCT00749983|DIETARY_SUPPLEMENT|Dextrose supplementation|
219038963|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
218905128|NCT07156188|OTHER|Absorbable|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed. An 0-0 polydioxanone suture (PDS) will be used to close the hernia defect in either a transverse or vertical interrupted fashion using either simple interrupted or figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
218905129|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
218905130|NCT07160972|OTHER|Lifestyle Management|Participants will use the X Life model via AR glasses or mobile terminal (smartphone/tablet) for 7 days. The system provides personalized dietary and exercise recommendations at dynamic trigger points (before/after meals, before/after exercise, before bedtime) using baseline clinical data, real-time CGM readings, dietary images, activity data, and wearable monitoring (activity, sleep, heart rate). Standard care guidance will also be provided in accordance with national dietary and physical activity guidelines.
218905131|NCT07164053|DEVICE|MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su|"MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes (ARveo 8/ARveo 8x) and other medical imaging systems. It is a digital accessory to an operating surgical microscope that enables the visualization of the surgical field through a visualization headset including:~* Display of surgical field illuminated and magnified by the surgical microscope (White Light).~* Display of fluorescence of fluorophores within the indicated excitation and emission ranges, as defined by the respective filters (accessories to the compatible surgical microscopes ARveo 8x such as GLOW400 and GLOW800)."
218905132|NCT07166380|DRUG|RK-4 injection|patients with LHI will take drug RK-4 (1 mg or 2 mg or 4 mg) by transcranial bone marrow injection once daily for consecutive 3 days.
218905133|NCT07161037|DRUG|VX-407|Tablets for oral administration.
218905134|NCT07168161|DRUG|BDB-001 injection|Intravenously administered
218905135|NCT07168161|DRUG|Cyclophosphamide|Intravenously administered
218905136|NCT07168161|BIOLOGICAL|Rituximab|Intravenously administered
218905137|NCT07168161|DRUG|Azathioprine|Intravenously administered
218905138|NCT07168161|DRUG|Prednisone|Intravenously administered
218905139|NCT07172412|DRUG|Selinexor|Selinexor 60 mg biw q21d
218905140|NCT07172412|DRUG|Anlotinib|Anlotinib 12mg d1-14 qd PO
218905141|NCT07172412|BIOLOGICAL|DLL3 CAR-NK cells|1.0×10\^9 DLL3-CAR-NK+ cells d5 q6w
218905142|NCT07172412|DRUG|Etoposide + Cisplatin/Carboplatin|Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5
218905143|NCT07172412|DRUG|Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab|Use immunotherapy according to the standard immunotherapy-combined-chemotherapy protocol.
218905144|NCT07160985|OTHER|AI-based Lifestyle Management|Participants will use the X Life model via smartphone/tablet for 28 days, receiving real-time, personalized dietary and exercise recommendations triggered by CGM and activity tracker data. Participants can interact with the system by uploading meal images, physical activity data, and wearable-derived metrics.
218905145|NCT07160985|OTHER|Lifestyle Management|Participants will receive guideline-based lifestyle counseling according to national prediabetes prevention guidelines, delivered via mobile terminal, without AI-generated recommendations.
218905146|NCT07175987|OTHER|RDTH002581|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
218905147|NCT07175987|OTHER|RDTH002580|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
218905148|NCT07175987|OTHER|RDTH002582|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
218905149|NCT07175987|OTHER|RDTH002578|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
218905150|NCT07175987|OTHER|RDTH002577|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
218905151|NCT07175987|OTHER|RDTH002579|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
218905152|NCT07179276|PROCEDURE|CO2gap-guided resuscitation strategy|"For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas:~* Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients.~* The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice)."
218905153|NCT07167121|DIAGNOSTIC_TEST|CPAx|"Evaluation of :~Respiratory function Cough Moving within the bed Supine to sitting on the edge of the bed Dynamic sitting Standing balance Sit to stand (starting position ≥ 90°) Transfering from bed to chair Stepping Grip strength (predicted mean for age and gender on the strongest hand)"
218905154|NCT07183657|OTHER|Education in inhalation technique|Education in inhalation technique
218905155|NCT07181902|PROCEDURE|Erector Spinae Plane Block (ESP)|Ultrasound-guided ESP block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
218905156|NCT07181902|PROCEDURE|Retrolaminar Block (RLB)|Ultrasound-guided Retrolaminar Block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
219038964|NCT03949829|DIAGNOSTIC_TEST|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
218905157|NCT07176104|DIETARY_SUPPLEMENT|Functional Bovine Milk|Functional milk product enriched with standardised bioactive peptides, provided daily for 12 months.
219612929|NCT03900052|DEVICE|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
218905158|NCT07176104|DIETARY_SUPPLEMENT|Non-Functional Bovine Milk|Standard bovine milk with identical caloric and macronutrient profile to the functionalized milk, without enrichment, provided daily for 12 months.
218905159|NCT07177287|BEHAVIORAL|IMB navigator app|Mobile application developed based on the IMB model, supported by a navigator nurse. Includes educational content, reminders and behavioral support. Patients will be followed for 6 months.
218905160|NCT07181499|DRUG|Befotertinib|Befotertinib was administered orally at a starting dose of 75 mg per day for 21 days, which could be increased to 100 mg per day if grade 2 or higher thrombocytopenia or headache did not occur within 21 days, or maintained at the original dose (75 mg per day) if grade 2 or higher thrombocytopenia or headache occurred within 21 days.
218905161|NCT07181499|DRUG|Pemetrexed + Carboplatin|pemetrexed (500 mg/m²) and carboplatin (AUC 5), administered every 3 weeks, for a total of 2\~4 cycles.
218905162|NCT07181837|GENETIC|MVX-220|AAVhu68 viral vector
218905163|NCT07187310|PROCEDURE|EXORA block|in a supine position, a linear Ultrasound probe (L6-12 RS linear array transducer (6-12 MHz) on GE Healthcare Logiq P7, made in Korea) will be sagittally applied at the parasternal line, lateral to the sternum and xiphoid process. The probe will be manipulated craniocaudally to identify the 6th, 7th, and 8th costal cartilages. At the level of the 8th costal cartilage, a transverse orientation will be used to visualize the rectus abdominis muscle and the costal cartilage beneath. An 88-mm, 22-gauge needle will be directed in-plane from medial to lateral. After confirming the needle position below the rectus abdominis muscle using 4 ml isotonic saline as a hydro-dissection, 25 ml of plain bupivacaine 0.25% concentration will be injected. the spread of the local anesthetic is to be observed to advance laterally under the external oblique muscle and medially under the rectus muscle. The same procedure will be repeated on the other side.
218905164|NCT07187310|PROCEDURE|Erector Spinae Plane block|in a right lateral position, the linear Ultrasound probe will be placed vertically 3 cm lateral to the midline at the level of the 7th thoracic spinal process, identifying the T7 transverse process, and the overlying erector spinae (ES) muscle. An 88-mm, 22-gauge needle will be advanced craniocaudally in-plane until hitting the T7 transverse process. After using hydro-dissection with 4 ml of isotonic saline to confirm the correct needle position, 25 ml of 0.25% bupivacaine will be administered below the erector spinae muscle. The same procedure will be repeated on the other side.
218905165|NCT07187297|DEVICE|Thermage FLX|The Thermage FLX System ('System') is a monopolar, capacitively coupled radiofrequency System designed for use in non-invasive dermatological procedures
218905166|NCT07189130|OTHER|Exercise: 80% 1 RM with 2 minutes break|Participant will do resistance exercise at 80% 1RM with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
218905167|NCT07189130|OTHER|Exercise: 80% 1RM with1 minute break|Participant will do resistance exercise at 80% 1RM with 1 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
218905168|NCT07189130|OTHER|Exercise: accenuated eccentric exercise|Participant will do accenuated eccentric resistance exercise at 80% 1RM in concetric part of movement and 110% 1RM in eccentric part of movement with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
218905169|NCT07189130|OTHER|Control|Timeline of events will be same as in exercise protocol (blood withdrawal and Stroop test), except participants will not do any kind of exercise protocol, instead they will be seating.
218905170|NCT07187518|DEVICE|Measurements with the POROUS R4C ultrasound device at the midshaft tibia|The POROUS R4C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
219038965|NCT04155515|DRUG|TG-2349|TG-2349 400mg
219038966|NCT04155515|DRUG|DAG181|DAG181 200mg
219612930|NCT03900052|DEVICE|typical cane|Typical training cane loading training
219612931|NCT00456300|DRUG|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
218905171|NCT07187518|DEVICE|DXA measurement of the hip and lumbar spine|The following DXA measurements are to be performed: • Spine L1-4 • Hip left • Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R4C ultrasound scan.
218905172|NCT07190066|OTHER|Data Collection campaign|Participants will be asked to download the MELIROA app, compatible with iOS and Android, to their smartphones and test it for 14 days. The app will prompt the user to set a weekly goal on physical activity and support daily self-monitoring and step count tracking. Τhe app will also offer culturally adapted educational material through mini-courses, motivational and practical tips and an embedded library of materials relevant to physical activity, healthy diet and alcohol consumption. To boost motivation, it will also include reminders and gamification features like badges and points.
219038967|NCT04155515|DRUG|Ribavirin|Ribavirin 1000mg/1200mg
219204347|NCT06883864|DRUG|Medication|Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.
219612932|NCT00456300|DRUG|Insulin|Each subject received a baseline study with insulin alone
218905173|NCT07191288|DEVICE|VR (VR-Breathing+Mystical)|The VR-based slow-paced breathing application is designed to provide rewarding biofeedback for a specific breathing pattern characterized by prolonged exhales. As users extend their exhales, a veil of fog gradually lifts, introducing a mystical type experience. Over time, users are rewarded with a full 360-degree panoramic view of the beautiful nature scene, accompanied by relaxing music. After approximately 5 minutes of prolonged exhales, the nature scene responds to the user's breathing by slowing down, with falling snowflakes moving more slowly, further enhancing the mystical atmosphere. This intervention was designed to be visually captivating, mystically evocative, and emotionally engaging. Duration: 10 minutes.
218905174|NCT07191288|DEVICE|VR (VR-Mystical)|Users will experience the gradual unveiling of a beautiful natural landscape as the fog lifts, and eventually, the scene slows down similar to the VR Breathing+Mystical condition. However, this application does not provide any biofeedback or breathing instructions. Users are invited to passively observe the unfolding experience, immersing themselves in the environment for 10 minutes. Relaxing music accompanies the scene. This condition relies solely on the immersive and aesthetic qualities of the virtual environment to potentially induce relaxation.
218905175|NCT07191288|DEVICE|Computer (Non-VR-Breathing)|In this conventional breathing intervention, participants will be instructed to follow a slow-paced breathing pattern guided by a simple visual cue (an expanding and contracting circle) displayed on a computer screen for 10 minutes. This condition is designed to guide slow-paced breathing without incorporating any rewarding elements.
218905176|NCT07191288|DRUG|VR (VR-Control)|In the control condition, participants will watch a neutral documentary for 10 minutes in VR. This condition is used to control for the effects of the immersive VR experience. It does not include any components related to guided breathing or mystical-type content, or any form of rewarding elements.
219520454|NCT02754401|OTHER|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
219520455|NCT05627427|DRUG|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
218905177|NCT07184281|BEHAVIORAL|12-hour time-restricted eating|Based on the current health education model, the subjects in the experimental group were administered for 12 hours of TRE. Carry out the propaganda and education of the 12-hour TRE feeding mode, the core content is that the eating time window is limited to 12 hours/day, the last meal is no later than 19:00, the study subjects can freely choose the eating time window, do not restrict energy intake during eating, and during the fasting period, they are allowed to drink non-calorie, sugar-free drinks (water, tea, coffee). Record the time of eating every day.
218905178|NCT07184281|BEHAVIORAL|health education|"The current health education model is adopted, that is, health education is carried out in accordance with the Guiding Outline for Health Education in Primary and Secondary Schools."
218905179|NCT07185776|DRUG|HRS-5632 Injection|HRS-5632 injection.
218905180|NCT07185776|DRUG|HRS-5632 Injection Placebo|HRS-5632 injection placebo.
219038968|NCT04560634|DRUG|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
219038969|NCT04560634|DEVICE|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
219520456|NCT05627427|DRUG|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
219520457|NCT03884166|DIAGNOSTIC_TEST|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
219520458|NCT04525248|PROCEDURE|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
219520459|NCT04525248|PROCEDURE|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
219520460|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
219520461|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
219520462|NCT04408404|PROCEDURE|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
219520463|NCT03492580|DRUG|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
219520464|NCT03492580|DRUG|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
219520465|NCT03492580|DRUG|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
219520466|NCT03492580|DRUG|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
219520467|NCT03492580|DRUG|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
219520468|NCT03492580|DRUG|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
218905181|NCT07188467|BEHAVIORAL|Digitized SH+|Digitized SH+ is a group-based, stress management program (adapted from the original Self-Help Plus intervention developed by the World Health Organization), that utilizes animated videos and group discussions to teach participants skills such as Grounding, Unhooking (from difficult thoughts), Being Kind (to self and others), Identifying Values, and Making Room for Difficult Thoughts and Feelings.
219038970|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
219038971|NCT02244333|DRUG|ALNA®|
219038972|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
219038973|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
219038974|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
219038975|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
219038976|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
219038977|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
219038978|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
219038979|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
219038980|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
219038981|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
219038982|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
219038983|NCT00003255|DRUG|carboplatin|
219038984|NCT00003255|DRUG|topotecan hydrochloride|
219038985|NCT00664716|BIOLOGICAL|Baminercept alfa 1|experimental - one dose level
219038986|NCT00664716|BIOLOGICAL|Placebo|Placebo comparator
219038987|NCT00664716|BIOLOGICAL|Baminercept alfa 2|experimental - second dose level
219520469|NCT03492580|DRUG|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
219038988|NCT00664716|BIOLOGICAL|Baminercept alfa 3|experimental - third dose level
219520470|NCT03492580|DRUG|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
219520471|NCT03492580|DRUG|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
219038989|NCT00664716|BIOLOGICAL|Baminercept alfa 4|experimental - fourth dose level
219038990|NCT00664716|BIOLOGICAL|Baminercept alfa 5|experimental - fifth dose level
219038991|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
219038992|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
219204348|NCT06883864|PROCEDURE|(ELEVATE-AF X) experimental group|Subsequent ablations may be considered for patients with recurrence，and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
219204349|NCT06883864|PROCEDURE|(ELEVATE-AF X) control group|All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
218905182|NCT07187466|DRUG|mirabegron|Mirabegron is a beta-3-agonist, which acts upon the noradrenergic system and avoids the cognitive and gastrointestinal side effects of anticholinergic bladder relaxants.
219038993|NCT06679634|DRUG|Chemoplaque also referred to as Episcleral Topotecan|Sustained Release Episcleral Topotecan
219038994|NCT04342104|OTHER|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
219038995|NCT04342104|OTHER|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
219038996|NCT02981381|DEVICE|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
219204350|NCT06884280|DRUG|Monofer (iron isomaltoside 1000)|Intravenous iron infusion, administered in this study up to every 3 months. Dosage determined by haemoglobin and weight.
218905183|NCT07187466|BEHAVIORAL|Exercise-based behavioral therapy|The exercise-based behavioral therapy is a comprehensive training program administered individually by a trained nurse practitioner interventionist to address urinary incontinence and other lower urinary tract symptoms.
219520472|NCT03249584|DEVICE|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
219520473|NCT06176287|PROCEDURE|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
218905184|NCT07199426|OTHER|Physical-Cognitive Training|Participants will receive an 8-week physical-cognitive training program using the Blazepod device, consisting of exercises targeting both balance and cognitive skills. Sessions will be conducted three times per week, each lasting one hour.
218905185|NCT07199426|OTHER|Conventional Balance Training|Participants will receive an 8-week conventional balance training program. Sessions will be conducted three times per week, each lasting one hour.
218905186|NCT07199816|PROCEDURE|Fluoroscopy-Guided Caudal Epidural Block|Under fluoroscopic guidance, the patient in the prone position will receive a caudal epidural injection through the sacral hiatus. A 22-gauge, 3.5-inch spinal needle (Spinocan®, BRAUN) is used to inject 1 mL of contrast media (Omnipaque 300) to confirm correct needle placement. Then, 10 mL of treatment solution (8 mL of 0.5% lidocaine and 2 mL of 8 mg dexamethasone) is administered.
218905187|NCT07199816|PROCEDURE|Combined Lumbar Sympathetic Ganglion Block and Caudal Epidural Block|Patients will receive both a caudal epidural block and a lumbar sympathetic ganglion block (LSGB) under fluoroscopic guidance. The LSGB is performed at the L2 or L3 vertebral body on the affected side using a 21-gauge Chiba needle. After confirming needle position with contrast imaging, 10 mL of solution (2 mL of 8 mg dexamethasone + 8 mL of 1% lidocaine) is injected. A caudal block is then performed as described above.
218905188|NCT07199075|BEHAVIORAL|Questionnaires|"Questionnaires~* Oswestry Disability Index (ODI)~* Pain NRS lower back and (wors side) leg~* EQ-5D-3L"
218905189|NCT07199075|RADIATION|Computer Tomography|One additional CT scan is performed for some patients
218905190|NCT07198854|OTHER|Not applicable- observational study|This is a retrospective cohort study and intervention is not applicable.
218905191|NCT07199348|DEVICE|Embobio|Embolization with the device Embobio
218905192|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ia)~Low dose group， Middle dose group； High dose group； Control group ：Placebo"
218905193|NCT07198555|DRUG|Placebo|Placebo(phase Ia)
218905194|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group~Control group ：Placebo"
218905195|NCT07198555|DRUG|Placebo|Placebo（phase Ib）
218905196|NCT07199140|BEHAVIORAL|Haptonomy|Pregnant participants will receive a four-session haptonomy intervention, each lasting approximately 45 minutes. The sessions aim to enhance body awareness, reduce childbirth-related anxiety, and support birth self-efficacy. The intervention includes breathing exercises, relaxation techniques, and activities promoting maternal-fetal interaction.
218905197|NCT07199491|BEHAVIORAL|Healthy Liver/Hígado Sano program|Participants will attend weekly classes over the 6-month period. This consists of 16 core sessions delivered in the first 6 months (weekly, but with flexibility to skip weeks as necessary due to holidays, etc). The sessions are 30-60 minutes long, conducted in a group setting, with a CDC-certified Lifestyle Coach facilitating the sessions.
218905198|NCT07199491|BEHAVIORAL|Usual Care|participants will first complete a 30- to 45-minute questionnaire that will cover topics such as physical activity, diet, alcohol use, and stress.Participants will then be asked to wear an accelerometer for 7 days and complete a log to identify when it was worn and removed each day.Height and weight will also be measured and a Fibroscan® assessment (to measure amount of fat and scar tissue in the liver), as well as blood work to monitor the liver enzymes will be done
218905199|NCT07198581|BEHAVIORAL|LLM-assisted chemotherapy side effect management|Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.
218905200|NCT07199543|DRUG|benzydamine HCl|The investigational medicinal products were tasted during two study ambulatory visits, separated by a wash-out of at least 3 days
218905201|NCT07198932|DRUG|Cofrogliptin add to insulin|Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.
218905202|NCT07198932|DRUG|Linagliptin add to insulin|Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.
218905203|NCT07199010|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
219038997|NCT02981381|DEVICE|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
219204351|NCT06884280|DRUG|Ferrous Sulfate|Oral iron tablet taken once daily for duration of study.
219520474|NCT06176287|PROCEDURE|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
219520475|NCT02898909|DEVICE|nuclear lens fragmentation in 8 pieces|
219520476|NCT02898909|DEVICE|nuclear lens fragmentation in 16 pieces|
218905204|NCT07198841|DRUG|IBI351 combined with cetuximab β|Subjects will receive treatment with IBI351 plus cetuximab β, consisting of oral IBI351 administered at 600 mg twice daily (BID) either in a fasting or fed state, combined with intravenous infusion of cetuximab β injection dosed at 500 mg/m² (body surface area) every two weeks. Each treatment cycle spans two weeks. Therapy will continue until disease progression, unacceptable toxicity, or meeting other protocol-defined criteria for treatment discontinuation-whichever occurs first. Dose adjustments may be implemented throughout the study based on drug-related toxicities.
218905205|NCT07199569|BIOLOGICAL|Jynneos|MVA-BN manufactured in primary CEF cells. MVA-BN (CEF) vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U and is an LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
218905206|NCT07199569|BIOLOGICAL|MVA-BN (Quail)|MVA-BN manufactured in CCX.E10 quail cell line. Vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U. and is a LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
218905207|NCT07199270|BIOLOGICAL|GR2303 injection|single dose
218905208|NCT07199270|BIOLOGICAL|Placebo|single dose
218905209|NCT07199270|BIOLOGICAL|GR2303 injection|multiple dose
218905210|NCT07199270|BIOLOGICAL|Placebo|multiple dose
218905213|NCT07198178|OTHER|Peer Training|"Peer Selection Fourth-year nursing students who have completed the Clinical Practice-I course and are currently attending the Clinical Practice-II course and are in clinical practice four days a week will be invited to volunteer to become peer tutors after being informed about the purpose of the study. These volunteer peer tutors will be selected from among students with strong academic achievement (grade point average of 3.50 or above) and good communication skills, taking into account their clinical experience.~Peer Training Fourth-year students selected as peers will receive a training program consisting of four 40-minute sections, each lasting 160 minutes, prepared by the faculty members and aligned with the Fundamentals of Nursing course curriculum. This training aims to equip peers with the knowledge and skills to guide, provide feedback, and support to first-year students during clinical practice. The training will utilize active learning methods such as role-playing and case st"
218905214|NCT07199868|PROCEDURE|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.
218905215|NCT07198243|DRUG|STW 5-II|"STW 5-II is an herbal medicinal product for the symptomatic treatment of functional dyspepsia with main symptoms such as epigastric pain, epigastric burning, postprandial fullness and early satiation, but often also loss of appetite, excessive belching and heartburn. STW5-II consists of six herbal extracts: bitter candy tuft, camomile flower, caraway fruit, melissa leaf, peppermint leaf, and licorice root.~STW 5-II will be a solution for oral intake, for the treatment of FD, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention"
218905216|NCT07198243|DRUG|Placebo|Matching placebo will be a solution for oral intake, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention.
218905217|NCT07198373|DRUG|Maintenance Therapy Group|Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.
218905218|NCT07199881|PROCEDURE|Stepwise PSV adjustment protocol|Patients will undergo standardized stepwise PSV changes (baseline, ±3 cmH₂O, ±6 cmH₂O, return to baseline), with 2-minute stabilization and repeated measurements of ventilatory parameters.
218905219|NCT04833114|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
218905220|NCT04833114|DRUG|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
219204352|NCT06884488|DEVICE|repetitive transcranial magnetic stimulation (Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|The paradigm will be applied over the dominant cerebral hemisphere for 10 minutes (600 pulses) over the dominant pharyngeal motor cortex capped at 120% of pharyngeal resting motor threshold.
219204353|NCT06884488|DEVICE|pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|The PES (0.2-ms pulses, 280 V) was delivered at a set frequency (5 Hz), intensity (75% of maximal tolerated), and duration (10 minutes), which have been reported as the most effective parameters for PES.
219520477|NCT05727137|PROCEDURE|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
219520478|NCT05727137|PROCEDURE|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
219520479|NCT02392793|DRUG|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
219520480|NCT02392793|DRUG|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
219520481|NCT02392793|DRUG|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
219520482|NCT02392793|DRUG|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.
219520483|NCT02392793|DRUG|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
219520484|NCT01345045|DRUG|ABT-639|ABT-639 Twice Daily for six weeks.
219520485|NCT01345045|DRUG|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
219520486|NCT01345045|DRUG|Placebo|Placebo twice daily for 6 weeks.
219520487|NCT00620048|BIOLOGICAL|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
219520488|NCT04353791|DRUG|OST-122|Active dose
219520489|NCT04353791|DRUG|Placebo|Placebo
218905221|NCT04833114|DRUG|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
218905222|NCT04833114|DRUG|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
218905223|NCT04833114|DRUG|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
219204354|NCT06884488|DEVICE|sham repetitive transcranial magnetic stimulation(Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|Sham rTMS is delivered with the coil tilted to its side at 90 degrees and with the identical stimulation conditions as active 1 Hz rTMS.
219204355|NCT06884488|DEVICE|sham pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|For sham pharyngeal stimulation, the same method including the insertion of the catherter will be employed without actual electrical stimulation.
219520490|NCT02191891|DRUG|Xentuzumab|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
219520491|NCT02191891|DRUG|Afatinib|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
219520492|NCT04370665|DEVICE|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
219038998|NCT02981381|DEVICE|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
219038999|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
219039000|NCT04905316|DRUG|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
219520493|NCT01864330|DEVICE|Thealoz Duo®|Eye Drops
219039001|NCT04905316|DRUG|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
219204356|NCT06886984|BEHAVIORAL|Social media motivation|Reminding the oral hygiene instructions using social media tools to keep their oral hygiene stable
219520494|NCT01864330|DEVICE|Hyabak®|Eye Drops
219204357|NCT06888739|PROCEDURE|MR4|The study is a clinical retrospective study and does not involve any interventional measures.
219204358|NCT06888063|COMBINATION_PRODUCT|Hepatic Arterial Infusion Pump chemotherapy with floxuridin|Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)
218905228|NCT07198087|DRUG|Tirabrutinib|Administered orally
218905229|NCT07199907|BEHAVIORAL|Associative Inference|Objects, faces, and scenes will be arranged into 12 ABC triads presented as overlapping AB and BC pairs. AB pairs will comprise objects; BC pairs will consist of the same B object paired with a face or scene (C). Twelve non-overlapping (NO) pairs will serve as controls. Participants will study overlapping (AB, BC) and NO pairs (4s) across two 5-minute fMRI runs. Each pair will be presented three times within a run. Following learning, participants will complete a self-paced 3-alternative forced choice (AFC) inference task during which they will select the C item that shares a common relationship with an A cue. Foils for inference trials will be C items from other ABC triads, of the same face/scene subcategory. Participants will then complete a final, self-paced 3-AFC memory test of premise associations (AB, BC) and NO pairs. To quantify memory retrieval and how overlapping events are organized, before and after learning, participants will view the A and C items during fMRI scanning.
219204359|NCT06887673|OTHER|No Interventions|No study treatment other than the standard of care management.
219204360|NCT06887673|DIETARY_SUPPLEMENT|Sports Pro Resolve 4 g|Sports Pro Resolve 4 tabs (2 g) twice daily
219204361|NCT06887673|DIETARY_SUPPLEMENT|Double Wood SPM 4 g|Double Wood SPM 4 tabs (2 g) twice daily
219204362|NCT06887673|DIETARY_SUPPLEMENT|20 California Sweet Almonds|10 California Sweet Almonds twice daily
219204363|NCT06887673|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast 10 Mg Oral Tablet daily
219204364|NCT06887673|COMBINATION_PRODUCT|Montelukast 10 Mg Oral Tablet and SPM 4 g|Montelukast 10 Mg Oral Tablet and SPM 4 g
219520495|NCT01864330|DEVICE|Hydrabak®|Eye Drops
219520496|NCT01922648|PROCEDURE|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
219520497|NCT02693210|DRUG|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
219520498|NCT02693210|DRUG|Methotrexate|Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks
219520499|NCT02693210|OTHER|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
219520500|NCT02693210|OTHER|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
219520501|NCT02693210|OTHER|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
218905230|NCT07199907|BEHAVIORAL|Probabilistic Inference|"Participants will visit a virtual zoo, which is divided into three zones, each containing the same five monsters, but with different likelihoods of occurrence. Participants learn the underlying likelihood distributions by virtually navigating each zone. On each trial, two monsters appear; participants select the monster that they predict will next appear (6s). After making their choice, the correct monster appears and feedback is provided (2s). Participants tour each zone four times across 9 runs. Following learning, participants are tested on probabilistic inference. Here, participants see a series of monster photographs and are asked to infer in which zone they were taken. On each trial, a sequence of individual monster images (3.5s each) will then appear (1-6 monsters) prior to a decision screen, in which participants choose which of the two zones most likely produced the photos (4s) and are given feedback (1.5s). Participants will perform nine fMRI runs of the inference task."
218905231|NCT07199712|OTHER|Ozone Therapy (In-Office and Home-Based Treatment)|The intervention consists of professional in-office ozone therapy delivered with the Ozono DTA device (Sweden-Martina) applied to oral mucosal lesions. The first treatment is administered at baseline and additional sessions are performed at 48 hours, day 5, day 8, day 12, and day 15, if clinically required. Alongside in-office therapy, participants perform a 15-day domiciliary regimen with ozonated oral care products, including toothpaste with 2% ozonated sunflower oil, a mouthrinse with 4% ozonated sunflower oil solution, and a topical gel with 15% ozonated sunflower oil, each used twice daily. Clinical outcomes are assessed at each visit from baseline to day 15 with the WHO oral mucositis scale and the Visual Analogue Scale for pain.
219204365|NCT06887673|DIETARY_SUPPLEMENT|Cold- Pressed Almond Oil 30 mL|Cold- Pressed Almond Oil 30 mL every morning
219204366|NCT06890182|DRUG|Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed|furmonertinib 80mg/d for 12 weeks and carboplatin AUC5 d1 iv / cisplatin 75mg/m2 d1 iv+ pemetrexed 500mg/m2 d1 iv at 21 day cycles for 4 cycles
219520502|NCT02693210|DRUG|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
219204367|NCT06889454|DRUG|GLP-1 receptor agonist|30 women will receive lifestyle modification and GLP-1 receptor agonists
219520503|NCT01826123|DEVICE|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
219520504|NCT01826123|DEVICE|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
219520505|NCT06311942|DRUG|HAIC plus PD-1 inhibitors plus lenvatinib|Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
219520506|NCT06311942|DRUG|PD-1 inhibitors plus lenvatinib|The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
219520507|NCT02884232|PROCEDURE|Nasofibroscopy|
218905232|NCT07197970|DEVICE|NxiDIME™ Intracranial Drug-Eluting Stent System|The experimental group will receive the NxiDIME™ Intracranial Drug-Eluting self-expanding Stent System (RICOTON Technology Co., Ltd.)
218905233|NCT07197970|DEVICE|NOVA DES Intracranial Drug-Eluting Stent|The experimental group will receive the NOVA DES Intracranial Drug-Eluting balloon-expandable stent System
218905234|NCT07200180|DRUG|Аrgon-oxygen breathing mixture|Patients receive a course of inhalations with an argon-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
218905235|NCT07200180|DRUG|Nitrogen-oxygen breathing mixture|Patients receive a course of inhalations with an nitrogen-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
218905236|NCT07198035|DRUG|PF-07248144|Participants will receive a single dose of PF-07248144 by mouth in Period 1 on Day 1 and Period 2 on Day 14, with a washout period of at least 14 days between two doses of PF-07248144
218905237|NCT07198035|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for Day 1 through 3, then twice a day for Day 4 through 7, and then three times daily for Day 8 through 20 in Period 2.
218905238|NCT07198360|OTHER|No intervention|Not found
219204368|NCT06889454|DRUG|Oral contraceptive|30 women will receive lifestyle modification and oral contraceptive
219204369|NCT06889454|DRUG|Metformin|30 women will receive lifestyle modification and metformin
219204370|NCT06889454|OTHER|Lifestyle modification|30 women will receive only lifestyle modification
219204371|NCT06885476|BIOLOGICAL|Infusion of alloreactive NK cells|Infusion of alloreactive NK cells for acute leukemia patients harboring minimal residual disease after conventional chemotherapy and prior to allogeneic stem cell transplantation
219204372|NCT06886360|DRUG|norucholic acid|500 mg norucholic acid film-coated tablets; 3 tablets/day
219520508|NCT05527678|OTHER|Questionnaires|Written or by phone
219520509|NCT05395247|OTHER|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
219520510|NCT00006734|BIOLOGICAL|filgrastim|Given IV
219520511|NCT00006734|DRUG|cyclophosphamide|Given IV
219520512|NCT00006734|DRUG|doxorubicin hydrochloride|Given IV
219520513|NCT00006734|DRUG|etoposide|Given IV
219520514|NCT00006734|DRUG|ifosfamide|Given IV
219520515|NCT00006734|DRUG|vincristine sulfate|Given IV
219520516|NCT00006734|PROCEDURE|adjuvant therapy|
219520517|NCT00006734|PROCEDURE|conventional surgery|
219520518|NCT00006734|PROCEDURE|neoadjuvant therapy|
219520519|NCT00006734|RADIATION|brachytherapy|
219520520|NCT00006734|RADIATION|radiation therapy|
219520521|NCT00005576|BIOLOGICAL|monoclonal antibody Ch14.18|Given IV
219520522|NCT00005576|DRUG|isotretinoin|Given orally
219520523|NCT00005576|BIOLOGICAL|aldesleukin|Given IV
219520524|NCT00005576|BIOLOGICAL|sargramostim|Given IV
219039002|NCT04905316|RADIATION|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
219039003|NCT04905316|DRUG|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
219039004|NCT05232851|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
219039005|NCT05232851|BIOLOGICAL|Pembrolizumab|Given IV
219039006|NCT05232851|PROCEDURE|Computed Tomography|Undergo CT, FDG-PET/CT
219039007|NCT05232851|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
219520525|NCT05915403|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire|diagnostic tests
219520526|NCT04004312|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
219204373|NCT06886789|BEHAVIORAL|Text Messaging|On 3 days/week they receive a text about 1 of the 3 behaviors (weight maintenance or loss, physical activity, and medication adherence) in randomized order with guidance for maintaining or improving these behaviors to reach program-provided goals. The system compares their last week's adherence to the responder criteria. They receive feedback praising adherence and instructions for a theory-driven behavioral strategy (e.g., stimulus control) to increase adherence. Feedback is tailored to the patient's adherence or existence of self-monitoring data.
218905242|NCT07198672|DRUG|Herombopag|Each T-DM1 treatment cycle typically lasts 3 weeks, with prophylactic administration of eltrombopag continuing until 21 days after the end of that T-DM1 treatment cycle. Oral administration of eltrombopag ethanolamine tablets begins on the evening of the first day of each T-DM1 treatment cycle, starting at a dose of 7.5 mg once daily.
218905243|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke with AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the AI-based decision support system (CO-AIDER). Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
218905244|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke without AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the clinical team based on their expertise. Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
218905245|NCT07198022|DRUG|Cryotherapy|Using crytotherapy as topical anesthetic
218905246|NCT07198022|DRUG|topical anesthetic|Comparing the two versions (the room temperature and + 4°C) of the gold standard of local anesthetics, the solution, which contains lidocaine.
218905247|NCT07198022|DRUG|Topical anesthetic gel|Tolerable taste, containing benzocaine at gel formula.
218905248|NCT07198022|DRUG|Placebo|The placebo participants will be informed to have the standard topical anesthetic spray.
219520527|NCT04829227|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219039008|NCT05232851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219039009|NCT05232851|PROCEDURE|Biopsy|Undergo biopsy
219039010|NCT06639698|DIETARY_SUPPLEMENT|Diosgenin|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
219520528|NCT04394676|PROCEDURE|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
219520529|NCT00487500|DEVICE|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
219039011|NCT06059404|BEHAVIORAL|Meals + RD services only|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
219039012|NCT06059404|BEHAVIORAL|Meals + OT services only|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
219039013|NCT06059404|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
219520530|NCT01221376|DRUG|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
219520531|NCT02351466|OTHER|Observational|
218905250|NCT07198971|OTHER|Music therapy|"Music therapy sessions in addition to nursing consultations:~creation of a soundtrack to listen to in order to help quit smoking"
218905251|NCT07199595|DRUG|Dexamedomedine|"Group A (the Dexmedetomidine group):~Dexmedetomidine: loading dose 1 µg/kg IV over 10 min after induction and then maintenance dose 0.2- 0.7 µg/kg/hr based on hemodynamic response."
218905252|NCT07199595|DRUG|MgSO4|Magnesium Sulfate: Used as an IV loading dose at 20 mg/kg IV over 17 minutes as an induction agent, followed by maintenance of 10 mg/kg/h
218905253|NCT07199413|BIOLOGICAL|SV-BR-1-GM Vaccine|\~20 X 10\^6 cells across 4 injection sites
218905254|NCT07199413|DRUG|Cyclophosphamide|300 mg/m\^2 Intravenous
218905255|NCT07199413|DRUG|Pembrolizumab|200 mg/m\^2 Intravenous
218905256|NCT07199413|DRUG|Interferon|0.18 mcg subcutaneous
218905257|NCT07198789|OTHER|Altograno® Bakery Foods|Altograno® Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
218905258|NCT07198789|OTHER|Standard Whole-Grain Bakery Foods|Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
218905259|NCT07198750|DEVICE|HI-PEMF - Knee (Chronic Pain Protocol)|"High-intensity pulsed electromagnetic field (HI-PEMF) therapy applied to the symptomatic knee using the Chronic Pain protocol of the BTL-6000 Super Inductive System, 10-minute duration per session, applied twice per week over 5 weeks (total of 9 sessions). The applicator is positioned 2-3 cm above the patella, without skin contact, with the patient seated or in supine position."
218905260|NCT07198750|DEVICE|HI-PEMF - Quadriceps (Muscle Strengthening Protocol)|"HI-PEMF therapy will be applied to both the symptomatic knee and the quadriceps muscle (rectus femoris). The knee application will follow the same procedure as in Group A, using the Chronic Pain protocol of the BTL-6000 Super Inductive System. In addition, the quadriceps will be treated using the Muscle Strengthening protocol. Each site will receive 10 minutes of therapy per session, twice per week over 5 weeks (total of 9 sessions). The applicator for the quadriceps will be positioned perpendicular to the muscle belly, without skin contact, with the patient lying supine and a cushion under the knee for slight flexion."
219520532|NCT01522664|DRUG|DEDN6526A|Multiple ascending doses
219520533|NCT03223233|OTHER|procalcitonin level|serum procalcitonin level will be measured in both groups.
219520534|NCT06091878|OTHER|Observation|Observational study, no intervention
218905261|NCT07198750|BEHAVIORAL|Home-Based Exercise Program|Standardized home-based exercise program prescribed to both groups. It includes five exercises: isometric quadriceps contractions, straight leg raises, seated knee extensions, sit-to-stand from chair, and stationary marching. Participants are instructed to perform the exercises three times per week during the 5-week intervention. Printed instructions and a video guide are provided. Adherence is reinforced via weekly follow-up.
218905262|NCT07199361|DEVICE|Peripheral Transcutaneous Magnetic Stimulation from MagVenture|"MagVenture Pain Therapy System: It is an FDA-cleared magnetic stimulator system that provides brief and focused magnetic pulses to non-invasively stimulate peripheral nerves and provide relief of chronic intractable, post-traumatic, and post-surgical pain for patients 18 years or older. It is a relatively new technique in the US for pain relief in the clinical setting and thus not very widespread yet. Evidence shows Magnetic Peripheral Nerve Stimulation to have a promising average pain relief of up to 87%\*. Using magnetic pulses, MagVenture Pain Therapy engages sensory, pain, and motor fibers mechanistically to recondition the central nervous system by eliminating noxious pain signals to the brain, reducing chronic neuropathic pain for responsive patients.~\*Bedder M, Parker L.: Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain, 2023"
218905263|NCT07198516|DRUG|Addition of Hengge Liejing treatment for 48 weeks|Treatment with Hengge Liejing for 48 weeks, drug formulation: tablets. Dosage: 10mg qd, taken orally in the morning, before or after breakfast, for 48 consecutive weeks
218905264|NCT07198191|DRUG|SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)|Exposure to SGLT2 inhibitors following AMI in patients with T2DM
218905265|NCT07198191|DRUG|DPP4 inhibitors|Exposure to DPP4 inhibitors following AMI in patients with T2DM
218905266|NCT07198347|DRUG|AG2001|Oral administration, three times daily for 7 days.
219520535|NCT03729297|DRUG|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
219520536|NCT04550065|BEHAVIORAL|Digital game|A digital family game with theme-based mini games (epidemic prevention, exercise, diet, communication and parenting)
219520537|NCT03982485|DRUG|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
219520538|NCT03982485|DRUG|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
219520539|NCT03982485|DRUG|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
219520540|NCT03982485|PROCEDURE|Surgery|Surgery
219520541|NCT00486837|DRUG|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
219520542|NCT02724800|BEHAVIORAL|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
219520543|NCT02724800|BEHAVIORAL|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
219520544|NCT02468778|DEVICE|HeartMate PHP|The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
219520545|NCT02468778|DEVICE|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
218905267|NCT07198347|DRUG|AG20011|Oral administration, three times daily for 7 days.
218905268|NCT07198347|DRUG|AG20012|Oral administration, three times daily for 7 days.
218905269|NCT07199257|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
218905270|NCT07199257|BIOLOGICAL|Placebo|Placebo
218905271|NCT07197996|DEVICE|Intermittent Pneumatic Compression|The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.
218905272|NCT07197996|DEVICE|geko® T3|The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.
219520546|NCT01037283|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
219520547|NCT05240222|BEHAVIORAL|Pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
219520548|NCT05240222|OTHER|Sham comparator|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
219520549|NCT00858923|DEVICE|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
219520550|NCT05070260|DRUG|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
219520551|NCT05070260|DRUG|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
219520552|NCT00350246|PROCEDURE|Laser Refractive Surgery|
219520553|NCT00743548|DEVICE|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
218905273|NCT07199478|PROCEDURE|Integrated mHealth and ERAS Digital Rehabilitation via WeChat Mini-Program|"This intervention arm is distinguished by the following key features:~Theory-Driven Design: Uniquely integrates three established behavioral theories into its core functionality: Bandura's Self-Efficacy Theory, the Health Belief Model, and Illeris's Learning Model. This theoretical foundation directly informs the app's features to target psychological and behavioral barriers to recovery.~Multi-Functional Platform: Combines several evidence-based components into a single, cohesive platform within the ubiquitous WeChat ecosystem. Key features include:~Visual Goal and Progress Tracking: Provides patients with mastery experiences.~Peer Community (Modeling Community): Features patient stories and videos to provide vicarious experiences and social support.~AI-Powered Persuasion System: Delivers automated, personalized feedback and remote encouragement from healthcare providers.~Built-in Emotional Management Tools: Includes an emotion diary"
219520554|NCT00743548|DEVICE|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
218905274|NCT07199478|PROCEDURE|Standardized ERAS Protocol|Participants received only the standardized Enhanced Recovery After Surgery (ERAS) protocol, representing the conventional care model.
219520555|NCT00147030|PROCEDURE|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
219520556|NCT00262964|DRUG|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
219520557|NCT00262964|DRUG|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
219039014|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
219039015|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
219039016|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
219039017|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
219520558|NCT00262964|DRUG|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
218905275|NCT07198217|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|The enrolled population consists of patients with stage IIIB/C-IV non-small cell lung cancer who are driver gene negative or unknown, as well as those with driver gene positive targeted drug resistance. The patients reaching SD, PR, or CR after 4 cycles of platinum based dual drug chemotherapy. The patient will receive SBRT radiotherapy combined with Tislelizumab treatment, followed by Tislelizumab maintenance therapy.
218905276|NCT07199842|OTHER|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment
218905277|NCT07199764|DRUG|Odetiglucan|Odetiglucan 4 mg/kg IV every 3 weeks
218905278|NCT07199764|DRUG|Mitazalimab|Mitazalimab 0.9 mg/kg IV every 3 weeks
219520559|NCT00920764|DRUG|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
219520560|NCT00920764|DRUG|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
219520561|NCT00920764|DRUG|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
219520562|NCT00920764|DRUG|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
219520563|NCT02590159|DEVICE|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
219520564|NCT04154579|BEHAVIORAL|HeRe We Arts|Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
219612933|NCT06156332|DRUG|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
219612934|NCT02982837|DRUG|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
219612935|NCT02982837|DRUG|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
219612936|NCT01229137|DEVICE|SRD-1 conversion|
219612937|NCT02784561|DRUG|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
219612938|NCT02784561|DRUG|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
219612939|NCT02784561|DRUG|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
219612940|NCT02784561|DRUG|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
218905279|NCT07199933|DRUG|Diacerein 50 mg Capsule|Drug:Diacerein 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
218905280|NCT07199933|DRUG|Placebo 50 mg|Drug:Placebo 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
218905281|NCT07200115|DEVICE|Cervical Ripening Double Balloon (CRDB) Catheter|The physician will place a CRDB catheter for overnight cervical preparation. The CRDB catheter is comprised of two balloons that can be inflated with up to 80 mL of sterile water.
218905282|NCT07200115|DEVICE|Osmotic Dilators|Osmotic dilators (e.g., laminaria and Dilapan-S) are mechanical dilators that are placed in the cervix prior to gynecologic procedures and facilitate dilation through the slow absorption of moisture. The physician will place osmotic dilators in the standard fashion.
218905283|NCT07198802|OTHER|No Intervention|This project involves no therapeutic intervention for the subjects.
218905284|NCT07198698|OTHER|Paloma Sahid Method, a patented technique (PCT/CL2023/050061)|The participants will receive treatment that integrates manual and mechanical lymphatic drainage through linear sliding movements directed toward relevant lymph nodes. Each session lasts approximately one hour. This intervention was complemented by compression therapy, applying 30-40 mmHg at the ankle, 70% compression at the calf, and 30% compression at the thigh.
218905285|NCT07199244|DIETARY_SUPPLEMENT|marine-based heme iron|Participants will consume 9mg of SalmoFer on day 1, followed by 6mg each day for 56 days.
218905286|NCT07199777|DRUG|SNP318|Once daily, oral administration
218905287|NCT07199777|DRUG|Placebo|Once daily, oral administration
218905288|NCT07198867|BIOLOGICAL|A-CAR028|A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens
218905289|NCT07199283|OTHER|Bundle Intervention|Bundle intervention
218905290|NCT07199855|DRUG|blinatumomab combined with venetoclax as maintenance therapy|blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation
218905291|NCT07198659|COMBINATION_PRODUCT|Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents|Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.
218905292|NCT07198451|DRUG|Gemcitabine Submucosal Injection|A chemotherapeutic agent. Administered via submucosal injection into the bladder wall using a specialized injection gun. Dosage: 1000mg per injection. Regimen: One injection immediately post-TURBT, followed by one injection every three months for a total of four injections.
218905293|NCT07198451|DRUG|Gemcitabine Intravesical Instillation|Standard therapy. Administered by instilling a solution into the bladder via a catheter. Dosage: 2000mg dissolved in 50mL normal saline per instillation. Regimen: One instillation immediately post-TURBT, followed by an induction phase (once weekly for 8 weeks) and a maintenance phase (once monthly for 10 months). The solution is retained for 30-60 minutes.
218905294|NCT07198399|DIETARY_SUPPLEMENT|Auri Super Mushroom Daily Gummies|Each gummy contains a blend of 12 functional mushroom extracts (300 mg equivalent each).
219039018|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
219039019|NCT05837130|OTHER|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
219520565|NCT04154579|BEHAVIORAL|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
219520566|NCT01064570|DRUG|all-trans retinoic acid (ATRA)|
219520567|NCT02552342|DRUG|methylprednisolone|
219520568|NCT02552342|DRUG|Normal saline|
219520569|NCT01139437|BIOLOGICAL|Standard Dose HPIV2 Vaccine|10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
219520570|NCT01139437|BIOLOGICAL|Low dose HPIV2 vaccine|10\^5 TCID50 administered in a single dose
219520571|NCT01139437|OTHER|Placebo|Matched placebo
218905295|NCT07198828|BEHAVIORAL|mHealth Smoking Cessation Application|"Participants receive the mHealth smoking cessation application with:~* Educational content about smoking risks and cessation benefits~* Motivational messages and progress tracking~* Social support features~* Interactive elements and quizzes~* Monthly monitoring and support"
219039020|NCT05837130|OTHER|Blood sample collection|No study drug will be administered to study participants.
219039021|NCT06957808|DRUG|Diroximel fumarate (DRF)|Diroximel fumarate is an immunomodulating drug licensed for use in multiple sclerosis. It has been found to cross the blood brain barrier and increase brain glutathione levels.
218905296|NCT07198828|BEHAVIORAL|Paper-based Control Materials|"Participants receive paper-based smoking cessation module containing equivalent content:~* Motivational content and cessation benefits~* Ex-smoker success stories~* Trigger identification and coping strategies~* Weekly quizzes with prizes (online access)~* Monthly check-ins"
218905297|NCT07198165|DRUG|PD-1 inhibitor based immunotherapy|Short-course radiotherapy (25Gy/5Fx) followed by 4 cycles of CAPOX regimen (Oxaliplatin 130mg/m² IV infusion, Capecitabine 1000mg/m² orally for 14 days, Q3w) combined with Bevacizumab (7.5mg/kg IV infusion, D1, Q3w) + PD-1 inhibitor (Toripalimab 240mg IV infusion, D1, Q3w).
219039022|NCT06957808|DRUG|Placebo|A placebo pill given to participants.
219520572|NCT03916497|DIAGNOSTIC_TEST|Quantiferon CMV|Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
219520573|NCT01258725|PROCEDURE|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI\<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
219520574|NCT06195618|BIOLOGICAL|Peptide (neoantigen) pulsed autologous Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses, one weekly after surgery.
219520575|NCT02303808|DEVICE|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
219520576|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
219039023|NCT05040152|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary recommendations
219039024|NCT05040152|OTHER|Exercise Intervention|Complete home exercises
219039025|NCT05040152|OTHER|Informational Intervention|Receive education brochures
219039026|NCT05040152|OTHER|Questionnaire Administration|Ancillary studies
219039027|NCT05040152|BEHAVIORAL|Telephone-Based Intervention|Receive telephone-based weight loss intervention
219039028|NCT00726570|DEVICE|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
219039029|NCT00726570|DRUG|Dalteparin|"* 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg"
219520577|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
219520578|NCT04559854|BEHAVIORAL|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
219520579|NCT03130699|BEHAVIORAL|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
219612941|NCT02784561|DRUG|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
219039030|NCT00726570|PROCEDURE|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery"
219039031|NCT01539187|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
219039032|NCT01978314|DEVICE|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
218905298|NCT07198711|DRUG|Propofol - Emergence-from-LOR Protocol|Intravenous propofol infusion that meets the criteria: (1) maintenance of spontaneous ventilation, (2) sedation level corresponding to a Patient State Index (PSI) no lower than 25; and (3) loss of responsiveness (LOR) defined by the Richmond Agitation Sedation Scale (RASS) = -5 \[unarousable\]. Anesthesia is then maintained at that level for 30 minutes, followed by spontaneous emergence.
218905299|NCT07198711|DRUG|Propofol - Light Sedation Protocol|Intravenous propofol infusion titrated stepwise to reach a state where participants are sedated but have behavioral responsiveness. Sedation is maintained at this level for 30 minutes.
219039033|NCT03905785|BEHAVIORAL|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
219039034|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
219039035|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
219039036|NCT00485316|PROCEDURE|Laparoscopic assisted resection of colorectal carcinoma|
219039037|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
219039038|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
219039039|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
219039040|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
219039041|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
219204374|NCT06886789|BEHAVIORAL|Fully Automated Online Program|Patients receiving the fully automated online program will select a weight loss or a weight maintenance curriculum based on their goals. Patients will receive 8 weeks of fully automated lessons covering the 3 key behaviors: weight (management or loss), physical activity, and medication adherence. All 3 behaviors are discussed weekly, but the lessons first prioritize PA, then weight management, and then medication adherence to mimic the emphasis in Phase II. Total weekly lesson time is 20-30 minutes. Patients retain access to lessons. They self-monitor calories, weight, moderate-to-vigorous physical activity, and medication adherence. Tracking data are seamlessly integrated into the system. They manually enter their medication adherence data and receive encouraging feedback on each of the behaviors the next week.
219520580|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
219520581|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
219520582|NCT01199861|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
219039042|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
219612942|NCT01478373|DRUG|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
218905300|NCT07199231|OTHER|AI clinical reference tool|Residents will use OpenEvidence clinical reference tool in the course of routine clinical care. They must also use a Gold Standard clinical reference tool (e.g. PubMed, UpToDate) to mitigate risk.
219039043|NCT03948685|DRUG|Placebo|Placebo
219039044|NCT05398640|BIOLOGICAL|OOS AMTAGVI|Patients will undergo preparative lymphodepleting chemotherapy. Infusion of lifileucel is then given and is followed by administration of IL-2.
219039045|NCT00748267|OTHER|questionnaire administration|
219039046|NCT00748267|PROCEDURE|hypnotherapy|
219039047|NCT00748267|PROCEDURE|therapeutic conventional surgery|
219039048|NCT01295515|DRUG|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
219039049|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
219039050|NCT05850169|OTHER|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
219039051|NCT03754959|DRUG|BI 1358894|Film-coated tablet
219039052|NCT03754959|DRUG|Placebo|Film-coated tablet
219039053|NCT03754959|DRUG|Midazolam|Solution for injection
219039054|NCT00915369|DRUG|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
219520583|NCT01199861|DRUG|Placebo|Matching placebo capsules for oral administration.
218905301|NCT07198906|OTHER|Determination of VEXUS score and onset of chronic renal failure|The aim is to prospectively evaluate the association between the ultrasound score (VEXUS) and the occurrence of acute renal failure post-operatively following cardiac surgery. The VEXUS (Venous Excess UltraSound) score is an ultrasound tool used in medicine to assess systemic venous congestion, i.e. excess pressure in the venous system linked to volume overload or right heart failure. The VEXUS score relies on ultrasound of the inferior vena cava (IVC) to assess the extent of congestion in this vein. score 0 : Normal IVC + Normal Dopplers; score 1 : Dilated IVC + altered hepatic venous Doppler, but normal portal vein; score 2 : Portal vein shows significant pulsatility; score 3 : Severe pulsatility + marked alteration of hepatic and portal flow
218905302|NCT07199296|DRUG|Orelabrutinib|orelabrutinib 150mg/day PO once daily
218905303|NCT07199296|DRUG|Rituximab (R)|rituximab 375 mg/m² IV on day 1, 8, 15, 22 in Cycle 1, then day 1/cycle
218905304|NCT07199296|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|the reference doses are as follows (each center may adjust them as appropriate based on actual conditions): carmustine 300mg/m² IV d-1; etoposide 200mg/m² IV d-6-(-3); cytarabine 200mg/m² IV d-6-(-3); melphalan 140mg/m² IV d-2.
218905305|NCT07199296|DRUG|orelabrutinib maintenance|orelabrutinib 150mg/day PO once daily
218905306|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 1|Subject receives dietary supplement for 90 days
218905307|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 2|Subject receives dietary supplement for 90 days
218905308|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 3|Subject receives dietary supplement for 90 days
218905309|NCT07199829|OTHER|Placebo|Subject receives placebo for 90 days
218905310|NCT01704027|RADIATION|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)"
218905311|NCT01704027|DRUG|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
219039055|NCT04390581|DEVICE|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
219039056|NCT04329312|RADIATION|Thoracic computed tomography|Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
218905312|NCT06525285|PROCEDURE|Connective tissue graft wall technique|Harvested connective tissue graft will be placed over the exposed root surface like a wall to cover the gingival recession
218905313|NCT06173830|OTHER|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
218905314|NCT06173830|OTHER|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
218905315|NCT00432484|DRUG|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
218905316|NCT01519323|DRUG|vemurafenib|Cohort 1 (participants \>=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
218905317|NCT00445549|DRUG|Vandetanib|300 mg daily dose, 28 day cycle
218905318|NCT06077721|DRUG|Milrinone|giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
218905319|NCT02493439|BEHAVIORAL|Best Possible Self|
218905320|NCT02493439|BEHAVIORAL|Daily Activities|
219039057|NCT00063869|DRUG|Etanercept|
219039058|NCT04972019|DEVICE|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
219612943|NCT03098082|DEVICE|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
219612944|NCT05503576|DEVICE|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
218905321|NCT04325971|OTHER|Neuroimaging|MR, EEG recordings
218905322|NCT05378685|PROCEDURE|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
218905323|NCT05498610|DRUG|NNC0480 0389|"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
218905324|NCT05498610|DRUG|Semaglutide|"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
218905325|NCT05354661|DEVICE|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
218905326|NCT03908801|BEHAVIORAL|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
218905327|NCT01572207|BEHAVIORAL|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
218905328|NCT01572207|BEHAVIORAL|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
218905329|NCT00379535|DRUG|potassium iodide|per os
218905330|NCT00379535|DRUG|placebo|per os
218905331|NCT03658421|DRUG|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
219520584|NCT01199861|BIOLOGICAL|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
219520585|NCT01199861|BIOLOGICAL|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
219520586|NCT04551885|DRUG|FT516|Experimental Interventional Therapy
219520587|NCT04551885|DRUG|Avelumab|Monoclonal antibody
219520588|NCT04551885|DRUG|Cyclophosphamide|Lympho-conditioning agent
219520589|NCT04551885|DRUG|Fludarabine|Lympho-conditioning agent
219520590|NCT04551885|DRUG|IL-2|Biologic response modifier
219520591|NCT00843609|DEVICE|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
219520592|NCT05055921|DEVICE|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|"The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.~Other Names:~* Unpinning Termination Therapy~* Multi-stage therapy~* Multi-stage electrotherapy~* MultiPulse Therapy"
219520593|NCT06075654|OTHER|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
219520594|NCT06307028|BEHAVIORAL|SISTA-P Intervention|This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
219520595|NCT00669864|DRUG|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
219520596|NCT00669864|DRUG|metformin|Tablets, 1000 - 2000 mg daily
219520597|NCT02899390|BEHAVIORAL|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
219520598|NCT00212069|DRUG|gemcitabine, carboplatin|
219520599|NCT00450307|BIOLOGICAL|monoclonal antibody 3F8|
219520600|NCT00450307|BIOLOGICAL|sargramostim|
219520601|NCT00140517|DRUG|sulphadoxine-pyrimethamine|
219520602|NCT00140517|DRUG|chloroquine|
219520603|NCT05864976|DEVICE|Support Vector Machine|Machine learning algorithm
219520604|NCT02437149|BEHAVIORAL|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
219520605|NCT02437149|BEHAVIORAL|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
219520606|NCT02437149|BEHAVIORAL|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
219520607|NCT01241942|DEVICE|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
219612945|NCT04793594|OTHER|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
219520608|NCT01241942|OTHER|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
219520609|NCT00462852|DRUG|dalteparin|
219520610|NCT00462852|DRUG|gemcitabine hydrochloride|
219612946|NCT04793594|OTHER|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
218905332|NCT03658421|PROCEDURE|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
218905333|NCT03658421|DEVICE|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
219520611|NCT00462852|OTHER|diagnostic laboratory biomarker analysis|
219520612|NCT06063135|OTHER|Physical Exercise Intervention|Two strength training session per week and one endurance training session per week
219520613|NCT00535106|DEVICE|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
219612947|NCT04793594|OTHER|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
219612948|NCT03928301|BEHAVIORAL|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
219612949|NCT03928301|BEHAVIORAL|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
219520614|NCT00535106|DEVICE|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
218905334|NCT03658421|PROCEDURE|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
218905335|NCT00383552|DRUG|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
218905336|NCT00383552|DRUG|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
219520615|NCT00535106|OTHER|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
219520616|NCT03473314|DRUG|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
219520617|NCT02385097|DRUG|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
219520618|NCT02385097|DRUG|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
219520619|NCT01303978|DRUG|APD421|Single dose
219520620|NCT01822548|DRUG|Vildagliptin|100 mg daily
219520621|NCT01822548|DRUG|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
219520622|NCT01822548|DRUG|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
219520623|NCT03229655|PROCEDURE|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
219520624|NCT02545998|OTHER|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
219520625|NCT05187026|OTHER|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
219520626|NCT03091946|OTHER|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
219520627|NCT03091946|OTHER|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
219520628|NCT04782726|OTHER|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
219520629|NCT04782726|OTHER|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
219520630|NCT03909659|BEHAVIORAL|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
219520631|NCT05295758|BEHAVIORAL|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
219520632|NCT02678195|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
219520633|NCT02678195|DRUG|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
219520634|NCT05722600|OTHER|Grape juice|Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
219520635|NCT05722600|OTHER|Placebo drink|Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
219520636|NCT01341366|OTHER|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
219520637|NCT01341366|OTHER|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
219520638|NCT01328730|DEVICE|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
219520639|NCT01328730|DEVICE|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
219520640|NCT00854321|DRUG|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
219520641|NCT00854321|DRUG|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
219612950|NCT01467440|DEVICE|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
218905337|NCT00383552|DRUG|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
218905338|NCT00383552|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
218905339|NCT00489996|DRUG|gemcitabine|
218905340|NCT00489996|DRUG|cisplatin|
218905341|NCT01590030|PROCEDURE|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
218905342|NCT01925560|OTHER|Agave Inulin|3x3 Latin square with 3 periods
218905343|NCT01925560|OTHER|Placebo|control- 0 (zero) grams/day inulin
218905344|NCT00002328|DRUG|Azithromycin|
218905345|NCT05738135|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
218905346|NCT05738135|DRUG|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
218905347|NCT00232765|DEVICE|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
219520642|NCT05078008|PROCEDURE|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
218905348|NCT00232765|DEVICE|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
218905349|NCT05574686|BEHAVIORAL|Telehealth Blood Pressure Monitoring and Food Insecurity|Telehealth Blood Pressure Monitoring and Food Insecurity
218905350|NCT03096834|BIOLOGICAL|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
218905351|NCT03096834|BIOLOGICAL|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
218905352|NCT00242268|DRUG|Simvastatin|
218905353|NCT00836368|DIETARY_SUPPLEMENT|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
219520643|NCT05078008|PROCEDURE|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
219520644|NCT02463149|BEHAVIORAL|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
219520645|NCT00696449|DRUG|Adapalene|All Subjects will treat the face once daily in the evening.
219520646|NCT00696449|BEHAVIORAL|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
219520647|NCT00696449|BEHAVIORAL|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
218905354|NCT02669953|DRUG|Aflibercept|
218905355|NCT00433173|PROCEDURE|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
218905356|NCT00433173|DRUG|testosterone|transdermal 7.5 g/per day for 3 months
218905357|NCT00433173|DRUG|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
218905358|NCT00433173|DRUG|goserelin acetate implant|single depot injection 10.8 mg 3 months
218905359|NCT00433173|PROCEDURE|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
219520648|NCT00696449|BEHAVIORAL|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
219520649|NCT00696449|BEHAVIORAL|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
219520650|NCT05238493|DRUG|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
219520651|NCT05238493|DRUG|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
218905360|NCT00433173|PROCEDURE|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
218905361|NCT00433173|PROCEDURE|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
218905362|NCT00433173|PROCEDURE|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
218905363|NCT00433173|PROCEDURE|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
218905364|NCT00433173|PROCEDURE|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
218905365|NCT01043068|DRUG|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
219520652|NCT01493908|DRUG|High price|Acetaminophen label as high price
219520653|NCT01493908|DRUG|Low price|Acetaminophen label as low price
219520654|NCT01493908|DRUG|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
219520655|NCT01493908|DRUG|No price|acetaminophen. No price - price issue not introduced to participants.
218905366|NCT04085575|DRUG|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
218905367|NCT00966654|DRUG|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
218905368|NCT00966654|DRUG|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
218905369|NCT06290115|OTHER|Questionnaires set 1|Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
218905370|NCT06290115|OTHER|Questionnaires set 2|Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
218905371|NCT06290115|OTHER|Questionnaires set 3|Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
219039059|NCT04972019|OTHER|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
219039060|NCT00314574|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
219039061|NCT00314574|DRUG|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
219520656|NCT01493908|DRUG|Free of charge|Acetaminophen. participants aware the product is free of charge
219520657|NCT04567342|OTHER|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
219520658|NCT04567342|OTHER|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
219520659|NCT04567342|OTHER|No personal contact attempt|No personal contact attempts will be made.
219520660|NCT04567342|OTHER|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
219520661|NCT04820608|DEVICE|Cross-linking|Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
219520662|NCT05554653|DIETARY_SUPPLEMENT|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
219520663|NCT05554653|DIETARY_SUPPLEMENT|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
219520664|NCT00699322|DRUG|Sitagliptin|100mg P.O. per day for 1month
218905372|NCT04890860|OTHER|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
219520665|NCT00699322|DRUG|Glimepiride|2mg P.O. per day for 1 month
219520666|NCT06298435|PROCEDURE|Intermittent Positive pressure ventilation|Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
219520667|NCT00922532|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
219520668|NCT00922532|DRUG|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
219520669|NCT05015556|PROCEDURE|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
219520670|NCT04525807|DIAGNOSTIC_TEST|Multi-omics|Use multi-omics to analyze
219520671|NCT01054599|DRUG|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
219520672|NCT01054599|OTHER|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
219612951|NCT01199380|BEHAVIORAL|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
219612952|NCT01199380|BEHAVIORAL|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
218905373|NCT00575185|DRUG|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
218905374|NCT00575185|DRUG|placebo|Placebo tablets orally twice daily for 21 days.
219039062|NCT00314574|DRUG|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
218905375|NCT02156843|DRUG|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
218905376|NCT02156843|DRUG|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
219520673|NCT01054599|DRUG|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
219520674|NCT00001090|BIOLOGICAL|APL 400-047|
218905377|NCT04416204|OTHER|glycogen loading|Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
218905378|NCT04416204|OTHER|No Glycogen Loading|Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
218905379|NCT02516280|DEVICE|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
218905380|NCT02516280|DEVICE|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
218905381|NCT02372604|DRUG|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))"
218905382|NCT02372604|DRUG|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet"
218905383|NCT04892498|RADIATION|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
219520675|NCT00001090|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219520676|NCT00001090|DRUG|Sargramostim|
219520677|NCT05468229|DRUG|Dorzagliatin|single oral dose of dorzagliatin 50 mg
219520678|NCT05468229|DRUG|Placebo|Matching placebo
219520679|NCT01075139|BEHAVIORAL|Brief Motivational Intervention|30 minute one-on-one meeting
219520680|NCT01075139|BEHAVIORAL|Educational information|Educational handouts/brochures
218905384|NCT04892498|DRUG|PD-1 inhibitor|q3w, until PD
218905385|NCT04892498|DRUG|GM-CSF|200μg, D1-D7, ≥8 cycles
218905386|NCT04892498|DRUG|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
219520681|NCT03208426|DRUG|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
219520682|NCT03208426|DRUG|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
218905387|NCT04456504|BIOLOGICAL|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
218905388|NCT05718947|DIAGNOSTIC_TEST|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
219520683|NCT03208426|DRUG|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
219520684|NCT03208426|DRUG|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
219520685|NCT03208426|DRUG|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
219520686|NCT03208426|DRUG|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
219520687|NCT03208426|DRUG|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
219520688|NCT03208426|DRUG|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
219520689|NCT03887689|BEHAVIORAL|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
219520690|NCT00794079|DIETARY_SUPPLEMENT|omega-3 fatty acids|4 grams per day for 8 weeks
219520691|NCT00794079|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 8 weeks
218905389|NCT04017221|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
218905390|NCT04017221|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
218905391|NCT04017221|DRUG|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
218905392|NCT03472625|DIAGNOSTIC_TEST|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
219039063|NCT00314574|DRUG|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
219039064|NCT04263974|OTHER|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
219039065|NCT04263974|OTHER|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
219039066|NCT04196478|DEVICE|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
219039067|NCT06049056|OTHER|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
219039068|NCT00449956|DRUG|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
219520692|NCT04209920|DEVICE|CAD-CAM milled PMMA crown|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
218905393|NCT03571230|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
218905394|NCT03571230|DRUG|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
219039069|NCT00449956|DRUG|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
219039070|NCT00449956|DRUG|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
218905395|NCT03571230|DRUG|one proton pump inhibitor(PPI)|All the patients need this drug.
218905396|NCT03571230|DRUG|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
218905397|NCT03571230|DRUG|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
219039071|NCT01253252|RADIATION|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
219520693|NCT04209920|OTHER|Cast metal coping using nickel chromium alloy|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
219520694|NCT03114956|PROCEDURE|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
219520695|NCT03114956|PROCEDURE|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
219039072|NCT01253252|RADIATION|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
219612953|NCT01199380|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
219612954|NCT05149326|DRUG|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
219612955|NCT05149326|DRUG|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
219612956|NCT03940131|DRUG|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
219612957|NCT02371473|DRUG|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
218905398|NCT00972413|RADIATION|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
218905399|NCT00972413|RADIATION|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
218905400|NCT00972413|RADIATION|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
218905401|NCT01405768|DRUG|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
219039073|NCT01253252|BIOLOGICAL|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
219039074|NCT04637958|DEVICE|THA|Total hip arthroplasty
218905402|NCT01405768|DRUG|Non-buffered lidocaine|
218905403|NCT05383469|OTHER|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
218905404|NCT05383469|OTHER|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
218905405|NCT05383469|OTHER|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
218905406|NCT05383469|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
219039075|NCT05087654|OTHER|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
218905407|NCT03692208|BEHAVIORAL|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
219039076|NCT04013620|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
219039077|NCT05428475|DIAGNOSTIC_TEST|[18F]FDG-PET Scan|185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
218905408|NCT06377176|OTHER|Massage therapy|the intervention group underwent ten sessions of twice-weekly mother and infant massage therapy for five weeks.
218905409|NCT05041049|DEVICE|Comparing Visual Reality to High-fidelity mannequin Stimulation|"This is a prospective, randomized, non-inferiority study. VR will be compared to HFS, which will be considered the a priori gold standard for residents simulation training.~The study will be divided into two phases. In the pre-test phase, participants will be randomly allocated to receive either a VR or HFS scenario (scenario 1, see below). In the post-test phase, all participants (regardless the initial grouping) will undergo a HFS scenario (scenario 2, see below).~All scenarios have been chosen from critical events published by the Society of Pediatric Anesthesia48 and adult sources49.~The study will be conducted at the McGill University Health Center - Research Institute (MUHC-RI)."
219039078|NCT06240156|OTHER|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
219039079|NCT06240156|OTHER|flat Insole group|General Insole without any special features
219039080|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
219039081|NCT01397175|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
219039082|NCT01397175|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
219612958|NCT02371473|DRUG|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
219039083|NCT01397175|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
219039084|NCT00994331|PROCEDURE|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
219039085|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
219039086|NCT02009033|DRUG|Hydroxyethylstarch|
219039087|NCT01446965|DEVICE|wearable defibrillator|LifeVest wearable defibrillator
219039088|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
219039089|NCT06103006|OTHER|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
219039090|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
218905410|NCT05664321|OTHER|Observational, case-control study|obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].
218905411|NCT04935996|DEVICE|Pleuropulmonary echography|Pleuropulmonary echography is performed, in addition of the chest X-ray already performed in routine care
218905412|NCT01992796|DRUG|Irbesartan|75 mg/per os/for 15 days
219039091|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
219039092|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
219039093|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
219520696|NCT03114956|PROCEDURE|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
218905413|NCT03424564|DRUG|Perampanel|Oral Tablet
219520697|NCT03114956|PROCEDURE|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
219520698|NCT02184728|DEVICE|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
219520699|NCT01478620|DRUG|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
219520700|NCT00313885|DRUG|eplivanserin (SR46349)|oral administration
219520701|NCT00313885|DRUG|placebo|oral administration
219520702|NCT02139514|BEHAVIORAL|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
219520703|NCT00152165|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
219520704|NCT02492399|PROCEDURE|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
218905414|NCT02125396|OTHER|Transarterial chemoembolization|Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
218905415|NCT02125396|OTHER|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
218905416|NCT01412177|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
218905417|NCT01412177|DRUG|Placebo|Single intratympanic injection of placebo
218905418|NCT01866332|OTHER|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
218905419|NCT01866332|DEVICE|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
218905420|NCT02249806|OTHER|PH target therapy according to physician|Patients receiving PH target therapy
218905421|NCT06043024|DEVICE|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
218905422|NCT05787340|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation.
218905423|NCT01777035|OTHER|early PT OT|"1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
218905424|NCT06453148|OTHER|Non-interventions|Usual care evaluations
218905425|NCT00210535|DRUG|Topiramate; Placebo|
218905426|NCT00126035|DEVICE|Migraid|
218905427|NCT03177902|DRUG|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
218905428|NCT03629964|DEVICE|Wiersma Head Stabilizer|Experimental device attached to treatment table.
218905429|NCT03629964|DEVICE|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
218905430|NCT00132743|DEVICE|Stent|Stent
219039094|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
219039095|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
219039096|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
219039097|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
219039098|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
219039099|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
219039100|NCT00643370|OTHER|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
219039101|NCT05005858|PROCEDURE|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
219039102|NCT05005858|DEVICE|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
219039103|NCT06493630|BEHAVIORAL|Hypnobreastfeeding Education|Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
219039104|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
219039105|NCT00638703|DRUG|Placebo|placebo
219039106|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
218905431|NCT00132743|BEHAVIORAL|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
218905432|NCT00132743|DRUG|Cilostazol|Cilostazol, 100 mg twice a day
218905433|NCT05951114|DIAGNOSTIC_TEST|Maximum inspiratory/Expiratory manoeuvre for patients can follow the order|Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre
218905434|NCT01381016|DRUG|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
218905435|NCT01381016|DRUG|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
218905436|NCT01381016|DRUG|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
218905437|NCT03298360|OTHER|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
218905438|NCT04428398|DIAGNOSTIC_TEST|Analysis of urine samples with flow cytometry|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
219039107|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
219039108|NCT02719158|OTHER|Sham|
219039109|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
219039110|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
219520705|NCT02492399|PROCEDURE|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
219520706|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
219520707|NCT02527096|DRUG|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
219520708|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
219520709|NCT02057848|OTHER|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
219520710|NCT02057848|OTHER|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
219520711|NCT02057848|OTHER|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
219520712|NCT00672854|DRUG|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
219520713|NCT00672854|DRUG|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
219520714|NCT03491358|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
219612959|NCT06578273|DEVICE|NeuroGlove|"The NeuroGlove is a plastic chamber with multiple apertures along its length to allow for puffs of air to be directed to the volar surface of the distal forearm, the palm, and the fingers. The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development. A pneumatic pump delivers intermittent puffs of air cycling between one second on and two seconds off. The hand with the palm facing up is placed within the device chamber on a gel pad to provide a comfortable resting surface for the duration of the treatment, which lasts approximately thirty minutes.~The device facilitates the rehabilitation, improvement, or restoration of motion in patients with neurological disorders."
219612960|NCT05600673|DRUG|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
218905439|NCT05883969|BEHAVIORAL|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
218905440|NCT05883969|BEHAVIORAL|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
218905441|NCT05822934|DRUG|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
218905442|NCT00414856|DRUG|AFQ056|
219204375|NCT06886789|BEHAVIORAL|Low-Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
219520715|NCT03491358|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
219520716|NCT04644133|OTHER|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
219520717|NCT04644133|OTHER|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
219520718|NCT03383744|DIETARY_SUPPLEMENT|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
219520719|NCT04291066|DRUG|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
219520720|NCT05249907|OTHER|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
219612961|NCT05600673|DEVICE|CO2 fractional laser|CO2 fractional laser treatment
219520721|NCT01198236|DRUG|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1\*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells\> 0.5\*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
219520722|NCT02215577|PROCEDURE|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
219520723|NCT02215577|PROCEDURE|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
219520724|NCT02487784|PROCEDURE|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
219612962|NCT01088230|OTHER|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
218905443|NCT03450863|DRUG|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
218905444|NCT00467077|BIOLOGICAL|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
218905445|NCT00467077|DRUG|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
218905446|NCT05183061|DRUG|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
218905447|NCT02539004|OTHER|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
218905448|NCT01274481|DRUG|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
218905449|NCT02454738|RADIATION|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
218905450|NCT03671941|DRUG|D578|D578 Tab.1T single oral administration under fasting condition
218905451|NCT03671941|DRUG|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
218905452|NCT05635656|DEVICE|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
218905453|NCT02761226|PROCEDURE|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
218905454|NCT02761226|PROCEDURE|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
218905455|NCT01316523|DRUG|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
218905456|NCT01316523|DRUG|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
218905457|NCT03498807|DEVICE|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
219612963|NCT01088230|OTHER|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
218905458|NCT03498807|DEVICE|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
218905459|NCT05937763|OTHER|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
218905460|NCT01451723|DRUG|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
218905461|NCT01451723|OTHER|Placebo|Matching placebo capsules
218905462|NCT05682755|DRUG|Chidamide|initial time：platelet count ≥50×10\^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10\^9/L-increased by 5 mg 20×10\^9/L≤ platelet count \<50×10\^9/L-remains unchanged platelet count \<50×10\^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
218905463|NCT04507022|DRUG|Estradiol Valerate|2mg three times daily
218905464|NCT04507022|DRUG|Progesterone|100 mg daily intramuscular
219612964|NCT00682474|BEHAVIORAL|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
219612965|NCT00682474|BEHAVIORAL|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
218905465|NCT04507022|DRUG|Aromatase inhibitor|2.5 mg twice daily for 5 days
218905466|NCT04897217|DRUG|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
218905467|NCT04897217|DRUG|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
219520725|NCT02487784|PROCEDURE|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
219520726|NCT04025879|BIOLOGICAL|Nivolumab|Specified dose on specified days
219520727|NCT04025879|DRUG|Carboplatin|Specified dose on specified days
219520728|NCT04025879|DRUG|Cisplatin|Specified dose on specified days
219520729|NCT04025879|DRUG|Paclitaxel|Specified dose on specified days
219520730|NCT04025879|DRUG|Pemetrexed|Specified dose on specified days
219520731|NCT04025879|DRUG|Placebo|Specified dose on specified days
219520732|NCT04025879|DRUG|Docetaxel|Specified dose on specified days
219520733|NCT02380183|DEVICE|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
219520734|NCT02888171|DRUG|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
219520735|NCT02888171|DRUG|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
219520736|NCT01136642|DRUG|Nicotrol|
219520737|NCT00322400|DRUG|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
219520738|NCT00322400|DRUG|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
219520739|NCT00322400|DRUG|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
219520740|NCT00254111|DEVICE|Ultra Probe Laser System|
219520741|NCT04192500|BIOLOGICAL|OVX836|One single administration intramuscularly at Day 1.
219520742|NCT04192500|BIOLOGICAL|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
219520743|NCT03423225|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
219039111|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
219039112|NCT03365674|DEVICE|Vibration|Vibration applied with vibrator switch-on state (100Hz)
219520744|NCT05810766|OTHER|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
219520745|NCT05810766|OTHER|conventional physical therapy|Hot pack for 15 minutes
219520746|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
219520747|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
219520748|NCT05825300|BEHAVIORAL|Email message|Email message encourages patients to donate blood
219520749|NCT05825300|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
219520750|NCT02473809|DRUG|Liraglutide|Once daily
219520751|NCT02473809|DRUG|Placebo|Once daily
219520752|NCT02403700|DEVICE|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
219039113|NCT03365674|DEVICE|Placebo vibration|Vibrator applied with switch-off state
219039114|NCT06207539|DRUG|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
219520753|NCT04659538|DEVICE|CAPTIS Embolic Protection device|The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
219520754|NCT02073630|OTHER|active cerebellar stimulation|
219520755|NCT02073630|OTHER|sham cerebellar stimulation|
219520756|NCT02837965|DRUG|treatment with topical superpotent corticosteroid therapy|
219520757|NCT02837965|DRUG|treatment with systemic therapy (methotrexate)|
219520758|NCT02837965|DRUG|treatment systemic therapy (prednisone)|
219520759|NCT02837965|DRUG|treatment with systemic therapy (prednisone)|
219520760|NCT02837965|DRUG|treatment with systemic therapy (doxycycline)|
219520761|NCT04882293|DRUG|Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose|1 tablet once a day, 20 mg /160 mg, Orally
219520762|NCT04882293|DRUG|Atorvastatin (Lipitor ®)|1 tablet once a day, 20 mg, Orally
219520763|NCT03876561|PROCEDURE|Pelvic floor prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
219520764|NCT00938210|PROCEDURE|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
218905468|NCT02136966|OTHER|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
219520765|NCT04825938|DRUG|Toripalimab , Carboplatin, Nab-paclitaxel|Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
219520766|NCT01411332|RADIATION|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
218905469|NCT01631435|OTHER|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
218905470|NCT01631435|DEVICE|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
218905471|NCT04245111|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
218905472|NCT02547311|BEHAVIORAL|Team Clinic|
218905473|NCT02197312|DEVICE|NobelProcera Bridge Shaded Zirconia|
218905474|NCT05767008|OTHER|Sunscreen -R43|Long wear metal oxide particles
218905475|NCT01442246|DRUG|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
218905476|NCT05356377|DRUG|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
218905477|NCT04210648|DEVICE|Mobile app|Mobile app for self-managing emotional dysregulation
219520767|NCT01411332|RADIATION|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
219520768|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
218905480|NCT03087396|DEVICE|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
218905481|NCT00269178|BEHAVIORAL|Peer Health Education Programme|
219520769|NCT00469586|DRUG|metformin|Tablets, 2000 mg/day.
219520770|NCT00469586|DRUG|glimepiride|Tablets, 4 mg/day.
219520771|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
218905482|NCT06112665|DRUG|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
218905483|NCT06304103|DRUG|AND017|Administer AND017 once per day (QD)
219520772|NCT03231670|PROCEDURE|Blood sampling|5ml blood will be taken in addition to standard sampling
219520773|NCT01229020|OTHER|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
219520774|NCT04617769|BEHAVIORAL|Psychoeducation|psychoeducational materials on trauma and safety behaviors
218905484|NCT04580238|DRUG|Botox 200 UNT Injection|"Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites"
219520775|NCT04617769|BEHAVIORAL|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
219520776|NCT02952248|DRUG|BI 754091|
219520777|NCT03396133|DIAGNOSTIC_TEST|Snap|screen, transmission, and analysis ECG automated
219520778|NCT05432843|DRUG|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
219520779|NCT05432843|DRUG|Placebo|Patients receive a treatment with placebo for 8 weeks
219520780|NCT02787278|DRUG|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
219520781|NCT02787278|DRUG|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
219520782|NCT02787278|DRUG|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
219520783|NCT03680898|DEVICE|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
219520784|NCT03709862|DIAGNOSTIC_TEST|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
219520785|NCT02218164|DRUG|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
219204376|NCT06886789|BEHAVIORAL|High Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily and attend a once weekly virtual meeting with a CR case manager. Meetings are modeled after Phase II and focus on tailored exercise prescription, addressing cognitive, behavioral, and environmental adherence barriers, and support. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
219520786|NCT02218164|DRUG|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
219520787|NCT02218164|DRUG|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
219520788|NCT01471522|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
219520789|NCT01471522|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
219520790|NCT01471522|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
219520791|NCT01471522|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
219520792|NCT01471522|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
219520793|NCT06683638|DRUG|Doxycycline 200mg daily for 14 days|Doxycycline will be taken as a single dose of 200mg daily, rather than the current CDC-recommended 100mg twice daily regimen for early syphilis. The duration will still be 14 days of therapy.
219520794|NCT05670171|PROCEDURE|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
219520795|NCT05670171|PROCEDURE|Stent Angioplasty|Nickel-titanium self-expanding bare stent
219520796|NCT06818487|DRUG|Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
219520797|NCT06818487|DRUG|Sodium Hyaluronate|Participants received 0.1% sodium hyaluronate eye drop
219520798|NCT06818487|DRUG|1/2Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 5 g per time for a duration of 4 weeks.
219520799|NCT06818487|DRUG|Placebo|Participants will receive the following placebo Chinese herbal granules, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
219520800|NCT06904508|BEHAVIORAL|Facing Your Fears (FYF) Intervention: A CBT Focused Group Treatment for Autistic Youth with Anxiety|FYF is an outpatient, multi-family, evidence-based CBT group treatment for children and adolescents ages 8-14 with average intellectual abilities, and a primary co-occurring anxiety diagnosis (social, generalized, separation anxiety, or specific phobia).
219612966|NCT03822104|DIETARY_SUPPLEMENT|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
219612967|NCT03822104|DIETARY_SUPPLEMENT|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
219612968|NCT01074944|DRUG|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
219612969|NCT01445704|DIETARY_SUPPLEMENT|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
218905485|NCT04580238|COMBINATION_PRODUCT|Non Botox based Standard of Care Treatments for Headache/Migraine|Control Group will receive normal standard of care Non-Botox based interventions.
218905486|NCT04543396|OTHER|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
219612970|NCT01445704|DIETARY_SUPPLEMENT|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
218905487|NCT02314663|DEVICE|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
218905488|NCT05288647|PROCEDURE|TMJ injection|four sodium hyaluronate injections in superior TMJ space
218905489|NCT00010400|DRUG|Cyclophosphamide|
218905490|NCT00010400|DRUG|filgrastim|
218905491|NCT05323695|BEHAVIORAL|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
218905492|NCT03192176|DRUG|Fezolinetant|Oral Capsule
218905493|NCT03192176|DRUG|Placebo|Oral Capsule
218905494|NCT05671692|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
218905495|NCT05671692|DRUG|Placebo|Same as active comparator, except placebo dispensed.
218905496|NCT06362850|OTHER|Tele-support|via real-time audio-video connection through an experienced physician
218905497|NCT05108246|BEHAVIORAL|Dual-Task Exercise Training|Simultaneous cognitive-motor training
218905498|NCT05983458|PROCEDURE|Transaortic valve replacement|"TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view."
218905499|NCT05833958|DRUG|GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin|As described previously
218905500|NCT05833958|DRUG|Metformin|As described previously - Experimental Arm, 175mg at night
219039115|NCT06207539|DRUG|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
219039116|NCT02174835|DRUG|AVP-786|
219039117|NCT02174835|DRUG|AVP-923|
219039118|NCT01110746|DRUG|Viaject 7|100IU/mL administered subcutaneously
219039119|NCT01110746|DRUG|LISPRO|100IU/mL administered subcutaneously
218905501|NCT05833958|DRUG|Metformin|As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
218905502|NCT03532542|DRUG|Casimersen|Casimersen solution for IV infusion
218905503|NCT03532542|DRUG|Golodirsen|Golodirsen solution for IV infusion
218905504|NCT05097820|DEVICE|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
219039120|NCT01895673|OTHER|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
219039121|NCT02790346|PROCEDURE|arthrodesis talonavicular|
219039122|NCT02790346|PROCEDURE|tendon gestures|
219039123|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
219039124|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
219039125|NCT00620594|DRUG|BEZ235|
219039126|NCT00797082|DEVICE|MRI|MRI = Myocardial Perfusion Stress
219039127|NCT00797082|DEVICE|MPS|MPS = Myocardial Perfusion Scintigraphy
219039128|NCT03588637|OTHER|No intervention|No intervention
219039129|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
219039130|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
219039131|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
219039132|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
219039133|NCT06291142|DEVICE|Observation - Nailfold capillaroscopy|Nailfold capillaroscopy examination
219039134|NCT00001442|DRUG|paclitaxel concurrent with radiation therapy|
219039135|NCT02530112|OTHER|Survey|
219039136|NCT04976036|DRUG|Nintedanib|150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
219039137|NCT04976036|DRUG|Placebo|150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
219204377|NCT06739798|DIAGNOSTIC_TEST|Exp Group|Binocular Spectacle prescription are therapeutic tools used to correct refractive errors in visually impaired patients. They improve Visual acuity as well as other visual functions in Amblyopic and visual impairment patients. They stimulate weaker eye to generate visual impulse and stimulate visual cortex to improve stereopsis and fusion.
219520801|NCT06907966|BEHAVIORAL|Engaging Families home practice app|"The intervention is a smartphone application (or app) that was developed to support caregiver home practice of intervention skills. The app was designed to support caregivers participating in the Bridges program, an evidence-based, family-based preventive intervention. Features of the app were developed to help caregivers overcome common barriers to practicing intervention skills at home."
219520802|NCT06907966|OTHER|Scheduling app|The Cozi Family Organizer is a smartphone application that will be given to caregivers randomized to the active control group. Cozi is a highly rated family organization app with features that include a family calendar, to do list, shopping list, and daily agenda. Cozi is available on Android and iPhone devices.
219520803|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
219520804|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
218905505|NCT04787224|OTHER|immediate implant with vestibular socket therapy|A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
218905506|NCT05294315|PROCEDURE|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
218905507|NCT05294315|PROCEDURE|Single level erector spinae block|erector spinae block at 4th transverse process
219612971|NCT05011604|DEVICE|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
218905508|NCT03166514|DIETARY_SUPPLEMENT|Commercially Available Food Bar|
218905509|NCT03166514|DIETARY_SUPPLEMENT|Placebo|
219612972|NCT00762112|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
219612973|NCT02348112|DEVICE|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
219612974|NCT02348112|DEVICE|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
218905510|NCT06139341|DRUG|BI 765845|BI 765845
218905511|NCT06139341|DRUG|Placebo|Placebo
219204378|NCT06739798|DIAGNOSTIC_TEST|Control Group|Patching therapy is a gold standard tool used world wide to correct visual acuity in amblyopic patients. This tool is used by occluding stronger eye with a patch or bandage or fogging lens and stimulating amblyopic eye to generate visual stimulus to motivate visual cortex.
219520805|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
218905512|NCT06389526|BIOLOGICAL|CHS-1000|Specified dose on specified days
218905513|NCT06389526|BIOLOGICAL|Toripalimab|Specified dose on specified days
218905514|NCT03604367|DEVICE|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
218905515|NCT01349517|PROCEDURE|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
218905516|NCT01349517|PROCEDURE|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
218905517|NCT01349517|PROCEDURE|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
218905518|NCT01349517|PROCEDURE|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
218905519|NCT03847766|BEHAVIORAL|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
218905520|NCT03847766|BEHAVIORAL|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
218905521|NCT02302768|DIETARY_SUPPLEMENT|Selenomethionine|
218905522|NCT02302768|OTHER|Placebo|
218905523|NCT01733875|DRUG|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
218905524|NCT01733875|DRUG|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
218905525|NCT01733875|DRUG|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
218905526|NCT01733875|DRUG|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
219520806|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
219520807|NCT04124861|DRUG|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
219520808|NCT05271539|DRUG|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
219612975|NCT02103855|DRUG|Belatacept|
219612976|NCT00745550|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
219612977|NCT03181412|DIAGNOSTIC_TEST|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
219612978|NCT02319278|DRUG|Ferumoxytol|Infusion following between paired MRI scans
219612979|NCT03741400|DEVICE|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
218905527|NCT01733875|DRUG|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
218905528|NCT01733875|DRUG|Placebo|A single dose of placebo will be administered orally once a day.
218905529|NCT01733875|DRUG|CC-220|CC-220 4 mg will be administered orally once a day
218905530|NCT01733875|DRUG|CC-220|CC-220 6 mg will be administered orally once a day
218905531|NCT01733875|DRUG|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
218905532|NCT02418871|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
218905533|NCT02418871|PROCEDURE|Cataract surgery|Performed using standard microsurgical techniques
218905534|NCT00153036|DRUG|rt-PA 0.9 mg/kg verum or placebo Intravenous|
218905535|NCT00127634|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
219039138|NCT04076774|DEVICE|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
219612980|NCT05019300|BIOLOGICAL|Exposure: COVID-19 severity|COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
219612981|NCT04477070|PROCEDURE|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
219612982|NCT04477070|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
218905536|NCT00127634|DRUG|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
218905537|NCT00127634|DRUG|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
218905538|NCT04315155|DRUG|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
219039139|NCT04076774|DEVICE|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
218905539|NCT04315155|DRUG|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
218905540|NCT04315155|DRUG|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
218905541|NCT04315155|DRUG|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
218905542|NCT04315155|DRUG|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
218905543|NCT03701139|PROCEDURE|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
218905544|NCT03701139|PROCEDURE|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
218905545|NCT02314052|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
218905546|NCT02558517|DRUG|prednisone discontinuation|randomization
218905547|NCT00965666|DRUG|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
218905548|NCT00117637|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
219520809|NCT05271539|DRUG|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
219520810|NCT02637232|OTHER|Mirvaso® / Onreltea TM|
219520811|NCT05554809|OTHER|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
219520812|NCT05706337|DRUG|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
219520813|NCT05706337|DRUG|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
219520814|NCT00002889|DRUG|flutamide|
219520815|NCT00002889|DRUG|goserelin|
219520816|NCT00002889|DRUG|leuprolide acetate|
219520817|NCT00002889|RADIATION|low-LET photon therapy|
219520818|NCT02999178|DRUG|Nintedanib|
219520819|NCT02999178|DRUG|Placebo|
219520820|NCT03746093|DIETARY_SUPPLEMENT|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
219520821|NCT03746093|DIETARY_SUPPLEMENT|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
218905549|NCT00117637|DRUG|Interferon|Interferon
218905550|NCT01618032|OTHER|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
218905551|NCT01618032|OTHER|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
218905552|NCT01618032|OTHER|placebo|Manual contact during a period of time similar of teh other interventions
219520822|NCT04983706|PROCEDURE|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
219520823|NCT02837757|OTHER|Biological samples|blood and tumor tissue samples
219520824|NCT03914066|BEHAVIORAL|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
219520825|NCT00090857|DRUG|Letrozole|
219520826|NCT00090857|OTHER|Placebo|
219520827|NCT02977026|BEHAVIORAL|CYD|
219520828|NCT02977026|BEHAVIORAL|AHC|
219520829|NCT05851131|OTHER|Approach to Diagnosis and Treatment of Osteoporosis Questionnaire|"The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report."
219520830|NCT06219473|DRUG|Fascia lata membrane|novel allogenic derived acellular matrix produced from human fascia lata allograft
219520831|NCT06219473|DRUG|Platlet Rich fibrin membrane|Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
219520832|NCT06219473|DRUG|subepithelial connective tissue graft|The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
219520833|NCT05097326|DRUG|Mifepristone|Mifepristone 200mg taken orally
219520834|NCT05097326|DRUG|Misoprostol|Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
219520835|NCT05405725|BIOLOGICAL|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
219520836|NCT05405725|BIOLOGICAL|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
219520837|NCT06264024|PROCEDURE|Corneal collagen cross linking (CXL)|Use of Avedro Inc. KXL 1 system to stop progression of keratoconus
219520838|NCT06264024|PROCEDURE|Transepithelial phototherapeutic keratectomy (t-PTK)|Use Alcon Wavelight 500, excimer laser to remove the epithelium and some of the stroma over apex
218905553|NCT01654926|PROCEDURE|blood ultrafiltration|
218905554|NCT02417883|DRUG|Furosemide|Evaluate urinary excretion rate fo furosemide
218905555|NCT04215926|OTHER|No intervention; cross-sectional study|No intervention; cross-sectional study
218905556|NCT01476007|DRUG|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
218905557|NCT01476007|DRUG|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
219039140|NCT03663283|DRUG|Liposomal Bupivacaine|Interscalene Nerve Blocks
219612983|NCT05871554|BEHAVIORAL|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
218905558|NCT03431298|BEHAVIORAL|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training"
218905559|NCT03431298|BEHAVIORAL|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down"
218905560|NCT03881839|OTHER|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
218905561|NCT05740488|DRUG|Apalutamide|240mg, po, qd
218905562|NCT05740488|DRUG|89Sr|100\~150MBq(based on weight), iv, q90d
218905563|NCT05740488|DRUG|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
219612984|NCT03714828|DRUG|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
218905564|NCT00537602|DRUG|miglustat|
218905565|NCT00537602|DRUG|placebo|
218905566|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
218905567|NCT01620060|DRUG|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
218905568|NCT02180581|DIETARY_SUPPLEMENT|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months
218905569|NCT02180581|DIETARY_SUPPLEMENT|Placebo|Placebo for 6 months
218905570|NCT06378034|DIETARY_SUPPLEMENT|Lactium|300 mg per day, taken 30 min to 60 min before bedtime
218905571|NCT06378034|DIETARY_SUPPLEMENT|Placebo|300 mg per day, taken 30 min to 60 min before bedtime
218905572|NCT03016572|BEHAVIORAL|Standard of Care|Follow-Up Calls, Questionnaires
218905573|NCT03016572|BEHAVIORAL|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
218905574|NCT03016572|BEHAVIORAL|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
218905575|NCT01402401|DRUG|AUY922|
218905576|NCT01402401|DRUG|Trastuzumab|
218905577|NCT06349694|OTHER|Transcutaneous MPN stimulation (T-MPNS)|Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
218905578|NCT06349694|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
218905579|NCT06349694|OTHER|BT (Control group)|Conventional bladder training
218905580|NCT04985721|DRUG|Pamiparib|40 mg orally twice a day
218905581|NCT04985721|DRUG|Tislelizumab|200 mg IV every 21 days
218905582|NCT01361022|DRUG|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
218905583|NCT01361022|DRUG|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
218905584|NCT05218369|DRUG|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
219039141|NCT03663283|DRUG|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
219039142|NCT04259957|DEVICE|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
219039143|NCT02667483|DRUG|DS-5141b|DS-5141b, Subcutaneous injection
219039144|NCT06647030|DEVICE|CURATE.DTx sessions|"Participants will interact with CURATE.DTx twelve minutes per day, three days a week, for ten weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force."
219204379|NCT06737991|OTHER|Range of motion exercises|Range of motion Exercises, soft tissue massage, positioning to prevent pressure sores, stretch pole for 20 minutes
219039145|NCT06647030|BEHAVIORAL|Interview|After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use thematic analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
218905585|NCT01792310|DRUG|LAM561|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
218905586|NCT01582061|DRUG|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
218905587|NCT05924061|OTHER|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
218905588|NCT00231777|DRUG|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
218905589|NCT00231777|DRUG|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
218905590|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
218905591|NCT05425602|DRUG|MAX-40279-01: 50mg/70mg|\[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
218905592|NCT00297219|DRUG|Low dialysate calcium|1.25 mmol/L dialysate calcium
218905593|NCT00297219|DRUG|high dialysate calcium|1.75 mmol/L dialysate calcium
218905594|NCT00702468|DRUG|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
219039146|NCT06213402|OTHER|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
219520839|NCT06158516|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
219520840|NCT06158516|DRUG|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
218905595|NCT00702468|DRUG|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
218905596|NCT05858086|OTHER|Novel same-day discharge protocol after total joint arthroplasty|Preoperative gait/stair training with physical therapy, then postoperative ambulation with nursing after total joint arthroplasty
218905597|NCT05858086|OTHER|Conventional postoperative physical therapy clearance|Physical therapy evaluation and clearance after total joint arthroplasty
218905598|NCT04458636|DRUG|Prednisolone|Oral
218905599|NCT05691881|DRUG|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
218905600|NCT02579668|OTHER|Language Therapy|
218905601|NCT03308344|BEHAVIORAL|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
218905602|NCT05089006|PROCEDURE|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
219520841|NCT01553838|DEVICE|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
218905603|NCT02190526|DRUG|Mesalazine(asacol 800 mg)|
218905604|NCT02190526|DRUG|Amitriptyline|
219520842|NCT02060110|DEVICE|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
219520843|NCT02060110|DEVICE|MADIT-CRT ICD ONLY ARM|
219520844|NCT03192696|DEVICE|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
219520845|NCT03299296|DRUG|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
219612985|NCT03714828|DRUG|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
219520846|NCT03299296|DRUG|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
219520847|NCT00653471|DEVICE|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
219520848|NCT00653471|DEVICE|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
218905605|NCT02190526|DRUG|placebo like asacol|
218905606|NCT02190526|DRUG|placebo like amitriptyline|
218905607|NCT05975255|DRUG|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
218905608|NCT03839368|PROCEDURE|fixation of angle fracture|open reduction and internal fixation of angle fracture
218905609|NCT04698343|DEVICE|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
218905610|NCT02931019|PROCEDURE|Intubation|
218905611|NCT05583916|PROCEDURE|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
218905612|NCT03488836|PROCEDURE|reciproc|rotary reciprocating protocol
218905613|NCT03488836|PROCEDURE|race rotary|race rotary group protocol
218905614|NCT02756338|DEVICE|BioMonitor 2 Insertable Cardiac Monitor|
218905615|NCT00961155|DRUG|cyklezonid|160 mcg once daily
218905616|NCT00961155|DRUG|montelukast sodium|5 or 10 mg according to age once daily
219039147|NCT06646029|DEVICE|RMO flexion orthosis (splint)|RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
219039148|NCT06646029|OTHER|Standard of care|Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
219520849|NCT00653471|DEVICE|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
219520850|NCT04671888|OTHER|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
219520851|NCT05325047|PROCEDURE|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
219520852|NCT02143765|DRUG|Mitiglinide|three times a day, orally, for 12 weeks
219520853|NCT02143765|DRUG|Acarbose|three times a day, orally, for 12 weeks
219520854|NCT02684344|DRUG|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
218905617|NCT00961155|DRUG|placebo|fluticasone placebo twice daily, montelukast placebo once daily
218905618|NCT00961155|DRUG|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
218905619|NCT06160232|DRUG|Psilocybin (high dose)|Psilocybin-assisted therapy
218905620|NCT06160232|DRUG|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
218905621|NCT00219063|DRUG|aliskiren|
218905622|NCT03395899|DRUG|Atezolizumab|PD-L1 antibody
219039149|NCT02346136|BEHAVIORAL|Tai Chi training|
219520855|NCT02684344|OTHER|Education|Education about signs and symptoms of urinary retention
219520856|NCT00331526|BIOLOGICAL|aldesleukin|
219520857|NCT00331526|BIOLOGICAL|therapeutic autologous lymphocytes|
218905623|NCT03395899|DRUG|Cobimetinib|Highly selective small-molecule inhibitor of MEK1 and MEK2
219039150|NCT02346136|BEHAVIORAL|Educational Control|
219520858|NCT00331526|PROCEDURE|adjuvant therapy|
219520859|NCT00331526|PROCEDURE|conventional surgery|
219520860|NCT04529746|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
218905624|NCT03395899|DRUG|Ipatasertib|Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
218905625|NCT03395899|DRUG|Bevacizumab|Highly specific humanized monoclonal antibody that targets VEGF
218905626|NCT04309110|DEVICE|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
218905627|NCT02334930|OTHER|Biopsy|
218905628|NCT02724332|DRUG|Rapamycin|2mg,po,bid
218905629|NCT05107544|OTHER|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
219520861|NCT03480425|DIAGNOSTIC_TEST|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
219520862|NCT02486822|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
219520863|NCT02486822|DRUG|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
219520864|NCT02486822|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
219520865|NCT06011122|PROCEDURE|Distal radius fracture ORIF with a specific volar plate|Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
219520866|NCT03970122|DRUG|GFB-887|IMP
219520867|NCT03970122|DRUG|Placebo|Matching
219520868|NCT01658293|BEHAVIORAL|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
219520869|NCT01658293|BEHAVIORAL|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
219520870|NCT03596372|DRUG|BAY1834942|"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."
219520871|NCT02956772|DRUG|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
219520872|NCT02956772|DRUG|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
219520873|NCT03100630|DRUG|RO7239361|Specified dose on specified days
219520874|NCT04114448|OTHER|Therapeutic exercise|Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
219520875|NCT04114448|OTHER|Usual physical therapy care|Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
218905630|NCT01858792|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
219039151|NCT05203263|DEVICE|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
219039152|NCT05203263|DEVICE|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
219039153|NCT05203263|DEVICE|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
219039154|NCT01666756|DIETARY_SUPPLEMENT|Chinese herbal formulation PHY906|Given PO
219039155|NCT01666756|DRUG|sorafenib tosylate|Given PO
219039156|NCT01666756|OTHER|laboratory biomarker analysis|Correlative studies
219039157|NCT01666756|OTHER|pharmacological study|Correlative studies
219520876|NCT05687630|OTHER|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
219520877|NCT00396526|DRUG|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
219520878|NCT02506582|DIETARY_SUPPLEMENT|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
219520879|NCT02506582|DIETARY_SUPPLEMENT|placebo|40 g powdered rice flour
218905631|NCT01858792|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
218905632|NCT01858792|OTHER|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
218905633|NCT00300755|DRUG|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
218905634|NCT00276263|DRUG|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
218905635|NCT05532826|OTHER|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
219364868|NCT06912074|RADIATION|Hypofractionated Radiation Therapy|"All patients will receive hypofractionated radiotherapy once daily, five days per week, followed by a boost. Three weeks after the completion of the first phase of hypofractionated radiotherapy, tumor response and cardiopulmonary function will be evaluated. For patients who achieve a partial response, have no deep esophageal ulcers on endoscopy, and have cardiopulmonary function tolerating the radiotherapy boost, a second phase of radiotherapy will be planned using a new CT simulation and radiotherapy design.~First Phase of Radiotherapy: Total dose of 2500 cGy in 5 fractions (500 cGy per fraction) Second Phase of Radiotherapy: Total dose of 2500 cGy in 10 fractions (250 cGy per fraction) The interval between the two phases of radiotherapy will be 28 days."
219520880|NCT04112082|BEHAVIORAL|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
219612986|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
219520881|NCT04112082|OTHER|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
219520882|NCT04165148|DEVICE|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
219520883|NCT04165148|DEVICE|conventional laparoscopy|conventional laparoscopy
219520884|NCT04165148|OTHER|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
218905636|NCT04442542|OTHER|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
218905637|NCT04442542|OTHER|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
218905638|NCT03284606|DEVICE|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
219364869|NCT06912074|RADIATION|Conventional Fractionated Radiation Therapy|Patients will receive a total dose of 5000 cGy in 25 fractions, with 200 cGy per fraction.
219364870|NCT06912074|DRUG|Concurrent Chemotherapy|Capecitabine oral administration, 1000 mg/m², twice daily
219364871|NCT06910644|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of 0.5 μg/kg/h.
219364872|NCT06910644|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5mg/kg/h.
219364873|NCT06910644|DRUG|Isotonic saline|Patients will receive intravenous isotonic saline 0.9% in the same volume and manner as the study drugs.
219520885|NCT04165148|OTHER|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
218905639|NCT03284606|PROCEDURE|Common rehabilitation|Common rehabilitation for hemiplegic patients
218905640|NCT02333461|DIETARY_SUPPLEMENT|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
218905641|NCT02333461|DIETARY_SUPPLEMENT|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
218905642|NCT02333461|DIETARY_SUPPLEMENT|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
218905643|NCT02333461|DIETARY_SUPPLEMENT|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
218905644|NCT02333461|DIETARY_SUPPLEMENT|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
218905645|NCT02503592|OTHER|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
218905646|NCT03547778|DRUG|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
218905647|NCT03547778|DRUG|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
218905648|NCT03192826|DRUG|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
218905649|NCT03192826|DRUG|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
219039158|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
218905650|NCT03192826|DRUG|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
218905651|NCT02694744|DRUG|patiromer|8.4 g/day starting dose, administered orally
219520886|NCT04165148|OTHER|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
219520887|NCT05561426|OTHER|Ad libitum breakfast and dinner meals for 12 days|Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
219520888|NCT05885165|BEHAVIORAL|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
218905652|NCT01379417|DIETARY_SUPPLEMENT|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
218905653|NCT01842802|DEVICE|Diode Laser|Diode Laser for treatment of subcutaneous fat
219039164|NCT01039181|DRUG|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
218905654|NCT01842802|DEVICE|YAG laser|YAG laser for treatment of subcutaneous fat
218905655|NCT05224115|OTHER|[11C]CHDI-00485180-R|Mutant huntingtin aggregate binding PET radioligand.
218905656|NCT05224115|OTHER|[11C]CHDI-00485626|Mutant huntingtin aggregate binding PET radioligand.
218905657|NCT00686777|BIOLOGICAL|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
218905658|NCT00686777|DRUG|Ribavirin|Ribavirin 400 mg/day orally
218905659|NCT00516113|DRUG|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
218905660|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
218905661|NCT01370902|DRUG|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
218905662|NCT01370902|DRUG|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
218905663|NCT01370902|DRUG|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
219039165|NCT03007394|DRUG|Lorcaserin|Lorcaserin Capsule
219039166|NCT03007394|DRUG|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
219364874|NCT06913712|OTHER|Weight loss without pharmacotherapy|The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.
219364875|NCT06913959|DIAGNOSTIC_TEST|Prospective|Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research
218905664|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
218905665|NCT01370902|DRUG|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
218905666|NCT06012123|PROCEDURE|Aortoiliac angioplasty and stenting|Covered endovascular reconstruction of aortic bifurcation (CERAB) in patient with aorto-iliac occlusive disease
218905667|NCT01320358|DRUG|ECMPS-IEM|ECMPS-IEM
218905668|NCT01808859|DEVICE|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
218905669|NCT03803306|COMBINATION_PRODUCT|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
218905670|NCT03803306|OTHER|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
218905671|NCT01945021|DRUG|Crizotinib|
218905672|NCT03707353|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
219039167|NCT03662438|OTHER|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
219039168|NCT03662438|DEVICE|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
219520889|NCT05885165|BEHAVIORAL|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
219520890|NCT00983684|DEVICE|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
219520891|NCT00983684|RADIATION|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
219520892|NCT04048005|DIAGNOSTIC_TEST|Fractional flow reserve|
219520893|NCT00913705|DRUG|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
219520894|NCT00913705|DRUG|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
219520895|NCT00913705|PROCEDURE|Surgery|Surgery
219520896|NCT01001845|DRUG|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
219520897|NCT01001845|DRUG|vit E|200 mg twice daily for 3 weeks
219520898|NCT01001845|DRUG|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
219520899|NCT01288131|DRUG|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
219520900|NCT01288131|DRUG|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
218905673|NCT03582215|DRUG|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
218905674|NCT03582215|DRUG|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
218905675|NCT03582215|DRUG|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
218905676|NCT03582215|DRUG|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
218905677|NCT03582215|DRUG|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
218905678|NCT03582215|DRUG|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
219039169|NCT00899691|GENETIC|protein expression analysis|
218905679|NCT03582215|DRUG|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
218905680|NCT03582215|DRUG|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
218905681|NCT01911715|DRUG|MDV3100|Oral
218905682|NCT02319330|BEHAVIORAL|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
218905683|NCT02319330|BEHAVIORAL|Treatment as Usual|Routine HIV clinic-based counseling
218905684|NCT05238077|PROCEDURE|Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy|Patients will have different kinds of light shined on different areas
218905685|NCT02163902|DRUG|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
218905686|NCT02163902|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
218905687|NCT04127721|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
218905688|NCT04127721|DRUG|Busulfan|Given IV
218905689|NCT04127721|DRUG|Fludarabine|Given IV
218905690|NCT04127721|DRUG|Itacitinib|Given PO
218905691|NCT04127721|DRUG|Methotrexate|Given IV
218905692|NCT04127721|DRUG|Tacrolimus|Given IV and PO
218905693|NCT03636581|BEHAVIORAL|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
218905694|NCT00572377|DRUG|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
219039170|NCT05077943|BEHAVIORAL|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
219039171|NCT05077943|BEHAVIORAL|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
219039172|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
219039173|NCT00281203|PROCEDURE|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
219520901|NCT03814239|OTHER|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was \>15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained \>15%, administration of noradrenaline infusion was considered.
219520902|NCT01400022|OTHER|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
219520903|NCT01400022|OTHER|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
219520904|NCT05081258|PROCEDURE|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
218905695|NCT00572377|DRUG|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
218905696|NCT05665036|COMBINATION_PRODUCT|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
218905697|NCT03961334|DRUG|Dabigatran|150mg 2x/d
218905698|NCT03961334|DRUG|Apixaban|5mg 2x/d
218905699|NCT03961334|DRUG|Edoxaban|60mg 1x/d
218905700|NCT03961334|DRUG|Aspirin|100mg 1x/d
218905701|NCT03961334|DRUG|Clopidogrel|75mg 1x/d
218905702|NCT02174731|DRUG|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
218905703|NCT02174731|DRUG|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
218905704|NCT03792659|OTHER|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
218905705|NCT03668795|PROCEDURE|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
218905706|NCT03119259|BEHAVIORAL|ABC Clinical Program|"The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary."
218905707|NCT03119259|BEHAVIORAL|BCN|"BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others."
218905708|NCT04785222|DRUG|dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine|Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
218905709|NCT00983346|DRUG|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
218905710|NCT01032616|OTHER|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
218905711|NCT01032616|OTHER|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
218905712|NCT01140308|DRUG|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
218905713|NCT01140308|DRUG|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
218905714|NCT03267368|BEHAVIORAL|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
218905715|NCT05868603|OTHER|Remineralization gel|Remineralization gel
219039174|NCT00281203|PROCEDURE|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
219039175|NCT02508571|OTHER|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
219039176|NCT02508571|OTHER|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
219520905|NCT05081258|PROCEDURE|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
219520906|NCT05682118|PROCEDURE|roadmap|"FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg."
219520907|NCT05682118|PROCEDURE|iFR/FFR|Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
218905716|NCT02262585|DRUG|BIBR 277 tablet|
218905717|NCT02262585|DRUG|BIBR 277 capsule|
218905718|NCT02050438|PROCEDURE|Total Knee Arthroplasty|
218905719|NCT01286675|DRUG|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
219520908|NCT01382290|PROCEDURE|MRI|
218905720|NCT03293615|OTHER|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
218905721|NCT05371769|OTHER|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
218905722|NCT05371769|OTHER|No intervention|No intervention will be made.
219520909|NCT04810416|OTHER|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
218905723|NCT00003468|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
218905724|NCT06560203|PROCEDURE|Mechanical thrombectomy|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
218905725|NCT00655265|DRUG|Colesevelam hydrochloride film-coated tablets|tablets
218905726|NCT00655265|DRUG|Placebo|Tablets
218905727|NCT01893996|DRUG|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
218905728|NCT01893996|DRUG|Placebo|
218905729|NCT04892641|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
218905730|NCT04892641|DRUG|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
218905731|NCT00739401|DEVICE|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
218905732|NCT01723241|DRUG|XAF5, concentration A|
219520910|NCT04810416|OTHER|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
219520911|NCT04810416|OTHER|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
218905733|NCT01723241|DRUG|XAF5, concentration B|
218905734|NCT01723241|DRUG|XAF5, concentration C|
219520912|NCT04810416|OTHER|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
219520913|NCT00266006|DRUG|eptacog alfa (activated)|
219520914|NCT06381609|BEHAVIORAL|Quality life questionnaire AQoLS|Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
218905735|NCT01723241|DRUG|Placebo|
218905736|NCT04056416|DEVICE|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
218905737|NCT05478642|OTHER|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
218905738|NCT01663870|BEHAVIORAL|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
218905739|NCT01663870|BEHAVIORAL|Focus Group Session|Focus group session taking 60-90 minutes.
218905740|NCT01663870|OTHER|Website Session|10-15 minute session with the HealthATM website.
218905741|NCT01663870|BEHAVIORAL|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
219520915|NCT06381609|BEHAVIORAL|Quality life questionnaire Euroqol EQ-5D-5L|Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
219520916|NCT06381609|OTHER|Peer support consultations|"For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.~Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up"
219520917|NCT02137993|DRUG|A-prexa|A-prexa 5-20 mg for 6 weeks
219520918|NCT02137993|DRUG|Zyprexa|Zyprexa 5-20 mg for 6 weeks
218905742|NCT05356416|OTHER|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
219039177|NCT02508571|OTHER|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
219612987|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
218905743|NCT05356416|OTHER|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
218905744|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
218905745|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
218905746|NCT04986163|DEVICE|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
218905747|NCT04430920|OTHER|Intensive intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 80 mmHg.
218905748|NCT04430920|OTHER|Conventional intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
218905749|NCT03796273|OTHER|Best Practice|Undergo standard surgery
218905750|NCT03796273|DRUG|Ketoconazole|Given PO
218905751|NCT05648253|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
219039178|NCT03758196|DEVICE|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
219039179|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
219039180|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
219039181|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
219039182|NCT00853554|DRUG|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
219039183|NCT00853554|DRUG|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
219039184|NCT01845792|DRUG|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
219039185|NCT01845792|DRUG|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
219039186|NCT00045747|DRUG|7-hydroxystaurosporine|
219039187|NCT00045747|DRUG|fluorouracil|
219039188|NCT01087086|BEHAVIORAL|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
219520919|NCT01471847|DRUG|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
219039189|NCT01087086|BEHAVIORAL|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
219039190|NCT03742141|DEVICE|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
219039191|NCT03742141|DRUG|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
219612988|NCT05911061|BIOLOGICAL|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
219612989|NCT05911061|BIOLOGICAL|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
219612990|NCT05911061|BIOLOGICAL|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
219612991|NCT05911061|BIOLOGICAL|Placebo group|saline
219612992|NCT03560128|DEVICE|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
219612993|NCT03560128|DEVICE|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
219039192|NCT00190801|DRUG|pemetrexed|
219039193|NCT00190801|DRUG|cisplatin|
219039194|NCT04283643|OTHER|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
219039195|NCT04283643|OTHER|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
219039196|NCT03766178|DRUG|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
219039197|NCT00003294|BIOLOGICAL|filgrastim|
219039198|NCT00003294|DRUG|amifostine trihydrate|
219039199|NCT00003294|DRUG|carboplatin|
218905752|NCT04575155|BEHAVIORAL|TEAM Strategy|"1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
218905753|NCT01021735|DRUG|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
219039200|NCT00003294|DRUG|paclitaxel|
219039201|NCT06016452|DRUG|Chlorophyllin|Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
219520920|NCT01471847|DRUG|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
219520921|NCT00448097|DRUG|cetuximab|No verifiable data available, PI relocated
218905754|NCT01021735|DRUG|Rituximab|1g x2 by IV infusion repeated every 5 months or more
219039202|NCT00850395|DRUG|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
219039203|NCT04365868|DRUG|belapectin|intravenous
219039204|NCT04365868|DRUG|Placebo|intravenous
219039205|NCT03676530|DEVICE|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
219520922|NCT00448097|DRUG|docetaxel|No verifiable data available, PI relocated
219520923|NCT03469297|DEVICE|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
219520924|NCT02793453|OTHER|periodontal smears|
219520925|NCT03100305|OTHER|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
219520926|NCT03416647|PROCEDURE|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
219520927|NCT05017298|BIOLOGICAL|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
219520928|NCT02195245|DEVICE|memsorb|
219520929|NCT01386047|OTHER|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
219520930|NCT05868447|PROCEDURE|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
219520931|NCT02244034|PROCEDURE|hypothermia|
219520932|NCT02456779|OTHER|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
219039206|NCT00409383|DRUG|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
219520933|NCT02456779|OTHER|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
219520934|NCT02456779|OTHER|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
219520935|NCT06443307|DRUG|Irinotecan Liposome|The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
219520936|NCT02548637|PROCEDURE|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
219520937|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
219520938|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
219520939|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
219520940|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
219520941|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
219520942|NCT02424188|OTHER|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
219520943|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
219520944|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
219520945|NCT03846388|DIAGNOSTIC_TEST|follicular stimulating hormone|in the serum of our patients
219520946|NCT03846388|DIAGNOSTIC_TEST|Anti-mullerian hormone|in the serum of our patients
219520947|NCT03846388|RADIATION|Basal antral follicle count|by ultrasound
219520948|NCT02622945|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
219520949|NCT02622945|DEVICE|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
219520950|NCT00630305|DEVICE|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
218905755|NCT02388581|DRUG|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
218905756|NCT02266316|DEVICE|Air warming mask|Mask that warms air at the mouth
218905757|NCT06020898|DRUG|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
218905758|NCT06020898|DRUG|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
218905759|NCT02851303|DRUG|Morphine|Morphine wean protocol as described in arm description
218905760|NCT02851303|DRUG|Methadone|Methadone wean protocol as described in arm description
219039207|NCT00409383|DRUG|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
219520951|NCT00630305|DEVICE|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
219520952|NCT00630305|DEVICE|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
219520953|NCT06223347|DIAGNOSTIC_TEST|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
219520954|NCT04949698|DEVICE|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
218905761|NCT06451302|DRUG|cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide|The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
219520955|NCT04902157|DIAGNOSTIC_TEST|Cycle threshold|cycle threshold number
219039208|NCT00409383|DRUG|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
219039209|NCT00565279|DRUG|ASF1057|Twice daily, topical
219039210|NCT00565279|DRUG|ASF1057|Twice daily, Topical
219039211|NCT01779193|DIETARY_SUPPLEMENT|lactic acid bacteria|oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
219520956|NCT00467220|BEHAVIORAL|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
219520957|NCT05294094|BEHAVIORAL|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
219520958|NCT05294094|BEHAVIORAL|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
219520959|NCT00404131|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
219520960|NCT02086188|DRUG|Mirabegron|see detailed information in associated Arm Description
219520961|NCT02086188|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
219612994|NCT01587287|DEVICE|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
219612995|NCT02523261|PROCEDURE|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
218905762|NCT06011408|OTHER|TDtect|Collecting video data on abnormal movement
219520962|NCT01701024|DRUG|ACYC|ACYC active, topically applied to the face for 12 weeks
219520963|NCT01701024|DRUG|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
219520964|NCT02753842|DEVICE|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
219520965|NCT04639765|OTHER|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
219520966|NCT04639765|OTHER|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
219520967|NCT04639765|OTHER|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
219520968|NCT04639765|OTHER|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
218905763|NCT01747512|DRUG|C-PERT|Patients with thyroid and Head and Neck cancer
219520969|NCT04639765|OTHER|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
219520970|NCT04639765|OTHER|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
219520971|NCT05019469|DEVICE|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
219520972|NCT04910126|DRUG|Camrelizumab|Camrelizumab 200mg q3w up to 2 years
219520973|NCT04910126|DRUG|Adriamycin|adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
219520974|NCT05257746|PROCEDURE|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
219520975|NCT00448695|PROCEDURE|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
219612996|NCT02523261|PROCEDURE|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
218905764|NCT01747512|DRUG|G-PERT|Patients with thyroid and Head and Neck cancer
219520976|NCT01504698|PROCEDURE|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
219520977|NCT01504698|PROCEDURE|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
219520978|NCT01058278|PROCEDURE|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
219520979|NCT03571893|BEHAVIORAL|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
219612997|NCT03149276|OTHER|Interpreter services|
219612998|NCT03740373|DRUG|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
219612999|NCT03740373|DRUG|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
218905765|NCT02572323|DRUG|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
219039212|NCT01779193|DIETARY_SUPPLEMENT|cranberry|oral cranberry capsule, one pill daily
219039213|NCT01779193|DIETARY_SUPPLEMENT|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
219039214|NCT06407466|OTHER|taping|"Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa."
219039215|NCT06407466|OTHER|Control|The routine training program will continue without intervention.
218905766|NCT06262789|OTHER|"Return-to-work after cancer consultation"|"The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation."
218905767|NCT02967146|DEVICE|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
218905768|NCT05887986|OTHER|hand-held fan airflow stimulation|"Outcome dyspnea measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the dyspnea level will be evaluated.~Outcome comfort measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the comfort level of the patients will be evaluated."
218905769|NCT03168477|OTHER|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
218905770|NCT03168477|OTHER|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
218905771|NCT03168477|OTHER|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
218905772|NCT03168477|OTHER|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
218905773|NCT03168477|OTHER|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
218905774|NCT00660192|DRUG|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
218905775|NCT00660192|OTHER|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
218905776|NCT02734693|DRUG|dasotraline 4mg|dasotraline 4mg/day
218905777|NCT02734693|OTHER|Placebo|placebo/day
218905778|NCT04954508|DIAGNOSTIC_TEST|The hug-up test|It is a new physical test used to detect supraspinatus tear
219039216|NCT06407466|OTHER|mobilization|Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
219039217|NCT05883137|DEVICE|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
219039218|NCT04060056|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
219520980|NCT03571893|BEHAVIORAL|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
219520981|NCT03471078|DRUG|Avatrombopag|Oral avatrombopag tablet
219520982|NCT03471078|DRUG|Placebo Oral Tablet|Placebo comparator tablet
219520983|NCT05525871|DIETARY_SUPPLEMENT|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
218905779|NCT04954508|DIAGNOSTIC_TEST|EC test|It is a traditional physical test used to detect supraspinatus tear
219039219|NCT04060056|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
219520984|NCT05525871|DIETARY_SUPPLEMENT|Control product|Fruit puree
219520985|NCT02248597|DRUG|fludarabine phosphate|Given IV
219520986|NCT02248597|DRUG|busulfan|Given IV
219520987|NCT02248597|DRUG|cyclophosphamide|Given IV
219520988|NCT02248597|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
219520989|NCT02248597|DRUG|tacrolimus|
219520990|NCT02248597|DRUG|mycophenolate mofetil|
219520991|NCT04697745|DRUG|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
219520992|NCT04697745|DRUG|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
219520993|NCT01124929|DRUG|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
219520994|NCT01124929|DRUG|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
219520995|NCT01269801|DRUG|onabotulinumtoxinA|"* Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
218905780|NCT04954508|DIAGNOSTIC_TEST|FC test|It is a traditional physical test used to detect supraspinatus tear
218905781|NCT04954508|DIAGNOSTIC_TEST|Neer impingement sign|It is a traditional physical test used to detect supraspinatus tear
218905782|NCT04954508|DIAGNOSTIC_TEST|Hawkins-Kennedy impingement sign|It is a traditional physical test used to detect supraspinatus tear
218905783|NCT04954508|DIAGNOSTIC_TEST|diagnostic arthroscopy|The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (\>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
218905784|NCT02866058|PROCEDURE|Cesarean Section|
218905785|NCT01067677|DRUG|Metaclopramide|0.5 mg/kg for rescue after PONV
218905786|NCT01067677|DRUG|Ondansetron|0.1 mg/kg (max 4 mg0
218905787|NCT01067677|DRUG|diphenhydramine|0.25 mg/kg (max 25 mg)
218905788|NCT01067677|DRUG|Saline|equal volume (5 ml)as experimental rescue medications
218905789|NCT05239481|DEVICE|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
218905790|NCT05239481|DEVICE|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
218905791|NCT06163963|DIAGNOSTIC_TEST|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
219039220|NCT04060056|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
219364876|NCT06917573|DRUG|Cemiplimab|"Patients will receive Cemiplimab administered by IV infusion over 30 minutes every 28 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a high affinity hinge-stabilized IgG4P human antibody to the PD-1receptor (PDCD1, CD279) that blocks PD 1/PD L1 mediated T cell inhibition. Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.~Route of administration: Intravenous infusion."
219520996|NCT01269801|DRUG|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
218905792|NCT06163963|DIAGNOSTIC_TEST|charcoal injection to uterus to map sentinel lymph nodes|During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
218905793|NCT02730481|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
218905794|NCT05670522|DEVICE|Transcranial direct current stimulation|"Transcranial direct-current stimulation (tDCS), over the motor cortex, is a potential therapy option for motor control deficits in children with CP. The application of tDCS involves positioning 2 rubber electrodes sheathed in saline-soaked pads onto the scalp, held in place by a rubber strap. Low-intensity, direct-current, of 1 to 2 mA, is delivered to cortical areas from the device.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
219039221|NCT02979340|PROCEDURE|MRI|non-invasive assessment of hepatic fibrosis and steatosis
219039222|NCT00328913|DRUG|5-hydroxytryptophan (food supplement)|
219039223|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
219039224|NCT04180020|OTHER|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
219039225|NCT04180020|OTHER|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
219520997|NCT03127904|PROCEDURE|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
219613000|NCT01093092|DIETARY_SUPPLEMENT|Calcitriol|Given PO
219613001|NCT01093092|DRUG|Cisplatin|Given IV
219613002|NCT01093092|DRUG|Gemcitabine Hydrochloride|Given IV
219613003|NCT01093092|OTHER|Pharmacological Study|Correlative studies
218905795|NCT05670522|DEVICE|Virtual reality|"Virtual reality rehabilitation is an emerging therapy for motor rehabilitation of children with CP. The therapy is provided through a computer-simulated environment where they interact with real-world-like objects and events through sight, sound, and touch. The Wii Remote was used as the interactive interface, and standard computer/television screens were used as the display hardware. Therefore, VR therapy was of the non-immersive type.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
218905796|NCT03121859|OTHER|Neck stabilization exercise|Exercise
218905797|NCT03121859|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS)
219520998|NCT03127904|PROCEDURE|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
219520999|NCT05498480|BIOLOGICAL|Relatlimab|Specified dose on specified days
219521000|NCT05498480|BIOLOGICAL|Nivolumab|Specified dose on specified days
218905798|NCT03121859|OTHER|IFC|Interferential current therapy(IFC)
218905799|NCT02787395|PROCEDURE|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
218905800|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
218905801|NCT03389022|DRUG|Saline|Intravenous injection given pre-incisional in the operating room.
218905802|NCT03389022|DRUG|Ketamine|0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
218905803|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.
219521001|NCT02473640|DRUG|SYN-004|
218905804|NCT03389022|DRUG|Ketamine|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
218905805|NCT03626259|DRUG|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
218905806|NCT03626259|DRUG|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
219521002|NCT02473640|DRUG|Esomeprazole|
219521003|NCT02473640|DRUG|Ceftriaxone|
219521004|NCT02395822|BIOLOGICAL|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
219521005|NCT02715622|PROCEDURE|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
219521006|NCT05760872|OTHER|Placing esophageal probe|Placing an esophageal probe through the mouth
219521007|NCT02648620|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
219521008|NCT02648620|PROCEDURE|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
219521009|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
219521010|NCT02609139|DRUG|PF-06650833|100mg modified release tablet administered under fasted conditions
219521011|NCT02609139|DRUG|PF-06650833|20mg modified release tablet administered under fasted conditions
219521012|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
219521013|NCT02609139|DRUG|PF-06650833|100mg modified released tablet administered with high fat meal food intake
219521014|NCT02609139|DRUG|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
219521015|NCT02975141|DRUG|Afatinib 30Mg Tab|Study Drug
219521016|NCT02975141|DRUG|Afatinib 40Mg Tab|Study Drug
219521017|NCT02975141|DRUG|Gemzar|Chemotherapy Backbone
218905807|NCT00934453|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
218905808|NCT00934453|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
218905809|NCT02050477|PROCEDURE|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
218905810|NCT00526292|BIOLOGICAL|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
218905811|NCT00526292|DRUG|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
218905812|NCT00526292|DRUG|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
219039226|NCT05450471|DRUG|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
219039227|NCT05450471|OTHER|Placebo|Placebo
219521018|NCT02975141|DRUG|Abraxane|Chemotherapy Backbone
218905813|NCT03899714|OTHER|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
218905814|NCT02278406|OTHER|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
218905815|NCT03418155|DRUG|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
218905816|NCT03418155|DRUG|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
218905817|NCT01718379|DRUG|Lenalidomide|Lenalidomide:10 mg per day during 21 days
218905818|NCT01718379|DRUG|Epoetin beta|Epoetin beta: 60,000 Units/week.
218905819|NCT02263469|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
218905820|NCT04069559|OTHER|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
218905821|NCT04077021|DRUG|CCW702|Investigational immunotherapy for prostate cancer
218905822|NCT00837902|DRUG|Atenolol (β-blocker)|25 mg tablet
218905823|NCT03072446|DEVICE|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
218905824|NCT04888624|DEVICE|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
219039228|NCT03447665|BEHAVIORAL|Bedtime routine|Tailored bedtime routine
219039229|NCT03447665|BEHAVIORAL|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
218905825|NCT04888624|DEVICE|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
218905826|NCT04013308|PROCEDURE|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
218905827|NCT03180385|DEVICE|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
218905828|NCT03180385|DEVICE|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
218905829|NCT04338282|DRUG|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
218905830|NCT05403996|BEHAVIORAL|Activa-Mente|Active break program
218905831|NCT03289793|OTHER|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
218905832|NCT03289793|OTHER|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
218905833|NCT03289793|OTHER|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
218905834|NCT05096624|OTHER|DD-TENS system|Use of DD-TENS system
218905835|NCT05096624|OTHER|Gold Standard|Gold standard
218905836|NCT05096624|OTHER|Digital Denture system|Use of Digital Denture system
218905837|NCT01301807|DRUG|Carfilzomib|Given IV
218905838|NCT01301807|DRUG|Panobinostat|Given PO
218905839|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
218905840|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
218905841|NCT00896714|DEVICE|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
218905842|NCT05724732|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
219039230|NCT03447665|BEHAVIORAL|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
219039231|NCT03447665|BEHAVIORAL|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
219039232|NCT04291339|PROCEDURE|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
218905843|NCT02693808|PROCEDURE|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
218905844|NCT02693808|PROCEDURE|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
218905845|NCT04931264|DIAGNOSTIC_TEST|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
218905846|NCT01222845|DRUG|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
218905847|NCT02898454|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219039233|NCT04291339|PROCEDURE|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
218905848|NCT02898454|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
218905849|NCT02898454|DRUG|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension~Route of administration: Intranasal"
218905850|NCT00148902|DRUG|lapatinib|lapatinib
219039234|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
219364877|NCT06917573|DRUG|Carboplatin|"Patients will receive Carboplatin administered by IV infusion for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin.~Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion."
219521019|NCT04437862|DEVICE|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
219521020|NCT04206644|OTHER|biological analysis|biological analysis of the Concentration of CCL18
219521021|NCT06218680|DRUG|Propofol|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
219521022|NCT06218680|DRUG|Normal saline|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
218905851|NCT00148902|DRUG|docetaxel|docetaxel
218905852|NCT03144739|OTHER|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
218905853|NCT03144739|OTHER|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
219039235|NCT00037921|PROCEDURE|Bacterial colonization|
219039236|NCT06300164|DIETARY_SUPPLEMENT|Unripre Carob|The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
219039237|NCT04360564|OTHER|Recurrent pregnancy loss|As described before.
219364878|NCT06917573|DRUG|Paclitaxel|"Patients will receive Paclitaxel administered by IV infusion for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20- epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately).~The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
219364879|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation
219364880|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation of localized intermediate-risk prostate cancer
219364881|NCT06916182|OTHER|MRI sequence|This sequence is a 2D spin-echo sequence for the generation of synthetic maps
219364882|NCT05192187|OTHER|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ"
219364883|NCT01235676|BEHAVIORAL|diet|calorie restriction to reduce weight gain
219364884|NCT01235676|BEHAVIORAL|Exercise|Exercise to reduce weight gain
219364885|NCT00510705|OTHER|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
219364886|NCT00510705|OTHER|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
219364887|NCT00510705|OTHER|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
219364888|NCT03575026|BEHAVIORAL|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
219364889|NCT03575026|BEHAVIORAL|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
218905854|NCT01476423|DRUG|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
218905855|NCT05823402|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
218905856|NCT00106847|DRUG|Infliximab|
219521023|NCT05369247|OTHER|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
219521024|NCT05369247|OTHER|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
219521025|NCT00153803|DRUG|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
219521026|NCT00153803|DRUG|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
219521027|NCT01882647|DRUG|000-0551 Lotion|
219521028|NCT01882647|DRUG|Vehicle Lotion|
219521029|NCT01887262|DEVICE|BCM-guided fluid management|
219521030|NCT01887262|PROCEDURE|Fluid management based on the clinical information alone|
219521031|NCT05550519|OTHER|Entecavir (ETV)|ETV will continue throughout screening and will be stopped at baseline.
218905857|NCT02953600|DIETARY_SUPPLEMENT|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
218905858|NCT02953600|OTHER|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
218905859|NCT02953600|DIETARY_SUPPLEMENT|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
218905860|NCT05993663|BEHAVIORAL|Arts in health group intervention|12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
218905861|NCT02764463|DEVICE|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
218905862|NCT00002998|DRUG|cisplatin|
218905863|NCT00002998|DRUG|gemcitabine hydrochloride|
219039238|NCT06539117|OTHER|Early feeding post caesarean section|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
219039239|NCT00363779|DRUG|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
219039240|NCT00363779|GENETIC|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
219039241|NCT00363779|GENETIC|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
219039242|NCT00363779|OTHER|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
219521032|NCT05550519|OTHER|Tenofovir Disoproxil Fumarate (TDF)|TDF will continue throughout screening and will be stopped at baseline.
219521033|NCT05550519|OTHER|Tenofovir Alafenamide (TAF)|TAF will continue throughout screening and will be stopped at baseline.
219521034|NCT05880056|DRUG|Nerkardou (5 mg) & (10 mg)|Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
219521035|NCT05119439|DRUG|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
219521036|NCT05218798|DIAGNOSTIC_TEST|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial"
219521037|NCT00038675|DRUG|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
219521038|NCT00587470|DRUG|Candesartan|Maximum vasodilation.
219521039|NCT00587470|DRUG|atacand|maximum vasodilation
219521040|NCT00587470|DRUG|Placebo|Placebo
219521041|NCT03292653|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
219521042|NCT03292653|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
219521043|NCT06157710|BEHAVIORAL|Digital intervention through modules|"* Introduction~* Goal Setting Techniques~* Motivation~* Barriers to Action~* Managing Maladaptive Thoughts and Beliefs~* Value Clarification~* Moving Forward"
219521044|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months) and more one avaliation with an interval of 12 months at 24 months."
219521045|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
219521046|NCT02223741|OTHER|Korean medical treatment|acupuncture and herbal drugs
219521047|NCT04720664|DRUG|SM-88|"* SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~* Methoxsalen, One 10 mg capsule taken orally once daily.~* Phenytoin, One 50 mg tablet taken orally once daily.~* Sirolimus, One 0.5 mg tablet taken orally once daily."
219521048|NCT04507711|DRUG|0 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
218905864|NCT00649844|DRUG|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
218905865|NCT00649844|DRUG|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
219039243|NCT00256152|DEVICE|AF Suppression Pacing Algorithm|
219039244|NCT01002833|BIOLOGICAL|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
219039245|NCT06973993|OTHER|live music|live music will be played during waiting time in ER room
219521049|NCT04507711|DRUG|1 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
219521050|NCT04507711|DRUG|10 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
218905866|NCT01622959|PROCEDURE|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
218905867|NCT01601535|DRUG|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
218905868|NCT01601535|DRUG|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
218905869|NCT01601535|DRUG|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
218905870|NCT00647296|DRUG|Placebo|Placebo: 2 tablets taken orally twice daily
218905871|NCT00647296|DRUG|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
218905872|NCT00647296|DRUG|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
218905873|NCT00647296|DRUG|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
218905874|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
218905875|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
219521051|NCT04507711|DRUG|100 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
218905876|NCT05753839|OTHER|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
219521052|NCT06485869|OTHER|Measure the improvement in quality of life|Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire
219521053|NCT06485869|OTHER|Measure the level of satisfaction of patients and nursing staff|Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.
219521054|NCT06485869|OTHER|Measurement of anxiety and pain|Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)
219521055|NCT06485869|OTHER|Measurement of depressive state|Depressive State is measured by HAD score
219521056|NCT06485869|OTHER|measuring fatigue levels|Fatigue levels is measured by Visual Analogue Scale (VAS).
218905877|NCT03151629|OTHER|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
219039246|NCT06973993|OTHER|recorded music|recorded music will be transmitted during waiting time in ER room
219039247|NCT06973993|OTHER|no music|no music will be played or transmitted during waiting time in ER room
219521057|NCT06485869|OTHER|measurement of acute nausea and vomiting|acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)
219521058|NCT05317052|BEHAVIORAL|Massage group|Massage and music therapy
218905878|NCT01917383|DRUG|Trabodenoson|Ophthalmic eye drop
218905879|NCT01917383|DRUG|Latanoprost|Ophthalmic eye drop
218905880|NCT01917383|DRUG|Timolol|Ophthalmic eye drop
218905881|NCT01787461|DIETARY_SUPPLEMENT|Imedeen|Two tablets per day for 6 months
218905882|NCT01787461|DIETARY_SUPPLEMENT|Placebo|Two tablets per day for 6 months
218905883|NCT02304939|PROCEDURE|changeover|
219039248|NCT03821493|DRUG|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
219521059|NCT06027879|BIOLOGICAL|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
218905884|NCT02304939|DEVICE|use of automatic infusion pump|
218905885|NCT02304939|BEHAVIORAL|datas collection|
218905886|NCT03679728|BEHAVIORAL|First trimester|Analysis of sensorimotor outcomes
218905887|NCT03679728|BEHAVIORAL|Second trimester|Analysis of sensorimotor outcomes
218905888|NCT04582786|DRUG|Morphine|Repeated bolus according to pain score
218905889|NCT04582786|DRUG|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
218905890|NCT04582786|DRUG|STR-324|Infusion of solution for intravenous administration
218905891|NCT05009498|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
218905892|NCT05009498|OTHER|Placebo|Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
218905893|NCT01736111|BEHAVIORAL|one way text|
218905894|NCT01736111|BEHAVIORAL|Personal feedback|
219039249|NCT03821493|DRUG|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
218905895|NCT00359255|BEHAVIORAL|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
218905896|NCT00359255|BEHAVIORAL|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
218905897|NCT03596502|DRUG|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
218905898|NCT03596502|DRUG|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
218905899|NCT00352677|DRUG|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
218905900|NCT02609061|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
218905901|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
218905902|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
218905903|NCT01034514|DEVICE|Real-time Position Management system|Standard of Care
218905904|NCT01034514|DEVICE|Discovery ST multislice PET/CT scanner|Standard of Care
218905905|NCT01034514|DEVICE|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
219521060|NCT03311646|OTHER|Normal nicotine content cigarettes (NNC, Baseline)|Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
218905906|NCT01034514|DEVICE|Pinnacle3 treatment planning system|Standard of Care
218905907|NCT01034514|DEVICE|SKYLight nuclear camera|Standard of Care
218905908|NCT01034514|DRUG|DTPA|1 mCi; inhalation
218905909|NCT01034514|DRUG|TECHNETIUM TC 99M MAA|3 mCi; iv
218905910|NCT00720590|DRUG|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
218905911|NCT00720590|DRUG|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
218905912|NCT00720590|DRUG|Placebo|Daily dose of placebo for 4 weeks
218905913|NCT05743803|OTHER|Sensititization campaign on preoperative fasting rules|"* Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~* Reminder display in surgical wards and consults.~* Individualized fasting cards for patients.~* Short message service reminder on pre-operative fasting rules for patients.~* Medical fasting prescription with clear fasting times."
218905914|NCT06123078|BEHAVIORAL|CaCBT|Culturally adapted Self help guide and modules total eight 80 hour session per week
218905915|NCT06313216|PROCEDURE|duoteck membrane|the dehisced bone defect will be covered with duoteck membrane
218905916|NCT06313216|PROCEDURE|autogenous demineralized tooth graft|the dehisced bone defect will be covered with autogenous demineralized tooth graft
218905917|NCT06313216|PROCEDURE|autogenous demineralized tooth graft and plate|the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
218905918|NCT06124963|DRUG|WX390|WX390 tablet, 0.9 mg once a day
218905919|NCT06124963|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
218905920|NCT01019070|DRUG|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
218905921|NCT05120362|DRUG|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
218905922|NCT03883581|DRUG|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
218905923|NCT04612725|BIOLOGICAL|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
218905924|NCT04612725|BIOLOGICAL|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
218905925|NCT02624271|OTHER|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
218905926|NCT04712955|OTHER|Bloodflow restricted exercise|Low-intensity bloodflow restricted resistance exercise is conducted as traditional knee extension exercise with a load corresponding to 30% of 1 repetition maximum (RM), with concurrent partial occlusion of the circulation by means of inflatable pneumatic cuffs wrapped around the proximal part of the thighs. Cuffs are inflated to a pressure corresponding to 50% of the arterial occlusion pressure, which only compromises venous but not arterial blood flow.
219039250|NCT01017237|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
219039251|NCT01017237|DRUG|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
219039252|NCT01017237|DRUG|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
219521061|NCT03311646|OTHER|Very low nicotine content (VLNC)|Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
219521062|NCT04812756|BEHAVIORAL|Step-2-It - text messaging program|participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
219521063|NCT01347788|DRUG|cabozantinib|Cabozantinib PO QD
219521064|NCT05759975|DEVICE|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
219521065|NCT05759975|DEVICE|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
219521066|NCT03765502|DEVICE|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
219521067|NCT03765502|DEVICE|GEK|Used to administer glucagon intramuscularly (IM)
218905927|NCT03659318|PROCEDURE|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
218905928|NCT03659318|PROCEDURE|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
218905929|NCT06313229|PROCEDURE|implant placement 6 months after ridge augmentation|the deficient ridge was grafted first followed by implant placement after 6-monthes
218905930|NCT06313229|PROCEDURE|implant placement Simultaneously with ridge augmentation|the deficient ridge was grafted and followed by implant placement simultaneously
218905931|NCT04854785|OTHER|[18F]FEPPA PET scan|One \[18F\]FEPPA PET for TSPO VT, and one MRI scan
218905932|NCT04854785|OTHER|[11C]SL25.1188 PET scan|One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
218905933|NCT06848881|PROCEDURE|Cryoablation|The eligible patient will be randomized to cryoablation group to receive cryoablation.
218905934|NCT06848881|PROCEDURE|Thoracoscopic Surgery|The eligible patient will be randomized to thoracoscopic surgery group to receive surgery.
218905935|NCT00456404|DRUG|peppermint water|
218905936|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
218905937|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
218905938|NCT04699656|DRUG|Plazomicin Injection|single dose of plazomicin
218905939|NCT02354235|DRUG|Teneligliptin|
218905940|NCT02354235|DRUG|Canagliflozin|
219039253|NCT01548612|DRUG|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
218905941|NCT02354235|DRUG|Placebo|
219039254|NCT01548612|DRUG|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
219039255|NCT00483964|DRUG|Bacopa monnieri|
219039256|NCT00483964|DRUG|Nardostachys jatamansi|
219039257|NCT00483964|DRUG|Olanzapine|
219039258|NCT03404479|DRUG|Diacerein|For 12 weeks, administered twice a day by oral.
219039259|NCT03404479|DRUG|Celecoxib|For 12 weeks, administered twice a day by oral.
219039260|NCT02485106|DRUG|Rifaximin|400mg three times per day for 28 days
219521068|NCT03765502|DRUG|IM Glucagon|Administered IM via GEK
218905942|NCT06148207|RADIATION|[18F]BF3-BPA Injection for PET Imaging|Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
218905943|NCT05931367|DRUG|Retatrutide|Administered SC
218905944|NCT05931367|DRUG|Placebo|Administered SC
218905945|NCT06051578|OTHER|Abdominal wall tension measurement|"All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
218905946|NCT05790460|OTHER|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
218905947|NCT05135377|OTHER|Observational|Not applicable - observational study
218905948|NCT02210728|DRUG|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
219039261|NCT02485106|DRUG|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
219039262|NCT04128163|DRUG|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
219039263|NCT04128163|DRUG|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
219039264|NCT01314209|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
219039265|NCT00004065|DRUG|tanespimycin|
218905949|NCT02210728|BEHAVIORAL|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
218905952|NCT05986370|PROCEDURE|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
218905953|NCT05986370|PROCEDURE|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
218905954|NCT05986370|PROCEDURE|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
218905955|NCT05568446|BEHAVIORAL|Social virtual reality|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
218905956|NCT05568446|BEHAVIORAL|Traditional social skills|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
218905957|NCT04273334|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
218905958|NCT00663364|DRUG|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
218905959|NCT04959396|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
218905960|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
218905961|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
218905962|NCT02728180|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
218905963|NCT02728180|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
219039266|NCT04246606|DIAGNOSTIC_TEST|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk"
219039267|NCT00005828|DIETARY_SUPPLEMENT|green tea extract|
219039268|NCT05415696|PROCEDURE|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
219521069|NCT00683020|BEHAVIORAL|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
219521070|NCT03064022|OTHER|Growth|Some preterm infants grow at higher rates than others
219521071|NCT02716025|PROCEDURE|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
218905964|NCT06667089|OTHER|Povidone-Iodine|The povidone-iodine group will receive a 10% povidone-iodine solution or gel applied directly to the wound after gentle cleaning, with the treatment applied according to a set frequency, typically twice daily. This antiseptic will be left on the wound for a brief period to enhance its antimicrobial action.
219039269|NCT01747083|DRUG|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
219521072|NCT03814343|DRUG|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
219521073|NCT03814343|DRUG|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
219521074|NCT01272336|DRUG|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
218905965|NCT06667089|OTHER|Chlorhexidine|The chlorhexidine group will receive a chlorhexidine solution, usually at a concentration of 0.5% to 2%, applied similarly after cleaning the wound. This solution will remain on the wound according to protocol guidelines, also typically applied twice daily. Both groups will be monitored for adverse reactions, signs of infection, and the overall effectiveness of wound healing throughout the treatment period.
219521075|NCT01272336|OTHER|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
218905967|NCT06674642|OTHER|Traditional Indigenous Foods diet|A diet composed of traditional indigenous foods will be given to participants.
218905968|NCT04902339|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
218905969|NCT04902339|OTHER|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
218905970|NCT04902339|BEHAVIORAL|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
218905971|NCT06689241|DRUG|Enoxaparin|40mg
218905972|NCT06689241|DRUG|rivaroxaban|10mg
218905973|NCT06727097|DIAGNOSTIC_TEST|Posturography|"Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns."
219039270|NCT03030079|DEVICE|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
219039271|NCT01976832|BEHAVIORAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
219039272|NCT01976832|BEHAVIORAL|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
219521076|NCT04809675|DEVICE|Hard occlusal splint|Use of a hard occlusal splint at times they considered helpful.
219521077|NCT04809675|DEVICE|Flexible customized mouthguard|Use of a flexible customized mouthguard at times they considered helpful.
219521078|NCT00004099|DRUG|cisplatin|
219521079|NCT00004099|DRUG|fluorouracil|
219613004|NCT03322644|BEHAVIORAL|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
218905974|NCT06727097|DIAGNOSTIC_TEST|Walking Speed|The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.
218905975|NCT06727097|DIAGNOSTIC_TEST|Instrumented 7M Timed UP and GO|This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.
219521080|NCT00004099|DRUG|leucovorin calcium|
219521081|NCT00004099|PROCEDURE|neoadjuvant therapy|
219521082|NCT00989352|DRUG|Methotrexate|3g/m² i.v. max. 9 times
219521083|NCT00989352|DRUG|Lomustine|110 mg/m² p.o., max. 3 times
219521084|NCT00989352|DRUG|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
219521085|NCT00989352|DRUG|Rituximab|375 mg/m² i.v., max. 10 times
219521086|NCT03127137|DRUG|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
219613005|NCT02986867|RADIATION|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
219521087|NCT03127137|DRUG|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
218905976|NCT06727097|OTHER|Fall Event Records|A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.
218905977|NCT06727097|DIAGNOSTIC_TEST|MRI (3T)|Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
218905978|NCT06928376|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75 mg/m2/day, days 1 to 7). Cytarabine (75-100 mg/m2 bid, days 1 to 5). Aclacinomycin(20 mg/day, days 1,3,5). Chidamide (30 mg/day , days 1,4,8,11). Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
218905979|NCT06928376|DRUG|"3+7"|"IA regimen:~Idarubicin (8-10 mg/m2) for 3 days . Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~Daunorubicin(60 mg/m2) for 3 days. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
218905980|NCT06938620|OTHER|Bottle with a flow restrictor|Flow restrictors added to liquid medicine bottles to determine whether they limit accessibility of liquid bottle contents to young children compared with control bottles without flow restrictors.
218905981|NCT06938620|OTHER|Control bottle|Traditional bottle either no cap or an incompletely-closed child-resistant cap
218905982|NCT06938204|DRUG|INV-101|SAD MAD
218905983|NCT06938204|DRUG|INV-101 Placebo|SAD MAD
218905984|NCT06937424|OTHER|Dry cotton pellet group|The contaminated dentine surface was scrubbed with a dry cotton pellet until no visible sealer remnants were observed
218905985|NCT06937424|OTHER|Ethanol-saturated cotton pellet 7 seconds group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet for 7 seconds
218905986|NCT06937424|OTHER|Ethanol-saturated cotton pellet visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed.
218905987|NCT06937424|DEVICE|Ethanol-saturated cotton Pellet + air polishing group|After the contaminated dentine surface scrubbing with an 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed, air polishing was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Sodium bicarbonate powder (Velopex) was applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
218905988|NCT06937424|OTHER|Microbrush 7 sec group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush for 7 seconds
218905989|NCT06937424|OTHER|Microbrush visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush until no visible sealer remnants were observed.
218905990|NCT06937424|DEVICE|Air abrasion group|Air abrasion was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Aluminium oxide particles (53 µm, Velopex) were applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
218905991|NCT06938139|OTHER|None-placebo|None, observational study
218905992|NCT06937112|OTHER|PET-CT examination|Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination
218905993|NCT06938217|DEVICE|Low-flow ECMO|low-flow ECMO, defined as 1-2.5 L of blood flow/min.
218905994|NCT06938659|DRUG|Emicizumab Injection|Emicizumab 0.8-1.5mg/kg weekly for 4 weeks as loading dose. Then 0.8-1.5mg/kg 4-weekly for 24 weeks will be used in Emicizumab group-I and Emicizumab Group- WI
218905995|NCT06938659|DRUG|Factor VIII (FVIII)|10-15 unit/Kg thrice weekly (for conventional half-life products) or twice weekly (for extended half-life products) for 28 weeks. Inj. Factor VIII is available in 250U, 500U, 750U \& 1,000 IU vail sizes. Dose will be round up to full nearest full vail strength.
219613006|NCT03423940|BEHAVIORAL|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
219613007|NCT03629184|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
219613008|NCT03629184|DRUG|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
219613009|NCT01263938|DRUG|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
219613010|NCT04892537|DEVICE|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
219613011|NCT04892537|PROCEDURE|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
219613012|NCT03169088|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
218905996|NCT06937632|BEHAVIORAL|sleep hygiene intervention|sleep program was done three times a week for 2 weeks for the study group (6 sessions in total). It took roughly 30 minutes for each session. sessions were demonstrated during the first 3 sessions, re-demonstration of all the 3 of other sessions. Over a course of two sessions, the older adults in the intervention group were taught how to perform sleep program. The telephone number of each subject was taken to check their consistency with the proposed nursing interventions.
218905997|NCT06938737|BEHAVIORAL|laughter yoga|Laughter yoga sessions begin with gentle warm-up techniques that include stretching and flexing movements, songs, applause and body movements. These techniques aim to break down any inhibitions against laughter and develop childlike playfulness. Breathing exercises prepare the lungs for laughter and are combined with a series of laughter exercises that follow.
218905998|NCT06938243|DEVICE|Vagus Nerve Stimulation in early stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
218905999|NCT06938243|DEVICE|Vagus Nerve Stimulation in late stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
218906000|NCT06938893|OTHER|Exercise|Cardiac output (CO) was measured after exercise intervention in patients with normal cardiac function
218906001|NCT06937268|DIAGNOSTIC_TEST|DOTATATE-PET scan|DOTATATE tracer PET scan for meningioma
218906002|NCT06938750|DEVICE|SECHOLD DEVICE|PLACEMENT OF A MULTIPLE THERAPY GRIPPING DEVICE TO FIX THE DRIPPER SYSTEMS ALONG ITS PATH TO SOME SURFACE OR SPACE, AVOIDING IT TO REMAIN IN THE AIR, WITHOUT MARKING OR LABELING AND FAVORING ITS ORGANIZATION. SECHOLD is a vascular access fixation device designed for critical clinical environments such as ICU and operating rooms. It allows the simultaneous connection of 3-6 parenteral therapies to the same vascular access, ensuring clear and protocolized identification of each drug by means of labels with name, concentration and infusion range, in addition to a universal color code. This reduces the risk of drug administration errors and facilitates optimal visualization of essential information. SECHOLD also organizes infusion systems connected to the same vascular access, preventing knots and pulls that can compromise catheter integrity in case of accidental infusion bag drops.
218906003|NCT06939374|DEVICE|Intracoronary Cryotherapy|Intracoronary cryotherapy for stabilization of High-risk coronary plaque
218906004|NCT06938503|DRUG|AG regimen|Patients will receive 4 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
219039273|NCT05669456|DEVICE|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
219039274|NCT04306809|BEHAVIORAL|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
219039275|NCT02692677|DRUG|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
219039276|NCT03397082|DRUG|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
219613013|NCT05816109|DIAGNOSTIC_TEST|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
219039277|NCT03397082|DRUG|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
219039278|NCT03274986|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
219039279|NCT03274986|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
219039280|NCT03274986|PROCEDURE|Cataract surgery|IOL bilateral implantation
219613014|NCT05816109|DIAGNOSTIC_TEST|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
219613015|NCT02100488|DEVICE|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
219039281|NCT05014022|DIAGNOSTIC_TEST|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
219039282|NCT00261742|DRUG|Penicillin versus cefuroxim per os|
218906005|NCT06938503|DRUG|Nimotuzumab|Patients will receive 4 cycles of Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
219204380|NCT06739018|OTHER|pentacam scheimpflug tomography|"Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy."
219204381|NCT06738706|DEVICE|intermittent hypoxia-hyperoxia treatment|The intermittent hypoxia-hyperoxia training refers to 4 cycles of 10-minute hypoxia inhalation interspersed with 20-minute hyperoxia, which is performed once daily for 14 days within 2 to 3 weeks.
219204382|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (low dose)|Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
219204383|NCT06740149|DRUG|Solvent of CG-BM1|Administered intravenously, once a week for a total of 4 doses.
219204384|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (medium dose)|Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
219521088|NCT02885337|OTHER|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
219613016|NCT02100488|OTHER|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
219613017|NCT02905032|BEHAVIORAL|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
219613018|NCT05994885|PROCEDURE|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
219613019|NCT05955183|DRUG|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
219613020|NCT05955183|DRUG|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
219613021|NCT00559533|DRUG|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
218906006|NCT06937190|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.
218906007|NCT06937190|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.
218906008|NCT06939400|PROCEDURE|Photodynamic therapy (PDT)|GBM patients recevied surgical combination photodynamic therapy
218906009|NCT06939400|PROCEDURE|GBM patients recevied traditional treatment options|GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
218906010|NCT06938451|OTHER||This is an observational study and does not involve an intervention
218906011|NCT06937645|DRUG|Hyaluronic Acid (HA)|hyaluronic acid PRP preparation used to wash the endometrium on the day of oocytes retrieval
218906012|NCT06937645|DRUG|platlet rich plasma (PRP)|PRP preparation used to wash the uterine cavity on the day of oocytes retrieval
218906013|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
218906014|NCT02926638|DRUG|Erlotinib Hydrochloride|Given PO
218906015|NCT02926638|OTHER|Laboratory Biomarker Analysis|Correlative studies
218906016|NCT02926638|BIOLOGICAL|Rilotumumab|Given IV
218906017|NCT00187252|DEVICE|Atrial Overdrive Pacing|Pacemaker/ ICD implant
218906018|NCT01308697|PROCEDURE|Operative fixation of flail chest|Plate fixation
218906019|NCT01308697|OTHER|Non Operative management|Non Operative treatment of Flail Chest
218906020|NCT05542654|OTHER|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
218906021|NCT07199673|DRUG|Injection Sclerotherapy|identifying the hemorrhoidal pedicle, 3-5 ml of 5% phenol in almond oil is injected into the submucosal plane of the hemorrhoid pedicle
218906022|NCT07199673|DEVICE|Rubber Band Ligation|knee-elbow position is used. After identifying the hemorrhoids with a proctoscope, a rubber band is applied at the base of each hemorrhoid using Barron's Gun and Elise's tissue forceps.
218906023|NCT07200193|GENETIC|CRMA-1001|Epigenetic gene silencing therapy delivered by intravenous (IV) infusion
218906024|NCT07199920|DEVICE|Achieva 3.0T dStream Philips|Classic and MRF sequences will be carried out on the clinical machine (Achieva 3.0T dStream Philips) of the IRMaGe platform (CHUGA, Université Grenoble Alpes, Inserm, CNRS).
218906025|NCT07198815|DRUG|Investigational Eye Drops (NPDR-01)|NPDR-01 is an investigational ophthalmic solution administered as one drop (50 μL) to the affected eye(s) once daily for a period of 6 months. It is designed to reduce retinal microaneurysms and slow the progression of non-proliferative diabetic retinopathy.
218906026|NCT07198321|DRUG|GFH276|GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
218906027|NCT06526338|DRUG|1.0% IP-001 for injection|Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation
219039283|NCT05320991|DRUG|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
219039284|NCT05320991|DRUG|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
219039285|NCT01622855|BEHAVIORAL|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
219039286|NCT03700697|BEHAVIORAL|Family Stress Module Intervention|as above
219039287|NCT06095791|DRUG|Immunomodulators with FDA approval on the 1st January 2023.|Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
219039288|NCT00603746|DRUG|GW685698X|GW685698X
219039289|NCT05516082|DEVICE|Lens A|DDH contact lens for 15 minutes
219039290|NCT05516082|DEVICE|Lens B|DDSH contact lens for 15 minutes
219521089|NCT02885337|OTHER|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
219521090|NCT00405678|BEHAVIORAL|Exercise Training|Subjects receiving chemo with exercise training
219521091|NCT00405678|BEHAVIORAL|Chemo only|Subjects receiving chemo only
219521092|NCT03031054|PROCEDURE|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
219521093|NCT03031054|PROCEDURE|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
218906028|NCT06526338|PROCEDURE|Surgical Resection and Local Ablation|Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
218906029|NCT06526338|PROCEDURE|Local Ablation Alone|Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
218906030|NCT07200037|BEHAVIORAL|inspiratory muscle training|This intervention will include a long term program of 8 weeks IMT in PMV patients who these patients who have required at least 6h of mechanical ventilation for 21 consecutive days.
218906031|NCT07198607|OTHER|Pistacia lentiscus Oil Nasal Drops (Bactorinol®)|Bactorinol® nasal drops (medical device containing ultra-fractioned and winterized Pistacia lentiscus oil). Participants will receive isotonic saline nasal wash plus 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
219039291|NCT01318096|DRUG|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
219039292|NCT01318096|DRUG|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
219039293|NCT05233566|DRUG|Ketamine|NMDA antagonist
219039294|NCT05233566|DRUG|Normal saline|IV fluid acting as a placebo
219039295|NCT00451867|DRUG|Mycophenolate Mofetil|
219039296|NCT00451867|DRUG|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
219039297|NCT00451867|DRUG|Placebo|Placebo
219039298|NCT01810029|BEHAVIORAL|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
219039299|NCT02098590|BIOLOGICAL|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
219039300|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
219039301|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
219039302|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
219039303|NCT02098590|DRUG|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
219521094|NCT02037997|DRUG|docetaxel|docetaxel 75mg/m2 ivgtt D1
219204385|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (high dose)|Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
219204386|NCT06740851|PROCEDURE|Touch® Trapeziometacarpal Joint Arthroplasty|The intervention involves primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis, a dual-mobility implant designed for the treatment of osteoarthritis in the thumb.
219521095|NCT02037997|DRUG|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
219521096|NCT02037997|DRUG|Erlotinib|Erlotinib 150mg qd
219521097|NCT03377881|PROCEDURE|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.
219521098|NCT03377881|PROCEDURE|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
219521099|NCT00079807|DRUG|Alpha-Lipoic Acid|
219521100|NCT03043547|DRUG|nal-IRI|nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
219521101|NCT03043547|DRUG|5-FU|5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)
218906032|NCT07198607|OTHER|Placebo Nasal Drops (matched to Bactorinol®)|Placebo nasal drops identical in appearance and administration to Bactorinol®. Participants will receive isotonic saline nasal wash plus placebo drops, 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
218906033|NCT07197918|DEVICE|portable MRI scanner|Participants will receive 2-3 portable MRI scans: \<6 hours, 6-24 hours, and within 12 (+/- 12) hours of conventional MRI
218906034|NCT07197944|DRUG|Glepaglutide|Subcutaneous (SC) injections twice weekly
218906035|NCT07197944|OTHER|Placebo|SC injections twice weekly
218906036|NCT07198425|OTHER|Successful decannulation group|Patients who successfully completed the decannulation process and had their tubes removed, with no reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours after decannulbation.
218906037|NCT07198425|OTHER|Successful decannulation group|Patients who did not pass the decannulation process, and the multidisciplinary team advised against removal of the tracheostomy tube; or patients who passed the decannulation process and had the tracheostomy tube removed but required reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours due to medical conditions.
218906038|NCT07199517|OTHER|HRP Sampling period|During a 28-day sampling period, participants randomized to HRP are instructed to try their selected HRP (ECIGS, IQOS, or ONPs) and will complete daily e-diaries of cigarette smoking behavior and product uptake.
219039304|NCT05712408|BEHAVIORAL|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
219039305|NCT02165319|DEVICE|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
219039306|NCT02165319|DEVICE|Tapered|Tapered-shaped tube will be used during general anesthesia.
219039307|NCT04842539|OTHER|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
219039308|NCT04842539|OTHER|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
219204387|NCT06740669|BEHAVIORAL|Virtual reality glasses (VR) application|It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).
219521102|NCT03043547|DRUG|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
219521103|NCT05806710|DIETARY_SUPPLEMENT|GourMed© meal|patients receive GourMed© meal as lunch for 7 consecutive days
219521104|NCT01870180|DEVICE|EyeBag|fabric bag of beads which can be heated in a microwave
219521105|NCT01870180|OTHER|Placebo|
219521106|NCT03858712|OTHER|Active Care Team Alert|"2\) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
219521107|NCT03858712|OTHER|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
219521108|NCT06233266|DRUG|Ticagrelor-Test product|Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
219521109|NCT06233266|DRUG|Ticagrelor-Reference product|Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
219521110|NCT01684969|DRUG|Haloperidol|0.5 mg iv x one dose
219521111|NCT01684969|DRUG|Placebo|0.5 mg iv , one dose
219521112|NCT04509180|PROCEDURE|Catheter ablation|Endovascular approach
219521113|NCT04509180|PROCEDURE|Convergent procedure|Surgical and endovascular approach
219521114|NCT04457999|DEVICE|Lipiflow Thermal pulsation|Single vectored thermal pulsation treatment for dry eye
219521115|NCT05425888|OTHER|Hemophilia group|Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
219521116|NCT05844722|BEHAVIORAL|Mindfulness-based intervention therapy|Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
219521117|NCT05844722|OTHER|usual care|Usual care means received standard multidisciplinary stroke care
218906039|NCT07199517|OTHER|NPL Sampling period|During a 28-day sampling period, participants randomized to NPL are instructed to try nicotine patches and nicotine lozenges and will complete daily e-diaries of cigarette smoking behavior and product uptake.
218906040|NCT07198204|OTHER|isometric exercises|Isometric quadriceps exercise: Patients lie in a supine position. A rolled-up towel was put beneath the knee. They were instructed to maximally activate their thigh muscles to straighten their knee and hold the contraction for 5 seconds (Group A), 10 seconds (Group B), or 20 seconds (Group C).
218906041|NCT07198204|OTHER|therapeutic ultrasound|all patients will reciece ultrasound for 5 minutes using 1MHz frequency, 0.8 wc2, 5cm2 head with adequate gel as a coupling medium
219521118|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
219039309|NCT01524627|DRUG|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
219039310|NCT01524627|DRUG|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
219039311|NCT04104009|OTHER|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
219039312|NCT04104009|OTHER|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
219039313|NCT02360163|PROCEDURE|Traditional Landmark Technique (TLT)|
219039314|NCT02360163|DEVICE|ultrasound guided peripheral intravenous access (USGPIVA)|
219521119|NCT00020826|OTHER|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
219521120|NCT05782647|DEVICE|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
219521121|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
219204388|NCT06740669|BEHAVIORAL|Those who are applied expressive touch|Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
219204389|NCT06740669|BEHAVIORAL|Focus|. The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
219521122|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
219039315|NCT05172661|BEHAVIORAL|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks
219039316|NCT05172661|BEHAVIORAL|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
219039317|NCT00022321|DRUG|gemtuzumab ozogamicin|
219039318|NCT00062465|DRUG|TwHF|
219039319|NCT03139890|OTHER|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
219039320|NCT03139890|OTHER|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
219039321|NCT03139890|OTHER|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
219039322|NCT00717769|DRUG|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
219039323|NCT00717769|DRUG|Placebo|Placebo, orally (tid) for 28 days of SUN13834
219039324|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
219204390|NCT06737367|OTHER|CT radiomic analysis|Radiomic features of tumor and peritumor tissue
219521123|NCT02255708|OTHER|Proprioceptive Neuromuscular Facilitation - PNF|
219521124|NCT03415802|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
219521125|NCT00006174|DRUG|Letrozole|
219521126|NCT01425060|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
219521127|NCT01425060|OTHER|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
219613022|NCT06551233|DRUG|9MW2821|Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
219613023|NCT04366947|DEVICE|NIO® (Intraosseous access)|obtaining intravascular access using a ready intravenous NIO needle set
219613024|NCT04366947|DEVICE|Standard of Care (Intravenous access)|obtaining intravascular access using a standard intravenous cannula
219613025|NCT01358747|DRUG|BEACOPPesc|
219613026|NCT01358747|DRUG|BEACOPPesc - ABVD - PET2|
219613027|NCT02658760|DRUG|Dexmedetomidine|dexmedetomidine plus placebo
219613028|NCT02658760|DRUG|Bupivacaine|dexmedetomidine and Bupivacaine
219613029|NCT04141982|DIAGNOSTIC_TEST|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
219613030|NCT00329082|DRUG|LY2062430|"1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks"
219613031|NCT00329082|DRUG|Placebo|5: Placebo QW IV for 12 weeks
219613032|NCT00003274|BIOLOGICAL|gp100 antigen|
219613033|NCT00003274|BIOLOGICAL|incomplete Freund's adjuvant|
218906042|NCT07198204|OTHER|Transcutanous electrical nerve stimulation|all participants will recieve TENS for 30 minutes per session. the parameters will be Burst TENS, with main frequency of 100Hz, burst frequency of 4 Hz, intensity to the comfortable muscle twitch, electrodes size according to the size of the patients knee.
219521128|NCT04718506|BEHAVIORAL|Exercise|Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises \[squat, bench press, deadlift and bench pull\]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
218906044|NCT07198009|DIETARY_SUPPLEMENT|2-HOBA (Hobamine)|Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.
218906045|NCT07200089|DRUG|NT-I7|NT-I7 will be supplied by NeoImmuneTech Inc
218906046|NCT07200089|DRUG|Placebo|Placebo will be supplied by NeoImmuneTech Inc
218906047|NCT07200089|BIOLOGICAL|B-cell Maturation Antigen (BCMA) CART-T therapy|Standard of care
219521129|NCT04718506|BEHAVIORAL|Inspiratory muscle training|Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
219521130|NCT04718506|BEHAVIORAL|Controls|Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
219521131|NCT00035581|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
219521132|NCT00091052|BIOLOGICAL|sargramostim|
219521133|NCT00091052|RADIATION|radiation therapy|
218906048|NCT07199634|OTHER|"Undetectable & You HIV treatment literacy app"|The app delivers information on the transmission prevention benefits of HIV treatment through the Undetectable Equals Untransmutable (U=U) message, alongside real-life video testimonials of patients living with HIV (PLHIV) and their partners. It underscores the key behavioral skills required for U=U, namely, ART adherence and viral load monitoring.
219039325|NCT00831532|DRUG|Dimebon|Dimebon 5mg in healthy controls
219039326|NCT00831532|DRUG|Dimebon|Dimebon 5mg in mild hepatic impairment patients
219039327|NCT00831532|DRUG|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
219039328|NCT00831532|DRUG|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
219039329|NCT06058195|PROCEDURE|Quadratus lumborum plane block|QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
218906049|NCT07198997|OTHER|digital anesthesia|mandibular anestezi ile digital intrsosseoz anesteziyi kıyasslayan calısma yok.
218906050|NCT07198386|DRUG|CS060380|Oral QD
218906051|NCT07198386|DRUG|Placebo|Oral QD
218906052|NCT07199803|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
218906053|NCT07199309|DRUG|MAR001|Subcutaneous Injection
218906054|NCT07199309|DRUG|Placebo|Subcutaneous Injection
219039330|NCT06058195|PROCEDURE|Transverse abdominis plane block|TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
219039331|NCT06058195|PROCEDURE|Intravenous analgesia|IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
219039332|NCT03226340|DRUG|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
219039333|NCT03226340|DRUG|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
219039334|NCT02273219|DRUG|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
219613034|NCT00003274|BIOLOGICAL|sargramostim|
219613035|NCT00003274|BIOLOGICAL|tyrosinase peptide|
218906055|NCT07198152|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
218906056|NCT07198685|DRUG|bedaquiline|Administer 400 mg orally once daily for 2 weeks, followed by 200 mg orally three times a week for 22 weeks
218906057|NCT07198685|DRUG|Delamanid (DLM)|Administer 100 mg orally, twice daily for 24 weeks.
218906058|NCT07198685|DRUG|Linezolid (LZD)|Administer 600 mg orally, once daily for 24 weeks.
218906059|NCT07198685|DRUG|Levofloxacin|test group:Administer 800 mg orally, once daily for 24 weeks;control group:Administer 800 mg orally, once daily for 72 weeks
218906060|NCT07198685|DRUG|Cycloserine|Administer 250mg orally, twice daily for 72 weeks.
218906061|NCT07198685|DRUG|Clofazimine|Administer 100 mg orally, once daily for 72 weeks
218906062|NCT07198633|DRUG|QLC5508|B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol.
218906063|NCT07198633|DRUG|abiraterone acetate|An oral CYP17 inhibitor; abiraterone acetate will be administered orally at the dose and dosing frequency specified in the protocol
219039335|NCT02273219|DRUG|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
219039336|NCT02023450|DRUG|saquinavir and ritonavir|micro and low dose
219521134|NCT05319665|DEVICE|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
219039337|NCT02023450|DRUG|saquinavir and ritonavir|standard dose
219039338|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
219039339|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
219039340|NCT00316979|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
219039341|NCT02382081|PROCEDURE|Patient-initiated shared care|
219039342|NCT00571506|DRUG|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
219039343|NCT00571506|DRUG|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
219039344|NCT03044405|DIAGNOSTIC_TEST|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
219039345|NCT03044405|DIAGNOSTIC_TEST|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
219039346|NCT01303575|BEHAVIORAL|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
219039347|NCT01303575|BEHAVIORAL|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
219039348|NCT04049656|DEVICE|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
219039349|NCT03476304|DEVICE|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
219039350|NCT03476304|DEVICE|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
219521135|NCT05149118|PROCEDURE|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
218906064|NCT07198633|DRUG|enzalutamide|An oral androgen receptor inhibitor; enzalutamide will be administered orally at the dose and dosing frequency specified in the protocol.
219039351|NCT03476304|DEVICE|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
219521136|NCT05086523|DEVICE|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
218906065|NCT07198633|DRUG|QLH12016|An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol
218906066|NCT07199166|BEHAVIORAL|Autobiographical Rewriting Workshops|10 two-hour autobiographical rewriting workshop sessions, held weekly. This program encourages participants to explore their own history in a way that fosters narrative resilience, highlighting their ability to overcome challenges, transform failures into learning opportunities, express themselves creatively, reexamine their memories, and rebuild a more positive sense of identity that better aligns with the needs of accurate self-recognition of their potential. This program is particularly inspired by the concepts of resilience (Boris Cyrulnik), identification (Karine Gros), the Hero's Journey (Joseph Campbell), narrative therapy (David Denborough), and works on various types of story structures (Blake Snyder).
218906067|NCT07199166|BEHAVIORAL|Non-specific writing workshops|10 sessions of 2 hours of non-specific writing, held weekly. To increase the active role of the participants, they will be encouraged to write on the theme of the session during the time between sessions. The writing themes are non-specific, unlike the intervention group, and include topics such as poetry, historical events, nature reports, imaginary interviews, children's stories, etc.
219039352|NCT04908670|BEHAVIORAL|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
219039353|NCT04908670|PROCEDURE|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
219039354|NCT02265822|DRUG|melatonin in children premedication|
219039355|NCT02265822|DRUG|midazolam in children premedication|
219039356|NCT04425746|DRUG|Afamelanotide|
219039357|NCT04425746|DRUG|Placebo|
219039358|NCT01251588|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
219039359|NCT01251588|PROCEDURE|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
218906068|NCT07198945|PROCEDURE|6-month follow-up|Eligible patients randomized to the 6-month follow-up arm will undergo their first surveillance procedure 6 months after the removal of their large polyp to check for recurrent polyp tissue.
218906069|NCT07198945|PROCEDURE|12-month follow-up|Eligible patients randomized to the 12-month follow-up arm will undergo their first surveillance procedure 12 months after the removal of their large polyp to check for recurrent polyp tissue.
218906070|NCT07198126|PROCEDURE|Pterygium Excision with Conjunctival Autograft|Excision of primary Grade II or Grade III pterygium Conjunctival autograft harvested and transplanted at the excision site Graft secured with sutures
218906071|NCT07197892|OTHER|CIRCA Texting Platform|Two-way texting platform that uses artificial intelligence to match patient texts to clinician-vetted responses and send educational content
218906072|NCT07199452|DRUG|MK-4646|Oral Capsule
218906073|NCT07199452|DRUG|Rifabutin|Oral Capsule
218906074|NCT07199946|DRUG|Verapamil (Part A)|Verapamil 3-6mg/kg body weight and 24 hrs
218906075|NCT07199946|DRUG|Placebo|Placebo given in part B, the comparator arm of the double blind randomized trial
218906076|NCT07199621|PROCEDURE|uterine incision by scissors versus scalpel|procedure in uterotomy in cs
218906077|NCT07199374|BEHAVIORAL|PARCA|PARCA is an s an app to facilitate goal management, resource allocation, and managing progress.
218906078|NCT07198568|DIAGNOSTIC_TEST|Surface electromyography|A previous other study has examined the suprahyoid muscle activity patterns in sarcopenic dysphagia patients using surface electromyography (sEMG). However, there was a lack of research analyzing the swallowing dynamics of sarcopenic dysphagia alongside Videofluoroscopic Swallowing Study (VFSS). VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. Therefore, the present study aims to investigate the characteristics of sarcopenic dysphagia across phases using sEMG and VFSS. Additionally, the investigators aim to analyze the relationship between suprahyoid muscle activity patterns and swallowing dynamics utilizing these modalities.
218906079|NCT07198568|DIAGNOSTIC_TEST|Videofluoroscopic swallowing study (VFSS)|VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. The investigators will utilize Videofluoroscopic Dysphagia Scale (VDS), that composed of fourteen categories, which can be divided into oral and pharyngeal phases to assess scores based on VFSS results. The oral phase composed of 7 items (lip closure, bolus formation, mastication, apraxia, tongue-to-palate contact, premature bolus loss, and oral transit time). The pharyngeal phase also included 7 items (triggering of pharyngeal swallowing, vallecular residues, pyriform sinus residues, laryngeal elevation, coating of pharyngeal wall, pharyngeal transit time, and aspiration). VDS can assess the components of dysphagia in such detail. Therefore, investigators can evaluate the etiology of dysphagia more precisely.
218906080|NCT07198724|DRUG|Elacestrant|Selective estrogen receptor degrader (SERD), film-coated tablet, taken orally per protocol.
218906081|NCT07198724|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody-drug conjugate, vial, via intravenous (into the vein) infusion per standard of care
218906082|NCT07199959|PROCEDURE|venipuncyure|venipuncture as clinical practical setting
218906083|NCT07199959|DRUG|Entrectinib|600mg, oral, once daily
218906084|NCT05319587|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
218906085|NCT05319587|DRUG|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
218906086|NCT00361556|BEHAVIORAL|The Back Book|A book on how to prevent back pain
218906087|NCT00361556|BEHAVIORAL|The Back Guide|A guide for the prevention of back pain.
218906088|NCT00361556|BEHAVIORAL|General health book|A book on general health
218906089|NCT04373928|PROCEDURE|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
218906090|NCT03049462|DRUG|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
218906091|NCT03049462|OTHER|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
218906092|NCT06348628|BEHAVIORAL|Motivational Interview|4 Motivational interviews within first 6 months
219039360|NCT01581632|DEVICE|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
219039361|NCT01209910|OTHER|Water|Subjects in this arm will be able to drink water with some conditions.
219521137|NCT05086523|DEVICE|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
218906093|NCT06348628|BEHAVIORAL|Placebo|Advices on standard of care treatment of NAFLD within first 6 months
218906094|NCT05328752|DRUG|XXB750|XXB750
218906095|NCT05328752|DRUG|Placebo|Placebo
218906096|NCT05322226|BEHAVIORAL|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
218906097|NCT02965430|DEVICE|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
218906098|NCT05389033|DIETARY_SUPPLEMENT|Probiotic bacteria|28 days daily supplementation with active probiotic
218906099|NCT05389033|OTHER|Placebo Capsule|28 days daily supplementation with placebo
219039362|NCT03034785|DEVICE|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
219039363|NCT04932785|OTHER|Regular diet|Regular diet
219039364|NCT04932785|OTHER|Clear Liquid Diet|Clear Liquid Diet
219039365|NCT04010266|DEVICE|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
219521138|NCT05488613|DRUG|Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
218906100|NCT06085508|BEHAVIORAL|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
219039366|NCT04010266|DRUG|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
219039367|NCT04492891|DRUG|Cyclosporine|2.5 mg/kg PO BID 7 days
219039368|NCT04492891|OTHER|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
219039369|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
219039370|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
219521139|NCT04173936|BEHAVIORAL|tai chi|12-week community-based tai chi program
218906101|NCT04124640|OTHER|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
218906102|NCT04875052|DEVICE|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
218906103|NCT04875052|DEVICE|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
218906104|NCT04875052|OTHER|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
219039371|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
219039372|NCT02679911|DRUG|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
219039373|NCT02679911|DRUG|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
219039374|NCT01889680|DRUG|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
219521140|NCT01893957|PROCEDURE|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
219521141|NCT01893957|PROCEDURE|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
219521142|NCT01893957|DEVICE|Neurodyn High Volt Model (IBRAMED)|
218906105|NCT00379015|BIOLOGICAL|trastuzumab|
218906106|NCT00379015|DRUG|cyclophosphamide|
218906107|NCT00379015|DRUG|docetaxel|
219039375|NCT01889680|DRUG|LV|400 mg/m2 IV day 1 every 14 days until disease progression
219039376|NCT01889680|DRUG|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
219521143|NCT01225146|DRUG|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
219521144|NCT01659307|DRUG|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
219521145|NCT01659307|DRUG|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
219521146|NCT01659307|DRUG|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
219039377|NCT01889680|DRUG|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
219039378|NCT05861791|DRUG|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
219039379|NCT05861791|DRUG|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
219039380|NCT04640948|DEVICE|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
219521147|NCT01239121|OTHER|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
218906108|NCT00379015|DRUG|epirubicin hydrochloride|
218906109|NCT00379015|PROCEDURE|conventional surgery|
218906110|NCT00379015|PROCEDURE|neoadjuvant therapy|
218906111|NCT00286858|DEVICE|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
218906112|NCT05164393|DRUG|AVX001|Topical gel treatment for once daily application
218906113|NCT01733420|DRUG|Biodentine pulpotomy|
218906114|NCT01733420|DRUG|White MTA pulpotomy|
218906115|NCT01733420|DRUG|Tempophore pulpotomy|
218906116|NCT05461859|PROCEDURE|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
218906117|NCT00675714|PROCEDURE|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
218906118|NCT00675714|PROCEDURE|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
218906119|NCT00675714|PROCEDURE|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
218906120|NCT00675714|DRUG|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
218906121|NCT00675714|DRUG|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
218906122|NCT00675714|DRUG|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
218906123|NCT00675714|DRUG|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
218906124|NCT00675714|DRUG|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
218906125|NCT00675714|DRUG|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
218906126|NCT00675714|DRUG|Placebo|placebo to be given once a day for up to two years post burn injury.
219521148|NCT01239121|OTHER|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
219521149|NCT01659203|RADIATION|IG-IMPT|Daily, Monday-Friday for about 6 weeks
219521150|NCT01659203|RADIATION|IG IMRT|Daily, Monday-Friday for about 6 weeks
219521151|NCT02080923|BEHAVIORAL|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
219521152|NCT04360993|RADIATION|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
219521153|NCT04180007|DRUG|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
218906127|NCT00675714|BEHAVIORAL|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
218906128|NCT00675714|BEHAVIORAL|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
218906129|NCT03496493|DEVICE|All patients|Peripheral arterial oxygen saturation recording with both study devices
218906130|NCT02607059|OTHER|Registry|
218906131|NCT05246917|PROCEDURE|Handsewn anastomosis|To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
218906132|NCT03293602|DEVICE|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
218906133|NCT04590274|DRUG|Hydroxychloroquine|Hydroxychloroquine
218906134|NCT04590274|DIETARY_SUPPLEMENT|Vitamins and Minerals|elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
218906135|NCT04590274|DRUG|Azithromycin|Azithromycin
218906136|NCT01456637|BEHAVIORAL|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
218906137|NCT06223334|OTHER|No intervention|observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
218906138|NCT00644423|DRUG|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
218906139|NCT00644423|DRUG|Placebo|Matching Placebo
218906140|NCT00002327|DRUG|Cidofovir|
218906141|NCT01769742|BEHAVIORAL|Early mobility bundle|
219521154|NCT03259100|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
219521155|NCT05549856|PROCEDURE|Wet suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). Before puncturing the lesion, flush the needle with 5ml saline, then use a 10 ml syringe in order to replacing the column of air with fluid. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
219039381|NCT04640948|DEVICE|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
219039382|NCT02258204|DRUG|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
219039383|NCT02258204|DRUG|Placebo|
218906142|NCT04936906|BEHAVIORAL|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
218906143|NCT04936906|OTHER|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
218906144|NCT01908426|DRUG|Cabozantinib tablets|
219039384|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
219039385|NCT05702593|PROCEDURE|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides \[Bretischwerdt\]. The technique was repeated three times, with a 15-second rest interval between each repetition.
219039386|NCT05702593|PROCEDURE|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
219039387|NCT02933177|BEHAVIORAL|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
219521156|NCT05549856|PROCEDURE|Dry suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). The stylet is removed and a 10 ml air-filled pre-vacuum syringe is attached. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
218906145|NCT01908426|DRUG|Placebo tablets|
218906146|NCT00007592|DRUG|Chlorthalidone|
218906147|NCT00007592|DRUG|Furosemide|
218906148|NCT00100035|PROCEDURE|Polarity therapy|
218906149|NCT03335384|DIAGNOSTIC_TEST|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
219521157|NCT04113239|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
219521158|NCT04113239|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
218906150|NCT03335384|DIAGNOSTIC_TEST|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
218906151|NCT03335384|DIAGNOSTIC_TEST|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
218906152|NCT03011320|DRUG|EC1456|intravenous (IV) bolus dose
219364922|NCT02658422|DRUG|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
219364923|NCT03609619|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
219364924|NCT03609619|DRUG|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
219364925|NCT02312804|DRUG|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
219364926|NCT02312804|DRUG|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
218906153|NCT03011320|DRUG|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
218906154|NCT03240601|DEVICE|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
218906155|NCT00182026|BEHAVIORAL|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
218906156|NCT05974241|DRUG|Methylphenidate, aripiprazole, and combination|Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
219364927|NCT02312804|DRUG|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
218906157|NCT02657096|PROCEDURE|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
218906158|NCT02657096|PROCEDURE|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
218906159|NCT01647789|DRUG|CFG920|
218906160|NCT01782898|DRUG|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
218906161|NCT01782898|DRUG|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
218906162|NCT06447558|BEHAVIORAL|palatal stimulation with a finger in premature infants|Oral administration of breast milk droplets, palatal stimulation with a finger in premature infants
218906163|NCT04750291|DRUG|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
218906164|NCT04750291|OTHER|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
218906165|NCT00793988|PROCEDURE|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
218906166|NCT00793988|PROCEDURE|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
218906167|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
218906168|NCT01373463|DRUG|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
218906169|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
218906170|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
218906171|NCT01373463|DRUG|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
219039388|NCT02933177|BEHAVIORAL|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
219613036|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
218906172|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
218906173|NCT01373463|PROCEDURE|Lobectomy|Surgery
218906174|NCT01373463|PROCEDURE|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
218906175|NCT00367328|DEVICE|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
218906176|NCT04443634|PROCEDURE|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
218906177|NCT04443634|PROCEDURE|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
219039389|NCT05625763|DIAGNOSTIC_TEST|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
219039390|NCT01461772|RADIATION|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
219039391|NCT01461772|DRUG|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
219039392|NCT01461772|DRUG|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
219039393|NCT04536727|BEHAVIORAL|Fit & Strong!|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
219039394|NCT04536727|BEHAVIORAL|Wait list|Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
219039395|NCT00454090|DRUG|AZD8330|oral tablet
219039396|NCT05540964|OTHER|Antiretroviral Therapy Interruption(ATI)|Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
218906178|NCT04443634|PROCEDURE|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
218906179|NCT04443634|DRUG|Bupivacaine 20 ml|20ml bupivacaine 0.5%
219613037|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
218906180|NCT04443634|DRUG|Bupivacaine 30ml|30ml bupivacaine 0.5%
218906181|NCT04443634|DRUG|Bupivacaine 10ml|10ml bupivacaine 0.5%
218906182|NCT01638663|DRUG|Tolvaptan|15 mg pr day for 1 day
218906183|NCT01638663|DRUG|Placebo|1 tablet Unikalk 1 pr day for 1 day
218906184|NCT04085419|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|denosumab 60 mg subcutaneously every 6 months
219039397|NCT01867593|DEVICE|C-11 methionine PET|
219039398|NCT05595317|DEVICE|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
219039399|NCT05595317|DEVICE|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
219039400|NCT04160793|DEVICE|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
219039401|NCT01116258|DRUG|AZD5847|oral suspension, 15 days
219039402|NCT01116258|DRUG|Placebo|oral suspension, 15 days
219039403|NCT02188615|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
219039404|NCT02188615|DRUG|Cisplatin|only Radical Chemoradiotherapy
219039405|NCT02188615|DEVICE|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
219039406|NCT00885599|DRUG|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
219039407|NCT00885599|DRUG|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
219039408|NCT00885599|DRUG|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
219039409|NCT00885599|DRUG|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
219039410|NCT01939587|DRUG|PBF-680 5 mg|
219613038|NCT01042769|DRUG|Aleglitazar|aleglitazar 150 micrograms po daily
219613039|NCT01042769|DRUG|Placebo|placebo control po daily
218906185|NCT04085419|DRUG|Zoledronic Acid|zoledronic acid 5 mg intravenously once a year
218906186|NCT02780401|OTHER|Laboratory Biomarker Analysis|Correlative studies
218906187|NCT02780401|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
218906188|NCT02780401|BIOLOGICAL|Sargramostim|Given ID
218906189|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
219039411|NCT01939587|DRUG|PBF-680 20 mg|
219039412|NCT01939587|DRUG|Placebo|
219039413|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
219613040|NCT00153972|DRUG|Cabergoline|
219613041|NCT00153972|DRUG|Levodopa|
219613042|NCT00934167|BIOLOGICAL|heparin sodium - Hipolabor|5.000 UI/0,25mL
219613043|NCT00934167|BIOLOGICAL|Heparin sodium - APP|5.000 USP/mL
218906190|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
218906191|NCT00621374|BEHAVIORAL|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
219039414|NCT03272919|OTHER|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
219039415|NCT03272919|OTHER|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
219039416|NCT03127969|OTHER|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
219039417|NCT03127969|OTHER|Joint protection and exercise|joint protection and exercise
219039418|NCT02299531|OTHER|Varying meal energy density and portion size|
219039419|NCT05242081|DRUG|S-ketamine|S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
219039420|NCT05242081|DRUG|Sufentanil|Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
219039421|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:200,000|
219039422|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:80,000|
219039423|NCT05756972|DRUG|PM8002|IV infusion
219204391|NCT05252312|BEHAVIORAL|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
219204392|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
219521159|NCT04666909|DIAGNOSTIC_TEST|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP \> 135 mm Hg or DBP \> 85 mmHg (based on the average of 3 BP readings); or average SBP \> 130 mm Hg or DBP \> 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
219521160|NCT05502978|BEHAVIORAL|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
219039424|NCT05756972|DRUG|Carboplatin|IV infusion
219039425|NCT05756972|DRUG|Pemetrexed|IV infusion
219039426|NCT05007561|DRUG|Naltrexone Hydrochloride|oral naltrexone
219039427|NCT05007561|DRUG|Placebo|oral sugar pill
219039428|NCT05028205|BEHAVIORAL|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
219204393|NCT05871151|DEVICE|taVNS|Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
219204394|NCT05871151|BEHAVIORAL|Exercise|All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
219613044|NCT03855267|DRUG|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
218906192|NCT00621374|BEHAVIORAL|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
219039429|NCT01232101|DEVICE|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
219039430|NCT05294848|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
219039431|NCT05294848|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
219039432|NCT05294848|BEHAVIORAL|Neutral Control|Dot-probe task using only neutral stimuli with no training toward threat
219039433|NCT02105610|DRUG|desflurane, isoflurane, sevoflurane|
219039434|NCT02105610|DRUG|total intravenous anesthetics|
219039435|NCT05804175|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
219039436|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
219039437|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
219039438|NCT03480672|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
219039439|NCT03480672|OTHER|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
219039440|NCT04917744|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219039441|NCT04917744|OTHER|Laboratory Biomarker Analysis|Ancillary studies
219039442|NCT04917744|OTHER|Medical Chart Review|Review of medical charts
219039443|NCT00938145|PROCEDURE|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
219039444|NCT00938145|DRUG|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
219039445|NCT00938145|PROCEDURE|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
219039446|NCT04828889|DEVICE|Anal dilators|Anal sphincter training for relaxation
219613045|NCT03855267|DRUG|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
219613046|NCT01207310|BEHAVIORAL|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
219613047|NCT01207310|DRUG|Nicotine patch|8 weeks' worth of nicotine patches
218906193|NCT02542046|DRUG|Barium|Administration of barium oral contrast agent prior to CT scan
218906194|NCT02542046|DRUG|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
218906195|NCT02542046|DRUG|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
219039447|NCT04828889|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
219039448|NCT06670053|DRUG|Testosterone|"Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician."
219039449|NCT01719887|DEVICE|Conservative treatment|Conservative treatment with functional brace.
219039450|NCT01719887|PROCEDURE|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
219039451|NCT01719887|OTHER|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
219039452|NCT00256698|DRUG|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
219039453|NCT00256698|DRUG|Anastrozole|1 mg oral tablet
219039454|NCT06856720|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants will receive NMES application for 30 minutes, three times a week, over a period of 12 weeks. The sessions will be supervised by a physiotherapist. Large muscle groups (quadriceps) will be used, with the following current parameters: frequency of 5 Hz, pulse width of 400 μs, 4 seconds of stimulation (on) for 12 seconds of rest (off), and intensity adjusted to the maximum tolerable level for the patient. These parameters are based on studies that have shown significant improvements in glycemic control and insulin sensitivity, especially in older adults with type 2 diabetes.
219039455|NCT06856720|BEHAVIORAL|Aerobic and resistance exercise|This group will participate in an exercise program combining aerobic and resistance activities, performed three times per week for 12 weeks. The activities will be adapted to the participants' physical capabilities and supervised by a physiotherapist. The program follows the international recommendations and it includes a 5-minute warm-up with flexibility exercises, 20 minutes of aerobic exercise at 60-75% of maximum heart rate or moderate perceived exertion, 20 minutes of resistance exercise at 50-70% of one-repetition maximum (1RM) focusing on large muscle groups (10-15 repetitions per exercise, 1-3 sets), and a 5-minute cool-down with static stretching and breathing exercises for relaxation.
219039456|NCT06856720|BEHAVIORAL|Health literacy education|Participants will receive educational sessions on diabetes management, the role of exercise in glycemic control, and strategies to enhance adherence to physical activity.
219039457|NCT04399928|DEVICE|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
219613048|NCT01207310|DEVICE|alphanumeric pager|therapeutic messages to be delivered for three months
219613049|NCT00828165|DRUG|ARRY-300, MEK inhibitor; oral|single dose, escalating
218906196|NCT01179321|OTHER|Early referral to Dietitian for assessment and nutrition support|
218906197|NCT03443141|DRUG|Vitamin E|The applied dressing will be embebbed in Vitamin E
218906198|NCT03443141|DRUG|Standard dressing|The applied dressing is a normal one without adding any product to it.
219521161|NCT06023147|PROCEDURE|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
218906199|NCT02208102|PROCEDURE|Radio-frequency catheter ablation|
218906200|NCT03867214|DRUG|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
219521162|NCT00944697|DRUG|Oxycodone Naloxone|Oxycodone Naloxone tablets
218906201|NCT03867214|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
218906202|NCT01005251|DRUG|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
218906203|NCT01005251|DRUG|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
218906204|NCT01005251|DRUG|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
218906205|NCT01005251|DRUG|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
218906206|NCT01005251|DRUG|Placebo|oral,capsules, bid for 4 w
218906207|NCT05987358|DRUG|TQB3454 tablets|TQB3454 is a selective IDH1 mutant enzyme inhibitor.
218906208|NCT05987358|DRUG|TQB3454 tablets matching placebo|Placebo tablets without active substance.
218906209|NCT04463472|BIOLOGICAL|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
219039458|NCT06666387|DIAGNOSTIC_TEST|PET-MR examination|PET-MR examination
219521163|NCT00944697|DRUG|Placebo tablets|Placebo Oxycodone Naloxone tablets
219613050|NCT00828165|DRUG|Placebo|matching placebo
219613051|NCT03447743|DRUG|XR-NTX community location|XR-NTX will be administered at the local health care clinic
218906210|NCT04463472|BIOLOGICAL|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
218906211|NCT03546985|DEVICE|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
218906212|NCT03546985|DEVICE|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
218906213|NCT01311817|BIOLOGICAL|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
218906214|NCT03777358|DEVICE|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
218906215|NCT03675503|OTHER|Fall Prevention Decision Support|Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
218906216|NCT01687361|DIETARY_SUPPLEMENT|branched-chain amino acids (BCAA) supplementation|
219039459|NCT02734602|DRUG|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
219039460|NCT03101137|DRUG|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
219521164|NCT01056770|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
218906217|NCT01687361|DRUG|PLACEBO|
218906218|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
218906219|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
218906220|NCT01898455|DEVICE|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
218906221|NCT04579991|OTHER|Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel|Topical product, apply small amount on mucosal surface of vulva included clitoris once daily
218906222|NCT04579991|OTHER|Emulgel-only|Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
218906223|NCT02690181|BIOLOGICAL|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
219521165|NCT01273181|BIOLOGICAL|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
219521166|NCT01273181|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
219521167|NCT01273181|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
219521168|NCT01273181|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
219521169|NCT04172649|OTHER|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
219613052|NCT02046603|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
219613053|NCT02046603|DRUG|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
219613054|NCT02046603|DRUG|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
219613055|NCT02046603|DRUG|Methotrexate|Methotrexate per investigator's discretion.
219613056|NCT05101343|BEHAVIORAL|Breathing meditation|Daily, 5-minute breathing meditation for one week.
218906224|NCT03976479|OTHER|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
218906225|NCT02326038|DRUG|Methylphenidate|single oral administration of 20 mg tablet
218906226|NCT01776658|DRUG|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
218906227|NCT01776658|DRUG|Placebo|Ocular topical administration of placebo for 10 consecutive days
218906228|NCT01909440|BEHAVIORAL|exercise intervention|Receive whole body RT
218906229|NCT01909440|DIETARY_SUPPLEMENT|nutritional supplementation|Given whey protein supplementation PO
218906230|NCT01909440|PROCEDURE|quality-of-life assessment|Ancillary studies
218906231|NCT01909440|OTHER|questionnaire administration|Ancillary studies
218906232|NCT01909440|OTHER|pharmacological study|Correlative studies
219039461|NCT03101137|DRUG|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
219039462|NCT03101137|DRUG|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
219039463|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
219521170|NCT04172649|OTHER|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
219521171|NCT02803242|OTHER|Patient Reported Outcomes|
219521172|NCT06012903|OTHER|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
219521173|NCT06012903|OTHER|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
219613057|NCT03062761|OTHER|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
218906233|NCT01909440|OTHER|laboratory biomarker analysis|Correlative studies
218906234|NCT01905098|OTHER|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
218906235|NCT01905098|OTHER|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
219521174|NCT06012903|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
219521175|NCT06012903|OTHER|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
219613058|NCT03062761|OTHER|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
219613059|NCT02671747|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
218906236|NCT02870777|COMBINATION_PRODUCT|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
219613060|NCT00325247|DRUG|ZINC|
219613061|NCT01323361|PROCEDURE|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
219613062|NCT02065076|DRUG|Sodium polystyrene sulfonate|
219613063|NCT02065076|DRUG|Lactose with carob gum|
218906237|NCT06208553|OTHER|QI toolkit implementation|Patients and clinicians will have access to online toolkits of resources (e.g., video, checklist, rehabilitation tracker, quick guides) reflecting quality indicators for rehabilitation care after total hip and knee replacement surgery.
218906238|NCT00003714|DRUG|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
218906239|NCT01077635|DRUG|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
218906240|NCT04426929|OTHER|Conventional exercise therapy|Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.
218906241|NCT04426929|OTHER|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
219521176|NCT06012903|OTHER|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
219521177|NCT03657160|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
219521178|NCT03657160|DRUG|Vedolizumab|Vedolizumab IV infusion.
219521179|NCT04452734|PROCEDURE|Platelet Rich Plasma (PRP)|PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
219521180|NCT04452734|PROCEDURE|Surgical Extraction|Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
219521181|NCT04366141|DEVICE|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
219613064|NCT00714194|PROCEDURE|Normal continuous sedation|Normal continuous sedation.
218906242|NCT04426929|OTHER|Video Based Exercise Group|Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
218906243|NCT00937352|DRUG|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
219039464|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
219039465|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
219039466|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
219613065|NCT00714194|OTHER|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
219039467|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
219039468|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
219039469|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
219521182|NCT03682562|DIAGNOSTIC_TEST|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
219521183|NCT05991726|OTHER|Other: Survey|Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
219521184|NCT02462330|DRUG|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
219521185|NCT02462330|DRUG|Placebo comparator|injections of human albumin
219521186|NCT03006965|DRUG|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
219521187|NCT03006965|DRUG|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
219521188|NCT04280757|PROCEDURE|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
219613066|NCT02390882|DRUG|Placebo|Placebo
219613067|NCT02390882|DRUG|HGP0412 capsule|Tamsulon high dose
219613068|NCT02390882|DRUG|HIP1402 capsule|Tamsulon high dose
218906244|NCT05805631|DRUG|Pemetrexed|Intrathecal Pemetrexed
218906245|NCT02855008|BEHAVIORAL|STEPS|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius. We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.
218906246|NCT02855008|BEHAVIORAL|Food for Life|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
219521189|NCT00507234|DRUG|formoterol fumarate inhalation solution|
218906247|NCT03977792|DRUG|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
218906248|NCT03977792|DRUG|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
218906249|NCT00000266|DRUG|Flupenthixol|
218906250|NCT00141453|DRUG|olmesartan medoxomil|Tablets 10, 20, or 40 mg
219039470|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
219039471|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
219039472|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
219039473|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
219039474|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
219039475|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
219039476|NCT06688175|DRUG|IMRT combined with lobaplatin-based concurrent chemotherapy|IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
219039477|NCT06880861|OTHER|Non-Interventional Study|Non-Interventional Study
219204395|NCT06713889|BIOLOGICAL|Biocollection|"At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml."
219204396|NCT06713889|BEHAVIORAL|Quality of life questionnaires|EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up
219521190|NCT04922112|DIAGNOSTIC_TEST|Obstructive sleep apnea testing|"* Functional Outcomes of Sleep Questionnaire (FOSQ-10)~* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)~* Epworth Sleepiness Scale (ESS)~* Adult Comorbidity Evaluation (ACE 27)~* University of Washington Quality of Life Questionnaire (UW-QOL)~* Chronic Pain Assessment Questionnaire"
219204397|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
219204398|NCT06734494|DEVICE|Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation|Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
219204399|NCT06734910|BEHAVIORAL|HealthyPregnancy|"A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle."
219204400|NCT05771467|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
219521191|NCT02161913|BEHAVIORAL|Multi-Family Group Treatment|
219521192|NCT02161913|BEHAVIORAL|SCI Education Control Group|
219613069|NCT04997863|DEVICE|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
218906251|NCT00141453|DRUG|Placebo Tablets|Matching placebo tablets
218906252|NCT04773392|DRUG|Twice-daily Tacrolimus|Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.
218906253|NCT04773392|DRUG|Once-daily envarsus XR|Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
218906254|NCT04773392|DRUG|Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)|Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.
218906255|NCT04773392|DRUG|Methylprednisolone, prednisone|Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.
218906256|NCT04773392|DRUG|Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)|Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
218906257|NCT04773392|DRUG|Azathioprine|Azathioprine (1-3 mg/kg) will be administered once a day.
218906258|NCT02568969|DEVICE|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
219039478|NCT06881693|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The Wellbeing Course for New and Expecting Parents (WCNEP) is an adaptation of the Wellbeing Course (developed and evaluated at Macquaire University, Australia) and the Wellbeing Course for New Moms (a Canadian adaptation of the Wellbeing Course for new moms). The WCNEP is a transdiagnostic ICBT intervention designed for perinatal parents experiencing depression and/or anxiety, and will be offered by the Online Therapy Unit, a unit providing routine care ICBT services in Canada. The WCNEP will be evaluated in phases; phase 1 will evaluate the course for birthing parents only and phase 2 will evaluate the course for birthing and non-birthing parents. Therapist support will be offered for 8 weeks, with the possibility to extend the support to 12 weeks. Therapists will spend \~15 minutes/week communicating with each client, via secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist feel cannot be addressed in messages.
219039479|NCT06699797|DEVICE|Acclaim Cochlear Implant|Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
218906259|NCT05506540|DRUG|ENN0403 1mg|ENN0403 capsules for oral use
218906260|NCT05506540|DRUG|ENN0403 4mg|ENN0403 capsules for oral use
219039480|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 1|Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
219039481|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 2|Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
219039482|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 1|Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
219039483|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 2|Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
219039484|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 1|Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
219039485|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 2|Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
219039486|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine HTD formulation 2|Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
219204401|NCT06079216|BEHAVIORAL|Volunteer Led Making Connections Thru Music|Volunteer led Group music therapy-based intervention
219521193|NCT03157388|DRUG|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
219521194|NCT03263637|DRUG|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
218906261|NCT05506540|DRUG|ENN0403 10mg|ENN0403 capsules for oral use
218906262|NCT05506540|DRUG|ENN0403 20mg|ENN0403 capsules for oral use
218906263|NCT05506540|DRUG|ENN0403 30mg|ENN0403 capsules for oral use
218906264|NCT05506540|DRUG|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
218906265|NCT05506540|DRUG|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
219039487|NCT06702449|COMBINATION_PRODUCT|Placebo|Placebo administered intramuscularly according to a 0, 2 months administration schedule.
219039488|NCT06722521|DRUG|Pitavastatin 4mg and ezetimibe 10mg, taken once daily|Intensive lipid-lowering therapy without aspirin
219039489|NCT06722521|DRUG|Pitavastatin 2 mg with aspirin 100 mg, taken once daily.|Moderate-intensity lipid-lowering therapy with aspirin
219039490|NCT06888804|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms.
219039491|NCT06888804|OTHER|Control Group|No intervention
219039492|NCT06716138|DRUG|ANS03|ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).
219039493|NCT05732506|DRUG|Edoxaban|There are not intervention.
218906266|NCT05506540|DRUG|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
218906267|NCT05506540|DRUG|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
218906268|NCT05506540|DRUG|Placebo|Placebo capsules for oral use
218906269|NCT03824223|DIAGNOSTIC_TEST|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
218906270|NCT00184834|BEHAVIORAL|quality of life|
218906271|NCT05750251|PROCEDURE|levator muscle resection surgery|conventional ptosis surgery
218906272|NCT05750251|PROCEDURE|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
218906273|NCT05750251|PROCEDURE|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
218906274|NCT06473064|OTHER|Benelli technique for nipple sparing mastectomy in surgical treatment of grade 3 and 4 gynecomastia|".The Nipple areola complex (NAC )margins on both sides are marked as circular. -Around the initial circle, a second circle (external) was drawn 1 cm broader than the boundary.~* The skin was resected, with deepithelialization between the two circles.~* A transdermal incision was made through the border of the external circle.~  -. The breast tissue around the pedicle was lifted over the pectoral fascia and excised by preserving the NAC and the underlying breast pedicle~* The base of the mammary pedicle under the NAC was infixed at the farthest end of the mastectomy area by using 3/0 absorbable multifilament suture material~  * Hence, the space formed after mastectomy was filled with a breast pedicle located posterior to the NAC.~ * The closure of the circular deepithelialized area around the NAC with a diameter of 1 cm accomplished by using 4/0 absorbable monofilament suture material and the surgery was completed"
218906275|NCT04522895|DRUG|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
219613070|NCT04997863|DEVICE|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
218906276|NCT06705647|OTHER|Chronic Obstructive Pulmonary Disease (COPD)|The base line acoustic and mel frequency ceprtum coefficients will be analysed statistically between COPD voices and healthy control groups to highlight the correlation between COPD and its effects on voice production.
218906277|NCT05357625|BEHAVIORAL|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
218906278|NCT04375150|DRUG|Tyrosine kinase inhibitor (TKI)|TKIs
218906279|NCT04375150|DRUG|Immuno-oncology (IO)|IOs
218906280|NCT05297877|OTHER|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
218906281|NCT05297877|OTHER|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
218906282|NCT01393275|OTHER|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
219521195|NCT04909437|DIETARY_SUPPLEMENT|Mycobiotic|2 sachet/day, 21 days, oral
219613071|NCT01949402|OTHER|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
218906283|NCT01393275|OTHER|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
218906284|NCT00443040|DRUG|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
218906285|NCT00443040|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
218906286|NCT04477408|OTHER|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
218906287|NCT01222013|DRUG|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
218906288|NCT03357107|PROCEDURE|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
218906289|NCT01149317|PROCEDURE|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
218906290|NCT01582815|DRUG|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
218906291|NCT01582815|DRUG|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
218906292|NCT02222571|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
219039494|NCT06760039|DRUG|R-CMOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally
219039495|NCT06760039|DRUG|R-CHOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally
219521196|NCT04909437|DIETARY_SUPPLEMENT|Placebo|2 sachet/day, 21 days, oral
219521197|NCT02512978|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
218906293|NCT02222571|BEHAVIORAL|Supervision for Safety|group-based safety intervention for parents
218906294|NCT02316028|DRUG|Decitabine|"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"
218906295|NCT06181526|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
219204402|NCT06079216|BEHAVIORAL|Staff Led Making Connections Thru Music|Staff led Group music therapy-based intervention
218906296|NCT06181526|DEVICE|intravenous injection|According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping
218906297|NCT06181526|DEVICE|intrathecal injection|According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.
218906298|NCT04051359|OTHER|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)
218906299|NCT03798106|DRUG|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
219039496|NCT06767228|BEHAVIORAL|Reformer Pilates|This intervention involves a structured reformer pilates program designed to enhance core endurance, posture, and body awareness. The program includes exercises such as Footwork Series, Pelvic Lift, Arm Circles, Leg Circles, Frog Series, Long Box Series, Short Box Series, Elephant, Knee Stretch Series, Stomach Massage, and Side Stretch. The program emphasizes progressive resistance, controlled movements, and professional supervision to ensure safety and effectiveness. Sessions are conducted twice weekly for six weeks.
219521198|NCT06394505|OTHER|Data Collection Tools|"Safety Climate Scale: Since a customized safety climate perception measurement tool for nurses could not be found in the literature, the Safety Climate Scale (SAS), developed by Choudry et al. in 2009 and adapted to Turkish by Türen et al. in 2014, was used on healthcare workers and electronics industry workers. The scale consists of two subscales: 10 items evaluating the management's perspective and rules (YÖBAK) and 4 items evaluating colleagues and safety training (İAGE). Participants rate the statements in the scale between strongly agree (five points) and strongly disagree (one point). The total score of the scale is calculated by taking the average of the item scores, and as the average gets closer to five, the safety climate improves, and as it gets closer to one, it gets worse. The Cronbach Alpha reliability coefficient of the scale was determined as 0.93 in the study conducted by Türen et al., and in this study it was calculated as 0.82."
219521199|NCT01118247|PROCEDURE|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
218906300|NCT04678583|PROCEDURE|Resection of colorectal liver metastases|Comparison of two liver surgery methods
218906301|NCT04346095|DRUG|Oral Sedatives with or Without Analgesia|The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
218906302|NCT04346095|DRUG|Intravenous Sedatives with or Without Analgesia|The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
218906303|NCT02681809|DRUG|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
218906304|NCT02681809|DRUG|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
218906305|NCT02681809|DRUG|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
218906306|NCT04479397|PROCEDURE|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
218906307|NCT04479397|PROCEDURE|No sling in postoperative care|No sling will be used in postoperative care.
218906308|NCT02039115|DRUG|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
218906309|NCT02039115|DRUG|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
218906310|NCT04084158|DRUG|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
218906311|NCT04084158|DRUG|Paclitaxel, Albumin-Bound|Paclitaxel
218906312|NCT04084158|RADIATION|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
218906313|NCT04084158|DRUG|Platinum-Based Drug|carboplatin
219204403|NCT03800017|BIOLOGICAL|Hyperoxia|Participants breathe 60% oxygen during exercise
218906314|NCT04271852|DEVICE|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
218906315|NCT04392739|DRUG|Tpoxx|oral antiviral
218906316|NCT03316196|BEHAVIORAL|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
218906317|NCT03316196|BEHAVIORAL|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
218906318|NCT04247139|OTHER|Kefir|commercial versus traditional kefir
218906319|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
218906320|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
218906321|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
218906322|NCT03405883|OTHER|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
218906323|NCT03856060|OTHER|Questionnaire Administration|Complete questionnaires
218906324|NCT03856060|OTHER|Video|Watch videos of doctor and patient interaction in different settings
218906325|NCT04587947|DRUG|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
219521200|NCT03677648|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
219521201|NCT03677648|DRUG|Placebos|Placebos
219521202|NCT03268109|OTHER|assessment of cognitive impairment|Measure of Global Deficit Score
219521203|NCT05459727|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
219521204|NCT05459727|PROCEDURE|Control periodontal treatment|Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
219521205|NCT01101230|OTHER|Almonds|1.5 oz almonds/day
219521206|NCT04586088|DRUG|Apatinib plus Camrelizumab|Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
219521207|NCT02707653|DRUG|Misoprostol|400 mcg sublingual misoprostol
219521208|NCT04638153|BIOLOGICAL|Recifercept|Recifercept
219521209|NCT02829268|DRUG|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
219521210|NCT00002549|BIOLOGICAL|filgrastim|
218906326|NCT02159586|DEVICE|gastric electrical stimulator|
218906327|NCT06400069|OTHER|Evaluation of serum NLRP6 levels|intervention: Evaluation of serum NLRP6 levels control: Evaluation of serum NLRP6 levels
218906328|NCT06147843|OTHER|Blood sample|Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss
218906329|NCT05272683|DRUG|GLPG3667|On day 1 and day 8, participants will receive a single dose
218906330|NCT05272683|DRUG|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
218906331|NCT05083273|OTHER|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
218906332|NCT04218721|OTHER|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
219521211|NCT00002549|DRUG|busulfan|
219521212|NCT00002549|DRUG|cyclophosphamide|
218906335|NCT06790420|DRUG|Rituximab Pfizer|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
218906336|NCT06790420|DRUG|Rituxan|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
218906337|NCT06785467|OTHER|eDoula App|eDoula is an app that will give patients reading material and videos to watch based on their due date. It also provides helpful postpartum device.
218906338|NCT06366737|DEVICE|KILBON Appliance|palatal TAD assissted lingual appliance for en-mass retraction
218906339|NCT06366737|DEVICE|CAT appliance|palatal TAD assissted clear aligner
218906340|NCT03661723|DRUG|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
218906341|NCT03661723|DRUG|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
218906342|NCT03661723|RADIATION|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
218906343|NCT04371783|PROCEDURE|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
218906344|NCT04371783|PROCEDURE|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
218906345|NCT06445348|DEVICE|Cervical pedicle screw|cervical pedicle screw
218906346|NCT06384066|OTHER|GetWell Mobile Application|GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.
218906347|NCT06384066|OTHER|Standard of Care|Office Based Pathway
218906348|NCT05979064|PROCEDURE|Laparoscopically harvested omental tissue autograft|"1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity."
219521213|NCT00002549|DRUG|cytarabine|
219521214|NCT00002549|DRUG|daunorubicin hydrochloride|
219521215|NCT00002549|DRUG|etoposide|
219521216|NCT00002549|DRUG|idarubicin|
219521217|NCT00002549|DRUG|mesna|
219521218|NCT00002549|DRUG|mitoxantrone hydrochloride|
219521219|NCT00002549|PROCEDURE|allogeneic bone marrow transplantation|
219521220|NCT00002549|PROCEDURE|autologous bone marrow transplantation|
219521221|NCT00002549|PROCEDURE|peripheral blood stem cell transplantation|
219521222|NCT00002549|RADIATION|radiation therapy|
219521223|NCT02019290|DRUG|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
219521224|NCT02019290|DRUG|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
219521225|NCT00898079|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219521226|NCT00270959|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
218906349|NCT05765682|OTHER|Mepivacaine Spinal|spinal block using 60mg of mepivacaine
218906350|NCT05765682|OTHER|Bupivacaine Spinal|spinal block using 10mg of bupivacaine
218906351|NCT06025916|DRUG|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
218906352|NCT04237467|OTHER|No intervention|There was no intervention.
218906353|NCT05757843|DIAGNOSTIC_TEST|Signatera ctDNA test|The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. ctDNA testing will be repeated approximately every 4 weeks until two consecutive negative analyses occur. ctDNA testing will be otherwise discontinued after progressive disease or after up to 1 year of consolidation treatment per standard medical practice is considered complete, whichever occurs first.
218906354|NCT05757843|DRUG|Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Durvalumab will be stopped after two consecutive negative ctDNA analyses occur.
218906355|NCT05791253|OTHER|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
218906356|NCT06510933|DEVICE|Heel cups in different BMI index and its correlation to physical activity in children|Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
218906357|NCT06797024|DRUG|JY231 Injection|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion. A total of 3 dose groups were established to conduct a 3+3 dose-escalation study. The doses were divided into two categories: non-lymphodepletion and lymphodepletion pretreatment. The three dose groups for lymphodepletion included: 2×10\^8 TU, 4×10\^8 TU, and 8×10\^8 TU. The three dose groups for non-lymphodepletion included: 2×10\^9 TU, 4×10\^9 TU, and 8×10\^9 TU. The decision to perform lymphodepletion was based on the lymphocyte count and function during the patient screening period.
218906358|NCT04909710|OTHER|Mobile Game System for Potential Treatment of Developmental Delays|Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
219204404|NCT06450314|DRUG|Discontinuation of the anti-HER2 maintenance therapy|Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
218906359|NCT06479343|DEVICE|Liquid Embolic System (Tonbridge)|Endovascular treatment with Liquid Embolic System (Tonbridge).
218906360|NCT06479343|DEVICE|Onyx Liquid Embolic System (Medtronic)|Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
218906361|NCT05318131|OTHER|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
218906362|NCT05318131|OTHER|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
218906363|NCT04175730|DEVICE|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
218906364|NCT04175730|DEVICE|Ultrasound|A single subsequent ultrasound guided prostate biopsy
218906365|NCT02519608|DRUG|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
218906366|NCT02519608|DRUG|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
219204405|NCT06450314|DEVICE|Monitoring with signatera test|"ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week)."
219521227|NCT00270959|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
219521228|NCT00270959|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
219521229|NCT00270959|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
218906367|NCT02519608|DRUG|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
218906368|NCT00718510|DRUG|L-Arginine|3 grams, twice daily, oral administration
218906369|NCT02760966|OTHER|Alcohol 70º|
218906370|NCT02760966|OTHER|Soap|
218906371|NCT03074708|OTHER|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
218906372|NCT01895075|DRUG|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
219521230|NCT02829970|BEHAVIORAL|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).
219613072|NCT01949402|OTHER|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
219613073|NCT01949402|OTHER|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
219613074|NCT01949402|OTHER|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
219613075|NCT00193050|DRUG|Gemcitabine|Gemcitabine
219613076|NCT00193050|DRUG|Epirubicin|Epirubicin
218906373|NCT01895075|DRUG|Normal saline|2 ml normal saline by inhalation
218906374|NCT02084485|DRUG|PH-797804|30 MG Single dose
218906375|NCT02084485|DRUG|Placebo|matching placebo
218906376|NCT03028233|BEHAVIORAL|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
218906377|NCT03028233|BEHAVIORAL|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
218906378|NCT06512064|DIAGNOSTIC_TEST|AWARE|AWARE testing to estimate lung function and aid in disease diagnosis
218906379|NCT01416402|DRUG|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
219204406|NCT06741514|DEVICE|Precice IMLL|Parents or legal guardians of children that previously received the Precice IMLL will complete a survey. No additional or new interventions will be administered.
219613077|NCT00193050|DRUG|Docetaxel|Docetaxel
218906380|NCT01416402|DRUG|Febuxostat|80 mg once daily orally for 5 weeks
219204407|NCT04629547|DRUG|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
218906381|NCT01416402|DRUG|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
218906382|NCT05684458|PROCEDURE|Reiki|Reiki, a non-invasive, free and safe complementary therapy method, is practiced with a series of hand positions held on the patient's body to help balance the life force energy.
218906383|NCT00006053|DRUG|imatinib mesylate|
218906384|NCT00325455|DRUG|MK0859|
218906385|NCT04481412|DRUG|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
218906386|NCT04481412|DRUG|Placebo|96% ethanol that will be applied once daily.
218906387|NCT04481412|DRUG|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
218906388|NCT04297865|DRUG|A dose as CJ-15314|A dose as CJ-15314, 1 capsule
218906389|NCT04297865|DRUG|B dose as CJ-15314|B dose as CJ-15314, 1 capsule
218906390|NCT04297865|DRUG|C dose as CJ-15314|C dose as CJ-15314, 1 capsule
218906391|NCT04297865|DRUG|D dose as CJ-15314|D dose as CJ-15314, 2 capsules
218906392|NCT04297865|DRUG|E dose as CJ-15314|E dose as CJ-15314, 1 capsule
218906393|NCT04297865|DRUG|F dose as CJ-15314|F dose as CJ-15314, 2 capsules
218906394|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
218906395|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
218906396|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
218906397|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
218906398|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
218906399|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
218906400|NCT04859322|DRUG|Glucagon|Pancreatic clamp
218906401|NCT03604952|DIAGNOSTIC_TEST|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
218906402|NCT06403007|BEHAVIORAL|Phonics plus morphology|This intervention trains teachers to teach phonics plus morphology to at-risk poor readers
219204408|NCT04629547|DRUG|Placebo|Placebo will be taken nightly for 24 months.
219521231|NCT02829970|BEHAVIORAL|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
219521232|NCT04006171|DIAGNOSTIC_TEST|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
219521233|NCT01393288|DRUG|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
219521234|NCT01393288|DRUG|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
219521235|NCT01393288|DRUG|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
219521236|NCT06247657|DRUG|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
219521237|NCT03138330|OTHER|this study is observational, it is not an intervention|
219521238|NCT03599505|PROCEDURE|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
219613078|NCT01705379|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
219613079|NCT00712790|DRUG|Sorafenib|Tablet, 400mg orally, twice daily
219613080|NCT00712790|RADIATION|SIR-Spheres|one time treatment and capped at 3.0 Gbq
219613081|NCT01373138|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
218906403|NCT06403007|BEHAVIORAL|Phonics plus set-for-variability|This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
218906404|NCT04730908|OTHER|DENTIFRICE|GEL -DENTIFRICE FOR BRUSHING TEETH
218906405|NCT03397979|BEHAVIORAL|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
218906406|NCT02793726|PROCEDURE|NMR|NMR
218906407|NCT03159416|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
218906408|NCT04757207|OTHER|survey|International Physical Activity Questionnaire (short form)
218906409|NCT02832648|DIETARY_SUPPLEMENT|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
218906410|NCT03313869|DIETARY_SUPPLEMENT|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
218906411|NCT03313869|DIETARY_SUPPLEMENT|control diet|habitual diet to be followed
218906412|NCT02640274|BEHAVIORAL|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
218906413|NCT02640274|OTHER|Usual care|
218906414|NCT05511181|DEVICE|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
219613082|NCT00061932|DRUG|bortezomib|Given IV
219613083|NCT00061932|DRUG|irinotecan|Given IV
219613084|NCT00121537|DEVICE|Wound Care -Wound Vacuum Assisted Closure (VAC)|
218906415|NCT05511181|DEVICE|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
218906416|NCT02345135|PROCEDURE|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
218906417|NCT02345135|PROCEDURE|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
218906418|NCT02345135|BEHAVIORAL|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
218906419|NCT02715739|OTHER|No intervention|
219521239|NCT05577845|DRUG|Ramosetron|Ramosetron, 4 weeks
219521240|NCT03248362|DEVICE|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
219521241|NCT03248362|DEVICE|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
219521242|NCT03316001|OTHER|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
219521243|NCT02330848|DIETARY_SUPPLEMENT|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
219521244|NCT02330848|DIETARY_SUPPLEMENT|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
219521245|NCT06155630|OTHER|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
219521246|NCT02624557|DRUG|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
219613085|NCT00121537|PROCEDURE|Wound Care - Wet to Dry Dressing Changes|
219613086|NCT00886509|BIOLOGICAL|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
219613087|NCT00886509|OTHER|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
219613088|NCT05880511|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
218906420|NCT04418791|BEHAVIORAL|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
218906421|NCT04418791|BEHAVIORAL|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
218906422|NCT04701008|DRUG|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
218906423|NCT03870919|DRUG|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
218906424|NCT03870919|OTHER|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
218906425|NCT05954858|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
218906426|NCT03740022|PROCEDURE|ACL plasty|standard ligamentoplasty by Kenneth Jones
218906427|NCT03740022|PROCEDURE|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
218906428|NCT05748275|DIAGNOSTIC_TEST|Argos|Biometry measurements first with the Argos device, then the IOLMaster 700 device.
218906429|NCT05748275|DIAGNOSTIC_TEST|IOLMaster 700|Biometry measurements first with the IOLMaster 700 device, then the Argos device.
218906430|NCT05837390|DEVICE|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
218906431|NCT05837390|OTHER|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
218906432|NCT05837390|OTHER|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
218906433|NCT05954468|OTHER|standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social \& health psychology
218906434|NCT05655598|DRUG|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
218906435|NCT05655598|DRUG|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
218906436|NCT05655598|DRUG|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
218906437|NCT05655598|DRUG|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
218906438|NCT03023202|OTHER|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
218906439|NCT05553509|OTHER|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
218906440|NCT04737512|BEHAVIORAL|Mindfulness-Based ADHD Treatment for Children|MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
219039497|NCT05491551|BEHAVIORAL|Mindfulness-Based Treatment-Regulation of Craving|"Participants will be trained in using the MBT-based mindfulness strategy as described above (notice craving and accept the feeling without judgment or reaction). Participants will then be instructed to think of accepting and non-reactive responses when they see the instruction ACCEPT during ROC-T. On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see ACCEPT and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale."
219039498|NCT05491551|BEHAVIORAL|Cognitive-Based Therapy-Regulation of Craving|"Participants will be trained in using the CBT strategy by first considering and reading about the negative consequences of drinking. Participants will then be instructed to think of those negative consequences (Focus on the negative consequences associated with drinking) when they see the instruction REFRAME during ROC-T.On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see REFRAME and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale"
219521247|NCT05288127|DRUG|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
219521248|NCT00440557|DRUG|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
219521249|NCT00440557|DRUG|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
219521250|NCT00440557|DRUG|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
219521251|NCT03206866|DIAGNOSTIC_TEST|serum regucalcin antibody|serum regucalcin antibody
219521252|NCT00171821|DRUG|Deferasirox|
219521253|NCT00902109|DEVICE|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
219521254|NCT00902109|DEVICE|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
219521255|NCT00902109|DEVICE|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
219521256|NCT05165056|DEVICE|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
219521257|NCT05110677|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
219521258|NCT04019678|PROCEDURE|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
219521259|NCT02687074|DEVICE|HFNC|patients treated with high flow nasal cannula
219521260|NCT02687074|DEVICE|NIV|patients treated with noninvasive ventilation
219521261|NCT01973348|DEVICE|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
219521262|NCT01973348|DEVICE|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
219521263|NCT01973348|DEVICE|2-hour patching|2-hour patching for moderate amblyopia
219521264|NCT01973348|DEVICE|6-hour patching|6-hour patching for severe amblyopia
219613089|NCT05880511|DEVICE|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
219039499|NCT06127511|OTHER|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
219521265|NCT00714740|DRUG|acetazolamide|acetazolamide 2 times 250mg per day
219521266|NCT04934917|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
219521267|NCT03356821|BIOLOGICAL|Mesenchymal Stem Cells|One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
219521268|NCT04386759|OTHER|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
219039500|NCT06899516|OTHER|The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)|The LAPS is a established tool for measuring the emotional bond between humans and their animal companions. Animal attachment is assessed according to three factors: the bond between owners and their dogs or cats, the closeness of the human-animal relationship, and the importance of the animal in the owner's life (Johnson et al., 1992). Higher scores indicate greater attachment.
219521269|NCT00874237|DRUG|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
219521270|NCT00874237|DRUG|Inhaled placebo|Inhaled Staccato placebo single dose
219521271|NCT00874237|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg
219521272|NCT00874237|DRUG|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
219521273|NCT01162226|BEHAVIORAL|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
219521274|NCT03447860|BEHAVIORAL|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
219521275|NCT03447860|BEHAVIORAL|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
219521276|NCT02355431|DRUG|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
219521277|NCT02355431|DRUG|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
218906441|NCT04737512|BIOLOGICAL|Goal-Standard Medication (Treatment as Usual)|"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."
218906442|NCT03886506|BIOLOGICAL|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
219613090|NCT05880511|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
218906443|NCT03874468|DEVICE|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
218906444|NCT05346575|BEHAVIORAL|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
218906445|NCT05346575|BEHAVIORAL|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
218906446|NCT06547437|DRUG|Papaverine|papaverine a smooth muscle relaxant
218906447|NCT06547437|DRUG|normal saline|normal saline 0.9% 100 cc
218906448|NCT06297187|DEVICE|CUSA (Cavitronic Ultrasonic Surgical Aspirator)|CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
218906449|NCT06063161|BEHAVIORAL|Music therapy intervention|Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.
218906450|NCT06063161|OTHER|Non-guided music listening|Participants will listen to generic music playlists.
218906451|NCT06063161|OTHER|Standard of care|placebo arm, routine standard of care
218906452|NCT04133883|PROCEDURE|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
218906453|NCT06054607|DIETARY_SUPPLEMENT|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
218906454|NCT06054607|OTHER|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
218906455|NCT05622604|BEHAVIORAL|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
218906456|NCT05622604|BEHAVIORAL|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
218906457|NCT01745926|DEVICE|MECHANICAL CHEST COMPRESSION|
218906458|NCT03693521|DEVICE|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
218906459|NCT03693521|OTHER|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
218906460|NCT02083471|DIETARY_SUPPLEMENT|Specific Oral Tolerance Induction with Egg or Cow's milk|
218906461|NCT02428101|GENETIC|polymorphism analysis|
218906462|NCT06085534|DRUG|LNK01001|Capsules for oral use
218906463|NCT06085534|DRUG|Placebo|Capsules for oral use
218906464|NCT00467740|DRUG|BI 1744 CL|
218906465|NCT04484558|DRUG|Actilyse|Infusion
218906466|NCT02903160|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
218906467|NCT02903160|DRUG|Prednisone|5 mg PO twice a day
218906468|NCT02903160|DRUG|Radium-223 dichloride|50 kBq/kg IV monthly
219613091|NCT02575833|DRUG|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
219613092|NCT02575833|DRUG|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
218906469|NCT02903160|DRUG|cabazitaxel|25 mg/m2 IV every 3 weeks
218906470|NCT02903160|DRUG|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
218906471|NCT02903160|DRUG|Enzalutamide|160 mg PO daily
218906472|NCT01838317|DRUG|Pioglitazone|
218906473|NCT01664910|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
218906474|NCT01664910|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
218906475|NCT01664910|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
218906476|NCT01664910|DRUG|Bendamustine Hydrochloride|Given IV
218906477|NCT01664910|DRUG|Fludarabine Phosphate|Given IV
218906478|NCT01664910|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
218906479|NCT01664910|DRUG|Methotrexate|Given IV
219039501|NCT05716139|PROCEDURE|Natural Cycle|The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
219039502|NCT05716139|PROCEDURE|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
219039503|NCT06900621|OTHER|ice water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (5-9 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of ice water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
219204409|NCT06742320|BEHAVIORAL|Asthma education|There are very few studies examining the asthma knowledge level, quality of life and asthma control of children in Turkey.
219204410|NCT06750393|OTHER|Barre exercise along with gym ball exercises|"The Barre exercises will be administer to the participant of Group A for a period of 3 month.~Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. Gym ball exercises program include Knee tucks, leg curls, back extension exercises"
219204411|NCT06750393|OTHER|Barre exercises|"The Barre exercises for a period of 3 month Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. During"
219521278|NCT02355431|DRUG|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
219613093|NCT05115175|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
219613094|NCT01456806|OTHER|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
219613095|NCT03093259|DRUG|ABX464|ABX464 is a new Anti-inflammatory drug
219613096|NCT03093259|DRUG|Placebo oral capsule|Placebo matching with ABX464
218906480|NCT01664910|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
218906481|NCT01664910|BIOLOGICAL|Rituximab|Given IV
218906482|NCT01664910|DRUG|Tacrolimus|Given IV or PO
218906483|NCT02203877|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
219364928|NCT01182038|DEVICE|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
219364929|NCT05749757|DEVICE|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
219364930|NCT05749757|DEVICE|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
219364931|NCT01750814|BIOLOGICAL|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
219364932|NCT01750814|BIOLOGICAL|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
219521279|NCT01974648|DRUG|propofol|
219521280|NCT01974648|DRUG|propofol and remifentanil|
219521281|NCT03129425|BEHAVIORAL|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
219521282|NCT03129425|OTHER|General Educational Program|5 sessions in groups of 15-20 people
219521283|NCT03077516|DEVICE|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
219613097|NCT04881786|DEVICE|Orthodontic forces|56g force and 224g force
219613098|NCT03537131|DRUG|Dapagliflozin 10 MG Oral Tablet|taken once a day
219613099|NCT00445146|DRUG|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
218906484|NCT02203877|DIETARY_SUPPLEMENT|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
219364933|NCT01749384|BIOLOGICAL|Bevacizumab|Given IV
219364934|NCT01749384|OTHER|Laboratory Biomarker Analysis|Correlative studies
219613100|NCT00445146|DRUG|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
219521284|NCT03850639|BEHAVIORAL|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
218906485|NCT02737007|DRUG|[14C]-GSK3191607|\[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
218906486|NCT02149381|BEHAVIORAL|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
218906487|NCT02149381|BEHAVIORAL|Befriending|Social support intervention, sessions once per week
218906488|NCT02149381|OTHER|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
218906489|NCT00274248|DRUG|MLN518|
218906490|NCT01009541|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
218906491|NCT01009541|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
218906492|NCT01009541|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
218906493|NCT01009541|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
218906494|NCT01892670|OTHER|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
218906495|NCT03272750|DIETARY_SUPPLEMENT|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
219521285|NCT01257009|DRUG|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
218906496|NCT03272750|DIETARY_SUPPLEMENT|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
218906497|NCT03272750|DIETARY_SUPPLEMENT|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
218906498|NCT02527681|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
218906499|NCT03236896|BEHAVIORAL|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
218906500|NCT03236896|BEHAVIORAL|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
218906501|NCT05244512|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
218906502|NCT05244512|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
218906503|NCT02006316|PROCEDURE|Microsurgical subinguinal varicocelectomy|
218906504|NCT00302809|DIETARY_SUPPLEMENT|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
218906505|NCT06112483|BEHAVIORAL|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn \& Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
218906506|NCT02374164|DRUG|Febuxostat XR|Febuxostat XR capsules
218906507|NCT04376216|DRUG|Prednisone|60 mg with dose tapering over 2 months
218906508|NCT01127243|PROCEDURE|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
219364935|NCT01749384|OTHER|Pharmacological Study|Correlative studies
219364936|NCT01749384|DRUG|Tivantinib|Given PO
219364937|NCT06461598|DRUG|Chemotherapy|All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
219364938|NCT00589641|BEHAVIORAL|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
219364939|NCT00589641|BEHAVIORAL|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
219364940|NCT05102526|BEHAVIORAL|"Experimental: Young Millie prevention program, active teachers"|"Prevention program: Young Mili, in collaboration with the teacher"
219364941|NCT05102526|BEHAVIORAL|"Prevention program: Young Mili, non active teachers"|"Prevention program: Young Mili, without the participation of the teacher"
219521286|NCT06213688|OTHER|blood sampling|blood sampling at inclusion
219521287|NCT06213688|OTHER|urine sampling|urine sampling at inclusion
219521288|NCT03912337|DRUG|Placebo|Placebo once every 4 weeks. SC injection.
219521289|NCT03912337|DRUG|Erenumab|Erenumab once every 4 weeks. SC injection.
219521290|NCT03752528|DIAGNOSTIC_TEST|Blood sample collection|Determination of buprenorphine and norbuprenorphine plasma concentrations
218906509|NCT01127243|PROCEDURE|inpatient LSH|patients discharged home the day after the operation
218906510|NCT01082250|DRUG|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
218906511|NCT04969029|DRUG|Tirelizumab|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
219521291|NCT03752528|DIAGNOSTIC_TEST|Urine sample collection|Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
219521292|NCT06391983|OTHER|resistance training (elastic band)|The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.
219521293|NCT00721747|DRUG|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
219521294|NCT05857098|OTHER|Local Field potential recording|Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
219521295|NCT04196452|DRUG|Ipilimumab|Specified dose on specified days
219521296|NCT06631157|DEVICE|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
219613101|NCT00445146|DRUG|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
219613102|NCT06751758|OTHER|C1-C2 Mobilization|Participants in both Group A and Group B will receive manual mobilization targeting the C1-C2 region. This specific mobilization technique is chosen for its potential to improve joint mobility and alleviate stiffness in the upper cervical spine. The mobilization will be performed by trained physiotherapists to ensure precision and safety.
218906512|NCT00730158|DRUG|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
218906513|NCT00730158|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
218906514|NCT00730158|DRUG|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
218906515|NCT04678115|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.
218906516|NCT04678115|DEVICE|Kinesiotape Frontalis Sling (KTFS)|Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
218906517|NCT01051674|OTHER|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
218906518|NCT01012986|OTHER|Assessment of reading skills|
218906519|NCT01055561|OTHER|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
219521297|NCT04739020|DIAGNOSTIC_TEST|Resp-Aer-Meter|Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.
219521298|NCT04739020|DIAGNOSTIC_TEST|Spirometry|Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.
219521299|NCT04739020|DIAGNOSTIC_TEST|Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations|Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).
219521300|NCT03736382|OTHER|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
219521301|NCT03736382|OTHER|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
219521302|NCT03736382|OTHER|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
219521303|NCT01112280|DEVICE|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
219521304|NCT01772030|OTHER|Use of the Achieve catheter followed by ICE-guided mapping catheter|
218906520|NCT04220346|OTHER|Tablet group|Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
218906521|NCT04034303|GENETIC|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
219521305|NCT06328348|DIETARY_SUPPLEMENT|supplementation|group receiving a course of Black Cohosh, Soy Isoflavones, and SDG Lignans
219521306|NCT06328348|OTHER|placebo|placebo
219521307|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
219521308|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
219521309|NCT00106548|DRUG|Placebo|iv / month
219521310|NCT00106548|DRUG|Methotrexate|10-25mg/week
219521311|NCT00537030|DRUG|Asparaginase|Given IM
219521312|NCT00537030|OTHER|Laboratory Biomarker Analysis|Correlative studies
218906522|NCT05757986|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
218906523|NCT01459484|DRUG|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
218906524|NCT01459484|OTHER|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
218906525|NCT04249856|DIAGNOSTIC_TEST|Dynamic Spectral Imaging (DYSIS)|Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
218906526|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
218906527|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
218906528|NCT01168349|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
218906529|NCT01757106|DRUG|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
218906530|NCT01757106|DRUG|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
218906531|NCT01475591|BEHAVIORAL|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
218906532|NCT01368250|PROCEDURE|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
218906533|NCT02257034|OTHER|Taichi|
218906534|NCT02257034|OTHER|Dance|
218906535|NCT04538638|PROCEDURE|Mesenteric sparing ileocolic resection|Mesentery left in situ
218906536|NCT04538638|PROCEDURE|Central mesenterectomy ileocolic resection|Mesentery is taken up to the level of the ileocolic trunk
218906537|NCT03535974|DIETARY_SUPPLEMENT|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
218906538|NCT03535974|DIETARY_SUPPLEMENT|Placebo|Placebo administration for 6 weeks bid
218906539|NCT00844376|DRUG|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
218906540|NCT00844376|DRUG|Lipitor|A single dose of 80 mg Lipitor tablet
218906541|NCT06466694|BEHAVIORAL|Modified Dialectical Behavioural Therapy|The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. To evaluate through a patient lens content of the Dialectical Behavior Therapy (DBT) through the lens of an Indigenous Knowledge Carrier (Elder)
218906542|NCT04485897|DEVICE|icare HOME device (Icare Oy, Vanda, Finland)|icare HOME device versus hospital based measurements
218906543|NCT02185703|DEVICE|Chordate System S020 in treatment mode|
218906544|NCT02185703|DEVICE|Chordate System S020 in placebo mode|
218906545|NCT02068326|BEHAVIORAL|Mentalization Based Treatment|
218906546|NCT02068326|BEHAVIORAL|Treatment As Usual|Treatment As Usual
218906547|NCT04059549|BEHAVIORAL|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
218906548|NCT04059549|BEHAVIORAL|A-CHESS|A-CHESS control group
218906549|NCT05011227|DRUG|Camrelizumab|2 cycles Camrelizumab before endoscopic surgery and one year after
219521313|NCT00537030|OTHER|Pharmacological Study|Correlative studies
219521314|NCT00414765|DRUG|Aldesleukin|
219521315|NCT02458469|DRUG|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
219521316|NCT02458469|DRUG|Trazodone|100 mg dose before bed-time
219521317|NCT02458469|DRUG|Placebo|One placebo pill before bed-time
219521318|NCT03682159|OTHER|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
219521319|NCT04795154|OTHER|Yoga excercise|Yoga exercise in pre-eclampsia \>20 weeks of pregnancy woman, treatment number was 4 times.
219521320|NCT02524197|DRUG|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
219521321|NCT02524197|DRUG|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
219521322|NCT02524197|DRUG|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
219521323|NCT02524197|DRUG|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
219521324|NCT06470880|DRUG|Adaptive Therapy|A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.
219613103|NCT06751758|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Following C1-C2 mobilization, each participant will undergo a 20-minute session of TENS. TENS involves the application of low-voltage electrical currents through electrodes placed on the skin. This modality aims to modulate pain perception by stimulating nerve fibers, leading to the release of endorphins - the body's natural painkillers. The 20-minute duration is chosen based on established guidelines for effective TENS application.
218906550|NCT05011227|DRUG|Chemotherapy|2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
218906551|NCT05011227|PROCEDURE|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
218906552|NCT04676295|BEHAVIORAL|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
218906553|NCT04581226|DIAGNOSTIC_TEST|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
219039504|NCT06900621|OTHER|room temperature water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (15-24 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of room temperature water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
219039505|NCT06877364|BIOLOGICAL|GcMAF|GcMAF is an immunomodulatory protein derived from vitamin D-binding protein via enzymatic deglycosylation. In this study, GcMAF will be administered (e.g., subcutaneously) once or twice-weekly for 12-16 weeks, followed by a 4-8-week observation period. The primary objectives include assessing clinical efficacy in chronic inflammatory conditions and confirming safety. GcMAF activates macrophages and dendritic cells, modulates M1/M2 profiles, and may reduce inflammatory markers such as CRP and ESR.
219204412|NCT05047952|DRUG|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
219613104|NCT06751758|OTHER|Suboccipital Distraction|"Suboccipital distraction is a manual technique aimed at relieving tension in the upper cervical spine. This intervention involves the gentle separation of the suboccipital muscles and associated structures, promoting relaxation and reducing pain. The technique is intended to enhance the range of motion in the cervical region by targeting the upper cervical structures.~Procedure:~5-7 repetitions of intermittent distraction 20-30 seconds on, 10-15 seconds off~Administration:~Suboccipital distraction will be performed by skilled physiotherapists trained in this technique. Close monitoring will ensure correct application and participant safety."
219613105|NCT06751758|OTHER|Traction|"Traction is a therapeutic technique that involves applying a controlled, manual force to stretch and mobilize the cervical spine. The primary goal of this intervention is to reduce compression on the cervical structures, alleviate pain, and improve the range of motion. It is typically used for its potential to decompress the spine and relieve pressure on nerves.~Procedure:~Traction will be administered manually by trained physiotherapists, who will ensure that the correct amount of force is applied and that the treatment is both safe and effective. The application will be carefully tailored to the individual's needs.~Administration:~Participants will undergo traction treatments with close monitoring throughout the study period, allowing for necessary adjustments to the treatment plan based on individual responses."
218906554|NCT02639494|DEVICE|Self-Centering Guide Catheter|
218906555|NCT02663011|OTHER|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
218906556|NCT02678351|DRUG|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
218906557|NCT02678351|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
218906558|NCT02678351|PROCEDURE|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
218906559|NCT03195816|BEHAVIORAL|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
218906560|NCT00988884|BIOLOGICAL|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
218906561|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
218906562|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
218906563|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
218906564|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
218906565|NCT00741052|DRUG|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
218906566|NCT00741052|DRUG|Azithromycin|1 gm Azithromycin single dose
218906567|NCT01919229|DRUG|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
218906568|NCT01919229|DRUG|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
218906569|NCT06473415|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography using the Sleep-Profiler device
218906570|NCT00700596|DRUG|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
218906571|NCT00700596|DRUG|Placebo|Control or Placebo SA (30 % ethanolic solution)
218906572|NCT03806621|PROCEDURE|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
218906573|NCT00752050|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
218906574|NCT00752050|DRUG|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
218906575|NCT01632020|DRUG|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
218906576|NCT01632020|DRUG|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
218906577|NCT04368260|DEVICE|Control swab|FDA-cleared nasopharyngeal swab
218906578|NCT04368260|DEVICE|Prototype swab|Injection molded polypropylene flocked nylon nasopharyngeal swab
218906579|NCT03550612|DIAGNOSTIC_TEST|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
219613106|NCT05717660|COMBINATION_PRODUCT|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
218906580|NCT03550612|DIAGNOSTIC_TEST|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
218906581|NCT05553795|PROCEDURE|Early removal of chest drain|Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.
218906582|NCT05553795|PROCEDURE|Chest drain|The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
218906583|NCT02906423|OTHER|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
218906584|NCT00420576|DRUG|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
218906585|NCT01239966|DEVICE|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
218906586|NCT01929590|DRUG|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
218906587|NCT01929590|DRUG|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
218906588|NCT01929590|DRUG|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
219204413|NCT05047952|DRUG|Placebo|A placebo pill will be taken once daily.
219204414|NCT06744764|DEVICE|PEMF (1mT)|1mT of field strength will be given to patients/healthy volunteers for 10 minutes, twice per week for 4 consecutive weeks.
219613107|NCT00625820|DRUG|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
219613108|NCT00625820|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
218906589|NCT04272346|BEHAVIORAL|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
218906590|NCT04272346|BEHAVIORAL|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
218906591|NCT04272346|BEHAVIORAL|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
218906592|NCT00549640|DRUG|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
218906593|NCT00549640|DRUG|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
219521325|NCT06470880|DRUG|Standard of Care|Encorafenib and binimetinib delivered to UK standard of care.
218906594|NCT05406011|DIETARY_SUPPLEMENT|Pelleted sour cherry (anthocyanin) containing chewing gum usage.|Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).
218906595|NCT05406011|DIETARY_SUPPLEMENT|Pelleted chewing gum for stimulated saliva sampling.|Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.
218906596|NCT05406011|PROCEDURE|Scaling|Scaling after a 1-week control period without chewing the sour cherry gum.
218906597|NCT03022396|BIOLOGICAL|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
218906598|NCT03022396|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
219521326|NCT02156739|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
219521327|NCT02156739|DRUG|Gadobutrol|Given IV
218906599|NCT02232035|DRUG|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
218906600|NCT00763113|DEVICE|Vanguard PS Knee|Vanguard PS Knee
218906601|NCT00763113|DEVICE|Vanguard CR Knee|Vanguard CR Knee
218906602|NCT00803283|DRUG|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
218906603|NCT00803283|DRUG|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
218906604|NCT01861626|DRUG|V0057 - A mg|Single oral administration
219521328|NCT02156739|DRUG|Gadoxetate Disodium|Given IV
219521329|NCT05461547|DIAGNOSTIC_TEST|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
219521330|NCT05461547|OTHER|Usual Care|Usual care to decide diagnosis and treatment
219521331|NCT02468024|PROCEDURE|Lung Surgery|Sublobar Lung Resection
219521332|NCT02468024|RADIATION|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
219521333|NCT01081730|BIOLOGICAL|anti-TNF biologics|as prescribed
219521334|NCT01081730|OTHER|general population|non-treated cohort
219521335|NCT01081730|BIOLOGICAL|non-anti-TNF biologics|as prescribed
219521336|NCT01081730|BIOLOGICAL|ustekinumab|as prescribed
219521337|NCT01081730|DRUG|systemic non-biological treatments|as prescribed
219521338|NCT06002971|DEVICE|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
219521339|NCT03259763|DEVICE|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
219521340|NCT03259763|DEVICE|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
219521341|NCT05660642|DRUG|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
219521342|NCT00917033|DEVICE|GlideScope|Orotracheal intubation
219613109|NCT02309307|DEVICE|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
219613110|NCT00115414|DRUG|pegfilgrastim|
219613111|NCT00115414|DRUG|docetaxel|
219613112|NCT00115414|DRUG|doxorubicin|
219613113|NCT00115414|DRUG|cyclophosphamide|
218906605|NCT01861626|DRUG|Isotretinoin|Single oral administration
219521343|NCT00917033|DEVICE|Macintosh direct laryngoscope|Orotracheal intubation
219521344|NCT04534283|DRUG|Abemaciclib|Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
219613114|NCT03902665|DRUG|Up-front allogeneic hematopoietic stem cell transplantation (HSCT)|"Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only."
218906606|NCT02028533|DRUG|Oxytocin|
218906607|NCT02028533|DRUG|Placebo|
218906608|NCT01655758|DRUG|0.5% timolol|
218906609|NCT01655758|DRUG|timolol-dorzolamide fixed combination|
218906610|NCT01655758|DRUG|Latanoprost|
219204415|NCT06744764|DEVICE|PEMF (0mT)|Healthy volunteers will place their legs in the PEMF device, twice per week for 4 consecutive weeks. However, no magnetic stimulation will be given.
219204416|NCT06743802|DRUG|Coenzyme Q10|Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).
219521345|NCT04534283|DRUG|LY3214996|Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
219521346|NCT00661505|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
219521347|NCT04544371|DEVICE|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
219521348|NCT04544371|PROCEDURE|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
219613115|NCT03759392|DRUG|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
219613116|NCT03759392|DRUG|Placebo|Oral placebo twice daily for up to 20 weeks
219613117|NCT01243957|DRUG|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
218906611|NCT01655758|DRUG|Travoprost|
218906612|NCT01655758|DRUG|Bimatoprost|
218906613|NCT05311735|PROCEDURE|Freeze-Dried Bone Allograft control|Bone grafting to prevent alveolar ridge collapse after tooth removal
218906614|NCT05311735|PROCEDURE|Mineralized Dentin Graft|Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
218906615|NCT05311735|PROCEDURE|Partial-Demineralized Dentin Graft|Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
218906616|NCT03630835|OTHER|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
218906617|NCT05714267|DEVICE|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
218906618|NCT05714267|DEVICE|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
218906619|NCT05714267|DEVICE|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
218906620|NCT00409071|DRUG|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
219204417|NCT06743802|OTHER|Placebo|The placebo was administered from hospital admission until one month after discharge.
219204418|NCT06743971|BEHAVIORAL|ocean sound concert|intervention group listened to the ocean sound, the control group continued their daily care routines
218906621|NCT00409071|DRUG|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
218906622|NCT04886323|DEVICE|Cold atmospheric plasma treatment device|Treat with cold atmospheric plasma treatment device.
218906623|NCT04886323|DRUG|Itraconazole Capsules|Treat with Itraconazole capsules
218906624|NCT03477734|DEVICE|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
218906625|NCT03502837|OTHER|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
218906626|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
218906627|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
218906628|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
218906629|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 30 mg (2\*15 mg) oral capsules.
219521349|NCT06542081|BEHAVIORAL|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
219521350|NCT03561883|DRUG|IW-3718|oral tablet
218906630|NCT04999839|OTHER|Placebo|Placebo matched to NDI-034858 oral capsules.
218906631|NCT01362348|DRUG|pazopanib eye drops|10 mg/mL (1 drop) four times daily
218906632|NCT00371592|DRUG|Acyclovir|800 mg tablet taken orally twice daily
218906633|NCT00371592|DRUG|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
218906634|NCT03963765|PROCEDURE|Group I (Standard DL-PDT)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
218906635|NCT03963765|PROCEDURE|Group II (DL-PDT with microneedles)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
218906636|NCT03963765|PROCEDURE|Group III (DL-PDT with CO2 laser)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass
218906637|NCT03963765|PROCEDURE|Group IV (DL-PDT with microdermabrasion)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
218906638|NCT04320004|BEHAVIORAL|Education|Subject receives education
218906639|NCT04320004|BEHAVIORAL|Education with Reminder|Subject receives education with reminder
219521351|NCT03561883|DRUG|placebo|oral tablet
219521352|NCT03561883|DRUG|Standard-dose PPIs QD|background therapy
219521353|NCT00965653|DRUG|folic acid|\>/= 5 mg po weekly
219521354|NCT00965653|DRUG|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
219521355|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
219521356|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
219521357|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
219521358|NCT02854280|BIOLOGICAL|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
219521359|NCT02854280|BIOLOGICAL|Isolated contractions of the quadriceps|Until exhaustion
218906640|NCT04320004|BEHAVIORAL|Education + Disposal Bag|Subject receives education and disposal bag
218906641|NCT04320004|BEHAVIORAL|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
218906642|NCT02579460|OTHER|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
218906643|NCT00332072|DRUG|bimatoprost/timolol fixed combination|
218906644|NCT00399516|DEVICE|Precision|
218906645|NCT02644759|BIOLOGICAL|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
218906646|NCT00120016|BEHAVIORAL|dietary counseling|telephone counseling
218906647|NCT04932928|DEVICE|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
218906648|NCT04932928|DEVICE|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
219521360|NCT00524758|DEVICE|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
219521361|NCT00524758|DRUG|MMC in Trabeculectomy|MMC in Trabeculectomy
219521362|NCT01283919|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
219521363|NCT02256007|OTHER|Paper and Pencil Assessments|Videogame Assessments
219613118|NCT01243957|DRUG|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
219613119|NCT03573622|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
219613120|NCT03573622|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
219613121|NCT00967330|DRUG|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
219613122|NCT00967330|DRUG|irinotecan|125mg/m2 iv every 2 weeks
218906649|NCT02631096|DRUG|ARB-001467|An IV infusion of ARB-001467
218906650|NCT02631096|OTHER|Placebo|An IV infusion of placebo
218906651|NCT04482517|OTHER|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
218906652|NCT04482517|OTHER|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
218906653|NCT04482517|OTHER|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
218906654|NCT04482517|OTHER|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
219039506|NCT06877364|OTHER|Placebo Injection (Saline)|Participants in the placebo arm will receive a visually matching injection of normal saline (placebo) on the same schedule as the GcMAF arm (e.g., once or twice-weekly for 12-16 weeks). This allows for double-blind comparison of safety and efficacy endpoints. The placebo is designed to be identical in appearance and administration route to maintain blinding for investigators and participants.
219039507|NCT03037398|DEVICE|Vercise Deep Brain Stimulation System|
219039508|NCT06750783|DRUG|Xuezhikang|The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
219521364|NCT06275191|BEHAVIORAL|Multicomponent intervention|The multicomponent intervention consists of (1) a single 45-60-minute academic detailing session with provider participants, plus (2) provision of patient post-extraction instruction materials and (3) provision of blister-packaged acetaminophen and ibuprofen for distribution to adolescent/young adult patients after tooth extraction in the course of clinical practice
219521365|NCT06275191|OTHER|Usual care|No intervention.
218906655|NCT05966649|OTHER|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
218906656|NCT05966649|OTHER|Placebo|Matching placebo
219521366|NCT06383572|DRUG|Cyclophosphamide|Given by IV
219521367|NCT06383572|DRUG|Fludarabine phosphate|Given by IV
219521368|NCT06383572|DRUG|Decitabine|Given by IV
219521369|NCT06383572|DRUG|Dexamethasone|Given by mouth
218906657|NCT05837338|DRUG|BXP154|BXP154 will be self-administered topically following wound induction
218906658|NCT05837338|DRUG|Placebo|Placebo will be self-administered topically following wound induction
218906659|NCT03957148|BEHAVIORAL|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
218906660|NCT05918796|DRUG|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
218906661|NCT05918796|DRUG|Dexamethasone|dexamethasone
218906662|NCT00756106|DRUG|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
218906663|NCT00756106|OTHER|Imaging biomarker analysis|MRI
219039509|NCT06750783|DRUG|Atorvastatin|The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.
219039510|NCT06885645|DRUG|KH815 for injection|KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.
219039511|NCT02917031|DRUG|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
219039512|NCT02917031|DRUG|Sitagliptin|50 mg or 100 mg, gray capsule
219039513|NCT02917031|DRUG|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
219039514|NCT02917031|DRUG|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
219039515|NCT07096518|OTHER|ChatGPT-Integrated Lecture|This group received a structured and interactive educational lecture integrated with ChatGPT, an AI language model, enabling students to learn collaboratively through guided activities related to endotracheal suctioning. Students compared the information obtained from ChatGPT with evidence-based, up-to-date clinical guidelines and discussed the comparison results together in the classroom. The instructor provided guidance throughout the process.
219039516|NCT06499350|DRUG|FC084CSA+Tislelizumab combination (dose escalation)|Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
219039517|NCT06499350|DRUG|RP2D of FC084CSA+Tislelizumab combination (dose expansion)|RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
219521370|NCT06077565|OTHER|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
219613123|NCT00967330|DRUG|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
218906664|NCT00756106|RADIATION|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
219039518|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
219039519|NCT07108751|DEVICE|Endoscopy|Endoscopy will be performed to all patient
219039520|NCT06924320|DRUG|MET233 and MET097|For subcutaneous administration
219039521|NCT06924320|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
218906665|NCT00900978|BIOLOGICAL|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
218906666|NCT03806192|BEHAVIORAL|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
218906667|NCT03806192|OTHER|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
218906668|NCT03806192|OTHER|Questionnaire Administration|Ancillary studies
218906669|NCT00441623|BEHAVIORAL|observational|effect of protein-bound uremic retention solutes
218906670|NCT03324776|DRUG|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
218906671|NCT03139760|BEHAVIORAL|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
218906672|NCT04274816|DRUG|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
218906673|NCT03735836|OTHER|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
218906674|NCT02675907|DRUG|N1539|
218906675|NCT02675907|DRUG|Intravenous Placebo|
218906676|NCT00539981|BIOLOGICAL|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
219039522|NCT06924320|DRUG|MET233|For subcutaneous administration
219039523|NCT06924567|DIAGNOSTIC_TEST|Implant motion provocation CT|Implant Movement Analysis. A low dose CT scan is performed with the hip fixed in external rotation. Then another low dose CT scan is performed with the hip fixed in internal rotation.The CT scans are then overimposed to each other and implant motion in relation to host bone is visualized,
219039524|NCT06924515|PROCEDURE|Intercostal suture|止血完成后使用结扎缝合引线器夹持1-0规格的PDS可吸收缝线在主操作口的头侧上一肋间穿入，于副操作空使用双关节分离钳在胸腔内抓持缝线后将缝线从结扎缝合引线器脱离，此时在主操作口足侧下一肋间穿入结扎缝合引线器，在胸腔内由分离钳夹持缝线经结扎缝合引线器钩爪夹持后将缝线牵拉出胸腔外，以此依次行连续缝合共5次缝合引线操作后拉拢缝线将主操作口闭合，打结结束缝合完成肋间肌及壁层胸膜的缝合。
219039525|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
219039526|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
219521371|NCT06077565|OTHER|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
219521372|NCT06077565|OTHER|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
219521373|NCT06354270|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
218906677|NCT00539981|BIOLOGICAL|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
218906678|NCT05298488|BEHAVIORAL|Home office|Working from home
219039527|NCT06924554|BEHAVIORAL|Motivational Training Program|This study presents the protocol for a non-randomized controlled trial evaluating a motivational-based training program for pre-service Physical Education teachers, grounded in Self-Determination Theory and the circumplex model. The program, embedded in a Master's in Physical Education Teacher Education, consists of theoretical and practical training to foster motivating teaching styles and minimize demotivating ones. The study will involve at least 38 pre-service teachers, divided into an experimental group (n = 19) and a control group (n = 19). The experimental group will participate in a 14-hour training program combining theoretical and practical components. The control group will follow the standard Physical Education Teacher Education curriculum.
219039528|NCT06924203|PROCEDURE|AmaIgam|(AmaIgam group): 30 carious moIars, wiII be restored with (amaIgam).
219039529|NCT06924203|PROCEDURE|Stainless steel|A pre-formed stainless steel crown will be cemented over the carious molar without extensive tooth preparation or caries removal.
219521374|NCT06354270|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
219521375|NCT06137183|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
219521376|NCT06137183|DRUG|Placebo|Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
219521377|NCT05245695|OTHER|Observational study, no intervention|Observational study, no intervention
219521378|NCT03092856|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
219521379|NCT03092856|DRUG|Axitinib|Given PO
219521380|NCT03092856|OTHER|Laboratory Biomarker Analysis|Correlative studies
219521381|NCT03092856|OTHER|Placebo|Given IV
219521382|NCT02736656|DRUG|SPN-812|"Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months.~Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months."
218906679|NCT05298488|BEHAVIORAL|Office|Working at the office
218906680|NCT01611792|OTHER|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
218906681|NCT01611792|OTHER|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
218906682|NCT05252546|DRUG|pyrotinib tablet|single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
218906683|NCT05252546|DRUG|Montmorillonite Power|3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
219039530|NCT06918353|DIAGNOSTIC_TEST|Diagnosis and Severity Grading of AECOPD Disease|Diagnosis and severity grading of AECOPD disease, as well as assessment of traditional Chinese medicine syndromes
219521383|NCT06436781|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
219521384|NCT06436781|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
219521385|NCT06106555|BEHAVIORAL|Dialectibal Behaviour Therapy|Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
218906684|NCT05252546|DRUG|Loperamide|4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
218906685|NCT02313220|DRUG|Dapagliflozin|Oral use
218906686|NCT02313220|DRUG|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
218906687|NCT02313220|DRUG|Placebo|Oral and Subcutaneous use.
218906688|NCT00409539|DRUG|Placebo|Placebo, 2 week duration.
218906689|NCT00409539|DRUG|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
218906690|NCT00409539|DRUG|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
218906691|NCT03324490|PROCEDURE|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected."
218906692|NCT03324490|PROCEDURE|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure."
218906693|NCT03324490|DRUG|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
219039531|NCT06924216|PROCEDURE|alveolar bone grafting|"cancellous iliac crest bone will be harvested following the usual surgical procedure. For patients of group a-PRF, it was mixed with 1 cc of the supernatant previously collected, in order to obtain a cohesive bone graft, easier to manipulate.~The oral mucosal lining will be closed, and a membrane of PRF (PRF group) will be put over the suture line. The alveolar cleft will be then filled with cancellous iliac crest bone along its entire height. A new membrane of PRF will be placed over the bone graft, in order to enclose and protect it. Finally, muco-periosteal flaps will be advanced and sutured without tension over the alveolar crest"
219204419|NCT06744907|BIOLOGICAL|10% Povidone-Iodine Arm|A second application of surgical antisepsis with a topical povidone-iodine in the subdermal layer after making an incision.
219204420|NCT06744907|PROCEDURE|Saline Arm|An application of saline in the subdermal layer after making an incision.
219521386|NCT05432232|DEVICE|HistoSonics Investigational System|The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
219521387|NCT04968249|OTHER|Observational|Observational Cohort to understand risk factors for early COPD.
219521388|NCT04675177|DRUG|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
219613124|NCT02623725|BIOLOGICAL|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
218906694|NCT03324490|DRUG|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
218906695|NCT03324490|DRUG|Fentanyl|Neuro-axially injected
219613125|NCT02623725|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
219613126|NCT04565574|DRUG|E7090|Oral tablet.
218906696|NCT03324490|DRUG|Dexmedetomidine|Neuro-axially injected
218906697|NCT06293521|PROCEDURE|Pulpotomy|After the chamber is deroofed and coronal pulp is amputated using a round-end fissure bur in a high-speed handpiece with adequate water spray and light pressure until canal orifices were reached, The access cavity is flushed with sterile normal saline solution. Saline-wetted cotton pellets were placed for about 5 minutes over amputation sites applying moderate pressure to control pulpal hemorrhage. After discarding the pellets, blood oozing was present, MTA+ Cerkamed will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by application of glass ionomer cement.
218906698|NCT06293521|PROCEDURE|Partial Pulpectomy|"Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of Zinc oxide and eugenol.~The tooth with then be restored with stainless steel crown"
218906699|NCT00689312|DRUG|Enfalyte|Each patient will receive one 250 ml dose.
219039532|NCT06924216|PROCEDURE|alveolar bone grafting Plus Platelet rich fibrin|"the PRF group: centrifugation at 1300 rpm during 5 minutes, collection of 1 cc of the supernatant, and centrifugation at 1300 rpm during 3 minutes. Careful removal of the clot and separation from the red blood cell fraction with scissors.~the Platelet-rich fibrin will be added to the surgical site mixed with the iliac crest bone graft and it will also be used as a membrane before closure of the mucoperiosteal flap"
219039533|NCT05238883|DRUG|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
219039534|NCT05238883|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
219039535|NCT01076712|OTHER|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
219521389|NCT04675177|PROCEDURE|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
219521390|NCT00528281|DRUG|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
219521391|NCT00528281|DRUG|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
219521392|NCT01939197|DRUG|ABT-450/r/ABT-267|tablet
219521393|NCT01939197|DRUG|ABT-333|tablet
219521394|NCT01939197|DRUG|ribavirin|tablet
218906700|NCT00689312|DRUG|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
218906701|NCT00689312|DRUG|Pedialyte|Each patient will receive one 250 ml dose.
218906702|NCT00073658|DRUG|Citalopram|
218906703|NCT00073658|DRUG|Risperidone|
218906704|NCT00466063|DRUG|Deferasirox|
218906705|NCT03179566|BEHAVIORAL|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
219039536|NCT01076712|OTHER|Education Classes|Education Classes
219039537|NCT05774847|OTHER|No intervention|No intervention
219039538|NCT04620681|BIOLOGICAL|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
219039539|NCT04620681|DRUG|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
219039540|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
219039541|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
219039542|NCT06276634|OTHER|Acute Intermittent Hypoxia|During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
219039543|NCT06276634|OTHER|Sham-Acute Intermittent Hypoxia|During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
219039544|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
219039545|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
219521395|NCT04738032|OTHER|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
219521396|NCT01834963|DRUG|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
219613127|NCT04565574|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
218906706|NCT03179566|BEHAVIORAL|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
218906707|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
218906708|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
218906709|NCT00629044|BIOLOGICAL|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
219521397|NCT01834963|DRUG|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
219521398|NCT00643877|PROCEDURE|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
219521399|NCT00643877|PROCEDURE|surgery|radical surgery only
218906710|NCT00877136|DEVICE|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
218906711|NCT03034486|DRUG|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
218906712|NCT01130753|DRUG|Erlotinib|Erlotinib 150mg per day for 8 weeks
218906713|NCT02662972|DRUG|Botulinum Toxin Type A|
218906714|NCT02600481|PROCEDURE|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
218906715|NCT02600481|PROCEDURE|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
219521400|NCT00004376|DRUG|guanfacine|
219521401|NCT04615156|DRUG|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
219521402|NCT01536223|DRUG|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
219521403|NCT01536223|DRUG|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
219521404|NCT00182806|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
219521405|NCT00182806|DRUG|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
219521406|NCT02126865|DRUG|Placebo to BI 1060469|tablet
219521407|NCT02126865|DRUG|BI 1060469 Healthy|tablet
219521408|NCT02126865|DRUG|Placebo to BI 1060469 asthmatics|tablet
219521409|NCT02126865|DRUG|BI 1060469 asthmatics|tablet
219521410|NCT01316653|BEHAVIORAL|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
219521411|NCT01316653|BEHAVIORAL|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
219521412|NCT02451605|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
218906716|NCT05118191|OTHER|OOLER|Following the baseline block (first four weeks), participants will use the OOLER device to power a cooling mattress pad each night during sleep for four weeks.
218906717|NCT05118191|OTHER|EmbrWave|Following the baseline block (first four weeks), participants will use the Embr Wave 2 device to provide pulsed warm sensations to the inner wrist each night during sleep for four weeks.
218906718|NCT00525512|DRUG|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
218906719|NCT00525512|DRUG|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
218906720|NCT01863459|DRUG|Lisdexamfetamine Dimesylate|
218906721|NCT01863459|DRUG|placebo|
218906722|NCT03841110|DRUG|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
219521413|NCT02451605|PROCEDURE|Total knee replacement surgery.|Total knee replacement surgery.
219521414|NCT03992859|PROCEDURE|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
219521415|NCT02231645|DEVICE|STN DBS|The DBS device is turned on and off by the physician.
219521416|NCT03159156|BEHAVIORAL|Applied Tension|Described above.
219521417|NCT03159156|BEHAVIORAL|Respiration Control|Described above.
219521418|NCT03159156|BEHAVIORAL|Applied Tension/Respiration Control|Described above.
218906723|NCT03841110|DRUG|Nivolumab|Immune Checkpoint Inhibitor
218906724|NCT03841110|DRUG|Pembrolizumab|Immune Checkpoint Inhibitor
219521419|NCT03847558|DIAGNOSTIC_TEST|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
219521420|NCT00005778|DRUG|High-dose immunoablative therapy|"1. High dose cyclophosphamide for 4 days.~2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
219521421|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
219521422|NCT04232605|OTHER|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
219521423|NCT04232605|OTHER|Placebo|Receive intravenous infusion saline
219521424|NCT00745095|DRUG|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
219521425|NCT04010799|DRUG|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
219521426|NCT04010799|DRUG|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
219521427|NCT06495762|OTHER|e-health assesment|This study is purely observational and does not forsee any intervention but only observational assesment of parents' wellbeing
218906725|NCT03841110|DRUG|Atezolizumab|Immune Checkpoint Inhibitor
218906726|NCT03841110|DRUG|Cyclophosphamide|Lympho-conditioning agent
218906727|NCT03841110|DRUG|Fludarabine|Lympho-conditioning agent
218906728|NCT03841110|DRUG|IL-2|Biologic response modifier
218906729|NCT00356681|DRUG|AMG 706 placebo|Blinded placebo
218906730|NCT00356681|DRUG|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
219521428|NCT04925024|BIOLOGICAL|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
219521429|NCT04351178|BEHAVIORAL|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
219521430|NCT04351178|BEHAVIORAL|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
219521431|NCT04757259|DRUG|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams \[mg\] twice daily \[BID\]).
219521432|NCT04085666|DRUG|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
219521433|NCT04085666|OTHER|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
219521434|NCT00618163|DRUG|Meloxicam|
219613128|NCT04565574|DRUG|Rifampin 600 mg|Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
218906731|NCT00356681|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
218906732|NCT00356681|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
218906733|NCT01239511|DRUG|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
218906734|NCT04905550|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
218906735|NCT04905550|RADIATION|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
219613129|NCT02814344|DEVICE|Electrohysterography|
218906736|NCT01383603|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
219039546|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
219613130|NCT03732963|DRUG|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
218906737|NCT03133611|OTHER|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
218906738|NCT03133611|OTHER|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
218906739|NCT01596803|PROCEDURE|Taking of blood|Taking venous blood samples to analyse oxidant stress
218906740|NCT01596803|DIETARY_SUPPLEMENT|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
218906741|NCT01596803|DIETARY_SUPPLEMENT|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
219613131|NCT03732963|DRUG|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
219613132|NCT04183621|DIAGNOSTIC_TEST|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
218906742|NCT01596803|DIETARY_SUPPLEMENT|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
218906743|NCT02609958|DRUG|Varlitinib|"varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID"
218906744|NCT04268186|DEVICE|Direct tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
218906745|NCT04268186|DEVICE|Indirect tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
218906746|NCT04268186|DEVICE|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
218906747|NCT04268186|DEVICE|Sham tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
218906748|NCT04809012|BIOLOGICAL|STI-3031|STI-3031 is an anti-PD-L1 antibody
218906749|NCT04228263|DRUG|Hydroxychloroquine|400mg
219521435|NCT03288766|PROCEDURE|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
219521436|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
219521437|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
219613133|NCT03957044|OTHER|The education of sensory integration with vestibular education|"Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used."
218906750|NCT04228263|DRUG|Folic Acid|5 mg
218906751|NCT04228263|DRUG|Low-dose aspirin|75 mg
218906752|NCT00809016|RADIATION|3-dimensional conformal radiation therapy|
218906753|NCT00809016|RADIATION|fludeoxyglucose F 18|
218906754|NCT00809016|RADIATION|intensity-modulated radiation therapy|
218906755|NCT01439516|BEHAVIORAL|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
218906756|NCT03289208|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
218906757|NCT05110638|DRUG|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
219039547|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
219039548|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
219521438|NCT00958243|BIOLOGICAL|Placebo|Placebo
219613134|NCT01780701|PROCEDURE|Magnetic Resonance Spectroscopy Imaging with rectal probe|
218906758|NCT01784991|DRUG|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
218906759|NCT01784991|DRUG|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
218906760|NCT00662207|DEVICE|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
218906761|NCT00662207|PROCEDURE|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
218906762|NCT00632216|DRUG|Risedronate Sodium|
218906763|NCT04264858|DRUG|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
218906764|NCT04264858|DRUG|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
219039549|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
219039550|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
219039551|NCT02460640|DRUG|Morphine|
219039552|NCT02460640|DRUG|Ropivacaine|
219039553|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
219039554|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
219039555|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
218906765|NCT05256485|BEHAVIORAL|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
218906766|NCT00798200|OTHER|Exercise program|All exercise programs will include endurance and strength exercises.
219521439|NCT02200965|OTHER|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
218906767|NCT06435208|OTHER|Subgingival instrumentation|All the participants will undergo scaling and root planning with hand scalers, curettes and ultrasonic scaler.
218906768|NCT01169025|DRUG|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
218906769|NCT01169025|DRUG|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
218906770|NCT06021925|OTHER|Obstetrical history|Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.
218906771|NCT06021925|OTHER|Anti-HLA Antibody tests|Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.
218906772|NCT02249416|DRUG|Tipranavir (TPV) low|
218906773|NCT02249416|DRUG|Ritonavir (RTV) low|Norvir®
218906774|NCT02249416|DRUG|Tipranavir (TPV) high|Retrovir®
218906775|NCT02249416|DRUG|Ritonavir (RTV) high|
218906776|NCT02249416|DRUG|Zidovudine|
218906777|NCT02530346|DRUG|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
218906778|NCT02530346|DRUG|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
218906779|NCT01259141|DRUG|Moxifloxacin|0.4 Qd for 7days
219039556|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
219039557|NCT00214994|DRUG|Gabitril|
219521440|NCT06114407|DRUG|Baricitinib 2mg|Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
219521441|NCT06114407|DRUG|Tofacitinib 5 mg|Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
219521442|NCT06170268|OTHER|Routine Care Documentation|Routine Care Documentation
219521443|NCT04916938|BEHAVIORAL|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
219521444|NCT04916938|BEHAVIORAL|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
219521445|NCT04916938|BEHAVIORAL|Interview|History and perception of the mother's issues.
219521446|NCT04916938|BEHAVIORAL|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
219521447|NCT00298870|DRUG|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
219521448|NCT00298870|DRUG|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
218906780|NCT01259141|DRUG|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
218906781|NCT02507765|OTHER|Laboratory Biomarker Analysis|Correlative studies
218906782|NCT02507765|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218906783|NCT02507765|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
219039558|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
219521449|NCT06217172|DEVICE|RHEUPP App|RHEUPP App; Monthly RAPID3 response; General recommendations for managing Flare through App and Social Monitor for appropriate orientation; 3 month consultation by telehealth.
219521450|NCT06217172|OTHER|Usual Follow-up|Usual Care in Rheumatoid Arthritis Ambulatory Service
219521451|NCT02636816|DRUG|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
219521452|NCT05639634|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
218906784|NCT06296186|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy for PTSD
218906785|NCT00457717|DRUG|0.25 % atropine|
218906786|NCT00457717|DRUG|0.5 % atropine|
218906787|NCT00457717|PROCEDURE|0.25 % atropine+auricular acupoints|
218906788|NCT03353675|BIOLOGICAL|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
218906789|NCT03353675|DRUG|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
218906790|NCT03353675|DRUG|Nivolumab|360 mg IV administration every 3 weeks
219521453|NCT05639634|OTHER|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
218906791|NCT04670341|OTHER|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
218906792|NCT04670341|OTHER|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
218906793|NCT05539066|DEVICE|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
218906794|NCT01938079|DRUG|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
218906795|NCT01938079|OTHER|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
219039559|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
219039560|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
219521454|NCT05639634|DIETARY_SUPPLEMENT|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
219521455|NCT03481205|DEVICE|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
219521456|NCT03571048|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
219521457|NCT03571048|BEHAVIORAL|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
219521458|NCT00963209|DRUG|tamoxifen citrate|
219521459|NCT00963209|OTHER|laboratory biomarker analysis|
219521460|NCT00963209|OTHER|pharmacological study|
219521461|NCT01143857|DRUG|Varenicline|Varenicline 2.0 mg/day or Placebo
219521462|NCT00058292|BIOLOGICAL|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
219521463|NCT00058292|BIOLOGICAL|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
219521464|NCT00058292|DRUG|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
219039561|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
219039562|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
219521465|NCT00058292|DRUG|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
219521466|NCT00058292|DRUG|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
218906796|NCT05354817|DRUG|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
218906797|NCT03649542|OTHER|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
218906798|NCT05075330|BEHAVIORAL|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
218906799|NCT05449821|DIAGNOSTIC_TEST|Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum and saliva samples will be collected from both groups for biochemical analysis.
218906800|NCT03524430|PROCEDURE|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at \~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
219521467|NCT00058292|DRUG|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
218906801|NCT04520607|DRUG|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
218906802|NCT04520607|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
218906803|NCT03217708|DEVICE|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
218906804|NCT01777074|OTHER|Data collection|Questionnaire, Vaccination book
218906805|NCT04028713|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
218906806|NCT04028713|PROCEDURE|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
218906807|NCT04028713|DRUG|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
218906808|NCT01078610|BIOLOGICAL|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
218906809|NCT02362724|DEVICE|Sapphire|silicone hydrogel contact lens
218906810|NCT02362724|DEVICE|Pearl|silicone hydrogel contact lens
218906811|NCT02025179|DRUG|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
218906812|NCT02025179|DEVICE|Vibration|Vibration 10 min/day for 12 months
218906813|NCT00402168|DRUG|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
218906814|NCT00402168|DRUG|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
218906815|NCT00402168|DRUG|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
218906816|NCT01854359|DRUG|Idebenone|
219364942|NCT04547322|OTHER|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
219364943|NCT04952623|OTHER|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
219521468|NCT00058292|PROCEDURE|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
218906817|NCT03146611|DIAGNOSTIC_TEST|nCD64|neutrophil CD64
218906818|NCT03146611|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
218906819|NCT02961608|DRUG|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
219521469|NCT00058292|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
218906820|NCT00656929|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
218906821|NCT00656929|OTHER|Placebo|Placebo tablets
218906822|NCT05853341|DRUG|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
218906823|NCT05853341|DRUG|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
218906824|NCT02435004|DEVICE|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
218906825|NCT01128049|BEHAVIORAL|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
219521470|NCT04029610|PROCEDURE|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
219521471|NCT04029610|DRUG|lidocaine and adrenalin|lidocaine and adrenalin
218906826|NCT01128049|PROCEDURE|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
218906827|NCT01128049|DRUG|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
218906828|NCT05182723|PROCEDURE|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
218906829|NCT02783365|BEHAVIORAL|Photo-elicitation and online group support|See above information.
218906830|NCT04234620|DRUG|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
218906831|NCT00707785|DIETARY_SUPPLEMENT|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
218906832|NCT06042959|OTHER|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
218906833|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
218906834|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
218906835|NCT03243136|OTHER|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
218906836|NCT02338726|OTHER|Gynecological examination|Comparison of questionnaires and gynecological examination
219521472|NCT04029610|DRUG|lidocaine and arterial blockage|lidocaine and arterial blockage
219521473|NCT01188746|BEHAVIORAL|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
218906837|NCT00358930|DRUG|ARQ 501|
218906838|NCT03847844|BIOLOGICAL|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
218906839|NCT03847844|OTHER|Placebo|Normal saline
218906840|NCT03073421|OTHER|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
218906841|NCT00928902|DRUG|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
218906842|NCT00928902|BIOLOGICAL|melanoma vaccine|six melanoma vaccines given over a 6-week period
219613135|NCT04385017|OTHER|COVID-19 patients|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
218906843|NCT01102036|OTHER|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
218906844|NCT01102036|OTHER|Yoghurt without probiotics|Yoghurt without probiotics
218906845|NCT04406766|DEVICE|Connected nutrition pump system|"For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution."
218906846|NCT01315171|DIETARY_SUPPLEMENT|Medium chain triglycerides|4 tablespoons/day for 2 weeks
219039563|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
219039564|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
219039565|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
219039566|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
219521474|NCT06232252|DRUG|BI 765423|BI 765423
219521475|NCT06232252|DRUG|Placebo matching BI 765423|Placebo matching BI 765423
219521476|NCT00455351|DRUG|Vorinostat|Increasing dosing, phase I
219521477|NCT05745805|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
219039567|NCT00000826|DRUG|Clarithromycin|
219039568|NCT00000826|DRUG|Rifabutin|
219613136|NCT02548143|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
219613137|NCT00471679|DRUG|ethanol|
219613138|NCT00366431|DRUG|MOA-728|
219613139|NCT05393167|DEVICE|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
219613140|NCT06772233|DRUG|regorafenib combined with envafolimab|"-Regorafenib: Specification: 40 mg/tablet Dosage: 120 mg, taken orally once daily for 3 weeks, followed by 1 week off, until disease progression or intolerable toxicity occurs.~* Envafolimab:~Specification: 200 mg/vial Dosage: 200 mg, administered via subcutaneous injection once every 2 weeks, until disease progression or intolerable toxicity occurs."
219521478|NCT02968186|BEHAVIORAL|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
218906847|NCT04070365|DEVICE|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
218906848|NCT00855621|PROCEDURE|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
218906849|NCT00395746|DRUG|sulfonylurea|SU agent
219613141|NCT06772233|DRUG|Control Group|The governing principle for physician decision-making in the control group was selection based on prior medication tolerability, genotype, etc.: a. Continued maintenance therapy with the originally effective TKI at the same dose: The patient achieved at least stable disease (SD) or partial response (PR) during prior treatment, with progression-free survival (PFS) exceeding 6 months, and the adverse reactions were tolerable. b. Combination therapy with two TKIs: Different drugs were selected for maintenance based on distinct actionable mutations identified in the patient's tissue or peripheral blood genetic testing, OR a combination of drugs previously effective and well-tolerated was used, OR the combination therapy was chosen by referencing past tolerability.
218906850|NCT00395746|DRUG|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
218906851|NCT00395746|DRUG|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
218906852|NCT02982564|BEHAVIORAL|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
218906853|NCT02982564|BEHAVIORAL|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
218906854|NCT02804334|PROCEDURE|Psychiatric Questionnaires|
218906855|NCT02804334|PROCEDURE|Blood draw|
218906856|NCT05279859|DRUG|ERAS-007|Administered orally
218906857|NCT05279859|DRUG|ERAS-601|Administered orally
218906858|NCT05279859|DRUG|Gilteritinib|Administered orally
218906859|NCT00871910|DRUG|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
218906860|NCT00871910|DRUG|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
218906861|NCT00871910|DRUG|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
218906862|NCT00871910|DRUG|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
218906863|NCT00871910|DRUG|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
218906864|NCT00871910|DRUG|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
218906865|NCT00871910|DRUG|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
218906866|NCT06524102|DEVICE|Magnetic Activated Cell Sorting|"The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use."
218906867|NCT04903561|DEVICE|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
218906868|NCT02747186|DRUG|Lidocaine|Intraoral maxillary field block
218906869|NCT00582361|PROCEDURE|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
219521479|NCT01641445|DRUG|Topiramate|Topiramate (200 mg daily)
219521480|NCT01641445|DRUG|Placebo|"Matching placebo capusules (sugar pills"
219039569|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
219039570|NCT00000826|DRUG|Dapsone|
219039571|NCT00000826|DRUG|Fluconazole|
219039572|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
218906870|NCT00582361|DEVICE|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
218906871|NCT02365155|OTHER|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
218906872|NCT02365155|OTHER|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
218906873|NCT02365155|OTHER|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
218906874|NCT02365155|OTHER|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
218906875|NCT02365155|OTHER|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
218906876|NCT02365155|OTHER|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
218906877|NCT00016328|DRUG|temsirolimus|Given IV
218906878|NCT00016328|OTHER|laboratory biomarker analysis|Correlative studies
218906879|NCT00016328|OTHER|pharmacological study|Correlative studies
218906880|NCT03137992|DRUG|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
218906881|NCT03137992|DRUG|Test Product (tiotropium bromide inhalation powder)|Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
218906882|NCT03137992|DRUG|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
218906883|NCT06025006|OTHER|alternative to incarceration|place of respite with housing plus intensive follow-up
218906884|NCT02370420|BIOLOGICAL|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
218906885|NCT02370420|BEHAVIORAL|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
218906886|NCT03077542|PROCEDURE|haploidentical stem cell transplant|haploidentical stem cell transplant
218906887|NCT03077542|DRUG|Sirolimus|conditioning regimen
218906888|NCT03077542|DRUG|Alemtuzumab|conditioning regimen
218906889|NCT03077542|DRUG|Pentostatin|conditioning regimen
218906890|NCT03077542|DRUG|Cyclophosphamide|conditioning regimen
218906891|NCT03077542|DRUG|Hydroxyurea|conditioning regimen
218906892|NCT03077542|DRUG|Filgrastim|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
218906893|NCT01333293|DRUG|injections|subcutaneous injections
218906894|NCT05983419|PROCEDURE|ESD|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
218906895|NCT00236353|DRUG|risperidone|
218906896|NCT00795704|DRUG|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
218906897|NCT00795704|DRUG|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
218906898|NCT05287386|DRUG|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
218906899|NCT03980730|DRUG|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
218906900|NCT03980730|DRUG|Placebo|Matching placebo capsule administered orally, once daily
218906901|NCT00286585|DRUG|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
218906902|NCT00286585|DRUG|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
219039573|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
219364944|NCT02155933|OTHER|Blood sampling|Blood sampling for later hormone measurements
219364945|NCT02327260|BEHAVIORAL|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
219364946|NCT02327260|BEHAVIORAL|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
219364947|NCT06024525|DEVICE|Paclitaxel-Coated Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
219364948|NCT06024525|DEVICE|Paclitaxel-Releasing Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
219364949|NCT02987894|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
219364950|NCT05133830|DRUG|Obeticholic acid|OCA will be administered
219364951|NCT05133830|DRUG|Linerixibat|Linerixibat will be administered
218906903|NCT01300728|DRUG|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
218906904|NCT01300728|OTHER|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
218906905|NCT05161923|PROCEDURE|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
218906906|NCT01949974|DRUG|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
218906907|NCT01949974|OTHER|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
218906908|NCT02392806|DEVICE|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
218906909|NCT02392806|DEVICE|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B\&B Bubbler at time of extubation
218906910|NCT00622037|DRUG|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
219039574|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
219039575|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
219039576|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
219364952|NCT04548557|BIOLOGICAL|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
218906911|NCT00622037|DRUG|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
219039577|NCT03100786|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
219039578|NCT03100786|OTHER|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
219039579|NCT03369717|DRUG|Amoxi Clavulanate|Postoperative antibiotics
219039580|NCT05929235|DRUG|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
219039581|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
219364953|NCT04213404|DRUG|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
219364954|NCT04213404|DRUG|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
219364955|NCT06337435|OTHER|multi-looped wire|using multi-looped wire as a retainer
219364956|NCT05072444|DRUG|QPX7728|beta lactamase inhibitor
219364957|NCT05072444|DRUG|QPX2014|antibiotic
219364958|NCT01496157|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
219364959|NCT03526289|BIOLOGICAL|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
219364960|NCT03526289|OTHER|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
219364961|NCT04523974|PROCEDURE|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
219364962|NCT03233932|DRUG|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
219364963|NCT03233932|DRUG|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
219364964|NCT01734876|BEHAVIORAL|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
219364965|NCT01734876|BEHAVIORAL|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
219364966|NCT03757884|BEHAVIORAL|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
219364967|NCT03757884|BEHAVIORAL|Diagnostic Checklist|Checklist reminder for diagnosis
219364968|NCT03757884|BEHAVIORAL|Noise cancelling headphones|Noise cancelling headphones
219364969|NCT03757884|BEHAVIORAL|Privacy tablescreen|Privacy Tablescreen
219364970|NCT03757884|BEHAVIORAL|Diagnostic assistance application|Diagnostic assistance application
219364971|NCT04288024|BEHAVIORAL|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
219364972|NCT01424592|DEVICE|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
219364973|NCT02245048|OTHER|Carotid Intima-Media Thickness (CIMT)|
218906912|NCT06152510|OTHER|Virtual Reality Rehabilitation System|In a single session to evaluate postural control, both children with ASD and typically developing peers will participate in an activity utilizing the Virtual Reality Rehabilitation System (VRRS) in conjunction with a stabilometric balance platform. During the assessment task, participants will stand on the balance platform with their eyes open, focusing on a fixed point displayed on the VRRS screen for a duration of one minute. This process will be repeated three times for each participant. The combined use of VRRS and the stabilometric balance platform aims to provide a comprehensive evaluation of postural control abilities in both groups, allowing for the observation and measurement of potential differences in stability and balance performance between children with ASD and their neurotypical counterparts.
218906913|NCT00395356|BEHAVIORAL|calorie controlled diet|
218906914|NCT06173414|OTHER|No intervention measures|No intervention measures
218906915|NCT00880620|DRUG|Placebo|Placebo
218906916|NCT00880620|DRUG|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
218906917|NCT00880620|DRUG|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
218906918|NCT00880620|DRUG|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
219521481|NCT01974141|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
219521482|NCT01974141|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
219521483|NCT01264120|BEHAVIORAL|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
219521484|NCT06522958|DIETARY_SUPPLEMENT|High Dissolving Transitional Food|Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
219521485|NCT01624766|BIOLOGICAL|Anakinra|Given SC
219521486|NCT01624766|BIOLOGICAL|Denosumab|Given SC
218906919|NCT00880620|DRUG|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
219613142|NCT06770036|BEHAVIORAL|Implementation Resource Package for Caregivers|The implementation resource package for caregivers is a set of resources provided to caregivers that aims to support their use of evidence-based behavior management practices and home-school communication strategies.
219613143|NCT02795247|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
218906920|NCT02536898|OTHER|Fracture Liaison Service|
218906921|NCT02536898|OTHER|Current treatment|
218906922|NCT03125226|DEVICE|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
219521487|NCT01624766|DRUG|Everolimus|Given PO
219521488|NCT04757415|OTHER|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
219521489|NCT04757415|OTHER|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
219521490|NCT01968382|DRUG|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
219521491|NCT01968382|DRUG|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
219521492|NCT00950872|DEVICE|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
219613144|NCT06208540|DRUG|Cerebrolysin|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
219613145|NCT06208540|OTHER|olfactory and gustatory trainings|olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
219613146|NCT02552901|DRUG|0.1 mg/kg ICG Dose|least efficacious dose
218906923|NCT05006235|DRUG|Epinephrine Inhalation Solution|
219521493|NCT02471066|DEVICE|rTMS|"* Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
219613147|NCT02552901|DRUG|0.5 mg/kg ICG dose|per package insert
218906924|NCT05006235|DRUG|Salbutamol|
218906925|NCT05006235|DRUG|Saline Inhalants|
218906926|NCT01467011|DRUG|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
218906927|NCT00301808|DRUG|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
218906928|NCT00301808|DRUG|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
218906929|NCT00301808|DRUG|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
218906930|NCT00301808|RADIATION|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
218906931|NCT03798613|DEVICE|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
218906932|NCT03798613|DEVICE|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
218906933|NCT06102096|BEHAVIORAL|Culturally Adapted iCBT|A culturally adapted iCBT targeting mild to moderate mental health problems among Arabic-speaking refugee and migrant youth.
218906934|NCT04494074|OTHER|External Cooling|External Cooling
218906935|NCT02620839|DRUG|Alpelisib|Given PO
218906936|NCT02620839|DRUG|Cisplatin|Given IV
218906937|NCT03212898|OTHER|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
218906938|NCT03332459|DRUG|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
219613148|NCT00619723|DRUG|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
218906939|NCT03332459|DRUG|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
218906940|NCT05971550|OTHER|Absence of antibiotic treatment|Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
218906941|NCT05971550|DRUG|Ceftriaxone|Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
218906942|NCT02186275|DRUG|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"* Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
219521494|NCT00913107|DRUG|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days."
219521495|NCT00913107|DRUG|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days."
218906943|NCT02186275|DRUG|Vitamin D3 800 UI/day then 800 UI/day|"* Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
218906944|NCT06443372|OTHER|Clinical periodontal measurements, GCF sampling|"Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
218906945|NCT03444610|BIOLOGICAL|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
219521496|NCT05876195|BIOLOGICAL|Keyhole-Limpet Hemocyanin|Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)
219521497|NCT05876195|DRUG|Saline|Placebo intervention.
219521498|NCT05876195|DRUG|Montanide ISA 51 VG|Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant
219521499|NCT05876195|DRUG|Alhydrogel|Alhydrogel is a vaccine adjuvant
219521500|NCT00192608|DRUG|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
219521501|NCT00192608|DRUG|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
218906946|NCT05924880|DRUG|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
218906947|NCT00194805|BEHAVIORAL|Telehealth for Diabetes Self Management|
218906948|NCT00194805|OTHER|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
218906949|NCT05893862|DRUG|MK-8189|Oral Tablet
218906950|NCT05893862|DRUG|Moxifloxacin|Oral Tablet
218906951|NCT05893862|DRUG|Placebo|Oral Tablet
219039582|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219039583|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219039584|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
219521502|NCT01032369|OTHER|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
219521503|NCT01032369|OTHER|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
219521504|NCT06317246|GENETIC|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
219613149|NCT00619723|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
218906952|NCT05915299|DEVICE|OCS Heart|"The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
218906953|NCT06895928|DRUG|SHR-A2102|SHR-A2102 for injection.
218906954|NCT06895928|DRUG|Bevacizumab Injection|Bevacizumab injection.
218906955|NCT06895928|DRUG|Adebelimab Injection|Adebelimab injection.
218906956|NCT06895928|DRUG|Ametinib Mesylate Tablets|Ametinib mesylate tablets.
218906957|NCT06895928|DRUG|Osimertinib Mesylate Tablets|Osimertinib mesylate tablets.
218906958|NCT06841731|DRUG|HRS-8427|HRS-8427 for injection.
218906959|NCT06841731|DRUG|Meropenem|Meropenem for injection.
218906960|NCT06937528|BIOLOGICAL|Extracellular vesicles|Intra-articular extravascular vesicles injection.
218906961|NCT02429830|DEVICE|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
218906962|NCT04306263|DIETARY_SUPPLEMENT|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
218906963|NCT04306263|DIETARY_SUPPLEMENT|Standard formula|Infants receiving a standard infant formula.
218906964|NCT04306263|DIETARY_SUPPLEMENT|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
218906965|NCT04406298|PROCEDURE|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
218906966|NCT04406298|PROCEDURE|Large Volume Paracentesis|Large Volume Paracentesis \> 5litres
218906967|NCT01893463|DEVICE|iTClamp50|
218906968|NCT03189368|DEVICE|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~* Interpolar distance for the first left ventricular pulse \>30mm (i.e. non-sequential poles used)~* Nearly simultaneous (Δt=5msec) second left ventricular pulse and~* Threshold of ≤3.5V@0.5msec"
218906969|NCT02426580|BEHAVIORAL|wechat|The wechat model of dietary education every 1 month by cellphone
218906970|NCT02686372|BIOLOGICAL|TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
219521505|NCT00113425|DEVICE|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
218906971|NCT02686372|BIOLOGICAL|No intervention and TCR-T (at crossover)|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
218906972|NCT00034307|DRUG|sitaxsentan sodium|
218906973|NCT01414634|BIOLOGICAL|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
218906974|NCT03046186|DIAGNOSTIC_TEST|Mixed meal test with double tracer technique|
218906975|NCT05515965|OTHER|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
218906976|NCT05515965|OTHER|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
218906977|NCT04070781|DRUG|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
218906978|NCT04070781|DRUG|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
218906979|NCT02202421|BEHAVIORAL|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
218906980|NCT03901170|DRUG|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
219521506|NCT01139164|DRUG|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
219521507|NCT01139164|DRUG|Regimen B|Other malignancies not addressed in A or C
219521508|NCT01139164|DRUG|Regimen C|B-Cell Lymphomas
219521509|NCT02187978|OTHER|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
219521510|NCT02187978|OTHER|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
219613150|NCT00619723|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
219521511|NCT01933607|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
219521512|NCT04531228|PROCEDURE|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
219613151|NCT03901976|DEVICE|bed exit detection|bed exit detection to avoid patients fall
219613152|NCT07095803|DRUG|Ivonescimab (20mg/kg Q3W)|Patients received intravenous everciximab (20mg/kg Q3W) within 1 week before and after radiofrequency ablation.
218906981|NCT01048879|PROCEDURE|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
218906982|NCT01048879|PROCEDURE|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
218906983|NCT05482308|DRUG|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
218906984|NCT05482308|DRUG|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
218906985|NCT05433246|BEHAVIORAL|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
218906986|NCT05397327|OTHER|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
219039585|NCT05653960|OTHER|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
219039586|NCT06237140|OTHER|PNF+ biofeedback exercise group|Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
219521513|NCT02319928|PROCEDURE|Colonoscopy|
219521514|NCT05256628|OTHER|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
219521515|NCT05256628|OTHER|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
219521516|NCT03104738|OTHER|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
219521517|NCT02847806|BIOLOGICAL|Estradiol (Insulin sensitivity)|
219521518|NCT02847806|BIOLOGICAL|Testosterone (Insulin sensitivity)|
219521519|NCT03055949|BEHAVIORAL|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
219521520|NCT01737190|OTHER|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
219613153|NCT07095803|PROCEDURE|radiofrequency ablation|Patients received radiofrequency treatment for less than three lesions.
219039587|NCT02914496|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
219039588|NCT04784585|BEHAVIORAL|Enhanced Education|"The Enhanced Education intervention option seeks to: 1) enhance understanding of personal health-behavior links, 2) improve health literacy by checking the adequacy of participant understanding, and 3) remind participant of important elements of Behavioral Obesity Treatment (BOT) dietary goals."
219521521|NCT00417209|DRUG|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
219521522|NCT00417209|DRUG|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
218906987|NCT02760459|DRUG|Dexamethasone|
219521523|NCT00417209|DRUG|Capecitabine|administered orally from Day 1 to Day 14 q3w
219521524|NCT02363790|PROCEDURE|LVHR PFC|Information included in arm description
218906988|NCT02760459|DRUG|Normal saline solution|
218906989|NCT03893396|DEVICE|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
218906990|NCT04156061|OTHER|Delivery of CT scan results|Method of results delivery - verbal or visual.
218906991|NCT05195164|OTHER|No intervention|There was no intervention
219521525|NCT02363790|PROCEDURE|Bridging LVHR|Information included in arm description
218906992|NCT05835765|DEVICE|Dynamic Elastometric Body in Preterm Newborns|The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
218906993|NCT00268918|DRUG|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
218906994|NCT00268918|DRUG|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
219521526|NCT01973049|DRUG|Daclatasvir|
219521527|NCT01973049|DRUG|Asunaprevir|
219521528|NCT01973049|DRUG|BMS-791325|
219521529|NCT01973049|DRUG|Ribavirin|
218906995|NCT03242486|DEVICE|toric intraocular lens|
218906996|NCT05041231|DEVICE|Photobiomodulation therapy (PBT)|"Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm)."
218906997|NCT05041231|DEVICE|Sham Photobiomodulation therapy (Sham PBT)|Similar to active PBT, however, the device will not provide the active electromagnetic waves)
218906998|NCT04687657|DRUG|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
218906999|NCT03707795|DRUG|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
218907000|NCT04233008|DEVICE|Foley catheter length|see arm description
218907001|NCT01103167|BEHAVIORAL|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
218907002|NCT01479101|OTHER|MammaPrint 70-gene expression profile|
218907003|NCT01479101|OTHER|BluePrint 80 gene expression profile|
218907004|NCT01991392|DEVICE|Nasogastric tube|For nasogastric decompression.
218907005|NCT01991392|DEVICE|No nasogastric tube|For nasogastric decompression.
219364974|NCT02151344|BIOLOGICAL|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
219364975|NCT02151344|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
219364976|NCT02984800|OTHER|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
219364977|NCT02984800|OTHER|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
219364978|NCT02984800|OTHER|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
219364979|NCT03530384|OTHER|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
219364980|NCT03530384|OTHER|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
219364981|NCT03283202|DRUG|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
219521530|NCT01973049|DRUG|Placebo matching Ribavirin|
219521531|NCT01759290|DEVICE|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
219364982|NCT03283202|DRUG|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
219364983|NCT03283202|DRUG|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
219364984|NCT03283202|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
219364985|NCT03283202|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
219364986|NCT03751267|PROCEDURE|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
218907006|NCT01235091|BEHAVIORAL|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
218907007|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
219521532|NCT04374084|OTHER|Moxibustion plus Cupping|"Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes."
219521533|NCT01148082|PROCEDURE|Self administered Surveys|
219521534|NCT01148082|PROCEDURE|Interviews|
219521535|NCT03080649|DEVICE|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
219521536|NCT03080649|DEVICE|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
219521537|NCT01353495|DEVICE|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
219521538|NCT01353495|OTHER|Wound Debridement|Wounds debrided in both arms of study
219521539|NCT00406848|DRUG|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
219521540|NCT00406848|DRUG|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
219521541|NCT03605238|BIOLOGICAL|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
219521542|NCT01722448|DIETARY_SUPPLEMENT|Choline|4 capsules with 480 mg choline per day
219521543|NCT01722448|DIETARY_SUPPLEMENT|Placebo|
219521544|NCT02068040|DIETARY_SUPPLEMENT|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
218907008|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
218907009|NCT04863170|PROCEDURE|orthognathic surgery|surgical intervention of the maxilla and / or mandible that includes orthodontic treatment before and after surgery
218907010|NCT05448495|OTHER|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
219521545|NCT00847548|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
219521546|NCT00847548|BEHAVIORAL|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
219521547|NCT00276757|DRUG|leucovorin calcium|
219521548|NCT00276757|DRUG|methotrexate|
219521549|NCT00276757|DRUG|prednisolone|
218907011|NCT05448495|OTHER|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane
219521550|NCT00276757|DRUG|vinblastine sulfate|
219521551|NCT04588753|OTHER|active isolated stretch|"Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
218907012|NCT04190602|DEVICE|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
218907013|NCT00416624|DRUG|darbepoetin alfa|
218907014|NCT00416624|DRUG|epoetin alfa|
218907015|NCT00416624|PROCEDURE|fatigue assessment and management|
218907016|NCT00416624|PROCEDURE|quality-of-life assessment|
218907017|NCT03147846|PROCEDURE|delayed cord clamping|delay of cord clamping for 60 seconds
218907018|NCT03147846|PROCEDURE|cord milking|active cord milking 5 times
218907019|NCT06260566|DRUG|N-Acetylcysteine|"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."
218907020|NCT01095640|DRUG|adapalene 0.3% topical gel|once a day, 84 days
218907021|NCT03876717|DRUG|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
218907022|NCT03876717|DRUG|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
218907023|NCT01019187|PROCEDURE|Quality-of-Life Assessment|Ancillary Studies
218907024|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
218907025|NCT01019187|OTHER|Placebo|Given orally
218907026|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
218907027|NCT01019187|PROCEDURE|Sleep Disorder Therapy|
218907028|NCT01019187|DRUG|Armodafinil|Given orally
218907029|NCT01019187|PROCEDURE|Quality-of-life assessment|Ancillary studies
218907030|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
219364987|NCT05821361|DRUG|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
219364988|NCT02626676|OTHER|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
219364989|NCT04474327|DRUG|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
219364990|NCT05034640|PROCEDURE|Conventional multiport thoracoscopic surgery|Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
219364991|NCT05034640|PROCEDURE|Single port site thoracoscopic surgery|Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
219364992|NCT01487421|DRUG|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
218907031|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
218907032|NCT01019187|PROCEDURE|Management of Therapy|
218907033|NCT01019187|PROCEDURE|Sleep disorder therapy|
218907034|NCT01019187|PROCEDURE|cognitive assessment|
218907035|NCT01019187|PROCEDURE|Quality of Life assessment|Ancillary Studies
218907036|NCT01019187|OTHER|Questionnaire Administration|Ancillary studies
218907037|NCT01019187|OTHER|Placebo|Given orally
218907038|NCT01019187|PROCEDURE|Fatigue assessment and management|
218907039|NCT01019187|PROCEDURE|Management of therapy and complications|
218907040|NCT01019187|PROCEDURE|Sleep disorder therapy|
218907041|NCT01019187|DRUG|Armodafinil|Given orally
218907042|NCT01019187|PROCEDURE|Cognitive Assessment|
218907043|NCT01019187|PROCEDURE|Quality of Life Assessment|Quality of Life Assessment
218907044|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
218907045|NCT01019187|PROCEDURE|Fatifue assessment and management|
218907046|NCT01608711|BIOLOGICAL|AGS-1C4D4|Intravenous Infusion
218907047|NCT01608711|BIOLOGICAL|gemcitabine|Intravenous Infusion
218907048|NCT02660788|OTHER|Standard Reminder Postcard|
218907049|NCT02660788|OTHER|Family Physician Reminder Letter|
218907050|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
218907051|NCT00768989|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
218907052|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
218907053|NCT00768989|DRUG|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
218907054|NCT00768989|DRUG|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
218907055|NCT01753622|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
218907056|NCT02021201|DRUG|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
218907057|NCT02021201|DRUG|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
218907058|NCT06425861|DRUG|THB335 single dose|Single dose as oral capsule
218907059|NCT06425861|DRUG|Single dose placebo|Single dose as oral capsule
218907060|NCT06425861|DRUG|THB335 fasted/fed|Single dose fasted and fed as oral capsule
218907061|NCT06425861|DRUG|Placebo fasted/fed|Single dose fasted and fed as oral capsule
218907062|NCT06425861|DRUG|THB335 multiple dose|Multiple ascending doses oral capsule
218907063|NCT06425861|DRUG|Multiple dose placebo|Multiple doses oral capsule
219039589|NCT04784585|BEHAVIORAL|Self-Efficacy|"This intervention option is based on a previously established self-efficacy intervention for weight loss, which is a multi-component intervention for increasing self-efficacy. To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either prompt: 1) attainable intention setting related to dietary adherence (e.g., I will focus on eating mostly fruits/vegetables in my next meal/snack in order to take back control of my eating); 2) barrier identification for adhering to dietary goals along with a brief problem-solving exercise; 3) devising a small self-reward; OR 4) self-assessment of thoughts/behaviors that could interfere with dietary adherence in the next several hours with coping strategies (e.g., stimulus control, social support)."
219039590|NCT04784585|BEHAVIORAL|Motivation|"To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either: 1) guide participants in identifying values related to weight control (e.g., longevity, quality of life, being a role model) and connect those values to their behavior in the current moment.; 2) use a collaborative non-judgmental approach to explore the consequences of letting barriers drive behavior (e.g., Take a moment to consider the effect on your longevity if you let your preference for sweets determine your behavior.); 3) prompt participants to identify reasons for change, thereby eliciting change talk; OR 4) engage participants in a brief self-assessment of motivation for dietary adherence (i.e., On a scale of 1-10, how important to you is it to stick to your dietary goals today)."
219039591|NCT04784585|BEHAVIORAL|Self-Regulation|"There are 4 independent modules that prompt self-monitoring and self-awareness efforts: 1) advise participants to record everything that they eat before they eat it, with attention to eating in the subsequent few hours; 2) use the traffic light model to enhance awareness of dietary intake. This module provides the traffic light categories of foods (i.e., green=healthiest choices, yellow=sometimes choices, and red=rare choices), and asks participants to check-off foods that they intend to eat vs. stay away from in the next few hours; 3) advise participants to track portion sizes carefully and provide a portion size guide that is available to them until the following EMA survey; OR 4) provide a tutorial on noticing hunger/satiety cues and slowing down rate of eating, with an experiential exercise for use during their next eating episode."
219039592|NCT04784585|BEHAVIORAL|Generic Risk Alert (Active Comparator)|"Participants will be notified that the JITAI algorithm has determined heightened lapse risk in the following 2-3 hours (i.e., We have detected that your risk of lapsing from your weight loss diet is higher than usual and may require attention.)."
219521552|NCT04588753|OTHER|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2\. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
219521553|NCT00352690|DRUG|Paclitaxel poliglumex|
219521554|NCT00352690|DRUG|Carboplatin|
218907064|NCT03387670|DRUG|Simvastatin|"* One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months"
219521555|NCT00352690|RADIATION|External beam radiation therapy|
219521556|NCT04008784|DRUG|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
219521557|NCT04008784|DRUG|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
219521558|NCT01767428|DRUG|Paracetamol|500 mg immediate release paracetamol formulations
219521559|NCT05427383|DRUG|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
219521560|NCT05427383|DRUG|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
218907065|NCT03387670|DRUG|Placebo|"* One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months"
218907066|NCT02724358|PROCEDURE|TACE|iodized oil (5ml) + Pirarubicin (20mg)
219521561|NCT05427383|DRUG|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
219521562|NCT05427383|DRUG|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
219613447|NCT04774484|OTHER|High Intensity Interval Training|After the acclimatization session and assessment of eligibility, a graded exercise test (GXT) will be given to the participant. After checking their vitals, the HIIT program will be performed on recumbent cycles. The first two weeks of training will consist of a gradual ramp where subjects will perform a moderate intensity cycling program consisting of a 5-minute warm up followed by progressively longer continuous cycling starting at 15 minutes and progressing up to 30 minutes prior to starting the HIIT training. For the HIIT training subjects will perform 5 minutes of low to moderate steady state cycling to warm up. Following the warm up, the subjects will complete the 4x4 HIIT program. This will consist of 4 minutes of cycling at 85% of the subject's maximum heart rate (HR) followed by 4 minutes of a low intensity cycling period for recovery.
219613448|NCT03910985|DRUG|Duovent HFA|bronchodilation
219613449|NCT02223988|PROCEDURE|subglottic secretion removal|
219613450|NCT02756611|DRUG|Venetoclax|Tablets for oral administration
218907067|NCT02724358|DRUG|Rg3|20mg, BID, maintained though Month 12.
218907068|NCT02724358|OTHER|TACE + Rg3|
218907069|NCT02724358|PROCEDURE|protective therapy|standard liver protective therapy
218907070|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
218907071|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
218907072|NCT04532307|BEHAVIORAL|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
218907073|NCT04532307|BEHAVIORAL|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
218907074|NCT04532307|BEHAVIORAL|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
218907075|NCT04532307|BEHAVIORAL|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
219039593|NCT04784585|BEHAVIORAL|Online Behavioral Obesity Treatment|The online BOT consists of: (a) 12 weekly multimedia lessons for training in behavioral weight loss skills; (b) online tools for self-monitoring weight, diet, and physical activity; and (c) weekly automated text-based feedback on progress to date. Participants are given a goal of losing 1-2lbs per week to achieve a total weight loss of ≥10% of initial body weight. Participants are prescribed a calorie goal of 1200-1800 kcal/day tailored on initial weight. Participants are given guidelines to follow a lowfat or Mediterranean diet to meet the prescribed calorie goal. Participants are given a physical activity goal tailored on initial activity level that gradually increases to 200 min/wk of activity, emphasizing brisk walking as the primary form of activity. They also receive a primer in self-monitoring weight, diet, and physical activity. Participants are instructed to self-monitor and follow the prescribed diet for the 6-month study period.
219039594|NCT04926961|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
219039595|NCT04926961|DEVICE|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
219364993|NCT01487421|DRUG|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
219521563|NCT01621165|DRUG|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
219521564|NCT01621165|DRUG|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
219521565|NCT05962879|BEHAVIORAL|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
219521566|NCT02589171|DEVICE|Neo Close Abdominal Closure|Neo Close Abdominal Closure
219521567|NCT02589171|DEVICE|Carter Thomason Device|Carter Thomason Device
219521568|NCT04227639|PROCEDURE|T-piece trial|T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
219521569|NCT04227639|PROCEDURE|Pressure-support trial|Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
219521570|NCT04325100|BEHAVIORAL|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
219613451|NCT00784108|DEVICE|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
219613452|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
219613453|NCT01587157|PROCEDURE|capnography|
219613454|NCT05592457|DIAGNOSTIC_TEST|MSCT|multislice computed tomography
219613455|NCT00179881|DRUG|Carboplatin|
219613456|NCT00179881|DRUG|Thalomid|
219613457|NCT00179881|PROCEDURE|External Beam Radiation Therapy|
218907076|NCT03549975|DRUG|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
218907077|NCT02745197|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
219039596|NCT03564340|DRUG|Ubamatamab|Administered per the protocol
219039597|NCT03564340|DRUG|Cemiplimab|Administered per the protocol
219039598|NCT03564340|DRUG|Sarilumab|Administered per the protocol
219039599|NCT03564340|DRUG|Tocilizumab|Administered per the protocol
219364994|NCT04261530|BEHAVIORAL|Self-hypnosis/self-care|
219364995|NCT04261530|BEHAVIORAL|Music/self-care|
219364996|NCT04261530|BEHAVIORAL|Self-care|
219364997|NCT04261530|BEHAVIORAL|Psycho-education|
219364998|NCT02472847|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
219613458|NCT00100828|DRUG|irinotecan hydrochloride|
218907078|NCT02745197|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
219521571|NCT04325100|BEHAVIORAL|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
218907079|NCT05267080|DEVICE|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
218907080|NCT01323023|BEHAVIORAL|varies by project|
218907081|NCT01778790|DEVICE|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
218907082|NCT01157702|BIOLOGICAL|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
218907083|NCT00228280|PROCEDURE|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
218907084|NCT03065816|DRUG|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
219039600|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
218907085|NCT03065816|DRUG|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
218907086|NCT03070288|OTHER|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
219039601|NCT03783507|BEHAVIORAL|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
219039602|NCT03783507|BEHAVIORAL|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
219039603|NCT03783507|BEHAVIORAL|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
219039604|NCT03783507|BEHAVIORAL|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
219039605|NCT06365827|OTHER|observational study|no intervention of interest
219039606|NCT05087875|BEHAVIORAL|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
219521572|NCT00448175|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
219521573|NCT00448175|DRUG|Tolterodine|
218907087|NCT06325059|OTHER|Study of renal progenitors|Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
219521574|NCT05116670|OTHER||this is an observation study, no intervention is needed
219613459|NCT00857571|DRUG|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
219613460|NCT00857571|DRUG|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
219613461|NCT00857571|DRUG|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
219613462|NCT00857571|DRUG|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
219613463|NCT00857571|DRUG|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
218907088|NCT00965601|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
218907089|NCT05025839|OTHER|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
218907090|NCT01308541|DRUG|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
218907091|NCT01308541|DRUG|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
218907092|NCT01308541|DRUG|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
218907093|NCT02253914|DRUG|BILR 355 BS, solution|
218907094|NCT02253914|DRUG|BILR 355 BS, tablet|
218907095|NCT02253914|DRUG|Ritonavir|
219521575|NCT03657056|DEVICE|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
218907096|NCT02253914|DRUG|Placebo|
218907097|NCT03585660|PROCEDURE|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
218907098|NCT03585660|PROCEDURE|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
218907099|NCT03585660|DEVICE|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
218907100|NCT00204152|BEHAVIORAL|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
218907101|NCT00116103|DRUG|Tacrolimus Inhalation Aerosol|
218907102|NCT00435409|DRUG|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
218907103|NCT00435409|DRUG|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
219039607|NCT05087875|OTHER|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
219039608|NCT04844554|OTHER|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
219039609|NCT04844554|OTHER|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
219039610|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
219613464|NCT00857571|DRUG|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
219613465|NCT00857571|DRUG|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
219613466|NCT00857571|DRUG|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
219613467|NCT00857571|DRUG|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
219613468|NCT00857571|DRUG|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
218907104|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
218907105|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
218907106|NCT05836441|RADIATION|Exposure to white patches|Exposure to white patches
218907107|NCT05836441|RADIATION|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
218907108|NCT01553656|DRUG|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
218907109|NCT01553656|DRUG|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
218907110|NCT05635461|DRUG|CVN424|150 mg of either tablet or suspension formulation
218907111|NCT01666249|BIOLOGICAL|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
218907112|NCT04794855|DIAGNOSTIC_TEST|laboratory tests|routine laboratory tests and biomarkers tests
218907113|NCT05322798|PROCEDURE|High-frequency SCS|Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
218907114|NCT05322798|PROCEDURE|Low-frequency SCS|Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
218907115|NCT03860649|OTHER|Nordic Walking|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218907116|NCT03860649|OTHER|Jogging|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218907117|NCT03860649|OTHER|Dance|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218907118|NCT03860649|OTHER|Pilates Training|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
218907119|NCT04581278|DIAGNOSTIC_TEST|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
218907120|NCT03519074|DRUG|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
218907121|NCT06052475|DEVICE|Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
218907122|NCT06052475|DEVICE|Continued RV Pacing (Right Ventricular Pacing)|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
218907123|NCT03753334|COMBINATION_PRODUCT|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
218907124|NCT03753334|DIETARY_SUPPLEMENT|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
219039611|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
219039612|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
219039613|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
219521576|NCT01678547|DEVICE|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
219521577|NCT01678547|DEVICE|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
219521578|NCT01678547|OTHER|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
219521579|NCT03407365|BEHAVIORAL|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
219521580|NCT03407365|BEHAVIORAL|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
218907125|NCT04436991|DIAGNOSTIC_TEST|Blood sampling|"At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day)."
218907126|NCT04436991|DIAGNOSTIC_TEST|Sputum sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
219039614|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
219039615|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
219364999|NCT02472847|DRUG|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
219365000|NCT03561233|DRUG|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
219521581|NCT03947242|DRUG|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
219039616|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
219365001|NCT00221364|DRUG|Mass treatment with oral azithromycin to an entire village|
219365002|NCT01348230|OTHER|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
219365003|NCT00623831|BIOLOGICAL|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
219365004|NCT02562625|DRUG|Pembrolizumab|Powder solution for infusion
219365005|NCT02562625|RADIATION|Radiotherapy|24Gy
219365006|NCT00700856|DRUG|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
219365007|NCT00700856|DRUG|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
219365008|NCT02377102|PROCEDURE|Physical Therapy|12 weeks of supervised physical therapy.
219521582|NCT03806803|BIOLOGICAL|Lyophilized fecal microbiota transplant|15 capsules
219521583|NCT03806803|BIOLOGICAL|Lyophilized sterile fecal filtrate|15 capsules
219521584|NCT01798836|PROCEDURE|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
219521585|NCT01798836|PROCEDURE|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
219521586|NCT02701114|PROCEDURE|Proximal Adductor Canal Block|Continuous Nerve Block
219521587|NCT02701114|PROCEDURE|Distal Adductor Canal Block|Continuous Nerve Block
219521588|NCT02719522|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
219521589|NCT01113606|OTHER|Obagi New-Derm System|
219521590|NCT01113606|OTHER|Standard of Care|
219521591|NCT00425256|DRUG|Bremelanotide|
219521592|NCT00351845|BEHAVIORAL|Low carbohydrate diet (behavior)|
218907127|NCT04436991|DIAGNOSTIC_TEST|Hemoculture|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
218907128|NCT04436991|DIAGNOSTIC_TEST|Urine sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
218907129|NCT05884554|DRUG|PF-07817883|Experimental
218907130|NCT05344950|BEHAVIORAL|Audio + Radio (AURA)|Participants will receive personalized self-care information based on their symptoms and signs of complications (e.g., fatigue) from interacting with our voice assistant device, connected to a system that integrating the patient-reported outcome and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home.
218907131|NCT04474470|DRUG|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
218907132|NCT04474470|DRUG|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
218907133|NCT04474470|DRUG|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
218907134|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
218907135|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
218907136|NCT05070936|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
219521593|NCT02134522|DEVICE|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
219521594|NCT03424291|DRUG|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
219521595|NCT04582721|OTHER|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~* 1\) CON-SCS with Subcutaneous stimulation~* 2\) HF-SCS~* 3\) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
219521596|NCT04627376|OTHER|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
219521597|NCT02090439|DRUG|Silodosin|
219521598|NCT05277389|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
219521599|NCT05277389|OTHER|Sham Control|Practice of Movement task without START
219521600|NCT06149780|DEVICE|Patients treated with laser|Patients treated with laser with topical steroid Patients treated with laser with vehicle
219521601|NCT03264664|DRUG|E7386|Oral immediate release tablets.
219521602|NCT05231642|OTHER|Nutritional Interventional|Individualised postprandial glucose and vascular risk responses
219521603|NCT01570699|GENETIC|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
219521604|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
219521605|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
219521606|NCT00926744|BEHAVIORAL|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
219521607|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan + exercise group|Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
219521608|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan group|Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
219521609|NCT05052164|BEHAVIORAL|Active Comparator: Celiac controls group|Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
219521610|NCT03883607|DRUG|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
219521611|NCT03883607|DRUG|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
219521612|NCT06268522|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement: (MORE) group|Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
219521613|NCT06268522|BEHAVIORAL|Psychoeducation|Education on the neurobiology of pain, healthy eating, diet, sleep and stress
219521614|NCT04183881|DRUG|Brodalumab 210mg SC|210 mg, subcutaneous dosing, every 2 weeks
219521615|NCT04885127|OTHER|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
219521616|NCT01190293|DRUG|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
219521617|NCT04469153|OTHER|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
219521618|NCT07036094|OTHER|Manual breast milk expression|"Manual breast milk expression: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was suckling from one breast, milk was expressed from the other breast, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes.~The mothers' food records were analyzed for 3 days before the milk sample was taken and on the day the milk sample was taken."
219521619|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + Postural Correction Exercises|Physiotherapy exercises of Shoulder and Neck Strengthening + Postural Correction Exercises for shoulder and neck pain
219521620|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + soft tissue mobilization|Physiotherapy exercises of Shoulder and Neck Strengthening + soft tissue mobilization Exercises for shoulder and neck pain
219521621|NCT07035574|OTHER|Conventional Denture Teeth|Complete dentures fabricated using conventional techniques with prefabricated acrylic denture teeth.
218907137|NCT04875325|OTHER|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
218907138|NCT01853020|DRUG|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
219521622|NCT07035574|OTHER|3D Printed Denture Teeth|Complete dentures fabricated using additive manufacturing techniques with advanced resin materials.
219521623|NCT06925373|OTHER|Indoor Air Purification|An indoor air purifier with a dual HEPA/activated carbon filter, a usage tracker, and an indoor air quality monitor will be installed in public housing residences.
219521624|NCT06925373|OTHER|Neighborhood Improvements|Improved built environment (green space, sidewalks, street lights) and social environment (educational and workforce development programs, wrap-around social services, Internet access).
219521625|NCT06925373|OTHER|Housing Improvements|High-quality public housing
219521626|NCT06450002|OTHER|physical therapy|Tens and Hot packs for 20 minutes, ultrasound for 5 minutes on the back and back exercise in form of bridging exercise and core stability exercise
218907139|NCT01853020|DRUG|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
218907140|NCT05953532|OTHER|A1Control|diabetes self-management and diabetes technology education software
219521627|NCT02078700|OTHER|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
218907141|NCT02498925|BEHAVIORAL|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
218907142|NCT03891706|DRUG|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
218907143|NCT03891706|DRUG|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
218907144|NCT05511259|OTHER|exercise|Square stepping exercise
218907145|NCT05517135|OTHER|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
219039617|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
219039618|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
219039619|NCT00470288|PROCEDURE|bladder flap during cesarean section|
219039620|NCT03960502|DRUG|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
219039621|NCT03960502|DRUG|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
219521628|NCT06241430|DEVICE|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
218907146|NCT05517135|OTHER|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
218907147|NCT05517135|OTHER|Arm 3|"IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)"
218907148|NCT05517135|OTHER|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
218907149|NCT05517135|OTHER|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
218907150|NCT05208476|PROCEDURE|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
218907151|NCT06114121|PROCEDURE|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
218907152|NCT06114121|DRUG|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
218907153|NCT06114121|DRUG|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
218907154|NCT06114121|DRUG|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
219039622|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
219039623|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
219039624|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
219039625|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
219039626|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
219039627|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
218907155|NCT06288581|OTHER|Traditional toothbrush group|Children in this group will use a traditional brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a U shaped brush with a traditional toothpaste for another 30 days.
218907156|NCT06288581|OTHER|U shaped toothbrush group|Children in this group will use a U shaped brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a traditional brush with a traditional toothpaste for another 30 days.
218907157|NCT05120830|BIOLOGICAL|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
218907158|NCT05120830|OTHER|Normal Saline IV Administration|The administration of IV normal saline
218907159|NCT04101968|DIAGNOSTIC_TEST|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
218907160|NCT04101968|DIAGNOSTIC_TEST|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
218907161|NCT05749146|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
219039628|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
219039629|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
219521629|NCT06797726|BEHAVIORAL|Cognitive behavioral therapy|Session 1: Functional analysis, motivational approach and psycho-education (advantages/disadvantages of consumption ; effect of addiction on mental disorders and interaction ADHD/behavioral addiction) Session 2: Follow-up to psycho-education session 1, treatment plan Session 3: ADHD: compensation strategies; reducing distractibility distractibility Session 4: ADHD: calendar and organization worksheet Session 5: ADHD: mood disorders and emotions Session 6: Recognizing and managing emotions Session 7: Analysis of functional elements in addictive disorder addictive disorders in patients with ADHD Session 8: Risk situations, psycho-education (emotions) Session 9: Managing craving; analysis of the functional elements of of addiction Session 10: Relapse and relapse prevention, problem solving and social pressure
219521630|NCT06916858|DEVICE|home sleep test|Apnealink air
219521631|NCT01459874|BEHAVIORAL|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
219039630|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
219521632|NCT02295878|DIETARY_SUPPLEMENT|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
219521633|NCT02295878|DIETARY_SUPPLEMENT|Placebo|
219521634|NCT04751578|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
219521635|NCT01706926|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
219521636|NCT01706926|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
219521637|NCT01706926|BIOLOGICAL|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
219521638|NCT01706926|OTHER|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
219521639|NCT00814099|BEHAVIORAL|Team approach to sedation management|"The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance"
219521640|NCT00814099|BEHAVIORAL|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
219521641|NCT03941223|PROCEDURE|PECSII and paravertebral blocks|Regional anesthesia for mastectomy outcomes
219521642|NCT05189184|DRUG|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
219521643|NCT02051309|DRUG|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
219521644|NCT02051309|DRUG|Placebo|
219521645|NCT03654196|DRUG|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
219521646|NCT03654196|DRUG|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
219521647|NCT03267745|DIETARY_SUPPLEMENT|Amino Acid|23.7 g amino acid 3 times daily for 28 days
219521648|NCT03267745|DEVICE|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
218907162|NCT03760029|OTHER|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
218907163|NCT05973942|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
219039631|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
219039632|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
219521649|NCT03267745|OTHER|Placebo|Excipient-matched placebo 3 times daily for 28 days
219521650|NCT00775177|DRUG|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
219521651|NCT04872257|DRUG|Oral Vitamin D|Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
219521652|NCT04872257|PROCEDURE|NB-UVB Phototherapy|NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
219521653|NCT04872257|DRUG|Placebo|Administered orally daily for 6 months
219521654|NCT03208543|DEVICE|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
219521655|NCT00592098|DRUG|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
219521656|NCT00592098|DRUG|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
219521657|NCT00991445|PROCEDURE|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
219521658|NCT00991445|PROCEDURE|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
219521659|NCT01781598|DEVICE|Total knee arthroplasty (TKA) (Smith &Nephew®)|
219521660|NCT02510547|PROCEDURE|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
219521661|NCT02510547|PROCEDURE|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
219521662|NCT03229005|PROCEDURE|implant insertion|during surgery soft tissues will be measured
219521663|NCT03229005|PROCEDURE|operculectomy|during second surgery soft tissues will be measured again
219521664|NCT03229005|PROCEDURE|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
219521665|NCT03474510|DRUG|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
219521666|NCT03474510|OTHER|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
218907164|NCT05804838|OTHER|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
218907165|NCT05941793|DRUG|MBS-COV|MBS-COV for inhalation
219521667|NCT00610090|DEVICE|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
219521668|NCT05717036|DEVICE|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
218907166|NCT05941793|DRUG|Placebo|Placebo for inhalation
218907167|NCT03137654|OTHER|Affective Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
219521669|NCT05922449|PROCEDURE|Thoracic Paravertebral Block|Patients randomly assigned to PV group will be placed in lateral position, and punctured using the out of plane technique guided by ultrasound (Shenzhen Huasheng Navi low-frequency convex array probe). 15 ml of 0.5% ropivacaine was administered to the T4 and T7 thoracic paravertebral spaces respectively, for a total of 30 ml. After injection, the pleura of the punctured segment and adjacent segments could be obviously moved down. Upon successful puncture, the patient was transferred to the supine position. After 5, 10, and 15 minutes, the range of sensory blockage was tested at T3\~T8 to cover the surgical area.
219521670|NCT02539485|OTHER|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
219521671|NCT04583852|OTHER|AIVÍA, Ultra-Brightening Spot Micro-needle Patch|a dissolving micro-needle patch, contains active ingredients
219521672|NCT04583852|OTHER|Placebo Micro-needle Patch|matching placebo will be provided as a dissolving micro-needle patch
218907168|NCT03137654|OTHER|Neutral Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
218907169|NCT04890652|BEHAVIORAL|Digital intervention|All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
218907170|NCT02969122|PROCEDURE|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
218907171|NCT02969122|PROCEDURE|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
218907172|NCT02969122|PROCEDURE|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
218907173|NCT02969122|OTHER|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
218907174|NCT02969122|OTHER|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
218907175|NCT04806724|BEHAVIORAL|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
218907176|NCT04806724|BEHAVIORAL|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
218907177|NCT02542657|DRUG|Clarithromycin|Given PO
218907178|NCT02542657|DRUG|Dexamethasone|Given PO
218907179|NCT02542657|DRUG|Ixazomib Citrate|Given PO
219521673|NCT00073177|DRUG|Roflumilast|
219521674|NCT00994253|DRUG|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
218907180|NCT02542657|DRUG|Pomalidomide|Given PO
218907181|NCT05195710|DRUG|Yttrium-90 (Y-90) resin microspheres|Given by scan
219521675|NCT00994253|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
219521676|NCT03456570|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
219521677|NCT03456570|DRUG|Placebo Oral Tablet|oral tablets twice daily
219521678|NCT00419770|DRUG|deferasirox|20 mg/kg enterally per day
219521679|NCT00419770|DRUG|Placebo|
219521680|NCT00419770|DRUG|Liposomal amphotericin B|
219521681|NCT05651230|DIETARY_SUPPLEMENT|Rhamnan sulfate|A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
218907182|NCT04108364|BEHAVIORAL|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
218907183|NCT03122639|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
218907184|NCT03122639|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
218907185|NCT05846126|BEHAVIORAL|RehabCovid_Telematic|A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
218907186|NCT05846126|BEHAVIORAL|RehabCovid_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
219521682|NCT00005948|BIOLOGICAL|aldesleukin|
218907187|NCT05846126|BEHAVIORAL|Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
218907188|NCT02455193|BEHAVIORAL|Exercise|
218907189|NCT02455193|BEHAVIORAL|Diet|
218907190|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
218907191|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
218907192|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
218907193|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
218907194|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
218907195|NCT05380973|OTHER|Short fiber resin composite|resin composite reinforced with short glass fibers
218907196|NCT05380973|OTHER|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
219039633|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
219039634|NCT05531162|OTHER|Cognition and emotional neuropsychologicl evaluations|Cognitive ans sensory performances during repetitive micro and partial gravity exposure
219039635|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
219039636|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
218907197|NCT05828862|PROCEDURE|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
218907198|NCT05972278|DRUG|Obicetrapib|1 tablet daily
218907199|NCT05174247|OTHER|FFRct analysis|Software analysis of Cardiac CT to show extent of pericardial stenoses
218907200|NCT04688359|BEHAVIORAL|Guided Self Determination|Nurse lead intervention in primary care
219039637|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
219039638|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
219521683|NCT00005948|BIOLOGICAL|recombinant interferon alfa|
218907201|NCT00001917|DRUG|O15|
219039639|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
219039640|NCT01914666|DRUG|Duloxetine|Administered orally
219039641|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
219039642|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
219039643|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
219521684|NCT00005948|BIOLOGICAL|sargramostim|
219521685|NCT00005948|DRUG|busulfan|
219521686|NCT00005948|PROCEDURE|peripheral blood stem cell transplantation|
219521687|NCT01627457|DEVICE|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
219521688|NCT01705769|OTHER|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
219521689|NCT01705769|OTHER|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
218907202|NCT00001917|DRUG|[F-18] FP-TZTP|
218907203|NCT04146168|DIAGNOSTIC_TEST|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
218907204|NCT00493493|PROCEDURE|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
218907205|NCT06271408|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Aerosolized albuterol
218907206|NCT06271408|DEVICE|Vibrating Mesh Nebulizer|A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
218907207|NCT06271408|DEVICE|Metered Dose Inhaler|A metered dose inhaler will be used to deliver aerosolized albuterol
218907208|NCT06271408|DEVICE|Jet Nebulizer|A jet nebulizer will be used to deliver aerosolized albuterol
218907209|NCT03474614|DRUG|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
218907210|NCT03474614|GENETIC|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
218907211|NCT06408870|DRUG|BI 1015550|BI 1015550
218907212|NCT03839524|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
218907213|NCT03354013|PROCEDURE|AOA|100% ICSI-AOA will be performed.
218907214|NCT03354013|DIAGNOSTIC_TEST|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
218907215|NCT03354013|DIAGNOSTIC_TEST|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
218907216|NCT06235515|OTHER|rehabilitation program|conventional treatment (hotpack and TENS and exercise)
218907217|NCT06235515|OTHER|virtual reality|virtual reality treatment
218907218|NCT04584424|OTHER|The study does not required|The study is prospective multi-center COVID-19 patient cohort
218907219|NCT05512403|DRUG|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction"
218907220|NCT04885569|BEHAVIORAL|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
218907221|NCT04885569|BEHAVIORAL|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
219039644|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
219039645|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
219039646|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
219521690|NCT01705769|OTHER|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
218907222|NCT04885569|BEHAVIORAL|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
219039647|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
219039648|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
219521691|NCT02848326|DRUG|Atogepant|Atogepant capsule.
219521692|NCT02848326|DRUG|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
219521693|NCT00927992|OTHER|Epidemiological Non interventional|Epidemiological Non interventional
219521694|NCT01412580|OTHER|observational follow-up|observational follow-up
219613469|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
218907223|NCT06361563|DRUG|Nivolumab|As per product label
218907224|NCT05125159|PROCEDURE|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
218907225|NCT04179552|DEVICE|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
218907226|NCT02284204|DRUG|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
218907227|NCT02284204|DRUG|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
218907228|NCT05772819|DIAGNOSTIC_TEST|exercise MRI|All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
218907229|NCT02253615|OTHER|Machines exercises|Resistance training in pneumatic machines.
218907230|NCT02253615|OTHER|Elastic exercises|Resistance training with elastic tubes.
218907231|NCT05259345|PROCEDURE|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
219039649|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
218907232|NCT05259345|PROCEDURE|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
218907233|NCT05259345|PROCEDURE|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
218907234|NCT01784731|BEHAVIORAL|Willingness to pay|
218907235|NCT03222700|PROCEDURE|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
218907236|NCT00938158|BIOLOGICAL|albiglutide|single dose of subcutaneously injected albiglutide
219039650|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
219039651|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
219039652|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
219039653|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
219039654|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
219204421|NCT06745141|PROCEDURE|Periodontal surgery|"In the intervention group, patients underwent a comprehensive periodontal evaluation conducted by periodontists at a dental clinic. All permanent teeth, except for third molars, were assessed using dental mirrors and periodontal probes. Each tooth was examined at four sites (vestibular, distal, lingual, and mesial) to evaluate visible plaque, probing depth, probing bleeding, and attachment loss.~During the first treatment session, patients were provided with information about periodontal disease, emphasizing the importance of controlling supragingival bacterial biofilms for successful treatment. Plaque-retentive factors (calculus) were removed. Temporary materials were used to restore carious lesions, root remnants were extracted, and maladaptive restorations were adjusted. Supragingival calculus was removed using periodontal scalers, followed by cleaning with a rubber cup, prophylaxis paste, dental floss, and/or interdental brushes. No prophylactic antibiotics were used prior to the"
219613154|NCT07097090|BEHAVIORAL|Emotion Recognition Training Program: A structured school-based intervention designed to enhance children's ability to recognize emotions through facial expressions, tone of voice, and body language.|"Emotion Recognition Training Program Integrated CASEL-based activities with CBT principles and digital tools to enhance emotional attribution and recognition in primary school children.~The intervention consisted of three structured activities based on the CASEL framework (Collaborative for Academic, Social, and Emotional Learning), integrated with cognitive-behavioral principles inspired by the model of Albert Ellis. Sessions included interactive use of digital whiteboards and narrative tools (e.g., emotion-themed interactive stories), aimed at improving children's ability to attribute emotions to others and to emotionally evaluate events.~In addition, a neurostimulative component was included, exposing children to visual stimuli with either neutral or fear-inducing emotional valence. Participants were asked to rate the perceived emotional intensity, supporting the development of self-regulation and emotional differentiation."
218907237|NCT04854018|DRUG|Indocyanine green|Intravenous or intraparenchymal injection
218907238|NCT05870514|DRUG|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
218907239|NCT05870514|DRUG|Propofol|Propofol
219039655|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
219039656|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
219204422|NCT06745219|DRUG|herombopag|receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
219204423|NCT06888492|BIOLOGICAL|EXG202|EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration（wAMD） with a single intravitreal injection and administration.
219204424|NCT06891430|PROCEDURE|Procedure: Anatomical Single-Bundle ACL Reconstruction|Patients undergo anatomical single-bundle ACL reconstruction with femoral and tibial tunnel drilling.
218907240|NCT04289181|OTHER|Medically Tailored Meals|4 weeks of medically tailored meals
218907241|NCT03564288|DRUG|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
218907242|NCT04694235|DIETARY_SUPPLEMENT|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
219204425|NCT06891430|PROCEDURE|Procedure: Central Axial Single-Bundle ACL Reconstruction|Patients undergo central axial single-bundle ACL reconstruction with optimized tunnel positioning.
219204426|NCT06891430|PROCEDURE|Procedure: Double-Bundle ACL Reconstruction|Patients undergo double-bundle ACL reconstruction targeting AMB and PLB footprints.
218907243|NCT04733326|DRUG|Ketorolac Tromethamine|final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
218907244|NCT04733326|OTHER|Cryotherapy|final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
219613155|NCT07097090|BEHAVIORAL|No Intervention: Observational Cohort|Control group received no intervention in order to serve as a baseline for comparison, isolating the effects of the emotion recognition training on behavioral and cognitive outcomes.
218907245|NCT04733326|OTHER|Saline|final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
218907246|NCT02222935|BEHAVIORAL|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
219613470|NCT03975933|DIAGNOSTIC_TEST|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
218907247|NCT02222935|BEHAVIORAL|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
218907248|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
218907249|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
218907250|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
218907251|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
218907252|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
218907253|NCT02655328|OTHER|blood sample|blood sample
218907254|NCT02655328|OTHER|urine sample|urine sample
218907255|NCT03255902|BEHAVIORAL|Parenting classes|Parenting Classes:The Incredible Years curriculum
218907256|NCT04721678|BEHAVIORAL|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
218907257|NCT01324817|DEVICE|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
218907258|NCT01324817|DEVICE|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
218907259|NCT02905097|PROCEDURE|Knee Replacement|Surgical replacement of arthritic knee with an implant
218907260|NCT05003466|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|"2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose.~Administer as an intramuscular injection into the lateral deltoid of the upper arm."
218907261|NCT05003466|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
218907262|NCT04073121|DEVICE|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
218907263|NCT03393585|OTHER|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
218907264|NCT04401735|DRUG|Polydeoxyribonucleotides|PDRN injection to epidural space
218907265|NCT04401735|DRUG|Normal saline|Normal saline
218907266|NCT03979898|BIOLOGICAL|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10\^7cells/5mL 15kg \~ 25kg : 1x10\^8cells/10mL 25kg over : 1.5x10\^8cells/15mL
218907267|NCT01752426|OTHER|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
218907268|NCT01752426|DRUG|PCI-32765|420 mg orally once daily.
218907269|NCT01081691|BIOLOGICAL|CNTO 5825|10 mg/kg single dose IV or matching placebo
218907270|NCT01081691|BIOLOGICAL|CNTO 5825|3 mg/kg single dose IV or matching placebo
218907271|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
218907272|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
218907273|NCT01081691|BIOLOGICAL|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
218907274|NCT01081691|BIOLOGICAL|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
218907275|NCT01081691|BIOLOGICAL|CNTO 5825|1 mg/kg single dose IV or matching placebo
218907276|NCT03658122|BEHAVIORAL|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
218907277|NCT06401369|PROCEDURE|Lingual brackets|These brackets will be used on the lingual surfaces of the upper and lower teeth.
218907278|NCT06401369|PROCEDURE|Buccal brackets|These brackets will be used on the vestibular surfaces of the upper and lower teeth.
218907279|NCT04365972|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
218907280|NCT04681235|OTHER|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
218907281|NCT02269124|DEVICE|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
218907282|NCT03278314|DRUG|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
219039657|NCT05686681|BEHAVIORAL|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
219039658|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
219039659|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
219039660|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
218907283|NCT05814185|DEVICE|Periodontal distractor|different activation protocols of periodontal distractor
218907284|NCT04808115|DRUG|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
219039661|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
219521695|NCT05411692|OTHER|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
219521696|NCT05411692|OTHER|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
219521697|NCT05411692|OTHER|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
219613156|NCT07097805|BEHAVIORAL|GLITTER comprehensive management|The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
219613157|NCT07095205|DRUG|Nicotine transdermal patch|The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
219613158|NCT07095205|DRUG|PET Scan with [18F] VAT|All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
219613159|NCT07097194|BEHAVIORAL|EX program|Quit plan with interactive exercises, educational videos, and tailored text messages and emails; peer support; coach chatting; nicotine replacement therapy (patches, gum, or lozenges). All components are self-selected.
219613160|NCT07095777|PROCEDURE|visual perceptual learning|Participants in the VPL group performed 40 minutes of daily monocular training at home for three months, with follow-up evaluations conducted at 1 month and 3 months after training initiation.
219613161|NCT07097454|DEVICE|Hypotension Prediction Index Monitoring|HPI monitoring is performed using the Edwards Lifesciences HemoSphere platform to provide real-time hypotension prediction based on arterial pressure waveform analysis. Interventions such as fluid bolus or vasopressor are administered per protocol when HPI ≥ 85.
218907285|NCT01207700|BEHAVIORAL|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
218907286|NCT04149834|PROCEDURE|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
218907287|NCT04149834|PROCEDURE|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
218907288|NCT01378559|OTHER|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
218907289|NCT03663829|OTHER|Non-Interventional|Non-Interventional
218907290|NCT03663829|OTHER|Non-Interventional|Non-Interventional
219521698|NCT05023005|OTHER|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
219521699|NCT03101878|DRUG|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
219521700|NCT03101878|DRUG|Placebo|Saline .9%
219521701|NCT01636570|DRUG|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
219521702|NCT01636570|DRUG|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
219613162|NCT07097454|OTHER|Standard PACU Monitoring|Standard monitoring in the post-anesthesia care unit (PACU), including non-invasive blood pressure, heart rate, and oxygen saturation measurements. No Hypotension Prediction Index (HPI) monitoring is used. Interventions are performed according to routine institutional practices.
219613163|NCT07096154|BEHAVIORAL|Group CBT Anxiety Management|An 8-session Group Cognitive Behavioural Therapy for anxiety management.
218907291|NCT01881191|OTHER|MRI|
218907292|NCT02348476|OTHER|No Intervention|No study drug is administered in this study.
218907293|NCT00839189|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
219039662|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
218907294|NCT04579146|OTHER|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
219039663|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
219039664|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
219039665|NCT00276718|BIOLOGICAL|bleomycin sulfate|
219039666|NCT00276718|DRUG|carboplatin|
219039667|NCT00276718|DRUG|etoposide|
219039668|NCT00276718|PROCEDURE|conventional surgery|
219039669|NCT00431171|DRUG|Lithium carbonate|
219521703|NCT02958111|DRUG|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
219521704|NCT00000566|PROCEDURE|ventilation-perfusion ratio|
219521705|NCT00000566|PROCEDURE|angiography|
219521706|NCT05647031|OTHER|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
219521707|NCT02680626|DRUG|Magnesium Sulfate|Given via transversus abdominis plane block
219521708|NCT02680626|DRUG|Ropivacaine|Given via transversus abdominis plane block
219521709|NCT03973177|DRUG|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
219613164|NCT07095257|DRUG|ZX-7101A for oral suspension|ZX-7101A will be administered as oral suspension in a single dose on Day 1. Oseltamivir phosphate matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
219613165|NCT07095257|DRUG|Oseltamivir phosphate for oral suspension|Oseltamivir phosphate will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive ZX-7101A matching placebo as oral suspension, single dose on Day 1.
219613166|NCT03398603|PROCEDURE|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
219613167|NCT00990925|BEHAVIORAL|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
219613168|NCT00990925|OTHER|Usual Care|Care as usual
218907295|NCT04790188|DIETARY_SUPPLEMENT|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
218907296|NCT04790188|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin lemon flavor (HSN®).
219039670|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
219039671|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
219039672|NCT06255652|DRUG|Cephradin|Velosef
219613169|NCT04598386|OTHER|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
219613170|NCT04598386|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
219613171|NCT00226980|DRUG|Thalidomide|
219613172|NCT00226980|DRUG|Capecitabine|
219613173|NCT06011707|BEHAVIORAL|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
218907297|NCT05075746|DEVICE|enVista Toric|enVista Toric IOL
219521710|NCT03973177|DRUG|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
218907298|NCT05075746|DEVICE|enVista non-Toric (spherical)|enVista non-Toric (spherical) IOL
218907299|NCT04136808|DRUG|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
218907300|NCT03274284|COMBINATION_PRODUCT|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
218907301|NCT01045460|BIOLOGICAL|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
218907302|NCT01045460|BIOLOGICAL|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
218907303|NCT01045460|DRUG|Cyclophosphamide|Administered at 2.5 g/m\^2.
218907304|NCT01045460|BIOLOGICAL|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
219039673|NCT01911507|DRUG|INC280|Given PO
219039674|NCT01911507|DRUG|erlotinib hydrochloride|Given PO
219039675|NCT05932446|DRUG|LY3819469|Administered SC.
219521711|NCT00957814|BEHAVIORAL|Nutritional education|Systematic nutritional orientation program
219521712|NCT03341481|OTHER|Femaltiker|Patient had taken twice a day the product
219521713|NCT03341481|OTHER|Placebo|Patient had taken twice a day the placebo
219521714|NCT04526210|DRUG|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
219521715|NCT04526210|DRUG|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
219521716|NCT05471817|DRUG|Elinzanetant (BAY3427080)|Capsule, oral, single dose
219521717|NCT05471817|DRUG|Dabigatran etexilate|Capsule, oral, single dose
219521718|NCT05710341|DIETARY_SUPPLEMENT|Water with added nitrate|Water with added nitrate
219521719|NCT05710341|DIETARY_SUPPLEMENT|Water without added nitrate|Water without added nitrate
219521720|NCT00812734|PROCEDURE|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
219521721|NCT06248450|OTHER|Medical yoga|Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.
219521722|NCT04334590|PROCEDURE|Cleft Lip/Nose Repair without PSIO|Standard of care surgical repair of cleft lip/nose without PSIO.
219521723|NCT04334590|PROCEDURE|Presurgical Infant Orthopedic Therapy|Standard of care surgical repair of cleft lip/nose with PSIO.
219613174|NCT06011707|OTHER|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
219613175|NCT03985540|BEHAVIORAL|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
218907305|NCT01045460|PROCEDURE|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
218907306|NCT01045460|DRUG|Melphalan|100 mg/m\^2/day given on Days -2 and -1.
218907307|NCT01045460|BIOLOGICAL|Autologous stem cell transplant|Infused on Day 0.
218907308|NCT04356222|DRUG|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
218907309|NCT04356222|DRUG|methotrexate|Intrathecal chemotherapy specified dose on specified days
219039676|NCT01654965|OTHER|Laboratory Biomarker Analysis|Correlative studies
219521724|NCT05853484|OTHER|Bimodal lifestyle program|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
219521725|NCT02012244|DRUG|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
219521726|NCT02012244|DRUG|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
219521727|NCT02937701|BIOLOGICAL|ABP 710|Administered by intravenous infusion
219521728|NCT02937701|BIOLOGICAL|Infliximab|Administered by intravenous infusion
219521729|NCT00614289|DEVICE|Epikeia Coatings|Topical skin coating
219521730|NCT00138515|DRUG|vildagliptin|
219521731|NCT04155281|OTHER|urine analysis|New Psychoactive Substances research in urine at admission in unit care
219521732|NCT05321316|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
219521733|NCT02837822|DEVICE|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
219521734|NCT02837822|PROCEDURE|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
219521735|NCT03323125|OTHER|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
219521736|NCT05474248|BEHAVIORAL|Experimental group|Diaphragmatic Breathing Training
219521737|NCT04090892|PROCEDURE|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
219521738|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
219521739|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
219521740|NCT06004726|OTHER|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~* Orientation about Training Programme using PowerPoint slides~* Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~* Distribution of informational booklet on basics about substance abuse~Module 2:~* Role play to develop a positive attitude towards the prevention of substance abuse.~* Case-based scenario to increase resistance to peer pressure.~* Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
219521741|NCT02069626|PROCEDURE|compression time of the laparoscopic linear stapler|
219521742|NCT03408626|DRUG|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
219521743|NCT03408626|DEVICE|conventional rotary|traditional rotary method
219521744|NCT05825495|DRUG|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
219521745|NCT05825495|OTHER|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
219521746|NCT04648358|DRUG|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
219521747|NCT04648358|DRUG|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
219521748|NCT02392364|DRUG|Intravitreal Aflibercept Injection|
219039677|NCT01654965|BIOLOGICAL|Pegfilgrastim|Given SC
219521749|NCT04033952|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
219039678|NCT01654965|OTHER|Pharmacological Study|Correlative studies
219039679|NCT01654965|DRUG|Tivantinib|Given PO
219521750|NCT04818242|DEVICE|Dexcom G6 CGM with GTS|CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to \< 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) \> 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
219521751|NCT04818242|DIAGNOSTIC_TEST|POC Blood Glucose Test + Blinded CGM|Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between \<80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
219521752|NCT02256085|DEVICE|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
219039680|NCT01654965|DRUG|Topotecan Hydrochloride|Given IV
219521753|NCT02256085|DEVICE|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
218907310|NCT04103216|OTHER|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
218907311|NCT04103216|OTHER|Nitazoxanide|Nitazoxanide with placebo
218907312|NCT05030181|OTHER|kinesiotaping and exercise|kinesiotaping group, ''I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
218907313|NCT05030181|OTHER|exercise|exercise
219521754|NCT02256085|DEVICE|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
219521755|NCT02475915|DRUG|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
219521756|NCT02475915|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
219521757|NCT02475915|DRUG|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
219521758|NCT02475915|DRUG|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
219521759|NCT02475915|DRUG|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
219521760|NCT02475915|DRUG|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
219521761|NCT02475915|DRUG|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
219521762|NCT04533607|BEHAVIORAL|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
219521763|NCT04069637|COMBINATION_PRODUCT|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
219521764|NCT05080751|BEHAVIORAL|Eating Behaviors|Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
219613176|NCT03985540|BEHAVIORAL|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
218907314|NCT00335491|BEHAVIORAL|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
218907315|NCT00335491|PROCEDURE|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
218907316|NCT00335491|PROCEDURE|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
218907317|NCT00335491|PROCEDURE|physical therapy|12 weeks of 3x/week training on the eccentron
218907318|NCT03964103|DIETARY_SUPPLEMENT|gQ-lab daily|probiotics
218907319|NCT03964103|DIETARY_SUPPLEMENT|Placebo|powdered skim milk, lactose
219039681|NCT02342704|DRUG|natalizumab|Administered as specified in the treatment arm
219613177|NCT03985540|BEHAVIORAL|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
219613178|NCT03985540|BEHAVIORAL|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
219613179|NCT04952922|OTHER|Treatment for recurrent oropharyngeal cancer (curative/ palliative)|Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.
219613180|NCT06956560|RADIATION|PET/MRI or separate PET/CT and MRI|"PET/MRI or separate PET/CT and MRI using the following imaging protocol: 15O-H20 (myocardial perfusion, up to 10 min dynamic PET scan), \[68Ga\]Ga-DOTA-Cys-ATH001 (PDGFRß PET, up to 60 min dynamic + static full body PET scans), and Gd-MRI (extracellular volume in infarct, around 10 min MRI scan).~Cohort 1 and 2 are examined twice, first one week after PCI/stent and then a second examination 2 to 8 months after the first. Cohorts 3, and 4 are examined once."
219613181|NCT03897244|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
219613182|NCT03897244|DRUG|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
218907320|NCT01692184|DRUG|50 mg AVL-292|
218907321|NCT01692184|DRUG|100 mg AVL-292|
218907322|NCT01692184|DRUG|200 mg AVL-292|
219039682|NCT02342704|DRUG|fingolimod|Administered as specified in the treatment arm
219039683|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
219039684|NCT02347527|BEHAVIORAL|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
219039685|NCT02347527|BEHAVIORAL|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
218907323|NCT01692184|DRUG|350 mg AVL-292|
218907324|NCT01692184|DRUG|Placebo capsules|
218907325|NCT01029496|PROCEDURE|different time of umbilical cord clamping|"1. for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~   control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~2. for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
219039686|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
219039687|NCT01819805|DRUG|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
218907326|NCT01600885|DRUG|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
218907327|NCT01600885|DRUG|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
218907328|NCT02319200|DRUG|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
219521765|NCT04480398|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
219521766|NCT03227445|DEVICE|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
219521767|NCT03227445|DEVICE|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
219521768|NCT03227445|DEVICE|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
219521769|NCT03227445|OTHER|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
219521770|NCT02287545|PROCEDURE|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
219521771|NCT02835482|PROCEDURE|Femtolaser surgery|
219521772|NCT02835482|PROCEDURE|Phacoemulsification|
219521773|NCT04200482|BEHAVIORAL|One Diet and Physical Activity Session|Attend 1 remote diet and physical activity session
219521774|NCT04200482|OTHER|Electronic (e) Health (eHealth) Communication Intervention|Receive eHealth communication intervention
219521775|NCT04200482|BEHAVIORAL|Twelve Diet and Physical Activity Group Sessions|Attend 12 remote diet and physical activity sessions in 6 months
219521776|NCT04200482|OTHER|Questionnaire Administration|Ancillary studies
219521777|NCT04200482|OTHER|Quality-of-Life Assessment|Ancillary studies
219521778|NCT02025465|DRUG|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
219613183|NCT03897244|DRUG|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
219521779|NCT02025465|DRUG|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
219521780|NCT01977469|BEHAVIORAL|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
219613184|NCT05210764|DRUG|propofol|General anesthesia is induced and maintained mainly with propofol.
219613185|NCT05210764|DRUG|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
218907329|NCT02319200|DRUG|placebo tablet|4 tablets per day for 36 months
218907330|NCT00436332|BIOLOGICAL|bevacizumab|
218907331|NCT00436332|DRUG|erlotinib hydrochloride|
218907332|NCT00456053|DRUG|FG2216|
218907333|NCT02268149|DRUG|BIIL 284 BS|
219521781|NCT01977469|BEHAVIORAL|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
219521782|NCT01977469|BEHAVIORAL|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
219613186|NCT05210764|DRUG|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
219613187|NCT03649048|DRUG|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
219613188|NCT03649048|DRUG|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
218907334|NCT02268149|DRUG|Prednisone|
218907335|NCT02268149|DRUG|Placebo|
218907336|NCT00738998|BEHAVIORAL|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
218907337|NCT00738998|OTHER|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
218907338|NCT02910817|DRUG|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
218907339|NCT02910817|OTHER|Placebo|Placebo
218907340|NCT00716963|DRUG|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
218907341|NCT00716963|DRUG|budesonide 400 mcg|budesonide 400 mcg
219039688|NCT01358318|OTHER|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
219039689|NCT03793907|DEVICE|FitBit|Wear Fitbit
219521783|NCT01880073|DEVICE|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
219521784|NCT00755196|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
219521785|NCT00755196|DRUG|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
219521786|NCT01532622|DIETARY_SUPPLEMENT|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
219521787|NCT01532622|OTHER|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
219521788|NCT02745522|DRUG|Oxytocin|
219521789|NCT02745522|DRUG|Placebo|
219039690|NCT03793907|OTHER|Quality-of-Life Assessment|Ancillary studies
219039691|NCT03793907|OTHER|Questionnaire Administration|Ancillary studies
219521790|NCT04878146|PROCEDURE|Sacro-spinous fixation|Uterine cervix will be attached to the sacro-spinous ligament
219521791|NCT04878146|PROCEDURE|Subtotal hysterectomy|Done on both arms
219613189|NCT03649048|RADIATION|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
219613190|NCT06819839|BEHAVIORAL|Village Health Worker (VHW) Care Model|VHW care model includes four components: (1) universal screening of all non-pregnant adults over 40 for elevated CVD risk (2) confirmatory visit to confirm diagnoses of hypertension, diabetes and elevated CVD risk (predicted 10-year risk \>10%) (3) monthly household visits by VHW; (4) an mHealth tool (tablet computer) to assist with determination of study eligibility and provide recommendations for initiation of medications according to local guidelines. VHW household visits include: health education on smoking cessation, healthy diet, physical activity and medication adherence; assessment of possible medication side effects, measurement of blood pressure and (when applicable) blood glucose; review monitoring results with the treating clinician household delivery of medications; and facilitate referral and transport to higher levels of care.
219613471|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
219613472|NCT03119779|DRUG|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
219039692|NCT03793907|OTHER|Resistance Training|Complete strength training
219039693|NCT03793907|BEHAVIORAL|STEPS to Enhance Physical Activity|Complete a walking program
219521792|NCT04878146|PROCEDURE|Sacrocolpopexy|Uterine cervix is attached to sacral promontory with two synthetic meshes
219521793|NCT00677118|DRUG|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
218907342|NCT00716963|OTHER|Placebo|Placebo
218907343|NCT02767271|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
218907344|NCT03497663|OTHER|VIA Family intervention|Family based intervention
218907345|NCT03497663|OTHER|Treatment As Usual|Treatment As Usual
218907346|NCT06404814|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|(TENS) is a method of pain relief involving the use of a mild electrical current
219039694|NCT00302003|RADIATION|radiation therapy|Undergo radiation therapy
219039695|NCT00302003|DRUG|doxorubicin hydrochloride|Given IV
219039696|NCT00302003|DRUG|vincristine sulfate|Given IV
219039697|NCT00302003|DRUG|prednisone|Given orally
219039698|NCT00302003|DRUG|cyclophosphamide|Given IV
219039699|NCT00302003|DRUG|ifosfamide|Given IV
219039700|NCT00302003|DRUG|vinorelbine tartrate|Given IV
219039701|NCT00302003|DRUG|dexamethasone|Given IV
219039702|NCT00302003|DRUG|etoposide phosphate|Given IV
219521794|NCT00677118|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
219039703|NCT00302003|DRUG|cisplatin|Given IV
219039704|NCT00302003|DRUG|cytarabine|Given IV
219039705|NCT00302003|BIOLOGICAL|filgrastim|Given IV or subcutaneously
219039706|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
219039707|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules
219039708|NCT05365438|DRUG|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
219039709|NCT06441734|DIAGNOSTIC_TEST|cbc serum ferritin serum iron|by using sample of blood to do cbc and serum ferritin and serum iron during 1year
219039710|NCT03111420|DRUG|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
219521795|NCT04366336|PROCEDURE|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
219521796|NCT04366336|PROCEDURE|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
219521797|NCT04670913|DRUG|Camrelizumab|A human anti-PD-1 monoclonal antibody
219521798|NCT04670913|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
219521799|NCT04734964|BEHAVIORAL|exercise training|Exercise training session for 45 minutes.
219521800|NCT02845895|OTHER|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
219521801|NCT02845895|OTHER|Classic strategy|Classic organization with the training of the department team
219521802|NCT00002579|DRUG|CMF regimen|
219521803|NCT00002579|DRUG|cyclophosphamide|
219521804|NCT00002579|DRUG|fluorouracil|
219521805|NCT00002579|DRUG|methotrexate|
219521806|NCT00002579|DRUG|tamoxifen citrate|
218907347|NCT06404814|DIAGNOSTIC_TEST|Muscle Energy Technique|n Spencer's technique, there are seven steps as follows: shoulder extension along with elbow flexion, shoulder flexion with elbow extension, circumduction with compression, circumduction with distraction, shoulder abduction and internal rotation with elbow flexion, shoulder adduction and external rotation with elbow
218907348|NCT05953545|DRUG|Peginterferon Lambda|Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
218907349|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
218907350|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
218907351|NCT00005906|DRUG|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
218907352|NCT05323136|DRUG|MT1002 for Injection|single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
218907353|NCT01258543|OTHER|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
218907354|NCT06013735|DRUG|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
219521807|NCT00002579|PROCEDURE|conventional surgery|
219521808|NCT00002579|RADIATION|radiation therapy|
219521809|NCT03757364|DRUG|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
219521810|NCT02933775|GENETIC|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
219521811|NCT02933775|DRUG|Fludarabine|30 mg/m\^2/day×4 days
219521812|NCT02933775|DRUG|Cyclophosphamide|500 mg/m\^2/day×2 days
219521813|NCT01703832|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
219521814|NCT01991470|DEVICE|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
219521815|NCT05696470|DEVICE|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
219521816|NCT00243932|DRUG|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
218907355|NCT06013735|DRUG|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
218907356|NCT06013735|DRUG|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
218907357|NCT06013735|OTHER|Distilled water|placebo distilled water
218907358|NCT01841879|BEHAVIORAL|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
218907359|NCT01841879|BEHAVIORAL|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
218907360|NCT04780165|DEVICE|Blephademodex|During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
218907361|NCT04189705|DRUG|MCT-SR|Rebamipide 150mg
218907362|NCT04189705|DRUG|Mucosta Tab.|Rebamipide 100mg
219521817|NCT00243932|DRUG|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
219521818|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
219521819|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
219521820|NCT03365037|DRUG|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
219521821|NCT03365037|DRUG|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
219521822|NCT00088062|DRUG|STA-5326|
219521823|NCT05653596|BEHAVIORAL|Virtual reality-based cognitive intervention|This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
219521824|NCT04605107|DRUG|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
219521825|NCT04605107|DRUG|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
219521826|NCT04095871|OTHER|Observational study|No intervention, patients record the time of CISC
219521827|NCT06235398|BIOLOGICAL|Hematopoietic stem-cell transplantation|Upfront related donor transplantation
219521828|NCT00353353|PROCEDURE|consumption of fortified bread|
219613473|NCT03119779|DRUG|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
218907363|NCT04629755|BEHAVIORAL|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
218907364|NCT05062174|DRUG|Mifepristone 200 MG|Orally, one time dosage of 200 mg
218907365|NCT05062174|PROCEDURE|Prophylactic mastectomy|Planned prophylactic mastectomy (having one or both breasts removed).
218907366|NCT00947375|DRUG|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
218907367|NCT00947375|DRUG|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
218907368|NCT00287898|BEHAVIORAL|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
218907369|NCT00287898|BEHAVIORAL|Usual Care|subjects will receive standard in-person genetic counseling
218907370|NCT01099371|OTHER|exercise|progressive resistance training
218907371|NCT00667888|RADIATION|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
218907372|NCT00667888|RADIATION|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
219521829|NCT03213886|DRUG|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
219613191|NCT06792084|BEHAVIORAL|motivational interviewing|Motivational interviewing is a directive and client-centered approach used to elicit behavioral change by helping the client explore and resolve ambivalence. Motivational interviewing is a specific method of helping individuals understand their problems and take action for change. In this study, the motivational interview program created in line with the literature (Li et al, 2023; Miller and Rollnick, 2013; Çelik Örücü, 2020) consists of 5 sessions in total, one session per week. There are specific goals and objectives for each session.
219613192|NCT06788340|DRUG|PK-model to decide when to dose Vedolizumab and Ustekinumab|the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
219613193|NCT06796790|BEHAVIORAL|Media instruction|Caregivers will be asked to implement joint media sessions with their child four times per week for 12 weeks using lightly adapted versions of the commercially-available Super Why! program, which focuses on early literacy skills, including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week
218907373|NCT02753803|DRUG|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
218907374|NCT02753803|DRUG|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
219613194|NCT06796790|BEHAVIORAL|Storybook intervention|Caregivers will be asked to implement joint storybook reading sessions with their child four times per week for 12 weeks using adapted versions of the commercially -available Super-Why! storybooks, which focus on early literacy skills including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week.
219613195|NCT05962372|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
219613196|NCT05962372|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
219613474|NCT05899738|DRUG|Iberdomide|Specified dose on specified days
219613475|NCT00044408|DRUG|Ruboxistaurin mesylate|
218907375|NCT02753803|DRUG|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
218907376|NCT02753803|DRUG|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
218907377|NCT02753803|DRUG|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
219613476|NCT03385317|BEHAVIORAL|Mindfulness|
218907378|NCT02753803|DRUG|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
218907379|NCT02684773|PROCEDURE|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
218907380|NCT02684773|PROCEDURE|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
218907381|NCT03796507|DRUG|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
219039711|NCT03111420|DEVICE|Platelet function test|Blood is drawn for testing of platelet aggregation activity
219039712|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
218907382|NCT04978883|OTHER|No intervention|No intervention
218907383|NCT05936112|OTHER|Fecal calprotectin dosage|Dosing calprotectin in infants' feces + questionnaire/interview with parents
218907384|NCT05936112|OTHER|Questionnaire and interview with parents|Dosing calprotectin in infants' feces + questionnaire/interview with parents
218907385|NCT05932277|DRUG|BMS-986419|Specified dose on specified days
218907386|NCT05932277|DRUG|Caffeine|Specified dose on specified days
218907387|NCT05932277|DRUG|Bupropion|Specified dose on specified days
219521830|NCT02529280|BEHAVIORAL|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
219521831|NCT00566800|DRUG|erlotinib hydrochloride|
219521832|NCT00566800|OTHER|laboratory biomarker analysis|
219521833|NCT00566800|PROCEDURE|biopsy|
219521834|NCT06521983|OTHER|Whole body vibration|Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine
219521835|NCT01206153|DRUG|metformin|
219521836|NCT03678038|DRUG|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
219521837|NCT03678038|DRUG|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
219613197|NCT04639986|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
219613198|NCT04639986|DRUG|Eribulin Mesylate Injection|Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
218907388|NCT05932277|DRUG|Flurbiprofen|Specified dose on specified days
218907389|NCT05932277|DRUG|Omeprazole|Specified dose on specified days
218907390|NCT05932277|DRUG|Midazolam|Specified dose on specified days
218907391|NCT05932277|DRUG|Fexofenadine|Specified dose on specified days
218907392|NCT05854108|DIAGNOSTIC_TEST|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
218907393|NCT05854108|DIAGNOSTIC_TEST|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
218907394|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
218907395|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
218907396|NCT02140047|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
218907397|NCT00883779|DRUG|Placebo|po on days 15-28 of each 4 week cycle until disease progression
218907398|NCT00883779|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
218907399|NCT00883779|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
218907400|NCT00883779|DRUG|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
218907401|NCT00499681|DRUG|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
219039713|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
219039714|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
219039715|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
219521838|NCT02030353|BEHAVIORAL|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
219613199|NCT04639986|DRUG|Capecitabine Oral Product|Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
219613200|NCT04639986|DRUG|Gemcitabine Injection|Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
219613477|NCT03518008|DEVICE|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
218907402|NCT00499681|DRUG|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
218907403|NCT00499681|OTHER|placebo|Given once daily for 2 weeks
218907404|NCT04942587|BEHAVIORAL|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
218907405|NCT03186612|BEHAVIORAL|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
218907406|NCT00380237|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
218907407|NCT05842317|DRUG|Lenvatinib Plus Tislelizumab|Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
219039716|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
219039717|NCT04188262|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
219521839|NCT02030353|BEHAVIORAL|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
218907408|NCT05842317|DEVICE|Transarterial Chemoembolization(TACE)|A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
218907409|NCT05566535|DRUG|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
219039718|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
219039719|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
219039720|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
219039721|NCT02919670|OTHER|Standard Supportive Care|
219039722|NCT01466270|DRUG|donepezil hydrochloride|Given PO
219521840|NCT00894283|DRUG|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
219521841|NCT00894283|DRUG|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
219521842|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
218907410|NCT01665196|DRUG|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
218907411|NCT06036277|OTHER|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
218907412|NCT06036277|OTHER|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
219521843|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
219521844|NCT00890526|OTHER|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from \~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
219613201|NCT04639986|DRUG|Vinorelbine injection|Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
219613202|NCT01473914|DIETARY_SUPPLEMENT|Low dose: supplemental zinc, selenium and vitamin E|"1. ZINC 25mg (AS ZINC SULFATE)~2. SELENIUM 50 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
219613203|NCT01473914|DIETARY_SUPPLEMENT|Standard renal vitamin: B and C renal vitamin|"1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)"
219613204|NCT01473914|DIETARY_SUPPLEMENT|Medium dose: supplemental zinc, selenium and vitamin E|"1. ZINC 50 mg (AS ZINC SULFATE)~2. SELENIUM 75 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
219613205|NCT00982787|DRUG|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
218907413|NCT05101590|DEVICE|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
218907414|NCT01754103|OTHER|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
219039723|NCT01466270|DRUG|Placebo|Given PO
219039724|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
219039725|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
219039726|NCT00028756|DRUG|vinblastine sulfate|Given IV
219039727|NCT00028756|DRUG|methotrexate|Given IV
219039728|NCT00028756|DRUG|cisplatin|Given IV
219039729|NCT00028756|BIOLOGICAL|filgrastim|Given SC
219039730|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
219613478|NCT03518008|DEVICE|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
219613479|NCT04967326|DRUG|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
219039731|NCT00004923|DRUG|docetaxel|
219039732|NCT00004923|DRUG|irinotecan hydrochloride|
219039733|NCT01556672|DRUG|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
218907415|NCT04383509|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
218907416|NCT04383509|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
218907417|NCT00003464|DRUG|temozolomide|
218907418|NCT00003464|RADIATION|radiation therapy|
218907419|NCT01983475|DRUG|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
219039734|NCT01556672|DEVICE|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
219039735|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
219039736|NCT01459172|OTHER|limonene containing massage oil|daily massage application to the breast for 4 weeks
219039737|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
219039738|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
219039739|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
219039740|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
219039741|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
219521845|NCT00890526|OTHER|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
218907420|NCT01983475|DRUG|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
218907421|NCT01904409|DRUG|Placebo|
218907422|NCT01904409|DRUG|Rifaximin SSD 40 mg IR tablet|
218907423|NCT01904409|DRUG|Rifaximin SSD 80 mg IR tablet|
218907424|NCT01904409|DRUG|Rifaximin SSD 40 mg SER tablet|
219039742|NCT00024362|DRUG|BBR 3464|
219039743|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
219039744|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
219039745|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
219039746|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
219039747|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
219613206|NCT02571478|BEHAVIORAL|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
219613207|NCT02902588|OTHER|ICG-PULSION|Intravenous administration of indocyanine green
219613480|NCT00107848|DRUG|Modafinil|
219039748|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
218907425|NCT01904409|DRUG|Rifaximin SSD 80 mg SER tablet|
218907426|NCT01904409|DRUG|Rifaximin SSD 80mgIR/80mgSER tablet|
219039749|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
219039750|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
219039751|NCT01489046|DRUG|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
219039752|NCT01489046|DRUG|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
218907427|NCT00659061|DIETARY_SUPPLEMENT|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
218907428|NCT00659061|BEHAVIORAL|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
218907429|NCT00605852|DRUG|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
218907430|NCT00605852|DRUG|Placebo|Placebo will be given to subjects.
218907431|NCT00079040|DRUG|cisplatin|Given IV
218907432|NCT00079040|DRUG|etoposide|Given IV
218907433|NCT00079040|BIOLOGICAL|bevacizumab|Given IV
218907434|NCT00079040|OTHER|laboratory biomarker analysis|Correlative studies
218907435|NCT01277744|PROCEDURE|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
218907436|NCT01277744|DRUG|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
218907437|NCT03688269|DRUG|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
218907438|NCT03688269|DRUG|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
218907439|NCT03688269|DRUG|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
218907440|NCT04694222|DEVICE|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
218907441|NCT02341560|DRUG|QPI-1007 Injection - 1.5 mg|
218907442|NCT02341560|DRUG|QPI-1007 Injection - 3.0 mg|
218907443|NCT02341560|OTHER|Sham Injection Procedure|Sham Procedure
219521846|NCT00890526|OTHER|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
218907444|NCT06329908|DRUG|LG002|Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
218907445|NCT04506840|OTHER|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
218907446|NCT06493760|DRUG|SSGJ-707|bispecific antibody
218907447|NCT06493760|DRUG|Bevacizumab|VEGF antibody
218907448|NCT06493760|DRUG|Oxaliplatin|chemotherapy
218907449|NCT06493760|DRUG|Capecitabine|chemotherapy
218907450|NCT06493760|DRUG|Calcium Folinate|chemotherapy
218907451|NCT06493760|DRUG|5-fluorouracil|chemotherapy
218907452|NCT00580619|OTHER|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
218907453|NCT00580619|OTHER|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
218907454|NCT00580619|DRUG|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
218907455|NCT00580619|DRUG|methyldopa|Aldomet oral twice a day for 12 weeks
218907456|NCT04056819|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
218907457|NCT00325897|DRUG|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
218907458|NCT00325897|DRUG|Placebo|Placebo taken on a daily basis
218907459|NCT03380728|DRUG|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
218907460|NCT05781178|DIETARY_SUPPLEMENT|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
218907461|NCT02366494|DRUG|Bicalutamide|ANDROGEN BLOCKADE
218907462|NCT02366494|DRUG|Leuprolide|ANDROGEN BLOCKADE
219521847|NCT00890526|OTHER|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
219613208|NCT02902588|DEVICE|LiMON, Pulsion Medical Systems|Application of near infrared light
218907463|NCT02366494|DRUG|Goserelin|ANDROGEN BLOCKADE
218907464|NCT02366494|DRUG|Triptorelin|ANDROGEN BLOCKADE
218907465|NCT02366494|DRUG|Docetaxel|Chemo hormonal therapy
219613209|NCT02902588|OTHER|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
219521848|NCT04314869|PROCEDURE|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
219521849|NCT00162669|DRUG|bevacizumab|
219521850|NCT00437658|DRUG|Elagolix|Provided as tablets for oral administration
218907466|NCT02366494|DRUG|Abiraterone|Chemo hormonal therapy
218907467|NCT02366494|DRUG|Apalutamide|Nonsteroidal antiandrogen medication
218907468|NCT02366494|DRUG|Enzalutamide|Nonsteroidal antiandrogen medication
218907469|NCT04991649|BEHAVIORAL|Acceptance and Commitment Therapy-based Asthma Management Training Program|In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
218907470|NCT04991649|BEHAVIORAL|Treatment-as-usual Group|Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
218907471|NCT06172452|BEHAVIORAL|Project Body Neutrality SSI|Online, 30-minute self-guided intervention for youth ages 13-17
218907472|NCT06172452|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-guided activity for youth ages 13-17
218907473|NCT03915717|DEVICE|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
219521851|NCT00437658|DRUG|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
219613210|NCT04911517|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
218907474|NCT03915717|DEVICE|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
218907475|NCT03093909|DRUG|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
218907476|NCT06542029|BEHAVIORAL|Groups 4 Health (G4H)|"Groups 4 Health, G4H, (Ryhmät kuntoon) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention."
218907477|NCT06542029|BEHAVIORAL|The study psychologists' group intervention|University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
219521852|NCT00437658|DRUG|Placebo to Elagolix|Matching placebo tablets for oral administration
219521853|NCT00437658|DRUG|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
219613211|NCT05343780|DRUG|Heptex|Dukung Anak 200 mg + Milk thistle 100 mg
219521854|NCT02068105|DRUG|ALKS 5461|Sublingual tablet
219521855|NCT02068105|DRUG|Placebo|Sublingual tablet
219521856|NCT04641130|OTHER|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
219521857|NCT01568476|PROCEDURE|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
219521858|NCT01568476|PROCEDURE|Interneural|Sciatic nerve blockade at the site of bifurcation
219521859|NCT00213304|BIOLOGICAL|varicella vaccine (VARIVAX)|
219521860|NCT05372926|DEVICE|high flow nasal canulae|high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.
219613212|NCT05343780|OTHER|Rice bran|Placebo
219613213|NCT01050829|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
219613214|NCT01050829|DRUG|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
219613215|NCT01626482|OTHER|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
219613216|NCT01626482|OTHER|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
218907478|NCT06542029|BEHAVIORAL|Towards better well-being and studying -online course|"Towards better well-being and studying -online course (Kohti parempaa opiskelua) is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion."
218907479|NCT05668234|OTHER|interview|semi-directive interview
218907480|NCT03808090|DIETARY_SUPPLEMENT|Normal Individuals|"Controlled Dietary phase: Low oxalate fixed diet~4 days of fixed normal calorie diet with low oxalate (\< 60 mg/day), normal calcium (800-1200 mg/day)"
218907481|NCT05405920|BEHAVIORAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
218907482|NCT05405920|BEHAVIORAL|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
218907483|NCT03748823|COMBINATION_PRODUCT|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
218907484|NCT03748823|BIOLOGICAL|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
218907485|NCT06120712|BIOLOGICAL|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
218907486|NCT00590187|DRUG|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
218907487|NCT00590187|DRUG|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
218907488|NCT00590187|DRUG|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
219521861|NCT05372926|DEVICE|Ventury mask|Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.
218907489|NCT00590187|DRUG|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
219039753|NCT01489046|DRUG|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
219521862|NCT01126125|DIETARY_SUPPLEMENT|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
219521863|NCT02188953|DRUG|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
219521864|NCT02188953|DRUG|Calcium carbonate placebo|
219521865|NCT00770445|DRUG|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
219521866|NCT00770445|DRUG|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
219613481|NCT05611866|PROCEDURE|Fecal Microbiota Transplantation|FMT at Week 0
219613482|NCT03376919|DEVICE|CLs++ gait training|CLs++ gait training
218907490|NCT00590187|DRUG|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
218907491|NCT00590187|DRUG|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
218907492|NCT00590187|DRUG|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
218907493|NCT00590187|DRUG|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
218907494|NCT00590187|DRUG|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
218907495|NCT05003479|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
218907496|NCT05003479|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
218907497|NCT03345251|DEVICE|Hydrotubation|
218907498|NCT03929185|DIAGNOSTIC_TEST|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
218907499|NCT03929185|DIAGNOSTIC_TEST|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
219039754|NCT01489046|DRUG|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
219039755|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
219039756|NCT01586468|DRUG|NaCl Solution|NaCl Solution
219521867|NCT00770445|DRUG|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
219521868|NCT04407806|DEVICE|Continous Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
219521869|NCT04407806|DEVICE|Intermittent Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
219521870|NCT00161356|DRUG|Ambisome|5mg/kg IV - one time dose during liver transplant
219521871|NCT00161356|PROCEDURE|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
219521872|NCT04017156|PROCEDURE|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
219521873|NCT02513056|OTHER|MRI|MRI
219521874|NCT02465697|BEHAVIORAL|Reappraisal Training|
219521875|NCT04713709|COMBINATION_PRODUCT|Nasus Pharma FMXIN001|A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
218907500|NCT04479085|OTHER|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
219521876|NCT04713709|COMBINATION_PRODUCT|Nasal Naloxone liquid spray|A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
219521877|NCT06561750|OTHER|Rooibos tea|Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water
219613217|NCT01402570|DIETARY_SUPPLEMENT|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
219613218|NCT03804957|OTHER|Autologous blood patch injection (ABPI)|Autologous blood patch injection (ABPI) through a coaxial needle at the site of biopsy
219613219|NCT03804957|OTHER|CT-guided core needle biopsy (CNB)|Standard 18g lung core biopsy
219613220|NCT02236260|PROCEDURE|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
218907501|NCT00984477|DRUG|AZD5122|A single dose of oral suspension
218907502|NCT00984477|DRUG|Placebo|A single dose of oral suspension
218907503|NCT00984477|DRUG|AZD5122|A single intravenous infusion
218907504|NCT05675319|DRUG|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
218907505|NCT05675319|DRUG|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
218907506|NCT05675319|DRUG|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
218907507|NCT05675319|DRUG|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
218907508|NCT05675319|DRUG|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
218907509|NCT05675319|DRUG|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
218907510|NCT05675319|DRUG|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
218907511|NCT05675319|DRUG|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
218907512|NCT05675319|DRUG|Autologous Stem Cells|Autologous Stem Cell Transplantation
218907513|NCT05675319|DRUG|daratumumab/pomalidomide/dexamethasone (DPD)|triple regimen for first relapse should be applied according to latest SmPC version
218907514|NCT05675319|DRUG|isatuximab/carfilzomib/dexamethasone (Isa-KD)|triple regimen for first relapse should be applied according to latest SmPC version
218907515|NCT05675319|DRUG|selinexor/bortezomib/dexamethasone (SVD)|triple regimen for first relapse should be applied according to latest SmPC version
218907516|NCT04421170|BEHAVIORAL|smartphone app for smoking cessation|Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
219613221|NCT02236260|DRUG|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
219613222|NCT03514459|OTHER|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement \[CQI\] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
219613483|NCT00154661|DRUG|pentoxifylline|
218907517|NCT04730765|PROCEDURE|left elective colectomy (Surgical Experimental Group)|Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.
218907518|NCT04730765|DRUG|antibiotic therapy (medical Control Group)|Antibiotic treatement for 10 days by oral or intravenous administration
218907519|NCT02742961|OTHER|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
218907520|NCT05241379|DEVICE|Amber UI System|The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
218907521|NCT00143910|OTHER|observation|
218907522|NCT01754974|BIOLOGICAL|Peginterferon Lambda-1a|
218907523|NCT01754974|DRUG|Ribavirin|
218907524|NCT01754974|BIOLOGICAL|Peginterferon alfa-2a|
218907525|NCT05354908|OTHER|scientific and academic productivity|Number and quartile of scientific products generated by the group
219521878|NCT06561750|OTHER|Control|Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea
219521879|NCT06139588|DEVICE|acellular dermal matrix implant for breast reconstruction|acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
219521880|NCT00318383|BIOLOGICAL|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
218907526|NCT01011673|DRUG|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
218907527|NCT01011673|DRUG|Ketorolac|ketorolac 30mg IVSS
218907528|NCT03242629|DRUG|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
218907529|NCT03242629|DRUG|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
218907530|NCT04199507|OTHER|physical fitness assessment|assessment
218907531|NCT02828761|DEVICE|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
218907532|NCT02828761|PROCEDURE|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
218907533|NCT03225235|RADIATION|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
218907534|NCT03651635|DIAGNOSTIC_TEST|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1
218907535|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
218907536|NCT01682408|DRUG|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
218907537|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
218907538|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
218907539|NCT01682408|DRUG|Ranitidine|150 mg ranitidine
218907540|NCT04958499|BEHAVIORAL|Bio-healthy Park|Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
218907541|NCT00064285|DRUG|alvocidib|
218907542|NCT00064285|DRUG|imatinib mesylate|
218907543|NCT02028481|PROCEDURE|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
218907544|NCT03833492|BEHAVIORAL|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
218907545|NCT02774980|BEHAVIORAL|Recurrent depression|
218907546|NCT00184223|BEHAVIORAL|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
218907547|NCT00184223|OTHER|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
218907548|NCT00626275|DRUG|ADL5859|
218907549|NCT00626275|DRUG|Naproxen|
218907550|NCT00626275|DRUG|Placebo|
218907551|NCT00626275|DRUG|ADL5859|
218907552|NCT00626275|DRUG|Placebo|
219039757|NCT04206293|DEVICE|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
219039758|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
219039759|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
219039760|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
219039761|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
219039762|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
219039763|NCT00599937|DRUG|ATRA|early introduction of ATRA
219521881|NCT00318383|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
219521882|NCT05606393|OTHER|virtual reality speech training|virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software
219521883|NCT05606393|OTHER|traditional speech therapy|traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
219521884|NCT03368508|BEHAVIORAL|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
219521885|NCT03368508|BEHAVIORAL|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
219521886|NCT03495622|BEHAVIORAL|Motivational Interviewing/Text messaging|"The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial"
219521887|NCT01594203|OTHER|F18-FGD PET/CT|
219521888|NCT01378039|DRUG|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
219521889|NCT02137135|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
219521890|NCT02137135|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
219204427|NCT06890442|DEVICE|CT|"Thickened Medial Pterygoid Plates In bony atresia, excessive thickening of the medial pterygoid plates is common. Narrowing or Fusion of the Posterior Choanae Complete bony or membranous obstruction at the choanal opening. Abnormal Sphenoid Bone Development Hypoplasia or deformity in the sphenoid sinus, affecting adjacent structures. Vomer Deviation or Hypertrophy The vomer bone is often displaced or abnormally thickened, contributing to obstruction.~Abnormal Development of the Hard Palate"
219521891|NCT02137135|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
219521892|NCT00857935|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
219521893|NCT00857935|DRUG|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
219521894|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
219521895|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
219521896|NCT01498003|DRUG|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
219521897|NCT01498003|DRUG|normal saline solution|same use as tirofiban
219521898|NCT01433497|DRUG|Masitinib|
219521899|NCT01433497|DRUG|Placebo|
219521900|NCT00431197|DRUG|Ketoconazole, Dexamethesone, Androgel,GnRH|
219521901|NCT02731157|DRUG|Rejuvesol|
219521902|NCT02731157|PROCEDURE|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
219521903|NCT05194748|OTHER|No intervention, observational only|No intervention, observational only
219521904|NCT06126848|DEVICE|Ambient sensor system|Main study: A contactless non-intrusive ambient sensor system including infrared motion sensors combined with a contactless Emfit bed sensor will be installed in the home of single living study patients by using a commercially available System (Domo Health®, Lausanne) after informed consent has been obtained. Sensor data are prospectively followed over 3-6 months for predefined indicators of health deterioration. If indicators for health deterioration are present, patients will be called in to the hospital for cardiology consult by the study team including blood analysis for follow-up of BNP values and if necessary, therapy adaption.
219521905|NCT03291548|DIETARY_SUPPLEMENT|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
219521906|NCT03291548|DIETARY_SUPPLEMENT|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
219521907|NCT01470560|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
219521908|NCT01470560|BEHAVIORAL|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
219521909|NCT02495558|OTHER|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
219521910|NCT05833581|OTHER|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
219521911|NCT03601663|BEHAVIORAL|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
219521912|NCT03601663|BEHAVIORAL|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
219521913|NCT03601663|BEHAVIORAL|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
219521914|NCT06110039|OTHER|Cervicothoracic Junction Mobilization|The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.
219613484|NCT05976880|OTHER|Conventional treatment of isometric hand grip training exercises|In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
218907553|NCT04736914|DRUG|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
218907554|NCT02760615|DRUG|Caffeine|Caffeine tablets
218907555|NCT02760615|DRUG|Losartan|Losartan tablets
218907556|NCT02760615|DRUG|Omeprazole|Omeprazole capsules
218907557|NCT02760615|DRUG|Dextromethorphan|Dextromethorphan capsules
218907558|NCT02760615|DRUG|Midazolam|Midazolam syrup
218907559|NCT02760615|DRUG|Vedolizumab|Vedolizumab solution for IV infusion
218907560|NCT03326388|DRUG|Selumetinib|Selumetinib Intermittent Dosing
218907561|NCT01651481|DRUG|HCP1102|
218907562|NCT01651481|DRUG|Singulair and Xyzal|
218907563|NCT05157295|DRUG|OnabotulinumtoxinA|100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
218907564|NCT06140602|OTHER|Intervention shake|The pecan shake contains 69g of pecans
218907565|NCT04361071|DEVICE|stent|stent
218907566|NCT04361071|DEVICE|plaque excision system|plaque excision system
218907567|NCT04335617|DRUG|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
218907568|NCT04335617|OTHER|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
218907569|NCT02719808|DRUG|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
218907570|NCT02719808|DRUG|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
218907571|NCT02719808|DRUG|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
218907572|NCT02719808|DRUG|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
218907573|NCT00040586|DRUG|Monoclonal Antibody J591|
218907574|NCT00040586|DRUG|Recombinant Interleukin-2|
218907575|NCT03207126|DIAGNOSTIC_TEST|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
218907576|NCT03367728|DRUG|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
218907577|NCT03367728|DRUG|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
218907578|NCT03761927|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
218907579|NCT03761927|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
219613485|NCT05976880|OTHER|Conventional treatment along with power ball training|In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
218907580|NCT03761927|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
218907581|NCT05647681|DRUG|Douloff|topic gel
218907582|NCT05647681|DRUG|paracetamol|tablets
218907583|NCT03740048|OTHER|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
218907584|NCT03740048|DRUG|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
218907585|NCT00000214|DRUG|Buprenorphine|
218907586|NCT02337868|BIOLOGICAL|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
218907587|NCT02337868|OTHER|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
218907588|NCT00348712|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
218907589|NCT00348712|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
218907590|NCT00348712|DRUG|metformin|Tablets, 2000 mg/day.
218907591|NCT05901701|RADIATION|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
218907592|NCT05901701|DEVICE|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
218907593|NCT05095961|DRUG|Prednisone|5 day course of oral prednisone pre-operatively. 30mg per day.
218907594|NCT00647179|PROCEDURE|Transsphenoidal adenomectomy|Surgery
218907595|NCT01480661|DRUG|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
218907596|NCT01480661|DRUG|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
218907597|NCT01480661|RADIATION|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
218907598|NCT03918616|DRUG|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
219521915|NCT06110039|OTHER|Upper Thoracic Spine Manipulation:|The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
219521916|NCT00389636|DEVICE|TheraGauze|TheraGauze
219521917|NCT00389636|DRUG|Regranex|Regranex + TheraGauze
219521918|NCT00921336|DRUG|KW-2450|Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
219521919|NCT04212949|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
219521920|NCT04212949|DRUG|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
219521921|NCT01407536|DEVICE|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
218907599|NCT03901417|DEVICE|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
218907600|NCT03901417|DEVICE|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
218907601|NCT05818488|OTHER|Experimental mind-body intervention|A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
218907602|NCT01798693|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|
218907603|NCT01798693|DIETARY_SUPPLEMENT|Multi-nutrient Blend|
218907604|NCT04816448|OTHER|cervical mobilization (Headache SNAG)|For cervical mobilization the patient's position is sitting on a chair in the erect posture. The therapist handled C2 spinous process with the middle phalanx of one hand. With the other hand, he performed ventral glide asked the patient to move neck in all directions (Flexion, Extension, Side bending and rotation) one by one and then slowly move the neck back to its starting position while the therapist maintained the ventral glide.
218907605|NCT04816448|OTHER|Sub-occipital myofascial release|"For the application of the technique , the patient position is supine lying with the head fully supported on therapist's hands and therapist places 3 middle fingers just inferior to the nuchal line, lifts the fingers tips towards the ceiling while resting the head on the table and then therapist will apply a gentle upward pull. This procedure done for 2 to 3 minutes and 5 to 7 repetitions, 3 sessions per week on alternate days were given for 6 weeks.~Evaluation was done before treatment, during treatment at 4th week and after treatment at 6th week. Outcomes will be measured by NDI, PNRS and Universal Goniometer."
218907606|NCT00171379|DRUG|Enteric-Coated Mycophenolate Sodium|
218907607|NCT04980534|DIETARY_SUPPLEMENT|Viusid and Asbrip|Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
218907608|NCT04980534|DRUG|COVID-19 Standard Therapy|Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
218907609|NCT05975723|BEHAVIORAL|MIND diet education|An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).
218907610|NCT05975723|BEHAVIORAL|Routine follow-up and general advice|Routine follow-up administered by trained staff.
219521922|NCT03955757|BEHAVIORAL|Boot Camp Translation|Communities in the intervention arm will participate in the Boot Camp translation process, where stakeholders will come together to develop and implement locally relevant materials to promote adolescent vaccination.
219521923|NCT03955757|OTHER|Control|No intervention. Communities will continue to behave as usual.
219521924|NCT05133609|BIOLOGICAL|ChAdOx1 nCoV-19 vaccine (AZD1222)|ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
219521925|NCT02175264|GENETIC|Blood sample|
219613486|NCT05398328|DEVICE|active metal appliance|fixed metal labial orthodontic appliance MBT 0.022'' slot
219613487|NCT05398328|DEVICE|active esthetic appliance|fixed ceramic labial orthodontic appliance MBT 0.022'' slot
219613488|NCT05398328|COMBINATION_PRODUCT|retention fixed appliance|fixed lingual metal retention appliance
219613489|NCT05398328|COMBINATION_PRODUCT|retention removable appliance|removable clear termoplastic retention appliance
218907611|NCT00292942|DRUG|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
218907612|NCT00292942|DRUG|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
218907613|NCT02848469|DIETARY_SUPPLEMENT|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
218907614|NCT00644358|DRUG|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
218907615|NCT02141087|DRUG|Pirfenidone|
218907616|NCT05476445|PROCEDURE|Control|Root canal treatment
218907617|NCT05476445|PROCEDURE|Laser|Root canal treatment+Laser application
218907618|NCT05476445|PROCEDURE|Cryotherapy|Root canal treatment + Cryotherapy application
218907619|NCT03496259|DEVICE|On-Q pump|Type of pain control device used
218907620|NCT03496259|DEVICE|Epidural catheter|Type of pain control device used
218907621|NCT03327493|DIAGNOSTIC_TEST|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
218907622|NCT03045367|PROCEDURE|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
218907623|NCT06389630|OTHER|video-assisted training group|This group will be taught subcutaneous insulin injection through video-supported training.
218907624|NCT06389630|OTHER|low fidelity simulation model group|This group will be taught subcutaneous insulin injection on a low-fidelity simulation model.
218907625|NCT00049023|RADIATION|90Y-DOTA-tyr3-OCTREOTIDE|
218907626|NCT02826746|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
218907627|NCT02826746|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
218907628|NCT00651924|BEHAVIORAL|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
218907629|NCT01356160|DRUG|GS-5885|tablet, 30 mg QD
218907630|NCT01356160|DRUG|GS-9451|tablet, 200 mg QD
218907631|NCT01356160|BIOLOGICAL|peginterferon alfa-2a|(solution for injection) 180 µg/week
218907632|NCT01356160|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
218907633|NCT01356160|DRUG|GS-9451 Placebo|Placebo to match GS-9451 QD
218907634|NCT03630796|DRUG|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
218907635|NCT03630796|DRUG|TIVA|Total intravenous anesthesia
218907636|NCT05249023|OTHER|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
218907637|NCT05405010|OTHER|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
218907638|NCT05405010|OTHER|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
218907639|NCT05405010|OTHER|Seated control|Seated control
218907640|NCT00960063|DRUG|Temozolomide|
219039764|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
218907641|NCT00960063|DRUG|Vincristine|
218907642|NCT00960063|DRUG|Ifosfamide|
218907643|NCT00960063|DRUG|Irinotecan|
218907644|NCT00960063|BIOLOGICAL|Robatumumab|
218907645|NCT00960063|DRUG|Doxorubicin|
218907646|NCT00960063|DRUG|Cyclophosphamide|
218907647|NCT00960063|DRUG|Etoposide|
218907648|NCT02859922|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
218907649|NCT02859922|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
218907650|NCT01406301|DRUG|fondaparinux|fondaparinux
218907651|NCT01672645|BIOLOGICAL|NIC7-001|Intramuscular, multiple dose
218907652|NCT01672645|BIOLOGICAL|NIC7-003|Intramuscular, multiple dose
218907653|NCT01672645|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
218907654|NCT03341416|DEVICE|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
218907655|NCT03341416|DEVICE|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
218907656|NCT04480320|PROCEDURE|pericapsular nerve group block|Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
218907657|NCT03771755|DRUG|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
218907658|NCT03771755|DRUG|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
218907659|NCT01636765|DRUG|No Intervention|No intervention.
218907660|NCT01386164|BIOLOGICAL|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
218907661|NCT01386164|BIOLOGICAL|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
218907662|NCT03944928|OTHER|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
218907663|NCT00976131|DRUG|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
218907664|NCT00976131|OTHER|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
218907665|NCT00976131|DRUG|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
218907666|NCT00976131|DRUG|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
218907667|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
218907668|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
218907669|NCT03678272|PROCEDURE|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
218907670|NCT03678272|PROCEDURE|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
219613490|NCT03629262|DRUG|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
218907671|NCT04102397|PROCEDURE|Vojta therapy after standard therapy|Vojta Therapy \~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
219039765|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
218907672|NCT04102397|PROCEDURE|Standard therapy|"\~50 minutes/session:~* TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~* Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~* Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~* Cryotherapy (5 minutes)."
218907673|NCT00531765|OTHER|sodium bicarbonate infusion|short infusion of sodium bicarbonate
218907674|NCT03975010|DRUG|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
218907675|NCT04839939|OTHER|Conventional physical therapy|Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
218907676|NCT04839939|OTHER|Ankle Foot Orthosis|Solid prescribed AFO with a wearing schedule of 6-12 hours per day
218907677|NCT04839939|OTHER|Combination Taping|Combination between elastic and inelastic taping
219365009|NCT00948961|BIOLOGICAL|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
219365010|NCT00948961|BIOLOGICAL|CDX-1401|
218907678|NCT03273426|PROCEDURE|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
218907679|NCT03273426|PROCEDURE|wide excision|Surgical wide excision of the biopsied area.
219039766|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
219039767|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
219365011|NCT00948961|BIOLOGICAL|Resiquimod|
219365012|NCT00948961|BIOLOGICAL|poly-ICLC|
218907680|NCT05313113|BEHAVIORAL|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
218907681|NCT05083351|DEVICE|MightySat|Noninvasive pulse oximeter
218907682|NCT00871767|DRUG|AZD5672|40 mg tablet (Test formulation)
218907683|NCT00871767|DRUG|AZD5672|40 mg tablet (Reference formulation)
218907684|NCT00871767|DRUG|AZD5672|100 mg tablet (Test formulation)
218907685|NCT00871767|DRUG|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
218907686|NCT05604846|DIETARY_SUPPLEMENT|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
218907687|NCT01152658|BIOLOGICAL|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
218907688|NCT01152658|OTHER|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
218907689|NCT03297957|DEVICE|Hands-free goggle system|-Manufactured at Washington University
218907690|NCT01792700|DRUG|esomeprazole|
218907691|NCT01792700|DRUG|tripotassium dicitrate bismuthate|
218907692|NCT01792700|DRUG|metronidazole|
218907693|NCT01792700|DRUG|tetracycline|
218907694|NCT01792700|DRUG|moxifloxacin|
219521926|NCT02154321|DEVICE|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
218907695|NCT01792700|DRUG|amoxicillin|
219039768|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
219521927|NCT05515926|PROCEDURE|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
218907696|NCT04937985|OTHER|Performance Tests|Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
218907697|NCT01402440|DRUG|AEB071|
218907698|NCT04097431|BEHAVIORAL|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
218907699|NCT00259909|OTHER|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
218907700|NCT00259909|OTHER|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
218907701|NCT00259909|OTHER|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
218907702|NCT00259909|OTHER|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
218907703|NCT01759420|DRUG|Ondansetron|4mg of intravenous ondansetron
218907704|NCT00166218|DEVICE|near-infrared spectroscopy|
218907705|NCT01998256|DEVICE|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
218907706|NCT05389098|OTHER|Hand-Eating|eat-hands type food mode
218907707|NCT05389098|OTHER|Control|Usual eating mode
218907708|NCT04326920|DRUG|Sargramostim|Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
218907709|NCT04326920|OTHER|Control|Standard of care
218907710|NCT05106127|DRUG|EG-007|A Repurposed Drug
219039769|NCT02773043|DEVICE|CZT SPECT camera|
219039770|NCT00962130|DEVICE|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
219039771|NCT00430092|DRUG|Difluprednate|
219039772|NCT00430092|DRUG|Difluprednate|
219039773|NCT00430092|DRUG|Placebo|
219039774|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
219039775|NCT04966338|BIOLOGICAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
218907711|NCT05106127|DRUG|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
218907712|NCT05106127|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
218907713|NCT04325802|DRUG|Naltrexone|50mg Naltrexone daily
218907714|NCT04325802|OTHER|Placebo|Placebo (Mannitol) daily
219039776|NCT04966338|BIOLOGICAL|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
218907715|NCT03920345|DEVICE|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
218907716|NCT04896528|DRUG|Avatrombopag|"* Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment."
218907717|NCT01129622|DRUG|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
219521928|NCT05515926|PROCEDURE|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
219521929|NCT02151032|BEHAVIORAL|Booklet|Participants read a booklet about colorectal cancer screening tests.
219521930|NCT02151032|BEHAVIORAL|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
219521931|NCT02151032|BEHAVIORAL|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
218907718|NCT00004838|DRUG|succimer|
218907719|NCT02900794|DEVICE|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
218907720|NCT02900794|PROCEDURE|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
218907721|NCT02949349|DRUG|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
218907722|NCT02949349|DRUG|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
218907723|NCT02949349|DRUG|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
218907724|NCT05046223|PROCEDURE|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
218907725|NCT05046223|PROCEDURE|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
219039777|NCT01352390|BEHAVIORAL|Planning Prompt|A prompt to have their child their health test reminder mailing to color
219521932|NCT02151032|BEHAVIORAL|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
219521933|NCT02151032|BEHAVIORAL|Questionnaires|Questionnaire completion before and after viewing the program.
219521934|NCT04450043|BEHAVIORAL|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
218907726|NCT02733263|DIETARY_SUPPLEMENT|15 g RMD|15 grams of resistant maltodextrin
218907727|NCT02733263|DIETARY_SUPPLEMENT|25 g RMD|25 grams of resistant maltodextrin
218907728|NCT02733263|DIETARY_SUPPLEMENT|0 g RMD|0 grams of resistant maltodextrin
218907729|NCT04256694|DIAGNOSTIC_TEST|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
218907730|NCT00002814|BIOLOGICAL|filgrastim|
218907731|NCT00002814|DRUG|paclitaxel|
218907732|NCT00002814|DRUG|topotecan hydrochloride|
218907733|NCT03585478|DRUG|Latiglutenase|Latiglutenase administered orally (daily)
218907734|NCT03585478|OTHER|Placebo|Placebo administered orally (daily)
218907735|NCT04364477|PROCEDURE|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
219039778|NCT01352390|BEHAVIORAL|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
219039779|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 1
219039780|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 2
219039781|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 3
219039782|NCT01529424|DRUG|Placebo|Dose 1
219039783|NCT01529424|DRUG|Placebo|Dose 2
219039784|NCT01529424|DRUG|Placebo|Dose 3
219521935|NCT04450043|BEHAVIORAL|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
219521936|NCT04450043|BEHAVIORAL|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
219521937|NCT00738803|PROCEDURE|Total hip replacement|Total hip replacement typically preformed for hip arthritis
219521938|NCT01807208|OTHER|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
219521939|NCT00430079|DRUG|etanidazole|Given IV
219521940|NCT00430079|PROCEDURE|conventional surgery|Undergo surgery
219521941|NCT00430079|OTHER|pharmacological study|Correlative studies
219521942|NCT00430079|OTHER|laboratory biomarker analysis|Correlative studies
218907736|NCT03101280|DRUG|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
218907737|NCT03101280|DRUG|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
218907738|NCT01204099|DRUG|Docetaxel|
218907739|NCT01204099|DRUG|PX-866|
218907740|NCT05329844|DRUG|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
218907741|NCT00591006|DRUG|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
219039785|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
219039786|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
219521943|NCT05141864|BIOLOGICAL|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
219521944|NCT05141864|DRUG|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
219521945|NCT05141864|OTHER|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
219039787|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
219039788|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
219039789|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
219039790|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
219039791|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
219039792|NCT00854503|DRUG|Simvastatin|20 mg/day in one oral administration
219039793|NCT00854503|DRUG|Rosuvastatin|20 mg/day in one oral administration.
219521946|NCT04366232|DRUG|Anakinra alone (stages 2b/3)|Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
219521947|NCT04366232|DRUG|Anakinra and Ruxolitinib (overcome stage 3)|Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
219521948|NCT04366232|OTHER|Standard of care|Routine clinical care for Covid-19
219521949|NCT04804800|OTHER|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
219521950|NCT04804800|OTHER|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
219521951|NCT00197210|BIOLOGICAL|Rotavirus|
219521952|NCT04182152|DEVICE|Indocyanine green (ICG)|Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
219521953|NCT04182152|DEVICE|Electromagnetic navigation bronchoscopy|Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
219521954|NCT04182152|DEVICE|Hook wire|Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
219521955|NCT05614570|DEVICE|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
219521956|NCT05614570|OTHER|SCAT5|The Sport Concussion Assessment Tool version 5
219521957|NCT05618470|DRUG|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
219521958|NCT05618470|DRUG|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
218907742|NCT00591006|DRUG|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
218907743|NCT00591006|DRUG|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
219521959|NCT02802436|PROCEDURE|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
219521960|NCT04978532|OTHER|Guided Imagery|The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
219521961|NCT04978532|OTHER|Control Group|No intervention was made in the children.
219521962|NCT03299400|DEVICE|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
219039794|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
219039795|NCT01225445|DRUG|Ramipril|2.5 mg daily
219039796|NCT00280254|PROCEDURE|Hemodynamically Oriented Echocardiography-based Strategy|
219521963|NCT00237549|PROCEDURE|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
219521964|NCT01783171|DRUG|Akt Inhibitor MK2206|Given PO
219521965|NCT01783171|DRUG|Dinaciclib|Given IV
219521966|NCT01783171|OTHER|Laboratory Biomarker Analysis|Correlative studies
219521967|NCT01783171|OTHER|Pharmacological Study|Correlative studies
219039797|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
219039798|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
219039799|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
219039800|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
219039801|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
219039802|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
219039803|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
219039804|NCT03848546|BEHAVIORAL|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
219039805|NCT03848546|OTHER|Control (no intervention)|No intervention
219039806|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219521968|NCT04392271|DRUG|LY3372689|Administered orally.
219521969|NCT04392271|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered intravenously (IV).
219039807|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
218907744|NCT04368026|OTHER|No intervention (survey study for medical doctors).|No intervention
218907745|NCT00054392|DRUG|carboplatin|
219039808|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
219039809|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
219039810|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|\- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
219521970|NCT01309607|DRUG|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously"
219039811|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
219521971|NCT05303909|DRUG|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
219521972|NCT05303909|DRUG|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
219521973|NCT01611389|DEVICE|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
219039812|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
219521974|NCT01611389|DEVICE|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
219521975|NCT01987271|DEVICE|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
219521976|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
219521977|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
219521978|NCT00623779|DRUG|AZD0837|ER formulation
219521979|NCT00623779|DRUG|Aspirin|Oral form
219521980|NCT01014728|DRUG|propofol|100-200mcg/kg/min by infusion
219613223|NCT06007001|DEVICE|Telemedicine|"Pilot 1a/b : the tele-rehabilitation intervention in BC or H\&N operated patients will consist of a series of exercises. The physiotherapist during teleconsultation rehabilitation program will explain to the patient how to perform the movements and regulate breathing. Practical advice on correct and incorrect habits will also be dispensed by the physiotherapist during the teleconsultation.~Pilot 2: the tele-rehabilitation intervention will consist of tele psychological support performed by a trained psychologist in each participating center It will consist of the learning of techniques for managing negative emotions, for relaxation and for implementing effective behavioural and coping strategies.~For each group, the TC will be scheduled every week for 8 weeks. The session will be available on a secure platform (Edumeet). Moreover, if they agree to, patients will also wear a smart watch to monitor physical parameters such as physical activity, sleeping and heart rate."
218907746|NCT00054392|DRUG|gemcitabine hydrochloride|
219521981|NCT01014728|DRUG|sevoflurane|1-3% of sevoflurane (expired)
219521982|NCT03287609|DRUG|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
218907747|NCT00054392|DRUG|paclitaxel|
218907748|NCT04207034|PROCEDURE|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
219039813|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
219039814|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
219039815|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
219521983|NCT03287609|DRUG|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
219521984|NCT06025448|PROCEDURE|BIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).
219521985|NCT06025448|PROCEDURE|MIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).
219521986|NCT03806062|DRUG|domperidone|10 mg domperidone 3 times a day after meals
219521987|NCT03806062|DEVICE|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
219613224|NCT02730910|OTHER|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
218907749|NCT04207034|PROCEDURE|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
218907750|NCT03576508|DRUG|CNTX-4975-05|1 mg (2mL) IA injection
218907751|NCT03576508|DRUG|Qutenza|8% topical patch
218907752|NCT03576508|DRUG|Lidocaine (without epinephrine)|15 mL IA injection of 2% lidocaine (without epinephrine)
218907753|NCT05213832|DRUG|Isoflurane Inhal Soln|Administration of isofluorane in patients with severe SAH
218907754|NCT01064063|DEVICE|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
218907755|NCT01064063|DEVICE|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
218907756|NCT01334060|BIOLOGICAL|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
218907757|NCT06091696|OTHER|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
218907758|NCT06091696|OTHER|Aerobic exercises|Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).
218907759|NCT03009786|OTHER|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
218907760|NCT03400618|OTHER|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
218907761|NCT03400618|OTHER|Higher carbohydrate diet|50 E % carbohydrates included in the diet
218907762|NCT05594459|PROCEDURE|Mini invasive analgesic technique|patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
218907763|NCT05594459|DRUG|high opioids dosages|patients will be treated with high opioids dosages
218907764|NCT00689390|BIOLOGICAL|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
218907765|NCT00689390|BIOLOGICAL|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
218907766|NCT00689390|BIOLOGICAL|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
218907767|NCT00689390|DRUG|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
218907768|NCT00689390|OTHER|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
218907769|NCT01434277|OTHER|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
218907770|NCT02343263|DRUG|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
218907771|NCT02343263|BIOLOGICAL|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
218907772|NCT04068402|DEVICE|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
219039816|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
219039817|NCT04210154|DEVICE|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
219204428|NCT06732479|BEHAVIORAL|Behavioural Skill Training Programme|"BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently"
219521988|NCT03806062|DEVICE|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
219521989|NCT05696639|PROCEDURE|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
218907773|NCT00701285|DRUG|pitavastatin|pitavastatin 4mg once daily
218907774|NCT00701285|DRUG|pravastatin|pravastatin 10mg once daily
218907775|NCT03174184|DRUG|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
218907776|NCT03174184|DRUG|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
219039818|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
219521990|NCT02749513|DRUG|Itraconazole|
219521991|NCT02520505|DRUG|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
219521992|NCT02520505|BEHAVIORAL|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
219521993|NCT02520505|PROCEDURE|Intrauterine Insemination|Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
219521994|NCT01696097|BEHAVIORAL|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
219521995|NCT02977520|PROCEDURE|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
219521996|NCT04208503|DIAGNOSTIC_TEST|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
219521997|NCT02768064|DEVICE|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
219521998|NCT03097900|DRUG|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
219521999|NCT03097900|OTHER|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
219613225|NCT02730910|OTHER|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
219613226|NCT05264038|DRUG|OC514 (Low dose)|Low dose level of OC514
219522000|NCT01434693|BIOLOGICAL|Trichuris suis ova|single dose
219522001|NCT01434693|OTHER|Placebo|
219522002|NCT01440283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
219522003|NCT00444197|BEHAVIORAL|Mentoring and violence prevention curriculum with parental monitoring|
219522004|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
219613227|NCT05264038|DRUG|OC514 (Mid dose)|Mid dose level of OC514
219613228|NCT05264038|DRUG|OC514 (High dose)|High dose level of OC514
219613229|NCT05264038|OTHER|Placebo|Placebo to match
219613230|NCT03239535|BIOLOGICAL|Mesenchymal stem cells|Intramuscular injection
219613231|NCT03239535|BIOLOGICAL|Normal saline|Intramuscular injection
219613232|NCT03869619|OTHER|Real-life epidemiological platform of lymphoma in France|"The REALYSA database will be described with the following characteristics:~* Number of patients included per month in total and according to subtype of lymphoma~* Number of patients in each region in total and according to subtype of lymphoma"
219613233|NCT03456102|DRUG|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
218907777|NCT03174184|DRUG|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
218907778|NCT03174184|DRUG|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
218907779|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
218907780|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
218907781|NCT00973752|DRUG|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
218907782|NCT00973752|DRUG|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
218907783|NCT00973752|DRUG|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
218907784|NCT00973752|DRUG|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
218907785|NCT00973752|DRUG|Cytarabine|Intrathecally during Induction and CNS therapy
218907786|NCT00973752|DRUG|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
218907787|NCT00973752|DRUG|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
219039819|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
219039820|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
219522005|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
219522006|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
219522007|NCT03755609|DRUG|Oxycodone|0.1 mg/kg intravenously
219522008|NCT03755609|DRUG|fentanyl|1ug/kg intravenously
219522009|NCT00376922|PROCEDURE|music therapy|music played for patient during bone marrow biopsy collection
219522010|NCT00539266|BIOLOGICAL|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
219522011|NCT00539266|BIOLOGICAL|placebo|40 IM injections (calf muscle) of placebo suspension
219522012|NCT05267366|DRUG|PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed|PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
219522013|NCT00377390|BIOLOGICAL|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
219522014|NCT02865564|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|
219522015|NCT02865564|DIETARY_SUPPLEMENT|Placebo|
219522016|NCT02865564|DRUG|ampicillin and gentamicin|
219522017|NCT05856903|DIAGNOSTIC_TEST|ACT|"ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers"
219522018|NCT01388270|DEVICE|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
219522019|NCT04999670|PROCEDURE|Fascial closure method during caesarean section via pfannenstiel incision.|Comparison of three different methods of fascial closure.
219522020|NCT00254956|DRUG|ciclesonide (XRP1526)|
219522021|NCT04763005|BEHAVIORAL|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
219522022|NCT04763005|BEHAVIORAL|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
219522023|NCT02869425|DRUG|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
219522024|NCT02869425|DRUG|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
218907788|NCT00973752|DRUG|Clofarabine|Intravenously during Consolidation 1 Therapy
218907789|NCT00973752|DRUG|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
218907790|NCT02023424|DRUG|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
219522025|NCT03827863|DEVICE|TTE|TTE to detect the heart function
219522026|NCT03229018|DIAGNOSTIC_TEST|Voxel size|200 μm and 300 μm Voxel Sizes
219522027|NCT01683032|DRUG|MPH|a capsule containing 20 mg
219522028|NCT04173650|DRUG|AGLE-102|Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations
218907791|NCT01723735|DRUG|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218907792|NCT01723735|DRUG|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
218907793|NCT01723735|DRUG|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
218907794|NCT01723735|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
218907795|NCT05633563|DRUG|Trimetazidine|Oral intake of capsules
218907796|NCT05633563|DRUG|Placebo|Oral intake of capsules
219522029|NCT02514655|DEVICE|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
219613491|NCT03629262|DRUG|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
218907797|NCT01780116|BEHAVIORAL|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
218907798|NCT04872361|PROCEDURE|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
218907799|NCT04872361|PROCEDURE|High PEEP|PEEP of 10 cm H2O will be applied
218907800|NCT04872361|PROCEDURE|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
218907801|NCT04872361|DEVICE|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
218907802|NCT01713959|DEVICE|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
218907803|NCT01713959|DEVICE|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
218907804|NCT05668832|DIETARY_SUPPLEMENT|UVB-exposed button mushrooms|Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
218907805|NCT00392392|DRUG|nab-paclitaxel|ABI-007
218907806|NCT00392392|DRUG|Bevacizumab|Bevacizumab
218907807|NCT00392392|DRUG|Trastuzumab|Trastuzumab
218907808|NCT05334368|DRUG|Depemokimab|Depemokimab will be administered.
218907809|NCT05334368|OTHER|Placebo|Matching placebo will be administered.
218907810|NCT00490464|DRUG|Nicardipine and Nipride|
218907811|NCT00931034|BEHAVIORAL|South Beach Diet with South Beach Diet Products|
219613234|NCT03662802|OTHER|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
218907812|NCT00931034|BEHAVIORAL|American Diabetes Association Diabetes Meal Plan|
218907813|NCT05701293|PROCEDURE|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
218907814|NCT03153696|BEHAVIORAL|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
218907815|NCT06519812|PROCEDURE|Combined Intrarenal Surgery and percutaneous nephrolithotomy|A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
218907816|NCT00663013|OTHER|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
219039821|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
219039822|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
219039823|NCT03624868|BEHAVIORAL|Tai Chi|See above description
219039824|NCT03624868|BEHAVIORAL|Wellness Education|See above description
219613492|NCT02813915|DEVICE|NICOM|Use of NICOM and PLR to obtain patient fluid status
219613493|NCT00347984|OTHER|Systane Lubricant eye drops|
218907817|NCT03495466|PROCEDURE|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
218907818|NCT01682733|DRUG|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
219039825|NCT04809688|DIETARY_SUPPLEMENT|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
219039826|NCT04809688|DIETARY_SUPPLEMENT|Dried Saskatoon berry|Prediabetic patients (fasting glucose 5.6-6.9 mM/L, HbA1c 5.7-6.9%, or OGTT 2 h glucose 7.8-11 mM/L) will be randomized in two groups. One group participants will take 40g of dried Saskatoon berry/day for 12 weeks. Another group will take 40g of dried Saskatoon berry/day for 12 weeks,
219039827|NCT00044954|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219039828|NCT00044954|DRUG|cyclosporine|
219039829|NCT00044954|DRUG|fludarabine phosphate|
219039830|NCT00044954|DRUG|mycophenolate mofetil|
218907819|NCT01682733|DEVICE|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
218907820|NCT06306209|OTHER|Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management|All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.
218907821|NCT03494270|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
218907822|NCT03494270|DRUG|Monorova|Rosuvastatin 20mg
219039831|NCT00044954|PROCEDURE|allogeneic bone marrow transplantation|
219522030|NCT02514655|OTHER|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
219522031|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from TIMP microbiome project will be analyzed with NGS techniques.
219522032|NCT06525831|DIAGNOSTIC_TEST|MR-elastography exam|Imaging acquisition
219522033|NCT06525831|DIAGNOSTIC_TEST|Ultrasound exam|Imaging acquisition
219522034|NCT06181825|BEHAVIORAL|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
218907823|NCT00394199|DRUG|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
218907824|NCT00394199|DRUG|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
218907825|NCT00394199|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
218907826|NCT02416999|DRUG|Ultra-low dose Bevacizumab|
218907827|NCT02416999|DRUG|Temozolomide|
219039832|NCT00044954|PROCEDURE|peripheral blood stem cell transplantation|
219039833|NCT00044954|RADIATION|radiation therapy|
219522035|NCT04963309|OTHER|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
219522036|NCT04598243|DIETARY_SUPPLEMENT|Smart Energy System|A nutritional /herbal combination
219522037|NCT01891409|DEVICE|Male circumcision using the Shang Ring device|
219522038|NCT00177593|BEHAVIORAL|behavioral weight loss|
219522039|NCT03778905|OTHER|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
219522040|NCT05265806|DRUG|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
218907828|NCT01176734|DEVICE|tVNS-Device|Active treatment with the t-VNS device.
218907829|NCT04604041|DIAGNOSTIC_TEST|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
218907830|NCT00085163|DRUG|celecoxib|
218907831|NCT00085163|DRUG|fluorouracil|
218907832|NCT00085163|DRUG|leucovorin calcium|
218907833|NCT00085163|PROCEDURE|adjuvant therapy|
219039834|NCT03758638|BEHAVIORAL|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an \~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
219522041|NCT05265806|DRUG|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
219522042|NCT05265806|DRUG|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
219522043|NCT02679183|DIETARY_SUPPLEMENT|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
219522044|NCT02679183|OTHER|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
219522045|NCT06093425|DRUG|TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
219522046|NCT06093425|DRUG|Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
219522047|NCT02173236|OTHER|platform-switched implants|
219522048|NCT02173236|OTHER|platform-matched implant|
219522049|NCT00188656|PROCEDURE|CT thorax|
219522050|NCT00534703|GENETIC|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
219613235|NCT04947215|DIAGNOSTIC_TEST|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
219613236|NCT06119893|DRUG|submucosal 8 mg (2 mL) dexamethasone application|The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
219613237|NCT06119893|DRUG|submucosal 2 mL 0.9% isotonic sodium chloride application|The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
219613238|NCT05454891|DRUG|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
219522051|NCT00534703|DRUG|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
219522052|NCT00582400|DRUG|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
219613239|NCT05454891|DRUG|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
219613240|NCT03205878|OTHER|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
219522053|NCT05436756|OTHER|Biological sampling and collection|"* Biological sampling and collection:~  * whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~ * urine: 1 bottle of 30ml~* Freezing of serum after centrifugation~* Storage~* Collection of clinico-biological data on a dedicated eCRF"
219613241|NCT03205878|DEVICE|CPAP|Patients will receive CPAP according to standard care
219613242|NCT05362188|DRUG|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel)."
219613243|NCT04692311|DEVICE|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
219613244|NCT04692311|OTHER|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
218907834|NCT02066766|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
218907835|NCT05606666|OTHER|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
218907836|NCT05869435|DEVICE|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
218907837|NCT05833529|BEHAVIORAL|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
218907838|NCT05833529|OTHER|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
219039835|NCT03758638|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
219039836|NCT01515683|BEHAVIORAL|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
219522054|NCT02161848|OTHER|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
219522055|NCT03257085|OTHER|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
219522056|NCT03257085|OTHER|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
219613245|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
219613246|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219613247|NCT01290068|DEVICE|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
219613248|NCT05442151|DRUG|PET/CT ([F-18]FAPI-74)|PET/CT using \[18F\] FAPI-74 injection
219613249|NCT05399472|DIAGNOSTIC_TEST|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
218907839|NCT05833529|BEHAVIORAL|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
218907840|NCT02316730|DRUG|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
218907841|NCT02316730|DRUG|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
218907842|NCT01112137|DRUG|Clopidogrel|
218907843|NCT01112137|DRUG|Clopidogrel|
218907844|NCT01112137|DRUG|Clopidogrel|
219522057|NCT01936948|PROCEDURE|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
219522058|NCT02589223|OTHER|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
219522059|NCT02589223|OTHER|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
219522060|NCT02007122|OTHER|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
219522061|NCT02007122|OTHER|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
219522062|NCT03494322|DRUG|Avelumab|Avelumab 10 mg/kg given IV
219522063|NCT03494322|DRUG|Cetuximab|"Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in."
218907845|NCT01112137|DRUG|Clopidogrel|
219039837|NCT01515683|BEHAVIORAL|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
219522064|NCT05039190|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
219522065|NCT05039190|DRUG|Placebo|Placebo Injection
219522066|NCT02781727|DRUG|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
219522067|NCT02781727|DRUG|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
219522068|NCT02327130|DEVICE|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
219522069|NCT06144710|DRUG|SG301 SC Injection|Subcutaneous injection every two weeks
219522070|NCT06144710|DRUG|SG301 SC Placebo|Subcutaneous injection every two weeks
219522071|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
219522072|NCT03393858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
219522073|NCT03393858|BIOLOGICAL|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
219522074|NCT03393858|DEVICE|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
219522075|NCT06431594|DRUG|GSK5733584|GSK5733584 will be administered
218907846|NCT05093816|BEHAVIORAL|Common Elements Toolbox|The Common Elements Toolbox (COMET) is an online single-session intervention. It is entirely self-guided and lasts about 60 minutes. Participants complete a series of reading and writing exercises focused on four modules: cognitive restructuring, behavioral activation, gratitude, and self-compassion. The intervention is entirely unguided and completed in a single sitting.
218907847|NCT00732212|DEVICE|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
218907848|NCT00732212|OTHER|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
218907849|NCT04258423|DRUG|Tacrolimus|Low dose Tacrolimus
218907850|NCT04258423|DRUG|Everolimus|Everolimus
219039838|NCT01515683|BEHAVIORAL|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
219039839|NCT01515683|BEHAVIORAL|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
219039840|NCT06287346|DEVICE|dental implant|ceramic dental implant
219039841|NCT02586493|DRUG|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
219522076|NCT00003706|DRUG|pemetrexed disodium|
218907851|NCT04129593|BEHAVIORAL|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
218907852|NCT04129593|BEHAVIORAL|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
218907853|NCT02361359|OTHER|Psychological questionnaires|
218907854|NCT02584946|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
218907855|NCT02372643|OTHER|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
219522077|NCT05720572|DRUG|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
219522078|NCT05720572|DRUG|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
219522079|NCT00495326|DRUG|Nevirapine based therapy|"* Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
219522080|NCT00495326|DRUG|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
218907856|NCT02588599|DEVICE|Erchonia LUNULA|Active low level laser light therapy
218907857|NCT04254393|BEHAVIORAL|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
218907858|NCT04254393|OTHER|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
218907859|NCT02567981|DIETARY_SUPPLEMENT|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
219522081|NCT00495326|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"* Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase."
219522082|NCT05188937|PROCEDURE|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
219522083|NCT05602519|DRUG|propofol, rocuronium and fentanyl|In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
219522084|NCT05783284|DEVICE|Holocare Studio 2 (HS2)|3D HV
219522085|NCT04641559|OTHER|Personalized nutrition group|"A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI."
219522086|NCT04641559|OTHER|Personalized Plan group|Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
219522087|NCT04641559|OTHER|Control group|The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
219522088|NCT00988624|DRUG|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
219522089|NCT00988624|DRUG|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
219522090|NCT00988624|DRUG|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
219522091|NCT00988624|DRUG|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
219522092|NCT00988624|DRUG|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
219522093|NCT02226458|DRUG|EPI-743|
219522094|NCT02450981|DRUG|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
219522095|NCT00721604|DRUG|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
219522096|NCT01918800|BEHAVIORAL|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
219522097|NCT01918800|BEHAVIORAL|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
219522098|NCT03960970|DRUG|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
219039842|NCT02586493|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
219522099|NCT03960970|DRUG|Mefoxin 2g|Standard Prophylaxis
219522100|NCT02609464|DEVICE|Interrupted Knotted Sutures|
219522101|NCT02609464|DEVICE|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
219522102|NCT04285749|DRUG|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
219522103|NCT04285749|OTHER|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
219522104|NCT04285749|OTHER|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
219522105|NCT02566278|OTHER|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
219522106|NCT02601482|BEHAVIORAL|CON|
219522107|NCT02601482|BEHAVIORAL|IW-60|
219522108|NCT02601482|BEHAVIORAL|IW-45|
219522109|NCT02409472|OTHER|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
219522110|NCT03122522|DRUG|ipilimumab|ipilimumab 3mg/kg
219522111|NCT03122522|DRUG|nivolumab|nivolumab 1mg/kg
219522112|NCT03828942|DRUG|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
219522113|NCT03432845|OTHER|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
219522114|NCT05856045|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week."
219522115|NCT05856045|OTHER|PBBT (pertubation based balance training)|"Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week."
219522116|NCT05856045|OTHER|PNF and PBBT intervention group|proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
219522117|NCT03116386|OTHER|run-in period|observational time i.e. baseline situation
219522118|NCT03116386|DEVICE|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
219522119|NCT03116386|DEVICE|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
219522120|NCT01378975|DRUG|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
219522121|NCT06640192|DRUG|Standardised triple antiretroviral therapy|patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.
219522122|NCT06640192|DRUG|High doses Triple therapy antiretroviral drugs|dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
218907860|NCT02567981|DIETARY_SUPPLEMENT|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
218907861|NCT02567981|DIETARY_SUPPLEMENT|Ferrous sulphate|"Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
218907862|NCT02567981|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
218907863|NCT00644696|DRUG|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
219039843|NCT04632251|DEVICE|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
219039844|NCT04066426|DRUG|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
219039845|NCT03002051|DEVICE|EUS-guided drainage|"* Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
219039846|NCT01675882|BIOLOGICAL|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
219039847|NCT01675882|BIOLOGICAL|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
219039848|NCT01675882|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
219522123|NCT04663152|BEHAVIORAL|INSTACARE|CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
218907864|NCT03007550|PROCEDURE|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
218907865|NCT03007550|PROCEDURE|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
218907866|NCT02772601|DRUG|Caffeine|
218907867|NCT02772601|DRUG|Warfarin|
218907868|NCT02772601|DRUG|Omeprazole|
218907869|NCT02772601|DRUG|Metoprolol|
218907870|NCT02772601|DRUG|Midazolam|
218907871|NCT02772601|DRUG|Risankizumab|
219039849|NCT01675882|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
219039850|NCT02795559|OTHER|Glucose|75g glucose dissolved in 300ml water
219039851|NCT02795559|OTHER|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
219039852|NCT02795559|OTHER|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
219039853|NCT05080452|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT)|Visualizing hot spots
219039854|NCT02561975|OTHER|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
219039855|NCT05017194|DRUG|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
219039856|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
219039857|NCT00420524|DRUG|Patupilone/EPO906|
219039858|NCT04508270|BEHAVIORAL|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
219522124|NCT05969197|OTHER|Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
219522125|NCT05969197|OTHER|Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
218907872|NCT03306914|OTHER|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
218907873|NCT03306914|OTHER|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
218907874|NCT03306914|DRUG|Albumin 5%|Infusion of Albumin 5% intra-operatively
218907875|NCT03306914|DRUG|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
218907876|NCT04187118|OTHER|Quality of life|Quality of life one year post chemo-therapy
219522126|NCT05857332|DRUG|SG1906|Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
218907877|NCT04864522|DRUG|SLAMF7 FPBMC|Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
218907878|NCT02254811|BIOLOGICAL|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
219522127|NCT04659681|DIAGNOSTIC_TEST|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
219522128|NCT04659681|DIAGNOSTIC_TEST|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
218907879|NCT02649413|DRUG|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
218907880|NCT00101231|DRUG|alvocidib|Given IV
218907881|NCT03363737|BEHAVIORAL|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
218907882|NCT01319708|PROCEDURE|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
218907883|NCT01319708|PROCEDURE|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
218907884|NCT05036096|DEVICE|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
218907885|NCT05036096|DEVICE|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
218907886|NCT01329315|BEHAVIORAL|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
218907887|NCT01329315|BEHAVIORAL|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
218907888|NCT02031575|BEHAVIORAL|Interactive Treatment|Mobile phone text messaging service about reproductive health
218907889|NCT02031575|BEHAVIORAL|Basic Treatment|Mobile phone text messaging service about reproductive health
218907890|NCT02031575|OTHER|Control, comparator arm|
218907891|NCT01441999|DEVICE|Less rigid rod|Titanium rod with semi rigid end
218907892|NCT01441999|DEVICE|Rigid Rod|Rigid Titanium rods
218907893|NCT04172584|BEHAVIORAL|correct use of the contraceptions|know the emergency contraception and how to use
219039859|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
219522129|NCT02281942|BEHAVIORAL|Yoga|
219522130|NCT02281942|BEHAVIORAL|Education|
219522131|NCT03010748|DEVICE|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
219522132|NCT02032368|PROCEDURE|transarterial chemoembolization (TACE)|
218907894|NCT03346434|DRUG|Dupilumab|Solution for injection, subcutaneous (SC)
219522133|NCT02097446|DEVICE|Guardix-FL|
219522134|NCT02097446|DEVICE|Interceed|
219522135|NCT03435198|DIAGNOSTIC_TEST|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
219522136|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
219522137|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
219522138|NCT03054103|DRUG|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
219522139|NCT03486613|OTHER|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
218907895|NCT03346434|DRUG|Matching placebo|Solution for injection, subcutaneous (SC)
218907896|NCT05717361|DRUG|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
218907897|NCT05717361|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
218907898|NCT03991221|OTHER|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
218907899|NCT03991221|OTHER|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
218907900|NCT03991221|OTHER|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
218907901|NCT00297310|DRUG|tacrolimus|
218907902|NCT00805350|DRUG|Eplivanserin|one 5 mg tablet once a day
218907903|NCT00805350|DRUG|Placebo|Placebo of Eplivanserin one tablet once a day
218907904|NCT01095185|DRUG|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
218907905|NCT01095185|DRUG|Placebo|Simvastatin placebo
218907906|NCT04697667|OTHER|Exercise|Supervised exercise program
218907907|NCT04697667|BIOLOGICAL|PRP|Intra-articular PRP injections to knee joint
218907908|NCT03525444|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
218907909|NCT03525444|DRUG|IVA|Participants received IVA orally once daily in the evening
218907910|NCT03525444|DRUG|Placebo|Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
218907911|NCT00460876|DRUG|Topotecan|
218907912|NCT05134688|DRUG|Magnesium sulfate|Tocolytic to stop preterm labor
218907913|NCT01544296|DRUG|KHK6188|
218907914|NCT01544296|DRUG|Placebo|
218907915|NCT02332538|PROCEDURE|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
219522140|NCT03486613|OTHER|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
219522141|NCT03708913|DEVICE|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
218907916|NCT02332538|PROCEDURE|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
218907917|NCT02332538|PROCEDURE|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
218907918|NCT05378165|OTHER|Music group|The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The music group listened to Acemasiran-type classical Turkish music.Acemasiran-type music affects the human brain and provides a sense of creativity to people. This musical tone has pain- relieving and antispasmodic
218907919|NCT05378165|OTHER|Stress ball group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
218907920|NCT05378165|OTHER|Video group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Video group allowed to watch a licensed virtual reality application,A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
218907921|NCT05378165|OTHER|Control group|"The study was divided into three stages; (1) before; (2) during; and (3) after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Control group, without any additional intervention."
218907922|NCT04879030|DRUG|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
218907923|NCT04879030|DRUG|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
219522142|NCT02343120|DRUG|Zanubrutinib|Oral administration by capsule
219522143|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
219522144|NCT01369277|DRUG|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
218907924|NCT04391374|PROCEDURE|an arterial reconstructive procedure|
218907925|NCT04227808|DRUG|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
218907926|NCT01052727|PROCEDURE|Laparoscopic Cholecystectomy|
218907927|NCT03470688|BIOLOGICAL|Originator|Originator anti-TNF agents
218907928|NCT03470688|BIOLOGICAL|Biosimilar|Biosimilar anti-TNF agents
218907929|NCT01650532|BEHAVIORAL|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
219522145|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
219522146|NCT03947580|OTHER|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
219039860|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
218907930|NCT01650532|BEHAVIORAL|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
218907931|NCT00852683|DRUG|Pregabalin|75 mg twice a day
218907932|NCT00852683|DRUG|Placebo|75 mg twice a day
218907933|NCT05813106|DRUG|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
218907934|NCT05813106|DRUG|normal saline|normal saline
219039861|NCT05983718|DEVICE|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
219039862|NCT05983718|PROCEDURE|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
219039863|NCT00735371|DRUG|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
219039864|NCT00735371|DRUG|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
219039865|NCT00735371|DRUG|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
219039866|NCT00735371|DRUG|Placebo|Placebo will be identical to test product.
219522147|NCT03947580|OTHER|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
219039867|NCT02182375|DRUG|BI 201335 NA|
219039868|NCT02182375|DRUG|Raltegravir|
219039869|NCT03941522|OTHER|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
219039870|NCT02492139|DEVICE|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
219039871|NCT02492139|DEVICE|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
219039872|NCT00994448|DRUG|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
219039873|NCT00994448|DRUG|Placebo tablets|One placebo tablet twice daily
219039874|NCT03995381|OTHER|Decision aids|Shared decision making with decision aids
219522148|NCT03947580|OTHER|Use of no pad|Description is not needed
219522149|NCT00413556|BIOLOGICAL|ALK Grass tablet|
219522150|NCT03788265|DEVICE|Lipogems|harvest and inject micro-fragment adipose tissue
219522151|NCT05985330|OTHER|Measurement of FeNO|Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
219613250|NCT05399472|DIAGNOSTIC_TEST|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
219613251|NCT06524050|BEHAVIORAL|standard care|standard care
219613252|NCT00105859|BEHAVIORAL|Education and Counseling|
219613253|NCT00080912|RADIATION|radiation therapy|Given in a single fraction or multiple fractions
218907935|NCT01221896|PROCEDURE|C11-Choline PET/CT|
218907936|NCT04436354|PROCEDURE|vaginoscopic office hysteroscopy|comparison of procedural time and pain scores of patients in different gynecologycal positions
218907937|NCT04461275|OTHER|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
218907938|NCT01183689|BEHAVIORAL|Small Behavior Changes|"The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level."
219039875|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
218907939|NCT01183689|BEHAVIORAL|Large Behavior Changes|"The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking."
218907940|NCT03960749|DEVICE|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
218907941|NCT03960749|DEVICE|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
218907942|NCT03960749|DEVICE|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
218907943|NCT03960749|DEVICE|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
218907944|NCT03960749|DEVICE|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
219039876|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
219039877|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
219039878|NCT00820612|DRUG|Indomethacin|100 mg PR once at the time of ERCP
219039879|NCT00820612|OTHER|Placebo suppositories|2 placebo suppositories at the time of ERCP
219039880|NCT01811095|OTHER|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
219039881|NCT04888546|DRUG|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
219039882|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
219039883|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
219039884|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
219039885|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
219039886|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
219522152|NCT00347503|DRUG|ketorolac 0.4%, bromfenac 0.09%|
218907945|NCT03960749|DEVICE|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
219522153|NCT01872143|DEVICE|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
218907946|NCT02675946|DRUG|CGX1321|
218907947|NCT02675946|DRUG|Pembrolizumab|
218907948|NCT02675946|DRUG|encorafenib|
218907949|NCT02675946|DRUG|cetuximab|
218907950|NCT00546806|OTHER|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
218907951|NCT01419236|DRUG|Testosterone Solution 2%|Administered topically
219039887|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
219522154|NCT01986582|DRUG|Oxymetazoline|Intranasal application
219522155|NCT01986582|OTHER|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
219522156|NCT01986582|OTHER|Placebo (lactose powder)|Intranasal application
219522157|NCT00018447|DRUG|PTH 1-34|
219522158|NCT00018447|DRUG|MFPSR-fluoride|
219522159|NCT00252551|PROCEDURE|Osteosynthesis|
219522160|NCT00252551|PROCEDURE|Simple surgery|Surgery without device
219522161|NCT01136538|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
219522162|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field|
218907952|NCT01419236|DRUG|Placebo Solution|Administered topically
218907953|NCT01140529|DRUG|Dexmedetomidine|Bolus and continuous infusion
218907954|NCT01140529|DRUG|Haloperidol|Bolus doses
218907955|NCT01140529|DRUG|Saline|Bolus and continuous infusion
218907956|NCT00001483|DRUG|buproprion (Wellbutrin)|
218907957|NCT00001483|DRUG|sertraline (Zoloft)|
218907958|NCT00001483|DRUG|venlafaxine (Effexor)|
219522163|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field Placebo Sham|
218907959|NCT04504734|DRUG|Bucillamine|100mg tablets
218907960|NCT04504734|DRUG|Placebo|100mg tablets
218907961|NCT04504734|DRUG|Bucillamine|200mg tablets
218907962|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
218907963|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
218907964|NCT01452906|DRUG|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
218907965|NCT01452906|DRUG|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
219522164|NCT06404307|BEHAVIORAL|Self-administration|patients will self administer their antimicrobial treatment
219613254|NCT05335486|DEVICE|RELEARN Neurofeedback|"Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception."
218907966|NCT01452906|DRUG|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
218907967|NCT03021785|BIOLOGICAL|TK001|TK001 will be administered intravitreal injection.
218907968|NCT00896857|GENETIC|RNA analysis|
218907969|NCT00896857|GENETIC|polymerase chain reaction|
218907970|NCT00896857|GENETIC|protein expression analysis|
218907971|NCT00896857|GENETIC|reverse transcriptase-polymerase chain reaction|
218907972|NCT00896857|GENETIC|western blotting|
218907973|NCT00896857|OTHER|immunoenzyme technique|
218907974|NCT00896857|OTHER|immunohistochemistry staining method|
218907975|NCT00896857|OTHER|laboratory biomarker analysis|
219522165|NCT03266237|DRUG|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
218907976|NCT00896857|PROCEDURE|breast duct lavage|
218907977|NCT04326972|DEVICE|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
219522166|NCT05343637|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
219522167|NCT05903326|OTHER|Dexmedetomidine|this was an observational study only based on a change of practice
219522168|NCT03120117|PROCEDURE|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
219522169|NCT06672081|PROCEDURE|Early Catheter-Interventional Treatment|Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
219522170|NCT06672081|DRUG|Conventional care|reperfusion treatment
218907978|NCT06078241|DRUG|Intravenous lidocaine infusion|Intravenous lidocaine infusion
218907979|NCT06078241|OTHER|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
218907980|NCT06078241|OTHER|Intravenous infusion of normal saline|Intravenous infusion of normal saline
218907981|NCT06078241|OTHER|ESPB with normal saline|Unilateral ESPB with normal saline
218907982|NCT06397170|OTHER|Graded repetitive arm supplementary program|Patients in Group A will receive Graded repetitive arm supplementary program
218907983|NCT06397170|OTHER|Task based training|Patients in Group B will receive Task based training.
218907984|NCT01703910|DRUG|Arm A chemotherapy|
218907985|NCT01703910|DRUG|arm B chemotherapy|
218907986|NCT06499298|DRUG|Nivolumab|As per product label, as prescribed by treating physician
218907987|NCT03998306|DIETARY_SUPPLEMENT|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
218907988|NCT03998306|OTHER|No intervention|No intervention
218907989|NCT04912258|DRUG|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
218907990|NCT06378229|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
219039888|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
219039889|NCT01471548|DRUG|TKI258|
219039890|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
219039891|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
219039892|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
218907991|NCT02649582|BIOLOGICAL|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle"
218907992|NCT04149912|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
218907993|NCT02061787|DEVICE|balloon pulmonary angioplasty|patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
218907994|NCT04901793|BEHAVIORAL|Virtual Reality Headset and handheld remote control.|Brand name: Oculus Quest
218907995|NCT01131507|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
218907996|NCT00591682|DRUG|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
218907997|NCT01964651|DRUG|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
218907998|NCT01964651|DRUG|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
218907999|NCT01964651|DRUG|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
218908000|NCT01964651|DRUG|Placebo|Matching placebo orally administered once daily for 10 days.
218908001|NCT04142203|OTHER|23 h surgery|Patients were treated in 23 surgical unit
218908002|NCT02849418|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
218908003|NCT02849418|DRUG|Placebo|Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
218908004|NCT01517399|DRUG|tivantinib|three oral 120 mg tablets administered twice a day
218908005|NCT01517399|DRUG|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
218908006|NCT01517399|DRUG|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
218908007|NCT01517399|DRUG|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
219522171|NCT03375242|DRUG|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
219522172|NCT06259435|BEHAVIORAL|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
219522173|NCT06259435|BEHAVIORAL|Usual diet|Subjects will follow time-restricted eating of the usual diet
219522174|NCT00855556|GENETIC|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~1. Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~2. Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~3. No fasting, activity or medication restrictions are required prior to or following blood collection.~4. Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
219522175|NCT01170442|DRUG|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
219522176|NCT01170442|DRUG|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
218908008|NCT01517399|DIETARY_SUPPLEMENT|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
219522177|NCT01170442|DRUG|Placebo|placebo orally, daily for six months
219522178|NCT04121455|DRUG|Olaptesed pegol|Olaptesed pegol continuous i.v. administration
219522179|NCT04121455|RADIATION|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
219522180|NCT04121455|DRUG|Bevacizumab|Bevacizumab every 2 weeks i.v. infusion
218908009|NCT01517399|DRUG|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
218908010|NCT01517399|DRUG|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
218908011|NCT04874025|DRUG|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
218908012|NCT02534376|DRUG|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
218908013|NCT03177863|PROCEDURE|Expectancy|Clinical monitoring. See arm description
218908014|NCT03694405|BIOLOGICAL|MenACWY-CRM|Booster vaccination with MenACWY-CRM
218908015|NCT03694405|BIOLOGICAL|MenACWY-DT|Booster vaccination with MenACWY-DT
219039893|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
219039894|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
219039895|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
219039896|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
219522181|NCT04121455|DRUG|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
219522182|NCT04121455|DRUG|Temozolomide (TMZ)|oral treatment according to current SPC
219522183|NCT04819971|DRUG|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
219522184|NCT04819971|DRUG|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
219522185|NCT04819971|DRUG|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
219522186|NCT04819971|DRUG|S1|S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
219522187|NCT04819971|DRUG|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
219522188|NCT05135442|DRUG|Bortezomib Injection|Bortezomib should be administered immediately after each plasma exchange, and the interval between the next plasma exchange is\> 24h. Plasma exchange continued until the patient's platelet count was \>100×109/L for 2 consecutive days, and then changed to once every other day for a total of two times and then stopped.
219522189|NCT00922597|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
219522190|NCT05190510|OTHER|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
219522191|NCT05190510|PROCEDURE|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
218908016|NCT03694405|BIOLOGICAL|MenACWY-TT|Booster vaccination with MenACWY-TT
218908017|NCT01393158|DRUG|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
218908018|NCT00924521|DIETARY_SUPPLEMENT|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
218908019|NCT00924521|DIETARY_SUPPLEMENT|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
218908020|NCT01869608|PROCEDURE|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
218908021|NCT04621981|DRUG|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
218908022|NCT04621981|DRUG|Normal Saline|This group was treated with normal saline.
218908023|NCT03413007|DIAGNOSTIC_TEST|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
219522192|NCT05190510|OTHER|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
219522193|NCT03034226|OTHER|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
218908024|NCT00582439|DEVICE|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
218908025|NCT00747903|DRUG|aminolevulinic acid hydrochloride|
218908026|NCT03245203|PROCEDURE|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4\~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4\~8 weeks.
218908027|NCT03245203|PROCEDURE|CRT|total dose of radiotherapy was 40\~50Gy, a subdose of 1.8\~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
218908028|NCT04823403|DRUG|Nivolumab|Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
219039897|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
219039898|NCT04758767|DRUG|CID-103|anti-CD38 antibody
219039899|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
218908029|NCT04823403|DRUG|Ipilimumab|"Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~* (D1) Starting dose : 50 mg; n=3 to 6~* (D2) 2nd dose-level : 100 mg; n=3 to 6~* (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)"
218908030|NCT03272802|DRUG|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
218908031|NCT03272802|DRUG|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
218908032|NCT01254253|DEVICE|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
218908033|NCT04292275|DEVICE|Biobeat Wrist Watch|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.
218908034|NCT04292275|OTHER|Standard of Care|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
218908035|NCT02476149|PROCEDURE|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
218908036|NCT06390722|DRUG|Upadacitinib|Oral Tablet
218908037|NCT06390722|DRUG|Placebo for Upadacitinib|Oral Tablet
219522194|NCT01088126|PROCEDURE|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
219613255|NCT05335486|OTHER|Standard care control|"Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
218908038|NCT01372709|DEVICE|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
218908039|NCT00762359|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
218908040|NCT00762359|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
218908041|NCT01453049|DRUG|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
218908042|NCT01453049|DRUG|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
218908043|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
218908044|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
218908045|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
218908046|NCT06077656|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
219522195|NCT03254251|BEHAVIORAL|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
219613256|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
218908047|NCT04734639|BEHAVIORAL|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
218908048|NCT04734639|BEHAVIORAL|Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.|Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
218908049|NCT04734639|BEHAVIORAL|Def-EI. Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
219039900|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
219039901|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
219039902|NCT02279186|DRUG|Tranexamic Acid|Intravenous Injection
218908050|NCT06301958|DRUG|Dextrose prolotherapy|A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
218908051|NCT02685319|PROCEDURE|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
218908052|NCT01366768|OTHER|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
218908053|NCT01366768|OTHER|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
218908054|NCT00668421|DRUG|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
219039903|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
219039904|NCT01664143|DRUG|Placebo|Multiple doses of placebo
219039905|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
218908055|NCT00882440|DRUG|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
218908056|NCT00882440|DRUG|Placebo|Placebo capsule to losartan
218908057|NCT00882440|DRUG|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
218908058|NCT04803318|DRUG|Combination of three inhibitors Trametinib, Everolimus and Lenvatinib|Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
219522196|NCT04608643|DIAGNOSTIC_TEST|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
219522197|NCT02401334|DEVICE|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
219522198|NCT03688373|BEHAVIORAL|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
219522199|NCT04566159|BEHAVIORAL|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
219522200|NCT04566159|OTHER|Standard Care|Standard tobacco treatment care offered by the inpatient care
218908059|NCT02773381|DRUG|semaglutide|Oral administration once-daily.
218908060|NCT02773381|DRUG|placebo|Oral administration once-daily.
218908061|NCT00213616|PROCEDURE|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
218908062|NCT05366335|DRUG|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
218908063|NCT05366335|DRUG|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
218908064|NCT05366335|DRUG|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
219039906|NCT00025285|DRUG|carboplatin|
219039907|NCT00025285|DRUG|irinotecan hydrochloride|
219039908|NCT00025285|DRUG|thalidomide|
219039909|NCT01069055|OTHER|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
219039910|NCT01069055|DRUG|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
219522201|NCT00368953|DEVICE|Yukon Choice stent system|coronary stent implantation
219522202|NCT00368953|DEVICE|Taxus Liberté stent system|coronary stent implantation
219522203|NCT04713696|OTHER|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
219522204|NCT04713696|OTHER|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
219522205|NCT05441202|DEVICE|transdermal therapy|transdermal therapy with Chinese medicine
219522206|NCT02282436|OTHER|No specific intervention for this study|No specific intervention for this study
219522207|NCT00221507|BEHAVIORAL|Reminder-Recall-Outreach|
219522208|NCT00221507|BEHAVIORAL|Case Management|
219039911|NCT01069055|DRUG|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
219039912|NCT04900077|DEVICE|Carriere® Motion™ Appliance|class II malocclusion corrector
218908065|NCT03287791|DRUG|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
218908066|NCT03287791|DRUG|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
218908067|NCT03287791|DRUG|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
218908068|NCT03287791|OTHER|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
218908069|NCT03287791|OTHER|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
218908070|NCT03287791|OTHER|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
218908071|NCT03287791|OTHER|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
218908072|NCT00828243|DRUG|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
218908073|NCT03010917|DRUG|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
218908074|NCT03010917|DRUG|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
218908075|NCT03441477|DEVICE|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
218908076|NCT03441477|DEVICE|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
218908077|NCT03441477|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
218908078|NCT02506543|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
218908079|NCT02506543|BEHAVIORAL|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
219039913|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
219039914|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
219039915|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (5)|5 mg of THC
219039916|NCT06471647|DRUG|Placebo|Placebo - dextrose
219039917|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (10)|10 mg of THC
219039918|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
219039919|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
219613257|NCT01590225|DRUG|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.
218908080|NCT01512485|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
218908081|NCT05529108|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits everyday during intervention period.
219613258|NCT01590225|DRUG|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.
218908082|NCT05529108|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
218908083|NCT05529108|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
218908084|NCT02474446|DIETARY_SUPPLEMENT|Vitamin D|150,000 IU of Vitamin D3 Oral solution
218908085|NCT03261648|OTHER|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
218908086|NCT03261648|OTHER|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
219039920|NCT01241903|DRUG|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
219039921|NCT01241903|DRUG|placebo|frequency and duration
219039922|NCT05942248|OTHER|No Intervention|No Intervention
219039923|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
219039924|NCT01434524|DRUG|LIVACT|LIVACT contains 13.0 g of free amino acids
219039925|NCT00843921|DRUG|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
219039926|NCT04308317|DRUG|Tetrandrine|Tetrandrine 60mg QD for 1week
219039927|NCT06247046|DRUG|Live SK08 powder|Oral Powder
219039928|NCT06247046|DRUG|Placebo|Oral Powder
219613259|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
219613260|NCT01590225|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.
219613261|NCT01590225|DRUG|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks."
219613262|NCT02569125|DRUG|Everolimus|4.5 mg/m² daily
219613263|NCT02099786|OTHER|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
219613264|NCT02099786|OTHER|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
219039929|NCT06425055|DRUG|Vonafexor|"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"
219039930|NCT03914196|DIAGNOSTIC_TEST|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
219522209|NCT00221507|BEHAVIORAL|Patient Navigator|
219522210|NCT04627506|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
219522211|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by Experts|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. To generate diagnostic results of pCLE, two pCLE experts dignosed independent. Any discrepancies are then resolved by a third expert.
219522212|NCT06981819|DIAGNOSTIC_TEST|magnifying endoscopy with blue laser imaging|Magnifying Endoscopy with Blue Laser Imaging (ME-BLI) is an advanced endoscopic imaging technique that combines high-resolution magnification with laser-enhanced visualization to improve the detection and characterization of gastrointestinal (GI) mucosal lesions. Developed by Fujifilm, BLI utilizes specific laser wavelengths to enhance surface and vascular patterns, making it particularly useful for diagnosing early-stage cancers and precancerous conditions in the stomach, colon, and esophagus. To generate diagnostic results of ME-BLI, two ME-BLI experts dignosed independent. Any discrepancies are then resolved by a third expert.
219522213|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by trainees|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. The diagnosis results of CLE trainees are generated by each trainee themselves.
219522214|NCT04375293|OTHER|Microbiome swabs|Swabs for analysis of microbiome
219522215|NCT06665178|DRUG|Sacituzumab Govitecan|Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
219522216|NCT05635279|OTHER||
219522217|NCT06597214|DEVICE|AVACore Technologies, Inc. warmUP Sleeve|AVAcore Technologies's warmUP (WU-20) Temperature Management System was developed based on work with the Aquarius Medical Acrotherm device and prior human hypothermic subject data showing a rewarming rate of \~1ºC in 5 minutes when heat and vacuum application was tested. AVAcore Technologies received FDA acceptance of its Section 510(k) premarket notification for the warmUP (vH1) Temperature Management System in 2005. This product was used on over 100 patients in the US in 2005-2006 timeframe.
219522218|NCT06597214|DEVICE|Arizant Healthcare Bair Hugger®|The Arizant Healthcare Bair Hugger® Temperature Management System proposed for use in this study is a 'forced air' system providing convective warming via the circulation of warmed air through a specially designed blanket which is placed over a portion of the patient's body. This product has been in use in the US for over 20 years in a majority of hospitals.
219522219|NCT02236715|DRUG|Atrovent®|
219039931|NCT03616353|PROCEDURE|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
219522220|NCT05059522|DRUG|Avelumab|oral
219522221|NCT05059522|DRUG|Lorlatanib|oral
219522222|NCT05059522|DRUG|Talazoparib|oral
219522223|NCT05059522|DRUG|Pemetrexed|IV (intravenous) infusion
219522224|NCT05059522|DRUG|Axitinib|oral
219522225|NCT05059522|DRUG|CMP 001|IT (intratumoral) or SC (subcutaneous)
219522226|NCT05059522|DRUG|Utomilumab|IV infusion
219522227|NCT05059522|DRUG|PF04518600|IV infusion
219613265|NCT03836300|BEHAVIORAL|Parent-Infant Inter(X)action Intervention (PIXI)|Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
218908087|NCT00777140|DRUG|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
218908088|NCT04471714|DRUG|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
218908089|NCT03095651|BIOLOGICAL|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
218908090|NCT03095651|BIOLOGICAL|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
219522228|NCT03544138|DEVICE|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
219522229|NCT03704220|DRUG|Warfarin|Removal of anticoagulation with warfarin
219613266|NCT01417156|DRUG|Nintedanib|150 mg bid
219613267|NCT01417156|DRUG|Pirfenidoneone|Existing treatment
219613268|NCT01837511|OTHER|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
218908091|NCT03095651|BIOLOGICAL|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
218908092|NCT03095651|BIOLOGICAL|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
219039932|NCT03616353|PROCEDURE|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
219039933|NCT01524861|DRUG|Placebo|a placebo tablet bis in die for 12 months
219039934|NCT01524861|DRUG|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
219522230|NCT03268668|OTHER|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
219522231|NCT02851290|PROCEDURE|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
219522232|NCT02851290|PROCEDURE|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
219522233|NCT01766778|DRUG|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
219522234|NCT01766778|DRUG|Metformin|Metformin maximum tolerance dose
219522235|NCT04359095|DRUG|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
219522236|NCT04359095|DRUG|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
219522237|NCT04359095|DRUG|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
219522238|NCT04359095|OTHER|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
219522239|NCT02728037|PROCEDURE|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
219522240|NCT02728037|PROCEDURE|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
219039935|NCT01524861|DRUG|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
219039936|NCT04963582|PROCEDURE|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
219039937|NCT04183556|DRUG|Naproxen|use of naproxen twice a day orally in mens time
219039938|NCT04183556|DIETARY_SUPPLEMENT|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
219039939|NCT02815748|DRUG|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
218908093|NCT03095651|BIOLOGICAL|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
218908094|NCT03095651|BIOLOGICAL|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
218908095|NCT03095651|DRUG|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
218908096|NCT03095651|BIOLOGICAL|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
219039940|NCT05561842|PROCEDURE|mHealth US-breast biopsy|During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
219039941|NCT03266328|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
218908097|NCT00610870|DRUG|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
218908098|NCT02921035|DRUG|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
218908099|NCT00783523|DRUG|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
219039942|NCT01334658|PROCEDURE|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
219039943|NCT01334658|DRUG|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
219039944|NCT01334658|DRUG|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
219039945|NCT00046735|DRUG|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
219039946|NCT01373749|DRUG|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
219039947|NCT01373749|DRUG|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
219039948|NCT05888129|PROCEDURE|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
219039949|NCT00712465|DRUG|AZD1305|Extended Release tablet, repeated administration
219039950|NCT00712465|DRUG|Digoxin|Tablet, repeated administration
219039951|NCT02363465|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
219039952|NCT05747144|DIAGNOSTIC_TEST|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
219039953|NCT05747144|DIAGNOSTIC_TEST|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
219039954|NCT05747144|DIAGNOSTIC_TEST|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
219039955|NCT05747144|DIAGNOSTIC_TEST|Microperimetry|1\) fixation pattern 2) retinal sensitivity map
219039956|NCT05747144|DIAGNOSTIC_TEST|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
219522241|NCT02728037|DRUG|lidocaine|
219039957|NCT02086110|DIETARY_SUPPLEMENT|Synbiotic|
219039958|NCT02086110|DIETARY_SUPPLEMENT|Prebiotic|
219039959|NCT00191503|DRUG|Pemetrexed|
219039960|NCT00191503|DRUG|Gemcitabine|
218908100|NCT03156101|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
218908101|NCT00656357|DRUG|SYN117 Placebo|Placebo
218908102|NCT00656357|DRUG|SYN117 80 mg|SYN117 80 mg
218908103|NCT00656357|DRUG|SYN117 160 mg|SYN117 160 mg
218908104|NCT00656357|DRUG|Cocaine 10mg|IV Cocaine 10mg
218908105|NCT00656357|DRUG|Cocaine 20mg|IV Cocaine 20mg
218908106|NCT00656357|DRUG|Cocaine 40mg|IV Cocaine 40mg
219522242|NCT02728037|DRUG|magnesium sulfate, bicarbonate, dextrose.|
219522243|NCT03863678|OTHER|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
219522244|NCT03863678|OTHER|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
219522245|NCT01853306|DRUG|Veliparib|veliparib
219522246|NCT01104662|DRUG|Vancomycin|
219522247|NCT01104662|DRUG|Daptomycin|
218908107|NCT00656357|DRUG|Saline|IV Cocaine Placebo
218908108|NCT06285435|DIAGNOSTIC_TEST|prothrombin fragment 1+2|Blood sample
218908109|NCT05034367|DIAGNOSTIC_TEST|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
218908110|NCT00520949|DRUG|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
218908111|NCT00520949|DRUG|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
218908112|NCT00520949|DRUG|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
218908113|NCT00520949|DRUG|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
218908114|NCT00817297|DEVICE|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
218908115|NCT02250326|DRUG|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
218908116|NCT02250326|DRUG|CC-486|Oral CC-486
218908117|NCT02250326|DRUG|Duravalumab|
219039961|NCT05999006|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
218908118|NCT05150028|BEHAVIORAL|Patient participation|Questionnaire
218908119|NCT05150028|OTHER|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
219039962|NCT01649258|DRUG|granisetron transdermal system|Given granisetron transdermal system patch
218908120|NCT05596136|DIAGNOSTIC_TEST|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
218908121|NCT01109264|DRUG|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
218908122|NCT01109264|DRUG|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
218908123|NCT02292108|BEHAVIORAL|dietetic counselling|
219522248|NCT01104662|DRUG|Semi-Synthetic Penicillin|
219039963|NCT01649258|DRUG|fosaprepitant dimeglumine|Given IV
219039964|NCT01649258|OTHER|laboratory biomarker analysis|Correlative studies
219039965|NCT03445624|DRUG|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
219039966|NCT04849156|OTHER|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
219039967|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
219522249|NCT05561114|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
219522250|NCT05561114|OTHER|Control|Standard Endoscopic Dilation
219522251|NCT00556127|DRUG|Rituximab|375 mg/m2 on day 1
218908124|NCT02292108|BEHAVIORAL|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
218908125|NCT06593483|BEHAVIORAL|Motivational Interview with Self-Talk Video|Participants will engage in an interview based in motivational interviewing techniques and then record a self talk video discussing their goals and reasons for reducing their drinking.
218908126|NCT06593483|BEHAVIORAL|Motivational Interviewing|Participants will engage in an interview based in motivational interviewing
218908127|NCT05691894|DRUG|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
218908128|NCT05691894|DRUG|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
218908129|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
218908130|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Audio-track.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
218908131|NCT05478941|BEHAVIORAL|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
218908132|NCT04758702|BIOLOGICAL|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
218908133|NCT04758702|BIOLOGICAL|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
219039968|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
219039969|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
219039970|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
219522252|NCT00556127|DRUG|Epirubicin|110 mg/m2 on day 3
219522253|NCT00556127|DRUG|Cyclophosphamide|1200 mg/m2 on day 3
219522254|NCT00556127|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
219522255|NCT00556127|DRUG|Prednisone|40 mg/m2 from day 1 to 5
219522256|NCT00556127|DRUG|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
219522257|NCT00556127|DRUG|Mitoxantrone|8 mg/m2 for 3-day
218908134|NCT04758702|DEVICE|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
218908135|NCT04388592|OTHER|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
218908136|NCT03635463|DEVICE|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
218908137|NCT03635463|DEVICE|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
218908138|NCT00205335|DEVICE|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
218908139|NCT00205335|DEVICE|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
219039971|NCT02877628|OTHER|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
219039972|NCT00402675|PROCEDURE|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
219039973|NCT02619695|DRUG|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
219204429|NCT06738576|DRUG|allogeneic mesenchymal stem cells|"Cell implantation is carried out in the following steps:~1. \- Patient anesthesia~2. \- Identification of the external urinary sphincter and the incompetent area responsible for incontinence through intraurethral cystoscopy.~3. \- Resuspension of the cells by gentle manual shaking of the vials. Once the cells are resuspended, they will be used immediately.~4. \- Injection of the cell suspension with a long, fine needle (those usually used in endoscopic puncture, \<22G) at 2 points of the sphincter that will coincide with the 3 o'clock and 9 o'clock position of the hands of a clock). The injection will be superficial, trying not to go deeper than 2 mm to create a wheal in each injection visible endoscopically.~5. \- Cellular remains, if any, and the vials used will be eliminated following the usual procedures used for the management of hospital surgical waste."
219204430|NCT06738576|DRUG|Placebo|Placebo implantation is carried out in the same way as the drug implantation
219204431|NCT06736119|BEHAVIORAL|Task Oriented Intervention|Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
219204432|NCT06748508|DRUG|Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib|Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
219204433|NCT05144516|BEHAVIORAL|Behavioral: COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
219522258|NCT00556127|DRUG|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
219522259|NCT00556127|DRUG|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
219522260|NCT00556127|DRUG|Carmustine BCNU|300 mg/m2 on day -7
219522261|NCT00556127|DRUG|Etoposide|100 mg/m2/12 hours
219522262|NCT00556127|DRUG|Melphalan|140 mg/m2 on day -2
218908140|NCT05363553|DIETARY_SUPPLEMENT|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
218908141|NCT05363553|DIETARY_SUPPLEMENT|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
218908142|NCT02867410|OTHER|No intervention|
218908143|NCT04098822|DEVICE|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
218908144|NCT04673214|DRUG|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
219039974|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
219039975|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
219039976|NCT03365206|OTHER|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
219039977|NCT01869192|DRUG|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
219039978|NCT01869192|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
219039979|NCT01869192|DRUG|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
219039980|NCT01869192|DRUG|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
219039981|NCT01869192|RADIATION|Radiation Therapy|Standard dosing, fields depending on clinical findings
219204434|NCT06840457|BEHAVIORAL|Mindfulness + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to train the user in mindfulness practices."
219522263|NCT00556127|RADIATION|Radiotherapy|Involved Field Radiotherapy (IF-RT)
218908145|NCT04673214|DRUG|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
218908146|NCT06420882|OTHER|The experimental group.|In the experimental group, in addition to home exercises, patella mobilization, muscle strengthening exercises, range of motion exercises and home exercises will be performed 3 days a week for 3 sessions with a therapist.
218908147|NCT06420882|OTHER|The home exercise group|Participants in both groups will be included in a 3-week treatment programme.
219522264|NCT00556127|PROCEDURE|PBSC reinfusion|ASCT
219522265|NCT03797755|RADIATION|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
219522266|NCT05733195|OTHER|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
219522267|NCT02511509|DEVICE|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
219522268|NCT02511509|DEVICE|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
219522269|NCT05337956|PROCEDURE|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
219522270|NCT03267056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
219522271|NCT04813809|DEVICE|BARRIER EasyWarm|Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
219522272|NCT00046865|PROCEDURE|acupressure therapy|
219522273|NCT00046865|PROCEDURE|management of therapy complications|
219522274|NCT00046865|PROCEDURE|nausea and vomiting therapy|
219522275|NCT04620109|DRUG|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
219522276|NCT04620109|DRUG|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
219522277|NCT00280371|DRUG|Formoterol Fumarate|
219522278|NCT05814848|DRUG|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
219522279|NCT05978427|PROCEDURE|interscalene block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.
219522280|NCT05978427|PROCEDURE|superior trunk block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
219522281|NCT03321565|OTHER|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
219522282|NCT02079532|DRUG|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
219522283|NCT04175951|DEVICE|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
219613269|NCT06198231|OTHER|Pilates exercises|Pilates exercises
218908148|NCT03684863|DRUG|Capecitabine|observation
218908149|NCT03743441|OTHER|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
219522284|NCT06337006|PROCEDURE|Placement of the laryngeal mask airway|Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
219522285|NCT03346564|BEHAVIORAL|Ritual training program|Ritual training program including education and demonstration
219522286|NCT03346564|BEHAVIORAL|Routine care|
219522287|NCT02924948|PROCEDURE|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
219613270|NCT06198231|OTHER|Flexibility ,strength and endurance excercises|flexibility ,strength and endurance excercises
219613494|NCT04124445|PROCEDURE|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
219613495|NCT06659263|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
218908202|NCT05306626|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
218908203|NCT05355571|DIETARY_SUPPLEMENT|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
218908204|NCT05355571|DIETARY_SUPPLEMENT|Placebo|Placebo
218908205|NCT05682170|DRUG|ZN-d5 ZN-c3|Oral agent
218908206|NCT05682170|DRUG|ZN-c3|Oral agent
218908207|NCT06068309|OTHER|CareAide App Usage|The study participant uses the CareAide app in addition to prescribed usual therapeutic care
218908208|NCT02529852|DRUG|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
218908209|NCT02529852|DRUG|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
218908210|NCT02529852|DRUG|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
219040473|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
218908211|NCT02529852|DRUG|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
218908212|NCT02529852|DRUG|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
218908213|NCT02529852|DRUG|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
218908214|NCT04087018|DRUG|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
218908215|NCT06585046|PROCEDURE|pancreatic surgery|patients who did pancreas-related surgery
219040474|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
219040475|NCT02383667|DEVICE|Electrocardiogram holter|
219613723|NCT04107909|PROCEDURE|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
219040476|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
219613724|NCT02655497|BEHAVIORAL|Cognitive training|
218908216|NCT03422835|PROCEDURE|R-TME|Conventional Robotic Total Mesentery Excision
218908217|NCT03422835|PROCEDURE|R-TaTME|Robotic Transanal Total Mesentery Excision
218908218|NCT02102789|DRUG|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
218908219|NCT02102789|DRUG|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
218908220|NCT00003663|BIOLOGICAL|rituximab|
218908221|NCT00003663|DRUG|dexamethasone|
218908222|NCT06305286|DRUG|AT-1501|AT-1501 is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40.
218908223|NCT06207786|OTHER|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
218908224|NCT06207786|DIAGNOSTIC_TEST|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
218908225|NCT06207786|DRUG|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
218908226|NCT03296514|BEHAVIORAL|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
219040477|NCT02970968|OTHER|Placebo|placebo oral
219040478|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
218908227|NCT01968486|DRUG|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
219522699|NCT02444403|BEHAVIORAL|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
219522700|NCT00625911|DRUG|morphine|intravenous patient controlled analgesia, standard protocol
219522701|NCT00625911|DRUG|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
219522702|NCT02467036|BEHAVIORAL|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
219522703|NCT03344510|DEVICE|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
219522704|NCT03344510|OTHER|Control|One injection will be administered without the kinetic anesthesia device.
219522705|NCT01074710|DRUG|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
219522706|NCT01074710|DRUG|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
219522707|NCT03535168|DRUG|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
219522708|NCT03535168|DRUG|Matching placebo|Matching placebo for BAY1902607
219522709|NCT03535168|DRUG|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
219522710|NCT05676866|PROCEDURE|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
219522711|NCT03862248|DRUG|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
219522712|NCT03862248|DRUG|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
219522713|NCT03862248|DRUG|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
219522714|NCT01475838|DRUG|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
219522715|NCT01475838|DRUG|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
219522716|NCT01475838|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
219522717|NCT01475838|DRUG|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
219613725|NCT02655497|BEHAVIORAL|Psychosocial education|
219613726|NCT01391897|BEHAVIORAL|psychotherapy|"multimodal complex psychotherapy"
219522718|NCT04066361|OTHER|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
219522719|NCT04066361|OTHER|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
219522720|NCT00048568|DRUG|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
219522721|NCT00048568|DRUG|Methotrexate|Tablets, Oral, \>= 15 mg, weekly, 1 year
219522722|NCT00048568|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
219522723|NCT00098878|DRUG|carboplatin|
219613727|NCT02085447|BEHAVIORAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
219613728|NCT05170282|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
219613729|NCT04521127|OTHER|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
219641840|NCT02511392|PROCEDURE|Sham rTMS|
219641841|NCT03918902|BEHAVIORAL|Qestinnaires|Questionnaires
219641842|NCT04223635|DRUG|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
219641843|NCT04443062|DRUG|177Lu-PSMA-617|PSMA radioligand therapy
219641844|NCT00268177|DRUG|Salmeterol/fluticasone propionate 50/500mcg Diskus|
219522724|NCT03831048|DEVICE|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
219613730|NCT04521127|OTHER|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
218908228|NCT01968486|DRUG|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
218908229|NCT01968486|DRUG|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
218908230|NCT00800566|DRUG|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
218908231|NCT04550858|DRUG|Rebamipide|rebamipide use for ttt of h.pylori infection
218908232|NCT00973726|OTHER|Glucose test|Subjects ingest an oral glucose tolerance test.
218908233|NCT03282461|DRUG|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
218908234|NCT05971316|DEVICE|Foam Roller|General Warm-up + Foam Roller
218908235|NCT02926872|OTHER|There is no intervention in the study|
218908236|NCT01360671|DRUG|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
218908237|NCT02646826|OTHER|Placebo|Subjects are treated with Placebo tablets
219613731|NCT01500473|DRUG|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
219613732|NCT03705429|DRUG|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
218908238|NCT02646826|DRUG|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
218908239|NCT02646826|DRUG|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
218908240|NCT02646826|DRUG|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
218908241|NCT05106881|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
218908242|NCT00941941|PROCEDURE|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
218908243|NCT00941941|PROCEDURE|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
218908244|NCT05853016|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
218908245|NCT03965975|DEVICE|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
219641845|NCT00806663|DRUG|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
218908246|NCT03965975|DEVICE|S-There|"Second intervention (assigned to the All participants arm)."
218908247|NCT03282058|DEVICE|Silastic Stent|The silastic stent is a splint made of silicone.
218908248|NCT05239052|OTHER|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
218908249|NCT05239052|OTHER|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
218908250|NCT04480489|OTHER|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
218908251|NCT04480489|OTHER|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
218908252|NCT00323323|DRUG|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
219040479|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
219522725|NCT03831048|OTHER|Cold Storage|Active comparator intervention
219522726|NCT04083859|OTHER|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
219522727|NCT04083859|OTHER|Lung health video|Web-based video about guideline recommended exercise for lung health
218908253|NCT00323323|DRUG|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
219040480|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
219522728|NCT06545201|BIOLOGICAL|RE001 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
219522729|NCT01161667|DRUG|naratriptan hydrochloride|2.5 mg tablet
219522730|NCT03576846|OTHER|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
219522731|NCT03576846|OTHER|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
219522732|NCT00560235|DRUG|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
219522733|NCT01365650|DRUG|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
219522734|NCT01365650|DRUG|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
219522735|NCT01365650|DRUG|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
219522736|NCT04677764|OTHER|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
218908254|NCT00323323|PROCEDURE|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
218908255|NCT05594550|OTHER|Data collection|"Demographic data:~Age, Sex, weight, height, main history and treatments.~\- Biological data: CRP, PCT, albumin, pre-albumin"
218908256|NCT05594550|OTHER|analysis of thoracic scans|muscle area calculated on the T7 and T12 thoracic slices
218908257|NCT00271635|DRUG|Placebo|Placebo 4 capsules b.i.d. during 1 year
218908258|NCT00271635|DRUG|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
219522737|NCT04677764|OTHER|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
219522738|NCT01806090|DRUG|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
219522739|NCT01806090|OTHER|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
219522740|NCT06139003|DEVICE|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
219522741|NCT06139003|DEVICE|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
219522742|NCT01595503|PROCEDURE|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
219522743|NCT01595503|PROCEDURE|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
219522744|NCT03827109|BEHAVIORAL|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
219522745|NCT03827109|BEHAVIORAL|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
219522746|NCT03827109|BEHAVIORAL|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
219522747|NCT03827109|BEHAVIORAL|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
219522748|NCT03827109|BEHAVIORAL|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
218908259|NCT03897959|DEVICE|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
218908260|NCT03776864|BIOLOGICAL|Pembrolizumab|Given IV
219040481|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
219040482|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
219522749|NCT03827109|BEHAVIORAL|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
219522750|NCT01110265|BEHAVIORAL|attention training|
219522751|NCT01110265|BEHAVIORAL|placebo training|
219522752|NCT05065645|DRUG|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
219522753|NCT05065645|DRUG|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
219641846|NCT06068673|DRUG|Clindamycin 600 mg|Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
218908261|NCT03776864|DRUG|Umbralisib|Given PO
218908262|NCT04900012|PROCEDURE|Distal pancreatectomy|We are going to collect all cases
218908263|NCT06524609|DRUG|Epigallocatechin-3-Gallate|After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).
218908264|NCT06524609|DRUG|Alcohol|After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).
218908265|NCT04344808|DEVICE|Dynamic navigation system|The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
218908266|NCT04344808|DEVICE|Freehand implant placement|Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
218908267|NCT00192881|DEVICE|Bx Sonic & Cypher stent from Cordis|
218908268|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
218908269|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
218908270|NCT03196908|OTHER|Placebo|Lime juice, water, and cherry flavoring
218908271|NCT01950858|BIOLOGICAL|Weight reduction|
218908272|NCT06464354|PROCEDURE|The mammary artery harvesting by the pedicle technique|The mammary artery harvesting by the pedicle technique was used in the LIMA pedicle study group.
219522754|NCT00996320|OTHER|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
218908273|NCT06464354|PROCEDURE|The mammary harvesting using the skeletonization technique|The mammary harvesting using the skeletonization technique was used in the LIMA skeletonized study group.
218908274|NCT06464354|PROCEDURE|No intervention|No intervention was used in the control study group.
219522755|NCT01245166|DRUG|Acarbose|Acarbose 50 mg, per orem, thrice daily
219522756|NCT01245166|DRUG|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
218908275|NCT03452540|DRUG|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
218908276|NCT00648336|DRUG|Mercaptopurine 50 mg|50mg, single dose fasting
218908277|NCT00648336|DRUG|Purinethol® Tablets 50 mg|50mg, single dose fasting
218908278|NCT00524485|DRUG|aminolevulinic acid|
218908279|NCT00524485|PROCEDURE|laser therapy|
218908280|NCT05189275|DIETARY_SUPPLEMENT|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
218908281|NCT01457651|PROCEDURE|Alveolar recruitment|"Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)"
219522757|NCT00852436|DRUG|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
219613733|NCT05784025|DEVICE|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
219641847|NCT06068673|DRUG|standard regimen|standard regimen
218908282|NCT00472108|RADIATION|Photodynamic Therapy (PDT)|
218908283|NCT00472108|DRUG|Metvix cream|
218908284|NCT00472108|DRUG|Placebo Cream|
218908285|NCT02538744|DRUG|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
218908286|NCT02538744|DRUG|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
218908287|NCT02538744|DRUG|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
218908288|NCT02538744|DRUG|Placebo|
218908289|NCT05475249|OTHER|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
218908290|NCT04389775|DRUG|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
218908291|NCT04389775|DRUG|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
218959150|NCT04223492|DIAGNOSTIC_TEST|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
219522758|NCT00852436|DRUG|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
219522759|NCT05123690|DEVICE|Neurofeedback|A device that assists in training patients in relaxing.
219522760|NCT00055978|DRUG|celecoxib|Given orally. 400mg twice daily for 6 months.
219522761|NCT00055978|OTHER|placebo|Given orally
219522762|NCT04461665|OTHER|vitamin D|vitamin D supplement 10 μg daily for 2 months
219522763|NCT06038539|BIOLOGICAL|PERT-IJS plus trastuzumab, carboplatin and docetaxel|PERT-IJS is a monoclonal antibody, which has been developed by Biocon Biologics (earlier in collaboration with Viatris) as a proposed biosimilar to European Union (EU)-approved and United States (US) licensed Perjeta.
219522764|NCT06038539|BIOLOGICAL|Perjeta plus trastuzumab, carboplatin and docetaxel|EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).
218908292|NCT04389775|DRUG|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
218908293|NCT04389775|DRUG|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
219522765|NCT05938556|BEHAVIORAL|hybrid asynchronous-synchronous group coaching program|A hybrid asynchronous-synchronous program. The synchronous part has two weekly recorded live group coaching calls for four months. The asynchronous consist of 1) on-demand replies to recorded coaching calls, 2) Self-coaching through weekly self-study modules and worksheets, and 3) written Ask A Coach. Content modified per needs of APPs by a physician, a certified coach, and an APP who is also a Co-I. The curriculum has weekly themes that build. Month-1 consists of 1) Introduction to the Model, 2) How to Feel Better, 3) Defining Your Purpose, and 4) Living Your Purpose. Month-2 consists of 1) Growth Mindset, 2) Welcoming Feedback and Assessment Bias, 3) Feeling Valued and Belonging, and 4) How to Deal with Hidden Expectations. Month-3 consists of 1) Imposter Syndrome, 2) Perfectionism, 3) Approval Addiction, and 4) How to Change Your Thoughts. Month-4 consists of 1) How to deal with Ambiguity, 2) Confidence, 3) Self-Appreciation and Self-Compassion, and 4) Celebrate the New You.
218908294|NCT00450970|DRUG|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
219522766|NCT05938556|OTHER|treatment as usual group (TAU)|The treatment as usual group will consist of any structural or programmatic interventions, resources, lectures, curriculum, etc. offered at the participants' hospital of employment. Thus, this active control is designed to represent a best-case alternative to group coaching, making it a more rigorous form of control. Participants randomly assigned to TAU will also continue any structural or programmatic interventions or resources they were previously participating in.
219522767|NCT05871736|OTHER|Turkish version of Child Engagement in Daily Life Measure V2|Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.
219613734|NCT06124729|DRUG|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
219613735|NCT00434369|DRUG|CoFactor (ANX-510)|
219613736|NCT00378144|DRUG|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
218908295|NCT01394055|DRUG|RM-131|100 μg subcutaneously once
218908296|NCT01394055|DRUG|Placebo|Matching placebo volume subcutaneously once
218959151|NCT01488344|DRUG|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
219613737|NCT00739063|DRUG|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
219613738|NCT04779879|BIOLOGICAL|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
219613739|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
219613740|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
219613741|NCT02716545|DEVICE|balloon assisted enteroscopy|Patients with recurrent bleeding (\>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
219613742|NCT03377374|DIETARY_SUPPLEMENT|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
218908297|NCT04642625|OTHER|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and \>7cm are the indicators of severe pain."
218908298|NCT04642625|OTHER|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
219613743|NCT03377374|OTHER|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
219613744|NCT02854527|DRUG|Digoxin|single dose
218908299|NCT00883363|PROCEDURE|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
218908300|NCT01274949|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
218908301|NCT02749396|DRUG|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908302|NCT02749396|DRUG|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908303|NCT02749396|DRUG|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908304|NCT02749396|DRUG|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908305|NCT02749396|DRUG|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
219522768|NCT00758849|DRUG|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
219522769|NCT00758849|DRUG|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
218908306|NCT02749396|DRUG|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908307|NCT02749396|OTHER|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
218908308|NCT04078841|DIETARY_SUPPLEMENT|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
218908309|NCT04078841|OTHER|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
218908310|NCT03439306|DEVICE|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
218908311|NCT01628146|DEVICE|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
218908312|NCT03553901|PROCEDURE|Acupressure|Acupressure was performed before the injection onto GB30 point
219522770|NCT02009800|BIOLOGICAL|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
219522771|NCT00318994|DRUG|Meropenem|
219613745|NCT02854527|DRUG|Furosemide|single dose
219613746|NCT02854527|DRUG|Metformin|single dose
219613747|NCT02854527|DRUG|Rosuvastatin|single dose
219613748|NCT02854527|DRUG|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
219613749|NCT02854527|DRUG|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
219613750|NCT02854527|DRUG|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
218959152|NCT03667300|DRUG|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
219522772|NCT01315249|DRUG|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
219522773|NCT01315249|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
219522774|NCT01315249|DRUG|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
219522775|NCT01315249|DRUG|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
219522776|NCT02511405|DRUG|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
219522777|NCT02511405|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
219613751|NCT02854527|DRUG|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
219613752|NCT02461160|DRUG|TAK-915 suspension|TAK-915 oral suspension
219613753|NCT02461160|DRUG|Midazolam|Midazolam oral solution
219613754|NCT02461160|DRUG|Placebo|Placebo-matching TAK-915 suspension
219613755|NCT02461160|DRUG|TAK-915 tablet|TAK-915 tablet
219613756|NCT04296591|DIAGNOSTIC_TEST|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
219613757|NCT05183880|DIETARY_SUPPLEMENT|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
219613758|NCT05183880|DIETARY_SUPPLEMENT|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
219613759|NCT03169231|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
219613760|NCT03169231|OTHER|Placebo|Intravenously delivered
219613761|NCT00004073|DRUG|suramin|
219613762|NCT00004073|RADIATION|radiation therapy|
219641848|NCT05122247|OTHER|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
219641849|NCT06683651|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution
219641850|NCT06683651|DRUG|STN1013800 ophthalmic solution Liquid Base, without STN1013800|Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
219522778|NCT00584311|OTHER|MRI and Ultrasound|MRI and US of the joint
219522779|NCT04988061|OTHER|counselling|Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
219522780|NCT01740661|OTHER|Cryotherapy|The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
219522781|NCT01740661|OTHER|Control|The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
219522782|NCT00290147|BIOLOGICAL|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
218908313|NCT00576355|BEHAVIORAL|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
218908314|NCT00576355|BEHAVIORAL|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
218908315|NCT00174577|DRUG|Risperidone|
218908316|NCT03821896|BEHAVIORAL|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
218908317|NCT03821896|BEHAVIORAL|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
218908318|NCT02800538|DIETARY_SUPPLEMENT|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
218908319|NCT02986126|BEHAVIORAL|Resiliency Class|See Arm Description
219522783|NCT06441396|OTHER|Telerehabilitation|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. The individuals in this group were made to do the exercises together online via the WhatsApp program. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The main program consists of 15 calisthenic exercises involving the lower extremity, upper extremity and trunk large muscle groups. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The number of repetitions of each exercise started with 10 and was increased by 5 repetitions every two weeks until it reached 20 repetitions.
218908320|NCT02986126|OTHER|Resource for Services (RS)|See Resource for Services (RS) Description
218908321|NCT02441023|BEHAVIORAL|Nutritional therapy and education|"1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
218908322|NCT02441023|BEHAVIORAL|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
218908323|NCT05206721|OTHER|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
218908324|NCT05259735|COMBINATION_PRODUCT|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
218908325|NCT05259735|OTHER|Comparator|In this arm usual management of T2DM without any clinical guideline
218908326|NCT01339689|DRUG|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
218908327|NCT01339689|DRUG|Placebo|capsules, bid, up to 12 weeks
218908328|NCT02350517|DRUG|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
218908329|NCT03188159|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
218908330|NCT01299844|BEHAVIORAL|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
218908331|NCT02738814|DRUG|propofol|When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
219522784|NCT06441396|OTHER|Video-based rehabilitation (VTR)|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. Participants were asked to exercise by watching these videos. In addition, these individuals were interviewed once a week to check the progress of the exercise program. Video images were sent to the intervention group for informational purposes, and the individuals in this group were made to do the exercises together online via the WhatsApp program.
219522785|NCT05558891|BEHAVIORAL|THRIVE|Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).
219522786|NCT05558891|BEHAVIORAL|Usual Care|Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
219522787|NCT02480465|DRUG|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
219641851|NCT06428721|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
218908332|NCT00188552|DRUG|pentoxifylline|
218908333|NCT00188552|DRUG|α-Tocopherol|
218908334|NCT03617562|PROCEDURE|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
218908335|NCT03617562|PROCEDURE|Partial Repair|Rotator cuff is repaired with residual defect remaining.
218908336|NCT04571944|DRUG|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
218908337|NCT04571944|DRUG|Placebo|Suvorexant-matching placebo administered QD via oral tablet
218908338|NCT02360566|BEHAVIORAL|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
218908339|NCT01180465|DRUG|LIPO-102|LIPO-102 High dose
218908340|NCT01180465|DRUG|LIPO-102 Low|LIPO-102 Low dose
218908341|NCT01180465|DRUG|LIPO-102, Placebo|Placebo
218908342|NCT04740983|OTHER|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
218908343|NCT00966186|PROCEDURE|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
218908344|NCT04139330|DRUG|NPC-06|Infuse NPC-06 intravenously
218908345|NCT04610359|DRUG|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
218908346|NCT03380897|OTHER|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
218908347|NCT03380897|OTHER|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
218908348|NCT00471653|DRUG|temozolomide|
218908349|NCT00471653|GENETIC|comparative genomic hybridization|
218908350|NCT00471653|GENETIC|polymorphism analysis|
219060595|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
219522788|NCT02480465|DRUG|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
219522789|NCT03156062|DRUG|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
219522790|NCT01677962|BIOLOGICAL|Poly-ICLC|
219522791|NCT01677962|BIOLOGICAL|dendritic cell|
219522792|NCT00527657|DRUG|Lomustine|Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.
218908351|NCT00471653|OTHER|laboratory biomarker analysis|
218908352|NCT00471653|OTHER|pharmacological study|
218908353|NCT00471653|RADIATION|radiation therapy|
218908354|NCT03442816|DEVICE|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
218908355|NCT03864835|BEHAVIORAL|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
218908356|NCT02229058|DRUG|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
218908357|NCT02229058|DRUG|S-1|40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.
218908358|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
218908359|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
218908360|NCT03936998|COMBINATION_PRODUCT|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
218908361|NCT03936998|COMBINATION_PRODUCT|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
218959153|NCT03667300|DRUG|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
218959154|NCT03625908|DEVICE|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
218959155|NCT03625908|DEVICE|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
218959156|NCT05926076|OTHER|Treatment plan|Patients with different diagnoses will get different treatment options
219522793|NCT00527657|DRUG|Temozolomide|75 mg/m\^2 by mouth daily on Days 1 to 42.
219522794|NCT00527657|DRUG|Thalidomide|200 mg/m\^2 by mouth daily.
219522795|NCT03136666|DRUG|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
218908362|NCT01811771|BIOLOGICAL|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
218908363|NCT06066216|DRUG|Cadonilimab|Injectable solution
218908364|NCT06066216|DRUG|Carboplatin|Injectable solution
218908365|NCT06066216|DRUG|Cisplatin|Injectable solution
218908366|NCT06066216|DRUG|Paclitaxel|Injectable solutionS
218908367|NCT06427213|DRUG|Zanubrutinib,Obinutuzumab|"Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease； Obinutuzumab ：Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks，up to 20 doses. 1 cycle = 28 days.~Maintenance: Zanubrutinib, 160mg PO BID"
218908368|NCT06427213|DRUG|Zanubrutinib and R-BAC|"Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression"
218908369|NCT05305352|OTHER|Very low carbohydrate dietary intervention|The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
218908370|NCT01476670|OTHER|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
218908371|NCT06119126|DRUG|SDF1|Topical SDF application
218908372|NCT06119126|DEVICE|Diode Laser|Irradiating Enamel by Diode laser
218908373|NCT06119126|DRUG|Pit Fissure Sealant|Sealing occlusal pits and fissures
219522796|NCT00849901|DRUG|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
219522797|NCT00849901|DRUG|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
219522798|NCT00849901|DRUG|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
219522799|NCT03904966|DEVICE|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
219522800|NCT03904966|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
219522801|NCT00262223|BEHAVIORAL|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
219522802|NCT00262223|DRUG|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
219522803|NCT00262223|DRUG|Pill placebo|
219522804|NCT03828734|DEVICE|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
219522805|NCT03828734|DEVICE|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
219522806|NCT03828734|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
219522807|NCT00842595|DRUG|rituximab|6 courses every 28 days
218908374|NCT04944459|DEVICE|Muse-S headband; InteraXon Inc., RRID:SCR_014418|"Muse-S is used as a technology-supported Mindfulness Training (tsMT) device as a way to introduce meditation as a method for managing chronic pain in individuals as it facilitates the learning process, requires minimal training to use and provides mechanisms to enhance compliance and track progress. The availability of direct feedback data from Muse-S may encourage the participant to perform meditation sessions and may increase time spent in the calm brain state."
218908375|NCT00664547|BEHAVIORAL|Diet Weight Loss|
218908376|NCT00664547|BEHAVIORAL|Exercise Weight Loss|
218908377|NCT00664547|BEHAVIORAL|Exercise Without Weight Loss|
218908378|NCT02028923|DRUG|Morphine gel|Topical
218908379|NCT02028923|OTHER|Neutral gel|Topical
218908380|NCT06387823|DRUG|Sivelestat sodium|Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
218908381|NCT06387823|DRUG|Dexamethasone|Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)
218908382|NCT06387823|DRUG|Sivelestat sodium placebo|Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
218908383|NCT06387823|DRUG|Dexamethasone placebo|Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
219522808|NCT00842595|DRUG|vinorelbine|6 courses every 28 days
219522809|NCT00842595|DRUG|ifosfamide|6 courses every 28 days
219522810|NCT00842595|DRUG|Mitoxantrone|6 courses every 28 days
219522811|NCT00842595|DRUG|Prednisone|6 courses every 28 days
219522812|NCT03462524|PROCEDURE|Esophagectomy|FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
219522813|NCT00076934|DRUG|RG2077 (CTLA4-IgG4m)|RG2077
219522814|NCT02476799|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
219522815|NCT02476799|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
219522816|NCT02476799|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
219522817|NCT02476799|DRUG|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
219522818|NCT01804270|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
218908384|NCT02971917|RADIATION|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
219613763|NCT04253665|BEHAVIORAL|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
218908385|NCT02971917|RADIATION|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image"
218908386|NCT02971917|RADIATION|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
218908387|NCT05485740|OTHER|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
219522819|NCT00816569|DEVICE|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
219522820|NCT04464330|OTHER|no intervention|This is an observation study, with no intervention
219522821|NCT02260830|DRUG|Lu AF11167|
219522822|NCT00709566|BEHAVIORAL|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
219522823|NCT00709566|BEHAVIORAL|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
219522824|NCT00724230|DRUG|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
219522825|NCT00724230|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
219613764|NCT04248530|DEVICE|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
219613765|NCT01944163|OTHER|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
219613766|NCT06353763|OTHER|Immersive virtual reality learning program|The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
219613767|NCT04712279|DRUG|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
219613768|NCT04712279|DRUG|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
219613769|NCT04712279|DRUG|Placebo|Placebo q.d.for 05 days
219613770|NCT04712279|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
219613771|NCT00018538|DRUG|calcifidiol|
219522826|NCT00270322|DRUG|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
219522827|NCT00270322|DRUG|Morphine sulphate|
219522828|NCT00815763|DRUG|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
219613772|NCT01313052|BEHAVIORAL|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
218908388|NCT05485740|OTHER|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
218908389|NCT00056095|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218908390|NCT00056095|DRUG|cyclophosphamide|
219522829|NCT00815763|DRUG|placebo|infusion placebo once a day and continued for 14 day
219522830|NCT00978822|DRUG|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
219613773|NCT01313052|BEHAVIORAL|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
219613774|NCT01480245|DRUG|GSK2402968|6mg/kg/week
219613775|NCT04359147|DRUG|"Yohimbine"|Effects on neural correlates of decision-making under risk and selective attention to threat
218908391|NCT00056095|DRUG|cyclosporine|
219522831|NCT04231838|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
219613776|NCT04359147|DRUG|"Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
218908392|NCT00056095|DRUG|fludarabine phosphate|
218908393|NCT00056095|PROCEDURE|allogeneic bone marrow transplantation|
218908394|NCT00056095|PROCEDURE|peripheral blood stem cell transplantation|
218908395|NCT05860088|OTHER|Beef Diet|Controlled-Feeding Diet Intervention
218908396|NCT05860088|OTHER|Vegetarian Diet|Controlled-Feeding Diet Intervention
218908397|NCT00086866|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
218908398|NCT00086866|BIOLOGICAL|SB-AS02B adjuvant|
218908399|NCT00086866|BIOLOGICAL|SB-AS15 adjuvant|
218908400|NCT00697502|DRUG|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
218908401|NCT04076085|OTHER|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
218908402|NCT00646139|DRUG|Src kinase inhibitor KX2-391|
218908403|NCT00646139|OTHER|immunoenzyme technique|
218908404|NCT00646139|OTHER|pharmacological study|
218908405|NCT02367573|PROCEDURE|2D laparoscopic TAPP inguinal hernia repair|
218908406|NCT02367573|PROCEDURE|3D laparoscopic TAPP inguinal hernia repair|
218908407|NCT02571114|DIETARY_SUPPLEMENT|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
218908408|NCT02571114|DIETARY_SUPPLEMENT|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
218908409|NCT02571114|DIETARY_SUPPLEMENT|Control 1|White bread (serving size = 25 g available carbohydrate)
218908410|NCT02571114|DIETARY_SUPPLEMENT|Control 2|White bread (serving size = 25 g available carbohydrate)
219522832|NCT04231838|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
219613777|NCT04359147|DRUG|"Yohimbine + Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
219613778|NCT04359147|DRUG|"Placebo"|Effects on neural correlates of decision-making under risk and selective attention to threat
219613779|NCT06077474|OTHER|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
218908411|NCT02934802|DEVICE|Total Knee prothesis e motion PS Pro|
218908412|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
218908413|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
218908414|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
218908415|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
218908416|NCT02812836|DEVICE|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
218908417|NCT02319941|DRUG|ticagrelor|
218908418|NCT02319941|DRUG|clopidogrel|
218908419|NCT02212808|OTHER|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
218908420|NCT02212808|OTHER|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
218908421|NCT03295435|OTHER|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural \& Prosthetic units present Group C: No natural units present"
218908422|NCT01918124|RADIATION|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
218908423|NCT01918124|DRUG|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
218908424|NCT01918124|DRUG|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
218908425|NCT01918124|DRUG|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
218908426|NCT01650558|DRUG|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
219522833|NCT03152981|DRUG|Desflurane|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
219522834|NCT03152981|DRUG|propofol|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
219522835|NCT03152981|DRUG|remifentanil|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
219522836|NCT03507335|DEVICE|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
219522837|NCT01406418|BIOLOGICAL|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
219522838|NCT01406418|BIOLOGICAL|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
219522839|NCT01406418|BIOLOGICAL|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
219522840|NCT01406418|BIOLOGICAL|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
219522841|NCT01406418|BIOLOGICAL|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
219522842|NCT01406418|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion
219522843|NCT02603224|DRUG|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
219522844|NCT02603224|DRUG|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
219522845|NCT00000221|DRUG|Buprenorphine|
218908427|NCT01650558|DRUG|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
219522846|NCT02932696|OTHER|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
219522847|NCT00233597|DRUG|ferumoxytol or oral iron|
219522848|NCT03894605|DEVICE|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
219522849|NCT01856205|DRUG|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
219522850|NCT06073548|OTHER|Questionnaires and interviews|Patients wiill be asked to fulfill questionnaires at inclusion and 6 months after. An interview will be offered to a sub-sample of patients (approximately 20 patients).
219613780|NCT01226927|OTHER|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
219522851|NCT01230580|DRUG|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
219522852|NCT01230580|DRUG|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
219613781|NCT02899962|DRUG|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
219613782|NCT02899962|DRUG|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
219613783|NCT02367976|DRUG|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
219613784|NCT00932191|PROCEDURE|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
218908428|NCT01110824|DRUG|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
219613785|NCT00932191|PROCEDURE|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
219613786|NCT00003080|DRUG|endocrine-modulating drug therapy|
218908429|NCT03062735|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
218908430|NCT03062735|OTHER|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
218908431|NCT02578407|OTHER|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
218908432|NCT05620316|DRUG|BOTOX® Injection|100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
219040483|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
219613787|NCT00003080|DRUG|melphalan|
219613788|NCT00003080|DRUG|mitoxantrone hydrochloride|
219613789|NCT00003080|DRUG|tamoxifen citrate|
219613790|NCT00003080|DRUG|thiotepa|
219613791|NCT00003080|PROCEDURE|peripheral blood stem cell transplantation|
219613792|NCT00842192|DRUG|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
218908433|NCT05620316|OTHER|Prick skin|patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.
218908434|NCT05330013|DRUG|Dapagliflozin|Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).
218908435|NCT05330013|DEVICE|MRI scan|For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).
218908436|NCT05330013|DEVICE|CMR imaging|Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
218908437|NCT01476722|DEVICE|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
218908438|NCT01985295|DRUG|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
218908439|NCT04123522|PROCEDURE|anterior approach|anterior approach
218908440|NCT04123522|PROCEDURE|posterior appraoch|posteiror appraoch
218908441|NCT04499755|DRUG|Nucleo CMP Forte|Nucleo CMP Forte twice daily for 6 weeks
218908442|NCT00737646|BEHAVIORAL|Usual care|No intervention will be conducted in this arm of the study.
218908443|NCT00737646|BEHAVIORAL|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
218908444|NCT00737646|BEHAVIORAL|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
219613793|NCT03000062|BEHAVIORAL|Intervention group|Please see the preceding section
219613794|NCT03299582|DEVICE|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
219613795|NCT03299582|DEVICE|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
219613796|NCT02315131|DRUG|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
219613797|NCT02315131|DRUG|Placebo|Placebo Comparator
218908445|NCT02097862|PROCEDURE|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
218908446|NCT05603117|BEHAVIORAL|Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)|CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
218908447|NCT03261336|DRUG|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
218908448|NCT01155713|DRUG|TKI258|
218908449|NCT05478408|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
218908450|NCT02306681|OTHER|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
218908451|NCT02528084|PROCEDURE|yoga|patients watch and follow an online yoga video.
219613798|NCT03872973|OTHER|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
219613799|NCT03872973|OTHER|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
219613800|NCT06461000|OTHER|Survey|online survey for participants
219613801|NCT04422600|OTHER|There is no other intervention, only clinical treatment.|The investigators will then correlate that exposure with neurodevelopmental outcomes.
218908452|NCT02528084|PROCEDURE|standard exercises|patients watch and follow an online standard exercises video.
218908453|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
219613802|NCT03833687|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
219613803|NCT01849237|GENETIC|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
219613804|NCT01849237|DRUG|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
219613805|NCT03930537|DEVICE|Hip replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
218908454|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
218908455|NCT06060236|DRUG|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
218908456|NCT06060236|DRUG|Dexketoprofen|Dexketoprofen 50 Mg İV
218908457|NCT01869738|DEVICE|MGuard Prime|
218908458|NCT01869738|DEVICE|(BMS/DES)|
218908459|NCT00562367|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
218908460|NCT03174353|DRUG|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
218908461|NCT02462044|DRUG|240 mg Iodine|
218908462|NCT02462044|DRUG|300 mg Iodine|
218908463|NCT02462044|DRUG|370 mg Iodine|
218908464|NCT01069484|OTHER|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
219522853|NCT04937348|DIAGNOSTIC_TEST|Acquisition and analysis of milk samples|"In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits."
219522854|NCT04937348|DIAGNOSTIC_TEST|Collection, preparation and analysis of mother's blood samples.|Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.
219522855|NCT04937348|DIAGNOSTIC_TEST|Body composition assessment|The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
219522856|NCT04937348|OTHER|Anthropometric measurements|"Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis."
219522857|NCT06048146|DRUG|Experimental: FOLFOXIRI and Lateral lymph node dissection|Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
219522858|NCT06048146|DRUG|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
218908465|NCT06240637|OTHER|Telemonitoring|A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
218908466|NCT02710656|DEVICE|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
218908467|NCT02710656|DEVICE|Standard PTA|Percutaneous angioplasty performed with a standard balloon
218908468|NCT02296164|DRUG|Valchlor|Valchlor gel 0.016%
218908469|NCT01052792|DRUG|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
218908470|NCT00683111|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
218908471|NCT00683111|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
218908472|NCT02027012|DEVICE|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
218908473|NCT02282852|DEVICE|Wireless Capsule Endoscopy|
218908474|NCT02282852|DEVICE|Magnetically steerable capsule endoscopy|
218908475|NCT04976985|PROCEDURE|Osteopathic Manipulative Therapy (OMT)|"Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~1. Occipital- Alanto release~2. Muscle energy and soft tissue to mid trapezius muscle~3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~5. Soft tissue to cervical paraspinal muscles~6. Myo-fascial release of frontal forehead~7. CV4 cranial technique"
218908476|NCT04976985|OTHER|Standard of care|Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
218908477|NCT00079326|BIOLOGICAL|trastuzumab|Given IV
218908478|NCT00079326|DRUG|ixabepilone|Given IV
218908479|NCT00079326|OTHER|laboratory biomarker analysis|Correlative studies
218908480|NCT03597815|DRUG|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
219060596|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
219522859|NCT05908266|OTHER|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
218908481|NCT03597815|DIAGNOSTIC_TEST|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
218908482|NCT03597815|DEVICE|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
218908483|NCT03191617|DIETARY_SUPPLEMENT|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
218908484|NCT03829085|OTHER|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
219522860|NCT05908266|OTHER|Disease Assessment|Disease stage assessed by trained professionals
219522861|NCT03079050|DRUG|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
218908485|NCT02843269|BEHAVIORAL|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
219522862|NCT03953950|DRUG|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
219522863|NCT03953950|DRUG|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
219522864|NCT05820958|OTHER|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~* face and chest; 4 types of movements 10reps each;~* upper extremity; 4 types of movements, 10 reps each (left and right separately);~* abdomen; 2 types of movements, 10 reps each;~* lower extremity; 3 types of movements, 10 reps each (left and right separately);~* back; 2 types of movements, 10 reps each;~* final integration; 3 types of movements, 10 reps each."
219522865|NCT02276339|OTHER|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
219522866|NCT05502484|BEHAVIORAL|Integrative Dialectical Behavioural Therapy (DBT)|8 weeks outpatient pre-treatment DBT followed by integrative, inpatient DBT of 40 weeks, using standard DBT, augmented with an experience-oriented, body-oriented skills training based on DBT-principles by trained DBT-therapists, and a follow-up phase of 12 weeks outpatient aftercare (maximal 8 sessions individual DBT and 4 booster sessions) and 12 weeks no DBT. The inpatient treatment takes place in a living environment that is based on the principles of DBT and takes into account several aspects of autism.
219522867|NCT04109417|PROCEDURE|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
219522868|NCT04109417|PROCEDURE|osteotomy site following the surgical intervention was left empty|
219522869|NCT01469767|DRUG|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
219522870|NCT03694782|BEHAVIORAL|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
219522871|NCT03694782|BEHAVIORAL|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
219522872|NCT03694782|BEHAVIORAL|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
219522873|NCT02006160|DRUG|dalfampridine|10 mg bid
219522874|NCT02006160|DRUG|placebo|10 mg bid
219522875|NCT02696694|OTHER|Progesterone 25-75|Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
218908486|NCT02478008|DEVICE|CardiAQ TMVI System (Transapical DS)|
218908487|NCT02732600|OTHER|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
218908488|NCT03032562|DIAGNOSTIC_TEST|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
218908489|NCT02151487|DRUG|Ropivacaine|Ropivacaine alone
218908490|NCT02151487|DRUG|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
218908491|NCT02151487|DRUG|Ropivacaine and clonidine|Ropivacaine combination with clonidine
218908492|NCT02151487|DRUG|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
218908493|NCT02774460|DRUG|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
218908494|NCT02774460|DRUG|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
218908495|NCT02774460|DRUG|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
218908496|NCT02774460|DRUG|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
218908497|NCT02774460|DRUG|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
218908498|NCT02774460|DRUG|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
218908499|NCT02774460|DRUG|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
218908500|NCT02929953|OTHER|chart review|data from charts and from registries will be compared
218908501|NCT01616628|BEHAVIORAL|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
218908502|NCT01269866|DRUG|Cymbalta|Cymbalta 60 to 120 mg PO QD
218908503|NCT00528957|DRUG|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
218908504|NCT00528957|DRUG|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
218908505|NCT00528957|DRUG|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
218908506|NCT04400357|PROCEDURE|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
218908507|NCT04400357|PROCEDURE|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
218908508|NCT00549692|DRUG|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
218908509|NCT00382772|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
218908510|NCT03201796|DRUG|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
219522876|NCT02696694|OTHER|Progesterone <25, >75|Impact of serum progesterone concentrations (\<25, \>75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
218908511|NCT03201796|DRUG|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
218908512|NCT00771914|DRUG|Aspirin|Aspirin 81mg tablet
218908513|NCT00771914|DRUG|Lovaza|Lovaza 4 grams
218908514|NCT00771914|DRUG|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
218908515|NCT00771914|OTHER|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
219040484|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
219522877|NCT02254174|DRUG|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
219522878|NCT02254174|DRUG|Serevent® Diskus®|
219522879|NCT02254174|DRUG|Spiriva®|
219522880|NCT05908864|DRUG|Magnesium sulfate|Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
219522881|NCT01219322|DRUG|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
219522882|NCT01219322|DRUG|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
219522883|NCT01413581|DRUG|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
219522884|NCT01413581|DRUG|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
219522885|NCT04751734|BIOLOGICAL|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
219522886|NCT03452501|DRUG|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
218908516|NCT03655145|OTHER|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
218908517|NCT03655145|OTHER|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
218908518|NCT05421949|OTHER|Exercise group|Incremental Shuttle Walking Test
218908519|NCT02192515|DRUG|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
218908520|NCT02192515|DRUG|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
218908521|NCT02192515|DRUG|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
218908522|NCT02192515|DRUG|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
218908523|NCT02192515|DRUG|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
219040485|NCT00324779|BIOLOGICAL|rituximab|
219522887|NCT03393728|DRUG|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
219522888|NCT01066182|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
219522889|NCT01066182|DIETARY_SUPPLEMENT|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
218908524|NCT02192515|DRUG|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
218908525|NCT02192515|DRUG|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
218908526|NCT02192515|DRUG|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
218908527|NCT02654782|DRUG|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
218908528|NCT02654782|DRUG|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
218908529|NCT04565626|OTHER|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
218908530|NCT00752700|OTHER|Conventional resistance training|Conventional resistance training program (CRT)
218908531|NCT00752700|OTHER|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
218908532|NCT02978417|DRUG|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
218908533|NCT02978417|DRUG|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
218908534|NCT03111875|DEVICE|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
218908535|NCT03111875|DEVICE|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
218908536|NCT01361555|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
219522890|NCT01354860|OTHER|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
219613806|NCT04902937|RADIATION|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
219613807|NCT04902937|DRUG|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
219613808|NCT02153983|DRUG|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
219613809|NCT02153983|DRUG|Placebo capsules given|Placebo capsules given twice daily
218908537|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
219613810|NCT02153983|DRUG|Colchicine 0.6Mg Tab|Open-label colchicine
219613811|NCT02732873|DEVICE|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
219613812|NCT03567980|DRUG|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
219613813|NCT01034020|DRUG|Nicotine|
219613814|NCT01398046|DRUG|Dasatinib|dasatinib (100mg) PO x1
218908538|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
218908539|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
218908540|NCT03485924|DIAGNOSTIC_TEST|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
218908541|NCT03485924|DIAGNOSTIC_TEST|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
218908542|NCT02522247|PROCEDURE|UPP|surgery with cold steel in general anesthesia
218908543|NCT05890248|PROCEDURE|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
218908544|NCT05288816|DRUG|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
218908545|NCT03762408|DEVICE|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
218908546|NCT03762408|DEVICE|Durolane|60 mg HA crosslinked in 3 ml
218908547|NCT00467246|DRUG|Levemir|
218908548|NCT03360903|DRUG|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline"
218908549|NCT03360903|DRUG|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate"
218908550|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
218908551|NCT03184064|DIETARY_SUPPLEMENT|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
218908552|NCT03184064|DIETARY_SUPPLEMENT|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
219613815|NCT01398046|DRUG|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
219613816|NCT01398046|DRUG|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
219613817|NCT05999214|DIAGNOSTIC_TEST|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
219613818|NCT03700502|DIAGNOSTIC_TEST|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
219613819|NCT00580502|DEVICE|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
218908553|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
218908554|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
218908555|NCT05294926|DRUG|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure \< 60 mmHg and heart rate \< 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate \< 40 bpm) are used to prevent hypotension or bradycardia
218908556|NCT05294926|DEVICE|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
218908557|NCT01323582|DRUG|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
218908558|NCT01323582|DRUG|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
218908559|NCT00672698|PROCEDURE|SURGERY|ELECTIVE SURGICAL PROCEDURES
218908560|NCT05219357|OTHER|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
218908561|NCT05219357|DRUG|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
219040486|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
219060597|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
219613820|NCT04446247|DIAGNOSTIC_TEST|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
219613821|NCT06261645|OTHER|Early Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
218908562|NCT03561675|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
218908563|NCT03561675|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
218908564|NCT01422161|DRUG|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
218908565|NCT01422161|DRUG|Placebo|The control group will receive a placebo injection.
219522891|NCT01354860|OTHER|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
218908566|NCT02970799|DEVICE|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
218908567|NCT04040374|DIAGNOSTIC_TEST|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
218908568|NCT04040374|DIAGNOSTIC_TEST|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
218908569|NCT05597202|DRUG|Semaglutide, 2.0 mg/mL|Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
218908570|NCT00960375|BEHAVIORAL|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
218908571|NCT00960375|BEHAVIORAL|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
218908572|NCT04743115|DRUG|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
219522892|NCT00972218|BIOLOGICAL|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
219522893|NCT01328093|DRUG|LY2140023|Administered orally
219613822|NCT06261645|OTHER|Delayed Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
219613823|NCT05626205|DEVICE|PARO robot|PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.
219613824|NCT03330873|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
218908573|NCT01416818|DRUG|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
218908574|NCT01416818|DRUG|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
218908575|NCT01416818|DRUG|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
218908576|NCT04842708|DIAGNOSTIC_TEST|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
219613825|NCT03330873|DEVICE|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
218908577|NCT02051764|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
218908578|NCT02051764|DRUG|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
219522894|NCT01328093|DRUG|Aripiprazole|Administered orally
219522895|NCT05879471|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
219522896|NCT01133353|DRUG|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
219522897|NCT01133353|DRUG|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
219522898|NCT01162603|DEVICE|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
219522899|NCT01162603|DRUG|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
219522900|NCT01162603|DRUG|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
218908579|NCT02051764|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
218908580|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
219522901|NCT05488834|OTHER|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
219522902|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
219522903|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
219522904|NCT05075798|OTHER|No intervention,|pure observational study
218908581|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
218908582|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
218908583|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
218908584|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
219040487|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
219522905|NCT04667494|COMBINATION_PRODUCT|Sonotherapy|Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion
219522906|NCT05932524|DRUG|Baricitinib 2 MG|Baricitinib 2 mg q.d., p.o., for 6 consecutive months.
219522907|NCT05932524|DRUG|Dexamethasone|Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)
219522908|NCT02997150|DRUG|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
219522909|NCT02017119|DRUG|Comparison between Lactulose and Lactulose-Paraffin|
219522910|NCT01060618|OTHER|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
219522911|NCT04180709|DEVICE|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
219522912|NCT00369447|PROCEDURE|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
219522913|NCT00369447|BIOLOGICAL|nimotuzumab|weekly dose until disease progression
219522914|NCT02576249|DRUG|Ropivacaine|4cc 0.5% ropivacaine
219522915|NCT02576249|DRUG|Normal saline|4cc of sterile normal saline (0.9%)
219522916|NCT02576249|DRUG|Methylprednisolone|1cc 40mg methylprednisolone
219613826|NCT06036186|DEVICE|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
219522917|NCT02417636|OTHER|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
219522918|NCT03490721|OTHER|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
219613827|NCT06036186|DEVICE|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
219613828|NCT00550459|DRUG|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
218908585|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
218908586|NCT00364585|DEVICE|GreenLight Model 120 Laser System|
218908587|NCT06064630|DEVICE|Automatic continuous positive airway pressure|Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
218908588|NCT05771103|DEVICE|thermal Radiofrequency neurolysis of Stellate ganglion|Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
218959157|NCT04504058|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
218959158|NCT00555308|OTHER|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
219522919|NCT05954650|BEHAVIORAL|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
219522920|NCT05150964|DEVICE|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
218908589|NCT00976807|OTHER|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
218908590|NCT06430697|DRUG|paracetamol administration|Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
218908591|NCT01969708|DRUG|aflibercept|
218908592|NCT01969708|DRUG|bevacizumab|
219522921|NCT05083299|DRUG|Sarpogrelate|Anpl-one SR
218908593|NCT04387448|DRUG|GFB-887|Investigational Medicinal Product (IMP)
218908594|NCT04387448|DRUG|Placebo|Matching
218908595|NCT00724841|DRUG|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
219522922|NCT02567838|DRUG|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
219522923|NCT02567838|DRUG|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
219522924|NCT03270293|DEVICE|Profhilo|
219522925|NCT04985422|BEHAVIORAL|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
219522926|NCT04985422|BEHAVIORAL|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
219522927|NCT01856309|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
219522928|NCT01856309|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
219522929|NCT01856309|DRUG|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
219522930|NCT04946877|DIAGNOSTIC_TEST|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
219522931|NCT01075711|DRUG|Prednisone|According to SPC
219522932|NCT00832377|DRUG|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
219522933|NCT02297451|PROCEDURE|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
219522934|NCT04558151|BEHAVIORAL|preoperative inspiratory muscle training|Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
219613829|NCT00550459|DRUG|Placebo|Placebo tablet given once daily for 21 days
219613830|NCT01742897|DRUG|TTS-fentanyl|
218908596|NCT00724841|DRUG|Temozolomide|
219522935|NCT04926883|OTHER|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
219522936|NCT01284205|BIOLOGICAL|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
219522937|NCT01284205|BIOLOGICAL|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
219613831|NCT02404805|DRUG|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
219613832|NCT02404805|DRUG|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
219613833|NCT05131672|PROCEDURE|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
219613834|NCT05131672|PROCEDURE|cast immobilization|immobilization in a cast without reduction
218908597|NCT02892994|OTHER|ultrasound|
218908598|NCT04386200|OTHER|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
218908599|NCT04386200|BEHAVIORAL|traditional approach|"traditional face-to-face educational approach"
218908600|NCT00786669|DRUG|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
218908601|NCT00786669|DRUG|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
218908602|NCT00786669|DRUG|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
218908603|NCT00786669|DRUG|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
218959159|NCT03681223|DEVICE|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
218908604|NCT00786669|DRUG|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
219522938|NCT01022047|DRUG|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
219522939|NCT01022047|DRUG|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
219522940|NCT02513797|DEVICE|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
219522941|NCT02513797|DEVICE|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
219522942|NCT05995470|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for drinkers with psychological distress
219522943|NCT05995470|BEHAVIORAL|Monthly health education|General health information and sharing sessions
219522944|NCT01723995|RADIATION|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
219522945|NCT00488865|DEVICE|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
219522946|NCT00002260|DRUG|Alovudine|
219522947|NCT02629757|DRUG|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
219522948|NCT05689463|BIOLOGICAL|characterisation of immunoglobulin subclasses|For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed
219522949|NCT04043065|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
219522950|NCT04043065|OTHER|Placebo|Saline
219522951|NCT01561274|DRUG|2 ml bupivacaine|2 ml bupivacaine
219522952|NCT01561274|DRUG|1.5 ml bupivicaine.|1.5 ml bupivicaine.
219522953|NCT04345965|PROCEDURE|Endovascular procedure|Endovascular therapies for erectile dysfunction
219522954|NCT04480073|PROCEDURE|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
219522955|NCT05494567|DRUG|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
219522956|NCT05494567|DRUG|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
219522957|NCT05494567|DRUG|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
219522958|NCT00213421|DRUG|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
219613835|NCT00254592|DRUG|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
219613836|NCT00254592|DRUG|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
218908605|NCT00300417|DRUG|VRC-WNVDNA020-00-VP|
218908606|NCT00000547|DRUG|enalapril|
219522959|NCT01881321|BEHAVIORAL|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
219522960|NCT01390337|DRUG|AC220|Oral Liquid
219522961|NCT01390337|DRUG|daunorubicin|Intravenous Infusion
219040488|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
219522962|NCT01390337|DRUG|cytarabine|Intravenous Infusion
219522963|NCT05108571|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
219522964|NCT05108571|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
219522965|NCT02879682|PROCEDURE|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
219522966|NCT02879682|PROCEDURE|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
219522967|NCT01449630|DRUG|LY3031207|Administered orally
219522968|NCT01449630|DRUG|Placebo|Administered orally
219522969|NCT01449630|DRUG|Celecoxib|Administered orally
219522970|NCT00122629|DRUG|peg-interferon alfa-2b|
219522971|NCT00122629|DRUG|ribavirin|
219522972|NCT00122629|DRUG|amantadine|
219522973|NCT01888263|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
219613837|NCT00254592|DRUG|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
218908607|NCT02553213|OTHER|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
219522974|NCT04692610|BEHAVIORAL|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
219522975|NCT04692610|BEHAVIORAL|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
219522976|NCT04692610|BEHAVIORAL|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
219522977|NCT04692610|BEHAVIORAL|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
219522978|NCT02016612|DEVICE|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
219522979|NCT02854579|BIOLOGICAL|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
219522980|NCT02854579|BIOLOGICAL|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
218908608|NCT02553213|OTHER|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
218908609|NCT02553213|OTHER|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
218908610|NCT02553213|OTHER|easy digestible diet|
218908611|NCT04050046|DEVICE|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
218908612|NCT04050046|BEHAVIORAL|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
218908613|NCT03740256|BIOLOGICAL|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
218908614|NCT05797012|OTHER|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
218959160|NCT03681223|DEVICE|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
219613838|NCT00254592|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
218959161|NCT03681223|PROCEDURE|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
219522981|NCT02854579|BIOLOGICAL|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
219522982|NCT03256942|DEVICE|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
219522983|NCT04064632|DRUG|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
219522984|NCT04097600|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
219522985|NCT04250662|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
219522986|NCT04250662|DEVICE|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
219040489|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
219613839|NCT00254592|DRUG|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
219613840|NCT00254592|DRUG|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
219613841|NCT00254592|DRUG|Bevacizumab|10mg/kg q 2 wks
219613842|NCT05096910|PROCEDURE|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
219613843|NCT00147459|BIOLOGICAL|HBV vaccine booster|
219522987|NCT04250662|DEVICE|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
219522988|NCT04250662|DEVICE|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
219522989|NCT03799029|OTHER|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
219522990|NCT04203030|BEHAVIORAL|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
219522991|NCT01735630|DRUG|ELND005|
219522992|NCT01735630|DRUG|Placebo|
219522993|NCT01820923|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
219522994|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
219522995|NCT01820923|DEVICE|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
218908615|NCT06268652|OTHER|Organoid-guided personalized treatment|After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
218908616|NCT06268652|DRUG|Gemcitabine|1000mg/m2，IV, days 1, 8, q3w
219522996|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
219522997|NCT03621579|PROCEDURE|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
219613844|NCT00154154|BEHAVIORAL|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
218908617|NCT06268652|DRUG|Capecitabine|1000mg/m² , PO, bid, days1-14, q3w
219613845|NCT00154154|BEHAVIORAL|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
219613846|NCT02102854|DRUG|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
219613847|NCT00763633|DRUG|vitamin B6|high dose of vitamin B6
219613848|NCT00763633|DRUG|vitamin B6|low vitamin B6
219613849|NCT04184427|OTHER|Anterior Power Arm|Crimpable stainless steel hook placed on orthodontic base arch wire.
219613850|NCT01452516|DEVICE|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
219613851|NCT01452516|DEVICE|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
219613852|NCT06361680|DRUG|Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets|Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
218908618|NCT06268652|DRUG|Vinorelbine|25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
218908619|NCT06268652|DRUG|Eribulin|1.4mg/m², IV, days 1 and 8, q3w
218908620|NCT03155724|DEVICE|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
218908621|NCT03633851|DEVICE|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
218908622|NCT03633851|OTHER|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
219040490|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
219060598|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
219060599|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
219060600|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
219522998|NCT03099538|DRUG|Ixekizumab|Subcutaneous injection
219522999|NCT05090332|OTHER|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
219523000|NCT05090332|OTHER|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
219523001|NCT06266052|PROCEDURE|Triangular Flap|Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
219613853|NCT06178627|DRUG|Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
219040491|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
219523002|NCT06266052|PROCEDURE|Berwick Flap|Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
219523003|NCT06266052|PROCEDURE|Saurez Flap|In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
219523004|NCT06266052|PROCEDURE|Heitz Flap|Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
219523005|NCT01067885|DEVICE|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
219523006|NCT03044171|DEVICE|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
219523007|NCT03044171|DRUG|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
219523008|NCT03044171|DRUG|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
219523009|NCT05964777|DEVICE|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.
219523010|NCT01276730|DRUG|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
219523011|NCT01276730|DRUG|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
219523012|NCT02102425|PROCEDURE|Patients with or without bandage over exit site|
219523013|NCT05738525|DEVICE|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
219523014|NCT00949312|GENETIC|RNA marker analysis of lymph node and primary tumors|
219523015|NCT00949312|GENETIC|microarray profiling of primary tumors|
219523016|NCT00949312|GENETIC|reverse transcriptase-polymerase chain reaction of lymph node specimens|
219523017|NCT00949312|OTHER|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
219523018|NCT00949312|PROCEDURE|regional lymph node dissection|
219523019|NCT00949312|OTHER|lymph node staining for H&E and pancytokeratin IHC|
219523020|NCT03195374|OTHER|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
219613854|NCT06178627|DRUG|Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
219523021|NCT04067102|DRUG|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
219523022|NCT04067102|DRUG|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
219613855|NCT01960660|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|
219613856|NCT00277329|DRUG|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
219060601|NCT03299192|BEHAVIORAL|Tai Chi|Yang Style Tai Chi
218908623|NCT05139043|DRUG|Dexamethasone|Given IV and PO
218908624|NCT00293657|DRUG|Lornoxicam 8 mg|
218908625|NCT00293657|DRUG|Lornoxicam 16 mg|
218908626|NCT00293657|DRUG|Placebo|
218908627|NCT02987725|BEHAVIORAL|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
218908628|NCT02987725|BEHAVIORAL|Attention Control|A 30-minute historical story read by a research clinician.
218908629|NCT02897648|DRUG|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
218908630|NCT05255471|DRUG|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
218908631|NCT05255471|DRUG|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~* Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~* Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~* Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
218908632|NCT01859234|DRUG|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
218908633|NCT01991808|RADIATION|Radiotherapy|
218908634|NCT04608981|DRUG|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
218908635|NCT04608981|DRUG|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
218908636|NCT04608981|DRUG|Placebo|Starch
218908637|NCT03383861|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
218908638|NCT03980015|OTHER|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
218908639|NCT00321789|BEHAVIORAL|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
218908640|NCT04970277|OTHER|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
219523023|NCT02555111|DRUG|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
218908641|NCT04970277|OTHER|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
218908642|NCT02346045|PROCEDURE|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
218908643|NCT03243617|OTHER|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
218908644|NCT03243617|OTHER|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
218908645|NCT03053375|DEVICE|MDCure|Battery powered portable pulsed electromagnetic therapy device
219523024|NCT04901377|COMBINATION_PRODUCT|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
219523025|NCT05879549|OTHER|Closed Chain Exercise Group|Closed Chain Exercise Group
218908646|NCT04777617|OTHER|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
218908647|NCT03309020|PROCEDURE|Cataract surgery|Cataract surgery and aqueous humor sampling.
218908648|NCT03770312|DRUG|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
218908649|NCT03770312|DRUG|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
219523026|NCT05879549|OTHER|Proprioceptive Exercise Group|Proprioceptive Exercise Group
218908650|NCT02106000|DEVICE|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
218908651|NCT01102114|BIOLOGICAL|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
218908652|NCT01102114|BIOLOGICAL|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
218908653|NCT04434417|DEVICE|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
218908654|NCT01849601|DEVICE|percutaneous transluminal angioplasty balloon catheter|
218908655|NCT05563129|OTHER|First aid lessons|The school children will have first aid training
218908656|NCT00000235|DRUG|Buprenorphine|
219060602|NCT03299192|BEHAVIORAL|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
219523027|NCT06415201|OTHER|Interactive Artificial Intelligence|scenario based AI to assess, classify, explain and conduct supportive interviews
219523028|NCT02096718|DRUG|Afatinib healthy|
219523029|NCT02096718|DRUG|Afatinib severe renally impaired|
218908657|NCT04874714|BIOLOGICAL|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
218908658|NCT04874714|BIOLOGICAL|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
218908659|NCT04874714|BIOLOGICAL|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
218908660|NCT04874714|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
218908661|NCT06262386|DRUG|Cisplatin based chemottherapy|adjuvant therapy for high risk patient
218908662|NCT02859714|OTHER|screening data|
218908663|NCT06206538|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218908664|NCT06206538|BEHAVIORAL|Rehabilitation therapy|"he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
218908665|NCT01319981|DRUG|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
218908666|NCT01319981|DRUG|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
218908667|NCT01319981|DRUG|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
218908668|NCT01319981|DRUG|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
219523030|NCT02096718|DRUG|Afatinib moderate renally impaired|
218908669|NCT01319981|DRUG|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
218908670|NCT01319981|DRUG|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
218908671|NCT01319981|DRUG|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
218908672|NCT01319981|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
218908673|NCT01319981|DRUG|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
218908674|NCT01319981|DRUG|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.
218908675|NCT01319981|DRUG|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
218908676|NCT01319981|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
218908677|NCT05039957|OTHER|joint preparation|fixation of fracture with joint preparation
218908678|NCT05039957|OTHER|without joint preparation|fixation of fracture without joint preparation
218908679|NCT05345457|DRUG|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
218908680|NCT05345457|DRUG|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
219040492|NCT01627613|DRUG|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
219040493|NCT01627613|DRUG|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
219040494|NCT00002510|BIOLOGICAL|filgrastim|
219040495|NCT00002510|DRUG|cyclophosphamide|
219040496|NCT00002510|DRUG|etoposide|
219040497|NCT00002510|DRUG|mesna|
219040498|NCT00002510|PROCEDURE|peripheral blood stem cell transplantation|
219040499|NCT00002510|RADIATION|radiation therapy|
219060603|NCT03299192|OTHER|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
219060604|NCT00177437|BEHAVIORAL|home testing kit|
219523031|NCT02818439|OTHER|evaluation of frailty|
219523032|NCT03682900|OTHER|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
219523033|NCT03682900|OTHER|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
219523034|NCT03062046|DEVICE|RF ablation|RF ablation
219523035|NCT04448886|DRUG|Pembrolizumab|(iv) fixed dose, administered once per cycle
219523036|NCT04448886|DRUG|Sacituzumab Govitecan|(iv) fixed dose, administered twice per cycle
219523037|NCT04997993|DRUG|Leflunomide|Leflunomide, 20-50mg PO daily
219523038|NCT06234189|DEVICE|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|30 minutes without DIMS and 30 minutes with DIMS
219523039|NCT06577779|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
219523040|NCT00716495|BIOLOGICAL|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
219523041|NCT06340802|DEVICE|VNS Treatment|Vagus nerve stimulation is started 2-week after the implantation
218908681|NCT06630494|DRUG|Recombinant human thrombopoietin for injection (rhTPO)|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
218908682|NCT02919761|DRUG|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
218908683|NCT02919761|DRUG|Placebo|Matching placebo 1 mL for subcutaneous injection
218908684|NCT06590090|BIOLOGICAL|Natrunix 400 mg|"The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.~Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0."
218908685|NCT06590090|DRUG|Placebo|Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
218908686|NCT06590090|DRUG|Methotrexate (MTX)|Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.
218908687|NCT03852134|PROCEDURE|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
218908688|NCT03852134|PROCEDURE|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
218908689|NCT06612879|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
219523042|NCT03143400|DRUG|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
219523043|NCT01173770|DRUG|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
219523044|NCT01173770|DRUG|ADC3680B|ADC3680B or Placebo for 7 days
219523045|NCT01173770|DRUG|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
219523046|NCT03205553|PROCEDURE|SoC Staged Silo Closure|Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
219523047|NCT03205553|DRUG|Peritoneal Dialysis Solution/Dextrose 1.5%|Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
219523048|NCT03009448|OTHER|Interview|Each subject will be interviewed using a semi constructed interview.
219523049|NCT02461771|DRUG|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
218908690|NCT01586949|BEHAVIORAL|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
218908691|NCT01231958|BEHAVIORAL|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
219060605|NCT01920815|OTHER|No interventions|
219613857|NCT06060431|OTHER|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
219613858|NCT04951869|DRUG|Protescal gel|Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
218908692|NCT01796925|DEVICE|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
218908693|NCT06039553|PROCEDURE|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
219613859|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by Alt-RAMEC protocol.
218908694|NCT06878690|OTHER|Online Questionnaire|Completion of an online questionnaire via the secure RedCap platform
218908695|NCT06716437|BEHAVIORAL|Prehabilitation|"Patients will undergo a physiotherapy-led digitally-enabled prehabilitation program before lung resection surgery.~The intervention will be delivered through a mobile app and supported by tele-health and will consist of:~i) watching six educational videos embedded on the app on relevant topics to prepare for surgery, such as the importance of physical fitness, breathing exercises after surgery, and pain management.~ii) a physical activity coaching program to increase daily activity with feedback iii) a home-based, unsupervised exercise program consisting of 10 whole body strengthening exercises delivered in a video format iv) an inspiratory muscle training program using a hand-held device to be performed twice daily."
218908696|NCT06887335|PROCEDURE|Deep Sedation Under Proceduralist Direction with Pre-emptive Endotracheal Intubation|"If an eligible subject consents to participate in the study, deep sedation and preemptive endotracheal intubation will be performed, followed by bronchoscopy. Deep sedation will be administered according to the study protocol, with final approval of sedative administration given by the proceduralist. Oxygen will be supplied at a flow rate of 4-6 L/min via a nasal cannula before sedative administration.~To achieve a deep sedation state (Modified Observer's Assessment of Alertness/Sedation \[MOAA/S\] score ≤ 2, defined as the patient not opening their eyes despite repeated verbal stimuli), an initial dose of 50 mcg fentanyl will be administered, followed by 2.5-5 mg of remimazolam. The sedation depth will be assessed every two minutes using the MOAA/S score. If the patient has not reached deep sedation, an additional 2.5 mg of remimazolam will be administered.~Once deep sedation is achieved, lidocaine will be sprayed onto the trachea and bronchi using a bronchoscope for local anesthe"
218908697|NCT06726694|DEVICE|class II molar relation correction by advanced molar distalization appliance|correction of class II molar relation by a novel miniscrews distalizer
218908698|NCT06704568|OTHER|exercise|Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group: Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
218908699|NCT06922305|DRUG|HR19042 Capsule, Tarpeyo®, Budenofalk®|In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.
218908700|NCT05229484|OTHER|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
218908701|NCT06725082|BIOLOGICAL|Recombinant Humanized Type III Collagen Injection|rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
218908702|NCT06750458|DRUG|Dapagliflozin placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative
219523050|NCT03752788|BEHAVIORAL|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
219523051|NCT03752788|BEHAVIORAL|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
219523052|NCT05777707|DRUG|PD-1 blockade|PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
219523053|NCT05777707|DRUG|Albumin paclitaxel|Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
219523054|NCT05777707|DRUG|Carboplatin/Nedaplatin|Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
219613860|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with conventional protocol|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by conventional protocol
219613861|NCT00029003|DRUG|gefitinib|Given orally
219613862|NCT00029003|OTHER|laboratory biomarker analysis|Correlative studies
219613863|NCT02908971|BEHAVIORAL|soy based formula at infancy|The intervention is only past history of soy consumption
218908703|NCT06750458|DRUG|Placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
218908704|NCT06750458|DRUG|DexamethasoneGroup III (n=25) (Dexamethasone group)|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
218908705|NCT06837493|OTHER|Resistance based hand exercises and functional task-oriented hand exercise|The interventions for HEG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
218908706|NCT06837493|OTHER|Cognitive training|The interventions for CTG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
218908707|NCT06894342|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonographic evaluation of the masseter muscle
218908708|NCT05086705|DEVICE|EMBr Wave|Use EMBr Wave
218908709|NCT05086705|OTHER|Questionnaire Administration|Ancillary studies
218908710|NCT06881342|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|The first-stage intervention is eSMHP Plus in the intervention arm and eSMHP in the control arm. In the intervention arm, adolescents receive eSMHP Plus from teachers and non-specialists, while in the control arm, they receive eSMHP from teachers. eSMHP, based on developmental, behavioral, social, and cognitive theories, enhances teachers' mental health literacy, training them in early identification, basic counseling, life skills, positive discipline, parental engagement, referrals, and teacher well-being. The second-stage intervention is a CBT-based self-help app. At six weeks, adolescents scoring ≥28 on PSC in both arms (indicating psychosocial distress) are re-randomized to continue their initial treatment (eSMHP Plus or eSMHP) or receive a step-up, CBT-based guided self-help app for two months.
218908711|NCT06922006|PROCEDURE|Percutaneus nephrolithotomy (PCNL)|Percutaneus nephrolithotomy (PCNL) for removal of large kidney stones
218908712|NCT06939010|DEVICE|3d-interlocking miniplate|3d-interlocking miniplate
218908713|NCT06939010|DEVICE|Conventional miniplates|double miniplates in the conventional configuration
218908714|NCT06937359|OTHER|Reiki healing|Each client received four treatments with Healing Space Reiki Therapy: a foundation of Reiki, combined with a fully customized treatment with trauma processing and adjustments in diet and lifestyle at Dojo In Reiki treatments. In the Dojo In, there were 8 futons, with two Reiki Therapists at each futon treating one client. During these sessions, participants receive 4 Reiki treatments, each lasting about an hour, over 4 consecutive weeks. During these days, 2 trained and/or still training Reiki Therapists per treatment table provide a Reiki treatment under the supervision of the founders of Healing Space.
218908715|NCT06937138|PROCEDURE|AI-Assisted Screw Path Planning|The trajectory for screw placement during femoral neck fracture fixation will be guided by an AI algorithm based on intraoperative X-ray imaging. The system will automatically suggest the screw entry point and trajectory on the robotic navigation platform. The surgeon will proceed with the operation after confirming the feasibility of the AI-generated plan. In principle, surgeons are advised not to modify the AI-recommended trajectory unless necessary, to preserve the independent evaluative value of the AI-assisted plan. If significant disagreement arises between the surgeon's judgment and the AI-recommended trajectory, a third-party orthopedic specialist-blinded to group allocation-will conduct an independent postoperative assessment of the screw placement's appropriateness and accuracy.
218908716|NCT06937138|PROCEDURE|Surgeon-Directed Screw Path Planning|The screw trajectory will be entirely determined manually by the operating surgeon, based on personal experience and under guidance from the robotic navigation system and intraoperative fluoroscopy, without reliance on any AI recommendation module.
219040500|NCT04270500|BEHAVIORAL|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
218908717|NCT06938542|BEHAVIORAL|Family Centered pediatric palliative care for family caregivers of children with rare diseases.|Child with rare disease who is unable to participate in medical decision making/family caregiver/support person triads will be randomized at a 1:1 ratio to one of two study arms, either the 3 session FACE-Rare intervention or the enhanced Treatment as Usual. Assessments will be completed at baseline, 3, 6 and 12 month outcomes.
218908718|NCT06939244|DIETARY_SUPPLEMENT|Krill oil|Krill oil supplement
218908719|NCT06938425|OTHER|intratissue percutaneous electrolysis|Using fine needles guided by ultrasound to apply electrical stimulation directly to the affected tissue (for example, damaged muscles or tendons).
218908720|NCT06938425|OTHER|deep dry needling|Insertion of fine needles into muscle trigger points (without injection of drugs) to relieve muscle pain and release tension.
218908721|NCT06938425|PROCEDURE|Standard physiotherapy|It includes manual techniques such as therapeutic massage and mobilization, along with stretching and strengthening exercises to improve range of motion and reduce pain.
218908722|NCT06938932|OTHER|High temperature exposure|Subjects will be exposed to 35 degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
218908723|NCT06938932|OTHER|Moderate temperature exposure|Subjects will be exposed to 24degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
218908724|NCT06938633|OTHER|mass spectrometry analysis|The collected urine samples will be analyzed to determine medication adherence during study visits
219040501|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
219613864|NCT03654833|DRUG|Rucaparib|PARP inhibitor
219613865|NCT03654833|DRUG|Abemaciclib|CDK4/6 inhibitor
219613866|NCT03654833|DRUG|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
219613867|NCT03654833|DRUG|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
219613868|NCT03654833|DRUG|Dostarlimab and Niraparib|IG Antibody, PARP Inhibitor
219613869|NCT01068483|DRUG|BKM120|
219613870|NCT05611554|BEHAVIORAL|ACT|Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
218908725|NCT00673777|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219523055|NCT04191980|OTHER|Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists|"The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95\_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes"
219523056|NCT00383890|DRUG|Dexmedetomidine HCL Injection|
218908726|NCT02696213|OTHER|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
218908727|NCT02696213|OTHER|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
218908728|NCT01789437|DEVICE|Dexamethasone Intravitreal Implant (Ozuredex)|
218908729|NCT03167775|DRUG|Elemene Injection/Elemene Oral Emulusion|
218908730|NCT02790801|OTHER|observation|observation
218908731|NCT01216137|OTHER|Exercise: Vestibular Rehabilitation|Balance and eye movement training
218908732|NCT01216137|OTHER|Exercise|Bicycle ergometry and stretching
218908733|NCT03125551|DIETARY_SUPPLEMENT|Ginger|Ginger dosage at daily recommended allowance
218908734|NCT03125551|DIETARY_SUPPLEMENT|Garlic|Garlic dosage at daily recommended allowance
219523057|NCT00383890|DRUG|Placebo|
219523058|NCT00154414|DRUG|liraglutide|
219523059|NCT03366909|BEHAVIORAL|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
219523060|NCT03366909|BEHAVIORAL|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
219523061|NCT03436680|OTHER|Best Practice|Receive standard of care
218908735|NCT03125551|DIETARY_SUPPLEMENT|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
218908736|NCT03125551|DIETARY_SUPPLEMENT|Ginseng|Ginseng dosage at daily recommended allowance
218908737|NCT03125551|OTHER|Placebo|Daily dosage strategy
218908738|NCT03057015|DRUG|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
219523062|NCT03436680|BEHAVIORAL|Neurofeedback|Complete neurofeedback training sessions
219523063|NCT03436680|OTHER|Quality-of-Life Assessment|Ancillary studies
219523064|NCT03436680|OTHER|Questionnaire Administration|Ancillary studies
219523065|NCT05258942|OTHER|Observational|Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.
218908739|NCT03057015|DRUG|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
218908740|NCT03057015|DRUG|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
219523066|NCT04604704|DRUG|Naltrexone|Naltrexone at 4.5 mg/day
219523067|NCT04604704|DIETARY_SUPPLEMENT|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
219613871|NCT03744247|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
218908741|NCT03057015|DRUG|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
218908742|NCT03057015|DRUG|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
218908743|NCT04721223|DRUG|JAB-3068|JAB-3068 administrated orally as a tablet.
218908744|NCT04721223|DRUG|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
218908745|NCT00003229|BIOLOGICAL|aldesleukin|
218908746|NCT00003229|BIOLOGICAL|gp100 antigen|
218908747|NCT00003229|BIOLOGICAL|tyrosinase peptide|
218908748|NCT00948064|DRUG|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
218908749|NCT00948064|DRUG|Azacitidine|75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
218908750|NCT02231515|DEVICE|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
218908751|NCT02231515|DEVICE|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
219523068|NCT02602925|OTHER|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
219523069|NCT02602925|OTHER|Usual care|Usual care
219613872|NCT03744247|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
219523070|NCT02222766|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
218908752|NCT02962401|DRUG|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
218908753|NCT02962401|DRUG|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
218908754|NCT05550779|BEHAVIORAL|Mental Exercise|Participant perform a 10-minute mental exercise
219523071|NCT02222766|BEHAVIORAL|Control|Minimal attention control- 9 weekly mailed information on general child development
218908755|NCT06551051|DRUG|duloxetine|Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
218908756|NCT03349723|DRUG|BI 1265162|Single rising dose groups
218908757|NCT03349723|DRUG|Placebo|Single rising dose groups
218908758|NCT05482139|PROCEDURE|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
218908759|NCT00684866|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
218908760|NCT00684866|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
218908761|NCT02923141|BEHAVIORAL|Neutral Writing|
218908762|NCT02923141|BEHAVIORAL|Expressive Writing|
218908763|NCT02923141|BEHAVIORAL|Contingency Management|
218908764|NCT02741128|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
218908765|NCT02741128|BIOLOGICAL|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
219365260|NCT03839108|DRUG|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
219523072|NCT04471675|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
219523073|NCT01941030|DEVICE|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
219523074|NCT01941030|DEVICE|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
219613873|NCT03744247|DRUG|Placebo|Intravenously every 2 weeks
218908766|NCT03589716|OTHER|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
218908767|NCT03589716|OTHER|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
218908768|NCT03589716|OTHER|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
218908769|NCT03589716|OTHER|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
218908770|NCT03589716|OTHER|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
218908771|NCT05000398|OTHER|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
218908772|NCT05000398|OTHER|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
218908773|NCT05000398|OTHER|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
218959162|NCT03681223|PROCEDURE|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
218959163|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
219523075|NCT05628636|DRUG|AC-OLE-01-VA|formulation of tricaprilin
219523076|NCT02178826|DEVICE|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
219523077|NCT02178826|DEVICE|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
219523078|NCT00281125|DRUG|PTK787 and Pemetrexed with or without Cisplatin|
219523079|NCT04016532|DIETARY_SUPPLEMENT|Personalized dietary management at home|"Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions"
219523080|NCT00148564|DRUG|olanzapine|treatment with either Olanzapine or Ziprasidone
219523081|NCT00148564|DRUG|Ziprasidone|treatment with either Olanzapine or Ziprasidone
219523082|NCT02384174|DIETARY_SUPPLEMENT|Resistant starch|
219523083|NCT02384174|DIETARY_SUPPLEMENT|Dietary fibre (arabinogalactan, gum guar, pectin)|
219613874|NCT05391373|BEHAVIORAL|Laughter therapy|Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
218908774|NCT05000398|OTHER|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
218908775|NCT05000398|OTHER|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
218908776|NCT05000398|OTHER|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
218908777|NCT05000398|OTHER|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
218908778|NCT05000398|OTHER|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
218908779|NCT05000398|OTHER|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
218908780|NCT01649349|DEVICE|two-piece nasogastric tube|one week period
218908781|NCT01404741|PROCEDURE|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
218908782|NCT01404741|PROCEDURE|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
219040502|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
219523084|NCT01502943|DRUG|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
219523085|NCT01502943|DRUG|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
219523086|NCT01502943|DRUG|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
219523087|NCT01502943|DRUG|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
219613875|NCT05066360|DIAGNOSTIC_TEST|serum antimullerian hormone|serum antimullerian hormone will be analyzed for all participants
218908783|NCT02973100|DRUG|Dulaglutide|Administered SC
218908784|NCT02973100|DRUG|Placebo|Administered SC
218959164|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene free form|One capsule with Pterostilbene free form
219613876|NCT03119402|BEHAVIORAL|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
219613877|NCT03119402|DEVICE|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
218959165|NCT02068768|DEVICE|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
218959166|NCT06409832|DRUG|Rimegepant 75 mg|Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
218959167|NCT02715297|RADIATION|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
218959168|NCT04180449|OTHER|Screening for dysphagia along clinical routine|Screening for dysphagia using the water swallow test in intermediate care unit patients
218959169|NCT06437704|OTHER|Brain training game Lumosity|. Group A, the experimental group will be trained using five selected games i.e. Speed Match, Memory Matrix, Tidal treasure, Ebb and Flow and Lost in Migration from Lumosity for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
218959170|NCT06437704|OTHER|Simulation game simcity buildit|Group B, the active control will be trained for the same number of sessions using a simulation game, SimCity Build it, for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
218959171|NCT02463552|DRUG|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
218908785|NCT01419769|DEVICE|AXIOS Stent & Delivery System|"The AXIOS Stent \& Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
218908786|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
218908787|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
218908788|NCT00878501|DRUG|Placebo|Oral, during 4 weeks
218908789|NCT05410522|DEVICE|EMS Program|Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
218908790|NCT00960622|DRUG|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
218908791|NCT00960622|DRUG|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
218908792|NCT00960622|DRUG|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
218908793|NCT00799786|BEHAVIORAL|Building Better Caregivers Online Workshop|
218908794|NCT03562364|OTHER|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
218908795|NCT04985617|OTHER|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
218908796|NCT05893745|OTHER|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
218908797|NCT05893745|OTHER|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
218908798|NCT02941081|DIETARY_SUPPLEMENT|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
218908799|NCT02941081|DIETARY_SUPPLEMENT|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
218908800|NCT02941081|OTHER|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
218908801|NCT00812708|DEVICE|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
218908802|NCT01082016|OTHER|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
218908803|NCT02266368|DEVICE|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
218908804|NCT01959503|DEVICE|Progel Vascular Sealant|
219523088|NCT01502943|DRUG|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
219523089|NCT03635125|DRUG|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
219523090|NCT03635125|DRUG|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
219523091|NCT03635125|OTHER|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
218908805|NCT01959503|DEVICE|Gelfoam Plus|
218908806|NCT05641337|DRUG|Insulin Degludec and Insulin Aspart|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
219040503|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
219040504|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
219523092|NCT05048992|OTHER|ELDOA method|group A will receive
219523093|NCT05048992|OTHER|Post-facilitation stretching|Group B will receive
218908807|NCT05482997|DIETARY_SUPPLEMENT|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
219040505|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
219040506|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
219040507|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
219523094|NCT05654779|BIOLOGICAL|LCAR-AMDR Cells Product|Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
219523095|NCT00162123|DRUG|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
219523096|NCT03414749|PROCEDURE|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
218908808|NCT05482997|DIETARY_SUPPLEMENT|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
218908809|NCT02857517|DRUG|conbercept|0.05ml conbercept
218908810|NCT01600326|PROCEDURE|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
218908811|NCT01600326|DRUG|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
218908812|NCT03043014|DRUG|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
218908813|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
218908814|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg per day
218908815|NCT03484754|BIOLOGICAL|botulinum toxin|injection of botulinum toxina in two different facial sites
218908816|NCT03128294|OTHER|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
218908817|NCT06378944|OTHER|Application of green indocyanine colorant|The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
218908818|NCT06378944|DRUG|Technetium99|Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
218908819|NCT00848809|PROCEDURE|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
218908820|NCT00848809|PROCEDURE|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
219040508|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
219040509|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
219040510|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
219040511|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
219040512|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
219523097|NCT03414749|PROCEDURE|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
219523098|NCT05886543|BEHAVIORAL|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
219613878|NCT05457777|BEHAVIORAL|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
219040513|NCT06719973|DRUG|M9466|Participants will receive an escalating doses of M9466 orally in 21-day cycles until disease progression, intolerable toxicity, death, withdrawal of study or study consent, lost to follow-up, or end of study.
219613879|NCT03286153|OTHER|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: \[50kg + (2.3kg\*every inch over 5 feet)\].
219613880|NCT03286153|OTHER|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
218908821|NCT04696120|DRUG|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
218908822|NCT04696120|DRUG|Placebo|All patients who are assigned to placebo group will receive placebo
219040514|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously on Day 1 of each 21-day cycle.
219040515|NCT06719973|DRUG|Etoposide|Etoposide will be administered intravenously as per standard of care.
219040516|NCT06719973|DRUG|Atezolizumab|Atezolizumab will be administered intravenously as per standard of care.
219040517|NCT06719973|DRUG|M9446|M9446 dose will be further investigated in Module 2 Part A of the study.
219040518|NCT06719973|DRUG|M9446|M9446 recommended Dose for Expansion (RDE) will be further investigated in Module 2 Part B of the study.
218908823|NCT00077246|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219040519|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously as per standard of care.
219523099|NCT05886543|BEHAVIORAL|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
218908824|NCT05734027|DEVICE|Sectional matrix|The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion
218908825|NCT05734027|DEVICE|Circumferential matrix|Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
218908826|NCT05642351|OTHER|Autobiographical reminder|"The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)"
218908827|NCT06046924|OTHER|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
218908828|NCT06046924|DRUG|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
219523100|NCT04438057|BIOLOGICAL|CCP|Randomized open label study to receive 2:1 CCP to standard of care
218908829|NCT06046924|OTHER|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
218908830|NCT01796340|BEHAVIORAL|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
219040520|NCT04406064|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
219523101|NCT00193622|DRUG|Bevacizumab|
219523102|NCT00193622|DRUG|Erlotinib|
219523103|NCT05823090|DEVICE|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
219523104|NCT00284674|DEVICE|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
219523105|NCT02930005|DRUG|Meclofenamic acid|
219523106|NCT02930005|DRUG|Pentosan polysulfate sodium|
218908831|NCT01796340|BEHAVIORAL|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
219523107|NCT05689762|BEHAVIORAL|Healthy lifestyle counseling and E-health support|Promotion of healthy lifestyle behaviors through counseling and access to E-health platform
219523108|NCT05431166|BEHAVIORAL|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
218908832|NCT02161770|DRUG|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
218908833|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
218908834|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
218908835|NCT05862753|DRUG|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
219523109|NCT05431166|BEHAVIORAL|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
219523110|NCT04362891|PROCEDURE|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
219523111|NCT01793194|OTHER|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
219523112|NCT01524718|RADIATION|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
219613881|NCT03385889|PROCEDURE|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
218908836|NCT06403787|DRUG|Aerobic exercise + Ginkgo Biloba Extract|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
219613882|NCT03385889|PROCEDURE|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
218908837|NCT06403787|DRUG|Aerobic exercise + Calcined magnesia (placebo)|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
218908838|NCT06403787|DRUG|Aerobic exercise + Atorvastatin|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
218908839|NCT06333249|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
218908840|NCT05213975|DEVICE|Kinesio tape|Kinesio taping
218908841|NCT06272240|OTHER|Ovarian Cancer Organoids|To characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
218908842|NCT00149877|DRUG|Tegaserod|
218908843|NCT01716286|DIETARY_SUPPLEMENT|low fat vs. essence yoghurt|
218908844|NCT06333184|OTHER|Food|Fruit ingested in whole form or as either commercially available, or home-made smoothies
218908845|NCT02324881|BEHAVIORAL|Telephone-Based Intervention|Use PSMA
218908846|NCT02324881|OTHER|Questionnaire Administration|Ancillary studies
219040521|NCT03299842|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
218908847|NCT04529733|DEVICE|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
218908848|NCT03770234|DRUG|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
218908849|NCT02113696|DIETARY_SUPPLEMENT|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
218908850|NCT02113696|DIETARY_SUPPLEMENT|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
219040522|NCT00960518|DRUG|adefovir|adefovir at 10 mg daily for 48 weeks
219040523|NCT00960518|PROCEDURE|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
219040524|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
219040525|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
219040526|NCT02659215|DEVICE|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
219040527|NCT02659215|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
219040528|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
219040529|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
218908851|NCT02389166|DEVICE|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
218908852|NCT02389166|DEVICE|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
219040530|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
218908853|NCT04419025|DRUG|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
219040531|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
219523113|NCT04587557|BEHAVIORAL|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
219523114|NCT04587557|BEHAVIORAL|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
219523115|NCT04587557|OTHER|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
219523116|NCT04587557|OTHER|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
219523117|NCT05003635|DEVICE|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
219523118|NCT00138385|BIOLOGICAL|FluMist|
219523119|NCT00138385|BIOLOGICAL|Fluzone|
219523120|NCT00933751|DEVICE|Central vein catheterization|Blood samplings from IVC catheter
219523121|NCT03033420|DEVICE|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
219523122|NCT04292561|DRUG|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
219523123|NCT04292561|DRUG|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
219523124|NCT02945215|DRUG|IBI301|IBI301 375mg/㎡
219523125|NCT02945215|DRUG|Rituximab|Rituximab 375mg/㎡
219523126|NCT06545149|DIETARY_SUPPLEMENT|BioNutri AR-1,|intervention with fermented and nutritionally balanced food twice a day
219523127|NCT02125266|DRUG|V404|Sustained Release
219523128|NCT02011204|DEVICE|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
219523129|NCT01288664|DRUG|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
219523130|NCT01313416|BIOLOGICAL|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
219523131|NCT01313416|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
219523132|NCT00487669|DRUG|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
219523133|NCT05936710|DEVICE|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
219523134|NCT05936710|DEVICE|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
218908854|NCT03224130|OTHER|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
218959172|NCT03947411|DRUG|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
219523135|NCT03005522|DRUG|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
219523136|NCT03005522|DRUG|Placebo Oral Capsule|dosed with placebo
219523137|NCT00319358|DIETARY_SUPPLEMENT|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
219523138|NCT00319358|DIETARY_SUPPLEMENT|Placebo|placebo
219523139|NCT01895296|DRUG|Pasireotide|somatostatin analogue pasireotide
219523140|NCT01895296|DRUG|Placebo|placebo s.c.
219523141|NCT04012632|OTHER|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
219613883|NCT00286104|DEVICE|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
219613884|NCT00286104|DEVICE|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
219613885|NCT02046044|DRUG|Digoxin|
219523142|NCT01806805|DRUG|zonegran|
219523143|NCT01806805|DRUG|placebo|
219523144|NCT00822926|DRUG|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
219523145|NCT00822926|DRUG|Saline|Subcutaneous injection of saline into scar tissue
219523146|NCT05352087|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
219523147|NCT04185935|OTHER|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
219523148|NCT04185935|OTHER|Questionnaire Administration|Ancillary studies
219613886|NCT02046044|DRUG|Ivabradine|
218908855|NCT03224130|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
218908856|NCT02985827|DRUG|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
218908857|NCT02985827|DRUG|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
218908858|NCT02198014|OTHER|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
218908859|NCT02198014|OTHER|Educational Physiotherapy|"* Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
218908860|NCT05119777|DEVICE|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
218908861|NCT05849142|DEVICE|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
218908862|NCT03886285|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
218908863|NCT00966836|DRUG|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
218908864|NCT00966836|DRUG|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
218908865|NCT00966836|DRUG|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
218908866|NCT00966836|DRUG|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
218908867|NCT00144807|DRUG|rituximab|
218908868|NCT00144807|DRUG|doxorubicin|
219040532|NCT03661814|DEVICE|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
219523149|NCT01765530|DEVICE|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
219523150|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
218908869|NCT00144807|DRUG|cyclophosphamide|
218908870|NCT00144807|PROCEDURE|autologous stem cell transplantation|
218908871|NCT05443308|DIAGNOSTIC_TEST|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral \[15O\]H2O PET before and after diamox infusion
218908872|NCT05132153|DRUG|Milrinone|will be given by nebulization
218908873|NCT05132153|DRUG|Normal saline|will be given by nebuliztion
218908874|NCT05011981|DEVICE|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
218908875|NCT05020821|PROCEDURE|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
218959173|NCT03947411|DRUG|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
218959174|NCT05098977|PROCEDURE|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
219040533|NCT04916184|OTHER|aerobic exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
218908876|NCT05020821|PROCEDURE|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
218908877|NCT00851357|DRUG|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
218908878|NCT00851357|BEHAVIORAL|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
218908879|NCT00851357|DRUG|Placebo|Placebo nicotine patch
218908880|NCT00851357|OTHER|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
218908881|NCT01657864|DRUG|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
218908882|NCT02437045|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
218908883|NCT02437045|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
219523151|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
219523152|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
219523153|NCT01930461|BIOLOGICAL|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
219523154|NCT01540032|BEHAVIORAL|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
219523155|NCT01540032|BEHAVIORAL|Normal diet|Patients will eat their usual diet.
219523156|NCT03776903|OTHER|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
219523157|NCT00486083|DRUG|Atomoxetine Hydrochloride|
219523158|NCT00486083|DRUG|Methylphenidate Hydrochloride|
219523159|NCT01124396|DRUG|DSP-3025|
219523160|NCT01124396|DRUG|Placebo|
219613887|NCT02120638|DRUG|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
219613888|NCT02120638|DRUG|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
219613889|NCT00542633|DRUG|VIAject™|Dosage as individually required
218908884|NCT05690139|PROCEDURE|Pre-operative LSG patients|Baseline
218908885|NCT05690139|PROCEDURE|Post-operative patients 1st month|1 month after surgery
218908886|NCT05690139|PROCEDURE|Post-operative patients 3rd month|3 months after surgery
218908887|NCT05690139|PROCEDURE|Post-operative patients 6th month|6 months after surgery
218908888|NCT03820596|DRUG|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
219040534|NCT04916184|OTHER|combined exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
219523161|NCT02304432|DRUG|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
219523162|NCT02304432|DRUG|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
219523163|NCT02304432|DRUG|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
219523164|NCT06347042|OTHER|qigong exercise + routine medical treatment +Anti-inflammatory diet|1\. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.
219523165|NCT06347042|OTHER|routine medical treatment +Anti-inflammatory diet only|"1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment"
219613890|NCT00542633|DRUG|Regular Human Insulin|Dosage as individually required
218908889|NCT03820596|DRUG|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
218908890|NCT02847377|OTHER|Injection of [18F]-ODS2004436 radiotracer|
218908891|NCT02714400|DRUG|Venlafaxine|Venlafaxine 50mg before sleep
218908892|NCT02714400|DRUG|Placebo|One piece of placebo before sleep
218908893|NCT03793049|DEVICE|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
218908894|NCT05328609|DIETARY_SUPPLEMENT|Semaine Hormonal Imbalance & The Daily|All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
218908895|NCT01682239|OTHER|RVAP|In this arm pacemaker leads will be placed in the RV apex.
218908896|NCT01682239|OTHER|RVSP|In this arm pacemaker leads will be placed in the RV septum.
218908897|NCT04006041|DRUG|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
218908898|NCT04006041|DRUG|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
218908899|NCT04006041|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
218908900|NCT04006041|PROCEDURE|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
218908901|NCT03664531|OTHER|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
218908902|NCT03664531|OTHER|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
218908903|NCT03664531|OTHER|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
219613891|NCT01237119|DRUG|Liraglutide|1.8 mg once daily, subcutaneous injection
218908904|NCT02435186|DRUG|p53 gene|p53 gene will be given intraperitoneally.
218908905|NCT02435186|DRUG|Cisplatin|150 mg/m\^2 cisplatin will be given intraperitoneally.
218908906|NCT02435186|DRUG|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
219613892|NCT01237119|OTHER|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
219613893|NCT02284477|OTHER|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
219613894|NCT02284477|OTHER|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
218908907|NCT01760057|BEHAVIORAL|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
218908908|NCT01760057|BEHAVIORAL|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
218908909|NCT05851651|BEHAVIORAL|Antenatal milk expression and breastfeeding self-efficacy enhancement|A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
218908910|NCT03623113|BEHAVIORAL|BCC intervention|Structured training and education i basic carbohydrate counting principles
218908911|NCT03623113|BEHAVIORAL|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
218908912|NCT03623113|BEHAVIORAL|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
218908913|NCT00811161|DEVICE|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
218908914|NCT02383381|PROCEDURE|lateral rectus recession|typical surgery for correcting intermittent exotropia
218908915|NCT00543036|DEVICE|H-Coil deep TMS|
218908916|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
218908917|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
218908918|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
218908919|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
218908920|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
218908921|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
218908922|NCT03866070|OTHER|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
218908923|NCT03866070|OTHER|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
218908924|NCT03976765|OTHER|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
218908925|NCT00167115|DRUG|Alcohol|
218908926|NCT02572544|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
218908927|NCT02237326|PROCEDURE|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
218908928|NCT02237326|PROCEDURE|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
218908929|NCT05118971|DIAGNOSTIC_TEST|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
218908930|NCT00315835|DRUG|Buprenorphine transdermal delivery system|
218908931|NCT05690451|DIAGNOSTIC_TEST|non-contrast abbreviated MRI|"Liver MRI without contrast injection. The following sequences will be obtained from all of the participants.~* Axial heavily and regular T2 WI~* precontrast fat-suppressed T1 WI~* Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000"
218908932|NCT05690451|DIAGNOSTIC_TEST|Contrast enhanced liver CT|"Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained~* precontast, arterial phase, portal venous phase and delayed phase"
218908933|NCT03868215|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
218908934|NCT04620785|OTHER|methylene blue / IPL|therapeutic
218908935|NCT04620785|OTHER|IPL|therapeutic
218908936|NCT04620785|OTHER|saline|placebo
218908937|NCT00208728|DEVICE|PC/SMART cardiopulmonary bypass circuit|
218908938|NCT00208728|DEVICE|PMEA modified cardiopulmonary bypass circuit|
218908939|NCT00208728|DEVICE|Standard of care uncoated cardiopulmonary bypass circuit|
218908940|NCT05427981|DRUG|Belbuca Buccal Product|Buprenorphine Buccal Films
218908941|NCT05427981|OTHER|Placebo|Placebo Buccal Films
218908942|NCT03924622|DEVICE|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
218908943|NCT03924622|DEVICE|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
219613895|NCT06071624|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
219613896|NCT02000492|BEHAVIORAL|Football|
219613897|NCT02000492|BEHAVIORAL|Running|
218908944|NCT04446416|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
218908945|NCT04446416|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
218908946|NCT02398916|BEHAVIORAL|Music listening|
218908947|NCT06322849|BEHAVIORAL|Psychoeducation|Psychoeducation is a potential active element of Project ABC. In psychoeducation, participants learn about the cognitive model of behavior and how they can take action to change their moods.
219365261|NCT03235687|DIAGNOSTIC_TEST|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
219365262|NCT04698525|DRUG|Valproate Sodium|Comparison between two actives
219365263|NCT04698525|DRUG|Memantine|Memantine
219365264|NCT00546923|DRUG|Venlafaxine XR|
219613898|NCT02000492|BEHAVIORAL|Circuit training|
219613899|NCT04522440|OTHER|to relieve the pain of inpatients in the hospice Ward|This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
219613900|NCT00800267|DRUG|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
219365265|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
219365266|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
218908948|NCT06322849|BEHAVIORAL|Testimonials and Saying is believing exercises|Testimonials and Saying is believing exercises is a potential active element of Project ABC. In this element, participants learn about how others have taken action to improve their mood and complete one exercise where they give advice to a virtual peer who is stuck in a negative spiral.
218908949|NCT06322849|BEHAVIORAL|Action planning|Action planning is a potential active element of Project ABC. In this element, participants plan in detail an action they can take to get out of the negative mood spiral.
218908950|NCT06322849|BEHAVIORAL|Breathing exercise|Participants will be presented with a one-minute breathing exercise.
218908951|NCT04166422|OTHER|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
218908952|NCT04166422|OTHER|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
218908953|NCT04992312|DRUG|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
218908954|NCT02412306|DRUG|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
218908955|NCT05387083|DRUG|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
218908956|NCT05387083|DRUG|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
218908957|NCT05387083|DRUG|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
218908958|NCT05845385|PROCEDURE|lumbar epidural analgesia with bupivacaine|postoperative analgesic method
218908959|NCT05845385|PROCEDURE|transversus abdominis plane block with bupivacaine|postoperative analgesic method
218908960|NCT05845385|PROCEDURE|wound infiltration with bupivacaine|postoperative analgesic method
218908961|NCT05708196|OTHER|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
218908962|NCT05708196|OTHER|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
218908963|NCT06345716|DRUG|paracétamol tramadol|Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
218908964|NCT06345716|DRUG|Paracétamol cafeine|Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
218908965|NCT06345716|DRUG|Placebo|Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
218908966|NCT05989126|DRUG|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
218908967|NCT04019379|OTHER|High Phosphorus Diet|Controlled research diet of high phosphorus (with low calcium)
218908968|NCT04019379|OTHER|Low Phosphorus Diet|Controlled research diet of low phosphorus (with low calcium)
218908969|NCT04002141|DRUG|Placebo oral tablet|1 tablet oral daily
218908970|NCT04002141|DRUG|Letrozole|5mg oral daily
218908971|NCT04530981|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
218908972|NCT04530981|DRUG|Repaglinide|Oral antihyperglycemic agent
218908973|NCT05627271|OTHER|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
218908974|NCT05627271|OTHER|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
218908975|NCT05627271|OTHER|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
218908976|NCT01290458|DIETARY_SUPPLEMENT|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
218908977|NCT02325596|GENETIC|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
218908978|NCT04006418|OTHER||
218908979|NCT00111046|DRUG|Ibuprofen|
218908980|NCT00111046|DRUG|Tramadol|
218908981|NCT04228588|DRUG|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
218908982|NCT06050265|DEVICE|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
218908983|NCT03359629|DEVICE|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
218908984|NCT03359629|DEVICE|YSI 2300 Stat Plus|Reference commercial glucometer
218908985|NCT05563103|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
218908986|NCT05563103|OTHER|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
218908987|NCT05563103|OTHER|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
218908988|NCT05563103|OTHER|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
218908989|NCT05820412|OTHER|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
218908990|NCT05131945|OTHER|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
218908991|NCT05131945|OTHER|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
218908992|NCT04310540|PROCEDURE|Biopsy|Undergo biopsy
218908993|NCT04310540|PROCEDURE|Computed Tomography|Undergo CT
218908994|NCT04310540|DRUG|Gallium Ga 68 Gozetotide|Given IV
218908995|NCT04310540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218908996|NCT04310540|PROCEDURE|Positron Emission Tomography|Undergo PET
218908997|NCT00072462|DRUG|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
218908998|NCT00072462|DRUG|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
218908999|NCT04984031|DIAGNOSTIC_TEST|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
218909000|NCT04349891|DEVICE|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
218909001|NCT04349891|DEVICE|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
218909002|NCT03679247|OTHER|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
218909003|NCT03679247|OTHER|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
218909004|NCT03800095|DRUG|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
218909005|NCT02927301|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
218909006|NCT03028766|DRUG|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
218909007|NCT03028766|DRUG|Cisplatin|Chemotherapy drug
218909008|NCT03028766|RADIATION|Radiotherapy|Intensity Modulated Radiotherapy
218909009|NCT05884307|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
218909010|NCT06526260|BEHAVIORAL|Very Brief Exposure to Facial Expressions|In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
218909011|NCT04534244|DEVICE|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
218909012|NCT05796557|BIOLOGICAL|Platelet Transfusion|Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
218909013|NCT06047093|PROCEDURE|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
218909014|NCT06047093|BIOLOGICAL|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
218909015|NCT06047093|OTHER|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and after the FNA has been performed.
219613901|NCT00800267|DRUG|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
218909016|NCT04179097|DIAGNOSTIC_TEST|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
218909017|NCT06553092|OTHER|Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey|The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
218909018|NCT05740254|BEHAVIORAL|Early Time Restricted Eating|Early Time Restricted Eating 7 AM to 3 PM
219613902|NCT00800267|DRUG|timolol 0.5%|one drop in the morning and evening
218909019|NCT05740254|BEHAVIORAL|Late Time Restricted Eating|Late Time Restricted Eating 12 PM to 8 PM
219040535|NCT04782908|DEVICE|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
219613903|NCT00238017|DRUG|amodiaquine-artesunate versus amodiaquine|
219613904|NCT02863796|DEVICE|WhiteSwell System|To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
219613905|NCT01364012|DRUG|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
219613906|NCT01364012|DRUG|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
219613907|NCT01364012|DRUG|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
219523166|NCT01636609|DRUG|Azacitidine|Given IV or SC
218909020|NCT04851691|BEHAVIORAL|EHR CDS|"When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation."
218909021|NCT04851691|OTHER|Usual Care|Patients will receive usual care from their physicians.
218909022|NCT05702463|DRUG|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
218909023|NCT05702463|DRUG|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
218909024|NCT05702463|DRUG|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
218909025|NCT05901298|DEVICE|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
218909026|NCT04055220|DRUG|Treatment by Regorafenib|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
218909027|NCT04055220|DRUG|Treatment by Placebo|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
218909028|NCT05642741|OTHER|Response to medical and research questionnaires|Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
218909029|NCT04247347|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
218909030|NCT04247347|OTHER|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
218909031|NCT04247347|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
218909032|NCT05413590|OTHER|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
218909033|NCT05413590|OTHER|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
218909034|NCT05413590|OTHER|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
218909035|NCT03066206|DRUG|Poziotinib|Given PO
218909036|NCT03562195|DRUG|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
218909037|NCT03562195|DRUG|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
219523167|NCT01636609|DRUG|Cytarabine|Given SC
219523168|NCT01636609|DRUG|Tosedostat|Given PO
219523169|NCT00322803|DRUG|ELB139|
219523170|NCT00948519|DEVICE|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
219523171|NCT00948519|DEVICE|Laser only|same only without ICG
219523172|NCT03991494|DRUG|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
219613908|NCT01364012|DRUG|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
218909038|NCT03562195|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
218909039|NCT05641545|BIOLOGICAL|IVAC|IVAC is a personalized peptide vaccine
218909040|NCT03949569|BEHAVIORAL|Therapy Dog|Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
218909041|NCT03949569|BEHAVIORAL|Stuffed Toy Dog|Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
218909042|NCT03949569|BEHAVIORAL|5 Minute Puppy Video|Children will watch a 5 minute puppy video.
219613909|NCT04840303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
218909043|NCT02730858|BEHAVIORAL|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
218909044|NCT02730858|BEHAVIORAL|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
218909045|NCT06247813|DIETARY_SUPPLEMENT|Inflammation Support Formula|Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).
218909046|NCT06247813|DIETARY_SUPPLEMENT|Nerve Health Formula|Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).
218909047|NCT06247813|DIETARY_SUPPLEMENT|Redox Support Formula|N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).
218909048|NCT00923520|DRUG|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
218909049|NCT02571712|DRUG|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
218909050|NCT02056743|DRUG|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
218909051|NCT02056743|DRUG|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
218909052|NCT02056743|DIETARY_SUPPLEMENT|Red ginseng|During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
218909053|NCT02056743|DIETARY_SUPPLEMENT|Fermented-red ginseng|During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
218909054|NCT05357573|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
218909055|NCT06306833|OTHER|Surface Electromyography (sEMG) Biofeedback|Biofeedback sEMG therapy through the use of virtual aids like digital therapeutics would help reduce chronic low back pain in patients by overcoming their psychophysiological manifestations. All participants in the intervention group will receive sEMG biofeedback as an alternative therapy.
218909056|NCT02913703|DRUG|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
218909057|NCT02913703|OTHER|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
218909058|NCT00976846|DEVICE|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
218909059|NCT01022736|DRUG|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
218909060|NCT04664153|DRUG|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
218909061|NCT04664153|DRUG|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
218909062|NCT06373016|DIETARY_SUPPLEMENT|Glucose|A glucose drink is administered midway through one of the scan sessions.
218909063|NCT06373016|DIETARY_SUPPLEMENT|Ketones|A ketone drink is administered midway through one of the scan sessions.
218909064|NCT01184586|DEVICE|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
218909065|NCT01184586|DEVICE|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
218909066|NCT06072911|BEHAVIORAL|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
218909067|NCT06072911|BEHAVIORAL|General exercise|A general progressive resistance exercise program
218909068|NCT06072911|BEHAVIORAL|Physical Activity Counseling|Advice on increasing physical activity
219523173|NCT05786222|BEHAVIORAL|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator \[a trained CSH employee\] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
219523174|NCT03239145|DRUG|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
218909069|NCT01233804|OTHER|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
218909070|NCT00097500|DRUG|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
218909071|NCT00097500|DRUG|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
218909072|NCT00097500|DRUG|Metformin|Patients usual dosage
219040536|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
219040537|NCT00000735|DRUG|Ampligen|
219040538|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
219040539|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
219040540|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
219040541|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
219040542|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
219523175|NCT03239145|DRUG|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
219523176|NCT04536805|DRUG|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
219040543|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
219040544|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
219523177|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
219523178|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
219523179|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
219523180|NCT00098371|DRUG|alvocidib|
219523181|NCT01314742|DRUG|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
218909073|NCT04891614|DEVICE|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
218909074|NCT01199354|PROCEDURE|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
218909075|NCT03388346|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
218909076|NCT00252421|DRUG|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
218909077|NCT00252421|DRUG|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
218909078|NCT04053335|BEHAVIORAL|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~* Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~* Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~* Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~* Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~* Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
219040545|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
219040546|NCT00784511|DIETARY_SUPPLEMENT|cholecalciferol|4000 IU/d
219040547|NCT00784511|OTHER|microcrystalline cellulose|1/d
219040548|NCT05669079|DRUG|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
219040549|NCT05669079|BIOLOGICAL|umbilical cord blood|MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
218909079|NCT00189098|DRUG|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
218909080|NCT00189098|DRUG|Placebo|
218909081|NCT01404507|DRUG|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
218909082|NCT01404507|DEVICE|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
218909083|NCT01404507|OTHER|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
218909084|NCT04306471|DRUG|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
218909085|NCT04306471|OTHER|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
218909086|NCT05320081|BIOLOGICAL|CD30 CAR-T|"Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10\^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition."
218909087|NCT05320081|DRUG|Camrelizumab|Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
218909088|NCT00474123|DRUG|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
218909089|NCT00474123|DRUG|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
218909090|NCT00330577|DRUG|timolol maleate 0.5%|
218909091|NCT00330577|DRUG|latanoprost/timolol fixed combination|
218909092|NCT00330577|DRUG|placebo (artificial tears)|
218909093|NCT00987376|DEVICE|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
218909094|NCT00639197|PROCEDURE|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
218909095|NCT00639197|PROCEDURE|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
218909096|NCT00642356|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
218909097|NCT00642356|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
218909098|NCT05030025|COMBINATION_PRODUCT|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
218909099|NCT05030025|COMBINATION_PRODUCT|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
218909100|NCT03469752|BEHAVIORAL|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
218909101|NCT01009060|DRUG|GSK239512|Histamine H3 Antagonist
218909102|NCT01009060|DRUG|Placebo|Placebo to match GSK239512
218909103|NCT01304264|DEVICE|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
218909104|NCT03939546|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
218909105|NCT06247917|DRUG|Fludarabine, Busulfan and Melphalan|Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
218909106|NCT02868112|OTHER|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
218909107|NCT02868112|OTHER|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
218909108|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
218909109|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
218909110|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
218909111|NCT01460212|DRUG|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
218909112|NCT01460212|BEHAVIORAL|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
218909113|NCT00015210|DRUG|Nefazodone|
218909114|NCT00015210|BEHAVIORAL|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
219523182|NCT01314742|OTHER|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
219523183|NCT03767192|DEVICE|Active Stimulation|SPG stimulation and standard of care
218909115|NCT02264730|DRUG|ClotFoam|Patient has not received blood products between screenings
218909116|NCT05706298|BEHAVIORAL|Active Breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
218909117|NCT03003026|OTHER|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
218909118|NCT03003026|OTHER|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
218909119|NCT05906719|OTHER|video recording|Patients' performance of MDS-UPDRS III will be recorded.
218909120|NCT03379181|DRUG|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
218909121|NCT04197245|DRUG|saline injection therapy in post-acne atrophic scars|saline injection contains 0.9% isotonic sodium chloride solution
218909122|NCT06322186|OTHER|Ready-Heat Chemical Heating Blankets|Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.
218909123|NCT06322186|OTHER|Warmed blankets or FAWB|The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
219523184|NCT03767192|DEVICE|Sham Stimulation|Sham SPG stimulation and standard of care
218909124|NCT04232319|BEHAVIORAL|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
218909125|NCT04592939|PROCEDURE|immediate weight bearing after surgery|immediate weight bearing
218909126|NCT04592939|PROCEDURE|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
219523185|NCT00003898|DIETARY_SUPPLEMENT|glutamine|Oral
218909127|NCT04918420|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
218909128|NCT05575453|OTHER|Kvatchii Portal|Online education portal
218909129|NCT00259662|DRUG|atorvastatin|
218909130|NCT04602390|DRUG|ANK-700|Intravenous (IV) infusion
218909131|NCT04602390|DRUG|Placebo|Intravenous (IV) infusion
218909132|NCT06527560|DRUG|Cefuroxime|Intravenous cefuroxime 750 mg every 8 hours
218909133|NCT06527560|DRUG|Cefuroxime Axetil|Oral cefuroxime 500 mg every 12 hours
219040550|NCT05669079|DRUG|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
219523186|NCT02268500|BIOLOGICAL|Influenza vaccine|Influenza vaccine
219523187|NCT02141256|DIETARY_SUPPLEMENT|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
219523188|NCT06037200|DEVICE|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
219523189|NCT02348268|OTHER|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
219523190|NCT02348268|OTHER|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
219523191|NCT02348268|DEVICE|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
219523192|NCT02534493|DEVICE|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
219040551|NCT05669079|DRUG|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
219523193|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 NODAGA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
219613910|NCT03248115|DIETARY_SUPPLEMENT|Green tea and green coffee extract tablets|"1. Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.~2. Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).~3. Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
219613911|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
218909134|NCT04005846|DEVICE|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
218909135|NCT02641847|DRUG|docetaxel|
218909136|NCT02641847|DRUG|doxorubicin or epirubicin|
218909137|NCT02641847|DRUG|cyclophosphamide|
218909138|NCT02641847|DRUG|gemcitabine|
219523194|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
219613912|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
218909139|NCT02641847|DRUG|cisplatin|
218909140|NCT00119847|PROCEDURE|PCI|
218909141|NCT00119847|DRUG|Optimal Medical Therapy|Guideline-directed drug therapies after MI
219040552|NCT05669079|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
219040553|NCT01331616|DRUG|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
219040554|NCT00938483|OTHER|Nutramigen Lipil (Infant formula)|
219040555|NCT04217486|OTHER|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
219365267|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
219613913|NCT02409927|DIETARY_SUPPLEMENT|Control|vehicule (skim milk) with a standardized breakfast
219613914|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
218909142|NCT03043534|OTHER|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
218909143|NCT03043534|OTHER|Brush|All subjects randomized to brush will use the brush with each shave
218909144|NCT00265564|BEHAVIORAL|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
218909145|NCT00265564|BEHAVIORAL|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
218909146|NCT05931081|DEVICE|Thermal imaging in diagnostics of chronic ulcers|atypical: vasculitic or pyoderma gangraenosum ulcers
218909147|NCT06001203|PROCEDURE|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
218909148|NCT03584750|OTHER|Floating|Floating in specialized tank with full floatation and sensory deprivation.
218909149|NCT03584750|OTHER|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
218909150|NCT06184633|DRUG|Semaglutide 3.2 MG/ML|Intervention arm receives semaglutide in addition to combined lifestyle intervention
219040556|NCT04217486|OTHER|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
219040557|NCT04297930|DEVICE|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
219040558|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
219365268|NCT02086331|BEHAVIORAL|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
219365269|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|
219365270|NCT02950792|DEVICE|ViewRay MRI|ViewRay Magnetic Resonance Imaging
218909151|NCT06184633|DRUG|Placebo|Control arm receives placebo in addition to combined lifestyle intervention
218909152|NCT04257890|BEHAVIORAL|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
218909153|NCT04257890|OTHER|Education material about IGD|Printed education material introducing IGD will be distributed.
218909154|NCT04257890|OTHER|Education material about CBT|Printed education material introducing CBT will be distributed.
218909155|NCT02601157|DRUG|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
218909156|NCT02601157|DRUG|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
218909157|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
218909158|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
218909159|NCT00286442|DRUG|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
218909160|NCT02726620|PROCEDURE|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
218909161|NCT02726620|PROCEDURE|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
218909162|NCT02726620|PROCEDURE|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
218909163|NCT02726620|PROCEDURE|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
218909164|NCT02726620|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
219523195|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTATATE PET/CT|All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
219523196|NCT01993875|DRUG|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
219613915|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
218909165|NCT02726620|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
218909166|NCT02726620|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
218909167|NCT02726620|DEVICE|Pager system|The mobile pager system through which alerts can be sent
218909168|NCT02726620|PROCEDURE|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
218909169|NCT02726620|PROCEDURE|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
218909170|NCT02726620|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
218909171|NCT02726620|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
218909172|NCT02726620|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
218909173|NCT02726620|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
218909174|NCT02726620|DRUG|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
218909175|NCT02726620|DRUG|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
218909176|NCT02726620|DRUG|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
218909177|NCT02726620|DRUG|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
218909178|NCT02726620|DRUG|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
218909179|NCT02726620|DRUG|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
218909180|NCT02726620|DRUG|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
218909181|NCT02726620|DRUG|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
218909182|NCT02726620|DRUG|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
218909183|NCT02726620|DRUG|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
218909184|NCT02726620|DRUG|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
218909185|NCT02726620|DRUG|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
218909186|NCT02726620|DRUG|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
219523197|NCT01993875|DRUG|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
219523198|NCT05060900|PROCEDURE|Ligament Reconstruction with Allograft Ligament|Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
219523199|NCT00002027|DRUG|Diclazuril|
219523200|NCT04578470|DRUG|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
219523201|NCT04578470|DRUG|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
218909187|NCT02726620|DRUG|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
218909188|NCT02726620|DRUG|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
218909189|NCT02726620|DRUG|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
218909190|NCT02726620|DRUG|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
218909191|NCT02726620|DRUG|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
218909192|NCT02726620|DRUG|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
219523202|NCT01662466|DRUG|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
219523203|NCT01662466|DIETARY_SUPPLEMENT|DHEA|DHEA 25mg tid
218909193|NCT02726620|DRUG|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
218909194|NCT02726620|DRUG|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
218909195|NCT02726620|DRUG|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
218909196|NCT02726620|DRUG|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
218909197|NCT02726620|DRUG|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
218909198|NCT02726620|DRUG|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
218909199|NCT02726620|DRUG|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
219523204|NCT01662466|DRUG|Placebo|Carrier cream without added testosterone in the identical type of pump
219523205|NCT02158832|DEVICE|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current \>sensation threshold \& maintained at a level that is comfortable/painless \& does not elicit skeletal muscle contractions (\~5mA, \<10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', \~15⁰ perpendicular to the skin, \~15⁰ lateral to the midline. Depth: \~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' \~15⁰ perpendicular to the skin, \~15⁰ medial. Depth: \~1.5 cm (secure anchorage)."
219523206|NCT05765565|DEVICE|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
219523207|NCT05765565|DEVICE|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
219523208|NCT05310565|PROCEDURE|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
219523209|NCT03415997|DRUG|Iohexol|Iodinated contrast media
219523210|NCT01521988|PROCEDURE|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
219523211|NCT01521988|PROCEDURE|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
219523212|NCT05327166|OTHER|ED-LINC|The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
219523213|NCT00910364|OTHER|Exercise|Exercise
219523214|NCT06143865|OTHER|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
219523215|NCT05686759|BIOLOGICAL|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
219523216|NCT05686759|BIOLOGICAL|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
219523217|NCT01874951|DRUG|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
219523218|NCT01874951|DRUG|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
219523219|NCT06988514|OTHER|Standardized stool collection from healthy volunteers|The only interventions are clinical examination, dietary restrictions and samples collection (stool, and urine for the pregnancy tests (when applicable).
218909200|NCT02726620|DRUG|Procaine|Local anesthetic used for central neuraxial anesthesia.
218909201|NCT02726620|DRUG|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
218909202|NCT02726620|DRUG|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
218909203|NCT02726620|DRUG|Articaine|Local anesthetic used for central neuraxial anesthesia.
218909204|NCT03113032|OTHER|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
218909205|NCT03113032|OTHER|Normal pre-surgical care|Routine pre-surgical care
218909206|NCT00737776|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218909207|NCT02542865|DIETARY_SUPPLEMENT|Fortified malt based food|Fortified malt based food
219523220|NCT05647213|BIOLOGICAL|iPSC-CL|Autologous IPSCL
219523221|NCT01540175|OTHER|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
219613916|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
219613917|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
219613918|NCT02641327|DEVICE|EarlySense (Passive monitoring)|Passive contact-free monitoring
219523222|NCT06614517|OTHER|Birdwatching Intervention|Description: Participants will attend three birdwatching sessions, where they will enjoy direct contact with nature in selected environments such as forests and farms. These outings will be guided by an expert, who will also introduce participants to the use of binoculars and tools for identifying the birds observed during the excursions. During the outings, participants will learn the body scan technique, which will help them focus on physical sensations without making judgments. This exercise will encourage them to pay attention to details such as muscle tension, temperature, or surface contact, allowing them to be more present and connected to their surroundings during the birdwatching sessions. In addition to the in-person outings, participants will receive digital materials via WhatsApp to complement the intervention.Birdwatching Intervention
218909208|NCT05289115|DEVICE|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
218909209|NCT05289115|DEVICE|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
218909210|NCT00811603|DRUG|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
218909211|NCT05644119|DEVICE|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
218909212|NCT05644119|DEVICE|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
218909213|NCT01445444|BEHAVIORAL|Habit Reversal Training|"* 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
218909214|NCT00920751|PROCEDURE|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
219523223|NCT00006259|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
219523224|NCT00101543|DEVICE|Electrical Stimulation with Intramuscular Electrodes|
219523225|NCT00101543|PROCEDURE|Body Weight Supported Treadmill Training|
219613919|NCT04871776|BEHAVIORAL|Messaging informed by construal level theory|"Messages are informed by construal level theory, which suggests that emphasizing why elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing how is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake."
219613920|NCT04871776|BEHAVIORAL|Usual Care|Usual messaging sent by Mass General Brigham
219613921|NCT05522192|DRUG|Mitoxantrone liposome|Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
219613922|NCT05522192|DRUG|Venetoclax|Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
219613923|NCT01296776|OTHER|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
219613924|NCT01296776|DEVICE|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
219613925|NCT00653627|BIOLOGICAL|BCG|Mycobacterium bovis Bacille Calmette-Guerin
218909215|NCT00920751|PROCEDURE|Air insufflation|Conventional air insufflation colonoscopy
218909216|NCT02608944|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
218909217|NCT02608944|DRUG|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
218909218|NCT02608944|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
218909219|NCT02608944|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
218909220|NCT02608944|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
218909221|NCT04055675|DIAGNOSTIC_TEST|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
218909222|NCT01882673|BEHAVIORAL|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
219523226|NCT05658367|PROCEDURE|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
219523227|NCT05658367|PROCEDURE|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
219523228|NCT05658367|PROCEDURE|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
218909223|NCT01882673|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
218909224|NCT02848963|DRUG|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
218909225|NCT05661344|DRUG|BI 1015550|BI 1015550
218909226|NCT05221411|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
218909227|NCT05221411|DRUG|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
218909228|NCT04260685|DRUG|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
218909229|NCT04260685|DRUG|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
218909230|NCT06527014|PROCEDURE|Pulse Radiofrequency to the suprascapular nerve|Pulse radiofrequency ablation to the Suprascapular nerve
218909231|NCT06555185|OTHER|Potentiation warm-up protocol|The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.
218909232|NCT06555185|OTHER|Usual warm-up protocol|The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
218909233|NCT04630665|OTHER|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
218909234|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
218909235|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
218909236|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
219040559|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
219040560|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
219613926|NCT01741038|BIOLOGICAL|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
219613927|NCT01741038|PROCEDURE|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
219613928|NCT01741038|OTHER|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
218909237|NCT04187898|BIOLOGICAL|Eflapegrastim|Administered in Cycles 1-4, 30 mins after TC chemotherapy.
218909238|NCT04187898|DRUG|Docetaxel|"75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
218909239|NCT04187898|DRUG|Cyclophosphamide|"600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
218909240|NCT06249685|DEVICE|Bilateral hearing devices|Three week trial while wearing bilateral hearing devices.
218909241|NCT06344871|DEVICE|NeuroLF|NeuroLF Scan
218909242|NCT06344871|DEVICE|Conventional PET scan|Scan on conventional PET system
218909243|NCT03106571|DRUG|Pomaglumetad methionil|Tablets twice daily
218909244|NCT03106571|DRUG|Placebo|1-4 tablets twice daily
218909245|NCT03106571|DRUG|Methamphetamine|intravenous methamphetamine
218909246|NCT02828475|OTHER|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
218909247|NCT02828475|BEHAVIORAL|Standard Care|Previous standard of care based on surgeon judgement alone.
218909248|NCT01150526|DIETARY_SUPPLEMENT|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
218909249|NCT01150526|DIETARY_SUPPLEMENT|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
218909250|NCT01150526|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
218909251|NCT01150526|DIETARY_SUPPLEMENT|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
218909252|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
218909253|NCT04477265|DRUG|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
218909254|NCT04477265|BEHAVIORAL|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
218909255|NCT06092762|DRUG|AK120|subcutaneous injection every 2 weeks
218909256|NCT04669808|DRUG|STP705|Dry powder for intra-and peri-lesional injection.
218909257|NCT06005935|OTHER|Survey|Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
218909258|NCT05794425|DRUG|Cyclosporine A|3-5 mg per kilogram per day.
218909259|NCT05794425|BIOLOGICAL|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
219523229|NCT04130256|DEVICE|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
218909260|NCT05388786|BEHAVIORAL|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
219523230|NCT06544668|OTHER|Breast cancer patients with bone metastasis|This study is an observational study
219523231|NCT06544668|OTHER|Breast cancer patients without bone metastasis|This study is an observational study
219523232|NCT02756325|DEVICE|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
218909261|NCT02536612|OTHER|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
218909262|NCT02536612|OTHER|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
219523233|NCT03057392|OTHER|immersion|participants will sit in a 34-35C while receive dialysis
219523234|NCT03057392|OTHER|sham session|dialysis while sitting in the dialysis chair
219523235|NCT03494595|PROCEDURE|Pediatric Liver transplantation|Pediatric Liver transplantation
219613929|NCT06020911|DRUG|Biodentine|17 primary second molars of 17 children will be capped with Biodentine
218909263|NCT04913610|DRUG|ABBV-4083|Oral Capsule
218909264|NCT04913610|DRUG|Placebo for ABBV-4083|Oral Capsule
218909265|NCT04913610|DRUG|Albendazole|Oral encapsulated tablets
218909266|NCT04913610|DRUG|Placebo for Albendazole|Oral Capsule
218909267|NCT00826644|DRUG|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
218909268|NCT00826644|DRUG|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
218909269|NCT00826644|DRUG|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
218909270|NCT06490289|OTHER|Denpro oral gel|Experimental group was given Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan)
218909271|NCT05408338|OTHER|Low Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)
218909272|NCT05408338|OTHER|High Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
218909273|NCT00771394|DRUG|Tamsulosin hydrochloride|oral
218909274|NCT00771394|DRUG|Solifenacin succinate|oral
218909275|NCT00280982|BIOLOGICAL|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
218959175|NCT05098977|PROCEDURE|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
218959176|NCT00002952|BIOLOGICAL|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
218959177|NCT00002952|BIOLOGICAL|recombinant MAGE-3.1 antigen|
219523236|NCT01762358|OTHER|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
219523237|NCT01762358|OTHER|Physiotherapy|Twelve times standardized Physiotherapy
219613930|NCT06020911|DRUG|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
219613931|NCT00692692|PROCEDURE|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
219613932|NCT00692692|PROCEDURE|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
219523238|NCT04623736|BEHAVIORAL|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
219523239|NCT01469546|DRUG|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST \[Response Evaluation Criteria In Solid Tumors\] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
219523240|NCT00003148|BIOLOGICAL|aldesleukin|
219523241|NCT03154658|DRUG|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
219523242|NCT04190290|OTHER|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
219523243|NCT04190290|DIAGNOSTIC_TEST|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
219523244|NCT04238767|DRUG|Dolutegravir|Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
219523245|NCT04987164|DIETARY_SUPPLEMENT|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
219523246|NCT04297228|BEHAVIORAL|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
219523247|NCT03202277|BEHAVIORAL|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
219523248|NCT03202277|BEHAVIORAL|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
219523249|NCT05752994|OTHER|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
219523250|NCT05752994|OTHER|Home program|Home program
219523251|NCT03619408|DRUG|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
219523252|NCT03269409|OTHER|Lactated Ringers|Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
219523253|NCT03269409|DEVICE|The Celution 800/GP System (Cytori Therapeutics)|The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
219613933|NCT06033937|DEVICE|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
218909276|NCT05358236|OTHER|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area"
218909277|NCT01999452|BEHAVIORAL|Paleolithic diet|
218909278|NCT01999452|BEHAVIORAL|Diabetes diet|
218909279|NCT01264341|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
218909280|NCT01264341|DRUG|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
218909281|NCT01879111|OTHER|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
218909282|NCT00231426|DEVICE|ICD|
218909283|NCT01210716|DEVICE|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
218909284|NCT03530397|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
218909285|NCT03530397|DRUG|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
218909286|NCT03530397|DRUG|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
218909287|NCT03530397|BIOLOGICAL|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
218909288|NCT03530397|DRUG|Paclitaxel or Nab-Paclitaxel|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
218909289|NCT05104853|DRUG|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
218909290|NCT05104853|DRUG|Placebo|CNP-104 Placebo
218909291|NCT03607214|OTHER|Placebo|"Placebo nasal spray~Film Sequence"
218909292|NCT02571426|DRUG|Sevoflurane|anesthetic agent
218909293|NCT02571426|DRUG|propofol|anesthetic agent
219523254|NCT03269409|BIOLOGICAL|Adipose Derived Regenerative Cells (ADRC)|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
219523255|NCT02683967|PROCEDURE|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
219523256|NCT00633399|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
218909294|NCT00329966|BIOLOGICAL|Surface Antigen, Inactivated, Influenza (form.2006-07)|
219613934|NCT06470451|DRUG|Hypericin|HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
218909295|NCT05179252|DRUG|Shen-Fu injection|Chinese patent medicine made by modern technology
218909296|NCT05179252|DRUG|normal saline|0.9% normal saline, used for sham control
218909297|NCT00872963|BIOLOGICAL|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
218909298|NCT03399058|OTHER|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
218909299|NCT03399058|BEHAVIORAL|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
218909300|NCT03399058|BEHAVIORAL|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
218909301|NCT01885429|DIETARY_SUPPLEMENT|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
218909302|NCT01885429|DIETARY_SUPPLEMENT|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
218909303|NCT01885429|DIETARY_SUPPLEMENT|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
218909304|NCT01885429|DIETARY_SUPPLEMENT|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
218909305|NCT01885429|DIETARY_SUPPLEMENT|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
218909306|NCT05602493|DRUG|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
218909307|NCT05602493|DRUG|sterile saline|sterile saline
219523257|NCT00633399|DRUG|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
218909308|NCT01622439|DRUG|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
218909309|NCT01622439|DRUG|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
218909310|NCT01622439|DRUG|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
218909311|NCT01622439|DRUG|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
218909312|NCT01622439|DRUG|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
218909313|NCT01622439|DRUG|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
218909314|NCT01706172|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
218909315|NCT01706172|OTHER|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
218909316|NCT00637611|DRUG|Fexofenadine HCl|
219523258|NCT05745870|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
219523259|NCT01137539|DEVICE|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
219613935|NCT06470451|DRUG|Placebo|Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
219613936|NCT06236438|DRUG|Livmoniplimab|Intravenously (IV) Infusion
218909317|NCT03080155|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
218909318|NCT04657679|DRUG|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
218959178|NCT00002952|BIOLOGICAL|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
218909319|NCT04459143|BEHAVIORAL|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
218909320|NCT04841863|DEVICE|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
218909321|NCT04841863|OTHER|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
218909322|NCT05774353|OTHER|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
218909323|NCT05767515|DRUG|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
218909324|NCT05699187|PROCEDURE|Face allotransplantation|Facial allotransplantation
218909325|NCT05343754|DRUG|Hyperbaric oxygen|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
218909326|NCT05343754|OTHER|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
218909327|NCT04418024|DRUG|AG10|TTR stabilizer administered orally twice daily (BID)
218909328|NCT04418024|DRUG|Placebo|Non-active control
219523260|NCT03290326|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
219523261|NCT06038019|DIAGNOSTIC_TEST|Oral food challenge|Patients will undergo oral food challenge with increasing amounts of food allergen
219523262|NCT00637117|BIOLOGICAL|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
219523263|NCT05086835|OTHER|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
219523264|NCT05086835|OTHER|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
218909329|NCT02358473|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered by IV infusion.
218909330|NCT02358473|DRUG|Docetaxel|Docetaxel will be administered by IV infusion.
218909331|NCT06415890|OTHER|4-7-8 Breathing Technique|The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
218909332|NCT05773846|DRUG|Ropivacaine|A long acting formulation of ropivacaine
218909333|NCT04097470|DRUG|Decitabine|Decitabine dosage 20mg/m2 i.v.
218909334|NCT04097470|DRUG|Midostaurin|Midostaurin 50 mg b.i.d.
218909335|NCT05476289|OTHER|No intervention|No intervention
218909336|NCT06178796|DEVICE|Dental implant|Dental implant placement
218909337|NCT02588690|PROCEDURE|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
218909338|NCT02588690|OTHER|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
218909339|NCT02588690|PROCEDURE|Blood pressure measurement|Blood pressure measurement
218909340|NCT06292169|PROCEDURE|Pectoralis Minor Release|The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.
218909341|NCT06292169|PROCEDURE|RSA|RSA is the current Standard of Care (SOC)
218909342|NCT05234411|OTHER|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
218909343|NCT00316537|DRUG|ATG002 (study drug)|
218909344|NCT00002403|DRUG|Zintevir|
218909345|NCT06103396|BIOLOGICAL|Transplantation of autologous MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
218909346|NCT06103396|BIOLOGICAL|Transplantation of allogeneic MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
218909347|NCT06285487|BEHAVIORAL|Group Program|Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
218909348|NCT01259817|DRUG|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
218909349|NCT01259817|DRUG|Aspirin|81 or 100 mg daily.
218909350|NCT01527123|DRUG|GSK2585823|CLDM1%/BPO3%
218909351|NCT01213394|DRUG|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
218909352|NCT01213394|OTHER|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
218909353|NCT04350281|DRUG|Interferon Beta-1B|Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
218909354|NCT04350281|DRUG|Hydroxychloroquine|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
218909355|NCT05719649|DIETARY_SUPPLEMENT|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
218909356|NCT05719649|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
218909357|NCT05830708|DIETARY_SUPPLEMENT|Lactobacillus sp. probiotic|The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
218909358|NCT05830708|BEHAVIORAL|Acceptance and commitment therapy|The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
218909359|NCT05830708|DIETARY_SUPPLEMENT|Placebo|The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
218909360|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
218909361|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
218909362|NCT05967598|DEVICE|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
218959179|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
218959180|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
218959181|NCT03647787|OTHER|observational study|This study is a longitudinal observational study
218959182|NCT00344942|DRUG|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
218959183|NCT00344942|DRUG|placebo|a double spray into each nostril once daily
218959184|NCT02721771|PROCEDURE|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
218959185|NCT04879602|BEHAVIORAL|suction with bronchoscopy|suction with bronchoscopy
218959186|NCT03048136|DRUG|Nivolumab|Specified dose on specified days
218959187|NCT03048136|DRUG|Ipilimumab|Specified dose on specified days
218959188|NCT00294710|DRUG|Aliskiren|
218959189|NCT04783688|OTHER|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
218959190|NCT04309799|DEVICE|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
218959191|NCT05946304|BEHAVIORAL|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
218909363|NCT02240485|BEHAVIORAL|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
218909364|NCT02240485|BEHAVIORAL|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
218909365|NCT04262700|DEVICE|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
218909366|NCT00953667|DRUG|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
218909367|NCT00213863|DEVICE|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
218909368|NCT03320668|OTHER|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
218909369|NCT03337230|BEHAVIORAL|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
218909370|NCT03337230|BEHAVIORAL|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
218909371|NCT03337230|BEHAVIORAL|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
218909372|NCT00391885|DEVICE|Closed-loop anesthesia system|
218909373|NCT04819945|DEVICE|GATT-Patch|Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
218909374|NCT03038321|DRUG|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
218909375|NCT03038321|DRUG|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
218909376|NCT03038321|DRUG|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
218909377|NCT00475670|DRUG|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
218909378|NCT00475670|DRUG|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
219040561|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
219523265|NCT03558945|BIOLOGICAL|Personalized neoantigen vaccine|Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
219523266|NCT02833389|DRUG|Placebo|UTTR1147A matching placebo will be administered SC.
219523267|NCT02833389|DRUG|UTTR1147A|UTTR1147A will be administered SC.
219613937|NCT06236438|DRUG|Budigalimab|IV Infusion
219613938|NCT06236438|DRUG|Pembrolizumab|IV Infusion
218909379|NCT03602677|DEVICE|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
218909380|NCT01961505|DRUG|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
218909381|NCT01961505|DRUG|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
218909382|NCT05407389|DRUG|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
218909383|NCT06576505|PROCEDURE|peripheral blood sampling, bronchoscopy, upper airway and faeces sampling|"1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml/year but never more than 100 ml/ month.~2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times/year.~3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times/year.~4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment."
218909384|NCT04949191|DRUG|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
218909385|NCT04949191|DRUG|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
218909386|NCT04949191|DRUG|Pembrolizumab|Commercially labeled products
218909387|NCT04494256|DRUG|BIIB105|Administered as specified in the treatment arm.
218909388|NCT04494256|DRUG|Placebo|Administered as specified in the treatment arm.
218909389|NCT03011788|DRUG|Golytely Oral Solution|Bowel purge prior to,colonoscopy
218909390|NCT01460966|PROCEDURE|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
218909391|NCT01460966|PROCEDURE|Thrombus aspiration catheter|Thrombus aspiration catheter only
218909392|NCT02483780|BEHAVIORAL|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
218909393|NCT01742273|DRUG|Vitamin K1|Vitamin K1 to slow vascular calcification
218909394|NCT02121379|BEHAVIORAL|pulmonary rehabilitation|
218909395|NCT05043350|DRUG|Loratadine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
218909396|NCT05043350|DRUG|Famotidine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
218909397|NCT03659799|DRUG|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
218909398|NCT03659799|DRUG|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
218909399|NCT03659799|OTHER|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
218909400|NCT03659799|OTHER|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
218909401|NCT04268082|DEVICE|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
218909402|NCT04268082|OTHER|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
218909403|NCT05071170|BEHAVIORAL|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
218909404|NCT00523757|DRUG|Spironolactone|
218909405|NCT00523757|DRUG|Placebo|
219040562|NCT02588924|OTHER|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
219040563|NCT02588924|OTHER|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
219613939|NCT06236438|DRUG|Pemetrexed|IV Infusion
218909406|NCT06052228|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
218909407|NCT06360146|OTHER|Early mobilisation|Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
218909408|NCT02707068|BEHAVIORAL|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
219613940|NCT06236438|DRUG|Cisplatin|IV Infusion
219613941|NCT06236438|DRUG|Carboplatin|IV Injection
219613942|NCT06236438|DRUG|Carboplatin|IV Infusion
218909409|NCT01988714|OTHER|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
218909410|NCT01988714|OTHER|(CG) plus evidence-based SE|(CG) plus evidence-based SE
218909411|NCT02913482|DRUG|Risdiplam|Risdiplam will be administered orally.
218909412|NCT03360266|COMBINATION_PRODUCT|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
218909413|NCT03360266|COMBINATION_PRODUCT|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
219523268|NCT06074289|BEHAVIORAL|Family connections program|Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
219523269|NCT05060926|PROCEDURE|Awake prone positioning|Awake prone position as long as possible according to the patients' tolerance
219523270|NCT01781325|DEVICE|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
219613943|NCT03440125|DRUG|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
218909414|NCT03360266|DRUG|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
218909415|NCT06421857|PROCEDURE|suturing|laparoscopic cystectomy for endometrioma and hemostasis was done using suturing
218909416|NCT06421857|PROCEDURE|bipolar electrocoagulation|laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
218909417|NCT04183114|BIOLOGICAL|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
218909418|NCT04183114|BIOLOGICAL|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
218909419|NCT04508166|DRUG|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
218909420|NCT04508166|DRUG|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
219040564|NCT01791738|PROCEDURE|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
218909421|NCT04508166|DRUG|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
218909422|NCT04508166|BEHAVIORAL|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
218909423|NCT04532671|OTHER|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
218909424|NCT04532671|OTHER|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
218909425|NCT04532671|OTHER|indirect resin composite|CADCAM resin composite blocks using milling process
219040565|NCT01417403|DRUG|hydroxychloroquine|Given PO
219040566|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
219523271|NCT04370639|DEVICE|AccuFlow sensor|AccuFlow sensor will be worn and survey completed
219523272|NCT04370639|OTHER|Survey|Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
219523273|NCT02994810|OTHER|Breastfeeding guidance|Breastfeeding guidance
219523274|NCT04277390|OTHER|clinical intervention for microbial analysis and MIR155 as biomarker|Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
219523275|NCT00001018|DRUG|Letrazuril|
219523276|NCT03422653|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
218909426|NCT01983228|BEHAVIORAL|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
218959192|NCT05946304|BEHAVIORAL|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
219613944|NCT03440125|DEVICE|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
219613945|NCT03440125|PROCEDURE|Massage|10 minutes of classical massage of low back pain area.
218959193|NCT05428189|DIAGNOSTIC_TEST|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
218959194|NCT05428189|DEVICE|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
218959195|NCT02014870|OTHER|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
218959196|NCT02014870|OTHER|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
218959197|NCT02014870|OTHER|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
218959198|NCT01622283|DRUG|Levocetirizine|Levocetirizine
218959199|NCT01622283|DRUG|Cetirizine|Cetirizine
218959200|NCT00211744|DRUG|topiramate|
219040567|NCT01433107|DRUG|Terbinafine|1% single application
219040568|NCT01433107|DRUG|Terbinafine Placebo|single application
219040569|NCT01749722|DEVICE|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
219523277|NCT03422653|DRUG|Placebo|IV medication delivered three times/week
219523278|NCT03199547|DRUG|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
219523279|NCT03199547|DRUG|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
218909427|NCT03155165|DEVICE|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
218909428|NCT04338672|OTHER|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
218909429|NCT04472052|OTHER|appendectomy|Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
218909430|NCT06032910|DEVICE|Surgical mesh|Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.
218909431|NCT00768612|DRUG|SCA-136 50mg/day|
218909432|NCT00768612|DRUG|SCA-136 150 mg/day|
218909433|NCT00768612|DRUG|SCA-136 300mg/day|
218909434|NCT00768612|DRUG|Risperidone 4mg/day|
218909435|NCT03028298|DRUG|Low dose sildenafil citrate|
218909436|NCT03028298|DRUG|High dose sildenafil citrate|
218909437|NCT00788463|DRUG|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
218909438|NCT00788463|DRUG|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
218909439|NCT00830544|DRUG|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
218909440|NCT00830544|DRUG|Chemotherapy|Neoadjuvant chemotherapy
218909441|NCT00830544|DRUG|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
218909442|NCT00790426|DRUG|TKI258|
218909443|NCT05622630|PROCEDURE|Four-cell bath|Four-cell bath:Treatment with direct current
218909444|NCT05622630|PROCEDURE|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
218909445|NCT00443144|DRUG|recombinant human growth hormone|
218909446|NCT02003326|OTHER|Inflammatory markers|
218909447|NCT06317558|DRUG|Neoadjuvant immunotherapy|Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.
218909448|NCT06317558|DRUG|Other drugs for neoadjuvant treatment|Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
218909449|NCT01140841|DRUG|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
219523280|NCT02769715|DEVICE|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
219523281|NCT02769715|OTHER|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
219523282|NCT05439109|DEVICE|Topographical landmark technique of endotracheal tube placement|An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.
219523283|NCT05439109|DEVICE|Intubation guide mark technique of endotracheal tube placement|An endotracheal tube will be placed in this group by using the intubation guide mark.
218909450|NCT01140841|DRUG|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
218909451|NCT00878241|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
218909452|NCT01046565|DRUG|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
218909453|NCT01046565|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
218909454|NCT02179008|DRUG|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
218909455|NCT02179008|DRUG|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
218909456|NCT02179008|DRUG|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
218909457|NCT02179008|DRUG|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
218909458|NCT02179008|DRUG|DE-117 High Dose ophthalmic solution|High Dose DE-117
218909459|NCT02179008|DRUG|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
218909460|NCT02098330|DRUG|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
218909461|NCT02098330|DRUG|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
218909462|NCT01998230|DIETARY_SUPPLEMENT|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
219523284|NCT03265522|BEHAVIORAL|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
219523285|NCT03265522|BEHAVIORAL|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
219523286|NCT03265522|BEHAVIORAL|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
219523287|NCT01101022|DRUG|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
219523288|NCT01101022|OTHER|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
219523289|NCT00985894|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
219523290|NCT00985894|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
218909463|NCT03395483|OTHER|Haemodynamic monitoring|see Group description
219523291|NCT01519661|DRUG|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
219523292|NCT01139047|DRUG|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
219613946|NCT04935333|PROCEDURE|Collection of Leiomyoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
219613947|NCT04935333|PROCEDURE|Collection of Leiomyosarcoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
219613948|NCT04935333|PROCEDURE|Collection of control samples|Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
219613949|NCT04031625|OTHER|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
219613950|NCT02627651|OTHER|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
218909464|NCT04400630|OTHER|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
218909465|NCT04722614|OTHER|Music|Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property
219365271|NCT02950792|RADIATION|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
219523293|NCT01139047|DRUG|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
219523294|NCT01521533|DRUG|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
219523295|NCT03067818|PROCEDURE|Unaffected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to unaffected hemisphere site prior to practice
219523296|NCT03067818|PROCEDURE|Affected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to affected hemisphere site prior to practice
218909466|NCT04722614|OTHER|Essential oil|Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.
218909467|NCT04722614|OTHER|Control|The routine intensive care unit sedation protocol
218909468|NCT01815723|DRUG|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
218909469|NCT01815723|DRUG|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
218909470|NCT01815723|DRUG|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
218909471|NCT01815723|DRUG|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
218909472|NCT05919407|DRUG|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
218909473|NCT05919407|DRUG|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
218909474|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
218909475|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
218909476|NCT00918385|DRUG|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
218909477|NCT00918385|DRUG|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
218909478|NCT00002643|BIOLOGICAL|filgrastim|
218909479|NCT00002643|DRUG|amifostine trihydrate|
218909480|NCT00002643|DRUG|cyclophosphamide|
218909481|NCT00002643|DRUG|doxorubicin hydrochloride|
218909482|NCT00002643|DRUG|etoposide|
218909483|NCT00002643|DRUG|ifosfamide|
218909484|NCT00002643|DRUG|topotecan hydrochloride|
218909485|NCT00002643|DRUG|vincristine sulfate|
218909486|NCT00002643|PROCEDURE|conventional surgery|
218909487|NCT00002643|RADIATION|low-LET cobalt-60 gamma ray therapy|
218909488|NCT00002643|RADIATION|low-LET electron therapy|
218909489|NCT00002643|RADIATION|low-LET photon therapy|
218909490|NCT01893541|PROCEDURE|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
218909491|NCT01893541|DRUG|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
218909492|NCT01893541|DEVICE|a multiband ligation device|
218909493|NCT02005016|BEHAVIORAL|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
219523297|NCT03067818|PROCEDURE|Control Transcranial Magnetic Stimulation|Non-invasive brain stimulation to control site prior to practice
219523298|NCT03864575|DRUG|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
219523299|NCT02282189|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
219613951|NCT06751173|OTHER|Static Core Stability exercises|"i. Plank: Press the hands and knees to the floor with the back in a neutral position and wrists aligned directly under the shoulders.~ii. Side Plank: Lie on the side with knees bent and prop the upper body up on the elbow.~iii. Shoulder Bridge: Raise the pelvis off the floor until only the head, neck, shoulders, and feet are touching the mat. Place the hands at the waist.~iv. Static Crunch: Lie on the back with feet flat on the floor and knees bent at a 90-degree angle.~v. Leg Lift: Lie straight on the floor, keep the arms at the sides, and slowly lift both legs into the air."
218909494|NCT05769296|DEVICE|Headpulse measurements|Placement of headset on subject
218909495|NCT01599156|PROCEDURE|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
218909496|NCT05605808|OTHER|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
218909497|NCT05605808|OTHER|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
218909498|NCT06276062|PROCEDURE|Distal radius fracture fixation in pediatrics.|using double short titanium elastic nails in treatment of pediatric distal radius fractures.
218909499|NCT00409643|DRUG|valsartan+amlodipine combination|
218909500|NCT00409643|DRUG|valsartan|
218909501|NCT00409643|DRUG|amlodipine|
218909502|NCT04446637|DRUG|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI|Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
218909503|NCT04446637|DRUG|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI|Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
218909504|NCT03669614|DRUG|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
218909505|NCT03669614|DRUG|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
218909506|NCT02843230|RADIATION|Avastin|
218909507|NCT02843230|RADIATION|Lomustine|
218909508|NCT02843230|RADIATION|Temozolomide|
218909509|NCT02843230|DEVICE|MRI|
218909510|NCT02843230|DEVICE|MRS|
218909511|NCT02843230|DEVICE|DSC|
218909512|NCT05114824|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
218909513|NCT05765422|OTHER|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
218909514|NCT00994552|OTHER|Pressure support ventilation|Pressure support ventilation
218909515|NCT00994552|OTHER|Pressure control ventilation|Pressure control ventilation
218909516|NCT03755713|DRUG|ASP0892|Intradermal
218909517|NCT03755713|DRUG|Placebo|Intradermal; normal saline solution
218909518|NCT06313255|DRUG|PegIFNα2b|The patients receive PegIFNα2b therapy
218909519|NCT06313255|DRUG|PegIFNα2b+probiotics|The patients receive both PegIFNα2b and probiotics therapy
218909520|NCT06313255|DRUG|Nucleoside analog|The patients receive nucleoside analog therapy
218909521|NCT06313255|DRUG|Nucleoside analog+probiotics|The patients receive both nucleoside analog and probiotics therapy
218909522|NCT05359458|BEHAVIORAL|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
218909523|NCT06444035|DRUG|HA35 injection|HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
218909524|NCT00956163|PROCEDURE|magnetic resonance imaging|Undergo whole-body MRI
218909525|NCT00956163|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
218909526|NCT00956163|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
218909527|NCT00956163|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
218909528|NCT00956163|RADIATION|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
218909529|NCT00956163|OTHER|laboratory biomarker analysis|Correlative studies
218909530|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
218909531|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
218909532|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
218909533|NCT01593826|DRUG|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
218909534|NCT01593826|DRUG|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
218909535|NCT01593826|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
218909536|NCT01593826|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
218909537|NCT00083889|DRUG|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
218909538|NCT00083889|DRUG|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
218909539|NCT03624881|DEVICE|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
218909540|NCT05919576|DEVICE|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
218909541|NCT05449418|BEHAVIORAL|Full Intervention|A small group of employees who work at facilities randomized to this arm will be invited to develop tailored COVID-19 vaccination promotion materials in teams with other long-term care staff sharing the same or similar language and/or cultural affinity. These employees will also help promote these materials to all of the employees who work at their facilities.
218909542|NCT05449418|OTHER|Enhanced Usual Care|Employees who work at facilities randomized to this arm will see COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention \[CDC\] or other national organization.
218909543|NCT03590444|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
219365272|NCT02765074|DRUG|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
219365273|NCT02459379|RADIATION|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
219365274|NCT00510276|DRUG|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
219365275|NCT00510276|DRUG|Placebo|twice a day, by mouth for 12 weeks
219365276|NCT03329378|DRUG|Docetaxel|Docetaxel 75mg/m2 IV, day 1
219365277|NCT03329378|DRUG|Carboplatin|Carboplatin AUC 6 IV, day 1
219365278|NCT03329378|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
219365279|NCT03329378|DRUG|Pertuzumab|Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
219365280|NCT03329378|DRUG|Pegfilgrastim|Pegfilgrastim 6mg SC, day 2 Cycled as per arm
219365281|NCT03329378|DRUG|Trastuzumab|Trastuzumab 6mg/kg every 21 days to complete 1 year
219365282|NCT03329378|DRUG|Paclitaxel|Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
219365283|NCT03329378|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 IV day 1
219365284|NCT03329378|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 IV day 1
219365285|NCT03329378|DRUG|Paclitaxel|80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
219365286|NCT05313542|BEHAVIORAL|Physical Activity|Physical Activity in the format of Self-defence Training
218909544|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
218909545|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
218909546|NCT04303455|DIAGNOSTIC_TEST|blood sampling|sampling serum renin
218909547|NCT02113917|BIOLOGICAL|Identification of biological markers|
218909548|NCT03557970|DRUG|Edicotinib|Given PO
218909549|NCT03557970|OTHER|Pharmacokinetic Study|Correlative studies
218909550|NCT03402802|DRUG|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
218909551|NCT00112736|DRUG|erlotinib|Given orally
218909552|NCT00112736|DRUG|temsirolimus|Given IV
218909553|NCT00112736|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
218909554|NCT00112736|OTHER|laboratory biomarker analysis|Correlative studies
218909555|NCT00112736|OTHER|pharmacological study|Correlative studies
218909556|NCT03215017|DEVICE|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
218909557|NCT03215017|DRUG|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
218909558|NCT04672642|DEVICE|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
218909559|NCT04609098|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
218909560|NCT04609098|DRUG|Tafenoquine 100mg [Arakoda]|Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
218909561|NCT02656277|OTHER|Decision Tool|
218909562|NCT02656277|OTHER|Information on Shoulder Dislocation|
218909563|NCT03521349|OTHER|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
218909564|NCT03521349|OTHER|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
218909565|NCT05255523|DRUG|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
218909566|NCT04731636|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
218909567|NCT03473236|DRUG|GB002|Inhaled GB002
218909568|NCT03473236|DEVICE|Generic Dry Powder Inhaler|dry powder inhaler used for inhalation of active drug or placebo
218909569|NCT03473236|DRUG|Placebo|Inhaled placebo
218909570|NCT04760847|OTHER|Intermittent Fasting|These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
218909571|NCT04760847|OTHER|No intermittent fasting|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
219365287|NCT05490706|BEHAVIORAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
219365288|NCT05490706|BEHAVIORAL|Walking|Performing a 30 minute minute walk after dinner at home
219365289|NCT03209284|PROCEDURE|transcrestal sinus floor elevation|augmentation procedure with xenograft
219365290|NCT02250209|DRUG|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
218909572|NCT03796650|OTHER|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
218909573|NCT03796650|DRUG|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
218909574|NCT04038541|DIETARY_SUPPLEMENT|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
218909575|NCT04038541|DIETARY_SUPPLEMENT|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
218909576|NCT05546151|DRUG|BMS-986322|Specified dose on specified days
218909577|NCT05546151|OTHER|Placebo for BMS-986322|Specified dose on specified days
218909578|NCT01820286|BEHAVIORAL|Positive psychology intervention|
218909579|NCT01820286|BEHAVIORAL|Recollection intervention|
218909580|NCT02893709|DRUG|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
218909581|NCT02172144|DRUG|BI 1744 CL solution for inhalation|
218909582|NCT02172144|DRUG|Placebo matching BI 1744 CL|
218909583|NCT02172144|DRUG|Moxifloxacin (Avalox®)|
219365291|NCT02250209|DRUG|Capecitabine|"Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
219365292|NCT02250209|DRUG|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
219365293|NCT06343779|DRUG|Deucrictibant, Placebo|Deucrictibant Soft Capsules for Oral Use
219365294|NCT05375279|PROCEDURE|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
219523300|NCT00947908|BIOLOGICAL|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
219523301|NCT01941095|DRUG|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
219523302|NCT01941095|DRUG|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
219523303|NCT01941095|DRUG|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
218909584|NCT04540263|DIAGNOSTIC_TEST|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
218909585|NCT00849940|DEVICE|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
219040570|NCT06441383|OTHER|Pittsburgh Sleep Quality Index|"The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum.~The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders."
219523304|NCT01941095|DRUG|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
219523305|NCT01941095|DRUG|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
219523306|NCT01941095|DRUG|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
219523307|NCT01941095|DRUG|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
219523308|NCT01724502|BEHAVIORAL|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO\_2 max determination, exercise periods and muscle biopsies.
219523309|NCT01924858|DRUG|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
219523310|NCT01924858|DRUG|[18F]GSK2647544 IV bolus|\[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
219523311|NCT04734184|DIAGNOSTIC_TEST|DCFPyL|Single dose injection
219613952|NCT06751173|OTHER|Mckenzie exercises|"i. Prone Extension (Positioned): Lie on the stomach with pillows placed under the chest for comfort.~ii. Prone Extension on Elbow: Keep the back and buttocks relaxed and rise up on the elbows as high as possible.~iii. Prone Press-ups: Place the hands beside the shoulders. Keep the back and buttocks relaxed, and use the arms to press up.~iv. Standing Extension: Stand with feet apart and hands on the small of the back with fingers pointing backward. Bend backward at the waist, supporting the trunk with the hands.~v. Side glide in Standing: Stand at a right angle to the wall about 2 feet away. Lean the shoulder into the wall."
219523312|NCT02463695|PROCEDURE|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
219523313|NCT00726739|BIOLOGICAL|aldesleukin|IL-2 Alone - administer 10 x 10\^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
219523314|NCT00726739|BIOLOGICAL|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI \[1 x 10\^7, 5-μm silica spheres\]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
219523315|NCT00724542|DRUG|Voglibose tablets|0.2mg Tid
219523316|NCT01139034|DEVICE|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
219523317|NCT01537861|DRUG|Filgrastim|
219523318|NCT01537861|DRUG|Bortezomib|
219523319|NCT01537861|DRUG|Carfilzomib|
219613953|NCT06751173|OTHER|Spinal Mobilization|Central-Unilateral posterio anterior and lateral glide
218909586|NCT00297388|DRUG|Risperidone, long-acting injectable|
219523320|NCT01537861|DRUG|Dexamethasone|
218909587|NCT01863823|DRUG|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
218909588|NCT01863823|DRUG|Mouth washing|Two time washing mouth per day
218909589|NCT02611973|OTHER|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
219040571|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
219040572|NCT01982253|DRUG|Fasiglifam|Fasiglifam tablets
219040573|NCT01982253|DRUG|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
219040574|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
219040575|NCT00291122|DRUG|celecoxib 400 mg BID|
219523321|NCT01537861|DRUG|Cyclophosphamide|
219523322|NCT01537861|DRUG|Thalidomide|
218909590|NCT02611973|OTHER|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
218909591|NCT02611973|OTHER|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
218909592|NCT02611973|DRUG|Hydroxyurea treatment (HU)|HU maintenance
218909593|NCT06002620|DIETARY_SUPPLEMENT|CSB+|standard care
218909594|NCT06002620|DIETARY_SUPPLEMENT|Enriched nutrition food (CEF)|enriched cricket flour at 20%
218909595|NCT06002620|BEHAVIORAL|Nutrition education|regular videos, sms reminders and face to face interaction
218909596|NCT06002620|COMBINATION_PRODUCT|Combined nutrition and education|combined enriched cricket flour and nutrition education
218909597|NCT02195908|OTHER|single point Neiguan(PC6) plus antiemetic drug|
218909598|NCT02195908|OTHER|single point Zhongwan(CV12) plus antiemetic drug|
218909599|NCT02195908|OTHER|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
218909600|NCT02195908|DRUG|only antiemetic drug|
218909601|NCT03142386|OTHER|Osteopathic manipulative treatment|
219523323|NCT01537861|DRUG|Lenalidomide|
219523324|NCT01537861|DRUG|Pomalidomide|
219523325|NCT02918877|DRUG|Sevoflurane|Volatile Anesthetic
219523326|NCT02918877|DRUG|Propofol|Intravenous Anesthetic
219613954|NCT04005066|DRUG|Elunate®|The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
219613955|NCT05493501|DRUG|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
218909602|NCT03142386|OTHER|Physiotherapy|
218909603|NCT02752594|BIOLOGICAL|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
218909604|NCT02752594|OTHER|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
218909605|NCT04687306|DIAGNOSTIC_TEST|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
218909606|NCT00534365|DEVICE|tension-free vaginal tape|Retropubic mid-urethral sling
218909607|NCT00534365|DEVICE|TVT-SECUR device|Mid-urethral mini-sling
218909608|NCT02899936|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
218909609|NCT02899936|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
218909610|NCT04731285|DIAGNOSTIC_TEST|Pressure wire fractional flow reserve|Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
218909611|NCT04731285|DIAGNOSTIC_TEST|CFD-based RuiXin-FFR|"CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour"
218909612|NCT00434408|BEHAVIORAL|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
218909613|NCT00434408|BEHAVIORAL|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
218909614|NCT00434408|BEHAVIORAL|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
218909615|NCT06235866|OTHER|Pulmonary rehabilitation|According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
218909616|NCT02585401|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
218909617|NCT00706368|DEVICE|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
218909618|NCT03466385|DEVICE|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
218909619|NCT03466385|DEVICE|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
218909620|NCT03107481|DRUG|Acetaminophen|Acetaminophen 1g IV
218909621|NCT03107481|DRUG|Hydromorphone|Hydromorphone 1mg IV
219523327|NCT03625856|DIETARY_SUPPLEMENT|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
219523328|NCT03625856|DIETARY_SUPPLEMENT|Placebo|Starch 1500 mg
219523329|NCT02811523|DRUG|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
219523330|NCT05818137|BIOLOGICAL|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
219523331|NCT04925089|OTHER|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
219523332|NCT01699607|DRUG|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
219613956|NCT05493501|DRUG|Osimertinib monotherapy|80 mg tablet administered orally, once daily
219613957|NCT05493501|DRUG|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
219613958|NCT05493501|DRUG|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
219613959|NCT05493501|DRUG|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
219613960|NCT05493501|DRUG|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
219613961|NCT05493501|DRUG|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
219523333|NCT01035528|DRUG|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
219523334|NCT01035528|DRUG|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
219523335|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
219523336|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
219523337|NCT00464165|DRUG|rimonabant|
218909622|NCT05467241|BEHAVIORAL|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
218909623|NCT04618003|BEHAVIORAL|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
218909624|NCT02501252|PROCEDURE|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
218909625|NCT04435483|DRUG|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
218909626|NCT04435483|DRUG|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
219040576|NCT02809430|DEVICE|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
219523338|NCT05357157|OTHER|Electroacupuncture|Subjects will be administered electroacupuncture as described in the electroacupuncture group description
219613962|NCT05493501|DRUG|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
219613963|NCT03145675|DRUG|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
219613964|NCT03145675|DRUG|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
219613965|NCT03145675|DRUG|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
218909627|NCT04435483|DRUG|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
218909628|NCT00003316|DRUG|gemcitabine hydrochloride|
219613966|NCT03145675|DRUG|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
219613967|NCT01509274|BIOLOGICAL|Plasma|3 ml plasma injected once into the plantar fascia
219613968|NCT01509274|BIOLOGICAL|Saline|3 ml of saline injected once into the plantar fascia
219040577|NCT06290310|DEVICE|EIT|continuous electric impedance tomography measurement
219040578|NCT06290310|DEVICE|patient-ventilator asynchrony assessment|patient-ventilator asynchrony assessment by flow/time curve and machine learning
219040579|NCT01080313|OTHER|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
219613969|NCT01509274|OTHER|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
219613970|NCT02449980|PROCEDURE|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
219613971|NCT02449980|PROCEDURE|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
219613972|NCT07084025|OTHER|Perceive, Recall, Plan and Perform-Intervention protocol (PRPP-I)|"delivered over a 4-week period, in 12 sessions (45/60 min, 3 days a week for 4 weeks) for all patients according to the PRPP-I protocol. The intervention will be carried out by a PRPP-certified occupational therapist working on a Master's degree.~It will consist of :~* Implementation of training in functional cognitive strategies and meta-prompts through performance in home activities,~* Repeated measurement of performance judgment criteria ;~* Assessment of cognitive strategies~* personalized implementation of the PRPP-I cognitive strategy training protocol.~* Collection of feasibility modalities when tracking the intervention (e.g., time, transport, etc.)."
218909629|NCT05930119|DRUG|HMPL-453|300 mg HMPL-453
219523339|NCT05357157|DIETARY_SUPPLEMENT|Nutrition|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
219523340|NCT05357157|DIETARY_SUPPLEMENT|Dietary supplement|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
219523341|NCT03047226|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
219523342|NCT02532764|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
219523343|NCT02532764|DRUG|Placebo|Normal Saline
219523344|NCT04177381|PROCEDURE|Cesarean section|"1. Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~2. The fascia will be then incised sharply at the midline~3. The transversalis fascia and pre peritoneal fat will be dissected carefully~4. The peritoneum will be then incised.~5. Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~6. Delivery of the Fetus and placenta.~7. Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
219523345|NCT04177381|PROCEDURE|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
219523346|NCT04177381|DEVICE|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
219613973|NCT01654692|DRUG|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
219613974|NCT06904872|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
219613975|NCT06904872|DRUG|Matched Placebo Powder for Oral Solution|Matched Placebo Powder for Oral Solution
218909630|NCT05930119|DRUG|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
218909631|NCT00884546|DRUG|BMS-833923|Capsule, Oral, Once daily, 6 months
219523347|NCT05341232|BEHAVIORAL|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
219523348|NCT05341232|BEHAVIORAL|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
219523349|NCT05341232|BEHAVIORAL|Board Games|Participants will play board games with each other.
219523350|NCT04456361|BIOLOGICAL|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
219523351|NCT03527745|DRUG|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
219523352|NCT03527745|DRUG|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
219523353|NCT03527745|DRUG|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
219523354|NCT03527745|DRUG|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
219523355|NCT03527745|DRUG|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
219523356|NCT04699422|PROCEDURE|Serratus anterior plane block|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
219523357|NCT04699422|DRUG|PCIA with Piritramide|A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
219523358|NCT05159206|PROCEDURE|CT group|This group will do a preoperative CT scan for templating. The same scan is then used for per-operative navigation. After surgery, a postoperative CT will validate the templating/navigation, and then subsequent CT scans (postoperative, 3 months, 1 and 2 years) will be done to measure prosthetic migration over time.
219523359|NCT04245826|OTHER|Change in LCSBs Intake|Effect of changing LCSBs intake
219523360|NCT04245826|OTHER|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
219523361|NCT03988127|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
219523362|NCT01717976|BEHAVIORAL|DISPO ED|primary care based nurse telephone support
219523363|NCT00483899|DRUG|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
218909632|NCT00884546|DRUG|Lenalidomide|Capsule, Oral, Once daily, 6 months
218909633|NCT00884546|DRUG|Dexamethasone|Capsule, Oral, Once a week, 6 months
218909634|NCT00884546|DRUG|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
218959201|NCT01190787|DRUG|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
219523364|NCT00483899|DRUG|Placebo|Placebo matching GW870086X will be administered by subjects
219523365|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
219523366|NCT01188837|OTHER|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
218909635|NCT04527640|DIETARY_SUPPLEMENT|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
218909636|NCT04527640|OTHER|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
218909637|NCT02856412|OTHER|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
218909638|NCT02856412|OTHER|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
218909639|NCT06971926|BEHAVIORAL|Home visist|Caregivers and children will receive home visits twice a month delivered by the social assistance service within the PI-SUAS/CF during 12 months
218909640|NCT06483230|DEVICE|Intensive Visual Stimulation Device|The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
218909641|NCT02099864|DRUG|Enzalutamide|Given PO
218909642|NCT01400698|DRUG|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
219523367|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
218909643|NCT01400698|DRUG|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
218909644|NCT01400698|OTHER|Observation only|Subjects were only observed.
218909645|NCT00035490|DRUG|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
218909646|NCT00035490|DRUG|placebo|placebo tablet, once daily for one year
218909647|NCT00035490|DRUG|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
218909648|NCT00751686|PROCEDURE|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
218909649|NCT00751686|OTHER|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
218909650|NCT04566471|OTHER|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
218909651|NCT00000140|DRUG|Perfluoropropane|
218909652|NCT00000140|DRUG|Sulfur Hexafluoride|
218909653|NCT00000140|DRUG|Silicone Oil|
218909654|NCT06699927|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
218909655|NCT06704412|BEHAVIORAL|floss band|"The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
219040580|NCT05160428|BIOLOGICAL|COVID-19 vaccination|different types of covid-19 vaccinations.
219040581|NCT04501731|OTHER|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
218909656|NCT06704412|BEHAVIORAL|Sham (No Treatment)|The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
219523368|NCT05960409|PROCEDURE|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
219523369|NCT06850090|COMBINATION_PRODUCT|TAS-102|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Concurrent administration of TAS-102 at a dose of 35 mg/m² twice daily at the 1st, 3rd and 5th week of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 85 mg/m² on day 1 combined with TAS-102 at 35 mg/m² twice daily from day 1 to day 5, repeated every 14 days for a total of 6 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy:~Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)."
219613976|NCT05197543|DIAGNOSTIC_TEST|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
219613977|NCT06344273|BEHAVIORAL|ROM exercises|Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session.
219613978|NCT06522217|DEVICE|nasoalveolar molding appliance|making impression then make the conventional lab procedures for group A for the production of conventional appliances
219613979|NCT06522217|DEVICE|digital nasoalveolar molding appliance|group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
219613980|NCT07095049|DRUG|Apo-Si-K170A-C76|Apo-Si-K170A-C76 is an small interfering RNA (siRNA) against SARS-CoV-2
218909657|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
218909658|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
218909659|NCT00399308|DEVICE|Control (compression bandaging)|Multi-layer compression bandaging
218909660|NCT03409796|DIETARY_SUPPLEMENT|Gluten|Gluten powder.
218909661|NCT01679288|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
219613981|NCT07095049|DRUG|Placebo|5% glucose, 0.5% benzyl alcohol in RNase free water
218909662|NCT04307797|DRUG|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
218909663|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
218909664|NCT04307797|DRUG|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
218909665|NCT04307797|DRUG|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
219040582|NCT04501731|OTHER|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
219040583|NCT04501731|OTHER|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
218909666|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
218909667|NCT04307797|DRUG|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
218909668|NCT06280924|BEHAVIORAL|Supported Exercise|Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.
218909669|NCT06280924|BEHAVIORAL|Standard Care|Participants will receive standard care
218909670|NCT02452307|BIOLOGICAL|Peptide vaccine|subcutaneous
218909671|NCT02452307|DRUG|Montanide ISA-51|subcutaneous
218909672|NCT02452307|DRUG|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
218909673|NCT02452307|DRUG|Imiquimod|epicutaneous
218909674|NCT02452307|DRUG|mRNA|subcutaneous
218909675|NCT02452307|DRUG|Protamin|subcutaneous
218909676|NCT02452307|PROCEDURE|local hyperthermia|
218909677|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
218909678|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
219040584|NCT04501731|OTHER|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
219040585|NCT00764621|PROCEDURE|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
219040586|NCT00764621|PROCEDURE|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
218909679|NCT04462640|OTHER|Management of Infant Digestive Disorders and Quality of Life|The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
218909680|NCT03195881|OTHER|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
218909681|NCT01602224|DRUG|Placebo|Administered IV
218909682|NCT01602224|DRUG|Dexamethasone|Administered orally
218909683|NCT01602224|DRUG|Bortezomib|Administered SQ
218909684|NCT01602224|BIOLOGICAL|Tabalumab|Administered IV
218909685|NCT04299165|DEVICE|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
218909686|NCT04299165|OTHER|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
218909687|NCT06473389|PROCEDURE|Suprascapular nerve pulse radiofrequency ablation|Pulse RF application will be applied to the suprascapular nerve once under US guidance with a TOP-TLG10 STP generator at a maximum temperature of 42 degrees, 2 Hz, 20 ms and 45 V for 2 minutes.
218909688|NCT06473389|PROCEDURE|Suprascapular Nerve Block Group|Suprascapular block will be applied once with a mixture consisting of 5 ml (1 ml betamethasone, 2% lidocaine 2 ml, 0.9% saline 2 ml).
218909689|NCT06473389|PROCEDURE|Steroid Group|Intra-articular steroid application will be made with a mixture consisting of 5 ml (2 ml of 2% lidocaine, 2 ml of 0.9% saline and 1 ml of betamethasone 5 mg).
218909690|NCT05757713|BIOLOGICAL|teplizumab|CD3-directed humanized monoclonal antibody
218909691|NCT01352117|DRUG|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
218909692|NCT01352117|DRUG|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
218909693|NCT00633477|DRUG|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
218909694|NCT00633477|DRUG|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
218909695|NCT00261690|BEHAVIORAL|Virtual Reality Distraction|Using virtual reality distraction during a procedure
218909696|NCT02539823|DRUG|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
218909697|NCT02539823|DRUG|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
218909698|NCT02539823|DRUG|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
218909699|NCT00770653|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
218909700|NCT00770653|DRUG|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
218909701|NCT02022059|DRUG|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
218909702|NCT02022059|DRUG|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
218909703|NCT04505059|PROCEDURE|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
218909704|NCT04505059|PROCEDURE|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
218909705|NCT01024517|DRUG|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
218909706|NCT01024517|DRUG|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
218909707|NCT02996344|OTHER|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
218909708|NCT02996344|OTHER|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
218909709|NCT01417546|DRUG|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
218909710|NCT01373021|DRUG|Fentanyl|Fentanyl 2500mcg+NS50ml
218909711|NCT01373021|DRUG|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
218909712|NCT00289653|DRUG|Nicoderm|
218909713|NCT04580355|PROCEDURE|One-Stage Full Mouth Debridement|Periodontal debridement
218909714|NCT04580355|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
218909715|NCT04580355|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
218909716|NCT04580355|DRUG|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
218909717|NCT04580355|DRUG|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
218909718|NCT02217839|DRUG|DG3173|
218909719|NCT02217839|DRUG|DG3173+Octreotide|
218909720|NCT02217839|DRUG|Octreotide|
218909721|NCT02217839|DRUG|DG3173 Placebo|
218909722|NCT02217839|DRUG|DG3173 Placebo+Octreotide Placebo|
218909723|NCT02217839|DRUG|Octreotide+DG3173 Placebo|
219523370|NCT06850090|COMBINATION_PRODUCT|Capecitabine|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Capecitabine administered orally at a dose of 825 mg/m² twice daily on days of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 130 mg/m² on day 1 combined with capecitabine at 1000 mg/m² twice daily from day 1 to day 14, repeated every 21 days for a total of 4 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy: Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)"
219523371|NCT05666752|DIETARY_SUPPLEMENT|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
219523372|NCT05666752|DIETARY_SUPPLEMENT|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
219523373|NCT05956678|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
219523374|NCT05956678|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
219523375|NCT04833998|DRUG|Extremecare|The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
219523376|NCT04833998|DRUG|Placebo|Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
219523377|NCT00000588|DRUG|Chelation therapy|After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
219523378|NCT00000588|OTHER|Placebo|Placebo given at same time points as the Intervetnion for each clinical condition.
219523379|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
219523380|NCT01309945|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
219523381|NCT01309945|DRUG|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
219523382|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
219523383|NCT01309945|DRUG|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
219523384|NCT01762748|DRUG|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
219523385|NCT00115882|BEHAVIORAL|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
219523386|NCT00308529|DRUG|irinotecan|
219523387|NCT00308529|DRUG|carboplatin|
219523388|NCT00308529|DRUG|bevacizumab|
219523389|NCT00308529|PROCEDURE|Radiation Therapy|
219613982|NCT07097064|COMBINATION_PRODUCT|standard radiotherapy with chemotherapy|intensity-modulated conformal radiotherapy (IMRT) 50-54 Gy in 25-30 fractions with concomitant Xeloda 800-825 mg/m2 morning and evening 5d/7.
219613983|NCT07097064|RADIATION|MRI-guided adaptive stereotactic radiotherapy (SMART)|MRI-guided adaptive stereotactic radiotherapy (SMART) 50 Gy / 5 fractions without concomitant chemotherapy.
219613984|NCT07097597|DEVICE|Comparison 1: New Snoring Application|Measurements obtained from the snoring application under development
219613985|NCT07097597|DEVICE|Comparison 2: Commercially Available Snoring Application|Measurements from a commercially available snoring application
219523390|NCT01008657|PROCEDURE|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
219523391|NCT00581646|BEHAVIORAL|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
219523392|NCT05352386|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
219523393|NCT01604850|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
219523394|NCT01604850|DRUG|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
219523395|NCT01604850|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
219523396|NCT01604850|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
219523397|NCT03201302|OTHER|School physical education class|Children participated only in school physical education classes only.
219523398|NCT03201302|OTHER|Taekwondo|Children participated only in taekwondo training only.
219613986|NCT07097597|DEVICE|Comparison 3: Polysomnography|Measures taken from home or in laboratory polysomnography
218909724|NCT00187291|DEVICE|T-Wave Alternans test|
218909725|NCT02044354|DRUG|Taxotere|
218909726|NCT02044354|DRUG|Jevtana|
218909727|NCT01962792|DRUG|Ibrutinib|
218909728|NCT01962792|DRUG|Carfilzomib|
218909729|NCT01962792|DRUG|Dexamethasone|
218909730|NCT01439789|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
218909731|NCT01439789|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
218909732|NCT04906499|BEHAVIORAL|Physical Activity Promotion|"After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (\<10 days with \<1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day."
218909733|NCT05503836|PROCEDURE|abdominal surgeries|abdominal surgeries
218909734|NCT00002044|DRUG|Zidovudine|
218909735|NCT02326623|OTHER|distraction|distraction using an iPad with a selection of child-appropriate games
218909736|NCT02326623|OTHER|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
218909737|NCT02318160|OTHER|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
218909738|NCT01198886|OTHER|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
218909739|NCT01198886|OTHER|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
218909740|NCT03121313|DRUG|tegafur-uracil|
218909741|NCT06378021|DRUG|Calcium Chloride|5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft
218909742|NCT06378021|DRUG|Sodium Chloride 0.9% Inj|0.9% sodium chloride injection during on pump during Coronary artery bypass graft
218909743|NCT01502748|OTHER|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
218909744|NCT01723098|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
218909745|NCT06465940|DEVICE|Total hip arthroplasty|Replacement of hip joint
218909746|NCT03058120|OTHER|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
218909747|NCT03897426|BEHAVIORAL|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
218909748|NCT03323892|OTHER|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
218909749|NCT04935658|DEVICE|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
218909750|NCT04935658|DRUG|local anesthesia|standard anesthesic procedure
218909751|NCT04862715|DRUG|Ferinject|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
218909752|NCT04862715|OTHER|Placebo: NaCl (sodium chloride 0.9%)|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
218909753|NCT01288573|DRUG|plerixafor|160 μg/kg subcutaneous (SC) injection
218909754|NCT01288573|DRUG|plerixafor|240 μg/kg subcutaneous (SC) injection
218909755|NCT01288573|DRUG|plerixafor|320 μg/kg subcutaneous (SC) injection
218909756|NCT03449511|OTHER|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
218909757|NCT03449511|OTHER|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
218909758|NCT03449511|OTHER|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
218909759|NCT03449511|OTHER|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
218909760|NCT04478201|OTHER|back sleep positioning|sleeping on the back.
218909761|NCT04478201|OTHER|side sleep positioning|sleeping on the side
218909762|NCT03029806|OTHER|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
218909763|NCT03029806|OTHER|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
218909764|NCT03029806|OTHER|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
219523399|NCT03201302|OTHER|Martial arts|Children participated only in martial arts training only.
219523400|NCT03201302|OTHER|Climbing|Children participated only in climbing training only.
219523401|NCT03201302|OTHER|Volleyball|Children participated only in volleyball training only.
219523402|NCT03201302|OTHER|Artistic gymnastics|Children participated only in artistic gymnastics training only.
218909765|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (tablet)
218909766|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (capsule)
218909767|NCT04861129|PROCEDURE|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
218909768|NCT04861129|PROCEDURE|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
218909769|NCT00179621|DRUG|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
218909770|NCT00179621|DRUG|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
219040587|NCT00764621|PROCEDURE|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
219523403|NCT03201302|OTHER|Swimming|Children participated only in swimming training only.
219523404|NCT03201302|OTHER|Dance|Children participated only in dance training only.
219523405|NCT03201302|OTHER|Basketball|Children participated only in basketball training only.
219523406|NCT03201302|OTHER|Wrestling|Children participated only in wrestling training only.
219523407|NCT03201302|OTHER|Football (soccer)|Children participated only in football (soccer) training only.
219613987|NCT07096245|BEHAVIORAL|Vaccine Information Video Dissemination|"The intervention is a brief, community-informed educational video (2-3 minutes) focused on seasonal flu and COVID-19 vaccination. The video was developed using human-centered design and community-based participatory methods with Indigenous community members in California. It aims to promote trust in vaccines by presenting clear, culturally relevant health information.~The video is disseminated using three behavioral delivery strategies: (1) paid advertisements on Facebook and Instagram targeting adults in California, (2) peer-to-peer sharing by participants who previously enrolled in the study and are invited to serve as seeds who share the video with their personal contacts, and (3) distribution by trusted community-based organizations (CBOs) using their existing communication networks, including WhatsApp, social media, email, and newsletters. All viewers are prompted to complete a one-question trust poll and invited to participate in an optional anonymous survey on vaccine attitud"
219613988|NCT07097883|PROCEDURE|Percutaneous Nephrolithotomy|Patients underwent percutaneous nephrolithotomy (PCNL) for renal calculi \>2 cm.
218909771|NCT00179621|DRUG|Placebo|Placebo, matching to active study drug arms
218909772|NCT05622734|BEHAVIORAL|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
218909773|NCT03432325|DEVICE|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
218909774|NCT03084211|OTHER|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
218909775|NCT00270985|BEHAVIORAL|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
218909776|NCT00270985|BEHAVIORAL|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
218909777|NCT03567564|DIAGNOSTIC_TEST|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
218909778|NCT01866540|DRUG|FLUENZ|live attenuated influenza vaccine
218909779|NCT05858541|BEHAVIORAL|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
218909780|NCT05858541|BEHAVIORAL|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
218909781|NCT04272918|BEHAVIORAL|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
219040588|NCT01665274|DRUG|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
219523408|NCT03201302|OTHER|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
219523409|NCT03201302|OTHER|Track and field|Children participated only in track and field training only.
219523410|NCT03201302|OTHER|Tennis|Children participated only in tennis training only.
219523411|NCT03201302|OTHER|Combination of activities 1|Children participated in two weight-bearing activities.
219523412|NCT03201302|OTHER|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
219523413|NCT01185808|BIOLOGICAL|Vitamin D|Vitamin D 5000IU/day for 6 weeks
219523414|NCT03538587|BEHAVIORAL|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
219523415|NCT03538587|BEHAVIORAL|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
219523416|NCT03802370|PROCEDURE|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
219523417|NCT03925870|DRUG|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
218909782|NCT04272918|BEHAVIORAL|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
218909783|NCT04027855|PROCEDURE|collection of peripheral blood mononuclear cells from healthy volunteers|"1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
219523418|NCT01247259|DRUG|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
218909784|NCT02722564|BEHAVIORAL|self estimation of breath alcohol content|
218909785|NCT02722564|DEVICE|breath alcohol content as measured by Alco Sensor IV device|
218909786|NCT02722564|OTHER|drink a beer|drink a beer, repeat until breath alcohol content 0.1
218909787|NCT02250742|OTHER|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
218909788|NCT05602298|OTHER|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
218909789|NCT06235372|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph .
218909790|NCT03422913|PROCEDURE|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still \>5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) \> 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
218909791|NCT00837252|DRUG|Finasteride|Participants received 5mg of oral finasteride daily for three months.
218909792|NCT05887869|BEHAVIORAL|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
218909793|NCT03896139|DRUG|Kinase inhibitor|Patients treated with kinase inhibitors for cancer or other conditions
218909794|NCT00907595|DRUG|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
218909795|NCT00907595|DRUG|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
218909796|NCT02726503|DRUG|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
218959202|NCT01190787|DRUG|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
219040589|NCT01665274|DRUG|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
219040590|NCT01665274|PROCEDURE|D2 resection|D2 resection
219523419|NCT04238442|DEVICE|A&D TM-2657W oscillometric device|Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
219523420|NCT02925442|PROCEDURE|t-RFA|standard thermal genicular radiofrequency ablation
219523421|NCT02925442|PROCEDURE|C-RFA|Cooled radiofrequency ablation
219523422|NCT02925442|PROCEDURE|Control|Simulated radiofrequency ablation for placebo controlled group
219523423|NCT02270970|BIOLOGICAL|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
219613989|NCT07097298|BEHAVIORAL|empathy and compassion training|A 6-week empathy and compassion training will be designed and delivered involving PD patients and caregivers. During the compassion training participants will do mindfulness, writing and poetry exercises
219613990|NCT07096583|BIOLOGICAL|METR-NK cell（metabolic remodeling nature killer cells）|100 mL METR-NK cells were diluted in 500 mL 0.9% sodium chloride normal saline at 37℃, and the infusion volume of METR-NK cells was not less than 2×107 cells/kg for 1 day as a course of treatment, and the infusion time was maintained for 30 minutes on the 10th day before chemotherapy.
218909797|NCT02438163|DEVICE|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
219040591|NCT00913744|DRUG|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
219523424|NCT00771537|BEHAVIORAL|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
219523425|NCT05911607|PROCEDURE|Low power laser|Phototherapy for extraction sockets using two different lasers.
219523426|NCT02827409|PROCEDURE|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
219523427|NCT02827409|PROCEDURE|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
219523428|NCT00893256|DRUG|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
219613991|NCT07096609|DRUG|Lenvatinib Capsules|Lenvatinib will be administered orally once daily at a dose of 12 mg (for patients weighing ≥ 60 kg) or 8 mg (for patients weighing \< 60 kg). Each treatment cycle consists of 4 weeks (i.e., 28 days).
218909798|NCT03084146|OTHER|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
218909799|NCT03641417|DRUG|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
219613992|NCT07095400|OTHER|strength training|"An intervention based on the application of a strength training protocol for multi-joint and single-joint muscles will be implemented, performed with a slow-moderate execution speed. This intervention will be carried out over 12 weeks, with a total of 24 sessions (2 sessions per week), each lasting 45 minutes. In all of these sessions, free weights will be used, performing three sets at 60-80% of 1RM for 8-12 repetitions.~The exercise protocol will include:~* Squats~* Deadlifts~* Rows~* Bicep curls~* Bench press~* Shoulder press~Each set will be performed to muscular failure, progressing in the number of repetitions (from 8 to 12). Once 12 repetitions are reached, the load volume will be increased by adding 5% to the weight."
219613993|NCT07095647|PROCEDURE|Hysteroscopy|Hysteroscopic-guided suction evacuation and double-layer laparoscopic repair of the niche were performed concomitantly and followed by second-look hysteroscopy to ensure the competence of the repair.
219613994|NCT07095556|OTHER|Low-level laser therapy|"The low-level laser applications will be made on the same day as the standard of care treatment (day 1), and then day 3, and day 7 by a study team member who is trained in the use of the laser device.~The laser photobiostimulation will be applied using LightWalker® laser (FOTONA), with following settings, Nd:YAG laser 1064 nm, MSP modality (pulse duration), 0.5 W (power), 10 Hz (frequency), 1 min/ 1 cm2 spot using Genova handpiece from buccal, lingual, and occlusal aspects. The Genova handpiece will be placed 1 cm away from gingival tissue.~Participants and operators will wear glasses to protect their eyes from laser beam in all sessions."
219613995|NCT07095465|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
219613996|NCT07095439|RADIATION|Total Neoadjuvant Treatment|Participants in this arm receive 4 cycles of induction chemotherapy CAPEOX (or 5 cycles of FOLFOX6), followed by short course radiotherapy (25 Gy in 5 fractions) delivered via IMRT technique ,then consolidation chemotherapy in the form of : 2 cycles of CAPOX (or, 4 cycles of FOLFOX6). Total mesorectal excision (TME) will be performed for non-metastatic patients within 8-12 weeks of the short course radiotherapy.
219613997|NCT07097363|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219613998|NCT07097363|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219613999|NCT07097363|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219614000|NCT07097363|PROCEDURE|Computed Tomography|Undergo CT scan
219614001|NCT07097363|DRUG|Cyclophosphamide|Given IV
219614002|NCT07097363|DRUG|Doxorubicin|Given IV
219614003|NCT07097363|PROCEDURE|Echocardiography Test|Undergo echocardiography
219614004|NCT07097363|BIOLOGICAL|Epcoritamab|Given SC
218909800|NCT03641417|OTHER|Placebo|Same as GLWL-01, but no active ingredient
218909801|NCT01305720|DEVICE|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
218909802|NCT06456567|BIOLOGICAL|Telitacicept|Subcutaneous injection
218909803|NCT06456567|DRUG|Placebo|Subcutaneous injection
218959203|NCT01190787|DRUG|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
219040592|NCT00913744|DRUG|Sham injection|Sham injection
219523429|NCT00893256|DRUG|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
219523430|NCT00893256|DRUG|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
219523431|NCT00893256|DRUG|Placebo|Placebo: once daily
219523432|NCT03305237|OTHER|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
219523433|NCT03305237|OTHER|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
219523434|NCT05666583|OTHER|Art therapy|The intervention group is the group in which art therapy is applied. They receive chemotherapy.
219523435|NCT01802697|DRUG|IdeS|
219523436|NCT01802697|DRUG|Placebo|
219523437|NCT04560881|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
219523438|NCT04560881|BIOLOGICAL|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
219523439|NCT03742102|DRUG|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
219523440|NCT03742102|DRUG|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
219523441|NCT03742102|DRUG|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
219523442|NCT03742102|DRUG|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
219523443|NCT03742102|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
219523444|NCT03742102|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
219204516|NCT06857149|OTHER|Human milk|"In accordance with the physiology of breastfeeding, mothers will be asked to milk and deliver their milk to the ICU once every 3 hours. The mother will be asked to completely empty her breast with a milking machine. Before milking, the mother will wash her hands, and the parts of the milking machine that come into contact with the milk will also be boiled and disinfected after it is provided to be used. The mother will put the milk she has milked into a milking bag and deliver it to the researcher by writing the date and time on it. Feeding will be initiated by the neonatal specialist with the determination that the newborn is stable. During the period when mothers' babies are in the neonatal intensive care unit, the feeding of the babies in the circadian rhythm group will be carried out taking into account the date and day/night practice.~The milk that the mother expresses at night will be given to her baby at night, and the milk that she expresses during the day will be used for dayt"
218909804|NCT01102335|PROCEDURE|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
218909805|NCT01102335|DRUG|Telbivudine|anti-HBV drug
218909806|NCT05077826|DEVICE|North Coast Medical Activadose II|tES device model Activadose II (North Coast Medical, Morgan Hill, CA, USA) programed to deliver tES.
218909807|NCT02602366|OTHER|HEC Placebo Gel|
218909808|NCT02602366|OTHER|Placebo Vaginal Insert|
218909809|NCT02602366|OTHER|Placebo Vaginal Film|
218909810|NCT02602366|OTHER|Placebo Intravaginal ring (IVR)|
218909811|NCT04445935|DRUG|Bivalirudin Injection|The patients will receive iv Bivalirudin according to the institutional HIT protocol.
218909812|NCT04445935|DRUG|Standard treatment|This group will receive standard anticoagulation with LMWH/UFH
218909813|NCT01273766|DRUG|deferasirox|Given orally
218909814|NCT01273766|OTHER|laboratory biomarker analysis|Correlative studies
218909815|NCT01273766|OTHER|enzyme-linked immunosorbent assay|Correlative studies
218909816|NCT01262417|PROCEDURE|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
219523445|NCT04635618|BEHAVIORAL|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
219523446|NCT04635618|BEHAVIORAL|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
219523447|NCT04635618|BEHAVIORAL|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
219523448|NCT01187862|DRUG|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
218909817|NCT01262417|PROCEDURE|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
218909818|NCT00262860|DRUG|bortezomib|
218909819|NCT00262860|DRUG|gemcitabine hydrochloride|
219523449|NCT04002388|BEHAVIORAL|activity monitor group|will receive a FitBit and will be asked to wear this for one year
219523450|NCT04002388|BEHAVIORAL|usual care group|will NOT receive a FitBit
218909820|NCT03965130|BIOLOGICAL|Glucagon|PINTA study with glucagon
218909821|NCT03965130|OTHER|Control Study|The same participants will not receive glucagon during the PINTA study
218909822|NCT01751061|BEHAVIORAL|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
218909823|NCT01751061|OTHER|Usual care|usual ICU care
218909824|NCT01048008|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
218909825|NCT02446977|DRUG|Vitamin B2 Streuli®|4ml IV
218909826|NCT02446977|OTHER|Solution for injection|4ml IV
218909827|NCT00733785|DRUG|Rosiglitazone XR|Rosiglitazone extended release formulation
218909828|NCT02590796|OTHER|No intervention given to participants|This is an observational study. Participants will receive no intervention.
218909829|NCT02490735|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
218909830|NCT00503750|DRUG|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
218909831|NCT00503750|DRUG|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
218909832|NCT00503750|DRUG|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
218909833|NCT00875186|OTHER|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
218909834|NCT00875186|OTHER|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
218909835|NCT05138302|OTHER|Observation|This study is an observe research
219523451|NCT04465188|PROCEDURE|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
219523452|NCT06297889|BEHAVIORAL|core strength training 1-6weeks|Behaviour: core strength training intervention for 1-6 weeks. Experimental: The experimental group performed core strength training during weeks 1-3. Subjects were first provided with basic information, familiarised with the content of the first phase of core strength training and watched a core strength video to understand its importance. The initial intervention was designed to ensure that subjects were proficient in core strength training, including warm-up and stretching patterns. During weeks 4-6, subjects will be supervised and assisted and a test will be organised at the end of week 6. Variables related to physical fitness and skills were recorded to assess whether core strength training improved physical fitness and skills.
218909836|NCT04834570|BEHAVIORAL|Quality of life in Breast Cancer Survivors|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B"
218909837|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
218909838|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
218909839|NCT03827408|DRUG|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
218909840|NCT03827408|DRUG|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
218909841|NCT03827408|DRUG|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
218909842|NCT01419002|RADIATION|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
218909843|NCT01419002|PROCEDURE|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
218909844|NCT04789252|BIOLOGICAL|Bioinformatics analysis of single cell transcriptomics data|"1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry"
219040593|NCT05940935|PROCEDURE|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
219040594|NCT00721695|DRUG|OMS302|OMS302 Irrigation Solution
219040595|NCT00721695|DRUG|OMS302-PE|OMS302-PE HCI Irrigation Solution
219040596|NCT00721695|DRUG|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
219040597|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
219040598|NCT00805935|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
219040599|NCT00805935|DRUG|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
219040600|NCT00805935|DRUG|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
219523453|NCT06297889|BEHAVIORAL|core strength training 7-12weeks|"Behaviour: core strength training intervention #7-12 weeks#.~Experimental: Weeks 7-9 were the experimental group:~Continued to warm up before each training session. The training content will increase in difficulty during this phase, and the supervisor should explain the training content and watch videos of the movements prior to training and prepare the training equipment in advance to protect the athlete from injury. Weeks 10-12: This is an advanced stage, requiring equipment and difficult movements to complete, please supervisors to arrange personnel to do a good job of protection to ensure that the subjects can complete the training tasks. A test will be conducted the day after Week 12 to measure the athlete's physical fitness and skills."
219523454|NCT05167357|BIOLOGICAL|COVID19|"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."
218909845|NCT03972059|OTHER|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
218909846|NCT03972059|OTHER|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
218909847|NCT03972059|OTHER|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
218909848|NCT02226393|BEHAVIORAL|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
219040601|NCT00805935|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
219040602|NCT00805935|DRUG|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
219614005|NCT07097363|DRUG|Etoposide|Given IV
219040603|NCT02945410|OTHER|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
219040604|NCT02945410|OTHER|Protein|Participants will consume 1.7 g protein/kg BW/day.
219040605|NCT02945410|OTHER|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
219040606|NCT02945410|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
219040607|NCT02945410|OTHER|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
218909849|NCT02226393|BEHAVIORAL|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
218909850|NCT04604600|DRUG|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
218909851|NCT06005415|DIETARY_SUPPLEMENT|Wire-cut cookie|Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
218909852|NCT01176201|DRUG|SLV337 suspension|400 mg experimental
218909853|NCT01176201|DRUG|SLV337 capsule|5 x 200 mg immediate release capsule
218909854|NCT03869658|BEHAVIORAL|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
218909855|NCT05732298|DEVICE|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
218909856|NCT02367898|OTHER|Lumosity Cognitive Training|adaptive online cognitive training
218909857|NCT02367898|OTHER|Crossword Puzzles|timed online crossword puzzles
218909858|NCT00412009|PROCEDURE|Comprehensive package of activities|
218909859|NCT06297369|DRUG|N acetyl cysteine|N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
218909860|NCT03850379|DRUG|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
218909861|NCT03850379|DRUG|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
218909862|NCT05203614|BEHAVIORAL|Household Contribution|Questionnaires
218909863|NCT05203614|BEHAVIORAL|Outside Contribution|Questionnaires
218909864|NCT05203614|BEHAVIORAL|Control|Questionnaires
218909865|NCT03371498|DRUG|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
218909866|NCT03371498|DRUG|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
218909867|NCT01223534|DRUG|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
218909868|NCT01223534|DRUG|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
218909869|NCT05525897|OTHER|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
218909870|NCT05326087|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
218909871|NCT05326087|DRUG|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
218909872|NCT01194830|DRUG|Linagliptin|Active drug 1 tablet PO QD
218909873|NCT01194830|DRUG|Placebo|1 Tablet PO QD
218909874|NCT00698854|DEVICE|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
219523455|NCT03034083|BEHAVIORAL|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
219040608|NCT04607993|BEHAVIORAL|Prone position ventilation technique|"1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day"
219040609|NCT00347295|DRUG|Brotizolam|
219040610|NCT00347295|DRUG|Estazolam|
219523456|NCT00947258|OTHER|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
219523457|NCT04449484|DRUG|MEDI1341|Intravenous infusion over 60 minutes
219614006|NCT07097363|OTHER|Fludeoxyglucose F-18|Given fludeoxyglucose
219040611|NCT01170728|DEVICE|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
219040612|NCT05794256|OTHER|No interventions are planned|No interventions are planned
219040613|NCT04585516|PROCEDURE|endoscopy|Colonoscopy or gastroscopy
219040614|NCT02061969|DRUG|linagliptin|5mg linagliptin tablets
219040615|NCT02061969|DRUG|insulin glargine|
219614007|NCT07097363|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
218909875|NCT00698854|DEVICE|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
218909876|NCT00061087|DRUG|Methylphenidate|Methylphenidate 80mg/day
218909877|NCT00061087|DRUG|Bupropion|Bupropion 400mg/day
218909878|NCT00061087|OTHER|Placebo|Placebo
218909879|NCT04861597|BEHAVIORAL|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
218909880|NCT04861597|BEHAVIORAL|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
218909881|NCT00162487|DRUG|Albuterol (1,200 μg) through metered-dose inhaler|
218909882|NCT01815918|DRUG|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
218909883|NCT01815918|DRUG|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
218909884|NCT06435936|DRUG|Single Ascending Dose of SAB-176|Single ascending dose
218909885|NCT06435936|DRUG|Single Ascending Dose of Placebo|Single ascending dose
218909886|NCT04682197|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
218909887|NCT00148278|DRUG|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
218909888|NCT00148278|DRUG|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
218909889|NCT03284710|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
219040616|NCT02030171|OTHER|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
219523458|NCT04449484|OTHER|Placebo|Intravenous infusion over 60 minutes
219523459|NCT01453075|DRUG|Valacyclovir|Valacyclovir 1.5 mg po bid
219523460|NCT01453075|DRUG|Placebo|Matching placebo twice daily
219523461|NCT00527800|DRUG|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
219523462|NCT00527800|DRUG|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
219523463|NCT00527800|DRUG|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
219523464|NCT00166842|DRUG|sirolimus, cyclosporine, tacrolimus|
219523465|NCT01909869|DEVICE|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
218909890|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
218909891|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection
218909892|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
218909893|NCT06430996|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
218909894|NCT04445285|DRUG|Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
218909895|NCT04445285|DRUG|0.9%sodium chloride|Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
218909896|NCT04714606|OTHER|Sibling support group|The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.
218909897|NCT04714606|OTHER|None - control condition|The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
219040617|NCT01095588|DRUG|200 mg Avanafil|2 X 100mg tablets avanafil
219040618|NCT01095588|DRUG|Placebo|2 tablets
219040619|NCT01344369|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
219040620|NCT01344369|DRUG|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
219614008|NCT07097363|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219614009|NCT07097363|DRUG|Prednisone|Given PO
218909898|NCT04595968|DEVICE|Vestal DM Active device|Battery powered non-invasive neurostimulation device
218909899|NCT04595968|BEHAVIORAL|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
218909900|NCT04595968|DEVICE|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
218909901|NCT01673308|DRUG|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
218909902|NCT03238716|OTHER|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
218909903|NCT03238716|OTHER|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
218909904|NCT03238716|OTHER|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
218909905|NCT04723511|OTHER|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session"
218909906|NCT04723511|OTHER|Kendall exercises|"exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop."
218909907|NCT06220214|DIAGNOSTIC_TEST|CEDM|Contrast Enhanced Digital Mammography
218909908|NCT06220214|DIAGNOSTIC_TEST|CEDBT|Contrast-Enhanced Digital Breast Tomosynthesis
219040621|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
219040622|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
219365295|NCT04291144|RADIATION|PET-CT using FEOBV|We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
219614010|NCT07097363|BIOLOGICAL|Rituximab|Given IV
219614011|NCT07097766|BEHAVIORAL|"HBM-Based Education and Motivational Interviewing"|This intervention consists of a structured 3-session educational program and motivational interviews based on the Health Belief Model (HBM). It aims to increase knowledge about HPV infection and improve HPV vaccination awareness among women aged 18-45.
218909909|NCT06220214|DRUG|Omnipaque 350mgI/mL Solution for Injection|Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
218909910|NCT02348177|DRUG|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
218909911|NCT02348177|DRUG|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
218909912|NCT02592031|DRUG|XM17|300 IU corresponds to an injection volume of 0.5 mL.
218909913|NCT02592031|DRUG|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
218909914|NCT02592031|DRUG|Zoladex®|3.6 mg
218909915|NCT03154866|DIETARY_SUPPLEMENT|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
218909916|NCT03154866|DIETARY_SUPPLEMENT|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
218909917|NCT05941702|BEHAVIORAL|Body Signal Integration Training|Information and protocol uploaded to documents.
218909918|NCT05782868|OTHER|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
218909919|NCT05782868|OTHER|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
218909920|NCT05782868|OTHER|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
218909921|NCT05889728|DRUG|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
219040623|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
219040624|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
219523466|NCT04099888|DRUG|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
219523467|NCT04099888|DRUG|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
219523468|NCT05739045|DRUG|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
219614012|NCT07096466|OTHER|DHA stain|On day 1, the volar forearm test area will undergo DHA staining (250μl of 10% DHA solution applied under occlusion with Finn Chambers for 8 hours)
219614013|NCT07096466|OTHER|No DHA stain|On day 1, the volar forearm test area will not undergo DHA staining.
218909922|NCT00568295|DRUG|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
218909923|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
218909924|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
218909925|NCT02085967|DRUG|rifampin 600 mg|
218909926|NCT02085967|DRUG|itraconazole 200 mg|
218909927|NCT02085967|DRUG|midazolam 2 mg with bupropion 75 mg|
218909928|NCT02085967|DRUG|E2006|
218909929|NCT02814916|DRUG|Dalbavancin|Dalbavancin was administered intravenously over 30 (± 5) minutes.
218909930|NCT02814916|DRUG|Vancomycin|Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
218909931|NCT02814916|DRUG|Oxacillin|Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
218909932|NCT02814916|DRUG|Flucloxacillin|Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
218909933|NCT02814916|DRUG|Cefadroxil|Cefadroxil was administered orally every 12 hours.
218909934|NCT02814916|DRUG|Clindamycin|Clindamycin was administered orally every 8 hours.
219523469|NCT04538170|BEHAVIORAL|pain after surgery|
219523470|NCT00144625|DRUG|MRA(Tocilizumab)|8mg/kg/4weeks
219614014|NCT07096466|OTHER|Cosmetic product application - forearm|The cosmetic product will be applied twice daily for two weeks to the volar forearm test area.
219614015|NCT07096466|OTHER|No cosmetic product application - forearm|The cosmetic product will not be applied for two weeks to the volar forearm test area.
218909935|NCT03804840|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.
218909936|NCT03804840|DRUG|Placebo|Placebo
218909937|NCT05626738|DEVICE|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
218909938|NCT04951115|DRUG|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
218909939|NCT04951115|DRUG|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
218909940|NCT04951115|DRUG|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
218909941|NCT04951115|DRUG|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
218909942|NCT04951115|RADIATION|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
218909943|NCT06446921|DIETARY_SUPPLEMENT|Ginger formula|supplement delivering a minimum of 20 mg of gingeroids / d
219614016|NCT07096466|OTHER|Cosmetic products application - face|For two weeks on the face (excluding eye area), a cleansing cosmetic product containing Mitopure will be applied twice daily, and the cosmetic test product (that is used on forearms) will be applied once daily.
218909944|NCT06446921|DIETARY_SUPPLEMENT|Placebo|arabic gum
218909945|NCT04335253|DRUG|EOS884448|Multiple Ascending Dose
218909946|NCT04819451|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
218909947|NCT04959435|OTHER|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
218909948|NCT04126798|OTHER|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
218909949|NCT06070779|OTHER|neuro linguistic programming|neuro linguistic programming
218909950|NCT05700669|DRUG|AsiDNA|All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.
218909951|NCT05700669|DRUG|Olaparib|Olaparib is given orally in combination with AsiDNA
218909952|NCT06498583|DRUG|Ropivacaine|0.25 % ropivacaine ( 0.5ml / kg )
218909953|NCT06498583|PROCEDURE|erector spinae plane block|After the operation, unilateral erector spinae plane block was performed at the T5 level under ultrasound guidance.
218909954|NCT06498583|PROCEDURE|Incision infiltration of local anesthesia|After the operation, Incision infiltration of local anesthesia is performed around the surgical incisions.
218909955|NCT05002868|DRUG|RP12146|starting dose of 100 mg QD
218909956|NCT05955612|PROCEDURE|Procalcitonin measurement|Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
218909957|NCT05351944|BEHAVIORAL|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
218909958|NCT05351944|DRUG|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
218909959|NCT00910104|DRUG|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
218909960|NCT05720143|PROCEDURE|Osseodensification|Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
218909961|NCT05720143|PROCEDURE|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
218909962|NCT05720143|PROCEDURE|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
218909963|NCT05835206|DRUG|Microbiome Therapeutic|"Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
219523471|NCT00637299|OTHER|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
219523472|NCT00637299|OTHER|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
218909964|NCT05835206|DRUG|Placebo|"Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
219523473|NCT02857842|DRUG|Prednisolone|
219523474|NCT02850770|BEHAVIORAL|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
219523475|NCT02850770|BEHAVIORAL|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
219523476|NCT02850770|BEHAVIORAL|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
219523477|NCT04549844|DRUG|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
219523478|NCT00051025|DRUG|ONTAK|
219523479|NCT01357278|PROCEDURE|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
219523480|NCT04118478|BEHAVIORAL|multi-component phased training program|The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
219523481|NCT06350656|OTHER|Clinical data collection|Post-retrieval from the medical record
219523482|NCT06350656|OTHER|Therapeutic data collection|Post-retrieval from the medical record
219523483|NCT06350656|OTHER|IntraCranial Pression (ICP) values collection|Post-retrieval of ICP values from the monitor
219523484|NCT04234100|OTHER|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
218909965|NCT06511973|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
218909966|NCT06511973|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
218909967|NCT06511973|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch
218909968|NCT06511973|DRUG|A solution of 0.2% SLS|0.2% SLS will be dispensed directly on the patch.
219523485|NCT02171754|DRUG|BIBW 2992|
219523486|NCT02171754|DRUG|Ritonavir|
219523487|NCT01213901|PROCEDURE|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
219523488|NCT03369860|BEHAVIORAL|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
219614017|NCT07095153|BEHAVIORAL|Neuroathletic Training (NAT)|The intervention group will undergo an 8-week Neuroathletic Training program, conducted three times a week. The program consists of exercises designed to enhance visual-motor coordination, reaction time, balance, and proprioception, integrated with classical judo training. Each session lasts approximately 20-25 minutes and includes 6 to 8 different exercises targeting cognitive and neuromotor skills.
218959204|NCT01067924|BEHAVIORAL|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
219523489|NCT02400957|OTHER|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
218909969|NCT04014829|DIAGNOSTIC_TEST|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
218909970|NCT04014829|DIAGNOSTIC_TEST|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
218909971|NCT04014829|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
218909972|NCT04014829|DIAGNOSTIC_TEST|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
218909973|NCT04014829|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
218909974|NCT04014829|DIAGNOSTIC_TEST|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
218909975|NCT04014829|DIAGNOSTIC_TEST|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
218909976|NCT04014829|DIAGNOSTIC_TEST|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
218909977|NCT04014829|DIAGNOSTIC_TEST|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
218909978|NCT04014829|DIAGNOSTIC_TEST|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
218909979|NCT04014829|DIAGNOSTIC_TEST|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
218909980|NCT06310187|OTHER|High Oxidant Unflavored Little Cigar - Group A|Subjects will be provided with high oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant unflavored little cigar to use for outcome measure data collection in the lab)
218909981|NCT06310187|OTHER|Low Oxidant Unflavored Little Cigar - Group B|Subjects will be provided with low oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant unflavored little cigar to use for outcome measure data collection in the lab)
219040625|NCT04287907|DEVICE|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
219040626|NCT03316833|DEVICE|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score \<33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
219040627|NCT03848845|DRUG|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
219523490|NCT02400957|OTHER|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
219523491|NCT05487274|PROCEDURE|Total Shoulder Arthroplasty + augmented glenoid component|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components. A prosthetic component is also implanted to correct for the amount of bone loss in the shoulder and restore stability.
219523492|NCT05487274|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
219523493|NCT06091007|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
219523494|NCT02769637|DRUG|PPI treatment|PPI treatment or no PPI treatment
218909982|NCT06310187|OTHER|High Oxidant Flavored Little Cigar - Group C|Subjects will be provided with high oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant flavored little cigar to use for outcome measure data collection in the lab)
218909983|NCT06310187|OTHER|Low Oxidant Flavored Little Cigar - Group D|Subjects will be provided with low oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant flavored little cigar to use for outcome measure data collection in the lab)
218909984|NCT06310187|OTHER|Usual Cigarette - Group E|Subjects will use one of their own cigarettes in the collection of outcome measure data in the lab.
219523495|NCT00867542|OTHER|no intervention|no intervention
219523496|NCT05047107|OTHER|No intervention|Non-interventional study
218909985|NCT06310187|OTHER|Unlit Little Cigar - Group F|Subjects will be provided with an unlit little cigars to use for outcome measure data collection in the lab. This will be the control group for outcome measure data.
218909986|NCT05953181|PROCEDURE|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
218909987|NCT05976256|OTHER|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
218909988|NCT05976256|OTHER|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
218909989|NCT05976256|OTHER|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
218909990|NCT02081924|OTHER|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
218909991|NCT02081924|OTHER|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
218909992|NCT02081924|OTHER|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
218909993|NCT02081924|OTHER|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
218909994|NCT04904692|PROCEDURE|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
218909995|NCT04904692|PROCEDURE|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
218909996|NCT04904692|PROCEDURE|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
218909997|NCT05562128|BEHAVIORAL|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
218909998|NCT05562128|BEHAVIORAL|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
218909999|NCT02997631|DEVICE|MEDi Robot|Distraction therapy using an interactive humanoid robot
218910000|NCT03541850|DRUG|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
218910001|NCT03541850|OTHER|Quality-of-Life Assessment|Ancillary studies
219523497|NCT01097993|OTHER|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
219523498|NCT01097993|OTHER|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
219523499|NCT00274937|DRUG|Amifostine|Given subcutaneously
219523500|NCT00274937|DRUG|Cisplatin|Given IV
219523501|NCT00274937|DRUG|Fluorouracil|Given IV
219523502|NCT00274937|OTHER|Laboratory Biomarker Analysis|Correlative studies
218910002|NCT03541850|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218910003|NCT04709068|DEVICE|Current Health|wearable device and tablet used to collect health measures at home
218910004|NCT06314217|DEVICE|Everads Injector|Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector
218910005|NCT03392896|DRUG|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
218910006|NCT03392896|DRUG|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
218910007|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
218910008|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
218910009|NCT06204679|DRUG|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
218910010|NCT05136976|DRUG|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
218910011|NCT05136976|DRUG|Placebo infusion|2 infusions of placebo at a 2 week interval.
218910012|NCT05136976|DRUG|Premedications|"Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
218910013|NCT04204447|OTHER|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
218910014|NCT04204447|OTHER|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
218910015|NCT04672590|OTHER|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
218959205|NCT03357939|DRUG|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
218959206|NCT03357939|DRUG|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
218959207|NCT03433729|OTHER|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
218959208|NCT01874678|DRUG|TS-1/Cisplatin|
218959209|NCT00430131|PROCEDURE|Cognitive Orientation to Occupational Performance|
218959210|NCT00430131|PROCEDURE|Contemporary Treatment Approach|
218959211|NCT01114230|DRUG|AGS-16M8F|IV
218959212|NCT02735499|DRUG|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
219523503|NCT00274937|RADIATION|Radiation Therapy|Undergo radiotherapy
219523504|NCT02189941|DRUG|Deferiprone sustained-release|Deferiprone sustained-release tablets
218910016|NCT06512961|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
218910017|NCT06512961|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
218910018|NCT06512961|OTHER|Training Protocol|The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
218910019|NCT03859024|DRUG|Oxycodone|oxycodone tablet
218910020|NCT03859024|DRUG|Acetaminophen|acetaminophen tablet
218910021|NCT03859024|DRUG|Gabapentin|gabapentin tablet
218910022|NCT03859024|DRUG|celebrex|Celebrex tablet
218910023|NCT03859024|DRUG|Bupivacaine|bupivacaine injection
218910024|NCT03859024|DRUG|Ibuprofen 800 mg|ibuprofen tablet
219040628|NCT03848845|DRUG|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
219040629|NCT01606046|DEVICE|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
219040630|NCT01606046|DRUG|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
219040631|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
219523505|NCT02189941|DRUG|Deferiprone immediate-release|Deferiprone immediate-release tablets
218910025|NCT03859024|DRUG|Dexamethasone|Dexamethasone injection
218910026|NCT05040659|DEVICE|AROMHA Longitudinal Smell Test|The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
218910027|NCT01489319|DRUG|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
218910028|NCT01489319|DRUG|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
218910029|NCT05871541|BIOLOGICAL|JCXH-105|As IM injection
218910030|NCT05871541|BIOLOGICAL|Active Control (Shingrix)|As IM injection
218910031|NCT04921670|DIAGNOSTIC_TEST|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
218910032|NCT05626101|DRUG|BCG|Intravsical induction and maintenance BCG injections.
218910033|NCT05626101|DRUG|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
218910034|NCT02854072|DRUG|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
218910035|NCT02854072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
218910036|NCT02854072|DRUG|Capecitabine|Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
218910037|NCT04489316|OTHER|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
219040632|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
219040633|NCT00219674|BEHAVIORAL|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
219523506|NCT00538421|DRUG|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
219523507|NCT00538421|DRUG|Sevoflurane|0,7-1,5 MAC
219523508|NCT04526964|BEHAVIORAL|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
219523509|NCT01652079|DRUG|CRLX101|q 14 days
219523510|NCT03002597|DEVICE|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
218910038|NCT03628092|DEVICE|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
219040634|NCT00219674|BEHAVIORAL|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
219040635|NCT00219674|BEHAVIORAL|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
218910039|NCT03628092|DEVICE|Placebo|Sham Device
219523511|NCT00163605|DEVICE|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
219523512|NCT00778505|DRUG|Propofol|closed-loop administration using bispectral index as the controller
219523513|NCT00778505|DRUG|remifentanil|closed-loop administration using bispectral index as the controller
219523514|NCT00778505|DRUG|Propofol|manual administration according bispectral index values
219523515|NCT00778505|DRUG|Remifentanil|manual administration according bispectral index values
219523516|NCT05992805|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
219523517|NCT01381705|BIOLOGICAL|rituximab|
219523518|NCT01381705|GENETIC|DNA analysis|
219523519|NCT01381705|GENETIC|gene expression analysis|
219523520|NCT01381705|GENETIC|polymorphism analysis|
219523521|NCT01381705|OTHER|laboratory biomarker analysis|
219523522|NCT01381705|OTHER|medical chart review|
219523523|NCT05596877|BEHAVIORAL|Music therapy|Performing music therapy during a course of pulmonary rehabilitation (25 mins)
218910040|NCT01706458|BIOLOGICAL|sipuleucel-T|Given IV
218910041|NCT01706458|BIOLOGICAL|DNA Vaccine|Given ID
218910042|NCT05095636|DRUG|Apatinib Mesylate|oral Apatinib once everyday
218910043|NCT05095636|DRUG|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
218910044|NCT01028443|DRUG|Sandimmune|
218910045|NCT01028443|DRUG|Artelose|
218910046|NCT00701454|OTHER|No intervention|No intervention
218910047|NCT01584869|DEVICE|capsule endoscopy|
218910048|NCT03228446|BEHAVIORAL|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
218910049|NCT03228446|BEHAVIORAL|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
218910050|NCT03228446|OTHER|no training (control)|no training applied
218910051|NCT03938311|OTHER|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
218910052|NCT00759590|PROCEDURE|CT scan and Pressure volume curve|CT scan
218910053|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
218910054|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day after transplant
218910055|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
218910056|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
218910057|NCT05500287|OTHER|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
218910058|NCT04538521|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
218910059|NCT00702481|DRUG|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
218910060|NCT00702481|DRUG|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
218910061|NCT00702481|RADIATION|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
218910062|NCT06174246|BEHAVIORAL|Pain self-management program|"Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/"
219523524|NCT03222817|BEHAVIORAL|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
219523525|NCT00445003|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
219523526|NCT00445003|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
219523527|NCT00445003|BEHAVIORAL|Sham injection|Sham injection at baseline and 4 weeks
219523528|NCT00445003|PROCEDURE|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
219523529|NCT01741844|DRUG|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
219523530|NCT05371444|BEHAVIORAL|Training with restriction of the DoF|The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
219523531|NCT05371444|BEHAVIORAL|Training without restriction of the DoF|The intrevention is based in the training of the upper extremity movements without the restriction of DoF
219523532|NCT03672604|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
219523533|NCT02027909|DEVICE|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
219523534|NCT01883271|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
218910063|NCT06174246|BEHAVIORAL|Additional support for self-management program|"This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program."
218910064|NCT00335699|DRUG|Rosuvastatin|
218910065|NCT03101969|OTHER|Call|not called, not reached, and spoken to
218910066|NCT00907426|DRUG|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
219523535|NCT01883271|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
219523536|NCT02410928|DEVICE|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
219523537|NCT02410928|DEVICE|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
219523538|NCT02410928|DEVICE|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
219523539|NCT02923635|PROCEDURE|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
219523540|NCT02923635|PROCEDURE|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
219523541|NCT04280263|DRUG|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
219523542|NCT04280263|DRUG|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
219523543|NCT03981341|DRUG|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
219614018|NCT07095153|BEHAVIORAL|Routine Judo Training|The control group will continue with their usual judo training program, which follows the training plans and technical development programs set by the Turkish Judo Federation for athletes aged 10-18. This program focuses on maintaining and improving existing technical, tactical skills, physical conditioning, and sports culture without any additional neuroathletic training interventions.
219523544|NCT00429234|DRUG|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
219523545|NCT00429234|DRUG|Gemcitabine|Starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
218910067|NCT00907426|DRUG|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
218910068|NCT01533792|PROCEDURE|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
218910069|NCT01533792|PROCEDURE|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
218910070|NCT03547518|DEVICE|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
218910071|NCT03547518|DEVICE|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
218910072|NCT04457739|OTHER|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
218910073|NCT04457739|OTHER|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
219523546|NCT06366906|DIAGNOSTIC_TEST|The Resnet50 deep learning (DL) model|The predictive capability of the above Resnet50 deep learning (DL) model was validated in the test set. Based on the AUC and ACC, the best prediction model was identified. To explore the robust of the selected model, ROC analysis was performed the in the external validation set. Moreover, the Log-rank test was applied to evaluate the prognostic value of the model.
219523547|NCT06412549|BEHAVIORAL|Health care practices and routines|"The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team."
219523548|NCT03236207|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
219523549|NCT03236207|OTHER|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
219523550|NCT01471093|DRUG|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
219523551|NCT01471093|DRUG|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
218910074|NCT04457739|OTHER|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
218910075|NCT02956395|OTHER|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
218910076|NCT04742556|DRUG|BI 3011441|BI 3011441
218910077|NCT02616640|DRUG|Durvalumab|
218910078|NCT02616640|DRUG|Pomalidomide|
218910079|NCT02616640|DRUG|Dexamethasone|
218910080|NCT04601818|PROCEDURE|Experimental: Preserving of Donor Lungs|lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
218910081|NCT03789669|DEVICE|IntraLase iFS femtosecond laser and patient interface|Commercial ophthalmic laser surgical system
218910082|NCT03789669|DEVICE|Cheetah femtosecond laser and cheetah patient interface|Ophthalmic laser surgical system
219523552|NCT04234256|OTHER|Static stretching exercise|Standing quadriceps stretch, Gastrocnemius stretch, Standing split, Adductor stretch, Half kneeling groin stretch, Hamstring stretch on the bench, Prayer squat, Seated adductor and hamstring stretch, Hurdle seat, Seated glute stretch, Lying glute stretch, Seated groin abduction, Soleus stretch, Half kneeling quad stretch, Split hamstring stretch
219614019|NCT07095608|BEHAVIORAL|Pressure and stretch sensitivity testing|"We will measure pressure sensitivity by applying gradual pressure (50 kPa/s) at the site of testing using a digital pressure algometer. In healthy subjects, we will perform these measurements on the lateral tongue on the left and the right side. In cancer patients, we will first test on the unaffected contralateral matched site and then at the site of the cancer. We will define pressure sensitivity as the mean of three threshold measurements.~For measuring stretch sensitivity, we will use a visual analog scale (VAS) recording of pain scores associated with tongue stretching. Participants will be asked to perform tongue range of motions (ROM): protrusion, elevation, right and left lateralization, and rate sensitivity score on the VAS scale after holding the tongue in position for five seconds. We will define stretch sensitivity as the sum of VAS scores for protrusion, elevation, right and left lateralization."
218910083|NCT05757505|DEVICE|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
218910084|NCT05757505|DEVICE|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
218910085|NCT04080635|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
218910086|NCT04080635|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
218910087|NCT03486821|RADIATION|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
218910088|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
218910089|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
218910090|NCT03381521|DEVICE|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
218910091|NCT03381521|DRUG|Normal saline|The normal saline was used for injection solution
219523553|NCT04234256|OTHER|Dynamic stretching exercise|Downward dog to runner's lunge, Dynamic squat stretch, Crescent to hamstring stretch, Half kneeling hamstring stretch, Side to side lunge with reach, Standing calf and hamstring stretch, Hurdles, Side to side lunge with step, IT band stretch, Walking quad stretch, Swing the leg forward and back, Swing the leg cross, Knee pull, Standing quat stretch, Standing gluteus stretch
219523554|NCT00604877|BEHAVIORAL|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
219523555|NCT00604877|BEHAVIORAL|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
219523556|NCT03460951|DIAGNOSTIC_TEST|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
218910092|NCT04982731|OTHER|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
218910093|NCT00003461|PROCEDURE|surgical procedure|
218910094|NCT00003461|RADIATION|astatine At 211 monoclonal antibody 81C6|
218910095|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
218910096|NCT02201524|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
218910097|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
218910098|NCT02201524|OTHER|Placebo|Subjects will receive placebo for 4 weeks
218910099|NCT05175092|PROCEDURE|Living Donor Liver Transplantation|The LDLT will be performed by the UW Division of Transplantation in accordance with the standard of care for this operation.
218910100|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
218910101|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
218910102|NCT04384809|BIOLOGICAL|Leukocyte rich platelet rich plasma|Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon
218910103|NCT04384809|DEVICE|Percutaneous Tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
219523557|NCT02475954|BEHAVIORAL|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
219523558|NCT02475954|OTHER|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
219523559|NCT05778448|DEVICE|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
219614020|NCT07097077|OTHER|Effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI.|The effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI. Differences in brain activation will be assessed between timepoint t0 (after ACL reconstruction surgery and before the start of training) and timepoint t1 (after completion of the training).
219614021|NCT05620082|DIETARY_SUPPLEMENT|Standard liquid-based oral nutritional supplement|An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
218910104|NCT05635344|DRUG|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
218910105|NCT05851118|BEHAVIORAL|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
218910106|NCT04042220|DRUG|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
218910107|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
218910108|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
218910109|NCT01949935|DRUG|Mupirocin|
218910110|NCT00921271|DEVICE|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
218910111|NCT02022137|DIETARY_SUPPLEMENT|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
218910112|NCT02022137|DIETARY_SUPPLEMENT|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
218910113|NCT02022137|DIETARY_SUPPLEMENT|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
218910114|NCT00389948|DRUG|Lanzoprazole|
218910115|NCT05404139|DRUG|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
218910116|NCT05404139|OTHER|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
218910117|NCT05036304|OTHER|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
219523560|NCT04892511|OTHER|Adjusted medication|"In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~* Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~* Patients with TICI 2c-3: systolic blood pressure \<140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered."
219523561|NCT03105830|DRUG|iv paracetamol|iv paracetamol
219523562|NCT04606420|BEHAVIORAL|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds \& nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
219523563|NCT00383656|DRUG|GnRH|75 ng/kg GnRH IV
219523564|NCT00383656|DEVICE|Pump|portable, infusion pump for GnRH
219040636|NCT00219674|BEHAVIORAL|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
219040637|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
219523565|NCT04714307|DIAGNOSTIC_TEST|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
219040638|NCT01262885|DRUG|GSK2251052|500 mg tablet, dose levels detailed in Arm description
219523566|NCT04714307|DIAGNOSTIC_TEST|Cognitive Testing|"Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test"
219523567|NCT04714307|DIAGNOSTIC_TEST|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
219523568|NCT04714307|DIAGNOSTIC_TEST|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
219614022|NCT05620082|DIETARY_SUPPLEMENT|Fortified porridge|Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
219614023|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
219614024|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
219614025|NCT05980078|OTHER|Interactive consent|They were randomized to complete an interactive consent.
219040639|NCT01262885|DRUG|Placebo|matching placebo tablet
219040640|NCT04168177|PROCEDURE|PCA|Patient controlled analgesia
219040641|NCT04168177|PROCEDURE|ESP|erector spinae plane block
219040642|NCT05262634|OTHER|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
219614026|NCT05980078|OTHER|Standard consent|They were randomized to complete a standard written consent.
219040643|NCT04169867|BIOLOGICAL|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
219523569|NCT04714307|DIAGNOSTIC_TEST|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
219614027|NCT04075487|OTHER|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
219523570|NCT04714307|DIAGNOSTIC_TEST|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
219523571|NCT02932878|DRUG|DSXS topical|topical treatment
219523572|NCT03503578|DRUG|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
219523573|NCT03503578|DRUG|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
219523574|NCT03656783|DRUG|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
219523575|NCT05376007|BEHAVIORAL|Serious game 'Broodles'|The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson \& Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
219523576|NCT01974297|DRUG|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
219523577|NCT01974297|DRUG|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
219523578|NCT02337309|DRUG|SF1126|SF1126 in IV form with be given to patients on this study.
219523579|NCT03675828|BEHAVIORAL|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
219523580|NCT01918397|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
219523581|NCT01918397|DRUG|Optimized background regimen (OBR)|"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
219523582|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
219523583|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
219523584|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
219523585|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
219523586|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
219523587|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
219523588|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
219523589|NCT00864097|OTHER|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
219523590|NCT01961973|PROCEDURE|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
219523591|NCT01961973|PROCEDURE|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
219523592|NCT03962673|RADIATION|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
219523593|NCT05194839|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
219523594|NCT05194839|DRUG|Placebo|Matching placebo
219523595|NCT00620022|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219523596|NCT00620022|DRUG|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219523597|NCT02700750|DEVICE|OCT exam|OCT exam
219523598|NCT04135027|OTHER|no interventions|no interventions
219523599|NCT01470482|PROCEDURE|No use of tourniquet|Tourniquet is not applied i 25 pts
219523600|NCT01470482|PROCEDURE|Tourniquet|Use of tourniquet
219523601|NCT05414760|DEVICE|Womed Leaf|Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
218910118|NCT05036304|OTHER|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park)
219040644|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
219040645|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
219040646|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
219040647|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
219040648|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
219040649|NCT02481895|BEHAVIORAL|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
219040650|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
219040651|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
219040652|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
219040653|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
219040654|NCT04679077|OTHER|Cytocam-IDF imaging device|Observation of the microcirculation
219040655|NCT03298828|BIOLOGICAL|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
218910119|NCT05472935|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
218910120|NCT02720393|OTHER|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
219040656|NCT03298828|BIOLOGICAL|CD19 CAR T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
219040657|NCT04210635|OTHER|ZEN cart|essential oils + relaxing music + dim light
219040658|NCT00254995|BIOLOGICAL|None administered in this study|N/A in this study
218910121|NCT02720393|OTHER|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
218910122|NCT02182622|DRUG|Docetaxel|
218910123|NCT02182622|DRUG|Prednisone|
218910124|NCT02182622|DRUG|LDE225|
219040659|NCT01489969|DRUG|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
219040660|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
219040661|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
219040662|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
219040663|NCT00853177|PROCEDURE|MEOPA inhalation|N2O of 50% and 50% O2
219040664|NCT00853177|PROCEDURE|xylocaine|Ampoule-bottle of 20 ml
219040665|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
219040666|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
219040667|NCT06305533|DEVICE|LASER disinfection|In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.
219523602|NCT00233194|PROCEDURE|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
218910125|NCT01261988|DEVICE|VIPER|Comparison of ostomy systems
218910126|NCT01261988|DEVICE|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
219523603|NCT04714294|DRUG|HPP737 or placebo|HPP737 or placebo will be randomized to assign to subjects
219523604|NCT02911662|DRUG|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
219523605|NCT02911662|DRUG|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
219523606|NCT02775565|DEVICE|AngioVac|
219523607|NCT01207986|RADIATION|Low dose computed tomography (CT)|
219523608|NCT00890422|BIOLOGICAL|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
218910127|NCT05103007|PROCEDURE|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
218910128|NCT05103007|PROCEDURE|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
218910129|NCT05894460|DEVICE|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
218910130|NCT06385769|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|The TTNS will be conducted unilaterally, with the patient in a supine position, using a surface electrode dual stimulation channel stimulation device. Two self-adhesive round surface electrodes will be positioned with the negative electrode 2 cm behind the medial malleolus and the positive electrode 10 cm proximal to it. The ground electrode will be placed on the ipsilateral limb. Channel 1 will provide active stimulation, while channel 2 will remain inactive.
218910131|NCT06385769|OTHER|Sham Transcutaneous tibial nerve stimulation (TTNS)|Sham TTNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the TTNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
218910132|NCT02914639|DRUG|SF0166 Topical Ophthalmic Solution|
218910133|NCT01814774|OTHER|No Intervention|No treatment (intervention) was administered.
218910134|NCT04938908|DRUG|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
218910135|NCT04938908|DRUG|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
219040668|NCT06305533|DEVICE|Photodynamic therapy|the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin
219040669|NCT06305533|PROCEDURE|Root surface debridement|For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
219040670|NCT06249282|PROCEDURE|Biopsy|Undergo biopsy
219040671|NCT06249282|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219523609|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
219040672|NCT06249282|DRUG|Carfilzomib|Given IV
219040673|NCT06249282|PROCEDURE|Computed Tomography|Undergo CT
219523610|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
218910136|NCT04938908|DIETARY_SUPPLEMENT|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
219040674|NCT06249282|PROCEDURE|Echocardiography|Undergo ECHO
219040675|NCT06249282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219040676|NCT06249282|DRUG|Sotorasib|Given PO
219523611|NCT05286957|DRUG|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
218910137|NCT04938908|DIETARY_SUPPLEMENT|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
218910138|NCT04668469|DRUG|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
219040677|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
219040678|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
219040679|NCT02403505|BIOLOGICAL|CEA protein antigen plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix"
219040680|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
219040681|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
219523612|NCT03682263|BEHAVIORAL|Full Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
219523613|NCT03682263|BEHAVIORAL|Basic Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
219523614|NCT04463602|DRUG|Desidustat|100 mg once daily
219523615|NCT04463602|OTHER|Standard of Care|Standard of care as per local authority
219523616|NCT01279902|DRUG|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
219523617|NCT05342285|DIAGNOSTIC_TEST|Flow mediated dilation|flow mediated dilation in brachial artery
219523618|NCT06354166|PROCEDURE|Unscheduled hospital admissions|Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
219523619|NCT01428830|PROCEDURE|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
219523620|NCT01428830|PROCEDURE|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
219523621|NCT01516983|DRUG|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
219523622|NCT01516983|RADIATION|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
219523623|NCT02334722|DRUG|Levetiracetam|
219614028|NCT05579782|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
219523624|NCT01118936|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
219523625|NCT01118936|DIETARY_SUPPLEMENT|Placebo|3 tablets of placebo daily for 12 weeks
219523626|NCT00911235|DRUG|Fesoterodine|Single 8 mg oral dose of fesoterodine
219523627|NCT00911235|DRUG|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
219523628|NCT04175366|OTHER|Shared Decision Making|Shared Decision Making including adapted decision aid.
219523629|NCT02305225|BEHAVIORAL|Sleep Deprivation|
219614029|NCT06279715|OTHER|Preimplantation Genetic Testing for Aneuploidy|PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
219040682|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
219040683|NCT00614913|RADIATION|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
219523630|NCT00856388|DRUG|fludarabine phosphate|Given IV
219523631|NCT00856388|DRUG|melphalan|Given IV
219523632|NCT00856388|RADIATION|total-body irradiation|Undergo total-body irradiation
219523633|NCT00856388|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
219523634|NCT00856388|BIOLOGICAL|anti-thymocyte globulin|Given IV
219523635|NCT03527017|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
219523636|NCT03527017|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
219523637|NCT01975064|DRUG|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
219523638|NCT01975064|DRUG|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
219523639|NCT01051193|DRUG|Oxcarbazepine|
219523640|NCT03644147|DRUG|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
219523641|NCT04085107|BEHAVIORAL|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
219614030|NCT06496139|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavioural therapy|The intervention consists of 8 weeks of therapist-guided self-help ICBT.
219614031|NCT04697680|BEHAVIORAL|Algorithm 1|A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
219040684|NCT05225896|GENETIC|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
219040685|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
219523642|NCT05866497|DIAGNOSTIC_TEST|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
219523643|NCT05866497|DIAGNOSTIC_TEST|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
219523644|NCT03661528|DRUG|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
218910139|NCT04668469|DRUG|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
218910140|NCT04668469|BEHAVIORAL|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
218910141|NCT01460108|DEVICE|AeriSeal System|20 mL
218910142|NCT03243851|DRUG|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
218910143|NCT03243851|DRUG|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
218910144|NCT03025425|DEVICE|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
219040686|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
219040687|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
219523645|NCT03661528|DRUG|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
219523646|NCT01880034|OTHER|Lipid Emulsion Survey|
218910145|NCT01018030|DRUG|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
219523647|NCT04403880|OTHER|Sample collection|"* Optional nasal specimen(s)~* Blood collection"
219523648|NCT00643578|DRUG|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
219523649|NCT00643578|DRUG|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
219523650|NCT00643578|DEVICE|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
219523651|NCT03998865|DEVICE|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
218910146|NCT01018030|DRUG|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
218910147|NCT01018030|DRUG|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
218910148|NCT04392323|DIAGNOSTIC_TEST|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
218910149|NCT03701776|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
218910150|NCT03701776|BEHAVIORAL|Balance Training|Standard of care
218910151|NCT01149850|BIOLOGICAL|bevacizumab|Given IV
218910152|NCT01149850|DRUG|temozolomide|Given orally
218910153|NCT01149850|OTHER|laboratory biomarker analysis|Correlative studies
218910154|NCT01149850|OTHER|immunohistochemistry staining method|Correlative studies
218910155|NCT01149850|GENETIC|microarray analysis|Correlative studies
218910156|NCT01149850|GENETIC|DNA methylation analysis|Correlative studies
219040688|NCT01878539|DEVICE|coagulometer|
219040689|NCT01878539|BEHAVIORAL|training programme|
219040690|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
219523652|NCT00281866|DRUG|erlotinib hydrochloride|
219523653|NCT06246474|PROCEDURE|physical therapy program|Arm Description: Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
219523654|NCT01617668|DRUG|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
219523655|NCT01617668|DRUG|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
218910157|NCT04605601|OTHER|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
218910158|NCT04605601|OTHER|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
218910159|NCT02481154|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
219523656|NCT04504396|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
219523657|NCT04504396|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
219523658|NCT01132963|OTHER|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
219523659|NCT01132963|OTHER|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
219523660|NCT02017964|DRUG|Carboplatin|Given IV
219523661|NCT02017964|OTHER|Cognitive Assessment|Optional ancillary studies
219523662|NCT02017964|DRUG|Cyclophosphamide|Given IV
219523663|NCT02017964|DRUG|Etoposide|Given IV
219523664|NCT02017964|OTHER|Laboratory Biomarker Analysis|Correlative studies
219523665|NCT02017964|DRUG|Methotrexate|Given IV
219523666|NCT02017964|DRUG|Vincristine Sulfate|Given IV
219523667|NCT00925769|DRUG|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
219523668|NCT00925769|DRUG|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
219523669|NCT00925769|DRUG|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
219523670|NCT01867723|OTHER|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
219523671|NCT00406913|DRUG|mupirocin ointment|
219523672|NCT00406913|OTHER|SOC sterilization|
219523673|NCT02005536|BIOLOGICAL|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
219523674|NCT03450564|BEHAVIORAL|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
218910160|NCT05397717|OTHER|observational|Observational, without interfering the patient care of treating doctors
218910161|NCT02843724|OTHER|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
218910162|NCT02843724|OTHER|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
219523675|NCT03450564|BEHAVIORAL|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
219523676|NCT03450564|OTHER|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
219523677|NCT00686959|DRUG|Pemetrexed|infusion over 10 minutes
219523678|NCT00686959|DRUG|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
218910163|NCT03617172|DRUG|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
218910164|NCT03617172|OTHER|Placebo|Two capsules twice per day
218910165|NCT01153386|DRUG|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
219523679|NCT00686959|DRUG|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
219523680|NCT00686959|DRUG|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
219523681|NCT00686959|DRUG|Paclitaxel|administered as a 3-hour infusion
219523682|NCT00686959|DRUG|Carboplatin|administered per local practice guidelines over 30 minutes
219523683|NCT00686959|RADIATION|Thoracic Radiation Therapy (TRT)|
219523684|NCT04590300|OTHER|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
219523685|NCT06484933|BEHAVIORAL|Focus groups of health professionals and users of primary care|"2 phases of Focus Group will be organized :~* the participants of the first 4 Focus Groups will propose an operational definition of the notion of a professional team in primary care (validation by consensus based on the definitions in the literature)~* 12 subsequent Focus Groups will be organized in 12 primary care teams to describe the ways in which risks are managed in primary care"
219523686|NCT02303678|DRUG|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
218910166|NCT04277975|OTHER|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
218910167|NCT04277975|OTHER|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
218910168|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
218910169|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
218910170|NCT05993806|DRUG|L04RD1|1 tablet of L04RD1
218910171|NCT05993806|DRUG|L04TD3|1 tablet of L04TD3
218910172|NCT04789707|BEHAVIORAL|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
218910173|NCT01172106|BEHAVIORAL|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
218910174|NCT01172106|BEHAVIORAL|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
218910175|NCT01172106|BEHAVIORAL|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
218910176|NCT06473727|OTHER|Omnichoroma|Patients with anterior non-carious cervical lesions were treated with Omnichoroma. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
218910177|NCT06473727|OTHER|Charisma Topaz One|Patients with anterior non-carious cervical lesions were treated with Charisma Topaz One. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
219523687|NCT00759928|DRUG|Erlotinib|150 mg once daily by mouth
218910178|NCT04205448|BEHAVIORAL|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
218910179|NCT05963334|DRUG|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
218910180|NCT00189540|GENETIC|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
218910181|NCT00189540|GENETIC|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
219614032|NCT04697680|BEHAVIORAL|Algorithm 2|A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
218910182|NCT03826706|DEVICE|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
218910183|NCT03826706|DEVICE|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
219523688|NCT00759928|DRUG|Sorafenib|400 mg twice daily by mouth
219523689|NCT05328804|DRUG|rhTPO|subcutaneous injection
219523690|NCT05328804|DRUG|Herombopag|Orally by mouth
219523691|NCT03202914|BEHAVIORAL|Usual protein and phosphorus diet|Diet intervention
219523692|NCT03202914|BEHAVIORAL|Low protein and phosphorus diet|Diet intervention
219523693|NCT03202914|BEHAVIORAL|Very low protein and phosphorus|Diet intervention
218910184|NCT00004249|BIOLOGICAL|QS21|
218910185|NCT00004249|BIOLOGICAL|keyhole limpet hemocyanin|
218910186|NCT00004249|DRUG|polysialic acid|
218910187|NCT05072158|OTHER|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
218910188|NCT00068068|DRUG|Talaporfin sodium (LS11)|
218910189|NCT00068068|DEVICE|LED-based light infusion device|
219614033|NCT04697680|BEHAVIORAL|Algorithm 3|A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
218910190|NCT00068068|DEVICE|Light emitting diodes (LED)|
218910191|NCT00068068|PROCEDURE|Photodynamic therapy|
218910192|NCT00068068|PROCEDURE|Phototherapy|
218910193|NCT00068068|PROCEDURE|Chemotherapy|
218910194|NCT01089504|DRUG|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
218910195|NCT01089504|DRUG|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
218910196|NCT00062439|DRUG|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes
218910197|NCT00062439|DRUG|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
218910198|NCT00062439|DRUG|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
218910199|NCT00062439|PROCEDURE|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
218910200|NCT00062439|RADIATION|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
219614034|NCT06411652|OTHER|Reflexology|"1. First, the patient's foot will be cleaned with cotton dipped in warm water,~2. In order not to disturb the patient, the hands will be warmed and one or two ccs of baby oil will be used to facilitate the massage.~3. Before applying the main technique, the first two minutes of each session will be spent using the relaxation technique, which involves back and forth movements with the palm of the palm on the outer edge of the foot, from the outer part of the ankle to the little toe, to relieve muscle tension and spasm.~4. Then, alternate pressure will be applied to the reflex points of the right thumb by taking the heel of one foot in the left hand."
218910201|NCT01924845|DRUG|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
218910202|NCT03351842|DRUG|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
218910203|NCT03351842|PROCEDURE|Undergo surgery|Therapeutic conventional surgery, R0 resection
218910204|NCT01994252|DEVICE|Optimal Medical therapy plus ICD|
218910205|NCT01994252|DEVICE|Optimal Medical therapy plus CRT/ICD|
218910206|NCT00380939|DRUG|Atorvastatin|
218910207|NCT00380939|DRUG|Pravastatin|
218910208|NCT01889667|DRUG|ORMD-0801 Dose # 1|Oral Insulin Formulation
218910209|NCT01889667|DRUG|ORMD-0801 Dose # 2|Oral Insulin Formulation
218910210|NCT01889667|DRUG|Placebo|Oil Capsules
218910211|NCT04424537|DIETARY_SUPPLEMENT|Control diet|Meal replacement beverages made with whey protein
218910212|NCT04424537|DIETARY_SUPPLEMENT|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
218910213|NCT04424537|DIETARY_SUPPLEMENT|Low protein diet|meal replacement beverages(MRBs) containing low protein
218910214|NCT00001832|DRUG|gp100:209-217 (210M)|"gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
218910215|NCT00001832|DRUG|Montanide ISA-51|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
218910216|NCT00001832|DRUG|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
218910217|NCT00001832|DRUG|MART-1:26-35(27L)|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
218910218|NCT00001832|BIOLOGICAL|Abl cells|Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
218910219|NCT00001832|DRUG|Fludarabine|5x25 mg/m\^2 intravenous
218910220|NCT00001832|DRUG|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
218910221|NCT00001832|BIOLOGICAL|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.
218910222|NCT00001832|PROCEDURE|Apheresis|
218910223|NCT03828032|PROCEDURE|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
218910224|NCT03828032|PROCEDURE|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
218910225|NCT05856877|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
219040691|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
219040692|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
218910226|NCT05856877|OTHER|Placebo|Single dose of placebo solution as nasal spray
218910227|NCT03382132|BEHAVIORAL|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
218910228|NCT03382132|BEHAVIORAL|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
219040693|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
218910229|NCT04944277|OTHER|ThoughtFullChat Application|A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
218910230|NCT05926817|DEVICE|Placebo-VR headsets|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
218910231|NCT05926817|DEVICE|QTC-VR headsets|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
219040694|NCT04019691|DEVICE|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
219040695|NCT04019691|DEVICE|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
219040696|NCT04019691|DEVICE|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
218910232|NCT00517764|DRUG|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
219523694|NCT06127498|BIOLOGICAL|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
219523695|NCT06127498|OTHER|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
219523696|NCT02625558|DRUG|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
219523697|NCT02625558|DRUG|Placebo|Placebo given three times a day
219523698|NCT06342076|PROCEDURE|Patients undergoing subcostal transversus abdominis plane block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a subcostal transversus abdominis plane block in addition to the posterior transversus abdominis plane block to a group of patients who underwent surgery with a midline incision due to major gynecological cancer.
218910233|NCT04922086|PROCEDURE|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
218910234|NCT04922086|PROCEDURE|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
218910235|NCT01700413|DRUG|Idarubicin|
218910236|NCT02546609|DRUG|Leu-Met-Sil 0.5|NS-0200 low dose
218910237|NCT02546609|DRUG|Leu-Met-Sil 1.0|NS-200 high dose
218910238|NCT02546609|DRUG|Placebo|Placebo
218959213|NCT03513107|OTHER|ospeoporosis score|"* Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass \& Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein \& Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~* Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
218959214|NCT02036554|DRUG|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
218959215|NCT02036554|DRUG|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
218959216|NCT02036554|DRUG|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
218959217|NCT00510965|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
218959218|NCT04479462|PROCEDURE|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
218959219|NCT02128100|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
218959220|NCT02128100|RADIATION|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
218910239|NCT02517931|PROCEDURE|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
218910240|NCT02517931|PROCEDURE|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
218910241|NCT02616510|PROCEDURE|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
218910242|NCT00914849|DRUG|AMD3100|
218910243|NCT00914849|PROCEDURE|Leukopheresis|
219523699|NCT06342076|PROCEDURE|Patients undergoing rectus sheat block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a rectus sheath block in addition to the posterior transversus abdominis plane block to a group of patients who were operated on through a midline incision due to major gynecological cancer.
219523700|NCT00150462|DRUG|Carfilzomib|Administered as an IV bolus dose
219523701|NCT00150462|DRUG|Dexamethasone|Administered orally prior to carfilzomib
219523702|NCT01212874|DRUG|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
219523703|NCT01212874|DRUG|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
219523704|NCT01872546|DRUG|HUMIRA 40mg|
219523705|NCT02166138|PROCEDURE|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
219523706|NCT03589534|DIAGNOSTIC_TEST|home pregnancy test|Each participant will use 4 different home pregnancy tests
219523707|NCT02654912|DRUG|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
219523708|NCT01464866|OTHER|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
219523709|NCT01464866|OTHER|Hospital food|Typical hospital food given daily at meals
218910244|NCT00914849|PROCEDURE|Stem cell transplant|
218959221|NCT04079673|PROCEDURE|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
218959222|NCT04079673|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
218959223|NCT05959005|OTHER|No intervention|There is no intervention.
218959224|NCT04598256|PROCEDURE|Endoscopic procedure|Esophagogastroscopy and colonoscopy
218959225|NCT02635646|OTHER|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
218959226|NCT02635646|OTHER|individual approach|"individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
218959227|NCT01753050|DEVICE|Stroke volume monitoring|Pulse contour stroke volume monitoring
218959228|NCT05404984|OTHER|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
218959229|NCT05404984|OTHER|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
218959230|NCT03240744|BIOLOGICAL|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
218959231|NCT03295565|DRUG|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
218959232|NCT03295565|DRUG|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
218959233|NCT03295565|DRUG|Enzalutamide|Enzalutamide 160mg oral taken daily
218959234|NCT01567228|OTHER|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
218959235|NCT02582177|DRUG|Candicort®|Apply on the affected area and around it twice a day
218959236|NCT02582177|DRUG|Nizoral®|Apply on the affected area and around it twice a day
218959237|NCT02582177|DRUG|Baycuten N®|Apply on the affected area and around it twice a day
218910245|NCT02965911|DRUG|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
218910246|NCT02965911|DRUG|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
218910247|NCT02385929|BEHAVIORAL|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
218910248|NCT00000306|DRUG|Dextroamphetamine|
218910249|NCT03541551|PROCEDURE|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
218910250|NCT03541551|PROCEDURE|Trab Trab|combined trabeculotomy with trabeculectomy
218910251|NCT05106959|BEHAVIORAL|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
218910252|NCT00080158|DRUG|fluoxetine|
218910253|NCT00080158|DRUG|sertraline|
218910254|NCT00080158|DRUG|citalopram|
218910255|NCT00080158|DRUG|escitalopram|
219523710|NCT01444443|DEVICE|Closed-loop control|Blood glucose controlled by algorithm
219523711|NCT01444443|OTHER|Open-loop control|Blood glucose controlled by patient
219523712|NCT00193284|DRUG|Gefitinib|
218910256|NCT00080158|DRUG|bupropion|
219040697|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
219523713|NCT00193284|DRUG|Docetaxel|
219523714|NCT00193284|DRUG|Carboplatin|
219523715|NCT00193284|DRUG|Fluorouracil|
219523716|NCT04564482|RADIATION|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
219523717|NCT04564482|RADIATION|SCPRT|25 Gy in 5 Gy fractions over 5 working days
219523718|NCT04564482|RADIATION|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
219523719|NCT04564482|DIAGNOSTIC_TEST|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
219523720|NCT01220076|DRUG|tamoxifen|
218910257|NCT00080158|DRUG|mirtazapine|
218910258|NCT00080158|DRUG|venlafaxine|
218910259|NCT00080158|DRUG|lithium|
218910260|NCT00080158|BEHAVIORAL|Cognitive Behavioral Therapy|
218910261|NCT01559636|BIOLOGICAL|bivalent oral polio vaccine|vaccine given during immunization campaigns
218910262|NCT03558659|DEVICE|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
218910263|NCT02452736|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
218910264|NCT05274997|DRUG|YY-20394|Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
218910265|NCT04989751|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
218910266|NCT04989751|DIAGNOSTIC_TEST|IDEAL MRI|Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
218910267|NCT01292486|DEVICE|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
219523721|NCT02979015|DRUG|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
218910268|NCT05467059|OTHER|Napping|Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
218910269|NCT05177393|OTHER|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
219040698|NCT02191189|DRUG|Nevirapine suspension|
219040699|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
219040700|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
219523722|NCT02979015|DRUG|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219523723|NCT05948891|DRUG|Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)|observational, prospective, multicentric, international, cohort study
219523724|NCT01196052|DRUG|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
219523725|NCT05313425|OTHER|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
219523726|NCT01908725|DRUG|Lamazym|ERT, i.v. infusions weekly
219523727|NCT02178722|DRUG|MK-3475|IV infusion
219523728|NCT02178722|DRUG|INCB024360|Oral daily dosing
219523729|NCT04225663|BEHAVIORAL|Guided Meditation|Participants will meditate in response to the guidance provided by a trained meditation coach in person.
219523730|NCT02995057|DEVICE|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
218910270|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
218910271|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
218910272|NCT04662021|OTHER|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
218910273|NCT04369404|BEHAVIORAL|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
218910274|NCT04369404|BEHAVIORAL|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
218910275|NCT04369404|BEHAVIORAL|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
218910276|NCT04514887|OTHER|mild intraoperative hyperventilation|Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
218910277|NCT03136887|DEVICE|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
218910278|NCT04367727|DEVICE|Light emitting diode|Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
219365296|NCT04291144|RADIATION|MRI-scan|All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
219365297|NCT04291144|DIAGNOSTIC_TEST|Cognitive assessment|Full neuropsychometric examination including tests in 5 cognitive domains.
219365298|NCT04291144|DIAGNOSTIC_TEST|Clinical assessment|Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
219614035|NCT06411652|OTHER|Therapeutic Touch|"1. The procedure will be explained to the woman,~2. The procedure will be performed in the patient's bed.~3. The practitioner will center by making his body, mind and emotions quiet and focused, prepare himself for the practice and remain centered throughout the intervention,~4. There will be good intentions to help the woman get treatment,~5. In order to scan the energy field, the patient's entire body will be held with the palms of the practitioner's hands facing the patient, it will be moved with a soft movement from"
218910279|NCT05537909|OTHER|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
218910280|NCT01995708|BIOLOGICAL|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
218910281|NCT01995708|OTHER|Standard of care|No vaccines
218910282|NCT05383118|BEHAVIORAL|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors"
218910283|NCT05383118|BEHAVIORAL|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment"
218910284|NCT04309734|DRUG|AT-777|Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
218910285|NCT04309734|DRUG|Placebo|Administered orally, as one or two placebo capsules, depending on the arm.
218959238|NCT02582177|DRUG|Canesten®|Apply on the affected area and around it twice a day
218959239|NCT04065165|DRUG|Telotristat Ethyl|250 mg TID orally
218959240|NCT04065165|DRUG|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
218959241|NCT05677672|BIOLOGICAL|Human TH-SC01 Cell Injection|Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg
218959242|NCT05677672|OTHER|Saline solution|saline solution will be given at the same quantity and following the same schedule
218959243|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
218959244|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
218959245|NCT02442401|DEVICE|The negative pressure wound therapy|
218959246|NCT00233909|DRUG|Zosuquidar|
218959247|NCT00233909|DRUG|gemtuzumab ozogamicin|
218959248|NCT05843773|PROCEDURE|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
218910286|NCT04309734|DRUG|AT-527|Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
218910287|NCT06458283|OTHER|hiybrid simulation|The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.
218910288|NCT06458283|OTHER|control grup|low fidelity simulator
218910289|NCT01553084|DRUG|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
218910290|NCT01553084|DRUG|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
219365299|NCT03472508|DRUG|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
219365300|NCT03472508|DRUG|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
219365301|NCT03472508|DRUG|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
219365302|NCT02119520|DRUG|Platelet rich fibrin +Atorvastatin|
219523731|NCT04247308|OTHER|Sensory Stimulation|Auditory, tactile, visual, vestibular and oro motor stimulation
219523732|NCT04247308|OTHER|Movement therapy|Passive range of movements, antigravity movements in prone and supine
219523733|NCT04247308|OTHER|Routine hospital care|Maintaining the vitals
218910291|NCT01553084|DRUG|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
218910292|NCT01452438|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
218959249|NCT03448874|DEVICE|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
218959250|NCT06000267|PROCEDURE|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
218959251|NCT01932879|OTHER|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
218959252|NCT01932879|OTHER|Jello|
218959253|NCT00021372|DRUG|estramustine phosphate sodium|
218959254|NCT00021372|DRUG|paclitaxel|
218959255|NCT05354674|DRUG|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
218959256|NCT04032574|COMBINATION_PRODUCT|Herbal Medicinal Product|
218959257|NCT04032574|OTHER|Placebo|
218959258|NCT02989987|BEHAVIORAL|Narrative Exposure Therapy|
218959259|NCT02989987|BEHAVIORAL|Social Support|A local counselors provides social support on demand.
218959260|NCT03383705|DEVICE|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
219365303|NCT02119520|DRUG|Platelet rich fibrin|
219365304|NCT02119520|PROCEDURE|open flap debridement|
219365305|NCT01349647|BIOLOGICAL|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
218959261|NCT02398994|DRUG|Intravenous Methylprednisolone|
218959262|NCT02398994|DRUG|Intravenous Immunoglobulin|
218959263|NCT00167869|BEHAVIORAL|dairy peptides|
219365306|NCT01349647|BIOLOGICAL|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
219365307|NCT03486392|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
219365308|NCT03486392|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
219365309|NCT03486392|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
219365310|NCT03486392|DRUG|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
219365311|NCT03486392|DRUG|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
219523734|NCT03553823|PROCEDURE|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
219523735|NCT01572948|DRUG|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
218910293|NCT03988400|BEHAVIORAL|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
218910294|NCT03988400|BEHAVIORAL|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
218910295|NCT00245323|BEHAVIORAL|Smoking status as a routine vital sign|
218910296|NCT04400877|DIAGNOSTIC_TEST|Diagnostic examination for venous thromboembolism|Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
219614036|NCT06580509|DRUG|Tranexamic Acid Injectable Product|Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
219614037|NCT06580509|OTHER|Normal Saline|Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
218910297|NCT02199002|DEVICE|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
218910298|NCT03560297|BEHAVIORAL|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
218910299|NCT03560297|BEHAVIORAL|Delayed Intervention|Participants receive intervention after delay
218910300|NCT05335330|OTHER|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
218910301|NCT03448796|PROCEDURE|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
218910302|NCT03448796|OTHER|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
218910303|NCT03909789|DIETARY_SUPPLEMENT|Plant based bioequivalent Nitrate supplementation|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
218910304|NCT03909789|DIETARY_SUPPLEMENT|Placebo|Placebo
218910305|NCT05682508|OTHER|Education group|"Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable."
218910306|NCT05139680|DRUG|tafamidis|80 or 61 milligrams (mg)
219614038|NCT06242808|BEHAVIORAL|Food resource coaching|Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.
218910307|NCT06184529|BEHAVIORAL|Virtual Reality|The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
218959264|NCT02995369|DEVICE|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
219523736|NCT01572948|DRUG|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
218910308|NCT06510660|DRUG|adebrelimab|The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
218910309|NCT05661149|DEVICE|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
218910310|NCT06369870|DRUG|Levobupivacaine Hydrochloride 0.25 % Injectable Solution|After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
218910311|NCT06369870|DRUG|Sodium chloride 0.9%|Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the intervention description of the IPP-PSP block.
218910312|NCT02344654|DRUG|Indocyanine green|
218910313|NCT02344654|DEVICE|Near-infrared illumination|To see the fluorescence from indocyanine green
219523737|NCT03340727|DRUG|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
219523738|NCT03340727|DRUG|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
218910314|NCT02344654|DRUG|Urografin|
219523739|NCT04043884|OTHER|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
219523740|NCT04043884|OTHER|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
219614039|NCT06242808|OTHER|Free community food support|Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)
219614040|NCT06242808|BEHAVIORAL|Medically tailored groceries|A pantry staff member helps patients select medically tailored groceries (MTG) from the free community food market inventory by prepopulating MTG in their pantry cart.
219614041|NCT04591990|DRUG|Administration of AVP|Administration of AVP
219614042|NCT04591990|DRUG|Administration of placebo AVP|Administration of placebo AVP
218910315|NCT02344654|RADIATION|X-ray|
218910316|NCT04201431|BIOLOGICAL|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
218910317|NCT03941756|DRUG|Indocyanine Green|Given IV
219614043|NCT04591990|DRUG|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
219614044|NCT04591990|DRUG|Administration of hydrocortisone|Administration of hydrocortisone
218910318|NCT03941756|PROCEDURE|Lymphangiography|Undergo lymphangiography
218910319|NCT03941756|PROCEDURE|Lymphovenous Bypass|Undergo LVB
218910320|NCT03538197|OTHER|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
218910321|NCT04899843|DIETARY_SUPPLEMENT|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
218910322|NCT04899843|DIETARY_SUPPLEMENT|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
218910323|NCT03591718|DRUG|BI 456906|Solution for injection
218910324|NCT03591718|DRUG|Placebo|solution for injection
219523741|NCT05687864|DIAGNOSTIC_TEST|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
218910325|NCT01546857|DRUG|Placebo|Normal Saline
218910326|NCT01546857|DRUG|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
218910327|NCT06289933|DRUG|BR3005|One tablet administered alone, Once a day
218910328|NCT06289933|DRUG|BR3005-1|One tablet administered alone, Once a day
218910329|NCT06289933|DRUG|BR3005-2|One tablet administered alone, Once a day
219040701|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
219523742|NCT02598479|OTHER|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
219523743|NCT04901221|DEVICE|Extrusion arch|one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
219614045|NCT02363335|OTHER|Placebo|mixed meal
219614046|NCT02363335|OTHER|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
219040702|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
219040703|NCT05905588|DIETARY_SUPPLEMENT|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
219040704|NCT05905588|DIETARY_SUPPLEMENT|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
219040705|NCT02299050|DRUG|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
219040706|NCT02619409|DRUG|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
219040707|NCT02619409|DRUG|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
219523744|NCT03733509|PROCEDURE|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
219523745|NCT03733509|PROCEDURE|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
219523746|NCT03733509|PROCEDURE|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
219523747|NCT03733509|PROCEDURE|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
219523748|NCT02183688|DRUG|Low dose ASA|
219523749|NCT02183688|DRUG|High dose ASA|
219523750|NCT02183688|DRUG|Low dose paracetamol|
219523751|NCT02183688|DRUG|High dose paracetamol|
219523752|NCT02183688|DRUG|Caffeine|
219523753|NCT02183688|DRUG|Placebo|
219040708|NCT02619409|DRUG|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
219040709|NCT02619409|DRUG|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
219040710|NCT02619409|DRUG|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
219040711|NCT00004881|BIOLOGICAL|MVA-MUC1-IL2 vaccine|
219365312|NCT04320524|DEVICE|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
219365313|NCT00923117|DRUG|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
219365314|NCT01560273|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
219365315|NCT01028625|BEHAVIORAL|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
219365316|NCT01028625|OTHER|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
219365317|NCT00024427|DRUG|fluorouracil|High dose 5-FU
219365318|NCT00024427|DRUG|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
219365319|NCT00024427|DRUG|triacetyluridine|6 grams (12 tablets)
219614047|NCT02363335|OTHER|Sitagliptin|This is already known to increase GLP-1 \&amp; GIP secretion.
219614048|NCT02363335|OTHER|Roflumilast|This is already known to increase GLP-1 \&amp; GIP secretion
219614049|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
219614050|NCT05344443|DRUG|Lemborexant|A dual orexin antagonist
219614051|NCT05344443|DRUG|Placebo|A placebo that looks and tastes like Lemborexant tablets
219614060|NCT06109493|BEHAVIORAL|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
219614061|NCT05505565|DEVICE|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
218910330|NCT06322563|DRUG|LTC004+regorafenib|LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
218910331|NCT00866424|PROCEDURE|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
218910332|NCT02987231|PROCEDURE|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
218910333|NCT02987231|DEVICE|ES|Local electric stimulation for 120 seconds, once a day for a week
218910334|NCT02987231|DEVICE|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
218910335|NCT01813396|OTHER|joint mobilization plus massage|
218910336|NCT01813396|OTHER|joint mobilization/shoulder physical activity guide|
218910337|NCT00435916|DRUG|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
218910338|NCT04773951|BIOLOGICAL|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
218910339|NCT04818658|OTHER|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
218910340|NCT00317473|BIOLOGICAL|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
218910341|NCT00317473|BIOLOGICAL|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
218910342|NCT05129748|DRUG|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
218910343|NCT03416868|BEHAVIORAL|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
218910344|NCT01486875|DRUG|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
218910345|NCT00357630|DRUG|gemcitabine hydrochloride|
218910346|NCT00357630|PROCEDURE|quality-of-life assessment|
219040712|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
219365320|NCT00355316|OTHER|Blood draw|
219365321|NCT06301178|DRUG|Cholecalciferol|Vitamin D has various critical regulatory roles, including inflammatory control, cellular proliferation and differentiation, and wound healing regulation.
218910347|NCT03178214|DRUG|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
218910348|NCT03883256|DEVICE|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
218910349|NCT03883256|DEVICE|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
218959265|NCT02995369|OTHER|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
219365322|NCT00703313|DRUG|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
219365323|NCT00703313|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
219365324|NCT00703313|DRUG|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
219365325|NCT02606994|DRUG|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
219365326|NCT02606994|DRUG|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
219365327|NCT02606994|DRUG|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
219365328|NCT05797714|DRUG|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 144 weeks
218910350|NCT02854085|BEHAVIORAL|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
218910351|NCT02854085|BEHAVIORAL|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
218910352|NCT05435339|BIOLOGICAL|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
218910353|NCT00988832|BIOLOGICAL|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
218910354|NCT04055064|DIETARY_SUPPLEMENT|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
218910355|NCT01283555|DRUG|Tenofovir|Delivered using prefilled and user-filled applicator
218910356|NCT03104881|DEVICE|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
219523754|NCT03737578|OTHER|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
219523755|NCT05137483|OTHER|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
219523756|NCT03643328|BIOLOGICAL|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
219523757|NCT03643328|BIOLOGICAL|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
219523758|NCT04999709|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
219523759|NCT06484647|PROCEDURE|Percutaneous Coronary Intervention|"Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique."
219523760|NCT03563105|DEVICE|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
219614062|NCT05505565|OTHER|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
219614063|NCT04569318|DEVICE|Treatment Beam|One of the subject's eyes will be treated with the treatment beam (20mW) up to 8 times for 15 minutes.
218910357|NCT03104881|DEVICE|2D end-effector type robot|2 dimension end-effector type upper extremity robot
218910358|NCT04468646|DRUG|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
218910359|NCT06406764|OTHER|Plyometric training|Participants undergo a plyometric training program. The plyometric training consists of exercises in the horizontal, lateral, and vertical directions of movement. Exercises are progressively focused on maximal performance with short ground contact (\<250 ms). The training sessions are twice per week.
218910360|NCT06406764|OTHER|Control training|Participants continues their regular sports activities without additional plyometric training. The training sessions are twice per week.
218910361|NCT06221995|DIAGNOSTIC_TEST|Indirect Calorimetry|Resting energy expenditure measurement
218910362|NCT04983017|DIETARY_SUPPLEMENT|Dietary supplement|iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
218910363|NCT04983017|OTHER|Placebo|Matched Placebo to Intervention
219523761|NCT00721305|DRUG|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
219523762|NCT00721305|OTHER|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
219523763|NCT03601962|DIETARY_SUPPLEMENT|Aqualief|400mg oral mucoadesive tablets
219523764|NCT03601962|OTHER|Placebo|400mg Placebo oral mucoadesive tablets
219523765|NCT06383962|DEVICE|Synergy cervical spine disc replacement|motion preservation disc
219523766|NCT01388465|BEHAVIORAL|Mobile phone text messaging|Daily assessment followed by feedback
219523767|NCT01941966|DRUG|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
219614064|NCT06393868|DRUG|Omeprazole 20 mg Oral Tablet|Omeprazole once daily for 90 days
219614065|NCT06393868|OTHER|Placebo|Placebo once daily for 90 days
219614066|NCT04932993|BEHAVIORAL|Writing down goals|Patient will write their health goals down before the visit.
218910364|NCT04217382|OTHER|patient with melanoma pre transplantation|survival time without melanoma recurrence
218910365|NCT03140514|DRUG|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
218910366|NCT04924816|PROCEDURE|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
218910367|NCT01548547|OTHER|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
218910368|NCT02681198|DRUG|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
218910369|NCT02681198|DRUG|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
218910370|NCT04896996|DIETARY_SUPPLEMENT|whole eggs|whole eggs
218910371|NCT04896996|DIETARY_SUPPLEMENT|yolk-free egg substitutes|yolk-free egg substitutes
218910372|NCT00416208|DRUG|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
218910373|NCT03467347|DRUG|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
218910374|NCT04068701|OTHER|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
218910375|NCT02172963|BIOLOGICAL|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
218910376|NCT04960449|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
218910377|NCT05009875|OTHER|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
218910378|NCT05009875|OTHER|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
218910379|NCT00507013|DEVICE|QuickClose device|
218910380|NCT02864589|BEHAVIORAL|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
218910381|NCT02864589|BEHAVIORAL|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
218910382|NCT03315741|DRUG|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
219523768|NCT01941966|DRUG|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
218910383|NCT06400017|DEVICE|microelectrode stimulation of DBS|"Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour"
218910384|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
218910385|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
218910386|NCT02552914|DEVICE|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
219040713|NCT03696524|DEVICE|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
219040714|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
218910387|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
218910388|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
218910389|NCT03991845|DRUG|Vit D|Vit D supplementation was done
218910390|NCT00872235|DRUG|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
219523769|NCT01941966|RADIATION|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
219523770|NCT03820466|DRUG|Aspirin|Once daily application of platelet inhibiting medication
219523771|NCT03820466|DRUG|Atorvastatin|Once daily application of lipid lowering medication
219523772|NCT03820466|DRUG|Placebo Aspirin|Once daily application of placebo
219523773|NCT03820466|DRUG|Placebo Atorvastatin|Once daily application of placebo
218910391|NCT01927497|PROCEDURE|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
219523774|NCT05354648|PROCEDURE|Hypoxic-hyperoxic preconditioning|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
219523775|NCT05354648|PROCEDURE|Placebo|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
219523776|NCT00716248|DRUG|bucillamine|bucillamine 100 mg, twice a day
219523777|NCT00716248|DRUG|methotrexate|methotrexate 6 mg or more per week
218910392|NCT01927497|PROCEDURE|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
218910393|NCT04859088|DIETARY_SUPPLEMENT|Partial Enteral Nutrition|Dietary intervention (Liquid food replacement intervention)
218910394|NCT04871841|BIOLOGICAL|Sputnik V|Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
218910395|NCT03052790|PROCEDURE|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
219040715|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
219040716|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
219040717|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
219040718|NCT04322396|DRUG|Azithromycin|Azithromycin
219040719|NCT04322396|DRUG|Hydroxychloroquine|Hydroxychloroquine
219614067|NCT04825834|OTHER|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.
219040720|NCT04322396|DRUG|Placebo oral tablet|Placebo Azithromycin
219040721|NCT04322396|DRUG|Placebo oral tablet|Placebo Hydroxychloroquine
219523778|NCT01926548|DRUG|CJ Imatinib mesylate tablet|
219523779|NCT01926548|DRUG|Gleevec film-coated tablet 2 x 100mg|
219523780|NCT05061290|OTHER|Control Porridge|Maize porridge containing 54Fe as iron sulfate
219523781|NCT05061290|OTHER|Reference Porridge A|Maize porridge counting 58Fe as iron sulfate with ascorbic acid
219523782|NCT05061290|OTHER|Test Porridge B|Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
219523783|NCT05061290|OTHER|Test Porridge C|Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
219523784|NCT05061290|OTHER|Test Porridge D|Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
219523785|NCT02491346|PROCEDURE|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
219614068|NCT03183609|OTHER|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
219614069|NCT03183609|OTHER|Rice Flour in Protein Shake|15 Grams Rice Flour BID
219614070|NCT06636175|DRUG|64Cu-LLP2A|64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
219614071|NCT06636175|DEVICE|PET/CT|The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
219614072|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
219523786|NCT02491346|PROCEDURE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
219523787|NCT06318702|OTHER|Education|is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
219523788|NCT00968552|PROCEDURE|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
219523789|NCT05000619|BEHAVIORAL|Outreach mailer|Postcard or letter
219523790|NCT05000619|BEHAVIORAL|Humor/Salience|Funny cartoon
219523791|NCT05000619|BEHAVIORAL|Doctor's authority|Letter from a doctor
219523792|NCT05000619|BEHAVIORAL|Information|Information about benefits of the appointment
219523793|NCT00516880|DRUG|rosiglitazone|
218910396|NCT03052790|DEVICE|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
218910397|NCT06265181|BEHAVIORAL|Diabetes coaching|Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.
218910398|NCT03914417|DRUG|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
218910399|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
218910400|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
218910401|NCT04918706|GENETIC|Allogeneic MSC|These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
218910402|NCT04918706|DRUG|Placebo|The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
218910403|NCT00210574|DRUG|topiramate|
218910404|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D|
218910405|NCT01121796|OTHER|Water or milk|
218910406|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D enriched milk|
218910407|NCT02111421|DRUG|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
218910408|NCT02111421|DRUG|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
218910409|NCT05408377|OTHER|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
218910410|NCT05408377|OTHER|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
218910411|NCT06378775|PROCEDURE|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
218910412|NCT06378775|PROCEDURE|Robotically-assisted minimally-invasive direct coronary artery bypass|Robotically-assisted minimally-invasive direct coronary artery bypass
218910413|NCT06378775|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
219040722|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
219040723|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
219040724|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
219523794|NCT01829308|BEHAVIORAL|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
219040725|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
219365329|NCT04088448|DRUG|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
219365330|NCT04088448|DRUG|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
219365331|NCT04420364|OTHER|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
219365332|NCT06460571|OTHER|Standard Cardiac rehabilitation with Delorme technique|Aerobic training will be provided three alternate days a week at 60-70% of maximum heart rate for eight weeks. Resistance training for 3 sets and 10 repetitions (10 lifts with 50%of 10RM, then 75% of 10RM and will progress to 100% of 10RM) will involve seven exercises (abdominal curl ups, bicep curls, triceps extension, back extension, leg curls, side leg raises and knee extensions).
219523795|NCT01829308|BEHAVIORAL|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
218910414|NCT00310765|DRUG|Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
218910415|NCT00310765|DRUG|Placebo first followed by open label pregabalin|Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
218910416|NCT04247217|RADIATION|HDR salvage brachytherapy|In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.
218910417|NCT00328939|DRUG|ARIXTRA infusion|
218910418|NCT00328939|DRUG|Enoxaparine infusion|
218910419|NCT01239849|DRUG|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100\~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130\~159 mg/dl is 20 mg, 160\~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol"
218910420|NCT00271674|DEVICE|Q-switched YAG laser|
218910421|NCT05666323|BEHAVIORAL|Single Text Messaging (TM1)|Receives single text message
218910422|NCT05666323|BEHAVIORAL|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
218910423|NCT05666323|BEHAVIORAL|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
218910424|NCT05569434|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
218910425|NCT03361137|DRUG|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
218910426|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
218910427|NCT03626727|DRUG|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
218910428|NCT00149968|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
218910429|NCT03201068|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement capsule
218910430|NCT03201068|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
218910431|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
218910432|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
218910433|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
219523796|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
219523797|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
219523798|NCT04407962|BEHAVIORAL|SMS group|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
218910434|NCT03009058|BIOLOGICAL|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
218910435|NCT03009058|DRUG|Gemcitabine|Standard of Care chemotherapy
218910436|NCT03009058|DRUG|Nab-paclitaxel|Standard of Care chemotherapy
219523799|NCT03232008|DIETARY_SUPPLEMENT|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
219523800|NCT03232008|DIETARY_SUPPLEMENT|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
218910437|NCT03009058|DRUG|Capecitabine|Standard of Care chemotherapy
218910438|NCT03009058|DRUG|Folinic Acid|Standard of Care chemotherapy
218910439|NCT03009058|DRUG|Fluorouracil|Standard of Care chemotherapy
218910440|NCT03009058|DRUG|Irinotecan|Standard of Care chemotherapy
218910441|NCT03009058|DRUG|Oxaliplatin|Standard of Care chemotherapy
218910442|NCT03009058|BIOLOGICAL|cetuximab|Standard of Care immunotherapy
218910443|NCT03009058|BIOLOGICAL|Anti-PD1|Standard of Care immunotherapy
218910444|NCT03009058|BIOLOGICAL|Ipilimumab|Standard of Care immunotherapy
218910445|NCT03009058|DRUG|Cyclophosphamide|Standard of Care chemotherapy
218910446|NCT03401775|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
218910447|NCT02936817|DEVICE|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
218910448|NCT02936817|RADIATION|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
218910449|NCT02956694|BEHAVIORAL|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
218910450|NCT04990258|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.
218910451|NCT05656534|DRUG|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
218910452|NCT05656534|OTHER|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
218910453|NCT02103309|DEVICE|Nelfilcon A contact lenses|
218910454|NCT02103309|DEVICE|Etafilcon A contact lenses|
218910455|NCT02798393|OTHER|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
219040726|NCT00748644|DRUG|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
218910456|NCT02798393|OTHER|Sham|
218910457|NCT02168868|DIAGNOSTIC_TEST|Blood draw|A blood sample (5 mL) will be collected.
218910458|NCT02168868|DIAGNOSTIC_TEST|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
218910459|NCT02168868|DIAGNOSTIC_TEST|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
218910460|NCT00711698|PROCEDURE|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
218910461|NCT00711698|DRUG|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
218910462|NCT05139472|DRUG|Empagliflozin 10 MG|Daily Empagliflozin
218910463|NCT05420935|DIAGNOSTIC_TEST|IgG group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml"
218910464|NCT05420935|DIAGNOSTIC_TEST|IgE group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling"
218910465|NCT05420935|DIAGNOSTIC_TEST|IgG group + IgE group|"* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling"
218910466|NCT04818619|DIAGNOSTIC_TEST|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
219040727|NCT00748644|DRUG|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
218910467|NCT03479229|DEVICE|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm\^2
218910468|NCT03479229|DEVICE|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
218910469|NCT00821808|DEVICE|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
218910470|NCT00821808|DEVICE|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
218910471|NCT03469063|DIETARY_SUPPLEMENT|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
218910472|NCT05549817|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
218910473|NCT05549817|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
218910474|NCT03240887|BEHAVIORAL|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
218910475|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
218910476|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
218910477|NCT00426920|DRUG|Insulin|
218910478|NCT01486966|DRUG|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
218910479|NCT01486966|DRUG|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
218910480|NCT01486966|DRUG|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
218910481|NCT01486966|DRUG|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
218910482|NCT01486966|DRUG|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
218910483|NCT04084171|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
218910484|NCT06593132|PROCEDURE|endoscopic breast conserving surgery|Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.
218910485|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
218910486|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
218910487|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
218910488|NCT06199713|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography|research scan 3-4 weeks after start of immunotherapy
218910489|NCT06925243|DRUG|Neoadjuvant apatinib combined with sintilimab and perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid) Apatinib: 250mg, po, day1-21, for 3 cycles preoperatively
219365333|NCT06460571|OTHER|standard cardiac rehabilitation|The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique. The control group will not perform any specific training but will be given a diet chart to follow
219365334|NCT01440335|DRUG|Oral R,R'-Fenoterol|
218910490|NCT06925243|DRUG|Neoadjuvant sintilimab combined with perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)
218910491|NCT06757075|DRUG|Ibuprofen|10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery
218910492|NCT06757075|DRUG|Acetominophen|15 mg/kg/dose of acetominophen will be given every 6 hours for 24 hours post surgery
218910493|NCT06926790|DRUG|Nivolumab & Ipilimumab|This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.
218910494|NCT05376384|DIAGNOSTIC_TEST|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
218910495|NCT05376384|PROCEDURE|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
218910496|NCT04785495|OTHER|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
218910497|NCT06350786|OTHER|P-Dragees blue Lichtenstein, Placebo dragees|"In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points:~1. Opioids work by telling the body that participants are not experiencing as much pain;~2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies);~3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid;~4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids."
218910498|NCT06350786|OTHER|Control group (EM)|"In the EM control group, the focus lies on the electronic monitoring (EM) of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points:~1. The collection of EM data allows for greater patients' sense of agency over medication treatment;~2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies);~3. The EM is a useful tool, and daily recording of opioid medication intake should be done;~4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids."
218910499|NCT06932848|DRUG|Curcumin in Nanogels|Participants will apply curcumin nanogels to affected oral areas three times daily for 4 weeks.
218910500|NCT06932848|DRUG|0.1% Fluocinolone Acetonide Oral Paste|Participants will apply 0.1% fluocinolone acetonide oral paste to the affected oral mucosa three times daily for 4 weeks. This corticosteroid paste is the standard treatment for oral lichen planus.
218910501|NCT06937723|OTHER|Device: Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
218910502|NCT06938555|BEHAVIORAL|Prolonged Nightly Fasting|At the start of the intervention (week 1) PNF participants will be asked to engage in fasting (14 hours a night, starting no later than 8pm) six nights a week (for the 8-week study duration). Participants will be asked to track their fasting start/stop times on a tracking sheet provided by study staff. During the nightly fast, participants will be allowed to drink water, coffee or tea (without dairy or sweeteners). Study staff will meet with participants via phone for weekly check-in calls (\~10-15 mins) to collect weekly fasting start/stop dates/times (entered into REDCap); alternately, participants may elect to email or text their fasting start/stop date/times to the study staff.
218910503|NCT06938555|BEHAVIORAL|Health Education Videos|Provision of HED is a retention strategy and can influence outcomes. Thus, all participants will receive HED. Each week, participants will receive hyperlinks to videos focused on health educational content unrelated to fasting, diet and outcome measures. Participants will be asked to view the videos (\~10-15 min) prior to their weekly check-in calls with the study staff (\~5-10 mins for HED-Only Control group). They will receive each week's videos on a Monday, and receive a reminder to view on Friday. Study staff will follow a scripted HED weekly check-in call to ensure consistency of data collected. Weekly topics are as follows: W1: Internet safety, W2: Sun safety, W3: Home safety, W4: Driving safety, W5: Hydration, W6: Dental health, W7: Working environment, W8: Communication. Data collected on electronic forms during all participant/staff check-in calls will be stored in participant-specific ASU Dropbox files.
218910504|NCT06939127|DRUG|Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy|"Eligible patients will start the study treatment (7-14 days between pathological diagnosis and cryoablation). Patients first undergo cryoablation of the primary tumor. Then, 7±3 days after cryoablation, they start treatment with tislelizumab (200 mg) plus platinum-based doublet chemotherapy, given every 3 weeks for 3-4 cycles.~The following platinum-based doublet chemotherapy regimens are allowed in this trial:~* Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)~* Cisplatin/carboplatin + albumin-bound paclitaxel/paclitaxel (squamous NSCLC)"
218910505|NCT06939127|PROCEDURE|Surgery|After completing neoadjuvant therapy, surgery should be performed as soon as possible within 4-6 weeks after the last dose of neoadjuvant therapy.
219040728|NCT00052845|DRUG|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
219040729|NCT00052845|DRUG|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
219040730|NCT00052845|DRUG|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
219060606|NCT01418209|DRUG|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
219614073|NCT05792189|OTHER|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
218910506|NCT06939127|DRUG|Adjuvant tislelizumab|"Patients receiving adjuvant therapy must meet the following criteria:~* ECOG performance status score of 0 or 1~* Recovery from surgery and adequate organ function as determined by the investigator based on laboratory values During the adjuvant phase, patients will receive tislelizumab as adjuvant therapy. The first dose of tislelizumab (cycle 1 of the adjuvant phase) should be administered within 2-8 weeks after surgery. Patients will continue to receive tislelizumab (400 mg, Q6W) as adjuvant therapy every 6 weeks until one of the following events occurs: completion of 8 cycles of tislelizumab adjuvant therapy, disease recurrence, unacceptable adverse events (AEs), death, or decision by the patient and/or investigator to discontinue study treatment."
218910507|NCT03906539|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg per day
218910508|NCT03906539|DIETARY_SUPPLEMENT|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
218910509|NCT03906539|OTHER|Placebo|Placebo capsule - 1 capsule per day
218910510|NCT05981469|DEVICE|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
218910511|NCT05981469|OTHER|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
218910512|NCT00211328|DRUG|anecortave acetate|
218910513|NCT02631980|DRUG|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
218910514|NCT02631980|DRUG|IV placebo|Intravenous 0.9% saline (250 ml)
218910515|NCT05016479|DEVICE|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
218910516|NCT00263094|DRUG|Rofecoxib|
218910517|NCT02363920|DEVICE|HOF|the addition of high oxygen flow to patients breathing spontaneously
218910518|NCT02363920|DEVICE|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
218910519|NCT01929421|DRUG|Gemcitabine/S-1|
218910520|NCT04450238|BEHAVIORAL|Routine care inpatient treatment|All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
218910521|NCT04230889|OTHER|Usual Diet Group|three main meals and two snacks
218910522|NCT04230889|OTHER|Group 1 Nutritional Shake|2 servings per day
218910523|NCT04230889|OTHER|Group 2 Nutritional Shake|2 servings per day
219614074|NCT05792189|OTHER|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
218910524|NCT02273479|DRUG|Asasantin®|Asasantin® extended release (RAD-SP)
218910525|NCT02273479|DRUG|Placebo|
218910526|NCT00281463|DEVICE|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
218910527|NCT02632799|DEVICE|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
218910528|NCT02632799|DEVICE|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
219365335|NCT01440335|DRUG|Oral Racemic Fenoterol|
218910529|NCT02632799|DEVICE|CPAP|Nsal CPAP 5cm H2o by face mask
218910530|NCT04530617|DRUG|Camostat Mesilate|Tablets
218910531|NCT04530617|DRUG|Artemisia Annua Leaf|Tea bags
218910532|NCT02356276|PROCEDURE|D2 lymphadenectomy|
218910533|NCT02356276|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.
218910534|NCT02356276|DRUG|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
218910535|NCT02249663|DRUG|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
219365336|NCT00806104|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
219365337|NCT00806104|DIETARY_SUPPLEMENT|Maltodextrins|Dietary supplementation for 4 weeks
219365338|NCT02803957|DEVICE|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
219365339|NCT02803957|DEVICE|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
219365340|NCT04719351|BEHAVIORAL|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
218910536|NCT02249663|DRUG|Dymista™|137/50 mcg Nasal Spray
218910537|NCT02249663|OTHER|Placebo|Nasal spray with no pharmaceutically active content
218910538|NCT01361230|DEVICE|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
218910539|NCT03693703|DIAGNOSTIC_TEST|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
218910540|NCT03693703|DIAGNOSTIC_TEST|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
218910541|NCT05471271|OTHER|[18F]AlF-RESCA-IL2 PET scan|Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment
218910542|NCT01557153|DRUG|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
218910543|NCT01557153|DRUG|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
218910544|NCT06131632|PROCEDURE|Breast conserving surgery|Remove only a small part of the breast
218910545|NCT06131632|PROCEDURE|Radical modified mastectomy|Remove all the breast parenchyma, nipple and skin
218910546|NCT00414635|DRUG|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
218910547|NCT00991861|DRUG|LAS41007 o.d.|Once daily, topical application
218910548|NCT00991861|DRUG|LAS41007 b.i.d.|Twice daily, topical application
219614075|NCT05792189|OTHER|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
218910549|NCT00991861|DRUG|LAS106521|Twice daily, topical application
218910550|NCT05243823|DRUG|Vagifem®|According to local clinical practice - independent of inclusion in this study
218910551|NCT05243823|DRUG|Non-Vagifem® LDVE, Estradiol|According to local clinical practice - independent of inclusion in this study
218910552|NCT01841281|DRUG|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
218910553|NCT01841281|DRUG|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
218910554|NCT05440097|OTHER|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
218910555|NCT00631514|DRUG|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
218910556|NCT00631514|DRUG|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
218910557|NCT00631514|DRUG|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
218910558|NCT00431990|DRUG|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
218910559|NCT00431990|DRUG|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
218910560|NCT00431990|DRUG|dexamethasone|20mg for 2 days with each dose of bortezomib
219040731|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
219614076|NCT05792189|OTHER|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
219040732|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
219365341|NCT00686816|DIETARY_SUPPLEMENT|Low calorie diet|low calorie diet
219365342|NCT00686816|DIETARY_SUPPLEMENT|Olestra|low calorie Olestra diet
218910561|NCT05296226|PROCEDURE|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
218910562|NCT01572597|DRUG|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
218910563|NCT01572597|DRUG|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
218910564|NCT03282656|BIOLOGICAL|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
218910565|NCT02891174|DRUG|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
218910566|NCT02891174|DRUG|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
218910567|NCT04649541|DRUG|MRX-8|novel semi-synthetic polymyxin B analog.
218910568|NCT04649541|DRUG|Placebo|5% dextrose in water
218910569|NCT04785443|DRUG|ICG|"During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months."
218910570|NCT04785443|PROCEDURE|Control group|"During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months."
218910571|NCT04124939|DRUG|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
218910572|NCT03732339|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
218910573|NCT06211920|OTHER|Non-invasive ventilation|The application of NIV will be performed using af a facemask as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.
218910574|NCT03512821|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
218910575|NCT03512821|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
219523801|NCT01720264|DRUG|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
218910576|NCT04427319|DIETARY_SUPPLEMENT|β-alanine|7 days of consumption
218910577|NCT04427319|DIETARY_SUPPLEMENT|wheat semolina|7 days of consumption
218910578|NCT05719103|BEHAVIORAL|With and Without Awake Prone Positioning|"1. HFNC flow at 60 L/min or maximum tolerable flow at supine position~2. HFNC flow at 60 L/min or maximum tolerable flow at prone position~3. CPAP with full face mask at 10 cmH2O at supine position~4. CPAP with full face mask at 10 cmH2O at prone position~5. MC at supine position~6. MC at prone position"
218910579|NCT04235140|DRUG|LUM/IVA|LUM/IVA granules for oral administration
218910580|NCT04404426|DIETARY_SUPPLEMENT|L-citrulline|Administration of citrulline enterally for 7 days.
218910581|NCT04404426|OTHER|Placebo|Administration of placebo (water) enterally for 7 days
219523802|NCT04738084|BEHAVIORAL|Meru Health Program|Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
218910582|NCT06201260|OTHER|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
218910583|NCT06201260|OTHER|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
218910584|NCT06107777|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
218910585|NCT06107777|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
218910586|NCT01517932|DRUG|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
219523803|NCT01980732|DRUG|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
219523804|NCT00877032|BIOLOGICAL|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
218910587|NCT01517932|DRUG|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
218910588|NCT00375271|PROCEDURE|perioperative hemodynamic optimization protocol|
219614077|NCT05530486|DEVICE|CC|Application of placebo LASER
219614078|NCT05530486|DEVICE|LG1|Application of LASER GasAs 660nm 4 J/cm².
218910589|NCT00434681|DRUG|paracetamol 4.8% paediatric oral suspension|
218910590|NCT00945958|DRUG|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
218910591|NCT06223711|RADIATION|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
218910592|NCT06223711|DRUG|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
218910593|NCT06223711|RADIATION|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
218910594|NCT06223711|DRUG|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
218910595|NCT03531489|DEVICE|AIR-AD|Non-significant risk medical device as decided by institutional review board
218910596|NCT01865266|DRUG|Ulinaststin for injection|
218910597|NCT01865266|DRUG|placebo|
218910598|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
218910599|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
218910600|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
218910601|NCT00003343|DRUG|endocrine-modulating drug therapy|
219614079|NCT05530486|DEVICE|LG2|Application of LASER GasAs 660nm 8 J/cm².
218910602|NCT00003343|DRUG|mitoxantrone hydrochloride|
218910603|NCT00003343|DRUG|prednisone|
218910604|NCT00003343|DRUG|prinomastat|
218910605|NCT03600272|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
218910606|NCT03600272|PROCEDURE|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
218910607|NCT04864756|OTHER|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
218910608|NCT01836588|PROCEDURE|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
218910609|NCT02102035|PROCEDURE|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
219523805|NCT00877032|BIOLOGICAL|Placebo|intravenous, single dose with experimental dose.
219523806|NCT00306371|DEVICE|1450nm diode laser|
218910610|NCT01192997|BIOLOGICAL|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
218910611|NCT01192997|BIOLOGICAL|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
218910612|NCT02152891|BEHAVIORAL|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
218910613|NCT05260671|DRUG|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
219523807|NCT00924326|DRUG|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
218910614|NCT04052490|OTHER|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
218910615|NCT05045768|DRUG|(Gelsectan, Devintec Sagl)|Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
218910616|NCT04101071|OTHER|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
219523808|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
219523809|NCT00924326|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
219523810|NCT00924326|DRUG|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
219523811|NCT00924326|DRUG|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
219523812|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
219523813|NCT06077526|BEHAVIORAL|P.E.A.K. Rx|Pain Education + Physical Activity Group Based Intervention
219523814|NCT06077526|OTHER|Usual Care|Participants will receive the community hospital's usual care.
219614080|NCT05530486|DEVICE|LG3|Application of LASER GasAs 660nm 12 J/cm².
219614081|NCT05530486|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
218910617|NCT04101071|OTHER|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
218910618|NCT03246971|DRUG|Wafermine™ 50 mg|Administered as needed for 12 hours
218910619|NCT03246971|DRUG|Wafermine™ 75 mg|Administered as needed for 12 hours
218910620|NCT03246971|DRUG|Placebos|Administered as needed for 12 hours
218910621|NCT03246971|DRUG|Wafermine™ 25 mg|Administered as needed for 12 hours
218910622|NCT01913561|DEVICE|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
218910623|NCT01913561|DEVICE|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
219040733|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
219040734|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
218910624|NCT00308802|PROCEDURE|Kidney transplantation|Participants in this study will have had a kidney transplant
218910625|NCT01941511|DRUG|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
218910626|NCT01046981|PROCEDURE|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
218910627|NCT01046981|PROCEDURE|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
218910628|NCT06169202|DEVICE|fruquintinib|4 mg orally once daily, D1-14, repeated every 3 weeks.
218910629|NCT06169202|DRUG|Irinotecan|180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
218910630|NCT06169202|DRUG|Capecitabine|1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
219040735|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
219614082|NCT03458117|GENETIC|Talimogene Laherparepvec (T-VEC)|a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
219614083|NCT03741192|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
218910631|NCT01383746|DEVICE|Yttrium microsphere injection|Radiation therapy
218910632|NCT04356495|DIETARY_SUPPLEMENT|Vitamins|2 tablets daily from the first day (day 0) to day 9
218910633|NCT04356495|DRUG|Telmisartan|1 tablet daily from the first day (day 0) to day 9
218910634|NCT04356495|DRUG|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
218910635|NCT04356495|DRUG|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
218910636|NCT00419393|DRUG|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
218910637|NCT00350025|DRUG|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
218910638|NCT00350025|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
218910639|NCT03021057|DRUG|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
218910640|NCT04516746|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
218910641|NCT04516746|BIOLOGICAL|Placebo|Commercially available 0.9% (n/V) saline for injection.
219365343|NCT02392260|DEVICE|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
219365344|NCT02862691|DRUG|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
218910642|NCT05809921|DRUG|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
218910643|NCT05809921|DRUG|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
219365345|NCT02862691|DRUG|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
219365346|NCT05077488|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Sterile gel in disposable syringe
219365347|NCT04371367|BIOLOGICAL|avdoralimab|intravenous administration of avdoralimab
219365348|NCT04371367|OTHER|Placebo|intravenous administration of placebo
219365349|NCT00503165|BIOLOGICAL|Menitorix (MenC and Hib conjugate)|
219365350|NCT01736956|PROCEDURE|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
219365351|NCT04856514|BEHAVIORAL|PEERS|16 week telehealth intervention; parallel teen and parent/caregiver groups; 90 minutes each week.
219366268|NCT06469060|DRUG|neoadjuvant anti-PD-1 with DOC chemotherapy|"Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1\. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle."
218910644|NCT02629029|PROCEDURE|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
218910645|NCT02629029|DEVICE|Computed tomography angiography (CTA)|
218910646|NCT00206635|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
218910647|NCT01640002|DRUG|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
218910648|NCT01640002|DRUG|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
218910649|NCT00778934|OTHER|Intimate Health Gel|Intimate Health Gel
218910650|NCT00315926|DRUG|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
219040736|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
219040737|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
219040738|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
219040739|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
219040740|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
219040741|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
219040742|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
219040743|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
219040744|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
219040745|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
219040746|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
218910651|NCT00315926|DRUG|Placebo|a mixture of ethanol and physiological saline
218910652|NCT02455921|DRUG|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
218910653|NCT02455921|DRUG|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
219040747|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
219040748|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
218910654|NCT00322777|BEHAVIORAL|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
219040749|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
219040750|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
219523815|NCT00662740|DRUG|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
219523816|NCT00662740|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
219523817|NCT00662740|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
219523818|NCT00662740|DRUG|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
218910655|NCT06186323|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
219040751|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
219040752|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
219040753|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
219040754|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
219040755|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
219040756|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
219040757|NCT04895384|DEVICE|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
219040758|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
219040759|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
219523819|NCT00662740|DRUG|Tiotropium (Spiriva®)|Tiotropium, Spiriva®
219523820|NCT05598658|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
219614084|NCT04514913|RADIATION|Multidetector Computed Tomography (MDCT) Scan|This is a low-dose CT scan of the chest using no contract material.
218910656|NCT06186323|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
218910657|NCT06186323|BEHAVIORAL|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
218910658|NCT02489435|DRUG|VM-1500|VM-1500
218910659|NCT02489435|DRUG|Placebo|Placebo
218910660|NCT02537977|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
218910661|NCT01870206|BIOLOGICAL|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
218910662|NCT01870206|BIOLOGICAL|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
218910663|NCT02698696|OTHER|ECo program|
218910664|NCT02698696|OTHER|CRT program|
218910665|NCT02698696|OTHER|Supportive psychotherapy|
218910666|NCT01190397|DEVICE|Warming goggles|
219040760|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
219523821|NCT05598658|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
219614085|NCT04514913|PROCEDURE|Virtual Navigation Bronchoscopy (VNB)|This is a procedure where a camera will be inserted into the lung in order to guide sample collection of bronchoalveolar lavages, bronchail brushes and endobronchial biopsies.
219523822|NCT06031792|PROCEDURE|Piezo endodontic surgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex, the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth using piezotome. apical preparation will be performed and Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament suture will be applied. Finally, Post-operative parallel Digital view.
219614086|NCT05659563|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
219614087|NCT05659563|DRUG|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
218910667|NCT01190397|DEVICE|warm and moist compresses|
218910668|NCT04386304|DRUG|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
218910669|NCT00446849|DRUG|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
218910670|NCT03954366|DRUG|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
218910671|NCT03954366|DRUG|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
218910672|NCT03954366|DRUG|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
218910673|NCT00904943|DRUG|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
218910674|NCT00904943|DRUG|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
219366269|NCT05154695|DEVICE|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
219366270|NCT05154695|DEVICE|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
219366271|NCT05154695|DRUG|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
219614088|NCT02721732|OTHER|Laboratory Biomarker Analysis|Correlative studies
219614089|NCT02721732|BIOLOGICAL|Pembrolizumab|Given IV
219614090|NCT02721732|OTHER|Questionnaire Administration|Ancillary studies
219614091|NCT06583655|RADIATION|SLND(clinical low risk)|treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
219614092|NCT06583655|RADIATION|SLND(clinical high risk, genomic low risk)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
218910675|NCT04456127|PROCEDURE|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
218910676|NCT03446794|OTHER|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
218910677|NCT03115359|BEHAVIORAL|Mindfulness Based Therapy|"The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
219366272|NCT04690010|PROCEDURE|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
218910678|NCT03115359|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
218910679|NCT00023959|DRUG|hydroxyurea|Given orally
218910680|NCT00023959|DRUG|fluorouracil|Given IV
218910681|NCT00023959|BIOLOGICAL|bevacizumab|Given IV
218910682|NCT00023959|RADIATION|radiation therapy|Undergo radiotherapy
218910683|NCT00023959|BIOLOGICAL|filgrastim|Given subcutaneously
218910684|NCT00023959|OTHER|laboratory biomarker analysis|Correlative studies
218910685|NCT03285724|DEVICE|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
218910686|NCT04739644|DEVICE|Specific wrist rehabilitation by WRISTBOT device|The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
218910687|NCT04739644|OTHER|Specific wrist rehabilitation performed by the physiotherapist|Passive, active and assisted mobilization
218910688|NCT04739644|OTHER|General rehabilitation|Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
218910689|NCT02994238|DEVICE|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
218910690|NCT03078114|OTHER|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
218910691|NCT03078114|OTHER|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
218910692|NCT02818309|DRUG|Lesogaberan|120 mg bid
218910693|NCT02818309|DRUG|Placebo|Placebo
218910694|NCT04231669|BEHAVIORAL|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
218910695|NCT00628368|GENETIC|gene expression analysis|
218910696|NCT00628368|GENETIC|mutation analysis|
218910697|NCT00628368|GENETIC|polymorphism analysis|
218910698|NCT00628368|OTHER|laboratory biomarker analysis|
218910699|NCT00628368|PROCEDURE|biopsy|
218910700|NCT00628368|PROCEDURE|endoscopic biopsy|
218910701|NCT04340895|OTHER|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
218910702|NCT04340895|OTHER|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
218910703|NCT00566774|OTHER|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
219366273|NCT04690010|PROCEDURE|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
219614093|NCT06583655|RADIATION|SLND alone ,clinical high risk and genomic high risk group|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
218910704|NCT00566774|OTHER|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
218910705|NCT06024941|RADIATION|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
218910706|NCT05535946|DRUG|ABX464|Administered once daily, preferably in the morning, with food
218910707|NCT05535946|DRUG|Placebo|Administered once daily, preferably in the morning, with food
219614094|NCT06583655|RADIATION|Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
218910708|NCT03480048|BEHAVIORAL|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
218910709|NCT03656003|DEVICE|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
218910710|NCT03656003|DEVICE|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
218910711|NCT01958372|DIETARY_SUPPLEMENT|soy isoflavones|Given PO
219523823|NCT06031792|PROCEDURE|Conventional endodontic surgery|After the soft tissue curettage and exposure of the root apex, the osteotomy will be performed using a conventional surgical handpiece. The same steps will be followed to prepare and restore the root, as well as to reposition the flap.
218910712|NCT01958372|DRUG|cisplatin|Given IV
219523824|NCT02072486|OTHER|Laboratory Biomarker Analysis|Correlative studies
219523825|NCT02072486|DRUG|Sorafenib Tosylate|Given PO
219523826|NCT03749369|DRUG|Salvadora Persica Root|Salvadora Persica Gel
219523827|NCT03749369|PROCEDURE|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
219523828|NCT00615069|DEVICE|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
219614095|NCT01121861|PROCEDURE|Phacoemulsification with implantation of toric IOL|
219614096|NCT02848001|DRUG|CC-90009|CC-90009
219614097|NCT04837820|PROCEDURE|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
218910713|NCT01958372|DRUG|etoposide|Given IV
218910714|NCT01958372|DRUG|pemetrexed disodium|Given IV
218910715|NCT01958372|RADIATION|radiation therapy|Undergo RT
218910716|NCT03583099|OTHER|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
218910717|NCT03583099|OTHER|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
218910718|NCT04364386|DEVICE|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
218910719|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage).|Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.
218910720|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).|Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
218910721|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
218910722|NCT05543265|BEHAVIORAL|Default appointment scheduling|Default primary care appointment scheduling
218910723|NCT05543265|BEHAVIORAL|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
218910724|NCT05543265|BEHAVIORAL|Nudge Reminders|Primary care appointment reminders
219040761|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
219040762|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
219523829|NCT02148484|BEHAVIORAL|Prolonged Exposure for Adolescents|
219523830|NCT02148484|BEHAVIORAL|Client Centered Therapy|
219523831|NCT06215352|OTHER|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
219523832|NCT00375700|DIETARY_SUPPLEMENT|Nutritional Supplement|
219523833|NCT01929642|DRUG|Sirolimus|
219523834|NCT01929642|DRUG|Everolimus|
219523835|NCT02636959|OTHER|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
219523836|NCT04136899|OTHER|Dukes scale|collection of questionnaires
219523837|NCT00669942|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
219523838|NCT00669942|DRUG|Placebo|Placebo to AIN457
219523839|NCT01988909|DRUG|WR 279,396|Paromomycin + Gentamicin Topical Cream
219523840|NCT00000961|DRUG|Anti-HIV Immune Serum Globulin (Human)|
219523841|NCT00000961|DRUG|Zidovudine|
219523842|NCT02008305|DEVICE|protocol of optimization ALARA|
219523843|NCT02008305|DEVICE|protocol of optimization Philips|
218910725|NCT05316597|BEHAVIORAL|Forest bathing|Participants will be seated in a forest environment for an hour-long exposure to the forest
218910726|NCT04776083|DRUG|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
218910727|NCT04776083|RADIATION|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
218910728|NCT06472661|DEVICE|Echopulse or Echopulse HD|The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.
218910729|NCT06472661|DRUG|PolyICLC|PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
218910730|NCT05526716|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
218910731|NCT05526716|BIOLOGICAL|QIV|Single 0.5 mL IM injection
219523844|NCT00354198|DRUG|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
219523845|NCT00354198|DRUG|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
219523846|NCT04022798|OTHER|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
219523847|NCT04389320|DRUG|Hydroxychloroquine|assess its role in the coarse of covid 19 virus infection
219614098|NCT04837820|PROCEDURE|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
219614099|NCT04837820|OTHER|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
218910732|NCT05526716|BIOLOGICAL|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
218910733|NCT05763017|OTHER|Relative Motion Splint|Six weeks relative motion splint wear.
218910734|NCT05763017|OTHER|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
218910735|NCT04141605|DEVICE|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
218910736|NCT03767933|DRUG|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
218910737|NCT03767933|DRUG|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
218910738|NCT03767933|DRUG|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
218910739|NCT03767933|DRUG|Acetaminophen placebo|Oral liquid
218910740|NCT03767933|DRUG|Hydromorphone placebo|Oral liquid
218910741|NCT04750824|DRUG|Afatinib|Afatinib
218910742|NCT04750824|DRUG|other systemic therapy|other systemic therapy
218910743|NCT00807911|DRUG|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
218910744|NCT00807911|DRUG|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
218910745|NCT04024865|DRUG|Domperidone|Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
218910746|NCT04024865|DRUG|No domperidone|Women with no prescription for domperidone during the six months following delivery.
218910747|NCT06005194|BEHAVIORAL|InMotion|A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
218910748|NCT00642200|PROCEDURE|Lichtenstein hernioplasty|
218910749|NCT00642200|PROCEDURE|Laparoscopic TEP|
218910750|NCT04645368|DRUG|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
218910751|NCT00176696|DEVICE|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
218910752|NCT04357717|DIAGNOSTIC_TEST|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
218910753|NCT04557410|DRUG|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
218910754|NCT04780867|BEHAVIORAL|Delayed vaccination|First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
218910755|NCT01325077|OTHER|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
219040763|NCT02053727|DRUG|Placebo|
219040764|NCT04462042|RADIATION|Proton radiotherapy|Proton radiotherapy
219040765|NCT04462042|RADIATION|Photon radiotherapy|Conventional photon radiotherapy
219040766|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
218910756|NCT00006359|DRUG|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
218910757|NCT00006359|DRUG|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
218910758|NCT00006359|RADIATION|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
218910759|NCT00006359|RADIATION|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
218910760|NCT02492035|BEHAVIORAL|Lifestyle intervention|
218910761|NCT00099801|DRUG|FTY720|
218910762|NCT02570984|DRUG|Omalizumab|anti-ige injection
219040767|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
219040768|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
219040769|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
219523848|NCT04056182|DRUG|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
218910763|NCT02570984|DRUG|Placebo|placebo comparator arm, injection similar to active
218910764|NCT01616966|DRUG|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
219523849|NCT02786030|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
219523850|NCT02786030|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
219523851|NCT02301325|BEHAVIORAL|Smoking research cigarettes with or without NRT|
218910765|NCT01616966|DRUG|propofol|Maintenance of anesthesia with propofol
218910766|NCT01951443|DIETARY_SUPPLEMENT|Ginseng|400mg of encapsulated Rg3-KRG
218910767|NCT01951443|DIETARY_SUPPLEMENT|Wheat Bran|400mg of encapsulated wheat bran
218910768|NCT00375063|PROCEDURE|Percutaneous Coronary Intervention|
219040770|NCT06445335|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement.
219040771|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
219040772|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
219040773|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
219040774|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
219040775|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
219040776|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
219523852|NCT01708824|BEHAVIORAL|Dietary|"Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily"
219523853|NCT01708824|BEHAVIORAL|Physical activity|"Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
218910769|NCT00375063|PROCEDURE|Coronary Artery Bypass Grafting|
218910770|NCT05672654|DIAGNOSTIC_TEST|Blood draw|Blood draw
218910771|NCT04854135|DEVICE|CGM4Home|FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
218910772|NCT04252911|OTHER|Bispectral index score|Bis value from two sites gives similar results
218910773|NCT00360841|PROCEDURE|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
218910774|NCT00360841|PROCEDURE|Sham auricular acupuncture|
218910775|NCT02314468|PROCEDURE|Negative pressure wound therapy|NPWT changed twice a week.
218910776|NCT02314468|PROCEDURE|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
219040777|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
218910777|NCT05989581|DRUG|Labetalol or Nifedipine|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs \<130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP\<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
218910778|NCT04962711|OTHER|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
218910779|NCT04962711|OTHER|Usual care|provided by participants' usual healthcare professional(s)
218910780|NCT05282095|OTHER|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
218910781|NCT06552286|BEHAVIORAL|STRW-T|The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).
218910782|NCT06552286|BEHAVIORAL|PEERS-T|PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
218910783|NCT06396598|OTHER|Educational Activity|Review education materials
218910784|NCT06396598|OTHER|Electronic Health Record Review|Ancillary studies
218910785|NCT06396598|OTHER|Internet-Based Intervention|Participate use the electronic symptom monitoring program to log symptoms
218910786|NCT06396598|OTHER|Media Intervention|Watch a video
218910787|NCT06396598|OTHER|Survey Administration|Ancillary studies
218910788|NCT01154920|DRUG|Paclitaxel|135 mg/m\^2 weekly, Weeks 1 - 6
218910789|NCT01154920|DRUG|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
218910790|NCT01154920|DRUG|Cetuximab|"PCC Arm: 400 mg/m\^2 by vein over about 1-2 hours on Day 1; 250 mg/m\^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
218910791|NCT01154920|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
218910792|NCT01154920|DRUG|Cisplatin|100 mg/m\^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
219040778|NCT04987073|PROCEDURE|skin biopsy|A skin biopsy to cultivate fibroblasts.
219040779|NCT03357484|PROCEDURE|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
219040780|NCT03357484|PROCEDURE|Blood clot|Natural blood clot formed within extraction socket
218910793|NCT01154920|DRUG|Fluorouracil|700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
218910794|NCT01154920|RADIATION|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
219040781|NCT03237728|DRUG|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
219040782|NCT03237728|DRUG|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
219040783|NCT03237728|DRUG|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
219040784|NCT03237728|DRUG|Placebos|Placebos,Q8h,Day1-Day7
219040785|NCT04509843|BEHAVIORAL|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
219040786|NCT04693585|BEHAVIORAL|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
218910795|NCT01154920|OTHER|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m\^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
218910796|NCT06245941|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
218910797|NCT06245941|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
219040787|NCT04693585|BEHAVIORAL|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
219523854|NCT00259012|DRUG|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
218910798|NCT05817890|DRUG|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
218910799|NCT05830812|DIAGNOSTIC_TEST|Invasiveness diagnosis|To predict the invasiveness of patients with small-sized lung adenocarcinoma intraoperatively based on multi-modal information.
218910800|NCT06572865|OTHER|Screening for depression and anxiety|Parents respond to questionnaires assessing depression and anxiety.
218910801|NCT04592874|DRUG|AL002|Administered via intravenous (IV) infusion
218910802|NCT04592874|DRUG|Placebo|Administered via intravenous (IV) infusion
218910803|NCT06360302|DIAGNOSTIC_TEST|Exercise test|"Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes."
218910804|NCT06360302|DIAGNOSTIC_TEST|Blood sample|"A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements"
218910805|NCT06360302|DIAGNOSTIC_TEST|Impedancemetry|measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
218910806|NCT05253209|DRUG|L-citrulline|Intravenous L-citrulline given for up to 48 hours
218910807|NCT05253209|DRUG|Plasmalyte A|Intravenous Plasmalyte A given for up to 48 hours
218910808|NCT06383858|DIAGNOSTIC_TEST|Screening method|All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
218910809|NCT06383858|DIAGNOSTIC_TEST|Screening method|In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
218910810|NCT01894139|OTHER|High-Protein/Low-GI Diet|
218910811|NCT01894139|OTHER|Low-protein/High-GI Diet|
218910812|NCT05442749|DRUG|Niraparib|"Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB \>1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB \>1.5 ULN and up to 3ULN and/or ASAT/ALAT \> 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin \< 1.5ULN) and 2) no grade \>1 related AE are reported."
218910813|NCT04230759|DRUG|Chemotherapy|"Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
218910814|NCT04230759|RADIATION|Radiation|PTV\_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV\_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV\_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV\_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
218910815|NCT04230759|DRUG|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
218910816|NCT03803293|DIAGNOSTIC_TEST|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
218910817|NCT02855203|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
218910818|NCT02855203|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
218910819|NCT04781478|OTHER|Application of Biorepair Gel|Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
219040788|NCT04422145|BEHAVIORAL|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
219040789|NCT04422145|OTHER|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
219523855|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
218910820|NCT04781478|OTHER|Irrigation of Chlorhexidine 1.00% gel|Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
218910821|NCT00006088|DRUG|vinorelbine tartrate|
219040790|NCT03221595|DEVICE|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
219040791|NCT01091792|DRUG|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
219040792|NCT02146482|OTHER|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
219523856|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
219523857|NCT02916290|DRUG|Fuzhenghuayu|
219523858|NCT02916290|DRUG|UDCA|
219523859|NCT06214364|DEVICE|Active Transcranial Direct Current Stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
219523860|NCT06214364|DEVICE|Sham Transcranial Direct Current Stimulation|"The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
218910822|NCT03808116|DEVICE|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process."
218910823|NCT01493323|BEHAVIORAL|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
218910824|NCT01493323|BEHAVIORAL|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
219523861|NCT02226952|DRUG|BILN 2061 W, low dose|
219523862|NCT02226952|DRUG|BILN 2061 W, medium dose|
218910825|NCT01493323|BEHAVIORAL|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
218910826|NCT01493323|PROCEDURE|Cyber ball game|functional neuroimaging
218910827|NCT01493323|PROCEDURE|Iowa Gambling Task|functional neuroimaging
218910828|NCT01493323|PROCEDURE|Microcomputer|functional neuroimaging
219366274|NCT02049047|DRUG|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
219523863|NCT02226952|DRUG|BILN 2061 W, high dose|
218910829|NCT01493323|PROCEDURE|blood sample|blood sample
218910830|NCT06079138|DEVICE|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
219040793|NCT05372796|OTHER|IASTM|instrument-assisted soft tissue mobilization
219040794|NCT05372796|OTHER|home exercise|home exercise
219040795|NCT05372796|DEVICE|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
219366275|NCT03963609|RADIATION|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
219366276|NCT03400800|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
219366277|NCT03400800|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
219366278|NCT00214123|RADIATION|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
219366279|NCT01814163|DRUG|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
219523864|NCT02226952|DRUG|Placebo|
219523865|NCT03533270|PROCEDURE|Urethroplasty|Surgical repair of Urethral injury
219523866|NCT02312700|BEHAVIORAL|Interactive empowerment tool|
219523867|NCT01612871|DRUG|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
219523868|NCT03027115|DRUG|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
219523869|NCT05532527|DRUG|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
219523870|NCT04267627|BEHAVIORAL|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
219523871|NCT00882180|DRUG|ALN-VSP02|IV infusion administered every two weeks
219523872|NCT02167165|DRUG|Digoxin Injection|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
219523873|NCT03148886|OTHER|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
219523874|NCT02828917|DEVICE|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
218910831|NCT06079138|DEVICE|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
218910832|NCT06079138|OTHER|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
218910833|NCT03690817|BEHAVIORAL|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
218910834|NCT02457390|PROCEDURE|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
218910835|NCT05749341|DIAGNOSTIC_TEST|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
218910836|NCT03596216|OTHER|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
218910837|NCT03596216|OTHER|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
218910838|NCT02802306|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
218910839|NCT05623332|DIAGNOSTIC_TEST|Maraciclatide|Imaging marker that binds to AVB3/5 lesions
218910840|NCT05288309|OTHER|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
218910841|NCT05288309|OTHER|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
218910842|NCT03854058|DIAGNOSTIC_TEST|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
218910843|NCT01824238|DRUG|Anacetrapib|
218910844|NCT01824238|DRUG|Placebo for anacetrapib|
218910845|NCT05366023|BEHAVIORAL|BUD1|10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
218910846|NCT05366023|BEHAVIORAL|BUD2|10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
219523875|NCT03803800|OTHER|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
218910847|NCT05366023|BEHAVIORAL|TDD1|10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
219523876|NCT03803800|OTHER|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
218910848|NCT05366023|BEHAVIORAL|TDD2|10 hours of top-down driven computerized cognitive training designed to improve executive function
218910849|NCT05366023|BEHAVIORAL|CSA10|10 hours of computerized games
218910850|NCT05366023|BEHAVIORAL|CSA20|20 hours of computerized games
218910851|NCT05366023|BEHAVIORAL|CSA30|30 hours of computerized games
218910852|NCT05366023|BEHAVIORAL|CSA40|40 hours of computerized games
218910853|NCT02669810|DRUG|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
218910854|NCT02669810|DRUG|Standard Treatment for CHF post AMI|
218910855|NCT04265963|BIOLOGICAL|CD123 CAR-T cells|CD123 CAR-T cell therapy
218910856|NCT03120884|PROCEDURE|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
219523877|NCT03803800|DIETARY_SUPPLEMENT|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
218910857|NCT03120884|PROCEDURE|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
218910858|NCT06240234|DEVICE|Capnodynamic method|All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
218910859|NCT00967564|OTHER|epidemiologic study|QoL assessment
218910860|NCT02990026|BEHAVIORAL|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
218910861|NCT03188016|BEHAVIORAL|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
218910862|NCT03188016|BEHAVIORAL|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
219040796|NCT02079688|DRUG|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
219040797|NCT02079688|DRUG|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
219523878|NCT06405009|OTHER|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
219523879|NCT01646788|DEVICE|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
219523880|NCT01245907|BEHAVIORAL|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
219523881|NCT05807932|DRUG|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
218910863|NCT03171402|DIAGNOSTIC_TEST|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
219523882|NCT05807932|DRUG|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
219523883|NCT05807932|DRUG|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
219523884|NCT05807932|DRUG|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
219523885|NCT05807932|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
218910864|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
218910865|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
218910866|NCT01801566|PROCEDURE|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
218910867|NCT00154570|DEVICE|EGG, 24 hour esophageal pH monitor|
218910868|NCT04948047|DIAGNOSTIC_TEST|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
218910869|NCT04948047|DIAGNOSTIC_TEST|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
219523886|NCT05077566|OTHER|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
219523887|NCT05077566|OTHER|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
219523888|NCT05352360|DIAGNOSTIC_TEST|Pilates Exercises|Exercises with Kinesio Taping
219523889|NCT05352360|DIAGNOSTIC_TEST|Muscle Energy Technique|Exercises with Kinesio Taping
219040798|NCT02212587|DRUG|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
218910870|NCT04361370|DRUG|Olaparib-Pembrolizumab-Bevacizumab|"* Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
218910871|NCT01429675|DRUG|bonviva|150mg Ibandronate once a month
218910872|NCT03081702|DRUG|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
218910873|NCT03081702|DRUG|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
218910874|NCT01176032|DRUG|Aliskiren|Aliskiren 300 mg film coated tablets
218910875|NCT01176032|DRUG|Losartan|Losartan 100 mg tablets
218910876|NCT01176032|DRUG|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
218910877|NCT01176032|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
218910878|NCT01469221|DRUG|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
218910879|NCT01469221|DRUG|Placebo|6 weekly multi-instillation of matching placebo in 40mL
218910880|NCT06022861|DRUG|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
218910881|NCT06022861|DRUG|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
219040799|NCT04400396|DIETARY_SUPPLEMENT|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
219040800|NCT04400396|DIETARY_SUPPLEMENT|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
219040801|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
219040802|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
219523890|NCT01340430|DRUG|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
219523891|NCT02721264|BIOLOGICAL|Fecal Microbiota Transplant|
219523892|NCT02721264|OTHER|Standard Medical Treatment|
219523893|NCT04835246|DEVICE|Spectra IMDx system|The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
219523894|NCT04908332|BEHAVIORAL|Kangaroo Baby Massage|The Kangaroo Baby Massage is an intervention that arose from nursing practice in 1996. It is a therapy that does not require an incubator, fuses massage, kangaroo position and music. KBM is available on video
219523895|NCT03663803|BEHAVIORAL|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
219523896|NCT01054534|PROCEDURE|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
219523897|NCT01293422|DRUG|Rifampicin|Rifampicin 600 mg daily for a week
218910882|NCT06022861|DRUG|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
218910883|NCT06022861|DRUG|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
218910884|NCT01349426|DEVICE|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
218910885|NCT04471350|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
218910886|NCT03833323|COMBINATION_PRODUCT|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
218910887|NCT00375999|DRUG|Docetaxel and epirubicin|
218910888|NCT05414461|DRUG|Combinations|PD-1 inhibitor-based combinaiton treatment
218910889|NCT02397798|BEHAVIORAL|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
218910890|NCT02397798|BEHAVIORAL|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
219040803|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
219040804|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
218910891|NCT04749940|OTHER|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
218910892|NCT03960541|DRUG|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
219523898|NCT00493831|DRUG|nicotine polacrilex, transdermal system or inhaler|on label use of Nicotine replacement therapy (NRT)
219523899|NCT04193566|DRUG|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information\_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
219523900|NCT02463513|DIETARY_SUPPLEMENT|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
219523901|NCT02463513|DIETARY_SUPPLEMENT|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
219523902|NCT02463513|DIETARY_SUPPLEMENT|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
219523903|NCT06062771|DEVICE|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
219523904|NCT06062771|DEVICE|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
219523905|NCT04347837|DEVICE|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
219523906|NCT01106326|BEHAVIORAL|Intervention|"Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
219523907|NCT02545946|DEVICE|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I\&D
219523908|NCT02545946|OTHER|traditional I&D with or without packing|abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
219523909|NCT04792749|DRUG|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
219614100|NCT04837820|OTHER|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
218910893|NCT03960541|DRUG|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
219523910|NCT03741348|PROCEDURE|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
219523911|NCT03741348|PROCEDURE|control|in control group, Erector Spinae Plane Block will not be done
219523912|NCT05425147|OTHER|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
219523913|NCT02696681|BEHAVIORAL|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
219523914|NCT01447563|DRUG|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
219614101|NCT00627159|OTHER|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
219614102|NCT00627159|OTHER|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
218910894|NCT03882060|DRUG|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
218910895|NCT03882060|DRUG|Normal saline|Control group, no intervention.
218910896|NCT00936234|DRUG|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
218910897|NCT05005260|DRUG|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
219040805|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
218910898|NCT05005260|DRUG|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
218910899|NCT03164668|OTHER|menthol flavored e-cigarette|menthol flavored e-cigarette
219523915|NCT01447563|DRUG|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
219523916|NCT01278056|DRUG|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
219523917|NCT01210456|DRUG|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
219523918|NCT00870870|DRUG|Gemcitabine|"1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]"
219523919|NCT00870870|DRUG|Cisplatin|"75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]"
219523920|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]"
219523921|NCT00870870|BIOLOGICAL|Cetuximab|"400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]"
219523922|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
219523923|NCT00870870|BIOLOGICAL|Cetuximab|"500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
219523924|NCT00870870|DRUG|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin"
219523925|NCT04438005|DRUG|ICP-022|ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
219523926|NCT05017857|DEVICE|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
219523927|NCT05017857|BEHAVIORAL|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
219523928|NCT04468802|OTHER|Case fatality rate|Mortality rate caused by SARS CoV-2
219523929|NCT03104166|DEVICE|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
219523930|NCT03104166|DEVICE|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
218910900|NCT03164668|OTHER|tobacco flavored e-cigarette|tobacco flavored e-cigarette
218910901|NCT01561014|DRUG|erlotinib hydrochloride|Given PO
219523931|NCT03117569|DRUG|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
219523932|NCT05602064|DRUG|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
219523933|NCT05602064|DRUG|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
219523934|NCT05602064|OTHER|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
219523935|NCT03811080|DRUG|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
219523936|NCT03811080|DRUG|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
219523937|NCT03811080|DRUG|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
219523938|NCT03125200|DRUG|ADCT-502|Intravenous Infusion
219614103|NCT01568567|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
219614104|NCT03922542|COMBINATION_PRODUCT|riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
218910902|NCT01561014|DRUG|oxaliplatin|Given IV
218910903|NCT01561014|DRUG|fluorouracil|Given IV
218910904|NCT01561014|RADIATION|radiation therapy|Undergo radiotherapy
218910905|NCT01561014|PROCEDURE|conventional surgery|Undergo surgical resection
218910906|NCT01561014|OTHER|immunohistochemistry staining method|Correlative study
218910907|NCT01561014|PROCEDURE|positron emission tomography|Correlative study
219523939|NCT00301769|DRUG|SJG-136|Given IV
219523940|NCT01023074|BEHAVIORAL|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
219523941|NCT01023074|OTHER|MS: Control Activity|MS group not receiving auditory training, doing control activity
219614105|NCT03922542|COMBINATION_PRODUCT|Riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
219614106|NCT02338648|DRUG|SUN-131 1.5% TDS|Active transdermal patch
219614107|NCT02338648|DRUG|Placebo TDS|Placebo transdermal patch for blinding
219523942|NCT00970697|DRUG|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
218910908|NCT01561014|PROCEDURE|computed tomography|Correlative study
218910909|NCT01561014|PROCEDURE|laboratory biomarker analysis|Correlative study
218910910|NCT01561014|GENETIC|gene expression analysis|Correlative study
218910911|NCT01561014|RADIATION|fludeoxyglucose F 18|Undergo F18 PET and CT scan
218910912|NCT01626014|BEHAVIORAL|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
219523943|NCT00970697|DRUG|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
219523944|NCT00119379|DRUG|NucleomaxX|NucleomaxX 36 grams TID every other day
218910913|NCT01626014|BEHAVIORAL|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
218910914|NCT01122641|DRUG|Vildagliptin|Vildagliptin 50mg bid
218910915|NCT01122641|DRUG|Placebo|Matched tablets
218910916|NCT01762696|BEHAVIORAL|MET|Motivational Enhancement Therapy only
218910917|NCT01762696|BEHAVIORAL|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
218910918|NCT04706364|BEHAVIORAL|Neuropsychological Testing|Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
219523945|NCT00119379|DRUG|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
219523946|NCT00028691|DRUG|chlorambucil|
219523947|NCT00028691|RADIATION|radiation therapy|
218910919|NCT04706364|GENETIC|(Optional) Saliva Collection|"The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes.~Genetic testing is funded by Boston Children's Hospital."
218910920|NCT04706364|DEVICE|Sensory Testing|"Three different tests will be completed:~the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold).~Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist).~The second sensory visit will be another version of the PPI testing involving hearing and sound."
218910921|NCT04706364|DEVICE|Electroencephalogram (EEG)|A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.
219523948|NCT01575223|DEVICE|NeilMed sinus rinse|High volume saline irrigation
218910922|NCT04706364|DEVICE|Transcranial Magnetic Stimulation|"Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex.~There will be two - four identical TMS testing visits."
218910923|NCT04993651|DEVICE|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
218910924|NCT05683847|OTHER|User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)|Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
219523949|NCT01575223|DEVICE|Salinex|Low volume saline irrigation
219523950|NCT06015126|DRUG|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
219523951|NCT01312922|DRUG|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
219523952|NCT01312922|DRUG|Citalopram|oral once daily administration
219523953|NCT01312922|DRUG|Pipamperone|oral once daily administration
219523954|NCT01938586|OTHER|Steri-Strip|
219523955|NCT01938586|OTHER|Superficial sutures|
218910925|NCT03382717|DEVICE|Excilor Forte|1 application per day during 6 months
218910926|NCT03382717|DRUG|Loceryl 5%|1 application per week during 6 months
218910927|NCT03919396|DEVICE|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material."
219523956|NCT01038791|DEVICE|heated humidification|temperature 35°
219523957|NCT01038791|DEVICE|heat and moisture exchanger|single patient device
219523958|NCT01038791|DEVICE|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
219614108|NCT01195896|DEVICE|New NPWT system|According clinical routine (Instruction for Use)
219614109|NCT05659199|DEVICE|extracorporeal shockwave|Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
218910928|NCT06250699|PROCEDURE|Tubeless laparoscopic adrenalectomy|No drainage tube placed after laparoscopic adrenalectomy
218910929|NCT06250699|PROCEDURE|Drainage tube|Placing drainage tubes after laparoscopic adrenalectomy
218910930|NCT03954639|DRUG|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
218910931|NCT03954639|DRUG|Bupivacaine Hydrochloride|Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
218910932|NCT00790803|DRUG|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
219523959|NCT03236753|PROCEDURE|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
219523960|NCT03236753|PROCEDURE|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
219523961|NCT02227121|DEVICE|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
219523962|NCT03236766|OTHER|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
219523963|NCT04898062|DEVICE|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
219523964|NCT02120053|DEVICE|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
219614110|NCT05659199|BEHAVIORAL|myofascial release|pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
218910933|NCT01575821|DIETARY_SUPPLEMENT|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
218910934|NCT01575821|DIETARY_SUPPLEMENT|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
218910935|NCT01575821|DIETARY_SUPPLEMENT|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
218910936|NCT01575821|DIETARY_SUPPLEMENT|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
218910937|NCT00176384|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
219040806|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
219523965|NCT02120053|DEVICE|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
219523966|NCT03929367|DRUG|Oxytocin|Single IV administration of oxytocin
219523967|NCT01937390|DRUG|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
219614111|NCT01410097|BEHAVIORAL|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
219614112|NCT01410097|BEHAVIORAL|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
218910938|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
218910939|NCT01363375|PROCEDURE|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
218910940|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
218910941|NCT03572920|DEVICE|Objective sleep evaluation by actigraphy|Each subject will wear a wrist activity monitor (actigraphy) to detect his/her sleep behaviour during hospitalization.
218910942|NCT03572920|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Each subject will fill twice the Pittsburgh Sleep Quality Index (PSQI), before hospitalization and after the 10th day, to evaluate his/her subjective sleep quality.
218910943|NCT03728907|DEVICE|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
218910944|NCT00301899|BIOLOGICAL|pertuzumab|
218910945|NCT00301899|BIOLOGICAL|trastuzumab|
218910946|NCT02160080|DRUG|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
219523968|NCT01937390|DRUG|Indacterol 300 µg|inhalation powder
219523969|NCT01937390|DRUG|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
219523970|NCT01937390|DRUG|Indacterol 150 µg|inhalation powder
219523971|NCT03354104|DEVICE|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
219523972|NCT03354104|DEVICE|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
219523973|NCT00733616|DRUG|DOX: Docetaxel, oxaliplatin, Capecitabine|"* Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
219523974|NCT00515203|DRUG|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
219523975|NCT00515203|DRUG|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
219523976|NCT00411203|DRUG|Tamoxifen Citrate|
219523977|NCT00411203|DRUG|Placebo|
219523978|NCT00636896|DRUG|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
219523979|NCT00636896|DRUG|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
219523980|NCT03061734|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
219523981|NCT03061734|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
219523982|NCT03061734|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
219523983|NCT03061734|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
219523984|NCT03061734|DRUG|Matching Placebo|Two Placebo capsules
219523985|NCT06880588|BEHAVIORAL|Brief Infant Sleep Questionnaire|"The Brief Infant Sleep Questionnaire will be used to assess sleep. Infant sleep problems are among the most common problems presented to healthcare professionals. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood. This questionnaire has been translated into Turkish and assessed sleep environment and sleep problems in infants. It consists of 33 items, is based on parent reports of infant or toddler sleep patterns and is used to validate the data. It is associated with daily records and parent reports of sleep. Its sensitivity in documenting developmental sleep trends is well established"
219523986|NCT06880588|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of Sensory Function in Infants is frequently used to evaluate the sensory processing
219523987|NCT06880588|BEHAVIORAL|Peabody Motor Development Scale-2|It was planned to use the Peabody Motor Development Scale-2 to evaluate motor development. The Peabody Motor Development Scale-2 was designed to determine developmental delays in children aged 0-72 months.
219523988|NCT04279639|BEHAVIORAL|qigong|Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.
219614113|NCT06156397|OTHER|Standard Physiotherapy Exercise Group|At the beginning of the treatment, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions. Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks.
219614114|NCT06156397|OTHER|Telerehabilitation Based Supervised Exercise Group|Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks. In the telerehabilitation group, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks at the beginning of the treatment, through a meeting with the patients via zoom application. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights.
219614115|NCT06156397|OTHER|Mobile Application Supported Exercise Group|With the videos uploaded to the Becure application, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied in the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. Between weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weight. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions.
219614116|NCT00725283|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
219614117|NCT06379048|PROCEDURE|Mattress Suturing|Horizontal mattress suture in interrupted fashion
219614118|NCT06379048|PROCEDURE|Primary Suturing|Horizontal primary suture in interrupted fashion
219614119|NCT06379048|PROCEDURE|Continuous Subcutaneous Suturing|Subcutaneous suture in continuous fashion
219614120|NCT00659451|DRUG|Losartan|tablets; 50, 100 mg; od; 12 months
219614121|NCT00659451|DRUG|Amlodipine|tablets; 5, 10 mg; od; 12 months
219614122|NCT01668745|BIOLOGICAL|Early measles vaccine|
219614123|NCT00652054|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
218910947|NCT04162249|OTHER|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
218910948|NCT04162249|OTHER|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
218910949|NCT04162249|OTHER|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
218910950|NCT04162249|DIAGNOSTIC_TEST|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions \<72 hours after ablation.
219523989|NCT05618119|DRUG|[18F]MC225|\[18F\]MC225 PET scan
219614124|NCT00908570|DRUG|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
218910951|NCT03882294|OTHER|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
218910952|NCT03882294|OTHER|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
218910953|NCT05537753|DEVICE|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
218910954|NCT05537753|DEVICE|FDA-approved PFO closure device|Chosen by the investigator
218910955|NCT05872737|BEHAVIORAL|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
218910956|NCT05872737|BEHAVIORAL|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
218910957|NCT04739982|DEVICE|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
218910958|NCT05031819|OTHER|Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.|"* TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH"
219040807|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 weekly for 4 doses
219040808|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 weekly for 4 doses
219040809|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|1 μg vaginal dose of AZU-101 weekly for 4 doses
219040810|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses
219040811|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
219040812|NCT00004903|BIOLOGICAL|filgrastim|
219040813|NCT00004903|BIOLOGICAL|recombinant interferon alfa|
219523990|NCT01230151|DEVICE|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
219523991|NCT01230151|DEVICE|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
219523992|NCT05811156|BEHAVIORAL|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
219523993|NCT00905853|PROCEDURE|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
219523994|NCT00905853|DRUG|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
219523995|NCT01517256|BEHAVIORAL|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
219523996|NCT01517256|OTHER|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
219523997|NCT03418441|OTHER|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
219614125|NCT00908570|DRUG|Placebo|Placebo cream
219614126|NCT02471729|DEVICE|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
219614127|NCT06544200|DEVICE|Polymeric Hydrogel Matrix|application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
219614128|NCT00000914|DRUG|Indinavir sulfate|
218910959|NCT06444659|BEHAVIORAL|Adaptive Physical Activity Classes|The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.
218910960|NCT04539496|DRUG|XZP-3287|"* 20-560 mg QD, oral~* 240-480 mg BID, oral"
218910961|NCT04539496|DRUG|XZP-3287;Letrozole;Anastrozole;Fulvestrant|XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
219040814|NCT00004903|DRUG|cisplatin|
219614129|NCT00000914|DRUG|Ritonavir|
219614130|NCT00000914|DRUG|Nelfinavir mesylate|
219614131|NCT00000914|DRUG|Efavirenz|
219614132|NCT05252299|OTHER|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
219614133|NCT06578299|DRUG|Inetetamab and Paclitaxel ± Pertuzumab|"Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination."
219614134|NCT02289599|DRUG|E2307|
219040815|NCT00004903|DRUG|cyclophosphamide|
219040816|NCT00004903|DRUG|cytarabine|
219040817|NCT00004903|DRUG|etoposide|
219614135|NCT02289599|DRUG|E2307 Matching Placebo|
218910962|NCT04539496|DRUG|XZP-3287|480 mg BID, oral
218910963|NCT05854966|DRUG|CPI 613|"For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent."
218910964|NCT05854966|DRUG|Metformin|"For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent"
218910965|NCT05854966|BIOLOGICAL|Blood draws|In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
219040818|NCT00004903|DRUG|melphalan|
219040819|NCT00004903|PROCEDURE|peripheral blood stem cell transplantation|
219040820|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
219040821|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
219365381|NCT00866099|OTHER|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
219365382|NCT01363687|DEVICE|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
219365383|NCT01225341|DRUG|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
219365384|NCT01225341|OTHER|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
219365385|NCT03715426|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
219365386|NCT00712374|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
219365387|NCT03557567|DIAGNOSTIC_TEST|NGS molecular screening|
219365388|NCT00207467|BEHAVIORAL|Patient-delivered partner treatment|
219365389|NCT00207467|BEHAVIORAL|Booklet-enhanced partner referral|
219365390|NCT04873492|OTHER|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
219365391|NCT03544112|BEHAVIORAL|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
218910966|NCT05854966|PROCEDURE|Bone marrow biopsy|After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
218910967|NCT03234595|DRUG|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
218910968|NCT04079296|BIOLOGICAL|ASP7517|Intravenous (IV)
218910969|NCT06561451|PROCEDURE|intracytoplasmic sperm injection and artificial oocyte activation|A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
218910970|NCT06561451|PROCEDURE|intracytoplasmic sperm injection|A single sperm will be injected within 4 hours after the follicular aspiration.
218910971|NCT05182372|BEHAVIORAL|Enhanced dCBT-I|Telehealth Coaching
218910972|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization."
218910973|NCT06280950|DRUG|Tacrolimus (continued reduction)|"* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction"
218910974|NCT06280950|DRUG|Tacrolimus (maintain 50% reduction)|\- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
218910975|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen."
218910976|NCT05068752|DRUG|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
218910977|NCT05068752|DRUG|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
218910978|NCT06133816|BEHAVIORAL|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
218910979|NCT06133816|BEHAVIORAL|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
218910980|NCT06133816|BEHAVIORAL|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
218910981|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
218910982|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
218910983|NCT06133816|BEHAVIORAL|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
218910984|NCT06114537|DRUG|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
218910985|NCT01346358|BIOLOGICAL|IMC-CS4|
218910986|NCT02839096|DRUG|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
218910987|NCT02839096|DRUG|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
219040822|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
219614136|NCT05906108|BEHAVIORAL|Self-initiated learning|A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.
219523998|NCT01880333|OTHER|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
219614137|NCT05906108|BEHAVIORAL|Personalized and interactive behavioural support|The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.
219614138|NCT05906108|BEHAVIORAL|General health information|Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
219614139|NCT01511042|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
219614140|NCT01511042|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
219614141|NCT01511042|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
219614142|NCT00711243|DRUG|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
218910988|NCT05687656|DEVICE|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
218910989|NCT04148807|BEHAVIORAL|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
218910990|NCT04148807|BEHAVIORAL|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
218910991|NCT00207155|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
218910992|NCT05345353|BEHAVIORAL|Fat For Fight (FFF), The Aarhus Protocol|A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
218910993|NCT05345353|BEHAVIORAL|The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol|A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
218910994|NCT03285802|DRUG|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
218910995|NCT03285802|DRUG|Everolimus|Everolimus 10mg daily q 28 days
218910996|NCT00003605|BIOLOGICAL|rituximab|
219614143|NCT00711243|DRUG|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
219614144|NCT00711243|DRUG|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
219614145|NCT04776629|DRUG|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
219614146|NCT04776629|DRUG|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
219614147|NCT03765489|DEVICE|electrical muscle stimulation|electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
219614148|NCT03765489|PROCEDURE|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
219614149|NCT02661880|BEHAVIORAL|preferred music|listening to preferred music choices
219614150|NCT02764892|DRUG|V81444|Single oral dose of V81444
218910997|NCT00003605|DRUG|cyclophosphamide|
218910998|NCT03402542|PROCEDURE|Cholecystectomy|Cholecystectomy
218910999|NCT04984967|DEVICE|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
218911000|NCT04984967|OTHER|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
219523999|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
219524000|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
218911001|NCT06262152|DIAGNOSTIC_TEST|Actigraphy, blood and salivary sample, and sleep evaluation|"* For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment.~* 7 days actigraph recording through wearing of Actiwatch spectrum plus at home~* Standardized sleep questionnaire administration"
218911002|NCT00702702|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
218911003|NCT00702702|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
218911004|NCT00702702|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
218911005|NCT03228108|DRUG|Ciprofloxacin|see study arms.
218911006|NCT03228108|DRUG|Trimethoprim/Sulfamethoxazole|see study arms.
218911007|NCT03228108|DRUG|Fosfomycin|see study arms.
218911008|NCT03228108|DRUG|Pivmecillinam/augmentin|see study arms.
218911009|NCT00373581|DRUG|Vigabatrin|
218911010|NCT00373581|DRUG|Cocaine|
218911011|NCT02113709|DEVICE|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
218911012|NCT02113709|DEVICE|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
218911013|NCT00436449|DRUG|Avotermin|
218911014|NCT04635449|OTHER|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
218911015|NCT05441384|BEHAVIORAL|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
219524001|NCT03664973|PROCEDURE|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
219524002|NCT00002005|DRUG|CD4 Antigens|
219614151|NCT01164020|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
218911016|NCT05776017|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
218911017|NCT05776017|BIOLOGICAL|Anti-Rabies Vaccine|Control vaccine
218911018|NCT01281618|PROCEDURE|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
218911019|NCT05604040|BEHAVIORAL|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
218911020|NCT03717688|DRUG|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
218911021|NCT03717688|DRUG|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
218911022|NCT03717688|DRUG|Placebos|No treatment
218911023|NCT05123534|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.
218911024|NCT04239898|OTHER|Red cabbage microgreens|2 cups per day
218911025|NCT04239898|OTHER|Red beet microgreens|2 cups per day
218911026|NCT00823251|DEVICE|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
218911027|NCT05816811|OTHER|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
218911028|NCT03101995|DRUG|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
218911029|NCT03366545|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
218911030|NCT02004236|DEVICE|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
218911031|NCT02004236|DEVICE|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
218911032|NCT02004236|DEVICE|tRNS with sham|the subjects receive 35 session with sham
218911033|NCT03484130|DIETARY_SUPPLEMENT|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of \>180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
219524003|NCT05546827|PROCEDURE|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
219524004|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
219524005|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
219524006|NCT03069274|BEHAVIORAL|Intervention|General nutritional recommendations, change drinking habits
219524007|NCT03069274|BEHAVIORAL|General nutritional recommendations|Only general nutritional recommendations were given
219524008|NCT01706536|DRUG|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
219524009|NCT01706536|DRUG|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
219524010|NCT01706536|DRUG|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
219524011|NCT01706536|DRUG|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
219524012|NCT01706536|DRUG|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
219524013|NCT02519322|BIOLOGICAL|Ipilimumab|Given IV
219524014|NCT02519322|OTHER|Laboratory Biomarker Analysis|Correlative studies
219524015|NCT02519322|BIOLOGICAL|Nivolumab|Given IV
219524016|NCT02519322|BIOLOGICAL|Relatlimab|Given IV
219524017|NCT02519322|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219524018|NCT06241378|DEVICE|perineometer device for physiotherapy|measuring the vaginal pressure for stress urinary incontinence patients
219524019|NCT04190693|DRUG|IMCY-0098 or placebo|Long-term follow-up
218911034|NCT03484130|DIETARY_SUPPLEMENT|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
218911035|NCT06175338|DRUG|Rituximab|Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
218911036|NCT06175338|DRUG|MabThera®|MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
218911037|NCT04535843|OTHER|Biomarkers and omics data|To detect disease-related biomarkers and omics data, in this prospective MG cohort.
218911038|NCT05121766|DRUG|Omega-3 (EPA+DHA)|"Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA."
218911039|NCT05121766|DRUG|Placebo|3 Soybean Oil Placebo capsules
218911040|NCT01579227|DEVICE|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
218911041|NCT01579227|DIETARY_SUPPLEMENT|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
218911042|NCT01579227|DEVICE|Tamoxifen Cream|Tamoxifen cream
218911043|NCT01579227|DEVICE|Placebo cream|Placebo cream
218911044|NCT01579227|DIETARY_SUPPLEMENT|placebo capsule|placebo capsule
218911045|NCT01404169|DRUG|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
218911046|NCT01404169|DRUG|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
218911047|NCT04281615|OTHER|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
218911048|NCT06279741|BIOLOGICAL|Endotracheopulmonary Instillation, Suspension|"The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant."
218911049|NCT04578951|DEVICE|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
218911050|NCT02447965|DRUG|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
218911051|NCT02447965|DRUG|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
219524020|NCT06112535|DEVICE|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
218911052|NCT03239834|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
218911053|NCT05123872|DEVICE|tDCS|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
218911054|NCT05665439|RADIATION|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
218911055|NCT00405080|DRUG|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
218911056|NCT00405080|DRUG|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
218911057|NCT05302674|OTHER|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
218911058|NCT02955589|DRUG|HBI-8000|Oral, twice weekly
218911059|NCT03894488|DIAGNOSTIC_TEST|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
218911060|NCT00723996|BEHAVIORAL|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
218911061|NCT05035524|DRUG|Sodium Bicarbonate Solution|Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
218911062|NCT05035524|DRUG|Placebo|Placebo
218911063|NCT02960217|DRUG|UX007|liquid for oral (PO) administration
218911064|NCT02960217|DRUG|Placebo|liquid safflower oil for PO administration
218911065|NCT03838185|DRUG|J147|Single oral dose of J147
218911066|NCT03838185|DRUG|Placebo|Single oral dose of corn oil
218911067|NCT05826483|DRUG|Almonertinib|Almonertinib Mesilate Tablets
218911068|NCT02268890|DRUG|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
218911069|NCT02919228|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
218911070|NCT02153268|PROCEDURE|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
218911071|NCT00161200|DRUG|Ranitidine & Pantoprazole|
219614152|NCT01164020|OTHER|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
218911072|NCT01003301|DRUG|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
218911073|NCT01003301|DRUG|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
218911074|NCT00918281|DRUG|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
218911075|NCT05683093|OTHER|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
218911076|NCT00175526|BEHAVIORAL|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
218911077|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
218911078|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
219524021|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
218911079|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
218911080|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
218911081|NCT00333125|DRUG|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
218911082|NCT00333125|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
218911083|NCT00333125|OTHER|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
218911084|NCT04604145|DIAGNOSTIC_TEST|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
218911085|NCT02848820|DRUG|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
218911086|NCT02848820|PROCEDURE|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
218911087|NCT03844776|DRUG|Co-Amoxiclav|amoxicillin + clavulanic acid orally
218911088|NCT03844776|DRUG|Paracetamol|paracetamol orally
218911089|NCT03844776|DRUG|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
218911090|NCT03844776|DRUG|Normal saline|0.9% normal saline irrigation
218911091|NCT03844776|DRUG|Amoxicillin 500 Mg|Amoxicillin 500 orally
218911092|NCT03844776|DRUG|Metronidazole|metronidazole 500 mg orally
218911093|NCT00388349|DRUG|Gemcitabine|
219524022|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
219524023|NCT02459704|PROCEDURE|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
219524024|NCT02459704|DEVICE|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
219524025|NCT02226328|DRUG|Propofol sedation|
219524026|NCT02226328|DRUG|Midazolam and Fentanyl sedation|
219524027|NCT03537781|BEHAVIORAL|Food labelling versus no food labelling|Food labelling availability and satiety status
219524028|NCT03759821|BEHAVIORAL|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
219614153|NCT01164020|OTHER|Resistance training|resistance training twice a week for 24 weeks
218911094|NCT00388349|DRUG|Vinorelbine|
218911095|NCT00388349|DRUG|Carmustine|
218911096|NCT00388349|DRUG|Etoposide|
218911097|NCT00388349|DRUG|Cyclophosphamide|
218911098|NCT00388349|PROCEDURE|Autologous HCT|
218911099|NCT00168844|DRUG|Tiotropium Inhalation Solution|
218911100|NCT00168844|OTHER|Placebo|
218911101|NCT04992117|OTHER|NO INTERVENTION|NO INTERVENTION
218911102|NCT01186263|DRUG|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
218911103|NCT01186263|DRUG|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
218911104|NCT01648465|DRUG|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
218911105|NCT02735967|OTHER|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
219524029|NCT03759821|BEHAVIORAL|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
219524030|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
219524031|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
219524032|NCT01813461|DRUG|14C-labeled prodrug isavuconazonium sulfate|oral
219524033|NCT00245713|DRUG|levetiracetam|
219524034|NCT00993187|DRUG|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
219524035|NCT00993187|DRUG|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
219524036|NCT00993187|DRUG|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
219524037|NCT00993187|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
219524038|NCT00683293|PROCEDURE|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
219524039|NCT00683293|PROCEDURE|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
219524040|NCT03741595|BEHAVIORAL|Item spacing|Spatial proximity of items to one another
219524041|NCT01630980|OTHER|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
219614154|NCT05739422|PROCEDURE|Neuropilates online exercise class|Online, remotely supervised neuropilates exercise class
219524042|NCT00274326|DRUG|SR121463B|
219524043|NCT06546410|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
219524044|NCT00681720|DRUG|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
219524045|NCT00681720|DRUG|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
219524046|NCT06483581|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
219524047|NCT06483581|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
219524048|NCT02453425|OTHER|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
219524049|NCT02453425|OTHER|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
219524050|NCT02453425|OTHER|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
219524051|NCT03262012|DRUG|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
219524052|NCT03262012|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
219524053|NCT03262012|DRUG|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
219524054|NCT03262012|DRUG|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
219524055|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
219524056|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
219614155|NCT05739422|PROCEDURE|Online generalised exercise class|Online, remotely supervised generalised exercise class
219614156|NCT05739422|PROCEDURE|Unsupervised home exercise programme|Unsupervised, home based generalised exercise programme
218911106|NCT02735967|DEVICE|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
219614157|NCT03558581|OTHER|Educational|
219614158|NCT05744518|OTHER|Response monitoring|Other: Response monitoring (no intervention)
219614159|NCT06091813|BEHAVIORAL|Nutrition Counseling|Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
219614160|NCT04623619|DIETARY_SUPPLEMENT|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
219524057|NCT05742633|OTHER|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
219524058|NCT05742633|OTHER|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
218911107|NCT02249338|DRUG|BIIL 284 BS|
218911108|NCT02249338|DRUG|Placebo|
218911109|NCT02138890|DEVICE|APS|Intra-articular Injection
218911110|NCT02138890|DEVICE|Saline|Intra-articular injection
218911111|NCT04932395|DRUG|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
218911112|NCT04932395|DRUG|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
218911113|NCT04564417|BIOLOGICAL|W0180|Participants will receive W0180 in a 21-day cycle.
218911114|NCT04564417|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
218911115|NCT01605006|DEVICE|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
218911116|NCT06165809|DRUG|TQB3015 tablets|TQB3015 is a protein inhibitor
219040823|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
218911117|NCT01598766|DEVICE|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
218911118|NCT05112575|RADIATION|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
218911119|NCT05208502|DEVICE|DSA monitor|Next Generation SedLine features an enhanced signal processing engine, which provides processed EEG parameters. This four channel EEG monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan
218911120|NCT02267239|DRUG|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
219524059|NCT02710201|BEHAVIORAL|Descriptive Social Norm|
219524060|NCT02710201|BEHAVIORAL|Descriptive-plus-Injunctive Social Norm|
219524061|NCT05819398|DRUG|Spesolimab Formulation 1|Spesolimab Formulation 1
219524062|NCT05819398|DRUG|Spesolimab Formulation 2|Spesolimab Formulation 2
219524063|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
219524064|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
219524065|NCT06903403|OTHER|Front-of-package label|Participants will see packaged food and beverage items displayed with labels as specified by their assigned group
219524066|NCT02924038|BIOLOGICAL|IMA950|IMA950 vaccine
219524067|NCT02924038|BIOLOGICAL|poly-ICLC|poly-ICLC vaccine
219524068|NCT02924038|BIOLOGICAL|Varlilumab|Intravenous solution
219524069|NCT02836847|PROCEDURE|biological test|mutation and signal pathway activation status analysis
218911121|NCT02267239|DRUG|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
218911122|NCT02267239|DRUG|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
218911123|NCT02267239|DRUG|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
218911124|NCT02267239|PROCEDURE|professional oral cleaning|scaling and polishing teeth of the volunteers
218911125|NCT02267239|PROCEDURE|Plaster cast|Taking a plaster cast of the volunteers' mouth
218911126|NCT02267239|DEVICE|IDODS|Specific intraoral device which carries six glass disks
218911127|NCT00004380|DRUG|relaxin|
218911128|NCT06222632|OTHER|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
219040824|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
219040825|NCT05263999|BIOLOGICAL|Itolizumab|Itolizumab \[Bmab600\]
219040826|NCT05263999|DRUG|EQ001 Placebo|EQ001 Placebo
219040827|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
219040828|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
219040829|NCT00219128|DRUG|aliskiren|
219524070|NCT02836847|DRUG|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
218911129|NCT06222632|OTHER|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 \&amp; 12 of the intervention.
218911130|NCT06222632|OTHER|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
218911131|NCT00537394|DRUG|Enfuvirtide|90mg subcutaneously twice daily
218911132|NCT00537394|DRUG|Raltegravir|400 mg twice daily
218911133|NCT00537394|DRUG|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
218911134|NCT00537394|DRUG|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
218911135|NCT00537394|DRUG|Etravirine|Two 100-mg tablets twice daily
218911136|NCT00537394|DRUG|Maraviroc|Dosage dependent on regimen in which maraviroc is included
218911137|NCT06342934|DIAGNOSTIC_TEST|Ultrasound|Ultrasound images are collected and stored. The images stored during your preoperative ultrasound will be exported in anonymous format from the ultrasound system, and sent to the coordinating center (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano). There, images will be submet to radiomic analysis through the application of a dedicated software; that will allow to evaluate the intrinsic characteristics of the tissue according to different parameters (shape, intensity, grade of heterogeneity and many others) of the 'pixels' (gray dots) that constitute the ultrasound imag
218911138|NCT04828421|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
218911139|NCT04828421|DIETARY_SUPPLEMENT|Placebo|Placebo
218911140|NCT04712188|DIAGNOSTIC_TEST|Musculoskeletal ultrasonography|The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
218911141|NCT04712188|OTHER|Wheelchair propelling test|Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
218911142|NCT06126614|DRUG|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
218911143|NCT06126614|DRUG|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
218911144|NCT06126614|OTHER|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
218911145|NCT06126614|OTHER|Saline|saline for irrigation
218911146|NCT01468285|DRUG|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
218911147|NCT01468285|OTHER|placebo|placebo tablets b.i.d., six weeks treatment
218911148|NCT00995761|DRUG|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
218911149|NCT03756519|BEHAVIORAL|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
218911150|NCT03756519|BEHAVIORAL|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
218911151|NCT03756519|BEHAVIORAL|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
218911152|NCT03756519|OTHER|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
218911153|NCT05324293|DRUG|HMI-115|Once Every 2 weeks, subcutaneously injection
219040830|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
219040831|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
219040832|NCT00651482|DRUG|Everolimus|
219040833|NCT00651482|DRUG|Bevacizumab|
219040834|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
219040835|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
219040836|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
218911154|NCT05099809|OTHER|Hyperthermia|Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
219524071|NCT02836847|DRUG|Cetuximab|
218911155|NCT03291496|OTHER|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
218911156|NCT03291496|OTHER|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is \>24 hours old.
218911157|NCT03291496|OTHER|Adult Blood collection|One Time 1 ml of whole blood collected
218911158|NCT05565365|PROCEDURE|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
219040837|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
219040838|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
218911159|NCT05565365|PROCEDURE|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
218911160|NCT00685165|DRUG|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
218911161|NCT00685165|DRUG|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
219040839|NCT00154453|PROCEDURE|obtain surgical specimen for analysis|
219040840|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
219040841|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
219040842|NCT00048542|DRUG|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
219040843|NCT00048542|DRUG|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
219040844|NCT01892631|OTHER|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
219040845|NCT01892631|OTHER|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
219040846|NCT00578175|BIOLOGICAL|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
219040847|NCT00578175|BIOLOGICAL|ProQuad®|One subcutaneous injection.
219040848|NCT00578175|BIOLOGICAL|Havrix®|Two intramuscular injections.
219040849|NCT00578175|BIOLOGICAL|Prevnar®|One intramuscular injection.
218911162|NCT00506870|DEVICE|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
219040850|NCT05126927|BIOLOGICAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
219040851|NCT03751085|DEVICE|AW frame|AW stereotactic frame for intracranial lesion biopsy
219040852|NCT05243212|BIOLOGICAL|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
219524072|NCT02836847|DRUG|Trastuzumab|
219524073|NCT02836847|DRUG|Gefitinib|
219524074|NCT02836847|DRUG|Lapatinib|
218911163|NCT00506870|DEVICE|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
218911164|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
218911165|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
219040853|NCT05358496|DIAGNOSTIC_TEST|Data collection|Clinical data collection
219040854|NCT06448936|OTHER|Patient-reported outcome measures (PROMs)|Administration of questionnaires investigating the impact of facial difficult-to-treat basal cell carcinoma treated by surgery on patient's quality of life over the course of one year. The questionnaires will be submitted at baseline (i.e., before surgery) and at 3-months follow up.
219040855|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
219040856|NCT00577512|DRUG|DTPACE|"* Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4"
219040857|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
219040858|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
219040859|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
219040860|NCT04780425|BEHAVIORAL|DESMOND|as previously described
219040861|NCT04780425|OTHER|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
219040862|NCT00963339|DEVICE|Foresee Home|Home Monitoring
219040863|NCT02272413|DRUG|BI 695502|
219040864|NCT02272413|DRUG|Avastin|
219040865|NCT04951934|DEVICE|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
219524075|NCT02836847|DRUG|Everolimus|
219524076|NCT02836847|DRUG|Sorafenib|
219524077|NCT02836847|DRUG|Crizotinib|
219524078|NCT00218205|DRUG|Epirubicin|
219524079|NCT00218205|DRUG|Estramustine Phosphate|
219524080|NCT00218205|DRUG|Celecoxib|
219524081|NCT03859466|DEVICE|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
218911166|NCT01377584|BEHAVIORAL|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
218911167|NCT01377584|BEHAVIORAL|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
219040866|NCT04951934|PROCEDURE|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
219524082|NCT00115726|DRUG|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
219524083|NCT00115726|DRUG|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
219524084|NCT01845662|OTHER|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
219524085|NCT01497652|DRUG|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
218911168|NCT01377584|DEVICE|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
218911169|NCT01377584|OTHER|No intervention|No intervention will be received.
219040867|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
219040868|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
219040869|NCT03348358|BEHAVIORAL|quiet music|playing quiet music during labor
219040870|NCT03348358|BEHAVIORAL|Rhythmic music|playing rhythmic music during labor
219524086|NCT01497652|DRUG|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
219524087|NCT03601637|DRUG|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
219524088|NCT03601637|DRUG|IVA|FDC granules (LUM/IVA).
219524089|NCT01248247|DRUG|Erlotinib|150 mg by mouth each day of a 28 day cycle.
219040871|NCT03348358|BEHAVIORAL|control|No music during labor
219040872|NCT05039346|OTHER|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
219524090|NCT01248247|DRUG|AZD6244|100 mg by mouth daily of a 28 day cycle.
219524091|NCT01248247|DRUG|MK-2206|100 mg by mouth every week of a 28 day cycle.
219524092|NCT01248247|DRUG|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
219524093|NCT01248247|DRUG|Erlotinib|150 mg by mouth daily of a 28 day cycle.
219524094|NCT01248247|DRUG|MK-2206|135 mg by mouth every week of a 28 day cycle.
219524095|NCT03164889|DRUG|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
219524096|NCT03164889|DRUG|Entecavir|Antiviral drug for hepatitis b virus (HBV)
219524097|NCT03797547|OTHER|AFLIBERCEPT|Patients will be treated following a real life protocol and according to the French recommendation
219524098|NCT05872217|OTHER|conventional upper extremity therapeutic program|"• This group will receive conventional UE therapeutic program for 60 minutes each session including:~* Exercises based on neurodevelopment technique .~* Gentle manual stretching for tight muscles of the affected UE from proximal to distal segments for 5minutes.~* Weight-bearing exercises for 10minutes for UE from prone lying, side sitting and quadriped position.~* Strengthening exercises for 10 minutes for muscles of UE as push-up from prone lying position, quadriped position, 3 point exercise, walk on hand, climbing, hanging on a bar, squeeze stress balls, cutting usescissors to strengthen hand .~* Goal directed training for 10 minutes the child will practice specific tasks that are needed for everyday life and which they find a challenge like (3 daily tasks as cleaning mirror, dressing and undressing, using pen and ruler to draw shapes, brushing teeth .~* Fine motor activities as reach, grasp, carry and release activities."
219524099|NCT05872217|OTHER|full immersive VRapeutic software gaming technology|• Children in this group will receive the same conventional UE therapeutic program as control group for 60 minutes in addition to virtual reality session using VRapeutic software gaming technology, Archeeko module (figure 3) for 30 min/3 sessions/week for 8 weeks
219524100|NCT01854008|OTHER|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut\_publica/itineraris/index"
219524101|NCT01854008|OTHER|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
219524102|NCT05107323|BEHAVIORAL|Compassionate Mind Training for Teachers|Compassionate Mind Training for Teachers is a biopsychosocial evidence-based approach that aims to foster compassion, affect regulation, prosocial qualities and wellbeing in teachers.
219524103|NCT04756752|OTHER|Fit and Vitaal program|Intervention type: training
219524104|NCT00736970|DRUG|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
218911170|NCT04875013|DEVICE|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
218911171|NCT02960386|OTHER|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
218911172|NCT06365879|DRUG|CMAB007|300mg, SC, Q4W
218911173|NCT06365879|DRUG|Xolair|300mg, SC, Q4W
218911174|NCT00788307|BIOLOGICAL|Ad5-CMV-NIS|
218911175|NCT00788307|DRUG|liothyronine sodium|
218911176|NCT00788307|GENETIC|reverse transcriptase-polymerase chain reaction|
218911177|NCT00788307|OTHER|laboratory biomarker analysis|
218911178|NCT00788307|RADIATION|iodine I 131|
218911179|NCT03917797|BIOLOGICAL|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
218911180|NCT03917797|DRUG|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
219524105|NCT00736970|DRUG|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
219524106|NCT03962023|OTHER|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
219524107|NCT01231490|DRUG|Placebo|Placebo
219524108|NCT01231490|DRUG|Naproxen|Capsule
218911181|NCT03917797|DRUG|Placebo|MSC infusion vehicle
218911182|NCT00828971|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
218911183|NCT00828971|DRUG|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
218911184|NCT02579200|DEVICE|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.
218911185|NCT02579200|DEVICE|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
218911186|NCT04729725|BIOLOGICAL|Anti-TGF-beta Monoclonal Antibody SAR-439459|Given IV
218911187|NCT04729725|BIOLOGICAL|Cemiplimab|Given IV
218911188|NCT05135871|DRUG|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
218911189|NCT00959608|BEHAVIORAL|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
218911190|NCT00959608|BEHAVIORAL|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
218911191|NCT05200065|PROCEDURE|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
218911192|NCT05200065|PROCEDURE|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
219040873|NCT04370691|DEVICE|JETi lower extremity arterial thrombosis|The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
219524109|NCT03003871|DEVICE|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
219524110|NCT03003871|DEVICE|Manual toothbrush|Oral-B® Pro-Health All-In-One
219524111|NCT03003871|OTHER|Toothpaste|Colgate Maximum Cavity Protection®
219524112|NCT03003871|OTHER|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
219524113|NCT05689905|DIAGNOSTIC_TEST|HLA typing of the children|The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
219524114|NCT03318471|DRUG|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
219524115|NCT03318471|DRUG|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
219524116|NCT00206583|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
219524117|NCT05088005|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
219524118|NCT02877147|OTHER|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
219524119|NCT04715477|BEHAVIORAL|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
219524120|NCT05343143|DEVICE|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
219524121|NCT03172351|DEVICE|EDoF1|extended depth of focus IOL - EDoF1
219524122|NCT03172351|DEVICE|Monofocal|Monofocal IOL
219524123|NCT03172351|DEVICE|EDoF2|Comparison EDoF2 IOL
218911193|NCT02364908|OTHER|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
219524124|NCT03326180|DRUG|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
219524125|NCT03326180|DRUG|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
219524126|NCT00479258|DRUG|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
219524127|NCT00479258|DRUG|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
219524128|NCT02808702|BEHAVIORAL|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
219524129|NCT00373217|BIOLOGICAL|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
218911194|NCT05998122|OTHER|nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
218911195|NCT03650491|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
218911196|NCT00062712|DRUG|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
218911197|NCT04261556|DEVICE|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
218911198|NCT04261556|DEVICE|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
219524130|NCT00373217|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally or subcutaneously
219524131|NCT00373217|DRUG|carboplatin|Given IV
219524132|NCT00373217|DRUG|paclitaxel|Given IV
219524133|NCT00373217|PROCEDURE|conventional surgery|Patients undergo primary optimal cytoreductive surgery
219524134|NCT05033834|OTHER|covid-19 vaccines registered in Egypt|Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
218911199|NCT04403334|DRUG|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
218911200|NCT04403334|DRUG|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
218911201|NCT05167435|OTHER|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
218911202|NCT05167435|OTHER|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
218911203|NCT02428777|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
218911204|NCT02428777|DRUG|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
219524135|NCT03838393|OTHER|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
219524136|NCT01008878|BEHAVIORAL|interdisciplinary intervention|
219524137|NCT01860105|DRUG|MDCO-157|intravenous administration
219524138|NCT01860105|DRUG|PLAVIX|oral administration
219524139|NCT06278545|DRUG|modified FOLFORINOX|"One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours"
219524140|NCT06278545|DRUG|Modified FOLFOX|"One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours"
219524141|NCT02942953|DEVICE|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
219524142|NCT03141398|DIAGNOSTIC_TEST|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
218911205|NCT02428777|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
218911206|NCT03661320|BIOLOGICAL|Nivolumab|Specified dose on specified days
218911207|NCT03661320|DRUG|Gemcitabine|Specified dose on specified days
218911208|NCT03661320|DRUG|Cisplatin|Specified dose on specified days
218911209|NCT00000669|DRUG|Didanosine|
218911210|NCT06132269|DIETARY_SUPPLEMENT|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
218911211|NCT06132269|DIETARY_SUPPLEMENT|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
218911212|NCT02869711|OTHER|Health care quality management|
218911213|NCT01420861|DRUG|GTx-758|two GTx 758 tablets per day
218911214|NCT00402857|BEHAVIORAL|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
218911215|NCT03269526|DRUG|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
218911216|NCT05254626|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
218911217|NCT05254626|DRUG|Pioglitazone 30 mg|Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
218911218|NCT01805011|OTHER|minimum 4 months of breastfeeding|
218911219|NCT05242029|DRUG|Placebo|Participants will receive placebo in a clinical setting.
218911220|NCT05242029|DRUG|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
218911221|NCT01247324|DRUG|Interferon beta-1a|
218911222|NCT01247324|DRUG|Ocrelizumab-matching placebo|
218911223|NCT01247324|DRUG|Ocrelizumab|
218911224|NCT01247324|DRUG|Interferon beta-1a-matching placebo|
218911225|NCT02490449|DRUG|Dexlansoprazole MR|Administration of drug after or before diet
218911226|NCT05737914|PROCEDURE|Endoscopic thoracic T3 sympathectomy|Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
218911227|NCT05737914|PROCEDURE|ThoracicT3 radiofrequency ablation|radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
219524143|NCT03141398|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
219524144|NCT03141398|DIAGNOSTIC_TEST|T2* MRI of the Pancreas|MRI \[Magnetic resonance imaging\] of the pancreas which is safe and takes around 30 minutes.
219524145|NCT03456947|DRUG|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
219524146|NCT03073330|DIAGNOSTIC_TEST|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
219524147|NCT03073330|DIAGNOSTIC_TEST|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
219524148|NCT02126137|DRUG|Ezetimibe|
218911228|NCT04983277|OTHER|no intervention|no intervention
218911229|NCT04131023|BEHAVIORAL|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
218911230|NCT01832077|DEVICE|90 D|rural doctors exam eye fundus by 90 D
218911231|NCT01832077|DEVICE|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
218911232|NCT04061122|DIAGNOSTIC_TEST|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
218911233|NCT04350632|DIAGNOSTIC_TEST|Shear wave elastography assessment of the external anal sphincter|"Assessment of the external anal sphincter viscoelastic properties using shear wave elastography technology~* Women in lithotomy position with an empty bladder~* The linear probe is applied on transversal plane on the perineal with a transperineal approach~* The external anal sphincter will be identified in 2D ultrasound using a SL 18-5 linear probe~* Viscoelastic properties of the muscle will be assessed by measuring the shear modulus at rest, Valsalva maneuver and contraction~* Exactly the same investigations will be performed for the two visits planned in the protocol. In the first visit, it will be one single observer and for the second it will be 2 observers.~* Data about the mode of delivery and the occurrence of OASI will be collected into women's medical fil"
218911234|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
218911235|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
218911236|NCT05144373|BEHAVIORAL|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
218911237|NCT06219525|DIETARY_SUPPLEMENT|Higher dose of enteral zinc|Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
219040874|NCT03616990|BEHAVIORAL|TASC Service Linkages - Discharge Area Only|Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
219524149|NCT01108094|DRUG|Itraconazole|"* Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
218911238|NCT06219525|DIETARY_SUPPLEMENT|Standard dose of enteral zinc|Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
218911239|NCT05367778|DRUG|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
218911240|NCT03201588|DIETARY_SUPPLEMENT|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
218911241|NCT01691794|DRUG|Atazanavir|
218911242|NCT01691794|DRUG|Ritonavir|
218911243|NCT04965324|OTHER|Anaesthesia Depth|
218911244|NCT04972786|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
218911245|NCT01606072|DRUG|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
218911246|NCT00628017|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
218911247|NCT02559102|DRUG|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
218911248|NCT02559102|DRUG|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
218911249|NCT02559102|PROCEDURE|Caudal anaesthesia|single shot caudal anaesthesia
218911250|NCT02559102|PROCEDURE|Inguinal hernia surgery|Infant inguinal hernia repair.
219524150|NCT02403791|DEVICE|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
219524151|NCT02403791|DEVICE|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
219614161|NCT01144702|DRUG|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
218911251|NCT04107246|DEVICE|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
218911252|NCT01799096|DIETARY_SUPPLEMENT|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
218911253|NCT01799096|DIETARY_SUPPLEMENT|Aspartame|Intensely sweetened soft drink (no energy content)
218911254|NCT04604535|DIETARY_SUPPLEMENT|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
218911255|NCT04604535|DIETARY_SUPPLEMENT|Placebo|70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
218911256|NCT00844844|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
218911257|NCT00532662|DRUG|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
218911258|NCT04666285|OTHER|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
219524152|NCT02185872|OTHER|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
219524153|NCT02185872|OTHER|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
218911259|NCT02512549|OTHER|Pulmonary Rehabilitation|
218911260|NCT04778735|PROCEDURE|Liver Transplantation|Liver Transplantation is performed under spesific conditions to increase the life time of patients with liver diseases.
219524154|NCT03726866|DRUG|Sequence 1|D326, D337 or CKD-828 for 9 days
219614162|NCT04074941|OTHER|Dietary intervention|Intervention include low sodium or usual sodium diet
219614163|NCT04801303|DRUG|Calcitriol|Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)
218911261|NCT02893319|BEHAVIORAL|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
218911262|NCT01943344|DEVICE|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
218911263|NCT01003808|BIOLOGICAL|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
218911264|NCT05903508|OTHER|Functional task training and functional therapy program|Functional task training group this will receive walking and no walking activities
218911265|NCT05903508|OTHER|Functional therapy program Group|Functional therapy program Group this will receive goal directed training
218911266|NCT04809831|OTHER|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
218911267|NCT04809831|OTHER|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
218911268|NCT01581918|DRUG|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
218911269|NCT02931617|OTHER|Chest Physiotherapy|
218911270|NCT02931617|DEVICE|Post-therapy lung volume measurements|In both intervention groups.
218911271|NCT05998018|DEVICE|pdSTIM System Therapy|Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
218911272|NCT05189743|PROCEDURE|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
219524155|NCT03726866|DRUG|Sequence 2|D326, D337 or CKD-828 for 9 days
219524156|NCT03726866|DRUG|Sequence 3|D326, D337 or CKD-828 for 9 days
219524157|NCT03726866|DRUG|Sequence 4|D326, D337 or CKD-828 for 9 days
219524158|NCT03726866|DRUG|Sequence 5|D326, D337 or CKD-828 for 9 days
219524159|NCT03726866|DRUG|Sequence 6|D326, D337 or CKD-828 for 9 days
219524160|NCT02822820|DEVICE|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
219524161|NCT02822820|DEVICE|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
219524162|NCT06410222|PROCEDURE|Recurrence after undergo spinal cord stimulation|"1. To investigate the pain relief and recurrence of patients with herpes zoster neuralgia after spinal cord stimulation treatment.~2. To analyze the risk factors related to recurrence after spinal cord stimulation treatment in patients with herpes zoster neuralgia, and build a recurrence prediction model."
219524163|NCT04826679|DRUG|Camrelizumab, nab-paclitaxel, cisplatin|"Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
219524164|NCT01662284|DRUG|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
219524165|NCT05059249|PROCEDURE|Hot Pack|Superficial Heating
219524166|NCT05059249|PROCEDURE|Manual Traction|Manual Traction for 10 minutes
219524167|NCT05059249|PROCEDURE|Mechanical Traction|Mechanical Traction for 10 minutes
218911273|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\_06 Group and ABCWY low dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\_01 Group, ABCWY low doseS\_02 Group and ABCWY low doseS\_06 Group in study Phase II (Sourcing).
218911274|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\_06 Group and ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\_01 Group, ABCWY high doseS\_02 Group and ABCWY high doseS\_06 Group in study Phase II (Sourcing).
218911275|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\_06 Group, ABCWY low dose\_02 Group, ABCWY high dose\_06 Group, ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding).
218911276|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
218911277|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
218911278|NCT03676842|COMBINATION_PRODUCT|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
218911279|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
218911280|NCT02891447|DRUG|Cisplatin|Given intraperitoneally
218911281|NCT02891447|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
219524168|NCT05059249|PROCEDURE|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
219524169|NCT05059249|PROCEDURE|TENS|TENS for 10 minutes with hot pack
218911282|NCT02891447|DRUG|Mitomycin|Given intraperitoneally
218911283|NCT05061238|DEVICE|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
218911284|NCT06642454|OTHER|Transcutaneous auricular vagus nerve stimulation|"Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz."
218911285|NCT04160182|BEHAVIORAL|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
218911286|NCT04527796|OTHER|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
218911287|NCT06491446|DRUG|ABI-2280|"Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered."
218911288|NCT05270057|DRUG|Etoposide|Dose level -2=50 mg/m\^2; dose level -1=50 mg/m\^2; dose level 1=50 mg/m\^2; dose level 2=60 mg/m\^2; dose level 3=72 mg/m\^2; dose level 4=86.4 mg/m\^2; dose level 5=103.7 mg/m\^2; dose level 6=124.4 mg/m\^2; dose level 7=149.3 mg/m\^2
219040875|NCT03616990|BEHAVIORAL|SRC Overnight Stay|Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
219040876|NCT03616990|BEHAVIORAL|TASC Services Linkages - SRC Onsite|While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
219040877|NCT03616990|BEHAVIORAL|APN Appointment|Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
219040878|NCT04486846|OTHER|eVisit|electronic surveillance program in lieu of in-person clinic visit
219040879|NCT04374890|DEVICE|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
219040880|NCT01783951|BIOLOGICAL|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
219040881|NCT01783951|DRUG|S-1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
219040882|NCT01783951|DRUG|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
219040883|NCT02162290|OTHER|Interval exercise training|Exercise bouts in low and high intensities
219040884|NCT02162290|OTHER|Continuous exercise training|
219524170|NCT01759277|DRUG|Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
219524171|NCT01759277|DRUG|Experimental: Adductor Canal perineural local anesthetic infusion|The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
219524172|NCT01012635|OTHER|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
219040885|NCT00389116|DRUG|gastrograffin|ingestion
219040886|NCT00389116|DRUG|water|oral water ingestion
219524173|NCT01012635|OTHER|Meditation|"Meditation: focus on a single word (one) for the entire session."
219524174|NCT01012635|OTHER|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
219040887|NCT01112293|DRUG|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
219040888|NCT03715608|OTHER|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
219040889|NCT06321874|PROCEDURE|Oxygen|
219040890|NCT02117037|OTHER|blood sample|
219040891|NCT01807052|OTHER|laboratory biomarker analysis|Correlative studies
219040892|NCT03778151|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
219040893|NCT05520008|OTHER|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
219040894|NCT00233727|PROCEDURE|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
219040895|NCT00233727|PROCEDURE|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
218911289|NCT05270057|DRUG|Doxorubicin|Dose level -2=10 mg/m\^2; dose level -1; dose level -1=10 mg/m\^2; dose level 1=10 mg/m\^2; dose level 2=12 mg/m\^2; dose level 3=14.4 mg/m\^17.3 mg/m\^2; dose level 4=17.3 mg/m\^2; dose level 5=20.7 mg/m\^2; dose level 6=24.8 mg/m\^2; dose level 7=29.8 mg/m\^2.
219040896|NCT06186778|PROCEDURE|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
219040897|NCT06186778|PROCEDURE|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
219524175|NCT01012635|OTHER|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
219524176|NCT02452164|OTHER|Teaching|
219524177|NCT02452164|DEVICE|(CellScopeOTO)|
219524178|NCT01542190|DRUG|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
219524179|NCT04715152|DRUG|ACB group|Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
219524180|NCT04715152|DRUG|IA group|Patients will receive intra-articular bupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline
219524181|NCT02407275|OTHER|Biological sample|
219524182|NCT00528905|DRUG|AZD3480|oral capsule
219524183|NCT05187949|OTHER|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
219524184|NCT05512442|PROCEDURE|the centric relation|All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.
219524185|NCT01630733|DRUG|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
218911290|NCT05270057|DRUG|Cyclophosphamide|Dose level -2=480 mg/m\^2; dose -1=600 mg/m\^2; dose level 1=750 mg/m\^2; level 2=900 mg/m\^2; level 3=1080 mg/m\^2; level 4=1296 mg/m\^2; level 5=1555 mg/m\^2; level 6=1866 mg/m\^2; level 7=2239 mg/m\^2.
218911291|NCT05270057|DRUG|Rituximab|Level -2 through level 7: 375 mg/m\^2
218911292|NCT05270057|DRUG|Vincristine|Level -2 through level 7: 0.4 mg/m\^2/day
218911293|NCT05270057|DRUG|Prednisone|Level -2 through level 7: 60 mg/m\^2/twice daily (BID)
218911294|NCT05270057|DRUG|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
218911295|NCT05270057|DRUG|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
218911296|NCT05270057|DRUG|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
218911297|NCT01406886|BEHAVIORAL|Eating rate|
218911298|NCT01071057|DRUG|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
218911299|NCT01071057|DRUG|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
218911300|NCT03844555|DRUG|Elafibranor|120mg oral single dose
218911301|NCT05638165|DRUG|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
218911302|NCT04190914|OTHER|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
218911303|NCT02413307|OTHER|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
218911304|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
218911305|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
218911306|NCT00756366|OTHER|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
218911307|NCT01740713|DRUG|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
218911308|NCT01740713|DRUG|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
218911309|NCT01740713|DRUG|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
218911310|NCT03081026|DIAGNOSTIC_TEST|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
218911311|NCT04945083|OTHER|Experimental Nutritional Pudding|High Calorie, High Protein pudding
218911312|NCT00953602|OTHER|Genetically modified potato|Genetically modified potato
218911313|NCT01404039|BEHAVIORAL|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
218911314|NCT01404039|BEHAVIORAL|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
218911315|NCT01404039|BEHAVIORAL|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
218911316|NCT01404039|BEHAVIORAL|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
219524186|NCT01630733|DRUG|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
219040898|NCT05706688|PROCEDURE|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
219614164|NCT04801303|OTHER|Blood analysis for frataxin's level measurement|"1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~* Age- and gender-matched controls (supposedly non-heterozygous)."
218911317|NCT01404039|DEVICE|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
218911318|NCT06162988|DRUG|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
218911319|NCT06230627|OTHER|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
218911320|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
218911321|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
218911322|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
218911323|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
218911324|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
218911325|NCT06593353|OTHER|Systems Analysis and Improvement Approach (SAIA)|SAIA an evidence-based, multi-prong, implementation strategy to improve systems thinking amongst frontline care teams to optimize care quality and continuity. The intervention includes monthly meetings where patient care cascades, process mapping and continuous quality improvement are used to identify bottlenecks and prioritize clinic based solutions.
218911326|NCT01591707|BEHAVIORAL|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
218911327|NCT06651749|DRUG|Propofol injection|hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
218911328|NCT06665945|DIAGNOSTIC_TEST|Platelet RNA expression|The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.
218911329|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
218911330|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
219614165|NCT04801303|DIAGNOSTIC_TEST|Blood analysis for hypercalcemia's control|Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
219040899|NCT06210087|OTHER|Spontaneous pushing technique|Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
219040900|NCT04446065|DRUG|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
219040901|NCT04446065|DRUG|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
219040902|NCT06366880|OTHER|Parenteral nutrition cycling|"This study is a single-centre, non-blinded RCT in the NICU of Pediatric Hospital of Sinaloa, Northwest, Mexico.~A total of 66 infants born ≥34 weeks of gestation who have a high likelihood of intolerance to enteral nutrition (EN) for at least 10 days will be randomised to PNC o PNT after informed parental consent. In both groups, EN will be commenced as early as clinically feasible."
219040903|NCT01503827|RADIATION|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
219365392|NCT03544112|DRUG|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
219365393|NCT04960085|DEVICE|echocardiography|philips IE33
219365394|NCT01175798|DRUG|Cholecalciferol|50,000 IU PO weekly x 6 weeks
219365395|NCT05429879|OTHER|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
219040904|NCT00782262|DIETARY_SUPPLEMENT|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
219040905|NCT05179733|DRUG|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
219040906|NCT05179733|DRUG|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
219040907|NCT02731872|DEVICE|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
219040908|NCT01753635|DEVICE|supraglottic airway placement and use|
219040909|NCT00855309|DRUG|acyclovir sodium|Given IV
219040910|NCT00004028|DRUG|carmustine|
219040911|NCT00004028|PROCEDURE|conventional surgery|
219040912|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
219040913|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
219040914|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
218911331|NCT06051435|OTHER|lumbar proprioception training|"a) Sensorimotor training: Sensorimotor training and reconditioning of proprioceptive senses have recently been found to be helpful in increasing motor performance and coordination, muscle strength, sensorimotor abilities, increasing intermuscular control, and improving one's response to sensory information and muscle tone. Reconditioning of proprioceptive senses and sensorimotor training increases one's muscle adjustment ability, maximizes the sensory input in different parts of the body and aids in improving one's motor adjustment ability (Hwang et al ., 2013).~Position Exercise methods as Hollowing exercise: Participants will be asked to contract the abdominal muscles, raising the center of movement toward the navel in a quadruped position."
218911332|NCT06051435|OTHER|Hot packs|hot application in the form of hot packs on the lower abdomen and lower back for a total duration of 30 minutes, once per day, during the first two days of menstruation
218911333|NCT06051435|OTHER|Pelvic rocking exercise|Pelvic rocking exercise
218911334|NCT06599827|RADIATION|moderately hypofractionated radiotherapy|35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.
219040915|NCT05349162|DEVICE|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
219524187|NCT05115357|PROCEDURE|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
219524188|NCT05115357|PROCEDURE|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
218911335|NCT06599827|DRUG|chemotherapy|CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
218911336|NCT06599827|DRUG|immunotherapy|Serplulimab 300 mg IV infusion on day 1 every 21 days.
218911337|NCT06599827|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
219040916|NCT02757079|DRUG|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
219040917|NCT05105308|BEHAVIORAL|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
219040918|NCT05105308|BEHAVIORAL|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
218911338|NCT06604221|BEHAVIORAL|Resistance exercise intervention|The exercise prescription, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.
219524189|NCT03329326|OTHER|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
218911339|NCT06604221|BEHAVIORAL|Routine care|"1.Pre-dialysis Assessment:~1. Vital Signs: Monitor blood pressure, heart rate, temperature.~2. Access Care: Check the vascular access site for signs of infection and patency. 2.During Dialysis:~（1）Monitoring: Continuous vital signs and machine settings monitoring. （2）Fluid Management: Control fluid removal based on pre-dialysis weight. 3.Post-dialysis Care:~1. Observation: Monitor for complications like hypotension, cramps, or bleeding.~2. Weight Check: Weigh post-dialysis to verify fluid removal. 4.Education and Support:~（1）Diet: Educate on dietary restrictions (potassium, phosphorus, fluids). （2）Medications: Advise on medication adjustments. 5.Psychosocial Support:~（1）Provide emotional support and counseling."
218911340|NCT00952991|DRUG|LAF237 = vildagliptin|
219524190|NCT02489526|DRUG|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
219524191|NCT02489526|DRUG|Placebo|Placebo group will receive the corresponding amount of placebo.
219040919|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
219524192|NCT04411966|DIAGNOSTIC_TEST|18F-fluorothymidine|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
219524193|NCT04040426|OTHER|Human split thickness skin allograft|Application of a fenestrated human skin graft
219524194|NCT04040426|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
219524195|NCT04040426|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
219524196|NCT04040426|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
219524197|NCT03261310|DRUG|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
219524198|NCT04953676|PROCEDURE|round tunnel technique|Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill
219524199|NCT04953676|PROCEDURE|flat tunnel technique|Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
219524200|NCT01659580|DRUG|T89 high dose|225mg bid
219524201|NCT01659580|DRUG|T89 Low dose|150mg bid
219524202|NCT01659580|DRUG|Sanqi+Bingpian|225 mg bid
219524203|NCT01659580|DRUG|Placebo|225mg bid
219524204|NCT03374462|BEHAVIORAL|Telemedicine Intervention|Home-based telemedicine visits
219524205|NCT05388318|BEHAVIORAL|Prolonged nightly fasting|14 hour nightly fast from caloric food and beverage; followed by 10 hour eating window. 8-week intervention duration.
219524206|NCT05388318|BEHAVIORAL|Health Education Control|Weekly health education video viewing related to general health topics
219524207|NCT02088463|PROCEDURE|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
219524208|NCT02088463|PROCEDURE|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
219524209|NCT02088463|DEVICE|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
219524210|NCT00005877|DRUG|rubitecan|
219524211|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
219524212|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
218911341|NCT04498715|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
218911342|NCT04498715|DRUG|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
218911343|NCT04498715|DEVICE|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
218911344|NCT03968679|RADIATION|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
218911345|NCT03755921|OTHER|bried and intensive therapy|Speech Therapy Exercises
218911346|NCT05136586|OTHER|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
218911347|NCT05136586|OTHER|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
218911348|NCT05136586|OTHER|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
218911349|NCT05136586|OTHER|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
218911350|NCT05472090|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
218911351|NCT05472090|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
219524213|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
219614166|NCT01965743|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
219614167|NCT03798015|OTHER|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
218911352|NCT04227470|DRUG|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
218911353|NCT05968716|OTHER|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
218911354|NCT03495661|PROCEDURE|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
219614168|NCT02350101|DEVICE|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
219614169|NCT05360810|DEVICE|Wei Nasal Jet Tube|"comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures~airway devices which can use for gastrointestinal procedures"
219614170|NCT05360810|DEVICE|Gastro Laryngeal Tube|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
218911355|NCT03827434|DEVICE|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
218911356|NCT03827434|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
218911357|NCT06699823|OTHER|Greek version of QoR-15|Greek version of QoR-15
218911358|NCT06705101|DRUG|Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin|In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.
219524214|NCT05349695|DEVICE|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
218911359|NCT06705101|OTHER|Placebo Oral Tablet|The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.
218911360|NCT06706089|OTHER|Nurse-led educational intervention|"This nurse-led educational intervention included: a) an oral training session regarding glaucoma by the P.I. lasting 15 minutes, b) provision of printed informational material (leaflet) and c) provision of appropriately selected free informational videos from the World Glaucoma Association on the YouTube -online platform. All of the above mentioned educational methods focused on the disease, its treatment and its long-term management. The oral training session took place in an appropriate, quiet and clean area, respecting the patient's privacy. During this process, study participants had the opportunity and time to ask questions and ask for clarifications or additional information."
219040920|NCT06447090|DRUG|Mitoxantrone hydrochloride liposome|Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
219040921|NCT03364296|OTHER|Blood Samples|Blood sample retrieved for biological assessment and biobanking
219040922|NCT01371656|DRUG|levofloxacin|Given PO or IV
219040923|NCT03588364|OTHER|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
219040924|NCT05961566|DEVICE|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
219040925|NCT01325779|DRUG|heparin|subcutaneous heparin 5000 units every 8 hours
219040926|NCT01325779|DRUG|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
218911361|NCT06722378|OTHER|Access to medical notes|Inpatient notes shared in real-time on a hospital-owned bedside tablet linked to their child's records.
218911362|NCT06749314|PROCEDURE|Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression|The LE-ULBD: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression is a single portal through lamina with instrument to decompression both side of the spinal canal, giving strength of preserve facet joint, preserve spinal musculature, mitigate the risk of adjacent fusion and lesser bleeding
219040927|NCT04412330|OTHER|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
219040928|NCT04384965|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
219040929|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
218911363|NCT06887582|PROCEDURE|Free-hand sinus lift augmanted by particulate autologous dentin graft + free-hand implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous free-hand implant placement
219040930|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
219040931|NCT03812965|DRUG|Botulinum toxin type A|2 units/point of botulinum toxin type A
219524215|NCT00420303|DRUG|Etanercept|50 mg injection once weekly
219524216|NCT00420303|OTHER|Placebo|placebo
219524217|NCT00739947|OTHER|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
219524218|NCT05729594|DRUG|Bimatoprost Ophthalmic|eyedrops
219040932|NCT04733963|DRUG|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
218911364|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift augmanted by particulate autologous dentin graft + computer-guided implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
219040933|NCT04733963|DRUG|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
219040934|NCT03007511|DEVICE|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
219524219|NCT05289674|DIETARY_SUPPLEMENT|High Calorie Formula|The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
219524220|NCT04891120|DIAGNOSTIC_TEST|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
219040935|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
219040936|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
219040937|NCT05551143|OTHER|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
219040938|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class A
219524221|NCT01446094|DRUG|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
219524222|NCT00247195|BEHAVIORAL|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
219524223|NCT00081848|DRUG|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
219524224|NCT00081848|DRUG|rF-CEA(6D)/TRICOM|
219524225|NCT00081848|DRUG|Recombinant Fowlpox-GM-CSF|
219524226|NCT00081848|DRUG|Celecoxib|
219614171|NCT02892955|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
219614172|NCT03806114|PROCEDURE|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
219614173|NCT03806114|PROCEDURE|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
219614174|NCT03806114|PROCEDURE|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
219614175|NCT04618523|DRUG|Artesunate-amodiaquine|Artemisinin-based combination treatment
219614176|NCT04618523|DRUG|Artemether-lumefantrine|Artemisinin-based combination treatment
219614177|NCT03648736|OTHER|blood withdrawal|"* peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~* central-venous during TASH"
219614178|NCT05433818|BEHAVIORAL|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
218911365|NCT06887582|PROCEDURE|Free-hand sinus lift with autologous dentin block graft +free-hand immediate implant placement|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous free-hand implant placement
219524227|NCT00312039|DRUG|Elvucitabine|Elvucitabine 10 mg QD for 14days
219524228|NCT00312039|DRUG|Lamivudine|Lamivudine 300 mg QD for 14 days
219524229|NCT05383794|OTHER|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
219524230|NCT06242613|PROCEDURE|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
219524231|NCT06242613|PROCEDURE|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
219524232|NCT04598984|DIAGNOSTIC_TEST|serum adipokines|Level of serum adipokines will be measured with flow cytometry
219524233|NCT04900584|OTHER|Checklist|Checklist of guideline-based treatment before discharge
219614179|NCT05433818|OTHER|Group B|education with a structured and expert opinion-based breastfeeding brochure
218911366|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift with autologous dentin block graft +computer-guided immediate implant placement.|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
218911367|NCT06784154|OTHER|Non-interventional|Non-interventional
218911368|NCT06887595|PROCEDURE|Free-hand linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting
218911369|NCT06887595|PROCEDURE|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided crestal ridge splitting expansion after linear micro perforation osteotomy will be performed using electromagnetic mallet
218911370|NCT05324358|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
218911371|NCT05324358|DRUG|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
218911372|NCT05324358|OTHER|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
218911373|NCT05324358|OTHER|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
218911374|NCT05038475|DIAGNOSTIC_TEST|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
218911375|NCT03402737|RADIATION|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy (day 1-4)~* 3x 6-8Gy (day 1-4-7)~* 3x 6-10Gy (day 1-4-7)~* 3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
218911376|NCT04079361|DIAGNOSTIC_TEST|Blood samples|Bood samples during prenatal and postnatal visits
218911377|NCT06935136|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
218911378|NCT03641937|DEVICE|INVSENSOR00011|INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
218911379|NCT01350999|DRUG|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
218911380|NCT01350999|DRUG|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
218911381|NCT01594619|DRUG|Naloxegol|Oral 25mg tablet
219040939|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class B
218911382|NCT01594619|DRUG|Diltiazem XR|Oral 240mg tablet
218911383|NCT03593044|DRUG|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
218911384|NCT04464863|OTHER|Kinematic metrics|kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
218911385|NCT01941485|DEVICE|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
218911386|NCT01941485|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
218911387|NCT01414868|DRUG|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
218911388|NCT05493202|DEVICE|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
218911389|NCT06486025|DRUG|maintenance magnesium sulphate1g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
218911390|NCT06486025|DRUG|maintenance magnesium sulphate2g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
218911391|NCT01910285|DRUG|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
218911392|NCT01910285|DRUG|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
218911393|NCT03270436|BEHAVIORAL|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
218911394|NCT03270436|BEHAVIORAL|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
218911395|NCT03887923|BEHAVIORAL|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
218911396|NCT00368888|DEVICE|Urine collection bag for infants|
218911397|NCT03400735|COMBINATION_PRODUCT|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
218911398|NCT03400735|DRUG|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
218911399|NCT03612817|DRUG|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
218911400|NCT04475458|PROCEDURE|Ultrasound-guided dorsal penile nerve block|This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
219040940|NCT00651027|DRUG|PF-868554|200 mg, healthy volunteers
219040941|NCT03525197|DIETARY_SUPPLEMENT|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
219040942|NCT03525197|DIETARY_SUPPLEMENT|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
218911401|NCT01364896|PROCEDURE|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing"
218911402|NCT06357481|PROCEDURE|Endodontic Retreatment|A single operator procedured in one visit of non-surgical endodontic retreatment. Teeth were anesthetized using articaine hydrochloride with epinephrine 1:200,000 for mandibulary premolar teeth with one root canal. Each tooth was isolated with a rubber dam and then coronal restorations and caries were removed using sterile high-speed burs under water cooling. After preperation of the cavity access and localization of the canal orifice, all microorganisms that may have entered the root canal system are eliminated by removing the old canal filling with the One Flare and MicroMega REMOVER files in the MicroMega retreatment kit.
218911403|NCT01977547|BIOLOGICAL|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
218911404|NCT01195766|DRUG|Ofatumumab|Ofatumumab in addition with ESHAP therapy
218911405|NCT02541097|BEHAVIORAL|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
218911406|NCT00672555|PROCEDURE|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
218911407|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
218911408|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
218911409|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
218911410|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
218911411|NCT04066283|OTHER|No intervention|There was no intervention in this study
218911412|NCT06222866|DIAGNOSTIC_TEST|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
218911413|NCT05361395|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
218911414|NCT05361395|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
218911415|NCT05361395|DRUG|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
218911416|NCT05361395|DRUG|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
219040943|NCT01465464|DRUG|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
219040944|NCT01465464|DRUG|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
219040945|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
219040946|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
219040947|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
219040948|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
219040949|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
219040950|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
219524234|NCT04900584|OTHER|Education|Heart failure education before discharge
219524235|NCT04900584|OTHER|Telephone monitoring|Telephone monitoring after discharge
218911417|NCT05361395|DRUG|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
218911418|NCT02384551|OTHER|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
218911419|NCT04088877|BEHAVIORAL|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
218911420|NCT04088877|BEHAVIORAL|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
218911421|NCT04297904|BEHAVIORAL|Sedentary behaviour|To assess sedentary behaviour each participant will wear an activity monitor (PAL Technologies, Scotland). The resident will wear the monitor on their right thigh for 24 hours per day over seven days continuously.
218911422|NCT04297904|DIAGNOSTIC_TEST|Urinary Incontinence|The presence of IU, assessed by the Minimum Data Set (MDS) version 3.0, and used together with the International Consultation on Incontinence Questionnaire-Short Form to characterize the incontinence.
218911423|NCT03679923|DIETARY_SUPPLEMENT|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
218911424|NCT03679923|DIETARY_SUPPLEMENT|Placebo|Placebo
219040951|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
219524236|NCT03169348|DRUG|sofosbuvir daclatasvir|oral tablets
219524237|NCT03169348|DRUG|Ledipasvir/sofosbuvir|oral tablets
219524238|NCT04549584|DIAGNOSTIC_TEST|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
219614180|NCT01962103|DRUG|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
218911425|NCT06350032|DRUG|preservative-free parenteral treprostinil|Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
218911426|NCT04935034|DIETARY_SUPPLEMENT|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
218911427|NCT06579768|DIAGNOSTIC_TEST|different types of computed tomography (CT) scans|For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
218911428|NCT05164120|DRUG|Belnacasan|Oral administration
218911429|NCT05164120|DRUG|Placebo|Tablet containing 0mg of API
218911430|NCT05682625|OTHER|No intervention|No intervention
218911431|NCT04853173|OTHER|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
218911432|NCT06211114|DRUG|PD-(L)1 inhibitor|Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks
218911433|NCT06211114|DRUG|Axitinib|axitinib 5mg orally twice daily
218911434|NCT04192565|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
218911435|NCT02439853|BEHAVIORAL|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
218911436|NCT04435704|DRUG|Oxytocin|Intravenous Oxytocin
218911437|NCT03631940|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
219040952|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
219524239|NCT03368755|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
219524240|NCT03368755|DIAGNOSTIC_TEST|Respiratory Muscle Strength and Endurance|CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
219524241|NCT04177368|DIETARY_SUPPLEMENT|Theragran 60ml|history,examination and biochemical values
219524242|NCT02172105|DRUG|BI 1744 CL|
219524243|NCT02172105|DRUG|Placebo|
218911438|NCT03631940|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
218911439|NCT03035032|DRUG|Leuprolide|Subcutaneous Injection
218911440|NCT04206124|PROCEDURE|Brown Fat Harvest During Anterior Neck Surgery|During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
218911441|NCT06306105|DIETARY_SUPPLEMENT|Marine Collagen Peptides|consume 1 bottle per day
218911442|NCT06306105|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
218911443|NCT06289751|DRUG|Cadonilimab|10 mg/kg (body weight), 60 min, IV. Repeat every 3 weeks for a total of 3 cycles
218911444|NCT06289751|DRUG|Paclitaxel-albumin|260 mg/m2 for 30 min. Repeat every 3 weeks for a total of 3 cycles.
218911445|NCT06289751|DRUG|Cisplatin|75-80 mg/m2, IV, 1 mg/min. Repeat every 3 weeks for a total of 3 cycles.
218911446|NCT06289751|PROCEDURE|Extrafascial hysterectomy|Extrafascial hysterectomy + pelvic lymphadenectomy (or SLN mapping) (For participants who meet ConCerv criteria)
218911447|NCT06289751|PROCEDURE|Radical hysterectomy|Radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy (or SLN mapping) (For participants who do not meet ConCerv criteria)
218911448|NCT06289751|PROCEDURE|Cone biopsy|Cold knife conization (CKC) (For participants with tumor size ≤2 cm after 3 cycles of chemo-immunotherapy)
218911449|NCT04961710|DRUG|Hetrombopag Olamine|Hetrombopag Olamine; once daily
218911450|NCT04961710|DRUG|Placebo|Placebo; once daily
218911451|NCT06566989|DRUG|[¹⁴C]Opevesostat|Oral solution
218911452|NCT06566989|DRUG|Prednisone|Tablet
218911453|NCT06566989|DRUG|Fludrocortisone|Tablet
219524244|NCT00885456|BEHAVIORAL|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
219614181|NCT01962103|DRUG|nab-paclitaxel|IV infusion
218911456|NCT06581705|PROCEDURE|Video Laryngoscope|Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
219040953|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
219040954|NCT01465646|DRUG|levothyroxine|
219040955|NCT01465646|DRUG|levothyroxine|
218911457|NCT04745910|DRUG|Pegloticase|Given IV
219040956|NCT02513524|PROCEDURE|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
219614182|NCT01321749|PROCEDURE|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
218911458|NCT04745910|DRUG|Rasburicase|Given IV
218911459|NCT06123325|PROCEDURE|Clipping|Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
218911460|NCT06123325|PROCEDURE|Endovascular embolization|Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
218911461|NCT06123325|DIAGNOSTIC_TEST|Surveillance imaging|Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
218911462|NCT03122041|DRUG|Sitagliptin|
218911463|NCT03122041|BEHAVIORAL|Lifestyle intervention|
219040957|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
219040958|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
219040959|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
219040960|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
219040961|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
219040962|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
218911464|NCT02162550|DRUG|Bydureon|once weekly injection
218911465|NCT02162550|DRUG|placebo|once weekly injection
218911466|NCT06133244|DIAGNOSTIC_TEST|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
218911467|NCT06227871|PROCEDURE|Exploratory laparotomy|Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
218911468|NCT00836589|DEVICE|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
218911469|NCT00115570|DRUG|Insulin glulisine|Subcutaneous injection
218911470|NCT00115570|DRUG|insulin lispro|Subcutaneous injection
218911471|NCT00115570|DRUG|insulin glargine|Subcutaneous injection once daily
218911472|NCT00115570|DRUG|NPH insulin|subcutaneous injection twice daily
218911473|NCT01105819|PROCEDURE|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
218911474|NCT01105819|PROCEDURE|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
218911475|NCT02259673|OTHER|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
218911476|NCT02259673|OTHER|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
218911477|NCT00447720|BEHAVIORAL|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
218911478|NCT03326596|DRUG|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
218911479|NCT04453865|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
218911480|NCT04453865|OTHER|Online Resources and Referrals|Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
218911481|NCT04637386|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
218911482|NCT04637386|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
218911483|NCT03078322|DRUG|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218911484|NCT03078322|DRUG|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218911485|NCT05472337|DRUG|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
218911486|NCT04414241|DRUG|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
218911487|NCT03284177|DRUG|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
218911488|NCT03284177|DRUG|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
218911489|NCT03284177|OTHER|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
218911490|NCT00495768|BEHAVIORAL|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
218911491|NCT01598935|OTHER|nutrition|protein-based food
218911492|NCT02529917|DIETARY_SUPPLEMENT|Hemp powder|Hemp powder supplement
218911493|NCT02529917|DIETARY_SUPPLEMENT|Soy Powder|Soy powder supplement
218911494|NCT05730296|DEVICE|TMS|10 rTMS sessions combined with cognitive training
218911495|NCT05730296|DEVICE|TMS|10 rTMS sessions
218911496|NCT05730296|DEVICE|TMS|10 sham coils sessions without cognitive training
218911497|NCT00120926|DRUG|Parenteral Nutrition|
218911498|NCT02763059|DRUG|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
218911499|NCT02763059|DRUG|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
218911500|NCT02763059|DRUG|Placebo|This group receives 1 hour before surgery placebo.
219524245|NCT00885456|BEHAVIORAL|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
219524246|NCT04527575|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
218911501|NCT02763059|DRUG|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
218911502|NCT02004730|DEVICE|ABSORB implantation|ABSORB implantation for long (\> 24mm) single vessel disease
218911503|NCT00497029|DRUG|fluoride varnish|
218911504|NCT00497029|BEHAVIORAL|patient education|
218911505|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
218911506|NCT00746681|DRUG|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
218911507|NCT00746681|DRUG|Placebo|Placebo, Oral, twice daily for 4 weeks
218911508|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
218911509|NCT00746681|DRUG|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
219524247|NCT04527575|OTHER|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
219524248|NCT02149745|PROCEDURE|Calling the patient's name|calling the patient's name during anesthesia reversal
219524249|NCT02149745|PROCEDURE|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
219524250|NCT00003040|PROCEDURE|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
219524251|NCT00003040|RADIATION|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
218911510|NCT00628121|DRUG|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
218911511|NCT00860808|DRUG|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
218911512|NCT04935385|OTHER|Collecting blood specimens|Blood samples will be collected from all study participants at different required timelines
218911513|NCT06406712|OTHER|retroclavicular block|regional anesthesia
218911514|NCT00013572|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
218911515|NCT04294121|OTHER|Food marketing on product packaging|Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
218911516|NCT01962935|DRUG|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
218911517|NCT01962935|DRUG|Placebo|Part A - multiple ascending dose daily
218911518|NCT01962935|DRUG|AZD5069|Part B - one dose decided after part A, twice a day
218911519|NCT06366607|OTHER|high-alert medication administration|high-alert medication administration
218911520|NCT03213340|OTHER|Catechin Cohort 1|\- 4 capsules taken with water 1 hour prior to meal
218911521|NCT03213340|OTHER|Curcuminoid Cohort 2|\- 2 capsules taken with water 1 hour prior to meal
219040963|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
218911522|NCT03213340|OTHER|Flavonoid Cohort 3|\- \~ 1 oz. serving consumed 30 minutes before meal
218911523|NCT02571023|PROCEDURE|microscope surgery|
218911524|NCT02571023|PROCEDURE|neuroendoscope surgery|
218911525|NCT06459375|OTHER|modified otago exercises|patients will receive modified Otago exercises with conventional treatment.
219040964|NCT02235376|OTHER|weaning trial of mechanical ventilation|
219040965|NCT01443247|DRUG|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
219040966|NCT05180461|DRUG|emodepside|emodepside tablet
218911526|NCT06459375|OTHER|Action Observation Training|Patients will receive Action Observation Training with conventional treatment.
218911527|NCT02275702|DRUG|Dexamethasone IV|It will be administered at the induction of the anesthesia
218911528|NCT02275702|DRUG|Saline solution|
218911529|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
218911530|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
218911531|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
218911532|NCT00442169|BIOLOGICAL|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
218911533|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
218911534|NCT00442169|BIOLOGICAL|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
218911535|NCT00242931|OTHER|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
218911536|NCT01526499|DRUG|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
218911537|NCT01526499|DRUG|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
219040967|NCT05180461|DRUG|matching placebo of emodepside|emodepside matching placebo tablet
219040968|NCT05180461|DRUG|ivermectin|ivermectin tablet (overencapsulated for blinding)
219524252|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
219524253|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
219524254|NCT02772289|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
218911538|NCT05874674|DRUG|Nafamostat Mesylate|Comparison effect of nafamostat and cnoxan
219524255|NCT02639741|DRUG|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
219524256|NCT02639741|DRUG|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
218911539|NCT05081908|PROCEDURE|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
218911540|NCT04731701|DIAGNOSTIC_TEST|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
219524257|NCT02639741|OTHER|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
219524258|NCT01532141|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
219524259|NCT01532141|DRUG|Rasagiline|1 mg rasagiline (single-dose)
219524260|NCT02857322|OTHER|Accompanying patient's specific perioperative|
218911541|NCT02570178|OTHER|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
218911542|NCT01890343|DRUG|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
218911543|NCT01890343|DRUG|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
218911544|NCT02595983|DRUG|Revusiran|500mg Revusiran by subcutaneous (sc) injection
218911545|NCT05856500|DIETARY_SUPPLEMENT|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
219524261|NCT00219297|DRUG|Patupilone|
219524262|NCT04126811|DRUG|Apatinib Mesylate, Pirarubicin, Ifosfamide|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
219524263|NCT04126811|DRUG|Apatinib Mesylate|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
219524264|NCT04126811|DRUG|Pirarubicin, Ifosfamide|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
219524265|NCT04455633|DRUG|LX9211|Oral Tablets
219524266|NCT04455633|DRUG|LX9211 Matching Placebo|Oral Tablets
219524267|NCT00379548|BEHAVIORAL|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
219524268|NCT06543966|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
219524269|NCT06543966|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds
219524270|NCT00706745|DIETARY_SUPPLEMENT|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
219524271|NCT00706745|DIETARY_SUPPLEMENT|placebo|identical placebo capsules.
219614183|NCT05994339|DRUG|Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
218911546|NCT05856500|DIETARY_SUPPLEMENT|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
218911547|NCT01626326|BEHAVIORAL|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
218911548|NCT05817903|DRUG|Axitinib|Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
218911549|NCT05817903|DRUG|Nivolumab|Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
218911550|NCT02918370|DRUG|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
218911551|NCT02918370|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
218911552|NCT04156022|OTHER|Dystonia Coalition is an observational study.|This is not an interventional study.
218911553|NCT02456012|DRUG|oral esomeprazole 20 mg twice daily|for 36 weeks
218911554|NCT02456012|DRUG|oral esomeprazole 20 mg once daily|for 36 weeks
219524272|NCT03946501|OTHER|Data collection|
219524273|NCT06130735|BEHAVIORAL|Cognitive Computerized Training|Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
219524274|NCT03282136|DRUG|Incretin Effect|The patients will receive incretins therapy.
219524275|NCT03282136|DEVICE|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
219524276|NCT03282136|DRUG|SGLT-2 inhibitor|The patients will receive SGLT2i therapy.
219524277|NCT04249973|OTHER|Collection of urine and feces|Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
219614184|NCT00376649|BEHAVIORAL|lifestyle changing workshop|
219614185|NCT03825939|DRUG|Intravenous Placebo|IV 0.9% sterile saline
219614186|NCT03825939|DRUG|Intravenous Tranexamic Acid|1g TXA IVPB (intravenous piggyback)
219614187|NCT05740033|PROCEDURE|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
218911555|NCT03550118|DEVICE|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
218911556|NCT03908034|OTHER|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
219524278|NCT04071444|OTHER|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
219524279|NCT02565095|PROCEDURE|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
219524280|NCT01064349|DRUG|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
219524281|NCT02215161|DRUG|Selinexor|Given PO
219524282|NCT05806203|DEVICE|Low intensity shockwave treatment to pelvic floor region plus typical physical therapy|Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes
219524283|NCT05806203|DEVICE|Sham shockwave treatment plus typical physical therapy|Inactive dose of shockwave treatment
219524284|NCT04986332|BEHAVIORAL|Physical activity program|24-weeks moderate-intensity physical activity program
219524285|NCT04986332|OTHER|Global therapeutic remodeling|Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
219524286|NCT04015232|COMBINATION_PRODUCT|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
219524287|NCT04015232|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
219524288|NCT01512407|PROCEDURE|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
218911557|NCT03908034|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
218911558|NCT04910295|DRUG|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
218911559|NCT06082206|PROCEDURE|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
219040969|NCT05180461|DRUG|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
219040970|NCT01603446|DRUG|L-Arginine|NOW® L-Arginine powder
218911560|NCT06082206|PROCEDURE|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
218911561|NCT04404179|OTHER|COVID-19 FACILITY|A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
218911562|NCT01187017|DRUG|Cyclophosphamide|60 mg/kg
218911563|NCT01187017|DRUG|Fludarabine|125 mg/m squared
218911564|NCT02931188|DRUG|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
218911565|NCT02931188|DRUG|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
218911566|NCT02931188|DRUG|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
218911567|NCT01571102|BEHAVIORAL|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
218911568|NCT01571102|BEHAVIORAL|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
219040971|NCT02797847|DRUG|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
219040972|NCT02797847|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219040973|NCT02889640|OTHER|SAGA Innovations|An intensive math tutoring program
219040974|NCT02889640|OTHER|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
219040975|NCT02889640|OTHER|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
219040976|NCT00437684|DRUG|LPV/r|200/50 mg 2 cpr bid monotherapy
219040977|NCT00437684|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
219040978|NCT00437684|DRUG|Ribavirin|Ribavirin 1-1.2 g/day
219040979|NCT00437684|DRUG|NUCS|Nucleoside Reverse Transcriptase Inhibitors
218911569|NCT06256185|PROCEDURE|esophagectomy|Resection of esophageal tumor and lymph node dissection
218911570|NCT05595655|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
219524289|NCT05020847|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml
219524290|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 with CMV|Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
219524291|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 without CMV|Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
218911571|NCT04107662|DEVICE|Tbit system|Suspected traumatic brain injury with head CT
218911572|NCT02399215|OTHER|Laboratory Biomarker Analysis|Correlative studies
218911573|NCT02399215|DRUG|Nintedanib|Given PO
218911574|NCT02399215|OTHER|Pharmacological Study|Correlative studies
218911575|NCT02399215|OTHER|Quality-of-Life Assessment|Ancillary studies
218911576|NCT04068025|OTHER|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
218911577|NCT03560882|DRUG|Atorvastatin|Atorvastatin tablet, 80mg
218911578|NCT00772538|DRUG|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
218911579|NCT00772538|DRUG|placebo|Matching placebo
218911580|NCT03381690|PROCEDURE|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
218911581|NCT04638907|PROCEDURE|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
218911582|NCT02262936|DRUG|Desmopressin|
218911583|NCT02262936|DRUG|Fesoterodine|
218911584|NCT00524511|DEVICE|Surgical skin staples|Standard method to close abdominal surgical wounds
218911585|NCT00524511|DEVICE|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
218911586|NCT04161859|DIETARY_SUPPLEMENT|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
218911587|NCT04043910|DEVICE|fNIRS|The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
218911588|NCT04043910|OTHER|Speech intelligibility|Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
218911589|NCT04043910|OTHER|Sound localisation|Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
218911590|NCT04043910|OTHER|Speech assessments|Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
218911591|NCT04043910|OTHER|Quality of Life|Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
218911592|NCT04616755|OTHER|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
218911593|NCT00497458|DRUG|Testosterone|testosterone 40 or 80 mg once a day
218911594|NCT06061874|DIAGNOSTIC_TEST|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
219040980|NCT03561415|OTHER|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
219040981|NCT03561415|OTHER|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
219040982|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
219040983|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
219040984|NCT01590407|DRUG|ALS-002200|ALS-002200
219040985|NCT01590407|DRUG|Placebo|Placebo
219365396|NCT05429879|OTHER|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
219366280|NCT03280160|DRUG|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
219366281|NCT03287128|DRUG|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
218911595|NCT06410430|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
218911596|NCT02740946|OTHER|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
218911597|NCT03603782|DIETARY_SUPPLEMENT|2.5% protein|2.5%
218911598|NCT03603782|DIETARY_SUPPLEMENT|protein 5%|5%
218911599|NCT03603782|DIETARY_SUPPLEMENT|protein 10%|10%
218911600|NCT03603782|DIETARY_SUPPLEMENT|protein 15%|15%
218911601|NCT03603782|DIETARY_SUPPLEMENT|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
218911602|NCT03603782|DIETARY_SUPPLEMENT|B2: only breakfast (no product)|only breakfast
218911603|NCT03603782|DIETARY_SUPPLEMENT|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
218911604|NCT03603782|DIETARY_SUPPLEMENT|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
218911605|NCT06491186|OTHER|Point of Care Ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
218911606|NCT01101217|DRUG|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
218911607|NCT01101217|DRUG|placebo|placebo daily for 6 weeks
218911608|NCT00000376|BEHAVIORAL|Cognitive therapy|
218911609|NCT00000376|DRUG|Desipramine|
218911610|NCT04410497|OTHER|Porcine xenograft (wound dressings)|commercial porcine xenograft, derived from acellular dermis from porcine.
218911611|NCT04410497|OTHER|Silver foam (wound dressings)|commercial silver containing foam dressing
218911612|NCT05390073|DIAGNOSTIC_TEST|growth hormone level and insulin like growth factor 1|laboratory test
218911613|NCT00298324|DRUG|Myfortic|1440mg twice daily
218911614|NCT00298324|DRUG|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
218911615|NCT00713609|DRUG|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
218911616|NCT00713609|DRUG|Clindamycin gel|1% clindamycin phosphate applied topically once a day
218911617|NCT00713609|DRUG|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
219040986|NCT04328974|PROCEDURE|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
218911618|NCT00713609|DRUG|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
218911619|NCT00713609|DRUG|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
219040987|NCT01554618|DRUG|Exenatide Once Weekly|2 mg exenatide once weekly
219040988|NCT01554618|DRUG|Placebo|Placebo
219040989|NCT01566448|DRUG|Ketamine|20mg/5ml swish and spit four times daily
219040990|NCT02131480|DRUG|Doxorubicin|60 mg/m²
219040991|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
219524292|NCT05052138|OTHER|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
219524293|NCT05129098|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
219524294|NCT05129098|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
219524295|NCT02621775|BEHAVIORAL|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
218911620|NCT01903356|DRUG|Trajenta duo|Linagliptin and Metformin
218911621|NCT00020800|BIOLOGICAL|rituximab|
218911622|NCT00020800|DRUG|fludarabine phosphate|
218911623|NCT01387828|PROCEDURE|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
218911624|NCT01387828|PROCEDURE|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
218911625|NCT03488095|BEHAVIORAL|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
218911626|NCT00095693|DRUG|sorafenib tosylate|Given PO
218911627|NCT00095693|OTHER|laboratory biomarker analysis|Correlative studies
218911628|NCT00095693|OTHER|pharmacological study|Correlative studies
218911629|NCT00095693|RADIATION|fludeoxyglucose F 18|Correlative studies
218911630|NCT00095693|PROCEDURE|positron emission tomography|Correlative studies
218911631|NCT00095693|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
218911632|NCT03728868|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
219524296|NCT02621775|BEHAVIORAL|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
219524297|NCT02621775|OTHER|Waiting list|The patients are followed by their General Practitioners without change in treatment .
219524298|NCT05914103|PROCEDURE|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
219524299|NCT02164838|DRUG|Axitinib|
219524300|NCT01027780|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
219524301|NCT06261892|DIAGNOSTIC_TEST|Collect HPV DNA from urine|Use a sample collector to collect urine
219614188|NCT05740033|PROCEDURE|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
219614189|NCT03427294|OTHER|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
219614190|NCT06504277|PROCEDURE|Low Pressure Penumoperitoneum|Maintained Pneumoperitoneum with low pressure of 10 mm Hg
219614191|NCT06504277|OTHER|Standard Pressure Group (No intervention- active comparator)|Maintained Pneumoperitoneum at standard pressure of 15 mm Hg
219614192|NCT03649035|DEVICE|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
218911633|NCT03728868|DIETARY_SUPPLEMENT|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
218911634|NCT03728868|DIETARY_SUPPLEMENT|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
218911635|NCT00160186|DRUG|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
218911636|NCT00160186|DRUG|Placebo|Placebo
218911637|NCT00118183|DRUG|docetaxel|Given IV
218911638|NCT00118183|BIOLOGICAL|cetuximab|Given IV
218911639|NCT00118183|DRUG|bortezomib|Given IV
219614193|NCT04179838|BEHAVIORAL|Sleep-Deprived|Sleep for 4 hours at home.
219614194|NCT04179838|BEHAVIORAL|Non-Sleep Deprived|Sleep for 8 hours at home.
219614195|NCT01606358|DRUG|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
219614196|NCT06162364|OTHER|VR|playing a video using VR
219614197|NCT06162364|OTHER|theoretical training|Training was provided through theoretical education
218911640|NCT02144181|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
218911641|NCT05026528|OTHER|Digital diabetes self management education and support system|Digital diabetes self management and support system
218911642|NCT04529083|DEVICE|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
218911643|NCT04814303|PROCEDURE|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
218911644|NCT04814303|PROCEDURE|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
219040992|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
219040993|NCT05310110|DRUG|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
219614198|NCT06162364|OTHER|training with video|Training was given with two-dimensional video
219614199|NCT00324818|DRUG|metronidazole and azithromycin|
219614200|NCT06576518|OTHER|Therapeutic exercise|An individualised incremental exercise programme was simultaneously supported by an adherence plan to assess and promote compliance.
219614201|NCT00163618|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
219614202|NCT01667718|DRUG|Bismuth|Bismuth 220mg b.i.d for 2 weeks
219614203|NCT01667718|DRUG|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
219614204|NCT01667718|DRUG|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
218911645|NCT04814303|PROCEDURE|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
218911646|NCT00003989|BIOLOGICAL|ISIS 3521|
218911647|NCT00933699|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
218911648|NCT02470286|DRUG|SA001 60mg or Placebo|"* Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)"
218911649|NCT02470286|DRUG|SA001 120mg or Placebo|"* Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
218911650|NCT02470286|DRUG|SA001 180mg or Placebo|"* Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)"
218911651|NCT02470286|DRUG|SA001 240mg or Placebo|"* Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)"
218911652|NCT02470286|DRUG|SA001 300mg or Placebo|"* Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
218911653|NCT05399069|DRUG|VGR-R01|Gene Replacement Therapy
218911654|NCT03305666|DRUG|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
218911655|NCT03305666|DRUG|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
218911656|NCT01293903|DRUG|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
218911657|NCT01293903|DRUG|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
218911658|NCT00783159|PROCEDURE|Power Training|Power training, Vitamin D substitution
218911659|NCT00783159|PROCEDURE|Strength Training|Strength training, Vitamin D substitution
218911660|NCT00783159|OTHER|Control|Vitamin D substitution, Lifestyle consultation
218911661|NCT00196547|DRUG|Montelukast (drug)|
218911662|NCT06091475|DRUG|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
219524302|NCT05381623|PROCEDURE|Simplified suture-less approach|Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.
219524303|NCT05381623|PROCEDURE|Application of hemostatic sponges and compressive sutures|Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
219614205|NCT01667718|DRUG|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
219614206|NCT03161470|OTHER|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
218911663|NCT06009939|OTHER|Occlusion of the circulation in the arm and foot|A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
218911664|NCT03969485|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser Device
218911665|NCT02739230|DRUG|Exparel|
218911666|NCT02739230|DRUG|On-Q pain intra-articular catheter|
218911667|NCT06540053|OTHER|Active Static Hamstring Stretch Exercise|In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.
218911668|NCT06540053|OTHER|Waiting List|Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
218911669|NCT01615146|OTHER|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
218911670|NCT02064803|PROCEDURE|Gastro-entero anastomosis only|Gastro-entero anastomosis only
218911671|NCT02064803|PROCEDURE|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
218911672|NCT01434017|DRUG|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
218911673|NCT01434017|DRUG|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
218911674|NCT01434017|DRUG|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
218911675|NCT02005549|DRUG|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
219614207|NCT03161470|OTHER|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
218911676|NCT02005549|DRUG|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
219614208|NCT03161470|OTHER|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
219614209|NCT05639049|DEVICE|Enova GF3|Enova GF3, monofocal IOL
219614210|NCT05639049|DEVICE|Tecnis 1-piece ZCB00|Tecnis 1-piece ZCB00, monofocal IOL
218911677|NCT02005549|DRUG|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
218911678|NCT03799146|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
218911679|NCT03799146|OTHER|Waiting List|Waiting List control group
218911680|NCT00521950|GENETIC|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
218911681|NCT00521950|DRUG|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
218911682|NCT04195646|DEVICE|EndoVigilant CAD Software|The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
218911683|NCT01729741|PROCEDURE|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
218911684|NCT02728115|BIOLOGICAL|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
218911685|NCT02728115|BIOLOGICAL|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
218911686|NCT00169182|DRUG|DOCETAXEL|75 mg/m 2 on day 1
218911687|NCT00169182|DRUG|Cisplatin|75 mg/m 2 on day 1
218911688|NCT00169182|DRUG|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
218911689|NCT05247372|OTHER|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
218911690|NCT02587221|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
218911691|NCT02587221|BIOLOGICAL|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
218911692|NCT04268459|DEVICE|Provox prosthesis exchange|Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
218911693|NCT04558060|OTHER|Virtual Standardized Patient|Computer program that presented a virtual human patient
218911694|NCT04558060|OTHER|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
218911695|NCT00241384|PROCEDURE|External beam radiation|
218911696|NCT00241384|PROCEDURE|Pd-103|
218911697|NCT04612335|OTHER|Rate control|Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
218911698|NCT04612335|OTHER|Pharmacological or electrical cardioversion|Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
218911699|NCT02944110|DRUG|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
218911700|NCT02944110|DRUG|Placebo|Oral dose of placebo tablets
218911701|NCT02196896|OTHER|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
219614211|NCT06067256|DRUG|Female Contraceptive|Effimia® exerts its action by means of a gonadotropin suppression mechanism through the estrogenic and progestin action exerted by EE and NGM. The contraceptive effect of Effimia® is based on the interaction of various factors, the most important of which consist of ovulation inhibition and endometrial modifications.
219614212|NCT04562168|DIAGNOSTIC_TEST|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
218911702|NCT02196896|OTHER|Information|The patients receive online information about depression once a week for 90 days.
219524304|NCT01416766|OTHER|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
219524305|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
219040994|NCT05310110|DRUG|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
219040995|NCT05310110|DRUG|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
219524306|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
218911703|NCT05225311|OTHER|Observation|Patients will be followed by the registry for life-long outcomes.
218911704|NCT05711576|OTHER|Placebo mouthwash|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash
218911705|NCT05711576|OTHER|Full mouth disinfection|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
219040996|NCT05310110|DRUG|Placebo of cisatracurium|Intravenous normal saline during induction
218911706|NCT04099563|DRUG|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
218911707|NCT04648462|OTHER|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
218911708|NCT03809728|PROCEDURE|endoscopic biopsy|Per-endoscopic biopsies
218911709|NCT03809728|PROCEDURE|samples of the oral cavity|7 samples of the oral cavity with a swab
218911710|NCT03809728|PROCEDURE|Samples of the resected specimen|if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
219040997|NCT05310110|DRUG|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
219040998|NCT04759625|OTHER|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
219040999|NCT04759625|OTHER|Placebo biscuit|Daily consumption of placebo biscuit
219524307|NCT03097120|DRUG|placebo tablets|two placebo tablets daily
219524308|NCT06395857|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
219524309|NCT02631629|OTHER|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
219614213|NCT04811872|BIOLOGICAL|Intact umbilical cord milking (I-UCM)|Umblical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.
219614214|NCT04811872|BIOLOGICAL|Cut-umbilical cord milking(C-UCM)|This technique involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM.
219614215|NCT04811872|BIOLOGICAL|Delayed Cord Clamping (DCC)|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60 seconds before clamping the cord.
219614216|NCT01839890|DEVICE|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
218911711|NCT05612854|PROCEDURE|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
218911712|NCT05612854|DEVICE|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
219041000|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
219041001|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for three months|period of treatment
219041002|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for six months|period of therapy
219041003|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
219614217|NCT01839890|DEVICE|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
219614218|NCT00770783|DEVICE|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
219614219|NCT00770783|DEVICE|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
219614220|NCT04595188|OTHER|Sulphur amino acids|"For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine)."
219614221|NCT02447211|DRUG|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
218911713|NCT05321901|OTHER|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
218911714|NCT05321901|OTHER|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
218911715|NCT06433791|DRUG|Ascorbate-Meglumine|Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
218911716|NCT05671107|DIAGNOSTIC_TEST|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
218911717|NCT00809263|DRUG|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
218911718|NCT01074775|BIOLOGICAL|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
218911719|NCT05272007|PROCEDURE|EUS-biliary drainage|EUS-GBD with LAMS
218911720|NCT03546309|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
218911721|NCT03546309|OTHER|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists
218911722|NCT03763032|BEHAVIORAL|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
218911723|NCT02726997|DRUG|Carboplatin|Given IV
218911724|NCT02726997|BIOLOGICAL|Durvalumab|Given IV
218911725|NCT02726997|OTHER|Laboratory Biomarker Analysis|Correlative studies
218911726|NCT02726997|DRUG|Paclitaxel|Given IV
218911727|NCT02726997|OTHER|Pharmacological Study|Correlative studies
218911728|NCT02726997|OTHER|Quality-of-Life Assessment|Ancillary studies
218911729|NCT00792844|DIETARY_SUPPLEMENT|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
218911730|NCT00792844|DIETARY_SUPPLEMENT|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
218911731|NCT04756310|DIETARY_SUPPLEMENT|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
218911732|NCT04756310|DIETARY_SUPPLEMENT|Theavit|antioxidants micronutrients
218911733|NCT01099696|DIETARY_SUPPLEMENT|B. infantis 35624|B. infantis 35624 in white capsules
218911734|NCT01099696|DIETARY_SUPPLEMENT|placebo|white placebo capsules
219041004|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
219041005|NCT01049724|OTHER|Tear collection|Tear collection
219041006|NCT00892164|DEVICE|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
219366282|NCT04880187|DRUG|AXA1125|AXA1125 administered BID with or without food
219366283|NCT04880187|DRUG|Placebo|Matching Placebo administered BID with or without food
219366284|NCT05030688|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
219366285|NCT02647073|DEVICE|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
219366286|NCT05490797|OTHER|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
219366287|NCT05490797|OTHER|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
219366288|NCT03073473|DIAGNOSTIC_TEST|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
219366289|NCT03240146|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
219366290|NCT01859247|DEVICE|rTMS|
219366291|NCT04915040|BEHAVIORAL|Behavioral Activation for Depression|Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate \& (b) gather feasibility data for home-based Behavioral Activation + Caregiver
219366292|NCT01660217|OTHER|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
219041007|NCT00892164|DEVICE|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
218911735|NCT05219825|BEHAVIORAL|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
218911736|NCT03814811|DIAGNOSTIC_TEST|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
218911737|NCT04549285|BIOLOGICAL|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10\^6 cells/kg (up to a maximum dose of 100x10\^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
218911738|NCT00534326|PROCEDURE|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
218911739|NCT00534326|PROCEDURE|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
218911740|NCT00830999|BEHAVIORAL|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
218911741|NCT00830999|BEHAVIORAL|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
218911742|NCT00830999|BEHAVIORAL|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
218911743|NCT00830999|BEHAVIORAL|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
218911744|NCT00830999|BEHAVIORAL|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
218911745|NCT03667482|DRUG|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
219041008|NCT06492161|DEVICE|Physical activity measure|After surgery, patients patients will be fitted with GT3X ActiGraph's activity monitor to capture and record continuous physical activity.
219204517|NCT06857149|OTHER|Control Group|"The application in the control group is similar to the application in the cycadian rhythm group (mother's milking technique, collection method, storage and appropriate transportation, etc.) instead of the milk expressed first is given first condition used in routine practice, without taking into account the day and night characteristics of the expressed breast milk. will be brought. The routine practice of the clinic will continue. In line with the practice of the Turkish Neonatology Association (2018) and the clinic, the information of babies given breast milk fortifiers in the expressed breast milk of enterally fed babies will be recorded. In order to ensure that the data is collected safely and to facilitate monitoring, it will be recorded in the Breastfeeding Follow-up Form, as in every feeding intervention group. The monitoring of babies is the same as in the circadian rhythm group. For the first month, the baby's weight and height will be measured and recorded twice a week."
219204518|NCT06878183|OTHER|Routine laboratory tests of the patients were examined (such as hemogram, biochemistry, bleeding parameters).|Data obtained from routine examinations, laboratory tests and hospital reports were evaluated.
219204519|NCT06873828|DEVICE|ATP-C135|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 14 days.
219524310|NCT02631629|OTHER|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
219524311|NCT06545253|DIAGNOSTIC_TEST|microRNAs analysis|Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
219524312|NCT00421005|DRUG|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
219524313|NCT05405998|OTHER|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~1. before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~2. after the installation of the pump following the above mentioned hospitalization."
219524314|NCT00232336|DRUG|quetiapine|
219524315|NCT02789306|PROCEDURE|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
219524316|NCT03621748|PROCEDURE|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
219524317|NCT03621748|PROCEDURE|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
219524318|NCT03488342|PROCEDURE|Repair for primary inguinal hernia|Repair for primary inguinal hernia
218911746|NCT03667482|DRUG|Cetuximab|Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
219524319|NCT02465658|OTHER|Medical records were reviewed.|retrospective study
219524320|NCT00727571|OTHER|Observations|This is a non-interventional, observational study; no investigational product is being used
219524321|NCT02831569|DRUG|Loxoprofen sodium|
219614222|NCT02447211|OTHER|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
219614223|NCT03302169|PROCEDURE|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
219614224|NCT03302169|PROCEDURE|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
219614225|NCT00933023|DRUG|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
218911747|NCT04205240|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
218911748|NCT04205240|DRUG|Cyclophosphamide|Given IV
218911749|NCT04205240|BIOLOGICAL|Daratumumab|Given IV
218911750|NCT04205240|DRUG|Fludarabine|Given IV
218911751|NCT04205240|DRUG|Melphalan|Given IV
218911752|NCT04205240|DRUG|Mycophenolate Mofetil|Given IV or PO
218911753|NCT04205240|DRUG|Tacrolimus|Given PO or IV
218911754|NCT03456128|OTHER|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
218911755|NCT01810471|DEVICE|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
218911756|NCT01791244|DRUG|Rebif®|
218911757|NCT00367822|DRUG|Lisuride|
218911758|NCT00367822|DRUG|Ropinirole|
219524322|NCT02831569|DRUG|Methocarbamol|
218911759|NCT00367822|DRUG|Placebo|
218911760|NCT04742491|DRUG|Immediate Intervention Arm Truvada in the US|Truvada in the United States
218911761|NCT04742491|DRUG|Deferred Intervention Arm Truvada in the US|Truvada in the United States
218911762|NCT04742491|DRUG|Immediate Intervention Arm Truvada in Brazil|Truvada in Brazil
218911763|NCT04742491|DRUG|Deferred Intervention Arm Truvada in Brazil|Truvada in Brazil
218911764|NCT04742491|DRUG|Immediate Intervention Arm Descovy in the US|Descovy in the United States
218911765|NCT04742491|DRUG|Deferred Intervention Arm Descovy in the US|Descovy in the United States
218911766|NCT05924984|DEVICE|perforator locator|During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
218911767|NCT00212108|DRUG|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
218911768|NCT01254136|DRUG|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
218911769|NCT01254136|DRUG|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
218911770|NCT01254136|DRUG|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
218911771|NCT05298514|OTHER|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
218911772|NCT06218316|DRUG|botulinum toxin A|Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
218911773|NCT06218316|DEVICE|Transcranial Magnetic Stimulation|Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
218911774|NCT06218316|OTHER|Rehabilitation Training Protocol|Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
219204520|NCT06873828|DEVICE|ATP-C75|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 7 days.
219524323|NCT03164772|DRUG|Durvalumab|anti-PD-L1
219524324|NCT03164772|DRUG|Tremelimumab|anti-CTLA-4
219524325|NCT03164772|BIOLOGICAL|BI 1361849|mRNA Vaccine
219524326|NCT03164772|DEVICE|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
219524327|NCT01029353|PROCEDURE|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
219524328|NCT01029353|PROCEDURE|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
219524329|NCT01889836|BIOLOGICAL|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
218911775|NCT01490151|DEVICE|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
218911776|NCT05841186|OTHER|Timing of pegfilgrastim administration|Timing of pegfilgrastim administration
218911777|NCT03359538|DRUG|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
218911778|NCT03359538|DRUG|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
218911779|NCT02925286|OTHER|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
218911780|NCT06151405|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
218911781|NCT06151405|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
218911782|NCT06151405|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
218911783|NCT04293575|DEVICE|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
218911784|NCT01863784|DRUG|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
218911785|NCT00279175|BIOLOGICAL|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
218911786|NCT00279175|BIOLOGICAL|Placebo medium supplemented with autologous serum|
218911787|NCT01149096|PROCEDURE|Bone Marrow Donation|Undergo bone marrow harvest
218911788|NCT01149096|BIOLOGICAL|Filgrastim|Given subcutaneously
218911789|NCT01149096|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218911790|NCT05783141|DIETARY_SUPPLEMENT|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
218911791|NCT05783141|DIETARY_SUPPLEMENT|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
218911792|NCT04328714|DRUG|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
218911793|NCT02866786|DRUG|Metformin|
218911794|NCT02866786|DRUG|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
218911795|NCT01350947|DRUG|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
218911796|NCT00900653|DRUG|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
218911797|NCT03288532|DRUG|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
218911798|NCT03288532|DRUG|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
219204521|NCT06750172|DIAGNOSTIC_TEST|The oral sodium loading test|The subjects underwent an oral high-salt diet test with an additional 10g of salt per day for 3 consecutive days, and 24-hour urine measurements of aldosterone, sodium, potassium and creatinine were obtained on days 2 and 3
218911799|NCT05890833|DIAGNOSTIC_TEST|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
218911800|NCT03853473|PROCEDURE|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
218911801|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
218911802|NCT04268641|OTHER|Arm 1|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
218911803|NCT04268641|OTHER|Arm 2|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion"
218911804|NCT04268641|OTHER|Arm 3|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair"
218911805|NCT04268641|OTHER|Arm 4|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
218911806|NCT04268641|OTHER|Arm 5|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion"
218911807|NCT04268641|OTHER|Arm 6|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair"
218911808|NCT04910048|OTHER|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
219366293|NCT04340973|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
219366294|NCT01625520|DRUG|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
219524330|NCT01889836|BIOLOGICAL|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
218911809|NCT04910048|OTHER|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
219614226|NCT00933023|DRUG|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
219614227|NCT01198223|DRUG|garlic , nystatin|mouthwash
219614228|NCT00038181|DRUG|Thalidomide|
218911810|NCT06469294|PROCEDURE|Control (C) - Saline Gel|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.
218911811|NCT06469294|PROCEDURE|Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue|After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
218911812|NCT04039087|DRUG|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
218911813|NCT04039087|DRUG|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
218911814|NCT06526494|DRUG|Metformin|Oral ingestion for 12 weeks
218911815|NCT06526494|OTHER|Placebo|Oral placebo for 12 weeks
218911816|NCT04786743|OTHER|endoscopic intervention|performing endoscopy
218911817|NCT03939624|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
218911818|NCT03939624|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
218911819|NCT04829292|BEHAVIORAL|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
218911820|NCT03796559|DEVICE|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
218911821|NCT04799964|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
218911822|NCT04799964|DEVICE|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
218911823|NCT06314711|DIAGNOSTIC_TEST|Ultrasound|High-frequency ultrasound of ex vivo specimen
218911824|NCT06563726|DIAGNOSTIC_TEST|point-of-care milk sodium testing|Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.
218911825|NCT05992675|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
218911826|NCT05992675|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
218911827|NCT06437301|OTHER|Baseline measure of ETCO2 without mask|Baseline
218911828|NCT06437301|OTHER|Baseline ETCO2 with mask|Mask
218911829|NCT06437301|OTHER|ETCO2 after 200 meter walk with mask|200 meter walk and mask
218911830|NCT06437301|OTHER|ETCO2 after 200 meter walk without mask|200 meter walk
219366295|NCT01282229|DEVICE|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
219366296|NCT02635971|PROCEDURE|Transcatheter arterial infusion|
219366297|NCT02635971|PROCEDURE|Intravenous chemotherapy|
219366298|NCT02635971|DRUG|Gemcitabine|
219366299|NCT02635971|DRUG|Oxaliplatin|
219366300|NCT04345666|DRUG|Testosterone cypionate|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
219366301|NCT04345666|DRUG|Placebos|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
219366302|NCT04146922|OTHER|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
219366303|NCT04146922|OTHER|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
218911831|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and placebo (NPL)|Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
218911832|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and ketones (NKE)|Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
218911833|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and placebo (HPL)|Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
218911834|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and ketones (HKE)|Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
218911835|NCT05058365|BEHAVIORAL|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
218911836|NCT04413071|OTHER|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
218911837|NCT02511665|DRUG|Metformin|Given metformin
218911838|NCT02511665|RADIATION|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
219041009|NCT06261268|PROCEDURE|Strip graft with Mucograft|"An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures."
219041010|NCT06261268|PROCEDURE|Free gingival graft|The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
219041011|NCT02157987|DRUG|bevacuzimab spray|
219524331|NCT04682002|OTHER|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
219041012|NCT02067377|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
219041013|NCT02067377|DIETARY_SUPPLEMENT|Placebo (for serum bovine immunoglobulin)|
219041014|NCT00000796|DRUG|Cycloserine|
219041015|NCT00000796|DRUG|Ethionamide|
219204522|NCT06876545|DIAGNOSTIC_TEST|systematical screening of at risk patients based on predefined hemorrhagic criteria|"Patients selected if condition present:~Hematuria (blood in urine)~Macroscopic hematuria (visible blood in urine) Hematuria detected by urine dipstick or microscopic analysis Ecchymoses (bruising)~Epistaxis (nosebleeds)~Petechiae (small pinpoint hemorrhages on the skin)~Gastrointestinal bleeding~Upper GI bleeding: Hematemesis (vomiting blood) Lower GI bleeding: Melena (black tarry stools) Positive fecal occult blood test (FOBT) Cerebral hemorrhage (brain bleeding)"
219524332|NCT04682002|OTHER|Usual care|Administration of routine care based on international guidelines
218911839|NCT02511665|DRUG|Placebo|Given placebo
218911840|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
218911841|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
218911842|NCT06473922|PROCEDURE|Reginal anesthesia|General anesthesia
218911843|NCT05564949|OTHER|CKD|Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
219041016|NCT00000796|DRUG|Capreomycin sulfate|
219041017|NCT00000796|DRUG|Aminosalicylic acid|
219041018|NCT00000796|DRUG|Streptomycin sulfate|
219041019|NCT00000796|DRUG|Ethambutol hydrochloride|
219041020|NCT00000796|DRUG|Amikacin sulfate|
219041021|NCT00000796|DRUG|Isoniazid|
219041022|NCT00000796|DRUG|Pyrazinamide|
219041023|NCT00000796|DRUG|Pyridoxine hydrochloride|
219041024|NCT00000796|DRUG|Levofloxacin|
219041025|NCT00000796|DRUG|Rifampin|
218911844|NCT00818610|DRUG|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
218911845|NCT00818610|DRUG|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
218911846|NCT04038359|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) inhibitor
218911847|NCT04915846|DRUG|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
218911848|NCT04915846|DRUG|Placebo|placebo comparator
218911849|NCT00703014|DRUG|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
218911850|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
218911851|NCT00703014|DRUG|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
218911852|NCT00703014|DRUG|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
218911853|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
218911854|NCT00703014|DRUG|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
218911855|NCT00703014|BIOLOGICAL|hCG|In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
218911856|NCT00703014|BIOLOGICAL|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
218911857|NCT05983211|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks."
218911858|NCT05549219|DRUG|GLM101|GLM101 IV Infusion
218911859|NCT06410027|OTHER|Pain Neuroscience Education + Virtual Reality + Therapeutic Exercise|Patients will receive 1-hour pain neuroscience education session + 30-minutes exposure to exercise with virtual reality + therapeutic exercise
218911860|NCT06410027|OTHER|Therapeutic Exercise|Patients will receive therapeutic exercise
218911861|NCT02893293|DRUG|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
218911862|NCT02893293|DEVICE|Magentic Resonance Imaging|Both arms will receive MRI
219041026|NCT00000796|DRUG|Clofazimine|
219041027|NCT04683185|DRUG|E6742|E6742 tablets.
219041028|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
219041029|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
218911863|NCT05574322|OTHER|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology"
219041030|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
219041031|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
219041032|NCT02109328|DRUG|Placebo|Placebo oral tablets
219041033|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
219041034|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
218911864|NCT05574322|OTHER|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
218911865|NCT03264274|DRUG|Aflibercept|Antiangiogenic
218911866|NCT03264274|PROCEDURE|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
218911867|NCT04325893|DRUG|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
218911868|NCT04325893|DRUG|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
218911869|NCT01224119|DEVICE|Amplex|225 micrograms of B2A per cc of ceramic granules
218911870|NCT01224119|PROCEDURE|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
218911871|NCT01885156|DRUG|Naftin 1% Cream|Topically applied once a day
218911872|NCT01885156|DRUG|Placebo Cream|Topically applied once a day
218911873|NCT02970981|BIOLOGICAL|Nivolumab|
218911874|NCT02970981|BIOLOGICAL|Ipilimumab|
218911875|NCT01059097|PROCEDURE|Pancreaticoduodenectomy|
218911876|NCT01033240|DRUG|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
219041035|NCT05180084|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
219041036|NCT03768115|DRUG|Autologous Plasma Eye Drop|Autologous plasma crimped segments
219041037|NCT01640366|DEVICE|PICO|Single-use Negative Pressure Wound Therapy System
218911877|NCT01033240|DRUG|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
218911878|NCT01033240|DRUG|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
218911879|NCT01033240|DRUG|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
218911880|NCT01033240|DRUG|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
218911881|NCT01033240|DRUG|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
218911882|NCT05468814|PROCEDURE|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
219204523|NCT06887868|PROCEDURE|Mobilization with movement|Manual application of a sustained translational or rotational glide force, either medial or lateral, on the tibia, while an active partial weight-bearing lunge movement was performed.
219524333|NCT04682002|OTHER|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
218911883|NCT05468814|PROCEDURE|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
218911884|NCT01773317|OTHER|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
218911885|NCT01773317|OTHER|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
219524334|NCT04682002|OTHER|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
219524335|NCT04682002|OTHER|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
218911886|NCT04716426|DRUG|Tetracycline hydrochloride 3%|Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
218911887|NCT04716426|DRUG|Placebo|Formulation composed of FDA approved inactive ingredients.
218911888|NCT02494193|OTHER|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
218911889|NCT02494193|OTHER|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
218911890|NCT02494193|OTHER|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
218911891|NCT02494193|OTHER|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
218911892|NCT02494193|OTHER|Definitive restoration|Definite restoration will be performed using composite.
218911893|NCT00551759|DRUG|5-Fluorouracil|given IV
218911894|NCT00551759|DRUG|Oxaliplatin|given IV
218911895|NCT00551759|DRUG|Cetuximab|given IV
218911896|NCT00551759|DRUG|Docetaxel|given IV
219041038|NCT02045511|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
219041039|NCT02045511|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
219041040|NCT04686864|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
219041041|NCT03175094|BEHAVIORAL|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
218911897|NCT00551759|PROCEDURE|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
218911898|NCT00551759|RADIATION|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
218911899|NCT02655848|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
218911900|NCT02655848|PROCEDURE|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
218911901|NCT02655848|PROCEDURE|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
218911902|NCT00588926|DRUG|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
219524336|NCT04682002|OTHER|Coaching|There will be five personalized coaching sessions during the pregnancy.
219524337|NCT06261853|RADIATION|3D-CBCT|CBCT provides a three-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. CBCT radiation doses are typically in the range of 60 microSv.
219524338|NCT06261853|RADIATION|2D-OPG|An OPG provides a two-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. OPG radiation doses are typically in the range of 20 microSv.
219524339|NCT01373970|DRUG|Placebo|Placebo, one tablet daily for 12 weeks
218911903|NCT00773448|DEVICE|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
218911904|NCT00773448|OTHER|Limited Malignancy Screening|"1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year."
218911905|NCT01774201|OTHER|Breathing exercises|Breathing exercises with positive expiratory pressure.
218911906|NCT01182636|DRUG|Adapalene|0.1% Topical Gel
219204524|NCT06887868|PROCEDURE|Sham mobilization with movement|The physiotherapist mimicked the pain-reducing glide direction without applying glide force while the participants performed the active lunge movement. To achieve this, the physiotherapist's hands lightly touched the knee skin, with one hand on the tibia and the other on the femur over the joint surfaces.
219524340|NCT01373970|DRUG|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
219524341|NCT01900730|DRUG|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
219524342|NCT01900730|DRUG|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
219524343|NCT01900730|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
219524344|NCT01900730|BEHAVIORAL|Pill Diary|Patient given a pill diary to record the time each dose taken.
219614229|NCT05063513|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
218911907|NCT01182636|DRUG|Differin®|0.1% Topical Gel
218911908|NCT01182636|DRUG|Placebo|Gel Base
218911909|NCT05167851|DRUG|Lazertinib , a combination group of SBRT|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
218911910|NCT05167851|DRUG|Lazertinib single administration group|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
218911911|NCT01228279|OTHER|DIANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
218911912|NCT01228279|OTHER|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
219524345|NCT01900730|BEHAVIORAL|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
219524346|NCT02589964|DIETARY_SUPPLEMENT|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
219524347|NCT02589964|OTHER|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
218911913|NCT02244541|DRUG|ANAVEX2-73 Oral|
218911914|NCT02244541|DRUG|ANAVEX2-73 Intravenous|
218911915|NCT02244541|DRUG|ANAVEX2-73 Oral|30 mg hard gelatin capsule
218911916|NCT02244541|DRUG|ANAVEX2-73 Oral|50 mg hard gelatin capsule
218911917|NCT06309940|OTHER|Prognostic factors of surgical evacuation of basal ganglionic haemorrhage|Surgical evacuation of basal ganglionic haemorrhage
219524348|NCT00936260|DRUG|alendronate|several duration of treatment
219524349|NCT03581422|DRUG|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
219524350|NCT03146130|BIOLOGICAL|Variation of behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
219524351|NCT02152566|DEVICE|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
219524352|NCT03728296|BIOLOGICAL|islet body|Transplanting islet bodies under the diaphragm
219524353|NCT00711360|DEVICE|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
219524354|NCT01846585|BEHAVIORAL|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
219524355|NCT01846585|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
219524356|NCT01160926|DRUG|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
219524357|NCT01160926|DRUG|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
219614230|NCT05063513|DRUG|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
218911918|NCT00214045|DEVICE|Flexible Cystoscopy|
218911919|NCT00214045|DEVICE|Rigid Cystoscopy|
218911920|NCT06175676|DRUG|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
218911921|NCT06175676|DRUG|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
218911922|NCT06175676|DRUG|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
218911923|NCT00625131|DRUG|Nicotine|Delivered through transdermal nicotine patch
218911924|NCT00625131|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
218911925|NCT00625131|DRUG|Bupropion Sustained Release (SR)|Antidepressant
218911926|NCT00625131|DRUG|Placebo patch|Pre-treatment placebo transdermal patch
218911927|NCT04279886|OTHER|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
218911928|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
218911929|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
218911930|NCT00801736|DRUG|Cisplatin, Paclitaxel|"* Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1"
218911931|NCT03433937|DEVICE|Negative pressure wound therapy|Wound dressing
218911932|NCT03433937|OTHER|Micropore tape|Wound dressing
218911933|NCT02133495|PROCEDURE|Non Cadaveric Human Acellular Dermal Tissue|
218911934|NCT02300207|DEVICE|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
218911935|NCT01901445|BEHAVIORAL|Educational action with focal group|
218911936|NCT02721940|PROCEDURE|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
218911937|NCT02721940|BIOLOGICAL|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
219524358|NCT03037372|DRUG|ART, Atorvastatin|ART, Atorvastatin
219524359|NCT03037372|DRUG|ART, Rosuvastatin|ART, Rosuvastatin
219524360|NCT03037372|DRUG|ART, No statin|ART, No statin
219524361|NCT03037372|DRUG|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
219524362|NCT03512366|PROCEDURE|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
219524363|NCT03512366|PROCEDURE|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
219524364|NCT03603314|DRUG|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
219524365|NCT03603314|OTHER|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
219524366|NCT03603314|DRUG|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
219524367|NCT05468021|OTHER|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
219524368|NCT05037006|DRUG|Sevoflurane - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
219524369|NCT05037006|DRUG|Sevoflurane - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
219524370|NCT05037006|DRUG|Sevoflurane - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
219524371|NCT05037006|DRUG|TIVA - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
219524372|NCT05037006|DRUG|TIVA - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
218911938|NCT02721940|BIOLOGICAL|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
218911939|NCT02721940|DRUG|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
219524373|NCT05037006|DRUG|TIVA - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
219524374|NCT03450070|DEVICE|Light Therapy Mask Cream|test panel
219524375|NCT02588677|DRUG|Masitinib (4.5)|4.5 mg/kg/day
219524376|NCT02588677|DRUG|Riluzole|
219524377|NCT02588677|DRUG|Placebo|
219524378|NCT02588677|DRUG|Masitinib (3.0)|3 mg/kg/day
219524379|NCT03657329|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
219524380|NCT03607097|PROCEDURE|Secondary prevention program for drug related problems|The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
219614231|NCT00818766|DRUG|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
219614232|NCT00818766|DRUG|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
219041042|NCT03767218|COMBINATION_PRODUCT|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
219041043|NCT03767218|COMBINATION_PRODUCT|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
219524381|NCT05160350|DRUG|Probiotic|Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
219524382|NCT02581748|DRUG|HLX02|
219524383|NCT02581748|DRUG|Herceptin|
219524384|NCT05404386|OTHER|Training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence.|After the participants enrolled in the study, a training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence will be given to the participants.
219524385|NCT05404386|OTHER|3 months follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test (baseline), intermediate follow-up test (6th week), and post-test (12th week).
219524386|NCT05404386|BEHAVIORAL|"Mobile application which named as My Fighting with Incontinence"|"The mobile application My Fighting with Incontinence aims to reduce incontinence symptoms of women with UI, ensure compliance with Kegel exercises, increase health belief and quality of life regarding UI and kegel exercises, and also allow researchers to be included in the awareness and management process."
219524387|NCT05266521|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
219524388|NCT03843593|BEHAVIORAL|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
219524389|NCT03843593|BEHAVIORAL|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
219524390|NCT03843593|BEHAVIORAL|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
219524391|NCT03843593|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
219041044|NCT05210127|PROCEDURE|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
219041045|NCT04725435|BEHAVIORAL|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
219041046|NCT04725435|BEHAVIORAL|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
219041047|NCT03661437|DEVICE|Actigraph|Wear Actiwatch
219041048|NCT03661437|OTHER|Questionnaire Administration|Ancillary studies
219041049|NCT03661437|PROCEDURE|Systematic Light Exposure|Undergo BWL treatment
219041050|NCT03661437|PROCEDURE|Systematic Light Exposure|Receive DWL treatment
219041051|NCT01289808|DRUG|Glucose 25%|1ml of glucose 25% once
219524392|NCT03843593|BEHAVIORAL|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].
219524393|NCT03843593|BEHAVIORAL|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
219524394|NCT04712071|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
219524395|NCT00581971|DRUG|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
219524396|NCT00581971|DRUG|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
219524397|NCT00581971|DRUG|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
219614233|NCT03525405|DRUG|napabucasin|Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
218911940|NCT02721940|DRUG|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
218911941|NCT01590264|DEVICE|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
219041052|NCT01289808|DRUG|Glucose 25%|1ml glucose once per os
219041053|NCT00847288|OTHER|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
219524398|NCT00581971|RADIATION|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
219524399|NCT05232877|OTHER|SHAM tDCS|The control group will follow cognitive training with a combined sham tDCS. Intervention will last for 4-week with 3 sessions per week (12 sessions).
219524400|NCT05232877|OTHER|tDCS|The intervention group will follow sessions of tDCS combined with a simultaneous cognitive training on tablet
218911942|NCT02830737|PROCEDURE|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
218911943|NCT02830737|PROCEDURE|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
218911944|NCT02014324|PROCEDURE|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)"
219524401|NCT01804777|DRUG|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
219524402|NCT01804777|DRUG|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
219524403|NCT01954264|PROCEDURE|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
219524404|NCT01954264|OTHER|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
219524405|NCT05868564|DEVICE|Atherectomy+Drug-coated balloon|Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group
219524406|NCT05868564|DEVICE|Drug-coated balloon|drug-coated balloon only in the active comparator group.
219524407|NCT01390233|DRUG|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
219524408|NCT01390233|DEVICE|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
218911945|NCT04420377|DIETARY_SUPPLEMENT|Carnipure|Supplement contains L-carnitine tartrate.
218911946|NCT04420377|OTHER|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
219041054|NCT00847288|OTHER|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
219041055|NCT00913809|DRUG|Desipramine HCL 100 mg Tablets Cord Laboratories|
219041056|NCT00913809|DRUG|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
219204525|NCT06887270|OTHER|Continued DOAC|The continued DOAC group will continue their DOAC peri-procedurally as routine without interruption.
218911947|NCT05271981|OTHER|Retrospective data collection|Data collection from the medical file of the patients
219524409|NCT01390233|OTHER|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
219524410|NCT01496183|DRUG|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
219524411|NCT01496183|DRUG|Placebo|Placebo capsule administered orally at bedtime for 14 days
219524412|NCT02479893|PROCEDURE|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
219524413|NCT04258150|DRUG|Nivolumab|6 mg/kg IV q4w
219524414|NCT04258150|DRUG|Ipilimumab|1 mg/kg IV twice q6w
219524415|NCT04258150|DRUG|Tocilizumab|8 mg/kg IV q4w
219524416|NCT04258150|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
219524417|NCT03002077|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
219524418|NCT01013467|BEHAVIORAL|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
219524419|NCT04591717|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
219524420|NCT00738868|BIOLOGICAL|cetuximab|
219524421|NCT00738868|RADIATION|stereotactic body radiation therapy|
219524422|NCT06293872|DEVICE|12*2 mm length miniscrew|"Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots"
219524423|NCT06336733|DRUG|ANAKINRA|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
219524424|NCT06196242|DIAGNOSTIC_TEST|MRI and CT scan|"An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes."
219524425|NCT01599338|DRUG|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
219524426|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
218911948|NCT05271981|OTHER|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
219614234|NCT06328205|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
218911949|NCT00564681|BIOLOGICAL|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
218911950|NCT00564681|BIOLOGICAL|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
218911951|NCT00564681|DRUG|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
218911952|NCT05945420|DRUG|Desmopressin Acetate|This arm will receive tamsulosin and desmopressin acetate daily a
218911953|NCT05945420|DRUG|Placebo|This arm will receive tamsulosin and placebo
218911954|NCT05249140|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
218911955|NCT00080665|DRUG|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
218911956|NCT00080665|DRUG|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
218911957|NCT03784872|PROCEDURE|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
218911958|NCT04730440|OTHER|AD-TAR|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
219524427|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
218911959|NCT04730440|OTHER|AD-Cognitive Stimulation|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
218911960|NCT04960527|DIETARY_SUPPLEMENT|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate \[CherryActive, UK\] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
218911961|NCT04960527|OTHER|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
218911962|NCT01848015|OTHER|detection of CTCs|
218911963|NCT06472674|OTHER|No intervention|No intervention
219041057|NCT05091008|DRUG|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
219041058|NCT06410144|BEHAVIORAL|Program A|Subjects in the Control group will receive 1) National Kidney Foundation information, and 2) support from a kidney therapy educator.
219041059|NCT06410144|BEHAVIORAL|Program B|Subjects in the intervention group will receive 1) a video and paper decision aid, and 2) coaching from a decision support specialist. The visits will be aimed at supporting patients with kidney therapy decision-making.
219041060|NCT02242851|DRUG|Telmisartan|
219041061|NCT03553732|OTHER|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
219041062|NCT04100707|PROCEDURE|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
219041063|NCT05812014|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
219041064|NCT05812014|DRUG|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
219041065|NCT05931328|DRUG|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
219041066|NCT03530579|BEHAVIORAL|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
219524428|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
218911964|NCT02066363|DIETARY_SUPPLEMENT|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
219524429|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
219524430|NCT00193141|DRUG|Paclitaxel|
219524431|NCT00193141|DRUG|Carboplatin|
218911965|NCT02066363|DIETARY_SUPPLEMENT|Parenteral nutrition|Supportive parenteral nutrition.
218911966|NCT02356458|DRUG|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
218911967|NCT02356458|DRUG|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
218911968|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting without the use of collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Suturing of the wound in the donor site."
219524432|NCT00193141|DRUG|5-Fluorouracil|
219524433|NCT04701619|OTHER|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
219524434|NCT04887077|DEVICE|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
218911969|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting with collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Adaptation of sterile collagen matrix to the donor site~4. Suturing of the wound in the donor site"
219524435|NCT04887077|BEHAVIORAL|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
219524436|NCT05589818|DRUG|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219524437|NCT06032299|PROCEDURE|Single Distal Femur Implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
219614235|NCT06328205|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
218911970|NCT06131255|DRUG|Citalopram|Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
218911971|NCT01026844|DRUG|erlotinib|Taken orally once a day
218911972|NCT01026844|DRUG|hydroxychloroquine|Taken orally once a day
218911973|NCT01260649|DRUG|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
218911974|NCT01260649|OTHER|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
218911975|NCT01260649|PROCEDURE|ECT|ECT will be administered as per standard of care
219614236|NCT06328205|DRUG|Lidocaine Hydrochloride|When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.
218911976|NCT01260649|DRUG|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
218911977|NCT01260649|DRUG|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
218911978|NCT02245477|DEVICE|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
218911979|NCT02245477|OTHER|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
218911980|NCT02211560|OTHER|Phosphatidylserine|
219614237|NCT06328205|BEHAVIORAL|placebo injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. 1 milliliter of normal saline will be used for injection.
219614238|NCT04496804|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
219614239|NCT04496804|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
219614240|NCT03973125|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
219614241|NCT05350657|BEHAVIORAL|Ketogenic Diet|2 week isocaloric, high protein and low carbohydrate ketogenic diet
218911981|NCT02211560|OTHER|Placebo|
218911982|NCT01446159|DRUG|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
218911983|NCT01446159|DRUG|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
218911984|NCT03546023|OTHER|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
218911985|NCT03766789|DEVICE|Cell phone application|cell phone to organize medications
218911986|NCT04444817|DRUG|Tacrolimus|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
218911987|NCT02327546|DRUG|AKB-6548|
218911988|NCT02327546|DRUG|Ferrous Sulfate|
218911989|NCT05830552|OTHER|Receving feedback|Receving regular feedback from a health provider
218911990|NCT05830552|OTHER|No regular feedback|No regular feedback from a health provider
219524438|NCT06032299|PROCEDURE|Dual Distal Femur Implant|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
219524439|NCT02546167|BIOLOGICAL|CART-BCMA|
219524440|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
219524441|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
219041067|NCT03530579|BEHAVIORAL|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
219524442|NCT03348943|BEHAVIORAL|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
219524443|NCT03348943|BEHAVIORAL|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
219524444|NCT03348943|BEHAVIORAL|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
219524445|NCT03348943|BEHAVIORAL|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
219614242|NCT05120986|OTHER|IND/GLY/MF|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study when attending participating community pharmacies with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor
219614243|NCT00810667|DRUG|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
219614244|NCT00810667|DRUG|Placebo|twice daily oral dose
219614245|NCT01080638|DRUG|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
219614246|NCT05984524|BEHAVIORAL|Gamma-Music Based Intervention|Gamma or Control lights with Music-Based Intervention for 8 week period
219614247|NCT00126828|PROCEDURE|External beam radiotherapy|
219041068|NCT03811756|DIETARY_SUPPLEMENT|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
219041069|NCT03811756|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
219524446|NCT05293054|OTHER|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
219524447|NCT00472290|DRUG|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
219524448|NCT05891977|OTHER|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
219524449|NCT05891977|OTHER|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
219524450|NCT01325675|BEHAVIORAL|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
219524451|NCT00777829|DRUG|zolpidem|Participants will receive one dose of 10 mg before each nap.
219524452|NCT00777829|DRUG|Placebo|Participants will receive a dose of placebo before each nap.
219524453|NCT00071136|DRUG|pemetrexed|
219524454|NCT00071136|DRUG|gemcitabine|
219524455|NCT03665649|PROCEDURE|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
219524456|NCT02877056|PROCEDURE|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
219524457|NCT03344445|OTHER|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
219524458|NCT00692653|BEHAVIORAL|P4|Tailored online decision support system for prostate cancer treatment decision making
219524459|NCT05223556|DEVICE|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
219614248|NCT05884736|OTHER|Neuromonitoring|Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
219614249|NCT01446536|OTHER|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
219614250|NCT01866462|OTHER|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
219524460|NCT05223556|DEVICE|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
218911991|NCT06005467|PROCEDURE|Open reduction and internal fixation of mandibular angle fracture using V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
218911992|NCT02558725|DRUG|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
218911993|NCT06082934|DRUG|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
218911994|NCT04894968|DIAGNOSTIC_TEST|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~1. Symptoms of heart failure (e.g. dyspnea on extertion)~2. Preserved ejection fraction (Left ventricular ejection fraction ≥50%~3. NT-proBNP ≥125 pg/mL~4. Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~   * Left atrial volume index \>34 mL/m²~  * Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~  * E/e' ≥13~  * Septal e' \<9 cm/s"
218911995|NCT00334880|DRUG|NRP104|
218911996|NCT03523819|DRUG|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
218911997|NCT03523819|DRUG|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
218911998|NCT01794429|DRUG|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
218911999|NCT01794429|DRUG|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
218912000|NCT06100588|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
218912001|NCT06100588|OTHER|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
218912002|NCT05487612|DEVICE|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
218912003|NCT05487612|DEVICE|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
218912004|NCT00256594|DEVICE|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
219524461|NCT06206395|DEVICE|Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging|"2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment."
219524462|NCT02359305|DRUG|Acetaminophen|Acetaminophen given by IV
219524463|NCT02359305|DRUG|Acetaminophen|Acetaminophen suppository given rectally
218912005|NCT05023642|OTHER|resistance training|"Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
218912006|NCT06038409|DRUG|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
218912007|NCT03923166|DRUG|Pyrotinib|400mg qd
218912008|NCT03923166|DRUG|capecitabine|capecitabine 500mg tid
218912009|NCT02559284|OTHER|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
218912010|NCT02578147|BEHAVIORAL|Mighty Girls|
219524464|NCT02001948|DRUG|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
219524465|NCT02001948|DRUG|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
219524466|NCT02001948|DEVICE|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
219614251|NCT01686672|BEHAVIORAL|Web Intervention|Behavioral
219614252|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
219614253|NCT00086684|DRUG|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
219614254|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
218912011|NCT02578147|BEHAVIORAL|Game Girls|
218912012|NCT06348927|DRUG|sunvozertinib in combination with Anlotinib|"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."
218912013|NCT04997486|BEHAVIORAL|Time restricted eating|Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
218912014|NCT05942365|DRUG|ZSP1273|Drug Warfarin oral Drug midazolam oral
218912015|NCT02923973|OTHER|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
218912016|NCT01336933|DRUG|prednisone|Given PO
219524467|NCT02001948|DRUG|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
219524468|NCT03719222|OTHER|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
218912017|NCT01336933|DRUG|cyclophosphamide|Given IV
219524469|NCT06001034|DEVICE|Occlusion training|Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
219524470|NCT02242292|DRUG|Hyoscine butylbromide|
219524471|NCT02242292|DRUG|Placebo|
219524472|NCT00169195|DRUG|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
219524473|NCT03267628|PROCEDURE|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
219524474|NCT03267628|PROCEDURE|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
218912018|NCT01336933|DRUG|etoposide|Given PO or IV
218912019|NCT01336933|DRUG|Vincristine|Given IV
218912020|NCT01336933|DRUG|pralatrexate|Given IV
218912021|NCT01336933|OTHER|laboratory biomarker analysis|Correlative studies
219041070|NCT04448210|BEHAVIORAL|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
219524475|NCT03267628|PROCEDURE|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
219524476|NCT03267628|PROCEDURE|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
219524477|NCT04096703|PROCEDURE|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is \> 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
219524478|NCT01582672|DRUG|Standard Treatment|Standard treatment for Renal Cell Carcinoma
219524479|NCT01582672|BIOLOGICAL|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
219524480|NCT02980978|BEHAVIORAL|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
219524481|NCT01968265|DRUG|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
219524482|NCT01968265|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
219614255|NCT01996241|BEHAVIORAL|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
219614256|NCT02340403|PROCEDURE|NMR Spectroscopy|
219614257|NCT06018675|OTHER|kinesiotherapy|Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
219614258|NCT02496078|DRUG|Daclatasvir|Daclatasvir tablet 60mg
219614259|NCT02496078|DRUG|Asunaprevir|Asunaprevir soft capsule 100 mg
219614260|NCT02043795|DEVICE|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
219614261|NCT02826486|DRUG|BL-8040|BL-8040 subcutaneous (SC) injections
218912022|NCT01336933|GENETIC|comparative genomic hybridization|Correlative studies
218912023|NCT01336933|GENETIC|gene expression analysis|Correlative studies
219041071|NCT03861260|PROCEDURE|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
219524483|NCT04047095|DIETARY_SUPPLEMENT|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
219524484|NCT04047095|DIETARY_SUPPLEMENT|Normal daily meal|Normal daily meal (75-80 g protein)
219524485|NCT03210636|DEVICE|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
218912024|NCT01336933|GENETIC|nucleic acid sequencing|Correlative studies
218912025|NCT01336933|GENETIC|mutation analysis|Correlative studies
218912026|NCT01336933|OTHER|immunohistochemistry staining method|Correlative studies
218912027|NCT01336933|GENETIC|microarray analysis|Correlative studies
218912028|NCT01336933|GENETIC|RNA analysis|Correlative studies
218912029|NCT01796717|DRUG|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
218912030|NCT01796717|DRUG|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
219614262|NCT02826486|DRUG|Pembrolizumab|Pembrolizumab will be given as a 30-minute IV infusion
219614263|NCT02826486|DRUG|Chemotherapy|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
219614264|NCT05162703|DIAGNOSTIC_TEST|AsthmaTuner|Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
218912031|NCT02602886|BEHAVIORAL|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
219524486|NCT05617703|DRUG|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
219524487|NCT00486109|DEVICE|I-Port(TM) Injection Port|
218912032|NCT04340635|OTHER||Without intervention
218912033|NCT02666872|BEHAVIORAL|Motivational interviewing|
218912034|NCT00153296|DRUG|Carbamazepine|
219524488|NCT01756937|DRUG|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
219524489|NCT01756937|DRUG|Placebo|1 capsule once daily for 24 weeks
218912035|NCT03541122|DIAGNOSTIC_TEST|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
218912036|NCT02819921|DRUG|Desvenlafaxine succinate 100mg|Pristiq 100mg
218912037|NCT02819921|DRUG|Desvenlafaxine succinate 50mg|Pristiq 50mg
218912038|NCT02819921|DRUG|Placebo|Placebo
219041072|NCT03861260|PROCEDURE|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
219041073|NCT04617691|DRUG|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
219041074|NCT05715372|BEHAVIORAL|Mediterranean diet|12-week structured program for Mediterranean diet.
219041075|NCT05715372|BEHAVIORAL|AHA walking program|12-week structured AHA walking program.
219041076|NCT05715372|BEHAVIORAL|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
219041077|NCT05715372|BEHAVIORAL|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
219041078|NCT05715372|BEHAVIORAL|Unstructured walking program|Unstructured 12-week walking program.
219041079|NCT05715372|BEHAVIORAL|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
218912039|NCT01427582|DRUG|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
218912040|NCT04728958|BEHAVIORAL|Gratitude|A positive psychology intervention using expressions of gratitude
218912041|NCT06157515|DEVICE|Breath-actuated vibrating mesh nebulizer|The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
218912042|NCT06157515|DEVICE|Continuous vibrating mesh nebulizer|When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
218912043|NCT02883569|PROCEDURE|open or endoscopic discectomy|FDA approved surgical procedures
218912044|NCT02883569|PROCEDURE|epidural block|epidural block
218912045|NCT02883569|OTHER|exercise|educated exercise
218912046|NCT02883569|DRUG|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
218912047|NCT02883569|PROCEDURE|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
218912048|NCT02883569|PROCEDURE|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
218912049|NCT02883569|DRUG|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
218912050|NCT02883569|PROCEDURE|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
218912051|NCT03210558|DRUG|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
218912052|NCT03210558|DRUG|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
219041080|NCT00694967|PROCEDURE|McDonald cerclage placement|Transcervical McDonald cerclage placement
219041081|NCT00694967|DRUG|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
219041082|NCT03975907|BIOLOGICAL|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
219041083|NCT05507983|DRUG|Tranexamic acid|Tranexamic acid 1500 mg
219041084|NCT05507983|DRUG|Placebo|Placebo, sodium chloride 0.9%
219041085|NCT00291668|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
219524490|NCT03980288|DRUG|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
219524491|NCT01835678|DRUG|Linagliptin|orally 5 mg/d for 4 weeks
219524492|NCT01835678|DRUG|Placebo|orally once a day for 4 weeks
219524493|NCT01345149|BEHAVIORAL|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
219524494|NCT00275353|BEHAVIORAL|Individualized Symptom Education|
218912053|NCT04767659|DEVICE|MAMMOT2|Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
218912054|NCT06097221|BEHAVIORAL|CRT-Advance|Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
218912055|NCT06097221|BEHAVIORAL|Treatment as usual|Treatment as usual in the outpatient psychiatric unit.
219524495|NCT01819623|OTHER|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
218912056|NCT06179199|DEVICE|SOOMA™ tDCS™|The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
219524496|NCT04862078|DIAGNOSTIC_TEST|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
219524497|NCT04862078|DIAGNOSTIC_TEST|Usual care|standard follow-up according to the institutional practice
219524498|NCT03699644|DEVICE|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
219524499|NCT03699644|DEVICE|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
219524500|NCT03699644|DEVICE|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
219524501|NCT03699644|DIAGNOSTIC_TEST|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
219524502|NCT03699644|DEVICE|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
219524503|NCT02625454|DRUG|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
219524504|NCT02625454|DRUG|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
218912057|NCT05295212|DRUG|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
218912058|NCT06347731|DEVICE|Proton Radiation Therapy|All enrolled participants will be treated with Proton radiation therapy using the medical device Varian ProBeam360° Proton Therapy System. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up which is 3 months after treatment completion and long-term follow-up which is 5 years after treatment completion.
219041086|NCT00291668|OTHER|Placebo|"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"
219041087|NCT05768477|OTHER|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
219041088|NCT05768477|PROCEDURE|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
219041089|NCT05768477|DRUG|Baxter therapy|Ketamine or Linisol baxter therapy
219041090|NCT05768477|BEHAVIORAL|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
219041091|NCT04162028|DRUG|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
219041092|NCT00704028|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
219041093|NCT00704028|DRUG|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
219041094|NCT04693390|PROCEDURE|Acupuncture|Application of acupuncture
219041095|NCT02883296|OTHER|Pelvis Magnetic resonance imaging|
219060607|NCT01418209|DRUG|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
219060608|NCT01418209|DRUG|Placebo|The placebo is an inactive pill that looks like the active medication.
219524505|NCT00582088|BIOLOGICAL|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
219524506|NCT03221374|BEHAVIORAL|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
219524507|NCT04597086|OTHER|Best Practice|Receive standard of care
219524508|NCT04597086|PROCEDURE|Bright White Light Therapy|Receive BWLT
219524509|NCT04597086|OTHER|Survey Administration|Ancillary studies
219524510|NCT00018252|BEHAVIORAL|exercise|
218912059|NCT06052761|DEVICE|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
219524511|NCT05679648|DIAGNOSTIC_TEST|ultrasonography|studying degree of steatosis
219524512|NCT00258271|BIOLOGICAL|filgrastim|
219524513|NCT00258271|DRUG|cladribine|
219524514|NCT00258271|DRUG|cytarabine|
219524515|NCT00258271|DRUG|imatinib mesylate|
219524516|NCT04448678|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group descriptions\]
219524517|NCT04448678|OTHER|Usual Care|\[See arm/group descriptions\]
219524518|NCT02567968|DRUG|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
219524519|NCT02567968|DRUG|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
219524520|NCT05719090|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
219524521|NCT01301573|BIOLOGICAL|rAAV-GAD|
219524522|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties|All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
218912060|NCT06176742|OTHER|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
218912061|NCT06176742|OTHER|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
219524523|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse|All children in the control group will consume on daily basis vegetable and fruit mousse for six months
219524524|NCT05140070|BEHAVIORAL|Dietary and physical activity counselling|All children in the study will obtain 4 dietary and physical activity advice during the course of the study
219524525|NCT01024439|PROCEDURE|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
219524526|NCT01024439|PROCEDURE|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
219524527|NCT02016170|DRUG|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
219524528|NCT02016170|DRUG|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
219614265|NCT05659732|DRUG|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
218912062|NCT06211179|DRUG|Treatment A: Mavacamten intact oral capsule|Specified dose on specified days
219614266|NCT04025840|OTHER|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
219614267|NCT04025840|DRUG|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
219614268|NCT04515251|DIAGNOSTIC_TEST|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
219614269|NCT00006207|DRUG|PRO 2000|
219524529|NCT02016170|DRUG|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
219524530|NCT00014105|DRUG|carboplatin|
219524531|NCT00014105|DRUG|temozolomide|
218912063|NCT06211179|DRUG|Treatment B: Mavacamten open capsule in suspension|Specified dose on specified days
219524532|NCT03818230|OTHER|None (observational study)|None (observational study)
219524533|NCT00473356|DIETARY_SUPPLEMENT|receive amino acid supplement|Receive amino acid supplement
219524534|NCT05877170|DIETARY_SUPPLEMENT|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
219524535|NCT05877170|DRUG|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
219614270|NCT04515147|BIOLOGICAL|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
218912064|NCT06211179|DRUG|Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)|Specified dose on specified days
218912065|NCT03454295|BEHAVIORAL|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
218912066|NCT03454295|BEHAVIORAL|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
219524536|NCT02522806|PROCEDURE|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
219524537|NCT01483508|OTHER|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]
219524538|NCT01483508|OTHER|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]
219524539|NCT01483508|OTHER|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
219524540|NCT04281992|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
219524541|NCT01245322|DRUG|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
219524542|NCT00547677|RADIATION|stereotactic radiosurgery|
219524543|NCT02501057|BEHAVIORAL|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
219524544|NCT02501057|BEHAVIORAL|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
218912067|NCT03454295|BEHAVIORAL|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
218912068|NCT06584890|OTHER|decision|decision-making process regarding patient discharge from the Intensive Care Unit (ICU)
218912069|NCT00556075|DRUG|Proellex 25 mg|1 capsule daily for 4 months
218912070|NCT00556075|DRUG|Placebo|1 capsule daily for 4 months
218912071|NCT00556075|DRUG|Proellex 50 mg|2 capsules daily for 4 months
218912072|NCT04863391|DIAGNOSTIC_TEST|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
218912073|NCT01276262|DRUG|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
218912074|NCT01276262|DRUG|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
219524545|NCT02501057|BEHAVIORAL|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
219524546|NCT05627141|OTHER|Photobiomodulation; Cryotherapy, Massage|"Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session."
219614271|NCT04515147|BIOLOGICAL|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
219614272|NCT04515147|BIOLOGICAL|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
219614273|NCT04515147|BIOLOGICAL|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
219614274|NCT04515147|BIOLOGICAL|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
218912075|NCT01276262|DRUG|Placebo|Oral tablets BID, repeated doses for 21 days
219524547|NCT06063005|PROCEDURE|Translocation ILM Flap|After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
218912076|NCT00869466|BEHAVIORAL|behavioral dietary intervention|
218912077|NCT00869466|BEHAVIORAL|exercise intervention|
218912078|NCT00869466|OTHER|counseling intervention|
219041096|NCT06244264|PROCEDURE|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
219041097|NCT04508842|BIOLOGICAL|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
219524548|NCT06063005|PROCEDURE|ILM Peeling|After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
219524549|NCT00336479|DRUG|Telaprevir|tablet
219524550|NCT00336479|DRUG|Ribavirin|tablet
219524551|NCT00336479|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
219524552|NCT00336479|OTHER|Placebo|matching placebo tablet
219524553|NCT00377871|DEVICE|biological heart valve prosthesis|Two heart valve designs
219524554|NCT00429000|DEVICE|thermospot|
219524555|NCT01479439|DRUG|Losartan|Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months
219524556|NCT02365207|DRUG|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
219524557|NCT01924078|DRUG|Capecitabine|metronomic use: capecitabine 500mg/tid
219524558|NCT01924078|DRUG|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
219614275|NCT04713605|DEVICE|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
219524559|NCT03627585|DEVICE|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
219524560|NCT01962337|DRUG|FPA008|Infusion
219524561|NCT01962337|DRUG|Placebo|Infusion
219614276|NCT02866305|PROCEDURE|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
218912079|NCT00869466|OTHER|educational intervention|
218912080|NCT00869466|OTHER|laboratory biomarker analysis|
218912081|NCT00869466|OTHER|questionnaire administration|
218912082|NCT00869466|PROCEDURE|quality-of-life assessment|
218912083|NCT00869466|PROCEDURE|support group therapy|
218912084|NCT02485691|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
218912085|NCT02485691|DRUG|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
218912086|NCT02485691|DRUG|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
218912087|NCT02485691|DRUG|prednisone|Pharmaceutical form: tablet Route of administration: oral
218912088|NCT00225901|DRUG|Recombinant human hepatocyte growth factor|
219524562|NCT01541150|BEHAVIORAL|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
219524563|NCT01722877|DEVICE|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
219524564|NCT02597101|DRUG|Metformin|background drug
219524565|NCT02597101|DRUG|saxagliptin|background drug
219524566|NCT02597101|DRUG|AZD9668|study drug
219524567|NCT02597101|DRUG|placebo|placebo for AZD9668 to be added to background drugs
219524568|NCT01066806|BEHAVIORAL|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
219524569|NCT01066806|OTHER|observation|observe normal dairy intake
219524570|NCT03299907|DIAGNOSTIC_TEST|Spirometry|
219524571|NCT01395030|DIAGNOSTIC_TEST|Computed Tomography|Undergo FCH PET/CT
219524572|NCT01395030|DRUG|18F-fluoromethylcholine|Undergo FCH PET/CT
219524573|NCT01395030|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo FCH PET/CT
219524574|NCT02079766|DRUG|florbetapir F 18|370 megabecquerel (MBq) IV single-dose
219524575|NCT02079766|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
219614277|NCT02866305|PROCEDURE|Chest tube insertion|Conventional chest tube insertion.
219614278|NCT02866305|DRUG|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
219524576|NCT05836805|DRUG|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
219524577|NCT06165562|PROCEDURE|PSV|Pressure support ventilation applied from the start of subcutaneous suture until extubation.
219524578|NCT06165562|PROCEDURE|Intermittent Manual Assistance|Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.
219524579|NCT06165562|PROCEDURE|EEG-Guidance|Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64
218912089|NCT00604565|DRUG|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
218912090|NCT00604565|OTHER|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
219524580|NCT06165562|PROCEDURE|Obey Command|Extubation criteria include obeying commands (eye-opening or handgrip).
218912091|NCT02451059|BEHAVIORAL|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
219524581|NCT06165562|PROCEDURE|Spontaneous Respiration|"Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min"
219524582|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
218912092|NCT02451059|BEHAVIORAL|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
218912093|NCT02451059|BEHAVIORAL|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
218912094|NCT04292535|DRUG|Placebo into the intranasal mucosa|6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
218912095|NCT04292535|DRUG|20 IU NovoLog Insulin aspart into the intranasal mucosa|5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
218912096|NCT04292535|DRUG|40 IU NovoLog Insulin aspart into the intranasal mucosa|4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
219041098|NCT05129878|PROCEDURE|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
219041099|NCT05129878|PROCEDURE|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
219524583|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
219524584|NCT05273866|OTHER|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
219524585|NCT02077270|PROCEDURE|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
219524586|NCT02265783|DEVICE|Nellcor USB Pulse Oximeter Monitor Interface Cable|Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
219524587|NCT02177981|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
219524588|NCT02177981|PROCEDURE|Control|The cuff will be placed around the arm but not inflated.
219524589|NCT05299047|OTHER|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
219614279|NCT02866305|RADIATION|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
219614280|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
219524590|NCT05299047|OTHER|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
219524591|NCT03379103|DRUG|Sevoflurane|Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
219524592|NCT03379103|DRUG|Propofol|Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
219524593|NCT01658228|DRUG|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
218912097|NCT04292535|DRUG|60 IU NovoLog Insulin aspart into the intranasal mucosa|3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
218912098|NCT04292535|DRUG|80 IU NovoLog Insulin aspart into the intranasal mucosa|2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
218912099|NCT04292535|DRUG|100 IU NovoLog Insulin aspart into the intranasal mucosa|1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
218912100|NCT04292535|DRUG|120 IU NovoLog Insulin aspart into the intranasal mucosa|6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
219041100|NCT05129878|PROCEDURE|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
219041101|NCT00313612|DRUG|oxaliplatin|Given IV
219041102|NCT00313612|DRUG|topotecan|Given IV
219041103|NCT05913895|OTHER|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
219524594|NCT01658228|DRUG|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
219041104|NCT01139333|GENETIC|gene expression analysis|
219524595|NCT01658228|DRUG|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
219041105|NCT01139333|GENETIC|western blotting|
219041106|NCT01139333|OTHER|flow cytometry|
219041107|NCT01139333|OTHER|laboratory biomarker analysis|
219041108|NCT04118309|BEHAVIORAL|Exercise|
219041109|NCT04118309|OTHER|Placebo|
219041110|NCT06040021|OTHER|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
219041111|NCT00451035|DRUG|LBH589|
219041112|NCT05904457|DRUG|bevacizumab|Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
219041113|NCT05904457|DRUG|erlotinib|Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
219041114|NCT02445495|DEVICE|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
219524596|NCT01658228|DRUG|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
219524597|NCT02406898|DEVICE|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
219041115|NCT01965288|DEVICE|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
219041116|NCT01965288|DEVICE|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
219041117|NCT01625143|OTHER|laboratory biomarker analysis|Correlative studies
219041118|NCT03738943|DRUG|Adenosine Triphosphate|See arm/group descriptions
219041119|NCT03738943|DRUG|Acetylcholine|See arm/group descriptions
219041120|NCT03738943|DRUG|Sodium Nitroprusside|See arm/group descriptions
219041121|NCT03738943|DRUG|Adenosine Diphosphate|See arm/group descriptions
219041122|NCT03738943|DRUG|Adenosine Monophosphate|See arm/group descriptions
219041123|NCT03738943|DRUG|Uridine Triphosphate|See arm/group descriptions
219041124|NCT03738943|DRUG|Adenosine|See arm/group descriptions
219041125|NCT03738943|DRUG|Vitamin B 6|See arm/group descriptions
219041126|NCT03738943|DRUG|Pyridoxal 5'-Phosphate|See arm/group descriptions
219041127|NCT02653742|DRUG|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
219041128|NCT02653742|DRUG|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
219041129|NCT06148922|OTHER|Brief Mental Health First Aid Workshop|a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
219041130|NCT06148922|OTHER|Semi-structured interviews|One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
219524598|NCT01852435|DRUG|R-CEOP-70|
219524599|NCT01852435|DRUG|R-CEOP-90|
219524600|NCT01852435|DRUG|R-CHOP-50|
219524601|NCT01486121|OTHER|Therapy strategy|Sedation \& mechanical ventilation
219524602|NCT05067647|DEVICE|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
219614281|NCT04066452|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
219524603|NCT05728385|DIETARY_SUPPLEMENT|Modified Specific carbohydrate diet for 3 months|"All children at the start of the study will be subjected to:~1. Full history taking including demographic and medical history~2. Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~3. Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~4. At the beginning of the study and at the end~   1. The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~  2. Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~  3. Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score"
219524604|NCT04166032|DEVICE|Alertgy non-invasive continuous glucose monitoring device (ANICGM)|Alertgy non-invasive continuous glucose monitoring device (ANICGM)
219524605|NCT02874586|OTHER|Plasma exchange combination of immunosuppressive regimens|
218912101|NCT05708092|BEHAVIORAL|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
218912102|NCT01739998|DIETARY_SUPPLEMENT|functional oil|
218912103|NCT01739998|DIETARY_SUPPLEMENT|Placebo|
218912104|NCT00121017|DRUG|Kaletra (lopinavir/ritonavir)|
218912105|NCT00121017|DRUG|Sustiva (efavirenz)|
219524606|NCT01884740|DRUG|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
219524607|NCT02348983|BEHAVIORAL|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
219524608|NCT05826262|PROCEDURE|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
219524609|NCT00002654|DRUG|chemotherapy|
218912106|NCT00121017|DRUG|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
218912107|NCT03515577|PROCEDURE|Computed Tomography|Undergo PET/CT
219524610|NCT00002654|DRUG|cisplatin|
219524611|NCT00002654|RADIATION|low-LET cobalt-60 gamma ray therapy|
218912108|NCT03515577|DRUG|Fluciclovine F18|Given fluciclovine F18
218912109|NCT03515577|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
218912110|NCT03515577|OTHER|Laboratory Biomarker Analysis|Correlative studies
218912111|NCT03515577|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218912112|NCT01992588|DRUG|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
218912113|NCT01992588|DRUG|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
218912114|NCT01897025|DEVICE|real-tDCS with MI-BCI|As in Arm Description
218912115|NCT03836625|OTHER|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
218912116|NCT00980187|DRUG|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
218912117|NCT00980187|DRUG|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
218912118|NCT04762511|BIOLOGICAL|Lower dose formulation of HSV vaccine (GSK4108771A)|2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
218912119|NCT04762511|BIOLOGICAL|Low dose formulation of HSV vaccine (GSK4108771A)|2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
218912120|NCT04762511|BIOLOGICAL|Medium dose formulation of HSV vaccine (GSK4108771A)|2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
218912121|NCT04762511|BIOLOGICAL|High dose formulation of HSV vaccine (GSK4108771A)|2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
218912122|NCT04762511|DRUG|Placebo (saline)|2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
218912123|NCT03167892|DEVICE|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
218912124|NCT00949182|DRUG|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
218912125|NCT00949182|OTHER|laboratory biomarker analysis|
218912126|NCT04764162|DIETARY_SUPPLEMENT|Choline|1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)
218912127|NCT04764162|DIETARY_SUPPLEMENT|Placebo|Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules
218912128|NCT03413891|DRUG|Tranexamic Acid|Mouthwash
218912129|NCT03413891|OTHER|Placebo|Mouthwash
219524612|NCT00002654|RADIATION|low-LET electron therapy|
219524613|NCT00002654|RADIATION|low-LET photon therapy|
219614282|NCT04066452|DIAGNOSTIC_TEST|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
218912130|NCT04555486|DRUG|DCR-PHXC|Intervention, drug, DCR-PHXC
218912131|NCT04555486|DRUG|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
219204526|NCT06887270|OTHER|Interrupted DOAC|The interrupted DOAC group will take their last DOAC dose on Day -2, unless their DOAC is Dabigatran and their creatinine clearance is \< 50mL/min (Cockcroft-Gault equation), in which their last dose will be on Day -3. The DOAC will be resumed on Day +1.
219524614|NCT04341285|PROCEDURE|ECMO Implantation|Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
218912134|NCT05760365|OTHER|3D printed educational model|3D printed cardiac catheterization model
218912135|NCT05760365|OTHER|Slide-based presention|Slide-based presention
218912136|NCT05358366|BEHAVIORAL|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
218912137|NCT01264796|BEHAVIORAL|culturally tailored diabetes education|lifestyle modification group education
218912138|NCT04272294|DEVICE|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
218912139|NCT06573996|DEVICE|Active TENS Device|"Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device"
218912140|NCT06573996|DEVICE|Intervention 2: Placebo/Sham Device|"The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device"
218912141|NCT05168839|DRUG|FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).|"In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded."
218912142|NCT04483206|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
218912143|NCT04483206|DRUG|Melphalan|Given IV
218912144|NCT04483206|OTHER|Questionnaire Administration|Ancillary studies
218912145|NCT03044509|DIAGNOSTIC_TEST|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
218912146|NCT03044509|DIAGNOSTIC_TEST|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
218912147|NCT04905134|DEVICE|Nasopharyngoscope|Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
218912148|NCT06455228|DEVICE|insert catheter|A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
218912149|NCT05404828|OTHER|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
218912150|NCT05404828|OTHER|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
218912151|NCT05404828|OTHER|Blood and urine sample|Na, K, Creat, Osm, Urea
219524615|NCT00791947|DRUG|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
218912152|NCT06132451|OTHER|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
218912153|NCT05224271|OTHER|Electronic Health Record Review|Medical records are collected
219524616|NCT02904837|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
219524617|NCT02904837|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
219524618|NCT02461823|DEVICE|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
219524619|NCT02461823|DEVICE|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
219524620|NCT00857623|DRUG|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
219614283|NCT03052751|DRUG|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
219524621|NCT00857623|DRUG|Placebo|Capsule, once daily
219524622|NCT04785677|BEHAVIORAL|Resiliency in Stressful Experiences (RISE) Program|The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
219524623|NCT05247658|OTHER|Therapeutic lens alone|Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
219524624|NCT05247658|OTHER|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
219524625|NCT00050856|DRUG|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
219524626|NCT05764044|DRUG|cisplatin, gemcitabine|Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.
219524627|NCT05764044|OTHER|Follow-up|Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
218912154|NCT05224271|OTHER|Medical Device Usage and Evaluation|Fitbit information is collected
218912155|NCT05224271|OTHER|Survey Administration|Complete surveys
218912156|NCT06253832|PROCEDURE|conservative surgery for placenta accreta spectrum|The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
218912157|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
218912158|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
218912159|NCT06399666|OTHER|Blood sampling|Blood sampling
219524628|NCT03916094|DRUG|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
219524629|NCT00886171|BEHAVIORAL|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
219524630|NCT00886171|BEHAVIORAL|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
219524631|NCT02748161|PROCEDURE|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
219524632|NCT00555230|DRUG|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
219524633|NCT00555230|DRUG|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
219524634|NCT02717390|BEHAVIORAL|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
219614284|NCT03052751|OTHER|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
219614285|NCT03232359|DIAGNOSTIC_TEST|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
219524635|NCT02717390|BEHAVIORAL|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
219524636|NCT06291792|OTHER|telerehabilitation otago exercise program|telerehabilitation otago exercise program
219041131|NCT04675216|PROCEDURE|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
219041132|NCT06497049|DRUG|GP40221|Solution for Subcutaneous Administration 1.34 mg/ml
219041133|NCT06497049|DRUG|ozempic|Solution for Subcutaneous Administration 1.34 mg/ml
219041134|NCT02752009|PROCEDURE|Axillary Lymph Node Sampling Clip|
219041135|NCT00218517|DRUG|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
219614286|NCT04197804|OTHER|Routine tests perform|The subjects of the Tourette group and control group are subjected to routine tests performed at Tourette Center and Extrapyramidal Diseases. Both groups are initially subjected to an evaluation that aims to identify the IQ and therefore 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) related to the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration about 3 minutes) the language field. These evaluations are in practice at the Center for Tourette patients; the tasks will be administered to both groups.
219614287|NCT00328601|DRUG|Thioctic Acid|
219614288|NCT01067105|DRUG|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
219614289|NCT01225198|DIETARY_SUPPLEMENT|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
219041136|NCT00218517|DRUG|Placebo|Matching placebo capsules using blue 00 capsules
219041137|NCT04813796|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
218912160|NCT05556265|DRUG|Deucravacitinib|Specified dose on specified days
218912161|NCT05556265|OTHER|Placebo|Placebo was administered.
219524637|NCT06291792|OTHER|face to face otago exercise program|face to face otago exercise program
218912162|NCT00712751|BEHAVIORAL|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
218912163|NCT00712751|BEHAVIORAL|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
218912164|NCT06298084|DRUG|Patritumab deruxtecan|5.6 mg/kg every 21 days
218912165|NCT06298084|DRUG|Olaparib|100 mg b.i.d PO days 8-14 every 21 days
218912166|NCT05219695|PROCEDURE|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
218912167|NCT04359810|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
218912168|NCT04359810|BIOLOGICAL|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
219524638|NCT04758260|DIETARY_SUPPLEMENT|Antioxidant|Oral antioxidant oral intake in the 3 months prior to inclusion in the study
219524639|NCT04607863|DIAGNOSTIC_TEST|Case control|Is a case-control research
219524640|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback|See information included in arm/group descriptions.
219524641|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Biofeedback|See information included in arm/group descriptions.
219524642|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback|See information included in arm/group descriptions.
219041138|NCT04813796|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219524643|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback|See information included in arm/group descriptions.
219524644|NCT02803398|OTHER|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann \& Rauscher).
219524645|NCT04616066|OTHER|Dates|The effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
219524646|NCT04616066|OTHER|Raisins|The effect of raisins phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
219524647|NCT06237023|OTHER|epidemyolojical|The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
219524648|NCT00006370|RADIATION|yttrium Y 90-edotreotide|
219041139|NCT04813796|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219041140|NCT06104501|DEVICE|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
219041141|NCT02510378|RADIATION|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
219524649|NCT01134848|DRUG|Morphine|10mg IM
219524650|NCT01134848|DRUG|Neostigmine|1mg IM
219524651|NCT01134848|DRUG|0.9% saline|0.1 ml/kg
219524652|NCT01134848|DRUG|Secretin|1 unit/kg IV
219524653|NCT01134848|DRUG|0.9% saline|1ml IM
219524654|NCT04675580|BEHAVIORAL|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
219524655|NCT03961425|BEHAVIORAL|NO CO2|Traditional mechanical Deairing
219524656|NCT03961425|DEVICE|CO2 Cannula|NON specific, low cost delivery system
219524657|NCT03961425|DEVICE|CO2 Cardia|Specific Commercial CO2 Diffuser
219524658|NCT05939180|DRUG|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
219041142|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
219041143|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
219524659|NCT05939180|DRUG|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
219524660|NCT02059746|OTHER|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
219524661|NCT06252025|COMBINATION_PRODUCT|Memo-gration|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
219524662|NCT06252025|OTHER|Picture reminiscence therapy|Picture reminiscence therapy
219041144|NCT01886248|DRUG|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
219524663|NCT03858257|DEVICE|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
219524664|NCT03858257|DEVICE|Standard oxygenation|Supplemental oxygen through a facemask.
219524665|NCT02123979|DRUG|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
219041145|NCT00587379|DRUG|Atorvastatin|40 mg atorvastatin pill daily
219041146|NCT00587379|DRUG|placebo|40 mg pill per day
219614290|NCT01225198|OTHER|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
219614291|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
219614292|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
219041147|NCT03689556|DIAGNOSTIC_TEST|FLT PET/CT|Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
219524666|NCT00709553|DRUG|midazolam|
219524667|NCT00709553|DRUG|ZD4054|ZD4054 10 mg od
219524668|NCT00694551|BIOLOGICAL|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
219524669|NCT00694551|DRUG|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
219524670|NCT03231956|DEVICE|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
219524671|NCT05879328|PROCEDURE|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
219524672|NCT01439893|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
219524673|NCT01439893|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
219614293|NCT00593723|RADIATION|IMRT|
219041148|NCT00344773|DRUG|Gefitinib|250mg tablet oral tablet once daily
219041149|NCT02366078|BEHAVIORAL|SMART|Paced breathing meditation with cognitive training
219041150|NCT05967962|BEHAVIORAL|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
219041151|NCT05967962|BEHAVIORAL|non-traumatic (neutral) film|non-traumatic (neutral) film
219041152|NCT02766244|DEVICE|ICG/SPY|indocyanine green fluorescence imaging
219524674|NCT02425579|DRUG|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
219041153|NCT02766244|DRUG|Antibiotic Ointment|Antibiotic ointment
219041154|NCT00714259|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
219041155|NCT00714259|RADIATION|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
219041156|NCT00714259|OTHER|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
219041157|NCT02729649|DEVICE|ArmAssist robotic training|
219041158|NCT02729649|OTHER|Conventional therapy|
219524675|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
219524676|NCT02425579|DRUG|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
219614294|NCT01634048|DIETARY_SUPPLEMENT|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
219614295|NCT01268982|PROCEDURE|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
219524677|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
219524678|NCT03559387|DRUG|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
219524679|NCT03559387|DRUG|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
219524680|NCT01569152|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
219524681|NCT01569152|DRUG|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
219524682|NCT01569152|DRUG|Methotrexate|MTX dosed at the stable dose receive upon study entry
219524683|NCT01614730|DEVICE|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
219524684|NCT01614730|DEVICE|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
219524685|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
218912169|NCT03221556|BEHAVIORAL|Engagement-Focused Care Coordination (EFCC)|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
218912170|NCT03221556|BEHAVIORAL|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
218912171|NCT04414111|DIAGNOSTIC_TEST|Highly suppressive Treg measurement|Circulating highly suppressive Treg measurement
218912172|NCT03267550|DEVICE|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
218912173|NCT00879021|DRUG|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
218912174|NCT00879021|DRUG|matching placebo|150 mg by mouth ,twice a day for 49 weeks
218912175|NCT02336282|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level \< 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
218912176|NCT02336282|DEVICE|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
218912177|NCT02336282|OTHER|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
219614296|NCT02302833|DRUG|Cabozantinib S-malate|Given PO
219614297|NCT02302833|OTHER|Laboratory Biomarker Analysis|Correlative studies
218912178|NCT02336282|OTHER|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
218912179|NCT05506631|PROCEDURE|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
219524686|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
219524687|NCT05324982|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
219524688|NCT05324982|DRUG|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
219524689|NCT06246032|OTHER|Modified feeding Protocol|"Initiation of feeding (fixed): 10cc/kg~Advancement based on birthweight (fixed):~\<750g: 15cc/kg/d 750-999g: 20cc/kg/d 1000-1249g: 25cc/kg/d 1250-1499g: 25cc/kg/d 1500-1749g: 35cc/kg/d 1750-2000g: 35cc/kg/d~Starting Human milk fortification when feed reach at 70cc/kg/d"
219524690|NCT00059865|DRUG|gemcitabine hydrochloride|
219524691|NCT00059865|DRUG|pemetrexed disodium|
219524692|NCT06992674|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
219614298|NCT02302833|OTHER|Questionnaire Administration|Ancillary studies
219524693|NCT06992674|DRUG|Placebo|Take 75mg qd of placebo
219524694|NCT05331664|PROCEDURE|Pars plana vitrectomy|Standard of care surgery
219524695|NCT05331664|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
218912180|NCT05506631|PROCEDURE|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
218912181|NCT06058442|DRUG|NORTASE®|10-15 capsules of NORTASE® per day - over 6 months
219524696|NCT05331664|DRUG|Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin|Antibiotic eye drop 4 times per day for 1 week after surgery
219524697|NCT05331664|DRUG|Prednisolone 1%|Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
218912182|NCT06058442|DRUG|Placebo|10-15 capsules of placebo per day - over 6 months
219524698|NCT05331664|DRUG|Atropine 1%|Eye drop daily for 1 week after surgery
219524699|NCT05005156|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
218912183|NCT02216708|OTHER|Rapid dehydration|
218912184|NCT02216708|OTHER|Slow rehydration|
218912185|NCT03724942|DRUG|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
218912186|NCT02668497|DRUG|Botulinum Toxin Type A|
218912187|NCT06236971|BEHAVIORAL|MRI scanning first at supine position and then turn into lateral position|Magnetic resonance imaging was used to scan the upper airway of sedated subjects, first at supine position and then turn into lateral position.
218912188|NCT06602518|PROCEDURE|Orthodontic Treatment|All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
218912189|NCT06598098|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
218912190|NCT06589284|PROCEDURE|Silk 0-0 suture covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
218912191|NCT06589284|PROCEDURE|2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
219041159|NCT02729649|OTHER|Extended conventional therapy|
219041160|NCT02141074|DRUG|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
219524700|NCT06203314|OTHER|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
219524701|NCT05069636|OTHER|Lymphatic OMM|Patients receive lymphatic myofascial release and thoracic pump techniques.
219524702|NCT05069636|OTHER|Light Touch|Patients receive a series of light touch techniques.
219524703|NCT05451836|OTHER|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
219524704|NCT05451836|OTHER|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
219524705|NCT04164771|OTHER|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
219524706|NCT02126306|DRUG|Beta Glucosylceramide|Beta Glucosylceramide
219524707|NCT02126306|DRUG|Placebo|normal saline
219524708|NCT03686358|PROCEDURE|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~* Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~* Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~* Identification of prognostic factors"
219524709|NCT00191009|DRUG|atomoxetine hydrochloride|
218912192|NCT06601348|OTHER|Nutrition education, physical activity intervention, and health promoting school model trials|A nutrition education and physical activity intervention, combining a pilot health promoting school model that includes health education and recreational enhancement with the curriculum of a government-designated healthy school, was designed to reduce childhood overweight and obesity. The programme was implemented over 6 months. This program has been widely conducted in several countries, but there are still many differences from previous studies, especially in terms of strengthening qualitative studies in the first stage, then in the intervention stage using a Cluster Randomised Controlled Trial design. Another advantage of this study is the combination of intervention and health promoting school. In Indonesia, there are few intervention studies in reducing overweight and obesity in children, some only focus on descriptive studies such as nutritional knowledge, physical activity measures using questionnaires to determine the relationship or measure BMI.
218912193|NCT04689516|DEVICE|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
218912194|NCT01574586|DEVICE|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
218912195|NCT06596590|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
218912196|NCT06592092|BIOLOGICAL|QH104 Cell injection|Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.
219524710|NCT00191009|DRUG|placebo|
219524711|NCT06673706|OTHER|Front-of-package label|Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group
219524712|NCT07008885|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) :~starting dose: 5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg.~If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg.~Phase 2 : dose of RP2D."
218912197|NCT06603649|OTHER|ECPR for out-of-hospital cardiac arrest|Patient with out-of-hospital cardiac arrest enrolled in the ECPR protocol
218912198|NCT06600477|DRUG|olanzapine|7.5 mg
218912199|NCT06599814|PROCEDURE|vital pulp therapy|vital pulp therapy using two bioactive materials TheraCal and RetroMTA as direct pulp caping materials conventionally and test using Diode laser before application of these materials
218912200|NCT06603415|PROCEDURE|Total thyroidectomy|Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
218912201|NCT06989905|BEHAVIORAL|Up-conditioning of the wrist extensor motor evoked potential|At the beginning of each session, EMG recording and nerve stimulating electrodes are placed over the arm. In all sessions, MEPs will be measured while the sitting subject provides a pre-set level of background muscle EMG with joint angles fixed. In 225 control trials of each baseline sessions and the first 20 trials of conditioning sessions the subject will receive no feedback as to MEP size (i.e., control MEPs). In 225 conditioning trials of each conditioning session, the subject will be encouraged to increase the target muscle MEP, and will receive immediate feedback as to whether MEP size was above a criterion (i.e., whether the trial was a success).
218912202|NCT06991569|PROCEDURE|Non-surgical perforation repair|Root perforation repair using MTA or other perforation repair material
218912203|NCT06595173|BEHAVIORAL|Therapeutic Intervention|"group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated."
218912204|NCT06999135|DRUG|Silodosin|Silodosin is an oral medication primarily used to treat benign prostatic hyperplasia (BPH) by relaxing the muscles in the prostate and bladder neck to improve urine flow. It belongs to a class of drugs called alpha-1 adrenergic antagonists, which block receptors responsible for muscle contraction in these areas. This action helps relieve symptoms such as difficulty urinating, urgency, and weak urine stream. Silodosin is taken once daily with food and is known for its high selectivity for alpha-1A receptors, contributing to its effectiveness and safety profile
218912205|NCT06999525|DEVICE|Therapeutic virtual reality headset (CRVT)|Contribution of the use of a Therapeutic Virtual Reality Headset in the management of anxiety and discomfort in digestive endoscopy
218912206|NCT06998017|OTHER|Low Volume High Intensity Interval Training|Participants will conduct aerobic exercise on a total body recumbent stepper to get their heart rates to levels consistent with high intensity exercise.
219524713|NCT07008885|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
219524714|NCT07008885|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
219524715|NCT03187002|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
218912207|NCT06998888|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to cancer.
219524716|NCT03187002|DRUG|Moderate IV Sedation|IV sedation with fentanyl and versed
219524717|NCT03187002|OTHER|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
218912208|NCT06998797|OTHER|Data collection|Data collection from medical records
218912209|NCT05805020|PROCEDURE|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
218912210|NCT01869907|DRUG|Minocycline|100 mg once daily by mouth during 14 days
218912211|NCT01869907|DRUG|placebo|once daily by mouth during 14 days
219524718|NCT03187002|OTHER|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
218912212|NCT01869907|DRUG|Amitriptyline|25mg once daily by mouth during 14 days
218912213|NCT04449913|BEHAVIORAL|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
218912214|NCT04449913|BEHAVIORAL|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
218912215|NCT05183178|DRUG|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
218912216|NCT05183178|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
219524719|NCT03734965|DEVICE|AWAKEN INTUBATION|Intubation
219524720|NCT02098993|DRUG|Unfractionated heparin|
219524721|NCT05822518|DIETARY_SUPPLEMENT|Neo-mune powder (otsuka pharmaceutical)|"* Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~* Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
219524722|NCT05822518|DRUG|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
219524723|NCT05282654|BEHAVIORAL|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
219524724|NCT00522613|BEHAVIORAL|Recovery Group Project|Recovery Group Workbook \& Group Sessions
219524725|NCT04989036|PROCEDURE|pulpotomy|Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
218912217|NCT03316092|DIAGNOSTIC_TEST|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
218912218|NCT00193336|DRUG|ZD1839|
218912219|NCT01766050|DRUG|Caffeine|
218912220|NCT01766050|DRUG|Losartan|
218912221|NCT01766050|DRUG|Omeprazole|
218912222|NCT01766050|DRUG|Dextromethorphan|
218912223|NCT01766050|DRUG|Midazolam|
218912224|NCT01766050|BIOLOGICAL|Belatacept|
218912225|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
218912226|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
219041161|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
219524726|NCT02845258|PROCEDURE|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
219524727|NCT03167671|DEVICE|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
219524728|NCT03167671|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
218912227|NCT06349798|DRUG|NaCl 0.9%|50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
218912228|NCT03991780|DRUG|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
218912229|NCT03057093|OTHER|Non interventional study|retrospective noninterventional study
218912230|NCT02361385|OTHER|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
219524729|NCT03556566|BIOLOGICAL|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
219524730|NCT00662766|DIETARY_SUPPLEMENT|black currant seed press residue|Black currant seed press residue, baked into bread
219524731|NCT00662766|DIETARY_SUPPLEMENT|Bread without black currant seed press residues|Same bread but without seeds
219524732|NCT00662766|DIETARY_SUPPLEMENT|Baseline data|No supplement was administered.
219524733|NCT01623128|BEHAVIORAL|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
219524734|NCT01245790|DRUG|fostamatinib|Oral tablets, single dose
218912231|NCT03577275|DRUG|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
219041162|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
219041163|NCT00874068|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
219041164|NCT00874068|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
219041165|NCT05709184|COMBINATION_PRODUCT|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
219524735|NCT06114004|DRUG|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
219524736|NCT06114004|DRUG|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
219524737|NCT02920996|DRUG|Merestinib|Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
219524738|NCT04008979|DRUG|Aspirin|Aspirin - lipid complex
219524739|NCT00154102|DRUG|Cetuximab|Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
219524740|NCT00154102|DRUG|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
219524741|NCT00463606|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
218912232|NCT03577275|DRUG|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
218912233|NCT03577275|DRUG|Moxifloxacin 400mg|Active comparator with known effect on QT interval
218912234|NCT03577275|DRUG|NST-4016 2000mg|Supratherapeutic dose of NST-4016
218912235|NCT02299596|OTHER|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
218912236|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
218912237|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
218912238|NCT00782535|DRUG|Placebo|Inhaled solution, single dose of placebo
219041166|NCT05709184|DRUG|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
219041167|NCT02753894|DRUG|ASP1585|Oral
219060609|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
219060610|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
219060611|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
219524742|NCT00463606|DRUG|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
219524743|NCT00463606|DRUG|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
219524744|NCT03772496|DIAGNOSTIC_TEST|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
219041168|NCT02459392|OTHER|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
219041169|NCT02459392|DRUG|Hyaluronic Acid|Drug administration
219041170|NCT02459392|DRUG|DepoMedrol|Drug administration
219524745|NCT03772496|DIAGNOSTIC_TEST|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
219524746|NCT02593851|DRUG|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
218912239|NCT05866666|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
219041171|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
219041172|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
219041173|NCT01589432|DRUG|Placebo|2 placebo capsules
219041174|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
219041175|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
219041176|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
219041177|NCT06239779|OTHER|Education|The education intervention will involve a PowerPoint presentation delivered individually by a physician to each participant in intervention group, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
219041178|NCT04793360|DEVICE|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
219524747|NCT02593851|DRUG|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
219524748|NCT00628160|DRUG|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
219524749|NCT00628160|DRUG|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
219524750|NCT04351516|DRUG|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
219524751|NCT04351516|OTHER|Placebo|Placebo: Film Coated Tablette
219524752|NCT01081717|DRUG|systemic non-biological treatments|as prescribed
219524753|NCT01081717|BIOLOGICAL|anti-TNF biologics|as prescribed
219524754|NCT01081717|BIOLOGICAL|golimumab|as prescribed
219524755|NCT01081717|BIOLOGICAL|non-anti-TNF biologics|as prescribed
219524756|NCT01081717|OTHER|general population|non-treated cohort
219524757|NCT06101225|OTHER|MindRegulation Intervention|The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
219524758|NCT06101225|OTHER|Relaxation|The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
219524759|NCT06101225|OTHER|Waiting List Control Group|No Intervention.
219524760|NCT06266962|DRUG|1% Atropine drops|Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
219524761|NCT06266962|DRUG|Epinephrine|Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
219524762|NCT00789984|DEVICE|noncontact specular microscopy|
219524763|NCT03654625|BEHAVIORAL|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
218912240|NCT03609645|PROCEDURE|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
218912241|NCT03609645|PROCEDURE|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
218912242|NCT03889808|DIAGNOSTIC_TEST|Determination of serum anti-toxin Abs for C. difficile|
218912243|NCT01873937|RADIATION|Red LED|Phototherapy with red LED on temporomandibular area
219524764|NCT03654625|BEHAVIORAL|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
219524765|NCT03654625|BEHAVIORAL|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
219524766|NCT05791032|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
219524767|NCT05865197|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
219524768|NCT02228174|DEVICE|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
219524769|NCT01427023|DEVICE|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
219524770|NCT00401804|DRUG|Dexamethasone, Bortezomib, Doxorubicin|
219524771|NCT02373332|OTHER|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
219524772|NCT01732978|BEHAVIORAL|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
219524773|NCT03863730|DIETARY_SUPPLEMENT|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
219524774|NCT03863730|DIETARY_SUPPLEMENT|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
219524775|NCT05266430|OTHER|Standard of Care|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
219524776|NCT05266430|DRUG|AU-011|Previously received
219524777|NCT03109132|DEVICE|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
219524778|NCT03109132|DEVICE|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
219614299|NCT06468436|DRUG|Dexmedetomidine-Esketamine Combination|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
219524779|NCT03109132|DEVICE|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
219524780|NCT03109132|DEVICE|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
219524781|NCT03109132|DEVICE|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
219524782|NCT03109132|DEVICE|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
219524783|NCT00438828|DRUG|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
219524784|NCT02688257|OTHER|MRI|Functional magnetic resonance imaging
218912244|NCT01873937|RADIATION|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
219524785|NCT02688257|OTHER|Ultrasound|Optoacoustic imaging
219524786|NCT02682602|DEVICE|DePuy Synthes total hip arthroplasty|
219524787|NCT02682602|RADIATION|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
219524788|NCT02682602|RADIATION|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
219524789|NCT00922909|BEHAVIORAL|Simon task|Reaction time task
219524790|NCT05982860|BEHAVIORAL|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries \& sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
219524791|NCT00113789|OTHER|PI Discretion|PI Discretion
218912245|NCT01873937|RADIATION|LASER|Phototherapy with LASER INFRARED on temporomandibular area
218912246|NCT00576706|DRUG|Rebamipide|Rebamipide 100㎎, 12 weeks
219524792|NCT02366949|DRUG|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 \> (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
219524793|NCT02366949|DRUG|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
219524794|NCT07003399|OTHER|Diaphragmatic Ultrasound and EMG Assessment|Non-invasive assessment of diaphragmatic morphofunction and respiratory drive using ultrasound imaging and diaphragm electromyography (EMG). This evaluation will be performed once per participant without any therapeutic intervention.
219524795|NCT03476980|PROCEDURE|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
219524796|NCT03476980|PROCEDURE|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
219524797|NCT05047003|DIAGNOSTIC_TEST|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
219524798|NCT01342328|OTHER|Normal saline infusion|Normal saline infusion
218912247|NCT00576706|DRUG|Misoprostol|Misoprostol 200㎍ 12 weeks
218912248|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912249|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912250|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912251|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912252|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912253|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
218912254|NCT00089297|BIOLOGICAL|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
218912255|NCT00089297|DRUG|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
219041179|NCT05627518|DRUG|Linaprazan glurate|100 mg
219041180|NCT05747066|OTHER|No intervention|No intervention
219041181|NCT06183320|PROCEDURE|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
218912256|NCT00089297|DRUG|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
218912257|NCT00089297|RADIATION|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
219614300|NCT06468436|DRUG|Dexmedetomidine|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
218912258|NCT00403377|BEHAVIORAL|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
218912259|NCT04432935|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
218912260|NCT04432935|OTHER|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
218912261|NCT05731583|DEVICE|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
218912262|NCT02825693|PROCEDURE|Conventional cataract surgery (phacoemulsification)|
218912263|NCT02825693|PROCEDURE|Femtosecond laser assisted cataract surgery|
218912264|NCT02030808|DRUG|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
219614301|NCT06447194|DRUG|Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail|Please refer to description for interventional group.
218912265|NCT02030808|DRUG|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
218912266|NCT03406377|DRUG|OPK-88003|OPK-88003 subcutaneous injection
218912267|NCT03406377|DRUG|Placebo|Placebo subcutaneous injection
218912268|NCT02900729|DEVICE|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
218912269|NCT02900729|DRUG|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
218912270|NCT03481088|PROCEDURE|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
218912271|NCT02167971|OTHER|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
218912272|NCT02167971|OTHER|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
218912273|NCT04521790|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
218912274|NCT01806441|OTHER|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
218912275|NCT01806441|OTHER|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
218912276|NCT02088008|DRUG|cinidipine, valsartan|
218912277|NCT03742076|DIETARY_SUPPLEMENT|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
218912278|NCT03742076|DIETARY_SUPPLEMENT|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
219614302|NCT06447194|OTHER|Placebo|100mL paraspinal normal saline injection intraoperatively, once.
219614303|NCT00002881|DRUG|flutamide|
219614304|NCT00002881|DRUG|goserelin acetate|
218912279|NCT03742076|DIETARY_SUPPLEMENT|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
219524799|NCT01342328|DRUG|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
219524800|NCT01342328|DRUG|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
219524801|NCT03544632|DRUG|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
219524802|NCT07009002|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) : starting dose:~5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg. If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg. Phase 2 : dose of RP2D."
219524803|NCT07009002|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
219524804|NCT07009002|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
219524805|NCT02753335|BEHAVIORAL|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
219524806|NCT02753335|BEHAVIORAL|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
219524807|NCT05551078|BIOLOGICAL|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
218912280|NCT01910298|PROCEDURE|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
218912281|NCT01910298|PROCEDURE|Two Stage Breast Reconstruction|
218912282|NCT00717574|DRUG|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
219041182|NCT06183320|PROCEDURE|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
219524808|NCT06627738|RADIATION|Cyberknife irradiation|Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
219524809|NCT06631547|DRUG|Progesterone|Hormonal treatment
219524810|NCT06631547|DRUG|The usual head trauma care|the basic treatment
218912283|NCT00717574|DRUG|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
218912284|NCT03037385|DRUG|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
218912285|NCT00144547|DRUG|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
218912286|NCT04058938|BEHAVIORAL|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
218912287|NCT04058938|BEHAVIORAL|Control|Standard patient counseling
219041183|NCT04561986|DRUG|Tocilizumab|Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor
219041184|NCT05545735|DRUG|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
219524811|NCT07025395|BEHAVIORAL|- Core Training Protocol|This structured training intervention incorporates progressive core exercises designed to enhance neuromuscular activation, balance, and muscle hypertrophy. Participants perform eight exercise triads per session, progressing from core stability drills to high-intensity power movements over eight weeks.
219614305|NCT00002881|DRUG|leuprolide acetate|
218912288|NCT02535481|DEVICE|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
218912289|NCT02535481|PROCEDURE|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
218912290|NCT02130817|DRUG|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
218912291|NCT02130817|DRUG|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
218912292|NCT02130817|PROCEDURE|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
218912293|NCT02130817|DRUG|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
218912294|NCT02130817|DRUG|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
218912295|NCT02130817|DRUG|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
218912296|NCT00294450|DEVICE|Fistula Pouching System|3 different sizes of fistula pounching system
218912297|NCT05165771|DRUG|GS-5718|Tablets administered orally
218912298|NCT05165771|DRUG|GS-5718|Tablets administered orally
218912299|NCT05165771|DRUG|Placebo to match GS-5718|Tablets administered orally
218912300|NCT05165771|DRUG|Tofacitinib 5 mg|Tablets administered orally
218912301|NCT05165771|DRUG|Placebo to match Tofacitinib|Tablets administered orally
218912302|NCT02764385|OTHER|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
219524812|NCT07025395|BEHAVIORAL|Control Group Core Routine|Control group participants engage in general core activation exercises twice per week, without progressive intensity or specialized neuromuscular adaptation.
219524813|NCT07029321|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises for 12 weeks
219524814|NCT07027800|DIETARY_SUPPLEMENT|Creatine Monohydrate|20 gram loading of creatine monohdyrate for 5 days, followed by 5 grams per day for 6 weeks
219524815|NCT07027800|DIETARY_SUPPLEMENT|Placebo|20 grams daily of non-caloric placebo + 5 grams daily non-caloric placebo for 6 weeks
219524816|NCT07029516|OTHER|Cosmetic patch containing urea applicated daily for 3 months|Daily application of the patch on toes, 3 months treatment
219524817|NCT07029516|OTHER|Placebo patch application|Daily application of a placebo patch on toes for a 3 months treatment
219524818|NCT07028996|DEVICE|Daily use of the PEASY urine collection device for 5 days|"The PEASY device features a non-adhesive attachment system to the penis, unlike penile sheaths which are used for the same indications and whose attachment system is based on an adhesive system. Fixation of the PEASY device to the penis involves the use of a clamp on the foreskin. The clamp has a certain elasticity and has been developed to be atraumatic.~The medical device comprises a glans cup which covers the urinary meatus. This cup therefore rests on the glans."
219614306|NCT00002881|DRUG|suramin|
218912303|NCT02764385|OTHER|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
218912304|NCT04665401|BEHAVIORAL|Tailored MERIT|see arm description
218912305|NCT04665401|BEHAVIORAL|Standard MERIT|see arm description
218912306|NCT00593216|DEVICE|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
218912307|NCT04494841|DEVICE|Duotherm VibraCool Back Device|Low back plate belt with mechanicothermal and pressure intervention options.
218912308|NCT01703195|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
218912309|NCT01703195|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
218912310|NCT02783534|DEVICE|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
218912311|NCT02783534|DEVICE|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
218912312|NCT02783534|BEHAVIORAL|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
218912313|NCT05260736|PROCEDURE|Infraclavicular brachial plexus block|Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
219614307|NCT00002881|DRUG|therapeutic hydrocortisone|
219614308|NCT00002881|PROCEDURE|orchiectomy|
219524819|NCT07028996|OTHER|Daily collection of patient feedback using a visual analog scale (0-100)|Daily collection of patient feedback using a visual analog scale (0-100) and any suggestions for improving the device during an open interview at the end of the test period.
218912314|NCT03938233|BEHAVIORAL|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
218912315|NCT04312178|OTHER|cash incentive|cash incentive (20€ gift card)
218912316|NCT04312178|OTHER|no intervention|no intervention
218912317|NCT04312178|OTHER|return vaginal self-swab kit in person|hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
219524820|NCT07030725|DRUG|Menthol Gel|Menthol (5% L-menthol) will be applied to the anterior thorax.
219524821|NCT07030725|DRUG|Sham|Sham gel applied to the anterior thorax.
219524822|NCT07030725|BEHAVIORAL|Time control|No gel applied to anterior thorax.
219524823|NCT07036289|PROCEDURE|Mechanical Treatment|manual quadrant scaling and root planing followed by dental prophylaxis within 4 weekly sections and oral hygiene instructions
219524824|NCT07035210|BEHAVIORAL|Group and 1:1 occupational therapy sessions|Patients will be educated on the goal setting process and setting self-directed goals aimed at occupations they identified as important in both group and 1:1 treatment sessions.
219614309|NCT05417789|DRUG|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
219614310|NCT05417789|DRUG|Placebo|Matching placebo administered once every 2 weeks (q2w)
218912318|NCT03915197|DIAGNOSTIC_TEST|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
218912319|NCT04484077|BIOLOGICAL|hCT-MSC|2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
218912320|NCT03429335|BEHAVIORAL|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
218912321|NCT03429335|BEHAVIORAL|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
219524825|NCT07037329|DIAGNOSTIC_TEST|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a non-invasive electrotherapy technique used to manage pain and modulate physiological responses such as blood pressure. In this study, patients in Group 1 received TENS therapy as the primary intervention.
219041185|NCT05462600|OTHER|Position change|Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
219060612|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
219060613|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
219524826|NCT07037329|DIAGNOSTIC_TEST|Electrical Muscle Stimulation (EMS)|EMS is a form of electrotherapy that causes muscle contractions through electrical impulses delivered via surface electrodes. In this study, patients in Group 2 received EMS therapy to investigate its effect on hemodynamic parameters in individuals with hypertension.
219614311|NCT04205565|DRUG|Test group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
219614312|NCT04205565|DRUG|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
219614313|NCT04205565|DRUG|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
219614314|NCT02631486|OTHER|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
219614315|NCT00934024|DRUG|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
219614316|NCT04634006|DEVICE|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
219614317|NCT02439216|DRUG|Edasalonexent|
219614318|NCT02439216|DRUG|Placebo|
219060614|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
219524827|NCT07035366|PROCEDURE|stabled resection|diaphragmatic plication of sever eventration by stabled resection
219524828|NCT07035366|PROCEDURE|running sutures|plication of diaphragmatic eventration by running sutures
219614319|NCT02094300|DEVICE|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
219524829|NCT07037394|DRUG|Probiotic plus lactulose|Probiotic and lactulose will be administered per the dose and schedule specified in the arms.
219524830|NCT07037394|DRUG|Rifaximin plus lactulose|Rifaximin and lactulose will be administered per the dose and schedule specified in the arms.
219524831|NCT07037394|DRUG|L-ornithine-L-aspartate plus latulose|LOLA and lactulose will be administered per the dose and schedule specified in the arms.
219614320|NCT01111318|DRUG|BI 10773|2 tablets BI 10773 25 mg single dose
219524832|NCT07037394|DRUG|Lactulose|Lactulose will be administered per the dose and schedule specified in the arms.
219524833|NCT07035743|OTHER|Exercise|5 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
219524834|NCT07035743|OTHER|Exercise|15 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
219524835|NCT07035834|DRUG|Gliflozin|Our study will enroll non diabetic patients affected by chronic kidney disease secondary to lupus nephritis and ANCA associated vasculitis. Other studies have so far investigated only diabetic patients affected by the above mentioned diseases.
219524836|NCT07036016|DRUG|EGFR-TKI|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib
219524837|NCT07036016|DRUG|PD-1/PD-L1 inhibitor|ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
219614321|NCT02091856|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
219614322|NCT01892956|OTHER|Nutritional intervention|"2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet"
218912322|NCT03429335|BEHAVIORAL|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
218912323|NCT04607668|DRUG|Trilaciclib|Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
218912324|NCT04607668|DRUG|Placebo|Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
218912325|NCT05119647|DEVICE|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
219060615|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
219060616|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
219524838|NCT07036016|DRUG|EGFR-TKI combined with PD-1/PD-L1|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib combined with ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
219524839|NCT07037524|RADIATION|Radiation Therapy|Low single-dose wholw-heart radiotherapy
219524840|NCT07036367|DRUG|Sublingual Melatonin|Participants in this group received 3 mg of sublingual melatonin, administered 60 minutes before cataract surgery. The melatonin was given in the form of a rapidly dissolving sublingual tablet to enhance bioavailability and ensure consistent preoperative absorption. The goal of the intervention was to reduce preoperative anxiety, improve sedation level, and stabilize hemodynamic parameters. The melatonin tablets were indistinguishable in appearance from the placebo and were prepared and dispensed by a pharmacy technician not involved in data collection or patient care
219524841|NCT07036367|DRUG|Sublingual Placebo|Participants in this group received an identical-appearing sublingual placebo tablet containing inert ingredients, administered 60 minutes before cataract surgery. The placebo was visually indistinguishable from the melatonin tablets and was used to maintain double blinding in the trial. Tablets were prepared by the pharmacy team to ensure concealment and eliminate bias. This group was designed to serve as a control to evaluate the effectiveness of sublingual melatonin on anxiety and sedation levels in elderly patients
218912326|NCT04434482|DRUG|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
218912327|NCT01838694|BIOLOGICAL|Ala-Cpn10|
218912328|NCT01838694|DRUG|Placebo|
218912329|NCT00055393|DRUG|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
218912330|NCT00055393|DRUG|Placebo|21 subjects received Placebo.
218912331|NCT03623243|DRUG|Siponimod|Siponimod 2mg tablets taken once daily
218912332|NCT04623788|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with contrast
218912333|NCT01801163|DRUG|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
218912334|NCT01801163|RADIATION|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
218912335|NCT02177695|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218912336|NCT02177695|DRUG|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
218912337|NCT02177695|DRUG|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218912338|NCT02177695|DRUG|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218912339|NCT02177695|DRUG|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218912340|NCT02177695|DRUG|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
219060617|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
219524842|NCT07036640|OTHER|Heat exposure|Heat exposure during exercise
219524843|NCT07037563|OTHER|An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia|It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.
219524844|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched with mushrooms|Patients will receive the MeD personalized plan plus commercial mushrooms
219524845|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched the Lebanese herbal mixture Za'atar|Patients will receive the MeD personalized plan plus natural products/extracts of endemic plants (olive oil, herbs like Lebanese Za'atar).
219524846|NCT07035704|DIETARY_SUPPLEMENT|MeD Diet + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)|Patients will receive counselling and personalized dietary strategy aimed at increasing the adherence to Mediterranean diet by means of use of visual communication (e.g., comics, cartoons, videos) and digital tools (i.e., games, apps), including a physical activity program with a personal trainer + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)
219524847|NCT07035418|BEHAVIORAL|Clinical Decision-Making Scenarios and Preferences Assessment|Participants complete a socio-demographic questionnaire and decision-making preferences scale, including hypothetical clinical scenarios, to identify their preferred decision-making role (active, collaborative, or passive) and the influence of providers or family. Delivered electronically via secure link; reminders sent as needed.
219524848|NCT07036302|PROCEDURE|35% TCA combined with croton oil peel|3 sections every 30 days of 35% TCA combined with croton oil peel
219524849|NCT07036302|PROCEDURE|Isolate 35% TCA peel|3 sections every 30 days of isolate 35% TCA peel
218912341|NCT04445961|DIAGNOSTIC_TEST|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
219524850|NCT07036302|RADIATION|Erbium-YAG laser|3 sections every 30 days of Er-YAG laser
219524851|NCT07036302|RADIATION|Neodymium -YAG laser Q-switched|3 sections every 30 days of ND-YAG laser
219524852|NCT07036770|DIAGNOSTIC_TEST|Coronary CT scan using photon-counting CT|A dedicated cardiac UHR PCCT will be conducted within a maximum of 24 hours in ACS subjects and 72 hours in CCS subjects prior to the invasive CAG. Additionally, patients are also eligible for inclusion in case no PCCT is conducted prior to CAG, as long as no PCI is performed during the initial CAG. In these cases, the PCCT must be conducted within 24 hours for ACS patients and within 72 hours for CCS patients.
219524853|NCT07037199|DRUG|SHR-A1811 + dalpiciclib+ endocrine therapy|sequential SHR-A1811 followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors)
219524854|NCT07037602|OTHER|Sexual Health Education|After the Personal Information Form, Sexual Myths Scale and Sexual Self-Awareness Scale are applied as a pre-test to all women, sexual health training will be given to the women in the experimental group. The training will be given in 4 sessions over 2 weeks. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.
219524855|NCT07037602|OTHER|No Interventions|No intervention will be made.
218912342|NCT04445961|DIAGNOSTIC_TEST|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
219041186|NCT02983383|PROCEDURE|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
219524856|NCT07036601|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
219524857|NCT07036601|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
219524858|NCT07036926|OTHER|Artificial Intelligence Video Education Arm|A novel, AI-generated, interactive peri-operative video education program. AI videos will be personalized using medical record chart data, specifically the patient's name, surgery date, and past medical history.
219524859|NCT07036315|OTHER|Music intervention|Participants will be asked to select different music clips based on meaning, enjoyment and preference.
219524860|NCT07035496|OTHER|Benson's relaxation exercise|The Benson's relaxation exercise is based on the principle of choosing a word that is meaningful to the individual and focusing on it, breathing deeply and relaxing all the muscles in the body.The Benson relaxation exercise is a simple and easy-to-learn method.
219041187|NCT02983383|PROCEDURE|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
219524861|NCT07036965|DEVICE|CardiPulse|abc
219524862|NCT07036965|DEVICE|FaraPulse|bcd
219524863|NCT06723041|PROCEDURE|Acupressure Therapy|Undergo true acupressure
219524864|NCT06723041|PROCEDURE|Acupressure Therapy - placebo|Undergo sham acupressure
219524865|NCT06723041|PROCEDURE|Acupressure Therapy - self-administered|Undergo self-administered acupressure
219524866|NCT06723041|OTHER|Health Promotion and Education|Receive educational handouts
219524867|NCT06723041|OTHER|Survey Administration|Ancillary studies
219524869|NCT06768476|BIOLOGICAL|CART123 Cells|1.3x10\^8 CART123 cells
219524870|NCT06768476|DRUG|Ruxolitinib 10 MG Oral Tablet|Twice Daily
219524871|NCT06768476|DRUG|Ruxolitinib 5 MG|Twice Daily
219524872|NCT06927869|OTHER|designed physical therapy , pully system exercise|Participants assigned to the intervention group will engage in a specially designed physical therapy program focusing on pulley system exercises. The program is scheduled to occur three times per week, which is frequent enough to potentially induce meaningful improvements while allowing adequate rest between sessions to prevent fatigue and overtraining
218912343|NCT06031519|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
218912344|NCT04540185|BIOLOGICAL|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
219524873|NCT06105047|BEHAVIORAL|Cognitive tests|". Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task~* quiz : Geneva Music Induced Checklist, GMIAC, Coutinho \& Scherer, 2017"
219524874|NCT06630247|DRUG|XL495|oral doses of XL495
219524875|NCT06630247|DRUG|ADC cytotoxic agents|intravenous infusion of anti-cancer combination agent
219524876|NCT04709809|DEVICE|Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating|Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
219524877|NCT06818461|OTHER|Corvis St Before and after lasik, PRK, CXL|corneal biomechanics measurment using corvis St
219524878|NCT02417805|PROCEDURE|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
219524879|NCT00756080|DRUG|citrulline|0.06 G/kg three times/day during 7 days
219524880|NCT00756080|DRUG|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
219524881|NCT00868010|DRUG|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
219524882|NCT00868010|DRUG|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
219524883|NCT03363503|DRUG|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
219524884|NCT03363503|DRUG|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
219524885|NCT05940909|DRUG|Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet|"Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine."
219524886|NCT02236494|BEHAVIORAL|Brief Negotiated Interview|As per arm
219524887|NCT02236494|BEHAVIORAL|General Health Information|As per arm (this is the active comparator)
218912345|NCT04540185|BIOLOGICAL|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
218912346|NCT04540185|DRUG|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
218912347|NCT04540185|DRUG|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
219524888|NCT01796886|OTHER|pupillometry data|
219614323|NCT00648778|DRUG|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
218912348|NCT04540185|COMBINATION_PRODUCT|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
218912349|NCT04540185|COMBINATION_PRODUCT|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
218912350|NCT02986217|OTHER|regular structured assessment of surgical performance|
218912351|NCT02767817|PROCEDURE|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
219524889|NCT03744364|DRUG|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
219524890|NCT03744364|DRUG|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
219524891|NCT04349917|DRUG|Methylphenidate|A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
219524892|NCT04349917|OTHER|Placebo|A matching placebo pill will be administered on the placebo day.
219524893|NCT00003114|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
219524894|NCT00003114|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
219524895|NCT00003114|DRUG|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
219524896|NCT00003114|DRUG|lomustine|Patients receive oral lomustine on day 1.
219524897|NCT00003114|DRUG|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
219614324|NCT00648778|DRUG|Loxitane® Capsules 25 mg|25mg, single dose fasting
219524898|NCT00003114|RADIATION|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
218912352|NCT02767817|BIOLOGICAL|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
218912353|NCT02767817|BIOLOGICAL|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
218912354|NCT01011998|DRUG|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
218912355|NCT01106599|DRUG|GDC-0623|Repeating oral dose
218912356|NCT00979901|DRUG|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
219041188|NCT06068582|BEHAVIORAL|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
219041189|NCT06068582|BEHAVIORAL|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
219041190|NCT00931749|DEVICE|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
219041191|NCT00931749|DEVICE|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
219060618|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
219524899|NCT06366581|DIAGNOSTIC_TEST|Transcriptomic analysis|high-throughput sequencing technology
219524900|NCT01861379|PROCEDURE|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
219524901|NCT05125419|DIAGNOSTIC_TEST|Homocysteine level|diagnostic test
219524902|NCT03514420|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx solution for SC injection.
219524903|NCT00410865|GENETIC|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
219524904|NCT06217224|OTHER|Preventive photobiomodulation Therapy (PBMT)|The application of preventive TLBP will be performed with a laser device containing an aluminum phosphide and indium gallium diode (InGaAlP) emitting radiation in the red region of the electromagnetic spectrum (660 nm) with a power of 100mW and a beam area of 0.03 cm2 . An energy of 1J/point and an energy density of 33.3 J/cm2/point were determined, which will be applied punctually, with a distance between the points of 1cm, for 10s per point, totaling 9 points per region.
219524905|NCT00371722|PROCEDURE|Appendectomy|
219524906|NCT03377894|PROCEDURE|blunt uterine incision expansion|blunt uterine incision expansion
219524907|NCT03377894|PROCEDURE|sharp uterine incision expansion|sharp uterine incision expansion
219524908|NCT05792072|DEVICE|rTMS|High-frequency rTMS
219524909|NCT05792072|DEVICE|Sham rTMS|sham rTMS
219524910|NCT06196515|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
219524911|NCT06196515|DRUG|nano calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
219524912|NCT00000310|DRUG|Risperidone|
219524913|NCT04915053|DIETARY_SUPPLEMENT|ABG+ Black Garlin|Daily tablet intake during three months
219524914|NCT04915053|DIETARY_SUPPLEMENT|Crystalline Cellulose|Daily tablet intake during three months
219524915|NCT02885285|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
219524916|NCT02885285|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
219524917|NCT02885285|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
219524918|NCT02885285|OTHER|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
219524919|NCT02071303|DRUG|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
219524920|NCT02071303|DRUG|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
219524921|NCT02071303|DRUG|Placebo|A placebo will be given to 70 women before the procedure.
219524922|NCT01978743|DRUG|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
218912357|NCT00979901|DRUG|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
219524923|NCT02548234|OTHER|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
219524924|NCT02548234|OTHER|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
218912358|NCT00979901|DRUG|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
218912359|NCT00979901|DRUG|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
219524925|NCT01107093|DRUG|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
219524926|NCT01107093|DRUG|Placebo|single oral dose
219614325|NCT04238078|DRUG|Contraceptive|Oral contraceptive pill
219524927|NCT00745420|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
219524928|NCT06534996|DRUG|SCD-2101|Tradictional Chinese Medicine formula (SCD-2101)
219524929|NCT04991779|DIAGNOSTIC_TEST|AI-assisted cEEG detection tool|"This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association."
219524930|NCT02063841|DEVICE|lead-free protective drape containing bismuth and antimony (RADPAD®)|
218912360|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
219524931|NCT02063841|DEVICE|sterile identical sham drape|
219524932|NCT02264106|DRUG|Lefradafiban tablet|
219524933|NCT02264106|DRUG|Lefradafiban double chamber sachet|
219524934|NCT02264106|DRUG|Pantoprazole|
218912361|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
218912362|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
218912363|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
218912364|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
218912365|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
219041192|NCT05798390|DRUG|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
219614326|NCT03532529|OTHER|not applicable, it is an observational study|not applicable, it is an observational study
218912366|NCT03904017|OTHER|Oxygen|100% Oxygen air
218912367|NCT03904017|OTHER|placebo|medical air
218912368|NCT04970745|OTHER|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
218912369|NCT04970745|OTHER|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
218912370|NCT04800965|BEHAVIORAL|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
218912371|NCT04800965|BEHAVIORAL|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
218912372|NCT04800965|BEHAVIORAL|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
218912373|NCT01718288|DRUG|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
219041193|NCT06591429|RADIATION|Radiotracer [11C]-CS1P1|Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
219041194|NCT06591429|RADIATION|Radiotracer [11C]-DPA-713|Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
219524935|NCT00000229|DRUG|Buprenorphine|
219524936|NCT05767619|DIAGNOSTIC_TEST|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
219524937|NCT05767619|DIAGNOSTIC_TEST|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
219614327|NCT04443972|OTHER|PD VitalOs cement®|PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
219041195|NCT06591429|DRUG|anti-CD20 MS treatment|MS treatment taken indepenently after initial testing
219041196|NCT06591429|RADIATION|Radiotracer [12F]-FDG|used in PET/CT scans of the head and neck Dose: 5-7 mCi
219060619|NCT03998007|DEVICE|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
219524938|NCT02658045|DEVICE|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
219524939|NCT02658045|DEVICE|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
219524940|NCT00416845|DRUG|FTY720|
219524941|NCT00437138|BEHAVIORAL|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
219614328|NCT04443972|OTHER|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
219524942|NCT00088829|DRUG|paclitaxel|subjects will receive paclitaxel neoadjuvantly
219524943|NCT00088829|GENETIC|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
219524944|NCT00088829|PROCEDURE|biopsy|All subjects will have a biopsy to collect tissue
218912374|NCT01718288|DRUG|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
218912375|NCT00555958|DEVICE|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
219524945|NCT00088829|PROCEDURE|neoadjuvant therapy|paclitaxel is given neoadjuvantly
219524946|NCT00088829|DRUG|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
219041197|NCT06809049|BEHAVIORAL|Dalcroze music education|Dalcroze is a type of music education which focuses on free and improvised movement, as well as structure and choreographed sequences. It has been successfully applied to similar populations as an effective, accessible, and sustainable intervention. We hope to use Dalcroze music education to employ a holistic approach to improve the brain-heart symptoms of children with congenital DM1.
219041198|NCT05938790|OTHER|Continuous Fetal Monitoring|Fetal doppler used to monitor fetal heart rate in triage
219524947|NCT02711449|DRUG|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
219524948|NCT02711449|DRUG|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
219524949|NCT01194648|OTHER|questionnaire administration|
219524950|NCT01194648|PROCEDURE|assessment of therapy complications|
219524951|NCT01194648|PROCEDURE|high-intensity focused ultrasound ablation|
219524952|NCT01194648|PROCEDURE|multiparametric magnetic resonance imaging|
219524953|NCT01194648|PROCEDURE|quality-of-life assessment|
219524954|NCT01194648|PROCEDURE|transperineal prostate biopsy|
219524955|NCT01194648|PROCEDURE|transrectal prostate biopsy|
219041199|NCT05938790|OTHER|Point of Care Handheld Ultrasound|Point of Care Handheld Ultrasound
219041200|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive premixed intrathecal fentanyl and bupivacaine in the same syringe.
219041201|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive intrathecal fentanyl and bupivacaine in separate syringes.
219041202|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive manually mixed intrathecal fentanyl and bupivacaine in the same syringe.
219524956|NCT06627699|DEVICE|Total Knee Arthroplasty|Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
219524957|NCT01358344|DRUG|Pantoprazole|40 mg delayed-release tablet administered orally in the morning of Days 1-7
219524958|NCT01358344|DRUG|SCH 530348 (high percentage)|2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
219614329|NCT04443972|OTHER|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
219614330|NCT01927575|DEVICE|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
219041203|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the Sub Lingual (SL) space.
219041204|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space
219524959|NCT01358344|DRUG|SCH 530348 (standard percentage)|2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
219524960|NCT01209793|BIOLOGICAL|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
219524961|NCT06062277|DRUG|Colchicine 0.5 MG|one oral tablet daily for 30 days
219524962|NCT05781282|DEVICE|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
219524963|NCT06486246|PROCEDURE|Adductor canal block|Injection of the local anesthetic prior to the surgery, either in the the adductor canal or in the genicular nerves by the anesthesiologist under ultrasound guidance.
219524964|NCT05817916|PROCEDURE|ESP block|ESP block: ultrasound guided erector spina plane block
219524965|NCT05817916|PROCEDURE|LP block|LP block: ultrasound guided lumbar plexus block
219524966|NCT06547190|BEHAVIORAL|High AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The High AGEs diet was cooked for example by baking and grilling.
219524967|NCT06547190|BEHAVIORAL|Low AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The low AGEs diet was cooked for example by steaming and boiling.
219524968|NCT05749172|OTHER|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
219524969|NCT05749172|OTHER|Controlled group|Two hours of parkour training for two days a week.
219524970|NCT04602507|DRUG|Ivermectin|Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
219524971|NCT04602507|OTHER|Placebo|Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
219524972|NCT02822781|OTHER|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
219524973|NCT02091882|DRUG|Placebo|Oral placebo-embedded IEM tablet.
219614331|NCT01927575|DEVICE|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
219614332|NCT01927575|DEVICE|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
219614333|NCT04505969|OTHER|Questionnaire to assess needs|Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD
219524974|NCT02091882|COMBINATION_PRODUCT|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
219524975|NCT00813046|BIOLOGICAL|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
218912376|NCT01672385|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
218912377|NCT00681044|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
218912378|NCT00681044|DRUG|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
218912379|NCT00681044|PROCEDURE|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
218912380|NCT03888443|DEVICE|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
218912381|NCT03010696|OTHER|No interventions, questionnaire, collect specimen|
218912382|NCT02962700|DEVICE|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
218912383|NCT05685914|PROCEDURE|endoscopic surgery|Emergency or elective surgery
218912384|NCT02153086|DRUG|Ramelteon|Ramelteon tablets 8 mg
219524976|NCT04287426|DRUG|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
219524977|NCT04287426|DRUG|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
219524978|NCT02788448|DEVICE|VIVASURE CLOSURE DEVICE|Large hole closure device
219524979|NCT06096740|BEHAVIORAL|Cognitive Processing Therapy|"Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms."
219524980|NCT05227625|BEHAVIORAL|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
219524981|NCT05227625|BEHAVIORAL|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
219614334|NCT03405025|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
219614335|NCT03405025|DEVICE|ultrasound|ultrasound
218912385|NCT04953494|DIAGNOSTIC_TEST|Patient information collection, exon sequencing and follow-up.|Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
218912386|NCT04457297|DRUG|trifluridine and tipiracil|Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
218912387|NCT04457297|DRUG|Placebo|Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
218912388|NCT02859220|OTHER|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
219041205|NCT00705107|BIOLOGICAL|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
219041206|NCT00705107|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
219041207|NCT00417443|DRUG|Clonidine|
218912389|NCT02859220|OTHER|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
219041208|NCT00975533|DEVICE|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
219041209|NCT00975533|DRUG|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
219041210|NCT06660238|OTHER|No interventions|No interventions
218912390|NCT04236817|BEHAVIORAL|Pre-packed blisters for distribution of medications|
219041211|NCT06923956|DRUG|Bempedoic Acid Film Coated Tablet|1 tablet of 180 mg Bempedoic Acid
219041212|NCT06923956|DRUG|Nilemdo® (Bempedoic Acid) Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
219524982|NCT03160352|OTHER|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
219524983|NCT00954915|BIOLOGICAL|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
218912391|NCT04236817|BEHAVIORAL|Routine distribution of medications|
219524984|NCT01287013|DEVICE|Cone-beam computed tomography (CT)|Imaging
219524985|NCT01287013|DEVICE|Conventional Computed Tomography (CT)|Imaging
219524986|NCT05146596|DEVICE|use low level light therapy,The Dr.Tai's energy cap|30 minutes each time, three times a week, a total of 12 times.
218912392|NCT05560477|DRUG|AM3101|Injectable drug product.
218912393|NCT05560477|DRUG|Saline Placebo|2 mL 0.9% normal saline
218912394|NCT01317472|DRUG|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
218912395|NCT01317472|DRUG|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
218912396|NCT05158270|PROCEDURE|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
219524987|NCT01832701|OTHER|Coffee|coffee versus placebo
219524988|NCT01832701|OTHER|Placebo comparator|maltodextrine with caffeine
219524989|NCT03328260|DEVICE|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
219524990|NCT02109042|DRUG|Blosozumab|Administered subcutaneously
219524991|NCT03203447|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
219524992|NCT03203447|DRUG|suprachoroidal sham|sham suprachoroidal procedure
219524993|NCT03203447|DRUG|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
219524994|NCT04140188|DIAGNOSTIC_TEST|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
219524995|NCT00662571|DRUG|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
218912397|NCT05158270|PROCEDURE|Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block|Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
218912398|NCT05158270|OTHER|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
218912399|NCT02546271|BEHAVIORAL|GPS|
218912400|NCT04829201|PROCEDURE|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
218912401|NCT05546476|DRUG|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
219524996|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose
219524997|NCT00936871|DRUG|Placebo|Placebo single dose
218912402|NCT05546476|DRUG|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
219524998|NCT00936871|DRUG|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
218912403|NCT03985930|DEVICE|Distraction with virtual reality|Distraction content delivered through virtual reality goggles
218912404|NCT03985930|OTHER|Treatment as Usual|Treatment as Usual
218912405|NCT02012439|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
219524999|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
219525000|NCT00936871|DRUG|Placebo|Placebo single dose
219525001|NCT00936871|DRUG|Moxifloxacin|Moxifloxacin 400 mg single dose
219525002|NCT01192230|DRUG|Endostatins|7.5mg/m2 qd \*14d,q3w
219525003|NCT01192230|DRUG|Docetaxel|75mg/m2 D1, q3w,4-6cycles
219525004|NCT04990817|OTHER|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
219525005|NCT04990817|OTHER|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
219525006|NCT02134405|DRUG|Rebamipide|Rebamipide 100mg tid
219525007|NCT02134405|DRUG|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
219525008|NCT02134405|DRUG|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
219525009|NCT03839303|DEVICE|Infra-zygomatic Mini Implant Supported Appliance|"1. leveling and alignment of the four maxillary incisors~2. infra zygomatic mini-implant will be placed bilaterally~3. wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~4. a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~5. orthopedic force will be delivered from the mini-implants to the wire frame work"
219525010|NCT03839303|DEVICE|high pull head gear|"1. acrylic maxillary splint is made with flying tubes~2. high pull head gear is adapted to be inserted in the flying tubes"
219525011|NCT02291562|DRUG|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
219525012|NCT02291562|DRUG|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
219525013|NCT02291562|DRUG|placebo|placebo (capsule, once) oral intake
218912406|NCT02012439|BEHAVIORAL|Cognitive Therapy|
219041213|NCT06108349|DRUG|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
219525014|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
219525015|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
219525016|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
219525017|NCT02226185|DRUG|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
219525018|NCT02226185|DRUG|placebo|supplement of placebo two times per day for 2-3 years
219525019|NCT02495415|DRUG|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
219525020|NCT05998265|DEVICE|FeetMe rehabilitation|Home based rehabilitation program with real time biofeedback using a connected device
219525021|NCT05998265|OTHER|Physiotherapy|Conventional physiotherapy as prescribed by the neurologists
219525022|NCT01541891|DRUG|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
219525023|NCT01541891|DRUG|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
219525024|NCT06390501|DRUG|Semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks, 0.1 mg semaglutide once weekly for four weeks, 1.7 mg semaglutide once weekly for four weeks followed by 2.4 mg semaglutide once weekly for eight weeks
219525025|NCT06390501|DRUG|Placebo|Solution for subcutaneous (s.c. - under the skin) injection
218912407|NCT04013997|DEVICE|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
218912408|NCT00494182|DRUG|Carboplatin|Given IV
218912409|NCT00494182|DRUG|Paclitaxel|Given IV
218912410|NCT00494182|DRUG|Sorafenib|Given PO
218912411|NCT06397079|BEHAVIORAL|Electric toothbrush|Teach Bass brushing technique and bursh teeth using electric toothbrush dental hygiene three times a day.
218912412|NCT06397079|BEHAVIORAL|Soft bristle toothbrush|Teach Bass brushing technique and bursh teeth using soft bristle toothbrush dental hygiene three times a day.
218912413|NCT03301311|OTHER|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
218912414|NCT03301311|OTHER|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
218912415|NCT04096430|BEHAVIORAL|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
218912416|NCT06353997|DRUG|Pembrolizumab|Drug will be delivered per standard-of-care as established by trial Keynote-522.
218912417|NCT06353997|DRUG|INBRX-106|INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
219525026|NCT00115128|DRUG|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
219525027|NCT02925247|BEHAVIORAL|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
219525028|NCT03290820|RADIATION|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
219525029|NCT03290820|DRUG|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
219525030|NCT03290820|DRUG|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
219525031|NCT02109692|OTHER|blood sample|dosage of miRNA
219525032|NCT03798262|OTHER|Gluten|Tereos
219525033|NCT03798262|OTHER|Placebo|Whey protein from Nestlé Healthy Science
218912418|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
219060620|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
219525034|NCT01645839|DRUG|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
219525035|NCT04821401|DIETARY_SUPPLEMENT|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
219525036|NCT04821401|DIETARY_SUPPLEMENT|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
219525037|NCT04065035|OTHER|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
219525038|NCT04065035|OTHER|Body Cleanser|Body cleanser to be used by study participants
219525039|NCT04065035|OTHER|Sunscreen|Sunscreen to be applied after application of moisturizer
219525040|NCT04065035|OTHER|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
219525041|NCT00380198|DRUG|Apadenoson|
219525042|NCT05746897|DRUG|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
219525043|NCT05746897|DRUG|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
219525044|NCT03478397|OTHER|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
219614336|NCT01553357|DRUG|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
219614337|NCT02938143|PROCEDURE|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
218912419|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
219525045|NCT00486395|DEVICE|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
219525046|NCT00486395|DEVICE|Mechanical ventilation|Volume guarantee strategy
219525047|NCT04799314|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy
219525048|NCT01223820|DRUG|Capsaicin|5x nasal application in one day, 1 hour between each application
219525049|NCT03827291|DRUG|Exparel|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
219614338|NCT02938143|PROCEDURE|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
218912420|NCT01782027|DRUG|3H-cholesterol bound to albumin|up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
218912421|NCT02050061|OTHER|compression stocking|study the impact of compression stocking
218912422|NCT01489540|DEVICE|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
218912423|NCT02182895|DRUG|Saxagliptin|2.5-5 mg daily
218912424|NCT02102646|DRUG|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
218912425|NCT02102646|PROCEDURE|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
218912426|NCT06177496|PROCEDURE|local ablation|treatment of HCC
218912427|NCT06177496|PROCEDURE|TACE|treatment of HCC
218912428|NCT06177496|DRUG|Sorafenib|treatment of HCC
218912429|NCT02953652|DRUG|HBI-8000|Orally twice weekly
218912430|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
218912431|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
218912432|NCT06272799|DRUG|T-DM1 adjuvant|Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
218912433|NCT06571253|BEHAVIORAL|Digital Exercise Intervention|Participants in this intervention arm used the Fiziu Digital Physiotherapy Platform. This digital platform provided a structured 6-week corrective exercise program through visual and auditory-guided videos. The intervention included interactive features such as reminders and progress tracking to enhance adherence and engagement.
218912434|NCT06571253|BEHAVIORAL|Paper-Based Exercise Intervention|Participants in this intervention arm followed a traditional paper-based exercise program. This included printed exercise instructions and illustrations for a 6-week period. The program was designed to mimic standard physical therapy exercises without digital support.
218912435|NCT01481922|DEVICE|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
218912436|NCT01481922|DEVICE|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
218912437|NCT03813355|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
218912438|NCT03217344|PROCEDURE|conservative treatment|immobilization on sling of the injured arm
219041214|NCT04909632|DIAGNOSTIC_TEST|Liquid chromatography-mass spectrometry (LC-MS) analysis|The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
219041215|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
219041216|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
219614339|NCT05583695|BEHAVIORAL|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
219614340|NCT05583695|BEHAVIORAL|mindfulness-based therapy|eight weekly sessions of mindfulness
219614341|NCT05583695|BEHAVIORAL|routine care|eight weekly sessions of routine care
219614342|NCT03018184|OTHER|MRI and Muscle Dynamometer|
219614343|NCT02736552|DRUG|S-1 for 6 months|6 months S-1 after D2 resection
219614344|NCT02736552|DRUG|S-1 for 1 year|1 year S-1 after D2 resection
219614345|NCT06134037|DRUG|Aminophylline|Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
219614346|NCT00919295|DRUG|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
218912439|NCT04982562|OTHER|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
218912440|NCT03047941|DIAGNOSTIC_TEST|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
219614347|NCT00919295|DRUG|placebo|placebo
219614348|NCT00725491|DRUG|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
219614349|NCT00725491|DRUG|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 \<= 50 pg/ml (\<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
219614350|NCT01753180|BIOLOGICAL|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
219614351|NCT01753180|DRUG|saline|Local intra-coronary administration of saline at or into the CTO
218912441|NCT05033197|BEHAVIORAL|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
218912442|NCT01285141|BIOLOGICAL|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
218912443|NCT00060528|DRUG|Recombinant Fowlpox-GM-CSF|
218912444|NCT00060528|DRUG|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
218912445|NCT00060528|DRUG|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
218912446|NCT00060528|DRUG|Recombinant Human GM-CSF|
219041217|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
219041218|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
219525050|NCT03827291|OTHER|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia
219525051|NCT01036360|OTHER|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
219525052|NCT02482090|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
219525053|NCT02482090|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
219525054|NCT02482090|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
219614352|NCT04069819|DRUG|Cilostazol 50 MG Oral Tablet|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
219614353|NCT04069819|DRUG|Escitalopram|Escitalopram 20 mg tablet once daily for 6 week
219614354|NCT04069819|DRUG|Placebo|placebo
219525055|NCT02482090|DRUG|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
219525056|NCT02942264|DRUG|Zotiraciclib (TG02)|"Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study."
219614355|NCT01495000|DRUG|denosumab|60mg subcutaneous injection, single dose
219614356|NCT01495000|DRUG|placebo|placebo subcutaneous injection, single dose
219614357|NCT04131088|OTHER|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
219614358|NCT00684372|DRUG|leflunomide|"Screening: If BK viremia (BK PCR \>10 000 copies/ml in serum) i. Reduced immunosuppression~1. MMF / AZA withdrawal~2. CNI reduction~   1. Tacrolimus 5 ng/ml in serum~  2. Cyclosporin 100 ng/ml in serum~3. Prednisolone to maintenance level~If effective =\> continue~* Stable renal function (P-Krea)~* \>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~* Negative PCR at \> 3 months after diagnosis~If failure =\> add leflunomide~* Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~* \<50% reduction in PCR at 4 weeks after diagnosis~* Positive PCR at \>3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~1. Starting at 20 mgx1 PO daily~2. Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 \>40 ug/ml"
219614359|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
219614360|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
219614361|NCT03499067|DEVICE|Test lens|Contact lens
219614362|NCT03499067|DEVICE|Control lens|Contact lens
219614363|NCT05576090|BEHAVIORAL|Mindfulness Meditation|The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for questions and group discussion. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
219614364|NCT05576090|BEHAVIORAL|Sleep Education|The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for questions. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.
219614365|NCT03658044|OTHER|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
219614366|NCT03658044|OTHER|Placebo|No intervention performed. Patients are offered to read the open pages on the website
219525057|NCT02942264|DRUG|Temozolomide (TMZ)|"Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design."
219525058|NCT02136290|BEHAVIORAL|Prepackaged meals|Portion-controlled prepackaged meals
219525059|NCT02136290|BEHAVIORAL|Usual Care|Usual care dietary counseling
219525060|NCT02664103|DRUG|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
219525061|NCT00954395|OTHER|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
219525062|NCT05630586|DRUG|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
219525063|NCT05630586|OTHER|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
218912447|NCT00739921|PROCEDURE|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
219525064|NCT05167981|OTHER|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
219525065|NCT04907838|DRUG|Insulin clamp|Continous infusion insulin + glucose
219525066|NCT04907838|DRUG|BQ123|Continuous infusion of Insulin + glucose + BQ123
218912448|NCT01592734|DRUG|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
218912449|NCT01592734|DEVICE|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
219041219|NCT06865885|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 months and 9 month visit.
219041220|NCT05886296|BEHAVIORAL|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
219041221|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
219525067|NCT04907838|DRUG|BQ123 + BQ788|Continous infusion of insulin + glucose + BQ123 + BQ788
219525068|NCT02536950|DEVICE|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
219525069|NCT02536950|DEVICE|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
219525070|NCT03850795|DRUG|HC-1119|oral once daily 80 mg
219525071|NCT03850795|DRUG|Enzalutamide|oral once daily 160 mg
219525072|NCT03893318|DRUG|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
219525073|NCT03893318|DRUG|Placebos|Saline
219614367|NCT01934439|DEVICE|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
219614368|NCT04413513|OTHER|Integrated Attention Training Program (IATP)|Integrated attention training program (IATP) is a newly developed cognitive training programs that combined relaxation technique with integrated attentional training into daily life activity.
219614369|NCT04413513|OTHER|Health Education|Health educational sessions on health concerns and physical diseases commonly found in old age
219614370|NCT04122521|DIAGNOSTIC_TEST|MRI|MRI
219614371|NCT02234908|BEHAVIORAL|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
219614372|NCT02234908|BEHAVIORAL|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
219614373|NCT00954759|PROCEDURE|Chiropractic treatment|
219041222|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
219041223|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
219525074|NCT06416826|DEVICE|Vibroacoustic Therapy System - VTS 1000|Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
219614374|NCT00954759|PROCEDURE|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
219614375|NCT02548832|DRUG|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
219525075|NCT05935631|DIETARY_SUPPLEMENT|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
219525076|NCT06221319|OTHER|sacral erectör spinae plane group|sacral erectör spinae plane will be applied to patients in Group S
219525077|NCT03748303|DRUG|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
219525078|NCT04664621|DIAGNOSTIC_TEST|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
219525079|NCT02188303|DRUG|LY2944876|Administered SC
219525080|NCT02188303|DRUG|Placebo|Administered SC
219525081|NCT01945164|DRUG|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
219525082|NCT04206332|DRUG|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
219525083|NCT04206332|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
219525084|NCT06337721|BEHAVIORAL|SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction)|This behavioral group intervention will consist of multiple group sessions to reduce AUDs and alcohol-related harms in Pacific Islander young adults. It will infuse culturally resonant narratives, language, and elements into existing evidence-based strategies.
219525085|NCT05664919|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
219525086|NCT03059628|OTHER|Personalized Normative Feedback|"This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking."
219525087|NCT03059628|OTHER|Brief Therapeutic Intervention|BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
219614376|NCT02548832|DRUG|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
219614377|NCT02548832|DRUG|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
218912450|NCT02913339|OTHER|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
219525088|NCT03059628|OTHER|Evaluation questionnaire|The patient have to fill the same evaluation questionnaire at J0, M6 and M12
219525089|NCT01618097|BEHAVIORAL|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
219614378|NCT00116506|DRUG|erlotinib|
219614379|NCT00116506|DRUG|FOLFOX|
219614380|NCT00116506|DRUG|bevacizumab|
219614381|NCT03565900|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
218912451|NCT04091620|PROCEDURE|Transanal Total Mesorectal Excision|As above
218912452|NCT04091620|PROCEDURE|Robotic Total Mesorectal Excision|As above
218912453|NCT03962036|DEVICE|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
219614382|NCT03565900|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
218912454|NCT02515916|OTHER|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
218912455|NCT03539406|BIOLOGICAL|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
218912456|NCT03539406|DRUG|Chemotherapy|Cyclofosfamide/fludarabine treatment
218912457|NCT04673318|BEHAVIORAL|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
219525090|NCT01618097|BEHAVIORAL|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
219525091|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
219525092|NCT00989274|BIOLOGICAL|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
219614383|NCT03565900|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
219525093|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
219525094|NCT02110953|COMBINATION_PRODUCT|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
218912458|NCT04673318|BEHAVIORAL|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
219614384|NCT00413101|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
219614385|NCT04775160|DEVICE|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
219614386|NCT05241340|DRUG|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
219614387|NCT05241340|RADIATION|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
218912459|NCT01950182|DRUG|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
219525095|NCT02110953|PROCEDURE|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
219614388|NCT05241340|PROCEDURE|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
219614389|NCT03805386|DRUG|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
219614390|NCT03805386|DRUG|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
219614391|NCT02719886|DEVICE|Ultrasound|Estimation of fetal weight by ultrasound
218912460|NCT01950182|DRUG|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
218912461|NCT05182086|OTHER|Group physical therapy and dietary improvements|20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
218912462|NCT02230410|DEVICE|CryoBalloon Focal Ablation|
218912463|NCT06460545|BIOLOGICAL|sIPV (booster dose at 18 months of age)|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose at 18 months of age for the booster one
218912464|NCT06460545|BIOLOGICAL|HepA-L|Freeze-dried/lyophilized live-attenuated hepatitis A virus vaccine, 1.0mL for each dose at 18 months of age
219041224|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
219041225|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
218912465|NCT06460545|BIOLOGICAL|HepA-I|Inactivated hepatitis A virus vaccine, 0.5mL for each dose, two doses at 18 and 24 months of age, respectively
219060621|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
219525096|NCT00485394|DRUG|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
219525097|NCT00485394|DRUG|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
219525098|NCT00485394|DRUG|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
219525099|NCT06201650|DIAGNOSTIC_TEST|Neurofilament light chain|Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
219525100|NCT03977649|DRUG|erenumab|erenumab 140 mg sc every 4 weeks
219525101|NCT03977649|DRUG|placebo|placebo sc every 4 weeks
219525102|NCT04052503|BEHAVIORAL|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
219525103|NCT00003064|BIOLOGICAL|filgrastim|
219525104|NCT00003064|DRUG|carboplatin|
219525105|NCT00003064|DRUG|etoposide phosphate|
219525106|NCT00003064|DRUG|paclitaxel|
219525107|NCT00003064|DRUG|thiotepa|
219525108|NCT00003064|DRUG|topotecan hydrochloride|
219525109|NCT00003064|PROCEDURE|peripheral blood stem cell transplantation|
219525110|NCT00061321|DRUG|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
219525111|NCT03289884|OTHER|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
219525112|NCT03289884|OTHER|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
219525113|NCT03289884|OTHER|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
219525114|NCT03289884|OTHER|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
219525115|NCT03289884|OTHER|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
219525116|NCT05855785|BEHAVIORAL|dual task exercise|8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
219525117|NCT05855785|BEHAVIORAL|home exercise|60-minute light intensity home exercise, 4 times a week for 8 weeks
219525118|NCT05246293|DRUG|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
219525119|NCT02401607|OTHER|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
219525120|NCT05570084|DRUG|Silodosin|Cap silodosin for medical expulsion therapy
219525121|NCT05570084|DRUG|Tamsulosin|Cap tamsulosin
219525122|NCT05688306|DRUG|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
219525123|NCT02485522|OTHER|No Intervention|No intervention
219525124|NCT02997800|DRUG|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
219525125|NCT02997800|DRUG|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
219525126|NCT02997800|DRUG|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
219525127|NCT02997800|OTHER|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
219525128|NCT02997800|OTHER|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
219525129|NCT02278835|OTHER|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
219525130|NCT02278835|DEVICE|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
219525131|NCT02278835|DEVICE|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
219525132|NCT02278835|DEVICE|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
219525133|NCT04360694|PROCEDURE|Incremental hemodialysis|95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
219525134|NCT04360694|PROCEDURE|Conventional hemodialysis|95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
219525135|NCT04866524|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
219525136|NCT04866524|OTHER|Physical development and General Health|Physical development and General health examination
219525137|NCT04866524|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
219525138|NCT04805411|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
219525139|NCT04805411|BIOLOGICAL|Placebo|Placebo
219525140|NCT00734019|DEVICE|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
219525141|NCT06094517|OTHER|Interview|Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
219525142|NCT03162315|PROCEDURE|Freeze all|
219525143|NCT02572921|BEHAVIORAL|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
218912466|NCT03939143|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
218912467|NCT03939143|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
218912468|NCT06092723|DIETARY_SUPPLEMENT|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
218912469|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 1,Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
218912470|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 2,Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
218912471|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
219525144|NCT02572921|BEHAVIORAL|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
219525145|NCT03684538|OTHER|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
219525146|NCT03684538|OTHER|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
219525147|NCT03684538|OTHER|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
219525148|NCT03684538|OTHER|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
219525149|NCT02535611|DRUG|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
219525150|NCT02535611|DRUG|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
219525151|NCT02507427|DEVICE|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
219525152|NCT05393960|OTHER|Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program.|Manual therapy, mobility exercise therapy and a home-based self-stretching program. Manual mobilization postero-anterior glides at lumber facets joints, Transverse glides at spinous process \& Posterior-anterior glides at SI joint. Glides will be performed 3 times with 5 repetitions. Mobility exercise therapy.
219525153|NCT05393960|OTHER|home based self strechings program only.|Home based self-stretching program includes 3 repetitions of 15 seconds duration stretch (with 20 seconds rest between each repetition). Repeat stretching exercises twice a day for 3 alternate days for 1 week. Piriformis stretch: in supine crook lying, placing the lateral side of the foot over the contralateral knee and pulling towards the chest with the hands. Quadriceps stretch: stand on your left leg, one knee touching the other, hold a chair or the wall to keep you steady if needed, grab your right foot, using your right hand, and pull it towards your butt. Hamstring stretch: To stretch the right leg, sit on the ground with the left leg bent at the knee with the foot facing inward. This is called the butterfly position. Extend the right leg, keeping it slightly bent at the knee. Bend forward at the waist, making sure to keep the back straight.
219525154|NCT05096780|OTHER|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
218912472|NCT05671146|DEVICE|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
219041226|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
219525155|NCT03824691|DRUG|Cabozantinib|cabozantinib 40 mg orally once daily
219525156|NCT03824691|DRUG|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
219525157|NCT00242866|DRUG|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
219525158|NCT00242866|OTHER|Placebo|Placebo to Match GW274150
219525159|NCT00695162|OTHER|quiet|no noise
219525160|NCT00695162|OTHER|non-speech noise|noise without speech
219525161|NCT00695162|OTHER|speech noise|noise with speech present
219525162|NCT06059326|DRUG|HSK7653 10 mg|Tablet, HSK7653 10 mg Q2W, 12 weeks
219525163|NCT06059326|DRUG|HSK7653 25 mg|Tablet, HSK7653 25 mg Q2W, 12 weeks
219525164|NCT06059326|DRUG|HSK7653 50 mg|Tablet, HSK7653 50 mg Q2W, 12 weeks
219525165|NCT06059326|DRUG|Placebo|Tablet, 0 mg Q2W, 12 weeks
219525166|NCT02458482|DEVICE|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
219525167|NCT02458482|DRUG|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
219525168|NCT01631565|BEHAVIORAL|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
219525169|NCT01631565|BEHAVIORAL|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
219525170|NCT01631565|BEHAVIORAL|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
219525171|NCT05809765|OTHER|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
219525172|NCT01367340|BEHAVIORAL|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
219525173|NCT01367340|BEHAVIORAL|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
219525174|NCT02199392|DRUG|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
219525175|NCT03200067|BEHAVIORAL|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
219525176|NCT03318796|DEVICE|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB \& SB
218912473|NCT05671146|OTHER|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
218912474|NCT05671146|OTHER|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
218912475|NCT03868423|DRUG|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
219525177|NCT00016419|BIOLOGICAL|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
219525178|NCT00016419|DRUG|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
219525179|NCT00595608|DRUG|Sterimar Spray|Post-op nasal spray, three times a day
219525180|NCT00595608|DRUG|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
219525181|NCT01297036|DRUG|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
219525182|NCT01297036|DRUG|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
219525183|NCT01357707|GENETIC|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
219614392|NCT04241588|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
219614393|NCT04241588|OTHER|Control|A 3D printed hand with be fitted to simulate a prosthesis.
219614394|NCT06013007|PROCEDURE|ICI-guided JINS approach|OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
218912476|NCT03868423|OTHER|Laboratory Biomarker Analysis|Correlative studies
218912477|NCT03868423|OTHER|Quality-of-Life Assessment|Ancillary studies
218912478|NCT03868423|OTHER|Questionnaire Administration|Ancillary studies
218912479|NCT04196686|DEVICE|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
219041227|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
219041228|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
219525184|NCT00193037|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin
219525185|NCT00193037|DRUG|Docetaxel|Docetaxel
219614395|NCT00942357|DRUG|Carboplatin|Given IV
219525186|NCT03336411|BEHAVIORAL|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
219525187|NCT03336411|BEHAVIORAL|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
219525188|NCT00125307|DRUG|tacrolimus|
219525189|NCT05091385|BIOLOGICAL|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
219525190|NCT00858156|DRUG|BG9928|Oral 75 mg single dose
219525191|NCT03681509|DRUG|Pramipexole|Pramipexole
219525192|NCT03681509|DRUG|Placebo|Lactose placebo capsule
219525193|NCT04522609|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session."
219525194|NCT02835261|OTHER|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
219525195|NCT00569374|DRUG|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
219525196|NCT01346163|DRUG|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
219525197|NCT01346163|OTHER|Placebo|Placebo will be used as a comparator to the active arm.
219525198|NCT04382937|DRUG|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
218912480|NCT04196686|OTHER|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
218912481|NCT02051452|DRUG|Methylphenidate|
218912482|NCT02051452|OTHER|Saline|
218912483|NCT02135861|PROCEDURE|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
218912484|NCT02135861|OTHER|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
218912485|NCT01166139|DRUG|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
218912486|NCT05680714|OTHER|Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention|
218912487|NCT00573222|DRUG|Symbicort|
219525199|NCT04382937|DRUG|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
219525200|NCT02448927|DEVICE|balloon aortic valvuloplasty|
218912488|NCT04141748|DEVICE|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
218912489|NCT04141748|PROCEDURE|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
219525201|NCT02448927|DEVICE|Transcatheter Aortic Valve Implantation|
218912490|NCT04636125|DRUG|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
218912491|NCT04665141|BIOLOGICAL|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
218912492|NCT04665141|BIOLOGICAL|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
218912493|NCT04665141|BIOLOGICAL|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
219041229|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
219614396|NCT00942357|DRUG|Cisplatin|Given IV
219614397|NCT00942357|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
219614398|NCT00942357|DRUG|Paclitaxel|Given IV
219614399|NCT00942357|OTHER|Quality-of-Life Assessment|Ancillary studies
218912494|NCT04665141|BIOLOGICAL|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
218912495|NCT04665141|BIOLOGICAL|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
218912496|NCT05852119|OTHER|Outpatient treatment with standard anticoagulant therapy|All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
219041230|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
219041231|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
219525202|NCT03428594|BIOLOGICAL|CKD-11101|
219525203|NCT03428594|BIOLOGICAL|NESP|
219525204|NCT02197195|DIETARY_SUPPLEMENT|Chocolate Milk|
219525205|NCT02197195|DIETARY_SUPPLEMENT|Fruit Drink|
219525206|NCT02197195|BEHAVIORAL|Exercise|
219525207|NCT00041496|DRUG|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
219525208|NCT00041496|OTHER|Placebo|Placebo to match SB-207266
219525209|NCT00002349|DRUG|Stavudine|
219525210|NCT04896164|DRUG|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
219614400|NCT00942357|RADIATION|Radiation Therapy|Undergo radiation therapy
219614401|NCT06404957|BEHAVIORAL|Mindfulness-based Applied|Mindfulness-Based Practices is planned to be an 8-week program of mindfulness meditation and gentle Hatha yoga taught in an online class for up to 14 participants.
219614402|NCT06404957|BEHAVIORAL|Active Comparator: Control groups|No intervention will be made in this group.
219525211|NCT04896164|OTHER|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
219525212|NCT03004300|PROCEDURE|Rapid maxillary expansion|Device
219525213|NCT03004300|PROCEDURE|Adenotonsillectomy|Surgery
219525214|NCT04942756|DEVICE|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
219525215|NCT04942756|DEVICE|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
219525216|NCT00740493|DRUG|warfarin|18 months of warfarin therapy
219525217|NCT00740493|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy
219525218|NCT02992678|DRUG|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
219525219|NCT02992678|DRUG|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
219525220|NCT02506309|DEVICE|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
219525221|NCT02506309|DEVICE|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
219525222|NCT04574648|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
219525223|NCT05425381|BEHAVIORAL|Enhanced version of Interconnected Systems Framework|"* District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~* Detailed memoranda of understanding between schools and collaborating mental health centers~* Community mental health clinicians meaningfully participate in MTSS teams~* Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~* Universal screening of students' social, emotional, behavioral, and academic functioning~* Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~* Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~* Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~* A Community of Practice (Wenger, 2010) among the ISFE schools"
219525224|NCT05425381|BEHAVIORAL|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"* PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai \& Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~* SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
219525225|NCT00172055|DRUG|Zoledronic acid|
219614403|NCT01960257|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
219614404|NCT01960257|OTHER|SOC DOT|
219614405|NCT05553821|OTHER|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
219614406|NCT05553821|OTHER|A sand bag|A sand bag
219614407|NCT02002221|DRUG|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
218912497|NCT06556706|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|"UA is produced by the gut microbiome following the digestion of dietary precursors (polyphenols such as ellagitannins and punicalagins) present in fruits and nuts such as pomegranate, nuts and berries.~In mouse models of aging and muscle dystrophy, UA was shown to induce mitophagy and mitochondrial function in the skeletal muscle. This was associated with improved muscle strength and endurance (Nat. Med, 2016; Sci Tran Med, 2021). In humans, UA was shown to be safe and bioavailable in multiple clinical studies (Nat. Met, 2019; Cell Rep Med, 2022; JAMA Network Open, 2022)."
218912498|NCT06556706|DIETARY_SUPPLEMENT|Placebo|Placebo containing excipients other than Urolithin A (Mitopure)
218912499|NCT06227481|PROCEDURE|Scar subcision|"* Subcision will be performed with18 gauge cannula at the margin of the scars on both sides of the face.~* The cannula will be directed in a forward and backward motion producing a tunnel. Then, the it will be passed in sideways in a sweeping action to freeing up the scars from their bases.~* Once finish, the pressure will be applied to reduce the bleeding and swelling. The topical antibiotic will be applied for 3 days."
218912500|NCT06227481|PROCEDURE|Platelet rich plasma injection|• 20 ml of autologous whole blood will be collected into tubes containing acid citrate dextrose and centrifuged at 1500 rpm for 10 minutes in order to get PRP at the top of the test tube. Then, the PRP will be further centrifuged at 3700 rpm for 10 minutes at room temperature of 22°C in order to obtain a platelet count 4.5 times higher than the base line. Platelet-poor plasma (PPP) will be partly removed and partly used to resuspend the platelets. Calcium gluconate will be added as an activator (1:9), i.e., 1 ml of calcium gluconate in 9 ml of PRP
218912501|NCT06227481|PROCEDURE|Polydioxanone mono threads insertion|"* Topical anesthetic cream will be applied for halfan hour on the involved area.~* polydioxanone mono threads (50 mm, 27 G) will be inserted at 1-cm spacing into the dermal layer of the skin; the threads will be arranged in a transverse and vertical line in the form of a mesh similar to cross-hatching technique.~* The total numbers will range from 8 to 10 each side. The skin of the face will be stretched by the non-dominant hand of the physician and the needle will be inserted by the other hand through the required point."
218912502|NCT06227481|DEVICE|Fractional carbon dioxide laser|"* Topical anesthetic cream will be applied for 30 minutes before the procedure.~* BX300 device from AMI inc.,Korea will be used.~* Different settings will be used according to each individual case regarding the type of scar, severity and skin type fluence ranging from 36 to 42 j/cm2 will be used and pulse duration 1.8 ms.~* In an attempt to avoid common side effects that occur with fractional laser treatment, a lower fluence will be used in the first session and depending on the results, the fluence will be increased per treatment session."
218912503|NCT02862678|OTHER|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
218912504|NCT02212015|DRUG|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
218912505|NCT01048593|DRUG|IBI-10090|Single intraocular injection
219060622|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
219525226|NCT05567874|OTHER|Nosocomial SARS-COV 2 Infection proportion|Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
219525227|NCT05561335|DEVICE|hearing aid -novel program|novel microphone configuration
219525228|NCT05561335|DEVICE|hearing aid - standard program|standard microphone configuration
219525229|NCT00828035|PROCEDURE|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
219525230|NCT02381210|DEVICE|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
219525231|NCT03061526|OTHER|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
219525232|NCT01743326|PROCEDURE|Radio Frequency Denervation|
219525233|NCT01743326|PROCEDURE|Local Anesthesia|
219525234|NCT00050778|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
219525235|NCT00050778|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).
219525236|NCT00050778|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
219525237|NCT03933956|DRUG|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
219525238|NCT00999037|DRUG|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
219525239|NCT00999037|OTHER|Placebo|1 inert tablet tid x 12 weeks
219525240|NCT03608215|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
219525241|NCT03608215|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
219525242|NCT04259528|DEVICE|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
219525243|NCT00002361|DRUG|Indinavir sulfate|
219525244|NCT00002361|DRUG|Ritonavir|
219614408|NCT02002221|DRUG|Placebo|Matching placebo of vildagliptin 50 mg twice daily
219614409|NCT02002221|DRUG|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
219614410|NCT02002221|DRUG|Metformin|Patients continued their prescribed metformin dose, if applicable.
219614411|NCT01274702|OTHER|Visual Reconstitutions Therapy|
219614412|NCT01274702|OTHER|Saccadic Eye Movement Training|
218912506|NCT03780452|DEVICE|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
218912507|NCT03670823|DEVICE|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
218912508|NCT05132556|OTHER|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
219525245|NCT01876576|OTHER|Clear liquids|Clear liquids
219525246|NCT01876576|OTHER|Low residue breakfast and lunch|Low residue
219525247|NCT01450462|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
219525248|NCT01450462|DIETARY_SUPPLEMENT|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
219525249|NCT02389491|DIETARY_SUPPLEMENT|normal density formula (Necocate)|In control group,there are 32 infants
219525250|NCT02389491|DIETARY_SUPPLEMENT|high density formula(Infatrini)|In intervention group,there are 32 infants
219525251|NCT01582126|OTHER|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
219525252|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
219525253|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
218912509|NCT02991222|DRUG|SPARC001 type I|Treatment type I
218912510|NCT02991222|DRUG|SPARC001 type II|Treatment type II
218912511|NCT02991222|DRUG|Reference001 type I|Hydrocodone-Acetaminophen
218912512|NCT02991222|DRUG|Reference001 type II|Hydrocodone-Acetaminophen
219614413|NCT04464174|DRUG|Ipatasertib|Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
219614414|NCT04464174|DRUG|Capecitabine|Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
219614415|NCT04464174|DRUG|Eribulin|Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
219614416|NCT04464174|DRUG|Carboplatin|Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
219614417|NCT04464174|DRUG|Gemcitabine|Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
219614418|NCT03405831|DRUG|Ivabradine|Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
219614419|NCT03405831|DRUG|Placebo|Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
219525254|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
219525255|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
219614420|NCT03347110|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
218912513|NCT06036225|BEHAVIORAL|Prehabilitation|Remote prehabilitation multi-component.
218912514|NCT03609073|DEVICE|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
218912515|NCT02905461|BEHAVIORAL|Contraceptive text messages|
219041232|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
219525256|NCT01208363|DIETARY_SUPPLEMENT|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
219525257|NCT01903317|OTHER|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
219614421|NCT00155311|PROCEDURE|orthodontic treatment|
219614422|NCT01900769|DRUG|Blood Volume Dilution|
219614423|NCT01004354|DRUG|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
218912516|NCT02905461|OTHER|Text messages not about contraception|
219041233|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
219041234|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
219525258|NCT01903317|OTHER|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
219614424|NCT02892045|DEVICE|MMG|neuromuscular monitoring device
219614425|NCT03271801|BEHAVIORAL|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
219614426|NCT03271801|BEHAVIORAL|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
219614427|NCT00665405|RADIATION|CT scan|Thoracic CT scan
218912517|NCT03992560|DEVICE|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
218912518|NCT04701814|OTHER|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
218912519|NCT04732312|OTHER|Home help|Setting up of a formal home help
218912520|NCT04589741|DRUG|Toripalimab Combined With CAV/IE chemotherapy|"CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
218912521|NCT04589741|DRUG|CAV/IE alternate chemotherapy|"CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
218912522|NCT01001221|DRUG|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1"
218912523|NCT01001221|DRUG|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1."
218912524|NCT03160638|DRUG|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
218912525|NCT01312857|DRUG|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
218912526|NCT01312857|DRUG|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
218912527|NCT06225128|OTHER|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, Day of post-cycle 1 and post-cycle 6 evaluation.
218912528|NCT06225128|OTHER|Bone marrow specimens|"Additional volume of 2mL (EDTA)~* at screening for correlative studies,at Day 7 for smears and for correlative studies.~* Post-cycle 1 and post-cycle 6 evaluations for correlative studies.~Optionnal :~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
218912529|NCT04935346|OTHER|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
219041235|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
219525259|NCT01903317|OTHER|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
219525260|NCT02472184|PROCEDURE|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
219525261|NCT02472184|PROCEDURE|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
219525262|NCT04873310|OTHER|Triple P online with professional support|The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
219525263|NCT04873310|OTHER|Triple P online without professional support|The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
219525264|NCT04274114|DRUG|L Glutamine|Powder
219525265|NCT04274114|DRUG|Placebos|Powder
219525266|NCT03098108|RADIATION|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
219525267|NCT01359566|DRUG|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
219525268|NCT01359566|DRUG|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
219525269|NCT01359566|DRUG|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
219525270|NCT01359566|DRUG|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
219525271|NCT01126736|DRUG|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
219525272|NCT01126736|DRUG|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
219614428|NCT03630497|DRUG|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
219614429|NCT02591277|DRUG|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
219614430|NCT02901353|DEVICE|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
219525273|NCT01126736|DRUG|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
219614431|NCT01404767|DRUG|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
219614432|NCT01404767|DRUG|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
219614433|NCT02877901|DRUG|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
219614434|NCT02877901|DRUG|placebo|one tablet at bed time
219614435|NCT01518322|DEVICE|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
219614436|NCT01308125|PROCEDURE|PICSO|"* Baseline (hemodynamic) measurement~* Intra coronary~* Blood sampling~* LAD occlusion: for 3 min or until pain with and without PICSO~* Break recovery: the patient can recover from pain for 3 min~* CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~* PICSO: start automatically and continued for 10 min.~* PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~* 24h Follow up: additional blood samples every 6 hours (4 times)~* 30 days follow up."
219614437|NCT04242277|DEVICE|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
219614438|NCT05132062|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
219614439|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w/o Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
219525274|NCT04181190|DIAGNOSTIC_TEST|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
219525275|NCT04181190|DIAGNOSTIC_TEST|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
219525276|NCT04181190|DIAGNOSTIC_TEST|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
219525277|NCT04181190|DIAGNOSTIC_TEST|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
219525278|NCT02554370|BEHAVIORAL|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
219525279|NCT06089538|DIAGNOSTIC_TEST|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
219525280|NCT04932252|DRUG|A4368 or placebo tablet|orally administered
219525281|NCT02679053|BEHAVIORAL|Aerobic exercise|
219525282|NCT02679053|BEHAVIORAL|Placebo control|
219614440|NCT03104192|BEHAVIORAL|MOWI Weight Loss Maintenance|Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).
219614441|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w Fitbit|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
219614442|NCT03104192|DIETARY_SUPPLEMENT|Develop & Refine MOWI w Fitbit/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
219614443|NCT06295172|DEVICE|Lafullen15|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
219614444|NCT06295172|DEVICE|Lafullen|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
219614445|NCT01571323|DRUG|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
219614446|NCT01571323|DRUG|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
219614447|NCT01571323|DRUG|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
219614448|NCT02792517|DRUG|Erenumab|A single dose of erenumab administered in the abdomen.
219614449|NCT02792517|DRUG|Ethynil Estradiol/Norgestimate Oral Contraceptive|Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
219614450|NCT02931864|OTHER|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
219614451|NCT02931864|OTHER|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
219614452|NCT04784091|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
219614453|NCT04784091|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
219614454|NCT05221541|PROCEDURE|vibration|whole-body vibration and soleus tendon vibration will be applied to participants
219614455|NCT03243110|DIAGNOSTIC_TEST|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
219614456|NCT05642871|RADIATION|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
219525283|NCT00535951|DRUG|LBH589|
219525284|NCT01346397|DRUG|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
219525285|NCT03538405|OTHER|Supporting cushions|Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
219525286|NCT03538405|OTHER|Harmonic techniques|Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
219525287|NCT00064753|DRUG|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
219525288|NCT00064753|DEVICE|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
219525289|NCT03366805|BEHAVIORAL|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
219525290|NCT03366805|BEHAVIORAL|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
219060623|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
219525291|NCT03333291|DIETARY_SUPPLEMENT|fecal suspension|helathy donor fecal suspension administered by duodenal scope
219525292|NCT06061666|OTHER|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
219525293|NCT03389438|BIOLOGICAL|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
219525294|NCT03436225|DRUG|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
219525295|NCT03436225|DRUG|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
219525296|NCT03436225|DRUG|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
219525297|NCT03436225|DRUG|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
219525298|NCT02210390|BEHAVIORAL|Psycho education|Psycho-education Sessions will be offered weekly basis
219525299|NCT00784823|DRUG|Bortezomib 1 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
219525300|NCT00784823|DRUG|Bortezomib 1.3 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
219525301|NCT00784823|DRUG|Bortezomib 1.6 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
219525302|NCT00784823|DRUG|Melphalan|"* Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight"
219525303|NCT04455581|DRUG|SHR-1209|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
219525304|NCT01194609|BIOLOGICAL|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
219525305|NCT01194609|RADIATION|Low dose radiation|20cGy whole body radiation every three weeks for three times
219525306|NCT05110209|OTHER|Aflibercept|intravitreal injection
219525307|NCT05110209|OTHER|Ranibizumab|intravitreal injection
219525308|NCT05110209|OTHER|Bevacizumab|intravitreal injection
219525309|NCT00130988|BEHAVIORAL|DEPENAS cognitive and behavioural techniques|
219525310|NCT03056937|OTHER|Bariatric surgery|evaluations pre and post bariatric surgery.
219525311|NCT03056937|OTHER|Control|without intervention, it will be performed only evaluations
219525312|NCT03834870|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
219525313|NCT02550678|BIOLOGICAL|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
219525314|NCT02550678|DRUG|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
219525315|NCT00841178|PROCEDURE|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
219525316|NCT00841178|PROCEDURE|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
219525317|NCT00813293|DRUG|Sorafenib|
219525318|NCT00813293|PROCEDURE|radiofrequency ablation|
219525319|NCT04053348|PROCEDURE|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
219525320|NCT04175964|BEHAVIORAL|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
219525321|NCT04175964|COMBINATION_PRODUCT|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
219525322|NCT04175964|BEHAVIORAL|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
219525323|NCT00768742|DEVICE|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
219525324|NCT03991260|DIAGNOSTIC_TEST|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
219525325|NCT01087476|DRUG|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
219525326|NCT02107092|DRUG|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
219525327|NCT02149888|DRUG|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
219525328|NCT01586611|DRUG|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
219525329|NCT01586611|DRUG|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
219525330|NCT00707161|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
219525331|NCT00707161|DRUG|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
219525332|NCT00707161|PROCEDURE|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
219525333|NCT03808064|BEHAVIORAL|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
219525334|NCT02832752|PROCEDURE|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is \< 60 minutes, and from emergency department (ED) arrival to ECMO flows \< 30 minutes.
219525335|NCT00819507|DRUG|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
219525336|NCT02052947|RADIATION|SPECT-DaTscan|"* Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~* LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
219525337|NCT03265977|BIOLOGICAL|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
218912530|NCT02388269|DEVICE|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
218912531|NCT03820843|OTHER|Art therapy and standard orthophonic rehabilitation|In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
219525338|NCT03265977|OTHER|Placebo|Normal saline
219525339|NCT01789905|DRUG|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
219525340|NCT02661295|DRUG|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and \< 50% and ferritin ≥ 200 and \< 500 ng/ml after a 2 week wash out period.
219525341|NCT01364194|DRUG|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
219525342|NCT01364194|DRUG|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
219525343|NCT03787030|DRUG|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
219525344|NCT03787030|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
219525345|NCT01545830|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
219525346|NCT04037839|OTHER|Questionnaire|"Medical records of children aged 0-18 years who were prescribed a HFNC device at Schneider Children's between 2014-2018 for use in the home setting will be reviewed retrospectively. As part of the telephone consent process, parents will be offered to opt out at the beginning of the interview."
219614457|NCT04712344|BIOLOGICAL|COVID-19 convalescent plasma|Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.
219614458|NCT00793962|RADIATION|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
219614459|NCT00793962|RADIATION|conventional fractionation radiotherapy|50Gy/25/f/5w
219614460|NCT01144065|PROCEDURE|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
219614461|NCT00856193|DRUG|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
219614462|NCT00856193|DRUG|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
218912532|NCT03724136|PROCEDURE|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
219525347|NCT04539470|DRUG|Efmarodocokin Alfa|Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
218912533|NCT03724136|PROCEDURE|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
219525348|NCT05482893|DRUG|Spevatamig (PT886)|Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
219525349|NCT05482893|DRUG|Paclitaxel|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C1
219525350|NCT05482893|DRUG|Gemcitabine|Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: Cohort C2
219525351|NCT05482893|DRUG|Abraxane|Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: Cohort C2
219525352|NCT05482893|DRUG|KEYTRUDA® (pembrolizumab)|Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D: Cohort D2, D3 and D4.
219525353|NCT05482893|DRUG|Oxaliplatin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
218912534|NCT03724136|PROCEDURE|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
219525354|NCT05482893|DRUG|Leucovorin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
219525355|NCT05482893|DRUG|Fluorouracil|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
219525356|NCT05482893|DRUG|Capecitabine|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
219614463|NCT00794690|DRUG|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
218912535|NCT00603317|DRUG|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
218912536|NCT00603317|DRUG|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
218912537|NCT03448406|DRUG|Empagliflozin|Film-coated tablet
218912538|NCT03448406|DRUG|Placebo|Film-coated tablet
218912539|NCT05741424|DIAGNOSTIC_TEST|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
218912540|NCT05741424|DIAGNOSTIC_TEST|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
218912541|NCT00854750|DRUG|ACTHAR|SQ weekly injections
218912542|NCT00854750|DRUG|ACTHAR|SQ weekly injections
218912543|NCT00854750|DRUG|ACTHAR|SQ weekly injections
218912544|NCT00854750|DRUG|ACTHAR|SQ weekly injection
218912545|NCT02328924|OTHER|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
218912546|NCT00685412|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
218912547|NCT04298320|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
218912548|NCT04298320|DRUG|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
219525357|NCT05482893|DRUG|FOLFIRINOX|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C3
219525358|NCT03435796|GENETIC|Gene-modified (GM) T cell therapy|No investigational product will be administered
219525359|NCT01243996|DRUG|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
218912549|NCT03130738|DRUG|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
218912550|NCT03130738|DRUG|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
218912551|NCT03130738|DRUG|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
218912552|NCT02704325|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
218912553|NCT02704325|OTHER|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
218912554|NCT03516123|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
219041236|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
219041237|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
219041238|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
219041239|NCT06207682|DRUG|Avacopan|Orally via capsules
219041240|NCT06207682|DRUG|Simvastatin|Orally via tablets
219525360|NCT04060823|OTHER|Easy Breathing program|Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
219525361|NCT04255719|PROCEDURE|DBS|Unilateral DBS for treatment of patients with PD
219525362|NCT01148095|DRUG|AZD2516|Oral, single, daily, 11 days
219525363|NCT01148095|DRUG|Placebo|
219525364|NCT01635322|DEVICE|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
219525365|NCT06343805|DRUG|AJ1-11095|Type II JAK2 Inhibitor
219525366|NCT06238986|OTHER|Non-Interventional Study|Non-interventional study
219525367|NCT00802100|DRUG|Olanzapine|Daily tablets of 10 to 30 mg
219525368|NCT00802100|DRUG|Perphenazine|Daily tablets of 8 to 24 mg
219525369|NCT00802100|DRUG|Aripiprazole|Daily tablets of 10 to 30 mg
219525370|NCT00802100|DRUG|Metformin|Daily tablets of 850 to 2550 mg
219525371|NCT00802100|DRUG|Simvastatin|Daily tablets of 20 to 40 mg
219525372|NCT00802100|DRUG|Benztropine|Daily tablets of 1 to 2 mg
219614464|NCT01585974|OTHER|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
219614465|NCT01186068|DRUG|V-101|Cream QD
219614466|NCT01186068|OTHER|vehicle|Cream QD
219525373|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
219525374|NCT06139783|PROCEDURE|Exercise and dietary recommendations|Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
219525375|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
219525376|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
219525377|NCT02688556|DRUG|cyclosporine|
219525378|NCT02688556|DRUG|vehicle of OTX-101|
219525379|NCT02952495|BEHAVIORAL|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
219525380|NCT02403752|BEHAVIORAL|Paired PLIE Program|Integrative exercise as described above
219525381|NCT00565448|DRUG|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
219525382|NCT00565448|DRUG|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
219525383|NCT00565448|DRUG|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
219525384|NCT02472288|DEVICE|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
219525385|NCT02472288|DEVICE|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
218912555|NCT03063528|BEHAVIORAL|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
218912556|NCT03063528|BEHAVIORAL|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
218912557|NCT06205836|DRUG|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
218912558|NCT06205836|DRUG|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
219525386|NCT01575509|OTHER|Berry product|Sugar infused dried lingonberry
219525387|NCT01575509|OTHER|Bread product|Brown bread
219525388|NCT01575509|OTHER|Bread product|Whole grain bread
219525389|NCT01575509|OTHER|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
219525390|NCT01575509|OTHER|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
219525391|NCT03139019|BEHAVIORAL|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
219525392|NCT03139019|BEHAVIORAL|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
219525393|NCT03139019|BEHAVIORAL|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
219525394|NCT04856449|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.
219525395|NCT04856449|BEHAVIORAL|EMDR|EMDR sessions will be conducted to reprocess trauma-related memories.
219525396|NCT04299178|DEVICE|X-PLO2R POC|Portable Oxygen Concentrator (POC)
219525397|NCT00302952|DRUG|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
219525398|NCT00302952|DRUG|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
219525399|NCT04764565|DIETARY_SUPPLEMENT|Nuun Instant|Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
218912559|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 1
218912560|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 2
218912561|NCT06310876|DRUG|Placebo|• single oral dose
218912562|NCT06310876|DRUG|Moxifloxacin 400mg|• single oral dose
218912563|NCT03098641|PROCEDURE|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
218912564|NCT02775188|DEVICE|interACTION|
218912565|NCT02775188|OTHER|Standard of Care Physical Therapy|
218912566|NCT02490683|DIETARY_SUPPLEMENT|Luna Rich X|
218912567|NCT02490683|DIETARY_SUPPLEMENT|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
218912568|NCT02490683|DIETARY_SUPPLEMENT|Reliv Now|
218912569|NCT03502005|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
218912570|NCT03115944|DEVICE|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
218912571|NCT04771156|DRUG|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
218912572|NCT04771156|DRUG|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
218912573|NCT06230575|PROCEDURE|erector spinae block|Erector spinae plane block
218912574|NCT06230575|PROCEDURE|retrolaminar block|Retrolaminar block
219525400|NCT04764565|OTHER|Water|water
219525401|NCT04764565|DIETARY_SUPPLEMENT|Nuun Electrolyte|Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
218912575|NCT06230575|PROCEDURE|serratus anterior block|Serratus anterior plane block
218912576|NCT06230575|PROCEDURE|pectoral nerve block|Pectoral nerve block
218912577|NCT04768504|DRUG|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
218912578|NCT06478420|BIOLOGICAL|Omicron BA.5 SARS-CoV-2 challenge virus|The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
218912579|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
218912580|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
218912581|NCT06204965|BEHAVIORAL|Time-restricted eating|Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
218912582|NCT03186209|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
218912583|NCT03186209|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
218912584|NCT05830500|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
218912585|NCT03383601|OTHER|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
218912586|NCT03383601|OTHER|Smoking combustible cigarettes|Current smoking of combustible cigarettes
218912587|NCT01440959|DRUG|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
218912588|NCT00002088|DRUG|Saccharomyces boulardii|
218912589|NCT03796728|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
218912590|NCT00000928|BEHAVIORAL|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
218912591|NCT00333775|DRUG|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
218912592|NCT00333775|DRUG|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
218912593|NCT00333775|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
218912594|NCT02157818|DRUG|midazolam|
218912595|NCT02157818|DRUG|Dexmedetomidine|
218912596|NCT05214534|OTHER|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
218912597|NCT04156841|DIAGNOSTIC_TEST|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
218912598|NCT04156841|PROCEDURE|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
218912599|NCT03284463|DRUG|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
219525402|NCT04845165|OTHER|Biopsy|Biopsy of subcutaneous adipose tissue
219525403|NCT01692405|DEVICE|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
219614467|NCT04936763|DEVICE|Janesse 20 (Cross-linked Hyaluronic Acid)|Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
219614468|NCT01227473|BEHAVIORAL|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
219614469|NCT01227473|BEHAVIORAL|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
219614470|NCT06966492|DRUG|Stannous Fluoride Toothpaste (SnF)|stannous fluoride toothpaste
219614471|NCT06577961|DRUG|Vorolanib|stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
218912600|NCT03284463|DRUG|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
219614472|NCT06577961|DRUG|cadonilimab|stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
218912601|NCT00178295|RADIATION|Radiation Therapy|standard of care for the cancer being treated
219525404|NCT01692405|PROCEDURE|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
219525405|NCT01900080|OTHER|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
219525406|NCT01900080|OTHER|Standard ART Initiation|Standard ART Initiation
219525407|NCT01900080|OTHER|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count \>500 cells/mm3 (CD4 count within 7 days of HIV test)
219525408|NCT01900080|OTHER|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count \>500 cells/mm3
219525409|NCT01092351|DRUG|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
219525410|NCT04599699|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
219525411|NCT02373098|DRUG|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
219525412|NCT05451030|DEVICE|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
219525413|NCT05070286|BEHAVIORAL|Observational Study.|Semi-structured interviews.
219525414|NCT03666585|OTHER|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
219525415|NCT03666585|OTHER|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
219525416|NCT04414605|DRUG|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
219525417|NCT04414605|DRUG|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
219525418|NCT02923388|DRUG|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
219525419|NCT02923388|DRUG|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
219525420|NCT02923388|DRUG|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
218912602|NCT03926208|PROCEDURE|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
218912603|NCT03926208|PROCEDURE|Clorhexadine scrub|Clorhexadine scrub (standard of care).
218912604|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
218912605|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 of a 21-day cycle.
219525421|NCT02923388|DRUG|Placebo pill|Placebo pill orally thrice daily for 5 weeks
219525422|NCT06360913|DIAGNOSTIC_TEST|High resolution mass spectrometry|Metabolomics study
219525423|NCT05921955|DEVICE|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
219525424|NCT04305782|DEVICE|Release/Relock Socket - In Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.
219525425|NCT04305782|DEVICE|Release/Relock Socket - Out of Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.
219525426|NCT04305782|DEVICE|Release/Relock Socket & Control|The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
219525427|NCT04091256|OTHER|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
219525428|NCT02420444|BIOLOGICAL|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
219525429|NCT02420444|BIOLOGICAL|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
219525430|NCT02420444|BIOLOGICAL|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
219525431|NCT01740219|BEHAVIORAL|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
219525432|NCT01740219|BEHAVIORAL|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
219525433|NCT02763085|DEVICE|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
219525434|NCT00801970|BEHAVIORAL|Psychological Treatment|15 weekly therapy sessions.
219525435|NCT00801970|BEHAVIORAL|Group Therapy|3 months of weekly group therapy sessions.
218912606|NCT04623346|PROCEDURE|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
219525436|NCT04759885|DRUG|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
219525437|NCT04759885|DRUG|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
219525438|NCT04759885|DRUG|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
219525439|NCT04759885|DRUG|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
219525440|NCT04759885|DRUG|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
219525441|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK|horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror
219525442|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK|horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
219614473|NCT05115851|OTHER|Anodal tDCS cerebellar stimulation group|three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
219614474|NCT05115851|OTHER|Anodal tDCS cerebral (M1) stimulation group|three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
218912607|NCT02968134|DRUG|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
218912608|NCT03162926|COMBINATION_PRODUCT|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
218912609|NCT03314103|BIOLOGICAL|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
219525443|NCT00420238|DRUG|Etanercept (Enbrel)|50 mg injection once weekly
219525444|NCT00420238|OTHER|Placebo|placebo
219525445|NCT05214560|DEVICE|Spinal needle|Insertion of a spinal needle to perform the neuraxial procedure.
218912610|NCT03314103|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
219525446|NCT01799681|BEHAVIORAL|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
219525447|NCT01799681|BEHAVIORAL|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
219525448|NCT04734665|DRUG|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
219525449|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program|Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
219525450|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise|Passive knee flexion-extension movements + Incremental cycle ergometer exercise
219525451|NCT01850420|DRUG|IMC-1|
219525452|NCT04662996|BIOLOGICAL|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
219525453|NCT03639311|DRUG|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
219525454|NCT03639311|DRUG|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
218912611|NCT06560385|DIETARY_SUPPLEMENT|BLHK03|BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds
218912612|NCT06560385|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 5mcg of Vitamin B7
219525455|NCT03639311|DRUG|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
219525456|NCT03639311|DRUG|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
219525457|NCT00185705|DRUG|Telmisartan|
219525458|NCT04624412|OTHER|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down"
219525459|NCT04624412|OTHER|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down"
218912613|NCT03197298|DRUG|Clopidogrel|
218912614|NCT03197298|DRUG|Ticagrelor|
218912615|NCT01402089|DRUG|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
218912616|NCT01402089|DRUG|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
218912617|NCT01402089|DRUG|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
218912618|NCT01402089|DRUG|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
218912619|NCT01383928|DRUG|Ixazomib|Ixazomib capsules
218912620|NCT01383928|DRUG|Lenalidomide|Lenalidomide capsules
218912621|NCT01383928|DRUG|Dexamethasone|Dexamethasone Tablets
218912622|NCT06562205|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
218912623|NCT06562205|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
218912624|NCT00259597|PROCEDURE|breast ductal lavage|breast ductal lavage and nipple aspiration done once
218912625|NCT03770546|BIOLOGICAL|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
219525460|NCT01101802|DRUG|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
219525461|NCT01101802|DRUG|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
219525462|NCT01190163|DRUG|Dinoprostone|
219525463|NCT01190163|DRUG|Oxytocin|
219525464|NCT06080321|OTHER|WhatsApp reminders|"Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
219525465|NCT06080321|OTHER|Instagram reminders|"Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
219525466|NCT06080321|OTHER|Phone calls|"Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
219525467|NCT06080321|OTHER|Application alerts|"Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
219525468|NCT00032903|DRUG|Gimatecan® (ST 1481)|
219525469|NCT05297032|DIETARY_SUPPLEMENT|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
219525470|NCT02155205|DRUG|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
219525471|NCT02155205|DRUG|Placebo|Matching placebo
219525472|NCT02155205|DRUG|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
218912626|NCT03770546|DRUG|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
219525473|NCT02615847|DRUG|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
219525474|NCT05449249|PROCEDURE|Long-term fasting|The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
219525475|NCT00493142|OTHER|Exercise|
219525476|NCT00493142|OTHER|Usual care|
219525477|NCT03018249|DRUG|Entinostat|Given PO
219525478|NCT03018249|PROCEDURE|Hysterectomy|Undergo hysterectomy
219525479|NCT03018249|OTHER|Laboratory Biomarker Analysis|Correlative studies
219525480|NCT03018249|DRUG|Medroxyprogesterone Acetate|Given IM
219525481|NCT00699491|BIOLOGICAL|Cixutumumab|Given IV
219525482|NCT00699491|OTHER|Laboratory Biomarker Analysis|Correlative studies
219525483|NCT00699491|OTHER|Pharmacological Study|Correlative studies
219525484|NCT00699491|DRUG|Temsirolimus|Given IV
219525485|NCT01886326|OTHER|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
219525486|NCT01891266|PROCEDURE|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
219525487|NCT01891266|PROCEDURE|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
219525488|NCT05493930|OTHER|The hospital where the treatment is performed|
219525489|NCT00338481|DRUG|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
219525490|NCT00338481|DRUG|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
219525491|NCT03943433|PROCEDURE|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
219525492|NCT03943433|PROCEDURE|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
219525493|NCT03168633|BEHAVIORAL|web-based DM2 information pages|"Each email will include information on one of the following topics:~1. The importance of physical activity~2. Correct nutrition~3. The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
219525494|NCT03832257|OTHER|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
219525495|NCT03832257|OTHER|Matched Non-Participating Facilities|Matched Non-Participating Facilities
219525496|NCT02342054|RADIATION|MRI-TRUS fusion guided Single Frac HDR|
219525497|NCT02378571|BEHAVIORAL|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
219525498|NCT01114022|DEVICE|Experimental 1|oeso pharyngeal device
219525499|NCT01114022|DEVICE|Experimental|oeso pharyngeal device
219525500|NCT01114022|DEVICE|experimental 3|oeso pharyngeal device
219525501|NCT01114022|DEVICE|Active comparator|oeso pharyngeal device
219525502|NCT01194492|RADIATION|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
219525503|NCT00254644|PROCEDURE|Morphological and functional MRI|one time
218912627|NCT04438486|BEHAVIORAL|Group A|specific dietary advice for Hyperuricemia
218912628|NCT04438486|DIETARY_SUPPLEMENT|Group B|Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
218912629|NCT01630148|DRUG|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
219525504|NCT01054027|DRUG|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
219525505|NCT04881968|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
219525506|NCT04067180|OTHER|allogeneic stem cell transplantation with a haplo-identical family donor graft|"The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil."
219525507|NCT04067180|OTHER|allogeneic stem cell transplantation with a matched unrelated donor graft|"Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied."
219525508|NCT00304083|BIOLOGICAL|filgrastim|Given subcutaneously
219525509|NCT00304083|DRUG|doxorubicin hydrochloride|Given IV
219525510|NCT00304083|DRUG|etoposide|Given IV
219525511|NCT00304083|DRUG|ifosfamide|Given IV
219525512|NCT00304083|PROCEDURE|conventional surgery|Patients undergo surgery
219525513|NCT00304083|RADIATION|radiation therapy|Patients undergo radiotherapy
219525514|NCT01589783|OTHER|completion of a questionnaire|Completion of a questionnaire
219525515|NCT01589783|OTHER|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
219525516|NCT05292651|PROCEDURE|PCI|percutaneous coronary intervention
219525517|NCT02144753|DIETARY_SUPPLEMENT|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
219614475|NCT05115851|OTHER|Sham Group|three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
219614476|NCT01946620|DRUG|Flutiform|
218912630|NCT04741581|DIETARY_SUPPLEMENT|ThickenUp® Gel Express|Thickening gel
218912631|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
218912632|NCT05027321|BEHAVIORAL|Conversational Hypnosis|Conversational Hypnosis during examination
218912633|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
218912634|NCT05940103|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
218912635|NCT04519008|DEVICE|Mobile app|Medical device for improving emotion dysregulation
218912636|NCT04519008|COMBINATION_PRODUCT|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
218912637|NCT03039309|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
218912638|NCT04572217|DRUG|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
218912639|NCT04572217|DRUG|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
219525518|NCT02144753|DRUG|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
219525519|NCT00715702|DRUG|AZD5672|100 mg oral single dose
218912640|NCT06961552|OTHER|reflexology masaj group|The women in the reflexology group will receive a reflexology massage with proven regional applications, pressure sliding and circular pressure three times with baby oil for two cycles by the researcher, starting at the end of menstruation (5-7th days of the cycle), for a total of 30 minutes in a single session for each foot, starting at 15 minutes per foot. A total of 8 reflexology massage sessions will be performed, one session per week (Monday) for 8 weeks.
218912641|NCT01349543|BIOLOGICAL|RSV A Memphis 37|Intranasal administration
219041241|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
219041242|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|\- One-on-one 15-minute counseling sessions once per week for 8 weeks
219525520|NCT02287675|DRUG|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
219614477|NCT01946620|DRUG|Formoterol|
219614478|NCT06445738|RADIATION|Arm A: Radiotherapy Omission|Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.
219614479|NCT06445738|OTHER|Arm B: Standard Treatment|Ineligible for RT omission on study; includes management of MRI-detected lesions.
219614480|NCT00435669|DRUG|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
219614481|NCT00435669|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
219614482|NCT05623501|DRUG|Dihydromyricetin|Dose-escalation and lysine preparation
218912642|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
219041243|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|\- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
219041244|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|\- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
219614483|NCT05215951|DRUG|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
219614484|NCT04488341|OTHER|aerobic exercises in addition to diet recommendations|aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
219614485|NCT04488341|OTHER|diet recommendations|control group will receive diet recommendations for 12 weeks
218912643|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
219525521|NCT02287675|DRUG|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
219525522|NCT05470972|DRUG|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
219525523|NCT03966365|DRUG|PRO-122|"* PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic."
219525524|NCT03966365|DRUG|Krytantek Ofteno®|"* \- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* \- Route of administration: topical ophthalmic."
218912644|NCT00929214|DRUG|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
219041245|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
219041246|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
219041247|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
219041248|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
219525525|NCT06035315|DIETARY_SUPPLEMENT|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
219525526|NCT03227497|DIETARY_SUPPLEMENT|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
219525527|NCT02578953|DRUG|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
219525528|NCT02578953|DRUG|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
219525529|NCT01044732|DEVICE|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
218912645|NCT00929214|PROCEDURE|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
219041249|NCT05565287|COMBINATION_PRODUCT|ultra early physiotherapy intervention|"* NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
219041250|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
219041251|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
219041252|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
219041253|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
218912646|NCT05800860|DRUG|GH001|GH001 administered via inhalation
218912647|NCT05800860|DRUG|Placebo|Placebo administered via inhalation
218912648|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
218912649|NCT05258240|OTHER|Virtual Reality|Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
218912650|NCT05258240|OTHER|Conventional Physical Therapy|Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
218912651|NCT05057312|OTHER|Enhancing Accessibility to Health Care|Receive enhanced access to vaccination
218912652|NCT05057312|OTHER|Informational Intervention|Receive standard CDC information
218912653|NCT05057312|OTHER|Informational Intervention|Receive video narratives
218912654|NCT05057312|OTHER|Informational Intervention|Receive written narratives
218912655|NCT05057312|OTHER|Interview|Ancillary studies
218912656|NCT05057312|OTHER|Questionnaire Administration|Ancillary studies
218912657|NCT01856270|DRUG|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
218912658|NCT03655340|DRUG|Alprolix|Extended half-life factor IX product
218912659|NCT03873883|DRUG|EOS100850|Oral administration
218912660|NCT03873883|DRUG|Pembrolizumab|IV Infusion
218912661|NCT03873883|DRUG|Chemotherapy|Standard of Care IV Infusion
218912662|NCT06105502|BEHAVIORAL|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
218912663|NCT05932329|BEHAVIORAL|Dietary Advice|Dietary Advice provided
218912664|NCT06047210|OTHER|Blood Draws Data Collection|
218912665|NCT05625737|DRUG|Fruquintinib|Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
218912666|NCT05625737|DRUG|Sintilimab|Sintilimab will be administrated as 200mg once every 3 weeks.
219525530|NCT03918278|BIOLOGICAL|MK-0482|IV infusion
219525531|NCT03918278|BIOLOGICAL|pembrolizumab|IV infusion
218912667|NCT06535880|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm
218912668|NCT06577181|DRUG|hCG + estradiol|Human chorionic gonadotropins
218912669|NCT06577181|OTHER|Observation arm|estradiol only wuithout giving hcg
218912670|NCT05502562|DRUG|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
218912671|NCT03680053|DRUG|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
218912672|NCT03680053|DRUG|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
218912673|NCT06504992|DRUG|Vancomycin 1000 MG|Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
218912674|NCT05444855|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
218912675|NCT06497959|DRUG|SonoVue|Placental contrast ultrasound using SonoVue by maternal intravenous injection
218912676|NCT05847192|DIAGNOSTIC_TEST|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.
218912677|NCT02242942|DRUG|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
219525532|NCT03918278|DRUG|Paclitaxel|IV infusion
219525533|NCT03918278|DRUG|Nab-paclitaxel|IV infusion
219525534|NCT03918278|DRUG|Gemcitabine|IV infusion
218912678|NCT02242942|DRUG|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
218912679|NCT02242942|DRUG|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
218912680|NCT01806220|PROCEDURE|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
218912681|NCT01806220|PROCEDURE|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
218912682|NCT03259230|OTHER|Blood Draws|
218912683|NCT03259230|OTHER|Data Collection|
218912684|NCT03541083|DRUG|Blinatumomab|prephase and consolidation (I and II)
218912685|NCT06107140|OTHER|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
218912686|NCT04396535|DRUG|Bintrafusp Alfa|Given IV
218912687|NCT04396535|DRUG|Docetaxel|Given IV
219041254|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
219525535|NCT03918278|DRUG|Carboplatin|IV infusion
219525536|NCT03918278|DRUG|Pemetrexed|IV infusion
219525537|NCT00769041|DRUG|moxifloxacin|400mg
219525538|NCT00769041|DRUG|avanafil|100mg single dose
219525539|NCT00769041|DRUG|avanafil|800mg single dose
219525540|NCT00769041|DRUG|sugar pill|single dose
218912688|NCT03358277|DRUG|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
219614486|NCT01754155|RADIATION|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
218912689|NCT02699658|DRUG|Levofloxacin|
218912690|NCT05618522|PROCEDURE|vacuum-dehydrated amnion membrane (omnigen)|applying the lens loaded with Omnigen on the cornea
218912691|NCT05618522|DEVICE|the lens loaded with Omnigen|the lens loaded with Omnigen
218912692|NCT00802581|PROCEDURE|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
218912693|NCT00802581|PROCEDURE|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
218912694|NCT02506894|DRUG|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
218912695|NCT02506894|OTHER|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
218912696|NCT05379179|DRUG|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
218912697|NCT05379179|DRUG|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
218912698|NCT00192933|PROCEDURE|NovoSeven treatment according to guideline|
218912699|NCT02411630|DRUG|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
218912700|NCT05914623|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
218912701|NCT05914623|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
218912702|NCT05042674|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 2 additional blood draws
218912703|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams|after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws
218912704|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams, daily for 1 week|a blood draw will be administered after a week of consuming 25mg ergothioneine daily
218912705|NCT01095549|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
219525541|NCT04137211|BEHAVIORAL|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
219525542|NCT04137211|BEHAVIORAL|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
219525543|NCT04137211|BEHAVIORAL|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
219525544|NCT00003961|BIOLOGICAL|sargramostim|
219525545|NCT04510077|BEHAVIORAL|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
219525546|NCT04510077|OTHER|Survey Administration|Ancillary studies
218912706|NCT01095549|DEVICE|Placebo device|A device without far infrared therapy
218912707|NCT02099851|DEVICE|Carotid body ablation (Cibiem)|
218912708|NCT05039749|DEVICE|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
218912709|NCT01124110|BEHAVIORAL|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
219060624|NCT01863472|DEVICE|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
219060625|NCT01863472|DEVICE|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
219060626|NCT00296556|DRUG|Rivenprost (drug)|
219525547|NCT00081783|DRUG|Xcellerated T Cells|
219614487|NCT06966817|DRUG|control group(chlorhexidine)|The sponge swab is dipped in 0.25% chlorhexidine solution and used once for each part of the mouth, 4 times a day to provide oral care.
219525548|NCT03455348|OTHER|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
219525549|NCT00258947|BIOLOGICAL|Smallpox vaccine, LISTER strain, from chick embryo cells|
219525550|NCT00899028|GENETIC|comparative genomic hybridization|
218912710|NCT01124110|OTHER|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
219525551|NCT00899028|GENETIC|fluorescence in situ hybridization|
218912711|NCT04435925|DRUG|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
218912712|NCT04435925|DRUG|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
219525552|NCT00899028|GENETIC|gene expression analysis|
219525553|NCT00899028|GENETIC|microarray analysis|
219525554|NCT00899028|GENETIC|protein expression analysis|
219525555|NCT00899028|OTHER|immunohistochemistry staining method|
219525556|NCT00899028|OTHER|laboratory biomarker analysis|
219525557|NCT00899028|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
219525558|NCT00899028|OTHER|medical chart review|
219525559|NCT00899028|PROCEDURE|diagnostic bronchoscopy|
219525560|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
219525561|NCT05666349|DRUG|Niraparib|100 mg, 200 mg, or 300mg oral niraparib once daily.
219525562|NCT05666349|RADIATION|Re-irradiation (re-RT)|Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.
219525563|NCT01523899|DEVICE|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
219525564|NCT01523899|DIAGNOSTIC_TEST|Standard culture|
219525565|NCT05412732|OTHER|prospective biomedical research study|A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
218912713|NCT04045860|PROCEDURE|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
218912714|NCT04045860|OTHER|Observation|Standard of care is currently observation
218912715|NCT02972775|OTHER|no interventions. observational study|
218912716|NCT05397730|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
218912717|NCT04842747|DRUG|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
218912718|NCT00028067|DRUG|Atazanavir|
218912719|NCT00028067|DRUG|Nelfinavir mesylate|
218912720|NCT04831645|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
218912721|NCT04831645|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
218912722|NCT01862146|PROCEDURE|smoke expose|
218912723|NCT00688896|DRUG|JTT-705 600 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
218912724|NCT00688896|DRUG|JTT-705 300 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
218912725|NCT00688896|DRUG|Placebo and pravastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
219525566|NCT05411809|DRUG|drug adjuvant therapy|The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
219525567|NCT00824265|DRUG|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
219525568|NCT00824265|DRUG|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
219525569|NCT01195259|DRUG|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
219525570|NCT04752748|DRUG|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48."
219525571|NCT03917771|OTHER|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
219525572|NCT03917771|OTHER|Usual follow-up|Usual follow-up carried out in GO consultation
219525573|NCT05249413|PROCEDURE|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
219525574|NCT01624220|RADIATION|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
219525575|NCT01624220|RADIATION|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
219525576|NCT01624220|PROCEDURE|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
219525577|NCT01624220|BEHAVIORAL|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
218912726|NCT05003401|DEVICE|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
218912727|NCT00474422|BEHAVIORAL|Proactive assignment to attend a breastfeeding clinic|
218912728|NCT02996201|OTHER|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
218912729|NCT00517946|DRUG|pseudoephedrine hydrochloride|
219525578|NCT05245643|DEVICE|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
219525579|NCT00002012|DRUG|Interferon alfa-n3|
219614488|NCT06966817|DRUG|Experimental Group(cetylpyridinium chloride)|The mouth is cleaned by dipping a sponge swab into 0.05% cetylpyridinium chloride solution and using it once for each part of the mouth, 4 times a day.
219614489|NCT05966506|BEHAVIORAL|Dyad-based Zoom health coaching|This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 \&11) for 45 minutes
219614490|NCT05966506|BEHAVIORAL|Fitbit activity monitor|"Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep."
219525580|NCT01740609|DRUG|Placebo|Placebo
219614491|NCT05966506|OTHER|Electronic newsletters|Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
219525581|NCT01740609|BIOLOGICAL|PF-06342674 Dose A|Single SC Dose
219525582|NCT01740609|BIOLOGICAL|PF-06342674 Dose B|Single SC Dose
219525583|NCT01740609|BIOLOGICAL|PF-06342674 Dose C|Single SC Dose
219614492|NCT03674697|DEVICE|Green LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
219614493|NCT03674697|DEVICE|White LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
218912730|NCT00517946|DRUG|cetirizine hydrochloride|
218912731|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
219060627|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
219614494|NCT05119257|BIOLOGICAL|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
219614495|NCT05481710|DIAGNOSTIC_TEST|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
218912732|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
218912733|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
219525584|NCT01740609|BIOLOGICAL|PF-06342674 Dose D|Single SC Dose
219060628|NCT01719692|DRUG|Rituximab|
219060629|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
219525585|NCT01740609|BIOLOGICAL|PF-06342674 Dose E|Single SC Dose
219525586|NCT01740609|BIOLOGICAL|PF-06342674 Dose F|Single IV Dose
219525587|NCT01740609|BIOLOGICAL|PF-06342674 Dose G|Single SC Dose
219525588|NCT01740609|BIOLOGICAL|PF-06342674 Dose H|Single IV Dose
219525589|NCT01740609|BIOLOGICAL|PF-06342674 Dose I|Single SC Dose
219525590|NCT01740609|BIOLOGICAL|PF-06342674 Dose J|Single IV Dose
219060630|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
219060631|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
219525591|NCT01695551|OTHER|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
219525592|NCT01226069|DRUG|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
219525593|NCT01226069|DRUG|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
219525594|NCT01226069|OTHER|No application|No application
219525595|NCT01471366|DIETARY_SUPPLEMENT|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
219525596|NCT01471366|DIETARY_SUPPLEMENT|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
219525597|NCT01471366|DIETARY_SUPPLEMENT|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
219525598|NCT01471366|DIETARY_SUPPLEMENT|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
219525599|NCT04851301|BEHAVIORAL|Active Virtual Reality|Participants will be assigned to an immersive VR environment.
219525600|NCT04851301|BEHAVIORAL|sham Virtual Reality|Participants will be assigned to a sham VR environment without the immersive experience.
219525601|NCT04851301|OTHER|No Intervention|Participants will experience tonic pain tolerance tests without exposure to any environments.
219525602|NCT04851301|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
219525603|NCT04851301|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
219525604|NCT04851301|OTHER|Natural history|Participants will not be provided Naloxone or Saline.
219525605|NCT00216502|DRUG|galantamine hydrobromide|
219525606|NCT00912353|DRUG|AZD7268|Single Oral
219525607|NCT00912353|DRUG|Placebo|Single Oral
219525608|NCT06159803|BEHAVIORAL|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
219525609|NCT01096290|DRUG|lubiprostone|24mcg BID, capsule, oral 30days
219525610|NCT01096290|DRUG|Matched placebo|Twice daily for 30days, oral
219525611|NCT00357448|BIOLOGICAL|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
219525612|NCT00357448|PROCEDURE|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
219525613|NCT00357448|OTHER|laboratory biomarker analysis|Correlative studies
219525614|NCT00357448|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219525615|NCT00357448|OTHER|flow cytometry|Correlative studies
219525616|NCT01402947|DRUG|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
219525617|NCT01402947|DRUG|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
219525618|NCT05697471|DRUG|Dienogest|Dienogest 2 mg per day
219525619|NCT05697471|DRUG|Danazol|Danzol 200MG per day
219525620|NCT00385684|DRUG|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
219525621|NCT00385684|DRUG|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
219525622|NCT00385684|DRUG|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
219525623|NCT03634709|BEHAVIORAL|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
219525624|NCT03220867|DRUG|Risperidone: Xian Risperdal (test)|Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.
219525625|NCT03220867|DRUG|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
219525626|NCT07003074|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
219614496|NCT02766335|DRUG|Docetaxel|Given IV
219614497|NCT02766335|BIOLOGICAL|Durvalumab|Given IV
218912734|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
218912735|NCT00868634|DRUG|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
219614498|NCT02766335|OTHER|Laboratory Biomarker Analysis|Correlative studies
219614499|NCT02396511|BIOLOGICAL|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
219614500|NCT02396511|BIOLOGICAL|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
219614501|NCT01223378|DRUG|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
219614502|NCT01223378|DRUG|Latanoprost|0.005% ophthalmic solution, QD 28 days
219614503|NCT02436161|BEHAVIORAL|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
218912736|NCT06217042|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|"Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks."
218912737|NCT06217042|DRUG|gemcitabine; capecitabine|Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
219525627|NCT07003074|DRUG|Docetaxel combined + Trastuzumab +Pertuzumab|Positive control.
219525628|NCT02801877|BEHAVIORAL|IntelliCare|
219525629|NCT02801877|BEHAVIORAL|Hub App with the Recommender System|
219525630|NCT02801877|BEHAVIORAL|Coaching|
219614504|NCT00191126|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
219614505|NCT00191126|DRUG|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
219614506|NCT00191126|PROCEDURE|surgery|surgery
219614507|NCT01384110|DIETARY_SUPPLEMENT|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
219614508|NCT03739281|DIAGNOSTIC_TEST|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
219614509|NCT03739281|DIAGNOSTIC_TEST|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
219614510|NCT06042595|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of the University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers, and physiotherapists.
219525631|NCT00591630|DRUG|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
219614511|NCT02392117|DRUG|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
219614512|NCT02336321|DEVICE|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
219614513|NCT04583735|BIOLOGICAL|TEPEZZA|Intravenous infusion
219614514|NCT04583735|DRUG|Placebo|Intravenous infusion
219614515|NCT00124917|RADIATION|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.\[1\]
219614516|NCT04765930|OTHER|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
219614517|NCT01389050|RADIATION|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
218912738|NCT06236906|DEVICE|Device supported behavioural treatment|The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
218912739|NCT04637568|DIAGNOSTIC_TEST|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
218912740|NCT01828177|DRUG|PDI-320|
218912741|NCT01828177|DRUG|PDI-320 Monad #1|
218912742|NCT01828177|DRUG|PDI-320 Monad #2|
218912743|NCT01828177|DRUG|Vehicle|
218912744|NCT01260493|OTHER|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
218912745|NCT04175223|DIETARY_SUPPLEMENT|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
218912746|NCT04094597|DRUG|Lactoferrin|lactoferrin is given orally in comparsion to placebp
218912747|NCT04094597|DRUG|Placebos|placebp is given in 2 ml saline
218912748|NCT01451606|DRUG|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
218912749|NCT01451606|DRUG|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
219525632|NCT00591630|DRUG|Carmustine|300 mg/m\^2 by vein.
219525633|NCT00591630|DRUG|Etoposide|200 mg/m\^2 by vein every 12 hours.
219525634|NCT00591630|DRUG|Cytarabine|200 mg/m\^2 by vein every 12 hours.
219525635|NCT00591630|DRUG|Melphalan|140 mg/m\^2 by vein.
219525636|NCT00591630|DRUG|Rituximab|"Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
219525637|NCT00591630|PROCEDURE|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
219525638|NCT00331578|DEVICE|Excel drug-eluting coronary artery stent|
219525639|NCT03815838|DIAGNOSTIC_TEST|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
219525640|NCT07035392|DRUG|Adebrelimab|Adebrelimab 1200mg，ivgtt，D1，Q3W
219525641|NCT07035392|DRUG|chemotherapy|"Queue A (lung squamous cell carcinoma patients):~Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W~Queue B (lung adenocarcinoma patients):~Pemetrexed 500 mg/m2, ivgtt，D1，Q3W Carboplatin AUC=5, D1，Q3W"
219525642|NCT07036380|DRUG|MP0317 + Gemcitabine + Cisplatine + Durvalumab|"* MP0317: 3 mg/kg IV(intraveinous), day 1, every 3 weeks for a maximum of 5 administrations~* Immuno-chemotherapy (ICT): cycle 1-5~  * Durvalumab 1500 mg IV, day 8 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 8 and 15 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 8 and 15 every 3 weeks~* Immuno-chemotherapy (ICT): cycle 6-8~  * Durvalumab 1500 mg IV every 3 weeks~ * Gemcitabine 1000 mg/m² at day 1, 8 every 21 days~ * Cisplatin 25 mg/m² at day 1, 8 every 21 days~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
219525643|NCT07036380|PROCEDURE|CT-Scan|at baseline, every 6 weeks (± 1 week) for the first 24 weeks and then every 8 weeks until progression, at end of treatment visit, At each follow-up visit : Only for patients who have not progressed during treatment phase
219525644|NCT07036380|DRUG|Gemcitabine + Cisplatin + Durvalumab|"* Immuno-chemotherapy (ICT) for 8 cycles :~  * Durvalumab 1500 mg IV, day 1 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 1 and 8 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 1 and 8 every 3 weeks~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
219525645|NCT07037160|COMBINATION_PRODUCT|Kegel exercises|Kegel exercises, also known as pelvic floor exercises, involve contracting and relaxing the muscles of the pelvic floor to strengthen them. These exercises can help improve urinary and fecal continence, potentially enhance sexual function, and are recommended for both men and women.
219525646|NCT07037160|COMBINATION_PRODUCT|Kegel exercises with Foam Rolling|Foam rolling can be a helpful tool to prepare for or complement Kegel exercises by releasing tension in surrounding muscles and improving overall pelvic floor function. Foam rolling can help address tight muscles in the hips and lower back that can contribute to pelvic floor dysfunction. By releasing these tight areas, foam rolling can allow for better engagement and control of the pelvic floor muscles during Kegel exercises.
219525647|NCT07035899|DRUG|Caesarean Section|Cesarean section was performed as routine surgical procedure
219525648|NCT07035561|DRUG|Rituximab (Mabthera)|"In Chronic hypersensitivity pneumonitis patients with no improvement in lung function (deterioration in their FVC% predicted more than or equal 5%) after a minimum of 6 months treatment including antigen avoidance and immunosuppressive therapy. Rituximab will be administered by an intravenous infusion.~* Two doses of Rituximab will be given, the first dose at day 0 and the second dose at day 15, 1 gram of Rituximab will be given in each dose.~* Patients will be given acetaminophen and antihistamine before each infusion.~* Rituximab will be diluted in an infusion bag of either 0.9% sodium chloride or 5% dextrose.~* No other drugs will be mixed with it, and patients will be closely monitored for any infusion reactions."
219525649|NCT07036354|OTHER|Human-Animal Interaction|HAI - participants spend a specific amount of time with a therapy dog in a controlled environment.
219525650|NCT07036354|OTHER|General Health Education|GHE - participants will be educated on strategies to assist in managing general and academic anxiety.
219525651|NCT07037654|DRUG|ondansetron lingual film|8 mg of the lingual film form of ondansetron, given 15 minutes before spinal anesthesia
219525652|NCT07037654|DRUG|Placebo|a placebo lingual film form, given 15 minutes before spinal anesthesia
219525653|NCT07036471|BEHAVIORAL|myCare Start|The service consists of two 10-minute, semi-structured and tailored consultations delivered by community pharmacists during the first 6 weeks of a patient initiating a new long-term medication, followed by tailored feedback to the patient's physician.
219525654|NCT07037537|PROCEDURE|Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation|Laparoscopic assisted mastectomy with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch, immediate one-step breast reconstruction and simultaneous autologous fat transplantation
219525655|NCT07036237|DRUG|Tramadol group|Drug used as final irrigant
219525656|NCT07036237|DRUG|Dexamethasone Group|drug used as a final irrigant
219525657|NCT07037251|OTHER|there is no intervention|there is no intervention only observation
219525658|NCT07037212|BEHAVIORAL|Intensive Medical Nutrition Therapy (MNT)|Participants will receive individualized intensive medical nutrition therapy (MNT) with weekly dietary counseling and follow-ups for 12 weeks. The intervention focuses on improving glycemic control, reducing systemic inflammation, and enhancing gut barrier function.
219525659|NCT07037212|BEHAVIORAL|Standard Dietary Counseling|Participants will receive standard dietary advice in a single counseling session at baseline. No further dietary intervention will be provided.
219525660|NCT07035301|DRUG|Normal Saline (Placebo)|During anesthesia induction, an equal volume of normal saline was used instead of rocuronium for anesthesia.
219525661|NCT07035301|DRUG|Lidocaine Intravenous Infusion|Lidocaine was administered at a dose of 0.5mg/kg for the induction of anesthesia.
219525662|NCT07035301|DRUG|Remimazolam Tosilate|Remimazolam was administered at a dose of 0.2 mg/kg for the induction of anesthesia.
219614518|NCT01389050|RADIATION|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
219614519|NCT05469672|OTHER|Low-level laser therapy|For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
219525663|NCT07035301|DRUG|Remifentanil|Remifentanil was administered at a dose of 3 micrograms per kilogram for the induction of anesthesia.
218912750|NCT05049590|BIOLOGICAL|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
218912751|NCT02424396|DRUG|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
218912752|NCT02424396|DRUG|Placebo|
218912753|NCT02989493|DRUG|Doxazosin|Doxazosin
218912754|NCT02989493|OTHER|Placebo|Placebo
218912755|NCT03017963|DRUG|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
218912756|NCT02082496|DRUG|Liraglutide|S.c. liraglutide 3.0mg once daily
218912757|NCT02559622|DRUG|Secukinumab|300 mg secukinumab
218912758|NCT02559622|OTHER|Placebo|Placebo followed by 300 mg secukinumab
218912759|NCT02559622|OTHER|Placebo|Placebo followed by 150 mg secukinumab
218912760|NCT02559622|DRUG|Secukinumab|150 mg secukinumab
218912761|NCT02163538|DEVICE|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
218912762|NCT02163538|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
218912763|NCT04643808|DEVICE|transcutaneous auricular vagus nerve stimulation|Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
218912764|NCT04496817|OTHER|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
219525664|NCT07035301|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium was administered at a dose of 0.15mg/kg for the induction of anesthesia.
218912765|NCT04496817|OTHER|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
218912766|NCT04906928|DEVICE|MRI|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~* 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
219525665|NCT07035860|RADIATION|Carbon ion radiotherapy|Patients will receive platinum-based doublet chemotherapy and immunotherapy, followed by carbon iron radiotherapy and immunotherapy. The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
219525666|NCT07035860|DRUG|Chemotherapy|platinum-based doublet chemotherapy
218912767|NCT02662673|DEVICE|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
218912768|NCT01412996|PROCEDURE|surgery|single ACCESS laparoscopic cholecystectomy
218912769|NCT01412996|OTHER|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
218912770|NCT03037996|OTHER|patients' response|patients' satisfaction to anesthesia services
218912771|NCT05951400|DRUG|Dydrogesterone Tablets|used for pituitary suppression in ICSI cycle
218912772|NCT05951400|DRUG|Cetrorelix|GnRH antagonist for pituitary suppression
218912773|NCT04750317|DRUG|Tofacitinib|Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
218912774|NCT05072639|BEHAVIORAL|Guided Meditation|23 minute audio recording
218912775|NCT03668873|BEHAVIORAL|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
218912776|NCT03668873|BEHAVIORAL|Sleep Parent Education|SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
218912777|NCT05088564|PROCEDURE|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
218912778|NCT05088564|PROCEDURE|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
218912779|NCT02343835|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
219525667|NCT07035860|DRUG|Immunotherapy|The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
219525668|NCT07036939|PROCEDURE|Immediate LVA|Bilateral cervical lymphatic-venous anastomosis (LVA) performed within 2 weeks after baseline assessments.
219525669|NCT07036939|PROCEDURE|Delayed LVA|Identical LVA procedure performed at 6 months (±2 weeks) post-baseline
218912780|NCT03793244|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
218912781|NCT03446625|DRUG|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
219525670|NCT07035639|BEHAVIORAL|The Baduanjin intervention was designed following traditional Chinese health preservation principles and conducted under the guidance of certified instructors. The training sessions were led by nation|The Baduanjin group received training guided by national-level social sports instructors certified by the Institute of Sports Medicine, General Administration of Sport of China. The intervention consisted of Baduanjin training 4 times per week for 8 consecutive weeks, with a total duration (including warm-up and breaks) of ≥30 minutes per session. The training protocol included 16 minutes of Baduanjin exercise, a 2-minute break, and an additional 16 minutes of Baduanjin exercise.
219525671|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) and Oscillatory Positive Expiratory Pressure (OPEP) group|Patients with bronchiectasis using ACT and OPEP simultaneously
219525672|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) group|Patients will receive only ACBT for airway clearance.
218912782|NCT03446625|DRUG|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
219525673|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine.
218912783|NCT01010828|PROCEDURE|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
218912784|NCT01010828|PROCEDURE|Incision technique|Mini Mid-Vastus Approach
218912785|NCT02642601|DRUG|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
219525674|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine.
219525675|NCT07035964|DIETARY_SUPPLEMENT|human lactoferrin|effera human lactoferrin
219525676|NCT07035964|DIETARY_SUPPLEMENT|Placebo|Placebo Control
219525677|NCT06876207|DEVICE|Tandem t:slim X2 with Control-IQ technology|Control-IQ is one of the second-generation AID technologies currently available worldwide and is approved for people \> 6 years. Control-IQ can predict glucose levels 30 minutes in advance and automatically adjust basal insulin delivery, providing corrective boluses if needed. The system can prevent hypoglycemia by suspending insulin delivery if glucose is predicted to drop below 70 mg/dl (8). Additionally, the device offers specific settings for circumstances such as sleep or exercise. When the exercise mode is activated, the system temporarily raises the minimum glucose target from 112.5 to 140 mg/dl to minimize the risk of hypoglycemia, a common effect of physical activity.
219525678|NCT07037069|COMBINATION_PRODUCT|Desensitization Training|Participants in this group received desensitization training aimed at reducing hypersensitivity and pain perception through progressive exposure to different tactile stimuli. Use of soft and coarse textures (cotton, wool, Velcro, brush). Rubbing, tapping, rolling over the affected wrist and hand.
219525679|NCT07037069|COMBINATION_PRODUCT|Graded Motor Imagery (GMI)|Training Sample Size: 20 participants Participants underwent a progressive 3-phase motor training program designed to target cortical reorganization and improve movement without provoking pain. Phases: Laterality Recognition - identifying left/right hand images (Recognise™ app or cards). Explicit Motor Imagery - visualizing wrist movements without actual motion. Mirror Therapy - using a mirror box to simulate movement of the affected wrist. Sessions: 30-45 minutes/day, 5 times/week, for 4 weeks.
219525680|NCT07037368|BEHAVIORAL|Impact of Delivery Mode|investigates the impact of delivery mode vaginal delivery versus cesarean section on the prevalence and severity of three postpartum musculoskeletal complications: coccydynia, pelvic girdle pain (PGP), and rectus diastasis (RD). Conducted on postpartum females
219525681|NCT07036731|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
219614520|NCT05469672|OTHER|High-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
218912786|NCT01874002|DEVICE|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
218912787|NCT02183675|DRUG|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
218912788|NCT02183675|DRUG|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
218912789|NCT02183675|DRUG|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
218912790|NCT00549146|DRUG|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
218912791|NCT00549146|DRUG|fluticasone propionate DISKUS 500mcg|
218912792|NCT01521117|DRUG|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
218912793|NCT01521117|DRUG|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
218912794|NCT04282161|DEVICE|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
218912795|NCT01394237|OTHER|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
218912796|NCT01926223|OTHER|Home visiting|
218912797|NCT03088696|OTHER|stimulation|activation of the acupuncture point
218912798|NCT03088696|OTHER|no stimulation|no activation of the acupuncture point
218912799|NCT01857219|BEHAVIORAL|Tai chi|
218912800|NCT01423500|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
218912801|NCT01423500|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
218912802|NCT01423500|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
218912803|NCT01423500|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
219525682|NCT07037667|OTHER|Pilates exercises|Single leg lifts:The participant is in supine lying position with knees bent and feet parallel and hip-width apart. Head, neck and shoulders totally relaxed and arm extended and relaxed beside the body. Then the participant is asked to inhale first without moving her leg then exhale while bringing one leg up towards chest , drawing her pelvic floor and abdominals up and in like gently tightening a belt and maintaining 90 degrees angle at the knee and then put her leg down while inhaling. One leg circle:The participant is in supine lying position with one leg raised towards the ceiling and the other leg on the floor and both knees slightly bent.Then the participant is asked to inhale first without moving her leg and to make sure to use the abdominal muscles to try to maintain a neutral pelvis while doing the exercise then makes a small circle while exhaling and inhale when she completes the circle and reaches the starting position.
219525683|NCT07037667|OTHER|Dietary recommendations|Dietary recommendations as healthy snacks that are rich in magnesium and vitamin B-6.
219525684|NCT07037173|COMBINATION_PRODUCT|Kinesiology Taping|Elastic therapeutic tape applied over the SiJ region using a standardized protocol. Therapy sessions were supervised and conducted at a rehabilitation center three times per week for six weeks.
218912804|NCT01423500|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
218912805|NCT01423500|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
219525685|NCT07037173|COMBINATION_PRODUCT|Yoga Therapy|A structured yoga program including asanas, pranayama, and mindfulness practices focused on enhancing flexibility, core strength, and posture. conducted at a yoga center
219525686|NCT07037342|OTHER|Manual acupuncture|Manual acupuncture on acupoint (ST32, ST34, ST36, SP10) the needles will be inserted perpendicularly for 20 minutes.
219614521|NCT04722432|DEVICE|Outside the Scope (OTS), Detachable Catheter System|Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
218912806|NCT01423500|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
218912807|NCT02480972|PROCEDURE|magnetic resonance imaging|"multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   \------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
218912808|NCT00784563|BEHAVIORAL|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
218912809|NCT00784563|BEHAVIORAL|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
218912810|NCT03874546|OTHER|Questionnaire|"* Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
218912811|NCT00033332|DRUG|dexamethasone|
218912812|NCT00033332|DRUG|pamidronate disodium|
218912813|NCT00033332|DRUG|thalidomide|
218912814|NCT00033332|DRUG|zoledronic acid|
218912815|NCT03404817|DRUG|Original formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
218912816|NCT03404817|DRUG|New formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
218912817|NCT02228681|DRUG|Everolimus|10mg daily by mouth
218912818|NCT02228681|DRUG|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
218912819|NCT02228681|DRUG|Letrozole|2.5mg once a day by mouth
218912820|NCT02228681|DRUG|Medroxyprogesterone Acetate|200 mg daily by mouth
218912821|NCT04117555|DIAGNOSTIC_TEST|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
218912822|NCT03305614|PROCEDURE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
218912823|NCT03305614|PROCEDURE|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
218912824|NCT01241864|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
218912825|NCT01241864|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
218912826|NCT04003701|BEHAVIORAL|Usual care|Control group: minimal distraction
218912827|NCT04003701|BEHAVIORAL|Robot-assisted puncture procedure|Experimental group: distraction with robot
218912828|NCT00788216|OTHER|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
218912829|NCT04906564|OTHER|Identification of genetic variants|Identification of genetic variants
218912830|NCT02743208|DEVICE|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
218912831|NCT02743208|DEVICE|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
218912832|NCT05684536|DEVICE|liagsure device|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
218912833|NCT04609956|OTHER|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
218912834|NCT04609956|OTHER|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
218912835|NCT02680249|DRUG|CTP-656|
219525687|NCT07037342|OTHER|Electro acupuncture|Electro acupuncture on acupoint (ST32, ST34, ST36, and SP10) for 20 minutes.
218912836|NCT05684822|OTHER|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
219525688|NCT07037342|OTHER|Sham acupuncture|Is a needle insertion at wrong points or non-points (locations that are not known acupuncture points)
218912837|NCT03896438|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
218912838|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
219525689|NCT07036913|DIAGNOSTIC_TEST|somatocognitive therapy|In somatocognitive therapy which includes drawing( three days prior to menustration in first two months and the first day of menustration in third month) and music(in the first 12 hours of menustration)along with TENS(thirty minutes on abdominal region, upon the onset of dysmonarrhea).
219525690|NCT07036913|COMBINATION_PRODUCT|Stretching exercises|Stretching exercises of abdominal, lumbar or pelvic region will be performed as a treatment. Frequency:15 minutes;three times per week.
219525691|NCT06713590|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
219525692|NCT07037030|BEHAVIORAL|Guided deep breathing|Children will complete a brief, 5-minute, deep breathing intervention using the Domi tool to help maintain a 5-second breath pace
219525693|NCT07035717|OTHER|Patient interview|A semi-structured interview with five questions will be conducted, with audio recording, which will later be transcribed verbatim.
219525694|NCT07035808|COMBINATION_PRODUCT|2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy|The enrolled patients first receive 2 cycles of combined drug induction therapy: paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706, every 3 weeks for 2 cycles; After induction therapy, synchronous radiotherapy and chemotherapy combined with immunotherapy: extracorporeal irradiation+post loading radiotherapy+synchronous chemotherapy+immunotherapy. During radiotherapy, single agent cisplatin/carboplatin treatment for 5 courses per week+QL1706 treatment every 3 weeks for 3 courses; After the end of radiotherapy and chemotherapy, immune maintenance therapy will be administered for six months: treatment with QL1706 every 3 weeks for 9 courses, followed by a follow-up period until the end of radiotherapy for 2 years or death.
219525695|NCT07036575|BEHAVIORAL|Standard Visual Health Education|Participants receive conventional eye health education using standard visual materials, explained by an instructor.
219525696|NCT07036575|BEHAVIORAL|Easy-Read Instructor-Guided Education|Participants receive Easy-Read health education through 16 simplified images with instructor-guided explanation using plain language and pictorial content.
218912839|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
218912840|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
219525697|NCT07036575|BEHAVIORAL|Easy-Read Audio-Based Self-Learning|Participants use a voice-assisted pen device to self-learn Easy-Read materials (16 images) with audio explanations, without additional teacher guidance.
219525698|NCT07035314|PROCEDURE|Dexamethasone|1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and paracetamol.
219614522|NCT04700670|BIOLOGICAL|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
219614523|NCT01012895|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
219060632|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
219060633|NCT01974050|BEHAVIORAL|Text message surveillance|
219060634|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
219525699|NCT07035314|DRUG|NSAIDs|2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.
219525700|NCT07035314|DRUG|Control (Standard treatment)|3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsillectomy medications in our department.
219525701|NCT07035912|COMBINATION_PRODUCT|PIONEER Protocol|"* Oral nutritive stimulus with every feed (minimum 5mL)~* Esophageal stimulation with up to 15 stimulations given at least 5 times per week with stimulation catheter~* High resolution esophageal manometry as much as weekly if feasible throughout protocol~* Parent biofeedback (during manometry studies) and education on at least a weekly basis with focus on their participation in oral feeding"
219614524|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
219614525|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
219614526|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
219614527|NCT01012895|DRUG|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
219614528|NCT01012895|DRUG|Ribavirin|"Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
218912841|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
219525702|NCT07036055|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.
219525703|NCT07036055|DEVICE|Sham Stimulation|Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.
219525704|NCT07036055|BEHAVIORAL|Mindfulness Training|Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.
219525705|NCT07036887|DIAGNOSTIC_TEST|First Rib Mobilization + Respiratory Physiotherapy|Patients were given post isometric relaxation for restricted first rib in sitting position and therefore the affected elevated first rib, opposite foot of therapist was placed on the table and patient non affected arm is 'dropped' on the therapist flexed knee. The practitioner's conjointly flexes the elbow on the non-affected side placed anterior to shoulder with the hand supporting the patient facet of head. Then therapist makes contact with the tubercle of the first rib with fingers or thumb of affected side (patient) disposing of available soft tissue. slack as steady force is applied in inferior direction. The therapist eases his flexed leg and uses his supported hand to encourage patient's neck into a side flexion and rotation to affected side thus unloading the scalene tension thereon side and encourage the first rib to move anteriorly and inferiorly
219525706|NCT07036887|COMBINATION_PRODUCT|Scalene Muscle Energy Technique (MET) + Respiratory Physiotherapy|MET for the scalene muscle, the participants were made to lie supine with a cushion or towel under the upper thoracic area. The PT placed his hand on the side of the participant's face/forehead to resist the isometric contraction and the other hand on the sternum. The participants were asked to perform the action of the anterior scalene muscle against PT resistance and hold it for 7-8 seconds followed by relaxation. (42) Along with the same respiratory physiotherapy protocol used in Group A. The treatment protocol was given for three sessions per week for four weeks
219525707|NCT07037108|COMBINATION_PRODUCT|Reflexology + Generalized Stretching|Participants in Group 1 received a combination of foot reflexology and generalized stretching exercises. focusing on specific reflex points related to the endocrine, nervous, and reproductive systems. Each reflexology session lasted for 20 minutes, conducted three times per week for 6 weeks.
219525708|NCT07037108|COMBINATION_PRODUCT|Stretching Only|Generalized Stretching Only Method: Generalized Stretching Exercises Details: Participants in Group 2 received only generalized stretching exercises without any reflexology treatment. The stretching protocol included exercises for major muscle groups such as the neck, shoulders, back, hips, hamstrings, and calves. Each session will last for 20-25 minutes, which included a 5-minute warm-up, 15-20 minutes of static stretching, and a 5-minute cool-down.
219525709|NCT07035782|DEVICE|temperature monitoring|Core temperature will be measured in the distal esophagus. The esophageal probe will be inserted after intubation to the depth from the upper incisors recommended by Bloch et al,1 specifically one-quarter of the patient's height plus 4.5 cm.
219525710|NCT07035782|DRUG|Sevoflurane|Anesthesia induction will be standardized for all participants., the children will undergo inhalational induction using 8% sevoflurane with a fresh gas flow of 5 L/min in 100% oxygen. Once children loses consciousness, the sevoflurane concentration will be reduced to 3%-5% and then maintained as close as possible to 1.2 MAC, age-adjusted
219525711|NCT07037693|DIAGNOSTIC_TEST|Comprehensive complication index (CCI)|Comprehensive complication index (CCI)
219525712|NCT07037693|DIAGNOSTIC_TEST|Clavien-Dindo-Classification (CDC)|Clavien-Dindo-Classification (CDC)
219525713|NCT07036497|DRUG|Vitamin B12|Vitamin B12 treatment was initiated in male patients with vitamin B12 deficiency due to anemia etiology.
219525714|NCT05280132|PROCEDURE|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
219525715|NCT05280132|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
219525716|NCT03559023|PROCEDURE|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
219525717|NCT03559023|PROCEDURE|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
219525718|NCT03559023|PROCEDURE|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
219614529|NCT01153828|DRUG|Retapamulin|Prescription for retapamulin
219614530|NCT01153828|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
219614531|NCT01153828|DRUG|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
219614532|NCT05140044|DEVICE|Balance Exercises - Smartphone Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
218912842|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
218912843|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
218912844|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
218912845|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
219525719|NCT03559023|PROCEDURE|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
219525720|NCT06894355|OTHER|hydrotherapy|hydrotherapy in addition to physical therapy
219525721|NCT06894355|OTHER|control group|regular physical therapy treatments
219525722|NCT06751043|OTHER|Fasting|"Process: Fasting pre-procedure~Tube feeding will be stopped at least 8 hours before the patient's scheduled surgery or procedure time."
219525723|NCT06751043|OTHER|Not fasting|"Process: Not fasting pre-procedure~Tube feeding will be continued until patient transfer to the operating room/procedure area."
219525724|NCT06795893|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index,compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022,respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
219525725|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
219525726|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
219525727|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
219614533|NCT05140044|OTHER|Balance Exercises - Traditional Paper Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
219614534|NCT01834534|BEHAVIORAL|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
219614535|NCT03797911|COMBINATION_PRODUCT|Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
219614536|NCT03797911|COMBINATION_PRODUCT|Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
219614537|NCT01971528|DEVICE|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
218912846|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
218912847|NCT04106297|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
218912848|NCT04106297|DRUG|Placebo oral solution|Placebo for oral administration
218912849|NCT04106297|DRUG|GLPG3970 capsule|GLPG3970 for oral administration
218912850|NCT04611386|DRUG|computerized tomography|Anti Factor Xa level
219525728|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
219525729|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
219525730|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed
219525731|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
219525732|NCT03716011|DEVICE|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
219525733|NCT04201171|DEVICE|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
219525734|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
219525735|NCT06756607|OTHER|SUPPORT toolkit|The SUPPORT toolkit comprises of the SUPPORT CT website and interaction with a SUPPORT navigator.
219525736|NCT06930703|DRUG|Cannabidiol|Cannabidiol (CBD) twice daily taken orally for 4-weeks
219525737|NCT06930703|DRUG|Placebo|Placebo equivalent twice daily taken orally for 4-weeks
219614538|NCT01971528|OTHER|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
219614539|NCT01515423|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
219614540|NCT01515423|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
219525738|NCT04137393|COMBINATION_PRODUCT|brushing|mechanical and chemical plaque removal
219525739|NCT02214264|BEHAVIORAL|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
219525740|NCT02214264|BEHAVIORAL|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
219525741|NCT02214264|BEHAVIORAL|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
219525742|NCT02214264|BEHAVIORAL|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
219525743|NCT02341261|BEHAVIORAL|Standard Care Counseling|
219525744|NCT02341261|BEHAVIORAL|Supervised Exercise and Counseling|
219525745|NCT05254301|OTHER|Intervention group|This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance \& follow-up, low-threshold activities, homebased functional training \& better follow-up guidance afterwards).
219525746|NCT03412357|PROCEDURE|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
219525747|NCT03412357|PROCEDURE|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
219525748|NCT05197322|DRUG|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
219525749|NCT02992938|DRUG|Acetazolamide|
219525750|NCT02992938|DRUG|Placebo Oral Tablet|
219525751|NCT05961423|PROCEDURE|Robotic surgery|The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
219525752|NCT04188106|DRUG|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
219525753|NCT04188106|DRUG|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
219525754|NCT01382641|DEVICE|Hoya AF-1 IOL|The patients will be assessed for three months
219525755|NCT01382641|DEVICE|Revital vision|The patients will be assessed for three months.
219525756|NCT00705536|DRUG|Humalog|
219525757|NCT00705536|DRUG|Humulin-R|
219525758|NCT00705536|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
219525759|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 1|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets."
219525760|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 2|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets."
219525761|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 3|"The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets."
219614541|NCT01515423|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
219614542|NCT01515423|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
219614543|NCT01515423|DRUG|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
219614544|NCT01515423|DRUG|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
219614545|NCT01515423|DRUG|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
219614546|NCT01515423|DRUG|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
219614547|NCT01515423|DRUG|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
219614548|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
218912851|NCT03025282|DRUG|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
218912852|NCT03025282|DRUG|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
218912853|NCT03025282|DRUG|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
218912854|NCT03025282|DRUG|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
219525762|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 4|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets."
219525763|NCT05221242|PROCEDURE|Conventional Resin Cement vs Preheated Resin Composite|For this study, variolink esthetic resin cement will be used to bond ceramic partial laminate veneers in one side of the maxillary anterior teeth (left or right upper incisors and canines), while, the other side will receive ceramic partial laminate veneers bonded with a preheated resin composite
219525764|NCT05926570|DRUG|Cinacalcet|calcimimetic
219525765|NCT01356693|DRUG|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
219525766|NCT01356693|DRUG|Placebo|Placebo with mimicking characteristics of experimental drug
218912855|NCT03025282|DRUG|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
218912856|NCT03025282|DRUG|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
218912857|NCT00181272|DRUG|azithromycin|
218912858|NCT00006394|DRUG|growth hormone|
218912859|NCT03711513|BEHAVIORAL|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
218912860|NCT02318316|OTHER|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
218912861|NCT05862220|DIAGNOSTIC_TEST|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
219525767|NCT00441467|DRUG|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
219614549|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
219614550|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
218912862|NCT02761330|DRUG|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
218912863|NCT02761330|PROCEDURE|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
218912864|NCT05280340|DRUG|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
218912865|NCT00897481|GENETIC|gene expression analysis|
218912866|NCT00897481|GENETIC|mutation analysis|
218912867|NCT00897481|OTHER|diagnostic laboratory biomarker analysis|
218912868|NCT00897481|OTHER|immunohistochemistry staining method|
218912869|NCT00897481|PROCEDURE|sentinel lymph node biopsy|
218912870|NCT01456884|BEHAVIORAL|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
219614551|NCT02919189|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
219614552|NCT04469595|DRUG|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
218912871|NCT01456884|BEHAVIORAL|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
218912872|NCT03216525|DRUG|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
218912873|NCT03216525|DRUG|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
218912874|NCT04907682|DRUG|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
218912875|NCT04907682|DRUG|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
218912876|NCT06009562|PROCEDURE|Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
218912877|NCT06251557|OTHER|Lumbopelvic Massage|10 minutes abdominal massage and 10 minutes lower back massage will be applied in each session. It will take 20 minutes in total.
219525768|NCT02289963|DRUG|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
219525769|NCT02289963|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
219525770|NCT02289963|DRUG|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
219525771|NCT00322166|OTHER|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
219525772|NCT00322166|OTHER|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
219525773|NCT00322166|OTHER|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
218912878|NCT06251557|OTHER|Exercise Training|Exercise training will last approximately 10 minutes in each session. In the exercise training, lumbopelvic stabilization exercises (bridge, cat-and-cow and squatting exercises) will be performed for 10 repetitions, lumbopelvic flexibility exercises (child position, happy baby position, adductor muscle stretching, psoas muscle stretching) will be performed for 20 seconds and 5 repetitions, and diaphragmatic breathing exercises will be performed for 5 repetitions in supine, side lying and sitting positions.
218912879|NCT06251557|DEVICE|Pelvic Floor Electromyography (EMG) Biofeedback Therapy|Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
218912880|NCT06251557|BEHAVIORAL|Standard Urotherapy|The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
218912881|NCT00374140|DRUG|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
218912882|NCT06417840|DIETARY_SUPPLEMENT|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (\>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.
218912883|NCT06417840|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control
218912884|NCT05054075|BIOLOGICAL|Marine liquid and fluids|Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
218912885|NCT05054075|BIOLOGICAL|Impregnation|SARS / COVID-19 fluid/liquid - impregnation
218912886|NCT05054075|BIOLOGICAL|Incubation|SARS / COVID-19 fluid-bivalve-incubation
218912887|NCT05054075|BIOLOGICAL|Manipulation|Bivalve Manipulation - Stress inducing
218912888|NCT05054075|BIOLOGICAL|Refrigeration|Refrigerated fluid to check for maintained response
218912889|NCT03220971|OTHER|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
218912890|NCT04576988|BIOLOGICAL|Sotatercept|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
218912891|NCT04576988|DRUG|Placebo|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
218912892|NCT04576988|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
218912893|NCT02547181|BEHAVIORAL|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
218912894|NCT02547181|BEHAVIORAL|Splint|fibreglass splint
218912895|NCT06353594|DEVICE|Primary PCI|Coronary percutaneous revascularization
219041255|NCT05910580|BEHAVIORAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
219041256|NCT02517034|OTHER|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
219525774|NCT01820208|DRUG|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
219525775|NCT01820208|DRUG|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
219614553|NCT04469595|DRUG|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
219525776|NCT04471610|OTHER|Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day|Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
219525777|NCT04140318|DRUG|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
219525778|NCT04140318|DRUG|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
219525779|NCT00269776|DRUG|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
219041257|NCT02517034|OTHER|Quality-of-Life Assessment|Ancillary studies
219525780|NCT00269776|DRUG|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
219525781|NCT00269776|DRUG|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
218912896|NCT01576341|DRUG|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
218912897|NCT04820595|DIAGNOSTIC_TEST|RASS|Richmond Agitation-Sedation Scale
218912898|NCT04820595|DIAGNOSTIC_TEST|CAM-ICU|Confusion Assessment Method for the ICU
218912899|NCT03983733|OTHER|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
218912900|NCT02068924|OTHER|Slow freezing versus vitrification|
218912901|NCT02352480|DEVICE|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
218912902|NCT00617734|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
218912903|NCT00617734|BIOLOGICAL|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
218912904|NCT01844765|DRUG|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
218912905|NCT03371836|DRUG|Clobazam|Clobazam is used as an adjunct medicine for all participants.
219525782|NCT01972165|PROCEDURE|Mini-incision carpal tunnel release|
219525783|NCT01972165|PROCEDURE|Endoscopic carpal tunnel release|
218912906|NCT02847962|OTHER|Corn Soy Blend Plus (CSB+)|
218912907|NCT02847962|OTHER|Corn Soy Blend 14 (CSB14)|
218912908|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 1|
218912909|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 2|
218912910|NCT02847962|OTHER|Red Sorghum Cowpea Blend|
218912911|NCT02847962|OTHER|White Sorghum Soy Blend|
218912912|NCT05638256|DRUG|68Ga-NY104|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
218912913|NCT05196763|BEHAVIORAL|the Supplemental Nutrition Assistance Program-Education|The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
218912914|NCT06073626|BEHAVIORAL|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
218912915|NCT06073626|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
218912916|NCT02973971|OTHER|volumeric MRI|
218912917|NCT01004952|BEHAVIORAL|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
218912918|NCT04897711|BEHAVIORAL|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
218912919|NCT05977413|OTHER|CAC Notification|Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
219041258|NCT02517034|OTHER|Questionnaire Administration|Ancillary studies
219041259|NCT02517034|OTHER|Survey Administration|Ancillary studies
219041260|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
219041261|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
219525784|NCT03776422|BEHAVIORAL|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
219525785|NCT01042522|BIOLOGICAL|Bleomycin Sulfate|Given IV
219525786|NCT01042522|DRUG|Carboplatin|Given IV
219525787|NCT01042522|DRUG|Cisplatin|Given IV
219525788|NCT01042522|DRUG|Etoposide Phosphate|Given IV
219525789|NCT01042522|OTHER|Laboratory Biomarker Analysis|Correlative studies
218912920|NCT05977413|OTHER|Clinician Guideline Reminder|The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
219525790|NCT01042522|DRUG|Paclitaxel|Given IV
218912921|NCT05208944|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
218912922|NCT05208944|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
219041262|NCT04615949|DRUG|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
219041263|NCT04615949|DRUG|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
219525791|NCT00793663|DRUG|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
219525792|NCT00793663|DRUG|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
219525793|NCT00793663|DRUG|Dexamethasone|Intravenous use, 4 mg, single shot
219525794|NCT00793663|DRUG|NaCl|Intravenous use; single shot
219525795|NCT00793663|DRUG|Ondansetron|Intravenous use; 4 mg; single shot
219525796|NCT00793663|DRUG|NaCl|Intravenous use; single shot
219525797|NCT00318812|DRUG|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
219525798|NCT00318812|DRUG|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
219525799|NCT00675935|OTHER|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
219525800|NCT00549718|DRUG|Lurasidone HCl|Once daily
219525801|NCT06163079|BEHAVIORAL|No intervention|No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
219525802|NCT00630149|DRUG|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
219525803|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
219525804|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
218912923|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
218912924|NCT04029233|DEVICE|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
218912925|NCT03678207|OTHER|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
219041264|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
219041265|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
219525805|NCT01825447|DRUG|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
219525806|NCT01825447|DRUG|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
219525807|NCT01825447|DRUG|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
219525808|NCT01507051|DRUG|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
218912926|NCT02367508|BEHAVIORAL|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
219525809|NCT01507051|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
218912927|NCT03226002|DEVICE|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
218912928|NCT03218384|DRUG|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
218912929|NCT03218384|DRUG|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
218912930|NCT03218384|DEVICE|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
218912931|NCT00265694|DRUG|vinorelbine, gemcitabine and carboplatin|
218912932|NCT06239584|PROCEDURE|Biopsies performed via bronchoscopy|An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
218912933|NCT05659108|BEHAVIORAL|CPR|HIGH QUALITY CPR
218912934|NCT02203734|PROCEDURE|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
219041266|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
219041267|NCT03332238|DEVICE|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
219041268|NCT03332238|DEVICE|Ringer's solution|Ringer's solution
219525810|NCT01507051|DRUG|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
219525811|NCT01507051|DRUG|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
219525812|NCT00027053|DRUG|Trazodone|50 to 150 mg qhs
218912935|NCT02203734|PROCEDURE|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
218912936|NCT05759507|PROCEDURE|abdominal surgery|
218912937|NCT02488577|PROCEDURE|Transanal minimally invasive total mesorectal excision|
218912938|NCT02488577|PROCEDURE|transanal minimally invasive locoregional resection|
218912939|NCT05529498|BEHAVIORAL|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
218912940|NCT05529498|BEHAVIORAL|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
218912941|NCT00132392|DRUG|ALGRX 4975|
218912942|NCT00466544|DEVICE|Plasmaknife|
218912943|NCT00466544|DEVICE|Monopolar|
218912944|NCT02078206|OTHER|Neurocognitive stimulation|
218912945|NCT03021200|DEVICE|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
218912946|NCT03660462|DIETARY_SUPPLEMENT|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
218912947|NCT03660462|DIETARY_SUPPLEMENT|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
218912948|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
218912949|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
218912950|NCT00096902|PROCEDURE|Tilt table test|
218912951|NCT05428969|DRUG|Bexmarilimab|Intravenous
218912952|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
218912953|NCT05428969|DRUG|Venetoclax|Oral
218912954|NCT03844347|BEHAVIORAL|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
219041269|NCT05084053|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
219525813|NCT00027053|DRUG|Placebo|
219525814|NCT00080951|DRUG|fluorouracil|
219525815|NCT00080951|DRUG|irinotecan hydrochloride|
219525816|NCT00080951|DRUG|leucovorin calcium|
219525817|NCT00080951|DRUG|oxaliplatin|
219525818|NCT01992991|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
219614554|NCT03599817|BEHAVIORAL|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
218912955|NCT05059652|DEVICE|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
218912956|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
219041270|NCT06581835|DEVICE|Observational|The study objective requires placement of a jugular venous bulb catheter in the right or left jugular venous bulb with ultrasound guidance. A venous and radial arterial line will be placed. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
219041271|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
219041272|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
219060635|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
219525819|NCT05167760|DRUG|Apraclonidine|1-2 drops per eye every 8 hours for 2 weeks
219525820|NCT06093802|DIAGNOSTIC_TEST|Drug-induced Sleep Endoscopy findings (identified obstruction sites)|As described above
219525821|NCT02311361|BIOLOGICAL|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
219525822|NCT02311361|BIOLOGICAL|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
219525823|NCT02311361|RADIATION|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
219525824|NCT05088577|DIETARY_SUPPLEMENT|Whole egg|Daily consumption of two whole eggs during 8 weeks
219525825|NCT05088577|DIETARY_SUPPLEMENT|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
219614555|NCT05548114|PROCEDURE|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
219614556|NCT05548114|PROCEDURE|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic or robotic techniques (preferred) or open technique (if these methods fail), as clinically appropriate.
219614557|NCT06557642|DRUG|Entonox|30 minute inhalation using demand valve and mouthpiece
219614558|NCT06557642|DRUG|Medical Air|30 minute inhalation using demand valve and mouthpiece
219614559|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
219614560|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
219614561|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
218912957|NCT05153837|OTHER|oral water|500 ml oral water
218912958|NCT06155526|OTHER|Activity|patients taking an active rest after swimming sets
218912959|NCT05891431|DEVICE|Untire mobile app|"The Untire app is an mHealth intervention (digitally delivered using a smartphone app).~Untire offers a comprehensive program to help you understand cancer fatigue and gives a physical activity program, stress reduction exercises and tips to manage your energy level."
219060636|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
219060637|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
219525826|NCT05088577|DIETARY_SUPPLEMENT|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
218912960|NCT03573882|DRUG|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
218912961|NCT04921436|PROCEDURE|cardiac surgery|prophylactic use of antibiotic-inhibitors
218912962|NCT04191538|PROCEDURE|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
218912963|NCT04191538|PROCEDURE|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
218912964|NCT04191538|PROCEDURE|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
218912965|NCT04166006|BIOLOGICAL|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
218912966|NCT04166006|DRUG|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
218912967|NCT01253291|DRUG|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
218912968|NCT03826719|BIOLOGICAL|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
218912969|NCT03826719|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains(trivalent)
218912970|NCT06098469|DEVICE|Neurofeedback sessions|10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
219525827|NCT05046860|DRUG|Dalbavancin|"The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg."
218912971|NCT01919528|PROCEDURE|ultrasound|catheterization of the axillary vein under ultrasound guidance
218912972|NCT03808974|OTHER|Educational video|Short educational video describing the mid-urethral sling procedure
218912973|NCT03808974|OTHER|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
218912974|NCT05255575|DRUG|Ertapenem|Patients will receive ertapenem therapy.
218912975|NCT01344915|PROCEDURE|Locked knee brace|
218912976|NCT01344915|PROCEDURE|Locked knee brace|
218912977|NCT03799796|BEHAVIORAL|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
218912978|NCT03373578|DEVICE|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
218912979|NCT05772741|OTHER|Biological sample collection|Collection of biological samples
218912980|NCT05672290|OTHER|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
218912981|NCT05672290|OTHER|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
218912982|NCT04783350|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
218912983|NCT00004100|DRUG|cisplatin|
218912984|NCT00004100|DRUG|gemcitabine hydrochloride|
218912985|NCT00004100|DRUG|vinorelbine tartrate|
218912986|NCT03816033|PROCEDURE|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
218912987|NCT03816033|PROCEDURE|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
219525828|NCT03387072|OTHER|Non interventional study|mental stress test and Blood (or salivary) sample
219525829|NCT02653664|BEHAVIORAL|PsychoEducation|Condition #1
219525830|NCT02653664|BEHAVIORAL|Self-Hypnosis Training|Condition #2
219525831|NCT02653664|BEHAVIORAL|Mindfulness Meditation|Condition #3
219525832|NCT00485472|DRUG|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
219525833|NCT00485472|OTHER|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
218912988|NCT06206447|PROCEDURE|Tunnel-cuffed Catheter|Tunnel-cuffed Catheter in right internal jugular vein
218912989|NCT06206447|PROCEDURE|Non-ccuffed Catheter|Non-ccuffed Catheter in right internal jugular vein
218912990|NCT02254603|DEVICE|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
218912991|NCT02254603|BEHAVIORAL|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
218912992|NCT02432443|BEHAVIORAL|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
218912993|NCT02432443|OTHER|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
218912994|NCT03111823|BEHAVIORAL|Exercise Intervention|Undergo aerobic exercise sessions
218912995|NCT03111823|OTHER|Quality-of-Life Assessment|Ancillary studies
219525834|NCT01789385|DRUG|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
218912996|NCT03111823|OTHER|Questionnaire Administration|Ancillary studies
218912997|NCT03550027|DEVICE|PleurX|Positioning of drainage PleurX
218912998|NCT03550027|DEVICE|Pleurocath|Positioning of drainage Pleurocath
218912999|NCT06209658|DIAGNOSTIC_TEST|breastfeeding education of Teach Back|breastfeeding education simple explanation is given and the woman is asked to explain and practice.
218913000|NCT06209658|OTHER|breastfeeding education simple explanation|breastfeeding education simple explanation
218913001|NCT05968820|BEHAVIORAL|Sleep Health Enhancement Intervention|The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
218913002|NCT04563377|BIOLOGICAL|ChAdOx1.HTI and MVA.HTI|ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu
218913003|NCT02433626|DRUG|COTI2|COTI-2 is a third generation thiosemicarbazone.
218913004|NCT02433626|DRUG|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
219525835|NCT06561399|COMBINATION_PRODUCT|TACE, Lenvatinib combination with Sintilimab sequential radiotherapy|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team
219525836|NCT00403715|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
219525837|NCT02455492|OTHER|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
219525838|NCT01274988|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
219525839|NCT01274988|OTHER|methadone maintenance treatment|methadone maintenance treatment
219525840|NCT02889848|OTHER|Saline|Saline injection
219525841|NCT02889848|DRUG|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
219525842|NCT04438239|OTHER|none, this study is observational|none, this study is observational
219525843|NCT00633594|DRUG|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
219525844|NCT00633594|DRUG|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
218913005|NCT00037167|DEVICE|Exercise poles|
218913006|NCT03905096|DRUG|BI 425809|Film coated tablet
218913007|NCT03905096|DRUG|Donepezil|Film coated tablet
218913008|NCT02016781|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
218913009|NCT02016781|PROCEDURE|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
219525845|NCT00633594|DRUG|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
219525846|NCT03535896|OTHER|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
218913010|NCT05198921|DEVICE|repetitive Transcranial Magnetic Stimulation|"To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~\------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds"
218913011|NCT05198921|DEVICE|sham repetitive Transcranial Magnetic Stimulation|Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
219525847|NCT03535896|DRUG|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
218913012|NCT06044675|DRUG|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
219060638|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
219525848|NCT06293196|OTHER|acupressure|Massage acupoints and non-acupoint areas around the eyes.
219614562|NCT03926351|DIETARY_SUPPLEMENT|Omega-3 capsules|BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
219525849|NCT01887548|OTHER|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
219525850|NCT04207983|COMBINATION_PRODUCT|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
219525851|NCT02851771|OTHER|Nasopharyngeal Swab|
219525852|NCT05539339|OTHER|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
218913013|NCT06044675|BEHAVIORAL|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
219525853|NCT03029663|PROCEDURE|Transurethral resection of the bladder tumour|
219525854|NCT01444703|OTHER|licorice solution|licorice (0.5 g)
219525855|NCT01444703|OTHER|sugar solution|sugar (5 g).
219525856|NCT05585957|DIAGNOSTIC_TEST|INTERLEUKIN 6|role of interleukin 6 in the diagnosis of neonatal sepsis in comparison with the routine diagnostic markers of neonatal sepsis
219525857|NCT04900090|OTHER|Epidemiological study|"* Clinical phenotypic assessment and neurosensory measures~* Biological, genetic and metabolomic evaluation~* Questionnaires (quality of life, gout, life habit, comorbidities)~* Morphological evaluation by Dual-energy CT scan"
219525858|NCT02767232|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
219525859|NCT02767232|DRUG|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
219525860|NCT05737992|OTHER|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
219525861|NCT04168463|DEVICE|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
219525862|NCT02925364|RADIATION|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
218913014|NCT04156373|BEHAVIORAL|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
218913015|NCT05017415|DEVICE|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
218913016|NCT05017415|DEVICE|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
218913017|NCT06999785|BIOLOGICAL|Blood test|a blood test before and after the first oxygen therapy session, as well as after the last session
218913018|NCT01673607|PROCEDURE|Biopsie liver|
219041273|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
219041274|NCT02837432|DRUG|Hydrocortisone acetate|
219041275|NCT02837432|DRUG|Placebo|
219525863|NCT01191320|DRUG|Placebo|Placebo capsule 1x daily for 3 months
219525864|NCT01191320|DRUG|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
219525865|NCT03560544|BEHAVIORAL|Breaking up sitting|"A three-part behaviour change intervention, including:~1. Supportive organisational culture and knowledge of consequence of prolonged sitting~2. Environmental Modification~3. Behavioural Changes"
219525866|NCT02208726|OTHER|Sucrose pillules|Unmedicated sucrose pillules
219525867|NCT02208726|OTHER|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
219525868|NCT01979081|OTHER|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
219525869|NCT04788238|BEHAVIORAL|Dual-Task Zumba Gold|Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
219525870|NCT00365300|DRUG|pantoprazole|
219525871|NCT00365300|DRUG|Placebo|
219525872|NCT03832400|BIOLOGICAL|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
219525873|NCT03832400|DRUG|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
219525874|NCT02859662|PROCEDURE|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
219525875|NCT01179048|DRUG|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
219614563|NCT03926351|DIETARY_SUPPLEMENT|Olive oil|Soft gelatine capsule containing 1000 mg olive oil, refined.
219525876|NCT01179048|DRUG|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
219525877|NCT04343690|BEHAVIORAL|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
219525878|NCT04489264|DRUG|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
219525879|NCT02903888|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
219525880|NCT00060307|DRUG|erlotinib hydrochloride|Given orally
219525881|NCT00060307|OTHER|laboratory biomarker analysis|Correlative studies
219525882|NCT03764709|DEVICE|Vital signs wireless monitoring system|WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
219525883|NCT00528606|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
219525884|NCT00528606|BIOLOGICAL|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
219525885|NCT00020397|BIOLOGICAL|NY-ESO-1 peptide vaccine|
219525886|NCT00020397|BIOLOGICAL|aldesleukin|
219525887|NCT04470180|BEHAVIORAL|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
219525888|NCT04470180|BEHAVIORAL|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
219525889|NCT02332148|DRUG|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
219525890|NCT02332148|DRUG|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
219525891|NCT05173207|DIAGNOSTIC_TEST|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
219525892|NCT00874887|DRUG|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
219525893|NCT00874887|DRUG|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
219614564|NCT04655547|OTHER|Dietary guidance|Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
219614565|NCT04421131|DEVICE|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
219614566|NCT04421131|OTHER|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
219525894|NCT02047071|DEVICE|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
219525895|NCT06083389|BEHAVIORAL|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
219525896|NCT06083389|DEVICE|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
219525897|NCT05813340|PROCEDURE|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
219525898|NCT00959660|BEHAVIORAL|Exercise|walking, treadmill and bicycle exercise
219525899|NCT00959660|DIETARY_SUPPLEMENT|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
219525900|NCT00959660|BEHAVIORAL|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
219525901|NCT00959660|OTHER|Attention Control|control group- continue their previously randomized life style
219525902|NCT00142662|BEHAVIORAL|diet|
219525903|NCT00142662|BEHAVIORAL|financial incentives|
219525904|NCT02600286|DRUG|EllaOne|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
219525905|NCT02600286|DRUG|EllaOne placebo|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
219614567|NCT02015611|DIETARY_SUPPLEMENT|Vitamin D|2,000 IU/ day of Vitamin D3
219614568|NCT02015611|DIETARY_SUPPLEMENT|Placebo|Placebo
219614569|NCT06491537|BEHAVIORAL|Early Time-Restricted Eating (eTRE)|12 weeks of eTRE intervention. Study staff will provide 7 support sessions with brief behavioral support, including evidence based strategies of problem-solving, action planning, and motivational interviewing.
219614570|NCT06491537|BEHAVIORAL|Control|The control group will be instructed to maintain their average eating window for the 12-week period. Study staff will contact participants 7 times to encourage maintenance.
219614571|NCT06141083|DIETARY_SUPPLEMENT|TCI188 Probiotic|take two tablets per day
219614572|NCT06141083|DIETARY_SUPPLEMENT|Placebo|take two tablets per day
219614573|NCT03680677|PROCEDURE|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
219525906|NCT04768309|OTHER|Ex vivo exploration of the effect of a probiotic over precursor indole production|Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
219525907|NCT01805583|OTHER|Acceptance and Commitment Therapy (ACT)|
219525908|NCT01805583|OTHER|workplace intervention (WPI)|
219525909|NCT06324682|DEVICE|Cardiac pacing - Conventional RV pacing|Implantation of devices for cardiac pacing/defibrillation
219525910|NCT06324682|DEVICE|Cardiac pacing - Conduction System Pacing|Implantation of devices for cardiac pacing/defibrillation
219525911|NCT06324682|DEVICE|Cardiac pacing - Cardiac resynchronization therapy (pacing - CRTP - or defibrillation - CRTD)|Implantation of devices for cardiac pacing/defibrillation
219525912|NCT06324682|DEVICE|Cardiac pacing - Epicardial pacing|Implantation of devices for cardiac pacing/defibrillation
219525913|NCT06324682|DEVICE|Cardiac pacing - Leadless pacing|Implantation of devices for cardiac pacing/defibrillation
219525914|NCT00012948|PROCEDURE|Telephone Care|
219525915|NCT01591122|DRUG|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
219525916|NCT01591122|DRUG|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
219525917|NCT03943238|BIOLOGICAL|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of \>10 x10\^6 cells /Kg, 100 x 10\^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10\^6/Kg.
219525918|NCT01297348|DRUG|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
219525919|NCT01297348|DRUG|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
219525920|NCT00000190|PROCEDURE|Parotid Gland|
219525921|NCT05558930|DEVICE|iTBS stimulation|standard iTBS burst pattern:3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals. 600 pulses on both side of cerebellar with an interval of 5 minutes.
219525922|NCT05558930|DEVICE|sham stimulation|Participants receive a sound stimulation with the same pattern with iTBS stimulation,but without magnetic field
219525923|NCT00518830|OTHER|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
218913019|NCT04684888|PROCEDURE|Visumax Femto-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
218913020|NCT04684888|PROCEDURE|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
218913021|NCT03795571|DRUG|Rituximab|Rituximab 375mg/m2，d0
218913022|NCT03795571|DRUG|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
218913023|NCT03795571|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2，d1
218913024|NCT03795571|DRUG|Dexamethasone|Dexamethasone 40mg/d，d1\~d4
218913025|NCT03795571|DRUG|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle
218913026|NCT02755428|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
218913027|NCT00558142|DRUG|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
219525924|NCT00518830|OTHER|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
219525925|NCT05343078|DRUG|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
219525926|NCT01520909|DRUG|Eltrombopag|Thrombopoietin receptor agonist
219525927|NCT01520909|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
219525928|NCT02066207|DRUG|Fenofibrate|
219525929|NCT02066207|DRUG|Atorvastatin|
219525930|NCT01748630|DRUG|dexmedetomidine|
219525931|NCT01748630|DRUG|Midazolam|
219525932|NCT01748630|DRUG|fentanyl|
219525933|NCT02775357|BEHAVIORAL|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
219525934|NCT02775357|BEHAVIORAL|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
219525935|NCT03918486|DEVICE|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
219525936|NCT02792426|DRUG|Research ENDS S-TA-U001|
219525937|NCT02792426|DRUG|Nicorette Inhalator|
219525938|NCT04487132|BEHAVIORAL|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
219525939|NCT04487132|BEHAVIORAL|Recess or lunch time activities|group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
219525940|NCT05508659|DRUG|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
218913028|NCT00558142|DRUG|Visipaque 320|100mls IV dose as single dose
219525941|NCT05508659|DRUG|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
219525942|NCT04865952|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
219525943|NCT04865952|OTHER|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
219525944|NCT00650793|DRUG|Extended Release OROS® Paliperidone|
219525945|NCT03824119|DRUG|Ibuprofen 600 mg|Standard postpartum care (including administration of NSAIDs)
219525946|NCT03824119|OTHER|Standard Postpartum Care without NSAIDs|NSAID administration will be withheld from this group.
219525947|NCT02373319|BEHAVIORAL|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
219525948|NCT02373319|BEHAVIORAL|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
219525949|NCT02373319|BEHAVIORAL|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
219525950|NCT02373319|BEHAVIORAL|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
219525951|NCT00319345|DRUG|Mannitol, Sodium-Lactate|
219525952|NCT04465864|DRUG|Intracanalicular Dexamethasone, 0.4 mg insert|Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
219525953|NCT04383431|PROCEDURE|PACK-CXL|Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.
219525954|NCT00912288|DRUG|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
219525955|NCT00912288|DRUG|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
219525956|NCT03232437|DEVICE|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
218913029|NCT00558142|DRUG|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
218913030|NCT04515771|BEHAVIORAL|PARTNER-MH|The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
218913031|NCT00278343|DRUG|cediranib maleate|30mg given PO, daily
218913032|NCT00278343|OTHER|laboratory biomarker analysis|Correlative studies
218913033|NCT00000385|DRUG|Lithium|Lithium 600 mg to 2700 mg per day
218913034|NCT00000385|DRUG|Placebo|Matching placebo
218913035|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
218913036|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
218913037|NCT01021020|DRUG|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
218913038|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
218913039|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
219525957|NCT04349735|OTHER|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
219525958|NCT04869787|DEVICE|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
219525959|NCT05088252|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
219525960|NCT05088252|DRUG|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
219525961|NCT01675232|OTHER|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
219525962|NCT01675232|OTHER|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
219525963|NCT01453556|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
219525964|NCT02857088|BEHAVIORAL|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
218913040|NCT00879736|OTHER|placebo|
218913041|NCT04625504|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
219525965|NCT02857088|BEHAVIORAL|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
218913042|NCT00948246|DEVICE|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
219525966|NCT02857088|BEHAVIORAL|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
219525967|NCT01985893|DRUG|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
219525968|NCT03205254|OTHER|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
219525969|NCT03205254|OTHER|Fast food diet|four days of participant-scaled isocaloric fast food meals
219525970|NCT00004907|DRUG|busulfan|
218913043|NCT03598036|DRUG|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
218913044|NCT01820299|DRUG|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
219041276|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
218913045|NCT01820299|DRUG|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
219525971|NCT00004907|DRUG|cyclophosphamide|
219525972|NCT00004907|DRUG|etoposide|
218913046|NCT00796939|DEVICE|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
219525973|NCT00004907|PROCEDURE|allogeneic bone marrow transplantation|
219525974|NCT00004907|PROCEDURE|bone marrow ablation with stem cell support|
218913047|NCT00796939|DEVICE|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
219041277|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
219525975|NCT00004907|PROCEDURE|peripheral blood stem cell transplantation|
219525976|NCT00004907|RADIATION|radiation therapy|
219525977|NCT04348162|OTHER|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
219525978|NCT01544127|BEHAVIORAL|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
219614574|NCT03680677|OTHER|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
219614575|NCT03680677|DIAGNOSTIC_TEST|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
219614576|NCT02501928|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
219614577|NCT02501928|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
218913048|NCT00646165|DRUG|Forodesine|
219041278|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
219041279|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en\_index.html) will be distributed in an electronic form and sent via a mobile message.
219060639|NCT04908813|DRUG|HLX22|IV Q3W D1
219060640|NCT04908813|DRUG|Placebo|IV Q3W D1
219525979|NCT01544127|BEHAVIORAL|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
219525980|NCT01544127|OTHER|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
219525981|NCT04083846|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
219525982|NCT04083846|DRUG|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
219525983|NCT04083846|DRUG|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
219525984|NCT04074174|DRUG|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
219525985|NCT04074174|DRUG|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
219525986|NCT04074174|DRUG|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
219525987|NCT00533273|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
219525988|NCT02870920|DRUG|Tremelimumab|
219525989|NCT02870920|DRUG|Durvalumab|
219525990|NCT02870920|OTHER|Best Supportive Care|
219525991|NCT06075173|DIAGNOSTIC_TEST|Resting full-cycle ration (RFR) measurments|RFR and FFR measurements in main vessel and side branch lesions
218913049|NCT01213888|DRUG|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
219525992|NCT03619746|BEHAVIORAL|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
219525993|NCT02867930|DRUG|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
219525994|NCT02867930|DRUG|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
218913050|NCT01213888|DRUG|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
219525995|NCT01799330|PROCEDURE|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
219525996|NCT01799330|OTHER|Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
219525997|NCT03411330|DRUG|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
219525998|NCT03411330|DRUG|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
219525999|NCT03411330|DRUG|Bupivacaine|bupivacaine (0.5%)
218913051|NCT05632159|DRUG|Mg sulphate|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
219526000|NCT04507425|OTHER|Standard of Care - Nasal Cannula|Standard of care. Flexible tube to provide extra oxygen when patients need a little help, but are not in respiratory distress.
219526001|NCT04507425|OTHER|High-flow nasal cannula|Same as nasal cannula, except the oxygen is heated or humidified and the flow is stronger, pushing air into the lungs to help keep the airway open.
219526002|NCT04507425|OTHER|HFNC plus non-invasive ventilation|This method uses HFNC as described above and adds noninvasive ventilation which is similar to CPAP machine and uses a mask rather than having to intubate (putting a tube down your throat to keep your airway from collapsing).
219526003|NCT01303848|OTHER|Blood Sampling|Blood Sampling over 24 hours
219526004|NCT03343730|DIAGNOSTIC_TEST|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
219526005|NCT03343730|DIAGNOSTIC_TEST|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
219526006|NCT05194722|BEHAVIORAL|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
219526007|NCT04414072|PROCEDURE|sleeve gastrectomy with loop bipartition|operations to decrease weight
219526008|NCT00533663|PROCEDURE|Healing Touch|every other week (during their infusion)
219526009|NCT00533663|OTHER|Standard care|Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
219041280|NCT06784882|DEVICE|continuous peripheral nerve block with OnQ pump|For continuous nerve blocks, the infusion pump that will be used are OnQ pumps (Avanos, Alpharetta, GA) and pre-filled with ropivacaine 0.2% and provided by UCSD's Investigational Drug Services.
219526010|NCT00533663|PROCEDURE|guided relaxation|
219526011|NCT02883335|OTHER|Observational registry|
218913052|NCT05632159|DRUG|conventional anaesthesia|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
218913053|NCT03572517|PROCEDURE|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
218913054|NCT03572517|PROCEDURE|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
218913055|NCT00257413|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
218913056|NCT02821234|OTHER|MRI|
218913057|NCT01556022|DEVICE|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
219526012|NCT05205759|DRUG|Bamlanivimab Etesevimab|Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
219526013|NCT05205759|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
219060641|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
219060642|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
219614578|NCT02501928|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
219614579|NCT02501928|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
219526014|NCT05205759|DRUG|Casirivimab-Imdevimab|Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
219526015|NCT00363506|BEHAVIORAL|Serotona Plus and dietary behavior management|
219526016|NCT02433106|OTHER|GAA 15|Neuromuscular injury prevention training
218913058|NCT01556022|DEVICE|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
219526017|NCT02433106|OTHER|Control|Usual training
219526018|NCT02914600|DRUG|Filgotinib|Tablet administered orally once a day
219526019|NCT02914600|DRUG|Placebo|Tablet administered orally once a day
219526020|NCT03088670|DRUG|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
219041281|NCT06784882|DRUG|single injection nerve block|An adductor canal single injection nerve block will be performed per standard of care. The adductor canal will be identified by ultrasound in the short-axis view. The distal aspect of the femoral triangle (and beginning of the adductor canal) will be identified distal to the mid-thigh in the ipsilateral limb. Using ultrasound guidance, a standard Tuohy block needle will be advanced through a skin wheal of lidocaine until its tip is in the hypoechoic area immediately distal saphenous nerve adjacent to the femoral artery. Twenty milliliters of ropivacaine 0.5% will be injected in divided doses with repeated negative aspiration.
219041282|NCT01920932|DRUG|brentuximab vedotin|Given intravenously (IV).
219526021|NCT03088670|DRUG|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
219526022|NCT03088670|DRUG|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
219526023|NCT04819633|OTHER|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
219526024|NCT00454909|BIOLOGICAL|Meningococcal vaccine 134612|Single dose intramuscular injection.
219526025|NCT00454909|BIOLOGICAL|Menactra®|Single dose intramuscular injection.
219526026|NCT05293847|BEHAVIORAL|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
219526027|NCT01500876|RADIATION|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
219526028|NCT05553197|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
219526029|NCT05553197|OTHER|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
218913059|NCT02759614|DRUG|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
219041283|NCT01920932|DRUG|etoposide|Given IV.
219041284|NCT01920932|DRUG|prednisone|Given orally (PO).
219526030|NCT02457520|DRUG|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
219526031|NCT03064880|OTHER|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change \< 10% and maintained for 20 minutes
219526032|NCT05070676|DIAGNOSTIC_TEST|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
219526033|NCT05606562|PROCEDURE|Dental care|Participants will be offered free dental care
219526034|NCT00257673|DRUG|MEM 1003|30 mg twice a day
219526035|NCT00257673|DRUG|MEM 1003|90 mg MEM 1003 twice a day
219526036|NCT00257673|DRUG|Placebo for MEM 1003|Placebo twice a day
218913060|NCT02759614|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
219041285|NCT01920932|DRUG|doxorubicin|Given IV.
219041286|NCT01920932|DRUG|cyclophosphamide|Given IV.
219041287|NCT01920932|DRUG|Dacarbazine(R)|Given IV.
219041288|NCT01920932|DRUG|filgrastim|Given subcutaneously (SQ) as clinically indicated.
219041289|NCT01920932|OTHER|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
219526037|NCT03923465|PROCEDURE|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
219526038|NCT03923465|DEVICE|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
219526039|NCT03923465|DEVICE|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
219526040|NCT01559220|DEVICE|Deep Brain Stimulation|Implanted device
219526041|NCT03429920|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
219526042|NCT03429920|DIETARY_SUPPLEMENT|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
218913061|NCT05834634|DEVICE|Ultrasound|The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
218913062|NCT03005444|DRUG|Rivaroxaban|10mg/day, for 2 years
218913063|NCT00202280|DRUG|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
218913064|NCT00135031|DRUG|Bifidobacterium infantis 35624|
218913065|NCT00551317|DRUG|Darapladib (SB480848)|
219526043|NCT00282048|DRUG|AG-013736 (axitinib)|AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
219526044|NCT02703948|DEVICE|Restylane Silk with Lidocaine|
219526045|NCT01292330|PROCEDURE|nutritional support before operation|nutritional support before operation for more than 4 days
219526046|NCT01327690|BEHAVIORAL|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
219526047|NCT01327690|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
219526048|NCT05320679|OTHER|Implementation of Questionnaire|Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
219526049|NCT02649803|BEHAVIORAL|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
218913066|NCT01870349|PROCEDURE|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
218913067|NCT05924243|DRUG|RO7486967|For up to approximately 28 days
218913068|NCT05924243|DRUG|Placebo|For up to approximately 28 days
218913069|NCT04896866|BEHAVIORAL|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
218913070|NCT04346745|BEHAVIORAL|Peer Mentoring Program|The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
219526050|NCT01002638|OTHER|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
219526051|NCT01002638|PROCEDURE|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
219526052|NCT03522675|DEVICE|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
219526053|NCT04349592|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
219526054|NCT04349592|DRUG|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
219526055|NCT04349592|OTHER|Placebo Tablet|Oral, one tablet three times a day for 7 days
219526056|NCT04349592|OTHER|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
219614580|NCT06243276|PROCEDURE|One stage implant surgery|It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
219614581|NCT06243276|PROCEDURE|Two stage implant surgery|It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
219614582|NCT03435471|OTHER|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
219614583|NCT03435471|OTHER|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
218913071|NCT05625113|DEVICE|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
218913072|NCT06600347|DIETARY_SUPPLEMENT|DASH diet|The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
218913073|NCT06600347|OTHER|Progressive muscle relaxation|The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
219526057|NCT04877080|BIOLOGICAL|Fast Dual CAR-T Injection|Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA. A single infusion of CART cells will be administered intravenously.
219526058|NCT05280262|DIAGNOSTIC_TEST|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
219526059|NCT06303726|PROCEDURE|ACL reconstruction single bundle|We will do surgery of ACL reconstruction with patellar ligament.
219614584|NCT00428272|DRUG|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
219614585|NCT00428272|DRUG|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
219614586|NCT00428272|DRUG|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
219526060|NCT06303726|PROCEDURE|ACL reconstruction double bundle|We will do surgery of ACL reconstruction with hamstring ligament.
218913074|NCT06600347|DRUG|Anti hypertensive drugs|All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
218913075|NCT04199351|DRUG|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
218913076|NCT04199351|DRUG|Placebo|AMG 171 placebo
218913077|NCT01497041|DRUG|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
218913078|NCT01497041|DRUG|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
218913079|NCT04888117|PROCEDURE|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
218913080|NCT04888117|PROCEDURE|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
218913081|NCT06742931|OTHER|Discontinuation of antiplatelet agent group|In this group, antiplatelet monotherapy will be discontinued at the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, all antiplatelet agents will be discontinued after randomization.
218913082|NCT06742931|OTHER|Continuation of antiplatelet agent group|In this group, lifelong antiplatelet monotherapy will be continued after the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, DAPT will be changed to single antiplatelet therapy (aspirin or clopidogrel). The choice between aspirin or clopidogrel will be determined by the physician's discretion.
218913083|NCT03376438|OTHER|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
218913084|NCT05306925|DIETARY_SUPPLEMENT|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
218913085|NCT04511481|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
218913086|NCT05657340|DIAGNOSTIC_TEST|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
219041290|NCT01920932|RADIATION|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
219041291|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
219041292|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
219041293|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
219041294|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
219041295|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
219060643|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
219526061|NCT02763865|DEVICE|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
219526062|NCT02763865|DEVICE|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
219526063|NCT02758691|DRUG|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
219614587|NCT00428272|DRUG|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
218913087|NCT00492245|PROCEDURE|PTK with mitomycin in Adenoviral Opacities|
218913088|NCT03365102|DEVICE|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
218913089|NCT03365102|DEVICE|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
218913090|NCT03365102|DEVICE|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
219041296|NCT02311465|OTHER|Palliative Care|"Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
219060644|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
219060645|NCT06364826|RADIATION|IMRT|IMRT
219526064|NCT02758691|DRUG|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
219526065|NCT00696020|DRUG|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
219526066|NCT00696020|DRUG|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
219526067|NCT00696020|DEVICE|Respimat® Inhaler|
219526068|NCT01933373|PROCEDURE|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
219526069|NCT01933373|PROCEDURE|Dor|Anterior partial fundoplication plus myotomy.
219526070|NCT01387022|DRUG|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
219526071|NCT06340139|OTHER|conventional treatment|conventional treatment with Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage
219526072|NCT06340139|OTHER|experimental treatment|1 being a fixation point and phase 2 including head and eye movements
219526073|NCT01237522|DRUG|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
219526074|NCT04869722|BEHAVIORAL|Liquid Model|Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
219526075|NCT04869722|BEHAVIORAL|Solid Model|Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
219526076|NCT04195022|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
219526077|NCT04195022|PROCEDURE|Dental Restoration with Bulk fill resin composite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with bulk fill resin composite.
219526078|NCT05311501|OTHER|Non-surgical periodontal treatment|Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
219526079|NCT00388544|BEHAVIORAL|Activity matched to interest|Recreational activities are tailored to subject's style of interest
219526080|NCT00388544|BEHAVIORAL|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
219526081|NCT00388544|BEHAVIORAL|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
219526082|NCT02076022|DEVICE|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
218913091|NCT00474487|BIOLOGICAL|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
218913092|NCT00474487|BIOLOGICAL|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
218913093|NCT00474487|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
218913094|NCT00474487|BIOLOGICAL|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
219526083|NCT02076022|PROCEDURE|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
219526084|NCT02462317|DRUG|botulinum A toxin|botulinum toxin injection
219526085|NCT02462317|DRUG|Baclofen|baclofen oral tablet
219526086|NCT02462317|DRUG|Placebo toxin|placebo injection
218913095|NCT00331201|DRUG|SAFEstart|
218913096|NCT05093855|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
218913097|NCT04323696|PROCEDURE|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
218913098|NCT02228707|DRUG|BIIB061|Participants receive BIIB061
218913099|NCT02228707|OTHER|Placebo|Matched placebo
218913100|NCT00297544|DRUG|Viagra|
218913101|NCT06129240|COMBINATION_PRODUCT|LIQ861|trepostinil inhalation powder
218913102|NCT01488045|DRUG|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
218913103|NCT01488045|DRUG|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
219614588|NCT00556868|OTHER|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
219614589|NCT05122169|DRUG|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
218913104|NCT01488045|DRUG|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
218913105|NCT05043363|DEVICE|LumenEye X1 digital rectoscope|The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
218913106|NCT00989911|DRUG|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
218913107|NCT01380353|DRUG|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
218913108|NCT01472640|DRUG|liraglutide|1.8 mg sc QOD
218913109|NCT01472640|DRUG|placebo|1 U sc QOD
219526087|NCT02462317|DRUG|placebo baclofen|placebo oral tablet
219526088|NCT00312663|BIOLOGICAL|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
219614590|NCT05122169|DRUG|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
219614591|NCT01059656|DRUG|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
218913110|NCT04675970|OTHER|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
218913111|NCT02096445|DEVICE|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
218913112|NCT02096445|OTHER|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
218913113|NCT01874236|DRUG|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
219526089|NCT05326841|DRUG|Vitamin D3|cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks
219526090|NCT02426710|DEVICE|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
219526091|NCT04048369|DIAGNOSTIC_TEST|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
219526092|NCT00601302|DRUG|Amlodipine|
219526093|NCT04927208|OTHER|exercise and nutritional support|"resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks"
219526094|NCT05956366|BEHAVIORAL|Family-based treatment|Open-end family therapy ad modum The Maudsley model
219526095|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
219526096|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
219526097|NCT01577303|BEHAVIORAL|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
219526098|NCT01577303|BEHAVIORAL|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
219526099|NCT01577303|BEHAVIORAL|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
219526100|NCT01577303|BEHAVIORAL|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
219526101|NCT00599664|DRUG|OMS201|OMS201 irrigation solution during surgery
219526102|NCT00599664|DRUG|Vehicle|Vehicle irrigation solution during surgery
219526103|NCT02038608|DEVICE|PET|
219526104|NCT05275179|OTHER|Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
219526105|NCT03241784|BIOLOGICAL|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
219526106|NCT03241784|BIOLOGICAL|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
219614592|NCT00189124|DRUG|Dehydroepiandrosterone (DHEA)|
218913114|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
218913115|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
219060646|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
219060647|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
219060648|NCT00766415|DRUG|Placebo|Placebo
218913116|NCT05842616|OTHER|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
218913117|NCT05842616|OTHER|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
218913118|NCT00002298|DRUG|Ribavirin|
218913119|NCT00736541|DRUG|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
218913120|NCT05494840|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
218913121|NCT03405792|DRUG|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
218913122|NCT03405792|DEVICE|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
219526107|NCT04005859|DRUG|Exparel|"2\. Liposomal bupivacaine TAP block (experimental arm)~1. Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~2. A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~3. The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~4. Adhesive tapes will be applied at the level of the TAP block puncture sites."
219526108|NCT04005859|DRUG|IV Lidocaine|"1\. Intravenous Lidocaine infusion (control arm, current standard of care)~1. 100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~2. 1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~3. Adhesive tapes will be applied at the presumed level of TAP block puncture sites."
218913123|NCT03405792|DRUG|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
219526109|NCT03341585|OTHER|expiration lente prolongée|l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
219526110|NCT04772807|DEVICE|Kinocardiograph|Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
219526111|NCT04879888|BIOLOGICAL|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
219526112|NCT00535054|DRUG|Tears Again|Liposome Eye Spray
219526113|NCT00097383|DRUG|ALIMTA plus Epirubicin|
219526114|NCT00122577|DRUG|Tenofovir|
219526115|NCT00122577|DRUG|Atazanavir|
219526116|NCT00122577|DRUG|Ritonavir|
219526117|NCT01259583|PROCEDURE|CO2|CO2 insufflation
219526118|NCT01259583|PROCEDURE|Warm water|warm water irrigation
219526119|NCT03080597|DEVICE|PrEP Smart app|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart."
219526120|NCT00122798|PROCEDURE|Stroke treatment|
219526121|NCT03331497|PROCEDURE|Tonsillotomy|About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
219526122|NCT03250286|DEVICE|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
219041297|NCT04667403|OTHER|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
219041298|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
219526123|NCT03250286|DEVICE|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
219526124|NCT04321850|DRUG|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
219526125|NCT04321850|DRUG|Placebo oral tablet|The tablets were manufactured specifically for this study.
219526126|NCT02719223|DEVICE|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
219526127|NCT02712827|PROCEDURE|Progrip|Self-fixating mesh
219041299|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
219041300|NCT05226286|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Stimulation of the tibial nerve using Medtronic's tibial neuromodulation device.
219041301|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
219041302|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
219526128|NCT02712827|PROCEDURE|Non-Progrip|Non self-fixating mesh with the use of glue
219526129|NCT06272331|OTHER|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink
219526130|NCT06272331|OTHER|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
219526131|NCT06272331|OTHER|Cow's milk|Ingestion of cow's milk
219526132|NCT01530620|DRUG|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
219526133|NCT01530620|DRUG|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
219041303|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
219041304|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
219041305|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
219041306|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
219041307|NCT04561076|DRUG|HLX70|Single-dose, intravenous infusion
219041308|NCT04561076|OTHER|Placebo|Single-dose, intravenous infusion
219041309|NCT05466019|DRUG|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
219526134|NCT04517162|DRUG|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
219526135|NCT03639662|OTHER|sophrology sessions|"Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
219526136|NCT00817960|DRUG|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
219614593|NCT00858494|DRUG|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
219614594|NCT04937140|DIAGNOSTIC_TEST|14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients|assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
219614595|NCT05354037|PROCEDURE|Enamel matrix derivative application for treatment of intrabony defects|EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
219614596|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
219614597|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
219614598|NCT03442556|DRUG|Carboplatin|Given IV
219614599|NCT03442556|DRUG|Docetaxel|Given IV
219614600|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
219614601|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
219614602|NCT03442556|DRUG|Rucaparib|Given PO
219614603|NCT06484556|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
219614604|NCT06484556|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
219614605|NCT03427736|DRUG|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
219041310|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
219041311|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
219041312|NCT06955338|PROCEDURE|Music intervention|The music for the study will be the 'MusiCure® 9 Scandinavia' compositions specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) (MusiCure, 2024). The compositions include melodies with harp, cello, strings and sounds from nature (birds, forest and night sounds) in a soft rhythm between 60-80 bpm for relaxation, based on research into the acoustic environment of hospitals and shown to have a positive effect on patients' symptoms such as pain, fear and anxiety. Two minutes after the child starts listening to the music, oral mucositis care will be started. Five minutes after the end of the procedure, the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale will be applied and the duration of the procedure will be recorded.
219041313|NCT06955338|PROCEDURE|Virtual reality|In this group, children will be shown a short film with virtual reality glasses. In the study, the short film 'MusiCure® The Journey' specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) will be preferred in the virtual reality group. The duration of the film is 16 minutes (MusiCure, 2024). Two minutes after the child starts watching the film, oral mucositis care will be started. Five minutes after the end of the procedure, the duration of the procedure will be recorded by applying the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale.
219041314|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
219041315|NCT02400723|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
219041316|NCT02400723|BEHAVIORAL|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
219614606|NCT03427736|DRUG|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
219614607|NCT03427736|DRUG|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
219614608|NCT03427736|DRUG|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
219614609|NCT03427736|DRUG|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
219614610|NCT04941131|DRUG|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
218913124|NCT06070883|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
218913125|NCT04670588|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
219526137|NCT02829762|OTHER|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
219526138|NCT02360462|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
219526139|NCT02360462|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
219526140|NCT02722980|DIETARY_SUPPLEMENT|Placebo|The intervention consists of capsules containing placebo.
219526141|NCT02722980|DIETARY_SUPPLEMENT|: Probiotic capsules|The intervention consists of capsules containing probiotics.
218913126|NCT06208969|BEHAVIORAL|intensive nutrition counseling|individualized regular nutrition education
219041317|NCT02400723|OTHER|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
219526142|NCT00301366|DRUG|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
219526143|NCT03212573|COMBINATION_PRODUCT|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
219526144|NCT03212573|COMBINATION_PRODUCT|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
219526145|NCT05567965|OTHER|Home care intervention|The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
219526146|NCT01510730|DRUG|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
219614611|NCT06586827|OTHER|VCU-RRTC Online Course|"Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment"
219614612|NCT06586827|OTHER|Zoom Technical Assistance Sessions (6 total)|Technical Assistance sessions will be provided to small groups of participants of 5-7 via Zoom technology. There will be one virtual TA session for each of the six modules that will last for 1 hour. The TA sessions will be provided by a trained SE expert/ mentor. The TA sessions will have instructional plans so that they are delivered consistently and will align with the associated module's content and will entail application and discussion that facilitates implementation and reflection of the material.
219614613|NCT06983925|DRUG|GS1-144 Tablet with new preparation (T)|GS1-144 Tablet with new preparation (T)
219614614|NCT06983925|DRUG|GS1-144 Tablet with present preparation (R)|A single oral dose of GS1-144 Tablet with present preparation
219526147|NCT05037422|PROCEDURE|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
219526148|NCT01371786|DRUG|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
219526149|NCT01371786|DRUG|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
219526150|NCT03694665|OTHER|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
219526151|NCT02549092|DRUG|Optimized Medical Treatment|Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.
219526152|NCT02549092|DRUG|Levodopa-Carbidopa Intestinal Gel|
219614615|NCT02782663|DRUG|ABT-494|Tablet: Oral
219614616|NCT05531812|OTHER|G2R with individual coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
219526153|NCT02549092|DEVICE|Nasojejunal (NJ) tube|optional prior to PEG-J placement
219526154|NCT02549092|DEVICE|Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube|
219526155|NCT03463369|BIOLOGICAL|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
219526156|NCT03463369|BIOLOGICAL|Placebo|Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
219526157|NCT03463369|DRUG|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
218913127|NCT05405062|DEVICE|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
219526158|NCT04540523|BEHAVIORAL|Exergaming intervention group|In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
219526159|NCT04540523|BEHAVIORAL|Traditional physical activity comparison|Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
219526160|NCT05345236|DRUG|Aflibercept|Intravitreal (IVT) injection
218913128|NCT05338684|DEVICE|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
218913129|NCT05720182|DEVICE|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg."
218913130|NCT05720182|PROCEDURE|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
219526161|NCT00838149|DIETARY_SUPPLEMENT|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
219614617|NCT05531812|OTHER|G2R with group coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
219614618|NCT05276050|DEVICE|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
219614619|NCT05276050|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
219614620|NCT06983821|DRUG|Cyclophosphamide|IV Cyclophosphamide 15mg/kg/dose (age and eGFR adjusted), 2 doses 2 weeks apart
219614621|NCT06983821|DRUG|Standard of Care (SOC)|Participants will receive standard of care induction agent and glucocorticoid taper, at investigator discretion
219614622|NCT06983821|DRUG|Prednisone|4 weeks prednisone taper
219614623|NCT06983821|DRUG|Rituximab (R)|Rituximab infusions, dosing and schedule at clinician/investigator discretion
219614624|NCT05806840|BEHAVIORAL|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
219614625|NCT05806840|BEHAVIORAL|Standard Implementation|Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
219614626|NCT06200831|PROCEDURE|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
219041318|NCT00506090|PROCEDURE|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
219526162|NCT00838149|DIETARY_SUPPLEMENT|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
219526163|NCT04713137|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water.
219526164|NCT04713137|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
219526165|NCT04713137|DIETARY_SUPPLEMENT|Sucralose|0.0558g sucralose dissolved in 300mL tap water.
219526166|NCT04713137|DIETARY_SUPPLEMENT|Water|300mL tap water.
219526167|NCT02170311|DRUG|Z-213|
219526168|NCT01790347|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week."
219526169|NCT01434147|DRUG|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
218913131|NCT05720182|OTHER|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
218913132|NCT04282486|OTHER|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
218913133|NCT00770263|DRUG|Erlotinib|
218913134|NCT00770263|DRUG|Temsirolimus|
218913135|NCT05134584|DRUG|Linaclotide|290μg once daily, 4 weeks
218913136|NCT05134584|DRUG|Lactulose|20mL once daily, 4 weeks
218913137|NCT05134584|DRUG|Omeprazol|20mg twice daily for the first 10 days
218913138|NCT05134584|DRUG|Itopride|50mg three times daily for the first 10 days
218913139|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913140|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913141|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913142|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913143|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913144|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913145|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913146|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
218913147|NCT00941746|BIOLOGICAL|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
218913148|NCT01735422|DRUG|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
219614627|NCT06200831|PROCEDURE|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
218913149|NCT01735422|DRUG|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
218913150|NCT01735422|DRUG|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
219041319|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
219614628|NCT03577782|BIOLOGICAL|Entyvio (Vedolizumab)|"1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
219614629|NCT06247410|DRUG|Rotigotine 8Mg/24Hrs Patch|Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
219041320|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
219041321|NCT00004258|DRUG|cilengitide|dose escalation of cilengitide
219041322|NCT06323252|DIETARY_SUPPLEMENT|MastihaOil|1 soft gel capsule of Mastiha oil every day for 3 months
219526172|NCT04128943|OTHER|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
219526173|NCT04128943|OTHER|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
219526174|NCT04128943|OTHER|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
219526175|NCT04128943|OTHER|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
219526176|NCT00743964|DRUG|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
219526177|NCT00743964|DRUG|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
219526178|NCT02511782|DEVICE|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
219526179|NCT03702894|DRUG|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
218913151|NCT06069193|BEHAVIORAL|Touch Intervention|"The participants will be examined, with various areas in the neck and upper back being palpated. Subsequently, the exercises to be performed at home will be demonstrated by the experimenter. The experimenter will ensure correct execution by touching specific areas in the neck and upper back of the participants. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
219526180|NCT03702894|DRUG|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
219526181|NCT03982862|DRUG|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
219526182|NCT03982862|DRUG|Lidocaine|0.1ml 2% Xylocaine
219526183|NCT03982862|DRUG|Botulinum toxin A|4U Botox® diluted to 0.1 ml
219526184|NCT01623726|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
219526185|NCT03627091|DRUG|Ontamalimab|SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
219526186|NCT03627091|OTHER|Placebo|SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
219041323|NCT06323252|BEHAVIORAL|nutritional counsel|nutritional counsel
219041324|NCT05785364|DEVICE|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
219041325|NCT02674412|DRUG|Buspirone|
219041326|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
219526187|NCT01603862|PROCEDURE|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
219526188|NCT05526573|DEVICE|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
219526189|NCT01723748|DRUG|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
219526190|NCT05375604|DRUG|CDK-004|ASO-STAT6 exosome administered Intravenously
219526191|NCT05398718|DRUG|Sotrovimab|collect local clinical evidence for sotrovimab effect in the real-life setting
219060649|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
219526192|NCT02356302|DEVICE|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
219526193|NCT02356302|DEVICE|MK-2048 IVR|Contains 30 mg MK-2048.
219526194|NCT02356302|DEVICE|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
219526195|NCT02356302|DEVICE|Placebo IVR|
219526196|NCT03959683|DEVICE|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
219526197|NCT03959683|DEVICE|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
219526198|NCT03352518|DEVICE|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
219526199|NCT00518518|DRUG|Staloral 300|Staloral 300
219526200|NCT00518518|DRUG|placebo|placebo
219526201|NCT02495467|DRUG|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
219526202|NCT02495467|DRUG|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
219526203|NCT06486129|PROCEDURE|Noninvasive ventilation volume targetted|he aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (BiPAP) on cardiac parameters and myocardial biomarkers in patients with OHS
219526204|NCT01392430|OTHER|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
219526205|NCT05184426|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
219526206|NCT05184426|DIAGNOSTIC_TEST|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
219526207|NCT05184426|DIAGNOSTIC_TEST|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
219526208|NCT05184426|DIAGNOSTIC_TEST|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
219526209|NCT04770857|OTHER|Visual analogue scale|Post procedural pain assessment using the visual analogue scale (VAS) will be performed in patients undergoing ERCP
219526210|NCT02324725|DRUG|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
219526211|NCT01376167|DRUG|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
219526212|NCT01376167|DRUG|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
218913152|NCT06069193|BEHAVIORAL|Control|"The participants will be examined, and they will be asked to describe as accurately as possible the regions where they experience pain. Subsequently, the experimenter will demonstrate the exercises to be performed at home. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
218913153|NCT03905018|DRUG|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
219526213|NCT01376167|DRUG|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
219614630|NCT04097340|DEVICE|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
219614631|NCT04097340|DEVICE|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
219614632|NCT06340997|DEVICE|Transesophageal echocardiography|"* D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)"
219614633|NCT03106428|DRUG|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
219614634|NCT06568224|DRUG|Mesalazine|oral mesalazine 1g qid
219614635|NCT02810925|PROCEDURE|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
218913154|NCT04232722|DRUG|Arsenicals|As4 S4
218913155|NCT05910684|DIAGNOSTIC_TEST|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
219060650|NCT01312467|DRUG|metformin hydrochloride|
219526214|NCT01376167|DRUG|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
219526215|NCT01376167|DRUG|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
219526216|NCT01376167|DRUG|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
219526217|NCT01376167|DRUG|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
219526218|NCT01376167|DRUG|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
219526219|NCT01376167|DRUG|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
219526220|NCT01376167|DRUG|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
219526221|NCT01376167|DRUG|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
219526222|NCT03064334|PROCEDURE|Total Knee Arthroplasty|surgical knee joints Arthroplasty
219526223|NCT01357863|DRUG|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
219526224|NCT01319123|DEVICE|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
219526225|NCT02646865|BEHAVIORAL|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
219526226|NCT02646865|BEHAVIORAL|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol
219614636|NCT02810925|PROCEDURE|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
219526227|NCT01757600|OTHER|Microperimetry|
219614637|NCT02810925|DIETARY_SUPPLEMENT|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
219614638|NCT02810925|DIETARY_SUPPLEMENT|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
219526228|NCT01826409|DIETARY_SUPPLEMENT|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
219526229|NCT01826409|DIETARY_SUPPLEMENT|Placebo|Placebo 2.7g/day for 4 weeks
219526230|NCT01139320|GENETIC|DNA analysis|
219526231|NCT01139320|GENETIC|polymerase chain reaction|
218913156|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
219526232|NCT01139320|OTHER|laboratory biomarker analysis|
219526233|NCT01139320|OTHER|pharmacological study|
219526234|NCT05439148|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
219526235|NCT03541941|DRUG|Exparel|Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
219526236|NCT03541941|DRUG|Bupivacaine Hcl 0.25% Inj|Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
219526237|NCT03541941|DRUG|Placebo|Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
219526238|NCT01486147|BEHAVIORAL|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
219526239|NCT01486147|BEHAVIORAL|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
219526240|NCT00202605|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
219526241|NCT04658745|DEVICE|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
219614639|NCT01306266|DRUG|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
219614640|NCT01306266|DRUG|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
218913157|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
218913158|NCT03614182|DEVICE|physical training concurrent with cognitive training|The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
219526242|NCT04658745|BEHAVIORAL|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
219526243|NCT04658745|DEVICE|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
219526244|NCT04658745|BEHAVIORAL|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
219526245|NCT03325426|DEVICE|FitBit|Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
219526246|NCT01173692|DRUG|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
219526247|NCT01173692|DRUG|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
219526248|NCT01240291|DIETARY_SUPPLEMENT|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
219526249|NCT01240291|DIETARY_SUPPLEMENT|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
219526250|NCT05658783|OTHER|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
219526251|NCT05672264|OTHER|Whole-Body Electromyostimulation|Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.
219526252|NCT05672264|OTHER|Physiotherapy|Six standardised physiotherapy sessions (20 min each)
219614641|NCT00838526|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
219614642|NCT00838526|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
219526253|NCT00196651|DRUG|IL-2|
219526254|NCT00196651|BIOLOGICAL|LIPO-6T|
219526255|NCT00196651|BIOLOGICAL|ALVAC VIH 1433|
219526256|NCT03785301|DEVICE|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
218913159|NCT03614182|DEVICE|physical training followed by cognitive training|The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
219526257|NCT05200663|DRUG|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
219526258|NCT05200663|DRUG|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
219526259|NCT01842750|DEVICE|Endorectal Balloon insertion|
219526260|NCT00678639|OTHER|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
219526261|NCT03611608|DRUG|LY3316531|Administered IV
218913160|NCT03614182|DEVICE|physical training without cognitive training|The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
218913161|NCT03882021|PROCEDURE|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
218913162|NCT02485873|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
218913163|NCT02485873|DRUG|Vitamin K antagonists|As prescribed by treating physicians
218913164|NCT05018000|BEHAVIORAL|Financial navigation|The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.
218913165|NCT05018000|BEHAVIORAL|Enhanced usual care|The financial resource sheet lists and describes existing internal and community resources available to KP members
218913166|NCT05255679|DEVICE|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
219041327|NCT03125512|DEVICE|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
219526262|NCT03611608|DRUG|Placebo|Administered IV
219526263|NCT00045877|DRUG|Recombinant Human Interleukin-2 and Rituximab|
219526264|NCT03679377|DEVICE|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
219526265|NCT05796310|DIAGNOSTIC_TEST|Salivary collection|Collection of saliva via swab for miRNA processing
219614643|NCT00972790|PROCEDURE|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
219614644|NCT02287181|DRUG|Remifentanil|short acting opiate
219614645|NCT02287181|DRUG|Propofol|hypnotic drug
219614646|NCT02287181|OTHER|Bispectral index|electroencephalograph
218913167|NCT05255679|DEVICE|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
219041328|NCT03125512|DEVICE|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
219041329|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
219614647|NCT03455088|BEHAVIORAL|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
219614648|NCT03455088|DRUG|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
219614649|NCT00520897|DRUG|Raltegravir (MK0518)|400mg BID; 48 weeks
219041330|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
219526266|NCT05796310|DIAGNOSTIC_TEST|eye-tracking recorder|Administration of eye-tracking session recording Saccadic Eye Movements, fixation duration and pupillary response.
219526267|NCT05796310|DIAGNOSTIC_TEST|neuropsychological assessment|Administration of neuropsychological tests and collected patient medical history
219526268|NCT03803865|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
219526269|NCT03803865|BEHAVIORAL|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
219614650|NCT00520897|DRUG|Placebo|400mg QD
219614651|NCT00520897|PROCEDURE|Leukopheresis|pack of cells as per protocol
219614652|NCT00520897|PROCEDURE|Sigmoid Biopsy|gut samples as per protocol
219526270|NCT05622461|BEHAVIORAL|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
219526271|NCT05898919|OTHER|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
219526272|NCT05898919|OTHER|Sham acupuncture|Participants will receive sham acupuncture at sham points.
219526273|NCT05898919|DRUG|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
218913168|NCT04151212|DRUG|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
218913169|NCT00270881|PROCEDURE|Cord blood transplantation|unrelated cord blood transplantation
218913170|NCT00270881|RADIATION|TBI|Total body irradiation (TBI) 12Gy
218913171|NCT00270881|DRUG|cyclophosphamide|cyclophosphamide 120mg/kg
218913172|NCT00270881|DRUG|cytarabine|cytarabine 3g/m2x4
218913173|NCT02251262|DEVICE|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
218913174|NCT00939549|DRUG|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
218913175|NCT04100083|DRUG|Spironolactone 50 MG|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
218913176|NCT04100083|DRUG|Spironolactone 100mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
218913177|NCT04100083|DRUG|Spironolactone 200 mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
218913178|NCT03889184|OTHER|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
218913179|NCT02682953|DRUG|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
219526274|NCT01866449|DRUG|Cabazitaxel|
219526275|NCT03090932|OTHER|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
219614653|NCT06577207|OTHER|Initial investigations for all cases|Initial investigations for all cases: 1. Pulse oximetry. 2. Complete blood count. 3. Electrolytes. 4. Kidney function test. 5. Random blood glucose 6. Other investigations ordered for certain cases according to clinical manifestation \& previous findings \> Lines of treatment will be recorded
218913180|NCT02682953|PROCEDURE|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
218913181|NCT02682953|DRUG|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
218913182|NCT00971659|DRUG|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
218913183|NCT00971659|DRUG|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
218913184|NCT00971659|DRUG|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
219041331|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
219526276|NCT01671514|DIETARY_SUPPLEMENT|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
219526277|NCT01671514|OTHER|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
219526278|NCT02099981|DRUG|Aminoguanidine|
219526279|NCT04342481|OTHER|Educational Screening tool|Educational Screening tool
219614654|NCT00348829|PROCEDURE|mitral valve repair|surgical mitral valve repair
219614655|NCT05643872|DRUG|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
219614656|NCT05698433|OTHER|No intervention|No intervention
219614657|NCT02680951|DRUG|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
219526280|NCT03609983|OTHER|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
218913185|NCT05873049|DEVICE|MolecuLight|MolecuLight is a handheld fluorescence imaging device that is utilized to help real-time visualize clinically undetectable fluorescent bacteria in wounds. It emits a 405 nm wavelength of safe violet light, which interacts with the wound tissue and bacteria causing certain bacteria to emit red or cyan fluorescence. The fluorescence signals were then captured by MolecuLight and those with bacteria at levels of ≥ 10\^4 colony forming units per gram (CFU/g) will be detected and displayed on the screen.
219526281|NCT03609983|OTHER|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
219526282|NCT00986245|DRUG|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
219526283|NCT00132262|BEHAVIORAL|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
219526284|NCT00132262|BEHAVIORAL|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
219526285|NCT06558162|BEHAVIORAL|Mindfetalness|"They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks."
219526286|NCT06558162|BEHAVIORAL|Sadovsky|"They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month"
219614658|NCT02680951|DRUG|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
219614659|NCT02680951|DRUG|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
219614660|NCT02680951|DRUG|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
219614661|NCT02680951|DRUG|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
218913186|NCT03011268|OTHER|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
219041332|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
219041333|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
219614662|NCT06328465|DIAGNOSTIC_TEST|Diffusion whole body MRI|Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
219614663|NCT03051477|DRUG|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
219614664|NCT01320293|DRUG|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
219614665|NCT01160328|DRUG|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
218913187|NCT03011268|OTHER|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
219041334|NCT00698269|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219041335|NCT00698269|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219526287|NCT02816788|BEHAVIORAL|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
219526288|NCT05519800|DIETARY_SUPPLEMENT|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
219526289|NCT05519800|DIETARY_SUPPLEMENT|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
219526290|NCT02158494|DEVICE|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
219526291|NCT02158494|DEVICE|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
218913188|NCT04244448|DRUG|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
218913189|NCT04244448|DRUG|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
218913190|NCT04244448|DRUG|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
219041336|NCT00698269|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219041337|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
219041338|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
219041339|NCT02889094|OTHER|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
219041340|NCT00697346|DRUG|Alisertib|Alisertib (MLN8237) PIC or ECT
219526292|NCT01214850|BIOLOGICAL|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
219526293|NCT01214850|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
219526294|NCT01214850|BIOLOGICAL|Japanese Encephalitis vaccine|
219526295|NCT05293353|OTHER|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
219526296|NCT06245278|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|A total of 60 individuals, 15 with IBD and periodontitis, 15 with IBD and periodontal health, 15 with systemic health and periodontitis, and 15 with systemic and periodontal health, will be included in the study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and serum, saliva and gingival samples will be obtained from all individuals. Individuals with periodontitis will receive non-surgical periodontal treatment in half jaws within 2 weeks. Clinical measurements, serum and saliva sample collection will be repeated 3 months after the treatment. Biomarker levels in serum and saliva samples will be analysed by ELISA.
219526297|NCT06812403|DEVICE|the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
219526298|NCT03968718|BEHAVIORAL|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
219526299|NCT03664908|OTHER|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
219614666|NCT01160328|DRUG|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
219041341|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
219041342|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
219041343|NCT01381861|BIOLOGICAL|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
219041344|NCT04914910|DEVICE|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
219041345|NCT02530424|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
219041346|NCT02530424|DRUG|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
219041347|NCT02530424|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
219041348|NCT02530424|DRUG|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
219041349|NCT03221933|BIOLOGICAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
219041350|NCT03221933|BIOLOGICAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
219526300|NCT04659915|DRUG|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
219526301|NCT04659915|DRUG|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
219526302|NCT01844219|PROCEDURE|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
219526303|NCT02392897|BEHAVIORAL|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
219526304|NCT02392897|BEHAVIORAL|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
219526305|NCT02576925|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
219526306|NCT06075667|DRUG|Tirzepatide|Administered SC
218913191|NCT00601224|BEHAVIORAL|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
219526307|NCT06075667|DRUG|Placebo|Administered SC
219526308|NCT01229852|DEVICE|DSF-rTMS|Effective Transcranial Magnetic Stimulation
219526309|NCT04478019|DRUG|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
219526310|NCT01955590|BEHAVIORAL|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
218913192|NCT00601224|BEHAVIORAL|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
218913193|NCT04162288|OTHER|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
219041351|NCT06402188|DEVICE|ColoSeal ICD Device|The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
219041352|NCT00017706|BEHAVIORAL|physician-delivered weight control|
219526311|NCT01955590|BEHAVIORAL|EMDR|8-12 sessions of manualized EMDR
219614667|NCT01823367|BEHAVIORAL|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
219614668|NCT05944146|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
219041353|NCT02244203|DRUG|BI 60732|
219041354|NCT02244203|DRUG|Placebo|
219526312|NCT01955590|BEHAVIORAL|Treatment as usual|8-12 sessions of treatment of usual
219526313|NCT02849652|BEHAVIORAL|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
219526314|NCT02849652|BEHAVIORAL|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
219526315|NCT06039982|OTHER|no intervention|no intervention
219526316|NCT01416246|PROCEDURE|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is \< or = to 50 and/or age \> 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
219614669|NCT05944146|DRUG|Dobutamine|infusion dobutamine
219041355|NCT03383328|DRUG|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
219614670|NCT04343131|BEHAVIORAL|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
219614671|NCT01026246|DRUG|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
218913194|NCT04162288|OTHER|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
218913195|NCT05665634|DEVICE|Concurrent transcranial magnetic stimulation and electroencephalogram|Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
218913196|NCT00217984|OTHER|Usual Care|Referral to smoking cessation clinic
218913197|NCT00217984|BEHAVIORAL|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
219526317|NCT01863745|DRUG|nilotinib|Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
218913198|NCT02443467|OTHER|No intervention|
218913199|NCT05298579|OTHER|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
218913200|NCT03866122|DEVICE|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
218913201|NCT02065830|DEVICE|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
218913202|NCT06242132|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
218913203|NCT06242132|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
218913204|NCT02476617|DRUG|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
218913205|NCT02476617|DRUG|dasabuvir|dasabuvir tablets
218913206|NCT02476617|DRUG|ribavirin|ribavirin tablets
218913207|NCT02661321|OTHER|No intervention was used in this study, this was an observational study|
218913208|NCT02241616|DRUG|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
218913209|NCT05933317|DIAGNOSTIC_TEST|Functional lung MRI|Functional lung MRI
218913210|NCT00635206|DEVICE|BiPap auto with Fi Flex|"* MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3"
218913211|NCT00635206|DEVICE|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)
219041356|NCT03383328|DRUG|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
219041357|NCT03383328|DRUG|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
219041358|NCT03383328|DRUG|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
219041359|NCT03383328|DRUG|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
219041360|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
219041361|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
219041362|NCT01364090|DRUG|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
219526318|NCT00193609|DRUG|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
219526319|NCT00193609|DRUG|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
219526320|NCT04834037|BEHAVIORAL|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
219526321|NCT04680364|OTHER|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
219526322|NCT03956264|DEVICE|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
219526323|NCT03956264|DRUG|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
218913212|NCT03987269|BEHAVIORAL|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
218913213|NCT03987269|BEHAVIORAL|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
219041363|NCT01364090|DRUG|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
219041364|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
219041365|NCT01163409|PROCEDURE|exercise training|exercise training comprises aerobic and strength training
219041366|NCT01163409|PROCEDURE|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
219041367|NCT01163409|PROCEDURE|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
219041368|NCT01041625|DRUG|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
219041369|NCT03672435|DRUG|Topical Solution|proparacaine 0.5% eye drop
219041370|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
219041371|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
219041372|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
219041373|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
219041374|NCT04488029|OTHER|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
219526324|NCT00370006|BIOLOGICAL|Towne CMV vaccine|
219614672|NCT01026246|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
219041375|NCT04488029|OTHER|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
219041376|NCT06291558|OTHER|Exercise|The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
219526325|NCT01890382|DIETARY_SUPPLEMENT|Whey protein|30 g in total; twice a day (morning and evening)
219526326|NCT01890382|DIETARY_SUPPLEMENT|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
219614673|NCT02541968|BEHAVIORAL|Cognitive-behavioral therapy (face-to-face)|
219526327|NCT01890382|DIETARY_SUPPLEMENT|leucine supplementation|7.5 g/d in total; three times per day
219526328|NCT01890382|DIETARY_SUPPLEMENT|soy protein|30 g in total; twice a day
219526329|NCT01890382|DIETARY_SUPPLEMENT|creatine|6.0 g in total; twice a day
219526330|NCT01890382|DIETARY_SUPPLEMENT|placebo|
219526331|NCT05189405|DEVICE|INVOcell IVC|Embryo development in intravaginal incubation
218913214|NCT05661643|DRUG|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
218913215|NCT03916133|DIAGNOSTIC_TEST|Intervention group|6s PBV mapping will be conducted
218913216|NCT02505607|OTHER|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
218913217|NCT04020549|BEHAVIORAL|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
218913218|NCT04020549|BEHAVIORAL|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
219041377|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
219526332|NCT01157091|DRUG|pazopanib hydrochloride|Given orally
218913219|NCT03486912|DRUG|BMS-986036|Specified dose on specified days.
218913220|NCT03486912|OTHER|Placebo|Specified dose on specified days.
218913221|NCT03518853|RADIATION|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
218913222|NCT06351228|OTHER|Conization plus nodal evaluation|Conization plus nodal evaluation
218913223|NCT01495949|DRUG|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
218913224|NCT01495949|DRUG|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
218913225|NCT02491684|DRUG|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
218913226|NCT02491684|DRUG|Placebo|Placebo solution for once daily inhalation for 14 days
218913227|NCT00005975|DRUG|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
219041378|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
219041379|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
219614674|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy|With therapist support
219614675|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy without therapist support|
218913228|NCT00005975|DRUG|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
218913229|NCT00005975|DRUG|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
218913230|NCT00005975|DRUG|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
218913231|NCT00368407|DEVICE|308-nm excimer laser|
218913232|NCT04137068|BEHAVIORAL|Reduced Activity|Participants reduce their activity level to \<5,000 steps/day and \<50 % of baseline steps.
218913233|NCT06337799|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
218913234|NCT05941546|DIAGNOSTIC_TEST|anti-TBEV serology|we will measure by ELISA in microplates the anti-TBEV IgG as well as the anti-TBEV IgM on the sera + in TBEV IgG. We will then send a patient questionnaire with an information note to document the context of this TBEV seropositivity and to eliminate false-positivities (vaccination). Finally, we will perform PCR on CSF if serum positive and CSF available
218913235|NCT04197700|OTHER|Target MAP Management|Target MAP Management
218913236|NCT01263769|DRUG|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
218913237|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
219041380|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
219041381|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
219041382|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
219041383|NCT06391866|OTHER|extracorporeal circulation|extracorporeal circulation during cardiosurgical operation
219041384|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
219041385|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
219526333|NCT01157091|OTHER|laboratory biomarker analysis|Correlative studies
219526334|NCT01157091|OTHER|immunologic technique|Correlative studies
219526335|NCT03865654|OTHER|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
219526336|NCT00854308|DRUG|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
219526337|NCT00854308|DRUG|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
219526338|NCT00854308|DRUG|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
219526339|NCT05536518|BEHAVIORAL|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
219614676|NCT02561325|DRUG|Sodium Bicarbonate and Sodium chloride|
219614677|NCT02907060|DEVICE|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
218913238|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
219526340|NCT06373705|DEVICE|Cardiac simulator|A computer software cardiac simulator for surgical planning in complex Congenital Heart Disease (CHD) pediatric patients.
219526341|NCT05928481|OTHER|Simulation-based postpartum bleeding management training|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
219526342|NCT03872999|OTHER|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
219526343|NCT01180569|DRUG|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
218913239|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
219526344|NCT04806308|BEHAVIORAL|Otolaryngology stretching micro-breaks (OSMB)|Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
218913240|NCT03255603|OTHER|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
219526345|NCT03518281|DIETARY_SUPPLEMENT|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing \>50% Beta Glucan
219526346|NCT03518281|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
219526347|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
219526348|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
219526349|NCT00003332|DRUG|cisplatin|
218913241|NCT06144307|PROCEDURE|plane block|injection of local anesthetic to the myofascial plane
218913242|NCT01500733|DRUG|PCI 32765|420 mg daily
219526350|NCT00003332|DRUG|gemcitabine hydrochloride|
219526351|NCT00003332|PROCEDURE|surgical procedure|
219526352|NCT00003332|RADIATION|radiation therapy|
219526353|NCT00167739|DRUG|Quinine plus sulfadoxine-pyrimethamine|
218913243|NCT05632653|PROCEDURE|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
218913244|NCT01950416|DRUG|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
219526354|NCT04817709|OTHER|Educational Intervention|Review workbook
219526355|NCT04817709|OTHER|Usual Care|Receive educational materials
219526356|NCT04817709|OTHER|Media Intervention|Watch video
219526357|NCT04817709|OTHER|Medical Chart Review|Review of medical records
219526358|NCT04817709|OTHER|Questionnaire Administration|Complete questionnaires
218913245|NCT01950416|DRUG|Clopidogrel 600mg loading dose and 150mg maintenance dose|
218913246|NCT04836052|DRUG|Omega 3 fatty acid|omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
218913247|NCT05329246|DEVICE|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
218913248|NCT02424773|DEVICE|High Flow Nasal Canula (HFNC)|
218913249|NCT02424773|DEVICE|Venturi mask|
218913250|NCT02424773|DRUG|Oxygen|
219041386|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
219041387|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
219041388|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
219060651|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
219526359|NCT04514393|DRUG|Methotrexate|Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
219526360|NCT04514393|DRUG|Ibrutinib|Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
219526361|NCT04514393|DRUG|Temozolomide|Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
218913251|NCT05945784|OTHER|Use of Rare Beauty makeup products|Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
219526362|NCT02324803|DRUG|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
218913252|NCT06352580|OTHER|Survey|26 survey questions were administered face to face to parents, which they could answer in a short time.
218913253|NCT03071120|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
218913254|NCT05400291|DIAGNOSTIC_TEST|Chondroitin Sulfate Staining|Staining of histopathological slides
218913255|NCT02395458|DRUG|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
218913256|NCT02395458|DRUG|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
218913257|NCT01365923|DRUG|remifentanil|remifentanil effect site-TCI 2-4ng/ml
218913258|NCT01365923|DRUG|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
218913259|NCT01063049|DRUG|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
218913260|NCT01063049|DRUG|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
219526363|NCT00610363|BIOLOGICAL|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
219526364|NCT00610363|OTHER|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
219526365|NCT03048500|OTHER|Laboratory Biomarker Analysis|Correlative studies
219526366|NCT03048500|DRUG|Metformin Hydrochloride|Given PO
219526367|NCT03048500|BIOLOGICAL|Nivolumab|Given IV
219526368|NCT01461850|DRUG|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
219526369|NCT01461850|PROCEDURE|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
218913261|NCT01063049|DRUG|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
218913262|NCT01063049|DRUG|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
218913263|NCT01740167|BEHAVIORAL|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
218913264|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
218913265|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
218913266|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
218913267|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
218913268|NCT02521506|DEVICE|Verio Pattern Alert® activated|
218913269|NCT02521506|DEVICE|Verio Pattern Alert® deactivated|
218913270|NCT02641925|PROCEDURE|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
218913271|NCT02641925|PROCEDURE|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
218913272|NCT01384981|PROCEDURE|pulmonary rehabilitation|
218913273|NCT04011540|BEHAVIORAL|Digital data|Receiving digital data prior to a scheduled mental health session
218913274|NCT02676414|BEHAVIORAL|Interactive hypertension education program of the DHL©|
218913275|NCT05883501|BEHAVIORAL|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
218913276|NCT01256268|DRUG|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
219526370|NCT05439824|BIOLOGICAL|SYS6006 20 μg|SARS-CoV-2 mRNA Vaccine
219526371|NCT05439824|BIOLOGICAL|SYS6006 30 μg|SARS-CoV-2 mRNA Vaccine
219526372|NCT05439824|BIOLOGICAL|Placebo|Placebo
219526373|NCT00439075|PROCEDURE|CPAP|
219526374|NCT00439075|DRUG|standard treatment|
219526375|NCT05664464|DRUG|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
219526376|NCT05664464|DRUG|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
219526377|NCT05664464|DRUG|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
219526378|NCT05664464|DRUG|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
219526379|NCT05664464|RADIATION|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
219526380|NCT00957151|DRUG|Creon|
219526381|NCT04526496|DRUG|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
218913277|NCT01256268|DRUG|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
219526382|NCT04526496|DRUG|Placebo, single dose|Placebo matched to FTP-198, oral suspension
219526383|NCT04526496|DRUG|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
218913278|NCT01256268|DRUG|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
218913279|NCT03998540|DIAGNOSTIC_TEST|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
219060652|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
219526384|NCT04526496|DRUG|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
219526385|NCT03807141|OTHER|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
219526386|NCT02995070|PROCEDURE|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
219526387|NCT02995070|DEVICE|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
219526388|NCT02995070|DEVICE|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
219526389|NCT05517681|OTHER|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
219526390|NCT05517681|DRUG|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
219526391|NCT03876054|DEVICE|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
219526392|NCT03876054|DEVICE|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
219526393|NCT02866188|DEVICE|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
219526394|NCT00013351|PROCEDURE|Prevention of Falls|
219526395|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 1 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
219526396|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 2 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
219614678|NCT02907060|DRUG|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
218913280|NCT03998540|OTHER|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
218913281|NCT03998540|OTHER|Mass Spectometry|samples previously used for western blotting will be subjected to mass spectrometry analysis
218913282|NCT03998540|OTHER|RNA seq|analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
219526397|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection placebo combined with Linezolid|After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
219526398|NCT03660839|DRUG|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
218913283|NCT06026384|OTHER|text in non-narrative form|Participants will be asked to read a text and give feedback afterwards
219060653|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
219526399|NCT03660839|DRUG|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
219060654|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
219060655|NCT00199745|DRUG|atorvastatin|
219526400|NCT00665821|BEHAVIORAL|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
219526401|NCT00665821|BEHAVIORAL|General health education|General health education: a booklet describing general norms for maintaining good health
219526402|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
219614679|NCT01555216|DRUG|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
219614680|NCT01555216|DRUG|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
219614681|NCT01553955|PROCEDURE|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
219526403|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
219526404|NCT00401778|DRUG|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
219526405|NCT00141466|BEHAVIORAL|Education for professionals|
219526406|NCT00141466|BEHAVIORAL|Distribution of educational materials|
219526407|NCT00141466|BEHAVIORAL|Feedback for professionals|
218913284|NCT06026384|OTHER|text in narrative form|Participants will be asked to read a text and give feedback afterwards
218913285|NCT06026384|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and give feedback afterwards
219526408|NCT00141466|BEHAVIORAL|Reminders for professionals|
218913286|NCT06026384|OTHER|animated video in narrative form|Participants will be asked to watch a video and give feedback afterwards
218913287|NCT00774371|BEHAVIORAL|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
219526409|NCT00720330|DRUG|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
219526410|NCT00720330|DRUG|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
218913288|NCT05694390|OTHER|Use of sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
218913289|NCT05892224|PROCEDURE|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
218913290|NCT03730909|DRUG|Sodium Lactate|IV infusion
218913291|NCT03730909|DRUG|Sodium chloride|IV infusion
219526411|NCT00720330|OTHER|placebo|placebo
218913292|NCT00623948|DEVICE|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
218913293|NCT03249636|DIAGNOSTIC_TEST|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
218913294|NCT03019406|DRUG|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
218913295|NCT03019406|DRUG|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
218913296|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
218913297|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
218913298|NCT00988494|DRUG|Placebo ophthalmic solution|Topical ocular application
218913299|NCT00382486|PROCEDURE|Reduce the risk of allograft rejection|
218913300|NCT03710187|DRUG|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
218913301|NCT02608190|BEHAVIORAL|Working memory training|See protocol
218913302|NCT06525298|DRUG|EIS-12656|EIS-12656 tablets given daily
219365462|NCT00971126|DRUG|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
219365463|NCT05009901|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600 mg daily for 8 weeks
219365464|NCT05009901|DRUG|Placebo|Placebo one tablet daily for 8 weeks
219365465|NCT01271140|DRUG|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
219365466|NCT00737139|PROCEDURE|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
219365467|NCT00737139|PROCEDURE|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
219365468|NCT01705847|DRUG|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
219365469|NCT05086601|PROCEDURE|colorectal cancer surgery|Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
219365470|NCT01310335|DEVICE|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
219365471|NCT02774993|DRUG|Doxycycline|
219365472|NCT02774993|DRUG|placebo|
219365473|NCT00217347|DEVICE|Esophageal Capsule Endoscopy|
219365474|NCT02649634|BEHAVIORAL|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
219614682|NCT02312414|DRUG|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
219526412|NCT03587649|DRUG|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
219526413|NCT06496035|DEVICE|Blood Flow Restriction with low load exercise|Cuff/tourniquet will be applied to proximal leg at hip crease and inflated to 60-80% of limb occlusion pressure to decrease venous blood flow in the limb while performing exercise.
219526414|NCT06496035|OTHER|Therapeutic Exercise|Exercise performed at appropriate load as guided by physical therapist
219526415|NCT00804063|PROCEDURE|drawing blood sample|fasting blood sample
218913303|NCT06525298|DRUG|Olaparib|as per USPI/SmPC
218913304|NCT06525298|DRUG|Trastuzumab deruxtecan|as per USPI/SmPC
218913305|NCT00468169|DRUG|Cetuximab|250mg/m2(day 1, weekly x 10);
218913306|NCT00468169|DRUG|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
218913307|NCT00468169|DRUG|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
218913308|NCT00468169|RADIATION|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
218913309|NCT00468169|DRUG|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
218913310|NCT00468169|RADIATION|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
218913311|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
219526416|NCT00985257|DEVICE|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
219526417|NCT05983874|BIOLOGICAL|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|100µg Month 0 and Month 3
219614683|NCT00425321|DRUG|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
219614684|NCT00425321|DRUG|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
219614685|NCT00425321|DRUG|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
218913312|NCT00231816|BIOLOGICAL|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
218913313|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
218913314|NCT02011906|DIETARY_SUPPLEMENT|omega 3|
218913315|NCT02011906|DIETARY_SUPPLEMENT|vitamin E|
218913316|NCT02011906|DIETARY_SUPPLEMENT|placebo of omega 3|
218913317|NCT02011906|DIETARY_SUPPLEMENT|placebo of vitamin E|
218913318|NCT05588336|DRUG|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
218913319|NCT03735303|DIETARY_SUPPLEMENT|VD3 group|VD3 50000 IU/ week for 8 weeks
218913320|NCT03735303|DIETARY_SUPPLEMENT|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
219614686|NCT00425321|DRUG|Placebo|Placebo once daily for up to 12 weeks
219614687|NCT00931411|OTHER|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
219614688|NCT00931411|OTHER|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
218913321|NCT03735303|DIETARY_SUPPLEMENT|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
218913322|NCT03735303|OTHER|control group|no intervention was given
218913323|NCT05975827|DEVICE|Sterile Wound Care Liquid Dressing|Sterile wound care liquid dressing is used in the wound treatment
218913324|NCT04562922|DIETARY_SUPPLEMENT|Lifemel|
218913325|NCT04372017|DRUG|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
218913326|NCT04372017|DIETARY_SUPPLEMENT|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
218913327|NCT05403606|DEVICE|GASPARD®|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
218913328|NCT02890797|RADIATION|radiology|The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
218913329|NCT01126749|DRUG|Gemcitabine|Gemcitabine
218913330|NCT01126749|DRUG|E7389|E7389
219526418|NCT03963063|PROCEDURE|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2"
219526419|NCT03963063|PROCEDURE|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg"
219526420|NCT03252353|DRUG|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
219526421|NCT03252353|DRUG|Matching placebo|Matching placebo capsules
219614689|NCT02280200|DEVICE|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
218913331|NCT01126749|DRUG|Cisplatin|Cisplatin
218913332|NCT05559450|DRUG|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
218913333|NCT05559450|OTHER|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
218913334|NCT06432153|OTHER|observation|Participants who receive routine clinical care, without additional intervention from the study
218913335|NCT05864729|DIAGNOSTIC_TEST|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
218913336|NCT02666781|OTHER|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
218913337|NCT01283139|BIOLOGICAL|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
218913338|NCT01283139|BIOLOGICAL|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
218913339|NCT01283139|BIOLOGICAL|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
218913340|NCT01283139|OTHER|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
218913341|NCT04517123|OTHER|Prone Positioning|Prone Positioning
218913342|NCT02991183|BEHAVIORAL|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
218913343|NCT03631485|OTHER|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
218913344|NCT04357743|OTHER|Chin supported Arm ergometry with pursed lip breathing|"The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week"
218913345|NCT04357743|OTHER|Arm ergometry with pursed lip breathing|"The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week."
218913346|NCT00407121|DRUG|Bevacizumab|
219526422|NCT01702584|PROCEDURE|stent assisted embolization|stent assisted embolization and anti-thrombotic management
219526423|NCT00473486|DRUG|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
219526424|NCT00473486|DRUG|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
219526425|NCT03220919|OTHER|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
219614690|NCT05754268|PROCEDURE|Chinese version of the surgical risk assessment system|There is no need to interfere with the patient. Investigators can observe the outcome after using the system for evaluation.
219614691|NCT00811967|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
219614692|NCT00811967|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
218913347|NCT00407121|PROCEDURE|Intravitreal Injection of Bevacizumab|
219526426|NCT03220919|OTHER|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, \>10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, \> 20 mmol/L."
218913348|NCT02135250|DRUG|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
218913349|NCT02135250|OTHER|placebo|the placebo is not drug.
219526427|NCT06325189|OTHER|Aerobic Interval Training|Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
218913350|NCT02404961|OTHER|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
218913351|NCT03224208|DRUG|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
218913352|NCT03224208|DRUG|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
218913353|NCT00688116|DRUG|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
218913354|NCT05211947|DRUG|BI 425809|BI 425809
218913355|NCT01623102|DRUG|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
218913356|NCT01623102|DRUG|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
218913357|NCT02475538|DEVICE|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
218913358|NCT02475538|DEVICE|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
218913359|NCT00007202|DRUG|Atazanavir|
218913360|NCT00007202|DRUG|Stavudine|
218913361|NCT00007202|DRUG|Didanosine|
218913362|NCT06062563|DRUG|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
218913363|NCT06079008|OTHER|calcified cardiac valve|patients have cardiac cardiac valve before surgery
219526428|NCT02008565|DRUG|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
219526429|NCT02008565|DRUG|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
219041389|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
219526430|NCT02008565|BEHAVIORAL|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
219526431|NCT02008565|BEHAVIORAL|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
219526432|NCT00391105|DRUG|Remifentanil|
219526433|NCT00467662|DRUG|Acyclovir 5%|
219526434|NCT00467662|DRUG|Docosanol 10%|
219526435|NCT00467662|DEVICE|Superlysine gel|
219526436|NCT04095247|DEVICE|Vagus nerv stimulator|pulse triggered autostimulation
219526437|NCT02193178|DEVICE|comfilcon A Toric|Contact lenses
218913364|NCT03753802|OTHER|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
218913365|NCT03753802|OTHER|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
219526438|NCT03435081|DRUG|Baricitinib|Administered orally
219526439|NCT03435081|DRUG|Placebo|Administered orally
219526440|NCT02706236|DRUG|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
219526441|NCT02706236|DRUG|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
219526442|NCT04219566|DEVICE|VeNS|Non-invasive electrical vestibular nerve stimulation
219526443|NCT04219566|DEVICE|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
219526444|NCT02719249|OTHER|Dried blood spot test|
218913366|NCT01463501|OTHER|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
219526445|NCT00499642|DRUG|Lecozotan SR|
219526446|NCT00499642|DRUG|Moxifloxacin|
219526447|NCT02344784|DEVICE|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
219526448|NCT02344784|DRUG|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
218913367|NCT01463501|OTHER|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
219526449|NCT04619810|OTHER|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
219526450|NCT03095222|DRUG|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
219526451|NCT03095222|DRUG|Opioids|Standard of care for pain management.
219526452|NCT05805657|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
218913368|NCT05732467|DEVICE|visual function training software|Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.
219526453|NCT05805657|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
219526454|NCT05805657|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
219526455|NCT00085696|DRUG|VELCADE and rituximab|
219526456|NCT04063358|DRUG|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
219526457|NCT02243930|DEVICE|Disposable distal attachment|
219526458|NCT03230149|DIAGNOSTIC_TEST|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
219526459|NCT03206619|OTHER|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
219526460|NCT00054106|DRUG|buserelin|
218913369|NCT05732467|OTHER|occlusion therapy|Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.
218913370|NCT05732467|OTHER|corrective glasses|corrective glasses
218913371|NCT01855529|DRUG|Ropivacaine in one arm and placebo (NaCl) in the other arm|
218913372|NCT04716764|OTHER|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
218913373|NCT03559114|DRUG|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
218913374|NCT03559114|DRUG|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
218913375|NCT01942928|OTHER|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
218913376|NCT01942928|OTHER|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
218913377|NCT00001986|DRUG|1-Octanol|
218913378|NCT01614249|DIETARY_SUPPLEMENT|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
218913379|NCT01614249|DIETARY_SUPPLEMENT|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
218913380|NCT02954536|DRUG|pembrolizumab|
218913381|NCT02954536|DRUG|trastuzumab|
218913382|NCT02954536|DRUG|capecitabine|
219526461|NCT00054106|DRUG|custirsen sodium|
219526462|NCT00054106|DRUG|flutamide|
219526463|NCT00054106|PROCEDURE|conventional surgery|
218913383|NCT02954536|DRUG|cisplatin|
218913384|NCT02954536|DRUG|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
218913385|NCT02954536|DRUG|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
218913386|NCT05498649|DEVICE|DT1fA|DT1fA contact lenses
219526464|NCT00054106|PROCEDURE|neoadjuvant therapy|
219526465|NCT04734288|DIETARY_SUPPLEMENT|Vit.D3 5000 IU, Immune Active|"The subjects will receive monthly (for either 3 or 6 months):~1. Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.~2. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.~3. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire."
219526466|NCT03151057|DRUG|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
218913387|NCT04004234|DRUG|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
218913388|NCT04004234|DRUG|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
218913389|NCT04004234|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
219526467|NCT03151057|DRUG|Placebo Oral Tablet|placebo
219526468|NCT00128154|DRUG|Chromium picolinate|
219526469|NCT01596166|DRUG|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
218913390|NCT04004234|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
218913391|NCT04524949|DRUG|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
218913392|NCT04524949|DRUG|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
218913393|NCT04524949|DRUG|Placebo|Solvent: alum hydroxide
218913394|NCT06340295|OTHER||
218913395|NCT02234882|DRUG|Rosuvastatin|
218913396|NCT02234882|DRUG|BMS-663068|
218913397|NCT01239199|OTHER|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
219526470|NCT01596166|DRUG|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
219526471|NCT01809171|DRUG|Vitamin D3|ampoule
219526472|NCT01809171|DRUG|Placebo|ampoule
219526473|NCT06150027|OTHER|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
219526474|NCT03540056|DIAGNOSTIC_TEST|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
219526475|NCT06282809|DEVICE|HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy|Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
218913398|NCT04169035|DEVICE|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
219526476|NCT00168883|DRUG|Carboplatin|
219526477|NCT00168883|DRUG|Paclitaxel|
218913399|NCT04169035|PROCEDURE|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
218913400|NCT00568022|DRUG|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
218913401|NCT00568022|DRUG|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
219526478|NCT00168883|DRUG|Vinorelbine|
219526479|NCT02551445|BEHAVIORAL|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
218913402|NCT02946580|DRUG|MOVANTIK™ (naloxegol)|
218913403|NCT02946580|DRUG|Sugar Pill|
218913404|NCT06207331|DRUG|Dexmedetomidine 0.5 μg/kg|Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
218913405|NCT06207331|DRUG|Dexmedetomidine 1 μg/kg|Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
219526480|NCT01582607|DRUG|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
219526481|NCT01582607|DRUG|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
219526482|NCT01582607|DRUG|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
219526483|NCT01582607|DRUG|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
219526484|NCT01582607|DRUG|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
219526485|NCT01582607|DRUG|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
219526486|NCT02161965|DRUG|Rivaroxaban|20mg or 15mg
219526487|NCT02161965|DRUG|Fluindione|
219526488|NCT02161965|DRUG|Warfarin|
219526489|NCT04007133|OTHER|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
219526490|NCT01967108|OTHER|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
219526491|NCT04361266|DEVICE|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
219526492|NCT04361266|PROCEDURE|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
219526493|NCT01734291|BEHAVIORAL|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
219526494|NCT03979703|OTHER|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
219526495|NCT00214422|RADIATION|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
219526496|NCT01989091|DEVICE|B-Lock|Antimicrobial Catheter Lock Solution
219526497|NCT01989091|DRUG|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
219526498|NCT06287905|DRUG|Prazosin Oral Tablet|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
219526499|NCT05717257|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
219526500|NCT03929393|BEHAVIORAL|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
219526501|NCT03929393|OTHER|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
219526502|NCT03576040|DEVICE|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
219526503|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
219526504|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
219526505|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
219526506|NCT04165096|DRUG|diphenhydramine|PO
219526507|NCT04165096|DRUG|acetaminophen|PO
219526508|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
219526509|NCT04763161|PROCEDURE|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
219526510|NCT04763161|PROCEDURE|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
219614693|NCT07032402|BEHAVIORAL|Education and Counseling|Mothers who consent will have the ABÖS-M App installed on their smartphones and will create a personal login. Researchers will provide brief training on how to use the app. The intervention consists of four educational modules designed with individualized and gamified content. Mothers are expected to complete all modules within two weeks. The app monitors their progress and provides automated feedback based on their performance, encouraging mothers to review topics if needed. Weekly WhatsApp reminders will be sent to promote app engagement, and researchers will track login frequency and usage time. Mothers who fail to complete the modules within the specified timeframe will be excluded from the study. Participants will also be asked to fill out a daily care diary throughout the intervention period.
218913406|NCT06207331|DRUG|Saline|Participants inhale atomized 2 ml 0.9% saline.
219526511|NCT03897998|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
219526512|NCT03897998|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
219526513|NCT04912739|BEHAVIORAL|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
219526514|NCT05084781|PROCEDURE|Coblation Debridement (FLOW90)|bipolar radiofrequency energy
218913407|NCT02265458|BEHAVIORAL|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
218913408|NCT00459459|PROCEDURE|Fine needle aspiration of the thyroid|
218913409|NCT00904449|DRUG|Oxymorphone ER|10mg, 20mg, and 40mg PO
218913410|NCT01751529|PROCEDURE|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
219526515|NCT02602041|OTHER|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
219526516|NCT00202319|PROCEDURE|Sedation management protocol|
219526517|NCT02744352|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
219526518|NCT02744352|DRUG|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
218913411|NCT01751529|DRUG|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
219526519|NCT04149964|DRUG|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
218913412|NCT03075787|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
219526520|NCT04149964|DRUG|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
219526521|NCT04149964|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
219526522|NCT04149964|DRUG|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
219526523|NCT04753437|DRUG|Clarithromycin|Clarithromycin tablets.
219526524|NCT04753437|DRUG|Amoxicillin|Amoxicillin capsules.
219526525|NCT04753437|DRUG|Bismuth potassium citrate|Bismuth potassium citrate tablets.
219526526|NCT04753437|DRUG|Esomeprazole|Esomeprazole tablets.
219526527|NCT04753437|DRUG|Vonoprazan|Vonoprazan tablets.
219526528|NCT05763238|OTHER|INTERVENTION GROUP|"Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup"
219526529|NCT05763238|OTHER|CONTROL GROUP|"Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup"
219614694|NCT07032402|OTHER|Standard Care|"After obtaining written and verbal consent, the ABÖS-M App will be installed on their smartphones, and researchers will provide face-to-face instructions on its basic use. Mothers in the control group will receive routine newborn care education provided by clinical nurses, which includes non-standardized safe sleep information typically given before hospital discharge. No structured or individualized training will be provided by the researchers during the study period. For one month, control group participants will have limited access to certain app features, including the About Us section, care diary, and assessment tools. Mothers will be asked to complete the care diary daily, and researchers will send regular reminders."
219614695|NCT07030907|BIOLOGICAL|OPB-101|An autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine
219614696|NCT01673230|PROCEDURE|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
219614697|NCT06069167|OTHER|Collection of data related to bowel urgency|Data will be extracted from the patient's medical record and patients will be interviewed to collect data specific to the research
219526530|NCT04175379|OTHER|group 40|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
219526531|NCT04175379|OTHER|group 50|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
218913413|NCT03020251|OTHER|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
218913414|NCT03020251|OTHER|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
218913415|NCT03638453|OTHER|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
219526532|NCT04175379|OTHER|group 60|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
218913416|NCT03638453|OTHER|Usual Care|Standard care per hospital guidelines.
218913417|NCT04291781|BIOLOGICAL|RC18 160mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
218913418|NCT04291781|BIOLOGICAL|RC18 240mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
218913419|NCT04291781|BIOLOGICAL|placebo|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
218913420|NCT03041740|DRUG|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
218913421|NCT06384079|PROCEDURE|Antegrade and retrograde pyelogram|Participation in the study will guarantee that participants will receive this procedure.
218913422|NCT05656859|BEHAVIORAL|Single group|Survey
218913423|NCT03043313|DRUG|Trastuzumab|Given intravenously (into the vein; IV)
218913424|NCT03043313|DRUG|Tucatinib|Given orally
219526533|NCT01189669|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
219526534|NCT01189669|DIETARY_SUPPLEMENT|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
219614698|NCT05597319|PROCEDURE|Liver resection|Liver resection, different kind of according to pathology
219614699|NCT04065360|BEHAVIORAL|Group Cognitive behavioural family intervention (CBFI)|four-week, four-session CBT-based family intervention programme
219614700|NCT04065360|BEHAVIORAL|Usual group psychoeducation|Treatment as usual in the institution studied
218913425|NCT05296473|DEVICE|ADHD Therapy|investigational game-play therapy
218913426|NCT05296473|DEVICE|Control Therapy|control game-play therapy
218913427|NCT06584188|DRUG|anti-inflammatory ketorolac tromethamine|"* Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}."
219614701|NCT03552848|BIOLOGICAL|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
218913428|NCT03294694|DRUG|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
218913429|NCT03294694|DRUG|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
219614702|NCT03810040|DEVICE|140 microns denuding pipette|the degranulated needle size was 140 microns
219614703|NCT03810040|DEVICE|150 microns denuding pipette|the degranulated needle size was 150 microns
219614704|NCT02586155|DRUG|Apabetalone|100 mg capsule
219614705|NCT02586155|DRUG|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
218913430|NCT03294694|DRUG|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
218913431|NCT00980954|DRUG|carboplatin|Intravenously
218913432|NCT00980954|DRUG|cisplatin|Intravenously
218913433|NCT00980954|DRUG|paclitaxel|Intravenously
218913434|NCT00980954|RADIATION|intensity-modulated radiation therapy|Daily fractions
218913435|NCT00980954|RADIATION|standard external beam radiation therapy|Daily fractions
218913436|NCT00980954|RADIATION|Optional brachytherapy boost|Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.
218913437|NCT02657889|DRUG|niraparib|
218913438|NCT02657889|BIOLOGICAL|pembrolizumab|
219614706|NCT02586155|DRUG|Atorvastatin|High-Intensity Statin
219614707|NCT02586155|DRUG|Rosuvastatin|High-Intensity Statin
219614708|NCT03352687|PROCEDURE|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
219614709|NCT03352687|PROCEDURE|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
219614710|NCT00002897|DRUG|cisplatin|
219614711|NCT00002897|DRUG|fluorouracil|
219614712|NCT00002897|PROCEDURE|conventional surgery|
219614713|NCT05582070|OTHER|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
219526535|NCT01655628|DRUG|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
219614714|NCT02633787|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
219614715|NCT02668575|BEHAVIORAL|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
219041390|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
219614716|NCT06581380|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
218913439|NCT06110013|DEVICE|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
218913440|NCT04214340|OTHER|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
218913441|NCT04879056|DIAGNOSTIC_TEST|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
218913442|NCT04643275|DEVICE|BTL-899|Treatment with study device.
218913443|NCT02306330|DEVICE|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
218913444|NCT02306330|OTHER|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
218913445|NCT04281290|PROCEDURE|Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|"Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)"
218913446|NCT02028806|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
218913447|NCT05627973|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
218913448|NCT00347789|PROCEDURE|Glaucoma surgery- Bleb revision|
219041391|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
219041392|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
219614717|NCT06581380|DRUG|Topotecan|Topotecan will be administered per drug label.
219614718|NCT00316290|BEHAVIORAL|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
218913449|NCT00670423|DRUG|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
218913450|NCT00670423|DRUG|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
219041393|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
219614719|NCT00316290|BEHAVIORAL|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
219614720|NCT00266279|DRUG|Oxaliplatin, Capecitabine|"Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"
219614721|NCT00681421|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219041394|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
219041395|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
219041396|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
219526536|NCT01655628|DRUG|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
218913451|NCT00670423|DRUG|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
218913452|NCT02468817|PROCEDURE|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
218913453|NCT02468817|PROCEDURE|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
218913454|NCT04215224|DIAGNOSTIC_TEST|Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
218913455|NCT01271777|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
218913456|NCT01271777|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
218913457|NCT02121223|DEVICE|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (\>=16atm) for at least 15 seconds.
219614722|NCT00664079|OTHER|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
219614723|NCT02456740|DRUG|Erenumab|Administered by subcutaneous injection once a month
219041397|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
219526537|NCT03153930|BEHAVIORAL|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
219526538|NCT03153930|BEHAVIORAL|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
218913458|NCT02121223|DEVICE|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
218913459|NCT06024070|OTHER|Rigid Tape|"The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips"
218913460|NCT03247257|PROCEDURE|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
218913461|NCT03247257|PROCEDURE|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
218913462|NCT05881018|DIETARY_SUPPLEMENT|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
218913463|NCT05881018|DIETARY_SUPPLEMENT|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
218913464|NCT05881018|BEHAVIORAL|Physical activity|Participants will include physical activity units
218913465|NCT03760991|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
218913466|NCT05153577|OTHER|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
218913467|NCT05153577|OTHER|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
218913468|NCT02356822|OTHER|Patient registry|Oncology data registry
219614724|NCT02456740|DRUG|Placebo|Administered by subcutaneous injection once a month
219614725|NCT03434522|DEVICE|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
219614726|NCT04785547|DRUG|Blinatumomab|15 mcg/m2/day for 28 days
219041398|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
219041399|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
219614727|NCT04720105|DRUG|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
219614728|NCT01026753|BEHAVIORAL|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
219526539|NCT03392909|DRUG|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
218913469|NCT04190459|PROCEDURE|LSG|Bariatric surgery
218913470|NCT04190459|PROCEDURE|LRYGB|Bariatric surgery
219526540|NCT03096821|DRUG|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
218913471|NCT04146181|DRUG|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
218913472|NCT03925623|OTHER|Novel approaches for the design of child resistant closures|"Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system."
218913473|NCT05236517|DRUG|Semaglutide D Dose 1|Tablet given orally
218913474|NCT05236517|DRUG|Semaglutide D Dose 2|Tablet given orally
218913475|NCT05236517|DRUG|Semaglutide D Dose 3|Tablet given orally
218913476|NCT05236517|DRUG|Semaglutide C Dose 4|Tablet given orally
218913477|NCT05236517|DRUG|Semaglutide C Dose 5 (50 mg)|Tablet given orally
218913478|NCT05236517|DRUG|Placebo (Semaglutide C)|Tablet given orally
218913479|NCT05236517|DRUG|Placebo ( Semaglutide D)|Tablet given orally
218913480|NCT01769313|DEVICE|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
218913481|NCT01769313|DEVICE|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
218913482|NCT00517296|PROCEDURE|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
218913483|NCT00517296|DRUG|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
218913484|NCT00517296|PROCEDURE|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
218913485|NCT04567069|BIOLOGICAL|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
218913486|NCT04567069|BIOLOGICAL|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
218913487|NCT04567069|DRUG|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
218913488|NCT05460104|DEVICE|Experimental|Virtual reality sessions with a psychologist (30 minutes per session) once a week for 10 weeks. Work of the psychologist on a virtual environment created for the protocol in partnership with the company.
218913489|NCT05460104|OTHER|Control|Standard care is medical follow-up, no specific psychological care.
218913490|NCT03636555|DRUG|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
218913491|NCT03636555|DRUG|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
218913492|NCT00647517|DRUG|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
219526541|NCT03325114|DRUG|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
219526542|NCT03382457|DEVICE|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
218913493|NCT00791934|DEVICE|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
218913494|NCT00829738|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
219526543|NCT06949202|OTHER|breating exercises|diaphragmatic breathing
219614729|NCT02005380|OTHER|Text-based task|Participants are required to take text-based exercise.
219614730|NCT02005380|OTHER|Graphic-based Task|Participants are required to take the graphic-based exercise.
218913495|NCT05685628|OTHER|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates."
218913496|NCT05685628|OTHER|Charcoal dressing|Use of a secondary non-occlusive activated charcoal dressing (brand of your choice)
219614731|NCT02934243|DEVICE|laryngeal mask insertion|airway management with laryngeal mask
219614732|NCT01869933|DRUG|OC-10X|
219614733|NCT02483676|DEVICE|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
219614734|NCT02483676|BEHAVIORAL|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
218913497|NCT02977663|OTHER|Magnetic Resonance Imaging (MRI)|"* Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit"
219526544|NCT05018416|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
219526545|NCT02372149|DRUG|10% intravenous immunoglobulin (IVIg)|
219526546|NCT02372149|DRUG|0.9% sodium chloride|
219614735|NCT00477880|BIOLOGICAL|Cetuximab|
218913498|NCT06204341|RADIATION|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
218913499|NCT03497637|DIAGNOSTIC_TEST|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
218913500|NCT03497637|DIAGNOSTIC_TEST|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
218913501|NCT06679686|OTHER|Role Playing|The group will analyse the instant cases given by the researchers using the role-play method.
218913502|NCT06679686|OTHER|Digital Storytelling|The group will analyse the ethical analysis of the cases containing ethical problems written by themselves by using digital storytelling
219526547|NCT01049607|PROCEDURE|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
219614736|NCT02350465|BEHAVIORAL|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
219614737|NCT02350465|BEHAVIORAL|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
218913503|NCT00001711|PROCEDURE|MRI|scan of healthy volunteers.
218913504|NCT03642873|DRUG|Humibid®|Humibid® 1200 mg (single extended release) tablet
218913505|NCT03642873|DRUG|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
218913506|NCT03642873|DRUG|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
218913507|NCT05690269|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases. SpO2 will be recorded during that time and up to 10 minutes.
219041400|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
219041401|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
219614738|NCT00308204|DRUG|Raptiva|injection
219614739|NCT04135937|DRUG|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
218913508|NCT00010036|DRUG|carboplatin|
218913509|NCT00010036|DRUG|irinotecan hydrochloride|
218913510|NCT00010036|RADIATION|radiation therapy|
218913511|NCT04230187|DRUG|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
218913512|NCT04230187|DRUG|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
218913513|NCT04531085|PROCEDURE|Operative treatment|Surgery
218913514|NCT04531085|PROCEDURE|Long arm cast|cast immobilization
218913515|NCT04760782|DRUG|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
218913516|NCT04760782|DEVICE|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
218913517|NCT05121272|BEHAVIORAL|cognitive task|cognitive task
219041402|NCT00049062|DRUG|anastrozole|
219041403|NCT00049062|DRUG|gefitinib|
219526548|NCT01049607|PROCEDURE|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
219526549|NCT01822483|DRUG|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
219526550|NCT01822483|DRUG|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg\*h ml-1.
219526551|NCT04742283|DRUG|DE-126 Ophthalmic Solution 0.002% QD|DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
219526552|NCT04742283|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution BID (morning and evening)
219614740|NCT04135937|DRUG|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
219614741|NCT04135937|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
219614742|NCT04135937|DRUG|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
219614743|NCT04135937|BEHAVIORAL|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
219614744|NCT06757647|DRUG|Acalabrutinib|Given PO
218913518|NCT06444568|OTHER|Dietary Intervention|The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
218913519|NCT05730023|DEVICE|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
218913520|NCT05730023|BEHAVIORAL|individualized language training|individualized language training
218913521|NCT05730023|DEVICE|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
218913522|NCT05090696|DEVICE|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
218913523|NCT01739166|OTHER|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
218913524|NCT03525379|DRUG|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
218913525|NCT03525379|DRUG|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
218913526|NCT04076540|DRUG|AZD4041|Administration by Oral syringe
218913527|NCT04076540|DRUG|Placebo|Administration by Oral syringe
218913528|NCT02955056|DRUG|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
218913529|NCT00453895|DRUG|Sunitinib|50mg Sunitinib
218913530|NCT05933746|BEHAVIORAL|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
218913531|NCT05933746|BEHAVIORAL|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
218913532|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
219041404|NCT04514575|BIOLOGICAL|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
219041405|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
219526553|NCT02424097|DRUG|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~\- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
219526554|NCT02424097|DRUG|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
219526555|NCT04783051|DRUG|Sulfadoxine pyrimethamine|Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine
219614745|NCT06757647|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219614746|NCT06757647|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218913533|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
218913534|NCT02234843|DRUG|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
218913535|NCT03321357|DIAGNOSTIC_TEST|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
218913536|NCT04467749|OTHER|Suspension Wheel|Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
218913537|NCT00425035|DRUG|Panitumumab (ABX-EGF)|
218913538|NCT02787564|BEHAVIORAL|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
219041406|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
219041407|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
219041408|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
219041409|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
218913539|NCT03322956|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
218913540|NCT00841841|DRUG|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
218913541|NCT05411562|DIAGNOSTIC_TEST|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
218913542|NCT00002649|BIOLOGICAL|aldesleukin|Given IV
219041410|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
219526556|NCT04783051|DRUG|Pyramax|Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
219526557|NCT02545205|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
219526558|NCT02545205|OTHER|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
219526559|NCT01641068|OTHER|Cognitive Intervention|Participate in memory and thinking skills workshop
219526560|NCT01641068|OTHER|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
219526561|NCT01641068|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
219526562|NCT01641068|OTHER|Memory Intervention|Participate in memory and thinking skills workshop
219526563|NCT01641068|OTHER|Quality-of-Life Assessment|Ancillary studies
219526564|NCT01641068|OTHER|Questionnaire Administration|Ancillary studies
219614747|NCT06757647|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219614748|NCT06757647|PROCEDURE|Computed Tomography|Undergo CT
218913543|NCT00002649|BIOLOGICAL|filgrastim|Given SC or IV
218913544|NCT00002649|DRUG|cyclophosphamide|Given IV
218913545|NCT00002649|DRUG|etoposide|Given IV
218913546|NCT00002649|RADIATION|radiation therapy|Undergo radiation therapy
218913547|NCT00002649|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
218913548|NCT00002649|PROCEDURE|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
218913549|NCT00609102|DRUG|Placebo|one capsule BID
218913550|NCT00609102|DRUG|n-aceylcysteine|450 mgm BID
218913551|NCT06705725|DRUG|CBG002 CAR-T Cell Suspension|"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."
218913552|NCT04921241|OTHER|In Utero Exposure to SARS-CoV-2|Born to mother with SARS-CoV-2 infection during pregnancy
218913553|NCT05910073|DEVICE|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
218913554|NCT06322160|OTHER|Interview|Interview with individual participant will take place via online videoconferencing MS Teams
218913555|NCT05758116|DRUG|Tislelizumab|Tislelizumab: 200mg d1,q21d\*17
218913556|NCT04094285|DRUG|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
219526565|NCT06036498|DEVICE|Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography|We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
219526566|NCT04609722|OTHER|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
219526567|NCT03016858|PROCEDURE|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
219526568|NCT03004105|DRUG|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
219526569|NCT03004105|DRUG|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
219526570|NCT03004105|BEHAVIORAL|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
219526571|NCT04132622|DRUG|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
219614749|NCT06757647|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
218913557|NCT04094285|DRUG|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
218913558|NCT03851523|OTHER|No intervention|No intervention
219041411|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
219041412|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
219526572|NCT04132622|DRUG|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
219526573|NCT01675622|DRUG|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
219526574|NCT01675622|DRUG|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
219614750|NCT03097627|DRUG|ICG Intervention|The intervention to be administered is the drug indocyanine green.
219614751|NCT03097627|DEVICE|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
219526575|NCT04127656|OTHER|Amino Acid-Based Experimental Study Formula|Amino Acid-Based Formula; fed ad libitum
219526576|NCT01086254|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
219526577|NCT01086254|DRUG|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
219526578|NCT01086254|DRUG|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
219526579|NCT04282954|DRUG|JP-1366|JP-1366, QD
218913559|NCT06255275|OTHER|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
219614752|NCT03577080|OTHER|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
218913560|NCT05497830|OTHER|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
218913561|NCT02818907|OTHER|Additional biological samples|blood and tumor tissue samples
218913562|NCT05523674|OTHER|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
218913563|NCT05523674|OTHER|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
218913564|NCT06338774|BEHAVIORAL|Cognitive training|Computerized cognitive training completed on any computer or tablet with internet
218913565|NCT06338774|BEHAVIORAL|Exercise|Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
218913566|NCT06569212|DRUG|Metoprolol|"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
218913567|NCT06569212|DRUG|Placebo|"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
218913568|NCT04398433|DRUG|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
218913569|NCT04398433|DEVICE|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
218913570|NCT06091111|DEVICE|THD, THN|New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
218913571|NCT03392064|BIOLOGICAL|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
218913572|NCT05672550|DRUG|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
218913573|NCT05672550|DRUG|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
219041413|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
219526580|NCT04282954|DRUG|JP-1366 placebo|JP-1366 placebo, QD
219526581|NCT04282954|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, QD
219526582|NCT04282954|DRUG|Esomeprazole placebo|Esomeprazole placebo, QD
219526583|NCT04032977|DEVICE|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
219526584|NCT04032977|DEVICE|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
219526585|NCT03018717|OTHER|Telemonitoring Constant|telemedicine of Constant
219526586|NCT03018717|OTHER|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
219526587|NCT04262934|DRUG|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
219526588|NCT04262934|OTHER|No vitamin D administration|No vitamin D administration
219526589|NCT00817661|DIETARY_SUPPLEMENT|Vitamin A|10000 IU Vitamin A or placebo per week
219526590|NCT00817661|DIETARY_SUPPLEMENT|Placebo|10000 IU Vitamin A or placebo per week
219526591|NCT02880761|PROCEDURE|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
219526592|NCT06161961|DEVICE|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
219526593|NCT03871361|DRUG|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly
219526594|NCT02909478|DRUG|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
219614753|NCT04196569|DEVICE|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
219614754|NCT04053621|DIETARY_SUPPLEMENT|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
219526595|NCT02909478|DRUG|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
219526596|NCT03808805|DRUG|Aprepitant 80 mg|oral therapy - daily dose - 14 days
219526597|NCT03808805|DRUG|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
219526598|NCT03808805|DRUG|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
219614755|NCT04053621|OTHER|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
218913574|NCT05891379|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
219526599|NCT03808805|DRUG|Placebo of Aprepitant|oral therapy - daily dose - 14 days
219614756|NCT04053621|DRUG|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
219614757|NCT00821743|DEVICE|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
219614758|NCT00371579|DRUG|rosuvastatin|
218913575|NCT05891379|DRUG|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
218913576|NCT05795166|OTHER|No treatment given|No treatment given
218913577|NCT02598284|OTHER|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
218913578|NCT02598284|OTHER|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
219526600|NCT01134094|PROCEDURE|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
218913579|NCT02719821|BEHAVIORAL|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
219526601|NCT01134094|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
219526602|NCT02093494|DEVICE|Initial Specimen Diversion Device (ISDD)|
219526603|NCT02093494|PROCEDURE|Lab standard practice (LSP)|
219526604|NCT02093494|DEVICE|Peripheral Intravenous Catheters (PIVC)|
219526605|NCT05612867|DIETARY_SUPPLEMENT|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
219526606|NCT02106156|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
219526607|NCT02106156|DRUG|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
219614759|NCT04748107|DIAGNOSTIC_TEST|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
219614760|NCT01573585|BEHAVIORAL|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
219614761|NCT01573585|BEHAVIORAL|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
219614762|NCT04873947|DEVICE|Pulse Oximeter|The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
219614763|NCT06750107|BEHAVIORAL|Safe South Africa|"The Safe South Africa intervention is a gender- and developmentally-tailored, designed to reduce actual or intended HIV risk behaviors, actual or intended IPV perpetration frequency, and endorsement of IPV supportive attitudes. This intervention comprises 2-hour sessions, held once a week for a total of two weeks. The intervention also includes take-home activities to deepen behavioral engagement with received sessions and to prime the pump for up-coming sessions. Part 2 involves behavioral practice, including bystander intervention techniques."
218913580|NCT01001975|DRUG|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
218913581|NCT01001975|DRUG|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
218913582|NCT01001975|DRUG|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
219526608|NCT02485977|DEVICE|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
218913583|NCT04761263|OTHER|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
218913584|NCT04761263|OTHER|Selected Physical therapy program|"* Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Facilitation of protective reaction from standing position by pushing the child in different directions.~* Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~* Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~* Jumping in place and jumping a board."
218913585|NCT06026033|DRUG|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
218913586|NCT02814006|OTHER|health educational video|visualization of health educational video
218913587|NCT00498940|DEVICE|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
218913588|NCT00498940|DEVICE|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
218913589|NCT00005800|BIOLOGICAL|Filgrastim|
218913590|NCT00005800|DRUG|Docetaxel|
218913591|NCT00005800|DRUG|Doxorubicin|
218913592|NCT00005800|PROCEDURE|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
218913593|NCT06186050|DIETARY_SUPPLEMENT|Beetroot drink|Drink containing 10g of beetroot powder in 250 mL cold tap water
218913594|NCT06186050|DIETARY_SUPPLEMENT|Placebo|Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
218913595|NCT06186050|DIETARY_SUPPLEMENT|Control|Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
218913596|NCT05935553|DRUG|Baclofen 30 mg|"* baclofen 10 mg capsule (for the 30 mg-baclofen 30 mg arm)~* Dosage: 3 capsules of baclofen 10 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
218913597|NCT05935553|DRUG|Baclofen 60 mg|"* baclofen 20 mg capsule (for the 60 mg baclofen arm)~* Dosage: 3 capsules of baclofen 20 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
218913598|NCT05935553|DRUG|Placebo|"* placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
219526609|NCT04138745|OTHER|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
219526610|NCT03224494|DEVICE|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
218913599|NCT05379803|DRUG|Furmonertinib|furmonertinib 160 mg orally QD
218913600|NCT05701423|DRUG|Natalizumab|Administered as specified in the treatment arm.
219526611|NCT03224494|OTHER|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
219526612|NCT03224494|OTHER|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
219526613|NCT00409162|DEVICE|Eraser TM device, with washing fluid|
219526614|NCT03059966|PROCEDURE|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
219526615|NCT03059966|BIOLOGICAL|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
219526616|NCT06559735|DEVICE|CereVu Device|Observational, non-invasive measurements
219526617|NCT00581139|BEHAVIORAL|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
219526618|NCT00581139|DRUG|Midazolam|0.5 mg/kg oral midazolam
219526619|NCT00581139|BEHAVIORAL|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
219526620|NCT00581139|OTHER|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
218913601|NCT05279196|OTHER|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
218913602|NCT06523569|OTHER|Digital Blood Pressure Monitoring System|As a part of the bundled digital health intervention, the participant will receive instructions on how to follow a link in their electronic patient portal that will allow direct input of home blood pressure readings for clinical review.
218913603|NCT06523569|OTHER|Mobile health application|As a part of the bundled digital health intervention, the participant will be given a lifestyle change mobile health application.
218913604|NCT04262388|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
218913605|NCT04262388|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
218913606|NCT05313984|DEVICE|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
218913607|NCT03406884|BIOLOGICAL|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
218913608|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
218913609|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
218913610|NCT01766453|BEHAVIORAL|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
218913611|NCT01766453|BEHAVIORAL|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
218913612|NCT04482660|PROCEDURE|Positron emission tomography with 18F-RO6958948|tau PET ()
218913613|NCT05305443|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
219526621|NCT06161623|BEHAVIORAL|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
219526622|NCT00377416|GENETIC|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
218913614|NCT05305443|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
218913615|NCT05305443|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
218913616|NCT05305443|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
218913617|NCT05961722|OTHER|preoperative IV 0.9% saline 400 ml|Group 1 will be infused with IV 0.9% saline 400 mL.
218913618|NCT05961722|OTHER|preoperative dextrose 5% 400 ml|Group 2 will be infused with dextrose 5% Dekstroz 400 ml.
218913619|NCT05961722|OTHER|preoperative and intraoperative dextrose 5% 400 ml|Group 3 will be infused with dextrose preoperative 200 ml and intraoperative 200 ml 5% dextrose infusion.
218913620|NCT05655299|DRUG|VTX958 Dose A|Dose A
218913621|NCT05655299|DRUG|VTX958 Dose B|Dose B
218913622|NCT05655299|DRUG|VTX958 Dose C|Dose C
218913623|NCT05655299|DRUG|VTX958 Dose D|Dose D
218913624|NCT05655299|DRUG|Placebo|Placebo
219041414|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
219526623|NCT04638179|OTHER|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
218913625|NCT04386317|DRUG|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
219614764|NCT00886080|PROCEDURE|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
219614765|NCT01333592|DRUG|KAD-1229|
219614766|NCT01043692|OTHER|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
219614767|NCT07086105|DRUG|Adze1.C|Conditionally replicative oncolytic adenovirus expressing CD40L, administered by intratumoural injection in dose escalation cohorts.
218913626|NCT02977403|BEHAVIORAL|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
218913627|NCT02977403|BEHAVIORAL|Sham Comparator: AB Control|"Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location"
218913628|NCT06275451|OTHER|Semi-structured interview|Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
218913629|NCT03710746|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
218913630|NCT03710746|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
218913631|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
218913632|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
218913633|NCT05307874|DRUG|ICT01|anti-BTN3A mAb IV Q3W
218913634|NCT05307874|DRUG|Proleukin Injectable Product|1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
218913635|NCT05307874|DRUG|Pembrolizumab injection|200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W
218913636|NCT05762757|OTHER|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
218913637|NCT06593964|DEVICE|Thermosensitive Nanogel Embolic Agent|Thermosensitive Nanogel Embolic Agent
218913638|NCT06600295|OTHER|tests/questionnaires|EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
218913639|NCT06600295|BIOLOGICAL|biological samples|blood, saliva, tongue mucus
218913640|NCT06600295|OTHER|evaluation|strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
218913641|NCT06597045|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels)."
218913642|NCT06589947|OTHER|Intensified BP control|Treatment goal in the intensified group will be lowering BP ≤60th pct.
218913643|NCT06589947|OTHER|Standard Treatment|Standard treatment is to achieve BP levels \&lt;90th pct.
218913644|NCT06592690|OTHER|Atrial pacing support|Use a pacing mode with atrial pacing including a rate-resposive sensor.
219041415|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
219041416|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
219041417|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
219041418|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
219041419|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
219041420|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
219614768|NCT01380600|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
219614769|NCT07088705|DEVICE|SML 577 nm|"A 577 nm yellow and 810 nm red lasers will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retina between the vascular arches, including the foveal region according to the study protocol.~Patient preparation will include obtaining informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. Next, a Volk macular contact lens (Volk Optical, Mentor, OH, USA) will be placed on the cornea using a viscoelastic agent. A modern 577 nm yellow laser (Supra Scan 577, Quantel Medical, Cedex, France) will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retinal area between the vascular arches, including the foveal region."
219614770|NCT07088705|DEVICE|SML 810 nm|Preparation for SML using an 810 nm red laser will involve informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort during the procedure, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. A Volk macular contact lens (Volk Optical, Mentor, OH, USA) will then be placed on the cornea using a viscoelastic agent. Central retinal stimulation will be performed using an 810 nm SML. The panmacular stimulation protocol will be used, with the laser covering the entire central retinal area between the vascular arcs, including the foveal region. During one session, approximately 1500-2000 confluent local applications of 200 μm diameter will be performed using 1.4 W of power with a duration of 0.15 seconds and a 5% duty cycle.
218913645|NCT06592690|OTHER|Atrial tracking pacing mode|A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
218913646|NCT06603467|PROCEDURE|non-guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested without guide
218913647|NCT06603467|PROCEDURE|guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested with digital guide
218913648|NCT06586385|BEHAVIORAL|disaster education|The ADDIE Instructional Design Model will be used due to its suitability for adult education. General Disaster Awareness Training will be prepared according to the ADDIE instructional design model, which consists of five stages: analysis, design, development, implementation and evaluation. The trainings to be given will be given 1 week after the pre-test, 1 training per week, for a total of 3 trainings.
218913649|NCT06601088|DEVICE|Neuromuscular Electrical Stimulation|Patients will be instructed to apply the wearable NMES-therapy continuously, both day and night at least 10h/daily.
218913650|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Superficial skin biopsy Skin swab
218913651|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
218913652|NCT06589856|DIETARY_SUPPLEMENT|Placebo|Placebo (300 mL salt water, NaCl) = CTR
218913653|NCT06589856|DIETARY_SUPPLEMENT|LAC5|5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
218913654|NCT06589856|DIETARY_SUPPLEMENT|LAC10|10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
218913655|NCT06589856|DIETARY_SUPPLEMENT|LAC20|20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
218913656|NCT06604377|OTHER|Observe|Ruijin
218913657|NCT03735875|DRUG|Quizartinib|Given PO
218913658|NCT03735875|DRUG|Venetoclax|Given PO
218913659|NCT06612320|BEHAVIORAL|Questionnaire about acceptance|Questionnaire about acceptance
218913660|NCT06612320|BEHAVIORAL|Questionnaire about refusal|Questionnaire about refusal
218913661|NCT06612944|DRUG|Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation|"1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1"
218913662|NCT06003283|DRUG|Rituximab|IV rituximab
218913663|NCT06592404|DEVICE|Robot Tessa|"Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale."
218913664|NCT06585878|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.
219041421|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
219041422|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
219041423|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
219041424|NCT00004436|DRUG|leuprolide|
219041425|NCT00004436|DRUG|prednisone|
219041426|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
219041427|NCT04269967|OTHER|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
219526624|NCT01332864|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
219526625|NCT01332864|PROCEDURE|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
219526626|NCT03545828|DIAGNOSTIC_TEST|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
219526627|NCT02080845|DIETARY_SUPPLEMENT|no caffeine|
219526628|NCT02080845|DIETARY_SUPPLEMENT|high caffeine|
219526629|NCT02080845|DIETARY_SUPPLEMENT|no theobromine|
219526630|NCT02080845|DIETARY_SUPPLEMENT|low theobromine|
219526631|NCT02080845|DIETARY_SUPPLEMENT|high theobromine|
219526632|NCT02982356|PROCEDURE|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16\~24 weeks, 24\~27+6 weeks,\>28weeks
219526633|NCT02982356|DRUG|Potassium Chloride|
219526634|NCT03633474|BIOLOGICAL|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
219526635|NCT03633474|OTHER|PBS only|Sterile PBS only containing no bacteria
218913665|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with obstetric care providers
218913666|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with study RN.
218913667|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine and beetroot juice|Combined effect of beetroot juice and caffeine intake on muscular strength, power and endurance performance
218913668|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine|single effect of caffeine intake on muscular strength, power and endurance performance
218913669|NCT06596395|DIETARY_SUPPLEMENT|Acute beetroot juice|single effect of beetroot juice intake on muscular strength, power and endurance performance
218913670|NCT06596395|DIETARY_SUPPLEMENT|Placebo|single effect of placebo on muscular strength, power and endurance performance
218913671|NCT06990529|DRUG|Leniolisib|All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).
218913672|NCT06998368|DRUG|Nimodipine Capsules|Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
218913673|NCT06998368|RADIATION|5G RF-EMF|Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency \[TDD\] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.
218913674|NCT06998472|OTHER|Tuina|According to traditional Chinese medicine (TCM), children's physiological characteristics include immature and delicate internal organs, as well as underdeveloped qi and physical form. Pathologically, their organ systems are described as light and responsive, meaning they react quickly to both internal and external stimuli. Therefore, pediatric tuina must prioritize gentleness in technique. The applied pressure should not exceed 0.3 kilograms, and the depth of skin indentation should not go beyond 0.3 centimeters.
218913675|NCT06998472|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
218913676|NCT02422706|DRUG|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
218913677|NCT02422706|DRUG|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
218913678|NCT02422706|DRUG|Omeprazole|Omeprazole 20 twice daily
218913679|NCT02422706|DRUG|Clarithromycin|KLacid twice daily
218913680|NCT02422706|DRUG|Levofloxacin|Tavanic. Tavacin
218913681|NCT02422706|DRUG|Doxicycline|Vibramycin 100 mg twice daily
218913682|NCT06998979|BEHAVIORAL|Music therapy|"The music was generated using a beta version of the RIFFUSION program, which is still in its development phase and being refined based on user input. This software operates using neural networks similar to Generative Adversarial Networks (GANs), known as diffusion models. These models begin with random noise and gradually transform it into a musical composition through a process that involves two phases: a diffusion phase-where an existing musical sample is disordered by adding random noise-and a reverse phase, in which the noise is removed to reconstruct a new and distinct musical piece.~The prompt entered into the program was: Relaxing slow music for people with great stress and extreme anxiety and panic caused by dental surgery with effects of wind and waterfall. A total of 20 songs were generated and merged to achieve a combined duration of 49.20 minutes."
218913683|NCT06600464|DIAGNOSTIC_TEST|Ultrasound|The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound.
218913684|NCT06600464|OTHER|Assessment of Muscle Strength in Both Hands|Muscle strength in both hands was evaluated using grip strength measured with a dynamometer (Jamar Hydraulic Hand Dynamometer, Nottinghamshire, UK)
218913685|NCT06600464|OTHER|Assessment of Pain Threshold|Pressure pain threshold (PPT) for painful and non-painful finger joints was assessed using a hand-held algometer
218913686|NCT06997991|PROCEDURE|adipose micro-grafts injection|Patients were positioned supine, and local anesthesia was administered. A small incision was made to introduce a blunt cannula attached to a Luer-lock 60-cc syringe. Klein sterile solution, containing saline and lidocaine, was injected into the subcutaneous fat layer of either the abdominal or thigh region. Subsequently, approximately 30 mL of adipose tissue was extracted. The collected lipoaspirate was processed under sterile conditions in a closed system using Rigenera® technology (HBW, Turin, Italy). Before injecting, the skin was sterilely dressed, and the injection of 2-3 mL of aMAT was performed into TMC joint with a superolateral approach, under fluoroscopic X-ray guidance and using a disposable 20G needle and a 3 mL Luer-Lock Syringe.
219041428|NCT01968018|DRUG|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
219614771|NCT07088705|OTHER|Sham SML|It is worth emphasizing that the experiment was designed as a factorial study design with the patient blinded. To this end, patient preparation, laser treatment duration, and auditory and visual sensations during the sham procedure will be the same as those experienced with a truly lasered eye. Consequently, fellow eye of an each RP eye that undergone the SML stimulation in either arm 1 or 2 will be included in the sham group (60 eyes).
219614772|NCT03727451|COMBINATION_PRODUCT|iNO|inhaled nitric oxide
219614773|NCT07096336|DIETARY_SUPPLEMENT|vitamin D3 capsule|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
219614774|NCT07096284|DIAGNOSTIC_TEST|PvCO2-PaCO2/CaO2-CvO2 ratio|"Patients diagnosed with septic shock will undergo serial measurements of arterial and venous blood gas analyses, arterial lactate levels, and calculation of the Pv-aCO₂/Ca-vO₂ ratio at predefined time points: H0 (baseline), H2, H6, H12, and H24.~Calculation Formulas:~1. Arterial Oxygen Content (CaO₂):CaO2 = SaO2 × Hb × 1,34 + PaO2 × 0,0031~2. Venous Oxygen Content (CvO₂):CvO2 = SvO2 × Hb × 1,34 + PvO2 × 0,0031~3. Pv-aCO₂/Ca-vO₂ Ratio: P(v-a) CO2/C(a-v)O2=(PcvCO2-PaCO2)/(CaO2 -CcvO2)."
219614775|NCT07096960|BEHAVIORAL|STrAtegies for RelaTives (START) - Brazilian version|Eight individualized, weekly, home-based sessions will be delivered by trained community general health workers (CGHW). The intervention includes coping strategies, behavior management, and communication skills. Caregivers receive printed materials and structured exercises. CGHW receive a facilitator manual.
219526636|NCT04320420|OTHER|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
219614776|NCT07097675|BEHAVIORAL|Art Therapy|"Art Therapy Session Plan The sessions are designed to stimulate positive feelings, satisfaction, and calmness while reducing social isolation and fostering group connections. The focus will be on pleasant experiences and positive life moments, with an emphasis on identifying current strengths and capabilities. Every session begins with a sharing activity: Name three good things that happened this morning or Name three things you are grateful for today.~Session Structure:~Mood check-in → Warm-up task → Main task → Reflection → Mood check-out."
219614777|NCT07095907|PROCEDURE|Pars plana vitrectomy with epiretinal membrane peeling and controlled macular detachment|Currently, vitrectomy with epiretinal membrane peeling is the standard procedure; however, its ability to improve visual acuity in these patients remains limited. In this context, controlled macular detachment is emerging as a surgical alternative that could optimize the anatomical and functional restoration of the retina.
219614778|NCT07095387|BEHAVIORAL|Making room for climate emotions in the classroom|This intervention combined creative arts workshops using drawing, photography, painting and collage to introduce a theme related to climate change and promote emotional expression. The artistic creation was followed by a philosophical inquiry group discussion on a theme related to the artistic creation to allow critical thinking and sharing perceptions.
219614779|NCT07096531|OTHER|Suit therapy|Patients will receive suit therapy.
218913687|NCT06589310|DEVICE|Exact Sciences Multicancer Early Detection (MCED) Test|Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.
219614780|NCT07096531|OTHER|Suit therapy + Dual-task exercises|Patients will receive suit therapy in addition to dual-task exercises.
218913688|NCT06589492|DIAGNOSTIC_TEST|Measurement of MMP-9 and SIRT-1 levels in blood serum|Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
218913689|NCT06999057|DEVICE|Joint Effusion via 60 mL Sterile Saline|Injection of sterile saline into the knee joint to simulate joint swelling and induce quadriceps inhibition.
218913690|NCT06999057|DRUG|Intra-articular Lidocaine|Injection of 7 mL lidocaine into the knee joint to simulate deafferentation by temporarily blocking sensory input.
218913691|NCT06999057|OTHER|Sham injection|Simulated knee injection using a stage needle without skin penetration, used to blind participants and serve as control.
218913692|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells administered via Ommaya reservoir；2.0\*10\^7 cell/dose
219526637|NCT01887691|DRUG|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
219614781|NCT07096882|BIOLOGICAL|SDT-M001 injection|Cascade primed immune cells(CAPRI); SDT-M001 injection is administered at three dose levels:1.5e9 cells, 3e9 cells,6e9 cells. The cells will be reinfused in 3 divided doses, administered every other day, and the total process will take 5 days.
219614782|NCT07096778|DRUG|Inobrodib|40 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
219614783|NCT07096778|DRUG|Pomalidomide|4 mg orally once daily on Day 1 to 21 of each 28-day cycle
219614784|NCT07096778|DRUG|Dexamethasone|40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle
219614785|NCT07097207|COMBINATION_PRODUCT|CAR-T cell|Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T or CD19-CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.
219614786|NCT07095998|DIAGNOSTIC_TEST|Threshold Tracking Nerve Conduction Studies|Measurement of nerve excitability parameters, including response to sub-threshold pre-pulses and other stimuli. The DS5 0 Isolated Bipolar Constant Current Stimulator is a non-invasive, non-therapeutic device that provides controlled electrical stimuli for detailed function assessment of the superficial radial, superficial peroneal, ulnar, and sural nerves.
219614787|NCT07096128|DRUG|[177Lu]Lu-PSMA-XT|\[177Lu\]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells.
219614788|NCT07095673|BEHAVIORAL|HealthyWE|Following baseline assessment, 60 residents will be enrolled in HealthyWE Corps program. HealthyWE Corps includes training sessions on keeping a healthy weight, healthy diet, and mental health wellness. The content of the HealthyWE protocol was carefully designed choosing skills shown to be efficacious in keeping a healthy weight and reducing pain. Self-efficacy theory guides the intervention. Behavioral interventions for reducing and managing obesity focus on building adults' self-management skills to be implemented in their daily lives. To achieve the therapeutic effects, individuals have to execute self-management skills in their daily lives. Self-efficacy is defined as a person's belief in his/her ability to perform specific skills to reduce and manage obesity.
218913693|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；Low-dose group; 2.5\*10\^6 cell/dose
218913694|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；High-dose group; 1.0\*10\^7 cell/dose
218913695|NCT06999434|DRUG|[ 18F]3F4AP|PET Scan #3
218913696|NCT06999434|DRUG|[18F]MK6240|PET Scan #2
218913697|NCT06999434|DRUG|[11C]PIB|PET Scan #1
219614789|NCT07096492|OTHER|Standard Swimming Training|Warm-Up: 1500 meters. Main set: 2000-3000 meters. Post-set: 1000 meters. Cool-Down: 200-400 meters.
219614790|NCT07096492|OTHER|Plyometric Training|The plyometric training intervention will focus on developing explosive power and reaction speed through various jumping and landing exercises. Progressive overload principles will be applied, with progression achieved through increasing sets and intensity. Plyometric exercises will be performed twice a week, similar to the strength group, and will begin with 3 sets of 3 repetitions in the first week. As the body adapts to the exercises, one additional set will be added each week until the third week, which will conclude with 5 sets. In the fourth week, a deload will be incorporated with 2 sets to allow for recovery. After the deload week, intensity will increase, either by performing exercises faster or exerting maximum effort during each repetition. Upper-body exercises will include the medicine ball slam, sitting medicine ball side passes, and medicine ball chest passes, focusing on explosive upper body movements. Lower-body exercises will consist of standing long jumps, partner med
219041429|NCT01450410|DRUG|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
218913698|NCT06601530|PROCEDURE|Transversus Thoracic Muscle Plane Block|Transversus thoracic muscle plane block is a single-shot nerve block technique that provides analgesia for the anterior chest wall Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
218913699|NCT06601530|DRUG|Tramadol|Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
218913700|NCT06999512|PROCEDURE|Comprehensive Geriatric Assessment|"CGA:~* Preoperative geriatric consultation~* Perioperative tailored intervention if needed~* Postoperative geriatric follow-up~* M3 geriatric consultation"
218913701|NCT04243499|BIOLOGICAL|IV ICT01|humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
218913702|NCT06999356|DEVICE|CGM Device|Fruits and Vegetables and some groups will get CGM devices along with Fruits and Vegetables
219041430|NCT01450410|DRUG|Placebo|Placebo treatment will last for 12 weeks.
219041431|NCT01965808|DRUG|LY2157299|Administered orally
219041432|NCT03003975|DEVICE|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
218913703|NCT06999252|DRUG|Rimegepant|Take 75 mg every other day
218913704|NCT06999252|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
218913705|NCT06998719|DRUG|Durvalumab|Neoadjuvant durvalumab (MEDI 4736)and platinum-based chemotherapy, followed by either surgery and adjuvant durvalumab or CRT and consolidation durvalumab, in borderline resectable stage III NSCLC
218913706|NCT06999941|DRUG|Deucravacitinib 6mg po qd|oral administration
218913707|NCT04875975|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
218913708|NCT04875975|DRUG|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
218913710|NCT06997952|DRUG|Febuxostat 40 mg|Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.
219041433|NCT03003975|DEVICE|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
218913711|NCT06998459|OTHER|Bian-Stone therapy|Once a week, each session lasting 30 minutes, for a duration of six months.
218913712|NCT06998459|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
218913713|NCT06998238|BEHAVIORAL|Mediterranean-based, carbohydrate restricted, calorie reduced diet|Dietary intervention - calorie reduced (300-500 kcal/day below estimated energy needs), carbohydrate restricted (\<100 grams of available carbohydrates per day), Mediterranean-based (high fat diet with an emphasis on the addition of healthy fats - nuts, avocados, olive oil, increasing whole grains, increasing fruit and vegetables, replacing red meats with fish and poultry, reducing dairy, and reducing added sugars) diet.
219526638|NCT01996527|DEVICE|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
219526639|NCT01996527|DEVICE|CEST-MRI|Undergo CEST-MRI
219526640|NCT01996527|DEVICE|DW-MRI|Undergo DWI-MRI
218913714|NCT06434337|DIAGNOSTIC_TEST|"Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)"|Given by Diagnostic Test
218913715|NCT06998641|PROCEDURE|Chitosan-covered-gauze application|Effectiveness of chitosan-covered-gauze in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
218913716|NCT06998641|PROCEDURE|Suturation|Effectiveness of suturation in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
218913717|NCT06999733|BIOLOGICAL|KB801|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-based vector delivering functional, full-length human nerve growth factor (NGF)
218913718|NCT06999733|DRUG|Placebo|Vehicle
218913719|NCT06999083|DRUG|HB0043|HB0043 Drug Product
219526641|NCT01996527|DEVICE|DCE-MRI|Undergo DCE-MRI
218913720|NCT06999083|DRUG|Placebo|Placebo
218913721|NCT06999421|DEVICE|Robot with interactive animations, gesture recognition, and touch/voice-based input|A humanoid educational robot that provides GDM-related content using animated videos, emotional facial expressions, gesture movements, and voice/touch-based interaction. Designed to increase engagement, reduce anxiety, and improve health literacy among pregnant women.
219526642|NCT01996527|DEVICE|DSC-MRI|Undergo DSC-MRI
219526643|NCT01996527|DRUG|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
219526644|NCT06328491|DRUG|Erdafitinib|Protein Kinase Inhibitor
219526645|NCT03627780|DIAGNOSTIC_TEST|DNA extraction|DNA will be extracted from white cells
219526646|NCT05017480|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
219614791|NCT07096492|OTHER|Strength Training|The strength training intervention was designed to supplement standard swim training with a structured, full-body resistance program aimed at enhancing muscular strength and swimming biomechanics through progressive overload. Participants in the strength group engaged in two sessions per week for each major muscle group. Training commenced with 3 sets of 8 repetitions per exercise during the first week, with weekly increases in training volume until the third week (5 sets), followed by a deload week (3 sets) to promote recovery. The subsequent four weeks maintained a consistent 5-set structure, with progression achieved through incremental increases in load. Each session began with lower-body exercises to prioritize large muscle group activation and maximize session efficiency. Lower-body exercises included dumbbell goblet squats, step-ups, Romanian deadlifts, TRX hamstring curls, and calf raises, while upper-body work featured push-ups, TRX rows, dumbbell rows, and dumbbell shoulder p
219614792|NCT07097311|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg/day. The dose will be titrated from Day 1-24.
219614793|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|"Adductor Canal Block (ACB) in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gaugusing a 22-gauge 100-mm short-bevelled regional block needle.~IPACK Block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of bupivacaine 0.25% will be injected after negative aspiration."
219614794|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block (sham injection)|All patients will receive Adductor Canal Block in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gauge 100-mm short-bevelled regional block needle IPACK block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of normal saline will be injected after negative aspiration.
219614795|NCT07097844|DRUG|0.8 mL/kg of 0.25% bupivacaine|0.8 mL/kg of 0.25% bupivacaine
219526647|NCT05017480|DRUG|Placebo|subcutaneous(SC) injection
218913722|NCT06999421|DEVICE|Standard tablet (video playback only).|A standard touchscreen tablet used to deliver pre-recorded educational videos on GDM. This intervention provides passive viewing without any robot interaction or feedback.
218913723|NCT06617312|DRUG|Cytisinicline|Targets α4β2 nicotinic acetylcholine receptors
218913724|NCT06617312|DRUG|Placebo Oral Capsule|Matched to active drug, cytisinicline
218913725|NCT06589739|DEVICE|Virtual Reality Headset|A virtual reality headset will be placed on patients\&#39; head before and during chest drain insertion
219041434|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
219526648|NCT03521765|OTHER|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
219526649|NCT01794039|DRUG|Dexamethasone|Given PO
219526650|NCT01794039|DRUG|Lenalidomide|Given PO
219526651|NCT01794039|DRUG|Pomalidomide|Given PO
219614796|NCT07095348|OTHER|Serum Xanthine Oxidase Level Assessment|Blood samples were collected from each participant and serum was separated by centrifugation. Serum xanthine oxidase (XO) levels were measured using a Human XO ELISA Kit (Cat No. E3495Hu) according to the manufacturer's instructions. This intervention involved no therapeutic intent and was performed for observational biomarker analysis only.
219614797|NCT07096648|DEVICE|Continuous vital sign monitoring|Continuous monitoring of vital signs performed using up to three CE- and FDA approved devices measuring heart rate, respiratory rate, systolic- and diastolic blood pressure, and SpO2. Data is transmitted to a CE-approved smartphone application that generates alerts in response to deviations based on predefined thresholds for duration and severity.
218913726|NCT06594172|DRUG|Memantine Oral Tablet|"Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily."
218913727|NCT06594172|DRUG|Pioglitazone 15mg|"Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily."
218913728|NCT06594172|RADIATION|Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)|Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).
218913729|NCT03234699|DRUG|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
218913730|NCT03234699|DRUG|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
218913731|NCT03234699|DRUG|Warfarin Pill|5 mg (Days 7 and 105)
218913732|NCT03234699|DRUG|Omeprazole Pill|20 mg (Days 7 and 105)
218913733|NCT03234699|DRUG|Bupropion Pill|150 mg (Days 1 and 99)
218913734|NCT04752618|BEHAVIORAL|P-STAIR|PCIT+ STAIR
218913735|NCT04752618|BEHAVIORAL|Supportive Counseling|Non-trauma focused psychotherapy
218913736|NCT00694629|DRUG|rifampin|tablet, 10 mg/kg, daily, 8 weeks
218913737|NCT00694629|DRUG|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
218913738|NCT00694629|DRUG|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
218913739|NCT00694629|DRUG|rifapentine|20 mg/kg, daily, 8 weeks
218913740|NCT06547619|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
218913741|NCT06084026|OTHER|ActivPal|Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
218913742|NCT04093297|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
219041435|NCT00091299|DRUG|warfarin|
218913743|NCT06236893|OTHER|VH-01 vaginal suppository tablet|Participants will be instructed to take VH-01 Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
218913744|NCT06236893|OTHER|Placebo vaginal suppository tablet|Participants will be instructed to take the placebo on Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
218913745|NCT06589752|DRUG|TARPEYO 4 MG Delayed Release Oral Capsule|TARPEYO dispensing claim for any dose is exposure
218913746|NCT06589752|DRUG|RAS inhibitor|RASi dispensing claim for any dose is reference
218913747|NCT06592716|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free HPV-DNA.
218913748|NCT06599489|PROCEDURE|surgery ..operation|sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
218913749|NCT06869252|BIOLOGICAL|Autologous Adipose Cells Therapy|Participants will receive Autologous Adipose Cells therapy treatment, and the safety and efficacy of the treatment will be monitored by the primary investigator up to 25 weeks.
218913750|NCT06595225|BEHAVIORAL|Nutrition education sessions|Participants received nutrition education each month, covering topics ranging from general nutrition knowledge, nutrition knowledge related to their diagnosis of living with HIV infection whether during the acute or chronic phase. In addition, specific information was shared about other comorbidities the participant could be living with, finally information was shared on ways to improve mental health and enhance physical activity levels.
219041436|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
219041437|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
219365475|NCT02649634|BEHAVIORAL|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
219526652|NCT01136382|DRUG|budesonide|pMDI, inhalation, bid, 6 weeks
219614798|NCT07096635|DRUG|Melatonin|Patients will receive oral melatonin 10 mg (two 5 mg tablets) one hour before the operation plus intra-articular analgesia at the end of surgery.
219614799|NCT07096635|OTHER|Starch tablets|Patients will receive two oral inert starch tablets of the same shape and color one hour before the operation plus intra-articular analgesia at the end of surgery.
219614800|NCT07095881|OTHER|Zirconia-based composite customized healing abutment|using Zirconia-based composite in customized healing abutment fabrication
219526653|NCT01136382|DRUG|placebo|pMDI, inhalation, bid, 6 weeks
219526654|NCT00963482|BEHAVIORAL|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
219526655|NCT00963482|BEHAVIORAL|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
219041438|NCT05180903|OTHER|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
219526656|NCT02072577|BEHAVIORAL|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
219526657|NCT06559670|OTHER|Blood sampling|\- Collection and analysis of blood samples
219041439|NCT02908113|BEHAVIORAL|collection data|
219526658|NCT05074472|DRUG|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
219526659|NCT04707040|OTHER|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
219614801|NCT07095881|OTHER|Conventional composite customized healing abutment.|using conventional composite in customized healing abutment fabrication
219614802|NCT07096986|DRUG|Forxiga|dapagliflozin treatment at a dose of 10 mg per os daily for 6 months
219041440|NCT02908113|BEHAVIORAL|IRM|
219041441|NCT02018289|PROCEDURE|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
219526660|NCT04660656|DIAGNOSTIC_TEST|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
219614803|NCT07096089|PROCEDURE|Conventional physical therapy program and Sling exercise therapy|The control group received a conventional physical therapy program in addition to sling exercise therapy (SET) for 60 minutes.
219614804|NCT07096089|PROCEDURE|Whole body vibration|The study group received the same selected conventional physical therapy program in addition to sling exercise therapy (SET) given to the control group (for 30 minutes) besides whole body vibration (WBV) (for 30 minutes).
219614805|NCT07096596|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219041442|NCT02018289|PROCEDURE|No triclosan|Suture of the abdominal wall with suture without triclosan coat
219041443|NCT04949269|DRUG|Deucravacitinib|Specified dose on specified days
219526661|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
219526662|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
219526663|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
219041444|NCT04949269|DRUG|Famotidine|Specified dose on specified days
219526664|NCT00746798|BIOLOGICAL|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
219526665|NCT04164589|DEVICE|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
219526666|NCT04230525|DIAGNOSTIC_TEST|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
219526667|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on saturated fat.
219526668|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
219526669|NCT05113056|DEVICE|Acutus Medical Pulsed Field Ablation System|All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
219526670|NCT04915352|DRUG|Nasal provocation test - 725 Dermatophagoides Pteronyssinus|"3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months"
219526671|NCT04915352|OTHER|Negative control|Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
219526672|NCT02896361|DEVICE|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
219526673|NCT00302705|DRUG|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
219526674|NCT00302705|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
219526675|NCT00302705|PROCEDURE|Missing one dose|Patients skip the dose the second day of monitoring
219526676|NCT03818945|DRUG|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
219526677|NCT03818945|DRUG|Sodium fluoride varnish|5% sodium fluoride \[22,600 ppm F-\]
219526678|NCT05116228|DRUG|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
219526679|NCT05116228|DRUG|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
219526680|NCT03503448|PROCEDURE|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
219526681|NCT03503448|PROCEDURE|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
219526682|NCT00556049|DRUG|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
219526683|NCT00556049|DRUG|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
219526684|NCT05852847|DRUG|Baricitinib 2 MG [Olumiant]|Oral baricitinib was given at a dose of 2 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
219526685|NCT05852847|DRUG|Danazol|Danazol was given at a dose of 200 mg bid for 6 months
219526686|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
219526687|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
219614806|NCT07095335|OTHER|education intervention A-CHARM|Didactic education plus virtual simulation regarding discrimination in the hospital setting
218913751|NCT01360697|OTHER|JADE|"1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information."
218913752|NCT01360697|OTHER|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
218913753|NCT06871683|DEVICE|ClotTriever® Thrombectomy System|ClotTriever® Thrombectomy System use for treatment of patients with deep vein thrombosis with acute severe symptoms.
218913754|NCT06276322|OTHER|Low back pain group|The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
218913755|NCT06276322|OTHER|Healthy group|Low back pain kinematics compare them with asymptomatic kontrols
218913756|NCT06284005|DEVICE|WRL ATP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
218913757|NCT00380055|BEHAVIORAL|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
218913758|NCT00380055|BEHAVIORAL|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
218913759|NCT05943834|OTHER|Series of cognitive tasks during a semi-automated call|"Tasks:~* Verbal learning recall (immediate) or Story Recall task (immediate)~* Narrative Storytelling /free speech~* Verbal fluency task~* Verbal learning recall (delayed) or Story Recall task (delayed)"
219041445|NCT00011089|DRUG|Tenofovir disoproxil fumarate|
219614807|NCT07094945|DRUG|Remimazolam|Remimazolam 0.3 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 0.6-1.0 mg/kg·h is used for anesthesia maintenance.
219614808|NCT07094945|DRUG|Propofol|Propofol 2 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 4-12 mg/kg·h is used for anesthesia maintenance
219614809|NCT07097181|BEHAVIORAL|web-based sensory awareness training|"The girl in the intervention group of the study 4 weeks to inform students, raise awareness and provide sensory education. Sensory awareness training will be provided throughout. Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program.~protocol will be applied."
219614810|NCT07095686|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
218913760|NCT05856422|DEVICE|Respiratory rate measure based on PPG|"Testing was conducted under normal office environment conditions. Each subject was connected to the reference EtCO2 monitor (GE Datex-Ohmeda) and the Device Under Test, the Gabi SmartCare Gabi Band. A waveform collected from an EtCO2 measurement was used to determine performance of respiratory rate metrics. Each subject was given a nasal cannula that allowed for measurement of the EtCO2 respiratory rate.~The reference respiratory rate was measured simultaneously with the Device Under Test. Data was marked for stable quiet periods that were useable for analysis."
219041446|NCT00198016|DEVICE|Coil|
219614811|NCT03065192|DRUG|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
219614812|NCT00955617|OTHER|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
219041447|NCT05645822|OTHER|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
219041448|NCT04720365|DEVICE|play-based rehabilitaion|usual re-education treatment by their physiotherapist
219041449|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
219526688|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
219526689|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
219526690|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
219614813|NCT07097740|DEVICE|Polymer Prosthetic Heart Valve|Surgical implantation of polymer prosthetic valve.
218913761|NCT06702319|OTHER|Exercise|Home exercises and home exercises with internal focus exercises or external focus exercises
219526691|NCT00503152|DRUG|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
219526692|NCT00503152|DRUG|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
219526693|NCT00503152|DRUG|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
219526694|NCT03673488|DEVICE|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
219526695|NCT03021720|PROCEDURE|Arterial access|Location of arterial puncture
219526696|NCT05575180|DRUG|Acetazolamide 250Mg Tab|Oral acetazolamide
219526697|NCT05575180|DRUG|Methazolamide Pill|Oral Methazolamide
219526698|NCT05575180|DRUG|Placebo|Oral placebo
219526699|NCT02298465|PROCEDURE|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
219526700|NCT02298465|PROCEDURE|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
219526701|NCT02298465|DEVICE|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
219526702|NCT04043871|DIAGNOSTIC_TEST|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
219614814|NCT07095816|DRUG|Acetaminophen|A prospective randomized controlled trial was conducted involving pediatric patients with solid tumors. Participants who met the inclusion criteria were randomly assigned using a computer-generated random number table. The APAP group was administered acetaminophen orally at a dose of 10 mg/kg body weight 2 hours before the surgical procedure.
219614815|NCT07095816|DRUG|Sterilized water|The placebo group was administered 10 mg/kg of sterile water orally two hours before the surgical procedure.
218913762|NCT06704282|BEHAVIORAL|VR Mindfulness Meditation Program|A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
218913763|NCT06702644|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
218913764|NCT06702644|DEVICE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
219614816|NCT07097051|OTHER|real tACS|Those who randomized into real tACS arm will receive ten-session of individually tailored tACS targeting peak alpha power for 20-minutes
218913765|NCT06704555|RADIATION|radiation therapy|received radiation (dose:18～24Gy)
219614817|NCT07097051|OTHER|sham tACS|Those who randomized into sham tACS arm will receive ten-session of active sham tACS intervention for 20-minutes
219614818|NCT06076733|DEVICE|high definition-transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219614819|NCT06076733|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219614820|NCT01532401|OTHER|sodium chloride|sodium chloride 500mg
219614821|NCT01532401|OTHER|Methylcellulose crystalline|Methylcellulose 37 ml
219614822|NCT00003405|BIOLOGICAL|recombinant interferon alfa|
219614823|NCT00003405|DRUG|amifostine trihydrate|
219614824|NCT00003405|DRUG|bromodeoxyuridine|
219614825|NCT00003405|DRUG|cytarabine|
219614826|NCT00003405|DRUG|idarubicin|
218913766|NCT06704555|DRUG|Tiselizumab|200 mg iv day 1
219614827|NCT00003405|DRUG|idoxuridine|
219614828|NCT00003405|DRUG|isotretinoin|
219614829|NCT00003405|DRUG|mitoxantrone hydrochloride|
219614830|NCT06774521|OTHER|control|There is no intervention
218913767|NCT06704555|DRUG|Rituximab|375 mg/m2 intravenous \[IV\] day 2
218913768|NCT06704555|DRUG|Cyclophosphamide|750 mg/m2 IV day 3
218913769|NCT06704555|DRUG|Doxorubicin|50 mg/m2 IV day 3
218913770|NCT06704555|DRUG|Vincristine|1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
218913771|NCT06704555|DRUG|Prednisone|100 mg oral days 3-7
218913772|NCT06705777|DRUG|Combinations|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
218913773|NCT06706011|OTHER|Virtual Patient|Interactive Educational Activity
219526703|NCT06217653|BEHAVIORAL|mother baby yoga|"Yoga Video Content Plan~* Mood Regulation: Abdominal/Belly Breathing~* Warm Touch from the Heart~* Chair Posture~* Bucket Wrapping~* Bukka Bukka (Heart)~* Vortex Generation~* Fertile Falls~* One Hand Two Hands~* Tiny Stretches~* Here and Now Awareness~* Dolphin Pose Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes."
219526704|NCT06113653|OTHER|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
219526705|NCT04131751|DIAGNOSTIC_TEST|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
219526706|NCT00156247|DRUG|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
219614831|NCT06774521|OTHER|reformer|"Reformer exercises:~Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star"
218913774|NCT06706180|OTHER|Exercise for Mood video|As per arm of the same name
218913775|NCT06706180|OTHER|Exercise for Fitness video|As per arm of the same name
218913776|NCT06704308|BEHAVIORAL|Web Application|A web application for vaccine-hesitant parents and their teens with brief, 90-second narrative videos and tailored, motivational content
218913777|NCT06704308|BEHAVIORAL|Provider Elaborated Prompts|A component for providers that suggests elaborated prompts to be used with parents that align with the content of the web application, are tailored to parent concerns, and are motivational in nature
218913778|NCT06704529|BEHAVIORAL|pitching motion|participants pitch fastball to the strike zone
218913779|NCT06704438|DIAGNOSTIC_TEST|D-Lactate|D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
218913780|NCT04104854|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
218913781|NCT06706388|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
218913782|NCT06706037|OTHER|Exercise|A 6 week reformer pilates exercise program
218913783|NCT06705244|PROCEDURE|Trans-nasal sphenopalatine nerve block|"The patient was placed supine with shoulders slightly elevated to flex the neck and extend the head.~Then anterior nares were inspected for polyps, tumors, or significant septal deviation.~Long cotton-tipped applicators saturated with lidocaine 2% were inserted into each naris, until properly seated in the posterior nasopharynx.~These were left in place for 10 minutes to lubricate and anesthetize the mucous membrane, making the procedure more comfortable.~Then a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg were injected through the applicators in the sphenopalatine area in each nostril.~Then the patient was positioned sitting and pain assessments were recorded."
218913784|NCT06705244|PROCEDURE|Greater and lesser occipital nerve block|"The back of the head was sterilized with an antiseptic solution and the landmarks at the base of the skull were identified while the patient in the prone position.~The landmarks were located on the medial third of a line drawn from occipital protuberance to mastoid process. At this level, the greater and lesser occipital nerves lie along the superior nuchal line medial to the occipital artery, halfway between the occipital protuberance and mastoid process.~Under Ultrasound guidance, the skin was infiltrated with 1-2 mL of lidocaine 2%, using a 25-gauge needle. Then the block was performed in this area with a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg to block greater and lesser occipital nerves. Then the procedure was repeated on the other side.~After the procedure, the presence of bilateral occipital numbness was confirmed after 30 minutes. The patient was then positioned sitting and pain scoring was assessed."
218913785|NCT06706531|PROCEDURE|Standard treatment|All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
218913786|NCT06706531|PROCEDURE|Sham Dry needling|The sham dry needling group will also receive 6 sessions of sham dry needling on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes.Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm.The plantar and medial surface of the foot and ankle will be cleaned with alcohol. The sham dry needling will be performed for 5 minutes.
219614832|NCT06774521|OTHER|mat|"Mat exercises:~Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises"
219614833|NCT06948136|DRUG|Delta-9-THC Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
219614834|NCT06948136|DRUG|Placebo|Small amount of sterile ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
219614835|NCT06948136|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes
219614836|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
218913787|NCT06706531|PROCEDURE|Dry needling|The dry needling group will receive 6 sessions of dry needling using a standardized trigger point protocol on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes. Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm. The calf, plantar and medial surface of the foot and ankle will be cleaned with alcohol. Following insertion, needles will be manipulated bi-directionally to elicit a sensation of aching, tingling, deep pressure, heaviness or warmth. The needles will then left in situ for 5 minutes.
219041450|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
219526707|NCT01511939|DRUG|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
219526708|NCT04568408|DEVICE|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
219614837|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
219614838|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
219614839|NCT01110590|DRUG|Placebo|Placebo
218913788|NCT06705556|PROCEDURE|Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking|"The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day"
218913789|NCT06705556|PROCEDURE|incentive spirometer, percussion, 3-minute of walking|"The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day"
218913790|NCT06706375|PROCEDURE|Using ultrasound for penile nerve block|30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi
218913791|NCT06706375|PROCEDURE|Dorsal Penile Block Anesthesia using landmarks|Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
218913792|NCT06705049|RADIATION|MRI|On MRI, some lesions present as linear enhancement, while others exhibit nodular enhancement
218913793|NCT05262075|OTHER|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
218913794|NCT04045535|OTHER|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
218913795|NCT04045535|OTHER|Usual care|Usual clinical care based on current clinical practice guidelines.
218913796|NCT06704360|DEVICE|immersive VR pathfinding training|Pathfinding training with immersive VR.
218913797|NCT06704360|OTHER|Occupational therapy|Only receive conventional cognitive training group
218913798|NCT06705920|DRUG|topical oxygen gel|In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab
218913799|NCT03082690|DRUG|DuoGel|1% IQP-0528 in gel formulation
218913800|NCT02914158|DRUG|Goserelin|
218913801|NCT02914158|DRUG|Tamoxifen|
218913802|NCT02914158|DRUG|Aromatase Inhibitors|
218913803|NCT02914158|DRUG|Leuprolide|
219526709|NCT01163760|DEVICE|etafilcon A|daily disposable contact lens
218913804|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
218913805|NCT06933927|OTHER|(Group A: Bioflx crowns)|Minimal preparation will be required due to their flexural adaptability:1. Choose an appropriately sized Bioflex (Nusmile) crown of similar size to the mesiodistal width.2. The tooth will be prepared using a flame stone for occlusal reduction by 1-1.5 mm, including the central groove .3Proximal preparation will be around 0.5 mm, by using a fine, long, tapered diamond stone to cut interproximal slices mesially and distally.4. The crown will be placed with a snug fit and cemented using glass ionomer
218913806|NCT06933927|OTHER|(Group B) : Preformed Zirconia crown|1\. Size Determination can be achieved by holding a crown up to the existing tooth or, if available, using digital x-ray measurements to match the patient's interproximal width to the corresponding crown size.2. OcclusalPerform an occlusal reduction of about 1.5-2 mm, ensuring adequate space for the crown material. 3. Axial ReductionReduce the buccal and lingual surfaces uniformly, ensuring the removal of any prominent buccal bulges to allow for a passive crown fit. 4. Interproximal ReductionClearance: Ensure sufficient interproximal space by removing enough tooth structure to allow the crown to seat without interference.5. Subgingival PreparationMargin Placement: Extend the preparation subgingivally by approximately 2 mm to achieve optimal crown retention and aesthetics. This involves removing the chamfer margin at the tissue level and ensuring a smooth transition from the root to the coronal tooth structure
219041451|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
219526710|NCT01163760|DEVICE|ocufilcon D|daily disposable contact lens
219526711|NCT00324168|DRUG|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
219526712|NCT00324168|DRUG|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
219526713|NCT00324168|DRUG|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
219526714|NCT02987491|BEHAVIORAL|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
219614840|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
219614841|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
219526715|NCT05966571|PROCEDURE|Ovary Biopsie|Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
219526716|NCT03171493|BIOLOGICAL|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
219526717|NCT04433871|OTHER|No intervention, observational|No intervention, observational
219526718|NCT01836341|DRUG|Afatinib|
219526719|NCT01836341|DRUG|Cisplatin|
219614842|NCT05971940|DRUG|Orforglipron|Administered orally.
218913807|NCT03307109|OTHER|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
218913808|NCT06932198|DRUG|Selexipag Film Coated Tablets|1 tablet
218913809|NCT06932198|DRUG|Uptravi® Film Coated Tablets|1 tablet
218913810|NCT06938048|OTHER|short stretch bendage (Lohmann e Raucher)|extensibility between 10% to 100% of the lenght
218913811|NCT06938048|OTHER|high stretch bandage (Coban)|extensibility above 100% of the lenght
218913812|NCT02017197|DRUG|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
218913813|NCT02017197|DRUG|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
218913814|NCT02017197|DRUG|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
218913815|NCT06706349|BEHAVIORAL|APA managed by qualified instructor|Each session will be led by a qualified APA professional and will include a mix of aerobic, anaerobic, and 'mind-body' activities like yoga, tailored to participant preferences. Intensity will range from moderate to vigorous, with activities such as walking, cycling, and club-based exercises for at least 20 minutes per session. Participants will be progressively involved in session planning to support continued practice post-study. Heart rate monitoring will be used during exercises like the 6-minute walk test and chair rise test, while a daily activity calendar will help ensure adherence, documenting session dates, durations, subjective intensity, and activity type.
219041452|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
219614843|NCT05971940|DRUG|Placebo|Administered orally
219614844|NCT05230862|DIETARY_SUPPLEMENT|Ladder Supplement|Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
219614845|NCT05230862|DIETARY_SUPPLEMENT|Placebo|Placebo
218913816|NCT06706349|BEHAVIORAL|Autonomous APA|A leaflet highlighting the importance of non-sedentary behavior according to WHO recommendations will be provided to them. They will have the opportunity to engage in physical activity autonomously according to their preference.
218913817|NCT03593499|DRUG|omaveloxolone|
218913818|NCT03593746|OTHER|Physical training|Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
219041453|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
219041454|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
219041455|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
219041456|NCT00413725|OTHER|Placebo|Placebo
219526720|NCT01836341|DRUG|Carboplatin|
219526721|NCT01836341|DRUG|Pemetrexed|
219614846|NCT05627193|OTHER|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
219614847|NCT05627193|OTHER|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
219614848|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219614849|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMPT
219614850|NCT01893307|OTHER|Laboratory Biomarker Analysis|Correlative studies
218913819|NCT03593746|OTHER|Light-Emitting Diode (LED) therapy|Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
218913820|NCT03059134|DRUG|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
219526722|NCT01836341|RADIATION|Radiation therapy|
219526723|NCT03649841|DRUG|Antiandrogen Therapy|Undergo ADT
219526724|NCT03649841|DRUG|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
219526725|NCT03649841|DRUG|Prednisone|Undergo Prednisone Treatment SOC
218913821|NCT04948216|OTHER|No intervention|No intervention
218913822|NCT02994108|BEHAVIORAL|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
219526726|NCT03649841|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
219526727|NCT06140264|OTHER|Acupuncture dry needle|The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
219614851|NCT01893307|RADIATION|Photon Beam Radiation Therapy|Undergo IMRT
219614852|NCT01893307|RADIATION|Proton Beam Radiation Therapy|Undergo IMPT
219614853|NCT01893307|OTHER|Quality-of-Life Assessment|Ancillary studies
219614854|NCT06241729|OTHER|Algorithms to predict the probability of a primary refractory state|Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
218913823|NCT02994108|BEHAVIORAL|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
219526728|NCT05847205|DRUG|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
218913824|NCT00000827|DRUG|Anti-HIV Immune Serum Globulin (Human)|
218913825|NCT00170586|DEVICE|Underglove coating (skin barrier)|
218913826|NCT02558959|DRUG|Irinotecan|
218913827|NCT02558959|DRUG|Capecitabine|
218913828|NCT02081677|DEVICE|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
218913829|NCT02081677|DEVICE|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
218913830|NCT02081677|DEVICE|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
218913831|NCT02081677|DEVICE|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
218913832|NCT05602246|PROCEDURE|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
218913833|NCT05602246|PROCEDURE|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
218913834|NCT01097668|BIOLOGICAL|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
218913835|NCT03063177|PROCEDURE|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
219526729|NCT03497897|DRUG|LYS006 20 mg|LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
218913836|NCT01831024|DEVICE|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
218913837|NCT02786849|OTHER|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
218913838|NCT02786849|OTHER|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
218913839|NCT03630289|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
218913840|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
218913841|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
219041457|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
219041458|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
219526730|NCT03497897|DRUG|LYS006 2 mg|LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
219526731|NCT03497897|DRUG|Placebo|Matching placebo, capsules, oral administration, BID, for 12 weeks
219526732|NCT01529060|DRUG|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
219526733|NCT01529060|DRUG|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
219526734|NCT00914394|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
219526735|NCT00914394|DRUG|Phenylephrine|1µg/kg/min, infusion period 20 minutes
219614855|NCT01114802|BEHAVIORAL|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
219614856|NCT01114802|BEHAVIORAL|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
218913842|NCT05240820|PROCEDURE|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
218913843|NCT02443688|DRUG|CTX-4430|
218913844|NCT02443688|DRUG|Placebo|
218913845|NCT01334177|DRUG|TLR8 agonist VTX-2337|Given SC
218913846|NCT01334177|BIOLOGICAL|cetuximab|Given IV
218913847|NCT01334177|OTHER|laboratory biomarker analysis|Correlative studies
218913848|NCT01334177|OTHER|pharmacogenomic studies|Correlative studies
218913849|NCT05100550|DIETARY_SUPPLEMENT|Zinc|Zinc is given as written in the arm description, two hours after lunch
219041459|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
219041460|NCT04931901|DEVICE|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
219041461|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
219041462|NCT04498962|DRUG|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
219526736|NCT00914394|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
219526737|NCT00914394|DEVICE|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
219526738|NCT00914394|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
219614857|NCT02696668|OTHER|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
219614858|NCT02696668|OTHER|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~1. Limits of stability training with eyes open / eyes closed~2. Self induced movement strategies with eyes open / eyes closed~3. Gaze stability exercises in sitting / standing / walking~4. Sensory integration~5. Habituation exercises"
219614859|NCT06102174|DRUG|Placebo|Placebo
219526739|NCT00914394|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
219614860|NCT06102174|DRUG|Active|Sisunatovir
219614861|NCT05687448|DRUG|Apixaban 5 MG Oral Tablet|Patients treated with apixaban 5 mg twice daily (BID)
218913850|NCT05100550|OTHER|Control|This group will not receive zinc
218913851|NCT00688987|DRUG|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
218913852|NCT00688987|DIETARY_SUPPLEMENT|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
218913853|NCT05665231|OTHER|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
218913854|NCT05665231|OTHER|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
218913855|NCT05665231|OTHER|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
219526740|NCT04603209|RADIATION|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
219614862|NCT05687448|DRUG|Aspirin 75 to 100mg once a day|Patients treated with Aspirin 75 to 100mg once a day
219614863|NCT06149845|PROCEDURE|Full Pulpotomy|Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
219614864|NCT05631717|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (1 × 10 \^6 cells / kg body weight, suspended in 30ml saline), intravenous drip once.
219614865|NCT05631717|DRUG|Interleukin-2|IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
219614866|NCT02897102|BEHAVIORAL|Training|Training program based on abacus and other activities
219614867|NCT02897102|OTHER|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
219614868|NCT00386451|DEVICE|Catheter locking systems|
219614869|NCT05771181|DRUG|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
219614870|NCT05771181|DRUG|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
219614871|NCT05771181|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
219614872|NCT05494502|PROCEDURE|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
219614873|NCT05494502|PROCEDURE|Control group|General anesthesia alone.
219614874|NCT05953766|DRUG|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
219614875|NCT05953766|DRUG|Normal saline injection|Sham block using 20 mL of normal saline (0.9% sodium chloride)
219614876|NCT04964206|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
219614877|NCT04964206|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
219614878|NCT00613808|DRUG|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
219614879|NCT05821231|COMBINATION_PRODUCT|SBRT + MEDI5752|"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
219614880|NCT04861714|DEVICE|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
219614881|NCT04861714|PROCEDURE|Standard repair|Standard subscapularis repair
219614882|NCT06284382|OTHER|High score at Childhood Trauma Questionnaire.|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
219614883|NCT06284382|OTHER|Low score at Childhood Trauma Questionnaire.|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
219614884|NCT00505830|OTHER|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
219041463|NCT01143090|DRUG|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
219041464|NCT03145441|DEVICE|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
219365476|NCT05549115|DRUG|clarithromycin-sensitive(first-line)|esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
219365477|NCT05549115|DRUG|clarithromycin-resistant(first-line)|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
219365478|NCT05549115|DRUG|empirical therapy group first-line|esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
219365479|NCT05549115|DRUG|levofloxacin-sensitive(rescue treatment)|esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
219365480|NCT05549115|DRUG|levofloxacin-resistant(rescue treatment)|esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
219365481|NCT05549115|DRUG|empirical therapy group rescue treatment|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
219365482|NCT03726684|DEVICE|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
219365483|NCT01420484|OTHER|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
219365484|NCT03274921|DIAGNOSTIC_TEST|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
219365485|NCT05223595|DRUG|Gentuximab|Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
219365486|NCT00692367|BEHAVIORAL|Physical Activity|1\. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
219365487|NCT02476318|DEVICE|ArterX Vascular Sealant|
218913856|NCT05665231|OTHER|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
219526741|NCT03663478|DRUG|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
219526742|NCT03663478|DRUG|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
219526743|NCT04329988|OTHER|questionnaire|A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
219526744|NCT00126906|DRUG|Monthly sulfadoxine/pyrimethamine|
219526745|NCT00126906|DRUG|2-dose sulfadoxine/pyrimethamine|
219526746|NCT02962934|OTHER|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
219526747|NCT02962934|OTHER|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
219526748|NCT02841488|PROCEDURE|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
219526749|NCT02841488|DRUG|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
218913857|NCT05665231|OTHER|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
218913858|NCT05665231|OTHER|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
218913859|NCT05665231|OTHER|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
218913860|NCT05665231|OTHER|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
218913861|NCT05665231|OTHER|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~1. interdental distance~2. bucco-palatal distance (BPD)~3. presence of papilla~r. global volume."
218913862|NCT05665231|OTHER|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
219041465|NCT06298175|BEHAVIORAL|Self management training|The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
219526750|NCT02841488|DRUG|Ropivacaine|
219526751|NCT02841488|DEVICE|Perineural catheter|
219526752|NCT01538251|DRUG|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
219526753|NCT01538251|DRUG|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
219614885|NCT00137501|DRUG|Nifedipine|"Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
219614886|NCT00961857|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
219614887|NCT00961857|DRUG|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
219614888|NCT00961857|DRUG|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
219526754|NCT03735251|OTHER|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
219614889|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
219614890|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
219614891|NCT00961857|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
219614892|NCT04823325|PROCEDURE|Orthognathic Surgery|The duration for presurgical orthodontic treatment was; 7,7 ± 1,7 months.
219614893|NCT03759548|OTHER|Assessment of nutritional status|Observational study. Assessment of nutritional status.
219614894|NCT04781426|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg|PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily
219526755|NCT04452656|PROCEDURE|bilateral erector spinae block|"An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12."
219526756|NCT01735409|DRUG|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
219526757|NCT01735409|DRUG|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
219526758|NCT01735409|DRUG|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
219526759|NCT00783861|DRUG|Lactic Acid|Lactic Acid (Dermacyd Femina)
219614895|NCT05457504|BEHAVIORAL|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
219614896|NCT05457504|BEHAVIORAL|Usual Care|Participants assigned to this arm will participate in a placebo intervention
218913863|NCT05665231|OTHER|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~1. interdental distance;~2. bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
218913864|NCT05665231|OTHER|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
218913865|NCT02178345|PROCEDURE|diffusion weighted (DW) MRI|
218913866|NCT02178345|PROCEDURE|dynamic contrast agent (DCE) MRI|
218913867|NCT06178419|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
218913868|NCT06178419|DEVICE|sham-RIC|Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
218913869|NCT01327625|DRUG|azithromycin + N-acetylcystein + inhaled corticosteroid|"* Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months"
218913870|NCT03626454|DRUG|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
218913871|NCT03626454|DRUG|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
218913872|NCT03626454|DRUG|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
218913873|NCT03626454|DRUG|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
218913874|NCT00001188|PROCEDURE|radiation therapy following surgery|
219041466|NCT06174324|DEVICE|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
219041467|NCT01211028|BIOLOGICAL|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
219526760|NCT04503993|OTHER|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
219526761|NCT01643005|BEHAVIORAL|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
219526762|NCT01643005|BEHAVIORAL|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
219526763|NCT00021528|DRUG|citalopram|
219526764|NCT00021528|DRUG|BuproprionSR|
219614897|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
219614898|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
219614899|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
219614900|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
219614901|NCT00749905|OTHER|low fiber diet|Low fiber diet for 5 days prior to colon capsule
219041468|NCT02304224|OTHER|eye masks|eye masks from 21:00 to 6:00 each night during admission
219614902|NCT00749905|OTHER|regular diet|Regular diet until 1 day before colon capsule
219041469|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
219041470|NCT03926234|OTHER|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
219041471|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
218913875|NCT01128374|PROCEDURE|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
219526765|NCT00021528|DRUG|buspirone|
219526766|NCT00021528|DRUG|Lithium|
219526767|NCT00021528|DRUG|mirtazapine|
219614903|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables)|Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
218913876|NCT01691534|DRUG|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
219041472|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
219041473|NCT00548860|DRUG|Ferric Carboxymaltose|
219041474|NCT00548860|DRUG|Standard Medical Care (SMC)|
219041475|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
219041476|NCT06037746|OTHER|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
219041477|NCT06037746|OTHER|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
219041478|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
219041479|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219041480|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
219041481|NCT03023865|PROCEDURE|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
219041482|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
219041483|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
219041484|NCT02612532|DEVICE|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
219041485|NCT01414335|DIETARY_SUPPLEMENT|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
219526768|NCT00021528|DRUG|nortriptyline|
219526769|NCT00021528|DRUG|sertraline|
219526770|NCT00021528|DRUG|tranylcypromine|
219526771|NCT00021528|DRUG|VenlafaxineXR|
219526772|NCT00021528|BEHAVIORAL|Cognitive Therapy|
219526773|NCT00021528|DRUG|T3 (Triiodothyronine)|
219526774|NCT03334825|OTHER|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
219526775|NCT03334825|OTHER|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
219614904|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables and exergames)|Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
218913877|NCT01691534|DRUG|PA-824 (PA)|PA-824 200mg Days 1-14
218913878|NCT01691534|DRUG|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
219526776|NCT01604694|PROCEDURE|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
219526777|NCT04901962|DEVICE|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
219526778|NCT06294080|OTHER|Dance|Exercise intervention
219614905|NCT01290549|DRUG|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
219614906|NCT01290549|DRUG|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
219526779|NCT06294080|OTHER|Tai Chi|Exercise intervention
218913879|NCT01691534|DRUG|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
218913880|NCT01691534|DRUG|Rifafour|Rifafour e-275 mg dosed by weight
218913881|NCT06356454|OTHER|Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease|"Creating the questionnaire: The self-administered questionnaire was designed based on literature review. The questions of the questionnaire were based on the 3 main components of the World Health Organisation's Knowledge, Attitude and Practice framework. The questions were evaluated by experts in the field such as cardiologists working in paediatric cardiology. The questionnaire, which was finalised with the questions updated according to expert opinions, has 5 sections:~* Section 1: Socio-demographic questions~* Section 2: Questions on the level of knowledge about CR~* Section 3: Questions on attitudes about CR~* Section 4: Questions on Practices about CR"
218913882|NCT03248908|DIAGNOSTIC_TEST|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
218913883|NCT03248908|OTHER|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
219041486|NCT01414335|OTHER|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
219041487|NCT04616807|DRUG|Mexiletine|Observational Study
219041488|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
219041489|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
219526780|NCT02335840|OTHER|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
219526781|NCT02335840|OTHER|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
219526782|NCT02335840|OTHER|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
219526783|NCT02335840|OTHER|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
219526784|NCT04299594|OTHER|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
219526785|NCT03888794|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
219526786|NCT05212766|BIOLOGICAL|COVID infection|Infections with COVID 19
219041490|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
219041491|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
219041492|NCT05414643|OTHER|Standard care|No interventions were used, as this is an observational study.
219041493|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
219041494|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
219041495|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
219041496|NCT04089540|PROCEDURE|New intubation method|
219041497|NCT04089540|PROCEDURE|Conventional intubation method|
219526787|NCT05212766|BIOLOGICAL|COVID vaccination|Vaccination against COVID 19
219526788|NCT05212766|DIAGNOSTIC_TEST|Oral examination|Assessment of oral and periodontal health status
219526789|NCT05565664|DRUG|Ketamine hydrochloride|"Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
219526790|NCT05565664|DRUG|Magnesium sulfate|"A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
219526791|NCT05336708|OTHER|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
219041498|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
219041499|NCT04892576|OTHER|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
219041500|NCT00660062|DRUG|escitalopram|10 mg daily
219041501|NCT00660062|DRUG|escitalopram|20 mg daily dosage
219041502|NCT00660062|DRUG|escitalopram|30 mg daily dosage
219041503|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
219041504|NCT05724849|DRUG|Venlafaxine|See arm/group description.
219614907|NCT02416063|DRUG|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
219614908|NCT02416063|DRUG|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
219526792|NCT05336708|OTHER|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
219526793|NCT00771485|DRUG|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
219526794|NCT00771485|DRUG|Marketed Bowel Cleanser|Marketed bowel cleanser
219526795|NCT00800709|DRUG|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
219526796|NCT01672515|DEVICE|RIPC group|
219526797|NCT01672515|DEVICE|Control group|
219526798|NCT06491524|DEVICE|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone <2cm|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
218913884|NCT02628288|DEVICE|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
218913885|NCT02303496|BIOLOGICAL|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
218913886|NCT02303496|BIOLOGICAL|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
218913887|NCT04016935|OTHER|Observational|Observational
218913888|NCT05829226|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
218913889|NCT05829226|DRUG|Venetoclax|Bcl-2 inhibitor
218913890|NCT05829226|DRUG|Azacitidine|Hypomethylating agent
218913891|NCT05829226|DRUG|Decitabine|Hypomethylating agent
218913892|NCT04336774|DEVICE|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
218913893|NCT04699617|DEVICE|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
218913894|NCT02516761|OTHER|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
218913895|NCT02516761|OTHER|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
219041505|NCT05724849|DRUG|Placebo|See arm/group description.
219526799|NCT00358449|DRUG|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
219526800|NCT06248853|OTHER|Garston technique|the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot
219526801|NCT06248853|OTHER|exercise program|the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
219526802|NCT04416230|BEHAVIORAL|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
218913896|NCT02516761|OTHER|Control group|With this group no intervention is done, but they are assessed like the other groups.
218913897|NCT05419583|DIAGNOSTIC_TEST|Coronary computed tomography angiography|CT scan of the heart arteries
218913898|NCT05419583|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
218913899|NCT05419583|DIAGNOSTIC_TEST|Transthoracic echocardiography|Ultrasound scan of the heart
218913900|NCT05419583|DIAGNOSTIC_TEST|Cardiac MRI scan|An MRI scan to assess the heart structure and function
218913901|NCT05419583|DRUG|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
219041506|NCT01263548|DRUG|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
218913902|NCT05419583|DRUG|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
218913903|NCT05419583|DRUG|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
218913904|NCT05419583|DRUG|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
218913905|NCT04764071|PROCEDURE|percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.
219041507|NCT00699010|DRUG|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
219041508|NCT00699010|DRUG|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
219041509|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
219041510|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
218913906|NCT04764071|PROCEDURE|ultra-mini percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
218913907|NCT06956612|DIETARY_SUPPLEMENT|Control (Placebo comparator)|The control group will consume a placebo supplement, entirely free of nitrate, in the form of juice (70 ml) for four weeks while maintaining their habitual diet.
218913908|NCT06956612|DIETARY_SUPPLEMENT|Juice (Active comparator)|The juice group will consume a beetroot supplement enriched with \~400 mg of nitrate in juice form (70 ml) for four weeks while maintaining their habitual diet.
218913909|NCT06956612|DIETARY_SUPPLEMENT|Crystals (Experimental)|The crystals group will consume a beetroot supplement enriched with \~400 mg of nitrate in crystals form (20g) for four weeks while maintaining their habitual diet.
219041511|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
219041512|NCT02973763|DRUG|Alflutinib|
219041513|NCT04152226|DRUG|Janthinobacterium lividum|Investigational Product
219041514|NCT04797260|GENETIC|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
219365488|NCT01486199|OTHER|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
219366304|NCT05346614|BEHAVIORAL|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
219366305|NCT04909684|DRUG|Pembrolizumab|The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
218913910|NCT00733668|DRUG|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
218913911|NCT00616759|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy as usual
218913912|NCT00616759|PROCEDURE|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
218913913|NCT00616759|DRUG|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
218913914|NCT01605708|DRUG|REGN846|Dose 1
218913915|NCT05108259|DRUG|PBP1502|40 mg/0.4 mL single SC injection via PFS
218913916|NCT05108259|DRUG|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
218913917|NCT05108259|DRUG|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
218913918|NCT00956319|DRUG|Zolpidem MR|oral
218913919|NCT00956319|DRUG|Estazolam|oral
219366306|NCT04515966|DRUG|Methylprednisolone Injection [Solu-Medrol]|A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
219366307|NCT04515966|DEVICE|wrist splint|A standard wrist splint
219366308|NCT05936320|BEHAVIORAL|Information leaflets with illustrations about hearing aid functions|The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
219366309|NCT05936320|BEHAVIORAL|Information leaflets with only text about hearing aid functions|The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
219366310|NCT04986787|DEVICE|tACS|a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms
219366311|NCT04986787|DEVICE|TMS|a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain, it will be specifically cerebellar stimulation
219366312|NCT04986787|DEVICE|TIS|temporal interference stimulation targeted to striatum, a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms deep in the brain
219366313|NCT00713362|PROCEDURE|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
219366314|NCT00713362|PROCEDURE|chest tube drainage|Chest tube drainage for pneumothroax
219366315|NCT00757731|DRUG|milnacipran|hard capsule
219366316|NCT00757731|DRUG|Placebo|hard capsule
219366317|NCT04901039|OTHER|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
219366318|NCT04901039|OTHER|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
219366319|NCT04901039|OTHER|Peripheral venous pressure|Assessment of peripheral venous pressure
219366320|NCT04901039|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging
219366321|NCT04901039|OTHER|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
219526803|NCT04416230|BEHAVIORAL|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
219526804|NCT03866330|BIOLOGICAL|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
218913920|NCT03170596|DRUG|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
218913921|NCT03170596|DEVICE|Microneedling|Microneedling is a method of percutaneous collagen induction
219526805|NCT02042664|DRUG|BYETTA treatment|
219526806|NCT02042664|DRUG|Metformine|
219526807|NCT02746484|OTHER|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
219526808|NCT02746484|OTHER|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
219526809|NCT05703048|DRUG|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
218913922|NCT06392165|OTHER|self-adhesive device|Test device which is self-adhesive
218913923|NCT05533606|DRUG|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
218913924|NCT05479877|DRUG|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
219614909|NCT02416063|DRUG|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
218913925|NCT05479877|DRUG|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
218913926|NCT04234477|DRUG|Beta-blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
219526810|NCT05703048|DRUG|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
219526811|NCT01367457|OTHER|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
219526812|NCT03084822|BEHAVIORAL|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
218913927|NCT04234477|DRUG|Calcium channel blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
218913928|NCT04234477|DRUG|Physician preference strategy|"This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil."
218913929|NCT04501523|DRUG|Tislelizumab|200mg, q3w, for 1 year
218913930|NCT04501523|DRUG|capecitabine|600-750 mg/m2 PO Bid，continuous, for 1 year
218913931|NCT03633032|DIAGNOSTIC_TEST|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
219526813|NCT03478748|OTHER|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
219526814|NCT05179681|OTHER|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
219526815|NCT02575222|DRUG|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
219526816|NCT02170506|DEVICE|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
219526817|NCT02158182|DRUG|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
219526818|NCT02158182|DRUG|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
219526819|NCT02158182|DRUG|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
219526820|NCT02158182|DRUG|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
219614910|NCT02930499|DEVICE|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
219614911|NCT02930499|DEVICE|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
219614912|NCT05294978|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Data of macular optical coherence tomography (OCT)
219614913|NCT06548100|DRUG|mibavademab|Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
219614914|NCT02839538|PROCEDURE|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
219614915|NCT02839538|PROCEDURE|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
219366322|NCT02758535|DEVICE|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
219526821|NCT01366079|PROCEDURE|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
218913932|NCT03351452|DEVICE|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
219526822|NCT01366079|PROCEDURE|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
218913933|NCT03351452|DEVICE|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
218913934|NCT03351452|DEVICE|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
218913935|NCT02682524|DRUG|Pelubiprofen CR 45mg tab.|
219526823|NCT01901705|DRUG|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
219526824|NCT01901705|DRUG|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
219526825|NCT05220683|DEVICE|digital marking system|Verion or Callisto, digital marking system
219526826|NCT02589808|DEVICE|Full TTE|Full transthoracic echocardiogram, with Doppler.
219526827|NCT02589808|DEVICE|GE Vscan|Handheld echo.
218913936|NCT02682524|DRUG|Aceclofenac 100mg tab.|
218913937|NCT00006086|DRUG|BMS-188797|
219526828|NCT03171285|OTHER|Less than 35 years old|Clinical and laboratory evaluations
219526829|NCT03171285|OTHER|Greater than or equal to 35 years|Clinical and laboratory evaluations
219526830|NCT01114048|DRUG|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
219526831|NCT01074879|DIETARY_SUPPLEMENT|Whey protein|Dietary supplement after training
219526832|NCT01074879|DIETARY_SUPPLEMENT|Milk protein|Dietary supplement after training
219526833|NCT01074879|DIETARY_SUPPLEMENT|Carbohydrates|Dietary supplement after training
219526834|NCT05217225|PROCEDURE|Simple restorative treatment|Simple Occlusal Cavity class I then followed by final restoration
219526835|NCT01297179|DRUG|Mirabegron|Oral
219526836|NCT01297179|DRUG|Minidril|Oral
219526837|NCT01297179|DRUG|Placebo|Oral
219526838|NCT02957318|DIETARY_SUPPLEMENT|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
219526839|NCT02957318|DIETARY_SUPPLEMENT|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
219526840|NCT02957318|DIETARY_SUPPLEMENT|Placebo|Low-fiber control
219526841|NCT04036539|PROCEDURE|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
219614916|NCT01557504|DRUG|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
218913938|NCT00006086|DRUG|carboplatin|
218913939|NCT05517252|OTHER|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
218913940|NCT05517252|OTHER|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
218913941|NCT02851277|DRUG|ASP0892 Intradermal|Intradermal injection
218913942|NCT02851277|DRUG|ASP0892 Intramuscular|Intramuscular injection
218913943|NCT02851277|DRUG|Placebo Intradermal|Intradermal injection
218913944|NCT02851277|DRUG|Placebo Intramuscular|Intramuscular injection
218913945|NCT06389019|OTHER|Deep learning system for prognostication prediction in bladder cancer|develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
218913946|NCT06956469|OTHER|Identification of types of anti-HLA-specific memory LBs|Using blood sample, it will be perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. It will be further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.
218913947|NCT05330481|OTHER|Moderate-intensity (relative) exercise with glucose ingestion|120 minutes of cycling at 95% of lactate threshold ingesting 90 g/h of glucose
219526842|NCT02209285|BEHAVIORAL|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
219526843|NCT04926805|DEVICE|CPAP with Mask A|CPAP mask
219614917|NCT01557504|DRUG|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
219614918|NCT01557504|DRUG|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
218913948|NCT05330481|OTHER|Moderate-intensity (absolute) exercise with glucose ingestion|120 minutes of cycling at a power matched to participant in the \<70 kg body mass group, ingesting 90 g/h of glucose
218913949|NCT06796361|DRUG|Ketanserin 40mg plus Psilocybin 40mg|40mg Ketanserin oral will be administered followed by 40mg Psilocybin.
218913950|NCT06796361|DRUG|40mg Psilocybin|Placebo oral followed by 40mg Psilocybin one hour later.
218913951|NCT06796361|DRUG|20mg Psilocybin|Placebo oral followed by 20mg Psilocybin one hour later.
218913952|NCT06796361|DRUG|10mg Psilocybin|Placebo oral followed by 10mg Psilocybin oral one hour later.
218913953|NCT06796361|DRUG|5mg Psilocybin|Placebo oral followed by 5mg Psilocybin one hour later
218913954|NCT06796361|OTHER|Placebo|Oral Placebo followed by oral Placebo one hour later
218913955|NCT06825260|DRUG|Senna|Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days
218913956|NCT06825260|DRUG|Polyethylene glycol 3350|Polyethylene Glycol 3350, oral, 17g, daily for 7 days
218913957|NCT01231984|DEVICE|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
218913958|NCT01231984|DEVICE|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
218913959|NCT01231984|DEVICE|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
218913960|NCT04445753|OTHER|Tai Chi exercise|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
218913961|NCT04445753|BEHAVIORAL|Education (control group)|Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
218913962|NCT02818972|DEVICE|RelayPro|Endovascular treatment with investigational device.
218913963|NCT04841447|OTHER|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
218913964|NCT01274793|DRUG|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
219614919|NCT01557504|DRUG|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
218913965|NCT01274793|DEVICE|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
218913966|NCT01274793|DEVICE|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
218913967|NCT03207971|PROCEDURE|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
219526844|NCT04926805|DEVICE|CPAP with Mask B|CPAP mask
219614920|NCT05368818|OTHER|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
219614921|NCT03458585|OTHER|Self-administered questionnaire|Self-administered questionnaire
219526845|NCT05050071|DRUG|Allium Sativum|Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
218913968|NCT06387264|DEVICE|Medical Adhesive|Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.
218913969|NCT06387264|DEVICE|ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter|ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
218913970|NCT04552652|BEHAVIORAL|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
218913971|NCT04552652|BEHAVIORAL|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
218913972|NCT05499065|PROCEDURE|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
218913973|NCT05499065|DRUG|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
219041515|NCT05949996|OTHER|A nurse-led symptom distress screening program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
219041516|NCT05992792|BEHAVIORAL|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
219041517|NCT05992792|BEHAVIORAL|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
219041518|NCT05992792|BEHAVIORAL|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
219041519|NCT05992792|BEHAVIORAL|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
219041520|NCT00639834|BIOLOGICAL|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
219041521|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
219041522|NCT04291885|DRUG|Placebo|Placebo IV infusion
219041523|NCT05117411|DIAGNOSTIC_TEST|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
219041524|NCT03067805|BEHAVIORAL|Sexual Infidelity Condition|
219614922|NCT02571491|DRUG|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
219614923|NCT02571491|OTHER|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
218913974|NCT05820035|DEVICE|Pulsed Field Ablation Device and CF-Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the pulsed field ablation device and CF-sensing pulsed field ablation catheter in the management of their paroxysmal supraventricular tachycardia
219041525|NCT03067805|BEHAVIORAL|Emotional Infidelity Condition|
219041526|NCT03067805|BEHAVIORAL|Neutral Condition|
219041527|NCT03067805|BEHAVIORAL|Player in Jealousy Condition|
219041528|NCT03067805|BEHAVIORAL|Player in Non-Jealousy Condition|
219041529|NCT01452412|DRUG|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
219041530|NCT01452412|DRUG|Placebo|To be taken on the same schedule as the active arm
219041531|NCT06116149|BEHAVIORAL|In-person health coach delivery of the GLB|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
219526846|NCT05050071|DEVICE|Polymerase chain reaction|Change in the bacterial load in response to different treatment procedures
219526847|NCT02163837|DRUG|rifaximine|
219614924|NCT02571491|DRUG|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
219614925|NCT02571491|DRUG|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
219614926|NCT05374317|BIOLOGICAL|Yellow Fever Vaccine|Administered subcutaneously once.
219614927|NCT00075907|DRUG|Efavirenz + 2 NRTIs|
219614928|NCT00075907|DRUG|Lopinavir/Ritonavir + 2 NRTIs|
219614929|NCT00075907|PROCEDURE|Therapeutic Drug Monitoring|
218913975|NCT05732311|DEVICE|intermittend theta burst stimulation|intermittend theta burst stimulation
218913976|NCT06309628|DIAGNOSTIC_TEST|Breathe sample|Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
219366323|NCT02758535|DEVICE|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
219614930|NCT03862313|DEVICE|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
219614931|NCT03862313|DEVICE|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
219614932|NCT03334240|DRUG|CLS003|CLS003
219614933|NCT03334240|DRUG|Vehicle|Vehicle
219614934|NCT06392022|OTHER|watching cartoons with music|The purpose of this study was to evaluate the effect of watching musical cartoons on anxiety and vital signs in children undergoing rectal irrigation.
218913977|NCT06563700|OTHER|spectacle lens|one of ZEISS BD spectacle lens designs 1 to 5
219366324|NCT02481635|DRUG|Gemcitabine|
218913978|NCT06563700|OTHER|single vision lens|single vision lens
218913979|NCT05746611|BIOLOGICAL|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
218913980|NCT05746611|BIOLOGICAL|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
218913981|NCT05559177|BIOLOGICAL|Chimeric exosomal tumor vaccines|Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
219366325|NCT02481635|DRUG|Nab-paclitaxel|
219366326|NCT02481635|RADIATION|Radiation Therapy|
219366327|NCT02481635|PROCEDURE|Surgical Resection|
219366328|NCT06549088|DEVICE|Spatial Frequency Domain Imaging|Resected lung tissue will be removed from the surgical field and labeled with sutures per standard of care. The specimen will then be immediately analyzed using two SFDI devices in the operating room using sterile technique. Each specimen will be recorded up to three times to ensure at least one high fidelity recording is captured. The SFDI data will be analyzed and compared to the official pathology report from the electronic medical record.
219366329|NCT01578031|DEVICE|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
219366330|NCT01578031|OTHER|Usual Care|Usual care.
219366331|NCT03094195|DRUG|EMA401|EMA401
219366332|NCT03094195|DRUG|Placebo|Placebo
219366333|NCT02238847|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
219366334|NCT03632980|DEVICE|"Ablatherm Foc/Dyn or Focal One HIFU treatment"|"Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application."
219366335|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
219366336|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
219366337|NCT00529737|PROCEDURE|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
219366338|NCT00529737|PROCEDURE|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
219366339|NCT03693248|DRUG|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
219366340|NCT03611426|DRUG|rhThrombin ( Topical )|Active Substance
219366341|NCT03611426|DRUG|placebo|saline solution
219614935|NCT02810626|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
219614936|NCT02750618|BIOLOGICAL|Burosumab|solution for subcutaneous injection
219614937|NCT00848913|OTHER|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
219614938|NCT00848913|OTHER|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
219614939|NCT05908565|BEHAVIORAL|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
219366342|NCT00360399|DRUG|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
219366343|NCT00360399|DRUG|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
219366344|NCT00360399|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
219366345|NCT03887130|DRUG|oral vinorelbine|Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles
219366346|NCT03887130|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
219366347|NCT03887130|DRUG|Gemcitabine 1250 mg/m²|Gemcitabine 1250 mg/m² on day 1 \& day 8
219366348|NCT03887130|DRUG|Gemcitabine 1000 mg/m²|Gemcitabine: 1000 mg/m² on day 1 \& 8
219366349|NCT03887130|DRUG|Paclitaxel|Paclitaxel 175 mg/m² on day 1
219366350|NCT03887130|DRUG|Docetaxel|Docetaxel 75 mg/m² on day 1
219366351|NCT01709188|BEHAVIORAL|Musical Dual Task Training|
219366352|NCT01709188|BEHAVIORAL|Walking and Talking|
219366353|NCT02926703|OTHER|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
219366354|NCT04082663|DEVICE|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
219366355|NCT06439030|BEHAVIORAL|Recovery program|The practices included in the program are: Cinema Film Screening and Emotion/Thought Sharing, Laughter Yoga Practice, Stress Coping Techniques Training, Progressive Relaxation, Loss/Mourning Process Training, Expressive Art Therapy Practice, Healthy Lifestyle Behaviors Training.
219366356|NCT06314464|DEVICE|Praxis|Praxis' gaze stabilization exercises are delivered via the tablet-based VestAid software that uses the tablet camera to automatically assess compliance in the conduct of vestibulo-ocular reflex exercises. The smooth pursuit, saccade, agility, and dual tasking exercises are delivered in the form of military-themed mixed reality games using the HTC Vive Focus 3 headset.
219366357|NCT06314464|BEHAVIORAL|Supervised cardiovascular exercise|The supervised cardiovascular exercise does not incorporate gaze stabilization exercises (vestibulo-ocular reflex exercises) or smooth pursuit, saccade, agility, and dual tasking exercises.
219366358|NCT00392028|DRUG|ertapenem|
219366359|NCT02613455|PROCEDURE|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
219366360|NCT02613455|DRUG|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
219366361|NCT02613455|DRUG|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
219526848|NCT02195193|OTHER|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
219526849|NCT02388971|DRUG|MLN1202|MLN1202 solution
219526850|NCT02388971|DRUG|Placebo|MLN1202 placebo-matching solution
219526851|NCT04028440|BIOLOGICAL|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
219526852|NCT06264960|BEHAVIORAL|Music therapy|After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
219526853|NCT06264960|BEHAVIORAL|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
219614940|NCT05908565|BEHAVIORAL|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
219614941|NCT01038336|BEHAVIORAL|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
219614942|NCT01038336|BEHAVIORAL|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
219614943|NCT03077737|BEHAVIORAL|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
219614944|NCT03077737|BEHAVIORAL|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
218913982|NCT05301959|DEVICE|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
218913983|NCT05301959|DEVICE|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
218913984|NCT05301959|OTHER|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
219041532|NCT06116149|BEHAVIORAL|Technology-assisted health coach delivery of the GLB|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
219526854|NCT01608269|DRUG|Abacavir/Lamivudine|one tablet once a day
219526855|NCT03950336|DIETARY_SUPPLEMENT|Prebiotics|Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks
219526856|NCT03950336|OTHER|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
219614945|NCT00954811|DRUG|300IU rec-LH|luteal alternate doses
219614946|NCT00954811|DRUG|progesterone 600mg|luteal support
219526857|NCT03950336|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
219526858|NCT03950336|OTHER|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
219526859|NCT00705003|DRUG|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
219526860|NCT00705003|DRUG|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
218913985|NCT03779256|PROCEDURE|2D transvaginal ultrasound|"Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively."
218913986|NCT03291535|OTHER|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
218913987|NCT03291535|OTHER|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
218913988|NCT00476125|BEHAVIORAL|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
218913989|NCT00476125|BEHAVIORAL|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
218913990|NCT00476125|BEHAVIORAL|16 Hour Fast|Subjects will fast for 16 hours.
218913991|NCT03297047|DEVICE|combi cast|upper arm or forearm combi cast
219041533|NCT00217542|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
219041534|NCT00217542|DRUG|amifostine/azacitidine|Given SC
219526861|NCT00705003|DRUG|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
219526862|NCT01626287|OTHER|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
219526863|NCT01626287|OTHER|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
219526864|NCT01233622|DRUG|Vildagliptin|
219526865|NCT01233622|DRUG|Placebo|
219526866|NCT01668264|PROCEDURE|Echocardiograph|
219526867|NCT01668264|PROCEDURE|Magnetic Resonance Imaging (MRI)|
219526868|NCT05602103|DRUG|use of anticancer drugs in monotherapy or in combination therapy|Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
219526869|NCT06310460|PROCEDURE|Papillectomy|Papillectomy prior to bile duct cannulation during ERCP
218913992|NCT02626585|PROCEDURE|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
218913993|NCT03212911|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
218913994|NCT02946086|BEHAVIORAL|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
218913995|NCT02946086|BEHAVIORAL|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
218913996|NCT05471765|DEVICE|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
218913997|NCT05471765|DEVICE|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
218913998|NCT02278510|DRUG|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
219041535|NCT01653093|PROCEDURE|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
219041536|NCT01653093|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
219041537|NCT01653093|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219041538|NCT01653093|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
219526870|NCT05019560|DRUG|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
219526871|NCT05019560|DRUG|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
218913999|NCT02278510|DRUG|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
219041539|NCT04552691|DRUG|Pegunigalsidase Alfa|Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
219526872|NCT03690960|PROCEDURE|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
219526873|NCT03690960|PROCEDURE|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
219526874|NCT06046430|OTHER|Assessment|The same assessments will be made to participants in both groups.
219526875|NCT02539589|BEHAVIORAL|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
219526876|NCT02539589|BEHAVIORAL|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
219526877|NCT06423066|DIAGNOSTIC_TEST|Pleural ultrasound|Patients who examine pleural ultrasound preoperatively.
219526878|NCT03505463|OTHER|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
219526879|NCT03505463|OTHER|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
219526880|NCT03505463|OTHER|Clinical examination|Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
219526881|NCT02376348|BEHAVIORAL|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
219526882|NCT04013425|PROCEDURE|Ice Cream Cone Technique|Guided bone regeneration
219526883|NCT04883801|DIAGNOSTIC_TEST|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
219526884|NCT01056861|DRUG|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
219526885|NCT02994186|PROCEDURE|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
218914000|NCT02278510|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
218914001|NCT01004068|OTHER|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
218914002|NCT01004068|DRUG|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
219041540|NCT04889742|DEVICE|loco-regional hyperthermia|loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
219041541|NCT02486380|DEVICE|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
219041542|NCT02006277|DRUG|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
219041543|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
219526886|NCT02994186|OTHER|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
218914003|NCT01004068|BEHAVIORAL|Structured exercise program plus hypocaloric diet|SET plus diet
219041544|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
219041545|NCT02006277|DRUG|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
219041546|NCT02006277|DRUG|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
219526887|NCT01302496|BIOLOGICAL|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
219526888|NCT01171690|DRUG|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
219526889|NCT01038856|DRUG|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
219526890|NCT02020707|BIOLOGICAL|Bevacizumab|Given IV
219526891|NCT02020707|OTHER|Laboratory Biomarker Analysis|Correlative studies
219526892|NCT02020707|DRUG|Nab-paclitaxel|Given IV
218914004|NCT06352723|DRUG|Cenobamate|"Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7"
218914005|NCT02731586|DRUG|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
218914006|NCT03464734|DRUG|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
218914007|NCT00269061|DRUG|pioglitazone|
218914008|NCT04475978|DEVICE|IVUS-guide DCB PTCA|IVUS-guide DCB PTCA
219526893|NCT02020707|OTHER|Pharmacological Study|Correlative studies
219526894|NCT03151278|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
218914009|NCT04475978|DEVICE|Angio-guide DCB PTCA|Angio-guide DCB PTCA
218914010|NCT01449162|DRUG|Masitinib|6 mg/kg/day
218914011|NCT01449162|DRUG|Placebo|
218914012|NCT04784325|DIAGNOSTIC_TEST|Blood draw through TAP II|Two self-administered blood draws through TAP II device
218914013|NCT04784325|DIAGNOSTIC_TEST|Blood draw through ADx cardT|One self-administered ADx card blood draw
219526895|NCT03151278|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
219526896|NCT03615300|DIAGNOSTIC_TEST|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
219526897|NCT01643707|BEHAVIORAL|Evidence based guidelines and tools|Education, guidelines, tools
219526898|NCT02183571|DRUG|Merck Glucophage® high dose|Part I: Treatment A
219526899|NCT02183571|DRUG|BMS Glucophage® high dose|Part I: Treatment B
219526900|NCT02183571|DRUG|Merck Glucophage® low dose|Part II: Treatment C
219526901|NCT02183571|DRUG|BMS Glucophage® low dose|Part II: Treatment D
219526902|NCT02438878|BEHAVIORAL|Baby Behavior|
219526903|NCT04872075|OTHER|Concert|People attending a concert in a closed area, with a mask
218914014|NCT04784325|DIAGNOSTIC_TEST|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
218914015|NCT02197884|DRUG|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
218914016|NCT02197884|DRUG|Itraconazole 200 mg|Itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.
218914017|NCT02197884|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
218914018|NCT00579215|BEHAVIORAL|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
219041547|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
219041548|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
219041549|NCT02006277|DRUG|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
219526904|NCT04872075|DIAGNOSTIC_TEST|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
218914019|NCT00579215|BEHAVIORAL|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
219041550|NCT02006277|DRUG|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
219041551|NCT05081856|OTHER|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
219041552|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
219526905|NCT04872075|DIAGNOSTIC_TEST|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
219526906|NCT06199297|DRUG|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
219614947|NCT01660633|DRUG|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
218914020|NCT05222334|PROCEDURE|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
218914021|NCT05222334|PROCEDURE|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
219526907|NCT06199297|DRUG|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
219526908|NCT06199297|PROCEDURE|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
219526909|NCT02689297|OTHER|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
219614948|NCT01660633|OTHER|Autologous Transplantation|Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
219614949|NCT01353599|DRUG|Mometasone furoate|220mcg once daily, for eight weeks
219614950|NCT04992806|PROCEDURE|hip arthroscopy|Use epidural anesthesia or general anesthesia. The patient lies on the orthopedic traction bed to protect the perineum and perform traction of the lower limbs on the surgical side. Under arthroscopy, check the labrum, acetabular articular surface and femoral head cartilage, and round ligament in turn. The acetabular labrum with tear degeneration was treated with labrum suture or labrum revision surgery according to the injury. Perform femoral head and neck plastic or acetabular plastic surgery, osteoid osteoma debridement, etc.
219614951|NCT02572570|DEVICE|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
219041553|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
219614952|NCT02572570|DEVICE|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
219614953|NCT04797104|DRUG|lerodalcibep|300 mg Q4W
219041554|NCT00144365|DRUG|Antiretroviral therapy|
218914022|NCT05222334|DRUG|Bupivacaine|bupivacaine
218914023|NCT02610296|DRUG|QPI-1002|IV injection
218914024|NCT02610296|OTHER|Placebo|isotonic saline
218914025|NCT06066034|DIAGNOSTIC_TEST|HOMA-IR，ESHRE/ASRM|Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003
218914026|NCT03149679|DRUG|Cyclophosphamide|Chemotherapy
218914027|NCT03998410|DEVICE|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
218914028|NCT01146769|OTHER|Pelvic floor exercise|Pelvic floor strengthening exercise
218914029|NCT01277016|DRUG|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
218914030|NCT03715114|DRUG|GV-971|Oral GV-971
218914031|NCT03715114|DRUG|Placebo|Oral Placebo
218914032|NCT03402217|BEHAVIORAL|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
219526910|NCT02689297|OTHER|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
219526911|NCT01391793|DRUG|Placebo|Twice daily for 3 days
218914033|NCT01680341|DRUG|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
218914034|NCT01680341|DRUG|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
218914035|NCT05613569|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
218914036|NCT04351542|DIETARY_SUPPLEMENT|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
218914037|NCT04351542|OTHER|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
218914038|NCT06419465|BEHAVIORAL|Peer-Led Health Protection and Promotion Training Program|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with peers, encouraging physical activity using the Google Fit mobile application. In order to provide social interaction, walking with peer leaders, health protection and development issues, receiving questions and opinions and giving guidance by individual phone calls regarding E-Nabiz and Google Fit mobile applications, holding peer group meetings and any of the Health Protection and Development Training Program targets. It consists of interventions such as giving a success badge for the relevant behavior if it reaches someone. Individual phone calls are also included in the intervention program.
218914039|NCT06419465|BEHAVIORAL|Health Protection and Promotion Training Program under the Leadership of a Public Health Nurse|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with nurses, encouraging physical activity using the Google Fit mobile application. To achieve any of the Health Protection and Development Training Program targets by walking with the nurse, taking individual phone calls regarding health protection and promotion issues, E-Nabiz and Google Fit mobile applications, receiving questions and opinions and giving guidance, holding group meetings in order to provide social interaction and social interaction. It consists of interventions such as giving a success badge for the relevant behavior. Individual phone calls are also included in the intervention program.
218914040|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
218914041|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
218914042|NCT03596034|OTHER|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
219041555|NCT05440292|DEVICE|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
219041556|NCT02626143|OTHER|Investigational nutrient-rich whey protein formula|
219041557|NCT02626143|OTHER|Cow's milk based formula|
219526912|NCT01391793|DRUG|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
219526913|NCT00905658|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
219526914|NCT00905658|PROCEDURE|standard follow-up care|Patients undergo standard monitoring
219526915|NCT05439252|BEHAVIORAL|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
219526916|NCT01568762|DRUG|VAK694|Intravenous infusion
219526917|NCT01568762|DRUG|VAK694 placebo|Intravenous infusion
219614954|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
219614955|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
219614956|NCT02763046|DRUG|Placebo - Secukinumab (AIN457) 150 mg s.c.|Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
218914043|NCT02640586|DEVICE|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
219526918|NCT01568762|DRUG|QAX576|Intravenous infusion
219526919|NCT01568762|DRUG|QAX576 placebo|Intravenous infusion
219526920|NCT01666730|DRUG|metformin hydrochloride|Given PO
219526921|NCT01666730|DRUG|oxaliplatin|Given IV
219526922|NCT01666730|DRUG|leucovorin calcium|Given IV
219526923|NCT01666730|DRUG|fluorouracil|Given IV
219526924|NCT01666730|OTHER|laboratory biomarker analysis|Correlative studies
219526925|NCT04335578|DRUG|Zampilimab|Participants will receive zampilimab (UCB7858) at pre-specified time-points.
219614957|NCT04829968|OTHER|gingival conditions control|"Peri-implant mucositis: It was diagnosed on the basis of the following criteria:~1. Visual inspection demonstrating the following signs of inflammation in the peri-implant region: red as opposed to pink colour, swollen tissues as opposed to no swelling, and soft as opposed to firm tissue consistency.~2. Presence of profuse (line or drop) bleeding and/or suppuration on probing.~3. An increase in probing pocket depths (PPDs) compared to baseline. • Peri-implantitis: It was diagnosed on the basis of the following criteria:~1\. Visual inflammatory changes in the peri-implant soft tissues combined with bleeding on probing and/or suppuration.~2\. Increasing PPDs as compared to measurements recorded at the time of placement of supra-structures."
219614958|NCT02884050|DRUG|Topiramate|antiepilepsy drug
219614959|NCT02884050|DRUG|Placebo|non-active placebo
218914044|NCT01426100|DRUG|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
218914045|NCT01426100|DRUG|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
219041558|NCT01734551|DRUG|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue."
219041559|NCT01734551|DRUG|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
219041560|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
219041561|NCT03013543|DRUG|Setmelanotide|RM-493 QD SC injection
219526926|NCT04335578|DRUG|Placebo|Participants will receive matching placebo (PBO) at pre-specified time-points.
219526927|NCT02953223|OTHER|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
219526928|NCT05290194|RADIATION|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
219526929|NCT05290194|DRUG|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
219614960|NCT06200194|DEVICE|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
219614961|NCT06200194|DRUG|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
219526930|NCT05290194|DRUG|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
219614962|NCT05029154|BEHAVIORAL|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
218914046|NCT01426100|DRUG|Telmisartan 80mg|Telmisartan 80mg monotherapy
219526931|NCT05702567|DEVICE|RF + PFMT|"During each session the patient is lying face up, with knees bent and feet resting on the stretcher.~Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency. The device is started at 15% intensity and adapting to a 10-point Likert scale, at point 3 or 4 of intensity.~At the same time that the radiofrequency is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are three:~* 10 fast contractions of one second each, with 10 seconds of rest.~* 5 seconds of sustained contraction and 10 seconds of rest.~* 10 seconds of contraction maintained with 10 seconds of rest.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
218914047|NCT00005942|DRUG|liposomal daunorubicin citrate|Given IV
218914048|NCT00005942|DRUG|semaxanib|Given IV
218914049|NCT00005942|OTHER|laboratory biomarker analysis|Correlative studies
219526932|NCT05702567|OTHER|PFMT + Placebo RF|"The intervention is exactly the same as the group RF + PFMT, unlike the non-functioning of the RF in the patients belonging to this group.~The patient is lying face up, with knees bent and feet resting on the stretcher. Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency, the device is started at 15% intensity, but in this case, the program does not work or apply radiofrequency to the patients.~At the same time, that the radiofrequency's probe is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are the three named in the Radiofrequency + PFMT.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
218914050|NCT06567145|BEHAVIORAL|Narrative Enhancement Cognitive Therapy (NECT)|The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
218914051|NCT00481832|DRUG|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
218914052|NCT00481832|DRUG|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
218914053|NCT00481832|DRUG|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
218914054|NCT00481832|DRUG|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
218914055|NCT00481832|DRUG|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
218914056|NCT00481832|DRUG|Cyclosporine|5mg/kgbid,variable, po or IV
218914057|NCT00481832|DRUG|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
218914058|NCT00481832|DRUG|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
218914059|NCT00481832|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
218914060|NCT00481832|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
219526933|NCT02886468|OTHER|skin ultrasound|
219526934|NCT00758186|PROCEDURE|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
219526935|NCT00758186|PROCEDURE|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
218914061|NCT00481832|PROCEDURE|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
219526936|NCT03380819|DIAGNOSTIC_TEST|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
219526937|NCT03405402|PROCEDURE|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
219526938|NCT00182442|DRUG|Olanzapine & Quetiapine|
219526939|NCT01716793|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics."
218914062|NCT00481832|DRUG|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
218914063|NCT00481832|DRUG|Solu-Medrol|1 mg/kg, Day-11 to Day-7
218914064|NCT04614363|DRUG|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
218914065|NCT02558894|DRUG|MEDI4736 monotherapy|MEDI4736 via IV infusion.
218914066|NCT02558894|DRUG|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
218914067|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
218914068|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
218914069|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
219614963|NCT05029154|BEHAVIORAL|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
219614964|NCT00009204|DRUG|Citalopram [Celexa]|
218914070|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
218914071|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
218914072|NCT02992288|DRUG|Placebo|Orally once daily for 20 weeks
218914073|NCT06205277|PROCEDURE|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
218914074|NCT05839964|DIETARY_SUPPLEMENT|CBN and CBD|CBN and CBD in Gummy Format
219526940|NCT01716793|OTHER|Autologous transplantation|"* In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling."
219526941|NCT01716793|OTHER|Allogeneic HLA-identical sibling transplantation|"* Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
219526942|NCT01716793|OTHER|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
219526943|NCT02830022|OTHER|physiological explorations|
219526944|NCT03021538|DEVICE|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
219526945|NCT03021538|DEVICE|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
219614965|NCT00009204|DRUG|Perphenazine [Trilafon]|
218914075|NCT03416985|DEVICE|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
218914076|NCT03416985|DEVICE|BURST Sonic Oral Care|Electric sonic toothbrush
218914077|NCT03416985|DEVICE|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
218914078|NCT05173194|OTHER|Exercise|Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
218914079|NCT02006472|DRUG|Pridopidine|22.5 mg and 45 mg capsules
218914080|NCT02006472|OTHER|Placebo|Capsules matching drug
218914081|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
218914082|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
218914083|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
218914084|NCT00499486|DRUG|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
218914085|NCT05128669|PROCEDURE|CPIP|CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.
218914086|NCT05128669|PROCEDURE|ECS|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
219526946|NCT02087904|BIOLOGICAL|ABT-981|
219526947|NCT02087904|OTHER|Placebo|
219526948|NCT02263092|BEHAVIORAL|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
219526949|NCT02263092|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
219526950|NCT02263092|BEHAVIORAL|Rest|15 or 30 minutes seat without move the legs
219526951|NCT04115280|DIAGNOSTIC_TEST|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
219526952|NCT02186730|BEHAVIORAL|Stressbusters|cCBT
219526953|NCT02186730|BEHAVIORAL|Websites|Self help websites
219614966|NCT02123004|DRUG|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
219614967|NCT02123004|DRUG|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
219614968|NCT01697072|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
219614969|NCT01697072|OTHER|Placebo|Placebo
219614970|NCT01697072|DRUG|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
219614971|NCT01697072|DRUG|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
219614972|NCT01697072|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine.
218914087|NCT02043756|DRUG|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
218914088|NCT02043756|DRUG|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
219526954|NCT01327963|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
219526955|NCT05034055|DRUG|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
218914089|NCT01803009|BEHAVIORAL|Patient views NCI CRC RAT|
218914090|NCT01803009|BEHAVIORAL|View presentation regarding current chance of having an advanced adenoma|
218914091|NCT00169286|PROCEDURE|Telephone care management|
219041562|NCT02048553|DEVICE|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
219526956|NCT03025880|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
219526957|NCT03025880|DRUG|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
219614973|NCT01608750|DRUG|Pantoprazol|40mg/day, oral, 28 days
219614974|NCT01608750|DRUG|Folic Acid|5 mg/day, oral, 28 days
219614975|NCT03610204|OTHER|Buffalo horn technique|The participants receive a 30-min massage session, twice a week for a total 6 sessions.
219614976|NCT06278740|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|Upper extremity pathologies of participants with ultrasound
219614977|NCT03096938|DIAGNOSTIC_TEST|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
218914092|NCT00169286|PROCEDURE|peer-led chronic disease self-management workshop|
218914093|NCT00169286|PROCEDURE|professionally-led cognitive behavioral psychotherapy group|
218914094|NCT06389422|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
218914095|NCT06389422|DRUG|Pembrolizumab|One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
218914096|NCT00002894|DRUG|carboplatin|
218914097|NCT00002894|DRUG|cisplatin|
218914098|NCT00002894|DRUG|paclitaxel|
218914099|NCT00656513|DRUG|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
219041563|NCT02048553|PROCEDURE|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
219041564|NCT00006484|DRUG|carboplatin|
218914100|NCT00656513|PROCEDURE|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
218914101|NCT03651310|OTHER|Music Listening Group|Waiting in preoperative area with music listening.
218914102|NCT01969136|DRUG|Drug: EVP-6124|
218914103|NCT01969136|DRUG|Placebo|
218914104|NCT02856568|DRUG|Cisplatin|Given IV
218914105|NCT02856568|DRUG|Gemcitabine Hydrochloride|Given IV
218914106|NCT02856568|OTHER|Laboratory Biomarker Analysis|Correlative studies
218914107|NCT02856568|OTHER|Pharmacological Study|Correlative studies
218914108|NCT02856568|DRUG|Ricolinostat|Given PO
218914109|NCT00441909|DRUG|UC-781|0.1% UC-781 Vaginal Gel
218914110|NCT00441909|DRUG|UC-781 placebo|Vaginal Gel Placebo
218914111|NCT00801957|DRUG|tacrolimus ointment 0.03%|topical application
218914112|NCT00801957|DRUG|hydrocortisone acetate ointment 1%|topical application
219041565|NCT00006484|DRUG|paclitaxel|
219041566|NCT00006484|DRUG|tirapazamine|
219614978|NCT02351414|DEVICE|Total Knee Arthroplasty (EVOLUTION®)|
219614979|NCT04750395|DRUG|Haloperidol Solution|Oral transmucosal haloperidol solution 2.5mg
219614980|NCT04750395|DRUG|Olanzapine Tablets|Oral transmucosal olanzapine tablet 5.0mg
219614981|NCT04755114|OTHER|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
219526958|NCT04343066|DEVICE|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
219526959|NCT03705065|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
219614982|NCT04755114|OTHER|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
219614983|NCT00513695|DRUG|sunitinib malate|Given PO
219614984|NCT00513695|DRUG|paclitaxel|Given IV
218914113|NCT00801957|DRUG|hydrocortisone butyrate ointment 0.1%|topical application
218914114|NCT00801957|BIOLOGICAL|Meningitec|im injection
218914115|NCT00801957|BIOLOGICAL|AC VAX|im injection
218914116|NCT00418678|DRUG|Cesamet|2 mg BID on Days 2-5.
218914117|NCT04257357|BEHAVIORAL|8-weeks supervised exercise program|Please refer to group description
218914118|NCT04257357|BEHAVIORAL|Active control|Please refer to group description
218914119|NCT04429711|DRUG|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
219526960|NCT02562365|DRUG|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
219526961|NCT01823965|DRUG|ranibizumab|
219614985|NCT00513695|DRUG|doxorubicin hydrochloride|Given IV
219614986|NCT00513695|DRUG|cyclophosphamide|Given PO
219614987|NCT00513695|BIOLOGICAL|filgrastim|Given SC
218914120|NCT05524025|DIAGNOSTIC_TEST|Salivary TTMV-HPV DNA Test|Mouthwash rinse
218914121|NCT05524025|DIAGNOSTIC_TEST|Blood TTMV-HPV DNA Test|Blood test
218914122|NCT00087152|DRUG|Capecitabine|1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
218914123|NCT00087152|DRUG|Imatinib mesylate|400 mg by mouth daily
218914124|NCT04182516|DRUG|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
218914125|NCT06052579|PROCEDURE|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
218914126|NCT01708356|BEHAVIORAL|Cycling on a residential route|
218914127|NCT05173558|BEHAVIORAL|Uninterrupted motionless standing|Participants remained 20 minutes of uninterrupted motionless standing
219041567|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
219041568|NCT06297707|OTHER|aquatic high intensity resistive training|The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.
218914128|NCT05173558|BEHAVIORAL|Uninterrupted motionless sitting|Participants remained 20 minutes of uninterrupted motionless sitting
218914129|NCT05173558|BEHAVIORAL|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
218914130|NCT00653510|DRUG|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
219526962|NCT04258982|OTHER|no intervention|no intervention
219614988|NCT00513695|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219614989|NCT00513695|OTHER|laboratory biomarker analysis|Correlative studies
219614990|NCT00513695|OTHER|flow cytometry|Correlative studies
219614991|NCT05948150|OTHER|using a breastfeeding pillow|To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
218914131|NCT00944853|DIETARY_SUPPLEMENT|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
218914132|NCT00944853|DIETARY_SUPPLEMENT|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
218914133|NCT00944853|DIETARY_SUPPLEMENT|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
218914134|NCT05632042|BEHAVIORAL|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
218914135|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
218914136|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
218914137|NCT02689427|PROCEDURE|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
218914138|NCT02689427|DRUG|Enzalutamide|Given PO
218914139|NCT02689427|OTHER|Laboratory Biomarker Analysis|Correlative studies
219614992|NCT05948150|OTHER|not using a breastfeeding pillow|The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
219526963|NCT02743130|DIETARY_SUPPLEMENT|Blackcurrant Nectar|Consumption of a single dose (300 ml)
218914140|NCT02689427|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
219614993|NCT04562350|OTHER|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
219526964|NCT02743130|DIETARY_SUPPLEMENT|Lingonberry Nectar|Consumption of a single dose (300 ml)
218914141|NCT02689427|DRUG|Paclitaxel|Given IV
219526965|NCT02743130|DIETARY_SUPPLEMENT|Reference|Consumption of a single dose (300 ml)
219614994|NCT06574750|DRUG|CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
219526966|NCT00893464|DRUG|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
219526967|NCT01389102|DRUG|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
219526968|NCT01389102|DRUG|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
219526969|NCT01389102|DRUG|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
219526970|NCT01389102|DRUG|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
219526971|NCT01389102|DRUG|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
219614995|NCT06574750|DRUG|JuvedermⓇ (Q-Med AB, Uppsala, Sweden)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
218914142|NCT02689427|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
218914143|NCT05506384|BEHAVIORAL|Relaps Preventions Therapy|The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
218914144|NCT05506384|BEHAVIORAL|Treatment as usual|This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
218914145|NCT00004217|BIOLOGICAL|filgrastim|5 μg/kg/day IV or SC
218914146|NCT00004217|BIOLOGICAL|sargramostim|5 μg/kg/day IV or SC starting d 15
219526972|NCT01389102|DRUG|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
219526973|NCT05287438|DIAGNOSTIC_TEST|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
219526974|NCT05287438|DIAGNOSTIC_TEST|Standard Culture|Standard of care culture and sensitivity
219526975|NCT01493752|DIETARY_SUPPLEMENT|beetroot juice|250mls daily beetroot juice
219526976|NCT04903600|DIETARY_SUPPLEMENT|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
219526977|NCT04903600|DIETARY_SUPPLEMENT|Placebo|Eat 16 g for once, and twice a day
219526978|NCT02910037|DEVICE|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
219526979|NCT00436553|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
218914147|NCT00004217|DRUG|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
218914148|NCT00004217|DRUG|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
218914149|NCT00004217|DRUG|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
219526980|NCT00436553|DRUG|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
219526981|NCT00436553|DRUG|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
219526982|NCT00436553|DRUG|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
218914150|NCT04271878|OTHER|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
218914151|NCT05293769|OTHER|questionnaire|questionnaire will be filled in by all participants
218914152|NCT00598338|DRUG|Prucalopride|4 mg o.d.
218914153|NCT00598338|OTHER|Placebo|o.d.
218914154|NCT00512889|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
218914155|NCT00512889|GENETIC|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
218914156|NCT00512889|DRUG|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
218914157|NCT00512889|RADIATION|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
218914158|NCT03581279|DEVICE|T2Lyme Panel testing|The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
218914159|NCT05164003|DRUG|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
218914160|NCT05164003|DRUG|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
218914161|NCT06101212|OTHER|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
218914162|NCT02829424|DRUG|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
218914163|NCT02829424|DRUG|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
218914164|NCT02967991|DEVICE|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
218914165|NCT03732573|BEHAVIORAL|Text messages|Text messages conveying 3 specific behaviour change techniques
218914166|NCT00754962|DRUG|protriptyline|10 mg tablet
218914167|NCT05831033|BIOLOGICAL|BEN101|"Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."
218914168|NCT04665453|DIAGNOSTIC_TEST|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
218914169|NCT04665453|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
219526983|NCT04127045|PROCEDURE|IMN-Group|Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
219526984|NCT04127045|PROCEDURE|HA-Group|In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
219526985|NCT02379247|DRUG|BYL-719 (alpelisib)|Oral PI3K inhibitor
219526986|NCT02379247|DRUG|Nab-paclitaxel|IV taxane
219526987|NCT03867994|DRUG|Atorvastatin|
218914170|NCT04665453|DRUG|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
218914171|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
218914172|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
218914173|NCT01419964|DRUG|Group 01|ACH24
218914174|NCT01419964|DRUG|Group 02|Placebo
218914175|NCT03983707|DEVICE|Purastat®|Use of Purastat®
218914176|NCT05906953|DRUG|HG004|Low dose Medium dose High dose
218914177|NCT05585788|DEVICE|Addinex Device (ADX-27)|"The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians."
218914178|NCT05818254|BEHAVIORAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
218914179|NCT05818254|BEHAVIORAL|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
219526988|NCT03867994|DRUG|Carvedilol|
219526989|NCT03867994|DRUG|saline|
219526990|NCT05642494|DEVICE|SDF|Silver Diamine Fluoride 38% (Applied bianually)
219526991|NCT05642494|DEVICE|NaF|Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
218914180|NCT06644573|PROCEDURE|PROSOMNIA Sleep Therapy™ (PSTx)|PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
218914181|NCT06644573|PROCEDURE|Anesthesia-Induced Sleep Therapy|"1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy."
218914182|NCT06644573|DRUG|Diprivan (propofol), Astra-Zeneca|Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA\_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
218914183|NCT06644573|DEVICE|Continuous EEG Monitoring|Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
218914184|NCT05984121|DRUG|Local ozon injections|"Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively."
218914185|NCT05984121|DRUG|Local dextroz prolotherapy injections|Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
218914186|NCT05984121|OTHER|Exercise Group|Patients will receive a conventional therapy program consisting of exercises
218914187|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219526992|NCT01174680|PROCEDURE|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
219614996|NCT01272050|RADIATION|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
218914188|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
218914189|NCT06088823|OTHER|Heart surgery|Adult cardiac surgery
218914190|NCT05235009|DIAGNOSTIC_TEST|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
219526993|NCT01563965|DIETARY_SUPPLEMENT|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
219526994|NCT01563965|OTHER|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
219526995|NCT03047265|DRUG|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
219526996|NCT03047265|DRUG|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
219526997|NCT01056965|DRUG|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
219526998|NCT01056965|DRUG|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
219614997|NCT06070519|DIAGNOSTIC_TEST|CPET and related variables evaluation|"At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~* Echocardiography (LVEF)~* Blood sample (Na+, MDRD, Hb)~* Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)"
218914191|NCT03659266|OTHER|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
218914192|NCT03659266|OTHER|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
218914193|NCT01436149|DRUG|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
218914194|NCT01436149|DRUG|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
218914195|NCT01874639|DEVICE|standard bipolar coagulation|
218914196|NCT01874639|DEVICE|Aquamantys® probe for liver hemostasis|
219526999|NCT04857125|OTHER|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
219527000|NCT04857125|OTHER|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
219527001|NCT03192930|OTHER|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
219527002|NCT02770625|DRUG|ISU302|60 U/kg given intravenously
219527003|NCT01498848|DIETARY_SUPPLEMENT|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
219527004|NCT00403039|DRUG|Ranibizumab (Lucentis )|
218914197|NCT04717037|BIOLOGICAL|Olive Oil Massage|olive oil massage application.
219041569|NCT06297707|OTHER|usual care|The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
219041570|NCT02885155|OTHER|Echocardiography|planned at regular intervals
219041571|NCT02885155|OTHER|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
219041572|NCT05510869|PROCEDURE|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
219041573|NCT05510869|PROCEDURE|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
219041574|NCT05510869|PROCEDURE|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
219041575|NCT05181111|DEVICE|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
218914198|NCT05960097|BIOLOGICAL|CV0701 Bivalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
218914199|NCT05960097|BIOLOGICAL|CV0701 Bivalent Medium dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
218914200|NCT05960097|BIOLOGICAL|CV0701 Bivalent Low dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
219041576|NCT05181111|OTHER|Usual Care|Usual Care Monitoring
219527005|NCT01474668|DRUG|GDC-0941|Single oral dose\\n \\n\\n\\n\\n
218914201|NCT05960097|BIOLOGICAL|CV0601 Monovalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
219527006|NCT01275586|DRUG|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
219527007|NCT03203863|DIAGNOSTIC_TEST|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
219527008|NCT02437279|PROCEDURE|Surgery of the tumor|
219527009|NCT02437279|DRUG|Infusion with ipilimumab 3 mg/kg q3wks|
219527010|NCT02437279|DRUG|Infusion with nivolumab 1 mg/kg q3wks|
219527011|NCT02865746|DRUG|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
218914202|NCT05960097|BIOLOGICAL|Control vaccine|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
218914203|NCT05960097|BIOLOGICAL|CV0801 Monovalent|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
219041577|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
219041578|NCT03602937|DIETARY_SUPPLEMENT|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
219614998|NCT06439550|DRUG|Serplulimab|300mg, q3w
219614999|NCT06439550|DRUG|Trastuzumab|First dose 8mg/kg, maintenance 6mg/kg, q3w
219527012|NCT02865746|DRUG|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
218914204|NCT06521723|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
219527013|NCT01787708|PROCEDURE|Red light|
219527014|NCT06284538|DEVICE|NOVA.EMOSTOP RE-EPITHELIZING|RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
219527015|NCT01270919|DEVICE|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
219527016|NCT02731365|DEVICE|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
218914205|NCT06521723|DEVICE|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
218914206|NCT04332822|DRUG|R-pola-mini-CHP|"* Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
218914207|NCT04332822|DRUG|R-mini-CHOP|"* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
218914208|NCT04578769|PROCEDURE|conventional myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
219527017|NCT00944203|DRUG|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
219527018|NCT04158570|PROCEDURE|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~* Guy's scoring system (GSS).~* Seoul renal stone complexity scoring system (S-ReSC).~* S.T.O.N.E. nephrolithometry scoring system.~* CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
219527019|NCT00998556|DRUG|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
219527020|NCT03855332|DRUG|Sildenafil|See above
219041579|NCT01556529|PROCEDURE|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
219041580|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
219041581|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
219527021|NCT03855332|DRUG|Cilostazol|See above
219527022|NCT03855332|DRUG|Placebo|Overencapsulated placebo
219527023|NCT02683837|DRUG|Remifentanil|
219527024|NCT02683837|DEVICE|Pupillometry|Pupillary diameter measured every 5 minutes
219527025|NCT02683837|DRUG|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
219041582|NCT03296306|DRUG|Treatment duration of cisplatin based chemotherapy|"* GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
219041583|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
219527026|NCT05975853|OTHER|Binaural beat music group (BBM group)|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
219527027|NCT05975853|OTHER|Control group|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
219527028|NCT00194753|DRUG|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
219527029|NCT00194753|DRUG|Doxorubicin|24 mg/m2 IV weekly x 12
219527030|NCT00194753|DRUG|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
219527031|NCT00194753|DRUG|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
219527032|NCT01914497|DEVICE|Acutus Medical System Mapping|
219527033|NCT00987805|DIETARY_SUPPLEMENT|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
219527034|NCT00987805|DIETARY_SUPPLEMENT|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
219527035|NCT04107454|DEVICE|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
219527036|NCT04107454|DEVICE|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
219527037|NCT02549651|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
219527038|NCT02549651|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
219527039|NCT02549651|DRUG|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
219527040|NCT04857697|PROCEDURE|Biopsy|Undergo biopsy
219527041|NCT04857697|PROCEDURE|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
219527042|NCT04857697|DRUG|Probiotic|Given PO
218914209|NCT04578769|PROCEDURE|short myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
218914210|NCT04578769|PROCEDURE|full-thickness myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
218914211|NCT04578769|PROCEDURE|tailored myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
218914212|NCT05772390|RADIATION|Partial breast re-irradiation|partial breast re-irradiation
219527043|NCT04857697|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219527044|NCT04925817|OTHER|Electronic Health Record Review|Medical record reviewed
219527045|NCT04925817|PROCEDURE|Ultrasound Microvessel Imaging|Undergo 3D ultrasound microvessel imaging
218914213|NCT05473988|OTHER|Admission to General Ward|Admission to General Ward
219527046|NCT02819934|DRUG|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
219527047|NCT04031131|DRUG|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
219527048|NCT04031131|OTHER|KY Gel|Lubricant Gel
218914214|NCT05473988|OTHER|Admission to Intensive Care Unit|Admission to Intensive Care Unit
218914215|NCT05473988|OTHER|30 Day Mortality|30 Day Mortality
218914216|NCT05261386|DRUG|CBT-008|Treat MGD
218914217|NCT03893071|DRUG|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
219041584|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
219041585|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
219527049|NCT02193880|DEVICE|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
219527050|NCT02544594|DEVICE|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
219527051|NCT01510262|BEHAVIORAL|Tailored Socio-Contextual Intervention|"1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard."
219615000|NCT06439550|DRUG|Oxaliplatin + Tegafur|oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
219527052|NCT01510262|BEHAVIORAL|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
218914218|NCT05811936|BEHAVIORAL|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
219527053|NCT02039362|DRUG|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
219527054|NCT03136380|DRUG|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
219527055|NCT03136380|DRUG|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
219527056|NCT03548389|OTHER|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
219527057|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
218914219|NCT00002754|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
218914220|NCT03151044|DRUG|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
219527058|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
219527059|NCT02951962|DRUG|Twynsta 80/5mg|Hypertension
219615001|NCT06518460|DIAGNOSTIC_TEST|Functional Efficiency of Self-sufficiency Test|The Barthel Index has 10 items focusing on mobility, feeding, grooming, hygiene, dressing, bladder control and bowel control. It scores from 0-100 points. A higher score indicates better performance. The Action Research Arm Test is 19-item observational measure used for the assessment of UE performance in stroke recovery. Scores range from 0-57 points. A higher score indicates a better outcome.
219615002|NCT05634421|OTHER|E-learning|The E-learning is under development at the department of Dermatology from MUMC+.
219615003|NCT01907490|DRUG|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
218914221|NCT03151044|DRUG|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
219527060|NCT02951962|DRUG|Crestor 20mg|Hyperlipidemia
219527061|NCT01924091|DRUG|Dapivirine gel|
219527062|NCT01924091|DRUG|Dapivirine film|
219527063|NCT04556240|DEVICE|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
219615004|NCT04247113|BEHAVIORAL|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
219615005|NCT04751552|PROCEDURE|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
219527064|NCT02698982|DEVICE|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
219527065|NCT02698982|PROCEDURE|moderate risk surgery|
219527066|NCT02550340|OTHER|acute alcohol intake|Smart phone based ECG recording
218914222|NCT06347198|DRUG|Fruquintinib|Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
218914223|NCT06347198|DRUG|Sintilimab|Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
218914224|NCT06347198|DRUG|Inulin|Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
218914225|NCT04281407|DIETARY_SUPPLEMENT|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
219527067|NCT04625348|DEVICE|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
219527068|NCT04625348|OTHER|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
219527069|NCT02620930|DEVICE|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
219527070|NCT00558857|DEVICE|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
219527071|NCT02778165|OTHER|MyCaRe (my cardiac recovery Android application)|Android application \& Fitbit Inspire 2 activity monitor
219527072|NCT01361048|DRUG|oral metronidazole|2 gm oral once
219527073|NCT01361048|DRUG|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
219527074|NCT01361048|DRUG|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
219527075|NCT02208492|DRUG|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
219527076|NCT02208492|DRUG|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
219527077|NCT01661686|DEVICE|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
218914226|NCT00322881|DRUG|Paclitaxel|
219527078|NCT01661686|DEVICE|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
219527079|NCT01020734|BIOLOGICAL|anti-thymocyte globulin|
219527080|NCT01020734|DRUG|busulfan|
219527081|NCT01020734|DRUG|cyclophosphamide|
218914227|NCT00322881|DRUG|Carboplatin|
218914228|NCT00623272|OTHER|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
218914229|NCT04836468|DIAGNOSTIC_TEST|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
218914230|NCT03113851|RADIATION|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
218914231|NCT03113851|DRUG|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
218914232|NCT00352508|BEHAVIORAL|Dietary advice|
219041586|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
219041587|NCT00353678|DRUG|YM150|
219527082|NCT01020734|DRUG|cyclosporine|
219527083|NCT01020734|DRUG|fludarabine phosphate|
219527084|NCT01020734|DRUG|methotrexate|
219527085|NCT01020734|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219527086|NCT04766281|DIETARY_SUPPLEMENT|MLC901|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
219527087|NCT04766281|GENETIC|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
219527088|NCT04753710|DRUG|Ocular gel|Instillation
219527089|NCT03110302|BEHAVIORAL|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
219527090|NCT01550900|DRUG|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
219527091|NCT01550900|OTHER|Placebo|Placebo tablets by mouth 1 time a day.
218914233|NCT02779439|BIOLOGICAL|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
218914234|NCT01258777|DRUG|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
218914235|NCT01258777|DRUG|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
218914236|NCT03527849|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
219041588|NCT04225923|DRUG|NPC-21 Low dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
219041589|NCT04225923|DRUG|NPC-21 High dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
219527092|NCT03535207|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
219527093|NCT01450085|OTHER|GeneXpert|Point of care GeneXpert
218914237|NCT03527849|BEHAVIORAL|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
218914238|NCT00561652|BEHAVIORAL|Education & Exercise|Education \& Exercise
218914239|NCT00561652|PROCEDURE|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education \& Exercise)
218914240|NCT04527952|BEHAVIORAL|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
218914241|NCT03904394|OTHER|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
218914242|NCT04964635|DEVICE|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
218914243|NCT06333314|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
218914244|NCT06333314|DRUG|Chemotherapy|"* mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin."
218914245|NCT04982653|OTHER|Quality-of-Life Assessment|Ancillary studies
218914246|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
218914247|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
218914248|NCT00573508|DRUG|Placebo|Oral Administration
219527094|NCT01450085|OTHER|LED Microscopy|Point of care LED Microscopy
219527095|NCT03554707|GENETIC|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
219527096|NCT03554707|RADIATION|Radiation|Standard radiation plan
218914249|NCT00573508|DRUG|Solifenacin Succinate|Oral Administration
218914250|NCT00010816|DRUG|Herbal remedies|
218914251|NCT04559568|DRUG|LY3522348|Administered orally.
218914252|NCT04559568|DRUG|Placebo|Administered orally.
218914253|NCT04559568|DRUG|Midazolam|Administered orally to some participants.
218914254|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
219527097|NCT03554707|DRUG|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
219527098|NCT03554707|DRUG|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
219527099|NCT03554707|DRUG|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
219527100|NCT03514771|DEVICE|Fraxel DUAL 1550/1927|
219527101|NCT03514771|DRUG|oral isotretinoin|oral isotretinoin
219527102|NCT03514771|DRUG|oral valacyclovir|Oral valacyclovir
218914255|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
218914256|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
218914257|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
219527103|NCT00672178|RADIATION|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
219527104|NCT00553280|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
219527105|NCT03874871|PROCEDURE|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
219527106|NCT03874871|PROCEDURE|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
218914258|NCT04443244|OTHER|Normal Saline|Placebo Comparator: Normal Saline
218914259|NCT04484961|DEVICE|Blood flow restriction (BFR)|The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
218914260|NCT04044950|BIOLOGICAL|E7 TCR|The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
218914261|NCT01667900|DRUG|Dulaglutide|
218914262|NCT01667900|DRUG|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
218914263|NCT01740830|DEVICE|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
219527107|NCT05934071|DRUG|SGLT2 inhibitor|optimization of the medical therapy for heart failure with reduced ejection fraction with SGLT2 inhibitor, according to clinical guidelines
218914264|NCT02438176|PROCEDURE|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
218914265|NCT02438176|PROCEDURE|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
218914266|NCT01468558|DRUG|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
218914267|NCT01468558|DRUG|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
218914268|NCT01468558|DRUG|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
218914269|NCT01205217|DRUG|Lapatinib|Lapatinib 1000 mg orally once daily continuously
218914270|NCT01205217|DRUG|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
218914271|NCT01205217|DRUG|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
218914272|NCT01205217|DRUG|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
218914273|NCT01205217|DRUG|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
218914274|NCT01761916|DRUG|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
218914275|NCT01761916|DRUG|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
218914276|NCT05544526|BIOLOGICAL|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
218914277|NCT05207774|DRUG|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
218914278|NCT05207774|DRUG|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
218914279|NCT00384345|DEVICE|Bright Light Therapy|
219041590|NCT04225923|DRUG|NPC-21 Placebo|Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
218914280|NCT00384345|BEHAVIORAL|Exercise|
218914281|NCT00298012|DRUG|Methotrexate|
218914282|NCT03497936|BEHAVIORAL|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
219041591|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
219041592|NCT01113125|DRUG|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
218914283|NCT00976274|DIETARY_SUPPLEMENT|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
218914284|NCT00976274|DIETARY_SUPPLEMENT|starch|5 capsules three times everyday for 12 weeks
218914285|NCT01075243|DRUG|Paracetamol 1000 mg|Paracetamol 1000mg
218914286|NCT01075243|DRUG|Paracetamol 650 mg|Paracetamol 650 mg
218914287|NCT01075243|DRUG|Placebo|Placebo
218914288|NCT01318577|DEVICE|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
219041593|NCT01113125|DRUG|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
219041594|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
219041595|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
219041596|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
218914289|NCT01318577|DEVICE|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
218914290|NCT04927546|BEHAVIORAL|Exercise|Thirty minutes of aerobic exercise in a treadmill.
218914291|NCT00627393|DRUG|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
218914292|NCT00627393|BIOLOGICAL|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
218914293|NCT00627393|DRUG|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
218914294|NCT00627393|DEVICE|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
218914295|NCT05512897|PROCEDURE|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
218914296|NCT02329444|PROCEDURE|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
219041597|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
219041598|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
219041599|NCT04576533|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
219041600|NCT01417481|DIETARY_SUPPLEMENT|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
219527108|NCT05506462|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
219615006|NCT01524159|DIETARY_SUPPLEMENT|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
219615007|NCT01524159|DIETARY_SUPPLEMENT|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
219615008|NCT04544241|BEHAVIORAL|Cancer Survivorship Leadership Training for Clergy Wives and Widows|We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
218914297|NCT02329444|PROCEDURE|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
218914298|NCT03361800|DRUG|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
218914299|NCT05587270|OTHER|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
218914300|NCT05587270|RADIATION|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
219527109|NCT05738382|DRUG|BG2109|oral administration once daily
219527110|NCT05738382|DRUG|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
218914301|NCT04805502|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
218914302|NCT00541372|DEVICE|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
218914303|NCT00347022|DRUG|Xenetix|300 mg of iodine/ml
218914304|NCT00347022|DRUG|Visipaque|270 mg of iodine/ml
218914305|NCT00004563|DRUG|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
218914306|NCT00004563|DRUG|Placebo|Matching gelcaps 25 mgs
218914307|NCT05616286|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
218914308|NCT06375161|BIOLOGICAL|anti-CD19-CAR-T cells|"Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc."
219041601|NCT01417481|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
219041602|NCT00829296|DRUG|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
219041603|NCT00829296|DRUG|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
219527111|NCT06129227|BEHAVIORAL|Dual-task training|This group will receive 30 min of dual-task exercise training and 30 min of stretching exercises in each session. The dual-task component involves walking activities performed in conjunction with cognitive activities. For the stretching exercise component, no cognitive load will be added.
219527112|NCT06129227|BEHAVIORAL|Single-task training|This group will undergo 30 min of single-task mobility training and another 30 min of single-task cognitive activities. The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately. No extra cognitive load will be imposed during the mobility exercises. No additional motor demand will be imposed during the cognitive exercises, as the participants will be sitting.
219527113|NCT06129227|BEHAVIORAL|Control group|This group will undergo 30 min of stretching exercises (same as the dual-task group) and another 30 min of upper limb strengthening exercises performed primarily in the sitting or lying position. No cognitive load will be added.
219527114|NCT00206544|DRUG|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
219527115|NCT00206544|DRUG|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
219615009|NCT04332900|DEVICE|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
219527116|NCT00206544|OTHER|placebo|adjunctive placebo daily in oral capsule
219527117|NCT04391062|DRUG|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
219527118|NCT04391062|DEVICE|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
219527119|NCT06406491|DEVICE|active microprocessor-controlled knee|Active microprocessor-controlled knees are motorized prosthesis, actively supporting the users while walking, getting up, and climbing stairs.
219527120|NCT01423526|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
219527121|NCT01423526|DRUG|Placebo|Placebo tablets, oral administration, single administrations
219615010|NCT04332900|DEVICE|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
219204527|NCT06886321|DEVICE|Prostate Irreversible Electroporation|The Prostate Irreversible Electroporation procedure was performed in our institution by a single urologist using an Prostate Irreversible Electroporation device and 18-gauge electrodes (Nanoknife®; Angiodynamics, Queensbury, NY, USA). All patients were positioned in lithotomy position under general anesthesia. A transrectal ultrasound was used to visualize the prostate and a brachytherapy grid was used to place the electrodes. An indwelling catheter was placed to empty the bladder. Four to six electrodes were placed through the perineum via the template grid to surround the targeted lesion. The lesion was defined based on prostate biopsy and MRI images. The active tip varied between 15- and 20-mm exposure. The distances between the electrodes were measured using TRUS and entered into the Nanoknife system. An initial ten pulses were delivered to ensure sufficient current was delivered between the electrodes (20-40 A). If sufficient then the remaining 80 pulses were given.
219615011|NCT06574659|PROCEDURE|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol
218914309|NCT04917172|DIAGNOSTIC_TEST|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell \[WBC\] count and C-Reactive Protein \[CRP\]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
218914310|NCT00437112|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
219041604|NCT06095466|DEVICE|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
219204528|NCT06726811|DRUG|Droperidol injection|2.5 mg
219204529|NCT06694181|OTHER|AI-PERSONALIZED CLINICAL DECISION SUPPORT|AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
219527122|NCT02794974|OTHER|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
219527123|NCT02794974|OTHER|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
219527124|NCT02794974|OTHER|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
219527125|NCT00428857|PROCEDURE|non invasive ventilation|non invasive ventilation
219527126|NCT04969757|DEVICE|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
219527127|NCT02164448|DRUG|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
219527128|NCT02164448|DRUG|the control group|saline infusion from induction of anesthesia to end of surgery
219615012|NCT06574659|PROCEDURE|The standard SBT guiding weaning group|The standard SBT guiding weaning protocol
219615013|NCT02835547|OTHER|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
219615014|NCT04656756|BEHAVIORAL|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
219527129|NCT05477030|DEVICE|Medtronic MiniMed 780G with SmartGuard activation|Insulin pump implemented with alghoritm for automatic modulation of insulin delivery (to increase time in glucose range 70-180 mg/dl)
219527130|NCT05477030|DEVICE|Medtronic MiniMed 780G without SmartGuard activation|Insulin pump implemented with alghoritm for low glucose insulin suspension (to reduce hypoglycemia rate)
219527131|NCT03983564|OTHER|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
219527132|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
219527133|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
219615015|NCT00311948|BEHAVIORAL|Telephone counseling + interactive website = more abstinence|
219615016|NCT00311948|BEHAVIORAL|Behavioral: interactive website|
219615017|NCT03411031|DRUG|Elotuzumab|Elotuzumab according to dosing schedule outlined in treatment arms.
219615018|NCT03411031|DRUG|Lenalidomide|Lenalidomide according to dosing schedule outlined in treatment arms.
219615019|NCT03411031|DRUG|Dexamethasone|"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."
219615020|NCT03710967|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the primary motor cortex
219615021|NCT02236962|DRUG|Placebo|
219615022|NCT02236962|DRUG|Ephedrine, pioglitazone|
219615023|NCT04141241|DRUG|Ecklonia cava Phlorotannin|Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
219615024|NCT03686605|OTHER|Thai version of the Edmontom Symptom Assessment System (ESAS)|Screening and diagnostic questionaire for depression
218914311|NCT00437112|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
219527134|NCT01873586|PROCEDURE|Posterolateral Fusion|
219527135|NCT05440903|BEHAVIORAL|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
219527136|NCT05440903|BEHAVIORAL|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
219527137|NCT00531856|DRUG|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
219527138|NCT00531856|DRUG|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
219527139|NCT00531856|DRUG|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
219527140|NCT00531856|DRUG|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
219527141|NCT00531856|DRUG|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
219527142|NCT01743547|OTHER|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
219527143|NCT02996682|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
219527144|NCT02996682|DRUG|RBV|Capsules administered orally in a divided daily dose
219527145|NCT04334174|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
219615025|NCT06575205|BEHAVIORAL|Educational video|Participants will view a brief 3-to-5-minute educational video (VIDEO), covering information that is already printed on FDA labels for OTC NSAIDs, on their own device covering themes such as: defining OTC NSAIDs, potential harms of NSAIDs, and alternatives.
219615026|NCT00980863|BEHAVIORAL|lifestyle intervention to increase physical activity|
219615027|NCT03859167|OTHER|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
219615028|NCT03691701|OTHER|strict blood pressure control|Home SBP target \< 120 mmHg or 90th percentile for age and height (whichever is lower)
219615029|NCT05706272|OTHER|Comprehensive geriatric assessment (CGA)|The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
218914312|NCT01762410|DRUG|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
218914313|NCT01056822|DRUG|1|Continue with same dose of MMF as patient was taking before randomisation
218914314|NCT01056822|DRUG|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
218914315|NCT04398771|DRUG|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
219615030|NCT05706272|OTHER|Care as usual|The control group will receive care as usual at the matched control primary care centers
219615031|NCT02999750|OTHER|individual therapy|Patient will be treated with individual therapy.
219527146|NCT05165680|COMBINATION_PRODUCT|combination of aerobic exercise and healthy diet|"The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks"
219527147|NCT02006173|DRUG|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
219527148|NCT02006173|DRUG|Normal Saline|
219527149|NCT00190814|DRUG|duloxetine|
219527150|NCT00190814|DRUG|placebo|
219527151|NCT02171637|DRUG|BIBW 2992|escalating doses
219527152|NCT06119841|PROCEDURE|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
219527153|NCT06119841|PROCEDURE|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
219527154|NCT04269460|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
219527155|NCT01467765|OTHER|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
219527156|NCT01972204|BEHAVIORAL|Intensive adherence instruction|Instruction with educational brochure
219527157|NCT01972204|BEHAVIORAL|Control|Instruction as per usual practice
219527158|NCT03636763|DRUG|data report|"the information gliptin exposure will be reported"
219527159|NCT05122286|PROCEDURE|Bailout angioplasty|Use balloons or stents for bailout angioplasty
218914316|NCT06005688|DRUG|Vepdegestrant|Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.
218914317|NCT06005688|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
218914318|NCT03593902|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
218914319|NCT03593902|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
219527160|NCT05122286|PROCEDURE|Standard therapy|Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
218914320|NCT03593902|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
219527161|NCT01352663|BIOLOGICAL|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
219527162|NCT01352663|BIOLOGICAL|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
219527163|NCT01165086|OTHER|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
219527164|NCT05841316|DRUG|Sugammadex|"During the surgery, the desired level of neuromuscular block will be deep and followed by post-tetanic-count (PTC) of 1 to 3 in every 5 minutes. 0.3-1mg/kg/h rocuronium will be infused to ensure PTC of 1 to 3.~At the end of the surgery, 0,6 mg sugammadex will be given as a bolus in the first patient of the study. The duration between the completion of sugammadex injection and the first measurement of Train-of-four ratio (TOFR) of 0.4 will be recorded.~If the TOFR is achieved to 0.4 after sugammadex bolus of 0,6 mg/kg in 5 minutes, the result of reversal will be evaluated as positive. The consecutive patient will be given the same or decreased dose of sugammadex by 0,2 mg/kg according to the randomisation scheme.~If the patient fails to recover from deep neuromuscular block to superficial block in 5 minutes after a given dose of sugammadex, the consecutive patient will be administered increased dose of sugammadex by 0,2 mg/kg."
219615032|NCT06171243|DRUG|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours."
219615033|NCT04878432|DRUG|MBG453|Solution for intravenous infusion
218914321|NCT03593902|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
218914322|NCT03593902|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
218914323|NCT03593902|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
218914324|NCT03593902|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
218914325|NCT03593902|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
218914326|NCT03593902|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
218914327|NCT04382950|COMBINATION_PRODUCT|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
218914328|NCT04324034|DEVICE|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
219527165|NCT04441463|BIOLOGICAL|Blood sampling for tryptase analysis|"3 bloods test~* One blood sample taking from the mother's vein punction, during the delivery.~* One blood sample tanking from umbilical cord.~* One blood sample taking from the baby in day 3 of life, during the Guthrie test."
219527166|NCT04920708|DRUG|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
218914329|NCT04324034|PROCEDURE|laparoscopy|The surgery by conventional laparoscopy is used
218914330|NCT05301660|DRUG|Nicotine transdermal patch|14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
218914331|NCT06266481|DRUG|Topical dexamethasone|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
218914332|NCT06266481|DRUG|10% lidocaine was sprayed over the tube for the second group|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
218914333|NCT05328102|BIOLOGICAL|Plamotamab|Biological
218914334|NCT05328102|BIOLOGICAL|Tafasitamab|Biological
218914335|NCT05328102|DRUG|Lenalidomide|Drug
219041605|NCT06095466|DIAGNOSTIC_TEST|Histopathology and Immunohistochemistry|"In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide."
219527167|NCT04920708|DRUG|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
219527168|NCT04920708|DRUG|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
219527169|NCT04920708|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
219527170|NCT05165823|BEHAVIORAL|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
218914336|NCT04308122|DEVICE|Cervical Orthosis (CO)|Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
218914337|NCT04308122|DEVICE|No Orthosis|The NO group will have no specific precautions applied to their neck range of motion.
219041606|NCT00099463|PROCEDURE|Blood Test|
218914338|NCT01569191|OTHER|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
218914339|NCT01569191|DEVICE|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
218914340|NCT01569191|DRUG|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
219041607|NCT00099463|PROCEDURE|Urine Test|
219527171|NCT06062914|DRUG|oral nutritional supplements|Only ONS was used as enteral nutrition
219527172|NCT00524264|DRUG|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
219041608|NCT00099463|PROCEDURE|Physical Exam|
219041609|NCT00099463|DRUG|Vaccine|
219615034|NCT04878432|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous administration
219041610|NCT00099463|DRUG|VRC-SRSDNA015-00-VP|
219615035|NCT04878432|DRUG|Decitabine|Solution for intravenous administration
219615036|NCT04878432|DRUG|INQOVI (oral decitabine)|Tablet for oral administration
219615037|NCT06532292|DEVICE|Biofeedback|To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.
219615038|NCT06532292|DEVICE|HIFEM|The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
219615039|NCT06962514|OTHER|Blood flow restriction cuff|Use of blood flow restriction cuff during resistance training. The cuff pressure is set at 50% of the participant's arterial occlusion pressure.
218914341|NCT00003149|BIOLOGICAL|recombinant interleukin-12|
218914342|NCT04134416|DRUG|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
219041611|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
219041612|NCT03862664|PROCEDURE|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
219041613|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
219041614|NCT00062569|BEHAVIORAL|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
219527173|NCT03067207|BEHAVIORAL|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
219527174|NCT04058288|DEVICE|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
219527175|NCT01987011|BIOLOGICAL|MG1109|
219527176|NCT01987011|BIOLOGICAL|Placebo|
219527177|NCT06121193|BEHAVIORAL|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
219527178|NCT06121193|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
219527179|NCT01868971|DEVICE|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
219527180|NCT05430698|DRUG|PD-1antibody plus GEMOX|"1. PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~3. Three weeks is a course of treatment,a total of 6-8 courses."
219527181|NCT01536405|BIOLOGICAL|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
219527182|NCT01536405|BIOLOGICAL|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
219527183|NCT02646397|DRUG|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
219527184|NCT02646397|DRUG|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
219527185|NCT02646397|DRUG|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
219527186|NCT01292720|DRUG|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
219527187|NCT01292720|DRUG|Placebo|Placebo in matching volumes
219527188|NCT06323876|DIAGNOSTIC_TEST|HRCT|High resolution computed tomography (HRCT) scan is a medical imaging technique used to obtain detailed internal images of the body. HRCT images will be obtained at 0 and 12 months.
219527189|NCT06323876|DIAGNOSTIC_TEST|Blood Draw|During blood draw, someone uses a needle to take blood from a vein, usually in your arm.
219527190|NCT00003674|DRUG|dalteparin|
219527191|NCT00003674|DRUG|standard therapy|
219527192|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
219527193|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
219527194|NCT01273974|BIOLOGICAL|intradermal influenza vaccine|0.25ml ,intradermal
219527195|NCT01273974|BIOLOGICAL|intramuscular influenza vaccine|0.5ml,intramuscular
219527196|NCT04050930|OTHER|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
219527197|NCT01759901|PROCEDURE|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
219527198|NCT04988763|OTHER|Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose
219527199|NCT05351918|OTHER|acupuncture|Acupuncture points are punctured with needles.
219527200|NCT00886275|DRUG|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
219615040|NCT06962514|OTHER|Exercise without BFR cuff|Resistance exercise performed without blood flow restriction. Same protocol as BFR group but without cuff application.
219615041|NCT04251364|DRUG|Acetazolamide|Daily acetazolamide pill intake
219615042|NCT04251364|DRUG|Atorvastatin|Daily atorvastatin pill intake
219527201|NCT00886275|DRUG|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
219527202|NCT00886275|DRUG|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
219527203|NCT01695720|PROCEDURE|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
219527204|NCT00287092|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
219527205|NCT00287092|BIOLOGICAL|Infanrix® -IPV+Hib|0.5 mL, IM
219615043|NCT04251364|DRUG|Placebo oral tablet|Daily placebo pill intake
218914343|NCT04134416|BEHAVIORAL|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
219615044|NCT06096662|BEHAVIORAL|Verb Network Strenghtening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
218914344|NCT04134416|DEVICE|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
218914345|NCT00691613|DRUG|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
218914346|NCT00691613|DRUG|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
218914347|NCT04225195|DRUG|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
218914348|NCT04692064|OTHER|There is no intervention|There is no intervention
218914349|NCT00762164|DRUG|Vytorin|Vytorin 10/80 split into 4
218914350|NCT00762164|DRUG|Simvastatin|Simvastatin 20 milligrams
218914351|NCT04965701|DRUG|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
218914352|NCT03138369|DEVICE|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
218914353|NCT03138369|DEVICE|Sham vestibular stimulation|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
219041615|NCT00062569|BEHAVIORAL|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
219041616|NCT03610243|BEHAVIORAL|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
219615045|NCT06292221|OTHER|A mobile Health (mHealth) tool called 'DepWatch'|The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
218914354|NCT03812731|DRUG|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
218914355|NCT03812731|DRUG|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
218914356|NCT04100486|OTHER|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
218914357|NCT04100486|OTHER|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
218914358|NCT04100486|OTHER|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
218914359|NCT04100486|OTHER|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
218914360|NCT04100486|OTHER|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
219527206|NCT06217614|OTHER|(Manuka honey-green tea)|"Manuka honey is a natural honey, and green tea are herbs Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. Green tea plus ginger mouthwash was prepared by adding 50% green tea extract and 50% ginger extract. After extraction, the extract was filtered and taker to the vacuum evaporator to remove the solvent.~The mouthwash was prepared by adding 3 gm of each extract, 0.12 gm sodium saccharin, and one liter distilled water, then every 20 ml of Manuka honey were added in 100 ml of (green tea and ginger solution). Finally, the mixture was stirred vigorously until all the particles were dissolved. Thereafter the obtained mixture was filtered. The mouthwash then filled in sterilized amber color bottles of 250 ml each.~According to similar studies performed in this field, the patients used a 20ml of (Manuka honey-green tea- ginger) mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out"
219527207|NCT00103623|DRUG|Plenaxis|
219527208|NCT00450190|DEVICE|Saizen® E-Device|Saizen® (recombinant human growth hormone \[r-hGH\]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
219527209|NCT01273779|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
219527210|NCT01273779|DRUG|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
218914361|NCT04100486|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
218914362|NCT05707728|DEVICE|intraoperative ultrasound|intraoperative cranial ultrasound
219527211|NCT05026671|PROCEDURE|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
219527212|NCT05026671|PROCEDURE|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
219615046|NCT05820126|BIOLOGICAL|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C
219615047|NCT06849271|PROCEDURE|Radical Nephrectomy (RN)|"Complete remove of the kidney. In addition as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
219615048|NCT06849271|PROCEDURE|Partial nephrectomy (PN)|"Partial remove of a section in the kidney. In addition, as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
219615049|NCT06849271|PROCEDURE|Radical Prostatectomy (RP)|"Complete remove of the prostate gland. In addition as part of the intervention, two procedures termed Lysis of abdominal adhesions and/or Lymphadenectomy  (removal of regional lymph nodes) may be performed according to patient medical condition and/or surgeon criteria."
218914363|NCT01269203|DRUG|Curcumin|1000 mg per day
218914364|NCT01269203|OTHER|Placebo|Administered daily same as Curcumin.
218914365|NCT06246292|PROCEDURE|Ultrasound-guided ESPB|The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
218914366|NCT06246292|PROCEDURE|Anatomical landmark-guided ESPB|The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
218914367|NCT02405689|DRUG|Remifentanil|
218914368|NCT02405689|DRUG|Dexmedetomidine|
218914369|NCT02405689|DRUG|Sevoflurane|
218914370|NCT06118021|DRUG|HS-20094|Administered SC
218914371|NCT06118021|DRUG|Placebo|Administered SC
218914372|NCT04094558|DEVICE|Ingestible capsule|Participants will swallow capsules and collect in stool concurrent with stool samples
218914373|NCT04094558|PROCEDURE|Sedated EGD|Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.
219615050|NCT05017246|DRUG|Bupivacaine|-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
218914374|NCT04094558|DIAGNOSTIC_TEST|Lactulose Breath Test|Hydrogen and methane breath test with lactulose substrate
218914375|NCT00273221|PROCEDURE|Glaucoma Implant Surgery|
218914376|NCT00273221|PROCEDURE|trabeculectomy|
218914377|NCT00273221|PROCEDURE|phacoemulsification|
218914378|NCT00412334|DRUG|Copegus|1200-1600mg/day po
218914379|NCT00412334|DRUG|Copegus|1000-1200mg/day po
218914380|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
218914381|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
218914382|NCT03371667|DRUG|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
219041617|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
219041618|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
219041619|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
219041620|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
219527213|NCT05026671|PROCEDURE|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
219615051|NCT05017246|DRUG|Morphine|-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
219615052|NCT05017246|DRUG|Lidocaine|-Lidocaine infusion 1 mg/kg ideal body weight (IBW)
219615053|NCT04208152|DRUG|anle138b|capsule containing excipient and anle138b
219615054|NCT04208152|DRUG|Placebo|matching placebo capsule containing excipient
219615055|NCT04179318|DIAGNOSTIC_TEST|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
219615056|NCT04459234|DRUG|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations"
219615057|NCT04172935|DEVICE|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
219615058|NCT03877679|DRUG|Triamcinolone|Triamcenolone +napolycarboxylate
219615059|NCT03877679|DRUG|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
219615060|NCT02636478|OTHER|questionnaire for travel habits|questionnaire has been used to collect information about travelling
219615061|NCT01897428|DRUG|Test-Bepotastine salicylate 9.64 mg|
219615062|NCT01897428|DRUG|Reference-bepotastine besilate 10 mg|
219615063|NCT05943717|DEVICE|lung ultrasound and electrical cardiometry|: B-lines of lung ultrasound and the parameters of cardiometry will be measured at the mid-week HD session before starting the session by 30 min then every 30min during HD session for 180 min and then after the end of the session of HD by 30 min and then The specificity and sensitivity of both techniques will be compared to each other
219615064|NCT06187428|OTHER|PainSMART-strategy|"Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management."
219615065|NCT06187428|OTHER|Usual physiotherapy management|Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
219615066|NCT06194968|DRUG|Urokinase|administered intravenously
219615067|NCT06194968|DRUG|Alteplase|administered intravenously
219615068|NCT02943837|PROCEDURE|Device: 22G FNA needle|
219615069|NCT02943837|PROCEDURE|Device: 20G FNB needle|
219615070|NCT01514461|DRUG|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
219615071|NCT01514461|DRUG|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
219615072|NCT00241670|DRUG|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
219615073|NCT02754050|DEVICE|Tandem Snare|
219041621|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
219041622|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
219041623|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
219041624|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
219527214|NCT05026671|PROCEDURE|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
219527215|NCT03252509|PROCEDURE|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
219527216|NCT02848742|DEVICE|Dermal Cooling System|Dermal cryotherapy
218914383|NCT03371667|DRUG|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
219527217|NCT02976662|PROCEDURE|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
219527218|NCT01779544|OTHER|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
219527219|NCT01779544|OTHER|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
219527220|NCT05683665|DEVICE|scintigraphy DaTSCAN|DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
219527221|NCT05668520|DIAGNOSTIC_TEST|Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system|"Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference"
219527222|NCT01536574|DRUG|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
219527223|NCT02605148|DIETARY_SUPPLEMENT|Gluten free diet|Gluten free diet during 18 months.
219527224|NCT02605148|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Omega 3 fatty acid
219527225|NCT02605148|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 800 U/day
219527226|NCT02605148|DIETARY_SUPPLEMENT|Probiotics|Probiotics
219527227|NCT05293886|OTHER|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
218914384|NCT03566602|DEVICE|Dura Sealant Patch|Adjunctive bioresorbable patch
219041625|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
219527228|NCT05293886|OTHER|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
219527229|NCT01447615|BEHAVIORAL|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
219527230|NCT01447615|BEHAVIORAL|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
219527231|NCT01447615|OTHER|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
219527232|NCT00656305|DEVICE|ExAblate MRfFUS|MR guided focused ultrasound.
219527233|NCT00656305|DEVICE|Sham|sham comparator
219041626|NCT02808845|OTHER|microalbuminuria|
219527234|NCT04710381|DRUG|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
218914385|NCT04298047|OTHER|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
218914386|NCT01164514|BIOLOGICAL|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
218914387|NCT01164514|BIOLOGICAL|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
218914388|NCT01164514|DRUG|Placebo|Normal saline.
219527235|NCT01667627|DIETARY_SUPPLEMENT|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
219527236|NCT01667627|OTHER|Placebo|Identical placebo
219527237|NCT02193165|DRUG|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
218914389|NCT06301490|OTHER|Myofascial Release|Myofascial release is a popular hands-on method manual therapy technique that uses carefully guided low load, long duration mechanical pressures to modify the myofascial complex (directly or indirectly), with the goal of restoring appropriate length, decreasing discomfort, and improving range of motion, muscle recovery, and physical performance in healthy persons.
219527238|NCT02193165|DRUG|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
218914390|NCT03094416|DRUG|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
218914391|NCT03094416|DRUG|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
218914392|NCT03094416|DRUG|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
219527239|NCT02193165|DRUG|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
219527240|NCT01778517|OTHER|Group Psychotherapy|
219527241|NCT01778517|OTHER|Cognitive behavior therapy based on self help|
219527242|NCT01125137|PROCEDURE|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
219527243|NCT05069961|PROCEDURE|ESPB|Ropivacaine is injected near the nerves in the back
218914393|NCT03690193|BEHAVIORAL|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
218914394|NCT03733717|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
218914395|NCT05682430|BEHAVIORAL|Heart rate based HIIT|Week1,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week2,90% HRmax long duration HIIT + 90% long duration HRmax HIIT. Week3,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week4,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week5,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week6,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week7,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week8,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week9,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week10,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week11,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week12,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT.
219527244|NCT05069961|PROCEDURE|TEA|Bupivacaine is injected into the space around the spinal cord.
219527245|NCT03203980|OTHER|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
219527246|NCT01498120|DRUG|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day"
219527247|NCT04058080|OTHER|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
218914396|NCT05682430|BEHAVIORAL|VIFT speed-based HIIT with mechanical work|Week1,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week2,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week3,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week4,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week5,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week6,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week7,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week8,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week9,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week10,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week11,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT. Week12,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT.
218914397|NCT05230134|PROCEDURE|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
218914398|NCT01542047|DRUG|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
218914399|NCT01542047|DRUG|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
218914400|NCT02677441|PROCEDURE|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
219527248|NCT04058080|OTHER|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
219527249|NCT05857085|DRUG|Semaglutide Pen Injector [Ozempic]|GLP 1 agonist
219527250|NCT05857085|DRUG|Empagliflozin 10 MG|SGLT 2 inhibitor
218914401|NCT02677441|PROCEDURE|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
218914402|NCT03922100|DRUG|NMS-03592088|Route of administration: Oral
218914403|NCT06229626|OTHER|intensive reeducation|"* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks"
218914404|NCT05916183|BEHAVIORAL|Fluid loss and consumption|Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
219527251|NCT04222790|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
219527252|NCT04222790|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
219527253|NCT00616408|DRUG|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
218914405|NCT03525236|OTHER|Tasting of flavours|"* Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
219527254|NCT02783352|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
218914406|NCT05623124|OTHER|No intervention|No intervention
218914407|NCT00295555|DRUG|Effects of doxazosin on morning surge in diabetic patients|
218914408|NCT03135600|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
218914409|NCT04609943|DRUG|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
218914410|NCT04246684|DRUG|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
218914411|NCT04246684|DRUG|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
218914412|NCT04246684|DRUG|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
218914413|NCT04246684|DRUG|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
218914414|NCT04246684|DRUG|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
218914415|NCT04246684|DRUG|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
219527255|NCT02783352|PROCEDURE|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
219527256|NCT00845715|OTHER|Early motion|Early referral to physical therapy for range of motion (2 days post)
218914416|NCT04246684|RADIATION|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
218914417|NCT04246684|DRUG|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
218914418|NCT04246684|DRUG|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
218914419|NCT04246684|RADIATION|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
218914420|NCT04246684|DRUG|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
218914421|NCT04246684|DRUG|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
219041627|NCT04116710|BIOLOGICAL|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
219041628|NCT04116710|BIOLOGICAL|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
219041629|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
219041630|NCT05017610|DRUG|Liothyronine|Given PO
219041631|NCT05017610|DRUG|Lomustine|Given PO
219041632|NCT05017610|DRUG|Methimazole|Given PO
219041633|NCT03002168|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
218914422|NCT06223893|DEVICE|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
219527257|NCT00845715|OTHER|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
218914423|NCT06443762|DRUG|[68Ga] MDM2/MDMX Peptide|"Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability."
218914424|NCT06583668|OTHER|Therapeutic Story|Listening and watching the therapeutic story in digital media
219527258|NCT04603092|BEHAVIORAL|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
218914425|NCT05050331|PROCEDURE|Muscle Energy Technique|MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening
218914426|NCT05050331|PROCEDURE|Trigger Point Release|Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.
219041634|NCT03002168|DIETARY_SUPPLEMENT|Placebo|Placebo tablets identical in appearance to the active comparator
219041635|NCT03002168|RADIATION|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
219041636|NCT03002168|RADIATION|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
219527259|NCT04360447|DEVICE|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
219527260|NCT04360447|OTHER|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
219527261|NCT02824484|BEHAVIORAL|GWDP|"In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
219527262|NCT02824484|BEHAVIORAL|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
219527263|NCT06319963|DRUG|Two IM injections Lenti-HPV-07|two Lenti-HPV-07 intramuscular injections one month apart
219527264|NCT06319963|DRUG|One IM injection Lenti-HPV-07|a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
219527265|NCT01214226|DRUG|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
219527266|NCT01214226|DRUG|placebo|prolonged-release tablets 3 time per day for 1 month
219527267|NCT01642511|RADIATION|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
219527268|NCT01642511|PROCEDURE|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
219527269|NCT01642511|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
219527270|NCT01642511|DEVICE|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
219527271|NCT01642511|PROCEDURE|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
219527272|NCT01642511|PROCEDURE|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
219527273|NCT04723602|BIOLOGICAL|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
219041637|NCT06373679|BEHAVIORAL|Switching to E-Cigarette|Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
219527274|NCT04723602|BIOLOGICAL|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
219527275|NCT01171963|BIOLOGICAL|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
219527276|NCT01171963|BIOLOGICAL|Placebo|Oral administration
219527277|NCT01171963|BIOLOGICAL|Infanrix™|Intramuscular administration
219041638|NCT06373679|BEHAVIORAL|Switching using Medication|Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
219041639|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
219527278|NCT01171963|BIOLOGICAL|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
219527279|NCT00724191|PROCEDURE|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
219527280|NCT05789238|BEHAVIORAL|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
219615074|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
219041640|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
219041641|NCT04818359|BEHAVIORAL|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
219527281|NCT05789238|BEHAVIORAL|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
219527282|NCT06158451|COMBINATION_PRODUCT|Zinc oxide propolis|"Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached."
219527283|NCT06158451|COMBINATION_PRODUCT|Modified triple antibiotic paste|"Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~* After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~* The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency"
219527284|NCT01007500|DRUG|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
219527285|NCT01007500|DRUG|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
219527286|NCT00000132|DRUG|Betaxolol|
219527287|NCT00000132|PROCEDURE|Argon Laser Trabeculoplasty|
219527288|NCT04349605|BEHAVIORAL|Meditation|Meditation involves guided breathing and mindfulness training.
219527289|NCT04349605|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
219527290|NCT03948347|DRUG|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
219527291|NCT02041169|OTHER|Subsequent walking performance|Subsequent walking performance
219041642|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
219041643|NCT00544596|DRUG|cisplatin|Given IV
219041644|NCT00544596|DRUG|etoposide|Given IV
219041645|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
219204530|NCT06869421|OTHER|Questionnaire|group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes: knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics
219527292|NCT03380754|DIETARY_SUPPLEMENT|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
219527293|NCT03380754|OTHER|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
219527294|NCT00465764|OTHER|Alternate protein infant formula|Feed as per HCP directions
219527295|NCT00465764|OTHER|Standard infant formula|Feed as per HCP directions
219527296|NCT02012153|BIOLOGICAL|Mesenchymal Stromal Cells|
219527297|NCT05614960|OTHER|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
219527298|NCT04168788|OTHER|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
219527299|NCT00500487|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
219527300|NCT00500487|BEHAVIORAL|HIV Prevention Skills|12-session group intervention including sexual health skills training.
219527301|NCT00500487|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of health topics.
219527302|NCT04205201|DRUG|Drugs, Investigational|To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
219527303|NCT05566015|OTHER|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
219527304|NCT03447678|DRUG|Pembrolizumab|humanized antibody used in cancer immunotherapy
219527305|NCT04981938|PROCEDURE|Lobectomy with pulmonary artery reconstruction|"Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space~Subgroups : different types of pulmonary artery reconstruction such as :~* Tangential vascular reconstruction with direct suture~* Circumferential resection and end-to-end anastomosis~* bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch"
219527306|NCT01929122|DIETARY_SUPPLEMENT|Placebo-Control Meals and Snacks|
219527307|NCT01929122|DIETARY_SUPPLEMENT|Cooked Navy Bean Powder Meals and Snacks|
219527308|NCT01929122|DIETARY_SUPPLEMENT|Rice Bran Meals and Snacks|
219527309|NCT02164279|OTHER|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)
219527310|NCT00002994|BIOLOGICAL|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
219527311|NCT00002994|BIOLOGICAL|rhuMAb|90 min IV infusion day 7 of each cycle
219527312|NCT01223365|DRUG|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
219615075|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (\<50 lux)."
219615076|NCT02058069|DEVICE|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
219204531|NCT06680635|DIETARY_SUPPLEMENT|Flavonoid-enriched juice and a low-calorie diet|Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
219204532|NCT06680635|DIETARY_SUPPLEMENT|Food supplement: placebo juice and a low calorie diet|Placebo juice (200 ml/day) and a low calorie diet
219527313|NCT00839605|DRUG|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
219527314|NCT02738242|DEVICE|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
219527315|NCT04150627|OTHER|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
219615077|NCT00620386|DEVICE|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
219615078|NCT00620386|DEVICE|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
219527316|NCT05859841|OTHER|Music listening|Music listening under instruction by music therapist, min 3 hours daily
219527317|NCT05859841|OTHER|Control|Standard treatment, care and rehabilitation
219527318|NCT03012178|PROCEDURE|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
219527319|NCT03750097|BEHAVIORAL|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
219527320|NCT03750097|BEHAVIORAL|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
219615079|NCT01880866|DRUG|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
219615080|NCT06581510|PROCEDURE|esthetic dental crowns|Minimal Preparation of esthetic dental crown
219207762|NCT05460520|BEHAVIORAL|VOR Habituation|The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
219527321|NCT03750097|BEHAVIORAL|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
219615081|NCT06581510|PROCEDURE|control group|Nuu smile ready-made zirconia crown with its well-known reduction
219615082|NCT01299103|DEVICE|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
219615083|NCT00991393|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
219615084|NCT06378515|OTHER|Physical activity, postural changes and cognitive tasks|"1. Measuring while patients are sitting in rest for 5 minutes.~2. Supine to stand test: lying down (5 min) standing up (5 min)~3. Repeated sit stand test: sitting (10 sec) ↔ standing (10 sec), changing position every 10 seconds for 5 minutes.~4. Paced breathing in sitting position: letting patients breath 6 breaths/minute (0.1Hz) for 5 minutes.~5. Breath hold manoeuvre in sitting position: 60s normal breathing, then 32s breath hold + 88s normal breathing repeated 3 times.~6. Arithmetic stress test by giving the subject single digit addition. To give the pressure, subject needs to do as many as possible calculation within 1 minute with 1 minute break. This is repeated 3 times."
219615085|NCT01689051|OTHER|human glucagon-like peptide 1 (7-36)amide|
219615086|NCT01689051|OTHER|human glucagon-like peptide 1 (9-36)amide|
219615087|NCT04810208|DRUG|Docetaxel|Docetaxel in NanoZolid formulation, for intratumoural injection
219615088|NCT01841684|DRUG|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
219527322|NCT04558905|OTHER|Face-to-face medical visits|Face-to-face medical visits
219527323|NCT04558905|OTHER|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
219527324|NCT00480350|BEHAVIORAL|rice based food supplement|
219527325|NCT04499170|OTHER|Muscular Energy Technique G1|Group of older (G1) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
219615089|NCT01841684|DRUG|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
219615090|NCT03014154|OTHER|Training|
219615091|NCT00002578|DRUG|cytarabine|
219615092|NCT00002578|DRUG|gallium nitrate|
219615093|NCT00002578|DRUG|leucovorin calcium|
219615094|NCT00002578|DRUG|methotrexate|
219615095|NCT01629511|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
219615096|NCT01629511|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219615097|NCT01629511|DRUG|Busulfan|Given IV
219615098|NCT01629511|DRUG|Clofarabine|Given IV
219615099|NCT01629511|BIOLOGICAL|Filgrastim|Given SC
219615100|NCT01629511|DRUG|Gemcitabine|Given IV
219615101|NCT01629511|DRUG|Methotrexate|Given IV
219615102|NCT01629511|DRUG|Tacrolimus|Given PO
219615103|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
219615104|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
219615105|NCT00256178|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
219527326|NCT04499170|OTHER|Muscular Energy Technique G2|Group of young people (G2) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
219527327|NCT03567174|OTHER|Integrated care van (ICV)|Structural service delivery intervention
219527328|NCT00380445|DRUG|Vildagliptin|
219527329|NCT03731598|PROCEDURE|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
219527330|NCT02005705|OTHER|Outpatient Management of Low-risk Patients|"* Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30"
219527331|NCT02005705|OTHER|Inpatient Management of Low-risk Patients|"* Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30"
219527332|NCT03306160|OTHER|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
219527333|NCT06234163|BEHAVIORAL|Assigned intervention|"Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition."
219527334|NCT02628834|OTHER|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
219615106|NCT05143060|DIETARY_SUPPLEMENT|Cereal powder|Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.
219615107|NCT05143060|DIETARY_SUPPLEMENT|Pure glucose powder|Pure glucose powder
218914427|NCT05050331|PROCEDURE|Self-Stretching of Calf and Plantar Fascia|Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily
218914428|NCT02211794|OTHER|data collection|
218914429|NCT04756427|DRUG|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
218914430|NCT04664491|BEHAVIORAL|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
218914431|NCT04664491|OTHER|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
218914432|NCT04528641|BIOLOGICAL|GRAd-COV2|Single intramuscular administration.
219615108|NCT00428701|DRUG|Esomeprazole Sodium|
219615109|NCT00780338|OTHER|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
219615110|NCT01397357|OTHER|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
219615111|NCT00200863|DEVICE|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
219615112|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
219615113|NCT01709825|DIETARY_SUPPLEMENT|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
219615114|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
218914433|NCT03674528|OTHER|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
218914434|NCT03674528|DIAGNOSTIC_TEST|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
218914435|NCT01431612|DRUG|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
218914436|NCT01431612|DRUG|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
218914437|NCT01431612|DRUG|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
218914438|NCT03380650|DEVICE|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
218914439|NCT03380650|DEVICE|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
218914440|NCT03264586|DRUG|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~\- EMLA cream was applied, 1 hour before the expected time of birth."
218914441|NCT03264586|DRUG|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic"
219041646|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
219366362|NCT01902732|DEVICE|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
219366363|NCT02628860|DRUG|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
219366364|NCT00018954|DRUG|asparaginase|
219366365|NCT00018954|DRUG|cyclophosphamide|
219366366|NCT00018954|DRUG|cytarabine|
219366367|NCT00018954|DRUG|daunorubicin hydrochloride|
219366368|NCT00018954|DRUG|doxorubicin hydrochloride|
219366369|NCT00018954|DRUG|etoposide|
219366370|NCT00018954|DRUG|ifosfamide|
219366371|NCT00018954|DRUG|mercaptopurine|
219366372|NCT00018954|DRUG|methotrexate|
219366373|NCT00018954|DRUG|prednisone|
219366374|NCT00018954|DRUG|vincristine sulfate|
219366375|NCT00018954|PROCEDURE|conventional surgery|
219366376|NCT00018954|RADIATION|radiation therapy|
219366377|NCT02440581|DRUG|Alendronate|
219366378|NCT02440581|DRUG|Teriparatide|
219366379|NCT02440581|DRUG|Cinacalcet|
219366380|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
219366381|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
219366382|NCT00611494|DRUG|MMF|Gradual optimization of drug dosage, as clinically tolerated.
219366383|NCT00611494|DRUG|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
219366384|NCT05190952|DRUG|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
219366385|NCT05190952|DRUG|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
219366386|NCT05190952|DRUG|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
219366387|NCT05706935|DIAGNOSTIC_TEST|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
219366388|NCT04230447|OTHER|No intervention|No intervention
219366389|NCT03430986|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.
219366390|NCT03430986|OTHER|No-treatment control|No treatment during the control period.
219366391|NCT03478384|BEHAVIORAL|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
219366392|NCT05104047|OTHER|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
219366393|NCT05104047|OTHER|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
219366394|NCT05104047|OTHER|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
219615115|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
219615116|NCT05584384|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
219615117|NCT05584384|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
219615118|NCT03982732|BIOLOGICAL|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
218914442|NCT03264586|PROCEDURE|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
218914443|NCT05918601|OTHER|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
218914444|NCT05918601|OTHER|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
218914445|NCT05918601|OTHER|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
218914446|NCT05918601|OTHER|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
218914447|NCT05918601|OTHER|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
218914448|NCT05918601|OTHER|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
219366395|NCT01232478|BEHAVIORAL|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
219615119|NCT04858932|DEVICE|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
219366396|NCT00067210|DEVICE|Head and Neck Cooling System|
219615120|NCT04858932|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
219615121|NCT04858932|DEVICE|Food Weight Scale|a scale to measure food weight
218914449|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
218914450|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
218914451|NCT04366349|OTHER|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
218914452|NCT04357535|DRUG|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
219366397|NCT00003414|BIOLOGICAL|aldesleukin|
219366398|NCT00003414|BIOLOGICAL|recombinant interferon gamma|
219366399|NCT00003414|DRUG|busulfan|
219366400|NCT00003414|DRUG|cyclophosphamide|
219366401|NCT00003414|DRUG|cyclosporine|
219366402|NCT00003414|PROCEDURE|peripheral blood stem cell transplantation|
219366403|NCT00003414|RADIATION|radiation therapy|
219366404|NCT05775328|OTHER|Intense pulsed light|Already described in the arm/group description
219366405|NCT02022826|DEVICE|SmartPill Monitoring System|
219366406|NCT04590456|OTHER|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
219366407|NCT05152381|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219366408|NCT03540186|DIETARY_SUPPLEMENT|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
219366409|NCT03540186|PROCEDURE|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
219366410|NCT01962779|OTHER|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
219366411|NCT06477692|DRUG|ENI using IMRT with or without chemotherapy|This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
219366412|NCT06477692|RADIATION|INRT|INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
219366413|NCT06477692|RADIATION|ENI|ENI using IMRT with or without chemotherapy
219366414|NCT04077905|DRUG|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
219366415|NCT04077905|DRUG|Etoposide|100mg/m² ivgtt on day 1
219366416|NCT04077905|DRUG|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
219527335|NCT02628834|OTHER|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
219527336|NCT03243630|DRUG|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
219527337|NCT03243630|DRUG|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
218914453|NCT01280006|OTHER|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
218914454|NCT01280006|DRUG|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
218914455|NCT01280006|DRUG|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
218914456|NCT01280006|DRUG|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
218914457|NCT03926286|DRUG|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
218914458|NCT05919342|DIAGNOSTIC_TEST|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
219527338|NCT03243630|DRUG|green apple|green apple will be added to the menthol flavor
219527339|NCT03243630|DRUG|green apple and menthol|menthol and green apple will be the active intervention
219527340|NCT04061005|PROCEDURE|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
219527341|NCT04061005|PROCEDURE|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
219527342|NCT04061005|PROCEDURE|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
219527343|NCT02140060|DRUG|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
219527344|NCT02140060|DRUG|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
219527345|NCT02140060|DRUG|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
219527346|NCT02140060|DRUG|Brinzolamide 1% ophthalmic suspension AZOPT®|
219527347|NCT02140060|DRUG|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
219527348|NCT02140060|DRUG|Travoprost solution vehicle|Inactive ingredients used for masking purposes
219615122|NCT04858932|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
219615123|NCT03963193|DRUG|Etoposide|Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
219615124|NCT03963193|DRUG|Irinotecan|Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
218914459|NCT01779765|DIETARY_SUPPLEMENT|PHGG|
218914460|NCT01779765|DIETARY_SUPPLEMENT|Maltodextrin|
218914461|NCT02981147|DRUG|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
218914462|NCT02878499|OTHER|polysomnography|
219615125|NCT01380561|DRUG|asimadoline|10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
219527349|NCT02140060|DRUG|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
219527350|NCT04849520|DEVICE|High flow nasal cannula|Oxygen supplement via high flow nasal cannula at a rate of 2 liters/kg/min
219527351|NCT04849520|DEVICE|Buccal oxygenation|Oxygen supplement intra-orally via oral Ring-Adair-Elwyn endotracheal tube connected to oxygen at a rate of 0.5 liters/kg/min
219527352|NCT00279357|PROCEDURE|Narrow Band Imaging|
219527353|NCT01856426|DRUG|EDP239|
219527354|NCT01856426|DRUG|Placebo|
219527355|NCT02845739|OTHER|Kidney transplanted patients|
219527356|NCT00862550|OTHER|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
219527357|NCT07036757|OTHER|Meal Kit and Nutrition Education|Meal kits contain ingredients for 3 meals designed for 4 servings, along with nutrition education materials, recipes, and information on how to store and prepare the meals. Weekly educational content focused on healthy eating, food security, and meal planning will be provided, either via print materials or through an online platform (e.g., email or app-based resources).
219527358|NCT07035223|DRUG|4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-fr|Group D: patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-free normal saline, 0.5 ml will be withdrawn)
219527359|NCT07035223|DRUG|fentanyl|Group F:patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
219527360|NCT07037264|DEVICE|Non-ablative fractional laser treatment|The entire scar area is sealed with local anesthetic for 60 minutes before laser treatment. Give the study side 1565 nm non-ablative fractional laser treatment, spot diameter 10～16 mm, energy 40～45 mJ/cm2, spot density 150～200/cm2,1\~2passes.
218914463|NCT01242423|DEVICE|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
218914464|NCT03341299|BIOLOGICAL|LY900014|Administered SC
218914465|NCT03341299|BIOLOGICAL|Insulin Lispro|Administered SC
219527361|NCT07036107|DEVICE|ABLE Exoskeleton|Participants will receive a 24-session rehabilitation treatment program with the ABLE Exoskeleton, 3 times a week for up to 8 weeks
219527362|NCT07036107|OTHER|Conventional therapy|"Participants will receive a 24-session conventional therapy program for gait rehabilitation, 3 times a week for up to 8 weeks.~Conventional therapy includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers)."
219527363|NCT07035587|OTHER|Serial Blood Sampling for Molecular Profiling|Cancer patients will undergo serial peripheral blood sampling at baseline (prior to surgery or chemotherapy), after treatment, and during follow-up visits. Blood samples will be analyzed for circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), RNA, and protein biomarkers. The purpose is to detect variant allele frequency (VAF) and evaluate its relationship with tumor dynamics and treatment outcomes, including recurrence and survival.
219527364|NCT07035587|OTHER|One-Time Blood Sampling for Molecular Profiling|Control participants, including individuals with asymptomatic gallstones, benign polyps, or those undergoing health screening, will provide a one-time peripheral blood sample. The sample will be analyzed for cfDNA, RNA, and protein biomarkers and used as a baseline reference to compare molecular characteristics between non-cancer and cancer groups.
219527365|NCT07035613|DRUG|BXD treatment|The BXD extract was obtained from Sun Ten Pharmaceutical Company and is manufactured according to the standard procedures outlined in the Taiwan Herbal Pharmacopeia IV. The extract is produced using a fixed herbal composition and ratio based on the traditional BXD formula to yield a concentrated powder. The administration of BXD in this study follows the dosage and usage guidelines specified in the Pharmacopeia.
219527366|NCT07037147|COMBINATION_PRODUCT|instrument assistance soft tissue mobilisation|In this group instrument assistance soft tissue mobilisation will be given followed by conventional therapy. IASTM will be given by using IASTM tool M2T blade. In this process patient will be asked to sit in a chair by resting its forearm in front of the table.
219527367|NCT07037147|COMBINATION_PRODUCT|Bowen technique|In this group Bowen technique will be given after the basic conventional therapy. For this technique patient will be asked to lie in a prone position where the neck of the patient will be supported with the help of a small pillow. Therapist thumb will be placed on the affected side of the muscle.
219527368|NCT07036133|DRUG|Pralatrexate Injection|Pralatrexate will be administered based on Child-Pugh Classification of liver impairment
218914466|NCT00299767|PROCEDURE|sequential cord blood transplantation|Infused on Day 0
218914467|NCT01235897|DRUG|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
218914468|NCT01235897|DRUG|Paclitaxel|80 mg/m2 weekly - paclitaxel
218914469|NCT01235897|DRUG|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
218914470|NCT01891253|DEVICE|non-invasive determination of cardiac output|
218914471|NCT03083925|DEVICE|TIPS|Transjugular Intrahepatic Portosystemic Shunt
218914472|NCT02257398|DRUG|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
218914473|NCT02257398|DRUG|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
218914474|NCT02257398|DRUG|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
219527369|NCT07035600|PROCEDURE|Targeted leaderled training program|"Training program:~After inclusion and consent the patients are instructed through an online group training program consisting of specific training of levator, abdominal, quadriceps (all portions), and gluteal muscles as well as endurance training. They are given information about WHO recommendations about physical activity. The patients are asked to sign up for two specific training occasions per week where no group will be larger than 10 patients. Group based exercise sessions consist of 45-minute supervised online zoom exercise sessions. Apart from the supervised sessions patients are encouraged to perform one functional training session, unsupervised, as well as follow the WHO recommendation for aerobic exercise"
219527370|NCT07035600|PROCEDURE|Control arm with WHO recommendation on physical activity|Training will be in accordance with WHO recommendations of 30 min aerobic physical activity five times per week (150 min per week) plus strength sessions twice weekly. The patients will be individually adviced on how to perform the training at inclusion in the trial. This is considered standard care and will not include any on-line supervision, but will include a coaching/reminder by a phone call from a research nurse/short message service (by choice of the patient) at regular intervals before and after surgery
219527371|NCT07035236|PROCEDURE|maxillary sinus lifting|The schneiderian membrane will be tented using titanium mesh.
219527372|NCT07035236|PROCEDURE|Maxillary sinus lifting|The Schneiderian membrane will be elevated using bone screws
219527373|NCT06263348|DRUG|Dorzagliatin tablets|During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
219527374|NCT00567177|DRUG|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
219527375|NCT00803764|DRUG|Naproxen Tablets, 500 mg|
219527376|NCT00633256|DRUG|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
219527377|NCT00633256|DRUG|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
219527378|NCT05240495|BEHAVIORAL|Internet-based Cognitive-behavioural therapy|Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.
219527379|NCT05240495|BEHAVIORAL|Work-focused Cognitive-behavioural therapy|The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
219527380|NCT04472078|DIAGNOSTIC_TEST|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
219527381|NCT00139178|DRUG|Different HAART regimens|
219527382|NCT04587778|DRUG|Ketamine Hydrochloride|intravenous infusion
219527383|NCT04587778|DRUG|Esketamine|intravenous infusion
219527384|NCT04587778|DRUG|Placebo|intravenous infusion
219527385|NCT04587778|DRUG|Pilot study II: Esketamine|intravenous infusion
219527386|NCT04587778|DRUG|Pilot study II: Placebo|intravenous infusion
219527387|NCT05172219|BEHAVIORAL|Physician Sent Outreach with Embedded Asynchronous Care in Portal Message|PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
219527388|NCT05172219|BEHAVIORAL|Physician Sent Outreach without Embedded Asynchronous Care in Portal Message|Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
219527389|NCT05172219|BEHAVIORAL|System Sent Outreach with Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
219615126|NCT02023983|OTHER|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
219615127|NCT02023983|OTHER|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
219615128|NCT05933018|DIAGNOSTIC_TEST|liver elastography|the imaging of the liver will perform in the fasting state, in the morning hours by one specialist, dedicated to this procedure,
219615129|NCT03773523|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
219615130|NCT02913911|OTHER|feedback|Sit to stand training with external feedback
219615131|NCT04298398|BEHAVIORAL|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
218914475|NCT02257398|DRUG|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
219527390|NCT05172219|BEHAVIORAL|System Sent Outreach without Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
219527391|NCT01722474|DEVICE|ASI Device|
219527392|NCT03991026|BEHAVIORAL|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
219527393|NCT00081952|DRUG|L-norleucine|
218914476|NCT04771494|OTHER|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP \> 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
218914477|NCT06121102|PROCEDURE|Supervoltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
219041647|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
219041648|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
219041649|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
219041650|NCT05853133|OTHER|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
219041651|NCT05853133|OTHER|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
219527394|NCT01415700|DEVICE|Functional electrical stimulator|The stimulator is surgically implanted
219527395|NCT01415700|DEVICE|feet orthosis|feet orthosis specifically mold
219527396|NCT00911898|DRUG|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
219527397|NCT05437744|OTHER|Cyanoacrylate glue|8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.
219527398|NCT05437744|OTHER|Platelet-rich fibrin (PRF)|8 sockets that will be treated by immediate implant placement and sealed by PRF.
219527399|NCT06131502|DEVICE|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
219527400|NCT01316549|DRUG|Fludarabine|Given as injection
219527401|NCT02173418|DRUG|Phrenic nerve block with Ropivacaine|
218914478|NCT06121102|PROCEDURE|Standard voltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
218914479|NCT00467688|DEVICE|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
219527402|NCT02173418|DRUG|Phrenic nerve block with saline|
218914480|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
218914481|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
218914482|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
218914483|NCT03545555|DIETARY_SUPPLEMENT|Placebo|Effect of placebo on lipid status
218914484|NCT02717234|OTHER|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
218914485|NCT05023733|DEVICE|CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®|Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1
218914486|NCT05421624|DEVICE|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
218914487|NCT05421624|BEHAVIORAL|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
219041652|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
219041653|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
219527403|NCT02817841|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
219527404|NCT00085150|BIOLOGICAL|LMB-2 immunotoxin|
219527405|NCT05380024|DRUG|Ensartinib|Ensartinib 225mg QD 8 weeks
219527406|NCT03762564|DRUG|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
218914488|NCT02599571|OTHER|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
218914489|NCT02599571|OTHER|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
219041654|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
219041655|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
219041656|NCT03857633|DIAGNOSTIC_TEST|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
219041657|NCT05323955|DRUG|Trastuzumab|Administer per current package insert based on site standard of care guidelines
219041658|NCT05323955|DRUG|Trastuzumab Emtansine (T-DM1)|Administer per current package insert based on site standard of care guidelines
219041659|NCT05323955|DRUG|Pertuzumab|Administer per current package insert based on site standard of care guidelines
219041660|NCT05323955|DRUG|Tucatinib|300 mg orally twice daily (21 Day Cycle)
219041661|NCT04891029|DIAGNOSTIC_TEST|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers. Clinical tests will also be administered as a comparator (CA-125 blood test and TVUS).
219041662|NCT04990960|OTHER|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
219041663|NCT01353378|DRUG|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
219041664|NCT01619033|DRUG|BF2.649|single dose 20 mg
219041665|NCT05269693|OTHER|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
219527407|NCT03762564|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
219527408|NCT00161564|DRUG|Rituximab|
218914490|NCT04733638|DEVICE|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
219527409|NCT05843279|PROCEDURE|Myofunctional therapy|In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
219527410|NCT04385771|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
219527411|NCT04385771|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
219527412|NCT02985593|DRUG|KHK4083|
219527413|NCT02985593|DRUG|Placebo|
219527414|NCT04373278|OTHER|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
219615132|NCT04298398|BEHAVIORAL|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice \& Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott \& Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
219615133|NCT04298398|OTHER|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
219615134|NCT05194826|PROCEDURE|Test|immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
219615135|NCT05194826|PROCEDURE|Control|immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
218914491|NCT06407414|OTHER|control|classical physiotherapy methods
218914492|NCT06407414|OTHER|Exercise|In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
218914493|NCT06270147|DRUG|Bupivacaine-epinephrine|A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
219041666|NCT02739191|DEVICE|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
219527415|NCT06043843|COMBINATION_PRODUCT|Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram|"1. Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing~   1. Fasting and exemptions~  2. Self-monitoring of blood glucose~  3. Acute diabetes complications and treatment~  4. Ramadan nutritional plan~  5. Safe physical activity You will be taught to record~   <!-- -->~   1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan.~2. Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction \< 8% 30% 8 to 10% 15% \> 10% None~2\) Glucose monitoring~1. up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week~2. uploaded into an online portal for data collection, without remote monitoring."
219527416|NCT00934934|OTHER|Normal Saline|Normal Saline
219527417|NCT00934934|DRUG|anidulafungin|TBA
219527418|NCT02785003|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
219615136|NCT03472014|BIOLOGICAL|IMVAMUNE®|IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
219615137|NCT00004310|DRUG|Clomipramine|
219615138|NCT04882813|DRUG|Dapagliflozin|Dapagliflozin dispensing claim is used as the exposure group.
219615139|NCT04882813|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference group.
219615140|NCT04127279|BIOLOGICAL|Cream|"The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils"
219615141|NCT05638464|DEVICE|multisite HD-tDCS EMG-driven robot hand|Multisite HD-tDCS will individual stimulation montages with robot hand training will be applied on chronic stroke survivors. In the multisite HD-tDCS group, 5-8 sintered Ag/AgCl ring electrodes will be placed based on the neuroimaging and computation modelling. The location of the electrodes will be identified by the individual brain activity in the primary motor cortex derived from tasked-based fMRI. The Finite Element Model (FEM) will be used to simulate the electric field distribution on individual brain. Optimization of stimulation montages will be based on the derived activation pattern of the brain. After 20-minute multisite HD-tDCS, EMG-driven robot hand training will be conducted.
218914494|NCT02018562|DEVICE|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
218914495|NCT04467736|DEVICE|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
218914496|NCT03755206|OTHER|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
218914497|NCT04444076|DEVICE|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
218914498|NCT05194124|DRUG|Setmelanotide 2 mg|Administered as SC injection
218914499|NCT05194124|DRUG|Setmelanotide 2.5 mg|Administered as SC injection
219366417|NCT02282683|DRUG|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
218914500|NCT05194124|DRUG|Setmelanotide 3 mg|Administered as SC injection
218914501|NCT05194124|DRUG|Setmelanotide 20 mg|Administered as SC injection
218914502|NCT05194124|DRUG|Setmelanotide 25 mg|Administered as SC injection
218914503|NCT05194124|DRUG|Setmelanotide 30 mg|Administered as SC injection
218914504|NCT06676735|DEVICE|Inflatable warming system|Inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient\&#39;s temperature is normal, it can be adjusted back to 38 ℃.
219366418|NCT03608917|DRUG|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
219366419|NCT03608917|DEVICE|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
219366420|NCT03608917|DRUG|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
218914505|NCT06676735|DIAGNOSTIC_TEST|Prediction of intraoperative hypothermia risk|According to the Intelligent Care For The Elderly (ICE, an optimized model based on the existing prediction model of our research group after dynamic incremental training), patients are divided into intraoperative hypothermia lowrisk group and intraoperative hypothermia high risk group.
218914506|NCT06676735|OTHER|The difference between axillary temperatature and core temperature in elderly patients|Previous studies have shown that the difference and standard deviation between esophageal temperature and axillary temperature are core 0.05 ℃ and 0.26 ℃, respectively. In light of 10% dropout rate, a integer sample size of 400 achieves 95% power to detect a mean of paired differences of 0.05 with an estimated standard deviation of paired differences of 0.26 and with a significance level (alpha) of 0.05 using a two-sided paired t-test. So 400 patients in the Model optimization group need to undergo core temperature (esophageal temperature or nasopharyngeal temperature).
218914507|NCT06676735|OTHER|Measurement of tympanic membrane temperature|As a intraoperative core temperature reference (measure every 15 minutes) for patients without esophageal temperature or nasopharyngeal temperature monitoring.
219366421|NCT05920967|DRUG|Dexamethasone Palmitate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
219366422|NCT05920967|DRUG|Dexamethasone Sodium Phosphate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
219366423|NCT01609842|OTHER|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
219366424|NCT04936074|PROCEDURE|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
219366425|NCT04936074|PROCEDURE|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
219366426|NCT04023955|BEHAVIORAL|Twitter|Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
218914513|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
218914514|NCT04706208|BEHAVIORAL|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
218914515|NCT04706208|OTHER|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
218914516|NCT04706208|BEHAVIORAL|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
218914517|NCT04706208|BEHAVIORAL|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
219527419|NCT02785003|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
219527420|NCT02785003|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
219527421|NCT02785003|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
219527422|NCT02785003|DRUG|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
219527423|NCT05391685|OTHER|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
218914518|NCT04706208|OTHER|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
219527424|NCT00881088|DRUG|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
219527425|NCT00881088|DRUG|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
219527426|NCT04003350|DRUG|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
219527427|NCT04003350|DRUG|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
219527428|NCT04003350|DRUG|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
219527429|NCT04003350|DRUG|Meloxicam|Meloxicam 15 mg as need once per day
219527430|NCT04003350|DRUG|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
219527431|NCT04003350|DRUG|Metaxalone|Metaxalone 800mg TID
219527432|NCT04003350|DRUG|Esomeprazole 20mg|Esomeprazole 20mg daily
219527433|NCT02087514|PROCEDURE|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
219527434|NCT02087514|OTHER|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks"
219527435|NCT01287910|OTHER|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
219527436|NCT06118970|OTHER|Neuropsychological tasks and self-report questionnaires|Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.
219527437|NCT00062790|DRUG|Dutasteride|
219527438|NCT02236247|DRUG|ivabradine|5 mg oral twice daily
219527439|NCT02236247|DRUG|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
219527440|NCT01113424|DRUG|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
219615142|NCT05638464|DEVICE|Sham HD-tDCS EMG-driven robot hand|"Sham stimulation with robot hand training will be applied on chronic stroke survivors.~After the sham stimulation, EMG-driven robot hand training will be conducted."
219615143|NCT00001042|BIOLOGICAL|Aluminum hydroxide|
218914519|NCT05159440|DRUG|TORL-2-307-MAB|monoclonal antibody
218914520|NCT05757128|BEHAVIORAL|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
218914521|NCT05397145|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
218914522|NCT06559696|RADIATION|internal mammary nodal irradiation|chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
218914523|NCT06559696|RADIATION|No internal mammary node irradiation|chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
218914524|NCT03264859|DIAGNOSTIC_TEST|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
218914525|NCT03685760|OTHER|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
218914526|NCT03685760|OTHER|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
219527441|NCT01113424|DRUG|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
219527442|NCT01546766|DEVICE|Pupillometry testing.|
219527443|NCT04572659|OTHER|Group psychosocial intervention|Several couples attended a total of six group psychotherapy sessions conducted by a psychologist. Between 4 and 7 couples were treated in each group session.
219527444|NCT04572659|OTHER|Couple psychosocial intervention|The couple attended a total of six psychotherapy sessions conducted by a psychologist. Each couple was attended particularly.
219527445|NCT03196570|BEHAVIORAL|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
219527446|NCT03196570|BEHAVIORAL|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
219527447|NCT03941925|DIETARY_SUPPLEMENT|Prebiotic fructans|Prebiotic group receiving the prebiotic fructans in two doses during the 4-week intervention period.
219527448|NCT03941925|DIETARY_SUPPLEMENT|Non-prebiotic maltodextrin|Placebo group receiving the non-prebiotic maltodextrin in two doses during the 4-week intervention period.
219527449|NCT01393366|OTHER|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
219527450|NCT01393366|OTHER|Usual Practice|None, only usual practice.
219527451|NCT03280394|DIAGNOSTIC_TEST|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
219527452|NCT03175718|OTHER|Incisional Negative Pressure Wound Therapy (INPWT)|A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.
219527453|NCT03175718|OTHER|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
219527454|NCT02157636|DRUG|CPI-0610|
219527455|NCT01746017|DRUG|Placebo|Administered orally as capsules
219041667|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
219527456|NCT01746017|DRUG|LY2922470|Administered orally as capsules
219615144|NCT00001042|BIOLOGICAL|Lipid A, Monophosphoryl|
218914527|NCT04710901|BEHAVIORAL|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
218914528|NCT04710901|BEHAVIORAL|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
219527457|NCT00928525|DRUG|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
219527458|NCT00397488|DRUG|sunitinib malate|
219615145|NCT00001042|BIOLOGICAL|Lipid A, Liposome-encapsulated monophosphoryl|
219615146|NCT00001042|BIOLOGICAL|Syntex adjuvant formulation|
219615147|NCT00001042|BIOLOGICAL|MF59|
219615148|NCT00001042|BIOLOGICAL|Threonyl Muramyl Dipeptide|
219041668|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
219041669|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
219041670|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
219041671|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
219041672|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
219041673|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
219041674|NCT06115538|OTHER|Levodopa|Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
219041675|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
219041676|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
219041677|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
219041678|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
219527459|NCT03557632|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|As above.
219527460|NCT03557632|BEHAVIORAL|Relapse Prevention Drug Education|As above.
219527461|NCT04074915|OTHER|Placebo mouth rinse|Normal saline
219527462|NCT04074915|DRUG|Chlorhexidine mouth rinse|Chlorhexidine gluconate
219527463|NCT04074915|DRUG|Test group|Chamomile mouth rinse
219615149|NCT00001042|BIOLOGICAL|rgp120/HIV-1 SF-2|
219615150|NCT00001042|BIOLOGICAL|MTP-PE/MF59|
219041679|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
219041680|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
219041681|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
219041682|NCT02396836|OTHER|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
219041683|NCT02396836|OTHER|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
219041684|NCT01771432|DRUG|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
219041685|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
219041686|NCT02180334|DRUG|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
219041687|NCT02180334|DRUG|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
219527464|NCT04171570|PROCEDURE|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
219527465|NCT05113147|OTHER|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
219527466|NCT03067753|DRUG|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
219527467|NCT03067753|DRUG|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
219041688|NCT02180334|DRUG|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
219527468|NCT03067753|DRUG|Prednisolone|
219527469|NCT05278325|OTHER|Telephone intervention|Two planned phone call between clinical controls
219527470|NCT00465439|DRUG|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
219527471|NCT02158572|DRUG|AG200-15|Transdermal contraceptive delivery system
219527472|NCT05236634|DRUG|Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
219615151|NCT04812444|DEVICE|Zylox Peripheral Venous Stent|Self-expanding stent implantation during the index procedure.
219615152|NCT04812444|DEVICE|Zilver Vena Venous Stent|Self-expanding stent implantation during the index procedure.
219615153|NCT03501823|OTHER|Photoacoustic tomography|A non-invasive, safe modality that relies on light and sound to generate images.
219615154|NCT00659308|PROCEDURE|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
219615155|NCT00659308|PROCEDURE|anterior stromal puncture|the other group is submitted to anterior stromal puncture
219615156|NCT03743051|DRUG|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
219615157|NCT03743051|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
219615158|NCT03830489|DRUG|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
219615159|NCT03830489|DRUG|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
219615160|NCT00383318|PROCEDURE|Gene mutation sample|
218914529|NCT04710901|BEHAVIORAL|uTECH|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention."
218914530|NCT06268704|DRUG|Dexamethasone|This is a non-particulate steroid commonly used to treat SI joint pain.
218914531|NCT06268704|DRUG|Methylprednisolone|This is a particulate steroid commonly used to treat SI joint pain.
218914532|NCT06268704|DRUG|2% Lidocaine HCl Injection|Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
218914533|NCT04723992|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
218914534|NCT01407510|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
219527473|NCT05236634|DRUG|Alpha Blockers|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
219527474|NCT05236634|DRUG|Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
219527475|NCT03075761|DEVICE|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
219527476|NCT03075761|BEHAVIORAL|30-minute education session|
219527477|NCT03203876|BIOLOGICAL|Lirilumab|Specified dose on specified days
219527478|NCT03203876|BIOLOGICAL|Nivolumab|Specified dose on specified days
219527479|NCT03203876|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219527480|NCT04486794|DEVICE|Restylane®|Hyaluronic acid
219527481|NCT05705180|BIOLOGICAL|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
219527482|NCT06440499|DIAGNOSTIC_TEST|US|Us
218914535|NCT03538418|OTHER|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
218914536|NCT04827264|DIAGNOSTIC_TEST|Safe Return to Play Following ACL Reconstruction Checklist|"All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports"
219527483|NCT03597256|DEVICE|Restylane Defyne|Intradermal injection
219615161|NCT02720718|DEVICE|Stratafix|
218914537|NCT04144153|COMBINATION_PRODUCT|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
218914538|NCT04144153|COMBINATION_PRODUCT|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
218914539|NCT06546163|BEHAVIORAL|Baseline survey|Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
219527484|NCT00356785|BEHAVIORAL|health education|
219527485|NCT00356785|BEHAVIORAL|food supplementation|
219615162|NCT02720718|DEVICE|Vicryl|
219615163|NCT02768818|DIETARY_SUPPLEMENT|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
219615164|NCT02768818|DIETARY_SUPPLEMENT|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
219615165|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Subcutaneous|
218914540|NCT06546163|BEHAVIORAL|Heart rate variability biofeedback|Participants randomized to the intervention arm will receive a standardized HRV sensor and accompanying smartphone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be asked to practice their HRVB skills at home for 10 minutes for two weeks.
218914541|NCT06546163|BEHAVIORAL|Educational materials|Participants randomized to the waitlist control arm will receive educational materials on eating disorders and stress management and will be sent home with these materials after completing the baseline survey. They will be encouraged to read the materials over the next two weeks before coming in for T2 survey.
218914542|NCT01748747|DRUG|Montanide ISA 51 VG|Given SC
218914543|NCT01748747|BIOLOGICAL|MART-1 antigen|Given SC
218914544|NCT01748747|OTHER|laboratory biomarker analysis|Correlative studies
219527486|NCT00356785|BEHAVIORAL|food supplementation combined with physical activity program|
219527487|NCT01688934|DRUG|V116517 50-mg tablets|Taken orally twice daily
219527488|NCT01688934|DRUG|V116517 30-mg tablets|Taken orally twice daily
219527489|NCT01688934|DRUG|Naproxen 500-mg capsules|Taken orally twice daily
219527490|NCT01688934|DRUG|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
219527491|NCT02442934|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
219527492|NCT02442934|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
219615166|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Intramuscular|
219615167|NCT00711087|DRUG|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
219615168|NCT00711087|OTHER|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
218914545|NCT01748747|BIOLOGICAL|Gag:267-274 peptide vaccine|Given SC
218914546|NCT01748747|DRUG|resiquimod|Applied topically
218914547|NCT05927818|DIAGNOSTIC_TEST|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
218914548|NCT02331056|OTHER|fluid loading|"Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
219041689|NCT06481722|OTHER|cerebral palsy|no intervention
219041690|NCT04950777|BEHAVIORAL|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
219041691|NCT05685290|OTHER|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
219041692|NCT05685290|OTHER|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
219041693|NCT02421133|OTHER|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
219041694|NCT02421133|OTHER|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
219041695|NCT00847444|DRUG|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
219041696|NCT00847444|BEHAVIORAL|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
219527493|NCT02442934|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
219527494|NCT06370754|DRUG|JS001|240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
219527495|NCT06370754|DRUG|JS004|200 mg by IV infusion Q3W, given on cycle day 1.
219527496|NCT06370754|DRUG|JS007|3mg/kg by IV infusion Q3W, given on cycle day 1.
219527497|NCT06370754|DRUG|JS015|600mg by IV infusion Q3W, given on cycle day 1.
219527498|NCT06370754|DRUG|Irinotecan Liposome Injection|60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
219527499|NCT06370754|DRUG|5-Fluorouracil (5-FU)|2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
219527500|NCT06370754|DRUG|Leucovorin (LV)|400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
219041697|NCT00006412|DRUG|Pravastatin sodium|
219041698|NCT00006412|DRUG|Fenofibrate|
219527501|NCT06370754|DRUG|Nab paclitaxel|125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
219527502|NCT06370754|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
219527503|NCT04167267|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
219527504|NCT04167267|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
219527505|NCT04306133|PROCEDURE|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
219527506|NCT04306133|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
218914549|NCT02331056|PROCEDURE|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
218914550|NCT02331056|PROCEDURE|thoracotomy|the patient group for scheduled open pulmonary lobectomy
219527507|NCT04092751|DRUG|PRA|Single oral 20-mg dose of PRA on Day 1 AM
219527508|NCT04092751|DRUG|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
219527509|NCT03670485|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
218914551|NCT03474588|BEHAVIORAL|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
218914552|NCT03474588|BEHAVIORAL|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
218914553|NCT01493206|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
218914554|NCT03902418|DRUG|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
218914555|NCT02784080|OTHER|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)"
218914556|NCT03448926|OTHER|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
218914557|NCT03448926|DEVICE|7-gene biosignature|Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
218914558|NCT03804528|BEHAVIORAL|Aerobic Exercise|"Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines)."
218914559|NCT06487988|DEVICE|direct conventional laryngoscopy|direct conventional laryngoscopy will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.
218914560|NCT06487988|DEVICE|fiberoptic guided intubation|fiberoptic guided intubation will be performed.
219527510|NCT02943447|DRUG|Cilofexor|Tablet(s) administered orally once daily, with food
219615169|NCT00494637|DRUG|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
218914561|NCT05203510|DRUG|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
218914562|NCT05203510|DRUG|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
218914563|NCT05110456|BEHAVIORAL|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~1. encourage the use of online material;~2. identify strategies for overcoming obstacles;~3. help apply content to real-life settings; and~4. underscore the participants' success in using effective coping strategies"
219041699|NCT05908279|OTHER|Walking test|Walk with and without a metronome
219527511|NCT02943447|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily, with food
218914564|NCT04223115|BEHAVIORAL|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
218914565|NCT04223115|OTHER|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
218914566|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
218914567|NCT03433651|DRUG|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
218914568|NCT03433651|DRUG|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
218914569|NCT01607957|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
219041700|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
219041701|NCT02897128|OTHER|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
219527512|NCT00722124|DRUG|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
219527513|NCT00722124|DRUG|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
219527514|NCT00722124|OTHER|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
219527515|NCT01907334|DRUG|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
219527516|NCT01907334|DRUG|Flovent Diskus 100 µg|Flovent Diskus 100 µg
219615170|NCT00811733|BIOLOGICAL|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
219615171|NCT03426111|DEVICE|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
219615172|NCT03426111|BEHAVIORAL|Lifestyle modification|Hypocaloric diet and moderate physical exercise
219615173|NCT00793871|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
219527517|NCT01907334|DRUG|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
219527518|NCT01907334|DRUG|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
219527519|NCT02069158|DRUG|PF-05212384|iv administrartion
219527520|NCT02069158|DRUG|Paclitaxel|iv administration
219527521|NCT02069158|DRUG|Carboplatin|iv administration
219527522|NCT02345941|OTHER|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
218914570|NCT01607957|DRUG|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
218914571|NCT04570930|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
218914572|NCT04570930|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
218914573|NCT04536909|OTHER|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
219041702|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
219041703|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
219041704|NCT06190730|OTHER|Voice-Assisted Remote Symptom Monitoring System (VARSMS)|Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
219527523|NCT02345941|OTHER|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
219527524|NCT05636319|BIOLOGICAL|ABO1020|Vaccine
219527525|NCT05636319|BIOLOGICAL|Placebo|Placebo
219527526|NCT04013919|DRUG|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
219527527|NCT04013919|DRUG|Single insulin injections|Basal insulin injections only
219527528|NCT03826745|OTHER|Plasma/Urine|Plasma of normal male and female normotensive, hypertensive, and/or resistant hypertensive subjects.
219527529|NCT03751345|BEHAVIORAL|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
219527530|NCT01294787|DRUG|indacaterol and glycopyrronium bromide (QVA149)|
219527531|NCT01294787|DRUG|placebo|
219527532|NCT01294787|DRUG|tiotropium|
219527533|NCT04816253|DRUG|Normal saline|Normal saline irrigation and No other drug placed after extraction
218914574|NCT04536909|PROCEDURE|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
219041705|NCT04705285|DEVICE|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
219527534|NCT04816253|DRUG|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
219527535|NCT04816253|DRUG|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
219041706|NCT04705285|BEHAVIORAL|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
219041707|NCT05148312|DRUG|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
219041708|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
219041709|NCT00013663|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219527536|NCT04816253|DRUG|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
219527537|NCT00006682|DRUG|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
219527538|NCT00006682|DRUG|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
219527539|NCT03978923|DEVICE|preparation of the implant site with Piezosurgery vs drill|"The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0."
219527540|NCT06317454|DIAGNOSTIC_TEST|Blood and saliva analysis|Phenotyping and genotyping characterization using blood and saliva
219615174|NCT06080269|DEVICE|technology based intervention along with conventional therapy|Technology based intervention are training session given to the participants through devices which has software installed to train cognitive functions for patients with cognitive deficit.
219615175|NCT06080269|OTHER|conventional therapy alone|Participants in the control group will receive only conventional therapy
219527541|NCT04394962|DEVICE|Virtual reality|Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
218914575|NCT00584948|DRUG|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
218914576|NCT00584948|DRUG|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
218914577|NCT02515747|PROCEDURE|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
219527542|NCT04503603|DRUG|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
219527543|NCT04503603|OTHER|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
219527544|NCT04908098|DEVICE|diode laser|It is the application of the laser tip parallel to the inner surface of the periodontal pocket
219527545|NCT04908098|PROCEDURE|scaling - root planning|Scaling is the removal of calculus and other deposits in the root of the tooth.Root planning is the removal of necrotic cementum on the tooth root surface. Scaler and gracey curettes are used for these operations.
219527546|NCT05163743|DIETARY_SUPPLEMENT|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
218914578|NCT02515747|PROCEDURE|coronary artery bypass grafting|elective surgical myocardial revascularisation
218914579|NCT01662167|DRUG|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
218914580|NCT01662167|DRUG|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
218914581|NCT02560259|OTHER|Physiotherapy|Physiotherapy
218914582|NCT02560259|OTHER|Conservative treatment|Conservative treatment
218914583|NCT05025787|DRUG|CNTX-6970|CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
218914584|NCT05025787|DRUG|Placebo|BID
218914585|NCT04973124|DRUG|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
218914586|NCT04973124|DRUG|Placebo|These participants will not receive intraoperative dexmedetomidine.
218914587|NCT06295185|OTHER|application MARO|It is a mental healthcare application aim to improve mental health.
218914588|NCT06295185|OTHER|Sham application|It is a sham application in order to control spill over bias.
218914589|NCT06396884|DEVICE|Oscillometric intermittent non-invasive blood pressure|The hemodynamic management followed liberal fluid therapy, as determined by the attending anesthetist's discretion
218914590|NCT06396884|DEVICE|ClearSight|The hemodynamic management will be conducted in accordance to a goal-directed fluid therapy (GDFT) utilizing the Clearsight system monitoring.
218914591|NCT05460754|BEHAVIORAL|Conventional-fed beef|Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.
218914592|NCT05460754|BEHAVIORAL|Organic grass-fed beef|Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
218914593|NCT00670215|DRUG|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
218914594|NCT00670215|DRUG|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
219041710|NCT00013663|DRUG|Aldesleukin|
218914595|NCT00945009|BIOLOGICAL|Dactinomycin|Given IV
218914596|NCT00945009|DRUG|Doxorubicin Hydrochloride|Given IV
218914597|NCT00945009|RADIATION|Radiation Therapy|Undergo radiation therapy
218914598|NCT00945009|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
218914599|NCT00945009|DRUG|Vincristine Sulfate|Given IV
218914600|NCT05299307|DIAGNOSTIC_TEST|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
218914601|NCT05387278|DRUG|EV-Pure™ and WJ-Pure™|The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
218914602|NCT05387278|DRUG|Placebo|Cryopreservation media plus standard care
219615176|NCT00997841|PROCEDURE|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
219615177|NCT02446041|OTHER|Non-Interventional Study|Non-Interventional Study
219041711|NCT04332289|OTHER|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
219041712|NCT04594850|BIOLOGICAL|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
219527547|NCT05093309|BEHAVIORAL|Educational Webinar|At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
219527548|NCT05093309|BEHAVIORAL|Resources|After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
219527549|NCT05093309|BEHAVIORAL|Reminders|Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
219527550|NCT02656186|DIETARY_SUPPLEMENT|Pre-intervention|First 2-weeks : keeping routine dietary habit
219527551|NCT02656186|DIETARY_SUPPLEMENT|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
219527552|NCT03306394|DRUG|Trifluridine/Tipiracil hydrochloride (S95005)|
219527553|NCT00120198|DRUG|CDOP plus rituximab|
219527554|NCT00070915|BEHAVIORAL|Tai chi|
219527555|NCT00070915|BEHAVIORAL|Mindfulness-based Stress Reduction program|
219527556|NCT00070915|PROCEDURE|Therapeutic massage|
219527557|NCT02807987|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
219527558|NCT01452815|DRUG|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
219527559|NCT01452815|DRUG|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
219527560|NCT01452815|DRUG|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
219527561|NCT01548677|DRUG|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
219527562|NCT04657770|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
219527563|NCT01886768|DEVICE|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
219527564|NCT01886768|DEVICE|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
219527565|NCT01805934|DRUG|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
219527566|NCT01805934|DRUG|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
219615178|NCT02600936|DEVICE|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
219615179|NCT03412136|DIETARY_SUPPLEMENT|Control|Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate \& Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.
218914603|NCT06220032|DRUG|Dexrazoxane|Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.
218914604|NCT06220032|DRUG|Rituximab|Day 1 Cycle 1-6: 375 mg/m2 (iv)
218914605|NCT06220032|DRUG|Cyclophosphamide|Day 1 Cycle 1-6: 750 mg/m2 (iv)
218914606|NCT06220032|DRUG|Doxorubicin|Day 1 Cycle 1-6: 50 mg/m2 (iv)
218914607|NCT06220032|DRUG|Vincristine|Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)
218914608|NCT06220032|DRUG|Prednisolone|Day 1-5 Cycle 1-6: 100 mg (oral)
218914609|NCT06220032|DRUG|Lenalidomide|Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.
218914610|NCT06220032|DRUG|Pegfilgrastim|6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
218914611|NCT06037590|COMBINATION_PRODUCT|Levodopa Cyclops®|Orally inhaled dry powder levodopa from the Cyclops® dry powder inhaler
218914612|NCT06037590|COMBINATION_PRODUCT|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
218914613|NCT06202482|OTHER|Connect Active Program|Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
218914614|NCT06147986|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
218914615|NCT06147986|OTHER|Control group|Standard-of-care for STEMI
218914616|NCT06060925|DIAGNOSTIC_TEST|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
218914617|NCT06060925|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
218914618|NCT06060925|DIAGNOSTIC_TEST|Electromyography|High density electromyography
218914619|NCT06060925|DIAGNOSTIC_TEST|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
218914620|NCT03583853|DEVICE|real time PCR|real time PCR will be used for determination of expression of autophagy genes
218914621|NCT04607005|DRUG|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
218914622|NCT04607005|DRUG|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
218914623|NCT04607005|DRUG|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
218914624|NCT02142699|DRUG|Heme arginate|
218914625|NCT05653973|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
218914626|NCT05653973|DRUG|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
218914627|NCT03919773|DRUG|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
218914628|NCT03919773|DRUG|Albumin|This will be the matching placebo used in the study.
218914629|NCT04659044|DRUG|Polatuzumab Vedotin|Given IV
219366427|NCT01893333|PROCEDURE|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
219366428|NCT01136343|OTHER|lifestyle modified project|education, counseling
219366429|NCT04743180|DEVICE|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
218914630|NCT04659044|BIOLOGICAL|Rituximab|Given IV
219366430|NCT03186989|DRUG|IONIS MAPTRx|IONIS MAPTRx injections.
219366431|NCT03186989|OTHER|Placebo|Artificial CSF injections.
219366432|NCT01583374|DRUG|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
219366433|NCT01583374|DRUG|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
219366434|NCT01583374|DRUG|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
219366435|NCT01265524|DRUG|CLP|Oral administration
219366436|NCT01265524|DRUG|Placebo|Oral administration
219366437|NCT02905175|PROCEDURE|blood sample|
219366438|NCT02905175|PROCEDURE|synovial tissue|synoviocytes from synovial tissue
219366439|NCT00393575|BEHAVIORAL|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
219366440|NCT03771742|PROCEDURE|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
219366441|NCT03771742|PROCEDURE|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
219366442|NCT03349814|PROCEDURE|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
219366443|NCT03349814|PROCEDURE|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
219366444|NCT00783588|BIOLOGICAL|ISF35|Subjects participating in this study will receive up to two doses of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
219366445|NCT00460343|OTHER|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
219366446|NCT00460343|OTHER|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
219366447|NCT02504229|BIOLOGICAL|autologous dendritic cells co-cultured with cytokine-induced killer cells|
219366448|NCT02504229|DRUG|Gimeracil and Oteracil Porassium Capsules|
219366449|NCT02504229|DRUG|Oxaliplatin|
219366450|NCT03741166|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
219366451|NCT00808041|DEVICE|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
219366452|NCT03657615|DEVICE|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
219366453|NCT02002260|DEVICE|Levonorgestrel intrauterine system|
219366454|NCT02002260|DRUG|Combined oral contraceptives|
218914631|NCT04659044|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219527567|NCT03071029|BEHAVIORAL|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
219527568|NCT01094067|DRUG|ACT-050089|5 mg/h intravenously, Tezosentan
219527569|NCT01094067|OTHER|Placebo|Matching placebo
219527570|NCT00929929|DIETARY_SUPPLEMENT|L-leucine.|10 g of leucine per day, during 12 weeks.
218914632|NCT04659044|DRUG|Venetoclax|Given PO
218914633|NCT01708408|GENETIC|Biomarker studies|
219041713|NCT02187328|OTHER|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
219041714|NCT02187328|OTHER|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
219041715|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
219041716|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
219041717|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
219527571|NCT00929929|DIETARY_SUPPLEMENT|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
219527572|NCT00929929|BEHAVIORAL|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
219527573|NCT04863768|DIAGNOSTIC_TEST|Gene panel|comprehensive cancer gene panel targeting regions in 37 clinically relevant cancer genes in FFPE tumor tissue blocks
219527574|NCT02529592|BIOLOGICAL|Endotoxin|
219527575|NCT02529592|BIOLOGICAL|Placebo|
219527576|NCT02064088|DRUG|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
219527577|NCT02064088|DRUG|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
219527578|NCT06334445|BEHAVIORAL|Control group|Wearables/sensors and ePsycHeart App
219527579|NCT06334445|BEHAVIORAL|Intervention group|Wearables/sensors and ePsycHeart App and eHealtHeart
219527580|NCT03157362|OTHER|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
219615180|NCT03412136|DIETARY_SUPPLEMENT|Glucose|Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
218914634|NCT06297083|DRUG|Peanut Oral Powder [PEANUT POWDER]|Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
218914635|NCT06297083|DIETARY_SUPPLEMENT|Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)|Probiotic or placebo-probiotic given daily for 18 months
218914636|NCT04038619|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
218914637|NCT04038619|DRUG|Loperamide|Given PO
218914638|NCT03589859|DIAGNOSTIC_TEST|VOR Test|Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
218914639|NCT03589859|OTHER|Computer Game|Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
218914640|NCT03589859|OTHER|Nausea Scale|Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
218914641|NCT05343182|OTHER|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
218914642|NCT05343182|OTHER|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
219527581|NCT03157362|OTHER|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
219527582|NCT03157362|OTHER|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
219527583|NCT03157362|OTHER|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
219527584|NCT00112645|BIOLOGICAL|anti-thymocyte globulin|
219527585|NCT00112645|DRUG|busulfan|
219527586|NCT00112645|DRUG|cyclosporine|
219527587|NCT00112645|DRUG|melphalan|
219527588|NCT00112645|DRUG|methotrexate|
219527589|NCT00112645|DRUG|methylprednisolone|
219527590|NCT00112645|PROCEDURE|allogeneic bone marrow transplantation|
219527591|NCT00112645|PROCEDURE|peripheral blood stem cell transplantation|
219527592|NCT00112645|PROCEDURE|umbilical cord blood transplantation|
219615181|NCT03412136|DIETARY_SUPPLEMENT|Protein|Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
219615182|NCT05680519|OTHER|theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
219615183|NCT05680519|OTHER|Control group|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice.
218914643|NCT05518812|DRUG|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
218914644|NCT05538741|DRUG|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
218914645|NCT05538741|DRUG|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
218914646|NCT06466746|OTHER|Raising the Pulse faba bean-enriched bread|100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
218914647|NCT06466746|OTHER|Conventional White Bread|100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
218914648|NCT04161950|OTHER|Assessment of the safety and validity of echoendoscope|"1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment"
219366455|NCT05622539|COMBINATION_PRODUCT|CONVENTIONAL ACUTE STROKE MANAGEMENT|Conventional treatment for acute stroke patients, with or without reperfusion treatments
219366456|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
219366457|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
219366458|NCT05025215|BEHAVIORAL|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
219366459|NCT05025215|BEHAVIORAL|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
219366460|NCT06810375|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|preoperative erector spinae block with bupivacaine (Marcaine®)
219366461|NCT06810375|DRUG|Intercostal nerve block|intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)
219366462|NCT01604005|RADIATION|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
219366463|NCT02281591|DRUG|BIA 2-093|Tablets containing 900 mg
219366464|NCT02281591|DRUG|S-licarbazepine|capsules containing 225 mg
219366465|NCT02281591|DRUG|R-licarbazepine|capsules containing 225 mg
219366466|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
219366467|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
219366468|NCT05400187|BEHAVIORAL|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
219366469|NCT06703554|OTHER|Sage Oil Mouthwash|Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
219366470|NCT06703554|BIOLOGICAL|Chlorohexidine Mouthwash|0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
219366471|NCT03227809|BEHAVIORAL|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
219527593|NCT03121443|OTHER|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
219527594|NCT04318821|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
219527595|NCT05729529|OTHER|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
218914649|NCT02331134|DRUG|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
218914650|NCT01568177|BEHAVIORAL|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
219041718|NCT05107258|DIAGNOSTIC_TEST|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
219041719|NCT01020058|PROCEDURE|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
219527596|NCT05729529|DRUG|Placebo|Placebo oral gel used on tongue
219527597|NCT01502566|BEHAVIORAL|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
219527598|NCT03655106|DEVICE|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
219527599|NCT03655106|DEVICE|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
219527600|NCT02104960|OTHER|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
218914651|NCT01568177|OTHER|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
219527601|NCT02104960|OTHER|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
219527602|NCT02104960|OTHER|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
219527603|NCT00822497|BEHAVIORAL|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
219527604|NCT00822497|BEHAVIORAL|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
219527605|NCT03785548|OTHER|Usage of a mirror|using a mirror during the pelvic examination
219041720|NCT05134207|DIETARY_SUPPLEMENT|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
219041721|NCT02630784|PROCEDURE|Non-Invasive Ventilation with Homecare ventilator|
219041722|NCT02630784|PROCEDURE|Non-Invasive Ventilation with ICU ventilator|
219041723|NCT02232581|DRUG|Alovudine - low|
219527606|NCT00698230|DRUG|INCB013739|INCB013739 5 mg QD tablet
219527607|NCT00698230|DRUG|INCB013739|INCB013739 15 mg QD tablet
219527608|NCT00698230|DRUG|INCB013739|INCB013739 50 mg QD tablet
219527609|NCT00698230|DRUG|INCB013739|INCB013739 100 mg QD tablet
219527610|NCT00698230|DRUG|INCB013739|INCB013739 200 mg QD
219527611|NCT00698230|DRUG|Placebo comparator matching INCB013739|Orally once daily tablet
219527612|NCT00698230|DRUG|Metformin|
219527613|NCT02109354|BIOLOGICAL|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
219527614|NCT02109354|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
219527615|NCT02109354|BIOLOGICAL|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
219527616|NCT02109354|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
219527617|NCT02109354|BIOLOGICAL|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
219527618|NCT02109354|BIOLOGICAL|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
219527619|NCT02109354|BIOLOGICAL|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
218914652|NCT01568177|OTHER|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
218914653|NCT01568177|OTHER|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
218914654|NCT01568177|PROCEDURE|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
219041724|NCT02232581|DRUG|Alovudine - medium|
219041725|NCT02232581|DRUG|Alovudine - high|
219041726|NCT02232581|DRUG|Placebo|
219041727|NCT02259309|DRUG|Misoprostol - buccal|buccal administration
219041728|NCT02259309|DRUG|Misoprostol - vaginal|vaginal administration
219527620|NCT02109354|BIOLOGICAL|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
218914655|NCT04266873|DEVICE|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
218914656|NCT02157532|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
218914657|NCT02157532|DRUG|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
219041729|NCT00732810|DRUG|SCH 727965|SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.
219041730|NCT00732810|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
219041731|NCT00732810|DRUG|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
219041732|NCT03258827|PROCEDURE|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
219041733|NCT03258827|PROCEDURE|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
219041734|NCT04366167|OTHER|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
219041735|NCT05041933|DRUG|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
219041736|NCT03214627|DEVICE|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
219527621|NCT02404662|OTHER|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
219527622|NCT02404662|OTHER|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
219527623|NCT01423760|BIOLOGICAL|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
219527624|NCT01423760|OTHER|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
219527625|NCT01814462|DEVICE|6 months CPAP|
219527626|NCT03222765|DRUG|Placebo, metformin, linagliptin, linagliptin + metformin|
219615184|NCT04316338|DEVICE|Intermittent theta-burst stimulation (iTBS)|Non-invasive brain stimulation technique
219615185|NCT04683861|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
219615186|NCT04319471|DRUG|Capecitabine/S-1|Drug: Capecitabine/S-1
219615187|NCT04319471|DRUG|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
219615188|NCT04319471|RADIATION|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
219615189|NCT04319471|OTHER|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
219615190|NCT00639756|DRUG|Allopurinol|Allopurinol 300 mg
219615191|NCT00639756|DRUG|Placebo|Placebo given for 2 weeks
219615192|NCT01936844|DRUG|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
219615193|NCT01936844|DRUG|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
219615194|NCT01936844|DRUG|Placebo|Placebo twice daily for days 1, 2, and 3
218914658|NCT02641548|DEVICE|Sock of silicone|
218914659|NCT02641548|OTHER|Heel cream|
218914660|NCT04966013|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
218914661|NCT04966013|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
218914662|NCT06342128|OTHER|No intervention|No intervention
218914663|NCT03562273|RADIATION|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
218914664|NCT04315948|DRUG|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
219041737|NCT03214627|DRUG|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
219041738|NCT03214627|DRUG|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
219041739|NCT05606042|DEVICE|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
218914665|NCT04315948|DRUG|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
219527627|NCT01452022|DEVICE|Inductigraft|Synthetic bone graft
219527628|NCT04993664|DRUG|Pelacarsen (TQJ230)|The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
218914666|NCT04315948|DRUG|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
218914667|NCT04315948|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
218914668|NCT04315948|OTHER|Standard of care|Standard of care
218914669|NCT04315948|DRUG|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
218914670|NCT04315948|OTHER|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
218914671|NCT02601612|BIOLOGICAL|D46cpΔM2-2 vaccine|Delivered as nose drops
218914672|NCT02601612|BIOLOGICAL|Placebo|Delivered as nose drops
219615195|NCT01936844|DRUG|Placebo|Placebo daily for days 4-14
219615196|NCT05606640|DIAGNOSTIC_TEST|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
219615197|NCT00192582|BEHAVIORAL|Motivational Interview with care plan and education|
219615198|NCT01113892|DEVICE|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
219041740|NCT04489706|DRUG|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
219527629|NCT04993664|DRUG|Placebo|The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
219615199|NCT03693131|DRUG|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
219615200|NCT03693131|DRUG|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
219615201|NCT04760080|OTHER|pre-treatment data|"We will evaluate in all patients pre-treatment data :~* Melanoma staging at treatment initiation~* Melanoma characteristics at initial diagnosis~* Number and location of metastasis~* Performans status~* Demographic information"
219615202|NCT04760080|OTHER|during study treatment|"We will evaluate in all patients during study treatment :~* Rate of adverse events~* Type of adverse events~* Radiological response to treatment by CTscans that are routinely performed every three months."
218914673|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content, and Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms, in addition they also receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
218914674|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content|Participants receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
218914675|NCT06229444|BEHAVIORAL|Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms.
218914676|NCT06229444|BEHAVIORAL|No Intervention|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive IILI-related health educational content
219041741|NCT03887364|OTHER|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
219527630|NCT03611478|DIETARY_SUPPLEMENT|Probiotic formulation|Probiotic capsule
219527631|NCT03611478|DIETARY_SUPPLEMENT|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
219615203|NCT03359616|PROCEDURE|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
219615204|NCT03359616|PROCEDURE|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
219615205|NCT02569801|DRUG|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
219615206|NCT02569801|DRUG|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
219615207|NCT00428246|DRUG|paricalcitol|1 mcg or 2 mcg for 4 weeks.
219615208|NCT00428246|DRUG|Placebo|Placebo
218914677|NCT02203903|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
218914678|NCT05010707|DRUG|Transdermal patch|Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
218914679|NCT05010707|DIAGNOSTIC_TEST|Pro-thrombotic markers|Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
219527632|NCT00595166|DEVICE|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
219527633|NCT01095692|PROCEDURE|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
218914680|NCT05010707|DIAGNOSTIC_TEST|Metabolic markers|Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
218914681|NCT05010707|DIAGNOSTIC_TEST|Hormone Profile|Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
218914682|NCT05010707|DRUG|Daily Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
218914683|NCT05010707|DRUG|BID Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
218914684|NCT05010707|DRUG|Spironolactone|All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
219041742|NCT03887364|OTHER|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
219041743|NCT03337282|PROCEDURE|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
219527634|NCT01095692|PROCEDURE|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
219527635|NCT00511069|DRUG|Bortezomib|
219527636|NCT04697017|OTHER|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
219527637|NCT00275730|DRUG|indometacine (drug) effect on ocular blood flow|
219527638|NCT05318157|DRUG|AIT drops|Once a day
219527639|NCT05318157|DRUG|Clarityne, Rhinocort and Emedastine Difumarate Eye Drops|The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
219527640|NCT00151047|DRUG|Capecitabine|
218914685|NCT02420847|DRUG|Doxorubicin Hydrochloride|Given IV
219527641|NCT00151047|DRUG|Docetaxel|
218914686|NCT02420847|DRUG|Gemcitabine Hydrochloride|Given IV
218914687|NCT02420847|DRUG|Ixazomib Citrate|Given PO
218914688|NCT04049032|BEHAVIORAL|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
218914689|NCT04049032|BEHAVIORAL|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
218914690|NCT06143852|BEHAVIORAL|Mindfulness|12 minute daily guided meditation
218914691|NCT06143852|BEHAVIORAL|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
219041744|NCT04328376|DIAGNOSTIC_TEST|ECG coupled to phonocardiography|"A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography."
219041745|NCT04925011|DRUG|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
219615209|NCT03468517|OTHER|Bathe method:|BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
219615210|NCT00762255|DRUG|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
219527642|NCT05119270|DEVICE|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|"The LenSx laser (Alcon Laboratories Inc., USA) automates key steps in the procedure including capsulorhexis, incision making and phaco. The Frequency Domain - Optical Coherence Tomography (FD-OCT) optical imaging system provides high-resolution, real-time visualization of ocular structures and their dimensions. The device sends the results to the interface which programs the laser and indicates the exact location, size and depth of the desired incisions.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
219527643|NCT05119270|PROCEDURE|Standard phacoemulsification with the Active Sentry handpiece|"Phacoemulsification is done by using the Active Sentry handpiece to allow for a better control of the intraocular pressure throughout the surgery.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
219527644|NCT05119270|PROCEDURE|Standard phacoemulsification with the OZil handpiece|"Phacoemulsification is done by using the traditional OZil handpiece that allows rotational movement of the phaco tip.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
219615211|NCT00762255|DRUG|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
219615212|NCT00762255|DRUG|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
219615213|NCT02200055|DEVICE|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
219615214|NCT01114035|GENETIC|blood samples and skin biopsies|to detect mutations
219615215|NCT01114035|GENETIC|Skin biopsies|to detect mutations
219615216|NCT01614496|OTHER|Algorithm for insulin administration|
219615217|NCT03822091|DRUG|Terlipressin|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1. 1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~2. A dose of 20gram/day to 60gram/day in the following days."
218914692|NCT06195748|OTHER|Kinesiotaping|According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
218914693|NCT06195748|OTHER|Placebo kinesiotaping|The same tape will be used for the interventional application with 0 tension.
218914694|NCT03518086|DRUG|Mirikizumab|Administered IV
218914695|NCT03518086|DRUG|Placebo|Administered IV
219527645|NCT00822822|BEHAVIORAL|First Questionnaire|Complete questionnaire before completing health history
219527646|NCT00822822|BEHAVIORAL|Health History|Complete electronic health history
219527647|NCT00822822|BEHAVIORAL|Second Questionnaire|Complete questionnaire after completing electronic health history
219527648|NCT02676024|DEVICE|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
219527649|NCT02676024|DEVICE|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
219527650|NCT02676024|DEVICE|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
218914696|NCT06066788|OTHER|CHAMPS|Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
218914697|NCT05967260|DEVICE|DailyDose Smart Snack app|A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
218914698|NCT05967260|DEVICE|Dexcom G6 CGM|A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
218914699|NCT04086927|DEVICE|Unna Boot|The unna boot is a zinc coated compression dressing
218914700|NCT02437916|DRUG|AMG 228|AMG 228 will be administered intravenously
218914701|NCT03482726|BEHAVIORAL|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
218914702|NCT03064802|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
218914703|NCT01832636|DIETARY_SUPPLEMENT|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
218914704|NCT01673529|DRUG|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
218914705|NCT01673529|DRUG|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
218914706|NCT00832663|DRUG|NSAID|Effect of NSAID ingestion on muscle regeneration
219527651|NCT04775745|DRUG|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
219527652|NCT04775745|DRUG|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
219527653|NCT00483626|DRUG|oral sildenafil|
219527654|NCT02548403|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
219527655|NCT02548403|DRUG|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
219527656|NCT03799653|OTHER|No intervention|This is a prospective observational study, and there is no intervention.
219527657|NCT04982094|BEHAVIORAL|Mental Health First Aid and Relationship Building Training|"Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
218914707|NCT00832663|DRUG|placebo|receive placebo
218914708|NCT05468099|OTHER|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
218914709|NCT05468099|DEVICE|High volume evacuator|High volume evacuator held by assistant to capture dental spray
219527658|NCT04982094|BEHAVIORAL|Mental Health First Aid|"Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
219527659|NCT02898168|DEVICE|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
219527660|NCT02898168|OTHER|Control|Conventional rehabilitation therapy and gait training without WA.
219527661|NCT00763763|DRUG|Imatinib mesylate|imatinib 600 mg/day for 2 years
219527662|NCT00763763|DRUG|Interferon|45 micrograms per week during 2 years
219527663|NCT00763763|DRUG|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
219527664|NCT00763763|DRUG|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
219527665|NCT04222881|PROCEDURE|AVF anastomosis|Type of arteriovenous anastomosis
219527666|NCT05673317|OTHER|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
219527667|NCT04881435|DEVICE|Hydrogen gas therapy|Hydrogen gas therapy three times one day for 5 days
219527668|NCT02054845|BEHAVIORAL|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~1. Body scan~2. Psychoeducation~3. Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~4. Body Awareness Training~5. Exposure training (imaginary exposure to induce response fluctuations)~6. Training in cueing techniques to overcome problems with initiation and freezing~7. Visual Feedback training~8. Relaxation techniques"
219527669|NCT02054845|OTHER|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
219615218|NCT03822091|DRUG|Terlipressin and Noradrenaline|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours."
218914710|NCT05468099|DEVICE|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
218914711|NCT05468099|DEVICE|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
218914712|NCT04834505|OTHER|Diagnostic imaging modalities for validation sample|Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.
218914713|NCT04834505|OTHER|EUS for derivation sample|Endoscopic ultrasound was performed.
218914714|NCT00626106|DRUG|AMG 479|AMG 479 administered with exemestane or fulvestrant
218914715|NCT00626106|DRUG|Placebo|Placebo administered with either exemestane or fulvestrant
218914716|NCT05510583|OTHER|Control group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
219527670|NCT03860415|DIETARY_SUPPLEMENT|Vivomixx|Two months of 2 sachets vivomixx each morning and 2 sachets each night. Each sachet of viviomixx contains 450 billion live bacteria.
219527671|NCT03860415|DIETARY_SUPPLEMENT|Placebo|Two months of 2 sachets placebo each morning and 2 sachets each night. Each sachet of placebo contains 450 billion live bacteria.
219527672|NCT01108029|DRUG|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
219527673|NCT01108029|DRUG|placebo|2 tablets of placebo 1 time a day in the morning
218914717|NCT05510583|OTHER|Treated group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
218914718|NCT05417438|BEHAVIORAL|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
219527674|NCT05327491|DRUG|Sotorasib|Oral Tablet
219527675|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results."
219615219|NCT01700062|DIETARY_SUPPLEMENT|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
219527676|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results."
219527677|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results."
219527678|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
219527679|NCT04628117|DIETARY_SUPPLEMENT|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
219527680|NCT00939718|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
219527681|NCT03756259|BEHAVIORAL|Mobile Health (mHealth) for Pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
219527682|NCT02142556|DRUG|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
219527683|NCT05316428|DRUG|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
219527684|NCT05316428|OTHER|alcohol|0.5 g/kg alcohol
219527685|NCT05316428|DRUG|TPN171H tablet|10 mg TPN171H tablet QD
219527686|NCT01868191|DRUG|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
219527687|NCT01868191|DRUG|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
219527688|NCT04555889|DEVICE|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
219527689|NCT01138540|OTHER|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
219527690|NCT04362020|OTHER|Distal radial access|Distal radial access and No anticoagulation
219527691|NCT04362020|OTHER|Distal radial access|Distal radial access and ACT-guided anticoagulation
219527692|NCT02095782|DRUG|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
219527693|NCT01418586|DRUG|Torrent's Alfuzosin Extended Release Tablet|
219527694|NCT05974163|DIAGNOSTIC_TEST|radiomic of CT|Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.
219527695|NCT05463822|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
219527696|NCT03427164|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
219527697|NCT05076253|DRUG|Ivermectin|Ivermectin plus standard care
219527698|NCT05076253|DRUG|Placebo|Standard care
219527699|NCT04957953|OTHER|Patient's consent|Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
219527700|NCT04957953|OTHER|Inclusion form|"This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate."
219615222|NCT02528877|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
219615223|NCT02528877|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
219041746|NCT04155008|DRUG|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
219615224|NCT02528877|DRUG|Fludarabine Phosphate|Given IV
219615225|NCT02528877|OTHER|Laboratory Biomarker Analysis|Correlative studies
219615226|NCT02528877|DRUG|Melphalan|Given IV
219615227|NCT02528877|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
219615228|NCT02528877|OTHER|Pharmacological Study|Correlative studies
219615229|NCT02528877|DRUG|Ruxolitinib Phosphate|Given PO
219615230|NCT02528877|DRUG|Sirolimus|Given PO
219615231|NCT02528877|DRUG|Tacrolimus|Given IV or PO
219615232|NCT03863535|DRUG|Conbercept|Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.
219041747|NCT04155008|DRUG|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
219366472|NCT03227809|BEHAVIORAL|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
219366473|NCT06899919|DEVICE|Treatment with light compression systeme during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)|Treatment with light compression system during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)
219366474|NCT06899919|DEVICE|Light compression system of the mixed leg ulcer stage C6 / C6r of the CEAP classification|Etiological treatment of mixed leg ulcer stage C6 / C6r of the CEAP classification
219366475|NCT04768127|OTHER|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
219366476|NCT04768127|OTHER|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
219366477|NCT06916169|DRUG|AG2304|AG2304, Single-dose Oral Administration
219366478|NCT06916169|DRUG|AG23041 and AG23042|AG23041/AG23042, Single-dose Oral Administration
219366479|NCT06916117|DRUG|Neoadjuvant Chemotherapy (NACT)|"Neoadjuvant chemotherapy:~The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.~Concurrent chemoradiotherapy:~Radical dose to the pelvic concurrent with cisplatin.~Consolidative immunotherapy:~Following the completion of chemoradiotherapy, Sintilimab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total of 6 cycles, starting 3-4 weeks after chemoradiotherapy."
219366480|NCT06915740|OTHER|Exercise|virtual rehabilitation, including endurance exercise, strength training, breathing exercises, patient education, dietary advice
219366481|NCT06935266|BIOLOGICAL|TAK-881|TAK-881 SC injection.
219366482|NCT06935266|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
219366483|NCT00379860|DRUG|LXR-623|
219366484|NCT05630157|BEHAVIORAL|Unplugged plus gambling component|12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
219366485|NCT05018858|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219366486|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
219366487|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
219366488|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
219366489|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
219366490|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
219366491|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
219366492|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
219366493|NCT03561402|DRUG|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
219366494|NCT03048955|DEVICE|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
219366495|NCT03048955|PROCEDURE|Direct decompression Surgery|A surgical procedure - the control
219366496|NCT02863068|DRUG|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
219366497|NCT02863068|OTHER|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
219366498|NCT04259853|PROCEDURE|PCI|Revascularization on non culprit vessel
219527701|NCT04957953|OTHER|Adverse reaction report form.|One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
219527702|NCT04957953|DIAGNOSTIC_TEST|Follow-up report form.|In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
219527703|NCT00270777|DRUG|adrenaline, promethazine, hydrocortisone|
219527704|NCT04106193|OTHER|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
219527705|NCT04106193|OTHER|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
219527706|NCT04106193|OTHER|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
219527707|NCT02897791|BEHAVIORAL|written evaluations|answering questions about pictures and stories
219527708|NCT02380560|DEVICE|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
219527709|NCT03598101|DEVICE|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
219527710|NCT01725958|DIETARY_SUPPLEMENT|Nutritional supplement and protein shakes|
219527711|NCT02005419|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219527712|NCT02005419|DRUG|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
218914719|NCT03426670|DEVICE|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
218914720|NCT06594536|DIETARY_SUPPLEMENT|Sulforaphane|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
219527713|NCT02005419|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219366499|NCT06045988|DEVICE|Non-Contact Sleep Quality Monitor System|Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
219527714|NCT04019834|DRUG|regional nerve block with local anesthesia of bupivacaine with steroid|Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
219527715|NCT04019834|OTHER|Placebo regional nerveblock with normal saline|Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
219527716|NCT04547517|OTHER|Evaluation of Counselling competencies|To complete a set of questionnaires
219527717|NCT06407206|OTHER|Sub occipital muscle inhibition technique and conventional therapy|Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
219527718|NCT06407206|OTHER|conventional therapy|Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
218914721|NCT06594536|OTHER|Placebo|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
219366500|NCT00522067|BIOLOGICAL|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
219366501|NCT01009957|DRUG|Everolimus|0.75 mg x 2 / day
219366502|NCT00956943|DRUG|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
219366503|NCT00956943|DRUG|placebo|placebo patch
219366504|NCT03057366|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
219366505|NCT03057366|DRUG|[14C]-Pevonedistat|\[14C\]-Pevonedistat intravenous infusion.
219366506|NCT03057366|DRUG|Docetaxel|Docetaxel intravenous infusion.
219527719|NCT04513587|BEHAVIORAL|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
219527720|NCT04513587|BEHAVIORAL|Control|Treatment as usual
219527721|NCT04433611|DRUG|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
219366507|NCT03057366|DRUG|Carboplatin|Carboplatin intravenous infusion.
219366508|NCT03057366|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
219366509|NCT03820245|DIETARY_SUPPLEMENT|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
219366510|NCT03820245|DIETARY_SUPPLEMENT|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
219366511|NCT03820245|DIETARY_SUPPLEMENT|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
219527722|NCT04433611|DRUG|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
219527723|NCT04535830|DEVICE|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
219527724|NCT01082523|OTHER|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
218914722|NCT06593301|OTHER|Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training|Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)
219527725|NCT03187522|DEVICE|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
219527726|NCT05934825|BIOLOGICAL|Injectable suspension of allogeneic adult mesenchymal stem cells|Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).
218914723|NCT04053036|DRUG|MDMA|Participants will be given 1.5mg/kg of MDMA
218914724|NCT04053036|DRUG|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
218914725|NCT06589921|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
218914726|NCT06589921|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
218914727|NCT06599177|OTHER|Informational leaflet|"An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services."
218914728|NCT06586073|OTHER|cosmetic products|All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream.
218914729|NCT06588335|DRUG|BTLA inhibitor (JS004)|BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
218914730|NCT06588335|DRUG|Toripalimab|Toripalimab:240mg,intravenous infusion, d1, Q3W;
218914731|NCT06588335|DRUG|Paclitaxel, Cisplatin|Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
219527727|NCT05934825|OTHER|Placebo|The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.
219527728|NCT01274039|DRUG|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
219527729|NCT03031184|DRUG|Mirtazapine|
219527730|NCT03031184|OTHER|Placebo|
219527731|NCT00002053|DRUG|Pentamidine isethionate|
219615233|NCT03863535|PROCEDURE|Panretinal coagulation|The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
219615234|NCT01871623|PROCEDURE|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
219615235|NCT01871623|PROCEDURE|One-piece Le Fort I Osteotomy|conventional approach
218914732|NCT06598826|DEVICE|Graston technique (IASTM)|Group A includes 26 patients post ND who received Graston technique (IASTM) , in additional to traditional treatment (ROM exercise, strengthening exercise, and stretching exercise) for 1 month
218914733|NCT06598826|OTHER|Kinesio taping|Group B includes 26 patients who received Kinesiotaping, in addition to traditional treatment (ROM exercise, strengthening exercise, and stretching exercises) for 1 month
218914734|NCT06589375|DIAGNOSTIC_TEST|Sniffin'Sticks|The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.
219527732|NCT05038293|DEVICE|Automated mouthpiece-based toothbrush|One-time use during study visit.
219527733|NCT05038293|DEVICE|Manual toothbrush|One-time use during study visit.
219527734|NCT02708693|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
219527735|NCT02708693|DEVICE|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
219527736|NCT02708693|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
219527737|NCT01171989|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, one dose.
219615236|NCT03442751|DRUG|Test Article A|Riboflavin Ophthalmic Solution A
219615237|NCT03442751|DRUG|Test Article B|Riboflavin Ophthalmic Solution B
219615238|NCT03442751|DRUG|Placebo|Placebo Vehicle of Test Article
219615239|NCT03442751|DEVICE|KXL medical device system|Mock UVA light source
219615240|NCT03442751|DEVICE|KXL medical device system|Cross-linking UVA light source
219615241|NCT04997252|DRUG|Apalutamide|apalutamide as neoadjuvant therapy
219527738|NCT01171989|BIOLOGICAL|Infanrix hexa™|Intramuscular, one dose.
219527739|NCT01171989|BIOLOGICAL|Menjugate™|Intramuscular, one dose.
219527740|NCT01171989|BIOLOGICAL|NeisVac-C™|Intramuscular, one dose.
219527741|NCT01171989|BIOLOGICAL|Synflorix™|Intramuscular, one dose.
219527742|NCT02887339|OTHER|Training Website|Additional training website can be found at gtextraing.org
219615242|NCT00498394|BEHAVIORAL|Clinical diet trial|
219615243|NCT04311866|DEVICE|Synthetic pants|The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.
219615244|NCT04311866|DEVICE|Spica cast|The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
219615245|NCT05183139|DRUG|Ixazomib|Ixazomib capsules
219615246|NCT05183139|DRUG|Pomalidomide|Pomalidomide capsules
219527743|NCT02887339|OTHER|Control|Standard training given by OPOs and GTEx staff
219527744|NCT04166734|DRUG|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
219527745|NCT04166734|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
219527746|NCT01627158|DRUG|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
219527747|NCT01627158|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler
219527748|NCT01627158|DRUG|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
219527749|NCT01627158|DRUG|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
219527750|NCT06042335|DEVICE|DAISe EZ|DAISe Thrombectomy System for mechanical thrombectomy
219527751|NCT02339558|OTHER|Laboratory Biomarker Analysis|Correlative studies
219527752|NCT02339558|BIOLOGICAL|Nivolumab|Given IV
219527753|NCT02259283|DEVICE|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
219527754|NCT03587493|OTHER|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
219527755|NCT02697747|OTHER|Education|Educational intervention in the use of ultrasound to identify landmarks
219527756|NCT04043377|DRUG|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
219527757|NCT00906477|PROCEDURE|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
219527758|NCT01185691|DEVICE|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
219527759|NCT05310591|DRUG|Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )|"Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
219527760|NCT05310591|DRUG|Nivolumab starting at day -1|"It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
219527761|NCT00645762|DEVICE|RS-Series Rhinosinusitis Treatment System|Single arm
219527762|NCT00645762|DEVICE|FinESS Balloon|
219527763|NCT04253366|DEVICE|Clinical investigation device class IIa not marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
219527764|NCT04533269|OTHER|Arnica montana, Ledum palustre|Homeopathic
219615247|NCT05183139|DRUG|Lenalidomide|Lenalidomide capsules
219615248|NCT05183139|DRUG|Dexamethasone|Dexamethasone tablets
219615249|NCT02896634|BIOLOGICAL|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
218914735|NCT06595472|DIETARY_SUPPLEMENT|Palm Oil Enriched with Plant Sterols|The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.
219615250|NCT03651154|PROCEDURE|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
219615251|NCT06402110|OTHER|Femoral Triangle Block|Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.
219527765|NCT04690101|OTHER|none, this is an observational study|none, this is an observational study
219527766|NCT02875769|PROCEDURE|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
219527767|NCT02875769|DRUG|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
219527768|NCT02875769|DRUG|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
219527769|NCT02875769|OTHER|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
219527770|NCT02875769|OTHER|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
219527771|NCT01247701|DRUG|Busulfan|Busulfan dosing will be as follows: Patients \< 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \> 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
219527772|NCT01247701|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
219527773|NCT01247701|DRUG|Fludarabine|Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients \> 10 kg: 40 mg/m\^2.
218914736|NCT06595472|DIETARY_SUPPLEMENT|Palm oil|The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
218914737|NCT06600334|DIAGNOSTIC_TEST|dexa scan|Bone density scans
218914738|NCT06595056|BEHAVIORAL|Multi-technology MVPA intervention|Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
218914739|NCT06989320|DIETARY_SUPPLEMENT|Low-oxalate diet and glycolate dosing|Low-oxalate diet 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
218914740|NCT06989320|DIETARY_SUPPLEMENT|Oral glycolate dosing|Oral 13C-glycolate dosing (0.5 mg/kg)
218914741|NCT06989320|DIETARY_SUPPLEMENT|Oral 13C- ascorbic acid dosing|Oral 13C- ascorbic acid dosing (0.75 mg/kg)
218914742|NCT02360579|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
218914743|NCT06998823|COMBINATION_PRODUCT|Probiotics|Participants will intake 90days Probiotics
219527774|NCT01247701|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
219527775|NCT01795872|PROCEDURE|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
219527776|NCT04166630|DEVICE|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
219527777|NCT04351425|DEVICE|Weaning to crib|We weaned the infants into two groups. Group A, 1.6 kg
219527778|NCT04351425|DEVICE|Weaning from incubator|We weaned the infants into two groups. group B, 1.4 kg
219527779|NCT04747535|DEVICE|Auto-CPAP|AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
218914744|NCT06704789|DEVICE|Measurement of brain activity (fNIRS, EEG)|Brain activity assessments are conducted as a single session lasting approximately 60 minutes
218914745|NCT06705985|DEVICE|Implantation of lateral meniscus prosthesis|Implantation of a lateral meniscus prosthesis after meniscectomy.
219527780|NCT04747535|DEVICE|CPAP since before|A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
219527781|NCT01628835|BEHAVIORAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
219527782|NCT01628835|BEHAVIORAL|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
219527783|NCT00001135|DRUG|Nevirapine|
219527784|NCT05420896|OTHER|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
219527785|NCT04574102|DEVICE|Omega Refractive Capsule with FDA approved Intraocular Lens|Omega Refractive Capsule with FDA approved Intraocular Lens
219527786|NCT04574102|DEVICE|FDA approved Intraocular lens|FDA approved Intraocular lens
219527787|NCT04579770|DIETARY_SUPPLEMENT|Ketone ester|75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.
219527788|NCT04579770|OTHER|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
219527789|NCT04579770|OTHER|Placebo|Placebo
219615252|NCT06402110|OTHER|Adductor Canal Block|Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
219615253|NCT02923778|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219615254|NCT02923778|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219615255|NCT02923778|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219615256|NCT02923778|RADIATION|Radiation Therapy|Undergo radiation therapy
219615257|NCT02923778|BIOLOGICAL|Talimogene Laherparepvec|Given IT or via intralesional injection
219615258|NCT04009278|OTHER|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
218914746|NCT06704425|OTHER|For observational studies, participants are not assigned an intervention as part of the study.|For observational studies, participants are not assigned an intervention as part of the study.
218914747|NCT03253393|DEVICE|Smart Touch Technology packaging|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
218914748|NCT03253393|DEVICE|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
218914749|NCT03253393|DEVICE|EDTA|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
218914750|NCT06736457|PROCEDURE|AdvanCore bone grafting|AdvanCore medical device is implanted making sure that is in direct contact with all surfaces of the defect area.
218914751|NCT05860946|DEVICE|Remote ischemic conditioning|The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
218914752|NCT02609919|DRUG|Gadoteric Acid|MRI Contrast Agent
218914753|NCT02874872|BEHAVIORAL|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
218914754|NCT00727467|DEVICE|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
218914755|NCT01212835|PROCEDURE|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
218914756|NCT01212835|PROCEDURE|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
218914757|NCT00509054|PROCEDURE|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
218914758|NCT01156662|DEVICE|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
218914759|NCT01156662|DEVICE|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
218914760|NCT01395797|DRUG|PIO|0, 15, and 45 mg per day.
218914761|NCT01395797|DRUG|Placebo|Placebo
218914762|NCT04567628|OTHER|No Intervention|As this was an observational study, no intervention was administered.
218914763|NCT00896896|OTHER|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
218914764|NCT00896896|OTHER|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
219041748|NCT04155008|DRUG|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
219366512|NCT03820245|DIETARY_SUPPLEMENT|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
219366513|NCT00191672|DRUG|Gemcitabine|
219366514|NCT00191672|DRUG|Paclitaxel|
219366515|NCT00191672|DRUG|Docetaxel|
219366516|NCT01400932|DRUG|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
219366517|NCT01400932|DRUG|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
219366518|NCT02653950|PROCEDURE|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
219366519|NCT02653950|PROCEDURE|Traditional septoplasty|septoplasty under direct vision
219366520|NCT03793439|DRUG|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
219366521|NCT03793439|DIAGNOSTIC_TEST|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
219366522|NCT03793439|GENETIC|RNA Sequencing|RNA sequencing test at baseline and week 16
219366523|NCT03793439|DIAGNOSTIC_TEST|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
219366524|NCT03793439|DRUG|Corticosteroid|Taper corticosteroids starting at week 4
219366525|NCT03793439|DRUG|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
219366526|NCT02131857|BEHAVIORAL|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
219366527|NCT03244059|BIOLOGICAL|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
219366528|NCT03244059|DRUG|Placebo|An identically appearing placebo infusion.
218914765|NCT04004741|PROCEDURE|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
218914766|NCT04004741|PROCEDURE|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
219527790|NCT05176015|DEVICE|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
218914767|NCT02027155|DRUG|AR09 solution|moderate levels of sedation
218914768|NCT02027155|DRUG|placebo|Sterile Saline, USP
218914769|NCT04396756|DRUG|PLN-74809|PLN-74809
218914770|NCT04396756|DRUG|Placebo|Placebo
218914771|NCT00189722|DRUG|Tacrolimus|
218914772|NCT00485979|DRUG|larotaxel (XRP9881)|intravenous administration
218914773|NCT00485979|DRUG|docetaxel|intravenous administration
219615259|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
219615260|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
218914774|NCT00485979|DRUG|trastuzumab|intravenous administration
218914775|NCT00603408|DRUG|Cisplatin|
218914776|NCT00603408|RADIATION|Radiation Therapy|
218914777|NCT00603408|PROCEDURE|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
218914778|NCT05949736|DEVICE|The Online intervention platform|Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.
218914779|NCT03520829|DEVICE|Intuitive Plan|dosimetric planning software
218914780|NCT00385671|DRUG|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
218914781|NCT00385671|DRUG|pregabalin|Pregabalin (PGB) orally (PO)
218914782|NCT00385671|DRUG|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
218914783|NCT06403397|OTHER|Experimental group: CEASE Care Package and Remember Me Tool|"Before the intervention, the intervention group will first undergo the 'Nurse Identification Form' and the 'Alarm Fatigue Scale'. The current root cause analysis of monitor alarms in the clinical setting will be conducted through the 'CEASE Care Package' and the 'Current Situation Analysis Form'. Each patient monitor in the intensive care unit will be observed and recorded by two observers for a period of 24 hours.The Monitor Alarm Control Tool - Remember Me will be attached beneath each monitor to facilitate easier monitoring by nurses. Nurses are expected to use the tool for a period of 15 days. After intervention; Two observers will conduct a re-evaluation using the CEASE Care Package and the Current Status Analysis Form. Monitor alarms will be continuously assessed and recorded for 24 hours. Following the completion of this stage, the Alarm Fatigue Scale will be reapplied to the intervention group."
218914784|NCT00698763|DRUG|Levosimendan|from 0.125 mg to 2 mg in escalating doses
218914785|NCT00698763|DRUG|Placebo|Placebo capsules are identical in appearance to active capsules
218914786|NCT05781542|BIOLOGICAL|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
218914787|NCT05781542|BIOLOGICAL|IL-12 DNA|0.1 mg or 0.4 mg
218914788|NCT05781542|BIOLOGICAL|Trimer 4571|100 mcg
219527791|NCT05176015|DIAGNOSTIC_TEST|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
219527792|NCT00096447|DRUG|lapatinib ditosylate|
219527793|NCT03397251|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
219527794|NCT03696745|OTHER|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
219527795|NCT03696745|DRUG|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
219527796|NCT05361330|DRUG|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
219615261|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
219615262|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
219615263|NCT02603887|OTHER|Laboratory Biomarker Analysis|Correlative studies
219615264|NCT02603887|BIOLOGICAL|Pembrolizumab|Given IV
219615265|NCT05334641|OTHER|Listening Music|The patients in the experimental group were listened to music.
219615266|NCT05334641|OTHER|Not Listening Music|The control group was not listened to music.
218914789|NCT05781542|BIOLOGICAL|3M-052-AF|5 mcg
218914790|NCT05781542|DRUG|Alum|500 mcg
218914791|NCT02435953|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
218914792|NCT02435953|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
218914793|NCT04785313|BIOLOGICAL|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
218914794|NCT04785313|OTHER|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
218914795|NCT03763084|DRUG|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
218914796|NCT03763084|DRUG|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
219615267|NCT04539002|BEHAVIORAL|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
218914797|NCT00087841|BEHAVIORAL|Self-hypnotic relaxation|
218914798|NCT01183806|DRUG|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
218914799|NCT01183806|OTHER|Exercise training program|Exercise training program
218914800|NCT01775501|DRUG|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218914801|NCT01775501|DRUG|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218914802|NCT01775501|DRUG|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218914803|NCT01775501|DRUG|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218914804|NCT04841122|DEVICE|Camera observation|Supplemental camera observation directly linked to the nurse's phone
218914805|NCT06472518|DEVICE|pharmaco mechanical thrombolysis|arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
218914806|NCT04143035|OTHER|No Intervention|No Intervention
218914807|NCT05479695|DEVICE|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
218914808|NCT05479695|DEVICE|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
218914809|NCT04086901|RADIATION|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
218914810|NCT03818646|DIAGNOSTIC_TEST|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
218914811|NCT02166346|DRUG|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
218914812|NCT02166346|DRUG|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
218914813|NCT01432041|BEHAVIORAL|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
218914814|NCT05739721|BEHAVIORAL|Attractiveness|Visual attractiveness scale 0-7
218914815|NCT05739721|BEHAVIORAL|Self-Esteem|Self Esteem scale
218914816|NCT05739721|BEHAVIORAL|Trustworthiness|Trustworthiness scale 0-7
218914817|NCT06292260|DEVICE|mHealth app|The eSkinHealth app is a tablet application that can be used as a portable patient chart for dermatological conditions in areas with poor internet connectivity, and for teledermatology when in need.
218914818|NCT00311675|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
218914819|NCT02323789|DRUG|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
218914820|NCT04422184|DRUG|Sensodyne Repair and Protect|Dentifricie with NOVAMIN technology
218914821|NCT04422184|DRUG|Dentalclean Daily Regenerator|Dentifricie with Refix technology
218914822|NCT04422184|DRUG|Dentalclean Daily Regenerator with potassium citrate|Dentifricie with Refix technology+ potassium citrate
218914823|NCT05417646|OTHER|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
218914824|NCT05417646|DRUG|Placebo|Placebo comparator to empagliflozin
218914825|NCT05417646|DRUG|Empagliflozin|Single-dose, 25 mg, two hours before clamp
218914826|NCT05600634|PROCEDURE|Skin allotransplantation|Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
218914827|NCT04183660|DEVICE|MOBYBOX System|extracorporeal cardiopulmonary support
219615268|NCT04539002|BEHAVIORAL|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
219615269|NCT03935698|OTHER|Physiotherapy|
219615270|NCT00137150|PROCEDURE|Placement of implants|
219615271|NCT05611983|BEHAVIORAL|sensory relearning|feasibility of early sensory relearning
219615272|NCT02877225|DRUG|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
219615273|NCT02877225|DRUG|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
218914828|NCT00707083|DRUG|dexamethasone|Given oral
218914829|NCT00707083|DRUG|mercaptopurine|Given orally
218914830|NCT00707083|DRUG|methotrexate|Given orally
218914831|NCT00707083|DRUG|vincristine sulfate|Given IV
218914832|NCT05991635|BEHAVIORAL|Gatekeeper training (e-learning)|"The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care"
218914833|NCT02706977|DRUG|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
218914834|NCT02706977|DRUG|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
219041749|NCT04155008|BEHAVIORAL|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
219041750|NCT05420558|DIAGNOSTIC_TEST|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
219041751|NCT05830474|PROCEDURE|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
219041752|NCT03533387|DRUG|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
219041753|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
219041754|NCT01010048|DRUG|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
219041755|NCT04605328|OTHER|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
219041756|NCT04832464|OTHER|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
219527797|NCT05361330|DRUG|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
219527798|NCT00002662|DRUG|docetaxel|
218914835|NCT02706977|DEVICE|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
218914836|NCT02706977|OTHER|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
219527799|NCT00002662|DRUG|paclitaxel|
219527800|NCT05522361|DRUG|Risdiplam|administered to participants per product label insert
219527801|NCT04510545|DIAGNOSTIC_TEST|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
219527802|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, fructooligosaccharides, inulin|"The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
219527803|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin|"The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
219615274|NCT04390919|OTHER|elevated monocyte count|The monocyte count at admission was higher than 0.445×10\*9 cells/L
219527804|NCT05215535|RADIATION|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
219527805|NCT05215535|RADIATION|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
219527806|NCT03601819|DRUG|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
219615275|NCT02741726|DEVICE|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
218914837|NCT02706977|OTHER|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
218914838|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
218914839|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
219615276|NCT02741726|DEVICE|no stimulation|patients were only attached electrodes without electric current
218914840|NCT00003403|DRUG|GPX-100|
218914841|NCT00190918|DRUG|Pemetrexed|
218914842|NCT00874510|BEHAVIORAL|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
218914843|NCT04675593|BEHAVIORAL|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
218914844|NCT04675593|BEHAVIORAL|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
218914845|NCT06954077|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
218914846|NCT04970134|OTHER|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
218914847|NCT04970134|OTHER|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
219615277|NCT05236114|OTHER|Observation|No intervention
219615278|NCT06519357|DRUG|Lamivudine 300 MG|Participants receive 300 mg of Lamivudine daily for 24 weeks
219615279|NCT06668168|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].
219615280|NCT06668168|BEHAVIORAL|Ketogenic diet|Ketogenic diet (\<50 g carbohydrate per day)
219615281|NCT03994172|DRUG|Teriparatide or human parathyroid hormone (PTH) 1-34|Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
219615282|NCT03994172|DRUG|Cinacalcet|This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
218914848|NCT04970134|OTHER|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
218914849|NCT05833763|DRUG|Glofitamab|Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
218914850|NCT05833763|DRUG|Pirtobrutinib|Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
218914851|NCT05833763|DRUG|Obinutuzumab|Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
218914852|NCT05833763|DRUG|Tocilizumab|Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
218914853|NCT04293406|OTHER|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
218914854|NCT04879589|DRUG|Abiraterone Acetate|ATRS-2002
218914855|NCT00262340|OTHER|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
218914856|NCT01444612|DRUG|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
218914857|NCT01444612|DRUG|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
218914858|NCT01444612|DRUG|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
218914859|NCT01444612|DRUG|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
219041757|NCT01393405|DRUG|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
219527807|NCT03220802|DIETARY_SUPPLEMENT|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
219527808|NCT03827356|DEVICE|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
218914860|NCT03007966|PROCEDURE|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
218914861|NCT03007966|PROCEDURE|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
219527809|NCT02537093|BEHAVIORAL|Psychiatric Consultation|
219527810|NCT04292873|OTHER|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
219527811|NCT06562452|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
219527812|NCT04675372|DRUG|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
219527813|NCT04675372|DRUG|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
219527814|NCT01893008|OTHER|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
218914862|NCT03007966|DRUG|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
218914863|NCT03007966|DRUG|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
218914864|NCT03007966|DRUG|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
218914865|NCT01630369|DRUG|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219041758|NCT03942978|OTHER|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
219041759|NCT00370474|DEVICE|Bi-ventricular lead placement|
219041760|NCT03664752|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
219041761|NCT03664752|DRUG|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
219527815|NCT06563336|OTHER|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick."
219527816|NCT06563336|OTHER|conventional occupational training|This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
219527817|NCT04995783|DIAGNOSTIC_TEST|Coral FRS test|A novel clinical test to predict autoimmune medication response
219527818|NCT04470791|BIOLOGICAL|F(ab)2 antivenom therapy (antivipmyn®).|Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
219527819|NCT04470791|PROCEDURE|Local cryotherapy.|Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
218914866|NCT02963246|BEHAVIORAL|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
218914867|NCT02655120|PROCEDURE|Drilling|
218914868|NCT02655120|BIOLOGICAL|Bone Marrow +BMP7|
219207763|NCT05460520|BEHAVIORAL|Visual Motion Desensitization|The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
219527820|NCT04088760|DRUG|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
219527821|NCT03964662|DEVICE|WeReha|Rehabilitation of stroke patients with the device WeReha
219527822|NCT00607230|BIOLOGICAL|BCG|BCG vaccination at 0 and 4 weeks
219527823|NCT00607230|BIOLOGICAL|Saline|Saline vaccination at 0 and 4 weeks
219527824|NCT04839367|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
219527825|NCT01848301|DEVICE|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
219527826|NCT01848301|DRUG|Acetylcholine|Infusion in the coronary artery to study endothelial function
219527827|NCT01848301|PROCEDURE|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
219527828|NCT05702424|DRUG|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
219527829|NCT00764777|DEVICE|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
219527830|NCT02434055|DEVICE|AVERT PLUS|
219527831|NCT01416753|DEVICE|UCR|BVM-based regulation of ultrafiltration and conductivity
218914869|NCT01181063|DRUG|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
219527832|NCT01416753|DEVICE|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
219527833|NCT02460653|DEVICE|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
219527834|NCT02300103|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
219527835|NCT02300103|DRUG|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219527836|NCT04091971|DRUG|Ketamine|"Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks)."
219527837|NCT03734263|DRUG|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
219527838|NCT03016650|DRUG|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
219527839|NCT03016650|DRUG|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
219527840|NCT05600322|DRUG|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
218914870|NCT04062786|OTHER|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
218914871|NCT02260687|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
218914872|NCT03773224|PROCEDURE|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
219527841|NCT05600322|DEVICE|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
219527842|NCT06437691|PROCEDURE|Self-Expandable Metallic Stent Placement|
219527843|NCT06626555|DRUG|Letermovir|Letermovir 480mg PO once daily
219527844|NCT03135236|BEHAVIORAL|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
219527845|NCT04466111|DEVICE|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
219527846|NCT01317927|DRUG|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
219527847|NCT00105196|DRUG|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
219527848|NCT00105196|DRUG|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
219527849|NCT00004314|DRUG|aminomidazole carboxamide riboside|
219527850|NCT01123681|DEVICE|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
219527851|NCT00595062|RADIATION|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
219527852|NCT01371162|DRUG|RO5428029|Multiple ascending doses
219527853|NCT01371162|DRUG|placebo|multiple doses
219527854|NCT00000957|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
218914873|NCT02336152|DEVICE|Anaesthesia, Teles Pro, Body suit|
218914874|NCT04763395|OTHER|No intervention|No intervention
218914875|NCT02231112|RADIATION|Whole breast RT on prone position|
219527855|NCT04135820|DRUG|BPI-7711|BPI-7711 180 mg
219527856|NCT01202448|PROCEDURE|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
219527857|NCT01631422|DRUG|RO4602522|Single radiolabeled dose
219615283|NCT03994172|DRUG|placebo tablet|The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
218914876|NCT00002534|BIOLOGICAL|anti-thymocyte globulin|
218914877|NCT00002534|DRUG|cyclophosphamide|
218914878|NCT00002534|DRUG|cytarabine|
218914879|NCT00002534|DRUG|methylprednisolone|
218914880|NCT00002534|DRUG|thiotepa|
218914881|NCT00002534|PROCEDURE|allogeneic bone marrow transplantation|
218914882|NCT00002534|PROCEDURE|in vitro-treated bone marrow transplantation|
218914883|NCT00002534|RADIATION|low-LET electron therapy|
219527858|NCT01382719|DRUG|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
219527859|NCT02015390|PROCEDURE|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
219527860|NCT02015390|PROCEDURE|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
219527861|NCT04350970|OTHER|High flow nasal therapy|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
219527862|NCT04350970|OTHER|Non-invasive ventilation|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
219527863|NCT04350970|OTHER|Control|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
219527864|NCT01535859|DRUG|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
219527865|NCT01535859|DRUG|Placebo|1 tablet daily for 8 days.
219527866|NCT01285037|DRUG|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
219527867|NCT01285037|DRUG|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
218914884|NCT00002534|RADIATION|low-LET photon therapy|
218914885|NCT00003127|DRUG|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
218914886|NCT00003127|DRUG|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
218914887|NCT00003127|DRUG|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
218914888|NCT03524846|DRUG|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
218914889|NCT03524846|DRUG|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
218914890|NCT03524846|DRUG|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
219527868|NCT01285037|DRUG|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
218914891|NCT04866784|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
218914892|NCT05024539|OTHER|nonintervention|
218914893|NCT04188743|BIOLOGICAL|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
218914894|NCT04188743|BIOLOGICAL|Autologous FMT|Transplantation of autologous fecal microbiota
218914895|NCT02132962|DIETARY_SUPPLEMENT|Amino acid infusion|
218914896|NCT02132962|OTHER|Bloodsamples, Biopsies.|
218914897|NCT04230629|DEVICE|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
218914898|NCT04230629|DEVICE|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
218914899|NCT01485029|PROCEDURE|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
218914900|NCT00248625|DRUG|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
218914901|NCT00248625|DRUG|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
218914902|NCT03432676|DRUG|Epacadostat|Given PO
218914903|NCT03432676|BIOLOGICAL|Pembrolizumab|Given IV
218914904|NCT00293098|DRUG|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
218914905|NCT04009408|DEVICE|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
218914906|NCT03519035|OTHER|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
218914907|NCT00730717|DRUG|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
218914908|NCT00730717|DRUG|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
219527869|NCT01285037|DRUG|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
219527870|NCT01285037|DRUG|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
218914909|NCT06429917|OTHER|Subgingival instrumentation|All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
218914910|NCT05856721|DIAGNOSTIC_TEST|stool analysis|"Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients."
218914911|NCT04162418|DEVICE|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
219041762|NCT02094001|RADIATION|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
219041763|NCT03493334|OTHER|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
219041764|NCT03493334|OTHER|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
219041765|NCT03402438|DRUG|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
219041766|NCT03946397|OTHER|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
219041767|NCT00607763|DRUG|Micafungin (Mycamine)|IV
219041768|NCT01224249|DIETARY_SUPPLEMENT|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
219041769|NCT00189735|DRUG|FK778|
219041770|NCT04365699|DRUG|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
218914912|NCT05330559|OTHER|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
219041771|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
219041772|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
219041773|NCT05667233|OTHER|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
219527871|NCT01878825|BIOLOGICAL|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
218914913|NCT01094236|BEHAVIORAL|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
219041774|NCT02540954|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
219527872|NCT00830232|DEVICE|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
218914914|NCT01852877|BEHAVIORAL|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
218914915|NCT05077202|DEVICE|ultra sound|chest ultrasound
218914916|NCT04228523|OTHER|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~* A first round table is organized to know the needs and issues related to drug management of patients.~* The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~* The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~* The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
218914917|NCT04228523|OTHER|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
218914918|NCT03182374|DEVICE|nSTRIDE APS|Intra-articular injection
218914919|NCT03182374|DEVICE|Synvisc-One|Intra-articular injection
218914920|NCT04790617|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
218914921|NCT04103138|DEVICE|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
218914922|NCT04103138|DEVICE|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
218914923|NCT02360254|DRUG|Insulin degludec|Once daily injection of insulin degludec
218914924|NCT04231578|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
219041775|NCT03411876|DEVICE|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
219041776|NCT03411876|DEVICE|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
219041777|NCT01005004|BIOLOGICAL|HuCNS-SC cells|intracerebral transplantation
219041778|NCT04300569|OTHER|Non-interventional|No intervention will be administered.
219041779|NCT01933906|DRUG|P1101|
219527873|NCT00830232|DEVICE|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
219041780|NCT01794091|DRUG|Eplerenone|Eplerenone 25 mg daily for 6 months
219041781|NCT01794091|DRUG|Placebo|
219041782|NCT02752932|OTHER|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
219041783|NCT02676531|OTHER|Exercise|Walking meditation exercise program
219527874|NCT02419937|DRUG|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
219527875|NCT02419937|DRUG|Placebo|Saline injection
219527876|NCT04843878|DIAGNOSTIC_TEST|COVID Detect|The study is determining the efficacy of a new rapid COVID testing method.
219041784|NCT00915512|DRUG|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
219041785|NCT03639766|DRUG|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
219041786|NCT03639766|OTHER|Saline solution|Non-bacteriostatic saline solution
219041787|NCT02825303|OTHER|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
219041788|NCT03571919|DRUG|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
219207764|NCT05460520|BEHAVIORAL|Opposing visual motion stimulus|"The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between."
219527877|NCT00941837|DIETARY_SUPPLEMENT|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
218914925|NCT01148368|DRUG|fimasartan|single administration of fimasartan 120mg
218914926|NCT02629718|DRUG|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
218914927|NCT02629718|PROCEDURE|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
218914928|NCT00894816|DIETARY_SUPPLEMENT|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
218914929|NCT00894816|DIETARY_SUPPLEMENT|Placebo|Infant cereals without any addition
218914930|NCT03085095|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
219041789|NCT03571919|DRUG|Saline infusion|Intravenous bolus of saline and then infusion
219041790|NCT06357611|OTHER|Simulated technique|"The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed."
219041791|NCT06357611|OTHER|Muscle energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets."
219041792|NCT06357611|OTHER|4th ventricle technique and muscular energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series."
219041793|NCT01519856|DRUG|piribedil (Clarium)|oral tablets, 50 mg
219041794|NCT02469116|DRUG|Docetaxel|
219041795|NCT02469116|DRUG|Carboplatin|
219041796|NCT02469116|DRUG|Pegylated G-CSF|
219041797|NCT04082988|DIAGNOSTIC_TEST|18F-FDG PET-CT|18F-FDG PET-CT scan
219041798|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
219041799|NCT00917891|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
219041800|NCT00917891|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
219527878|NCT01725698|DRUG|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
219527879|NCT03488667|DRUG|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
219527880|NCT03488667|DRUG|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
219527881|NCT01981720|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
219527882|NCT02167620|DRUG|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
218914931|NCT03085095|DRUG|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
218914932|NCT06380491|DRUG|Melatonin 3 MG Oral Tablet|Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
218914933|NCT02572102|DIETARY_SUPPLEMENT|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
218914934|NCT02572102|DIETARY_SUPPLEMENT|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
219527883|NCT02167620|DRUG|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
219527884|NCT02830386|DEVICE|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
219527885|NCT01423006|PROCEDURE|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
219615284|NCT03994172|DIETARY_SUPPLEMENT|Calcium citrate tablet|Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
218914935|NCT02572102|OTHER|Placebo|Lime juice, water and cherry flavoring
218914936|NCT00408317|DRUG|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
219041801|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
218914937|NCT00408317|DRUG|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
218914938|NCT00813241|DRUG|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
218914939|NCT00813241|DRUG|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
218914940|NCT00813241|DRUG|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
219041802|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
218914941|NCT00813241|DRUG|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
218914942|NCT05649215|OTHER|No intervention will be applied.|This is a questionnaire study.
218914943|NCT02545985|DEVICE|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
218914944|NCT01110902|DRUG|Agomelatine (AGO178C)|
219041803|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
219041804|NCT02199405|OTHER|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
219041805|NCT02199405|OTHER|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
219527886|NCT01813006|DRUG|Omega-3|
219527887|NCT01813006|DRUG|placebo|
219527888|NCT00184600|DRUG|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
218914945|NCT01110902|DRUG|Placebo|
218914946|NCT05771987|PROCEDURE|pace maker implant guided by acute hemodynamic testing|To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
218914947|NCT03694886|DRUG|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
218914948|NCT03694886|OTHER|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
218914949|NCT03694886|DRUG|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
218914950|NCT03694886|OTHER|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
218914951|NCT05642403|DRUG|XW001|Inhaled XW001
218914952|NCT05642403|DRUG|Placebo|Matched inhaled placebo
219041806|NCT02199405|OTHER|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
219041807|NCT02199405|OTHER|Cervical traction|
219207765|NCT04962139|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
219207766|NCT04962139|OTHER|Vehicle Cream|ON101 Cream Placebo
219207767|NCT06717295|DIAGNOSTIC_TEST|DiNanoQ: A multi-cancer early detection (MCED) blood test|"Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer."
219527889|NCT00184600|DRUG|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
219527890|NCT00184600|DRUG|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
219527891|NCT00398515|DRUG|lenalidomide|Given orally
219527892|NCT00398515|DRUG|temsirolimus|Given IV
219527893|NCT00398515|OTHER|pharmacological study|Correlative studies
219527894|NCT00398515|OTHER|laboratory biomarker analysis|Correlative studies
219527895|NCT04742478|PROCEDURE|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
219527896|NCT03314298|DRUG|testosterone anastrozole|subcutaneous testosterone and anastrozole
219527897|NCT02674477|DEVICE|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
219615285|NCT03994172|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
218914953|NCT05765916|BEHAVIORAL|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
218914954|NCT04461717|DEVICE|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
218914955|NCT03822117|DRUG|Pemigatinib|Pemigatinib administered orally once daily (QD).
218914956|NCT02279914|DRUG|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D\&E procedure
218914957|NCT02279914|DRUG|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D\&E procedure
219527898|NCT02674477|OTHER|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
218914958|NCT04317287|DIETARY_SUPPLEMENT|Cardio formulation|Tomato-based formulation with dietary supplement softgels
218914959|NCT04317287|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
218914960|NCT04144608|DRUG|Toripalimab|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
219615286|NCT06163040|DRUG|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
219615287|NCT06163040|DRUG|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
218914961|NCT01074502|DRUG|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
218914962|NCT03117010|DRUG|Steroids|High dose dexamethasone 20 mg PO or IV
219204533|NCT06870292|PROCEDURE|Posterior nasal nerve combined with anterior ethmoid neurotomy|"First, a vertical incision was made in the posterior portion of the middle nasal turbinate. Dissection was performed along the bone to elevate the mucosal flap to expose the thick orbital process of the vertical plate of the palatine bone and the sphenopalatine foramen. The 3-4 mm of mucosal and submucosal neurovascular bundles surrounding the sphenopalatine foramen were subjected to full radiofrequency ablation, directly to the bone. The mucoperiosteal flap is reposited back. The bilateral nasal cavity was packed with Merocel nasal pack and hemostasis was achieved.~The anterior ethmoidal nerves of the lateral nasal branch and septal branch of the nasal cavity were cut off with a plasma treatment needle. Below 30°, the mucous membrane of the posterior lateral wall of the nasal colliculus was cut down to the bone surface using the needle of the nasal endoscope plasma therapy instrument. The contralateral side was then treated in the same way, with an arc cut line and a length of 2cm."
219527899|NCT05681247|DRUG|ezetimibe tablet|The subjects randomly received single oral administration of ezetimibe tablet 10 mg
219527900|NCT05681247|DRUG|ezetimibe tablet(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
219527901|NCT00278980|DRUG|C-peptide|
219527902|NCT00006027|DRUG|cisplatin|
219527903|NCT00006027|DRUG|paclitaxel|
219527904|NCT00006027|PROCEDURE|adjuvant therapy|
219615288|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
219615289|NCT05017025|DRUG|Osimertinib|Given PO
219615290|NCT05264025|DRUG|Fexofenadine|tablet
219615291|NCT05264025|DRUG|Placebo|tablet
219615292|NCT05326230|DEVICE|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
218914963|NCT03117010|DRUG|Etoposide|Etoposide 150mg/BSA
218914964|NCT03874338|DRUG|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
219527905|NCT00006027|RADIATION|radiation therapy|
219527906|NCT00624065|DRUG|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
219527907|NCT00624065|DRUG|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
219527908|NCT05757245|GENETIC|GMCN-508A Drug Product|Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.
219615293|NCT05326230|DEVICE|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
218914965|NCT01708200|OTHER|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
218914966|NCT04506229|GENETIC|Whole exome sequencing|MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
218914967|NCT03198715|DRUG|DS1040b|DS-1040b in solution for intravenous infusion
219041808|NCT01495845|OTHER|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
219041809|NCT04752501|OTHER|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
219041810|NCT04752501|OTHER|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
219527909|NCT00002905|DRUG|cyclophosphamide|
219527910|NCT00002905|DRUG|didanosine|
219615294|NCT03627988|OTHER|Patients with invasive breast cancer will receive:|"* Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
219615295|NCT04028557|OTHER|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
218914968|NCT03198715|DRUG|Placebo|Saline solution for intravenous infusion
218914969|NCT00615303|DRUG|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
219041811|NCT00053794|DRUG|perifosine|
219041812|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
219041813|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
219041814|NCT00834912|DRUG|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
219527911|NCT00002905|DRUG|doxorubicin hydrochloride|
218914970|NCT00615303|DRUG|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
218914971|NCT06514625|DEVICE|splint|ready night splints
218914972|NCT04105036|OTHER|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
219041815|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
219041816|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
219041817|NCT04953533|OTHER|no intervention|
219527912|NCT00002905|DRUG|etoposide|
219527913|NCT00002905|DRUG|mitoxantrone hydrochloride|
219527914|NCT00002905|DRUG|prednimustine|
219527915|NCT00002905|DRUG|zidovudine|
219527916|NCT06305897|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
219527917|NCT06305897|DEVICE|CRYONOVE (EC+05_1osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
219527918|NCT06305897|DEVICE|CRYONOVE (EC+05_2osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
219527919|NCT00904345|DRUG|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
219527920|NCT00904345|RADIATION|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
219527921|NCT04970420|OTHER|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).|In this study, individual training, training via mobile application and telephone counseling will be given to the experimental group. During the meetings, attention will be paid to the pandemic rules.
219527922|NCT04970420|OTHER|Control group|Individual training, mobile application and telephone counseling will be given to the control group after the study data is collected.
219527923|NCT00526734|BIOLOGICAL|filgrastim|
218914973|NCT00520182|BEHAVIORAL|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids \[MUFA\]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
218914974|NCT00520182|BEHAVIORAL|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
219527924|NCT00526734|BIOLOGICAL|pegfilgrastim|
219527925|NCT00526734|DRUG|melphalan|
219527926|NCT00526734|PROCEDURE|autologous hematopoietic stem cell transplantation|
219527927|NCT01262469|DRUG|lapatinib + capecitabine|"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."
219527928|NCT02096510|DRUG|Solu-Cortef|administration by pump for minimum 2 weeks
219041818|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
219527929|NCT02096510|DRUG|Cortef|tablet treatment 2 ro 3 times per day for 14 days
219527930|NCT02469805|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
219527931|NCT02469805|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
219527932|NCT02469805|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
219527933|NCT02469805|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
219527934|NCT02469805|DEVICE|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
219527935|NCT03901768|DRUG|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
219527936|NCT03901768|DRUG|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
219527937|NCT03901768|DRUG|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
219527938|NCT00296647|DRUG|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
219527939|NCT00296647|DRUG|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
219527940|NCT00296647|DRUG|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
219527941|NCT00296647|DRUG|bupropion|dosage according to prescription directions: 12 weeks
219527942|NCT00296647|DRUG|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
219527943|NCT00296647|DRUG|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
219527944|NCT02140398|PROCEDURE|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
219527945|NCT01985347|DEVICE|CPAP|Continuous positive airway pressure( CPAP)
219527946|NCT01947218|PROCEDURE|bronchial biopsies|
219527947|NCT01947218|OTHER|Determination of CO in exhaled air|
219527948|NCT01629381|DRUG|Rivaroxaban|10 mg os once daily for 1 week
219527949|NCT01629381|DRUG|placebo|10 mg os once daily for 1 week
219527950|NCT03235388|OTHER|Audit filters|Institutional implementation of audit filters
219527951|NCT03846765|DRUG|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
219527952|NCT03846765|DRUG|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
219527953|NCT00021463|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
219527954|NCT00021463|DRUG|Abacavir sulfate|
219527955|NCT00021463|DRUG|Efavirenz|
219527956|NCT00021463|DRUG|Nevirapine|
219527957|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
219527958|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
218914975|NCT00520182|BEHAVIORAL|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
218914976|NCT04334967|DRUG|Hydroxychloroquine|Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.
219527959|NCT04038710|DRUG|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
219527960|NCT02419456|DRUG|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
219527961|NCT02419456|DRUG|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
219527962|NCT01965522|DRUG|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
219527963|NCT01965522|DRUG|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
218914977|NCT04334967|DIETARY_SUPPLEMENT|Vitamin C|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
218914978|NCT03553693|OTHER|RAPID-VL study intervention|"* Viral load (VL) ordering flowsheet with periodic health facility performance feedback~* Rapid near-point-of-care VL testing and telephone delivery of results~* Structured VL counseling package"
218914979|NCT04254380|BIOLOGICAL|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
218914980|NCT04254380|BIOLOGICAL|Humalog|Route of administration: subcutaneous injection
218914981|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
218914982|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
218914983|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
218914984|NCT04154072|DRUG|NLY01|exenatide and polyethylene glycol (PEG)
218914985|NCT04154072|DRUG|Vehicle|Saline (Sodium Chloride)
219527964|NCT01965522|DRUG|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
219527965|NCT01965522|DRUG|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
219527966|NCT01233505|DRUG|veliparib|Given PO
219527967|NCT01233505|DRUG|capecitabine|Given PO
219527968|NCT01233505|DRUG|oxaliplatin|Given IV
218914986|NCT02784886|BIOLOGICAL|Women at high risk of MAP|Blood sample
218914987|NCT03906019|PROCEDURE|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
218914988|NCT03906019|DIAGNOSTIC_TEST|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
218914989|NCT03906019|DIAGNOSTIC_TEST|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
218914990|NCT00976183|DRUG|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
218914991|NCT00976183|DRUG|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
218914992|NCT05728437|PROCEDURE|Resistance exercise|The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
218914993|NCT04306276|DRUG|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
218914994|NCT01417806|DRUG|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
218914995|NCT00834977|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
218914996|NCT00834977|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
219527969|NCT01233505|OTHER|pharmacological study|Correlative studies
219527970|NCT01233505|OTHER|laboratory biomarker analysis|Correlative studies
219527971|NCT00735904|DRUG|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
219527972|NCT00735904|DRUG|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
219527973|NCT00735904|DRUG|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
219527974|NCT02841800|DEVICE|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
219527975|NCT02808065|DRUG|Tacrolimus|Administered dose were individualized according to their own prescription
219527976|NCT02808065|DRUG|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
219527977|NCT03687515|DRUG|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
219527978|NCT03687515|DRUG|budesonide|nasal spray 256μg BID
219527979|NCT03687515|DRUG|Prednisone|oral prednisone 24mg QD
218914997|NCT05650606|OTHER|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
218914998|NCT05650606|OTHER|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
218914999|NCT03376880|OTHER|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
218915000|NCT01283841|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
218915001|NCT03119987|DIAGNOSTIC_TEST|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
218915002|NCT03585881|DEVICE|3DPrinted Windowed Bracket- Positioning tray|3 D printed tray with windows for accurate positioning of brackets
218915003|NCT00169416|DRUG|valaciclovir HCl granules|
218915004|NCT00726063|DEVICE|Nanotite dental implant|Nanotite root form titanium dental implant
219041819|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
219041820|NCT01971658|DRUG|Thalidomide®|
219527980|NCT02543554|PROCEDURE|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
219527981|NCT01390844|DRUG|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
219527982|NCT01390844|DRUG|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
218915005|NCT00726063|DEVICE|Osseotite dental implant|Osseotite Root form titanium dental implant
218915006|NCT02007096|DRUG|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight \>100kg: 60ml total
218915007|NCT02007096|DRUG|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight \>100kg: 60ml
218915008|NCT01529892|DRUG|A single oral 5 mg of duterium labeled methamphetamine|
218915009|NCT03041519|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
218915010|NCT03041519|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
218915011|NCT02437344|DRUG|CI-581aa|92 minute infusion of CI-581aa
218915012|NCT02437344|DRUG|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
218915013|NCT06293599|OTHER|scapular stabilization exercises|the patients will receive scapular stabilization exercises in the form of scapular orientation exercises,Forward/Backward Bear Crawls,Lateral Bear Crawls and assisted stretch for pectoralis minor
218915014|NCT06293599|OTHER|virtual reality exercises|"The exercises described were done in a consistent manner, emphasizing low intensity, and using lightweight dumbbells (range, 3 to 30 pounds). The weight of the dumbbell was individually selected by the subject for each exercise.~1. elevation of the arm in the sagittal plane (shoulder flexion~2. elevation of the arm in the scapular plane with humeral external rotation (shoulder scaption~3. elevation of the arm in the coronal plane (shoulder abduction)~4. rowing~5. horizontal shoulder abduction~6. horizontal abduction with humeral external rotation~7. push-up with hands apart~8. push-up with a plus-normal push-up adding maximum shoulder and scapular protraction with elbows fully extended~9. dumbbell bench press~10. dumbbell military press~11. shoulder shrug~12. deceleration exercise-simulating the pitching followthrough~13. shoulder extension prone~14. shoulder internal rotation~15. shoulder external rotation~16. press-up"
219041821|NCT01971658|DRUG|Cyclophosphamide|
219041822|NCT01971658|DRUG|Velcade®|
219041823|NCT01971658|DRUG|Dexaméthasone|
219041824|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
219527983|NCT01390844|DRUG|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
219527984|NCT01390844|DRUG|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
219527985|NCT01390844|DRUG|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
219615296|NCT03825224|PROCEDURE|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
219041825|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
219041826|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
219041827|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
219041828|NCT01892696|DEVICE|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
219527986|NCT03613259|DRUG|Fluorothymidine F-18|Given IV
219527987|NCT03613259|OTHER|Laboratory Biomarker Analysis|Correlative studies
219527988|NCT03613259|PROCEDURE|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
219615297|NCT03348618|BIOLOGICAL|IVIG|Intravenous immunoglobulin
219615298|NCT04859452|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
219615299|NCT04859452|DRUG|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
218915015|NCT06293599|OTHER|regular routine exercises|the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,
219527989|NCT04605861|DRUG|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
219527990|NCT04605861|DRUG|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
219527991|NCT02042846|DEVICE|SportWelding Fiji Anchor|
219527992|NCT00076050|DIETARY_SUPPLEMENT|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
219527993|NCT00076050|DIETARY_SUPPLEMENT|Placebo|Placebo soy isoflavones
219527994|NCT01316445|DRUG|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
219527995|NCT03205241|DIETARY_SUPPLEMENT|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
219527996|NCT03205241|DIETARY_SUPPLEMENT|Placebo|Olive oil capsules
219527997|NCT02495545|PROCEDURE|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
219615300|NCT04859452|DRUG|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
219615301|NCT04859452|DRUG|Valsartan Capsules|Drug: Valsartan, capsule, oral
218915016|NCT03740451|OTHER|Active mobilization of soft tissues|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
218915017|NCT03740451|OTHER|Passive mobilization|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
218915018|NCT00006461|DRUG|cisplatin|Given IV
218915019|NCT00006461|DRUG|cyclophosphamide|Given IV
218915020|NCT00006461|DRUG|vincristine sulfate|Given IV
218915021|NCT00006461|DRUG|etoposide|Given PO
218915022|NCT00006461|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218915023|NCT00006461|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
218915024|NCT05030337|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
218915025|NCT04595656|OTHER|verbal autopsy interview|The study involves filling of verbal autopsies for deaths in SEACTN villages. This is an observational study being conducted as a substudy of rural febrile project of SEACTN program.
218915026|NCT05539625|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
218915027|NCT05539625|OTHER|Placebo|Placebo
218915028|NCT05003505|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
219041829|NCT03671291|BEHAVIORAL|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
219041830|NCT03829046|DRUG|Placebo|12 weeks of treatment
219041831|NCT03829046|DRUG|Evolocumab|12 weeks of treatment
219527998|NCT02495545|PROCEDURE|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
219527999|NCT00490594|DEVICE|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
219528000|NCT00547781|PROCEDURE|PGD|
219528001|NCT04792944|DRUG|Urokinase|Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
219528002|NCT04792944|PROCEDURE|Endovascular treatment|Aneurysm treatment through endovascular methods
219615302|NCT04859452|DRUG|Simvastatin tablets|Drug: Simvastatin, tablet, oral
219615303|NCT00501995|DRUG|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
219615304|NCT02905604|DEVICE|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
219615305|NCT02905604|DEVICE|dmPFC Sham iTBS|Sham iTBS
219615306|NCT06062550|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
219528003|NCT04792944|PROCEDURE|Clipping|Surgical clipping of brain aneurysms
219528004|NCT04792944|PROCEDURE|External ventricular drain|Insertion of an external ventricular drain to treat acute hydrocephalus
219528005|NCT00378690|DRUG|leuprorelin acetate|LHRH antagonist
219528006|NCT03204539|DRUG|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
219528007|NCT04932837|BIOLOGICAL|Blood and Saliva collection|Serological, viral RNA and antigenic test
219528008|NCT04520464|DIAGNOSTIC_TEST|Cervical samples for identification of HR-HPV DNA via real-time PCTR.|Identification of HR-HPV DNA via real-time PCTR.
219528009|NCT04853459|PROCEDURE|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
219528010|NCT01624064|DRUG|Enalapril|2.5-20 mg/day
219528011|NCT01624064|DRUG|Calcium Supplement|Calcium 2.5-20 mg/day
219528012|NCT04350580|DRUG|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
219528013|NCT04350580|DRUG|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
219528014|NCT02456948|DRUG|Minocycline|6 weeks 200mg/day Minocycline add-on
219528015|NCT02456948|DRUG|Placebo|6 weeks Placebo add-on
219528016|NCT03113006|PROCEDURE|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
219528017|NCT01751594|BEHAVIORAL|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
219528018|NCT01751594|BEHAVIORAL|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
219528019|NCT05093205|DRUG|PF-06882961|Tablets
219528020|NCT05093205|DRUG|Atorvastatin|Tablets
219528021|NCT05093205|DRUG|Midazolam|Syrup
219528022|NCT05093205|DRUG|Levonorgestrel & Ethinyl Estradiol|Tablet
219528023|NCT01698476|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
219041832|NCT01037946|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
219041833|NCT00571129|PROCEDURE|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
219528024|NCT01698476|DRUG|Placebo tablets|
219528025|NCT06475924|DIAGNOSTIC_TEST|Caesarean scar defect evlauation by ultraosund|"Women will be examined in the lithotomy position with an empty bladder. The uterus will be examined in a standardized way excluding causes of abnormal uterine bleeding or pelvic pain (myoma, polyp, pelvic inflammatory disease, adenomyosis).~Upon detection of the SCD, the following will be measured:~In the midsagittal plane: the depth (the vertical distance between the base and apex of the defect), width (the length of the widest gap along the cervicoisthmic canal), residual myometrial thickness (RMT) overlying the defect, and the adjacent myometrial thickness fundal to the defect.~In the transverse plane: the length of the defect.~The uterine position will be classified as anteverted or retroverted.~Clinical symptoms of the patients will be reviewed such as :Postmenstrual spotting, Abnormal uterine bleeding, Pain, Secondary infertility."
219528026|NCT00048126|DRUG|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
219528027|NCT00048126|DRUG|capecitabine [Xeloda]|1000mg po bid
219528028|NCT00818337|DRUG|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
219528029|NCT06280690|DRUG|SGM-101|SGM-101 is cea-targeted fluorescent dye
219528030|NCT03361228|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
219528031|NCT03361228|DRUG|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
219528032|NCT03361228|DRUG|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
219528033|NCT03079271|DRUG|Lacrisert, 5 Mg Ophthalmic Insert|
219528034|NCT01274364|OTHER|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
219528035|NCT01274364|OTHER|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
219528036|NCT00005856|DRUG|oxaliplatin|Given IV
219528037|NCT00005856|OTHER|pharmacological study|Correlative studies
219528038|NCT05822232|DEVICE|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
219528039|NCT05822232|DEVICE|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
219528040|NCT05822232|DEVICE|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
219528041|NCT04862702|DEVICE|mechanical instrumentation using rotary file system|the mechanical preparation will be performed using rotary file system
219528042|NCT02328443|DRUG|Midazolam|
219528043|NCT02328443|DRUG|itraconazole|
219528044|NCT02328443|DRUG|rifampicin|
218915029|NCT05284773|OTHER|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
218915030|NCT05284773|OTHER|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
218915031|NCT05719311|DRUG|adrulipase|Enteric microgranule formulation of adrulipase.
218915032|NCT05176314|DRUG|Rosuvastatin|Administered Orally.
218915033|NCT05176314|DRUG|Pirtobrutinib|Administered Orally.
218915034|NCT06264843|DEVICE|MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes|Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
218915035|NCT04922944|DRUG|COVID-19 vaccine|Two-dose COVID-19 vaccine
218915036|NCT05515484|OTHER|prone position with airbags|prone position with airbags
219528045|NCT03123237|DIAGNOSTIC_TEST|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.
218915037|NCT05515484|OTHER|prone position without airbags|prone position without airbags
219528046|NCT01123265|DRUG|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
219528047|NCT01123265|DRUG|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
219528048|NCT00360360|DRUG|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
219528049|NCT00360360|DRUG|carboplatin|Carboplatin AUC 6.0 IV Day 1
219528050|NCT00360360|DRUG|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
219528051|NCT00360360|DRUG|erlotinib|Erlotinib 150 mg by mouth daily
219528052|NCT06327607|OTHER|Control Group|Standard care for breast cancer
219528053|NCT06327607|OTHER|Psychosexological intervention|The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.
219528054|NCT03571880|DEVICE|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
219615307|NCT05115695|OTHER|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
218915038|NCT05021354|DEVICE|Dry needling|dry needling, stretching and eccentric exercise
218915039|NCT05021354|DEVICE|Topical gel|aplication of topical gel to the epicondyle
218915040|NCT05021354|DRUG|NSAIDs|oral intake of NSAIDs
218915041|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
219041834|NCT04518007|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
219041835|NCT04709666|PROCEDURE|Endsocopic Retrograde ColangioPancreatography (ERCP)|
219528055|NCT03693430|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
219528056|NCT03693430|DRUG|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
219528057|NCT02702817|DRUG|Naproxen|pale blue oval tablets
219528058|NCT02702817|DRUG|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
219528059|NCT03435705|BEHAVIORAL|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
219528060|NCT01578694|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
219528061|NCT04132908|DIETARY_SUPPLEMENT|Dietary Supplement: nutraceutical|Subjects will consume two capsules at breakfast and dinner for ten weeks.
219528062|NCT04132908|DIETARY_SUPPLEMENT|Placebo|Subjects will consume two capsules at breakfast and dinner for ten weeks.
219528063|NCT03365115|DRUG|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
219528064|NCT03365115|DRUG|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
219528065|NCT00945165|BEHAVIORAL|Exercise intervention|various exercise characteristics
218915042|NCT03988309|DIAGNOSTIC_TEST|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
218915043|NCT05716958|RADIATION|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
218915044|NCT00434317|DRUG|Zoledronic acid|
218915045|NCT00017212|DRUG|exatecan mesylate|
218915046|NCT02179697|OTHER|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
218915047|NCT02179697|PROCEDURE|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
218915048|NCT03090360|DIETARY_SUPPLEMENT|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
218915049|NCT03090360|DIETARY_SUPPLEMENT|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
219528066|NCT00945165|BEHAVIORAL|No exercise|No exercise control period
219528067|NCT02045550|DRUG|Prospan Syrup|2.5 ml twice daily for 4 weeks
219528068|NCT01890239|OTHER|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
218915050|NCT05635019|BEHAVIORAL|BWL+VOUCHER|This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.
219041836|NCT05962411|OTHER|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
219041837|NCT01930292|DRUG|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
219528069|NCT05267405|OTHER|no interventions, only observation|no interventions, only observation
219528070|NCT01719731|BEHAVIORAL|Education|This group will receive the psychoeducation
219528071|NCT01719731|BEHAVIORAL|Non-Education|This group will not receive the psychoeducation
219528072|NCT05633485|OTHER|Animation-Supported Education|Expert support was received for the design and preparation of animation videos.
219528073|NCT01988974|BEHAVIORAL|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
219528074|NCT01988974|BEHAVIORAL|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
219528075|NCT00401947|DRUG|ACH-0137171|
219528076|NCT05605301|DRUG|Oral 2-Deoxy-D-Glucose (2DG)|2DG will be formulated as an solid dosage form and administered orally.
219528077|NCT01746329|OTHER|Tea|Oral intake of tea containing 75 grams of glucose
219528078|NCT01746329|OTHER|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
219528079|NCT01746329|OTHER|Placebo|Oral intake of 75 grams of glucose in water
218915051|NCT05635019|BEHAVIORAL|BWL+HOME|This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.
218915052|NCT05635019|BEHAVIORAL|Behavioral weight loss counseling (BWL)|The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
218915053|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Single Dose|Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
218915054|NCT04277897|DRUG|Placebo|Placebo to match Hepenofovir Fumarate Tablets
219528080|NCT03430830|DRUG|Ravidasvir 50mg|50mg, Tablet
218915055|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Dose4|Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
219528081|NCT03430830|DRUG|Ravidasvir 200mg|200mg, Tablet
219528082|NCT04589195|BEHAVIORAL|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
218915056|NCT05918523|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
218915057|NCT05250284|BEHAVIORAL|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
218915058|NCT05250284|BEHAVIORAL|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
218915059|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
218915060|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
218915061|NCT00286468|DRUG|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
218915062|NCT06182137|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.
218915063|NCT03454763|DRUG|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
218915064|NCT03454763|DRUG|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
218915065|NCT05132907|BIOLOGICAL|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
218915066|NCT03494660|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
219041838|NCT01930292|DRUG|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
219041839|NCT01930292|DRUG|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
219041840|NCT01930292|DRUG|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
219528083|NCT00816504|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
219528084|NCT00003630|DRUG|arsenic trioxide|
219528085|NCT03583593|DIETARY_SUPPLEMENT|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
219528086|NCT03583593|DIETARY_SUPPLEMENT|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
219528087|NCT03163680|DRUG|Omeprazole 40 MG|Omperazole 40 mg twice daily
219528088|NCT00887263|DRUG|Budesonide|3 mg TID
219528089|NCT00887263|DRUG|Placebo|0 mg TID
219528090|NCT00362765|DRUG|Fenofibrate|160 mg
218915067|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
218915068|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
218915069|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
218915070|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
218915071|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
218915072|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
218915073|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
218915074|NCT06548126|BEHAVIORAL|Online Parenting Program|Online Parenting Program comprised of 12 online modules. Caregivers do one module per week for 12-15 weeks; each unit takes about 20 minutes to do. The Caregiver also practices the tools they learn for Parenting their Children between sessions.
218915075|NCT06548126|OTHER|No online parenting program|List of Parenting resources.
218915076|NCT05703945|OTHER|Progressive training program|The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.
218915077|NCT05703945|OTHER|Control group|The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
218915078|NCT06513858|BEHAVIORAL|Communal Drumming|Communal drumming
218915079|NCT06513858|BEHAVIORAL|Communal drumming recordings|Recordings of drumming taken from the music made during a previous component of the study
218915080|NCT06580444|DRUG|Brexanolone|The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
219041841|NCT00326664|DRUG|Cediranib Maleate|Given orally
219041842|NCT00424151|DRUG|Rituximab|
219041843|NCT01831232|DRUG|pravastatin sodium|Given PO
219041844|NCT01831232|DRUG|idarubicin|Given IV
219528091|NCT00362765|DRUG|Metformin|2000 mg
219528092|NCT00362765|DRUG|Placebo|Placebo
219528093|NCT04844489|OTHER|Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19|"Blood samples at:~* D0 (the day of the injection of the SARS-CoV-2 vaccine),~* during the 2nd injection as part of the national vaccination campaign (on D28)~* during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~* then to M1, M6 and M12 of the last injection"
219528094|NCT04185909|DEVICE|Renuvion Dermal System|The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
219528095|NCT04035603|DRUG|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
219615308|NCT05115695|OTHER|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
219615309|NCT02776943|BIOLOGICAL|umbilical cord mesenchymal stem cells|
219615310|NCT02776943|DEVICE|Hyaluronic acid|
219615311|NCT01903798|DRUG|Mycophenolate mofetil|Immunosuppressive agent
218915081|NCT06581016|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
219041845|NCT01831232|DRUG|cytarabine|Given IV
219041846|NCT01831232|OTHER|laboratory biomarker analysis|Correlative studies
219041847|NCT05624346|OTHER|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
219615312|NCT01903798|DRUG|Prednisolone|Corticosteroid
219615313|NCT01903798|DRUG|Rilonacept|
219041848|NCT02201303|DRUG|Danirixin|Powdered form for in-vitro administration to blood sample
219615314|NCT01007669|BEHAVIORAL|Physical activity and Health check|Strength training, aerobic capacity training.
219615315|NCT01007669|BEHAVIORAL|Health check only|Health check
219615316|NCT01123057|PROCEDURE|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.~The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
219615317|NCT01123057|DEVICE|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
219615318|NCT03618017|BEHAVIORAL|CCC website|ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
218915082|NCT06581016|DEVICE|Ambu aScope Gastro Large|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
219041849|NCT02201303|OTHER|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
219041850|NCT01638962|DRUG|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
219041851|NCT01638962|OTHER|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
219041852|NCT00924911|DRUG|GSK1322322|Four different formulations of 1000mg of GSK1322322
219528096|NCT04035603|DRUG|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
219615319|NCT03618017|BEHAVIORAL|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
219615320|NCT03903302|DRUG|CS1-Sodium Valproate|Single and multiple dose evaluation of CS1
219615321|NCT01015534|DRUG|Temozolomide|
219615322|NCT01015534|RADIATION|Whole brain irradiation|
219615323|NCT04786002|DRUG|Busulfan|The BU administration regimen was four times a day (Q6h), continuous intravenous infusion for 2 hours, 3 or 4 days in a row.
219615324|NCT05392868|DEVICE|SDF|38% silver diamine fluoride solution
219615325|NCT05392868|DEVICE|KNO3|5% potassium nitrate solution
218915083|NCT06581016|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
218915084|NCT06581016|DEVICE|Therapeutic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
218915085|NCT05265429|GENETIC|Data and Specimen Collection|"* Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
218915086|NCT05156047|DRUG|Open-label pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
218915087|NCT05156047|DRUG|Double-blind placebo|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
218915088|NCT05156047|DRUG|Double-blind pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
219528097|NCT04035603|BEHAVIORAL|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
219528098|NCT04035603|DRUG|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
219528099|NCT01395186|PROCEDURE|varicocelectomy|varicocelectomy for painful varicocele
219528100|NCT03983486|OTHER|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
218915089|NCT06102954|OTHER|Falls prevention intervention including exercise and educational components|This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
219528101|NCT01417078|DRUG|Diazepam|single-dose; dosage in mg, based on patient body weight
219528102|NCT04458649|DEVICE|Dexcom continuous glucose monitor|Measurement of interstitial glucose
219528103|NCT00626548|DRUG|ZD4054|10 mg once daily oral dose
219528104|NCT00626548|DRUG|Palcebo|Matching Plcebo oral tablet once daily
219528105|NCT00048581|DRUG|Abatacept|Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
219528106|NCT00048581|DRUG|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
219528107|NCT00048581|DRUG|Abatacept|Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
219528108|NCT05493007|PROCEDURE|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
219528109|NCT05493007|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
219528110|NCT02518581|PROCEDURE|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
219528111|NCT05677698|OTHER|Lemon oil|Lemon oil with massage
219528112|NCT05677698|OTHER|peppermint oil|peppermint oil with massage
219528113|NCT05677698|OTHER|Almond oil|Almond oil massage
219528114|NCT04078048|DIETARY_SUPPLEMENT|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
219528115|NCT00002064|DRUG|Pyrimethamine|
219528116|NCT00002064|DRUG|Clindamycin|
219528117|NCT00535808|DRUG|nitroprusside|Administration of nitroprusside
219528118|NCT00535808|DRUG|nitroglycerine|Administration of nitroglycerine
219528119|NCT00535808|DRUG|sevoflurane|Administration of Sevoflurane
218915090|NCT03790332|DRUG|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
218915091|NCT02271919|DRUG|Nicotine Lozenge|Given PO
218915092|NCT02271919|DRUG|Nicotine Patch|Given via patch
219528120|NCT05703308|BIOLOGICAL|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
218915093|NCT02271919|OTHER|Placebo|Given PO or via patch
218915094|NCT02271919|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
218915095|NCT02271919|DRUG|Varenicline|Given PO
219528121|NCT02769208|DEVICE|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
219615326|NCT06979102|OTHER|Real Patient Interactive Stoma Care Management Teaching|"The real patient interactive stoma care management teaching will be carried out with ileostomy patients who have recently undergone ileostomy surgery and their caregivers in the intervention group. The 2nd month after discharge, the newly ileostomy patients and their caregivers will be asked one open-ended question to elicit their thoughts and suggestions regarding the real patient interactive stoma care management teaching. The question is: A real patient with a previous ileostomy participated in the stoma care management teaching. He demonstrated how to perform ileostomy care on himself and shared his experiences and suggestions regarding adapting to life with an ileostomy. What are your thoughts and suggestions regarding this teaching?"
219615327|NCT06979102|OTHER|Standard Stoma Care Management Teaching|The standard stoma care management teaching will be carried out with ileostomy patients who have recently had their ileostomy opened and their caregivers in the control group.
219615328|NCT02412917|DRUG|FV-100|antiviral nucleoside analog
219615329|NCT02412917|DRUG|valacyclovir|antiviral nucleoside analog
219615330|NCT06390709|OTHER|Lab Collection Only|2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
219615331|NCT03376334|OTHER|Mental Motor Imagery|
219615332|NCT02475928|DIETARY_SUPPLEMENT|zinc gluconate|Zinc supplementation plus nutritional education
219615333|NCT02475928|DIETARY_SUPPLEMENT|Placebo|
218915096|NCT06177080|OTHER|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
218915097|NCT04816825|DEVICE|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
219528122|NCT00000482|DRUG|estrogen|
219528123|NCT00000482|DRUG|clofibrate clofibrate|
219528124|NCT00000482|DRUG|dextrothyroxine sodium|
219528125|NCT00000482|DRUG|niacin|
219528126|NCT01059903|DRUG|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
219528127|NCT03895684|DRUG|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
219528128|NCT01934673|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
219615334|NCT02475928|BEHAVIORAL|Nutritional education|
219615335|NCT06601465|DRUG|Vericiguat|Tablet - 2.5 mg, 5 mg, 10 mg
219615336|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 1
219615337|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 2
219615338|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 3
219615339|NCT06841445|DRUG|HRS9531 Tablet placebo|HRS9531 Tablet placebo
219615340|NCT05273151|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
219615341|NCT03483012|DRUG|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
219615342|NCT03483012|PROCEDURE|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
219615343|NCT06609408|OTHER|Nature and Game Based Activities|Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
219615344|NCT02063568|DRUG|Oxytocin|
219615345|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
218915098|NCT04816825|OTHER|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
218915099|NCT05662410|DRUG|Three monthly injections of intravitreal aflibercept|Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
218915100|NCT06638931|DRUG|Nivolumab|"The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death."
218915101|NCT02923726|DEVICE|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
219041853|NCT00924911|DRUG|GSK1322322|GSK1322322 1000mg
219528129|NCT01709474|DRUG|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
219528130|NCT01709474|DRUG|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
219528131|NCT01874756|DRUG|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
219528132|NCT01874756|DRUG|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
219615346|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
219615347|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
219615348|NCT06455813|DRUG|Bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
219528133|NCT01874756|DRUG|Placebo|6 placebo capsules daily for 8 weeks
219615349|NCT06455813|DRUG|Macrogol 3350 and electrolytes|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
219615350|NCT06455813|DRUG|A combination of macrogol 3350 and electrolytes and bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
219615351|NCT00673699|PROCEDURE|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
219615352|NCT05061589|PROCEDURE|permanent colostomy|An operation that creates an opening for the colon through the abdomen
219615353|NCT00794768|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
219615354|NCT00794768|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
219528134|NCT01874756|DRUG|LY500307 25mg|LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
219528135|NCT01616602|OTHER|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
219528136|NCT01616602|OTHER|Standard Position|The traditional left-lateral decubitus position
219528137|NCT01049893|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
218915102|NCT02923726|DEVICE|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
219528138|NCT05306470|PROCEDURE|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
219528139|NCT05306470|PROCEDURE|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
219528140|NCT05448430|DEVICE|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
219528141|NCT00385593|DRUG|Symbicort (budesonide/formoterol) Turbuhaler|
219528142|NCT00385593|DRUG|Conventional treatment|
219528143|NCT00381537|DRUG|phenobarbitone|
219528144|NCT00381537|DRUG|carbamazepine|
219528145|NCT03829098|OTHER|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
219528146|NCT03416764|DEVICE|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
219528147|NCT01270048|DRUG|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
219528148|NCT01270048|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
219528149|NCT03487107|DRUG|SOF|400 mg tablet administered orally once daily
219528150|NCT03487107|DRUG|DAG181|100 mg capsule administered orally once daily
219615355|NCT05422001|DRUG|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
218915103|NCT05629988|DEVICE|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
218915104|NCT04146051|DRUG|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
219528151|NCT03992586|OTHER|Wearing pink glasses|Wearing pink-colored lenses
219528152|NCT03992586|OTHER|Wearing clear glasses|Wearing clear glasses
219615356|NCT05422001|DRUG|Placebo (saline)|Isotonic Saline
219041854|NCT00895791|DEVICE|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
219041855|NCT00895791|DEVICE|culotte stenting (Xience V)|implantation of stent
219041856|NCT00563238|DRUG|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
219041857|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
219528153|NCT02344992|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
219528154|NCT02344992|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
219528155|NCT02873910|DIETARY_SUPPLEMENT|IQP-AS-119|
219528156|NCT02873910|DIETARY_SUPPLEMENT|Placebo|
219528157|NCT00319735|PROCEDURE|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
219528158|NCT00319735|PROCEDURE|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
219528159|NCT00319735|PROCEDURE|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
219528160|NCT02485808|OTHER|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
219528161|NCT02485808|PROCEDURE|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
219528162|NCT02485808|OTHER|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
219528163|NCT02485808|OTHER|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
219528164|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
219528165|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
219528166|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
219528167|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
219528168|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
219528169|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
219528170|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
219528171|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
219528172|NCT00958178|DRUG|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
219528173|NCT00969566|DRUG|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
218915105|NCT05011942|DEVICE|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
218915106|NCT04474080|BEHAVIORAL|Virtual Peer Support Platform|The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
218915107|NCT04474080|BEHAVIORAL|Control Period|The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
218915108|NCT03158844|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
219615357|NCT00318890|DRUG|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
219615358|NCT00318890|DRUG|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
218915109|NCT04839406|BEHAVIORAL|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
218915110|NCT04144569|DRUG|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
218915111|NCT05794620|OTHER|Stool sample|Stool sample
218915112|NCT05817656|DRUG|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
218915113|NCT05659953|DRUG|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
218915114|NCT05659953|DRUG|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
219528174|NCT03820713|PROCEDURE|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
219528175|NCT03820713|PROCEDURE|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
219528176|NCT06375408|DEVICE|Real transcranial alternating electrical stimulation|The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
219615359|NCT00318890|PROCEDURE|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
219615360|NCT00318890|DRUG|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
219615361|NCT06044142|DRUG|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
219615362|NCT06044142|DEVICE|Laser|Low level laser therapy
219615363|NCT04809532|PROCEDURE|Transverse abdominis plane (TAP) block|Ultrasound guide bilateral TAP block at end of cesarean section
219615364|NCT04809532|DRUG|Bupivacain|20ml 0.25% bupvicaine
219615365|NCT04809532|DRUG|Tramadol|intravenous tramadol
219041858|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
219041859|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
219528177|NCT06375408|DEVICE|Sham transcranial alternating electrical stimulation|The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
218915115|NCT03015766|OTHER|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
219615366|NCT04417621|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
218915116|NCT03015766|OTHER|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
218915117|NCT03446235|BEHAVIORAL|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
218915118|NCT03446235|BEHAVIORAL|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
218915119|NCT03324607|DRUG|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
218915120|NCT03324607|DRUG|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
218915121|NCT04366414|OTHER|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
218915122|NCT04366414|OTHER|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
218915123|NCT00074711|DRUG|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
218915124|NCT00074711|DRUG|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
218915125|NCT01958996|DRUG|idarubicin|
218915126|NCT02340793|DIETARY_SUPPLEMENT|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
218915127|NCT03466658|DEVICE|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
218915128|NCT05365217|DRUG|Nonacog beta pegol|Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
219615367|NCT04417621|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
219615368|NCT04417621|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
219615369|NCT04417621|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
219615370|NCT06994754|DEVICE|clear aligners|aligners made with 1mm thickness sheet and covering the whole palate
218915129|NCT06066177|DIAGNOSTIC_TEST|Triglyceride glucose index TyG|Triglyceride glucose index is an indicator of insulin resistance
218915130|NCT00890734|DRUG|CYT003-QbG10|subcutaneous injection
218915131|NCT00890734|DRUG|Placebo|subcutaneous injection
218915132|NCT03696160|DRUG|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
218915133|NCT03696160|DRUG|Symtuza|Protease inhibitor used to treat HIV-1 infection
218915134|NCT03864783|DIETARY_SUPPLEMENT|Curcumin (Meriva®)|"Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)"
219528178|NCT03458871|DEVICE|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
219528179|NCT02530762|OTHER|Novel Fiber|novel fiber supplemented beverage provided in one serving
219528180|NCT02530762|OTHER|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
219528181|NCT02530762|OTHER|Negative Control|No added fiber beverage
219528182|NCT00191295|DRUG|Atomoxetine|
219528183|NCT00191295|DRUG|Placebo|
219528184|NCT03394209|DRUG|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
219528185|NCT03394209|DRUG|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
219528186|NCT03420300|DRUG|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
219528187|NCT02501005|PROCEDURE|VT ablation|Catheter ablation of ventricular tachycardia
219615371|NCT06995391|BEHAVIORAL|Contemporary Guideline-Adherence|Participants randomized to Contemporary Guideline-Adherence will receive weekly app and text-based messaging encouraging them not to exceed guideline-directed amounts of alcohol, as well as messaging explaining that abstinence is acceptable and may be the best way to avoid AF and that, if a participant decides to consume alcohol, a Mediterranean drinking pattern may be the most healthy.
218915135|NCT03864783|DRUG|Placebo Oral Tablet|"Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®."
218915136|NCT06252181|OTHER|electromagnetic pulsed therapy|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
218915137|NCT06252181|OTHER|elliptical exercise|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
218915138|NCT05766397|DRUG|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
218915139|NCT01809938|OTHER|Black tea|300ml of tea without milk
218915140|NCT01809938|OTHER|Tea with milk|250ml of black tea with 50ml of full fat milk
219528188|NCT00308022|DEVICE|High Frequency Percussive Ventilation|
219528189|NCT03030196|DRUG|Denosumab|NaCl 0.9% injection is used as placebo
219528190|NCT05055349|OTHER|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
219528191|NCT04355455|DRUG|Citalopram|40 mg citalopram intravenously
218915141|NCT02210572|DIETARY_SUPPLEMENT|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
218915142|NCT02210572|DIETARY_SUPPLEMENT|Low- FODMAPs diet|
218915143|NCT01007903|BEHAVIORAL|Tai Chi exercise|12-week tai chi exercise class
218915144|NCT05608603|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
218915145|NCT05608603|DIAGNOSTIC_TEST|Cardiorespiratory stress test|Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.
218915146|NCT05608603|DIAGNOSTIC_TEST|Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer|The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
219528192|NCT04355455|DRUG|Placebo|Saline solution
219528193|NCT04633109|PROCEDURE|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
219528194|NCT04633109|DIAGNOSTIC_TEST|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
219528195|NCT04633109|DIAGNOSTIC_TEST|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
219528196|NCT04633109|DIAGNOSTIC_TEST|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
219615372|NCT06995391|BEHAVIORAL|Alcohol Abstinence|Participants randomized to Alcohol Abstinence will receive weekly app and text-based messaging encouraging avoiding all alcohol consumption.
219615373|NCT03390803|OTHER|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
219615374|NCT06538415|OTHER|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
218915147|NCT06150612|BEHAVIORAL|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
218915148|NCT01657383|PROCEDURE|HPB Surgery|Hepatopancreatico Biliary Surgery
218915149|NCT03446872|DRUG|ONIVYDE|irinotecan liposome injection
218915150|NCT03446872|DRUG|5-fluorouracil|a nucleoside metabolic inhibitor
218915151|NCT03446872|DRUG|Leucovorin|an active metabolite of folic acid
218915152|NCT02648308|BEHAVIORAL|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
218915153|NCT01612338|BEHAVIORAL|Targeted|Targeted letter and booklet
218915154|NCT01612338|BEHAVIORAL|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
218915155|NCT02359318|PROCEDURE|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
218915156|NCT02359318|PROCEDURE|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
219615375|NCT06538415|OTHER|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
218915157|NCT03481478|DIAGNOSTIC_TEST|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
219528197|NCT04633109|DIAGNOSTIC_TEST|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
219528198|NCT04633109|DIAGNOSTIC_TEST|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
219528199|NCT04633109|OTHER|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
218915158|NCT00186576|PROCEDURE|nonmyeloablative allogeneic hematopoietic cell transplant|
219528200|NCT04633109|OTHER|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
218915159|NCT00683436|DRUG|Adipiplon|bilayer tablets 6 mg
218915160|NCT00683436|DRUG|Placebo|Placebo
218915161|NCT00683436|DRUG|Ambien CR|Ambien CR 12.5 mg
218915162|NCT00683436|DRUG|Adipiplon|bilayer tablets 9 mg
219528201|NCT05813028|OTHER|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
219528202|NCT03280797|PROCEDURE|Blood sample|2ml blood taken into TruCulture tube
218915163|NCT01225874|DRUG|SC-PEG E. coli L-asparaginase|Given IM
218915164|NCT01225874|DRUG|cytarabine|Given IT
218915165|NCT01225874|DRUG|daunorubicin hydrochloride|Given IV
219615376|NCT04782076|DRUG|Dabigatran|Administered orally.
219615377|NCT04782076|DRUG|Selpercatinib|Administered orally.
219615378|NCT00462917|BEHAVIORAL|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
219615379|NCT00462917|BEHAVIORAL|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
218915166|NCT01225874|DRUG|dexamethasone|Given orally
218915167|NCT01225874|DRUG|methotrexate|Given IT
218915168|NCT01225874|DRUG|pegaspargase|Given IM
218915169|NCT01225874|DRUG|prednisone|Given orally
218915170|NCT01225874|DRUG|vincristine sulfate|Given IV
218915171|NCT00129402|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
219041860|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
218915172|NCT00129402|DRUG|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
218915173|NCT04645355|DRUG|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
218915174|NCT03802006|DIAGNOSTIC_TEST|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
218915175|NCT01527149|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
218915176|NCT01527149|DRUG|Cyclophosphamide|Given IV
218915177|NCT01527149|DRUG|Cytarabine|Given IV
218915178|NCT01527149|DRUG|Dexamethasone|Given IV or PO
218915179|NCT01527149|DRUG|Doxorubicin Hydrochloride|Given IV
218915180|NCT01527149|OTHER|Laboratory Biomarker Analysis|Correlative studies
218915181|NCT01527149|DRUG|Methotrexate|Given IV
218915182|NCT01527149|BIOLOGICAL|Ofatumumab|Given IV
219528203|NCT02644434|PROCEDURE|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.~Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
219528204|NCT02644434|PROCEDURE|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
219528205|NCT00229645|DRUG|Quetiapine Fumarate (Seroquel®)|
219528206|NCT07036588|DEVICE|Modified Transanal Drainage Tube|Patients with rectal adenocarcinoma will undergo elective laparoscopic/robotic low anterior resection. After the anastomosis is completed and the air leak test is confirmed to be negative, a modified TDT (occlusive balloon catheter) will be inserted. The balloon will be placed 5 cm above the anastomosis and filled under laparoscopic visualization (approximately 25 ml) to slightly dilate the intestinal lumen and occlude the intestinal cavity (under laparoscopic monitoring to ensure it does not affect the blood supply of the intestine). The external part of the tube will be sutured to the perianal skin and further secured with a 3M transparent dressing on the outside. It will be connected to a drainage bag (with an inner diameter greater than 8 mm) and left in place for 7 days, or until the drainage function is lost due to obvious defecation around the anal tube, at which point the catheter will be removed.
219615380|NCT00462917|BEHAVIORAL|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
219615381|NCT00462917|BEHAVIORAL|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
219615382|NCT02574598|DRUG|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
219615383|NCT02574598|DRUG|Docetaxel|Use on both arms as standard of care.
219615384|NCT05323708|BIOLOGICAL|Bmab 1000|60mg/ml Prefilled syringe single dose
219615385|NCT05323708|BIOLOGICAL|Prolia®|60mg/ml Prefilled syringe single dose
219615386|NCT03466450|DRUG|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
219615387|NCT03466450|DRUG|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
219615388|NCT02179762|BEHAVIORAL|moderate exercise intervention|Perform moderate exercise therapy
219615389|NCT02179762|BEHAVIORAL|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
218915183|NCT01527149|DRUG|Vincristine Sulfate|Given IV
218915184|NCT02472821|BEHAVIORAL|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
219615390|NCT02179762|OTHER|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
219615391|NCT02179762|OTHER|laboratory biomarker analysis|Correlative studies
219615392|NCT02179762|BEHAVIORAL|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
218915185|NCT02472821|BEHAVIORAL|Internet-based educational booster|Visit to an educational Web site focused on hearing health
218915186|NCT05625308|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
219615393|NCT02179762|BEHAVIORAL|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
219615394|NCT02179762|BEHAVIORAL|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
218915187|NCT00761423|BIOLOGICAL|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
218915188|NCT00761423|BIOLOGICAL|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
218915189|NCT00811122|RADIATION|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
218915190|NCT00811122|RADIATION|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
219528207|NCT07036510|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye.
219528208|NCT07036510|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
219615395|NCT02179762|BEHAVIORAL|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
219528209|NCT00047606|DRUG|IOP Lowering Medications|
218915191|NCT03889496|RADIATION|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
218915192|NCT03082521|BEHAVIORAL|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
219615396|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
219528210|NCT05363111|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
218915193|NCT05943691|DRUG|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
218915194|NCT05943691|DRUG|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
219615397|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
219528211|NCT05363111|BIOLOGICAL|Daratumumab|Given IV
219615398|NCT04910100|DRUG|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
219615399|NCT04910100|DRUG|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
219528212|NCT05363111|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
219041861|NCT04990934|BEHAVIORAL|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
218915195|NCT03913455|DRUG|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
219041862|NCT01228630|DRUG|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
219041863|NCT01228630|DRUG|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
219528213|NCT01458561|DEVICE|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
219528214|NCT01458561|DEVICE|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
219528215|NCT05378724|DEVICE|Hospital Fit 2.0, HFITAPP0, release 05, Maastricht Instruments B.V., the Netherlands|Hospital Fit consists of a smartphone app combined to the MOX accelerometer. Hospital Fit provides patients and physiotherapists direct feedback on patients' physical activity behavior. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. Hospital Fit also gives patients insight into their own recovery process. During every treament, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
219528216|NCT00789230|PROCEDURE|primary suture closure|primary suture closure of hernia
219528217|NCT00789230|DEVICE|mesh enforced closure|mesh enforced closure of hernia
219528218|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
219528219|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
219528220|NCT04019951|DIETARY_SUPPLEMENT|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
219615400|NCT05401981|OTHER|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
219615401|NCT06018467|DRUG|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
218915196|NCT03913455|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 5
218915197|NCT05104138|DRUG|Eplerenone|The patients underwent eplerenone treatment for 6 months
218915198|NCT05104138|DEVICE|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
218915199|NCT03125395|DRUG|LUM/IVA|Participants received LUM/IVA every q12h.
218915200|NCT01611714|OTHER|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
218915201|NCT01611714|OTHER|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
218915202|NCT03636074|PROCEDURE|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
219528221|NCT01304823|DIETARY_SUPPLEMENT|lactisole|flavoring agent/sweet taste antagonist
219528222|NCT01304823|OTHER|mixed liquid meal|Ensure Plus
219615402|NCT06018467|DIETARY_SUPPLEMENT|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
219615403|NCT06018467|DIETARY_SUPPLEMENT|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
219615404|NCT06997848|PROCEDURE|colonic stent|colonic stent deployment
219528223|NCT02381834|PROCEDURE|Bladder stimulation technique|
219528224|NCT04355104|BEHAVIORAL|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
219528225|NCT04355104|BEHAVIORAL|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
219528226|NCT00878878|DRUG|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
219528227|NCT00878878|DRUG|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
219528228|NCT02071797|DEVICE|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
218915203|NCT02199184|DRUG|Cyclophosphamide|Given IV
218915204|NCT02199184|DRUG|Doxorubicin Hydrochloride|Given IV
219528229|NCT01239862|OTHER|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
219528230|NCT04466553|DEVICE|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
219528231|NCT01395563|BEHAVIORAL|strength training|strength training, high intensity, twice up to 3 times per week
219615405|NCT02051556|BEHAVIORAL|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
219615406|NCT02051556|BEHAVIORAL|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
219615407|NCT02051556|BEHAVIORAL|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
219615408|NCT07005726|BIOLOGICAL|BCG Vaccine|The WHO-prequalified BCG-Japan or BCG-Denmark
219615409|NCT05712395|BEHAVIORAL|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
218915205|NCT02199184|DRUG|Etoposide|Given IV
218915206|NCT02199184|BIOLOGICAL|Ofatumumab|Given IV
218915207|NCT02199184|DRUG|Prednisone|Given PO
218915208|NCT02199184|BIOLOGICAL|Rituximab|Given IV
218915209|NCT02199184|DRUG|Vincristine Sulfate|Given IV
218915210|NCT00037843|DRUG|I-131 Iodocholesterol|
218915211|NCT04218240|DRUG|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
218915212|NCT04218240|DRUG|Placebo oral tablet|oral Placebo
218915213|NCT04218240|DRUG|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
218915214|NCT06027580|DEVICE|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
218915215|NCT06027580|OTHER|Standard Care Therapy option|Standard of care Therapy without the use of trunk orthosis
219041864|NCT01358617|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219041865|NCT02957175|OTHER|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
219041866|NCT04859868|DEVICE|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
219041867|NCT00244712|DRUG|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
219041868|NCT00244712|DRUG|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
219528232|NCT05316922|DRUG|Levothyroxine|Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
219528233|NCT04365309|DRUG|Aspirin 100mg|on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
218915216|NCT06070454|DIAGNOSTIC_TEST|Vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
218915217|NCT06582901|BEHAVIORAL|Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)|Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
218915218|NCT06582901|BEHAVIORAL|Enhanced - Treatment as Usual|The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
218915219|NCT05467007|DIAGNOSTIC_TEST|BioFire® Respiratory Panel 2.1-EZ|BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
218915220|NCT04488679|OTHER|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
218915221|NCT05876689|DEVICE|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
218915222|NCT05062655|OTHER|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
218915223|NCT01643668|DRUG|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
218915224|NCT01643668|DRUG|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
218915225|NCT01643668|PROCEDURE|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
218915226|NCT03304561|OTHER|Traditional rehabilitation|traditional ACL rehabilitation program
218915227|NCT03304561|OTHER|Cross-over training|Cross-over training addition to the traditional rehabilidation
218915228|NCT02495428|PROCEDURE|Kinesio Tape Method|
219528234|NCT06424145|DIAGNOSTIC_TEST|Superior radial artery|Upper radial artery, 1 ml of lidocaine
219528235|NCT06424145|DIAGNOSTIC_TEST|Right side of radial artery|Right side of the radial artery,1ml of lidocaine
219528236|NCT04832399|DRUG|Natalizumab|As described in the treatment arm.
219528237|NCT02961309|DRUG|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
219528238|NCT00343278|DRUG|Valaciclovir Hydrochloride|
219528239|NCT00674505|DEVICE|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
219528240|NCT02970656|BEHAVIORAL|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
219528241|NCT01215266|DRUG|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
218915229|NCT03549923|DEVICE|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
218915230|NCT03549923|DEVICE|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
218915231|NCT03549923|DRUG|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
218915232|NCT03549923|DRUG|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
218915233|NCT01025908|BEHAVIORAL|Psychotherapy|Cognitive Behavioral Therapy
218915234|NCT01025908|BEHAVIORAL|Supportative psychotherapy|Supportative psychotherapy
219528242|NCT01215266|DRUG|Placebo|Day 3-21 2x2 800 mg(milligram) daily
219528243|NCT05008640|DEVICE|TrueLoo™|TrueLoo™ is an Internet-connected, smart toilet seat that uses computer vision technology to log and capture daily bowel movements and urinations. This data is then categorized by physical excreta characteristics to train and develop machine learning algorithms that are intended to eventually identify significant changes in stool and urine in real-time.
219528244|NCT01353469|DRUG|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
219528245|NCT01353469|DRUG|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
219528246|NCT02222805|PROCEDURE|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
219528247|NCT02222805|PROCEDURE|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
219528248|NCT01523730|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
219615410|NCT05426369|BIOLOGICAL|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
219615411|NCT06072859|OTHER|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
219615412|NCT06072859|OTHER|Forest oils and audio-visual forest exposure|60mls Limonene in 200mls water humidified with a diffuser and audiovisual Forest sights and sounds on Surface Pro tablet.
218915235|NCT01422096|DRUG|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if \> 37.5 kg im once
218915236|NCT04079439|BEHAVIORAL|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
218915237|NCT02799836|DEVICE|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
218915238|NCT03797651|DRUG|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
218915239|NCT03797651|DRUG|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
218915240|NCT06281587|PROCEDURE|penetrating keratoplasty|replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
218915241|NCT04595071|DEVICE|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
218915242|NCT06512584|DRUG|PJ009|subcutaneous injections, 0.05 mg/kg once daily
218915243|NCT06512584|DRUG|PJ009 Placebo|subcutaneous injections, once daily
219041869|NCT00249470|BEHAVIORAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
219041870|NCT00249470|BEHAVIORAL|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
219041871|NCT04436523|DEVICE|Blood flow restriction (Delfi Personalized Tourniquet System)|The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
219041872|NCT04436523|OTHER|Standard rehabilitation|Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
219204534|NCT06870292|DRUG|Drug therapy group|Subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. Oral antihistamines or nasal antihistamines are preferred, and nasal hormones (budesonide nasal spray), or a combination of two or three drugs, may be used in severe cases.
219528249|NCT01523730|DEVICE|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
219528250|NCT04769648|DRUG|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
219528251|NCT04769648|DRUG|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
219528252|NCT04257474|BEHAVIORAL|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
219528253|NCT04257474|BEHAVIORAL|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
219528254|NCT01249222|PROCEDURE|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
219528255|NCT01249222|OTHER|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
219528256|NCT01221922|DEVICE|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
219528257|NCT02160925|OTHER|Preoperative 99mTc-Sestamibi SPECT/CT|
219528258|NCT01882257|DEVICE|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
218915244|NCT03701958|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
218915245|NCT02122016|DEVICE|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
218915246|NCT02122016|OTHER|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
218915247|NCT03253796|BIOLOGICAL|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
218915248|NCT03253796|BIOLOGICAL|Placebo|Injections of matching placebo for golimumab.
219041873|NCT00819416|DRUG|5% albumin|5% albumin for the first 7 days of care in the ICU
219528259|NCT01882257|DEVICE|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
219528260|NCT05168670|COMBINATION_PRODUCT|Protection of eyes with tinted soft scleral eye shields|In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids
219528261|NCT02259270|OTHER|Record review|Record review. No intervention with patient or physician. No effect on outcome.
219528262|NCT02259270|OTHER|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
219528263|NCT04152174|PROCEDURE|Combined extracorporeal blood purification|Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
219528264|NCT04152174|PROCEDURE|CRRT|Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
219528265|NCT04249271|OTHER|serum sampling|repeated serum sampling during pregnancy and thereafter
219528266|NCT00162474|DRUG|Warfarin|
219528267|NCT00162474|DRUG|Phenytoin|
219528268|NCT01375660|DRUG|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
219528269|NCT01375660|DRUG|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
219528270|NCT04468503|OTHER|Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional|In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
219528271|NCT03116659|DRUG|Doxycycline|Doxycycline 100 mg PO BID x 14 days
219528272|NCT03116659|DRUG|Imiquimod|up to 2 packs 3/ week x 28 days
219615413|NCT07010276|DEVICE|DBS Arm|Patients in the DBS treatment arm will undergo surgical DBS implantation.
219615414|NCT07010276|DEVICE|VNS arm|Patients in the VNS treatment arm will undergo surgical VNS implantation.
219615415|NCT06756035|DRUG|CT-95|Weekly IV dosing
219041874|NCT00819416|DRUG|Normal Saline|Normal Saline for the first 7 days of care in the ICU
219528273|NCT04446559|PROCEDURE|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
219528274|NCT06314022|OTHER|Mobile application for colonoscopy preparation instructions|The APP will also consider the comorbidities and drugs of each patient. It can be adapted to the different types of laxative (4, 2 or 1 litre) and notify the need to discontinue anticoagulant and/or antiplatelet treatments by contacting with the primary care physician. Additionally, the application may ask short questions to the patient to control the laxative intake instruction. The user must confirm the appointment 48 hours in advance.
219528275|NCT01336322|DRUG|Metformin|Metformin 850 mg bid
219528276|NCT01336322|DRUG|Sitagliptin|Sitagliptin 100 mg qd
219615416|NCT01949662|DRUG|Lorazepam|3 mg by vein one time only.
219615417|NCT01949662|DRUG|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
219615418|NCT01949662|DRUG|Haloperidol decanoate|8 mg/day by vein.
219615419|NCT01949662|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
219615420|NCT04891510|DEVICE|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
219615421|NCT04891510|DEVICE|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
219615422|NCT04891510|PROCEDURE|Viality|The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
219041875|NCT00624806|BEHAVIORAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
219528277|NCT01336322|DRUG|Sitagliptin + Metformin|sitagliptin 100mg + metformin 850mg
219528278|NCT05000658|DRUG|Dexamethasone phosphate|HSC injection of 4mL
219528279|NCT06181175|DRUG|PEAPROSTIL 600 + Tamsulosin 0.4 mg|PEAPROSTIL 600 mg one sachet oral daily+ Tamsulosin 0.4 mg one tablet oral daily
219528280|NCT06181175|DRUG|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg one tablet oral daily
219528281|NCT06181175|DRUG|PEAPROSTIL 600 mg|PEAPROSTIL 600 mg one sachet oral daily
219528282|NCT04529863|DRUG|Tocilizumab|Tocilizumab claim is used as the reference group.
219528283|NCT04529863|DRUG|Abatacept|Abatacept claim is used as the exposure group.
219528284|NCT02058498|BEHAVIORAL|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
219528285|NCT00487565|DEVICE|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
219528286|NCT04264130|DRUG|Artesunate-Pyronaridine|Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
219528287|NCT04264130|DRUG|Artemether-Lumefantrine|subjects received artemether-lumefantrine according to their body weight twice per day for three days.
219041876|NCT00624806|BEHAVIORAL|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
219528288|NCT04264130|DRUG|Artefenomel-Ferroquine|Subject received a single dose of artefenomel-ferroquine according to their body weight
219528289|NCT01163825|DRUG|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
219528290|NCT04128826|OTHER|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
219528291|NCT03217903|DIAGNOSTIC_TEST|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
219528292|NCT02209441|DRUG|Phase I Dose-finding Study of Sorafenib Study|
219528293|NCT00304603|OTHER|No intervention|No treatment was given to the patients as this is an observational study.
219528294|NCT04792450|DEVICE|Thermography|Measure Temperature using Thermal Camera
219528295|NCT04792450|DEVICE|Tympanic Thermometer|Measure Temperature using Tympanic Thermometer
219528296|NCT04792450|DEVICE|Forehead Thermometer|Measure Temperature using Forehead Temperature
219528297|NCT04792450|DEVICE|62 Max + Infra-red thermometer|Measure Temperature using 62 Max + Infra-red thermometer
219528298|NCT03585790|DEVICE|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
219528299|NCT03585790|DEVICE|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
219528300|NCT02011295|PROCEDURE|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
219528301|NCT02011295|OTHER|Bone Marrow Aspirate injection|
219528302|NCT04073394|BEHAVIORAL|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
219528303|NCT04073394|BEHAVIORAL|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
219528304|NCT03660384|PROCEDURE|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
219041877|NCT00684606|DRUG|Oxytocin IV|5 miu/1000ml Glu/Saline
219528305|NCT03660384|PROCEDURE|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
219528306|NCT04908007|OTHER|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
219528307|NCT04908007|OTHER|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
219041878|NCT02361710|PROCEDURE|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
219528308|NCT04908007|OTHER|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
219528309|NCT04908007|OTHER|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
219528310|NCT04135235|DRUG|TAF|Propofol tenofovir fumarate
219528311|NCT04135235|DRUG|TDF|Dipirofurate fumarate tenofovir
219528312|NCT02753959|OTHER|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
218915249|NCT02285855|DRUG|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
219615423|NCT07017569|BEHAVIORAL|Mobile health application|"This group will receive the mHELP mobile and watch application with full functionality which provides weekly self-assessment and self-reported events PLUS self-management functionality. The self- management functionality includes additional on-demand features (see the attached list of features). These include~* a breath functionality that provides a times breathing exercise similar to the one provided by the Apple iWatch; users can see changes in their heart rate during the breathing exercise and will see a summary of heart rate changes~* a calendar features that allows students to upload their class schedule and see different activities such as self-assessments~* a journaling feature that allows participants to write a journal~* a task list to take note of major tasks and add them to calendar~* a set of relaxation media including videos and audios that participants can use on demand"
219615424|NCT07017634|DEVICE|Novosis Putty|Single Level TLIF surgery with Novosis Putty
219615425|NCT07017634|OTHER|Standard of Care|Single Level TLIF surgery with standard of care bone graft
218915250|NCT02285855|OTHER|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
219528313|NCT02753959|OTHER|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
219528314|NCT00834743|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
219528315|NCT00834743|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
218915251|NCT02285855|RADIATION|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
218915252|NCT00181896|DRUG|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
219204535|NCT06442995|DRUG|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
219615426|NCT05609981|OTHER|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
218915253|NCT01581801|PROCEDURE|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
218915254|NCT01581801|PROCEDURE|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
218915255|NCT04662385|DRUG|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
218915256|NCT04662385|DRUG|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
218915257|NCT00528112|DRUG|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
218915258|NCT00528112|DRUG|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
218915259|NCT03403803|DEVICE|Optune|"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."
218915260|NCT04504500|BEHAVIORAL|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
218915261|NCT04504500|BEHAVIORAL|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
218915262|NCT04504500|BEHAVIORAL|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
218915263|NCT04504500|BEHAVIORAL|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
218915264|NCT04504500|BEHAVIORAL|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
218915265|NCT04504500|BEHAVIORAL|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
218915266|NCT04504500|BEHAVIORAL|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
218915267|NCT04504500|BEHAVIORAL|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
218915268|NCT04504500|OTHER|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
219204536|NCT06442995|DRUG|Injection of Isotonic saline + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
219204537|NCT06752057|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
219528316|NCT04855058|OTHER|online survey(or phone survey)|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over google survey(or the phone survey) for patients.
219528317|NCT02507128|DRUG|liraglutide|Liraglutide were taken 30 min before PCI.
219528318|NCT02507128|DRUG|placebo|Placebo were taken 30 min before PCI.
219528319|NCT03867721|DEVICE|Ventilator|Comparison of two ventilators for mouthpiece ventilation
219528320|NCT00864591|PROCEDURE|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
219528321|NCT00864591|PROCEDURE|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
219615427|NCT07017777|BIOLOGICAL|PCV13i|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
219615428|NCT07017777|BIOLOGICAL|Prevnar 13|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
219615429|NCT07017244|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
219615430|NCT07017244|DIETARY_SUPPLEMENT|Active comparator|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
219615431|NCT07017322|DEVICE|Alpha-Stim AID|Subjects will receive non-invasive cranial electrotherapy stimulation (CES) treatment in 20-minute group sessions taking place immediately prior to breakfast, lunch, and dinner. This study uses the Alpha-Stim AID® CES device which will be set to the highest amplitude that is tolerated by the participant (with a minimum of 200 microampere (µA) and a maximum of 500 µA stimulation) at 0.5 hertz for a duration of 20 minutes per session, 3 sessions per day, for 3 separate days of stimulation (180 minutes of stimulation total).
219615432|NCT07017231|OTHER|histamine dihydrochloride|A small drop of histamine dihydrochloride (1%, in saline) will be applied to two previously determined areas followed by a prick through the drop.
219615433|NCT07017231|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
219615434|NCT07017907|DEVICE|Heart rate-based AI software for detecting thyrotoxicosis|A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.
219528322|NCT00000966|DRUG|Azithromycin|
219528323|NCT00000966|DRUG|Pyrimethamine|
219528324|NCT00000966|DRUG|Leucovorin calcium|
219528325|NCT05298267|DEVICE|Do Not Disturb While Driving|Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
219615435|NCT04748822|OTHER|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
219615436|NCT07016906|OTHER|MRI|Knee MRI at different degrees of flexion
219615437|NCT07017153|OTHER|Questionnaire B|Questionnaire regarding patient decision aid: How Do I Control My Blood Pressure? Lifestyle Options and Choices of Medicines.
219615438|NCT07017153|OTHER|Questionnaire A|Questionnaire regarding patient decision aid: Hypertension - How to Prevent Cardiovascular Diseases
219615439|NCT07018310|OTHER|blood sampling|Additional blood sampling as part of routine care
219615440|NCT07016763|DIETARY_SUPPLEMENT|Oral fatty acid|Intervention therapy (treatment group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) and oral supplementation of FAs (550 mg/tablet), vitamin B6 (0.21 mg/tablet), perilla frutescens (20 mg/tablet) and liquorice (200/mg/tablet) (2 tablets a day with meals)
219615441|NCT07016763|DRUG|Mometasone Furoate Nasal Spray (MFNS)|Standard therapy (control group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) only
219615442|NCT07018063|DRUG|nab-paclitaxel|Nab-paclitaxel is administered as an intravenous (IV) infusion at a dose of 125 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
219204538|NCT06752057|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
219615443|NCT07018063|DRUG|oxaliplatin|Oxaliplatin is administered as an intravenous (IV) infusion at a dose of 85 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
219041879|NCT04527861|PROCEDURE|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
219041880|NCT04527861|PROCEDURE|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
219041881|NCT06242210|OTHER|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
219528326|NCT05101044|BEHAVIORAL|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
219528327|NCT00425672|BIOLOGICAL|ONTAK|Given IV
219528328|NCT00425672|OTHER|flow cytometry|Correlative studies
219528329|NCT00425672|OTHER|immunohistochemistry staining method|Correlative studies
219528330|NCT00425672|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219528331|NCT00425672|OTHER|laboratory biomarker analysis|Correlative studies
219528332|NCT00425672|GENETIC|protein expression analysis|Correlative studies
219528333|NCT04423263|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
219528334|NCT04423263|PROCEDURE|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
219528335|NCT00086996|DRUG|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
219615444|NCT07018063|DRUG|S-1|"S-1 is administered orally twice daily (BID) on days 2 to 15 of each 3-week cycle, for a total of 3 cycles. The dose is based on body surface area (BSA) as follows:~BSA \< 1.25 m²: 40 mg BID (total 80 mg/day); BSA 1.25-1.5 m²: 50 mg BID (total 100 mg/day); BSA \> 1.5 m²: 60 mg BID (total 120 mg/day)"
219615445|NCT07018063|DRUG|sintilimab|Sintilimab is administered as an intravenous (IV) infusion at a fixed dose of 200 mg on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
219615446|NCT07018063|PROCEDURE|D2 Gastrectomy|Curative-intent D2 radical gastrectomy is performed 3 to 6 weeks after completion of neoadjuvant therapy. The procedure includes either proximal, distal or total gastrectomy depending on tumor location, with en bloc resection of the stomach and systematic D2 lymphadenectomy according to Japanese Gastric Cancer Association (JGCA) guidelines. D2 lymph node dissection involves removal of both perigastric (N1) and second-tier (N2) lymph nodes.
219615447|NCT07017725|DRUG|CID-103|Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of six months.
219615448|NCT01870089|DEVICE|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
219615449|NCT05975073|DRUG|AMG 193|Administered PO
219615450|NCT05975073|DRUG|IDE397|Administered PO
219528336|NCT00086996|DRUG|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
219528337|NCT00086996|PROCEDURE|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
219528338|NCT00086996|RADIATION|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
219528339|NCT03447717|DEVICE|ActiGait|implanted device for peroneal nerve stimulation
219528340|NCT05959681|DEVICE|Compression garment with Vari-pad microdots ink-printed on inside.|Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
219528341|NCT02983110|PROCEDURE|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
219528342|NCT02983110|PROCEDURE|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
219528343|NCT02983110|PROCEDURE|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
219528344|NCT00659321|DRUG|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
219615451|NCT07034820|DIETARY_SUPPLEMENT|Nimsai Herbal|Oral Nimsai Herbal is a novel botanical formulation, administered as one 600 mg capsule per day for a duration of 10 consecutive days. It is specifically designed to target the underlying venous congestion hypothesized by the War-Drill Model, aiming to promote hemorrhoid regression and symptom resolution.
219615452|NCT07034820|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of an oral placebo, formulated to be identical in appearance, taste, and packaging to Nimsai Herbal. It was administered as one capsule per day for 10 consecutive days to ensure blinding and serve as a control for comparison.
219615453|NCT06708338|PROCEDURE|Needle bevel orientation for arteriovenous fistula puncture|"For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group"
219615454|NCT06705816|OTHER|None interventional|This is an observational study
219615455|NCT01001754|DRUG|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
219615456|NCT01001754|DRUG|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
219615457|NCT01001754|DRUG|Ribavirin|Daily oral administration (400-600 mg BID)
219615458|NCT05845983|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
219615459|NCT05845983|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
219615460|NCT07045818|BEHAVIORAL|Emotional provocation task involving multisensory aversive stimuli|To elicit hemodynamic responses in the dorsolateral prefrontal cortex (DLPFC) and activate the sympathetic nervous system, we used a standardized multisensory aversive stimulation protocol comprising: (i) Visual stimuli: 72 high-arousal images from the GAPED database (moral violations, legal violations, fear-related) shown in 12 blocks (6 images/block, 5 s each) with 20 s baseline and 30 s stimulation; (ii) Auditory stimuli: each block paired with 30 s of calibrated 90 dB(A) high-frequency narrowband white noise (4 kHz center frequency), shown to increase heart rate; (iii) Cold-pain stimuli: during each block, participants placed both hands on 0 °C ice-filled bottles for pain-induced sympathetic activation. This tri-modal task reliably provokes DLPFC engagement and autonomic responses.
219615461|NCT06731270|BIOLOGICAL|Atezolizumab|Given atezolizumab
219528345|NCT00659321|DRUG|placebo|16 weeks treatment with placebo
218915269|NCT04504500|OTHER|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
219528346|NCT03875755|DIETARY_SUPPLEMENT|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
219528347|NCT03875755|OTHER|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
219528348|NCT00149500|BEHAVIORAL|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
219528349|NCT04000100|PROCEDURE|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
219528350|NCT04898361|PROCEDURE|PFO closure|Interventional closure of a patent foramen oval preceded by an electrophysiological study
219528351|NCT04300673|PROCEDURE|Radio guided surgery (RGS) using Indium-labelled PSMA|Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
219528352|NCT01758627|DRUG|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
219528353|NCT00004562|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
219528354|NCT00004562|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
219528355|NCT00004562|PROCEDURE|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
219528356|NCT00004562|DRUG|ACE Inhibitors|Participants will receive ACE inhibitors.
219528357|NCT00567762|DRUG|FK506|Opthalmic suspension
219528358|NCT00567762|DRUG|placebo|placebo eye drops
219528359|NCT05884762|OTHER|electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist."
219528360|NCT05884762|OTHER|SHAM electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the SHAM group, the visual feedback and haptic feedback are randomly generated"
219528361|NCT00001862|DRUG|Enbrel|
219528362|NCT02964260|DRUG|Chemotherapy drug|Doxorubicin/Platinum agents
219528363|NCT02964260|DRUG|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
219528364|NCT02964260|PROCEDURE|Simultaneously|1-3 days
219528365|NCT02964260|PROCEDURE|Sequentially|1 month
219528366|NCT02964260|DEVICE|Ablation|Radiofrequency ablation/Microwave ablation
219615462|NCT06731270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219615463|NCT06731270|BIOLOGICAL|Cemiplimab|Given cemiplimab
219615464|NCT06731270|PROCEDURE|Computed Tomography|Undergo CT
219615465|NCT06731270|DRUG|Diclofenac Potassium|Given PO
219615466|NCT06731270|OTHER|Electronic Health Record Review|Ancillary studies
219615467|NCT06731270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219615468|NCT06731270|BIOLOGICAL|Nivolumab|Given nivolumab
219615469|NCT06731270|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
219615470|NCT06731270|PROCEDURE|Positron Emission Tomography|Undergo PET
219615471|NCT06718439|PROCEDURE|Restrictive Transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 70 g/L or to maintain a hemoglobin target range of 70-80 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
219615472|NCT06718439|PROCEDURE|Liberal transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 90 g/L or to maintain a hemoglobin target range of 90-100 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
219615473|NCT06924853|OTHER|Platelet lysate|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis (Beckman Coulter DxH 500 Series). Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. Once flow is confirmed, the physician will inject 4mL of the PL, and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest. A 0.22 micron filter will be used.
219041882|NCT06242210|OTHER|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
219528367|NCT05831462|DRUG|Ticagrelor 60mg|Standard vs Low dose ticagrelor in post PPCI patients
219528368|NCT03871920|OTHER|physical therapy treatment|any treatment chosen by treating physiotherapist
219528369|NCT01652794|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219528370|NCT01652794|DRUG|carboplatin|Given IV
219528371|NCT01652794|DRUG|gemcitabine hydrochloride|Given IV
219041883|NCT00500370|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
219041884|NCT00500370|DRUG|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
219528372|NCT01652794|OTHER|laboratory biomarker analysis|Optional correlative studies
218915270|NCT04504500|OTHER|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
218915271|NCT04504500|OTHER|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
218915272|NCT04504500|OTHER|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
219204539|NCT06752057|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219528373|NCT01652794|OTHER|pharmacogenomic studies|Optional correlative studies
219528374|NCT04104165|DEVICE|Foley Catheter|Foley catheter used for treatment of urinary retention
219528375|NCT05700565|OTHER|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
219528376|NCT05700565|OTHER|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
219528377|NCT03257722|DRUG|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
219528378|NCT03257722|DRUG|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
219528379|NCT03929822|DIAGNOSTIC_TEST|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
219528380|NCT02648334|DEVICE|IN.PACT drug coated balloon|
219528381|NCT02648334|DEVICE|Lutonix drug coated balloon|
219528382|NCT04274686|DEVICE|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
219528383|NCT04274686|OTHER|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
219528384|NCT02326610|DRUG|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
219204540|NCT06753682|BEHAVIORAL|Healthy Plant Based Diet|Registered Dietician will assist in modifying the patient's diet
219528385|NCT00489112|DRUG|Alfuzocine XL 10 mg once a day|
219528386|NCT05445310|DRUG|Furmonertinib|Furmonertinib 80mg/d
219528387|NCT02738723|RADIATION|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
219528388|NCT02738723|RADIATION|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
219528389|NCT02738723|DRUG|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
219528390|NCT00376623|DRUG|BI 2536|Intravenous Infusion
219528391|NCT05899855|OTHER|No intervention|No intervention
219528392|NCT00034684|DRUG|Farnesyl Protein Transferase Inhibitor|
219528393|NCT00949585|OTHER|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
219528394|NCT01386593|DRUG|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
219528395|NCT01386593|DRUG|"Basel Cocktail"|
219528396|NCT01386593|DRUG|Basel cocktail + Rifampicin|
219528397|NCT02561793|DRUG|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
219528398|NCT02561793|DRUG|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
219528399|NCT01004237|DRUG|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
219528400|NCT01482377|DRUG|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
219615474|NCT06924853|OTHER|Saline control|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis; same as active treatment to maintain blinding. Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. (6) Once flow is confirmed, the physician will inject 4mL of sterile saline (0.9%), and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest.
218915273|NCT04504500|OTHER|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
218915274|NCT04504500|OTHER|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
218915275|NCT00556569|OTHER|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
218915276|NCT02403557|BEHAVIORAL|Waitlist|Weekly check up.
218915277|NCT02403557|BEHAVIORAL|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
218915278|NCT02718898|DRUG|Ixekizumab|Administered SC
218915279|NCT02718898|DRUG|Placebo|Administered SC
218915280|NCT01161940|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
218915281|NCT01161940|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
218915282|NCT02659163|BEHAVIORAL|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
218915283|NCT02659163|BEHAVIORAL|mHealth scale|A wireless scale used by participants to measure and record daily weight.
218915284|NCT02659163|BEHAVIORAL|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
219528401|NCT01482377|DRUG|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.
219528402|NCT01482377|DRUG|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
219528403|NCT01482377|DRUG|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
219528404|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
219528405|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
218915285|NCT02659163|BEHAVIORAL|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
218915286|NCT02659163|BEHAVIORAL|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
218915287|NCT02659163|BEHAVIORAL|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
218915288|NCT03252769|OTHER|Self-sampling|
218915289|NCT00589225|GENETIC|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
218915290|NCT01861808|OTHER|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
218915291|NCT03784443|DRUG|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
218915292|NCT03784443|DRUG|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
218915293|NCT03784443|PROCEDURE|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
218915294|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous
219528406|NCT00286754|BEHAVIORAL|UC|Usual Care
219528407|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
219528408|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
219528409|NCT00286754|BEHAVIORAL|UC|Usual Care
219528410|NCT02409953|OTHER|Lying in a bath during 2 hours|
219528411|NCT02409953|OTHER|Lying in a bed during 2 hours|
219528412|NCT02651753|DRUG|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
219528413|NCT02651753|DRUG|CKD-337|Test Drug: CKD-337
219528414|NCT04138147|PROCEDURE|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
219528415|NCT04138147|PROCEDURE|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
219528416|NCT02625077|PROCEDURE|Laparoscopic gastroesophageal valvuloplasty|
219528417|NCT02625077|PROCEDURE|Laparoscopic Toupet fundoplication|
219528418|NCT01532297|DEVICE|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
219528419|NCT01532297|DEVICE|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
219528420|NCT03310697|OTHER|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
219615475|NCT06889350|DRUG|HD-P023|Single dose administration of HD-P023
218915295|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous.
219615476|NCT06889350|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
219615477|NCT06889350|DRUG|Empagliflozin High|Single does administration of Teneligliptin and Empagliflozin High
219615478|NCT07045116|DEVICE|Electronic anesthesia|The child will receive electronic anesthesia to the right side of the upper jaw; the pain and anxiety level will be assessed.
219615479|NCT07045116|DEVICE|Conventional anesthesia|The child will receive conventional anesthesia to the maxillary left side
219615480|NCT04229667|OTHER|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
219615481|NCT06741345|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles for oral administration
219615482|NCT03245112|DRUG|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
219615483|NCT01872286|DEVICE|AKE-1|
219615484|NCT01872286|DEVICE|Pillcam SB2|
218915296|NCT01384175|PROCEDURE|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
218915297|NCT01384175|PROCEDURE|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
218915298|NCT01384175|PROCEDURE|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
218915299|NCT01243164|OTHER|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
218915300|NCT02462694|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
218915301|NCT02462694|BEHAVIORAL|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
218915302|NCT00611936|DRUG|Placebo|Placebo
218915303|NCT00611936|DRUG|Atomoxetine|20mg maximum of d-amphetamine
218915304|NCT03458338|DIAGNOSTIC_TEST|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
218915305|NCT00894803|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
219528421|NCT03310697|OTHER|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
218915306|NCT00894803|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
219528422|NCT01773330|PROCEDURE|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
219528423|NCT01773330|DIETARY_SUPPLEMENT|Gatorade|The patient will be given Gatorade to drink at various times during the study.
219204541|NCT06869681|DRUG|Topical Sertaconazole 2%|After cleaning the identified lesions, the patients will topically self-apply the both products/creams using a cotton swab applicator, where the applied amount will be able to make the lesions be covered with a thin layer of medication. Both the creams will be applied topically twice daily for 4 weeks.
219528424|NCT01773330|OTHER|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
219528425|NCT01773330|OTHER|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
219528426|NCT01773330|PROCEDURE|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
219204542|NCT06869681|DRUG|Clotrimazole 1%|Same as above
219528427|NCT01773330|PROCEDURE|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
218915307|NCT04871906|OTHER|stretching exercises|Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
218915308|NCT00253812|PROCEDURE|flexible sigmoidoscopy|
219528428|NCT00492960|DRUG|larazotide acetate|gelatin capsules
219528429|NCT00492960|DRUG|placebo|gelatin capsules
219528430|NCT00492960|DIETARY_SUPPLEMENT|900 mg gluten|gelatin capsules
219528431|NCT06326762|OTHER|comparaison|description indicate
219528432|NCT02867280|DRUG|Sorafenib|red round tablet
219528433|NCT05595694|OTHER|No intervention|This is a retrospective review of 1320 patients in our database who underwent elective primary and revision TJA in Queen Mary Hospital, Hong Kong from from January 2018 to December 2021. No intervention was involved.
219528434|NCT03543462|DEVICE|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
219204543|NCT06875375|DIETARY_SUPPLEMENT|probiotic LH76|Intervention with LH76 (30 billion CFU/ day, 3g) was administered daily for 8 weeks. Store in a cool, dry place.
219204544|NCT06875375|DIETARY_SUPPLEMENT|Placebo|Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.
219204545|NCT06760429|PROCEDURE|Pectoral Nerve Block Type II|In the PECS II group,once the needle tip reached the fascial plane between the pectoralis minor and serratus anterior muscles and there was no blood aspiration, 15 mL of 0.375% ropivacaine was injected. Then the needle was withdrawn until the needle tip reached the fascial plane between the pectoralis major and pectoralis minor muscles, and another 15 mL of 0.375% ropivacaine was injected. After the nerve block was implemented, the area of sensory block was marked, and the spread of the local anesthetic was monitored by ultrasound. Alcohol swabs and pinprick tests were used to detect cold and pain sensations.
219204546|NCT06760429|PROCEDURE|Subserratus Plane Block|In the RISS group,the linear ultrasound probe was placed in the sagittal plane at the level of the 5th to 6th thoracic vertebrae (T5-6), just medial to the scapula, to identify the trapezius, rhomboid major, and intercostal muscles. A 21-gauge puncture needle was inserted in a cranial-to-caudal direction into the plane between the rhomboid major and intercostal muscles. When there was no blood aspiration, 20 mL of 0.375% ropivacaine was injected. After that, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for performing the subserratus block at the level of the 8th to 9th thoracic vertebrae (T8-9). The puncture needle was advanced from the previous position, and when there was no blood aspiration again, an additional 20 mL of 0.375% ropivacaine was injected.
219615485|NCT05372965|OTHER|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
219615486|NCT05372965|OTHER|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
219615487|NCT01799044|DEVICE|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
219615488|NCT03653884|DIAGNOSTIC_TEST|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
218915309|NCT03173885|DIAGNOSTIC_TEST|Preimplantation Genetic Screening|"* laser assisted hatching~* trophectoderm biopsy~* next generation sequencing"
218915310|NCT04228471|PROCEDURE|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
218915311|NCT04228471|PROCEDURE|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
219528435|NCT03482427|BEHAVIORAL|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
218915312|NCT04031599|DEVICE|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
218915313|NCT04031599|DEVICE|Insulin pump|Tandem Diabetes Care
219528436|NCT02336165|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
219528437|NCT02336165|RADIATION|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
219615489|NCT02845700|BEHAVIORAL|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
218915314|NCT04031599|DEVICE|Continuous glucose monitoring system|Dexcom G6
218915315|NCT04031599|DRUG|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
218915316|NCT04031599|OTHER|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
218915317|NCT04031599|OTHER|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
218915318|NCT04031599|OTHER|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
218915319|NCT04031599|OTHER|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
218915320|NCT04031599|OTHER|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
218915321|NCT04031599|OTHER|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
219528438|NCT02336165|BIOLOGICAL|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
219615490|NCT02845700|BEHAVIORAL|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
219615491|NCT03068039|OTHER|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
219615492|NCT03068039|OTHER|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
219615493|NCT01022697|OTHER|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
219615494|NCT05641844|DEVICE|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
218915322|NCT05414526|OTHER|InterCARE package|"The InterCARE package includes:~1. Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~2. Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~3. Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
219528439|NCT04351074|PROCEDURE|LIFT|ligation of the intersphincteric fistula track
219041885|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
219528440|NCT04351074|PROCEDURE|fistulectomy|excision of the fistulous track with its internal and external orifices
219528441|NCT00015626|DRUG|Metformin|
219528442|NCT00015626|PROCEDURE|skin biopsy|
219528443|NCT00015626|BEHAVIORAL|diet and exercise|
219528444|NCT00015626|DRUG|pioglitazone|
219528445|NCT00015626|DRUG|rosiglitazone|
219528446|NCT01579357|OTHER|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
219528447|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind+|Virtual Reality Exposure Self-Therapy led by a participant
219528448|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind|Treatment with Virtual Reality Exposure Therapy led by a therapist
219528449|NCT03895957|BEHAVIORAL|Cognitive Behavioral Therapy|Standard treatment for social phobia led by a therapist
219528450|NCT01911520|DRUG|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
219528451|NCT01911520|DRUG|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
219528452|NCT01911520|PROCEDURE|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
219528453|NCT01911520|PROCEDURE|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
219528454|NCT03274830|DEVICE|aneXys|150 patients with the aneXys cup
219528455|NCT05731674|OTHER|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
219528456|NCT06302686|DEVICE|engAGE system|The experimental group use the engAGE system at both healthcare organization and home. At the healthcare organization, the subject interacts with Pepper robot. The interaction is supervised by the formal caregivers and includes the following activities: dialoguing with the robot, storytelling, drama play, cognitive and physical games. This interaction is planned to last about 1 hour twice a week for 6 months. At home, the older user interacts with the tablet supervised by the informal caregiver. The user plays cognitive and physical games installed on MEMAS app. This activity is performed for 0.5 hour, every day for 6 months. Throughout the whole period of experimentation, the older user wears the smartwatch that measures his/her physiological parameters and the steps. Any activity performed by the seniors is assigned by formal caregiver and can be personalized taking into account the user's abilities, lifestyle, and social interactions.
219528457|NCT06302686|OTHER|Group practicing with only the support of a booklet|To the control group will be given a booklet containing information and activities on well-being to do at home.
219528458|NCT00550563|DIETARY_SUPPLEMENT|cholecalciferol|Oral
218915323|NCT01378364|DRUG|AbGn-168H|single very low dose of AbGn-168H i.v.
218915324|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H i.v.
219528459|NCT00550563|GENETIC|polymerase chain reaction|companion study
219615495|NCT05641844|OTHER|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
218915325|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
218915326|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
219528460|NCT00550563|GENETIC|polymorphism analysis|companion study
219528461|NCT00550563|GENETIC|protein expression analysis|companion study
218915327|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
218915328|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
219528462|NCT00550563|GENETIC|reverse transcriptase-polymerase chain reaction|companion study
219528463|NCT00550563|GENETIC|western blotting|companion study
219528464|NCT00550563|OTHER|high performance liquid chromatography|companion study
219528465|NCT00550563|OTHER|laboratory biomarker analysis|companion study
219528466|NCT00550563|OTHER|pharmacological study|companion study
219528467|NCT00550563|PROCEDURE|adjuvant therapy|Additional therapy
219528468|NCT00550563|PROCEDURE|immunoscintigraphy|additional testing
219528469|NCT01054586|DRUG|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
219528470|NCT01054586|DRUG|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
219528471|NCT01054586|DRUG|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
219528472|NCT01054586|DRUG|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
219528473|NCT01054586|DRUG|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
219528474|NCT04336696|PROCEDURE|Total thyroidectomy and central neck dissection|
219528475|NCT03957239|OTHER|Cranberry Beverage|The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
219528476|NCT03957239|OTHER|Control Beverage|The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
219528477|NCT00910663|DRUG|Mycophenolate Mofetil|250 mg Capsule
219528478|NCT00910663|DRUG|CellCept®|250 mg Capsule
219615496|NCT02072980|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses
219615497|NCT06498843|OTHER|administration of an isotonic seawater solution (9g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
219615498|NCT06498843|OTHER|administration of a hypertonic seawater solution (21g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
219615499|NCT04319354|DIAGNOSTIC_TEST|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
218915329|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H i.v.
218915330|NCT01378364|DRUG|AbGn-168H|single high dose of AbGn-168H i.v.
218915331|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H s.c.
218915332|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
218915333|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
218915334|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H s.c.
218915335|NCT00370058|PROCEDURE|ECT treatment|
218915336|NCT05057611|OTHER|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
218915337|NCT05057611|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
218915338|NCT00654667|DRUG|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
218915339|NCT00654667|DRUG|Resveratrol|
218915340|NCT02236026|DRUG|Supratherapuetic dose of Nestorone|
218915341|NCT02236026|DRUG|Placebo|
219528479|NCT02865850|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
218915342|NCT02236026|DRUG|Moxifloxacin|
219528480|NCT02865850|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
219528481|NCT01960569|DRUG|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
219528482|NCT01960569|OTHER|Placebo assigned to arm 2|
219528483|NCT02726581|BIOLOGICAL|Nivolumab|Specified dose on specified days, IV (intravenous)
219528484|NCT02726581|BIOLOGICAL|Elotuzumab|Specified dose on specified days, IV
219528485|NCT02726581|DRUG|Pomalidomide|Specified dose on specified days, PO (by mouth)
219528486|NCT02726581|DRUG|Dexamethasone|Specified dose on specified days, PO
219528487|NCT00215410|DRUG|Formoterol Fumarate|
219528488|NCT00552669|DRUG|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
218915343|NCT01964508|OTHER|Fine needle aspiration|
218915344|NCT00791349|DRUG|Immediate release (IR) Paliperidone|
218915345|NCT03449017|BEHAVIORAL|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
218915346|NCT04160052|DRUG|Azacitidine|Given SC or IV
219528489|NCT00552669|DEVICE|Drug Eluting stent|Any Drug eluting stent
219528490|NCT02024646|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
219528491|NCT02024646|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
219528492|NCT02024646|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
219615500|NCT07057167|OTHER|Diagnostic Laparoscopy videos|"Diagnostic laparoscopy videos will be collected and stored on internal hard drives.~Pseudo-anonymized laparoscopic videos will be annotated by expert clinicians. Artificial intelligence (AI)-based solutions will be developed, trained, and validated."
219528493|NCT01762618|BEHAVIORAL|Cognitive Behavioral Therapy Group|Therapy Groups
218915347|NCT04160052|DRUG|Venetoclax|Given PO
218915348|NCT01259063|DRUG|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
218915349|NCT02164253|DRUG|Deferiprone|30 mg/kg per day, oral use
218915350|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
218915351|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
218915352|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 3)|Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
218915353|NCT04943952|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Participants will receive JZP458 via intramuscular injection.
218915354|NCT03337308|COMBINATION_PRODUCT|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
218915355|NCT03337308|DRUG|Bempedoic Acid|bempedoic acid 180 mg tablet
218915356|NCT03337308|DRUG|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
219528494|NCT01090713|DRUG|lisdexamfetamine|oral; 20-70mg/day
219528495|NCT01090713|DRUG|Placebo control|20-70mg; oral
219528496|NCT04542603|DRUG|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
219528497|NCT01844375|DIETARY_SUPPLEMENT|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
219528498|NCT01844375|OTHER|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
219528499|NCT00176306|DRUG|Levofloxacin 750 mg IV|PK in obesity
219528500|NCT03347032|PROCEDURE|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
219528501|NCT03347032|PROCEDURE|Control|Serial inflations and deflations as detailed in the arm/group descriptions
219528502|NCT01593007|OTHER|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
219528503|NCT01593007|OTHER|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
219615501|NCT06338579|OTHER|Questionnaire|"A questionnaire is distributed and self-administered 4 weeks before the start of an embarked mission on a surface ship at the Toulon naval base, during an embarked mission of at least 4 weeks.~The questionnaire consists of 2 parts:~* A section on socio-demographic characteristics~* A section on self-medication practices during this deployment"
219615502|NCT01848600|BEHAVIORAL|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
219528504|NCT02634437|DRUG|Ulipristal acetate|
219528505|NCT03352271|PROCEDURE|Individualized Incremental hemodialysis|Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
219528506|NCT03352271|PROCEDURE|Conventional thrice weekly hemodialysis|Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
219528507|NCT03879915|PROCEDURE|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
219528508|NCT04649411|DRUG|ferric citrate|oral tablets
219528509|NCT04649411|DRUG|standard of care|administered per the approved label and at the Investigator's discretion
219528510|NCT06292871|BEHAVIORAL|Additional GDM management through social media|Usual care provided by a diabetes nurse educator and dietitian. Additional educational resources for dietary management care received, and for any queries to be addressed by dietitian via social media platform from baseline to one-month follow-up visit.
219528511|NCT06292871|BEHAVIORAL|Usual care|Usual care provided by a diabetes nurse educator and dietitian.
219528512|NCT01772537|DRUG|Propofol|Intravenous anesthetic
218915357|NCT03337308|DRUG|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
218915358|NCT01668784|BIOLOGICAL|Nivolumab|
218915359|NCT01668784|DRUG|Everolimus|
218915360|NCT04503070|BEHAVIORAL|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort"
218915361|NCT00232063|DRUG|ciclosporin|
219528513|NCT01772537|DRUG|isoflurane|
219528514|NCT01814930|BEHAVIORAL|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
219528515|NCT01689792|DRUG|MOVIPREP|
219528516|NCT01689792|DRUG|CitraFleet|
219528517|NCT06011538|OTHER|On-line, multi-media information on a specifically designed website for Same Day Discharge following Laparoscopic Hysterectomy|A patient educational website that provides clear, easily accessible, patient friendly information explaining what SDD after laparoscopic hysterectomy is, why SDD may be beneficial and what to expect from decision for surgery, through to the admission to hospital and immediate, short and long term recovery.
219528518|NCT00641394|BEHAVIORAL|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
219528519|NCT00641394|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
219528520|NCT01394562|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
219528521|NCT01394562|OTHER|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
219528522|NCT03195491|BIOLOGICAL|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
219528523|NCT03983057|DRUG|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
219528524|NCT04186182|BEHAVIORAL|CICI - Feasibility trial study group|The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
219528525|NCT00760448|DRUG|insulin detemir|
219528526|NCT00760448|DRUG|insulin NPH|
219528527|NCT03735030|DRUG|Human hCG 10'000 IU|A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
219528528|NCT03735030|DRUG|Recombinant hCG 6'500 IU|A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
219528529|NCT05213273|BEHAVIORAL|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
219528530|NCT05634772|DEVICE|dormia basket|Use of dormia basket in management of proximal stent migration
219528531|NCT05634772|DEVICE|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
219528532|NCT01263704|DRUG|Cyclophosphamide|150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
219528533|NCT01263704|DRUG|Fludarabine|12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
219528534|NCT01263704|DRUG|Rituximab|375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
219528535|NCT04000386|OTHER|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
219528536|NCT04000386|OTHER|placebo socks|placebo socks were given to subjects for 2 weeks
219528537|NCT01707134|DRUG|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
219528538|NCT01707134|DRUG|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
219528539|NCT01707134|DRUG|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
219528540|NCT03182114|OTHER|supine position|the patient will be placed in regular supine position after spinal anesthesia
219528541|NCT03182114|OTHER|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
219528542|NCT03182114|DRUG|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
219528543|NCT04720638|OTHER|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
219528544|NCT04720638|OTHER|Conventional resin composite restoration|Microhybrid resin composite
218915362|NCT01702207|DRUG|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
218915363|NCT01702207|DRUG|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
218915364|NCT02010892|PROCEDURE|Stent Grafting (ESR)|
218915365|NCT02010892|PROCEDURE|Open Surgery (OSR)|
219615503|NCT01757275|DRUG|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
219615504|NCT01757275|DRUG|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
219528545|NCT00413764|DRUG|tibolone|tibolone (2.5 mg) over 24 weeks
219528546|NCT00413764|DRUG|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
219528547|NCT03357003|OTHER|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
219528548|NCT05188742|DRUG|mirabegron|mirabegron 50mg QD
219528549|NCT05188742|PROCEDURE|TTNS|transcutaneous tibial nerve stimulation
219528550|NCT03020615|DRUG|Hydroxyurea|Given orally once daily.
219528551|NCT03499171|DRUG|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
219528552|NCT03499171|DRUG|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
219615505|NCT01757275|DRUG|Esomeprazole Mg|40 mg tablet once daily for 27 days
219615506|NCT02139137|OTHER|Computerized Cognitive Training - active|Cognitive training using working memory span task
218915366|NCT01862289|OTHER|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
218915367|NCT02337413|DRUG|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
219528553|NCT01704677|PROCEDURE|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
219528554|NCT01704677|BEHAVIORAL|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
219528555|NCT02336854|DRUG|Tacrobell tab. 2mg|
219528556|NCT02336854|DRUG|Prograf cap. 2mg|
219528557|NCT03292354|OTHER|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
219528558|NCT05357898|BIOLOGICAL|SQZ-eAPC-HPV|Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.
219528559|NCT05357898|BIOLOGICAL|Pembrolizumab|programmed cell death 1 (PD-1) blocking antibody
219528560|NCT00724477|DRUG|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
218915368|NCT02337413|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
218915369|NCT02337413|BEHAVIORAL|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
218915370|NCT02015273|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
219528561|NCT01777347|DRUG|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
219528562|NCT01777347|DRUG|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
219528563|NCT00357201|DRUG|Food supplement (T1675)|
219528564|NCT04953832|BEHAVIORAL|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
219528565|NCT01590420|DEVICE|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
219528566|NCT02903901|DRUG|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
219528567|NCT02903901|DRUG|Placebo|10 mg liquid placebo at 7 pm for 1 week
219528568|NCT04458701|DEVICE|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
219528569|NCT00252720|DRUG|candesartan|32 mg oral tablet
219528570|NCT03247920|DRUG|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
219528571|NCT03247920|DRUG|Antibiotics|Intravenous antibiotic therapy following local protocol
219528572|NCT03060694|OTHER|diabetes|"1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
219615507|NCT02139137|OTHER|Computerized cognitive training - sham|Sham training condition
219615508|NCT00233233|BEHAVIORAL|Standardized Asthma Education Program|
219615509|NCT04665986|DRUG|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
219615510|NCT04665986|DRUG|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
219615511|NCT00795652|BEHAVIORAL|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
219615512|NCT01488773|DRUG|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
218915371|NCT04686461|DRUG|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
218915372|NCT06009965|DRUG|CsA+ATG+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
218915373|NCT06009965|DRUG|CsA+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
218915374|NCT01917058|DRUG|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
218915375|NCT01917058|DRUG|placebo|
218915376|NCT00173472|DRUG|Chemotherapy|
218915377|NCT04880980|DRUG|Terbinafine Pill|Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
219528573|NCT02613260|BEHAVIORAL|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
219528574|NCT03851965|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
219528575|NCT01415557|OTHER|Non-Fortified Control Product|Non-Fortified Control Beverage
219528576|NCT01415557|OTHER|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
219615513|NCT01488773|DRUG|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
219615514|NCT02601014|BIOLOGICAL|Ipilimumab|Given 1 mg/kg IV
219615515|NCT02601014|BIOLOGICAL|Nivolumab|Given 3 mg/kg IV
219615516|NCT02601014|DRUG|Enzalutamide|given orally per standard of care
219615517|NCT01168427|DEVICE|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
219615518|NCT03190031|OTHER|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
218915378|NCT04880980|DRUG|Itraconazole capsule|Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
218915379|NCT01413035|BIOLOGICAL|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
218915380|NCT06365359|OTHER|Blood sample for analysis of plasma of organochlorine pesticides concentration|A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
218915381|NCT06365359|OTHER|Blood sample for cell collection|"A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells)."
219615519|NCT03190031|OTHER|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
219615520|NCT02624180|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
219615521|NCT02624180|DRUG|Placebo|A substance containing no medication
218915382|NCT05899257|BEHAVIORAL|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
218915383|NCT02475590|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
219615522|NCT06632964|BIOLOGICAL|Recombinant oncolytic adenovirus injection solution of VT-101|Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
219615523|NCT02771977|OTHER|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
219615524|NCT06165276|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
218915384|NCT02475590|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
218915385|NCT03377582|OTHER|Exercise|Both interventions uses exercises
218915386|NCT02560038|DRUG|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
218915387|NCT02560038|DRUG|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
218915388|NCT02560038|DRUG|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
218915389|NCT03542812|DRUG|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
218915390|NCT04853758|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
219528577|NCT02627066|BEHAVIORAL|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
219528578|NCT02627066|BEHAVIORAL|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
219528579|NCT01310920|OTHER|observation|genotyping
219528580|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
219528581|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
219528582|NCT04859920|OTHER|Questionnaires|QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data
218915391|NCT04853758|DRUG|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
218915392|NCT05552846|RADIATION|thoracic radiotherapy|Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
218915393|NCT00579033|OTHER|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
218915394|NCT00579033|OTHER|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
219528583|NCT04859920|OTHER|Collection of clinical data and treatments|clinical data and treatments
219528584|NCT06346730|DEVICE|Virtual reality glasses to intervention group|experimental and control ,a randomized pretest-posttest study to examine
219528585|NCT05901922|BEHAVIORAL|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
218915395|NCT05068258|PROCEDURE|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
218915396|NCT01400308|DRUG|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
219528586|NCT03962686|DRUG|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
219528587|NCT05332496|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
219528588|NCT05332496|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
219528589|NCT01942863|PROCEDURE|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
219528590|NCT01942863|PROCEDURE|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
219528591|NCT01942863|OTHER|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
219528592|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
219528593|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
218915397|NCT01400308|DEVICE|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
218915398|NCT01516905|DRUG|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
218915399|NCT02867436|OTHER|Gluten-free diet|
218915400|NCT06032871|PROCEDURE|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
219528594|NCT06180512|DIETARY_SUPPLEMENT|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
219615525|NCT06165276|BIOLOGICAL|Meningococcal Group C-CRM197 Conjugate Vaccine|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
218915401|NCT06032871|PROCEDURE|Chest physiotherapy|Participants received chest physiotherapy twice a day
218915402|NCT05101902|OTHER|Pre-Screening|No intervention given
218915403|NCT06552871|BEHAVIORAL|Forming Love around Autistic People to Prevent Suicide|Four-part virtual educational intervention
218915404|NCT04523714|BEHAVIORAL|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
219528595|NCT01314417|DRUG|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
219528596|NCT01760408|OTHER|all patients on Home Parenteral Nutrition|
219528597|NCT00938106|RADIATION|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
219528598|NCT00189956|BIOLOGICAL|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
219528599|NCT03735485|OTHER|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
219528600|NCT03735485|OTHER|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
219528601|NCT03735485|OTHER|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
219528602|NCT01828697|DRUG|Low dose nadroparin|"Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily"
219528603|NCT01828697|DRUG|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily."
219528604|NCT01828697|DRUG|Low dose enoxaparin|"Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily"
219528605|NCT01828697|DRUG|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily."
219528606|NCT01828697|DRUG|Low dose dalteparin|"Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily"
219528607|NCT01828697|DRUG|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily."
219528608|NCT01828697|DRUG|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily"
219528609|NCT01828697|DRUG|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily."
219528610|NCT01683682|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
219528611|NCT01683682|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
219528612|NCT01683682|DRUG|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
219528613|NCT02977260|OTHER|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
219528614|NCT02977260|OTHER|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
219615526|NCT05978401|DRUG|GLS-012+GLS-010|Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
218915405|NCT04523714|BEHAVIORAL|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
218915406|NCT03280719|DEVICE|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
218915407|NCT03280719|RADIATION|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
218915408|NCT03280719|DEVICE|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
218915409|NCT03280719|RADIATION|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
219528615|NCT02977260|OTHER|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
219528616|NCT02977260|OTHER|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
219528617|NCT00723476|BEHAVIORAL|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
219528618|NCT00723476|BEHAVIORAL|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
219528619|NCT02330380|DRUG|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
218915410|NCT06007872|DEVICE|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
219528620|NCT02330380|DRUG|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
218915411|NCT02783690|RADIATION|Hypofractionation|40 Gy (RBE) in 15 daily fractions
219528621|NCT02330380|DRUG|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
219528622|NCT02330380|DRUG|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
219615527|NCT05978401|DRUG|GLS-012+GLS-010|Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
218915412|NCT04515615|DRUG|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
218915413|NCT04515615|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
219041886|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
219041887|NCT02953899|BEHAVIORAL|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
219041888|NCT02953899|BEHAVIORAL|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
219041889|NCT03806582|DRUG|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
219041890|NCT06577493|DRUG|Phenazopyridine Hydrochloride 99.5 MG|Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
219528623|NCT02330380|DRUG|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
219528624|NCT02330380|OTHER|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
219528625|NCT02330380|OTHER|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
218915414|NCT04515615|DRUG|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
219041891|NCT00436943|DRUG|nicotine replacement therapy and bupropion|3-6 months
219528626|NCT01838720|PROCEDURE|zero ischemia laparoscopic RFA assisted TE|
219528627|NCT01838720|PROCEDURE|ischemia|conventional laparoscopic partial nephrectomy
219528628|NCT02325531|OTHER|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
219528629|NCT02325531|OTHER|Medium support|"Same as provided to the low support arm, PLUS~* STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~* ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 \& 3."
218915415|NCT04414748|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
218915416|NCT04414748|DRUG|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
218915417|NCT02167490|PROCEDURE|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
218915418|NCT04069689|DRUG|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
218915419|NCT04069689|DRUG|Placebos|Placebo to match EPX-100
218915420|NCT04523194|OTHER|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
218915421|NCT03747549|OTHER|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
218915422|NCT03747549|OTHER|Home Exercise Alone|The prescribed home exercise program alone.
219041892|NCT00436943|BEHAVIORAL|smoking cessation counseling and referrals|Organizational counseling and referrals
219041893|NCT00347724|DRUG|Tramadol HCl ER|
218915423|NCT04156087|DRUG|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
218915424|NCT04156087|DRUG|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
218915425|NCT04156087|DRUG|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
218915426|NCT04156087|PROCEDURE|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
218915427|NCT05178173|OTHER|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
218915428|NCT05178173|OTHER|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
218915429|NCT05178173|OTHER|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
218915430|NCT04732520|DEVICE|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
218915431|NCT00519441|OTHER|pH study|All patients will have 48 hour pH study
218915432|NCT00236223|DRUG|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
218915433|NCT00236223|DRUG|Placebo|Matching placebo
218915434|NCT02450370|BEHAVIORAL|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
218915435|NCT02450370|BEHAVIORAL|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
218915436|NCT01723384|DRUG|Intermittent Oral Naltrexone|
218915437|NCT01723384|DRUG|Placebo|
218915438|NCT00671736|DRUG|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
219528630|NCT02325531|OTHER|High support|"Same as provided to the low and medium support arms, PLUS~\- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
219528631|NCT02325531|OTHER|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
219528632|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
219528633|NCT04007640|RADIATION|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
219528634|NCT04007640|PROCEDURE|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
218915439|NCT00671736|DRUG|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
218915440|NCT05642728|OTHER|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
218915441|NCT05138653|DRUG|CVL-354|Oral solution/suspension
218915442|NCT05138653|DRUG|Placebo|Placebo matched to CVL-354
218915443|NCT05138653|DRUG|CVL-354|Capsule
218915444|NCT06585111|OTHER|Intervention|"In the first motivational interview, the HAPA Model Prenatal Motivation Interview Questionnaire, the first part of the Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, and the Breastfeeding Intention Scale for Pregnant Women Expecting Twins were applied. A brochure on breastfeeding twin babies prepared by the researcher was distributed to women. In the second interview, the HAPA Model Postpartum Motivation Interview Scale, the second part of which was the Personal Information Form, Breastfeeding Follow-up Form, Breastfeeding Motivation Scale and Postpartum Breastfeeding Self-Efficacy Scale were applied. In the third meeting, the Breastfeeding Follow-up Form was applied. Breastfeeding Motivation Scale, Postpartum Breastfeeding Self-Efficacy Scale and Breastfeeding Follow-up Form were applied in the fourth and fifth interviews, and Breastfeeding Follow-up Form was applied in the sixth interview."
218915445|NCT04495218|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
219528635|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
219528636|NCT03872674|BIOLOGICAL|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
219528637|NCT02514122|DRUG|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
219528638|NCT02514122|DRUG|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
219528639|NCT04239872|DRUG|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
219528640|NCT04239872|DRUG|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
219528641|NCT05026567|DRUG|2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)|Intramuscular injection
218915446|NCT05794321|DRUG|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
219528642|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh|Intramuscular injection
218915447|NCT04671901|DRUG|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
218915448|NCT06041737|OTHER|consultation|nephrology consultation during 2020
218915449|NCT04825574|DRUG|Avapritinib|avapritinib tablet
218915450|NCT03564275|RADIATION|Proton Boost|13-15 treatments with proton therapy given as a boost to standard of care photon therapy
219528643|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area|Intramuscular injection
219528644|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh|Intramuscular injection
219528645|NCT06362772|RADIATION|Iodine-125 brachytherapy|"In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions."
219528646|NCT01026363|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
219528647|NCT01026363|DRUG|Calcitriol|0.25 mcg tablet once daily for 14 days
218915451|NCT02624596|DRUG|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
218915452|NCT02624596|DRUG|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
218915453|NCT04507412|DRUG|dexamethasone|perioperatively 9 mg i.v subministration
218915454|NCT05391503|BEHAVIORAL|Light therapy|Morning bright light for 60 minutes after awakening
218915455|NCT05391503|BEHAVIORAL|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
218915456|NCT04906122|OTHER|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling.|The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group. The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
218915457|NCT06653972|DRUG|Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.|Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
218915458|NCT06654362|BEHAVIORAL|nutritional interventions include education and modifying company's restaurant menu|"* Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake."
219041894|NCT03771833|DEVICE|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
219041895|NCT04441294|BEHAVIORAL|ACE-Plus|
219528648|NCT03676686|DEVICE|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
219528649|NCT00714090|OTHER|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
218915459|NCT06654973|OTHER|GMP-produced SARS-CoV-2 Delta strain|The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.
219528650|NCT00714090|OTHER|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
219528651|NCT00714090|OTHER|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
219528652|NCT04690166|OTHER|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
218915460|NCT02257593|OTHER|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
218915461|NCT03491059|DRUG|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
219615528|NCT05978401|DRUG|GLS-012+GLS-010+pemetrexed+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
219615529|NCT05978401|DRUG|GLS-012+GLS-010+paclitaxel+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with paclitaxel and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
218915462|NCT03491059|RADIATION|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
218915463|NCT04199221|BEHAVIORAL|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
219615530|NCT04252027|OTHER|Sample collection|Plasma and urine sample collection
219615531|NCT03987789|OTHER|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
219615532|NCT03987789|OTHER|Low PEEP|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
219615533|NCT03358927|BEHAVIORAL|Immediate Fast-Track Care|Eligible for fast-track care at enrollment
219615534|NCT03358927|BEHAVIORAL|Deferred Fast-Track Care|Eligible for fast-track care after 6 months on ART
219615535|NCT00882752|PROCEDURE|molecular analysis|bowel disease
219615536|NCT04705792|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
219615537|NCT03926429|OTHER|Standardised data collection|The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
219615538|NCT02477644|DRUG|Olaparib|Tablets, per os, 300 mg twice daily;
219615539|NCT02477644|DRUG|Placebo|Tablets, per os, 300 mg twice daily.
219615540|NCT03177525|BEHAVIORAL|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
218915464|NCT04199221|BEHAVIORAL|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
218915465|NCT02845297|DRUG|pembrolizumab|Intravenous pembrolizumab
218915466|NCT02845297|DRUG|Azacitadine|Intravenous or subcutaneous
218915467|NCT06810960|OTHER|No Intervention|This is a non-interventional study.
218915468|NCT06594913|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
218915469|NCT06599242|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy is an exercise approach belonging to physiotherapists
218915470|NCT06599242|OTHER|American football team training|American football team training
218915471|NCT06601608|DRUG|Herbal therapy|rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
218915472|NCT06601608|DRUG|Placebo Drug|a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
219528653|NCT04739566|DRUG|Dabrafenib|Given PO twice daily
219528654|NCT04739566|DRUG|Trametinib|Given PO once daily
219528655|NCT04340011|OTHER|Colposcopy|prospective resident education for colposcopy
219528656|NCT04809961|OTHER|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
219615541|NCT03177525|BEHAVIORAL|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
218915473|NCT06594250|DIAGNOSTIC_TEST|Nasal swab|Nasal swab to detect nasal carriage of S. aureus
218915474|NCT06594250|BIOLOGICAL|Venous sampling|Peripheral venous sampling to collect peripheral blood mononuclear cells.
218915475|NCT06594250|BIOLOGICAL|Antibiotic treatment|Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus
218915476|NCT06594250|DEVICE|Nasal swab|A new nasal swab will be taken using the same technique, to see whether or not the carriage persists
218915477|NCT06594250|BIOLOGICAL|Intracellular reservoir test|In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.
218915478|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|"Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.~Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore \&amp;amp; Associates) to create a final 6-mm shunt."
218915479|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|After successful puncture, in the 8-mm shunt group, a balloon with a diameter of 6 mm was used to expand the shunt, and then an 8-mm covered stent was implanted (Viatorr; WL Gore \&amp; Associates, Inc.).
219615542|NCT04207658|BEHAVIORAL|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
219615543|NCT01872312|DEVICE|treatment with valves (The Spiration® IBV Valve System)|treat BPF
219615544|NCT04537884|DRUG|UBX1325|Investigational drug intravitreal injection
218915480|NCT06598839|DRUG|Thymosin Alpha1|subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
218915481|NCT06586996|OTHER|no intervention|no intervention
218915482|NCT06600958|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
218915483|NCT06596551|BEHAVIORAL|Pre-Post ARCH Intervention|Stroke dyads, consisting of a survivor and primary family caregiver, will engage in a 4 weekly, 1.5 hour experiential dyadic sessions, totalling 6 hours of participation. In Week 1, dyads acknowledge the losses occurring after the stroke to normalize feelings of grief and sadness and find comfort within the familial space. In Week 2, dyads interpret their post-stroke losses within the framework of their existing knowledge for managing adversities (strengths, resources, and values) and identify changes that are most meaningful to them. In Week 3, dyads set specific, measurable, and achievable goals to actualize the meaningful changes identified in Week 2. Finally in Week 4, dyads bring together their individually derived strengths from the previous sessions to culminate into strengthened dyadic bonds. The exercise will also encourage participants to expand beyond the dyadic space to seek support from their communities, social networks and care services that are available to them.
218915484|NCT06595654|OTHER|repetitive Transcranial Magnetic Stimulation|"* Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized."
218915485|NCT06603194|DIETARY_SUPPLEMENT|Bovine or Marine Collagen|Bovine or Marine Collagen
218915486|NCT06596239|DEVICE|lower-clear-plate-based intermaxillary traction (LCP-IMT)|The patient is instructed to apply elastics between the upper molar bands and the hooks on the lower clear plates.
218915487|NCT06596239|DEVICE|Removable mandibular retractor (RMR)|An appliance is worn on the upper jaw, which affects the lower jaw by using an inferiorly extended labial bow.
218915488|NCT06729658|DRUG|Madopar|Experimental group participants will receive Madopar 125mg for 6 days.
218915489|NCT06729658|DRUG|Placebo|Control group participants will receive placebo for 6 days.
218915490|NCT03066869|DRUG|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
218915491|NCT06655571|PROCEDURE|Ultrasound guided caudal Block|caudal block using Ultrasound
218915492|NCT06655571|PROCEDURE|Conventionel|Caudal Block based on anatomical landmarks
218915493|NCT04272242|DRUG|Dolutegravir (DTG)|Administered orally
218915494|NCT04272242|DRUG|Isoniazid (INH)|Administered orally
218915495|NCT04272242|DRUG|Rifapentine (RPT)|Administered orally
218915496|NCT04272242|DRUG|Antiretroviral Therapy (ART)|Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
218915497|NCT04272242|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
218915498|NCT02702492|DRUG|KPT-9274|
218915499|NCT02702492|DRUG|Niacin ER|
218915500|NCT02702492|DRUG|Nivolumab|
218915501|NCT06596720|OTHER|Aerobic Exercise|After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
218915502|NCT06592573|OTHER|CBT_ONLINE|10-12 sessions of cognitive behavioural therapy conducted online
218915503|NCT06592573|OTHER|CBT_IN PERSON|10-12 sessions of cognitive behavioural therapy conducted in-person.
219528657|NCT02365454|DEVICE|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
219528658|NCT00054626|DRUG|cisplatin|
218915504|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow|All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.
218915505|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol|For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
218915506|NCT06603909|OTHER|group 1: Use AI to assist nutrition management|group1：AI-assisted nutrition management. group 2：Traditional nutrition management（through the hospital dietitian）.group 3:control.
218915507|NCT06603909|OTHER|group 2：Traditional nutrition management（through the hospital dietitian）|group 2：Traditional nutrition management（through the hospital dietitian）
218915508|NCT06597903|DRUG|NRL994|"In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid."
218915509|NCT06592950|OTHER|No treatment given|Online survey
218915510|NCT06592950|OTHER|No treatment given|Interviews
218915511|NCT06592469|PROCEDURE|Ureteroscopy|URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter
218915512|NCT06596109|BEHAVIORAL|honey intake and lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
218915513|NCT06596109|BEHAVIORAL|lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
218915514|NCT06589193|OTHER|HOCl|10ml,twice a day
218915515|NCT06589193|OTHER|CHX|10ml,twice a day
218915516|NCT06842615|DIAGNOSTIC_TEST|Pantum detect test|epitope detection in monocyte (EDIM)
218915517|NCT06989593|BEHAVIORAL|Narrative Medicine Journaling Intervention|Participants will complete the GAD-7 anxiety assessment at baseline. They will then receive a physical journal containing 5 structured, therapeutic writing prompts designed to help process emotions related to their child's diagnosis. Prompts focus on processing experiences with diagnosis, addressing uncertainty, coping with stigma, and developing resilience. Parents will be instructed to complete the 5 journal entries, spending 15-20 minutes on each writing session at least once per week. Following completion of the journaling intervention, participants will complete a follow-up GAD-7 assessment and take part in a 30-45 minute qualitative interview to further assess perceived changes in anxiety, stress, and coping strategies, and to gather feedback on potential group-based writing programs.
218915518|NCT06585995|DRUG|vitamin D (cholecalciferol) supplementation|"This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses"
218915519|NCT06593171|BEHAVIORAL|Mentoring program|This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.
219041896|NCT04976530|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
219041897|NCT04976530|DEVICE|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
219528659|NCT00054626|DRUG|gemcitabine hydrochloride|
219528660|NCT00054626|PROCEDURE|adjuvant therapy|
219528661|NCT04818892|DIAGNOSTIC_TEST|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
219528662|NCT00159848|BEHAVIORAL|Treatment Optimization Program (educational material)|
219528663|NCT00319930|DRUG|CNF1010 (17-AAG)|
219528664|NCT05079425|DRUG|NXC736|Oral administration
219528665|NCT05079425|DRUG|Placebo|Oral administration
219528666|NCT03675269|OTHER|HBOT|Standard practice
219528667|NCT03675269|BEHAVIORAL|Standard wound care|Standard wound care
219528668|NCT04543760|OTHER|Prone position|prone positioning in spontaneous ventilation
219528669|NCT04543760|OTHER|Supine position|supine positiong in spontaneous ventilation
219528670|NCT00687063|DRUG|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
219528671|NCT06218108|DIAGNOSTIC_TEST|Taulí-T1 versus conventional classifications|All the slides of each case will be reviewed, selecting the one that contains the most invasive section, and this will be digitized to take measurements in micrometers with greater precision. To measure the degree of infiltration, the measurement of residual healthy submucosa (hrSB) will be used, which is the distance between the point of greatest infiltration and the muscularis propria. The total thickness of the submucosa in the tumor area will also be measured, taking as a reference the muscularis of the mucosa or, in its absence, the surface of the lesion, to calculate the percentage of infiltration of the submucosa. This percentage will be calculated as the inverse percentage of invasion with respect to the hrSB: (total thickness of the submucosa - hrSB / total thickness of the submucosa) x 100. The qualitative categories will be obtained: sm1 (\< 33.3%), sm2 (33.3% - 66.6%) and sm3 (\> 66.6%). Measurements will be also taken in micrometers for the conventional classifications.
219528672|NCT03644264|DRUG|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
219528673|NCT03644264|DRUG|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
219528674|NCT01067183|BEHAVIORAL|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
219528675|NCT05984251|DRUG|CCX168|Administered orally.
219528676|NCT05984251|DRUG|Placebo|Administered orally.
219528677|NCT04417933|DEVICE|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
219528678|NCT03115177|DRUG|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
219528679|NCT03115177|DRUG|Cefazolin|
219615545|NCT02620995|DRUG|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
219615546|NCT02620995|OTHER|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
219615547|NCT06464484|DIETARY_SUPPLEMENT|Probiotics (Lactobacillus rhamnosus GG (ATCC 53103)|Already mentioned in arm/group descriptions
219615548|NCT02769507|DEVICE|DC Stimulator PLUS (NeuroConn)|
219615549|NCT01987778|OTHER|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
219615550|NCT01941615|DRUG|faldaprevir|oral doses for 10 days (period B)
219528680|NCT03957447|OTHER|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
219528681|NCT05084677|COMBINATION_PRODUCT|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
219528682|NCT00648947|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
219528683|NCT00648947|DRUG|Plavix® Tablets 75 mg|75mg, single dose fasting
219528684|NCT03611374|PROCEDURE|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
219528685|NCT01583127|BEHAVIORAL|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
219528686|NCT00747162|DEVICE|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
219615551|NCT01941615|DRUG|Microgynon®|oral doses for 23 days (period A+B)
219528687|NCT00747162|DEVICE|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
219528688|NCT05195762|DRUG|NFX-179 Gel 1.50%|"Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi."
219528689|NCT01188135|BEHAVIORAL|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
219615552|NCT01941615|DRUG|BI 207127|oral doses for 10 days (period B)
219615553|NCT00420420|DRUG|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
219615554|NCT00420420|DRUG|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
219615555|NCT03289091|BEHAVIORAL|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
218915520|NCT06593171|BEHAVIORAL|Control (placebo) group|This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
219204547|NCT06786793|DEVICE|Computer-aided detection (CADe)|Endo-Aid CADe system is an AI-assisted computer-aided lesion detection application on ENDO-AID hardware. It uses a complex algorithm created via a neural network developed and taught by Olympus. With this new app, the sophisticated machine learning system can alert the endoscopist in real-time when a suspicious lesion appears on the screen. The image from the vision processor is transferred to the CADe device. The computer application recognizes the shape of the polyps and marks their place on the monitor screen.
219528690|NCT00112463|DRUG|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
219528691|NCT03287310|DRUG|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
219528692|NCT03287310|DRUG|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
219528693|NCT03287310|DRUG|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
219528694|NCT06562855|GENETIC|Peripheral blood sampling|
219528695|NCT01118312|DRUG|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day for 6 months
219615556|NCT03289091|BEHAVIORAL|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
219528696|NCT01118312|OTHER|Placebo|Intranasal placebo spray
219528697|NCT03544008|OTHER|The use of AXIOS in Endoscopic transmural drainage|
219528698|NCT01703975|OTHER|Training in pairs (Dyad training)|
219528699|NCT00307697|PROCEDURE|receipt of copy of psychiatic assessment letter|
219528700|NCT03065374|BIOLOGICAL|IMM-529|IMM-529
219528701|NCT03065374|OTHER|Placebo|Matching placebo
219615557|NCT02364765|DRUG|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
219615558|NCT06118476|BEHAVIORAL|3D animation|Education with 3D animation videos
219615559|NCT02626091|PROCEDURE|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
219615560|NCT00273182|DEVICE|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
219615561|NCT00273182|DEVICE|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
219615562|NCT04821076|OTHER|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
219528702|NCT05880576|DEVICE|Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy|Infants will have monitoring three times a day with resonance Raman spectroscopy device during arch watch period. They will have continuous monitoring with pulse oximetry and near infrared spectroscopy. They will have intermittent blood pressure monitoring.
218915521|NCT06999668|DEVICE|Virtual reality cognitive function training|"Participants will receive VR-based cognitive training over 4-5 days prior to surgery, with three daily 30-minute sessions (8:00-10:00 AM, 12:00-2:00 PM, and 5:00-7:00 PM), ensuring a total preoperative training duration ≥6 hours.~The intervention utilizes an immersive VR environment that simulates real-world scenarios and tasks. Training modules target multiple cognitive domains, including memory, executive function, calculation, and abstract reasoning, designed as engaging, game-like activities with a gradual learning curve.~Each participant's regimen is personalized based on baseline cognitive assessments or physician prescriptions, adhering to the 6-hour rule for standardized efficacy evaluation. The system incorporates adaptive difficulty adjustment, dynamically modifying task complexity in response to real-time performance."
218915522|NCT06999668|DEVICE|Virtual scene intervention|The control group will receive non-interactive VR exposure using identical equipment and session duration as the training group (3×30-minute daily sessions for 4-5 days, totaling ≥6 hours), with all interactive functions disabled to eliminate potential media-related biases (e.g., 2D/3D cognitive load differences from tablet-based interventions) and ensure between-group differences stem solely from interactive training while maintaining blinding integrity through equivalent hardware deployment.
218915523|NCT06999746|OTHER|Control|Sleep hygiene education
218915524|NCT06999746|DEVICE|Oropharyngeal Exercise|Device-monitoring oropharyngeal exercise, 1-5 days a week for three months
218915525|NCT06999746|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure, 1-5 days a week for three months
218915526|NCT06999746|DEVICE|Continuous positive airway pressure and oropharyngeal exercise|Continuous positive airway pressure and device-monitoring oropharyngeal exercise, 1-5 days a week for three months
218915527|NCT06998212|BEHAVIORAL|Offer to record encounter|Patient will be given the option to record their clinical encounter on their personal smartphone
219615563|NCT04821076|OTHER|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
219528703|NCT02810886|DRUG|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
219615564|NCT04821076|OTHER|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
219615565|NCT05475314|DIETARY_SUPPLEMENT|ReFerm(R)|Enemas of approx 250 mL twice daily
219615566|NCT03870815|PROCEDURE|CABG|Patients who undergoing CABG
219615567|NCT03870815|PROCEDURE|PCI|Patients who undergoing PCI with DES
219615568|NCT00949637|BEHAVIORAL|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
219615569|NCT00949637|BEHAVIORAL|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
219615570|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
219615571|NCT03411161|DRUG|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
219615572|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
219615573|NCT05702333|DRUG|Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan|Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
219615574|NCT04114682|OTHER|Multi parametric MRI scan|There will be no intervention to the standard of care these patients receive. However, consented participants will be asked to make two study visits where a multiparametric MRI scan will be performed - these visits will be defined as visit 2 and visit 3. An optional echocardiogram may be included at Visit 2.
218915528|NCT06998186|BEHAVIORAL|Discharge Education And Telephone Counseling|"Providing training on discharge education to parents of cardiac surgery patients.~Providing telephone counseling for 6 months"
218915529|NCT06998849|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is defined as the ratio of pulsatile light absorption to continuous light absorption, denoted as AC/DC. Initially used as a quality signal indicator in pulse oximetry, PI has increasingly been recognized for its potential in non-invasive hemodynamic monitoring. Since PI changes with peripheral blood flow, it may reflect peripheral temperature gradients and, consequently, thermoregulatory responses like peripheral vasoconstriction. Studies have reported that the core-to-peripheral temperature difference correlates with peripheral PI. The findings suggest that both peripheral and core temperatures contribute to the threshold for shivering and that PI reflects the vasoconstriction induced by thermoregulatory responses that precede shivering
218915530|NCT06998693|DRUG|5-ASA (5-Aminosalicylate)|Specialist doctors decide the administration method of 5-ASA based on the patient's condition (all groups), mainly including topical therapy, or oral therapy (2-4 gram/day).
219528704|NCT02642835|PROCEDURE|vaginal wall mesh|retrospective review of case series
219528705|NCT01854463|DRUG|Vitamin D3|2000IU per day
219528706|NCT01854463|DRUG|placebo|elemental calcium 200mg per day per 24 weeks
219528707|NCT00704821|DRUG|PTC299|Oral
219528708|NCT00704821|DRUG|Docetaxel|Intravenous infusion
219528709|NCT05907421|BEHAVIORAL|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
219528710|NCT01507337|DRUG|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
219615575|NCT00856492|BIOLOGICAL|bevacizumab|Given IV
219615576|NCT00856492|BIOLOGICAL|pegfilgrastim|Given subcutaneously
219615577|NCT00856492|DRUG|cyclophosphamide|Given IV
219615578|NCT00856492|DRUG|doxorubicin hydrochloride|Given IV
219615579|NCT00856492|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219615580|NCT00818350|DRUG|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
219615581|NCT04069273|DRUG|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
219615582|NCT04069273|DRUG|Ramucirumab|Ramucirumab 10 mg/kg IV
218915531|NCT06998693|PROCEDURE|Colon Endoscopy Procedure|Participants in all groups will receive a standard Colon Endoscopy Procedure at 48-week.
218915532|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 4-week|Participants in will receive a standard Blood Routine Test at 4-week.
218915533|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 8-week|Participants in will receive a standard Blood Routine Test at 8-week.
218915534|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 12-week|Participants in will receive a standard Blood Routine Test at 12-week.
218915535|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 4-week|Participants in will receive a standard Stool Routine Test at 4-week.
218915536|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 8-week|Participants in will receive a standard Stool Routine Test at 8-week.
218915537|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 12-week|Participants in will receive a standard Stool Routine Test at 12-week.
218915538|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 4-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 4-week.
218915539|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 8-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 8-week.
218915540|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 12-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 12-week.
218915541|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 4-week|Participants in will receive a standard C-reactive Protein Test at 4-week.
218915542|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 8-week|Participants in will receive a standard C-reactive Protein Test at 8-week.
219041898|NCT05791461|BEHAVIORAL|MARS (Measures Against Work-related Stress)|"The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended."
219041899|NCT06775678|RADIATION|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy
219528711|NCT06018532|DEVICE|PRESAGE CARE|PRESAGE Care informations from the application will be processed by the PRESAGE Care algorithm in real time, and may generate alerts indicating an increased risk of hospitalization or emergency department visits within 7 to 14 days. These alerts will be transmitted to a Care Manager platform, who will analyse the situation, initiate the healthcare intervention and coordinate its implementation. In practice, a care manager (coordinating nurse) will process the alert and carry out an initial assessment of the beneficiary's situation, using the information feedback platform, then by telephone, contacting the older adults beneficiary and the relative. The care manager may or may not implement preventive measures. If necessary, the patient may be offered an outpatient medical consultation, a home visit, a consultation with his or her GP and/or social or paramedical interventions.
219528712|NCT03506386|OTHER|No Intervention|As it was an observational study, no intervention was administered.
219528713|NCT05660655|DRUG|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
219528714|NCT05660655|DRUG|Baricitinib 2 MG|baricitinib 4mg once daily in group A
219528715|NCT05454553|OTHER|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
219528716|NCT05735925|DIAGNOSTIC_TEST|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
219528717|NCT01390493|BEHAVIORAL|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
218915543|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 12-week|Participants in will receive a standard C-reactive Protein Test at 12-week.
218915544|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 4-week|Participants in will receive a standard Liver Function Test at 4-week.
218915545|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 8-week|Participants in will receive a standard Liver Function Test at 8-week.
218915546|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 12-week|Participants in will receive a standard Liver Function Test at 12-week.
218915547|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 4-week|Participants in will receive a standard Kidney Function Test at 4-week.
218915548|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 8-week|Participants in will receive a standard Kidney Function Test at 8-week.
218915549|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 12-week|Participants in will receive a standard Kidney Function Test at 12-week.
218915550|NCT07000019|BEHAVIORAL|CARAT: combined aphasia and robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy combined with a standardized picture-word verification therapy task with the goal of improving language and arm movements.
218915551|NCT07000019|BEHAVIORAL|Robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy with the goal of improving arm movements.
218915552|NCT06999408|DEVICE|Scalp tattoo|A micropigmentation scalp tattoo will be applied at baseline to mark consistent photographic sites.
218915553|NCT06999408|DEVICE|Canfield HairMetrix®|Canfield HairMetrix® imaging will be utilized to capture global and trichoscopic hair measurements.
218915554|NCT06999408|DEVICE|TargetCool|Boosting will be used to apply exosomes
218915555|NCT06999408|DEVICE|Microneedle-facilitated lidocaine application|Microneedling will be performed to a depth of 0.5 mm.
218915556|NCT06998342|RADIATION|Short course radiation|The radiation arm in this study involves Short Course Radiation Therapy (SCRT), which consists of 5 fractions delivered twice a week (either Monday/Thursday or Tuesday/Friday).
219041900|NCT06775678|RADIATION|Conventional fractionated radiotherapy|Conventional fractionated radiotherapy
219041901|NCT04448717|DIAGNOSTIC_TEST|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
218915557|NCT06998342|OTHER|Active Surveillance|The Active Surveillance arm (Group M) aims to monitor participants with moderate-risk cutaneous squamous cell carcinoma (cSCC) after surgical resection, without immediate intervention unless disease progression occurs. Participants will undergo regular clinical evaluations, physical exams, and skin checks to detect new lesions or signs of recurrence. Imaging, including ultrasound and CT/MRI scans, will be performed every 6 months for up to 3 years to monitor for metastasis or progression. Blood samples will be collected for future biomarker analysis to identify indicators of disease recurrence. Participants will also complete quality of life assessments using the EORTC QLQ-C30 and Skin Cancer Index (SCI) to evaluate the impact of surveillance on their daily lives. If disease progression is detected, radiation therapy may be initiated. The study will track overall survival without initiating radiation, as well as disease progression and quality of life outcomes, to determine if active s
219528718|NCT05417425|COMBINATION_PRODUCT|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
219528719|NCT06426056|RADIATION|radiotherapy|Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
219615583|NCT04069273|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV
219615584|NCT03852953|OTHER|Under- or overdiagnosed cancer|Diagnosed with a cancer that was visible on prior mammograms
219615585|NCT03852953|OTHER|Screening|Invited or attended BreastScreen Norway
219615586|NCT06024408|DRUG|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
219615587|NCT06024408|DRUG|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
218915558|NCT06998745|BEHAVIORAL|Medication Therapy Management (MTM) model|MTM model comprising five core elements: Medication Therapy Review (MTR), Personal Medication Record (PMR), Medication-Related Action Plan (MAP), interventions \& referrals, and documentation \& follow-up
219041902|NCT05847569|BIOLOGICAL|Belantamab Mafodotin|Given IV
219041903|NCT05847569|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219615588|NCT07073586|PROCEDURE|Lymphovenous Anastomosis|Microsurgical creation of multiple lymphatic-venous connections in the most affected limb under general anaesthesia.
219041904|NCT05847569|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
219041905|NCT05847569|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
219528720|NCT06426056|DRUG|Nab paclitaxel|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
219615589|NCT07073586|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy, comprising bandaging, skin care and exercise, followed by compression garments.
219615590|NCT04239755|DRUG|Doxycycline 100 MG Oral Tablet|doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
219615591|NCT04239755|OTHER|placebo|placebo in addition to the standard treatment.
219615592|NCT05012618|DRUG|LUNA18|LUNA18 Capsule
219615593|NCT05012618|DRUG|Cetuximab|Cetuximab as a IV infusion
219615594|NCT06814756|BIOLOGICAL|phage therapy|Single anti-Morganella morganii bacteriophage drug product
219615595|NCT02290444|DRUG|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
219615596|NCT05797974|OTHER|MyChart enabled virtual weight loss coach|MyChart-enabled virtual coach utilized to aid in preoperative weight loss.
219615597|NCT05797974|OTHER|Standard preoperative weight loss tools|Participants will utilize current standard preoperative weight loss tools.
219528721|NCT06426056|DRUG|Cisplatin|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
219615598|NCT06903728|DEVICE|continous glucose monitoring|Pregnant women with type 2 diabetes are given a sensor \< week 14 of their pregnancy and will use it until 4-6 post partum. They will receive training in how to use the sensor, and support when needed.
219615599|NCT07087080|OTHER|Blood sampling|Single blood sampling (16 ml) after study inclusion before undergoing the PET-CT scan
219615600|NCT07091513|PROCEDURE|group ESP|. In the ESP group, a high frequency linear transducer (HFL50XP, SonoSite Inc., Bothell, WA, USA ) was located vertically approximately 3 cm lateral to the projection point with identification of the spinous process, lamina, transverse process, and the erector spinae muscle. The skin and subcutaneous tissues were infiltrated using 5 mL of 1% Lidocaine Hydrochloride. A 22-G peripheral nerve block needle (50 mm) (SonoTAP, Pajunk, Geisingen, Germany) was inserted in-plane from caudal to cranial between the fascia of the erector spinae muscle and the transverse process under the ultrasound guidance. After hydro-localization using 1 ml of with normal saline, this plane was opened. The same 20 mL mixture of LA was injected after negative aspiration of blood.
218915559|NCT06263010|DRUG|Allopregnanolone|Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
219528722|NCT02543671|OTHER|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
219528723|NCT02543671|OTHER|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
218915560|NCT05465174|DRUG|Tovorafenib|Given orally
218915561|NCT02711891|DRUG|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
218915562|NCT02711891|DRUG|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
218915563|NCT04883281|RADIATION|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
219041906|NCT05847569|PROCEDURE|Computed Tomography|Undergo CT scan
219528724|NCT02512393|DEVICE|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
219528725|NCT02512393|DEVICE|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
219528726|NCT04723810|DRUG|Indocyanine Green|The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
219528727|NCT04109469|DEVICE|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
219528728|NCT02420210|DRUG|Bendamustine Hydrochloride|Given IV
219528729|NCT02420210|BIOLOGICAL|Obinutuzumab|Given IV
219528730|NCT02420210|DRUG|Dexamethasone|Given PO
219528731|NCT02420210|OTHER|Quality-of-Life Assessment|Ancillary studies
219528732|NCT02420210|OTHER|Laboratory Biomarker Analysis|Correlative studies
219528733|NCT04400123|DRUG|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
219528734|NCT01167205|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin 20mg for 12 weeks
219528735|NCT01185821|DRUG|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
219528736|NCT03527147|DRUG|AZD9150|AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
219528737|NCT03527147|DRUG|Acalabrutinib|Acalabrutinib will be administered orally twice daily (bid).
219615601|NCT05170503|DRUG|Sintilimab|Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
218915564|NCT04883281|DRUG|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
219041907|NCT05847569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219041908|NCT05847569|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219041909|NCT05524545|DRUG|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
219041910|NCT05524545|DRUG|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
219528738|NCT03527147|DRUG|AZD6738|AZD6738 will be administered orally twice daily (bid).
219528739|NCT03527147|DRUG|Hu5F9-G4|HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
219615602|NCT07097649|DEVICE|Textured lateral wedge insole|Participants in the experimental group will wear custom-designed textured lateral wedge insoles made from EVA material. These insoles incorporate lateral wedging to offload the medial knee compartment and a textured surface to enhance plantar sensory input. Participants will use the insoles during daily activities for a period of 8 weeks, with no additional intervention or exercise protocol.
219528740|NCT03527147|DRUG|Rituximab|Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
219528741|NCT03527147|DRUG|AZD5153|AZD5153 will be administered orally once per day (qd).
219528742|NCT03264898|DEVICE|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
219528743|NCT02426762|PROCEDURE|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~* 4-5 trocar-produced incisions (5/10mm, minor incision)~* 1 sample-retrieval incision (4-5cm, small incision)"
219528744|NCT02426762|DEVICE|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
219528745|NCT04060147|DRUG|Cilofexor|Tablets administered orally once daily
219615603|NCT07097649|DEVICE|Use of lateral wedge flat insole|Participants in this arm will use a customized lateral wedge flat insole with the same lateral inclination as the experimental insole but without any textured surface. This design allows for controlling the mechanical effect of the wedge while eliminating additional sensory stimulation.
219615604|NCT07095530|PROCEDURE|titanium membrane|surgical treatment for horizontal ridge augmentation by titanium mesh and PVDF membrane
219615605|NCT07097389|DIETARY_SUPPLEMENT|Cellobiose|Cellobiose powder (Savanna Ingredients GmbH), 5 g per day and 10 g per day, mixed into \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
219615606|NCT07097389|DIETARY_SUPPLEMENT|Oligofructose P95|Oligofructose (Orafti® P95, Beneo GmbH), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
219615607|NCT07097389|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin powder (Special Ingredients Limited), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
219615608|NCT07097103|BEHAVIORAL|Mediterranean Diet Intervention|Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
219615609|NCT07097103|BEHAVIORAL|Intensive Physical Activity Intervention|Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
219615610|NCT07097103|OTHER|Control|Participants will continue their usual medical management for early Parkinson's disease according to current clinical guidelines, without any additional dietary or exercise interventions provided by the study, and will be monitored through standard follow-up visits but will not receive any study-specific dietary or physical activity programs.
219528746|NCT00578552|DRUG|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
219528747|NCT00578552|DRUG|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
219615611|NCT07097714|PROCEDURE|Piezocision with ribose cross-linked collagen matrix (Ossix® Volumax)|A full-thickness mucoperiosteal flap will be elevated to expose the alveolar bone. Vertical corticotomy grooves (piezocision) will be created in strategic locations to accelerate orthodontic tooth movement. The Ossix® Volumax collagen matrix will be trimmed and applied directly onto the decorticated bone surface to support bone regeneration and soft tissue augmentation.
219615612|NCT07097714|PROCEDURE|control|A minimally invasive full thickness flap will be raised to expose the alveolar bone. Vertical corticotomy grooves will be performed in strategic locations to accelerate orthodontic tooth movement. The Deepitelized Free Gingival Graft (DFGG) will be placed and secured over the areas of decortication to promote soft tissue healing and augmentation.
219528748|NCT00578552|DRUG|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
218915565|NCT03300128|BEHAVIORAL|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
218915566|NCT03300128|OTHER|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
219041911|NCT04744454|DRUG|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
219528749|NCT02057458|DRUG|Sildenafil (Acute-1 hour)|Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
219041912|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
219041913|NCT06985901|PROCEDURE|Persistent atrial fibrillation ablation using Pulsed-field ablation|Pulmonary vein isolation with pulsed-field ablation coupled with 3D electroanatomic mapping. Follow-up with insertable cardiac monitor.
219528750|NCT02057458|DRUG|Sildenafil (Subchronic-4 weeks)|Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
219528751|NCT02057458|DRUG|Placebo|Sugar pill designed to mimic the sildenafil treatment
219528752|NCT06092658|OTHER|No Intervention|no intervention
219528753|NCT02149693|OTHER|high-fidelity simulation and teamwork training|
219528754|NCT02149693|OTHER|traditional resuscitation training|
219528755|NCT03212339|OTHER|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
219528756|NCT00510172|DRUG|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
219528757|NCT00510172|DRUG|Placebo|NaCL 0,9%
219528758|NCT04811794|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
219528759|NCT04811794|OTHER|Personal history|Personal history on diagnosis, treatment, and socioeconomic factors
219528760|NCT03767361|BIOLOGICAL|packed red blood cells transfusion|packed red blood cells transfusion
219528761|NCT02960594|BIOLOGICAL|INO-1400|
219528762|NCT02960594|BIOLOGICAL|INO-9012|
219528763|NCT02960594|BIOLOGICAL|INO-1401|
219528764|NCT03781739|DRUG|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
219528765|NCT00100620|DRUG|Zoledronic Acid|
219528766|NCT05601674|OTHER|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
219528767|NCT05601674|OTHER|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
219528768|NCT03097107|DRUG|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
219041914|NCT06592586|BIOLOGICAL|GBS-NN/NN2 vaccine|0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)
219204548|NCT06872372|DRUG|N-Acetylcysteine (NAC) Treatment|Participants in this group received N-Acetylcysteine (NAC) at a dose of 140 mg/kg orally or via a nasogastric tube every 4 hours for the first 16 hours, followed by the same dose at intervals of 6-8 hours for a total of 3 days, alongside standard supportive care for acute liver failure.
219528769|NCT03097107|DRUG|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
219528770|NCT03097107|DRUG|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
219528771|NCT03097107|DRUG|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
219528772|NCT04889586|DEVICE|EMG-biofeedback armband (REMO)|After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
219528773|NCT05642286|DEVICE|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
219528774|NCT01334307|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
219528775|NCT01334307|DEVICE|Control|Standard of Care
219528776|NCT03969693|RADIATION|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
219528777|NCT06464120|OTHER|Increasing load strength training|The Smith machine was used to intervene with athletes by employing an incremental load approach.
219528778|NCT06464120|OTHER|Constant load strength training|The Smith machine was used to intervene with athletes by employing a constant load approach.
219615613|NCT07090005|DEVICE|EndoZip System|The EndoZip System is a single-use automated suturing device, designed to create multiple internal gastric segmentations in the stomach using an endoscopic approach.
219615614|NCT07090005|DEVICE|OverStitch Endoscopic Suturing System (ESG)|The OverStitch ESG is suturing device, designed to create manual suturing in the stomach using an endoscopic approach.
219615615|NCT07097571|PROCEDURE|Glenohumeral Joint Injection and Suprascapular Nerve Block|An intra-articular injection into the glenohumeral joint will be performed using 4 cc of normal saline and 1 cc of betamethasone. Additionally, a suprascapular nerve block will be administered with 5 cc of lidocaine(%2).
219615616|NCT07095179|BEHAVIORAL|Eupnea|Participants will breathe normally.
219615617|NCT07095179|BEHAVIORAL|Intermittent inspiratory muscle training (IIMT)|Intermittent inspiratory muscle training (IIMT) will be conducted throughout the trial
219615618|NCT07097012|BIOLOGICAL|Tdap Vaccine Administration|The Tdap vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
219615619|NCT07097012|BIOLOGICAL|RSV Vaccine|The RSVpreF vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
219615620|NCT07097012|OTHER|Saline (as a placebo)|Normal saline (0.5mL) will be administered as a placebo according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
219615621|NCT07097246|OTHER||We do not intervene with the subjects; we only observe their body composition data.
219615622|NCT07095426|DIETARY_SUPPLEMENT|inulin|6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid
219615623|NCT07096869|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|IV infusion, 260 mg/m\^2
219615624|NCT07096869|DRUG|Abraxane®|IV infusion, 260 mg/m\^2
219615625|NCT07096934|OTHER|Standard of Care (SOC)|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded.
219615626|NCT07096934|BIOLOGICAL|SoC + Low dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. Low dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
219528779|NCT04862429|OTHER|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
219528780|NCT04862429|OTHER|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
219615627|NCT07096934|BIOLOGICAL|SoC + High dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. High dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
219528781|NCT02074605|BIOLOGICAL|Interferon alpha|
218915567|NCT06602661|PROCEDURE|Fissureless Lobectomy with Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler equipped with the ENDOPATH™ stapler line reinforcement. The ENDOPATH™ device uses bioabsorbable buttress material made from Polyglactin and Polydioxanone, designed to enhance the durability and effectiveness of the staple line.~The reinforcement tool is a novel preloaded device with a click and go mechanism, making it easy to load and use during surgery.~The primary objective is to reduce the average duration of hospital length of stay (LOS) directly caused by prolonged air leak (PAL). Secondary objectives include improving intraoperative characteristics (such as duration and amount of blood loss) and postoperative outcomes (such as incidence and duration of PALs, number of chest tube days, and incidence of hospital."
219528782|NCT00860223|DRUG|Digoxin|
219528783|NCT00860223|DRUG|Neratinib|HKI-272
219528784|NCT05436509|BIOLOGICAL|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
219528785|NCT05856604|BEHAVIORAL|Music Therapy|"Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017)."
219528786|NCT05856604|BEHAVIORAL|Storytelling|"Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation."
219528787|NCT03677622|DRUG|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
219528788|NCT00940693|DRUG|duloxetine|60 mg capsule once per day for 6 weeks
219528789|NCT00940693|DRUG|placebo|one capsule of placebo taken one a day for 6 weeks
219528790|NCT04391621|PROCEDURE|Autologous Adipose Derived stem cell transplantation|Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
219528791|NCT04391621|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
219528792|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
219528793|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
219528794|NCT01565096|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
219528795|NCT01565096|DRUG|Glimepiride|Glimepiride at individual dose
219615628|NCT07097116|OTHER|Hiking Bench Exercise Program|The training is performed 2 times per week over 8 weeks. It includes 4 progressive phases using a hiking bench, simulating hiking posture exercises targeting endurance, trunk control, and leg strength.
219615629|NCT07097116|OTHER|Structured Land-Based Exercise Program|This protocol adds aerobic warm-up, dynamic stretching, foundational strength (glutes, core), and cool-down flexibility work. Exercises are adapted to sailing-specific demands and performed 2 times per week alongside hiking bench work.
219528796|NCT05564819|DRUG|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
219615630|NCT07097038|DRUG|Oliceridine|Intraoperative analgesia should be administered with Oliceridine
219615631|NCT07097038|DRUG|Oxycodone|Oxycodone is used for intraoperative analgesia
219615632|NCT07096323|PROCEDURE|Nanofat only|"Fat was collected from either the lower abdomen or lateral upper thigh. A blunt-tipped infiltration cannula (Luer Lock Mercedes Gold Liposuction Cannula 4mm x 30 cm, Pakistan) was used for injection of Klein solution for tumescent anesthesia. Liposuction cannula was then used, connected to a 50 ml syringe mounted with a stopper to generate negative pressure for liposuction. The lipoaspirate was washed to obtain pure adipose tissue, and mechanical emulsification was achieved by transferring the fat through progressively smaller sieves (2.2 mm, 1.5 mm, 1.2 mm) between two 10 ml syringes connected with Luer-Lock connectors, with at least 30 passages each. The emulsion was not filtered and is referred to as Nanofat 2.0."
219528797|NCT05564819|DRUG|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
219528798|NCT03955237|PROCEDURE|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
219528799|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|10 mEq/day
219528800|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|300 mEq/day
219528801|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|150 mEq/day dietary sodium
219528802|NCT06051240|DRUG|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
219528803|NCT06051240|DRUG|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
219528804|NCT04991090|RADIATION|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
219528805|NCT04784598|OTHER|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
219528806|NCT02582541|PROCEDURE|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
219528807|NCT02582541|PROCEDURE|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
219528808|NCT03608722|OTHER|SLUMS|A pen and paper screening tool of cognitive impairment
219528809|NCT03608722|OTHER|MMSE|A pen and paper screening tool of cognitive impairment
219528810|NCT03608722|OTHER|MoCA|A pen and paper screening tool for cognitive impairment
219528811|NCT03608722|DEVICE|BrainCheck|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
219528812|NCT04231084|DRUG|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
219528813|NCT04231084|DRUG|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
219528814|NCT00585689|DRUG|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
219528815|NCT00585689|DRUG|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
219528816|NCT00585689|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
219528817|NCT00585689|PROCEDURE|Radical Cystectomy|
219528818|NCT03375853|BEHAVIORAL|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
219528819|NCT03375853|BEHAVIORAL|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
219528820|NCT02479503|PROCEDURE|Antibiotic prophylaxis in adult heart transplantation|
219528821|NCT02704182|DEVICE|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
219528822|NCT02704182|DEVICE|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
219528823|NCT04873011|DRUG|Quinine Hydrochloride|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion
219528824|NCT04873011|DRUG|Placebo|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
219528825|NCT04189250|DEVICE|Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments|The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
219528826|NCT02560194|PROCEDURE|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
219528827|NCT02560194|OTHER|Fecal occult blood test|Test for hemoglobin in faeces
219528828|NCT00550537|DRUG|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
219528829|NCT00550537|DRUG|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
219615633|NCT07096323|PROCEDURE|Nanofat mixed with PRP|Nanofat is prepared the same way as arm 1. PRP was prepared as follows: Ten milliliters of venous autologous whole blood were collected with tri-sodium citrate as an anticoagulant, then centrifuged at 112g (1000 rpm) for 10 minutes. The plasma was transferred to new tubes without tri-sodium citrate and centrifuged again at 448g (2000 rpm) for 10 minutes to separate the platelet pellet and platelet-poor plasma (PPP). PRP was kept for mixing it with nanofat while PPP was discarded
219615634|NCT07095712|DRUG|nL-TARD-001|Personalized antisense oligonucleotide
219615635|NCT03816475|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
219528830|NCT00550537|DRUG|erlotinib hydrochloride|150 mg taken by mouth daily
218915568|NCT06602661|PROCEDURE|Fissureless Lobectomy with Non-Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler without any additional reinforcement. This means the staple lines are created using the standard stapler without the use of bioabsorbable buttress materials.~The ECHELON™ 3000 stapler is used to divide the lung parenchyma, pulmonary artery branches, veins, and bronchus without any reinforcement, relying solely on the standard stapling mechanism."
218915569|NCT05342961|PROCEDURE|spinous balloon dilatation catheter (Plastic-Blade)|To treat Coronary artery disease
219528831|NCT00550537|DRUG|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
219528832|NCT00550537|GENETIC|gene expression analysis|Blood and tissue collection.
219615636|NCT07096505|BEHAVIORAL|Early time restricted eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 08:00 to 16:00. Dietary compliance was monitored by dietitian through food consumption records.
219615637|NCT07096505|BEHAVIORAL|Delayed Time Restricted Eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 12:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
219615638|NCT07096505|BEHAVIORAL|Control group with calorie restriction|Participants followed a diet with 25% energy restriction and a usual eating window from 08:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
219615639|NCT07097233|PROCEDURE|Virtual Reality Haptic Simulator|Students will use a virtual reality haptic simulator as an adjunct educational tool before treating real patients in the clinical setting.
219615640|NCT07097233|PROCEDURE|Mobile app|Students will use a mobile app as an adjunct educational tool before treating real patients in the clinical setting.
219615641|NCT07097233|PROCEDURE|Control|Students will directly treat real patients without using virtual reality haptic simulator or mobile app.
219615642|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
219615643|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
219615644|NCT06915038|DIAGNOSTIC_TEST|NavDx|NavDx is a clinically validated blood test to detect circulating tumor HPV DNA (ctHPVDNA). In this study, ctHPVDNA results, in conjuction with specimen analysis, will be used to assign post-surgical adjuvant treatment.
219615645|NCT06915038|RADIATION|Adjuvant Radiation 30 Gray|If undetectable postoperative ctHPVDNA levels and five or more positive nodes, or confirmed extranodal extension (ENE) (greater than 2 mm) deintensified radiation treatment of 30 gray.
219615646|NCT06915038|RADIATION|Adjuvant Radiation 40 Gray|If detectable postoperative ctHPVDNA, then reimage to evaluate for potentially operable disease, followed by appropriate surgery as indicated. If surgery is performed, repeat ctHPVDNA levels will be checked, and if then negative, subject will be placed in observation if N0 or N1 disease, and 30 Gy of radiation if N2 disease on final pathologic staging. If repeat ctHPVDNA level is positive, or shows no obvious operable disease, then subject will undergo 40 Gy of radiation.
219528833|NCT00550537|GENETIC|protein expression analysis|Blood and tissue collection.
219528834|NCT00550537|GENETIC|proteomic profiling|Blood and tissue collection.
219528835|NCT00550537|OTHER|laboratory biomarker analysis|Blood and tissue collection.
218915570|NCT05342961|PROCEDURE|spinous balloon dilatation catheter(lacrosse NSE)|To treat Coronary artery disease
219204549|NCT06872372|OTHER|Standard supportive care|Participants in this group received only standard supportive care for acute liver failure, without N-Acetylcysteine (NAC). Standard supportive care included measures to prevent hypoglycemia, administration of broad-spectrum antimicrobials, proton pump inhibitors, fluid and electrolyte balance maintenance, and supportive treatment for hepatic encephalopathy.
219528836|NCT00003647|DRUG|allovectin-7|
219528837|NCT00003647|DRUG|allovectin-7/dacarbazine|
219528838|NCT00003647|DRUG|dacarbazine|
219528839|NCT04520386|DRUG|OMT-111|Pre-filled Syringe
219528840|NCT03827174|OTHER|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
219528841|NCT03827174|BEHAVIORAL|Behaviour Change Ability Program|"1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation and problem-solving.~3. Patient-specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work"
219528842|NCT01853566|DRUG|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
218915571|NCT06700824|DEVICE|OTR4132|OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
218915572|NCT06700824|DEVICE|Placebo|saline solution
218915573|NCT06705127|DRUG|TORIPALIMAB INJECTION(JS001 )|"Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles."
218915574|NCT06705127|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
218915575|NCT06704230|DEVICE|video googles|Patients undergoing surgery use video googles and a headphone to distract from surgery
218915576|NCT06879678|BEHAVIORAL|Web-Based Exercise Program|Web-Based Exercise Program + standard protocol
218915577|NCT03277482|DRUG|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
218915578|NCT03277482|DRUG|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
219528843|NCT00617305|DRUG|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
219528844|NCT00617305|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
219528845|NCT00617305|DRUG|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
218915579|NCT03277482|RADIATION|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
218915580|NCT06723106|DRUG|RAY121|Injection
218915581|NCT06706466|OTHER|observational study|Non-interventional
218915582|NCT06705608|DRUG|Fingolimod|patients who received fingolimod for treating RRMS
218915583|NCT06705608|DRUG|Natalizumab|patients who received natalizumab for treating RRMS (active comparator)
218915584|NCT06705608|DRUG|Dimethyl fumarate (DMF)|patients who received dimethyl fumarate for treating RRMS (active comparator)
218915585|NCT06705608|DRUG|Alemtuzumab|patients who received alemtuzumab for treating RRMS (active comparator)
218915586|NCT06705608|DRUG|Teriflunomide|patients who received teriflunomide for treating RRMS (active comparator)
218915587|NCT06705231|BEHAVIORAL|The Aarhus-intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
218915588|NCT06578039|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|allogeneic umbilical cord-derived mesenchymal stem cell
218915589|NCT02081781|PROCEDURE|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
218915590|NCT02886819|OTHER|vibration|Whole body vibration
218915591|NCT00018148|DRUG|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
218915592|NCT00018148|DRUG|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
218915593|NCT03863795|OTHER|Survey Administration|Respond to SurveyGizmo survey online
218915594|NCT00641433|DEVICE|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
218915595|NCT00641433|DRUG|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
219528846|NCT00617305|DRUG|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
219528847|NCT04934618|DRUG|Carelizumab Combined With Irinotecan and Apatinib|Three-drug regimen was used in second-line treatment of Advanced gastric cancer
219615647|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
219615648|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
219615649|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
219615650|NCT05546021|PROCEDURE|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
218915596|NCT00781768|DRUG|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
218915597|NCT00781768|DRUG|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
218915598|NCT00150436|DRUG|Pregabalin|
218915599|NCT05882591|PROCEDURE|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
218915600|NCT02025686|DRUG|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
218915601|NCT02025686|OTHER|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
218915602|NCT00079417|DRUG|Carboplatin|Given IV
218915603|NCT00079417|PROCEDURE|Cryosurgery|
218915604|NCT00079417|PROCEDURE|Infrared Laser Therapy|
219528848|NCT02380807|DEVICE|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
219528849|NCT02380807|OTHER|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
219528850|NCT02900443|DRUG|Mycophenolate mofetil|
219528851|NCT02900443|DRUG|Azathioprine|
218915605|NCT00079417|RADIATION|Iodine I-125|Undergo radioactive therapy
218915606|NCT00079417|RADIATION|Radiation Therapy|Undergo radioactive therapy
219528852|NCT03575234|DRUG|Cyclophosphamide|Given IV
219528853|NCT03575234|BIOLOGICAL|IRX-2|Given SC
219528854|NCT03575234|BIOLOGICAL|Nivolumab|Given IV
219528855|NCT03575234|PROCEDURE|Surgery|Undergo surgery
218915607|NCT00079417|RADIATION|Ruthenium Ru-106|Undergo radioactive therapy
218915608|NCT00079417|DRUG|Vincristine Sulfate|Given IV
219528856|NCT03764748|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
219528857|NCT06562023|OTHER|Botulinum Toxin Type A|Patients will receive BTA injection within a period of 5 days after primary closure.
219528858|NCT06562023|OTHER|Mesotherapy|Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
218915609|NCT02458313|DRUG|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
219528859|NCT04510285|DRUG|Trastuzumab|Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
219528860|NCT04510285|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
219528861|NCT06346223|BEHAVIORAL|Mindfulness and psychoeducation|The single-session mindfulness intervention includes a 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit. All of the teaching contents will be closely related to dementia caregiving and delivered by a mindfulness teacher who has received 40 hours training in dementia caregiving. A weekly mindfulness practice reminder will be sent to the participants through SMS for 8 weeks. The caregivers will also be provided with access to a social media online platform for sharing their practice experience with their classmates online. The interventionist will address their difficulties and challenges via the platform to reinforce skill mastery.
218915610|NCT02458313|OTHER|Placebo|Placebo capsules b.i.d. for 12 weeks
218915611|NCT05684237|PROCEDURE|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
218915612|NCT05527977|BEHAVIORAL|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H\&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
218915613|NCT04017052|DRUG|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
218915614|NCT04174417|PROCEDURE|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
218915615|NCT04174417|PROCEDURE|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
219204550|NCT06817629|OTHER|Effects of ventilation with tidal volume adjusted on driving pressure on ventilation/perfusion ratios and hemodynamics in ARDS|To ventilated patients with ARDS with an objective of driving pressure than a tidal volume set on predicted body weight
219528862|NCT06346223|BEHAVIORAL|Psychoeducation|The caregivers in the control group will receive brief education on dementia with the same group size and of the same duration (90-minutes) as the sessions in the intervention arm. The nurse will deliver brief education (15 minutes) on dementia in the session, followed by group sharing and discussion on their daily caregiving experience. The caregivers in the control group will be provided with a toolkit with education materials about the common health problems of older adults and also be given access to a social media platform in which they can communicate and share their caregiving experiences with classmates.
219528863|NCT00048958|GENETIC|cytogenetic analysis|
219528864|NCT04058223|DEVICE|Hemorrhoidopexy|stapled hemorrhoidopexy
219528865|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
219528866|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
219528867|NCT04774757|PROCEDURE|Para-aortic lymph node dissection|Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
219528868|NCT00992771|DRUG|varenicline|up to 1mg BID for 8 weeks
219528869|NCT00992771|DRUG|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
219528870|NCT03097783|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
219528871|NCT02215083|DIETARY_SUPPLEMENT|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
219528872|NCT04864548|BIOLOGICAL|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
219528873|NCT04047147|OTHER|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
219528874|NCT04047147|OTHER|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
219528875|NCT00540020|OTHER|Rehabilitation|
218915616|NCT00904969|DEVICE|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
218915617|NCT00904969|DEVICE|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
218915618|NCT03502928|OTHER|Motor Control|Neck Motor Control
218915619|NCT03502928|OTHER|Manual Therapy|Massage + Joint Mobilizations
218915620|NCT03502928|OTHER|Dry Needling|Dry Needling in Neck Muscles
219528876|NCT04384978|BEHAVIORAL|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
218915621|NCT04267354|OTHER|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
218915622|NCT02947321|PROCEDURE|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
219528877|NCT04384978|BEHAVIORAL|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
218915623|NCT02947321|PROCEDURE|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
218915624|NCT01843829|DRUG|Oxaliplatin|
218915625|NCT01843829|DRUG|Capecitabine|
218915626|NCT01843829|DRUG|Carboplatin|
218915627|NCT01843829|DRUG|Paclitaxel|
218915628|NCT01843829|RADIATION|Radiotherapy|
218915629|NCT01843829|PROCEDURE|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
218915630|NCT02405078|DRUG|Chemotherapy|Given standard salvage chemotherapy
219528878|NCT03555305|DRUG|Insulin Glargine|Administered SC
219528879|NCT03555305|DRUG|Lantus|Administered SC
219528880|NCT02478190|OTHER|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
218915631|NCT02405078|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT scan
218915632|NCT02405078|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
218915633|NCT02405078|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT scan
218915634|NCT04363008|DIAGNOSTIC_TEST|serum inflammatory biomarkers|Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)
218915635|NCT03712696|DEVICE|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
218915636|NCT00199381|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
218915637|NCT05684835|PROCEDURE|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
218915638|NCT02137746|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
218915639|NCT03140241|PROCEDURE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
219528881|NCT02478190|OTHER|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
219528882|NCT03586726|DRUG|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
219528883|NCT03586726|DRUG|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
219528884|NCT00766168|OTHER|HDS HI 1.54; pahrifocon A|Contact Lens
219528885|NCT00766168|DEVICE|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
219528886|NCT06105034|PROCEDURE|interventional techniques, the severity of placental invasion, and various placental positions and suture techniques|Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
219615651|NCT06828471|BEHAVIORAL|Social Cognition Training|Neuroplasticity-based social cognition training that targets a range of social cognition skills, including visual and vocal affect perception, social cue perception, theory of mind, self-referential style, and empathy
219615652|NCT07104604|DRUG|Liposomal Irinotecan|In this study, the novel drug liposomal irinotecan was added, replacing the conventional formulation of irinotecan, and used as an intensified chemotherapy regimen (liposomal irinotecan + capecitabine) combined with immunotherapy and radiotherapy for neoadjuvant treatment of mid-lower rectal cancer.
219528887|NCT04888572|RADIATION|Peri-Apical X-ray|"Using a PCP UNC 15 Hu Friedy® periodontal probe and a gentle horizontal sweeping motion through the peri-implant tunnel or sulcus the examiner will assess bleeding on probing, the main factor in determining peri-implant inflammation and subsequently possible peri-implantitis. Then, using the same instrument, the author will examine whether there is an increase in the values of pocket depths compared to the initial values, highlighting an installation of peri-implant disease. Radiographically, evidence of bone loss after healing through taking a digital x-ray that will be viewed on DBSWIN® software will help authors make a diagnosis of peri-implantitis as well. It will be required that the digital film be perfectly parallel to the axis of the implant and the X-ray tube perpendicular to them in order to have an orthogonal radiograph."
219528888|NCT02209922|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
219528889|NCT02209922|DEVICE|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
219528890|NCT03226054|BEHAVIORAL|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
219528891|NCT01718886|DEVICE|Obalon Gastric Balloon|
219615653|NCT06222931|DEVICE|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
219615654|NCT06222931|DEVICE|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
219615655|NCT06222931|OTHER|Sham vibration|Simulated vibration
219615656|NCT07097727|DRUG|acetyl cysteine 600 mg|patients received acetyl cysteine 600 mg/ 12h IV in addition to antibiotics
219528892|NCT03520517|DRUG|BHV-0223|BHV-0223, 40 mg BID
219528893|NCT02803450|PROCEDURE|Epidural needle|Medication administration via epidural needle.
219528894|NCT02803450|PROCEDURE|Catheter Administration|Medication administration via epidural catheter.
219528895|NCT02803450|PROCEDURE|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
219615657|NCT07097727|DRUG|antibiotics and saline.|patients received only antibiotics and saline
219615658|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
219615659|NCT03309501|DRUG|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
219615660|NCT03309501|DRUG|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
219615661|NCT07113366|DRUG|FAE cream|Ficus awkeotsang Makino extract (FAE)
219615662|NCT07113366|DRUG|Placebo|Placebo
219615663|NCT07111910|DEVICE|Virtual Reality Infection Control Training|This study evaluates a VR training program designed specifically to improve infection control skills among healthcare workers during the Hajj pilgrimage, one of the world's largest mass gatherings. Unlike traditional training, this VR intervention offers immersive, realistic simulations tailored to the unique cultural and environmental challenges of Hajj. It focuses on practical skill-building and clinical readiness in crowded, high-risk settings. Using a rigorous randomized controlled trial design, the study aims to show that VR training is more effective than conventional methods, potentially setting a new standard for infection control education in mass gathering healthcare.
219528896|NCT02161445|DEVICE|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
219615664|NCT07113522|DRUG|MT-501|MT-501 Tablets
219528897|NCT06124235|COMBINATION_PRODUCT|Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles|"insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position."
219528898|NCT06124235|COMBINATION_PRODUCT|Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles|Non-coated orthodontic miniscrews
218915640|NCT03828825|OTHER|Patent Foramen Ovale closure|"The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care."
218915641|NCT03074136|DEVICE|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
218915642|NCT03074136|DEVICE|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
218915643|NCT03074136|DRUG|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
218915644|NCT02473848|DRUG|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
218915645|NCT05864859|OTHER|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
219528899|NCT05499572|DEVICE|Inhalation maneuver with placebo Inbrija and placebo Cyclops|Patients perform the inhalation maneuvers with placebo inhalers (Inbrija and Cyclops) during a Parkinson's off episode.
219528900|NCT01840735|DRUG|GS-5737|
219528901|NCT01840735|DRUG|Placebo|
219615665|NCT07112534|OTHER|Static stretching|Static stretching: 3 sets of 1 minute and 30 seconds of rest between sets
219615666|NCT07112534|OTHER|Foam rolling|Foam rolling: 3 sets of 1 minute and 30 seconds of rest between sets
219615667|NCT07111325|BIOLOGICAL|iEV|induced pluripotent stem cell-derived extracellular vesicles
219615668|NCT07111325|BIOLOGICAL|PRP|PRP injection
219615669|NCT07111325|OTHER|immobilization|immobilization
219615670|NCT07113535|OTHER|RAM cannula|RAM cannula as an interface for non invasive ventilation in preterm newborns
219615671|NCT07113535|OTHER|Short binasal prong|Short binasal prong as an interface for non invasive ventilation in preterm newborns
219615672|NCT07112209|COMBINATION_PRODUCT|Rezvilutamide combined with docetaxel|"Intervention Description:~Drug:Rivarestatine Description: 240mg, po, qd Drug:Docetaxel Description:75mg/m2，ivgtt q3w Drug:Prednisone Description:5mg,po,bid"
219615673|NCT07112352|COMBINATION_PRODUCT|Smart devices with Personalised data feedback and habit coaching|Smart devices (smartwatch and sleep mat) with a bespoke 'Healthy Habits' application with three healthy habit coaching and data feedback modules, focused on active minutes, steps and sedentary time, viewable on a tablet.
219528902|NCT04453748|OTHER|Complex diagnostic panel|Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
219528903|NCT05669768|DRUG|Pamiparib/Tamoxifen|Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
218915646|NCT00436696|OTHER|Laboratory Biomarker Analysis|Correlative studies
218915647|NCT00381901|BIOLOGICAL|trastuzumab|
218915648|NCT00381901|GENETIC|polymorphism analysis|
218915649|NCT00381901|PROCEDURE|adjuvant therapy|
218915650|NCT01786005|DEVICE|Transcranial magnetic stimulation|
218915651|NCT01940952|DRUG|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
218915652|NCT01940952|DRUG|Placebo + Donepezil 5mg or 10mg|
218915653|NCT01940952|DRUG|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
218915654|NCT04944992|DRUG|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
219528904|NCT00059371|PROCEDURE|male circumcision|
219528905|NCT01491880|BEHAVIORAL|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
219528906|NCT01491880|BEHAVIORAL|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
219528907|NCT00323193|BEHAVIORAL|MOVE!|group based psychoeducation, motivation and support
219528908|NCT00622232|GENETIC|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
219528909|NCT01779323|OTHER|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
219528910|NCT03132727|OTHER|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
219528911|NCT03708835|OTHER|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
219528912|NCT02100228|DRUG|Apixaban|Oral, 2.5 or 5 mg BID
219528913|NCT02100228|DRUG|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
219528914|NCT01051505|DRUG|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
219528915|NCT01051505|DRUG|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
219528916|NCT05834231|DRUG|Memantine|oral
219528917|NCT05834231|DRUG|Placebo|oral
219528918|NCT03148808|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
219528919|NCT00291057|DRUG|MALG|30 minute application
219528920|NCT02879877|DRUG|UCB7858|
219528921|NCT02879877|DRUG|Placebo|
219528922|NCT03180866|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
219528923|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
219615674|NCT07112352|DEVICE|Smart devices with data feedback|"Smart devices (smartwatch and sleep mat) with a standard off-the-shelf data feedback application (WithingsTM App) providing generalised data feedback from the participant's smartwatch and sleep mat, viewable on a tablet for 6 months."
219615675|NCT07112352|OTHER|Control|Standard care where they will be signposted to National Health Service (NHS) guidance on Healthy Ageing for older adults.
219528924|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
218915655|NCT04944992|DRUG|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
218915656|NCT01295814|DRUG|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
218915657|NCT01295814|OTHER|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
218915658|NCT05148468|DEVICE|Active spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
218915659|NCT05148468|DEVICE|Sham spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
219528925|NCT05057650|DIETARY_SUPPLEMENT|Vegan diet|Provide
219528926|NCT04395677|DRUG|AB-106|"Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD"
219528927|NCT01320696|BIOLOGICAL|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
219528928|NCT01837862|DRUG|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
219528929|NCT01837862|DRUG|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients \< 12kg: 0.05 mg/kg; for patient \> 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
219528930|NCT01837862|DRUG|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
219528931|NCT01837862|DRUG|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
219528932|NCT01837862|DRUG|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
219528933|NCT01837862|DRUG|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
219528934|NCT02878109|DEVICE|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
219528935|NCT02878109|DEVICE|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
218915660|NCT02495506|OTHER|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
219615676|NCT07111949|OTHER|SSC Group 1 (Operation room)|"Salivary cortisol sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the operating room (OR) (2)1 hour (h) after admission to the post-op room (PR) (3)at least 1 h after admission to the maternity ward (MW) The stress levels of the newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, the heart rate and O2 saturation will be measured and recorded.~1. At least 5 min after the initiation of SSC in the OR~2. During the Hep-B vaccination in the PR~3. At least 30 min after SSC after admission to the MW~4. At least 24 h after birth in the MW, at least 30 min after SSC. The success of the newborn sucking will be assessed using the LATCH at the following 3 measurement times.~(1) At least 5 min after the initiation of SSC in the OR (2)At least 1 h after admission to the MW, during SSC (3)At least 24 h after birth in the MW during SSC."
218915661|NCT02495506|OTHER|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
218915662|NCT01031212|DRUG|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
218915663|NCT01031212|DRUG|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
218915664|NCT01031212|DRUG|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
218915665|NCT01031212|DRUG|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
218915666|NCT06245343|DEVICE|Functional inspiratory muscle training group|"Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients."
218915667|NCT06245343|DEVICE|Control group|The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
219528936|NCT04339894|OTHER|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
219528937|NCT05411536|OTHER|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order."
219528938|NCT01821144|BEHAVIORAL|Salt reduction|Salt reduction
219528939|NCT01821144|OTHER|Control|No salt awareness education
219528940|NCT03992066|DRUG|Vadadustat|oral 150 mg tablet
219528941|NCT03992066|DRUG|Darbepoetin alfa|solution intravenous injection
219528942|NCT03992066|DRUG|Epoetin alfa|solution for intravenous injection
219615677|NCT07111949|OTHER|SSC Group 2 (Post-operation room)|"SC sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the OR (2)1 hour (h) after admission to the PR (3)At least 1 h after admission to the MW.~The stress levels of newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, and heart rate and oxygen saturation will be measured and recorded.~(1)At least 5 min after birth under radiant heater in the baby care room (BCR) (2)At least 10 min after being taken to the BCR during Hep-B vaccination under radiant heater (3)At least 5 min after being admitted to the maternity ward after SSC (4)5 min after being held in the mother's arms Newborn sucking success will be assessed using LATCH at the following 3 measurement times.~(1)At least 5 min after starting SSC in the post-op care unit (2)During SSC after being admitted to the MW (3)At least 24 h after being held in the mother's arms in the MW."
219615678|NCT07111585|OTHER|Personalized health coaching program|"Clinical: Pre-discharge education on HF management (e.g., symptoms, treatment, diet, medication, lifestyle) is provided with a booklet and website link. A digital scale is given. After discharge, 12-week phone coaching monitors medication adherence, weight, and sodium intake.~Functional: Patients are referred to cardiac rehab for tailored exercise plans. Education on home exercise and oxygen monitoring is provided, with QR-linked videos. Coaching supports exercise adherence.~Psycho-cognitive: Emotional support is based on the PERMA model. Patients with severe issues are referred to psychiatry. Post-discharge, coaching includes psychiatric appointment support and use of the 100-Day Diary for self-care and gratitude journaling.~Social: Nurses foster trust and social reintegration. Referrals to community services are made as needed. Weekly calls ensure service connection and address unmet needs via social workers."
218915668|NCT04733469|BEHAVIORAL|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~* A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~* Take-home and online copies of the video for repeat viewing~* A video summary~* A question prompt list patients can use to ask clinicians more questions about palliative care~* Contact information and brochures for local palliative care programs"
218915669|NCT04733469|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~* Usual care~* A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
218915670|NCT02353208|OTHER|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
218915671|NCT02353208|OTHER|Placebo|Participants will not be asked to chew bacon bits
218915672|NCT01376258|DRUG|5ARI|dutasteride or finasteride
218915673|NCT03568214|OTHER|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
218915674|NCT03414983|BIOLOGICAL|Nivolumab|Specified dose on specified days
218915675|NCT03414983|DRUG|Oxaliplatin|Specified dose on specified days
218915676|NCT03414983|DRUG|Leucovorin|Specified dose on specified days
218915677|NCT03414983|DRUG|Fluorouracil|Specified dose on specified days
218915678|NCT03414983|DRUG|Bevacizumab|Specified dose on specified days
218915679|NCT01254617|BIOLOGICAL|Cetuximab|Given IV
219528943|NCT02815319|DRUG|Dexamethasone|Steroid prophylaxis
219528944|NCT04795609|OTHER|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening."
219528945|NCT05313698|DIAGNOSTIC_TEST|No intervention|cross-sectional study/psychometric study
219528946|NCT01073657|OTHER|Supported Education|Rehabilitation counseling using peers to achieve educational goals
218915680|NCT01254617|OTHER|Laboratory Biomarker Analysis|Correlative studies
218915681|NCT01254617|DRUG|Lenalidomide|Given PO
218915682|NCT00269217|DRUG|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
218915683|NCT00269217|DRUG|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
218915684|NCT00269217|DRUG|Comparator: simvastatin|Duration of Treatment 12 Weeks
218915685|NCT00638677|DIETARY_SUPPLEMENT|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
219528947|NCT01073657|OTHER|General Peer Support|Matched peer support for any personal goal other than education
219528948|NCT03255148|DRUG|Oxytocin|Syntocinon nasal spray
218915686|NCT00638677|DIETARY_SUPPLEMENT|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
218915687|NCT00638677|DIETARY_SUPPLEMENT|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
218915688|NCT02928887|OTHER|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
218915689|NCT00303069|BIOLOGICAL|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
218915690|NCT00303069|BIOLOGICAL|Comparator: Placebo|Single dose of saline placebo intramuscularly
218915691|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)
219528949|NCT03255148|DRUG|Placebo|Placebo nasal spray
219615679|NCT07111585|OTHER|standard care|Participants in the control group will receive standard care, including guideline-directed medical therapy, based on the latest clinical guidelines currently provided to patients with HF at the hospital, as well as HF education. HF education will be provided using a booklet that includes information on HF (definition, causes, symptoms, diagnosis, treatment, medications, and self-management), an exercise poster, a symptom log, a symptom checklist, fall prevention tips, and a dietary guide. Additionally, nutritionist consultations on HF-related diets, cardiac rehabilitation exercises, and financial support available through the social work department, if necessary, will be provided.
219528950|NCT03909516|DEVICE|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
219528951|NCT01975688|DRUG|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
219528952|NCT04714047|OTHER|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
219615680|NCT06918574|OTHER|Breastfeeding Education with Breastfeeding Roadmap|"Information about the Breastfeeding Roadmap prepared by the researchers will be explained to the mothers in the intervention group and hung in poster rooms."
219615681|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
219615682|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
219615683|NCT04745221|OTHER|autologous fecal bacteria|autologous fecal bacteria transplantation
219615684|NCT05442801|DRUG|Cyclopentolate|Well known eye drop used for cycloplegic refraction among children.
219615685|NCT05442801|DRUG|Tropicamide|Well known eye drop used for cycloplegic refraction among children.
219615686|NCT07112469|BEHAVIORAL|Health promotion communication|"1. Students (Research subjects):~   * All students: Students perform plays during flag-raising ceremonies for all grades. These plays emphasize the importance of increasing physical activity for better health.~  * Selected students from Phase 1: Students selected in Phase 1 are guided to play games that help them identify healthy behaviors. They also receive flyers with messages about the benefits of physical activity.~2. Parents:~   Parents receive flyers with messages about the benefits of physical activity.~3. Schools:~Research team advises school principals and discusses ways to adjust factors that affect students' physical activity time. These factors are assessed based on cross-sectional study results, literature reviews, and the evaluation of the current situation at each school."
219615687|NCT07112469|BEHAVIORAL|Guidance and practice in developing physical activity plans|"The intervention is exclusively implemented for students who participated in the Phase 1 survey. These students are being guided to create weekly physical activity plans by keeping a journal. They are also encouraged to self-monitor their progress. A Facebook page has been created to launch the Active Moments with Family challenge and provide regular health-related updates. Teachers are sharing this page with parents to promote participation in the challenge and enhance their health knowledge."
219615688|NCT06463028|DRUG|Sapanisertib|Oral
219615689|NCT06463028|DRUG|Serabelisib|Oral
219615690|NCT06463028|DRUG|Paclitaxel|Infusion
219615691|NCT06932484|PROCEDURE|parameters|during surgery hemodynamic will be optimized based on percentage variation of different variables
219615692|NCT06949436|PROCEDURE|GK SRS|Under local anaesthesia, a Leksell stereotactic head frame is fixed to the patient's head to allow for complete cranial immobilization during treatment. The retrogasserian (i.e., mid-cisternal) target will be utilized at a single 4 mm isocenter, and 40 Gy will be administered to the 50% isodose line while limiting the brainstem to 12 Gy.
219615693|NCT00858273|DIETARY_SUPPLEMENT|Antioxidant supplement|1 capsule daily with dinner
219615694|NCT00858273|OTHER|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
218915692|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
219615695|NCT00858273|DRUG|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
219615696|NCT03285412|DRUG|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
218915693|NCT06472232|DRUG|Chloroprocaine|Selection of low concentration of chloroprocaine as local anesthetic for labor analgesia
219615697|NCT03285412|OTHER|Endocrine therapy|Hormone therapy
218915694|NCT04664686|PROCEDURE|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
218915695|NCT04664686|PROCEDURE|AV node ablation|AV node ablation
219615698|NCT03266640|DRUG|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
219615699|NCT04571749|BEHAVIORAL|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
219615700|NCT05721261|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
219615701|NCT05721261|DEVICE|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
219615702|NCT04042753|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
219615703|NCT04042753|DRUG|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
219615704|NCT04042753|DRUG|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
219615705|NCT03244384|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219615706|NCT03244384|OTHER|Clinical Observation|Undergo observation
219615707|NCT03244384|PROCEDURE|Computed Tomography|Undergo a CT scan
219615708|NCT03244384|PROCEDURE|CT Urography|Undergo a CT urography
219615709|NCT03244384|PROCEDURE|Cystoscopy|Undergo a cystoscopy
219615710|NCT03244384|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
219615711|NCT03244384|BIOLOGICAL|Pembrolizumab|Given IV
219615712|NCT03244384|OTHER|Pharmacological Study|Correlative studies
219615713|NCT03244384|OTHER|Quality-of-Life Assessment|Ancillary studies
219615714|NCT03244384|OTHER|Questionnaire Administration|Ancillary studies
219615715|NCT05775913|DEVICE|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
219615716|NCT05996419|OTHER|DSB-I|Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
219615717|NCT05030038|BIOLOGICAL|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
219615718|NCT05030038|BIOLOGICAL|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
218915696|NCT04073173|PROCEDURE|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
219615719|NCT06443164|BEHAVIORAL|Empowered Relief|Pain Management Course that has been used to treat pain in patients with different pain conditions.
218915697|NCT04073173|PROCEDURE|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
218915698|NCT04073173|DRUG|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
219615720|NCT06443164|OTHER|Standard of Care|Gender Affirming surgery without any attention to pain conditions prior to surgery.
219615721|NCT05277714|OTHER|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
219615722|NCT05277714|OTHER|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
219615723|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
219615724|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
219615725|NCT06197802|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
219615726|NCT06197802|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
219615727|NCT06633900|DRUG|IM naltrexone|The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.
219366529|NCT02457234|BEHAVIORAL|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
219366530|NCT04321811|OTHER|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
219366531|NCT02103686|DRUG|Lyrica|
219366532|NCT02103686|DRUG|Experimental drug|sustained release formulation of pregabalin
219366533|NCT02103686|DIETARY_SUPPLEMENT|High fat meal|
219366534|NCT02103686|DIETARY_SUPPLEMENT|fasted|
219366535|NCT02201758|DIETARY_SUPPLEMENT|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
219366536|NCT02201758|OTHER|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
219366537|NCT00138216|DRUG|irinotecan hydrochloride|
219366538|NCT00138216|DRUG|temozolomide|
219366539|NCT00138216|DRUG|vincristine sulfate|
219204551|NCT06870084|OTHER|Ultrasonography|The masseter muscle thickness measurements were performed in B mode of ultrasound, midline between the zygomatic arch and mandibular plane, parallel to the mandibular plane and perpendicular to the mandibular ramus. Prior to the examination being performed in the resting position, the patient was instructed to make minimal contact between the lips without the teeth touching each other.The first USG image was recorded in this position. The patient was then requested to clench their teeth as firmly as possible, after which a second USG image was recorded from the same area. The thickness of the muscles was measured again on second recorded images. To ensure the reliability of the measurements, these procedures were repeated by the same researcher after the patients rested for five minutes.
218915699|NCT05557084|PROCEDURE|laparoscopic vertical clip gastroplasty (LVCG) with Bariclip.|The investigator performed laparoscopic vertical clip gastroplasty, This procedure consists of a nonadjustable clip that is vertically placed around the stomach, parallel to the lesser curvature, mimicking the effect of sleeve gastrectomy. The clip restricts oral intake, the anatomy of the stomach is not permanently changed, the small bowel remains untouched, the digestive pathway is not diverted, no stapling or resection are required and the magnitude of restriction is supposed to remain constant during the years. The vertical clip is thus placed without risks of staple line leak, malabsorption side effects, changes in anatomy, and is potentially reversible \[9\]. creating a 4-cm window to enter the lesser sac while lifting the stomach to create sufficient space to be able to suture. Plication of the antrum for 3-5 cm is performed. Fluid testing for patency is performed with methylene blue or normal saline and the procedure is terminate.
219615728|NCT06633900|BEHAVIORAL|Usual Care|Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
219615729|NCT00070564|BIOLOGICAL|pegfilgrastim|Given IV
219528953|NCT04714047|OTHER|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
218915700|NCT00574197|DRUG|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
218915701|NCT00751296|DRUG|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
219528954|NCT04714047|OTHER|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
219615730|NCT00070564|DRUG|AC regimen|Given IV
219615731|NCT00070564|DRUG|cyclophosphamide|Given IV
219615732|NCT00070564|DRUG|doxorubicin hydrochloride|Given IV
219615733|NCT00070564|DRUG|paclitaxel|Given IV
219615734|NCT05437965|OTHER|Treatment made by experienced clinicians|Treatment made by experienced clinicians
218915702|NCT00007254|DRUG|Pain relief for pressure ulcers|
218915703|NCT03077971|BEHAVIORAL|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
218915704|NCT03077971|BEHAVIORAL|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
218915705|NCT03574584|DRUG|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
219615735|NCT04812912|DIAGNOSTIC_TEST|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
219615736|NCT04812912|BEHAVIORAL|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
219615737|NCT04740736|PROCEDURE|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
219615738|NCT05284721|BEHAVIORAL|Family Peer Navigator for Early Psychosis|The Family Peer Navigator model is theoretical underpinning by the Social-Ecological Model and the Social Cognitive Theory, that incorporates a mixture of evidence- and research-based strategies, to include three key components: 1) Introduction and Assessment; 2) Individual Psychoeducation; 3) Six Brief Check-In
219204552|NCT06870084|OTHER|Lateral cephalometric radiography|Standard lateral cephalometric radiographs were obtained from the patients.
219528955|NCT04714047|OTHER|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
218915706|NCT03574584|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
219528956|NCT00854100|DRUG|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
218915707|NCT03574584|DRUG|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
219528957|NCT00854100|DRUG|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
219528958|NCT00854100|DRUG|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
219528959|NCT04350086|DRUG|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
219528960|NCT05250245|DRUG|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
219528961|NCT05250245|OTHER|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
219528962|NCT01459003|OTHER|beauty care|beauty care performed before each chemo cycle
219528963|NCT00183794|DRUG|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
219528964|NCT01228409|DRUG|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
219615739|NCT05284721|BEHAVIORAL|Care Coordination|active control, treatment as usual including services provided by the coordinated specialty care program for first-episode psychosis.
218915708|NCT05535296|BEHAVIORAL|Risk profile|Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
218915709|NCT01622166|BEHAVIORAL|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
219528965|NCT04004676|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
219528966|NCT04004676|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
219528967|NCT06981754|DRUG|Dexamethasone palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
218915710|NCT06070064|OTHER|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
219204553|NCT06870084|OTHER|Facial photograph|Standard facial photographs were taken from a distance of 1.5 metres.
219204554|NCT06870084|OTHER|Weigth and Heigth|The Body Mass Index is calculated by measuring with a standardised scale and height chart.
219204555|NCT06870084|OTHER|Electronic caliper|The intermaxillary distance is measured from the cervical level of the palatal surfaces of the first permanent molars to their mesial corners using an electronic caliper.
218915711|NCT03234322|OTHER|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
218915712|NCT02958917|DRUG|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
218915713|NCT02958917|OTHER|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
218915714|NCT06025773|DRUG|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
218915715|NCT06025773|DRUG|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
218915716|NCT00181168|DRUG|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
218915717|NCT04672278|DIETARY_SUPPLEMENT|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
218915718|NCT02656771|DEVICE|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
218915719|NCT06350331|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
218915720|NCT06382038|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
218915721|NCT06462937|BEHAVIORAL|Exercise with supervision|Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.
218915722|NCT06462937|BEHAVIORAL|Exercise without supervision|Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.
218915723|NCT02325102|OTHER|No intervention|As this is an observational study, no intervention was conducted.
218915724|NCT05115331|RADIATION|Experimental Radiation Dose|16 Gy in 2 fractions
218915725|NCT05115331|RADIATION|Conventional Radiation Dose|8 Gy in a single fraction
218915726|NCT00830882|DRUG|levosalbutamol|2 puffs four times a day for 2 weeks
218915727|NCT00830882|DRUG|racemic salbutamol|2 puffs four times a day for 2 weeks
218915728|NCT00830882|DRUG|placebo|2 puffs four times a day for 2 weeks
218915729|NCT02170376|DRUG|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
218915730|NCT02170376|DRUG|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
218915731|NCT02170376|DRUG|Placebo|PLC, placebo
218915732|NCT02170376|DRUG|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
219204556|NCT04201184|BEHAVIORAL|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
219528968|NCT06981754|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
218915733|NCT03975985|OTHER|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~\- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
218915734|NCT03975985|OTHER|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
219204557|NCT04201184|BEHAVIORAL|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
219528969|NCT03486990|DRUG|TIMP-GLIA|intravenous infusion.
219528970|NCT04960488|PROCEDURE|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
219528971|NCT02216071|DRUG|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
219528972|NCT02216071|DRUG|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
218915735|NCT05026593|DRUG|Carboplatin|Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
219528973|NCT01934621|BEHAVIORAL|Strategy Training|
219528974|NCT01934621|BEHAVIORAL|Attention Control|
219528975|NCT02398071|DEVICE|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
218915736|NCT05026593|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
218915737|NCT05026593|DRUG|Etoposide|Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
219528976|NCT00385125|DRUG|Bendamustine|
218915738|NCT05026593|DRUG|Sintilimab|Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
218915739|NCT05026593|DRUG|IBI110|IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
219528977|NCT00385125|DRUG|Rituximab|
219528978|NCT00252811|DRUG|Gefitinib|
219528979|NCT04500353|OTHER|Face mask application for CPAP and/or PPV delivery|Face mask application for CPAP and/or PPV delivery
219528980|NCT03079128|BEHAVIORAL|Intervention|Weight Watchers Intervention
219528981|NCT06146153|DIAGNOSTIC_TEST|digital impression|intra oral scanning
219528982|NCT02359474|DRUG|Trabectedin|
219528983|NCT02359474|GENETIC|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
218915740|NCT03780244|DEVICE|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
218915741|NCT03780244|DEVICE|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
218915742|NCT03428984|DRUG|EXPAREL|EXAPREL 266 mg in 20 mL
218915743|NCT03659396|OTHER|individualized Tai Chi|individualized Tai Chi training exercise
218915744|NCT03659396|OTHER|Entire Tai Chi|the classical Yang style Tai Chi program
218915745|NCT03659396|OTHER|home-based program|Home-based exercise
218915746|NCT05996016|OTHER||
218915747|NCT04424095|DIAGNOSTIC_TEST|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
218915748|NCT04424095|DIAGNOSTIC_TEST|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
219528984|NCT02209480|BEHAVIORAL|Alexander Technique|
219528985|NCT02209480|DEVICE|Heat pad application|
219528986|NCT02209480|BEHAVIORAL|guided imagery|
219528987|NCT02069665|OTHER|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
219528988|NCT02069665|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
219528989|NCT02069665|DRUG|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
219528990|NCT02069665|DRUG|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
218915749|NCT01695226|DRUG|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
218915750|NCT01695226|DRUG|Placebo|pre-operative placebo twice daily for two to three weeks
218915751|NCT06001047|PROCEDURE|Group A|Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
218915752|NCT06001047|DRUG|Group B|"The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol."
218915753|NCT00628667|DRUG|Esomeprazole|40mg orally twice daily
219528991|NCT02069665|DRUG|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
218915754|NCT00628667|DRUG|Placebo|
219528992|NCT02069665|DRUG|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
219528993|NCT02069665|DRUG|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
219528994|NCT02069665|DRUG|Ibuprofen Suspension|taken under prescription
219528995|NCT02069665|DRUG|salbutamol|taken under prescription
219528996|NCT05639062|BEHAVIORAL|Narrative-based card game|This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
218915755|NCT03629535|DEVICE|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
219528997|NCT00389064|DRUG|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
219528998|NCT00389064|DRUG|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
219528999|NCT03104101|COMBINATION_PRODUCT|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
219529000|NCT03104101|DEVICE|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
218915756|NCT03629535|DEVICE|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
219529001|NCT03328936|OTHER|Laboratory Biomarker Analysis|Correlative studies
219529002|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
219529003|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
219529004|NCT03328936|OTHER|Pharmacological Study|Correlative studies
219529005|NCT02917902|OTHER|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
219529006|NCT02512952|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
219529007|NCT02512952|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
219529008|NCT02512952|PROCEDURE|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
219529009|NCT05608161|DIAGNOSTIC_TEST|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
219529010|NCT00762307|DEVICE|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
219529011|NCT02478957|DRUG|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
219529012|NCT02478957|DRUG|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
219529013|NCT00336622|DEVICE|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
219529014|NCT04995822|DEVICE|hip arthroplasty|Hip prosthesis surgery
219529015|NCT02264054|DRUG|[14C]talsaclidine, oral|
219529016|NCT02264054|DRUG|[14C]talsaclidine, iv|
219529017|NCT01064128|PROCEDURE|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
219529018|NCT01064128|PROCEDURE|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
219529019|NCT05589311|OTHER|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
219529020|NCT05589311|OTHER|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
219529021|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
219529022|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
218915757|NCT04927195|DRUG|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
218915758|NCT04927195|DRUG|Placebo|Placebo oral capsule
218915759|NCT00998686|DRUG|dutogliptin|400 mg
218915760|NCT00998686|DRUG|sitagliptin|100 mg
218915761|NCT00901836|RADIATION|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
218915762|NCT00901836|PROCEDURE|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
218915763|NCT03902444|DEVICE|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
218915764|NCT04645758|COMBINATION_PRODUCT|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
218915765|NCT04424134|DRUG|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
219615740|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
219615741|NCT03159897|DRUG|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
218915766|NCT04424134|DRUG|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
218915767|NCT02364700|DEVICE|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)"
218915768|NCT01010880|DRUG|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
218915769|NCT03123692|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
218915770|NCT03123692|DRUG|Placebo|14 days treatment with placebo
218915771|NCT00394017|BEHAVIORAL|Reminder letters|3 mailed reminder letters
218915772|NCT01323114|PROCEDURE|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
218915773|NCT01323114|OTHER|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
218915774|NCT05348538|OTHER|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~1. Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~2. Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~3. Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
218915775|NCT02289586|PROCEDURE|invasive ventilation|
218915776|NCT02289586|PROCEDURE|interventional bronchoscopy|
218915777|NCT02289586|DEVICE|noninvasive ventilation|
218915778|NCT02289586|DRUG|sedation(dezocine and midazolam)|
218915779|NCT02289586|DRUG|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
219529023|NCT01701128|OTHER|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
219615742|NCT03159897|DRUG|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
219615743|NCT03159897|DRUG|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
218915780|NCT02273934|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
218915781|NCT02273934|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
218915782|NCT02558088|DRUG|Salmeterol|
218915783|NCT04301960|OTHER|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
218915784|NCT04301960|OTHER|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
219529024|NCT05122208|DRUG|Famotidine Tablets|160 mg/day Famotidine
219529025|NCT01820793|DRUG|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
219615744|NCT03159897|DRUG|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
218915785|NCT04427267|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
218915786|NCT00804908|DRUG|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
219529026|NCT04972656|DRUG|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
219529027|NCT04972656|DRUG|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
219529028|NCT05586256|RADIATION|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
219615745|NCT01977105|BEHAVIORAL|Grow Together peer group|"Participants in this intervention will:~* Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~* Complete an intervention video activity approximately weekly:~  * 1\. View educational videos addressing topics related to healthy infant growth~ * 2\. Create photos/videos modeling healthy behaviors and post them to the group~ * 3\. Provide and receive feedback on posts~ * 4\. Be encouraged to share information with key caregivers of their child~* Attend group party soon after enrollment, to meet peers and group leader in person.~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~* Have basic program information provided to pediatrician to enhance conversation during office visits."
219615746|NCT01491568|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
218915787|NCT00804908|DRUG|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
218915788|NCT00804908|OTHER|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
218915789|NCT04550429|DEVICE|MyoSure Hysteroscopic Morcellator Device|This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
218915790|NCT05277415|BIOLOGICAL|Ghrelin|Ghrelin infusion
218915791|NCT05277415|BIOLOGICAL|Placebo|Placebo
218915792|NCT00222612|OTHER|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
219615747|NCT03883997|OTHER|No intervention|Cross-sectional
219615748|NCT02064998|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
219615749|NCT02064998|BEHAVIORAL|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
219615750|NCT02064998|BEHAVIORAL|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
219615751|NCT01247584|GENETIC|DNA analysis|
219615752|NCT01247584|GENETIC|mutation analysis|
219615753|NCT01247584|GENETIC|polymerase chain reaction|
219615754|NCT01247584|OTHER|laboratory biomarker analysis|
219615755|NCT02581579|DIETARY_SUPPLEMENT|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
219615756|NCT02581579|OTHER|Placebo|Placebo, 1 capsule per day during 14
219615757|NCT03605121|PROCEDURE|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
219615758|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
219615759|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
219615760|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
219615761|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
219615762|NCT05201287|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
218915793|NCT00222612|DRUG|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
218915794|NCT00222612|DRUG|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
218915795|NCT01280903|BEHAVIORAL|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
219204558|NCT06954376|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy (HBOT) using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
219204559|NCT06954376|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
218915796|NCT01280903|BEHAVIORAL|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
218915797|NCT03453164|RADIATION|Radiotherapy|Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.
219529029|NCT06215079|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that modulates the cortical excitability of the targeted motor area. While single-pulse TMS is generally used to explore the functioning of the brain, repetitive TMS is employed to induce lasting changes in brain activity. High-frequency rTMS leads to an increase in excitability in the motor cortex, whereas low-frequency application results in inhibition of motor cortical excitability. Theta-burst stimulation (TBS) is a form of rTMS that can be delivered continuously (cTBS) or intermittently (iTBS), thus modulating the excitability of corticospinal neurons beneath the stimulation area to either decrease or increase. rTMS is a growing research area in pain management, proven to be a safe and well-tolerated method. Studies have shown that rTMS applied to the motor cortex is a promising treatment method for chronic pain
219529030|NCT06215079|DEVICE|Sham transcranial magnetic stimulation|Patients in the control group will receive sham transcranial magnetic stimulation with sham coil for 35 minutes a day, 5 sessions in total, together with conventional rehabilitation.
219529031|NCT06215079|DEVICE|conventional rehabilitation program|Patients will receive 5 minutes of continuous ultrasound (1MHz, 2W/cm2, 1:4)), followed by a 20-minute contrast bath, and 15 minutes of TENS (frequency: 100 Hz; pulse duration: 50-100 ms; and amplitude adjusted to avoid discomfort or muscle contraction to the patient).
219529032|NCT02395003|OTHER|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
219529033|NCT01520623|OTHER|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
219529034|NCT04347642|PROCEDURE|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
219529035|NCT04347642|PROCEDURE|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
219615763|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
219615764|NCT06243666|OTHER|No intervention|No intervention was implemented.
219615765|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
218915798|NCT03453164|DRUG|Nivolumab|Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
219615766|NCT00533481|DRUG|MK0557|
219615767|NCT00931528|DRUG|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
219615768|NCT00931528|OTHER|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
219615769|NCT04928612|DRUG|CBP-1018|CBP-1018 for injection, IV infusion
219615770|NCT05825638|OTHER|Continuous training session|Continuous training consists of a 5 minute warm up, 5 minute cool down and 20 minutes of moderate intensity work. The workload is set at 60% of the patient's maximum power
219615771|NCT05825638|OTHER|Interval training session|Interval training consists of a 5-minute warm-up, a 5-minute cool-down and 20 minutes of alternating 60 seconds of high-intensity work (100% of the maximum power recorded in the incremental test that was carried out when the patient was admitted to the pulmonary rehabilitation department) and 60 seconds of unloaded pedalling or rest.
218915799|NCT05683353|OTHER|None intervention|None intervention.
218915800|NCT05134038|DIAGNOSTIC_TEST|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
218915801|NCT06520501|DIETARY_SUPPLEMENT|Herbal Medicine Sambiloto|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
218915802|NCT06520501|BEHAVIORAL|Brisk Walking|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
218915803|NCT06520501|COMBINATION_PRODUCT|Brisk Walking and Herbal Medicine Sambiloto|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute. Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days
218915804|NCT04003467|DRUG|EBP05|tablets
218915805|NCT04003467|DRUG|Placebo of EBP05|tablets
218915806|NCT01125592|DEVICE|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
218915807|NCT04718077|OTHER|Intraosseus|IO dexamethasone injection Dexamethasone 4 mg
218915808|NCT04718077|OTHER|Submucoal|SM dexamethasone injection Dexamethasone 4 mg
219615772|NCT05940181|BIOLOGICAL|XH001+ sintilimab|During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
218915809|NCT04880278|DRUG|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
218915810|NCT04880278|DRUG|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
219615773|NCT04985292|DIETARY_SUPPLEMENT|Probiotic, Lactobacillus|10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
218915811|NCT06956794|BEHAVIORAL|VirtualDONA Multimodal Program|A group-based behavioral intervention using immersive virtual reality without headsets. The 8-week program includes 16 sessions combining mindfulness, cognitive training, and physical exercises, designed to improve cognitive health and emotional well-being in older women living alone and at risk of poverty.
219529036|NCT01900236|BEHAVIORAL|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
218915812|NCT02561884|DRUG|Olostar Tab.|
218915813|NCT02561884|DRUG|Co-administration of Olmetec and Crestor|
218915814|NCT04849247|DRUG|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
219529037|NCT02449707|PROCEDURE|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
218915815|NCT06491277|OTHER|Flossband|The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.
218915816|NCT06491277|OTHER|Controlled Group|Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
218915817|NCT03879733|BEHAVIORAL|Thrive by Three|"The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no"
218915818|NCT03879733|BEHAVIORAL|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
219529038|NCT02449707|DEVICE|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
219529039|NCT02449707|DEVICE|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
219529040|NCT02449707|DEVICE|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
219529041|NCT02449707|DEVICE|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
219529042|NCT02449707|PROCEDURE|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
219529043|NCT02449707|PROCEDURE|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
219529044|NCT00827853|PROCEDURE|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
219529045|NCT00827853|PROCEDURE|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
219529046|NCT05063500|DRUG|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
219529047|NCT05063500|DRUG|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
219529048|NCT00731926|DIETARY_SUPPLEMENT|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
219615774|NCT04985292|DIETARY_SUPPLEMENT|Placebo|Inactive substance packaged to be identical to active treatment
219615775|NCT02619084|PROCEDURE|STN DBS|Bilateral STN DBS
219615776|NCT06424327|OTHER|Patient-Reported Outcomes Measurement Information System|Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
218915819|NCT04060498|BEHAVIORAL|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
219529049|NCT00731926|DIETARY_SUPPLEMENT|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
219529050|NCT00731926|OTHER|placebo|twice a day for 1 month
219615777|NCT00001271|DRUG|IgG-RFB4-SMPT-dgA|
219615778|NCT02943954|PROCEDURE|Angiography guided PCI|
218915820|NCT04060498|BEHAVIORAL|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
218915821|NCT02065037|DEVICE|room temperature air insufflation|control arm
219529051|NCT03451201|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
219529052|NCT03451201|BEHAVIORAL|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
219529053|NCT03451201|OTHER|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
219529054|NCT02613156|PROCEDURE|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
219529055|NCT02992093|OTHER|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
219615779|NCT02943954|DEVICE|Fractional Flow Reserve (FFR)|
219615780|NCT02730429|DRUG|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
219615781|NCT02730429|DRUG|Letrozole|Letrozole is standard of care in both arms
218915822|NCT02065037|DEVICE|warmed carbon dioxide insufflation|comparator arm
218915823|NCT03475095|OTHER|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
218915824|NCT04333563|DEVICE|CPAP|Continuous positive airway pressure
218915825|NCT04333563|DEVICE|NIV NAVA|Non-invasive neurally adjusted ventilatory assist
218915826|NCT05740072|OTHER|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
218915827|NCT05740072|OTHER|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
218915828|NCT05809557|OTHER|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
218915829|NCT05809557|OTHER|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
218915830|NCT02902458|OTHER|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
218915831|NCT04057950|OTHER|cosmetic product|Disulfure de sélénium versus placebo formula
218915832|NCT00751582|DIETARY_SUPPLEMENT|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
218915833|NCT00751582|BEHAVIORAL|Nutrition education|Nutrition education for children for three months
218915834|NCT00751582|OTHER|Control Group|No Nutrition Education
219529056|NCT05522062|PROCEDURE|surgical treatment for humerus shaft fracture|surgical treatment for humerus shaft fracture
219529057|NCT02296515|PROCEDURE|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
219529058|NCT01617954|DEVICE|MammaPrint|All subjects
219615782|NCT02185079|BEHAVIORAL|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
219615783|NCT02185079|BEHAVIORAL|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
219615784|NCT04647903|DRUG|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
219615785|NCT04647903|DRUG|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
219615786|NCT04647903|DRUG|Placebo|placebo for oral and intranasal administration
219615787|NCT00300690|DEVICE|6 mm Uni-graft® (B-Braun)|
219615788|NCT00300690|DEVICE|6 mm Gore-Tex® (WL Gore)|
218915835|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
218915836|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
218915837|NCT01428258|OTHER|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
219615789|NCT03659214|BEHAVIORAL|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
219615790|NCT06515119|BEHAVIORAL|Resources-Oriented Salutogenic (ROS) intervention|Participants in intervention group will receive an online ROS course via Zoom meeting, post daily salutogenic recordings and comments on Facebook. A closed Facebook group will be created to deliver resources booklet, zoom meeting links, as well as encourage participants share their daily salutogenic recording, give comments and thumps-up by group members.
219529059|NCT06781853|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being.
219529060|NCT03098277|OTHER|Accelerometer|Wear Microsoft Band 2
219529061|NCT03098277|OTHER|Laboratory Biomarker Analysis|Correlative studies
219529062|NCT03098277|OTHER|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
219529063|NCT03098277|BEHAVIORAL|Telephone-Based Intervention|Complete PRO questionnaires
219529064|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
219529065|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
219529066|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
219529067|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
219529068|NCT04010331|DIETARY_SUPPLEMENT|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
219529069|NCT04010331|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
219529070|NCT02435043|OTHER|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
219529071|NCT02435043|OTHER|standard management after stroke|standard management after stroke is individualised.
219615791|NCT05396898|DRUG|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
219529072|NCT02040376|DRUG|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
219529073|NCT02040376|DRUG|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
219529074|NCT01727271|DRUG|Tenofovir|
219529075|NCT01727271|BIOLOGICAL|Pegylated interferon alpha-2b|
219529076|NCT04487262|PROCEDURE|Cardiac surgery|Elective open heart surgery
219529077|NCT01387737|DRUG|TA-7284-Low|TA-7284-Low
219529078|NCT01387737|DRUG|TA-7284-High|TA-7284-High
219529079|NCT01360970|BIOLOGICAL|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
219529080|NCT04041843|DRUG|Apixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
219529081|NCT00060918|DRUG|carvedilol|
219529082|NCT00060918|DRUG|metoprolol|
219529083|NCT03552081|OTHER|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
219529084|NCT01950637|BEHAVIORAL|No treatment given|Completion of 90-item online questionnaire.
219615792|NCT05396898|DRUG|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
219529085|NCT01950637|BEHAVIORAL|survey|Completion of 58-item online questionnarie.
219529086|NCT02982408|DIETARY_SUPPLEMENT|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
219529087|NCT02982408|BEHAVIORAL|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
219615793|NCT03098212|OTHER|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
219615794|NCT05941312|PROCEDURE|autologous products|After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
218915838|NCT01428258|OTHER|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
218915839|NCT00000670|DRUG|Probenecid|
218915840|NCT00000670|DRUG|Zidovudine|
219529088|NCT02982408|BEHAVIORAL|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
219529089|NCT03137108|DEVICE|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
219529090|NCT04414917|DRUG|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
219615795|NCT06487793|BEHAVIORAL|Enhanced Insomnia Coach|The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).
219615796|NCT06487793|BEHAVIORAL|Sleep hygiene comparator|Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
219615797|NCT03321682|OTHER|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
219615798|NCT03321682|OTHER|Strength Training|Exercises carried out using weights and involving the main muscle groups.
219615799|NCT05229094|DEVICE|Eva Nexus|Eva Nexus vitrectomy device
219615800|NCT00000929|DRUG|Nonoxynol-9|
219615801|NCT02561429|PROCEDURE|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
219615802|NCT04621344|DIAGNOSTIC_TEST|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
219615803|NCT02378129|DRUG|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
219615804|NCT02378129|DRUG|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
219615805|NCT01207180|OTHER|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
219615806|NCT01207180|OTHER|Satisfaction survey|Patients will be given a satisfaction survey.
218915841|NCT06051201|OTHER|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
218915842|NCT02214797|DEVICE|Etafilcon A, Lotrafilcon B , Senofilcon A|
218915843|NCT03276507|DIAGNOSTIC_TEST|Pulmonary function studies|
218915844|NCT03276507|DIAGNOSTIC_TEST|Echocardiogram|
218915845|NCT03276507|DIAGNOSTIC_TEST|Electrocardiogram|
218915846|NCT03276507|DIAGNOSTIC_TEST|Chest radiography|
218915847|NCT03276507|DIAGNOSTIC_TEST|Blood test|
219615807|NCT01207180|OTHER|Control group --- no intervention|Control group
219615808|NCT01687894|DRUG|Vasopressins|Vasopressins propofol vasopressins sevoflurane
219615809|NCT01687894|DRUG|Placebo|Placebo propofol \& placebo sevoflurane
219615810|NCT01687894|DRUG|propofol|vasopressin propofol \& placebo propofol
219615811|NCT01687894|DRUG|sevoflurane|vasopressins sevoflurane placebo sevoflurane
219615812|NCT02493660|DEVICE|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
219615813|NCT02493660|PROCEDURE|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
219615814|NCT03073876|DRUG|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
219615815|NCT03073876|DRUG|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
219529091|NCT04414917|DEVICE|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
219529092|NCT05518890|OTHER|Diet Only|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
219615816|NCT01980030|DRUG|Romiplostim|
219615817|NCT05074368|BIOLOGICAL|ChAdOx1-nCov-19 (Astra-Zeneca)|vaccine inoculation and mixed inoculation
219615818|NCT05074368|BIOLOGICAL|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine|vaccine inoculation and mixed inoculation
219529093|NCT05518890|OTHER|Diet plus Exercise|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
219529094|NCT03659006|BIOLOGICAL|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
219529095|NCT01616381|DRUG|Sildenafil|PDE-5 Inhibitor
219529096|NCT01616381|DRUG|Placebo|Placebo for sildenafil 40mg x 3 daily
219529097|NCT06031766|DIETARY_SUPPLEMENT|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
219529098|NCT03828981|PROCEDURE|fast-track recovery program|"Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain."
219529099|NCT00899483|DRUG|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
219529100|NCT00239278|DRUG|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
219529101|NCT00239278|DRUG|prednisolone, 30 mg once daily and placebo|
219529102|NCT02486445|DRUG|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
219529103|NCT01215981|BIOLOGICAL|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
219529104|NCT01215981|BIOLOGICAL|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
219529105|NCT00659763|OTHER|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
219529106|NCT00659763|OTHER|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
219529107|NCT04298918|DRUG|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
219529108|NCT04298918|DRUG|Venetoclax|Participants will receive oral venetoclax.
219529109|NCT04298918|DRUG|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
219529110|NCT03421834|PROCEDURE|Catheter ablation of ventricular tachycardia|Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.
219529111|NCT03421834|DRUG|Optimal medical treatment|Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
219529112|NCT02464553|OTHER|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
219529113|NCT02606708|RADIATION|Accelerated intensity modulated radiation therapy (AIMRT)|
219529114|NCT03267381|OTHER|Blood draw (before surgery)|Blood will be drawn before surgery
219615819|NCT01847404|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
219615820|NCT01847404|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
219615821|NCT01847404|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
219615822|NCT01847404|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
219615823|NCT05147935|BEHAVIORAL|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
219615824|NCT01521650|DIETARY_SUPPLEMENT|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
219615825|NCT04552795|DRUG|3TC|12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
219615826|NCT05718934|DRUG|Neostigmine and glycopyrrolate|See arm descriptions
219615827|NCT05718934|DRUG|Sugammadex|See arm descriptions
219529115|NCT03267381|OTHER|Blood draw (every 3 months)|Blood will be drawn every 3 months
219529116|NCT03267381|OTHER|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
219529117|NCT00349843|DEVICE|Soft contact lens|
219615828|NCT04435834|DRUG|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
219615829|NCT05731518|DRUG|SC0245|SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
219615830|NCT05731518|DRUG|Irinotecan|Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
219529118|NCT00349843|DRUG|Marketed soft lens multipurpose disinfection regimen|
219529119|NCT01224535|DIETARY_SUPPLEMENT|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
219529120|NCT00840632|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
219529121|NCT00840632|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
219529122|NCT02821897|PROCEDURE|Target-controlled intravenous anaesthesia|
219529123|NCT02821897|PROCEDURE|Total anaesthesia|
219529124|NCT03006705|DRUG|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
219529125|NCT03006705|DRUG|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
219529126|NCT03006705|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
219529127|NCT03006705|DRUG|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
219529128|NCT03006705|DRUG|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
219529129|NCT04551261|DRUG|GLS4|It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
219615831|NCT01200446|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
219615832|NCT01200446|DIETARY_SUPPLEMENT|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
219529130|NCT04551261|DRUG|RTV|"1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human."
219529131|NCT04551261|DRUG|TAF|It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
219529132|NCT03701191|PROCEDURE|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
219529133|NCT00426647|DRUG|Buprenorphine|
219615833|NCT06203613|RADIATION|[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12|The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
219615834|NCT04699929|DRUG|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
219615835|NCT05116501|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
219529134|NCT00426647|DRUG|Tramadol|
219529135|NCT00276848|DRUG|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
219529136|NCT00276848|DRUG|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
219529137|NCT03036085|DRUG|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
219529138|NCT03036085|DRUG|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
219529139|NCT03036085|DRUG|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
219529140|NCT03036085|DRUG|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
219529141|NCT04354974|BEHAVIORAL|Evaluation|Evaluation of a cognitive remediation program for mood disorders
219529142|NCT01148030|DRUG|3M Skin and Nasal Antiseptic|Intra-nasal dosing
219615836|NCT05158673|DIETARY_SUPPLEMENT|Placebo of Cocoa flavonoids|Dietary supplement: The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks
218915848|NCT03276507|BEHAVIORAL|Quality of life questionnaire|
218915849|NCT00904605|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
218915850|NCT00904605|DRUG|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
218915851|NCT05902689|PROCEDURE|alveolar ridge preservation with bio-oss collagen|Alveolar ridge preservation with bio-oss collagen is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting bio-oss collagen in the socket and covering the biological barrier membrane.
218915852|NCT05902689|PROCEDURE|alveolar ridge preservation with sticky bone|Alveolar ridge preservation with sticky bone is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting sticky bone in the socket and covering the biological barrier membrane.
218915853|NCT02365025|OTHER|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
218915854|NCT01451112|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
218915855|NCT02242604|OTHER|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)"
218915856|NCT02770014|DRUG|Erlotinib|
218915857|NCT03925090|DRUG|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
218915858|NCT03925090|DRUG|Cisplatin+placebo|chemotherapy
219529143|NCT00858793|PROCEDURE|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
219615837|NCT05158673|DIETARY_SUPPLEMENT|Cocoa flavonoids|Dietary supplement: Two 500 mg capsules of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours (one in the morning and one at night) for 12 weeks
219615838|NCT00935116|DRUG|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
219615839|NCT02480517|DEVICE|Ultrasound|
219615840|NCT02480517|DEVICE|Sham Ultrasound|
218915859|NCT02172274|DRUG|[14C]-BI 10773 - oral solution|
218915860|NCT00445042|DRUG|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
219529144|NCT02562378|DRUG|Trastuzumab and non-pegylated liposomal doxorubicin|"3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV"
219529145|NCT02152397|BEHAVIORAL|Therapist-led brief intervention (TBI)|
219615841|NCT01480323|DRUG|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
218915861|NCT03459079|DRUG|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
218915862|NCT03459079|OTHER|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
218915863|NCT02040324|DEVICE|Laryngeal mask with gastric access|
218915864|NCT02040324|DEVICE|Endotracheal tube|
218915865|NCT05681182|COMBINATION_PRODUCT|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
218915866|NCT01112917|DEVICE|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
218915867|NCT01112917|PROCEDURE|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
218915868|NCT04681443|DRUG|Crystallized phenol application|Crystallized phenol application into the sinus tract
219615842|NCT01480323|DRUG|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
219615843|NCT04365010|DRUG|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
219615844|NCT04365010|DRUG|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
218915869|NCT00667199|DRUG|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
218915870|NCT00003449|DRUG|dexamethasone|
218915871|NCT00003449|DRUG|gemcitabine hydrochloride|
218915872|NCT00003449|DRUG|paclitaxel|
218915873|NCT03182049|PROCEDURE|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
218915874|NCT03182049|PROCEDURE|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
218915875|NCT00887536|DRUG|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
218915876|NCT00887536|DRUG|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
218915877|NCT00887536|DRUG|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
218915878|NCT00887536|DRUG|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
218915879|NCT00887536|DRUG|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]
218915880|NCT03264677|COMBINATION_PRODUCT|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
218915881|NCT03264677|COMBINATION_PRODUCT|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
218915882|NCT03264677|COMBINATION_PRODUCT|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
219529146|NCT06427161|PROCEDURE|LLLT application|The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.
219529147|NCT06427161|PROCEDURE|dextrose injection|25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
219529148|NCT01725529|DRUG|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
219529149|NCT01725529|DRUG|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
219529150|NCT01725529|DRUG|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
219529151|NCT01725529|DRUG|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
218915883|NCT00643747|BIOLOGICAL|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
218915884|NCT06322628|DRUG|VSA006|every 12 weeks, subcutaneous injections
218915885|NCT06322628|DRUG|Placebo|every 12 weeks, subcutaneous injections
219529152|NCT04899089|BEHAVIORAL|Cognitive Training|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
219615845|NCT02392481|PROCEDURE|Biofluid sampling|
219615846|NCT01410214|DRUG|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
218915886|NCT00898417|BIOLOGICAL|bevacizumab|
218915887|NCT00898417|DRUG|carboplatin|
218915888|NCT00898417|DRUG|paclitaxel|
218915889|NCT00898417|GENETIC|proteomic profiling|
218915890|NCT00898417|OTHER|laboratory biomarker analysis|
218915891|NCT00898417|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
218915892|NCT05085938|PROCEDURE|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
218915893|NCT04754048|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
218915894|NCT02433418|PROCEDURE|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
218915895|NCT02433418|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
219529153|NCT04899089|BEHAVIORAL|Trivia Training|The computerized trivia training asks participants to answer general questions related to pop culture, science, geography, etc. Participants can use online sources to search for answers and will be provided feedback on their accuracy.
219529154|NCT01104025|DRUG|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
219615847|NCT01410214|DRUG|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
219529155|NCT01104025|DRUG|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
218915896|NCT05630924|OTHER|SI! Program-NYC|SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
218915897|NCT02177123|DEVICE|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
218915898|NCT01112826|DRUG|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
218915899|NCT05753943|DRUG|QUALI|Medication 1 pill at night
218915900|NCT05686902|OTHER|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
218915901|NCT05690308|OTHER|Visual perturbation treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.
218915902|NCT05690308|OTHER|Regular treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill
219041915|NCT06988332|BEHAVIORAL|Problem Management Plus (PM+)|"Problem Management Plus (PM+) will be delivered according to the Spanish version of the WHO protocol (OMS, 2016).~PM+ is a low-intensity, transdiagnostic psychological intervention based on Cognitive Behavioral Therapy (CBT). The protocol incorporates evidence-based strategies, including problem-solving, stress management, behavioral activation, and accessing social support.~The intervention consists of five individual 90-minute sessions provided by healthcare professionals without previous expertise in mental health care (WHO, 2018). PM+ helpers will be supervised by master trainers specifically trained for Chile.~Two systematic reviews have demonstrated the effectiveness of PM+ in reducing symptoms of common mental disorders, such as depression and anxiety (Schäfer et al., 2023) and specific symptoms of post-traumatic stress (Akhtar et al., 2022)."
219529156|NCT01104025|DRUG|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
219529157|NCT01104025|DRUG|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
219529158|NCT01104025|DRUG|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
219529159|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
219529160|NCT04927013|BEHAVIORAL|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
218915903|NCT06845761|BEHAVIORAL|Self-Guided Cognitive Behavioral Therapy|Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) is a set of seven modules that consist of different skills trainings that can be accessed by devices with an internet connection. The version of CBT4CBT that will be provided is the alcohol-based CBT4CBT.
218915904|NCT02070575|OTHER|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
218915905|NCT01968447|OTHER|hypocapnia|Hyperventilation to the level of hypocapnia
218915906|NCT01968447|OTHER|normocapnia|Normal ventilation to the level of nromocapnia
218915907|NCT03776968|DRUG|HC1119|oral
218915908|NCT04050358|DIETARY_SUPPLEMENT|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
218915909|NCT04050358|DIETARY_SUPPLEMENT|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
218915910|NCT06177132|BEHAVIORAL|VIS-REHAB protocol|The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasises gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
218915911|NCT06394050|DIAGNOSTIC_TEST|Diagnostic Test|there is no intervention
219529161|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
219529162|NCT04927013|BEHAVIORAL|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
218915912|NCT02946138|RADIATION|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
218915913|NCT02766023|BIOLOGICAL|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
218915914|NCT02766023|DRUG|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
218915915|NCT02766023|OTHER|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
218915916|NCT00408057|OTHER|no intervention|no intervenion
218915917|NCT05902962|DRUG|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
219529163|NCT01948258|DEVICE|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
219529164|NCT04234334|OTHER|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
219529165|NCT04234334|OTHER|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
218915918|NCT04018755|BIOLOGICAL|anakinra|anakinra single-use prefilled glass syringes
218915919|NCT06085625|BEHAVIORAL|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
218915920|NCT06085625|BEHAVIORAL|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
219529166|NCT02372747|PROCEDURE|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
219529167|NCT02372747|PROCEDURE|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
219529168|NCT06265298|PROCEDURE|Conjunctival reconstruction|Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
219529169|NCT05401786|DRUG|Ipilimumab|Anti-CTLA-4
219529170|NCT05401786|DRUG|Cemiplimab|PD-1 inhibition
219529171|NCT05401786|RADIATION|SBRT|Stereotactic Body Radiotherapy
219529172|NCT03979768|OTHER|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
219529173|NCT01730638|DRUG|• TF2 and 68 Ga-IMP-288|
219529174|NCT05267093|PROCEDURE|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
218915921|NCT06271993|DEVICE|ColActivePlus Collagen Matrix Dressing|The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
219529175|NCT05267093|PROCEDURE|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
219529176|NCT04002024|OTHER|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
219529177|NCT04002024|OTHER|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
218915922|NCT05946057|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
218915923|NCT00131768|DEVICE|Synvisc (hylan G-F 20)|
219529178|NCT06385236|BIOLOGICAL|Dupilumab|"Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training."
219529179|NCT06385236|BIOLOGICAL|Benralizumab|"Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training."
219529180|NCT03757845|OTHER|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
219615848|NCT03690050|PROCEDURE|Diode 577 nm subthreshold micropulse laser|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
219615849|NCT03690050|PROCEDURE|Standard threshold laser (532 nm laser)|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
219615850|NCT00268450|BIOLOGICAL|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
219615851|NCT00268450|DRUG|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
219615852|NCT00268450|DRUG|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
219615853|NCT00268450|DRUG|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
219615854|NCT00268450|PROCEDURE|cysectomy|
219615855|NCT01068639|BEHAVIORAL|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
219615856|NCT02380339|BEHAVIORAL|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
219615857|NCT02380339|BEHAVIORAL|Psych-Educational and BF sessions|Psych-Educational and BF sessions
219615858|NCT02780258|DEVICE|Restylane Silk|
219615859|NCT05370625|DIETARY_SUPPLEMENT|Totum-854|To compare Totum-854 with Placebo on blood pressure
218915924|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock and pectointercostal block|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib and pectointercostal plane block (0,25% bupivacaine 15 ml) will perform at 4-5.th intercostal space. Both 2 blocks will perform bilaterally
218915925|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib to the all patients
219041916|NCT06858696|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
219041917|NCT06992726|DIETARY_SUPPLEMENT|Fish oil intervention|The diet was based on the principles of a balanced diet, and subjects in this group were additionally supplemented with n-3 PUFA (provided as 1.36 g fish oil capsules), with the rest of the intervention being the same as in the control group.
219615860|NCT05370625|DIETARY_SUPPLEMENT|Placebo|Five capsules per day to consume orally in two intakes
219615861|NCT02476019|DRUG|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
219615862|NCT02476019|DRUG|Placebo|Placebo administered subcutaneously
218915926|NCT05989009|OTHER|Breastfeeding|Mothers will breastfeed their newborns
218915927|NCT05788510|OTHER|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
219041918|NCT06992726|OTHER|Placebo intervention|Diet based on the principles of a balanced diet, taking placebo capsules with the same appearance and odor as the fish oil capsules.
219041919|NCT06923319|DEVICE|Odòn, Kiwi, Simpson skills|time 0, time 1 month and 2 months
219615863|NCT02502149|BIOLOGICAL|rFVIIIFc|As per arm description
219615864|NCT05464979|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
219615865|NCT05464979|DRUG|midazolam, fentanyl|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score.
219615866|NCT00005575|DRUG|Imipramine|
219615867|NCT00005575|BEHAVIORAL|Cognitive-behavior therapy|
219615868|NCT01644656|DEVICE|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
219529181|NCT03914365|PROCEDURE|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
219615869|NCT02766270|DRUG|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
219529182|NCT05679024|DRUG|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
219529183|NCT03502889|PROCEDURE|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
219529184|NCT03502889|PROCEDURE|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
219529185|NCT03502889|DRUG|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
219529186|NCT03502889|DEVICE|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
219529187|NCT02053454|DRUG|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
219529188|NCT02053454|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219529189|NCT00460733|DRUG|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
219529190|NCT00460733|DRUG|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
219529191|NCT05413096|COMBINATION_PRODUCT|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
219529192|NCT05413096|OTHER|placebo|placebo
219529193|NCT03528187|OTHER|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
219529194|NCT03528187|OTHER|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
219529195|NCT01368991|DEVICE|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
219615870|NCT02766270|RADIATION|Radiotherapy|
219615871|NCT02968576|DRUG|TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|
219615872|NCT02968576|DEVICE|Proteus Sensor System|
219615873|NCT04333160|DRUG|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
219529196|NCT01368991|PROCEDURE|Conventional closure|conventional closure, no kryptonite applied
219529197|NCT05157477|BEHAVIORAL|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
219529198|NCT06409377|DRUG|Precedex 200 MCG in 2 ML Injection|Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
219529199|NCT06409377|OTHER|C group:|Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
219529200|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
219529201|NCT01811953|DRUG|Metformin|oral administration
219529202|NCT01811953|DRUG|Empagliflozin|low dose of Empagliflozin oral administration
219529203|NCT01811953|DRUG|Empagliflozin/Metformin|low dose of Empagliflozin
219529204|NCT01811953|DRUG|Metformin|oral administration
219529205|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
219529206|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
219529207|NCT01811953|DRUG|Metformin|oral administration
219529208|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
219529209|NCT05937451|OTHER|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
219529210|NCT03579303|OTHER|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
219615874|NCT04333160|DEVICE|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
219615875|NCT04333160|OTHER|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
219615876|NCT05755880|PROCEDURE|Intrathecal dexamethason|After general anesthesia intrathecal dexamthasone will be added
219615877|NCT03855774|GENETIC|Polymorphisms|Classification of sleep disorders using 22 genetic polymorphisms
219615878|NCT02545582|DEVICE|VITARIA System|Implantable vagus nerve stimulator
219615879|NCT02222922|DRUG|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
219615880|NCT02222922|DRUG|fluconazole|combination drug used for drug-drug interaction sub-study
218915928|NCT05891704|PROCEDURE|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
218915929|NCT05891704|PROCEDURE|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
218915930|NCT01827137|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
218915931|NCT01827137|BIOLOGICAL|GM-CSF|subcutaneous injection
218915932|NCT01827137|OTHER|Montanide|adjuvant
218915933|NCT01827137|DRUG|lenalidomide|optional post-ASCT therapy
218915934|NCT01827137|DRUG|bortezomib|optional post-ASCT therapy
219529211|NCT02110277|DEVICE|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
218915935|NCT05967585|DEVICE|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
218915936|NCT04882735|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
218915937|NCT04092504|OTHER|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for elderly patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
218915938|NCT03095495|DEVICE|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
219529212|NCT02007733|OTHER|Serial Weights|We will collect serial weights on all children enrolled in this study.
219529213|NCT02007733|OTHER|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
219529214|NCT02007733|OTHER|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
219529215|NCT04741477|DRUG|CBD|CBD will be topically applied
219529216|NCT04741477|DRUG|THC|THC will be topically applied
219529217|NCT04741477|DRUG|Placebo|a placebo product (without cannabinoids) will be topically applied
219529218|NCT04198090|BEHAVIORAL|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
219615881|NCT02222922|DRUG|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
218915939|NCT03095495|DEVICE|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
218915940|NCT06407726|OTHER|virtual reality training group|Participants will receive 40-minute sessions five days per week for six weeks of Virtual Reality intervention and conventional therapy.
218915941|NCT06407726|OTHER|vestibular exercise group|Participants will receive 40-minute sessions five days per week for six weeks of Vestibular Exercises and conventional therapy.
219041920|NCT05255588|DEVICE|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
219041921|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
219529219|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
219529220|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
219529221|NCT02286817|DRUG|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
219529222|NCT04970368|PROCEDURE|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
219529223|NCT04970368|PROCEDURE|Selective staging|Intraoperative consultation (IOC)
219529224|NCT02046746|OTHER|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
219529225|NCT00004359|DRUG|methoxsalen|
219529226|NCT04095117|PROCEDURE|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
219529227|NCT02380989|DEVICE|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
219529228|NCT02380989|DEVICE|Placebo|
219529229|NCT04874389|DIAGNOSTIC_TEST|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
219529230|NCT01012934|DRUG|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
219529231|NCT01012934|DRUG|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
218915942|NCT06296953|DEVICE|PERIsign examination|Patients will be examined with the new device, PERIsign
218915943|NCT05274815|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218915944|NCT01565200|DRUG|T-DM1|3.6 mg/kg iv every 3 weeks
218915945|NCT01565200|PROCEDURE|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
218915946|NCT05705024|BIOLOGICAL|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
218915947|NCT05705024|OTHER|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
219529232|NCT04132011|DRUG|Extended Release Opioid Formulation, Shortened Intervals|Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
219529233|NCT04132011|DRUG|Extended Release Opioid Formulation, Standard intervals|Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
219529234|NCT04132011|DRUG|Placebo oral tablet|Lactose pill manufactured to mimic extended release opioid formulation
218915949|NCT03557294|DRUG|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
218915950|NCT03557294|DRUG|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
219529235|NCT06558656|DRUG|NTQ5082 capsule|"Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle."
219529236|NCT02262377|BEHAVIORAL|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
219529237|NCT05697419|BEHAVIORAL|deep breathing, muscle relaxation, and mindfulness|5-10-minute group sessions will be administered to DPT students teaching them the NIH recommended strategies of deep breathing, muscle relaxation or mindfulness.
219529238|NCT04115332|BIOLOGICAL|bio-feedback training|The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
219529239|NCT06421870|DRUG|Dapagliflozin 10mg Tab|Patients will be given dapagliflozin 10 mg once daily
219529240|NCT06421870|DRUG|Pentoxifylline 400 MG|Patients will be given pentoxyifylline 400 mg twice daily
219529241|NCT05710562|OTHER|Name not applicable|In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
219529242|NCT01604902|OTHER|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
219615882|NCT02222922|DRUG|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
219615883|NCT01254643|BIOLOGICAL|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
219615884|NCT03010228|BIOLOGICAL|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
219615885|NCT03010228|BIOLOGICAL|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
219615886|NCT01598961|OTHER|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
218915951|NCT03557294|DRUG|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
218915952|NCT06187896|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
218915953|NCT06187896|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
219041922|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
219041923|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
219041924|NCT06625047|DRUG|Temozolomide|Given PO
219041925|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
219529243|NCT00000294|DRUG|Carvedilol|
219529244|NCT02227186|OTHER|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
219529245|NCT00953498|DRUG|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
219529246|NCT00953498|DRUG|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
219529247|NCT03500003|OTHER|Acute milk intake|Food matrix: milk
219529248|NCT03500003|OTHER|Acute Yogurt intake|Food matrix: yogurt
219529249|NCT01721681|BIOLOGICAL|FACTOR X|
219529250|NCT00281749|PROCEDURE|TELEPHONE CALL|
219529251|NCT05338047|DRUG|Pegfilgrastim|Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
219529252|NCT03523039|DEVICE|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
219529253|NCT00371839|PROCEDURE|Audiological Evaluation|Tests of hearing, cognition, and speech perception
219529254|NCT06315530|DRUG|Telitacicept+SOC|160mg once a week for 48 weeks
219529255|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
219529256|NCT05344872|OTHER|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
218915954|NCT04026113|DRUG|Linaclotide|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
218915955|NCT04026113|DRUG|Placebo|Matching placebo
218915956|NCT05620628|DRUG|Durvalumab|Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
218915957|NCT05620628|DRUG|Savolitinib|Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
219529257|NCT04712422|OTHER|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
219615887|NCT01598961|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
219615888|NCT01598961|OTHER|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
219615889|NCT06160609|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
219615890|NCT06160609|DRUG|GSK3174998|GSK3174998 will be administered.
219615891|NCT01200693|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
219615892|NCT01200693|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
219615893|NCT01200693|DEVICE|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
218915958|NCT04861103|DRUG|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
218915959|NCT05562882|DRUG|Daratumumab Injection|intravenous daratumumab administration
218915960|NCT02887820|DEVICE|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
218915961|NCT03535584|BEHAVIORAL|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
218915962|NCT04077801|DIAGNOSTIC_TEST|diagnostic test|diagnostic test
218915963|NCT04077801|DIAGNOSTIC_TEST|Postpartum pain|test
218915964|NCT04077801|OTHER|Visual analogue scale|test TMJ /pelvic angle/lumber angle
219041926|NCT05798286|OTHER|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
218915965|NCT05398757|BEHAVIORAL|Mini mental state exame (MMSE)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
218915966|NCT05398757|BEHAVIORAL|Digit Symbol Substitution Test (DSST)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
218915967|NCT05398757|DIAGNOSTIC_TEST|Numeric rating Scale (NRS)|4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
218915968|NCT05398757|DIAGNOSTIC_TEST|Postoperative inflammation|All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
219041927|NCT05798286|OTHER|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
218915969|NCT05398757|DRUG|Midazolam|For sedation during surgery, patients in midazolam group will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg after spinal anesthesia.
218915970|NCT05398757|DRUG|Propofol|For sedation during surgery, patients in propofol group will receive i.v. propofol in dose 25-27 mcg/kg/min.
218915971|NCT05398757|DRUG|Dexmedetomidin|For sedation during surgery, patients in dexmedetomidin gropu will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
218915972|NCT04613362|BEHAVIORAL|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
219041928|NCT06880679|DEVICE|Point of Care Ultrasound|Point of Care Ultrasound during hospitalization
219041929|NCT06727344|OTHER|Blood Flow Restriction|Exercise with restriction of blood flow supply
219041930|NCT06727344|OTHER|Brace|Knee brace to restrict range of motion
219041931|NCT02777125|DEVICE|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
219615894|NCT03485144|BIOLOGICAL|TV003|Live attenuated virus vaccine-TetraVax-DV
219615895|NCT03485144|BIOLOGICAL|Placebo for TV003|Placebo
219615896|NCT03998267|DEVICE|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
219615897|NCT03998267|OTHER|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
219615898|NCT02761668|PROCEDURE|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
219615899|NCT02761668|PROCEDURE|ParS+Ortho 6M|Orthodontics 6 months post surgical
219615900|NCT03359850|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
219615901|NCT02783924|DRUG|Cholecalciferol|Vitamin D preparation
219615902|NCT02783924|DRUG|Placebo|placebo
218915973|NCT04613362|BEHAVIORAL|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
218915974|NCT04494672|PROCEDURE|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
218915975|NCT04494672|PROCEDURE|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
218915976|NCT06221280|PROCEDURE|Nerve block|"Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia."
218915977|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
219041932|NCT02777125|DEVICE|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
219041933|NCT06886373|DRUG|Systane Complete|Systane COMPLETE is an artificial tears that contain nano-emulsion of mineral oil and phospholipids.
219204560|NCT06953726|DRUG|Apixaban|Study participants will be randomized to twice daily oral administration of apixaban 5mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL.
219204561|NCT06953726|DRUG|Rivaroxaban|Study participants will be randomized to daily oral administration of rivaroxaban 20mg. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.
219204562|NCT05222984|DRUG|Decitabine|Given IV
219529258|NCT04712422|OTHER|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
219529259|NCT01830569|BEHAVIORAL|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
219529260|NCT01830569|OTHER|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
219529261|NCT01771705|OTHER|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
219615903|NCT03721120|DIAGNOSTIC_TEST|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
219615904|NCT03623503|OTHER|Observational study|
219615905|NCT02090088|DRUG|Not applicable- observational study|
219615906|NCT02265393|DRUG|OTO-104|
219615907|NCT02265393|DRUG|Placebo|
219615908|NCT03290378|DRUG|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
219615909|NCT03290378|OTHER|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
218915978|NCT05427344|OTHER|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
218915979|NCT05427344|OTHER|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
218915980|NCT05427344|OTHER|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
218915981|NCT02218372|DRUG|Fidaxomicin oral suspension|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
218915982|NCT02218372|DRUG|Fidaxomicin tablets|Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
219204563|NCT05222984|BIOLOGICAL|Navitoclax|Given PO
219529262|NCT04221425|PROCEDURE|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
219529263|NCT04221425|PROCEDURE|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
219529264|NCT00063856|BIOLOGICAL|Wetvax (APSV)|
219615910|NCT03952637|BIOLOGICAL|AAV9-GLB1|The risks of administering this treatment in a subject with GM1 gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject s immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.
219529265|NCT00723528|DRUG|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
219615911|NCT03952637|PROCEDURE|Abdominal ultrasound|Abdominal ultrasound will be performed as part of screening and safety follow- up studies. The ultrasound will be performed in a radiology department and will take approximately 20-30 minutes.
219615912|NCT03952637|DRUG|Rituximab|We are proposing the use of immune modulation to transiently deplete B-cells using rituximab. It will be infused at -21 days and -14 days before gene transfer.
219615913|NCT03952637|DRUG|Sirolimus|Sirolimus is a macrocytic lactone that inhibits T lymphocyte activation and proliferation by inhibiting activation of mammalian Target of Rapamycin (mTOR) kinase that suppresses cytokinedriven T-cell proliferation. We plan to give sirolimus from day -21 to Day 90 with option to extend to day 365 if clinically indicated.
218915983|NCT02218372|DRUG|Vancomycin oral liquid|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
218915984|NCT02218372|DRUG|Vancomycin capsules|Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
218915985|NCT05417542|OTHER|EEG|EEG recording during prematurity or around term
218915986|NCT05417542|OTHER|NIRS|NIRS recording during prematurity or around term
218915987|NCT05339555|OTHER|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
219529266|NCT00723528|DRUG|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
219529267|NCT00723528|DRUG|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
219615914|NCT03952637|DRUG|Methylprednisolone|Subjects will receive IV methylprednisolone 1 mg/kg or a maximum dose of 50 mg, 60-120 minutes prior to vector administration on day 0 to mitigate potential acute innate immune response against the vector.
218915988|NCT06513910|BEHAVIORAL|Music|Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
218915989|NCT05136560|DRUG|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
218915990|NCT05484102|DIETARY_SUPPLEMENT|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
219204564|NCT05222984|DRUG|Venetoclax|Given PO
219204565|NCT01837693|PROCEDURE|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
219204566|NCT05515705|DEVICE|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
219204567|NCT03873805|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
219204568|NCT03873805|DRUG|Cyclophosphamide|Given IV
219204569|NCT03873805|DRUG|Fludarabine|Given IV
219204570|NCT03873805|DRUG|Fludarabine Phosphate|Given IV
219529268|NCT00723528|DRUG|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
219615915|NCT03952637|DRUG|Prednisone|Prednisone (oral solution, dose 0.5 mg/kg) will be taken daily on Days 1-3.
219615916|NCT03952637|DIAGNOSTIC_TEST|Audiology assessment with ABR|The audiology assessment will be performed in the Audiology Clinic using a standard audiogram to measure thresholds for pure tones and speech, word recognition, tympanometry, and otoacoustic emissions if the subject is capable and tolerant of these measures. The assessment will take approximately 30 minutes. The ABR is a noninvasive neurophysiologic test to evaluate electrical signal transmission from the 8th cranial nerve to the brainstem and the cortex in response to specific tones. Electrodes are placed on the scalp and on each earlobe. An earphone gives off a brief click or tone and the electrodes pick up the brain's responses to these sounds and record them. This will be performed by a trained neurophysiology technician to monitor possible change in hearing during treatment. The procedure will be performed in the Interventional Radiology suite while the subject is sedated following the MRI, fMRI, and MRS of the brain.
219615917|NCT03952637|DIAGNOSTIC_TEST|Bone density scan (DEXA)|Type II subjects - This is a noninvasive enhanced form of X-ray that is used to measure bone loss. Loss of bone density is a known complication with GM1 gangliosidosis due to decrease in weight-bearing activities with disease progression. The procedure will be performed in the Nuclear Medicine Department. The subject s femur, spine, and whole body will be scanned at baseline and then yearly for 3 years. The procedure will take approximately 10 minutes and may be limited due to the subject s cooperation.
219615918|NCT03952637|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Performed as part of screening and for safety before sedated procedures. The ECG will take approximately 10 minutes and may be limited due to the subject s cooperation.
219615919|NCT03952637|DIAGNOSTIC_TEST|Echocardiogram|Performed as part of screening. The Echo will be done in the Echo Lab and may take approximately 20-30 minutes. The exam may be limited due to the subject s cooperation level.
218915991|NCT05484102|DIETARY_SUPPLEMENT|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
218915992|NCT05380466|OTHER|Quantum Touch|Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
218915993|NCT06415175|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
218915994|NCT04733768|DIAGNOSTIC_TEST|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
218915995|NCT02753283|DRUG|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
218915996|NCT02753283|DRUG|Placebo|Semi-annual saline injection
219041934|NCT06890481|DEVICE|Upper-limb planar robotic intervention|"The training sessions consist of three phases.~In the first, the therapist provides the patient with the necessary information for the session.~In the second, patients undergo a pre-scenario phase, in which the parameters of the robot (ratio between virtual and physical space, viscosity, and weight) are adjusted.~In the third phase, the scenario is used for motor and cognitive exercise.~Specifically, the scenario consists of a reaching exercise involving sequential stimuli placed in different spatial areas. The scenario has adaptive characteristics regarding:~* Type of stimuli~* Size of the stimuli~* Visual and auditory cues~* Number of stimuli, related to the space in which they are displayed.~Each of these characteristics is adjusted differently according to the scenario's difficulty level. Regardless of the difficulty level, the scenario provides assistance as needed through a guided path (both visual and movement-based) toward the target."
219041935|NCT06893393|DEVICE|Virtual travel-into-nature application Toujours Dimanche|The use of the virtual travel-into-nature application which features real natural environments from the Eastern Canada area.
219041936|NCT05677425|OTHER|Temperature measurement|Temperature measurement in the renal pelvis during ureteroscopic laser activation.
219041937|NCT04145778|OTHER|6-minute walk test|The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
219529269|NCT00723528|DRUG|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
219529270|NCT00723528|DRUG|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
219529271|NCT00723528|DRUG|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
219529272|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
218915997|NCT02753283|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
218915998|NCT05007405|OTHER|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
218915999|NCT04386291|BEHAVIORAL|Anxiety Reduction Training|Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
219529273|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
219529274|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
219529275|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
219529276|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
219529277|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
219529278|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
219529279|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
219529280|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
219529281|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
219529282|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
219529283|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
219529284|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
219529285|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
219529286|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
219529287|NCT04626856|BIOLOGICAL|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
219529288|NCT04626856|BIOLOGICAL|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
219529289|NCT04719949|BEHAVIORAL|Behavioral Activation (BA) Therapy|Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.
219529290|NCT04719949|BEHAVIORAL|Problem Solving Therapy (PST)|Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
219529291|NCT02779894|OTHER|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
219529292|NCT00406068|DRUG|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
219615920|NCT03952637|OTHER|Electroencephalogram (EEG) awake and extended overnight|Completed at baseline. The subject will also have an EEG if clinically indicated (for example encephalopathy, seizures, or other change in neurological status or if changes on the previous study are deemed to warrant a follow up study) during post treatment follow up. The procedures will be conducted in the Neurology Testing Department. The total time for an awake EEG, including lead placement, is approximately 40 minutes. An extended overnight EEG will take approximately 12 hours. The exam may be limited due to the subject s cooperation level.
219615921|NCT03952637|DIAGNOSTIC_TEST|Laboratory tests|Performed on blood and urine include safety labs, clinically indicated labs and research collections. Additional specimens may be collected for the PI s biorepository or as clinically indicated. Blood volumes for clinical diagnostic testing and research will be consistent with Clinical Center laboratory guidelines.
218916000|NCT04386291|BEHAVIORAL|Kundalini Yoga and Anxiety Reduction Training|Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
218916001|NCT04386291|BEHAVIORAL|Meditation and Anxiety Reduction Training|Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
218916002|NCT06206824|DRUG|Leucettinib-21|See arm's description.
219529293|NCT00164671|BEHAVIORAL|POWER|
219529294|NCT05564897|DRUG|H101, Camrelizumab|Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10\*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
218916003|NCT01300754|PROCEDURE|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
218916004|NCT01300754|PROCEDURE|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
218916005|NCT01300754|OTHER|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
218916006|NCT04331587|DEVICE|BF-P190 4 mm thin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
219529295|NCT01993030|DEVICE|HQ® Matrix Medical Wound Dressing|
219529296|NCT01993030|DEVICE|Sidaiyi® wound dressing|
219529297|NCT05617222|OTHER|Bed rest|5 days of strict bed rest
219615922|NCT03952637|PROCEDURE|Lumbar puncture|Performed to obtain cerebrospinal fluid (CSF) to measure GM1 ganglioside, beta-gal enzyme, AAV antibodies, Pentasaccharide biomarkers and other research tests. CSF will also be sent for cell count and differential, glucose, protein, and culture as well as CSF neurotransmitters. The amount of CSF obtained will be less than or equal to 0.75 mL/kg body weight. The procedure will be performed while under sedation following MRI imaging. If a sedated MRI is not being performed, then the LP will be performed in consultation with the pediatric consult service using conscious sedation and local anesthesia. The procedure will take approximately 15 minutes.
218916007|NCT04331587|DEVICE|BF-MP190F 3 mm ultrathin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
219529298|NCT05617222|OTHER|Neuromuscular electrical stimulation|Unilateral neuromuscular electrical stimulation (m. Quadriceps)
219529299|NCT01710657|DRUG|Lacosamide 50 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
219529300|NCT01710657|DRUG|Lacosamide 100 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use"
219529301|NCT01710657|DRUG|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
219615923|NCT03952637|PROCEDURE|Brain MRI/MRS/fMRI|Magnetic resonance imaging (MRI), functional MRI (fMRI) and spectroscopy (MRS) Procedure/Surgery - The subject will undergo noncontrast MRI, including DTI sequences, fMRI, and MRS in the 3T scanner using the same image acquisition sequences and the same MRS voxels to capture the same metabolites as prior sequencing under natural history protocol 02-HG0107. The MRI, fMRI, and MRS will be interpreted for signs of disease progression or stabilization and any signs of treatment toxicity by two board-certified radiologists with specialty training in neuroradiology. The scan will require anesthesia. Sedation will be administered by the anesthesia service after a preanesthesia consultation to assess risk. The type of sedation and whether the subject will be intubated for the procedure will be at the discretion of the anesthesia service.
219615924|NCT03952637|BEHAVIORAL|Neurocognitive testing|Type II Subjects - The Vineland-3 will be administered under the supervision of a psychologist. The Vineland-3 provides several types of scores, measure of personal and social independence designed to examine the domains of communication, daily living skills, social skills and motor development. Other standard neurocognitive instruments may be used depending on the subject s ability, and some visits will (may) include a measure of intelligence /cognitive development if the child is able to achieve a basal score. Neurocognitive testing will take approximately 2-3 hours depending on subject cooperation. The assessments will not address sensitive topics. Type I Subjects - Bayley Scales of Infant and Toddler Development (BSID-III), a well-normed and validated, examiner-administered evaluation of cognition, language, and motor skills for children from birth to 42 months of age.
219041938|NCT06023394|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
219041939|NCT06023394|DEVICE|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
219041940|NCT04949750|OTHER|Paper - based cognitive training|Cognitive training
219041941|NCT06903546|DRUG|Propolis drops|The intervention given is propolis drops that are approved by Indonesian Food and Drug Authority
219041942|NCT06903546|OTHER|Placebo|The given placebo are look-alike substance with no effect
219041943|NCT05023811|DRUG|[14C]RIST4271|\[14C\]RIST4271 oral solution
219041944|NCT06901778|BEHAVIORAL|DEAR weight management|"In the DEAR weight management model:~D (Diet) refers to dietary management, primarily based on a calorie-restricted balanced diet; E (Exercise) refers to exercise management, guided by the 10th edition of the ACSM Exercise Testing and Prescription Guidelines and the 2017 National Fitness Guidelines. Exercise prescriptions are tailored to the patient's daily activity levels (light, moderate, and vigorous) to match the corresponding intensity levels; A (Accompany) refers to peer education, which involves using peer education methods to provide health education for patients, build confidence, and alleviate anxiety; R (Refresh) refers to rejuvenation, which involves correcting unhealthy dietary and exercise habits and establishing good lifestyle practices."
219041945|NCT06901778|BEHAVIORAL|Standardized discharge care plan and follow-up schedule|Standardized discharge care plan and follow-up schedule providing patients and their families with professional and feasible pre-discharge education on disease-related knowledge, dietary and exercise recommendations, daily living advice, and psychological support to help patients establish healthy behaviors. Patients are provided with printed health education materials and a handbook on health and disease knowledge. A WeChat communication group is established to promptly answer patients' questions, encourage peer-to-peer experience sharing, and conduct regular telephone follow-ups and questionnaire surveys after discharge.
219041946|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application|Patients undergoing weight management are instructed to download the app from the app store (compatible with both iOS and Android platforms). Users in the control group can independently register and log in using their mobile phone numbers to access and use the app. The app will create an electronic health record for weight management for each user. Users can input their weight-related information, and the app features a data analysis function that displays weight trends through charts (e.g., BMI calculation and personal weight change curves). The app interface also provides professional guidance on diet and exercise, such as food calorie information, customized nutritional meal plans, and specialized exercise programs with training courses. By offering educational articles and instructional videos, the app aims to promote correct weight management concepts, disseminate scientific health knowledge, and enhance self-efficacy in weight loss.
219204571|NCT04745754|OTHER|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
219204572|NCT05922657|DEVICE|Cerene|Real world use of Cerene.
219529302|NCT00881322|DIETARY_SUPPLEMENT|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
219529303|NCT00881322|DIETARY_SUPPLEMENT|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD\&C yellow #5 Lake, FD\&C blue #1 Lake, FD\&C red #46 Lake and vegetable capsule"
219529304|NCT04196322|OTHER|observational study|observational study
219529305|NCT02187562|DRUG|Meloxicam|
219529306|NCT02187562|DRUG|Aspirin|
218916008|NCT04331587|DEVICE|Radial ultrasound probe (UM S20-17S)|-Olympus
218916009|NCT04331587|DEVICE|PeriView FLEX 21G Single Use Aspiration Needle|"* NA-403D-2021~* Gyrus ACMI, Inc."
218916010|NCT02674035|PROCEDURE|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
218916011|NCT05172128|DIETARY_SUPPLEMENT|lyophilized blueberry supplement|lyophilized blueberry supplement bid
218916012|NCT00671658|DRUG|Rituximab|375 mg/m2 by vein
218916013|NCT00671658|DRUG|Cyclophosphamide (CTX)|300 mg/m2 by vein
218916014|NCT00671658|DRUG|Doxorubicin|50 mg/m2 by vein
219366540|NCT04974788|OTHER|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
219529307|NCT03921294|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
218916015|NCT00671658|DRUG|Vincristine|2 mg by vein
219529308|NCT02601794|BEHAVIORAL|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
219529309|NCT05865691|OTHER|biomarker assay|blood sample on the day of inclusion
219529310|NCT00382694|DRUG|Fludarabine|
219529311|NCT01868529|DRUG|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
219529312|NCT01868529|DRUG|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
219529313|NCT00401089|DRUG|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
218916016|NCT00671658|DRUG|Dexamethasone|40 mg by vein or by mouth (P.O.)
218916017|NCT00671658|DRUG|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
218916018|NCT00671658|DRUG|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
218916019|NCT00671658|DRUG|G-CSF|10 ug/kg subcutaneous injection
218916020|NCT00671658|DRUG|Mesna|600 mg/m2 a day by vein
218916021|NCT00671658|DRUG|Pegylated asparaginase|2000 International units/m2 by vein
218916022|NCT00671658|DRUG|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
218916023|NCT00671658|DRUG|Solumedrol|40 mg by vein for Courses 2,4,6,8
218916024|NCT06420804|DEVICE|ZIIP Acne Treatment Device|Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
218916025|NCT01921205|DRUG|Lacosamide|"Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
219366541|NCT04974788|OTHER|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
219366542|NCT04974788|OTHER|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
219366543|NCT05121402|DRUG|TLL018|a TYK2/JAK1 inhibitor
219366544|NCT05121402|OTHER|Placebo|a TLL018 Placebo
219366545|NCT04217395|BEHAVIORAL|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
219366546|NCT03136939|OTHER|No intervention|No intervention
219366547|NCT00430118|DRUG|asparaginase|
219366548|NCT00430118|DRUG|cyclophosphamide|
219366549|NCT00430118|DRUG|cytarabine|
219366550|NCT00430118|DRUG|daunorubicin hydrochloride|
219366551|NCT00430118|DRUG|dexamethasone|
219366552|NCT00430118|DRUG|doxorubicin hydrochloride|
219366553|NCT00430118|DRUG|etoposide|
219366554|NCT00430118|DRUG|ifosfamide|
219366555|NCT00430118|DRUG|mercaptopurine|
219366556|NCT00430118|DRUG|methotrexate|
219366557|NCT00430118|DRUG|prednisone|
219366558|NCT00430118|DRUG|thioguanine|
219366559|NCT00430118|DRUG|vincristine sulfate|
219366560|NCT00430118|DRUG|vindesine|
219366561|NCT00430118|RADIATION|radiation therapy|
219366562|NCT02285400|PROCEDURE|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
219366563|NCT00868387|OTHER|energy-restricted, CHO-restricted diet|carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
219366564|NCT00868387|OTHER|energy-restricted, CHO-rich diet|carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
219615925|NCT03952637|OTHER|Neurology exam|Neurology exam will be performed by a neurologist in the screening and followup appointments to monitor for any adverse reactions and to assess for clinical response to the treatment. The exam will be scripted for consistency within subject visits and between subjects and will take approximately 30 minutes to one hour. The exam will be videotaped. The exam may be limited due to the subject s cooperation level.
218916026|NCT01921205|OTHER|Placebo|"Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
218916027|NCT02049775|PROCEDURE|NBI|
218916028|NCT04413500|BEHAVIORAL|Reminder|A reminder to take the anti-hypertension medication with adjustable frequency.
218916029|NCT04413500|BEHAVIORAL|Educational message|An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.
218916030|NCT04413500|BEHAVIORAL|Motivational messages|The motivational short messages to increase the motivational levels.
218916031|NCT04413500|BEHAVIORAL|showing trends|Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
218916032|NCT01779830|DRUG|LY2624803 - Capsules|Administered orally as capsules.
219529314|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
219529315|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
219529316|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
219529317|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
219529318|NCT00535860|DRUG|Teriparatide|Daily for 96 days
219529319|NCT01033565|DRUG|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
219529320|NCT04828720|DRUG|ozonated oil|All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
219529321|NCT03966560|DRUG|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
219615926|NCT03952637|BEHAVIORAL|PICC or other Central line placement|PICC line or other central line placement will be done under sedation in Interventional Radiology. The procedure will be done under sedation and may take 20 minutes. A chest Xray will be done after placement to confirm correct positioning of the catheter.
218916033|NCT01779830|DRUG|Zolpidem - Tablets|Administered orally as tablets.
218916034|NCT01779830|DRUG|Placebo - Capsules|Administered orally as capsules.
218916035|NCT01779830|DRUG|Placebo - Tablets|Administered orally as tablets.
218916036|NCT01578447|DRUG|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
218916037|NCT01578447|DRUG|Intramuscular DMPA|Intramuscular DMPA
218916038|NCT02678949|DRUG|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
218916039|NCT02678949|DRUG|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
218916040|NCT02678949|DRUG|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
218916041|NCT03910634|DRUG|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
218916042|NCT03910634|RADIATION|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
219529322|NCT03966560|DRUG|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
219529323|NCT03966560|DRUG|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
219529324|NCT03966560|DRUG|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
219529325|NCT03966560|DRUG|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
219529326|NCT03966560|DRUG|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
219529327|NCT00893386|PROCEDURE|LV Lead Extraction|Removal of a LV lead using any tools \& techniques.
218916043|NCT03910634|DRUG|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
218916044|NCT01082861|BIOLOGICAL|Cervarix|Cervarix, HPV vaccin
218916045|NCT01082861|BIOLOGICAL|Engerix-B|Engerix-B, HBV vaccin
218916046|NCT00754663|BEHAVIORAL|exercise training|walking training at least 3 times a week
218916047|NCT00758017|OTHER|Acupuncture 1|Application of individualised acupuncture
218916048|NCT00758017|OTHER|Acupuncture 2|Application of standardised acupuncture
218916049|NCT01721135|DRUG|GSK2190915 100mg|Film coated oral tablet
218916050|NCT01721135|DRUG|GSK2190915 200mg|Film coated oral tablet
218916051|NCT01721135|DRUG|moxifloxacin 400mg|Film coated oral tablet
218916052|NCT01721135|DRUG|moxifloxacin placebo|Film coated oral tablet
218916053|NCT01721135|DRUG|GSK2190915 placebo|Film coated oral tablet
218916054|NCT00023777|BIOLOGICAL|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
218916055|NCT00023777|BIOLOGICAL|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
218916056|NCT00023777|DRUG|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
218916057|NCT00023777|DRUG|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
218916058|NCT03398317|OTHER|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
218916059|NCT03398317|OTHER|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
218916060|NCT00456846|DRUG|ABI-007|100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
218916061|NCT01241721|DEVICE|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
218916062|NCT00497614|DRUG|adalimumab|
218916063|NCT01586546|BEHAVIORAL|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
218916064|NCT01586546|OTHER|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
218916065|NCT01586546|OTHER|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
218916066|NCT01586546|BEHAVIORAL|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
219529328|NCT05778422|DRUG|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
219529329|NCT05778422|PROCEDURE|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
219529330|NCT04769622|PROCEDURE|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
218916067|NCT00915252|DRUG|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
218916068|NCT00915252|DRUG|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
219529331|NCT04769622|OTHER|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~* adherence to Mediterranean Diet;~* sleep quality;~* physical activity;~* perceived stress."
219529332|NCT00152035|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
219529333|NCT03408119|DIETARY_SUPPLEMENT|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
218916069|NCT01519908|DEVICE|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
218916070|NCT05944302|BEHAVIORAL|EMDR group|Eye Movement Desensitization and Reprocessing
218916071|NCT01185236|DRUG|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
218916072|NCT01185236|DRUG|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
218916073|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate|
218916074|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate - double dose|
218916075|NCT02147639|DIETARY_SUPPLEMENT|Placebo|
218916076|NCT02147639|PROCEDURE|Increased exercise intensity|
218916077|NCT00400465|PROCEDURE|Normal dressing|Normal dressing
218916078|NCT00400465|PROCEDURE|Pressure dressing|Pressure dressing
218916079|NCT03379818|BEHAVIORAL|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
218916080|NCT03379818|BEHAVIORAL|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
218916081|NCT02496286|DRUG|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
218916082|NCT00771277|BEHAVIORAL|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
219529334|NCT03408119|DIETARY_SUPPLEMENT|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
219529335|NCT01003002|DRUG|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
218916083|NCT03572504|OTHER|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
218916084|NCT03199976|DRUG|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
218916085|NCT03199976|DRUG|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
219529336|NCT03000296|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
219529337|NCT01591785|DRUG|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
219529338|NCT01591785|DRUG|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
219529339|NCT03322709|PROCEDURE|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
219529340|NCT05275985|DIAGNOSTIC_TEST|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
219529341|NCT06340256|OTHER|Continuous spinal anesthesia|The Catheter will be then fed over the needle into the intrathecal space and Inserted 3cm cephalad into the subarachnoid space.The spinal needle and the modified Tuohy needle will be then removed, and a Luer connector and A filter previously filled with the anesthetic solution will be attached to the Catheter (priming volume 0.6ml). Plain bupivacaine 0.5% in 20ml vials will Be used CSA group received 1 ml(5 mg) of plain bupivacaine (0.5%) Together with fentanyl l25μg injected via the catheter at a rate of 0.2ml/15s. The level of the resulting sensory blockade will be tested using pin prick.
219529342|NCT06340256|OTHER|Continuous epidural anesthesia|The needle is advanced until the epidural space is identified by the loss-of-resistance technique, and then a 20G catheter is inserted 3 cm cephalad into the epidural space. a test dose of 3ml of 2% lignocaine with adrenaline (1:200000) will be injected into the catheter. Three minutes later, 10 ml of plain bupivacaine (0.5%) together with fentanyl l50μg will be injected via the catheter.
219529343|NCT05312827|BEHAVIORAL|Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
219529344|NCT01523626|OTHER|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
219204573|NCT04274881|PROCEDURE|Catheterization of internal jugular vein|"The right internal jugular vein will be cannulated under transesophageal echocardiographic (TEE) guidance in order to place the catheter tip in the mid-SVC.~The length of the catheter required to place the tip at the mid-SVC as guided by TEE will be regressed on the C-length or on the distance from the entry point to the surface point corresponding to the mid-SVC on the chest wall in order to obtain a predictive equation.~The accuracy of either equation will be assessed by estimation of the standard error of the estimate (SEest)."
218916086|NCT03199976|DRUG|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
218916087|NCT03249207|DRUG|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
218916088|NCT03249207|DRUG|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
218916089|NCT04389281|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
219529345|NCT01523626|OTHER|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
218916090|NCT04308421|DEVICE|Red light|Low irradiation 650 nm +/- 5 nm red light
219615927|NCT03952637|PROCEDURE|Skeletal survey|A skeletal survey will be performed to assess the degree of skeletal involvement of the disease. This will include X-rays of the a/p lateral spine, chest, and pelvis. The exam will take approximately 30 minutes. The exam may be limited due to the subject s cooperation level.
218916091|NCT05761782|BEHAVIORAL|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
218916092|NCT03505502|DRUG|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
218916093|NCT01532596|BEHAVIORAL|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
218916094|NCT05118945|DEVICE|Insulin pump Tandem: t:slim X2|"Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered."
218916095|NCT03868514|DEVICE|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
218916096|NCT04017663|OTHER|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
218916097|NCT02904681|OTHER|No intervention. Observational and descriptive study|
218916098|NCT03463057|DRUG|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
218916099|NCT03817216|DEVICE|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
219529346|NCT03827044|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
218916100|NCT01875653|BIOLOGICAL|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
219529347|NCT02360982|BEHAVIORAL|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
219529348|NCT02360982|BEHAVIORAL|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
219529349|NCT00006365|RADIATION|brachytherapy|
219529350|NCT00006365|RADIATION|iodine I 125|
219529351|NCT00006365|RADIATION|radiation therapy|
219529352|NCT03437304|BIOLOGICAL|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
219529353|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
219529354|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
219529355|NCT03437304|BIOLOGICAL|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
219529356|NCT03437304|DRUG|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
219529357|NCT03437304|BIOLOGICAL|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
219615928|NCT03952637|PROCEDURE|Skin biopsy|Skin biopsy will be performed on subjects who have not already had a skin biopsy under the 02-HG-0107 protocol. The procedure will be done under sedation using local anesthetic. After washing the skin with chlorhexidine and numbing the skin with injectable lidocaine, a 3mm circle of skin is removed under sterile conditions and the wound is dressed. The entire procedure takes approximately 5 minutes.
218916101|NCT01875653|BIOLOGICAL|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
218916102|NCT01780506|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
218916103|NCT01780506|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
218916104|NCT01780506|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
218916105|NCT01780506|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
219529358|NCT06377657|BEHAVIORAL|Exercise|The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino
218916106|NCT02322632|DRUG|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
218916107|NCT02527811|DRUG|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
218916108|NCT06368635|DIAGNOSTIC_TEST|Coronary angiography|target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8； or severe stenosis（\>80%）after successful PCI(percutaneous coronary intervention) and FFR ≥0.8
218916109|NCT05936073|DIAGNOSTIC_TEST|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
218916110|NCT03324087|DIAGNOSTIC_TEST|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
218916111|NCT06078254|DEVICE|ULTRASOUND|Ultrasound and CT chest for all patients
218916112|NCT03550599|OTHER|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
218916113|NCT03159429|BEHAVIORAL|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
218916114|NCT03159429|BEHAVIORAL|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
219204574|NCT04765098|DRUG|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
219204575|NCT04765098|DRUG|Etoposide|etoposide 50mg/m2 daily
219204576|NCT04996875|DRUG|bezuclastinib|Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
219529359|NCT06377657|DIETARY_SUPPLEMENT|Aloe vera|Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
219529360|NCT05867095|PROCEDURE|Surgical navigation|Patients will be operated with assistance of a navigation system
219529361|NCT05867095|PROCEDURE|Conventional|Patients will be operated using the conventional technique
219529362|NCT01998217|DRUG|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
219529363|NCT01998217|DRUG|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
219529364|NCT00158171|DRUG|Nicotine Replacement Therapies|Nicotine gum 2 \& 4 mg dependent on baseline smoking rate
218916115|NCT02684825|DEVICE|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
218916116|NCT02788552|DRUG|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
218916117|NCT00192985|DEVICE|Nitrofuranzone coated bladder catheter|
218916118|NCT03774732|RADIATION|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
219204577|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
219204578|NCT06167486|DRUG|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
219529365|NCT00158171|DRUG|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
219529366|NCT00158171|DIETARY_SUPPLEMENT|Folic Acid|400 mg
219529367|NCT00641420|PROCEDURE|Fractionated Laser Resurfacing|
219529368|NCT02713022|DEVICE|DEXA Scan|
219529369|NCT02713022|BEHAVIORAL|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
218916119|NCT03774732|DRUG|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
218916120|NCT03774732|DRUG|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
218916121|NCT04577521|DEVICE|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
218916122|NCT00200369|DEVICE|MEMS cap|
218916123|NCT04467684|DRUG|CB-0406 100 mg|Single oral dose
218916124|NCT04467684|DRUG|CB-0406 200 mg|Single oral dose
219529370|NCT03958422|DRUG|cardiomyopeptidin|The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
219529371|NCT04057222|OTHER|No intervention|Only propose water and wait for need to void
219529372|NCT05174325|DRUG|Sintilimab + chemotherapy|Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
219529373|NCT05087524|DIAGNOSTIC_TEST|BinaxNOW Ag Card|A nasal swab specimen is collected from the participant, 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The participant sample is inserted into the test card through the bottom hole of the swab well, and firmly pushed upwards until the swab tip is visible through the top hole. The swab is rotated 3 times clockwise and the card is closed, bringing the extracted sample into contact with the test strip. Test results are interpreted visually at 15 minutes based on the presence or absence of visually detectable pink/purple colored lines.
219529374|NCT03878719|DRUG|binimetinib|taken orally
219529375|NCT03878719|DRUG|encorafenib|taken orally
219615929|NCT03952637|PROCEDURE|Speech and modified barium swallow study|Performed as a marker of response to treatment and safety. The swallow assessments will include a parental swallowing questionnaire and cranial nerve assessment. The NIH Swallowing Questionnaire from the Speech Language Pathology Section is designed to identify the presence and or absence of functional swallowing dysfunction as perceived by the subject and or caregiver. This 4point scale assists with further identification of clinical/research assessments of oral pharyngeal swallowing function if indicated in the form of a modified barium swallow. In addition to swallow assessments, tape recording of speech will also be included with diadochokinetic tasks and sustained phonations as well as speech if able. Recordings will be stored on a shared drive accessible only by the study team. The assessment may take approximately 30 minutes to 1 hour.
218916125|NCT04467684|DRUG|CB-0406 400 mg|Single oral dose
218916126|NCT04467684|DRUG|CB-0406 800 mg|Single oral dose
219529376|NCT01049334|DRUG|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
218916127|NCT04467684|DRUG|CB-0406 1,000 mg|Single oral dose
218916128|NCT04467684|DRUG|Matched placebo|Color and size matched placebo
219529377|NCT01049334|DRUG|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
218916129|NCT02281916|DRUG|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
218916130|NCT02418572|DRUG|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
218916131|NCT02418572|DRUG|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
218916132|NCT04942574|OTHER|Total sleep deprivation|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
218916133|NCT04942574|OTHER|Normal sleep|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
218916134|NCT05236270|BEHAVIORAL|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
218916135|NCT05236270|BEHAVIORAL|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
219529378|NCT05309941|OTHER|Internal Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
219529379|NCT05309941|OTHER|External Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
219529380|NCT01458002|OTHER|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
218916136|NCT05236270|BEHAVIORAL|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
218916137|NCT06342258|DRUG|Ultradent Ultra Seal XT Plus|Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
218916138|NCT06208124|DRUG|IMM-6-415|Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.
218916139|NCT06346717|BEHAVIORAL|"Knee Prosthesis-M mobile application service"|"In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks."
218916140|NCT01023763|OTHER|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
218916141|NCT03260946|OTHER|Complementary medicine use|The prevalence of complementary medicine use
219529381|NCT01458002|OTHER|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
219529382|NCT03979079|RADIATION|external beam radiation therapy|
219529383|NCT00546897|DRUG|Lenalidomide|
219529384|NCT00242060|PROCEDURE|MRI|
219529385|NCT00987948|DRUG|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
219529386|NCT03204266|DRUG|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
219529387|NCT03204266|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
219529388|NCT05701930|BEHAVIORAL|symptom management|pecha kucha training
219529389|NCT02436057|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
219529390|NCT04751669|DIETARY_SUPPLEMENT|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
219529391|NCT04751669|DIETARY_SUPPLEMENT|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
218916142|NCT00460161|PROCEDURE|acupuncture|2 treatments/week for 4 weeks
218916143|NCT00460161|OTHER|placebo/sham acupuncture|2 treatments/week for 4 weeks
218916144|NCT00159393|OTHER|registry and database|data collection
218916145|NCT05310240|PROCEDURE|Hip arthroscopy|Arthroscopic surgery of the hip
219529392|NCT00002804|BIOLOGICAL|filgrastim|
219529393|NCT00002804|DRUG|doxorubicin hydrochloride|
219529394|NCT00002804|DRUG|ifosfamide|
219529395|NCT00002804|DRUG|mesna|
219529396|NCT00002804|DRUG|vincristine sulfate|
219529397|NCT00002804|PROCEDURE|conventional surgery|
219529398|NCT00002804|RADIATION|brachytherapy|
219529399|NCT00002804|RADIATION|low-LET cobalt-60 gamma ray therapy|
219529400|NCT00002804|RADIATION|low-LET electron therapy|
219529401|NCT00002804|RADIATION|low-LET photon therapy|
219529402|NCT01175616|DRUG|Creatine|Oral Creatine 5 grams daily.
219529403|NCT00003939|DRUG|trabectedin|
219529404|NCT05099822|DRUG|CC-97489|Specified dose on specified days
219529405|NCT05099822|OTHER|Placebo|Specified dose on specified days
219529406|NCT02440308|DRUG|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is \[4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl\]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
219529407|NCT02440308|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|
219529408|NCT02440308|PROCEDURE|Positron Emission Tomography (PET) scan|
219529409|NCT03370549|BEHAVIORAL|AWARE intervention|Group psychotherapy for Asian-American women
219529410|NCT04285359|PROCEDURE|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
219529411|NCT06254677|OTHER|Retrospective review of histological features|Correlate histopathology characteristics of acute kidney injury with molecular signatures, kidney function and aetiology of acute kidney injury to derive clinically validated scoring system for acute kidney injury and acute tubular injury
219529412|NCT01585259|DRUG|Anfibatide|Snake venom
219529413|NCT01585259|DRUG|Placebo|Saline
219529414|NCT00517530|DRUG|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
219529415|NCT01029522|DRUG|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
219529416|NCT01029522|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
219529417|NCT00667095|DRUG|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
219529418|NCT00667095|DRUG|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
219529419|NCT01900964|PROCEDURE|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
219529420|NCT01900964|PROCEDURE|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
219529421|NCT02967107|PROCEDURE|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
218916146|NCT03725397|BEHAVIORAL|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
218916147|NCT03725397|BEHAVIORAL|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
218916148|NCT06142058|DIAGNOSTIC_TEST|RecistTM criteria|RecistTM criteria and RECIST criteria were used to evaluate the efficacy of targeted therapy for NSCLC with positive driving gene.
218916149|NCT05176288|DRUG|Axitinib|Taken Orally
218916150|NCT05176288|DRUG|Palbociclib|Taken Orally
218916151|NCT05176288|DRUG|Avelumab|Intravenous infusion
218916152|NCT02922244|OTHER|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
218916153|NCT02922244|OTHER|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
218916154|NCT02922244|OTHER|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
218916155|NCT02922244|OTHER|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
219529422|NCT02967107|PROCEDURE|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
219529423|NCT00242788|DRUG|Gefitinib and capecitabine|
219529424|NCT01199848|DIETARY_SUPPLEMENT|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
219529425|NCT01199848|DIETARY_SUPPLEMENT|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
219529426|NCT01199848|DIETARY_SUPPLEMENT|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
219529427|NCT01199848|DIETARY_SUPPLEMENT|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
219615930|NCT03952637|PROCEDURE|Ophthalmology exam|The ophthalmology exam will be performed by an ophthalmologist in the screening and follow-up appointments to support subtype diagnosis and assess efficacy. Pictures of bilateral macula will be taken and saved to a secure database. OCT will also be performed. These exams will only be administered to Type I subjects.
218916156|NCT04730453|PROCEDURE|ENB-guided ablation therapy combined with VATS|After receiving multidisciplinary assessments, Lesion A will receive ENB-guided ablation therapy and Lesion B will receive VATS at the same time.
218916157|NCT01876836|DEVICE|i-gel|i-gel placed after induction
218916158|NCT01876836|DEVICE|C-LMA|placed after induction
218916159|NCT02940795|OTHER|Coke|Patients were given a 20 ounce bottle of Coke Cola.
218916160|NCT02940795|OTHER|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
218916161|NCT05876442|DEVICE|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
218916162|NCT05876442|DEVICE|High Intensity Laser Therapy|High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
218916163|NCT05876442|OTHER|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
218916164|NCT05829694|OTHER|Parental Status|The aim of the study is to assess the impact parenthood has on health outcomes.
218916165|NCT03373123|PROCEDURE|Endoscopy|Endoscopy
218916166|NCT03373123|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
218916167|NCT06413992|DRUG|Fluzoparib|During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
218916168|NCT06413992|DRUG|Camrelizumab|During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
218916169|NCT06413992|DRUG|paclitaxel (albumin bound)|Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
218916170|NCT06413992|DRUG|Carboplatin injection|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
218916171|NCT06413992|DRUG|Carboplatin|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
218916172|NCT06413992|RADIATION|External irradiation|Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
219529428|NCT01199848|DIETARY_SUPPLEMENT|Placebonofiber|Placebo without Fiber
219529429|NCT03933748|DRUG|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
219529430|NCT03786965|OTHER|On-pump CABG|On-pump CABG
219529431|NCT03786965|OTHER|Off-pump CABG|Off-pump CABG
219529432|NCT03786965|OTHER|Pump-assisted CABG|Pump-assisted CABG
219529433|NCT03786965|OTHER|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
219529434|NCT03786965|OTHER|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
219529435|NCT03447262|DRUG|VX-659/TEZ/IVA|Fixed-dose combination tablets for oral administration qd in the morning.
219529436|NCT03447262|DRUG|IVA|IVA tablet qd in the evening.
219529437|NCT00938834|OTHER|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
219529438|NCT00374335|PROCEDURE|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
219529439|NCT00374335|OTHER|Dermatologic Examination|Complete dermatologic examination
219529440|NCT00126932|DEVICE|SonoPrep|
219529441|NCT04680962|BIOLOGICAL|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
218916173|NCT03536208|DRUG|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
218916174|NCT00530478|DRUG|Donepezil|
218916175|NCT00101179|DRUG|Azacitidine|Given SC
219529442|NCT04680962|BIOLOGICAL|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
219529443|NCT04680962|BIOLOGICAL|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
219529444|NCT04914962|OTHER|glazed zirconium lithium silicate|monolithic glazed crown
219529445|NCT04914962|OTHER|polished zirconium lithium silicate|monolithic polishedcrowns
219529446|NCT01349374|OTHER|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
219529447|NCT02371343|DIETARY_SUPPLEMENT|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
219529448|NCT02371343|DIETARY_SUPPLEMENT|Sunflower Oil|
219615931|NCT04601766|DRUG|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
219529449|NCT00737490|OTHER|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
219529450|NCT00737490|OTHER|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
219529451|NCT02514941|DRUG|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
219529452|NCT02514941|DRUG|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
219529453|NCT02514941|DRUG|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
219615932|NCT04601766|DRUG|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
219615933|NCT03207776|OTHER|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
219615934|NCT03207776|OTHER|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
219615935|NCT02570620|DEVICE|Ultrasonography of the cervix|
219615936|NCT04949217|PROCEDURE|Inlay Bristow|A modified Bristow procedure
219615937|NCT04949217|PROCEDURE|Bristow|Traditional Bristow procedure
219615938|NCT00316732|PROCEDURE|IPSS Questionnaire|
219615939|NCT00316732|PROCEDURE|EQ-5D Questionnaire|
219615940|NCT02492373|DRUG|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
219615941|NCT02492373|DEVICE|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
219615942|NCT05638776|DRUG|REGEND001 cell therapy|Transplantation of the cell product
219615943|NCT05638776|DRUG|Placebo|Transplantation of Placebo
219615944|NCT05280392|OTHER|Self-administered questionnaires|4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)
218916176|NCT00101179|DRUG|Entinostat|Given orally
218916177|NCT01499940|DRUG|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
218916178|NCT00412984|DRUG|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
218916179|NCT00412984|DRUG|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
218916180|NCT05543603|DRUG|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
218916181|NCT05543603|DRUG|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
218916182|NCT05543603|DRUG|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
218916183|NCT05543603|DRUG|Distilled water|15 ml distilled water, one minute rinse
219529454|NCT02514941|PROCEDURE|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
219529455|NCT02514941|PROCEDURE|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
219529456|NCT02514941|PROCEDURE|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
219529457|NCT01832259|DRUG|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
219529458|NCT01832259|OTHER|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
219529459|NCT06281340|OTHER|Manual therapy|Each session will last approximately 50-60 minutes. Each session is composed of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to the criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy.
219615945|NCT05280392|OTHER|Semi-directive individual interviews|With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.
218916184|NCT02949336|RADIATION|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
218916185|NCT00004688|DRUG|carmustine|
219529460|NCT06281340|OTHER|Placebo manual therapy|Each session will last approximately 50-60 minutes. Each session consists of the placebo application of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy. In the techniques there will be no joint sliding, manipulations or myofascial inductions, being the only stimulus the contact of the physiotherapist with his hands and the pressure exerted with these, on the ankle.
219204579|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
218916186|NCT00004688|DRUG|mercaptopurine|
218916187|NCT00004688|DRUG|streptozocin|
218916188|NCT04218526|DEVICE|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
219529461|NCT02685462|DRUG|Rosuvastatin|
219529462|NCT02685462|DRUG|Atorvastatin|
219529463|NCT02685462|DRUG|Simvastatin|
218916189|NCT03743168|OTHER|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
218916190|NCT03743168|OTHER|Continuous stretch|2 minutes continuous stretch
218916191|NCT06409533|OTHER|Rate control|Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
218916192|NCT05426499|DRUG|Patients requiring cefotaxime treatment|Dosage according to SmPC
219615946|NCT05280392|OTHER|Semi-directive individual interviews|With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
218916193|NCT05426499|DRUG|Patients requiring meropenem treatment|Dosage according to SmPC
219529464|NCT02685462|DRUG|Digoxin|
219615947|NCT03525704|DEVICE|Saline Solution Enriched|Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
219615948|NCT03525704|DEVICE|Saline Rinse Solution|sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
219615949|NCT00116779|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
218916194|NCT05426499|DRUG|Patients requiring fluconazole treatment|Dosage according to SmPC
218916195|NCT05426499|DRUG|Patients requiring isavuconazole treatment|Dosage according to SmPC
218916196|NCT05426499|DRUG|Patients requiring anidulafungin treatment|Dosage according to SmPC
218916197|NCT01062958|OTHER|Neevo® (a medical food)|
218916198|NCT01062958|OTHER|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
219204580|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
219204581|NCT06580002|DRUG|Riluzole|Given PO
219529465|NCT02685462|DRUG|Caffeine|
219529466|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
219529467|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
219529468|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
219529469|NCT04854330|DIETARY_SUPPLEMENT|Ketone monoesters|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml.
219529470|NCT04854330|DIETARY_SUPPLEMENT|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
219529471|NCT00833339|DRUG|mifepristone|600 mg/day x 1 week
219529472|NCT00833339|DRUG|placebo|placebo
219529473|NCT05306639|OTHER|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
219615950|NCT03665740|DRUG|Resveratrol|resveratrol is an OTC supplement
219615951|NCT02105467|DRUG|Grazoprevir 100mg / Elbasvir 50 mg FDC|
219615952|NCT02105467|DRUG|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
218916199|NCT06329830|DRUG|177Lu-PSMA-617|7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
218916200|NCT06329830|DRUG|Niraparib abiraterone acetate|Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
218916201|NCT06329830|DRUG|Prednisone|5 mg orally twice per day
218916202|NCT04166643|BEHAVIORAL|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
218916203|NCT04166643|BEHAVIORAL|Education only control|Education at the start of the project
218916204|NCT06253442|PROCEDURE|Patients will receive Supra scapular nerve block and Axillary nerve block.|"Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique."
218916205|NCT06253442|PROCEDURE|Patients will receive Interscalene block.|Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
218916206|NCT04081493|OTHER|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
218916207|NCT04150614|DRUG|Granisetron Transdermal Patch|Antiemetic
218916208|NCT04150614|DRUG|Intravenous Dexamethasone|Antiemetic
218916209|NCT04150614|DRUG|Ondansetron|ondansetron
218916210|NCT03932344|DRUG|Anakinra|Anakinra according to prescription
218916211|NCT06329440|DIAGNOSTIC_TEST|Ultrasonographic measurement of diaphragm thickness|Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
218916212|NCT04430452|BIOLOGICAL|Durvalumab|Given IV
218916213|NCT04430452|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
218916214|NCT04430452|BIOLOGICAL|Tremelimumab|Given IV
218916215|NCT02854345|DEVICE|Tomoscintigraphic parathyroid imaging on a CZT camera|
218916216|NCT04735575|BIOLOGICAL|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
218916217|NCT03160118|DRUG|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
218916218|NCT04664517|PROCEDURE|Flexible intramedullary nail (FIN)|Both bone FIN
219529474|NCT06327243|OTHER|Elastic tape ( kinesio tape)|This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.
219615953|NCT04455867|BEHAVIORAL|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
219615954|NCT04455867|OTHER|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
219615955|NCT06575634|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
218916219|NCT04664517|PROCEDURE|Reduction auder general anesthesia and long arm cast|Reduction and cast
218916220|NCT04005378|OTHER|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
218916221|NCT04005378|OTHER|Usual Care|Usual Care provided by CSC center
219204582|NCT06580002|DRUG|Placebo|Given PO
219204583|NCT05252468|DEVICE|TaffiX™|Personal nasal powder spray.
219204584|NCT06775665|OTHER|No interventions were applied to the patients.|No interventions were applied to the patients.
219615956|NCT01690117|BEHAVIORAL|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
219615957|NCT01087918|DEVICE|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
219615958|NCT01087918|OTHER|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
219529475|NCT06327243|OTHER|Sham Taping|Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
219529476|NCT00496964|DRUG|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
219529477|NCT00496964|DRUG|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
219529478|NCT04109521|OTHER|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
219529479|NCT05652543|BIOLOGICAL|SCTV01E|Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
219529480|NCT05652543|BIOLOGICAL|Placebo (normal saline)|Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
219529481|NCT04781205|GENETIC|Mutation arrays, NGS panels, GWAS, WES, WGS,|DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
219529482|NCT04781205|DEVICE|wearable monitors|test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
219529483|NCT01334645|OTHER|Copeptin|"Patients with hyponatremia \< 135 mmol/L or troponin \> 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
219529484|NCT00004905|BIOLOGICAL|filgrastim|
219529485|NCT00004905|BIOLOGICAL|recombinant interferon alfa|
219529486|NCT00004905|DRUG|cyclophosphamide|
219529487|NCT00004905|DRUG|cytarabine|
219204585|NCT05442580|DRUG|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
219529488|NCT00004905|DRUG|etoposide|
219529489|NCT00004905|DRUG|idarubicin|
219529490|NCT00004905|PROCEDURE|peripheral blood stem cell transplantation|
219529491|NCT00004905|RADIATION|radiation therapy|
219529492|NCT00029198|PROCEDURE|massage|15 massage given tid
219529493|NCT00029198|PROCEDURE|Sham massage|non-massage touch
219529494|NCT02296177|BEHAVIORAL|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
219529495|NCT03195205|DIAGNOSTIC_TEST|OraQuick HCV Rapid Antibody Test|HCV Screening
219204586|NCT05442580|DRUG|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
219204587|NCT05442580|DRUG|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
219204588|NCT05442580|DRUG|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
219204589|NCT05442580|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
219529496|NCT06392594|GENETIC|xpert MTB , XDR assay|To determine how accurate Xpert MTB/RIF and XDR for diagnosis of pulmonary TB and Rifampicin resistance
219529497|NCT00532974|BIOLOGICAL|EP1090|Low dose
219529498|NCT00532974|BIOLOGICAL|EP1090|High dose
219529499|NCT02642367|DEVICE|McGrath videolaryngoscope|without use of stylet
219529500|NCT02642367|DEVICE|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
219529501|NCT02642367|DRUG|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
219529502|NCT05719922|OTHER|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
219529503|NCT04383366|DEVICE|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
219529504|NCT04383366|DEVICE|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
219529505|NCT04383366|DEVICE|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
219529506|NCT01948414|PROCEDURE|electroencephalography|
219529507|NCT01948414|BIOLOGICAL|Blood sampling|
219529508|NCT01948414|BEHAVIORAL|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
219529509|NCT03351335|DEVICE|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
219529510|NCT03928691|DRUG|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
219529511|NCT00946374|DRUG|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
219529512|NCT00946374|DRUG|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( \> 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
219615959|NCT05368324|BEHAVIORAL|CogFun-RV|CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
219615960|NCT00150735|DRUG|LEVETIRACETAM|
218916222|NCT04914364|OTHER|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
219041947|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application + Enhance the regular interaction, feedback, and supervision mechanism between medical teams and apps|Based on the intelligent app's comprehensive coverage on the user side and integrating the ABI concept, the app dynamically adjusts intervention strategies. This is achieved by real-time collection and analysis of user behavior data, providing users with all around and personalized weight management support across diet, exercise, psychological support, etc., thereby enhancing the effectiveness and sustainability of interventions. The research team has formed a professional and experienced medical team. All members hold a bachelor's degree or above and possess rich clinical weight management experience. Through the app, they provide users with scientific and rigorous supervision and guidance. During weight loss, users can obtain accurate, professional answers and personalized adjustment advice in real-time via the app's question-asking column if they encounter any problems.
219041948|NCT06908408|DIAGNOSTIC_TEST|Corrrelation between metabolic acidosis severity in patients on admission to the ICU and platelet count trend in 2 days following admission was investigated|The aim of the study was to investigate if there exists any correlation between metabolic acidosis severity in patients upon admission to the ICU and platelet count trend in 2 days, following admission.
219041949|NCT06909747|BEHAVIORAL|Posture Training|Training program consists of three sessions. It will cover proper body posture, the importance of spinal health, and targeted exercises to support spinal well-being.
219204590|NCT05442580|DRUG|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
219529513|NCT00946374|OTHER|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
219615961|NCT06262763|DEVICE|Laser Therapy|High-intensity
219615962|NCT06262763|OTHER|Traditional exercises|Hamstring and piriformis stretch, plank exercises and bird dog exercise
219615963|NCT06262763|OTHER|Placebo laser|Not directed radiation to participant
219615964|NCT03866213|DIAGNOSTIC_TEST|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
219615965|NCT01502319|BEHAVIORAL|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
219615966|NCT01037218|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
218916223|NCT06962592|BEHAVIORAL|MM+|Participants in both study arms will receive clinic-based HIV counseling, including urine tenofovir testing and biofeedback counseling on recent PrEP or ART use. Activities unique to women enrolled in the intervention arm include: Brief motivational interviewing sessions with a mentor mother focusing on 1) EtG testing and biofeedback on recent alcohol use, 2) counseling and mentorship on ways to reduce alcohol use.
219204591|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
219204592|NCT04425018|DRUG|Paclitaxel|Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
219529514|NCT04913376|DEVICE|Hilotherapy|Constant cooling device for hands and feet.
219529515|NCT00301691|BEHAVIORAL|behavioral dietary intervention|
219529516|NCT00301691|OTHER|educational intervention|
219529517|NCT00301691|OTHER|preventative dietary intervention|
219529518|NCT05632874|BEHAVIORAL|relaxing breathing exercise|"Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients."
219529519|NCT01162694|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
219615967|NCT01037218|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
219615968|NCT00731835|PROCEDURE|Endovascular Revascularization|"* angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~* stent placement~* atherectomy"
219615969|NCT03359993|PROCEDURE|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
219615970|NCT00987532|BEHAVIORAL|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
219615971|NCT00987532|BEHAVIORAL|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
218916224|NCT06962592|BEHAVIORAL|Enhanced HIV attention control (eSOC)|Participants in the enhanced HIV attention control arm (comparison group) will attend a similar number of study visits within the same time frame as intervention participants (5-6 sessions during 6-month timeframe including both pregnancy and postpartum). Control arm sessions will consist of one-on-one educational counseling on HIV risk, partner HIV testing modalities, as well as conducting PrEP/ART urine assay testing followed by real-time in-clinic adherence counseling delivered privately (different from study nurses delivering PrEP/ART biofeedback in MM+ intervention arm to avoid contamination), all coinciding with routine ANC visits.
218916225|NCT04097678|OTHER|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
219041950|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
219041951|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
219529520|NCT01162694|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
219529521|NCT00469417|DRUG|Metvix® cream|
219529522|NCT00469417|PROCEDURE|Hand held liquid nitrogen spray cryotherapy|
219529523|NCT05757908|DRUG|Long-Acting Beta Agonist|The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
219529524|NCT00089193|BIOLOGICAL|incomplete Freund's adjuvant|
219529525|NCT00089193|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
219529526|NCT00089193|BIOLOGICAL|sargramostim|
219529527|NCT01038947|BIOLOGICAL|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
219529528|NCT03723993|DEVICE|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
219529529|NCT03723993|DEVICE|Non inflated cuff|non inflated cuff around the arm for the control group
219529530|NCT03191474|BEHAVIORAL|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
219041952|NCT06908837|DRUG|Bupivacaine|Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.
219041953|NCT06909474|BIOLOGICAL|Anti-CD5 CAR NK cells|Each patient will initially receive a single infusion of CAR-NK cells on Day 0. If a suboptimal response is observed after the first infusion (assessed by Day 28) and the safety profile remains acceptable, a second infusion may be administered as a remedial dose after Day 28. CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
219529531|NCT04012112|DEVICE|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
219529532|NCT05730166|OTHER|Mechanical Conditioning stimulus|Mechanical stimulus on the upper trapezius of the non-dominant side.
219529533|NCT00909610|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
219529534|NCT00909610|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
219529535|NCT06279338|DRUG|Azacitidine Injection|On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
219529536|NCT04082858|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
219529537|NCT04082858|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
219529538|NCT03013634|DRUG|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
219529539|NCT03013634|DRUG|Normal saline|Equal volume normal saline substitute for dexmedetomidine
219529540|NCT05197634|OTHER|Not Applicable (observation)|Questionnaire
219529541|NCT02337218|DEVICE|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
219529542|NCT03790345|DRUG|Pyridoxine|Adjuvant daily treatment with 200mg of pyridoxine
219529543|NCT03790345|DRUG|Cobalamin|Adjuvant daily treatment with 2mg of cobalamin
219529544|NCT03790345|DRUG|Placebo Oral Tablet|Adjuvant daily treatment with placebo
219529545|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
219529546|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
219529547|NCT01623362|OTHER|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
219529548|NCT01623362|OTHER|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
219529549|NCT01623362|OTHER|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
219615972|NCT05356871|OTHER|VO2max validity and reliability assesment|Reliability assessment of VO2max determination with three repeated measures for two methods.
219041954|NCT06915662|DEVICE|Tulavi allay Nerve Cap|"The Tulavi allay Nerve Capfirst and only fully absorbable in situ forming technology designed to protect transected nerves, prevent axonal escape, and reduce the risk of neuroma formation.~https://tulavi.com/allay-nerve-cap/"
219529550|NCT00183521|BEHAVIORAL|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
219529551|NCT00183521|BEHAVIORAL|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
219529552|NCT00183521|BEHAVIORAL|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
219529553|NCT04767477|OTHER|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
219529554|NCT04767477|OTHER|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
219529555|NCT05410301|DEVICE|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
219529556|NCT05410301|DRUG|Lomustine|Chemotherapy drug
219529557|NCT05410301|DRUG|Bevacizumab|Chemotherapy and targeted therapy drug
219529558|NCT01751048|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
219529559|NCT01751048|BIOLOGICAL|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
219529560|NCT01751048|BIOLOGICAL|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
219529561|NCT01751048|DRUG|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
219529562|NCT06407622|OTHER|Foot Reflexology|In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
219529563|NCT03194139|DRUG|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
219041955|NCT06922968|PROCEDURE|TRUS-Guided TURP and enucleation|realtime TRUS guidance during the procedure (TURP and enucleation)
219041956|NCT06922968|PROCEDURE|Standard TURP and enucleation|No TRUS guidance during the procedure (TURP and enucleation)
219204593|NCT04425018|DRUG|Pertuzumab|Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
219204594|NCT04425018|DRUG|Margetuximab|Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
219529564|NCT03194139|DRUG|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
219529565|NCT03194139|DRUG|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
219529566|NCT00977522|DRUG|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
219529567|NCT00977522|DRUG|Placebo|Placebo tablet BID
219529568|NCT04786626|DIAGNOSTIC_TEST|Ultrasound evaluation|After vaginal, all patients were followed by traditional 2D US scanning and Doppler velocimetry on Days: 0, 2, 30, 60 and 90. Authors evaluated: scar diameter and Doppler velocimetry and resistance index (RI) of the uterine arteries, at their ascending branch
219529569|NCT05034757|OTHER|HA only|HA injection only
219529570|NCT05034757|OTHER|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
219615973|NCT04412356|PROCEDURE|Tracheotomy|Surgical procedure to secure airway
219041957|NCT06924359|DIAGNOSTIC_TEST|Multimodal Ophthalmic Imaging and plasma biomarker|Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
219204595|NCT04425018|DRUG|Trastuzumab|Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
219204596|NCT06241183|DRUG|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
219204597|NCT06241183|DRUG|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
219204598|NCT03099681|OTHER|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
218916226|NCT03694678|BEHAVIORAL|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
218916227|NCT05874843|DIAGNOSTIC_TEST|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
218916228|NCT02647099|DRUG|Acetylsalicylic acid|
218916229|NCT02647099|DRUG|Placebo|
218916230|NCT05131308|OTHER|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
219041958|NCT06924775|OTHER|Weighted jump rope training|Unlike isolated jump rope studies, this intervention was embedded within the participants' habitual CrossFit routine, enhancing ecological validity. Performing the jump rope protocol immediately prior to regular training-rather than as a stand-alone session-was intended to promote warm-up and neuromuscular priming benefits. The use of a weighted rope introduced a resistance stimulus that is rarely incorporated in jump rope interventions.
219041959|NCT06923397|BEHAVIORAL|Interrupted Sedentary Time Intervention|A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.
219529571|NCT05034757|OTHER|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
219529572|NCT00773422|DRUG|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
219529573|NCT00773422|DRUG|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
219529574|NCT00773422|DRUG|placebo|placebo
219529575|NCT04742790|DIAGNOSTIC_TEST|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
219529576|NCT04742790|DIAGNOSTIC_TEST|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
219529577|NCT04742790|DIAGNOSTIC_TEST|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero \& Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
219529578|NCT04742790|DIAGNOSTIC_TEST|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
219529579|NCT04742790|DIAGNOSTIC_TEST|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter \[variation coefficient of pupillary dilation, VCPD, Charier et al. 2017\]), light-evoked speed of pupil constriction \[maximum pupil constriction velocity, PCV, Connely et al., 2014\]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
219529580|NCT04742790|DIAGNOSTIC_TEST|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
219529581|NCT04742790|DIAGNOSTIC_TEST|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
219529582|NCT04742790|DIAGNOSTIC_TEST|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
219529583|NCT04742790|DIAGNOSTIC_TEST|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
219529584|NCT04742790|OTHER|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
219615974|NCT01475799|DEVICE|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
219615975|NCT03035591|DRUG|ODM-207|
218916231|NCT05773937|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
218916232|NCT05964842|BEHAVIORAL|SMS|Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
218916233|NCT05964842|BEHAVIORAL|Phone call|Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
218916234|NCT05964842|BEHAVIORAL|Mobile money incentive|Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
218916235|NCT05179785|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
219041960|NCT06923566|PROCEDURE|Targeted muscle reinnervation|"In 1ry TMR ,after the amputation is performed by the standard method , transected nerves will be replanted micro surgically to motor entry points (MEPS)in the hand as predetermined by Daugherty et al , Motor branches in the recipient muscles could be determined by a nerve stimulator intraoperatively.~In 2ry TMR , neuroma site will be explored and it will be excised ,the distal end of the transected nerve will be connected micro surgically to the nearest MEPS"
219204599|NCT06424249|OTHER|Virtual Reality|A progressive rehabilitation protocol (different levels according to success scores) consisting of several exercises using virtual and augmented reality with mechanical perturbations (pitching of the treadmill), interaction with the virtual environment, interaction with the virtual environment and augmented reality (projection of obstacles on the treadmill), and modification of the gait pattern with visual and/or audio biofeedback
219204600|NCT06424249|OTHER|Standard rehabilitation|A treadmill walking protocol with virtual reality to immerse the patient in a 3 x 5-minute walking session, without visual, mechanical or auditory disturbances, and without prompting the patient to modify their walking pattern.
219529585|NCT00139711|DRUG|Irinotecan|
219529586|NCT00139711|DRUG|Docetaxel|
219529587|NCT06118047|DRUG|Crisaborole Ointment|Crisaborole ointment to be applied twice daily.
219529588|NCT06118047|DRUG|Cetuximab|Cetuximab
219529589|NCT03174847|PROCEDURE|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
219529590|NCT03174847|DRUG|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
219529591|NCT02778451|OTHER|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
219615976|NCT04249960|BEHAVIORAL|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
219615977|NCT02676882|DIETARY_SUPPLEMENT|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
219615978|NCT00397462|DEVICE|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
219615979|NCT04879992|DRUG|Esomeprazole|Proton pump inhibitor
219615980|NCT04879992|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219615981|NCT04879992|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
219615982|NCT04879992|DRUG|amoxicillin rifabutin|Antibiotics for H. pylori eradication
219615983|NCT01371604|DRUG|IDX184|IDX184 50 mg tablet administered orally
219615984|NCT01371604|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
219529592|NCT03143686|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
219615985|NCT01371604|DRUG|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
219615986|NCT01371604|DRUG|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
219615987|NCT05709418|BEHAVIORAL|Intensiv support for first graders in Norway|Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
219615988|NCT00402909|DRUG|Nateglinide|
219615989|NCT01288807|DRUG|Milnacipram|Titration to 200mg PO daily
218916236|NCT05179785|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
218916237|NCT05153746|DEVICE|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
218916238|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
218916239|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
219529593|NCT03863002|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
219615990|NCT00958828|DEVICE|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
219615991|NCT00958828|DEVICE|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
219615992|NCT01164293|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
218916240|NCT04692233|BEHAVIORAL|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
219529594|NCT03988803|DRUG|BI 425809|Film coated tablet
219615993|NCT03711097|DRUG|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
219615994|NCT05628597|DEVICE|Fos Biomedical patch product|Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
219615995|NCT05628597|DEVICE|Fos Biomedical patch product:placebo|Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
219529595|NCT03988803|DRUG|Memantine|Film coated tablet
219529596|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
219615996|NCT02765997|BIOLOGICAL|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
219615997|NCT02765997|BIOLOGICAL|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
219615998|NCT01268553|DRUG|Treprostinil|Transition to inhaled treprostinil
219615999|NCT04977011|OTHER|relaxing music|30 minutes relaxing music for continuity 3 days since admission
219616000|NCT00183547|BEHAVIORAL|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
219616001|NCT00183547|BEHAVIORAL|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
219616002|NCT01942577|DEVICE|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
218916241|NCT04692233|BEHAVIORAL|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
219204601|NCT06098170|BEHAVIORAL|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
218916242|NCT06379659|DRUG|Growh hormone|In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
218916243|NCT06379659|OTHER|Placebo|Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
218916244|NCT05699642|BEHAVIORAL|Tai chi + wearable|The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.
218916245|NCT06218277|DIAGNOSTIC_TEST|ASTAR|Rapid AST with ASTAR
218916246|NCT04526340|DIAGNOSTIC_TEST|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
218916247|NCT04526340|DIAGNOSTIC_TEST|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
218916248|NCT04526340|DIETARY_SUPPLEMENT|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
218916249|NCT04526340|DIAGNOSTIC_TEST|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
218916250|NCT02933008|OTHER|aNMT Biofeedback|"aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention."
218916251|NCT02933008|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
218916252|NCT02933008|OTHER|Neuromuscular Training|Participants will complete a 12-session, pre-season training program, over 6 weeks.
219529597|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
219529598|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
219529599|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
219529600|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
219529601|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
219529602|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
219529603|NCT00706186|DRUG|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
219529604|NCT03251430|PROCEDURE|gastrectomy|Distal gastrectomy, Total gastrectomy
219529605|NCT03909620|DIAGNOSTIC_TEST|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
219616003|NCT05268653|BEHAVIORAL|Motivatıonal İnterviewing (Treatment Group)|Obese adolescents will be given a 6-session motivational interview.
219616004|NCT00149682|BEHAVIORAL|6-month educational program|
219616005|NCT00149682|BEHAVIORAL|6-month standard care program|
219529606|NCT04123548|BIOLOGICAL|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
219529607|NCT00557050|OTHER|Training|10-week eccentric hamstring muscle training
218916253|NCT06011759|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\]."
219204602|NCT06098170|BEHAVIORAL|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
219529608|NCT04757792|OTHER|File inquiry|Data extraction out of file registry
219529609|NCT04064892|BEHAVIORAL|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, \& Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
219529610|NCT06279286|DRUG|HS-10506|HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
219529611|NCT06279286|DRUG|Placebo|Placebo, placebo tablets matching the HS-10506 tablets
219529612|NCT02670772|DRUG|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
219616006|NCT02687451|DRUG|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
219616007|NCT02687451|DRUG|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
219616008|NCT02478944|DEVICE|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
218916254|NCT06011759|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
219204603|NCT03554902|PROCEDURE|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
219204604|NCT02390869|DRUG|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
219529613|NCT02670772|DRUG|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
219529614|NCT03192722|DEVICE|Colored near reading glasses|Participants are provided with colored near vision glasses.
219529615|NCT03192722|DEVICE|Lighting as determined by LuxIQ/2 or OttLite Cobra|Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
219529616|NCT00418184|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
219529617|NCT00418184|OTHER|Colored cellulose tainted with fishy odor|as arm 1
219529618|NCT02296008|DEVICE|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
219616009|NCT00927589|DRUG|carboplatin|Intravenous repeating dose
219529619|NCT05056974|BIOLOGICAL|UB-421|10 mg/kg, weekly UB-421 during the 8-week
219529620|NCT05056974|DRUG|chidamide|10 mg/dose, twice a week for 8 weeks
219529621|NCT01933360|DRUG|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
219529622|NCT01933360|DRUG|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
219529623|NCT01933360|DRUG|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
219529624|NCT01933360|DRUG|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
219529625|NCT01933360|DRUG|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
219529626|NCT01933360|DRUG|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
219616010|NCT00927589|DRUG|docetaxel|Intravenous repeating dose
219616011|NCT00927589|DRUG|trastuzumab|Intravenous repeating dose
219616012|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
219616013|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
219616014|NCT01125189|DRUG|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
219616015|NCT01125189|DRUG|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
219616016|NCT01125189|DRUG|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
219616017|NCT03760692|DEVICE|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
219616018|NCT03760692|DEVICE|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
219616019|NCT01396668|DRUG|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
219616020|NCT04135092|BIOLOGICAL|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
219616021|NCT04135092|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
218916255|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
218916256|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
218916257|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
218916258|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
218916259|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
218916260|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
219529627|NCT01933360|DRUG|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
219529628|NCT01933360|DRUG|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
219616022|NCT04135092|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
219616023|NCT04135092|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
218916261|NCT03292926|DRUG|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
218916262|NCT03292926|DEVICE|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
218916263|NCT03292926|DRUG|Dexamethasone|Dexamethasone will be used to prolong block duration
218916264|NCT06510439|BEHAVIORAL|Need to Be Needed Intervention|Interventionist-supported volunteering intervention that targets opportunities creating social connections that matter through focus on kindness and gratitude throughout the intervention.
218916265|NCT06510439|OTHER|Active Control Group|Weekly non-directive listening support
219204605|NCT02390869|DRUG|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
219529629|NCT01015625|PROCEDURE|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
219529630|NCT01015625|PROCEDURE|Surgery on Demand|if necessary local therapy on demand
219529631|NCT05186571|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
219529632|NCT04206410|DIETARY_SUPPLEMENT|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
219529633|NCT04206410|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
219529634|NCT05427643|PROCEDURE|study group|dental implant procedure under local anesthesia
219529635|NCT05427643|PROCEDURE|control group|dental implant procedure under local anesthesia
219529636|NCT00649753|PROCEDURE|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
219529637|NCT00649753|PROCEDURE|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
219529638|NCT00649753|PROCEDURE|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
219616024|NCT04135092|DRUG|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
219529639|NCT02898545|DEVICE|SEEQ monitor|An external cardiac rhythm monitor
219529640|NCT05813548|OTHER|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
219616025|NCT04304989|OTHER|mHealth program|mobile health applications
219616026|NCT04304989|OTHER|usual care|usual care
219616027|NCT01799629|DRUG|Glycerin suppositories|
218916266|NCT03350529|DEVICE|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
218916267|NCT02453737|RADIATION|Brachytherapy APBI|
219616028|NCT05669404|BEHAVIORAL|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
219529641|NCT05813548|OTHER|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
219529642|NCT03038048|PROCEDURE|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
219529643|NCT00006495|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219529644|NCT00006495|BIOLOGICAL|HIV-1 Immunogen|
219529645|NCT02728102|PROCEDURE|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
219529646|NCT02728102|PROCEDURE|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
219529647|NCT02728102|DRUG|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
219616029|NCT05669404|BEHAVIORAL|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
219616030|NCT05669404|BEHAVIORAL|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
219529648|NCT02728102|PROCEDURE|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
219529649|NCT02728102|BIOLOGICAL|Myeloma vaccine|The target dose is 3 x 10\^6 fusion cells per vaccine. A minimum of 3 x 10\^6 total fusion cells will be required to proceed with vaccine administration. Patients who have \<3 x 10\^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
219616031|NCT04062669|BIOLOGICAL|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.
219616032|NCT04062669|BIOLOGICAL|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.
218916268|NCT02453737|RADIATION|3D-CRT (photon) APBI|
218916269|NCT02453737|RADIATION|Proton APBI|
218916270|NCT04954339|DRUG|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
218916271|NCT04913272|DRUG|US-APR2020|US-APR2020 capsules 45 billion CFUs of the LBT.
218916272|NCT04913272|DRUG|Placebo|Placebo
218916273|NCT04852302|BEHAVIORAL|Cancer and Living Meaningfully (CALM) Therapy|The Cancer and Living Meaningfully (CALM) intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
218916274|NCT06486987|OTHER|Constraint induced movement therapy delivered by televideo|In-home Constraint induced movement therapy delivered by a therapist participating by televideo
218916275|NCT04711850|DRUG|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
219204606|NCT06415682|DEVICE|SMA+M1 Transcranial Magnetic Stimulation|"The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA)."
219529650|NCT02728102|DRUG|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
219529651|NCT02728102|DRUG|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
218916276|NCT03788213|RADIATION|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
219529652|NCT02472366|DRUG|ILUVIEN|
219529653|NCT03739749|PROCEDURE|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
219529654|NCT03142360|DRUG|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
218916277|NCT03788213|RADIATION|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
219616033|NCT04062669|BIOLOGICAL|Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
219616034|NCT04062669|BIOLOGICAL|Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
219616035|NCT04062669|DRUG|Saline Placebo|Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
219616036|NCT04062669|BIOLOGICAL|RabAvert|Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
219616037|NCT00920868|DRUG|dasatinib|dasatinib at 50 mg PO BID)
219616038|NCT00920868|DRUG|bevacizumab|7.5 mg/kg IV day 1
219616039|NCT00920868|DRUG|Oxaliplatin|130 mg/m2 IV day 1
219616040|NCT00920868|DRUG|Capecitabine|850 mg/m2 PO BID on days 1-14
219616041|NCT05832268|OTHER|Obstetric Anal Sphincter Injury|We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
219616042|NCT03559972|OTHER|on-label facial injection|Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
218916278|NCT03267277|DRUG|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
218916279|NCT06537193|DIAGNOSTIC_TEST|AMRI|The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
218916280|NCT06537193|DIAGNOSTIC_TEST|CT|CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage was from the basal lung to the iliac crest or pelvis.
219529655|NCT01182415|PROCEDURE|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
219529656|NCT01182415|DRUG|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
219529657|NCT02535494|OTHER|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
219529658|NCT04044326|PROCEDURE|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
219529659|NCT02424266|DEVICE|None invasive imaging of the tear film (AdOM)|White light tomography imaging
219529660|NCT05209009|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
219529661|NCT05209009|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
219204607|NCT06415682|DEVICE|M1 Transcranial Magnetic Stimulation|The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
219204608|NCT06415682|DEVICE|Sham Transcranial Magnetic Stimulation|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
219529662|NCT05479110|BEHAVIORAL|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
219529663|NCT05479110|OTHER|case studies|active control: case studies(text)
219616043|NCT05927012|DRUG|KER-047|Oral tablet, daily (or every other day) administration
219616044|NCT02264769|DRUG|Carbetocin|
219529664|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219529665|NCT01121276|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219616045|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
218916281|NCT06560372|PROCEDURE|Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV|"Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics)."
219529666|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219529667|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219529668|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
219529669|NCT02587962|DRUG|Birinapant|Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
219529670|NCT02587962|DRUG|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
219529671|NCT04990180|BEHAVIORAL|Shared Decision Making Intervention|Decision coaching will be provided to the Pulmonary Rehabilitation Specialists to provide the skills needed to facilitate shared decision making between themselves and patients (and carers). The patient decision aid will be an informational booklet which describes the available Pulmonary Rehabilitation options at the University Hospitals of Leicester. It will detail the risks and benefits of each option and provide interactive sections to engage patients with the content, guide them through it, encourage them to attribute personal meaning and preference to each one so they can make an informed and values-based decision about PR.
219529672|NCT03184480|DRUG|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
219529673|NCT00481520|DRUG|SAM-531|
219529674|NCT00481520|OTHER|placebo|
219529675|NCT05009225|OTHER|Comprehensive ED AF management tool|Managing atrial fibrillation (AF) patients in the emergency department (ED) is complex, often requiring many separate decisions: How to best reduce the heart rate? Should emergency physicians attempt cardioversion? If so, how? Does this patient need stroke prevention? The investigators' CDSS provides emergency physicians with a one-stop, evidence-based resource that addresses all aspects of ED AF management.
218916282|NCT04119986|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.
218916283|NCT04119986|DEVICE|drug eluted stent|with regular techniques
218916284|NCT03237624|DEVICE|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
218916285|NCT03237624|DEVICE|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
218916286|NCT03237624|BEHAVIORAL|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
219529676|NCT03232372|DEVICE|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
219529677|NCT03232372|DEVICE|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
219529678|NCT03232372|DEVICE|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
219529679|NCT03717350|DRUG|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
219529680|NCT03717350|DRUG|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
219529681|NCT00148772|DRUG|Erlotinib (Tarceva)|
219529682|NCT03828058|DRUG|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
219529683|NCT03828058|DRUG|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
219529684|NCT01488786|DEVICE|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
219529685|NCT02522234|BIOLOGICAL|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
218916287|NCT06527469|OTHER|PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP|Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
219204609|NCT05111093|DEVICE|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
219204610|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
219529686|NCT02522234|BIOLOGICAL|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
219529687|NCT00234286|BEHAVIORAL|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
219529688|NCT02605395|DRUG|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
219529689|NCT02605395|DRUG|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
219529690|NCT01422538|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
219529691|NCT01422538|DRUG|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
219529692|NCT01422538|OTHER|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
219529693|NCT02738190|DRUG|Albumin|Albumin 5% added to blood priming solution
219529694|NCT02738190|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
219529695|NCT00553228|BIOLOGICAL|Tdap|0.5 mL IM once at visit #2
219529696|NCT00553228|BIOLOGICAL|Td|0.5 mL IM once at visit #2
219529697|NCT02770820|BIOLOGICAL|Aldesleukin|Given SC
219529698|NCT02770820|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
219529699|NCT02770820|OTHER|Laboratory Biomarker Analysis|Correlative studies
219529700|NCT00720265|DRUG|Prograf|oral
219529701|NCT00720265|DRUG|MR4|oral
219529702|NCT04165239|DRUG|KH176|Oral administration of 50 mg KH176 twice daily
219529703|NCT04165239|DRUG|KH176|Oral administration of 100 mg KH176 twice daily
219529704|NCT04165239|DRUG|Placebo|Oral administration of matching placebo twice daily
219529705|NCT01414972|DRUG|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
219529706|NCT01414972|DRUG|placebo|1 cap placebo/day for 3 month
219529707|NCT04395417|DRUG|Hyaluronic Acid|Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
219204611|NCT01161732|PROCEDURE|Early surgery|Early surgery is performed within 2 months of randomization.
219529708|NCT04395417|BIOLOGICAL|Prolotherapy|Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
219529709|NCT03525860|PROCEDURE|Acupuncture|"The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~."
219529710|NCT04337320|OTHER|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
219529711|NCT00378131|DRUG|RC-1291|
219529712|NCT00378131|DRUG|placebo|
219529713|NCT01532674|DEVICE|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~* Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~* Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~* All the periodontal pockets will be treated subgingivally~* Elimination of the photosensitive by irrigation"
219529714|NCT01532674|PROCEDURE|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~\* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
219204612|NCT06949176|PROCEDURE|Root canal tratment using mecchanical and chemical preparation.|Root canal procedures including access cavity preparation, chemomechanical instrumentation, irrigation with sodium hypoclorite (NaOCl), microbiological sampling and obturation with warm vertical compaction.
219616046|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
218916288|NCT06088992|GENETIC|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
218916289|NCT06098755|BEHAVIORAL|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
218916290|NCT01379898|DRUG|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
218916291|NCT01379898|DRUG|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
218916292|NCT02685969|PROCEDURE|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
218916293|NCT06075082|DEVICE|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
218916294|NCT04769479|DRUG|acoramidis|acoramidis
218916295|NCT04007692|PROCEDURE|Esophageal stent placement|Exposure of interest is standard of care esophageal stent placement
218916296|NCT03745508|OTHER|Instant Coffee|Instant coffee prepared at different caffeine concentrations
219529715|NCT05223426|OTHER|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
219616047|NCT00707239|DRUG|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
218916297|NCT05379088|BEHAVIORAL|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
218916298|NCT05214001|DRUG|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
218916299|NCT05214001|DRUG|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
218916300|NCT03521570|RADIATION|IMRT|Undergo intensity-modulated radiation therapy
218916301|NCT03521570|BIOLOGICAL|Nivolumab|Given IV
218916302|NCT06301230|DEVICE|Portable Laparoscopic Trainer (PLET)|"The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation."
218916304|NCT04076696|DEVICE|Scatter corrected s-DCT|All patients will have a breath held s-DCT scan in an anterior-posterior direction
218916305|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
218916306|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
219529716|NCT05223426|OTHER|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
219529717|NCT00006226|DRUG|thalidomide|Given PO
219529718|NCT00006226|OTHER|laboratory biomarker analysis|Correlative studies
219529719|NCT04622657|OTHER|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
218916307|NCT03496844|DIAGNOSTIC_TEST|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
218916308|NCT04531176|OTHER|Weight Management Program (WMP)|Weight Management Program (WMP)
219529720|NCT00381225|PROCEDURE|Ultra-sound guided radio-frequency ablation|
219529721|NCT02134964|DRUG|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
218916309|NCT04531176|OTHER|Traditional care|Traditional care
219529722|NCT02134964|DRUG|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
219529723|NCT02841033|DRUG|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
219529724|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
219529725|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
219529726|NCT04459585|DRUG|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
219529727|NCT04459585|DRUG|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
219529728|NCT05253105|DRUG|TAB006|Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
219529729|NCT05253105|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
218916310|NCT04531176|DRUG|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
218916311|NCT04531176|DRUG|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
219529730|NCT02098876|DEVICE|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
219529731|NCT02098876|DEVICE|Xience Xpedition everolimus eluting stent|PCI with Xience stent
219529732|NCT02098876|DEVICE|Optical Coherence Tomography (OCT)|Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
219529733|NCT02098876|DEVICE|Intravascular Ultrasound (IVUS)|Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
219529734|NCT01159860|PROCEDURE|cryosurgery|freezing of lesion with liquid nitrogen
219529735|NCT01159860|PROCEDURE|Curettage|the lesion will be anesthetized and destroyed with a curette.
219529736|NCT03143920|COMBINATION_PRODUCT|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
219529737|NCT04202874|PROCEDURE|Surgeon-administered transversus abdominis plane (TAP)|Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.
218916312|NCT04531176|DRUG|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
218916313|NCT04531176|DRUG|Orlistat|Medication for chronic weight management (Rx)
219529738|NCT04455230|GENETIC|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
219529739|NCT02809469|DRUG|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
219529740|NCT05237310|DEVICE|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
219529741|NCT05237310|DEVICE|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
218916314|NCT06564571|DEVICE|Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
218916315|NCT03962465|DRUG|Inotuzumab ozogamicin|By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
218916316|NCT03962465|DRUG|Prednisone Pill|Taken daily days 1-28 by mouth
218916317|NCT03962465|DRUG|Daunorubicin|By IV, given on days 1, 8, 15, and 22
218916318|NCT03962465|DRUG|Vincristine|By IV, given on days 1, 8, 15, and 22
219529742|NCT05237310|DEVICE|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
219529743|NCT01061866|DRUG|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
218916319|NCT03962465|DRUG|Cytarabine|Intrathecal, administered on day 1 only
218916320|NCT03962465|DRUG|Methotrexate|Intrathecal, administered on days 8 and 29
218916321|NCT03962465|DRUG|Pegaspargase|By IV, given on day 4
218916322|NCT06010654|DEVICE|Software as a Medical device|The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
218916323|NCT04181359|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
218916324|NCT04181359|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
218916325|NCT02663492|DEVICE|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
218916326|NCT02663492|DRUG|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
218916327|NCT01250808|DRUG|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
218916328|NCT00003122|PROCEDURE|surgical procedure|
218916329|NCT03475004|DRUG|Pembrolizumab|An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
218916330|NCT03475004|DRUG|Bevacizumab|The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
218916331|NCT03475004|DRUG|Binimetinib|Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
218916332|NCT00311766|DRUG|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
218916333|NCT00311766|DRUG|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
218916334|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
218916335|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
218916336|NCT01648712|DEVICE|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
218916337|NCT01648712|DEVICE|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
218916338|NCT04614896|DIAGNOSTIC_TEST|Transoral ultrasound of tongue tumors|A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
218916339|NCT03605667|DRUG|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
218916340|NCT03605667|DRUG|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
218916341|NCT04939766|DEVICE|Activation of a closed loop device in an insulin pump device with GCM|After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
218916342|NCT06372626|BIOLOGICAL|ZG005|"ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage."
218916343|NCT06372626|DRUG|Etoposide|IV infusion
218916344|NCT06372626|DRUG|Cisplatin|IV infusion
219529744|NCT03086473|DRUG|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
219529745|NCT03086473|DRUG|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
219529746|NCT05764980|BEHAVIORAL|visual function evaluation|visual function evaluation
219529747|NCT04566848|DIAGNOSTIC_TEST|Flow cytometric analysis|Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
219529748|NCT01185886|GENETIC|gene expression analysis|
219529749|NCT01185886|GENETIC|mutation analysis|
219616048|NCT02501122|OTHER|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
218916345|NCT06372626|DRUG|Placebo|0.9% Sodium Chloride Injection
218916346|NCT00768417|BEHAVIORAL|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
218916347|NCT00768417|BEHAVIORAL|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
219529750|NCT01185886|GENETIC|polymorphism analysis|
219616049|NCT03942757|OTHER|bilirubin serum level determination|bilirubin serum level before and after phototherapy treatment will be measured
219529751|NCT01185886|OTHER|biologic sample preservation procedure|
219529752|NCT01185886|OTHER|laboratory biomarker analysis|
219529753|NCT01185886|OTHER|pharmacogenomic studies|
219529754|NCT06362486|OTHER|Severity of infection, time of infection.|Severity of infection, time of infection.
219529755|NCT06362486|OTHER|Mental health assessment|Mental health assessment
219616050|NCT03942757|OTHER|Phototherapy|Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
219616051|NCT02593695|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
218916348|NCT00768417|BEHAVIORAL|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
218916349|NCT06125834|DRUG|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
218916350|NCT01847521|DIETARY_SUPPLEMENT|Luteolin, Quercetin and Rutin combined in a capsule|
218916351|NCT05165667|OTHER|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
218916352|NCT06156020|PROCEDURE|Endoscopic endonasal surgery|Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
218916353|NCT01780311|DRUG|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
218916354|NCT01780311|PROCEDURE|Catheter Ablation|
218916355|NCT03659188|PROCEDURE|Cortico-alveolar perforations|Mechanical drills will be used on a handpiece
218916356|NCT03659188|PROCEDURE|Traditional Corticotomy|Piezo-surgery will be employed following flaps' elevation.
218916357|NCT00537134|DEVICE|Embolization, coiling|Endovascular embolization with platinum coils
218916358|NCT00006016|DRUG|thalidomide|Given orally
218916359|NCT00006016|DRUG|doxorubicin hydrochloride|Given transarterially (chemoembolization)
218916360|NCT00006016|OTHER|laboratory biomarker analysis|Correlative studies
218916361|NCT05418179|DIETARY_SUPPLEMENT|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
218916362|NCT05418179|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (1 capsule/day)
218916363|NCT04144686|OTHER|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
219529756|NCT06362486|OTHER|biological|Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
219529757|NCT06231784|DEVICE|LUMINA IOL|A standard technique of phacoemulsification was performed followed by implantation of the Lumina in the sulcus plane of the eye by using a standard disposable injector system with an adapted, proprietary, AkkoLens butterfly cartridge.
219529758|NCT03949179|DEVICE|The Low Back Pain and Disability Drivers Management (PDDM) model|The Low Back Pain and Disability Drivers Management (PDDM) model aims to identify the domains influencing pain and disability to guide clinical decisions. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers (i.e., somatic, inflammatory or mixed pain), 2) nervous system dysfunction (NSD) drivers (i.e., sensitization of the peripheral and/or central nervous system), 3) comorbidity drivers (i.e., physical and/or mental health comorbidities), 4) cognitive-emotional drivers (i.e., maladaptive cognitions and/or behaviors) and 5) contextual drivers (i.e., occupational-related and social environmental contextual drivers). This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.
218916364|NCT04696432|BIOLOGICAL|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
218916365|NCT06210646|DRUG|Citicoline 2000|The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
218916366|NCT06210646|DRUG|citocoline 1000|The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
218916367|NCT06334432|DRUG|NUV-1511|Novel small molecule
219616052|NCT02593695|OTHER|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
219616053|NCT02961595|BIOLOGICAL|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
219616054|NCT04711538|DEVICE|MRI|imaging inner ear and petrous bone of the candidate by MRI and CT
219616055|NCT03295838|BEHAVIORAL|Mentalization-based treatment|See Arm description
219616056|NCT01651117|BEHAVIORAL|Peer Mentoring|Patients will receive peer mentoring.
218916368|NCT02800668|DEVICE|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
218916369|NCT02401165|OTHER|Blood test|blood test
218916370|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
218916371|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
218916372|NCT02920632|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
218916373|NCT02920632|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
218916374|NCT04746391|DEVICE|Dialyzer type|Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers
218916375|NCT04746391|OTHER|Dialysis duration|Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
218916376|NCT03312231|DRUG|AS03|Oil-in-water emulsion based adjuvant system.
218916377|NCT03312231|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
218916378|NCT03312231|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
219616057|NCT05962385|DEVICE|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
219616058|NCT02714218|BIOLOGICAL|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
219616059|NCT02714218|BIOLOGICAL|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
219616060|NCT02714218|BIOLOGICAL|Nivolumab 1 mg/kg IV|
219616061|NCT02714218|BIOLOGICAL|Ipilimumab 3 mg/kg IV|
219616062|NCT02714218|BIOLOGICAL|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to \~ 480mg.
219616063|NCT03295071|OTHER|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
218916379|NCT00471055|DRUG|"0.0125% Capsaicin gel CAPSIKA gel"|
218916380|NCT00471055|DRUG|Placebo|Placebo
219529759|NCT00830700|OTHER|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
219529760|NCT05707507|OTHER|Place of treatment|Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
219529761|NCT00834756|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
219529762|NCT00834756|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
219529763|NCT05638971|DEVICE|ivWatch|The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
219529764|NCT03387176|OTHER|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
219529765|NCT04125576|DIAGNOSTIC_TEST|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
219529766|NCT05178095|DEVICE|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
219529767|NCT05178095|DEVICE|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
219529768|NCT01591447|DRUG|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
219529769|NCT01591447|DRUG|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
219529770|NCT06627725|BEHAVIORAL|Patient-Family Communication|Patient-Family Communication
219529771|NCT05839834|DIAGNOSTIC_TEST|Blood test|RNA sequencing of peripheral blood cells
219529772|NCT06317103|DEVICE|WADYMED endo|"Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)"
219529773|NCT06317103|OTHER|Control group (the endoscopists)|"Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists"
219529774|NCT02819323|DRUG|PEG-ELS|polyethylene glycol based bowel preparation
219616064|NCT03655171|DIAGNOSTIC_TEST|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
219616065|NCT05234801|DEVICE|DARCO™ Headed Cannulated Screw|The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
219616066|NCT05234801|DEVICE|ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
219616067|NCT05234801|DEVICE|ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
219616068|NCT06205862|PROCEDURE|fecal microbiota transplantation|We will use fecal suspensions and capsules prepared from the feces of healthy donors for fecal microbiota transplantation. Participants are required to complete one colonoscopy and infuse 150ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 2 days continuously (day 1-2), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules (20 capsules bid) at 3, 6, and 9 months (approximately every 75 to 90 days). Participants will undergo their first follow-up colonoscopy between 6 to 12 months(the high-risk adenoma group will receive colonoscopy at 6 months, and the low-risk adenoma group will receive colonoscopy at 12 months).
219616069|NCT06206304|OTHER|Root canal therapy|Traditional root canal therapy was performed with rubber-dam isolation.
218916381|NCT05037240|DIETARY_SUPPLEMENT|Quercetin|Quercetin (500 mg), 2 times a day for 3 months
218916382|NCT05037240|COMBINATION_PRODUCT|Placebo|500 mg, 2 times a day for 3 months
219204613|NCT06949176|DRUG|Sodium Hypochlorite.|Sodium Hypoclorite used as the primary irrigant in the root canal treatment at concentrations of 2.5% (Group A) and 5% (Group B).
219204614|NCT06949176|DRUG|Hydrogen peroxide.|Applied to the operating field and tooth as part of initial disinfection prior to cavity access.
219204615|NCT06949176|DRUG|Sodium Sulfate.|Used to inactivate sodium hypoclorite prior to sample collection.
219529775|NCT02819323|DRUG|BLI800|BLI800 bowel preparation
218916383|NCT05306899|DRUG|Ketamine|Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
219529776|NCT06561737|OTHER|Video|For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
219529777|NCT04044261|PROCEDURE|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
219529778|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in stroke group|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
219529779|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in healthy group|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
219529780|NCT04826718|OTHER|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
219529781|NCT04535076|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
219529782|NCT04535076|PROCEDURE|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
219529783|NCT03539003|DRUG|sevoflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
219529784|NCT03539003|DRUG|desflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
219529785|NCT03539003|DRUG|propofol and remifentanil|anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
219529786|NCT00439491|BEHAVIORAL|Hypocaloric diet|
219529787|NCT05875597|OTHER|Physical therapy exercise programme|Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
219529788|NCT05086562|OTHER|observation study|observation study
219529789|NCT00125086|DEVICE|autologous platelet gel|
219529790|NCT02519491|OTHER|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
219529791|NCT02519491|OTHER|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
219529792|NCT06368037|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
219529793|NCT03423056|OTHER|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
219529794|NCT02147925|DRUG|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
219529795|NCT02147925|DRUG|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
218916384|NCT05306899|OTHER|0.9% Saline|Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
218916385|NCT02320084|DRUG|Nitisinone|Nitisinone according to prescription
218916386|NCT00400179|DRUG|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
218916387|NCT00400179|DRUG|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
218916388|NCT06541938|DIETARY_SUPPLEMENT|low FODMAP diet|You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
218916389|NCT06541938|DIETARY_SUPPLEMENT|Lactose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk"
218916390|NCT06541938|DIETARY_SUPPLEMENT|Fructose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples"
219529796|NCT02147925|DRUG|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
219529797|NCT02590185|DRUG|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg"
219529798|NCT02608502|BIOLOGICAL|RSV-F Vaccine|
219529799|NCT02608502|BIOLOGICAL|Phosphate Buffer Placebo|
219529800|NCT02979353|BEHAVIORAL|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
219616070|NCT05733429|OTHER|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
219616071|NCT05733429|OTHER|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
218916391|NCT06541938|DIETARY_SUPPLEMENT|Sorbitol Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune"
219204616|NCT06949176|DEVICE|Root ZX mini apex locator (Morita).|Used to determine the working length of the root canal.
219204617|NCT06949176|DEVICE|Protaper Gold rotary files (Dentslpy Maillefer).|Used for coronal flaring in root canal instrumentation.
219529801|NCT05319990|DRUG|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
219529802|NCT05319990|DRUG|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
219529803|NCT04346927|OTHER|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
219616072|NCT05733429|OTHER|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
219616073|NCT04435912|DRUG|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
219204618|NCT06949176|DEVICE|Smarttrack and Hyflex totary files.|Used for root canal instrumentation to full working length.
219204619|NCT06949176|DEVICE|Endo-Eze 27G irrigation needle (Ultradent).|Used to deliver irrigant into the root canal.
219529804|NCT04346927|OTHER|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
219529805|NCT00760110|DEVICE|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
219529806|NCT01099943|OTHER|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
219529807|NCT03337997|PROCEDURE|Irreversible Electroporation|Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
219529808|NCT00086762|BEHAVIORAL|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
219529809|NCT00086762|BEHAVIORAL|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
219529810|NCT00086762|BEHAVIORAL|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
219529811|NCT00086762|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
219529812|NCT01079988|DRUG|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
219529813|NCT01079988|DRUG|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
219529814|NCT01079988|DRUG|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
219529815|NCT01079988|DRUG|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
219529816|NCT01079988|DRUG|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
219529817|NCT00385346|BEHAVIORAL|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
219529818|NCT01324193|DIETARY_SUPPLEMENT|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
219529819|NCT02853682|BIOLOGICAL|plasma|assesment of glycocalyx protein
219529820|NCT01042886|BEHAVIORAL|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
219529821|NCT01042886|BEHAVIORAL|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
219204620|NCT04626882|PROCEDURE|Staged in-hospital or Immediate complete revascularization|Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
219616074|NCT01352572|DRUG|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
219616075|NCT01352572|DRUG|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
219616076|NCT05587010|DEVICE|AFO|ankle foot orthosis
219616077|NCT05587010|DEVICE|lycra sock|custom fitted lycra sock
218916392|NCT06541938|DIETARY_SUPPLEMENT|Inulin Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic"
218916393|NCT06541938|DEVICE|AIRE-2 Portable breath analyzer|The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
218916394|NCT03090230|DEVICE|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
218916395|NCT01526447|PROCEDURE|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
218916396|NCT01526447|PROCEDURE|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
219616078|NCT05587010|DEVICE|OrthPed splint|novel compression splint
219529822|NCT02121886|PROCEDURE|venous reconstruction with the parietal peritoneum|
219529823|NCT00260039|BIOLOGICAL|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
219529824|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
219529825|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
219529826|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
219529827|NCT01705301|DEVICE|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
219616079|NCT03984864|OTHER|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
219529828|NCT00003186|DRUG|isosulfan blue|
219529829|NCT00003186|PROCEDURE|lymphangiography|
219529830|NCT00003186|PROCEDURE|sentinel lymph node biopsy|
219616080|NCT01433471|DRUG|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
219616081|NCT01823861|BEHAVIORAL|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
219616082|NCT03521388|BEHAVIORAL|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
219616083|NCT03521388|OTHER|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
218916397|NCT02753270|PROCEDURE|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
218916398|NCT02753270|PROCEDURE|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
219529831|NCT05269901|GENETIC|SLC7A11, GPX4, P53|Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
219529832|NCT00268905|DRUG|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
219616084|NCT03711188|DRUG|Nivolumab|Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
219616085|NCT03711188|DRUG|Ipilimumab|Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
219616086|NCT03711188|DRUG|IMM-101|A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
219616087|NCT03726697|OTHER|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
219616088|NCT01803698|BEHAVIORAL|Training in the use of IOM charts|
219616089|NCT03196583|DEVICE|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
218916399|NCT04236427|DRUG|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
218916400|NCT04236427|DRUG|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
219529833|NCT00268905|DRUG|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
219529834|NCT00268905|DRUG|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
219529835|NCT05565053|PROCEDURE|Bilateral thoracal erector spinae plane block|Bilateral upper thoracal erector spinae plane block with ultrasound
219529836|NCT05565053|PROCEDURE|Trapezius muscle trigger point injection|Trapezius muscle trigger point injection
219529837|NCT01540760|DRUG|MCAF5352A|Multiple ascending doses
219529838|NCT01540760|DRUG|Placebo|Matching MCAF5352A, multiple doses
219529839|NCT04093037|DIAGNOSTIC_TEST|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
219529840|NCT04093037|DIAGNOSTIC_TEST|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
219529841|NCT04093037|DIAGNOSTIC_TEST|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
219529842|NCT04093037|DIAGNOSTIC_TEST|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
219529843|NCT04093037|DIAGNOSTIC_TEST|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
219529844|NCT04355468|DRUG|Opioid Anesthesia|Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
219616090|NCT02493153|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
219616091|NCT04780893|DEVICE|Modius Sleep|The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
219616092|NCT03142477|OTHER|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
219616093|NCT03142477|OTHER|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
219616094|NCT03142477|OTHER|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
219616095|NCT02479620|DRUG|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
218916401|NCT00635414|DRUG|Esomeprazole|40mg oral
219616096|NCT04842331|DRUG|RESP301 (a nitric oxide generating solution)|Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
219616097|NCT04842331|DRUG|Standard of Care (SOC)|Participants will receive institutional SOC for the treatment.
219616098|NCT00000876|DRUG|CD4-IgG2|
219616099|NCT05580874|OTHER|Massage|The babies in the massage group were given a massage once a day.
219616100|NCT05580874|OTHER|Swaddling|Control group
219616101|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and tetracycline|14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
219616102|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
218916402|NCT00635414|DRUG|Esomeprazole|15 minute intravenous infusion
218916403|NCT00114569|DRUG|lorazepam|
218916404|NCT03880097|PROCEDURE|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
218916405|NCT06822062|OTHER|Meal A|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57, native chitin content = 1g)
218916406|NCT06822062|OTHER|Meal B|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + 2g of extrinsically added chitin
218916407|NCT06822062|OTHER|Meal C|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
218916408|NCT06822062|OTHER|Meal D|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58)
218916409|NCT06822062|OTHER|Meal E|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 1g of extrinsically added chitin
218916410|NCT06822062|OTHER|Meal F|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 3g of extrinsically added chitin
218916411|NCT06822062|OTHER|Meal G|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 54) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
219529845|NCT04355468|DRUG|Opioid Free Anaesthesia|"Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1."
219529846|NCT02170922|DRUG|BIBR 1048 MS tablet|
219529847|NCT02170922|DRUG|BIBR 1048 MS solution|
219529848|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
219529849|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
219529850|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
219529851|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
219529852|NCT00449592|DRUG|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
219529853|NCT00449592|DRUG|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
219529854|NCT05020925|DRUG|SHR-1701|Intravenous (IV) on Day 1 of each cycle
219529855|NCT05020925|DRUG|Famitinib|Famitinib, po, qd
219529856|NCT01746485|DRUG|UT-15C|
219616103|NCT00483444|BEHAVIORAL|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
219529857|NCT01122147|DRUG|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
219529858|NCT01122147|DRUG|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
219041961|NCT06924372|OTHER|Taking saliva samples of unstimulated saliva will be collected in sterile containers, salivets.|Subjects will sit in a filiological position in a dental chair. Samples of unstimulated saliva will be collected in sterile containers, salivets. A prerequisite for taking saliva samples will be that subjects do not take water and food until two hours before the examination, according to the manufacturer's instructions. SARSTED Salivette will be used. In a sterile manner, the swab will be removed from the salivette with sterile tweezers and applied to the patient's mouth on the buccal mucosa. The tampon will be held for a minimum of 2 minutes in the patient's mouth (with buccal mucosa). After the elapsed time, the tampon will be removed from the mouth, using sterile tweezers and sterile gloves and will be inserted into the saliva and closed. After sampling, the salivates will be transported to the Department of Microbiological Diagnostics of the Institute for Pulmonary Diseases of Vojvodina. Transport should be done in the shortest possible time.
219529859|NCT04660747|DRUG|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
219529860|NCT06561022|DRUG|Fluzoparib|Fluzoparib
219529861|NCT06561022|DRUG|Everolimus|Everolimus
219529862|NCT06561022|DRUG|Fulvestrant|Fulvestrant
219529863|NCT06561022|DRUG|Abemaciclib|Abemaciclib
219616104|NCT03497741|DIAGNOSTIC_TEST|procalcitonin measurement|For each patient were blood cultures were taken, a procalcitonin level was determined
219529864|NCT04443660|OTHER|Blood test|Blood samples taken to test levels of autophagy and apoptosis
219529865|NCT05372666|OTHER|Standard white bread|Bread to be consumed within 10 minutes after 10h fasting
219529866|NCT05372666|OTHER|Experimental white bread|Bread to be consumed within 10 minutes after 10h fasting
219616105|NCT03048708|PROCEDURE|Bariatric surgery|patients who had received treatment with bariatric surgery for medical reasons
219616106|NCT02042508|OTHER|strengthening|
219616107|NCT02042508|OTHER|hybrid training programme|
219616108|NCT06000150|DIAGNOSTIC_TEST|Corneal topography|AS-OCT,PENTACAM
219616109|NCT05861518|BEHAVIORAL|Hypnosis|In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
218916412|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
218916413|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
218916414|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
218916415|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
218916416|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
218916417|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
218916418|NCT05670093|DEVICE|Neural Pressure Support (mode of mechanical ventilation)|Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
218916419|NCT05907785|BEHAVIORAL|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
218916420|NCT00517387|DRUG|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
218916421|NCT06202365|DEVICE|Whole body Vibration|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
218916422|NCT06202365|OTHER|Sham Whole body vibration|They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
218916423|NCT05880134|PROCEDURE|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
218916424|NCT05880134|PROCEDURE|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
219041962|NCT06924372|OTHER|Dental status|Dental status in both groups of subjects will be assessed by clinical visual examination by determining the prevalence of caries of deciduous and permanent teeth using the KEP and KEPS indexes. The clinical examination will be carried out in a dental chair using artificial light-reflectors, using a dental mirror and a dental probe on all surfaces of the tooth, which are dried with air from the puster. On the basis of a dental examination, the prevalence of caries of deciduous and permanent teeth will be determined.
219041963|NCT06924372|OTHER|Periodontal status|The assessment of the presence of dental plaque will be determined visually using the Silness and Loe plaque index, while the condition of the gingiva will be determined using the gingival index Loe and Silness . Before the examination, the subject will be advised to rinse his mouth with water to remove food residues and dental plaque. Performed in the dental chair using artificial light-reflectors, by gently pulling the dental probe over the vestibular, oral, mesial and distal surfaces of all crowns of the present teeth. Four values will be entered for each tooth. The result will be obtained by adding up all the values.
219529867|NCT05372666|OTHER|Standard High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
219529868|NCT05372666|OTHER|Experimental High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
219529869|NCT01234103|BEHAVIORAL|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
219529870|NCT01384838|BEHAVIORAL|Counseling|Nutritional, lifestyle and sports counseling
219529871|NCT01384838|BEHAVIORAL|physical activity|counseling and controlled physical activity
219529872|NCT04702178|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
219529873|NCT04702178|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
219616110|NCT03875508|DRUG|Risankizumab|Risankizumab to be injected subcutaneously (SC)
219616111|NCT03875508|DEVICE|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
218916425|NCT05220618|BEHAVIORAL|Autobiographical Memory Specificity and Savoring Training: PESCAR|An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
218916426|NCT05609292|DEVICE|observational|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
218916427|NCT04602663|DEVICE|Esophageal Variceal Band ligation|Band ligation of OV
218916428|NCT01632696|DRUG|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
218916429|NCT05984017|OTHER|No treatment is included in this study|No drug intervention or tissue sampling will be included in this study.
218916430|NCT02647619|DRUG|Xiapex|Injection of collagenase of primary dupytren cord
218916431|NCT02647619|PROCEDURE|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
218916432|NCT01924338|DEVICE|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
218916433|NCT01924338|DEVICE|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
218916434|NCT01924338|PROCEDURE|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
218916435|NCT02209714|DRUG|BIIF 1149 BS|
219041964|NCT06923540|DRUG|IV Acetaminophen|This intervention will be administered to patients undergoing abdominal surgery who are nil per os (NPO) directly after surgery. This patient group has not been properly studied in other clinical studies using IV Acetaminophen. The study aim is to determine if patients who have an altered enteral route may benefit from IV Acetaminophen.
219041965|NCT06924580|OTHER|ECG screening|Each subject is subjected to ECG assessment.
219041966|NCT06924411|DEVICE|Direct Intubation|Direct laryngoscopy intubation
219529874|NCT04691830|BEHAVIORAL|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
219529875|NCT04691830|BEHAVIORAL|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
219529876|NCT03897088|DRUG|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
219529877|NCT03897088|DRUG|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
219529878|NCT02048306|BEHAVIORAL|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
219529879|NCT02048306|BEHAVIORAL|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
219529880|NCT00237003|BEHAVIORAL|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
219529881|NCT04473807|DRUG|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
219529882|NCT04046211|DRUG|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
219529883|NCT02392000|DEVICE|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
219529884|NCT02392000|BEHAVIORAL|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
219529885|NCT00204139|PROCEDURE|Routine midtrimester pregnany ultrasound scan|
218916436|NCT02209714|DRUG|Placebo|
218916437|NCT01105481|DRUG|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
219041967|NCT06924112|OTHER|Isometric exercises|The three isometric exercises were performed without the addition of BFR following the best evidence recommendations. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the maximal voluntary isometric contraction (MVIC), rest period after each exercise of 2 minutes, and pain level below 5 on the verbal Numeric Pain Rating Scale (NPRS).
218916438|NCT01105481|DRUG|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
218916439|NCT01883258|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
218916440|NCT01883258|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
218916441|NCT03506152|DIAGNOSTIC_TEST|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
218916442|NCT03010449|DEVICE|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
218916443|NCT05165134|OTHER|Kinesiotape|Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
218916444|NCT02403128|DRUG|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
218916445|NCT01972217|DRUG|Olaparib|Olaparib bid
218916446|NCT01972217|DRUG|Placebo|Placebo bid
218916447|NCT01972217|DRUG|Abiraterone|Abiraterone 1000 mg
218916448|NCT01972217|DRUG|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
218916449|NCT02799446|DRUG|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
219529886|NCT01638377|DRUG|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
219529887|NCT01638377|DRUG|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
218916450|NCT02799446|DRUG|Placebo|Matching Placebo intravenous (IV)
218916451|NCT00117351|DRUG|VELCADE|
218916452|NCT03247647|BEHAVIORAL|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
218916453|NCT03247647|BEHAVIORAL|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
218916454|NCT02670317|DRUG|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
218916455|NCT02670317|DRUG|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
218916456|NCT02670317|DRUG|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
218916457|NCT06327269|DRUG|Lenvatinib 10 mg|Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
219529888|NCT00925054|DRUG|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
219529889|NCT00925054|DRUG|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
219529890|NCT00925054|DRUG|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
219529891|NCT00925054|DRUG|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
219529892|NCT00925054|DRUG|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
219529893|NCT00512421|PROCEDURE|computer-assisted surgery|
218916458|NCT04495244|DIAGNOSTIC_TEST|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
218916459|NCT01487798|DRUG|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
218916460|NCT01487798|DRUG|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
218916461|NCT00948376|GENETIC|IFT80 screening|Natural History
218916462|NCT00670254|DRUG|Placebo|Application is identical to experimental arm
218916463|NCT00670254|DRUG|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
219529894|NCT05403684|OTHER|High-volume breastmilk|Preterm infants will be given high-volume breastmilk
219529895|NCT00781586|DIETARY_SUPPLEMENT|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
219529896|NCT00781586|DRUG|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
219529897|NCT00781586|DRUG|Placebo|Placebo 1 tablet at 1st visit
219529898|NCT02937415|PROCEDURE|Breath carbon monoxide|Breath carbon monoxide measurement.
219529899|NCT02937415|PROCEDURE|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
219529900|NCT02937415|PROCEDURE|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
219529901|NCT04316312|DEVICE|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
219529902|NCT04332627|DRUG|Sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
219529903|NCT04332627|DRUG|Neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
218916464|NCT03258385|DIETARY_SUPPLEMENT|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
218916465|NCT03258385|DIETARY_SUPPLEMENT|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
218916466|NCT02318706|DRUG|DS-5565|
218916467|NCT02318706|DRUG|placebo|
218916468|NCT02824653|BIOLOGICAL|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
218916469|NCT02556385|DEVICE|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
219529904|NCT05552781|DRUG|H002 capsule|Small molecule, Capsule
219529905|NCT01307722|OTHER|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
219529906|NCT00062283|DRUG|L-alanosine|
219529907|NCT04181853|OTHER|exercise|aerobic exercise
219529908|NCT00322465|DRUG|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
219529909|NCT00322465|OTHER|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
219529910|NCT00322465|DRUG|Doxycycline|100 mg orally, twice daily for 7 days.
219529911|NCT00322465|DRUG|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
219529912|NCT01790581|BEHAVIORAL|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
219529913|NCT01790581|BEHAVIORAL|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
219529914|NCT04770883|BEHAVIORAL|Internet based cognitive behavioral therapy.|Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.
219529915|NCT04770883|DIETARY_SUPPLEMENT|Low FODMAP diet therapy|Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.
219529916|NCT01371409|OTHER|continuous theta burst stimulation|80% active motor threshold, 600 pulses
219529917|NCT03438253|PROCEDURE|spinal anaesthesia|
219616112|NCT05418842|OTHER|Prehabilitation|In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
218916470|NCT02556385|DEVICE|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
218916471|NCT06289790|PROCEDURE|Erector Spinae Plane (ESP) block|Erector Spinae Plane (ESP) block with bupivacaine and for pain management in VATS procedure
218916472|NCT06289790|DRUG|Lignocaine|Lignocaine bolus and infusion for pain management in VATS procedure
218916473|NCT06289790|DRUG|Bupivacaine|Bupivicaine with adrenaline will be used to perform the ESP block
219041968|NCT06924112|DEVICE|Isometric exercises with BFR|Participants will perform three isometric exercises with BFR. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. The session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 60% of the maximum occlusion pressure. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the MVIC, rest period after each exercise of 2 minutes with cuff deflated (reperfusion), and pain level below 5 on the NPRS.
219204621|NCT04165213|BEHAVIORAL|Care of Older Persons in their Environment (COPE) online module training|An online module version of training for clinicians (OTs and RNs) in the evidence-based dementia caregiving program called Care of Older Persons in their Environment (COPE) is the intervention being tested for non-inferiority against the usual instructor-led COPE training. COPE modules include rich multimedia content, simulated scenarios, interactive assessments to keep the learner engaged The content is packaged into the latest the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions. Each of the ten modules last 45-60 minutes.
219204622|NCT06079840|DEVICE|mindfulness-based stress reduction app|mobile application (app) for caregivers
219529918|NCT02658604|OTHER|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
219529919|NCT04235881|BEHAVIORAL|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
219529920|NCT04235881|BEHAVIORAL|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
219529921|NCT04875793|DIAGNOSTIC_TEST|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
219529922|NCT03291925|PROCEDURE|Selective invasive angiography based on CT/CCTA imaging.|
219529923|NCT03291925|PROCEDURE|Procedure/Surgery: Invasive angiography|
219529924|NCT03133364|OTHER|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
219529925|NCT01552447|OTHER|EpiFix|Dehydrated placental tissue
219529926|NCT01552447|OTHER|Compression Therapy|Compression bandaging
219529927|NCT02629094|DRUG|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
219529928|NCT00006194|BEHAVIORAL|Exercise|
219529929|NCT05340010|DRUG|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
219529930|NCT06433141|PROCEDURE|treatment option for primary second molar|final restoration for primary second molars
219529931|NCT06433674|DRUG|Zinc Sulfate|The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
219529932|NCT06433674|OTHER|Sterile Water|The placebo group with will receive a similar amount of sterile water in a colored syringe
219616113|NCT03198442|PROCEDURE|F-18 FDG breast PET scan|
219616114|NCT04229693|OTHER|no intervention|no intervention, only observational.
219616115|NCT06205771|OTHER|H2S content|H2S content
219529933|NCT04024007|DIAGNOSTIC_TEST|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
219529934|NCT02960568|DRUG|Primaquine|30 mg oral primaquine one time
219529935|NCT02745899|DIETARY_SUPPLEMENT|Cow milk|Ingestion of 240 ml cow milk
219529936|NCT02745899|DIETARY_SUPPLEMENT|Soy milk|Ingestion of 240 ml soy milk
219529937|NCT07035873|BEHAVIORAL|Remote Programming|Use of the Advanced Bionics Target CI remote programming software to complete behavioral measurements of cochlear implant function and programming via telehealth.
219529938|NCT07035873|DIAGNOSTIC_TEST|Remote Speech Perception|Use of digital audio streaming (DAS) through a proprietary platform to complete remote speech perception testing of performance with cochlear implants via telehealth.
219616116|NCT04871360|DIETARY_SUPPLEMENT|L-Citrulline supplement|The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.
219616117|NCT04871360|DIETARY_SUPPLEMENT|Carboxymethyl cellulose supplement|The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.
219616118|NCT01400477|DRUG|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
219616119|NCT01400477|OTHER|Placebo|Placebo Comparator
219616120|NCT01874028|DRUG|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
219616121|NCT02720328|BIOLOGICAL|Blood samples for DOAC measurement|
219616122|NCT00316511|DRUG|Aroplatin|
219616123|NCT04465669|DEVICE|Orsiro stents|"Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent"
219616124|NCT04465669|DEVICE|Resolute Integrity® stents|"Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent"
219616125|NCT03036826|DRUG|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
219616126|NCT03036826|DRUG|Meropenem|antiinfective therapy with Meropenem within routine care
218916474|NCT04859738|DRUG|Lidocaine Spray|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
218916475|NCT04859738|DRUG|Benzokain Sprey|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
218916476|NCT04859738|OTHER|Alcohol|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
218916477|NCT03921957|RADIATION|stereotactic radiotherapy|first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
218916478|NCT01921595|OTHER|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
218916479|NCT01921595|OTHER|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
218916480|NCT02151864|DRUG|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
218916481|NCT05096403|DRUG|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
218916482|NCT04936945|PROCEDURE|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
218916483|NCT00451360|DRUG|diacerein|
218916484|NCT02869152|OTHER|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
218916485|NCT02869152|OTHER|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
218916486|NCT02869152|OTHER|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
218916487|NCT02869152|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
218916488|NCT02869152|PROCEDURE|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
218916489|NCT02869152|PROCEDURE|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
218916490|NCT03584477|DEVICE|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
218916491|NCT03584477|OTHER|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
218916492|NCT00497094|DEVICE|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
219616127|NCT04336280|OTHER|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
219616128|NCT04336280|DIAGNOSTIC_TEST|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
219616129|NCT01984320|PROCEDURE|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
219616130|NCT03665220|OTHER|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
218916493|NCT00648609|OTHER|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
219529939|NCT07035353|DRUG|T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.|The treatment plan will be recommended to the subject by the treating physician in accordance with current clinical practice guidelines and clinical practice, and the patient's decision to receive T-DXd (DS8201) should precede enrollment in this study. The strategy for administering a particular treatment to a subject is not determined a priori by the trial protocol, but should be in accordance with current clinical practice. Because of the non-interventional nature of this study, this study does not alter or interfere with the patient's actual current medical practice.
219529940|NCT04475861|DIETARY_SUPPLEMENT|L-arginine supplements and nutritional supports|The enrolled subjects will then be randomized into two groups. The subjects will receive either L-arginine (the study group) or another amino acid supplement (the control group), with 60 patients in each group. All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
219529941|NCT04201353|BEHAVIORAL|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
219529942|NCT01832350|DRUG|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
219529943|NCT04690881|BEHAVIORAL|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
219529944|NCT05162664|OTHER|Pressure pain thresholds|PPT will be performed firstly at the anterior tibial muscle halfway between the most superior attachment to the tibia and its tendon in the upper one third of the muscle belly (13) and secondly at the middle of the temporalis muscle (12), using a digital algometer (Wagner FPX 50) with a 1 cm2 rubber tip. The pressure algometer will apply a perpendicular increasing pressure (1kg/s) at the different test locations until the participant reports the first feeling of pain. The PPT of 4 series of ascending stimulus intensities, with an inter-stimulus interval (ISI) of 20sec between the different stimuli and an ISI of 60sec between the 2 locations, will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated.
219616131|NCT03665220|OTHER|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
219616132|NCT03665220|OTHER|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
218916494|NCT00648609|OTHER|Standard of care|Usual care for COPD patients
218916495|NCT02700061|PROCEDURE|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
218916496|NCT02700061|PROCEDURE|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
219041969|NCT06923085|OTHER|Observational Assessment Only|This is an observational study examining bilateral sensorimotor function in patients with cervical radiculopathy. No interventional procedures were applied. Participants underwent comprehensive assessments including pain evaluation (VAS), neck disability (NDI), upper extremity functionality (DASH), muscle strength measurements, sensory function testing, hand performance evaluation, kinesiophobia (TAMPA), and emotional status assessment (Beck Inventory). The study compared findings between different cervical radiculopathy groups and a control group with non-specific neck pain.
218916497|NCT04693819|DIAGNOSTIC_TEST|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
218916498|NCT00473239|DRUG|cholecalciferol.|100,000 IU of Vitamin D
218916499|NCT04398927|DRUG|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
218916500|NCT04398927|DRUG|Sintilimab|Sintilimab
218916501|NCT03762811|DEVICE|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
218916502|NCT04949997|OTHER|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
218916503|NCT04618536|OTHER|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
219529945|NCT05162664|OTHER|Thermal detection and pain thresholds|The thermal tests will be performed unilateral at tibial anterior, thenar and the forehead, using a TSA-2 (Neuro Sensory Analyzer, MEDOC). At first cold and heat detection thresholds will be measured. The patient will be asked to indicate when they feel a change in temperature. Afterwards the patient will be asked to indicate when the stimulus becomes painful to determine the cold and heat pain thresholds. The thresholds of 4 series of stimuli will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated for every location. The subject will push a button when the thresholds are reached. The baseline temperature will be 32°C and the stimuli will increase with 1°C/s (14).
219529946|NCT05162664|OTHER|Temporal summation|The temporal summation will be assessed at the thenar eminence (19,20) using a ramp and hold protocol with the TSA-2 (Neuro Sensory Analyzer, MEDOC). Heat stimuli will be applied for a duration of 15sec. The stimulus temperature will increase from a baseline temperature of 35°C for 9sec at a sensitivity-adjusted rate of about 1,5°C/s until the HTP 5/10 of the thenar is reached. Afterwards the temperature will remain steady for the next 6 seconds. The maximal pain rating should be 50 ± 10 NRS. Subjects rate the pain intensity at the end of the ramp (9sec) and at the end of the hold procedure (15sec) using the NRS. Afterwards the ramp and hold aftersensations are measured. The subjects have to rate the pain intensity every 5sec for 30sec after the termination of the heat stimulus.
219529947|NCT05162664|OTHER|Conditioned pain modulation|CPM will be assessed by comparing heat pain thresholds and pressure pain thresholds before and after giving a conditioning stimulus at a pain free distant zone by using a second thermode of the TSA-2 (17). The conditioning stimulus (HPT 4/10 (18) at the TA) will be applied for 120 seconds. The first test stimulus will be applied at the forehead 30 seconds after the start of the conditioning stimulus (17). The HPT will be measured twice with an ISI of 20 seconds. Immediately after the end of the application of the conditioning stimulus (120 seconds), the HPT at the forehead will be measured again twice, with an ISI of 20 seconds. Afterwards, there will be 10 minutes of rest to avoid bias.
218916504|NCT04618536|OTHER|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
218916505|NCT03831152|DRUG|ADV7103|Single group assignment
219529948|NCT01066143|DRUG|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
219529949|NCT00520988|BEHAVIORAL|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
219529950|NCT04192162|OTHER|Mud therapy application|Aplication the mud pack therapy from 20 minutes
219529951|NCT04192162|OTHER|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
219529952|NCT04192162|OTHER|Hygienic water|Exercise in hygienic water
219529953|NCT06219044|PROCEDURE|laparoscopic endometrioma laser vaporization|laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
219529954|NCT06017635|OTHER|Exposure factors|"1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
219529955|NCT00942968|DRUG|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
219529956|NCT06558981|RADIATION|Radiotherapy|Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
219529957|NCT06558981|OTHER|radioiodine treatment|RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
219529958|NCT03405454|DRUG|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
219529959|NCT03405454|DRUG|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
219529960|NCT01686451|DRUG|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
219529961|NCT01686451|DRUG|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
219529962|NCT02470247|OTHER|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
219529963|NCT02470247|OTHER|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
218916506|NCT04799834|OTHER|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
219041970|NCT06924463|OTHER|None AHT|This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.
219041971|NCT06924125|DIAGNOSTIC_TEST|Motor function scales|Evaluation of patients motor function using motor scales (MFM32, CHOP)
219529964|NCT01466166|BIOLOGICAL|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
219529965|NCT03733158|DEVICE|the standard Bougie stylet for difficult intubation|intubation with the standard Bougie stylet for difficult intubation and endotracheal tube 7.0 internal diameter
219529966|NCT03733158|DEVICE|The new Flexible Tip Bougie catheter|intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
219529967|NCT00834535|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
219529968|NCT00834535|DRUG|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
219529969|NCT01163435|DRUG|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
219529970|NCT01163435|DRUG|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
219529971|NCT01163435|DRUG|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
219529972|NCT01163435|DRUG|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
219529973|NCT05302128|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
219529974|NCT02681939|DRUG|Tulsi(Ocimum sanctum Linn.) capsules|
219529975|NCT01340495|RADIATION|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
219529976|NCT04621552|DEVICE|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
219529977|NCT05883215|OTHER|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
219529978|NCT05883215|OTHER|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
219529979|NCT05883215|OTHER|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
219616133|NCT02869243|DRUG|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
219616134|NCT00073203|DRUG|R228060|
219616135|NCT00073203|DRUG|Placebo and Paroxetine|
219616136|NCT01270438|DRUG|FOLFOX regimen|Given IV
219616137|NCT01270438|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219616138|NCT01270438|BIOLOGICAL|bevacizumab|Given IV
219529980|NCT05883215|OTHER|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
219529981|NCT02055963|DRUG|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
219529982|NCT02055963|DRUG|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
219616139|NCT01270438|DRUG|oxaliplatin|Given IV
219616140|NCT01270438|DRUG|leucovorin calcium|Given IV
218916507|NCT03819439|OTHER|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
219616141|NCT01270438|DRUG|fluorouracil|Given IV
219616142|NCT00518271|DRUG|Rapamune® (Sirolimus)|
219616143|NCT00518271|DRUG|Tacrolimus|
219616144|NCT00518271|DRUG|Corticosteroids|Perioperative
218916508|NCT01798043|OTHER|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
218916509|NCT01798043|OTHER|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
218916510|NCT01678235|DRUG|Insulin glulisine|
218916511|NCT01678235|DRUG|Insulin aspart|
218916512|NCT04273737|DRUG|Amantadine Hydrochloride|6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
218916513|NCT00045760|DRUG|Drotrecogin alfa (activated)|
218916514|NCT00967746|DRUG|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
219529983|NCT02055963|BEHAVIORAL|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
219529984|NCT01268787|BIOLOGICAL|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
219529985|NCT02131363|DEVICE|Ingrowing Toenail Treatment Kit|detailed in arm description
219529986|NCT01762605|OTHER|Supportive Care|
219529987|NCT01762605|PROCEDURE|Cast|
219529988|NCT06092125|DEVICE|PET/MR|PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
219529989|NCT06413290|OTHER|PIFP block group|Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery
219529990|NCT06413290|OTHER|Control group|No intervention
219529991|NCT02273622|DIETARY_SUPPLEMENT|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
219529992|NCT02273622|DIETARY_SUPPLEMENT|placebo|
219529993|NCT00812266|DRUG|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
219529994|NCT00812266|DRUG|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
219616145|NCT03101956|PROCEDURE|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
219616146|NCT03101956|PROCEDURE|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
219616147|NCT05773105|DRUG|Cadonilimab+regorafenib|cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
219616148|NCT03973606|OTHER|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
219616149|NCT01424007|BEHAVIORAL|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
219616150|NCT00015964|DRUG|ZD1839|
218916515|NCT00967746|DRUG|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
218916516|NCT00967746|DRUG|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
218916517|NCT00967746|DEVICE|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
218916518|NCT01029275|DRUG|Pre-treatment with octreotide|Pre-treatment with octreotide
219529995|NCT06036082|OTHER|Conventional physical therapy|"* Standing with feet together .~* Step standing .~* High step standing and trying to keep balanced.~* Single leg stance unilateral standing with assistance.~* Standing on a declined surface by using wedge.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
219529996|NCT00667862|DRUG|Panobinostat|
219529997|NCT01819597|PROCEDURE|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
218916519|NCT02798627|DRUG|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
218916520|NCT02798627|DRUG|placebo|Placebo pills identical in appearance to the NS2359 will be provided
218916521|NCT00385359|PROCEDURE|aerosol drug deposition strategies|
218916522|NCT00385359|DRUG|Albuterol|
218916523|NCT05036863|BEHAVIORAL|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
218916524|NCT05336162|OTHER|Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)|A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
218916525|NCT03821402|BIOLOGICAL|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
219041972|NCT06924125|DIAGNOSTIC_TEST|MUSCLE ULTRASOUND|Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).
219041973|NCT06924125|DIAGNOSTIC_TEST|Muscle Elastography|Assess the mechanical properties of muscles, such as stiffness and elasticity.
219041974|NCT06924125|OTHER|Complete physical examination|Complete physical evaluations including muscle power and goniometry measurements
219041975|NCT06924125|OTHER|Ventilatory/ respiratory and other support assessment|Assessment of ventilatory, respiratory, and other support needs to evaluate the necessity of assistive devices
219041976|NCT06924125|OTHER|Oromotor function and nutrition|Assessment of bulbar funcionality: feeding devices, nutritional status.
219041977|NCT06924125|OTHER|Motor Milestone Assessments|Motor milestones age of acquisition and loss
219041978|NCT06922838|OTHER|Virtual Reality intervention|The head-mounted virtual reality device is used to provide patients with relaxing videos of nature scenes accompanied by calming music and guided meditations.
219041979|NCT06922838|OTHER|Aromatherapy|The cotton ball soaked in lavender essential oil is placed near the patient's pillow.
219041980|NCT06924424|DRUG|Aponermin, pomalidomide, dexamethasone|Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days.
218916526|NCT03821402|BIOLOGICAL|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
218916527|NCT03821402|BIOLOGICAL|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
218916528|NCT03821402|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
218916529|NCT00992108|DRUG|lidocaine|1cc 1%
218916530|NCT00992108|DRUG|chemodenervation|botulinum toxin
219041981|NCT06923696|BEHAVIORAL|Diet therapy|One of the groups will follow a gluten-free diet therapy, while the other will follow a LOW FODMAP diet.
219204623|NCT03760939|OTHER|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
219529998|NCT02495857|DEVICE|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
219529999|NCT02495857|DEVICE|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
218916531|NCT00390143|BIOLOGICAL|Meningococcal vaccine 134612|One intramuscular dose during the primary study
218916532|NCT00390143|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose during the primary study
218916533|NCT00535639|DRUG|Betula Verrucosa allergen extract|
218916534|NCT03755258|DRUG|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
218916535|NCT03755258|DRUG|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
218916536|NCT03755258|DRUG|GCK 300 mg|GCK 300 mg, oral, 12 weeks
218916537|NCT03755258|DRUG|Placebo 300mg|Placebo 300mg, oral, 12 weeks
218916538|NCT02083900|DEVICE|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
218916539|NCT02083900|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
218916540|NCT01702311|DRUG|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
218916541|NCT00690508|PROCEDURE|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
218916542|NCT05133388|GENETIC|ARMS PCR|ARMS PCR using primer pairs that only amplify individual alleles
218916543|NCT03271658|BEHAVIORAL|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
218916544|NCT03271658|BEHAVIORAL|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
219530000|NCT02495857|DEVICE|Placebo|0.9% sodium chloride, sterile
218916545|NCT03079622|PROCEDURE|Electric Vacuum Aspiration|
218916546|NCT03079622|PROCEDURE|Manual Vacuum Aspiration|
218916547|NCT06210568|OTHER|no intervention|no intervention
218916548|NCT02404935|DRUG|Cetuximab|
219530001|NCT02991404|PROCEDURE|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
219530002|NCT02991404|PROCEDURE|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
219530003|NCT02991404|DRUG|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
219530004|NCT02991404|DRUG|Continuous infusion|Continuous infusion of 0.125% bupivacaine
218916549|NCT02404935|DRUG|FOLFIRI and cetuximab|
218916550|NCT04642027|RADIATION|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
218916551|NCT04642027|RADIATION|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
218916552|NCT03902431|BEHAVIORAL|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
218916553|NCT00441077|BEHAVIORAL|Education|
218916554|NCT01178047|DRUG|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
219530005|NCT04905017|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricusupid valve using Trisol System in a transcatheter approach
219530006|NCT04816838|DRUG|Osimertinib|"\* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~\- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)"
219530007|NCT05599438|OTHER|No intervention|No intervention
219530008|NCT00396279|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
219530009|NCT00396279|DIETARY_SUPPLEMENT|Calcium/Vitamin D|
219530010|NCT04825808|OTHER|usual care|according to recommendations
219530011|NCT03350347|DRUG|Molidustat (BAY85-3934)|Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
219530012|NCT03350347|DRUG|Darbepoetin alfa|Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
219530013|NCT03439982|BIOLOGICAL|FMT|FMT processed from routinely screened donors
219530014|NCT00846274|BIOLOGICAL|SK Antithrombin III|
219530015|NCT03135743|OTHER|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
219530016|NCT01194388|DEVICE|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
219530017|NCT03598374|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
219530018|NCT03598374|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
219530019|NCT03598374|BEHAVIORAL|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
218916555|NCT03916770|DEVICE|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
218916556|NCT03916770|DEVICE|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
219530020|NCT05983562|DIETARY_SUPPLEMENT|Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
219530021|NCT05983562|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
218916557|NCT02723708|OTHER|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
218916558|NCT04035460|DEVICE|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
218916559|NCT04035460|DEVICE|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
219616151|NCT06076993|BEHAVIORAL|BodyKind programme|"BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion \& social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~* To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~* To decrease levels of body dissatisfaction and self-criticism~* To improve levels of self-compassion, positive body image, psychological wellbeing"
218916560|NCT04291547|DEVICE|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
218916561|NCT03878563|DEVICE|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
218916562|NCT00578539|DRUG|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
218916563|NCT00578539|DRUG|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
218916564|NCT00578539|DRUG|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
218916565|NCT00578539|RADIATION|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
218916566|NCT00578539|BIOLOGICAL|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
218916567|NCT00578539|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
219530022|NCT01253590|BEHAVIORAL|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
219530023|NCT00927303|DEVICE|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
219530024|NCT00927303|DEVICE|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
219530025|NCT05229445|DEVICE|continuous glucose monitor based insulin bolus calculator|Participants will use the bolus calculator with meals to calculate their insulin bolus doses
219530026|NCT03821545|OTHER|Lidocaine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
219530027|NCT03821545|OTHER|Ketamine|Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
219616152|NCT00637845|DRUG|Esomeprazole Magnesium|40mg once daily
219616153|NCT00637845|DRUG|Lansoprazole|30mg twice daily
218916568|NCT05327348|DRUG|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
218916569|NCT05327348|DRUG|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
218916570|NCT01829620|BEHAVIORAL|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
219530028|NCT03821545|OTHER|Lidocaine and Ketamine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
219530029|NCT03821545|OTHER|Placebo (0.9% NaCl)|Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
219530030|NCT00654030|DRUG|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
218916571|NCT01829620|BEHAVIORAL|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, \& 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
218916572|NCT04938154|DEVICE|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
218916573|NCT04938154|DEVICE|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
219530031|NCT02010320|OTHER|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
219530032|NCT02010320|OTHER|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
219530033|NCT03301948|OTHER|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
219530034|NCT03301948|OTHER|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
219530035|NCT00905346|DRUG|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
219530036|NCT00905346|DRUG|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
219530037|NCT00905346|OTHER|Applesauce|Applesauce
219530038|NCT05886101|BEHAVIORAL|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
219530039|NCT00688363|PROCEDURE|weekly blood glucose profile|once daily self-control of urinary-glucose
219530040|NCT00688363|PROCEDURE|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
219530041|NCT00688363|PROCEDURE|no blood-glucose self-control|once daily self-control of urinary-glucose
219530042|NCT01435265|BEHAVIORAL|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
219530043|NCT01435265|BEHAVIORAL|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
219530044|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferal|400 IU/day
219530045|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferol|800 IU/day D3
219530046|NCT06200220|DRUG|Venetoclax|Observational study
219530047|NCT04113265|DEVICE|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
219530048|NCT00731744|PROCEDURE|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
219530049|NCT01699191|DIETARY_SUPPLEMENT|Probiotic|
219530050|NCT01699191|DIETARY_SUPPLEMENT|Placebo|
219530051|NCT04403997|PROCEDURE|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
219530052|NCT05225597|PROCEDURE|Intracameral administration of epinephrine and carbachol during cataract surgery|All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
219041982|NCT06924307|DEVICE|Executive Function Intervention|The intervention is an in-home cognition training system that provides parents with a modular series of short, easy-to-follow, collaborative cognitive training activities they will share with their child to address the needs of families with young children identified with deficits in executive function (EF), a critical cognitive process associated with self-control. The system employs a novel two-generational training model that views parental involvement as a critical component of the intervention process. In this model, an engaging, parent-facing smartphone application will deliver personalized daily training activities consisting of both traditional hands-on activities as well as collaborative, parent-controlled, child-facing video games. This approach supports multiple pathways for learning and building strong personal relationships between parent and child.
219041983|NCT00004733|DRUG|levodopa|
219530053|NCT01980693|DEVICE|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
219530054|NCT02071108|DEVICE|Shockwave Lithoplasty System|
218916574|NCT04665167|BEHAVIORAL|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
218916575|NCT04665167|BEHAVIORAL|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
218916576|NCT04106557|DRUG|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
218916577|NCT04106557|DRUG|Placebo|Matching placebo capsules to OV101 capsules.
218916578|NCT02388308|DEVICE|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
218916579|NCT03925285|DRUG|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
218916580|NCT01209689|DRUG|Tocilizumab|
218916581|NCT01209689|DRUG|Placebo|
218916582|NCT03175367|DRUG|Evinacumab|SC or IV administration
218916583|NCT03175367|DRUG|Matching placebo|SC or IV administration
219530055|NCT03770598|BEHAVIORAL|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
218916584|NCT03175367|OTHER|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
219530056|NCT03770598|BEHAVIORAL|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
219530057|NCT03770598|BEHAVIORAL|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
219530058|NCT03770598|BEHAVIORAL|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
219530059|NCT00008515|DRUG|Fluocinolone|
219530060|NCT06560515|DRUG|Vaginal Dinoprostone|induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
219530061|NCT03423680|DRUG|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
219530062|NCT03423680|DRUG|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
218916585|NCT00433420|BIOLOGICAL|pegfilgrastim|
218916586|NCT00433420|DRUG|cyclophosphamide|
219530063|NCT03548519|BEHAVIORAL|OCAT-only|online-contingent Attention Training without prior psychoeducation
219530064|NCT03548519|BEHAVIORAL|OCAT-sham|Placebo version of Online contingent Attention Training without prior psychoeducation
219530065|NCT03548519|BEHAVIORAL|OCAT-combo|Online contingent Attention Training with prior psychoeducation
219530066|NCT04847323|DEVICE|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
218916587|NCT00433420|DRUG|epirubicin hydrochloride|
218916588|NCT00433420|DRUG|fluorouracil|
218916589|NCT00433420|DRUG|paclitaxel|
218916590|NCT00433420|PROCEDURE|adjuvant therapy|
218916591|NCT02254135|DRUG|BEA 2180 BR - rising dose|
218916592|NCT02254135|DRUG|Placebo|
218916593|NCT04909996|DEVICE|Sentinox--Group A|"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
218916594|NCT04909996|DEVICE|Sentinox--Group B|"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
218916595|NCT06036745|DRUG|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
219530067|NCT04847323|DEVICE|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
219530068|NCT02035306|OTHER|non invasive co-oximetry haemaglobin measurement|
219616154|NCT03652051|DRUG|AZR-MD-001 Low Dose|AZR-MD-001 is an ophthalmic ointment
219616155|NCT03652051|DRUG|AZR-MD-001 Mid Dose|AZR-MD-001 is an ophthalmic ointment
219616156|NCT03652051|DRUG|AZR-MD-001 High Dose|AZR-MD-001 is an ophthalmic ointment
219616157|NCT03652051|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
219616158|NCT00004008|DRUG|bryostatin 1|
219616159|NCT00124189|DRUG|GRN163L|Weekly intravenous infusion
219616160|NCT04377204|DRUG|marcaine bupivacaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
219616161|NCT04377204|DRUG|Lidocaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
218916596|NCT06473857|BEHAVIORAL|Mental health literacy intervention|Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games
219530069|NCT05105945|PROCEDURE|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
219616162|NCT02545569|DEVICE|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
219616163|NCT04082026|BEHAVIORAL|Early Adolescent Skills for Emotions EASE)|"EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems"
219530070|NCT05105945|PROCEDURE|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
219530071|NCT00054301|PROCEDURE|adjuvant therapy|
219530072|NCT00054301|PROCEDURE|conventional surgery|Patients undergo excisional biopsy or surgery.
219616164|NCT00989482|BEHAVIORAL|Computer kiosk Education|computerized patient education; guidelines for physicians
219616165|NCT01307865|DRUG|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
219616166|NCT01656460|RADIATION|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
219616167|NCT01656460|RADIATION|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
219616168|NCT01656460|RADIATION|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
219616169|NCT01656460|RADIATION|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
219616170|NCT02385773|DIETARY_SUPPLEMENT|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
219616171|NCT02385773|DIETARY_SUPPLEMENT|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
219616172|NCT04280692|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites
219616173|NCT04280692|DRUG|Sulfadoxine-Pyrimethamine|Sub-curative 500mg/25mg single dose regimen
219616174|NCT04280692|DRUG|Piperaquine|Sub-curative 480mg single dose regimen
219616175|NCT04280692|DRUG|Artemether lumefantrine|Three day curative regimen 20mg/120mg
219616176|NCT04280692|DRUG|Primaquine|Single low dose regimen 0.25 mg base/kg
219616177|NCT04425057|OTHER|Interval training|
219616178|NCT00656656|DRUG|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
219616179|NCT01315392|PROCEDURE|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
219616180|NCT01315392|PROCEDURE|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
219616181|NCT05421819|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 plus flavonoids once per day.
219616182|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and prebiotic supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
219616183|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and flavonoid supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
218916597|NCT06473857|BEHAVIORAL|Non mental health intervention|Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
218916598|NCT01411046|DIAGNOSTIC_TEST|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
218916599|NCT01853670|RADIATION|concurrent chemo + IGRT|
218916600|NCT01853670|RADIATION|neoadjuvant chemo + IGRT|
218916601|NCT02722083|DRUG|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
218916602|NCT02722083|DRUG|Placebo|placebo tablet, single dose, orally
218916603|NCT02151058|DRUG|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
218916604|NCT02151058|DRUG|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
218916605|NCT02151058|OTHER|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
218916606|NCT00809185|DRUG|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
218916607|NCT00809185|OTHER|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
218916608|NCT00809185|PROCEDURE|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
218916609|NCT05642364|BEHAVIORAL|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
219530073|NCT00054301|RADIATION|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
218916610|NCT05642364|OTHER|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
218916611|NCT02181777|BEHAVIORAL|GRASP|GRoup trAining for Social skills in Psychosis
219530074|NCT01644058|PROCEDURE|Immediate loading|
219530075|NCT05985317|PROCEDURE|Collagen membrane over BMAC/bovine graft in sinus lift|Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
219530076|NCT05985317|PROCEDURE|PRF membrane over BMAC/bovine graft in sinus lift|PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
219616184|NCT04291287|DRUG|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)"
218916612|NCT02181777|BEHAVIORAL|Standard care|Treatment as usual
218916613|NCT06210997|BEHAVIORAL|Questionaires|The questionnaire was done online by the participants from second to fifth-year medical students.
218916614|NCT05625126|OTHER|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
218916615|NCT06029946|DIAGNOSTIC_TEST|elastography, ultrasound|First local anesthesia with lidocaine 2%, then 3 smears will be obtained for each nodule using a 20-22 gauge needle, multiple passes within the lesion will be made to obtain sufficient cells, the aspirate will be spread over a glass, fixed with ethanol 95% and submitted to the pathology department to be reported.
218916616|NCT03673800|OTHER|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
219530077|NCT04721795|DRUG|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
219530078|NCT04721795|DRUG|Standard anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
219530079|NCT05318365|DRUG|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
218916617|NCT03673800|OTHER|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
218916618|NCT02271269|BEHAVIORAL|Value Pricing Subsidies|"* Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
219530080|NCT05318365|BEHAVIORAL|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
219530081|NCT00944424|DRUG|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
219530082|NCT00944424|DRUG|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
219530083|NCT05612724|DEVICE|Testing for SARS CoV2 Antigen|Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
219530084|NCT00561834|DRUG|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
219530085|NCT00530725|PROCEDURE|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
219530086|NCT00530725|OTHER|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
219530087|NCT05001022|DRUG|ALG-020572|Single or multiple doses of ALG-020572
219530088|NCT05001022|DRUG|Placebo|Single or multiple doses of Placebo
219530089|NCT06280183|OTHER|Functional Inspiratory Muscle Training|Inspiratory muscle training is a technique that combines aerobic training with inspiratory muscle training. will be applied simultaneously with aerobic exercise. Participants will work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP.
219530090|NCT06280183|OTHER|Aerobic+Resistive Exercise Traning|Aerobic exercise is planned at 60-85% of the Maximum Heart Rate on a cycle ergometer for 30-40 minutes. Resistive exercise will cover all major muscle groups. The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles, and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body, abdominal, and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM).
219530091|NCT05290961|OTHER||The study is an observational trial, which don't have any intervention.
219530092|NCT02128997|DEVICE|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
219530093|NCT06225609|PROCEDURE|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
219530094|NCT06225609|PROCEDURE|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
219530095|NCT06376656|BEHAVIORAL|Cognitive stimulation|"The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions."
219530096|NCT06376656|BEHAVIORAL|Physical activity|"The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period."
219530097|NCT03644693|DIETARY_SUPPLEMENT|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
219530098|NCT03644693|DIETARY_SUPPLEMENT|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
219530099|NCT00747097|DRUG|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
219530100|NCT05417230|DRUG|RC48-ADC|2.5mg/kg, IV, d1, every 2 weeks;
219530101|NCT05417230|DRUG|Envafolimab|200mg, SC, d1, every 2 weeks;
219530102|NCT03848286|DRUG|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
219530103|NCT04123808|DEVICE|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
219530104|NCT03112863|DRUG|Bakuchiol|This group will receive bakuchiol
219530105|NCT03112863|DRUG|Retinol|This group will receive retinol
219530106|NCT00520923|DRUG|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
219530107|NCT00520923|DRUG|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
219530108|NCT00520923|DRUG|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
219530109|NCT00520923|DRUG|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
219530110|NCT00520923|DRUG|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
219530111|NCT00520923|DRUG|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
219530112|NCT00520923|DRUG|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
219530113|NCT02061917|OTHER|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
219530114|NCT02061917|OTHER|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
219530115|NCT02061917|OTHER|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
218916619|NCT03593369|DEVICE|KLOX BioPhotonic System (single treatment)+SOC|"KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
219530116|NCT03197285|OTHER|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
218916620|NCT03593369|DEVICE|KLOX BioPhotonic System (consecutive treatments)+SOC|"In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
218916621|NCT03593369|OTHER|Standard of Care (SOC)|Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
219530117|NCT03197285|OTHER|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
219530118|NCT04000815|DIAGNOSTIC_TEST|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
219530119|NCT03934047|DRUG|Tranexamic Acid 100 MG/ML|Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
219530120|NCT00239577|BIOLOGICAL|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
219530121|NCT00239577|BIOLOGICAL|Placebo|Placebo
219530122|NCT03622801|DRUG|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
219530123|NCT02631772|DRUG|Sofosbuvir/Ledipasvir x 12 weeks|
219530124|NCT02631772|DRUG|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
219530125|NCT05852886|DEVICE|Enable Oral Hygiene System (EOHS)|The Enable Oral Hygiene System (EOHS) is a manual toothbrush comprised of a handle and shaft with multiple surfaces of synthetic bristles extending off of the shaft at one end.
219530126|NCT02811666|DEVICE|Assessment of sarcopenia by CT-Scan|
219530127|NCT02811666|DEVICE|hand gauge|
219530128|NCT00725517|DRUG|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
219530129|NCT02659358|DEVICE|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
218916622|NCT06262815|PROCEDURE|Nasogastric tube placement|Conventional nasogastric tube placement done for decompression of small bowel obstruction
218916623|NCT06262815|DIAGNOSTIC_TEST|Clinical Frailty Scale|The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.
218916624|NCT00767988|DIETARY_SUPPLEMENT|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
218916625|NCT00767988|OTHER|Placebo|Capsule once daily at approximately the same time each day for 6 months.
218916626|NCT03181932|DRUG|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
218916627|NCT03181932|DRUG|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
218916628|NCT03181932|DRUG|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
219530130|NCT00439634|DRUG|AVE1625|oral administration
219530131|NCT00439634|DRUG|placebo|oral administration
219530132|NCT01488058|OTHER|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
219530133|NCT01488058|OTHER|Waitlist Control|Waitlist will receive iCBT at week 11
219530134|NCT01931007|DRUG|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
219530135|NCT01931007|DRUG|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
219530136|NCT02736721|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
219530137|NCT05595590|DRUG|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
219530138|NCT05595590|RADIATION|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
219530139|NCT00112190|DRUG|Itopride Hydrochloride|100 mg tid
219530140|NCT00112190|DRUG|itopride|100 mg three times daily
218916629|NCT02576483|BEHAVIORAL|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
219530141|NCT00603187|DRUG|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
219530142|NCT01021670|DRUG|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
219530143|NCT01021670|OTHER|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
219530144|NCT02386618|PROCEDURE|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
219530145|NCT03021018|DRUG|Brivaracetam|"* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous"
219530146|NCT03021018|DRUG|Lorazepam|"* Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous"
219530147|NCT00840099|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
219530148|NCT00840099|DRUG|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
219530149|NCT02778815|OTHER|Kindness for Mums|
219530150|NCT01032083|DRUG|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
219616185|NCT05516680|DEVICE|electro-acupuncture|Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm）will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 \~ 10 Hz and a current intensity of 1 \~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
218916630|NCT04698863|DEVICE|Oxygen reserve index|eveluating oxygen reserve in blood
218916631|NCT01590719|DRUG|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
218916632|NCT01590719|DRUG|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
218916633|NCT01590719|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
219204624|NCT02978521|OTHER|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
218916634|NCT01590719|DRUG|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
218916635|NCT01590719|DRUG|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
219530151|NCT01032083|DRUG|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
219530152|NCT05364853|BEHAVIORAL|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
219530153|NCT05364853|BEHAVIORAL|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
219530154|NCT00001085|DRUG|Amprenavir|
219530155|NCT00001085|DRUG|Lamivudine|
219530156|NCT00001085|DRUG|Zidovudine|
219530157|NCT01885052|BEHAVIORAL|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
219530158|NCT01885052|BEHAVIORAL|Low Contact|
219530159|NCT04533893|OTHER|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
219530160|NCT02193971|DEVICE|BS-DES (Biostable polymer drug-eluting stent)|
219530161|NCT02193971|DEVICE|BD-DES (Biodegradable polymer drug-eluting stent)|
219530162|NCT02193971|DRUG|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
218916636|NCT01590719|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
219530163|NCT05118412|OTHER|Lucerne protein concentrate shake|At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
219530164|NCT05118412|OTHER|Whey protein concentrate shake|At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
219530165|NCT05963035|DRUG|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
219530166|NCT03269838|DIAGNOSTIC_TEST|ECG|Primary Percutaneous coronary intervention
219530167|NCT06267703|OTHER|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
219616186|NCT05516680|DEVICE|MRI-navigated rTMS|MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of \>50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.
219530168|NCT00095108|DRUG|Recombinant Human Interleukin-21|
219616187|NCT02596204|OTHER|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
219616188|NCT02596204|DEVICE|FitBit|All subjects will wear a FitBit activity monitor.
219616189|NCT03527069|DRUG|Cipros 10 association|oral, once a day.
219616190|NCT03527069|DRUG|Crestor 10 mg|oral, once a day.
219616191|NCT06058572|DRUG|Rifaximin 200Mg Tab|Drug rifaximin 200 mg tablet form orally twice daily (with or without food) from day-8 of transplant to day + 60 of transplant
219616192|NCT06058572|PROCEDURE|allogenic hematopoietic stem cell transplantation|Control arm will undergo allogenic hematopoietic stem cell transplantation as standard of care
219616193|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
219616194|NCT02051348|BIOLOGICAL|Pylopass|Pylopass
218916637|NCT04631419|OTHER|Flapless laser corticotomy|The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
218916638|NCT04631419|OTHER|Canine retraction|canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
218916639|NCT00237302|DRUG|topiramate|
219530169|NCT05234502|OTHER|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
219530170|NCT05234502|OTHER|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
219530171|NCT02621996|DEVICE|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
219530172|NCT02621996|DEVICE|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
219530173|NCT00068991|BEHAVIORAL|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
219616195|NCT02051348|BIOLOGICAL|Placebo|Placebo
219530174|NCT00068991|BEHAVIORAL|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
219530175|NCT00068991|BEHAVIORAL|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
219530176|NCT05951192|DRUG|Daprodustat|Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
218916640|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.
218916641|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
218916642|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
219204625|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
219530177|NCT05971420|OTHER|VR activity-based|VR games activities were chosen for simulated cognitive-motor training in the VR group. The VR training modules for this study included fire drill, walking exercise, balancing game activities and community shopping practices. These training modules involved dual task components; the participant was expected to train up his/her physical and cognitive motor performances in an 8-week VR activity-based program. VR group participants received 2-sessions per week, 16 training sessions in total.
219530178|NCT05971420|OTHER|Exercise-based (Baduanjin)|The exercise group used a traditional Chinese Qigong Baduanjin exercise incorporating with a fall prevention education strategy.
219530179|NCT03205774|BEHAVIORAL|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
219530180|NCT00204074|DRUG|17-beta-estradiol (drug)|
219530181|NCT01971060|DEVICE|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
219530182|NCT03562091|OTHER|Data collection|The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).
219530183|NCT01319162|OTHER|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
219530184|NCT00328926|DRUG|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
219530185|NCT00328926|DRUG|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
219530186|NCT00328926|DRUG|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
219530187|NCT00328926|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
219530188|NCT00328926|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
219530189|NCT04760704|BIOLOGICAL|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
219530190|NCT03342157|DRUG|senna/docusate|Stimulant laxative
219530191|NCT03744481|OTHER|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
219530192|NCT01826058|RADIATION|Stereotactic body radiation therapy|
219530193|NCT02376777|OTHER|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
219530194|NCT00620074|DRUG|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
218916643|NCT00941213|DEVICE|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
219530195|NCT00620074|DRUG|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
219530196|NCT04989491|DRUG|Rituximab|One single dose of rituximab intravenously (IV)
219530197|NCT04989491|OTHER|control group|No treatment
219530198|NCT04798144|DEVICE|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
219530199|NCT04798144|DEVICE|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
219530200|NCT00836667|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
219530201|NCT00836667|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
218916644|NCT00941213|DEVICE|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
219530202|NCT03836560|DRUG|Nicotine patch|nicotine patch given for 8 weeks
219530203|NCT03836560|DRUG|Nicotine gum|nicotine gum given as requested
218916645|NCT00707889|DRUG|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
218916646|NCT00707889|DRUG|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
218916647|NCT00707889|DRUG|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
218916648|NCT00707889|DRUG|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
218916649|NCT00707889|DRUG|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
218916650|NCT00707889|DRUG|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
218916651|NCT03011918|OTHER|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
218916652|NCT03011918|OTHER|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
219530204|NCT06558669|OTHER|Fresh Sugarcane juice|Fresh sugarcane juice in different doses will be given to liver patients for 90 days
219530205|NCT00309101|DRUG|tacrolimus|Oral
219530206|NCT06502340|DIAGNOSTIC_TEST|high sensitive troponin I|high-sensitive Troponin I levels
219530207|NCT03977272|DRUG|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
219530208|NCT03977272|DRUG|Chemotherapy|modified-FOLFIRINOX
219530209|NCT01796730|DRUG|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
219530210|NCT01796730|DRUG|Placebo|
219530211|NCT03362710|DIAGNOSTIC_TEST|simplified tools|"1. Skin temperature on the back of the foot with infra-red thermometry~2. Toe saturometry~3. ABI with an automatic sphygmomanometry~4. Skin Recoloration time at the foot"
219530212|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
219530213|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
219530214|NCT02723981|DEVICE|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
219530215|NCT02723981|DRUG|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
219530216|NCT02723981|DEVICE|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
219530217|NCT02723981|DRUG|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
219530218|NCT01665586|DRUG|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
219530219|NCT05402358|OTHER|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
219530220|NCT01239017|BIOLOGICAL|REGN475|
219530221|NCT01239017|OTHER|Placebo|
219530222|NCT03251534|PROCEDURE|Centromedullary nailing|
218916653|NCT03011918|OTHER|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
219530223|NCT04102319|DIAGNOSTIC_TEST|serum hepcidin|it is a serum marker
219616196|NCT04629040|OTHER|Lateral wedge insole|Lateral wedge insole for knee osteoarthritis patient
219616197|NCT04629040|OTHER|Ordinary insole|Ordinary insole
219616198|NCT06547086|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
218916654|NCT03011918|OTHER|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
218916655|NCT05249556|DRUG|Ganaxolone|Ganaxolone
218916656|NCT05249556|DRUG|Placebo|Placebo (for ganaxolone)
218916657|NCT05329948|OTHER|Haptonomy application|Feeling the fetus by touching the mother's womb with meditation
218916658|NCT01792895|PROCEDURE|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
218916659|NCT01792895|PROCEDURE|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
218916660|NCT01792895|PROCEDURE|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
218916661|NCT03410277|OTHER|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
219530224|NCT06199219|OTHER|Sexual counseling, based on the extended (EX-PLISSIT)|"The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved (Taylor and Davis 2006; Punjani and Papathanasoglu, 2019)."
219530225|NCT02412384|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
219530226|NCT02412384|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219530227|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
219530228|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% \[3,18 \]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) \[41\]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
219530229|NCT05931315|DIETARY_SUPPLEMENT|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
219530230|NCT05931315|DIETARY_SUPPLEMENT|Placebo|One capsule to be taken immediately post-dinner / with dinner
219530231|NCT02615028|OTHER|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
219530232|NCT03037671|DEVICE|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
219530233|NCT05458583|PROCEDURE|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
219530234|NCT05458583|PROCEDURE|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
219530235|NCT05458583|PROCEDURE|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
219530236|NCT05458583|PROCEDURE|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
219530237|NCT06563011|OTHER|Counselling|Tailored Dietary Counselling
219530238|NCT00958451|DRUG|Paricalcitol|"1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
219530239|NCT00958451|DRUG|Ergocalciferol|"1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
219530240|NCT03114748|OTHER|EEG|
219530241|NCT03114748|OTHER|DBS switched OFF and ON|
219530242|NCT02753231|BEHAVIORAL|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219530243|NCT02753231|BEHAVIORAL|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219530244|NCT02753231|BEHAVIORAL|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219530245|NCT02753231|BEHAVIORAL|Conventional physical activity program|One Physical Education sessions / week
219530246|NCT04093245|BEHAVIORAL|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
219530247|NCT04093245|BEHAVIORAL|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
219616199|NCT06976723|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
219616200|NCT05330182|DRUG|LMN-201|"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
219616201|NCT05330182|DRUG|Placebo|Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
219616202|NCT04025398|BEHAVIORAL|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
219530248|NCT04093245|BEHAVIORAL|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
219530249|NCT04093245|BEHAVIORAL|medical follow-up appointment|a planned follow-up appointment with their family physician
219616203|NCT04025398|BEHAVIORAL|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
218916662|NCT00853307|DRUG|Alisertib|Alisertib capsules
218916663|NCT04894266|DRUG|Apabetalone|Apabetalone 100mg BID
218916664|NCT04894266|OTHER|Standard of care|Standard of Care
219530250|NCT04093245|BEHAVIORAL|follow-up phone call|a systematic follow-up phone call for discharged patients
219530251|NCT04093245|OTHER|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
219530252|NCT04093245|OTHER|Telemonitoring service|access to a community-based telemonitoring service
219616204|NCT00356226|DRUG|clonidine|
218916665|NCT00896077|DRUG|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
218916666|NCT01080079|DRUG|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
218916667|NCT01080079|OTHER|Purified Water|Purified Water
218916668|NCT00674817|DRUG|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
218916669|NCT00674817|DRUG|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
219204626|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
219530253|NCT00477945|DRUG|clofarabine|"Cohort N Clofarabine (mg/m2/day)~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
219530254|NCT04294303|OTHER|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
219530255|NCT04294303|OTHER|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
219616205|NCT04331613|BIOLOGICAL|CAStem|CAStem will be administered intravenously.
219616206|NCT05161338|DIAGNOSTIC_TEST|MICROBIOME GENETIC ANALYSIS|Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed
219616207|NCT05161338|DIAGNOSTIC_TEST|VAGINAL PH VALUE|Intravaginal Ph value meassurement.
219616208|NCT05161338|DIAGNOSTIC_TEST|SERUM PROGESTERONE LEVELS|Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
219616209|NCT05161338|DIAGNOSTIC_TEST|SERUM OESTRADIOL LEVELS|Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
219616210|NCT03438838|PROCEDURE|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
219530256|NCT00573066|DRUG|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
219530257|NCT05721586|OTHER|Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR|The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR
219530258|NCT05721586|OTHER|Fluoride varnish (DURAFLOR|A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
219530259|NCT03024086|DRUG|DWJ1252|DWJ1252 and Placebo of Gasmotin
219530260|NCT03024086|DRUG|Gasmotin|Gasmotin and Placebo of DWJ1252
219530261|NCT01838941|DRUG|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children \> 30 kg, in 4 divided doses (3 g at meal time and bed time)."
219530262|NCT03584919|DRUG|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
219530263|NCT03584919|DRUG|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
219530264|NCT03584919|OTHER|control subjects|no intervention
219530265|NCT01346735|OTHER|No intervention|
219530266|NCT02822235|OTHER|No Intervention|
219530267|NCT03214952|DRUG|Vonoprazan|Vonoprazan tablets
219530268|NCT06067243|DIAGNOSTIC_TEST|T2 mapping 3T MRI + hip arthroscopy|"1. 3T MRI~2. hip arthroscopy"
219616211|NCT03438838|PROCEDURE|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
219616212|NCT00681343|DRUG|Thymoglobulin|Induction
219530269|NCT05365932|DEVICE|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
219530270|NCT00005785|DRUG|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
219530271|NCT03596294|DRUG|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
219530272|NCT03596294|DRUG|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
219530273|NCT03596294|OTHER|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
219616213|NCT00681343|DRUG|Campath-1H|Induction
219530274|NCT02056691|PROCEDURE|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
219616214|NCT00681343|DRUG|Daclizumab|Induction
219616215|NCT00850811|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
219616216|NCT05716126|DRUG|[14C]Iruplinalkib (WX-0593)|Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
219616217|NCT04421599|OTHER|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
219616218|NCT03164551|DEVICE|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
219616219|NCT03164551|DEVICE|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
218916670|NCT00959855|OTHER|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
218916671|NCT04046913|BEHAVIORAL|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
218916672|NCT03040544|PROCEDURE|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
218916673|NCT03040544|PROCEDURE|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
219041984|NCT03420885|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
219041985|NCT03420885|BEHAVIORAL|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
219530275|NCT02056691|PROCEDURE|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
219530276|NCT05952544|DRUG|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
219530277|NCT05952544|OTHER|low protein diet|patients were on low protein diet only
219530278|NCT02968992|DRUG|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
219530279|NCT02968992|OTHER|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
219616220|NCT01722708|DRUG|Clindamycin|Oral clindamycin 300 Milligrams\*2/Day for a week
219616221|NCT01722708|DRUG|Metronidazole|Oral metronidazole 500 Milligrams\*2/Day for a week
219616222|NCT03197623|DRUG|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
219616223|NCT03197623|DRUG|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
218916674|NCT04490070|BEHAVIORAL|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
219530280|NCT00000925|DRUG|Optimune oral nutritional supplement|
218916675|NCT04169217|BEHAVIORAL|Prehabilitation|"A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform."
218916676|NCT04956796|BEHAVIORAL|Airway Video Library Training|A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
218916677|NCT04956796|BEHAVIORAL|Conventional Airway Training|The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
219530281|NCT01811758|BEHAVIORAL|Culturally Specific CBT|
219530282|NCT01811758|BEHAVIORAL|Standard CBT|
219530283|NCT01950715|DEVICE|sacral nerve stimulation|Sacral nerve stimulation
219616224|NCT01110018|DRUG|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
219616225|NCT01110018|DRUG|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
219616226|NCT03757819|DEVICE|tDCS|Brain Stimulation
219616227|NCT03757819|DEVICE|SHAM|Placebo device
219616228|NCT03490110|BEHAVIORAL|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total \~4.5 hours per week).
219616229|NCT03490110|OTHER|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
219616230|NCT05059613|OTHER|probiotics|one times a day during the whole treatment
219616231|NCT06010953|DRUG|SS109|on-demand treatment with SS109 at the time of a new hemorrhage event
218916678|NCT03826303|OTHER|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
218916679|NCT03826303|OTHER|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
218916680|NCT03826303|OTHER|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
219616232|NCT05824754|OTHER|Just-In-Time-Adaptive-Intervention (JITAI)|"Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies."
219616233|NCT05610215|PROCEDURE|hybrid ablation|simultaneous thoracoscopic epicardial and catheter endocardial ablation
218916681|NCT03826303|OTHER|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
218916682|NCT00043316|DRUG|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
219041986|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
219041987|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
219041988|NCT04743661|DRUG|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
219530284|NCT02140580|DEVICE|Minimally invasive surfactant therapy|Active Comparator
219530285|NCT02140580|OTHER|Continuation on CPAP|Sham Comparator
219530286|NCT03144050|DEVICE|SFDI Imaging|Imaging with SFDI device
219530287|NCT03992222|DEVICE|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
219616234|NCT05610215|PROCEDURE|catheter ablation|catheter endocardial ablation
219616235|NCT02174003|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
219616236|NCT06429722|DRUG|NMRA-335140 80 mg|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
219616237|NCT06429722|DRUG|Placebo|Placebo will be administered orally
219616238|NCT06855225|DRUG|Tremelimumab|Tremelimumab is administered at 300mg intravenously once at Cycle 1.
219616239|NCT06855225|DRUG|Durvalumab|Durvalumab is administered at 1500mg intravenously every 3 weeks for Cycles 1-8, then every 4 weeks for Cycles 9+.
219616240|NCT06855225|DRUG|Gemcitabine|Gemcitabine is administered at 1000mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
218916683|NCT03697252|DRUG|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
218916684|NCT03697252|DRUG|Placebo Capsules|Placebo Capsules
218916685|NCT03835195|OTHER|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
218916686|NCT03835195|OTHER|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
218916687|NCT03967977|DRUG|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
219204627|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
219530288|NCT04039334|OTHER|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
218916688|NCT03967977|DRUG|Placebo|Tislelizumab placebo to match
218916689|NCT03967977|DRUG|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
218916690|NCT03967977|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
218916691|NCT03967977|DRUG|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
219204628|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
219204629|NCT06784674|OTHER|No intervention|Observational study
219204630|NCT03131128|BEHAVIORAL|Mindfulness-based Intervention|"1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food."
219530289|NCT04039334|OTHER|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
219530290|NCT03769896|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
219530291|NCT03769896|DRUG|Placebo|capsule, corn starch, daily basis
219530292|NCT00938795|OTHER|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
219530293|NCT00938795|OTHER|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
219530294|NCT04739475|PROCEDURE|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
219530295|NCT05194059|BEHAVIORAL|Home-based physical activity|Participants will follow a personalized activity pacing program
219530296|NCT00268879|DRUG|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
219530297|NCT04927091|OTHER|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
219530298|NCT00974935|DRUG|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
219530299|NCT00974935|BIOLOGICAL|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
219616241|NCT06855225|DRUG|Cisplatin|Cisplatin is administered at 25mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
219616242|NCT04993131|PROCEDURE|Liver transplant|Liver transplant.
219616243|NCT06655805|DEVICE|Non-invasive ventilation, Invasive mechanical ventilation, high-flow nasal oxygen|No intervention is intended by the nature of this observational study.
219616244|NCT02902523|DRUG|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
219041989|NCT04743661|DRUG|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
219616245|NCT02902523|DRUG|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
218916692|NCT00005766|DRUG|Creatinine|
218916693|NCT03288675|DEVICE|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
219041990|NCT04743661|DRUG|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
219530300|NCT02054117|OTHER|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
219530301|NCT01960920|OTHER|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
219530302|NCT01960920|OTHER|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
219530303|NCT01960920|OTHER|Clean air|No pollution and no filter mask
219530304|NCT00377260|DRUG|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
219530305|NCT00377260|DRUG|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
219616246|NCT05836207|BEHAVIORAL|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
219616247|NCT05836207|BEHAVIORAL|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
219530306|NCT00490204|DRUG|Cetirizine|
219530307|NCT00829530|DRUG|Ramipril 10 mg capsule|1 x 10 mg
219616248|NCT03851237|DRUG|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
219616249|NCT03851237|DEVICE|PET/CT|-Standard of care
219616250|NCT06594926|DRUG|Testosterone Enanthate|Testosterone enanthate is a depot formulation used in Australia typically for androgen replacement in people with confirmed testosterone deficiency.
219616251|NCT03401463|OTHER|traning seminar|There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
219530308|NCT00829530|DRUG|Altace® 10 mg capsule|1 x 10 mg
219530309|NCT02510118|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
219530310|NCT02510118|DRUG|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
218916694|NCT03288675|BEHAVIORAL|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
218916695|NCT03288675|DRUG|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
219530311|NCT02510118|DRUG|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
218916696|NCT00209911|PROCEDURE|cardioversion|
218916697|NCT02250846|DRUG|EGFR-TKI|egfr-TKI treatment
218916698|NCT03955198|COMBINATION_PRODUCT|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
218916699|NCT01941810|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|Given PO
218916700|NCT01941810|OTHER|questionnaire administration|Ancillary studies
218916701|NCT01941810|PROCEDURE|quality-of-life assessment|Ancillary studies
219530312|NCT02510118|DRUG|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
219530313|NCT04354493|DEVICE|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
219530314|NCT00959153|DEVICE|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
219530315|NCT01320254|DRUG|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
219530316|NCT01320254|DRUG|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
219616252|NCT06252571|COMBINATION_PRODUCT|- Melatonin - Active light ttherapy|1 tablet per day, in the evening + morning light therapy over 6 weeks
219616253|NCT06252571|COMBINATION_PRODUCT|- Placebo drug - Placebo light therapy|1 tablet per day in the evening + morning placebo light therapy
219616254|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
219616255|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
218916702|NCT01941810|OTHER|laboratory biomarker analysis|Correlative studies
218916703|NCT03255122|BEHAVIORAL|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
218916704|NCT03255122|BEHAVIORAL|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
219204631|NCT03131128|BEHAVIORAL|Health Education Intervention|"1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia."
219204632|NCT05239169|DRUG|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
219204633|NCT05239169|DRUG|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
219530317|NCT01200043|OTHER|fructose restriction diet|fruits and vegetables only
219530318|NCT00840866|DRUG|cefprozil|500 mg Tablet
219530319|NCT00840866|DRUG|Cefzil®|500 mg Tablet
219530320|NCT03804749|DRUG|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
219530321|NCT03804749|OTHER|placebo|Placebo is 0.9% sodium chloride injection.
219530322|NCT04343794|DEVICE|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
219530323|NCT01110122|DIETARY_SUPPLEMENT|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
219530324|NCT05399446|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
219530325|NCT05399446|BEHAVIORAL|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
219530326|NCT04112823|DRUG|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
219530327|NCT04112823|DRUG|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
219616256|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
219616257|NCT00691717|OTHER|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
219616258|NCT04563936|DRUG|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
219616259|NCT04563936|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
218916705|NCT05920590|OTHER|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~* Application of the hold - relax technique to increase the range of motion of knee flexion.~* Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~* Application of stabilizing reversals from a sitting and standing position.~* Application of dynamic reversals from a standing position.~* Rhythmic stabilization.~* Combination of isotonics.~* Gait retraining."
218916706|NCT05920590|OTHER|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
219616260|NCT04061239|DRUG|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
219616261|NCT04061239|DRUG|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
219530328|NCT01260389|BEHAVIORAL|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
218916707|NCT05920590|OTHER|Control|Participants in this group will be given an exercise leaflet for home-based exercises and will be instructed to perform these exercises three times a week for the same period as the other two groups (6 weeks). They will also be given recommendations to maintain and increase their physical activity.
218916708|NCT02241824|DEVICE|In-elastic lumbar brace|
218916709|NCT02241824|DEVICE|Elastic abdominal binder|
219530329|NCT06627010|OTHER|description|study of file
218916710|NCT00131222|PROCEDURE|Food supplement: fortified spread|
218916711|NCT00131222|PROCEDURE|Food supplement: maize and soy flour|
218916712|NCT00406250|DRUG|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
218916713|NCT00406250|DRUG|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
218916714|NCT04030143|DRUG|Aripiprazole|Administered as an intramuscular (IM) depot injection.
218916715|NCT04030143|DRUG|Aripiprazole|Administered as an IM depot injection.
218916716|NCT02383576|OTHER|No Intervention|No intervention administered in this study.
218916717|NCT02435212|DRUG|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
218916718|NCT02435212|DRUG|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
218916719|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
218916720|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
218916721|NCT06577896|DEVICE|Onyx family|Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
218916722|NCT03042689|DRUG|Regorafenib|Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
219204634|NCT05239169|DRUG|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
219204635|NCT04174170|DRUG|Brexpiprazole|3 mg pill
218916723|NCT05164289|OTHER|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
218916724|NCT05164289|OTHER|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
219204636|NCT04174170|DRUG|Sertraline|150 mg pill
219204637|NCT04174170|OTHER|Placebo|Pill
218916727|NCT05398653|DRUG|MIL62|An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.
219204638|NCT04174170|DRUG|Brexpiprazole|2 mg pill
219530330|NCT01770938|DEVICE|Effective light-emitting diode therapy|
219530331|NCT01770938|DEVICE|Placebo light-emitting diode therapy|
219530332|NCT00625443|DRUG|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
219530333|NCT00625443|DRUG|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
219530334|NCT00625443|DRUG|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
219616262|NCT04061239|DRUG|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
219616263|NCT04061239|DRUG|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
219616264|NCT02757755|BIOLOGICAL|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
218916728|NCT05398653|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
219530335|NCT04949932|OTHER|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
219530336|NCT04949932|OTHER|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
219530337|NCT04327375|OTHER|Observational|Observational
219530338|NCT03661047|DRUG|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
219530339|NCT05479630|OTHER|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
219616265|NCT02757755|BIOLOGICAL|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
218916729|NCT03432598|DRUG|Tislelizumab|Administered 200 mg intravenously (IV) as specified in the treatment arm
218916730|NCT03432598|DRUG|Paclitaxel|Administered 175 mg/m² IV as specified in the treatment arm
218916731|NCT03432598|DRUG|Gemcitabine|Administered 1250 mg/m² IV as specified in the treatment arm
218916732|NCT03432598|DRUG|Etoposide|Administered 100 mg/m2 IV as specified in the treatment arm
219041991|NCT04743661|DRUG|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
219530340|NCT04336930|DIAGNOSTIC_TEST|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
219530341|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
219530342|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
219530343|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
219530344|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
219530345|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
219616266|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
219616267|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
218916733|NCT03432598|DRUG|Pemetrexed|Administered 500 mg/m² IV as specified in the treatment arm
218916734|NCT03432598|DRUG|Cisplatin|Administered 75 mg/m²/day IV as specified in the treatment arm
218916735|NCT03432598|DRUG|Carboplatin|Administered AUC 5 as specified in the treatment arm
218916736|NCT04849364|DRUG|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
219530346|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
219530347|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219530348|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
218916737|NCT04849364|DRUG|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
218916738|NCT04849364|DRUG|Pembrolizumab|Per standard of care.
218916739|NCT04849364|DRUG|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
219530349|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219530350|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
219530351|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
219530352|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
219530353|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
219530354|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
219530355|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
219530356|NCT00216463|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
219530357|NCT00216463|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
219530358|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
219530359|NCT05542108|BEHAVIORAL|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
219616268|NCT02680236|OTHER|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
219616269|NCT01963741|DRUG|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
219616270|NCT01963741|DRUG|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
219616271|NCT02294214|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
219616272|NCT02294214|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
219616273|NCT02294214|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
219616274|NCT03839420|DEVICE|CZM IOL|implantation of CZM IOL
219530360|NCT05542108|BEHAVIORAL|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
219530361|NCT02924883|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
219530362|NCT02924883|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
219530363|NCT02924883|OTHER|Placebo|Placebo matched to atezolizumab
219530364|NCT04386278|DEVICE|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
219530365|NCT04386278|DEVICE|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
219530366|NCT04386278|DEVICE|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
219616275|NCT03839420|DEVICE|Competitor IOL|implantation of Competitor IOL
219616276|NCT02689583|BIOLOGICAL|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.
219530367|NCT04386278|DEVICE|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
219530368|NCT04386278|DEVICE|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
219530369|NCT04386278|DEVICE|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
219530370|NCT04386278|DEVICE|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
219530371|NCT04386278|DEVICE|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
219530372|NCT01135927|DRUG|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
219530373|NCT01135927|DRUG|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
219530374|NCT01168557|DEVICE|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
219530375|NCT01479738|PROCEDURE|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
219530376|NCT00175617|DRUG|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
219530377|NCT00175617|DRUG|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
219530378|NCT04966455|DIETARY_SUPPLEMENT|Raisins|Daily supplementation of 50 g of rainsins for 3 months
219530379|NCT02742935|BIOLOGICAL|camrelizumab|A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)
219530380|NCT04121364|DEVICE|Tetranite|Dental Adhesive for increased implant stability
219530381|NCT05070611|DEVICE|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
219530382|NCT01846845|DEVICE|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
219530383|NCT01846845|DEVICE|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
219530384|NCT02993991|DRUG|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
219530385|NCT02993991|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
219530386|NCT01159132|DRUG|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
219530387|NCT03685565|PROCEDURE|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
219530388|NCT03685565|PROCEDURE|Dermabond|Laceration repaired with Dermabond
219530389|NCT00280904|DEVICE|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
219616277|NCT02689583|GENETIC|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
219616278|NCT02689583|DIETARY_SUPPLEMENT|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
219616279|NCT02630576|DEVICE|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
219616280|NCT01117896|OTHER|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
219616281|NCT01117896|OTHER|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
219616282|NCT01152073|DIETARY_SUPPLEMENT|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
219616283|NCT01152073|DIETARY_SUPPLEMENT|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
219616284|NCT01152073|DIETARY_SUPPLEMENT|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
219616285|NCT02336945|DEVICE|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
219616286|NCT00470470|DRUG|imatinib mesylate|Given orally
219616287|NCT00470470|OTHER|laboratory biomarker analysis|Correlative studies
219616288|NCT00221455|BEHAVIORAL|Patient diabetic self-management using the diabetic patient portal tools|
219530390|NCT05412173|DRUG|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
219530391|NCT03214822|DIETARY_SUPPLEMENT|H2MF|As described in the Experimental Arm description.
219616289|NCT00221455|BEHAVIORAL|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
219616290|NCT01101113|DRUG|cinacalcet|cinacalcet 25mg qd or 50 mg qd
219616291|NCT01101113|DRUG|control|vit D + P binder
219616292|NCT03110237|OTHER|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
219530392|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
219530393|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode|"Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam."
219530394|NCT01841866|OTHER|LMA removal|
219530395|NCT05481840|DEVICE|Continence material with sensor|"Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care."
219530396|NCT01765114|DRUG|PEG-Formulation|
219530397|NCT00940810|PROCEDURE|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
219530398|NCT00940810|PROCEDURE|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
219530399|NCT04764214|DRUG|3rd generation EGFR-TKI|Osimertinib will be administered orally at the dose of 80 mg once daily.
219530400|NCT04764214|RADIATION|Consolidative SRT|Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SRT until disease progression or intolerable toxicity.
219530401|NCT02345395|PROCEDURE|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
219530402|NCT00002911|DRUG|marimastat|
219530403|NCT02099747|DRUG|hATG|
219530404|NCT02099747|DRUG|CsA|
219616293|NCT03110237|OTHER|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
219530405|NCT02099747|DRUG|Eltrombopag|
219530406|NCT01278732|OTHER|no intervention performed|no intervention is performed
218916740|NCT03844997|DRUG|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
218916741|NCT03844997|DRUG|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
218916742|NCT00135226|DRUG|Aspirin|
218916743|NCT00135226|DRUG|Omega-3 Ethyl Esters|
218916744|NCT00135226|DRUG|Placebo Aspirin|
218916745|NCT00135226|DRUG|Placebo Omega-3 Ethyl Esters|
218916746|NCT06578364|DEVICE|Educational Program about Preconception Care|The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
219530407|NCT04807374|DEVICE|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
218916748|NCT04689139|DIAGNOSTIC_TEST|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
218916749|NCT05569044|OTHER|Control Group|No intervention
218916750|NCT05569044|OTHER|Oral Rehydration Solution|Participants will be administered ORS during one of the study visits
218916751|NCT05569044|OTHER|Water|Participants will be administered water during one of the study visits
219530408|NCT03857295|OTHER|No interventions|No intervention
218916752|NCT02647125|DRUG|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
218916753|NCT02647125|RADIATION|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
219530409|NCT04624620|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
218916754|NCT05454033|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
219530410|NCT04270448|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
219530411|NCT02598882|DEVICE|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
218916755|NCT05454033|OTHER|Control|No-treatment control
218916756|NCT02679313|DEVICE|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
218916757|NCT04531410|DIETARY_SUPPLEMENT|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
218916758|NCT04531410|DIETARY_SUPPLEMENT|oleic acid supplementation|Oils given at morning meal with extra enzymes
218916759|NCT04552301|BEHAVIORAL|Cognitive Processing Therapy|Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
218916760|NCT04552301|BEHAVIORAL|Psychotherapy|The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
219530412|NCT02598882|DEVICE|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
219530413|NCT03515967|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
219530414|NCT01747317|DEVICE|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
219530415|NCT06420986|PROCEDURE|Open Hemorrhoidectomy|Surgical treatment of Hemorrhoids. Removal of hemorrohids leaving the wounds open. Surgical technique described by Milligan Morgan
219530416|NCT06420986|PROCEDURE|Transanal Hemorrhoidal Dearterialization|Surgical treatment of Hemorrhoids. This operation involves no excision. The hemorrhoidal arteries are ligated and the hemorrhoial prolapse is treated by a suture mucopexi. Described by Rato
219530417|NCT01330186|OTHER|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
219530418|NCT01216839|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
219530419|NCT00772941|DRUG|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
219530420|NCT00637741|DEVICE|Everflex 200|
219530421|NCT04786184|BEHAVIORAL|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
218916761|NCT04552301|BEHAVIORAL|Targeted Asthma Education|The manualized 10-session program of asthma self-management
218916762|NCT04552301|BEHAVIORAL|General Asthma Education|A 10-session program of similar time
219616294|NCT03458611|BEHAVIORAL|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
219616295|NCT03458611|BEHAVIORAL|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
219616296|NCT00749450|DRUG|capecitabine|Given orally
219616297|NCT00749450|DRUG|fluorouracil|Given IV
219616298|NCT00749450|DRUG|oxaliplatin|Given IV
219530422|NCT04786184|BEHAVIORAL|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
219530423|NCT05136183|DEVICE|HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)|"* If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization."
219530424|NCT00783367|DRUG|Lenalidomide|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study
219616299|NCT00578201|DRUG|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
219616300|NCT00793455|BEHAVIORAL|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
219616301|NCT01809353|DRUG|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
219616302|NCT01809353|OTHER|Placebo|Single matching intravenous dose
219616303|NCT04355078|OTHER|Neuromuscular Training|Muscular and neural training by complex exercises
219616304|NCT04355078|OTHER|Strength Training|Strength Training
219616305|NCT01785082|DRUG|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
219616306|NCT02566772|DRUG|TAS3681|TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
219616307|NCT01268462|OTHER|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
219616308|NCT01268462|OTHER|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
218916763|NCT05722860|DRUG|L-Citrulline, capsule|5g/daily dose for the duration of 1 week intervention
219204639|NCT06217276|OTHER|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
218916764|NCT01184898|DRUG|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
218916765|NCT01184898|DRUG|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
218916766|NCT01184898|DRUG|Etoposide|100 mg/m2/day IV
218916767|NCT01184898|DRUG|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
218916768|NCT05375617|OTHER|Observational|No intervention
218916769|NCT06383871|DRUG|HRS-7058 capsule/ HRS-7058 tablet|HRS-7058 capsule/ HRS-7058 tablet
219530425|NCT00783367|DRUG|Dexamethasone|Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;
219530426|NCT00783367|DRUG|Rituximab|Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
219530427|NCT00505570|DEVICE|AMPLATZER® PFO Occluder Device|PFO device closure
219530428|NCT03861845|DEVICE|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
219616309|NCT01268462|OTHER|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
219616310|NCT01268462|OTHER|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
219616311|NCT06497907|DIETARY_SUPPLEMENT|polymeric formula|Patients with growth faltering received nutritional rehabilitation with polymeric formula and were reassessed after 12 weeks by anthropometric measurements
219616312|NCT06497907|DIETARY_SUPPLEMENT|peptide based formula|patients who were defined as non responders and underwent upper gastrointestinal endoscopy and diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula
219616313|NCT06996886|DRUG|AZD5004|Participants will be receiving three different formulations (F1, F3, and F4) as single dose of AZD5004 orally in fasted and fed state.
219616314|NCT03345680|OTHER|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
219616315|NCT03104517|BIOLOGICAL|AMDC-USR (iltamiocel)|Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
219616316|NCT03104517|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
219616317|NCT06863311|DRUG|XL092|100 mg orally
219616318|NCT06863311|DRUG|Nivolumab|480 mg intravenously.
219616319|NCT06671873|DRUG|100 µCi [14C] HMPL-306|D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose
219616320|NCT00477737|DRUG|Sevoflurane|
219616321|NCT00477737|DRUG|propofol|
219616322|NCT06856629|OTHER|Eccentric blood-flow restriction training|Eccentric blood-flow restriction training
219616323|NCT06856629|OTHER|Eccentric free-flow training|Eccentric free-flow training
219616324|NCT06688461|OTHER|Experimental group: Exercise training|HIIT program, 3 times per week for 12 weeks
219616325|NCT07018349|DRUG|2.5% Oral minoxidil|AGA patients will be randomly allocated in both groups using the envelopes method to reduce the biasness. For 3-months, patients in Group-A will get 2.5mg of minoxidil once daily, while those in Group-B will receive 1mg of minoxidil once daily orally. After starting therapy, patients will be asked to come back for evaluations 3 months later. Safety, satisfaction, and the effects of the treatment will be reported. Final outcomes will be evaluated at 3 months post treatment.
218916770|NCT06075901|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
219616326|NCT07018349|DRUG|1% Oral Minoxidil|Group-B will receive 1mg of minoxidil once daily orally
219616327|NCT07018141|OTHER|Bioactive Sealant with Etching: Participants in this group received a fluoride-releasing bioactive pit and fissure sealant (BeautiSealant, Shofu) applied after etching the tooth surface with 37% phosp|This group received BeautiSealant (a bioactive giomer-based sealant) applied after etching the enamel surface with 37% phosphoric acid for 15 seconds. The etching process creates micro-retentive patterns in the enamel to enhance micromechanical bonding, potentially improving the sealant's retention and wear resistance while also benefiting from the bioactive material's fluoride release and enamel remineralization properties.
218916771|NCT06075901|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
218916772|NCT06075901|OTHER|Training Protocol|The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
218916773|NCT04304495|OTHER|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
219041992|NCT04743661|DRUG|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
219366565|NCT06800053|BEHAVIORAL|FOCUS ON US|"This intervention will include 5 sessions cover 5 core content areas, represented by the acronym FOCUS. Family involvement (F) Outlook and meaning (O) Coping effectiveness (C) Uncertainty reduction (U) Symptom management (S) Content from every area is presented in the 3 longer in-depth sessions and reinforced in the 2 shorter check-in sessions. FOCUS encourages participants to work as a team, communicate openly, and support one another, and uses skill building (e.g., stress reduction techniques, healthy behaviors), education (e.g., symptom trajectories, information gathering), and problem-solving therapy to address here-and-now issues that impact QOL. The intervention is flexible, allowing more attention to be spent on issues relevant to particular patients/caregivers."
219616328|NCT07018141|OTHER|Bioactive Sealant without Etching: In this group, the same bioactive sealant (BeautiSealant, Shofu) was applied directly without acid etching. This simplified technique evaluates the sealant's effecti|In this group, BeautiSealant was applied directly to the tooth surface without prior etching. The goal was to simplify the procedure by eliminating the etching step, relying instead on the sealant's chemical bonding and bioactive properties (such as fluoride release and S-PRG technology) to maintain retention and resist wear, while reducing the risk of enamel alteration and improving clinical efficiency.
218916774|NCT05323474|OTHER|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
218916775|NCT05323474|OTHER|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
219530429|NCT03861845|DEVICE|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
219530430|NCT03861845|DEVICE|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
219530431|NCT03861845|BEHAVIORAL|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
219530432|NCT03861845|BEHAVIORAL|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
219530433|NCT02251886|OTHER|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
219530434|NCT02251886|OTHER|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
219530435|NCT00191204|DRUG|Duloxetine|
219366566|NCT02172651|DRUG|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
219530436|NCT06368869|OTHER|Livento press veneers luted with dual cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bifix QM dual cured cement
219530437|NCT06368869|OTHER|Livento press veneers luted with light cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bisco choice 2 light cured cement
219530438|NCT06368869|OTHER|Celtra duo veneers luted with dual cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted using Bifix QM dual cured cement
219530439|NCT06368869|OTHER|Celtra duo veneers luted with light cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted Bisco choice 2 light cured cement
219530440|NCT06558721|OTHER|Conventional rehabilitation|Lower extremity conventional rehabilitation in stroke patients
219616329|NCT07018141|OTHER|Conventional Resin-Based Sealant with Etching (Control): This group received a conventional resin-based sealant (Fisseal, Promedica) following standard acid etching. This technique represents the trad|This group served as the control and received Fisseal (a conventional resin-based sealant) applied following standard etching with 37% phosphoric acid. This method is considered the gold standard for fissure sealing, offering strong micromechanical adhesion and proven wear resistance, making it a reliable benchmark for evaluating the performance of newer bioactive materials.
219366567|NCT02172651|DRUG|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
219366568|NCT06582147|OTHER|Implementation of social determinants of health screening and referral|WE CARE is a relatively simple, low-intensity intervention that has two key components: (1) screening individuals using the WE CARE SDOH Screener for unmet social needs, and (2) providing individuals who have unmet social needs with SDOH Community Resource sheets
219530441|NCT06558721|OTHER|Mirror therapy|Mirror therapy of the lower extremity in stroke patients
219530442|NCT06558721|DEVICE|Bicycle ergometer with functional electric stimulation|Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
219530443|NCT01702987|DIETARY_SUPPLEMENT|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
219530444|NCT01702987|DIETARY_SUPPLEMENT|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
219530445|NCT01702987|DRUG|statin|statin was given for 1 month to 21 patients
219616330|NCT07017413|PROCEDURE|Transosseous Maxillary Sinus Lift using Osseodensification|A surgical procedure utilizing the Versah® osseodensification technique for transcrestal sinus floor elevation. The approach involves the use of specialized Densah® burs to prepare the osteotomy and elevate the sinus membrane through a transosseous (crestal) access, avoiding the lateral window technique. No grafting materials will be used in this procedure.
219616331|NCT07017270|DRUG|Semaglutide Pen|Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
219616332|NCT07017582|DIETARY_SUPPLEMENT|Soidum Bicarbonate|Supplementation with 0.03 g/kg of sodium bicarbonate
219616333|NCT07017582|DIETARY_SUPPLEMENT|Placebo|0.03 g·kg-1 body mass sodium chloride
219530446|NCT01691456|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
219530447|NCT00962611|DRUG|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
219530448|NCT06189833|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
219616334|NCT07017465|OTHER|Water melon (sugar baby)|Participants will consume a portion of watermelon Type A containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
219530449|NCT06189833|DRUG|Bortezomib|Bortezomib will be administered via a subcutaneous injection (SC)
219530450|NCT06189833|DRUG|Lenalidomide|Lenalidomide will be administered orally
219530451|NCT06189833|DRUG|Dexamethasone|Dexamethasone will be administered orally
219530452|NCT03247933|DEVICE|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
219530453|NCT00006051|DRUG|cisplatin|
219530454|NCT00006051|DRUG|fluorouracil|
219530455|NCT00006051|RADIATION|radiation therapy|
219616335|NCT07017465|OTHER|watermelon (Charleston gray)|Participants will consume a portion of watermelon Type B containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
219616336|NCT07017465|OTHER|watermelon (Crimson sweet)|Participants will consume a portion of watermelon Type C containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
219616337|NCT07018804|PROCEDURE|Bronchoscopic brushing|The collected samples are digested with tissue collagenase for the culture of airway basal cells (BCs).
219616338|NCT07018804|GENETIC|Single - cell cloning|After primary BCs are expanded in the P1 passage, single-cell cloning libraries are established by planting them into 384-well cell culture plates in a single-cell per well format using a flow chamber cell sorter. Ten samples are selected from the expandable clones for the identification of differentiation and proliferation capabilities, while the remaining clones are cryopreserved.
219616339|NCT07018804|GENETIC|Cell function identification|For single-cell samples of each patient, in vitro expansion culture is performed to observe the morphology of cells at each passage and calculate the clonogenic rate. Immunofluorescence technique is used to detect the expression of the cell proliferation marker Ki67, and the proliferation capacity is evaluated by combining with the CCK8 assay. Cells at passages P3-P5 are seeded on the permeable membrane of cell culture inserts at a density of \\(10\^6\\) cells/cm², and after 21 days of culture, the differentiated structures are collected. The expression of ciliated cell marker Ace-Tubulin and goblet cell marker MUC5AC is detected to assess the differentiation capacity. Meanwhile, cells are injected subcutaneously into NSG mice at \\(10\^6\\) cells/injection site for in vivo differentiation for 28 days, and the differentiated structures are collected for pathological analysis.
218916776|NCT06379529|OTHER|NuvoAir clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
218916777|NCT05734768|BEHAVIORAL|State-Trait Anxiety Inventory - Y ou STAI-Y|Questionnaire
219366569|NCT01431183|BEHAVIORAL|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
219366570|NCT00770055|OTHER|medical chart review|
219366571|NCT00770055|OTHER|questionnaire administration|
219366572|NCT00770055|OTHER|survey administration|
219366573|NCT00770055|PROCEDURE|psychosocial assessment and care|
219366574|NCT00182104|DRUG|Warfarin vs ASA|
219366575|NCT04066868|OTHER|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
219366576|NCT04066868|OTHER|CTCAE rating|CTCAE Ratings are conducted by clinicians
219366577|NCT04066868|OTHER|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
219366578|NCT03754660|DRUG|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
219366579|NCT03995719|OTHER|Preoperative education|65 patients were instructed to a preoperative stoma-education program
219366580|NCT03995719|OTHER|Postoperative education|73 patients, receiving the same information in postoperative period.
219366581|NCT02939131|BEHAVIORAL|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
219366582|NCT02939131|BEHAVIORAL|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
219366583|NCT06960746|BEHAVIORAL|lifestyle changing plus CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group (CPAP will be applied in this group that will contain 20 males, CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks plus lifestyle changes that will contain 3-session per-week 40-minute treadmill exercising and low-caloric/dietary 12-week restriction.
219366584|NCT06960746|OTHER|CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group. in this group CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks
219366585|NCT06960044|PROCEDURE|Procalcitonin-guided antibiotic management|After the randomization, PCT plasma concentration will be dosed and repeated every 24 hours and antimicrobial treatment will be withdrawn as soon as the PCT value will decrease \> 80% of peak value or will fall below 0.25 ng/mL. Patients with a normal baseline PCT value (below 0.25 ng/mL) will start the antimicrobial therapy, as clinically appropriate and PCT plasma concentration will be repeated every 24 hours, as indicated in the protocol. The antimicrobial agents will be managed according to the clinical and radiological evolution of the LRTI.
219366586|NCT06960044|PROCEDURE|Standard of care|Patients assigned to the control group will be treated according to the best standard of care and PCT will not be evaluated for the whole duration of the study.
219366587|NCT01254669|BEHAVIORAL|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
219366588|NCT01425385|OTHER|Near infrared spectroscopy monitoring|This is an observational study without interventions
219366589|NCT01425385|OTHER|Autoregulation monitoring|There are no interventions in this observational study
219366590|NCT02300493|BEHAVIORAL|Experimental|Asked to weigh themselves
219366591|NCT04024800|BIOLOGICAL|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in \> 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
219616340|NCT07018804|GENETIC|Identification of local microenvironmental changes|The air-liquid interface (ALI) differentiation culture medium is collected, and cell debris is removed by high-speed centrifugation. The supernatant is then collected to extract proteins. Target proteins are purified via immunoprecipitation or affinity chromatography, followed by desalting and concentration for mass spectrometry analysis to detect inflammatory cytokines and extracellular matrix (ECM). Real-time PCR and Western blot techniques are used to measure the expression levels of epithelial markers, mesenchymal markers, and ECM in cells across all groups, thereby evaluating changes in the local microenvironment around small airways.
219616341|NCT07018804|GENETIC|Gene editing|After plasmid construction, based on gene function, the CRISPR-Cas9-sgRNA (all-in-one) plasmid is transiently transfected into expanded single-cell strains via Nucleofection to knockout the target gene, or the CRISPR-dCas9 fusion-sgRNA plasmid is transiently transfected to activate or inhibit the target gene. After 3-5 days of culture, viable cells are sorted by FACS, and single cells are seeded into 96-well plates for two additional passages of expansion. Samples are collected for Sanger sequencing to screen successfully constructed cell lines.
219616342|NCT07018804|PROCEDURE|Prevention of ferret airway basal cell transplantation|Before surgery, basal cells (BCs) of recipient ferrets are collected by bronchoscopic brushing, followed by in vitro culture and identification. Prior to the onset of BOS, the cells are injected into recipient ferrets via bronchoscopy. Outcomes including ferret survival rate, body weight, CT imaging, and lung tissue pathology are collected to evaluate the preventive effect of BCs on BOS.
219616343|NCT07018804|PROCEDURE|Transplantation treatment of ferret airway basal cells|Stable cell lines with target gene knockdown are established in ferret basal cells (BCs). After ferrets develop bronchiolitis obliterans syndrome (BOS), the constructed cell lines are transplanted into recipient ferrets to validate the therapeutic effect of gene-corrected BCs on the disease.
219616344|NCT07017764|OTHER|Core stability exercises|Core stability exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. The program includes bed, wedge, and Swiss ball exercises. Bed exercises involve bridges, curl-ups, bird dog, and side bridges. Wedge exercises include curl-ups in various arm positions. Ball exercises involve bridges, curl-ups, bird dog, and push-ups. Each position is held for 7 seconds with 10 seconds of rest, repeated 10 times per set, for 2 sets per session with 60 seconds rest between sets.
219616345|NCT07017764|OTHER|Theraband resisted exercises|TheraBand resisted exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. Each session includes a 5-minute warm-up (stretching and joint mobilization), 30 minutes of resistance training for lower limbs (ankle, knee, hip), and a 5-minute cool-down with deep breathing and self-massage. Exercises include ankle flexion/extension, knee flexion/extension, and hip flexion/extension, abduction/adduction using elastic bands. Movements are done alternately on both sides, 10 reps each, 3 sets per session, with 1-2 min rest between sets. Yellow bands are used in weeks 1-4; green bands in weeks 5-8.
219616346|NCT07017764|OTHER|Traditional physical therapy program|All patients will receive a traditional physical therapy program consisting of ambulation training, stretching exercises for lower limb muscles, and range of motion exercises.
219616347|NCT07018557|DRUG|Eszopiclone 3 mg|Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
219616348|NCT07018557|DRUG|Placebo|Placebo pills identical to the active comparator.
219616349|NCT07018284|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling
219616350|NCT07018284|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
219616351|NCT07018284|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
219616352|NCT07018284|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability
219616353|NCT00946738|OTHER|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
219616354|NCT00946738|OTHER|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
219616355|NCT07042334|BEHAVIORAL|Serious game for transition readiness|The serious game is an interactive narrative fiction game in which players guide a character through a hospital setting, making choices that simulate real-life healthcare scenarios. The game is designed to improve skills such as communication with healthcare providers, understanding medical information, and managing appointments and medications. No drugs or medical devices are used in this intervention.
219616356|NCT02452476|DRUG|CHF5633|Rescue treatment (if needed)
219616357|NCT02452476|DRUG|Poractant alfa|Rescue treatment (if needed)
219616358|NCT02033031|DRUG|Lucentis intravitreal injection|Lucentis intravitreal injection
219366592|NCT04024800|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
219366593|NCT00450944|BIOLOGICAL|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
219366594|NCT03346174|OTHER|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
219366595|NCT03346174|OTHER|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
219366596|NCT00463476|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
218916778|NCT06094322|OTHER|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
218916779|NCT05960890|BEHAVIORAL|Remote monitoring assisted by community physicians|"Patients upload data such as wristband data, blood pressure, weight through their mobile phones, while physicians can check the data on the platform. Upon detecting alerts, community physicians review participant-related medical information, conduct structured symptom assessments via StarNet Home platform/phone within 2 hours, and initiate protocol-guided interventions (e.g., diuretic adjustment for fluid overload)."
218916780|NCT06194864|DRUG|Itraconazole|itraconazole 200 mg QD Days 6 to 16
218916781|NCT06194864|DRUG|rifampicin|rifampicin 600 mg QD Days 6 to 20
218916782|NCT06194864|DRUG|Ecopipam|89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
218916783|NCT03365414|BIOLOGICAL|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
218916784|NCT03365414|DRUG|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
218916785|NCT05520203|OTHER|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
219530456|NCT04992611|BEHAVIORAL|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
219530457|NCT04992611|BEHAVIORAL|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
219530458|NCT03235128|DIAGNOSTIC_TEST|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
219530459|NCT02086747|DRUG|Acetaminophen|100 ml iv, 4 times a day for 72 hours
219530460|NCT02086747|DRUG|Isotonic|100 ml iv, 4 times a day for 72 hours
219530461|NCT02895373|DRUG|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
219530462|NCT02895373|DRUG|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
219616359|NCT02033031|DRUG|Avastin intravitreal injection|Avastin intravitreal injection
219616360|NCT04874831|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
219616361|NCT02068612|BEHAVIORAL|Moderate Intensity Continuous Training+Interval Training|
219616362|NCT02068612|BEHAVIORAL|Low Intensity Continuous Training|
219616363|NCT04052620|DRUG|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
219616364|NCT04052620|DRUG|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
219616365|NCT04052620|OTHER|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
218916786|NCT00074165|DRUG|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
218916787|NCT00074165|DRUG|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
218916788|NCT00074165|DRUG|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
219530463|NCT06215976|DRUG|Metformin Hydrochloride 500 MG|Metformin 500mg tablets twice daily
218916789|NCT00074165|DRUG|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
218916790|NCT00074165|DRUG|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
218916791|NCT00074165|DRUG|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
218916792|NCT00074165|DRUG|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
218916793|NCT00074165|DRUG|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
218916794|NCT00074165|DRUG|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
219530464|NCT05350891|PROCEDURE|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
219530465|NCT00004694|DRUG|heparin|
219530466|NCT02527382|PROCEDURE|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
219530467|NCT06278844|DEVICE|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.
218916795|NCT05855798|DRUG|Bupivacain|Bupivacaine is a local anesthetic agent commonly used in ESP block.
218916796|NCT05855798|DRUG|Magnesium sulfate|Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
218916797|NCT05855798|DRUG|Ketamine Hydrochloride|Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
219616366|NCT03552380|DRUG|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
219530468|NCT06278844|DEVICE|Right ventricular apical pacing|This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
219530469|NCT02004535|PROCEDURE|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
219616367|NCT03552380|DRUG|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
219616368|NCT03552380|DRUG|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
219616369|NCT01801904|DRUG|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
219616370|NCT02201784|DRUG|Levobupivacaine|Comparison of Equipotent doses
219616371|NCT02201784|DRUG|Ropivacaine|Comparison of equipotent doses
219616372|NCT00168779|DRUG|telmisartan 80 mg / hydrochlorothiazide 25 mg|
219616373|NCT00168779|DRUG|valsartan 160 mg / hydrochlorothiazide 25 mg|
218916798|NCT04080661|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
218916799|NCT04080661|OTHER|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
219204640|NCT06798155|OTHER|Standardized Music Listening Therapy|"Type of Intervention: Pre- and postoperative listening to standardized music sequences designed specifically for relaxation and pain management.~Delivery Method: Sessions are conducted via the Music Care® application, using a tablet and headphones provided during hospitalization. Participants select their preferred music style, tempo, and tracks to tailor the experience to their preferences.~Duration and Schedule:~Pre-surgery: One 20-minute session in a dedicated room before entering the operating theater.~Post-surgery: Daily 20-minute sessions at home for 28 days post-surgery using participants' own devices (smartphone, tablet, or computer).~Purpose: To evaluate the effect of music on reducing postoperative pain, minimizing analgesic use, and improving the quality of life.~Distinctiveness: This intervention uniquely integrates patient-controlled music preferences with a structured listening regimen before and after surgery, offering a personalized approach to enhancing recovery outcom"
219616374|NCT00168779|DRUG|placebo|
219616375|NCT02494661|BEHAVIORAL|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
219616376|NCT02494661|BEHAVIORAL|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
219530470|NCT02307981|OTHER|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
219530471|NCT02350621|PROCEDURE|ACDF|
219530472|NCT02350621|PROCEDURE|minimal invasive Posterior Cervical Foraminotomy|
219530473|NCT02017223|DEVICE|Knowme Device Wear|
219530474|NCT06022237|DRUG|Ibandronate|Ibandronate 150 mg once monthly.
219530475|NCT06022237|DRUG|Calcium|Calcium 500 mg twice daily
219530476|NCT06022237|DRUG|Vitamin D3|Vitamin D3 - 1000 IU daily
219530477|NCT00717405|DRUG|Standard chemotherapy|As prescribed
219616377|NCT03161977|OTHER|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
219616378|NCT02841982|PROCEDURE|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
219616379|NCT02841982|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
219616380|NCT02841982|DEVICE|PAJUNK StimuLong|
219616381|NCT02841982|DRUG|single dose ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified."
219616382|NCT02841982|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
219616383|NCT01231776|OTHER|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
218916800|NCT03136744|BEHAVIORAL|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
218916801|NCT00660725|DRUG|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
218916802|NCT00660725|DRUG|Gemcitabine|30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.
218916803|NCT00660725|DRUG|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
219204641|NCT05556967|DRUG|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
219530478|NCT00717405|DRUG|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
219530479|NCT00717405|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
219530480|NCT02443220|DEVICE|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
219530481|NCT02443220|DEVICE|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
219530482|NCT02443220|DEVICE|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
219530483|NCT04123769|DRUG|Hydronidone|First take Hydronidone capsule, single-dose and then Multiple-dose
219530484|NCT03816072|DRUG|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
219530485|NCT03816072|OTHER|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).
219530486|NCT03816072|DRUG|Propofol|Propofol
219530487|NCT03816072|DRUG|Sevoflurane|Sevoflurane
219530488|NCT02209194|DEVICE|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
219530489|NCT04263649|DEVICE|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
219530490|NCT04035395|OTHER|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
219616384|NCT04200027|PROCEDURE|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
219616385|NCT00150280|DRUG|celecoxib and ibuprofen SR|
219616386|NCT00059592|DRUG|Valacyclovir|
219616387|NCT03078686|PROCEDURE|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
219616388|NCT03078686|PROCEDURE|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
219616389|NCT03078686|PROCEDURE|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
219616390|NCT03078686|PROCEDURE|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
219616391|NCT03078686|PROCEDURE|cSVF in Normal Saline IV|cSVF + NS for IV Placement
219530491|NCT04035395|OTHER|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
219616392|NCT03442439|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
219530492|NCT04035395|OTHER|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
219530493|NCT04035395|OTHER|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
219530494|NCT04035395|OTHER|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
219530495|NCT01982318|DRUG|VitroGro® ECM|
219530496|NCT01982318|DRUG|Dulbecco's Phosphate Buffered Saline|
219530497|NCT04671368|DIAGNOSTIC_TEST|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
219530498|NCT04671368|DIAGNOSTIC_TEST|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
219530499|NCT04671368|DIAGNOSTIC_TEST|Gold Standard|Firstly, the two expert pathologist(\>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(\>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
219530500|NCT01534520|DRUG|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
219530501|NCT01534520|DRUG|Placebo|KY Jelly
219530502|NCT05288881|BIOLOGICAL|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
219530503|NCT05288881|DRUG|Placebo|Participants will receive matching placebo administered by IV infusion.
219530504|NCT03834376|DRUG|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.
219530505|NCT00233415|DEVICE|Stereotactic Radiosurgery (Cyberknife)|
219530506|NCT00397787|DRUG|sunitinib malate|Given PO
219530507|NCT01783561|DRUG|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
219530508|NCT03553979|BEHAVIORAL|Stress management program (SM)|Participants follow the SM program.
219616393|NCT03442439|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
219530509|NCT03553979|BEHAVIORAL|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
219530510|NCT05169710|DRUG|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
219530511|NCT05169710|DRUG|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
219530512|NCT05169710|DRUG|Placebo|Placebo tablet (supplied in two tablets)
219616394|NCT00165763|DRUG|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
219616395|NCT05668702|OTHER|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
219204642|NCT00324415|BIOLOGICAL|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
219204643|NCT00324415|DRUG|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
219530513|NCT04660864|DEVICE|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
219616396|NCT01729949|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry and Blackcurrent extract
219616397|NCT01729949|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|without active components
219616398|NCT02431364|DRUG|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
219530514|NCT05043103|COMBINATION_PRODUCT|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
219530515|NCT00910052|DEVICE|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
219204644|NCT00324415|DRUG|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
219530516|NCT06421337|DEVICE|BraiN20(R)|"SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove."
219530517|NCT02828033|DRUG|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
219530518|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
219530519|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
219530520|NCT02729714|DRUG|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
219530521|NCT02729714|DRUG|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
219530522|NCT01633450|OTHER|Zinc biofortified rice|1.12 mg zinc per meal
219530523|NCT01633450|OTHER|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
218916804|NCT06072794|DRUG|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
219530524|NCT06350955|DRUG|Iron isomaltoside|single dose of 500 mg iron isomaltoside
219530525|NCT06350955|DRUG|Iron Carboxymaltose|single dose of 500 mg ferric carboxymaltose
219616399|NCT02431364|OTHER|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
219616400|NCT02715011|DRUG|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
219616401|NCT00916383|DRUG|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
219616402|NCT00916383|DRUG|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
219616403|NCT03878927|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
219616404|NCT03878927|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
219616405|NCT00258960|DRUG|Liposomal Doxorubicin|
219616406|NCT00258960|DRUG|Cyclophosphamide|
219616407|NCT00258960|DRUG|Trastuzumab|
219616408|NCT06551480|DEVICE|Biometry|Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
218916805|NCT06416566|DRUG|Subcutaneous Enoxaparin|Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
218916806|NCT03279081|DRUG|Cx601|Cx601 eASCs intralesional injection.
218916807|NCT03279081|OTHER|Placebo|Cx601 placebo-matching eASCs intralesional injection.
218916808|NCT04771455|BEHAVIORAL|Behavioral weight loss|Participants will receive behavioral weight loss intervention
218916809|NCT04771455|BEHAVIORAL|Intervention component: Decrease overvaluation of weight and shape|Participants will receive an intervention component to decrease overvaluation of weight and shape
218916810|NCT04771455|BEHAVIORAL|Intervention component: Decrease unhealthy weight control practices|Participants will receive an intervention component to decrease unhealthy weight control practices
218916811|NCT04771455|BEHAVIORAL|Intervention component: Decrease negative affect|Participants will receive an intervention component to decrease negative affect
218916812|NCT02575534|DRUG|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
219041993|NCT04743661|DRUG|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
219366597|NCT01061931|PROCEDURE|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
219366598|NCT00739284|DEVICE|nephrostomy tube and ureteral stent|
219616409|NCT05066880|OTHER|Exercise training|Exercise training for 8 weeks
219616410|NCT03561129|OTHER|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
219616411|NCT03419689|PROCEDURE|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
219616412|NCT03419689|PROCEDURE|Blood sample collection|"Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression"
219616413|NCT03419689|PROCEDURE|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
219616414|NCT03419689|PROCEDURE|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
219616415|NCT03355612|DRUG|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
219616416|NCT03355612|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
219616417|NCT04771559|OTHER|COVID-19 antibody test|5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
219616418|NCT04778475|OTHER|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
219616419|NCT04778475|OTHER|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
219041994|NCT04743661|DRUG|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
219616420|NCT01112059|DRUG|Doxycycline|100 mg twice a day for 8 days
219616421|NCT01112059|OTHER|placebo|placebo
219616422|NCT04132687|PROCEDURE|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
219616423|NCT03636178|PROCEDURE|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
219616424|NCT03636178|PROCEDURE|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
219616425|NCT01444261|DIETARY_SUPPLEMENT|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
219616426|NCT01444261|OTHER|control|No dietary supplements
219616427|NCT01922505|DRUG|PPI triple therapy|
219616428|NCT05462197|BEHAVIORAL|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
219616429|NCT03774355|DRUG|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
219616430|NCT03774355|DRUG|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
219041995|NCT04743661|DRUG|Antipyretic|An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
219366599|NCT00635973|DRUG|Gefitinib (Iressa)|Iressa
219366600|NCT05427578|OTHER|fNIRS measurement|measurement using functional near-infrared spectroscopy
219366601|NCT01690845|DEVICE|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
219366602|NCT03990870|OTHER|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
219366603|NCT03990870|OTHER|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
219366604|NCT05395221|OTHER|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
219366605|NCT04351802|DIAGNOSTIC_TEST|Lung ultrasound|Focused lung ultrasound examination
219366606|NCT01214486|DRUG|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
219366607|NCT01989221|DRUG|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
219530526|NCT03023150|OTHER|Ischemic Preconditioning|
219530527|NCT03023150|OTHER|Sham|
219530528|NCT00199277|DRUG|i.v. iron sucrose|
219530529|NCT00199277|DRUG|Oral iron|
219530530|NCT03853954|DEVICE|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
219530531|NCT00892892|DRUG|Rilmenidine|1 mg Rilmenidine per day versus
219530532|NCT00892892|DRUG|Nitrendipine|20 mg Nitrendipine per day
219530533|NCT00693628|DEVICE|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
219530534|NCT03579095|DIETARY_SUPPLEMENT|Cereboost|200mg Cereboost and Maltodextrin capsules
219616431|NCT04115215|BEHAVIORAL|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
219616432|NCT04115215|DEVICE|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
218916813|NCT04895839|BEHAVIORAL|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
218916814|NCT03664297|DRUG|SHR1459|SHR1459 will be administered continually till disease progression or unacceptable toxicity.
218916815|NCT00000211|DRUG|Buprenorphine|
218916816|NCT00500123|PROCEDURE|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
218916817|NCT02943174|BEHAVIORAL|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
218916818|NCT02943174|OTHER|Treatment as Usual (TAU)|Standard personalized treatment of cancer
218916819|NCT02916212|OTHER|Optimized alarm profiles|
219041996|NCT04743661|DRUG|Antihistamine|An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
219041997|NCT04743661|DRUG|anti-emetics|An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
219041998|NCT03395769|BIOLOGICAL|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
219041999|NCT04036500|DRUG|Estradiol|Patients will be given estradiol: 1 mg oral and 1 mg sublingual.
219042000|NCT02283788|DRUG|BIA 2-093|
219042001|NCT02283788|DRUG|Moxifloxacin|
219042002|NCT02283788|DRUG|Placebo|
219530535|NCT03579095|DIETARY_SUPPLEMENT|Placebo|200mg Maltodextrin capsules
219530536|NCT05451069|DIAGNOSTIC_TEST|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
219530537|NCT03347435|GENETIC|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
219530538|NCT03347435|OTHER|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
219530539|NCT03180606|OTHER|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
219530540|NCT04504526|DRUG|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
219530541|NCT03396523|DRUG|Losartan|administration of losartan (50 mg) (oral)
219530542|NCT03396523|DRUG|Placebo Oral Tablet|administration of placebo (oral)
219530543|NCT06327191|OTHER|No intervention as the study is observational.|No intervention as the study is observational.
219530544|NCT02092805|PROCEDURE|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
219530545|NCT02092805|PROCEDURE|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
219530546|NCT04192006|DEVICE|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
219530547|NCT01686438|BEHAVIORAL|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
219530548|NCT02192047|OTHER|Palm Olein|8 weeks
219530549|NCT02192047|OTHER|IE Palm olein|8 weeks
219530550|NCT02192047|OTHER|IE soybean oil-based|8 weeks
219530551|NCT05841225|BEHAVIORAL|Food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
219530552|NCT05841225|BEHAVIORAL|Non-food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
219530553|NCT02816905|DRUG|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
219530554|NCT02816905|DRUG|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
219530555|NCT02816905|DRUG|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
219530556|NCT01759940|DRUG|ropivacaine 0,375%|
219530557|NCT01759940|DRUG|ropivacaine 0,75%|
219042003|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219042004|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219530558|NCT04561622|BEHAVIORAL|Emotional Stroop Task|"Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too."
219530559|NCT03815669|PROCEDURE|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
219530560|NCT02967159|DRUG|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
219530561|NCT02967159|DRUG|AZD7594|Treatment B: AZD7594 440 μg via DPI
219530562|NCT02967159|DRUG|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
219530563|NCT02967159|DRUG|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
219530564|NCT06078072|PROCEDURE|Biomaterials augmented with mesenchymal stem/stromal cells|Combined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate)
219530565|NCT01938066|DEVICE|Procellera|bioelectric wound dressing
219530566|NCT01938066|DEVICE|negative pressure therapy|
219530567|NCT02321566|DEVICE|Epidural Motor Cortex Stimulation|
219616433|NCT04115215|OTHER|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
219616434|NCT02039193|BEHAVIORAL|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
219616435|NCT06328933|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
218916820|NCT02227914|DRUG|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
218916821|NCT02227914|DRUG|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
218916822|NCT03526133|DIAGNOSTIC_TEST|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
218916823|NCT05544162|DIETARY_SUPPLEMENT|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
218916824|NCT03210948|DEVICE|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
218916825|NCT03210948|DEVICE|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
218916826|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
218916827|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
218916828|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
218916829|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
219530568|NCT04228744|DEVICE|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
219616436|NCT06328933|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219616437|NCT06328933|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219616438|NCT06460805|DIETARY_SUPPLEMENT|Partial enteral nutrition|70% caloric intake from enteral nutrition formula and 30% caloric intake from a limited range of solid foods
219616439|NCT05919277|DIAGNOSTIC_TEST|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
219616440|NCT03700762|DIAGNOSTIC_TEST|ultrasound gray-scale ratio|RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
219616441|NCT03716362|DEVICE|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
218916830|NCT03118310|BEHAVIORAL|5:2 diet|Dietary intervention according to 5:2 diet during three months.
218916831|NCT03118310|BEHAVIORAL|LCHF|Dietary intervention according to LCHF diet during three months.
218916832|NCT03118310|BEHAVIORAL|Placebo diet|Placebo diet: normal dietary advice
219204645|NCT00324415|RADIATION|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
219204646|NCT06207253|DRUG|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
219616442|NCT05988580|OTHER|Pasta dish with resistant starch|Pasta dish with 20-22% of resistant starch
218916833|NCT02473081|BEHAVIORAL|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
218916834|NCT02473081|OTHER|Usual care|Usual care was given by their family physicians.
218916835|NCT01338441|DRUG|Erythromycin|4mg/Kg, IV during 20 min once
218916836|NCT01338441|DRUG|Placebo|4mg/Kg, IV during 20 min once
218916837|NCT04090918|DIAGNOSTIC_TEST|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
218916838|NCT05620667|DIETARY_SUPPLEMENT|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
218916839|NCT05620667|DIETARY_SUPPLEMENT|placebo|Drink 25mL for once, and once a day.
218916840|NCT05620667|BEHAVIORAL|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
218916841|NCT04160117|DRUG|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
218916842|NCT04160117|DRUG|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
219616443|NCT05988580|OTHER|Original version of pasta dish|Original pasta dish, not reinforced with resistant starch
219616444|NCT00026065|BEHAVIORAL|Biofeedback|
219616445|NCT02214992|DRUG|Telmisartan/Ramipril|Fixed dose combination tablet
219616446|NCT02214992|DRUG|Telmisartan|
219616447|NCT02214992|DRUG|Ramipril capsule|
219616448|NCT02214992|DRUG|Ramipril tablet|
219616449|NCT00556244|PROCEDURE|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
218916843|NCT03743272|DEVICE|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
218916844|NCT01650506|DRUG|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
218916845|NCT01650506|DRUG|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
218916846|NCT05246046|DRUG|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
218916847|NCT05320952|DEVICE|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
219616450|NCT02371434|BIOLOGICAL|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
219616451|NCT05387187|DRUG|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
219616452|NCT05387187|DRUG|Pentoxifylline|Pentoxifylline 100mg TID
219616453|NCT00033397|PROCEDURE|biopsy|
218916848|NCT04990024|OTHER|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
218916849|NCT04990024|OTHER|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to \<130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
218916850|NCT04837443|BEHAVIORAL|Rubber hand illusion|Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
218916851|NCT00329043|DRUG|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
218916852|NCT00329043|DRUG|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
218916853|NCT00329043|PROCEDURE|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
218916854|NCT01766440|DRUG|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
218916855|NCT01345240|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
218916856|NCT01345240|BIOLOGICAL|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
218916857|NCT01345240|BIOLOGICAL|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
218916858|NCT01345240|BIOLOGICAL|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
218916859|NCT01345240|BIOLOGICAL|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
218916860|NCT01345240|BIOLOGICAL|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
219616454|NCT00033397|PROCEDURE|magnetic resonance imaging|
219616455|NCT00033397|PROCEDURE|radiomammography|
219616456|NCT00033397|PROCEDURE|ultrasound imaging|
219616457|NCT00033397|RADIATION|gadopentetate dimeglumine|
219616458|NCT00033397|DRUG|chemotherapy|
219616459|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
219616460|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
219616461|NCT05582798|DRUG|Sodium chloride|Sodium chloride 09.% intravenous infusion
219616462|NCT03075020|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
219616463|NCT03075020|OTHER|AIR|Room air will be administered as placebo
219616464|NCT05579457|OTHER|Short Physical Performance Battery|The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
219530569|NCT03295474|OTHER|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
218916861|NCT01345240|BIOLOGICAL|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
218916862|NCT01345240|BIOLOGICAL|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
219042005|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219042006|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219042007|NCT05543928|DRUG|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
219530570|NCT04025450|DRUG|Chidamide+VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
219530571|NCT04025450|DRUG|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
219530572|NCT04018339|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
219530573|NCT04018339|DRUG|Placebo|Capsules containing an inert placebo
219530574|NCT02848924|OTHER|No intervention|
219530575|NCT05228626|DRUG|COVIDEX|COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
219616465|NCT01907230|DRUG|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
219616466|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
219042008|NCT05543928|DRUG|Placebo|Placebo
219042009|NCT05143970|DRUG|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
219042010|NCT06003556|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
219042011|NCT02401568|DEVICE|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
219042012|NCT02401568|PROCEDURE|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
219042013|NCT04400279|BEHAVIORAL|Yoga group|At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
219042014|NCT04400279|BEHAVIORAL|High Intensity Interval Training group|At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
219042015|NCT04400279|BEHAVIORAL|Combination|At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
219042016|NCT00204620|DRUG|Bendamustin|
219042017|NCT00869739|BEHAVIORAL|telephone-based intervention|
219204647|NCT06207253|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
219616467|NCT01508884|DRUG|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
219616468|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
218916863|NCT04554784|OTHER|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
219042018|NCT00869739|OTHER|educational intervention|
219204648|NCT04611880|DRUG|Crizanlizumab|Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
219204649|NCT05621954|PROCEDURE|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
219616469|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
218916864|NCT04554784|PROCEDURE|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
218916865|NCT04298697|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
218916866|NCT03594513|PROCEDURE|MCAF|Periodontal surgical technique to treat gingival recessions.
218916867|NCT03594513|PROCEDURE|PR|Restorative procedure to treat tooth structure loss.
218916868|NCT03594513|PROCEDURE|CTG|Autogenous graft harvested from palate placed in the surgical site.
219042019|NCT00869739|OTHER|partner-assisted coping skills training|
219042020|NCT00869739|OTHER|questionnaire administration|
219042021|NCT00869739|PROCEDURE|psychosocial assessment and care|
219042022|NCT00869739|PROCEDURE|quality-of-life assessment|
219042023|NCT03871127|PROCEDURE|Percutaneous coronary intervention|Using sirolimus eluting stent
219530576|NCT02731534|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
219530577|NCT02731534|DRUG|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
219530578|NCT01229618|DRUG|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
219530579|NCT03698981|BEHAVIORAL|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
219530580|NCT05596279|DIAGNOSTIC_TEST|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
219530581|NCT05596279|DIAGNOSTIC_TEST|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
219530582|NCT01565876|DEVICE|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
219530583|NCT02130856|DEVICE|Neonatal kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
219530584|NCT02601560|BIOLOGICAL|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
219530585|NCT02601560|BIOLOGICAL|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
219530586|NCT02601560|BIOLOGICAL|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
219530587|NCT03459807|DRUG|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
219530588|NCT03459807|PROCEDURE|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
219530589|NCT02109250|DRUG|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
219530590|NCT04728763|OTHER|Protein profile|Analysis of the protein content by proteomics of bronchoalveolar lavage
219530591|NCT01044485|DRUG|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
219530592|NCT01044485|DRUG|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
219042024|NCT03871127|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
219204650|NCT04772911|DEVICE|Optical Coherence Tomography (OCT)|OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
219204651|NCT04601051|BIOLOGICAL|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
219530593|NCT02002754|DRUG|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
219042025|NCT03422393|DRUG|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
219204652|NCT06807697|RADIATION|Curative radiotherapy for Head and Neck Cancers|Radiotherapy is a localized, non-invasive, painless therapy, mostly performed on an outpatient basis, capable of causing necrosis or the death of tumor cells through the use of high-energy radiation called ionizing radiation.
218916869|NCT03594513|PROCEDURE|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
219530594|NCT00275600|DRUG|Vitamin E, Evening Oil of Primrose, and Placebo|
219530595|NCT02745951|OTHER|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
219530596|NCT02745951|OTHER|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
219530597|NCT00083785|DRUG|Talaporfin sodium (LS11)|
219530598|NCT00083785|DEVICE|LED-based light infusion device|
219530599|NCT00083785|DEVICE|Light emitting diodes (LED)|
219530600|NCT00083785|PROCEDURE|Photodynamic therapy|
219530601|NCT00083785|PROCEDURE|Phototherapy|
219616470|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
218916870|NCT03594513|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
218916871|NCT03594513|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
218916872|NCT00449696|DEVICE|Gel-200|Single intra-articular injection
218916873|NCT00449696|DEVICE|Placebo|Single intra-articular injection
218916874|NCT00641771|DRUG|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
218916875|NCT00641771|DRUG|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
218916876|NCT02236286|BEHAVIORAL|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
218916877|NCT00057200|PROCEDURE|Telephone, videophone care|
218916878|NCT05711810|DRUG|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
218916879|NCT05711810|DIAGNOSTIC_TEST|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
218916880|NCT05711810|BEHAVIORAL|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
218916881|NCT05711810|DRUG|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
219530602|NCT00083785|PROCEDURE|Chemotherapy|
219530603|NCT04486196|DEVICE|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
219616471|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
219616472|NCT04877847|DEVICE|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
218916882|NCT05711810|DRUG|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
218916883|NCT05711810|DRUG|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
218916884|NCT05711810|DIETARY_SUPPLEMENT|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
218916885|NCT05711810|DIETARY_SUPPLEMENT|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
218916886|NCT05711810|DIETARY_SUPPLEMENT|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
219530604|NCT04486196|PROCEDURE|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
219530605|NCT00379600|DRUG|rosiglitazone XR|
219530606|NCT06082258|OTHER|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
219530607|NCT06082258|OTHER|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
219530608|NCT01406795|DEVICE|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
219530609|NCT00821834|DRUG|clopidogrel (SR25990)|"Form: tablets~Route: oral"
219616473|NCT04877847|DEVICE|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
219616474|NCT04166201|PROCEDURE|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
219616475|NCT01254773|DRUG|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
219616476|NCT03247569|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
219616477|NCT05961696|DRUG|Mosunetuzumab|Subcutaneous (SQ or Sub-Q) injection under the skin
219616478|NCT02654054|DRUG|Elagolix|Film-coated tablets
219616479|NCT02654054|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
218916887|NCT05711810|DRUG|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
218916888|NCT05711810|DRUG|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
218916889|NCT06360380|DEVICE|AquaPass System|a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
218916890|NCT01392144|PROCEDURE|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
218916891|NCT01392144|BEHAVIORAL|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
218916892|NCT01808755|DIETARY_SUPPLEMENT|D Mannose|1 gr. every 8 hours
218916893|NCT01808755|DRUG|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
219204653|NCT06333938|OTHER|Nonpharmacologic Treatment|At least one three nonpharmacologic treatments (Music Medicine, Aromatherapy, Battlefield Acupuncture) will be delivered. Music Medicine is the delivery of personal music players to listen to patient-preferred music before, during, or after surgical or non-surgical procedures. Aromatherapy is the delivery of personally-preferred AromaTabs before, during, or after surgical or non-surgical procedures. Battlefield Acupuncture is the delivery of Auricular Acutherapy by trained providers using acupuncture needles or acupressure beads before, during, or after surgical or non-surgical procedures.
219530610|NCT00821834|DRUG|ticlopidine|"Form: tablets~Route: oral"
219530611|NCT00821834|DRUG|Placebo|"Form: tablets~Route: oral"
219530612|NCT03119935|DEVICE|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
219530613|NCT03119935|DEVICE|Ambu bag|Participants ventilated the simulated patients by ambu bag
219530614|NCT00000804|DRUG|Indinavir sulfate|
219530615|NCT05124574|OTHER|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"* nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~* Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~* Sampling of amniotic fluid in case of cesarean section~* Sampling of the placenta for histological and virological study."
219530616|NCT05124574|OTHER|Samples concern newborns of SARS-COV-2 + mothers at birth|"* In the birth room:~  * Collection of gastric fluid (PCR SARS-COV-2),~ * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~* In the newborn at D3 of life:~  \- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~* In symptomatic newborns:~  * 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~ * nasopharyngeal PCR,"
219530617|NCT00683202|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
219530618|NCT00683202|DRUG|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
219530619|NCT05978479|OTHER|Teach-Back Method|No intervention will be given to the patients in the control group.
219530620|NCT00950625|DRUG|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
219530621|NCT00950625|DRUG|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
218916894|NCT02673372|DRUG|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
218916895|NCT02673372|DRUG|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
218916896|NCT04638088|OTHER|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
218916897|NCT02543684|OTHER|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
219530622|NCT05094713|OTHER|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
218916898|NCT02543684|OTHER|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
219530623|NCT05094713|OTHER|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
219530624|NCT03902028|OTHER|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
218916899|NCT02543684|OTHER|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
218916900|NCT02543684|OTHER|oral glucose load|glucose load providing 50g of carbohydrates
219204654|NCT06333938|OTHER|Standard Care|Patients will receive standard clinical care without the addition of Music Medicine, Aromatherapy, or Battlefield Acupuncture
219530625|NCT05480657|BIOLOGICAL|AT-1501 IV Infusion|Investigational study drug
219530626|NCT05480657|BIOLOGICAL|Isolated cadaveric islet cells|Infusion of human cadaveric islet cells into the portal vein
219530627|NCT02563808|OTHER|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
219530628|NCT02563808|OTHER|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
219530629|NCT01475396|BEHAVIORAL|exercise|
218916901|NCT03166917|PROCEDURE|3D printing implant|3D printing implants in bone defect
218916902|NCT03166917|PROCEDURE|autogenous bone grafting|3D printing implants in bone defect
218916903|NCT00774046|DRUG|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
218916904|NCT00774046|DRUG|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
218916905|NCT00774046|DRUG|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
218916906|NCT00812994|DRUG|Escitalopram|SSRI antidepressant
218916907|NCT00812994|DRUG|Placebo|
218916908|NCT05722925|DRUG|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
218916909|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
218916910|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
218916911|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
219530630|NCT05526118|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
219530631|NCT05829122|PROCEDURE|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
219530632|NCT02745925|DRUG|Ibuprofen|
219530633|NCT00855738|DRUG|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"* Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d"
219530634|NCT03971825|DRUG|CC-92252|CC-92252
219530635|NCT03971825|OTHER|Placebo|Placebo
219530636|NCT00993252|PROCEDURE|CT Scan|CT scan
219530637|NCT02751398|DRUG|Dapagliflozin 10mg|
219530638|NCT02751398|DRUG|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
219530639|NCT06320977|OTHER|Static Stretching|"The static stretching protocol will include the following muscle groups of the dominant lower limb:~* Gastrocnemius - Participants will assume a bipedal position facing a wall. Then, the leg that is not being stretched will be placed forward, with the knee in semi-flexion, and the leg that is being stretched, behind, with the knee in full extension. Instructions will be given in order to keep the calcaneus on the floor;~* Tibialis anterior - Participants will be facing a wall, with the entire foot in touch with the ground and toes pointing forward. Then, they will secure themselves to a handrail and project the hips back.~These stretchings will be held in a position where the participants refer discomfort, and will be maintained for 30 seconds or 90 seconds according to the condition."
219530640|NCT01205295|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
219530641|NCT03904303|DRUG|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
219530642|NCT02329678|PROCEDURE|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
219530643|NCT00761020|DRUG|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
219530644|NCT00761020|OTHER|Control|No Intervention
219530645|NCT02218905|BEHAVIORAL|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
219530646|NCT02281305|DRUG|Colchicine|
219530647|NCT02023853|PROCEDURE|ultrasonic|
219530648|NCT02023853|PROCEDURE|erythritol|
218916912|NCT04768738|DIAGNOSTIC_TEST|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
218916913|NCT01054014|DRUG|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
219530649|NCT02023853|DRUG|metronidazole gel|
219530650|NCT03286465|DEVICE|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
219530651|NCT03286465|DEVICE|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
219530652|NCT04470557|DIAGNOSTIC_TEST|D-dimer,CBC.ESR,CRP,|Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.
219616480|NCT02654054|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
219616481|NCT02654054|DRUG|Placebo for Elagolix|Film-coated placebo tablets
219616482|NCT07097155|OTHER|Daily Avocado Consumption|Participants follow their usual diet and consume one avocado per day for 4 months
218916914|NCT01054014|DRUG|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
218916915|NCT01054014|DRUG|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
219530653|NCT04470557|DIAGNOSTIC_TEST|Liver function tests ,serum ferritin and PCR for COVID-19 .|"Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),"
219530654|NCT05833594|DIETARY_SUPPLEMENT|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs|The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
219530655|NCT04302662|DRUG|MS1819-SD|Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
219530656|NCT00000171|DRUG|Melatonin|
219530657|NCT02146495|DEVICE|Simultaneous EEG and fMRI recordings|
219530658|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial|Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology
219530659|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial|Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.
219530660|NCT00584922|PROCEDURE|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
219530661|NCT05285020|OTHER|Alter G|"It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions)."
219530662|NCT05285020|OTHER|Parallel bars and Scale|It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
219616483|NCT07090317|DRUG|Iparomlimab and Tuvonralimab|The administration regimen of Iparomlimab and Tuvonralimab is: the recommended dose of Iparomlimab and Tuvonralimab is 5mg/kg, intravenous infusion, with a treatment cycle of 21 days. The subjects will continue to receive treatment with Iparomlimab and Tuvonralimab until the termination criteria are met.
219616484|NCT07094503|BEHAVIORAL|Wysa Digital Chatbot Program|Wysa is a digital rules-based chatbot program platform offering cognitive-behavioral therapy-based guided self-help modules, including five modules for eating and body image developed by our team. Participants in this arm will engage with the digital chatbot program daily for three months to complete all five modules.
219530663|NCT05285020|OTHER|Standard rehabilitation protocol|It is the hospital's standard protocol for that injuries once a day for two weeks.
219530664|NCT05277753|BIOLOGICAL|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
219530665|NCT02563197|DEVICE|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
219530666|NCT01295853|PROCEDURE|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
219530667|NCT01295853|PROCEDURE|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
219616485|NCT07097480|PROCEDURE|Blood samples collection|Blood samples of 40 ml will be taken.
219616486|NCT07097480|PROCEDURE|Saliva samples collection|Saliva samples will be collected
219616487|NCT07097610|OTHER|Mosaic Puzzle Intervention|This study aims to investigate the effect of mosaic puzzle application on nomophobia in adolescents. The data for the study will be collected over a 5-week period. The experimental group children will be asked to play mosaic puzzle games for 1 hour, 2 days a week for 5 weeks at a time deemed appropriate by the school under the supervision of the researcher. The control group children will not be given any application; they will only be observed, and a final test will be administered at the end of the 5 weeks. The study is planned as a single-center study, and a total of 30 children aged 12-14 with a nomophobia scale score of 60 or higher who meet the inclusion criteria will be included in the study.
219616488|NCT07095322|BEHAVIORAL|Strength Education Session|Strength education session given at the first 4 weeks of intervention to educate women on muscle-strengthening exercises
218916916|NCT03889223|PROCEDURE|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
218916917|NCT02474316|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
218916918|NCT02474316|DRUG|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
219366608|NCT05996796|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
219366609|NCT05996796|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
219616489|NCT07095322|BEHAVIORAL|Gym Membership|12 weeks gym membership to allow participant to go to the gym on their own
218916919|NCT03715556|DRUG|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
218916920|NCT03715556|DRUG|0.9% physiological solution|Administration of 0.9% physiological solution.
218916921|NCT03773640|DEVICE|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
218916922|NCT03773640|DRUG|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
218916923|NCT00647764|DRUG|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
218916924|NCT00593346|RADIATION|brachytherapy|brachytherapy (radioactive implants)
218916925|NCT05672758|BEHAVIORAL|Sprint training|One-year cycle including specific sprint-oriented athletic training
218916926|NCT05672758|BEHAVIORAL|Endurance training|One-year cycle including specific endurance-oriented athletic training
218916927|NCT05672758|BEHAVIORAL|Recreational Training|One year of nonspecific recreational training
219530668|NCT03607032|DEVICE|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
219530669|NCT03607032|OTHER|usual treatment|medical aerosol session followed by aspiration or not, as required
219530670|NCT04836078|PROCEDURE|open flap subgingival debridement|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
219530671|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly
219530672|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly
219530673|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (III); injected subgingivally with placebo chitosan 2% gel weekly
219530674|NCT00359489|DEVICE|cardiac echosonography|
219530675|NCT03500692|DEVICE|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
218916928|NCT04069234|DRUG|Ticagrelor|ticagrelor 60 mg BID for 30 days
218916929|NCT04069234|DRUG|Clopidogrel|clopidogrel 75mg OD for 30 Days
218916930|NCT01282034|PROCEDURE|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
218916931|NCT01282034|DEVICE|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
218916932|NCT02731469|BIOLOGICAL|BCD-131|
219530676|NCT04714268|PROCEDURE|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
219530677|NCT02822248|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-64-R84-070)
219530678|NCT02162069|DEVICE|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
219530679|NCT01376102|DRUG|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219530680|NCT04791670|OTHER|survey study|The surveys will include general data, the type of electronic devices in possession and the purpose of use. eHealth literacy will be assessed with the eHeals questionnaire. Platform's ease of use will be assessed with the System Usability Scale, and participants´ opinion about the digital path utility with six questions. These items will be answered with a Likert-scale. Finally, we added an open question for qualitative analysis.
219530681|NCT02779543|DEVICE|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
219616490|NCT07095322|BEHAVIORAL|Group Exercise Session|Optional exercise sessions from week 4 to week 12 of the intervention if the participants want to join
219616491|NCT07095322|BEHAVIORAL|Training Log|To record the exercise done for 24 weeks duration. Consist of date, day, exercise, set, repetitions, load, RPE
218916933|NCT02731469|BIOLOGICAL|Mircera®|
218916934|NCT02731469|BIOLOGICAL|Aranesp®|
218916935|NCT02364375|DEVICE|Menai mask (full face)|Prototype mask system (full face variant) with novel vent and humidification system
218916936|NCT02364375|DEVICE|Menai Standard mask (full face)|Prototype mask system (full face variant) with conventional vent and humidification system
218916937|NCT02364375|DEVICE|Menai mask (nasal)|Prototype mask system (nasal variant) with novel vent and humidification system
218916938|NCT02364375|DEVICE|Menai Standard mask (nasal)|Prototype mask system (nasal variant) with conventional vent and humidification system
218916939|NCT02364375|DEVICE|Menai mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
218916940|NCT02364375|DEVICE|Menai Standard mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
218916941|NCT03696836|DEVICE|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
218916942|NCT01670344|PROCEDURE|Treatment with investigational method (virtual implant positioning system)|
218916943|NCT01670344|PROCEDURE|Treatment with surgical standard of care|
218916944|NCT05459363|OTHER|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
218916945|NCT05188859|DRUG|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
219530682|NCT02779543|DEVICE|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
219530683|NCT02779543|DEVICE|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
219530684|NCT03965858|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
219530685|NCT03965858|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
219530686|NCT03965858|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
219616492|NCT07095322|BEHAVIORAL|Support group|For reminders and support for the participant for the first 12 weeks of intervention
219616493|NCT07095478|DRUG|Artesunate|Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.
219616494|NCT07097623|OTHER|respond to 3 rounds of online Delphi surveys|In the first round, the responses of the participants will be collected, coded, and categorised into several themes/factors anonymously. In the second round, the participants will obtain the controlled feedback of all other participants and rate the level of agreement of the factors using a 5-point Likert scale ('strongly agree', 'agree', 'neither agree or disagree', 'disagree', and 'strongly disagree'; or 'essential', 'important', 'don't know/depends', 'unimportant', and 'should not be considered'). In the third round, the participants will rank the importance of the factors. In each round, the participants will be expected to complete the survey within one month.
218916946|NCT05096195|DRUG|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
218916947|NCT05096195|OTHER|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
218916948|NCT05096195|DIAGNOSTIC_TEST|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
218916949|NCT05310955|OTHER|daily rehabilitation interventions|including Naikan therapy, Morita therapy, group art therapy, group painting therapy
219530687|NCT03965858|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
218916950|NCT05310955|OTHER|shen-based Qigong exercise|a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
218916951|NCT03481400|DRUG|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
218916952|NCT03481400|OTHER|Placebo|Isotonic saline
218916953|NCT04663763|DRUG|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
218916954|NCT04663763|DRUG|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
218916955|NCT04663763|DRUG|Oxaliplatin|Usage: 130mg/m2 d1 q3w
218916956|NCT02302599|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Infusion treatment
218916957|NCT02302599|BIOLOGICAL|Controlled suspension liquid|Infusion treatment
218916958|NCT00740038|BEHAVIORAL|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, \& provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
219530688|NCT00135941|DRUG|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
219530689|NCT00135941|DRUG|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
219530690|NCT05741437|DRUG|CKD-378, QD, PO Drug: D745, D150, QD, PO|Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
219530691|NCT03148704|DRUG|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
219530692|NCT03004820|DEVICE|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
219530693|NCT03707912|DRUG|Anaferon|Oral administration.
219530694|NCT03707912|DRUG|Placebo|Oral administration.
218916959|NCT00740038|BEHAVIORAL|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
219530695|NCT01678066|DEVICE|Bilateral cardiac output|
219530696|NCT07035522|OTHER|Ozone therapy|The study also aims to analyze the efficacy of ozone therapy in participants affected by endometriosis, enriching the knowledge base in the field of women's health/gynecology. The expected results will contribute to improving current therapeutic approaches, informing clinical decisions and encouraging future research. Understanding the technique and its clinical applicability will help health professionals to offer personalized and effective treatments. In addition, the insights obtained can direct new investigations, such as the optimization of protocols or the exploration of innovative therapeutic combinations for even more satisfactory results. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it may be possible that one of the approaches demonstrates a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of these participants will improve and i
219530697|NCT06717750|DRUG|CSCJC3456 tablet|"* Phase Ia: Single and Multiple Dose Escalation.~  1. Dosage form: tablet.~ 2. Dosage: 7 dose groups, 5 mg, 15 mg, 30 mg, 45 mg, 60 mg, 80 mg, 100 mg.~ 3. Frequency: once daily (tentative), or twice daily and other options (adjusted based on the results of the preliminary trials).~ 4. Duration: 5 mg(days 1-28; 28 days per cycle), other groups (days 1-14; 21 days per cycle) .~* Phase Ib: Cohort Expansion. Dosage and dosing regimen: according to the recommended dosage and dosing cycle from the Phase Ia study."
219530698|NCT03309709|DRUG|subcutaneous progesterone|25mg daily for 7 days
219530699|NCT06304701|DIAGNOSTIC_TEST|Cognitive and writing tests|"* Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing"
219530700|NCT06944145|DRUG|raloxifene|Participants in the Finasteride + Raloxifene Combination Therapy Arm will receive both Finasteride and Raloxifene as their intervention.
219530701|NCT06944145|DRUG|Finasteride|"Participants in the Finasteride Monotherapy arm will receive only Finasteride as their standard-of-care intervention.~Participants in the Finasteride + Raloxifene Combination Therapy arm will receive both Finasteride and Raloxifene as the study intervention."
219530702|NCT01802320|DRUG|Akt Inhibitor MK2206|Given PO
219530703|NCT01802320|OTHER|Laboratory Biomarker Analysis|Correlative studies
219530704|NCT01802320|OTHER|Pharmacological Study|Correlative studies
219530705|NCT06551584|DRUG|ORCA-T|On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
219530706|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
219530707|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
218916960|NCT00740038|BEHAVIORAL|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
219530708|NCT06358820|DRUG|Amino acid peritoneal dialysis solution|Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
219530709|NCT04815954|PROCEDURE|Urinary catheter removal|Removal of urinary catheter which was placed during kidney transplantation.
219530710|NCT06101238|DIETARY_SUPPLEMENT|supplementation with low dose elemental iron|65mg daily
219530711|NCT05627739|DRUG|Mycophenolate Mofetil|Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
219530712|NCT02773134|OTHER|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
219530713|NCT02773134|OTHER|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
218916961|NCT00740038|BEHAVIORAL|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
218916962|NCT01064388|DRUG|AZD9742|IV infusion, 15 days
218916963|NCT01064388|DRUG|Placebo|IV infusion, 15 days
218916964|NCT01263080|DRUG|mirtazapine|mirtazapine 30mg QD
219530714|NCT02640521|BEHAVIORAL|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
219530715|NCT03708991|DIAGNOSTIC_TEST|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
219530716|NCT03708991|DIAGNOSTIC_TEST|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
219530717|NCT00005591|BIOLOGICAL|cetuximab|
219530718|NCT00005591|DRUG|gemcitabine hydrochloride|
219530719|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
219530720|NCT02728856|OTHER|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
219530721|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
219530722|NCT03183037|PROCEDURE|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
219530723|NCT03183037|PROCEDURE|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
219530724|NCT03183037|OTHER|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
219616495|NCT07097623|OTHER|attend an individual semi-structured interview|The individual semi-structured interview will be audio-recorded, last for 45 minutes at maximum, and carried out by a trained and independent research assistant in a meeting room of PolyU or a room affiliated with the respective acute wards of the participating hospitals.
219616496|NCT07095374|OTHER|Rapid palatal expansion|Patients undergone orthopedic treatment with rapid palatal expander
219616497|NCT07095088|OTHER|Mind-body therapy|In addition to the 1-week birth preparation training at the Kayseri City Education and Research Hospital Pregnancy School, the intervention group received Mindfulness-Based Parenting and Birth Preparation Training. This training aimed to teach participants how to monitor their thoughts and emotional states, how to deepen their sensory awareness of their bodies, how to be more careful about how their minds work, and how to deepen their sensory self-awareness, so that they would be more sensitive during the birth and parenting processes. A total of 9 separate sessions were implemented. Mindfulness-Based Parenting and Birth Preparation Training was held once a week for 9 weeks, with the duration of each session varying according to the parents' compliance and needs in the program, and each session lasted an average of 150 minutes.
219616498|NCT06926894|DRUG|Rapidly generated virus specific T (R-MVST) cells|"Group A dose escalation schedule:~* Cohort (-1A): 0.25x10\^6 R-MVST TNC/kg~* Cohort (1A): 0.5x10\^6 R-MVST TNC/kg~* Cohort (2A): 1x10\^6 R-MVST TNC/kg~Groups B \& C dose escalation schedule:~* Cohort (-1B) + (-1C): 1x10\^6 R-MVST TNC/kg~* Cohort (1B) + (1C): 2x10\^6 R-MVST TNC/kg~* Cohort (2B) + (2C): 4x10\^6 R-MVST TNC/kg"
219616499|NCT07097467|OTHER|Buteyko Breathing Technique|The buteyko breathing technique is a breath holding technique mostly used in Asthma patients
218916965|NCT01263080|DRUG|folic acid placebo|folic acid placebo 1 tablet QD
218916966|NCT01263080|DRUG|mirtazapine placebo|mirtazapine placebo 1 tablet QD
218916967|NCT01263080|DRUG|folic acid|folic acid 0.4mg QD
218916968|NCT04916990|BEHAVIORAL|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
218916969|NCT04049786|PROCEDURE|Digestive biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
218916970|NCT04049786|DRUG|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
218916971|NCT04049786|PROCEDURE|Serial blood sampling for PK analysis|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
218916972|NCT04049786|DRUG|Metoprolol 100 mg for CYP2D6 phenotyping|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
218916973|NCT04049786|DRUG|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
219530725|NCT03183037|BEHAVIORAL|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
219530726|NCT00804960|DRUG|Letrozole|1\) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
219530727|NCT00804960|DRUG|Std IVF Protocol|2\) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
219530728|NCT06071299|BEHAVIORAL|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
219530729|NCT06071299|BEHAVIORAL|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
219530730|NCT05376319|DRUG|Obinutuzumab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
219530731|NCT05376319|DRUG|Rituximab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
218916974|NCT04049786|DRUG|Midazolam 2 mg for CYP3A4 phenotyping|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
219530732|NCT03421717|DEVICE|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
219530733|NCT01124175|DRUG|Losartan|100 mg Tablets
219530734|NCT01124175|DRUG|Cozaar®|100 mg Tablets
219530735|NCT04456842|OTHER|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
219530736|NCT05839470|DRUG|cadonilimab|Cadonilimab (6mg/kg, iv, Q2W, Day1)
219530737|NCT05839470|DRUG|irinotecan|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1
219530738|NCT05839470|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² iv continue for 2 hours,
219530739|NCT05839470|DRUG|leucovorin or levoleucovorin|leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
219530740|NCT05839470|DRUG|5-FU|5-FU 2400 mg/m² cont. inf. 46h
219530741|NCT00486863|DRUG|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
219530742|NCT00486863|OTHER|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
219530743|NCT00039286|PROCEDURE|positron emission tomography|
219530744|NCT00039286|PROCEDURE|radionuclide imaging|
219616500|NCT07095491|OTHER|Experimental|A structured hybrid training program based on self-care and self-efficacy will be implemented for the intervention group. The training will be conducted in two sessions, one day per week, over a total of two weeks.
218916975|NCT04049786|OTHER|Genotyping|Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
218916976|NCT05324462|DRUG|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
218916977|NCT05577247|OTHER|functional magnetic resonance imaging|Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
218916978|NCT04964180|DRUG|Indomethacin suppository|two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
218916979|NCT04964180|DRUG|Lidocaine 2% Injectable Solution|200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
218916980|NCT00210496|DRUG|topiramate; almotriptan malate|
218916981|NCT04032964|DRUG|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
218916982|NCT04032964|DRUG|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
218916983|NCT00888134|DRUG|Selumetinib|Given PO
218916984|NCT06514950|BEHAVIORAL|Ujjayi Yogic Breathing|Participants will undergo 6 weeks of resistive yogic breathing (Ujjayi) upon exhalation (first three weeks) and upon inhalation and exhalation (second three weeks).
219042026|NCT03422393|DRUG|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
219042027|NCT03645668|DRUG|Meropenem Injection|Different administration types between two groups
219042028|NCT02636465|OTHER|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
219042029|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
219530745|NCT00039286|RADIATION|fludeoxyglucose F 18|
219530746|NCT03040648|DEVICE|DSA|DSA was used for detection of intravascular injection
219530747|NCT03040648|DEVICE|RTF|RTF was used for detection of intravascular injection
219530748|NCT04330534|DRUG|BCX9930|BCX9930 capsules for oral administration
219530749|NCT04330534|DRUG|Placebo|placebo to match BCX9930 capsules for oral administration
218916985|NCT04777799|DEVICE|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
218916986|NCT01854411|OTHER|analgesic measure|ibuprofen and ketoprofen measured into breast milk
218916987|NCT03183869|DRUG|Fecal microbiota|fecal microbial transplantation
219530750|NCT00355797|DEVICE|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
219530751|NCT00355797|DEVICE|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
219530752|NCT00355797|DEVICE|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
219530753|NCT00501397|DRUG|ketoconazole|
219530754|NCT00501397|DRUG|GSK189075|
219530755|NCT02856347|OTHER|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
219530756|NCT00218257|DRUG|Progesterone|200mg progesterone twice daily
219530757|NCT00218257|OTHER|Placebo|placebo
219616501|NCT07095491|OTHER|Control|The control group will not receive any different intervention and will continue the process with routine nursing care (standard treatment).
219616502|NCT07096726|DEVICE|Five-point ultrasound|In-person study visits will be done on initial evaluation and then at least every 48 hours, during which serial five-point ultrasound will be performed to assess venous congestion. Each visit will not be at strict intervals; a reasonable time window is every 48 hours +/- 12 hours. Ultrasound may be performed more frequently if clinically indicated. During these visits or between them, ultrasound of the heart may additionally be performed. Each visit will last between 10 and 60 minutes.
219616503|NCT07096726|OTHER|Standard of care|Standard of care will most likely include radiographic investigations (chest X-ray, chest CT), laboratory evaluation (complete blood counts, metabolic panel, B-type natriuretic peptide, high-sensitivity troponin, electrolytes, renal function, urine testing), volume status, and cardiopulmonary physical exam.
219616504|NCT02841501|GENETIC|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
218916988|NCT04412863|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
218916989|NCT04412863|DRUG|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
219530758|NCT01400087|DEVICE|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
219530759|NCT04630834|DRUG|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
219530760|NCT04630834|DRUG|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
219616505|NCT03311204|DEVICE|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
219616506|NCT03311204|OTHER|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
219616507|NCT07110948|PROCEDURE|Tongue tie release|surgical release of tongue tie
219042030|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
219042031|NCT01945489|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
219042032|NCT01945489|DRUG|Normal saline|Normal saline (placebo) injected into the detrusor.
219530761|NCT04630834|DRUG|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
219530762|NCT03296722|BEHAVIORAL|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
219530763|NCT05329922|BEHAVIORAL|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
219530764|NCT04408586|DRUG|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
219530765|NCT04408586|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
219530766|NCT04408586|OTHER|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
219616508|NCT07113457|OTHER|Acute Intermittent Hypoxia (AIH)|This intervention involves breathing lowered levels of oxygen (similar to those experienced on a tall mountain) for 60 seconds at a time. This is immediately followed by 60 seconds of breathing normal room air. These bouts are repeated approximately 15 times. For the intervention, the participant is fitted with a non-rebreathing mask which supplies the two different air levels
219616509|NCT07111572|DIAGNOSTIC_TEST|fecal calprotectin|patients will accpet test of FC combine FIT
219530767|NCT04625153|BIOLOGICAL|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
219616510|NCT07111260|DEVICE|pHA130 Hemoadsorption + High-Flux Hemodialysis|A combination blood-purification procedure in which a pHA130 hemoperfusion cartridge is connected in series with a high-flux hemodialyzer. Blood first passes through the HP cartridge to adsorb protein-bound uremic toxins and is then dialyzed. In the 4-hour arm the HP cartridge remains online for the entire 4-hour session; in the 2-hour arm the cartridge is removed after 2 hours and dialysis continues alone for the remaining 2 hours. Blood-flow rates are 250-350 mL/min (4-hour arm) or 200-250 mL/min (2-hour arm).
219616511|NCT07111195|DEVICE|The ONCOhabitats software for MRI-based habitat segmentation|"ONCOhabitats is an MRI-based software platform designed to segment IDH-wildtype glioblastomas into four biologically distinct habitats (HAT, LAT, IPE, and VPE) based on vascular heterogeneity.~In this study, the software is applied preoperatively to generate imaging biomarkers that guide surgical sampling and are assessed for their ability to predict overall survival and stratify patients accordingly.~The intervention includes advanced perfusion imaging processing using the HTS methodology, non-invasive tumor characterization, and integration with molecular and histopathological data."
219616512|NCT07111611|PROCEDURE|Non-Traumatic Nasopharyngeal Suction Procedure|A modified suctioning technique that avoids deep catheter insertion and minimizes mucosal contact. Sterile saline (0.9%) is instilled into one nostril, and secretions are aspirated using external suction via the opposite nostril or mouth. This approach is designed to reduce pain and physiological stress compared to standard suction methods in preterm infants undergoing non-invasive ventilation.
219616513|NCT07112859|PROCEDURE|Complete Pulpotomy with Biodentine|"Administration of local anesthesia followed by rubber dam isolation.~Removal of coronal pulp tissue to perform a complete pulpotomy.~Hemostasis achieved with saline-soaked cotton pellet.~Placement of Biodentine as the pulp-capping agent on the radicular pulp.~Temporary restoration placed immediately after Biodentine placement.~Permanent composite restoration placed after 1 week.~Follow-up visits at 7 days, 1 month, and 3 months for clinical and radiographic evaluation."
219616514|NCT07113171|DEVICE|Conventional Direct Laryngoscope|The Macintosh laryngoscope blade was used for intubation. The technique involved neck extension to create a direct line of sight to the vocal cords for successful tracheal tube placement.
219616515|NCT07113171|DEVICE|Video Laryngoscope|The video laryngoscope allowed visualization of the glottis on a monitor without the need for cervical extension, facilitating intubation in anticipated difficult airway cases.
219616516|NCT07113444|OTHER|Tai Chi|Yang style of Tai Chi (24 form)
219616517|NCT07113444|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
218916990|NCT06453746|OTHER|Home-based cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
219530768|NCT04625153|BIOLOGICAL|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
219616518|NCT07113444|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
219616519|NCT07113392|DRUG|Suraxavir Marboxil|Suraxavir Marboxil will be administered as oral suspension: 40 mg (if weight ≥ 32 kg), or 20 mg (if weight \<32 kg).
218916991|NCT06453746|OTHER|Supervised cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
219042033|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
219042034|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
219042035|NCT01890772|DRUG|Telaprevir|
219042036|NCT01890772|DRUG|Peginterferon alfa-2a|
219530769|NCT05905718|OTHER|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
219530770|NCT05954741|OTHER|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
219530771|NCT05954741|OTHER|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
218916992|NCT06500390|DIAGNOSTIC_TEST|Examination of temporomandibular joint and masticator muscles|The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.
218916993|NCT04827407|DEVICE|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
218916994|NCT06400758|OTHER|questionary|"A questionnaire, based on the main sexual health topics frequently discussed, was given to students by the school management prior to an intervention.~The preventive intervention consisted of comprehensive prevention on the emotional and sexual lives of adolescents. It was carried out by health professionals and was based on questions from the students, who were able to leave their questions anonymously in a box in the school infirmary for several months.~These questions were collected and used to identify several themes for discussion:~emotional life, with notions of affection, love, friendship and the notion of normality, as well as consent and sexual violence physical and sexual aspects, with reminders of the menstrual cycle, contraception, sexually transmitted infections, pregnancy and abortion.~The same questionnaire was given to students after the intervention, to check whether the prevention intervention had improved their general knowledge."
218916995|NCT05633602|DRUG|Chemotherapy|Receive standard of care chemotherapy
218916996|NCT05633602|BIOLOGICAL|Pembrolizumab|Given IV
219530772|NCT05954741|OTHER|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
219530773|NCT02060747|BEHAVIORAL|Coordinator-based post fracture program|
219530774|NCT06561906|OTHER|Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing|Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
219530775|NCT05013463|DRUG|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
219530776|NCT05013463|DRUG|Indapamide Pill|Oral Indapamide, 2.5 mg OD
219530777|NCT04274374|DIETARY_SUPPLEMENT|Gluten-Free Diet|Dietary supplement without gluten
219530778|NCT04274374|DIETARY_SUPPLEMENT|Gluten Diet|Dietary supplement with gluten
219530779|NCT06485531|OTHER|Pranamaya|Pranamaya
218916997|NCT05633602|BIOLOGICAL|Ramucirumab|Given IV
218916998|NCT05928936|DRUG|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
219042037|NCT01890772|DRUG|Ribavirin|
219042038|NCT01890772|DIETARY_SUPPLEMENT|Vitamin D|
219530780|NCT06485531|OTHER|Pursed Lips Breathing|Pursed Lips Breathing
219530781|NCT01067963|BEHAVIORAL|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
219530782|NCT01067963|BEHAVIORAL|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
219530783|NCT06626815|BEHAVIORAL|Lateral Kangaroo Position|Newborns in the lateral kangaroo position group will be positioned diagonally on their mothers chests, with their heads placed between the mothers breast and collarbone.
219530784|NCT06626815|BEHAVIORAL|Reverse Kangaroo Position|Newborns in the reverse kangaroo position group will be positioned vertically with their backs in contact with the mothers chest.
219530785|NCT05146492|PROCEDURE|MRI|MRI with gadolinium contrast media injection
219530786|NCT04501003|DEVICE|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
219530787|NCT00428298|DRUG|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
219042039|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
219042040|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
219042041|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
219042042|NCT03569371|DRUG|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
219042043|NCT04114253|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219042044|NCT01515969|DRUG|Erlotinib hydrochloride|Given PO
219042045|NCT01515969|DRUG|Dovitinib lactate|Given PO
219042046|NCT00876473|PROCEDURE|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
218916999|NCT05928936|BEHAVIORAL|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
218917000|NCT05928936|DRUG|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
218917001|NCT06008795|DRUG|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
218917002|NCT06008795|PROCEDURE|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
218917003|NCT06092450|OTHER|develop and validate a deep learning radiomics model based on preoperative enhanced CT image|develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
218917004|NCT01171859|DRUG|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
218917005|NCT03879512|DRUG|depletion of regulatory T cells|oral metronomic cyclophosphamide
219530788|NCT00428298|DRUG|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
219530789|NCT06345053|BEHAVIORAL|Narrative Exposure Therapy|The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
219530790|NCT00070291|DRUG|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
218917006|NCT03879512|PROCEDURE|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
219530791|NCT04336605|OTHER|Age & Development|Age, sex, pubertal onset and development
219530792|NCT04336605|OTHER|Socioeconomy|Family structure and economy
219530793|NCT04336605|OTHER|Traumatic Events|Violence and other traumatic events
219530794|NCT04336605|OTHER|Psychosocial conditions|Family/social support
219530795|NCT04336605|OTHER|Lifestyle|Physical activity, BMI, nutrition, smoking …
219530796|NCT04336605|OTHER|Chronic conditions|I.e. Epilepsy or juvenile rheumatoid arthritis ...
219530797|NCT04336605|OTHER|Somatic symptoms|Headache, pain, sleep disturbances ...
219530798|NCT04336605|OTHER|Psychological symptoms|PTSS, anxiety, depressive symptoms \& loneliness ...
219530799|NCT04336605|OTHER|Non-prescription analgesics|Non-prescription analgesics
219530800|NCT04336605|OTHER|Prescription drugs|Analgetic, sedative \& anxiolytic medication
218917007|NCT03879512|BIOLOGICAL|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
219530801|NCT01783535|DRUG|vincristine|Given via minibag/gravity flow.
219530802|NCT01783535|DRUG|topotecan|Given IV over 30 minutes.
219530803|NCT01783535|DRUG|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is \>2,000/µL on one occasion after the expected nadir.
219530804|NCT01783535|DRUG|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is \>2,000/µL on one occasion after the expected nadir.
219530805|NCT01783535|DRUG|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
219530806|NCT01783535|OTHER|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
219530807|NCT01783535|DRUG|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
219530808|NCT01783535|DRUG|cyclophosphamide|Given IV.
219530809|NCT01783535|DRUG|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
218917008|NCT03879512|BIOLOGICAL|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
218917009|NCT05655351|BIOLOGICAL|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
219530810|NCT01783535|DRUG|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
219530811|NCT01783535|PROCEDURE|enucleation|Eye removal due to advanced disease in Strata C and D participants.
219616520|NCT07113392|DRUG|Oseltamivir|Oseltamivir will be administered as oral granules: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≤ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
218917010|NCT06100653|DRUG|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
218917011|NCT05764265|DRUG|LTP001|LTP001 will be administered orally once daily in the morning
218917012|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
218917013|NCT00464698|DRUG|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
218917014|NCT01903460|DRUG|LUM001|
218917015|NCT01903460|DRUG|Placebo|
218917016|NCT05269914|OTHER|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
218917017|NCT02928679|DRUG|Liraglutide 3 mg (Saxenda)|
218917018|NCT02928679|DRUG|Liraglutide 3 mg placebo|
218917019|NCT03268772|DRUG|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
218917020|NCT06002412|OTHER|Image quality control|The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
218917021|NCT01091064|OTHER|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
218917022|NCT06448143|DRUG|Indigotindisulfonate sodium 0.8% injection|Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
218917023|NCT05085353|PROCEDURE|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
218917024|NCT03330925|DEVICE|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
218917025|NCT05322707|DRUG|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
218917026|NCT05322707|DRUG|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
218917027|NCT05322707|DRUG|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
219042047|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
219042048|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
219042049|NCT02123199|DRUG|Indacaterol (Onbrez®) /QAB149|
219042050|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
219042051|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
219042052|NCT01236755|DEVICE|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
219530812|NCT01783535|RADIATION|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
219530813|NCT00507117|DRUG|Lunesta|Lunesta 3mg prior to PSG
219530814|NCT00507117|DRUG|Placebo control|matching placebo
219616521|NCT07111338|DRUG|Telitacicept 160mg|Telitacicept (RC18) is a recombinant TACI-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby inhibiting B-cell differentiation and plasma-cell survival. In this study, it is supplied as a sterile, preservative-free, lyophilized powder (160 mg/vial) that is reconstituted with 1 mL water for injection and administered subcutaneously into the abdomen or thigh at a fixed dose of 160 mg once weekly for 24 weeks. Each injection is performed by trained study personnel, and pre-filled backup syringes are available to ensure exact dosing. No dose escalation or tapering is planned; dose reductions or temporary discontinuation are allowed only for predefined safety criteria.
219530815|NCT05996926|DIAGNOSTIC_TEST|Three-Dimensional Transvaginal Ultrasound (3D TVS)|"In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~Procedure: A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches."
219530816|NCT05996926|DIAGNOSTIC_TEST|Saline-Infused Sonography (Sonohystrography)|The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
219530817|NCT01174225|DEVICE|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
219530818|NCT01174225|DEVICE|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
219530819|NCT02821728|DIETARY_SUPPLEMENT|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
219530820|NCT02821728|OTHER|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
219530821|NCT03217539|DIAGNOSTIC_TEST|Imaging|
219530822|NCT03491072|DEVICE|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
218917028|NCT02994563|DEVICE|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
218917029|NCT03728465|BIOLOGICAL|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
218917030|NCT03728465|BIOLOGICAL|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
218917031|NCT02425410|OTHER|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
219530823|NCT03491072|DRUG|Fentanyl|Patients will receive IV fentanyl
219530824|NCT00777972|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
219530825|NCT00520130|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
219530826|NCT00520130|DRUG|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
219530827|NCT00520130|DRUG|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
219530828|NCT00520130|DRUG|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
219530829|NCT00520130|DRUG|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
219530830|NCT00520130|DRUG|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
219530831|NCT00520130|DRUG|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
219530832|NCT00520130|BIOLOGICAL|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
219530833|NCT02028715|DRUG|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
219530834|NCT02028715|DRUG|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
219530835|NCT05058638|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
219530836|NCT05654103|DEVICE|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
219530837|NCT05654103|PROCEDURE|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
219530838|NCT06054581|BEHAVIORAL|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
219530839|NCT02945891|DEVICE|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
219530840|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
219530841|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
219530842|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
219530843|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
219530844|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
219530845|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
218917032|NCT02425410|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
218917033|NCT00240123|DRUG|Benadryl versus Placebo|
218917034|NCT01007201|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
218917035|NCT04412759|OTHER|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
218917036|NCT04202848|DIAGNOSTIC_TEST|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
218917037|NCT05020951|OTHER|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
219366610|NCT05450614|OTHER|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
219530846|NCT03026348|BIOLOGICAL|RSV F Vaccine with Aluminum Phosphate Adjuvant|
219530847|NCT03026348|BIOLOGICAL|RSV F Vaccine|
219530848|NCT03026348|BIOLOGICAL|Matrix-M1 Adjuvant|
219530849|NCT03026348|OTHER|Phosphate Buffer|
219530850|NCT01050088|DIETARY_SUPPLEMENT|sucrose solution|5cc 5% sucrose solution P/O
219530851|NCT01050088|DIETARY_SUPPLEMENT|Saline|5cc saline p/o
219530852|NCT05986448|BEHAVIORAL|Tai-chi exercise|Traditional Chinese Tai Chi Movement
219530853|NCT00830206|OTHER|Azithromycin|Oral Suspension
219530854|NCT00830206|DRUG|Zithromax®|Oral Suspension
219530855|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
219530856|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
219530857|NCT01942746|DIETARY_SUPPLEMENT|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
219530858|NCT01942746|DIETARY_SUPPLEMENT|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
219530859|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
219530860|NCT03518905|DEVICE|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
219530861|NCT03518905|PROCEDURE|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
219530862|NCT04758130|OTHER|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
219530863|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with \>= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves \> 60% of mucosa and extends to the lower third of mucosa."
219530864|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R\&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
219530865|NCT05238181|DIAGNOSTIC_TEST|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
219530866|NCT01082926|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given intratumorally
219530867|NCT01082926|BIOLOGICAL|aldesleukin|Given intratumorally
219530868|NCT01082926|OTHER|laboratory biomarker analysis|Optional correlative studies
219530869|NCT01082926|PROCEDURE|positron emission tomography|Optional correlative studies
218917038|NCT02524327|OTHER|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
219204655|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
218917039|NCT02524327|OTHER|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
218917040|NCT02246530|PROCEDURE|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
218917041|NCT02246530|DRUG|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
218917042|NCT03945383|DEVICE|Treatment with IPL device|Treatment with IPL device
218917043|NCT00829569|DIETARY_SUPPLEMENT|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
218917044|NCT00629980|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
218917045|NCT05776940|DRUG|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
218917046|NCT05776940|DRUG|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
218917047|NCT02916186|BIOLOGICAL|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
219530870|NCT05488808|DEVICE|repetitive Transcranial Magnetic Stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
219530871|NCT03396120|DIAGNOSTIC_TEST|Pulmonary function test|forced vital capacity and diffusing capacity
219616522|NCT06917963|DRUG|Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM)|This intervention consists of intensified intravenous omeprazole therapy specifically designed to reduce high-output ileostomy after surgery. It includes an initial loading dose of 80 mg omeprazole administered intravenously on the day before surgery (or on the day of surgery in emergency cases), followed by a continuous treatment of 40 mg intravenously twice daily (at 6:00 AM and 6:00 PM) during hospitalization and after discharge to complete 10 day therapy, distinguishing it from standard once-daily omeprazole dosing protocols typically used for gastrointestinal ulcer prophylaxis.
219530872|NCT04605094|BIOLOGICAL|Benralizumab|Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
218917048|NCT02916186|PROCEDURE|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
218917049|NCT03863886|PROCEDURE|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
218917050|NCT03293108|DRUG|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
218917051|NCT03293108|DIETARY_SUPPLEMENT|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
218917052|NCT03293108|DIETARY_SUPPLEMENT|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
218917053|NCT06054126|OTHER|Echocardiography|Cardiac function was evaluated by echocardiography at one year follow-up.
218917054|NCT03810677|DEVICE|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
218917055|NCT01817153|DRUG|hydrocortison hemisuccinate|
218917056|NCT01817153|DRUG|placebo followed by hydrocortisone hemisuccinate|
218917057|NCT05430178|OTHER|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
219530873|NCT04605094|BIOLOGICAL|Placebo / Benralizumab|Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
218917058|NCT05430178|OTHER|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
218917059|NCT05430178|OTHER|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
219204656|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
219530874|NCT02724462|BEHAVIORAL|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
219530875|NCT02724462|BEHAVIORAL|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
219530876|NCT01900691|DEVICE|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
219530877|NCT04381962|DRUG|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
219530878|NCT00979303|DEVICE|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
219530879|NCT00891800|DEVICE|Brachytherapy|SIR-Sphere contains radiation of Y-90.
219530880|NCT00891800|DEVICE|SIR-Sphere|Brachytherapy Radiation seeds
219530881|NCT04391933|DIAGNOSTIC_TEST|MRI 3 tesla|MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
219530882|NCT06391606|DIETARY_SUPPLEMENT|Coenzyme Q10|2 pills/day of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)
219530883|NCT06391606|OTHER|Placebo|2 pills/day
219530884|NCT02059070|DRUG|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
219530885|NCT02059070|DRUG|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
219530886|NCT06378242|DRUG|Disitamab Vedotin for injection|Intravesical instiliations into the bladder
219530887|NCT00242970|DEVICE|3-Dimensional Color Scanning|Color imaging of the face and neck.
219530888|NCT01954394|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
219530889|NCT01954394|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
219530890|NCT06046846|DEVICE|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
219530891|NCT04111263|DIETARY_SUPPLEMENT|FP|Fiber and polyphenol blend
219530892|NCT04111263|DIETARY_SUPPLEMENT|Placebo|Matched placebo
219530893|NCT04111263|OTHER|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
219530894|NCT04111263|OTHER|Sea level|Sea level environment in altitude chamber
219530895|NCT01975623|DEVICE|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
219530896|NCT01026623|BIOLOGICAL|Cixutumumab|Given IV
219530897|NCT01026623|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219530898|NCT01026623|DRUG|Temsirolimus|Given IV
219530899|NCT03481998|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
218917060|NCT06474455|DRUG|SHR-9839 ；SHR-A2009|SHR-9839 combined with SHR-A2009
218917061|NCT06474455|DRUG|SHR-9839 ； SHR-A1921|SHR-9839 combined with SHR-A1921
218917062|NCT06474455|DRUG|SHR-9839 ； pemetrexed ；carboplatin|SHR-9839 combined with pemetrexed + carboplatin
218917063|NCT06474455|DRUG|SHR-9839 ； Almonertinib|SHR-9839 combined with Almonertinib
218917064|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
218917065|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
218917066|NCT00888173|DRUG|Brivanib Alaninate|Given PO
218917067|NCT00888173|OTHER|Laboratory Biomarker Analysis|Correlative studies
219530900|NCT03481998|DRUG|Letrozole or anastrozole or Fulvestrant|Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
219530901|NCT06020924|OTHER|No intervention|This study is a retrospective observational study without intervention.
219530902|NCT03169595|PROCEDURE|Surgery|Patients affected by epithelioid hemangioma treated with surgery
219530903|NCT06000709|DRUG|6% aqueous phenol|1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
218917068|NCT01396304|DEVICE|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
218917069|NCT01396304|DEVICE|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
219530904|NCT06000709|DRUG|MethylPREDNISolone 40 MG|40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance
219530905|NCT06000709|DRUG|Intraarticular Knee Placebo|Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
219530906|NCT06000709|DRUG|Genicular Nerve Placebo|1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
219530907|NCT04794283|OTHER|Breast milk|Milk substitute given during the first 24h
219530908|NCT05796869|BEHAVIORAL|Assigned Interventions|The laughter therapy session will be administered to the application group face to face for 25-30 minutes once a week for 2 months by a researcher with a laughter therapy certificate. In the laughter therapy session, introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, maintaining the rhythm with music, turning laughter that starts like a child's play into reality and meditation practices will be carried out.
219530909|NCT01959750|BEHAVIORAL|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
219530910|NCT02584439|DRUG|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
219530911|NCT02584439|DRUG|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
219530912|NCT00770822|DEVICE|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
219530913|NCT00770822|DEVICE|Brachytherapy|Standard of care
219530914|NCT00184522|DRUG|Aflurax|
219530915|NCT00184522|DRUG|esomeprazole|
219530916|NCT06392438|DRUG|CycloSPORINE Ophthalmic|Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
219530917|NCT06392438|PROCEDURE|Intense Pulsed Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
219530918|NCT06392438|PROCEDURE|Sham Intense Pulse Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
219530919|NCT03429634|PROCEDURE|Balloon-Stent Kissing technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
218917070|NCT01730599|OTHER|neurological exam|motor and cognitive functions
218917071|NCT04065269|DRUG|Ceralasertib|ATR inhibitor
219530920|NCT03429634|PROCEDURE|Jailed Wire technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
219530921|NCT05648721|OTHER|Datos mobile health application|The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.
219530922|NCT05648721|OTHER|Regular follow-up|Regular follow-up according to the local clinic protocol
219530923|NCT01419093|OTHER|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
219530924|NCT06380023|DEVICE|Enclosure barrier|Surgical mask \& Enclosure tent compared with open suction
219530925|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
219530926|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
219530927|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
219530928|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
219530929|NCT01969747|DRUG|Empagliflozin medium|Empagliflozin medium
219530930|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
219530931|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
219530932|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
219616523|NCT06917963|DRUG|Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).|The control group will receive standard intravenous omeprazole therapy as per routine clinical practice for gastrointestinal prophylaxis. Participants will receive a single daily dose of 40 mg omeprazole intravenously administered at 6:00 AM during hospitalization. This standard dosing regimen serves as the comparator for assessing the efficacy of the intensified dosing regimen used in the experimental group.
218917072|NCT04065269|DRUG|Olaparib|PARP inhibitor
218917073|NCT04065269|DRUG|Durvalumab|Anti-PD-L1 immunotherapy
218917074|NCT04246788|OTHER|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
218917075|NCT04246788|OTHER|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
218917076|NCT00736021|DRUG|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
218917077|NCT04440475|PROCEDURE|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
218917078|NCT05810740|DRUG|Binimetinib 15 MG|Binimetinib 15 mg tablet
218917079|NCT05810740|DRUG|Binimetinib 45 MG|Binimetinib 45 mg tablet
218917080|NCT02233777|DRUG|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
218917081|NCT02233777|DRUG|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
218917082|NCT06256406|OTHER|in the field of rehabilitation and neonatal care: the combination of Kangaroo care method and music therapy|Kangaroo care is a practice involving skin-to-skin contact between the infant and a caregiver,. Music therapy is a therapeutic approach that utilizes the expressive and emotional qualities of music to address physical, emotional, cognitive needs of individuals.
219530933|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
219530934|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
219530935|NCT01969747|DRUG|Empagliflozin low|Empagliflozin low
219530936|NCT01969747|DRUG|Empagliflozin high|Empagliflozin high
219530937|NCT06110377|PROCEDURE|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
219530938|NCT06110377|PROCEDURE|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
219204657|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
219367301|NCT04928534|DIAGNOSTIC_TEST|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
219530939|NCT01232647|DRUG|Phylloquinone|1.0 mg daily of vitamin K1
218917083|NCT06140589|DRUG|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
218917084|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
219530940|NCT01232647|DRUG|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
219530941|NCT01232647|DRUG|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
219530942|NCT03430869|DRUG|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
219530943|NCT03430869|DRUG|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
219530944|NCT03125135|DEVICE|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
219530945|NCT00651586|DRUG|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
219616524|NCT07112768|DIAGNOSTIC_TEST|Serum levels of LH, FSH, testosterone, prolactin, and ferritin|Measurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin)
218917085|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
218917086|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
219530946|NCT00651586|DRUG|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
219530947|NCT02372266|OTHER|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
219530948|NCT02372266|OTHER|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
219530949|NCT02987439|OTHER|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
219530950|NCT02393417|BIOLOGICAL|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
218917087|NCT01488890|BIOLOGICAL|Yellow Fever|0.5 mL, Subcutaneous
218917088|NCT06417424|DEVICE|gastrointestinal external stimulation|We used the device Gastrointestinal multifunctional therapeutic instrument. The positive pole was placed 1 to 2cm above the umbilicus, and the negative pole was placed 4 to 10 cm to the right of the midpoint between the xiphoid process and the umbilicus.
218917089|NCT05712460|DRUG|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
218917090|NCT05712460|DRUG|Placebo|Placebo for sisunatovir
218917091|NCT05376150|DRUG|XEN1101 10 mg|XEN1101 oral capsule
218917092|NCT05376150|DRUG|XEN1101 20 mg|XEN1101 oral capsule
219530951|NCT02393417|OTHER|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
219530952|NCT02203058|OTHER|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
218917093|NCT05376150|DRUG|Placebo|Placebo capsule
218917094|NCT05077215|DRUG|EG-007|A Repurposed Drug
218917095|NCT05077215|DRUG|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
218917096|NCT05077215|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
218917097|NCT02233686|DRUG|XEN-D0501|
218917098|NCT02233686|DRUG|Placebo|
218917099|NCT06185725|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve Block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
219042053|NCT01236755|DEVICE|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
219616525|NCT04823897|DRUG|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
219616526|NCT05517330|BIOLOGICAL|Tislelizumab|200mg IV Q3W
219042054|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
219367302|NCT05906420|DIAGNOSTIC_TEST|ASTRAL prognostic score|ASTRAL prognostic score
219367303|NCT05886725|OTHER|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
219530953|NCT02203058|OTHER|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
219530954|NCT00264394|BEHAVIORAL|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
219530955|NCT00264394|BEHAVIORAL|Guidelines|provision of guidelines for CHD risk factor management only
219616527|NCT05517330|DRUG|Afatinib|30mg PO QD
219616528|NCT06950983|BEHAVIORAL|AYA-NAV|Support for AYA and vocational navigation sessions from clinical team
219530956|NCT00002062|DRUG|Spiramycin|
219530957|NCT05291702|PROCEDURE|PCNL|Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
219616529|NCT06756503|DIAGNOSTIC_TEST|fecal elastase|To investigate exocrine pancreatic insufficiency (EPI), all patients will be asked to provide a stool sample for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be refrigerated at 4-8 °C for no more than 48 hours. The concentration of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), with fecal elastase extracted and analyzed according to the manufacturer's instructions.
219616530|NCT06756503|DIAGNOSTIC_TEST|Serum cytokines|Cytokines will be quantified using the Bio-Plex Pro™ Human Cytokine 27-plex commercial kit (Bio-Rad Laboratories, USA) following the kit instructions.
219616531|NCT05502341|DRUG|Bictegravir|Tablets administered orally without regard to food
219042055|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
219042056|NCT00398853|DIETARY_SUPPLEMENT|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
219042057|NCT00398853|OTHER|Placebo|Placebo
219042058|NCT02072291|DRUG|Nifedipine|PO Nifedipine 5mg single dose
219367304|NCT05917288|BIOLOGICAL|Belimumab|Belimumab will be administered
219367305|NCT05917288|DRUG|Standard of care|Standard of care will be administered
219367306|NCT02246621|DRUG|Abemaciclib|Administered orally
219367307|NCT02246621|DRUG|Anastrozole|Administered orally
219367308|NCT02246621|DRUG|Letrozole|Administered orally
219530958|NCT02422264|BIOLOGICAL|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
219530959|NCT02422264|DRUG|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
219530960|NCT00025818|DRUG|Ophthalmic Emulsion|
219530961|NCT01203332|BEHAVIORAL|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
219616532|NCT05502341|DRUG|Lenacapavir|Tablets administered orally without regard to food
219616533|NCT05502341|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
218917100|NCT06185725|OTHER|Transversus Abdominal Plane Block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
219530962|NCT01503736|DRUG|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
219530963|NCT01503736|DRUG|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
219530964|NCT01503736|DRUG|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
219530965|NCT06458491|DEVICE|Evolution of urinary symptoms|Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
218917101|NCT06265233|OTHER|Group Improv sessions|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
218917102|NCT06265233|BEHAVIORAL|Group Exposure and Response Prevention (ERP) Therapy|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
218917103|NCT05264857|BEHAVIORAL|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
218917104|NCT01213680|DRUG|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
218917105|NCT01213680|DRUG|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
218917106|NCT02784756|DEVICE|Quantiferon-CMV assay|
218917107|NCT05900167|BEHAVIORAL|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
218917108|NCT02735863|DRUG|ABX464|50 mg or 150mg once daily for 28 days
218917109|NCT02735863|DRUG|Placebo|ABX464 matching placebo
218917110|NCT02375854|OTHER|Observation|
218917111|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
219530966|NCT04904120|DRUG|[203Pb]VMT01|Diagnostic imaging radiopharmaceutical; by intravenous infusion
219530967|NCT04904120|DRUG|[68Ga]VMT02|Diagnostic imaging radiopharmaceutical; by intravenous infusion
219530968|NCT00273026|DRUG|salmeterol xinafoate/fluticasone propionate|
219530969|NCT05217524|DEVICE|Galaxy BIA watch|Digital multifunction watch
219530970|NCT02344732|DRUG|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
218917112|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
218917113|NCT04421677|DRUG|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
218917114|NCT02333435|DIETARY_SUPPLEMENT|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
218917115|NCT02333435|DIETARY_SUPPLEMENT|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
218917116|NCT05446649|OTHER|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
219042059|NCT04904185|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
219042060|NCT04904185|DRUG|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
219042061|NCT04904185|BIOLOGICAL|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
219367309|NCT02246621|DRUG|Placebo|Administered orally
219367310|NCT05585242|BEHAVIORAL|Infertility ACTion Program|Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
219367311|NCT04849871|RADIATION|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
219367312|NCT05829512|OTHER|Validity and reliability study|Face-to-face questionnaire study
219367313|NCT03131817|DEVICE|Activa PC+S Prefrontal|
219367314|NCT02435355|BEHAVIORAL|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
219367315|NCT05308316|OTHER|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
219367316|NCT03152682|DIETARY_SUPPLEMENT|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
219367317|NCT03152682|OTHER|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
219367318|NCT04186455|DEVICE|proseal|laryngeal mask proseal
219367319|NCT04186455|DEVICE|baska-mask|laryngeal mask baska-mask
219367320|NCT03913156|OTHER|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
219367321|NCT05219188|RADIATION|3.7 mS, CT radiation|Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
219530971|NCT02344732|DRUG|Homatropine 2% eye drops thrice daily|
219530972|NCT02344732|DRUG|Oxygen gas|
219530973|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% BID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
219530974|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% QID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
219530975|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% Six times per day|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
219530976|NCT02648074|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
219530977|NCT02648074|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
219530978|NCT03944330|DIETARY_SUPPLEMENT|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
219530979|NCT02656368|DEVICE|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
219042062|NCT04904185|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
219530980|NCT02269657|DEVICE|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
219530981|NCT02196766|OTHER|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
219530982|NCT02196766|OTHER|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
219530983|NCT00186355|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
219530984|NCT05115123|DRUG|Duloxetine|60 mg duloxetine
219530985|NCT05115123|DRUG|Placebo|Placebo
219530986|NCT03590808|BIOLOGICAL|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
219530987|NCT01273350|DEVICE|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
219042063|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
219530988|NCT04074655|DEVICE|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
219530989|NCT00769964|DRUG|VA111913 TS / placebo|
219530990|NCT00045422|BIOLOGICAL|recombinant interferon alfa|
219530991|NCT00045422|DRUG|imatinib mesylate|
219530992|NCT01880853|OTHER|mammography|participants were screened by mammography alone every year
219530993|NCT01880853|OTHER|ultrasound|participants were screened by ultrasound alone every year
219530994|NCT01880853|OTHER|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
219530995|NCT06395194|DRUG|Cardiac outcomes on treatment with valsartan|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
219530996|NCT06395194|DRUG|Cardiac outcomes on treatment with amlodipine|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
219530997|NCT01888822|DRUG|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
219530998|NCT01888822|DRUG|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
219530999|NCT01888822|DRUG|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
219531000|NCT02527109|DRUG|Nifedipine|
219531001|NCT00309881|BIOLOGICAL|rituximab|
219531002|NCT00309881|DRUG|cyclophosphamide|
219531003|NCT00309881|DRUG|doxorubicin hydrochloride|
219531004|NCT00309881|DRUG|prednisone|
219531005|NCT00309881|DRUG|vincristine sulfate|
219531006|NCT06515054|BEHAVIORAL|wall squat|self-learnt wall squat exercise to be conducted for totally 24 weeks
219531007|NCT06515054|BEHAVIORAL|passive stretching|time-matched passive stretching exercise to be conducted for totally 24 weeks
219531008|NCT00851877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
219531009|NCT00851877|DRUG|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
219531010|NCT00851877|DRUG|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
219531011|NCT00851877|RADIATION|intensity-modulated radiation therapy|intensity-modulated radiation therapy
218917117|NCT05446649|OTHER|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
218917118|NCT05446649|OTHER|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
219531012|NCT05457231|OTHER|specific feedback based on an in-depth assessment tool for communication skills training|In addition to the specific feedback based on an in-depth assessment tool, four strategies modified from common strategies in the previous studies were incorporated into the intervention protocol, including lecture, patient interview, brief feedback, and self-reflection
219531013|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
219531014|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
219531015|NCT03450057|DRUG|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
219531016|NCT00933530|DRUG|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
219531017|NCT00933530|DRUG|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
219531018|NCT01034358|BIOLOGICAL|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
219531019|NCT04574219|OTHER|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
219531020|NCT05332002|DRUG|Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)|"This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric"
219616534|NCT05502341|DRUG|Stable Baseline Regimen|"SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk"
219616535|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
219616536|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
219616537|NCT05242393|OTHER|No intervention is planned|No intervention is planned
219616538|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
219616539|NCT04199104|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
219616540|NCT04199104|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
219616541|NCT04199104|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
219616542|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
218917119|NCT05611151|DIAGNOSTIC_TEST|Computer Aided Detection (CADe)|Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
218917120|NCT02780648|RADIATION|Stereotactic Body Radiation|
218917121|NCT05495815|DRUG|6 months of SAT|6 months of oral suppressive antibiotic therapy
218917122|NCT05495815|DRUG|12 months of SAT|12 months of oral suppressive antibiotic therapy
218917123|NCT05495815|DRUG|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
218917124|NCT04699864|DIAGNOSTIC_TEST|Screening of DR and DME with artificial intelligence using NeoRetina|Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
218917125|NCT04699864|DIAGNOSTIC_TEST|Routine ophthalmological evaluation of DR and DME|Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
219531021|NCT02473718|OTHER|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
219531022|NCT02473718|DEVICE|Ultrasound|
218917126|NCT04699864|DIAGNOSTIC_TEST|Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos|Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
218917127|NCT02649166|DEVICE|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
218917128|NCT02649166|DEVICE|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
219531023|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5mL oral dose
219531024|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
219531025|NCT04740632|BEHAVIORAL|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
219531026|NCT02950805|DRUG|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
219531027|NCT02950805|DRUG|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
219531028|NCT03701594|OTHER|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
219531029|NCT03701594|OTHER|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
219531030|NCT03701594|OTHER|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
219531031|NCT03501147|OTHER|Resistance training|15 minutes of resistance training during work every day
219531032|NCT02246166|DRUG|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
219531033|NCT02246166|OTHER|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
219531034|NCT04455139|DRUG|Topotecan|intravitreal or intra-arterial administration of topotecan
219531035|NCT04455139|DRUG|Melphalan|intravitreal or intra-arterial administration of topotecan
219531036|NCT05278221|DEVICE|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
218917129|NCT05560425|BEHAVIORAL|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
218917130|NCT05560425|BEHAVIORAL|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
218917131|NCT05499910|BEHAVIORAL|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
218917132|NCT04945746|PROCEDURE|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
218917133|NCT06222905|OTHER|non interventional|non interventional
218917134|NCT06399900|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
218917135|NCT06399900|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
219531037|NCT02069080|DRUG|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
219531038|NCT01526694|DRUG|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
219616543|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
219616544|NCT05319132|OTHER|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
218917136|NCT06399900|BEHAVIORAL|Home-based walking exercise|This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
218917137|NCT05206708|BEHAVIORAL|Personalized psychotherapy|Strategy including personalized psychotherapy
218917138|NCT05206708|BEHAVIORAL|Standard of care|Strategy based standard intregrative psychodynamic therapy
218917139|NCT06320054|BEHAVIORAL|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
218917140|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
218917141|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
218917142|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
219616545|NCT03414502|DRUG|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg daily.
219616546|NCT03414502|DRUG|Abatacept|Starting dose may be adjusted as needed at investigator's discretion.
219616547|NCT03414502|DRUG|Adalimumab|Starting dose may be adjusted as needed at investigator's discretion.
218917143|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
218917144|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
218917145|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
219531039|NCT01526694|DRUG|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
219531040|NCT01526694|DRUG|Dexamethasone|It's a corticosteroid.
219531041|NCT02430272|DRUG|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
219531042|NCT06486623|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
219531043|NCT06486623|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
219531044|NCT02603003|DRUG|JinFuKang|po.tid.30ml
219531045|NCT02603003|DRUG|Cisplatin|According to the individual patient's condition
218917146|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
218917147|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
219531046|NCT02603003|DRUG|Pemetrexed|According to the individual patient's condition
219531047|NCT03992118|BEHAVIORAL|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
219531048|NCT05643911|PROCEDURE|HFNC|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes.
219531049|NCT05643911|PROCEDURE|NIV|Patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance.
219531050|NCT03429959|DEVICE|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
219531051|NCT03429959|DEVICE|SIGVARIS Cotton|SIGVARIS Cotton
219531052|NCT00627016|DRUG|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
218917148|NCT00535314|DRUG|RTA 402 Dose1|
218917149|NCT00535314|DRUG|RTA 402 Dose2|
218917150|NCT02637245|OTHER|No intervention|No intervention
218917151|NCT06235775|DRUG|GV1001 Placebo|0.9% normal saline
218917152|NCT06235775|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
218917153|NCT05135767|BEHAVIORAL|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
219531053|NCT00627016|DRUG|Placebo|1 capsule, orally, once daily for 4 weeks
218917154|NCT04943744|DEVICE|Entero-tracker|Esophageal STRING test (Entero-tracker)
218917155|NCT04943744|BIOLOGICAL|omalizumab|Used in the parent study
218917156|NCT04943744|BIOLOGICAL|dupliumab|Used in the parent study
219531054|NCT05472350|DRUG|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
219531055|NCT05472350|OTHER|Placebo|placebo is 0.9% normal saline
219531056|NCT02200224|OTHER|Rapid Testing|
219531057|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
219531058|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
219531059|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
219531060|NCT01515592|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
219531061|NCT05839613|DIAGNOSTIC_TEST|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
219531062|NCT04373096|DEVICE|current IPAC-UHN PPE|"* Fit-tested N95 mask~* Open face shield~* Double extended-cuff"
219531063|NCT04373096|DEVICE|modified IPAC-UHN PPE|"* Fit-tested N95 mask~* Hood~* Double extended-cuff gloves"
219531064|NCT00052377|BIOLOGICAL|aldesleukin|Given SC
219531065|NCT00052377|BIOLOGICAL|recombinant interleukin-12|Given SC
219531066|NCT00052377|OTHER|laboratory biomarker analysis|Correlative studies
219531067|NCT05266313|BEHAVIORAL|Oncosexology program|Thematic workshops throughout the year
219531068|NCT03786341|DEVICE|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
219616548|NCT03414502|DRUG|Azathioprine|Starting dose may be adjusted as needed at investigator's discretion.
218917157|NCT02376634|BEHAVIORAL|Hypnosis|Patients will be taught self-hypnosis.
218917158|NCT04936607|PROCEDURE|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
218917159|NCT04936607|PROCEDURE|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
218917160|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
219531069|NCT01410630|DIAGNOSTIC_TEST|FLT-PET/CT|Standard of Care
219531070|NCT01410630|DIAGNOSTIC_TEST|FDG-PET/CT|Standard of Care
219531071|NCT01410630|DRUG|FLT|5 mCi IV
219531072|NCT01437501|DRUG|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
219531073|NCT01437501|DRUG|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
219531074|NCT06197529|OTHER|Homeostatic Plasticity|Anodal tDCS S1/M1
219531075|NCT06197529|DRUG|Topical alone (Capsaicin 8% Patch)|4x4 patch
219531076|NCT06197529|OTHER|Placebo Patch|4x4 patch
219531077|NCT06197529|OTHER|Homeostatic Plasticity (Sham)|sham Homeostatic Plasticity protocol over S1
219531078|NCT04277026|BEHAVIORAL|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
219531079|NCT06349967|DRUG|Nab-paclitaxel Combined With Cadonilimab (AK104)|Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
219531080|NCT01256684|DRUG|Placebo|Placebo vaginal suppository
219531081|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
219531082|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
219531083|NCT01729377|OTHER|Interview|
219616549|NCT03414502|DRUG|Baricitinib|Starting dose may be adjusted as needed at investigator's discretion.
218917161|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
218917162|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
218917163|NCT02260934|DRUG|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
218917164|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
218917165|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
219616550|NCT03414502|DRUG|Certolizumab|Starting dose may be adjusted as needed at investigator's discretion.
218917166|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
218917167|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
218917168|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
218917169|NCT02260934|DRUG|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
219616551|NCT03414502|DRUG|Etanercept|Starting dose may be adjusted as needed at investigator's discretion.
218917170|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
218917171|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
218917172|NCT02260934|BIOLOGICAL|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
219531084|NCT03169205|OTHER|observation registry|observation registry
219531085|NCT00223197|DRUG|Pregnenolone|
219531086|NCT00165594|DRUG|E7070|
219531087|NCT00946166|DRUG|simvastatin|40 mg daily in the evening for a maximum of 14 days
218917173|NCT01931540|BEHAVIORAL|Exercise Training|Three times a week, for four months.
218917174|NCT05231226|PROCEDURE|Immediately CR|Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD
219531088|NCT00946166|DRUG|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
219531089|NCT01386294|DRUG|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
219531090|NCT01386294|DRUG|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
219616552|NCT03414502|DRUG|Golimumab|Starting dose may be adjusted as needed at investigator's discretion.
219616553|NCT03414502|DRUG|Hydroxychloroquine|Starting dose may be adjusted as needed at investigator's discretion.
219616554|NCT03414502|DRUG|Infliximab|Starting dose may be adjusted as needed at investigator's discretion.
219616555|NCT03414502|DRUG|Leflunomide|Starting dose may be adjusted as needed at investigator's discretion.
219616556|NCT03414502|DRUG|Minocycline|Starting dose may be adjusted as needed at investigator's discretion.
219616557|NCT03414502|DRUG|Rituximab|Starting dose may be adjusted as needed at investigator's discretion.
219616558|NCT03414502|DRUG|Sarilumab|Starting dose may be adjusted as needed at investigator's discretion.
219616559|NCT03414502|DRUG|Sulfasalazine|Starting dose may be adjusted as needed at investigator's discretion.
219616560|NCT03414502|DRUG|Tofacitinib|Starting dose may be adjusted as needed at investigator's discretion.
219616561|NCT04021043|DRUG|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Given IV
219616562|NCT04021043|BIOLOGICAL|Ipilimumab|Given IV
219616563|NCT04021043|BIOLOGICAL|Nivolumab|Given IV
219616564|NCT04021043|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219616565|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
219616566|NCT06404112|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
219616567|NCT06404112|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
219616568|NCT06404112|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
219616569|NCT06404112|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
219531091|NCT02678286|DRUG|N1539|
219616570|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
219616571|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
219616572|NCT04151134|DIAGNOSTIC_TEST|Step serial sectioning histological processing|Step serial sectioning histological processing
219616573|NCT05979688|BEHAVIORAL|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
218917175|NCT05231226|PROCEDURE|Staged (within 45 days) CR|Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
218917176|NCT05829070|BEHAVIORAL|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
218917177|NCT05829070|BEHAVIORAL|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
219531092|NCT02678286|DRUG|Intravenous Placebo|
219531093|NCT02330068|DRUG|citalopram|Cases
219531094|NCT02220166|DIETARY_SUPPLEMENT|Triticum monococcum|
219616574|NCT03325062|BEHAVIORAL|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
219616575|NCT03325062|BEHAVIORAL|Experimental: MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
219616576|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
219616577|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
219616578|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
219531095|NCT02266264|DRUG|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
219531096|NCT04840264|DRUG|Docetaxel|25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
219531097|NCT04840264|DRUG|Oxaliplatin|85 mg/msquare metre, D1, D15, repeat every 4 weeks.
219531098|NCT04840264|DRUG|Fluorouracil|1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
219531099|NCT05723900|DRUG|Castor oil|"Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil"
219616579|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
219616580|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
219616581|NCT04797000|DRUG|Eltrombopag|Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
219616582|NCT04797000|DRUG|Placebo|Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
219616583|NCT05110144|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
219616584|NCT05110144|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
219616585|NCT05110144|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
219531100|NCT05723900|DRUG|Formocresol|Group II treated with formocresol
219531101|NCT02527278|PROCEDURE|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
219531102|NCT02527278|PROCEDURE|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
219531103|NCT06128811|DEVICE|Rubber Dam Isolation|Rubber dam isolation will be placed using a proper size dental clamp on the first permanent molar after topical anesthesia application.
219531104|NCT06128811|DEVICE|DryShieled isolation|For the DryShieled isolation, a pedo-size mouthpiece will be utilized with all the participants.
219531105|NCT06128811|OTHER|fissure sealant|After proper isolation, fissure sealant (Conseal-F TM SDI) will be applied following the manufacturer's instructions, and the quality of the applied fissure sealant will be checked with an explorer. An additional layer will be applied if any deficiency is detected
219531106|NCT01247545|PROCEDURE|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
219531107|NCT01247545|PROCEDURE|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
219531108|NCT02853162|RADIATION|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
219531109|NCT02697331|DRUG|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
219616586|NCT05110144|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
219616587|NCT05110144|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
219616588|NCT05110144|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
219616589|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
219616590|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
219616591|NCT06144450|OTHER|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
219531110|NCT02697331|OTHER|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
219616592|NCT06543212|OTHER|physiotherapy exercises|physiotherapy exercises to improve eye alignment and eye control post strabismus surgery
219616593|NCT06184061|COMBINATION_PRODUCT|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
219616594|NCT05229770|DIETARY_SUPPLEMENT|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
219616595|NCT02543788|PROCEDURE|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
219616596|NCT05303662|DIAGNOSTIC_TEST|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
219616597|NCT05303662|DIAGNOSTIC_TEST|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
219616598|NCT05303662|DIAGNOSTIC_TEST|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
219616599|NCT05303662|DIAGNOSTIC_TEST|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
219616600|NCT06002711|DIAGNOSTIC_TEST|MR scanning; Clinical data collection|Multi-dimensional spatial heterogeneity analysis of MRI
219616601|NCT05724043|DEVICE|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
219616602|NCT06009107|BIOLOGICAL|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
219616603|NCT06009107|DRUG|Cyclophosphamide|Administered intravenously.
219531111|NCT02466594|DEVICE|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
219531112|NCT04476329|DRUG|Regorafenib 40 MG|Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).
219616604|NCT06009107|DRUG|Fludarabine Phosphate|Administered intravenously.
219616605|NCT04821622|DRUG|talazoparib plus enzalutamide|experimental arm
219616606|NCT04821622|DRUG|Placebo plus enzalutamide|Active comparator arm
219616607|NCT06581965|OTHER|Short duration prophylaxis|"Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group)."
219531113|NCT05622422|BEHAVIORAL|EMPOWER-BKP|The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially at the first session and then again at the seventh session. The intervention will be provided in seven sessions the first three will be face-to-face at a community center and then the last four sessions will be through video conferencing and will be facilitated by three researchers. The participants will be invited to a focus group interview in week nine in order to collect quantitative data. Once the sessions are finished both qualitative and quantitative data will be collected and then analyzed.
218917178|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
218917179|NCT04854343|DIAGNOSTIC_TEST|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
218917180|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
218917181|NCT03597347|DRUG|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
218917182|NCT03597347|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
218917183|NCT02569385|OTHER|Spontaneous breathing trial|
218917184|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
218917185|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
218917186|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
218917187|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
218917188|NCT02532517|DEVICE|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
218917189|NCT03935984|DRUG|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
218917190|NCT03214601|DEVICE|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
218917191|NCT00886002|DRUG|Fentanyl; Buprenorphine; Naloxone|
218917192|NCT00723736|DRUG|Desloratadine|2.5 ml (1.25 mg) once daily
219531114|NCT05724810|DEVICE|Active deep transcranial magnetic stimulation (dTMS)|"First, the investigators will find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
219531115|NCT05724810|DEVICE|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
219531116|NCT01743508|PROCEDURE|Misoprostol treatment by midwife|Misoprostol treatment by midwife
219531117|NCT02865356|DRUG|Cyclosporine 5% solution|topical solution
218917193|NCT03670680|DEVICE|Use of the Lina LibrataTM|Use of the Lina LibrataTM
218917194|NCT04552951|DRUG|Cholecalciferol|Single doe of 100.000 IU
218917195|NCT05831228|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
218917196|NCT05831228|DIETARY_SUPPLEMENT|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
218917197|NCT05720897|OTHER|Auditory Alone|Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
218917198|NCT05720897|DEVICE|Relaxation Virtual Reality|Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
218917199|NCT04780061|DRUG|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
219531118|NCT02865356|DRUG|Placebo|topical vehicle solution
219531119|NCT04484493|DRUG|mometasone furoate nasal spray|dose of 2 puff in each nostril (100 µg once daily each nostril).
219531120|NCT03744715|DRUG|Poziotinib|Poziotinib
219531121|NCT03322111|DIAGNOSTIC_TEST|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
218917200|NCT04780061|DIETARY_SUPPLEMENT|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
218917201|NCT04780061|DIETARY_SUPPLEMENT|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
219531122|NCT00715377|DRUG|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
218917202|NCT04780061|OTHER|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
218917203|NCT04780061|OTHER|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
218917204|NCT05910996|PROCEDURE|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
218917205|NCT00509977|PROCEDURE|Light Treatment|Light treatment applied to half of the face at each study visit
218917206|NCT00509977|PROCEDURE|Laser Treatment|Laser treatment applied to half of the face at each study visit
219616608|NCT06581965|OTHER|Higher intensity and longer duration prophylaxis|"The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min)."
218917207|NCT05317403|DRUG|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
219531123|NCT03109977|DRUG|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
219531124|NCT03723395|DRUG|tucatinib|300mg dose, orally administered
219616609|NCT06581965|OTHER|Control|4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
219616610|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
218917208|NCT05317403|DRUG|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
218917209|NCT05317403|DRUG|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
218917210|NCT05317403|DRUG|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~1. \- 1.99 years old: 30 mg~2. \- 2.99 years old: 50 mg~   * 3 years old: 70 mg"
218917211|NCT05317403|DRUG|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
218917212|NCT05317403|DRUG|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
219531125|NCT03723395|DRUG|itraconazole|200mg dose
219531126|NCT03723395|DRUG|rifampin|600mg dose
219531127|NCT03723395|DRUG|gemfibrozil|600mg tablets
219531128|NCT03723395|DRUG|repaglinide|1mg dose
219616611|NCT02695251|OTHER|low AGE meal|Patients will receive a low AGE (eggs) meal
219616612|NCT02695251|OTHER|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
219616613|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
219616614|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
219616615|NCT06807970|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Patients in intervention group will have GLP-1RA semaglutide for 48 weeks and then stops for one month before and after TKR following the latest anesthesia guideline for GLP-1RA. Followed by TKR They will continue semaglutide for 48 weeks during the post-operative follow-up period. This is decided based on balancing treatment effect of semaglutide, waiting time for TKR, and TKR follow-up requirement. In Hong Kong, waiting time for TKR would be \~4 years and so a period of 12 months treatment of semaglutide is reasonable. And in the STEP 6 trial, weight loss at week 52 (-12%) is similar to that in study end at week 68(-13·2%), and STEP5 trial showed maintaining semaglutide to week 104 could maintain weight loss of similar degree as in week 52. And the consensus of assessing TKR Patient-Reported Outcome Measures (PROMs) is one year follow up.
219531129|NCT03723395|DRUG|tolbutamide|500mg dose
219531130|NCT03723395|DRUG|midazolam|2mg dose
219531131|NCT03723395|DRUG|digoxin|0.5 mg dose
219531132|NCT04667091|OTHER|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
219531133|NCT02218580|OTHER|Massage therapy|
219531134|NCT02218580|OTHER|Standard care|
219531135|NCT02331394|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
219531136|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
219531137|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
219531138|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
219531139|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
219531140|NCT02965326|PROCEDURE|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
219531141|NCT04444557|OTHER|Beck Depression Inventory (BDI)|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
219531142|NCT03446248|DEVICE|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
219531143|NCT03446248|DEVICE|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
219531144|NCT01313273|DRUG|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
219531145|NCT01313273|DRUG|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
219531146|NCT00344110|DRUG|Aliskiren|
219531147|NCT03687736|BIOLOGICAL|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
219531148|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
219531149|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
219531150|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
219531151|NCT03613337|OTHER|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
219531152|NCT04163354|PROCEDURE|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
219531153|NCT04163354|PROCEDURE|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
219531154|NCT00010205|DRUG|benzoylphenylurea|Given orally
219531155|NCT00010205|OTHER|pharmacological study|Correlative studies
219531156|NCT01861262|DEVICE|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
219531157|NCT01789294|DRUG|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
219616616|NCT06807970|OTHER|Control (Standard treatment)|If patients are randomized to the control group, they will receive routine follow-up with general advice on diet and physical activity but will not receive semaglutide, and will not be offered a specific management program for their weight. This is in line with current practice.
219616617|NCT03030378|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
219616618|NCT03030378|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219616619|NCT03030378|PROCEDURE|Computed Tomography|Undergo a CT scan
219616620|NCT03030378|BIOLOGICAL|Edodekin alfa|Given SC
219616621|NCT03030378|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
219616622|NCT03030378|BIOLOGICAL|Pembrolizumab|Given IV
219616623|NCT03030378|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219616624|NCT02874040|PROCEDURE|Endoresection|Endoresection of the tumor scar
219616625|NCT02874040|PROCEDURE|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
219616626|NCT06956664|OTHER|Conventional Physiotherapy|Standard physical-agent package delivered three times weekly for 6 weeks: 20 min moist hot-pack (≈70 °C hydrocollator packs); 5 min continuous therapeutic ultrasound (1 MHz, 1 W cm-²); 20 min biphasic TENS (100 Hz, 100 µs). Initiated 2 weeks after the caudal epidural steroid injection (CESI).
218917213|NCT06212856|OTHER|Plyometric training|"The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws"
218917214|NCT06212856|OTHER|Conventional|"The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running"
218917215|NCT05142787|DEVICE|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
219531158|NCT01789294|BEHAVIORAL|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
219531159|NCT06132074|BEHAVIORAL|School sessions on consent, reciprocity and sexual violence|The intervention consists of a 120-minute workshop led by a representative from Uppsala Tjej- och Transjour and aims to reduce the vulnerability and prevalence of sexual harassment, sexual violence and to counteract men's violence against women and violence in close relationships by raising awareness among pupils, school staff and guardians about sexual health among young people. The workshop covers areas of consent, reciprocity and sexual violence. The participants will do several valuation based and discussion based exercises regarding these topics and discuss issues, legality, and norms during the time.
219531160|NCT05492630|DRUG|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
219531161|NCT05492630|DRUG|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
219531162|NCT04960163|OTHER|No intervention|No intervention
219531163|NCT02496416|BEHAVIORAL|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
219531164|NCT02496416|BEHAVIORAL|Stretching Program|The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
219616627|NCT06956664|BEHAVIORAL|Aerobic Exercise Programme|Supervised treadmill walking three times weekly for 6 weeks: 5 min warm-up at \~40 % HR\<sub\>max\</sub\>; 10-25 min load at 55-80 % HR\<sub\>max\</sub\> (5 % weekly progression); 5 min cool-down. Heart-rate telemetry and Borg CR-10 used to titrate intensity. Starts 2 weeks post-CESI.
219616628|NCT06956664|BEHAVIORAL|Core-Stabilization Exercise Programme|Phased lumbopelvic motor-control regimen three times weekly for 6 weeks: Phase I isolated transversus abdominis/multifidus activation with pressure biofeedback; Phase II functional co-contraction with limb movements in quadruped, sitting, standing; Phase III dynamic tasks on Swiss-ball/BOSU with resistance. Progression requires pain ≤ 3/10 VAS and flawless technique. Begins 2 weeks post-CESI.
219616629|NCT05445830|PROCEDURE|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
219616630|NCT05445830|PROCEDURE|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
219616631|NCT05445830|PROCEDURE|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
218917216|NCT04060303|PROCEDURE|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
218917217|NCT05598333|DRUG|AB-1002|Intracoronary Infusion of AB-1002 or placebo
218917218|NCT06650709|DRUG|Olaparib|Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
219531165|NCT05319938|PROCEDURE|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
219616632|NCT05445830|PROCEDURE|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
219616633|NCT05445830|PROCEDURE|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
218917219|NCT06650709|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
218917220|NCT06650709|DRUG|Durvalumab|Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
218917221|NCT06590103|BEHAVIORAL|Physically Active Lessons|Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the Physical Education teacher) are in charge of designing and delivering the physically active classes.
218917222|NCT06312826|PROCEDURE|Abdominal US|The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.
218917223|NCT06312826|PROCEDURE|AMRI|The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
218917224|NCT01824836|DRUG|anastrozole|Given PO
218917225|NCT03378869|PROCEDURE|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
218917226|NCT06594822|DIETARY_SUPPLEMENT|probiotic plus standard treatment|Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily
218917227|NCT06594822|DRUG|standard treatment|diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
218917228|NCT06595849|BEHAVIORAL|4-week feeling tone intervention program|Participants will take part in a 4-week mindfulness of feeling tone intervention program taught by a registered mindfulness teacher, who is also a registered clinical psychologist. The intervention program includes 4 sessions, with each session lasting for about 2 hours. The program is taught in Cantonese, in a group setting, live online (via Zoom). Participants will practice meditation practices during the session, explore themes of the week, review and explore their meditation experiences. They will also practice meditation practices daily for at least 30 minutes at home, with meditation audio recordings provided by the teacher.
218917229|NCT06591052|OTHER|Passive stretching|The physiotherapist positioned each muscle in its maximum lengthened state and held it there for 30 seconds. This process was repeated three times, with a 30-second rest interval between each stretch of the different muscle groups.
218917230|NCT06591052|OTHER|PNF stretching|The physiotherapist initially positioned each muscle in its most extended state, similar to the positions used in passive stretching. In this extended position, the participants performed an isometric contraction against maximal resistance in the antagonist direction for 5-8 seconds. Following the isometric contraction, participants were instructed to actively relax, and after a 5-second waiting period to ensure complete relaxation, the movement range was passively increased. The new end point of the extended range of motion was held for 30 seconds. This stretching protocol was repeated three times for each muscle group, with a 30-second rest period between each stretch.
218917231|NCT06590831|DRUG|Lactoferrin|to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
219616634|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
219616635|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken once
219616636|NCT06377020|BEHAVIORAL|PACT2|Behavioral lifestyle intervention
219616637|NCT03968900|BEHAVIORAL|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB \[Time in Bed\]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
218917232|NCT06594666|DEVICE|VR/AR visual training group|Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
218917233|NCT06587711|PROCEDURE|acupuncture treatment|Patients in experimental group received acupuncture at specific acupoint on the face, patients in control group received sham acupuncture at non-acupoint on the face.
218917234|NCT06593145|BIOLOGICAL|FCTX-CL19-1 (Tarcidomgen Kimleucel)|"It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight"
218917235|NCT06609174|DIAGNOSTIC_TEST|KardiaRx ECG Screening and AI interpretation of ECG|The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
218917236|NCT06991335|DEVICE|Deep Brain Stimulation|Medtronic Percept PC with SenSight Directional Leads will be implanted to control the shape and size of stimulation
219204658|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1\. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
219204659|NCT04340882|DRUG|Docetaxel|Given IV
218917237|NCT06993285|OTHER|Protologic and LAnguage adaptation rehabilitation|Each patient will receive a maximum of 34 weeks of Protologic and LAnguage adaptation rehabilitation by a speech therapist at a rate of one or two speech therapy sessions per week, for a total of 30 sessions maximum. All sessions are filmed and at posteriori analysed with the help of ELAN© software
218917238|NCT03905707|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
218917239|NCT03907735|OTHER|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
218917240|NCT05730933|BEHAVIORAL|Intervention|Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
218917241|NCT06589557|OTHER|Virtual Reality (VR) and Standard Rehabilitation|"VR Rehabilitation:~The VR therapy includes exercises designed to improve the range of motion, coordination, and spatial awareness of the cervical spine. Each patient will complete 15 training sessions over three weeks (5 sessions per week, 2 hours per session), with an additional 30 minutes of daily VR exercises.~Standard Rehabilitation Program:~Manual Therapy: Mobilization and manipulation techniques are applied to enhance the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises focus on improving body position awareness, movement, and balance.~Strengthening and Stretching Exercises: Individually tailored exercises are provided to strengthen and stretch the neck muscles."
219204660|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
219204661|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
219204662|NCT02131584|OTHER|Questionnaire Administration|Ancillary studies
219531166|NCT05319938|PROCEDURE|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
219204663|NCT02131584|DRUG|Ruxolitinib Phosphate|Given PO
219204664|NCT03593811|DIAGNOSTIC_TEST|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
219204665|NCT03593811|DIAGNOSTIC_TEST|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
219204666|NCT03593811|DIAGNOSTIC_TEST|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
219204667|NCT03593811|DIAGNOSTIC_TEST|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
219204668|NCT03593811|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
219204669|NCT03593811|DRUG|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
218917242|NCT06589557|OTHER|Standard Rehabilitation|"Patients in this group will participate solely in the standard rehabilitation program.~Standard Rehabilitation Program:~Number of Sessions: Each patient will complete 15 training sessions, held 5 times per week for 3 weeks, with each session lasting 2 hours.~Program Components:~Manual Therapy: Mobilization and manipulation techniques will be applied to improve the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises aim to enhance body position awareness, movement control, and balance.~Strengthening and Stretching Exercises: Customized exercises will be provided to strengthen and stretch the neck muscles, tailored to individual needs."
218917243|NCT06997978|OTHER|Tele-rehabilitation|Patients at the Telerehabilitation group are contacted via laptops that have cameras, microphones, and a reliable internet connection. The therapist's laptop camera is positioned so the patient may watch the therapist while the therapist demonstrates the exercises. After the therapist performs the exercise on himself, the patient must see the therapist via a laptop camera and then perform the same activity again.
218917244|NCT06997978|OTHER|Hand rehabilitation program|"1. Free exercises:~   1\. Wrist flexion and extension 2. Wrist side movement 3. Thumb flexion and extension 4-Finger opposition 5. Palm up and down~2. Ball exercises:~   1. Ball grip~  2. Finger flexion~  3. Thumb extend~  4. The pinch exercise~  5. Opposition 6- Side squeeze~   7\. Extend out~3. Household exercises~   1. Roll movement~  2. Wrist curl~  3. Extending the wrist~4. Pen exercises~   1. Pinch and release~  2. Pen spine~5. Exercises with coins~   1. Coin drop~  2. Coin stacking"
218917245|NCT06999902|DRUG|20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks|Once daily oral
218917246|NCT06999902|DRUG|Placebo|Once daily oral
218917247|NCT06998810|DEVICE|cerebellar rTMS|Non-invasive magnetic stimulation targeting the cerebellum using a figure of eight coil
218917248|NCT07000032|OTHER|No Intervention: Observational Cohort|This is an observational cohort
218917249|NCT06998771|DRUG|JSKN003|JSKN003 is administered by intravenous infusion.
219531167|NCT05319938|PROCEDURE|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
219531168|NCT01037023|DRUG|Topotecan|patients administrated Topotecan according to the prescribing information
219531169|NCT03122990|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
219531170|NCT03122990|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
219531171|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
218917250|NCT06998771|DRUG|KN026|KN026 is administered by intravenous infusion.
218917251|NCT06998771|DRUG|Capecitabine|Capecitabine is for oral administration.
218917252|NCT06998771|DRUG|Enlonstobart|Enlonstobart is administered by intravenous infusion.
218917253|NCT06998771|DRUG|Oxaliplatin|Oxaliplatin is administered by intravenous infusion.
219204670|NCT03593811|DRUG|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
219204671|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
219204672|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
219531172|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219531173|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219531174|NCT03388203|DIAGNOSTIC_TEST|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
219531175|NCT02608788|DRUG|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
219531176|NCT02608788|DRUG|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
219531177|NCT02608788|DRUG|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
219531178|NCT02608788|DRUG|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
219531179|NCT00148837|DRUG|Peg-interferon alpha 2b (drug)|
219531180|NCT00148837|DRUG|Ribavirin (drug)|
219531181|NCT00148837|DRUG|Prazosin (drug)|
219531182|NCT06025188|OTHER|training set|LASSO regression analysis, Logistic regression analysis, Nomogram
219042064|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
219204673|NCT00076310|DRUG|Docetaxel|60 mg/m\^2 IV repeated every 21 days.
219531183|NCT04593628|BEHAVIORAL|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
219204674|NCT00076310|DRUG|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
219204675|NCT00076310|DRUG|Cisplatin|75 mg/m\^2 IV every 21 days.
219204676|NCT05592093|DRUG|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
219204677|NCT05592093|DRUG|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
219531184|NCT03227198|BIOLOGICAL|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
219531185|NCT03227198|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
219531186|NCT02459951|OTHER|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
219531187|NCT03128905|DRUG|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
219531188|NCT03128905|DRUG|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
219531189|NCT03800251|DIETARY_SUPPLEMENT|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
219531190|NCT06132698|DRUG|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
219531191|NCT00798447|DRUG|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
219531192|NCT00798447|DRUG|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
219204678|NCT04957849|PROCEDURE|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
219531193|NCT03995420|BEHAVIORAL|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
219531194|NCT03995420|OTHER|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
219531195|NCT01043380|DRUG|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
218917254|NCT06998771|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion.
218917255|NCT06998771|DRUG|Pembolizumab|Pembolizumab is administered by intravenous infusion.
218917256|NCT06999395|BEHAVIORAL|Virtual online pelvic health program|The program offers a multimodal approach to self-guided treatment for PVD. Its multimodal approach is exemplified by pain education focusing on pelvic health and neuroplasticity to provide the foundation for strategies strengthening the mind-body connection to the pelvis; mindful breathing and relaxation exercises to reduce nervous system overactivation and enhance mood; and gradual progression of exercises encouraging awareness, stretching, and strengthening to promote relaxation of the pelvic floor muscles and reduction of accessory muscle tension resulting from protective guarding. The program uses 3 separate yet interconnected modules: Learn (20 modules of pain science education and skills), Rewire (11 modules featuring mindfulness and relaxation), and Move (45 pelvic and other exercises).
218917257|NCT01243190|DRUG|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
218917258|NCT06998836|BEHAVIORAL|Dementia prevention education|Dementia prevention education:A structured dementia prevention education program developed based on qualitative focus group findings. The program includes multiple interactive sessions covering dementia knowledge, health beliefs, risk reduction strategies, and motivation for preventive actions.
218917259|NCT06998836|OTHER|General Health Education Leaflet|Participants received printed general health education leaflets not specifically related to dementia. The content included general wellness and health maintenance advice.
218917260|NCT06998394|DRUG|AK104 - Chemotherapy|AK104 (10mg/kg, q3w) + cisplatin weekly or every 3 weeks + radiotherapy (pelvic external beam radiotherapy + brachytherapy) until disease progression, intolerable toxicity, or the investigator judgment that the participant can no longer benefit, participant withdrawal of consent, or completion of 2 years of AK104 treatment.
218917261|NCT06599645|OTHER|CST+BFR+Tai Chi+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~3. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~4. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
218917262|NCT06599645|OTHER|CST+BFR+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
219204679|NCT04957849|PROCEDURE|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
219204680|NCT05037305|OTHER|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
219531196|NCT01043380|DRUG|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
219531197|NCT05005494|DRUG|Magnesium sulfate IV|Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)
219531198|NCT05005494|DRUG|Placebo|Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)
219531199|NCT05223894|BIOLOGICAL|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
219531200|NCT05223894|OTHER|Control|Coronary artery bypass grafting surgery only.
219531201|NCT05566860|PROCEDURE|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
219531202|NCT05566860|PROCEDURE|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
219531203|NCT05566860|PROCEDURE|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
218917263|NCT06599645|OTHER|Tai Chi +BFR+Education|"1. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
218917264|NCT06599645|OTHER|CST+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
218917265|NCT06587698|DRUG|Sitagliptin|100 mg QD for 3 month
218917266|NCT06587698|DRUG|BeiDouGen|60 mg BID for 3 month
218917267|NCT06587698|DRUG|Sitagliptin+BeiDouGen|100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
218917268|NCT06998303|OTHER|Bipolar DBS stimulation|All participants will receive bipolar DBS through stimulation contacts 3 (most dorsal GP contact) and contact 2 (adjacent to contact 3) as specified by the device manufacturer. Bipolar stimulation through contacts 3 and 2 may be different from the settings used by the participant for optimal clinical improvement, as determined by their DBS care provider
218917269|NCT06998290|OTHER|Blue-Line home telemonitoring program|"* A dedicated telemonitoring team with nurses and pediatric cardiologist~* A dedicated therapeutic patient education programme~* A home telemonitoring medical device with a dedicated platform"
218917270|NCT05020977|OTHER|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
219531204|NCT05566860|PROCEDURE|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI\>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
219531205|NCT05566860|PROCEDURE|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
218917271|NCT04802707|COMBINATION_PRODUCT|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over trid or bid for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 1825. Doses was chosen according to the safety and efficacy doses used in the literature.
218917272|NCT05878418|DEVICE|Thoracolumbosacral Spinal Orthosis (TLSO)|In the TE, PR, PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
218917273|NCT05878418|OTHER|Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)|The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
218959266|NCT03109912|BEHAVIORAL|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
219204681|NCT06036407|DIAGNOSTIC_TEST|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
219204682|NCT04684524|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219204683|NCT04684524|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219531206|NCT03173391|DRUG|HMS5552|BID Oral administration
219531207|NCT03173391|DRUG|Placebo|BID Oral administration
219531208|NCT01936194|DIETARY_SUPPLEMENT|DHA+EPA|
219531209|NCT01936194|DIETARY_SUPPLEMENT|High Olive Oil|
219531210|NCT01936194|DIETARY_SUPPLEMENT|DHA|
219531211|NCT05267691|PROCEDURE|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
219531212|NCT00481338|PROCEDURE|X-rays|X-rays (hip and knee) every 2 years
219531213|NCT00481338|BIOLOGICAL|biological samples|biological sample (blood and urine) every 2 years
219531214|NCT00481338|OTHER|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
219531215|NCT02062580|BIOLOGICAL|BCG|
219531216|NCT03079765|BEHAVIORAL|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
218917274|NCT06872996|DIAGNOSTIC_TEST|Prick-test|"Several foods may be tested for the same participant depending on the number of food allergies the patient has. PT are performed using the prick-to-prick method with lancets, in a single session per patient, using fresh and preserved native foods. Simultaneously, a positive control and a negative control are performed. The PT are performed and read by nursing or medical staff trained in the technique.~Participants' clinical follow-up is performed continuously for 30 minutes from the performance of the prick-tests and under the responsibility of the allergologist doctor, whose presence is mandatory during the performance of these tests.~For meat, fruit, vegetable, leguminous plant, milk, seafood and fish tests will be performed with fresh products and with products preserved for 3 months as well as with products preserved for 6 months \[-15 days; +15 days\].~For dry foods (nuts and peanuts), tests will be performed with products harvested over 3 separate and consecutive seasons."
219531217|NCT03079765|BEHAVIORAL|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
219531218|NCT04455126|DRUG|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
219531219|NCT05038657|DRUG|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
218917275|NCT06879431|BEHAVIORAL|cognitive-behavioral intervention|After enrollment in the experimental group, the guardians were asked to fill out a sleep diary every day before surgery to self-report the children's sleep, and to wear a somatic movement recorder to monitor sleep (non-dominant arm) (wGT3x-BT accelerometer, ActiGraph) during the preoperative hospitalization period, except during surgery, and then to wear it to record the sleep-related parameters until 7 days after surgery or before discharge from the hospital.Preoperative daily cognitive-behavioral interventions (developmental trials were guided with WeChat applets), including cognitive change, sleep hygiene, sleep restriction, stimulus control, and relaxation training
218917276|NCT06705738|DIETARY_SUPPLEMENT|SUPOL|Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
218917277|NCT06705738|OTHER|Dietary Pattern: MeDi|Adherance to Mediterranean dietary pattern to be followed for 12 months.
218917278|NCT06705309|BEHAVIORAL|Web-Based Education|The Effect of a Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer on Women's Prevention Methods
218917279|NCT06705296|DEVICE|Open Label Deep Brain Stimulation|Patients will receive open label deep brain stimulation
218917280|NCT06705296|DEVICE|Double blinded Deep Brain Stimulation|Patients will receive double blinded deep brain stimulation
218917281|NCT06705296|BEHAVIORAL|Prolonged exposure therapy|Patients will receive prolonged exposure therapy
218917282|NCT06705296|DEVICE|Closed loop Deep brain stimulation|Patients will receive closed loop deep brain stimulation
218917283|NCT06706713|DRUG|BEBT-109 Capsule|Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
218917284|NCT04051996|DRUG|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
218917285|NCT04051996|DRUG|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
218917286|NCT02677493|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
218917287|NCT02677493|BIOLOGICAL|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
218917288|NCT02677493|BIOLOGICAL|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
219531220|NCT05704426|DEVICE|Impulse Dynamics Optimizer Device|The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
219531221|NCT02694731|BEHAVIORAL|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
219531222|NCT02481830|DRUG|Nivolumab|
219531223|NCT02481830|DRUG|Topotecan|
219531224|NCT02481830|DRUG|Amrubicin|
218917289|NCT06704958|OTHER|AMPERE EMA app|AMPERE EMA smartphone app using MyCap
218917290|NCT06705322|DRUG|Cnidium Monnieri Detoxification Formula|"Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment."
219531225|NCT02406625|BEHAVIORAL|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
218917291|NCT06704711|DIETARY_SUPPLEMENT|Caffeine 300 MG|They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.
218917292|NCT06704711|COMBINATION_PRODUCT|Exercise|The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
218917293|NCT06704711|OTHER|Placebo|They will rinse 20 mL of distilled water in their mouth for 20 seconds.
219531226|NCT04997122|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
219531227|NCT04997122|OTHER|High oleic acid sunflower oil|Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
219531228|NCT03678844|BEHAVIORAL|Taekwondo practice|The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
219531229|NCT03678844|OTHER|CONTROL|The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
219531230|NCT05858463|OTHER|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
219531231|NCT04597463|PROCEDURE|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
219531232|NCT05218486|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
219531233|NCT01464112|DRUG|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
219531234|NCT04627038|DRUG|LY3556050|LY3556050 Given orally
219531235|NCT04627038|DRUG|Placebo|Placebo Given orally
219531236|NCT05607264|OTHER|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
219531237|NCT05607264|OTHER|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
219531238|NCT05607264|OTHER|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
219531239|NCT05151588|DRUG|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
219531240|NCT05151588|DRUG|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
219531241|NCT05151588|DRUG|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
219531242|NCT05151588|DRUG|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
219531243|NCT05151588|PROCEDURE|Surgery|Radical surgery
219531244|NCT05151588|OTHER|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
219531245|NCT06035107|DIAGNOSTIC_TEST|Radar blood pressure device|The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
219531246|NCT03254771|OTHER|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
219531247|NCT03251911|DRUG|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
218959267|NCT03109912|BEHAVIORAL|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
218959268|NCT03109912|BEHAVIORAL|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
219531248|NCT04512092|BEHAVIORAL|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
219531249|NCT02255097|BIOLOGICAL|pembrolizumab|
219531250|NCT04694391|GENETIC|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
219531251|NCT03207880|DEVICE|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
218917294|NCT05148364|BEHAVIORAL|interview|"A spiritual consultant and a psychologist will interview the participants about their experiences of chronic low back pain, how they interpret their pain experience and how they cope with the persistent pain. Each participant will be interviewed individually.~Questions related to the following three aspects will be asked:~1. Attributes: describe the changes in your personality, mood, and general happiness you have observed after you starting having chronic low back pain.~2. Pain resilience: How would you describe this persisting pain experience? How do you arrange your daily activity? What do you do to deal with this persistent pain?~3. Spirituality: As a person with chronic low back pain, how do you interpret this pain experience? Do you seek connections with higher powers (such as powers from religion) when you are desperate because of pain? Since the pain is chronic and persistent, it might not go away, how would you define your life?"
218917295|NCT06739746|OTHER|No intervention measures|No intervention measures
218917296|NCT06756880|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards
219531252|NCT02061891|PROCEDURE|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
219531253|NCT02061891|PROCEDURE|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
219531254|NCT00074230|BIOLOGICAL|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
219531255|NCT03985267|BEHAVIORAL|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
218917297|NCT00846976|DRUG|Bicalutamide|200mg daily
218917298|NCT01141517|BEHAVIORAL|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
218917299|NCT00570830|DEVICE|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
218917300|NCT02608684|DRUG|Pembrolizumab|Pembrolizumab IV solution
218917301|NCT02608684|DRUG|Gemcitabine|Gemcitabine IV solution
218917302|NCT02608684|DRUG|Cisplatin|Cisplatin IV solution
218917303|NCT02984813|DRUG|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
218917304|NCT02984813|DRUG|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
218917305|NCT02984813|DRUG|Placebo|No active ingredients
218917306|NCT06311487|BEHAVIORAL|Fasted-AM|Participants will engage in aerobic exercise within 4 hours of waking up, following a \>10h overnight fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~08:00, \~13:00, and \~19:00. Plasma metabolite samples will be drawn immediately pre- and post- exercise.
218917307|NCT06311487|BEHAVIORAL|Fed-AM|Participants will engage in exercise within 4 hours of waking up, approximately 1h after consuming breakfast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
218917308|NCT06311487|BEHAVIORAL|Fasted-PM|Participants will engage in exercise between 8-12 hours after waking up, following a \~10h fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00 and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
218917309|NCT06311487|BEHAVIORAL|Fed-PM|Participants will engage in exercise between 8-12 hours after waking up, approximately 1h after consuming dinner across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
219531256|NCT03921463|OTHER||This is an observational study
219531257|NCT04490941|OTHER|Ophthalmologist-delivered health education|The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
219531258|NCT04490941|OTHER|Usual care|Usual care follows standard procedure on diabetes management similar to the routine service provision.
219531259|NCT01773590|OTHER|Rhinovirus Infection|
218917310|NCT03819192|DIAGNOSTIC_TEST|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
218917311|NCT03819192|DIAGNOSTIC_TEST|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
219531260|NCT02294253|DRUG|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
218917312|NCT03819192|DIAGNOSTIC_TEST|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
218917313|NCT00136396|DRUG|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
218917314|NCT03544684|BEHAVIORAL|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
218917315|NCT06120374|RADIATION|Radiotherapy|"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
218917316|NCT06120374|DRUG|Chemotherapy|For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
218917317|NCT06120374|DRUG|Immunotherapy|For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
218917318|NCT04318873|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
218917319|NCT00689858|DRUG|Cilostazol, Ginkgo biloba and placebo|dosing time
218917320|NCT06225453|OTHER|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
218917321|NCT06225453|OTHER|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
218917322|NCT00312429|PROCEDURE|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
219531261|NCT05088343|DRUG|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
219531262|NCT05088343|DRUG|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
219531263|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
219531264|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
219531265|NCT03407781|DRUG|68Ga-BBN-IRDye800CW|PET/NIR fluorescent imaging-guided surgery
219531266|NCT04920929|DEVICE|Hydrophilic Biomaterial|PICC made out of a Hydrophilic Biomaterial
219531267|NCT04920929|DEVICE|Thermoplastic Polyurethane|PICC made out of a thermoplastic polyurethane material
219531268|NCT01745120|GENETIC|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
219531269|NCT00544180|DRUG|Risedronate|
219531270|NCT03956862|DRUG|GB001|film-coated oral tablet
219616638|NCT03968900|BEHAVIORAL|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
219616639|NCT05317728|DEVICE|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
219616640|NCT05317728|DEVICE|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
218917323|NCT04833582|DRUG|ZN-c3|ZN-c3 is an investigational drug.
218917324|NCT04833582|DRUG|Gemcitabine|Gemcitabine is an approved drug
218959269|NCT03109912|BEHAVIORAL|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
219531271|NCT03956862|DRUG|Placebo|film-coated oral tablet
219531272|NCT00852462|BEHAVIORAL|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
219531273|NCT04089592|DRUG|Dexmedetomidine|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
219531274|NCT04089592|DRUG|Fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline
219531275|NCT02129426|DRUG|Ketamine|Sedation medication
219531276|NCT02129426|DRUG|Midazolam|Sedation medication
219531277|NCT02129426|DRUG|Dexmedetomidine|Sedation medication
219531278|NCT05258474|DRUG|controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)|single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
219531279|NCT05258474|DRUG|Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
218917325|NCT05270720|BIOLOGICAL|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
218917326|NCT01108016|BEHAVIORAL|Videoconferencing support group|
218917327|NCT05176405|BEHAVIORAL|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
218917328|NCT05176405|BEHAVIORAL|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
218917329|NCT05251168|PROCEDURE|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
218917330|NCT05251168|PROCEDURE|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
218917331|NCT02168244|OTHER|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
219531280|NCT05258474|DRUG|Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)|single- and multiple-ascending dose (SAD/MAD)
219531281|NCT05258474|DRUG|Placebo Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
219531282|NCT04784520|DRUG|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
219531283|NCT00914420|DEVICE|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
219616641|NCT05317728|PROCEDURE|Cataract surgery|Phacoemulsification with a clear cornea incision
219616642|NCT06799650|DRUG|Gammora®|Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
219531284|NCT00914420|DEVICE|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
219531285|NCT00040391|DRUG|Investigational drug|
219616643|NCT06377930|DRUG|RAP-219|RAP-219 oral tablet
218917332|NCT02168244|OTHER|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
218917333|NCT04011046|DEVICE|Stent|
219531286|NCT00040391|DRUG|Irinotecan|
219531287|NCT00040391|DRUG|5-fluorouracil|
219531288|NCT00040391|DRUG|Leucovorin|
219531289|NCT05732857|DEVICE|valveless trocar|the valveless trocar will be used instead of the standard trocar - these trocars are used for insufflation of carbon dioxide into the abdomen
219531290|NCT05732857|DEVICE|standard trocar|standard trocar, usually camera port for robotic surgery
219531291|NCT06123130|DEVICE|Vectorcardiography (VECG)|Patients enrolled will undergo diagnostic ECG recording: three sets of simultaneous 30s recordings with the investigational device AIMIGo and a standard 12L ECG.
219531292|NCT00509730|PROCEDURE|Urodynamics|
219531293|NCT05527548|DRUG|Alendronate (ALN)|The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
219531294|NCT01526330|DRUG|YH14618|A mg/disc
219531295|NCT01526330|DRUG|YH14618|B mg/disc
219531296|NCT01526330|DRUG|YH14618|C mg/disc
219531297|NCT01526330|DRUG|Placebo|0mg/disc
219531298|NCT02975622|PROCEDURE|Central venous catheterization|Ultrasound guided central venous catheterization
219616644|NCT06014086|DRUG|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
219616645|NCT06375564|DRUG|177Lu-AB-3PRGD2 radioligand therapy|Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
219616646|NCT05411991|DIAGNOSTIC_TEST|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
219616647|NCT05411991|DRUG|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.
218917334|NCT00157677|PROCEDURE|D-dimer testing|Uniform D-dimer use
218917335|NCT00157677|PROCEDURE|D-dimer testing|Selective D-Dimer use
218917336|NCT05360004|DRUG|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
218917337|NCT01470521|BIOLOGICAL|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
218917338|NCT01470521|BIOLOGICAL|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
218917339|NCT04295720|DEVICE|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
218917340|NCT04818853|OTHER|Observation to monitor patients for these infections|We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
219042065|NCT03780842|DEVICE|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
219042066|NCT02690675|DIETARY_SUPPLEMENT|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
219531299|NCT06225622|DRUG|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
219531300|NCT06225622|DRUG|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
219531301|NCT06225622|DRUG|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
219531302|NCT06225622|DRUG|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
219531303|NCT06225622|DRUG|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
219531304|NCT06225622|DRUG|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
219531305|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
219531306|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
219531307|NCT00410774|BIOLOGICAL|bevacizumab|
219531308|NCT00410774|DRUG|gemcitabine hydrochloride|
219042067|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
219042068|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
219042069|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
219042070|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
219042071|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
219531309|NCT00410774|PROCEDURE|adjuvant therapy|
219531310|NCT04366401|BEHAVIORAL|Conventional Dietary Advice|"The education content in the control group will be centered on the acquisition of knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Culinary techniques: conservation of properties of the diet.~* \- Feeding in particular situations."
219531311|NCT04366401|BEHAVIORAL|Prebiotic/Probiotic Dietary Modulation|"The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Description and justification of prescribed prebiotic and probiotic diet.~* \- Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* \- Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* \- Feeding in particular situations."
219531312|NCT04737486|DRUG|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
219531313|NCT04737486|OTHER|Placebo|D-PBS
219531314|NCT02059863|BEHAVIORAL|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
219531315|NCT02468284|DRUG|degarelix|
219531316|NCT03609866|PROCEDURE|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
219531317|NCT03609866|PROCEDURE|inferior limb passive mobilization|it will be performed a passive mobilization technique on the patient
219531318|NCT02038621|DRUG|Paclitaxel|
218917341|NCT05642052|DIETARY_SUPPLEMENT|low carb diet|low carb meals will be 50% less carbs than the regular meals
218917342|NCT05642052|DIETARY_SUPPLEMENT|Regular diet|Regular diet
218917343|NCT05552937|DRUG|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
218917344|NCT03018652|DRUG|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
218917345|NCT03018652|DRUG|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
219531319|NCT02038621|DRUG|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
219531320|NCT03974438|PROCEDURE|Superficial dry needling / Acupunture|Se arm-description.
218917346|NCT00752349|PROCEDURE|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
218917347|NCT01407432|DRUG|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
218917348|NCT01407432|DRUG|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
218917349|NCT05458115|PROCEDURE|Liver resection|Patient underwent hepatic R0 resection within a week
218917350|NCT02461641|OTHER|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
219042072|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
219042073|NCT02547662|DRUG|Dexamethasone|Given PO
219042074|NCT02547662|DRUG|Ixazomib Citrate|Given PO
219042075|NCT02547662|OTHER|Laboratory Biomarker Analysis|Correlative studies
219042076|NCT02547662|DRUG|Pomalidomide|Given PO
219531321|NCT01331187|PROCEDURE|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
219531322|NCT01331187|OTHER|Usual care|No intervention, except for usual care (goal-directed diagnostics)
219531323|NCT00579670|DRUG|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
219531324|NCT03414593|DRUG|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
219531325|NCT04438707|OTHER|Pilates Method combined with Therapeutic exercice.|Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
219616648|NCT05411991|DRUG|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
219616649|NCT05411991|DRUG|Oral chlorthalidone OD|In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
218917351|NCT02461641|OTHER|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
218917352|NCT02461641|OTHER|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
218917353|NCT04176471|OTHER|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
219042077|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
219042078|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
219042079|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
219042080|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
219042081|NCT02433834|DRUG|Serevent Diskus 50 μg|
219042082|NCT02433834|DRUG|Placebo|
219042083|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
219531326|NCT04438707|OTHER|Therapeutic exercise|Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
219531327|NCT04365153|DRUG|Canakinumab Injection 600mg|Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
219531328|NCT04365153|DRUG|Canakinumab Injection 300mg|Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
219531329|NCT04365153|DRUG|Placebos|250 mL of 5% dextrose infused IV over 2 hours
219531330|NCT00440453|OTHER|Nutritional therapy|Nutritional therapy by dietician
219531331|NCT00850174|DRUG|Oxcarbazepine|600 mg Tablet
218917354|NCT04176471|OTHER|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
218917355|NCT03598686|DIAGNOSTIC_TEST|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
218917356|NCT04400201|DRUG|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
218917357|NCT04400201|DRUG|Propofol|Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
218917358|NCT00000197|DRUG|Propranolol|
219531332|NCT00850174|DRUG|Trileptal®|600 mg Tablet
219531333|NCT01363765|OTHER|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
218917359|NCT04214938|OTHER|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
218917360|NCT06009211|OTHER|QueaseEase|Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
218917361|NCT02018718|DEVICE|Magnetic Resonance Imaging (MRI)|
219531334|NCT01363765|OTHER|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
219531335|NCT00635492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
219531336|NCT00635492|DRUG|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
219531337|NCT01900626|DRUG|epidural catheter|epidural catheter with 0.3% ropivacaine
219531338|NCT03026374|BEHAVIORAL|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
219531339|NCT02451267|OTHER|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
219531340|NCT02451267|OTHER|physical therapy treatment|neck exercise strengthening program with neck massage
219531341|NCT03968601|OTHER|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
219531342|NCT04549272|OTHER|No interventions|No interventions - observational study
219531343|NCT02045563|OTHER|prise de sang|
219531344|NCT02045563|OTHER|magnetic resonance imaging and magnetic resonance spectroscopy|
219531345|NCT02881255|DEVICE|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
219531346|NCT00422214|DRUG|Quetiapine fumarate (Seroquel) SR|
219531347|NCT03239990|BEHAVIORAL|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
219531348|NCT01344707|DRUG|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
219531349|NCT06013293|PROCEDURE|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
219531350|NCT06013293|PROCEDURE|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
219042084|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
219042085|NCT00733720|DRUG|Suboxone|4/1mg, 8/2mg 16/4mg
219531351|NCT01736878|DRUG|Sorafenib|
219531352|NCT05209347|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
219042086|NCT01024543|DRUG|Angiotensin II|Angiotensin II
219042087|NCT01024543|DRUG|Phenylephrine|Phenylephrine
219042088|NCT01024543|DRUG|Placebo|
219531353|NCT04813692|PROCEDURE|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
219531354|NCT04813692|PROCEDURE|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
219531355|NCT04813692|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
219531356|NCT00622414|BIOLOGICAL|ziv-aflibercept|Given IV
219531357|NCT03666728|DRUG|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
219531358|NCT03666728|DRUG|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
219531359|NCT02167386|BEHAVIORAL|Enhanced PrEP Adherence|
219531360|NCT02167386|BEHAVIORAL|Standard PrEP Adherence|
219531361|NCT03502395|DRUG|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
219531362|NCT03502395|DRUG|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
218917362|NCT04301375|DRUG|Pertuzumab and trastuzumab FDC subcutaneous|Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
218917363|NCT04301375|DRUG|Paclitaxel|80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
219531363|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
219531364|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
219531365|NCT01517321|DRUG|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
219616650|NCT05411991|DRUG|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are \>5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
218917364|NCT04301375|DRUG|TDM1|3,6 mg/kg, 14 adjuvant cycles if not complete response
218917365|NCT04301375|DRUG|Endocrine therapy|Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
218917366|NCT04301375|PROCEDURE|Omission surgery|Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
218917367|NCT01456039|DRUG|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
218917368|NCT03614650|BIOLOGICAL|engineered immune cells|Engineered immune effector cells (EIE)
218917369|NCT00755183|DRUG|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
218917370|NCT00755183|DRUG|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
219042089|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
219531366|NCT01517321|DRUG|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
219531367|NCT04910178|DRUG|Empagliflozin 25 MG|tablets to be taken orally once a day
219531368|NCT04910178|DRUG|Ursodeoxycholic acid|tablets to be taken orally twice a day
219531369|NCT04910178|DRUG|Pentoxifylline 400 MG|tablets to be taken orally twice a day
219616651|NCT05411991|OTHER|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are \<4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration \<130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
219616652|NCT05411991|DRUG|Oral potassium supplements|If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels \>4 mmol/L
219616653|NCT05411991|OTHER|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration \<125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
219616654|NCT05411991|OTHER|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa \<80 mmol/L, intravenous diuretics are switched to an oral schedule including:~* Loop diuretics with dose \& frequency at the discretion of the treating physician~* Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~* Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
218917371|NCT01547078|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
218917372|NCT01547078|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
218917373|NCT03016728|BEHAVIORAL|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
218917374|NCT00148317|DRUG|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
219531370|NCT04910178|OTHER|placebo|just starch tablets without any active agents
219531371|NCT04055805|BEHAVIORAL|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
219531372|NCT05615454|DEVICE|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
219531373|NCT05615454|DEVICE|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
219531374|NCT02127463|DRUG|MC-1101|Topically, two times a day, morning and bedtime
219531375|NCT02127463|DRUG|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
218917375|NCT00148317|DRUG|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
218917376|NCT00148317|DRUG|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
218917377|NCT00148317|DRUG|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
218917378|NCT00148317|DRUG|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
218917379|NCT00755664|DIETARY_SUPPLEMENT|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
218917380|NCT06118632|OTHER|Observational|Observational
218917381|NCT06271577|DEVICE|AliveCor 12-lead ECG|The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
218917382|NCT00335777|DRUG|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
218917383|NCT00335777|DRUG|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
218917384|NCT00562224|DRUG|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
218917385|NCT03682419|PROCEDURE|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
218917386|NCT03682419|PROCEDURE|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
219531376|NCT06563258|DEVICE|Biodex Balance Training|"Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise."
219531377|NCT06563258|DEVICE|A vibration device|WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
219531378|NCT06563258|OTHER|traditional exercises|"1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)"
219531379|NCT00221299|DRUG|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
219531380|NCT00221299|DRUG|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
219531381|NCT05687552|DEVICE|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
219531382|NCT04822259|DEVICE|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
219531383|NCT04822259|DEVICE|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
219531384|NCT00223925|DRUG|Maribavir|
218917387|NCT04395976|OTHER|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
218917388|NCT04448535|DIETARY_SUPPLEMENT|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
218917389|NCT00533208|DRUG|MK0524|
218917390|NCT02271204|DRUG|Ibandronic acid|As prescribed by physician
218917391|NCT04639245|DRUG|Atezolizumab|Given IV
218917392|NCT04639245|DRUG|Cyclophosphamide|Given IV
218917393|NCT04639245|DRUG|Fludarabine|Given IV
218917394|NCT04639245|BIOLOGICAL|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
218917395|NCT04639245|BIOLOGICAL|PD1 Inhibitor|Given IV
219531385|NCT00223925|DRUG|Placebo|
219531386|NCT05250843|PROCEDURE|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
219531387|NCT05250843|DRUG|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
219531388|NCT05250843|DRUG|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
219531389|NCT05250843|PROCEDURE|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
218959270|NCT04294745|PROCEDURE|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
219531390|NCT05053763|DRUG|Remimazolam|The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
219531391|NCT01774435|DRUG|EN3342|
219531392|NCT01288352|OTHER|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
219531393|NCT02640183|DRUG|EMLA|
219531394|NCT02640183|OTHER|Placebo|
219531395|NCT03343795|DRUG|oral progesterone|daily
219531396|NCT03343795|DRUG|intramuscular progesterone|every week
219531397|NCT00846495|DRUG|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
219531398|NCT00846495|DRUG|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
219531399|NCT02308722|RADIATION|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV\_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV\_R) 10Gy/# (total dose 50Gy)"
219531400|NCT02670057|PROCEDURE|Transnasal SPG block|
219531401|NCT06141317|BIOLOGICAL|PASC transplantation (25 million PASCs/patient)|3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
219531402|NCT06141317|BIOLOGICAL|Control|0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
219531403|NCT03872505|DRUG|Durvalumab|IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
219616655|NCT05411991|OTHER|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
219616656|NCT05613985|OTHER|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
219616657|NCT05613985|DEVICE|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
219616658|NCT03886584|OTHER|Monitoring source test|Internal- and external-monitoring correct responses and inversions
219531404|NCT03872505|RADIATION|Radiation Therapy|The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
219531405|NCT03872505|DRUG|Carboplatin|IV administration weekly for 12 weeks
219531406|NCT03872505|DRUG|Paclitaxel|IV administration every week for 12 weeks
219616659|NCT05731128|DRUG|Dupilumab|injection solution subcutaneous
219616660|NCT05731128|DRUG|Placebo|injection solution subcutaneous
219616661|NCT04827862|DRUG|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
219616662|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
219531407|NCT01265056|DRUG|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
219531408|NCT01265056|DRUG|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
219531409|NCT01123694|OTHER|Survey Study|Survey regarding quality of life
219531410|NCT00155545|BEHAVIORAL|Motion analysis of patients|
218917396|NCT04985279|DEVICE|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
218917397|NCT04985279|DEVICE|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
218917398|NCT01167075|DIETARY_SUPPLEMENT|Fresubin Original|
218917399|NCT01167075|DIETARY_SUPPLEMENT|Intestamin plus Fresubin Original|
218917400|NCT03527459|BEHAVIORAL|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
218917401|NCT03527459|BEHAVIORAL|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
218917402|NCT01314313|DEVICE|TAVR Implantation with SAPIEN XT|Operable Group with SAPIEN XT
218917403|NCT01314313|DEVICE|SAVR Implantation|Control Group
218917404|NCT00495313|DRUG|doxycycline|COL-101, QD plus metronidazole
218917405|NCT00495313|DRUG|doxycycline|40 mg with metronidazole QD
219042090|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
219531411|NCT03289286|OTHER|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~* Completion of questionnaires using an electronic tool,~* Telephone follow-up if necessary between the nurse and the patient."
219531412|NCT05552833|OTHER|High intensity interval training|Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
219531413|NCT00064974|DRUG|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
219531414|NCT02431494|DEVICE|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
219531415|NCT02431494|DEVICE|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
219531416|NCT02431494|DEVICE|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
219531417|NCT03859102|DIETARY_SUPPLEMENT|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
219531418|NCT03859102|DRUG|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
219531419|NCT03859102|DRUG|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
219531420|NCT03859102|DRUG|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
219531421|NCT03859102|DRUG|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
219531422|NCT03859102|DRUG|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
219531423|NCT03859102|DRUG|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
218917406|NCT05371626|PROCEDURE|Suture-less surgical procedure|Suture-less technique will be used in treatment for cicatricial upper eyelid entropion
218917407|NCT04254458|DIAGNOSTIC_TEST|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
218917408|NCT06314802|OTHER|no intervention|No intervention
218917409|NCT04652752|DEVICE|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
218917410|NCT04812392|DEVICE|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
218917411|NCT00732030|DEVICE|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
218917412|NCT04383600|PROCEDURE|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
218917413|NCT02887677|DRUG|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
218959271|NCT04294745|PROCEDURE|Inferior alveolar nerve block|Standard technique of mandibular nerve block
219531424|NCT03859102|DRUG|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
219531425|NCT03859102|DRUG|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
219531426|NCT03859102|DRUG|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
219531427|NCT03859102|DRUG|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
219531428|NCT03859102|PROCEDURE|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
219531429|NCT03859102|PROCEDURE|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
219531430|NCT03859102|OTHER|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
219531431|NCT02409979|OTHER|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
219531432|NCT02409979|OTHER|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
219531433|NCT02409979|OTHER|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
219531434|NCT03725605|COMBINATION_PRODUCT|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
219531435|NCT05463653|DEVICE|Experimental|A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
219531436|NCT01944800|DRUG|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
219531437|NCT01944800|DRUG|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg
219531438|NCT06387771|DRUG|Tolcapone|Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
219531439|NCT00965185|DRUG|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
219531440|NCT00965185|DRUG|Placebo|Placebo
219531441|NCT04294108|OTHER|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
219531442|NCT01714570|DRUG|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
219531443|NCT01714570|DRUG|Imipenem|0.5g q6h, 5-10 days
219531444|NCT04473170|BIOLOGICAL|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
219531445|NCT04473170|DRUG|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
218917414|NCT02887677|DRUG|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
218917415|NCT01136161|BIOLOGICAL|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
219531446|NCT03661593|OTHER|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
219531447|NCT00002047|DRUG|Zidovudine|
219531448|NCT01083277|DEVICE|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
219531449|NCT01083277|OTHER|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
219531450|NCT02766075|BEHAVIORAL|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
219531451|NCT03300934|DEVICE|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
219531452|NCT03262688|DRUG|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
219531453|NCT03262688|DRUG|Bupivacaine HCl infiltration|Infiltration of the surgical site
219616663|NCT05918861|DRUG|Placebo|matching placebo tablets
219616664|NCT04515875|BEHAVIORAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
219531454|NCT00011570|DEVICE|Bladder & Bowel Control|
219531455|NCT03637153|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219531456|NCT03637153|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
218917416|NCT01136161|BIOLOGICAL|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
218917417|NCT01136161|BIOLOGICAL|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
218917418|NCT01136161|BIOLOGICAL|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
219042091|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
218917419|NCT04179669|DRUG|IBI306|Administered by subcutaneous injection
219531457|NCT05283070|OTHER|Questionnaires, physical tests, and heart rate variability measures|"The 2MWT will be conducted in an unobstructed hallway with patients being asked to walk at moderate intensity (brisk walk) for the duration of the activity (2 minutes). The amount of distance in metres will be recorded.~The EMLi movement consists of pushing a 2kg weighted ball from the chest level forward, and then raising the ball overhead, before returning it to the starting position (Figure 1). The number of repetitions done at moderate intensity will be recorded after 60 seconds.~HRV and questionnaires previously listed"
219531458|NCT05844553|DEVICE|Measurement of inhaled measuring hydrogen peroxide in exhaled breath|Participant exhales in to device
219531459|NCT01802853|DRUG|RO6811135|Single subcutaneous dose
219531460|NCT01802853|DRUG|RO6811135|Single intravenous dose
219531461|NCT02356354|PROCEDURE|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
218917420|NCT04179669|DRUG|placebo|Administered by subcutaneous injection
219531462|NCT01374750|DRUG|Sirolimus|Sirolimus
219531463|NCT01374750|DRUG|m-TOR inhibitor free|calcineurin inhibitors
219531464|NCT04023539|DIETARY_SUPPLEMENT|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
219531465|NCT04023539|OTHER|Placebo|Placebo capsules
219531466|NCT04048317|DRUG|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
219531467|NCT04048317|DRUG|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
218917421|NCT04349397|BEHAVIORAL|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
218917422|NCT04377893|DEVICE|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
218917423|NCT01949818|DRUG|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
218917424|NCT01949818|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
218917425|NCT01398709|OTHER|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
218917426|NCT01398709|OTHER|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
218917427|NCT02668562|PROCEDURE|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
218917428|NCT02668562|PROCEDURE|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
219042092|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
219042093|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
219042094|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
219042095|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
219042096|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
218917429|NCT05511233|DIETARY_SUPPLEMENT|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
218917430|NCT03829228|DIETARY_SUPPLEMENT|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
218917431|NCT03337477|DRUG|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
218917432|NCT03337477|DRUG|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
218917433|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
218917434|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
218917435|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
218917436|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
219531468|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
219531469|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
219531470|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
219531471|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
219531472|NCT04913909|DIETARY_SUPPLEMENT|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
219531473|NCT00591643|PROCEDURE|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
218917437|NCT01896167|OTHER|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
219531474|NCT00591643|RADIATION|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
219531475|NCT01050803|BEHAVIORAL|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
218917438|NCT01896167|OTHER|Placebo|Inhalation of atmospheric air
218917439|NCT05259189|DRUG|NBL-012 Injection|a single subcutaneous injection
218917440|NCT05259189|DRUG|Placebo|a single subcutaneous injection
218917441|NCT01887327|PROCEDURE|Phototherapy|Phototherapy starts within 30 minutes before or after injection
218917442|NCT01887327|DRUG|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
218917443|NCT01887327|DRUG|Placebo|Matching placebo administered by IM injection
218917444|NCT03027609|DRUG|AR-105|monoclonal antibody
218917445|NCT03027609|DRUG|Placebo|matching placebo (+ SOC antibiotics)
218917446|NCT04238923|DRUG|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
218917447|NCT00346580|DRUG|Nelfinavir|
218917448|NCT02187419|OTHER|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
218917449|NCT01434615|DEVICE|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
218917450|NCT01434615|OTHER|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
218917451|NCT05430399|DRUG|utidelone|Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
218917452|NCT05430399|DRUG|docetaxel|Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
218917453|NCT00499070|GENETIC|polymerase chain reaction|
218917454|NCT00499070|OTHER|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
218917455|NCT00499070|OTHER|immunologic technique|
219531476|NCT01050803|BEHAVIORAL|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
219531477|NCT02464709|DRUG|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
219531478|NCT02464709|DRUG|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
219531479|NCT03608878|BIOLOGICAL|adagloxad simolenin/OBI-821|"Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration."
219531480|NCT03608878|PROCEDURE|TACE|Transarterial chemoembolization
219531481|NCT01629069|BEHAVIORAL|Mindfulness based Resilience Training|6 weekly group sessions
219531482|NCT04125706|DRUG|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
219531483|NCT04125706|DRUG|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
219531484|NCT05400148|DRUG|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)
219531485|NCT02272777|DRUG|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
219531486|NCT02272777|DRUG|Nilotinib|Nilotinib 300mg BID or 400mg QD
219531487|NCT05275205|DRUG|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
219531488|NCT05275205|DRUG|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
218917456|NCT00499070|PROCEDURE|biopsy|
218917457|NCT01462370|DRUG|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
218917458|NCT01462370|DRUG|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
218917459|NCT01462370|DRUG|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
218917460|NCT01462370|DRUG|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
218917461|NCT01462370|DRUG|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
219042097|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
219042098|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
219531489|NCT02066922|DEVICE|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
219531490|NCT02066922|DEVICE|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
219531491|NCT02066922|DEVICE|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
219531492|NCT00167505|BEHAVIORAL|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
219531493|NCT00167505|BEHAVIORAL|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
219531494|NCT02947230|OTHER|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
219531495|NCT01852617|BEHAVIORAL|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
219531496|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
219531497|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
218917462|NCT03036202|DRUG|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
219531498|NCT03338660|BIOLOGICAL|Placebo|Subjects will receive infusion placebo (saline).
218917463|NCT02224807|BEHAVIORAL|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
219531499|NCT00440297|BIOLOGICAL|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
219531500|NCT00440297|BIOLOGICAL|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
219531501|NCT03751605|PROCEDURE|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
219531502|NCT03020641|PROCEDURE|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
219531503|NCT03020641|PROCEDURE|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
219531504|NCT01397630|DRUG|Oxytocin|Accelerated Oxytocin Titration
219531505|NCT01033305|DRUG|CyCol™|Orally, once per day for 4 weeks
219531506|NCT01033305|DRUG|Placebo|Orally, once per day for 4 weeks
219531507|NCT04181905|OTHER|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
219531508|NCT02648880|BEHAVIORAL|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
219531509|NCT02648880|OTHER|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
219531510|NCT05539222|OTHER|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
219531511|NCT01925092|DRUG|mifepristone|tablets
219531512|NCT04607720|PROCEDURE|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
219531513|NCT04607720|PROCEDURE|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
219531514|NCT02934347|PROCEDURE|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
219531515|NCT05984420|DEVICE|LimpiAD 2,5% plus cream|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
219531516|NCT05984420|OTHER|Vehicle|"Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component."
219531517|NCT05984420|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
219531518|NCT02978586|DEVICE|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
218917464|NCT02224807|BEHAVIORAL|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
218917465|NCT06175806|DRUG|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
218917466|NCT06175806|DRUG|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
218917467|NCT03341702|OTHER|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
218917468|NCT01834989|DRUG|Insulin-like growth factor I|
219531519|NCT06123533|OTHER|No intervention|There is no intervention.
219531520|NCT00050297|DRUG|YM598|
219531521|NCT00431691|DRUG|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
218917469|NCT01834989|DRUG|Placebo|
218917470|NCT00508794|BEHAVIORAL|Yoga Group|3 sessions of yoga each week for 6 weeks.
218917471|NCT00508794|BEHAVIORAL|Stretching Control Group|3 sessions of stretching each week for 6 weeks
218917472|NCT00508794|BEHAVIORAL|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
218917473|NCT00508794|OTHER|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
219531522|NCT00431691|DRUG|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
219531523|NCT00431691|DRUG|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
219531524|NCT00431691|DRUG|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
218917474|NCT02220920|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
218917475|NCT02220920|DRUG|Placebo|The patients will receive Placebo orally for 16 weeks
218917476|NCT02220920|DRUG|Insulin|
218917477|NCT01703143|PROCEDURE|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
218917478|NCT01939613|DRUG|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
218917479|NCT00473564|PROCEDURE|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
218917480|NCT00733018|BEHAVIORAL|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
218917481|NCT04743843|DEVICE|Omnyx Dynamyx Software|Digital pathology image management and viewing software.
218917482|NCT06525012|OTHER|Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin|During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
218917483|NCT06450899|DRUG|Prochlorperazine Maleate|Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.
219531525|NCT00229281|BEHAVIORAL|Group therapy|
219531526|NCT02686333|OTHER|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
219531527|NCT02039908|DRUG|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
219531528|NCT03622138|OTHER|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
219531529|NCT07037017|BEHAVIORAL|Cognitive-Behavioral Therapy|Manualized 12-week CBT protocol focused on reducing body image disturbance, distorted beliefs about food and appearance, and avoidance behaviors in individuals with anorexia nervosa. The intervention incorporates psychoeducation, cognitive restructuring, emotional regulation, food exposure, and body image work.
219531530|NCT07035652|OTHER|XH-S004 20 mg, 40 mg or 60 mg|Administered once per day for 140 days.
219531531|NCT07035652|OTHER|Placebo|Administered once per day for 140 days.
219531532|NCT07035977|RADIATION|Participants will receive a 1/6 views undersampling lung CBCT scan.|Participants will receive a 1/6 views undersampling lung CBCT scan. And the CBCT images will be reconstructed by DeepSparseCBCT model for further analysis.
219531533|NCT07036328|DEVICE|repetitive transcranial magnetic stimulation|20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus
219531534|NCT07036328|DEVICE|sham repetitive transcranial magnetic stimulation|20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus
219531535|NCT07037511|DRUG|Salbutamol|Meter-dose inhaler of salbutamol performed using large-volume spacer
219531536|NCT07037511|DRUG|Placebo|Meter-dose inhaler of placebo performed using large-volume spacer
219531537|NCT07037225|OTHER|Fluid challenge during one-lung ventilation (OLV) in the lateral decubitus position|During OLV, a lung recruitment maneuver will be performed, followed by measurements of CPI, CI, SVI, and MAP. A fluid challenge using 250 mL of normal saline (0.9% NaCl) will be administered. Hemodynamic parameters will be recorded at 2 and 5 minutes post-infusion. Patients will be classified as responders (SVI and MAP increase ≥10%) or non-responders. Changes in CPI will also be recorded accordingly.
219531538|NCT07037225|DEVICE|Hemodynamic monitoring|Invasive hemodynamic monitoring will be performed using the HemoSphere device (Edwards Lifesciences).
219531539|NCT04590443|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
219531540|NCT01256892|PROCEDURE|induction of labour|
219531541|NCT03190239|DRUG|Apatinib|Apatinib 250mg qd
219531542|NCT03190239|DRUG|Pemetrexed|Pemetrexed 500mg/m2 qm
218917484|NCT06450899|DRUG|Placebo|The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
219531543|NCT04882163|DRUG|CC-220|CC-220
219531544|NCT04882163|DRUG|Polatuzumab vedotin|Polatuzumab vedotin
219531545|NCT04882163|DRUG|Rituximab|Rituximab
219531546|NCT04882163|DRUG|Tafasitamab|Tafasitamab
219531547|NCT04882163|DRUG|Gemcitabine|Gemcitabine
219531548|NCT04882163|DRUG|Cisplatin|Cisplatin
219531549|NCT04882163|DRUG|Dexamethasone|Dexamethasone
219531550|NCT04882163|DRUG|Bendamustine|Bendamustine
219531551|NCT04882163|DRUG|Lenalidomide|Lenalidomide
219531552|NCT02598063|DRUG|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
219531553|NCT02598063|DRUG|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
218917485|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 1|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
218917486|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 2|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
219042099|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
219042100|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
219531554|NCT02598063|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
219531555|NCT05443386|PROCEDURE|colorectal surgery|we have included several types of colorectal surgery procedures, in emergency conditions
219531556|NCT01534663|DRUG|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
219531557|NCT01534663|DRUG|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
219531558|NCT06411847|BEHAVIORAL|Virtual appointments|This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
219531559|NCT05402137|BEHAVIORAL|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
219531560|NCT05620511|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
219531561|NCT04476511|DRUG|Cholecalciferol|tablet containing 30.000IU cholecalciferol
219531562|NCT04480983|DEVICE|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
219531563|NCT05999253|PROCEDURE|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia."
219531564|NCT05999253|PROCEDURE|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia"
219531565|NCT06203951|DIAGNOSTIC_TEST|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
219531566|NCT00295477|GENETIC|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
219531567|NCT04767347|OTHER|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
219531568|NCT04767347|OTHER|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
219042101|NCT03607916|DRUG|Morphine|100µg morphine
219042102|NCT02881294|DRUG|SUVN-G3031|
219042103|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
219042104|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
219042105|NCT04020302|BEHAVIORAL|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
219616665|NCT04515875|BEHAVIORAL|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
219616666|NCT05925023|DRUG|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
219616667|NCT05956340|BEHAVIORAL|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
219616668|NCT06346132|DEVICE|Virtual reality application|In this group, virtual reality will be added to usual care
219616669|NCT03175302|BEHAVIORAL|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
219616670|NCT05689736|BEHAVIORAL|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~1. Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~2. Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (\<70th %ile).~3. Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
219616671|NCT05689736|BEHAVIORAL|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
219531569|NCT04767347|OTHER|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
219531570|NCT04767347|OTHER|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
219042106|NCT03479866|OTHER|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
219531571|NCT04767347|OTHER|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
219531572|NCT04767347|OTHER|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
219042107|NCT03202004|DRUG|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
219042108|NCT03202004|DRUG|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
219042109|NCT00104533|DEVICE|Magnets|
219042110|NCT00895739|BIOLOGICAL|alemtuzumab|
219042111|NCT00895739|DRUG|cyclosporine|
219531573|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
219531574|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
218917487|NCT06004999|OTHER|Whole body vibration|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program on the vibration platform will be applied to the 1st group.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
218917488|NCT06004999|OTHER|The exercise program on flat ground without a vibration platform|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program will be applied to the group.~The exercise program will be applied to the 2nd group (controls) on flat ground without a vibration platform.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
218917489|NCT04723056|DEVICE|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
218917490|NCT05106894|BEHAVIORAL|smartphone application to promote nurturing care|see arm description
218917491|NCT05106894|BEHAVIORAL|printed caregiving materials|see arm description
218917492|NCT05021185|OTHER|Interactive Mobile Doctor (iMD)|Video educational tool
218917493|NCT05941481|COMBINATION_PRODUCT|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)|"1. Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid\*14d + oxaliplatin 130mg/m2, d1, q21d);~2. Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f."
219531575|NCT03107091|DRUG|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
218917494|NCT05697770|DRUG|Sodium bicarbonate|Sodium bicarbonate 8.4% will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
219042112|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
219042113|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
219042114|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
219042115|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
219042116|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
219042117|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
219531576|NCT05464394|DRUG|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
219531577|NCT05464394|DRUG|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
219531578|NCT02565160|PROCEDURE|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
219531579|NCT02565160|PROCEDURE|Joint irrigation washout|Procedural washout for treatment purposes
219531580|NCT02565160|PROCEDURE|Total Joint Arthroplasty|
219531581|NCT02565160|PROCEDURE|Revision Joint Arthroplasty|
219531582|NCT02332863|DEVICE|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
219531583|NCT02332863|DEVICE|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
219531584|NCT02069535|BIOLOGICAL|AVANZ Cupressus|AVANZ Cupressus
219531585|NCT03049215|DEVICE|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
218917495|NCT05697770|DRUG|5% Dextrose|5% dextrose will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
218917496|NCT05236816|OTHER|Fatigue (physical exercise)|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
218917497|NCT04441138|DRUG|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
218917498|NCT05561920|DEVICE|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
218917499|NCT05561920|DEVICE|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
219042118|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
219042119|NCT01099085|DRUG|Placebo|Placebo
219531586|NCT03049215|DEVICE|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
219042120|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
219042121|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
218917500|NCT05561920|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires
218917501|NCT02118584|DRUG|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
218917502|NCT03727217|DIAGNOSTIC_TEST|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
219042122|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
219042123|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
219042124|NCT03904459|OTHER|no intervention|
219042125|NCT04633096|BEHAVIORAL|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
219042126|NCT04633096|BEHAVIORAL|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
219042127|NCT02643251|DRUG|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
219042128|NCT02643251|DRUG|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
219042129|NCT00667238|BEHAVIORAL|Questionnaire|
219042130|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
219042131|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
219042132|NCT02129075|DRUG|Poly ICLC|Given SC
219042133|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
219042134|NCT00348556|DRUG|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
219042135|NCT05374811|OTHER|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
219531587|NCT05507619|OTHER|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
219531588|NCT05507619|OTHER|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
219531589|NCT02778230|DIETARY_SUPPLEMENT|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
219531590|NCT02778230|DIETARY_SUPPLEMENT|Control|Snacks (2 baked goods) without fiber fortification.
219531591|NCT04567186|DEVICE|Investigational senofilcon A C3 Multifocal Lens|TEST
219531592|NCT04567186|DEVICE|delefilcon A Multifocal Lens|Dailies Total 1® Multifocal Contact Lens
219531593|NCT05451446|DIETARY_SUPPLEMENT|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
219531594|NCT05451446|OTHER|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
219531595|NCT05451446|OTHER|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
219531596|NCT05506280|PROCEDURE|blood prolactin levels|The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
219531597|NCT03095846|PROCEDURE|Cooling|Individualized cooling protocol
219531598|NCT04161365|PROCEDURE|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
219531599|NCT04161365|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
219531600|NCT06189274|OTHER|Anatomy-Based Electrode Array Selection|Use of pre-operative imaging to select the appropriate length electrode vs standard of care
218917503|NCT03956849|OTHER|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
218917504|NCT01076478|DRUG|Cilostazol|100 mg, 200mg tablet Cilostazol
218917505|NCT01596010|DRUG|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
219042136|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
219042137|NCT00333229|DRUG|Placebo|Matching Placebo
219531601|NCT06189274|OTHER|Standard of Care Electrode Array Selection|Use of standard of care electrode which is the FLEX 28 electrode
219531602|NCT01707420|DRUG|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
219531603|NCT01707420|DRUG|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
219531604|NCT02175238|DRUG|BI 691751 fasted|single dose BI 691751 in fasted state
219531605|NCT02175238|DRUG|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
219531606|NCT03586700|DRUG|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
219531607|NCT03586700|RADIATION|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
219531608|NCT03586700|DRUG|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
219531609|NCT03885362|DEVICE|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
219531610|NCT01305226|DRUG|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
219531611|NCT01305226|DRUG|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
219531612|NCT05486780|BEHAVIORAL|Digital Window|For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
219531613|NCT01185548|DRUG|Tolbutamide|Administered orally
219531614|NCT01185548|DRUG|Tasisulam|Administered intravenously
218917506|NCT02559453|PROCEDURE|Debridement|Removing dead tissue from infected wounds.
218917507|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
218917508|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
218917509|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
218917510|NCT03692624|BEHAVIORAL|Biofeedback|Heart Rate Variability Biofeedback
218917511|NCT05040464|DRUG|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
219042138|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
219042139|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
219042140|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
219042141|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
219531615|NCT05321446|DEVICE|GoHand(TM)|The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
219531616|NCT03546777|DEVICE|magnetic resonance imaging|magnetic resonance imaging of shoulder
219531617|NCT02171793|DRUG|BI 1744 CL|
219531618|NCT02171793|DRUG|Placebo|
219531619|NCT02133105|DRUG|Levosimendan|
219531620|NCT02133105|DRUG|Dobutamine|
218917512|NCT05040464|DRUG|MTX|MTX 25 mg SC once a week
218917513|NCT05040464|BIOLOGICAL|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
218917514|NCT00335088|DRUG|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
218917515|NCT02748083|DEVICE|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
218917516|NCT02748083|DEVICE|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
218917517|NCT02614300|OTHER|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
218917518|NCT02614300|OTHER|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
219531621|NCT03959605|GENETIC|blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism
219531622|NCT03959605|DIAGNOSTIC_TEST|Ophtalmological examination|measurement of visual acuity, OCT and OCTA
219531623|NCT00290030|DRUG|Alfuzosin|
219531624|NCT00102440|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
219531625|NCT00102440|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
219531626|NCT00102440|DRUG|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
218917519|NCT02614300|OTHER|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
219042142|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
219042143|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
219042144|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
219042145|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
219531627|NCT03337386|DIAGNOSTIC_TEST|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
219616672|NCT05689736|BEHAVIORAL|Gamification|"Gamification will include four features:~1. Game-like graphical environment (e.g., avatars to represent the participant).~2. Digital rewards. Parents will receive points and badges for completing intervention activities.~3. Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~4. Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
219531628|NCT03337386|DIAGNOSTIC_TEST|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
219531629|NCT03337386|DIAGNOSTIC_TEST|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
219531630|NCT01533805|OTHER|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
218917520|NCT03103542|BIOLOGICAL|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
218917521|NCT01719016|PROCEDURE|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min"
218917522|NCT06242652|DRUG|608 Dose A|608 subcutaneous (SC) injection.
219531631|NCT01533805|OTHER|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
218917523|NCT06242652|DRUG|608 Dose B|608 subcutaneous (SC) injection.
218917524|NCT06242652|DRUG|608 Dose C|608 subcutaneous (SC) injection.
218917525|NCT06242652|DRUG|Adalimumab|Adalimumab subcutaneous (SC) injection.
219531632|NCT05340140|DIAGNOSTIC_TEST|deep learning model|deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
219531633|NCT00941174|DRUG|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
218917526|NCT06242652|DRUG|Placebo|Placebo subcutaneous (SC) injection.
218917527|NCT04721860|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
218917528|NCT04721860|BEHAVIORAL|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
218917529|NCT04971161|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
219042146|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
219042147|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
219042148|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
219616673|NCT05689736|BEHAVIORAL|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
219616674|NCT05689736|BEHAVIORAL|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
218917530|NCT04971161|DRUG|Placebo|One topical application with a syringe
218917531|NCT04730700|PROCEDURE|Radiofrequency Ablation with MEE|RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
218917532|NCT04730700|BEHAVIORAL|Conventional Medical Management|Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
218917533|NCT06329817|PROCEDURE|Incidence of regurgitation in two different position.|Preventing aspiration pneumonia in general anaesthesia in two different position supine v/s semi - Fowler
218917534|NCT03566511|DRUG|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
219042149|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
219042150|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
219042151|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
219616675|NCT06484790|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
218917535|NCT03566511|DRUG|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
219042152|NCT01726010|DEVICE|22-G Procore Needle|
219042153|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
219042154|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
219616676|NCT06484790|DRUG|NW-301D|TCR-T T cell targeting KRAS G12D mutation
218917536|NCT04538989|DRUG|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
218917537|NCT04538989|DRUG|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
218917538|NCT04538989|DRUG|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
218917539|NCT04538989|DRUG|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
218917540|NCT06366217|DEVICE|MydCombi Device|ophthalmic spray
218917541|NCT06366217|DRUG|MydCombi Drug|Tropicamide 1% and phenylephrine HCl 2.5%
218917542|NCT04196777|BEHAVIORAL|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
218917543|NCT04691648|DRUG|Gilteritinib Exposure|Oral
219531634|NCT03918174|DEVICE|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
219616677|NCT06092892|PROCEDURE|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
218917544|NCT06132659|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
218917545|NCT06132659|OTHER|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
218917546|NCT06224205|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
218917547|NCT05371717|OTHER|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
218917548|NCT05371717|OTHER|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
218917549|NCT02939287|DRUG|o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1|Add aprepitant to anti-emetic regimen
218917550|NCT02939287|DRUG|Olanzapine10 mg orally daily on Days -1,0,+1 and +2|add olanzapine to anti-emetic regimen
218917551|NCT02939287|DRUG|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
218917552|NCT00981656|DRUG|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
218917553|NCT00981656|DRUG|5-fluorouracil|Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
218917554|NCT00981656|DRUG|Mitomycin|IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
218917555|NCT00981656|RADIATION|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
218917556|NCT00687596|DRUG|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
218917557|NCT00687596|DRUG|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
218917558|NCT06471244|OTHER|Finger tapping|The volunteer is tapping with his/her right hand index finger.
218917559|NCT06471244|OTHER|Median nerve stimulation|Electrical pulses are applied at the wrist to the median nerve.
219042155|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
219042156|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
219616678|NCT06092892|RADIATION|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
219616679|NCT03983512|DEVICE|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
219616680|NCT05584826|DRUG|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
219616681|NCT04168125|DEVICE|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
218917560|NCT06471244|OTHER|Speech processing|German sentences are played to the volunteers and the volunteers have to fulfill a semantic task.
218917561|NCT06175767|DRUG|MT101-5|Tablet
218917562|NCT05292794|DEVICE|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
218917563|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.
218917564|NCT03406780|DRUG|Placebo|Placebo
219042157|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
219531635|NCT03918174|OTHER|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
219531636|NCT03596944|DRUG|Statin|Prescribed with statins for primary prevention
219531637|NCT04525365|PROCEDURE|Pleural aspiration|Pleural aspiration
219531638|NCT02246322|DEVICE|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
219531639|NCT02246322|DEVICE|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
219616682|NCT04168125|DEVICE|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
219616683|NCT06504134|DIAGNOSTIC_TEST|the Novel Esophageal Cell Collection Device|Using the novel cell collection device and the deep learning method to collect and classify esophogeal cell to identify if the participants are GERD patients
219616684|NCT05231811|OTHER|massage|Pregnant women by the researcher; Foot massage consisting of classical massage techniques will be applied in a room in the clinic reserved for this application. During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated. During the application, the researcher who performs the massage will pay attention to the precautions applied in the hospital.
219616685|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Urine|Search for SARS-CoV 2 RNA in urine through PCR
219616686|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Semen|Search for SARS-CoV 2 RNA in Semen through PCR
219531640|NCT04471272|PROCEDURE|RFA using gradual RF energy delivery mode with Octopus electrodes|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
219531641|NCT01700244|DEVICE|Pacemaker implant|
219531642|NCT03375463|DRUG|Tirzepatide|Administered SC
219531643|NCT03375463|DRUG|Tirzepatide|Administered IV
219531644|NCT03375463|DRUG|Placebo|Administered SC
219616687|NCT04446169|DIAGNOSTIC_TEST|Semen Qualitative Analysis|Search for Semen Alterations in patients with past SARS-CoV 2 infection
219616688|NCT04446169|DIAGNOSTIC_TEST|IIEF-5 questionnaire|IIEF-5 assessment in patients with past SARS-CoV 2 infection
219616689|NCT04446169|DIAGNOSTIC_TEST|Male Sexual Health Questionnaire (MSHQ)|Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection
219616690|NCT04446169|DIAGNOSTIC_TEST|IPSS questionnaire|IPSS assessment in patients with past SARS-CoV 2 infection
219531645|NCT03375463|DRUG|Tirzepatide|Administered IV
219531646|NCT04909190|PROCEDURE|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
219616691|NCT04446169|DIAGNOSTIC_TEST|SECRET questionnaire|SECRET questionnaire assessment in patients with past SARS-CoV 2 infection
219616692|NCT04446169|DIAGNOSTIC_TEST|Interleukin assessment in semen|Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
218917565|NCT05450835|PROCEDURE|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
218917566|NCT05450835|PROCEDURE|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
218917567|NCT04033926|DRUG|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
218917568|NCT04033926|DRUG|Placebo|Subcutaneous injection for 16 weeks
218917569|NCT04231773|DRUG|Nitric Oxide|40 parts per million dosage
218917570|NCT04231773|DRUG|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
218917571|NCT03884829|DRUG|CYC140|CYC140 single agent
218917572|NCT03299556|OTHER|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
218917573|NCT00287105|DRUG|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
219531647|NCT01880814|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
219531648|NCT01880814|BEHAVIORAL|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
219531649|NCT01602419|OTHER|Patients using Wilate as standard of care|Patients with von Willebrand Disease using Wilate for a period of 2 years.
219531650|NCT02883413|BEHAVIORAL|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
219531651|NCT02883413|BEHAVIORAL|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
219531652|NCT01792635|DRUG|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
219531653|NCT01792635|DRUG|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
219531654|NCT01268085|OTHER|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
219531655|NCT01268085|OTHER|Control|Control with no inverention
219531656|NCT00569153|DRUG|TAK-700|"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning"
219531657|NCT06358053|DRUG|CRTE7A2-01 TCR-T cell therapy|Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell
219531658|NCT01808794|DEVICE|Mucograft|Mucograft Collagen Matrix
219531659|NCT01808794|DEVICE|Dynamatrix|Dynamatrix
219531660|NCT02465320|DRUG|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
219531661|NCT02465320|DRUG|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
219531662|NCT04278391|DRUG|DWJ1421|1 tablet administered in fasting condition
219531663|NCT04278391|DRUG|DWC201903|1 tablet administered in fasting condition
219531664|NCT02062489|DRUG|Tamoxifen|20 mg(2#)/day, PO, daily
219531665|NCT02062489|DRUG|Placebo|2#/day, PO, daily
219616693|NCT03320343|OTHER|MRI|3D morphological MRI and diffusion tensor imaging
219616694|NCT01168232|DRUG|Ixabepilone|Given IV
219616695|NCT01168232|OTHER|Laboratory Biomarker Analysis|Correlative studies
219616696|NCT02059512|PROCEDURE|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
218917574|NCT05994612|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
218917575|NCT05994612|BEHAVIORAL|Services as Usual|Participants will receive services that they would normally receive in the community.
218917576|NCT00837434|DRUG|Etanercept|50 mg dose of etanercept by subcutaneous injection
218917577|NCT00837434|DRUG|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
218917578|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
219042158|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
219531666|NCT03961230|DRUG|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
219616697|NCT02059512|PROCEDURE|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
219616698|NCT02059512|PROCEDURE|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
219616699|NCT04576507|DRUG|Active Cannabis|2.98% THC:4.91% CBD cannabis.
219616700|NCT04576507|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
219616701|NCT06637358|BEHAVIORAL|Extended Scheduled Gradual Reduction (SGR)|The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
219616702|NCT06637358|BEHAVIORAL|Quit Coach|Weekly check-ins and support will be given to this group via the quit coach interactions. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
219616703|NCT04470518|OTHER|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
219616704|NCT03848715|BIOLOGICAL|Endotoxin|Endotoxin
219616705|NCT03848715|BIOLOGICAL|Placebo|Placebo
219531667|NCT03961230|DRUG|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
219531668|NCT05963321|DEVICE|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
219531669|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
219531670|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
219531671|NCT04656223|COMBINATION_PRODUCT|MF/IND/GLY plus sensor system|"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
219531672|NCT04656223|DRUG|FDC therapy|There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
219531673|NCT02431221|DRUG|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
219531674|NCT02431221|DRUG|Placebo|
218917579|NCT00758732|DRUG|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
218917580|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
218917581|NCT00758732|DRUG|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
219531675|NCT03045250|DEVICE|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
219531676|NCT03045250|PROCEDURE|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
219531677|NCT03045250|PROCEDURE|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
219531678|NCT03045250|OTHER|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
219531679|NCT00904423|DRUG|Vitamin D|up to 2400 mg; oral tablet
218917582|NCT02195765|DRUG|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
218917583|NCT02195765|PROCEDURE|Open flap debridement|Open flap debridement
218917584|NCT01122238|DRUG|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
218917585|NCT01122238|DRUG|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
218917586|NCT01122238|BEHAVIORAL|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
218917587|NCT01122238|BEHAVIORAL|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
218917588|NCT01122238|OTHER|No Intervention|No Intervention
218917589|NCT01122238|DRUG|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
219531680|NCT00276133|DRUG|Effects of atorvastatin versus probucol on small dense LDL|
219531681|NCT00861406|DRUG|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
219531682|NCT00861406|DRUG|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
219531683|NCT03144505|BEHAVIORAL|MCT combined with RT Group|
219531684|NCT03144505|BEHAVIORAL|HIIT combined with RT Group|
219531685|NCT03025945|DRUG|Nepafenac 0.3%|
219531686|NCT03025945|DRUG|Saline Solution|
219531687|NCT00438945|DRUG|Eprosartan|
219531688|NCT00704691|DRUG|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
219616706|NCT05310747|BEHAVIORAL|Artwork present|A virtual museum exhibit with a curated selection of artworks
219616707|NCT05310747|BEHAVIORAL|Artwork absent|The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
219042159|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
219042160|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
219042161|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
219042162|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
219531689|NCT01158274|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219531690|NCT01158274|DRUG|capecitabine|Given orally
219531691|NCT01158274|OTHER|laboratory biomarker analysis|Correlative studies
219531692|NCT01513174|DRUG|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
219531693|NCT01513174|DRUG|Olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
219531694|NCT04492774|COMBINATION_PRODUCT|Goldic serum|epidural injections
219616708|NCT05310747|BEHAVIORAL|Social connection high|Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
219616709|NCT05310747|BEHAVIORAL|Social connection low|Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
219616710|NCT06459284|OTHER|retrospective data analysis|Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
219531695|NCT04492774|DRUG|Steroid injections|epidural injections
219531696|NCT04492774|PROCEDURE|Manual therapy|Veno-lymphatic drainage
219531697|NCT02413320|DRUG|Paclitaxel|
219616711|NCT06166576|PROCEDURE|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
219616712|NCT03249831|DRUG|Cyclophosphamide|Orally daily
219531698|NCT02413320|DRUG|Carboplatin|
219531699|NCT02413320|DRUG|Doxorubicin|
219531700|NCT02413320|DRUG|Cyclophosphamide|
219531701|NCT02413320|DRUG|Docetaxel|
219531702|NCT01046474|BEHAVIORAL|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
219531703|NCT01922180|RADIATION|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
219616713|NCT03249831|DRUG|Pentostatin|Intravenous
218917590|NCT00683527|DRUG|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
219616714|NCT03249831|DRUG|Rabbit anti-thymocyte globulin|Intravenous
218917591|NCT01537666|DRUG|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
218917592|NCT01537666|DRUG|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
218917593|NCT02163239|DEVICE|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
218917594|NCT03041038|DRUG|Secukinumab|Anti IL-17A antibody
218917595|NCT03041038|DRUG|Placebo|
219616715|NCT03249831|DRUG|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
218917596|NCT01917617|DRUG|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
219531704|NCT04195360|OTHER|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
219531705|NCT05203562|PROCEDURE|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
219531706|NCT05203562|DRUG|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
219531707|NCT04131374|BEHAVIORAL|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
219531708|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
219531709|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
218917597|NCT01917617|DRUG|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
218917598|NCT02258737|BEHAVIORAL|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
219042163|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
219042164|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
219616716|NCT03249831|DRUG|Mycophenolate mofetil|IV or oral
218917599|NCT02258737|BEHAVIORAL|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
218917600|NCT02574624|PROCEDURE|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
218917601|NCT05908916|DRUG|AtezoBev with combined radiotherapy|Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.
218917602|NCT03331315|DRUG|Celecoxib|
218917603|NCT03331315|DRUG|Ketorolac|
219531710|NCT04368520|OTHER|Placebo|Hypromellose capsules, given daily for 3 months
219531711|NCT03476265|DEVICE|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
218917604|NCT03350997|BEHAVIORAL|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
218917605|NCT03350997|BEHAVIORAL|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
218917606|NCT02121158|DEVICE|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
219531712|NCT02096991|OTHER|Can 1|drink the beverage in a can and a glass bottle
219531713|NCT02096991|OTHER|Can 2|Consume two canned beverage
219531714|NCT02096991|OTHER|Glass|consume two glass bottled beverage
219531715|NCT00335348|DRUG|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
219616717|NCT03249831|BIOLOGICAL|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
218917607|NCT02121158|OTHER|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
218917608|NCT04420234|DRUG|narfurine hydrochloride orally disintegrating tablets|Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
218917609|NCT03732417|OTHER|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
218917610|NCT00360230|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
219531716|NCT00335348|DRUG|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
219531717|NCT04374448|PROCEDURE|Sinonasal Benign or Malignant Tumor Resection|During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.
219531718|NCT04374448|PROCEDURE|Skull Base Surgery (Assessment of Nasoseptal Flap)|In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.
219531719|NCT04374448|PROCEDURE|Endoscopic Sinus Surgery|During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.
219531720|NCT04374448|PROCEDURE|Posterior Epistaxis Management (SPA Ligation)|During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
219531721|NCT04312165|DEVICE|Duramesh Laparotomy Closure|Closure of midline laparotomy incision with experimental suture
219531722|NCT04312165|DEVICE|Conventional suture closure|Closure of midline laparotomy incision with standard suture
219531723|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|"In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W"
219531724|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|In Phase II study, eligible patients receive the dose determined in phase Ib cohort.
219531725|NCT00190840|DRUG|pemetrexed|
219616718|NCT06836440|DEVICE|Free Prescription Glasses|Participants can choose from a variety of frames, and the research team will customize the glasses according to their pupillary distance and prescription. Once the glasses are ready, they will be provided to the participants following standard usage instructions. In case of loss or damage, participants should report it to the project team and will be provided with replacement glasses as needed. Each year, participants in the intervention group will undergo an eye exam to assess changes in vision, and their glasses prescription will be updated if necessary.
219616719|NCT04982640|BEHAVIORAL|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
219616720|NCT04982640|BEHAVIORAL|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
218917611|NCT00360230|BIOLOGICAL|Rabipur|3-dose intramuscular injection.
218917612|NCT04734028|DRUG|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
218917613|NCT01954498|DIETARY_SUPPLEMENT|Walnuts|
218917614|NCT01954498|DIETARY_SUPPLEMENT|OTC multivitamin|
218917615|NCT01825460|OTHER|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
218917616|NCT01825460|OTHER|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
218917617|NCT00581308|DEVICE|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
219531726|NCT01844674|DRUG|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast \>/= 10 hours.
219531727|NCT01844674|DRUG|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
219616721|NCT04982640|BEHAVIORAL|Nutrition Counseling|One, 30-minute session with registered dietitian
218917618|NCT02042417|DEVICE|INRatio2 and CoaguChek|
218917619|NCT05889104|OTHER|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
219042165|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
219042166|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
219042167|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
219531728|NCT00485667|DRUG|SKY0402|Subects received either 300mg or 450mg
218917620|NCT05889104|OTHER|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
218917621|NCT00006396|DRUG|Nevirapine|
218917622|NCT00006396|DRUG|Zidovudine|
218917623|NCT01479296|BIOLOGICAL|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
218917624|NCT01479296|BIOLOGICAL|rAd5 env A|Given intramuscularly
218917625|NCT01479296|BIOLOGICAL|rAd5 env B|Given intramuscularly
218917626|NCT01479296|BIOLOGICAL|rAd5 env C|Given intramuscularly
218917627|NCT01479296|BIOLOGICAL|rAd5 gag-pol|Given intramuscularly
218917628|NCT01479296|BIOLOGICAL|Placebo Vaccine|Given intramuscularly
218917629|NCT05068297|OTHER|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
218917630|NCT05068297|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
218917631|NCT02309346|DRUG|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
218917632|NCT03219723|DRUG|Vonoprazan|Vonoprazan tablets
218917633|NCT03219723|DRUG|Amoxicillin hydrate|Amoxicillin hydrate (potency)
218917634|NCT03219723|DRUG|Clarithromycin|Clarithromycin (potency)
218917635|NCT03219723|DRUG|Metronidazole|Metronidazole
219042168|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
219042169|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
219042170|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
219042171|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
219531729|NCT00485667|DRUG|Moxifloxacin 400mg|
219531730|NCT00485667|DRUG|Placebo injection|
219531731|NCT00485667|DRUG|Placebo tablet|
219531732|NCT03134586|OTHER|Diagnostic imaging|
219531733|NCT04395586|OTHER|Culture|Culture
219531734|NCT00626184|DRUG|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
219531735|NCT05206318|DRUG|Topical Cysteamine|Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
219531736|NCT05206318|DRUG|Topical Vehicle Control|Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
219531737|NCT00900718|DEVICE|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
219531738|NCT00900718|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
219531739|NCT02682784|DRUG|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
219531740|NCT02682784|DRUG|Placebo|
219531741|NCT02553564|OTHER|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment"
219531742|NCT04146987|PROCEDURE|Rotator cuff repair surgery|Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
218917636|NCT06020820|OTHER|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
218917637|NCT06020820|OTHER|control group group B|"1. Relax shoulders and neck sufficiently~2. look down~3. turn face to the right~4. turn face to the left~5. incline head to the right~6. incline head to the left~7. turn shoulders round and round~8. slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
219042172|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
219531743|NCT05994859|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.
219531744|NCT00327379|DRUG|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
219531745|NCT00327379|DRUG|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
219531746|NCT05333809|DRUG|Pembrolizumab|an anti-PD-1 monoclonal antibody
219531747|NCT05333809|DRUG|Disitamab vedotin|HER2-ADC
219531748|NCT06151678|OTHER|Pain Education|Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
219531749|NCT05287061|BEHAVIORAL|Multicomponent Psychological Program (MPP)|"Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive."
219531750|NCT05029297|DRUG|Capsaicin|
219531751|NCT05910853|DIAGNOSTIC_TEST|Specimen Donation|Blood donation
219531752|NCT03671447|OTHER|ICU Usual Care|The control condition delivered at ICU is usual care.
219531753|NCT03671447|BEHAVIORAL|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
219531754|NCT00318045|DEVICE|Eyeglass lenses|
219531755|NCT04353063|BEHAVIORAL|Multidisciplinary care with a personalized care|During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
219531756|NCT02078791|DRUG|Botox infiltration|botox cervical infiltration in a group
219531757|NCT02078791|BEHAVIORAL|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
219531758|NCT02078791|OTHER|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
219531759|NCT00467363|DRUG|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
219531760|NCT00467363|DIETARY_SUPPLEMENT|Folic acid|400micrograms of folic acid.
219531761|NCT04962594|OTHER|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
219531762|NCT04962594|OTHER|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
219531763|NCT04962594|OTHER|Breast feeding (BF)|Exclusive breast feeding up to 4 months
219042173|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
219531764|NCT00002880|DRUG|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
219531765|NCT04839276|COMBINATION_PRODUCT|Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat|Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
219531766|NCT04839276|PROCEDURE|Injection Laryngoplasty with Autologous Fat|Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
219531767|NCT00609960|BEHAVIORAL|clowns present|clowns present during the proccess of induction of anesthesia
219531768|NCT00609960|DRUG|midazolam|midazolam
219531769|NCT06156644|DEVICE|PFA|Ablation to treat trail fibrillation
219531770|NCT04533594|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
219531771|NCT02938962|DRUG|Tranexamic Acid|
219531772|NCT01650974|DEVICE|HFNOT|high flow nasal oxygen therapy
219531773|NCT05305430|DEVICE|Synergy Cervical Disc System|motion preservation disc
219531774|NCT00056667|BEHAVIORAL|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
219531775|NCT00056667|BEHAVIORAL|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
219531776|NCT00056667|OTHER|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
219531777|NCT03883412|OTHER|Exercise|16 weeks of treatment
219531778|NCT03883412|DRUG|Liraglutide|16 weeks of Liraglutide
218917638|NCT05122338|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
218917639|NCT05122338|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
218917640|NCT05122338|DRUG|Compound lidocaine|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
218917641|NCT05122338|DRUG|Esketamine|Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
218917642|NCT00430014|DRUG|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
218917643|NCT04815941|OTHER|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
219042174|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
219042175|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
218917644|NCT03537989|DRUG|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
218917645|NCT05074992|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
218917646|NCT01328886|DRUG|Omalizumab|omalizumab lyophilized 150 mg injection
218917647|NCT06009133|PROCEDURE|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
218917648|NCT06009133|PROCEDURE|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
218917649|NCT00459316|BIOLOGICAL|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
218917650|NCT02286349|DEVICE|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
218917651|NCT02286349|DEVICE|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
218917652|NCT03922386|DEVICE|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
218917653|NCT03837223|DRUG|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
218917654|NCT01722617|OTHER|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
218917655|NCT01614886|DRUG|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
218917656|NCT01614886|DRUG|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
218917657|NCT01750151|DIETARY_SUPPLEMENT|Glucose Beverage|
218917658|NCT01750151|BEHAVIORAL|Video Game Playing|
218917659|NCT01750151|DIETARY_SUPPLEMENT|Control Beverage|
218917660|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
219042176|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
219042177|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
219042178|NCT01332617|DRUG|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
219531779|NCT02288195|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
218917661|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
218917662|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
218917663|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
218917664|NCT04323969|BEHAVIORAL|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
218917665|NCT04323969|BEHAVIORAL|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
218917666|NCT01239953|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
218917667|NCT01239953|DEVICE|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
218917668|NCT02116036|DRUG|Rivaroxaban|
218917669|NCT01682434|PROCEDURE|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
218917670|NCT03848325|BEHAVIORAL|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
218917671|NCT03044106|DEVICE|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
218917672|NCT00761995|DRUG|Azopt|topical eye drop dosed 1 drop 3 times daily
218917673|NCT00761995|DRUG|Cosopt|topical eye drop dosed 1 drop 2 times daily
218917674|NCT01207414|DRUG|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
218917675|NCT00842114|BIOLOGICAL|R+CVP+IFN|Immunochemotherapy
218917676|NCT01748292|DRUG|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
218917677|NCT02191111|BEHAVIORAL|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
219531780|NCT02288195|DRUG|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
219531781|NCT02288195|RADIATION|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
219531782|NCT04461379|BIOLOGICAL|BCG vaccine|A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
219531783|NCT04461379|OTHER|Placebo|A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
219531784|NCT04146766|COMBINATION_PRODUCT|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
219531785|NCT04055584|DIAGNOSTIC_TEST|Sputum|DNA extraction and perform a diversity of molecular diagnostic tests
219531786|NCT03892408|DEVICE|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
219531787|NCT05070052|BEHAVIORAL|cognitive behavioral therapy|9 sessions of CBT weekly treatment in group setting
219531788|NCT05070052|BEHAVIORAL|mindfulness-based cognitive therapy|9 sessions of MBCT weekly treatment in group setting
219531789|NCT00051233|PROCEDURE|World Wide Web-Based Psychoeducation|
219531790|NCT00000885|DRUG|Indinavir sulfate|
219531791|NCT00000885|DRUG|Abacavir sulfate|
219531792|NCT00000885|DRUG|Nelfinavir mesylate|
219531793|NCT00000885|DRUG|Efavirenz|
219531794|NCT00000885|DRUG|Levocarnitine|
219531795|NCT00000885|DRUG|Adefovir dipivoxil|
219531796|NCT00000885|DRUG|Lamivudine|
219531797|NCT00000885|DRUG|Stavudine|
218917678|NCT05163080|BIOLOGICAL|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
219042179|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
219042180|NCT03112161|OTHER|Eucaloric Feeding Period|
219042181|NCT03112161|OTHER|Overfeeding Feeding Period|
219042182|NCT03112161|OTHER|Underfeeding Feeding Period|
219531798|NCT00000885|DRUG|Zidovudine|
219531799|NCT00000885|DRUG|Didanosine|
219531800|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
219531801|NCT05506007|DRUG|DA-5216-R|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
219531802|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
219531803|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
219531804|NCT05419661|OTHER|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
219531805|NCT03667183|OTHER|Pilates|Specific postures in movement according to Pilates guidelines.
219531806|NCT03727828|DIAGNOSTIC_TEST|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
219531807|NCT04100733|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
219531808|NCT04100733|DIAGNOSTIC_TEST|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
218917679|NCT05778604|BEHAVIORAL|Physio-feedback|"The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9."
218917680|NCT05778604|BEHAVIORAL|Cognitive reframing|Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
218917681|NCT05778604|BEHAVIORAL|Peer-led exercises|The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
218917682|NCT05778604|BEHAVIORAL|CDC older adults fall prevention|Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
218917683|NCT01527370|BIOLOGICAL|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
218917684|NCT02057250|DRUG|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
219531809|NCT04327453|DEVICE|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
219531810|NCT04327453|DEVICE|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
219531811|NCT04327453|DEVICE|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
219531812|NCT03738605|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
219531813|NCT01223105|PROCEDURE|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
219531814|NCT01223105|PROCEDURE|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
219531815|NCT02210182|DRUG|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
219531816|NCT02210182|OTHER|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
219616722|NCT03510858|OTHER|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
219616723|NCT03510858|OTHER|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
219616724|NCT05453578|OTHER|Placebo|0.9 percent sodium chloride
219531817|NCT05388266|OTHER|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
219531818|NCT02169115|DRUG|Omalizumab|150mg, s.c., every 4 weeks
219531819|NCT02169115|DRUG|Omalizumab|300mg, s.c., every 4 weeks
219616725|NCT05453578|BIOLOGICAL|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
219616726|NCT05012098|DRUG|Bintrafusp alfa/M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
219616727|NCT05012098|DRUG|Ibuprofen|400 mg or comparable non-steroidal anti-inflammatory drugs (NSAIDs) dose up to 2 hours before and 8 hours after the start of each dose for prophylaxis of flu-like symptoms.
219616728|NCT05012098|DIAGNOSTIC_TEST|PET scan|Screening
218917685|NCT02057250|DEVICE|Auto-Injector Device (AID)|
218917686|NCT02057250|DEVICE|Pre-filled Syringe (PFS)|
218917687|NCT02057250|DRUG|Methotrexate|Dispensed according to local practice.
218917688|NCT02057250|DRUG|Sulfasalazine|Dispensed according to local practice.
218917689|NCT02057250|DRUG|Leflunomide|Dispensed according to local practice.
218917690|NCT02057250|DRUG|Hydroxychloroquine|Dispensed according to local practice.
218917691|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
218917692|NCT01503203|OTHER|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
218917693|NCT01503203|OTHER|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
218917694|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
219531820|NCT02169115|DRUG|Placebo|Placebo, s.c., every 4 weeks
219531821|NCT03546283|DRUG|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
219531822|NCT03546283|DRUG|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
219531823|NCT04503174|DEVICE|t:slim X2 pump with Control-IQ technology|Real-world use
219531824|NCT04836598|OTHER|laparoscopic cholecystectomy|A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
219531825|NCT03392454|PROCEDURE|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
219531826|NCT03392454|PROCEDURE|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
219531827|NCT03138967|DRUG|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
219531828|NCT03138967|DRUG|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
219531829|NCT03138967|DRUG|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
219531830|NCT03138967|DRUG|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
218917695|NCT01503203|OTHER|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
219531831|NCT00346385|DRUG|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
219531832|NCT05350787|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
219531833|NCT02184260|DRUG|Metamizole|
219531834|NCT02184260|DRUG|Placebo|
219531835|NCT02197260|DRUG|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
219531836|NCT02897414|OTHER|Surveillance of state medical examiner databases|
219531837|NCT01305681|DEVICE|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
219531838|NCT06009146|DEVICE|Endovascular treatment|Endovascular treatment for infrapopliteal arterial disease.
219616729|NCT05012098|DIAGNOSTIC_TEST|CT scan|Screening
219531839|NCT03018834|DRUG|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
219531840|NCT03018834|DRUG|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
219531841|NCT04107675|DRUG|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
219531842|NCT04107675|DRUG|Liposomal Placebo|Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
218917696|NCT05895188|DEVICE|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
218917697|NCT04959994|DEVICE|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
219531843|NCT03314870|GENETIC|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
219531844|NCT06254781|DRUG|Luspatercept|Erythroid Maturation Agent
219531845|NCT00359905|DRUG|Silodosin|8 mg daily for 12 weeks
219531846|NCT00359905|DRUG|Tamsulosin|0.4 mg daily for 12 weeks
219616730|NCT05012098|PROCEDURE|Tumor tissue biopsy|Baseline, and subsequent weeks as stipulated in the study calendar.
219616731|NCT05012098|DIAGNOSTIC_TEST|Brain MRI|Baseline
219616732|NCT05012098|DIAGNOSTIC_TEST|Dotate scan|Baseline
218917698|NCT01654354|DRUG|NEOVIST 370 INJ.(Iopromide 768.86mg)|
218917699|NCT01654354|DRUG|Ultravist 370 INJ.(Iopromide 768.86mg)|
218917700|NCT00497484|DRUG|recombinant human somatotropin|
219616733|NCT05012098|DIAGNOSTIC_TEST|PET FDG scan|Baseline
218917701|NCT04172181|PROCEDURE|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
218917702|NCT04843007|DRUG|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
218917703|NCT00349518|DRUG|Dasatinib|
218917704|NCT03177317|DRUG|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
218917705|NCT03772886|DEVICE|Peanut Ball|A peanut shaped exercise ball.
218917706|NCT01008020|DIETARY_SUPPLEMENT|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
219531847|NCT00359905|DRUG|Placebo|once daily for 12 weeks
219531848|NCT03713333|DIAGNOSTIC_TEST|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~* Handheld imaging - focused echocardiographic examination (Butterfly IQ)~* Smartphone iECG for cardiac rhythm assessments (Alivecor)~* Blood Pressure (CloudDX)~* Oxygen Saturation (CloudDX)~* Weight (CloudDX)~* Point-of-Care Genetic Testing (Phosphorous)"
219531849|NCT00407394|DRUG|Amoxycillin|
219531850|NCT03464240|DIETARY_SUPPLEMENT|Glucose|glucose drink
219531851|NCT03464240|DIETARY_SUPPLEMENT|Water|control
219531852|NCT01513486|BEHAVIORAL|immobilization|
219531853|NCT00904553|RADIATION|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
218917707|NCT03959514|BIOLOGICAL|NovoRapid|Rapid acting prandial insulin aspart
218917708|NCT03959514|BIOLOGICAL|Fiasp|Fast acting prandial insulin aspart
218917709|NCT03959514|BIOLOGICAL|AT247|Ultra rapid acting prandial insulin aspart
219531854|NCT05733884|OTHER|soft contact lens|soft contact lens
219531855|NCT03572777|DRUG|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
219531856|NCT03572777|DRUG|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
219531857|NCT03572777|DRUG|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
219531858|NCT03572777|DRUG|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
219531859|NCT03572777|DRUG|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
219616734|NCT05012098|DIAGNOSTIC_TEST|Nuclear bone scan|Baseline
219616735|NCT05012098|DIAGNOSTIC_TEST|EKG|Baseline
219616736|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
219616737|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
219616738|NCT04496674|DRUG|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
219616739|NCT04104438|DRUG|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
219616740|NCT05980767|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
219616741|NCT03076008|OTHER|Observational|No intervention
219616742|NCT03974113|DRUG|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
219616743|NCT06793696|OTHER|Nurse prompt|Nurse prompt to complete COWS
219616744|NCT06793696|OTHER|Provider prompt|Provider prompt to use EMBED CDS
219616745|NCT06793696|OTHER|Patient facing materials|Patient materials provided at discharge from ED
219616746|NCT06793696|OTHER|EMBED|Original EMBED CDS
219616747|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg orally once a day
219616748|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*2 orally once a day
218917710|NCT03520998|DRUG|GRF6019|GRF6019 for IV infusion
218917711|NCT03324269|DEVICE|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase."
218917712|NCT03924050|DRUG|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
218917713|NCT01473888|DRUG|T89(Dantonic)|capsule, 225mg B.I.D.
219531860|NCT03572777|DRUG|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
219531861|NCT03572777|DRUG|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
219531862|NCT03572777|DRUG|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
219531863|NCT03999684|DRUG|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
219531864|NCT05186662|OTHER|patient education|patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
219616749|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*3 orally once a day
219616750|NCT06796868|DRUG|Placebo|placebo orally once a day
219616751|NCT04635189|DRUG|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
219616752|NCT04635189|DRUG|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
218917714|NCT03997188|DEVICE|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
218917715|NCT05207488|DIETARY_SUPPLEMENT|Fructooligosaccharides (FOS)|FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
219531865|NCT05186662|OTHER|patient education|Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
219531866|NCT05479383|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
219531867|NCT05655845|OTHER|bowel function score(BFS) questionnaire survey|A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
219531868|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
219531869|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
219531870|NCT01639092|DRUG|Entecavir|Entecavir 1 mg daily Oral
219531871|NCT00836056|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
219531872|NCT00836056|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
219531873|NCT02569073|DRUG|Dronabinol|Dronabinol 5 mg, every other night, orally
219531874|NCT02569073|DRUG|Placebo|Placebo--no drug
219531875|NCT03513822|DRUG|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
219531876|NCT03513822|DRUG|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
219531877|NCT03513822|DRUG|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
219531878|NCT01851577|BEHAVIORAL|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
219531879|NCT01851577|BEHAVIORAL|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
219531880|NCT02812732|BEHAVIORAL|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
219531881|NCT04791150|OTHER|Fill in a form|Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs
219616753|NCT04635189|DRUG|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
219616754|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
219616755|NCT03722680|DRUG|Riluzole|Riluzole during chemotherapy (oxaliplatin)
219616756|NCT03722680|DRUG|Placebo Oral Tablet|placebo
219616757|NCT06558409|BEHAVIORAL|" Safer Still  Interactive Intervention"|An interactive intervention will be developed to help promote safe storage of firearms during the critical period immediately following high-risk care transitions.
218917716|NCT05207488|BEHAVIORAL|Exercise|During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
218917717|NCT05207488|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
218917718|NCT04961775|DRUG|Perflubutane Microspheres for Injection|16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.
218917719|NCT02032017|PROCEDURE|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
218917720|NCT02032017|PROCEDURE|Percutaneous assisted approach|
218917721|NCT02032017|PROCEDURE|Anterolateral approach|
218917722|NCT02032017|OTHER|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
219204684|NCT06070376|DEVICE|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
219616758|NCT06558409|OTHER|Enhanced Usual Care (EUC):|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
219616759|NCT05653518|DEVICE|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
219616760|NCT05653518|DEVICE|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
219616761|NCT05086419|OTHER|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
219616762|NCT06773910|DRUG|BMS-986489|BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
219616763|NCT06773910|DRUG|Durvalumab|Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
219616764|NCT06700512|DEVICE|Hearing Aid Signia Pure C&G 7IX|Receiver in Canal (RIC) hearing aid, M Receiver
219616765|NCT06700512|DEVICE|Own Hearing Aid|subjects' own hearing aids, any brand, any model
219616766|NCT01490086|DRUG|RP5063|daily
219616767|NCT01490086|DRUG|placebo|daily
219616768|NCT01490086|DRUG|aripiprazole|daily
219616769|NCT06018285|BEHAVIORAL|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
219616770|NCT05598320|DRUG|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
219616771|NCT05598320|DRUG|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
219616772|NCT06614725|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.
219616773|NCT06614725|COMBINATION_PRODUCT|Placebo|1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
219616774|NCT05899985|COMBINATION_PRODUCT|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
219616775|NCT06005649|BIOLOGICAL|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells"
219616776|NCT05825404|DEVICE|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
219616777|NCT05825404|OTHER|Control|Usual light.
219616778|NCT06181656|BIOLOGICAL|Pneumonia vaccine|Given by SC
219616779|NCT06183944|OTHER|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
219616780|NCT06172517|OTHER|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
219616781|NCT01749826|DRUG|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
219616782|NCT03261778|DEVICE|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
219616783|NCT03727919|BEHAVIORAL|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
219616784|NCT03699618|DRUG|Anti-VEGF|Standard of care treatment with anti-VEGF only
219616785|NCT03699618|OTHER|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
219616786|NCT05501418|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
219042183|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
219042184|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
219616787|NCT05501418|BIOLOGICAL|Controlled normal saline|Normal saline will be IV infusion with 12 months of follow up after treatment.
219616788|NCT01876771|DRUG|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
219616789|NCT05815628|DIAGNOSTIC_TEST|DISQVER|NGS based infection diagnosis
219616790|NCT03639753|BEHAVIORAL|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
219616791|NCT03639753|OTHER|Usual Practice|Standard care for teens who get licensed in the state of PA
219616792|NCT05842967|BIOLOGICAL|RSVpreF|120-µg
219616793|NCT05842967|OTHER|Placebo|Placebo
219616794|NCT05988996|BEHAVIORAL|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
219616795|NCT05974176|BEHAVIORAL|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
219616796|NCT05974176|BEHAVIORAL|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
218917723|NCT03854175|DRUG|sildenafil citrate|25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
218917724|NCT03854175|DRUG|Estradiol Valerate 2 MG|2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
218917725|NCT01434212|DRUG|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
218917726|NCT06319014|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
218917727|NCT06132672|BEHAVIORAL|Navigators (peer navigator) training|The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
218917728|NCT06132672|BEHAVIORAL|delayed-intervention|Those in the delayed-intervention group will be trained in year 5
218917729|NCT01988155|OTHER|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
218917730|NCT01988155|OTHER|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
218917731|NCT02578069|DEVICE|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
219531882|NCT06213506|BIOLOGICAL|Measles and Rubella vaccine|Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
219616797|NCT06462989|OTHER|ECHONEXT|ECHONEXT Artificial intelligence algorithm
219616798|NCT06406439|DEVICE|Smart Insulin Pen|During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.
219616799|NCT06406439|DEVICE|Injection of bolus insulin via conventional therapy using insulin pen|During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.
219616800|NCT04482348|OTHER|Explanation|Explanation provided to patients for more pain than expected
219616801|NCT03831230|GENETIC|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
219616802|NCT04715581|DIETARY_SUPPLEMENT|Preoperative nutritional optimization|"1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery."
218917732|NCT02578069|DEVICE|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
218917733|NCT06071247|OTHER|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
218917734|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose A - single-dose intravenous infusion
218917735|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose B - single-dose subcutaneous injection
218917736|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose C - single-dose subcutaneous injection
218917737|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose D - single-dose subcutaneous injection
218917738|NCT04859907|DEVICE|Clamp-like system|Craniotomy closure
218917739|NCT04859907|DEVICE|Plates and screws|Craniotomy closure
218917740|NCT00416910|BIOLOGICAL|Filgrastim|
218917741|NCT00416910|DRUG|Fludarabine|
218917742|NCT00416910|DRUG|Cyclophosphamide|
218917743|NCT00416910|DRUG|Mitoxantrone|
218917744|NCT01921309|DEVICE|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
218917745|NCT01921309|DEVICE|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
218917746|NCT04592302|DIAGNOSTIC_TEST|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
218917747|NCT00600262|DRUG|intravitreal bevacizumab|
218917748|NCT05073874|OTHER|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
218917749|NCT05738642|DRUG|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
218917750|NCT00910650|BIOLOGICAL|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
218917751|NCT00910650|DRUG|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
219531883|NCT06213506|BIOLOGICAL|Yellow Fever vaccine|Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
218917752|NCT03071588|DEVICE|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
218917753|NCT03071588|DEVICE|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
219042185|NCT06099262|BEHAVIORAL|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
219531884|NCT06213506|BIOLOGICAL|Pentavalent vaccine|Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
219531885|NCT06213506|BIOLOGICAL|Pneumococcal vaccine|Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
219531886|NCT06213506|BIOLOGICAL|Inactivated polio vaccine|Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
219531887|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose C|-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Dose C and Infants\_6W\_Dose C\_2 groups.
219531888|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose B|-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose B and Infants\_6W\_Dose B\_2 groups.
219531889|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose A|3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose A and Infants\_6W\_Dose A\_2 groups.
219616803|NCT04715581|BEHAVIORAL|Preoperative exercise training|"1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery."
219616804|NCT04715581|BEHAVIORAL|Postoperative exercise training|"1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge."
219616805|NCT03370263|DRUG|Benlysta|Benlysta will be administered intravenously or subcutaneously.
219616806|NCT04940000|OTHER|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
219616807|NCT06277310|OTHER|3 Wishes Project|palliative care initiative in which clinicians elicits and implements small acts of kindness for dying patients and their families
219616808|NCT00751699|DRUG|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
219616809|NCT00751699|DRUG|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
219616810|NCT00751699|DRUG|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
219616811|NCT05286229|DRUG|Etentamig|Intravenous (IV) Infusion
218917754|NCT03367793|DEVICE|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
219616812|NCT01051310|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
219616813|NCT03869320|DRUG|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
219616814|NCT03869320|OTHER|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
219616815|NCT03869320|DRUG|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
219616816|NCT03869320|OTHER|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
218917755|NCT03367793|DEVICE|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
219042186|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
219042187|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
219616817|NCT01823328|DRUG|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
219616818|NCT01823328|DRUG|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
219616819|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
219616820|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219616821|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219616822|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219616823|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219616824|NCT06092814|DEVICE|Active transcranial alternating current stimulation (tACS)|Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.
219616825|NCT05796219|RADIATION|Low dose mammogram|Low dose mammogram
219616826|NCT04030442|DRUG|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
219616827|NCT04030442|OTHER|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
219616828|NCT05831085|PROCEDURE|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
219616829|NCT05831085|PROCEDURE|standard CABG|Coronary-Artery Bypass Grafting
219616830|NCT00745862|BEHAVIORAL|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
219616831|NCT03176303|DEVICE|SpinalStim|PEMF osteogenesis stimulator
219616832|NCT04276961|OTHER|Acupuncture|Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
219616833|NCT02178657|DRUG|Autologous bone marrow mononuclear cell intra-arterial injection|
219616834|NCT01692041|DRUG|ivy leaves dry extract|5 ml twice daily po
219616835|NCT01692041|DRUG|Placebo|5 ml per os twice daily
219616836|NCT00751920|PROCEDURE|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
218917756|NCT03367793|DEVICE|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
218917757|NCT02435992|DRUG|RPC1063|
219616837|NCT00000594|DRUG|cholestyramine|
219616838|NCT06577142|OTHER|Burn 2 Learn|"The 'Burn 2 Learn' group encompassed the following components and implementations. A brief introductory seminar will be conducted with the principle, school event coordinator, school sports teacher and students from grade 8 to 10. The aim of this seminar is to provide a better understanding of the rationale and presenting evidence of the beneficial effects of high intensity interval training on overall wellbeing of students. The sessions will be conducted thrice a week for 10 to 15 minutes by the research team members for a period of 10 weeks. The sessions will consist of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities. The intervals ranging between 8-16, 30 second work out followed by 30 seconds rest, maintaining a 1:1 work rest ratio.~51 participants will be in the experimental group A giving them Burn 2 Learn exercise protocol along with the normal sports training plan for ten weeks."
219616839|NCT06577142|OTHER|Control Group|51 participants will be in control group B and will perform their routine school physical activities, sports games or any exercise routines.
219616840|NCT01406379|PROCEDURE|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
219616841|NCT01406379|PROCEDURE|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
218917758|NCT02435992|DRUG|Placebo|
219616842|NCT02739789|DEVICE|tDCS|tDCS
219616843|NCT02739789|DEVICE|Sham tDCS|Sham tDCS
218917759|NCT05216549|OTHER|Water-based exercise|8 weeks x 2 times per week for 45 min
218917760|NCT05216549|OTHER|Land-based exercise|8 weeks x 2 times per week for 45 min
218917761|NCT00260533|DRUG|atomoxetine|Flexible dose, up to 50 mg per day
218917762|NCT00260533|DRUG|placebo|placebo (matching to atomoxetine)
218917763|NCT00566319|BEHAVIORAL|PREPARE with pedometer|Structured educational programme with pedometer use
218917764|NCT00566319|BEHAVIORAL|PREPARE|Structured educational programme
218917765|NCT05512884|BEHAVIORAL|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
218917766|NCT01459211|DRUG|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
219042188|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
219042189|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
219531890|NCT06213506|BIOLOGICAL|MenACWY|-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B, Infants\_6W\_Control C and Infants\_6W\_Control\_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
219042190|NCT00077168|DRUG|anastrozole|
219531891|NCT06213506|COMBINATION_PRODUCT|DTPa-HBV-IPV+Hib|1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.
219531892|NCT06213506|DRUG|Placebo|1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.
219531893|NCT04033471|DRUG|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
219531894|NCT04078932|BEHAVIORAL|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
219531895|NCT03170323|DRUG|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
219531896|NCT03170323|DRUG|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
219531897|NCT05857891|DRUG|Human erythropoietin injection|Each subject in the test group received 40000iu of human erythropoietin intravenously
219531898|NCT05857891|DRUG|0.9%NaCl|Each subject in the control group was injected with an equal volume of 0.9%NaCl
219531899|NCT00507663|DRUG|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
219531900|NCT01209390|DEVICE|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
219042191|NCT00077168|DRUG|tamoxifen citrate|
219531901|NCT03892694|DEVICE|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
219531902|NCT03892694|OTHER|Sham|Sham control procedure
219531903|NCT00501345|DRUG|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
219531904|NCT05084066|OTHER|Repeated remote ischemic preconditioning|"An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention."
219042192|NCT00077168|PROCEDURE|adjuvant therapy|
219042193|NCT00077168|RADIATION|radiation therapy|
219616844|NCT01103180|DRUG|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
219616845|NCT01173523|DRUG|STA-9090|
219616846|NCT05648773|BEHAVIORAL|Messaging|Booster reminder message
219616847|NCT05648773|BEHAVIORAL|Financial Incentive|Financial Incentive for getting boosted within 2-weeks of the message
219616848|NCT05648773|OTHER|Placebo|Treatment as usual; no additional message and no incentive.
219531905|NCT05084066|OTHER|Simulation of repeated remote ischemic preconditioning (sham)|The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.
219531906|NCT01887145|PROCEDURE|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
218917767|NCT02891499|PROCEDURE|Low-level laser therapy|"1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
218917768|NCT02891499|PROCEDURE|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
218917769|NCT01761877|DRUG|Sulindac|
218917770|NCT04106492|DRUG|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
219042194|NCT02633956|DRUG|Obeticholic Acid|Once a day (QD) by mouth (PO)
219531907|NCT01887145|PROCEDURE|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
219531908|NCT00306462|DRUG|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.
219531909|NCT00306462|DRUG|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
219531910|NCT05297630|OTHER|Evaluation of the evolution of biological markers from the biobank.|The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
219531911|NCT02291263|BIOLOGICAL|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
219531912|NCT02291263|BIOLOGICAL|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
219531913|NCT02291263|BIOLOGICAL|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
219531914|NCT04148391|DRUG|Placebo Oral Capsule|Matching placebo capsules.
219531915|NCT04148391|DRUG|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
219531916|NCT01199718|DRUG|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
219531917|NCT00522886|DRUG|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
219531918|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
219042195|NCT02633956|DRUG|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
219042196|NCT02633956|DRUG|Placebo|Once a day (QD) by mouth (PO)
219531919|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
219616849|NCT01056783|DRUG|OC000459|OC000459 100mg, twice daily, tablet
218917771|NCT05087706|DRUG|Pyrotinib|Pyrotinib 400mg qd po
218917772|NCT05087706|DRUG|Bicalutamide|Bicalutamide was administered orally at a daily dose of 50 mg
218917773|NCT05087706|DRUG|Leuprorelin|Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
218917774|NCT03530215|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
218917775|NCT04514185|DEVICE|Passive industrial exoskeleton for the upper limb|The goal is to compare the human response to the simulated industrial tasks
218917776|NCT04514185|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
219042197|NCT01166594|DRUG|Bevacizumab|Intrableb injection
219042198|NCT01166594|DRUG|Control|intrableb BSS injection
219042199|NCT00065884|DRUG|Valproate|
219616850|NCT01056783|DRUG|Placebo|Placebo tablets to match OC000459 tablets, twice daily
219616851|NCT05362916|DRUG|Letermovir|Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
219616852|NCT01957514|OTHER|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
219616853|NCT01957514|OTHER|Laboratory Biomarker Analysis|Correlative studies
219616854|NCT01957514|OTHER|Quality-of-Life Assessment|Ancillary studies
219616855|NCT01957514|OTHER|Questionnaire Administration|Ancillary studies
218917777|NCT03542877|DRUG|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
218917778|NCT04965818|DRUG|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
218917779|NCT01424384|DRUG|Citalopram|Neurophysiological testing.
218917780|NCT01424384|DRUG|GSK424887|Neurophysiological testing
218917781|NCT01424384|DRUG|Plactebo To Match|Neurophysiological testing
218917782|NCT02195102|DEVICE|Transcatheter aortic valve Replacement|
218917783|NCT01310777|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
218917784|NCT01310777|DRUG|Brinzolamide 1% ophthalmic suspension|
219531920|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
219531921|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
219531922|NCT04987619|DIETARY_SUPPLEMENT|Beetroot juice|Subjects will drink juice 120 minutes before each visit
219531923|NCT04987619|OTHER|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
219531924|NCT04593134|BEHAVIORAL|exercise group|"exercise education: A 12-week regimen of homebased walking exercises, include moderate intensity for 40 min, three times a week.~We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the heart rate reserve, as determined by the Karvonen method, or 13-14 on the RPE.~Exercise education:~Weekly telephone or mobile application LINE consultations concerning exercise.we discussed whether participants' exercise fulfilled the prescribed intensity, duration, frequency and whether the participants experienced any adverse effects."
218917785|NCT01310777|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
219531925|NCT01802086|DRUG|Emla-cream|Topical anaesthetic
219531926|NCT01802086|DRUG|Miniderm cream|Topical
219531927|NCT05585866|DRUG|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
219531928|NCT02648347|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
219531929|NCT02648347|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
219531930|NCT01639222|DRUG|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
219531931|NCT01639222|OTHER|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
219531932|NCT03546842|BIOLOGICAL|9vHPV vaccine|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
219531933|NCT04772105|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
219531934|NCT04772105|DRUG|4.0mg of BAT5906|Specification: 4.0mg of BAT5906
219531935|NCT00214097|RADIATION|Radiotherapy|Daily radiation to prescribed dose
219531936|NCT01268709|DRUG|Doxepin|
219531937|NCT01268709|DRUG|Nortriptyline|
219531938|NCT01268709|DRUG|placebo|
219531939|NCT01884519|BIOLOGICAL|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
219531940|NCT04977245|OTHER|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
218917786|NCT03857854|DRUG|Pirfenidone|treatment group
218917787|NCT03857854|DRUG|Placebos|placebo group
218917788|NCT03466814|OTHER|Non-Interventional|Non-Interventional
218917789|NCT01795677|DRUG|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
218917790|NCT04337645|PROCEDURE|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
218917791|NCT05962060|OTHER|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
218917792|NCT05962060|OTHER|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
218917793|NCT06430970|DEVICE|endoscopy|upper and lower endoscopy
218917794|NCT00994513|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|1200 mg/day
218917795|NCT00994513|DIETARY_SUPPLEMENT|Placebo|1200 mg/day
218917796|NCT02203396|DRUG|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
218917797|NCT01713920|DRUG|SEVIKAR|
219531941|NCT04977245|OTHER|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
219531942|NCT05241808|BEHAVIORAL|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
218917798|NCT02928042|OTHER|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
219616856|NCT06192589|DRUG|Cannabidiol|Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
219616857|NCT06192589|DRUG|Placebo|Placebo will be administered orally twice daily for 28 days in Part 1
218917799|NCT05879185|BIOLOGICAL|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
218917800|NCT06522646|DEVICE|SPCM|During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis
219531943|NCT02329197|DRUG|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
219531944|NCT02449265|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
219616858|NCT06192589|DRUG|Citalopram|Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
219616859|NCT06192589|DRUG|Morphine|Morphine will be administered once at 15 mg on days 1, 4, and 11.
219531945|NCT02449265|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15\~18 fractions of 2 Gy 5 days per week for partial response (PR)."
219531946|NCT02449265|DRUG|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
219531947|NCT02449265|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
219531948|NCT02449265|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy.
219616860|NCT01867918|PROCEDURE|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
219616861|NCT01867918|DRUG|Standard Chemotherapy|
218917801|NCT06522646|DEVICE|Usual Prothesis|During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
218917802|NCT03171649|DEVICE|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
218917803|NCT03171649|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
219042200|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
219531949|NCT02449265|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy.
219531950|NCT05853666|BEHAVIORAL|CNH+|CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery \[evidence-based parent targeted education platform\]; Vicarious Experience \[observing other families similar to them succeeding in a task i.e., videos and photos\]; Verbal Persuasion \[in-person/virtual medical rounds and provision of social support\]; and Physiological States \[notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway\]).
219531951|NCT03548675|DRUG|TCA treatment|All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
219616862|NCT04627792|BEHAVIORAL|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
219616863|NCT05552820|DEVICE|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
219531952|NCT01870856|DEVICE|Spectacles|Per participant's habitual prescription
219531953|NCT01870856|DEVICE|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
218917804|NCT02878031|DRUG|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
218917805|NCT00488371|BIOLOGICAL|Pneumococcal Conjugated Vaccine (Prevnar®)|
218917806|NCT02396576|BEHAVIORAL|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
218917807|NCT00403520|DRUG|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
218917808|NCT00403520|DRUG|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
218917809|NCT01099722|DRUG|Flutiform|inhaler 2 puffs bd daily
219531954|NCT01870856|DEVICE|Etafilcon A contact lenses|Hydrogel single vision contact lenses
219531955|NCT00658762|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
219616864|NCT05552820|DEVICE|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
219616865|NCT01439802|DEVICE|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
219616866|NCT01804179|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
219616867|NCT01804179|OTHER|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
219616868|NCT01804179|OTHER|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
219616869|NCT01804179|OTHER|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
219616870|NCT01804179|OTHER|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
219616871|NCT01727752|PROCEDURE|Decompression|
219616872|NCT02201537|DEVICE|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
219616873|NCT05729737|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
219616874|NCT00696215|DRUG|placebo|Placebo 1 mg once a day
219616875|NCT00696215|DRUG|rasagiline|1mg
219616876|NCT01570478|DRUG|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
218917810|NCT01099722|DRUG|Symbicort Turbohaler|2 puffs bd daily
218917811|NCT00425776|DEVICE|acupuncture|
218917812|NCT00425776|DEVICE|Sham acupuncture|
218917813|NCT00643864|BEHAVIORAL|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
218917814|NCT04665947|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
219531956|NCT00658762|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
219531957|NCT00658762|DRUG|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
219531958|NCT00658762|DRUG|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
219531959|NCT05286203|DEVICE|Metagenomic Deep Sequencing (MDS)|MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.
219531960|NCT05286203|DIAGNOSTIC_TEST|Standard of Care (SOC)|SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
219531961|NCT02352259|PROCEDURE|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
219531962|NCT02352259|DEVICE|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
219531963|NCT02352259|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
218917815|NCT01697917|OTHER|Total Gastrectomy or Proximal Gastrectomy|
218917816|NCT02124837|BEHAVIORAL|Park walk during lunch break|
219531964|NCT05333159|DRUG|SGLT2 inhibitor|dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
219531965|NCT02258620|DRUG|dinitrate isosorbide|dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat
219531966|NCT02258620|DRUG|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
219531967|NCT05514860|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
219531968|NCT05514860|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
219531969|NCT01794715|PROCEDURE|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
219531970|NCT04887766|DEVICE|GS300|Gelesis300 hydrogel in gelatin capsules
219531971|NCT04887766|DEVICE|Placebo|Placebo capsules
219531972|NCT01732172|OTHER|Sperm sample|Sperm sample
219531973|NCT01387633|OTHER|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
218917817|NCT02124837|BEHAVIORAL|Relaxation during lunch break|
218917818|NCT02224560|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
218917819|NCT02224560|DRUG|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219531974|NCT01387633|OTHER|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
219531975|NCT01416584|BEHAVIORAL|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
219616877|NCT01570478|DRUG|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
219616878|NCT04468685|DRUG|Ondansetron|Interperitoneal administration in the gall bladder bed
218917820|NCT06296069|OTHER|exergame-based cognitive-motor training on an unstable surface|"The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side."
218917821|NCT06296069|OTHER|exergame-based cognitive-motor training on an stable surface|"The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces."
219042201|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
219042202|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
219616879|NCT04468685|DRUG|Normal saline|Interperitoneal administration in the gall bladder bed
219616880|NCT01722578|DRUG|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
219531976|NCT01416584|BEHAVIORAL|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
219531977|NCT05757765|OTHER|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
219531978|NCT05757765|OTHER|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
219531979|NCT03225456|DRUG|Syntocinon|Intra-nasal oxytocin
219531980|NCT03225456|DRUG|Placebos|Intra-nasal placebo
219531981|NCT03216577|OTHER|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
219531982|NCT04937101|DRUG|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
219531983|NCT01650350|DRUG|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
218917822|NCT04128852|DEVICE|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
218917823|NCT02461758|BIOLOGICAL|Standard dose Influenza vaccine (SDIV)|
218917824|NCT02461758|BIOLOGICAL|High dose influenza vaccine (HDIV)|
218917825|NCT04690660|OTHER|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
218917826|NCT04690660|OTHER|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
218917827|NCT04690660|OTHER|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
218917828|NCT04690660|OTHER|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
218917829|NCT04690660|OTHER|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
218917830|NCT06553703|OTHER|Acceptance and commitment therapy based group psychoeducation|Acceptance and commitment therapy-based group psychoeducation aimed at increasing nursing students' psychological flexibility and reducing their somatic symptoms.
219531984|NCT02711852|DRUG|Duvelisib|Administered as oral capsules
219531985|NCT00362024|DRUG|MK0952|
219531986|NCT00362024|DRUG|Comparator: Placebo|
219531987|NCT00741858|PROCEDURE|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
219531988|NCT00741858|PROCEDURE|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
219531989|NCT03117296|OTHER|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
219531990|NCT03117296|OTHER|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
219531991|NCT03117296|OTHER|OT post procedure|PT and OT Daily until goals met or patient discharge.
219531992|NCT03117296|OTHER|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
219531993|NCT03384602|OTHER|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
219531994|NCT03384602|OTHER|home exercise strength program|simple strength exercise program to perform individually at home
219531995|NCT05952986|DRUG|FB825 or Placebo in subcutaneous route|FB825 or placebo solution for SC injection
219616881|NCT01722578|DRUG|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
219616882|NCT04581993|DIETARY_SUPPLEMENT|Super Cereal - wheat soya blend with sugar|Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.
218917831|NCT04138940|BEHAVIORAL|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
218917832|NCT04111380|DRUG|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
219616883|NCT04581993|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement-medium quantity (LNS-MQ)|Children will receive LNS during 6-23 months of age.
218917833|NCT03165617|BIOLOGICAL|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
218917834|NCT03165617|BIOLOGICAL|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
218917835|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
218917836|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
218917837|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
218917838|NCT03435250|DRUG|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
218917839|NCT03435250|DRUG|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
219531996|NCT05952986|DRUG|FB825 in intravenous route|FB825 solution for IV infusion
219531997|NCT00725803|DRUG|GS-9450|GS-9450 capsules administered orally once daily
219531998|NCT00725803|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
219531999|NCT01638741|BEHAVIORAL|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
219532000|NCT02453386|DRUG|tozadenant|
219532001|NCT02453386|DRUG|placebo|
219532002|NCT02284490|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
219532003|NCT05166148|OTHER|Session (a)|Eccentric cycling
219532004|NCT05166148|OTHER|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
219532005|NCT05166148|OTHER|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
219532006|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention without motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks.. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks
219532007|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention with motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online and will also apply motivational strategies based on self-determination theory. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
219532008|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention without motivational strategies|Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
219616884|NCT04581993|BEHAVIORAL|Social and behavior change communication (SBCC)|SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
219616885|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219616886|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
219616887|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
219616888|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
219616889|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
219616890|NCT01008358|BIOLOGICAL|CP 675,206|
219616891|NCT05925465|PROCEDURE|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
219616892|NCT05925465|OTHER|Control|not receive any nerve block
219616893|NCT05965375|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
219616894|NCT02690831|OTHER|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
219616895|NCT02690831|OTHER|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
219616896|NCT02690831|DEVICE|Powerbreathe|
219616897|NCT01866826|DRUG|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
219616898|NCT01866826|OTHER|Placebo|subject will receive three capsules of placebo by mouth twice daily.
219616899|NCT04384094|DEVICE|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
219616900|NCT04513392|PROCEDURE|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
219616901|NCT05181046|DEVICE|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
219616902|NCT05181046|OTHER|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
219616903|NCT05624918|DRUG|Nab paclitaxel|125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
218917840|NCT03435250|DRUG|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
219532009|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention with motivational strategies|"Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional who will also apply motivational strategies. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center.~The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks."
219532010|NCT01547377|DIETARY_SUPPLEMENT|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
219532011|NCT01547377|OTHER|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
219532012|NCT02082392|DRUG|Escitalopram|
219532013|NCT02082392|DRUG|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
219616904|NCT05624918|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
219616905|NCT05624918|DEVICE|NovoTTF-200T(P)|Worn \> 18 hr /day starting C1D1 until completion of cycle 3
219616906|NCT05627843|DIETARY_SUPPLEMENT|Curcumin capsules 1 gm|Dietary supplement
219616907|NCT05627843|DIETARY_SUPPLEMENT|Placebo capsule|placebo corn starch
219532014|NCT03401086|OTHER|Kinesio Taping|Kinesio Taping
219532015|NCT01559428|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
219616908|NCT02347059|DRUG|L-dopa|Antiparkinsonian medication
219616909|NCT02347059|DRUG|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
219616910|NCT05832632|BEHAVIORAL|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
219532016|NCT01559428|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
219616911|NCT05832632|BEHAVIORAL|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
219616912|NCT05832632|BEHAVIORAL|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
219616913|NCT05832632|BEHAVIORAL|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
219616914|NCT06453499|OTHER|Physical therapy|ultrasound for 5 minutes,Tens and hot packs for 20 minutes, back exercise
219616915|NCT05108974|DRUG|Choline Bitartrate|Powdered drink mix for daily consumption
219532017|NCT01559428|DIETARY_SUPPLEMENT|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
219616916|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
219616917|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
219616918|NCT02083068|BIOLOGICAL|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
219616919|NCT00994812|DRUG|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
219616920|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
219616921|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time."
218917841|NCT02585856|DEVICE|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
218917842|NCT02585856|DEVICE|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
218917843|NCT03635281|PROCEDURE|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
219204685|NCT06070376|DEVICE|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
219204686|NCT06195150|OTHER|Blood collection|15ml of blood are harvested before surgery
219532018|NCT05643976|BEHAVIORAL|KardioPAC Mobile Application|"Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, \& a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable."
219532019|NCT05643976|OTHER|Standard of Care|During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
219532020|NCT06037772|OTHER|subcutaneous injection administration game|The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
219532021|NCT06037772|OTHER|control group|only
219616922|NCT05592171|PROCEDURE|Microwave ablation + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
219616923|NCT01662778|DRUG|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
219532022|NCT05344053|OTHER|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
219532023|NCT05344053|OTHER|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
219532024|NCT00802763|DEVICE|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
219532025|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
219532026|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
219532027|NCT01356849|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
219616924|NCT01662778|DRUG|6 microns at 50mg|STAG generated monodisperse 6 micron particles
219616925|NCT01662778|DRUG|Placebo Comparator|No drug just solvent
219616926|NCT01662778|DRUG|MDI FP|
219616927|NCT00742209|DRUG|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
219616928|NCT00742209|DRUG|Placebo|Placebo-control
219616929|NCT01061593|DIETARY_SUPPLEMENT|Immunoxel|1 lozenge once per day
219616930|NCT01061593|OTHER|Placebo|1 lozenge once per day
219616931|NCT03524651|DRUG|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
219616932|NCT03524651|DRUG|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
219616933|NCT03524651|DRUG|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
219616934|NCT03524651|DRUG|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
219616935|NCT03679689|DIETARY_SUPPLEMENT|artificially sweetened beverages|artificially sweetened beverages restriction
219616936|NCT02562066|DRUG|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
219532028|NCT01356849|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
219532029|NCT01681745|DEVICE|Cryo-Touch III|
219042203|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
219532030|NCT02767921|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219532031|NCT02767921|OTHER|Laboratory Biomarker Analysis|Correlative studies
219532032|NCT02767921|PROCEDURE|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
219532033|NCT02767921|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219532034|NCT02767921|PROCEDURE|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
219532035|NCT04444505|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
219532036|NCT02799108|DEVICE|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
219532037|NCT02799108|DEVICE|fMRI|fMRI acquisition under the same stimulation conditions
219532038|NCT00833937|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
219532039|NCT00833937|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
219532040|NCT04290845|BEHAVIORAL|Relief-Hybrid|A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
219532041|NCT01424293|DEVICE|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
219616937|NCT02562066|DRUG|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
219616938|NCT01736592|DRUG|Long term follow up in all patients who received SAR422459 in previous study TDU13583|Blood draw for the laboratory assessment
219042204|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
219042205|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
219532042|NCT01424293|DEVICE|The SPY® Intraoperative Imaging System|
219532043|NCT04419311|DEVICE|Vanguard® Knee System|Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
219532044|NCT04425447|DRUG|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
219532045|NCT04425447|DRUG|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
219616939|NCT01551771|DRUG|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
219616940|NCT01551771|DRUG|GW824575 matched-placebo|Placebo
219616941|NCT02287792|PROCEDURE|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
219616942|NCT00595621|DEVICE|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
219616943|NCT04305743|DRUG|OnabotulinumtoxinA 100 UNT|Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
219616944|NCT00087815|DRUG|dexamethasone|
219042206|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
219616945|NCT00087815|DRUG|hyperbaric oxygen|
219532046|NCT04425447|DRUG|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
219616946|NCT00087815|PROCEDURE|cognitive assessment|
219616947|NCT00087815|PROCEDURE|magnetic resonance imaging|
219616948|NCT00087815|PROCEDURE|positron emission tomography|
219616949|NCT00087815|PROCEDURE|quality-of-life assessment|
219616950|NCT00324987|BIOLOGICAL|Bevacizumab|Given IV
219616951|NCT00324987|DRUG|Imatinib Mesylate|Given PO
219616952|NCT00324987|OTHER|Laboratory Biomarker Analysis|Correlative studies
219616953|NCT00324987|OTHER|Pharmacological Study|Correlative studies
219616954|NCT04551456|BIOLOGICAL|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
219616955|NCT04610905|BEHAVIORAL|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
219616956|NCT04610905|BEHAVIORAL|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
219616957|NCT04904211|OTHER|Home-based chemotherapy|To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
219616958|NCT02138877|PROCEDURE|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
219616959|NCT02138877|PROCEDURE|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
219616960|NCT00348127|DEVICE|Neurovision|
219616961|NCT03295292|BIOLOGICAL|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
219616962|NCT03295292|OTHER|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
219616963|NCT04982289|DRUG|ALXN1830|Administered as an SC infusion.
219616964|NCT04982289|OTHER|Placebo|Administered as an SC infusion.
219616965|NCT02976857|BIOLOGICAL|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
219616966|NCT03817125|DRUG|Placebo for antibiotic|Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
219616967|NCT03817125|DRUG|Vancomycin pretreatment|Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
219616968|NCT03817125|DRUG|Nivolumab|Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
219616969|NCT03817125|DRUG|Matching Placebo for SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
219616970|NCT03817125|DRUG|SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
219616971|NCT00479999|DRUG|VRC-HIVADV027-00-VP|
219616972|NCT00479999|DRUG|VRC-HIVADV038-00-VP|
219616973|NCT04842071|DIAGNOSTIC_TEST|18F-sodium fluoride|Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
219616974|NCT03182231|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
219616975|NCT02246751|DEVICE|Targeted Training for trunk control|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
219616976|NCT03979391|DIAGNOSTIC_TEST|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
219616977|NCT06187129|DEVICE|nerve ultrasound|nerve ultrasound
219616978|NCT01797874|DRUG|Pazopanib|Experimental
219616979|NCT01797874|DRUG|Placebo|placebo arm
219532047|NCT05239819|BEHAVIORAL|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
219532048|NCT05239819|BEHAVIORAL|Regulated care and education|Regulated care and education will be applied
219532049|NCT04133623|DRUG|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
219532050|NCT04133623|DRUG|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
219616980|NCT06377774|OTHER|No intervention in this study|No intervention in this study
218917844|NCT03635281|PROCEDURE|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
218917845|NCT04963010|DIAGNOSTIC_TEST|second forward view|second forward view examination of the proximal colon
218917846|NCT06035159|BEHAVIORAL|online psychotherapy|6 modules
219042207|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
219042208|NCT04400721|DRUG|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
219042209|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
219042210|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
219042211|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
219042212|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
219042213|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
219532051|NCT01304641|OTHER|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
219532052|NCT01304641|OTHER|Simvastatin Initiators|Retrospective database analysis no intervention performed.
219532053|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
219616981|NCT03359148|DEVICE|Disposable ventilator system|
219616982|NCT03359148|DEVICE|Conventional reused ventilator system|
219616983|NCT01487967|OTHER|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
219616984|NCT00517504|DRUG|Methylphenidate|"* 1-week single blind placebo lead-in phase.~* step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
219616985|NCT03280810|OTHER|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
219616986|NCT05898724|PROCEDURE|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
219616987|NCT05898724|PROCEDURE|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
219616988|NCT05898724|PROCEDURE|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
219616989|NCT06431724|OTHER|Patient Survey|A simple data intake collection from the patients regarding their medical history that will allow the researchers to assess if recommended guidelines were followed.
219616990|NCT06431724|OTHER|Provider Survey|A survey will be used to evaluate providers' practices, knowledge and adherence to guidelines, and decision making related to current practice for cervical screening in women \>65.
219616991|NCT01998919|DRUG|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
218917847|NCT04031105|DEVICE|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
219042214|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
219042215|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
218917848|NCT05683028|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
219042216|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
219042217|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
219532054|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
219616992|NCT01998919|DRUG|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
219616993|NCT01998919|DRUG|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
219616994|NCT01998919|DRUG|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
219532055|NCT04544787|BIOLOGICAL|Placebo|sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)
219532056|NCT01458808|OTHER|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
219532057|NCT01458808|OTHER|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
219532058|NCT03211403|DRUG|SHR4640|SHR4640 or placebo once daily for a week
219532059|NCT03283943|RADIATION|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
219532060|NCT03283943|DRUG|Durvalumab|Durvalumab 1500 mg IV every 28 days
219532061|NCT01939717|OTHER|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
219616995|NCT01998919|DRUG|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
219616996|NCT00853008|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
219616997|NCT00853008|DRUG|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
219616998|NCT00853008|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
219616999|NCT00853008|DRUG|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
219617000|NCT00853008|DRUG|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
219042218|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
219532062|NCT01306630|DRUG|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
219532063|NCT03536130|DEVICE|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
219617001|NCT00853008|DRUG|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
219617002|NCT00853008|DRUG|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
219617003|NCT00853008|DRUG|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
219617004|NCT00853008|DRUG|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
219617005|NCT00853008|DRUG|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
219617006|NCT00853008|DRUG|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
219617007|NCT00853008|DRUG|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
219617008|NCT01358435|BIOLOGICAL|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
219617009|NCT01358435|BIOLOGICAL|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
219617010|NCT02084862|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
218917849|NCT05683028|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
218917850|NCT03316924|PROCEDURE|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
218917851|NCT06371612|OTHER|Standard Care|Parental Presence
218917852|NCT06371612|OTHER|Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use
218917853|NCT06371612|BEHAVIORAL|Ball Squeezing + Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
218917854|NCT04848298|BEHAVIORAL|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise."
219042219|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
219532064|NCT05599074|DEVICE|extrusion arch|A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
219532065|NCT00465270|DEVICE|AMPLATZER PFO Occluder|patent foramen ovale closure device
219532066|NCT00465270|OTHER|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
219532067|NCT00913406|OTHER|Lutein fortification|
219532068|NCT00913406|OTHER|Standard formula|
219532069|NCT02004509|DRUG|Anticoagulant|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
219532070|NCT04773470|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
219532071|NCT03696394|DEVICE|BioCartilage® Micronized Cartilage Matrix|BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
219532072|NCT04589091|OTHER|Refractive surgery|Refractive surgery for correction of error of refraction
219532073|NCT01453465|OTHER|Laboratory Biomarker Analysis|Correlative studies
219532074|NCT02155465|DRUG|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
219532075|NCT02155465|DRUG|Erlotinib|Erlotinib 150mg PO QD
219042220|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
219532076|NCT04395222|DRUG|Tocilizumab|Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
219532077|NCT04395222|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
219042221|NCT01248026|OTHER|Buttermilk|"Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)"
219042222|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
219042223|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
219042224|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
219532078|NCT04395222|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.
219532079|NCT04395222|DRUG|Anti-thymocyte globulin (rabbit)|Anti-thymocyte globulin (ATG) 1.5 mg/kg
219532080|NCT04395222|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
219617011|NCT02084862|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
218917855|NCT01341834|DRUG|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
218917856|NCT06513871|BEHAVIORAL|Social perception tasks|social perception tasks
218917857|NCT06629376|DRUG|Pegylated Recombinant Candida Utilis Uricase for Injection|According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
218917858|NCT05246592|PROCEDURE|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
218917859|NCT05246592|PROCEDURE|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
218917860|NCT02340026|OTHER|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
219532081|NCT03233724|DRUG|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
219532082|NCT03233724|DRUG|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
219532083|NCT03233724|DRUG|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
218917861|NCT02340026|OTHER|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
218917862|NCT03948971|PROCEDURE|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
218917863|NCT05199337|DRUG|ZN-d5|ZN-d5 will be administered orally
218917864|NCT05557916|OTHER|Standard rehab|Standard rehab protocol including knee orthosis following meniscal repair
219532084|NCT00807196|DRUG|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
218917865|NCT05557916|OTHER|accelerated rehab group|accelerated rehab group, no orthosis
218917866|NCT04819126|OTHER|Nintendo Wii Virtual Reality Application|The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
218917867|NCT06772376|DIAGNOSTIC_TEST|SERS sensor based on CHA reaction|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
219532085|NCT00807196|DRUG|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
219532086|NCT00807196|DRUG|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
219532087|NCT00807196|DRUG|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
219532088|NCT00807196|OTHER|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
219532089|NCT01448902|DRUG|OC000459|OC000459 200mg bid for 8 days
219532090|NCT01448902|DRUG|Placebo|Placebo bid for 8 days
219532091|NCT05437549|PROCEDURE|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
219532092|NCT03509545|DRUG|CHF Patients: ER Torsemide 40 mg|ER Torsemide 40mg given once daily to CHF patients
219532093|NCT03509545|DRUG|CHF Patients: Furosemide 40 mg|Stable CHF patients taking twice-daily 40 mg Furosemide
218917868|NCT01766609|DRUG|Triamcinolone Acetonide|
218917869|NCT05911984|DRUG|9MW3811 Injection|Intravenous injection
218917870|NCT06312150|OTHER|Analysis of peripheral blood (control group)|Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.
218917871|NCT06312150|OTHER|Analysis of biological sample (Substudy-solid neoplasms)|peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy
218917872|NCT06312150|OTHER|Analysis of biological sample (substudy-leukaemia patients)|sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
218917873|NCT06261320|DRUG|Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate|4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
219532094|NCT00314990|DRUG|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
219532095|NCT04967794|OTHER|Teleorientation and Tooth Brushing Orientation|Guide children in toothbrushing with a preventive purpose during the COVID-19 pandemic
219532096|NCT03373162|DRUG|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
219532097|NCT06144385|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
219532098|NCT02388191|DRUG|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
219532099|NCT02388191|OTHER|Placebo tablet|
219532100|NCT01467791|OTHER|Observation|Observe patients
219532101|NCT03135834|BIOLOGICAL|MenABCWY|N meningitidis group A, B, C, W, and Y vaccine
219532102|NCT03135834|BIOLOGICAL|Saline|Placebo
219532103|NCT03135834|BIOLOGICAL|rLP2086|Bivalent recombinant lipoprotein 2086 vaccine
219532104|NCT03135834|BIOLOGICAL|MenACWY-CRM|meningococcal group A, C, W-135, and Y conjugate vaccine
219532105|NCT02234661|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
219617012|NCT04504968|OTHER|Multimodal intervention|"1. Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure\<150/90 mmHg~2. The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~3. Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
219617013|NCT04504968|OTHER|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
219617014|NCT02675036|PROCEDURE|Tooth extraction|
219617015|NCT00776841|DRUG|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
219617016|NCT00776841|DRUG|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
218917874|NCT05582434|DRUG|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
218917875|NCT05582434|DRUG|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
218917876|NCT05582434|DRUG|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
219532106|NCT03301363|DEVICE|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
219532107|NCT03494894|DIAGNOSTIC_TEST|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
219532108|NCT03127826|PROCEDURE|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~\- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~\- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, \& graded exposure"
219532109|NCT03127826|PROCEDURE|Usual Care|Usual care at the general practitioner's discretion
219617017|NCT00776841|DRUG|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
219617018|NCT01302743|DRUG|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
219617019|NCT01302743|DIETARY_SUPPLEMENT|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
219617020|NCT01302743|DIETARY_SUPPLEMENT|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
219617021|NCT03024502|DRUG|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
219617022|NCT03024502|DRUG|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
219617023|NCT03024502|DRUG|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
219617024|NCT00004115|RADIATION|yttrium Y 90 monoclonal antibody HMFG1|
219617025|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
218917877|NCT01058980|PROCEDURE|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
218917878|NCT01058980|PROCEDURE|No additional ablation|Presence of dormant PV conduction, no additional ablation.
218917879|NCT01058980|PROCEDURE|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
218917880|NCT01058980|PROCEDURE|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
218917881|NCT05542641|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|real versus sham rTMS
219042225|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
219532110|NCT00584025|DRUG|levetiracetam|100 - 500mg IV q 15 min
219532111|NCT00584025|DRUG|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
219532112|NCT00057239|DRUG|Radafaxine|
218917882|NCT05614531|GENETIC|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
218917883|NCT04854174|DRUG|ZN-d5|Oral agent; 25 mg formulation
218917884|NCT06540079|DEVICE|Solia CSP S lead|The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.
218917885|NCT02380573|DRUG|Methylene Blue|
219532113|NCT02830516|OTHER|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
218917886|NCT02380573|DRUG|FD&C Blue # 2|
218917887|NCT02380573|DRUG|Phenazopyridine hydrochloride|
218917888|NCT04797585|OTHER|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
218917889|NCT04797585|OTHER|Vaginal hysterectomy|Vaginal hysterectomy
218917890|NCT02738801|DRUG|GLPG1690 600 mg QD|GLPG1690 capsules, administered at a dose of 600 mg, orally QD
219042226|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
219042227|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
219532114|NCT02559063|BEHAVIORAL|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
219532115|NCT02559063|BEHAVIORAL|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
219617026|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
219617027|NCT03492515|DRUG|recombinant human thrombopoietin|If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
219617028|NCT03492515|DRUG|Platelet Concentrate|according to the their conditions, use if necessary
219617029|NCT00837837|DRUG|Chlorpheniramine|
219617030|NCT00593515|BEHAVIORAL|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
219617031|NCT00593515|BEHAVIORAL|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
218917891|NCT02738801|DRUG|Placebo QD|Matching placebo capsules, administered orally QD
218917892|NCT01210313|OTHER|Physical exercise|Defined exercise program
218917893|NCT03501082|OTHER|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
218917894|NCT03501082|OTHER|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
218917895|NCT03501082|OTHER|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
218917896|NCT03501082|OTHER|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
218917897|NCT03193840|PROCEDURE|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
218917898|NCT02516696|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
218917899|NCT02516696|DRUG|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
218917900|NCT02516696|DRUG|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
218917901|NCT04877626|DRUG|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
218917902|NCT02958995|OTHER|No Intervention|
219532116|NCT02363634|DIETARY_SUPPLEMENT|magnesium threonate|nutritional product
219532117|NCT03805815|DEVICE|tunable crack sensor|blood pressure monitoring via crack sensor
219532118|NCT03047317|BIOLOGICAL|MABp1|Single dose of intravenous MABp1
219532119|NCT03686033|DRUG|Placebo|Participants will receive E2082-matched placebo tablets orally.
219532120|NCT03686033|DRUG|E2082|Participants will receive E2082 tablets orally.
219617032|NCT06391307|OTHER|Crystallized phenol|Crystallized phenol + Exosome + Stem Cell
219617033|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome|Crystallized phenol + Exosome will be applied to wound area.
219617034|NCT06391307|BIOLOGICAL|Crystallized phenol + Stem Cell|Crystallized phenol + Stem cell will be applied to wound area.
219617035|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome + Stem Cell|Crystallized phenol + Exosome + Stem Cell will be applied to wound area.
219617036|NCT00897715|DRUG|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
218917903|NCT00355108|DRUG|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
218917904|NCT01488604|DEVICE|Polymeric Nasal Spray|Experimental nasal spray
218917905|NCT01488604|DEVICE|Sham Nasal Spray|Sham nasal spray
218917906|NCT04006288|DRUG|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
218917907|NCT04006288|DRUG|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
218917908|NCT04006288|DRUG|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
218917909|NCT04006288|DRUG|aspirin|all patients will remain on aspirin
218917910|NCT04006288|DRUG|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
219532121|NCT05878483|DEVICE|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
219532122|NCT01045161|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
219532123|NCT01045161|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
219532124|NCT05114447|OTHER|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
219617037|NCT00897715|DRUG|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
219617038|NCT00554385|DRUG|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
219617039|NCT02321111|DRUG|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
219617040|NCT02321111|DRUG|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
218917911|NCT01796145|OTHER|Fibroscan|
218917912|NCT01710345|DRUG|Sufentanil NanoTab 20 mcg|
218917913|NCT01710345|DRUG|Sufentanil NanoTab 30 mcg|
218917914|NCT01710345|DRUG|Placebo NanoTab|
218917915|NCT04475081|BIOLOGICAL|MMR vaccine|Merck MMR-II vaccine
219042228|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
218917916|NCT04325672|BIOLOGICAL|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.
218917917|NCT03563339|BEHAVIORAL|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
219042229|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
219042230|NCT00628290|DRUG|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
219042231|NCT00628290|DRUG|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
219617041|NCT02265094|OTHER|Electroencephalography|EEG recordings during memory tests
219617042|NCT02265094|BEHAVIORAL|Neuropsychological assessment|patterns of eye gaze during cognitive tests
219617043|NCT01059838|BEHAVIORAL|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
219617044|NCT00576719|BEHAVIORAL|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
219617045|NCT00576719|BEHAVIORAL|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
219617046|NCT00576719|OTHER|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
219617047|NCT02386319|DRUG|Melatonin|Gelatin capsules
219617048|NCT02386319|DRUG|Placebo|Placebo capsules
219532125|NCT05114447|OTHER|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
218917918|NCT05062785|DRUG|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
219532126|NCT03197883|OTHER|Test Product|Restoring lipid balm
219532127|NCT03197883|OTHER|Cleanser|Moisturizing facial cleanser
219532128|NCT03197883|OTHER|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
219617049|NCT04478383|PROCEDURE|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
218917919|NCT05996575|OTHER|fNIRS measurement|Kernel Flow2 measurements.
219532129|NCT00807794|DRUG|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
219532130|NCT00807794|DRUG|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
219532131|NCT00807794|DRUG|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
219532132|NCT00807794|DRUG|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
219532133|NCT00807794|DRUG|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
219532134|NCT00433225|DRUG|Prednisolone Acetate|
219532135|NCT00433225|DRUG|Ketorolac 0.4%|
219532136|NCT00433225|DRUG|Gatifloxacin 0.3%|
219532137|NCT02371486|PROCEDURE|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
219532138|NCT02371486|PROCEDURE|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
219532139|NCT02371486|PROCEDURE|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
219617050|NCT04086056|OTHER|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
219617051|NCT01242293|OTHER|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
219617052|NCT01242293|OTHER|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
218917920|NCT05491265|BEHAVIORAL|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
219532140|NCT02371486|PROCEDURE|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
219532141|NCT00163514|DRUG|Ciclesonide|
219617053|NCT01242293|OTHER|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
219617054|NCT01342471|BEHAVIORAL|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
219617055|NCT01342471|BEHAVIORAL|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
218917921|NCT02439723|DRUG|Regorafenib|
218917922|NCT01502293|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
219532142|NCT01299363|BEHAVIORAL|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
219532143|NCT03677492|OTHER|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
219532144|NCT04531605|BEHAVIORAL|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
219532145|NCT06561724|DIETARY_SUPPLEMENT|Biscuits maltodextrin|Biscuits includes maltodextrin
219532146|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics tartoufa inulin|Biscuits prebiotics
219532147|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics chicory inulin|Biscuits prebiotics
219532148|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
219532149|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
219532150|NCT00858845|DRUG|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
219532151|NCT00858845|OTHER|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
218917923|NCT01502293|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
218917924|NCT05075265|DRUG|Methadone|Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
219042232|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
219617056|NCT01157793|DRUG|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
219617057|NCT01157793|DRUG|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
219617058|NCT04670328|DIAGNOSTIC_TEST|not required|Diagnostic tests( hematological parameters) were assessed.
219532152|NCT04841317|COMBINATION_PRODUCT|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
219617059|NCT02088177|DRUG|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
219042233|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
219042234|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
219042235|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
219042236|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
219617060|NCT01910493|BEHAVIORAL|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
219617061|NCT02534051|OTHER|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth \& well-being, counselling about birth risks, and discussion of breastfeeding.
219617062|NCT01774760|DRUG|18F-EF5|
219617063|NCT01774760|PROCEDURE|Pretreatment PET/CT-scan (performed two times)|
219617064|NCT05714592|OTHER|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
219617065|NCT00596531|DRUG|Acamprosate|Oral administration, 666 mg, tid, for 4 months
219617066|NCT00596531|DRUG|Placebo|Oral administration of 2 pills, tid, for 4 months
218917925|NCT01707342|DRUG|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
218917926|NCT04686474|DRUG|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
218917927|NCT00927108|OTHER|Progenitor Stem Cell Culture|
218917928|NCT00274586|DRUG|Aggrenox® modified release capsules|
219532153|NCT06533345|BEHAVIORAL|Behavior Change Coaching|Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
218917929|NCT00274586|DRUG|Aggrenox® modified release capsules matching placebo|
218917930|NCT04263623|DRUG|Dexmecamylamine HCl|Investigational drug
218917931|NCT04263623|OTHER|Placebo|Oral tablet containing no active drug.
218917932|NCT01783613|DIETARY_SUPPLEMENT|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
219042237|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
219042238|NCT00002275|DRUG|Fat Emulsion 2%|
219042239|NCT00002275|DRUG|Fat Emulsion 20%|
219042240|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219042241|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
218917933|NCT01783613|DIETARY_SUPPLEMENT|Placebo: 50 mg/kg/day during 12 months|
218917934|NCT00352768|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
218917935|NCT00352768|DRUG|Placebo|Placebo
218917936|NCT05917899|BEHAVIORAL|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
218917937|NCT03694353|DRUG|Pegvaliase|40-60mg/day
218917938|NCT05400967|DRUG|68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
218917939|NCT05415761|BEHAVIORAL|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
218917940|NCT05415761|BEHAVIORAL|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
218917941|NCT05415761|BEHAVIORAL|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
218917942|NCT06061991|BEHAVIORAL|Mobile instant messaging-based lifestyle intervention|Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.
218917943|NCT06061991|BEHAVIORAL|Text messaging reminders|Follow-up reminders via text messaging as attention control.
218917944|NCT06061991|BEHAVIORAL|Brief advice on GDM prevention|Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy
219042242|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
219042243|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
219042244|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219042245|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
219042246|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
219042247|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
219532154|NCT06533345|BEHAVIORAL|Nutrition|Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
219617067|NCT05582889|BEHAVIORAL|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
219617068|NCT01730989|DIETARY_SUPPLEMENT|Estromineral Serena Plus|
219617069|NCT01730989|DIETARY_SUPPLEMENT|Estromineral|
219617070|NCT01268631|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
219617071|NCT01268631|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
219042248|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
219042249|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
219617072|NCT03801135|DRUG|Fibrinogen concentrate|Haemocomplettan will be infused after plasma exchange procedure
219617073|NCT03801135|OTHER|Fresh Frozen Plasma|Fresh frozen plasma will be part of replacement fluid
218917945|NCT06061991|BEHAVIORAL|Usual care|Usual care provided by the prenatal clinic.
218917946|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 750 mg|750 mg administered orally
218917947|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 1500 mg|1500 mg administered orally
218917948|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 3000 mg|3000 mg administered orally
219617074|NCT01976026|DEVICE|Flow Diversion|
219617075|NCT01976026|DEVICE|Best Standard Therapy|
218917949|NCT06033222|DRUG|Placebo|Contains no active ingredient.
219532155|NCT06533345|OTHER|Autonomic Recalibration|Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
219532156|NCT06533345|PROCEDURE|Dry Needling|An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
219532157|NCT06533345|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
219617076|NCT01681446|DRUG|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
219617077|NCT01228201|BEHAVIORAL|Moderate continuous training|Three training sessions per week in a total of 12 weeks
219617078|NCT01228201|BEHAVIORAL|Aerobic interval training|Three training sessions per week in a total of 12 weeks
219617079|NCT02651701|PROCEDURE|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
218917950|NCT06006208|DEVICE|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
219617080|NCT05603169|OTHER|High intensity resistance Exercise Training|The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
219617081|NCT05603169|OTHER|High intensity aerobic Exercise Training|The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
219617082|NCT02420925|PROCEDURE|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
219617083|NCT01778530|DRUG|TRC105|Intravenous infusion.
219617084|NCT06327139|DEVICE|Conventional 5 point closed face immobilisation mask.|The conventional closed face mask is a standard of care immobilization device for head and neck cancer patients which covers and immobilizes the entire anterior portion of the patients head, neck and shoulders using a semi rigid thermoplastic material.
218917951|NCT03548532|DEVICE|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
218917952|NCT04327154|DEVICE|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
218917953|NCT06069128|DEVICE|Neurotrigger Basic. eye blinking stimulator|NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
218917954|NCT06332495|OTHER|Questioning the patient during hygiene care|The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
218917955|NCT04046497|OTHER|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
219042250|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
219042251|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
219532158|NCT06533345|BEHAVIORAL|Counseling Psychology|Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
219532159|NCT06533345|OTHER|Multiple Treatments|"Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description."
219617085|NCT06327139|DEVICE|5 point open face immobilization mask|The 5 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face or chest. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the level of their clavicle.
219617086|NCT06327139|DEVICE|3 point open face immobilization mask|The 3 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the below the patients chin. The three point mask does not cover the patients shoulders and does not extend inferiorly to the level of the clavicle.
218917956|NCT04046497|OTHER|Usual Care|Usual Care provided by CSC clinic
218917957|NCT03007732|DRUG|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
218917958|NCT03007732|DRUG|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
218917959|NCT03007732|DRUG|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
219532160|NCT02596100|DRUG|Betrixaban|
219532161|NCT04916548|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
219532162|NCT01353664|DRUG|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
219532163|NCT00987103|DRUG|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
219532164|NCT00688571|DEVICE|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
219532165|NCT00046527|DRUG|ABI-007|
218917960|NCT03007732|DRUG|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
218917961|NCT03007732|DRUG|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
218917962|NCT03007732|RADIATION|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
219532166|NCT04484545|DIAGNOSTIC_TEST|Prognostic score|Validation of scores of systemic inflammatory response
219617087|NCT01199939|DRUG|Etravirine|400mg once daily orally for 48 weeks
219617088|NCT01199939|DRUG|Ritonavir|100mg once daily orally for 48 weeks
219617089|NCT01199939|DRUG|Darunavir|800mg once daily orally for 48 weeks
218917963|NCT05929274|DEVICE|tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.
218917964|NCT05929274|DEVICE|sham tDCS|For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
219532167|NCT01964092|BEHAVIORAL|Individual Placement and Support|
219532168|NCT01964092|BEHAVIORAL|Ordinary employment schemes|
219532169|NCT03549364|BEHAVIORAL|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
219532170|NCT01165905|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
219532171|NCT01165905|DRUG|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
219617090|NCT03494712|DRUG|S 95010|Single administration of S 95010 in healthy volunteers
218917965|NCT06359015|DRUG|Metformin|"Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance."
219617091|NCT03494712|OTHER|Placebo|Single administration of placebo in healthy volunteers
218917966|NCT06359015|DRUG|Esomeprazole|40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
219532172|NCT05210062|OTHER|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
219532173|NCT02605928|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
219617092|NCT01962610|OTHER|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
218917967|NCT06651541|DRUG|BZ371A|Formulation with the active ingredient
219532174|NCT04874545|DRUG|Propofol|Total intravenous inhalational anesthesia
219532175|NCT02313064|DRUG|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
218917968|NCT06651541|DRUG|Placebo|Formulation without the active ingredient
218917969|NCT03096743|DIAGNOSTIC_TEST|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
218917970|NCT03096743|DIAGNOSTIC_TEST|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
218917971|NCT03096743|PROCEDURE|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
218917972|NCT03096743|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
219532176|NCT02313064|DRUG|CXA-10 placebo|
219532177|NCT05649228|DRUG|Capsaicin 0.1% Cream|A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
219532178|NCT05649228|DRUG|Capsaicin Palmitate 0.25% Cream|A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
219532179|NCT05649228|DRUG|Placebo Cream|A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
219532180|NCT01889719|BIOLOGICAL|MVA-CMDR|injections of MVA-CMDR vaccine
219532181|NCT01114893|DRUG|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
219532182|NCT01114893|DRUG|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
219532183|NCT01114893|DRUG|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
219532184|NCT03233386|BEHAVIORAL|Mantente REAL|substance abuse prevention curriculum for adolescents
219532185|NCT02866422|OTHER|No Intervention|Observational Study: No intervention
219532186|NCT04236401|PROCEDURE|electrosurgery will be used for abdominal incision|electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also
219532187|NCT04236401|PROCEDURE|scalpel will be used for abdominal incision|scalpel will be used for abdominal wall incision and thread will be used for haemostsis
219532188|NCT05212363|DEVICE|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
219532189|NCT05212363|BEHAVIORAL|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
219532190|NCT04168346|DRUG|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
219532191|NCT04168346|DRUG|Placebos|NaCl 0.9% infusion
219532192|NCT01089699|BEHAVIORAL|online support group|online support group
219532193|NCT01089699|BEHAVIORAL|online support group|online support group
219532194|NCT01089699|BEHAVIORAL|home study support materials|self-study materials
219532195|NCT00030446|DRUG|carboplatin|
219617093|NCT00535210|BEHAVIORAL|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
219532196|NCT00030446|DRUG|erlotinib hydrochloride|
219532197|NCT01592578|PROCEDURE|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
219532198|NCT01592578|PROCEDURE|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
218917973|NCT03096743|DIAGNOSTIC_TEST|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
218917974|NCT02700607|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
218917975|NCT02700607|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
218917976|NCT04458402|RADIATION|Hypofractionated WPRT|Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
218917977|NCT05536635|BEHAVIORAL|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
218917978|NCT06590766|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
218917979|NCT06596174|PROCEDURE|Transcutaneous spinal cord stimulation (tSCS)|The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).
218917980|NCT06596174|PROCEDURE|Short-term Machine-Assisted Ankle Movement Training with tSCS|The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time
218917981|NCT06596174|PROCEDURE|Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS|"The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS).~Each session will last for 30 minutes, conducted three times per week, over a period of four weeks."
218917982|NCT06595186|DRUG|JK-1201I|JK-1201I will be administered.
218917983|NCT06595186|DRUG|Temozolomide (TMZ)|Temozolomide will be administered.
218917984|NCT06596122|DRUG|Vitamin D (Cholecalciferol )|In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.
218917985|NCT06589817|DRUG|Hydrochloride Carliprazine capsules|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
218917986|NCT06589817|DRUG|Aripiprazole tablets|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
218917987|NCT06594341|PROCEDURE|Visit frequency|"Fortnightly visit frequency for moderate phase~Nutritional supplement: 1 daily sachet of RUTF as soon as a child admitted with MUAC\<115mm or edema reaches a MUAC=\>115mm or absence of edema."
218917988|NCT06594341|DIETARY_SUPPLEMENT|Suppression of the transition period|Transitioning children admitted with MUAC\<115mm or edema to receiving 1 daily sachet of RUTF as soon as they reach a MUAC=\>115mm and absence of edema
219532199|NCT00556790|PROCEDURE|Standard Care|standard fluid regime, delayed feeding
219617094|NCT00535210|BEHAVIORAL|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
219532200|NCT00556790|PROCEDURE|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
219617095|NCT05303610|OTHER|Observational|This is a cross sectional study. The aim of the study is to evaluate the myofascial chain lines in addition to the general evaluation parameters in patients with patellofemoral pain syndrome (PFPS) and to determine whether deviations from normal in the myofascial structure have an effect on the development of PFPS.
219617096|NCT04868695|PROCEDURE|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3|1\) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
219617097|NCT04952181|DEVICE|optical biometry|optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
218917989|NCT06594341|PROCEDURE|Simplified treatment|Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=\>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=\>125mm for 2 consecutive weeks.
218917990|NCT06588816|DEVICE|optical coherence tomography|"Optical coherence tomography (OCT) is a non-invasive imaging test . It uses light waves to take cross-section pictures of the retina .~With OCT, the ophthalmologist can see each of the retina's distinctive layers, and so we can use it to study the changes in pseudoexfoliation syndrome."
219532201|NCT02752126|RADIATION|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
219532202|NCT02752126|RADIATION|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
219532203|NCT06366477|DEVICE|Vibration stimulation combined with task-oriented training|Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
219532204|NCT03642548|DRUG|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
219532205|NCT03642548|DRUG|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
219532206|NCT01417390|DRUG|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
219532207|NCT01417390|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
219617098|NCT04952181|DEVICE|ultrasonic biometry|ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
219532208|NCT03743753|OTHER|Experimental|The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
219532209|NCT02612337|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
219617099|NCT04696224|DRUG|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
219617100|NCT04696224|OTHER|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
219617101|NCT06261424|PROCEDURE|IMPACT - rehabIlitation prograM for sPAstiC aTaxias|The rehabilitation program will last 12 weeks and consists of three training sessions of 60 minutes per week (2 sessions in a therapy room and 1 session in an adapted pool with multiple levels of water) for a total of 36 sessions. Participants will be divided into 7 subgroups of 6 participants and each sub-group will be supervised by one physiotherapist (PT) and one physiotherapy technologist for safety considerations. It will focus on these three domains: 1) postural control; balance, trunk-limbs and multi-joints control and coordination and 3) functional mobility. Each domain contains a standardized list of exercises with different difficulty levels and specific times allocation. All exercises will be executed by the participants at each session at the appropriate difficulty level. The initial level of difficulty for each exercise will be determined by the PT based on individual results of the pre-intervention assessment and on individual performance, fatigue level and safety.
219617102|NCT05379413|DRUG|Botulinum toxin type A|Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
219617103|NCT05417841|DRUG|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
219617104|NCT05417841|DRUG|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
219617105|NCT01894919|BIOLOGICAL|Bexsero® vaccine (1 dose at study month zero)|
219617106|NCT01894919|BIOLOGICAL|Bexsero® vaccine (2 doses 1 month apart)|
219617107|NCT02862236|DRUG|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
219617108|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (90µg)|The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
219617109|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (10µg)|This intervention serves as a control as they get the current recommended vitamin D dose
218917991|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at camp with the guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at camp will follow the same principles as the usual HABIT-ILE. The therapy will take place in a rehabilitation center, and caregivers will provide therapy during the sessions, coached by trained supervisors on site~* The intervention day will then take place, lasting for 5 hours with the constant presence of supervisors. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
218917992|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at home with the online guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at home will follow the same principles as the usual HABIT-ILE. The therapy will take place at children's home, caregivers will provide therapy during the sessions, coached by trained supervisors online~* The intervention day will then take place, lasting for 5 hours with the supervisors through online setting. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
218917993|NCT06596824|BEHAVIORAL|Training intervention|Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
219042252|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
219042253|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
219042254|NCT05418725|DEVICE|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
219042255|NCT05418725|DEVICE|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
218917994|NCT06604013|PROCEDURE|non-surgical full-mouth periodontal therapy without using adjunct disinfectants|Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
218917995|NCT06604013|DIAGNOSTIC_TEST|GCF level of adiponectin and resistin|Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
218917996|NCT06593613|BEHAVIORAL|RUBI-A|"The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills."
218917997|NCT06593613|BEHAVIORAL|R-ISLEA|R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
219042256|NCT02350205|BIOLOGICAL|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
219042257|NCT05923229|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
219042258|NCT05923229|OTHER|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
219042259|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
219042260|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
219042261|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
219532210|NCT02612337|DRUG|Placebo|Single intratympanic injection of placebo
219532211|NCT05372406|OTHER|• no intervention|• no intervention
219532212|NCT00000194|DRUG|Cycloserine|
219617110|NCT03164018|DRUG|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
219617111|NCT05951803|BEHAVIORAL|Brief Behavioral Intervention in Insomnia|Weekly intervention of 4 sessions where behavior therapy techniques are administered, such as stimulus control, sleep hygiene, sleep restriction and progressive muscle relaxation. Each session lasts 60 minutes.
219617112|NCT00372684|GENETIC|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
219617113|NCT00372684|GENETIC|with uncomplicated malaria|with uncomplicated malaria
219617114|NCT01255488|BEHAVIORAL|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
219617115|NCT00663793|DRUG|Acyline|300 mcg/kg
219617116|NCT00663793|DRUG|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
219617117|NCT00663793|DRUG|Finasteride|1 mg PO once daily \[day -2 to day 12) 14 days total
219532213|NCT00000697|DRUG|Foscarnet sodium|
219532214|NCT03726151|BEHAVIORAL|Parent Reminders|Automated, system-generated mailed or text message reminders
219532215|NCT03726151|BEHAVIORAL|Multicomponent clinic-system strategies|"1. Workflow modifications to reduce missed opportunities for vaccination~2. Provider- and clinic-level audit and feedback~3. Provider \& staff training on workflow modifications and communication strategies"
219532216|NCT03726151|BEHAVIORAL|Combined Condition|Parent reminders and multicomponent clinic-system strategies
219617118|NCT03700983|DIETARY_SUPPLEMENT|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
219617119|NCT03238651|DRUG|TAK-659|TAK-659 Tablets.
219617120|NCT01739465|PROCEDURE|Self expanding metallic stent (SEMS)|Self expanding metallic stent
219617121|NCT01739465|PROCEDURE|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
219617122|NCT01739465|PROCEDURE|Photodynamic therapy (PDT)|Photodynamic therapy
219617123|NCT00401648|DRUG|Brivaracetam|
219617124|NCT05947383|DRUG|Psilocybin|Psilocybin 25 mg oral capsule
219617125|NCT05947383|DRUG|Placebo|Niacin 100 mg oral capsule
219617126|NCT02066844|DRUG|Celestone|2cc
219617127|NCT02066844|DRUG|Lidocaine|5cc
218917998|NCT06590636|PROCEDURE|Expressive touching|"Woman's anxiety level was measured with the State-Trait Anxiety Inventory scale Following these measurements, expressive touching that lasted 15-20 minutes was performed in the following manner.~The hands of the expressive touching performer warmed to body temperature (should not be cold).~The woman's hand close to the performer was placed between the hands of the expressive touching performer.~The woman's palm was gently grasped with the palms of the expressive touching performer.~The hand below was fixed and the upper part of the woman's hand was gently rubbed with the hand above.~Before and after massaging, the woman's arms and shoulders were touched at intervals.~During the procedure, the woman was called by her name, and verbal communication with the woman was continued by holding her hands firmly and sincerely as if a handshaking done.~Before the woman's discharge from the center, her anxiety level was measured with the State-Trait Anxiety Inventory scale"
218917999|NCT06592898|BEHAVIORAL|straight leg raise|The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
219532217|NCT04668105|OTHER|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
219532218|NCT04668105|OTHER|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
219532219|NCT00803491|OTHER|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
219532220|NCT00803491|OTHER|Traditional rheumatology care.|Individually base.
219532221|NCT02134834|DRUG|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
219532222|NCT02134834|DRUG|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
219532223|NCT05245357|BEHAVIORAL|Lentil|Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.
219532224|NCT05245357|BEHAVIORAL|Control|Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
219532225|NCT05314023|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
219617128|NCT00725868|OTHER|Data private hospitals, angioplasty, sampling of blood|"* Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~* coronary angioplasty~* Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
218918000|NCT06592898|BEHAVIORAL|wall squat|The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.
219042262|NCT04508725|DIAGNOSTIC_TEST|Doppler Ultrasound|Power Doppler measurements will be made
219042263|NCT04508725|DEVICE|SIEMENS S3000 and Verasonics Vantage 256|Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics
219042264|NCT04508725|DRUG|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).
219042265|NCT04508725|DRUG|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI
219532226|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -B|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
219532227|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -A|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
219532228|NCT00799656|DRUG|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
219532229|NCT00799656|DRUG|placebo|oral administration once daily for 28 days
219532230|NCT02242201|DRUG|PNB Bupivacaine|Infusion
219532231|NCT02242201|DRUG|PAI Ropivacaine|Injection
219532232|NCT02242201|DRUG|PAI liposomal bupivacaine|Injection
218918001|NCT06592898|BEHAVIORAL|direct squat|The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle. The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
219532233|NCT02242201|DRUG|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
219532234|NCT02242201|DRUG|Ketorolac|Injection, 30 mg
219532235|NCT00098826|DRUG|ispinesib|Given IV
219532236|NCT00098826|OTHER|laboratory biomarker analysis|Correlative studies
219532237|NCT00098826|OTHER|pharmacological study|Correlative studies
219532238|NCT00017953|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
219532239|NCT00017953|BEHAVIORAL|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
218918002|NCT06592898|BEHAVIORAL|wall squat assisted by elastic bands|Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
218918003|NCT06601777|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
218918004|NCT06601777|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
218918005|NCT06590779|OTHER|Aminexil® active+ lotion|Aminexil® active+ lotion
218918006|NCT06590779|OTHER|Finasteride 1mg|Finasteride 1 mg
218918007|NCT06599112|OTHER|Densah Burs|Series of drilling burs inserted in the osteotomy with special design that have a large negative rake angle flute, a cutting chisel edge and a tapered shank, so as they enter deeper into the osteotomy and they have a progressively increasing diameter that controls the expansion process. These burs are used with a standard surgical engine and can densify bone by rotating in the noncutting direction (counterclockwise at 800-1,200 rotations per minute) or drill bone by rotating in the cutting direction (clockwise at 800-1,200 rotations per minute) with an in and out movement together with copious saline irrigation and increasing bone plasticity and ability to expand under rate dependent stress.
219042266|NCT06799403|BEHAVIORAL|Therapist-assisted online stress management|Participants gain access to an online program comprised by 14 modules covering psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relapse. Participants are followed by a therapist providing feedback on exercises and progress. The program extends over approx. 12 weeks.
219532240|NCT00408070|DRUG|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
219532241|NCT00408070|DRUG|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
219532242|NCT00408070|DRUG|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
219532243|NCT03038009|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
219532244|NCT03313349|BEHAVIORAL|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
219532245|NCT00152685|DRUG|human serum albumin|
219532246|NCT00122785|DRUG|dexamethasone|
219532247|NCT02374853|DRUG|Vancomycin|Topical prophylactic antibiotic
219532248|NCT02374853|OTHER|No Vancomycin|Placebo: Sterile water. No Vancomycin.
219532249|NCT02269995|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
219532250|NCT00931697|DRUG|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
219532251|NCT00931697|DRUG|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
219532252|NCT00931697|DRUG|Placebo|Over-encapsulated placebo to maintain blinding
219532253|NCT02281084|DRUG|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
219532254|NCT02281084|DRUG|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
219532255|NCT00590408|DIETARY_SUPPLEMENT|coenzyme Q10|60mg capsule twice daily for 12 weeks
219532256|NCT00590408|DIETARY_SUPPLEMENT|matching placebo|matching placebo capsule twice daily for 12 weeks
219532257|NCT00346814|DRUG|intravitreal injection|
219532258|NCT01895205|DRUG|Iron isomaltoside 1000|
219532259|NCT01895205|DRUG|Red blood cell transfusion|
219532260|NCT03902496|OTHER|HIT-6 Questionnaire|Headache Impact Test
219532261|NCT03902496|DEVICE|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
219532262|NCT03902496|DEVICE|Sham Spectacles|Sham
218918008|NCT06599112|OTHER|Osteotomes|The osteotomes kit are a series of tools that first designed by Summers in 1994. The concept was to maintain the existing bone by compressing trabecular bone laterally and apically with minimal trauma to improve the bone density. The condensed bone in this way will have to put in act a double repairing mechanism, from one side represented by the normal processes of osteointegration and on the other side from the processes of the reparation post fracture like that depends on BMU (bone modelling units) which create new spaces for the new vessels and afterwards filling all the gaps between the bone and the implant.
218918009|NCT06599112|OTHER|Conventional drilling|The implant drilling kit provided by the manufacturer will be used for the implant placement, using the pilot drill followed by consequent drills according to the size of the osteotomy needed.
218918010|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
218918011|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
218918012|NCT06586060|OTHER|lung ultrasound guided fluid balance strategy|"Lung ultrasound (LUS) guided fluid management based on B-Line score assessment using LUS within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first~In patients with BLS = 0-14, a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with BLS ≥ 15, a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15. To reach daily targeted FB, furosemide-induced diuresis and RRT will be used In case of shocked patients with BLS \&amp;amp;lt; 15: they will receive fluid boluses and packed RBCs to achieve a Hb of 10 and a MAP of \&amp;amp;gt;65 mmHg.~In case of shocked patients with BLS ≥ 15: they will start norepinephrine infusion to reach a MAP of \&amp;amp;gt;65 mmHg."
219042267|NCT06799403|BEHAVIORAL|Group-based face-to-face stress management|The group-based format consists of 8 sessions of each 3 hours spread across 12 weeks. The sessions cover psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relaps. A group includes 8-9 participants
219532263|NCT02351154|OTHER|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
219042268|NCT05778188|DRUG|RLS-0071|RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
219042269|NCT05778188|DRUG|Placebo|Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
219042270|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
219532264|NCT04699149|OTHER|Transcranial magnetic stimulation|Non-invasive brain stimulation
219532265|NCT04699149|OTHER|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
219532266|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell|Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
219532267|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
219532268|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
219617129|NCT02500589|BEHAVIORAL|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
219532269|NCT06176326|OTHER|Ethics Education Program in Nursing|In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
218918013|NCT06586060|OTHER|usual care guided fluid balance strategy|fluid balance management will be guided to maintain an adequate intravascular volume while minimising weight gain within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values To reach daily targeted fluid balance, furosemide-induced diuresis and RRT will be used
218918014|NCT06592430|OTHER|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
219532270|NCT03938402|OTHER|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
219532271|NCT02957097|DRUG|Gabapentin|Medication used for management of neuropathic pain conditions
219532272|NCT02957097|DRUG|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
219532273|NCT05378360|BIOLOGICAL|DWP708|Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
219532274|NCT02946125|COMBINATION_PRODUCT|MDD-administered EYN-1601|Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
219532275|NCT02946125|DRUG|Phenylephrine 2.5% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
219532276|NCT02946125|DRUG|Phenylephrine 10% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
219532277|NCT02541149|PROCEDURE|blood sample|
219532278|NCT05910632|BEHAVIORAL|Eccentrically strengthened resistance exercise|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with high intensity (ever 10 on the OMNI-RES Scale).
219532279|NCT05910632|BEHAVIORAL|Traditional resistance training|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8-12 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with moderate and high intensities (6 to 10 on the OMNI-RES scale).
219532280|NCT00962260|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
219532281|NCT03648658|DRUG|Paracetamol 120Mg/5mL Oral Suspension|The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
219532282|NCT01697696|DRUG|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
219532283|NCT01697696|DRUG|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
219532284|NCT01697696|DRUG|Placebo|Placebo to match QAB149
219532285|NCT04764916|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
218918015|NCT06592430|OTHER|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
219042271|NCT05288556|DEVICE|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
219532286|NCT04764916|DRUG|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
219532287|NCT01424644|BIOLOGICAL|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
219532288|NCT01424644|BIOLOGICAL|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
219532289|NCT01935440|BEHAVIORAL|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
219532290|NCT01935440|BEHAVIORAL|Prevention & Testing Control|7 group sessions
219532291|NCT01350765|BEHAVIORAL|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
219532292|NCT01350765|BEHAVIORAL|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
218918016|NCT06603506|OTHER|tumour and blood samples|Tumour and blood samples
219532293|NCT05226169|DRUG|Ferinject|"* Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~* Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin \< 100 ng/mL or TSAT \< 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
218918017|NCT00837382|BEHAVIORAL|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
218918018|NCT00837382|BEHAVIORAL|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
218918019|NCT06591104|DIAGNOSTIC_TEST|24 hour urinary protein|proteinuria and renal function impairment will be detected in patients of four groups
218918020|NCT06604676|PROCEDURE|guided soft tissue grafting|guided soft tissue grafting techniquea special digital guide was fabricated for one intervention non-guided soft tissue grafting technique receive the traditional technique without guide
218918021|NCT06604676|PROCEDURE|non-guided soft tissue grafting technique|the graft was taken with traditional technique without guide
218918022|NCT06654635|DRUG|Rhomboid intercostal plane block|The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
218918023|NCT06654635|OTHER|Erector spinae plane block|The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. Erector spinae plane block will be performed at the level of T9 bilaterally.
218918024|NCT06654635|OTHER|Control group|No block will be performed, and patient will receive general anesthesia (GA) only.
218918025|NCT06993168|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
218918026|NCT06591208|DEVICE|pulsed dye laser|PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm
218918027|NCT06591208|DEVICE|Carboxytherapy|"carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic popcorn appearance."
218918028|NCT06991244|BEHAVIORAL|EMDR 2.0 Group Protocol|A short-term trauma-focused group protocol adapted from EMDR 2.0, delivered in three sessions over one week, targeting PTSD, depression, and anxiety symptoms among earthquake survivors. The first session lasted 90 minutes, followed by two 60-minute sessions. The intervention was administered face-to-face in a container city in Malatya, Türkiye. All sessions were conducted by a certified EMDR therapist who had completed advanced EMDR 2.0 training.
218918029|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
219042272|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
219617130|NCT02500589|OTHER|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
219617131|NCT03901794|DEVICE|Non-invasive hemodynamic monitor|MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
219617132|NCT04191525|DIETARY_SUPPLEMENT|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
218918030|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
218918031|NCT06999538|OTHER|Radiologist interpretation|two interpretations (with and without Liflow, oncology imaging tool).
219617133|NCT04191525|DIETARY_SUPPLEMENT|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
219617134|NCT04647084|DRUG|Lidocaine 2% Injectable Solution|An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
219617135|NCT04647084|DEVICE|Buzzy|The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.
219617136|NCT03154983|DRUG|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
219617137|NCT02996409|DRUG|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
218918032|NCT06999759|DEVICE|cute serum box|After the children in the intervention group were made to draw pictures, they were glued to the designed cute serum box and chemotherapy drug serum was hidden and they were provided to receive their treatment.
218918033|NCT06999759|OTHER|coloring book and coloring pencils|Children in the intervention group were provided with a coloring book and coloring pencils to make a picture to hang on the picture box.
218918034|NCT06998121|OTHER|Intrarectal ıce application|Patients included in the study group will receive intrarectal ice application by researchers (E.K.D. and M.B.) in addition to the outpatient clinic's routine treatment and care practices. For each patient, a new glove (size 8) will be filled with water and frozen to obtain the cold application material. Immediately before the procedure, the lubricated ice will be inserted into the patient's rectum and held in place for 5 minutes (Caliskan and Mutlu, 2015).
218918035|NCT06597864|BEHAVIORAL|Seven-step phenomenological psychotherapy for self-disorders|Phenomenological exploration of anomalous self-experiences, meaning attributions and behavioral consequences. Psychoeducation. Dialogical approach focusing on self-narratives, searching for new meaning and understanding of self-disorders
218918036|NCT06600230|OTHER|Education and exercise|Training including information on pelvic floor and dysmenorrhea and exercise practices were given both theoretically and practically by physiotherapists.
218918037|NCT06600230|OTHER|Self-method like resting or heat|Classical self-methods such as rest and heat application were applied.
218918038|NCT06593535|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 4 days (7 capsules per day)
218918039|NCT06593535|OTHER|Astaxanthin (AST trial)|The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
218918040|NCT06603714|OTHER|Instrument assisted soft tissue mobilization|We will perform instrument assisted soft tissue mobilization on calf muscles. The intervention will last 9 min. For the first minute of treatment light pressure will be applied for tissue preparation. Afterwards, four different strokes will be applied by maintaining the tool at a 30° of inclination for one minute. This will be repeated for a second set, with a tool inclination of 45°.
218918041|NCT06382597|OTHER|Nordic hamstring exercise|Nordic Hamstring Exercise involves a controlled descent of the upright torso from a vertical kneeling position forward towards the ground (parallel to the ground) and returning to the starting position. The ankle joints are stabilized by the other person's grip during a series of exercises.
218918042|NCT04998331|OTHER|No Intervention|This is a non-interventional study.
218918043|NCT04887116|BEHAVIORAL|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person.
218918044|NCT06700135|OTHER|sensorimotor stimulation program sessions|The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
218918045|NCT06704737|DEVICE|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia
219532294|NCT05226169|OTHER|Conservative management|"* Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~* If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
219532295|NCT00662753|DEVICE|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
219532296|NCT00662753|OTHER|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
219532297|NCT06623643|DIAGNOSTIC_TEST|The investigation of melatonin and cortisol levels in the saliva|In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
219532298|NCT05593965|DEVICE|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
218918046|NCT06704737|DEVICE|Patching|Conventional patching therapy.
218918047|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Psychological Distancing|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
218918048|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Reinterpretation|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
218918049|NCT05926297|PROCEDURE|Application NaOCl gel + HA gel|First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel
218918050|NCT05926297|PROCEDURE|Non-surgical mechanical debridement|Only mechanical debridement with curettes ans scaler tips
218918051|NCT06705283|PROCEDURE|yoga and home exercise|"The intervention period for the study was determined as 6 weeks. It has been decided that yoga practice will be done 3 times a week for 45 minutes.~Poses to be practiced in the yoga group:~1. Tadasana (mountain pose)~2. Utkatasana (chair pose)~3. Trikonasana (triangle pose)~4. Malasana (squat pose):~5. Viparita Karani Variation (legs up the wall pose)~6. Salamba Set Bandhasana (supported bridge pose)~7. Supta Baddha Konasana (reclining bound angle pose)~8. Savasana (dead pose)"
218918052|NCT06705283|PROCEDURE|whole body vibration training and home exercise|A total of 40-45 minutes of training was planned for WBVT, including warm-up (10 minutes), active phase (25-30 minutes) and cooling phase (5 minutes).
218918053|NCT06705283|PROCEDURE|home exercise group|Pelvic floor muscle training will be done in the home exercise group. This training will be done in the form of slow and fast contractions of the pelvic floor muscles in supine, chin up, sitting, squat and standing positions.
218918054|NCT04668690|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
218918055|NCT04668690|DRUG|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
218918056|NCT06730126|DRUG|Soquelitinib|Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.
218918057|NCT06845644|OTHER|Quantitative neuromuscular MRI|Quantitative neuromuscular MRI is used to quantify a number of biomarkers associated with these pathophysiological processes
218918058|NCT06845644|OTHER|Neuromuscular ultrasound|Neuromuscular ultrasound is used to quantified nerve diameter variation
218918059|NCT06847217|OTHER|Mouth moisturization|This intervention will include mouth cleaning with water and gauze to remove plaque and debris. Water-based hydrating gels (bioXtra Dry Mouth Oral Gel, Lifestream Pharma N.V., Seneffe, Belgium) will be then applied to all oral structures, including the lips, tongue, palate, and cheeks, using gloved fingers or a small toothbrush. In the presence of dried secretions, the gels will be massaged into these areas and left to act for a few minutes to facilitate removal and reduce patient discomfort.
218918060|NCT06847217|OTHER|Mechanical oral hygiene care|Patients with natural teeth will be treated using a soft toothbrush and a sodium lauryl sulfate-free fluoride toothpaste (meridol® toothpaste, Colgate-Palmolive Company, Belgium). The teeth will be brushed using the modified BASS technique. Subsequently, the tongue will be cleaned with either a scraper. For participants wearing dentures, the dentures will be cleaned using a denture brush and soap.
218918061|NCT06847217|OTHER|Combined care|Patients will receive a comprehensive oral hygiene intervention incorporating mouth cleaning, mechanical oral hygiene, and moisturization. The procedure will begin with oral cleaning using water and gauze, followed by mechanical oral hygiene, and conclude with the application of the hydrating gel.
218918062|NCT06848439|DRUG|benmelstobart-Anlotinib-Chemo|"Neoadjuvant Treatment Regimen :~Benmelstobart: 1200mg, Day 1, IV (21 days per cycle); Anlotinib: 10mg, Days 1-14, orally (21 days per cycle); Cisplatin: 60mg/m², Day 1, IV (21 days per cycle); Albumin-bound Paclitaxel: 260mg/m², IV infusion, Day 1 (21 days per cycle). Total of 3 cycles.~Surgery is performed within 2 weeks after completing neoadjuvant therapy. Postoperative adjuvant treatment is selected based on pathological grading:~Group A (pCR): Postoperative RT alone: 40Gy/5 weeks. Group B (MPR): Postoperative RT alone: 50Gy/5 weeks. Group C (partial pathological response/no pathological response) : low and intermediate-risk patients: RT: 60Gy/6w; High-risk patients: CCRT: 60-66Gy/6-6.6w + cisplatin: 60mg/m2 Q3W, 2-3 cycles.~All patients also received adjuvant Benmelstobart 3-4 weeks after surgery, as well as maintenance Benmelstobart for a total duration of 1 year."
218918063|NCT06239493|DIAGNOSTIC_TEST|IVUS Guided|Those already undergoing an IVUS guided percutaneous vascular intervention
218918064|NCT06812819|DIAGNOSTIC_TEST|Cryostimulation is a form of cooling the body using low temperatures without causing tissue damage. The stimulus effect is achieved at temperatures below - 110⁰C, in a short time of 1-3 minutes. The p|PBC protocol involved the participant being in a JUKA cryosauna (model 0104-1), for 3 minutes at - 140 ° C± - 20 ° C with the lid at shoulder height and the head over the chamber. The cryosauna was cooled with liquid nitrogen, and the temperature was monitored by a computer. Participants entered the cabin wearing clogs, wool socks, shorts, gloves, caps, and disposable PP non-woven masks to protect against inhalation of nitrogen fumes. The temperature inside the cryosauna was recorded at 30-second intervals using a sensor placed on the bottom of the cabin. The temperature of the room where the cryosauna was located was 21.0 ± 0.9° C, and the humidity of the air during the treatment was 35 ± 2, 0 % monitored with a QUIGG type LE 2014.14 moisture absorber.
218918065|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
218918066|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
218918067|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
219042273|NCT04156815|RADIATION|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
219042274|NCT04156815|DRUG|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
219532299|NCT05593965|DEVICE|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
219532300|NCT05593965|DEVICE|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
219532301|NCT03066453|DRUG|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
219532302|NCT03066453|DRUG|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
218918068|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
218918069|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
218918070|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
218918071|NCT02153632|DRUG|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
218918072|NCT02153632|DRUG|Placebo|subjects are given an identical placebo tablet
218918073|NCT05888038|DEVICE|virtual reality|virtual reality
218918074|NCT02103387|BEHAVIORAL|Cognitive Behavioral Training|Cognitive Behavioral Training \[CBT\] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
218918075|NCT02103387|BEHAVIORAL|Relaxation Training|Relaxation Training \[RT\] (muscle relaxation, deep breathing, guided imagery, meditation)
218918076|NCT02103387|BEHAVIORAL|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
218918077|NCT02693366|OTHER|Bone marrow stem cell|Endovascular infusion of bone marrow derived cells in both renal arteries.
218918078|NCT05790720|DRUG|Propofol|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
218918079|NCT03215056|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
218918080|NCT03215056|DRUG|Normal saline|Placebo
218918081|NCT04029636|OTHER|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
218918082|NCT01203202|DRUG|Clomipramine|15mg and 30mg on demand
218918083|NCT05233306|DEVICE|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
218918084|NCT04464486|OTHER|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
218918085|NCT00072709|DRUG|TCH346|
219532303|NCT01061125|OTHER|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
219532304|NCT03437148|DEVICE|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
219532305|NCT03437148|DEVICE|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
219532306|NCT05396430|DEVICE|Urinary catheter|Duration of planned urinary cathterization following cesarean delivery
219532307|NCT01077596|DRUG|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
218918086|NCT02746653|DEVICE|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
218918087|NCT02252003|OTHER|Pain scales testing|
218918088|NCT02456415|DEVICE|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
218918089|NCT06102005|DRUG|Lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
218918090|NCT06102005|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219532308|NCT01077596|DRUG|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
218918091|NCT00512915|DEVICE|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
218918092|NCT02767414|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
218918093|NCT02767414|DEVICE|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
219532309|NCT01077596|DRUG|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
219532310|NCT01077596|DRUG|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
219532311|NCT03422770|DIAGNOSTIC_TEST|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
218918094|NCT02767414|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
218918095|NCT06185816|DEVICE|Active Treatment|The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
218918096|NCT06185816|DEVICE|Non-active Treatment|The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
218918097|NCT04214158|OTHER|Assessment|Assessment
218918098|NCT03742323|DRUG|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
218918099|NCT02946723|PROCEDURE|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
218918100|NCT02946723|PROCEDURE|X-ray|Lead implantation surgery for SNM using X-ray technique
218918101|NCT03176706|OTHER|no intervention|this is a completely observational study, NO INTERVENTION
218918102|NCT05189717|DRUG|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
218918103|NCT05800080|DRUG|Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
219617138|NCT02996409|DRUG|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
219532312|NCT03422770|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
219532313|NCT03422770|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
219617139|NCT02996409|OTHER|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
219617140|NCT02542007|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
219617141|NCT02542007|DEVICE|sirolimus-eluting stent system|
218918104|NCT01742026|PROCEDURE|Aspergillus PCR technique|Aspergillus DNA PCR technique
218918105|NCT01742026|PROCEDURE|Aspergillus AGA technique|Aspergillus AGA technique
218918106|NCT00125177|BEHAVIORAL|Knack therapy|
219532314|NCT03422770|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
219532315|NCT03422770|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
219617142|NCT05300815|OTHER|Delphi Questionaire|"This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2."
219617143|NCT00240721|DRUG|topiramate|
219617144|NCT04220515|BIOLOGICAL|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
218918107|NCT01245530|DRUG|Aricept|Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks
218918108|NCT01245530|DRUG|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
219532316|NCT05269381|DRUG|Cyclophosphamide|Given IV
219532317|NCT05269381|BIOLOGICAL|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
219532318|NCT05269381|BIOLOGICAL|Pembrolizumab|Given IV
219617145|NCT04731805|BEHAVIORAL|Moving On After Breast Cancer|Patient education intervention that is evidence-based, physical therapy, patient \& family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
219617146|NCT02954484|DRUG|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
219617147|NCT02954484|DRUG|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
219617148|NCT02954484|DRUG|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
218918109|NCT03408093|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
218918110|NCT01747395|OTHER|Exercise training|The heart failure patients are subjected to differents protocols of physical training
218918111|NCT01303016|DIETARY_SUPPLEMENT|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
218918112|NCT03474419|PROCEDURE|laser surgery|laser surgery
218918113|NCT00275912|DRUG|Oxcarbazepine|
218918114|NCT00124943|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
218918115|NCT00321620|DRUG|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
218918116|NCT00321620|BIOLOGICAL|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
218918117|NCT00905944|OTHER|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
218918118|NCT01238926|DIETARY_SUPPLEMENT|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
218918119|NCT01238926|OTHER|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
218918120|NCT01238926|OTHER|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
218918121|NCT02490098|OTHER|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
218918122|NCT02490098|OTHER|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
218918123|NCT02490098|OTHER|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
218918124|NCT02490098|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
218918125|NCT02490098|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
218918126|NCT02490098|DEVICE|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
218918127|NCT02490098|DEVICE|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
218918128|NCT00828776|BIOLOGICAL|Heparin sodic - Cristália|5000UI/mL
219532319|NCT05269381|BIOLOGICAL|Sargramostim|Given SC
218918129|NCT00828776|BIOLOGICAL|heparin - Liquemine (Roche)|5000UI/mL
218918130|NCT02962414|DRUG|everolimus|everolimus, 2mg dispersible tablets
218918131|NCT00807508|DIETARY_SUPPLEMENT|placebo|wheat meal capsules with each main meal
218918132|NCT00807508|DIETARY_SUPPLEMENT|leucine|daily leucine capsules with each main meal
219532320|NCT03585530|DRUG|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
218918133|NCT06371092|DRUG|UltraEZ|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
219532321|NCT01880593|DRUG|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
219532322|NCT01880593|DRUG|Ketamine|
219532323|NCT01880593|DRUG|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
219532324|NCT04191993|DEVICE|Total hip arthroplasty|Surgical intervention designed to replace arthritic joint with artificial implant
219532325|NCT04732195|DEVICE|Pilocarpine microneedle patch|Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
219532326|NCT04732195|DEVICE|Pilocarpine Iontophoresis|Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
219617149|NCT02954484|DRUG|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
218918134|NCT06371092|DRUG|Placebo|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
218918135|NCT06834295|DRUG|Vapendavir|Single oral dose of \[14C\]vapendavir
218918136|NCT06228170|BEHAVIORAL|Rehabilitation therapy|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
219532327|NCT03110003|DRUG|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
219532328|NCT03110003|DRUG|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
218918137|NCT06228170|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219042275|NCT04156815|OTHER|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
219042276|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
219042277|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
219532329|NCT02372630|DRUG|Linagliptin|5 mg daily oral tablets of linagliptin
219532330|NCT02372630|DRUG|Placebo|matching placebo giving orally daily
219532331|NCT00534443|PROCEDURE|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
219617150|NCT02954484|DRUG|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
219617151|NCT02954484|DRUG|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
219617152|NCT06550856|PROCEDURE|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
219617153|NCT06550856|PROCEDURE|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
219617154|NCT06409845|DRUG|Eptinezumab 100 or 300 mg ev|Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
219617155|NCT05410249|DIAGNOSTIC_TEST|Serum IL10 By ELISA|measurement Of IL10 by ELISA
219617156|NCT05410249|DIAGNOSTIC_TEST|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
219617157|NCT05410249|DIAGNOSTIC_TEST|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
219532332|NCT02623543|DEVICE|OrthoK|
219617158|NCT02140151|DRUG|Ranibizumab 0.5mg|
219532333|NCT03619005|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
219532334|NCT03619005|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
219532335|NCT04460105|DRUG|Lanadelumab|Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
219532336|NCT04460105|OTHER|Placebo|Participants will receive placebo matching IV infusion on Day 1 and Day 4.
219532337|NCT02911597|DRUG|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
219532338|NCT01690494|BEHAVIORAL|PACT|Couple-based behavioral HIV/STI preventive intervention
219532339|NCT01690494|BEHAVIORAL|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
219532340|NCT00847678|BIOLOGICAL|Efungumab (Mycograb)|
219532341|NCT00847678|BIOLOGICAL|placebo|
219532342|NCT00847678|BIOLOGICAL|Amphotericin B|
219532343|NCT00847678|BIOLOGICAL|5 flucytosine|
219532344|NCT05076305|OTHER|No specific intervention; cases are retrospective and patients have already been treated.|To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
219617159|NCT00520377|DRUG|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
219617160|NCT00520377|DEVICE|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
219617161|NCT04956744|BIOLOGICAL|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
219617162|NCT03778346|BIOLOGICAL|CAR-T therapy in Relapsed/Refractory multiple myeloma|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
219617163|NCT05545722|BEHAVIORAL|life coaching group with diabetes|Each patient was interviewed once a week. Coaching interviews were conducted one-on-one and in accordance with coaching principles.
219617164|NCT05224739|PROCEDURE|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
218918138|NCT00150085|DRUG|cyclosporine micro-emulsion|
218918139|NCT02844569|DEVICE|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
218918140|NCT02844569|DEVICE|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
218918141|NCT02844569|DEVICE|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
219532345|NCT02024932|DRUG|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
219532346|NCT02024932|DRUG|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
218918142|NCT03304626|DRUG|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
218918143|NCT03304626|DRUG|Standard of Care Prednisone|Prednisone taper (Standard of Care)
219532347|NCT05986357|DIAGNOSTIC_TEST|maternal serum C reactive protein|maternal serum high sensitivity C reactive protein
219532348|NCT05986357|DIAGNOSTIC_TEST|total leucocytic count levels|total leucocytic count levels
219532349|NCT05986357|DIAGNOSTIC_TEST|differential leucocytic count levels|differential leucocytic count levels
219532350|NCT00383097|GENETIC|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
219532351|NCT00383097|GENETIC|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
219532352|NCT02058797|BEHAVIORAL|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
219532353|NCT02058797|BEHAVIORAL|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
219532354|NCT03388671|PROCEDURE|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
219532355|NCT03388671|PROCEDURE|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
219532356|NCT03388671|DRUG|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
219532357|NCT03962348|BEHAVIORAL|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
219532358|NCT00938171|PROCEDURE|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
219532359|NCT00938171|PROCEDURE|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
218918144|NCT00027534|BIOLOGICAL|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
218918145|NCT01816035|OTHER|Laboratory Biomarker Analysis|Correlative studies
218918146|NCT01816035|OTHER|Pharmacological Study|Correlative studies
218918147|NCT01816035|BIOLOGICAL|Trastuzumab Emtansine|Given IV
218918148|NCT01501565|PROCEDURE|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
218918149|NCT02809482|OTHER|Eucaloric feeding|3 days of a diet designed to maintain energy balance
218918150|NCT02809482|OTHER|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
218918151|NCT05828147|DRUG|Rituximab|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
218918152|NCT02341183|DEVICE|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
218918153|NCT02341183|DEVICE|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
219617169|NCT02549781|OTHER|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
219617170|NCT00573690|DRUG|carboplatin|Given IV
219617171|NCT00573690|DRUG|cisplatin|Given IV
219617172|NCT00573690|DRUG|etoposide|Given IV
219617173|NCT00573690|DRUG|pemetrexed disodium|Given IV
218918154|NCT01213563|DRUG|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
218918155|NCT01213563|DRUG|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
218918156|NCT05784896|DIAGNOSTIC_TEST|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of \>96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
218918157|NCT06166732|BEHAVIORAL|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
218918158|NCT06166732|BEHAVIORAL|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
218918159|NCT04385277|PROCEDURE|Biospecimen Collection|Correlative studies
218918160|NCT04385277|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
218918161|NCT04385277|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
218918162|NCT04385277|PROCEDURE|Computed Tomography|Undergo CT
218918163|NCT04385277|BIOLOGICAL|Dinutuximab|Given IV
218918164|NCT04385277|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
218918165|NCT04385277|RADIATION|Iobenguane I-123|Undergo 123I-MIBG
218918166|NCT04385277|DRUG|Irinotecan|Given IV
218918167|NCT04385277|DRUG|Isotretinoin|Given PO
218918168|NCT04385277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218918169|NCT04385277|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218918170|NCT04385277|BIOLOGICAL|Sargramostim|Given SC or IV
219532360|NCT04513730|OTHER|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
218918171|NCT04385277|DRUG|Temozolomide|Given PO or via enteral tube
218918172|NCT02988466|BIOLOGICAL|Haplo HCT <55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
219532361|NCT05675215|DIAGNOSTIC_TEST|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer \& Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks \& Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun \& Kempenaers, 2007)."
219532362|NCT01885455|OTHER|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
219617174|NCT00573690|DRUG|sorafenib tosylate|Given orally
218918173|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"
218918174|NCT02988466|DRUG|GVHD Prophylaxis|"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"
219617175|NCT03238664|PROCEDURE|Biopsy|Undergo biopsy of bladder tumor
218918175|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 and < 65 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"
219042278|NCT04589676|BEHAVIORAL|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
219617176|NCT03238664|DEVICE|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
219042279|NCT04621890|BEHAVIORAL|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
218918176|NCT02988466|BIOLOGICAL|Haplo HCT ≥65 and ≤75 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"
219042280|NCT04063761|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
219042281|NCT03655002|DRUG|Cyclophosphamide|Given IV
219042282|NCT03655002|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
218918177|NCT02903771|DRUG|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
219532363|NCT01885455|OTHER|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
219617177|NCT03238664|OTHER|Laboratory Biomarker Analysis|Correlative studies
219617178|NCT03238664|PROCEDURE|Radical Cystectomy|Undergo RARC
218918178|NCT02903771|DRUG|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
218918179|NCT06268236|OTHER|Electroacupuncture|Electro-acupuncture at Shuigou and Yintang.
219617179|NCT03238664|DEVICE|Ultrasonography|Undergo CEUS
218918180|NCT06268236|OTHER|Sham electroacupuncture|Sham-EA at sham-Shuigou and sham-Yintang.
218918181|NCT02675465|DRUG|ATB200|
218918182|NCT02675465|DRUG|AT2221|
218918183|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk without vitamin D|710ml per day for 49 days
218918184|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
218918185|NCT00886379|DIETARY_SUPPLEMENT|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
218918186|NCT00886379|DIETARY_SUPPLEMENT|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
219617180|NCT02738918|DRUG|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
219617181|NCT00155064|DRUG|captopril, Losartan (drug)|
219617182|NCT04259164|DRUG|QVM149|Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
219617183|NCT04259164|DRUG|QMF149|Mometasone / Indacaterol
218918187|NCT00886379|DIETARY_SUPPLEMENT|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
218918188|NCT00886379|DIETARY_SUPPLEMENT|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
218918189|NCT04558125|DRUG|TNKase|Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
218918190|NCT04558125|DRUG|Placebo|Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
219617184|NCT04310202|OTHER|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
219617185|NCT04310202|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
218918191|NCT04558125|DRUG|Enoxaparin|All participants must also receive standard of care anticoagulation therapy.
218918192|NCT05311709|DRUG|sotorasib|single group, all patients receive sotorasib
218918193|NCT03137381|DRUG|CTP-543|Administered as tablets.
218918194|NCT03137381|DRUG|CTP-543 matching placebo|Administered as tablets.
218918195|NCT01684917|BEHAVIORAL|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
218918196|NCT02143804|BIOLOGICAL|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
219617186|NCT04310202|OTHER|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
218918197|NCT03146923|OTHER|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives"
218918198|NCT03146923|OTHER|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio"
218918199|NCT04690686|DEVICE|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
218918200|NCT04690686|DEVICE|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
218918201|NCT04690686|DEVICE|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
219617187|NCT02550561|DEVICE|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
219532364|NCT01612520|BEHAVIORAL|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
219532365|NCT00226317|DRUG|Aripiprazole|
218918202|NCT03730753|DEVICE|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
219617188|NCT03507361|OTHER|HRV-BASED MUSIC|Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
219617189|NCT04526028|DRUG|Fulvestrant Injectable Product|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
219617190|NCT04526028|DRUG|Palbociclib|Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
219617191|NCT02757001|OTHER|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
219617192|NCT02742662|DEVICE|Wearable technology, smartscale|
219617193|NCT02742662|BEHAVIORAL|Smartphone applications|
219617194|NCT02742662|BEHAVIORAL|Standard Weight Management Visits|
219617195|NCT02394600|DRUG|Grastek®|one tablet daily for four months
219617196|NCT02394600|DRUG|Placebo|one tablet daily for four months
218918203|NCT03730753|DEVICE|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
218918204|NCT03401346|COMBINATION_PRODUCT|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
218918205|NCT03401346|DRUG|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
219617197|NCT01080482|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
218918206|NCT03401346|COMBINATION_PRODUCT|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
218918207|NCT01106612|PROCEDURE|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
218918208|NCT01106612|PROCEDURE|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
218918209|NCT01980017|BEHAVIORAL|Ottawa Model for Smoking Cessation|
218918210|NCT05647317|OTHER|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
218918211|NCT03763838|OTHER|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
218918212|NCT03763838|OTHER|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
219532366|NCT05065229|DEVICE|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
218918213|NCT03763838|OTHER|Standard of Care|Fatigue management provided by participants' health care providers.
219617198|NCT00333320|PROCEDURE|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
219617199|NCT00333320|PROCEDURE|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
219617200|NCT05220982|BEHAVIORAL|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
219617201|NCT05220982|BEHAVIORAL|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
218918214|NCT00427453|BIOLOGICAL|MVA85A|
218918215|NCT05179135|OTHER|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
218918216|NCT05521607|DEVICE|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
218918217|NCT06300697|OTHER|Data and biospecimen collection|Enrolled participants will have health-related information and blood specimens collected.
218918218|NCT06300697|OTHER|Skin biopsies|Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
219042283|NCT03655002|BIOLOGICAL|Nivolumab|Given IV
219042284|NCT05080309|DIETARY_SUPPLEMENT|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
219042285|NCT05080309|OTHER|free water only|Women will have free access to water only
219042286|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
219042287|NCT06576830|DRUG|Methadone|Single-dose intraoperative intravenous methadone with initial dose at 0.15 mg/kg in children and 0.2 mg/kg in adolescents.
219042288|NCT06576830|DRUG|Fentanyl/Hydromorphone|Per routine care, given as needed
219042289|NCT06088810|OTHER|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
219042290|NCT06088810|OTHER|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
219042291|NCT02775344|DEVICE|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
219532367|NCT00278018|PROCEDURE|Immunotherapy treatment for solid tumors|
218918219|NCT06300697|OTHER|Oral Food Challenge (OFC) procedures|Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
219532368|NCT04549883|OTHER|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
219532369|NCT02152683|DEVICE|Renova|Low- Intensity Shockwave
219532370|NCT02404194|BEHAVIORAL|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
219617202|NCT05220982|BEHAVIORAL|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
219617203|NCT05220982|BEHAVIORAL|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
219532371|NCT02404194|BEHAVIORAL|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
219532372|NCT04005677|DIAGNOSTIC_TEST|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
219532373|NCT00477347|DEVICE|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
219532374|NCT00477347|DEVICE|Manual administration|intraoperative manual administration of propofol and remifentanil
219532375|NCT01833052|DEVICE|TAVI (Medtronic CoreValve)|
219617204|NCT01686373|DEVICE|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
219617205|NCT01686373|DEVICE|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
219532376|NCT01833052|DEVICE|Claret-Filter|
219532377|NCT05301361|DRUG|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
219532378|NCT05995275|BIOLOGICAL|mRNA-1769|Sterile liquid for injection
219617206|NCT04232865|DEVICE|Biop System|"Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa."
219617207|NCT00707148|DRUG|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
218918220|NCT05829551|DRUG|RAY1216 dose 1|RAY1216 dose 1 or Placebo
218918221|NCT05829551|DRUG|RAY1216 dose 2|RAY1216 dose 2 or Placebo
218918222|NCT05829551|DRUG|RAY1216 dose 3|RAY1216 dose 3 or Placebo
218918223|NCT05829551|DRUG|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 \&ritonavir or Placebo
218918224|NCT05829551|DRUG|RAY1216 dose 5|RAY1216 dose 5 or Placebo
218918225|NCT05829551|DRUG|RAY1216 dose 6|RAY1216 dose 6 or Placebo
218918226|NCT05829551|DRUG|RAY1216 dose 7|RAY1216 dose 7 or Placebo
218918227|NCT05829551|DRUG|RAY1216 dose 8|RAY1216 dose 8 or Placebo
219532379|NCT05995275|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
218918228|NCT05829551|DRUG|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
219532380|NCT05782478|DIAGNOSTIC_TEST|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
218918229|NCT05829551|DRUG|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
218918230|NCT06507254|DIETARY_SUPPLEMENT|Polyphenol Supplement|Dietary supplement taken twice daily for 12 months.
218918231|NCT06507254|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary supplement taken twice daily for 12 months.
218918232|NCT04659863|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
218918233|NCT04659863|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
218918234|NCT01932593|PROCEDURE|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
218918235|NCT02105740|BEHAVIORAL|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
218918236|NCT02105740|BEHAVIORAL|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
218918237|NCT02554292|DEVICE|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
218918238|NCT05041413|BEHAVIORAL|Moms Quit|Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
218918239|NCT05041413|BEHAVIORAL|Text4Baby|Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
219532381|NCT04907370|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
219532382|NCT04907370|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
219532383|NCT04907370|DRUG|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
219532384|NCT04907370|DRUG|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
218918240|NCT00079469|BEHAVIORAL|smoking cessation intervention|
218918241|NCT00079469|DRUG|bupropion hydrochloride|
218918242|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
218918243|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
219532385|NCT04907370|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
219532386|NCT04248543|DEVICE|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
219532387|NCT05790538|PROCEDURE|Assessment of Therapy Complications|Complete clinic assessments
219532388|NCT05790538|OTHER|Electronic Health Record Review|Medical records are reviewed
219532389|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear SmartSocks
219532390|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
219532391|NCT05790538|OTHER|Survey Administration|Complete survey
219532392|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
219532393|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
219532394|NCT05974293|DRUG|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
219532395|NCT05974293|DRUG|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
219532396|NCT03179904|DRUG|Anastrozole|Given PO
219532397|NCT03179904|DRUG|Denifanstat|Given PO
219532398|NCT03179904|DRUG|Exemestane|Given PO
219532399|NCT03179904|DRUG|Fulvestrant|Given IM
219532400|NCT03179904|PROCEDURE|Echocardiography|Undergo ECHO
219532401|NCT03179904|DRUG|Letrozole|Given PO
219532402|NCT03179904|DRUG|Paclitaxel|Given IV
219532403|NCT03179904|BIOLOGICAL|Trastuzumab|Given IV
219532404|NCT03179904|PROCEDURE|Computed Tomography|Undergo CT
219532405|NCT03179904|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219532406|NCT03179904|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218918244|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
219532407|NCT03179904|PROCEDURE|Biopsy|Undergo biopsy
219532408|NCT05637814|DIAGNOSTIC_TEST|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
219532409|NCT00716066|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219532410|NCT00716066|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
219532411|NCT00716066|DRUG|Carmustine|Given IV
219532412|NCT00716066|DRUG|Cytarabine|Given IV
219532413|NCT00716066|DRUG|Etoposide|Given IV
219532414|NCT00716066|OTHER|Laboratory Biomarker Analysis|Correlative studies
219532415|NCT00716066|DRUG|Melphalan|Given IV
219532416|NCT00716066|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
219532417|NCT00716066|DRUG|Prednisone|Given PO
219532418|NCT00716066|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
219532419|NCT04062045|DRUG|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
219532420|NCT04062045|DRUG|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
219532421|NCT00462345|DRUG|rituximab|1000 mg i.v. on Days 1 and 15
219532422|NCT00462345|DRUG|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
219532423|NCT00462345|DRUG|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
219532424|NCT00462345|DIETARY_SUPPLEMENT|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
219532425|NCT04904718|DEVICE|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
219532426|NCT04053296|OTHER|Observational study|We follow up the results of patients.
219532427|NCT01079585|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
218918245|NCT05354596|PROCEDURE|STRICT LUNG|Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
219532428|NCT03547622|DRUG|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
219617208|NCT00707148|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
218918246|NCT05354596|PROCEDURE|STAR LUNG|Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
219532429|NCT03547622|DRUG|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
219532430|NCT02018263|DRUG|Cocaine hydrochloride|
219532431|NCT02018263|BEHAVIORAL|Exercise|
219532432|NCT02018263|DRUG|Nicotine|
219532433|NCT05392621|BEHAVIORAL|Yoga|A single Hatha yoga session designed to support stress management.
219532434|NCT05392621|BEHAVIORAL|Deep Breathing|A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.
219532435|NCT05392621|BEHAVIORAL|Progressive Muscle Relaxation|A single session of progressive muscle relaxation designed to elicit relaxation.
219532436|NCT05392621|BEHAVIORAL|Quiet sitting|A single session of quiet sitting.
219532437|NCT00820326|DRUG|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
219532438|NCT00820326|DRUG|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
219532439|NCT05077124|DEVICE|CytoSorb|Sorbent hemoperfusion system
219532440|NCT03487224|DEVICE|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
219532441|NCT04915755|DRUG|Niraparib|Niraparib will be administered.
219532442|NCT04915755|DRUG|Placebo|Matching placebo will be administered
219532443|NCT06501040|OTHER|Web-based Educational Intervention|View web-based educational video
219532444|NCT06501040|OTHER|Questionnaire Administration|Pre video baseline survey and a post video educational survey
219532445|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
219532446|NCT04049669|DRUG|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
219532447|NCT04049669|RADIATION|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
219532448|NCT04049669|RADIATION|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine).
219532449|NCT04049669|DRUG|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
219532450|NCT04049669|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
219532451|NCT04049669|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
218918247|NCT00253149|DRUG|risperidone|
219532452|NCT04049669|DRUG|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
219532453|NCT04189614|DRUG|Cofetuzumab Pelidotin|Intravenous (IV) infusion
219532454|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
218918248|NCT01353898|DRUG|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
218918249|NCT01353898|DRUG|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
218918250|NCT02700321|DEVICE|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
218918251|NCT02700321|PROCEDURE|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
218918252|NCT00174408|DRUG|Genotropin|
218918253|NCT05370196|DEVICE|Test Product|Synthetic Male Condom
218918254|NCT05370196|DEVICE|Control Product|Latex Male Condom
218918255|NCT03558737|OTHER|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
218918256|NCT03558737|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
218918257|NCT00284947|DRUG|basiliximab|40 mg once every 28 days intravenously for 24 weeks
219532455|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
219532456|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
218918258|NCT00284947|DRUG|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
219042292|NCT05840146|OTHER|Kinesiotaping|"Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
219042293|NCT05840146|OTHER|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
219532457|NCT05946083|DIETARY_SUPPLEMENT|Inulin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
219532458|NCT05946083|DIETARY_SUPPLEMENT|Maltodextrin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
219532459|NCT04725773|DEVICE|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
219532460|NCT06427252|DRUG|HIPEC|In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
219617209|NCT06477198|OTHER|QLB|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).
218918259|NCT00284947|DRUG|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
218918260|NCT05584514|OTHER|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
218918261|NCT05584514|OTHER|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
219042294|NCT04205760|COMBINATION_PRODUCT|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
219042295|NCT03601806|OTHER|Laboratory Biomarker Analysis|Correlative studies
219042296|NCT03601806|DRUG|Pomalidomide|Given PO
219042297|NCT06491706|OTHER|the was no intervention|there was no intervention in this observational study
219042298|NCT04404777|PROCEDURE|Treatment for local recurrence with surgery or other treatments|All types of treatment for local recurrence will be evaluated
219532461|NCT06427252|DRUG|Systemic therapy|"1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;"
218918262|NCT03153592|PROCEDURE|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
218918263|NCT03153592|PROCEDURE|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
218918264|NCT05798494|BEHAVIORAL|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
218918265|NCT00103584|BIOLOGICAL|LC16m8 Smallpox Vaccine|
218918266|NCT01729780|DEVICE|EEG-NF|
218918267|NCT00022191|DRUG|cisplatin|
218918268|NCT00022191|DRUG|gemcitabine hydrochloride|
218918269|NCT00022191|DRUG|paclitaxel|
218918270|NCT04772001|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
218918271|NCT04772001|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
218918272|NCT04772001|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
218918273|NCT05954637|DEVICE|Optical coherence tomography|Heidelberg Engineering Spectralis
218918274|NCT00121498|DRUG|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
218918275|NCT04636268|BIOLOGICAL|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
218918276|NCT02964689|DRUG|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
218918277|NCT02964689|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
218918278|NCT02964689|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
218918279|NCT00810563|DRUG|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
218918280|NCT00810563|DRUG|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
219042299|NCT02902198|DIETARY_SUPPLEMENT|Placebo|Tap water 200ml
219042300|NCT02902198|DIETARY_SUPPLEMENT|Glucose|25g Glucose in 200ml tap water
219042301|NCT02902198|DIETARY_SUPPLEMENT|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
219042302|NCT02902198|DIETARY_SUPPLEMENT|Quinine|17mg quinine in 200ml tap water
219042303|NCT06800170|DIETARY_SUPPLEMENT|myo-Inositol plus DIoscorea Villosa|myo-Inositol + alpha-lactalbumin + folic acid once daily, Dioscorea Villosa + alpha-lactalbumin + Vitamin D twice daily
218918281|NCT03760094|DEVICE|Colour Doppler|evaluation of lymph nodes by Doppler
219042304|NCT04627064|DRUG|Abemaciclib|Tablet taken orally
219042305|NCT04627064|DRUG|MK-6482|Tablet taken orally
219532462|NCT06026098|BEHAVIORAL|Artificial Intelligence|Participants will use the Artificial Intelligence assistance tool for case reports.
219532463|NCT03660020|DRUG|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
219532464|NCT03660020|DRUG|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
219532465|NCT03638739|OTHER|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
219617210|NCT06477198|OTHER|ESPB|ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).
218918282|NCT01629264|DEVICE|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
218918283|NCT01629264|DEVICE|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
218918284|NCT01629264|OTHER|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
219532466|NCT02467205|OTHER|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
219532467|NCT05358860|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219532468|NCT03408691|DIETARY_SUPPLEMENT|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
219532469|NCT03408691|OTHER|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
219532470|NCT00875030|DRUG|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
219532471|NCT00875030|DRUG|Arsuamoon|single dose 50 mg arsuamoon tablet
219532472|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
219532473|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
219532474|NCT01516996|DRUG|docetaxel and cisplatin|"* The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
219532475|NCT01516996|RADIATION|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times"
219532476|NCT01516996|BIOLOGICAL|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13\~14 weeks
219617211|NCT06477198|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
218918285|NCT00006445|PROCEDURE|Ultrasound|
218918286|NCT00006445|PROCEDURE|Serum screen|
218918287|NCT03779009|OTHER|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
218918288|NCT02008799|PROCEDURE|Bone marrow stem cell injection|Injection should be in testis and testicular artery
218918289|NCT03094325|DEVICE|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
219042306|NCT03189628|BIOLOGICAL|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
219042307|NCT03189628|DRUG|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
219532477|NCT01552499|OTHER|Standard of care|
219042308|NCT06801535|DEVICE|Splint|Patients will use the splint at home 3 times daily for 10 minutes per session for 3 months total.
219532478|NCT01552499|OTHER|Applications of EpiFix|
219532479|NCT00657332|PROCEDURE|blood sample draw|
219617212|NCT01376999|DRUG|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
219617213|NCT03831009|PROCEDURE|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
218918290|NCT03094325|DEVICE|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
218918291|NCT03094325|DEVICE|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
219042309|NCT06385587|DEVICE|Oleena|Oleena™ is a software medical device for patients and their healthcare team which digitalizes some aspects of their supportive care, allows remote monitoring by healthcare professionals (HCP) and supports the management of targeted symptoms in adult cancer patients while they are being actively treated for their cancer.
219532480|NCT00657332|PROCEDURE|urine sample|
219532481|NCT01069536|DRUG|metoclopramide 10 mg|
219617214|NCT03831009|OTHER|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
218918292|NCT03094325|DEVICE|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
218918293|NCT05471466|PROCEDURE|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
218918294|NCT02826070|DRUG|Telbivudine|Telbivudine, 600mg, oral, daily
219532482|NCT01980823|DRUG|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
218918295|NCT02826070|DRUG|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
218918296|NCT02826070|OTHER|off-treatment follow-up|
218918297|NCT03041181|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
218918298|NCT03041181|DRUG|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
218918299|NCT03041181|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
218918300|NCT03041181|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
218918301|NCT06359951|BEHAVIORAL|Project YES|Digital SSI
218918302|NCT06494644|DRUG|AZD6793|Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
218918303|NCT06494644|DRUG|Itraconazole|Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
218918304|NCT06494644|DRUG|AZD6793+ Itraconazole|Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
218918305|NCT00863278|PROCEDURE|pulsed dye laser treatment|On one side of the face according to Arm placement.
219042310|NCT03469921|DRUG|administered therapeutic regimens|administered therapeutic regimens
219532483|NCT01980823|DRUG|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
218918306|NCT00863278|DRUG|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
218918307|NCT03224819|DRUG|Emerfetamab|Administered by intravenous (IV) infusion.
218918308|NCT03536572|BEHAVIORAL|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
218918309|NCT00278577|BIOLOGICAL|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
218918310|NCT00286728|BEHAVIORAL|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
219532484|NCT01980823|PROCEDURE|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
219532485|NCT04089735|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
219532486|NCT04089735|DRUG|APP13007, 0.1%|APP13007 eye drop, 0.1%
219532487|NCT04089735|DRUG|APP13007 Placebo, 0.05%|APP13007 placebo eyedrop, 0.05%
219532488|NCT04089735|DRUG|APP13007 Placebo, 0.1%|APP13007 placebo eyedrop, 0.1%
219532489|NCT01601145|DIETARY_SUPPLEMENT|consumption of lozenges|Each subject two lozenges a day for 6 weeks
219617215|NCT01607515|OTHER|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
218918311|NCT00000794|DRUG|Sulfadiazine|
218918312|NCT00000794|DRUG|Clarithromycin|
218918313|NCT00000794|DRUG|Atovaquone|
218918314|NCT00000794|DRUG|Pyrimethamine|
218918315|NCT00000794|DRUG|Leucovorin calcium|
218918316|NCT03662867|BEHAVIORAL|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
218918317|NCT03662867|OTHER|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
219042311|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
219042312|NCT03060746|OTHER|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
219042313|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
219042314|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
219617216|NCT01436513|DRUG|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
219617217|NCT01436513|DRUG|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
219617218|NCT01436513|DRUG|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
219617219|NCT01436513|DRUG|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
219617220|NCT03775616|OTHER|Educational Intervention|Receive financial navigation program intervention
219617221|NCT03775616|OTHER|Questionnaire Administration|Ancillary studies
219617222|NCT03775616|OTHER|Quality-of-Life Assessment|Ancillary studies
219617223|NCT03266653|DRUG|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
219532490|NCT04295122|DEVICE|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
219532491|NCT02974556|PROCEDURE|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
218918318|NCT03866746|DRUG|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
218918319|NCT03866746|OTHER|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
218918320|NCT06253988|DRUG|Probiotic Formula|intra-pocket formula (local delivery drug)
218918321|NCT06253988|DRUG|placebo formula|intra-pocket formula (local delivery drug)
218918322|NCT04299373|DRUG|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
218918323|NCT04299373|DRUG|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
218918324|NCT04649112|GENETIC|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
218918325|NCT00011596|PROCEDURE|Gait Training|
219617224|NCT04747158|BIOLOGICAL|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
218918326|NCT01017185|DRUG|HF10|
218918327|NCT00102466|DRUG|vildagliptin|
218918328|NCT00102466|DRUG|Gliclazide|
218918329|NCT00102466|DRUG|Metformin|
218918330|NCT03572946|PROCEDURE|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
218918331|NCT03572946|PROCEDURE|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
218918332|NCT00358475|DRUG|GW685698|
218918333|NCT01814111|PROCEDURE|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
218918334|NCT04735263|DRUG|Atorvastatin 80mg|Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
218918335|NCT03186300|DEVICE|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
218918336|NCT04973449|BIOLOGICAL|AZD1222|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
218918337|NCT04973449|BIOLOGICAL|AZD2816|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
218918338|NCT00521079|DEVICE|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
218918339|NCT00521079|DEVICE|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
218918340|NCT05495789|OTHER|Virtual Reality|A relaxing video will be watched with virtual reality glasses.
219617225|NCT03486808|DEVICE|IFG stimulation|stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
218918341|NCT05495789|OTHER|Music|Relaxing music will be played by wearing headphones.
219617226|NCT03486808|DEVICE|DLPFC stimulation|stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
219617227|NCT03486808|DEVICE|Sham stimulation|sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
219617228|NCT03859596|PROCEDURE|MGB/OAGB|BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
219617229|NCT06123091|OTHER|Questionnaires with patient reported outcome measures|Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.
218918342|NCT03586765|OTHER|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
218918343|NCT01506596|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
218918344|NCT03816696|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
219532492|NCT02974556|PROCEDURE|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
218918345|NCT03816696|DRUG|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
218918346|NCT06315712|OTHER|inspiratory exercise|The training consisted of 6 sets of 30 breaths per day, divided into 2 sessions per day. A one-minute rest interval between each set. Training was prescribed 5 days a week for 8 weeks
218918347|NCT06315712|OTHER|Pulmonary rehabilitation|Four resistive exercises, aerobic exercise, and deep breathing exercises, five sessions per week for 8 weeks
218918348|NCT02873858|OTHER|smell and taste tests|
218918349|NCT01314183|OTHER|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
218918350|NCT01314183|OTHER|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
218918351|NCT05657002|OTHER|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
219042315|NCT06218147|BEHAVIORAL|Nutrition-behavior lifestyle program|The 15 participants randomized to the intervention group will complete the activities described in the arm/group description.
219532493|NCT02974556|DRUG|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
219617230|NCT00791778|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
219617231|NCT00791778|DRUG|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
219617232|NCT04677777|BIOLOGICAL|PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)|PP-007 is PEGylated carboxyhemoglobin. Eligible patients will receive two doses of PP-007 (at least 24 hours apart) to evaluate extended drug exposure along with MT and/or IVT (individually or together) as SOC to evaluate safety in AIS patients.
219617233|NCT03306745|DIETARY_SUPPLEMENT|Profertil female|"For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
219617234|NCT03306745|DIETARY_SUPPLEMENT|Folic acid 400 mg|Folic acid 400 mg
219617235|NCT02435693|OTHER|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
219617236|NCT02435693|OTHER|Without PHARMACEUTICAL CARE programe|
219042316|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
219042317|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
219042318|NCT04019158|DEVICE|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
219042319|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
219042320|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
219042321|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
219042322|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
219042323|NCT02431858|DEVICE|E-Catheter (Pajunk)|
219042324|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
219042325|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
219042326|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
218918352|NCT05657002|OTHER|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
218918353|NCT05657002|OTHER|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
218918354|NCT05657002|OTHER|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
218918355|NCT06281132|DRUG|CKD-341, D956|A single dose of 1 tablet under fasting condition
218918356|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
219532494|NCT02973685|PROCEDURE|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
219532495|NCT02973685|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
219532496|NCT02973685|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
219532497|NCT02973685|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
219532498|NCT00752297|DRUG|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
219532499|NCT00752297|DRUG|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
219532500|NCT06009471|OTHER|Routine treatment in Neurology|Routine treatment in Neurology department, including drug treatment,etc.
219617237|NCT03143790|PROCEDURE|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
219617238|NCT00423878|DRUG|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
219617239|NCT00423878|DRUG|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
219042327|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
219042328|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
219042329|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
219617240|NCT00423878|DRUG|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
219617241|NCT00423878|DRUG|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
219617242|NCT05758870|PROCEDURE|surgical stabilization of low rib fratures|surgical stabiliazation of rib fractures by internal fixation
219617243|NCT05758870|OTHER|converstive treatment of low rib fratures|chest wall fixation band
219617244|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
218918357|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
218918358|NCT06294626|OTHER|Group 1|21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
218918359|NCT01564160|DIETARY_SUPPLEMENT|Fish Oil|Source of omega-3 fatty acids.
218918360|NCT01564160|DIETARY_SUPPLEMENT|PCSO-524|Extract of Greenshell Mussel
218918361|NCT05962528|DEVICE|Soft lens|Patients were randomly fitted with five different designs of soft lenses
218918362|NCT05215431|PROCEDURE|periodontal examination&amp;#39;s, determination of salivary antioxidants and cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid, Non-surgical therapy of periodontitis|Periodontal parameters has been recorded on six sites of each tooth using a manual periodontal probe. Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits. Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits . The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
218918363|NCT05215431|DIAGNOSTIC_TEST|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA)|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits.
218918364|NCT05215431|DIAGNOSTIC_TEST|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits .
219042330|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
219532501|NCT06009471|DEVICE|Routine treatment in Neurology and rTMS|Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
219617245|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
219617246|NCT00235755|DRUG|Placebo|Oral tablet.
219532502|NCT01305018|DIETARY_SUPPLEMENT|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
219532503|NCT01305018|DIETARY_SUPPLEMENT|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
219532504|NCT01305018|DIETARY_SUPPLEMENT|Placebo|14 g of alanine per day during 9 days
219532505|NCT03394235|DEVICE|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
219532506|NCT06558864|PROCEDURE|Subiculum RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform Subiculum RF-TC.
219532507|NCT04444479|OTHER|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
219532508|NCT04444479|OTHER|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
219532509|NCT03475303|BEHAVIORAL|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
219532510|NCT01543217|OTHER|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
219532511|NCT01543217|OTHER|Ususal care|Routine respiratory care.
219532512|NCT03483194|DEVICE|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
219532513|NCT03483194|DRUG|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
219532514|NCT03829891|DRUG|Beinaglutide|"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
219532515|NCT03829891|DRUG|glargine|"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
219532516|NCT01439880|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219532517|NCT01439880|OTHER|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
219532518|NCT01530880|DRUG|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
219532519|NCT01530880|DRUG|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
219532520|NCT05497362|DEVICE|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
219532521|NCT05497362|DEVICE|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
219532522|NCT05594420|PROCEDURE|Mitral valve replacement|Mitral valve replacement through median sternotomy and minimally invasive approach
219617247|NCT01105897|PROCEDURE|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
218918365|NCT05215431|PROCEDURE|Periodontal treatment|The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
218918366|NCT00522093|DRUG|TJ-100|TJ-100 2.5g three times per day for 6 weeks
218918367|NCT04008472|OTHER|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
218918368|NCT03038061|OTHER|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
218918369|NCT03606902|PROCEDURE|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
218918370|NCT03606902|DRUG|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
218918371|NCT03606902|DRUG|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
218918372|NCT03606902|PROCEDURE|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
218918373|NCT00140452|DRUG|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
219042331|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
219532523|NCT01212848|DEVICE|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
219532524|NCT01212848|DEVICE|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
219532525|NCT00859534|DRUG|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
219532526|NCT02713425|DEVICE|Entertaining Video Game|Children between 7 \& 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
219532527|NCT03874715|DRUG|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219532528|NCT03874715|DRUG|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219532529|NCT03874715|DRUG|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219532530|NCT00875550|DRUG|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
219532531|NCT00875550|DRUG|Midazolam|Rescue medication for sedation according to UMSS scores
219617248|NCT01459133|DRUG|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
219617249|NCT02056223|DRUG|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
219617250|NCT02056223|DRUG|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
219617251|NCT02314026|DEVICE|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
219532532|NCT00875550|DRUG|Fentanyl|Rescue medication for pain based on UMSS scores
219532533|NCT00875550|DRUG|Morphine|Rescue medication for pain based on UMSS scores.
219617252|NCT02314026|DEVICE|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
219532534|NCT06559566|PROCEDURE|USG|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
219532535|NCT06559566|PROCEDURE|BCT|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
219532536|NCT02053857|DIETARY_SUPPLEMENT|RUTF|
218918374|NCT04124809|DEVICE|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
219532537|NCT02053857|DIETARY_SUPPLEMENT|RUTF-P|
218918375|NCT03613441|BEHAVIORAL|Mindful Awareness Practices (MAPs)|Please refer to arm description
218918376|NCT03310138|DEVICE|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
219532538|NCT02053857|DRUG|Amoxicillin|
219532539|NCT04229121|OTHER|nonintervention|nonintervention
218918377|NCT03310138|DEVICE|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
218918378|NCT00048425|DRUG|Levosimendan|
219532540|NCT02956460|DEVICE|fanfilcon A|contact lens
219532541|NCT02956460|DEVICE|senofilcon A|contact lens
219532542|NCT02598089|BIOLOGICAL|Trivalent Seasonal Influenza Vaccine|
219532543|NCT02598089|OTHER|Placebo|0.5 mL of phosphate buffered saline
219532544|NCT00834067|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
219532545|NCT00834067|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
219532546|NCT01072890|DRUG|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
219532547|NCT05281341|DRUG|Growth Hormone|In GH groups (Group 4A \& 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B \& 3B) will receive only standard COS without GH supplementation
219532548|NCT05474365|OTHER|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
219532549|NCT04129346|BEHAVIORAL|Fit2ThriveMB App|The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
219532550|NCT04129346|BEHAVIORAL|Fitbit|The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
219532551|NCT04129346|BEHAVIORAL|Physical Activity Coaching Calls|Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
219532552|NCT04129346|BEHAVIORAL|Healthy Living Coaching Calls|Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
219532553|NCT04129346|BEHAVIORAL|Cancer.net app|Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
219532554|NCT00003484|DRUG|carmustine|
219532555|NCT00003484|DRUG|irinotecan hydrochloride|
219532556|NCT00003484|PROCEDURE|surgical procedure|
219532557|NCT00003484|RADIATION|iodine I 131 monoclonal antibody 81C6|
219617253|NCT01332344|DRUG|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
219617254|NCT01332344|DRUG|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
219617255|NCT03974867|DRUG|Prednisone 5Mg Tab|"Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;"
219617256|NCT03974867|DRUG|Methylprednisolone 40 mg|"Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;"
219617257|NCT06976307|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
219617258|NCT06976307|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
219532558|NCT03253003|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
218918379|NCT06442319|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction
218918380|NCT05382845|DIAGNOSTIC_TEST|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
218918381|NCT01539824|BIOLOGICAL|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
218918382|NCT01539824|RADIATION|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
218918383|NCT06532578|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
218918384|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q4W|Subcutaneous injection of CPX101 or placebo
218918385|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
218918386|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q4W|Subcutaneous injection of CPX101 or placebo
218918387|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q2W|Subcutaneous injection of CPX101 or placebo
218918388|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q2W|CPX101 or placebo 360mg Q2W
218918389|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q4W|CPX101 or placebo 360mg Q4W
218918390|NCT05679388|DRUG|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
218918391|NCT05679388|DRUG|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
219042332|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
219532559|NCT02350231|DRUG|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
219532560|NCT02350231|DRUG|Tonics group|Those patients will receive only tonics
219532561|NCT03465839|BEHAVIORAL|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
218918392|NCT05679388|DRUG|Itraconazole|A drug used to treat fungal infections.
218918393|NCT05452486|DIAGNOSTIC_TEST|English APD assessment|Materials presented in English
218918394|NCT05452486|DIAGNOSTIC_TEST|Spanish APD assessment|Materials presented in Spanish
218918395|NCT04632680|DEVICE|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
218918396|NCT04408989|DRUG|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
218918397|NCT04408989|DRUG|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
218918398|NCT04408989|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
218918399|NCT04211753|BEHAVIORAL|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
218918400|NCT04211753|DEVICE|Mobile app|Medical device for crisis intervention
218918401|NCT03645122|OTHER|Paired corticospinal-motoneuronal stimulation (PCMS)|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
218918402|NCT03645122|OTHER|Sham stimulation|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
218918403|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
218918404|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
218918405|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
218918406|NCT05133297|DRUG|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
218918407|NCT02402816|DEVICE|MultiPoint Pacing ON|MultiPoint Pacing ON
218918408|NCT02402816|DEVICE|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
218918409|NCT00446979|DRUG|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
218918410|NCT00446979|DRUG|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
218918411|NCT01402752|BIOLOGICAL|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
218918412|NCT03059849|DRUG|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
218918413|NCT00142155|DRUG|Rituximab|
219042333|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
219042334|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
219532562|NCT03465839|BEHAVIORAL|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
219532563|NCT01888523|BEHAVIORAL|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
219532564|NCT01888523|BEHAVIORAL|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
219042335|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
219532565|NCT04559386|OTHER|Survey|Questionnaire
218918414|NCT00142155|DRUG|monoclonal antibodies|
218918415|NCT06016803|DEVICE|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
218918416|NCT05198869|DEVICE|Spectral scan|Consenting participants will have a SpotLight-19 scan
218918417|NCT03698071|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
218918418|NCT03698071|BIOLOGICAL|urine sample|6 ml
218918419|NCT02658526|BEHAVIORAL|anesthesia - surgery|
218918420|NCT01249352|DRUG|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
218918421|NCT01249352|DRUG|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
218918422|NCT01249352|DRUG|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
219042336|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
219042337|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
219042338|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
219042339|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
219532566|NCT02896010|OTHER|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
219532567|NCT02896010|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
219532568|NCT05893290|OTHER|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
219532569|NCT05893290|OTHER|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
219532570|NCT02581553|DRUG|lesinurad/allopurinol 200/300 FDC tablets|
219532571|NCT02581553|DRUG|lesinurad 200 mg|
219532572|NCT02581553|DRUG|allopurinol 300 mg|
219532573|NCT02581553|DRUG|lesinurad/allopurinol 200/200 FDC tablets|
219532574|NCT02581553|DRUG|allopurinol 200 mg|
219532575|NCT04784338|BEHAVIORAL|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
219532576|NCT04784338|BEHAVIORAL|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
219532577|NCT00042874|DRUG|alvocidib|Given IV
219532578|NCT00042874|DRUG|irinotecan hydrochloride|Given IV
219532579|NCT00042874|DRUG|fluorouracil|Given IV
219532580|NCT00042874|DRUG|leucovorin calcium|Given IV
219532581|NCT00042874|OTHER|laboratory biomarker analysis|Correlative studies
219532582|NCT03512925|OTHER|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
218918423|NCT01249352|RADIATION|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
218918424|NCT05120180|PROCEDURE|axillary lymph node dissection with vein branches reservation|Spare the vein branches when ALND being performed
218918425|NCT05120180|PROCEDURE|axillary lymph node dissection without vein branches reservation|Don't spare the vein branches when ALND being performed
219532583|NCT01793558|PROCEDURE|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
218918426|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
218918427|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
218918428|NCT04235608|DRUG|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
218918429|NCT04235608|DRUG|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
218918430|NCT04137952|BEHAVIORAL|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
218918431|NCT06061926|DRUG|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
218918432|NCT06061926|DRUG|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
218918433|NCT05065060|OTHER|Observation|Observation
218918434|NCT04727970|DRUG|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
219042340|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
219042341|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
219532584|NCT03839719|PROCEDURE|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
219042342|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
219532585|NCT03839719|PROCEDURE|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
219532586|NCT03839719|PROCEDURE|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
219532587|NCT05579535|OTHER|gait training exercises|walking exercises in different directions
219532588|NCT04277403|RADIATION|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
219532589|NCT04277403|RADIATION|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
219532590|NCT01705574|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
219042343|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
218918435|NCT01838395|DRUG|Ara-C|IV (intravenous administration)
218918436|NCT01838395|DRUG|BL-8040|SC (subcutaneous injection)
218918437|NCT04088149|DRUG|GXNPC1|Autologous ADSCs
218918438|NCT05684419|OTHER|Fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers|Evaluation of the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.
218918439|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
218918440|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
218918441|NCT00002009|DRUG|Sargramostim|
218918442|NCT03951103|OTHER|rFVIIIFc|Drug according to prescription
218918443|NCT04610346|BEHAVIORAL|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
218918444|NCT00651742|DRUG|S-1|All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
219042344|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
219042345|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
218918445|NCT05106647|BEHAVIORAL|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
218918446|NCT06115642|DRUG|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219532591|NCT01705574|DRUG|ATV|300 mg capsule administered orally with food once daily
219532592|NCT01705574|DRUG|RTV|100 mg tablet administered orally with food once daily
219532593|NCT01705574|DRUG|FTC/TDF|200/300 mg tablet administered orally with food once daily
219532594|NCT01705574|DRUG|E/C/F/TDF Placebo|Tablet administered orally with food once daily
219532595|NCT01705574|DRUG|ATV Placebo|Tablet administered orally with food once daily
219532596|NCT01705574|DRUG|RTV Placebo|Capsule administered orally with food once daily
219532597|NCT01705574|DRUG|FTC/TDF Placebo|Tablet administered orally with food once daily
219617259|NCT05586100|DRUG|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
219617260|NCT01075789|DRUG|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
219617261|NCT01075789|DRUG|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
218918447|NCT06540742|DIAGNOSTIC_TEST|Artificial intelligence identifies liver hydatids|Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology
218918448|NCT03762590|OTHER|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
218918449|NCT03762590|OTHER|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
218918450|NCT05913882|DEVICE|Respiratory Muscle Strength Training (LVR+EMST)|Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
218918451|NCT05720286|DEVICE|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
218918452|NCT01088568|PROCEDURE|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
218918453|NCT01088568|PROCEDURE|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
218918454|NCT00693407|PROCEDURE|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.
218918455|NCT01570413|PROCEDURE|No Pelvic Exam|Will not receive pelvic examination.
218918456|NCT01570413|PROCEDURE|Pelvic Examination|Pelvic examination will be performed.
218918457|NCT04050553|DRUG|Tirzepatide|Administered SC
218918458|NCT04050553|DRUG|Placebo|Administered SC
218918459|NCT05824650|OTHER|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
218918460|NCT06081296|PROCEDURE|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
219617262|NCT04257214|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
218918461|NCT06081296|PROCEDURE|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
219532598|NCT01705574|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
219532599|NCT00949143|OTHER|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
219532600|NCT00949143|OTHER|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
219532601|NCT06457308|BIOLOGICAL|Physical training of agility|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training,
218918462|NCT06081296|PROCEDURE|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
218918463|NCT06081296|PROCEDURE|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
218918464|NCT01535040|DRUG|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
218918465|NCT01535040|DRUG|placebo|Placebo by mouth through completion of 12 weeks.
218918466|NCT03479814|RADIATION|IMRT-SIB plus sequential IG-RT boost|
218918467|NCT05430854|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
218918468|NCT02734875|OTHER|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
218918469|NCT04314284|BEHAVIORAL|I Can PIC|-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
218918470|NCT04314284|OTHER|Historical control survey|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
218918471|NCT04314284|OTHER|Post-intervention survey (I Can PIC participants)|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
218918472|NCT04314284|OTHER|Follow-Up survey (I Can PIC participants)|-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
218918473|NCT06114238|DRUG|Itepekimab AI|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
218918474|NCT06114238|DRUG|Itepekimab PFS|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
218918475|NCT00938704|DRUG|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
218918476|NCT00938704|DRUG|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
218918477|NCT05650749|BIOLOGICAL|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
218918478|NCT04638231|OTHER|Supportive messages|Daily supportive messages via SMS or email
218918479|NCT05375461|DRUG|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
218918480|NCT05375461|DRUG|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
218918481|NCT05375461|DRUG|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
218918482|NCT06204757|OTHER|questionary|questionary relating to birth trauma are completed by midwives and patients
218918483|NCT05083741|DEVICE|Chitogel|post-operative dressing within standard of care
218918484|NCT05083741|DEVICE|Nexfoam|post-operative dressing within standard of care
218918485|NCT05672784|PROCEDURE|GNB plus standard analgesia|When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
219042346|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
219042347|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
219042348|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
219042349|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
219042350|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
219042351|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
219042352|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
219042353|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
218918486|NCT05672784|PROCEDURE|GNB plus IPACK block plus standard analgesia|IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
218918487|NCT05672784|DRUG|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
218918488|NCT06584968|OTHER|training with visual feedback|Training with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams.
218918489|NCT06584968|OTHER|classical learning|Study of the test with practical applications on the researcher who plays the role of the patient
218918490|NCT06584695|DRUG|Transversus abdominis plane block|Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
218918491|NCT06584695|DRUG|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
218918492|NCT06584695|DRUG|Control group|"Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane."
218918493|NCT01652235|DEVICE|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
218918494|NCT06065670|DRUG|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
218918495|NCT06065670|DRUG|Placebo|Matched sugar tablet
219042354|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
219042355|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
219042356|NCT02889354|BEHAVIORAL|Cognitive-behavioral therapy|
219617263|NCT03329339|PROCEDURE|1 L PEG with ascorbic acid with prepackaged, low residue diet|Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
219617264|NCT02354729|OTHER|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
219617265|NCT02573961|DEVICE|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
218918496|NCT04718415|DRUG|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
218918497|NCT04718415|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
218918498|NCT06313515|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin
218918499|NCT06313515|BEHAVIORAL|Arm-crank bike exercise|Exercise using an arm-bike to target cardiovascular functioning.
218918500|NCT06313515|OTHER|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin.
218918501|NCT06547684|DEVICE|fESWT|"Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle."
219042357|NCT03448315|DEVICE|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
219042358|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
219042359|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
219042360|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
219042361|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
219042362|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
219042363|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
219042364|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
219042365|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
219042366|NCT02142127|DRUG|14C-labelled GFT505 120 mg|
219042367|NCT02679586|DEVICE|Diffusion weighted MRI|
219617266|NCT02573961|BEHAVIORAL|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
218918502|NCT03205709|OTHER|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
218918503|NCT03205709|OTHER|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
218918504|NCT02023086|PROCEDURE|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
218918505|NCT02023086|PROCEDURE|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
218918506|NCT02023086|PROCEDURE|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
218918507|NCT02023086|PROCEDURE|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
218918508|NCT02023086|DRUG|Tropicamide|Used to dilate patient's pupil during testing
218918509|NCT02023086|DEVICE|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
218918510|NCT03657628|OTHER|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
218918511|NCT06585397|OTHER|Grup 1|Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
218918512|NCT05819138|DRUG|Semaglutide Pen Injector|Semaglutide injection
218918513|NCT05819138|DRUG|Placebo|Semaglutide placebo injection
218918514|NCT04971642|DEVICE|Intraoral ultrasound|Intraoral ultrasound scanning of the periodontium complex
219042368|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
219042369|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
219042370|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
219042371|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
219532602|NCT06457308|BIOLOGICAL|Physical training of resistance|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars
219532603|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
219532604|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
219532605|NCT03939364|DRUG|SBS-101|Isotretinoin Oral-Adhesive Film
219532606|NCT03939364|DRUG|Placebo|Placebo
219532607|NCT00975494|DRUG|Sildenafil|
219532608|NCT00975494|DRUG|Placebo|
219532609|NCT05065346|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219532610|NCT01313949|OTHER|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
219617267|NCT02573961|BEHAVIORAL|low caloric diet|Tailored balanced low caloric diet
219617268|NCT05590611|OTHER|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
219617269|NCT05590611|OTHER|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
219617270|NCT00138008|DRUG|endocrine therapy|Drug: endocrine therapy
219617271|NCT00138008|PROCEDURE|radiotherapy|Procedure/Surgery: radiotherapy
218918515|NCT05005429|DRUG|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
218918516|NCT04764799|PROCEDURE|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
218918517|NCT06060899|PROCEDURE|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
218918518|NCT06060899|PROCEDURE|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
218918519|NCT06494267|BEHAVIORAL|Experimental (Video-Assisted Self-Assessment on Nasogastric Tube Insertion)|Students in the experimental group will be videotaped while practicing and students will make self-evaluations.
218918520|NCT05507138|DEVICE|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
218918521|NCT05507138|BEHAVIORAL|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
218918522|NCT05743335|BIOLOGICAL|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
218918523|NCT05743335|OTHER|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
218918524|NCT03581487|BIOLOGICAL|Durvalumab|Given IV
218918525|NCT03581487|DRUG|Selumetinib|Given PO
218918526|NCT03581487|BIOLOGICAL|Tremelimumab|Given IV
218918527|NCT00558584|DEVICE|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
218918528|NCT00558584|DEVICE|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
218918529|NCT05640830|DRUG|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
218918530|NCT01244841|PROCEDURE|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
218918531|NCT01343394|BIOLOGICAL|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
218918532|NCT06477055|DRUG|Osimertinib|Osimertinib, 80mg, po, qd.
218918533|NCT05380427|DRUG|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
218918534|NCT06621264|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\&#39;s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.
218918535|NCT06621264|OTHER|Control (Standard treatment)|Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices
218918536|NCT04249245|OTHER|Nasal Swab|All
219042372|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
219042373|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
219042374|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
219042375|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
218918537|NCT06652243|BIOLOGICAL|SN301A|"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."
218918538|NCT05878665|DIAGNOSTIC_TEST|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
218918539|NCT06978335|OTHER|Acupoint Stimulation|This intervention involves acupoint stimulation and auricular acupressure. Stimulation of selected body acupoints is administered by trained personnel following a standardized protocol. The intervention is provided once daily for three consecutive days, beginning post-surgery. For auricular acupressure, additional auricular points are chosen based on the involved abdominal organ and its corresponding viscera-meridian locations on the auricle. Vaccaria seeds are applied to the selected points with adhesive patches, and patients are instructed to apply pressure to the points regularly throughout the day.
218918540|NCT06978335|OTHER|Sham Acupoint Stimulation|Participants in this group will receive a sham acupoint stimulation procedure. Acupoint stimulation will be using identical procedures to the experimental group, without applying pressure. No stimulation or manipulation was performed. The frequency and timing of the sham intervention matched that of the experimental group.
218918541|NCT04713644|DRUG|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
218918542|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - EARLY|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
218918543|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - DELAYED|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
218918544|NCT05498883|OTHER|Score completion|completion of the SRI score
218918545|NCT06555120|BIOLOGICAL|blood sample|A 5-ml blood sample in a dry tube (or 500-µl cone) is taken and sent to the biochemistry laboratory for lipid analysis.
218918546|NCT06584604|OTHER|There is no intervention|There is no intervention
218918547|NCT04855552|BEHAVIORAL|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
218918548|NCT04855552|BEHAVIORAL|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
218918549|NCT04855552|BEHAVIORAL|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram"
218918550|NCT03472885|DRUG|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
218918551|NCT03472885|DRUG|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
218918552|NCT04380740|DRUG|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
218918553|NCT04380740|DRUG|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
218918554|NCT03390686|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
218918555|NCT03390686|DRUG|HD204|15 mg/kg IV every 3 weeks on Day 1
218918556|NCT03390686|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
218918557|NCT03390686|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
218918558|NCT05653492|DRUG|Sulforaphane|Dosing study one to four 30 mg/d tablets depending on weight
219042376|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
219042377|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
219042378|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
219617272|NCT04507295|DEVICE|cerebral oximetry ( INVOS 5100 )|"in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure"
219617273|NCT01532934|BEHAVIORAL|motivational enhancement therapy|Four 45-minute MET sessions
219617274|NCT01532934|OTHER|standard care|
218918559|NCT06466200|DIAGNOSTIC_TEST|Schiff Test|Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.
218918560|NCT06466200|OTHER|GOHAI questionnaire|Oral health-related quality of life assessment by questionnaire
218918561|NCT06466200|OTHER|OHIP questionnaire|Oral health-related quality of life assessment by questionnaire
218918562|NCT06466200|OTHER|DHEQ fr questionnaire|dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
218918563|NCT05978193|RADIATION|LDRT+CFRT|"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"
218918564|NCT05978193|DRUG|Immunotherapy|PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
218918565|NCT05978193|DRUG|Chemotherapy|Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
219532611|NCT06061146|DRUG|Arm A|anti-PD-1 immunotherapy
219532612|NCT06061146|DRUG|Arm A|chemotherapy
219617275|NCT05123313|BEHAVIORAL|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
219532613|NCT06061146|RADIATION|Arm A|Radiation Concurrent Radiation, 1.8Gy/f, 28f
219532614|NCT06061146|DRUG|Arm B|chemotherapy
219532615|NCT06061146|RADIATION|Arm B|Radiation Concurrent Radiation, 1.8Gy/f, 28f
219532616|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
219532617|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
219617276|NCT05699941|DEVICE|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
219617277|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
219042379|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
219042380|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
219042381|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
219532618|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
219042382|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
219042383|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
219042384|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
219042385|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
219042386|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
219042387|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
219042388|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
219042389|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
219042390|NCT00113659|DIETARY_SUPPLEMENT|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
219042391|NCT00113659|DIETARY_SUPPLEMENT|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
219042392|NCT04917055|DRUG|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
219042393|NCT04917055|DRUG|Saline|Injection of Saline behind knee using ultrasound guidance
219532619|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
219532620|NCT03124420|DRUG|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
219532621|NCT03124420|DRUG|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
219532622|NCT03124420|DRUG|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
219532623|NCT02293668|DRUG|FSH 225IU and hMG 225IU|
219532624|NCT02293668|DRUG|FSH 150IU and hMG 150IU|
219532625|NCT02293668|DRUG|Letrozole 5mg and hMG 150IU|
219532626|NCT02815527|OTHER|Fresubin intensive|Enteral nutrition containing a high protein concentration
219532627|NCT06095076|DIAGNOSTIC_TEST|Skin swabbing|Skin swabbing will be performed on CVC insertion site before CVC placement (baseline), and then every 3 days (or when dressing is changed) while CVC is in place, then at ICU discharge. Bacterial metagenomics using bacterial DNA extraction, 16S PCR amplification and Nanopore sequencing will allow for description of cutaneous microbiota and diversity evaluation through Shannon index. Evolution of alpha-diversity will be evaluated through time-series data analysis: comparison of Shannon index at various time points with baseline Shanonn index (before CVC placement). Standard microbiologic culture of skin swabbing will be performed.
219532628|NCT06095076|OTHER|Data collection|General patient characteristics and informations relative to CVC infection and treatment will be collected.
218918566|NCT06970236|OTHER|Exercise|Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
218918567|NCT06812442|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes)· Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes). RT sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
218918568|NCT06654479|OTHER|In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.|The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
219532629|NCT01167530|DRUG|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
219532630|NCT03245086|DEVICE|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
219532631|NCT03245086|PROCEDURE|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
219532632|NCT01798212|PROCEDURE|endoscopic full thickness plication|
219532633|NCT01115465|DEVICE|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
219532634|NCT06133725|PROCEDURE|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
219532635|NCT05066438|BEHAVIORAL|Antenatal hand expression|Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
219532636|NCT01433718|PROCEDURE|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
219532637|NCT02543203|BIOLOGICAL|Reconnect|Topical Essential Oils mixture and aromatic method
219532638|NCT02543203|BIOLOGICAL|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
219617278|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
219532639|NCT00300911|DRUG|Rosiglitazone(drug), cardiac adverse effects|
219532640|NCT00089661|DRUG|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
219532641|NCT00089661|DRUG|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
219617279|NCT05608681|DRUG|EP-104GI|Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle
219617280|NCT05608681|OTHER|Matching vehicle control|A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.
219617281|NCT06984302|OTHER|proactive therapy|drugs and fluids will be given based on the hypotension prediction index
219617282|NCT05821075|DRUG|Prednisolone|prednisolone 60mg tablet once daily for 5 days then tapering dose
219617283|NCT05821075|DRUG|Cerebrolysin|intramuscular Cerebrolysin 10 mg daily for 3 weeks
218918569|NCT06655103|OTHER|Educational movie|There are three groups in this research. The 1st group will be shown an educational movie about intrathecal chemotherapy treatment before intrathecal chemotherapy treatment, the 2nd group will be shown a cartoon movie before intrathecal chemotherapy treatment, and the 3rd group will not receive any intervention before intrathecal chemotherapy treatment. In all groups, measurements will be made in parallel; fear and pain scales as well as electrodermal activity, pulse, respiration and O2 saturation values 30 minutes before IT chemotherapy treatment, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
218918570|NCT06654869|BEHAVIORAL|lauhgter yoga|include laughter yoga effects on cancer patients' symptom management
219532642|NCT05382377|BIOLOGICAL|KD-025|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
219532643|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
219532644|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
219532645|NCT01273805|DRUG|Hydroxychloroquine|
219532646|NCT03493347|BEHAVIORAL|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
219532647|NCT00444847|DEVICE|Hyperbaric chamber|
219532648|NCT05044221|OTHER|Former ICU patient and caregiver workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
219532649|NCT05044221|OTHER|Health care professional workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
219532650|NCT03048812|DEVICE|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
219532651|NCT03048812|DEVICE|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
219532652|NCT02647944|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
219532653|NCT02647944|DRUG|Placebo|
219532654|NCT02077465|DRUG|Andecaliximab|400 mg andecaliximab administered intravenously
219532655|NCT02077465|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
219532656|NCT00115843|DEVICE|Mobile Cardiac Outpatient Telemetry|
219532657|NCT02776878|DRUG|dasatinib|
219532658|NCT05494671|PROCEDURE|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
219532659|NCT04400617|BEHAVIORAL|Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.|The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.
219532660|NCT01853657|OTHER|Virological monitoring|
219532661|NCT01246076|DRUG|Lenalidomide|
219532662|NCT01286922|OTHER|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
219532663|NCT05528744|OTHER|Observational Study|No intervention. This is an observational study
219532664|NCT05528744|OTHER|Sample collection only|Collection of blood and/or skin samples.
219532665|NCT06263972|DEVICE|Direct Stimulation Prefrontal Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.
218918571|NCT06654921|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
218918572|NCT06654921|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
219532666|NCT06263972|DEVICE|Shame cortex stimulation|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.
218918573|NCT06654921|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
218918574|NCT06653998|OTHER|Early mobilization and rehabilitation|"In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity."
218918575|NCT06654492|PROCEDURE|The dimension of the window for lateral window maxillary sinus elevation surgery|The window size for a single implant site should not exceed 25 square millimeters, while the window size for consecutive multiple implant sites should not exceed 40 square millimeters.
218918576|NCT06655116|BEHAVIORAL|Diabetic Foot Education|"Patients in the intervention group will be interviewed and their diabetic foot knowledge will be evaluated. During the interview, the individual's knowledge about the definition of diabetic foot, risk factors, symptoms, treatment, complications, care and prevention will be evaluated.~In order to systematically plan, implement and evaluate the training to be used in the intervention, it is aimed to implement androgogical training based on the 'Interpersonal Relations Theory'. In this context, the stages in the theory will be followed as follows."
218918577|NCT04647370|PROCEDURE|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
218918578|NCT04647370|PROCEDURE|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
218918579|NCT04835311|PROCEDURE|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
218918580|NCT01651728|DRUG|Simvastatin|Tablet 20 mg once daily for 30 days
218918581|NCT01651728|DRUG|Placebo|daily for 30 days
219617284|NCT06596759|BEHAVIORAL|Diaphragmatic Breathing|REDCap will be used to administer the Mayo Bloating Questionnaire (MBQ) and collect self-reported compliance to diaphragmatic breathing (DB) exercises over a 4 week follow up period. After completion of the MBQ, the patient will be taught DB techniques by an individual physical therapist face to face over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. Patients will receive a telephone call and electronic health record portal message to check progress and answer any questions. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing. The questionnaire will include prompts investigating perceived side effects and attitudes towards therapy, willingness to perform DB therapy, likelihood to attempt self-guided DB in the future, and if the participant would recommend the therapy to a friend.
219617285|NCT06603883|BIOLOGICAL|Fecal microbiota transplantation (FMT) by nasal jejunal tube|FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
219532667|NCT06263972|DEVICE|Direct Stimulation to Motor Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.
219532668|NCT06263972|BEHAVIORAL|erobic physical activity|Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
219617286|NCT06670222|DRUG|Arsenic Trioxide (ATO)|"Study treatment: oral Arsenic 5d/7 for 21 days over a 28-day cycle, three doses tested (0.10 mg/kg, 0.15 mg/kg and 0.20 mg/kg).~Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme, 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients.~Tolerability will be assessed after one treatment cycle. Response will be assessed after 3 cycles of treatment. Responders may continue study treatment until progression or limiting toxicity. Limiting toxicity is defined as any grade III/IV extra-hematological toxicity or grade IV hematological toxicity lasting more than 25 days."
219617287|NCT02154867|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
219617288|NCT02154867|OTHER|Placebo fecal transplant|Fecal transplantation with own feces
219617289|NCT04988919|DIETARY_SUPPLEMENT|4D|multi-ingredient supplement mixed with 24 ounces of water
218918582|NCT00704015|BEHAVIORAL|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
219532669|NCT02760368|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
218918583|NCT03183453|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
219532670|NCT02760368|DRUG|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
218918584|NCT00982293|DEVICE|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
218918585|NCT00982293|DEVICE|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
218918586|NCT01343953|PROCEDURE|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
218918587|NCT02201953|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
218918588|NCT02201953|DRUG|SOF|400 mg tablet administered orally once daily
218918589|NCT02201953|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218918590|NCT04546711|OTHER|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
218918591|NCT06589869|DEVICE|EM Chair|Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
219532671|NCT05770063|DIETARY_SUPPLEMENT|amino acid tablet|multiple essential amino acids supplements
219532672|NCT04471363|BEHAVIORAL|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
219532673|NCT01827163|DRUG|Paclitaxel|
219532674|NCT01827163|DRUG|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
219532675|NCT01827163|DRUG|Lapatinib|
219617290|NCT04988919|DIETARY_SUPPLEMENT|placebo|taste-matched placebo mixed with 24 ounces of water
219617291|NCT01149863|DRUG|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
219617292|NCT01851044|PROCEDURE|Platelet Rich Plasma|
219617293|NCT01851044|PROCEDURE|Whole Blood Injection|
219617294|NCT01851044|PROCEDURE|Saline Injection|
219617295|NCT01406574|DRUG|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
219617296|NCT01406574|DRUG|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
218918592|NCT06589869|OTHER|Standard of care|Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
218918593|NCT06592196|OTHER|stain|This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
218918594|NCT06603116|OTHER|treatment of class two cavities|restorations in class 2 cavities
219532676|NCT01827163|DRUG|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
219532677|NCT00022386|BIOLOGICAL|epoetin alfa|
219532678|NCT00022386|PROCEDURE|quality-of-life assessment|
219532679|NCT04448106|BIOLOGICAL|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
219532680|NCT02120937|BEHAVIORAL|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
219532681|NCT01875952|DRUG|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
219617297|NCT01833650|DIETARY_SUPPLEMENT|thymus honey mouthwash|
219617298|NCT04791137|BEHAVIORAL|Imagery cognitive bias modification|The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. It is hypothesised that via repeatedly practising imagining positive resolutions for ambiguous situations in the training sessions, a bias is trained to automatically imagine positive resolutions for ambiguous situations encountered in daily life.
219617299|NCT04505527|BEHAVIORAL|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
219617300|NCT04505527|BEHAVIORAL|Forward walking|Subjects will have a typical forward walking
219617301|NCT05256186|OTHER|Basketball Pre-injury Attack program|The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
219617302|NCT00102752|DRUG|Glufosfamide|
219617303|NCT00102752|DRUG|Gemcitabine|
218918595|NCT06398197|BEHAVIORAL|Nourish Intervention then No Intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.
218918596|NCT06398197|BEHAVIORAL|No Intervention then Nourish Intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
218918597|NCT06598904|OTHER|Aroma diffuser with single-note lavender essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.
218918598|NCT06598904|OTHER|Aroma diffuser with single-note orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
218918599|NCT06598904|OTHER|Aroma diffuser with deionized water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
218918600|NCT06591013|PROCEDURE|Fecal microbiota transplantation|Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
218918601|NCT06594718|PROCEDURE|Endoscopic diverticulotomy with Z-POEM|Endoscopic diverticulotomy with Z-POEM
218918602|NCT06594718|PROCEDURE|Endoscopic diverticulotomy using a non-tunnelization technique|Endoscopic diverticulotomy with diverticuloscope, Knife Septotomy, or Clutch Cutter
219042394|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
219042395|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
219042396|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
219617304|NCT02176954|DEVICE|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
219042397|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
219617305|NCT02176954|DEVICE|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
219617306|NCT02176954|DEVICE|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
219617307|NCT00584454|BIOLOGICAL|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
218918603|NCT06597136|OTHER|Diaphragmatic kinesiology taping|The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.
218918604|NCT06597136|OTHER|Accessory respiratory muscle kinesiology taping|Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.
218918605|NCT06597136|OTHER|Sham kinesiology taping|Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.
218918606|NCT06590818|PROCEDURE|High tibial osteotomy (HTO|To investigate the effect of body mass index (BMI) on the early efficacy of high tibial osteotomy (HTO) in the treatment of varus knee osteoarthritis
218918607|NCT06602713|OTHER|Questionnaires|Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
218918608|NCT06602713|OTHER|Exercices|isokinetic evaluation
218918609|NCT06595641|DEVICE|Transfer Energy Capacitive Resistive Therapy|It's a physical treatment modality commonly used to treat musculoskeletal pain. It normally uses a longwave radiofrequency of \~0.5 MHz. The system consists of a neutral plate and two different electrodes that can transfer energy in two modalities: capacitive and resistive
218918610|NCT06595641|OTHER|strength training program|"Each session includes five exercises, each performed for three sets of 10 repetitions:~Shoulder Retraction - Strengthens muscles between shoulder blades. Shoulder Scaption - Improves stability and range of motion. Shoulder External Rotation from Side Lying - Targets rotator cuff muscles. Shoulder Protraction - Enhances shoulder blade function. Shoulder Extension - Strengthens posterior shoulder muscles"
218918611|NCT06595979|DRUG|Polymyxin B|Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
218918612|NCT06595043|DEVICE|the tip opening angle to the left|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.
219042398|NCT02140034|PROCEDURE|Extensive Peritoneal Lavage|
219042399|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
219042400|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
219532682|NCT00800137|DRUG|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. \> 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
219532683|NCT00800137|DRUG|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
219532684|NCT03974685|DRUG|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
219532685|NCT06459271|OTHER|Managing Cancer And Living Meaningfully (CALM)|Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.
219532686|NCT03215693|DRUG|X-396 capsule|225mg once daily
219532687|NCT02294604|DEVICE|ethyl alcochol, chlorhexidine and moisturizers|
219532688|NCT02294604|DEVICE|chlorhexidine|
219532689|NCT02294604|DEVICE|povidone-iodine|
219532690|NCT02139839|OTHER|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
219532691|NCT02139839|DRUG|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
219532692|NCT03970421|OTHER|Observation|Check clinical status at different time intervals during 3 months
219532693|NCT01860521|PROCEDURE|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
218918613|NCT06595043|DEVICE|the tip opening angle to the right|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
218918614|NCT06602843|PROCEDURE|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
218918615|NCT06596512|DRUG|PARTICS using a single ICS add on|Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
219532694|NCT01860521|PROCEDURE|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
219532695|NCT01860521|PROCEDURE|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
219532696|NCT01860521|DRUG|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
219532697|NCT01860521|DEVICE|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
218918616|NCT06596512|DRUG|MART|Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
218918617|NCT06592729|BEHAVIORAL|education|intervention group was taken to scenario-based simulat
219617308|NCT05260294|PROCEDURE|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
219617309|NCT04400162|BEHAVIORAL|Usability of the CCT|Evaluation of the usability of the provided training.
219617310|NCT04400162|BEHAVIORAL|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
219532698|NCT01860521|DEVICE|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
219617311|NCT00051948|DRUG|TLK286|
219617312|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
218918618|NCT06595927|DIAGNOSTIC_TEST|Cervical extensor endurance test|Monitoring the clinical parameters of head and neck immobility during the cervical extensor endurance test to correlate them with muscular activity by MRI and other cervical clinical tests
219532699|NCT01860521|DRUG|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
219532700|NCT00478179|DRUG|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
219532701|NCT00629590|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
219617313|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
219532702|NCT05479487|DRUG|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
219532703|NCT05479487|DRUG|Fluzoparib Monotherapy|Fluzoparib 150mg bid
219617314|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
218918619|NCT06592560|DEVICE|ELISA|Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
218918620|NCT06594276|OTHER|Local instillation of antibiotics|Systemic antibiotics are usually used with needle aspiration of breast abscess. However local instillation of antibiotics will be an in intervention in this study.
218918621|NCT06593873|OTHER|Use of typodont head model in addition to theoretical periodontal education|Use of typodont phantom head model in addition to theoretical periodontal education
218918622|NCT06593873|OTHER|Theoretical periodontal education|Theoretical periodontal training only
219617315|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
219617316|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
218918623|NCT06591260|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
218918624|NCT06604273|DIAGNOSTIC_TEST|Fibroblast Activation Protein Inhibitor|PET CT imaging using the fibroblast activation protein inhibitor tracer
218918625|NCT06598566|OTHER|Nottingham Hip Fracture Score (NHFS) score|Nottingham Hip Fracture Score (NHFS) score in patients above 60 years undergoing hip fracture surgery.
218918626|NCT06598566|OTHER|Acute Physiology and Chronic Health Evaluation (APACHE)-II score|Acute Physiology and Chronic Health Evaluation (APACHE)-II score in patients above 60 years undergoing hip fracture surgery
218918627|NCT06603974|PROCEDURE|surgery|After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.
218918628|NCT06603974|DRUG|Benmelstobart|1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
218918629|NCT06603974|DRUG|tegafur|it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
218918630|NCT06603974|DRUG|oxaliplatin|130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
218918631|NCT06603974|DRUG|albumin paclitaxel|260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
218918632|NCT06601036|DRUG|Sevoflurane|Patients will undergo fiberoptic intubation under sevoflurane sedation.
218918633|NCT06601036|DRUG|2% Xylocaine (2 ml )|Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
219532704|NCT02902211|DEVICE|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
219532705|NCT02902211|OTHER|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
219617317|NCT00982657|DRUG|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
219617318|NCT05870384|BEHAVIORAL|Group Interpersonal Psychotherapy|Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
219532706|NCT02498847|BEHAVIORAL|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication"
219617319|NCT04504994|BEHAVIORAL|inclusion condition|cyberball game: ex- versus over-inclusion condition
219617320|NCT00676702|DIETARY_SUPPLEMENT|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
219617321|NCT00676702|DRUG|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
219617322|NCT05589077|BEHAVIORAL|Education on Female Athlete Nutritional Concerns|Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
219617323|NCT00725920|DRUG|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
219617324|NCT00725920|DRUG|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
219617325|NCT04558073|BEHAVIORAL|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
219617326|NCT04558073|BEHAVIORAL|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
219617327|NCT02000791|OTHER|Comparison of fibreoptic view|
219617328|NCT01959633|DRUG|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
218918634|NCT06591273|BIOLOGICAL|Infliximab-dyyb Biosimilar (Remsima)|Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
218918635|NCT00505271|GENETIC|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
219042401|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
219532707|NCT00059306|DRUG|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
219617329|NCT01959633|DRUG|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
218918636|NCT06590701|OTHER|Early dart throwing motion-mobilization|We compare two different mobilisations in the rehabilitation of patients following scapholunate ligament reconstruction
218918637|NCT06604572|PROCEDURE|Transabdominal preperitoneal approach|The enrolled patients underwent either open tension-free hernia repair or Transabdominal preperitoneal approach
218918638|NCT03493997|COMBINATION_PRODUCT|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
218918639|NCT03493997|RADIATION|Radiotherapy only|Radiotherapy only
218918640|NCT06585800|OTHER|sample collection|blood and/or tissue collection
218918641|NCT06592417|DRUG|JSKN016 injection|JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
218918642|NCT06604247|BEHAVIORAL|Cognitive Behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
218918643|NCT06988410|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
218918644|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies.
218918645|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies with Prefabricated Landmarks|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies with prefabricated landmarks in place.
218918646|NCT06592066|DEVICE|Splinted Open Top Tay Conventional Impression Technique|Splinted open-top tray conventional impression technique will be preformed by using medium body silicone impression material.
218918647|NCT06602557|DRUG|Amikacin|Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
218918648|NCT06602557|DRUG|Standard of care|Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
218918649|NCT06596070|OTHER|No intervention was carried out|This study is an observational study and no intervention was performed on the patients.
218918650|NCT05624632|OTHER|Remote cognitive testing|Remote cognitive testing
218918651|NCT06588114|OTHER|Antistress Ball|Hemodialysis patients will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention
218918652|NCT06588114|OTHER|The Valsalva maneuver|The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm.
218918653|NCT06588114|OTHER|Skin cooling|Hemodialysis patients will be provided with lowering of skin temperature with a skin cooling device by the researcher for 10 minutes before arteriovenous fistula intervention is made to hemodialysis patients
219042402|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
219532708|NCT00059306|DRUG|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
219532709|NCT00059306|OTHER|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
219617330|NCT01959633|DRUG|Cobimetinib|Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
219042403|NCT06094270|DEVICE|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
219042404|NCT05121519|OTHER|Consume coffee|Drink coffee regularly (recommend at least 1 cup of caffeinated coffee or one shot of espresso per day)
219042405|NCT05121519|OTHER|Avoid coffee|Abstain from coffee and other caffeinated products
219532710|NCT00059306|OTHER|placebo|an inactive substance
219617331|NCT03511027|DEVICE|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
219617332|NCT03511027|OTHER|SME only|At discharge, participants will be provided with self-medication education.
219617333|NCT04825392|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
219617334|NCT06468592|PROCEDURE|Tilted insertion of implants|Using osteotomes, implants are inserted and tilted from 30° to 45° into the palatal direction from the maxillary sinus.
219532711|NCT06056817|DEVICE|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
218918654|NCT06604052|PROCEDURE|Reduced-Port Fusion Surgery|(1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon\&#39;s trocar placement plan and the stoma therapist\&#39;s positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.
218918655|NCT06604052|PROCEDURE|Traditional surgery|(1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.
218918656|NCT06590805|PROCEDURE|Electrotherapy using Chattanooga stimulation unit|Electroacupoint stimulation using the Chattanooga intellect transport 2-channel electrotherapy stimulation unit 2783. It uses the influences energy flows by needling the acupuncture points which lie along the body meridians to achieve a harmonious balance between physical, emotional, and spiritual states. The same effect can be achieved without the use of needles. These needleless stimulations are noninvasive and nontraumatic and are useful for individuals who are scared of needles. They are also associated with decreased risk of infection or bruise.
218918657|NCT06590805|DIETARY_SUPPLEMENT|Balanced Diet using domperidone drug, iron, and folic acid supplementation.|"Postnatal care diet in form of balanced diet using domperidone drug, iron, and folic acid supplementation. Additionally, drinking sufficient clean water and routine postnatal care.~It was performed by asking the participant to take ten mg domperidone three times a day after meals. Iron and folic acid supplementation were also continue for three months after birth."
218918658|NCT05523089|DRUG|Saline placebo|Sterile normal saline for injection
218918659|NCT05523089|COMBINATION_PRODUCT|CD388|CD388 liquid for injection
218918660|NCT06996418|OTHER|Intergenerational mealtime (intervention + follow-up)|Intergenerational lunchtime at an intentional intergenerational dining room 4 days a week for 8 weeks. Once this period is over, this group will move on to a follow-up phase that will last for another 8 weeks, during which they will eat 5 days a week in different dining rooms with their generational peers, as they had been doing up to the time of the intervention. Finally, they will undergo a last follow-up period of about 2 weeks.
218918661|NCT06996418|OTHER|Intergenerational mealtime (wait + intervention)|Waiting period consisting of 8 weeks (while Intervention Group #1 is using the intergenerational dining room). During this period toddlers and older people will eat lunch 5 days a week with their generational peers in separate dining rooms as they have been doing before the intervention. They will then move to eating together lunch 4 days a week for 8 weeks in the intergenerational dining room. Once this period is over they will enter a final follow-up phase for about 2 weeks during which they will go back to eat in generationally separate dining rooms.
218918662|NCT03928132|BEHAVIORAL|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
218918663|NCT06998758|DRUG|Megestrol Acetate|Oral megestrol acetate at 625 mg/day is given from the beginning to the end of neoadjuvant chemotherapy.
218918664|NCT06998108|DRUG|BEBT-209 capsules|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
218918665|NCT06998108|DRUG|BEBT-209 Placebo capluses|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
218918666|NCT06998108|DRUG|Fulvestrant Injection|500 mg intramuscular injection, with a 28-day treatment cycle. Administration on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle.
218918667|NCT06604403|OTHER|Massage|After the hemodialysis, the patients will receive a 15-20 minute hand and foot massage. This application will be applied to the patients in two weekly dialysis sessions for a total of 8 sessions for four weeks. Before starting the massage applications, the patient's hands and feet will be washed and dried thoroughly. The patients will be given a semi-sitting or lying position that they can feel comfortable in. Before starting the hand and foot massage, the researcher will gently rub and warm their hands and wrists. The massages will start with a hand massage. A foot massage will be performed after the hand massage. 3-5 drops of baby oil applied at room temperature will be used to reduce friction during the massage. Effleurage, petrissage and friction styles of the massage will be applied.
219532712|NCT05030363|DRUG|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
219532713|NCT03001063|OTHER|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
219532714|NCT03001063|OTHER|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
219532715|NCT04701541|DEVICE|Diaphragmatic Ultrasound|Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
218918668|NCT07000071|DEVICE|NCPAP|Apply nasal continuous positive airway pressure in intubated patients with respiratory distress at time of weaning
218918669|NCT07000071|DEVICE|NIPPV|Apply nasal intermittent positive pressure ventilation in intubated patients with respiratory distress at time of weaning
218918670|NCT07000071|DEVICE|NHFOV|Apply nasal high frequency ventilation in intubated patients with respiratory distress at time of weaning
218918671|NCT06604585|BEHAVIORAL|Parenthood - a journey together. Digital tool to increase security in parenthood, a way to promote public health..|"The project involved the development of an internet-based parental support program to be delivered via the national Support and Treatment (Sob) platform and used in primary care to enhance traditional parental support within child healthcare, as needed. The innovation has been developed in collaboration with the Innovation Fund in Västra Götaland. The aim is to increase the experience of parental competence and a sense of security in parenting by reflecting on attitudes and approaches in interaction with the child through an interactive, digital parental support program. The four themes in the parental support program, Parenthood a journey together, are named: Being a good enough parent, understanding one's child, interacting with one's child, and meeting daily challenges as a parent regarding food, sleep, play, screen time, and physical activity. The four modules will include explanatory and psychoeducational texts, written exercises, videos, and homework."
218918672|NCT06998732|DRUG|remimazolam sedation|remimazolam sedation
218918673|NCT06601972|PROCEDURE|Beautifil II LS (Low-Shrinkage)|The most remarkable feature of this light-cured universal composite for anterior and posterior restorations is its unique shrinkage of 0.85 percent by volume
218918674|NCT06601972|PROCEDURE|Nanohybrid resin composite|Nanohybrid resin composites are the most popular, because they improve the distribution of fillers in the matrix by combining nanoparticles with submicron particles to achieve better mechanical, chemical, and optical properties
218918675|NCT06998511|OTHER|interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention|The observation group received interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention based on the COM-B model on the basis of routine care.
218918676|NCT06998511|OTHER|routine nursing intervention|The control group received routine nursing intervention, including basic drug treatment, diet and exercise guidance, psychological counseling, etc.
218918677|NCT06998654|BEHAVIORAL|Muli-app|The Muli-app is designed after a traffic-light model, indicating different levels of severity of emotional distress and need for help. Green parts represent self-management measures that can be taken to try to regulate themselves (coping plan, write notes for their next appointment , and exercises to reduce emotional distress.) Yellow parts represent contact-based measures when the patient needs someone to talk to outside office hours, to de-escalate emotional distress and to avoid further crisis. This function connects study participants with mental health professionals at the local psychiatric hospital outside office hours (chat, phone or videocall). When the patient activates this function, the staff at the local hospital have 30 minutes to reply. The red part also activates contact with the local psychiatric hospital, but with a need of acute response, activating acute measures stated in the coping plan, such as access to an open bed in the municipality.
219042406|NCT04644094|OTHER|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
219042407|NCT05634278|BEHAVIORAL|Preoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
219042408|NCT05634278|BEHAVIORAL|Postoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
219042409|NCT05634278|BEHAVIORAL|Mind wandering|"A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander."
219042410|NCT00046033|DRUG|Lopinavir/ritonavir|
219042411|NCT00046033|DRUG|Ritonavir|
219532716|NCT02130518|DRUG|Auriclosene Irrigation Solution, 0.2%|
219532717|NCT02130518|DRUG|Auriclosene Vehicle Solution|
219532718|NCT00995241|DRUG|Raltegravir|Raltegravir 800 mg / 24 hours.
219617335|NCT06468592|PROCEDURE|Straight insertion of implants|The implants are inserted in an axial direction into the maxillary sinus according to Summers' traditional technique.
219617336|NCT05373108|DRUG|Macitentan|Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
219617337|NCT05579028|DIETARY_SUPPLEMENT|Nutridrink ONS 200 ml|Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
219617338|NCT01185327|BEHAVIORAL|Breastfeeding|Breastfeeding
219617339|NCT03854760|BEHAVIORAL|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
219042412|NCT00046033|DRUG|Saquinavir|
219042413|NCT00046033|DRUG|Tenofovir disoproxil fumarate|
219042414|NCT00046033|DRUG|Amprenavir|
219042415|NCT04413123|DRUG|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
219042416|NCT04413123|DRUG|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
219042417|NCT04413123|DRUG|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
219042418|NCT06197789|BIOLOGICAL|TPX-105|Subjects will be administered with autologous fibroblasts through injection
219042419|NCT06197789|BIOLOGICAL|Placebo|Subjects will be administered with Placebo through injection
219532719|NCT04511910|PROCEDURE|Early Laparoscopic Cholecystectomy|
219532720|NCT00451412|DRUG|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
219532721|NCT00451412|DRUG|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
219532722|NCT00019812|BIOLOGICAL|trastuzumab|
219532723|NCT00019812|DRUG|paclitaxel|
219532724|NCT03617523|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219532725|NCT03617523|BIOLOGICAL|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219532726|NCT03617523|BIOLOGICAL|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219532727|NCT02408302|DRUG|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
218918678|NCT06602609|OTHER|Remote Patient Monitoring Strategy|Continuous remote monitoring with the SmartCardia device includes continuous heart rate and cardiac conduction rhythm tracking through a 7-lead ECG enhanced by machine learning. This system can detect cardiac rhythm disturbances, measure breathing and heart rate, and provide live-alert notifications. Daily 12-lead ECG will be collected from each patient for 7 days after discharge; patients are instructed to perform a daily 12-lead ECG on the SHL device, along with recording blood pressure and oxygen saturation levels. Each ECG is interpreted by the trial team, and a cardiologist\&#39;s interpretation is confirmed, and patients will undergo remote consultations with a cardiologist or research nurse each day if needed. During the initial 30 days of patient recruitment, if the individual exhibits potential cardiac symptoms, they can activate a remote consultation by performing an extra 12-lead ECG and recording blood pressure and oxygen saturation levels.
219532728|NCT00421850|BEHAVIORAL|UNITED Planned Care|
219617340|NCT05138861|DRUG|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
219617341|NCT06132061|OTHER|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
218918679|NCT06602609|OTHER|Standard Medical Therapy|No intervention is required. Patients in this arm will fill out a self-reported anxiety report (SHAI form) and provide recent admission information
218918680|NCT06593795|PROCEDURE|ultrasound|"before ECV procedure, an ultrasound will be performed to evaluate~* fetal biometry (BPD, HC, AC, FL, EFW);~* Occiput position (right, left);~* Back position (anterior, posterior, right, left);~* Breech variant (footling, frank, complete);~* Fetal leg posture (extended, flexed)~* Placental localization;~* Amniotic Fluid Index (AFI);~* Fore-bag of amniotic fluid;~* Eventual presence of nuchal cords;~* Fetal head ballottement (yes, no);~* Occiput-spine angle These parameters will be compared to find predictive factors for successful ECV"
218918681|NCT06587620|DRUG|Tranexamic acid|Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
218918682|NCT06587620|DRUG|Dexmedetomidine|Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
218918683|NCT06587620|OTHER|Saline (NaCl 0,9 %) (placebo)|IV infusion of 50 ml saline over 10 min before induction of anesthesia. IV saline infusion immediately after induction till 15 min before the end of surgery.
219042420|NCT01064557|DRUG|all-trans retinoic acid (ATRA)|
219042421|NCT04622553|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to \< 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to \< 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1"
219042422|NCT03241706|DRUG|Low Fructose|IV fructose (1.3 mg/kg/min)
219042423|NCT03241706|DRUG|Saline|Saline given as a comparison to fructose.
219042424|NCT03241706|DRUG|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
219042425|NCT03241706|DRUG|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
219042426|NCT03241706|DRUG|Glucagon|IV glucagon (0.65 ng/kg/min).
219617342|NCT06132061|OTHER|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
219617343|NCT06132061|OTHER|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
219617344|NCT06132061|OTHER|Waiting treatment.|Waiting treatment.
219532729|NCT04691895|OTHER|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
219532730|NCT05497921|DEVICE|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
219532731|NCT00801164|DRUG|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
219532732|NCT00801164|DRUG|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
219617345|NCT01522209|PROCEDURE|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
219042427|NCT03241706|DRUG|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
218918684|NCT06992856|PROCEDURE|Conventional colonoscope passage|Use conventional colonoscope passage through the sigmoid colon
218918685|NCT06992856|PROCEDURE|left colon water exchange colonoscope passage|Use left colon water exchange colonoscope passage through the sigmoid colon
218918686|NCT06992856|PROCEDURE|cap-assisted left colon water exchange colonoscope passage|Use cap-assisted left colon water exchange colonoscope passage through sigmoid colon
218918687|NCT06998160|OTHER|glycine subgingival sandblasting group and erythritol subgingival sandblasting group|Given glycine subgingival sandblasting group glycine subgingival sandblasting group. Swiss EMS ultrasonic therapy instrument and EMS glycine sandblasting were used. Before the operation, both parties should wear safety glasses and place the mouth opener after the patient gargled. The location of sandblasting was selected to be 1-2 mm below the gingiva. During the operation, the time of sandblasting in the planting area should be controlled within 10 minutes, and then the time of sandblasting at other sites with the same amount of water and power should be controlled within 5s. After sandblasting, the patient's mouth was continuously rinsed with normal saline for 20s. After the operation, the patient was informed of the precautions after the operation, and the patient was instructed to master the correct oral maintenance method, pay attention to maintaining the cleanliness around the implant, and adhere to regular periodontal maintenance.
218918688|NCT06998160|OTHER|control group|The control group was given ultrasonic subgingival curettage. With Swiss EMS ultrasonic therapy instrument, both the operator and the patient should wear safety goggles before operation. After the operator guides the patient to gargle, the mouth opener should be placed to perform ultrasonic subgingival curetting. The debridement time of the implant area should be controlled within 6 minutes, and the debridement time of other sites should be 5 s.
218918689|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|Sham tPCS current will be delivered through Channel 1, while active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via surface electrodes. The placement of electrodes will be exactly the same as the active tPCS montage.
218918690|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|This group will receive active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via 6\*9cm Silica gel electrodes on top of the tPCS that is delivered through Channel 1. The placement of the electrodes will be on the part of the spinal segment innervating the lower limbs (L1-L5), the adductor muscles and the gastrocnemius muscles.
218918691|NCT06998173|DRUG|DAT-1604 tablet|DAT-1604, a potent and selective oral small molecule inhibitor of DNA Polymerase θ (Pol θ).
218918692|NCT06998901|OTHER|FIFA 11+ Kids training program|Participants in this arm will receive the FIFA 11+ Kids training program in addition to their regular basketball practice. The program consists of structured neuromuscular warm-up exercises designed to improve balance, coordination, strength, and overall movement control. It will be implemented over a period of 7 weeks, with sessions conducted four times per week, each lasting approximately 15-20 minutes. The exercises are age-appropriate and follow a progressive format to enhance athletic performance and reduce injury risk in youth athletes.
218918693|NCT06998004|BIOLOGICAL|AVX70120 low dose level|Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
219042428|NCT03241706|DRUG|High Fructose|IV-fructose (6.5 mg/kg/min)
219042429|NCT05255770|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
219617346|NCT01522209|DEVICE|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
219617347|NCT01522209|RADIATION|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
219617348|NCT01522209|RADIATION|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
219042430|NCT05255770|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
219532733|NCT01074203|DRUG|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
219532734|NCT03137251|DEVICE|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
219532735|NCT03137251|DEVICE|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
219532736|NCT03137251|DEVICE|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
219617349|NCT07056920|PROCEDURE|Zirconia shell technique|Customized Zirconia membrane will be printed as a porous shell and will be used as a non resorbable membrane for horizontal ridge augmentation of deficient posterior mandibular region.
219617350|NCT06839170|OTHER|FM-IRDs assisted|A Foundation Model for Assisting the precision Diagnosis of Inherited Retinal Diseases: FM-IRDs
219617351|NCT06839170|OTHER|without FM-IRDs|without FM-IRDs
218918694|NCT06998004|BIOLOGICAL|AVX70120 middle dose level|Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
219532737|NCT04606628|OTHER|Eggshell membrane (ESM)|The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.
218918695|NCT06998004|BIOLOGICAL|AVX70120 high dose level|High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
218918696|NCT06998004|BIOLOGICAL|AVX70481 low dose level|Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
219532738|NCT04606628|OTHER|Placebo|The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks
218918697|NCT06998004|BIOLOGICAL|AVX70481 middle dose level|Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
218918698|NCT06998004|BIOLOGICAL|AVX70481 high dose level|High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
218918699|NCT06998004|OTHER|Placebo|Placebo
218918700|NCT06999889|DIAGNOSTIC_TEST|Recording of Periodontal Parameters.|Periodontal Parameters recording in terms of various indices,measurements and radiographs.
218918701|NCT06999369|OTHER|MedChef App|Once patients have been randomized to the MedChefs arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use.
218918702|NCT06999369|OTHER|MedChefs and Instacart food voucher|Once patients have been randomized to the MedChefs arm and voucher arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use and use of Instacart food vouchers. Patients will also be given a $100 voucher to buy food recommended by the app. Vouchers will be provided once a month for the 6 months of the study
218918703|NCT06998940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218918704|NCT06998940|PROCEDURE|Computed Tomography|Undergo CT scan
218918705|NCT06998940|DRUG|Fluorouracil|Given IV
218918706|NCT06998940|DRUG|Gemcitabine|Given IV
218918707|NCT06998940|DRUG|Irinotecan|Given IV
218918708|NCT06998940|DRUG|Irinotecan Sucrosofate|Given IV
218918709|NCT06998940|DRUG|Leucovorin|Given IV
218918710|NCT06998940|DRUG|Nab-paclitaxel|Given IV
218918711|NCT06998940|BIOLOGICAL|Panitumumab|Given IV
219532739|NCT04865653|DRUG|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
219532740|NCT04865653|DRUG|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
219532741|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
219532742|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
219532743|NCT04865653|OTHER|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
219532744|NCT03383354|OTHER|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
219532745|NCT02757105|DRUG|BEKINDA|
218918712|NCT06998940|OTHER|Questionnaire Administration|Ancillary studies
218918713|NCT06999681|OTHER|No Interventions|this is an observational cohort study. There was no intervention.
218918714|NCT06999681|OTHER|No interventions|No interventions in this study. This study is an observational study.
218918715|NCT06998316|OTHER|Screening questionnaire|Every patient will answer the 2 screening questionnaires given to them, once at baseline and a second time after 1 month.
218918716|NCT06999070|DRUG|Dexamethasone 0.1mg/kg|On incidence of Shivering after spinal anaethesia
218918717|NCT06999070|DRUG|Dexamethasone 0.3mg/kg|On incidence of Shivering after spinal anaethesia
218918718|NCT06999967|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|All study subjects will undergo monitoring via a portable electroencephalogram (pEEG), the CGX EEG system (a Research-grade 2-Channel EEG device) to measure the brainwaves of patients admitted to Stanford Medical Center. Investigators will then use the Lucidify software to allow for the interpretation of obtained brainwaves for the detection of delirium .
218918719|NCT06999343|DRUG|Metformin 850Mg Tab|Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.
218918720|NCT06999343|OTHER|Placebo|Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.
218918721|NCT06999551|DRUG|switch NPH to glargin|Switch of patients with type 2 diabetes mellitus from NPH insulin to insulin glargine
218918722|NCT05491811|DRUG|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
218918723|NCT05491811|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
218918724|NCT05270759|DIAGNOSTIC_TEST|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
218918725|NCT05270759|DIAGNOSTIC_TEST|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
219532746|NCT02757105|DRUG|Placebo|
219532747|NCT01401647|DRUG|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
218918726|NCT04167657|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab."
218918727|NCT06999031|BIOLOGICAL|BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell|Chimeric Antigen Receptor Autologous T-cell
218918728|NCT06541574|DRUG|Methotrexate Injection|Methotrexate injection
218918729|NCT06541574|DRUG|Methotrexate Infusion|Methotrexate Infusion
218918730|NCT06541574|DRUG|Sham Injection|Sham Injection
218918731|NCT06602700|BEHAVIORAL|HIIT|high-intensity interval training
218918732|NCT06602700|BEHAVIORAL|MICT|moderate-intensity continuous training
218918733|NCT06867380|DEVICE|Investigational sound coding strategy|SPARC (Stimulation Place and Rate Coding) sound coding strategies
218918734|NCT06867380|DEVICE|Cochlear default sound coding strategy|ACE (Advanced Combination Encoder) sound coding strategy
218918735|NCT06407921|DEVICE|Whole Body Vibration|On vibration plate pate child will do kneeling, and one leg standing, standing horizontally or vertically. Along routine physical therapy such as stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, elbow and wrist flexors, pronators, and ulnar deviators, each stretch will be given for 30 seconds with 3 repetitions.Strength training to hip flexor, knee extensor, and ankle dorsiflexors for 15 minutes 3 times a week for 8 weeks. Session will be of 30 minutes
218918736|NCT06407921|DEVICE|BOSU ball|Exercises such as (1) standing on a BOSU ball while throwing and catching a ball (2) 1-legged standing (affected leg) on the BOSU ball while throwing and catching a ball with therapist support; and (3) small jumps on the BOSU ball. Three sets of 6 repetitions for each exercise will be perform every 2 weeks up to a maximum of 10 repetitions if the participants were still able to perform the training easily. Total dose of balance training in 1 session will be 15 minutes
218918737|NCT04276870|BIOLOGICAL|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
218918738|NCT06089668|OTHER|Observational Study|None, this is a non-interventional trial
218918739|NCT05010629|DRUG|9-ING-41|Intravenous infusion
218918740|NCT05010629|DRUG|Carboplatin|Intravenous infusion
218918741|NCT06871267|BEHAVIORAL|General Healthy Diet|Participants will follow the quarter-quarter-half plate diet as per the Malaysian Healthy Plate guideline.
218918742|NCT06871267|BEHAVIORAL|Crohn's Disease Exclusion Diet (CDED)|Participants will follow the Crohn's Disease Exclusion Diet (CDED), which consists of three phases with specific dietary restrictions.
218918743|NCT06601582|DEVICE|Use of a operative blood salvage system|The surgical team will use a operative blood salvage system
218918744|NCT06596200|DEVICE|Spinal Cord Stimulation Implant|Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord
218918745|NCT05950035|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
218918746|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
218918747|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
218918748|NCT05950035|BEHAVIORAL|Waitlist|Waitlist for delayed intervention.
219042431|NCT05255770|DEVICE|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
219042432|NCT05581979|DIAGNOSTIC_TEST|68-Ga PSMA PET scan|"On the scheduled visit date for the study,~* An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes.~* PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously."
219532748|NCT01401647|DRUG|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
219532749|NCT01401647|OTHER|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
219532750|NCT00546988|BIOLOGICAL|allogeneic stem cell transplant|
218918749|NCT06690359|COMBINATION_PRODUCT|IM19 chimeric antigen receptor T cell injection|"IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose"
218918750|NCT05229887|PROCEDURE|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
218918751|NCT05229887|PROCEDURE|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
218918752|NCT06586697|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
218918753|NCT06596057|BIOLOGICAL|CAR-T/CAR-NK cells|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion
218918754|NCT05030597|DRUG|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
218918755|NCT05030597|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
218918756|NCT05030597|DIAGNOSTIC_TEST|Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.|"This observational study evaluates the application of paired FDG and FAPI PET/CT in oral cancer.~1. Baseline phase: All participants undergo baseline FDG and FAPI PET/CT scans.~2. Post-neoadjuvant phase: For patients with resectable locally advanced disease receiving neoadjuvant therapy (as per clinician decision), a second FAPI PET/CT scan is performed after 2 cycles of treatment to assess treatment response.~3. Purpose: To explore the utility of FAPI PET in (a) initial staging, (b) treatment response evaluation, and (c) prognostic value in oral cancer."
218918757|NCT04935372|OTHER|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
218918758|NCT06599775|DRUG|Adebrelimab injection|Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
219532751|NCT00471419|DRUG|Rimexolone|
219532752|NCT01457716|DRUG|Budesonide|Single inhalation
219532753|NCT01457716|DRUG|Formoterol|Single inhalation
219532754|NCT01457716|DEVICE|Easyhaler|Inhaler device
219532755|NCT01457716|DEVICE|Turbohaler Forte|Inhaler device
219532756|NCT04156919|BEHAVIORAL|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
219532757|NCT04156919|OTHER|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
219532758|NCT00752973|DRUG|MALG (malathion) Treatment|MALG applied for 30 minutes
219532759|NCT01862627|PROCEDURE|Optical coherence tomography|
219532760|NCT03034694|OTHER|teledermatology consult|teledermatology consult
219532761|NCT03034694|OTHER|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
219532762|NCT05428020|DEVICE|Indwelling foley catheter|short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
219532763|NCT05428020|OTHER|No foley catheter|No foley catheter is placed for surgery
219532764|NCT02261857|DEVICE|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
219532765|NCT03600480|DRUG|NNC0174-0833|Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
219532766|NCT03600480|DRUG|Semaglutide|Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
219532767|NCT03600480|DRUG|Placebo (NNC0174-0833)|Participants will receive once weekly injections of NNC0174-0833 matched placebo.
219532768|NCT00473330|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
219532769|NCT00473330|DRUG|Sham injection|
219532770|NCT03888430|PROCEDURE|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
219532771|NCT01975948|OTHER|Mental Health Practice Support Program|"1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
218918759|NCT06599775|DRUG|Albumin-Bound Paclitaxel|Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
218918760|NCT06599775|DRUG|Carboplatin injection|Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
218918761|NCT06695130|BIOLOGICAL|RIV (recombinant influenza vaccine)|Influenza, inactivated, split virus or surface antigen
218918762|NCT06695130|BIOLOGICAL|rC19 (dose 1)|Protein subunit
218918763|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 1)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
218918764|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 2)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
218918765|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 3)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
218918766|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 4)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
218918767|NCT06695130|OTHER|Placebo (0.9% NaCl)|Normal saline
218918768|NCT06630598|BEHAVIORAL|Online Family Violence Education Resource|"The VEGA Family Violence Education Resources (© 2020 VEGA Project, McMaster University) is an on-line suite of educational resources that target professionals who are likely to encounter survivors of family violence in professional and clinical settings. The resources provide information about family violence, appropriate clinical responses, legal obligations, and more. The resources are broken down into several training modules and include three interactive learning scenarios. The training modules include:~Know About Family Violence in Canada Creating Safety Recognizing and Responding Safely to Child Maltreatment Recognizing and Responding Safely to Intimate Partner Violence Voices of those with Lived Experiences of Family Violence"
218918769|NCT06448117|BEHAVIORAL|Mind Nutrition|"The 6-month nutrition intervention includes two individual and three group dietary counseling sessions. During the first individual meeting, a research dietitian will assess the participants' diet quality and eating habits, and each participant will set personal goals in cooperation with the research dietitian. At the second individual meeting, the attainment of the goals will be evaluated, and potential challenges and solutions discussed. Each group session has its theme and content in the following chronological order:~1. Introduction to the theme and importance of a regular meal frequency~2. Principals of health-promoting diet, mindful eating~3. Successful eating regulation skills, psychology of the long-term lifestyle changes.~Additionally, participants receive home assignments and a workbook containing informational material and exercises."
218918770|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
218918771|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
218918772|NCT05884645|PROCEDURE|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
218918773|NCT03600233|DRUG|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
218918774|NCT06701864|DIAGNOSTIC_TEST|Palpation|Identification of the cricothyroid membrane using PALPATION, a procedure used to prepare for front of neck airway access
219042433|NCT02180282|DEVICE|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
219042434|NCT00319826|OTHER|No intervention|This is an observational study with no intervention
219532772|NCT01975948|OTHER|Treatment as Usual|Physicians manage patients with depression as usual
219532773|NCT04807439|DEVICE|SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries \>3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
219532774|NCT01675765|BIOLOGICAL|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
218918775|NCT06701864|DIAGNOSTIC_TEST|Ultrasound|"Identification of the cricothyroid membrane, using ULTRASONOGRAPHY with either the String of pearls or TACA aproach as chosen by the participant , a procedure used to prepare for front of neck airway access"
219042435|NCT05422053|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
219532775|NCT01675765|BIOLOGICAL|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
218918776|NCT06632639|OTHER|Corrective exercise protocol|The program requires 60 minutes consisting of a ten-minute warm-up, a forty-minute Thera-band exercise, and a ten-minute cool-down. Thera-band exercises are to improve the external rotators, and the extensors and for strengthening the quadriceps and the gluteus. A set consists of 15 reps, each of the exercise methods consisted of three sets.
218918777|NCT06632639|OTHER|Lateral wedged insoles with subtalar strapping|A silicon rubber 10 mm lateral wedge has a 10 mm lateral elevation and a 75 mm width, which has an approximately 7.6 inclination. This silicon rubber material is usually used for cosmetic remodeling and has a natural form-fit to the skin. The 75 mm width silicon rubber is scaphoid shaped and it is suitable for attachment to a barefoot of all of the subjects. The rational for using this inclination is that 7.6 is approximately the median between 5 and 10. Patients will be instructed to use the wedge in an appropriate shoe (not high heels or narrow-toed shoes), 1 h a day during the first week. The duration of use gradually will be increased to the minimum of 8 h a day.
218918778|NCT05801120|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
218918779|NCT06700304|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
218918780|NCT06700304|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
218918781|NCT06702072|DEVICE|Endobronchial valve treatment|Endobronchial valve treatment
218918782|NCT06700473|OTHER|reiki|Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with a seventh VAS measurement and administration of the EC-4. The EC-4 will also be reassessed by the researchers online at six weeks postpartum
218918783|NCT06879626|OTHER|Pecan|2 oz of whole raw pecans
218918784|NCT06879626|OTHER|Pretzel|3.5 oz of pretzel snacks daily
218918785|NCT06704893|DRUG|ASA injection 40 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
218918786|NCT06704893|DRUG|ASA injection 20 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
218918787|NCT06704893|DRUG|HA injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
218918788|NCT06704893|DRUG|Normal saline injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
218918789|NCT06705361|DEVICE|Transparent Radial Artery Band (Screw-Type)|The researcher will randomly assign patients undergoing radial arterial line removal after open heart surgery into four groups: ice-bag pressure, transparent radial band compression device (screw type), transparent radial band compression device (air type), and control group. The researcher will assign specific card colors to each group: white for the control group, yellow for the ice-bag pressure group, pink for the Transparent Radial Band Compression Device - Screw Type group, and green for the Transparent Radial Band Compression Device - Air Type group. The researcher will place all these cards in a container, allowing the participant to select their preferred color, and then apply the intervention separately to each group.
218918790|NCT06706583|BEHAVIORAL|Telematic educational interviews + standard training|"Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview.~In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA)."
218918791|NCT06706583|BEHAVIORAL|Standard training|Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).
218918792|NCT06706297|OTHER|pranayama breathing exercise|Normal breathing, focusing on breathing, Alternative Nose Breathing, Cooling Breath, Bee Buzzing Sound, A breathing exercise of 20 minutes in total, consisting of 5 stages: normal breathing and focusing on breathing.
218918793|NCT06706193|PROCEDURE|Total hip arthroplasty using CPE|
218918794|NCT06706193|PROCEDURE|Total hip arthroplasty using HXLPE|
218918795|NCT06880341|OTHER|Standard of Care|Standard of care treatment of Transient Neurologic Events (TNEs) as needed
218918796|NCT06704490|OTHER|Cesarean section|Observational study without intervention
219042436|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
219532776|NCT01152840|DRUG|RAD001|"RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn."
218918797|NCT06706050|BIOLOGICAL|Microbiome Therapeutic LP-51|Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis
218918798|NCT06706050|OTHER|placebo cream (M23004-03)|placebo cream (M23004-03) was applied on the participants
218918799|NCT06704828|DRUG|SHR-4602|SHR-4602
218918800|NCT06705803|PROCEDURE|Prostate Ablation|Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
218918801|NCT06884592|PROCEDURE|Difficult Intubation|Determination of difficult intubation, according to the Cormack-Lehane scale, intubation will be considered easy for grade I or II and difficult for grade III or IV. If intubation could not be performed with the Macintosh laryngoscope in three attempts, the next step would be to perform intubation with the videolaryngoscope and the third step would be to place the laryngeal mask airway (LMA). The correct position of the tube in the trachea will be confirmed after intubation, preferably by visual confirmation of the tube passing through the glottic opening, auscultation of the chest with a stethoscope and a normal capnograph. If the LMA attempt fails, the patient will be allowed to awaken, with the final step being ventilation using a face mask and consideration of reversing the muscle relaxant effect with sugammadex (4-5 mg/kg). If intubation fails on the first attempt, an intubation stylet will be used if necessary. The intubation method used, total number of attempts for successful i
218918802|NCT06704880|OTHER|rehabilitation|children in the CIMT group will RECIEVE lower limb CIMT for the non-hemiplegic limb using whole leg orthosis. Children in cross-education group will receive strengthening training for the non-hemiplegic lower limb
218918803|NCT06705036|OTHER|surgery|Samples were obtained from patients by surgical excision and matched into groups
218918804|NCT06706635|DEVICE|Application of App|Full Access to Mobile App
218918805|NCT06704854|DIAGNOSTIC_TEST|Screening Platform|assessment of low-frequency fatigue using myocene
218918806|NCT06704984|BEHAVIORAL|Intervention Name: WeChat Intervention Based on the IMB Model|A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
218918807|NCT06706648|BEHAVIORAL|Nursing-Led Psychological Capital Interventions|The participating nurses received session about Nursing-Led Psychological Capital Interventions
218918808|NCT06704659|RADIATION|Breast conserving surgey and radiotherapy|The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
218918809|NCT06704659|PROCEDURE|Mastectomy|The patients will undergo mastectomy
218918810|NCT06704581|DRUG|5 mg BGM0504 injection|5mg BGM0504 injection administered subcutaneously (SC) once a week.
219042437|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
219042438|NCT05007782|DRUG|Denikitug|Administered Intravenously
219042439|NCT05007782|DRUG|Zimberelimab|Administered Intravenously
219042440|NCT05162911|BEHAVIORAL|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
219042441|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
218918811|NCT06704581|DRUG|10 mg BGM0504 injection administered subcutaneously (SC) once a week|10mg BGM0504 injection administered subcutaneously (SC) once a week.
218918812|NCT06704581|DRUG|15 mg BGM0504 injection|15mg BGM0504 injection administered subcutaneously (SC) once a week.
218918813|NCT06704581|DRUG|BGM0504 placebo|BGM0504 placebo administered SC once a week.
218918814|NCT06705179|BEHAVIORAL|Behavioral task performance|Measures of performance on behavioral tasks
218918815|NCT06917742|DRUG|CPTX2309|Single Escalating Dose of CPTX2309. CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
218918816|NCT06917742|DRUG|CPTX2309|Multiple Escalating Dose of CPTX2309.CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
218918817|NCT06656988|DRUG|CO2|CO2 will be used as contrast medium sparing strategy during peripheral angiography
218918818|NCT06656988|DRUG|Iodinated Contrast Media (ICM)|Iodinated contrast medium will be used as in routine care during peripheral angiography
218918819|NCT02077010|DRUG|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
218918820|NCT06736340|DRUG|Rupatadine|10mg tablets
218918821|NCT06604455|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
219042442|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
219532777|NCT05218772|OTHER|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
219532778|NCT01111864|DIETARY_SUPPLEMENT|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
218918822|NCT06604455|OTHER|acupressure/relaxation|The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
218918823|NCT06748209|DEVICE|Left prefrontal Transcranial Magnetic Stimulation (TMS)|FDA cleared TMS
218918824|NCT06748209|DEVICE|FDA cleared TMS for treating depression|This is FDA approved TMS
218918825|NCT06754670|DRUG|Sodium Glycerophosphate 216 MG/ML|Low phosphorus patients receive intravenous phosphate supplementation according to the clinical phosphate supplementation protocol at our center: patients with blood phosphorus \< 0.4mmol/L receive 40mmol of glycerol phosphate sodium intravenously via infusion or injection over 4-6 hours; patients with blood phosphorus 0.4-0.8mmol/L receive 30mmol of glycerol phosphate sodium intravenously via infusion or injection; Normal phosphorus patients do not require any special treatment.
218918826|NCT06874478|DIAGNOSTIC_TEST|Ultrasound|The main pulmonary artery will be seen between the pulmonary valve and the bifurcation of the right and left branches. The pulsed Doppler sample gate will be adjusted to 3 mm, and the angle of insonation will be kept at or around 15°. Doppler gain and scale will be tailored for optimizing the velocity waveform display, clearly showing the peak systolic velocity (PSV) and early diastolic notch. The MPA Doppler waveform will show a sharp systolic peak blood flow with a needle-like appearance. After the optimum fetal main pulmonary artery waveform, Doppler velocity will be manually traced three times, and the average will be taken.
218918827|NCT06839105|DRUG|Taxol|135\~175 mg/m2, Q3W
218918828|NCT06839105|DRUG|Cisplatin or Carboplatin|Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
218918829|NCT06839105|DRUG|Pemetrexed|500 mg/m2, Q3W
218918830|NCT06839105|DRUG|Oxaliplatin|130 mg/m2, Q3W
218918831|NCT06839105|DRUG|Capecitabine|1000 mg/m2, BID, day1-14, oral, q3w
218918832|NCT06839105|DRUG|Bevacizumab|7.5 mg/kg, Q3W
218918833|NCT06839105|DRUG|Renvastinib|8mg or 20mg, QD
218918834|NCT06839105|DRUG|AWT020|q3w or q2w, i.v.
218918835|NCT05844501|DRUG|Ondansetron 8mg|Ondansetron 8 mg orally twice daily for 28 days
218918836|NCT05844501|DRUG|Placebo|Matched placebo orally twice daily for 28 days
218918837|NCT06780891|BEHAVIORAL|Telephysical therapy|The experimental group is undergoing a tele-assisted therapeutic exercise program (T-TPT/T-FIS), which involves physical exercises aimed at improving cardiovascular fitness, muscle strength, and balance, among others. Participants will complete exercises under virtual supervision and submit progress reports.
219532779|NCT01111864|DIETARY_SUPPLEMENT|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
219532780|NCT03082872|DEVICE|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
219532781|NCT03082872|DEVICE|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
219532782|NCT00260650|BEHAVIORAL|Heart PACT Program|patient activation intervention
219532783|NCT05253950|OTHER|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
218918838|NCT06780891|BEHAVIORAL|Educational session|The educational session will focus on raising awareness about stroke risk factors, such as hypertension, diabetes, and smoking, while promoting healthy lifestyle changes. The goal is to empower them with the knowledge to reduce stroke risk and improve overall well-being.
218918839|NCT06772363|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
218918840|NCT04498598|DEVICE|A/Z Supraglottic airway|Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
218918841|NCT00595088|BIOLOGICAL|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
218918842|NCT06903637|OTHER|Hierarchical Cluster Analysis|The complexity of clinical follow-up stems from the wide range of variables involved, such as physical performance, mobility, pain, psychological well-being, and prosthetic functionality. Therefore, developing methods to identify the most relevant and interrelated clinical variables is critical for enhancing patient management. To address this need, Hierarchical Cluster Analysis (HCA) offers a powerful multivariate statistical approach for detecting relationships among clinical variables.
218918843|NCT06878547|DEVICE|Ultrasound|Non-invasive breast imaging using VisR ultrasound
218918844|NCT04323124|DRUG|PF-07059013|Participants will recieve PF-07059013
218918845|NCT04323124|DRUG|Placebo|Participants will recieve placebo
218918846|NCT04074044|BEHAVIORAL|BHmApp|Use of BHmApp for bladder education and training in pregnancy
218918847|NCT00489307|DRUG|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
218918848|NCT00489307|DRUG|Placebo|Placebo PO twice daily x 14 days
218918849|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
218918850|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
218918851|NCT06904586|OTHER|Thyromental distance|Distance between the chin and thyroid cartilage with a tape measure when the patient is in a neutral position
218918852|NCT06904586|OTHER|Neck circumference|Measurement of neck circumference with a tape measure when the patient is in a neutral position
218918853|NCT06904586|OTHER|Mouth opening distance|Distance between the upper and lower teeth at the point where the mouth opening is maximum when the patient is in a neutral position.
218918854|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in neutral position|Distance from mentum to hyoid bone with neck in neutral position by ultrasonography
218918855|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in extension|Ultrasound measurement of distance from mentum to hyoid bone with neck in extension
218918856|NCT06904586|OTHER|Distance between skin and trachea|Ultrasound measurement of distance between skin and trachea
218918857|NCT06904586|OTHER|Distance between skin and epiglottis|Distance between skin and epiglottis measured by ultrasonography
218918858|NCT06904586|OTHER|Distance between skin and anterior commissure of vocal cord:|Distance between skin and anterior commissure of vocal cord measured by ultrasonography
218918859|NCT06904586|OTHER|Distance between skin and hyoid bone|Distance between skin and hyoid bone measured by ultrasonography
218918860|NCT06904586|OTHER|Maximum Tongue Thickness|Measurement of Maximal Tongue Thickness by Ultrasonography
218918861|NCT03894124|DRUG|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
218918862|NCT06831110|PROCEDURE|Aquagenic Wrinkling|Participants will be asked to remove all jewelry from the hand(s) and wrist(s) that will be undergoing the aquagenic wrinkling procedures. Photographs will be taken of the palmar surface of the hand(s). The participant will submerge the hand(s) undergoing testing in a water bath for one minute. After one minute, they will remove their hand(s), dry them gently with a towel, and photographs will be taken of the palmar surface of the hand(s). The participant will re-submerge their hand(s) in the appropriate conditions for another minute and the process will be repeated 20 times for 20 total minutes submerged in the water.
218918863|NCT06653387|DEVICE|CGuard Prime 80cm stent system|This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
218918864|NCT04965623|DEVICE|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
218918865|NCT03204188|DRUG|Ibrutinib|Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
218918866|NCT03204188|DRUG|Fludarabine|Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.
218918867|NCT03204188|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
218918868|NCT06924697|DRUG|Application of GLP-1RAs drugs|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs
218918869|NCT06924697|DRUG|DPP-4i group|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.
218918870|NCT03904849|DRUG|Cannabidiol|Cannabidiol oral solution
218918871|NCT03904849|DRUG|Placebo|Placebo oral solution
219042443|NCT01216475|PROCEDURE|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
219532784|NCT02135263|DRUG|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
219532785|NCT02135263|DRUG|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
219532786|NCT02834663|DRUG|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
219532787|NCT02986386|PROCEDURE|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
219532788|NCT02986386|PROCEDURE|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
219532789|NCT04325724|OTHER|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
219532790|NCT04325724|OTHER|Dermatological evaluation|treatment and evaluation
219532791|NCT04325724|OTHER|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
218918872|NCT06932991|BEHAVIORAL|Cognitive Remediation|cognitive remediation
218918873|NCT03651752|DRUG|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
218918874|NCT06944106|DRUG|AK112|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with gemcitabine and nab-paclitaxel
218918875|NCT06844383|DRUG|Talazoparib with enzalutamide|Talazoparib (0.5 mg PO QD) and enzalutamide (160 mg PO QD) will be administered in continuous 28-day cycles.
218918876|NCT06844383|DRUG|Talazoparib|Talazoparib (1 mg PO QD) will be administered in continuous 28-day cycles.
218918877|NCT04433065|DEVICE|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
219532792|NCT04325724|OTHER|para clinical data|biological data, medical imaging data
219532793|NCT04325724|OTHER|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
219532794|NCT04303663|PROCEDURE|Fibular Plate|ORIF with Plating
219532795|NCT04303663|PROCEDURE|Fibular Nail|CRIF +/- ORIF with Fibular nail
219532796|NCT00820586|PROCEDURE|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
218918878|NCT06955546|DRUG|Toothpaste Product|"Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/"
218918879|NCT06955546|DRUG|Mouthwash Product|"Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/"
218918880|NCT06955546|DIETARY_SUPPLEMENT|Probiotic|Patients received a daily tablet of Curasept Prevent Probiotics. Link at: https://curaseptspa.it/prodotti/curasept-prevent-probiotico-integratore-alimentare/
218918881|NCT06955546|OTHER|Placebo|Patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.
219617352|NCT01458665|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
219532797|NCT05570981|DIAGNOSTIC_TEST|Laryngeal sensitivity testing|Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
219532798|NCT00365846|DRUG|Campath-1H|
219532799|NCT02081612|BEHAVIORAL|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
219532800|NCT02081612|PROCEDURE|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
219532801|NCT04405570|DRUG|Molnupiravir 200 mg|Oral capsule of molnupiravir
219532802|NCT04405570|DRUG|Molnupiravir 400 mg|Oral capsule of molnupiravir
219617353|NCT01458665|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
219617354|NCT00695344|DRUG|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
219617355|NCT00695344|DRUG|azathioprine or mycophenolate mofetil|2 times per day during 2 years
219617356|NCT01257269|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
219617357|NCT03717155|DRUG|Avelumab|Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
219617358|NCT03717155|DRUG|Cetuximab|Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
218918882|NCT05118022|OTHER|Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system|Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
219617359|NCT03717155|DRUG|Gemcitabine|Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
219617360|NCT03717155|DRUG|Cisplatin|Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
219617361|NCT03717155|DRUG|Carboplatin|In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
219617362|NCT03754010|PROCEDURE|Scaling and root planning|Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
219617363|NCT03754010|DRUG|Hyaluronic acid gel (HA) and SRP|In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
219532803|NCT04405570|DRUG|Molnupiravir 800 mg|Oral capsule of molnupiravir
219532804|NCT04405570|DRUG|Placebo (PBO)|placebo oral capsule
219532805|NCT03835715|DRUG|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
219532806|NCT01003054|DRUG|Busulfan|130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
219532807|NCT01003054|DRUG|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
219532808|NCT01003054|DRUG|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.
219532809|NCT01003054|PROCEDURE|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
219532810|NCT05358405|OTHER|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
219532811|NCT03522363|OTHER|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
219532812|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 0.5%|0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
219532813|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 1.0%|1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
219532814|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, Placebo|Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
219532815|NCT03625661|DRUG|Ferinject|Ferinject 50mg/ml, one injection
219532816|NCT04499963|DRUG|Theracurmin HP|The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
219532817|NCT03144453|DRUG|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
219532818|NCT03144453|DRUG|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
219532819|NCT04000464|BEHAVIORAL|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
219532820|NCT05222477|BEHAVIORAL|pelvic floor exercise|pelvic floor exercises(intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
219532821|NCT05222477|BEHAVIORAL|Abdominal muscles exercise|abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
219532822|NCT03503422|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for back pain|"Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
219532823|NCT03503422|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for back pain|"Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively"
219532824|NCT06403930|DEVICE|Maxillary Obturator|Maxillary obturators are prosthetic devices used to close maxillary defects resulting from surgical removal of part or all of the maxilla bone due to conditions like tumors or congenital anomalies. They separate the oral and nasal cavities, restore speech, swallowing, and mastication functions, provide facial support, and improve aesthetics and quality of life.
219532825|NCT00144014|DRUG|V10153|Single acute intravenous bolus dose up to 10 mg/kg
219532826|NCT06064799|DIAGNOSTIC_TEST|miRNA-223 & -214 detection|miRNA-223 \& -214 detection in GCF samples by PCR kits
219532827|NCT05113693|DRUG|CKD-393|QD, PO
219532828|NCT05113693|DRUG|CKD-501, D759, H053|QD, PO
219532829|NCT05854186|BEHAVIORAL|Telehealth solution: video conferencing|Telehealth solution: video conferencing
219532830|NCT02411552|BEHAVIORAL|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
219617364|NCT03754010|DRUG|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
219617365|NCT03754010|DRUG|HA mouthrinse+gel and SRP|In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
219617366|NCT01298232|OTHER|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
219617367|NCT01710787|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
219617368|NCT01710787|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
219617369|NCT01710787|DRUG|Placebo|3 unilateral intranasal sprays per dose
219617370|NCT03081832|DRUG|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
219617371|NCT03081832|OTHER|Control|Not treated.
219617372|NCT06328621|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219617373|NCT06328621|PROCEDURE|Computed Tomography|Undergo low-dose CT
218918883|NCT03493152|DRUG|Everolimus|mTOR inhibitor
218918884|NCT05527015|DEVICE|Bifocal Spectacles|Bifocals with a +3.00 Diopter flat top 35
218918885|NCT05527015|DEVICE|Single Vision Lenses|Single vision lens as prescribed by provider
218918886|NCT03493165|DRUG|Everolimus|mTOR inhibitor
218918887|NCT01615939|DRUG|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
218918888|NCT01615939|DRUG|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
219617374|NCT06328621|OTHER|Electronic Health Record Review|Review of medical records
219617375|NCT06328621|OTHER|Survey Administration|Complete survey
219617376|NCT02519374|DRUG|Placebo (including Maltodextrin)|
219617377|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 1
219617378|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 2
219617379|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 3
219617380|NCT03989882|OTHER|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
219617381|NCT03989882|OTHER|Control|corresponding control without wheat germ
218918889|NCT04671017|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
218918890|NCT02892344|DRUG|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
218918891|NCT02892344|DRUG|MF 200 μg|MF 200 μg o.d. via Twisthaler®
218918892|NCT04062539|DEVICE|Sentinel and Spider|Dual filter and single filter
218918893|NCT02611297|PROCEDURE|Cryoprobe|
218918894|NCT05661617|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|"Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests."
218918895|NCT04459884|PROCEDURE|mechanical ventilation|mechanical ventilation \> 48h
218918896|NCT02998463|DEVICE|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
219532831|NCT04054232|OTHER|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~1. Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~2. What peripheral artery disease is and why diagnosis may be important~3. Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~4. The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
219532832|NCT03444090|PROCEDURE|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
219617382|NCT06212531|PROCEDURE|Medical male circumcision using standard surgical technique.|Medical male circumcision using the WHO standard technique followed by examination of wound healing and behavioral risk assessment.
218918897|NCT05678881|DRUG|High dose RLS103|8 mg CBD inhaled powder
219617383|NCT01987440|DRUG|lubricating gel|
219617384|NCT02445716|DRUG|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
218918898|NCT05678881|DRUG|placebo inhaled powder|placebo inhaled powder
218918899|NCT05678881|DRUG|Low dose RLS103|4 mg CBD inhaled powder (open label)
218918900|NCT02705742|BIOLOGICAL|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
218918901|NCT03290066|DEVICE|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
219617385|NCT02445716|DRUG|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
219617386|NCT00006186|PROCEDURE|Autologous fresh whole blood|
219617387|NCT02508623|DRUG|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
219617388|NCT02508623|DRUG|Placebo|Placebo 1 tablet BID for 60 days
219617389|NCT00073164|DRUG|Divalproex Sodium Extended-Release Tablets|
219617390|NCT00073164|DRUG|Olanzapine|
218918902|NCT03290066|OTHER|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
218918903|NCT04524780|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
218918904|NCT01520506|DEVICE|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
218918905|NCT00425269|BEHAVIORAL|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
218918906|NCT03997344|BEHAVIORAL|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
219617391|NCT00073164|DRUG|Risperidone|
219617392|NCT01388959|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
219617393|NCT03645473|DEVICE|Monarch Airway Clearance System|HFCWO Airway Clearance Device
219617394|NCT00356382|DRUG|Lactobacillus (L.) casei|
219617395|NCT05670808|DRUG|Epinephrine injection|Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
218918907|NCT03997344|BEHAVIORAL|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
218918908|NCT03549936|OTHER|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
219532833|NCT00868413|DRUG|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
219532834|NCT00868413|DRUG|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
219532835|NCT00868413|DRUG|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
219532836|NCT00693290|OTHER|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
219532837|NCT02399917|DRUG|Azacitidine|Given SC or IV
219617396|NCT03818113|OTHER|cardioplegia with HTK-Bretschneider cardioplegic solution|cardioplegia with HTK-Bretschneider cardioplegic solution
219617397|NCT03818113|OTHER|cardioplegia with St. Thomas cardioplegic solution|cardioplegia with St. Thomas cardioplegic solution
219617398|NCT06885619|OTHER|Diagnostic Test: echocardiography and blood collection|Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.
219532838|NCT02399917|BIOLOGICAL|Lirilumab|Given IV
219617399|NCT07079813|DEVICE|EasyStars™ High Density Mapping Catheter|All patients underwent treatment for complex arrhythmias using EasyStars™ High Density Mapping Catheter.
219617400|NCT03323398|BIOLOGICAL|mRNA-2416|mRNA encoding human OX40L
219617401|NCT03323398|BIOLOGICAL|Durvalumab|PD-L1 inhibitor
219532839|NCT01208337|DRUG|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
218918909|NCT00758667|DRUG|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
218918910|NCT01546610|OTHER|insoles intervention|EVA insole with arch support and bar retrocapital
218918911|NCT01546610|OTHER|placebo insole|EVA insole flat
218918912|NCT03886896|DRUG|Lidocaine|Lidocaine infusion during surgery
218918913|NCT01980563|PROCEDURE|ultrasound|
219532840|NCT05048004|PROCEDURE|QMODE intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
219532841|NCT05048004|PROCEDURE|QMODE+ intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
219532842|NCT00365534|PROCEDURE|MEI|
219532843|NCT06560814|DRUG|Cabergoline plus timed intercourse|Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
219532844|NCT06560814|DRUG|Dydrogesterone plus timed intercourse|Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
219532845|NCT05593991|OTHER|Elevated heels|"Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer."
219617402|NCT02235454|DEVICE|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
218918914|NCT01980563|PROCEDURE|combined monitoring|
218918915|NCT04953858|OTHER|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
219617403|NCT03641469|DEVICE|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
219617404|NCT07090629|OTHER|Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring|Epicardial adipose tissue measurement
219617405|NCT07095127|DRUG|NVG-2089|Study Treatment
219617406|NCT07097857|OTHER|SFDI|SFDI imaging is performed on both treated and untreated limb.
219617407|NCT07096765|DRUG|Group O|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
219617408|NCT07096765|DRUG|Group T|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
219532846|NCT06562699|OTHER|Hot Matcha brew|"* Hot matcha brew will be prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 30 mL of hot water (75 ̊C). The first step will be to massage the matcha powder with a small amount of water until a smooth paste forms, then additional 50 mL of hot water will be added to dilute down the concentration. The matcha will then be vigorously shaken in a lidded jar.~* After 5 minutes of the acidic attack, participants will be instructed to swish 25 mL of matcha tea 34 times then swallow, and saliva samples will be collected (T2).~* Then saliva will be collected after 10 (T3), 20 (T4), 30 (T5), and 40 (T6) minutes."
219042444|NCT01216475|PROCEDURE|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
219204687|NCT06179485|DRUG|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
219532847|NCT06562699|OTHER|Water|Water (elano) at 13 ̊C swished 34 times then swallowed.
219532848|NCT06562699|OTHER|Cold matcha brew|25 mL of cold matcha brew prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 80 mL of cold water (13 ̊C) swished 34 times then swallowed.
219532849|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy|the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer
219532850|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection|the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer
219532851|NCT02107300|DRUG|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
219532852|NCT02107300|DRUG|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
219532853|NCT03663179|DEVICE|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
219532854|NCT03663179|DEVICE|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
219532855|NCT04785456|DEVICE|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
219532856|NCT04785456|DEVICE|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
219532857|NCT06469671|DEVICE|The system based on real - time artificial intelligence - assisted for colonoscopy|"Russian medical decision support system based on artificial intelligence ArtInCol"
219532858|NCT02152332|DRUG|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
219532859|NCT02152332|DRUG|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
219532860|NCT02152332|DRUG|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
219532861|NCT02152332|DRUG|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
219532862|NCT02152332|DRUG|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
219532863|NCT03226522|DRUG|AXS-05|AXS-05
219532864|NCT03226522|DRUG|Bupropion|Bupropion
219532865|NCT03226522|DRUG|Placebo|Placebo
219532866|NCT02972047|BEHAVIORAL|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
219532867|NCT02972047|BEHAVIORAL|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
219532868|NCT02319980|PROCEDURE|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
218918916|NCT02762916|OTHER|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
219532869|NCT00068731|DIETARY_SUPPLEMENT|lycopene|
218918917|NCT03521284|OTHER|Parental educational program|Behavior: psychotherapy, life hygiene advice
218918918|NCT03521284|OTHER|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
218918919|NCT06097715|DIAGNOSTIC_TEST|upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy to asses present of esophageal varices and will be done to all patient group
219204688|NCT06179485|DRUG|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
219532870|NCT01336660|BIOLOGICAL|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
219532871|NCT01336660|OTHER|Intensive care support plus placebo|Intensive care support as needed plus placebo
219532872|NCT04729660|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
219532873|NCT03113786|OTHER|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
219532874|NCT03113786|OTHER|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
219532875|NCT00984126|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
219532876|NCT00984126|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
219532877|NCT01001208|DRUG|Methotrexate|Methotrexate tablets over-encapsulated for blinding
219532878|NCT01001208|DRUG|Etanercept|1 mL for subcutaneous injection
219532879|NCT01001208|DRUG|Placebo|Matching placebo to methotrexate capsules
219532880|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
219532881|NCT04591405|BIOLOGICAL|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
219532882|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
218918920|NCT06097715|DIAGNOSTIC_TEST|1- Complete blood count 2- Coagulation profile|cmplete blood count to detect thrombocytopenia, liver function test to detect if they are elevated,and any impaired coagulation profile
218918921|NCT03531112|BEHAVIORAL|Appetite Awareness Treatment + Lifestyle Modification|The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
218918922|NCT03544749|DEVICE|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
218918923|NCT03544749|DEVICE|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
218918924|NCT01423175|DRUG|Clofarabine, ara-C|
218918925|NCT01423175|DRUG|FLAMSA|
218918926|NCT01084655|DRUG|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
219532883|NCT04591405|BIOLOGICAL|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
219532884|NCT04068441|OTHER|no intervention|No intervention
219532885|NCT04286802|DEVICE|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
219532886|NCT04286802|BEHAVIORAL|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
218918927|NCT01084655|DRUG|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
218918928|NCT01084655|DRUG|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
218918929|NCT01999881|BEHAVIORAL|exercise intervention|Receive aerobic and exercise intervention
218918930|NCT01999881|PROCEDURE|standard follow-up care|Receive usual care
218918931|NCT01999881|PROCEDURE|quality-of-life assessment|Ancillary studies
218918932|NCT01999881|OTHER|laboratory biomarker analysis|Correlative studies
218918933|NCT03554525|DIETARY_SUPPLEMENT|Fat-binder damm|3 sticks every day during 12 months
218918934|NCT03554525|DIETARY_SUPPLEMENT|Placebo|3 sticks every day during 12 months
218918935|NCT02931877|DRUG|sevoflurane|
218918936|NCT02931877|DRUG|propofol|
218918937|NCT02037971|PROCEDURE|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
218918938|NCT02037971|OTHER|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
218918939|NCT05894915|PROCEDURE|open surgery|Open surgery is a traditional surgery method.
218918940|NCT05894915|PROCEDURE|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
219042445|NCT03639337|DIETARY_SUPPLEMENT|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
218918941|NCT03072407|BIOLOGICAL|PB-119 injection|
218918942|NCT03072407|BIOLOGICAL|PB-119 injection placebo|
218918943|NCT06109896|OTHER|Self Report Questionaires|Collection and analysis of information from patient self-report assessments and integration with clinical information from assessments performed routinely during cancer treatment.
218918944|NCT05379374|COMBINATION_PRODUCT|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
218918945|NCT03980054|DRUG|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
218918946|NCT03980054|DRUG|Placebo|placebo 400mg, orally once daily for one year
218918947|NCT05019326|DRUG|Andrographis Paniculata|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
218918948|NCT05019326|DRUG|Boesenbergia|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
218918949|NCT05019326|OTHER|Standard supportive treatment|as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
218918950|NCT03638193|BIOLOGICAL|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
218918951|NCT02804113|DEVICE|Supera Peripheral Stent System|
218918952|NCT04179136|DIETARY_SUPPLEMENT|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
218918953|NCT04179136|DIETARY_SUPPLEMENT|Placebo treatment matching intervention|Placebo treatment matching intervention
218918954|NCT06016049|OTHER|EMLA® adjuvant|cutaneous forearm deafferentation
218918955|NCT06016049|BEHAVIORAL|Sensory training|Sensibility training of the median nerve
218918956|NCT02397161|OTHER|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
219532887|NCT05163132|DEVICE|Shearwave elastography|Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis
219532888|NCT00818545|DRUG|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
219532889|NCT00818545|DRUG|placebo|
219532890|NCT04550585|OTHER|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
219532891|NCT04550585|OTHER|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
218918957|NCT02397161|OTHER|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
218918958|NCT02397161|OTHER|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
218918959|NCT02084992|OTHER|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
218918960|NCT02084992|OTHER|Telephonic disease management|
219042446|NCT05945316|BEHAVIORAL|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
219042447|NCT06159764|PROCEDURE|Cardioneuroablation|radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
219042448|NCT05714917|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
218918961|NCT04255238|DRUG|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
219532892|NCT04550585|OTHER|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
218918962|NCT04255238|DRUG|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
218918963|NCT05910437|OTHER|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
218918964|NCT03045796|DEVICE|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
218918965|NCT03847597|PROCEDURE|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
218918966|NCT00248404|DRUG|NB1011|
218918967|NCT02415322|OTHER|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
218918968|NCT01507259|OTHER|cocoa|70% versus 34%
219617409|NCT07096765|DRUG|Group C|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
218918969|NCT00625170|DRUG|olanzapine|olanzapine 10 mg/day for 8 days
218918970|NCT00625170|DRUG|Haloperidol|haloperidol 3 mg/day for 8 days
219532893|NCT04550585|OTHER|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
219532894|NCT04550585|OTHER|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
218918971|NCT03098875|DRUG|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
219532895|NCT04550585|OTHER|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
218918972|NCT03098875|DRUG|Propofol|General anesthesia using propofol as a hypnotic agent
219532896|NCT01463761|DEVICE|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
219532897|NCT01518439|DEVICE|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
219532898|NCT01518439|DEVICE|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
219532899|NCT01518439|DEVICE|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
219532900|NCT01518439|DEVICE|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
218918973|NCT03098875|DRUG|Remifentanil|General anesthesia using remifentanil as an analgesic.
218918974|NCT04937218|BEHAVIORAL|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
218918975|NCT00535496|DRUG|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
218918976|NCT04428853|BEHAVIORAL|iyengar yoga|different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
218918977|NCT01841099|DRUG|Mesalamine|Mesalamine granules
218918978|NCT01841099|DRUG|Placebo granules|Provided by Ferring Pharma
218918979|NCT05056389|DRUG|Oxaliplatin|Administration of oxaliplatin intraperitoneally
218918980|NCT00239330|DRUG|Rosuvastatin|
218918981|NCT00239330|DRUG|Atorvastatin|
219042449|NCT00486265|DRUG|AZD4877|intravenous infusion administered on days 1, 2 and 3
219042450|NCT02596646|PROCEDURE|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
219042451|NCT02596646|PROCEDURE|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
219042452|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
219532901|NCT01518439|OTHER|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
219532902|NCT01864174|DRUG|Metformin XR|
219532903|NCT01864174|DRUG|Metformin IR|
219532904|NCT01864174|DRUG|Placebo matching with Metformin XR|
219617410|NCT07097402|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
219617411|NCT07096141|BEHAVIORAL|DBT-informed Group Psychotherapy for Emotion Regulation|An 8-session Dialectical Behaviour Therapy informed emotion regulation psychotherapy group.
219532905|NCT01864174|DRUG|Placebo matching with Metformin IR|
218918982|NCT03841461|OTHER|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
218918983|NCT03841461|OTHER|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; \>5 refers to poor sleep quality.
218918984|NCT03841461|OTHER|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
218918985|NCT03841461|OTHER|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
218918986|NCT01074814|DRUG|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
218918987|NCT01114243|DEVICE|Ultrasound imaging|
218918988|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
218918989|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
219532906|NCT03335761|DEVICE|InterStim Therapy|Device Programming
219532907|NCT01723397|DRUG|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
219532908|NCT01723397|OTHER|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
219532909|NCT01723397|BIOLOGICAL|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
219532910|NCT03555747|OTHER|Canine distalization|GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
219532911|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
219532912|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
219532913|NCT02078986|OTHER|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
219532914|NCT02078986|OTHER|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
219532915|NCT00133822|DRUG|Sertraline and Risperidone|
219617412|NCT07096817|BEHAVIORAL|Highly intensive individualized balance therapy|"In the form of a camp with total therapy hours of 40 hours with a central theme of Circus, children will receive individualized (1 therapist per child) intensive therapy. The intervention is functional, and divided in six activity categories: jumping, sitting balance, walking and running, circus, individual goals and group activities with focus on social interaction. Each category should: 1. partially or fully cover the multisystemic balance framework of Horak, with the overall program covering the entire framework, 2. be fun and focusing on collaboration rather than competition."
219532916|NCT03719898|DRUG|Brigatinib|Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
219532917|NCT03783793|BEHAVIORAL|Mindfulness Training App|Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
218918990|NCT00364104|DRUG|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
218918991|NCT00364104|DRUG|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
219532918|NCT03783793|BEHAVIORAL|Cognitive Training With 2048|The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
219532919|NCT03749512|DIAGNOSTIC_TEST|Complete blood count|During routine preoperative blood test complete blood count is taken.
219532920|NCT03749512|OTHER|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
219617413|NCT07096700|OTHER|VR and walking brace-based gait rehabilitation|The study implements the use of VR and wearable sensors to enhance gait analysis in clinical practice. Participants will take part in two outpatient sessions (T1 and T2) involving the use of VR and wearable sensors, during which they will be asked to complete standardized gait tests and questionnaires. These two sessions will be separated by a one-week home phase (Th), during which participants will wear the walking brace in their daily activities and their gait and physiological data will be recorded by wearable sensors. A final session (T3), conducted without VR, will be scheduled two months later to assess the long-term retention of the intervention effects.
219617414|NCT07096050|OTHER|HyaleXo|Treatment of HyaleXo 3 times
219617415|NCT07095244|DIETARY_SUPPLEMENT|Iron Supplement|FeraMAX Pd powder 15: NPN 80109337 FeraMAX Pd Therapeutic 150 capsules: NPN 80075623 (for an adolescent that can swallow capsules)
218918992|NCT00961077|DRUG|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
218918993|NCT02671708|DRUG|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
219532921|NCT02196675|DEVICE|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
219617416|NCT07095244|DIETARY_SUPPLEMENT|Comprehensive Nutrition Management|Standard nutrition care will depend on the results of the nutrition assessment, as well as underlying conditions, and will be performed regardless of iron supplementation. The intervention will be at the discretion of the dietician but may include; diet education, recommendations for vitamin and mineral supplements, optimization of tube feeds (if the child is tube fed), high protein or high energy diet education if the child is underweight, dddition of oral nutrition supplements (i.e., Pediasure or Ensure) to promote weight gain in orally fed children, discussion surrounding enteral feeding (for children who are orally fed, but severely malnourished and cannot meet their nutritional needs by mouth).
218918994|NCT02671708|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
218918995|NCT02671708|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
218918996|NCT03013803|DIETARY_SUPPLEMENT|Nutricomp Drink Plus Fibre|
218918997|NCT02667795|OTHER|Monitored walking based exercise|Monitored walking based exercise
219532922|NCT00798954|DEVICE|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
219532923|NCT00798954|DEVICE|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
219532924|NCT02158663|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS Device
219532925|NCT00770718|DRUG|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
218918998|NCT01391078|DEVICE|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
218918999|NCT01391078|DEVICE|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
218919000|NCT05024032|DRUG|Tirzepatide|Administered SC
218919001|NCT05024032|DRUG|Placebo|Administered SC
218919002|NCT00000817|DRUG|Amitriptyline hydrochloride|75 mg oral tablet taken daily
218919003|NCT00000817|DRUG|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
218919004|NCT00000817|PROCEDURE|Point acupuncture|Standardized or alternate acupuncture procedure
218919005|NCT00586378|DEVICE|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
218919006|NCT02231086|PROCEDURE|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
219042453|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
219042454|NCT05216874|DEVICE|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
218919007|NCT02231086|DRUG|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
218919008|NCT02231086|PROCEDURE|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
218919009|NCT01222052|DRUG|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
218919010|NCT04909047|DEVICE|parassacral transcutaneous electrostimulation|Use of parassacral transcutaneous electrostimulation
218919011|NCT02865447|DEVICE|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
218919012|NCT05727124|DEVICE|Poul Gjessing|maxillary canine retraction
218919013|NCT05727124|DEVICE|T loops|T loops
218919014|NCT05592717|DRUG|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
218919015|NCT03529032|DRUG|Methadone|methadone for control postoperative pain
218919016|NCT05939882|DRUG|low concentration atropine (0.01%)|low concentration atropine (0.01%)
218919017|NCT05939882|DRUG|low concentration atropine (0.02%)|low concentration atropine (0.02%)
218919018|NCT05939882|DRUG|low concentration atropine (0.04%)|low concentration atropine (0.04%)
218919019|NCT05939882|DRUG|Placebo|Placebo eye drop
218919020|NCT03591406|DRUG|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
218919021|NCT03591406|DRUG|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
218919022|NCT03599674|BEHAVIORAL|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
218919023|NCT02644421|DRUG|VVZ-149|
218919024|NCT02644421|DRUG|Lidocaine|
218919025|NCT02644421|DRUG|Placebo|
218919026|NCT02066181|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218919027|NCT02066181|OTHER|Placebo Administration|Given PO
218919028|NCT02066181|OTHER|Quality-of-Life Assessment|Optional ancillary studies
218919029|NCT02066181|DRUG|Sorafenib Tosylate|Given PO
218919030|NCT01083771|DIETARY_SUPPLEMENT|Olive Oil|Minimum of 3 tablespoon of olive oil per day
218919031|NCT04495595|OTHER|No intervention|There is no intervention due to the observational, cross-sectional design of the study
218919032|NCT00000982|DRUG|Zidovudine|
218919033|NCT00000982|DRUG|Didanosine|
218919034|NCT02695108|OTHER|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
218919035|NCT02695108|OTHER|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
218919036|NCT02334904|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
218919037|NCT02334904|DRUG|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
218919038|NCT01449968|OTHER|home visit|home visit of UMG
218919039|NCT01449968|OTHER|telephone management|telephone management of the situation reported by the patient's GP
218919040|NCT00379964|DRUG|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC\>500/mm3), and for up to 72 hours later.
219532926|NCT00770718|DRUG|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is \>1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
219532927|NCT00770718|BIOLOGICAL|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is \>4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to \>1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
218919041|NCT04446884|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
219042455|NCT02040610|RADIATION|Hypofractionated Proton Therapy|
218919042|NCT04446884|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
218919043|NCT02393378|DRUG|Namilumab|Namilumab injection
218919044|NCT02393378|DRUG|Adalimumab|Adalimumab SC injection
218919045|NCT02393378|DRUG|Methotrexate|Methotrexate tablet
218919046|NCT02393378|DRUG|Folic Acid|Folic Acid Tablet
219532928|NCT02813018|PROCEDURE|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
218919047|NCT05669911|DEVICE|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
218919048|NCT00939393|DEVICE|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
218919049|NCT00939393|DEVICE|Balloon Sinuplasty|Balloon dilatation of sinuses
218919050|NCT03461614|OTHER|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
218919051|NCT03461614|OTHER|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
218919052|NCT02851615|BEHAVIORAL|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
218919053|NCT00471939|DRUG|I-020502|1 mcg/mL TG-PDGF.AB
218919054|NCT04871126|OTHER|inflammatory indexes and CHA2DS2-VASc score|inflammatory indexes and CHA2DS2-VASc score
218919055|NCT06299046|PROCEDURE|robot-assisted radical prostatectomy|surgical removal of the entire prostate and the seminal vesicles, followed by the vescico-urethral anastomosis to restore the continuity of the lower urinary tract performed using Da Vinci Si and Xi Surgical System (Intuitive Surgical, Sunnyvale, California, USA)
218919056|NCT00438009|DRUG|Coxsackievirus A21|Two doses of drug, separated by 48 hours
219532929|NCT02813018|PROCEDURE|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
219617417|NCT07095062|DEVICE|HD-EEG recordings, combined with cognitive and motor assessment|Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.
219617418|NCT04433182|DRUG|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
218919057|NCT00354978|DRUG|5-Fluorouracil|"400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection."
218919058|NCT00354978|DRUG|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
218919059|NCT00354978|DRUG|Leucovorin|400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
218919060|NCT00354978|DRUG|Irinotecan|180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
218919061|NCT05764785|BEHAVIORAL|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
218919062|NCT01843621|BIOLOGICAL|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
218919063|NCT02389296|OTHER|Questionnaire|Questionnaires will be distributed to nursing staff
219042456|NCT01506973|DRUG|Hydroxychloroquine (HCQ)|no other names
219042457|NCT01506973|DRUG|Gemcitabine|no other names
219042458|NCT01506973|DRUG|Abraxane|no other names
218919064|NCT00714727|PROCEDURE|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
218919065|NCT03937570|DEVICE|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
218919066|NCT02670811|DIETARY_SUPPLEMENT|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
218919067|NCT02670811|DIETARY_SUPPLEMENT|Acidified milk|150 mL daily of artificially acidified milk
219532930|NCT01769183|DRUG|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
218919068|NCT03606369|DRUG|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
218919069|NCT03606369|DRUG|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
218919070|NCT00224575|OTHER|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
218919071|NCT00224575|OTHER|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
218919072|NCT02426021|DRUG|MLN1202|Subcutaneous administration of MLN1202
218919073|NCT02426021|DRUG|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
218919074|NCT00371150|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
219532931|NCT01184183|PROCEDURE|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
219532932|NCT00251030|DRUG|Nelfinavir and Omeprazole|
219532933|NCT03892863|DEVICE|active repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
219532934|NCT03892863|DEVICE|sham repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
219532935|NCT00007852|BIOLOGICAL|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
219532936|NCT00007852|DRUG|carmustine|BCNU 300 mg/M2 IV day -6
219532937|NCT00007852|DRUG|cytarabine|100 mg/m2 on days -5 through -2
219532938|NCT00007852|DRUG|etoposide|100mg/M2 BID on days -5 through -2
218919075|NCT03714672|DRUG|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
218919076|NCT03714672|DRUG|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
218919077|NCT03714672|DRUG|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
218919078|NCT03714672|DRUG|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
218919079|NCT02345070|DRUG|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219532939|NCT00007852|DRUG|melphalan|140 mg/m2 IV on day -1
219532940|NCT00007852|PROCEDURE|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
219532941|NCT04309981|BIOLOGICAL|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
219532942|NCT00498381|DEVICE|CPAP|
219532943|NCT03525522|DEVICE|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
219532944|NCT03525522|DRUG|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
219532945|NCT05082779|DRUG|CS0159|Tablets administered orally
219532946|NCT00537979|DRUG|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
219532947|NCT00537979|DRUG|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
219532948|NCT04308850|DRUG|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
219532949|NCT02603055|BIOLOGICAL|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
219532950|NCT02603055|BIOLOGICAL|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
219532951|NCT02009163|DRUG|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
219532952|NCT02009163|OTHER|Placebo|Placebo capsule once per day (double-blind period)
219532953|NCT00652288|DRUG|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
218919080|NCT02345070|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
218919081|NCT03081117|DRUG|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
218919082|NCT03081117|DRUG|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
218919083|NCT01533207|OTHER|Clinical Observation|Patients followed clinically
218919084|NCT01533207|DRUG|Docetaxel|Given IV
218919085|NCT01533207|DRUG|Doxorubicin Hydrochloride|Given IV
218919086|NCT01533207|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
219532954|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given separately
219532955|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
219532956|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given separately
219532957|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
219532958|NCT01817985|DRUG|GS-5816|
218919087|NCT01533207|DRUG|Gemcitabine Hydrochloride|Given IV
218919088|NCT01533207|BIOLOGICAL|Pegfilgrastim|Given SC
218919089|NCT04057326|DRUG|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
218919090|NCT04057326|DRUG|Placebo|2 tablets/time, 3 times daily,Oral Administration.
218919091|NCT04489836|DIETARY_SUPPLEMENT|Glutalytic®|Glutalytic® capsule
219532959|NCT06559748|DEVICE|transcranial magnetic thetaburst stimulation （TBS）|TBS group: iTBS was administered to stimulate RMFC, 80-100% RMT, 10 times a course, twice a day, for a total of 5 days; Conventional drugs group: pantoprazole 40 mg orally once a day; itopride 50 mg orally three times a day; treatment for 4 weeks. （Standard medication regimen）
219532960|NCT02755714|DRUG|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
219532961|NCT00833586|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
218919092|NCT04489836|DIETARY_SUPPLEMENT|DE111®|DE111® capsule
218919093|NCT04489836|OTHER|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
218919094|NCT01100619|DRUG|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
218919095|NCT01100619|DRUG|XL184|dosed with capsules daily
218919096|NCT02451722|DEVICE|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
219532962|NCT00833586|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
219532963|NCT03932058|DRUG|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
219532964|NCT04092647|DRUG|Ashwagandha|Ashwagandha 350 mg po BID
218919097|NCT05887388|BEHAVIORAL|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
218919098|NCT01287962|DRUG|apatinib|750 mg，po，QD； 28 days every cycle
219532965|NCT04092647|DRUG|Placebo|Placebo 350 mg po BID
218919099|NCT01287962|DRUG|placebo|po，QD； 28 days every cycle
218919100|NCT02515370|OTHER|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
218919101|NCT01123798|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
218919102|NCT05742542|OTHER|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
218919103|NCT06107608|PROCEDURE|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
218919104|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
218919105|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone
218919106|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
218919107|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
218919108|NCT05581680|OTHER|dental impressions|dental impressions
218919109|NCT05581680|OTHER|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
218919110|NCT05581680|OTHER|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
218919111|NCT05581680|OTHER|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
218919112|NCT06584318|OTHER|Intermittent hypoxia intervention|The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
218919113|NCT02020265|DEVICE|EEG neurofeedback|
218919114|NCT05358665|OTHER|mask use|long term mask use
218919115|NCT05917197|OTHER|survey based information|Only survey based information collected
218919116|NCT05378750|OTHER|Diuretic algorithm|Implementing diuretic algorithm
218919117|NCT02309242|BEHAVIORAL|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
218919118|NCT00635297|PROCEDURE|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
218919119|NCT06225414|OTHER|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
218919120|NCT06225414|BEHAVIORAL|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
218919121|NCT06225414|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
218919122|NCT06225414|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
218919123|NCT06225414|BEHAVIORAL|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
218919124|NCT06225414|BEHAVIORAL|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
218919125|NCT01202097|DRUG|Salmeterol/Fluticasone|
218919126|NCT01202097|DRUG|Seretide|
219532966|NCT01514617|PROCEDURE|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
219532967|NCT03360305|BEHAVIORAL|GAPcare intervention|Subjects will receive PT and pharmacist evaluation. PT will help determine whether subject may benefit from doing exercises to improve strength or balance. PT may also supply subject with an assist device. A pharmacist will ask patient about any medication they are taking and will make recommendations on how their medication could be changed to prevent falls. Pharmacists will communicate this information to subject's doctors. Subjects will receive a fall calendar for home, where they will record any falls they have after their discharge from the ED. They will receive a phone call at home asking about any recent falls and health care interactions. Study personnel will call subjects every 2 weeks for 6 months. Subjects may receive a referral for outpatient or home-based physical and occupational therapy at the end of the visit.
219532968|NCT01643135|DRUG|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
219532969|NCT01643135|DRUG|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
218919127|NCT06055270|PROCEDURE|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
218919128|NCT06055270|OTHER|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
218919129|NCT05670951|DRUG|ELGN-2112|Human insulin \[rDNA\]
218919130|NCT05670951|DRUG|Placebo|Placebo
218919131|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
218919132|NCT06238544|DRUG|HRS-5965 Capsules|HRS-5965 capsules.
219532970|NCT05259241|DIAGNOSTIC_TEST|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
219532971|NCT00304733|DEVICE|cast vs. shoe|
218919133|NCT03787511|OTHER|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
218919134|NCT03787511|OTHER|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
218919135|NCT03787511|OTHER|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
218919136|NCT04971499|DRUG|Dapansutrile|500 mg tablet
218919137|NCT04971499|DRUG|Pembrolizumab|Single-use vial containing 100 mg/4 mL of pembrolizumab
218919138|NCT03708614|OTHER|Controlled energy diet with elevated protein intake|Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
218919139|NCT04984616|DRUG|40 mg Atorvastatin/day for 120 days P.O.|Oral administration of Atorvastatin 40 mg/daily for 120 days
218919140|NCT04984616|DRUG|Atorvastatin 80|Oral administration of Atorvastatin 80 mg/daily for 120 days
218919141|NCT04984616|DRUG|Placebo|Oral administration of Placebo daily for 120 days
218919142|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
218919143|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
218919144|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
218919145|NCT02595125|DEVICE|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
218919146|NCT00002022|DRUG|Epoetin alfa|
218919147|NCT03181022|BEHAVIORAL|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
218919148|NCT02584686|DRUG|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
218919149|NCT02584686|DRUG|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
218919150|NCT04986072|DRUG|Sodium Nitroprusside|Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
218919151|NCT04986072|DRUG|5% Dextrose solution|Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
218919152|NCT05513534|OTHER|Yoga|A standard yoga program will be provided using Hatha poses.
218919153|NCT05513534|OTHER|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
218919154|NCT03891134|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
218919155|NCT00620451|DRUG|larazotide acetate|gelatin capsule
218919156|NCT00620451|DRUG|placebo|gelatin capsule
218919157|NCT04119115|DEVICE|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
218919158|NCT04119115|OTHER|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
218919159|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
218919160|NCT04897997|PROCEDURE|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
218919161|NCT02352025|DRUG|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
219532972|NCT04086030|OTHER|Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
219532973|NCT04086030|OTHER|Sham Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
219532974|NCT04857008|DEVICE|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
219532975|NCT03727100|COMBINATION_PRODUCT|Clonidine Micropellets|Injection
219532976|NCT03727100|OTHER|Sham|Injection
219532977|NCT01085825|PROCEDURE|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
219532978|NCT00830401|PROCEDURE|Treatment of predefined abnormality by hysteroscopic surgery|"* Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint"
218919162|NCT03480581|BEHAVIORAL|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
218919163|NCT03480581|BEHAVIORAL|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
218919164|NCT01709721|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
219532979|NCT00830401|DRUG|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
219532980|NCT00465010|BEHAVIORAL|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
219532981|NCT03922906|DEVICE|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
219532982|NCT05376683|DEVICE|Curate.AI|Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI
219532983|NCT05376683|BEHAVIORAL|Telemonitoring|Patients will report their blood pressure to a telemonitoring health platform
219532984|NCT05383222|BEHAVIORAL|Technical task|Simulated insertion of a central venous catheter
219532985|NCT05383222|BEHAVIORAL|Administrative task|Requesting a battery of investigations on the EPR
219532986|NCT03193177|OTHER|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
219532987|NCT02124122|BIOLOGICAL|Lactobacillus reuteri|Probiotic
219532988|NCT02124122|BIOLOGICAL|Placebo|Placebo
219532989|NCT00314886|DRUG|Diet|
219532990|NCT04004091|BIOLOGICAL|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
219532991|NCT02160210|DEVICE|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
219532992|NCT02089997|DRUG|Sodium Risedronate|Sodium risedronate tablets
219532993|NCT01855932|BEHAVIORAL|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
219532994|NCT01916408|DRUG|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
219532995|NCT01916408|DRUG|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
219532996|NCT02441309|DRUG|Mifamurtide|
219532997|NCT02441309|DRUG|Ifosfamide|
219532998|NCT05334173|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
219532999|NCT05704881|DIAGNOSTIC_TEST|End-Tidal CO2 measurement during COPD exacerbation|The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
218919165|NCT01709721|DEVICE|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
219042459|NCT00981032|BEHAVIORAL|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
219533000|NCT01850173|DEVICE|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
219533001|NCT02613000|OTHER|No intervention|
219533002|NCT02939729|OTHER|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
219533003|NCT02939729|DEVICE|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
219042460|NCT00981032|BEHAVIORAL|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
219533004|NCT02939729|OTHER|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
219533005|NCT02726425|BEHAVIORAL|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
218919166|NCT05549960|DEVICE|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
218919167|NCT06139276|PROCEDURE|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
218919168|NCT06139276|OTHER|Standard treatment|Standard treatment
218919169|NCT01781936|DRUG|Fluocinolone Acetonide|
219617419|NCT07111286|OTHER|Assessment|"Before and after the programme :~* Self-questionnaires: assessment of pain (visual analogue scale), functional disability (Oswestry), kinesiophobia (Tampa scale of Kinesiophobia), mood (Hospital Anxiety Depression Scale), quality of life (SF12), level of physical activity (Simple Physical Activity Questionnaire), and level of motor imagery (Kinesthesic and Visual Imagery Questionnaire-10)~* Functional tests: Sorensen test, Shirado test, Time Up and Go test (TUG), 6-minute walk test, 200-metre fast walk test, measurement of maximum isometric strength of back extensors/flexors, 3D analysis of locomotion, posture and trunk flexion.~* Evaluation of excitability and inhibition mechanisms within the primary motor cortex at rest and during motor imagery using single and double pulse TMS. Excitability between the brain and the erector spinae muscles and inhibition of the primary motor cortex will be measured at rest and during imagery of back flexion and extension movements"
218919170|NCT05564468|OTHER|Best Practice|Receive standard of care
218919171|NCT05564468|OTHER|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
218919172|NCT05564468|OTHER|Questionnaire Administration|Ancillary studies
218919173|NCT03817359|COMBINATION_PRODUCT|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
218919174|NCT02587676|OTHER|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
218919175|NCT03576586|BEHAVIORAL|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
218919176|NCT03576586|BEHAVIORAL|Attention placebo control|Brief cognitive task plus usual care in the maternity department
218919177|NCT03496311|DIAGNOSTIC_TEST|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
218919178|NCT03566290|DRUG|GTx-024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
218919179|NCT05929963|OTHER|HCV infection status|Divided into 3 groups based on HCVAb and HCVRNA status
218919180|NCT03733015|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
218919181|NCT06061796|PROCEDURE|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~* ratio P/F \> 150 mm Hg~* FiO2 \< 60%~* PEEP ≤ 10 cm d'H2O"
218919182|NCT05993858|DRUG|3cycles (Toripalimab + cetuximab)|"Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9."
218919183|NCT05993858|PROCEDURE|Surgery|After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
219617420|NCT07111286|OTHER|Motor imagery task sessions|3 sessions of 30 minutes per week
218919184|NCT05993858|RADIATION|Radiotherapy or chemoradiotherapy|Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
219042461|NCT00081614|DRUG|Avastin (bevacizumab)|
219042462|NCT00081614|DRUG|Tarceva (erlotinib HCl)|
219533006|NCT05420805|DIETARY_SUPPLEMENT|ALAC, inulin, FOS, and sodium butyrate|Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
219533007|NCT05420805|DIETARY_SUPPLEMENT|Sodium butyrate and zinc oxide|Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
218919185|NCT03104127|DEVICE|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
218919186|NCT03104127|OTHER|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
218919187|NCT02372955|DRUG|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
218919188|NCT02372955|DRUG|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
219533008|NCT04036422|DEVICE|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
219533009|NCT04036422|OTHER|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
219617421|NCT07111286|OTHER|Cognitive task sessions|3 sessions of 30 minutes per week
219617422|NCT07111286|OTHER|Assessment of satisfaction and tolerance|During the final assessment, which will take place after the programme. Satisfaction and tolerance will be assessed using a visual analogue scale.
219617423|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
219617424|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
219617425|NCT07110987|PROCEDURE|Phototherapy|Triple continuous phototherapy per AAP Guudelines
218919189|NCT00649038|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
218919190|NCT00649038|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
218919191|NCT02948127|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
218919192|NCT02948127|BIOLOGICAL|Placebo|Administered as nose drops
218919193|NCT00423579|DRUG|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
219617426|NCT07110987|DRUG|ursodeoxycholic acid (UDCA)|10mg/kg/day orally divided in two doses (URSORASHA) . Given with feeds untill the bilirubin level drop down to limits that don't need therapy due to AAP guidelines.
219617427|NCT04291612|OTHER|Physical exam|Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
219617428|NCT04214535|DEVICE|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
219617429|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
218919194|NCT00423579|DRUG|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
218919195|NCT02392637|DRUG|Cisplatin|Given IV
218919196|NCT02392637|DRUG|Gemcitabine Hydrochloride|Given IV
218919197|NCT02392637|OTHER|Laboratory Biomarker Analysis|Correlative studies
218919198|NCT02392637|DRUG|Nab-paclitaxel|Given IV
218919199|NCT01875796|BEHAVIORAL|Cognitive-Behavioral Therapy|
218919200|NCT01875796|BEHAVIORAL|Motivation Enhancement Therapy|
218919201|NCT01875796|BEHAVIORAL|Integrated Cannabis and Anxiety Reduction Treatment|
218919202|NCT01875796|BEHAVIORAL|False Safety Behavior Elimination Therapy|
218919203|NCT01048619|DRUG|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
219042463|NCT03601754|DIAGNOSTIC_TEST|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
219617430|NCT04124497|DRUG|Daratumumab|"* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
219617431|NCT04124497|DRUG|Pomalidomide|4 mg once daily on days 1-21
219617432|NCT04124497|DRUG|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
219533010|NCT04036422|OTHER|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
219533011|NCT05801497|PROCEDURE|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
219533012|NCT01967485|OTHER|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
218919204|NCT03367663|DRUG|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
219533013|NCT01967485|OTHER|Treatment as usual|Children will receive stimulant treatment for ADHD.
218919205|NCT03367663|DRUG|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
218919206|NCT02835378|OTHER|No intervention|
218919207|NCT05281302|DEVICE|Neck muscle vibration|Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
218919208|NCT05281302|DEVICE|Neck muscle vibration + sham-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device."
218919209|NCT05281302|DEVICE|Neck muscle vibration + anodal-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy."
218919210|NCT02192489|DRUG|CC-220 0.3 mg Daily|
218919211|NCT02192489|DRUG|CC-220 0.6mg Daily|
218919212|NCT02192489|DRUG|Placebo|
218919213|NCT02660151|DEVICE|Hyper-CL™ lens|
218919214|NCT02660151|DEVICE|Regular soft contact lens|
218919215|NCT02660151|DRUG|Salt solution|
218919216|NCT01412502|OTHER|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
219204689|NCT06426004|OTHER|patients will receive NPH education|Patients will benefit from the Hydrocephalus Association's (HA) educational strategy for idiopathic normal pressure hydrocephalus (iNPH) emphasizes patient collaboration in the development of educational materials specifically for this condition. HA has a library of assets that include PowerPoint presentations, videos, and online and print educational materials. There will be also in-person outreach resulting recruitment, website (the study website and HA website), webform (with a symptom of gait, dementia, and bladder symptoms), YouTube videos. The investigators will also go to the communities like senior centers, health fair, and churches, then we will give a talk about iNPH. These resources will be carefully adjusted to suit low-income demographics, guided by feedback from Baltimore audiences and HA's iNPH volunteers.
219204690|NCT06426004|OTHER|primary care physicians (PCPs) will receive professional NPH education|A comprehensive professional development program for PCPs and CHWs, featuring presentations, educational videos, webinars, and tools on iNPH diagnosis, treatment, and care management. Provider Continuing Medical Education (CME) credits will be offered for in-person lectures, aiming to equip PCPs with the skills needed to address iNPH in low-income settings effectively
219533014|NCT03521856|BEHAVIORAL|shoulder exercise|Exercises performed 3 times a week for 12 weeks
218919217|NCT03279744|DRUG|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
219533015|NCT03521856|BEHAVIORAL|education|
219533016|NCT02444715|BEHAVIORAL|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
218919218|NCT06387693|DIAGNOSTIC_TEST|Holter monitoring, intracoronary ECG|Holter monitoring device to track ECG abnormalities during spontaneous chest pain in the outpatient setting. Intracoronary ECG to evaluate perprocedural ECG responses
218919219|NCT04976400|PROCEDURE|semi-individualized total knee replacement treatment with a gender-specific design|Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.
218919220|NCT04976400|PROCEDURE|Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)|Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
218919221|NCT05182593|OTHER|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
219617433|NCT06369012|DRUG|Mefenamic acid 500 mg|To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
219617434|NCT06544525|OTHER|Physical therapy|The intervention will be physical therapy standard of care.
219617435|NCT03696654|PROCEDURE|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
219533017|NCT02444715|BEHAVIORAL|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
219533018|NCT02592226|PROCEDURE|Anesthesia: alveolar recruitment maneuver|
218919222|NCT05182593|OTHER|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
218919223|NCT00240513|DRUG|Minocycline|100 mg capsules OD for 3 months
218919224|NCT00240513|DRUG|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
218919225|NCT05900596|DIAGNOSTIC_TEST|Fetal blood sampling|Fetal scalp blood sampling and analysis
218919226|NCT00167843|DRUG|sulfadoxine-pyrimethamine|
218919227|NCT00106704|DRUG|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
218919228|NCT00106704|DRUG|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
218919229|NCT00106704|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
218919230|NCT04591613|OTHER|Questionnaire|Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
218919231|NCT04591613|OTHER|Biocollection|Total serum, plasma samples will be collected
218919232|NCT04591613|OTHER|Follow-up visit|All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
218919233|NCT03288103|DRUG|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
218919234|NCT00003153|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218919235|NCT01574729|DRUG|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
219533019|NCT02592226|PROCEDURE|Anesthesia: standardized|
219533020|NCT01944930|DEVICE|Laparoscopic narrow band imaging|
219533021|NCT01944930|DEVICE|Standard white-light laparoscopy|
219533022|NCT03863418|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|PROBIOTIC
219533023|NCT03863418|OTHER|placebo|placebo
219533024|NCT01851733|DEVICE|MRI-guided Laser Heat Ablation (MLA)|
219533025|NCT01851733|DRUG|Doxorubicin|
219533026|NCT01851733|OTHER|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
219533027|NCT01851733|DEVICE|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
219533028|NCT00901745|DRUG|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
219533029|NCT00901745|DRUG|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
219533030|NCT03257956|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219533031|NCT03257956|DEVICE|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219533032|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 1
219533033|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 11
219533034|NCT01613040|DRUG|RO4917838|Multiple daily low doses of RO4917838 for 10 days
219533035|NCT01613040|DRUG|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
219533036|NCT01613040|DRUG|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
219533037|NCT04829045|DEVICE|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
219533038|NCT04829045|OTHER|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
219533039|NCT04513379|DRUG|Efavirenz 600mg|EFV 600 mg per day given orally
219533040|NCT04513379|DRUG|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
219533041|NCT02335658|DRUG|DSP-5423P|40-80mg/day
219533042|NCT01804803|PROCEDURE|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
219533043|NCT01804803|PROCEDURE|Use of regular glucometer|
219533044|NCT00921622|DIETARY_SUPPLEMENT|Vitamin D|1000 IU twice daily for up to 10 days
219533045|NCT00921622|DIETARY_SUPPLEMENT|Vitamin C|500 mg twice daily for up to 10 days
218919236|NCT01574729|PROCEDURE|Surgery|Surgery plus post-surgery chemotherapy
219204691|NCT06426004|OTHER|A community health worker will assist PCP|A community health worker will assist PCP to identify barriers and help overcome these barriers in order for patient to access iNPH care.
219533046|NCT02726230|BEHAVIORAL|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
219533047|NCT00001748|PROCEDURE|Peripheral blood progenitor cell transplant|
219533048|NCT02305758|DRUG|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
219533049|NCT02305758|DRUG|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
219533050|NCT02305758|DRUG|Modified FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
219617436|NCT04874207|DRUG|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
219617437|NCT03800407|OTHER|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
218919238|NCT01161277|DRUG|Aripiprazole|Dose: 5-10 mg depending on subject weight
218919239|NCT01161277|DRUG|Haloperidol|Dose: 1-2 mg depending on subject weight
218919240|NCT01161277|DRUG|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
218919241|NCT02481674|DRUG|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
218919242|NCT02481674|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
218919243|NCT06002880|DEVICE|Optibond Universal|OBU™ will be used used for the cementation of indirect restorations (ceramic restorations, composite, zirconia and metal crowns) and pretreatment for indirect restoration, according to manufacturer's Instruction For Use in self-etch and total-etch modes.
218919244|NCT03691376|BIOLOGICAL|Aldesleukin|Given SC
218919245|NCT03691376|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
218919246|NCT03691376|OTHER|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
218919247|NCT03691376|DRUG|Melphalan|Given IV
218919248|NCT06560489|DRUG|Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
219617438|NCT03598426|DRUG|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
218919249|NCT02698215|DRUG|Varenicline|Varenicline 1 mg twice daily
218919250|NCT02698215|DRUG|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
219204692|NCT05377411|DEVICE|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
219533051|NCT02305758|DRUG|FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
219533052|NCT02305758|DRUG|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
219617439|NCT00947362|OTHER|Electro-thermo-coagulation|
218919251|NCT04971746|DRUG|Pirfenidone|On Days 1 and 13, participants will receive an oral dose of pirfenidone.
218919252|NCT04971746|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 daily.
219204693|NCT05377411|BEHAVIORAL|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
218919253|NCT04971746|DRUG|Nintedanib|On Days 1 and 13, participants will receive an oral dose of nintedanib.
218919254|NCT04393935|BEHAVIORAL|Pharmacy Delivered PrEP Intervention|Pharmacy client participants who are eligible and agree to the HIV test will be provided with a pre-packaged kit of a self-administered test for HIV and directed back to the private area of the pharmacy to perform their screening. Pharmacy client participants who test HIV negative will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Pharmacy client participants will be contacted after 3 months to determine whether they continued PrEP use.
218919255|NCT02374242|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
219204694|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
218919256|NCT02374242|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
218919257|NCT04680585|OTHER|Enhanced Usual Care|A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
219533053|NCT02305758|DRUG|Fluorouracil infusion|2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
219533054|NCT01954680|BEHAVIORAL|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
219533055|NCT01954680|BEHAVIORAL|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
218919258|NCT04680585|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
218919259|NCT00596414|PROCEDURE|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
218919260|NCT00596414|DRUG|placebo|
218919261|NCT00596414|DRUG|midazolam|
218919262|NCT00596414|DRUG|midazolam + pethidine|
218919263|NCT02798666|OTHER|High intensity exercise training|Exercise training using sprint interval exercise
218919264|NCT02798666|OTHER|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
218919265|NCT04421053|BEHAVIORAL|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
218919266|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
218919267|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
218919268|NCT02325934|DRUG|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
219204695|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
219533056|NCT02325271|OTHER|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
219617440|NCT00947362|DRUG|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
218919269|NCT02325934|DRUG|Stribild, crushed|Crushed Stribild tablet
218919270|NCT05356897|BIOLOGICAL|Trastuzumab|Given IV
218919271|NCT05356897|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
218919272|NCT05356897|DRUG|Tucatinib|Given PO
218919273|NCT02226367|DRUG|prazosin hydrochloride|study drug arm prazosin
218919274|NCT02226367|DRUG|placebo|study drug arm placebo
218919275|NCT05965258|DIAGNOSTIC_TEST|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
218919276|NCT04405791|PROCEDURE|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
219533057|NCT02032888|DRUG|Daclatasvir|
219533058|NCT02032888|DRUG|Sofosbuvir|
219533059|NCT01767298|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
219533060|NCT01767298|DRUG|Valsartan|Valsartan alone
219617441|NCT00947362|DRUG|saline|physiological saline
218919277|NCT05573633|PROCEDURE|ECG|the POAF will be diagnosed using a 12-lead ECG and according to the usual monitoring protocols for patients in the cardiac surgery department of Amiens University Hospital.
218919278|NCT05573633|PROCEDURE|scanwatch|POAF will be diagnosed with a Withings SM (ScanWatch). FAPO diagnosed by the SW will have to be confirmed by a 12-lead ECG.
218919279|NCT04240210|DRUG|Symtuza|The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
218919280|NCT03773978|DRUG|Baricitinib|Administered orally.
218919281|NCT03773978|DRUG|Placebo|Administered orally.
219204696|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
219204697|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
218919282|NCT02577172|BEHAVIORAL|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
218919283|NCT02577172|BEHAVIORAL|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
218919284|NCT05678608|PROCEDURE|surgical excision|posterior midline approach and total excision for spinal cord tumors
218919285|NCT03244878|BEHAVIORAL|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
218919286|NCT01237756|DEVICE|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
219533061|NCT01767298|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
219533062|NCT03502161|DEVICE|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
219617442|NCT06526949|BEHAVIORAL|Reiki|Reiki application was performed by a responsible researcher who has a Level 3 (Reiki Master) certificate. To prevent contamination between patients and to provide a suitable environment during the intervention, a curtain-screen system was used in the intensive care unit, and patients were fitted with earplugs to provide a quiet environment during the procedure. During the treatment (total time 30 minutes) the Reiki practitioner gently placed his/her hands on or above the patient's head and eyes, upper body from neck to pelvic area, arms and legs (standard Reiki hand positions). The application was limited and performed once due to the rapid changes in intubation time, intensive care unit stay and hemodynamic stability.
219617443|NCT06526949|OTHER|(Sham Reiki)|n the placebo (sham Reiki) group, treatments were performed by sham practitioners (not involved in the study) who had no experience with energy work and did not believe in energy therapy. In order to ensure blinding during the sham application, the patients were given the same hand movements as the experimental group for the same duration. In order not to distract the patients during the application, the area was separated with a curtain and screen system and earplugs were used. The sham practitioner gently placed his hands on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs for 30 minutes. The application was simulated in a manner similar to standard Reiki hand positions.
219617444|NCT04791839|DRUG|Zimberelimab|Zimberelimab will be supplied by Arcus Biosciences.
219617445|NCT04791839|DRUG|Domvanalimab|Domvanalimab will be supplied by Arcus Biosciences.
219617446|NCT04791839|DRUG|Etrumadenant|Etrumadenant will be supplied by Arcus Biosciences.
219617447|NCT05589181|DRUG|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
218919287|NCT03986970|DRUG|Tenofovir|Pre-exposure prophylaxis
218919288|NCT04603846|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
218919289|NCT04603846|DRUG|albumin bound paclitaxel|Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
219533063|NCT01506466|OTHER|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
219533064|NCT00577668|DRUG|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
218919290|NCT02706756|OTHER|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
218919291|NCT02706756|OTHER|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
218919292|NCT02706756|OTHER|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
218919293|NCT02706756|OTHER|Supervised neglect|Monitoring of group without formal intervention.
218919294|NCT06569901|BEHAVIORAL|Hope Intervention|"Group meetings after hospital discharge reflecting on themes that may have an impact on hope.~The Hope Intervention consists of four group meetings and two individual conversations during a four week period."
218919295|NCT06244628|DRUG|Iguratimod|Oral administration of Iguratimod, 25mg twice daily
218919296|NCT01245309|PROCEDURE|scratching|endometrial scratching before COH in IVF
218919297|NCT01245309|PROCEDURE|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
218919298|NCT05219851|RADIATION|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
218919299|NCT01082770|DEVICE|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
218919300|NCT01082770|DEVICE|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
218919301|NCT01033019|DRUG|LDE225 0.75%|0.75% cream
219533065|NCT02852980|OTHER|gestational diabetes women|No intervention.
219533066|NCT02041871|DIETARY_SUPPLEMENT|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
219617448|NCT05589181|DRUG|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
219617449|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
218919302|NCT01033019|DRUG|Vehicle|matching placebo cream to 0.75% LDE225 cream
219533067|NCT02041871|DIETARY_SUPPLEMENT|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
218919303|NCT06054490|BEHAVIORAL|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
218919304|NCT06054490|OTHER|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
218919305|NCT02683512|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
218919306|NCT03162146|OTHER|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
218919307|NCT01498068|DRUG|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
218919308|NCT01498068|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
218919309|NCT01498068|DRUG|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
218919310|NCT04423666|BEHAVIORAL|Walking using a wireless pedometer|See arm/group
218919311|NCT04046367|BEHAVIORAL|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
218919312|NCT04046367|BEHAVIORAL|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
218919313|NCT06035016|DRUG|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
218919314|NCT06035016|DRUG|treatment of physician's choice|Treatment of physician's choice
218919315|NCT05623878|DRUG|68Ga-labeled NY108|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
218919316|NCT03982121|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
218919317|NCT03982121|DRUG|Nivolumab|Nivolumab 240 mg
218919318|NCT03982121|DRUG|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
218919319|NCT03982121|DRUG|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
218919320|NCT00743834|DRUG|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
218919321|NCT00743834|BEHAVIORAL|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
218919322|NCT02252666|DEVICE|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
218919323|NCT01499836|OTHER|PVB|paravertebral block
218919324|NCT02528994|DIETARY_SUPPLEMENT|L-serine|Participants will take dietary serine supplementation daily
219204698|NCT05267496|DEVICE|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
219204699|NCT05267496|PROCEDURE|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry"
218919325|NCT06130761|PROCEDURE|Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block|"For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane."
219042464|NCT03237767|OTHER|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
218919326|NCT06130761|PROCEDURE|trans muscular quadratus lumborum block|With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
219533068|NCT04494867|DEVICE|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
219533069|NCT04494867|OTHER|Standard of Care|Standard temperature management and treatment
219533070|NCT03613922|OTHER|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
219533071|NCT03613922|OTHER|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
219204700|NCT05435547|DRUG|Dexamethasone|Will take Dexamethasone pre-operatively
219204701|NCT05435547|DRUG|Placebo|Will take Placebo pre-operatively
219533072|NCT04511507|PROCEDURE|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
219533073|NCT00430196|DRUG|BOTOX®|
219533074|NCT00430196|DRUG|Zanaflex®|
219533075|NCT01091090|BEHAVIORAL|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
219533076|NCT01091090|BEHAVIORAL|Control|Treatment as usual
219533077|NCT03616106|OTHER|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
219533078|NCT03550625|DIAGNOSTIC_TEST|Computer program|No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
219617450|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
219617451|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
219617452|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
219617453|NCT05708768|OTHER|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
219617454|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
219617455|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
219617456|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
219533079|NCT02804204|DRUG|Anti-TNF|
219533080|NCT02298322|DEVICE|CoolSculpting System|
219533081|NCT02548897|DEVICE|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
219533082|NCT02548897|OTHER|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
219533083|NCT02218411|OTHER|Exercise training|Exercises routine based on the Otago exercise programme
219533084|NCT00360997|BEHAVIORAL|Conventional UK physical therapy|
219533085|NCT00360997|PROCEDURE|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation \& Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
219533086|NCT04408144|DRUG|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
219533087|NCT01454544|BIOLOGICAL|AIT Tablet|1 tablet per day in 12 months
219533088|NCT03206177|DRUG|Galunisertib|Galunisertib 150mg po BID day 4-17
219533089|NCT03206177|DRUG|Paclitaxel|IV Day 1: Paclitaxel 175 mg/m2 over 3 hours
219533090|NCT03206177|DRUG|Carboplatin|IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
219533091|NCT02750124|DEVICE|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
219533092|NCT02750124|OTHER|Routine practice|The standard, annual renewed invitation to cervical screening.
219533093|NCT02445339|DRUG|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
218919327|NCT05698550|DRUG|Erzhi Tiangui Granule|The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
218919328|NCT05698550|DRUG|Erzhi Tiangui Placebo|The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
218919329|NCT01318915|DRUG|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
218919330|NCT01318915|DRUG|Rituximab|375 mg/m\^2 IV infusion on day -6 before transplant and on day 1 after transplant.
218919331|NCT01318915|DRUG|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
218919332|NCT01318915|DRUG|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
218919333|NCT01318915|DRUG|MMF|1 g twice daily on days 0 through 12
218919334|NCT02183662|DRUG|BI 224436|
218919335|NCT02183662|DRUG|Placebo to BI 224436|
219533094|NCT05914857|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
219533095|NCT05914857|BEHAVIORAL|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
218919336|NCT00453206|PROCEDURE|allogeneic bone marrow transplantation|
218919337|NCT00453206|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218919338|NCT00453206|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
218919339|NCT00453206|PROCEDURE|peripheral blood stem cell transplantation|
218919340|NCT06184217|OTHER|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
218919341|NCT06184217|OTHER|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
218919342|NCT00133783|BEHAVIORAL|intermedin|
218919343|NCT06072053|PROCEDURE|Burr Hole Craniostomy and Postoperative Exhaustive Drainage Strategy|According to the preoperative CT results, drilling and drainage was performed at the thickest level of the hematoma; during the operation, the hematoma cavity was adequately flushed with saline and a drainage tube was left in the hematoma cavity; after the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
219042465|NCT03237767|OTHER|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
219042466|NCT03047135|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
219533096|NCT05354479|DRUG|Paracetamol|babies will get expressed breast milk along with paracatamol for pain relief
219533097|NCT03365297|DRUG|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
219533098|NCT01442857|RADIATION|MRI|High resolution MRI of the brachial plexus
219533099|NCT05397093|BIOLOGICAL|ITIL-306|ITIL-306 is a cell therapy product derived from a participant's own TILs and contains a unique molecule designed to increase TIL activity when it encounters FOLR1 on the tumor. A portion of the participant's tumor is surgically removed to make a personalized ITIL-306 product. Once ITIL-306 has been made, the participant is treated with 3 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by 2 days of rest then a single infusion of ITIL-306.
219617457|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
219617458|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
219617459|NCT05655546|OTHER|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
218919344|NCT06072053|PROCEDURE|YL-1 puncture needle and Postoperative Exhaustive Drainage Strategy|Based on preoperative CT, the thickest level of the hematoma was selected and localized. During the operation, an electric drilling needle was used to rapidly break through the skull and dura to enter the cavity of the subdural hematoma, and the puncture needle was fixed to the skull to drain the subdural hematoma. After the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
219042467|NCT05790876|PROCEDURE|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
219042468|NCT06143566|DRUG|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
219533100|NCT04314505|DRUG|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
219533101|NCT04314505|DRUG|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
219533102|NCT01835093|DRUG|Tipepidine Hibenzate|
219533103|NCT02409693|PROCEDURE|Myringotomy with tube insertion|
219533104|NCT01670890|DRUG|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
219533105|NCT01670890|DRUG|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
219533106|NCT02877186|OTHER|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
219533107|NCT02877186|OTHER|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
219533108|NCT04953234|DEVICE|NovoTTF-100L|Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
219533109|NCT04236960|BIOLOGICAL|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
219533110|NCT02533362|DRUG|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
219533111|NCT02458586|DIETARY_SUPPLEMENT|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
219533112|NCT00091260|DRUG|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
219533113|NCT00091260|DRUG|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
219533114|NCT05900934|OTHER|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
219533115|NCT05900934|OTHER|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
219533116|NCT01713465|OTHER|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
219533117|NCT01448798|PROCEDURE|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
219533118|NCT01448798|PROCEDURE|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
219533119|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
219042469|NCT06143566|DRUG|Combined prescription of the individual medications|We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.
219042470|NCT00327704|DRUG|albumin|albumin 20% 100 ml/8 hours for 3 days
219042471|NCT00327704|DRUG|saline|saline 100 ml/8hours for 3 days
219042472|NCT03904771|BEHAVIORAL|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
219042473|NCT03904771|BEHAVIORAL|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
219042474|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
219042475|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
218919345|NCT03429699|BEHAVIORAL|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
218919346|NCT03429699|BEHAVIORAL|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
218919347|NCT01338740|DRUG|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
218919348|NCT01298089|DEVICE|Carriazo Pendular microkeratome|
218919349|NCT00013533|PROCEDURE|Stem cell transplantation|\>3 x 106/kg CD34+ stem cells by IV infusion
218919350|NCT01933737|DEVICE|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
218919351|NCT01933737|DEVICE|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
218919352|NCT03026595|OTHER|no intervention|no intervention
218919353|NCT00107341|DRUG|bortezomib|
219042476|NCT02583581|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
219042477|NCT02583581|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
219533120|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
219533121|NCT01436422|BIOLOGICAL|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
219533122|NCT02744820|DRUG|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
219533123|NCT02744820|OTHER|Placebo|Matching doses by oral route, once a day, 28 days
219617460|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
219533124|NCT00939003|BIOLOGICAL|Adalimumab|40 mg every other week up to Week 12
219533125|NCT00939003|BIOLOGICAL|Placebo|Placebo every other week up to Week 12
219617461|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
219617462|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
218919354|NCT00107341|DRUG|carboplatin|
218919355|NCT00107341|DRUG|paclitaxel|
218919356|NCT05471323|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
218919357|NCT00306501|PROCEDURE|Swallowing Training|Swallowing Training with press of button
218919358|NCT01236209|OTHER|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
218919359|NCT01236209|OTHER|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
218919360|NCT02507232|DEVICE|NovoTTF-200A|12 cycles
218919361|NCT02507232|DRUG|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
218919362|NCT06173687|DEVICE|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
219042478|NCT03624621|BEHAVIORAL|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
219533126|NCT00939003|BIOLOGICAL|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
219533127|NCT00191022|DRUG|LY686017|
219533128|NCT00191022|DRUG|paroxetine|
219533129|NCT00191022|DRUG|placebo|
219533130|NCT05128812|DIETARY_SUPPLEMENT|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
218919363|NCT04500366|BEHAVIORAL|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
218919364|NCT04500366|BEHAVIORAL|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
218919365|NCT04500366|COMBINATION_PRODUCT|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
218919366|NCT04500366|BEHAVIORAL|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
218919367|NCT03396796|PROCEDURE|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
218919368|NCT02712346|DRUG|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
218919369|NCT02712346|DRUG|Placebo|One inactive pill daily for twelve weeks
218919370|NCT02174965|DEVICE|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
218919371|NCT02174965|DEVICE|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
219533131|NCT04008498|DIAGNOSTIC_TEST|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
219533132|NCT05357417|DRUG|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
219533133|NCT05357417|DRUG|Bevacizumab|15mg/kg, day 1
219533134|NCT02359617|DRUG|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
219533135|NCT02359617|DEVICE|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
219533136|NCT04320147|DEVICE|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
219533137|NCT03338075|RADIATION|fractionated stereotactic radiotherapy|The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
219533138|NCT00727961|DRUG|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
219533139|NCT00932880|DRUG|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
219533140|NCT00932880|DRUG|Norvasc|10 mg dose (Pfizer, USA)
219533141|NCT02131129|DEVICE|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
219533142|NCT02131129|DEVICE|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
219617463|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
219617464|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
219617465|NCT06162468|PROCEDURE|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
219617466|NCT01534819|DEVICE|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
219617467|NCT01534819|PROCEDURE|endovascular treament|implantation of a device inserted through an artery
219533143|NCT03386019|OTHER|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
218919372|NCT03104868|BEHAVIORAL|TAKE IT Strategy|"The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
218919373|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
218919374|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
219617468|NCT06207942|DEVICE|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
219617469|NCT06207942|OTHER|High MAP|A mean arterial blood pressure (MAP) of \>85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
218919375|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
218919376|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
218919377|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
218919378|NCT00657319|DRUG|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
218919379|NCT01849510|RADIATION|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT
218919380|NCT01849510|RADIATION|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
218919381|NCT00548665|DEVICE|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
218919382|NCT00548665|BEHAVIORAL|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
219617470|NCT06207942|OTHER|Deep sedation|Deep sedation for at least 36 hours
218919383|NCT04757506|DRUG|Naltrexone|opioid receptor antagonist
218919384|NCT04757506|DRUG|Placebo|
218919385|NCT00003574|PROCEDURE|surgical procedure|
218919386|NCT00003574|RADIATION|brachytherapy|
218919387|NCT00003574|RADIATION|intraoperative radiation therapy|
218919388|NCT00003574|RADIATION|iodine I 125|
218919389|NCT02362815|OTHER|Apple juice|Intervention consists in allowing drinks during labour
219042479|NCT03624621|DEVICE|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
219042480|NCT03624621|BEHAVIORAL|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
219042481|NCT03624621|DEVICE|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
219042482|NCT00482755|DRUG|sunitinib malate|
218919390|NCT04789603|OTHER|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
219042483|NCT00482755|OTHER|immunohistochemistry staining method|
219042484|NCT00482755|OTHER|laboratory biomarker analysis|
219042485|NCT00482755|OTHER|pharmacological study|
219042486|NCT00482755|PROCEDURE|needle biopsy|
219042487|NCT00482755|PROCEDURE|neoadjuvant therapy|
219042488|NCT02703571|DRUG|ribociclib|Combination treatment with LEE and TMT
219042489|NCT02703571|DRUG|Trametinib|Combination treatment with LEE and TMT
219042490|NCT04347304|DIETARY_SUPPLEMENT|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
219042491|NCT04347304|DIETARY_SUPPLEMENT|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
219042492|NCT06423235|DRUG|regular dose of JiRui® Prunella oral liquid|Take 10ml twice a day
219617471|NCT06207942|OTHER|Fever control without a device|Management of fever in the intensive care unit without a device
219617472|NCT06207942|OTHER|Low MAP|A mean arterial blood pressure (MAP) of \>65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
219617473|NCT06207942|OTHER|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
219617474|NCT03685448|DRUG|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
219617475|NCT05334381|BEHAVIORAL|Adapted-STAT ED|Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
218919391|NCT04789603|OTHER|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
218919392|NCT04789603|OTHER|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
218919393|NCT04545749|BIOLOGICAL|UB-612|UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
218919394|NCT05958901|OTHER|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
218919395|NCT01292135|DRUG|PCI-32765|420 mg daily
218919396|NCT00566436|PROCEDURE|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
218919397|NCT00566436|PROCEDURE|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
218919398|NCT04696484|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.
218919399|NCT02769923|DEVICE|Westpharma ID adapter|device used for administering intradermal injection
218919400|NCT02769923|DEVICE|Star ID syringe|device used for administering intradermal injection
218919401|NCT02769923|DEVICE|BCG NS|syringe used for administering intradermal injection
218919402|NCT03050801|DEVICE|rTMS|Altering the connectivity of trans-synaptic pathways
218919403|NCT03817164|DEVICE|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
218919404|NCT03817164|DEVICE|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
218919405|NCT00005780|DRUG|EPOCH-R|EPOCH-R for 6 cycles
218919406|NCT00005780|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
218919407|NCT00005780|BIOLOGICAL|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
219533144|NCT03386019|OTHER|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
218919408|NCT03520881|OTHER|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
218919409|NCT02249364|PROCEDURE|Control|Routine practice
218919410|NCT02249364|PROCEDURE|Hypnosis|Hypnosis session before induction of anesthesia
218919411|NCT02249364|DRUG|propofol|Closed-loop administration of propofol for anesthesia induction
219042493|NCT06423235|DRUG|2x regular dose of JiRui® Prunella oral liquid|Take 20ml twice a day
219533145|NCT03386019|OTHER|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
219533146|NCT01848340|DRUG|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
219533147|NCT01848340|DRUG|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
219533148|NCT01848340|DRUG|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
219533149|NCT01467622|PROCEDURE|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
219533150|NCT04985474|OTHER|questionnaires|
218919412|NCT05656417|BEHAVIORAL|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
218919413|NCT00822614|DRUG|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
218919414|NCT00822614|DRUG|Opioid|Current optimized BTP treatment
218919415|NCT03987360|OTHER|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
219533151|NCT02865122|DRUG|NTRA-9620|Oral daily dose
219533152|NCT02865122|DRUG|Placebo|Oral daily dose
219533153|NCT05330754|DIETARY_SUPPLEMENT|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
218919416|NCT02803788|DRUG|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
218919417|NCT01131975|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
218919418|NCT03340389|PROCEDURE|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
218919419|NCT03667274|PROCEDURE|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
219042494|NCT06423235|DRUG|regular dose of placebo|Take 10ml twice a day
219042495|NCT06423235|DRUG|2x regular dose of placebo|Take 20ml twice a day
219042496|NCT05876091|OTHER|Vaping|Undergo vape puffing regimen
218919420|NCT03600909|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
218919421|NCT03600909|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
218919422|NCT03600909|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
218919423|NCT03600909|DRUG|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
218919424|NCT03600909|DEVICE|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
219617476|NCT05334381|BEHAVIORAL|Standard Enhanced Treatment|Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
219617477|NCT04496479|BIOLOGICAL|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
219617478|NCT02218463|DRUG|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
219617479|NCT02218463|DRUG|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
219617480|NCT06270589|BEHAVIORAL|MF-HIIT|A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.
218919425|NCT03600909|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
218919426|NCT05763043|DRUG|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
218919427|NCT03002961|DRUG|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
218919428|NCT03002961|DRUG|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
218919429|NCT02651675|GENETIC|AAV directed hLDLR gene therapy|AAV directed hLDLR gene therapy is a novel adeno-associated viral (AAV8) vector with human low-density lipoprotein receptor (hLDLR) gene
218919430|NCT03674411|DRUG|Fludarabine (FLU)|25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)
219617481|NCT06270589|BEHAVIORAL|MF-only|A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest
218919431|NCT03674411|DRUG|Cyclophosphamide (CY)|60 mg/kg IV over 2 hours
219617482|NCT06270589|BEHAVIORAL|HIIT-only|A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.
218919432|NCT03674411|DRUG|Total Body Irradiation (TBI)|165 cGy twice daily
218919433|NCT03674411|DRUG|Tacrolimus (Tac)|Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
219617483|NCT06270589|BEHAVIORAL|Sitting rest|Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
219617484|NCT05678647|DRUG|Sucrosomial Iron|20 capsules of Sucrosomial Iron 30 mg is given after blood donation
218919434|NCT03674411|DRUG|Mycophenolate Mofetil (MMF)|MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
218919435|NCT03674411|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5 ug/kg/d until the absolute neutrophil count (ANC) is \>2500/uL for 2 consecutive days
218919436|NCT03674411|DRUG|Busulfan (BU)|BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
218919437|NCT03674411|DRUG|Melphalan|50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min
218919438|NCT03674411|DRUG|MGTA 456 Infusion|The target cell dose is \>10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
218919439|NCT01748734|PROCEDURE|quality-of-life assessment|Ancillary studies
218919440|NCT01748734|OTHER|questionnaire administration|Ancillary studies
219617485|NCT05678647|DRUG|Iron Sulfate|20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
219617486|NCT05738187|PROCEDURE|local cryotherapy treatment|cryotherapy
219617487|NCT05136820|DEVICE|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
219617488|NCT05136820|DEVICE|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
219617489|NCT05308758|OTHER|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
218919441|NCT01748734|OTHER|counseling intervention|Undergo cognitive behavioral therapy
218919442|NCT01748734|BEHAVIORAL|behavioral intervention|Undergo cognitive behavioral therapy
218919443|NCT01066013|OTHER|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
219617490|NCT05308758|OTHER|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
219533154|NCT03880266|DRUG|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
218919444|NCT00619034|DRUG|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
218919445|NCT00619034|DRUG|Diclofenac|dicolfenac eyedrops twice daily i one eye
218919446|NCT00619034|DRUG|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
219617491|NCT05730257|PROCEDURE|Robot-Assisted Kidney Transplantation|Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
218919447|NCT04685863|OTHER|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
219533155|NCT03880266|DRUG|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
219533156|NCT04357639|OTHER|No intervention|No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
219533157|NCT02388620|DRUG|LEE011|400 mg
219533158|NCT03552250|BEHAVIORAL|Parenting for Lifelong Health for Young Children|In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
219533159|NCT06041061|BIOLOGICAL|Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
219533160|NCT06041061|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
219533161|NCT04011345|DIETARY_SUPPLEMENT|Folic Acid Supplement|1 milligram folic acid
218919448|NCT02012140|DRUG|ticagrelor|
218919449|NCT02858622|DRUG|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
219533162|NCT04011345|DIETARY_SUPPLEMENT|Placebo|Placebo
219533163|NCT02492568|DRUG|pembrolizumab|
219533164|NCT02492568|RADIATION|Stereotactic Body Radiation Therapy|
219533165|NCT02012920|DRUG|Seviteronel: given orally once daily in 28 day cycles|
219533166|NCT00118547|BEHAVIORAL|In home monitoring with feedback|Behavioral counseling
218919450|NCT02858622|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
218919451|NCT02858622|DRUG|perfalgan|intravenous paracetamol
218919452|NCT02858622|DRUG|fentanyl|
219533167|NCT03462654|BEHAVIORAL|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
218919453|NCT05721456|BIOLOGICAL|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
218919454|NCT06513845|BEHAVIORAL|Communal drumming recordings|Segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle. Segments will be categorized as highly synchronized
218919455|NCT06266429|DIAGNOSTIC_TEST|Blood collection|Collecting blood pre-op and post-op for metabolite levels.
219617492|NCT05730257|PROCEDURE|Open Kidney Transplantation|Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
219617493|NCT06090890|DRUG|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
219617494|NCT06090890|DRUG|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
219617495|NCT06090890|DRUG|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
219617496|NCT06090890|DRUG|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
219617497|NCT06090890|DRUG|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
219533168|NCT03462654|BEHAVIORAL|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
219533169|NCT00058955|DRUG|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
219617498|NCT06172088|OTHER|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
219617499|NCT06384417|BEHAVIORAL|Hello for Cancer game|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~The questions used in Hello for Cancer were modified from the original Hello game based on the results of phase 1 of testing this game in cancer populations. The modifications made to the game will be assessed for acceptability during this study."
219617500|NCT06384417|OTHER|Table Topics game|To play Table Topics, players are provided a deck of cards that have a variety of general conversation starter questions. The group takes turns selecting a card and reading it to the group for the group to answer. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
219617501|NCT03623646|DRUG|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
218919456|NCT01128933|PROCEDURE|Renal artery stenting|
218919457|NCT00247663|DRUG|Letrozole|
218919458|NCT06410274|DEVICE|Transcranial Doppler ultrasonography (TCD)|TCD will be used to measure cerebral blood velocity (CBv) in the middle and posterior cerebral arteries (MCA and PCA). Following confirmation of a suitable TCD window, participants will undergo a ten-minute rest period in the supine or semi-supine position. Continuous measurements of CBv, blood pressure (BP), heart rate, and end-tidal carbon dioxide will be recorded. Baseline BP will be measured using an automated BP device prior to each recording to allow calibration of the files offline for analysis. This will occur at the first visit and at follow-up, 4-7 days post-onset of intracerebral haemorrhage.
219042497|NCT05876091|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
219533170|NCT03161405|DRUG|TAK-906 Maleate|TAK-906 capsule
219617502|NCT03623646|DRUG|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
219533171|NCT03161405|DRUG|Itraconazole|Itraconazole solution
219533172|NCT04567147|DIETARY_SUPPLEMENT|Probiotic|Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).
219533173|NCT04567147|DIETARY_SUPPLEMENT|Placebo|Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
219533174|NCT03697798|BIOLOGICAL|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
219042498|NCT05876091|OTHER|Questionnaire Administration|Administer Quesitonnaire
219042499|NCT00139568|DRUG|Tegaserod|
219042500|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
219042501|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
219042502|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
219533175|NCT03488186|DRUG|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
219533176|NCT01721850|OTHER|control formula|commercial stage 1 infant formula
218919459|NCT06190171|BEHAVIORAL|Active respiratory muscle strength training|Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
218919460|NCT06190171|BEHAVIORAL|Sham respiratory muscle strength training|Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
218919461|NCT05865990|DRUG|Patritumab deruxtecan|HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
218919462|NCT05122975|DRUG|S48168 (ARM210)|Ryanodine Receptor modulator
218919463|NCT05122975|DRUG|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
218919464|NCT06198933|DEVICE|Pulsed-field ablation|Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
218919465|NCT04789655|DRUG|CC-96191|CC-96191
218919466|NCT05540132|DIETARY_SUPPLEMENT|maltodextrin|Pre-exercise carbohydrate, fast-acting
218919467|NCT05540132|DIETARY_SUPPLEMENT|super starch|Pre-exercise carbohydrate, slow-acting
218919468|NCT05082857|BEHAVIORAL|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
218919469|NCT05082857|BEHAVIORAL|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
218919470|NCT05625061|BEHAVIORAL|Core Behavioral Weight Loss (BWL) Intervention|"All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals."
218919471|NCT05625061|BEHAVIORAL|Behavior Change Technique 1 Message (Action Planning)|Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).
218919472|NCT05625061|BEHAVIORAL|Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)|Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
218919473|NCT05625061|BEHAVIORAL|Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)|Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).
218919474|NCT05625061|BEHAVIORAL|Behavior Change Technique 4 Message (Social Support)|Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).
218919475|NCT05625061|BEHAVIORAL|Behavior Change Technique 5 Message (Social Comparison)|Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).
218919476|NCT05625061|BEHAVIORAL|Behavior Change Technique 6 Message (Social Reward)|Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
218919477|NCT05625061|BEHAVIORAL|Behavior Change Technique 7 Message (Focus on Past Success)|Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
218919478|NCT04855916|DEVICE|ABLE Exoskeleton|Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
218919479|NCT04855916|DEVICE|KAFO Orthosis|Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
219533177|NCT01721850|OTHER|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
219533178|NCT01721850|OTHER|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
219533179|NCT01173263|OTHER|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
219533180|NCT01173263|OTHER|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
219533181|NCT01173263|OTHER|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
219533182|NCT03497247|BEHAVIORAL|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
219533183|NCT01194791|DRUG|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
219533184|NCT01194791|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
219533185|NCT01194791|DRUG|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
219533186|NCT01492894|DRUG|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
219533187|NCT01492894|DRUG|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
219533188|NCT03498391|DRUG|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
219533189|NCT03498391|DRUG|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
219533190|NCT01757886|OTHER|Biomarkers to analyze both intracoronary thrombi as blood|
219533191|NCT00361751|DRUG|fenofibrate|
219533192|NCT04478786|OTHER|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
219533193|NCT00837486|DEVICE|Reclaim™ DBS System|
219533194|NCT03024515|DRUG|opioids titration|Standard Practice Arm
219533195|NCT03024515|DRUG|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
218919480|NCT04324827|DEVICE|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
218919481|NCT04324827|OTHER|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
219533196|NCT05957003|PROCEDURE|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
219533197|NCT05957003|PROCEDURE|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
219533198|NCT03568565|BEHAVIORAL|ePREP Program|see arm descriptions
219533199|NCT03568565|BEHAVIORAL|OurRelationship Program|see arm descriptions
219533200|NCT05815056|DEVICE|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
218919482|NCT03807986|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
218919483|NCT03807986|PROCEDURE|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
218919484|NCT03807986|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
219042503|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
219533201|NCT05815056|DRUG|drug intervention|using sufentanyl 5mg intravenously during the surgery
219533202|NCT04729881|OTHER|Conventional Rehabiliation Group|Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise
219533203|NCT04729881|OTHER|Spesific Exercise Group|Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise
219533204|NCT04729881|OTHER|Control group|No intervention will be aplied
219533205|NCT03951363|BEHAVIORAL|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
219533206|NCT04906772|DRUG|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
219533207|NCT04906772|DRUG|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
219533208|NCT02435823|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
219533209|NCT01502254|OTHER|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
219533210|NCT00831428|OTHER|no intervention|this is a screening study, not an interventional study
219533211|NCT02187354|DRUG|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment \& no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) \& 28μg/day for the escalated dose after dose step should not be exceeded.
218919485|NCT02202122|OTHER|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
219042504|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
219042505|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
219533212|NCT02187354|OTHER|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
219533213|NCT02105103|DEVICE|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
219533214|NCT05130554|PROCEDURE|XEN45 gel stent implantation|The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
219533215|NCT04894097|DEVICE|magnetic therapy|High intensity low frequency magnetic therapy
219533216|NCT06785350|DRUG|0.012%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.5ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.012%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
219533217|NCT06785350|DRUG|0.009%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.375ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.009%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
219617503|NCT05965518|BEHAVIORAL|High-Intensity Interval Training|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
219617504|NCT05965518|BEHAVIORAL|Continuous Moderate Exercise|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
219617505|NCT06067230|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219617506|NCT02513160|DRUG|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
219617507|NCT02513160|DRUG|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
219617508|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
219617509|NCT02513160|DRUG|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
219617510|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
219617511|NCT06575803|OTHER|clinical measurements and evaluation|clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
219617512|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
219617513|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
219617514|NCT06452355|DEVICE|KOKO Device|The intrauterine drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
219617515|NCT05683145|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
219042506|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
219042507|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
219617516|NCT05745480|OTHER|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
219533218|NCT06785350|DRUG|0.006%diprospan+0.5ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.25ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.006%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
219617517|NCT05316116|DRUG|Siltuximab|Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
218919486|NCT01943643|PROCEDURE|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
218919487|NCT04672239|BEHAVIORAL|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
218919488|NCT04672239|BEHAVIORAL|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
218919489|NCT04672239|BEHAVIORAL|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
219533219|NCT06785350|DRUG|0.003%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.125ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.003%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
219617518|NCT05062239|DRUG|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
219617519|NCT05062239|DRUG|No-intervention.|Continuance of prior statin therapy
219617520|NCT06217159|DIETARY_SUPPLEMENT|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
219617521|NCT06217159|DIETARY_SUPPLEMENT|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
219617522|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
218919490|NCT04606134|DEVICE|Hybrid fractional laser|two treatments given one month apart
218919491|NCT04606134|OTHER|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
218919492|NCT04606134|OTHER|Cetaphil face cream|applied twice daily
218919493|NCT00000336|DRUG|Selegiline|
218919494|NCT04266067|OTHER|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
218919495|NCT04266067|OTHER|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
218919496|NCT00937313|OTHER|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
219617523|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
218919497|NCT01752335|OTHER|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
218919498|NCT04543708|PROCEDURE|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
219042508|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
219042509|NCT02172313|DRUG|semaglutide|For oral administration.
219042510|NCT00548704|DRUG|Dexrazoxane|
218919499|NCT04543708|PROCEDURE|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
218919500|NCT06139510|OTHER|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
218919501|NCT00006020|DRUG|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
218919502|NCT02961894|DEVICE|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
218919503|NCT03373240|BEHAVIORAL|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
218919504|NCT03373240|BEHAVIORAL|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
218919505|NCT03633370|OTHER|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
218919506|NCT03871777|OTHER|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
218919507|NCT03871777|OTHER|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
219042511|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
219042512|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
219042513|NCT05091905|DRUG|Continuous Infusion of ropivacaine 0.2%|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
219042514|NCT05091905|DRUG|Titratable Automated Intermittent Boluses of ropivacaine 0.2%|"Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout). In addition, the infusion pump will be set in a pause mode that delays initiation of the automated bolus doses by 5 hours (this can be over-ridden by patients if they would like to initiate their perineural infusion earlier than 5 hours). Lastly, subjects will be able to titrate the volume of their automated bolus up or down within the range of 1-16 mL."
219042515|NCT02244580|DEVICE|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
219533220|NCT06785350|DRUG|0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 15 ml of ropivacaine will be diluted to 30 ml with in 0.9% NaCl, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
219533221|NCT06783179|OTHER|Non-Interventional Study|Non-interventional study
219533222|NCT03963739|OTHER|Interview|Undergo interview
219533223|NCT03963739|OTHER|Questionnaire Administration|Ancillary studies
219533224|NCT03235739|DRUG|Naloxegol 25 MG|Oral Naloxegol 25 MG
219533225|NCT03235739|DRUG|Placebo|matching oral placebo
219533226|NCT04366791|RADIATION|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
219533227|NCT06847087|OTHER|Self-questionnaire|Assessment of the inadequacy between dietary and medicinal calcium intake by the Fardellone self-questionnaire and the patient's clinical record
219533228|NCT02847650|DRUG|Placebo|
219533229|NCT02847650|DRUG|PF-06649751|
219533230|NCT00333645|DRUG|Caspofungin|
219533231|NCT04551976|BEHAVIORAL|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
219533232|NCT03734718|DRUG|GIP|Infusion of Glucose-dependent insulinotropic peptide
219533233|NCT06111170|DEVICE|Compression dressing|Application of dressing
219617524|NCT05167565|OTHER|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (\~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
219533234|NCT02432976|DRUG|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
219533235|NCT02432976|DRUG|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
219533236|NCT03797872|DRUG|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
219533237|NCT03797872|DRUG|Sulfasalazine|Sulfasalazine up to 3g daily po
219533238|NCT03797872|DRUG|Leflunomide|Leflunomide 10-20mg daily po
219533239|NCT03797872|DRUG|Methylprednisolone|For IA or IM injection 20-120mg
219533240|NCT03797872|DRUG|Triamcinolone|For IA or IM injection 20-120mg
219533241|NCT03818581|DRUG|Suvorexant|10-mg or 20-mg Suvorexant capsules
219533242|NCT03818581|OTHER|Placebo|Matching placebo capsules
219533243|NCT04722458|OTHER|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
219533244|NCT04722458|OTHER|IPSS|International Prostate Symptom Score
219533245|NCT04722458|OTHER|UDI-6|Urogenital Distress Inventory
219533246|NCT03084250|DRUG|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
219533247|NCT03084250|DRUG|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
218919508|NCT04730102|PROCEDURE|Rectal washout|Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
218919509|NCT00370734|DRUG|Botulinum toxin A injection|
218919510|NCT02345447|DRUG|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
218919511|NCT02345447|DRUG|Placebo|Aqueous ethanol solution non-distinguishable from verum
218919512|NCT05428501|OTHER|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
218919513|NCT06326814|DRUG|Humanized anti-Factor Bb monoclonal antibody|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
218919514|NCT06326814|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
218919515|NCT00417326|DRUG|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
218919516|NCT00417326|DRUG|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
219533248|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
219533249|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
219533250|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
219533251|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
219533252|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
219533253|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
219617525|NCT05167565|OTHER|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
219617526|NCT05167565|OTHER|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
219533254|NCT02775045|OTHER|Observation Period|8 week observational period
219533255|NCT02299453|BEHAVIORAL|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
219533256|NCT03825328|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
219617527|NCT05167565|OTHER|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
219617528|NCT05167565|OTHER|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
219617529|NCT05167565|OTHER|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
219617530|NCT05167565|OTHER|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
219533257|NCT03825328|DRUG|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
219533258|NCT03825328|DRUG|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
219533259|NCT03825328|DRUG|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
219533260|NCT01383694|DRUG|Piperine|
219533261|NCT00500591|BEHAVIORAL|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
219533262|NCT02935517|BIOLOGICAL|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
219533263|NCT02767791|OTHER|Acupuncture|Acupuncture
219533264|NCT02767791|OTHER|Auriculotherapy|Auriculotherapy
219533265|NCT02517294|DEVICE|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
219533266|NCT02517294|DEVICE|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
219533267|NCT03777826|OTHER|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
219617531|NCT05167565|OTHER|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
219617532|NCT02904577|OTHER|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
219617533|NCT05258773|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
219617534|NCT04814693|DEVICE|EndoRotor® System (Interscope, Inc., Northbridge, MA USA),|The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
219617535|NCT04814693|PROCEDURE|Conventional endoscopic devices (according to standards of care)|Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
219617536|NCT05678218|PROCEDURE|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
219617537|NCT05277922|DRUG|C21|C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
219617538|NCT05277922|DRUG|Sodium Nitroprusside|Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control
219617539|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
219617540|NCT06961708|DRUG|Oral Fosmanogepix|Oral Tablet
219617541|NCT06961708|DRUG|IV Fosmanogepix|IV infusion
219617542|NCT06961708|DRUG|IV placebo|Matching IV placebo
219617543|NCT06961708|DRUG|oral placebo|Matching oral placebo
219617544|NCT03593473|DRUG|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
219617545|NCT03593473|DRUG|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
219617546|NCT04867954|OTHER|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
219617547|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
219617548|NCT04867954|OTHER|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required."
219617549|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
219617550|NCT04971096|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
219617551|NCT04971096|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
219617552|NCT04971096|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose.
219617553|NCT05582460|DIAGNOSTIC_TEST|Reporter Gene Assay|Transcription factor reporter gene assay using luciferase
219617554|NCT05582460|DIAGNOSTIC_TEST|Flow Cytometry|Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
219533268|NCT05681130|OTHER|questionaire|two questionaires for each group
219533269|NCT01424124|DRUG|YHD001 dose level 1|Tablet, three times daily / 8 weeks
219533270|NCT01424124|DRUG|YHD001 dose level 2|Tablet, three times daily / 8 weeks
219533271|NCT01424124|DRUG|Singulair|Tablet, one times daily / 8 weeks
219533272|NCT01424124|DRUG|Placebo|Tablet, one times daily / 7 days
219533273|NCT01646554|DRUG|Modified FOLFOX6|
219533274|NCT01646554|BIOLOGICAL|Aflibercept|Targeted therapy
218919517|NCT04634422|PROCEDURE|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
219533275|NCT01646554|PROCEDURE|Surgery|
219533276|NCT00834249|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
219533277|NCT00834249|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
219533278|NCT02758496|OTHER|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
219533279|NCT04354285|OTHER|Observational|Observational
218919518|NCT04827069|DRUG|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
219533280|NCT03702322|BEHAVIORAL|Voice therapy: respiratory|Abdominal voice onset
219533281|NCT03702322|BEHAVIORAL|Voice therapy: glottal closure|Pulling/pushing task
219533282|NCT03702322|BEHAVIORAL|Voice therapy: loud|Assertive task
219533283|NCT03702322|BEHAVIORAL|Voice therapy: Semiocclusion|Semi-occluded vocal tract
219533284|NCT03663322|PROCEDURE|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
219533285|NCT03663322|PROCEDURE|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
219617555|NCT06271564|DRUG|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
219617556|NCT06271564|DRUG|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
219617557|NCT06025721|BEHAVIORAL|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
219617558|NCT06228053|DRUG|SX-682|Specified dose twice daily
219617559|NCT06228053|DRUG|Enzalutamide|Specified dose once daily
219617560|NCT05895747|DRUG|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
219617561|NCT05895747|DRUG|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
219617562|NCT05895747|DRUG|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
219617563|NCT05895747|DRUG|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
219617564|NCT05895747|DRUG|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
219617565|NCT06630104|PROCEDURE|Biospecimen Collection|Undergo hair, buccal, and saliva sample collection
219617566|NCT06630104|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219617567|NCT06630104|OTHER|Electronic Health Record Review|Ancillary studies
219617568|NCT06630104|PROCEDURE|Follow-Up|Undergo CFU
219617569|NCT06630104|OTHER|Genetic Counseling|Receive genetic counselor consultation
219617570|NCT06630104|OTHER|Genetic Testing|Undergo sequencing analysis
219617571|NCT04510090|DRUG|EP547|EP547
219617572|NCT04510090|DRUG|Placebo|Placebo
219617573|NCT04755335|DIAGNOSTIC_TEST|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
219617574|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
219617575|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
219617576|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
219617577|NCT05873777|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
219617578|NCT05736666|BEHAVIORAL|Treadmill-based perturbation training|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. Through this task-specific training, participants should learn to control their trunk motion in a way that will cause them to avoid a trip or fall to the side.
218919519|NCT04599244|OTHER|emergency pulpotomy|removal of coronal pulp
218919520|NCT04551547|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml
218919521|NCT04551547|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml
218919522|NCT04551547|OTHER|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
218919523|NCT03010215|OTHER|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
218919524|NCT05552287|DRUG|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
219533286|NCT05022381|PROCEDURE|Radiofrequency thermal coagulation of articular branches of femoral and obturator nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Patients who do not have any complications after the procedure and who are mobilized are discharged in the 2nd hour.
219533287|NCT04362566|DRUG|Bupivacaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
219617579|NCT05736666|BEHAVIORAL|Education Control|Fall prevention educational material
219617580|NCT01127256|DRUG|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
219617581|NCT01127256|DRUG|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
219617582|NCT03938883|DEVICE|Ocular Bandage Gel (OBG)|A modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
219617583|NCT03938883|DEVICE|Bandage Contact Lens (BCL)|A bandage contact lens protects an injured or diseased cornea from the mechanical rubbing of the blinking eyelids, therefore allowing it to heal. It is a normal (usually soft, but not always) contact lens has no power. It is not intended to improve your vision.
219617584|NCT06396871|DIAGNOSTIC_TEST|Oral glucose tolerance test|75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min
218919527|NCT03043417|BEHAVIORAL|CHC's given the intervention|CHC's NOT given the intervention
219617585|NCT06396871|DIAGNOSTIC_TEST|Liver Ultrasound|A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.
219617586|NCT06396871|DIAGNOSTIC_TEST|Fibroscan of the Liver|FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).
219617587|NCT06396871|DIAGNOSTIC_TEST|Magentic Resonance Imaging (MRI) of the liver|The exact calculation of liver fat with proton density fat fraction will take place with MRI.
219617588|NCT01240681|PROCEDURE|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
219617589|NCT05252325|DEVICE|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
219617590|NCT05252325|DEVICE|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
219617591|NCT04434339|PROCEDURE|erector spinae block|A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine
219617592|NCT04434339|PROCEDURE|transversus abdominis block|A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
219617593|NCT01415518|DRUG|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
219617594|NCT01415518|DRUG|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
219617595|NCT01415518|DRUG|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
219617596|NCT05531123|DRUG|Tislelizumab|Tislelizumab 200 mg I.V. Q3W on the day 1
218919528|NCT05572255|DRUG|Cenobamate|200 mg Cenobamate Tablet
218919529|NCT00872820|BEHAVIORAL|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
218919530|NCT00872820|BEHAVIORAL|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
218919531|NCT05579678|BEHAVIORAL|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
218919532|NCT06064279|DRUG|Poly ICLC|Tol like receptor 3 agonist
218919533|NCT06064279|DRUG|IVIG|pooled IVIG
218919534|NCT06419920|OTHER|Flat terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on a level treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
218919535|NCT06419920|OTHER|Uneven terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
219617597|NCT05531123|DRUG|gemcitabine and cisplatin|Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
219617598|NCT05531123|RADIATION|Modified hypofractionation|"* Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W"
219617599|NCT00679211|DRUG|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
219617600|NCT01473823|DIETARY_SUPPLEMENT|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
218919536|NCT05818085|DRUG|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
219533288|NCT04362566|OTHER|Placebo Saline|Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
218919537|NCT05818085|DRUG|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
218919538|NCT05818085|OTHER|Placebo|ABP-671 matching placebo
218919539|NCT04876521|DRUG|Amisulpride|low dose of Amisulpride at 100-300 mg/day
218919540|NCT04876521|DRUG|Olanzapine-Fluoxetine Combination|Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
218919541|NCT05372757|PROCEDURE|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
218919542|NCT05408429|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
218919543|NCT05408429|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
218919544|NCT04139733|PROCEDURE|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
218919545|NCT04139733|PROCEDURE|Supine positon|Conventional supine position ventilation, no prone position.
218919546|NCT03327948|DEVICE|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
218919547|NCT05542069|DEVICE|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
219617601|NCT04295083|BEHAVIORAL|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
219617602|NCT05890924|OTHER|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
219617603|NCT00240448|DRUG|telmisartan 80 mg/hydrochlorothiazide 25 mg|
219617604|NCT00240448|DRUG|valsartan 160 mg/hydrochlorothiazide 25 mg|
219617605|NCT00240448|DRUG|placebo|
218919548|NCT05276596|DRUG|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
218919549|NCT05276596|DRUG|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
219204702|NCT05520515|OTHER|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
219533289|NCT01343303|DRUG|Placebo|Placebo tablet/capsule every 12 hours for 21 days
219533290|NCT01343303|DRUG|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
218919550|NCT06057766|OTHER|Physical activity tele coaching program|"The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented."
218919551|NCT06498349|PROCEDURE|bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment|according to widely accepted expert consensus paper
218919552|NCT06498349|DRUG|best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations|according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
218919553|NCT05569408|DRUG|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
218919554|NCT06116045|DRUG|BZ371A 7.5 mg (1.5 ml)|7.5 mg gel
218919555|NCT06116045|DRUG|BZ371A 5.0 mg (1.0 ml)|5.0 mg gel
218919556|NCT06116045|DRUG|BZ371A 2.5 mg (0.5 ml)|2.5 mg gel
218919557|NCT06116045|DRUG|Placebo (1.5 ml)|BZ371A-matched placebo
218919558|NCT06116045|DRUG|Placebo (1.0 ml)|BZ371A-matched placebo
218919559|NCT06116045|DRUG|Placebo (0.5 ml)|BZ371A-matched placebo
218919560|NCT06555406|BEHAVIORAL|Time-restricted eating for 8 weeks|limiting food intake to 10 hours per day
218919561|NCT06561919|PROCEDURE|bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper|Best medical treatment according to widely accepted expert consensus Paper
218919562|NCT06561919|DRUG|best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper|Best medical treatment according to widely accepted consensus Paper
218919563|NCT03459755|BEHAVIORAL|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
218919564|NCT05146882|DRUG|Belcesiran|Belcesiran will be administered subcutaneously (SC) in the treatment arm.
218919565|NCT04792645|DRUG|Placebo|Pill that contains no medicine
218919566|NCT04792645|DRUG|Memantine|Cognition-enhancing medication
218919567|NCT05308537|BEHAVIORAL|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
218919568|NCT03380312|PROCEDURE|rTARUP technique|robot-assisted rTARUP technique
218919569|NCT06704321|DIETARY_SUPPLEMENT|TOTUM-448|16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day)
218919570|NCT06704321|DIETARY_SUPPLEMENT|Placebo|16 weeks of placebo supplementation (8 capsules per day)
218919571|NCT04825678|DRUG|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
218919572|NCT00133484|BIOLOGICAL|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
218919573|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Bacillus anthrax|
218919574|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Escherichia coli|
218919575|NCT02512822|PROCEDURE|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
218919576|NCT02067078|DRUG|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
218919577|NCT02067078|DRUG|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
218919578|NCT02067078|DRUG|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
219533291|NCT01343303|DRUG|Naproxen|500 mg capsule every 12 hours for 21 days
219533292|NCT01343303|DRUG|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
218919579|NCT04336553|BEHAVIORAL|Social prescribing in Sweden (SPiS)|Social prescribing in sweden (SPiS)
218919580|NCT03827096|DRUG|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
218919581|NCT06080334|DEVICE|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
218919582|NCT06080334|DEVICE|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
219533293|NCT00111397|PROCEDURE|Cytokine therapy|
219533294|NCT00111397|DRUG|Interferon Gamma, GM-CSF|
218919583|NCT04106414|DRUG|Nivolumab|Nivolumab 480 mg every 4 weeks.
218919584|NCT04106414|DRUG|BMS- 986205|BMS-986205 100 mg every 4 weeks.
218919585|NCT05826314|OTHER|Boxing training|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
218919586|NCT05826314|OTHER|Exercise|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
218919587|NCT04052854|DRUG|Zanubrutinib|Zanubrutinib will be orally administered in participants with treatment naive or R/R WM
219533295|NCT00034905|DRUG|quetiapine fumarate vs risperidone|
219533296|NCT05215483|BEHAVIORAL|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
219533297|NCT05215483|BEHAVIORAL|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
218919588|NCT04895891|DEVICE|EOS hand imaging|For each patient, EOS images are compared with CT images
219533298|NCT05215483|BEHAVIORAL|LFT available|LFT availability: Enough lateral flow tests available at home
219533299|NCT05215483|BEHAVIORAL|No LFT available|LFT availability: No lateral flow tests available at home
219533300|NCT01163461|BEHAVIORAL|speech therapy|individuals will receive 60 hours of behavioral speech therapy
218919589|NCT05226442|DRUG|Argatroban|Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
219533301|NCT05671965|DIETARY_SUPPLEMENT|Xylitol|33.5g xylitol dissolved in 300mL tap water.
218919590|NCT05226442|DRUG|Unfractionated heparin|Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
219533302|NCT05671965|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
219533303|NCT05671965|DIETARY_SUPPLEMENT|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
219533304|NCT05671965|DIETARY_SUPPLEMENT|Water|300mL tap water.
219533305|NCT04738539|DRUG|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
219533306|NCT04738539|DIAGNOSTIC_TEST|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
219617606|NCT01042353|PROCEDURE|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
219617607|NCT01042353|PROCEDURE|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
219617608|NCT01730053|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
219617609|NCT01730053|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
219617610|NCT01730053|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
219617611|NCT01730053|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
219617612|NCT03944668|BEHAVIORAL|Exercise|36 sessions of comprehensive cardiac rehabilitation over 12 weeks
219617613|NCT01805518|DIETARY_SUPPLEMENT|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
219617614|NCT05460013|DIETARY_SUPPLEMENT|Traditional Control|Placebo control is a compounded made-up shake that is traditionally used by the Haematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be randomly assigned to consume the control twice daily for the duration of 7 days prior to the admission to the day of discharge.
219617615|NCT05460013|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be randomly assigned to consume the intervention twice a day for the duration of 7 days prior to the admission to the day of discharge.
219617616|NCT04904497|BEHAVIORAL|Early Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process"
219617617|NCT02549404|DRUG|KHK7580|Oral administration
219617618|NCT01470248|DRUG|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
218919591|NCT02825498|DEVICE|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
218919592|NCT00877500|OTHER|Best Practice|Receive standard of care
218919593|NCT00877500|DRUG|Ixabepilone|Given IV
218919594|NCT04309396|DEVICE|Hydrogen content recording|Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.
219533307|NCT06146972|DRUG|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
218919595|NCT06313736|BEHAVIORAL|Action Brings Change Project (15-minute adult version)|The ABC Project is a self-guided online single-session intervention based on principles of behavioral activation. In a slightly different form intended for adolescents, it has demonstrated efficacy in several studies. Its adult version has also shown some efficacy.
218919596|NCT06313736|BEHAVIORAL|Action Brings Change Project (10-minute adult version)|This is a 10-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
218919597|NCT06313736|BEHAVIORAL|Action Brings Change Project (6-minute adult version)|This is a 6-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
218919598|NCT06313736|BEHAVIORAL|Action Brings Change Project (2-minute adult version)|This is a 2-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
218919599|NCT04097938|DRUG|GLPG3667 oral suspension|GLPG3667 oral suspension
218919600|NCT04097938|DRUG|Placebos|Placebo oral suspension
218919601|NCT04097938|DRUG|GLPG3667 capsules|GLPG3667 capsules
218919602|NCT05995210|PROCEDURE|Kinesio taping|A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.
218919603|NCT05995210|PROCEDURE|Orthosis|They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.
218919604|NCT05995210|PROCEDURE|Control|An exercise program focused on the knee and hip muscles was given two days a week.
218919605|NCT04042441|DRUG|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
218919606|NCT04347798|OTHER|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
219533308|NCT03047343|OTHER|Retrospective data extraction in medical files|Retrospective data extraction in medical files
219533309|NCT01859858|DIETARY_SUPPLEMENT|curcumin|
219533310|NCT01859858|DRUG|Irinotecan|
218919607|NCT05109364|DRUG|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
219533311|NCT05044364|DRUG|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
219533312|NCT01015703|BIOLOGICAL|CoVaccine HT|intramuscular injection, dose escalation
219617619|NCT06426342|BEHAVIORAL|metaverse-based blended online intervention|A new metaverse-based blended online intervention was developed using an online program and coaching via metaverse to prevent depression among Generation MZ Employees in South Korea.
219617620|NCT05085834|DRUG|Zinc Gluconate|Two 45 mg capsules once daily
219617621|NCT05085834|DRUG|Placebo|Two placebo capsules once daily
219617622|NCT05708235|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
219617623|NCT05708235|DRUG|Abemaciclib|Abemaciclib is an orally administered CDK4/6 inhibitor
219617624|NCT05708235|DRUG|Inavolisib|Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
219617625|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
219617626|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
218919608|NCT05376917|DEVICE|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
218919609|NCT05376917|DEVICE|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
218919610|NCT05376917|DEVICE|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
218919611|NCT05376917|DEVICE|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
218919612|NCT04930445|DRUG|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
218919613|NCT06172959|BEHAVIORAL|Vocal Intonation Therapy (VIT)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Vocal Intonation Therapy is a music therapy technique consisting of breathing and vocal exercises to target respiratory function and vocal quality.
218919614|NCT06172959|BEHAVIORAL|Therapeutic Singing (TS)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Therapeutic Singing is a music therapy technique used to work on the rehabilitation of vocal and respiratory function.
218919615|NCT04033796|DIETARY_SUPPLEMENT|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);
218919616|NCT04033796|DIETARY_SUPPLEMENT|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);
218919617|NCT04033796|DIETARY_SUPPLEMENT|Placebo|A placebo (administered orally every two months) supplementation control group.
218919618|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
218919619|NCT01074970|DRUG|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
218919620|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
218919621|NCT02086175|DRUG|Imprime PGG|
218919622|NCT02086175|DRUG|Rituximab|
218919623|NCT00734149|DRUG|Bortezomib|
219533313|NCT05859425|DEVICE|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
218919624|NCT00734149|DRUG|Melphalan|
218919625|NCT00734149|DRUG|Prednisone|
218919626|NCT00161759|DRUG|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
218919627|NCT06521125|DIAGNOSTIC_TEST|High resolution Computed Tomography (HRCT) scans of the Chest|A chest high-resolution computed tomography (HRCT) scan will be performed
218919628|NCT06521125|DIAGNOSTIC_TEST|Pulmonary Function Testing (PFTs)|Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
218919629|NCT06521125|DIAGNOSTIC_TEST|Digital lung sounds auscultation|Lung sounds will be recorded using a manual approach with a digital stethoscope
218919630|NCT06521125|DIAGNOSTIC_TEST|Laboratory Assessments|Clinical laboratory tests will be collected from each participant
218919631|NCT06521125|GENETIC|DNA sequencing|A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
218919632|NCT01710982|DRUG|TZP-101|
219533314|NCT05859425|OTHER|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
219617627|NCT05047926|BEHAVIORAL|Behavioral Counseling|Undergo behavioral counseling
218919633|NCT01710982|OTHER|Placebo|
218919634|NCT05177965|OTHER|Exposure to shift work|Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
218919635|NCT06585098|OTHER|game based learning|"The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher."
218919636|NCT04205227|DRUG|ENB003|ENB003 is selective Endothelin B Receptor Antagonist
218919637|NCT04205227|DRUG|Pembrolizumab|anti-PD1
219533315|NCT02718326|DRUG|Intravitreal aflibercept injection [IAI]|
219533316|NCT02718326|DRUG|Sham|
219533317|NCT03122535|DEVICE|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
218919638|NCT06177483|DIETARY_SUPPLEMENT|95% curcumin extract powder|95% curcumin extract powder
218919639|NCT06177483|DIETARY_SUPPLEMENT|curQ+ curcumin formulation|curQ+ curcumin formulation
218919640|NCT03030586|OTHER|volumetric MRI|
218919641|NCT05048134|DRUG|HRS2300|HRS2300 monotherapy
218919642|NCT05048134|DRUG|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
218919643|NCT05048134|DRUG|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
218919644|NCT05048134|DRUG|HRS2300、trametinib|HRS2300 combined with trametinib
218919645|NCT05048134|DRUG|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
218919646|NCT03255408|DRUG|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
218919647|NCT03255408|DRUG|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
218919648|NCT03255408|DRUG|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
218919649|NCT03255408|DRUG|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
218919650|NCT03996824|OTHER|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
218919651|NCT06591143|PROCEDURE|ART|Caries excavation with hand instruments only and restoration with glass ionomer filling
218919652|NCT06591143|PROCEDURE|Hall technique|Stainless steel crown placement without tooth preparation
218919653|NCT06589427|OTHER|Invasive ventilation.|Patients were subjected to invasive ventilation.
218919654|NCT06443814|BEHAVIORAL|Health Education|This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
219617628|NCT05047926|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given Boost or Ensure
219617629|NCT05047926|OTHER|Physical Activity|Complete physical activity assignments
219617630|NCT05047926|OTHER|Survey Administration|Complete surveys
219617631|NCT05047926|PROCEDURE|Computed Tomography|Undergo CT scans
219617632|NCT05047926|PROCEDURE|Biospecimen Collection|Undergo blood collection
219617633|NCT05047926|BEHAVIORAL|Health Education|Complete Resilient Living program
219617634|NCT05047926|OTHER|Medical Device Usage and Evaluation|Wear a FitBit
218919655|NCT06443814|BEHAVIORAL|Transcendental Meditation|TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
218919656|NCT06599372|OTHER|The rTMS method|The patient receives treatment under naturalistic conditions in routine practice.
218919657|NCT06599372|OTHER|The cTBS method|The patient receives the treatment under naturalistic conditions in routine practice.
218919658|NCT06597552|OTHER|Training Group|"Inspiratory muscle training (IMT) was performed using the Threshold IMT device using the threshold loading method. The IMT was administered to the patients in the training group at 30% of the MIP value, 5 days a week, twice a day, for 15 minutes for 8 weeks. The patients in the training group were called for a check-up once a week and the MIP value was re-evaluated. The training workload for that week was determined by taking 30% of the new measured MIP value.~During the training, the patients were asked to sit with their upper body (shoulders and upper chest) in a relaxed position, and after the nose was closed with the clip, the mouthpiece of the device was tightly closed with the lips. While in this position, the patient was asked to inhale and exhale 5 times into the device, then remove the device from their mouth and listen for 5 breaths, and continue this cycle for 15 minutes."
218919659|NCT06597552|OTHER|Control Group|The training intensity of the control group was given at the lowest load (9 cm H2O) for 8 weeks, five days a week, twice a day for 15 minutes. To eliminate the effect of learning, the MIP measure of the control group was measured once a week, but the intensity of the training was not increased during the 8 weeks.
218919660|NCT06592235|OTHER|No intervention|No intervention
218919661|NCT06590714|DRUG|Experimental(Acelex cap m2mg)|"Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN)."
218919662|NCT06590714|DRUG|Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)|NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
218919663|NCT06861998|BEHAVIORAL|Message-based bedtime routine|The intervention group implemented sleep hygiene education and the Message-based bedtime routine, including nutritional activities-hygiene-communication-message.
218919664|NCT06861998|BEHAVIORAL|sleep hygiene education|Sleep hygiene education includes sleep environment, sleeping location, regular sleep schedule, bedtime routines, sleeping methods, and sleeping posture.
218919665|NCT06991491|COMBINATION_PRODUCT|GnP in combination with Ivonescimab and SBRT|Gemcitabine 1000mg/m2, ivgtt,vdays 1 and 8, nab-Paclitaxel 125mg/m2, ivgtt, days 1 and 8 in combination with Ivonescimab 20mg/kg d1, every 21 days. Cycle 2 will be synchronized with primary or metastatic SBRT.
218919666|NCT05919875|BEHAVIORAL|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~1. Awareness and automatic pilot~2. Living in our heads~3. Being present in the body~4. Recognizing aversion~5. Allowing / Letting be~6. How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
218919667|NCT05919875|BEHAVIORAL|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
218919668|NCT06369909|PROCEDURE|EUS-FNA|For patients with pancreatic masses, EUS-FNA is performed to confirm pathological diagnosis, and pancreatic biopsy samples and duodenal mucosal biopsy samples are collected.
218919669|NCT06993103|DIETARY_SUPPLEMENT|Standard care Cow's milk based formula|Standard hospital care would be given as as per local unit policy at the site.
218919670|NCT06993103|DIETARY_SUPPLEMENT|Dietary Supplement: PDHM Pasteurised Donor Human Milk|PDHM will be given to infants randomised to the intervention group
218919671|NCT06991426|DIETARY_SUPPLEMENT|CreaSafe® creatine|Will receive CreaSafe® creatine (0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
218919672|NCT06991426|COMBINATION_PRODUCT|Placebo 0.03 g/kg/day|will receive a placebo (microcrystalline cellulose; 0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
218919673|NCT06672120|BEHAVIORAL|Exercise training|Combined, home-based, supervised, video- assisted, endurance and resistance training
218919674|NCT06992128|DRUG|Romiplostim N01 combined with dexamethasone|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection within 4 days of dexamethasone treatment once a week for up to 6 months.
218919675|NCT06992128|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
219533318|NCT03122535|DEVICE|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
219533319|NCT01191996|BIOLOGICAL|MIS416|MIS416 intravenously every week
218919676|NCT06992830|PROCEDURE|cardioneuroablation|Participants diagnosed with medication-refractory variant angina or those unable or unwilling to take medications regularly will undergo a catheter-based cardioneuroablation (CNA) procedure. CNA targets epicardial cardiac ganglionated plexi (GP), which are clusters of autonomic ganglia involved in parasympathetic modulation of cardiac function. The procedure is designed to reduce parasympathetic overactivity contributing to coronary artery spasms. Ablation will be performed using a radiofrequency catheter to eliminate GP areas identified by anatomical landmarks and electrophysiological mapping. No control or sham procedure is included in this single-arm study.
218919677|NCT06991439|DEVICE|A self-monitoring mobile application for stress management at work|STAPP@Work is a digital self-monitoring intervention designed for the workplace to manage work-related stress. The app prompts users multiple times per day to self-monitor their stress by answering short questions about their current activity, mood, and stress signals. It provides real-time feedback, visual summaries of stress patterns over time, and practical tips for stress management.
218919678|NCT06991660|BEHAVIORAL|sleep hygiene education|This study will be conducted to examine the effects of sleep hygiene training, which is given to women in menopause to eliminate sleep problems and menopause symptoms that they often experience, on sleep and menopause symptoms experienced by women.
219533320|NCT03227835|OTHER|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR \>29mL/min/1.73m2
219533321|NCT01649011|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
219533322|NCT01649011|BEHAVIORAL|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
219533323|NCT05025345|DEVICE|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
219533324|NCT05025345|DEVICE|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
219533325|NCT06238791|OTHER|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
219533326|NCT03040362|DRUG|[14C]-lasmiditan|\[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
219533327|NCT04383574|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
219533328|NCT04383574|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
219617635|NCT06266182|BEHAVIORAL|Acceptance and Commitment Therapy|ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.
219617636|NCT06266182|BEHAVIORAL|Education|Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.
219617637|NCT06367231|OTHER|VibrantMinds|We are exploring the potential of computer games to reveal insights into the cognitive abilities of older adults. We developed the VibrantMinds (https://vibrant-minds.org/vibrantminds2/start) platform, featuring five games: Whack-a-Mole, Bejeweled, Mahjong Solitaire, Word Search, and Memory Game. Our evaluation focused on the usability of these games, their appeal to users, and their effectiveness in enhancing cognitive functions. The next phase of our study aims to determine whether these games can offer meaningful data on the cognitive skills of older adults.
219617638|NCT02157935|DRUG|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
219617639|NCT02157935|DRUG|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
219617640|NCT02157935|OTHER|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
218919679|NCT06414369|OTHER|Diathermy|A DT equipment (CET 400 VA - RET 130 Watts - Winback, France), with a frequency of 500 kHz and intensity at 40% will be used. It will be applied utilizing a flat capacitive head 4 cm in diameter. It will be applied using longitudinal and transverse movements and a conductive cream for DT. DT will be used over the TP of the right and left trochanteric prominence. The settings will be calibrated so that patients fell no more than mild warmth during the treatment.
218919680|NCT06414369|OTHER|Simulated Diathermy|This same intervention that has been given to the experimental group, will be simulated as placebo in the control group; the DT will not be activated during administration.
218919681|NCT02681523|DRUG|Eribulin|
218919682|NCT06999200|DRUG|neural therapy|This prospective study will be conducted with mothers who underwent general anesthesia for labor or elective cesarean delivery and local anesthesia for postoperative pain management during a one-year period following ethical approval.
218919683|NCT03914443|BIOLOGICAL|Nivolumab|240 mg or 360 mg
218919684|NCT03914443|DRUG|5-FU|750 or 800 mg\^2
218919685|NCT03914443|DRUG|CDDP|70 or 80 mg/m\^2
218919686|NCT03914443|DRUG|DTX|70 mg/m\^2
218919687|NCT06600555|PROCEDURE|metabolic surgery with SLEEVE technique|metabolic surgery with SLEEVE technique
218919688|NCT06600555|PROCEDURE|metabolic surgery with BY-PASS technique|metabolic surgery with BY-PASS technique
219533329|NCT04383574|BIOLOGICAL|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
219533330|NCT04383574|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
218919689|NCT06600061|OTHER|Erector Spinae Plane Block|Patients will receive erector spinae plane block after induction of anesthesia.
218919690|NCT06588361|OTHER|Training Based on Kolcoba Comfort Theory|Training Based on Kolcoba Comfort Theory
219617641|NCT02157935|OTHER|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
219617642|NCT06576180|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219617643|NCT06576180|DRUG|Paclitaxel （neoadjuvant）|Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219617644|NCT06576180|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219617645|NCT06576180|PROCEDURE|Surgical resection|Standard of care
218919691|NCT06603129|DIAGNOSTIC_TEST|prognostic nutritional index|Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.
218919692|NCT06600594|OTHER|Beginners dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
218919693|NCT06600594|OTHER|Experience dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
218919694|NCT06999499|OTHER|Scanner of the whole body using the VECTRA 3D|Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma
218919695|NCT02911168|PROCEDURE|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
218919696|NCT02911168|PROCEDURE|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
218919697|NCT06339372|DIETARY_SUPPLEMENT|Standard feeding|Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20\_35% from fats and 10-35% from protein)
218919698|NCT06339372|DIETARY_SUPPLEMENT|Omega 3 and dipeptiven|Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
218919699|NCT02415413|DRUG|carfilzomib|
218919700|NCT02415413|DRUG|Lenalidomide|
218919701|NCT02415413|DRUG|Dexamethasone|
218919702|NCT02415413|DRUG|Melphalan|
218919703|NCT04328077|DRUG|TERN-101|Investigational drug
218919704|NCT04328077|OTHER|Placebo|Matching placebo
219533331|NCT02226289|DRUG|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
219533332|NCT06133920|OTHER|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
219533333|NCT06133920|OTHER|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
219533334|NCT06559020|BEHAVIORAL|Kangroo mother care|Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
219533335|NCT03562962|BEHAVIORAL|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle \& Linnerooth, 2000; Kohlenberg \& Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg \& Tsai, 1991).
219533336|NCT00128791|DRUG|Nitroprusside|
219533337|NCT05034094|OTHER|VEMP recording|"* Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~* The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
219533338|NCT04776226|DRUG|Citalopram|Antidepressant use in patients with depression
219533339|NCT00766701|PROCEDURE|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
219533340|NCT04195230|BEHAVIORAL|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
219533341|NCT00850148|PROCEDURE|Anwar|Anwar surgical method
219533342|NCT00850148|PROCEDURE|Melles|Melles surgical method
219533343|NCT04582019|DEVICE|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
219533344|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
219533345|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
219617646|NCT06230926|OTHER|Validity, Reliability and Adaptation|The Hoehn \& Yahr Scale (HDS) and the Unified Parkinson's Disease Rating Scale (UPDRS) will be used for the clinical evaluation and disease staging of the individuals included in the study. In addition to the PDQoL-7 questionnaire, the 'Short Form-36' and 'Parkinson's Disease Questionnaire-39' questionnaires will be administered to patients to assess concurrent validity. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants. To determine the test-retest reliability, the PDQoL7 questionnaire will be administered again to the same patients after 2 weeks.
219617647|NCT01269216|DRUG|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
219617648|NCT01269216|DRUG|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
219617649|NCT06648395|BEHAVIORAL|CBT Text Messages|CBT text messages will be sent 3 times per week for 4 weeks
219617650|NCT06648395|BEHAVIORAL|Supportive Messages|Supportive text messages will be sent 3 times per week for 4 weeks
219617651|NCT01024504|DRUG|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
219617652|NCT01024504|DRUG|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
219617653|NCT01024504|DRUG|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
218919705|NCT01744106|DRUG|pseudoephedrine hydrochloride 30 mg tablets|
218919706|NCT01744106|DRUG|Placebo tablets|
219617654|NCT02194283|DRUG|Ambroxol - in single rising doses|
218919707|NCT06398756|OTHER|conventional rehabilitation|17 patients with cerebral palsy meeting the criteria will undergo conventional rehabilitation
218919708|NCT06398756|OTHER|aquatic therapy|17 patients with cerebral palsy meeting the criteria will undergo convertional rehabilitation and aquatic therapy
218919709|NCT00680108|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
218919710|NCT05514977|PROCEDURE|Erector spine plane block|Thoracic ESPB
218919711|NCT04089995|OTHER|data collection|No intervention
219533346|NCT05829421|OTHER|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
219533347|NCT04854798|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
219533348|NCT00077077|DRUG|DJ-927|
219533349|NCT00077077|DRUG|capecitabine|
219533350|NCT01964053|BEHAVIORAL|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
219533351|NCT01964053|BEHAVIORAL|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
218919712|NCT04402034|BEHAVIORAL|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
218919713|NCT05497999|OTHER|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
218919714|NCT05497999|OTHER|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
218919715|NCT02268357|DRUG|Propranolol|Oral propranolol capsules
218919716|NCT04841083|DEVICE|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
218919717|NCT00588497|PROCEDURE|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
218919718|NCT00588497|RADIATION|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
218919719|NCT00588497|PROCEDURE|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
218919720|NCT00588497|RADIATION|Hysterosalpingogram|Performed 3 months after micro-inserts placement
219533352|NCT00350753|DRUG|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
219533353|NCT04030845|PROCEDURE|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
219533354|NCT04030845|PROCEDURE|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
219617655|NCT02194283|DRUG|Placebo|
219617656|NCT01237171|RADIATION|Cesium-131 Brachytherapy Seed|85 Gray Dose
219617657|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + rituximab maintenance|RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
219617658|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + tacrolimus maintenance|RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
219617659|NCT05532111|DRUG|Glucocorticoid combined with cyclophosphamide induction + maintenance|PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
219533355|NCT00833209|PROCEDURE|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
219533356|NCT00833209|PROCEDURE|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
219533357|NCT00833209|PROCEDURE|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
219533358|NCT05347719|BEHAVIORAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
219533359|NCT03442491|PROCEDURE|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
219533360|NCT01613872|OTHER|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
219533361|NCT06523842|OTHER|questionnaire|cronell questionnaire for assessment muscloskeletal discomfort in sedentary and standing workers males and females
219533362|NCT04020952|OTHER|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
219533363|NCT04020952|OTHER|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
219533364|NCT04020952|OTHER|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
219533365|NCT05454683|DIETARY_SUPPLEMENT|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
219533366|NCT05454683|OTHER|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
219533367|NCT00003291|GENETIC|cytogenetic analysis|
219533368|NCT00003291|GENETIC|mutation analysis|
219533369|NCT00003291|OTHER|laboratory biomarker analysis|
219533370|NCT01956591|DRUG|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
219617660|NCT05348772|DRUG|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
219617661|NCT00572936|DRUG|Latanoprost|prostaglandin
219617662|NCT00572936|DRUG|Dorzolamide|carbonic anhydrase inhibitor
219617663|NCT00572936|DRUG|Timolol|beta blocker
219617664|NCT05737524|OTHER|Telerehabilitation (VAST 2)|The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
219533371|NCT03316963|DRUG|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
218919721|NCT04875143|DIETARY_SUPPLEMENT|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
218919722|NCT05205122|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
218919723|NCT01926457|OTHER|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
219204703|NCT05520515|OTHER|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
218919724|NCT01515553|DRUG|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
218919725|NCT01820338|BEHAVIORAL|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
219533372|NCT01558635|DEVICE|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
219533373|NCT01558635|PROCEDURE|Mitral Valve surgery|Classic mitral valve surgery was performed
219533374|NCT01558635|DEVICE|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
219533375|NCT01558635|PROCEDURE|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
219533376|NCT02322593|DRUG|TAS-118 plus Oxaliplatin|
219533377|NCT02322593|DRUG|S-1 plus Cisplatin|
219533378|NCT04834128|DRUG|TCB008|administration of gamma delta T cells by IV bolus injection
219533379|NCT00042783|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
219533380|NCT00042783|BIOLOGICAL|SB-AS02B adjuvant|
219533381|NCT06539273|DRUG|Exosome Complex, RNA|A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
219533382|NCT05636735|OTHER|data collection|evaluation of self -confidence
219533383|NCT06560801|DRUG|Dapagliflozin 10mg Tab|Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
219533384|NCT05637125|OTHER|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
219533385|NCT05637125|OTHER|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
219533386|NCT06342830|DRUG|nanocurcumin gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of nanocurcumin gel until shown fill the canal under magnification and by using lentulospirals
219617665|NCT02547428|DRUG|CTN SR|CTN SR tablets, daily, Orally.
219533387|NCT06342830|DRUG|Curcumin Gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of curcumin gel until shown fill the canal under magnification and by using lentulospirals
218919726|NCT01820338|BEHAVIORAL|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
219617666|NCT02547428|DRUG|Matching placebo|Matching-placebo tablets daily, orally.
219617667|NCT05138588|DEVICE|rTMS|For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
219617668|NCT04399616|OTHER|Risk Map|The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
218919727|NCT01820338|OTHER|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains \& carbohydrates. Topics will also include use of vitamin \& mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
218919728|NCT02928965|DRUG|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
218919729|NCT02928965|DRUG|Placebo|Matching placebo with appearance of over - encapsulated minocycline
218919730|NCT00744497|DRUG|Placebo|
218919731|NCT00744497|DRUG|Dasatinib|
218919732|NCT00744497|DRUG|Docetaxel|
218919733|NCT00744497|DRUG|Prednisone|
218919734|NCT03925012|BEHAVIORAL|Intervention|
218919735|NCT03928184|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
218919736|NCT03928184|DRUG|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
218919737|NCT05784038|DIAGNOSTIC_TEST|Viral genomic|Evaluation of mpox viral genomic
218919738|NCT05784038|DIAGNOSTIC_TEST|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
218919739|NCT04830332|DIAGNOSTIC_TEST|abdominal fluid CA-125 levels test|One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
219204704|NCT05520515|OTHER|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
219204705|NCT01287871|OTHER|supportive care|
219617669|NCT04572503|PROCEDURE|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
219617670|NCT01479465|BIOLOGICAL|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
219617671|NCT01479465|DRUG|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
219617672|NCT01479465|DRUG|Leucovorin|l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
219617673|NCT01479465|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
219617674|NCT01479465|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
219617675|NCT02807038|PROCEDURE|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
219617676|NCT00944931|DEVICE|DC Brain Polarization|
219617677|NCT04820465|OTHER|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
219042516|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
219533388|NCT06342830|DRUG|Ciprofloxacin 500 mg +ibuprofen 400mg|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
219617678|NCT03043326|DRUG|Tenofovir Disoproxil Fumarate and Emtricitabine|This is an observational study. Pre-exposure Prophylaxis with TDF/3TC will be distributed to all participants elegible to receive PrEP.
219617679|NCT01791673|DEVICE|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
219617680|NCT02162251|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
219617681|NCT04527718|DRUG|Placebo|placebo as a single SC injection on Day 1;
219533389|NCT06342830|DRUG|Metapaste [calcium hydroxide paste (control group)]|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
219533390|NCT00164463|DRUG|Moxifloxacin|400 mg po qd 5/7 days per week
219533391|NCT00164463|DRUG|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
219533392|NCT01342939|OTHER|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
219533393|NCT01342939|OTHER|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
219533394|NCT01342939|DIETARY_SUPPLEMENT|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
219617682|NCT04527718|DRUG|611|611 as a single SC injection on Day 1;
219617683|NCT01011751|DRUG|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
219617684|NCT01011751|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
219617685|NCT01011751|DRUG|Venlafaxine|Venlafaxine capsule.
219204706|NCT04194450|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
219042517|NCT03377777|OTHER|No intervention|
219204707|NCT04194450|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
219204708|NCT05142371|OTHER|Best Practice|Continue current activities of daily living
219204709|NCT05142371|OTHER|Exercise Intervention|Participate in exercise intervention
219204710|NCT05142371|OTHER|Quality-of-Life Assessment|Ancillary studies
219617686|NCT01011751|DRUG|Leuprorelin|Leuprorelin injection.
219617687|NCT01011751|DRUG|Flutamide|Flutamide tablet
219617688|NCT01011751|DRUG|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
219533395|NCT01342939|OTHER|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
218919740|NCT01116986|BEHAVIORAL|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
218919741|NCT01116986|BEHAVIORAL|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
219533396|NCT01342939|OTHER|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
219533397|NCT06561516|PROCEDURE|Arm I (Red ginseng)|"Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test."
219617689|NCT06309160|BEHAVIORAL|COMPASS Across Settings (CAST)|CAST will begin with an initial joint session with the student, caregiver, special education teacher, and pre-employment transition specialist that allows for discussion on the student's postsecondary goals, preferences, frustrations, challenges, and strengths related to social skills, adaptive/self-management, communication, problem behaviors, learning skills, and sensory sensitivities and preferences. This discussion will pinpoint critical social, communication, and work behavior/learning goals related to postsecondary goals and inform the intervention plans that are generated for each goal. Following this initial consultation, there will be four additional 1-hour sessions that incorporate evidence-based coaching, provided by the investigators, including performance feedback monitoring and instructional support. Each session is standardized and allows for assessment of student progress and intervention modification/self-reflection on the implementation of the intervention plans.
219617690|NCT00464958|DRUG|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
219617691|NCT06576414|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|the first hour of ACT intervention followed by 1 hour of back exercise class, which led by a trained ACT counsellor and a trained exercise trainer
219617692|NCT06576414|BEHAVIORAL|back exercise|1 hour of back exercise class led by a trained exercise trainer
218919742|NCT01116986|BEHAVIORAL|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
218919743|NCT01116986|BEHAVIORAL|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
218919744|NCT01116986|BEHAVIORAL|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
218919745|NCT01116986|DRUG|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
218919746|NCT01116986|DRUG|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
218919747|NCT01116986|DRUG|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
219204711|NCT05142371|OTHER|Questionnaire Administration|Complete questionnaires
219204712|NCT02252380|DEVICE|Transcranial ExAblate System|MR Guided Focused Ultrasound
219533398|NCT06040723|DEVICE|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
218919748|NCT01116986|DRUG|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
218919749|NCT01116986|DRUG|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
218919750|NCT05048277|BEHAVIORAL|Single Session Consultation|"Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources."
218919751|NCT05247671|GENETIC|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
218919752|NCT05247671|GENETIC|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
218919753|NCT03819114|DRUG|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
218919754|NCT04983446|DRUG|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
218919755|NCT04983446|OTHER|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
218919756|NCT01840241|DRUG|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
218919757|NCT01840241|DRUG|normal saline|
218919758|NCT01216553|OTHER|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
219533399|NCT02030223|PROCEDURE|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
219533400|NCT00834418|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
219533401|NCT00834418|DRUG|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
219533402|NCT02540603|DEVICE|F&P Jupiter Full Face Mask|Investigative F\&P Jupiter full face mask to be used for OSA therapy
219533403|NCT04303884|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
219533404|NCT03804762|PROCEDURE|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
219533405|NCT00614471|DRUG|Entecavir|0.5mg po daily for 24 weeks
219533406|NCT00614471|DRUG|Entecavir|0.5mg po daily from week 13 to week 36
219533407|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
219533408|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
219617693|NCT06576414|BEHAVIORAL|back care education|1 hour long interactive lesson to participants about LBP-related pathology, disability, psychology, and pain management skills.
219617694|NCT04158258|DRUG|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219617695|NCT04158258|DRUG|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219617696|NCT04158258|DRUG|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219533409|NCT04826653|OTHER|Suture removal|Suture removal after coronally advanced flap plus a connective tissue graft
219533410|NCT04738071|DEVICE|PFO closure|PFO closure after stroke or transient ischemic attack
219617697|NCT04158258|DRUG|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219533411|NCT03101540|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
219533412|NCT05516056|OTHER|ERAS clinical pathway|Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
219533413|NCT01564238|OTHER|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
219533414|NCT01564238|OTHER|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
219533415|NCT03597243|OTHER|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
219533416|NCT01599728|DRUG|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
219533417|NCT02554032|PROCEDURE|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
219533418|NCT02554032|PROCEDURE|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
218919759|NCT03247946|BEHAVIORAL|upright head position|Bottle feeding of infants with their head in upward and not supine head position
218919760|NCT02492763|DRUG|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
218919761|NCT02492763|DRUG|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
218919762|NCT02492763|DRUG|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
218919763|NCT02492763|DRUG|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
218919764|NCT04286945|PROCEDURE|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
218919765|NCT05027555|OTHER|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
218919766|NCT05027555|OTHER|Conventional training|Conventional training included strengthening, balance training and gait training
218919767|NCT03868657|DRUG|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
218919768|NCT03868657|DRUG|Placebo|Placebo
218919769|NCT03193502|DRUG|rivaroxaban|rivaroxaban
218919770|NCT04962308|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
218919771|NCT04962308|BIOLOGICAL|The SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
219042518|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
219533419|NCT01935076|BEHAVIORAL|Neonatal exposure to maternal obesity|
218919772|NCT03813927|DIETARY_SUPPLEMENT|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
219204713|NCT05890716|DIAGNOSTIC_TEST|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
219204714|NCT03857490|BEHAVIORAL|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
219533420|NCT04230330|DRUG|IV Nivolumab|240mg every 2 weeks.
218919773|NCT03813927|DIETARY_SUPPLEMENT|Placebo|Placebo with tablet 20 μg Vitamin each day.
218919774|NCT00489593|DRUG|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
218919775|NCT03532867|OTHER|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
219204715|NCT03130244|DEVICE|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
219204716|NCT03130244|DRUG|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
219533421|NCT04230330|DRUG|IV Nivolumab|Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
219533422|NCT04230330|DRUG|IV Gemcitabine|800mg/m2 on Days 1 and 8 every 21 days
219533423|NCT04230330|DRUG|IV Cisplatin|20mg/m2 on Day 1 to 4 every 21 days
219533424|NCT04230330|DRUG|IV/PO Dexamethasone|10mg on Days 1 to 4 every 21 days
219533425|NCT04230330|DRUG|IV L-asparaginase|6000 Units/m2 on Days 2 to 8 every 21 days
219533426|NCT06627140|DIAGNOSTIC_TEST|Diagnostic procedures|Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
219533427|NCT04504240|DRUG|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
219533428|NCT06029686|DEVICE|Stanford Glove|The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
219533429|NCT02355886|DRUG|Gabapentin|Given PO
219533430|NCT02355886|OTHER|Placebo|Given PO
219533431|NCT02355886|OTHER|Questionnaire Administration|Ancillary studies
219533432|NCT01200810|OTHER|placebo|Given orally
219533433|NCT01200810|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219533434|NCT01200810|DRUG|bicalutamide|Given orally
219617698|NCT04158258|DRUG|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219617699|NCT04158258|DRUG|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
219617700|NCT00172172|DRUG|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
219617701|NCT00172172|DRUG|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
219617702|NCT00172172|DRUG|placebo|Placebo injected subcutaneously and 700 mg calcium orally
219617703|NCT04469075|DRUG|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
219617704|NCT04469075|DRUG|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
219617705|NCT04680026|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
219617706|NCT04680026|DRUG|Placebo|Normal saline
219617707|NCT03364725|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
219617708|NCT05688566|DEVICE|pinnacle trainer|The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
219617709|NCT06578546|DRUG|Venetoclax|100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.
219533435|NCT02477202|DEVICE|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
219533436|NCT00614250|DRUG|AVE0657|capsules once a day at bedtime
219533437|NCT00614250|DRUG|placebo|capsules once a day at bedtime
219533438|NCT03976635|DEVICE|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
219533439|NCT03976635|DEVICE|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
219533440|NCT00208819|DRUG|risperidone|
219533441|NCT00208819|DRUG|quetiapine|
219533442|NCT00208819|DRUG|olanzapine|
219533443|NCT00208819|DRUG|divalproex|
219533444|NCT04887818|DRUG|2% Diltiazem ointment with 1.5% lidocaine|3 g of topical 2% diltiazem ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
219533445|NCT04887818|DRUG|0.3% Nifedipine ointment with 1.5% lidocaine|3 g of topical 0.3% nifedipine ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
219533446|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using modular dual mobility cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
219533447|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using conventional acetabular cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
219617710|NCT06578546|DRUG|Azacitidine|75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.
219617711|NCT06578546|DRUG|Orebatinib|20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
219617712|NCT00200447|DRUG|carbidopa/l-dopa|
219617713|NCT00200447|DRUG|carbidopa/l-dopa/entacapone|
219617714|NCT00200447|DRUG|Stalevo|
219617715|NCT00200447|PROCEDURE|[123I]-IBZM imaging|
219617716|NCT05023447|BEHAVIORAL|BRIDGE Intervention|Intensive clinical assessment; \>16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
219617717|NCT05023447|BEHAVIORAL|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
219617718|NCT03014583|DEVICE|Precision Spectra™ system|Neurostimulation procedures
219617719|NCT00726856|DRUG|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
219617720|NCT01449656|DEVICE|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
219617721|NCT01449656|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
219617722|NCT05319925|OTHER|Patient reported outcome measure|Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
219617723|NCT02806908|DRUG|JZP-110|
219533448|NCT05422521|OTHER|blood samples and 18FDG PET-CT exams|"* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
219533449|NCT01666899|PROCEDURE|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
219533450|NCT04344106|PROCEDURE|Prone positioning|The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.
218919776|NCT03532867|OTHER|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
218919777|NCT03532867|OTHER|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
219533451|NCT01181700|DRUG|Treatment A|PF-00241939 300 ug using inhaler A
219533452|NCT01181700|DRUG|Treatment B|PF-00241939 300 ug using inhaler A
219533453|NCT01181700|DRUG|Treatment C|PF-00241939 300 ug using inhaler A
219533454|NCT01181700|DRUG|Treatment D|PF-00241939 300 ug using inhaler B
219533455|NCT01181700|DRUG|Treatment E|PF-00241939 300 ug using inhaler B
219533456|NCT01181700|DRUG|Treatment F|PF-00241939 300 ug using inhaler B
219533457|NCT01181700|DRUG|Treatment G|PF-00241939 300 ug using inhaler B
219533458|NCT00501488|DRUG|rosiglitazone|
219533459|NCT01939756|DEVICE|Intravesical baobab oil|Intravesical baobab oil
219533460|NCT04596007|DRUG|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
219533461|NCT04596007|DRUG|Placebo|placebo
218919778|NCT00193661|DRUG|Testosterone Gel (1%)|
219533462|NCT01538888|PROCEDURE|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
219533463|NCT01855685|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
219533464|NCT02020915|PROCEDURE|lateral sphincterotomy|
219533465|NCT02020915|PROCEDURE|ultrasound guided lateral sphincterotomy|
219533466|NCT02570009|BEHAVIORAL|TEAMS (Talking about Eating, Activity, Mutual Support)|
219533467|NCT02570009|BEHAVIORAL|Need Support Training|
219533468|NCT01318551|DRUG|BAY85-3934|single dose, 20 mg
219533469|NCT01318551|DRUG|BAY85-3934|single dose, 40 mg (optional)
219533470|NCT01318551|DRUG|BAY85-3934|single dose, 80 mg (optional)
219533471|NCT02356978|DEVICE|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
219533472|NCT02356978|DEVICE|DRAP|
219533473|NCT02322983|BEHAVIORAL|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
219533474|NCT02008097|DEVICE|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
219533475|NCT05844605|PROCEDURE|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
219533476|NCT00960297|DRUG|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
219533477|NCT00960297|DRUG|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
219533478|NCT00960297|DRUG|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
219533479|NCT01033877|BIOLOGICAL|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
219533480|NCT01033877|BIOLOGICAL|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d)
219533481|NCT05763147|DEVICE|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
219533482|NCT06628102|DIAGNOSTIC_TEST|Chest CT Scan|Chest CT Scan
219533483|NCT01299454|DRUG|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
219533484|NCT03214276|DIETARY_SUPPLEMENT|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
219533485|NCT03214276|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
219533486|NCT05377931|DIAGNOSTIC_TEST|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
219533487|NCT05377931|DIAGNOSTIC_TEST|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
219533488|NCT03149874|DRUG|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
218919779|NCT01038843|DRUG|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
218919780|NCT01747876|DRUG|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
218919781|NCT02092610|DEVICE|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
218919782|NCT02092610|DEVICE|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
218919783|NCT02987426|BEHAVIORAL|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
218919784|NCT00685191|DRUG|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
218919785|NCT01790724|BEHAVIORAL|Walking exercise|
218919786|NCT04379856|DRUG|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
218919787|NCT05194644|OTHER|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
218919788|NCT05194644|OTHER|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
218919789|NCT02170571|DRUG|Dabigatran etexilate|
218919790|NCT00331097|DRUG|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
218919791|NCT00331097|DRUG|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
218919792|NCT00331097|DRUG|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
218919793|NCT00331097|DRUG|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
218919794|NCT02379728|DEVICE|PrenaBelt|"The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine."
218919795|NCT02379728|DEVICE|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
218919796|NCT02379728|DEVICE|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
218919797|NCT03891407|DIAGNOSTIC_TEST|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
218919798|NCT00740649|DRUG|HSD-016|
218919799|NCT00740649|DRUG|placebo|
218919800|NCT05295095|PROCEDURE|positive pressure during extubation procedure|positive pressure during extubation procedure
218919801|NCT03656159|BEHAVIORAL|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
218919802|NCT03656159|BEHAVIORAL|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
219533489|NCT03149874|DRUG|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
219533490|NCT02305394|DRUG|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
219533491|NCT02305394|DRUG|propofol and normal saline|propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
219533492|NCT03309774|DIAGNOSTIC_TEST|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)"
219617724|NCT02806908|DRUG|Placebo|
219617725|NCT04886583|DEVICE|Gabi Baby Band|Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
219617726|NCT04931030|OTHER|Dietary advice|Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
219617727|NCT04404543|DRUG|SYHA1807|Escalation Cohort Administration: Orally
219617728|NCT04404543|DRUG|SYHA1807|Dose Expansion Cohort Administration: Orally
219617729|NCT06152562|DIAGNOSTIC_TEST|VerifyNow antiplatelet therapy response test|VerifyNow testing after minimum of 2 hours and at latest 24 hours after the first four dosis of ASA
219617730|NCT04651855|DRUG|Mesenchymal stem cells isolated from Wharton's jelly|Intrathecal administration of mesenchymal stem cells
219617731|NCT00381082|DRUG|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
218919803|NCT05101122|DRUG|Dosing 1: Atomoxetine|Oral administration at bedtime
219617732|NCT00381082|DRUG|Banlice Mousse Aerosol (Pfizer, Australia)|
219617733|NCT00381082|DRUG|3) KP24 Medicated Foam (Nelson Laboratories)|
219617734|NCT04961385|BIOLOGICAL|Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine|Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
219617735|NCT04445272|DRUG|Tocilizumab|Treatment with Tocilizumab
219533493|NCT03309774|DIAGNOSTIC_TEST|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
219533494|NCT03309774|DIAGNOSTIC_TEST|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
219533495|NCT03309774|OTHER|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
219533496|NCT01208727|PROCEDURE|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
219533497|NCT01891994|DRUG|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
219533498|NCT03680248|DIETARY_SUPPLEMENT|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
219617736|NCT01760304|DRUG|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
219617737|NCT01760304|DRUG|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
219617738|NCT04429503|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
219617739|NCT04429503|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
219533499|NCT03680248|DIETARY_SUPPLEMENT|Fasting|Subjects will fast throughout the experiment.
219533500|NCT03680248|DIETARY_SUPPLEMENT|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
219533501|NCT03680248|DIETARY_SUPPLEMENT|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
219533502|NCT03680248|DIETARY_SUPPLEMENT|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
218919804|NCT05101122|DRUG|AD313|Escalating dose of AD313; Oral administration at bedtime
218919805|NCT04135417|BIOLOGICAL|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
219533503|NCT03680248|DIETARY_SUPPLEMENT|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
219533504|NCT03559491|DRUG|Intravitreal injection|Long term release steroid injection
219533505|NCT03965091|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm description.
219533506|NCT03965091|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
219533507|NCT00431730|PROCEDURE|flicker light stimulation|
219533508|NCT00202722|DRUG|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
219533509|NCT04215822|DIAGNOSTIC_TEST|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
219617740|NCT06094699|OTHER|Sleep friendly order set|"Every evening, the following orders (which comprise the sleep-friendly order set) will be input into the EMR:~Hold vital signs and neurological checks overnight Retime applicable medications outside of the nighttime window of 10pm-6am Retime daily lab draws outside of the nighttime window of 10pm-6am Order melatonin if no clinical contraindications Discontinue finger stick glucose measurements for patients with a stable blood glucose values Change DVT prophylaxis to enoxaparin for all clinically eligible patients"
219617741|NCT06094699|OTHER|Patient sleep menu|Patients will be given a menu of non-pharmacological options that support sleep by improving comfort and reducing anxiety.
219617742|NCT06161194|OTHER|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
219533510|NCT03354286|BEHAVIORAL|Developmental & Technological Demands|Education and training related to use of CGM in this age group
219533511|NCT03354286|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
219533512|NCT03354286|BEHAVIORAL|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
219533513|NCT03354286|BEHAVIORAL|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
219533514|NCT03354286|BEHAVIORAL|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
219533515|NCT02576938|DRUG|Baricitinib|Administered orally
219533516|NCT02576938|DRUG|Placebo|Administered orally
219533517|NCT02576938|DRUG|Triamcinolone (Optional)|Administered topically
219533518|NCT03500341|DEVICE|INVSENSOR00014|Noninvasive pulse oximeter sensor
219533519|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
219533520|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
219533521|NCT04678141|OTHER|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
219533522|NCT01377779|DRUG|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
219533523|NCT01377779|DRUG|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
219533524|NCT01010932|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
219533525|NCT01010932|OTHER|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
218919806|NCT04642092|BEHAVIORAL|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
218919807|NCT04642092|BEHAVIORAL|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
218919808|NCT03806361|PROCEDURE|Fat grafts supplemented with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
218919809|NCT03806361|PROCEDURE|Structural fat grafting|Fat grafts without supplementation of ADRC
218919810|NCT03131219|BIOLOGICAL|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
218919811|NCT03819530|DIETARY_SUPPLEMENT|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
218919812|NCT04155762|OTHER|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
218919813|NCT04155762|OTHER|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
219533526|NCT01355133|BIOLOGICAL|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
219533527|NCT04481815|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
219533528|NCT04481815|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
219533529|NCT04481815|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
219533530|NCT00982397|DEVICE|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
219533531|NCT00982397|DEVICE|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
219533532|NCT04435353|DEVICE|VibroLUNG|Lungs intensive therapy
219533533|NCT00838630|DRUG|Cilostazol 100 mg tablets|1 x 100 mg
219533534|NCT00838630|DRUG|Pletal® 100 mg tablets|1 x 100 mg
219533535|NCT05015114|OTHER|Sarcopenia Assessment|Sarcopenia Assessment
219533536|NCT00303940|DRUG|carboplatin|
219533537|NCT00303940|DRUG|talabostat mesylate|
219533538|NCT00303940|DRUG|temozolomide|
218919814|NCT05131737|PROCEDURE|High altitude exposure|Exposure to 2500m of altitude
218919815|NCT05131737|PROCEDURE|Low altitude exposure|Exposure to 490 m
218919816|NCT05357001|OTHER|Connective tissue manipulation|to remove muscle spasticity
219533539|NCT00303940|OTHER|pharmacological study|
218919817|NCT05357001|OTHER|stretching exercises|to remove muscle spasticity
218919818|NCT00600080|DEVICE|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
218919819|NCT00600080|DEVICE|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
218919820|NCT06201780|DIAGNOSTIC_TEST|serum levels of Janus Kinase 1and 2|assessment of serum levels of Janus Kinase 1and 2 by ELISA
218919821|NCT05621434|DRUG|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
218919822|NCT00991016|DRUG|PF-04805712|ascending single and multiple doses starting at 30 mg
219533540|NCT05537129|PROCEDURE|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
219533541|NCT01871662|DRUG|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
219533542|NCT01871662|DRUG|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
219533543|NCT01871662|DRUG|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
219533544|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
219533545|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
219533546|NCT01631383|DRUG|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
219533547|NCT01631383|DRUG|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
218919823|NCT04554680|DRUG|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day \& oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- \& post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
218919824|NCT04163952|BIOLOGICAL|Panitumumab|Given IV
218919825|NCT04163952|BIOLOGICAL|Talimogene Laherparepvec|Given IM
218919826|NCT06172062|OTHER|laparoscopic pancreaticoduodenectomy|we recorded the surgical videos of laparoscopic pancreaticoduodenectomy, and labeled the information in the video to build and test the algorithms.
218919827|NCT01497288|DRUG|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
219533548|NCT04167410|OTHER|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
218919828|NCT02146066|BIOLOGICAL|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
218919829|NCT05313295|OTHER|Home-based physiotherapy|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
219533549|NCT01333332|DRUG|Capecitabine|Capecitabine
219533550|NCT01333332|RADIATION|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
219533551|NCT02363803|DRUG|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
219533552|NCT02363803|DRUG|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
218919830|NCT05313295|OTHER|Usual Physiotherapy|Usual care provided for the management of neurological disorders in children
219533553|NCT01912898|DEVICE|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
218919831|NCT04374942|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
218919832|NCT04374942|DRUG|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
218919833|NCT04782583|OTHER|Questionnaire|questionnaire for the patients and the volontaire
218919834|NCT02194335|DRUG|BIBN 4096 BS - in single rising doses|
218919835|NCT02194335|DRUG|Placebo|
218919836|NCT01391546|BIOLOGICAL|ZOSTAVAX|1 dose 0.65 mL
218919837|NCT00312156|DRUG|insulin detemir|
218919838|NCT00312156|DRUG|insulin NPH|
218919839|NCT00312156|DRUG|insulin aspart|
218919840|NCT04945733|DRUG|Amivantamab|Amivantamab will be administered intravenously.
218919841|NCT04286984|OTHER|unified protocol of Patient Blood Management measure|upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level \< 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb\<12g/dL and/or ferritin \<300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb \< 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb \< 7 g/dL for the rest of patients in absence of active bleeding.
218919842|NCT03187392|DRUG|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
218919843|NCT03187392|DRUG|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
218919844|NCT04470154|DRUG|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
218919845|NCT04470154|DRUG|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
218919846|NCT04470154|DRUG|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
218919847|NCT04470154|DRUG|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
218919848|NCT04470154|DRUG|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
218919849|NCT04470154|DRUG|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
218919850|NCT05208060|BIOLOGICAL|MV130|Treatment administered sublingually
218919851|NCT05208060|OTHER|Placebo|Treatment administered sublingually
218919852|NCT00207077|DRUG|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
218919853|NCT05626621|DRUG|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
218919854|NCT05626621|DRUG|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
218919855|NCT05626621|DRUG|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
218919856|NCT04053777|DEVICE|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
218919857|NCT03666754|PROCEDURE|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
218919858|NCT03666754|PROCEDURE|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
218919859|NCT02897323|OTHER|description|
219533554|NCT03140631|DRUG|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
219533555|NCT01477476|DRUG|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
219533556|NCT01477476|OTHER|Placebo Comparator|A placebo will be given to 7 subjects.
219533557|NCT01152827|DRUG|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn"
219533558|NCT03774680|DRUG|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
219533559|NCT03774680|DRUG|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
219533560|NCT03324178|BEHAVIORAL|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
219533561|NCT03324178|BEHAVIORAL|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
219533562|NCT02372305|BIOLOGICAL|FlexHD|Patients will be randomized to receive FlexHD.
219533563|NCT02372305|BIOLOGICAL|Alloderm|Patient will be randomized to receive Alloderm.
219533564|NCT05970653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
219533565|NCT05970653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
218919860|NCT01392105|DRUG|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
218919861|NCT01392105|DRUG|Control group|No additional treatment of mesenchymal stem cells
218919862|NCT03580811|DEVICE|Dental Implant &ADMG|A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
218919863|NCT03580811|DEVICE|Dental implant & ADMG & BDX|Dental Implant will be placed with ADMG that covers the BDX
218919864|NCT03095859|OTHER|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
218919865|NCT00286247|GENETIC|INGN 201|
218919866|NCT06130488|BEHAVIORAL|KMC|KMC implementation as per protocol
219533566|NCT04509063|BEHAVIORAL|Information about hypothetical mammography screening without benefits|We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
219533567|NCT03325192|DRUG|Rapid pleurodesis protocol|"* The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
219533568|NCT03325192|OTHER|Placebo|"* The pleural space will be evacuated completely through the newly placed IPC~* Only placebo (normal saline) will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
219617743|NCT05516108|BEHAVIORAL|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
219617744|NCT05516108|BEHAVIORAL|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
219204717|NCT05858905|DEVICE|Intravascular Lithotripsy|The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
218919867|NCT01841411|DRUG|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
218919868|NCT01841411|DRUG|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
218919869|NCT01841411|DRUG|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
219204718|NCT05379725|OTHER|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
219204719|NCT05379725|OTHER|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
218919870|NCT03431207|OTHER|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
218919871|NCT02052258|DRUG|Oxytocin|
219617745|NCT05413343|DRUG|Ceftazidime-avibactam|Patients with severe sepsis and treatment with CAZ-AVI will be enrolled. Blood samples at 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of CAZ-AVI
218919872|NCT05114954|DEVICE|CardioPulsesTM pulsed field ablation system|Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
218919873|NCT01081652|DRUG|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
218919874|NCT01081652|DRUG|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
218919875|NCT00078585|BIOLOGICAL|PROSTVAC®-VF/TRICOM™|
218919876|NCT02206633|DEVICE|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
218919877|NCT00524836|DRUG|levocetirizine dihydrochloride|
218919878|NCT02047032|PROCEDURE|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
218919879|NCT02047032|DRUG|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
218919880|NCT02047032|PROCEDURE|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
218919881|NCT05660577|DEVICE|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
218919882|NCT02796599|DEVICE|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
218919883|NCT04295447|OTHER|Standard of care|"1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
218919884|NCT04295447|DRUG|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
218919885|NCT05198596|BIOLOGICAL|MVC-COV1901|Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
219042519|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
219042520|NCT05309603|OTHER|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
219617746|NCT04150939|PROCEDURE|Core Biopsy|Undergo core biospy
218919886|NCT05198596|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
218919887|NCT04758572|OTHER|Manual Therapy|Mobilization, massage and stretching
218919888|NCT04758572|OTHER|Massage muscle chain|Massage very soft following the directions of the muscle chains, massage and stretching
218919889|NCT02479399|DRUG|ipragliflozin|Tablets
218919890|NCT06254638|BEHAVIORAL|Multicomponent school-based intervention.|"Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the research team) are in charge of the physically active classes.~Active break: the intervention consists of 2 active pauses per day. The development of each pause is carried out through a specific digital platform in which students follow the instructions of an avatar, who is in charge of guiding the realization of the active break. Each active break takes a total of 4 minutes, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed.~Active break: The intervention consists of a daily active break, every school day of the week. The design and supervision of each active break will be carried out by the support technician and the teaching staff based on the students' tastes."
219042521|NCT05309603|OTHER|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
219617747|NCT04150939|PROCEDURE|Cryosurgery|Undergo cryoablation
219617748|NCT04150939|DRUG|Immunotherapeutic Agent|Receive standard of care immunotherapy
219533569|NCT02159950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219533570|NCT02159950|BIOLOGICAL|Sipuleucel-T|Given IV
219533571|NCT02159950|DRUG|Tasquinimod|Given PO
219533572|NCT00298350|DRUG|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
219042522|NCT05309603|OTHER|Walking|Walking three miles on a treadmill at a self-selected speed
219533573|NCT05494203|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
219533574|NCT00003659|BIOLOGICAL|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
219617749|NCT06853184|DRUG|Artesunate|Low Dose Artesunate: 2.4 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices High Dose Artesunate: 4.8 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices
219617750|NCT06853184|DRUG|Ganciclovir (GCV)|Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices
219617751|NCT02717507|DRUG|Carvedilol|Given PO
219617752|NCT02717507|OTHER|Laboratory Biomarker Analysis|Correlative studies
219617753|NCT02717507|OTHER|Pharmacogenomic Study|Correlative studies
219617754|NCT02717507|OTHER|Pharmacological Study|Correlative studies
219042523|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
219617755|NCT02717507|OTHER|Placebo Administration|Given PO
219617756|NCT02717507|OTHER|Quality-of-Life Assessment|Ancillary studies
219617757|NCT02717507|OTHER|Questionnaire Administration|Ancillary studies
219617758|NCT06332807|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
219042524|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
219533575|NCT00003659|BIOLOGICAL|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
219533576|NCT00003659|DRUG|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
218919891|NCT04822337|DRUG|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
218919892|NCT04804384|DEVICE|Prehension neuroprosthesis|"The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive."
219533577|NCT00003659|DRUG|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
219533578|NCT04280120|OTHER|Neural Mobilisation|Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.
219533579|NCT04280120|OTHER|Massage therapy|Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
219533580|NCT04280120|DIAGNOSTIC_TEST|Faradic electrical stimulation|Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
219617759|NCT06852807|DRUG|18F-MFBG|Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
219617760|NCT05309278|BEHAVIORAL|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
219617761|NCT05309278|BEHAVIORAL|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
219617762|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
219617763|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
219617764|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
218919893|NCT03363841|DRUG|SCY-078|Oral SCY-078
218919894|NCT00563056|DRUG|Flutiform|
218919895|NCT00563056|DRUG|Flixotide plus Foradil|
219533581|NCT04280120|OTHER|Exercises|Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
219533582|NCT00925860|PROCEDURE|non positive pressure mechanical ventilatory support|
219533583|NCT05324098|OTHER|STAND-T platform|Internet-based intervention comprised of evidence-based, patient materials and resources
219533584|NCT05324098|OTHER|Survey Administration|Satisfaction and follow-up surveys will be administered to participants
218919896|NCT03343912|DRUG|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
219533585|NCT05324098|OTHER|Text Messages|Participants will receive periodic text messages
219533586|NCT05915091|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
219533587|NCT05915091|OTHER|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
219533588|NCT03515694|DRUG|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
219533589|NCT02237820|DRUG|Dexamethasone|6 mg/day of Oral Dexamethasone
219617765|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg,q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
219617766|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
219617767|NCT01315431|DRUG|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
219617768|NCT04618731|DIAGNOSTIC_TEST|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
219617769|NCT03197441|OTHER|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
218919897|NCT03343912|DRUG|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
218919898|NCT03343912|DRUG|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
218919899|NCT01744977|BEHAVIORAL|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
219617770|NCT00709995|DRUG|Enzastaurin|Administered orally
219617771|NCT00709995|DRUG|Sunitinib|Administered orally
218919900|NCT00821795|DRUG|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
218919901|NCT00821795|DRUG|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
219533590|NCT02237820|DRUG|Prednisone|40 mg/day of Oral Prednisone
219533591|NCT02177422|DRUG|Telmisartan|telmisartan 80 mg once daily
219533592|NCT02177422|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
219533593|NCT04906148|OTHER|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
219533594|NCT04906148|OTHER|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
219533595|NCT06167122|PROCEDURE|Craniofacial reconstruction|"Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted."
219533596|NCT00987740|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
219533597|NCT05221021|DRUG|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
219533598|NCT05221021|DRUG|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
219617772|NCT00709995|DRUG|Placebo|Administered orally
218919902|NCT02156076|DRUG|BMS-919373|
218919903|NCT02156076|DRUG|Placebo (Matching with BMS-919373)|
219042525|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
219042526|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
218919904|NCT03713736|DIAGNOSTIC_TEST|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
218919905|NCT03713736|DIAGNOSTIC_TEST|Pregnancy test|Urinary pregnancy test
218919906|NCT03713736|BEHAVIORAL|Sexual activity questionnary|Sexual activity questionnary
218919907|NCT02327832|PROCEDURE|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
218919908|NCT02327832|DRUG|bone marrow-derived mesenchymal stem cells|
218919909|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
218919910|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
218919911|NCT00738933|DIETARY_SUPPLEMENT|placebo|Margarine product without plant stanol or sterol esters
218919912|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
218919913|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
218919914|NCT04734691|PROCEDURE|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
218919915|NCT06483295|OTHER|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
218919916|NCT00420446|BEHAVIORAL|Adjusted diet|
218919917|NCT01100801|DRUG|TS-1 with cisplatin|
218919918|NCT01100801|DRUG|TS-1 with oxaliplatin|
218919919|NCT02620748|DRUG|Tranexamic Acid|
218919920|NCT02620748|OTHER|Saline Solution|
218919921|NCT00004169|DRUG|carboplatin|
218919922|NCT00004169|DRUG|cyclophosphamide|
219533599|NCT03413839|BEHAVIORAL|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
219533600|NCT03413839|BEHAVIORAL|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
219533601|NCT05691322|DIAGNOSTIC_TEST|transvaginal ultrasound|Transvaginal ultrasound for endometriosis diagnosis (UBESS)
219533602|NCT05691322|DIAGNOSTIC_TEST|MRI|MRI for endometriosis diagnosis (Enzian classification)
219617773|NCT03650699|DEVICE|Electropalatography Biofeedback Training|The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
219617774|NCT05637216|DRUG|Losartan 25 milligram capsule|Losartan 25 milligram oral capsule
219617775|NCT05637216|DRUG|Placebo|Placebo 25 milligram oral capsule
219617776|NCT02386137|DEVICE|Contrast-enhancement ultrasound with Sonovue|
218919923|NCT00004169|DRUG|etoposide|
218919924|NCT00004169|PROCEDURE|peripheral blood stem cell transplantation|
218919925|NCT00004169|RADIATION|radiation therapy|
218919926|NCT02986295|DEVICE|BioMimeTM Stent, Ultimaster® Stent|
218919927|NCT02342236|DEVICE|cemented or cementless type of hip prothesis|
218919928|NCT06432218|OTHER|video education|A re-watchable video provided before pessary fitting which mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy.
218919929|NCT06432218|OTHER|conventional education|Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.
218919930|NCT04909281|DIAGNOSTIC_TEST|Self-sampling HPV|In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
218919931|NCT04737616|DEVICE|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
218919932|NCT04737616|DEVICE|OCT|Optical coherence tomography endoscope
218919933|NCT06119282|OTHER|inhaler|Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
218919934|NCT06119282|OTHER|Control Group|Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
218919935|NCT06119282|OTHER|massage|Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
219042527|NCT06101979|DEVICE|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
219042528|NCT03189030|BIOLOGICAL|pLADD|via IV infusion
219533603|NCT00503477|DRUG|AZD2171|oral tablet
219533604|NCT06015984|BEHAVIORAL|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
219533605|NCT03588923|DRUG|SH229|tablet, oral, 400 mg once daily for 3 days
219533606|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
219617777|NCT05045287|RADIATION|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
219617778|NCT02710721|OTHER|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
218919936|NCT05408741|OTHER|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
218919937|NCT05408741|OTHER|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
218919938|NCT05955482|OTHER|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
218919939|NCT04361396|OTHER|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
218919940|NCT00611104|DIETARY_SUPPLEMENT|standardized freeze-dried table grape powder|
218919941|NCT00611104|OTHER|laboratory biomarker analysis|
218919942|NCT00611104|OTHER|pharmacological study|
218919943|NCT03244332|OTHER|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
218919944|NCT03244332|OTHER|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
218919945|NCT02647996|PROCEDURE|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
218919946|NCT05101070|DRUG|S-531011|Administered by intravenous infusion
218919947|NCT05101070|DRUG|Pembrolizumab|Administered by intravenous infusion
218919948|NCT02085460|DRUG|Placebo|
218919949|NCT02085460|DRUG|2% Rebamipide liquid|
218919950|NCT02085460|DRUG|4% Rebamipide liquid|
218919951|NCT02476253|DRUG|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
218919952|NCT02234167|BEHAVIORAL|Risk behaviour and infectious diseases|through counselling, testing vaccination
219533607|NCT03588923|DRUG|SH229|tablet, oral, 600 mg once daily for 3 days
219533608|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
219533609|NCT03588923|DRUG|SH229|tablet, oral, 800 mg once daily for 3 days
219042529|NCT04122573|DIAGNOSTIC_TEST|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
219533610|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
219533611|NCT06559813|BEHAVIORAL|Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
219617779|NCT02710721|OTHER|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
218919953|NCT05493917|BIOLOGICAL|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
219042530|NCT04122573|DIAGNOSTIC_TEST|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
219042531|NCT04122573|DIAGNOSTIC_TEST|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
219204720|NCT04983511|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
219533612|NCT02714465|OTHER|hyperbaric oxygen therapy|hyperbaric oxygen therapy
219533613|NCT00209781|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
219533614|NCT00209781|DEVICE|ITNs|
219533615|NCT06558617|DIAGNOSTIC_TEST|SARC-F Questionnaire|The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
219533616|NCT06558617|DIAGNOSTIC_TEST|Calf Circumference Measurement|Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
218919954|NCT06184022|COMBINATION_PRODUCT|Augmented reality serious game design for promoting children's science education cognition:|"The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing.~The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter, and the children's behavioral characteristics were recorded. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test. Before and after the intervention, each participant's performance on the game was recorded."
218919955|NCT01293734|OTHER|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
218919956|NCT01293734|OTHER|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
218919957|NCT01293734|OTHER|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
218919958|NCT01293734|DRUG|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
218919959|NCT00213044|DRUG|Carraguard (PC-515)|
218919960|NCT02703597|BEHAVIORAL|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
219533617|NCT06558617|DIAGNOSTIC_TEST|SARC-CalF Questionnaire|This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
219533618|NCT00709254|DRUG|i.v. fentanyl|single dose, 200 ug
219533619|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
219533620|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
219533621|NCT03590795|OTHER|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
219533622|NCT04400890|DRUG|Resveratrol|Resveratrol vs placebo given for 15 days.
219533623|NCT04400890|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 100,000 IU given on day one.
219533624|NCT01414933|OTHER|Biopsy|Breast metastases biopsy
219617780|NCT02489188|PROCEDURE|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
219617781|NCT02489188|OTHER|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
219617782|NCT02489188|PROCEDURE|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
219617783|NCT05894707|DRUG|SCT650C|Recombinant anti-IL-17A antibody
219617784|NCT03145415|PROCEDURE|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
218919961|NCT02703597|BEHAVIORAL|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
219617785|NCT03145415|PROCEDURE|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
219042532|NCT04122573|DIAGNOSTIC_TEST|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
219042533|NCT04122573|DIAGNOSTIC_TEST|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
219533625|NCT00836849|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
219533626|NCT00836849|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
219617786|NCT02862015|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
219533627|NCT04892823|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219533628|NCT04892823|OTHER|Electronic Health Record Review|Review of medical records
219533629|NCT04892823|OTHER|Questionnaire Administration|Complete questionnaires
219533630|NCT01585792|DRUG|TAK-875|
219533631|NCT01585792|DRUG|TAK-875|
219533632|NCT01585792|DRUG|Glimepiride|
219533633|NCT01585792|DRUG|Placebo|
219533634|NCT06112626|BEHAVIORAL|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
219533635|NCT04697368|DEVICE|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
218919962|NCT02703597|BEHAVIORAL|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
219533636|NCT04697368|OTHER|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
219533637|NCT06261528|DEVICE|Light therapy|Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
219533638|NCT04915248|DRUG|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
219533639|NCT04915248|DRUG|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
219533640|NCT04915248|DRUG|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
219533641|NCT05661097|PROCEDURE|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
219533642|NCT03925532|BIOLOGICAL|Denosumab|Given SC
219533643|NCT06851936|BEHAVIORAL|Nicotine cessation program|All participants will complete a nicotine cessation program designed by Area Health Education Center (AHEC). The focus is on known tobacco cessation techniques and motivations to quit with additional focuses on cancer survivors and caregivers. The program consists of 4 sessions (each session is approximately 60 minutes long) that will be delivered by a Tobacco Treatment Specialist by either videoconference or by telephone. Dyad enrollees (i.e., cancer survivors and their caregiver/family member) will complete sessions together. Participants will also be eligible for free nicotine replacement therapy while on study if medically appropriate.
219617787|NCT02862015|DRUG|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
219617788|NCT02207205|DRUG|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
219617789|NCT01138787|DIETARY_SUPPLEMENT|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
219617790|NCT01138787|DIETARY_SUPPLEMENT|Placebo spread|Single dose (30 gr) of regular light margarine
219617791|NCT01138787|DIETARY_SUPPLEMENT|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
219617792|NCT02003209|DRUG|Aromatase Inhibition Therapy|Given at the investigator's discretion
219617793|NCT02003209|DRUG|Carboplatin|Given IV
219617794|NCT02003209|OTHER|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
219533644|NCT06173401|RADIATION|Single-fraction spine SRS|Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)
219533645|NCT06173401|RADIATION|Multi-fraction spine SRS|Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
219617795|NCT02003209|DRUG|Docetaxel|Given IV
219617796|NCT02003209|DRUG|Goserelin Acetate|Given SC
219617797|NCT02003209|OTHER|Laboratory Biomarker Analysis|Correlative studies
219617798|NCT02003209|BIOLOGICAL|Pertuzumab|Given IV
218919963|NCT00763035|DRUG|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
218919964|NCT00763035|DRUG|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
219042534|NCT03569670|DEVICE|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
219533646|NCT04018365|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
219617799|NCT02003209|OTHER|Quality-of-Life Assessment|Ancillary studies
219617800|NCT02003209|PROCEDURE|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
219617801|NCT02003209|BIOLOGICAL|Trastuzumab|Given IV
219617802|NCT02003209|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
219617803|NCT05051735|DRUG|Paracetamol|Paracetamol 500 mg
219617804|NCT05051735|DRUG|Placebo|Placebo
219617805|NCT06145841|DIAGNOSTIC_TEST|Pathogen metagenomic next-generation sequencing|In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
219617806|NCT05839314|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
219533647|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
219533648|NCT06561997|DEVICE|Robot-assisted|received percutaneous pedicle screw fixation (PPSF) with robotic assistance
219533649|NCT06561997|DEVICE|Free-hand|received percutaneous pedicle screw fixation (PPSF) without robotic assistance
219533650|NCT04577846|DRUG|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
219533651|NCT04577846|DRUG|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
219533652|NCT00723710|BIOLOGICAL|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
219533653|NCT05792774|DRUG|Bupivacain|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
219533654|NCT05792774|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
219533655|NCT00134394|DRUG|Etanercept plus tacrolimus|
218919965|NCT04970485|BEHAVIORAL|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
218919966|NCT01539421|BEHAVIORAL|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
218919967|NCT01716377|DRUG|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
218919968|NCT01371396|OTHER|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
218919969|NCT01371396|OTHER|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
218919970|NCT04627402|DRUG|Conbercept and TA|Intravitreous injection of Conbercept and TA
219533656|NCT04988464|BEHAVIORAL|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
219533657|NCT04988464|BEHAVIORAL|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
219533658|NCT01615198|DRUG|Olmesartan|10 mg, 20 mg, 40 mg capsules
219533659|NCT01615198|DRUG|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
219533660|NCT01615198|DRUG|LCZ696|100 mg, 200 mg tablets
219533661|NCT01852747|PROCEDURE|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
219533662|NCT02414152|DRUG|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
219533663|NCT02105779|OTHER|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
219617807|NCT05839314|DRUG|Renin-angiotensin-aldosterone system inhibitors (RASI)|"Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening."
218919971|NCT04627402|DRUG|Conbercept|Intravitreous injection of Conbercept
218919972|NCT03515486|OTHER|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
218919973|NCT03989258|DIAGNOSTIC_TEST|Mammography outside official screening|Radiologic study
218919974|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
218919975|NCT04663282|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
218919976|NCT04663282|DRUG|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
218919977|NCT02131259|DRUG|Afatinib dimaleate|20mg - 50mg
218919978|NCT05387200|DRUG|Masibone S|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
218919979|NCT05387200|DRUG|Fosamax|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
218919980|NCT05955716|DEVICE|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
218919981|NCT05394155|DIETARY_SUPPLEMENT|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
218919982|NCT00523510|PROCEDURE|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
218919983|NCT05410184|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
218919984|NCT05410184|OTHER|mural curtain group|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
218919985|NCT02796170|DRUG|Dapagliflozin|5mg pill taken once daily
218919986|NCT02796170|DRUG|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
218919987|NCT03823521|DRUG|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
218919988|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
218919989|NCT02029716|DRUG|Lotion vehicle/placebo|
218919990|NCT03216512|OTHER|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
218919991|NCT06486194|DEVICE|Targeted breast milk fortification using preemie device|Mother's breast milk will have additional macronutrient added to it based on analysis with the Preemie device, to ensure it meets current European recommendations for nutrient intakes for preterm infants
218919992|NCT06486194|DIETARY_SUPPLEMENT|Standard Breast milk fortification|Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants
218919993|NCT01753232|DEVICE|DALI-adsorber|Recording of treatment data. No extra interventional treatment
218919994|NCT01753232|DEVICE|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
218919995|NCT02614001|DEVICE|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
218919996|NCT02614001|OTHER|post-stroke rehabilitation program|
218919997|NCT02604394|PROCEDURE|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
218919998|NCT02604394|PROCEDURE|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
218919999|NCT04240496|OTHER|Determination of plasma concentration of clozapine/ Genotyping|Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
218920000|NCT03690687|PROCEDURE|Primary anastomosis|
218920001|NCT03690687|PROCEDURE|Delayed anastomosis|
218920002|NCT03690687|PROCEDURE|Enterostomy|
218920003|NCT05751187|BIOLOGICAL|Pembrolizumab|Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
218920004|NCT05751187|BIOLOGICAL|Bevacizumab|Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
218920005|NCT05751187|DRUG|Pemetrexed|Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
219533664|NCT02105779|OTHER|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
219617808|NCT05839314|DRUG|Ciclosporin soft capsules|"The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy."
218920006|NCT05751187|DRUG|Cisplatin|Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
218920007|NCT05751187|DRUG|Carboplatin|Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
218920008|NCT05751187|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
218920009|NCT05751187|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
218920010|NCT05751187|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
218920011|NCT03513159|BEHAVIORAL|Pathfinder support|A pathfinder will support the patient with structured activities.
218920012|NCT00089752|DEVICE|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
218920013|NCT00089752|DEVICE|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
218920014|NCT01686919|DIETARY_SUPPLEMENT|milk-free|milk-free diet during 8 preoperative weeks
218920015|NCT01271946|DEVICE|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
218920016|NCT02933749|DEVICE|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
218920017|NCT02933749|DEVICE|BIS|Bispectral index
218920018|NCT00424710|DRUG|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
218920019|NCT02850653|BIOLOGICAL|PCR : 16S ribosomal DNA and real-time targeted PCR|
218920020|NCT02850653|BIOLOGICAL|Sampling of aqueous humour|
218920021|NCT03013231|BEHAVIORAL|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
218920022|NCT01577992|DRUG|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
218920023|NCT01577992|PROCEDURE|determination of objective and subjective pain threshold|Test without levodopa intake
218920024|NCT05536401|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
218920025|NCT05536401|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
218920026|NCT02992795|DEVICE|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
218920027|NCT05266989|OTHER|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
218920028|NCT02161016|DEVICE|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
218920029|NCT05955248|DIETARY_SUPPLEMENT|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
219533665|NCT03037697|OTHER|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
219533666|NCT03037697|OTHER|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
219617809|NCT00638508|DRUG|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
219042535|NCT03569670|DEVICE|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
219533667|NCT01197248|PROCEDURE|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
219617810|NCT00638508|DRUG|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
218920030|NCT05955248|OTHER|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
218920031|NCT05955248|DIETARY_SUPPLEMENT|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
219617811|NCT05911334|BEHAVIORAL|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
219617812|NCT06269458|BEHAVIORAL|Baby Massage|In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Mothers were informed about the importan
219617813|NCT06269458|BEHAVIORAL|Monther-Baby Yoga|"Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mothers were informed about the importance of having the same treatment room for each treatment. All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research. At the end of four weeks, all mothers were evaluated for mother-infant attachment and the infant's sleep diary."
218920032|NCT00003475|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218920033|NCT00597220|DIETARY_SUPPLEMENT|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
218920034|NCT00597220|DRUG|Placebo|Placebo
218920035|NCT02972437|OTHER|sample taking|throat culture and oral cavity sample
218920036|NCT01403532|DRUG|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
218920037|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
218920038|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
218920039|NCT03818321|DRUG|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
218920040|NCT03818321|DRUG|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
218920041|NCT01961037|OTHER|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
219533668|NCT01197248|PROCEDURE|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
219533669|NCT01517854|DRUG|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
219533670|NCT01517854|DRUG|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
219533671|NCT01289262|PROCEDURE|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
219533672|NCT01289262|PROCEDURE|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
219533673|NCT00838279|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
219533674|NCT00838279|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
219533675|NCT04567082|DIAGNOSTIC_TEST|Examination of saliva|Collection of saliva samples
219533676|NCT02175602|DRUG|Escitalopram|10 milligrams administered each morning
219533677|NCT02175602|DRUG|Sertraline|50 milligrams administered each morning
219533678|NCT02175602|DRUG|DCV 3DAA FDC|Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
219533679|NCT02175602|DRUG|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
219533680|NCT06253403|BEHAVIORAL|psychotherapy|psychotherapy related to sexual intervention
219533681|NCT04882150|DRUG|BMS-986196|Specified dose on specified days
219533682|NCT04882150|OTHER|Placebo|Specified dose on specified days
219533683|NCT04306068|OTHER|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
219533684|NCT02137330|DEVICE|Swallowable Obalon® Gastric Balloon|
219533685|NCT03069586|PROCEDURE|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
219533686|NCT03069586|PROCEDURE|No pulmonary recruitment|At the end of surgery no intervention was completed
218920042|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
218920043|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
219533687|NCT01393054|DRUG|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
219617814|NCT00739713|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
219617815|NCT00739713|DIETARY_SUPPLEMENT|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
219533688|NCT03623230|PROCEDURE|Ultrasound Guided Femoral Nerve Block|Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
219533689|NCT03623230|OTHER|Dressing|Only dressing will be applied to related area to protect blindness between groups
219533690|NCT03623230|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
219533691|NCT03623230|DRUG|Bupivacaine 0.125% Injectable Solution|Perineural Injection
219533692|NCT04608149|DEVICE|Carpediem System|Continuous renal replacement therapy
219533693|NCT01823263|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
219533694|NCT01823263|PROCEDURE|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
219533695|NCT01823263|PROCEDURE|Interference task|30-minute interference task
219617816|NCT03606616|PROCEDURE|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
219617817|NCT01030419|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
218920044|NCT01107054|DRUG|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
218920045|NCT01107054|DRUG|placebo|A single oral dose of non-matched placebo on Day 4.
218920046|NCT05324852|DRUG|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
219533696|NCT01823263|BEHAVIORAL|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
219533697|NCT01823263|BEHAVIORAL|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
219533698|NCT01823263|BEHAVIORAL|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
218920047|NCT05324852|DRUG|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
218920048|NCT05185869|DRUG|SHR6390|SHR6390, Oral Administration
218920049|NCT05185869|DRUG|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
218920050|NCT05185869|DRUG|Gemcitabine|Gemcitabine, Intravenous Injection
218920051|NCT03216226|DRUG|dasiglucagon|Glucagon Analog
218920052|NCT03216226|DRUG|GlucaGen|Native Glucagon
218920053|NCT03354195|PROCEDURE|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
219042536|NCT03283423|DEVICE|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
219204721|NCT04263038|DRUG|Rivaroxaban|Anticoagulation
219204722|NCT04263038|DRUG|Placebo|Study drug without active agent
219533699|NCT01218867|BIOLOGICAL|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
219533700|NCT01218867|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
219617818|NCT01030419|BEHAVIORAL|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
219617819|NCT05972902|DRUG|Dydrogesterone|Dydrogesterone molecular structure and pharmacologic effects are closely related to endogenous progesterone
219617820|NCT05972902|DRUG|Cetrorelix acetate|GnRH antagonist
219533701|NCT01218867|BIOLOGICAL|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
219533702|NCT01218867|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
219533703|NCT01093963|DRUG|Lisdexamfetamine|oral; 20-70mg/day
219533704|NCT01093963|DRUG|Placebo|oral; 20-70mg/day
219617821|NCT05972902|DRUG|Triptorelin|GnRH agonist
219617822|NCT02486237|OTHER|None, observational study|None, it is an observational study
219617823|NCT04092309|DRUG|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
219617824|NCT00370552|DRUG|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m\^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
219617825|NCT00370552|DRUG|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m\^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
219617826|NCT00370552|DRUG|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
219617827|NCT00017693|BIOLOGICAL|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
219617828|NCT00017693|BIOLOGICAL|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
219617829|NCT04789993|OTHER|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
219617830|NCT00003744|DRUG|gemcitabine|
219617831|NCT01152372|PROCEDURE|Insulin, glucose and staple isotopes|
219617832|NCT00495807|BEHAVIORAL|No Words|Without any words was given during pain management
219042537|NCT02403245|OTHER|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
219042538|NCT04011410|DRUG|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
219617833|NCT00495807|BEHAVIORAL|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
219617834|NCT00495807|BEHAVIORAL|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
219042539|NCT05881473|DIAGNOSTIC_TEST|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
219042540|NCT02264002|DRUG|Cilobradine low dose 1|
219533705|NCT03792477|BIOLOGICAL|Test formulation|A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
219533706|NCT03792477|BIOLOGICAL|Reference formulation|A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
219533707|NCT04984473|DEVICE|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
219533708|NCT02100761|DRUG|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
219617835|NCT00495807|BEHAVIORAL|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
219617836|NCT00962897|PROCEDURE|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
219617837|NCT00962897|PROCEDURE|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
219617838|NCT03500198|DEVICE|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
219617839|NCT03500198|DEVICE|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
219533709|NCT01474551|DRUG|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
219533710|NCT02456714|DRUG|FOLFIRINOX|
219533711|NCT00488800|BIOLOGICAL|pneumococcal conjugate vaccine|
219533712|NCT02804945|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.
218920054|NCT05119881|BEHAVIORAL|mirror therapy|a mirror box will be placed in front of the participants with the mirror reflection side toward the non-paretic limb. The paretic arm will be placed behind the mirror, and the mirror box will block the vision of the paretic limb. Through this method, the patients can only view the movement of the non-paretic limb and its mirror reflection from the mirror. The participants will be instructed to move or perform functional tasks with their non-paretic limb and look at the mirror reflection of the non-paretic limb and mentally imagine that it is the paretic arm moving. At the same time, the participants will be encouraged to move the paretic arm along with the mirror reflection of the non-paretic arm. Activities practice during MT will include gross motor movements, fine motor movements, and functional tasks.
219533713|NCT05926479|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
219533714|NCT05926479|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
219533715|NCT05926479|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
219533716|NCT01351220|BEHAVIORAL|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
219533717|NCT01351220|BEHAVIORAL|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
219204723|NCT06250673|DIETARY_SUPPLEMENT|Diet experiment|For the isotretinoin users
219204724|NCT04991129|DRUG|WJ01024|5mg QD: WJ01024, Q4W, once per day
219533718|NCT02666300|OTHER|TaperGuard ETT|tracheal intubation with TaperGuard ETT
219617840|NCT06424548|DRUG|Administration of Sarpogrelate|Aspirin 100mg plus Sarpogrelate 100mg
219533719|NCT04699799|OTHER|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
219533720|NCT05454111|PROCEDURE|Multiscale entropy-guided ablation plus PVI|The multiscale entropy is calculated based on intracardiac electrical signals, higher multiscale entropy value indicates closer to the core of rotors which maintains the persistent atrial fibrillation.
219533721|NCT05454111|PROCEDURE|CARTO-Finder-guided ablation plus PVI|CARTO-Finder-guided ablation plus PVI
219533722|NCT05729061|DEVICE|Assist-Knee|Investigational prosthetic knee-ankle device
219533723|NCT05729061|DEVICE|Prosthetic Knee|Commercially available prosthetic knee devices
219533724|NCT05729061|DEVICE|Prosthetic Ankle|Commercially available prosthetic ankle devices
219533725|NCT05729061|DEVICE|Prosthetic Foot|Commercially available prosthetic foot devices
219533726|NCT05729061|DEVICE|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
219617841|NCT06424548|DRUG|Traditional administration of Clopidogrel|Aspirin 100mg plus Clopidogrel 75mg
219617842|NCT00531167|DRUG|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
219617843|NCT00326391|DRUG|methylphenidate hydrochloride extended-release tablets|
219617844|NCT05845801|OTHER|Register|Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.
219617845|NCT02904772|DRUG|alipogene tiparvovec|A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
219617846|NCT02904772|DRUG|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
219617847|NCT02904772|DRUG|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
219617848|NCT02904772|DRUG|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
219042541|NCT02264002|DRUG|Cilobradine low dose 2|
219042542|NCT02264002|DRUG|Cilobradine medium dose|
219042543|NCT02264002|DRUG|Cilobradine high dose 1|
219042544|NCT02264002|DRUG|Cilobradine high dose 2|
219042545|NCT02264002|DRUG|Metoprolol succinate tablets|
219042546|NCT02264002|DRUG|Placebo|
219204725|NCT04991129|DRUG|WJ01024|5mg BID: WJ01024, Q4W, twice per day
219533727|NCT05530447|DRUG|Samelisant|Tablet
219533728|NCT02609295|DIETARY_SUPPLEMENT|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
219533729|NCT02609295|DIETARY_SUPPLEMENT|ALA group|1.2 g (two capsules) of perilla oil
219533730|NCT03426241|OTHER|no intervention|this is cross-sectional study
219533731|NCT04813718|DIETARY_SUPPLEMENT|Omni-Biotic Pro Vi 5|Pre- and probiotic
219533732|NCT04813718|DIETARY_SUPPLEMENT|Placebo|Placebo
219533733|NCT04915534|DEVICE|Ambu® AuraGain™ Laryngeal Mask (LM)|Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
219533734|NCT00227136|DRUG|5-Hydroxy-Tryptamine|
219533735|NCT04495647|OTHER|Whole-Body Electromyostimulation|"Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention."
219533736|NCT04497181|DEVICE|Coil embolization surgery|Embolization of aneurysms with various coils system
219533737|NCT00071591|BEHAVIORAL|Functional Adaptation Skills Training (FAST)|
219533738|NCT04700254|OTHER|DASS questionnaire|The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
218920055|NCT05119881|DEVICE|tDCS|The tDCS will be delivered by a DC-stimulator (Soterix Medical Inc, New York, USA) through 2 saline-soaked surface sponge electrodes (anodal electrode size: 25 cm2; cathode electrode size: 25 cm2). The anodal electrode will be placed over the ipsilesional M1 while the cathodal electrode will be placed over the contralesional M1. The stimulation intensity will be ramped up to 2mA in 15 seconds, and maintained at 2mA throughout the 20-minute stimulation for the MT+tDCS group.
218920056|NCT05119881|BEHAVIORAL|sham mirror therapy|For the sham MT (s-MT) condition, the same mirror box will be used except that the mirror side will be made blurred to view; thus, the participants will not be able to view the mirror reflection of the paretic limb. The participants will perform the same activities as the real MT condition.
218920057|NCT05119881|DEVICE|sham tDCS|For the sham tDCS group, the electrodes will be placed on the brain regions as the real tDCS group. The intensity will first be ramped up to 2mA within 15 seconds and then the stimulator will be turned off gradually within the next 30 seconds.
219204726|NCT04991129|DRUG|WJ01024|10mg BID: WJ01024, Q4W, twice per day
219204727|NCT04991129|DRUG|WJ01024|40mg BIW: WJ01024, Q4W, twice per week
219533739|NCT04700254|OTHER|EAT-26 questionnaire|The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
219533740|NCT02503293|DEVICE|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
219617849|NCT03827265|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
219617850|NCT02165449|DRUG|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
218920058|NCT06324162|DEVICE|bracket removal pliers, LODI|Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
218920059|NCT00497081|DRUG|mirtazapine|mirtazapine 30 mg daily for 3 months
219204728|NCT04991129|DRUG|WJ01024|60mg BIW: WJ01024, Q4W, twice per week
218920060|NCT00497081|DRUG|placebo|placebo 30 mg daily for 3 months
218920061|NCT01671696|OTHER|Cardiac MRI|Cardiac MRI
218920062|NCT02386397|DRUG|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
219204729|NCT04991129|DRUG|WJ01024|80mg BIW: WJ01024, Q4W, twice per week
219204730|NCT04991129|DRUG|WJ01024|60mg QW: WJ01024, Q4W, once per week
219204731|NCT04991129|DRUG|WJ01024|80mg QW: WJ01024, Q4W, once per week
219204732|NCT04991129|DRUG|WJ01024|50mg QW: WJ01024, Q4W, once per week
219204733|NCT04991129|DRUG|WJ01024|40mg QW: WJ01024, Q4W, once per week
218920063|NCT02386397|DRUG|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
218920064|NCT03297450|DEVICE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
218920065|NCT03297450|BEHAVIORAL|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
218920066|NCT03297450|DEVICE|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
218920067|NCT06522620|PROCEDURE|Posterior Femoral Cutaneous Nerve Combined With Proximal Sciatic and Saphenous Nerve Block|All nerve blocks were performed under ultrasound guidance，single supragluteal approach sciatic nerve block using a nerve stimulator, 20 ml of drug was injected around the sciatic nerve, the extent of drug diffusion was observed, the needle tip was turned into the deep surface of the gluteus maximus muscle below the deep gluteal artery and 5 ml of drug was injected, followed by a retractile canal saphenous nerve block injected with 15 ml of drug, and the difference in sensation of the posterior thighs of the bilateral thighs was measured after 15 min to ensure posterior femoral cutaneous nerve were blocked
218920068|NCT06522620|PROCEDURE|Simple Sciatic and Saphenous Nerve Blocks|All nerve blocks were performed under ultrasound guidance，single subgluteal approach sciatic nerve block using a nerve stimulator, with 25 ml of drug injected around the sciatic nerve, followed by a retractile canal saphenous nerve block with 15 ml of drug injection
218920069|NCT04909450|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
218920070|NCT04909450|BIOLOGICAL|Vehicle Control|Matching vehicle control without the drug substance
218920071|NCT05249582|OTHER|Virtual Reality|Virtual reality wireless headset
218920072|NCT05249582|OTHER|Television Condition|Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
218920073|NCT03675126|DRUG|SRP-5051|SRP-5051 administered as an IV infusion.
218920074|NCT03772249|DRUG|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
218920075|NCT03772249|DRUG|Placebo for DCR-HBVS|Sterile 9% saline for injection.
218920076|NCT05609591|DIETARY_SUPPLEMENT|Liquid diet group|Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.
218920077|NCT05609591|DIETARY_SUPPLEMENT|Enteral nutrition group|100% short peptide enteral nutrition are given to children for bowel preparation
218920078|NCT05609591|DIETARY_SUPPLEMENT|Low residual diet group|Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
219533741|NCT02503293|DEVICE|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
219533742|NCT05099198|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference
219533743|NCT05099198|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference
219533744|NCT02305706|PROCEDURE|starting position in colonoscopy|
219533745|NCT01921062|BEHAVIORAL|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
219533746|NCT00127946|PROCEDURE|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
219533747|NCT03129022|PROCEDURE|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
219533748|NCT01854047|DRUG|Dupilumab|Solution for injection, Subcutaneous injection
219533749|NCT01854047|DRUG|placebo|Solution for injection, Subcutaneous injection
219533750|NCT01854047|DRUG|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
219533751|NCT01854047|DRUG|Salbutamol/albuterol|Oral inhalation as needed
219533752|NCT01854047|DRUG|Levosalbutamol/levalbuterol|Oral inhalation as needed
219533753|NCT00576056|DRUG|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
219533754|NCT00576056|DRUG|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
219533755|NCT05645367|OTHER|No intervention|This is a post-hoc analysis of a cross-sectional study.
219533756|NCT02109263|PROCEDURE|saccharose versus breast-feeding|saccharose versus breast-feeding
219533757|NCT05523986|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
219533758|NCT05523986|OTHER|Placebo|Placebo
219533759|NCT01778205|OTHER|Observational|
218920079|NCT06511258|BEHAVIORAL|Prehabilitation|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
218920080|NCT00001959|DRUG|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
218920081|NCT06153589|OTHER|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
218920082|NCT04757766|DRUG|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
218920083|NCT05176899|DEVICE|Use of Eko CORE electronic stethoscope|Recording of heart sounds using electronic stethoscope
218920084|NCT04651192|OTHER|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
218920085|NCT06016504|BEHAVIORAL|Health Education|Participate in an adaptive virtual consultation
218920086|NCT06016504|BEHAVIORAL|Health Education|Participate in a non-adaptive virtual consultation
219533760|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games|Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.
219533761|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games|Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
219533762|NCT06628336|DEVICE|HARMONY EVOLUTION|It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.
219617851|NCT00755742|OTHER|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
219617852|NCT01126242|DEVICE|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
218920087|NCT06016504|OTHER|Informational Intervention|Given information-only
218920088|NCT06016504|OTHER|Survey Administration|Ancillary studies
218920089|NCT03286036|OTHER|biomarkers|This is an observational study, there is no intervention
218920090|NCT03450161|DRUG|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
218920091|NCT01479842|DRUG|BTK inhibitor PCI-32765|Given PO
218920092|NCT01479842|BIOLOGICAL|rituximab|Given IV
218920093|NCT01479842|DRUG|bendamustine hydrochloride|Given IV
218920094|NCT01479842|OTHER|pharmacogenomic studies|Correlative studies
218920095|NCT01479842|OTHER|pharmacological study|Correlative studies
219042547|NCT02723149|BEHAVIORAL|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
219042548|NCT06520709|OTHER|No intervention|No intervention
218920096|NCT01479842|OTHER|laboratory biomarker analysis|Correlative studies
218920097|NCT03366610|OTHER|Non-interventional|Non-interventional
219042549|NCT02653651|DRUG|Ketamine|Ketamine infused at 0.1 mg/kg/hour
219042550|NCT02653651|DRUG|Lidocaine|Lidocaine infused at 1 mg/kg/hour
219042551|NCT02653651|DRUG|Placebo|An equal volume of saline
219533763|NCT04877210|DRUG|Topical Insulin|Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
218920098|NCT05455021|COMBINATION_PRODUCT|Vessel Restoration System (VRS)|"The VRS includes the following components:~* VRS 10-8-10 Dimer Coated Balloon Catheter~* VRS Light Fiber~* VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
218920099|NCT04189952|DRUG|Acalabrutinib|Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
218920100|NCT04189952|DRUG|Rituximab|Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
219042552|NCT06028945|DEVICE|HMD: Virtual Reality Exposure Therapy|The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.
219042553|NCT06028945|DEVICE|HMD: Neutral Game|The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
219533764|NCT02479633|OTHER|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
219533765|NCT01990391|DIETARY_SUPPLEMENT|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
219533766|NCT01990391|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
219533767|NCT03207503|PROCEDURE|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
219533768|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
219533769|NCT02291250|DIETARY_SUPPLEMENT|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
218920101|NCT04189952|DRUG|Ifosfamide|Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
218920102|NCT04189952|DRUG|Carboplatin|Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
218920103|NCT04189952|DRUG|Etoposide|Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
219042554|NCT05231265|OTHER|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
219042555|NCT04817228|DRUG|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
219042556|NCT01838642|DRUG|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
218920110|NCT06537700|DRUG|OnabotulinumtoxinA OBT-A|Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
218920111|NCT04762095|OTHER|mindfulness stress reduction program|mindfulness stress reduction program
218920112|NCT02884869|DEVICE|Intubating Laryngeal Mask|Direct laryngoscopy
219533770|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
218920113|NCT06666413|DRUG|Avalglucosidase alfa|Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion
218920114|NCT03737929|PROCEDURE|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
218920115|NCT03737929|PROCEDURE|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
218920116|NCT04091555|DIETARY_SUPPLEMENT|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
219617853|NCT01126242|DEVICE|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
219617854|NCT01126242|DEVICE|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
219617855|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
219617856|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
219617857|NCT03252405|DEVICE|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
219617858|NCT03252405|DEVICE|intravenous cannulation|induction is applied by using intravenous cannulation
219617859|NCT01983267|DRUG|cannabis|use of cannabis oil or cigarets
219617860|NCT04262648|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|Lactobacillus Reuteri NCIMB 30351
219617861|NCT04262648|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
218920117|NCT01052493|DRUG|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
218920118|NCT01052493|DRUG|Placebo|0.9% saline
218920119|NCT02524925|PROCEDURE|fast track protocol|Evaluation of postoperative stress
218920120|NCT03931941|DRUG|RBX2660|RBX2660 is a microbiota suspension administered as an enema
218920121|NCT00915746|DRUG|JNJ-31001074; ketoconazole|
219617862|NCT04347720|DRUG|Indomethacin|Intravenous formulation
219617863|NCT04347720|DRUG|Ibuprofen|Intravenous and oral formulations
219617864|NCT04347720|DRUG|Acetaminophen|Intravenous and oral formulations
219617865|NCT04544774|DRUG|AIT|AIT for airborn allergens (SCIT/SLIT)
219617866|NCT04544774|DIAGNOSTIC_TEST|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
219533771|NCT02291250|DIETARY_SUPPLEMENT|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
219533772|NCT05819918|DRUG|Calcifediol|Subjects hospitalized with COVID-19 treated with calcifediol
219533773|NCT05819918|DRUG|Best available therapy|Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
219617867|NCT04650217|DRUG|Carbidopa/levodopa|"L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose."
219617868|NCT04650217|DRUG|Placebo|Carbidopa/levodopa matched placebo
218920122|NCT02894346|OTHER|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
218920123|NCT00802308|DRUG|Morphine sulphate|Extended release tablet combined with alcohol or water
218920124|NCT05516446|DEVICE|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
218920125|NCT05516446|DEVICE|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
218920126|NCT00125255|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
219204734|NCT06248125|BEHAVIORAL|Singing intervention|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing.
219533774|NCT04519515|DEVICE|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
219533775|NCT06540716|DEVICE|Inspire System|Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
219533776|NCT03740295|DIETARY_SUPPLEMENT|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
219533777|NCT03740295|OTHER|Placebo|Lactose
219204735|NCT06248125|BEHAVIORAL|Music listening intervention|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing.
219533778|NCT05582915|DIAGNOSTIC_TEST|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
219533779|NCT03273153|DRUG|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
219533780|NCT03273153|DRUG|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
219533781|NCT03273153|DRUG|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
219533782|NCT05456763|DIETARY_SUPPLEMENT|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
219617869|NCT04650217|BEHAVIORAL|Exercise training|Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
219617870|NCT04650217|BEHAVIORAL|Control|Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
219533783|NCT05456763|OTHER|placebo|placebo
219533784|NCT06452472|DEVICE|I-LIMB|Use of a multi-grip myoelectric hand prosthesis (I-LIMB after using a standard myoelectric prosthesis)
219533785|NCT01301794|DIETARY_SUPPLEMENT|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
219533786|NCT01359696|DRUG|GDC-0425|Oral escalating dose
219533787|NCT01359696|DRUG|gemcitabine|Intravenous repeating dose
218920127|NCT00125255|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
219533788|NCT02846285|OTHER|No intervention|
219533789|NCT02740647|DRUG|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
218920128|NCT02811068|OTHER|venepuncture|single venepuncture
219617871|NCT01088477|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
218920129|NCT06474338|DIAGNOSTIC_TEST|detection by artificial intelligence|The bladder lesion(s) are detected by artificial intelligence algorithm.
218920130|NCT06474338|DIAGNOSTIC_TEST|detection by urologists|The bladder lesion(s) are detected by urologists.
219533790|NCT02740647|DRUG|Placebo|50 ml of 0.9% sodium chloride three times a day
219533791|NCT05323396|DRUG|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy or stool PCR) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with negative stool microscopy and negative stool PCR will not be administered treatment, thus will serve as controls."
219533792|NCT05675995|BEHAVIORAL|Qigong|6 sessions of combined external and internal qigong delivered in a group-based format once a week.
219617872|NCT03388151|DRUG|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
218920131|NCT00283296|DEVICE|Endeavor|Collapsible, forward folding manual wheelchair
219042557|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
219617873|NCT03388151|DRUG|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
219617874|NCT05111327|OTHER|Structured guideline|Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
219533793|NCT05279482|OTHER|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
219617875|NCT05204992|PROCEDURE|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
219617876|NCT02883972|OTHER|Intervention letter|Behavioural-insight informed letter template
219617877|NCT02883972|OTHER|Control letter|Invitation letter used by local area last year (updated as required)
219617878|NCT02883972|OTHER|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
219617879|NCT04333316|PROCEDURE|large head|implantation of large head total hip
219617880|NCT04333316|PROCEDURE|dual mobility cup|implantation of dual mobility total hip
219617881|NCT00857155|OTHER|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
219617882|NCT00839358|DRUG|albumin|albumine 40 g every 15 days
219617883|NCT00839358|DRUG|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
219617884|NCT00839358|DRUG|Placebo|saline solution
218920132|NCT03278275|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
218920133|NCT03278275|DEVICE|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
218920134|NCT02512705|DEVICE|Pinel Restraints|
218920135|NCT02512705|BEHAVIORAL|Seclusion Room|
218920136|NCT03942796|DRUG|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
218920137|NCT03942796|PROCEDURE|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
218920138|NCT05698485|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
218920139|NCT05698485|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
218920140|NCT05698485|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
218920141|NCT03193255|DEVICE|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
219533794|NCT04852380|PROCEDURE|PRP injections|The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
219533795|NCT03002779|DRUG|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
219533796|NCT04562662|DEVICE|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
219533797|NCT00907413|PROCEDURE|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
219617885|NCT02070250|BEHAVIORAL|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
219617886|NCT04897854|DRUG|Folfirinox|In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
219617887|NCT02035111|DRUG|Tianshu capsule|
219617888|NCT02035111|DRUG|Sugar pill|
219533798|NCT00907413|PROCEDURE|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
219533799|NCT04646213|BEHAVIORAL|Managing Cancer and Living Meaningfully (CALM) Therapy|6 sessions of individualized CALM therapy
219533800|NCT04517019|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
219533801|NCT05946460|DRUG|Aumolertinib|Aumolertinib treatment (110mg, p.o., QD) for 8 weeks
219533802|NCT01764347|PROCEDURE|therapeutic conventional surgery|Undergo robotic radical prostatectomy
219533803|NCT01764347|PROCEDURE|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
219533804|NCT01764347|PROCEDURE|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
219533805|NCT00803686|DRUG|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
219533806|NCT00803686|DRUG|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
219533807|NCT00803686|DRUG|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
219533808|NCT00803686|DRUG|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
219533809|NCT02416726|DEVICE|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
219533810|NCT01684657|DRUG|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
219533811|NCT00711386|DRUG|GSK706769|50mg, 100mg, 200mg, or 400mg
219533812|NCT00711386|OTHER|Placebo|Placebo
219533813|NCT01950611|DRUG|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
219533814|NCT00415363|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
219533815|NCT00415363|DRUG|placebo|oral, daily
219533816|NCT06562738|DRUG|Hetrombopag|Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
219533817|NCT02132663|OTHER|Control: Marketed routine infant formula|
219617889|NCT03975894|BIOLOGICAL|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% \<30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
219617890|NCT05635591|BIOLOGICAL|Autologous monocyte - derived DCs pulsed with EBV antigen|Patients will receive approximately （5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
219533818|NCT02132663|OTHER|An investigational infant formula containing an alternate source of DHA|
219533819|NCT03382548|DRUG|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
219533820|NCT03382548|DRUG|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
219533821|NCT05106465|DEVICE|Konectom platform|Administered as specified in the treatment arm.
219533822|NCT02183415|DRUG|BI 1356 BS, low dose|
219533823|NCT02183415|DRUG|BI 1356 BS, medium dose|
218920142|NCT00634777|OTHER|pet scan|pet scan
218920143|NCT01751698|BEHAVIORAL|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
218920144|NCT01751698|BEHAVIORAL|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
219533824|NCT02183415|DRUG|BI 1356 BS, high dose|
219533825|NCT02183415|DRUG|Placebo|
219533826|NCT02216006|PROCEDURE|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
219533827|NCT02216006|PROCEDURE|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
219533828|NCT05277779|DIAGNOSTIC_TEST|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
219533829|NCT00095212|DRUG|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
219533830|NCT00095212|DRUG|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
219617891|NCT03413462|DRUG|HS-25|HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
219533831|NCT05345665|OTHER|Echography|Neuronal blockade anesthesia for elective surgery of the hand was performed with an only echography.
219533832|NCT05345665|OTHER|Echography and neurostimulation|Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.
219533833|NCT05345665|OTHER|Echography, neurostimulation and active mobilization|Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.
219533834|NCT04920877|OTHER|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
219533835|NCT01653353|BEHAVIORAL|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
219533836|NCT02496546|DRUG|LEO 32731 cream|Applied for 3 weeks
219617892|NCT03413462|DRUG|Placebo of HS-25|Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
219617893|NCT05264662|DRUG|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
218920145|NCT05894109|DIETARY_SUPPLEMENT|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
218920146|NCT05894109|OTHER|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
218920147|NCT02552043|OTHER|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
218920148|NCT06103435|PROCEDURE|Extent od surgical resection|
219042558|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
219204736|NCT06248125|BEHAVIORAL|Book reading intervention|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent- infant interaction in non-musical (or less-musical) contexts.
219533837|NCT02496546|DRUG|LEO 32731 cream vehicle|Applied for 3 weeks
219617894|NCT02496182|DRUG|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
219617895|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
219533838|NCT00437853|DRUG|Anastrozole|
219617896|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
219617897|NCT01644240|DRUG|TD-8954|Intravenous infusion
219617898|NCT01644240|DRUG|Placebo - saline|Intravenous infusion
219617899|NCT03036657|DEVICE|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
218920149|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
218920150|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
218920151|NCT04744246|OTHER|load carriage|35 pound load carried on the back
218920152|NCT05804591|DRUG|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
218920153|NCT05804591|DRUG|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
218920154|NCT04365725|DRUG|Remdesivir|Compassionate provision
218920155|NCT00622050|BEHAVIORAL|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
218920156|NCT00622050|BEHAVIORAL|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
218920157|NCT06189521|OTHER|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
218920158|NCT06189521|OTHER|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
218920159|NCT06189521|OTHER|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
219042559|NCT04166838|BIOLOGICAL|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
219042560|NCT00259506|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|
219533839|NCT03348553|DIETARY_SUPPLEMENT|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
219533840|NCT03348553|DIETARY_SUPPLEMENT|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
219533841|NCT03348553|DIETARY_SUPPLEMENT|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
219533842|NCT03348553|DIETARY_SUPPLEMENT|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
219533843|NCT00175487|PROCEDURE|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
219533844|NCT06402539|BEHAVIORAL|family-centered empowerment program|The intervention will be carried out face to face in the Orthopedics and Traumatology outpatient clinic, and some interviews will be held by phone. The first interview is on the day the patient will be approved in the anesthesia department, the second interview is when the patient is admitted to the ward, the third interview is after the surgery and the fourth interview is in the ward on the day of discharge, the fifth interview is by phone 1 week after discharge, the sixth interview is at the outpatient clinic when the patient comes for a check-up 2 weeks after discharge, and the seventh interview is at the time of discharge. The eighth interview will be held by phone in the 3rd week after discharge, and the eighth interview will be held in the outpatient clinic in the 4th week after discharge.
219533845|NCT04301791|OTHER|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
219533846|NCT03133533|PROCEDURE|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
219533847|NCT03133533|PROCEDURE|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
219533848|NCT06329947|DRUG|Surufatinib 250mg/d qd once daily|mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
219617900|NCT03036657|DEVICE|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
219617901|NCT03253614|DIAGNOSTIC_TEST|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
219617902|NCT03253614|DIAGNOSTIC_TEST|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
219617903|NCT03253614|DIAGNOSTIC_TEST|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
219617904|NCT03095664|BEHAVIORAL|Intervention group|A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
218920160|NCT00742612|DRUG|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
218920161|NCT00742612|DRUG|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
218920162|NCT02277938|DRUG|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
218920163|NCT01151189|BIOLOGICAL|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
219533849|NCT05341622|BEHAVIORAL|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
219533850|NCT05341622|BEHAVIORAL|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
219533851|NCT05341622|BEHAVIORAL|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
219533852|NCT05341622|BEHAVIORAL|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
219533853|NCT05341622|BEHAVIORAL|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
219533854|NCT05341622|BEHAVIORAL|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
219533855|NCT00215319|DEVICE|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
219533856|NCT03919058|OTHER|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
219533857|NCT03919058|OTHER|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
219533858|NCT03919058|OTHER|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
219533859|NCT03919058|OTHER|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
219533860|NCT01169883|BEHAVIORAL|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
219533861|NCT01169883|BEHAVIORAL|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
219533862|NCT01169883|BEHAVIORAL|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
219533863|NCT01169883|BEHAVIORAL|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
218920164|NCT01151189|BIOLOGICAL|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
218920165|NCT04243564|DEVICE|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
218920166|NCT05386329|BEHAVIORAL|Mindset: Therapist-guided smartphone-delivered CBT|All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
219042561|NCT02385175|OTHER|Different objective clinical tests of Eustachian tube function|
219042562|NCT02385175|OTHER|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
219042563|NCT00208195|DRUG|Divalproex ER|
219042564|NCT03810274|DEVICE|3DV+TPS；VARIAN TPS；FonicsPlan|
219533864|NCT01169883|BEHAVIORAL|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
218920167|NCT01850121|DRUG|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
218920168|NCT01547611|OTHER|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
218920169|NCT01547611|OTHER|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
218920170|NCT05654974|OTHER|measurements and questionnaire|paper-based survey administration; erect penis length and girth measurements
218920171|NCT00534612|PROCEDURE|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
218920172|NCT05035537|PROCEDURE|PGDT|The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
218920173|NCT05795036|DEVICE|mHealth 1|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks.
218920174|NCT05795036|DEVICE|mHealth 2|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks. In addition, they will receive daily motivational text message.
218920175|NCT03542487|BEHAVIORAL|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
218920176|NCT03542487|BEHAVIORAL|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
219042565|NCT03322228|OTHER|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
219042566|NCT01467999|DRUG|Guanfacine|Guanfacine, 4mg given once daily
219042567|NCT01398956|DRUG|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
219042568|NCT04643262|PROCEDURE|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or \_\_\_\_\_proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
219533865|NCT02771353|RADIATION|WT_vDIBH|
219533866|NCT02771353|RADIATION|VMAT_FB|
219533867|NCT02947243|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
219533868|NCT02947243|DRUG|Morphine|As per unit's protocol
219533869|NCT06997523|BEHAVIORAL|Breath Therapy and Benson Relaxation Technique|Relaxing breathing therapy (4-7-8) and Benson relaxation technique will be applied to the intervention group for 6 weeks. No intervention will be made to the control group.
219533870|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae|granule
219533871|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix|granule
218920177|NCT03542487|BEHAVIORAL|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
218920178|NCT03542487|BEHAVIORAL|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
218920179|NCT00737672|DEVICE|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
218920180|NCT00737672|PROCEDURE|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
219533872|NCT00827047|PROCEDURE|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
218920181|NCT03632863|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
218920182|NCT03632863|BEHAVIORAL|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
218920183|NCT00296621|DRUG|L-Glutamine|L-Glutamine
218920184|NCT00296621|DRUG|placebo|placebo
218920185|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
218920186|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
218920187|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
218920188|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
218920189|NCT05459181|DIAGNOSTIC_TEST|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
218920190|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
219533873|NCT00827047|PROCEDURE|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
219617905|NCT04413019|OTHER|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
219617906|NCT00942084|DRUG|Acyclovir|"Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
218920191|NCT02694185|OTHER|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
219617907|NCT00247715|DRUG|algeldrate/magnesium oxide|
218920192|NCT06338787|OTHER|FeSC|Iron/yeast complex
218920193|NCT06052852|DRUG|BDC-3042|Dectin-2 agonist antibody
219042569|NCT03748199|DRUG|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
219533874|NCT00827047|PROCEDURE|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
219617908|NCT00247715|DRUG|ranitidine|
219042570|NCT03748199|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
219533875|NCT02658084|DRUG|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
219617909|NCT00247715|DRUG|pantoprazole|
219617910|NCT04348552|OTHER|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related
219617911|NCT00940628|BEHAVIORAL|Diet and Exercise|mildly hypocaloric diet and physical exercise
219617912|NCT00940628|DRUG|orlistat [Xenical]|120mg po tid
218920194|NCT06052852|DRUG|Cemiplimab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
218920195|NCT05525416|DRUG|Sodium Nitroprusside|A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
218920196|NCT05525416|DRUG|Phenylephrine Hydrochloride|A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
219533876|NCT02658084|DRUG|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
219533877|NCT01173042|DIETARY_SUPPLEMENT|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
219533878|NCT01173042|DIETARY_SUPPLEMENT|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
219533879|NCT01173042|DIETARY_SUPPLEMENT|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
219533880|NCT02071875|DEVICE|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
219533881|NCT02661529|PROCEDURE|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
219533882|NCT02661529|PROCEDURE|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
219533883|NCT02661529|OTHER|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
219533884|NCT02661529|OTHER|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
219533885|NCT01678638|PROCEDURE|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
219533886|NCT01678638|PROCEDURE|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
219533887|NCT03732443|DIAGNOSTIC_TEST|FAM-CAM|Family Confusion Assessment Method
219533888|NCT01051570|DRUG|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
219533889|NCT01051570|DRUG|RAD 001|5 mg orally starting on Day 2 then continuous
219533890|NCT01051570|DRUG|prednisone|5 mg orally twice a day starting on Day 1 then continuous
219533891|NCT01051570|OTHER|laboratory biomarker analysis|Samples will be collected from archival tissue.
219533892|NCT01051570|OTHER|pharmacological study|Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
219533893|NCT01379664|DRUG|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
219533894|NCT01379664|DRUG|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
219533895|NCT00824148|DEVICE|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
219533896|NCT00824148|OTHER|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
219533897|NCT05693597|DRUG|Imtenan Oil|Cold Press Oil
219533898|NCT05693597|DRUG|Baraka Capsules|Soft Gelatin Capsules
219533899|NCT03041025|DRUG|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
219533900|NCT03041025|DRUG|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
219533901|NCT01875315|OTHER|Diagnostic Cardiac Imaging|
219533902|NCT01069926|DRUG|AZD1656|Single dose oral tablet
219533903|NCT02963259|DEVICE|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
219533904|NCT05016063|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
219533905|NCT05016063|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
219533906|NCT05016063|BIOLOGICAL|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
219533907|NCT01472393|DIETARY_SUPPLEMENT|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
219533908|NCT01472393|DIETARY_SUPPLEMENT|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
219533909|NCT05683730|OTHER|Intermittent caloric restriction|"Intermittente caloric restriction:~1. st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~2. nd month: restriction of 50% of the caloric intake 2 days per week~3. rd month: restriction of 60% of the caloric intake 2 days per week~4. th month: restriction of 75% of the caloric intake 2 days per week"
218920197|NCT05525416|DRUG|Phenylephrine Hydrochloride|Investigators will give three incremental doses via brachial artery catheter to observe α1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
218920198|NCT05525416|DRUG|Norepinephrine|Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
219533910|NCT00055315|BEHAVIORAL|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
219533911|NCT00055315|BEHAVIORAL|Treatment As Usual (TAU)|
219533912|NCT00731705|PROCEDURE|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
219617913|NCT04885309|PROCEDURE|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
219042571|NCT05207020|DEVICE|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
219533913|NCT02828709|DEVICE|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
219533914|NCT05087134|DRUG|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
219533915|NCT00757874|DRUG|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
219533916|NCT00757874|DRUG|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
219533917|NCT03584139|DEVICE|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
219533918|NCT03584139|DEVICE|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
219533919|NCT03552692|DRUG|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
219533920|NCT01333150|DRUG|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
219533921|NCT01333150|DRUG|Placebo|One single dose of placebo
219533922|NCT03919630|OTHER|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
219533923|NCT03919630|OTHER|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
219533924|NCT00965874|DRUG|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
219533925|NCT00965874|DRUG|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
219533926|NCT00965874|DRUG|Placebos|serum salin
219533927|NCT00065312|DRUG|naveglitazar|
219533928|NCT04611789|DRUG|LY3832479|Administered subcutaneously
219533929|NCT04611789|DRUG|Placebo|Administered subcutaneously
219617914|NCT00234637|DRUG|Rivastigmine, memantine|
219617915|NCT04540991|PROCEDURE|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
219617916|NCT04540991|PROCEDURE|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
219617917|NCT04540991|DIAGNOSTIC_TEST|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
219617918|NCT00199420|DRUG|Istradefylline (KW-6002)|
219617919|NCT01381965|PROCEDURE|Vitreous surgery for macular hole|Vitreous surgery for macular hole
219533930|NCT02235662|DRUG|TFV IVR|
219617920|NCT01772589|PROCEDURE|New saw blade|
219617921|NCT01772589|PROCEDURE|Reprocessed saw blade|
219617922|NCT01276340|DEVICE|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
219617923|NCT04369391|DRUG|SEP363856 150 mg|SEP363856 tablet 150 mg
219617924|NCT04369391|DRUG|Placebo|Placebo tablet
219617925|NCT04369391|DRUG|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
219533931|NCT02235662|DRUG|TFV/LNG IVR|
219533932|NCT02235662|OTHER|Placebo IVR|
219533933|NCT01125059|DRUG|Methadone|0.2 mg/kg methadone IV bolus
219533934|NCT01125059|DRUG|Saline|3 mL saline IV bolus
219533935|NCT02851992|DEVICE|GTS cementless stem|Total Hip Arthroplasty
219533936|NCT02466880|DEVICE|Telemedicine|A diabetes self-management and education program delivered via telemedicine
219617926|NCT03981172|BEHAVIORAL|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
218920199|NCT05525416|OTHER|Isometric Handgrip and Post-Exercise Circulatory Occlusion|Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
219617927|NCT06359990|BEHAVIORAL|BrotherlyACT|BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.
218920200|NCT05525416|OTHER|Rhythmic Handgrip|Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
218920201|NCT05525416|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
218920202|NCT05525416|DRUG|Propranolol Hydrochloride|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
218920203|NCT05525416|DRUG|Phentolamine Mesylate|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
218920204|NCT03564808|DRUG|MSC|Adipose tissue enriched with mesenchymal stem cells
218920205|NCT05522439|DRUG|SHR-1703|SHR-1703 will be administered by SC injection.
218920206|NCT05522439|DRUG|SHR-1703 Placebo|Matching Placebo will be administered by the SC route.
218920207|NCT05369351|DRUG|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
218920208|NCT05369351|OTHER|Standard treatment|Standard treatment
218920209|NCT03628768|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
218920210|NCT02250222|DRUG|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)
218920211|NCT02250222|DRUG|Placebo (Captisol ®)|betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
218920212|NCT06008314|OTHER|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
218920213|NCT00614302|DRUG|TPV|
218920214|NCT03843814|PROCEDURE|APT MRI|
218920215|NCT01551186|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
219617928|NCT06359990|OTHER|BrotherlyACT Waitlist Control Group (WCG)|During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.
218920216|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
219617929|NCT01974622|DRUG|Visudyne|Half fluence verteporfin
219617930|NCT01451450|DRUG|QGE031|QGE031 liquid for subcutaneous injection.
219617931|NCT01451450|DRUG|Placebo|Placebo liquid for subcutaneous injection.
218920217|NCT04029883|BEHAVIORAL|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
218920218|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
218920219|NCT03391362|RADIATION|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
219042572|NCT05207020|BEHAVIORAL|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
219042573|NCT05207020|BIOLOGICAL|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
219042574|NCT05207020|BIOLOGICAL|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
218920220|NCT06964217|DRUG|Monotherapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two ore more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be monotherapy."
218920221|NCT06964217|DRUG|Combination therapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two or more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be combination therapy."
218920222|NCT03108131|DRUG|Atezolizumab|Given IV
219533937|NCT02466880|OTHER|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
218920223|NCT03108131|DRUG|Cobimetinib|Given PO
218920224|NCT04020809|DRUG|Atezolizumab|Anti-PD-L1 monoclonal antibody
218920225|NCT06458465|DIETARY_SUPPLEMENT|Curcumin|\- Curcumin capsules 500 mg twice daily for 6 months
218920226|NCT06458465|DRUG|Pentoxifylline 400 MG|\- Pentoxifylline 400 mg twice daily for 6 months.
218920227|NCT05820581|BEHAVIORAL|Mentalisation|Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
218920228|NCT06117618|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
218920229|NCT06117618|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
218920230|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 10μg|mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
218920231|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 30μg|mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
218920232|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 100μg|mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
218920233|NCT05972993|DRUG|Placebo|Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
218920234|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 3μg|mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
218920235|NCT03866577|BIOLOGICAL|Biological: M254|M254 administered as intravenous infusion
219533938|NCT01549080|DRUG|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
218920236|NCT03866577|DRUG|Placebo|Placebo administered as intravenous infusion
218920237|NCT03866577|BIOLOGICAL|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
218920238|NCT03671330|DRUG|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
218920239|NCT03671330|DRUG|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
218920240|NCT03671330|DRUG|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
218920241|NCT03671330|DRUG|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
218920242|NCT03671330|DRUG|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
218920243|NCT03818256|DRUG|Miricorilant|Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
218920244|NCT03818256|DRUG|Placebo|Placebo tablets for once-daily oral dosing
218920245|NCT05494190|DRUG|Docetaxel|60 mg/m2 i.v. day 1
218920246|NCT05494190|DRUG|Cisplatin|60 mg/m2 i.v. day 1-3
218920247|NCT05494190|DRUG|Capecitabine|750 mg/m2 po bid day 1-14
219533939|NCT02146118|DRUG|Erlotinib|Erlotinib 150 mg/day q 4 weeks
219533940|NCT02146118|DIETARY_SUPPLEMENT|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
219533941|NCT03222063|OTHER|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
219533942|NCT05551780|DEVICE|SoundBite Crossing System|Use of the SoundBite Crossing System to cross calcified chronic total occlusions
219533943|NCT04694586|DRUG|rifampicin|rifampicin 35 mg/kg
219533944|NCT04694586|DRUG|pyrazinamide|pyrazinamide 40 mg/kg
219533945|NCT04694586|DRUG|HRZE|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets
218920248|NCT05494190|RADIATION|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
218920249|NCT05494190|PROCEDURE|Surgery|Neck dissection and primary tumor resection
218920250|NCT04377100|BEHAVIORAL|Computer task questionnaires|MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
218920251|NCT03353688|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
219533946|NCT04694586|DRUG|HR|isoniazid 75 mg + rifampicin 150 mg combination tablets
219533947|NCT04480762|DRUG|SHR-1703|SHR-1703
219533948|NCT04480762|DRUG|Placebo|Placebo of the SHR-1703
219533949|NCT00873639|DRUG|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
219533950|NCT00873639|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
218920252|NCT05609565|DRUG|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
218920253|NCT05609565|DRUG|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
218920254|NCT04249999|BEHAVIORAL|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
218920255|NCT06305650|DIETARY_SUPPLEMENT|Probiotic|Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.
219533951|NCT00993122|DRUG|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
219533952|NCT00000661|DRUG|Oxazepam|
219533953|NCT00000661|DRUG|Zidovudine|
218920256|NCT06584903|OTHER|Temperature Ramp Protocol|Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
218920257|NCT04760613|DRUG|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
218920258|NCT04760613|DRUG|Placebo|identical capsules containing placebo (taken daily by mouth)
218920259|NCT05754645|OTHER|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
218920260|NCT06551610|OTHER|Triage Tool|Tool that uses patient characteristics to triage patients for an earlier procedure date vs the standard of care 12 week wait for procedure.
218920261|NCT06465147|BIOLOGICAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
218920262|NCT06578468|DEVICE|End-tidal oxygen monitor|"The only additional equipment required for this study is the Philips™ IntelliVue G7m Gas Analyser Module 866173. This provides a non-dispersive infrared measurement of respiratory gases and a paramagnetic measurement of oxygen. At Lincoln Medical Center, the gas analyser used will be a Philips G5 gas analyser connected to a Philips Intellivue MP 70. At the University of New Mexico Medical Center, the Masimo root monitor is used.~The gas analysers produce display waves for O2 and CO2, together with numerics for end-tidal values for O2 and CO2 and to our knowledge, there are no differences in values between the various devices used. The gas sampling occurs through a side-stream sampling tube at a rate of 200ml/min ±20 ml/min, which is either obtained from a nasal cannula in the spontaneously breathing patient or a sidestream line if connected to a BVM."
218920263|NCT05739019|OTHER|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
219533954|NCT01816490|DRUG|Intravenous Silibinin (iSIL)|
219533955|NCT01728181|DRUG|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
219533956|NCT01728181|DRUG|Erlotinib|150 mg/day for 28 day cycle. No rest period.
219533957|NCT01728181|OTHER|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
219533958|NCT03878654|DRUG|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
219533959|NCT06872034|DRUG|Venostasin (horse chestnut seed extract tablets)|Venostasin (horse chestnut seed extract tablets) ，twice daily, 400 mg per dose, for 14 days
219533960|NCT06872034|OTHER|standard treatment|standard treatment
219533961|NCT02350647|DEVICE|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
219533962|NCT02350647|DEVICE|Suture anchor Twinfix Ultra HA|
219533963|NCT04739384|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
219533964|NCT04739384|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
219533965|NCT04482465|DIAGNOSTIC_TEST|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
218920264|NCT04844827|GENETIC|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
218920265|NCT04499326|OTHER|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
218920266|NCT05148156|DEVICE|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
219533966|NCT07016425|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of essential tremor patients.
219533967|NCT02655679|DRUG|VTP-38543|VTP-38543 topical cream
219533968|NCT02655679|OTHER|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
219533969|NCT02655679|OTHER|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
219533970|NCT03105453|OTHER|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
219533971|NCT03851250|DRUG|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
219533972|NCT03851250|DRUG|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
219533973|NCT01577381|BIOLOGICAL|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
219533974|NCT01577381|BIOLOGICAL|Placebo|Intravenous, 11 doses, 30 minute infusion
219533975|NCT03871166|OTHER|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~\[Time Frame: 01/2007 - 12/2018\]"
219533976|NCT00911781|OTHER|No intervention|We are only asking for photographs from parents.
219533977|NCT00915694|DRUG|nelfinavir mesylate|
219533978|NCT00915694|DRUG|temozolomide|
219533979|NCT00915694|PROCEDURE|adjuvant therapy|
219533980|NCT00915694|RADIATION|radiation therapy|
219533981|NCT01421277|DRUG|Statin Therapy|Investigator's choice of any statin.
219533982|NCT02186821|DRUG|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
219533983|NCT04270721|BEHAVIORAL|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
219533984|NCT06461091|RADIATION|TMI|Observing the efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating adult acute lymphoblastic leukemia with a conditioning regimen including total marrow irradiation (TMI) in individuals aged 16 years and older: Primary Exploratory Endpoint: Event-free survival at 1 year post allogeneic hematopoietic stem cell transplantation (EFS).
218920267|NCT03043794|RADIATION|Stereotactic Body Radiation Therapy SBRT|Stereotactic Body Radiation Therapy to the breast to 21 Gy
219533985|NCT03989648|OTHER|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
219533986|NCT03989648|OTHER|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
219533987|NCT02587871|DRUG|Cytarabine|Given IV
219533988|NCT02587871|OTHER|Laboratory Biomarker Analysis|Correlative studies
219533989|NCT02587871|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
219533990|NCT02587871|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
219533991|NCT02587871|BIOLOGICAL|G-CSF mobilized peripheral blood cells|microtransplantation
219533992|NCT00497263|DEVICE|Niti CAR|
219533993|NCT00194454|BEHAVIORAL|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
219533994|NCT00194454|OTHER|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
219533995|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
218920268|NCT06306599|DIAGNOSTIC_TEST|S-Detect for Thyroid|"Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS."
218920269|NCT05819658|DRUG|GV1001 Placebo|0.9% normal saline
218920270|NCT05819658|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
218920271|NCT05819658|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
218920272|NCT04486768|OTHER|Survey Instrument|This registry contains several surveys that will be released for patient/caregiver completion at enrollment and at time points following enrollment. These surveys can be completed on any computer that is connected to the internet.
218920273|NCT06462794|DRUG|CX-801|Investigational drug
218920274|NCT06462794|DRUG|pembrolizumab|Standard of Care Therapy
218920275|NCT03600324|BEHAVIORAL|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
218920276|NCT05331638|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
218920277|NCT05331638|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
218920278|NCT05897658|DRUG|Levetiracetam|Tablets
218920279|NCT05897658|OTHER|Placebo|Tablets
219533996|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
219533997|NCT03372187|BEHAVIORAL|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
219533998|NCT04589910|DIAGNOSTIC_TEST|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
219533999|NCT01789177|DEVICE|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
219534000|NCT01789177|OTHER|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
219534001|NCT01549353|BEHAVIORAL|gum chewing|
219617932|NCT04807010|PROCEDURE|Prostate Artery Embolization|Prostate artery embolization reduces symptoms from benign prostatic hyperplasia by delivering embolic materials to the prostate through the prostatic arteries.
219042575|NCT05207020|BIOLOGICAL|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
219042576|NCT05207020|BIOLOGICAL|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
219534002|NCT04189848|DRUG|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
219534003|NCT04189848|DRUG|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
219617933|NCT04807010|PROCEDURE|Sham Prostate Artery Embolization|Angiogram without embolization initially. At 6 months patients will be allowed to crossover to prostate artery embolization.
218920280|NCT02444338|DEVICE|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
219042577|NCT05207020|OTHER|Test meal|taking a test meal before the various blood sugar measurements
219042578|NCT03272451|PROCEDURE|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
219042579|NCT03272451|PROCEDURE|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
219204737|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219534004|NCT01745783|OTHER|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
219534005|NCT01745783|OTHER|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
219617934|NCT00656422|DRUG|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
219617935|NCT00656422|DRUG|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
219617936|NCT01151124|BIOLOGICAL|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
218920281|NCT02444338|OTHER|standard of care|
218920282|NCT05205031|DEVICE|Intraosseous access|Needle placed in the bone marrow.
218920283|NCT05205031|DEVICE|Intravenous|Needle placed in a vein.
219534006|NCT03201523|OTHER|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
219042580|NCT02239809|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
219534007|NCT06000449|BEHAVIORAL|Center M|Digital mental health platform. Screening and prevention activities will be provided through the Center M platform, telehealth group mindfulness sessions, and digitally delivered home practice materials.
219534008|NCT06000449|BEHAVIORAL|Treatment as Usual|Paper screening and PD handout.
219534009|NCT05674513|DRUG|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
219534010|NCT05349513|OTHER|ESSME questionnaire|The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
219042581|NCT02239809|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
219534011|NCT04322500|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
219534012|NCT04322500|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
219534013|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
219534014|NCT00819741|DRUG|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
219534015|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
219534016|NCT07036185|DRUG|KJ015 Injection (Subcutaneous Injection)|KJ015 is administered via subcutaneous injection, with the dosing frequency set at either Q3W.
219534017|NCT07035821|DRUG|Olanzapine Tablets|Oral olanzapine tablets
219534018|NCT07035821|DRUG|Placebo|Oral placebo
219534019|NCT02989233|OTHER|Non-surgical periodontal treatment|Scaling and oral hygiene instructions with brochure, model or video
219534020|NCT03301285|DRUG|Zoledronic Acid|Treatment of osteoporosis
219534021|NCT00119015|DRUG|Placebo|
219534022|NCT00119015|DRUG|Montelukast|
219534023|NCT00119015|DRUG|Fluticasone propionate|
219534024|NCT01930227|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
219534025|NCT01930227|OTHER|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
219534026|NCT01597245|DRUG|80 mg ixekizumab Dosing Regimen|Administered SC
219534027|NCT01597245|DRUG|50 mg etanercept|Administered SC
219534028|NCT01597245|DRUG|Placebo|Administered SC
219534029|NCT01313780|DRUG|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
219534030|NCT01313780|DRUG|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
219534031|NCT03227302|PROCEDURE|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
219534032|NCT03227302|PROCEDURE|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
219534033|NCT03227302|PROCEDURE|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
219534034|NCT00889109|OTHER|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
219534035|NCT03592953|OTHER|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
219534036|NCT00000541|BEHAVIORAL|dietary supplements|
219534037|NCT00000541|DRUG|vitamin C|
219534038|NCT00000541|DRUG|vitamin E|
219534039|NCT00000541|DRUG|beta-carotene|
219534040|NCT00000541|DRUG|folic acid/Vitamin B6/Vitamin B12|
219534041|NCT01232426|PROCEDURE|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
219534042|NCT01232426|DEVICE|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
219617937|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
218920284|NCT04838171|OTHER|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
219534043|NCT01141426|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
219534044|NCT01141426|BEHAVIORAL|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
218920285|NCT05565742|DRUG|LY3819469|Administered SC
218920286|NCT05565742|DRUG|Placebo|Administered SC
218920287|NCT06500338|PROCEDURE|free-fall|"The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, hypergravity), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas."
218920288|NCT06284343|DRUG|Anticoagulant|Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
218920289|NCT02855125|DRUG|TAS-114|TAS-114 was a modulator of 5-fluorouracil (5-FU).
218920290|NCT02855125|DRUG|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
218920291|NCT06652893|DRUG|Sinovial|"A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea"
219042582|NCT01557400|DRUG|Ataluren|Oral powder for suspension
219042583|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
219534045|NCT04799028|OTHER|Traditional cow's milk|Fortified cow's milk
219534046|NCT04799028|OTHER|Experimental milk|Milk with synbiotics and fat blend
219534047|NCT04799028|OTHER|Habitual diet|Habitual diet
219534048|NCT00731783|DRUG|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
219534049|NCT00731783|DRUG|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
219534050|NCT00731783|BEHAVIORAL|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
219534051|NCT06248827|OTHER|Data Collection|Patient data : gender, age, height, weight, daily life (type of job) Diagnostic data : Description of first symptoms/medical history (pain), previous medical history, MRI exams
219534052|NCT01591603|PROCEDURE|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
219534053|NCT01591603|PROCEDURE|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
218920292|NCT04467905|DRUG|Etripamil|The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
218920293|NCT04467905|DRUG|Placebo|The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
219534054|NCT06945380|OTHER|Best Practice, Comparator Program|Receive access to a comparator program
218920294|NCT06809764|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.
218920295|NCT06291441|OTHER|No intervention|No intervention (observational study)
219534055|NCT06945380|OTHER|Best Practice, Usual Care|Receive usual care
219534056|NCT06945380|OTHER|Internet-Based Intervention|Receive access to the PNR program
219534057|NCT06945380|PROCEDURE|Massage Therapy|Perform the relaxation massage techniques
219617938|NCT02307942|PROCEDURE|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
219617939|NCT02445261|RADIATION|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
219617940|NCT02285361|DRUG|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
219617941|NCT02285361|DRUG|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
219617942|NCT02285361|DRUG|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
219617943|NCT05306002|COMBINATION_PRODUCT|Antioxidant therapy|Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
219617944|NCT02892669|OTHER|non interventional study|non interventional study
219617945|NCT05529927|DRUG|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
218920296|NCT06654817|DRUG|Ofatumumab subcutaneous injection|To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
218920297|NCT06655311|BIOLOGICAL|Enlicitide Chloride|Oral administration
218920298|NCT06655311|OTHER|Placebo|Oral administration
218920299|NCT06654583|BEHAVIORAL|Interactive Play Mat|Use of developed interactive play mat that utilizes haptic feedback vibrations to assist children with delayed milestones in achieving Gross Motor Skills. The play mat aims to provide a therapeutic and engaging experience by incorporating visuals, sounds, and lights to encourage movement that might otherwise be challenging for these children.
218920300|NCT06654583|BEHAVIORAL|Conventional Physical Therapy|Stretching and Strengthening exercises
218920301|NCT02873871|DEVICE|Standardized compressive dressing|Standardized compressive dressing
218920302|NCT02873871|DEVICE|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
219042584|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
219042585|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
219617946|NCT05529927|DRUG|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
219617947|NCT01109212|DRUG|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
219534058|NCT06945380|OTHER|Survey Administration|Complete surveys to assess CIPN symptoms, overall well-being and quality of life, and caregiver reaction and attitudes
218920303|NCT01664975|DRUG|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
218920304|NCT01664975|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
218920305|NCT00020488|DRUG|FOLFIRI regimen|
218920306|NCT00020488|DRUG|fluorouracil|
218920307|NCT00020488|DRUG|irinotecan hydrochloride|
218920308|NCT00020488|DRUG|leucovorin calcium|
218920309|NCT06598046|DRUG|Utidelone and capecitabine|Utidelone: intravenous capecitabine: oral
219534059|NCT04439656|DIAGNOSTIC_TEST|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
219534060|NCT03620175|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
219534061|NCT03023956|PROCEDURE|Locking plates were used for proximal humeral fractures.|
219534062|NCT05948683|DRUG|MDMA|The stimulant MDMA
219534063|NCT05948683|DRUG|Placebo|Dextrose
219534064|NCT05293145|OTHER|Building Futures Program Primary Services|Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
218920310|NCT06603168|OTHER|Autonomic Recalibration Treatment|An initial history to r/o pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance throughout the myofascial system. The pattern of sympathetic dominance (pattern of trigger point) is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. The absence of a trigger point indicates that the treatment is complete.
218920311|NCT06590922|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
218920312|NCT06590922|DEVICE|The conventional endoscopic biting group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
219534065|NCT06242145|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219534066|NCT06242145|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219534067|NCT05370417|OTHER|Use of fluoride toothpaste|The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
219534068|NCT05370417|RADIATION|Photobiomodulation|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point."
219534069|NCT05370417|PROCEDURE|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
219534070|NCT05370417|PROCEDURE|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
219534071|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
219534072|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
219534073|NCT05726526|DEVICE|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
219534074|NCT05802680|DEVICE|Transcranial photobiomodulation|Administration of Sham or 1064 (+/- 50) nanometers tPBM
219534075|NCT05802680|DEVICE|Sham transcranial photobiomodulation|Sham treatment
219534076|NCT06161558|DRUG|Erlotinib|Small-molecule tyrosine kinase inhibitor targeting EGFR
219534077|NCT06161558|DRUG|Lenvatinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
219534078|NCT06161558|DRUG|Axitinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
219534079|NCT06508411|OTHER|Pain screening|exploration of the relationship between pain and sexual health
219534080|NCT06163430|DRUG|TERN-701|TERN-701 orally QD
219534081|NCT02096211|DEVICE|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
219534082|NCT05095519|DRUG|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
219534083|NCT01281501|DRUG|Normal saline|10 ml of 0.9% sodium chloride solution
219534084|NCT01281501|DRUG|Pantoprazole|80 mg of intravenous pantoprazole
219534085|NCT01281501|DRUG|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
219534086|NCT01281501|DRUG|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
219534087|NCT02667405|PROCEDURE|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
219534088|NCT02667405|PROCEDURE|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
219534089|NCT01202422|DRUG|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
219534090|NCT01202422|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
219534091|NCT01202422|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
219534092|NCT01619930|BEHAVIORAL|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
219617948|NCT01109212|DRUG|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
219534093|NCT01619930|BEHAVIORAL|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
219534094|NCT01619930|BEHAVIORAL|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
219534095|NCT01619930|BEHAVIORAL|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
219534096|NCT06031857|OTHER|kinesio tape|kinesio tape was applied over the specific muscle of rotator cuff
219534097|NCT06031857|OTHER|Dry needling|dry needling was applied over the affected muscles
219534098|NCT01982981|OTHER|water provision|perception behavioral change at the beginning and at the end of the intervention
219534099|NCT01982981|OTHER|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
219534100|NCT05278481|BEHAVIORAL|Reward Message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
219534101|NCT05278481|BEHAVIORAL|Reward Message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
219534102|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
219617949|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
218920313|NCT06601413|OTHER|M-TAPA Block|M-TAPA block will administer ultrasound guided (Sonosite, Inc., Bothell, WA, USA) bilaterally by same anesthesiologist (E.E.) who had more than 10 years experience of regional anesthesia, before weaking from general anesthesia after the surgical procedure. A high-frequency (6-13 MHz) linear probe (HFL38) will be used to identify the transversus abdominis, internal oblique, and external oblique muscles on the costochondral angle in the sagittal plane at the 10th costal margin. In the midclavicular line, between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue, at the level of the 10th rib, 20 mL of 0.25 percent bupivacaine will be injected (arcus costarum). The same procedure will be followed on the other side.
218920314|NCT06601413|OTHER|Trocar site local anesthetic infiltration|At the end of surgery, infiltration analgesia will be applied to all trocar entry sites (4 port entries) by the surgeon with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
218920315|NCT06593223|DEVICE|Assess Non-invasive filling pressure(NIFP) in heart failure patients|Assess Non-invasive filling pressure(NIFP) in outpatients with stable heart failure and inpatients with acute heart failure in ward
219042586|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
219042587|NCT06162286|DRUG|Omadacycline|Omadacycline IV/PO
219042588|NCT06162286|DRUG|Moxifloxacin|Moxifloxacin IV/PO
219042589|NCT00386412|DRUG|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
219042590|NCT04222582|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
219534103|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
219534104|NCT05278481|BEHAVIORAL|Social norms message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
219534105|NCT05278481|BEHAVIORAL|Social norms message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
219534106|NCT02494479|DRUG|Prurisol|50mg tablet
219534107|NCT02494479|DRUG|Placebo|Sugar pill designed to match Purisol tablet
219534108|NCT00941811|DRUG|Imiquimod|Local Imiquimod three times weekly for 16 weeks
219534109|NCT01807793|BEHAVIORAL|Psychoeducation|
219534110|NCT01038661|DRUG|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
219534111|NCT01038661|DRUG|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
219534112|NCT01038661|OTHER|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
219534113|NCT05385601|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
219617950|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
219042591|NCT02281552|DRUG|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
219534114|NCT05644340|PROCEDURE|Speed 8 (Fast balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
218920316|NCT06596850|BEHAVIORAL|Wheelchair Skills Training Program|Participants will receive 5, 45-minute weekly WC skills training sessions that will take place in the community, in and around the participants home. Each session will be customized to the participant's' goals and based on the learner's impairments (i.e., weakness, spasticity, movement disorders \[e.g. ataxia, tremor\], contractures, cognition). The WSTP sessions will begin with a 5-minute review of goals/progress, followed by a 10-minute warm-up (wheeling activities, random practice of previously leaned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment.
218920317|NCT06597643|OTHER|Eccentric Training|"Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return"
218920318|NCT06597643|OTHER|Deep Friction Massage|The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
218920319|NCT06590272|DEVICE|TECNIS PCB00 intraocular lens|In this study, we select TECNIS PCB00 IOL for inserting in the eyes during the cataract surgery
218920320|NCT06590272|DEVICE|HumanOptics Diff-Aay intraocular lens|In this study, we select HumanOptics Diff-Aay IOL for inserting in the eyes during the cataract surgery
218920321|NCT06590272|DEVICE|TECNIS Symfony ZXR00 intraocular len|In this study, we select TECNIS Symfony ZXR00 IOL for inserting in the eyes during the cataract surgery
218920322|NCT06590272|DEVICE|ZEISS AT LISA tri 839MP intraocular len|In this study, we select ZEISS AT LISA tri 839MP IOL for inserting in the eyes during the cataract surgery
218920323|NCT06603272|DEVICE|The da Vinci robotic system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) was used for all robotic gastrectomy|"Surgical intervention was initiated after obtaining informed consent from all patients, which included the additional costs of robotic surgery, a comprehensive explanation of surgical risks, and potential alternative treatments, thus facilitating informed surgical approach choices (i.e., LG or RG) within the participating institutions. Adherence to the Japanese Gastric Cancer Treatment Guidelines was maintained for determining the extent of gastrectomy and lymphadenectomy."
218920324|NCT06594029|BEHAVIORAL|Community Navigator Intervention|see previous section
218920325|NCT06594029|OTHER|Control Group|Participants receive information on how to increase their community participation
219042592|NCT02281552|DRUG|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
219534115|NCT05644340|PROCEDURE|Speed 4 (Medium speed balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
219534116|NCT02102165|PROCEDURE|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
219204738|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219534117|NCT05378217|DIAGNOSTIC_TEST|AMR LFIA Assay|AMR LFIA will be performed in parallel to routine testing on appropriate sample types retrieved from routine testing : Blood, urine, BronchoAlveolar Lavage (BAL), Tracheal Aspirate (TA), Rectal swab
219534118|NCT04206358|BIOLOGICAL|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
219534119|NCT03569059|DEVICE|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
219534120|NCT03569059|BEHAVIORAL|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
219534121|NCT03569059|DEVICE|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
219534122|NCT00519194|DEVICE|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
219534123|NCT00519194|PROCEDURE|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
219534124|NCT03165994|DRUG|APX005M|APX005M IV infusion
218920326|NCT06591442|DIAGNOSTIC_TEST|This is an observational study|This study divides the elderly population into two groups: the Elderly group and the Advanced age group. By observing the enhanced recovery after spinal fusion surgery in these two distinct age groups of elderly patients, risk factors affecting postoperative enhanced recovery will be identified. Detection index: Blood routine examination, blood biochemistry, coagulation function, imaging examination (X-ray, CT 3D reconstruction), Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) pain score. The number of participants for all adverse events, serious adverse events, implant-related adverse events and drug-related serious adverse events, and the adverse events were summarized accordingly. The severity of adverse events will be rated according to NCI-CTCAE version 4.0.
218920327|NCT06600451|OTHER|observational study, no intervention is required|"Retrospective chart review, investigators provides data after reviewing patient\&#39;s existing medical record; no interaction with patients is required.~Patients were treated as per standard of care"
218920328|NCT06594003|PROCEDURE|Radiofrequency|There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves . Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support
218920329|NCT06591676|BEHAVIORAL|Dysfunctional Attitude Scale (DAS)|Dysfunctional Attitude Scale (DAS) is a self-report scale designed to measure the presence and intensity of dysfunctional attitudes. It is widely used to assess impaired cognitive patterns associated with depression and other mental health conditions. Initially developed in English, its usefulness can be extended by translating and culturally adapting it into Urdu language.
218920330|NCT06586099|DRUG|Aza, tislelizumab|combination chemotherapy for the refractory/relapsed AML
219534125|NCT03165994|RADIATION|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
219534126|NCT03165994|DRUG|Paclitaxel|Paclitaxel IV infusion
219534127|NCT03165994|DRUG|Carboplatin|Carboplatin IV infusion
219534128|NCT03165994|PROCEDURE|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-17
219204739|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219534129|NCT00716690|PROCEDURE|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
219534130|NCT00002318|DRUG|Doxorubicin hydrochloride (liposomal)|
219534131|NCT00002318|DRUG|Bleomycin sulfate|
219534132|NCT00002318|DRUG|Vincristine sulfate|
219534133|NCT00002318|DRUG|Doxorubicin hydrochloride|
219534134|NCT02996591|PROCEDURE|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
219534135|NCT02996591|PROCEDURE|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
219534136|NCT02996591|DRUG|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
219534137|NCT02996591|PROCEDURE|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
219534138|NCT02996591|PROCEDURE|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
219534139|NCT04564560|PROCEDURE|Endovascular aortic repair with Zenith Alpha Spiral-Z®|The Zenith Alpha Spiral-Z® stent graft may have an increased risk of thrombosis. The intervention in this study is to assess the extent and degree of thrombosis in patients treated with the Zenith Alpha Spiral-Z® during endovascular repair of aortic aneurysm
219534140|NCT05934643|DEVICE|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
219534141|NCT05934643|OTHER|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
219534142|NCT02597660|DRUG|Somatropin|Active drug
219534143|NCT02597660|DRUG|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
219617951|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
219617952|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
219617953|NCT05835440|OTHER|no intervention|interviews
219617954|NCT00490750|PROCEDURE|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
219617955|NCT00490750|PROCEDURE|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
219617956|NCT02090348|DRUG|dimethyl fumarate|Administered as specified in the treatment arm
219617957|NCT06546449|DRUG|LH-001|LH-001 will be administered oral
219617958|NCT06546449|DRUG|Placebo|Placebo will be administered oral
218920331|NCT05902260|DIETARY_SUPPLEMENT|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
218920332|NCT05902260|DRUG|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
218920333|NCT06586294|DRUG|Drug: AK129 Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
219534144|NCT02597660|OTHER|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
218920334|NCT06586294|DRUG|Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
218920335|NCT06596928|DIETARY_SUPPLEMENT|Essential Elements T-Hero Platinum|Participants will take two capsules daily for 90 days
218920336|NCT06596928|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take two placebo capsules daily for 90 days.
218920337|NCT06588790|OTHER|Home-based rapid testing|Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.
219534145|NCT02597660|PROCEDURE|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
219534146|NCT02232776|DRUG|Losartan|Dose of Losartan : 0.7mg/kg once daily.
219534147|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
219534148|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
219534149|NCT00152646|DRUG|placebo, aspirine, clopidogrel|
219617959|NCT05921903|BIOLOGICAL|RSVPreF3 OA Investigational Vaccine|0.5 mililiter dose was administered intramuscularly as 1 dose to RSV\_IC\_1 and RSV\_HA groups, and 2 doses to RSV\_IC\_2 group.
219617960|NCT04684147|BIOLOGICAL|single dose of CNCT19|Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
218920338|NCT06588790|OTHER|Community health worker rapid testing|Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.
218920339|NCT06986811|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
218920340|NCT06986811|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
218920341|NCT06857695|DRUG|AZD5004 film-coated tablet|oral, fasted
218920342|NCT06857695|DRUG|[14C]AZD5004 Solution for Infusion|intravenous, fasted
219534150|NCT04833504|BIOLOGICAL|CD19 CAR-T Expressing IL7 and CCL19|A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19
219534151|NCT00144534|DRUG|MRA (Tocilizumab)|8mg/kg/4 weeks
219534152|NCT03911258|PROCEDURE|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
219617961|NCT06089408|OTHER|Best Practice|Use a regular blanket
219617962|NCT06089408|OTHER|Supportive Care|Use a weighted blanket
219617963|NCT06089408|OTHER|Survey Administration|Ancillary studies
219617964|NCT06188520|DRUG|AZD8421|CDK2 inhibitor
218920343|NCT06857695|DRUG|[14C]AZD5004 Oral Solution|oral, fasted
218920344|NCT06606600|OTHER|Intensive Kebbi robot interventions|The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
218920345|NCT06594302|OTHER|Functional performance tests and scales measuring biopsychosocial characteristics|Functional performance tests and scales applications
218920346|NCT06600568|OTHER|Translation analysis|Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
218920347|NCT06591520|DRUG|AK112, Gemcitabine, Cisplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
218920348|NCT06591520|DRUG|Durvalumab, Gemcitabine, Cisplatin|Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
218920349|NCT06591962|OTHER|Questionnaire application for diabetes mellitus|Scales will be applied to individuals diagnosed with diabetes mellitus
218920350|NCT06591962|OTHER|Questionnaire application for without diabetes mellitus|Scales will be applied to individuals diagnosed without diabetes mellitus
218920351|NCT06602531|BIOLOGICAL|ARCT-2304|Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.
218920352|NCT06602531|BIOLOGICAL|Control vaccine younger adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
218920353|NCT06602531|BIOLOGICAL|Control vaccine older adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
219534153|NCT02816996|PROCEDURE|Hand-holding|Subject will have their hand held.
218920354|NCT06602531|OTHER|Placebo Vaccine|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
219204740|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219534154|NCT02816996|PROCEDURE|Stress Ball|Subject will be given a stress ball to hold.
219617965|NCT06188520|DRUG|Camizestrant|SERD
219617966|NCT06188520|DRUG|Ribociclib|CDK4/6 inhibitor
219617967|NCT06188520|DRUG|Palbociclib|CDK4/6 inhibitor
219617968|NCT06188520|DRUG|Abemaciclib|CDK4/6 inhibitor
219617969|NCT06621953|DEVICE|BFR|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to either 80% or 40% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum in Week 1, 25% in Week 2 and 30% in Week 3.
219617970|NCT06621953|OTHER|control group|Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
219617971|NCT05685472|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
219617972|NCT05873816|DEVICE|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
219617973|NCT05873816|DEVICE|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
219617974|NCT02409316|DRUG|[18F]FES|\[18F\]FES PET/CT scan
219534155|NCT04576234|DIETARY_SUPPLEMENT|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
219534156|NCT02003833|DEVICE|Poly-L-lactic acid|Sculptra injections
219534157|NCT02003833|DEVICE|Placebo comparator|saline injections
219617975|NCT06551181|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
219534158|NCT05368870|PROCEDURE|Carlevale implantation|Vitrectomy and Carlevale implantation
219534159|NCT03565133|DIETARY_SUPPLEMENT|Quinine sham feeding quinine|Oral sham feeding with quinine
219617976|NCT06551181|DRUG|Placebo|One dose of placebo is administered intramuscularly at Day 1.
219617977|NCT06427538|OTHER|Saline Flush|sterile saline 20 mL flushed into their catheter by trained nurses or study team members every 6 ± 2 hours
218920355|NCT06591663|BEHAVIORAL|Cognitive Therapy Rating Scale (CTRS)|"CBT is the Cognitive Therapy Rating Scale (CTRS), an important assessment tool designed to assess the quality and effectiveness of cognitive therapy sessions.~Mental health professionals, such as therapists and psychologists, commonly use the CTRS to evaluate various aspects of a therapy session. This includes the extent to which the therapist adheres to CBT principles, their skill in applying cognitive and behavioral techniques, their ability to develop a therapeutic relationship with the client, and the overall quality of the session. The scale may also include specific criteria or items that another trained therapist or researcher observes based on their observations during the therapy session (Pingol, 2023)."
219534160|NCT03565133|DIETARY_SUPPLEMENT|Gastric quinine|A gastric capsule containing quinine
219534161|NCT03565133|DIETARY_SUPPLEMENT|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
219534162|NCT03565133|DIETARY_SUPPLEMENT|Gastric placebo|A gastric capsule containing placebo (cellulose)
219534163|NCT00047099|DRUG|cyclophosphamide|
219534164|NCT00047099|DRUG|docetaxel|
219534165|NCT00047099|DRUG|epirubicin hydrochloride|
219534166|NCT00047099|DRUG|fluorouracil|
219534167|NCT00047099|DRUG|goserelin acetate|
219534168|NCT00047099|DRUG|tamoxifen citrate|
219534169|NCT00047099|PROCEDURE|adjuvant therapy|
219534170|NCT00047099|RADIATION|radiation therapy|
219534171|NCT00738049|DRUG|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
219534172|NCT00665470|DRUG|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
219534173|NCT03141671|DRUG|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
219534174|NCT03141671|DRUG|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
219534175|NCT03141671|RADIATION|Salvage radiation|Radiation
219534176|NCT03141671|DRUG|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
219534177|NCT03141671|DRUG|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
219534178|NCT03141671|DRUG|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
219534179|NCT00934050|DRUG|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
219534180|NCT00461786|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
219534181|NCT02816450|BEHAVIORAL|Water Intake|
218920356|NCT06603935|OTHER|QHSLab Digital Tools (AME and ARIS)|Participants will use the QHSLab digital platform, which includes two tools: the Allergy Management Evaluation (AME) and the Allergic Rhinitis Intervention Steps (ARIS). The AME provides a comprehensive digital assessment for identifying and monitoring allergic rhinitis symptoms. The ARIS offers personalized feedback based on patient-reported outcomes and continuously adjusts treatment recommendations through an algorithm. These tools support better symptom management, adherence to medication, and overall improvement in quality of life.
219617978|NCT04160624|PROCEDURE|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
218920357|NCT06596863|DIAGNOSTIC_TEST|The association of serum uromodulin with DN|Meta analysis of association of serum uromodulin with DKD
218920358|NCT06596863|DIAGNOSTIC_TEST|The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN|DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
218920359|NCT06589622|PROCEDURE|Atraumatic Restorative Treatment|Caries excavation with hand instruments only and restoration with Glass ionomer filling
218920360|NCT06589622|PROCEDURE|Hall technique|Crown placement without tooth preparation
218920361|NCT06590948|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system
218920362|NCT06587126|DEVICE|Curie Artificial Intelligence (AI) cough monitor|All patients are given nighttime cough monitors for home use for 3-4 months
219204741|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219617979|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
219617980|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
219617981|NCT06432803|OTHER|PET-Scan analysis|Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
219617982|NCT05317312|DRUG|MR-107A-02|MR-107A-02 oral tablet
219617983|NCT05317312|DRUG|Placebo|Placebo oral tablet
219617984|NCT01494675|OTHER|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
219617985|NCT04128930|DEVICE|PAP titration at home|Fixed CPAP or APAP titration at home
219617986|NCT04982861|DRUG|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
219617987|NCT04982861|DRUG|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
219617988|NCT04271228|DEVICE|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
219617989|NCT02700217|PROCEDURE|Bupivacaine and Diamorphine|
219617990|NCT02700217|PROCEDURE|Remifentanil, Propofol and Cistracurium|
219617991|NCT02700217|PROCEDURE|Bupivacaine and Rectus Sheath injection|
219617992|NCT02588898|DEVICE|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
219617993|NCT06613074|DEVICE|Ali Pay intelligent navigation applet|"The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
218920363|NCT06599307|DRUG|Rituximab|Rituximab 1gm vial diluted on 500 ml normal saline 0.9%
218920364|NCT06599307|OTHER|Saline (NaCl 0,9 %) (placebo)|500 ml of normal saline 0.9%
218920365|NCT06601205|DRUG|Flutamide|1 tablet daily until the day before surgery
218920366|NCT06601205|DRUG|Finasteride|1 tablet daily until the day before surgery
218920367|NCT06601205|OTHER|Placebo|1 tablet daily until the day before surgery
219534182|NCT03974035|DRUG|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
219204742|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
219534183|NCT05885971|DIAGNOSTIC_TEST|Administration of the SCOFF-F and EDE-Q questionnaires|The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
219617994|NCT05385653|BEHAVIORAL|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
219617995|NCT04327544|BEHAVIORAL|Frailty Intervention|In overall, participants will attend one session of frailty talk, 22 sessions of low to moderate intensity of multi-components exercise course and 6 session of nutrition education interventions. Both nutritional education and exercise intervention will be conducted concurrently for a 12-week (3-month) of intervention period. Noted that every session will be held in PPR flats' facility area or hall around 60 minutes that will be conducted by the dietitian or nutritionist and physiotherapist from the research team.
219617996|NCT05719935|DEVICE|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
219617997|NCT01867528|PROCEDURE|Laparoscopic adhesiolysis|
219617998|NCT01867528|PROCEDURE|Open adhesiolysis|
219617999|NCT05711420|BEHAVIORAL|Gamification method group|Gamification method group
219618000|NCT05711420|BEHAVIORAL|Flipped learning group|Flipped learning group
219618001|NCT06676878|DEVICE|Incremental exercise|A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
219618002|NCT07013422|OTHER|Psychoeducational support|Study Intervention: psychoeducational sessions, 5 sessions were given to the participants allocated to the intervention arm (60-90 minutes each) covering health education, stress management, coping strategies, and communication with children
219618003|NCT07015463|OTHER|Multi-component intervention in health literacy|Multi-component intervention aiming at increasing the health literacy of patients suffering from hypertension, in achieving the target blood pressure goal three months after the start of the intervention in poorly controlled hypertensive patients
219618004|NCT07017790|OTHER|Amino-acid PET|Patients received 18-fluoroDopa then a PET exam
219618005|NCT07017439|DRUG|Beta-3 agonists (Mirabegron/Myrbetriq)|Patients in this arm will receive the medication in pill form following their procedure
219618006|NCT07017439|OTHER|Placebo group post rezum|Patients in this arm will receive the placebo pill following their procedure.
219618007|NCT06624410|OTHER|Educational Intervention|"Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital."
219618008|NCT06443788|DIAGNOSTIC_TEST|transperineal ultrasound|"The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse"
219618009|NCT02291237|DRUG|Eleclazine|Tablet (s) administered orally once daily
219618010|NCT02291237|DRUG|Placebo|Placebo to match eleclazine administered orally once daily
219618011|NCT05430646|DEVICE|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
219618012|NCT05430646|DEVICE|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
219618013|NCT03903432|OTHER|MRI|candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
219618014|NCT06732921|DEVICE|Alertwatch - Recovery Control Tower|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
219618015|NCT02112851|OTHER|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
219534184|NCT01457300|OTHER|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
219534185|NCT01133470|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
219534186|NCT00835991|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
219534187|NCT00835991|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
219534188|NCT03400020|OTHER|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
219534189|NCT03400020|OTHER|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
219534190|NCT02561520|BIOLOGICAL|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
219534191|NCT02561520|BIOLOGICAL|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
219534192|NCT02553044|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
218920368|NCT06604611|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
218920369|NCT06596746|OTHER|Observation|In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
218920370|NCT06601244|OTHER|Pharmacokinetic|Biliary and blood concentration of the DALBAVANCINE
218920371|NCT06601491|BEHAVIORAL|Lifestyle Intervention|Participants in the intervention group receive structured, pesonalised lifestyle, dietary and physical activity consultations. They undergo various assessments such as aortic stiffness measurement, blood pressure measurement, and complete several questionnaires (e.g., whole exome sequencing, IPAQ, handgrip strength, socio-demographic, clinical history, quality of life, smoking, alcohol consumption, sleep patterns, stress assessment).
218920372|NCT06588062|OTHER|Picture Exchange Communication System (PECS)|Picture exchange communication System (PECS) is a widely useful tool for developing skills in ASD children. Visual supports rather work better for their intellectual level as these children usually respond less to verbal and written instructions. PECS is considered as an augmentative communication system commonly used with non-verbal ASD children. It is helpful for an individual with ASD to quickly acquire a functional means of communication. This is highly beneficial for the child to communicate with his parents and caregivers, as well as with their peers. Moreover, the pictorial approach of PECS is a source of facilitating element in attaining student's concentration. The reason for wide acceptance of this tool in clinical and social settings for children with ASD is its' ease of use, ability to teach two-way communication and inexpensiveness. PECS has demonstrated successful use in teaching various skills in ASD affected children lacking speech.
218920373|NCT06594874|DRUG|HS-10370|HS-10370 administered orally every day
218920374|NCT06594874|DRUG|Adebrelimab|Administered intravenously every 21 days; dose by label.
218920375|NCT06594874|DRUG|Cisplatin|Administered intravenously every 21 days; dose by label.
218920376|NCT06594874|DRUG|Carboplatin|Administered intravenously every 21 days; dose by label.
218920377|NCT06594874|DRUG|Pemetrexed|Administered intravenously every 21 days; dose by label.
218920378|NCT06601920|BEHAVIORAL|Forest healing activities|The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.
219618016|NCT01306305|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
219618017|NCT06301542|DEVICE|Functional electrical stimulation|The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.
218920379|NCT06593925|DEVICE|Production of polyoxymethylene telescopic denture|Remaining teeth will be prepared by conventional grinding technique, followed by impression, casting and scanning with extra oral scanner. Inner telescopic crowns will be made of cobalt-chromium alloy by milling technique and outer crowns together with denture framework will be made of polyoxymethylene by the method of single phase injection moulding. Denture delivery is done by inserting both inner and outer crown at the same time, during which the inner crown is cemented to the abutment tooth and the contact surfaces of the outer and inner crown are isolated so that the outer crown and denture framework can be removed.
219534193|NCT00315562|PROCEDURE|carotid endarterectomy|
219534194|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
219534195|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
218920380|NCT06593925|DEVICE|Production of conventional complex partial denture with clasps|A conventional complex partial denture is a removable partial denture with clasps combined with metal-ceramic surveyed crowns with milled surfaces for removable dentures. The metal-ceramic surveyed crowns are shaped in such a way that they build a morphological and functional whole with complementary elements of the removable partial denture's framework. In the control group, as well as in the experimental group, the remaining teeth are prepared using a conventional grinding technique, then an impression is taken for dedicated metal-ceramic crowns, casting, and milling of crowns, ceramic sintering, impression through the metal-ceramic surveyed crowns and fabrication of a removable partial denture's framework with clasps using the casting method. Dedicated fixed restorations will be made of Co-Cr alloy inside the crown and ceramic layer on the surface, and the framework and clasps of the removable partial denture will be made of Co-Cr-Mo alloy.
218920381|NCT06600932|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
218920382|NCT06600932|PROCEDURE|control group|The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
218920383|NCT06604260|DIAGNOSTIC_TEST|68Ga-FAPi-46|68Ga FAPi PET-CT scan
218920384|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
218920385|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
218920386|NCT04152018|DRUG|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
218920387|NCT04152018|DRUG|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
218920388|NCT06592651|BEHAVIORAL|Play Therapy Workshop|"4 session group intervention foucused on psycho-educational knowledge regarding tools for effective emotional coping with stressful events in the context of the Iron Swords war, focusing on building mental resilience in the parent-child dyad through play therapy. Each group consists of 5 parent-child dyads with children aged 3-6 years, who have been evacuated from war zones in the northern and southern regions of the country."
218920389|NCT06825520|BEHAVIORAL|Habit Reversal Training|Participants learn to identify when their tics occur and then learn a competing response to engage in instead of the 3 identified tics and then practice competing responses learned in session during the practice sessions throughout the week.
218920390|NCT06982807|PROCEDURE|Group 4.0-VISULYZE|The 4.0-VISULYZE group had their infusion rates precisely calibrated using 4.0-VISULYZE
219042593|NCT05939492|BEHAVIORAL|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
219042594|NCT02583932|DRUG|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
219534196|NCT05422391|DIETARY_SUPPLEMENT|3 day caloric restriction/metabolic reset|Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
219534197|NCT02149420|DRUG|VAY736|
219534198|NCT02149420|DRUG|Placebo|
219534199|NCT00833157|DRUG|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
219534200|NCT00833157|DRUG|ibuprofen|Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
219534201|NCT00833157|DRUG|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
219618018|NCT06745128|DRUG|Tirzepatide|Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period. Following the instructions of the FDA-approved prescribing label, participants or a licensed study clinician will administer the tirzepatide injection subcutaneously in either the abdomen, thigh, or upper arm once weekly for 32 weeks total. Following the instructions of the FDA-approved prescribing label, the dosing schedule will include a 4-week titration at a starting dosage of 2.5mg/week. After four weeks, dosage will be increased in 2.5mg increments. The recommended maintenance dosages per prescribing label are 5mg/week, 10mg/week, or 15mg/week injected subcutaneously. Maximum dosage (up to 15mg/week) will be optimized for each individual. We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue, MOUNJARO® may be dispensed as an alternative.
219618019|NCT03326193|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
218920391|NCT06982807|PROCEDURE|traditional group|The traditional group had their infusion rates based on past experience.
218920392|NCT06991309|BEHAVIORAL|MBSR|MBSR will be conducted as group sessions, with each session lasts for 2.5 hours, once a week for 8 weeks with another 45 minutes of home practice on daily basis. The MBSR sessions will be based on therapy format developed by Kabat-Zinn. All the sessions focus on mindfulness practices, sharing of experiences with others, and didactic teaching on stress. Mindfulness practices which will be discussed include body scan exercise, and mindful breathing meditation techniques, three-minute breathing exercises, five-minute seeing or hearing exercises, bodily mindfulness in movement and mindful stretching, yoga and sitting meditation. The therapists will review feedbacks for each session, acknowledge the thoughts, feelings, and senses, examine how participants practice mindfulness, and give assignments to encourage participants to continually practice mindfulness at home. Each participant will receive a CD detailing on meditation practices and a workbook on the mindfulness practices.
219534202|NCT04205123|GENETIC|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
219534203|NCT06801418|DRUG|Adagrasib|Specified dose on specified days
218920393|NCT06586944|BEHAVIORAL|Nursing Practices Based On Roy Adaptation Model Integrated With Virtual Reality|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group (Table...). In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals.Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions.
218920394|NCT06586944|BEHAVIORAL|Roy Adaptation Model|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals
218920395|NCT06992648|DRUG|Trifluridine/Tipiracil + Regorafenib|Trifluridine/tipiracil will be administered orally BID at a starting dose of 30 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Regorafenib will be administered orally QD at a dose-escalation strategy (80 mg/day, followed by weekly increase of 40 mg to 120 mg/day), if no significant drug-related adverse events occurred and 120 mg/day for 21 days of a 28-day cycle.
219042595|NCT02583932|BEHAVIORAL|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
219534204|NCT03167515|DEVICE|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
219534205|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
219534206|NCT05886660|DRUG|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
219534207|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
219534208|NCT05886660|DRUG|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
219534209|NCT03197415|OTHER|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
219534210|NCT05824481|DRUG|Cadonilimab|Injectable solution
219534211|NCT05824481|DRUG|Lenvatinib|Capsule
219534212|NCT06559722|DRUG|Insulin Degludec/liraglutide Injection|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
219534213|NCT06559722|DRUG|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
219534214|NCT03574558|DEVICE|MD-Logic Switch Advisor|Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
219534215|NCT00854659|DRUG|ABT-102|BID tablets, 7 days of treatment
219534216|NCT00854659|DRUG|Placebo|BID tablets, 7 days of treatment
219534217|NCT03536091|DIAGNOSTIC_TEST|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
219534218|NCT02378935|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
219534219|NCT02378935|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
219534220|NCT02378935|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219534221|NCT02649621|BIOLOGICAL|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
219534222|NCT06560099|DRUG|Oxytocin|will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
219534223|NCT03616535|OTHER|Cognitive training|The investigators will provide participants with tablets to play brain games.
219534224|NCT03616535|OTHER|Exercise training|The investigators will provide participants with foot peddlers.
219618020|NCT03326193|BIOLOGICAL|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
219618021|NCT07052864|DRUG|Dexamethasone|8 mg of Intravenous Dexamethasone in 100 ml Normal saline given 1 hour before anesthesia induction
219618022|NCT07052864|DRUG|Placebo|100ml of Normal saline administration 1 hour before anesthesia induction
219618023|NCT06736223|DRUG|ITF2357|ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
219618024|NCT04691427|DEVICE|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
218920396|NCT06992648|DRUG|Trifluridine/tipiracil + bevacizumab|Trifluridine/tipiracil will be administered orally BID at a starting dose of 35 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered IV every 2 weeks (day 1 and day 15).
218920397|NCT06992349|DEVICE|bioptron light therapy|"BIOPTRON® Hyperlight is a proprietary, optimized blend of visible and infrared light properties that Bio-stimulate cells and speeding up the healing process of a wide range of medical diseases.~Bioptron© light therapy has been utilized as a non-invasive treatment for wound healing, skin ulcers, and various musculoskeletal conditions(Abd Elhamid et al., 2020)."
218920398|NCT06992011|PROCEDURE|SMILE|Small Incision Lenticule Extraction
218920399|NCT06992011|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
219618025|NCT00978874|RADIATION|fludeoxyglucose F 18|
219618026|NCT00978874|RADIATION|fluorine F 18 EF5|
218920400|NCT06991361|BIOLOGICAL|EVE-Treg|Ex Vivo-Expanded (EVE) Regulatory T cells.
218920401|NCT06991517|OTHER|The ABC Bicuspid Sizing Algorithm|The ABC Bicuspid Sizing Algorithm is a valve sizing algorithm. It guides operators' evaluations of CT scans, helping inform (1) treatment allocation between TAVR and surgical aortic valve replacement, and (2) valve choice for patients undergoing TAVR. In select cases, the algorithm will suggest gated CT evaluation or artificial intelligence-based simulation models be used to further evaluate the risk of the planned valve size and deployment volume. The operators will consider the findings of the ABC Bicuspid Sizing Algorithm as well as other clinical factors when making their final treatment decisions.
218920402|NCT06992050|DEVICE|Submariner suit|Participants wearing full-body Submarine Escape Immersion Equipment (SEIE) suits
218920403|NCT06993337|DIETARY_SUPPLEMENT|35% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
219042596|NCT03385252|OTHER|Eggs|Eggs provided as complementary food for the infant
219042597|NCT03385252|BEHAVIORAL|Visits|Twice weekly household visits by study staff
219534225|NCT03616535|OTHER|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
219534226|NCT04185493|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
219534227|NCT04084197|DRUG|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
219534228|NCT04084197|DRUG|HIP1801|Tamsulosin 0.4mg
219534229|NCT01442753|BEHAVIORAL|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
219534230|NCT01375920|DRUG|Metyrapone|500 milligrams to be taken twice a day orally
219534231|NCT01375920|DRUG|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
219534232|NCT03199872|BIOLOGICAL|RV001V|Sc injection
219534233|NCT01631331|DRUG|vismodegib|Given PO
219534234|NCT01631331|PROCEDURE|Mohs surgery|Undergo Mohs surgery
219534235|NCT00366925|DEVICE|Adacolumn®|
219534236|NCT02779803|PROCEDURE|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
219534237|NCT04741217|OTHER|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
219534238|NCT04484883|OTHER|Observational|Observational
219618027|NCT04420494|OTHER|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
219618028|NCT05771389|DIAGNOSTIC_TEST|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
219618029|NCT03302676|DIETARY_SUPPLEMENT|Chewing gum|
218920404|NCT06993337|DIETARY_SUPPLEMENT|50% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
218920405|NCT06993337|DRUG|0.1% Topical Triamcinolone Acetonide in Orabase|Triamcinolone acetonide in orabase, a corticosteroid-based standard treatment for Recurrent Aphthous Stomatitis (RAS), is used for its strong anti-inflammatory and immunosuppressive effects. In this study, it serves as the conventional treatment against the novel therapy
218920406|NCT06992895|DEVICE|The visual presentation utilizes a three-dimensional holographic fan device.|This study is among the first to examine the effect of holographic fan technology on pain, anxiety, and fear in children during burn dressing. In comparison with other distraction methods, holographic fans represent a novel technological intervention designed to mitigate pain and anxiety by engaging children's attention through the use of visual illusions. Furthermore, extant studies on the effectiveness of this technology during prolonged and distressing procedures, such as burn dressing, have been found to lack sufficient data.
218920407|NCT06991946|GENETIC|Liquid Biopsy|Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
218920408|NCT06991946|GENETIC|Archival Tumor DNA|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
218920409|NCT06993246|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|The intervention involves the use of contrast-enhanced mammography (CEM) to supplement standard mammography for breast cancer screening. This method utilizes iodinated contrast medium to enhance the visualization of breast lesions by assessing tumor neovascularization. CEM will be offered to women with dense breast tissue who are currently awaiting supplemental ultrasound screening. It is designed to be performed in conjunction with regular mammography, offering a more efficient and cost-effective alternative to MRI, with comparable sensitivity in detecting breast cancer. Participants will undergo the CEM procedure in a single visit, allowing for reduced wait times and improved detection rates compared to traditional methods. The procedure is well-tolerated, with minimal side effects, and provides a quicker and more accessible option for supplemental breast cancer screening.
218920410|NCT06993493|GENETIC|CD19 CART|"The dose escalation is carried out according to the principle of 3+3 escalation, with a total of 3 dose groups set up.~Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases (i.e. ≥ 2/6 cases in this dose group), it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is MTD."
218920411|NCT06602882|BEHAVIORAL|chatbot-delivered screening and brief intervention|"1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking."
219204743|NCT03021330|DRUG|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
219204744|NCT03021330|DRUG|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
219534239|NCT02256683|DRUG|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
219534240|NCT02256683|DRUG|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
219618030|NCT02886780|BEHAVIORAL|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
219618031|NCT02886780|BEHAVIORAL|Self-help|
219618032|NCT01932866|OTHER|diabetic risk score|
219618033|NCT02272257|BEHAVIORAL|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
219618034|NCT02272257|BEHAVIORAL|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
219618035|NCT01688557|DEVICE|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
219618036|NCT01688557|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
218920412|NCT06596343|DRUG|Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy|"1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors."
218920413|NCT06603038|DIETARY_SUPPLEMENT|Gainful Daily Performance Greens|Daily supplementation for 28 days
218920414|NCT06594601|PROCEDURE|lung recruitment potential assessed by 3D EIT|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential."
219534241|NCT03630471|BEHAVIORAL|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
219534242|NCT03630471|BEHAVIORAL|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
219534243|NCT04414228|DEVICE|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
219534244|NCT04414228|DEVICE|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
219534245|NCT03647293|PROCEDURE|Ultrasound Guided Central Catheter Insertion|
219534246|NCT03647293|PROCEDURE|Peripherally Inserted Central Catheter|
219534247|NCT03289845|DEVICE|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
219534248|NCT02146105|OTHER|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
219534249|NCT05770648|DEVICE|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
219534250|NCT05770648|OTHER|The guidelines guide medication|The guidelines guide medication
219534251|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #1|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
219534252|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #2|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
219534253|NCT03832530|BEHAVIORAL|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
219534254|NCT00844922|DRUG|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
219534255|NCT00844922|DRUG|Placebo|Placebo
219534256|NCT04089917|DEVICE|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
219534257|NCT05832411|DEVICE|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
219042598|NCT02803918|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219042599|NCT02803918|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219042600|NCT02803918|DRUG|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219042601|NCT02803918|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219042602|NCT03900299|PROCEDURE|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
219618037|NCT01122186|BEHAVIORAL|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
219618038|NCT01122186|BEHAVIORAL|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
219618039|NCT00703872|DRUG|Oral HDV-Interferon + ribavarin|Naive pateints
219618040|NCT00703872|DRUG|Injectable HDV-Interferon + ribavarin|Nonresponders
219618041|NCT02713412|OTHER|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
219618042|NCT02713412|OTHER|Water|300ml water
219618043|NCT03933566|PROCEDURE|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
218920415|NCT06594601|PROCEDURE|PEEP titration by 3D eit|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The PEEP titriatino by 3D EIT fwas as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. RM: PEEP was switched to a 21cmH2O for 2min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) ≥90%.~3. PEEP was stepwise decrease from 21 to 0 cmH2O PEEP in steps of 3cm H2O every 2min.~4. 3D EIT was used to monitor regional ventilation distribution during PEEP titration."
218920416|NCT06594380|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination
218920417|NCT06594380|DEVICE|Endoscopic bite group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
218920418|NCT06586684|DRUG|Inclisiran|Patients with carotid plaques undergoing treatment with inclisiran
218920419|NCT06593821|DEVICE|Occlusal splint|The occlusal splint was fabricated from a 2 mm hard splinting resin material on the plaster model obtained by taking impressions of the patients\&amp;#39; upper jaw.
218920420|NCT06593821|BEHAVIORAL|preventive advice|Control group given protective advice such as supporting the jaw when yawning, not chewing gum, not opening the mouth for too long and not opening it too wide, and chewing on both sides when eating.
218920421|NCT06593821|DRUG|Botulinum toxin|A total of 50 U of botulinum toxin, 25 U in each muscle, was injected
218920422|NCT06604390|DIETARY_SUPPLEMENT|catechin extracts (health food)|"Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;"
218920423|NCT06604390|OTHER|plasebo|Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.
218920424|NCT06603233|DIAGNOSTIC_TEST|The Difference Between The AI Model and Dentists Group|The clinical feasibility of the best performing model, statistical hypothesis tests are performed that compares the predictions of the AI model with the assessments from three dentists.
218920425|NCT06603233|DIAGNOSTIC_TEST|Deep Learning Models|DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer were trained on 354 images and tested on 79 images.
219618044|NCT03933566|PROCEDURE|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
219618045|NCT06035978|DRUG|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
219618046|NCT06035978|DRUG|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
219618047|NCT06035978|DRUG|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
219618048|NCT06035978|DRUG|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
219618049|NCT06035978|DRUG|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
219534258|NCT03935880|DEVICE|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
219534259|NCT03935880|PROCEDURE|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
219618050|NCT06035978|DRUG|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
218920426|NCT06589544|DEVICE|Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)|"The CEREBRUM-VELA virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
219042603|NCT01224639|BIOLOGICAL|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
219534260|NCT02476994|DRUG|Clinolipid|
219534261|NCT02476994|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
219534262|NCT01607918|DRUG|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
219534263|NCT01607918|DRUG|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
219618051|NCT03237338|PROCEDURE|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
219618052|NCT03237338|PROCEDURE|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
219042604|NCT01224639|BIOLOGICAL|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
219534264|NCT02563561|DRUG|Apaziquone|One dose of apaziquone administered by intravesical administration
219534265|NCT02563561|OTHER|Placebo|Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
219534266|NCT03531294|DRUG|Aflibercept Injection|intravitreal 2mg aflibercept injection
219534267|NCT02129894|DEVICE|abdominal Binder|placement of abdominal binder
219534268|NCT05283850|DRUG|High Calcium, Low Sodium (HCLS) Crystalloid Therapy|Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
219534269|NCT05283850|DRUG|High Calcium, High Sodium (HCHS) Crystalloid Therapy|Normal saline IV drip and 1g IV bolus Calcium Chloride.
219618053|NCT03088761|DEVICE|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
219618054|NCT00699998|DRUG|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
219618055|NCT00699998|DRUG|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
219534270|NCT04347018|DEVICE|BRIUS|This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion
219534271|NCT02221921|DEVICE|MicroPort's Transcatheter Aortic Valve and Delivery System|
219534272|NCT02646124|DRUG|Naproxen|Naproxen 500mg by mouth two times a day, #20
219534273|NCT02646124|DRUG|Placebo|28 placebo capsules
219618056|NCT00699998|DRUG|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
219534274|NCT02646124|DRUG|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
219618057|NCT03093701|DRUG|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
218920427|NCT06589544|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)|"Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
218920428|NCT06589544|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
218920429|NCT06586554|OTHER|Static stretching|The SS group received static stretching, which was applied with gentle and firm pressure while pulling opposite the hamstring muscle contraction.
218920430|NCT06586554|OTHER|Myofascial release|Myofascial release is applied with cross-handed stretches over hamstring muscle
218920431|NCT06600503|BEHAVIORAL|RehabLung mobile application|Participants in the intervention group will receive in-person pulmonary rehabilitation during their surgical admission and access to a mobile pulmonary rehabilitation application for self-training. This program begins one month before surgery and continues for seven weeks after surgery. The application is designed to encourage participants to engage in pulmonary rehabilitation exercises from preoperative preparation through postoperative care. It offers guided chest breathing exercises, using visual and movement instructions created and remotely prescribed by a physical therapist. Participants will receive daily breathing exercise prescriptions throughout the study period.
218920432|NCT06600503|BEHAVIORAL|Lung cancer postoperative standard care|Participants in the usual care group will receive in-person pulmonary rehabilitation during surgical admission, pre-operative healthcare, and guidance on breathing exercises to practice before surgery. They will also receive post-operative breathing exercise prescriptions to follow at home.
219534275|NCT05624034|DEVICE|Electrogastrography|Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
219534276|NCT06368219|DRUG|ketamine- midazolam versus ketamine- propofol|"* Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg)~* Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)"
219534277|NCT04343196|RADIATION|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
219534278|NCT00840398|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
219534279|NCT00840398|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
218920433|NCT06600503|OTHER|Healthcare interactive Web Platform|The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.
219042605|NCT01224639|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
219042606|NCT03465878|DRUG|LY900014|Administered via SC injection
219042607|NCT03465878|DRUG|Insulin Lispro|Administered via SC injection
219042608|NCT03919461|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
219042609|NCT03919461|OTHER|Placebo|Placebo
219534280|NCT02255292|DRUG|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
219534281|NCT00151229|OTHER|target blood pressure|
219618058|NCT06833437|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|Patients in the 68Ga-Pentixafor PET/CT group will first undergo 68Ga-Pentixafor PET/CT, followed by adrenal venous sampling (AVS). The subsequent treatment will be guided based on the diagnostic results.
219618059|NCT06833437|DIAGNOSTIC_TEST|AVS|Patients in the adrenal venous sampling (AVS) group will first undergo adrenal venous sampling (AVS), followed by 68Ga-Pentixafor PET/CT. The subsequent treatment will be guided based on the diagnostic results.
219618060|NCT00367302|DRUG|buprenorphine|maintenance
219042610|NCT01433432|DRUG|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
219042611|NCT05970432|DRUG|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
219618061|NCT00367302|DRUG|methadone|maintenance
219618062|NCT03548727|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
219618063|NCT00473590|DRUG|Bevacizumab|15 mg/kg administered by intravenous infusion
219618064|NCT00473590|DRUG|Bortezomib|1.3 mg/m\^2 administered by intravenous bolus injection
219618065|NCT00473590|DRUG|placebo|Intravenous repeating dose
219618066|NCT06499675|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy / bariatric surgery
219618067|NCT06499675|PROCEDURE|Liver Biopsy|intraoperative liver biopsy
218920434|NCT06592976|DIETARY_SUPPLEMENT|Multi-strain Oral Probiotic (CDS22-formula)|All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
218920435|NCT06587542|OTHER|Injection of protein purified derivative|Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion
219534282|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
219534283|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
219534284|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
219534285|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
219534286|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
219534287|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
219534288|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
219618068|NCT03781687|PROCEDURE|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
219618069|NCT03781687|PROCEDURE|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
219618070|NCT03781687|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
219618071|NCT00395161|DRUG|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
219618072|NCT00395161|DRUG|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
219618073|NCT00395161|DIETARY_SUPPLEMENT|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
219618074|NCT00395161|DRUG|Selenium|one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
219042612|NCT05970432|DRUG|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
219534289|NCT02844660|BIOLOGICAL|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
219534290|NCT02844660|OTHER|Standard of Care|moist wound therapy and offloading
219618075|NCT00395161|OTHER|saline|equivalent volume of intravenous saline
219618076|NCT00395161|OTHER|sterile water|equivalent volume of sterile water
219618077|NCT00395161|OTHER|selenium|equivalent volume of sterile water
219618078|NCT00395161|DIETARY_SUPPLEMENT|whey-protein|one enteral dose daily of whey-protein
219618079|NCT02920671|OTHER|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
219042613|NCT05970432|DRUG|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
219042614|NCT05970432|DRUG|TQH2722 injection matching Placebo|Placebo without active substance.
219042615|NCT06310850|DRUG|Ketamine|Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
219534291|NCT02703194|DRUG|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
219534292|NCT02703194|DRUG|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
219534293|NCT05790772|BEHAVIORAL|Vigorous Exercise|50 minutes of running on a treadmill
219618080|NCT02920671|OTHER|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
219618081|NCT02920671|OTHER|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
219618082|NCT02920671|OTHER|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
219618083|NCT03062709|BEHAVIORAL|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
219618084|NCT03062709|BEHAVIORAL|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
219042616|NCT06310850|OTHER|Placebo|Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
219618085|NCT03062709|DIAGNOSTIC_TEST|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
219618086|NCT05107947|OTHER|Biocentric light|Light that changes in intensity and spectral distribution during the day to mimick daylight. High in intensity and high circadian stimulus during daytime and low intensity and low circadian stimulus during late afternoon and night.
219618087|NCT01756183|DRUG|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
219618088|NCT02647697|DRUG|Radiprodil oral|"* Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use"
219534294|NCT06008704|DIAGNOSTIC_TEST|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
218920436|NCT05393791|OTHER|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
219618089|NCT00795327|DEVICE|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
219618090|NCT01107691|OTHER|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
219618091|NCT04718831|DIETARY_SUPPLEMENT|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
218920437|NCT05393791|DRUG|Abiraterone acetate|Use of abiraterone or enzalutamide
218920438|NCT05393791|DRUG|Enzalutamide|Use of abiraterone or enzalutamide
218920439|NCT06596707|PROCEDURE|Zirconomer|zirconia modified glass ionomer
218920440|NCT06596707|PROCEDURE|Nanohybrid composite|conventional composite
219534295|NCT06008704|DIAGNOSTIC_TEST|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
219534296|NCT06008704|DIAGNOSTIC_TEST|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
219534297|NCT06008704|DIAGNOSTIC_TEST|Thermotest|The thermotest is performed to assess the pain perception threshold
219534298|NCT06008704|DIAGNOSTIC_TEST|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
219534299|NCT06008704|DIAGNOSTIC_TEST|[18F]-MPPF PET scan|The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
219534300|NCT03965169|PROCEDURE|Prone spinal surgery|spinal surgery in prone position under general anesthesia
219534301|NCT01851135|OTHER|Neuropsychological examination and quality of life measures|
219534302|NCT02525458|DEVICE|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
218920441|NCT06590415|PROCEDURE|Subcutaneous adipose tissue biopsy|Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
218920442|NCT06590415|OTHER|Blood sampling|One 4 mL tube of blood will be collected
219534303|NCT02525458|DEVICE|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
219534304|NCT06302335|DRUG|Povidone-iodine|Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
219534305|NCT06302335|DRUG|Saline solution|Application of saline solution to the surgical wound of patients submitted to colorectal resections.
219534306|NCT00857454|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
219534307|NCT03154047|DRUG|NEOD001|humanized monoclonal antibody
219534308|NCT05831449|DRUG|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
219534309|NCT05831449|DRUG|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
219534310|NCT05831449|DRUG|Placebo|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
219618092|NCT02486874|DEVICE|PoreSkin|a human acellular dermal matrix
219618093|NCT01656980|DRUG|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
219042617|NCT01411163|DRUG|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
219042618|NCT04395937|OTHER|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
219042619|NCT03531216|OTHER|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
219042620|NCT03531216|OTHER|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
219618094|NCT01656980|PROCEDURE|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
219618095|NCT00297076|DRUG|GW873140|
219618096|NCT00199394|DRUG|Istradefylline (KW-6002)|
219618097|NCT00896974|OTHER|Laboratory Biomarker Analysis|Correlative studies
219618098|NCT00896974|OTHER|Pharmacological Study|Correlative studies
218920443|NCT06672406|DIETARY_SUPPLEMENT|Lactobacillus reuterii|Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding \> 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics
218920444|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
218920445|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
218920446|NCT06992414|DIETARY_SUPPLEMENT|Creatine monohydrate|8 g/day creatine monohydrate powder
219534311|NCT01997983|DEVICE|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
219534312|NCT04244097|DRUG|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
219534313|NCT04244097|DRUG|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
219534314|NCT05824897|OTHER|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
219534315|NCT05647005|OTHER|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
219534316|NCT05647005|OTHER|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
219534317|NCT00992147|DRUG|Adipocell|autologous cultured adipocytes (ANTG-adip)
219618099|NCT00896974|DRUG|Retinoid 9cUAB30|Given orally
219618100|NCT03367819|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219618101|NCT03367819|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219618102|NCT01835041|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219618103|NCT01835041|DRUG|oxaliplatin|Given IV
219618104|NCT01835041|DRUG|leucovorin calcium|Given IV
219618105|NCT01835041|DRUG|irinotecan hydrochloride|Given IV
219618106|NCT01835041|DRUG|fluorouracil|Given IV
219618107|NCT01835041|OTHER|laboratory biomarker analysis|Correlative studies
219618108|NCT04805112|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
219618109|NCT00835302|PROCEDURE|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
219618110|NCT02833987|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
219618111|NCT02833987|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
219618112|NCT02833987|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
219618113|NCT02833987|DRUG|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
218920447|NCT06992687|DRUG|HB0052 Injection|An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
218920448|NCT06591559|DEVICE|Permobil Explorer Mini|The Explorer Mini (Permobil AB, Sweden) is a commercially available, FDA approved powered mobility device intended for young children between 12-36 months of age with mobility limitations (weight limit: 35 lbs; height limit: 39.4 inches). It is lightweight (52 lbs. including battery) and fits in most automobiles (length: 25 inches; width: 19 inches; adjustable height: 29-37 inches). The Explorer Mini runs on a 12-volt battery with a driving range of 3.5 miles and a maximum speed of 1.5 mph, is controlled via a joystick with a 360-degree turning radius, has proportional speed control with 5 speed options, and can be used in a seated or standing position.
219042621|NCT06018558|GENETIC|OCU410|Subretinal administration of OCU410
219042622|NCT01876069|DEVICE|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
219618114|NCT01007305|PROCEDURE|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
218920449|NCT06591559|DEVICE|Portable Mobility Aid for Children (PUMA)|The Portable Mobility Aid for Children (PUMA; Enliten LLC) is a portable canopy system that utilizes an overhead support rail structure and a counterweight. The rail structure consists of two rigid parallel beams that mount to the canopy structure and one perpendicular mobile beam that allows for freedom of movement in one direction. Freedom of movement in the opposite direction is achieved by a system of pulleys along the movable beam that connects the harness to a counterweight. The counterweight provides a passive vertical force, counteracting gravity. The PUMA provides 2-dimensional mobility support over 81 ft2 (9 ft x 9 ft). The overhead bar is connected at 4 points to a child-worn harness. Children are free to move through many postures including sitting, crawling, standing, and walking.
218920450|NCT06998589|OTHER|DPL|The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments..The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.
218920451|NCT06592170|DRUG|Linperlisib combination with obinutuzumab|"Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle."
218920452|NCT06595537|DEVICE|Hand held ultrasound|Determination of gastric feeding tube position with the use of Lumify handheld ultrasound
218920453|NCT04272086|DRUG|Bupivacaine|0.25%
218920454|NCT04272086|DRUG|Bupivacaine liposome|10mL
218920455|NCT04272086|DRUG|normal saline|10ml
218920456|NCT06617897|BIOLOGICAL|CSL511 Fibrinogen concentrate (human)|CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
218920457|NCT06617897|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate will be administered via IV infusion.
218920458|NCT06700668|DEVICE|MIT Powered Knee|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
219534318|NCT03407677|DEVICE|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
219534319|NCT06434753|DRUG|Zinc Acexamate|"The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.~The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose)."
219618115|NCT01007305|PROCEDURE|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
218920459|NCT06705569|DRUG|Tafamidis 61 mg free acid tablet (Test)|Tafamidis 61 mg free acid tablet (Test)
219534320|NCT00742547|OTHER|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
219534321|NCT02258347|DEVICE|Echopulse|
219534322|NCT01720147|DRUG|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
219534323|NCT03166345|OTHER|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
219618116|NCT03806673|DRUG|marcaine|epidural block
219618117|NCT01926431|OTHER|Exercise|
219618118|NCT01926431|OTHER|Rest|
219618119|NCT03334929|DEVICE|Virtual Reality headset|The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
218920460|NCT06705569|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
218920461|NCT06706115|OTHER|Intranasal human breast milk|"The information in the Physiologic Parameter Follow-up Form will be recorded by the investigator just 5 minutes before the intervention. The researcher will drip 0.2 ml of breast milk at room temperature (approximately 22 °C) into the nose of the infant lying in the supine position, 0.1 ml in the right nose-0.1 ml in the left nose. 5 minutes after the intervention (T1), 15 minutes after the intervention (T2) and 30 minutes after the intervention (T3), the data in the Physiologic Parameter Follow-up Form will be recorded by the researcher. After intranasal breast milk administration, the baby will be fed by the neonatal nurse as in routine practice. The implementation of the intervention in the study will last for three days and this process will be repeated three times every day (09.00, 12.00 and 15.00)."
218920462|NCT06704750|BEHAVIORAL|6-minute walk test|patients were instructed to walk back and forth in a marked 30-meter-long straight corridor as fast as they could tolerate
219534324|NCT01777711|BEHAVIORAL|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
219534325|NCT01777711|BEHAVIORAL|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
219618120|NCT05416840|DRUG|Clonidine controlled-release patch|"Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
219534326|NCT00365365|DRUG|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
219534327|NCT00365365|DRUG|Docetaxel (T) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
219534328|NCT00365365|DRUG|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
219534329|NCT00365365|DRUG|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
219534330|NCT00365365|DRUG|Bevacizumab and trastuzumab maintenance therapy|"* bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
219534331|NCT00365365|DRUG|Bevacizumab maintenance therapy|"\- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
219534332|NCT00781339|DRUG|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
219618121|NCT05416840|DRUG|Amlodipine|"Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
219618122|NCT03564457|OTHER|No interventions will take place (observational)|No interventions will take place (observational)
219618123|NCT01390025|BIOLOGICAL|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
219618124|NCT01390025|BIOLOGICAL|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
219618125|NCT04190992|OTHER|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
219618126|NCT04190992|OTHER|Usual care|A pamphlet introduce the introduction of types of surgery
219618127|NCT00263822|DRUG|erlotinib hydrochloride|
219618128|NCT05190939|DIAGNOSTIC_TEST|water as bladder distending media|water will be used for bladder dissension during cystoscopy
219618129|NCT05190939|DIAGNOSTIC_TEST|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
219618130|NCT05190939|DIAGNOSTIC_TEST|No intervention|Saline only, no dye
219618131|NCT02737774|DRUG|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
219618132|NCT02737774|DRUG|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
219534333|NCT00984022|DEVICE|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
219534334|NCT00984022|DEVICE|Type of dressing - Aquacel|Aquacel dressing
219618133|NCT03457181|OTHER|music|effect of music on anxiety scores
219618134|NCT03457181|OTHER|operating room noise|effect of operating room noise on anxiety scores
219618135|NCT03793608|DRUG|Dupilumab|Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
219618136|NCT00285064|PROCEDURE|CT|
219534335|NCT04736186|DRUG|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
219534336|NCT04736186|DRUG|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
219534337|NCT04736186|DRUG|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
219534338|NCT02193763|PROCEDURE|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
219534339|NCT01810419|DEVICE|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
219534340|NCT01810419|DEVICE|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
218920463|NCT06775587|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|"1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~3. The following is the general sequence of events during the 3 months evaluation period:~4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring."
218920464|NCT00735436|DRUG|Gliadel/Avastin/CPT-11|
218920465|NCT06497270|PROCEDURE|Theca and Granulosa Cell Isolation|These patients will receive standard procedure during the risk reducing surgery but their ovaries will be used to extract theca and granulosa cells which will be used for the 3D bioprinted device's realisation.
219534341|NCT03589313|DRUG|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
219534342|NCT03469843|OTHER|Non intervention|patients without intervention
219534343|NCT01153503|PROCEDURE|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
219534344|NCT04654143|DRUG|BVL-GSK098 capsule, placebo|Oral QD
219534345|NCT00573443|DRUG|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
219534346|NCT00573443|DRUG|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
219534347|NCT00573443|DRUG|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
219534348|NCT00905606|DRUG|Topiramate Tablets|
219534349|NCT00905606|DRUG|Topamax® Tablets|
219534350|NCT04596670|DRUG|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
219618137|NCT03752814|DEVICE|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
219618138|NCT01891864|DRUG|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
219618139|NCT01891864|DRUG|Enbrel|Enbrel is used as reference product to GP2015.
218920466|NCT06056596|DRUG|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
218920467|NCT06056596|DRUG|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
218920468|NCT04586205|DEVICE|active TMS|Participants receive active repetitive transcranial magnetic stimulation (rTMS) while performing the International Affective Picture System (IASP). Stimulation is delivered at 120% of resting motor threshold (RMT), in triplet 50 Hz bursts, repeated at 5 Hz (2s on, 8s off), totaling 600 pulses per session.
219534351|NCT03975075|BEHAVIORAL|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
219534352|NCT03975075|BEHAVIORAL|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
218920469|NCT04586205|DEVICE|sham TMS|Participants receive sham rTMS while performing the IASP task. Stimulation is mimicked without actual neural activation using the same schedule and coil placement as the active condition.
218920470|NCT04586205|BEHAVIORAL|IASP Task|Participants complete the IASP (emotional image viewing) task during each TMS session (active and sham). The task includes both high- and low-load trials, designed to activate the dorsolateral prefrontal cortex (DLPFC). Task order and load levels are consistent across both stimulation sessions.
218920471|NCT04586205|BEHAVIORAL|SST Task|In a separate MRI session prior to TMS sessions, participants complete the SST which includes both high-load and low-load trials. This cognitive task is used to examine baseline DLPFC activation and to contrast cognitive vs. emotional activation profiles.
218920472|NCT04586205|OTHER|MRI|Participants undergo MRI sessions to measure DLPFC cortical reactivity and connectivity.
218920473|NCT06940869|OTHER|NURTURE Registry|To improve pregnancy and birth outcomes for women with rheumatic diseases and to understand risk factors associated with poor pregnancy outcomes.
218920474|NCT06943534|DRUG|5mg/kg omalizumab injection|5mg/kg of omalizumab
218920475|NCT06943534|DRUG|15mg/kg omalizumab injection|15mg/kg of omalizumab
218920476|NCT04856358|DRUG|GLPG3121|GLPG3121 modified-release tablet
218920477|NCT04856358|DRUG|Placebo|Matching placebo
218920478|NCT05687851|DRUG|Cadonilimab（AK104）|q3w iv
218920479|NCT05687851|RADIATION|EBRT|45-50.4Gy
218920480|NCT05687851|RADIATION|BT|≥80Gy
218959272|NCT03761771|DEVICE|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
218959273|NCT02514954|DRUG|Biochaperone® Combo|Subcutaneous injection of an individualized dose
218959274|NCT02514954|DRUG|Humalog® Mix25|Subcutaneous injection of an individualized dose
219204745|NCT04282109|DRUG|Nivolumab + Paclitaxel|"Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
218959275|NCT05301374|BEHAVIORAL|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
218959276|NCT04013399|DEVICE|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
218959277|NCT02919384|OTHER|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
218959278|NCT03769376|DEVICE|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
218959279|NCT03769376|DEVICE|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
218959280|NCT04692727|OTHER|Exercise program|"* Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises"
218959281|NCT04692727|OTHER|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
218959282|NCT04692727|OTHER|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
218920481|NCT00204178|BEHAVIORAL|Oxidative stress in kidney transplant recipients|
218920482|NCT04103619|DEVICE|AccuTite|Subjects will undergo treatment with AccuTite
218920483|NCT04103619|DEVICE|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
219534353|NCT04599998|DIAGNOSTIC_TEST|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
219534354|NCT00443391|DRUG|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
218959283|NCT03653871|BEHAVIORAL|Performing Arts Instruction|Professionally delivered performing arts curriculum
218959284|NCT01171664|DRUG|Placebo|Tablet, one BID
219534355|NCT00459420|DRUG|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
219534356|NCT00459420|DRUG|placebo|placebo
219534357|NCT05080894|DEVICE|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
219534358|NCT01293474|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
219534359|NCT00849576|DRUG|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
219534360|NCT00849576|DRUG|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
219534361|NCT00849576|DRUG|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
219534362|NCT00849576|DRUG|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
219534363|NCT05236348|DEVICE|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
219534364|NCT03591458|DRUG|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
219534365|NCT03591458|DRUG|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
219534366|NCT00325663|PROCEDURE|Acupuncture|
219534367|NCT06167694|DRUG|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
219534368|NCT05547737|DRUG|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
219534369|NCT00804856|DRUG|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
219534370|NCT00804856|DRUG|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
219534371|NCT05193461|PROCEDURE|Pulsed mood radiofrequency on dorsal root ganglion|3\) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
219534372|NCT00418561|BIOLOGICAL|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
219534373|NCT00418561|BIOLOGICAL|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
218920484|NCT03913507|DEVICE|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
219534374|NCT00418561|BIOLOGICAL|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
219534375|NCT01796171|DRUG|10 MBq/kg Betalutin|
218920485|NCT06319690|OTHER|Lion's Breath Technique|"Patients receive training in Lion's Breath Technique, emphasizing deep diaphragmatic breathing and controlled exhalation.~Daily supervised Lion's Breath Technique sessions for 20 minutes for 1 week"
218920486|NCT06319690|OTHER|Chest Percussion Therapy|"Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week."
219534376|NCT01796171|DRUG|15 MBq/kg Betalutin|
219534377|NCT01796171|DRUG|20 MBq/kg Betalutin|
219534378|NCT01796171|DRUG|40 mg lilotomab|
219534379|NCT01796171|DRUG|100 mg/m2 lilotomab|
219618140|NCT04480684|DIAGNOSTIC_TEST|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
219618141|NCT04480684|DIAGNOSTIC_TEST|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
219618142|NCT04480684|DIAGNOSTIC_TEST|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
219618143|NCT04480684|DEVICE|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
219618144|NCT03793764|PROCEDURE|TAP block|USG guided TAP block
219618145|NCT03793764|PROCEDURE|QL block|USG guided QL block
219618146|NCT05491902|DIAGNOSTIC_TEST|[C11] Leucine PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.
218920487|NCT00821548|PROCEDURE|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
218920488|NCT04041635|PROCEDURE|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
219534380|NCT01796171|DRUG|60 mg/m2 lilotomab|
218959285|NCT01171664|DRUG|STAHIST|STAHIST in tablet form dosed one BID
218959286|NCT02793648|DRUG|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
219534381|NCT01796171|DRUG|Rituximab|
219534382|NCT01796171|DRUG|12.5 mBq/kg Betalutin|
219534383|NCT00829309|DRUG|Pravastatin|80 mg Tablet
219534384|NCT00829309|DRUG|Pravastatin|80 mg Tablets
219534385|NCT01036009|OTHER|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
219534386|NCT05569291|DEVICE|Automated Coaching Program (ACP)|A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
219534387|NCT05569291|OTHER|Manual Coaching Program (MCP)|A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
219534388|NCT05597982|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
219534389|NCT05597982|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
219534390|NCT04999501|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
219534391|NCT03651739|DEVICE|Knee Connect|An electronic goniometer with smart phone application
219534392|NCT05911152|PROCEDURE|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
219534393|NCT04278261|PROCEDURE|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
219534394|NCT04278261|PROCEDURE|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
219534395|NCT00404183|DRUG|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
218920489|NCT04041635|PROCEDURE|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
218920490|NCT03939689|DRUG|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
218920491|NCT03939689|DRUG|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
218920492|NCT00265993|DRUG|enoxaparin|"* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
218920493|NCT03384615|BEHAVIORAL|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
218920494|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
218920495|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
218920496|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
218920497|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
218920498|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
219534396|NCT00404183|DRUG|Placebo|2 tablets BID
219534397|NCT01683045|DEVICE|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
219534398|NCT05149066|BEHAVIORAL|#KindGirlsInACTion|9-session weekly cognitive-behavioural intervention to promote psychological well-being and prevent body image and eating-related disordered behaviours.
219534399|NCT03950362|DRUG|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
219534400|NCT03950362|DEVICE|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
219534401|NCT00455312|DRUG|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
219534402|NCT00455312|DRUG|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
219534403|NCT00455312|DRUG|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
219534404|NCT00455312|PROCEDURE|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
219534405|NCT00455312|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
219534406|NCT00455312|DRUG|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
219534407|NCT00455312|DRUG|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
219534408|NCT03763435|BEHAVIORAL|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
219534409|NCT02641444|PROCEDURE|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
219534410|NCT02641444|PROCEDURE|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
219534411|NCT02641444|PROCEDURE|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
219534412|NCT06485804|OTHER|Smartphone application guided exercises|"Participants in the intervention group will use a smartphone application to execute a self-rehabilitation program. The app will integrate:~* Basic information about neck pain and ergonomic advice.~* A series of evaluation questions on pain and function.~* Appropriate sets of exercises with videos and instructions.~* Daily reminders.~* Evaluation reports providing feedback and adherence."
219534413|NCT06095401|OTHER|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
219534414|NCT06095401|OTHER|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
219534415|NCT06028204|DRUG|Biologic Agent|Biologic group will have biological agent commenced if considered necessary as part of routine care.
219534416|NCT01693523|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day).
219534417|NCT01693523|OTHER|Placebo|Matching placebo capsules by mouth twice a day.
218920499|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
219534418|NCT01693523|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
218920500|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
218920501|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
218920502|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
218920503|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
218920504|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
218920505|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
218920506|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
218920507|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
218920508|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
218920509|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
218920510|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
218920511|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
219534419|NCT05187481|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
219618147|NCT05491902|DIAGNOSTIC_TEST|[18F] Flutemetamol PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.
218920512|NCT00320450|DRUG|SB-681323|
218920513|NCT00587522|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
218920514|NCT01586364|DRUG|Ospemifene 60Mg Oral Tablet|
218920515|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
218920516|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
219534420|NCT05187481|DRUG|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
219534421|NCT06094023|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
219534422|NCT06094023|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours.
218920517|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
218920518|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
218920519|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
218920520|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
218920521|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
218920522|NCT02121535|DRUG|T80/A5 mg FDC tablet|
218920523|NCT02121535|DRUG|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
218920524|NCT02121535|DRUG|H12.5 mg tablet|
218920525|NCT02121535|DRUG|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
218920526|NCT02121535|DRUG|H12.5 mf tablet|A HCTZ 12.5 mg tablet
218920527|NCT02121535|DRUG|T80/A5/H12.5 mg FDC tablet|
218920528|NCT01780740|DRUG|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
219534423|NCT02736123|DRUG|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
219534424|NCT02736123|DRUG|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
219534425|NCT02331823|DRUG|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
219618148|NCT05491902|DIAGNOSTIC_TEST|MRI scan|Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
219618149|NCT03906799|DRUG|OMT-28|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
219618150|NCT03906799|DRUG|Placebo|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
218920529|NCT01780740|DRUG|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
219618151|NCT00000947|DRUG|Azithromycin|
219618152|NCT03782168|OTHER|There is no other intervention, only clinical treatment.|The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.
218920530|NCT00091949|DRUG|pioglitazone|a thiazolidinedione drug
218920531|NCT00091949|DRUG|placebo|an inactive substance
218920532|NCT05969158|DRUG|Hetrombopag|"After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT \< 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5)."
218920533|NCT06176079|DRUG|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
218920534|NCT06176079|DRUG|Hyperpolarized 13C-Urea|Given intravenously (IV)
218920535|NCT06176079|PROCEDURE|Magnetic Resonance Imaging|Imaging procedure
218920536|NCT06176079|PROCEDURE|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
219534426|NCT02331823|DRUG|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
219618153|NCT00772863|DRUG|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
219618154|NCT05361863|DEVICE|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
219618155|NCT02698163|DEVICE|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
219618156|NCT02698163|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
219618157|NCT00452764|BEHAVIORAL|Withdrawal of medication|
218920537|NCT02769117|PROCEDURE|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
218920538|NCT02769117|PROCEDURE|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
218920539|NCT03390946|DRUG|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
218920540|NCT03390946|DRUG|Good responder group adjuvant chemotherapy|"Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
218920541|NCT04093102|DIAGNOSTIC_TEST|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
218920542|NCT04165577|DEVICE|rTMS|1-Hz rTMS targeting frontal pole
218920543|NCT04165577|DEVICE|sham rTMS|sham rTMS targeting frontal pole
218920544|NCT04240535|DRUG|OnabotulinumtoxinA 50 UNT [Botox Cosmetic]|Injections to the Depressor Anguli Oris
218920545|NCT03399019|DRUG|Dexmedetomidine|initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
219534427|NCT06115317|OTHER|Prism|Prism
219534428|NCT06115317|OTHER|Sham|Sham
219534429|NCT02765724|DRUG|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
219618158|NCT03207984|PROCEDURE|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
219618159|NCT03234543|PROCEDURE|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
219618160|NCT03234543|PROCEDURE|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
219618161|NCT03058627|PROCEDURE|PCI|FFR guided PCI
219618162|NCT01312376|BIOLOGICAL|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
219534430|NCT05832658|DEVICE|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
218920546|NCT03399019|DRUG|Propofol|continuous infusion (0.75-3mg/kg/hr)
218920547|NCT03399019|DRUG|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
219618163|NCT01312376|DRUG|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
219618164|NCT01312376|DRUG|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
218920548|NCT00890123|DIETARY_SUPPLEMENT|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
218920549|NCT04259814|BEHAVIORAL|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
218920550|NCT04259814|BEHAVIORAL|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
218920551|NCT03347721|DRUG|lidocaine gel|2% lidocaine jelly, injected into the urethra
218920552|NCT03347721|DRUG|Lubricant Gel|Lubricating gel
218920553|NCT04289064|DEVICE|Taking a fundus image|The participant only needs to take a fundus image as usual.
218920554|NCT05908825|DRUG|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
218920555|NCT05908825|DRUG|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
218920556|NCT02083354|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
218920557|NCT02083354|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
218920558|NCT03469453|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
218920559|NCT00844961|BEHAVIORAL|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
218920560|NCT04942821|PROCEDURE|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
218920561|NCT04942821|PROCEDURE|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
218920562|NCT03475836|DIETARY_SUPPLEMENT|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
218920563|NCT03475836|DIETARY_SUPPLEMENT|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
218920564|NCT04687982|BIOLOGICAL|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
218920565|NCT00139152|DRUG|Placebo|Saline, Sub-Cuteanous (SQ)
218920566|NCT00139152|DRUG|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
218920567|NCT05957835|DIETARY_SUPPLEMENT|BR-HIGH|4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
219534431|NCT05832658|BEHAVIORAL|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
219534432|NCT05832658|BEHAVIORAL|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
219534433|NCT03343535|DEVICE|OCS Lung Preservation|OCS Lung Preservation
219534434|NCT02300935|DRUG|trametinib|
219534435|NCT02300935|DRUG|nab-paclitaxel|
219618165|NCT01312376|DRUG|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
219618166|NCT01312376|DRUG|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
218920568|NCT05957835|DIETARY_SUPPLEMENT|BR-MOD|2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
218920569|NCT05957835|DIETARY_SUPPLEMENT|BR-LOW|1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
218920570|NCT05957835|DIETARY_SUPPLEMENT|PL|4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
219618167|NCT01313065|DRUG|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
218920571|NCT02757235|PROCEDURE|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
218920572|NCT02757235|PROCEDURE|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
218920573|NCT02853617|BIOLOGICAL|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
218920574|NCT02853617|BIOLOGICAL|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
218920575|NCT02853617|BIOLOGICAL|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
218920576|NCT02853617|BIOLOGICAL|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
218920577|NCT01680042|DRUG|Phenytoin paste|
218920578|NCT01680042|DRUG|Placebo|
218920579|NCT02983201|OTHER|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
218920580|NCT02983201|OTHER|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
219534436|NCT04215718|PROCEDURE|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\\0 sutures
219534437|NCT04215718|PROCEDURE|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
218920581|NCT02699424|RADIATION|External radiation therapy|
218920582|NCT06769334|OTHER|PLAY Program|The PLAY Program is a web-based program created for caregivers of childhood cancer survivors. The program consists of seven modules with the following topics: 1) Introduction to the program 2) Self-Care 3) Relationships 4) Getting Ready for School 5) Talking, Reading, and Counting together 6) Social and Emotional Development 7) Review Module. The program is meant to be completed over approximately three months, and caregivers in the program will meet with a coach on a weekly or bi-weekly basis to discuss what they learned in the modules and how to practice it in their daily lives.
218920583|NCT05291520|BIOLOGICAL|VH3810109|VH3810109 was administered.
218920584|NCT05291520|BIOLOGICAL|rHuPH20|rHuPH20 was administered.
218920585|NCT01347112|DRUG|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
218920586|NCT01347112|DRUG|placebo|sugar pill twice daily for 12 weeks
219534438|NCT01045018|DRUG|Placebo|placebo 400 mg
219534439|NCT01045018|DRUG|Mesalamine|
218920587|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
218920588|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
218920589|NCT05202886|DIAGNOSTIC_TEST|Liver from deceased donors|Liver donors photographed
218920590|NCT01679314|DEVICE|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
218920591|NCT02342808|BEHAVIORAL|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
218920592|NCT02342808|BEHAVIORAL|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
218920593|NCT01615120|DRUG|GTx-758 125 mg|One 125 mg tablet once a day
218920594|NCT01615120|DRUG|GTx-758 250 mg|two 125 mg tablets once daily
219534440|NCT01045018|DRUG|Mesalamine|
219534441|NCT02134379|DEVICE|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
219618168|NCT02689765|DIETARY_SUPPLEMENT|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
218920595|NCT00696072|DRUG|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
218920596|NCT00696072|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
218959287|NCT02793648|DRUG|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
218959288|NCT02793648|DRUG|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
219534442|NCT06440343|DIETARY_SUPPLEMENT|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
219534443|NCT06440343|DIETARY_SUPPLEMENT|Placebo|Placebo
219618169|NCT02689765|DIETARY_SUPPLEMENT|Placebo|Placebo capsules is identically packaged.
219618170|NCT02892331|BEHAVIORAL|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
219534444|NCT03059979|DRUG|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
219534445|NCT03059979|OTHER|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
219534446|NCT03407287|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
219534447|NCT03407287|PROCEDURE|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
219534448|NCT03407287|PROCEDURE|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
218920597|NCT05990010|DIAGNOSTIC_TEST|Berlin Questionnaire|The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
218920598|NCT06274736|DEVICE|Motiva Sizer|No intervention will be made,
218920599|NCT01601236|DRUG|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].
218920600|NCT01601236|DRUG|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
218920601|NCT02124369|DRUG|Abraxane|125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
219534449|NCT06561659|BEHAVIORAL|Exercise Condition|Already described in the arm description
218920602|NCT02124369|DRUG|Gemcitabine|1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
218920603|NCT00218868|PROCEDURE|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
218920604|NCT04371159|DEVICE|Velieve U.S.|The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
218920605|NCT01340846|DRUG|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
218920606|NCT01340846|DRUG|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
218920607|NCT01340846|DRUG|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
218920608|NCT01340846|DRUG|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
218920609|NCT01340846|DRUG|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
218920610|NCT04968002|DRUG|pablizumab combined with apatinib and neoadjuvant chemotherapy|The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
219534450|NCT06561659|BEHAVIORAL|Relaxation Control Condition|Already described in the arm description
219534451|NCT00041015|DRUG|cisplatin|
219534452|NCT00041015|DRUG|etoposide|
219534453|NCT00041015|DRUG|topotecan hydrochloride|
219534454|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
219534455|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
219534456|NCT01315990|DRUG|FOLFIRI + Cetuximab|"1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
218920611|NCT02398435|BIOLOGICAL|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
218920612|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
219618171|NCT02892331|BEHAVIORAL|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
218920613|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
218920614|NCT05682716|COMBINATION_PRODUCT|Controlled low central venous pressure (CLCVP) technology|Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.
218920615|NCT05682716|DRUG|Nitroglycerin|nitroglycerin (0.2-1 ug/kg \* min)
218920616|NCT01777386|PROCEDURE|preexpanded perforator flap surgery|
218920617|NCT02189317|DRUG|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
218920618|NCT01895413|PROCEDURE|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
218920619|NCT04195763|DRUG|asfotase alfa|This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
219618172|NCT01116167|DRUG|Letrozole -Berberine|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month."
219534457|NCT05257564|DEVICE|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
219534458|NCT00264108|DRUG|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
219534459|NCT00264108|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length.
218920620|NCT02351622|DRUG|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
218920621|NCT02351622|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
219534460|NCT00085293|DRUG|Decitabine|Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
219618173|NCT01116167|DRUG|Letrozole|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months"
219534461|NCT00085293|RADIATION|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
218920622|NCT02351622|DRUG|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
218920623|NCT02419001|DRUG|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
218920624|NCT02419001|DRUG|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
218920625|NCT02419001|DRUG|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
218920626|NCT02419001|DRUG|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
218920627|NCT02856672|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
218920628|NCT02856672|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
218920629|NCT05777499|BEHAVIORAL|Music Therapy|Music Therapy will comprise individual and group sessions 20-45 minutes. Participants usually have 1-2 individual sessions, and 1 group session/week. Group sessions include 2-6 participants. On average, participants receive an average 1 hour 30 minutes Music Therapy/week, timetabled when they would not otherwise be undergoing any therapy sessions. The Music Therapist will use the Nordoff Robbins approach and work flexibly as a musician. Techniques include (but are not limited to) empathic listening, musically matching, turn taking and sequencing, call and response. Sessions may also involve songwriting, singing familiar songs, listening to, sharing and discussing music, developing specific musical skills of interest to the participant, structured musical games and activities, joint working with other members of the therapy team in sessions focused on functional development and communication skills.
218920630|NCT05777499|BEHAVIORAL|Control Therapy|Control Therapy sessions will be carried out by a member of the clinical team, matched in duration and number to Music Therapy sessions as closely as possible. Participants will usually have 1-2 individual sessions and 1 group session/week. Group sessions include 2-6 participants. The Control Therapy intervention will continue throughout participant's rehabilitation program until participants have completed a total of 15 hours intervention, which will usually take 10 weeks to complete. The content of sessions is designed to reflect 'usual care' however control therapy sessions will not include access to specific specialist equipment such as MOTOmed, therabike or neuro-muscular electrical stimulation, to ensure the control group does not get additional specialist intervention beyond usual care. Content of control therapy sessions will therefore be restricted to the following five domains: gaming, education, mindfulness, current affairs discussions, and passive and dynamic stretching.
218920631|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
218920632|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
219534462|NCT00085293|BIOLOGICAL|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
219534463|NCT00085293|RADIATION|Fludeoxyglucose F 18|Optional correlative studies
219618174|NCT01116167|DRUG|Berberine|"Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
219618175|NCT01480869|DRUG|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
218920633|NCT00313014|DRUG|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
218959289|NCT00162955|DRUG|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
219618176|NCT01480869|DRUG|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL"
219618177|NCT01950455|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
219618178|NCT00610428|DRUG|Staccato Placebo|Inhaled Staccato Placebo
219618179|NCT00610428|DRUG|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
219618180|NCT00610428|DRUG|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
219618181|NCT05163483|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
219618182|NCT00752128|DEVICE|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
218920634|NCT05809375|OTHER|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
218920635|NCT06165289|OTHER|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
218920636|NCT01323101|DRUG|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
218920637|NCT01323101|OTHER|No doxycycline|
218920638|NCT02922322|OTHER|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
218920639|NCT01466712|DRUG|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
218920640|NCT01466712|DRUG|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
218920641|NCT00393731|DRUG|Misoprostol|
218920642|NCT00393731|DRUG|oxytocin|
218920643|NCT00188344|PROCEDURE|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
218920644|NCT00188344|PROCEDURE|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
218920645|NCT03515668|DRUG|Ritalin 20 mg Tablet|Single dose for all participants
218920646|NCT03515668|DRUG|Placebo Oral Tablet|Placebo with same appearance/taste
218920647|NCT04216056|BEHAVIORAL|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
219204746|NCT04282109|DRUG|Cetuximab + Paclitaxel|"Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
219204747|NCT01783587|DRUG|Afatinib|Taken orally once per day
219204748|NCT01783587|DRUG|Docetaxel|15 mg/m2, given intravenously once per week
219204749|NCT01783587|RADIATION|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
219204750|NCT04688333|OTHER|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
219204751|NCT04688333|OTHER|Quality-of-Life Assessment|Ancillary studies
219204752|NCT04688333|OTHER|Questionnaire Administration|Complete questionnaires
219534464|NCT00085293|PROCEDURE|Positron emission tomography|Optional correlative studies
219534465|NCT02006212|PROCEDURE|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
219534466|NCT00003766|DRUG|O6-benzylguanine|
219534467|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
219534468|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
219534469|NCT00777023|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
219534470|NCT00006218|DRUG|triapine|
219534471|NCT05464836|DRUG|CB-103|Given by PO
219534472|NCT05464836|DRUG|Venetoclax|Given by PO
219534473|NCT06407505|OTHER|Acupressure group|LI4 acupressure applied group.
219534474|NCT06407505|OTHER|Placebo group|Group where acupressure was applied to an area 1.5 cm away at the LI4 acupressure point
219534475|NCT04919005|OTHER|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
218920648|NCT00644800|DRUG|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
218920649|NCT00663182|DRUG|Entecavir|Entecavir 0.5 mg/d
218920650|NCT04350762|DIETARY_SUPPLEMENT|Protein shake + Fish Oil|2 shakes of protein as well as 1 fish oil daily.
218920651|NCT00999778|BEHAVIORAL|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
218920652|NCT00999778|BEHAVIORAL|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
218920653|NCT04743778|BEHAVIORAL|Virtual Diabetes Self-Management Education and Support|Diabetes self-management education and support delivered through Zoom for health.
218920654|NCT01896219|DEVICE|Navigation station (IMACTIS-CT®)|
218920655|NCT01896219|DEVICE|CT|Reference method for gestures (carried out under CT) guidance
218920656|NCT04988581|OTHER|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
218920657|NCT00231738|DRUG|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
218920658|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
218920659|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
218920660|NCT06079814|OTHER|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
218920661|NCT03162263|DEVICE|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
218920662|NCT04299607|DIAGNOSTIC_TEST|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
218920663|NCT05743491|OTHER|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
218920664|NCT05743491|BEHAVIORAL|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
218920665|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
218920666|NCT03980080|DRUG|Placebo|Vehicle study drug
218920667|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
218920668|NCT01597804|PROCEDURE|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
218920669|NCT04818788|DRUG|Biological Drug|we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
218920670|NCT06139120|DIAGNOSTIC_TEST|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
218920671|NCT01198795|DRUG|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
218920672|NCT03303963|DIAGNOSTIC_TEST|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
218920673|NCT03303963|DIAGNOSTIC_TEST|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis"
218959290|NCT00800462|DRUG|Oxybutynin Cl|15 mg qd for 3 months
218959291|NCT00800462|DRUG|Trospium Cl|20mg bid for 3 months
218959292|NCT00800462|DRUG|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
219042623|NCT01876069|DEVICE|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
218920674|NCT06284889|BEHAVIORAL|Behavioural activation|"Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log;~Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
218920675|NCT06284889|OTHER|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
218920676|NCT03298035|DEVICE|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
218920677|NCT03298035|DEVICE|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
219204753|NCT06367192|BEHAVIORAL|The adapted Kids in Transition to School Intervention|An intensive, school readiness intervention designed to improve preschoolers' social skills, early literacy, numeracy, and self-regulation skills at high risk for academic difficulties. The intervention is delivered virtually over 8 weeks with caregivers and intentionally occurs over the summer when there is a gap in preschool services.
219204754|NCT06367192|BEHAVIORAL|Standard school resources|Information about local preschool programs and age appropriate books for children will be provided.
219204755|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
219534476|NCT02419339|PROCEDURE|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
219534477|NCT02729090|OTHER|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
219534478|NCT02729090|OTHER|Device: treadmill Train_Comb_aerobic|Device: treadmill Train\_Comb\_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train\_Comb\_aerobic
219534479|NCT06628050|DEVICE|ORIGIN® PS Modular devices|Consecutive eligible subjects have been included which have been treated with the ORIGIN® PS Modular devices.
219534480|NCT02659150|DRUG|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
219534481|NCT06218524|DRUG|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
219534482|NCT06218524|DRUG|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
219534483|NCT06015035|DRUG|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
218920678|NCT01197118|RADIATION|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
218920679|NCT01197118|DRUG|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
218920680|NCT00936715|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
218920681|NCT05341141|DEVICE|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
218920682|NCT05341141|DRUG|ddEC-ddT|Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
219534484|NCT03699020|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
219534485|NCT03699020|OTHER|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
219534486|NCT03995030|DIAGNOSTIC_TEST|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
219534487|NCT04971668|OTHER|Aromatherapy|Three drops of the designated blend aromatherapy (ginger \& lavender) will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
219534488|NCT04971668|OTHER|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
219618183|NCT00349973|DRUG|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
218920683|NCT04862546|DEVICE|Laser Acupoint|Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject
218920684|NCT04862546|DEVICE|Tap water iontophoresis|"Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes."
218920685|NCT06271746|DEVICE|FibroNova (Active mode)|FibroNova neurostimulator of conditional pain modulation (CPM)
219534489|NCT04971668|OTHER|Controlled|Patients will inhale deeply with inert gauze and simulate like chewing gum for 5 minutes.
219618184|NCT00349973|OTHER|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
219618185|NCT06579209|DIETARY_SUPPLEMENT|Nicotinamide adenine dinucleotide|Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
218920686|NCT06271746|DEVICE|FibroNova (Sham mode)|FibroNova neurostimulator with an electrical output not intended for neurostimulation
218920687|NCT00003553|OTHER|HLA Matched Peripheral BLood Stem Cells|Cell Product
218920688|NCT05969834|DRUG|uHCG|Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
218920689|NCT05969834|DRUG|rHCG|Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
218920690|NCT05969834|DRUG|uHCG and GnRHa|Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
218920691|NCT05972980|OTHER|COVID-19|The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
218920692|NCT01337960|BEHAVIORAL|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
219534490|NCT04867252|DRUG|Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)|51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
218920693|NCT01337960|BEHAVIORAL|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
219534491|NCT04867252|DRUG|Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)|51 Patients with PCOS receiving Metformin and Pioglitazone 500 mg and 15 mg BD daily respectively
219534492|NCT04233320|DEVICE|silicone cream containing Allium Cepa extract|silicone cream containing Allium Cepa extract contains 10% of Allium cepa bulb extract.
219534493|NCT04233320|DEVICE|Commercial scar gel|Commercial scar gel is a topical silicone gel. It contains cyclic and polymeric siloxanes and Vitamin C ester.
219534494|NCT00470769|PROCEDURE|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
219534495|NCT03861065|PROCEDURE|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
219534496|NCT03861065|PROCEDURE|Historical Wound Closure|Participants wounds are left partially open to heal.
219534497|NCT02246920|DRUG|Fluticasone propionate|50 mcg/actuation Nasal Spray
219534498|NCT02246920|DRUG|Flonase®|50 mcg/actuation Nasal Spray
219534499|NCT02246920|DRUG|Placebo|Inactive Nasal Spray
219534500|NCT03642769|OTHER|Fluid administration|Fluid administration of bolus and maintenance fluids
219534501|NCT00197769|BIOLOGICAL|9 valent pneumococcal con jugate vaccine|
219534502|NCT04860804|DRUG|Aspirin and Ketamine|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
219534503|NCT04860804|DRUG|Oral Ketamine|Proprietary oral formulation of 0.5mg/kg of ketamine
219534504|NCT04572386|OTHER|light cure 3m single bond universal bond|light -cure universal bond
219618186|NCT03348540|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
219618187|NCT03348540|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
219618188|NCT03509064|OTHER|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
219618189|NCT04904250|DEVICE|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
219618190|NCT04904250|DEVICE|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
219618191|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
219618192|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
219618193|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
218920694|NCT01337960|BEHAVIORAL|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
219534505|NCT04572386|OTHER|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
219534506|NCT00448019|DRUG|Fludarabine|25 mg/m\^2 IV over 30 minutes daily for 3 days
218920695|NCT01772316|DRUG|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
218920696|NCT01418625|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
218920697|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
218920698|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
218920699|NCT02919839|OTHER|non-Interventional|
219042624|NCT04887662|OTHER|Fermented vegetable|Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
219534507|NCT00448019|DRUG|Cyclophosphamide|250 mg/m\^2 IV over 30 minutes daily for 3 days
219042625|NCT04656132|BEHAVIORAL|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
219534508|NCT00448019|DRUG|Rituximab|375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.
219534509|NCT00448019|DRUG|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
219534510|NCT02297932|BEHAVIORAL|Strength training|Participants will engage in a home-based strength training program.
219534511|NCT02297932|BEHAVIORAL|Stretching|Participants will engage in a home-based stretching training program
219534512|NCT00996788|DRUG|Rebamipide|Rebamipide 100 mg tid for 28 days
219534513|NCT06370507|DEVICE|Electrical impedance tomography assessment of ventilation distribution in course of sedation/general anesthesia for pediatric surgery|Assessment of ventilation distribution through electrical impedance tomography in pediatric patients subjected to sedation or general anesthesia for surgery
219534514|NCT02193061|BIOLOGICAL|Rotarix|
219534515|NCT02193061|BIOLOGICAL|RotaTeq|
219618194|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
219618195|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
219618196|NCT01161069|DRUG|Placebo|Placebo in oral solution, given once daily for 14 days
219618197|NCT05993364|DEVICE|Free Aspire with Expiratory Flow Accelerator (EFA) technology|Treatment sessions during which the EFA technology is used. Depending on the patient's clinical conditions, an oxygen additional support can be provided, while using the device. If present, during the sessions the tracheal cannula must be cuffed. Tracheal cannula aspiration must be provided when necessary. Sessions take place three times a day and take 20 minutes each time, from Monday to Saturday.
219618198|NCT05993364|DEVICE|In-Exufflator Machine|Sessions using the In-Exufflator machine to improve the cough function, when the oxygen saturation decreases and the bronchial secretions increases.
219618199|NCT05993364|OTHER|Traditional respiratory treatment|"Standard rehabilitative treatment to improve the secretions management, that includes:~* A change of the patient posture every three hours;~* Airways humidification depending on the secretions features;~* Aspiration in the tracheal cannula whenever necessary."
219618200|NCT05993364|OTHER|Traditional swallowing treatment|"Traditional rehabilitative treatment carried out by the speech and language pathologist in order to:~* Obtain decannulation (when a tracheal cannula is applied) following the Bargellesi Protocol steps;~* Improve oral structures strength and motility;~* Improve oral and perioral sensitivity with thermal or gustative or tactile stimulations;~* Improve the swallowing function with food trials of different consistencies, volume and temperature;~* Improve swallow efficacy and safety through the prescription of compensatory postures;"
219618201|NCT02510443|DEVICE|ESS305 (Essure, BAY1454032)|Bilateral insert placement
219618202|NCT00425243|DRUG|zolpidem-MR (SL800750)|
219618203|NCT04314037|DRUG|Cesol (Test)|Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
219618204|NCT04314037|DRUG|Biltricide (Reference)|Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
219618205|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
219534516|NCT03075553|OTHER|Laboratory Biomarker Analysis|Correlative studies
219534517|NCT03075553|BIOLOGICAL|Nivolumab|Given IV
219534518|NCT00938951|OTHER|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
219534519|NCT00272597|DRUG|Risperidone|See Detailed Description.
219534520|NCT00719745|DRUG|Prograf|oral
219618206|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
219618207|NCT02490631|DRUG|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
218920700|NCT06324513|DIETARY_SUPPLEMENT|Mediterranean Crohn's Disease Exclusion Diet (Med-CDED)|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
218920701|NCT06324513|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease.
218920702|NCT02960581|BIOLOGICAL|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
219534521|NCT00719745|DRUG|MR4|oral
219534522|NCT05033847|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
219618208|NCT06034106|BEHAVIORAL|Pomegranate (Punica granatum) peel compress|Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.
218920703|NCT02960581|BIOLOGICAL|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
218920704|NCT02960581|BIOLOGICAL|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
218920705|NCT02960581|BIOLOGICAL|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
218920706|NCT02960581|BIOLOGICAL|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
218920707|NCT03002337|BEHAVIORAL|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
218920708|NCT03002337|BEHAVIORAL|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
218920709|NCT01341353|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
218920710|NCT01341353|DRUG|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
218920711|NCT02190695|DRUG|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
218920712|NCT02190695|DRUG|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
218920713|NCT02190695|DRUG|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
218920714|NCT06428292|DEVICE|Virtual reality device branded ''Meta Quest 2''|Combining different exercise equipment with a virtual reality device and using them in a virtual environment can be used to decide which one is more effective.
219534523|NCT05033847|BIOLOGICAL|COVID-19 vaccine (Vero cells)|Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
219534524|NCT03620747|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"
219534525|NCT04534166|OTHER|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
219534526|NCT03050944|OTHER|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
219534527|NCT02514330|OTHER|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
219534528|NCT02514330|OTHER|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
219534529|NCT01661855|DRUG|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
219534530|NCT01661855|DRUG|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
219534531|NCT02514876|DEVICE|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
219534532|NCT02714062|DRUG|Placebo|po once daily
219534533|NCT02714062|DRUG|VI-0521 Mid Dose|po once daily
219534534|NCT02714062|DRUG|VI-0521 Top Dose|po once daily
219618209|NCT06034106|BEHAVIORAL|Hot compress|Hot compress was applied 3 days a week for 3 weeks.
219618210|NCT01370447|DRUG|EPI-743|EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
219618211|NCT07079449|PROCEDURE|Dry Needling|Dry needling applied to bilateral active trigger points in the masseter and temporalis muscles once per week for three weeks.
219618212|NCT07079449|PROCEDURE|Lidocaine Hydrochloride|Lidocaine (20 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
218920715|NCT00228267|DRUG|Propofol|
219534535|NCT03106662|BIOLOGICAL|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.
219534536|NCT03106662|DRUG|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
219534537|NCT05824325|DRUG|SHR-A1811|HER2 ADC
219534538|NCT05824325|DRUG|TROP2 ADC|TROP2 ADC
219534539|NCT05063903|OTHER|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
219534540|NCT01780870|DIETARY_SUPPLEMENT|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
219534541|NCT04396015|DIETARY_SUPPLEMENT|Bulletproof Brain Octane|Medium chain triglyceride oil (MCT)
219534542|NCT04396015|DIETARY_SUPPLEMENT|Placebo|Placebo (olive) oil
219534543|NCT04587570|PROCEDURE|Infiltration with PRP|Infiltration with 1.5 ml PRP
218920716|NCT03742557|DRUG|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
218920717|NCT03488953|PROCEDURE|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
218920718|NCT00648063|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
218920719|NCT00648063|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
218920720|NCT02135432|DRUG|Ivacaftor|
218920721|NCT02135432|DRUG|Placebo|
218920722|NCT00914316|DRUG|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
219534544|NCT04587570|PROCEDURE|Infiltration with Fat|Infiltration with 1.5 ml Fat
219534545|NCT04587570|PROCEDURE|Infiltration with PRP and Fat|Infiltration with 0.75 ml PRP and 0.75 ml Fat
219534546|NCT04587570|PROCEDURE|Infiltration with NaCl|Infiltration with 1.5 ml NaCl
219534547|NCT05075447|BEHAVIORAL|Emotion Control Treatment Program|Intervention programs include Child Training and Training in real scenes
219618213|NCT07079449|PROCEDURE|Mepivacaine Hydrochloride|Mepivacaine (30 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
219618214|NCT06866574|BIOLOGICAL|Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)|Participants received 3 doses of 9-valent HPV vaccine according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle of the upper arm)
219618215|NCT06866574|BIOLOGICAL|Aluminum Adjuvant|Participants received 3 doses of Aluminum Adjuvant according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle the upper arm).
218920723|NCT00914316|DRUG|Placebo|twice daily
218920724|NCT00242502|DRUG|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
218920725|NCT00242502|DRUG|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
218920726|NCT02802540|DRUG|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
218920727|NCT02802540|DRUG|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
218920728|NCT03843840|DEVICE|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
218920729|NCT03710499|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
218920730|NCT04513223|DRUG|SHR-A1811|There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
218920731|NCT01528332|DEVICE|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
218920732|NCT01528332|DEVICE|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
219042626|NCT03773731|BEHAVIORAL|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
219042627|NCT03773731|BEHAVIORAL|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
219042628|NCT00542581|DEVICE|The Acrysof toric SN60T3 IOL|Intraocular Lens
219534548|NCT05408897|DIAGNOSTIC_TEST|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
218920733|NCT04375280|OTHER|"Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness."|"Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)"
218920734|NCT03163303|BEHAVIORAL|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
218920735|NCT03163303|BEHAVIORAL|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
218920736|NCT03163303|DRUG|nicotine patch|14-day supply of nicotine patch
218920737|NCT05570825|PROCEDURE|Biopsy|Undergo biopsy
218920738|NCT05570825|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218920739|NCT05570825|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
218920740|NCT05570825|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
218920741|NCT05570825|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218920742|NCT05570825|BIOLOGICAL|Pembrolizumab|Given IV
218920743|NCT05570825|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218920744|NCT01157403|BIOLOGICAL|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
218920745|NCT00705952|OTHER|Lifestyle intervention|Diet, exercise and behavioural change intervention.
218920746|NCT00960882|DRUG|DMMET-01|1050.6 mg daily for 30 days
218920747|NCT05836506|DRUG|ABBV-903 Tablet Form 1|Oral Tablets
218920748|NCT05836506|DRUG|ABBV-903 Tablet Form 2|Oral Tablets
218920749|NCT06192654|PROCEDURE|Small intestinal submucosa (SIS) graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
218920750|NCT06192654|PROCEDURE|Autologous oral bucal mucosa graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
219204756|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
219534549|NCT03502148|DRUG|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
219534550|NCT04215510|PROCEDURE|endonasal endoscopic surgery|143 patients will undergo endonasal endoscopic surgery
218920751|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITH ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS
218920752|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITHOUT ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS WITH ELEVATOR SYSTEM
218920753|NCT00897832|OTHER|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
218920754|NCT04981483|PROCEDURE|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
218920755|NCT02261701|OTHER|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
218920756|NCT02261701|OTHER|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
218920757|NCT00225485|DRUG|Effexor XR|
219534551|NCT04215510|RADIATION|radiation therapy(IMRT)|143 patients will undergo radiation therapy.
219534552|NCT00904215|DRUG|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
219534553|NCT03890471|BEHAVIORAL|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
219534554|NCT01621893|PROCEDURE|Subchondroplasty|
219534555|NCT02516839|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
218920758|NCT05097079|DRUG|MYOBLOC Low Dose|Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
219534556|NCT02516839|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
219618216|NCT06782360|DEVICE|Active Neurostimulation|The stimulation frequency, pulse width, and amplitude will be varied in order to determine the optimal stimulation conditions for elongating the period of peak subject performance during the experimental tasks. Amplitude, pulse width, and frequency meet or exceed International Electrotechnical Commission (IEC) 60601-2-10:2016 requirements. The amplitude range specified is selectable for either channel with any frequency and pulse width combination. We will test an amplitude range of 0 mA - 5.0 mA. We will test a frequency range of 1 Hz - 150 Hz. We will test a pulse width range of 50 μs - 750 μs. The study coordinator should apply neurostimulation when the reported cognitive state metric corresponding to the performance task reaches different thresholds. These thresholds will be determined before execution of the study and will be chosen to maximize the likelihood of discovering an optimal trigger for neurostimulation based on reported cognitive state.
219618217|NCT06782360|DEVICE|Sham Stimulation|Modulation of stimulation frequency and amplitudes outside of the known physiological effective ranges during intervention periods.
218920759|NCT05097079|DRUG|MYOBLOC High Dose|Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
218920760|NCT05097079|DRUG|Placebo|Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
218920761|NCT04266704|BEHAVIORAL|Sharing Intervention|intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
218920762|NCT06212362|BEHAVIORAL|Step-by-step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
218920763|NCT06212362|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (90-120 minutes)"
218920764|NCT05369845|OTHER|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
218920765|NCT03499483|DRUG|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
218920766|NCT05189808|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation (non-experimental)
219042629|NCT01184274|DRUG|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. \- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. \- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
219042630|NCT03517709|OTHER|Primary Care Physician Management of blood pressure|"* You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
219042631|NCT03517709|DEVICE|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
219534557|NCT02516839|BEHAVIORAL|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
219534558|NCT02516839|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
219618218|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
219618219|NCT07089667|BEHAVIORAL|virtual reality exergame|virtual reality exergame using Nintendo RingFit
219618220|NCT07089667|BEHAVIORAL|Conventional|Conventional-based aerobic exercise using video aerobic exercise of the Ministry of Health (KEMENKES) protocol
219618221|NCT04052217|DEVICE|Penile Ring|Penile Ring at base of penis
218920767|NCT06802003|DEVICE|Biometric wearable and handheld devices|In this study, participants will be equipped with biometric wearable devices, i.e. ring and wristband, as well as with a handheld oscillometer, to measure their physiological parameters and lung mechanical changes (lung function).
218920768|NCT06523959|DRUG|Apixaban 2.5 MG|To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
218920769|NCT04941716|DRUG|Acalabrutinib|Given PO
219534559|NCT03916263|DRUG|Metformin|Traditional care including diet, exercise and metformin
218920770|NCT04941716|DRUG|Venetoclax|Given PO
218920771|NCT04941716|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219042632|NCT06097208|BEHAVIORAL|community-based health promotion and obesity prevention intervention|The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
219042633|NCT02022228|DRUG|triptorelin|0.2 mg triptorelin, ih
219042634|NCT02022228|DRUG|hCG|1000 IU hCG, im
219042635|NCT02022228|DRUG|hCG|500IU hCG, im
219042636|NCT03413059|DRUG|Morphine Sulfate|Thoracic Epidural morphine
219042637|NCT03413059|DRUG|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
218920772|NCT04941716|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
218920773|NCT04941716|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
218920774|NCT04941716|PROCEDURE|Computed Tomography|Undergo CT
218920775|NCT04941716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218920776|NCT03961672|DRUG|Duvelisib|Given PO
218920777|NCT01099605|DEVICE|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
218920778|NCT01099605|DEVICE|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
219042638|NCT01970839|DEVICE|tourniquet, sensory nerve conduction abnormality|
219042639|NCT02394938|OTHER|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
218920779|NCT05753449|DEVICE|Baseline (or standard of care) DBS programming|Baseline (or standard of care) DBS programming.
218920780|NCT05753449|DEVICE|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
219534560|NCT03916263|OTHER|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
219534561|NCT03916263|OTHER|Video Dietary Instruction|Participant receives video dietary instruction
219534562|NCT01275469|DRUG|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
219534563|NCT01275469|DRUG|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
219534564|NCT02104908|PROCEDURE|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
219534565|NCT02104908|PROCEDURE|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
218920781|NCT04587518|BEHAVIORAL|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
218920782|NCT05924633|DIETARY_SUPPLEMENT|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
218920783|NCT05924633|DIETARY_SUPPLEMENT|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
218920784|NCT06793917|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
219042640|NCT00331175|DRUG|Peptide YY3-36|
219042641|NCT00677807|DRUG|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
219204757|NCT03340428|BEHAVIORAL|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
219534566|NCT06093932|DRUG|Songling Xuemaikang Capsules|3 capsules at a time, three times a day, duration: 12 weeks
219534567|NCT06093932|BEHAVIORAL|Lifestyle intervention|everyday, duration: 12 weeks
219618222|NCT06902233|DEVICE|High-definition transcranial infraslow grey noise stimulation|HD-tIGNS will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator. The HD-tIGNS will be used to alter the functional connectivity strength between the three cortical networks \[namely the salience network (SN), the default mode network (DMN) and the somatomotor network (SMN)\] in the infraslow frequency spectrum (0.1 Hz). A total of fifteen circular Ag/AgCl electrodes \[eleven stimulation electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) and four electrodes with zero current (FC1, FC2, FC4, and FCz)\] will be placed on a neoprene head cap following the International 10-10 EEG system. The optimal montages has been created using the Stimweaver optimization software by the Neuroelectrics company, to specifically decrease the functional connectivity i.e., phase synchronization of the brain regions of the SN with the SMN and the DMN.
219534568|NCT06093932|DRUG|Placebo|3 capsules at a time, three times a day, duration: 12 weeks
219534569|NCT03650985|PROCEDURE|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
218920785|NCT06793917|DRUG|Oxaliplatin injection|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
218920786|NCT06793917|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
218920787|NCT06793917|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
219534570|NCT03055637|PROCEDURE|Furlow double opposing z-plasty|\* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
219534571|NCT03055637|PROCEDURE|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
218920788|NCT06793917|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 135mg/m2
218920789|NCT05856734|DEVICE|Weight and body composition change|1- Anthropometric Measurements: Body Weight (BW), Body Mass Index (BMI), Sitting Height Ratio (SHR), Waist to Hip Ratio (WHR), Finger Ratio (FR), Body Fat (BF%), and Weight-for-age growth charts. (Single measure)
218920790|NCT05856734|BEHAVIORAL|Change in dietary intake|"1. 24-hour recalls using Intake24 (online survey) over 3-day.~2. Self reported questionnaire. (Single measure)"
218920791|NCT05856734|DEVICE|Change in physical activity|"1. ActiGraph GT9X Link accelerometer over 7-day.~2. Self reported questionnaire. (Single measure)"
218920792|NCT05856734|BEHAVIORAL|Change in stress|1- Self reported questionnaire. (Single measure)
218920793|NCT05856734|BEHAVIORAL|Change in socio-demographic characteristics|1- Self reported questionnaire. (Single measure)
218920794|NCT05856734|DEVICE|Change in sleep|ActiGraph GT9X Link accelerometer over 7-day. (Single measure)
219042642|NCT00677807|DRUG|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
219042643|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
219534572|NCT03545451|DEVICE|Videogames|Videogames
219534573|NCT02503527|OTHER|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
218920795|NCT04560400|DIAGNOSTIC_TEST|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
219534574|NCT02503527|OTHER|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
219534575|NCT06626776|PROCEDURE|lateral sinus lift with using allograft and collagen membrane|sinus floor elevation with placing allograft and collagen membrane
219534576|NCT06626776|PROCEDURE|lateral sinus lift with using exteneded platelet rich fibrin|sinus floor elevation with placing eprf
219534577|NCT01890057|DRUG|Sugammadex|The dose of sugammadex
219534578|NCT01038817|DRUG|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
219534579|NCT00283608|GENETIC|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
219534580|NCT00283608|OTHER|high performance liquid chromatography|analysis of plasma concentrations of drugs
219534581|NCT00283608|OTHER|measurements by DXA|determine bone mineral density (BMD)
219534582|NCT00283608|OTHER|questionnaire administration|determine attitude changes
219534583|NCT00573417|DRUG|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
219534584|NCT00573417|DRUG|Placebo|
219534585|NCT00244764|DRUG|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
219534586|NCT00244764|DRUG|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
219534587|NCT05408884|OTHER|Social Support|"Social support phone buddy program."
219534588|NCT05408884|OTHER|Basic income|$750 per month for 12 months
219534589|NCT06558370|OTHER|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
219534590|NCT06558370|OTHER|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
219042644|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
219534591|NCT06560775|COMBINATION_PRODUCT|Standard Treatment for SLE|Standard Treatment for SLE
219534592|NCT01426633|DRUG|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
218920796|NCT04560400|DIAGNOSTIC_TEST|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
218920797|NCT05577507|DRUG|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
219042645|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
219042646|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
219534593|NCT05967715|BEHAVIORAL|exercise training|high intensity interval training
219534594|NCT05967715|OTHER|Probiotics|VSL#3# Probiotic
219534595|NCT05967715|OTHER|Placebo|Probiotic Placebo
219534596|NCT01746615|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter \& oxygen saturation
219534597|NCT01746615|OTHER|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
219534598|NCT00793832|BEHAVIORAL|supervised exercise|supervised exercise
219534599|NCT00793832|BEHAVIORAL|Diet advice|Diet Advice
219534600|NCT06043037|PROCEDURE|Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG
219534601|NCT06043037|PROCEDURE|Immediate Implant Placement Using Socket Shield Technique alone|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
219534602|NCT02701556|DEVICE|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
219534603|NCT02701556|DEVICE|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
219534604|NCT00572637|DRUG|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
219534605|NCT06466707|OTHER|Collection of microbiome samples|Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
218920798|NCT05577507|DRUG|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcimate 500 mg three times daily within meals
219042647|NCT05638646|OTHER|control group|Maintain current treatment
219042648|NCT01336686|DRUG|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
219042649|NCT01336686|DRUG|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
219042650|NCT01336686|DRUG|Placebo comparator|Matching placebo once daily for 4 weeks
219534606|NCT04023461|DEVICE|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
219042651|NCT01336686|DRUG|Colchicine|0.6 mg colchicine daily for flare prophylaxis
219042652|NCT00754754|PROCEDURE|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
219042653|NCT01358604|GENETIC|polymerase chain reaction|
219534607|NCT00670761|DRUG|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
219042654|NCT01358604|GENETIC|protein expression analysis|
219042655|NCT01358604|GENETIC|western blotting|
219042656|NCT01358604|OTHER|flow cytometry|
219534608|NCT00670761|PROCEDURE|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
219534609|NCT06027528|PROCEDURE|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
219534610|NCT06027528|PROCEDURE|dentin graft|extracted tooth will be grafted in the socket
219534611|NCT05890261|DEVICE|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
219534612|NCT00723047|PROCEDURE|Fibrin glue injection in fistula|
219534613|NCT01928147|DRUG|PPI-383|
219534614|NCT01928147|DRUG|Placebo|
219534615|NCT03113877|OTHER|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
219534616|NCT00858754|DRUG|methylnaltrexone|
219534617|NCT00858754|DRUG|placebo|
218920799|NCT01253278|DRUG|LY2393910|as capsules, administered orally once daily for two weeks
218920800|NCT01253278|DRUG|Placebo|as capsules, administered orally once daily for two weeks
218920801|NCT01101867|DRUG|Aspart fixed dose|fixed dose
218920802|NCT01101867|DRUG|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
218920803|NCT01213472|BIOLOGICAL|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
219042657|NCT01358604|OTHER|immunohistochemistry staining method|
218920804|NCT03421483|DIETARY_SUPPLEMENT|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
218920805|NCT03421483|DIETARY_SUPPLEMENT|Adult Multivitamin|Participants will receive an adult multivitamin supplement
218920806|NCT02600234|DEVICE|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
219042658|NCT01358604|OTHER|laboratory biomarker analysis|
219042659|NCT04019041|DRUG|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
219042660|NCT04019041|DRUG|placebo|placebo 2 mL pre-filled syringe
219042661|NCT01618357|RADIATION|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
219042662|NCT01618357|PROCEDURE|Lumpectomy/Mastectomy|Resection of breast cancer.
219042663|NCT01618357|DRUG|Veliparib|Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
219042664|NCT04278521|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
219042665|NCT05530122|BIOLOGICAL|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
219534618|NCT00937898|DIETARY_SUPPLEMENT|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
219534619|NCT00937898|DIETARY_SUPPLEMENT|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
219534620|NCT04727398|DEVICE|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
219534621|NCT04147845|OTHER|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
219534622|NCT04147845|OTHER|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
219534623|NCT04147845|OTHER|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
219534624|NCT04147845|OTHER|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
219534625|NCT00240747|DRUG|Synercid|
218920807|NCT02600234|OTHER|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
218920808|NCT02624076|OTHER|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
218920809|NCT02624076|OTHER|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
218920810|NCT04052880|DRUG|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
218920811|NCT04052880|DRUG|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
219534626|NCT01555645|BEHAVIORAL|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
218920812|NCT04052880|DRUG|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
218920813|NCT04052880|DRUG|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
218920814|NCT04052880|DRUG|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
218920815|NCT02910882|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
219534627|NCT01666262|BIOLOGICAL|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
219534628|NCT01666262|OTHER|Placebo:Stabilizer|5% sucrose
219618223|NCT06902233|DEVICE|Sham Comparator|The Actisham protocol (with FC2 as the itchy electrode) created by the Neuroelectrics will be used for the sham stimulation group. Similar to the active treatment group, the actisham will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator.Similar to active group, a total of fifteen circular Ag/AgCl electrodes will be placed on a neoprene head cap following the International 10-10 EEG system to appropriately blind the participant. The electrodes would comprise of four stimulation electrodes (FC1, FC2, FC4, and FCz) and eleven electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) with zero current.
219618224|NCT06906874|DRUG|Activated Charcoal|oral activated charcoal capsules
219618225|NCT06906874|DRUG|Phosphate Binders|calcium-based or non-calcium based (sevelamer) binders
218920816|NCT02910882|DRUG|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
218920817|NCT02910882|RADIATION|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
218920818|NCT01046708|DRUG|micronized progesterone|600mg in 3 separate doses per day
218920819|NCT02790892|BEHAVIORAL|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
218920820|NCT03687060|BEHAVIORAL|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
219534629|NCT03375047|DRUG|MRT5005|Nebulization of MRT5005
219534630|NCT03375047|DRUG|Normal saline|Normal Saline for Inhalation
219534631|NCT01837654|BEHAVIORAL|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
218920821|NCT03687060|BEHAVIORAL|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
218920822|NCT03687060|BEHAVIORAL|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
218920823|NCT02299843|PROCEDURE|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
218920824|NCT02299843|PROCEDURE|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
218920825|NCT03678519|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
218920826|NCT03770988|DRUG|Treatment with Poziotinib|Treatment with Poziotinib
219534632|NCT01837654|BEHAVIORAL|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
219534633|NCT04038801|PROCEDURE|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
219534634|NCT04038801|PROCEDURE|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
219534635|NCT04038801|PROCEDURE|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
219534636|NCT00906594|DRUG|latanoprost|
219534637|NCT01674166|DRUG|prucalopride|single dose 0.03 mg/kg prucalopride open label
219618226|NCT07092046|DRUG|Sevoflurane (Volatile Anesthetic)|An inhalational anesthetic agent will be used for the maintenance of anesthesia, administered at a concentration of 2-3% in a gas mixture consisting of 40% oxygen and air.
219618227|NCT07092046|DRUG|Propofol 1%|An intravenous hypnotic agent will be used for anesthesia induction at a dose of 2-3 mg/kg.
218920827|NCT02878343|BEHAVIORAL|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
218920828|NCT02878343|BEHAVIORAL|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
218920829|NCT04980404|DRUG|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
218920830|NCT01843413|RADIATION|stereotactic radiosurgery|Undergo SRS
219618228|NCT07092046|DRUG|Remifentanil 2 MG|A short-acting opioid will be administered intravenously for maintenance of anesthesia at a dose of 0.02-0.2 micrograms per kilogram per minute (μg/kg/min).
218920831|NCT01843413|PROCEDURE|quality-of-life assessment|Ancillary studies
219534638|NCT03410862|DRUG|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
218920832|NCT01843413|PROCEDURE|cognitive assessment|Ancillary studies
218920833|NCT05481463|DRUG|Surufatinib|surufatinib,250mg, qd, po, 28 days for a cycle
218920834|NCT05481463|DRUG|TAS-102|TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
218920835|NCT01510483|BEHAVIORAL|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
218920836|NCT01510483|BEHAVIORAL|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
219534639|NCT03410862|DRUG|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
219534640|NCT02600403|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
219534641|NCT02600403|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
219534642|NCT02600403|DIAGNOSTIC_TEST|Humphrey Visual Field (HVF)|Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
219534643|NCT02865005|DRUG|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
219534644|NCT02865005|OTHER|Placebo|Topical Gel
219534645|NCT02865005|DRUG|Dapsone 5.0% Gel (Allergan)|Topical Gel
219618229|NCT07092046|DRUG|Rocuronium 50 mg/5 ml|A neuromuscular blocking agent will be administered intravenously at a dose of 0.6-1.2 mg/kg for induction, and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
219534646|NCT05183503|DIAGNOSTIC_TEST|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
219534647|NCT03590782|OTHER|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
219534648|NCT04533295|DEVICE|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
219618230|NCT07092046|DRUG|Lidocaine %2 ampoule|This agent will be administered intravenously at a dose of 1-1.5 mg/kg prior to anesthesia induction to reduce injection pain and facilitate smooth induction.
219618231|NCT07092046|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|This agent will be administered intravenously at a dose of 0.1 mg/kg to treat intraoperative hypotension that does not respond to fluid replacement or adjustment of anesthetic depth.
218920837|NCT04090203|DRUG|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
218920838|NCT06488820|DEVICE|Catheter ablation using pulsed-field ablation (PFA) system|PFA will be used to isolate the pulmonary veins and additional left atrial structure as needed
218920839|NCT04225897|DRUG|RV521|RV521 is an RSV F protein inhibitor administered orally
218920840|NCT04225897|DRUG|Placebo|vehicle administered orally
219534649|NCT04533295|DEVICE|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
219534650|NCT02375386|PROCEDURE|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
219534651|NCT02375386|PROCEDURE|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
219534652|NCT02375386|PROCEDURE|fMRI|Both groups will receive an fMRI.
219618232|NCT07092046|DRUG|Sugammadex 200 MG in 2 ML Injection|Sugammadex will be administered intravenously at a dose of 2 mg/kg or 4 mg/kg, depending on the degree of neuromuscular blockade.
219618233|NCT07092046|DRUG|Fentanyl (IV)|Fentanyl will be administered intravenously as part of the anesthesia induction regimen, at a dose ranging from 1 to 2 micrograms per kilogram (µg/kg).
219618234|NCT07092046|DRUG|Atropine Sulphate 0.5mg/ml ampoule|In cases of intraoperative bradycardia, defined as a heart rate (HR) below 45 beats per minute (bpm), 0.5 mg of the agent will be administered intravenously.
219618235|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
219618236|NCT07092046|PROCEDURE|Mechanical Ventilation|Following endotracheal intubation, mechanical ventilation will be initiated using volume-controlled settings, with a tidal volume (TV) of 6-8 mL/kg, respiratory rate (RR) of 12 breaths per minute, and fraction of inspired oxygen (FiO₂) set at 50%. Ventilator parameters will be adjusted to maintain end-tidal carbon dioxide (ETCO₂) between 30 and 36 mmHg.
218920841|NCT06024824|RADIATION|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
219534653|NCT02375386|BEHAVIORAL|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
219534654|NCT02375386|OTHER|Questionnaires|Both groups will receive Questionnaires
219618237|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants will undergo peripheral intravenous cannulation with 18-20 gauge (G) IV (intravenous) cannulas placed on the dorsum of the hand prior to anesthesia induction.
218920842|NCT05773664|DRUG|Azeliragon|Given PO
218920843|NCT05773664|PROCEDURE|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
218920844|NCT05773664|PROCEDURE|Computed Tomography|Undergo CT scan
218920845|NCT05773664|DRUG|Dexamethasone|Given PO or IV
218920846|NCT05773664|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
218920847|NCT05705934|OTHER|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
219534655|NCT02375386|BEHAVIORAL|Physical Impairment|Both groups will receive testing on physical impairment.
218920848|NCT02212639|DRUG|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
219534656|NCT04293757|PROCEDURE|Rotational angiography|Preprocedural imaging before ablation
219618238|NCT07092046|DRUG|Crystalloid solutions|Participants will receive calculated maintenance fluid therapy with crystalloids administered via intravenous infusion, both prior to and throughout the surgical procedure.
219618239|NCT07092046|PROCEDURE|Endotracheal Intubation|Following induction of anesthesia and establishment of neuromuscular blockade, endotracheal intubation will be performed using a standard technique in all participants.
219618240|NCT07092046|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine monitoring in accordance with American Society of Anesthesiologists (ASA) guidelines, including noninvasive blood pressure, electrocardiogram (ECG, D2 lead), end-tidal carbon dioxide (ETCO₂), and peripheral oxygen saturation (SpO₂), will be performed in all patients starting from the preoperative period and continuing throughout the surgery.
219618241|NCT07092046|PROCEDURE|Minimal-Flow Anesthesia|In the minimal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be reduced to 0.5 L/min with a mixture of 45% oxygen (O₂) and 55% air, and maintained throughout the surgical procedure. At the end of surgery, the flow will be increased to 3 L/min to facilitate emergence. Disposable anesthesia circuits, bacterial filters, and face masks will be used for each patient, and carbon dioxide (CO₂) absorbers will be replaced daily.
218920849|NCT01285323|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
218920850|NCT01285323|DRUG|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
218920851|NCT02995746|DRUG|Dexamethasone|"* On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~* Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~* Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~* Anticipated duration of the study: 6 months"
218920852|NCT00237406|PROCEDURE|interactive voice response|
218920853|NCT01351181|BEHAVIORAL|Leaflet|Advice Leaflet
218920854|NCT01351181|BEHAVIORAL|Exercise Advice|Leaflet
218920855|NCT01351181|BEHAVIORAL|Normal Care|Normal Care
218920856|NCT02376998|DEVICE|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
218920857|NCT06003972|DRUG|Copaxone|Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
218920858|NCT06003972|DRUG|guideline directed medical therapy (GDMT)|GDMT for heart failure according to the AHA guidelines.
218920859|NCT01472289|OTHER|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
218920860|NCT01387477|DRUG|Lactate|Infusion of 66 mmol of lactate
218920861|NCT01387477|DRUG|Glucose|Infusion of 33 mmol of glucose
218920862|NCT01670084|DRUG|nilotinib|Given PO
218920863|NCT01670084|BIOLOGICAL|rituximab|Given IV
218920864|NCT01670084|DRUG|cyclophosphamide|Given IV
218920865|NCT01670084|DRUG|doxorubicin hydrochloride|Given IV
218920866|NCT01670084|DRUG|vincristine sulfate|Given IV
218920867|NCT01670084|DRUG|methotrexate|Given IV or IT
218920868|NCT01670084|DRUG|cytarabine|Given IV or IT
218920869|NCT01670084|DRUG|prednisone|Given PO
218920870|NCT01670084|DRUG|mesna|Given IV
218920871|NCT01670084|DRUG|dexamethasone|Given IV or PO
218920872|NCT01670084|DRUG|leucovorin calcium|Given IV
218920873|NCT05367596|BEHAVIORAL|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
218920874|NCT05367596|BEHAVIORAL|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
219042666|NCT06392243|DEVICE|Intracardiac ultrasound imaging system|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
219534657|NCT00919230|DRUG|Ferrous sulphate tablets|200mg twice daily for four weeks
219534658|NCT02272556|OTHER|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
219534659|NCT02272556|OTHER|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
219534660|NCT03575650|OTHER|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
219618242|NCT07092046|PROCEDURE|Normal-Flow Anesthesia|In the normal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be adjusted to 2 L/min and maintained during the surgical procedure. For emergence, the flow will be increased to 3 L/min. Disposable anesthesia circuits will be used, and daily maintenance protocols, including replacement of carbon dioxide (CO₂) absorbers, will be applied in the same manner as in the minimal-flow group.
219534661|NCT01638520|DRUG|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
218920875|NCT05367596|BEHAVIORAL|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
218920876|NCT05367596|BEHAVIORAL|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
219534662|NCT01638520|DRUG|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
219534663|NCT00909662|PROCEDURE|assessment of therapy complications|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
219534664|NCT00909662|PROCEDURE|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
219534665|NCT00909662|PROCEDURE|fatigue assessment and management|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
219534666|NCT03818841|DEVICE|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
219534667|NCT03818841|DEVICE|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
219534668|NCT01308164|DEVICE|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
219534669|NCT02842632|OTHER|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
219534670|NCT02842632|OTHER|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
219534671|NCT05990907|PROCEDURE|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
219534672|NCT03807037|DIETARY_SUPPLEMENT|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
219534673|NCT03807037|DRUG|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
219534674|NCT01625715|DRUG|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
219618243|NCT07092046|DIAGNOSTIC_TEST|Anesthesia Circuit Sampling|Sterile swab samples will be collected from both the inspiratory and expiratory limbs of the anesthesia circuit-once prior to circuit connection and again immediately after disconnection at the end of the surgical procedure. All samples will be processed for microbial culture and species-level identification.
219618244|NCT07092046|PROCEDURE|Body Temperature Monitoring|In addition to routine monitoring-including electrocardiogram (ECG), non-invasive blood pressure, peripheral oxygen saturation (SpO₂), and end-tidal carbon dioxide (ETCO₂)-body temperature will be continuously monitored in both study groups throughout the surgical procedure using appropriate thermal sensors. Temperature measurements will be recorded at 5-minute intervals and used to assess the impact of different fresh gas flow rates on intraoperative thermoregulation.
219618245|NCT07092046|DIAGNOSTIC_TEST|Nasopharyngeal Swab Collection|A sterile nasopharyngeal swab (Dry SWAB) will be collected from each patient upon arrival in the operating room, prior to anesthesia induction. Each sample will be labeled with the patient's identification number, date, time, and collection site, and will be transferred in appropriate transport medium to the microbiology laboratory for culture and microbiological analysis.
218920877|NCT05367596|BEHAVIORAL|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
219042667|NCT05839457|BEHAVIORAL|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
219042668|NCT00881192|PROCEDURE|IABP|preoperative IABP placement
219042669|NCT05145166|BIOLOGICAL|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
219042670|NCT03925727|DRUG|Tavilermide ophthalmic solution|BID topical dosing
219042671|NCT03925727|OTHER|Placebo|BID topical dosing
219534675|NCT02788240|DRUG|Peg GCSF|
219534676|NCT02788240|BIOLOGICAL|20% Albumin|
219534677|NCT02788240|DIETARY_SUPPLEMENT|Nutrition|
218920878|NCT05367596|BEHAVIORAL|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
219042672|NCT01388842|DRUG|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
219534678|NCT02788240|OTHER|Bowel wash|
219534679|NCT02788240|DRUG|Terlipressin 1- 4mg,if indicated|
219534680|NCT02788240|DRUG|Meropenem or Imepenem, if indicated|
219534681|NCT02788240|DRUG|Placebo|
219534682|NCT04022954|DEVICE|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
219534683|NCT06133933|DEVICE|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
219534684|NCT05170607|DIAGNOSTIC_TEST|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
219534685|NCT04530994|DRUG|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
219534686|NCT00231829|DRUG|Celecoxib|
219534687|NCT01499147|DRUG|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
219534688|NCT01499147|DRUG|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl).
219534689|NCT01499147|DRUG|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
219618246|NCT07092046|DIAGNOSTIC_TEST|Microbiological Culture and Identification|All collected swab samples-including both nasopharyngeal and anesthesia circuit specimens-will be cultured using the serial dilution method on 5% sheep blood agar within 15 minutes of arrival at the microbiology laboratory. Cultures will be incubated at 35-37°C for 48 hours. Colony growth will be evaluated by a clinical microbiologist, and microorganisms will be identified to the species level using an automated MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) system.
219618247|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
219618248|NCT07088211|DRUG|Sacituzumab Tirumotecan and Toripalimab|The dosing regimen for the combination of Sacituzumab Tirumotecan and Toripalimab is as follows: the recommended dose of Sacituzumab Tirumotecan is 5mg/kg, administered intravenously every 2 weeks, and Toripalimab is administered intravenously (without prophylactic medication), with a fixed dose of 240mg, and 3mg/kg is used for subjects with baseline body weight\<50kg. Each infusion lasts for 30 minutes (not less than 20 minutes, not more than 60 minutes), administered once every 2 weeks. The subjects will continue to receive combination therapy with Sacituzumab Tirumotecan and Toripalimab until the termination criteria are met.
219618249|NCT07090278|DRUG|ulinastatin|Ulinastatin for the treatment of sepsis patients during ICU stay
219618250|NCT07096414|DIETARY_SUPPLEMENT|Vitamin D3|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
219534690|NCT00242398|DEVICE|AN69 ST|
219534691|NCT03872128|DRUG|Pregnenolone300|300mg
218920879|NCT05367596|BEHAVIORAL|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
218920880|NCT01109472|OTHER|patient magazine|patient magazine individually tailored to patient's prior feedback
218920881|NCT00646880|DRUG|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
218920882|NCT00646880|DRUG|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
218920883|NCT04084236|DEVICE|electrical stimulation|electrical stimulation
218920884|NCT04084236|DEVICE|Sham|no stimulation
219534692|NCT03872128|DRUG|Pregnenolone500|500mg
219534693|NCT03872128|DRUG|Placebo|placebo
218920885|NCT06515197|OTHER|Motivational Music|Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
218920886|NCT06515197|OTHER|Self-Selected Music|Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
218920887|NCT02167698|DEVICE|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
219042673|NCT01388842|DRUG|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
219534694|NCT05838391|RADIATION|Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery|Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
219534695|NCT05838391|DRUG|Mitomycin-C|As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
219534696|NCT05838391|DRUG|5-Fluorouracil|As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
219534697|NCT05838391|DRUG|Capecitabine|As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
219042674|NCT03160053|DEVICE|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
219534698|NCT01090791|DEVICE|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
219534699|NCT01090791|DEVICE|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
219534700|NCT01352091|DRUG|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
219534701|NCT01352091|DRUG|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
219534702|NCT05901272|OTHER|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
219534703|NCT05901272|OTHER|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
218920888|NCT02167698|OTHER|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
218920889|NCT02167698|DRUG|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
219042675|NCT01464515|DEVICE|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
219042676|NCT01464515|DEVICE|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
219042677|NCT02800330|DRUG|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
219534704|NCT05901272|OTHER|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
219534705|NCT00007605|DRUG|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
219534706|NCT00007605|DRUG|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
219534707|NCT00550758|DRUG|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
219534708|NCT00550758|DEVICE|spirometry|spirometry
219534709|NCT02080663|PROCEDURE|Proximal row carpectomy|
219534710|NCT04267276|DRUG|Part 1: BI 1265162 - intravenous|Intravenous solution
219534711|NCT04267276|DRUG|Part 2: BI 1265162 - oral|Oral solution
219534712|NCT03285594|DRUG|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
219534713|NCT03285594|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219534714|NCT03285594|DRUG|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
219534715|NCT03285594|DRUG|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
219534716|NCT00492076|BIOLOGICAL|Pangramin Plus D. pteronyssinus 100%|"1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo"
219534717|NCT03702608|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug"
219534718|NCT00882505|DIETARY_SUPPLEMENT|vitamin D|Subject will receive vitamin d supplements
219534719|NCT00882505|OTHER|Placebo|Subject will receive a placebo.
219534720|NCT05058508|OTHER|"Just Move Exercise"|"Subjects complete Just Move Exercises Five Times Per Week"
219534721|NCT05058508|OTHER|Standard of Care Exercise|Subjects exercise/move as tolerated
219534722|NCT01312844|DRUG|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
219534723|NCT04946864|DRUG|APG-2575|APG2575 monotherapy
218920890|NCT02167698|OTHER|Restrictive fluid therapy|Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
218920891|NCT02167698|DRUG|sedo-analgesia titration|
218920892|NCT02167698|OTHER|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
219042678|NCT02800330|DRUG|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
219534724|NCT04946864|DRUG|Palbociclib|combination APG2575+pablociclib
219534725|NCT05943613|DRUG|Clonidine|compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
219534726|NCT02648438|DRUG|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
219534727|NCT02648438|DRUG|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
219534728|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
219534729|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
219534730|NCT02648438|DRUG|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
219534731|NCT03467399|DEVICE|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
219534732|NCT02258074|DRUG|Nicotinamide|
219534733|NCT02258074|DRUG|Lanthanum Carbonate|
219534734|NCT02258074|DRUG|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
219534735|NCT02258074|DRUG|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
218920893|NCT02167698|OTHER|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
218920894|NCT02167698|OTHER|Biomarker Assay|Biomarker Assay for patients in both arms
218920895|NCT02668653|DRUG|Chemotherapy|
218920896|NCT02668653|DRUG|Quizartinib|
218920897|NCT02668653|DRUG|Placebo|
218920898|NCT05318586|PROCEDURE|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
219534736|NCT04904861|BEHAVIORAL|Videoconference intervention group|A short face-to-face dyadic group workshop focused on increasing maternal sensitivity was adapted to be carried out virtually by videoconference. The intervention considers 4 sessions, with a weekly frequency, with a minimum of 3 and a maximum of 6 dyads per group led by a monitor (psychologist). The activities are protocolized in a manual and are designed to be carried out by the mother with the baby under one year of age. .
219534737|NCT04904861|OTHER|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks) in addition to the usual care in their primary care center
219618251|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|"After the evaluation, participants will receive feedback and physical activity training, along with an explanation of the benefits of exercise, provided in the form of a brochure. They will then be enrolled in the Blue Prescription program, which includes weekly follow-ups for 12 weeks and a re-evaluation at the end of the 12th week. Motivation and support will be offered in accordance with the Blue Prescription philosophy, addressing home exercise programs, physical activity selection, and overcoming obstacles. Participants will be encouraged to determine the most suitable program for themselves and maintain an activity diary.~Throughout the study, participants will have the opportunity to communicate with the physiotherapist via various methods such as phone, SMS, or email."
219618252|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
219618253|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Participants will engage in exercises with a physiotherapist three days a week for 12 weeks, and the effectiveness of the program will be re-evaluated at the end of the 12th week.
219618254|NCT07096557|DRUG|Coenzyme Q10|Coenzyme Q10 100 mg capsule once daily for 3 months
219618255|NCT07094958|BIOLOGICAL|stromal vascular fraction (SVF)|Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars. SVF was freshly prepared on the same day of injection using enzymatic digestion and centrifugation.
219618256|NCT07094958|OTHER|Normal Saline (NS)|Normal saline (NS) was injected intradermally into the contralateral side of the face and served as a placebo comparator to SVF in this split-face study on atrophic acne scars.
218920899|NCT05318586|PROCEDURE|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
218920900|NCT02294708|BEHAVIORAL|postoperative postures|two postoperative postures: supine and temporal-lateral
218920901|NCT05618977|BEHAVIORAL|Dramatization simulation|Ethical attitudes of nursing students will be evaluated with dramatization simulation application.
218920902|NCT05618977|BEHAVIORAL|In-class case studies|In-class case studies will be conducted with the control group students.
218920903|NCT05153616|DIAGNOSTIC_TEST|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
218920904|NCT05655741|OTHER|Questionnaire|"Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round."
218920905|NCT04137640|DRUG|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
218920906|NCT04137640|DRUG|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
218920907|NCT00979940|DRUG|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
218920908|NCT05362656|DEVICE|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
219042679|NCT02800330|DRUG|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
219042680|NCT04023877|DRUG|E2027|E2027 oral capsule.
218920909|NCT00974792|BIOLOGICAL|pegfilgrastim|
218920910|NCT00974792|BIOLOGICAL|rituximab|
219534738|NCT03700411|DRUG|Morphine|Morphine intravenous
219534739|NCT03700411|DRUG|Piritramid|Piritramid intravenous
219534740|NCT03700411|DRUG|Epidural|Perioperative epidural analgesia
219534741|NCT05996510|DEVICE|ultrasound|Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
219534742|NCT02927119|DIETARY_SUPPLEMENT|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
218920911|NCT00974792|DRUG|cyclophosphamide|
218920912|NCT00974792|DRUG|cytarabine|
218920913|NCT00974792|DRUG|doxorubicin hydrochloride|
218920914|NCT00974792|DRUG|etoposide phosphate|
218920915|NCT00974792|DRUG|ifosfamide|
218920916|NCT00974792|DRUG|leucovorin calcium|
218920917|NCT00974792|DRUG|methotrexate|
218920918|NCT00974792|DRUG|vincristine sulfate|
218920919|NCT04893369|OTHER|The Low Back Pain and Disability Drivers Management model|"PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability."
219534743|NCT04472156|PROCEDURE|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
219534744|NCT04886973|OTHER|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
218920920|NCT04893369|OTHER|Low back pain clinical practice guidelines|For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
218920921|NCT04780646|BEHAVIORAL|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
218920922|NCT04780646|BEHAVIORAL|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
218920923|NCT02046967|PROCEDURE|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
218920924|NCT02046967|PROCEDURE|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
218920925|NCT00732056|DRUG|GRN163L|25% dose escalation infused over 2 hours weekly
218920926|NCT00195364|DRUG|Etanercept|
218920927|NCT02405741|DEVICE|Hyperbaric chamber treatment|
218920928|NCT02158442|PROCEDURE|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
218920929|NCT02158442|DRUG|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
218920930|NCT01957995|DRUG|nanosomal docetaxel lipid suspension|Given IV
218920931|NCT01957995|OTHER|pharmacological study|Correlative studies
218920932|NCT02123901|OTHER|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
218920933|NCT02123901|OTHER|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
219534745|NCT02739997|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
219534746|NCT02739997|DRUG|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
219534747|NCT04059965|OTHER|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
219534748|NCT04059965|OTHER|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
219534749|NCT05132933|PROCEDURE|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
219534750|NCT00731978|PROCEDURE|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
219534751|NCT02290171|BEHAVIORAL|Activity groups|Children attend to activity groups weekly during the intervention periode.
218920934|NCT02123901|OTHER|No exercise|Sedentary life style.
218920935|NCT06338098|BEHAVIORAL|8-week wellness and relaxation meditation program|Heartfulness Meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
218920936|NCT04907058|DEVICE|novel device with a comfortable mask|Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
218920937|NCT01099176|DRUG|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
218920938|NCT03264326|OTHER|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
218920939|NCT03264326|OTHER|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
218920940|NCT03264326|OTHER|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
218920941|NCT02514135|OTHER|No intervention|
218920942|NCT02659254|DEVICE|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
218920943|NCT04885907|BIOLOGICAL|mRNA-1273 vaccine|COVID vaccine 3rd dose
218920944|NCT04885907|OTHER|Normal Saline Placebo|Normal Saline Placebo
218920945|NCT01294553|DRUG|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
218920946|NCT01475760|OTHER|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
218920947|NCT01475760|OTHER|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
218920948|NCT03800381|OTHER|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
219534752|NCT02290171|BEHAVIORAL|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
219618257|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group A patients received two cycles of QL1706, regorafenib, and CAPOX induction therapy, followed by sequential short-course radiotherapy, and then continued with four cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase.~Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase.~CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)).~Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
218920949|NCT04142931|COMBINATION_PRODUCT|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
218920950|NCT06474247|DEVICE|Postbiotic|Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
218920951|NCT06474247|DEVICE|Placebo|Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
218920952|NCT00648440|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
218920953|NCT00648440|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
218920954|NCT01646580|DRUG|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
218920955|NCT05799820|DRUG|QL1706|5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
218920956|NCT05799820|DRUG|Bevacizumab|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
218920957|NCT05799820|DRUG|Oxaliplatin injection|130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
218920958|NCT05799820|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
218920959|NCT06038604|BEHAVIORAL|Psychosocial Support Intervention|Participants will receive six weekly 60-minute sessions conducted by videoconference.
218920960|NCT01437657|DRUG|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
218920961|NCT01437657|DRUG|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
218920962|NCT01437657|DRUG|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
218920963|NCT03729739|DIAGNOSTIC_TEST|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
219534753|NCT02290171|BEHAVIORAL|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
219534754|NCT01286090|DRUG|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
219534755|NCT01286090|DRUG|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
219534756|NCT00749177|OTHER|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
219534757|NCT01305122|BEHAVIORAL|neurocognitive tests|"* inclusion~* 1 year~* 3 years~* 5 years"
219534758|NCT04943029|DRUG|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
218920964|NCT03729739|DIAGNOSTIC_TEST|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
218920965|NCT05713656|OTHER|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
218920966|NCT00926237|DEVICE|Sham rTMS - Sham repetitive transcranial magnetic stimulation|Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
218920967|NCT00926237|DEVICE|Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
219618258|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group B patients received short-course radiotherapy followed by six cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase. Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase. CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)). Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
219618259|NCT07095192|OTHER|Preimplementation of HCV Point of care testing|Exploring the pre-implementation of HCV Point of care antibody and RNA tests
219534759|NCT04943029|DRUG|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
219534760|NCT04943029|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
219534761|NCT04943029|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
219534762|NCT02241434|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
219534763|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
219534764|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
219534765|NCT05388305|BIOLOGICAL|CAR--γδT cells|Biological: CAR-γδT; Drug:
219534766|NCT02308475|DEVICE|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
219618260|NCT07096219|PROCEDURE|Catheter Ablation|A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.
219618261|NCT07096219|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa
218920968|NCT00926237|DEVICE|Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
219618262|NCT07097415|DEVICE|Continuous blood glucose monitoring assisted blood glucose management|(1) individualized health education sessions conducted by endocrinology healthcare providers covering CGM concepts, usage methods, advantages, risks, and precautions, along with hands-on device demonstration and provision of written materials and user manuals; (2) development of an integrated CGM data management platform that connects with community healthcare information systems for real-time data transmission, storage, and analysis; (3) establishment of standardized CGM response protocols for healthcare providers, including glucose target setting, dietary and exercise recommendations, personalized medication adjustments based on glucose fluctuations, and management procedures for hypoglycemic and hyperglycemic alerts; and (4) mobile application setup and data transmission configuration for patients.
218920969|NCT03771924|DIETARY_SUPPLEMENT|inorganic phosphate|Sodium phosphate
218920970|NCT03771924|DIETARY_SUPPLEMENT|placebo|Sodium chlorid
218920971|NCT05220072|DRUG|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
218920972|NCT00153244|DRUG|Lamotrigine|
218920973|NCT03800992|OTHER|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
219042681|NCT01652391|DEVICE|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
219534767|NCT03141047|OTHER|Lifespan Integration|A protocol based psychological treatment method
219534768|NCT03552393|DRUG|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
219534769|NCT04039594|DEVICE|VA ECMO|VA ECMO for cardiopulmonary support
219534770|NCT03328676|DRUG|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
218920974|NCT05525325|PROCEDURE|General Anesthesia|Patients randomized to the GA arm are intubated after anesthetic induction. For this purpose, they are pre-oxygenated with an oxygen mask and non-invasive monitoring is established. After sufficient pre-oxygenation has been applied, analgesic and sedative medication are administered. If the patient is sufficiently long nil by mouth they are manually ventilated before a muscle relaxant is administered. A rapid-sequence induction is performed with administration of an opioid, sedative and muscle relaxant in rapid succession and without intermediate manual ventilation in non-nil by mouth patients. To secure the airway, an endotracheal tube is inserted into the trachea with the aid of a laryngoscope. After insertion of the endotracheal tube, its endotracheal position is confirmed with auscultation and capnography. GA maintenance therapy with opioids, sedatives and catecholamines, if needed, will then be started.
218920975|NCT06333912|PROCEDURE|dental implant placement with ridge splitting.|ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement
218920976|NCT03558711|DIAGNOSTIC_TEST|18F-PSMA|18F-PET imaging
218920977|NCT02054689|RADIATION|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
218920978|NCT03108807|DIAGNOSTIC_TEST|D-dimer test|D-dimer test
218920979|NCT00632229|DRUG|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
218920980|NCT00632229|DRUG|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
218920981|NCT00026260|DRUG|semaxanib|
218920982|NCT06288997|DEVICE|Active transcranial alternating current stimulation|Hi-tACS with a current level of 15mA with a patented frequency of 77.5Hz.
218920983|NCT06288997|DEVICE|Sham transcranial alternating current stimulation|The device for the sham group has the same appearance and technical settings as the one used in the active group, designed to produce similar sensations on the scalp, but without effective penetration of the electric field into the brain.
218920984|NCT02323217|RADIATION|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
218920985|NCT02323217|DRUG|Idazoxan|Idazoxan block of \[11C\]BU99008
218920986|NCT02323217|DRUG|Isocarboxazid|Isocarboxazid block of \[11C\]BU99008
218920987|NCT05373459|BIOLOGICAL|Third COVID-19 booster|Third COVID-19 booster
218920988|NCT03658681|OTHER|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
218920989|NCT03658681|OTHER|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
218920990|NCT00577889|DRUG|gemcitabine hydrochloride|750 mg/m2 Given IV
218920991|NCT00577889|DRUG|tanespimycin|154 mg/m2 Given IV
218920992|NCT03146585|DEVICE|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
218920993|NCT05607758|BEHAVIORAL|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
218920994|NCT02261935|OTHER|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
218920995|NCT02261935|OTHER|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
218920996|NCT05063799|OTHER|pulmonary rehabilitation|pulmonary rehabilitation programs
218920997|NCT06146920|OTHER|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
218920998|NCT03745534|OTHER|eABR|eABR
218920999|NCT00110448|DRUG|Aspirin|Aspirin 81 mg or 100 mg per day
218921000|NCT00110448|DRUG|No aspirin|No aspirin use
218921001|NCT02667119|BEHAVIORAL|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
218921002|NCT02667119|BEHAVIORAL|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
218921003|NCT04864093|DIAGNOSTIC_TEST|muscular ultrasound|respiratroy and muscular ultrasound
218921004|NCT05676619|DEVICE|3D foot scanner|Reliability of 3D foot scanner during repeated scans
218921005|NCT05835817|OTHER|Magnetoencephalography|40 minutes of Magnetoencephalography with Optical Pump Magnetometer
219042682|NCT02832869|OTHER|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
219618263|NCT07096115|DRUG|Taiglididine|The first patient receives an intravenous injection of 1 mg taiglididine for anesthesia induction, followed by 1-2 mg/kg propofol. When the patient's bispectral index (BIS) drops below 60, eyelash reflex disappears, and MOAA/S score is 0, intravenous rocuronium 0.6 mg/kg is given, and a laryngeal mask is inserted by a senior anesthesiologist using a unified method 1 min later. From the second patient onward, the taiglididine dose is dynamically adjusted based on the previous patient's response to laryngeal mask insertion using BCD-UDM: if the previous patient shows a positive insertion response (positive response or MOAA/S ≥2 within 2 min after induction), the next patient's dose increases by 0.1 mg; if negative, a random number (1-95) generated by computer determines the dose: doses remain unchanged when the number is 6-95 (89% probability) and decrease by 0.1 mg when the number is 1-5 (11% probability). A collaborator not involved in result evaluation provides a sealed envelope with
219618264|NCT07095517|DRUG|Tirzepatide|Study drug injected subcutaneously once a week
219618265|NCT07096856|DEVICE|Robotic assisted cholecystectomy|Robotic assisted cholecystectomy
219618266|NCT07097350|DEVICE|computer-aided detection alone|colonoscopy with computer-aided detection
218921006|NCT05345600|OTHER|MILTA probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
218921007|NCT05345600|OTHER|placebo probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
218921008|NCT04011176|PROCEDURE|Standard treatment + placebo|Placebo microcurrent
218921009|NCT04011176|PROCEDURE|Standard treatment + Microcurrent Therapy|Actual microcurrent
218921010|NCT06122831|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
219534771|NCT03328676|DRUG|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
219534772|NCT03488147|DRUG|Esomeprazole|20 mg esomeprazole tablet
219618267|NCT07097350|DEVICE|transparent cap-assisted colonoscopy combined with computer-aided detection|transparent cap-assisted colonoscopy combined with computer-aided detection
219618268|NCT07096479|DRUG|Telpegfilgrastim Injection|Within 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.
218921011|NCT06122831|DRUG|TQB3617 Capsules|TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
219042683|NCT02832869|OTHER|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
219534773|NCT03488147|DRUG|Placebo Oral Tablet|resembling esomeprazole tablet
219534774|NCT03305263|DRUG|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
219534775|NCT03305263|DRUG|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
219534776|NCT04418310|PROCEDURE|Lay open and curettage|Lay open and curettage
219534777|NCT04418310|PROCEDURE|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
219534778|NCT00473863|PROCEDURE|Coronary Computed Tomographic Angiography|CCTA will be performed
219534779|NCT06456918|PROCEDURE|Quality of Recovery 15 questionnaire|return to daily life after surgery according to the patient's baseline or social norms
219534780|NCT01689311|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219534781|NCT01689311|DRUG|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219534782|NCT01689311|DRUG|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219618269|NCT07095166|BEHAVIORAL|Meal Location|The location at which the child will eat the experimental meal - home or lab
219618270|NCT07097831|DRUG|HRS-1301 Tablets|HRS-1301 tablets.
219618271|NCT07097831|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin calcium tablets.
219618272|NCT07095309|DRUG|Artesunate|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
219618273|NCT07095309|DRUG|Artesunate matching Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
219534783|NCT01689311|DRUG|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219534784|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
219618274|NCT04941092|OTHER|no intervention|no intervention, retrospective comparison
218921012|NCT04426734|DEVICE|Dextenza Dexamethasone Implant|The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.
218921013|NCT04426734|DRUG|Topical Prednisolone Acetate 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
218921014|NCT06237725|OTHER|Nutrition of Continuous|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
218921015|NCT06237725|OTHER|Nutrition of Bolus|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
218921016|NCT01404819|DRUG|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
218921017|NCT01404819|DRUG|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
219618275|NCT06817330|OTHER|Intervention group, listening to recorded music|Participants in the group receiving music will be offered a tablet with several pre-created playlists. When the patient has made a selection, they will listen to music via headphones for 30 minutes before each ECT treatment session. The headphones will be removed and the music stopped after the 30 minutes. After active ECT treatment, the headphones will be put back on the patient and the music played for another 12 minutes while the patient is recovering and moved to the recovery room. If patients protest against the music and/or headphones, the researcher will ask them to put the headphones back on. If the patient still protests after asking to put the headphones back on, this will be written down by the researcher, with the amount of time without the (control) intervention noted. No coercion will be used during the whole study process.
219618276|NCT06817330|OTHER|Control group, headphones with no music|The control group will wear headphones without music for the same duration as the music group (30 minutes before ECT and 12 minutes after ECT) to reduce bias and achieve a similar level of background-noise dampening.
219534785|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
219534786|NCT00019591|BIOLOGICAL|aldesleukin|
219534787|NCT00019591|BIOLOGICAL|ras peptide cancer vaccine|
219618277|NCT07103343|BEHAVIORAL|MOVI-OLE intervention|"In the MOVI-OLE! classrooms, traditional desks and chairs will be replaced by three dynamic learning zones:~A) Dynamic seating: an area with traditional wheeled desks combined with dynamic seats such as fitballs, stools, pedal desks, etc.; B) Standing desks: an area with manually adjustable high desks to allow standing work. Students will also have stools with small backrests and footrests for when they need to sit; C) Vertical boards: vertical boards (vinyl, paper, chalkboard paint, etc.) installed on walls for standing work.~To facilitate use and adapt to classroom routines, teachers will decide how to distribute students among the different zones, with the requirement that all students spend at least 20 minutes per school day in zone B.~In addition to the workstations, teachers will receive training and didactic support materials focused on student-centered methodologies and the use of open learning spaces."
219618278|NCT05296148|DEVICE|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
219618279|NCT01236716|DRUG|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
219618280|NCT01236716|DRUG|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
219618281|NCT07111741|DEVICE|Total contact cast|Arm with 51 patients was given total contact cast for offloading DFU
218921018|NCT00054886|DRUG|SU-011,248|
219042684|NCT01203592|DRUG|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
219534788|NCT00019591|PROCEDURE|adjuvant therapy|
219534789|NCT02601625|DRUG|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
219534790|NCT02601625|DRUG|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
219534791|NCT02601625|DRUG|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
219534792|NCT02601625|DRUG|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
219534793|NCT02601625|DRUG|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
219534794|NCT02601625|DRUG|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
219534795|NCT02285894|OTHER|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
219618282|NCT07111741|DEVICE|Posterior slab cast|Arm with 48 patients were given posterior slab cast for offloading DFU
219618283|NCT07112300|PROCEDURE|cervical nerve radiofrequency|Pulsed radiofrequency treatment is applied to the cervical 5-6-7 nerve roots defined under ultrasound guidance in the intertubercular or interscalene space by approaching the cervical 5-6-7 nerve roots with an inplane technique via a cannula electrode.
218921019|NCT05992883|DRUG|Ketorolac|Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
218921020|NCT05992883|DRUG|Triamcinolone|Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
219534796|NCT05640544|OTHER|Sound and light stimulation in Gamma band|"We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients."
219618284|NCT07111104|DRUG|Immunotherapy|"The immunotherapy intervention consists of treatment with immune checkpoint inhibitors, specifically Nivolumab (OPDIVO), Atezolizumab (TECENTRIQ), Pembrolizumab (KEYTRUDA).~These drugs are monoclonal antibodies that block PD-1 or PD-L1 pathways, aiming to enhance the immune system's ability to recognize and destroy cancer cells. The treatment is administered intravenously according to standard dosing schedules."
218921021|NCT04865159|DRUG|Tipifarnib|Cardiac Safety of Tipifarnib
218921022|NCT02338674|DRUG|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
218921023|NCT02338674|DRUG|Tenofovir|tenofovir administered at least 48 weeks
218921024|NCT05083234|OTHER|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
218921025|NCT05083234|OTHER|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
218921026|NCT05083234|OTHER|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
219534797|NCT01828528|PROCEDURE|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
219534798|NCT00560443|DRUG|ketorolac|0,5 mg/kg per os one time
219534799|NCT00560443|DRUG|tramadol|2,5 mg/ kg per os in one dose
219534800|NCT01926821|DRUG|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
219534801|NCT01683474|DEVICE|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
219534802|NCT01910688|DEVICE|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
219534803|NCT00359281|DRUG|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
219534804|NCT00359281|DRUG|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
218921027|NCT00594412|PROCEDURE|Diagnostic Radiology: 1H-MRS of the liver|
218921028|NCT01511406|BEHAVIORAL|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
218921029|NCT05194254|OTHER|MRI-ET|coupled fMRI and Eye Tracking tools
218921030|NCT02620774|DRUG|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
218921031|NCT02620774|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
218921032|NCT00474812|DRUG|dasatinib|
218921033|NCT00474812|PROCEDURE|laboratory biomarker analysis|Correlative study
218921034|NCT00474812|PROCEDURE|physiologic testing|Correlative study
218921035|NCT00700479|DRUG|aldosterone|4 hour infusion
218921036|NCT00700479|DIETARY_SUPPLEMENT|low or high sodium diet|
218921037|NCT00700479|DRUG|placebo|placebo
218921038|NCT04426422|DRUG|Metformin Hydrochloride|treated with metformin 1500-2000mg daily
218921039|NCT03911167|PROCEDURE|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
218921040|NCT03096808|RADIATION|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
218921041|NCT02059278|DRUG|T-2345|T-2345 Ophthalmic Solution
218921042|NCT02059278|DRUG|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
218921043|NCT03200249|RADIATION|Preoperative chemo-radiation with IG-IMRT dose escalation|
218921044|NCT02689635|OTHER|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
218921045|NCT02689635|OTHER|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
218921046|NCT01723982|DRUG|Barusiban (FE 200440)|
218921047|NCT01723982|DRUG|Placebo Comparator|
218921048|NCT04834661|OTHER|surgery inside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
219534805|NCT00359281|DRUG|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
219534806|NCT00359281|DRUG|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
219534807|NCT00359281|DRUG|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
219534808|NCT00359281|DRUG|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
219534809|NCT02375685|BIOLOGICAL|Gevokizumab|
219534810|NCT00448903|DRUG|Bemiparin|Bemiparin sodium
218921049|NCT04834661|OTHER|surgery outside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
218921050|NCT06345274|BEHAVIORAL|Measurement Based Care Training and Monthly Consultation|Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
218921051|NCT00446004|DRUG|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
218921052|NCT00446004|DRUG|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
218921053|NCT03529669|DEVICE|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
218921054|NCT05659589|OTHER|blood sample|Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.
219534811|NCT00448903|DRUG|Placebo|Sodium Chloride 0,9%
219534812|NCT05396963|DIETARY_SUPPLEMENT|Egg white|Intake of egg white
219618285|NCT07111104|RADIATION|Radiotherapy|The radiotherapy intervention involves targeted delivery of ionizing radiation to metastatic lesions. Radiotherapy may be given either concurrently with immunotherapy or sequentially afterward, depending on the patient's treatment plan. The purpose is to achieve local tumor control and potentially enhance the systemic immune response through immunogenic cell death. Different radiation techniques and dose regimens may be employed based on lesion size, location, and clinical considerations.
219618286|NCT07112625|OTHER|education and coaching|education associated to coaching
219618287|NCT07112625|OTHER|education|education without coaching
219618288|NCT06933355|DRUG|JARDIANCE 25mg|"The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients.~4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2.~4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2."
219618289|NCT06933355|DRUG|Placebo|The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients. 4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2. 4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2.
219618290|NCT06940063|PROCEDURE|Active music-based intervention|Musical experience includes playing an instrument, singing, or songwriting.
219618291|NCT06936436|OTHER|Implanon (Etonogestrel)|implanon is a long acting ,reversible contraceptive implants used to prevent pregnancy
218921055|NCT04363320|BEHAVIORAL|NIATx Coaching|NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.
218921056|NCT04363320|BEHAVIORAL|ECHO|The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.
218921057|NCT05632211|BIOLOGICAL|AVT05|Pre filled syringes filled with AVT05
218921058|NCT05632211|BIOLOGICAL|Simponi|Pre filled syringes filled with Simponi
219204758|NCT06557980|OTHER|toothpaste|group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
219534813|NCT05396963|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
219534814|NCT05396963|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
219534815|NCT05672433|DIETARY_SUPPLEMENT|Placebo|Capsule without cafestol twice daily
219534816|NCT05672433|DIETARY_SUPPLEMENT|Cafestol|Capsule with 6 mg cafestol twice daily
219534817|NCT04609917|PROCEDURE|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
219534818|NCT01111045|DRUG|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
219534819|NCT01111045|DRUG|Placebo|Placebo
219534820|NCT00407147|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
219534821|NCT06103058|OTHER|Cross sectional|Cross sectional
219534822|NCT04065867|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
218921059|NCT06685302|OTHER|US-guided PNM|The patient will be positioned in supine with approximately 20 degrees of knee flexion, supported by a cushion. The treatment area is sterilized in advance with 2% chlorhexidine, and new needles and ultrasound probe covers are used for each intervention. The femoral nerve is targeted under ultrasound guidance, just distal to the inguinal ligament, with an electrode patch placed on the patellar tendon to complete the circuit. A current of 2 Hz, 250 μs pulse width, and variable intensity is applied to reach the patient's comfortable contraction threshold without inducing pain, for a duration of 25 minutes, following the protocol established by MVClinic Institute. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
218921060|NCT06685302|OTHER|US-guided PE|The patient will be positioned in supine with approximately 20º of knee flexion, supported by a cushion. Prior to the EP procedure, the treatment area will be sterilized with 2% chlorhexidine, and new needles and ultrasound probe covers will be used for each session. Three EP interventions will be performed under ultrasound guidance following the protocol developed by MVClinic Institute (2) for treating tendinopathies, using a longitudinal, long-axis view of the patellar tendon. A galvanic current of 3 mA will be applied for 3 seconds, with slight three-dimensional adjustments in needle placement after each impact to administer a total of 3 impacts on the target tissue. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
218921061|NCT06685302|OTHER|EE|Three sets of 15 repetitions of single-leg squats on a 25º inclined plane, performed twice daily, following Young's protocol for patellar tendinopathies. The speed of execution may be increased as long as, if there is pain during the exercise, it does not exceed a 2-3 on the VAS scale.
218921062|NCT00541658|DRUG|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
218921063|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
218921064|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
218921065|NCT06274645|DEVICE|The OptiCross High Definition (60 MHz) and OptiCross (40MHz) Intravascular Ultrasound (IVUS) catheter from Boston Scientific|The IVUS-guided PCI procedure includes the use of IVUS before PCI (highly recommended) and after PCI (mandatory)
218921066|NCT05614817|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection
218921067|NCT05614817|DRUG|Placebo|subcutaneous(SC) injection
219534823|NCT02688023|DRUG|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
219534824|NCT06062498|DRUG|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
219534825|NCT05137184|DRUG|Methoxyflurane|Inhalation of Methoxyflurane
219534826|NCT05137184|DRUG|Fentanyl|Intranasal Fentanyl
219534827|NCT05137184|DRUG|Morphine hydrochloride|Intravenous Morphine
219534828|NCT04887415|BEHAVIORAL|Respiratory Strength Training (RST) Program|Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
218921068|NCT00495196|PROCEDURE|Experimental lung function test|Administration of several CO2 gas mixtures
218921069|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)"
219534829|NCT05363059|DRUG|Hypoglycemic drugs|drug
219534830|NCT05363059|PROCEDURE|Bariatric surgery|surgery
219534831|NCT03380845|DEVICE|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
219534832|NCT03380845|DEVICE|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
219534833|NCT03118557|OTHER|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
219534834|NCT04092023|OTHER|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
219534835|NCT03121716|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
219534836|NCT03121716|DRUG|Gemcitabine|gemcitabine
219534837|NCT03121716|DRUG|cis-platinum|cis-platinum
219534838|NCT01116362|PROCEDURE|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
219534839|NCT01116362|PROCEDURE|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
219534840|NCT02247752|OTHER|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
219534841|NCT00803153|PROCEDURE|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
219534842|NCT03491579|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
219534843|NCT03491579|DRUG|Cladribine|Standard chemotherapy
219534844|NCT03491579|DRUG|Cytarabine|Standard chemotherapy
218921070|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)"
219042685|NCT05949138|DEVICE|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
219534845|NCT00707408|DRUG|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
219534846|NCT03359356|DRUG|Dupilumab|A total of 24 doses
219534847|NCT03359356|DRUG|Placebo|A total of 24 doses
219534848|NCT06619041|BEHAVIORAL|HealthyTogether|HealthyTogether is a brief (8-session), virtual, dyadic weight management intervention.
219534849|NCT00308048|DRUG|Pegylated Interferon alfa 2b and ribavirin|
219534850|NCT01557712|DRUG|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
219534851|NCT01557712|DRUG|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
219534852|NCT02364063|OTHER|urotherapy with or without pharmacotherapy|Individualized
219534853|NCT04808557|OTHER|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
219534854|NCT04808557|OTHER|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair \& Protect for home oral hygiene for the following 30 days from the bonding procedure.
219534855|NCT03655535|DRUG|BTI320|Non-systemic galactomannan complex polysaccharide
218921071|NCT04440033|OTHER|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
219042686|NCT00903812|OTHER|No intervention|No intervention as observational study
219534856|NCT03655535|OTHER|Placebo|Placebo
219534857|NCT01701492|OTHER|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
219534858|NCT01701492|OTHER|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
219534859|NCT00840411|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
219534860|NCT00840411|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
219534861|NCT04031001|DEVICE|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
219534862|NCT01983761|DRUG|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
219534863|NCT01983761|DRUG|Fludarabine, Melphalan, ATG (Reduced Intensity)|
219534864|NCT01488630|OTHER|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
219534865|NCT00464048|PROCEDURE|controlled physical exercise|
219042687|NCT00314366|BIOLOGICAL|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
219534866|NCT01372579|DRUG|eribulin mesylate|Given IV
219534867|NCT01372579|DRUG|carboplatin|Given IV
219534868|NCT01372579|PROCEDURE|biopsy|Correlative studies
219534869|NCT05813678|DRUG|Pegvaliase|This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).
219534870|NCT06560086|DRUG|Ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
219534871|NCT06560086|DRUG|Luteinizing Hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
219534872|NCT06560580|DRUG|3% Diquafosol Sodium Eye Drops|Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
218921072|NCT04440033|OTHER|Speech assessments|"* Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)"
218921073|NCT04440033|OTHER|Audiology assessments|"* Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
218921074|NCT02570607|BIOLOGICAL|BNP dosage|
218921075|NCT05187689|BEHAVIORAL|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
218921076|NCT05187689|BEHAVIORAL|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
218921077|NCT04612504|BIOLOGICAL|SynOV1.1|SynOV1.1 will be administered intratumorally.
218921078|NCT01625299|DIETARY_SUPPLEMENT|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
218921079|NCT01625299|DIETARY_SUPPLEMENT|Placebo|Rice flour 1.0 g/kg/day
218921080|NCT04123470|GENETIC|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
218921081|NCT04123470|BIOLOGICAL|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
218921082|NCT05897203|DRUG|TAZCOV|Herbal Syrup
218921083|NCT05897203|DRUG|Vidicine|Herbal Syrup
218921084|NCT04080505|DRUG|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
218921085|NCT03175679|BIOLOGICAL|iNKT cells|The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.
218921086|NCT03175679|DRUG|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
219534873|NCT06561100|BEHAVIORAL|Sub-symptomatic Adaptable Exercise Treatment (SAET)|Each workout will be structured in a similar format. The first 5 minutes will be devoted to stretching and warm up exercises. Then the next 20 minute segment devoted to light to moderate aerobic exercise. The second 20 minutes of each exercise session will be composed of a series of 5 predetermined exercises that rotate every day. Each workout will have one or two alternatives that the patient can complete either for modification to accommodate a physical limitation or to optimize preference. Resistance training each day will include multi-joint functional movements along with stability work. The last five minutes of the session will include more mobility work, and/or cooling down.
218921087|NCT03175679|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
218921088|NCT05070923|BEHAVIORAL|HealthyLifetime|HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
218921089|NCT05530252|DRUG|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
218921090|NCT05530252|DRUG|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
218921091|NCT05530252|OTHER|SRP|only scaling and root planning was performed on the patient
218921092|NCT05196152|BEHAVIORAL|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
218921093|NCT05196152|BEHAVIORAL|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
219534874|NCT06561100|BEHAVIORAL|Stretching Control Group (SCG)|Each workout will be 50-60 minutes long and participants are instructed to not do any other type of exercise that may elevate their heart rate. Modifications will be available for stretches that may be too advanced for the individual.
218921094|NCT00305513|PROCEDURE|The phasic alerting treatment|
218921095|NCT05949333|DRUG|Eflapegrastim|long-acting granulocyte-colony stimulating factor
218921096|NCT00873483|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
219534875|NCT00002345|DRUG|Megestrol acetate|
218921097|NCT04370873|DRUG|Frespaciguat|Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
218921098|NCT04370873|DRUG|Placebo|Placebo administered as dry powder inhalation according to randomization
218921099|NCT05271240|DRUG|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
218921100|NCT05271240|DRUG|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
218921101|NCT06242574|OTHER|Survey|Each group will have to complete a questionnaire online, taking about 30 minutes.
218921102|NCT06133179|PROCEDURE|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
219618292|NCT05797870|COMBINATION_PRODUCT|Selective Internal Radiation Therapy with 188Re-SSS lipiodol|"The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.~Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).~The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT."
219618293|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
219618294|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
219618295|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
219618296|NCT05039801|DRUG|Capivasertib|Given by PO
219618297|NCT05556798|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
218921103|NCT02344108|DEVICE|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
219534876|NCT05782634|DEVICE|immediate satellite implant with immediate loading|"Infiltration anesthesia will be administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 . Injection to control pain and bleeding for hemostasis.~Dental extraction will be done with minimal force to avoid trauma to the bone. Flab will be released, different drilling sizes will be used to attain the final drill size of the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, a satellite implant device is attached to the implant's abutment placed on the buccal and palatal plates of bone and retention between the abutment and microplate will help in neglecting the lateral destructive forces . sutures will be done . Impression will be taken for immediate loading with the final crown. Cone beam will be done."
219534877|NCT05086783|OTHER|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
219618298|NCT05556798|DRUG|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
218921104|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (neoadjuvant)|Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
218921105|NCT05724329|PROCEDURE|surgery|Standard of care
218921106|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (adjuvant)|Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
219042688|NCT00314366|OTHER|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
219042689|NCT01393743|DRUG|Perampanel|
219042690|NCT01393743|DRUG|Placebo comparator|
219534878|NCT05086783|OTHER|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
219534879|NCT02003547|DRUG|AMA0076|
219534880|NCT02003547|DRUG|Placebo|
219618299|NCT05556798|DRUG|Pomalidomide|After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
219618300|NCT05180825|DRUG|Trametinib|Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
219618301|NCT05180825|DRUG|Vinblastine|weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
219618302|NCT06465316|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219618303|NCT06465316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219618304|NCT06465316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219618305|NCT06465316|PROCEDURE|Computed Tomography|Undergo PET/CT
219618306|NCT06465316|DRUG|Iberdomide|Given PO
219618307|NCT06465316|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
218921107|NCT05321134|DEVICE|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety \& quality event rate for SP platform transabdominal and transanal colorectal operations."
219534881|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Active|
218921108|NCT04482647|OTHER|Media Intervention|View instructional video
218921109|NCT04482647|PROCEDURE|Meditation Therapy|Perform meditation
218921110|NCT04482647|OTHER|Quality-of-Life Assessment|Ancillary studies
218921111|NCT04482647|OTHER|Questionnaire Administration|Ancillary studies
218921112|NCT04482647|PROCEDURE|Yoga|Perform breathing techniques
218921113|NCT03008291|PROCEDURE|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
218921114|NCT03008291|PROCEDURE|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
218921115|NCT03008291|PROCEDURE|Dual Chamber Pacemaker Implantation|
218921116|NCT01416220|DRUG|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
218921117|NCT01416220|DRUG|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
219534882|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Sham|
219534883|NCT05123495|BEHAVIORAL|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
219534884|NCT05123495|BEHAVIORAL|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
219534885|NCT06366009|DEVICE|NaoX in-ear EEG system|EEG recordings will be carried out simultaneously using standard EEG equipment (full set of electrodes according to the 10-20 system extended by additional temporal electrodes T9/T10) and the NAOX in-ear EEG system device.
219534886|NCT01762709|PROCEDURE|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
219534887|NCT01762709|PROCEDURE|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
219534888|NCT01762709|PROCEDURE|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
219618308|NCT06465316|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
219618309|NCT06465316|DRUG|Teclistamab|Given SC
219618310|NCT02546986|DRUG|CC-486|CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
218921118|NCT03670966|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given via infusion
218921119|NCT03670966|DRUG|Cyclophosphamide|Given IV
218921120|NCT03670966|RADIATION|Total-Body Irradiation|Undergo TBI
218921121|NCT03670966|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
218921122|NCT03670966|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
218921123|NCT03670966|DRUG|Mycophenolate Mofetil|Given IV or PO
218921124|NCT03670966|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given IV or SC
218921125|NCT03670966|DRUG|Fludarabine Phosphate|Given IV
219534889|NCT00175058|DEVICE|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
219534890|NCT01642342|OTHER|laboratory biomarker analysis|Correlative studies
219534891|NCT01642342|OTHER|pharmacological study|Correlative studies
219534892|NCT01642342|BIOLOGICAL|recombinant albumin fusion protein sEphB4-HSA|Given IV
219534893|NCT03115242|OTHER|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
219618311|NCT02546986|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
219618312|NCT02546986|DRUG|Placebo|Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
218921126|NCT03670966|DRUG|Tacrolimus|Given IV or PO
218921127|NCT03670966|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
218921128|NCT03670966|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218921129|NCT05271643|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
218921130|NCT03751241|DEVICE|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
218921131|NCT04163341|BEHAVIORAL|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
218921132|NCT05773755|DEVICE|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
218921133|NCT03161249|BEHAVIORAL|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
218921134|NCT03161249|OTHER|Control group|Group that does not receive any treatment added to its usual treatment
219534894|NCT03680222|PROCEDURE|Reversed Tracking Method|Reversed Tracking Method
219534895|NCT02433639|DRUG|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
219534896|NCT04743765|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
219534897|NCT04706026|OTHER|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
219534898|NCT04706026|OTHER|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
219534899|NCT06422923|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
219534900|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
219534901|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
219534902|NCT04811014|DRUG|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
219534903|NCT04811014|BEHAVIORAL|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
219534904|NCT04811014|BEHAVIORAL|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
219534905|NCT04811014|BEHAVIORAL|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
219534906|NCT04811014|BEHAVIORAL|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
219534907|NCT04811014|BEHAVIORAL|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
219534908|NCT06781762|OTHER|N/A (Usual Care)|BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
219534909|NCT06835049|DRUG|Doxorubicin|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Doxorubicin will be given at a dose of 75 mg/m2 Body surface area (BSA) on day 1 of each cycle as a intravenous infusion over 15 minutes.
219534910|NCT06835049|DRUG|Ifosfamide|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Ifosfamide will be given at a dose of 3 g/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 9 g/m2 BSA, as an intravenous infusion of 3 g/m2 daily over 4 hours.
219534911|NCT06835049|DRUG|Dacarbazine|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Dacarbazine will be given at a daily dose of 300 mg/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 900 mg/m2 BSA, as an intravenous infusion over 30 minutes.
219534912|NCT06835049|OTHER|Hyperthermia|Hyperthermia (HT) sessions are scheduled on days 1 and 3 of each chemotherapy cycle. The duration of the preheating phase is always 30 minutes. Together with the treatment phase of 60 minutes, the duration of a HT session is uniformly 90 minutes (Total treatment time). On days 2, chemotherapy will be applied without HT.
219534913|NCT06835049|RADIATION|Radiotherapy|"Radiotherapy (RT) treatment should start ideally 19 days after last chemotherapy dose received (range -4 / +7), preferably on a Monday to omit that the last RT fractions will be applied directly after the weekend. Start of RT can be postponed up to 14 days due to medical reasons without violating treatment protocol.~Patients will preferably receive normofractionated RT to a total dose of 50 Gy in 25 fractions of 2 Gy over 5 weeks23.~Alternatively, patients can receive a moderate hypofractionated RT to either a total dose of 42.75 Gy in 15 fractions of 2.85 Gy over 3 weeks or a total dose of 42 Gy in 14 fractions of 3 Gy over 2 weeks and four days41. The respective total treatment time changes respectively.~The RT treatment should be delivered once daily except on weekends."
219534914|NCT06835049|PROCEDURE|Surgery|"Standard of care surgical resection must be done by an experienced sarcoma surgeon. All lesions of the trunk and extremities will be resected after total neoadjuvant treatment with chemotherapy, HT and RT.~Surgery will take place preferentially 6 weeks (+/- 2 weeks) after end of radiation."
218921135|NCT06653907|DRUG|Levothyroxine Sodium (LT4) Tablets|"Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
219618313|NCT05016960|BEHAVIORAL|Sleep-SMART|Sleep-SMART is a telehealth delivered treatment for insomnia that follows the standard 6 session 50-minute Cognitive Behavioral Therapy for Insomnia (CBT-I) format. Sleep-SMART delivers CBT-I treatment along with training in select cognitive strategies from CogSMART to enhance intervention learning and adherence.
219618314|NCT03719105|DRUG|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
219534915|NCT05473143|OTHER|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
219534916|NCT05473143|OTHER|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
219534917|NCT06433765|OTHER|No intervention|No intervention
219534918|NCT05997446|DEVICE|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
219534919|NCT05665426|OTHER|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
219534920|NCT05665426|OTHER|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
219534921|NCT05902871|DEVICE|External Automatic Glaucoma Laser|Trans-limbal, direct selective laser trabeculoplasty (DSLT) instrument that directs laser energy through the sclera around the limbus overlying the trabecular meshwork and treats 360 degrees of the angle is treated simultaneously
219534922|NCT05902871|PROCEDURE|Direct Selective Laser Trabeculoplasty|Surgical procedure that utilizes a laser to improve fluid drainage in the eye and reduce intraocular pressure
219534923|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
219534924|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
219534925|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
219534926|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
219534927|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
219534928|NCT06542497|DRUG|0.75% phentolamine ophthalmic solution|Once daily dosing
219534929|NCT06542497|DRUG|Placebo|Once daily dosing
219534930|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (WT/OMI BA.2)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.2\]
219534931|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.1)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.1\]
219618315|NCT03719105|DRUG|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618316|NCT03719105|DRUG|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618317|NCT03719105|DRUG|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618318|NCT03719105|DRUG|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618319|NCT03719105|DRUG|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
218921136|NCT06653907|DRUG|Placebo|"Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
218921137|NCT06655129|DEVICE|intense pulsed light|intense pulsed light (IPL) using the Medical Device Anthelia
218921138|NCT06595017|DRUG|Magnesium sulphate|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
218921139|NCT06595017|DRUG|Lidocaine (drug)|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
218921140|NCT06595017|DRUG|Saline|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
218921141|NCT06594081|BEHAVIORAL|Intervention podcasts|Students in the experimental group will listen to podcasts.
218921142|NCT06595316|OTHER|Exercise intervention group|"Exercise will consist of two supervised sessions per week. Starting with vital signs monitoring (blood pressure, temperature, blood oxygen levels, heart rate).~The aerobic component consists of a 5-minute warm-up, followed by 3 bouts of 4-minute cycling at an intensity of 60-65% HRR, with 2-minute active recovery periods in between and a 5-minute cool down. The goal is to increase up to an intensity of around 80%-85% HRR by weeks 16 to 18. Intensity will be monitored with The Borg Rating Scale of Perceived Exertion (RPE). The resistance component will consist of upper body and lower body exercises (door frame rows, wall push-ups, glute bridges, triceps lifts and squat to calf rise) starting on week one with a set of 12 repetitions of each exercise, with 2-minute recovery in between exercises aiming to increase the number of sets and reducing the number of repetitions."
218921143|NCT06586424|DIAGNOSTIC_TEST|Anion gap|Patient was taken blood examination before PPCI
219534932|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
219534933|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
219618320|NCT03719105|DRUG|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618321|NCT03719105|DRUG|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
218921144|NCT06603142|DRUG|Febuxostat 20MG Tablets|Febuxostat 20MG Tablets
218921145|NCT06603142|DRUG|Febuxostat 20MG Placebo|Febuxostat 20MG Placebo
218921146|NCT06603142|DRUG|AR882 25MG|AR882 25 MG Capsules
218921147|NCT06603142|DRUG|AR882 12.5MG|AR882 12.5 MG Capsules
218921148|NCT06603142|DRUG|AR882 25MG Placebo|AR882 25MG Placebo
218921149|NCT06603142|DRUG|AR882 12.5MG Placebo|AR882 12.5MG Placebo
218921150|NCT06603142|DRUG|Febuxostat 40MG Tablets|Febuxostat 40MG Tablets
218921151|NCT06603142|DRUG|Febuxostat 40MG Placebo|Febuxostat 40MG Placebo
219534934|NCT05472038|BIOLOGICAL|BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BNT162b6 Wild Type and BNT162b6 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
218921152|NCT06599151|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
218921153|NCT02484391|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
219534935|NCT05472038|BIOLOGICAL|BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BNT162b7 Wild Type and BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
219534936|NCT05472038|BIOLOGICAL|BNT162b7 Monovalent (OMI BA.4/BA.5)|BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
219618322|NCT03719105|DRUG|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618323|NCT03719105|DRUG|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
219618324|NCT05120934|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
219618325|NCT05120934|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
219618326|NCT05120934|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
219618327|NCT05120934|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
219618328|NCT05120934|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
219618329|NCT05120934|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
219618330|NCT06846203|OTHER|Core stabilization Exercise Group|"This group will be subjected to following core stabilization exercises:~1: Sit-up-1, 2: Sit-up-2, 3: Back extention-1, 4: Back extention-2 , 5: Front plank, 6: Back bridge , 7: Quadruped , 8:Side bridge A combination of activities will be administered and alterations will be made every session.~Session will be held 3 times per week for 8 consecutive weeks."
218921154|NCT02484391|DRUG|Cytarabine|Given IV
219618331|NCT06846203|OTHER|Neuromuscular Fascilitation Exercise Group|"This group will be subjected to neuromuscular facilitation exercises :~Week 1: McGill curl up, Week 2: Bird dog stretch, Week 3: Side bridge or mermaid side bridge with bent knees, Week 4: Single leg stretching, Week 5: Shoulder bridge Week 6: Tai chi Warrior stance, Week 7 \& 8: Cat - cow - downward facing dog, Hip circumduction, hamstring stretching, starting position Session will be held 3 times per week for 8 consecutive weeks"
219618332|NCT05743036|DRUG|ZN-c3|ZN-c3 tablet by mouth, in combination with encorafenib
219618333|NCT05743036|DRUG|Encorafenib|Encorafenib capsule by mouth, in combination with ZN-c3
218921155|NCT02484391|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplant
218921156|NCT02484391|DRUG|Mitoxantrone Hydrochloride|Given IV
218921157|NCT06587503|BIOLOGICAL|BioNTech - Pfizer COVID-19 vaccine|Vaccine for protection from COVID-19
218921158|NCT06587503|BIOLOGICAL|1mL saline solution|Placebo
218921159|NCT06587503|BIOLOGICAL|rVSV∆G-ZEBOV-GP|Vaccine for protection from Zaire Ebola virus
218921160|NCT06591390|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
218921161|NCT06591390|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
218921162|NCT06599450|DEVICE|Root form dental implant|Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
218921163|NCT06595394|OTHER|Exercise|Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.
218921164|NCT06595394|OTHER|Home program|The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
218921165|NCT06593002|BEHAVIORAL|Therapeutic play|The children in the experimental group were given a therapeutic toy designed for them by the student nurse half an hour before the treatment, the toy and game were introduced, and they were allowed to play with this toy for half an hour, accompanied by the student nurse.
218921166|NCT06592339|DRUG|MK-0616|oral administration
218921167|NCT06587152|PROCEDURE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
218921168|NCT06593899|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiotherapy Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume
218921169|NCT06593899|DRUG|3 cycles of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)
218921170|NCT06591117|DEVICE|Vizio Aqueous Microshunt|Ocular microshunt placement for the treatment of Glaucoma
218921171|NCT06598748|OTHER|Mechanical Interface Mobilisation Technique|In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
218921172|NCT06598748|OTHER|Exercise Therapy|"Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26)."
218921173|NCT06604312|OTHER|Sacroiliac Joint Manipulation|Sacroiliac manipulation was performed using manual treatment method by lying patients on their sides. First, the patient was positioned firmly on the edge of the examination table, while the restricted sacroiliac joint remains on the upper side. Then, the physician's hand was positioned on the patient's hip, and the flexion was made on the lumbar spine with the movement from the hip to the upper thigh, and the impulse given by the HVLA technique was applied in the anteroinferior direction to the iliac crest and trochanter major.
218921174|NCT06593444|PROCEDURE|Thalamic Ventral Intermediate-DBS|Participants will undergo Thalamic Ventral Intermediate-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
218921175|NCT06655584|DEVICE|Virtual reality headset Bliss DTX|The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
218921176|NCT00911170|DRUG|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
218921177|NCT00911170|DRUG|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
219534939|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
219534940|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
219534941|NCT05636501|OTHER|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
219534942|NCT05636501|OTHER|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
219534943|NCT02792166|PROCEDURE|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
219618334|NCT05743036|DRUG|Cetuximab|Infusion
219618335|NCT04796961|OTHER|Implementation Intervention|The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
218921178|NCT00911170|BIOLOGICAL|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
218921179|NCT00911170|DRUG|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
218921180|NCT06987110|OTHER|Transverse thoracic plane block|Patients will receive a transverse thoracic plane block.
218921181|NCT06987110|OTHER|Midpoint transverse process plane to pleura block|Patients will receive a midpoint transverse process plane to pleura block.
218921182|NCT06987110|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
218921183|NCT05189314|PROCEDURE|Thyroidectomy|Surgical Resection of thyroid nodules
219534944|NCT02792166|PROCEDURE|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
219534945|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
219534946|NCT06134934|OTHER|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
219534947|NCT06134934|OTHER|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
219534948|NCT05374616|GENETIC|Observation|Retrospective and prospective Natural History Study
219534949|NCT05109975|DRUG|Debio 0123|Debio 0123 orally during 21-day treatment cycles.
219534950|NCT05998369|BEHAVIORAL|Empowered Relief for Youth|The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
219534951|NCT05452928|DRUG|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
219534952|NCT05452928|DRUG|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
219534953|NCT06176196|DRUG|VX-548|Tablets for oral administration.
219534954|NCT06176196|DRUG|Placebo|Tablets for oral administration.
219534955|NCT06533111|OTHER|Epic Health Record semi-structured handoff cognitive aid|Epic Health Record cognitive aid will be used for intraoperative anesthesia handoff
219534956|NCT06533111|OTHER|Usual care|Epic Health Record cognitive aid will not be used for intraoperative anesthesia handoff
219534957|NCT05240742|OTHER|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
219534958|NCT05895461|BEHAVIORAL|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
219534959|NCT05895461|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
219534960|NCT06230965|PROCEDURE|Lung protective ventilation strategy|They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
219534961|NCT06787131|DRUG|ZE50-0134 or placebo|The patients will receive ZE50-0134 or placebo.
219534962|NCT06787131|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg once daily (QD) on Day 1 and Day 2.
219534963|NCT06787131|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg twice per day.
219534964|NCT03857919|DEVICE|TearCare|The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.
219534965|NCT03857919|DEVICE|LipiFlow|The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
218921184|NCT05189314|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
218921185|NCT06665789|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
218921186|NCT02594124|DRUG|nusinersen|Administered by intrathecal (IT) injection
218921187|NCT04662255|DRUG|Pirtobrutinib|Oral
218921188|NCT04662255|DRUG|Ibrutinib|Oral
218921189|NCT04662255|DRUG|Acalabrutinib|Oral
218921190|NCT04662255|DRUG|Zanubrutinib|Oral
218921191|NCT06587594|BEHAVIORAL|Solution Focused Brief Therapy|A behavioral health intervention designed to help autistic adults to make a positive change in their life using strength-based approach.
218921192|NCT06598176|DEVICE|Colli-Pee 20mL device with UCM|Women will collect a first-void urine (the initial part of the urine stream) sample at home the day before a hospital appointment using the 20mL Colli-Pee device prefilled with urine conservation medium (UCM, Novosanis, Belgium).
219534966|NCT05369208|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.
219534967|NCT06956209|DEVICE|Direct Bladder Wall Stimulation|The Akyva System is an implantable device intended to electrically stimulate the bladder muscle that controls bladder emptying or urination
219534968|NCT05622708|DRUG|Secukinumab|Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.
219534969|NCT05622708|DRUG|Placebo|Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.
219534970|NCT05622708|DRUG|Secukinumab|"Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.~Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c."
218921193|NCT06598176|DEVICE|Evalyn Brush|Women will collect a vaginal self-sample using the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before a hospital appointment.
218921194|NCT06586866|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
218921195|NCT06592365|DIETARY_SUPPLEMENT|GTE|oral administration of GTE tablets once daily for 12 weeks
218921196|NCT06592365|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo tablets once daily for 12 weeks
218921197|NCT06601725|DIAGNOSTIC_TEST|Clusterin level|Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
218921198|NCT06602622|DRUG|Integrase inhibitor|Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
219534971|NCT04752592|DIAGNOSTIC_TEST|SeroSelectTB rapid TB test|The SeroSelectTB test is a rapid blood-based immunochemical lateral flow assay for the detection of active tuberculosis.
219534972|NCT06609239|DRUG|Lunsekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
219534973|NCT05108428|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
219534974|NCT05108428|RADIATION|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
219534975|NCT05108428|DRUG|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
219618336|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
219618337|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
218921199|NCT06602622|DRUG|Doravirine + tenofovir DF + lamivudine|Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
218921200|NCT06587022|RADIATION|Target volume delineation|Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
218921201|NCT06600113|OTHER|Education and teaching of coping strategies|the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
218921202|NCT06595836|DEVICE|Silicone Lubricated Synthetic polyisoprine condom|Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity
218921203|NCT06595836|DEVICE|Silicone Lubricated Natural Rubber Latex Condom|Natural rubber latex condoms are made from natural rubber
219534976|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.
219534977|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505
219534978|NCT02089217|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy
219534979|NCT02089217|DEVICE|Carotid Stenting (CAS)|Carotid stenting
219534980|NCT02089217|OTHER|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
219534981|NCT02089217|OTHER|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
219534982|NCT06687616|DEVICE|SynerGI|Standardized 8-week CBT program, used for 20-30 minutes per week
219534983|NCT06687616|DEVICE|Sham VR|Distraction-based VR program with 2D nature videos to be used for 8 weeks, 2-2 times a week for 10 minutes
219618338|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
219618339|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
219618340|NCT05986630|DEVICE|TEOSYAL® TPVM|"Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
219618341|NCT05986630|DEVICE|COMPARATOR|"Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
219618342|NCT06049134|BIOLOGICAL|PCV20|Given by Injection into the muscle
219618343|NCT02325973|DEVICE|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
219618344|NCT06570759|PROCEDURE|Early intervention for OMI|Early PCI for OMI (+) STEMI (-) patients
219618345|NCT06570759|PROCEDURE|Standard early intervention for STEMI|Early PCI for OMI (+) and STEMI (+) patients
218921204|NCT06596837|DEVICE|virtual reality|"The investigators manipulated the following two variables within the experimental design:~Immersion in the virtual environment. This was a nominal variable with two levels: a low-immersive environment (Other group) and a highly immersive environment (Experimental group) using the Cold River application.~Order of virtual reality (VR) deployment during the first session. This was also a nominal variable with two levels: VR during the first part of the dressing change (removing the dressing) and VR during the second part of the dressing change (cleaning the wound and applying a new dressing). In each subsequent session, the order of VR deployment was swapped for each participant.~The values of both variables were assigned to participants according to their numbers (e.g., 1. highly immersive, VR first; 2. low immersive, VR first; 3. highly immersive, VR last; 4. low immersive, VR last, etc.)."
219534984|NCT06832696|DEVICE|RUF-D|"We have developed a simplified fluid removal device (RUF-D) to address the challenges that patients face with being unable to remove the fluid they need with standard dialysis. Participants 01-09 will receive one week of baseline observation (three HD treatments) with two weeks of supervised intervention using RUF-D post HD on Mondays and Wednesdays for up to six hours (total three-week study).~Participants 10-18 will receive one week of baseline observation, two weeks of intervention (identical to cohort one above), with an additional week of intervention (total four weeks) where participants will be fitted with the RUF-D (ensuring functionality) before going home with the device in operation for up to six hours twice weekly."
218921205|NCT06587178|DIETARY_SUPPLEMENT|peptison liquid|CD patients requiring bowel resection and preoperative EEN were randomized to receive peptison liquid for 6 weeks.
218921206|NCT06587178|DIETARY_SUPPLEMENT|Enteral nutritional suspension|CD patients requiring bowel resection and preoperative EEN were randomized to receive enteral nutritional suspension for 6 weeks.
219618346|NCT06570759|PROCEDURE|Standard delayed intervention for NSTEMI|Medical stabilization and then PCI for OMI (-) and STEMI (-) patients
219618347|NCT05888779|OTHER|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
219534985|NCT05510895|DRUG|Binimetinib|Triplet combination administered neoadjuvant and adjuvant, depending on TRG
219534986|NCT05998031|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
219534987|NCT05998031|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
219534988|NCT03729115|PROCEDURE|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
219534989|NCT06363929|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
219534990|NCT05775796|DRUG|Serplulimab and Chemotherapy|Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
219534991|NCT02675647|DRUG|Heparin, IV route, based on patients body weights (UI/kg)|
219534992|NCT02675647|PROCEDURE|Cardiopulmonary bypass|
219534993|NCT02675647|DRUG|Protamin administration|
219534994|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
218921207|NCT06592105|PROCEDURE|Endovascular aortic aneurysm repair (EVAR)|Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
218921208|NCT06588998|DEVICE|Xengenic Cortical membranes|soft tissue surgery around dental implant dehiscence
219534995|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218921209|NCT06588998|PROCEDURE|connective tissue graft|soft tissue surgery around dental implant dehiscence
219534996|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
219534997|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
219534998|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
219534999|NCT06056895|DRUG|Tuparstobart|Given IV
219535000|NCT06056895|DRUG|Verzistobart|Given IV
219535001|NCT03993873|DRUG|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
219535002|NCT03595683|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks.
219535003|NCT03595683|BIOLOGICAL|EDP1503|Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).
219535004|NCT04752774|BIOLOGICAL|IPN10200|Powder and solvent for solution for injection
219535005|NCT04752774|DRUG|Placebo|Powder and solvent for solution for injection
219618348|NCT05888779|OTHER|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
219618349|NCT06494111|DRUG|Pravastatin|Given by PO
219618350|NCT06494111|DRUG|Pentoxifylline|Given by PO
219618351|NCT06494111|DRUG|Tocopherol|Given by PO
219618352|NCT04640987|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
219618353|NCT04640987|DEVICE|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
219618354|NCT04640987|DRUG|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
219535006|NCT04752774|BIOLOGICAL|Dysport|Powder for solution for injection
219535007|NCT02674152|DRUG|BI 836880|BI 836880
218921210|NCT06590597|BEHAVIORAL|EDUCATIONAL INTERVENTION FOR MALARIA PREVENTION|The intervention consisted of 4 modules administered in the same number of face-to-face sessions in which educational strategies such as classes, guided discussions, workshops and a booklet designed for the study were used.
218921211|NCT06601855|PROCEDURE|Cholecystectomy|Cholecystectomy, whether open or laparoscopic
218921212|NCT06598267|PROCEDURE|SASI|single anastomosis sleeve ileal bypass
219535008|NCT03410667|BEHAVIORAL|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
219535009|NCT03410667|BEHAVIORAL|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
219535010|NCT03410667|BEHAVIORAL|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
218921213|NCT06598267|PROCEDURE|RYGB|Roux-en-Y gastric bypass
218921214|NCT06599346|OTHER|Standard Care|Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.
218921215|NCT06599346|BIOLOGICAL|MSC Supernatant + Standard Care|"Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"
218921216|NCT06586476|BEHAVIORAL|Nightly Timed Awakening|Patients in this arm will be awakened 1-hr after going to bed by their caregiver(s) to use the restroom and then returned to sleep. This awakening will occur every night.
218921217|NCT06591689|OTHER|Evaluation of Cases with Quadriparetic Cerebral Palsy|20 quadriparetic cerebral palsy cases were evaluated with the Communication Function Classification System (CFCS), Pediatric Functional Independence Scale (WeeFIM) and Gross Motor Function Measure-88 (GMFM-88).
218921218|NCT06586463|OTHER|kinitic control training|"kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation."
218921219|NCT06603350|OTHER|No intenvention|No intenvention
218921220|NCT06596564|BEHAVIORAL|choice architecture|Display the sugar content of the drink on the platform.
218921221|NCT06596564|BEHAVIORAL|choice architecture|Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.
218921222|NCT06596564|BEHAVIORAL|choice architecture|The platform shows the information that the majority of their peers have chosen mineral water.
218921223|NCT06594952|OTHER|Questionnaire and Physical Exam|"Diagnosis of Anxiety using the state-trait anxiety inventory scale (STAI). Depression using Edinburgh Postnatal Depression Scale (EPDS)~* Coping using the Brief Coping Scale~* Socioeconomic using the Socioeconomic Scale of Egypt~* Personality using the short-form Eysenck Personality Questionnaire-Revised (EPQ-R)~* Behaviour using Impact of Erect Scale (IES-22)"
218921224|NCT06590753|DEVICE|osseodensification bur|osseodensification bur
218921225|NCT03396809|DEVICE|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
218921226|NCT06597851|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
218921227|NCT06597851|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic Clamp test|Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
218921228|NCT05488444|BEHAVIORAL|Navigator Phone Calls|"The patient navigator will call you every week as described above in Study Groups. These phone calls will continue until you begin receiving chemotherapy."
218921229|NCT05488444|BEHAVIORAL|Exit Interview|Participants will be asked to complete an exit interview either in person or by phone
218921230|NCT05607446|DRUG|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
219535011|NCT03410667|BEHAVIORAL|Aim 3|This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
218921231|NCT05607446|DRUG|Placebo tablets|The intervention drug is placebo.
218921232|NCT05607446|DRUG|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
219535012|NCT03925025|DRUG|Magnesium Sulfate|Treatment in addition to standard therapy
219535013|NCT03925025|DRUG|Nimodipine|Treatment in addition to standard therapy
219535014|NCT04934722|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
219535015|NCT04934722|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
219535016|NCT04934722|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
219618355|NCT06041958|DEVICE|Extracorporeal shock wave therapy|2 times/week for 12 weeks
219618356|NCT06041958|DEVICE|Pulse electromagnetic field therapy|2 times/week for 12 weeks
219618357|NCT06041958|OTHER|Rehabilitation|2 times/week for 12 weeks
219618358|NCT05569486|DEVICE|Green Light|This is a low-energy device. It produces almost no heat because it uses an LED source for light. The device does not store energy or electrical power that can be discharged later.
219618359|NCT03700125|PROCEDURE|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
218921233|NCT05607446|DRUG|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
218921234|NCT06612060|PROCEDURE|Cardiac surgery with the use of extracorporeal circulation|All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.
218921235|NCT06611501|DRUG|Metformin Hydrochloride|Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.
219535017|NCT04934722|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
219535018|NCT04174924|PROCEDURE|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
218921236|NCT06611501|DRUG|Placebo|1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
218921237|NCT06991920|DRUG|Blinatumomab|CD19-positive, Ph+ patients with favorable financial status may receive VP + TKI + blinatumomab therapy；CD19-positive, Ph- patients with favorable financial status may receive VCP + blinatumomab therapy.
218921238|NCT06991920|DRUG|Venetoclax|CD19-positive, Ph+ patients with poor financial status may receive VP + TKI + VEN therapy；CD19-negative or CD19-positive, Ph- patients ineligible for blinatumomab may receive VPCLP + VEN therapy.
218921239|NCT06992180|BEHAVIORAL|Generative Artificial Intelligence Intervention|The intervention is delivered via a generative artificial intelligence platform called Emohaa. Participants will register and gain access to the platform prior to the start of the trial. Emohaa's responses are based on Hill's helping skills theory in psychology and are designed to simulate the basic communication strategies of a human counselor. The system demonstrates strong capabilities in active listening, emotional mirroring, and empathy, supporting users in understanding their own thoughts and feelings, learning to cope with emotional challenges, and achieving a more optimistic and positive mental and emotional state.
218921240|NCT06992180|BEHAVIORAL|Individual Psychological Counseling|Participants in the traditional counseling group will receive individual psychological counseling sessions conducted by certified psychotherapists.
218921241|NCT06992765|DIETARY_SUPPLEMENT|Intervention|2 bottles of light green tea daily containing totally 684 mg of catechin
218921242|NCT06992765|DIETARY_SUPPLEMENT|Placebo|2 bottles of light green tea daily containing totally 108 mg of catechin
219366611|NCT05450614|BEHAVIORAL|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
219535019|NCT05704829|DRUG|Trastuzumab deruxtecan|T-DXd i.v.
219618360|NCT05609253|DRUG|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
219618361|NCT05609253|DRUG|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
219535020|NCT05704829|DRUG|Standard-of-Care|Chemotherapy+T+P
219535021|NCT04229979|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
219535022|NCT04229979|DRUG|Azacitidine|injection
219535023|NCT04229979|DRUG|Venetoclax|tablet
219618362|NCT04064138|PROCEDURE|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
219535024|NCT04229979|DRUG|Decitabine|injection
219535025|NCT04229979|DRUG|Cytarabine|injection
219535026|NCT04229979|OTHER|Observation|palliative management
219535027|NCT04229979|BIOLOGICAL|GM-CSF|subcutaneous injection
219535028|NCT04229979|OTHER|Montanide|adjuvant
219535029|NCT02720445|DRUG|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
219535030|NCT02720445|DRUG|Placebo Patch|Matching placebo patches worn during waking hours.
219535031|NCT04472949|DRUG|Durvalumab|Durvalumab: 1500 mg iv
218921243|NCT06992700|DEVICE|Dynamic perturbation-based intervention|The patient will be asked to perform simple motor tasks while wearing the glove at home under remote supervision of the staff involved in the study. In this way, in order to complete the task, the patient will be forced to overcome the elastic force and perform the movement with greater control. What is innovative compared to the common application of this device is its purpose: specifically, the orthosis will be used by applying resistance to the distal phalanx of the fingers of the hand characterised by a stenic deficit. Contrary to the usual application, which involves the use of this device to facilitate deficient movements, it is hypothesised that the application of resistance will induce the central nervous system (CNS) to create alternative strategies offering them the variety and difficulty necessary to stimulate adaptation without subjecting them to stress resulting from sudden and excessive levels of challenge.
218921244|NCT06992700|OTHER|Exercises without dynamic perturbations|Patients in this group will perform the exercises at home with the paretic upper limb wearing the orthosis (to stabilise the wrist and eliminate this possible confounding variable), but without the springs that determine resistance (i.e., eliminating the elastic resistance that is the subject of this study);
218921245|NCT06992115|BEHAVIORAL|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet|A dietary pattern which promotes the intake of olive oil, fish, leafy greens \& other vegetables, fruits, whole grains, and legumes, and discourages processed foods, red meat, and sugar.
218921246|NCT06992115|BEHAVIORAL|Small Group|Education and social support on topics related to multiple sclerosis such as disease-modifying therapies and MRI in MS.
218921247|NCT06992661|DRUG|ICF004 inhaled powder|"ICF004 is an investigational inhaled powder formulation containing epigallocatechin gallate (EGCG), the most biologically active polyphenol component derived from green tea extract. Developed for targeted pulmonary delivery, ICF004 utilizes a proprietary RS01 dry powder inhaler device to achieve localized therapeutic effects in lung tissue while minimizing systemic exposure.~The formulation consists of micronized EGCG (≥90% purity) in precisely dosed capsules (1mg or 4mg per unit). Preclinical studies demonstrate that inhaled administration achieves 10-20× higher lung concentrations compared to oral dosing, with correspondingly lower plasma levels - potentially reducing the hepatotoxicity risk associated with high oral EGCG doses (European Food Safety Authority recommends \<800mg/day orally)."
218921248|NCT06992661|DRUG|Oral Teavigo® capsules|Teavigo® is a standardized, high-purity epigallocatechin gallate (EGCG) supplement developed by DSM Nutritional Products. The oral capsules contain ≥94% pure EGCG extracted from green tea (Camellia sinensis), making them one of the most concentrated commercially available EGCG formulations.
218921249|NCT06993428|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
218921250|NCT06993428|DRUG|Alli® 60 mg|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
218921251|NCT06993428|DIETARY_SUPPLEMENT|Vi-Siblin® S|Vi-Siblin® S will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
218921252|NCT06993428|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
218921253|NCT06991582|BIOLOGICAL|Injectable composite resin restoration|Injectable composite Beautifil flow Plus X (Shofu INC., Koyoto, Japan)
218921254|NCT06991582|BIOLOGICAL|packable composite|Packable Composite Beautifil II (Shofu INC., Koyoto, Japan)
219366612|NCT02308644|DRUG|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
219366613|NCT02144779|BEHAVIORAL|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
219366614|NCT02144779|BEHAVIORAL|Usual Care|usual hospital care, not assigned to palliative care team
219535032|NCT04472949|DRUG|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
219535033|NCT04472949|DRUG|etoposide|Etoposide: 100 mg/m2 iv
218921255|NCT06992973|RADIATION|Treatment based on stereotactic radiosurgery|"Treatment based on stereotactic radiosurgery fractionated within 48-72, followed by surgery for symptomatic brain lesions, amenable to surgical treatment, associated or not with a maximum of 3 additional smaller metastatic brain lesions. The dose will be 27 Gy in three fractions (9 Gy per fraction) on alternate days.~If other lesions are present, up to a maximum of 3 lesions and a total volume of 35 cc, these will be treated with radical stereotactic radiosurgery according to guidelines."
218921256|NCT06992336|DRUG|Anlotinib ,|Anlotinib 8mg qd PO，357days
218921257|NCT06992336|DRUG|Benmelstobart|Benmelstobart 200mg i.v. Q3W
218921258|NCT06992336|DRUG|Capecitabine|Capecitabine 1000 or 1250 mg/m2 BID day1-14
219366615|NCT00917436|DRUG|Thiocolchicoside|
219366616|NCT03354689|RADIATION|Scintigraphy|Scintigraphy
219366617|NCT02834910|OTHER|collection of bacterial sample|
219366618|NCT01762514|DRUG|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
219366619|NCT01762514|DRUG|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
219366620|NCT05731921|BEHAVIORAL|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
219366621|NCT01279057|DRUG|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
219366622|NCT01279057|DRUG|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
219366623|NCT01279057|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
218921259|NCT06992219|OTHER|Non surgical periodontal treatment evaluated through probing pocket depth reduction|Patients were treated with Minimally invasive non surgical treatment (MINST) or quadrant-subgingival instrumentation (Q-SI). The efficacy of treatment in both groups was evaluated through Probin Pocket Depth reduction in millimetres measurement before and after treatment.
218921260|NCT06991881|OTHER|Biobank sampling for new biomarkers|Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies.
218921261|NCT06992206|OTHER|Metabolik taş analizi ile retrospektif gözlem|This study did not involve an active intervention. It retrospectively analyzed medical records of 506 patients who underwent compositional analysis of kidney stones to identify metabolic abnormalities. The aim was to evaluate stone composition in relation to metabolic parameters such as serum and 24-hour urine values, without modifying patient treatment.
218921262|NCT06991933|BEHAVIORAL|Plastination Model Group|"Model Specifications:~S10 silicone plastination models of brainstem structures (1:1 scale) with:~• Sectioned at 2mm intervals to reveal internal architecture"
218921263|NCT06991933|BEHAVIORAL|Traditional Methods Group|"1. Netter's Atlas of Human Anatomy (9th ed.)~2. Standardized PowerPoint lectures"
218921264|NCT06992388|OTHER|Manual Therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
218921265|NCT06992388|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
218921266|NCT06992388|OTHER|Tape elastic|The following intervention will be performed: application with an elastic band
219535034|NCT04472949|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
219535035|NCT02982694|DRUG|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
219535036|NCT02982694|DRUG|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
219535037|NCT06790966|COMBINATION_PRODUCT|Combination Treatment of PDS0101 and Pembrolizumab|"* Pembrolizumab (IV) every 3 weeks for up to 35 Cycles~* PDS0101 (SC) during Cycles 1, 2, 3, 4, and 12"
219535038|NCT06790966|DRUG|Pembrolizumab Monotherapy|Pembrolizumab (IV) every 3 weeks for up to 35 cycles.
219535039|NCT05090215|BEHAVIORAL|Aerobic and resistance training 12 week exercise programme|See arm/group description
219535040|NCT05090215|DIAGNOSTIC_TEST|Venous blood sampling|full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
219535041|NCT05090215|DIAGNOSTIC_TEST|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
219535042|NCT05090215|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
219535043|NCT05090215|BEHAVIORAL|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
218921267|NCT06992453|OTHER|Fecal microbiota transplantation (FMT)|Patients will receive a first donor FMT by colonoscopy, after a pre-conditioning with vancomycin and neomycin + bacitracin for 3 days, because data from our group show that pre-FMT antibiotics are associated with higher rates of microbial engraftment. Then they will receive two cycles, respectively after 3 and 7 days after colonoscopy - FMT, of frozen donor FMT capsules (15 capsules b.i.d. per 3 days). Patients will always receive feces from the same donor.
218921268|NCT06587581|OTHER|Control Group|Participants from the intervention group will receive the usual care over the 6-month intervention period
218921269|NCT06587581|OTHER|Intervention Group|Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
218921270|NCT06587867|BIOLOGICAL|efgartigimod|active drug efgartigimod to be administer
218921271|NCT06586502|OTHER|Model of Care|The intervention described in the RECOVER study involves developing, implementing, and evaluating a comprehensive Model of Care for childhood cancer survivors. This model, known as the RECOVER Model of Care, integrates digital health solutions and is co-designed with input from childhood cancer survivors, caregivers, and clinical experts. The intervention aims to address the long-term and late effects of cancer treatment by providing continuous, risk-based, interdisciplinary care. It includes steps such as identifying patients nearing the end of treatment, conducting health assessments, creating personalized care plans, and coordinating follow-up care through digital platforms. The study will assess the feasibility, acceptability, and effectiveness of this model in improving the quality of life and care experience for survivors and their families.
219535044|NCT06785948|DEVICE|active-tDCS|"2mA stimulation (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
219535045|NCT06785948|DEVICE|Sham-tDCS|"No intensity applied (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
219535046|NCT06321562|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye
219535047|NCT06321562|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
219535048|NCT04967833|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219535049|NCT04840589|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219535050|NCT04840589|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219535051|NCT04840589|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219535052|NCT04840589|PROCEDURE|Computed Tomography|Undergo a CT scan
218921272|NCT06587087|DEVICE|Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.|The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
219618363|NCT04064138|PROCEDURE|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
219535053|NCT04840589|BIOLOGICAL|Ipilimumab|Given IV
219535054|NCT04840589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219535055|NCT04840589|BIOLOGICAL|Nivolumab|Given IV
219535056|NCT04840589|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219535057|NCT04840589|PROCEDURE|X-Ray Imaging|Undergo x-ray
219535058|NCT06395129|DEVICE|Low dead-space syringes/needles|LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.
219535059|NCT06395129|DEVICE|Hepatitis C Antibody Rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
219535060|NCT06395129|DEVICE|HIV rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
219618364|NCT04064138|OTHER|General anesthesia|General anesthesia
218921273|NCT06590142|PROCEDURE|Observational study of tissue specimens|No intervention will be made
218921274|NCT06600841|DRUG|Immunotherapy（Adebrelimab）|Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
219366624|NCT00967265|BEHAVIORAL|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
219535061|NCT03687723|DEVICE|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
219618365|NCT00070031|DRUG|edotecarin|
219535062|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
219535063|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
219535064|NCT06154304|DRUG|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
219535065|NCT06154304|DRUG|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
219618366|NCT05696301|DEVICE|Winback® on|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated."
218921275|NCT06600841|DRUG|immunotherapy（Adebrelimab）|anti-PD-L1
218921276|NCT06593509|DEVICE|Maquet,Servo I.|Model number: 06487800, Serial Number: 19761, SKU#: Inv-00344191, Made in Sweden
219366625|NCT00967265|OTHER|Usual care|Usual care
218921277|NCT06593509|DEVICE|Vapotherm|INC ,100 domain drive Exeter, NH 03833, Made in U.S.A
218921278|NCT06593509|DEVICE|venturi mask|Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK.,REF. 1107085, LOT,31757961
218921279|NCT04574284|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
218921280|NCT04574284|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
219535066|NCT06154304|DRUG|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
219535067|NCT06154304|DRUG|Placebo|Placebo
219535068|NCT05059210|BEHAVIORAL|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
219535069|NCT05440643|BIOLOGICAL|Peanut SLIT-tablet|Peanut extract
219535070|NCT05440643|OTHER|Placebo|Placebo
219535071|NCT06795412|DRUG|PYX-201|Intravenous (IV) infusion.
219535072|NCT06795412|DRUG|pembrolizumab|IV infusion.
219535073|NCT05265624|BEHAVIORAL|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
219535074|NCT05265624|BEHAVIORAL|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
219535075|NCT03995966|BEHAVIORAL|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
219535076|NCT03995966|BEHAVIORAL|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
219618367|NCT05696301|DEVICE|Winback® off|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated."
219618368|NCT05696301|BEHAVIORAL|self-massage of the scar|The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
219618369|NCT05236205|PROCEDURE|Caries removal with a lowspeed drill|"1. Initial periapical and interproximal radiographs;~2. Prophylaxis with toothbrush and fluoride toothpaste;~3. Relative isolation with lip bumper, cotton roll, and aspirator;~4. Microbiological sampling with ear curette for standardization of volume of carious tissue;~5. Removal of carious dentin with carbide burs and manual instruments;~6. Additional microbiological sampling;~7. Clinical inspection of texture of remaining dentin with an exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
219618370|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~5. Second microbiological sample of remaining dentin with curette;~6. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~7. Restoration with glass ionomer cement;~8. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
219618371|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement;~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
218921281|NCT06999473|DEVICE|Virtual reality training|This training is built for the HMD Pico 4 Enterprise, which has six degrees of freedom, a 4k RGB display, a 101-degree field of view, and built-in eye-tracking hardware and software. The virtual environment is a 3-dimensional immersive environment in which the participant will be placed in three different virtual scenes: a picnic table, a kitchen, and a playground. This allows for the placement of stimuli in three different regions: near peripersonal (reaching) space, far peripersonal space, and extrapersonal (far) space. The goal of the game is to search for items that appear in front of the view, as accurately and quickly as possible.
218921282|NCT06999473|BEHAVIORAL|physiotherapy and occupational therapy|The conventional treatment consists of a problem-solving approach mainly based on the neurodevelopmental treatment approach. For VSN, the conventional treatment mainly consists of a mix of prism adaptation, visual scanning, and compensatory strategies based on the individual needs of the patient.
218921283|NCT06999473|DEVICE|Assessment|During assessments with SpatialSense, participants will sit in a wheelchair or on a straight-back chair. The trunk will be restricted to the chair. Finally, the data will be exported from SpatialSense and analyzed by investigators to define different search strategies while performing scanning tasks.
218921284|NCT06597708|BEHAVIORAL|keto diet|They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively.
218921285|NCT06597708|BEHAVIORAL|intermittent fasting with calorie restriction|The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period.
218921286|NCT06998862|DRUG|colchicine treatment in chronic kidney disease patients|colchicine treatment 0.5 mg/day
218921287|NCT06998862|DRUG|placebo treatment|placebo treatment 1 pill/day
219535077|NCT05809752|BIOLOGICAL|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
218921288|NCT06999291|BEHAVIORAL|Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)|The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.
218921289|NCT06999148|PROCEDURE|Sonodynamictherapy|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day1to day 5, followed by a 23-day rest period. Each cycle lasts 28 days. If well-tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
218921290|NCT06999148|DRUG|Radiotherapy plus temozolomide|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
219618372|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
219535078|NCT06794541|DRUG|Eravacycline 2mg/kg|intravenous (IV) infusion
219618373|NCT01279317|DIETARY_SUPPLEMENT|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
219618374|NCT01279317|DIETARY_SUPPLEMENT|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
219618375|NCT05902884|DEVICE|MSOT Acuity Echo|Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)
219366626|NCT00670826|DEVICE|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
219618376|NCT02133560|BEHAVIORAL|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
219618377|NCT02133560|BEHAVIORAL|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
219618378|NCT02133560|BEHAVIORAL|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
219618379|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
219618380|NCT06167499|OTHER|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
219618381|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
219618382|NCT04938310|DEVICE|support garment|A custom made support garment
219618383|NCT03779854|RADIATION|Total-Body Irradiation|Undergo TBI
219618384|NCT03779854|DRUG|Thiotepa|Given IV
219618385|NCT03779854|DRUG|Fludarabine|Given IV
219366627|NCT00670826|DEVICE|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
219366628|NCT01196442|OTHER|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
219535079|NCT06794541|DRUG|Eravacycline 1.5mg/kg|intravenous (IV) infusion
219535080|NCT02929303|DRUG|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
219535081|NCT04998604|DRUG|Dupilumab|solution for injection subcutaneous
219535082|NCT04998604|DRUG|Omalizumab|solution for injection subcutaneous
219618386|NCT03779854|DRUG|Cyclophosphamide|Given IV
219618387|NCT03779854|DRUG|Busulfan|Given IV
218921291|NCT06999603|DRUG|SNG001|SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing 0.65 mL of drug product solution containing 12 MIU/mL of IFNβ 1a.
218921292|NCT06999603|DRUG|Placebo|The placebo nebuliser solution is presented in glass syringes containing 0.65 mL of solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).
219535083|NCT04998604|DRUG|Placebo|solution for injection subcutaneous
219535084|NCT06834074|DRUG|NVL-655|Drug: NVL-655
218921293|NCT06998706|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
219535085|NCT04047628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|"1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
218921294|NCT06997913|COMBINATION_PRODUCT|Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）|The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.
218921295|NCT06999915|PROCEDURE|Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the test group, bone augmentation will be performed by adding biomaterial 3 mm beyond the Individual Phenotypical Dimension (IPD) to achieve over-contour augmentation. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth.
219366629|NCT01196442|OTHER|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
219535086|NCT04047628|BIOLOGICAL|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab"
219535087|NCT05022550|DEVICE|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
219366630|NCT00287742|DRUG|risperidone|
219366631|NCT01736904|DRUG|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
219535088|NCT04704661|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219366632|NCT01736904|DRUG|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
219366633|NCT01427309|BIOLOGICAL|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
219366634|NCT01427309|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
219366635|NCT06485193|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of archived diagnostic tissue samples.
219366636|NCT06028633|DRUG|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
219366637|NCT06028633|DRUG|lenvatinib|lenvatinib 8mg taken orally every day
219366638|NCT06028633|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
219535089|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219535090|NCT04704661|DRUG|Ceralasertib|Given PO
219535091|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219535092|NCT04704661|PROCEDURE|Echocardiography Test|Undergo ECHO
219535093|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219535094|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219535095|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219535096|NCT06465368|DRUG|PF-07220060|PF-07220060 given as tablet by mouth twice a day for 14 days.
219535097|NCT06465368|DRUG|letrozole|Letrozole given as tablet by mouth once a day for 14 days
219535098|NCT05073419|OTHER|Standard of Care|Routine monitoring of post AMI patient with clinic visits
219535099|NCT05073419|DEVICE|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
219535100|NCT05874479|DEVICE|Active PAC|The active PAC will contain HEPA filters inside the device.
219535101|NCT05874479|DEVICE|Sham PAC|The sham PAC will contain no HEPA filters inside the device.
219535102|NCT05828823|DEVICE|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
219535103|NCT05828823|OTHER|Hemodialysis thrice weekly|Conventional hemodialysis regimen
218921296|NCT06999915|PROCEDURE|Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the control group, bone augmentation will be performed by adding biomaterial up to the IPD line in order to achieve a contour augmentation with bone grafting remaining within the boundaries defined by the IPD. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth
219535104|NCT04613440|OTHER|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
218921297|NCT06586307|OTHER|quantitative analysis of DNA methylation at single-base resolution (QASM)|qPCR-based quantitative analysis for single-base methylation (QASM) The methylation percentage of each candidate CpG site was determined in multiple cohorts using a MethyLight-based QASM assay that has been developed and validated in our previous work. In short, the bisulfite-converted DNA was amplified, in which we exploited the locus-specific PCR primers flanking a pair of methylated and unmethylated probes labeled with the fluorescent dyes 6-carboxyfluorescein (6-FAM) and 2-chloro-7phenyl-1,4-dichloro-6-carboxyfluorescein (VIC), respectively. The methylation percentage was calculated by methylation/(methylation+unmethylation)×100%. QASM was performed using the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (Thermo).
218921298|NCT06591169|BEHAVIORAL|diet restriction and exercise|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes
218921299|NCT06591169|BEHAVIORAL|diet restriction|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily) and program of low diet intake
218921300|NCT06587048|PROCEDURE|periapical surgery|In piezo group, the periapical surgery will be performed using piezoelectric device.
218921301|NCT06587048|PROCEDURE|periapical surgery|In conventional bur group, the periapical surgery will be performed using rotary burs.
218921302|NCT05370495|DRUG|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
218921303|NCT05370495|DRUG|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
218921304|NCT05370495|DRUG|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
218921305|NCT05370495|DRUG|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
218921306|NCT02514083|DRUG|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
219535105|NCT04613440|OTHER|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
219618388|NCT03779854|PROCEDURE|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
218921307|NCT02514083|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
218921308|NCT06156514|DRUG|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
218921309|NCT06156514|DRUG|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
218921310|NCT06591494|DRUG|Classic quadruple therapy|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
218921311|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of bismuth|Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID
218921312|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of clarithromycin|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
219366760|NCT02524431|OTHER|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
219366761|NCT05274126|BEHAVIORAL|Patient group/Passvers|"Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness."
219535106|NCT04613440|OTHER|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
219535107|NCT04613440|OTHER|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
219535108|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
219618389|NCT03779854|DRUG|Tacrolimus|Given IV
219618390|NCT03779854|DRUG|Methotrexate|Given IV
218921313|NCT06601426|PROCEDURE|CSP|cold snare polypectomy
218921314|NCT06601985|PROCEDURE|J-pouch anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
218921315|NCT06601985|PROCEDURE|direct anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
218921316|NCT06585956|BEHAVIORAL|Comminication via Telemedicine|Comminication via Telemedicine With Patients
218921317|NCT06585956|BEHAVIORAL|Information|Informing the patient and their relatives
218921318|NCT01899040|DEVICE|neuromodulation for episodic migraine headache|
218921319|NCT03712358|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO.
218921320|NCT06778109|OTHER|hypnosis|T0) basal evaluation of physiological data T1) evaluation of physiological data after recollecting a negative memory for 3 minutes T2) evaluation of physiological data after that a brief session of hypnosis (performed with positive memories) T3) evaluation of physiological data recolling, for the second time, the negative memory.
218921321|NCT06771076|OTHER|Cream with CBD and natural ingredients|Topical application of the cream with CBD and natural ingredients on the injured areas, twice per day (after waking up, and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
218921322|NCT06771076|OTHER|Cream without CBD and natural ingredients|Topical application of the cream without CBD and natural ingredients on the injured areas, twice per day (after waking up and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
218921323|NCT05958251|OTHER|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
218921324|NCT05958251|OTHER|Standard Care (in control arm)|Standard care
218921325|NCT06896708|DRUG|Intensive lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation. If the target LDL-C level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
219366762|NCT06119880|DRUG|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
219535109|NCT05835141|OTHER|OCT Imaging|Each participant will receive imaging of the inferior sectors of the iridocorneal angle at 150°, and 180°, and 210° with the swept-source ANTERION AS-OCT system under standardized light and dark lighting conditions by a trained research technician
219535110|NCT00539071|DRUG|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
219535111|NCT00539071|DRUG|long acting injectable risperidone, Conventional Dose Group|Study dose remains 50 mg for the length of the study.
219535112|NCT00539071|DRUG|long acting injectable risperidone, High Dose Group|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
219535113|NCT06208163|PROCEDURE|Chiropractic|Chiropractic spinal adjustments
219535114|NCT00732563|DRUG|chemotherapy|Given IV and Orally
219535115|NCT00732563|PROCEDURE|lymphadenectomy|Removal of lymph nodes
218921326|NCT06896708|DRUG|Standard lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin, and the type and dosage of drugs can be adjusted according to the situation. If the target L-DLC level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
219366763|NCT06119880|OTHER|Routine treatment plan|Routine treatment plan without PERT
219366764|NCT02616913|OTHER|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
219535116|NCT00732563|PROCEDURE|neoadjuvant therapy|Tumor reduction
219535117|NCT00732563|PROCEDURE|quality-of-life assessment|Correlative Study
219535118|NCT00732563|PROCEDURE|therapeutic conventional surgery|Treatment for cancer
219366765|NCT02616913|OTHER|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
219366766|NCT02616913|OTHER|Placebo|Each subject consumes placebo in one of 3 treatment periods
219366767|NCT05779163|DRUG|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
219366768|NCT06544278|DIETARY_SUPPLEMENT|probiotic product|During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
219366769|NCT06544278|DIETARY_SUPPLEMENT|Maltodextrin|During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
219366770|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
219366771|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
218921327|NCT06134518|OTHER|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
218921328|NCT06134518|OTHER|the initial orientation from the PHCs|the initial orientation from the PHCs
219535119|NCT00732563|PROCEDURE|thoracic surgical procedure|removal of tissue
219535120|NCT00732563|RADIATION|fludeoxyglucose F 18|given IV
218921329|NCT05452863|DEVICE|O2matic administered oxygen|Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
218921330|NCT05452863|DEVICE|Manual oxygen supply and adjustments|Oxygen supply is adjusted from manual measurements of the oxygen saturation
218921331|NCT04684836|OTHER|Exposure to telemedicine, after the onset of the pandemic|The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
218921332|NCT04427813|BEHAVIORAL|questionaire to husband and wife|a form of questions will be asked to every partner
218921333|NCT02044640|PROCEDURE|Appendectomy|
218921334|NCT01963416|DIETARY_SUPPLEMENT|macro- and micro-nutrient matched control (240 ml)|
218921335|NCT01963416|DIETARY_SUPPLEMENT|Orange juice|
218921336|NCT01963416|DIETARY_SUPPLEMENT|whole orange fruit|
218921337|NCT01963416|DIETARY_SUPPLEMENT|Processed whole orange|
218921338|NCT00309491|DRUG|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
218921339|NCT00309491|DRUG|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
218921340|NCT05764447|BEHAVIORAL|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
218921341|NCT05764447|BEHAVIORAL|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
218921342|NCT02751723|OTHER|validated questionnaires|
218921343|NCT03821727|PROCEDURE|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
218921344|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
218921345|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
218921346|NCT04950647|DRUG|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
218921347|NCT04950647|DRUG|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
219366772|NCT03691415|DRUG|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
219366773|NCT00634231|BIOLOGICAL|AdV-tk|
219366774|NCT00634231|DRUG|valacyclovir|
219366775|NCT00634231|RADIATION|Radiation|
219535121|NCT00732563|RADIATION|radiation therapy|undergoing radiotherapy
219535122|NCT05757414|DEVICE|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
219535123|NCT05757414|DEVICE|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
219535124|NCT03674814|DRUG|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
219535125|NCT03674814|DRUG|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
219535126|NCT06308055|OTHER|Data Acquisition|Develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module.
219535127|NCT05029882|DRUG|ABBV-400|Intravenous (IV) Infusion
219366776|NCT02644408|DRUG|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
219366777|NCT02644408|RADIATION|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
219366778|NCT02644408|OTHER|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
219366779|NCT05373238|PROCEDURE|Early discharge|Early discharge
219535128|NCT05029882|DRUG|Trifluridine/Tipiracil|Oral Tablet
218921348|NCT04950647|DRUG|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
218921349|NCT06137417|DEVICE|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
218921350|NCT03714958|DRUG|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
218921351|NCT03714958|DRUG|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
218921352|NCT02937116|DRUG|IBI308|
218921353|NCT02937116|DRUG|IBI308\Cisplatinum\Pemetrexed|
218921354|NCT02937116|DRUG|IBI308\cisplatin\gemcitabine|
218921355|NCT02937116|DRUG|IBI308\oxaliplatin\capecitabine|
218921356|NCT02937116|DRUG|IBI308\etoposide\cisplatin|
218921357|NCT02937116|DRUG|IBI308\irinotecan\5-FU|
218921358|NCT05403346|DEVICE|CoviDx™ Covid-19 Antigen Self-Test|All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing
219535129|NCT05029882|DRUG|Bevacizumab|IV Infusion
219535130|NCT00467896|DRUG|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
219535131|NCT00467896|DRUG|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
219535132|NCT03772522|BEHAVIORAL|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
219618391|NCT03779854|PROCEDURE|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
219618392|NCT03779854|PROCEDURE|Echocardiography|Undergo ECHO
218921359|NCT06523361|DEVICE|H'ability|H'ability is introduced depending the randomization result, during the baseline (before session 4, 5, 6 or 7 with occupational therapist
218921360|NCT04122716|DRUG|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
218921361|NCT04122716|BEHAVIORAL|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
218921362|NCT05663606|COMBINATION_PRODUCT|Happy Bob|Application, which gives stars when subject reachs Time In Range
218921363|NCT05663606|DEVICE|CGM|Dexcom CGM
218921364|NCT00966134|OTHER|exposure to high altitude|
218921365|NCT00740311|DEVICE|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
219535133|NCT06045598|OTHER|Semmes Weinstein Monofilament Test|The 10 g Semmes-Weinstein monofilament assessment (SWME) is used to assess sensory loss and screen for diabetic neuropathy. In our study, the evaluation will be made on the plantar surfaces of the 1st fingers, the plantar surfaces of the 1st, 3rd, and 5th metatarsal heads, and the plantar surfaces of the heel in the right and left feet. The first force value felt will be taken as the evaluation data.
219618393|NCT03779854|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219618394|NCT03779854|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219618395|NCT03779854|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219618396|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219618397|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219618398|NCT03700138|DRUG|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
219618399|NCT03700138|DRUG|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
219618400|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
219618401|NCT03428958|DRUG|NUC-3373 + leucovorin|NUC-3373 + leucovorin
219618402|NCT03428958|DRUG|NUC-3373|NUC-3373
219618403|NCT03428958|DRUG|NUFOX|NUC-3373 + oxaliplatin
219618404|NCT03428958|DRUG|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
219618405|NCT03428958|DRUG|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
218921366|NCT04056390|PROCEDURE|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
219535134|NCT06045598|OTHER|Proprioception measurement|"Ankle proprioception will be measured with the participant's knees lying on their back in a semi-flexed position. The test will be performed for 10 degrees of dorsiflexion and 20 degrees of plantar flexion, respectively. Measurements will be made with an electrogoniometer device. The difference between the required degree and the degree in the position brought by the participant will be taken as evaluation data.~Lumbal region proprioception measurement will be made with lumbar flexion and extension movements. The participant will be asked to perform active lumbar flexion. Then, lumbar flexion movement will be performed up to 50% of the measured active flexion angle and it will be requested to stay in this position for 10 seconds. After the participant returns to the upright position, he will be asked to come back to the learned angle and the difference in angle will be taken as evaluation data. The same procedure will be done for the lumbar extension movement."
219535135|NCT06045598|OTHER|Postural control assessment|"Postural control evaluation will be done with the Gyko-Microgate software. Bluetooth data transmission enables real-time measurements to be transferred directly to the computer. After the device was placed on the body of the person thanks to the wearable vest, a connection was established with the software on the computer.~To evaluate postural control, with eyes open, eyes closed and eyes open on a hard surface, accompanied by a cognitive dual task; On soft ground, with eyes open, eyes closed and eyes open, the person is asked to remain in a stable balance for 30 seconds, accompanied by a cognitive dual task. For the cognitive dual task, two countdowns and K-A-S verbal fluency exercises will be performed in each assessment. As a result of each evaluation, data on ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained."
219535136|NCT06045598|OTHER|Dynamic balance assessment|Dynamic balance evaluation will be done with the Gyko device. To evaluate dynamic balance, walking with eyes open on hard ground, walking with cognitive dual task on hard ground; walking with eyes open on soft ground, and cognitive dual task on soft ground will be evaluated. The walking distance is determined as 6 meters. The first 1 meter and the last 1 meter will not be taken into consideration. The measurement will start at the 1st meter and end at the 5th meter. The measurement will be carried out at a distance of 4 meters. As a cognitive task, the participants will be given the task of counting down by two and K-A-S verbal fluency. As a result of each evaluation, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained.
219535137|NCT06045598|OTHER|Timed Up and Go Test|"The Timed Get Up and Walk Test is used to assess balance and fall risk. The participant stands up from the chair, walks 3 meters, turns back, and sits back on the chair. The time elapsed during these phases was recorded.~In our study, the patient will be asked to start the test after the Gyko device is fixed with a wearable vest. During the test, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be taken."
219535138|NCT06045598|OTHER|Montreal Cognitive Assessment|MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.
219535139|NCT03616730|DIAGNOSTIC_TEST|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
219535140|NCT02199665|DRUG|selinexor|Given PO
219535141|NCT02199665|DRUG|carfilzomib|Given IV
219535142|NCT02199665|DRUG|dexamethasone|Given PO or IV
219535143|NCT06445062|DRUG|RMC-6236|Oral tablet
219535144|NCT06445062|DRUG|mFOLFOX6 regimen|IV infusion
219535145|NCT06445062|DRUG|bevacizumab|IV infusion
219535146|NCT06445062|DRUG|mFOLFIRINOX regimen|IV infusion
219535147|NCT06445062|DRUG|cetuximab|IV infusion
219535148|NCT06445062|DRUG|gemcitabine|IV infusion
219535149|NCT06445062|DRUG|nab-paclitaxel|IV infusion
219535150|NCT06445062|DRUG|RMC-9805|Oral Tablet
219618406|NCT03428958|DRUG|NUFIRI|NUC-3373 + irinotecan
219618407|NCT03428958|DRUG|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
219618408|NCT03428958|DRUG|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
219618409|NCT03428958|DRUG|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
219618410|NCT06167434|DEVICE|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
219618411|NCT03874117|OTHER|Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis|Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
219618412|NCT03874117|OTHER|Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis|Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
219618413|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
219618414|NCT02971501|BIOLOGICAL|Bevacizumab|Given IV
219618415|NCT02971501|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219618416|NCT02971501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219618417|NCT02971501|PROCEDURE|Computed Tomography|Undergo CT scan
219618418|NCT02971501|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219618419|NCT02971501|DRUG|Osimertinib|Given PO
219618420|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
219618421|NCT05660109|OTHER|Placebo|Placebo
219618422|NCT04969133|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
218921367|NCT05128916|BIOLOGICAL|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
218921368|NCT05128916|DRUG|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
218921369|NCT03517878|BEHAVIORAL|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
218921370|NCT03008434|OTHER|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
218921371|NCT05650385|DRUG|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
218921372|NCT01699438|DRUG|Mesalazine|2400 mg q.d. for 8 weeks
218921373|NCT01699438|DRUG|Placebo|3 tablets q.d. for 8 weeks
218921374|NCT00104286|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
218921375|NCT04349332|DEVICE|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate \<30breaths/min and PaO2 \>75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
219618423|NCT05534269|BIOLOGICAL|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
218921376|NCT04053660|PROCEDURE|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
218921377|NCT04643210|BEHAVIORAL|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
219535151|NCT04487158|BEHAVIORAL|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
219535152|NCT04487158|BEHAVIORAL|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
219535153|NCT03699696|DRUG|Propofol|Induction of anesthesia prior to surgery with propofol
219535154|NCT03651804|PROCEDURE|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
219535155|NCT03651804|DRUG|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
219535156|NCT03651804|DRUG|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
219535157|NCT03651804|DRUG|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
219535158|NCT03651804|BEHAVIORAL|Physical therapy|Physical Therapy.
219618424|NCT05757700|BIOLOGICAL|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"
218921378|NCT04643210|OTHER|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
219618425|NCT05721937|DRUG|Abrocitinib|taken by mouth
218921379|NCT04626908|DRUG|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
219618426|NCT03018288|DRUG|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
219618427|NCT03018288|BIOLOGICAL|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
219618428|NCT03018288|DRUG|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
219618429|NCT03018288|OTHER|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
219618430|NCT03018288|PROCEDURE|Surgery|Tissue for vaccine production and neo-epitope monitoring.
219618431|NCT05681481|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
219618432|NCT05681481|DRUG|Prednisone|Oral Prednisone
219618433|NCT06031194|OTHER|Non-Interventional Study|Non-interventional study
219618434|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
219618435|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
219618436|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
219535159|NCT03651804|DRUG|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
219535160|NCT03399214|DRUG|IOP Injection|T1 and T2
219535161|NCT02175095|DRUG|Regorafenib|Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
219618437|NCT05785494|OTHER|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
219535162|NCT02175095|DIAGNOSTIC_TEST|[18F]FLT-PET|\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
219618438|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Active|The patients will be treated with cTBS and usual medical treatment after endovascular treatment
219618439|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Sham|The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
219618440|NCT05878730|DIAGNOSTIC_TEST|urine collection|"* Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~* at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~* Measure of 6-SMT will be made by a validated radio-immunology assay"
219618441|NCT05878730|DIAGNOSTIC_TEST|Level of Proteins|"* blood sample at V2 (2x3.5mL citrate tubes)~* measured by ELISA"
219618442|NCT05878730|DIAGNOSTIC_TEST|Level of mRNA and miRNA|"* blood sample at V2 (2x2.5mL PAX-gene tube)~* measured by quantitative RT-PCR"
219618443|NCT05878730|DIAGNOSTIC_TEST|Level of plasmatic and intraerythrocytic lithium|"* blood sample at V2 (mmol/L)~* 4mL EDTA tube"
219618444|NCT05293366|DIAGNOSTIC_TEST|Assessments of endocrinological phenotypes of LO-COCO patients|Assessment of:thyroid-stimulating hormone(TSH),free triiodothyronine (FT3), free thyroxine (FT4),calcitonin,antibodies against thyroglobulin (AbTG) and against thyroperoxidase (AbTPO),adrenocorticotropic hormone (ACTH),cortisol, luteinizing hormone (LH),follicle-stimulating hormone(FSH),Testosterone,17-beta estradiol,sex hormone binding globulin (SHBG),progesterone, prolactin (PRL), growth hormone (GH), insulin growth factor-1 (IGF-1), dehydroepiandrosterone sulphate (DHEAS),delta 4-androstenedione,aldosterone,renin,glycemia, insulinemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, vitamin D, adiponectin, irisin, IL-6.Thyroid and ovarian ultrasounds, pituitary and adrenal MRI will be performed as well. Body composition will be assessed with bioimpedance analysis and DXA scans.Female sexual dysfunctions will be evaluated with Female Sexual Function Index (FSFI), Sexual Inhibition and Sexual Excitation Scale (SIS/SES),Body Uneasiness Test (BUT).
219618445|NCT05293366|DIAGNOSTIC_TEST|Assessment of muscular phenotypes of LO-COCO patients|Questions will be collected regarding the tolerance to physical activity and modifications after diagnosis of Covid. Muscular strength will be assessed by means of tests (Medical Research Council Scale) and dynamometers. Balance will be assessed with a Romberg test, tolerance to stress will be assessed by means of cyclometer.
219618446|NCT05293366|DIAGNOSTIC_TEST|Assessment of neuropsychiatric phenotypes of LO-COCO patients|Validated questionnaires will be collected to investigate depression (Beck Depression Inventory-II, BDI-II), apathy (Apathy Evaluation Scale, AES), anxiety (Test Anxiety Inventory, TAI), attention and cognitive functions (Montreal Cognitive Assessment and Quick Mild Cognitive Impairment). Fatigue will be assessed by Fatigue Rating Scale (FRS) and Fatigue Severity Scale (FSS). Muscle power will be assessed by six-minute walking test and sit and stand up test. The presence of myopathy will be evaluated by mean electrophysiological study.
218921380|NCT02208310|DRUG|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
218921381|NCT02208310|DRUG|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
219535163|NCT02175095|DIAGNOSTIC_TEST|[18F]FDG-PET|\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
219535164|NCT06206031|DEVICE|Intraosseous ultrasonography at tibia before, during, and after a physiological vascular stimulation (venous occlusions, arterial occlusion, handgrip)|"Timing for sub-protocol 1 (performed twice with 2-to-10-day interval): donning in supine position - rest 5 minutes - venous occlusion to 40 mmHg 3 minutes - rest 10 minutes - arterial occlusion to 200mmHg 2 minutes - post-occlusion period 10 minutes - rest 10 minutes - static handgrip 30% Maximum Voluntary Force 3 minutes - recovery 2 minutes and doffing.~Timing for sub-protocol 2 (performed once). First, two sequences of intraosseous ultrasonography are performed in 45° head-up tilt position, with 10-minutes rest between sequences: donning and rest 5 minutes - occlusion to 80 mmHg 2 minutes - rest 10 minutes - occlusion to 180 mmHg 2 minutes - rest 10 minutes. During the first sequence, ultrasonography probe is positioned between middle and lower third of tibia for cortical bone measurement; during the second - at distal epiphysis of the tibia for trabecular bone measurement. After ultrasonography, subject is sitting down for 10 minutes for computed tomography."
219535165|NCT05052801|DRUG|Bemarituzumab|Intravenous (IV) infusion
218921382|NCT05483777|PROCEDURE|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
218921383|NCT05322681|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
218921384|NCT03510546|DRUG|Pyridostigmine|Study dose as per protocol.
219535166|NCT05052801|DRUG|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
219535167|NCT05052801|DRUG|Placebo|IV infusion
218921385|NCT03510546|DRUG|Placebo oral capsule|Study dose as per protocol.
218921386|NCT02141295|DRUG|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
218921387|NCT02141295|DRUG|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
218921388|NCT02141295|DRUG|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
218921389|NCT02141295|DRUG|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
218921390|NCT02141295|DRUG|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
218921391|NCT03902977|PROCEDURE|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
219535168|NCT06561074|DRUG|Decitabine|Given by vein
219535169|NCT06561074|DRUG|Venetoclax|Given by mouth
219535170|NCT06561074|DRUG|Calaspargase pegol-mknl|Given by vein
219535171|NCT02408367|BEHAVIORAL|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
219535172|NCT02408367|BEHAVIORAL|Relaxation|30
219535173|NCT04914663|BEHAVIORAL|Exercise training|Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
219535174|NCT03563248|DRUG|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
219535175|NCT03563248|DRUG|Losartan|Losartan is a drug that is used to lower blood pressure
219535176|NCT03563248|DRUG|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
219535177|NCT03563248|RADIATION|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
219535178|NCT03563248|PROCEDURE|Surgery|definitive surgical resection
219535179|NCT04699084|OTHER|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
219535180|NCT05283629|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
219535181|NCT05283629|BEHAVIORAL|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
219535182|NCT04701983|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
219535183|NCT04701983|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
219618447|NCT05293366|PROCEDURE|Muscle biopsy|Muscle biopsy will be performed upon need.
219618448|NCT05293366|DIAGNOSTIC_TEST|Assessment of pulmonary phenotypes of LO-COCO patients|Modified Medical Research council questionnaire will be administered for evaluating of the dyspnoea level. Complete respiratory status assessment, including global spirometry, CO lung diffusion capacity and arterial gases analysis will be run. HRCT - high resolution CT scan of the chest - will be performed in selected cases to rule out the eventual sequelae of SARS-Cov2 related pneumonia.
218921392|NCT03902977|PROCEDURE|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
218921393|NCT01710501|DRUG|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
218921394|NCT01710501|BIOLOGICAL|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
218921395|NCT01710501|DRUG|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
218921396|NCT01710501|DRUG|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
218921397|NCT06185543|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
218921398|NCT06185543|DRUG|Placebo|Placebo matches active drug in size, color and taste
218921399|NCT02536976|DRUG|mirabegron|
218921400|NCT02536976|DRUG|Placebo|
218921401|NCT03986086|DRUG|MPH966|RP2D tablet
218921402|NCT03986086|DRUG|Placebo|MPH966 placebo table
218921403|NCT03053817|OTHER|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
218921404|NCT00071890|DRUG|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
218921405|NCT00071890|DRUG|HAART|HAART from week 0 to week 24
219535184|NCT06141408|BEHAVIORAL|MPowerment PrEP Promotion Intervention|"In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection, promoting self-acceptance of sexual identity, teaching skills for navigating healthcare, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour activities focused on the aforementioned goals."
219535185|NCT01344291|DRUG|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
219535186|NCT04175613|DRUG|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
219535187|NCT06121219|DEVICE|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
219535188|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
219535189|NCT04756245|BEHAVIORAL|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
219535190|NCT04756245|BEHAVIORAL|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
219535191|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
218921406|NCT00071890|DRUG|Treatment interruption|HAART is interrupted from week 24 in both arms
218921407|NCT00301314|PROCEDURE|Autologous stem cell transplant|
218921408|NCT01671319|DRUG|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
218921409|NCT01709084|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
218921410|NCT01709084|DRUG|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
218921411|NCT01709084|DRUG|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
219535192|NCT05911165|OTHER|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
219535193|NCT05911165|OTHER|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
219535194|NCT05574777|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
219535195|NCT05409625|DEVICE|Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)|Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
219535196|NCT05409625|DEVICE|Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)|Intraoral camera used for caries detection in the occlusal and proximal surfaces.
218921412|NCT01709084|DRUG|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
218921413|NCT01955252|DRUG|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
219535197|NCT05409625|DEVICE|X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)|X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
219535198|NCT05409625|PROCEDURE|Oral cleaning|Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
218921414|NCT02144610|BIOLOGICAL|HGF Plasmid (AMG0001)|IM
219535199|NCT03697109|DRUG|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
219618449|NCT05293366|DIAGNOSTIC_TEST|Assessment of cardiological phenotypes of LO-COCO patients|Cardiological assessment will be run upon data collected from: Short Form-36 Health Survey (SF36), echocardiogram at rest and during stress tests, six-minute walking test, N-terminal fragment brain natriuretic peptides (NT-proBNP)
219535200|NCT03697109|OTHER|Placebo|Placebo matched to study drug
219535201|NCT06849700|OTHER|Active gamification|"The experimental group participated in a physical exercise program for primary school children, with 45-minute sessions three times a week, including warm-up, main activities, and awards. Designed to enhance engagement through game mechanics, the program progressed in three phases: Explorers in Action (Weeks 1-4) focused on coordination, agility, and teamwork with games like Conquering Territories; Movement Heroes (Weeks 5-8) emphasized endurance, collaboration, and strategy through activities like Quest for the Gems; and Health Guardians (Weeks 9-12) incorporated strength, planning, and teamwork challenges, culminating in a final integrated skills circuit. The program promoted continuous improvement in physical and cooperative abilities."
219618450|NCT05293366|DIAGNOSTIC_TEST|Assessment of vascular phenotypes of LO-COCO patients|The assessment of the potential post-thrombotic vascular damage will comprise the investigation of prevalence of previously unknown deep venous thrombosis by ultrasonography.
219618451|NCT05293366|DIAGNOSTIC_TEST|Assessment of dermatological phenotypes of LO-COCO patients|Dermatology evaluation will account on: thrichoscopy, dermoscopy, onychoscopy and capillaroscopy, confocal microscopy, skin ultrasonography
219618452|NCT05293366|PROCEDURE|Tissue biopsy|Tissue biopsy will be performed upon need.
218921415|NCT02144610|BIOLOGICAL|Matching Placebo|IM
219535202|NCT04935177|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
219535203|NCT04935177|PROCEDURE|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
219535204|NCT04935177|DRUG|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
219535205|NCT04935177|DRUG|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
219535206|NCT04935177|DRUG|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
219535207|NCT04935177|OTHER|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
219535208|NCT05116176|DEVICE|Implantable cardioverter-defibrillators|500 patients age \>65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
219535209|NCT06268418|OTHER|Artificial intelligence|Segmentation
219535210|NCT01056666|DEVICE|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
219535211|NCT01056666|DEVICE|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
219535212|NCT00834522|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
219535213|NCT00834522|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
219535214|NCT02517684|DRUG|Infliximab|
219535215|NCT02517684|DRUG|Prednisolone|
219535216|NCT02517684|OTHER|Exclusive enteral nutrition|
219535217|NCT02517684|DRUG|Azathioprine|
219535218|NCT03610113|DEVICE|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
219535219|NCT00283361|DRUG|ZP120|
219535220|NCT00283361|PROCEDURE|I.v. catherization|
219535221|NCT00283361|PROCEDURE|6-minutes walk performance|
219535222|NCT00283361|BEHAVIORAL|Dyspnea severity assessment|
219535223|NCT00283361|PROCEDURE|Blood sampling for laboratory tests|
219618453|NCT05975333|BEHAVIORAL|Writing|Participants will be asked to write about their experiences with cancer, guided by several specific open-ended writing prompts to spark ideas.
219618454|NCT05975333|BEHAVIORAL|Interview|Following completion of the writing exercise, participants will reflect on their experiences with the writing intervention in a semi-structured private interview with a member of the research team.
219618455|NCT06434909|DRUG|Cytalux™ (pafolacianine) for fluorescent imaging|"Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system."
219618456|NCT06434909|PROCEDURE|Image Guided Surgery|prostatectomy using appropriate imaging system
219618457|NCT04859296|DRUG|Placebo|Vaporized placebo
219618458|NCT04859296|DRUG|Low CBG|Vaporized CBG (5 mg)
219618459|NCT04859296|DRUG|High CBG|Vaporized CBG (15 mg)
219618460|NCT04859296|DRUG|Low THC|Vaporized THC (5 mg)
218921416|NCT03290885|COMBINATION_PRODUCT|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
218921417|NCT03290885|DEVICE|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
218921418|NCT02644499|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
218921419|NCT02644499|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
218921420|NCT02644499|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
218921421|NCT02644499|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
218921422|NCT02644499|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
219535224|NCT00283361|PROCEDURE|ECG|
219535225|NCT00283361|PROCEDURE|Physical examination|
219535226|NCT05246462|OTHER|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
219535227|NCT03232619|BIOLOGICAL|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.
219535228|NCT01816997|DRUG|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
219535229|NCT01816997|DRUG|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
219535230|NCT01816997|DRUG|Control|placebo
219535231|NCT06441097|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
219535232|NCT06441097|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
219535233|NCT06441097|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219535234|NCT06441097|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219535235|NCT06441097|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
219535236|NCT06441097|DRUG|Acalabrutinib|Acalabrutinib PO will be administered as per the schedule specified in the respective arm.
218921423|NCT04280250|OTHER|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
218921424|NCT04280250|OTHER|Control condition|Psychoeducational self-help sheet
218921425|NCT01288885|DRUG|ASP1941|Oral
218921426|NCT01288885|DRUG|Placebo|Oral
218921427|NCT01054885|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
219535237|NCT06441097|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
219535238|NCT06441097|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
219535239|NCT05557747|OTHER|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
219535240|NCT05557747|OTHER|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
219535241|NCT05557747|OTHER|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
219535242|NCT02209571|OTHER|Venous blood markers|Routine venous blood sampling
219535243|NCT01181622|DRUG|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
219535244|NCT01181622|DRUG|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
219535245|NCT03612960|DRUG|Very low nicotine content cigarettes|Very low nicotine content cigarettes
219535246|NCT03612960|DRUG|Normal nicotine content cigarettes|Normal nicotine content cigarettes
218921428|NCT01054885|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
218921429|NCT01054885|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
218921430|NCT01054885|DRUG|Placebo|Placebo
218921431|NCT00545454|DRUG|SSR150106|
219535247|NCT00991965|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
219535248|NCT05214924|BIOLOGICAL|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
219535249|NCT05214924|BIOLOGICAL|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
219618461|NCT04859296|DRUG|High THC|Vaporized THC (15 mg)
219618462|NCT05226507|DRUG|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
219618463|NCT06271850|OTHER|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
219618464|NCT06271850|OTHER|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
219618465|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219618466|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
219618467|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
219618468|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219618469|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
219618470|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided tumor biopsy
219618471|NCT01922037|DRUG|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
219618472|NCT03242850|BEHAVIORAL|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
219618473|NCT02068508|DRUG|Pioglitazone|Pioglitazone Tablets
219618474|NCT00004789|DRUG|heme arginate|
218921432|NCT00545454|DRUG|Placebos|
218921433|NCT04669626|OTHER|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with Octenilin® on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with Octenilin®~* Application of new dressing (according to the wound healing phases, medical prescription)"
218921434|NCT04669626|OTHER|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
219618475|NCT00004789|DRUG|tin mesoporphyrin|
219618476|NCT05110417|DRUG|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
219618477|NCT05502939|BEHAVIORAL|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
219618478|NCT05502939|BEHAVIORAL|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
219618479|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
219618480|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
219618481|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
219618482|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
219618483|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
218921435|NCT01453218|DRUG|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
218921436|NCT01639378|PROCEDURE|Renal Denervation|Symplicity Catheter System
218921437|NCT03056508|BEHAVIORAL|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
218921438|NCT03056508|BEHAVIORAL|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
218921439|NCT05558202|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
218921440|NCT03714152|DRUG|ABI-H2158|5 mg or 25 mg tablets
218921441|NCT03714152|DRUG|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
218921442|NCT02169427|DRUG|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
218921443|NCT05360121|OTHER|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
219535250|NCT05502250|DRUG|gemcitabine, cisplatin and tislelizumab|"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
219535251|NCT01566617|OTHER|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
219535252|NCT01566617|OTHER|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
219535253|NCT06795087|OTHER|Opioid Medication Disposal Education|Education on opioid medication disposal will be provided in the form of a pamphlet created by Atrium Health based on FDA resources and will be given to all participants at discharge (cystectomy, nephrectomy, prostatectomy) beginning in the second year, approximately 13 months from when the first participant is enrolled or until a minimum of 100 evaluable participants are enrolled in the pre-education cohort, whichever occurs last.
219535254|NCT01111461|DRUG|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
219535255|NCT02023229|DIETARY_SUPPLEMENT|Branched-chain aminoacids|
219535256|NCT02023229|OTHER|High-fiber high protein diet|
219535257|NCT05750394|PROCEDURE|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
219535258|NCT05750394|DEVICE|Suture Type|Barbed or smooth
219535259|NCT05750394|PROCEDURE|Endometrium|Included or excluded
219535260|NCT00784472|DRUG|oxycodone|intravenous according to patients weight, pn.
219535261|NCT00784472|DRUG|morphine|intravenous administration according to patients weight, pn.
219535262|NCT06119763|DIAGNOSTIC_TEST|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
219535263|NCT01022463|DRUG|Ivabradine|Ivabradine 5 mg BId for 4 weeks
219535264|NCT01022463|DRUG|Atenolol|50 mg od for 4 weeks
219535265|NCT03890796|BEHAVIORAL|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
219535266|NCT03890796|BEHAVIORAL|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
219535267|NCT01415232|DEVICE|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
219535268|NCT01112254|PROCEDURE|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
219535269|NCT00440518|DRUG|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
218921444|NCT05360121|OTHER|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
218921445|NCT05360121|OTHER|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
218921446|NCT05360121|OTHER|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
219618484|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
218921447|NCT05360121|OTHER|Back strengthening exercises|"1. Supine Abdominal Draw In~2. Supine Butt Lift with Arms at Side~3. Abdominal Draw In with Heel Slide~4. Abdominal Draw In with Knee to Chest~5. Abdominal Draw In with feet on the ball~6. Abdominal Draw In with feet on the ball- add movement"
218921448|NCT05360121|OTHER|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
219535270|NCT00440518|OTHER|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
218921449|NCT06342505|PROCEDURE|Venipunctures|Extra venipunctures
218921450|NCT01112839|BEHAVIORAL|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
219535271|NCT00440518|DRUG|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
219535272|NCT05901870|OTHER|Questionnaire administration|All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
218921451|NCT01112839|BEHAVIORAL|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
218921452|NCT00214201|DRUG|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
218921453|NCT00274729|BEHAVIORAL|Mono Unsaturated Fatty Acids in Obesity|
219535273|NCT00272779|DRUG|ATV|300mg Oral capsules for 96 weeks
219535274|NCT00272779|DRUG|RTV|100mg Oral Capsules for 96 weeks
219535275|NCT00272779|DRUG|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
219535276|NCT00272779|DRUG|LPV|400 mg (3 133mg capsules) BID for 96 weeks
219535277|NCT00271752|PROCEDURE|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
219535278|NCT00003015|DRUG|carboplatin|
219618485|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
219618486|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
219618487|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
219618488|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
219618489|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
218921454|NCT05022732|DIETARY_SUPPLEMENT|Polyglucosamine L112|750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients
218921455|NCT05022732|COMBINATION_PRODUCT|Placebo|excipients and gum arabic
218921456|NCT03944317|DRUG|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
218921457|NCT03944317|DRUG|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
218921458|NCT03038828|BIOLOGICAL|Leukocyte Interleukin, Injection|Immunotherapy
219535279|NCT00003015|DRUG|vincristine sulfate|
219535280|NCT00003015|PROCEDURE|conventional surgery|
219535281|NCT00003015|RADIATION|radiation therapy|
219535282|NCT06597370|OTHER|Gene expression mRNA of IgG anti-spike|"b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance."
219535283|NCT04700787|DRUG|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
219535284|NCT00561015|DRUG|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
219535285|NCT00561015|DRUG|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
219535286|NCT00561015|DRUG|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
219535287|NCT02440711|DEVICE|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
218921459|NCT04667130|BEHAVIORAL|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
218921460|NCT00006206|DRUG|naltrexone (Revia)|
218921461|NCT00006206|DRUG|acamprosate (Campral)|
218921462|NCT02442388|PROCEDURE|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
218921463|NCT02442388|PROCEDURE|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
218921464|NCT02442388|PROCEDURE|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
218921465|NCT04220541|BEHAVIORAL|Motor learning based exercise|Symptomatic exercise
219366780|NCT02521155|BEHAVIORAL|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
219535288|NCT02440711|DEVICE|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
219535289|NCT01980771|BEHAVIORAL|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
219535290|NCT01980771|BEHAVIORAL|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
219535291|NCT02373397|DEVICE|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
219535292|NCT02373397|DEVICE|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
219535293|NCT04435197|DRUG|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
219535294|NCT05155683|DEVICE|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
219535295|NCT05155683|DEVICE|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, \<8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
219535296|NCT05155683|DEVICE|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
219535297|NCT02277847|DRUG|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
219535298|NCT02277847|DRUG|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
219535299|NCT01196572|PROCEDURE|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
219535300|NCT04297891|OTHER|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
219535301|NCT04297891|OTHER|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
219535302|NCT04297891|OTHER|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
219535303|NCT04297891|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
219535304|NCT05232786|OTHER|No treatment given|No treatment given
219535305|NCT02311686|DIETARY_SUPPLEMENT|10 g ethanol|Alcohol single oral dose
219535306|NCT02311686|DIETARY_SUPPLEMENT|20 g ethanol|Alcohol single oral dose
219535307|NCT02311686|DIETARY_SUPPLEMENT|40 g ethanol|Alcohol single oral dose
219535308|NCT02311686|DIETARY_SUPPLEMENT|60 g ethanol|Alcohol single oral dose
219535309|NCT02311686|DIETARY_SUPPLEMENT|80 g ethanol|Alcohol single oral dose
219535310|NCT06185322|OTHER|Physical therapy program with upper cross syndrome specific exercises|Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.
219535311|NCT06185322|OTHER|Physical therapy program with conventional neck strengthening exercises|Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
219535312|NCT00163657|DRUG|Daclizumub|anti-rejection drug
219618490|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
219618491|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
219535313|NCT00163657|DRUG|Tacrolimus|anti rejection drug
219535314|NCT00163657|DRUG|Cyclosporine|anti rejection drug
218921466|NCT02256280|DRUG|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
219535315|NCT00163657|DRUG|MMF|anti rejection drug
219535316|NCT04490005|OTHER|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
219535317|NCT04485767|BEHAVIORAL|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
219535318|NCT04485767|BEHAVIORAL|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
219535319|NCT04559503|OTHER|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
219535320|NCT03532035|DRUG|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
219535321|NCT03532035|DRUG|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
219535322|NCT00387686|DRUG|rhBMP-2/CPM|
219535323|NCT00387686|DRUG|rhBMP-2/CPM|
219535324|NCT00387686|DRUG|rhBMP-2/CPM|
219535325|NCT00387686|DRUG|rhBMP-2/CPM|
219535326|NCT05084625|OTHER|Digitized support|Access to information about the disease, treatment, side effects and self-care
219618492|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
219618493|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
218921467|NCT02256280|DRUG|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
218921468|NCT03674905|PROCEDURE|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
218921469|NCT03674905|PROCEDURE|Peripheral nerve block|Pre-operative peripheral nerve block.
218921470|NCT01764880|DRUG|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
219204759|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
219535327|NCT05350917|DRUG|Tislelizumab|"Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
219535328|NCT02984696|DRUG|1 mg of transdermal estradiol daily and 10mg of oral MPA|
219535329|NCT03904381|DRUG|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
219535330|NCT03904381|PROCEDURE|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
219535331|NCT03904381|PROCEDURE|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
219618494|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
219535332|NCT01215279|DRUG|AZD2423|100 mg oral treatment once daily for 28 days
219535333|NCT01215279|DRUG|Placebo to AZD2423|Oral treatment once daily for 28 days
218921471|NCT05252780|BEHAVIORAL|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
219535334|NCT06150807|DEVICE|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
219618495|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
219535335|NCT06560983|OTHER|The investigators are planning to do a observational cohort study, hence won't be doing any intervention.|The investigators won't be doing any intervention since this is an observational study.
219535336|NCT01724515|OTHER|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
219535337|NCT05795504|OTHER|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
219618496|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
219618497|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
218921472|NCT02805829|DRUG|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
219535338|NCT05795504|OTHER|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
219535339|NCT05795504|DIETARY_SUPPLEMENT|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
219535340|NCT05345249|DRUG|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
219535341|NCT05345249|DRUG|Sodium chloride|Placebo comparator
219535342|NCT05244720|DIAGNOSTIC_TEST|Fibroscan|A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
219535343|NCT05244720|DIAGNOSTIC_TEST|Blood samples|Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
219535344|NCT00270582|DRUG|Taxotere, Cisplatin, Gemcitabine|
219618498|NCT06617208|DEVICE|Neuropixel probe recording|Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
218921473|NCT01399372|BIOLOGICAL|Rituximab|One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
218921474|NCT01399372|DRUG|Cytarabine|One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
218921475|NCT01399372|DRUG|Methotrexate|One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
219535345|NCT00274781|DRUG|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
219535346|NCT00274781|DRUG|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
219618499|NCT06356571|DRUG|Isatuximab SC-OBDS|Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS
219618500|NCT06356571|DRUG|Montelukast|Pharmaceutical form:As per local commercial product-Route of administration:Oral
219618501|NCT06356571|DRUG|Dexamethasone|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
219618502|NCT06356571|DRUG|Acetaminophen|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
219618503|NCT06356571|DRUG|Diphenhydramine|Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)
219618504|NCT06356571|DRUG|Methylprednisolone|Pharmaceutical form:As per local commercial product-Route of administration:IV
219618505|NCT06356571|DRUG|Carfilzomib|Pharmaceutical form:As per local commercial product-Route of administration:IV
219618506|NCT04721106|DRUG|Vizimpro|treatment group
218921476|NCT01399372|DRUG|Procarbazine|One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
218921477|NCT01399372|DRUG|Vincristine|One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
218921478|NCT01399372|RADIATION|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
219366781|NCT04779151|DRUG|Dostarlimab|Substance: immunoglobulin G4 (IgG4) humanized monoclonal antibody (mAb) that binds with high affinity to PD-1 Manufacturer: Tesaro Inc. Dose: 500 mg every 21 days for the first 4 cycles, followed by 1,000 mg every 42 days cycle (ie, Q6W)
219366782|NCT04779151|DRUG|Niraparib|Substance: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) Manufacturer: Tesaro Inc. Dose: Flat-fixed dose (if \<77kg or platelets \<150,000 μL: 200mg; if \>/=77kg and platelets \>/= 150,000μL: 300mg)
219366783|NCT02351232|DRUG|Liraglutide|
219366784|NCT02351232|DRUG|Placebo|
219366785|NCT02405533|DIETARY_SUPPLEMENT|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
219366786|NCT02405533|OTHER|Placebo|Placebo supplementation x 12 months
219366787|NCT01693172|BEHAVIORAL|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
219535347|NCT03510923|OTHER|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
218921479|NCT06355700|PROCEDURE|Liver biopsy|The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
218921480|NCT05641480|DEVICE|Transcutaneous electrical acupoint stimulation&Music therapy|"Procedure: electro-acupuncture;Points: Shenting（DU24）, Benshen（BG13）, Tou Wei （ST8）.The specially-made pad is stick on pierced acupoints, until local sour and heavy feeling coming. The electric stimulator is applied to bilateral BG13 and ST8, with dilatational wave,10/50 Hz and electric current 1-5mA(milliampere).Every session lasts for 30 min per day. The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each participants in all.~Selecting the participants' music of memory and music of favourite(Music is purchased and downloaded from music stores), forming a personalized music playlist, and the decibel level is suitable for participants.~The treatment is designed based on recent literature research in 10 years, former result and expert consensus.~Other Names:~* JS-502-A Intelligent and portable electroacupuncture~* apparatus(Han's low frequency neuromodulator, made in China)"
219535348|NCT03510923|OTHER|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
219535349|NCT03264339|BEHAVIORAL|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
219535350|NCT00134485|DRUG|torcetrapib/atorvastatin|
219618507|NCT01741311|BEHAVIORAL|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
219042691|NCT04246385|BEHAVIORAL|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
219535351|NCT00134485|DRUG|atorvastatin|
219535352|NCT05312216|DRUG|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
219535353|NCT02739503|DEVICE|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
219535354|NCT03641079|DRUG|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
219535355|NCT04638647|BIOLOGICAL|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
219535356|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
219535357|NCT03624751|RADIATION|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
219618508|NCT01741311|BEHAVIORAL|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
219618509|NCT04577014|DRUG|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
219535358|NCT06126666|DRUG|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
219535359|NCT06449027|DRUG|T Leuprolide Injectable Emulsion|Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
218921481|NCT05641480|DRUG|Donepezil hydrochloride tablets or carpalatine bitartrate tablets|"① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months."
218921482|NCT04669444|DEVICE|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
218921483|NCT02027441|OTHER|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
218921484|NCT05098431|OTHER|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
219366788|NCT02849639|OTHER|Placebo|Participants will receive educational materials, but will not receive MTM.
219042692|NCT02581384|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
219042693|NCT01076504|DRUG|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
219042694|NCT01076504|DRUG|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
219042695|NCT01076504|DRUG|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
219366789|NCT02849639|OTHER|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
219366790|NCT02849639|DRUG|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
219366791|NCT01958645|DRUG|MEDI8111|MEDI8111 lyophilisate for solution for infusion
219366792|NCT01958645|OTHER|Placebo|Placebo for MEDI8111 saline solution for infusion
219366793|NCT01023984|PROCEDURE|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
219535360|NCT06449027|DRUG|Leuprorelin Acetate Microspheres for Injection|Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
219535361|NCT06551454|DEVICE|Smart Textile Solution Biofeedback Method|The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.
219535362|NCT03181256|PROCEDURE|Biospecimen Collection|Undergo collection of sputum
219535363|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of nasal epithelium
219535364|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of buccal epithelium
219535365|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of blood
219535366|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of urine
219535367|NCT03181256|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
219535368|NCT03181256|PROCEDURE|Computed Tomography (CT)|Undergo chest CT
219535369|NCT03181256|OTHER|Laboratory Biomarker|Correlative studies
219535370|NCT05106296|DRUG|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
219535371|NCT05106296|DRUG|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
219535372|NCT05106296|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
219535373|NCT05106296|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
219535374|NCT05624749|DRUG|ianalumab|ianalumab s.c. monthly
219535375|NCT05624749|DRUG|placebo|placebo s.c. monthly
219535376|NCT06074588|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
219535377|NCT06074588|DRUG|Docetaxel|75 mg/m\^2 of docetaxel by IV Infusion
219535378|NCT06074588|DRUG|Pemetrexed|500 mg/m\^2 of pemetrexed by IV infusion
219535379|NCT06230159|BEHAVIORAL|Non-menthol Cigarette Smoking|Smoke a non-menthol cigarette
219535380|NCT06230159|BEHAVIORAL|Menthol Cigarette Smoking|Smoke a menthol cigarette
219535381|NCT06230159|BEHAVIORAL|Synthetic Cooling Agent Cigarette Smoking|Smoke a synthetic cooling agent cigarette
219535382|NCT06230159|BEHAVIORAL|Usual Brand Cigarette Smoking|Smoke usual brand cigarette
219535383|NCT06230159|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
219535384|NCT06230159|OTHER|Questionnaire Administration|Survey questionnaires
219535385|NCT06230159|DIAGNOSTIC_TEST|Nasal Epithelial Lining Fluid|Nasal strip inserted into the nare to collect nasal epithelial lining fluid.
219535386|NCT02361983|DEVICE|Double lumen tube|Patients managed with a double lumen tube for one lung ventilation
218921485|NCT00938067|BEHAVIORAL|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
219535387|NCT02361983|DEVICE|Bronchial blocker|Patients managed with a bronchial blocker for one lung ventilation
218921486|NCT05243511|DEVICE|Digital ACT|Participants in this arm receive Digital ACT as well as standard of care.
219535388|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
218921487|NCT05243511|OTHER|Digital Symptom Tracker|Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
218921488|NCT04976101|DEVICE|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
219535389|NCT06272487|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
219535390|NCT06272487|DRUG|Placebo|Placebo administered by SC injection
219535391|NCT02669225|OTHER|[18F]florbetaben|PET radiotracer to image Amyloid beta (AB) load in human brain.
219535392|NCT03583710|DRUG|Cisplatin|Given IV
219535393|NCT03583710|DRUG|Etoposide|Given IV
219535394|NCT03583710|DRUG|Mitotane|Given PO
219535395|NCT03583710|OTHER|Quality-of-Life Assessment|Ancillary studies
219535396|NCT05758480|BIOLOGICAL|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
219535397|NCT05758480|OTHER|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
219535398|NCT05353452|BEHAVIORAL|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
219535399|NCT05353452|BEHAVIORAL|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
219535400|NCT06324045|OTHER|Deprescribing|"1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient."
219535401|NCT02945800|DRUG|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
219535402|NCT02945800|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m\^2 intravenously (IV)
219535403|NCT06178159|DRUG|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
219535404|NCT06178159|DRUG|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
219535405|NCT06178159|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
219535406|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
219535407|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
219535408|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
219535409|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
219535410|NCT06207123|DRUG|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
219535411|NCT06207123|DRUG|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
219535412|NCT06207123|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
219535413|NCT06207123|DRUG|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
218921489|NCT04976101|DEVICE|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
218921490|NCT01432730|DRUG|Gefapixant|Oral tablets, BID
218921491|NCT01432730|DRUG|Placebo|Oral tablets, BID
218921492|NCT05461534|BEHAVIORAL|mindfulness yoga|Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
218921493|NCT05402488|BEHAVIORAL|Auditory stimulation|Auditory stimulation during sleep
218921494|NCT02505919|DEVICE|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
218921495|NCT02505919|PROCEDURE|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
218921496|NCT03881852|DRUG|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
218921497|NCT03881852|DRUG|Placebo|Dosed orally, twice daily for up to 3 weeks
218921498|NCT02297594|DRUG|AK0529|AK0529 capsule for oral administration
218921499|NCT02297594|DRUG|Placebo|Sugar placebo capsule for oral administration
218921500|NCT01421719|DRUG|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
218921501|NCT03924167|BEHAVIORAL|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
218921502|NCT03877328|OTHER|BiotechCoachForAll|A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
218921503|NCT00684008|DRUG|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
218921504|NCT00684008|DRUG|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
218921505|NCT02433808|DRUG|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
219535414|NCT06207123|DRUG|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
219535415|NCT04893109|DRUG|trastuzumab-emtansine|intravenous infusion
219535416|NCT04893109|DRUG|Trastuzumab SC|Muscular injection
219535417|NCT04893109|DRUG|Paclitaxel|intravenous infusion
219535418|NCT05126277|DRUG|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
219535419|NCT05126277|DRUG|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
219535420|NCT05126277|DRUG|placebo s.c.|placebo s.c. q4w in addition to SoC
219535421|NCT05707247|DEVICE|software|"The experimental medical device is a prototype software. It is a patient interface.~The device comes in the form of a smartphone with a touch screen"
219618510|NCT04577014|DRUG|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
218921506|NCT02433808|OTHER|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
218921507|NCT00500435|PROCEDURE|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
218921508|NCT05360797|OTHER|Outpatient|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
218921509|NCT05360797|OTHER|Medical home care|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
218921510|NCT05360797|OTHER|Hospitalization|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI\_1) in each center.
219535422|NCT05078944|DEVICE|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
219042696|NCT03738371|OTHER|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
219535423|NCT05078944|DEVICE|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
219535424|NCT05078944|DRUG|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
219535425|NCT04770324|DEVICE|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
219535426|NCT05667246|OTHER|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
219535427|NCT05667246|OTHER|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
219535428|NCT04294043|DRUG|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
219535429|NCT06079736|DRUG|PGN-EDO51|IV infusion
219535430|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
219535431|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
219535432|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
219535433|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
219535434|NCT06489028|DRUG|allo-APZ2-CVU|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
219535435|NCT06489028|DRUG|Placebo|Placebo
219618511|NCT04577014|DRUG|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
219618512|NCT05838690|OTHER|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
219618513|NCT06247956|DRUG|SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
219618514|NCT06247956|DRUG|Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
219618515|NCT06330025|OTHER|Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents|The group comprises 102 children aged between 2 and 8 years, hospitalized for at least 48 hours and their parents. The children's pathologies and medical treatments should not influence their food intake.
219618516|NCT03874923|OTHER|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
219042697|NCT02165046|DRUG|Budesonide|
219535436|NCT01726205|DRUG|Pregabalin and normal saline infusion, PRG|
219535437|NCT01726205|DRUG|Pregabalin and ropivacaine 02% infusion|
219535438|NCT01726205|DRUG|Placebo drug, normal saline infusion|
219042698|NCT02165046|DRUG|Procaterol|
219535439|NCT03748966|DRUG|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
219535440|NCT05789758|OTHER|No Intervention|Administered as specified in the treatment arm.
219042699|NCT02321462|DRUG|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
219535441|NCT01846923|BIOLOGICAL|PCV13|
219535442|NCT01109862|PROCEDURE|Total hip arthroplasty|All cemented THA
219535443|NCT01109862|PROCEDURE|Hemiarthroplasty|Cemented bipolar HAP
219535444|NCT04247282|DRUG|M7824|M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).
219535445|NCT04247282|DRUG|N803|N-803 (15 mcg/kg, subcutaneously) will be given on day 1 to patients enrolled in arm 3.
219535446|NCT04247282|BIOLOGICAL|TriAd vaccine|TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3
219535447|NCT00352820|BEHAVIORAL|Interview|Recorded face-to-face session.
219535448|NCT00352820|BEHAVIORAL|Questionnaire|Written survey lasting approximately 30 minutes.
219042700|NCT02321462|DRUG|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
219042701|NCT04434885|OTHER|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
219535449|NCT05478395|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
219535450|NCT00485771|DRUG|Olanzapine|
219535451|NCT00485771|DRUG|Fluoxetine|
219535452|NCT00485771|DRUG|Lamotrigine|
219535453|NCT06424444|DRUG|Reproxalap ophthalmic solution (0.25%)|Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks
219535454|NCT06424444|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
219535455|NCT02533479|OTHER|Caloric restriction|three alternate days weekly along 4 weeks.
219535456|NCT01196260|DRUG|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
219042702|NCT02724904|PROCEDURE|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
219042703|NCT02724904|DRUG|Fludarabine|Standard Treatment
219042704|NCT02724904|DRUG|Thiotepa|Standard Treatment
219042705|NCT02724904|DRUG|Methotrexate|IV Bolus
219535457|NCT01922765|DRUG|amoxicillin, clarithromycin, metronidazole, rabeprazole|
219535458|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
219535459|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
219042706|NCT02110316|OTHER|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
219042707|NCT05233436|DRUG|PF-07265028|PF-07265028 will be administered orally
219042708|NCT05233436|BIOLOGICAL|Sasanlimab|Administered subcutaneously
219042709|NCT03496688|PROCEDURE|Sinus floor augmentation|
219042710|NCT01183169|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
219042711|NCT01183169|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
219042712|NCT01183169|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
219535460|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
219535461|NCT00054873|DRUG|tezacitabine|
219535462|NCT00054873|DRUG|5-fluorouracil|
219535463|NCT02566239|OTHER|Share activity data with care team|Share participant in-home activity data with retirement community care team.
219535464|NCT00443716|DRUG|estrogen|
219535465|NCT03949153|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
219535466|NCT03949153|PROCEDURE|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
219535467|NCT03949153|DRUG|Ipilimumab Injection|In situ injection with ipilimumab at D2.
219535468|NCT06559423|DEVICE|non-ablative Er:YAG laser and high intensity Tesla magnetic stimulation (HITS)|Patients will initially undergo three monthly intravaginal treatments with the Er:YAG laser. Six weeks after the final laser treatment, patients will receive six sessions of magnetic stimulation. During these sessions, patients will sit on a specialized chair that generates a therapeutic magnetic field.
219535469|NCT05932680|OTHER|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
219535470|NCT05342597|DRUG|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
219535471|NCT01054898|BEHAVIORAL|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
219535472|NCT01054898|BEHAVIORAL|usual community services|standard care for abused women in the community
219535473|NCT05239832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219618517|NCT04778449|OTHER|Medical Chart Review|Medical charts are reviewed
219618518|NCT04778449|OTHER|Questionnaire Administration|Complete questionnaires
219618519|NCT05765643|OTHER|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
219618520|NCT01442480|DIETARY_SUPPLEMENT|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
219618521|NCT01442480|DIETARY_SUPPLEMENT|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
219535474|NCT01346007|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
218921511|NCT03782506|BEHAVIORAL|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
219042713|NCT01183169|DRUG|Placebo|ALV placebo soft gel capsules administered orally
219618522|NCT04136171|DRUG|Eplontersen|Eplontersen by subcutaneous injection
219042714|NCT01514396|DEVICE|Surgiseal|surgical glue
219042715|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
219042716|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
219042717|NCT00161707|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
219042718|NCT05019222|DRUG|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
219042719|NCT05019222|DRUG|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
219042720|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
219535475|NCT05431127|DEVICE|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
219535476|NCT06406361|BEHAVIORAL|online stress management program|"-Nurses should have an idea about stress management program Awareness develops about the importance of attending sessions regularly. Nurses have information about the training program. Joint session dates are determined. The educator makes statements about himself and education. The benefits of education for nurses are explained. Nurses are informed about the general rules of education. The importance of regular attendance at sessions is emphasized. Privacy rules and limits are determined. The necessity of completing homework is explained. Nurses are enabled to share their feelings and thoughts. Ensuring that nurses are able to recognize stress and reactions to stress and identify sources of stress in individual and business life.~Being informed about the effects of stress and negative workload perception Being able to recognize the tension created by stress in the body Learning breathing and deep relaxation techniques to reduce or eliminate symptoms of stress"
219535477|NCT06570915|DRUG|Daratumumab Injection|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
219535478|NCT05971251|DRUG|Loncastuximab Tesirine and Acalabrutinib|Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
219535479|NCT01926912|DRUG|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
219535480|NCT04794140|PROCEDURE|different number of passes|Each patient's operation process is the same, that is, after obtaining enough specimens for diagnosis by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique, additional three passes are performed. One of which is randomly selected as the one pass group, and the other two passes automatically as the two pass group. Please refer to the literature for EUS-FNB wet technique (Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.)
219535481|NCT00191763|DRUG|Gemcitabine|
219618523|NCT04136171|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
219618524|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
219618525|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
219618526|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
219618527|NCT06258148|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
219618528|NCT06258148|DRUG|Placebo|Placebo, SC, once a week
219618529|NCT05857488|DEVICE|Transnasal introduction tube|Imaging of the GI tract using the transnasal introduction tube and system. Optional gut microbiome sample collection using the microbiome brush and/or intestinal potential difference measurement using the intestinal potential difference probe.
219618530|NCT04932863|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
219618531|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
219535482|NCT00191763|DRUG|cisplatin|
219535483|NCT01037114|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
219535484|NCT01037114|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
219535485|NCT01037114|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
218921512|NCT03782506|BEHAVIORAL|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
218921513|NCT05467969|BEHAVIORAL|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
218921514|NCT01875406|OTHER|diagnostic exercises|
218921515|NCT04228380|OTHER|No intervention|No intervention
218921516|NCT01712399|BIOLOGICAL|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
218921517|NCT05650359|DEVICE|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
219618532|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
219618533|NCT04013802|BIOLOGICAL|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
219618534|NCT04521764|BIOLOGICAL|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
219618535|NCT04521764|PROCEDURE|Computed Tomography|Undergo CT scan
219618536|NCT04521764|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218921518|NCT05650359|OTHER|No intervention|No intervention
218921519|NCT03692299|DRUG|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
219042721|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
219618537|NCT04521764|PROCEDURE|Biopsy|Undergo tumor biopsy
219618538|NCT04521764|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219618539|NCT06583577|DEVICE|3D Ostomy simulator|The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
219618540|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
219618541|NCT02177461|DRUG|Telmisartan|
219618542|NCT02177461|DRUG|Enalapril|
219042722|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
219042723|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
219535486|NCT01061021|BEHAVIORAL|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
219535487|NCT01061021|BEHAVIORAL|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
219618543|NCT02177461|DRUG|Clonidine|
219618544|NCT00375986|PROCEDURE|Manual placental removal at Cesarean delivery|
219618545|NCT00375986|PROCEDURE|Spontaneous placental removal at Cesarean delivery|
219618546|NCT03224312|OTHER|no intervention|no intervention
219618547|NCT03472300|OTHER|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
219618548|NCT02800460|PROCEDURE|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
219618549|NCT03511105|DRUG|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
219618550|NCT03511105|DRUG|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
219618551|NCT03511105|DRUG|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
218921520|NCT03692299|DRUG|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
218921521|NCT05913765|DEVICE|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
219535488|NCT02256293|BEHAVIORAL|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
218921522|NCT02896803|DRUG|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
218921523|NCT01696110|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
218921524|NCT01696110|DRUG|heparin|heparin monotherapy
218921525|NCT01696110|DRUG|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
218921526|NCT03056092|DRUG|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
219535489|NCT03472105|DIETARY_SUPPLEMENT|New Nordic Renal Diet|One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
218921527|NCT02484118|PROCEDURE|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
218921528|NCT01942837|DRUG|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
219535490|NCT05598476|OTHER|5kg bag|a 5 kg bag is applied on the chest for 2 hours
219535491|NCT04314362|DRUG|AZR-MD-001 ointment/semi-solid drug|AZR-MD-001 (1.0%) and suitable excipient
219535492|NCT02959580|DRUG|Hydrocortisone Butyrate|topical use
219535493|NCT02959580|PROCEDURE|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
219535494|NCT00942318|DRUG|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
219535495|NCT04377009|DEVICE|Sleep Healthy Using the Internet (SHUTi)|Cognitive behavioral therapy delivered via internet-guided program customized for military service members
219535496|NCT04377009|OTHER|Education Control Program|Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
219535497|NCT03004209|DRUG|Erythropoietin|three times per a week 100IU / k
219535498|NCT04638452|BEHAVIORAL|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
219535499|NCT04638452|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
219535500|NCT06312488|DIAGNOSTIC_TEST|Clot Pro|This study enrolls patients admitted to the Adult ICU of Milan Policlinico Hospital with a diagnosis of sepsis or septic shock. A ClotPro® TPA test is performed at admission and on day 1, 2, 3, and 7. Specific markers of coagulation (PAI-1, Plasminogen, Protein C and S) and inflammation (Il-1beta, IL-6, IL-8, TNF-alpha, ADM) are tested at enrollment. Routine laboratory tests are performed daily. Hemorrhagic and thrombotic events are searched. The study ends at 28 days or upon ICU discharge.
219535501|NCT05132985|DRUG|Icotinib|125mg 1tt(Take 1 tablet 3 times a day) orally.
219535502|NCT05132985|DRUG|Cisplatin|75 mg/m2 (IV，Q3W)
219535503|NCT05132985|DRUG|Carboplatin|AUC 5 (IV, Q3W)
219535504|NCT05132985|DRUG|Pemetrexed|500 mg/m2 (IV, Q3W)
219535505|NCT01334632|PROCEDURE|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
219535506|NCT01334632|PROCEDURE|PCA morphine|Postoperative with iv self-administration of morphine
219535507|NCT01364532|PROCEDURE|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
219535508|NCT01364532|PROCEDURE|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
219535509|NCT03884088|OTHER|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
219535510|NCT06500624|DRUG|Pizotifen|Each subject will be given 0.5mg pizotifen with 10-20mg escitalopram in patients with depressive disorder
219535511|NCT02214615|DRUG|Carbamazepine|"Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.~Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days."
219535512|NCT02214615|DRUG|Placebo|
219535513|NCT03544411|BIOLOGICAL|olive oil|the intervention consist of 15 ml / day of olive oil
219535514|NCT03544411|BIOLOGICAL|bran oil|the intervention consist of 15 ml / day of bran oil
219535515|NCT02148497|PROCEDURE|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
219535516|NCT02212847|OTHER|vestibular stimulation|
219535517|NCT04977739|DIAGNOSTIC_TEST|No intervention|No intervention
219535518|NCT06047977|BIOLOGICAL|Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2|Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
218921529|NCT03404700|BEHAVIORAL|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
219535519|NCT03044587|DRUG|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
219535520|NCT03044587|DRUG|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
219535521|NCT05804370|DRUG|Gleolan|Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
219535522|NCT01392794|DRUG|YM060|oral, without water
219535523|NCT00476281|PROCEDURE|Urinary collect|
219535524|NCT00476281|PROCEDURE|Continuous Glucose Monitoring System (CGMS)|
219535525|NCT01499628|BEHAVIORAL|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
219535526|NCT01499628|BEHAVIORAL|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
219535527|NCT01499628|BEHAVIORAL|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
219535528|NCT03379467|OTHER|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
219535529|NCT03379467|OTHER|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
219535530|NCT00382707|DEVICE|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
219535531|NCT05162222|DRUG|Danicamtiv|Specified dose on specified days
219535532|NCT05162222|DRUG|Itraconazole|Specified dose on specified days
219535533|NCT05162222|DRUG|Diltiazem|Specified dose on specified days
219535534|NCT00471523|DRUG|Clomiphene citrate|
219535535|NCT00471523|DRUG|Metformin|
219618552|NCT03511105|DRUG|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
218921530|NCT03404700|BEHAVIORAL|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
218921531|NCT03404700|BEHAVIORAL|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
218921532|NCT03404700|BEHAVIORAL|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
218921533|NCT02267551|OTHER|Mimic dv-Trainer|
218921534|NCT02267551|OTHER|daVinci Skills Simulator|
219535536|NCT04560738|DRUG|[14C]-CC-92480|Oral
219535537|NCT05442021|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
219535538|NCT05442021|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
219535539|NCT03397056|OTHER|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
219535540|NCT05244798|DRUG|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
219618553|NCT03945305|DEVICE|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
219535541|NCT05244798|RADIATION|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
219535542|NCT05244798|DRUG|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
219535543|NCT02360761|PROCEDURE|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
219535544|NCT02360761|PROCEDURE|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
219535545|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
219535546|NCT03174080|RADIATION|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
219535547|NCT03284476|OTHER|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
219535548|NCT04819594|OTHER|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
219618554|NCT03945305|OTHER|Previous antihypertensive treatment|Patients are only treated with previous antihypertensive treatment.
219535549|NCT03950089|DEVICE|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
219535550|NCT05881525|BIOLOGICAL|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
218921535|NCT06172309|DRUG|NTQ1062|tablet(s) PO
218921536|NCT02628912|OTHER|blood draw|
219535551|NCT05881525|DRUG|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
219535552|NCT05881525|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219535553|NCT05881525|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219535554|NCT05881525|DRUG|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219535555|NCT03003091|OTHER|Needs-based patient education|
219535556|NCT03003091|OTHER|Traditional patient education|
219535557|NCT05381220|OTHER|early mobilization|Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
219535558|NCT01177020|OTHER|Biological specimen|Biological specimen taken from placenta
219535559|NCT01727180|OTHER|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
219535560|NCT02606825|OTHER|Registry of AML patients > 60 years|
219535561|NCT04138186|DEVICE|2.0g G-PUR®, oral administration|tid for 12 weeks
218921537|NCT02628912|BEHAVIORAL|study questionnaire|
218921538|NCT02628912|OTHER|cardiopulmonary exercise testing (CPET)|
218921539|NCT02628912|OTHER|DXA (dual-energy x-ray absorptiometry) scan|
218921540|NCT02201394|DRUG|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
218921541|NCT02201394|DRUG|Aspirin loading dose|Single loading dose of Aspirin 325 mg
219535562|NCT04138186|DEVICE|Placebo, oral administration|tid for 12 weeks
218921542|NCT02201394|DRUG|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
218921543|NCT02201394|DRUG|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
218921544|NCT01660048|PROCEDURE|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
218921545|NCT01660048|PROCEDURE|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
218921546|NCT02648919|DRUG|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
218921547|NCT01635166|DEVICE|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
219535563|NCT00118235|DRUG|cisplatin|Given IV
219535564|NCT00118235|DRUG|irinotecan hydrochloride|Given IV
218921548|NCT03252431|DRUG|F-627|single dose pre-filled syringe
218921549|NCT03252431|DRUG|Neulasta|single dose pre-filled syringe
219535565|NCT00118235|BIOLOGICAL|bevacizumab|Given IV
219535566|NCT00118235|OTHER|laboratory biomarker analysis|Correlative studies
219535567|NCT02955641|DRUG|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
219535568|NCT02955641|DRUG|Nepafenac 0.1%|four drops a day for four days after LPI treatment
219535569|NCT02955641|DRUG|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
219535570|NCT01010555|DEVICE|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
219535571|NCT01010555|DEVICE|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
219535572|NCT01010555|DEVICE|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
219535573|NCT01010555|DEVICE|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
219535574|NCT00968812|DRUG|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
219535575|NCT00968812|DRUG|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
218921550|NCT05692375|OTHER|"Invitation to play the game Save the shame!"|The experimental group was asked to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform . The control group neither used nor had access to the game. Afterwards both groups performed the ALS knowledge assessment test. It is a test with 20 multiple choice questions each scored as right (0.5 points) or wrong (0 points).
218921551|NCT04289974|DRUG|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
218921552|NCT00055757|DRUG|tipifarnib|Given orally
218921553|NCT00055757|DRUG|cisplatin|Given IV
219535576|NCT00968812|DRUG|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
219535577|NCT01004341|BEHAVIORAL|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
218921554|NCT00055757|DRUG|gemcitabine hydrochloride|Given IV
218921555|NCT00055757|OTHER|laboratory biomarker analysis|Correlative studies
218921556|NCT02650076|DRUG|SK-1405|
218921557|NCT05956015|OTHER|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
218921558|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
218921559|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
218921560|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
218921561|NCT02501291|DRUG|Thalidomide|
218921562|NCT01831388|OTHER|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~\- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
218921563|NCT01831388|BEHAVIORAL|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
219042724|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
219535578|NCT02914990|DRUG|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
219535579|NCT01593852|RADIATION|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
219535580|NCT01593852|RADIATION|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
219535581|NCT04425928|PROCEDURE|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
219535582|NCT04425928|PROCEDURE|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
219535583|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
219535584|NCT04487691|BIOLOGICAL|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (\~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
219535585|NCT04487691|OTHER|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
219535586|NCT00434265|BEHAVIORAL|Physical training|
218921564|NCT00912535|DRUG|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
218921565|NCT00912535|DRUG|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
218921566|NCT01152957|BEHAVIORAL|CARIÑO Project|Care Attention Resources Information Nutrition \& Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
218921567|NCT01152957|BEHAVIORAL|Enhanced Usual Care|Usual care plus 4 health education brochures
218921568|NCT01725516|PROCEDURE|Myofascial release technique|
218921569|NCT01424215|DRUG|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
218921570|NCT04125589|BEHAVIORAL|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
219535587|NCT02348463|DRUG|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
219535588|NCT01471886|DRUG|Ketorolac Tromethamine|Every 8 hours for 4 days.
219535589|NCT01471886|DRUG|Naproxen|Every 8 hours for 4 days.
218921571|NCT04125589|BEHAVIORAL|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
218921572|NCT02781714|BEHAVIORAL|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered"
218921573|NCT03642587|OTHER|There is no intervention in this study.|There is no intervention in this study.
218921574|NCT02396121|DIETARY_SUPPLEMENT|Oral nutritional supplement : Renutryl® Booster|
218921575|NCT02993107|BIOLOGICAL|AR101|AR101 powder provided in capsules \& sachets
218921576|NCT03549767|DEVICE|Springfusor|Springfusor for administration of magnesium sulphate
218921577|NCT03549767|PROCEDURE|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
218921578|NCT02817646|OTHER|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
218921579|NCT02817646|DIETARY_SUPPLEMENT|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
218921580|NCT01308177|DRUG|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
218921581|NCT05002712|OTHER|Heavy resistance training|Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
219042725|NCT03044197|DEVICE|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
219042726|NCT03044197|DEVICE|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
219042727|NCT01221961|DEVICE|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
219535590|NCT03266263|DEVICE|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
219535591|NCT03266263|OTHER|instructor-led feedback|feedback for CPR quality by instructors
219535592|NCT00988663|DRUG|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
219535593|NCT00988663|DRUG|Placebo|will give placebo that looks like memantine
219535594|NCT05287763|PROCEDURE|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
219535595|NCT02288221|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
219535596|NCT02288221|OTHER|Patient's answer without non pharmacological therapeutic|No installation at patient's home
219535597|NCT04705714|DRUG|Frankincense Extract|The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
219535598|NCT04645914|BEHAVIORAL|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
219535599|NCT03071666|DIETARY_SUPPLEMENT|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
219535600|NCT03071666|DIETARY_SUPPLEMENT|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
219535601|NCT00275366|DEVICE|Robotic Therapy|
219535602|NCT01149590|PROCEDURE|Computer Tomography Angiography|Computed Tomography Angiography
218921582|NCT05002712|OTHER|Contrast strength training|Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
218921583|NCT05002712|OTHER|Elastic resistance training|During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
218921584|NCT00972062|OTHER|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
218921585|NCT00972062|OTHER|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
218921586|NCT03874988|BEHAVIORAL|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
218921587|NCT03874988|BEHAVIORAL|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
219618555|NCT04540809|OTHER|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
218921588|NCT03874988|BEHAVIORAL|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
218921589|NCT03874988|BEHAVIORAL|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
218921590|NCT06025214|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
218921591|NCT06025214|DRUG|ADVAIR DISKUS® 500/50|2 inhalations in one study period
218921592|NCT03039218|DEVICE|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
218921593|NCT03039218|DEVICE|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
218921594|NCT04146948|OTHER|no intervention|no intervention in this study
218921595|NCT02183649|DRUG|pentoxyverine citrate|
218921596|NCT02183649|DRUG|Placebo|
219535603|NCT05108779|DRUG|QLF32004|In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
219535604|NCT00178802|OTHER|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
219535605|NCT03100084|OTHER|Blood sampling|Maternal blood sampling
219535606|NCT05970484|BEHAVIORAL|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
218921597|NCT03729700|OTHER|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
218921598|NCT02038933|DRUG|Nivolumab|
219618556|NCT02810457|DRUG|FKB238 (bevacizumab)|
218921599|NCT05979246|DEVICE|Lance CLEAR dental implant|The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
218921600|NCT02170623|DRUG|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
218921601|NCT02170623|DRUG|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
218921602|NCT02170623|DRUG|Pantoprazole|40 mg pantoprazole
218921603|NCT02170623|DRUG|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
218921604|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
218921605|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
218921606|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
219618557|NCT02810457|DRUG|Avastin (bevacizumab)|
219618558|NCT02810457|DRUG|Paclitaxel|
219618559|NCT02810457|DRUG|Carboplatin|
219618560|NCT03215680|OTHER|Climate|Hot and temperate climate
218921607|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
218921608|NCT04154904|OTHER|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
218921609|NCT03469414|OTHER|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
218921610|NCT03469414|OTHER|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
218921611|NCT03469414|OTHER|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
218921612|NCT03469414|OTHER|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
218921613|NCT03469414|OTHER|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
218921614|NCT03469414|OTHER|PART-O|The PART-O is a community participation measure.
218921615|NCT03469414|OTHER|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
218921616|NCT04611646|BEHAVIORAL|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
218921617|NCT04611646|BEHAVIORAL|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
218921618|NCT05930223|DRUG|VAL-1221|VAL-1221 20mg/kg intravenous (IV) infusion every other week
218921619|NCT04226742|BEHAVIORAL|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
218921620|NCT04226742|BEHAVIORAL|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
218921621|NCT05747235|RADIATION|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
218921622|NCT00053651|BEHAVIORAL|Survival Skills for Moms with New Babies|
218921623|NCT00528034|PROCEDURE|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
218921624|NCT04856800|DIETARY_SUPPLEMENT|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
218921625|NCT04856800|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
218921626|NCT04282603|COMBINATION_PRODUCT|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
219535607|NCT05970484|BEHAVIORAL|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
218921627|NCT01523093|DRUG|Ondansetron|Orally Disintegrating Tablets 8mg
218921628|NCT03631992|BEHAVIORAL|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
219618561|NCT02943980|DEVICE|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
218921629|NCT03631992|BEHAVIORAL|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
219535608|NCT02732821|PROCEDURE|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
219535609|NCT02679703|DEVICE|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
219535610|NCT02679703|DEVICE|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
219618562|NCT02943980|DEVICE|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
219618563|NCT01566188|DIETARY_SUPPLEMENT|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
219618564|NCT01566188|DIETARY_SUPPLEMENT|Placebo|6 months of supplementation with placebo
219618565|NCT02950415|BEHAVIORAL|virtual|Parent is present via an internet pad (iPad)
219618566|NCT02950415|BEHAVIORAL|coaching|Parent learns what to say verbally to soothe child
219618567|NCT02950415|BEHAVIORAL|physical|Parent is present in the operating room
218921630|NCT03979287|OTHER|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
218921631|NCT03979287|OTHER|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
218921632|NCT01047358|DRUG|Aromasin|25 mg table QD
218921633|NCT01047358|DRUG|Aromasin|25 mg table QD
218921634|NCT04683614|DRUG|Norepinephrine|5 mic/kg/hr norepinephrine
218921635|NCT04683614|BIOLOGICAL|Fresh frozen plasma|early administration of fresh frozen plasma
219535611|NCT02679703|OTHER|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
219535612|NCT02580279|DRUG|EGCG|
219535613|NCT02580279|DRUG|placebo|
218921636|NCT02556840|OTHER|insulin therapy|
218921637|NCT04761224|DEVICE|Fluido® Irrigation Fluid Heater System|"Patients in the Heated group will benefit from intraoperative warming by means of NaCl bags instilled using the Fluido® Irrigation warming cassette and with the use of specific instillation tubing (SEBAC laboratory, Set URO Fluido® Irrigation): this device allows continuous and precise heating of the solution with an instillation temperature of 38-39°C."
219535614|NCT05907733|DIAGNOSTIC_TEST|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
219535615|NCT02107456|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
219535616|NCT04527107|DRUG|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
219535617|NCT04527107|DRUG|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
219535618|NCT04527107|DRUG|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
219535619|NCT04527107|DRUG|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
219535620|NCT04527107|DRUG|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
219535621|NCT04527107|DRUG|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
219535622|NCT04527107|DRUG|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
219535623|NCT02774785|DEVICE|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
219535624|NCT05864807|DEVICE|UCon|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
218921638|NCT00997776|OTHER|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
219535625|NCT02900209|OTHER|Influenza Vaccination|
219535626|NCT00640562|DRUG|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
219535627|NCT00640562|DRUG|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
219535628|NCT00448591|DRUG|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
219535629|NCT00448591|DRUG|Taxane-based chemotherapy|As prescribed
219618568|NCT02950415|BEHAVIORAL|no coaching|Parent does not learn what to say verbally to soothe child
219618569|NCT04173507|DRUG|Avelumab|Given IV
219618570|NCT04173507|DRUG|Talazoparib|Given PO
219618571|NCT04173507|DRUG|Talazoparib Tosylate|Given PO
219618572|NCT00497068|BEHAVIORAL|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
219618573|NCT00497068|BEHAVIORAL|non-contingent|Participants receive vouchers regardless of tobacco use status
219618574|NCT00497068|BEHAVIORAL|control|this group receives no vouchers
219618575|NCT02215655|BEHAVIORAL|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
219618576|NCT05486039|BEHAVIORAL|Changing behaviour|Changing the lying position and mattress system
219618577|NCT03587402|OTHER|Transcutaneous perineal stimulation|Surface stimulation
218921639|NCT00997776|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
218921640|NCT05790369|BEHAVIORAL|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
218921641|NCT05790369|BEHAVIORAL|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
218921642|NCT00122083|DEVICE|Health education information|
218921643|NCT02979496|DIETARY_SUPPLEMENT|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
218921644|NCT02979496|DIETARY_SUPPLEMENT|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
219618578|NCT03587402|OTHER|Anal stimulation|Intra-cavitary stimulation
219618579|NCT05673980|DRUG|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
219618580|NCT05673980|OTHER|placebo|This group will not do any intervention
218921645|NCT02979496|DIETARY_SUPPLEMENT|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
218921646|NCT02979496|DIETARY_SUPPLEMENT|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
218921647|NCT00355966|DRUG|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
219618581|NCT00632268|DRUG|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
219618582|NCT00663936|DRUG|T-817MA|224 mg T-817 MA once daily
219618583|NCT00663936|DRUG|Placebo|Placebo once daily
219618584|NCT05304130|BIOLOGICAL|Otilimab|Otilimab will be administered via pre-filled syringe.
219618585|NCT06492135|DRUG|survodutide|survodutide
219618586|NCT06356714|DRUG|Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens|"Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged."
219618587|NCT01034202|DRUG|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
219618588|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
219618589|NCT01034202|DRUG|placebo|Placebo comparator
219618590|NCT01034202|DRUG|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
219618591|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
218921648|NCT00355966|DRUG|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
218921649|NCT01759446|DRUG|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
218921650|NCT01759446|DRUG|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
218921651|NCT01759446|DRUG|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
218921652|NCT01759446|DRUG|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
218921653|NCT01759446|DRUG|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
218921654|NCT04530084|DEVICE|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
218921655|NCT00195104|DRUG|Arsenic Trioxide (Tricenox)|
219618592|NCT04553731|BEHAVIORAL|empowerment program with mHealth|empowerment program with mHealth
219618593|NCT04606212|DRUG|Losartan|administration of losartan (50 mg) (oral)
219618594|NCT04606212|DRUG|Placebo Oral Tablet|administration of placebo (oral)
219618595|NCT02019472|BIOLOGICAL|adalimumab 40 mg|SC injections
219618596|NCT02019472|BIOLOGICAL|sirukumab 100 mg|SC injections
219618597|NCT02019472|BIOLOGICAL|sirukumab 50 mg|SC injections
219618598|NCT02019472|DRUG|Placebo|SC injections
219618599|NCT01543438|OTHER|Video Prescription (additional education)|receives video prescriptions
219535630|NCT04626167|PROCEDURE|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
218921656|NCT00195104|DRUG|Cytarabine|
218921657|NCT04112719|OTHER|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
218921658|NCT04112719|OTHER|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
218921659|NCT04112719|OTHER|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
218921660|NCT02338596|PROCEDURE|Total hip replacement|"1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
218921661|NCT00400166|BEHAVIORAL|Recovery Mentor|Provided Recovery Mentor services
218921662|NCT01751620|BEHAVIORAL|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
218921663|NCT01751620|BEHAVIORAL|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
218921664|NCT02755246|DIETARY_SUPPLEMENT|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
218921665|NCT02755246|DIETARY_SUPPLEMENT|Placebo supplementation|3 months of placebo intake (3 capsules/day)
218921666|NCT04204525|DIAGNOSTIC_TEST|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
218921667|NCT05825352|DEVICE|Carmellose eye drops|Ocular drops based upon carmellose
218921668|NCT02991872|PROCEDURE|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
219042728|NCT04697979|OTHER|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
219042729|NCT05409235|DRUG|OTT166|Participants will receive OTT166 ophthalmic solution
219042730|NCT05409235|DRUG|Vehicle control|Participants will receive vehicle control
219042731|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
219535631|NCT02937870|DEVICE|Test Product 1|Test adhesive 1 with a thin nozzle
219535632|NCT02937870|DEVICE|Test Product 2|Test adhesive 2 with a thin nozzle
219535633|NCT02937870|DEVICE|Reference Product|Adhesive Cream
219535634|NCT02937870|OTHER|Negative Control|No adhesive
219535635|NCT04390256|OTHER|Clove water extract|natural product
219535636|NCT04390256|OTHER|Carbopol|Bioadhesive polymer
219535637|NCT04390256|OTHER|Carboxymethyle cellulose|Bioadhesive polymer
219535638|NCT00235352|DRUG|CX516 (Ampakine)|
219535639|NCT03749252|DRUG|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
219535640|NCT00835432|DEVICE|Ossix|Test group
219535641|NCT00835432|DEVICE|Biogide|controls
219535642|NCT00633451|OTHER|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
219535643|NCT00633451|OTHER|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
219535644|NCT00219154|DRUG|aliskiren|
219535645|NCT00609674|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
219535646|NCT00609674|DRUG|Placebo|Placebo
219535647|NCT03098394|DEVICE|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
218921669|NCT03108326|BIOLOGICAL|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
218921670|NCT03548948|OTHER|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
218921671|NCT03548948|OTHER|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
218921672|NCT03548948|OTHER|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
218921673|NCT02606643|PROCEDURE|Slight traction|Slight traction will be applied to the balloon catheter
218921674|NCT02606643|PROCEDURE|Foley Catheter to no traction|Foley Catheter to no traction
219204760|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
219535648|NCT03098394|DEVICE|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
219535649|NCT04755387|DRUG|De-escalation strategy|De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).
219535650|NCT04755387|DRUG|Conventional strategy|Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.
219618600|NCT01441024|DRUG|DAS181|20 mg per day of DAS181-FO3 for 5 days
219618601|NCT01441024|OTHER|Placebo|20 mg per day of Lactose for 5 days
219618602|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
219618603|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
219618604|NCT05418881|DEVICE|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
219618605|NCT05418881|DEVICE|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
218921675|NCT05386420|DRUG|Hymecromone tablets|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
218921676|NCT05386420|OTHER|Placebo|Conventional treatment combined with Placebo.
218921677|NCT01068847|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
218921678|NCT04467203|DRUG|Fadanafil|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
218921679|NCT00180336|DEVICE|CRT-D|
218921680|NCT04805034|OTHER|Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level|Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
219535651|NCT02465060|DRUG|Adavosertib|Given PO
219535652|NCT02465060|DRUG|Afatinib|Given PO
219535653|NCT02465060|DRUG|Afatinib Dimaleate|Given PO
219535654|NCT02465060|DRUG|Binimetinib|Given PO
219535655|NCT02465060|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219535656|NCT02465060|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219535657|NCT02465060|DRUG|Capivasertib|Given PO
219535658|NCT02465060|PROCEDURE|Computed Tomography|Undergo computed tomography (CT)
219535659|NCT02465060|DRUG|Copanlisib|Given IV
218921681|NCT01011894|DRUG|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
218921682|NCT03418714|DRUG|Salvinorin A|Salvinorin A, blinded doses
218921683|NCT04782869|DEVICE|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
218921684|NCT03711968|OTHER|Rehabilitative treatment protocol|A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
218921685|NCT05468996|DRUG|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
218921686|NCT05586438|DRUG|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
218921687|NCT04313244|BIOLOGICAL|9vHPV Vaccine|9vHPV intramuscular injection
219366794|NCT01023984|PROCEDURE|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
218921688|NCT04313244|BIOLOGICAL|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
218921689|NCT01839955|DRUG|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
218921690|NCT01839955|DRUG|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
218921691|NCT01839955|OTHER|laboratory biomarker analysis|Correlative studies
218921692|NCT01839955|OTHER|pharmacological study|Correlative studies
218921693|NCT01839955|DRUG|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
219366795|NCT00389584|DRUG|irinotecan hydrochloride|
219366796|NCT00389584|PROCEDURE|cognitive assessment|
219366797|NCT00389584|PROCEDURE|management of therapy complications|
219366798|NCT00389584|RADIATION|radiation therapy|
219366799|NCT01772667|PROCEDURE|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
219535660|NCT02465060|DRUG|Copanlisib Hydrochloride|Given IV
219535661|NCT02465060|DRUG|Crizotinib|Given PO
219535662|NCT02465060|OTHER|Cytology Specimen Collection Procedure|Optional correlative studies
219535663|NCT02465060|DRUG|Dabrafenib|Given PO
219535664|NCT02465060|DRUG|Dabrafenib Mesylate|Given PO
219535665|NCT02465060|DRUG|Dasatinib|Given PO
219535666|NCT02465060|DRUG|Defactinib|Given PO
219535667|NCT02465060|DRUG|Defactinib Hydrochloride|Given PO
219535668|NCT02465060|PROCEDURE|Echocardiography Test|Undergo echocardiography (ECHO)
219535669|NCT02465060|DRUG|Erdafitinib|Given PO
219535670|NCT02465060|DRUG|Fexagratinib|Given PO
219535671|NCT02465060|DRUG|Ipatasertib|Given PO
219535672|NCT02465060|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
219535673|NCT02465060|DRUG|Larotrectinib|Given PO
219535674|NCT02465060|DRUG|Larotrectinib Sulfate|Given PO
219535675|NCT02465060|PROCEDURE|Magnetic Resonance Imaging|Undergo magnetic resonance imaging (MRI)
219535676|NCT02465060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219535677|NCT02465060|BIOLOGICAL|Nivolumab|Given IV
219535678|NCT02465060|DRUG|Osimertinib|Given PO
219535679|NCT02465060|DRUG|Palbociclib|Given PO
219535680|NCT02465060|BIOLOGICAL|Pertuzumab|Given IV
219535681|NCT02465060|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
219535682|NCT02465060|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219535683|NCT02465060|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
219535684|NCT02465060|BIOLOGICAL|Relatlimab|Given IV
219535685|NCT02465060|DRUG|Sapanisertib|Given PO
219535686|NCT02465060|DRUG|Sunitinib Malate|Given PO
219535687|NCT02465060|DRUG|Taselisib|Given PO
219535688|NCT02465060|DRUG|Trametinib|Given PO
219535689|NCT02465060|BIOLOGICAL|Trastuzumab|Given IV
219535690|NCT02465060|BIOLOGICAL|Trastuzumab Emtansine|Given IV
219535691|NCT02465060|DRUG|Ulixertinib|Give PO
219535692|NCT02465060|DRUG|Vismodegib|Given PO
219535693|NCT03985345|DEVICE|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
219535694|NCT05886049|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219535695|NCT05886049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219535696|NCT05886049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219535697|NCT05886049|DRUG|Cytarabine|Given IV
218921694|NCT03946475|OTHER|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
218921695|NCT03149562|DRUG|plasma transfusions|These critical ill neonates with plasma transfusions
218921696|NCT03149562|DRUG|non-plasma transfusions|These critical ill neonates without plasma transfusions
218921697|NCT06169969|DEVICE|magnetic therapy|Kegel exercises
218921698|NCT04725578|BEHAVIORAL|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
219535698|NCT05886049|DRUG|Daunorubicin|Given IV
219535699|NCT05886049|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219535700|NCT05886049|DRUG|Revumenib|Given PO
219618606|NCT03861390|DRUG|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
219618607|NCT03861390|DRUG|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
219618608|NCT02818452|OTHER|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
219618609|NCT02818452|OTHER|Oatmeal|
219618610|NCT02818452|OTHER|Hot cereal|
219618611|NCT01217112|DRUG|GWP42003|100 mg capsules, PO, BD, 91 days
219618612|NCT01217112|DRUG|GWP42003|5 mg capsules, PO, BD, 91 days
219618613|NCT01217112|DRUG|GWP42004|5 mg capsules, PO, BD, 91 days
219618614|NCT01217112|DRUG|Placebo|0 mg capsules, QDS, PO, 91 days
219618615|NCT03192488|DRUG|Cetirizine|Cetirizine tablet 10 mg
219618616|NCT03192488|DRUG|Placebo oral capsule|Gelatin placebo
219618617|NCT03192488|OTHER|Hypoxia|Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
219618618|NCT01401361|DEVICE|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
219618619|NCT03669211|DIAGNOSTIC_TEST|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
218921699|NCT00907335|DRUG|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
218921700|NCT00907335|DRUG|Vehicle control|Color-matched facial gel vehicle control used once daily
218921701|NCT03052270|DRUG|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
218921702|NCT04475796|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed after ERCP
219535701|NCT05886049|PROCEDURE|Transthoracic Echocardiography Test|Undergo transthoracic ECHO
219535702|NCT00176020|DRUG|nicotinic acid|
219535703|NCT00204373|DRUG|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
219535704|NCT03340376|DRUG|Atezolizumab|atezolizumab
219535705|NCT03340376|DRUG|Doxorubicin|Doxorubicin
219535706|NCT04255420|PROCEDURE|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
219618620|NCT01637428|DEVICE|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
219618621|NCT00389311|DRUG|Normosol-R|
219618622|NCT00389311|DRUG|Nonoxynol-9|
219618623|NCT00389311|PROCEDURE|Gastrointestinal instrumentation|
219618624|NCT00867529|BIOLOGICAL|rituximab|Given IV
219618625|NCT00867529|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
219618626|NCT00867529|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
219618627|NCT00867529|OTHER|pharmacological study|Correlative studies
219618628|NCT00867529|OTHER|laboratory biomarker analysis|Correlative studies
219618629|NCT02213172|DIETARY_SUPPLEMENT|Bifidobacterium longum R0175|
219535707|NCT04255420|DRUG|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
219535708|NCT01619891|DIETARY_SUPPLEMENT|Vitamin D|100mcg per day
219618630|NCT02213172|DIETARY_SUPPLEMENT|Lactobacillus paracasei HA-196|
219618631|NCT02213172|OTHER|Placebo|
219618632|NCT01660750|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
219618633|NCT01660750|DRUG|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
219618634|NCT01660750|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
219618635|NCT04310670|OTHER|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
219618636|NCT04310670|BEHAVIORAL|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
218921703|NCT00005966|BIOLOGICAL|recombinant interferon alfa|
218921704|NCT00005966|DRUG|thalidomide|
218921705|NCT00784914|DRUG|temsirolimus|Receive temsirolimus IV
218921706|NCT00784914|OTHER|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
218921707|NCT00784914|OTHER|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
218921708|NCT04444726|DEVICE|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
218921709|NCT04444726|DEVICE|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
218921710|NCT04444726|DRUG|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
218921711|NCT03879772|DRUG|Mometasone furoate nasal spray|intranasal administration
218921712|NCT03879772|DRUG|Beclomethasone dipropionate nasal spray|intranasal administration
218921713|NCT03879772|DRUG|Placebo nasal spray|intranasal administration
218921714|NCT03879772|DRUG|Chlorpheniramine maleate syrup|oral administration
219618637|NCT04310670|OTHER|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
219618638|NCT04903015|DIAGNOSTIC_TEST|MRI|"The following sequences of the MRI will be acquired during the inclusion visit:~* 3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~* multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~* continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~* resting-state fMRI: functional connectivity;~* 64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~* monovoxel spectroscopy of the mesencephalus with short echo time (TE)."
218921715|NCT06236269|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
218921716|NCT00183040|DRUG|Topical testosterone|
218921717|NCT00183040|DRUG|Recombinant human growth hormone|
218921718|NCT00157131|BIOLOGICAL|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
218921719|NCT00157131|OTHER|Staples|Administration by mechanical/multiple point fixation.
219618639|NCT00198718|DRUG|Vitamin A (retinyl palmitate)|
219618640|NCT00841386|DRUG|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
219618641|NCT00841386|DRUG|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
219618642|NCT01288677|DRUG|TMC649128|Escalated doses
219618643|NCT02332226|BEHAVIORAL|Representational approach|Representational approach to patient education
219618644|NCT00304798|BEHAVIORAL|Hospital admission|
219618645|NCT04528667|DRUG|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
218921720|NCT03856788|DRUG|Saline|40 mL sterile normal saline
218921721|NCT03856788|DRUG|Bupivacaine|40 mL 0.25% bupivacaine
218921722|NCT01642576|BEHAVIORAL|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
218921723|NCT05973032|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
218921724|NCT06048120|DRUG|BAY2701250 IV|Single does, intravenous infusion
218921725|NCT06048120|DRUG|Placebo IV|Matching placebo for BAY2701250 IV
218921726|NCT06048120|DRUG|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
218921727|NCT06048120|DRUG|Placebo SC|Matching placebo for BAY2701250 SC
218921728|NCT03415685|DEVICE|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
218921729|NCT01096875|DRUG|Atorvastatin|40mg/day once daily for two weeks prior to surgery
218921730|NCT01096875|DRUG|Placebo|1tb/day once daily for two weeks prior to surgery
218921731|NCT03189004|BEHAVIORAL|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring"
218921732|NCT02729532|DEVICE|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
218921733|NCT05708053|DRUG|Metformin|Metformin 500 mg twice
218921734|NCT06141525|DEVICE|Remote ischemic conditioning|An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).
219618646|NCT04528667|DRUG|Placebo|Placebo capsules
219618647|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
218921735|NCT01190462|BIOLOGICAL|cetuximab|
218921736|NCT01190462|DRUG|simvastatin|
219618648|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
218921737|NCT01190462|OTHER|laboratory biomarker analysis|
218921738|NCT00728689|DRUG|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
219535709|NCT05657860|DRUG|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
219535710|NCT05657860|OTHER|Placebo|Placebo will be administered concurrently with GXR during trials.
218921739|NCT00728689|DRUG|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
219535711|NCT01250080|DIETARY_SUPPLEMENT|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
219535712|NCT01250080|OTHER|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
219618649|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
218921740|NCT01525069|DRUG|Floxuridine|
218921741|NCT01525069|DRUG|Dexamethasone|
218921742|NCT01525069|DRUG|Gemcitabine|
218921743|NCT01525069|DRUG|Oxaliplatin|
219535713|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
219535714|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
218921744|NCT04210531|DIETARY_SUPPLEMENT|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
218921745|NCT04210531|DIETARY_SUPPLEMENT|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
218921746|NCT05248152|COMBINATION_PRODUCT|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
218921747|NCT05248152|DRUG|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
218921748|NCT05248152|DRUG|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
219042732|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
219042733|NCT00004918|BIOLOGICAL|PR1 leukemia peptide vaccine|Given SC
219042734|NCT00004918|DRUG|Montanide ISA 51 VG|Given SC
219535715|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23), Guselkumab (IL-23), or Ustekinumab (IL-12/23) as standard of care treatment.
219042735|NCT00004918|BIOLOGICAL|sargramostim|Given SC
219618650|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
219618651|NCT00118339|DRUG|chemoprotection|
219618652|NCT00118339|PROCEDURE|complementary or alternative medicine procedure|
219618653|NCT00118339|PROCEDURE|management of therapy complications|
219618654|NCT02512302|DRUG|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
219618655|NCT02512302|DRUG|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
219618656|NCT02512302|DRUG|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
219618657|NCT02512302|DRUG|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
219618658|NCT02512302|DRUG|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
219618659|NCT03426306|DIAGNOSTIC_TEST|4DCT-Ventilation|4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
219618660|NCT04144413|DRUG|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
218921749|NCT06403969|BEHAVIORAL|Applied Behavior Analysis|Applied Behavior Analysis focusing on nocturnal awakenings. It starts with identification of target behaviors and goals. A functional analysis is conducted to analyze the underlying function of a behavior in connection to the problem. A treatment plan is formulated, including strategies to achieve the goals, and methods to evaluate. Families receive education sleep hygiene. Adaptations focus on antecedents and consequences, with an emphasis on positive reinforcement of favorable behaviors. Various components of Cognitive Behavioral Therapy may be applicable. These include changes in sleep environment, stimulus control, bedtime routines with visual support and prompting. Sleep restriction and bedtime fading are included. Modified extinction techniques with parental presence can be applied, gradually phasing out parental immediate presence. The intervention continues until goals are achieved or for a maximum of 8 sessions (each lasting up to 60 minutes) spread over 8 weeks.
218921750|NCT04442828|DIAGNOSTIC_TEST|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
218921751|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
218921752|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
218921753|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
218921754|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
219618661|NCT04144413|DRUG|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
218921755|NCT06209307|BEHAVIORAL|Pelvic floor physical therapy|"Pelvic floor physical therapy (i.e., Kegel exercises):~* Finding the right muscles: To identify pelvic floor muscles, the patient should stop urination in midstream or tighten the muscles that keep from passing gas. These maneuvers use pelvic floor muscles. Once the pelvic floor muscles are identified, the patient can do the exercises in any position, although doing them lying down at first might be the easiest approach.~* Perfecting the technique: Tighten pelvic floor muscles, hold the contraction for three seconds, and then relax for three seconds. Try it a few times in a row. When muscles get stronger, try doing Kegel exercises while sitting, standing, or walking.~* Maintaining focus: For best results, focus on tightening only pelvic floor muscles. Be careful not to flex the muscles in the abdomen, thighs, or buttocks. Avoid breath-holding. Instead, breathe freely during the exercises.~* Repeat 3 times a day. Aim for three sets of 10 repetitions a day."
218921756|NCT03449290|OTHER|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
219535716|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
219535717|NCT01915186|DIETARY_SUPPLEMENT|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
219618662|NCT04144413|OTHER|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
218921757|NCT03449290|OTHER|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
218921758|NCT02661334|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
218921759|NCT02661334|DIETARY_SUPPLEMENT|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
218921760|NCT01523366|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
218921761|NCT01523366|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
219204761|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
219535718|NCT06027710|PROCEDURE|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
219618663|NCT00827008|DRUG|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
218921762|NCT03488017|DEVICE|Ocular Coil|Non-invasive ocular device
218921763|NCT00624182|BIOLOGICAL|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
218921764|NCT00624182|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
218921765|NCT01885130|OTHER|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
218921766|NCT02945488|OTHER|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
218921767|NCT02945488|OTHER|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
218921768|NCT02945488|OTHER|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
218921769|NCT00589394|BIOLOGICAL|pneumococcal vaccination (Pneumovax)|pneumovax was given
218921770|NCT05166200|OTHER|Experimental Formula|Diabetes-specific study formula
219535719|NCT00571064|DRUG|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
219535720|NCT02472197|PROCEDURE|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
218921771|NCT05166200|OTHER|Test Meal|Instant oatmeal
218921772|NCT02910531|DIETARY_SUPPLEMENT|Alpha lipoic acid|Already mentioned in arm/group descriptions.
218921773|NCT02910531|DRUG|Placebo|Already mentioned in arm/group descriptions.
219535721|NCT02472197|PROCEDURE|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
219535722|NCT06350591|OTHER|Immobilization|single-leg immobilization
219535723|NCT06350591|OTHER|Resistance training|Leg extension and leg press; 3 sets of 8-12 reps
219535724|NCT06311682|DRUG|Tralokinumab + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
219535725|NCT06311682|DRUG|Placebo + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
219535726|NCT04261673|PROCEDURE|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
219535727|NCT04261673|PROCEDURE|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
219535728|NCT06447805|DEVICE|Double Sequential Defibrillation (DSD)|The second defibrillator will be applyed with electrodes placed in the A-P position
219535729|NCT06447805|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
219535730|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
219535731|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
219618664|NCT06270381|OTHER|EMPOWER|The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.
219042736|NCT00004918|OTHER|laboratory biomarker analysis|Correlative studies
219042737|NCT05768932|DRUG|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
219042738|NCT05768932|COMBINATION_PRODUCT|Carboplatin|Carboplatin is an Antineoplastic agent
218921774|NCT03941288|DRUG|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
218921775|NCT03941288|OTHER|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
219618665|NCT06270381|OTHER|Treatment as usual (TAU)|The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
219618666|NCT01969149|DRUG|Exenatide|
218921776|NCT00399906|DRUG|BMS-582949|Tablets, Oral, Once daily, 12 weeks
218921777|NCT00399906|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks
218921778|NCT06295484|OTHER|Alternating traditional CPAP, NIPPV, and high CPAP|The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
218921779|NCT06521307|DIETARY_SUPPLEMENT|Nicotinamide riboside|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
218921780|NCT06521307|OTHER|Placebo|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
218921781|NCT00254696|DRUG|Extended-Spectrum-Lactamases (ESBLs)|
218921782|NCT04298242|DEVICE|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
218921783|NCT04543279|DRUG|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
218921784|NCT04543279|DRUG|Ruxolitinib|Ruxolitinib is commercially available.
218921785|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
218921786|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
218921787|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
218921788|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
218921789|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
218921790|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
219042739|NCT05768932|COMBINATION_PRODUCT|Paclitaxel|Paclitaxel is a natural product with antitumor activity
219535732|NCT04132362|BEHAVIORAL|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
219535733|NCT04132362|BEHAVIORAL|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
219535734|NCT04132362|BEHAVIORAL|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
219535735|NCT04604275|DRUG|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
219618667|NCT01969149|DRUG|Insulin|
219618668|NCT04126980|BEHAVIORAL|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
218921791|NCT01067053|DRUG|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
218921792|NCT06243536|DRUG|Semaglutide|Semaglutide will be administered through 12 weeks.
219618669|NCT00438581|DRUG|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
218921793|NCT06243536|DRUG|standard of care|Patients not assigned to receive semaglutide will receive standard of care.
219535736|NCT04604275|OTHER|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
219535737|NCT04572022|OTHER|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
219535738|NCT05296967|BEHAVIORAL|chewing|patients are asked to chew chewing gum X 3/ day
218921794|NCT00023660|DRUG|celecoxib|
218921795|NCT00023660|DRUG|cisplatin|
218921796|NCT00023660|DRUG|fluorouracil|
218921797|NCT00023660|RADIATION|brachytherapy|
219535739|NCT05615935|OTHER|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
219618670|NCT02764762|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
218921798|NCT00023660|RADIATION|radiation therapy|
218921799|NCT00782990|PROCEDURE|Surgical treatment: TVT|
218921800|NCT00782990|PROCEDURE|Surgical treatment: colposuspension|
218921801|NCT00393159|DEVICE|Ear Popper|
218921802|NCT00272584|DRUG|Risperidone|
218921803|NCT04712682|OTHER|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
218921804|NCT01850667|RADIATION|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
219042740|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
219535740|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
219535741|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
219535742|NCT02162849|DRUG|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
219535743|NCT02162849|DRUG|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
219535744|NCT02162849|DRUG|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
219535745|NCT02162849|DRUG|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
219535746|NCT02162849|BEHAVIORAL|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
219535747|NCT02162849|BEHAVIORAL|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
218921805|NCT05447052|DEVICE|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
218921806|NCT05447052|DEVICE|Innova Stent|Innova Stent implantation
218921807|NCT00456222|BEHAVIORAL|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
218921808|NCT00929695|DRUG|prednisone|immunosuppressive drug
218921809|NCT00929695|DRUG|methylprednisolone|immunosuppressive drug
219042741|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
219042742|NCT05112666|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
219042743|NCT05112666|DRUG|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
219042744|NCT05112666|DRUG|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
219042745|NCT04935476|DRUG|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
219042746|NCT04935476|DRUG|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
219535748|NCT02162849|OTHER|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
219618671|NCT02764762|DRUG|Adalimumab|Adalimumab injection for subcutaneous use.
219618672|NCT02764762|DRUG|Methotrexate|Methotrexate oral tablets.
219618673|NCT01434160|DRUG|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
219618674|NCT01002989|DEVICE|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
219618675|NCT01002989|DEVICE|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
218921810|NCT00929695|OTHER|questionnaire administration|Ancillary studies
218921811|NCT03184688|PROCEDURE|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
219535749|NCT02162849|OTHER|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
219618676|NCT06147999|DEVICE|Biophotonizer - a Biophoton Generator|A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
219618677|NCT03182504|DRUG|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
219618678|NCT03182504|DRUG|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
219535750|NCT05490511|DRUG|Tacrolimus single dose|5 mg once
219535751|NCT05490511|DRUG|Epidiolex single dose|Epidiolex 5 mg/kg
219535752|NCT05490511|DRUG|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
219535753|NCT06424015|OTHER|Intralipid and heparin|Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
219535754|NCT06424015|OTHER|Saline|Saline will be infused
219535755|NCT05082584|DRUG|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
219535756|NCT03591510|DRUG|Midostaurin|midostaurin 30mg/m2 bid
219535757|NCT03591510|DRUG|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
219535758|NCT03591510|DRUG|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
219535759|NCT03591510|DRUG|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
219535760|NCT03591510|DRUG|Mitoxantrone|10mg/m2/day D3 and D4
219535761|NCT03591510|DRUG|Etoposide|100mg/m2/day D1 to D5
219618679|NCT03742661|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
219535762|NCT04000152|DIAGNOSTIC_TEST|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
219618680|NCT06575855|OTHER|IASTM|Group A received IASTM by using Graston Tool
219618681|NCT06575855|OTHER|METS|Group B received METs
219618682|NCT01892501|PROCEDURE|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
218921812|NCT03184688|DRUG|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
218921813|NCT05669274|OTHER|Milk containing A1 and A2 beta-casein|Milk dose for 2 weeks
219618683|NCT01892501|DEVICE|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
219618684|NCT05685147|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
219618685|NCT03552068|DRUG|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
218921814|NCT05669274|OTHER|Milk containing only A2 beta-casein|Milk dose for 2 weeks
218921815|NCT04570007|PROCEDURE|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
218921816|NCT00002485|PROCEDURE|psychosocial assessment and care|
218921817|NCT01213628|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
218921818|NCT02870595|DEVICE|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
219042747|NCT04431791|DRUG|Regorafenib|oral regorafenib
219042748|NCT04431791|DRUG|Fruquintinib|oral fruquintinib
219535763|NCT04000152|OTHER|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
218921819|NCT02870595|DEVICE|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
218921820|NCT00425802|BIOLOGICAL|anti-thymocyte globulin|
218921821|NCT00425802|BIOLOGICAL|filgrastim|
218921822|NCT00425802|BIOLOGICAL|graft-versus-tumor induction therapy|
218921823|NCT00425802|BIOLOGICAL|rituximab|
219618686|NCT03552068|DRUG|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
219618687|NCT05923801|DEVICE|switch to BT electrode position|use of different electrode positions of ECT device
219618688|NCT05923801|DEVICE|continue with RUL electrode position|use of different electrode positions of ECT device
219535764|NCT06319287|BIOLOGICAL|PEP (Purified Exosome Product) / TISSEEL|"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"
219535765|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
219618689|NCT04070001|DRUG|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
219618690|NCT04070001|DEVICE|laser application|A single irradiation of laser after elastomeric separator placement
219618691|NCT04070001|OTHER|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
219618692|NCT05149625|DEVICE|Dexcom G6|continuous glucose monitoring device
219618693|NCT02790567|OTHER|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
219618694|NCT02790567|OTHER|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
218921824|NCT00425802|DRUG|cyclophosphamide|
218921825|NCT00425802|DRUG|cyclosporine|
218921826|NCT00425802|DRUG|fludarabine phosphate|
218921827|NCT00425802|DRUG|mycophenolate mofetil|
218921828|NCT00425802|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
218921829|NCT00425802|RADIATION|total-body irradiation|
218921830|NCT01592357|BEHAVIORAL|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
219042749|NCT00974714|DRUG|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
219535766|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
219618695|NCT02790567|OTHER|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
219618696|NCT02790567|OTHER|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
219618697|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
219618698|NCT05979103|BEHAVIORAL|Listening to Preferred Music|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to preferred music over the 4 weeks. Each day, we will remind them to listen to preferred music.
219618699|NCT05615818|DRUG|Futibatinib|Dose 20 mg once a day (QD)
218921831|NCT01592357|BEHAVIORAL|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
218921832|NCT03788512|OTHER|observational only- no intervention|observational only- no intervention
219618700|NCT05615818|DRUG|Ivosidenib|Dose 500 mg QD
219618701|NCT05615818|DRUG|Zanidatamab|Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
219618702|NCT05615818|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
219618703|NCT05615818|DRUG|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
219618704|NCT05615818|DRUG|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
219618705|NCT05615818|DRUG|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
219618706|NCT05615818|DRUG|Niraparib|Dose: 200 mg QD or 300 mg QD
219618707|NCT05615818|DRUG|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
219618708|NCT05615818|DRUG|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
219618709|NCT06642181|DRUG|Guanfacine pharmacotherapy|It is a pharmacotherapy
218921833|NCT04902976|OTHER|CPC+ZN|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the solution for 30 s
218921834|NCT04902976|OTHER|CPC|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the proposed solution for 30 s;
218921835|NCT04902976|OTHER|Negative Control|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of distilled water for 30 s.
218921836|NCT01526863|DIETARY_SUPPLEMENT|HA egg|Daily dose of HA egg or placebo for 6 months
218921837|NCT03430284|BEHAVIORAL|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
218921838|NCT03430284|DRUG|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
218921839|NCT03430284|OTHER|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
219618710|NCT06642181|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|It is a mindfulness intervention
219618711|NCT00789048|OTHER|radiograph|One radiograph with the patient lying on his contralateral side
219618712|NCT05382273|BEHAVIORAL|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~* The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~* The second week focuses on the emotional experience (e.g., anxiety, boredom).~* The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
219618713|NCT05862623|DRUG|AER-01|AER-01 solution for inhalation delivered via nebulizer
219618714|NCT05862623|DRUG|Placebo|Placebo for solution for inhalation delivered via nebulizer
218921840|NCT03430284|OTHER|General treatment|General treatment is carried out based on the device from the general practitioners at present.
218921841|NCT00002337|DRUG|Vesnarinone|
219535767|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
219535768|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
219535769|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
219535770|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
218921842|NCT00887809|DRUG|gemcitabine|
218921843|NCT00887809|DRUG|docetaxel|
218921844|NCT00887809|DRUG|bevacizumab|
218921845|NCT05393440|BIOLOGICAL|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
218921846|NCT05722392|PROCEDURE|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
219042750|NCT00974714|OTHER|placebo|oral placebo 2 g twice a day for 14 weeks
219535771|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
219618715|NCT01468714|DRUG|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
219042751|NCT01470391|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
219042752|NCT01470391|PROCEDURE|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
219042753|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
219042754|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
219535772|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
219535773|NCT06472817|OTHER|Non-Interventional Study|Non-interventional study
219535774|NCT05244421|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
218921847|NCT01615484|PROCEDURE|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
218921848|NCT01615484|DEVICE|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
218921849|NCT05627830|PROCEDURE|Prolotherapy|Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
218921850|NCT04565132|DEVICE|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
218921851|NCT06161246|DEVICE|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
218921852|NCT04356898|OTHER|No intervention|No intervention
218921853|NCT06222892|DRUG|Camlipixant|Camlipixant will be administered.
218921854|NCT03631251|DRUG|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
218921855|NCT02886455|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
218921856|NCT02886455|OTHER|New adhesive strip|This a newly developed adhesive strip.
219535775|NCT05873439|RADIATION|Genomically Guided Radiation Therapy (RT)|Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
219535776|NCT06261463|BEHAVIORAL|CAFES2|The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
219535777|NCT03417921|DRUG|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
219535778|NCT03417921|DRUG|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
219535779|NCT04765059|DRUG|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
219535780|NCT04765059|DRUG|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
219535781|NCT06536426|BEHAVIORAL|Knee Isometric Program (KIP)|"The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes"
219535782|NCT02689505|DRUG|BI 836880|Solution for intravenous infusion
219535783|NCT05815160|DRUG|Debio 0123|Administered as capsules.
219535784|NCT05815160|DRUG|Etoposide|Administered as IV infusion.
219535785|NCT05815160|DRUG|Carboplatin|Administered as IV infusion.
219535786|NCT05447598|OTHER|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
219535787|NCT05447598|OTHER|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
219535788|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
219535789|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
219535790|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
219535791|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
219042755|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
219042756|NCT00989833|DRUG|budesonide|400 yg x 1
219042757|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
219042758|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
219042759|NCT02518477|OTHER|exercise|progressive resistance training
219042760|NCT03302728|DRUG|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
218921857|NCT03131323|PROCEDURE|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~* Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~* The camera: fitted with Three-CCD (Charged Couple Device) sensors.~* A high resolution monitor.~* A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required \[8\].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
218921858|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
218921859|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
218921860|NCT01352715|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
218921861|NCT01352715|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
218921862|NCT01352715|DRUG|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
218921863|NCT01352715|DRUG|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
218921864|NCT01352715|DRUG|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
218921865|NCT01352715|DRUG|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
218921866|NCT01352715|DRUG|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
218921867|NCT01352715|DRUG|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
218921868|NCT03500718|DEVICE|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
218921869|NCT06019702|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
218921870|NCT03990961|DRUG|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
218921871|NCT01310452|DRUG|insulin detemir|insulin detemir once daily with metformin
218921872|NCT01310452|DRUG|neutral protamine insulin|neutral protamine insulin once daily with metformin
218921873|NCT06246773|BEHAVIORAL|Positive Parenting Program|During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.
218921874|NCT06246773|BEHAVIORAL|Usual Care|Participants will receive services available to them at the shelter or housing facility
218921875|NCT00871975|DEVICE|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
218921876|NCT05515809|DRUG|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
219535792|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
219535793|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
219535794|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
218921877|NCT05515809|DRUG|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
219535795|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
219535796|NCT06969430|DRUG|Debio 1562M|Administered as intravenous (IV) infusion
219535797|NCT02446600|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219535798|NCT02446600|DRUG|Carboplatin|Given IV
219535799|NCT02446600|DRUG|Cediranib Maleate|Given PO
219535800|NCT02446600|PROCEDURE|Computed Tomography|Undergo CT
219535801|NCT02446600|PROCEDURE|Echocardiography Test|Undergo ECHO
218921878|NCT03115866|BEHAVIORAL|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
218921879|NCT06555107|OTHER|questionnaire|Patients included in the study will be asked to complete a questionnaire 48 to 72 hours after surgery to assess their perception of pain and preoperative anxiety
218921880|NCT06555107|OTHER|phone call|Patients will then be interviewed by phone 3 months after their emergency surgery. During the interview, they will be questioned via a standardised questionnaire on the existence of CPSP
218921881|NCT03302325|PROCEDURE|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
218921882|NCT04438265|DRUG|levobupivacaine|local anesthetic
218921883|NCT04438265|DEVICE|ultrasound device|scream
218921884|NCT04349267|BIOLOGICAL|BMS-986315|Specified dose on specified days
218921885|NCT04349267|BIOLOGICAL|nivolumab|Specified dose on specified days
218921886|NCT04349267|BIOLOGICAL|cetuximab|Specified dose on specified days
218921887|NCT05589662|OTHER|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
218921888|NCT00870740|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
218921889|NCT00870740|DRUG|Placebo|Placebo SC injection
219042761|NCT03302728|DRUG|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
219535802|NCT02446600|DRUG|Gemcitabine|Given IV
219535803|NCT02446600|DRUG|Gemcitabine Hydrochloride|Given IV
219535804|NCT02446600|OTHER|Laboratory Biomarker Analysis|Correlative studies
219535805|NCT02446600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219535806|NCT02446600|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219535807|NCT02446600|DRUG|Olaparib|Given PO
219535808|NCT02446600|DRUG|Paclitaxel|Given IV
219535809|NCT02446600|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219535810|NCT02446600|OTHER|Pharmacological Study|Correlative studies
219535811|NCT02446600|OTHER|Quality-of-Life Assessment|Ancillary studies
219535812|NCT04041778|OTHER|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
219535813|NCT06845358|BIOLOGICAL|BCG TICE strain|BCG TICE strain is an attenuated, live culture preparation of the BCG strain of Mycobacterium bovis.
219535814|NCT06845358|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
219535815|NCT06845358|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
219535816|NCT04857684|DRUG|Atezolizumab|Intravenous Infusion
219535817|NCT04857684|DRUG|Bevacizumab|Intravenous Infusion
219535818|NCT04857684|RADIATION|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
219535819|NCT04108858|DRUG|Copanlisib|Given IV
219535820|NCT04108858|BIOLOGICAL|Pertuzumab|Given IV
219535821|NCT04108858|BIOLOGICAL|Trastuzumab|Given IV
219535822|NCT05861973|BEHAVIORAL|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless Bluetooth scale for 12 months.
219535823|NCT05861973|BEHAVIORAL|Diabetes Prevention Program (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
219535824|NCT05861973|BEHAVIORAL|Self-Guided Treatment (Self-Guided)|Provides paper and internet resources tailored to geographic area, educating on leading a healthier lifestyle, including information on wellness and physical activity. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
219535825|NCT05236439|DEVICE|Interposition supraciliary implant|Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
219535826|NCT02045472|DRUG|VIS410|
219535827|NCT02045472|DRUG|Placebo|
219618716|NCT06266325|OTHER|There is no intervention. Exposures are predictor variables of mortality.|Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
219618717|NCT01366417|DRUG|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
219618718|NCT01366417|DRUG|70% isopropyl alcohol|Curity Alcohol Prep Pads
219618719|NCT03979625|OTHER|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
218921890|NCT00148395|DRUG|Gemcitabine|
218921891|NCT00148395|DRUG|Navelbine|
219535828|NCT04608188|BEHAVIORAL|Summer Camp|The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
218921892|NCT00148395|DRUG|Carboplatin|
218921893|NCT00148395|DRUG|Cisplatin|
218921894|NCT00148395|DRUG|Mitomycin|
219535829|NCT06268665|DRUG|Tart Cherry Juice|Given PO
219535830|NCT06561867|DRUG|Ticagrelor 90 MG|Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
219535831|NCT06561867|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219618720|NCT06313541|RADIATION|SBRT or LDRT|Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.
218921895|NCT00148395|DRUG|Ifosfamide|
218921896|NCT05005234|DRUG|GFH925|Administered as an oral tablet formulation
218921897|NCT05919186|DRUG|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
219535832|NCT00838136|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
219535833|NCT00838136|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
218921898|NCT05919186|DEVICE|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
218921899|NCT05919186|DEVICE|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
218921900|NCT03755934|DRUG|MEDI7352|Participants will receive IV infusion of MEDI7352 as stated in arm description.
219535834|NCT05895383|DRUG|Nitrous oxide|Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
219535835|NCT05606744|DEVICE|Eccentric exercise / Eccentric exercise with blood flow restriction|Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
218921901|NCT03755934|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
218921902|NCT00817843|DRUG|Simvastatin|6 weeks of treatment with simvastatin 80 mg
218921903|NCT00817843|DRUG|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
218921904|NCT03557749|DIAGNOSTIC_TEST|Blood Sample|60 ml heparinized blood 10 ml serum
218921905|NCT03557749|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount
218921906|NCT03557749|DIAGNOSTIC_TEST|Urine Sample|10 ml
218921907|NCT03557749|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) fluid|10 ml
218921908|NCT03557749|DIAGNOSTIC_TEST|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
218921909|NCT03557749|DIAGNOSTIC_TEST|Skin biopsy|2-4 mm punch
218921910|NCT03557749|DIAGNOSTIC_TEST|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
218921911|NCT03557749|DIAGNOSTIC_TEST|Apheresis Product|Up to 10 ml of apheresis product
218921912|NCT03557749|DIAGNOSTIC_TEST|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
218921913|NCT02079896|DRUG|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
219618721|NCT06313541|DRUG|PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy|The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
219618722|NCT03604224|DRUG|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
218921914|NCT02079896|DRUG|Placebo|
218921915|NCT02681029|PROCEDURE|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
218921916|NCT02681029|PROCEDURE|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
218921917|NCT01720108|DRUG|rivaroxaban and ASA|
218921918|NCT00307801|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
218921919|NCT00307801|DRUG|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
218921920|NCT03431259|OTHER|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
218921921|NCT00785759|DRUG|AH110690 (18F) Injection|All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
218921922|NCT03476486|PROCEDURE|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
218921923|NCT00551642|DRUG|Nitric oxide|Nitric Oxide vapour (gas) for inhalation (400 ppm)
218921924|NCT00551642|DRUG|Placebo|Placebo gas for inhalation
218921925|NCT06059482|OTHER|Assessment|Evaluations will be made once.
218921926|NCT04822116|OTHER|goal directed intraoperative haemodynamic optimization|all interventions that were pre-specified to be administered as part of the protocol
218921927|NCT01481753|PROCEDURE|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
218921928|NCT01481753|PROCEDURE|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
218921929|NCT01808586|PROCEDURE|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
219535836|NCT01415986|DRUG|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
219535837|NCT01415986|DEVICE|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
219535838|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
219535839|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
219535840|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
219535841|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
219535842|NCT01434953|BEHAVIORAL|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
218921930|NCT01808586|PROCEDURE|Dexamethasone|4mg/mL
218921931|NCT01808586|PROCEDURE|Intramuscular Lidocaine|2%
218921932|NCT01808586|BEHAVIORAL|Home Exercise|Standardized home exercise program
218921933|NCT00131079|BEHAVIORAL|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
218921934|NCT00131079|BEHAVIORAL|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
219204762|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
219535843|NCT01434953|BEHAVIORAL|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
219535844|NCT01250912|DRUG|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128\_128 matrix) will be acquired beginning 15 minutes after tracer injection.
219535845|NCT01449383|DIETARY_SUPPLEMENT|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
219535846|NCT01449383|DIETARY_SUPPLEMENT|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
219535847|NCT06225921|DRUG|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
219535848|NCT06225921|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
219535849|NCT06225921|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
219535850|NCT03899077|DRUG|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
219535851|NCT03899077|DRUG|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
219535852|NCT03899077|DRUG|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
219535853|NCT03899077|DRUG|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
219535854|NCT03899077|DRUG|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
218921935|NCT03011099|DEVICE|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
218921936|NCT03011099|OTHER|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
218921937|NCT02968758|DEVICE|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
218921938|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
218921939|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
218921940|NCT02575963|DRUG|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
219618723|NCT03627975|PROCEDURE|Conservative treatment|"1. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~2. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~3. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
218921941|NCT02575963|BIOLOGICAL|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
219535855|NCT05822479|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg intramuscular (IM) meperidine was administered in the ward."
219535856|NCT05822479|OTHER|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg IM meperidine was administered in the ward."
219618724|NCT00400374|DRUG|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
218921942|NCT02575963|DRUG|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
218921943|NCT02575963|DRUG|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
218921944|NCT04181658|OTHER|Real tDCS and Physical Therapy|The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
219204763|NCT06966206|DRUG|Multiprofen-CC™ plus standard treatment|Standard care pain medications and topical Multiprofen-CC™ (1g TID) for 2 weeks
219618725|NCT00400374|DRUG|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
219618726|NCT01441648|OTHER|contact lens wear|tinted contact lens wear
219618727|NCT01483703|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
219535857|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
219535858|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
219535859|NCT03410784|DRUG|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
219535860|NCT03410784|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
218921945|NCT04181658|OTHER|Sham stimulation and Physical Therapy|The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
218921946|NCT02192580|DRUG|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
218921947|NCT06183762|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
218921948|NCT03675347|OTHER|angioplasty|angioplasty
218921949|NCT03902353|OTHER|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
218921950|NCT04692259|DIAGNOSTIC_TEST|MRI|Liver MRI before liver resection
218921951|NCT03238378|RADIATION|Brachytherapy|Brachytherapy d 1-5(6)
219618728|NCT01321879|DRUG|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
219618729|NCT06520618|DRUG|Qing Re He Ji|Oral administration of Qing Re He Ji
219618730|NCT06520618|DRUG|Shuanghuanglian Oral Liquid|Oral administration of Shuanghuanglian Oral Liquid
219618731|NCT05564156|BEHAVIORAL|Intervention groups|The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
218921952|NCT03238378|OTHER|Hyperthermia|Hyperthermia d 2 + 5
218921953|NCT04409925|DRUG|rhDNase I|Inhaled nebulisations
219204764|NCT06966206|OTHER|Placebo plus standard treatment|Standard care pain medications and visually identical topical placebo (1g TID) for 2 weeks
219204765|NCT06966245|DRUG|mastalgia-oil|External mastalgia-oil 1 ml/d per breast for 3 consecutive menstrual cycles
219204766|NCT06966245|DRUG|Mastalgia-oil placebo|External mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
219535861|NCT03410784|DRUG|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
219535862|NCT02477787|BIOLOGICAL|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
219535863|NCT03801980|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
219535864|NCT03801980|DRUG|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
219535865|NCT06288035|DRUG|Dexamethasone Oral|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
219535866|NCT06288035|DRUG|Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
219535867|NCT01575457|BEHAVIORAL|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
219618732|NCT01641640|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
219618733|NCT01641640|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219618734|NCT01641640|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
219618735|NCT03076892|DEVICE|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
219618736|NCT03076892|DEVICE|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
219618737|NCT02308969|DRUG|LSD|100ug per os, single dose
219618738|NCT02308969|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
218921954|NCT06473740|DRUG|Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)|"The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection."
218921955|NCT04885452|OTHER|biobank|"* Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
218921956|NCT06199843|DRUG|Rifaximin|Rifaximin 550 mg BD
218921957|NCT06199843|DRUG|Norfloxacin|Norfloxacin 400 mg OD
218921958|NCT02574117|PROCEDURE|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
218921959|NCT02786017|BIOLOGICAL|Conventional therapy|Patients will receive the conventional therapy.
218921960|NCT02786017|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
218921961|NCT01088867|OTHER|Acupuncture|Electroacupuncture
218921962|NCT03377608|DRUG|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
218921963|NCT03377608|DRUG|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
218921964|NCT01796808|PROCEDURE|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
218921965|NCT01796808|OTHER|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. \<200ml). Only a few cc's of fat are needed for injection into the foot."
218921966|NCT06286345|BEHAVIORAL|GLI-LEEF|"GLI-LEEF is an 18-week program, during which various lifestyle topics are discussed, such as nutrition, exercise, sleep, relationships and intimacy, and specific education about depression and its influence on lifestyle. GLI-LEEF is aimed at improving the activity level, quality of life and (cardiovascular) health of patients and thus increasing the general functioning and well-being of patients and at the same time reducing psychological complaints.~GLI-LEEF consists of 14 group meetings and 4 individual meetings, the group meetings last 90 minutes, the individual meetings 30 minutes. Patients are asked to wear a FitBit and to complete short homework assignments. Each group contains 8-10 patients. Patients are asked to find a buddy who can support them during the program."
219204767|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
219204768|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
219535868|NCT03122457|DRUG|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
219535869|NCT02704286|BEHAVIORAL|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
219535870|NCT02704286|BEHAVIORAL|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
219535871|NCT00614952|DEVICE|PSG (polysomnography)|POLYSOMNOGRAPHY
219535872|NCT00614952|OTHER|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
219535873|NCT02864615|RADIATION|SBRT|Dose and schedule will be depended on metastases location.
219618739|NCT06360172|BEHAVIORAL|Motivational Interviewing|Motivational interviewing, or MI, is a collaborative, person-centered counseling technique to uncover and enhance a person\&#39;s motivation for behavior change
219618740|NCT02598635|DRUG|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
218921967|NCT05893784|OTHER|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
219535874|NCT06375460|BEHAVIORAL|Focused App Prompt|Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).
218921968|NCT05686603|DEVICE|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
219535875|NCT06375460|BEHAVIORAL|No App Prompt|No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.
219618741|NCT02598635|DRUG|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
219618742|NCT00180843|DRUG|salbutamol + ipratropium bromide nebules|
219618743|NCT00180843|DRUG|nebulized saline|
218921969|NCT05686603|DEVICE|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
218921970|NCT00628420|DRUG|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
218921971|NCT00628420|DRUG|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
218921972|NCT00628420|DRUG|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
218921973|NCT01217229|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
219618744|NCT01839708|BEHAVIORAL|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
219618745|NCT04777942|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
219618746|NCT04777942|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
218921974|NCT05716802|BEHAVIORAL|dance/movement therapy|dance/movement therapy plus treat as usual
219535876|NCT06375460|BEHAVIORAL|Outreach for Missing Data|For participants randomized to proactive outreach, after 3 or more days of missing CGM data, the study team will reach out to participants by phone and/or text message to troubleshoot and support participants in re-connecting with CGM and apps. For participants randomized to not receive proactive outreach, participants will be instructed to reach out to the study team at their discretion when help is needed related to CGM or app connection.
219535877|NCT00210223|PROCEDURE|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
219535878|NCT03653507|DRUG|zolbetuximab|Zolbetuximab were administered as a minimum 2-hour IV infusion.
219535879|NCT03653507|DRUG|oxaliplatin|Oxaliplatin were administered as a 2-hour IV infusion.
219535880|NCT03653507|DRUG|capecitabine|Capecitabine were administered orally twice daily (bid).
219535881|NCT03653507|DRUG|placebo|Placebo were administered as a minimum 2-hour IV infusion.
219618747|NCT03540888|OTHER|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
219618748|NCT03540888|OTHER|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
218921975|NCT05716802|BEHAVIORAL|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
219535882|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
219535883|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
219535884|NCT05463666|OTHER|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
219618749|NCT03540888|OTHER|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
219618750|NCT03849924|BEHAVIORAL|Self-affirmation|Self-affirmation implementation intentions in the form of a questionnaire.
219618751|NCT04790903|DRUG|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
219618752|NCT04790903|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
219618753|NCT04790903|DRUG|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
219618754|NCT04790903|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
218921976|NCT05542420|OTHER|No treatment given|The study will be based on data already recorded in the medical record
218921977|NCT04796155|DIAGNOSTIC_TEST|Intrapartum ultrasound|Intrapartum ultrasound will be performed by suprapubic and transperineal approach for 30 seconds.
218921978|NCT03239392|DRUG|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
218921979|NCT01617824|DRUG|Linagliptin|Linagliptin 5 mg tablets for 4 days
218921980|NCT01617824|DRUG|Placebo|Placebo tablets for 4 days
218921981|NCT04278599|DRUG|Oral Zinc supplementation|In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
218921982|NCT04278599|DRUG|Oral placebo supplementation|In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
218921983|NCT00602602|BIOLOGICAL|bevacizumab|
218921984|NCT00602602|DRUG|fluorouracil|
218921985|NCT00602602|DRUG|gemcitabine hydrochloride|
218921986|NCT00602602|DRUG|oxaliplatin|
218921987|NCT00602602|OTHER|immunohistochemistry staining method|
219618755|NCT04790903|DRUG|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
219042762|NCT03672695|COMBINATION_PRODUCT|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
219535885|NCT03074487|DEVICE|Near-infrared spectroscopy|
219535886|NCT03074487|DEVICE|Long loop reflex measurements|
219535887|NCT06270498|DIETARY_SUPPLEMENT|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 24 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-16 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 24 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 24 weeks"
219535888|NCT06270498|OTHER|Placebo|"Placebo pills will be identical in shape, form and color of SI tablets; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin C.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
218921988|NCT00602602|OTHER|laboratory biomarker analysis|
218921989|NCT00602602|PROCEDURE|conventional surgery|
218921990|NCT00602602|PROCEDURE|endoscopic biopsy|
218921991|NCT00602602|PROCEDURE|laparoscopy|
218921992|NCT00602602|RADIATION|radiation therapy|
218921993|NCT03937934|BEHAVIORAL|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
218921994|NCT06436131|BEHAVIORAL|In-phase Bilateral Exercise|"The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks."
219535889|NCT05858320|OTHER|SmartHF application|Adaptive medication recommendations that can be shared with the participants HF provider.
219535890|NCT04408885|OTHER|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
219535891|NCT05365659|DRUG|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
218921995|NCT06436131|BEHAVIORAL|Conservative exercises|The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.
219535892|NCT06432738|DRUG|ZL-82|This group of subjects take ZL-82
219535893|NCT06432738|DRUG|ZL-82 placebo|This group of subjects take ZL-82 placebo
219535894|NCT04302324|DRUG|Daratumumab SC|Given as 1800mg via injection
219535895|NCT04302324|DRUG|Clarithromycin|Given as 500mg oral capsule
219535896|NCT04302324|DRUG|Pomalidomide|Given as 4mg oral capsule
218921996|NCT01925456|DRUG|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
218921997|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix with collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane"
218921998|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix (MPM) without collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM."
219535897|NCT04302324|DRUG|Dexamethasone|Given as 20mg IV and 20mg or 40mg oral tablets
219535898|NCT05758077|DEVICE|Selective Cytopheretic Device|"The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation."
219618756|NCT04790903|DRUG|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
219618757|NCT00422916|BEHAVIORAL|behavioral intervention|
219618758|NCT04341363|DEVICE|Tattoo machine|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
219618759|NCT02009553|OTHER|Information sheet|
219618760|NCT02009553|OTHER|No information sheet|
219618761|NCT01219816|DRUG|Epratuzumab|Combination of chemotherapy + Epratuzumab
219618762|NCT01219816|DRUG|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
219618763|NCT00063934|BIOLOGICAL|oblimersen sodium|Given IV
219618764|NCT00063934|DRUG|doxorubicin hydrochloride|Given IV
218921999|NCT03994081|DEVICE|tACS|XCSITE100
218922000|NCT03994081|DEVICE|Sham tACS|XCSITE100
218922001|NCT06521749|DEVICE|USB as a stylet|USB used as a bougie
218922002|NCT06521749|DEVICE|USB as a bougie|USB used as a bougie
219535899|NCT05758077|OTHER|Standard of Care|Standard of care CKRT for the subject's condition, as appropriate
219535900|NCT05325866|DRUG|Bemarituzumab|Intravenous (IV) infusion.
219535901|NCT05972967|BIOLOGICAL|OMS906|Biological: OMS906
219535902|NCT05673993|BIOLOGICAL|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
219535903|NCT05673993|BIOLOGICAL|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
219535904|NCT05673993|DRUG|Placebo|Subjects will be given subcutaneous placebo once a week.
219535905|NCT06343285|DEVICE|Encora Therapeutics Tremor Reduction Device|The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.
219535906|NCT06189157|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
219535907|NCT05080946|DRUG|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
219618765|NCT00063934|DRUG|docetaxel|Given IV
219618766|NCT00063934|BIOLOGICAL|filgrastim|Given SC
219618767|NCT00063934|BIOLOGICAL|pegfilgrastim|Given SC
219618768|NCT00063934|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219618769|NCT00063934|OTHER|pharmacological study|Optional correlative studies
219618770|NCT00063934|OTHER|laboratory biomarker analysis|Optional correlative studies
219618771|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.
219618772|NCT01428596|BIOLOGICAL|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
219618773|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.
219618774|NCT03941808|DRUG|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
219618775|NCT03941808|DRUG|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
219618776|NCT05348460|DIETARY_SUPPLEMENT|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
218922003|NCT03783078|DRUG|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
218922004|NCT04544813|DRUG|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
219535908|NCT05080946|DRUG|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
219535909|NCT04300335|OTHER|Individual Exercise|Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
219618777|NCT05348460|DIETARY_SUPPLEMENT|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
219618778|NCT05219760|DEVICE|LIVIA|"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."
219618779|NCT02863094|DEVICE|transcranial magnetic stimulation|
219618780|NCT05068180|DRUG|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
219618781|NCT05068180|DRUG|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
219618782|NCT04181294|BEHAVIORAL|Family meetings using time limited trials as default ICU communication and care planning approach|Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
219618783|NCT04181294|BEHAVIORAL|Usual practice|Baseline practice of ICU communication and care planning
219618784|NCT03560401|DEVICE|Knight-Taylor [chairback] brace|Knight-Taylor \[chairback\] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
219618785|NCT00210769|DRUG|paliperidone ER Oros|
219618786|NCT01963104|PROCEDURE|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219618787|NCT01963104|PROCEDURE|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219535910|NCT04300335|OTHER|Group Exercise|Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
218922005|NCT04544813|DRUG|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
219365489|NCT06077084|OTHER|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
219535911|NCT06799000|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
219535912|NCT06799000|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
219535913|NCT06799000|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
219535914|NCT06799000|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
219535915|NCT06449924|DEVICE|Endotracheal tube|Endotracheal Tube Inserted to the Level of the Hypopharynx
219535916|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
219535917|NCT00642980|DRUG|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
219535918|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
218922006|NCT02758210|DEVICE|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
218922007|NCT02758210|DEVICE|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
218922008|NCT04500912|DEVICE|Supraflex Cruz 60 Micron|percutaneous coronary intervention
218922009|NCT04500912|DEVICE|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
218922010|NCT03571438|COMBINATION_PRODUCT|CK2 and ATM inhibitors serine/ threonin Kinase combination|Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
218922011|NCT03571438|DRUG|Sunitinib|Treatment of cell culture with Sunitinib
218922012|NCT03571438|DRUG|Pazopanib|Treatment of cell culture with Pazopanib
218922013|NCT03571438|DRUG|Temsirolimus|Treatment of cell culture with Temsirolimus
218922014|NCT06226129|DRUG|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
218922015|NCT02346123|GENETIC|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
218922016|NCT00685230|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
218922017|NCT00685230|OTHER|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
218922018|NCT02997215|DRUG|Lidocaine|lidocaine infusion during surgery
218922019|NCT02997215|DRUG|Saline Placebo|saline infusion at same rate as intervention group during surgery
218922020|NCT03785015|OTHER|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
218922021|NCT03785015|OTHER|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
218922022|NCT00061438|DRUG|meropenem|
218922023|NCT05007054|PROCEDURE|PCI or CABG|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
219365490|NCT02509091|DRUG|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
219365491|NCT01263041|DRUG|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
219365492|NCT01263041|DRUG|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
219365493|NCT02388373|DRUG|Fluticasone 250/formoterol 10|
219365494|NCT02388373|DRUG|Fluticasone 250/salmeterol 25|
219365495|NCT02388373|DRUG|Fluticasone 125/formoterol 5|
219365496|NCT00844467|BIOLOGICAL|serotypes and resistance|screening patients with invasive pneumococci
219365497|NCT06549244|DIAGNOSTIC_TEST|Maximum Inspiratory Pressure monitoring|Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day
219365498|NCT02471716|BIOLOGICAL|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
219365499|NCT01539980|DEVICE|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
219365500|NCT04759300|DEVICE|C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS
219365501|NCT04759300|DEVICE|C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
219365502|NCT01893567|DRUG|Clobex Spray|
219365503|NCT05951283|DEVICE|Hybrid Closed Loop Insulin Pump|As above
219365504|NCT00626743|DRUG|SK3530 100mg, Placebo, Amlodipine|
219365505|NCT04660188|OTHER|Multidisciplinary collaborative care arm|Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
219365506|NCT01361763|DRUG|Dabigatran|110 mg twice daily
219365507|NCT01361763|DRUG|Antiplatelets|100mg once a day
219365508|NCT00165009|DEVICE|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
219365509|NCT01486862|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
219365510|NCT02978482|DRUG|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
219365511|NCT02978482|DRUG|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
219365512|NCT02211261|BIOLOGICAL|PF-06293620|subcutaneous, single dose 0.3 mg/kg
219365513|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
219365514|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
219365515|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
219365516|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 3 mg/kg
218922024|NCT06452563|DIETARY_SUPPLEMENT|ketoanalogue supplementation|This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021
218922025|NCT06452563|OTHER|intradialytic exercise|low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
218922026|NCT01623570|DRUG|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
218922027|NCT01623570|DRUG|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
218922028|NCT02953002|DEVICE|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
218922029|NCT02180100|DRUG|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
218922030|NCT02180100|DRUG|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
218922031|NCT04407754|DIETARY_SUPPLEMENT|Inositol supplement|Inositol supplements given to inositol arm
218922032|NCT04407754|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement given to placebo arm
218922033|NCT06318468|OTHER|Nursing health assessment teaching and discussion using humanoid diagrams|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
218922034|NCT06318468|OTHER|Nursing health assessment teaching and discussion using case study|The comparison group will receive the nursing health assessment teaching for 50 minutes and discussion using case study for 40 minutes to learn comprehensive nursing assessment.
218922035|NCT03955146|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
218922036|NCT03955146|DRUG|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
218922037|NCT04798183|DIAGNOSTIC_TEST|3-dimensional scan|Facial 3-dimensional scan according to posture
218922038|NCT06250205|DRUG|Obicetrapib|oral administration
218922039|NCT06250205|DRUG|Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)|oral administration
218922040|NCT06250205|DRUG|Drospirenone / Ethinyl Estradiol (COC)|oral administration
218922041|NCT03783572|OTHER|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
218922042|NCT03783572|OTHER|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
218922043|NCT02002598|DRUG|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2"
218922044|NCT02002598|DRUG|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2"
218922045|NCT02002598|DRUG|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
218922046|NCT06277687|DIAGNOSTIC_TEST|Virtual Augmented Reality Combined With Finder|After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
218922047|NCT02628873|DEVICE|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
219365517|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
219365518|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 6 mg/kg
219365519|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
219365520|NCT02211261|BIOLOGICAL|PF-06293620|Intravenous infusion single dose 1 mg/kg
219365521|NCT02211261|BIOLOGICAL|Placebo|Intravenous infusion normal saline single dose
219365522|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
219365523|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
219365524|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
219365525|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
219365526|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
219365527|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
219365528|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
219365529|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
219365530|NCT03387631|DRUG|Artemether-Lumefantrine|
219365531|NCT00887757|DRUG|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
219535919|NCT02770092|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
218922048|NCT04860323|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
218922049|NCT05338294|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
218922050|NCT05076006|DRUG|PF-06700841|Active study drug
218922051|NCT05076006|DRUG|Placebo|placebo comparator
218922052|NCT04501042|PROCEDURE|Bariatric surgery|Bariatric surgery
219535920|NCT06513351|BEHAVIORAL|Novel PPH Risk Prediction Model - Comparator Arm B|Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
219618788|NCT01963104|PROCEDURE|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219535921|NCT04960072|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219535922|NCT04280497|DRUG|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
219535923|NCT04319276|DRUG|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
219535924|NCT04319276|DRUG|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
219535925|NCT04319276|DRUG|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
219535926|NCT04319276|DRUG|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
219535927|NCT04319276|DRUG|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
219535928|NCT04319276|DRUG|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
219535929|NCT05692323|OTHER|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
218922053|NCT03772392|PROCEDURE|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
218922054|NCT06253351|DEVICE|Hybrid closed loop (HCL)|"* Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6"
218922055|NCT04353141|DIAGNOSTIC_TEST|standardized Lung Ultrasound (LUS) examination|14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
218922056|NCT03865979|DEVICE|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
219535930|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
219618789|NCT01963104|PROCEDURE|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
218922057|NCT02195518|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
218922058|NCT05227196|DRUG|Semaglutide D Dose 1|Tablet given orally
218922059|NCT05227196|DRUG|Semaglutide D Dose 2|Tablet given orally
218922060|NCT05227196|DRUG|Semaglutide D Dose 3|Tablet given orally
218922061|NCT05227196|DRUG|Semaglutide Dose 4|Tablet given orally
218922062|NCT05227196|DRUG|Semaglutide Dose 5|Tablet given orally
218922063|NCT05227196|DRUG|Semaglutide Dose 6|Tablet given orally
218922064|NCT01051895|OTHER|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
218922065|NCT01051895|OTHER|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
218922066|NCT04073875|DIAGNOSTIC_TEST|18F-GP1|18F-GP1 PET-CT scan
218922067|NCT03025971|DEVICE|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
219535933|NCT06091254|DRUG|Odronextamab|Administered by intravenous infusion (IV)
219535934|NCT06091254|DRUG|Rituximab|Rituximab will be administered by IV, or subcutaneously (SC)
219535935|NCT06091254|DRUG|Cyclophosphamide|Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
218922068|NCT06119308|OTHER|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing (led by pharmacist/clinician/psychologist) over a 10-week Trial.
218922069|NCT06585657|DEVICE|brain visual perception training group|Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
219535936|NCT06091254|DRUG|Doxorubicin|Administered by IV as part of CHOP chemotherapy
219535937|NCT06091254|DRUG|Vincristine|Administered by IV as part of CHOP, and CVP chemotherapy
219535938|NCT06091254|DRUG|Prednisone/prednisolone|Administered orally (PO) as part of CVP chemotherapy
219535939|NCT06091254|DRUG|Bendamustine|Administered by IV as part of chemotherapy (Rituximab-Bendamustine)
219535940|NCT05821660|OTHER|Five-day hypocaloric and ketogenic programme|Dietary intervention
219535941|NCT06403436|DRUG|TT125-802|TT125-802 administered orally
219535942|NCT04870437|OTHER|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
219535943|NCT06780670|DRUG|Investigators choice of SoC|The control treatment in Phase III is investigator's choice of SoC
219535944|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
219535945|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
219535946|NCT06780670|DRUG|AAA817|Investigational treatment is the Dose B of AAA817
219535947|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
219535948|NCT05754216|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
219535949|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
219535950|NCT05955456|OTHER|No intervention|No intervention is applied to participants. The risk calculator score is not released to the participants or care providers. Participants are followed up for risk calculator accuracy and recalibration.
219535951|NCT01701674|DRUG|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
218922070|NCT06275685|DEVICE|SeizureWise algorithm|An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
218922071|NCT06275685|DEVICE|Multi-day Visualizations|Multi-day visualizations of sensor derived data
218922072|NCT06601114|DRUG|Paracetamol Group|Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
218922073|NCT06601114|DRUG|Ibuprofen group|Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
218922074|NCT04223479|DRUG|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
218922075|NCT04223479|DRUG|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
218922076|NCT02449122|PROCEDURE|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
218922077|NCT06649578|PROCEDURE|Metabolic-bariatric surgery|Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
218922078|NCT06596421|OTHER|abdominal massage|abdominal massage
218922079|NCT06588179|DRUG|SHR-1501+SHR-2005|SHR-1501, instillation；SHR-2005, instillation
218922080|NCT06599853|OTHER|Fever Education|Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
219042763|NCT04642729|PROCEDURE|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
219365532|NCT00887757|DRUG|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
218922081|NCT06591702|OTHER|Questionnaire study|Questionnaire application
218922082|NCT06591910|DRUG|Chemoimmunotherapy|Induction Serplulimab combined with chemotherapy
219365533|NCT05452967|OTHER|Distraction technique|The post operative pediatric patients will be given mobile phone in recovery for plying games and watching cartoons and with the help of this distraction technique will assess that routine rescue analgesia is needed or not
219365534|NCT01037673|PROCEDURE|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
219365535|NCT01037673|PROCEDURE|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
219365536|NCT00382837|DRUG|Epratuzumab|
219365537|NCT00124345|DEVICE|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
219365538|NCT06000358|PROCEDURE|Bronchoscopic cryotherapy|The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.
219365539|NCT06000358|DRUG|Pembrolizumab|As a standard of care, patients will receive pembrolizumab.
219365540|NCT06000358|DRUG|Platinum based chemotherapy|As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.
219365541|NCT04897867|DEVICE|CoolSculpting® Elite System with CoolSculpting® Elite applicators|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
219365542|NCT01454804|DRUG|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
219365543|NCT01454804|DRUG|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
219365544|NCT01454804|DRUG|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
219365545|NCT01454804|DRUG|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
219365546|NCT02775032|BEHAVIORAL|Advance care planning conversations between patients and their GP|
219365547|NCT01814787|OTHER|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI \> 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
219365548|NCT02242500|PROCEDURE|Coronally Advanced Flap|
219365549|NCT02242500|DEVICE|Mucograft|
219535952|NCT01701674|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging \[MRI\] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
218922083|NCT06591910|PROCEDURE|Surgery|After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
218922084|NCT06591910|RADIATION|Radiation|After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.
218922085|NCT06594692|DRUG|Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab|"Radiotherapy Protocol:~Short-course radiotherapy using three-dimensional conformal or intensity-modulated radiation therapy techniques. The radiation field will be limited to the tumor bed of the primary colon lesion, excluding surrounding draining lymph nodes and enlarged lymph nodes. The dose is fractionated as 5Gy per fraction, for a total of 25Gy over 5 fractions. Titanium clips will be placed on the proximal and distal ends of the colonic lesion via colonoscopy to guide radiation therapy positioning.~Chemotherapy Protocol (CAPOX Regimen):~1. Oxaliplatin: 130 mg/m², administered intravenously (ivgtt), on day 1 (d1).~2. Capecitabine: 1000 mg/m², orally (po), twice daily (bid), from day 1 to day 14 (d1-14).~Immunotherapy Protocol:~During preoperative treatment, Sintilimab (immune checkpoint inhibitor) will be administered concurrently with each chemotherapy cycle."
218922086|NCT06594692|DRUG|CAPOX Chemotherapy|Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
218922087|NCT06603740|DEVICE|Arthrex Nanoscope|Arthrex's all-in-one disposable, 2 mm, chip-on-tip camera system now allows surgeons to miniaturize their treatment solutions
218922088|NCT06603740|DEVICE|Conventional Arthroscopy without Arthrex Nanoscope|partial meniscectomy using conventional arthroscopy
218922089|NCT06591039|PROCEDURE|The study did not involve intervention in the patient's treatment regimen|This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.
218922090|NCT06602986|DIAGNOSTIC_TEST|TACE|"study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima"
218922091|NCT06600035|DEVICE|Gastric ultrasound|A curved array, low-frequency (2-5 MHz) transducer providing a scan depth up to 30 cm will be used. Patients will be scanned in the supine position followed by right lateral decubitus (RLD) position. The sonographic appearance of the gastric antrum will be classified as Grade 0,1 or 2, signifying empty antrum, fluid detected in RLD position only and antral fluid in both supine and RLD positions, respectively, based on the appearance in both the positions. Cross-sectional area (CSA) will be calculated by using two perpendicular diameters-anteroposterior (AP) and craniocaudal (CC) and the formula for area of an ellipse:CSA = (AP × CC × π)/4
218922092|NCT06601816|PROCEDURE|maxillary sinus lift with reamer|Lateral window created with specially designed burs for lateral sinus lift
218922093|NCT06601816|PROCEDURE|maxillary sinus lift with piezzo|lateral window was created using piezo surgery and surgical guide
218922094|NCT06601816|PROCEDURE|maxillary sinus lift with conventional burr|the lateral window was created with conventional rotary instrument burs
219535953|NCT01701674|DRUG|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
219535954|NCT01701674|DRUG|Cyclophosphamide as Part of Lymphodepletion|
219535955|NCT01701674|DRUG|Fludarabine as Part of Lymphodepletion|
219535956|NCT01701674|DRUG|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
219535957|NCT01701674|BIOLOGICAL|Adoptive Cell Therapy with TIL|
219535958|NCT01199978|RADIATION|Fractionated proton radiation|Given daily for approximately 5.5 weeks
219535959|NCT01199978|DRUG|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
218922095|NCT06594224|DRUG|Ibuprofen|Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
219535960|NCT05604170|DRUG|Ganaxolone|GNX will be administered.
219535961|NCT06510556|DEVICE|Ablation Treatment|Subjects scheduled to undergo endocardial mapping and ablation therapy in the treatment of persistent atrial fibrillation or paroxysmal atrial fibrillation. Ablation of the pulmonary veins will be performed; ablation of the left atrial posterior wall, mitral isthmus (MI), LA roof line and/or cavo-tricuspid isthmus (CTI) is at the discretion of the investigator.
219535967|NCT05563844|DRUG|PM 8.4 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
219535968|NCT05563844|DRUG|PM 11.2 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
218922096|NCT06594224|DRUG|Nalbuphine|Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
219535969|NCT04036032|OTHER|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
219535970|NCT06833008|DRUG|IPN01195|IPN01195 will be administered at assigned dose level.
219535971|NCT03032172|DRUG|Risdiplam|Risdiplam will be administered orally once daily.
219618790|NCT01963104|PROCEDURE|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219535972|NCT06104592|RADIATION|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
219535973|NCT06104592|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
219535974|NCT06430385|DRUG|ION440|ION440 will be administered by intrathecal bolus (ITB) injection.
219535975|NCT06430385|PROCEDURE|Sham procedure|An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
219535976|NCT06361667|OTHER|Arts|Arts (music, cinema, dance).
218922097|NCT06590506|DEVICE|Wearable|Continuous monitoring thought data recorded with wearable (Vivosmart Garmin bracelet)
219535977|NCT06330402|OTHER|Hypertonic saline injection|0.25 mL injection with hypertonic saline (7%) to the infrapatellar fat pad.
219535978|NCT06330402|OTHER|Isotonic saline injection|Control injection with 0.25 mL isotonic saline (0.9%) to the infrapatellar fat pad.
219535979|NCT05111626|DRUG|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
219535980|NCT05111626|DRUG|Nivolumab|Nivolumab will be administered as IV infusion.
219535981|NCT05111626|DRUG|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
219535982|NCT05111626|OTHER|Placebo|Placebo will be administered as IV infusion.
219535983|NCT04644497|PROCEDURE|ACL-reconstruction|Surgery technique in skeletally immature patients
219535984|NCT04055311|BEHAVIORAL|Cancer Resource Information Support (CRIS)|Intervention support is patient initiated and accessed as needed
219535985|NCT04055311|BEHAVIORAL|Usual Care Enhanced|Usual care is enhanced with the addition of the NCI Facing Forward brochure
219535986|NCT02444429|DRUG|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
219535987|NCT02444429|OTHER|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
219535988|NCT02444429|OTHER|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
219042764|NCT02311491|DEVICE|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
219042765|NCT00132015|DRUG|tanespimycin|
219535989|NCT06307821|DIETARY_SUPPLEMENT|Probiotic|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
219535990|NCT06307821|DIETARY_SUPPLEMENT|Placebo|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
218922098|NCT06595732|BEHAVIORAL|Pelvic floor and abdominal training|Participants in this group will undergo 12 weeks of in-person training, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. Exercises will target both the pelvic floor muscles and the abdominal muscles. The exercises will be divided into three phases, with progressively increasing difficulty each month. The progression will be achieved by increasing the load, the number of repetitions, and the complexity of the exercises.
219618791|NCT01963104|PROCEDURE|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219618792|NCT01963104|PROCEDURE|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219618793|NCT01963104|PROCEDURE|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219618794|NCT01963104|PROCEDURE|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
219042766|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
219365550|NCT04941144|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
219365551|NCT00845988|DRUG|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
219365552|NCT01825031|DRUG|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
219365553|NCT01825031|DRUG|Fluconazole|100mg once daily for 12 weeks
219365554|NCT01825031|DRUG|Azithromycin|500mg once daily for 5 days
219365555|NCT01825031|DRUG|Albendazole|a single dose 400mg
219365556|NCT01825031|DRUG|Isoniazid|300mg taken immediately in combination with cotrimoxazole
219365557|NCT01825031|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
219365558|NCT01568203|DRUG|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
219365559|NCT01568203|DRUG|Placebo|Matching placebo control for AMG 579 at each dose level
219365560|NCT04591054|DEVICE|Extended Vision IOL|Vivity IOL implantation following cataract extraction
219365561|NCT04591054|DEVICE|Neutral Aspheric Monofocal IOL|enVista IOL implantation following cataract extraction
219365562|NCT02705898|BEHAVIORAL|LPA+Fitbit|
219365563|NCT02705898|BEHAVIORAL|HEC|
219365564|NCT03957967|OTHER|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
219365565|NCT01486030|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
219618795|NCT01963104|PROCEDURE|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
219618796|NCT00774501|PROCEDURE|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
219618797|NCT02257346|DRUG|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
219618798|NCT02257346|DRUG|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
219618799|NCT06053346|BEHAVIORAL|Pay For Performance (PFP)|Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
219618800|NCT06053346|BEHAVIORAL|Usual Care (UC)|Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
219618801|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
219618802|NCT02850146|DRUG|18F-AV-1451|
219618803|NCT04534530|OTHER|Systematic screening for ischemic heart disease in type 2 diabetic patients|Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.
218922099|NCT06595732|BEHAVIORAL|Abdominal Hypopressive Technique Exercises|Participants in this group will perform Hypopressive Abdominal Gymnastics exercises as proposed by Marcel Caufriez (1997). The training will last 12 weeks and be conducted in person, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by changing body positions, increasing the number of repetitions, and extending the duration of inspiratory apnea.
218922100|NCT06595732|OTHER|Pelvic floor muscle training|Participants in this group will undergo 12 weeks of in-person training, supervised by a specialist physical therapist, in groups of up to four women. Specific exercises targeting the pelvic floor muscles will be performed, with voluntary and maximal contractions, without involving other muscle groups. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by increasing the load (transitioning from gravitational to antigravitational positions), increasing the number of repetitions, and combining sustained and rapid contractions to enhance the difficulty of execution.
219365566|NCT02515149|DEVICE|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
219365567|NCT00997009|DRUG|paclitaxel|175 mg/m2 IV day 1, every 21 days
219365568|NCT00997009|DRUG|carboplatin|AUC 5 IV day 1 every 21 days
219365569|NCT00997009|DRUG|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
219365570|NCT06439368|DRUG|Dezocine|At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
219365571|NCT04097327|OTHER|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
219365572|NCT02190019|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
219365573|NCT04193930|DRUG|Letrozole|Oral tablet letrozole 2,5 mg/twice daily for 5 days
219365574|NCT04193930|DRUG|Menotropins|150 IU of highly purified menotropins intramuscular
219365575|NCT04193930|DRUG|recombinant Follicular stimulating hormone|recombinant Follicular stimulating hormone 300- 400 IU
219365576|NCT04228848|OTHER|new triple hop test|New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
219365577|NCT03871478|DRUG|Lidocaine|See Arm Description
219535991|NCT06848842|DRUG|Ivonescimab plus chemotherapy|Ivonescimab, 20mg/kg, D1, Q3W; Oxaliplatin, 130mg/m2, D1, Q3W; Capecitabine, 1000mg/m2, BID, D1-D14, Q3W
219535992|NCT03427593|GENETIC|FACS analyses|FACS analyses
219535993|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
219535994|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
219618804|NCT00840749|RADIATION|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
219618805|NCT00840749|PROCEDURE|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
218922101|NCT06591351|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
218922102|NCT06591351|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
218922103|NCT06594887|DEVICE|SpaceOAR Vue|Peri-rectal hydrogel spacer consists of a layer of polyethylene-glycol gel (SpaceOAR vue) in order to outdistance the prostate from anterior rectal wall
218922104|NCT06594887|DEVICE|BioProtect Balloon Implant System|The balloon spacer is a biodegradable balloon made of poly (L-Lactide-co-caprolactone) which is a co-polymer of Poly Lactide acid and epsilon Caprolactone (BioProtect Balloon Implant System, BioProtect Ltd) inflated with saline, providing around 18 mm space height , and can be deflated and repositioned if needed, both laterally and along the distal /proximal planes, for optimal uniformity of spacing.
218922105|NCT06586333|DRUG|stress ulcer prophylaxis|In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines
218922106|NCT06588933|OTHER|completion of a questionnaire|completion of a questionnaire by participant
218922107|NCT05813574|OTHER|Observational patient reported outcomes|Of COVID-19 patients
218922108|NCT06979440|OTHER|No intervention|No intervention
218922109|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
219618806|NCT03808649|DRUG|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
218922110|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
218922111|NCT06985732|OTHER|Virtual Reality|Use of virtual reality to elicit positive emotions and improve the well-being of elderly patients hospitalized in SMR
218922112|NCT06602323|COMBINATION_PRODUCT|TMLI/Flu/Mel|Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
218922113|NCT06597890|BEHAVIORAL|educational content (sleep hygiene)|app-based sleep hygiene-related educational content
218922114|NCT06597890|BEHAVIORAL|sleep hygiene strategies|app-based self-selection of sleep hygiene strategies
218922115|NCT06597890|BEHAVIORAL|reminders|daily reminders sent via push notifications
218922116|NCT06597890|BEHAVIORAL|review of behavioural goal|app-based review of behavioural goal
218922117|NCT06597890|BEHAVIORAL|educational content (sleep guidelines)|app-based educational content on recommended sleep guidelines
218922118|NCT06597890|BEHAVIORAL|comparison of current behaviour to ideal behaviour|use of smartwatch/smartphone data to assess current behaviour and compare it to ideal behaviour
218922119|NCT06597890|BEHAVIORAL|goal setting|prompt participant to set a goal in relation to targeted behaviour
218922120|NCT06597890|BEHAVIORAL|educational content (Vigorous Intermittent Lifestyle Physical Activity (VILPA))|app-based educational content on VILPA
219535995|NCT04497584|DRUG|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
219535996|NCT04453657|DEVICE|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
219535997|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
219535998|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
219618807|NCT03808649|DRUG|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
219618808|NCT06080035|OTHER|Topical Cetyl Tranexamate Mesylate|Topical product will be applied onto clean skin morning and night.
219618809|NCT00677664|DRUG|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
219618810|NCT00677664|DRUG|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
219618811|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (low dose)|\- subcurative regimen (500mg/25mg)
219618812|NCT02836002|DRUG|Piperaquine (low dose)|\- subcurative regimen (480 mg)
219618813|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (high dose)|\- curative regimen (1000mg/50mg)
218922121|NCT06597890|BEHAVIORAL|screentime breaks|repeated daily reminders to break up screentime
218922122|NCT06588764|PROCEDURE|modified deep lateral and/or medial wall decompression|Modified deep lateral orbital wall decompression is based on traditional outer wall decompression with combined abrasion of the deep outer orbital wall (including the greater pterygoid wing) to achieve adequate enlargement of the orbital cavity.
218922123|NCT06589843|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
218922124|NCT06586567|OTHER|Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas|"2\. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori"
218922125|NCT06586801|OTHER|Patient-reported outcome|"Patient-reported outcome data will be collected using the following instruments:EORTC QLQ-C30, EORTC QLQ-LC13, selected items from the PRO-CTCAE, EORTC-IL46.~The first collection of the information in questionnaires (EORTC QLQ-C30, EORTC QLQ-LC13, PRO-CTCAE \[select items\]), which defined as baseline- PROs, will be completed at Cycle 1, Day 1±7days prior to administration of study drug; then the rest times of collection will be completed at every two treatment cycle prior to administration of study drug (i.e., on Cycle 3, Day 1±7days; Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days) . EORTC-IL46 will be completed at Cycle 3, Day 1±7days (baseline) prior to administration of study drug; then at every other study treatment cycle prior to administration of study drug (i.e., on Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days)"
218922126|NCT06590246|BIOLOGICAL|Armored and GPC3-targeted autologous CAR T-cell|Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.
218922127|NCT06596967|DEVICE|Heat therapy|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will be set to warm the water to 42°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
218922128|NCT06596967|DEVICE|Sham|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will warm the water to 33°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
218922129|NCT06588881|DEVICE|nebulized application of the haemostatic surgical sealant after gastrointestinal endoscopic resection|ENDONEB, a nebulizing catheter containing the synthetic haemostatic-sealant Glubran®, is inserted in the operative channel of the endoscope until it is pushed out of the endoscope tip approximately 2 cm. The haemostatic-sealant is nebulized over the surface of the post resection mucosal defect by activating the propellant (medical-inert-gas) container. An amount of about 0.3 mL of Glubran® 2 (or more - depending on dimension of the lesion) is applied on mucosal or sub-mucosal defect in order to create a proper haemostaticsealant film.
218922130|NCT06598501|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|an open arm study of 10 gambling disorder subjects will be conducted to determine the efficacy and feasibility of a multimodalistic therapy of rTMS and Cognitive Behavioral Therapy (CBT) for gambling disorder in Indonesia.
218922131|NCT06585813|PROCEDURE|dental implant|we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery
219535999|NCT05244447|OTHER|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
218922132|NCT06585813|PROCEDURE|Fibrogide membrane|we were comparing the efficacy of Fibrogide with the Connective tissue graft
218922133|NCT06585813|PROCEDURE|connective tissue graft|the control group was the connective tissue graft group and the test group was the Fibrogide group
218922134|NCT06585813|PROCEDURE|second stage|second stage to determine the thickness gained after the graft and to place a healing abutment
218922135|NCT06590909|COMBINATION_PRODUCT|Fractional CO2 laser assisted PDT|Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
218922136|NCT06595511|DEVICE|Sensory Entrainment-Integrated Cognitive Game Kit|Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.
218922137|NCT06602505|PROCEDURE|Group A: Field Block Group|Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
219042767|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
219536000|NCT05710380|OTHER|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
219618814|NCT02836002|DRUG|Piperaquine (high dose)|\- curative regimen (960 mg)
219536001|NCT05710380|RADIATION|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
219536002|NCT05710380|PROCEDURE|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
219536003|NCT03946215|OTHER|Each participant will perform:|Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
219536004|NCT06081114|DIETARY_SUPPLEMENT|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
219536005|NCT05108870|DRUG|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
219536006|NCT05108870|DRUG|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
219365578|NCT03871478|DRUG|Bupivacaine|See Arm Description
219365579|NCT03871478|DRUG|Lidocaine and Bupivacaine|See Arm Description
219365580|NCT00706017|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219365581|NCT05607901|DRUG|Tacrolimus ointment|tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares
219365582|NCT05607901|DRUG|Hydrocortisone 1% cream|Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
219365583|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 0|"Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses."
219365584|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose -1|"Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
219536007|NCT05108870|DRUG|Carboplatin|Chemotherapy drug.
219536008|NCT05108870|DRUG|Paclitaxel|Chemotherapy drug.
219536009|NCT05108870|PROCEDURE|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
219536010|NCT06399692|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
219536011|NCT06399692|PROCEDURE|Percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
219536012|NCT06431386|BEHAVIORAL|Behavioural Activation (BA) Therapy|Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.
219536013|NCT06431386|DRUG|Esketamine|Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
219536014|NCT05292963|OTHER|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
219536015|NCT04705038|BEHAVIORAL|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
219536016|NCT06027151|DRUG|1ml of 1% metronidazole gel|Subgingivally at baseline visit
219536017|NCT06027151|DRUG|1ml of 2% minocycline gel|sub gingivally at baseline visit
219536018|NCT06027151|DRUG|1ml of combination of 1% metronidazole gel and 2% minocycline|subgingivally at baseline visit
219536019|NCT06349759|DRUG|phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist|Once daily dosing
219536020|NCT06349759|DRUG|Placebo|Once daily dosing
219536021|NCT02869867|OTHER|refrigerated cushion|refrigerated cushion
219536022|NCT06494488|DRUG|EPA|Fish oil
219536023|NCT06494488|DRUG|DHA|Fish oil
219536024|NCT05956626|DRUG|OCU410ST|Subretinal Administration of OCU410ST
219536025|NCT03626662|DRUG|AMG 890|Ascending Single Doses of AMG 890
219536026|NCT03626662|DRUG|Placebo|Calculated volume to match experimental drug.
218922138|NCT06592885|PROCEDURE|Atraumatic Restorative Treatment in treatment of carious primary molars|ART, which took place in Tanzania during the mid-1980s, is a conservative approach involving the removal of carious lesions using hand instruments, followed by the application of a glass ionomer restoration. This technique aims to be minimally invasive, promoting the preservation of tooth structure. The ART technique, employed in situations where ideal clinical conditions are challenging to achieve, has demonstrated effectiveness as a reliable method for managing cases where conventional treatment methods face resistance from children . However, concerns exist regarding the longevity of ART restorations and the impact of operator skill on outcomes.
218922139|NCT06592885|PROCEDURE|Hall Technique in treatment of carious primary molars|"The Hall technique, proposed by Norna Hall in the 1980s, involves the placement of preformed metal crowns on primary molars without any tooth preparation or local anesthesia.~Advocates of the Hall technique emphasize its simplicity, reduced need for traditional drilling, and high reported success rates in clinical studies.~However, concerns have been raised regarding long-term aesthetics and potential psychological impacts due to the visibility of metal crowns."
218922140|NCT06594471|OTHER|Questionnaire on late-term physical effects|Patients will be asked to indicate any potential late-term physical effects following cancer treatment: neurocognitive, auditory, ocular, oral/dental, dermatologic, cardiovascular, pulmonary, gastro-intestinal, urinary tract, genital, endocrine/metabolic, musculoskeletal, neurological, immune disorders and occurrence of any subsequent malignant neoplasms.
218922141|NCT06594471|OTHER|Questionnaire on sexual and reproductive health outcomes|Patients will be asked to complete the following questionnaires: Body Appreciation Scale-2 (BAS-2), Body Image Scale (BIS), EORTC QLQ-SH22, Body Image Scale in Gynecological Cancer (SABIS-G). Patients who underwent a fertility-sparing procedure will be asked to fill out the Reproductive Concerns after Cancer (RCAC) and Decision Regret Scale (DRS), whereas those who experienced iatrogenic menopause will complete the MENQOL questionnaire to assess menopause-related quality of life.
218922142|NCT06594471|OTHER|Questionnaire on psychological outcomes|Patients will be asked to complete the following questionaires: EORTC QLQ-C30, Clinical outcomes in Routine Evaluation (CORE-OM), Ten Item Personality Inventory (TIPI), Hospital Anxiety and Depression Scale (HADS), General Self-Efficacy (GSE) Scale, Mini-Mental Adjustment to Cancer (Mini-MAC), Cancer Worry Scale (CWS), Multidimensional Scale of Perceived Social Support (MSPSS), the Patient Health Engagement scale and the Supportive Care Needs Survey-Short Form (SCNS-SF34).
219536027|NCT06046287|DRUG|Daratumumab and hyaluronidase-fihj|subucatneous, fixed dose 1800mg combination drug product containing rHuPH20 drug substance (2000 U/mL) and daratumumab drug substance (120 mg/mL) will be administered weekly for the first 8 weeks, and then every 2 weeks from week 9 to week 24.
219536028|NCT05665608|DEVICE|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
219536029|NCT05665608|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
219536030|NCT04930094|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg
219536031|NCT04930094|OTHER|Placebo|Placebo
219536032|NCT04930094|BIOLOGICAL|Secukinumab 150 mg|Secukinumab
219536033|NCT03767244|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
219536034|NCT03767244|DRUG|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
219536035|NCT03767244|DRUG|Placebo|Participants will receive matching placebo oral tablets daily.
219536036|NCT06556147|BIOLOGICAL|VXB-241 60 mcg (Low Dose)|VXB-241 low dose, single, IM injection.
219618815|NCT02836002|BIOLOGICAL|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
219536037|NCT06556147|BIOLOGICAL|VXB-241 120 mcg (Medium Dose)|VXB-241 medium dose, single, IM injection.
219536038|NCT06556147|BIOLOGICAL|VXB-241 240 mcg (Medium-high Dose)|VXB-241 medium-high dose, single, IM injection.
219536039|NCT06556147|BIOLOGICAL|VXB-241 480 mcg (High Dose)|VXB-241 high dose, single, IM injection.
219536040|NCT06556147|BIOLOGICAL|VXB-241 240 mcg|VXB-241 240 mcg (RSV preF 120 mcg + hMPV preF 120 mcg) (based on 1 month post 1st IMP injection results) single, IM injection.
219536041|NCT06556147|OTHER|Placebo|Placebo, single, IM injection.
219618816|NCT02836002|DRUG|Atovaquone-proguanil|\- curative regimen: 1000/400 mg, for 3 days
219536042|NCT06556147|BIOLOGICAL|Arexvy 120 mcg|Arexvy 120 mcg, single, IM injection.
219536043|NCT06284525|DEVICE|Ankle resistance and biofeedback|An ankle exoskeleton will provide stance phase resistance and a plantar pressure biofeedback system will encourage late stance push-off.
219618817|NCT04785378|DEVICE|Medical mask|Participants will carry out field tests one day wearing a medical mask and the other day without a mask.
219618818|NCT04785378|OTHER|Field tests|Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
219536044|NCT03844815|DRUG|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
218922143|NCT06594471|OTHER|Questionnaire on social outcomes|Patients will be asked to complete the following questionaires: Medical Consumption Questionnaire (iMCQ), Productivity Cost Questionnaire (iPCQ) and the Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire.
218922144|NCT06590571|DEVICE|TRAcelet™|The group using TRAcelet™ after transradial angiography/intervention receives 2 hours and 15 minutes of compression from the device, followed by 3 stepwise releases every 15 minutes. There are two sizes of TRAcelet™ available, large and medium. Assuming that a Korean adult's wrist size is smaller than that of the Western population, we used a medium-sized TRAcelet™.
218922145|NCT06590571|OTHER|Gauze pad|Patients received radial artery compression by a gauze pad fastened with 3M™ Durapore™ surgical tape. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
218922146|NCT06589609|BIOLOGICAL|FluBHPVE6E7|Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.
218922147|NCT06596083|DIETARY_SUPPLEMENT|Placebo supplement|oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water
218922148|NCT06596083|DIETARY_SUPPLEMENT|Ketone ester supplement|Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
218922149|NCT06599970|OTHER|No intervention|This is an observational study. No experimental interventions included. The mobility of people will be studied.
218922150|NCT06999096|DIAGNOSTIC_TEST|Long-read whole genome sequencing|Pseudonymized blood samples will undergo high-molecular-weight DNA extraction, followed by long-read whole-genome sequencing (lrWGS) using Oxford Nanopore technology. Index cases will be sequenced at high depth (\>30X), while relatives will be multiplexed (\>15X). Sequencing data will be analyzed through a dedicated bioinformatics pipeline to detect SNVs, indels, structural variants, and repeat expansions. Results will be interpreted by expert teams and discussed in monthly clinical-genetic meetings. Variants of interest will be validated by appropriate molecular techniques, and family segregation will be assessed when relevant.
218922151|NCT06599164|OTHER|Anthrogenic Muscle Inhibition (AMI) Assessment Protocol|This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.
219536045|NCT03844815|DRUG|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
219536046|NCT05026645|PROCEDURE|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
219618819|NCT03458442|OTHER|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
219618820|NCT03458442|OTHER|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
219618821|NCT02083744|BEHAVIORAL|PsychoEducational Support|
219618822|NCT02083744|BEHAVIORAL|Usual Care|Standard Heart Failure Care
219618823|NCT05352620|OTHER|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
218922152|NCT06589206|OTHER|modified design of twin block|Vacuum formed twin block appliance with sagittal blocks
219618824|NCT01434095|PROCEDURE|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
219618825|NCT01621334|BEHAVIORAL|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
218922153|NCT06772740|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization within 7 days after randomization
218922154|NCT06906770|OTHER|Eye movement desensitization and reprocessing phobia treatment in virtual reality|Short form and frequent eye movement desensitization and reprocessing (EMDR) in virtual reality for specific phobia treatment.
218922155|NCT00905164|DRUG|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
218922156|NCT00905164|DRUG|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
218922157|NCT06939166|DRUG|UCAR T-cell|Universal allogeneic anti-CD19/BCMA CAR T-cells
218922158|NCT06939855|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg iv q3w
219536047|NCT05026645|PROCEDURE|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
219536048|NCT05026645|PROCEDURE|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
218922159|NCT02633124|DEVICE|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
219618826|NCT01621334|BEHAVIORAL|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
219618827|NCT01683435|OTHER|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
219618828|NCT00160303|DRUG|Prolotherapy|
219618829|NCT00160303|DRUG|Local Corticosteroid Therapy|
219618830|NCT01051960|DRUG|Ambrisentan|Ambrisentan 5mg or 10mg once daily
219618831|NCT02110082|BIOLOGICAL|Urelumab|
219618832|NCT02110082|BIOLOGICAL|Cetuximab|
219618833|NCT03481673|BEHAVIORAL|COPE for Asthma|The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
219618834|NCT02094274|DRUG|LAS40468|
219618835|NCT02094274|DRUG|Salmeterol/fluticasone propionate|
219618836|NCT02094274|DRUG|Placebo|
219618837|NCT02125682|DRUG|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
218922160|NCT02633124|DEVICE|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
219618838|NCT02125682|DRUG|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
218922161|NCT04374669|PROCEDURE|Neuroplasty with Racz catheter|The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
218922162|NCT03401801|PROCEDURE|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
218922163|NCT06215170|DEVICE|SafeMedWaste|SafeMedWaste opioid disposal kit
218922164|NCT03745612|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
219618839|NCT00754130|DRUG|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
219618840|NCT00754130|DRUG|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
219618841|NCT00661557|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|one dose, as intramuscular injection
219618842|NCT04735510|DRUG|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
219618843|NCT01836471|DRUG|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
219618844|NCT01836471|DRUG|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
219618845|NCT01836471|DRUG|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
219618846|NCT01836471|DRUG|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
219618847|NCT00128882|DRUG|Anti-D|Subcutaneous injection
219618848|NCT02564601|BEHAVIORAL|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
219536051|NCT06228625|BEHAVIORAL|Conventional Exercise Group|"* Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep."
219536052|NCT06228625|BEHAVIORAL|Body Awareness Training Group|"* Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing."
218922165|NCT03745612|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
218922166|NCT04475367|OTHER|App hypercross group|hypertensive patients using HyperCrossApp
219536053|NCT06228625|BEHAVIORAL|Rehabilitative Game Exercise Group|"* Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge."
219618849|NCT02564601|BEHAVIORAL|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
219536059|NCT05834244|DRUG|Azacitidine|Given by IV (vein)
219536060|NCT05834244|DRUG|Venetoclax|Given by PO
219536061|NCT05834244|DRUG|NK Cells|Given by IV (vein)
219536062|NCT06643884|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
219536063|NCT06643884|DEVICE|SCS Microinjector|Suprachoroidal Injection Device
219536064|NCT06643884|DEVICE|Laser|Laser Administration
219536065|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
219536066|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
219618850|NCT02637882|OTHER|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
218922167|NCT04475367|OTHER|without App hypercross group|Interdisciplinary health care
218922168|NCT06440434|BEHAVIORAL|Time of night shift|Early vs. late night split night shift
218922169|NCT01968200|DRUG|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
218922170|NCT03266510|OTHER|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
218922171|NCT03266510|OTHER|Sham training|Subjects will perform sham training for 6 weeks.
219536067|NCT05875168|DRUG|DS-3939a|One IV infusion Q3W on Day 1 of each 21-day cycle
219536068|NCT06644625|OTHER|Blood draw for the laboratory assessment|Screening blood sample collection to test for MGUS
219536069|NCT04260126|COMBINATION_PRODUCT|Pembrolizumab (KEYTRUDA®) and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
219618851|NCT02637882|OTHER|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
219618852|NCT02637882|OTHER|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
218922172|NCT05447780|PROCEDURE|regional anesthesia|regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
218922173|NCT01669837|DEVICE|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
219536070|NCT05916950|DEVICE|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
219536071|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
219536072|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
218922174|NCT01256788|DEVICE|Euflexxa|4 injections of 2ml of Euflexxa
218922175|NCT01256788|OTHER|Saline|4 injections of 3 ml of sterile saline
218922176|NCT01954446|DEVICE|3M|Conventional measuring of BP
218922177|NCT01954446|DEVICE|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
218922178|NCT01954446|DEVICE|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
218922179|NCT04911140|RADIATION|Photobiomodulation twice a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
218922180|NCT04911140|RADIATION|Photobiomodulation three times a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
218922181|NCT04911140|OTHER|Simulated Photobiomodulation|Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
218922182|NCT03405194|DRUG|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
218922183|NCT03405194|DRUG|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
218922184|NCT02750917|DRUG|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
218922185|NCT02750917|DRUG|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
219536073|NCT06577766|DRUG|NNC0638-0355|NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
219536074|NCT06577766|DRUG|Placebo (NNC0638-0355)|Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
219536075|NCT06577441|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
219536076|NCT06577441|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219536077|NCT06577441|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219536078|NCT06577441|DRUG|Decitabine and Cedazuridine|Given PO
219536079|NCT06577441|DRUG|Enasidenib|Given PO
219536080|NCT05501236|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
219536081|NCT04516967|DRUG|Avatrombopag|Oral avatrombopag tablet or sprinkle capsule
218922186|NCT01955421|DRUG|Erlotinib 100mg qd|
218922187|NCT01955421|DRUG|Gefitinib 250mg qd|
218922188|NCT04581213|PROCEDURE|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
219536082|NCT04516967|DRUG|Placebo|Placebo comparator tablet or sprinkle capsule
219536083|NCT03954145|PROCEDURE|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
219536084|NCT03954145|PROCEDURE|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
219536085|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
219536086|NCT02227251|DRUG|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
219536087|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
219536088|NCT03570749|DRUG|Baricitinib|Administered orally.
219536089|NCT03570749|DRUG|Placebo|Administered orally.
218922189|NCT03312634|DRUG|Palovarotene|Palovarotene was taken orally once daily at approximately the same time each day following a meal.
218922190|NCT05366738|DRUG|Vonoprazan|Orally via tablet
218922191|NCT05366738|DRUG|Vonoprazan|Orally via sprinkle pellets
218922192|NCT06465628|BEHAVIORAL|Self-administered acupressure|The participants should perform self-administered acupressure 12 weeks after training
218922193|NCT06465628|OTHER|Oral health education|The participants should perform general oral care by themselves after the oral health education relating to xerostomia
218922194|NCT05668052|OTHER|questionnaire|This survey was conducted in Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 2022 to December 2023. The research objects were patients with COVID-19.
218922195|NCT00000285|DRUG|Phenytoin|
218922196|NCT01931293|DIETARY_SUPPLEMENT|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
218922197|NCT02230995|DRUG|metformin|single dose of metformin given as tablets
219536090|NCT02651948|PROCEDURE|Transperineal, MRI-guided, prostate biopsy|
219536091|NCT02651948|PROCEDURE|Transrectal prostate biopsy (TRB):|
219536092|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
219536093|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
219536094|NCT02436005|DEVICE|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
219536095|NCT02436005|DEVICE|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
219536096|NCT03076593|OTHER|Exposure: Fall|Participants will be asked about prior falls
219042768|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
219536097|NCT06570291|DRUG|Mesenchymal Stem Cells|Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
219618853|NCT03696212|DRUG|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
219618854|NCT00774163|BIOLOGICAL|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
219618855|NCT00774163|OTHER|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
219618856|NCT06507410|DRUG|Propofol|Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.
219618857|NCT06507410|DRUG|Propofol combined with clonidine|Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
219618858|NCT06121817|OTHER|Food/meal intervention|2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.
219618859|NCT01580124|PROCEDURE|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
219536098|NCT06570291|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
219618860|NCT01580124|PROCEDURE|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
219618861|NCT00958958|OTHER|multifaceted strategy|"There are multifaceted Interventions Including~1. Distribution of educational materials: distribution of published or printed recommendations for clinical care.~2. Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~3. Reminders~4. Practical training"
219536099|NCT00755313|BIOLOGICAL|trastuzumab|
219536100|NCT00755313|DRUG|aromatase inhibition therapy|
219536101|NCT00755313|DRUG|carboplatin|
219536102|NCT00755313|DRUG|cyclophosphamide|
219536103|NCT00755313|DRUG|docetaxel|
219536104|NCT00755313|DRUG|doxorubicin hydrochloride|
219536105|NCT00755313|OTHER|metabolic assessment|
219618862|NCT01960413|DRUG|Montelukast added to Hydroxyurea|
219618863|NCT01960413|DRUG|Placebo added to Hydroxyurea|
219618864|NCT03995485|DRUG|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
219618865|NCT03995485|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
219618866|NCT00776035|PROCEDURE|PET (Positron Emission Tomography)|This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.
219618867|NCT00776035|PROCEDURE|Echocardiogram|An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.
218922198|NCT02230995|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
218922199|NCT02230995|DRUG|empagliflozin|single dose of empagliflozin given as tablet
218922200|NCT01660724|PROCEDURE|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
218922201|NCT01660724|PROCEDURE|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
219536106|NCT00755313|OTHER|questionnaire administration|
219536107|NCT00755313|OTHER|study of socioeconomic and demographic variables|
219536108|NCT00755313|PROCEDURE|cognitive assessment|
218922202|NCT00671294|DRUG|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
218922203|NCT00906204|BIOLOGICAL|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
218922204|NCT00906204|BIOLOGICAL|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
218922205|NCT04190641|DEVICE|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
218922206|NCT03208010|BEHAVIORAL|Diabetes Prevention Intervention|"* Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
218922207|NCT03208010|OTHER|Enhanced Usual Care|"* Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials"
219536109|NCT00755313|PROCEDURE|positron emission tomography|
219536110|NCT00755313|RADIATION|fludeoxyglucose F 18|
219536111|NCT05474079|OTHER|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
219536112|NCT06120075|DRUG|AB801|Administered as specified in the treatment arm
218922208|NCT01597596|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
218922209|NCT01597596|BIOLOGICAL|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
218922210|NCT06517420|OTHER|kefir consumption|Support and information was received from the Food Technology Department of a university's Experimental Medicine Application and Research Center. It was decided to choose the kefir to be used, which is produced from pasteurized cow's milk, lactase enzyme, probiotic culture (B. Lactis) and kefir culture, will meet the B12 need, contribute to increasing vitality and energy, and has the most suitable content in the market. Kefir, supplied by the researcher, was given to the patients at the end of each session in the amount that the patients should consume for a week, following the cold chain rule. While consuming kefir, it was recommended to gargle it in the mouth, hold it for a while, and then swallow. Patients were contacted for a week after the session to ensure that they applied kefir correctly.
218922211|NCT01684761|BIOLOGICAL|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
218922212|NCT01684761|BIOLOGICAL|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
218922213|NCT02876549|DRUG|Chloroquine|10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
218922214|NCT02876549|DRUG|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
218922215|NCT02876549|DRUG|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
218922216|NCT01610934|DRUG|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
218922217|NCT01610934|DRUG|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
219536113|NCT06120075|DRUG|Docetaxel|Administered as specified in the treatment arm
219536114|NCT05627128|OTHER|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
219536115|NCT04387552|BEHAVIORAL|Prenatal Safe Sleep Mobile Health (mHealth) Messaging|Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.
219536116|NCT04387552|BEHAVIORAL|Prenatal Breastfeeding Mobile Health (mHealth) Messaging|Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.
219536117|NCT04387552|BEHAVIORAL|Postnatal Safe Sleep Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.
219536118|NCT04387552|BEHAVIORAL|Postnatal Breastfeeding Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
219536119|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
219536120|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
219536121|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
219536122|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
219536123|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
219536124|NCT06799741|DRUG|AV-1 100 mg|"human monoclonal antibody (mAb) intravenous solution~or"
219536125|NCT06799741|DRUG|AV-1 300 mg|"human monoclonal antibody (mAb) intravenous solution~or"
219536126|NCT06799741|DRUG|AV-1 900 mg|"human monoclonal antibody (mAb) intravenous solution~or"
219536127|NCT06799741|DRUG|Placebo|(0.9% saline intravenous solution) 12:2
219536128|NCT06212661|DRUG|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536129|NCT06212661|DRUG|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536130|NCT06212661|DRUG|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536131|NCT06212661|DRUG|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536132|NCT06212661|DRUG|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536133|NCT06212661|DRUG|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536134|NCT06212661|DRUG|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
219536135|NCT06212661|DRUG|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
219536136|NCT06631313|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
219536137|NCT05454943|BEHAVIORAL|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
219536138|NCT05454943|BEHAVIORAL|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
219536139|NCT05454943|BEHAVIORAL|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
219536140|NCT05454943|BEHAVIORAL|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
219536141|NCT06470048|DRUG|Placebo|Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
219618868|NCT00776035|RADIATION|^15O-water|This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
219618869|NCT00776035|RADIATION|1-^11C-palmitate|This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
219618870|NCT00776035|RADIATION|1-^11C-glucose|This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
219618871|NCT05973188|DRUG|Warfarin|Anticoagulant
219618872|NCT05973188|DRUG|Rivaroxaban 20 MG Oral Tablet|Anticoagulant
219536142|NCT06470048|DRUG|Ianalumab|subcutaneous (s.c.) injection as defined in the protocol
219536143|NCT03744156|BEHAVIORAL|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
219536144|NCT03744156|BEHAVIORAL|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
219536145|NCT06502353|DEVICE|BLOOM43|Heat preconditioning
219536146|NCT06119594|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
219536147|NCT06439420|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is a non-pharmacological approach to treating sleep disturbance consisting of educational, behavioral, and cognitive intervention components with evidence-based strategies including sleep efficiency, stimulus control, and sleep hygiene modification. CBT-I includes at least 6 group sessions, each approximately 90 minutes in length, delivered over 6 weeks via telehealth.
219536148|NCT05877963|BIOLOGICAL|Ublituximab|Administered as an intravenous (IV) infusion.
219536149|NCT05877963|DRUG|Placebo|IV infusion
219536150|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
219536151|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
219536152|NCT04764942|DRUG|Carfilzomib|Given IV
219536153|NCT04764942|DRUG|Dexamethasone|Given PO
219536154|NCT04764942|DRUG|Pomalidomide|Given PO
219536155|NCT04764942|OTHER|Quality-of-Life Assessment|Ancillary studies
219536156|NCT04764942|OTHER|Questionnaire Administration|Ancillary studies
219536157|NCT04764942|DRUG|Selinexor|Given PO
219536158|NCT04764942|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219536159|NCT04764942|PROCEDURE|Computed Tomography|Undergo PET/CT
219618873|NCT05973188|DRUG|Apixaban 5mg or 2.5mg oral tablet|Anticoagulant
219618874|NCT06280911|OTHER|Date Fruit group|Consumption of Date Fruit
219618875|NCT06280911|OTHER|Nipple group|Nipple Stimulation
219618876|NCT01082328|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
218922218|NCT06514560|DRUG|Miltefosine|Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
218922219|NCT06472843|BEHAVIORAL|Exercise Intervention|The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).
218922220|NCT03217604|DRUG|Placebo|Treatment with placebo
218922221|NCT03217604|DRUG|PF-06852231|Treatment with PF-06852231
218922222|NCT00551811|DRUG|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
218922223|NCT00551811|DRUG|Placebo|Placebo tablets will be intended to be administered orally.
218922224|NCT00553878|DRUG|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
218922225|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
218922226|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
218922227|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
218922228|NCT04164875|DIAGNOSTIC_TEST|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
219536160|NCT04764942|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219536161|NCT04764942|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219536162|NCT04764942|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
218922229|NCT00941096|DRUG|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
218922230|NCT04248426|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
218922231|NCT04248426|DRUG|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
218922232|NCT00330434|OTHER|Trial Withdrawn 1|Trial Withdrawn 1
218922233|NCT00330434|OTHER|Trial Withdrawn 2|Trial Withdrawn 2
218922234|NCT00848601|DRUG|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
218922235|NCT01935778|DRUG|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
218922236|NCT01935778|DRUG|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
218922237|NCT06248749|DRUG|IV iron|Intravenous Iron supplement
218922238|NCT05959148|OTHER|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
218922239|NCT05959148|OTHER|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
218922240|NCT04433676|OTHER|no intervention|
218922241|NCT03024099|OTHER|Hippotherapy once a week|Hippotherapy once a week
218922242|NCT03024099|OTHER|Hippotherapy twice a week|Hippotherapy twice a week
218922243|NCT02694692|PROCEDURE|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
219536163|NCT04764942|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536164|NCT05574335|DRUG|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
219536165|NCT05153343|DRUG|flonoltinib 25mg|1 case,The starting dose.Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
219536166|NCT05153343|DRUG|flonoltinib 100mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
219536167|NCT05153343|DRUG|flonoltinib 150mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
219536168|NCT05153343|DRUG|flonoltinib 225mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
219536169|NCT05153343|DRUG|flonoltinib 50mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
219536170|NCT04007276|DRUG|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
219536171|NCT04007276|OTHER|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
219536172|NCT05495334|PROCEDURE|Treatment for Knee OA|Pain management treatment for knee OA.
219618877|NCT02462590|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
219618878|NCT02462590|DRUG|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
219618879|NCT03124368|DRUG|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
219618880|NCT05506046|BEHAVIORAL|Reduced nicotine message exposure|Participants will be shown two messages about harms of reduced nicotine cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that reduced nicotine cigarettes will still have the rest of the harmful chemicals and cause diseases as the regular cigarettes, but they would make it easier to quit.
219618881|NCT05506046|BEHAVIORAL|Modified risk message exposure|Participants will be shown two messages about electronic cigarettes as an alternative to regular cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that electronic cigarettes are less likely than regular cigarettes to cause severe diseases such as lung cancer.
219618882|NCT05506046|BEHAVIORAL|Combined message exposure (reduced nicotine + modified risk)|Participants will be shown two messages, one from the reduced nicotine message set and one modified risk message set.
219618883|NCT05506046|BEHAVIORAL|Control message exposure|Participants will be shown two messages about drinking bottled water. These will be selected from a pool of five message. The messages display specific water products and describe hydration as a healthy activity.
219618884|NCT04212325|PROCEDURE|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
219618885|NCT04212325|PROCEDURE|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
219618886|NCT03102346|OTHER|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
219536173|NCT02414789|PROCEDURE|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
219536174|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
219536175|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
219536176|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
219536177|NCT04530110|DRUG|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
219536178|NCT05625958|DEVICE|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
219536179|NCT05509608|DEVICE|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
219536180|NCT05509608|DEVICE|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
219536181|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
219536182|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
219536183|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
219536184|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
219536185|NCT05299125|DRUG|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
219536186|NCT05299125|DRUG|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
219536187|NCT05299125|DRUG|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
219536188|NCT06646016|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
219536189|NCT06646016|DRUG|Infliximab|Infliximab will be administered intravenously.
219536190|NCT06646016|DRUG|Vedolizumab|Vedolizumab will be administered intravenously.
219536191|NCT05454956|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
219536192|NCT05454956|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
219536193|NCT06471816|OTHER|Dialogue Based Early Detection|Before the biannual parent-teacher meeting, both the kindergarten teacher and the parents will complete the Early Worry Questionnaire containing 39 items related to development and well-being of the individual child. For each item the respondents are asked to indicate if they during the last three months have been concerned. In the parent-teacher meeting they will discuss their possible concerns and try to reach an agreement on how to evaluate the child. If necessary, possible supportive interventions or further assessments locally in the kindergarten or in the public services will be decided.
218922244|NCT02694692|BEHAVIORAL|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
218922245|NCT00660634|PROCEDURE|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
219204769|NCT06685432|BEHAVIORAL|Diet|"The effect of motivational interviewing techniques was examined in addition to diet treatment. The effect of motivational interviewing techniques on anthropometric measurements before and after the study was evaluated. The participants' indecisiveness was investigated and a self-directed change conversation was presented. Behavior change strategies including determining positive and negative aspects, using importance and confidence scales, and setting the agenda were applied by the researcher.~In the interviews that included motivational interviewing techniques:~1. A participant-centered interview was conducted by collaborating with the participant.~2. The researcher was impartial and did not assume the role of an expert.~3. At the beginning of the interview, an evaluation of what was discussed in the previous week was made.~4. First of all, an attempt was made to determine the agenda according to the topic the participant wanted to discuss.~5. The importance scale was used (1-10)."
219204770|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
219618887|NCT00766012|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
219618888|NCT00766012|DRUG|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
219618889|NCT00683722|DRUG|Prochymal™|IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
219618890|NCT00683722|DRUG|Placebo|IV infusion of excipient of Prochymal™.
219618891|NCT06323681|DRUG|Peginterferon α-2b based treatment group|Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.
218922246|NCT00161772|BIOLOGICAL|Tick-borne Encephalitis Vaccine|
218922247|NCT05145101|BIOLOGICAL|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
218922248|NCT05659186|DRUG|Tislelizumab|200mg IV Q3W
219618892|NCT06323681|DRUG|NAs monotherapy group|First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
219618893|NCT00505219|BIOLOGICAL|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
218922249|NCT05659186|DRUG|Anlotinib|12mg PO QD
218922250|NCT05659186|RADIATION|Radiotherapy|Multimodal Radiotherapy
218922251|NCT04585126|DRUG|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
218922252|NCT01150188|DIETARY_SUPPLEMENT|Amino acids|11 g amino acids two times per day for eight weeks
218922253|NCT01150188|DIETARY_SUPPLEMENT|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
218922254|NCT04082819|DEVICE|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
218922255|NCT04082819|DEVICE|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
218922256|NCT00169897|BEHAVIORAL|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
218922257|NCT03599739|BIOLOGICAL|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
218922258|NCT00897299|GENETIC|microarray analysis|
218922259|NCT00897299|GENETIC|protein expression analysis|
218922260|NCT00897299|OTHER|immunohistochemistry staining method|
218922261|NCT00897299|OTHER|laboratory biomarker analysis|
218922262|NCT04065672|DRUG|Low-dose IL-2|After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
219204771|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
219204772|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
219204773|NCT04120805|DEVICE|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
219618894|NCT00505219|OTHER|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
219618895|NCT01622218|BEHAVIORAL|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
219618896|NCT03144908|OTHER|Standard Operating Procedures|Observational on Standard Operating Procedures
219618897|NCT00165464|DRUG|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
219618898|NCT00165464|DRUG|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
219618899|NCT00165464|DRUG|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
218922263|NCT04065672|DRUG|Placebo|After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
218922264|NCT04989335|DRUG|Bisantrene|Combined escalated dose chemotherapy
219536194|NCT06471816|OTHER|Traditional parent-teacher meeting|This is an annual or biannual meeting that is prepared by the kindergarten teacher where (s)he reports on the child's appearance / behaviour and possible challenges as to development and behaviour from an educationalist's view. There are no common templates for the agenda of such meetings, however, usually the kindergarten teacher's perspective and opinion will dominate.
219536195|NCT05160636|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
219536196|NCT06121843|DRUG|BMS-986393|Specified dose on specified days
219536197|NCT06121843|DRUG|Alnuctamab|Specified dose on specified days
219536198|NCT06121843|DRUG|Mezigdomide|Specified dose on specified days
219536199|NCT06121843|DRUG|Iberdomide|Specified dose on specified days
219536200|NCT06121843|DRUG|Elranatamab|Specified dose on specified days
219536201|NCT00302146|DRUG|15-0 H20|
219536202|NCT05767034|DRUG|Secukinumab 300 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
219536203|NCT05767034|DRUG|Secukinumab 150 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
219536204|NCT05767034|OTHER|Placebo to secukinumab|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
219536205|NCT04656054|PROCEDURE|liposuction|liposuction procedure and observation of the hematological changes on the patients
218922265|NCT04989335|DRUG|Fludarabine|Combined escalated dose chemotherapy
218922266|NCT04989335|DRUG|Clofarabine|Combined escalated dose chemotherapy
218922267|NCT00781703|OTHER|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
219536206|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
219536207|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)
219536208|NCT06346392|DRUG|Ramucirumab+ paclitaxel|Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
219536209|NCT06346392|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
219618900|NCT00874575|DIETARY_SUPPLEMENT|Placebo|
219618901|NCT00874575|DIETARY_SUPPLEMENT|Vitamin D|
218922268|NCT01955330|PROCEDURE|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
219204774|NCT04120805|OTHER|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
219204775|NCT06690333|DEVICE|Pacemaker|Transvenous pacemaker with left bundle area pacing
219204776|NCT06690333|DEVICE|Pacemaker|Transcatheter pacemaker with MICRA AV
219536210|NCT06346392|DRUG|Docetaxel|Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
219536211|NCT06346392|DRUG|Irinotecan|Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
219536212|NCT06346392|DRUG|TAS-102|TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
219536213|NCT06346392|DRUG|Apatinib|Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
219536214|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
219536215|NCT06580743|OTHER|No intervention|This is an observational study
219536216|NCT05746442|BEHAVIORAL|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
219536217|NCT05746442|DRUG|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
219536218|NCT05746442|BEHAVIORAL|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
219536219|NCT05746442|BEHAVIORAL|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
219536220|NCT04361708|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
219536221|NCT04361708|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
219536222|NCT04361708|DRUG|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
219618902|NCT00874575|DIETARY_SUPPLEMENT|Beta-hydroxy-Beta-methylbutyrate|
219618903|NCT00874575|DRUG|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
219618904|NCT04754932|OTHER|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
219618905|NCT00234975|DRUG|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
219618906|NCT04967820|OTHER|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
219618907|NCT01498796|DRUG|Ketorolac|
219618908|NCT01498796|DRUG|Normal Saline|
219618909|NCT02173691|DRUG|Tiotropium inhalation powder capsules|
219618910|NCT02173691|DRUG|Salmeterol inhalation aerosol|
219618911|NCT02173691|DRUG|Placebo inhalation aerosol|
219536223|NCT04361708|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
219042769|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
219536224|NCT04361708|DRUG|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
219536225|NCT06399705|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
219536226|NCT06399705|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
219536227|NCT03216967|DRUG|everolimus|Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
219536228|NCT01935934|DRUG|Cabozantinib S-malate|Given PO
219536229|NCT01935934|OTHER|Laboratory Biomarker Analysis|Correlative studies
219536230|NCT01935934|OTHER|Pharmacological Study|Correlative studies
219536231|NCT06192160|DRUG|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
219536232|NCT06192160|DRUG|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
219536233|NCT06192160|DRUG|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
219536234|NCT06192160|DRUG|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
219536235|NCT06192160|DRUG|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
219536236|NCT06192160|DRUG|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
219536237|NCT06192160|DRUG|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
219536238|NCT06192160|DRUG|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
219536239|NCT06192160|DRUG|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
219618912|NCT02173691|DRUG|Placebo inhalation powder capsules|
219618913|NCT02773901|DEVICE|HS-1000|
219618914|NCT00292734|DRUG|Zolpidem|
219042770|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
219536240|NCT06192160|DRUG|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
219536241|NCT06192160|DRUG|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
219536242|NCT04224493|DRUG|Tazemetostat|"Stage 1 (Phase 1b):~Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
219536243|NCT04224493|DRUG|Tazemetostat|"Stage 2:~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
219536244|NCT04224493|DRUG|Placebo oral tablet|"Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy."
219536245|NCT04224493|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
219536246|NCT04224493|COMBINATION_PRODUCT|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
219536247|NCT03053141|DEVICE|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
219536248|NCT06665646|BIOLOGICAL|CD40.HIVRI.Env (VRIPRO)|To be administered subcutaneously as 1 mg admixed with Hiltonol, Poly-ICLC as a single dose.
219536249|NCT06665646|BIOLOGICAL|Hiltonol Poly-ICLC-adjuvant|Vaccine adjuvant
219536250|NCT04789902|OTHER|SurgeCon|The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
219618915|NCT00450099|DRUG|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
219618916|NCT05576142|DIAGNOSTIC_TEST|Oral examination|Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
219618917|NCT06578377|OTHER|descriptive study|It is a descriptive study
218922269|NCT05777356|DIAGNOSTIC_TEST|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
219536251|NCT06972355|PROCEDURE|Hiding the eyes|Patients will participate in walking rehabilitation sessions on a treadmill supported by a Lite Gait® harness. All treadmill sessions are consistent with regular rehabilitation sessions. A typical treadmill walking session will take place 3 times a week for 6 weeks, lasting 20 minutes. During the first minute, the speed of the treadmill is gradually increased until a comfortable speed is reached. From then on, the mask will be placed over the patient's eyes for 18 minutes at a constant, i.e. comfortable, speed. The last minute will be devoted to gradually decreasing the treadmill speed until it stops, and will also be performed without the mask.
219536252|NCT05646251|DEVICE|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
219536253|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
218922270|NCT05674305|DRUG|Radiotherapy|IMRT for primary and regional field
218922271|NCT05674305|DRUG|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
218922272|NCT01124006|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
218922273|NCT01124006|OTHER|Water for injection|Sterile water for injection
218922274|NCT04405453|PROCEDURE|trapezius muscle injection|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
218922275|NCT04405453|PROCEDURE|erector spina plane block|1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
218922276|NCT00565084|DRUG|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
218922277|NCT00565084|DRUG|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
218922278|NCT04812717|DEVICE|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
218922279|NCT03124342|OTHER|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals"
218922280|NCT06598085|DEVICE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
218922281|NCT05511584|PROCEDURE|VO2 estimation|"1. st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) \* minute volume (Volmin)~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
218922282|NCT05511584|PROCEDURE|SEVOup estimation|"1. st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) \* Volmin~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
219042771|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
219042772|NCT04804813|DRUG|Cabozantinib|Cabozantinib tablets
219042773|NCT02444091|DRUG|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
219042774|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
219042775|NCT00745914|DRUG|Placebo comparator|Placebo comparator
219042776|NCT04741165|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
219536254|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
219536255|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
219536256|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
219536257|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
219536258|NCT05317585|DEVICE|Continuous Glucose Monitor|Continuous Glucose Monitor
219042777|NCT04741165|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
219042778|NCT04741165|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle
219042779|NCT04516265|PROCEDURE|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
218922283|NCT04411498|DIAGNOSTIC_TEST|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
218922284|NCT01060332|OTHER|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
218922285|NCT02575638|DRUG|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
218922286|NCT01803607|DRUG|odanacatib|odanacatib 50 mg oral tablet
218922287|NCT01803607|OTHER|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
218922288|NCT02242526|DEVICE|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
218922289|NCT02242526|DEVICE|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
218922290|NCT04469907|DRUG|AZD9977|Participants will receive a single oral dose of AZD9977 under fasted conditions.
218922291|NCT03586492|DIAGNOSTIC_TEST|CZT SPECT acquisition|CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
218922292|NCT03478098|OTHER|Low GI mealtest|Meal with low glycaemic index (GI) is consumed over 20 min
218922293|NCT03478098|OTHER|Low GI mealtest and subsequent exercise|Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
218922294|NCT03478098|OTHER|High GI mealtest|Meal with high glycaemic index (GI) is consumed over 20 min
219536259|NCT05317585|DEVICE|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
219536260|NCT06136884|DRUG|AO-252|AO-252 will be administered oral tablets or capsules daily
219536261|NCT04609826|DRUG|JNJ-74856665|JNJ-74856665 will be administered orally.
219536262|NCT04609826|DRUG|AZA|AZA will be administered IV infusion or SC injection.
218922295|NCT03478098|OTHER|High GI mealtest and subsequent exercise|Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
218922296|NCT01815346|PROCEDURE|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
218922297|NCT01815346|BEHAVIORAL|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
218922298|NCT01815346|OTHER|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
218922299|NCT05410210|OTHER|Pharmaceutical care|The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
218922300|NCT04266145|DRUG|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
218922301|NCT04266145|DRUG|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
218922302|NCT03824769|BEHAVIORAL|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
219042780|NCT04516265|PROCEDURE|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
219042781|NCT04516265|PROCEDURE|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
219042782|NCT04222738|DIETARY_SUPPLEMENT|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
219536263|NCT04609826|DRUG|VEN|VEN tablet will be administered orally.
219536264|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
219536265|NCT06545942|DRUG|Olaparib|Olaparib administered orally
219536266|NCT05189093|DRUG|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
219536267|NCT06486454|DEVICE|HistoSonics Edison System|Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors
219536268|NCT05239754|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
219536269|NCT06425757|DRUG|ciprofol|Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
219536270|NCT05400733|DIETARY_SUPPLEMENT|Total Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
219536271|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
219536272|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
219536273|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Leucine|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
219536274|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids High|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
219536275|NCT05400733|DIETARY_SUPPLEMENT|Placebo Water|Water
219536276|NCT04557449|DRUG|PF-07220060|CDK4 inhibitor
219536277|NCT04557449|COMBINATION_PRODUCT|Letrozole|Endocrine Therapy
219536278|NCT04557449|COMBINATION_PRODUCT|Fulvestrant|Endocrine Therapy
219536279|NCT04557449|DRUG|Midazolam|Benzodiazepine used for DDI
219536280|NCT04557449|COMBINATION_PRODUCT|Enzalutamide|Androgen Receptor inhibitor
219536281|NCT05905575|BEHAVIORAL|Family dyad diabetes intervention|The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
219536282|NCT06047834|DRUG|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).
219536283|NCT06047834|OTHER|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
219536284|NCT06358209|PROCEDURE|Ventricular irrigation|Catheter ventricular irrigation can be employed by various forms. Lavage is performed with with each time at least 200ml of saline. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open.
219536285|NCT05243797|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
219536286|NCT05243797|DRUG|Lenalidomide|Lenalidomide will be administered orally
219536287|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
219536288|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
219536289|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
219536290|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
219536291|NCT05526313|DRUG|Purinostat Mesylate 1.2mg/m^2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
219536292|NCT05526313|DRUG|Purinostat Mesylate 2.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536293|NCT05526313|DRUG|Purinostat Mesylate 4.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536294|NCT05526313|DRUG|Purinostat Mesylate 6.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536295|NCT05526313|DRUG|Purinostat Mesylate 8.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536296|NCT05526313|DRUG|Purinostat Mesylate 11.2mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536297|NCT05526313|DRUG|Purinostat Mesylate 15mg/m^2|Take the medicine once on D1, D8, D11, D15.
219536298|NCT06975059|DEVICE|NUSHU shoe|The NUSHU shoe, created by Magnes AG, can measure real-time detection of gait analysis while providing vibrotactile stimulus to the study participant through machine learning sensors. This may provide a feedback mechanism that acts as therapy for gait difficulties.
219536299|NCT05653349|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
219536300|NCT05653349|DRUG|Placebo|Intravenous infusion, prepared from matching placebo
219536301|NCT05653349|DRUG|Corticosteroids|Oral or parental (if clinically justified)
218922303|NCT03824769|BEHAVIORAL|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
218922304|NCT01550224|DRUG|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
218922305|NCT01550224|DRUG|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
218922306|NCT04512157|BEHAVIORAL|Promoting Alternative Thinking Strategies (PATHS), Preschool Edition|PATHS® is a universal teacher implemented, and school-based intervention that aims to give preschool children a strategically timed boost in social emotional competence. Specifically, PATHS® encourages the use of interactive techniques to bolster children's ability to self-regulate, increase their adeptness at social cognitive problem solving, as well as to gain insight into their emotions and emotions of others.
218922307|NCT04269668|DEVICE|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
218922308|NCT04269668|DEVICE|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
218922309|NCT04664452|OTHER|Questionnaire|Participants will be asked to fill the questionnaire
218922310|NCT01281124|DRUG|Azacitidine|Given subcutaneously
218922311|NCT01281124|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
218922312|NCT01281124|OTHER|Pharmacological Study|Correlative studies
218922313|NCT03038100|DRUG|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
218922314|NCT03038100|DRUG|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
219536302|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
218922315|NCT03038100|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
219536303|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
219536310|NCT06256562|DRUG|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
219536311|NCT06256562|OTHER|Placebo|Administered the same volume as GZR18
219536312|NCT05259410|BEHAVIORAL|TRE|All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
219536313|NCT05259410|BEHAVIORAL|MedTRE|A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
219536314|NCT05347875|OTHER|Walking aid skills app|"The interventional app teaches users how to fit, walk with, and navigate stairs and chairs with a walking aid. It contains instructional videos with key components of these skills highlighted. The user can use their phone's video to record themselves performing the taught skills to enable them to review their usage of the walking aids."
218922316|NCT03038100|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
218922317|NCT03038100|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
218922318|NCT01697670|DRUG|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
218922319|NCT00013221|BEHAVIORAL|Exercise|
218922320|NCT00404144|DEVICE|Drug Eluting Balloon|PCI of small vessels single arm study
218922321|NCT03484208|OTHER|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
219204777|NCT05989763|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
219536315|NCT05347875|OTHER|Breathing skills app|This app has the same interface as the ICanWALK app. Instead, it teaches deep breathing for stress relief and breathing to improve lung function.
219536316|NCT06083090|PROCEDURE|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
219536317|NCT06083090|PROCEDURE|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
219536318|NCT04454528|RADIATION|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
219536319|NCT04454528|DRUG|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
219536320|NCT04454528|PROCEDURE|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
219536321|NCT06807983|DIAGNOSTIC_TEST|diagnostic strategy based on lung and cardiac ultrasonography|cardiopulmonary ultrasound performed by the emergency physician, immediately at patient's bed
219536322|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
219536323|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
219536324|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
219536325|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
219536326|NCT06730256|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion chimeric antigen receptor T cells
219536327|NCT04001777|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
219536328|NCT04001777|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
219536329|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
219536330|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
219536331|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
219536332|NCT03513185|DRUG|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
219536333|NCT05860699|DRUG|Placebo|Placebo made by the same manufacturer to look like the active pills
219536334|NCT05860699|DRUG|Half dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
219536335|NCT05860699|DRUG|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
219536336|NCT03677739|OTHER|Informational Intervention|Receive information focusing on skin cancer
218922322|NCT05760040|OTHER|vırtual reality|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
219536337|NCT03677739|OTHER|Informational Intervention|Receive information on healthy lifestyle
219536338|NCT03677739|OTHER|Survey Administration|Ancillary studies
219536339|NCT04501328|BEHAVIORAL|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
218922323|NCT05760040|OTHER|Control Group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
218922324|NCT06331936|BEHAVIORAL|Emotion regulation|Each participant will attend four intervention sessions. They will also be invited to a booster Session, where they will be invited for interviews to share what they have gained from the sessions. The contents of the intervention and the booster session are as follows: (1) understand emotions, (2) attention and positivity, (3) emotional regulation, (4) connectedness and intimacy, and (5) review and sharing.
218922325|NCT02651207|OTHER|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
218922326|NCT01744262|DRUG|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
219536340|NCT04501328|BEHAVIORAL|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
219536341|NCT05523583|OTHER|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
219536342|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
219536343|NCT04659603|DRUG|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
219536344|NCT04659603|DRUG|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
219536345|NCT01070433|DRUG|MEBO Wound Ointment (MEBO)|Topical application twice a day
219536346|NCT01070433|OTHER|Standard of Care|Topical application twice a day
219536347|NCT04604561|DEVICE|EnVisio SmartClip|The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
219536348|NCT04604561|DEVICE|EnVisio™ Navigation System|The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
219536349|NCT03254420|DEVICE|Calypso beacon implant|Calypso beacon implant before radiotherapy
219536350|NCT03254420|RADIATION|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
219618918|NCT05037201|BEHAVIORAL|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
219618919|NCT03776357|DEVICE|VERA clinic|A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
219618920|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Investigational Formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
219618921|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Control formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
219618922|NCT04508257|DIETARY_SUPPLEMENT|Breast feeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
219618923|NCT04900259|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
219618924|NCT06578611|COMBINATION_PRODUCT|Enhanced recovery after surgery|Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.
219618925|NCT06411158|OTHER|Interventionist-guided training|Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
219618926|NCT06411158|DEVICE|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
219536351|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
219536352|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
219618927|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
219042783|NCT05733143|OTHER|cardiopulmonary exercise stress test (CPEST)|The study is observational and purely exploratory. We will utilise cardiopulmonary exercise stress testing to assess levels of fitness and causes for symptoms in proposed groups.
219536353|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
219536354|NCT05765812|DRUG|Debio 0123|Administered as capsules.
219536355|NCT05765812|DRUG|Temozolomide|Administered as capsules.
219536356|NCT05765812|RADIATION|Radiotherapy|Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
219536357|NCT03225547|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
219536358|NCT03225547|DRUG|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
219536359|NCT04340531|OTHER|Best Practice|Receive usual care
219536360|NCT04340531|OTHER|Survey Administration|Ancillary studies
219536361|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive referred to counseling session
219618928|NCT06295874|OTHER|Effect of aromatherapy massage on vital signs, pain, anxiety and comfort level|The study applied a mixture of lavender, thyme and eucalyptus oil (5 drops of lavender oil, 4 drops of thyme oil, 3 drops of eucalyptus oil and 20 ml of almond oil in 20 ml) to patients who were monitored in intensive care on high-flow and oxygen, for three days. It was conducted as a randomized controlled single-blind study to evaluate the effects of aromatherapy massage applied twice a day for a total of 30 minutes on some physiological parameters, pain, anxiety and comfort levels.
219618929|NCT04055701|OTHER|assesment of thymus volume|assesment of thymus volume
219618930|NCT03335475|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
219618931|NCT03335475|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
219618932|NCT03971136|DIAGNOSTIC_TEST|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
219618933|NCT05071209|DRUG|Elimusertib|Given PO
219618934|NCT00232297|DRUG|SSR149744C|
218922327|NCT01744262|DRUG|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
218922328|NCT03109964|DEVICE|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
219536362|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive phone counseling
219536363|NCT04340531|OTHER|Training|Undergo training
219536364|NCT01231906|DRUG|Cyclophosphamide|Given IV
219536365|NCT01231906|DRUG|Dexrazoxane|
219536366|NCT01231906|DRUG|Doxorubicin Hydrochloride|Given IV
219536367|NCT01231906|DRUG|Etoposide|Given IV
219536368|NCT01231906|DRUG|Ifosfamide|Given IV
219536369|NCT01231906|OTHER|Laboratory Biomarker Analysis|Correlative studies
219536370|NCT01231906|DRUG|Topotecan Hydrochloride|Given IV
218922329|NCT03109964|DEVICE|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
218922330|NCT04899596|OTHER|No intervention|No intervention
218922331|NCT02739906|DRUG|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
219042784|NCT06227377|DRUG|QTX3034|QTX3034 will be administered at protocol defined dose
219042785|NCT06227377|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
219536371|NCT01231906|DRUG|Vincristine Sulfate|Given IV
219536372|NCT02747056|OTHER|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
219536373|NCT02747056|OTHER|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
219536374|NCT02747056|OTHER|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
219536375|NCT06777511|DRUG|5-aminolevulinic acid (5-ALA)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management.
219536376|NCT06777511|DEVICE|Photodynamic therapy (PDT)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device photodynamic therapy device as part of their standard stoma management.
219536377|NCT04529252|OTHER|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
219536378|NCT06389149|OTHER|LEAP therapy|Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting
219536379|NCT06389149|OTHER|no LEAP therapy|2.5 hours of uninterrupted prolonged sitting (no movement)
219536380|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
219536381|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
219536382|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
219536383|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
219536384|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
219536385|NCT05568095|DRUG|Domvanalimab|Intravenous (IV) Aqueous Solution
219536386|NCT05568095|DRUG|Zimberelimab|IV Aqueous Solution
219536387|NCT05568095|DRUG|Capecitabine|Oral Tablets
219536388|NCT05568095|DRUG|Fluorouracil|IV Aqueous Solution
219536389|NCT05568095|DRUG|Leucovorin|IV Aqueous Solution
219536390|NCT05568095|DRUG|Oxaliplatin|IV Aqueous Solution
219536391|NCT05568095|DRUG|Nivolumab|IV Aqueous Solution
219536392|NCT07122973|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
219536393|NCT07122973|OTHER|Cowhage|The spicules will be manually inserted. Approximately 30-35 spicules are gently rubbed into a 1 cm diameter skin area on the forearm/face
219536394|NCT07122973|OTHER|Capsaicin 8% Patch|Capsaicin patches (dosage form: transdermal patch 8% Qutenza, Astellas) will be applied on 3 squared areas in the face.
219536395|NCT07122973|OTHER|Demo patch|Placebo patch (demo patch, containing the same formulation as the active treatment with the exception of capsaicin) will be applied on 3 squared areas in the face.
219536397|NCT06531876|DEVICE|Dreem 3S recording|Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
218922332|NCT02739906|DRUG|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
218922333|NCT02739906|DRUG|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
218922334|NCT06249802|DRUG|Nebivolol|12-month intake of medication
218922335|NCT06249802|DRUG|Placebo|12-month intake of matching placebo
218922336|NCT01113086|DEVICE|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
218922337|NCT04381754|DEVICE|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
218922338|NCT01683357|PROCEDURE|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
218922339|NCT00478543|DRUG|Furosemide|
218922340|NCT02392624|DRUG|Omalizumab|Omalizumab 300 mg administered SC Q4W.
218922341|NCT02392624|DRUG|Placebo|Placebo matched to omalizumab administered SC Q4W.
218922342|NCT04199806|OTHER|Questionnaire review|Review data from questionnaires received about MMS experience.
218922343|NCT04557891|DEVICE|Active LIFUP Treatment|8 LIFUP Treatments
218922344|NCT04557891|DEVICE|Sham LIFUP Treatment|8 sham LIFUP treatments
218922345|NCT00706238|BIOLOGICAL|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
218922346|NCT05995106|OTHER|Heart4U|Mobile app.
218922347|NCT02518438|DRUG|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
218922348|NCT03898739|OTHER|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
218922349|NCT03833505|OTHER|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
218922350|NCT04836650|DIAGNOSTIC_TEST|Postural stability assessment with a force platform.|The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.
218922351|NCT04836650|DIAGNOSTIC_TEST|Muscular assessment with a electromyograph|The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
218922352|NCT05976412|RADIATION|Regional lymph node radiotherapy|Regional lymph node radiotherapy
218922353|NCT05976412|RADIATION|chest/whole breast irradiation|chest/whole breast irradiation
218922354|NCT04969302|DIAGNOSTIC_TEST|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
218922355|NCT05072600|DRUG|Pembrolizumab|pembrolizumab 200 mg Q3W
218922356|NCT00309374|DRUG|LPS 2ng/kg intravenous bolus|
218922357|NCT00309374|DRUG|Simvastatin 80mg; administered daily p.o. over 5 days|
218922358|NCT00309374|DRUG|Rosuvastatin 40mg; administered daily p.o. over 5 days|
218922359|NCT01698333|DRUG|122-0551|Applied twice daily for 2 weeks
218922360|NCT00874094|BIOLOGICAL|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
218922361|NCT04291898|DEVICE|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
218922362|NCT04291898|DEVICE|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
218922363|NCT04291898|DEVICE|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
218922364|NCT04441892|DEVICE|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
218922365|NCT01392339|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
218922366|NCT03841604|DRUG|Safinamide Methanesulfonate|50 mg, 100 mg
218922367|NCT03841604|OTHER|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
218922368|NCT05779540|DEVICE|Safeback SBX|The intervention consists in the test of the active device.
218922369|NCT05779540|DEVICE|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
218922370|NCT01635439|DRUG|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
218922371|NCT01635439|DRUG|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
218922372|NCT04168918|BEHAVIORAL|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
219536404|NCT05490433|PROCEDURE|Robot-assisted Nipple-Sparing Mastectomy (RNSM)|"Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision.~During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered."
218922373|NCT04723277|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf)|Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
219536405|NCT05490433|PROCEDURE|Conventional nipple sparing mastectomy(CNSM)|"Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted.~During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered."
219536406|NCT06842823|DRUG|navenibart|Navenibart will be administered as a subcutaneous injection.
219536407|NCT06842823|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
218922374|NCT04723277|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
218922375|NCT00370968|DRUG|Zinc sulphate|
219536410|NCT06319248|DRUG|Midodrine|Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
219536411|NCT06319248|OTHER|Standard of Care|Subjects will receive standard of care for sepsis treatment.
219618935|NCT05944913|DEVICE|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
219618936|NCT02755103|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
219536412|NCT06079879|DRUG|Bomedemstat|Oral Capsule
219536413|NCT06079879|DRUG|Anagrelide|Oral Capsule
219536414|NCT06079879|DRUG|Busulfan|Oral Tablet
219536415|NCT06079879|DRUG|Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b|Subcutaneous Solution
219536416|NCT06079879|DRUG|Ruxolitinib|Oral Tablet
219536417|NCT06587984|BEHAVIORAL|Text message reminder|One-time text message reminder with information about getting flu vaccine at CHOP
219536418|NCT05639114|DRUG|Ianalumab|ianalumab s.c. monthly or quarterly
219536419|NCT05639114|DRUG|Placebo|placebo s.c. monthly
219536420|NCT06669533|DRUG|Placebo|Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
219536421|NCT06669533|DRUG|Misoprostol|Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
219536422|NCT05691465|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219536423|NCT05691465|PROCEDURE|Computed Tomography|Undergo CT scan
219536424|NCT05691465|RADIATION|Gallium Ga 68-DOTATATE|Given IV
219536425|NCT05691465|DRUG|Lutetium Lu 177 Dotatate|Given IV
219536426|NCT05691465|PROCEDURE|Positron Emission Tomography|Undergo PET
219536427|NCT06655896|BIOLOGICAL|rapcabtagene autoleucel|single infusion of rapcabtagene autoleucel
219536428|NCT06655896|BIOLOGICAL|rituximab|rituximab intravenous infusion (i.v.) as per protocol
219536429|NCT04209504|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
219536430|NCT04209504|DRUG|Ropivacaine|Local anesthetic (numbing drug)
219618937|NCT01285362|DRUG|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
219618938|NCT01285362|DRUG|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
219618939|NCT03142139|BIOLOGICAL|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~* timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~* delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
219618940|NCT03142139|BIOLOGICAL|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~* timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~* delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
219536431|NCT04209504|DRUG|Bupivacaine|Local anesthetic (numbing drug)
219536432|NCT04209504|DEVICE|MediPines AGM100 Advanced Respiratory Monitoring System|Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
219536433|NCT05524935|DRUG|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
219618941|NCT03142139|BIOLOGICAL|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
219536434|NCT05524935|DRUG|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
219536435|NCT06194084|OTHER|Two-sequence of durian pulp doses (100 g and 200 g)|Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
219536436|NCT04234997|DRUG|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
218922376|NCT00984217|RADIATION|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
218922377|NCT00984217|DRUG|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
218922378|NCT01238068|DEVICE|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
218922379|NCT02642185|PROCEDURE|Microwave ablation|CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
218922380|NCT02642185|PROCEDURE|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
219536437|NCT04234997|DRUG|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
219536438|NCT06983158|DRUG|gene therapy|Intra-venous gene therapy
219536439|NCT06982521|DRUG|RLY-2608|400 mg orally BID administered daily on a 28-day treatment cycle
219536440|NCT06982521|DRUG|Capivasertib|400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
219536441|NCT06982521|DRUG|Fulvestrant|500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)
219536442|NCT06605833|DIAGNOSTIC_TEST|12-Lead ECG|"Participants will undergo a standard 12-lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
219536443|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
219618942|NCT05955937|OTHER|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
218922381|NCT04670302|PROCEDURE|Tendon repair procedure|"Tendon repair procedure:~1. Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~2. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~3. Then, double suturing of the supraspinatus tendon is performed."
218922382|NCT04670302|PROCEDURE|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
218922383|NCT02317900|BIOLOGICAL|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
218922384|NCT02317900|BIOLOGICAL|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
218922385|NCT02317900|BIOLOGICAL|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
218922386|NCT03877510|DRUG|IPX203|IPX203 extended release capsules
218922387|NCT04824924|DRUG|The combination of HHT, venetoclax, AZA, G-CSF|HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
218922388|NCT01417377|DRUG|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
218922389|NCT02113982|DRUG|Tagraxofusp|
218922390|NCT05333198|OTHER|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
218922391|NCT05333198|OTHER|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
218922392|NCT04281862|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
218922393|NCT04281862|DRUG|Topical Prednisolone|Standard of care topical drop treatment
219536444|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
219536445|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
219536446|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
219536447|NCT06598150|OTHER|Shoulder Abduction|Individuals will be visually cued to perform short, unilateral, isometric shoulder abduction tasks. A visual display will provide real-time feedback of the shoulder abduction torque, to help the participant target a predetermined torque level.
218922394|NCT00267059|DRUG|Lenalidomide|10 mg/day, orally once a day for 28 days
218922395|NCT02085161|DRUG|placebo to tiotropium + olodaterol|comparator
218922396|NCT02085161|DRUG|tiotropium+olodaterol|tiotropium 5 mcg once daily
218922397|NCT02085161|DRUG|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
218922398|NCT02085161|DRUG|tiotropium|tiotropium 5 mcg once daily fixed dose combination
219536448|NCT06588153|DRUG|Prolia®|Subcutaneous (SC) injection in pre-filled syringe.
219536449|NCT01138436|DRUG|MEBO Wound Ointment (MEBO)|Topical application once a day
219618943|NCT05955937|OTHER|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
218922399|NCT01376934|PROCEDURE|procedure hysteroscopy|office hysteroscopy with gas or saline solution
219042786|NCT01454921|BEHAVIORAL|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
219042787|NCT02582853|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
219042788|NCT02582853|PROCEDURE|Blood Sample|Blood sample
219536450|NCT01138436|PROCEDURE|Standard of Care|Application of Profore multilayer compression bandage system
219536451|NCT05632380|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
218922400|NCT04515316|DEVICE|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
219536452|NCT05632380|BIOLOGICAL|C-CAR088|C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
219536453|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
219536454|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
219618944|NCT01833481|RADIATION|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
218922401|NCT04515316|DEVICE|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
218922402|NCT06083740|DEVICE|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
218922403|NCT05411315|OTHER|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
219618945|NCT03578432|DRUG|Everolimus|Given PO
219618946|NCT03578432|OTHER|Laboratory Biomarker Analysis|Correlative studies
219618947|NCT03578432|OTHER|Survey Administration|Ancillary studies
219618948|NCT04736849|DEVICE|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
219618949|NCT02017158|OTHER|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
219618950|NCT05702931|DRUG|Semaglutide 14 MG [Rybelsus]|At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
218922404|NCT05411315|OTHER|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
218922405|NCT04591353|DRUG|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
218922406|NCT04591353|DRUG|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
218922407|NCT00218777|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|
218922408|NCT01647217|DRUG|Terpinen-4-ol|Lid scrub once or twice per day for one month.
218922409|NCT01647217|OTHER|Placebo|Lid scrub once or twice per day for one month
219204778|NCT05989763|DEVICE|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
218922410|NCT01774721|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
218922411|NCT01774721|DRUG|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
218922412|NCT04363970|OTHER|removal of the urinary catheter|in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
218922413|NCT06223984|DRUG|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
218922414|NCT01936870|DRUG|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
218922415|NCT03651479|OTHER|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
219204779|NCT04011839|DRUG|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
219536455|NCT06660355|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase inhibitor.
219536456|NCT06660355|DRUG|Prednisone|Prednisone is a glucocorticoid.
219536457|NCT06296056|BIOLOGICAL|Combi|Biological immune cell therapy
219536458|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
219536459|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
219536460|NCT06654037|DRUG|Abemaciclib|Given PO
219536461|NCT06654037|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219536462|NCT06654037|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536463|NCT06654037|DRUG|Fluorouracil|Given IV
219536464|NCT06654037|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
219618951|NCT05702931|DRUG|Placebo|Saline
218922416|NCT03651479|OTHER|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
218922417|NCT03054246|OTHER|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
218922418|NCT00988806|DRUG|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
218922419|NCT00988806|DRUG|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
218922420|NCT02524782|BIOLOGICAL|MEDI-4166|MEDI-4166 administered subcutaneously
218922421|NCT02524782|BIOLOGICAL|Placebo|Placebo administered subcutaneously
218922422|NCT02658396|DRUG|GO-203-2C|
218922423|NCT02658396|DRUG|Bortezomib|
218922424|NCT03762057|DIAGNOSTIC_TEST|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
218922425|NCT00543413|DRUG|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
218922426|NCT00543413|DRUG|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
219536465|NCT06824818|BEHAVIORAL|LHRH Agonist Therapy Discontinuation|The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
219536466|NCT04603014|COMBINATION_PRODUCT|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
219536467|NCT06985862|OTHER|Voice recording 4 times a day|"* Morning (first recording): Text reading (article 25.1 of the Declaration of Human Rights).~* Noon (second recording): Counting from 1 to 20 at normal speed~* Evening (third recording): Prolonged phonation of the vowel 'a' without catching your breath.~* Bedtime (fourth recording): Free expression describing stressful moments of the day and their impact on diabetes management, for at least 30 seconds."
219536468|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
218922427|NCT00543413|DRUG|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
218922428|NCT00232427|PROCEDURE|Hemodynamic monitoring system PiCCO|
218922429|NCT03848832|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
218922430|NCT03848832|DRUG|Placebo|Matching placebo oral solution
218922431|NCT01635504|BIOLOGICAL|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
218922432|NCT05757544|DRUG|IV Ganaxolone|IV Ganaxolone will be administered.
218922433|NCT05757544|DRUG|IV Placebo|IV Placebo will be administered
219536469|NCT06597396|DRUG|Abrocitinib|50 mg tablets
219536470|NCT06597396|DRUG|Placebo|Tablets
219536471|NCT06840392|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
219536472|NCT06840392|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
219536473|NCT06840392|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
219536474|NCT06840392|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
219536475|NCT02841748|DRUG|Pembrolizumab|200mg, every three weeks, iv, x 1 year
219536476|NCT02841748|DRUG|Placebo|iv, every three weeks, x 1 year
219536477|NCT05053347|DIETARY_SUPPLEMENT|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 4.5 g/d (ALA 2.5g/d). The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219536478|NCT05053347|DIETARY_SUPPLEMENT|Corn oil capsule|The participants were asked to take corn oil capsule 4.5 g/d. The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219536479|NCT06858865|DRUG|AD-228A|AD-228A Oral Tablet
219536480|NCT06858865|DRUG|AD-2281 and AD-2282|AD-2281 Oral Tablet + AD-2282 Oral Tablet
219536481|NCT06858579|DRUG|DNTH103|IV Infusion
219536482|NCT06858579|DRUG|DNTH103|SC injection
219536483|NCT06858579|DRUG|Placebo|SC injection
219536484|NCT06654752|OTHER|Immediate Oral Antibiotics|Increase airway clearance and start 14 days of preselected oral antibiotics right away
219536485|NCT06654752|OTHER|Tailored Treatment: Oral Antibiotics only if Additional Treatment needed|Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
219536486|NCT06859099|DRUG|Riliprubart Prefilled Pen (PFP)|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
219536487|NCT03238976|OTHER|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
218922434|NCT00240396|DRUG|Narcotics alone|
218922435|NCT00240396|DRUG|Narcotics and NSAIDS|
218922436|NCT04539132|BEHAVIORAL|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
218922437|NCT03400839|DIAGNOSTIC_TEST|Daily physical activity levels|Objectively measured physical activity using activity monitors.
218922438|NCT03400839|DIAGNOSTIC_TEST|6-minute walk test|Assessment of functional exercise capacity.
218922439|NCT03400839|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Assessment of maximal exercise capacity.
218922440|NCT03400839|DIAGNOSTIC_TEST|Muscle Function|Assessment of muscle force, muscle endurance and muscle fatigability
218922441|NCT03400839|DIAGNOSTIC_TEST|Lung Function|Assessment of whole-body plethysmography and spirometry.
218922442|NCT03400839|DIAGNOSTIC_TEST|Body composition|Assessment of bioelectrical impedance.
218922443|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SGRQ-I|"Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)"
218922444|NCT03400839|DIAGNOSTIC_TEST|Symptoms - UCSD/SOBQ|"Assessment of symptoms by the UCSD Short of breath questionnaire"
218922445|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SF36|"Assessment of Health-related quality of life by the SF-36 questionnaire"
219618952|NCT01471483|BEHAVIORAL|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
218922446|NCT03400839|DIAGNOSTIC_TEST|Anxiety and depression|"Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale"
218922447|NCT03400839|DIAGNOSTIC_TEST|Symptoms - mMRC|"Assessment of symptoms by the modified Medical Research Council (mMRC) scale"
218922448|NCT03400839|DIAGNOSTIC_TEST|Sleep quality|"Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)"
219042789|NCT06842875|BEHAVIORAL|RI-SPHERES|Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.
219204780|NCT05567003|PROCEDURE|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
219536488|NCT06989957|DRUG|Psilocybin|Experimental Psilocybin (exact dosages not disclosed)
219536489|NCT06989957|DRUG|Psilocybin|Comparator Psilocybin (exact dosages not disclosed)
219618953|NCT01471483|OTHER|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
219536490|NCT06989957|DRUG|MDMA|Experimental MDMA (exact dosages not disclosed)
219536491|NCT06989957|DRUG|MDMA|Comparator MDMA (exact dosages not disclosed)
218922449|NCT03400839|DIAGNOSTIC_TEST|Sleepiness|"Assessment of sleepiness by the Epworth Sleepiness Scale"
218922450|NCT03400839|DIAGNOSTIC_TEST|Inflammatory markers and oxidative stress|"blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP."
218922451|NCT03400839|DIAGNOSTIC_TEST|Functional performance tests|Timed-up-and-go at usual pace (TUGu) and at a fast pace (TUGf), four-metre gait speed test (4MGS), sit-to-stand test using three protocols: 30 seconds (30sec-STS), one minute (1min-STS) and five-repetition (5rep-STS) and Short Physical Performance Balance (SPPB).
218922452|NCT06519708|DRUG|Erector Spinae Plane Block|Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
219536492|NCT06988527|DRUG|Honey in orabase 1: 1 paste|The experimental drug was manufactured and packed at the Faculty of Pharmacy, Price Sattam University, SA. Production of a mucoadhesive paste involves a step-by-step process. in the final step, honey, comprising 50% of the total composition was thoroughly blended with the prepared base to ensure homogeneity
219536493|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
218922453|NCT06519708|DRUG|External Oblique Intercostal Plane Block|Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
218922454|NCT02399163|DRUG|Fluoride free toothpaste|Brushing with fluoride free toothpaste
218922455|NCT02399163|DRUG|Fluoride toothpaste|Brushing with fluoride containing toothpaste
218922456|NCT02399163|DRUG|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
218922457|NCT01357525|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
218922458|NCT04646044|DRUG|Bempegaldesleukin|Administered as an intravenous infusion
218922459|NCT04646044|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
218922460|NCT04646044|OTHER|Placebo|Administered as an intravenous infusion
218922461|NCT05808829|OTHER|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
218922462|NCT01326949|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
218922463|NCT01326949|PROCEDURE|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
218922464|NCT03035357|DRUG|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
218922465|NCT03199586|DRUG|NP-G2-044|capsule
218922466|NCT03910244|DRUG|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
218922467|NCT03910244|DRUG|Placebo oral capsule|Matching placebo will be given.
218922468|NCT02906748|PROCEDURE|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
218922469|NCT02906748|PROCEDURE|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
218922470|NCT03076151|DRUG|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
219204781|NCT06965205|DIETARY_SUPPLEMENT|MCT feeding|"MCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding:~* Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am.~* Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours~* Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration.~By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home.~For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding."
219204782|NCT06965205|DIETARY_SUPPLEMENT|Standard feeds|Nutrison Protein Plus 1.25kcal/ml.
218922471|NCT03594110|DRUG|Empagliflozin|Taken daily with or without food
218922472|NCT03594110|DRUG|Matching placebo|Taken daily with or without food
218922473|NCT05280067|COMBINATION_PRODUCT|ZetaMet™ (ZetaFuse™ Bone Graft)|ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
218922474|NCT06642220|DEVICE|Y-90 Selective Internal Radiation Therapy (SIRT)|Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
218922475|NCT03734692|DRUG|Rintatolimod|200 mg by IP administration over 1-2 hours
218922476|NCT03734692|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
218922477|NCT03734692|DRUG|Cisplatin|50mg/m\^2 solution
218922478|NCT03851991|DRUG|Arbidol|oral
218922479|NCT03851991|DRUG|Placebos|controle
218922480|NCT06161389|DEVICE|Partially inflated mask|Manikin ventilation with a partially inflated mask
218922481|NCT06161389|DEVICE|Fully inflated mask|Manikin ventilation with a fully inflated mask
218922482|NCT05955911|BEHAVIORAL|Exercise|20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.
218922483|NCT05955911|BEHAVIORAL|Coloring|20 minutes of coloring in adult coloring book
218922484|NCT02741063|BEHAVIORAL|screen low autistic subjects|screen subjects with low ASQ score
218922485|NCT02741063|BEHAVIORAL|screen high autistic subjects|screen subjects with high ASQ score
218922486|NCT02741063|DRUG|oxytocin|intranasal administration of oxytocin (24 IU)
218922487|NCT02741063|DRUG|placebo|intranasal administration of placebo (24 IU)
218922488|NCT01253837|DRUG|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
218922489|NCT00180778|DRUG|Low dose steroids|
218922490|NCT05994196|BEHAVIORAL|Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)|Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
218922491|NCT01522222|PROCEDURE|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
218922492|NCT00217399|DRUG|sorafenib tosylate|Given orally
218922493|NCT00217399|DRUG|anastrozole|Given orally
218922494|NCT00871416|DEVICE|NovoFine® needle 6 mm|
218922495|NCT00871416|DEVICE|NovoFine® needle 12 mm|
218922496|NCT03869047|DRUG|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
219042790|NCT06842875|BEHAVIORAL|Standard self-measured blood pressure program|Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.
219618954|NCT05704166|DRUG|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
219618955|NCT06190808|DIAGNOSTIC_TEST|Dexcom G7 Continuous Glucose Monitor|Continuous glucose monitor
219618956|NCT05365451|DRUG|MetFORMIN Oral Solution|liquid
219618957|NCT05365451|DRUG|Cimetidine 400 MG|tablet
219618958|NCT05365451|DRUG|Furosemide Oral Liquid Product|oral solution
219618959|NCT05365451|DRUG|Probenecid 500 MG|tablet
219618960|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
219042791|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
219042792|NCT03750903|BEHAVIORAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
219042793|NCT03750903|BEHAVIORAL|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
219618961|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
219618962|NCT04985435|DRUG|Filgotinib|200 mg tablet once daily or 100 mg once daily
219618963|NCT04985435|DRUG|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
219618964|NCT04985435|BEHAVIORAL|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
219618965|NCT03933904|DRUG|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
219618966|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
219618967|NCT05125809|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
219618968|NCT05125809|OTHER|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
218922497|NCT03869047|DRUG|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
218922498|NCT00720915|OTHER|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
218922499|NCT00720915|OTHER|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
218922500|NCT03371069|OTHER|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
218922501|NCT02631408|DRUG|Vancomycin|Locally, intrawound applied vancomycin powder
219536494|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
219536495|NCT06665906|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy (PainTrainer)|Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
219536496|NCT06665906|BEHAVIORAL|Social Intervention|At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
219536497|NCT06995521|DRUG|Vorinostat|"For Matched sibling and matched unrelated donor transplant recipients: Vorinostat will be given orally at a dose of 60 milligrams per square meter two times a day (BID) (120 mg/m2/day) from day -10 to day 30 post-transplant. The maximum dose will be 100 mg BID.~Haploidentical donor transplant recipients:~Vorinostat will be given orally at a dose of 60 mg/m2 BID (120 mg/m2/day) from day +5 (at least 24 hours after completion of the day +4 cyclophosphamide) through day 30 post-transplant. The maximum dose will be 100 mg BID.~Dosing may be rounded by +/- 10%. Patients that are able to take capsules and whose calculated dose is ≥91 mg may take 100 mg capsules."
219536498|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via a PFS
219536499|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via an AI
219536500|NCT05082571|DRUG|vadadustat|Vadadustat tablet orally once a day for 52 weeks
219536501|NCT06994923|BEHAVIORAL|BWLI-College|Behavioral modifications are based on empirically-supported principles for weight loss. Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention. Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant.
219536502|NCT06994923|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
219536503|NCT04751487|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
219536504|NCT04751487|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
219204783|NCT06964984|OTHER|Music intervention|The patient will be asked to choose their favorite music. The playlist will include ten songs from each music group (pop, Turkish classical music, local folk songs and religious music), a total of 50 songs. The options will be shown to the patient via the phone (Apple/ MU783TU/A) and the music they want will be added to the playlist. The selected music will be listened to for 15 minutes before the surgery.
219536505|NCT06182072|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
219536506|NCT06182072|DRUG|Gemcitabine, nab paclitaxel|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
219618969|NCT05458440|OTHER|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
219618970|NCT05385549|DRUG|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
219204784|NCT06964984|OTHER|stres ball|Stress balls will be given to the patient in both palms, they will be asked to count from one to five and squeeze twice. The patient will be shown and made to use the stress balls for 15 minutes before the surgery. When the 15 minutes are up, the patient will be informed by the nurse and the patient will be asked to release the balls.
219536507|NCT06822790|DRUG|Plozasiran Injection|ARO-APOC3 injection
219204785|NCT06964984|OTHER|Virtual Reality Glasses|The patient will be shown a video of a nature walk by the nurse providing nursing care to the patient. The patients will be shown a video with virtual reality glasses for 15 minutes before the surgery.
219536508|NCT05813327|DRUG|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
219536509|NCT05813327|DRUG|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
219536510|NCT05813327|RADIATION|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
219536511|NCT05813327|DRUG|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
219536512|NCT06746753|DRUG|Angiotensin II|randomized to receive Angiotensin II continuous infusion for up to 48 hours
219536513|NCT06746753|DRUG|Norepinephrine|randomized to receive Norepinephrine continuous infusion for up to 48 hours
219536514|NCT06586905|DEVICE|Medical Device|Multiplo Complete Syphilis (TP/nTP) Antibody Test
219536515|NCT07000591|OTHER|Experimental Group|"Patients will receive a neck massage based on Watson's Human Caring Model in addition to standard medical care. The massage will be performed three times a week for eight weeks, totaling 24 sessions. Sessions will last 30 minutes and follow evidence-based nursing interventions. Care will be individualized and delivered in a calming environment.~Pre- and post-intervention assessments will include the Epilepsy Self-Efficacy Scale and the Epilepsy Symptom Management Scale for patients, and the Zarit Burden Interview for caregivers. Caregivers will also complete an introductory form. All data will be collected at baseline and after eight weeks. The massage's impact on both patient outcomes and caregiver burden will be evaluated."
219536516|NCT06854692|OTHER|Cervical retraction exercise|Participants will perform end-range cervical retraction and cervical retraction with extension, holding the end-range of motion for 3 seconds and performing 10 repetitions of each exercise.
219536517|NCT06864104|DRUG|Tonlamarsen|Tonlamarsen will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
219536518|NCT06864104|DRUG|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
219536519|NCT01594047|DRUG|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
219204786|NCT06966830|DRUG|Lacosamide (LCM)|Intravenous lacosamide is given for the treatment of seizure termination in patients with status epilepticus
219536520|NCT01594047|DRUG|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
219536521|NCT06671496|DRUG|Zasocitinib|Zasocitinib tablets.
219536522|NCT06671496|DRUG|Placebo|Zasocitinib matching placebo.
219536523|NCT07005934|DEVICE|Theragun Prime|Percussion massager
219536524|NCT07109414|DRUG|NP-G2-044|NP-G2-044 will be provided as a tablet via oral route of administration in the study.
219536525|NCT07109414|DRUG|PLD|PLD will be provided as an infusion via intravenous route of administration in the study.
219536526|NCT07127874|DRUG|PHN-012|PHN-012 is an ADC
219536527|NCT06617962|DIAGNOSTIC_TEST|CBA method of live cells and fixed cells|"1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples."
219536528|NCT06868212|DRUG|Remibrutinib|Film-coated tablet, oral administration, 25 mg b.i.d.
219204787|NCT06536049|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536529|NCT06868212|DRUG|Remibrutinib matching placebo|Film-coated tablet, oral administration, b.i.d.
219536530|NCT06868212|DRUG|Dupilumab|Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks
219536531|NCT06868212|DRUG|Placebo solution for injection|Solution for injection in pre-filled syringe every 2 weeks
219536532|NCT07133100|DEVICE|Upper limb rehabilitation wearable device|The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises. No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback.
219536533|NCT07129252|DRUG|CRN09682|Study drug CRN09682 intravenously
219536534|NCT06678841|DEVICE|Personalized cardiac pacing|Personalized cardiac pacing treatment based each patient's height and baseline LVEF.
219204788|NCT06536049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219204789|NCT06536049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219204790|NCT06536049|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
219204791|NCT06536049|BIOLOGICAL|Epcoritamab|Given SC
219204792|NCT06536049|DRUG|Ibrutinib|Given PO
219204793|NCT06536049|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219536535|NCT07010081|PROCEDURE|Surveys|Several questionnaires will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
219536536|NCT06865742|BEHAVIORAL|Music intervention|This is the first study to evaluate the effects of music therapy on fatigue, sleep quality and mental well-being of individuals receiving HD treatment.
219536537|NCT06871579|DIAGNOSTIC_TEST|EnteroTracker(R) EST|The device consists of a gelatin-coated capsule with a collection string wrapped inside.
219536538|NCT07010484|DIAGNOSTIC_TEST|PET/MRI|PET/MRI at baseline and week 8
219536539|NCT07010484|DIAGNOSTIC_TEST|PET/CT with 18-FDG|PET/CT in patients not receiving PET/MRI
219536540|NCT06399614|OTHER|Occupational Therapy-led Hand Therapy Service|Types of interventions provided by the therapist will include splinting, targeted exercises and activities, occupation-based intervention, edema management, scar management; desensitisation, functional tasks completion, and education. All interventions provided are within occupational therapists' scope of practice and are evidence based. Number of treatment sessions will be individualised to the patient and guided by stages of recovery.
219536541|NCT06399614|OTHER|Care as usual|Care as usual group: Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services\&#39; protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
219536542|NCT07011888|DEVICE|SaeboStim GO with Saebo Glove Rehabilitation Program|The intervention consists of a comprehensive rehabilitation program for a chronic stroke patient, utilizing the SaeboStim GO device combined with the Saebo Glove orthosis to facilitate and strengthen hand and upper limb motor function. The program also includes therapeutic ultrasound to support tissue healing, and vestibular rehabilitation therapy (VRT) to enhance motor learning and engagement. This combined approach aims to improve motor skills, balance, gait, daily living activities, and cognitive functions over a treatment period of six months.
219536543|NCT03396276|DRUG|Suboxone|8mg of buprenorphine/2mg of naloxone
218922502|NCT00803569|BIOLOGICAL|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
218922503|NCT00803569|BIOLOGICAL|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
218922504|NCT05856617|DRUG|Remimazolam besylate|Remimazolam besylate anesthesia induction
219204794|NCT05258357|DEVICE|Ultrasound-assisted bone marrow biopsy|"After the usual landmark technique is performed and the potential site has been marked, the ultrasound machine fine tunes the drill site location. The probe is placed over the marked site in the transverse orientation. In this view, the location where the sacrum articulates near the ilium is visualized. The physician then searches for the location of the PSIS at its most superficial location, then the PSIS is centered. The probe is then rocked back and forth to determine the optimal drill angle.The skin is marked at the probe indicators on both long sides. In the sagittal orientation the PSIS is visualized and centered. The skin is then marked at the probe indicators on both long sides. The marker is then used to connect the marks, creating an X that marks the desired skin entry point"
219204795|NCT05258357|PROCEDURE|Landmark palpation bone marrow biopsy|The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
219536544|NCT03396276|BEHAVIORAL|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
219536545|NCT03396276|BEHAVIORAL|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
219536546|NCT03396276|BEHAVIORAL|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
219536547|NCT06689956|OTHER|Non-Interventional Study|Non-Interventional Study
219536548|NCT05255601|DRUG|Relatlimab|Specified Dose on Specified Days
219536549|NCT05255601|DRUG|Nivolumab|Specified Dose on Specified Days
219536550|NCT07013149|OTHER|Switch from Ambrisentan to Bosentan|This intervention refers to a therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) in adult patients with pulmonary arterial hypertension (PAH), performed as part of routine clinical care. The switch was not assigned by the investigators but was made based on clinical indications prior to study enrollment. Patients are followed prospectively for up to 6 months to assess changes in risk stratification, functional status, laboratory parameters, and safety outcomes.
219536551|NCT04616287|OTHER|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
219536552|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.
219536553|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.
219536554|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.
219536555|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
219536556|NCT06691217|DRUG|CANAKINUMAB (ILARIS®)|Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
219536557|NCT06691217|DRUG|Saline (NaCl 0,9 %) (placebo)|Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
219536558|NCT01754597|OTHER|Dosage of B-type natriuretic peptide (NT-proBNP)|"NT-proBNP concentration assessed at the following time points :~* T0: before induction of general anesthesia, NT-proBNP measurement~* T1: 30 minutes after induction of general anesthesia~* T2: at the end of the procedure~* T3: in the postoperative period, 6 hours after the end of the procedure~* T4: in the postoperative period, 24 hours after the end of the procedure"
219536559|NCT07021430|DRUG|Dihydroartemisinin Piperaquine|A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.
219536560|NCT03564327|PROCEDURE|External electric cardioversion|Three attempts (200-250 joules)
219536561|NCT06066203|DRUG|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
219536562|NCT06671483|DRUG|Zasocitinib|Zasocitinib over-encapsulated tablets.
218922505|NCT03622489|DRUG|Acetaminophen|mentioned above
218922506|NCT03622489|DRUG|Ibuprofen 400 mg|mentioned above
218922507|NCT03622489|DRUG|Dipyrone|mentioned above
218922508|NCT03622489|DRUG|Tramadol|mentioned above
218922509|NCT03622489|DRUG|Morphine|mentioned above
218922510|NCT03622489|DRUG|Tramal|mentioned above
218922511|NCT05535725|DRUG|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
218922512|NCT03846336|OTHER|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
218922513|NCT03846336|OTHER|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
219536563|NCT06671483|DRUG|Active Comparator|Active comparator capsule.
219536564|NCT06671483|DRUG|Placebo|Zasocitinib or active comparator matching placebo.
219536565|NCT07029412|DRUG|MBX 1416 (INN imapextide)|A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.
219536566|NCT07029828|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
219536567|NCT07029828|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
219536568|NCT06395753|DRUG|Debio 4228|Administered as IM injection.
219536569|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
219536570|NCT01588236|DRUG|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
219536571|NCT01588236|DRUG|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
219536572|NCT01588236|DRUG|Placebo|3 capsules of placebo tid (morning, midday, and evening)
219536573|NCT06876532|OTHER|Additional blood tests (CRP and serum albumin) and data collection.|"These blood tests will be carried out on several occasions (before, during and after treatment with Lu-177 oxodotreotide). No additional blood sampling is required.~In addition, patient clinical data and imaging data (standard examinations: thoraco-abdomino-pelvic CT +/- MRI and Ga-68 DOTA PET-CT) will be specifically collected for study purposes.~For IUCT-O patients only: blood samples may be taken (at cycles 1 and 2, then 12 months after inclusion) for bio-banking purposes."
219536574|NCT06873945|DRUG|Ritlecitinib 100 mg|100 mg Capsule
219536575|NCT06873945|DRUG|Ritlecitinib 50 mg|50 mg Capsule
219536576|NCT06873945|DRUG|Placebo - 100 mg|Capsule (to match Ritlecitinib 100 mg)
219536577|NCT06873945|DRUG|Placebo - 50 mg|Capsule (to match Ritlecitinib 50 mg)
219536578|NCT06711887|DRUG|Ianalumab|Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
219536579|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
219536580|NCT02587624|PROCEDURE|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
219536581|NCT07135986|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection
219536582|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Suspension-Route of administration:IM injection
219536583|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Lyophilized powder-Route of administration:IM injection
219536584|NCT06711588|DEVICE|As-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).
219536585|NCT06711588|DEVICE|Two categories stiffer than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories stiffer than the as-prescribed stiffness.
219536586|NCT06711588|DEVICE|Two categories less stiff than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories less stiff than the as-prescribed stiffness.
219536587|NCT07120789|OTHER|Application of Patient Knowledge Questionnaire on Pulmonary Hypertension|Participants will complete one version of the DICTA questionnaire, developed to assess patient knowledge about pulmonary arterial hypertension. Depending on the study phase, participants will contribute to content validation (expert judges), semantic validation (patients), or psychometric validation (patients). In the final phase, additional data including risk stratification (COMPERA 2.0), hospitalizations, and quality of life scores (CAMPHOR, SF-36, MBG) will be collected for correlational analysis.
218922514|NCT06278714|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
219042794|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9=5-9) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9=5-9) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
219536588|NCT06876662|DRUG|Pirtobrutinib|Administered orally.
219536589|NCT06876064|BIOLOGICAL|Blood test|A total of 60 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.
219536590|NCT06876064|BIOLOGICAL|Urine test|Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.
219536591|NCT06876064|OTHER|stool collection|Stool samples will be collected either at the hospital or at home using a dedicated kit.
219536592|NCT06876064|OTHER|saliva collection|5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.
219536593|NCT06876064|OTHER|Induced expectoration|inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms
218922515|NCT06026917|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|D1\~D6, 40mg/ tablet, 1 tablet per time, once a day, D7\~D10, 80mg/ tablet, 1 tablet per time, once a day, D11\~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11\~D42, 80mg/ tablet, one tablet each time, once a day.
218922516|NCT03779295|DEVICE|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
218922517|NCT03779295|DRUG|Clindamycin|The entire face (both halves) will receive clindamycin.
218922518|NCT00495352|DRUG|Hihg-doseNRT, Low-dose NRT, bupropion|
218922519|NCT06041607|BEHAVIORAL|Shared meditation|"Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
219618971|NCT02224157|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
218922520|NCT06041607|BEHAVIORAL|Meditation with patients oly|"Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
218922521|NCT04946409|OTHER|no intervention|no intervention
218922522|NCT04402372|DEVICE|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
218922523|NCT03423784|DEVICE|HA BPX V3.3|medical device containing HA
218922524|NCT03423784|OTHER|Dentinox-Gel N|Anaesthetic gel
218922525|NCT04252144|PROCEDURE|Dietary assessment|Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
219618972|NCT02224157|DRUG|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
218922526|NCT01465555|BEHAVIORAL|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
218922527|NCT01075529|DRUG|fluoxetine|fluoxetine 20 mg/d
218922528|NCT03583892|DRUG|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
218922529|NCT03216772|DEVICE|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
218922530|NCT00694941|DRUG|ONO-2506PO|1200mg QD / 5 years
218922531|NCT01486719|PROCEDURE|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
218922532|NCT06266247|DIAGNOSTIC_TEST|Take blood samples|Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
218922533|NCT04316845|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
218922534|NCT00000393|DRUG|Peptide T|
218922535|NCT01471288|DRUG|Carum Cravi|40mg/kg of body weight
218922536|NCT01471288|DRUG|Placebo|Placebo
218922537|NCT00852449|OTHER|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
218922538|NCT00417417|DRUG|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
218922539|NCT00417417|DRUG|Placebo|Normal saline subcutaneously at each treatment visit.
218922540|NCT05106400|DRUG|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
219536594|NCT06876064|OTHER|Hair and nails sampling|Hair and nails samples will be collected.
219536595|NCT06876064|OTHER|Schirmer test|To assess of tear secretion
219536596|NCT06876064|RADIATION|Ultrasound of hands and feet|To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.
219618973|NCT01639157|DRUG|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
219536597|NCT06876064|RADIATION|MRI Contrast|MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.
219536598|NCT06876064|OTHER|Patient questions|Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.
219536599|NCT06876064|DIAGNOSTIC_TEST|Dental panoramic X-ray|Performed as part of routine care to assess dental health
219536600|NCT06876064|OTHER|Consultation with a psychologist in certain centers|The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.
219536601|NCT06876064|OTHER|Measurement of heart rate variability.|The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).
219536602|NCT06703593|DRUG|Alpha lipoic acid|ALA effectively inhibits nuclear factor-kappa B with subsequent decreasing proinflammatory cytokines production (TNF-α, IL-6) and increasing the release of anti- inflammatory cytokines such as interleukin-10 (Haghighatdoost and Hariri, 2019). Relying on the antioxidant and anti-inflammatory effect of Alpha lipoic acid confirmed by a variety of studies in vitro and in vivo, ALA is selected to be studied in Egyptian breast cancer patients who will be treated with doxorubicin including regimens.
219536603|NCT07038200|DRUG|AOC-1020|Placebo
219536604|NCT07038200|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
219536605|NCT06709339|DRUG|Faricimab Injection [Vabysmo]|The investigational medicinal product (IMP) for this study is faricimab (RO6867461), as per clinical practice. No control treatment will be used for this study
219536606|NCT06887088|DRUG|Encorafenib + Binimetinib|Induction treatment with oral encorafenib 450 mg once daily (QD) + binimetinib 45 mg twice daily (BID)(combination: EB) for approximately two months (i.e. 8 weeks)
219536607|NCT06887088|DRUG|cemiplimab+fianlimab|cemiplimab 350 mg + fianlimab 1600 mg combination every 3 weeks (Q3W)(Combination: CF) administered to patients intravenously (IV) for up to two years.
219536608|NCT04321954|DRUG|LENVATINIB|Orally
219536609|NCT07044648|PROCEDURE|Middle Meningeal Artery Embolization|Middle meningeal artery embolization using particles or coils
219618974|NCT01639157|DRUG|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
219618975|NCT06582472|PROCEDURE|Ophthalmological examination including imaging assessments|Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)
219618976|NCT06582472|PROCEDURE|confocal analysis of cornea|Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
218922541|NCT05106400|DRUG|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
218922542|NCT05106400|DRUG|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
218922543|NCT05106400|DRUG|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
218922544|NCT00684021|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
218922545|NCT00684021|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
218922546|NCT00004854|DRUG|Carvedilol|
218922547|NCT06151457|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219042795|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
219042796|NCT04633655|OTHER|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
219536610|NCT06889844|DIAGNOSTIC_TEST|blood sampling|Patients will donate a blood sample for molecular analysis of molecular biomarkers in plasma, which being the only procedure in the study.
219536611|NCT06730919|DIAGNOSTIC_TEST|Estimated Blood Loss after cesarean delivery within 24 h|The total estimated blood loss was calculated by equation: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2
219536612|NCT06722235|DRUG|Mezagitamab|Mezagitamab injection administered SC.
219536613|NCT06722235|DRUG|Placebo|Mezagitamab placebo-matching injection administered SC.
219536614|NCT04544410|DRUG|Tildacerfont/Placebo|Tablet, administered daily
219536615|NCT05142241|PROCEDURE|Biopsy Procedure|Undergo biopsy
219536616|NCT05142241|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536617|NCT05142241|PROCEDURE|Computed Tomography|Undergo CT
219536618|NCT05142241|DRUG|Talazoparib|Given PO
219536619|NCT05142241|DRUG|Temozolomide|Given PO
219536620|NCT06726265|BIOLOGICAL|eftilagimod alfa|30 mg of efti every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
219536621|NCT06726265|DRUG|carboplatin plus paclitaxel|For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2
219536622|NCT06726265|DRUG|cisplatin or carboplatin + pemetrexed|For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks
219042797|NCT05364008|DRUG|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
218922548|NCT06151457|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
218922549|NCT02808117|DIETARY_SUPPLEMENT|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
218922550|NCT00402948|DRUG|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
218922551|NCT00402948|DRUG|ASM8|inhalation 0.25mg daily for 14 days
218922552|NCT02631239|DRUG|Methotrexate|1g/m2/d IV \*1d
218922553|NCT02631239|DRUG|Etoposide|200mg/d PO \*3d
218922554|NCT02631239|DRUG|Dexamethasone|40mg/d PO \*3d
218922555|NCT02631239|DRUG|Pegaspargase|2500IU/m2/d IM \*1d
219536623|NCT06726265|BIOLOGICAL|Pembrolizumab (KEYTRUDA®)|200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months
219536624|NCT06726265|OTHER|Placebo|efti-matching placebo every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
219536625|NCT06732102|BEHAVIORAL|DECIDE|Decision-making Education for Choices In Diabetes Everyday (DECIDE) is a self-management program in which education and problem-solving training are utilized to promote behavior change for optimal clinical outcomes.
219536626|NCT06732102|BEHAVIORAL|Community Health Worker Support|CHWs are expected to actively equip individuals and communities by enhancing health knowledge and promoting self-sufficiency through various activities such as outreach, community education, informal counseling, social support, and advocacy. They act as a crucial link between communities and healthcare providers, helping residents navigate the healthcare system. By offering guidance and social assistance, they improve community members' ability to communicate effectively with healthcare professionals. They also deliver health education that is culturally and linguistically appropriate, advocate for the health of individuals and communities, coordinate care through referrals and follow-up services, and assist eligible individuals in enrolling in federal, state, local, or nonprofit health and human services programs.
219536627|NCT07049172|DRUG|Rituximab|"* Dosage: 375 mg/m²~* Route: Intravenous infusion~* Frequency: Once a week~* Duration: 12 consecutive weeks~* Details: Diluted in 5% glucose solution. Infusion started at 25 ml/h, increased by 25 ml/h every 30 minutes if no adverse reactions, up to 100-150 ml/h."
219536628|NCT07049172|BEHAVIORAL|Targeted Nursing Care|A structured, individualized nursing approach involving joint goal-setting. Included health education, psychological support, relaxation techniques, dietary care, lifestyle guidance, complication management, and medication guidance. Delivered throughout hospital stay and reinforced during monthly follow-ups.
219536629|NCT07049172|DRUG|Baseline Glucocorticoid Therapy|Patients already on maintenance glucocorticoids continued their regimen. For relapse at admission, IV methylprednisolone (2 mg/kg/day), then oral prednisone (2 mg/kg/day, max 60mg/day) tapered according to standard protocols.
219536630|NCT07049172|DRUG|Tacrolimus|"* Dosage: Initial dose 0.05-0.1 mg/kg/day, adjusted to maintain target trough levels of 5-10 ng/mL.~* Route: Oral~* Frequency: Divided into two doses (morning and evening)~* Duration: Throughout the 6-month study period."
219536631|NCT06734039|DEVICE|Programming of cochlear implant audio processor frequency settings|Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software
219536632|NCT07046936|DIAGNOSTIC_TEST|muscle sample|"For participants undergoing standard of care interval cytoreductive surgery via laparotomy, a skeletal muscle biopsy from the rectus abdominis muscle (1 cm x 1 cm x 1 cm, \~300 mg) will be collected.~For participants who undergo standard of care interval cytoreductive surgery with a laparoscopic approach, a skeletal muscle biopsy will be taken from either the rectus abdominis (1 cm x 1 cm x 1 cm, \~300 mg) or the psoas (1 cm x 0.5 cm x 0.5 cm, \~200 mg) muscle."
219536633|NCT07046936|OTHER|blood draw|A total of approximately 60mL or 4 tablespoons of blood will be collected throughout the study
219536634|NCT06745180|BEHAVIORAL|Short Message System (SMS)|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors.
219536635|NCT06745180|BEHAVIORAL|Peer Coach|The peer coach will deliver an intervention that will help participants maintain physical activity.
219536636|NCT06745180|BEHAVIORAL|Usual Care|Participants will be given written materials providing advice on maintaining their physical activity.
219536637|NCT06745180|BEHAVIORAL|Peer Coach and SMS|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors. The peer coach will deliver an intervention that will help participants maintain physical activity.
219536638|NCT02583672|DRUG|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
219536639|NCT06894771|BIOLOGICAL|MK-4700|Administered via subcutaneous (SC) injection
218922556|NCT02631239|RADIATION|Radiotherapy|50-56Gy
218922557|NCT05871216|DIAGNOSTIC_TEST|Clinical tests and balance evaluation using the Delos Proprioceptive System|Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
218922558|NCT04041414|OTHER|Proud & Empowered!|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
219536640|NCT06894771|BIOLOGICAL|Pembrolizumab|Administered via intravenous infusion
219618977|NCT06582472|PROCEDURE|Dynamic Vessel Analyzer (DVA)|Dynamic Vessel Analyzer (DVA), a device that measures the response of retinal arteries and veins to a standardized stimulus (flickering light) allowing direct quantification of the inflammatory status of the retinal vasculature
219042798|NCT05364008|OTHER|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
219042799|NCT06636084|PROCEDURE|Guided bone regeneration (GBR)|A composite graft composed of a 50:50 proportion of autogenous bone and a demineralized bone mineral will be positioned around the bony defect or placed in the membrane, depending on the group randomization. The selected membrane will then be secured with screws to ensure a complete and stable coverage of the grafted area.
218922559|NCT03483402|PROCEDURE|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
218922560|NCT01537705|DRUG|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
218922561|NCT06066320|BEHAVIORAL|MMST|Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones
218922562|NCT06066320|BEHAVIORAL|TSST|Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
218922563|NCT01694914|PROCEDURE|corneal graft|
218922564|NCT00930046|DEVICE|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
218922565|NCT00930046|DEVICE|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
218922566|NCT04004988|DRUG|Tirzepatide|Administered SC
218922567|NCT04004988|DEVICE|Prefilled syringe (PFS)|PFS used to administer tirzepatide
218922568|NCT04004988|DEVICE|Auto-injector (AI)|AI used to administer tirzepatide
218922569|NCT01598532|DEVICE|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
218922570|NCT04346381|DRUG|Camrelizumab|Intravenous (IV) camrelizumab on Day 1 of each cycle
219536641|NCT06893471|OTHER|GAS for SAM|"This study adapts Goal Attainment Scaling (GAS) for group-level goal setting within systematic work environment management. Developed collaboratively with organizational stakeholders, the method is:~Tailormade - Allows flexibility in defining and scaling goals. Co-created - Encourages ownership and employee involvement. Standardized - Uses a five-level scale (-2 to +2) for tracking progress and enabling comparisons.~Data-driven - Includes a Progress Graph for systematic follow-up and documentation of goals and initiatives.~Managers in the experiment group will receive training before implementation begins"
219618978|NCT06582472|PROCEDURE|tear sampling collection|Collect and analyze tear samples to identify biomarkers in tears and at the endothelium of the ocular surface through impression conjunctival cytology and the quantitative/qualitative analysis of pro-inflammatory cytokines
219618979|NCT06582472|PROCEDURE|blood sampling collection|collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
218922571|NCT04346381|DRUG|Famitinib|famitinib po qd
218922572|NCT03144154|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
218922573|NCT02982746|OTHER|gPCC (Gothenburg Person Centred Care)|
218922574|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
218922575|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
218922576|NCT03873116|DRUG|Placebo oral capsule|Matching placebo capsules administered orally once daily
218922577|NCT00912808|DRUG|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
218922578|NCT00912808|DRUG|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
218922579|NCT04682366|DRUG|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
219536642|NCT06702696|DIETARY_SUPPLEMENT|Black chokeberry (Aronia melanocarpa)|The aronia group, who will consume 30 g of freeze-dried aronia powder (n=25)
219536643|NCT06702696|OTHER|Placebo powder|The placebo group, who will consume placebo powder (n=25).
219536644|NCT06805539|OTHER|No treatment given|No treatment given
218922580|NCT04682366|DRUG|Placebo|Oral drug: 10 days of identical-appearing placebo
218922581|NCT04600596|BEHAVIORAL|Recording of food intake.|The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
218922582|NCT02130843|DEVICE|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
218922583|NCT00813202|DRUG|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
218922584|NCT04051424|DEVICE|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
218922585|NCT04051424|DEVICE|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
219618980|NCT00002346|DRUG|Adefovir dipivoxil|
219618981|NCT05867615|DRUG|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
219618982|NCT05906628|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219618983|NCT05906628|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219618984|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
219618985|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
219618986|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
219618987|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
219618988|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
219618989|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
219618990|NCT01191034|DRUG|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
219618991|NCT05901974|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);
219618992|NCT05901974|DRUG|azactidine|azacitidine 75 mg/m2 subcutaneously once daily on days 1-7
219618993|NCT00461942|DRUG|Green Tea Polyphenols (EGCG/ECG)|
219618994|NCT02926066|DRUG|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
219618995|NCT03487471|DIAGNOSTIC_TEST|Real-time elastography|Breast ultrasound with real-time elastography
219618996|NCT03487471|DIAGNOSTIC_TEST|Shear wave elastography|Breast ultrasound with shear wave elastography
219618997|NCT00416611|BEHAVIORAL|Implementation of guidelines|
219618998|NCT00399061|DRUG|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
219618999|NCT01060072|DRUG|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
219619000|NCT01060072|DRUG|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
219619001|NCT00837148|DRUG|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
219619002|NCT01291355|OTHER|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
219619003|NCT01509339|DRUG|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
219619004|NCT05374655|OTHER|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c\<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
219619005|NCT03526068|DEVICE|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
218922586|NCT04051424|DEVICE|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
218922587|NCT00702221|BIOLOGICAL|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
218922588|NCT00702221|BIOLOGICAL|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
218922589|NCT03891108|DRUG|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
218922590|NCT03891108|DRUG|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
219619006|NCT00818077|OTHER|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
219619007|NCT03126773|DRUG|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
219619008|NCT03453775|DEVICE|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
219619009|NCT03453775|DEVICE|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
219619010|NCT00380874|DRUG|Pregabalin|150- 600 mg/day (double blind in divided doses)
219619011|NCT00380874|DRUG|Placebo|Placebo
219619012|NCT04159389|OTHER|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
219536645|NCT06894511|DRUG|AAA617|"Dose formulation: open-label vial~Dose level: 7.4 GBq (200 mCi) ± 10% Once, every 6 weeks for 6 cycles, intravenous administration"
219536646|NCT06894511|DRUG|ARPI: Abiraterone|"Dose formulation: tablet/capsule~Dose level: 160 mg (four 40 mg or two 80 mg soft capsules) as a single daily dose, oral administration"
219536647|NCT06894511|DRUG|ARPI: Enzalutamide|"Dose formulation: tablet~Dose level: 1000 mg daily (two 500 mg tablets or four 250 mg tablets as a single daily dose together with 5 mg oral prednisone 2 times a day, oral administration"
219536648|NCT04887935|DRUG|Dapagliflozin|-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
219536649|NCT06739811|DEVICE|Implantable Insulin Pump System|Medtronic Implantable Insulin Pump System (MIIPS 2020)
219536650|NCT06759376|OTHER|Vibration massage|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Performing vibration massage with a vibration massage device for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
219536651|NCT06759376|OTHER|Static stretching exercise|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Perform static stretching exercise for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
219536652|NCT06759376|OTHER|Usual Care|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Usual care,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
219536653|NCT07061678|DRUG|perineural dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg perineural dexamethasone
219536654|NCT07061678|DRUG|intravenous dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg intravenous dexamethasone
219536655|NCT07061678|DRUG|control|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine
219536656|NCT07053111|BEHAVIORAL|Wellness Intervention|Licensed counselors will provide evidence based curricula on the following: work/life balance, resilience building, stress management, self- care practices, imposter syndrome, psychological effects, compassion fatigue, peer support, and mindfulness practices.
219536657|NCT07054242|DRUG|Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab|SKB264 will be administered intravenously (IV) at a dose of 4 mg/kg every two weeks (Q2W); Pembrolizumab will be administered intravenously at a dose of 200mg every three weeks (Q3W)
219619013|NCT03839628|OTHER|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
219619014|NCT04959721|COMBINATION_PRODUCT|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
219619015|NCT02912702|DRUG|Pegaspargase|2000U/m2 day5
218922591|NCT03891108|DRUG|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
218922592|NCT03891108|DRUG|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
218922593|NCT05338619|DRUG|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218922594|NCT02986360|BEHAVIORAL|Vidscrip educational video|Vidscrip educational video provide to women
219536658|NCT06750666|DIAGNOSTIC_TEST|De-implementation of Urinary Dipsticks|In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
219619016|NCT02912702|DRUG|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
219536659|NCT06750666|OTHER|Usual practice with no intervention|In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
219536660|NCT05727020|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
219536661|NCT05727020|DIAGNOSTIC_TEST|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
219536662|NCT06784726|BIOLOGICAL|Odronextamab|Given IV
219536663|NCT06784726|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral or rectal swab samples
219619017|NCT02912702|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
219619018|NCT02912702|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
219619019|NCT02912702|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
219536664|NCT06784726|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219536665|NCT06784726|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219619020|NCT02912702|DRUG|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
219619021|NCT03699332|DRUG|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
218922595|NCT03497624|OTHER|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
218922596|NCT02989597|DRUG|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
218922597|NCT02989597|OTHER|Standard pain regimen|Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
218922598|NCT02989597|PROCEDURE|Spinal Fusion Surgery|Clinically-indicated spinal fusion surgery
218922599|NCT02989597|DRUG|Dexamethasone|Post operative swelling and pain control
218922600|NCT02989597|DRUG|Ketamine|Perioperative anesthesia medication
218922601|NCT02989597|DRUG|Remifentanil|Perioperative pain medication
219204796|NCT05259306|DEVICE|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
219204797|NCT05151731|DRUG|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
219536666|NCT06784726|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo CAR-T cell therapy
219536667|NCT06784726|PROCEDURE|Computed Tomography|Undergo PET/CT
219536668|NCT06784726|PROCEDURE|Leukapheresis|Undergo leukapheresis
219536669|NCT06784726|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219536670|NCT06784726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219536671|NCT06784726|OTHER|Questionnaire Administration|Ancillary studies
219536672|NCT06784726|PROCEDURE|Biopsy|Undergo tissue biopsy
219536673|NCT06897267|BEHAVIORAL|The Grow to Recovery program-Short Version|"The program is based on Pathways to Recovery:A Strengths Recovery Self-help Workbook. After completing the leader training program, one peer and one professional will conduct a 10-week Grow to Recovery program-Short Version for people with mental illness. This program covers recovery concepts, strengths, and goal setting, which will be helpful for people in recovery."
219536674|NCT06762795|GENETIC|Genome sequencing|Neonates enrolled in this study will undergo genome sequencing with parental controls as applicable.
219536675|NCT07063654|BEHAVIORAL|Heart2Heart|Heart2Heart is a mobile health program for teens with congenital heart disease. It includes information and interactive features to help teens learn about staying healthy with congenital heart disease.
219536676|NCT07065409|BIOLOGICAL|iPSC-EVs|iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.
219536677|NCT07062406|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|8 weekly sessions delivered by federally qualified health center behavioral health provider focusing on stimulus control, sleep restriction, and cognitive therapy
219536678|NCT07062406|OTHER|Usual care for diabetes management|Usual clinical care for management of diabetes (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
219536679|NCT07062406|OTHER|Usual care for treatment of insomnia|Usual clinical care for treatment of insomnia (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
218922602|NCT02989597|DRUG|Sufentanil|Perioperative pain medication
218922603|NCT01230983|DRUG|asparaginase|Given IV
218922604|NCT01230983|DRUG|cytarabine|Given IV
219536680|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).
219536681|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.
219619022|NCT03699332|RADIATION|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
219619023|NCT03699332|PROCEDURE|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
219619024|NCT03816423|OTHER|video|Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
219619025|NCT00474084|DEVICE|Intravascular Coronary Stent|
219619026|NCT01707290|DRUG|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
218922605|NCT01230983|DRUG|dexrazoxane hydrochloride|Given IV
218922606|NCT01230983|DRUG|doxorubicin hydrochloride|Given IV
218922607|NCT01230983|DRUG|leucovorin calcium|Given IV
218922608|NCT01230983|DRUG|mercaptopurine|Given orally
218922609|NCT01230983|DRUG|methotrexate|Given IV
218922610|NCT01230983|DRUG|prednisone|Given orally
218922611|NCT01230983|DRUG|therapeutic hydrocortisone|Given IT
219536682|NCT06769165|OTHER|EMDR therapy|In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.
218922612|NCT01230983|DRUG|vincristine sulfate|Given IV
219536683|NCT07068776|DEVICE|Shockwave treatment|The shockwave device will be set to an energy flux density of 0.1 mJ/mm² at 5 Hz, with approximately 25 impulses per centimeter of wound length. This means that one centimeter of the wound will be treated for 5 seconds. The shockwave treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
219536684|NCT07068776|DEVICE|Sham treatment|The applicator will not be connected to the shockwave device. The applicator treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
219536685|NCT05302908|BEHAVIORAL|NuestraSaludSegura|It blends peer navigation and mHealth
219536686|NCT04622150|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
219536687|NCT04622150|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
219536688|NCT05995353|DRUG|Risankizumab|Intravenous (IV) Infusion
219536689|NCT05995353|DRUG|Risankizumab|Subcutaneous (SC) Injection
219536690|NCT05644951|DEVICE|Hot AXIOS system used for EPASS|EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
219536691|NCT07188623|BEHAVIORAL|VR-Enhanced BA|"Participants will choose at least one activity per day to complete in the loaned HTC VIVE Flow Immersive Glasses extended reality over the course of the week. These activities are chosen from the headset and include video 360."
219619027|NCT05286736|DIAGNOSTIC_TEST|Neuroimaging|This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
219619028|NCT05286736|DIAGNOSTIC_TEST|Quantitative assessments|Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
218922613|NCT01230983|RADIATION|radiation therapy|Radiation to cranium
218922614|NCT00025181|BIOLOGICAL|MART-1 antigen|
218922615|NCT00025181|BIOLOGICAL|gp100 antigen|
218922616|NCT00025181|BIOLOGICAL|incomplete Freund's adjuvant|
218922617|NCT00025181|BIOLOGICAL|ipilimumab|
218922618|NCT00025181|BIOLOGICAL|tyrosinase peptide|
218922619|NCT00025181|PROCEDURE|adjuvant therapy|
218922620|NCT02406508|DEVICE|Melphalan/HDS|
218922621|NCT02406508|DRUG|Sorafenib|
218922622|NCT02531802|BIOLOGICAL|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~* Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~* E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~* E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~* E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~* E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
218922623|NCT02531802|BIOLOGICAL|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
218922624|NCT02531802|OTHER|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
218922625|NCT00419406|PROCEDURE|UVA1 phototherapy|
218922626|NCT00419406|PROCEDURE|NB-UVB phototherapy|
218922627|NCT01745939|OTHER|Lumbar Manipulation|Manual therapy intervention
218922628|NCT01745939|OTHER|Sham manipulation|Manual therapy intervention
218922629|NCT04029285|OTHER|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
219536692|NCT07191821|DRUG|XBD173|Small molecule experimental medication binding to mitochondrial protein TSPO
219536693|NCT07194954|DIETARY_SUPPLEMENT|Combined Dietary Fiber and Probiotics.|The intervention consisted of a daily oral administration of 20g of a mixed dietary fiber powder (FibroBalance®, containing inulin, pectin, and β-glucan) and one multi-strain probiotic capsule (ProbioCare Forte®, delivering 10\^9 CFU of Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bi-07, and Streptococcus thermophilus St-21).
219619029|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
219619030|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
219619031|NCT03447639|DRUG|Povidone-iodine irrigation|Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
219619032|NCT00931086|DRUG|belimumab|IV 10mg/kg q28days
219619033|NCT04251247|DIAGNOSTIC_TEST|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
219619034|NCT06858761|PROCEDURE|Robot-assisted surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a robotic approach. The robot used will be the Da Vinci X or Xi model (depending on the center) from the company Intuitive Surgical.
219619035|NCT06858761|PROCEDURE|Conventional laparoscopic surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a conventional laparoscopic approach
219619036|NCT06858761|OTHER|Visual analog scale|All patients will have pain evaluation with visual analog scale
219619037|NCT06858761|OTHER|EQ-5D-5L questionnaire|All patients will have quality of life assessment with EQ-5D-5L questionnaire
219619038|NCT06858761|OTHER|Impact of Weight on Quality of Life (IWQOL) questionnaire|All patients will have Quality of life assessment with IWQOL questionnaire
219619039|NCT01147068|BIOLOGICAL|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
219536694|NCT07194954|OTHER|Standard Nutritional Support|This included dietary counseling from a registered dietitian and, if necessary, a standard oral nutritional supplement (Ensure®) to meet estimated energy and protein requirements.
219536695|NCT07193030|BEHAVIORAL|Peer-led Alcohol Brief Intervention (identification + advice)|"The intervention consists of a peer-led ABI for university students. This intervention aligns with the ABI approach recommended by the WHO as a cost-effective strategy to reduce harmful alcohol use, particularly in primary care and community settings. The brief advice component of the intervention will incorporate Motivational Interviewing (MI) techniques, a client-centred, evidence-based counselling style intervention effective for reducing risky drinking behaviours. The brief advice will be tailored based on behavioural insights identified through formative research, such as individual perceived facilitators and barriers.~The Alcohol Use Disorders Identification Test- Consumption (AUDIT-C) will be used as the screening tool for identification.~A one-on-one Brief Advice sessions of 15-20 minutes will be delivered by trained peer educators, i.e., university students who are not healthcare professionals but have been specifically trained in delivering brief advice."
219619040|NCT03746132|DEVICE|EPIFLO|EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
219619041|NCT07112495|OTHER|pregnant women with|pregnant women with
219619042|NCT07111377|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Participants received an 8-session culturally adapted Brief Cognitive Behavioral Therapy intervention targeting suicidal ideation, psychological distress, and financial stress. Therapy included crisis stabilization, cognitive restructuring of maladaptive thoughts related to economic hardship, behavioral activation, problem-solving skills for financial and psychosocial stressors, and emotion-regulation training. It concluded with relapse prevention planning and connection to supportive community resources. Sessions were delivered weekly, either individually (60 minutes) or in groups (90 minutes), based on participant preference.
219204798|NCT05151731|DRUG|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
219619043|NCT02988960|DRUG|ABBV-927|Intravenous
219619044|NCT02988960|DRUG|ABBV-927|Intratumoral
219619045|NCT02988960|DRUG|ABBV-181|Intravenous
219619046|NCT02843984|DRUG|Lactoferrin|
219619047|NCT01522456|DRUG|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
219619048|NCT01522456|DRUG|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
218922630|NCT04111991|BEHAVIORAL|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
219536696|NCT07194720|DIETARY_SUPPLEMENT|Cornus mas lyophilisate|Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.
219619049|NCT04455165|PROCEDURE|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
219619050|NCT03856801|OTHER|Exercise|Whole-body vibration training in hypoxia and normoxia condition
219619051|NCT00298727|BEHAVIORAL|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
219619052|NCT00298727|BEHAVIORAL|ePBL|Online Problem-Based Course
219619053|NCT03859544|OTHER|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
219536697|NCT07194720|DIETARY_SUPPLEMENT|Placebo|Participants receiving a starch- and sugar-based placebo for 4 weeks.
219619054|NCT06353347|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
219619055|NCT06353347|DRUG|Placebo|Matching placebo administered orally BID as four capsules
219619056|NCT04306211|DEVICE|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
219619057|NCT03048227|DEVICE|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
219619058|NCT03681249|DRUG|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
219619059|NCT03681249|DRUG|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
219619060|NCT05593809|RADIATION|SPECT with pentavalent 99mTc DMSA|"A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV.~SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland)."
219619061|NCT05655130|DRUG|Dexamethasone|Intraoperative 10 mg IV Dose
219619062|NCT05655130|DRUG|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
219619063|NCT05655130|OTHER|Standard of Care|standard of care surgery
219619064|NCT03971786|BEHAVIORAL|Quality of life|Assessment of quality of life through measuring scales
219619065|NCT01597310|DRUG|Warfarin|single doses at specified time periods
218922631|NCT04111991|BEHAVIORAL|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
218922632|NCT04686669|DRUG|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
218922633|NCT04686669|DRUG|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
218922634|NCT00257985|DRUG|GTN|
218922635|NCT03345784|DRUG|Adavosertib|Given PO
219536698|NCT07194733|OTHER|VET FAM Product Box and Nutrition Education|Food boxes and nutrition education
219536699|NCT07192432|GENETIC|Dose Level 1, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
219536700|NCT07192432|GENETIC|Dose Level 2, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
219536701|NCT07192432|GENETIC|Dose Level 3, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
219536702|NCT07192432|GENETIC|Dose Level 4, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
219619066|NCT01597310|DRUG|Dexpramipexole|multiple doses
219619067|NCT00981487|DRUG|Ondansetron|24 mg one time
219619068|NCT00981487|DRUG|Ondansetron|24 mg, on time in the am
219619069|NCT01889147|BIOLOGICAL|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
219619070|NCT01889147|BIOLOGICAL|Placebo|
219536703|NCT07192419|BEHAVIORAL|Promoting Aging and Thriving with HIV (PATH)-Implementation of a Tailored Geriatric Assessment and Management Strategy for HIV Care Settings|"For the intervention arm, participants will be sent geriatric assessment questions through the patient portal in advance of a routine HIV appointment. If the participant is unable to complete the questions in advance, they will be done with the help of a research coordinator to go through on the day of appointment. Every attempt will be made to ensure the assessment can be done in advance of the appointment, however the study team will allow for visits after the regular appointment as in which case the provider will receive results after the patient has left clinic.~The provider will receive the PATH assessment responses and a discussion guide with suggested initial management steps. The provider ultimately determines with the participant when and if they will address concerns identified (that visit or future visit) based on participant priorities. The patient participant will also receive a copy of their screening results."
219536704|NCT07194642|OTHER|Dexcom G7 CGM|The Dexcom G7 is a continuous glucose monitor, FDA 510K cleared (K213919) for people with diabetes. Worn for 10 days at a time, the device monitors the glucose levels of interstitial fluid and, via bluetooth, transmits data every 5 minutes to a receiver.
219536705|NCT07193472|PROCEDURE|serratus intercostal plane block as analgesic technique|the SIPB will be applied after starting surgery and before general anaesthesia
219536706|NCT07193719|PROCEDURE|End-expiratory lung volume optimization maneuver with PEEP titration|PEEP titration (incremental/decremental) will be performed to optimize lung volume after surgery and find levels of PEEP corresponding to the best lung compliance. Typically PEEP levels between 10-20cmH2O will be applied based on individual response of patients' lung mechanics. Tidal volume will be kept constant at 6ml/kg in both arms. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate.
219536707|NCT07193719|PROCEDURE|Standard Care (in control arm)|Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O.
219619071|NCT05756582|DIAGNOSTIC_TEST|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
219536708|NCT07193771|OTHER|Geographic Altitude|Participants are grouped according to the altitude of the pediatric intensive care unit (PICU) where they are admitted: low altitude (0-1500 m), intermediate altitude (1501-2500 m), high altitude (2501-3500 m), and very high altitude (\>3500 m). Altitude is treated as the primary exposure variable. No therapeutic intervention is administered as part of this study.
219536709|NCT07202351|OTHER|Screening and management of sleep disorders|Patients in the intervention group will undergo a systematic and standardised screening of sleep disorders. If any trouble is identified, a specific treatment plan is offered at the Chronos centre, including for instance, cognitive behavioural therapy for insomnia, or nightmares will be treated with Image Rehearsal Therapy (IRT).
219536710|NCT07201844|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
219536711|NCT07201844|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
219619072|NCT04395482|OTHER|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
219619073|NCT01364376|DRUG|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
219619074|NCT04800640|OTHER|Experimental: Electroanalgesia|The sample will consist of 66 individuals, of both men and women, where they will be randomly included in two groups: Intervention group composed of 33 patients who will effectively receive the treatment through electroanalgesia via TENS;
219619075|NCT01565889|DRUG|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
219619076|NCT01565889|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
219619077|NCT01565889|DRUG|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
219619078|NCT01565889|DRUG|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
219619079|NCT01565889|DRUG|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
219619080|NCT01565889|DRUG|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
219619081|NCT01565889|DRUG|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
219619082|NCT01565889|DRUG|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
219619083|NCT01565889|DRUG|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
219619084|NCT01565889|DRUG|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
219619085|NCT01565889|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219619086|NCT05123430|PROCEDURE|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
218922636|NCT03345784|DRUG|Cisplatin|Given IV
218922637|NCT03345784|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219536712|NCT07201090|BEHAVIORAL|Brief Parent-Child Interaction Therapy with videos and virtual reality (360-degree VR)-films|"10 sessions of PCIT delivered by trained psychologists, supplemented with videos and 360-degree VR-films~Sessions follow the standard PCIT structure, with an initial phase focused on child-directed interaction, followed by a second, modified phase, focused on parent-directed interaction.~To support skill learning, families are provided with digital materials including conventional video modules at home and 360-degree virtual reality (VR) films. The VR films are shown during two sessions at the clinic. Additional videos are available online through a platform for parents to view and practice between sessions. These tools allow parents to rehearse skills flexibly in their home environment and reinforce the in-session training."
219536713|NCT07201415|PROCEDURE|minimally invasive suprachoroidal drainage|minimally invasive suprachoroidal drainage
219536714|NCT07201662|OTHER|Condensed and Revised Multifaceted Empathy Test|Experimental emotional decoding task that measures the cognitive and affective dimensions of empathy based on performance (Edele et al., 2013; Grynberg et al., 2017).Participants view 40 photos of faces expressing either a positive or negative emotion and must identify the emotion (decoding) and then rate on a 1-9 scale the extent to which they share it (emotional sharing). The task lasts approximately 10 minutes on average.
219536715|NCT07201662|OTHER|Hospital Anxiety and Depression Scale|"A self-administered scale with 14 items, divided into two subscales of seven items, used to detect the presence of depression and anxiety. Non-cases or asymptomatic individuals (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11).~The administration time is approximately 5 minutes."
219536716|NCT07201662|OTHER|Interpersonal Reactivity Index|The Interpersonal Reactivity Index (Davis, 1980; Guttman \& Laporte, 2002) is a 28-item self-report questionnaire measuring four dimensions of empathy: fantasy, perspective taking, empathic concern, and personal distress. Each item is rated on a 1-to-5 scale and provides a subscore for each dimension, with no overall total score. Administration takes approximately 5 minutes.
219536717|NCT07201662|OTHER|Vicarious Distress Questionnaire|The Vicarious Distress Questionnaire (Grynberg et al., 2012) is an 18-item self-report scale assessing distress experienced in response to others' suffering and its impact on prosocial behaviors. It includes three dimensions-distress, support, and avoidance-each yielding a specific subscore. Administration takes approximately 5 minutes.
219536718|NCT07201662|OTHER|Binge Eating Scale|The Binge Eating Scale (Gormally et al., 1982; Brunault et al., 2016) is a 16-item self-report questionnaire assessing the behavioral, emotional, and cognitive manifestations of binge eating disorder (BED) according to DSM-V criteria. The total score (0-46) reflects symptom severity and can be interpreted dimensionally or categorically (≥ 18 indicating significant symptomatology). Administration takes approximately 5 minutes.
219204799|NCT05151731|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
218922638|NCT01655732|PROCEDURE|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
218922639|NCT00823017|OTHER|Patient-preferred music|Music of patients' preference
218922640|NCT00823017|OTHER|Relaxation Music|Relaxation music compiled from results of first three stages of study
218922641|NCT00823017|OTHER|Standard Care Environment|Control, no interventions
218922642|NCT04318353|OTHER|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
218922643|NCT03160443|BEHAVIORAL|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
218922644|NCT05827172|PROCEDURE|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
218922645|NCT05827172|OTHER|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
219536719|NCT07200713|OTHER|Treatment as usual (TAU)|Best practice ordinary psychological treatment
219536720|NCT07200713|OTHER|Sensory motor arousal regulation treatment (SMART)|Psychological treatment using SMART room and associated techniques
219536721|NCT07200518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Hetox multistrain probiotic|OMNi-BiOTiC® Hetox multistrain probiotic
218922646|NCT04560699|OTHER|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
218922647|NCT04560699|OTHER|medical care|medical care three times during the study period; baseline, week 13 and week 26
218922648|NCT06515600|DEVICE|Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.|"All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min."
218922649|NCT03013270|OTHER|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
219536722|NCT07200518|DIETARY_SUPPLEMENT|Placebo|Placebo
219536723|NCT07200648|OTHER|Unconditional cash transfer|$1,000 unconditional cash transfer per month for 12 months
219536724|NCT07201129|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
219536725|NCT07201129|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
219536726|NCT07201545|DRUG|Bempedoic acid|"180 mg film coated tablet administered as FDC or co-administered with ezetimibe~Component of FDC"
219536727|NCT07201545|DRUG|Ezetimibe|"10 mg tablet administered as FDC or co-administered with bempedoic acid~Component of FDC"
219536728|NCT07201545|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
219536729|NCT07200934|DEVICE|Transcutaneous electrical stimulation (TENS)|"The negative/active pad surface electrode will be applied at the T6 dermatome on the abdomen (is located at the left upper quadrant of the abdomen, 2 cm below the ribcage at the left midclavicular line) for stimulation and the passive/positive electrode will be applied on the left T6 costovertebral junction to complete the circuit.~* The specific parameters of TENS will be burst mode, 2.0 Hz frequency, and 300 micro-seconds width~* The patients will receive 3 times 30 min session each week for a period of consecutive 12 weeks.~* The intensity of TENS will be gradually increased from 0 mA till the subject felt a comfortable tingling sensation beneath the electrode without any muscle contraction and pain."
219536730|NCT07200934|OTHER|Mediterranean Diet|The recommended composition of Mediterranean diet regimen: is characterized by a high intake of plant foods, fruits, vegetables, breads and other cereals (traditionally minimally refined), potatoes, beans, nuts and seeds; minimally processed, fresh fruits as a typical dessert, with sweets containing sugars or honey a few times per week; .a high intake of olive oil (especially virgin and extra-virgin olive oil) as the main source of fat; a moderate intake of dairy products (mostly as cheese and yoghurt); zero to four eggs per week; low to moderate amounts of fish and poultry; low amounts of red meat. The diet plan included generally 50% carbohydrates (from vegetables, fruits, legumes, and whole grains), 35% fats (from healthy oils, nuts, seeds, and fish), and 15% protein (from legumes, fish, nuts, dairy, poultry, and eggs).
219619087|NCT04967573|DRUG|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
218922650|NCT03013270|OTHER|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
219619088|NCT00524940|BIOLOGICAL|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
219619089|NCT01326845|DRUG|Deferasirox|
219536731|NCT07202208|PROCEDURE|"Delirium Zero protocol"|The protocol consists of: i) a patient orientation poster placed in the room in a visible location for the patient, with information updated daily by the family member/caregiver; ii) a clock hung on the wall next to the orientation poster; and iii) a verification sheet of the preventive measures taken by the caregiver/family member, where the caregiver/family member must indicate daily the frequency with which preventive activities have been performed. The caregiver/family member will have this document in the patient's room all day and will need to complete it at the end of the day, when the nurse will collect it for safekeeping. From that day until the patient is discharged, the nurse responsible for the patient's care will be responsible for providing a new verification sheet of the preventive measures taken by the family member/caregiver and collecting it at the end of the day once it has been completed by the family member/caregiver.
219536732|NCT07202208|PROCEDURE|Standard of Care to prevent Delirium.|All participants in the study, regardless of the assigned group, receive information on strategies to prevent delirium, which is provided in the participant information sheet and includes an infographic and a guide for patients and their families. Participants are advised to keep this document accessible throughout their stay for reference.
219619090|NCT02060305|DRUG|Bevacizumab intra-articular injection|Bevacizumab, 20\~40mg, intra-articular injection every 28 days for 4 times
219619091|NCT05667376|OTHER|Local drug delivery|Local application of curcumin gel into the periodontal pocket
218922651|NCT03013270|OTHER|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
219619092|NCT05667376|DRUG|curcumin gel|curcumin gel
219619093|NCT03564392|BEHAVIORAL|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
219619094|NCT06239727|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
219619095|NCT06239727|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
218922652|NCT03013270|OTHER|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
218922653|NCT04109261|DRUG|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
218922654|NCT02399176|BEHAVIORAL|Yoga|Subjects assume 10 physical postures for 30 seconds each
218922655|NCT04798196|BEHAVIORAL|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
219204800|NCT03492762|DRUG|Cu-DOTA-ECL1i|Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
219204801|NCT05770908|OTHER|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching."
219619096|NCT06239727|DRUG|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
219619097|NCT06239727|RADIATION|Reduced-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
218922656|NCT04798196|BEHAVIORAL|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
218922657|NCT04798196|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual (TAU)
219536733|NCT07200414|BEHAVIORAL|Integrated Adolescent Health Package|Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
218922658|NCT00911456|PROCEDURE|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
218922659|NCT00911456|PROCEDURE|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
219619098|NCT06239727|RADIATION|Conventional-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
219619099|NCT06239727|DRUG|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
218922660|NCT00911456|PROCEDURE|3 DUS|3 DUS
218922661|NCT01743222|GENETIC|eASC|"* First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
218922662|NCT01743222|DRUG|Placebo|"* First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
218922663|NCT03836313|DEVICE|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
218922664|NCT04252534|COMBINATION_PRODUCT|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
218922665|NCT04252534|BIOLOGICAL|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
219204802|NCT05770908|OTHER|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
219204803|NCT05770908|OTHER|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
219204804|NCT04965454|COMBINATION_PRODUCT|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
219536734|NCT07200414|OTHER|Routine Government Health Services|Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
219536735|NCT07201883|DRUG|Ondansetron (Zofran)|4 mg IV push
219536736|NCT07201883|OTHER|chewing gum|Peppermint sugar free chewing gum
219619100|NCT06239727|DRUG|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
219619101|NCT01057680|DIETARY_SUPPLEMENT|creatine monohydrate|Powder, 0.1 g per day, 12 months
219619102|NCT01057680|DIETARY_SUPPLEMENT|sugar placebo|powder, 0.1 g/day, 12 months
219619103|NCT00748592|DRUG|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
219536737|NCT07201883|COMBINATION_PRODUCT|Ondansetron + Chewing gum|Ondansetron 4 mg IV push Peppermint sugar free chewing gum
219536738|NCT07202195|DEVICE|electro-stimulation suit|"In EXOPULSE Mollii Suit is a multi-channel full-body suit with a low energy electrical stimulation - 20 Volt and 20 Hz. It generates 2 milliamp pulses (into 0-10,000 Ohms) with the following parameters:~* Pulse width: variable between 25 and 170 μs.~* Length of period: 50 ms.~* Maximum amplitude: 20 V. It is composed of a control unit, a jacket and pants, with 58 embed-ded electrodes, in direct contact with the skin, and pre-positioned to stimulate 40 key muscle groups.~The suit comes in different sizes. A trained medical staff pre-programs which nerves/muscles to be stimulated based on a clinical assessment of the user and the outcome is evaluated through standardized methods. The stimulation program is thus specific to each user."
219536739|NCT07202195|OTHER|Usual Care|The rehabilitation therapy that is being offered at the National MS Center Melsbroek, but somewhat reduced/adjusted to make time for initiation and follow-up of using the neuromodulation suit and potentially also during the weeks at home (i.e., rehabilitation being offered by municipalities).
219536740|NCT07200804|DIAGNOSTIC_TEST|Measurement of Serum Vitamin D Level|Vitamin D is made of two types, named ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). Vitamin D2 is produced by converting ergosterol, a fungi and plants sterol, when it is exposed to light from the sun. Vitamin D3 is made differently, as it is formed in animal skin such as human skin with the help of 7-dehydrocholesterol when the skin is exposed to sunlight (UVB radiation).
219536741|NCT07200804|OTHER|Measurement of Carotid Intima-Media Thickness|Samples were collected by measuring the carotid intima-media thickness (CIMT) with a Mind ray Real time ultrasound scanner DC-6 doppler machine that has a probe at a frequency of 7.5 MHz. The measurement was done from three different sites each 1 cm proximal to the carotid bulb. The average of three values was taken to determine the final value. If CIMT \> 0.8 mm, it was defined as thickened. The measurements adhered to the Mannheim CIMT Consensus (2004-2006)
219619104|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
219536742|NCT07201493|BEHAVIORAL|color temperature change mode|Subjects are asked to read a terminal display device for 50 minutes, featuring texts with different color temperature mode treatments. Specifically, they will read the same text content for 50 minutes with different color temperature mode. The participants will complete a total of 2 sets of tests in a random order.
219619105|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
219536743|NCT07200219|BEHAVIORAL|Psychological Performance Strategies Training|A structured 4-week program of psychological performance strategies training delivered to licensed athletes. The program consisted of 8 sessions (twice per week, 60 minutes each) including modules on goal setting, self-talk, emotional control, imagery, automaticity, action orientation, attention control/negative thinking management, and relaxation techniques. Training was conducted in a supervised group format by qualified instructors.
219536744|NCT07200440|PROCEDURE|Intervention 1|Digital scans using conventional scan bodies scanned with an intra-oral scanner.
219536745|NCT07200440|PROCEDURE|Intervention 2|Digital scans using intra-oral photogrammetry scanned with an intra-oral scanner.
219536746|NCT07200440|PROCEDURE|Intervention 3|Digital scans using calibrated scan flags scanned with an intra-oral scanner.
219536747|NCT07200440|PROCEDURE|Control|Digital scans using conventional scan bodies scanned with a desktop scanner.
219536748|NCT07202455|DEVICE|Active tDCS|Patients will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on/off ramp of 0.1 mA/s) delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
219536749|NCT07202455|DEVICE|Sham tDCS|Patients will receive 10 sessions of sham tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up, stimulation stopped after the current ramp), delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
219619106|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
219536750|NCT07201233|BIOLOGICAL|Umbilical cord blood|Umbilical cord blood transfusion should be performed 24 hours to 2 weeks after chemotherapy. One to multiple units of cord blood can be applied, and the minimum interval between two cord blood transfusions should be 2 weeks.
219536751|NCT07202234|DRUG|Phage cocktail administered via nebulization|Phage cocktail administered via nebulization，BID
219536752|NCT07202234|DRUG|Nebulized normal saline inhalation therapy|Nebulized normal saline inhalation therapy, BID
219536753|NCT07200336|DRUG|Mepolizumab|Subcutaneous injection of mepolizumab is administered every 4 weeks for a total treatment duration of 24 weeks.
219536754|NCT07200336|PROCEDURE|Simple Polypectomy|Removal of nasal polyps in the middle meatus and superior turbinate region via the middle meatus and olfactory cleft, without opening the involved sinuses and without resection of diseased bone.
219536755|NCT07200336|PROCEDURE|Extended Endoscopic Sinus Surgery|"1. Complete opening of all sinuses~2. Resection of diseased mucosa and hyperplastic bone~3. Ethmoid skeletonization with middle turbinectomy~4. Draf IIb/III frontal dissection when indicated by CT severity."
219619107|NCT03918629|BIOLOGICAL|Clostridium difficile|Toxoid-based Clostridium difficile vaccine
219619108|NCT03918629|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
219619109|NCT01615367|OTHER|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
219536756|NCT07201870|OTHER|Acces to Precare online platform|Precare is an online educational platform for patients on the waiting list for bariatric surgery. Precare offers personalized educational content as well as a calendar and appointment management system. It has been accredited by the Quebec Ministry of Health and Social Services.
218922666|NCT01834911|DRUG|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
219536757|NCT07201766|DRUG|intralesional bleomycin|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
219536758|NCT07201766|DRUG|5-flourouracil and triamcinolone acetonide|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
219536759|NCT07202299|OTHER|HFOV weaning protocol 1|weaning preterm neonates with RDS from HFOV directly to CPAP
219536760|NCT07202299|OTHER|HFOV weaning protocol 2|weaning of preterm neonates with RDS to CMV then to CPAP
219536761|NCT07201727|BIOLOGICAL|CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic|For patients with refractory and relapsed AML, CD123+CLL-1 dual-target CAR-T cells (JY017) are used for treatment. Then, for patients who cannot achieve the minimum residual negative, CD7-targeted CAR-T cells (JY008) are sequentially infused. Finally, allogeneic hematopoietic stem cell transplantation is performed based on patient conditions.
219536762|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
218922667|NCT00288132|BEHAVIORAL|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
218922668|NCT00288132|BEHAVIORAL|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
218922669|NCT03704896|OTHER|Lung function measurement|Spirometry-derived lung function measurements
219204805|NCT06238297|DIAGNOSTIC_TEST|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
219536763|NCT07202533|OTHER|Pain Neuroscience Education|A 6-week educational program with weekly sessions using slide presentations and interactive discussions, covering pain neurophysiology, central sensitization, and pain coping strategies, delivered by a certified physiotherapist.
219536764|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
219536765|NCT07200206|BIOLOGICAL|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
219536766|NCT07202364|DRUG|YL202|YL202 will be intravenously infused over 60±10 min
219536767|NCT07201805|OTHER|Early Physiotherapy Program|The physiotherapy program provided upon discharge will consist of family education programs that include parental contact and therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapist will provide training to integrate these programs into daily routines. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will consist of family education programs based on a goal-oriented model of active motor learning and sensory strategy development for the baby in an enriched environment, incorporating holding, carrying, and positioning into daily routines. If possible, the entire family will participate in these programs.
219536768|NCT07201805|OTHER|Control group|The control group will be shown one-time positioning and holding and carrying principles in addition to routine developmental NICU care at the time of discharge.
219536769|NCT07200830|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
219536770|NCT07200830|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536771|NCT07200830|PROCEDURE|Patient Monitoring|Undergo PSA monitoring
219536772|NCT07200830|PROCEDURE|Computed Tomography|Undergo CT
219536773|NCT07200830|PROCEDURE|Bone Scan|Undergo Bone Scan
219536774|NCT07200830|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
219536775|NCT07200830|PROCEDURE|MRI|Undergo MRI
219536776|NCT07200830|OTHER|Questionnaire Administration|Ancillary studies
219536777|NCT07200570|BEHAVIORAL|LLM-Powered HPV Vaccine Chatbot|A vaccine chatbot delivered via WeChat or a web browser, designed to provide information and health education about the HPV vaccine. The chatbot is powered by large language models and is trained on an expert-validated knowledge base derived from authoritative sources such as the WHO and China CDC to ensure accuracy. The knowledge base is validated by experts. The chatbot engages users in interactive, conversational dialogue to answer questions and address concerns regarding HPV and HPV vaccines.
219536778|NCT07200362|DRUG|Compound Nanying zhitong Ointment|Use Compound Nanying Pain Relief Ointment alone, or use it in conjunction with conventional Western medicine treatment, without using any other similar Chinese patent medicines or traditional Chinese medicines.
219536779|NCT07200362|OTHER|Do not use any other similar proprietary medicines or traditional Chinese medicines.|Do not use any other similar proprietary medicines or traditional Chinese medicines.
219536780|NCT07201623|BEHAVIORAL|web-based childbirth preparation education|group providing web-based childbirth preparation training
219536781|NCT07200947|DRUG|QL1706, nab-paclitaxel, carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1) in combination with nab-paclitaxel (260 mg/m², IV, day 1) and carboplatin (AUC=4-5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) every 21 days. Treatment will continue until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or meeting other protocol-defined criteria for discontinuation. The maximum duration of QL1706 treatment is 24 months, after which continuation will be at the investigator's discretion based on individual benefit-risk assessment.
219619110|NCT01615367|DRUG|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
219619111|NCT05215444|DIAGNOSTIC_TEST|some prognostic factors|cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
218922670|NCT01034332|PROCEDURE|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
218922671|NCT00637975|DRUG|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
218922672|NCT00637975|DRUG|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
218922673|NCT04496713|OTHER|Internet-connected computer tablet|An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
218922674|NCT00000715|DRUG|Pentamidine isethionate|
218922675|NCT00000715|DRUG|Sulfamethoxazole-Trimethoprim|
218922676|NCT03591211|BEHAVIORAL|Qigong Training|Eight-Section Brocades; participants were trained individually.
219536782|NCT07201558|BIOLOGICAL|Surovatamig|"Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Surovatamig in adult participants with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study consists of up to three parts:~Part 1 (SAD): Single ascending dose - participants receive one dose of Surovatamig.~Part 2 (sSUD): Single step-up dosing - participants receive two doses. Part 3 (dSUD): Double step-up dosing - participants receive three doses. Participants are assigned to a study part based on protocol-defined criteria. The study includes follow-up for a minimum of 179 days post-first dose, with extended monitoring up to 12 months for certain participants."
218922677|NCT03591211|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
218922678|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
219536783|NCT07200843|OTHER|Heel rise test and postural/tibial sway measurement|Participants undergo a heel rise test to assess plantar flexor muscle endurance. Postural and tibial sway are measured during single-leg stance using a wearable sensor under eyes-open and eyes-closed conditions. No therapeutic intervention is applied.
219536784|NCT07200986|BIOLOGICAL|Ixekizumab|80 mg (single dose), SC injection via PFS
219536785|NCT07200479|DRUG|CAR T cells chimeric antigen receptor cells|CT1194D cells infusion
219536786|NCT07202247|DRUG|Antiandrogen Therapy|Given ADT
219536787|NCT07202247|BEHAVIORAL|Behavioral Intervention|Receive fasting reminders via Oncpatient Companion Mobile Application
219536788|NCT07202247|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219536789|NCT07202247|PROCEDURE|Cardiac Computerized Tomographic Angiography|Undergo a coronary computerized tomography angiography
219536790|NCT07202247|PROCEDURE|Computed Tomography|Undergo CT
219536791|NCT07202247|OTHER|Electronic Health Record Review|Ancillary studies
219536792|NCT07202247|OTHER|Internet-Based Intervention|Complete survey and food diary collection via Oncpatient Companion Mobile Application
219536793|NCT07202247|BEHAVIORAL|Lifestyle Counseling|Receive diet and lifestyle counseling
219536794|NCT07202247|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
219536795|NCT07202247|OTHER|Nutritional Intervention|Receive AHA HHD guidelines
219536796|NCT07202247|OTHER|Nutritional Intervention|Receive AHA Life Essential 8 recommendations with personalized caloric intake
219536797|NCT07202247|OTHER|Questionnaire Administration|Ancillary studies
219536798|NCT07202247|RADIATION|Radiation Therapy|Undergo RT
219536799|NCT07202247|OTHER|Referral|Receive a referral to an endocrinologist
219536800|NCT07202247|DRUG|Semaglutide|Given SC
219536801|NCT07202247|OTHER|Short-Term Fasting|Participate in an overnight fast
219536802|NCT07202247|DRUG|Tirzepatide|Given SC
219536803|NCT07202520|DEVICE|IVR : H'Ability Home|H'Ability Home is a Dtx (Digital therapeutics) designed for the neurological rehabilitation of patients who have suffered a stroke, via a wireless virtual reality headset, with a simplified control interface on a tablet or PC
219536804|NCT07202520|DEVICE|Control: paper-based exercise guide|self-rehabilitation booklet used in current practice in centers
219536805|NCT07200232|DEVICE|Phase 1 Test Device Sensor and Adhesive and Reference Device|Test Device Sensor and Adhesive and Reference Device ECG Data Collection for 1 hour
219536806|NCT07200232|DEVICE|Phase 2 Test Device ECG Signal quality over a 10-day simulated use period|Evaluation of the ECG-signal quality of the Test Device sensor and adhesive applied to a single site on a subject's chest to collect ECG readings for a 10-day period.
219536807|NCT07200232|DEVICE|Test Device Sensor and Adhesive Variable Placement|Comparison of nine incorrect locations of Test Device Sensor and Adhesive to the ideal location
219536808|NCT07201831|OTHER|No treatment given|No treatment given
218922679|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
218922680|NCT02512783|DRUG|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
218922681|NCT02512783|DRUG|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
218922682|NCT02512783|DRUG|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
218922683|NCT02282618|DEVICE|Cardiac Sympathetic Blockade|
218922684|NCT03543644|OTHER|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
219536809|NCT07202468|DEVICE|Virtual Reality|"1. Aquarium VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Aquarium video. The video included underwater scenes with fish, sharks, and marine mammals. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to provide distraction.~2. Kaleidoscope VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Kaleidoscope video consisting of colorful, shifting geometric patterns. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to distract the child and reduce procedural pain and fear.~3. Routine Care (Control Group)~Children in this group received standard peripheral intravenous catheterization procedure in the pediatric surgery unit without any additional distraction intervention."
219536810|NCT07202377|DIAGNOSTIC_TEST|SPECIFIC REVEAL® Rapid AST system|The SPECIFIC REVEAL™ system uses biosensors capable of detecting volatile substances released by microorganisms during their growth. The detection of these volatile compounds by ultra-high-performance biosensors enables very early detection of bacterial growth compared with standard technologies based on visual systems (e.g. diffusion antibiogram or MICs determined by microdilution in liquid media) or optical density measurement systems (e.g. Vitek2)
219536811|NCT07202377|DIAGNOSTIC_TEST|antibiotic susceptibility testing on agar medium|Performance of an antibiotic susceptibility test on agar medium, with results expected between H18 and H24
219536812|NCT07201064|DRUG|SZ1003 injection|once every two weeks at a dose of SZ1003 injection per infusion.
219536813|NCT07202143|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ vial) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
219536814|NCT07202143|DRUG|Normal Saline|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
219536815|NCT07200908|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
219536816|NCT07200908|DRUG|Bulevirtide 2 mg and Brelovitug - 300 mg|Route of Administration- Subcutaneous Injection
218922685|NCT03543644|OTHER|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
218922686|NCT03543644|OTHER|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
219536817|NCT07200375|DRUG|Glofitamab|Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
218922687|NCT02955667|PROCEDURE|invivo microscopy group|patients receive invivo micro-colposcopy examination
218922688|NCT02955667|PROCEDURE|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
218922689|NCT03031015|DEVICE|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
218922690|NCT03031015|DEVICE|Plating|Fractures were reduced and then fixed with Plate.
219619112|NCT00475267|DEVICE|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
219619113|NCT04748484|DEVICE|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
219619114|NCT04935541|DRUG|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
218922691|NCT01874899|DEVICE|RestoreSensor Neurostimulation|
218922692|NCT06226493|DEVICE|Transcutaneous vagus nerve stimulation|The Parasym Plus device (https://parasym.io) is a transcutaneous auricular vagus nerve stimulator that has been deemed non-significant risk (NSR) by the FDA. Transcutaneous auricular vagus nerve stimulator is a non-significant risk device, as it involves electrical stimulation of the external ear using an ear clip, with no invasive components. The stimulation parameters will be limited to the confines of existing published data. tVNS is safe and well tolerated at doses tested in research studies. The Parasym device is considered low risk when used in accordance with the instructions for use. Participants will be properly trained to use the device, and those with contraindications will be excluded for extra precaution. A low incidence of skin irritation has been reported. No serious adverse events have been reported.
218922693|NCT02559141|DRUG|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
218922694|NCT01028820|DRUG|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
218922695|NCT04129996|DRUG|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
218922696|NCT04778137|DRUG|Omalizumab|Biological: CMAB007 Biological: Xolair
218922697|NCT06369727|DRUG|MOB015B|Topcal formulation
218922698|NCT06369727|DRUG|MOB015B vehicle|Topcal formulation
218922699|NCT06369727|DRUG|Negative irritant solution of 0.9% saline|Negative control
218922700|NCT01153932|DRUG|GSK2402968|Subcutaneous injection
218922701|NCT01153932|DRUG|matched placebo|Subcutaneous injection
218922702|NCT03611829|BEHAVIORAL|ACT Intervention|
218922703|NCT03611829|BEHAVIORAL|Standard Care|
219204806|NCT06965283|BEHAVIORAL|Providing training and Mentoring|The intervention packages are providing postpartum family planning training at each MCH units, Using WHO PPFP counseling toolkit, mentoring health care provider to fill knowledge and skill gap, contraceptive logistic availability, and regular supportive supervision
219204807|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
219536818|NCT07202416|PROCEDURE|Erector spinae plane block|Ultrasound-guided Erector Spinae Plane Block performed at the T9 level with 0,375%, ropivacaine 20 mL administered bilaterally at the end of surgery for postoperative analgesia following cesarean section.
219536819|NCT07202416|PROCEDURE|Intrathecal morphine|Intrathecal administration of 100 mcg of morphine in combination with a local anesthetic was performed at the time of spinal anesthesia for cesarean section.
219204808|NCT03049189|DRUG|Everolimus|Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
219204809|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
219204810|NCT06965959|BEHAVIORAL|Exergaming Intervention Group|A behavioral intervention involving the use of motion-based digital games such as table tennis, boxing, skiing, and bowling. Participants performed exergaming sessions twice per week for eight weeks. Each session lasted approximately 15 minutes and was conducted in pairs under supervision. The intervention aimed to promote physical activity, cognitive engagement, and social interaction among older adults in a nursing home setting.
219204811|NCT06965959|BEHAVIORAL|Autogenic Relaxation|A behavioral mind-body intervention in which participants practiced standardized verbal relaxation techniques focused on passive concentration and bodily awareness. Sessions were conducted in quiet rooms in small groups, twice per week for eight weeks, each lasting approximately 15 minutes. The goal was to enhance psychological well-being and reduce emotional tension in institutionalized older adults.
219204812|NCT06966466|DEVICE|HuGgy Compression vest|This intervention involves the use of a HUGgy compression vest, a wearable device that provides deep touch pressure (DTP) to pediatric patients undergoing tonsillectomy and adenoidectomy under general anesthesia. The vest is worn by patients immediately after surgery, and pressure is applied to provide calming sensory input. The pressure level is adjusted based on the manufacturer's guidelines, providing a gentle, even compression to reduce emergence agitation (EA) during the recovery period.
219204813|NCT06970483|DRUG|Tranexamic acid|Transamine1 gram was administered intravenously during the lower segment incision.
219536820|NCT07201311|DRUG|Combination of activated charcoal with polyethylene glycol for digestive decontamination|"A dose of 25-100g of activated charcoal via the nasogastric tube will be administered, followed by polyethylene glycol1L/15-20 kg ideal body weight at a flow rate of 1L/hour.~polyethylene glycol will be continued until clear stools are obtained, a maximum of 24h of treatment of until the maximum dose of 1L per 15 kg of ideal body weight are administered.~Serial activated charcoal 50g 6 times/day will be administered if prolonged-release forms or drugs with enterohepatic circulation were ingested."
219536821|NCT07201311|DRUG|Standard Treatment (Guideline-Based)|Patients receive activated charcoal according to French guidelines - activated charcoal 25-100g and serial activated charcoal 50g 6 times/day if sustained-release forms or drugs with enterohepatic circulation as routine treatment.
219536822|NCT07201636|DIAGNOSTIC_TEST|Motor Function Assessments|The planned functional motor assessments are specific to age and degree of motor impairment. Participants are expected to have varying degrees of motor impairment, for example some will be non-ambulant. There is also a wide range of ages of participants. Therefore, some assessments will not be applicable. Some participants may gain or lose these abilities during the study and the assessments they complete shall be tailored accordingly aiming to reflect their most typical abilities on the day assessed.
219536823|NCT07201636|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
218922704|NCT01387997|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
218922705|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT)|2x8 weeks of high-intensity interval training (HIIT)
218922706|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT) + intermittent fasting|2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
218922707|NCT05556044|DRUG|Empagliflozin 10 MG|This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
219536824|NCT07201636|DIAGNOSTIC_TEST|Respiratory Assessments|The planned respiratory assessments are tailored to the participant's age and respiratory capacity. Participants are expected to have varying degrees of respiratory impairment, and some assessments may not be applicable to all. As participants may gain or lose respiratory function over the course of the study, the assessments completed will be adapted accordingly to reflect their most typical respiratory abilities on the day of assessment.
219536825|NCT07201636|DIAGNOSTIC_TEST|Bulbar Function Questionnaires|The planned bulbar function assessments are age-specific and designed to reflect the participant's typical oral intake abilities. For participants aged 1-17 years, the Children's Eating and Drinking Activity Scale (CEDAS), will be used. For those aged 18 years and older, the Functional Oral Intake Scale (FOIS) will be applied. Both tools are part of a unified 7-item scale validated across paediatric and adult populations, ensuring continuity across age groups.
218922708|NCT04367818|PROCEDURE|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
218922709|NCT04367818|PROCEDURE|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
218922710|NCT04596267|DRUG|Pitolisant|8.9mg Pitolisant for 5 days
218922711|NCT04596267|DRUG|Placebo|Inert ingredients
218922712|NCT02511548|OTHER|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
218922713|NCT00071058|DRUG|XR9576 (Tariquidar)|
218922714|NCT02096302|DIETARY_SUPPLEMENT|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
218922715|NCT02096302|DIETARY_SUPPLEMENT|Standard formula|Standard formula without probiotics
218922716|NCT05781906|DRUG|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
218922717|NCT05781906|DRUG|150 µCi [14C]HMPL-523|D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
218922718|NCT01523106|DRUG|L-carnitine|dietary supplement
219536826|NCT07201636|DIAGNOSTIC_TEST|Clinical Global Impression (CGI)|The Clinical Global Impression (CGI) tool will be used to assess overall disease severity and improvement across three functional domains: Physical Motor Function, Respiratory Function, and Bulbar Function. Assessments are based on clinician judgment using all available clinical data and are conducted by clinicians experienced with the disease under study.
218922719|NCT01523106|OTHER|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
218922720|NCT02000440|DRUG|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
218922721|NCT06458881|COMBINATION_PRODUCT|Mixture of Simethicone and Tyndallized Bacillus Coagulans|. Enrolled infants were treated for 28 days with a mixture of Tyndallized B. Coagulans and Simethicone: 20 drops, four times a day. At enrolment, clinical and dietary history, obstetrical data and anthropometry were recorded. The subjects were classified as having IC based on their parents' responses to the validated questionnaires regarding IC according to Rome IV criteria.
218922722|NCT00981448|DIETARY_SUPPLEMENT|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
219536827|NCT07201636|OTHER|Quality of Life Questionnaires|The planned quality of life and functional status assessments are designed to capture the participant's overall well-being and daily functioning, taking into account the wide range of ages and disease severities in the study population. Validated questionnaires appropriate to age and functional level will be used to evaluate aspects such as health-related quality of life, fatigue, and daily activity limitations.
219536828|NCT07201636|PROCEDURE|Blood Sample Collection|Blood sample collection is usually done annually for NM patients as part of their standard of care. This is usually done by a nurse or a medical doctor according to standard guidelines for blood sampling. During routine blood sampling, additional blood will be collected and up to 20 ml of blood will be taken.
219536829|NCT07201350|OTHER|distraciton technices|UTETC is a distraction method used during ECG procedures.
219536830|NCT07200960|PROCEDURE|ESPB|Patient receiving ESPB for major oncological breast surgery Patient receiving Retrolaminar Block for major oncological breast surgery
219536831|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
218922723|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
219536832|NCT07201155|DEVICE|Continuous Glucose Monitoring Systems|"A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.~Patients monitored their blood glucose using fingerstick point-of-care (POC) measurements every 1-6 hours as needed and had routine arterial blood gas analysis 4-6 times a day. After 24 hours of patient wear, the arterial blood gas glucose (aBG) was used to calibrate the CGMS device at least twice a day. Nurses recorded CGMS data paired with POC values and aBG values in a 1:1 format."
218922724|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
218922725|NCT01134185|DRUG|prucalopride|single dose of 2 mg prucalopride
218922726|NCT01649778|DRUG|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
218922727|NCT04109547|DRUG|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
218922728|NCT04109547|DRUG|Placebo|Tablets to be taken once-daily for 26 weeks
218922729|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
218922730|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
218922731|NCT06318741|OTHER|aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.|aerobic exercise on the treadmill
218922732|NCT06318741|OTHER|Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.|Walking at an intensity of 12-13 RPE
218922733|NCT01656408|DRUG|MK-8150|
218922734|NCT01656408|DRUG|Placebo for MK-8150|
219204814|NCT06970483|DRUG|Misoprostol 200mcg Tab|Cytotec 400 micrograms were administered sublingually immediately after delivery of the baby and clamping of the umbilical cord.
219204815|NCT06972927|OTHER|Smoothie containing iron biofortified microgreens|30g of iron biofortified microgreens consumed within a smoothie for 28 days
219536833|NCT07201155|DEVICE|Continuous Glucose Monitoring|This study is a single-center, prospective, observational study conducted in the Intensive Care Unit (ICU) of Nanfang Hospital, Southern Medical University, from May 2024 to August 2024. Patients with elevated blood glucose levels (BG\>180 mg/dL) undergoing intravenous insulin therapy were included. Simultaneous blood glucose monitoring was performed using fingerstick blood samples and arterial blood gas analysis, along with the installation of CGMS for concurrent monitoring. CGMS data (CGM values) were recorded in a 1:1 paired format with fingerstick point-of-care (POC) values and arterial blood gas (aBG) values. The correlation of paired blood glucose data was examined using Pearson's correlation coefficient. The accuracy of CGMS was assessed using metrics such as Mean Absolute Relative Difference (MARD), ISO 15197-2013, CLSI POCT12-A3, and Clarke Error Grid Analysis, analyzed with R v.4.4.1 software.
219204816|NCT04408755|DRUG|AVP-786|oral capsules
219204817|NCT04408755|DRUG|Placebo|oral capsules
219619115|NCT04935541|DRUG|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
219619116|NCT00607321|DEVICE|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
219619117|NCT03288064|DIETARY_SUPPLEMENT|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
219204818|NCT04728230|DRUG|Carboplatin|Given IV
219204819|NCT04728230|BIOLOGICAL|Durvalumab|Given IV
219204820|NCT04728230|DRUG|Etoposide|Given IV
219204821|NCT04728230|DRUG|Olaparib|Given PO
219204822|NCT04728230|RADIATION|Radiation Therapy|Undergo consolidative thoracic radiation therapy
219204823|NCT05778617|DRUG|Ambroxol Hydrochloride (420mg)|Oral tablet
219204824|NCT05778617|DRUG|Placebo|Oral tablet
219204825|NCT02570347|DRUG|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
219204826|NCT02570347|BIOLOGICAL|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
218922735|NCT03469557|DRUG|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
218922736|NCT03469557|DRUG|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
219619118|NCT03288064|DIETARY_SUPPLEMENT|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
218922737|NCT03469557|DRUG|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
218922738|NCT03469557|DRUG|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
218922739|NCT03469557|DRUG|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
218922740|NCT06442943|BEHAVIORAL|Multi-domain Cognitive Intervention|"* Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly."
219536834|NCT07201155|DEVICE|Continuous Glucose Monitoring|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
218922741|NCT05465317|DRUG|Empagliflozin|Empagliflozin
218922742|NCT05465317|DRUG|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
218922743|NCT05100121|DEVICE|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
219204827|NCT00308997|DEVICE|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
219204828|NCT00308997|DEVICE|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
219204829|NCT03299426|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
219204830|NCT03299426|BIOLOGICAL|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
219204831|NCT05283330|DRUG|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
219204832|NCT03031249|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
219204833|NCT03031249|DRUG|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
219619119|NCT03288064|DIETARY_SUPPLEMENT|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
219619120|NCT02571699|OTHER|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
219619121|NCT04015973|DIETARY_SUPPLEMENT|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
219619122|NCT04105673|OTHER|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
219204834|NCT03031249|DRUG|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
219619123|NCT03631589|BIOLOGICAL|MSCs|mesenchymal stem cells therapy
219619124|NCT02826629|DEVICE|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
219619125|NCT02826629|DEVICE|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
219619126|NCT02826629|DEVICE|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
219619127|NCT02826629|OTHER|Psychopathological evaluations|
219619128|NCT02826629|OTHER|Neuropsychological evaluations|
219619129|NCT00270244|BEHAVIORAL|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
219619130|NCT00270244|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
218922744|NCT05100121|OTHER|Supportive Care|During the health dialogues with the nurse, the patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patients health record.
218922745|NCT01690143|DRUG|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
218922746|NCT01690143|DRUG|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
218922747|NCT05975684|DRUG|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
218922748|NCT05975684|DRUG|Placebo|Placebo three times a day for 4 weeks
219536835|NCT07201155|DEVICE|CGMS|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
219536836|NCT07201792|OTHER|Early Physiotherapy|The early physiotherapy program will begin when the infant is stable and continue until discharge. Depending on the infant's gestational age and respiratory needs, chest physiotherapy, developmental physiotherapy, or both will be administered, if necessary. The early family collaborative physiotherapy program will begin from the first day the infant is stable and parental contact is established, and will consist of routine-based care and family education programs that include therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will be based on a model of goal-oriented active motor learning and sensory strategy development in an enriched environment, and will include family education programs that integrate holding, carrying, and positioning training into daily routines. All parents will participate in the training.
219536837|NCT07202013|OTHER|Kinesio taping|Kinesio taping was applied in a fan-shaped pattern once weekly for four consecutive weeks. Elastic therapeutic tape was applied with 0-15% tension to the buttocks and thighs at standardized anatomical points, including the gluteus maximus (above the sacroiliac joint), posterior thigh (gluteal fold), and anterior thigh (above the anterior inferior iliac crest). This protocol was designed to promote lymphatic drainage, improve microcirculation, and enhance dermal density and structure in women with stage II cellulite.
219536838|NCT07200596|DRUG|SHR-3045 Injection|SHR-3045 injection.
219536839|NCT07200596|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
219536840|NCT07201974|OTHER|Virtual Reality Training|The VR intervention involves the intensive practice of community ambulation skills. The training sessions will be performed in a virtual environment. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
219536841|NCT07200297|OTHER|Active Comparator: Control|Patients who were given only a standard chlorhexidine oral care set
219536842|NCT07200297|OTHER|Experimental: Electric Toothbrush|Patients who were given an electric toothbrush and toothpaste along with a chlorhexidine set
219536843|NCT07200297|OTHER|Experimental: Manual Toothbrush|Patients who were given a manual toothbrush and toothpaste along with a chlorhexidine set.
219536844|NCT07202117|DEVICE|Sculptra Aesthetic|"Sculptra® Aesthetic is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%).~For this study, commercial products will be used. The study products are for single use only."
219536845|NCT07202117|DEVICE|Radiesse|"Radiesse® is manufactured by Merz Aesthetics. It is a sterile, non-pyrogenic, semi-solid injectable implant composed of synthetic CaHA suspended in a gel carrier of sterile water, glycerin, and sodium carboxymethylcellulose. Each pre-filled syringe contains 1.5 mL of product. The product includes 0.3% lidocaine for pain reduction during injection.~For this study, commercial products will be used. The study products are for single use only."
219536846|NCT07202481|DIETARY_SUPPLEMENT|Psyllium powder|Psyllium powder: soluble fiber gel forming, provided at 20 g per day (two doses of 10 g each)
219536847|NCT07202481|DIETARY_SUPPLEMENT|Fructooligosaccharide|Fructooligosaccharide: prebiotic, provided at 20 g per day (two doses of 10 g each)
219536848|NCT07202390|OTHER|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
219536849|NCT07202390|OTHER|Intervention|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
218922749|NCT05806580|DRUG|Relma-cel|Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
218922750|NCT04245150|OTHER|Stool sample|Stool sample
218922751|NCT04245150|OTHER|Skin Swab Sample|Skin Swab Sample
218922752|NCT03913533|DEVICE|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
219536850|NCT07201935|BEHAVIORAL|Cold Water Immersion|Participants will complete 14 daily sessions of cold-water immersion exposure.
219536851|NCT07201935|BEHAVIORAL|High Heat Sauna|Participants will complete 14 evening sessions in the high heat sauna
219536852|NCT07202338|BEHAVIORAL|CHRONOS therapy|Description: Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
219536853|NCT07201532|OTHER|eDelphi method|A Delphi consensus study will be undertaken to establish a core outcome set for disease modification in type 2 diabetes.
219536854|NCT07200466|DIAGNOSTIC_TEST|ENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.|The intervention group are patients receiving a personalized risk on lymph node metastases as predicted by the ENDORISK model, they also receive a treatment plan (hysterectomy + bilateral salpingo-oophorectomy with or without lymph node surgery) based on this personalized risk.
219536855|NCT07202312|DEVICE|Ozone-therapy after non-surgical therapy|The test group received ozone therapy immediately after non-surgical treatment, at a fixed concentration of 2100 ppm and 80% oxygen, applied three times at the site. Ozone was delivered into the periodontal pocket using a sterile syringe with a flat tip. Ozone was generated with the Ozone DTA Ozone Generator (Denta Tec Dental AS, Norway), which was operated for 20 seconds in accordance with the manufacturer's instructions.
219536856|NCT07200635|OTHER|HA injection|Using vacuum negative pressure technology, hyaluronic acid and other moisturizing nutrients are directly injected into the deep skin, effectively improving dermal dehydration and dryness from the muscle base, so that the skin can quickly replenish water.
219536857|NCT07200635|OTHER|Facial serum application|Dosage on face: About 0.5g/face for serum.
219536858|NCT07201012|DIAGNOSTIC_TEST|Sampling of suspected skin lesions (in accordance with good care practices).|Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.
219536859|NCT07201012|GENETIC|Constitution of a biobank|Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients
219536860|NCT07200856|OTHER|Nocturnal Blood Pressure Dipping|Patients will be classified as dippers (≥10% nocturnal BP fall) or non-dippers (\<10% nocturnal BP fall) based on 24-hour ambulatory blood pressure monitoring.
219536861|NCT07201688|DRUG|rhTNK-tPA|Each vial should be dissolved in 3mL of sterile water for injection to prepare a drug solution with a concentration of 5.33mg/mL. Calculate the total drug amount based on the participant's actual body weight, measure the required volume of the drug solution, and ensure the maximum dose does not exceed 25mg. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
219536862|NCT07201688|DRUG|Placebo|One vial is dissolved in 3mL of sterile water for injection. Calculate the total drug amount based on the participant's actual body weight, then measure the required volume of the drug solution. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
219536863|NCT07201220|BEHAVIORAL|meditation|The study is planned to include 60 pregnant women (30 in the experimental group and 30 in the control group) in the first stage of labor. After informing the participants about the study and obtaining informed consent, pre-test scales will be administered. Relaxation meditation will be applied during labor for the experimental group, followed by post-test scales.
219536864|NCT07200726|OTHER|Observational study design - no intervention|Observational study design - no intervention
219536865|NCT07201402|DRUG|Scapular-site insertion of etonogestrel contraceptive implant|Participants will undergo insertion of the etonogestrel contraceptive implant subdermally over the inferior edge of their non-dominant scapula
219536866|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
219536867|NCT02219620|BEHAVIORAL|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
219536868|NCT02219620|BEHAVIORAL|Social Control|social conversational group facilitated by care counselor
219536869|NCT00859872|DRUG|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
219536870|NCT00859872|DRUG|haloperidol|haloperidol IM injection (5-20mg/d)
219536871|NCT02895763|OTHER|Form administrations|
218922753|NCT03913533|DEVICE|Heart rate assessment using Tap-based smartphone application|At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
218922754|NCT00648102|BIOLOGICAL|CDX-1307|
218922755|NCT04337970|DRUG|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
218922756|NCT04337970|DRUG|Axitinib|5 mg PO BID
218922757|NCT04752215|DRUG|BI 765049|BI 765049
218922758|NCT04752215|DRUG|ezabenlimab|ezabenlimab
219536872|NCT02594358|DRUG|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
219619131|NCT00128440|DRUG|BEA 2180 BR|
219619132|NCT00128440|DRUG|tiotropium|
219619133|NCT06509802|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)|This study will be a two-arm randomised controlled trial to examine the efficacy of the We-SMILE for pre-practicum social work and/or counselling students by comparing to the We-SMILE intervention group and the no-intervention training-as-usual group.
219619134|NCT02142790|DRUG|paclitaxel liposome injection|
219619135|NCT04245254|DIETARY_SUPPLEMENT|Collagen Protien Powder|Collegen Protein Powser
218922759|NCT03777982|DRUG|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
218922760|NCT03777982|DRUG|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
218922761|NCT03777982|DRUG|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
218922762|NCT03777982|DRUG|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
218922763|NCT06388512|DEVICE|prototype prone positioning device|The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
218922764|NCT05647408|DRUG|Dexamethasone|The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
218922765|NCT03995368|OTHER|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
218922766|NCT00034177|DRUG|S-8184 Paclitaxel Injectable Emulsion|
219536873|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 6 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
219536874|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 9 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
219536875|NCT04766450|DRUG|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
219536876|NCT03090568|DRUG|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
219536877|NCT03428386|PROCEDURE|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
219536878|NCT00834795|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
219536879|NCT00834795|DRUG|COREG® 25 mg tablets|1 x 25 mg
218922767|NCT00034177|DRUG|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
218922768|NCT03675997|OTHER|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
218922769|NCT04351581|OTHER|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
218922770|NCT04351581|OTHER|Continuation of ACEi/ARB|Continuation of ACEi/ARB
218922771|NCT03167749|DIAGNOSTIC_TEST|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
219536880|NCT02005497|OTHER|HealthLinks|
219536881|NCT06083259|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
218922772|NCT00678782|DRUG|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
219536882|NCT06083259|PROCEDURE|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
219536883|NCT00579345|BIOLOGICAL|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
219536884|NCT00579345|BIOLOGICAL|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV\_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
219204835|NCT05804461|BEHAVIORAL|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase Pre-Exposure Prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
219536885|NCT00579345|BIOLOGICAL|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV\_a administered.
219536886|NCT00579345|BIOLOGICAL|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
219536887|NCT01921894|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
219536888|NCT05240989|PROCEDURE|pulmonary rehabilitation|one-year regular lung rehabilitation treatment and control the intensive monitoring of hemodynamic parameters
219536889|NCT05746104|DRUG|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
219536890|NCT00193115|DRUG|Docetaxel|
219536891|NCT00193115|DRUG|Doxorubicin|
219536892|NCT00193115|DRUG|Cyclophosphamide|
219536893|NCT02572713|PROCEDURE|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
219536894|NCT02572713|PROCEDURE|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
219536895|NCT02572713|DRUG|DaTSCAN™|
219536896|NCT02908776|DIETARY_SUPPLEMENT|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
219536897|NCT02908776|OTHER|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
219536898|NCT06558695|DRUG|Sevoflurane|Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
218922773|NCT00678782|DRUG|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
219536899|NCT06558695|DRUG|TIVA|TIVA was managed for maintenance of the general anesthesia during spinal surgeries
219536900|NCT05813847|DRUG|local anaesthetic injection|Local infiltration of study drug
219536901|NCT00650377|DRUG|Finasteride Tablets 5 mg|5mg, single dose fed
218922774|NCT03592186|BEHAVIORAL|Parenting Wisely+|Parenting Wisely+ experimental intervention
218922775|NCT03592186|BEHAVIORAL|Treatment as Usual|Treatment as Usual
218922776|NCT03841396|DRUG|Sodium chloride|All participants received a single dose of sodium chloride as placebo
219536902|NCT00650377|DRUG|Proscar® Tablets 5 mg|5mg, single dose fed
219536903|NCT05643677|DRUG|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
219536904|NCT05643677|DRUG|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
219536905|NCT00828815|DRUG|TMC125|
219536906|NCT04388722|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
219536907|NCT05761652|OTHER|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
219536908|NCT04356508|DRUG|Nivolumab|Single dose at 0.3mg/kg
219536909|NCT02404753|DRUG|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
219536910|NCT02404753|PROCEDURE|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
219536911|NCT02404753|PROCEDURE|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
219536912|NCT02404753|DRUG|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
219536913|NCT03255733|DEVICE|Intense Therapeutic Ultrasound Treatment|
219536914|NCT05309850|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
219536915|NCT00352989|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
219536916|NCT05284539|DRUG|Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab|Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
219619136|NCT03143283|BEHAVIORAL|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
219619137|NCT06265454|DRUG|low dose atropine eye drops|Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
219619138|NCT06265454|DRUG|Placebo|placebo
219619139|NCT06213077|DIETARY_SUPPLEMENT|Nitric Oxide|Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.
219619140|NCT06213077|DRUG|Tadalafil|Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
218922777|NCT04392622|DRUG|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
218922778|NCT04392622|RADIATION|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
218922779|NCT04392622|DRUG|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
218922780|NCT04392622|OTHER|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
218922781|NCT06180343|OTHER|Mandala|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
218922782|NCT02628990|OTHER|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
218922783|NCT02628990|OTHER|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
218922784|NCT02628990|OTHER|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
219536917|NCT06433258|BEHAVIORAL|Enhanced TSSC curriculum|In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
219536918|NCT06433258|BEHAVIORAL|Original TSSC curriculum|Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
218922785|NCT02628990|OTHER|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
218922786|NCT02628990|OTHER|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
218922787|NCT04487366|OTHER|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
218922788|NCT04263155|BEHAVIORAL|The Body Project|The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
218922789|NCT03160261|DRUG|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
218922790|NCT01069003|DRUG|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
218922791|NCT01069003|DRUG|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
219536919|NCT05411913|DRUG|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
219536920|NCT05411913|DRUG|Icy Hot|a FDA OTC registered topical analgesic.
219536921|NCT05411913|DRUG|Tiger Balm|a FDA OTC registered topical analgesic
219536922|NCT05411913|DRUG|Bengay|a FDA OTC registered topical analgesic.
219536923|NCT05411913|DRUG|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
219536924|NCT05411913|DRUG|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
219536925|NCT05411913|DRUG|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
219536926|NCT05411913|DRUG|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
219536927|NCT04629326|OTHER|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
219536928|NCT04299087|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
219536929|NCT04299087|OTHER|Control group|No application of rTMS
219536930|NCT04309968|DRUG|Drug: SYHA1801|Drug: SYHA1801 administered orally
218922792|NCT01069003|DEVICE|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
219536931|NCT00594035|DEVICE|Spinal Sealant System|
219536932|NCT00594035|DEVICE|Standard of care|Standard of care: devices intended to provide a watertight closure
218922793|NCT01809600|OTHER|No intervention (observational study)|
218922794|NCT04886635|OTHER|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
218922795|NCT00563875|DRUG|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
218922796|NCT04125927|DRUG|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
219536933|NCT00795821|DRUG|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
219536934|NCT00795821|DRUG|Placebo|Dose: 3 tablets QD for 10 weeks
219619141|NCT06213077|OTHER|Placebo|Nitric Oxide Placebo Compound
219619142|NCT06079372|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
219619143|NCT06079372|DRUG|asfotase alfa|Asfotase alfa will be administered via SC injection.
219536935|NCT01285713|DRUG|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
219536936|NCT01285713|DRUG|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
219536937|NCT05312554|DEVICE|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
219536938|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 \*120mg new formulation tablet as test treatment
218922797|NCT02222623|DRUG|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
218922798|NCT02222623|DRUG|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
218922799|NCT03631602|DRUG|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
218922800|NCT02596867|DRUG|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
218922801|NCT05058339|OTHER|Survey Administration|Complete survey
218922802|NCT05516381|DEVICE|Optetrak Logic CR Knee System|The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
218922803|NCT00361296|BIOLOGICAL|K562/GM-CSF cell vaccine|
219536939|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
219536940|NCT00416780|OTHER|counseling intervention|
218922804|NCT02269969|DRUG|Tobramycin|
218922805|NCT01884467|DRUG|Gentamicin|Comparison of Gentamicin versus placebo
218922806|NCT01884467|DRUG|Placebo|
219042800|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit of diagnostic processes (including data from the Safer DX Checklist and CPT E/M code usage) for patients aged ≥ 3 to 89 years with one or more of 26 diagnoses prone to error to compare cases of PWD with specific disabilities (major mobility impairments,1 mental health concerns,2,3 severe visual impairments/ blindness,4 severe hearing loss/deafness,5 and IDD6,7) versus without the disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying increased risk of DE will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DE, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of diagnostic processes among PWD post implementation of algorithms and EHR prompts, alerts and decision supports will be conducted post-intervention."
219042801|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
219042802|NCT01284283|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
219042803|NCT00665600|DRUG|Levalbuterol HCl|Levalbuterol 0.63 TID
219042804|NCT00665600|DRUG|Levalbuterol HCl|Levabuterol 1.25 mg TID
219536941|NCT00416780|OTHER|educational intervention|
219536942|NCT00416780|PROCEDURE|psychosocial assessment and care|
219536943|NCT04310345|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
219536944|NCT06513052|OTHER|Commercial cocoa|daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk
219536945|NCT06513052|OTHER|High flavonols Cocoa|Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
219536946|NCT02816177|OTHER|Telemedicine|
219536947|NCT02816177|OTHER|Usual Care|
219536948|NCT06230588|DRUG|TQH3906 capsule|TQH3906 is a kinase inhibitor.
219536949|NCT06230588|DRUG|TQH3906 placebo|Placebo Comparator
219536950|NCT05282199|OTHER|INSPIRATORY MUSCLE TRAINING|In the group of post-COVID-19 patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
219536951|NCT06217939|DRUG|Early hydrocortisone|"For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
219536952|NCT06217939|DRUG|Normal saline placebo|"For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
218922807|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
218922808|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
218922809|NCT03521128|PROCEDURE|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
218922810|NCT03521128|PROCEDURE|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
218922811|NCT00198822|DIETARY_SUPPLEMENT|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
218922812|NCT00502476|PROCEDURE|Bathing with Chlorhexidine Impregnated Washcloths|
218922813|NCT02032732|OTHER|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
218922814|NCT01186289|DRUG|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
219619144|NCT01756027|DEVICE|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
219619145|NCT01756027|DEVICE|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
219619146|NCT02044380|DRUG|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
218922815|NCT03141138|BIOLOGICAL|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
218922816|NCT03141138|BIOLOGICAL|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
219042805|NCT00665600|DRUG|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
219042806|NCT00665600|DRUG|Placebo|Placebo TID
219042807|NCT05651711|DRUG|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
219042808|NCT05651711|OTHER|Placebo|The matching placebo will be administered through a SC injection.
219042809|NCT02132585|PROCEDURE|Speckle tracking echocardiography|
219042810|NCT02632708|DRUG|AG-120|
219619147|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
219619148|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
219619149|NCT02125500|DRUG|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
219619150|NCT01317628|BEHAVIORAL|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
219619151|NCT04456140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219619152|NCT04456140|OTHER|Genetic Counseling|Watch pre-test genetic counseling video
219619153|NCT04456140|OTHER|Genetic Testing|Undergo genetic testing
219619154|NCT04456140|OTHER|Survey Administration|Ancillary studies
219042811|NCT02632708|DRUG|AG-221|
219042812|NCT02632708|DRUG|cytarabine|
219042813|NCT02632708|DRUG|daunorubicin|
219042814|NCT02632708|DRUG|idarubicin|
219042815|NCT02632708|DRUG|mitoxantrone|
219042816|NCT02632708|DRUG|etoposide|
219042817|NCT06386497|DEVICE|Nocturnal translational vestibular stimulation|Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.
219042818|NCT06915493|OTHER|General Anesthesia|Blood glucose measurements during general anesthesia
219619155|NCT06147882|BEHAVIORAL|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.
219619156|NCT02286713|BEHAVIORAL|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
219619157|NCT02286713|BEHAVIORAL|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
219619158|NCT02286713|BEHAVIORAL|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
219619159|NCT05982470|DRUG|Estradiol Gel|Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
219619160|NCT05982470|DRUG|Estradiol Placebo Gel|Estradiol placebo gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
219619161|NCT05982470|DRUG|Progesterone Soft Capsule|Progesterone soft capsules 100mg once daily (oral) for 12 months
219619162|NCT05982470|DRUG|Progesterone Placebo Soft Capsule|Progesterone placebo soft capsules 100mg once daily (oral) for 12 months
218922817|NCT03537755|OTHER|Observation|Examine thoughts and behaviors
218922818|NCT00963859|PROCEDURE|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
219536953|NCT06217939|DRUG|Open-label hydrocortisone|An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
218922819|NCT04232358|DRUG|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
218922820|NCT04232358|DRUG|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
218922821|NCT05773729|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
218922822|NCT00129246|DRUG|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
218922823|NCT00129246|DRUG|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
218922824|NCT01651156|DRUG|Tolvaptan|oral taken
218922825|NCT01651156|DRUG|Placebo|
218922826|NCT01427764|DEVICE|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
219204836|NCT06828822|OTHER|Neurodevelopmental assessment|This assessment will be conducted using the ASQ-3 test. (ASQ-3 stands for Ages and Stages Questionnaires, Third Edition, which is a common screening tool for evaluating developmental progress in young children.)
219204837|NCT06828822|OTHER|Meeting with the parents|This meeting will evaluate the parents' acceptance of the lesion and their quality of life using the MARKS test (Measure of Acceptance of Skin Marks). The results will provide insights into how the parents perceive the lesion and how it impacts their daily lives.
219204838|NCT06828822|OTHER|Patient quality of life assessment|Collection of patient quality of life data
219536954|NCT06962865|DRUG|RC108|RC108 in Combination With Furmonertinib
219619163|NCT04787471|COMBINATION_PRODUCT|30 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
219619164|NCT04787471|COMBINATION_PRODUCT|10 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
219619165|NCT03832686|OTHER|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
218922827|NCT02072668|DRUG|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
218922828|NCT02072668|DRUG|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
218922829|NCT01539161|DEVICE|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
218922830|NCT01539161|PROCEDURE|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
218922831|NCT04362241|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
219536955|NCT06962865|DRUG|Furmonertinib Mesilate Tablets Monotherapy|Furmonertinib
219536956|NCT05013372|DRUG|CD147- CAR T cells|CAR T cells targeting CD147
219536957|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
219536958|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
219536959|NCT02184026|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
219536960|NCT02922777|DRUG|BGB324|75 mg/m2 every 21 days
219536961|NCT02922777|DRUG|Docetaxel|75 mg/m2 given IV every 21 days
218922832|NCT03104907|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
218922833|NCT04934540|PROCEDURE|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
218922834|NCT05666869|DRUG|Esketamine perfusion|Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
218922835|NCT03460795|BIOLOGICAL|MSC and Tregs|conventional plus MSC and Tregs or placebo treatment
218922836|NCT04466943|DEVICE|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
218922837|NCT01621269|DRUG|Fingolimod|
218922838|NCT04046120|OTHER|Heel-free bandage|The bandage is made by leaving the heel uncovered.
218922839|NCT06595433|OTHER|Experimental|In the PAPE 90% protocol, participants performed a general warm-up (e.g., jogging on a treadmill) for 5 minutes and a weightlifting-specific warm-up for 5 minutes, followed by 2 minutes of rest. After resting, they were asked to perform ten repetitions of dip squats with body weight and rested for 1 minute.Then, unlike the unloaded protocol, they performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes. After resting, they performed a snatch to exhaustion with 75% of their maximum snatch weight. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions between sets was recorded.
218922840|NCT06595433|OTHER|Experimental|In the PAPE 50% protocol, 5 minutes of general warm-up (jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up were followed by 2 minutes of rest as in the other protocols. After resting, they were asked to perform ten repetitions of body-weighted dip squats and rested for 1 minute. Then, unlike the unloaded and PAPE 90% protocols, they performed eight repetitions of bottom squats with 50% of their maximal bottom squats for one repetition and rested for 4 minutes. After resting, they performed snatches with 75% of their maximum snatch weight until exhaustion. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions was recorded for statistical analysis.
219536962|NCT00541788|OTHER|Administration of Common Sage|Administration of Common Sage
219536963|NCT03161158|DEVICE|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
219536964|NCT03161158|OTHER|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
219536965|NCT03083574|DEVICE|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
218922841|NCT06595433|OTHER|unloaded protocol|In the unloaded protocol, subjects performed a 5-minute general warm-up (e.g., jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up followed by 2 minutes of rest. After resting, they performed ten repetitions of bottom squats with their body weight and then rested for 1 minute. After rest, they performed the snatch movement with 75% of their maximum snatch weight until exhaustion. Then, they rested for 2 minutes and again performed the snatch with 75% of their maximum snatch weight until exhaustion. The maximum number of snatch repetitions performed by the weightlifters was recorded for statistical analysis.
218922842|NCT05006352|DRUG|DNL343|Oral repeating dose
219619166|NCT07079930|DRUG|Psilocybin and D-Serine|"A single administration of the drug, with dosage divided as follows:~Cohort 1: 15 mg of Psilocybin and 5 gr of D-Serine Cohort 2: 25 mg of Psilocybin and 7 gr of D-Serine"
219619167|NCT07079930|DIAGNOSTIC_TEST|Physical Examination|The physical examination will include diagnosis and documentation of any significant clinical abnormalities or diseases. It will be performed during the baseline rating visit (preparation phase).
218922843|NCT05006352|DRUG|Placebo|Oral repeating dose
219042819|NCT01168024|DEVICE|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
219042820|NCT01168024|OTHER|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
219536966|NCT05135104|DRUG|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~* in combination with an aromatase inhibitor;~* in combination with fulvestrant in women who have received prior endocrine therapy."
219536967|NCT05238168|OTHER|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
219536968|NCT00101647|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
219536969|NCT02361905|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
219536970|NCT02361905|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
219536971|NCT04766697|BEHAVIORAL|Risk-Reduction Sessions|The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
219536972|NCT00583453|DRUG|Celecoxib|"Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
219536973|NCT00583453|DRUG|Placebo|"Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
219619168|NCT07079930|DIAGNOSTIC_TEST|Vital signs|"Vital sign measurements (blood pressure, pulse, and oxygen saturation) will be taken at screening, preparation, baseline rating, administration day, day 2, day 28, and day 84.~Vital signs will be assessed at the following time points on the administration day and on day 2: pre-administration, and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours post-administration."
219619169|NCT07079930|DIAGNOSTIC_TEST|ECG test|A 12-lead ECG will be performed to rule out underlying cardiac abnormalities. An ECG will be conducted for each patient during the screening and Day 2 visits.
219619170|NCT07079930|DIAGNOSTIC_TEST|Comprehensive Blood Panel|"A comprehensive blood panel will be performed to assess kidney and liver function, electrolyte balance, and glucose levels.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
219619171|NCT07079930|DIAGNOSTIC_TEST|Complete Blood Count|"Complete Blood Count will be performed to check for hematological abnormalities.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
219619172|NCT07079930|DIAGNOSTIC_TEST|Urinalysis|Urinalysis will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
219619173|NCT07079930|DIAGNOSTIC_TEST|Urine Toxicology Screen|Urine Toxicology Screen will be performed to rule out illicit drug use. It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
219619174|NCT07079930|DIAGNOSTIC_TEST|A pregnancy Urine test|A urine pregnancy test will be performed for women of childbearing potential only. It will be conducted during the screening and baseline rating visits. If the urine test is positive, a serum β-hCG test will be performed for confirmation.
219619175|NCT07079930|DIAGNOSTIC_TEST|Electroencephalogram|EEG will be performed during the baseline rating scale and Day 7 visits to evaluate brain activity
219619176|NCT07079930|DIAGNOSTIC_TEST|Plasma Amino Acid Levels|The following blood test parameters - D-Serine, L-Serine, and Glycine - will be assessed during the Screening and Day 28 visits.
218922844|NCT06593990|DEVICE|echocardography|"Patients will be subjected to transthoracic echocardiography including, the following parameters will be measured:~* Left ventricular (LV) dimensions: end diastolic and systolic dimensions and LV ejection fraction (EF).~* Trans- mitral Doppler flow velocities including early (E) and late(A) diastolic velocities, E/A ratio.~* LA anteroposterior diameter measure from 2D parasternal long axis view targeted M-mode.~* LA superior-inferior and medio-lateral diameters measure from the apical 4 chamber view.~* LA volume included:~* Maximal LA volume measure at the end of systole~* Minimal LA volume will be measured at end diastole just at the closure of the mitral valve.~* Pre contractile LA volume ( LAV pre-A\] measured at P-wave onset on ECG just before atrial contraction."
218922845|NCT06593990|DEVICE|musculoskeletal ultrasonography|Ultrasound detected synovitis t
218922846|NCT06593990|DIAGNOSTIC_TEST|lipid profile test|The lipid profile typically includes measurement of total cholesterol, HDL-cholesterol (often called good cholesterol), LDL-cholesterol (often called bad cholesterol), and triglycerides.
218922847|NCT06593990|DIAGNOSTIC_TEST|C reactive protein|A c-reactive protein test measures the level of c-reactive protein (CRP) in a sample of your blood. CRP is a protein that your liver makes. Normally, you have low levels of c-reactive protein in your blood. Your liver releases more CRP into your bloodstream if you have inflammation in your body. High levels of CRP may mean you have a serious health condition that causes inflammation.
219536974|NCT03394547|DEVICE|Allay|pulsed shortwave therapy treatment for painful periods
219536975|NCT03394547|DEVICE|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
219536976|NCT02651272|DRUG|macitentan|10mg macitentan tablets
219619177|NCT07079930|DIAGNOSTIC_TEST|Plasma Inflammation Markers|The following blood test parameters - Tumor Necrosis Factor Alpha (TNF-α), Interleukin-6 (IL-6), and C-Reactive Protein (CRP) - will be assessed during the Screening and Day 28 visits.
219619178|NCT07079930|DIAGNOSTIC_TEST|Plasma Brain-Derived Neurotrophic Facto|Plasma BDNF (Brain-Derived Neurotrophic Factor) levels will be measured during the screening and Day 28 visits.
219619179|NCT07079930|OTHER|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (MINI) will be administered during the screening visit to rule out any current or past major psychiatric disorders.
219619180|NCT07079930|OTHER|Family Psychiatric History Assessment|The Family Psychiatric History Assessment (FPHA) will be administered during the screening visit to help rule out any current or past major psychiatric disorders.
218922848|NCT06593990|DIAGNOSTIC_TEST|Complete blood count CBC|"A complete blood count, or CBC, is a blood test that measures many different parts and features of your blood, including:~Red blood cells, which carry oxygen from your lungs to the rest of your body. White blood cells, which fight infections and other diseases. There are five major types of white blood cells. A CBC test measures the total number of white cells in your blood. A different test called a CBC with differential measures the number of each type of these white blood cells.~Platelets, which stop bleeding by helping your blood to clot. Hemoglobin, a protein in red blood cells that carries oxygen from your lungs to the rest of your body.~Hematocrit, a measurement of how much of your blood is made up of red blood cells.~Mean corpuscular volume (MCV), a measure of the average size of your red blood cells."
219536977|NCT04523168|DEVICE|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
219536978|NCT00307996|DRUG|Coenzyme Q10 (drug)|
219536979|NCT00104481|BEHAVIORAL|cognitive behavior therapy|
219536980|NCT06561035|DRUG|Opiate Sparing|Subjects will receive medications in the Opiate Sparing arm for pain control.
219536981|NCT06561035|DRUG|Opiate Based|Subjects will receive medications in the Opiate Based arm for pain control.
219536982|NCT06223191|OTHER|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
219536983|NCT06223191|OTHER|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
219536984|NCT03831139|BEHAVIORAL|TIM&SARA|
218922849|NCT06593990|DIAGNOSTIC_TEST|Erythrocyte sedimentation rate (ESR).|An erythrocyte sedimentation rate (ESR) is a blood test that that can show if you have inflammation in your body. Inflammation is your immune system\&#39;s response to injury, infection, and many types of conditions, including immune system disorders, certain cancers, and blood disorders.
218922850|NCT06593990|DEVICE|x ray of the hand|The X-ray may show a hand with advanced rheumatoid arthritis. \&#34;Bone erosion\&#34; means cartilage and bone are worn away. \&#34;Bone displacement\&#34; means that a bone has moved out of its normal position. This X-ray shows how bone erosion and bone displacement can change the shape of the hand.
218922851|NCT06591650|DRUG|gemcitabine hydrochloride|800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
218922852|NCT06591650|DRUG|Cisplatin|25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.
218922853|NCT06591650|DRUG|Nab-paclitaxel|100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
218922854|NCT06591650|DRUG|Durvalumab|1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.
218922855|NCT06590311|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability evaluation through different domains
218922856|NCT06602284|COMBINATION_PRODUCT|Dermapen 4™|Dermapen 4™ conjunction with MG-CLR
218922857|NCT06586450|DEVICE|Low level laser therapy|The participants will receive Low Level Laser on lumbo-pelvic region for 20 min/sessions,3 sessions / week for 12 weeks, with the following parameters: Wavelength: 808 nm, continuous mode, Output power: 160 mw, Penetration depth: 4 cm, Power density:0.16 J/cm2.
218922858|NCT06586450|DEVICE|Interferential current|All participants will receive interferential current on lumbopelvic region ( quadripolar technique) for 25 min/session, 3 sessions/week for 12 weeks, with the following parameters: carrier frequency of 4 KHZ and sweep frequency 95 HZ, intensity based on patient's tolerance without muscle contraction.
218922859|NCT06586450|OTHER|Core stability exercise|The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.
218922860|NCT06601881|OTHER|Experimental|"Thoracic mobilization exercises will include:~1. Thoracic Spine Extension exersice~2. Thoracic rotation exersice~3. Cat-Camel Exercise~4. Lateral Flexion of the Thoracic Spine~5. Muscules Psoas Stretching~6. Diaphragm Release Technique~Diaphragmatic Breathing Training will include:~1. Diaphragmatic Breathing~2. Crocodile Breathing Technique~3. Breathing with an exercise band~4. Pursed lip breathing"
219536985|NCT04938635|DRUG|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
219536986|NCT04938635|DRUG|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
219536987|NCT04938635|DRUG|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
219536988|NCT04938635|DRUG|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
218922861|NCT06601881|OTHER|Control (placebo) group|"Placebo Thoracic mobilization exercises will include:~1. Placebo Thoracic Spine Extension exersice~2. Placebo Thoracic rotation exersice~3. Placebo Cat-Camel Exercise~4. Placebo Lateral Flexion of the Thoracic Spine~5. Placebo Muscules Psoas Stretching~6. Placebo Diaphragm Release Technique~Placebo Diaphragmatic Breathing Training will include:~1. Placebo Diaphragmatic Breathing~2. Placebo Crocodile Breathing Technique~3. Placebo Breathing with an exercise band~4. Placebo Pursed lip breathing"
219536989|NCT02573441|BEHAVIORAL|Jump Math|Jump Math is a workbook based program aimed at improving math skills
219536990|NCT02573441|BEHAVIORAL|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
219536991|NCT02573441|BEHAVIORAL|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
219536992|NCT01837810|DRUG|Ibuprofen|800mg every 8 hours as needed for pain
219536993|NCT06561672|DRUG|tramadol plus paracetamol|Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
219536994|NCT06561672|DRUG|Fentanyl|Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
219536995|NCT06561672|DRUG|propofol and muscle relaxant (cisatracurium)|propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
219536996|NCT06561672|DRUG|Propofol|propofol 2mg/kg
219536997|NCT03797703|DRUG|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
219619181|NCT07079930|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to assess baseline mood and to rule out depressive symptoms.
219619182|NCT07079930|OTHER|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory (STAI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to screen for anxiety disorders.
219619183|NCT07079930|BEHAVIORAL|Profile of Mood States|"The Profile of Mood States (POMS) will be administered to assess baseline mood and emotional state.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
219536998|NCT03868891|DEVICE|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
219536999|NCT02115165|DRUG|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
219537000|NCT03835286|DRUG|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
219537001|NCT03835286|DRUG|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
219537002|NCT00681798|DRUG|Vandetanib|100mg/300mg
219537003|NCT06508905|OTHER|Sleep buddy|The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
219537004|NCT03123094|DRUG|Spesolimab|single dose
219537005|NCT03123094|DRUG|Placebo|single dose
219537006|NCT06459765|DEVICE|Mi2000 TICI|Cochlear Implantation
219537007|NCT05125406|BEHAVIORAL|Exposure therapy with Virtual Reality.|Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
218922862|NCT06604182|OTHER|Community-based Simplified HCV Testing and Treatment Algorithm|The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
218922863|NCT06588517|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
218922864|NCT06588517|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
218922865|NCT06600529|DEVICE|Photo-Biomodulation|Application at acupuncture points for 20 seconds each week. using 810nm Laser probe
218922866|NCT06600529|BIOLOGICAL|Autologous PRP|IV injection of Autologous Plasma Rich Platelets (PRP) on Days 0, 15, 30, and 45.
218922867|NCT06600529|BIOLOGICAL|Exosome Therapy|IV injection of Umbilical Cord-Derived Exosomes at laser acupuncture points Umbilical Cord-Derived Exosomes
218922868|NCT06600529|OTHER|Standard Care (in control arm)|Routine conventional including Applied Behavioral Analysis (ABA) for Autism Spectrum Disorder (ASD)
218922869|NCT06588127|BEHAVIORAL|nudge|Nudge interventions are developed based on the scoping review and qualitative research by the research team, which involves commitment (behavioral contracts), norms (case and experience sharing), significance and framing effects (posters, health behavior identification posts), reminders, and incentives (arteriosclerosis detection). The content encompasses diet, physical activity, medication management, self-monitoring, and control of smoking and alcohol. From the viewpoint of bounded rationality in behavioral economics, and drawing on prior research that has pinpointed decision-making biases in patients' self-management behaviors, nudging strategies have been developed to assist individuals in overcoming these biases or to utilize the patterns of these biases to steer them toward making choices that are in line with their health.
218922870|NCT06402773|DEVICE|The Signati Separo™ Vessel Sealing System|Vessel Sealing System
219204839|NCT06977815|BEHAVIORAL|VR-Enhanced Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises, enhanced with 15-20 minutes of immersive virtual reality (VR) content per session. The VR component targets memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks.
219204840|NCT06977815|BEHAVIORAL|Standard Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises targeting memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks. No VR content is included.
219537008|NCT06129539|DRUG|Debio 4326|Administered as an intramuscular (IM) injection
219537009|NCT01154374|DRUG|MEBO Wound Ointment|Topical application twice daily
219537010|NCT01154374|PROCEDURE|Standard of Care (sterile saline moistened gauze)|
219537011|NCT06454864|BEHAVIORAL|Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
219537012|NCT06454864|BEHAVIORAL|Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
219537013|NCT06454864|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
219537014|NCT04731246|OTHER|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
219537015|NCT05809973|DIAGNOSTIC_TEST|VISA tool|Validation of VISA
218922871|NCT06993025|DRUG|Ivonescimab+chemotherapy|"Dosing Schedule:~1. Ivonescimab: 20 mg/kg, Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~2. Irinotecan Liposome: 70 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~3. Calcium Folinate (LV): 400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~4. 5-FU: 2400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W)."
218922872|NCT06993259|DEVICE|Virtual Reality|Children in the virtual reality (VR) group watched a 360° Ice Age video via headset starting three minutes before and continuing throughout the allergy test. The video, selected by pediatric experts, was age-appropriate, visually rich, and emotionally neutral. VR provided immersive distraction to reduce pain, fear, and anxiety. After the test, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction through structured forms.
218922873|NCT06993259|DEVICE|Serious game|Children in the serious game group played Subway Surfers on a tablet starting three minutes before and continuing throughout the skin prick test. The game was chosen by pediatric experts for its age-appropriateness and ability to sustain attention without overstimulation. As a fast-paced, interactive tool, it served as an effective distraction to reduce pain, fear, and anxiety. After the procedure, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction using structured feedback forms.
218922874|NCT06993311|DEVICE|Xen Gel Stent implantation|Consecutive patients who underwent either stand-alone Xen stent insertion with MMC(mitomycin C) or combined phacoemulsification between 2018 and 2022
218922875|NCT06866431|PROCEDURE|Piezoclean|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group.Test group sites will receive 90 seconds of ultrasonic cavitation treatment with 0.9% sodium chloride via a specific insert (Piezoclean, Esacrom, Imola, Italy) driven by a piezoelectric device with the following modalities: i) piezo settings: SURGERY 1 U 040 V 080 P 100; ii) no pressure should be applied to prevent the steel insert from coming into contact with the bone; iii) do not create a complete seal to avoid heating the liquid, which could cause potential discomfort or harm to the patient.~An X suture will be then applied using non-resorbable synthetic monofilament."
219204841|NCT06737471|OTHER|Intensive rehabilitation treatment|"A 3-hour daily rehabilitation treatment will be delivered to each patient 5 days a week for 5 weeks (45 hours) in the care units of the Hospital.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
219204842|NCT06737471|OTHER|Extensive rehabilitation treatment|"A 3-hour weekly rehabilitation treatment will be delivered to each patient for 15 weeks (45 hours) in an outpatient setting.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
219537016|NCT03590652|DRUG|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
219537017|NCT03590652|DRUG|Pomalidomide|4mg days PO 1-21/28 days
219537018|NCT03590652|DRUG|Dexamethasone|"40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg"
219537019|NCT03590652|DRUG|Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)|1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
219537020|NCT04762498|BIOLOGICAL|Pegloticase|IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
219204843|NCT06644690|BEHAVIORAL|CO-OP with Creative Dance|The CO-OP with Creative Dance intervention integrates the Cognitive Orientation to daily Occupational Performance (CO-OP) approach with structured creative dance sessions. The CO-OP approach focuses on improving cognitive and functional performance through goal-setting, problem-solving, and the use of metacognitive strategies. Creative dance sessions involve simple, rhythmic movements aimed at enhancing motor coordination, memory, and attention. This intervention is administered three times per week for 60 minutes over 8 weeks. The sessions alternate between CO-OP activities and creative dance exercises.
219537021|NCT04762498|DRUG|Methotrexate (MTX)|15 mg oral dose methotrexate administered weekly
219537022|NCT06409455|BEHAVIORAL|Positive Dementia Caregiving in 30 Days|Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
219537023|NCT06494462|OTHER|virtual reality training|students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
219537024|NCT06148584|BEHAVIORAL|General, status-neutral HIV education|General, status-neutral HIV education
219537025|NCT06148584|DIAGNOSTIC_TEST|HIV self-test kits|HIV self-test kits
219537026|NCT06148584|OTHER|Information about where to receive HIV prevention services|Information about where to receive HIV prevention services
219537027|NCT06148584|BEHAVIORAL|Barber-led peer support group education|Barber-led peer support group education
219537028|NCT06148584|BEHAVIORAL|Facility-based HIV risk reduction counseling|Facility-based HIV risk reduction counseling
219537029|NCT06148584|DIAGNOSTIC_TEST|Facility-based HIV testing|Facility-based HIV testing
219537030|NCT06148584|OTHER|Information about facility distributed HIV self-test kits|Information about facility distributed HIV self-test kits
219537031|NCT06148584|DIAGNOSTIC_TEST|STI testing|STI testing
219537032|NCT04218331|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
219537033|NCT04218331|BEHAVIORAL|PROMPT|PROMPT is a multidimensional oral-motor approach to speech production disorders.
219537034|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
219537035|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
218922876|NCT06866431|PROCEDURE|Control|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group. In control group, a simple 0.9% sodium chloride irrigation (control group) will be performed.~An X suture will be then applied using non-resorbable synthetic monofilament."
218922877|NCT06599801|PROCEDURE|Thoracodorsal artery perforator flap reconstruction surgery|Oral squamous cell carcinoma patients underwent reconstruction with thoracodorsal artery perforator (TDAP) flaps following tumor resection.
218922878|NCT06599801|PROCEDURE|Forearm flaps reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
218922879|NCT06599801|PROCEDURE|Anterolateral thigh flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection
218922880|NCT06599801|PROCEDURE|Fibula flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with fibula flaps after tumor resection
218922881|NCT06599801|PROCEDURE|Forearm flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
218922882|NCT06633588|DRUG|Polyhexanide|Participants will apply Prontoderm® Nasal Gel and perform whole-body wash with Prontoderm® Foam daily for 5 days before surgery.
218922883|NCT06633588|DRUG|Mupirocin and Chlorhexidine|Participants will apply Bactroban® Nasal ointment and perform whole-body wash with Lifo-Scrub® daily for 5 days before surgery.
218922884|NCT06706401|DRUG|Vesanoid|Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
218922885|NCT06706401|RADIATION|Standard radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
218922886|NCT06706401|RADIATION|Tailored radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 weeks (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
218922887|NCT06706401|DRUG|Cisplatin|"Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks)."
219619184|NCT07079930|BEHAVIORAL|Subjective Units of Distress Scale|"Subjective Units of Distress Scale (SUDS) will be administered to assess anxiety and stress levels.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
219619185|NCT07079930|OTHER|Five-Dimensional Altered States of Consciousness questionnaire|"The Five-Dimensional Altered States of Consciousness questionnaire (5D-ASC) will be used to assess the acute subjective psychedelic experience. It will be administered after the acute effects have subsided - at 6.0 hours post-administration on the administration day, and again on day 2 - to evaluate five key experiential dimensions: visual restructuralization, oceanic boundlessness, reduction of vigilance, anxious ego dissolution, and auditory alterations. Each item will be rated using a Visual Analogue Scale (VAS) ranging from NO, not more than usually (0 mm) to YES, much more than usually (100 mm)."
218922888|NCT06706401|DRUG|Cetuximab|"Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2."
218922889|NCT06714682|PROCEDURE|Modified Pectoral Plane block group|The patient will lay supine with the ipsilateral arm abducted and externally rotated and the elbow flexed at 90 degrees. The probe will be placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe will be pushed 1-2 cm caudally and medially. In a caudal tilt, within a biconvex space, the artery will be recognised. After that, the block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25 bupivacaine.
218922890|NCT06714682|PROCEDURE|Erector spinae plane block group.|The block will be performed with the patient in a sitting position , The high-frequency linear probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes identified, the block needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle, 20 mL of 0.25% bupivacaine will be administered for block performance.
219537036|NCT06133972|DRUG|Placebo|Placebo s.c. monthly
219537037|NCT06133972|DRUG|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
219537038|NCT06177665|OTHER|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
219619186|NCT07079930|BEHAVIORAL|Integration|The integration process is conducted to support participants in processing and incorporating their therapeutic experience into daily life, with the aim of enhancing emotional insight and psychological well-being. Integration will take place at the following visits: 8.0 hours post-treatment on the administration day, day 2, day 7, day 28, and day 84.
219619187|NCT07078136|DIAGNOSTIC_TEST|Multimodal AI Model|Patients' endoscopic images, EUS images, and clinical data will be analyzed by a multimodal AI model for lesion classification and GIST risk stratification.
219619188|NCT07078136|DIAGNOSTIC_TEST|Expert Endoscopist Assessment|Endoscopic ultrasound images will be interpreted by experienced endoscopists for comparison with the AI model.
219204844|NCT06644690|BEHAVIORAL|CO-OP Only|The CO-OP Only intervention involves the Cognitive Orientation to daily Occupational Performance (CO-OP) approach, which is designed to improve cognitive and functional performance through structured goal-setting, problem-solving, and metacognitive strategies. Participants engage in activities focused on improving their ability to perform daily tasks by using cognitive tools to develop and execute solutions. The intervention is administered three times per week for 60 minutes over an 8-week period. No additional physical or dance activities are included in this arm.
219204845|NCT06852560|BEHAVIORAL|Gratitude, exercise, and mindfulness program|"Participants will be enrolled in an 8-week GEM (Gratitude, Exercise, and Mindfulness) program conducted entirely in person at Blossoming Butterfly in Gainesville, Florida. Participants will attend weekly group sessions combining gratitude journaling, mindfulness-based stress reduction/emotional freedom technique, and physical activity goal-setting. Participants will also be provided with a toolkit to support at-home practices, including gratitude journaling, physical activity tracking, and mindfulness meditation.~Blood, saliva and urine will be collected from each participant at baseline and post-intervention to measure the following allostatic load biomarkers: fasting glucose or hemoglobin A1c; lipid panel (total cholesterol, LDL, HDL); C-reactive protein; dehydroepiandrosterone sulfate; cortisol; glomerular filtration rate; and albumin-to-creatinine ratio."
219537039|NCT06177665|OTHER|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
219537040|NCT04773522|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219619189|NCT07079631|BIOLOGICAL|BNT314|Intravenous (IV) infusion
219619190|NCT07079631|DRUG|BNT327|IV infusion
219619191|NCT07079631|DRUG|SoC chemotherapy treatment 1|IV infusion / IV bolus
219619192|NCT07079631|DRUG|SoC chemotherapy treatment 2|IV infusion / IV bolus / oral
219619193|NCT07079631|DRUG|Bevacizumab|IV infusion
219537041|NCT05113641|DIETARY_SUPPLEMENT|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
219619194|NCT05204927|DRUG|177Lu-PSMA-I&T|Radioligand therapy
219619195|NCT05204927|DRUG|Abiraterone with Prednisone or Enzalutamide|Hormone Therapy
218922891|NCT06705400|BEHAVIORAL|Multi-behavioural|The Bloom Study is implemented in an existing and highly accepted health service delivered by community health nurses. Beyond focusing on food, meals, motor skills and movement, the intervention also target sleep and family sense of security. The intervention commence in pregnancy and continues until the child is 2½ years old.
219619196|NCT07082608|DEVICE|Endoscopic Sleeve Gastropathy|"Weight loss through diet, exercise, and behavioural changes positively impacts sleep quality. Reduction in body weight can alleviate OSA symptoms and improve overall sleep architecture1,2,3 Surgical weight loss procedures play a crucial role in managing obesity-related health issues, including OSA.4 Endobariatric procedures, including Endoscopic Sleeve Gastroplasty (ESG), have gained attention as a weight loss solution with the potential for improving obesity-related health issues.~ESG involves suturing the stomach to reduce its size, limiting food intake. Unlike traditional bariatric surgeries, ESG doesn't require incisions. ESG has shown promise in achieving clinically significant weight loss, up to 20% of TBWL. By reducing stomach capacity, it promotes satiety and calorie restriction. ESG is generally safe, with fewer complications compared to more invasive procedures"
219619197|NCT07082608|OTHER|Lifestyle Modification alone|Participants will follow a structured program involving a low-calorie diet (typically 1200-1500 kcal/day), regular physical activity (150 minutes of moderate-intensity exercise per week), and behavioural therapy sessions.
218922892|NCT06706024|OTHER|breathing exercise|Patients Under Hemodialysis
218922893|NCT06705699|PROCEDURE|Urethral mobilisation|Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
219537042|NCT05113641|DRUG|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the dispensed by the clinic/hospital pharmacies.
218922894|NCT06705699|PROCEDURE|Mathieu|Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
218922895|NCT06705751|DIAGNOSTIC_TEST|Autonomic response in AAOCA|"Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited.~Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch.~The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions."
218922896|NCT06706128|OTHER|reflex rolling technique|received reflex rolling technique for 20 min, 5 days a week, for 2 weeks.
218922897|NCT06706128|OTHER|lung squeezing technique|lung squeezing technique for 20 min, 5 days a week, for 2 weeks
218922898|NCT06705114|PROCEDURE|complete denture|Each patient received a newly constructed conventional complete denture with optimal denture extension and lingualized balanced occlusal concept
218922899|NCT06705114|PROCEDURE|implant overdenture|Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.After 3-4 months, the dental implants were exposed and ball abutments were screwed into the implants. The housing of the ball attachments were incorporated into the fitting surface of the mandibular denture using a direct pick-up technique (Fig. 1B). The mandibular overdenture was then inserted into the patient's mouth and occlusal adjustment was done using articulating paper to remove any occlusal interferences. Follow-up visits were scheduled.
218922900|NCT06743256|DEVICE|Surgical System|Levita Magnetic Surgical System
219204846|NCT05570149|DRUG|Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution|migraine prophylaxis
219204847|NCT06655688|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
219204848|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
219537043|NCT05874375|DEVICE|Urge stimulation|Participants will receive stimulation for 60 seconds, when they feel an urgency.
219537044|NCT05874375|DEVICE|Time limited stimulation|Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
219537045|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as standalone therapy and another minimum of approximately 15 patients will receive ECCO2R using PrismaLung+ in combination with CRRT.
219537046|NCT06065150|PROCEDURE|Standard support|See arm/group descriptions
219537047|NCT06065150|PROCEDURE|Early surgery proposed according to the radiological score|"* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
219537048|NCT06562426|BEHAVIORAL|Descriptive group on vitamin D awareness|300 mothers of under-five children will be recruited in the descriptive study to assess their awareness about vitamin D and observe children for their health status outcome. Three tools will be used which are; sociodemographic characteristics of children and their mothers, Mothers' Awareness of Vitamin D Structured Interview Schedule, and Health Status Outcomes of Under- Five Years Children. Permission to conduct the study will be obtained from the administrative authorities of the settings after an explanation of the aim of the study. Each mother will be interviewed individually to obtain characteristics of mothers and their children, as well as knowledge and performance regarding Vitamin D. Each child will be observed for the manifestation of vitamin D deficiency and to measure their weight and height.
219537049|NCT03674489|OTHER|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
219619198|NCT07112807|OTHER|Strengthening Exercises|Strengthening exercises targeting the middle and lower trapezius and serratus anterior muscles will be performed. The program will progress by increasing the number of exercises and the amount of resistance.
219619199|NCT07112807|OTHER|ShoulderSphere Exercises and Resistive Exercises|In addition to strengthening exercises, exercises will be performed using the ShoulderSphere in the frontal, sagittal and transverse planes with the shoulders in 90° flexion and the elbows in extension.
219619200|NCT07112807|OTHER|Bodyblade Exercises and Resistive Exercises|In addition to strengthening exercises, 15 minutes of exercises using the Bodyblade will be performed. Individuals will perform oscillation exercises in the frontal, sagittal, and transverse planes while holding the Bodyblade bar firmly with their shoulders in 90° flexion and elbows in extension.
219619201|NCT01804790|DRUG|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
218922901|NCT06775002|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period. 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
219537050|NCT03674489|OTHER|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
218922902|NCT06764407|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery and intraoperative period.
218922903|NCT06764407|OTHER|No Music|Patients will not listen to music.
218922904|NCT06786676|DRUG|AS-S603|Oral administration of AS-S603 tablet
219204849|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
219204850|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
219204851|NCT05088356|DRUG|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10\^6 cells/ kg to 3x10\^6 cells/kg"
219537051|NCT03674489|OTHER|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
219537052|NCT02544386|PROCEDURE|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
219537053|NCT03944447|DRUG|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
219537054|NCT03944447|DEVICE|RYAH-Medtech Inhaler|Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
219537055|NCT05752734|DRUG|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
219619202|NCT01804790|RADIATION|Radiotherapy 50 Gy|5 radiations per week of 2 Gy for 5 weeks
219619203|NCT01804790|DRUG|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
219619204|NCT01804790|PROCEDURE|TME surgery|
219204852|NCT05088356|DRUG|Fludarabine|Fludarabine (160 mg/m2)
219204853|NCT05088356|DRUG|Melphalan|Melphalan (50 mg/m2)
219204854|NCT05088356|DEVICE|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
219204855|NCT05088356|DRUG|Tacrolimus|4-6ng/mL
219204856|NCT05088356|DRUG|Cyclophosphamide|40mg/kg
219204857|NCT05088356|DRUG|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
219204858|NCT05088356|DRUG|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
219204859|NCT05088356|DRUG|Thiotepa|Thiotepa 10 mg/kg
219204860|NCT05088356|DRUG|Mycophenolate Mofetil (MMF)|MMF 1000 mg BID
218922905|NCT06786676|DRUG|Placebo|Oral administration of Placebo tablet
218922906|NCT06810609|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Surgical removal of the tumor in patients with resectable or borderline resectable NSCLC
218922907|NCT06810609|RADIATION|Chemoradiotherapy|Chemoradiotherapy
218922908|NCT06810609|DRUG|Immunotherapy|Immunotherapy (Durvalumab).
218922909|NCT06822257|DRUG|Alcohol beverage|moderate dose of alcohol
218922910|NCT06822257|OTHER|Non-alcohol beverage|No alcohol given
218922911|NCT03294707|DRUG|AG10 oral tablet|Active single ascending dose
218922912|NCT03294707|DRUG|Placebo Oral Tablet|Placebo single dose
219537056|NCT05752734|DRUG|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
219537057|NCT03743961|OTHER|geriatric intervention|Geriatric intervention
219537058|NCT04477005|DEVICE|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
219537059|NCT05178927|DEVICE|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
219537060|NCT03126747|DRUG|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
218922913|NCT06911372|DRUG|Intradermal Microdialysis|A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site). After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow with sodium nitroprusside.
218922914|NCT06911372|OTHER|Brain Blood Flow Tests|Participants will complete CO2 breathing procedures to evaluate brain blood vessel health.
218922915|NCT06911372|OTHER|Local Heating|A dime-sized heater will be placed on the skin to evaluate cutaneous microvascular function
218922916|NCT06351124|BIOLOGICAL|Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's|Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.
219204861|NCT05088356|DRUG|Ruxolitinib|Ruxolitinib 5 mg BID
219537061|NCT00276926|DRUG|STI571|
219619205|NCT01804790|DRUG|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
219619206|NCT07085273|DRUG|Irinotecan Liposomal|FOLFIRINOX + Karelizumab Irinotecan liposomal: 60 mg/m2, IV infusion, d1; 5-FU: 400 mg/m2, IV infusion, d1, followed by 1200 mg/m2/d x 2 days of continuous IV infusion (total 2400 mg/m2, 46-48h infusion); Calcium folinate: 400 mg/m2, IV infusion, d1; Oxaliplatin: 85 mg/m2, IV infusion, d1; Karelizumab: 200 mg, IV infusion, d1; Repeat every 2 weeks.
219619207|NCT05160532|DRUG|Placebo|5ml of normal saline (NS)
219537062|NCT00678717|PROCEDURE|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
219537063|NCT05247463|OTHER|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
219619208|NCT05160532|DRUG|Dextrose prolotherapy (DPT)|25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
219619209|NCT07076329|DIETARY_SUPPLEMENT|Ambrosia bar|"The experimental intervention involves the AMBROSIA bar alongside healthy dietary counseling.~The AMBROSIA bar is a novel chocolate bar designed for older Heart Failure (HF) and Atrial Fibrillation (AF) patients to prevent undernutrition. Its distinguishing features are:~* Unique Composition: It contains a unique and specific blend of probiotic strains and a cocktail of micro/macronutrients.~* Patented Probiotic Efficacy: The SYNBIO® blend is patented (RM2004A000166, EP1743042) for its exceptional intestinal mucosal adhesion, ensuring effective colonization and persistence.~* Optimal Delivery Matrix: The chocolate bar serves as a palatable and effective vehicle for probiotic delivery, confirmed to maintain probiotic viability.~* Targeted Nutritional Strategy: The bar aims to modulate gut microbiota and address undernutrition, inflammation, and cachexia in the target."
219619210|NCT07087184|BEHAVIORAL|Whole Milk-Skim Milk|If randomized to the whole milk-skim milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only whole milk for the first 2 months and to only skim milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
218922917|NCT06519942|DIAGNOSTIC_TEST|Blood sampling|Fasting blood samples will be obtained.
218922918|NCT06519942|DIAGNOSTIC_TEST|Electromyoneurography (EMNG)|Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
218922919|NCT06519942|PROCEDURE|Muscle biopsy|Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
219537064|NCT05247463|OTHER|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
218922920|NCT06519942|RADIATION|Quantitative peripheral computed tomography (qPCT)|A qPCT scan of the calf will be performed.
218922921|NCT06519942|DEVICE|Mechanography|Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
218922922|NCT06519942|DIAGNOSTIC_TEST|Electrocardiography (ECG)|A 15-minute resting ECG will be performed.
218922923|NCT06519942|OTHER|Questionnaires|Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
218922924|NCT06519942|OTHER|Anthropometry|Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.
219537065|NCT05247463|DIAGNOSTIC_TEST|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
219537066|NCT03670017|DEVICE|OptiScanner® 5000 Glucose Monitoring System|The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
218922925|NCT05174221|DRUG|Mezagitamab|TAK-079 subcutaneous injection.
218922926|NCT06827717|DRUG|irinotecan liposome (II) + temozolomide + fluzoparib|"Drug Irinotecan Hydrochloride Liposome Injection（II）56.5mg/m2, IV infusion administered on day 1 of every 28-day cycle until disease progression, unacceptable toxicity or death. Other names: HR070803.~Drug Fluzoparib 50mg PO bid, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle. Other names: SHR-3162.~Drug Temozolomide 30mg/m2 PO qd, administered on day 1 to day 5 of every 28-day cycle until disease progression, unacceptable toxicity or death."
218922927|NCT06412159|OTHER|Selective laser melting framework was fabricated using completely digital workflow|completely digital work flow Conventional technique versus complete digital technique
219537067|NCT00673647|BEHAVIORAL|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
218922928|NCT06921551|DEVICE|ABLE Exoskeleton|Participants will undergo 60-min gait training sessions with the exoskeleton once a week for up to12 months
218922929|NCT06915142|DRUG|HRS-7058 + SHR-1316|HRS-7058 + SHR-1316
218922930|NCT06915142|DRUG|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
218922931|NCT06915142|DRUG|HRS-7058 + Cetuximab|HRS-7058 + Cetuximab
218922932|NCT06915142|DRUG|HRS-7058 + SHR-1826|HRS-7058 + SHR-1826
219204862|NCT06589674|DIAGNOSTIC_TEST|Pulse variability index measurement|Peripheral perfusion index (PI) is an easy-to-implement and low-cost monitoring procedure obtained by interpreting non-invasive data obtained from pulse oximetry via plethysmography. It is a tool that allows interpretation of fluid status through changes in pulse oximetry waves caused by respiration. High perfusion indices are interpreted as low arterial tone. Changes in perfusion index are interpreted as indicators of vascular tone or fluid deficit problems in patients. The ratio of the highest and lowest PI values gives the Pleth Variability Index (PVI) (3,4). Hypotension can be predicted during anesthesia induction with PVI
219537068|NCT04613258|DIETARY_SUPPLEMENT|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
219537069|NCT04613258|OTHER|Counseling|21 subjects in the control group (C) who only received dietary counseling
218922933|NCT06915142|DRUG|HRS-7058 + SHR-1826 + SHR-1316|HRS-7058 + SHR-1826 + SHR-1316
218922934|NCT06331819|DIAGNOSTIC_TEST|In-lab polysomnography|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
218922935|NCT06331819|DEVICE|Continuous positive airway pressure|A machine that uses air pressure to keep breathing airways open while patients sleep.
218922936|NCT06331819|DIAGNOSTIC_TEST|Home sleep study device|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
218922937|NCT06917287|DIETARY_SUPPLEMENT|Native CT-II® (undenatured type II collagen)|"Strength: 40 mg in 3 capsules~Dose Regimen:~3 yellow capsules containing MCC after breakfast with water 3 blue capsules containing 40 mg Native CT-II® \& MCC after dinner with water Route of administration: Oral"
218922938|NCT06917287|DIETARY_SUPPLEMENT|Glucosamine HCL + Chondroitin Sulphate (G+C) [Comparator]|2700 mg (1500 mg G + 1200 mg C) 3 yellow capsules containing G+C orally after breakfast with water \& 3 blue capsules containing G+C after dinner with water
218922939|NCT06917287|DIETARY_SUPPLEMENT|Placebo [Microcrystalline Cellulose (MCC)|2700 mg excipient 3 yellow capsules containing MCC orally after breakfast with water 3 blue capsules containing MCC after dinner with water.
218922940|NCT06936566|DRUG|Ruxolitinib|Ruxolitinib twice daily for 56 days followed by a short taper Given orally
218922941|NCT06936566|DRUG|Methylprednisolone|Starting dose 2 mg/kg/d for at least three days, then taper Given IV or orally
218922942|NCT02633059|DRUG|Dexamethasone|Given PO
218922943|NCT02633059|DRUG|Idasanutlin|Given PO
218922944|NCT02633059|DRUG|Ixazomib Citrate|Given PO
218922945|NCT02633059|OTHER|Laboratory Biomarker Analysis|Correlative studies
218922946|NCT02633059|OTHER|Pharmacological Study|Correlative studies
219537070|NCT04741620|OTHER|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
218922947|NCT06507774|DEVICE|3D Reconstruction Technology|Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.
218922948|NCT06507774|DEVICE|No 3D reconstruction is used|This group did not use 3D reconstruction for surgical navigation
218922949|NCT06819852|OTHER|Acute hospital care at home|Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.
218922950|NCT06819852|OTHER|Standard medical treatment|Standard acute and emergency care delivered in a brick-and-mortar hospital setting.
218922951|NCT06952140|DIETARY_SUPPLEMENT|Ketone ester|Ketone ester: 3-hydroxybutyrate as enteral bolus (500 mg/kg)
218922952|NCT06952140|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isovolumic and isocaloric placebo) as enteral bolus
218922953|NCT04730804|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
218922954|NCT04730804|DRUG|Placebo|Placebo will be administered as SC infusion(s).
218922955|NCT05825560|DRUG|OFA multimodal analgesia|Multimodal opioid free analgesia
219537071|NCT04741620|OTHER|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
219537072|NCT04741620|OTHER|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
218922956|NCT05825560|DRUG|Standard multimodal analgesia|Standard remifentanil analgesia
218922957|NCT04004364|OTHER|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
218922958|NCT04874246|DRUG|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
218922959|NCT00554216|DRUG|VI-0521|3.75 mg phentermine/23 mg topiramate
218922960|NCT00554216|DRUG|VI-0521|15 mg phentermine/92 mg topiramate
218922961|NCT00554216|DRUG|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
218922962|NCT01209416|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
218922963|NCT01209416|DRUG|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
218922964|NCT01209416|OTHER|Placebo|placebo tablets or saline infusion
218922965|NCT05194735|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"
218922966|NCT05194735|BIOLOGICAL|Aldesleukin (IL-2)|To support growth and activation of TCR-T cell drug product
218922967|NCT04704596|DEVICE|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
219537073|NCT04741620|OTHER|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
219537074|NCT04741620|OTHER|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
219537075|NCT04741620|OTHER|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
219537076|NCT00582673|DRUG|AFQ056|
219537077|NCT00582673|DRUG|Placebo|
219537078|NCT06372457|DRUG|Approved Hypertrophic Cardiomyopathy drug treatments|As per product label
219537079|NCT06372457|DRUG|Mavacamten|As per product label
219537080|NCT00835536|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
218922968|NCT04704596|DEVICE|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
218922969|NCT02721472|PROCEDURE|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
218922970|NCT02721472|PROCEDURE|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
218922971|NCT00549835|PROCEDURE|Real Acupuncture|
218922972|NCT00549835|PROCEDURE|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
219537081|NCT00835536|DRUG|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
219537082|NCT01141374|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
218922973|NCT04889638|OTHER|Cessation Intervention|"1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging"
218922974|NCT01096355|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
218922975|NCT01096355|OTHER|diagnostic laboratory biomarker analysis|
218922976|NCT01096355|OTHER|pharmacogenomic studies|
218922977|NCT01096355|OTHER|pharmacological study|
219537083|NCT01141374|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
219537084|NCT03173547|DRUG|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
219537085|NCT03173547|DRUG|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
219537086|NCT05945030|OTHER|Clinical Examination|T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
219537087|NCT00871247|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
219537088|NCT00871247|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
219537089|NCT00657553|DRUG|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
219537090|NCT04820920|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
219537091|NCT04820920|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
219537092|NCT04820920|BEHAVIORAL|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
219537093|NCT01196000|PROCEDURE|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
219537094|NCT01196000|PROCEDURE|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
218922978|NCT04590521|BIOLOGICAL|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
218922979|NCT05345899|DIAGNOSTIC_TEST|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
218922980|NCT05345899|OTHER|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
219537095|NCT01196000|PROCEDURE|quality-of-life assessment|Ancillary studies
219537096|NCT01196000|OTHER|questionnaire administration|Ancillary studies
219537097|NCT00520429|BEHAVIORAL|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
219537098|NCT03982030|DRUG|Dalbavancin|Dalbavancin 1.5g IV at day 0, day 8-10
219537099|NCT02691130|BIOLOGICAL|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
219537100|NCT02691130|BIOLOGICAL|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
219537101|NCT02691130|BIOLOGICAL|Saline|0.9% NaCl in double distilled water
219537102|NCT00446563|DRUG|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
219537103|NCT00446563|DRUG|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
218922981|NCT05147363|DEVICE|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
218922982|NCT00842335|DRUG|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
218922983|NCT00541541|PROCEDURE|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
219537104|NCT00446563|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
219537105|NCT00446563|DRUG|Losartan|100 mg tablets taken orally once daily in the morning.
218922984|NCT03570710|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
218922985|NCT03570710|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
218922986|NCT03570710|DRUG|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
218922987|NCT04764422|BIOLOGICAL|Normal Saline|0.9% normal saline for injection
218922988|NCT04764422|BIOLOGICAL|NDV-HXP-S vaccine|Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
218922989|NCT01715324|DRUG|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
219619211|NCT07087184|BEHAVIORAL|Skim Milk-Whole Milk|If randomized to the skim milk-whole milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only skim milk for the first 2 months and to only whole milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
219619212|NCT07094243|BEHAVIORAL|Motivational Psychotherapy|A structured short-term intervention based on motivational psychotherapy, delivered in individual sessions over 8 weeks to improve adolescent depression and academic self-concept.
219537106|NCT01202734|DRUG|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
219537107|NCT02403947|DRUG|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
219537108|NCT02403947|DRUG|Suspension media|injection suspension media
219537109|NCT03769025|BEHAVIORAL|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
218922990|NCT02532803|OTHER|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
218922991|NCT05132023|DRUG|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
219537110|NCT03769025|OTHER|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
219537111|NCT01169558|DRUG|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
219537112|NCT01169558|DRUG|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
219619213|NCT07096180|DRUG|Chemotherapy drug|Participants in the standard care group receive conventional chemotherapy for breast cancer according to clinical guidelines. Treatment includes 8 cycles of chemotherapy administered every 3 weeks. No Traditional Chinese Medicine (TCM) is provided in this group.
218922992|NCT05132023|DRUG|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
219537113|NCT03776058|DRUG|Cinacalcet|Tablets for oral administration
219619214|NCT07096180|OTHER|Integrative Treatment (Chemotherapy + TCM)|Participants in the integrative care group receive conventional chemotherapy combined with Traditional Chinese Medicine (TCM) treatment. Herbal formulas are prescribed by licensed TCM physicians based on syndrome differentiation and are aimed at strengthening vital qi and harmonizing stomach function. Treatment is conducted under Taiwan's National Health Insurance coverage.
218922993|NCT02153320|PROCEDURE|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
219619215|NCT07096791|DRUG|KH607 tablet|oral，once daily for 14 days
219619216|NCT07096791|DRUG|placebo|oral，once daily for 14 days
219619217|NCT07097636|OTHER|Video education|A video demonstrating the steps of the urodynamic procedure was shown, and afterward, participants' questions were answered by an experienced nurse who performed the procedure.
219619218|NCT07097636|OTHER|No intervention|Children scheduled to undergo urodynamic testing for any reason received the procedure without any prior video-based education being provided to their parents
219537114|NCT03776058|DRUG|Placebo|Tablets for oral administration
219537115|NCT06102213|DRUG|B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)|PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
219537116|NCT04532684|DRUG|Duloxetine|
219537117|NCT04532684|DRUG|Pregabalin|
219537118|NCT04211779|DEVICE|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
219537119|NCT04211779|DEVICE|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
218922994|NCT00220896|DRUG|Donepezil|
218922995|NCT02944149|PROCEDURE|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
218922996|NCT02368587|BIOLOGICAL|WJMSCs Vs. placebo|WJMSCs Vs. placebo
218922997|NCT02368587|BIOLOGICAL|Placebo|WJMSCs Vs. placebo
218922998|NCT00832299|DRUG|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
218922999|NCT00832299|PROCEDURE|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
218923000|NCT02732574|DEVICE|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
218923001|NCT02732574|DEVICE|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
219537120|NCT04211779|OTHER|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
219537121|NCT02184936|OTHER|standard of care|
219537122|NCT06321835|PROCEDURE|Endotracheal tube cuff pressure measurement|This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
219537123|NCT02702882|DIETARY_SUPPLEMENT|Fenugreek Seeds Extract|Furosap one caps OD
219537124|NCT00910221|DRUG|Atorvastatin|Atorvastatin tablet
219537125|NCT00910221|DRUG|Placebo|Placebo tablet
219537126|NCT02749266|OTHER|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
219537127|NCT02749266|OTHER|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
219537128|NCT06559358|DEVICE|electrical stimulation|A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
219537129|NCT01310257|OTHER|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
219537130|NCT04215705|PROCEDURE|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
219537131|NCT03251807|DEVICE|Twin-block|Functional treatment will be achieved using the Twinblock appliance
219537132|NCT03251807|OTHER|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
218923002|NCT00149266|PROCEDURE|Surgery: abdominal and transhiatal approach|
218923003|NCT00149266|PROCEDURE|Surgery: left thoraco-abdominal approach|
218923004|NCT03758053|OTHER|No intervention|No intervention
218923005|NCT03256461|BEHAVIORAL|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
218923006|NCT03256461|BEHAVIORAL|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
218923007|NCT03256461|BEHAVIORAL|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
218923008|NCT00165477|DRUG|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
218923009|NCT00165477|RADIATION|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
218923010|NCT02930824|GENETIC|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
219537133|NCT03077451|OTHER|Laboratory Biomarker Analysis|Correlative studies
219537134|NCT03077451|DRUG|Nelfinavir Mesylate|Given PO
219537135|NCT04188080|DIETARY_SUPPLEMENT|Jarlsberg Cheese|Oral daily intake of Jarlsberg cheese
219537136|NCT06562517|OTHER|Digital training module|The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
218923011|NCT01534702|DRUG|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
219537137|NCT03022786|OTHER|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
219537138|NCT03022786|OTHER|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
219537139|NCT03022786|OTHER|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
219537140|NCT04709081|DRUG|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
219537141|NCT04709081|DRUG|Midazolam|Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
218923012|NCT03586154|COMBINATION_PRODUCT|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
219537142|NCT04709081|DRUG|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
219537143|NCT04709081|DRUG|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
219537144|NCT04489641|BEHAVIORAL|Psychological treatment|Psychological treatment
219537145|NCT04489641|DRUG|Medication|Pharmacological intervention
219537146|NCT06556043|OTHER|cM1 transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
219537147|NCT06556043|OTHER|cPPC transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
219537148|NCT06556043|OTHER|iCBM transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
219537149|NCT06556043|OTHER|sham transcranial direct current stimulation|For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
219537150|NCT03916393|DRUG|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
219537151|NCT03916393|OTHER|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
219537152|NCT00852696|DRUG|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
219537153|NCT00852696|OTHER|Placebo|Take orally once daily for 9 weeks.
219537154|NCT02512900|DRUG|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
219537155|NCT02962752|DIETARY_SUPPLEMENT|Blackadder Juice|
219537156|NCT02962752|OTHER|Placebo|
219537157|NCT00031395|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
219537158|NCT00031395|DRUG|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
219537159|NCT00031395|OTHER|placebo|an inactive substance
219537160|NCT02409355|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
218923013|NCT03586154|DRUG|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
218923014|NCT02324192|OTHER|Ultrasonography|imaging findings
218923015|NCT06384014|DEVICE|retrograde and orthograde root canal filling|Apical resection application after root canal filling
218923016|NCT04558034|OTHER|cryotherapy|cryotherapy will be delivered
218923017|NCT03834181|DEVICE|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate"
218923018|NCT02431962|PROCEDURE|Computed Tomography|Low dose chest CT screening annually x 3
218923019|NCT02431962|BEHAVIORAL|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
219537161|NCT02409355|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
218923020|NCT02431962|BEHAVIORAL|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
218923021|NCT00183482|BEHAVIORAL|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
218923022|NCT00183482|BEHAVIORAL|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
218923023|NCT05136924|DRUG|OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo|OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo
218923024|NCT05136924|OTHER|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
218923025|NCT02459483|BEHAVIORAL|Nurse phone call|
218923026|NCT04986267|OTHER|ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
218923027|NCT06374628|PROCEDURE|breast reconstruction|breast reconstruction in two-stages using tissue expander entirely wrapped by acellular dermal matrix
218923028|NCT02298582|DRUG|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
218923029|NCT03283501|PROCEDURE|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
218923030|NCT00628108|DRUG|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
218923031|NCT00628108|OTHER|Placebo|Placebo oral liquid once a day for two weeks
218923032|NCT02540629|PROCEDURE|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
219537162|NCT02409355|DRUG|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m\^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
219537163|NCT02409355|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 (when coadministered with carboplatin) or 1250 mg/m\^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
218923033|NCT05756959|DEVICE|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
218923034|NCT05756959|DEVICE|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
218923035|NCT05756959|DEVICE|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
218923036|NCT02292589|DEVICE|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
218923037|NCT02292589|DEVICE|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
218923038|NCT02292589|DEVICE|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
218923039|NCT04617626|DRUG|Azithromycin|Single dose of azithromycin suspension
218923040|NCT00668278|DEVICE|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
218923041|NCT00668278|DEVICE|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
218923042|NCT00668278|OTHER|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
219537164|NCT02510391|BEHAVIORAL|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
219537165|NCT00838539|DRUG|Neratinib|
219537166|NCT00838539|DRUG|Temsirolimus|
219537167|NCT06563271|DRUG|Dexketoprofen Trometamol 50 Mg/mL Solution for Injection|Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
219537168|NCT06563271|DRUG|Ibuprofen 100 MG/ML Solution for Injection|"Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion)."
218923043|NCT01886066|BIOLOGICAL|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
218923044|NCT01737437|DRUG|group C|0.9% normal saline was applied to trachea and laryngoscope blade
218923045|NCT01737437|DRUG|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
218923046|NCT01737437|DRUG|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
218923047|NCT01737437|DRUG|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
218923048|NCT04840823|DRUG|Enoxacin|Oral 200mg tablet
218923049|NCT04840823|DRUG|Placebo|Oral tablet
218923050|NCT03074838|PROCEDURE|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
218923051|NCT03074838|PROCEDURE|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
218923052|NCT02538224|DRUG|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
218923053|NCT02538224|DRUG|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
218923054|NCT04202107|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
218923055|NCT04202107|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
218923056|NCT00693771|DRUG|Insulin Glargine|Once daily and up-titrate accordingly
218923057|NCT00193271|DRUG|Docetaxel|
218923058|NCT00193271|DRUG|Estramustine|
218923059|NCT03413488|OTHER|kinesio taping|Apply exercise and kinesio taping for intervention
219619219|NCT07095036|OTHER|Spinal cord stimulation (SCS)|After implantation of SCS trial leads - which is standard of care for evaluating whether SCS improves chronic pain - patients will visit clinic before the trial leads are explanted. During these visits, stimulation will be turned off and the leads will be disconnected from the clinical external pulse generator and reconnected to an external research stimulator. Patients will be seated in a chair and will interface with a touch-screen display where they will participate in a psychophysical task (a two-alternative forced-choice task). More specifically, the task will involve selecting between two options on a screen while spinal stimulation is delivered through the leads. As the patients perform the tasks, audio or video recordings will be made for future research analysis, education, or scientific communication. The research stimulator will also collect epidural signals through the stimulation leads.
219619220|NCT07095699|DEVICE|EndoSCell System|EndoSCell Scaner (ES) is a new type of intraoperative cell-level fluorescence-guided imaging technology that can be used for direct and rapid intraoperative tissue cell interpretation. This technology uses a handheld cell microscope system to magnify local tissue by about 1280 times, and can perform rapid real-time scanning and imaging of in vivo or excised ex vivo tissue.
218923060|NCT03413488|OTHER|exercise|Apply only exercise intervention
218923061|NCT05060029|DRUG|Lactobacillus Species|Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
218923062|NCT05060029|OTHER|Placebo|Coconut Oil Fatty Acids
218923063|NCT05731063|PROCEDURE|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
218923064|NCT03859310|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
219204863|NCT06589674|OTHER|Diastolic shock index|The Diastolic Shock Index (DSI) is a hemodynamic parameter calculated by dividing the heart rate (HR) by the diastolic blood pressure (DBP). It reflects the balance between cardiac output and systemic vascular resistance, particularly in critically ill patients. A higher DSI can indicate impaired vascular resistance and may be useful for predicting the need for vasopressor support, especially in conditions like septic shock. However, its application in predicting hypotension during anesthesia induction is still under investigation.
218923065|NCT04106752|DIETARY_SUPPLEMENT|Caffeine|Provide caffeine supplements with or without meal before exercise
219537169|NCT06563271|DRUG|Paracetamol 10 Mg/mL Solution for Injection|Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
219537170|NCT06563271|DRUG|isotonic saline|Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
219537171|NCT01255085|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
219537172|NCT01255085|DIETARY_SUPPLEMENT|yellow pea fiber|Served in a tomato soup
219537173|NCT01255085|DIETARY_SUPPLEMENT|Control Tomato Soup|Served in a tomato soup
218923066|NCT04199988|DIAGNOSTIC_TEST|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
218923067|NCT06030024|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
218923068|NCT03960996|PROCEDURE|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
218923069|NCT05971082|OTHER|Follow-up|Follow-up study of progression/remission of liver disease
218923070|NCT00588835|DRUG|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
219619221|NCT07095413|DIAGNOSTIC_TEST|Wesper Lab Home Sleep Apnea Test|Subjects will wear the Wesper Lab home sleep apnea tests, which includes 2 wireless sensors and a pulse oximeter.
219619222|NCT07096570|BEHAVIORAL|Selected Multisensory Training (SMST)|A 12-week supervised exercise program involving two 40-minute sessions weekly. The program includes proprioceptive challenges on progressively firmer surfaces, vestibular activation with gait drills and head movements, and visual tracking tasks. Intensity progresses every three weeks by increasing surface instability, adding handheld weights, and reducing visual input (eyes open to eyes closed). The intervention aims to improve neuromuscular activation, balance, and sensory integration in older women with diabetic peripheral neuropathy.
218923071|NCT00588835|DRUG|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
219537174|NCT04418349|PROCEDURE|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
219537175|NCT01704105|BEHAVIORAL|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
219537176|NCT01704105|BEHAVIORAL|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
219537177|NCT01704105|BEHAVIORAL|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
219537178|NCT01704105|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
219537179|NCT04349475|DIETARY_SUPPLEMENT|Intervention Omega 3 Supplementation|Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
219537180|NCT04349475|DIETARY_SUPPLEMENT|Control Safflower Oil|Participants will consume 2.5g of a Safflower oil supplement daily
219537181|NCT01908205|DRUG|Intranasal Oxytocin|
219537182|NCT01908205|DRUG|Placebo|
219619223|NCT07097142|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219619224|NCT07097142|DRUG|Cisplatin|Given IV
219619225|NCT07097142|DRUG|Gemcitabine|Given IV
219619226|NCT07097142|DRUG|Mitomycin|Given IV
219619227|NCT07097142|DRUG|Fluorouracil|Given IV
219619228|NCT07097142|PROCEDURE|Computed Tomography|Undergo CT scan
219619229|NCT07097142|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218923072|NCT05046561|DRUG|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
218923073|NCT05046561|DRUG|Placebo|Placebo oral capsule
218923074|NCT04237597|DRUG|K-877|K-877 tablets
218923075|NCT04237597|DRUG|CSG452|CSG452 tablets
218923076|NCT01154257|PROCEDURE|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
218923077|NCT01154257|PROCEDURE|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
218923078|NCT02024919|DRUG|intracoronary administration of diltiazem|
218923079|NCT02024919|DRUG|intracoronary injection of 5 mL saline|
218923080|NCT03071926|DRUG|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
218923081|NCT04099199|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
219619230|NCT07097142|PROCEDURE|Positron Emission Tomography|Undergo PET scan
218923082|NCT05684393|OTHER|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
218923083|NCT06519474|DEVICE|Theraband chest compression|Chest compression applicated via a Red Theraband over the upper or lower chest region
218923084|NCT02198404|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
218923085|NCT03200288|DEVICE|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
218923086|NCT03200288|DEVICE|Placebo|2 ml intra-articular single injection
218923087|NCT00736762|OTHER|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
218923088|NCT03501849|DEVICE|Polypectomy using a cold snare|Polypectomy by cold-snare technique
218923089|NCT03308071|BEHAVIORAL|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
219537183|NCT05528588|COMBINATION_PRODUCT|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
218923090|NCT03788252|DRUG|Renamezin|7 capsules once, three times a day, for 48 weeks
218923091|NCT01377103|DRUG|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
219537184|NCT05528588|DRUG|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
219537185|NCT04940312|BEHAVIORAL|App-based physical activity coaching|Individualized app-based coaching via a smartphone
219537186|NCT04940312|BEHAVIORAL|No Intervention: Observational Cohort|no Intervention
219537187|NCT04940312|BEHAVIORAL|Intervention Group 1|pedometer-based tracking of physical activity
219619231|NCT07097142|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and urine sample collection
219619232|NCT07097142|OTHER|Survey Administration|Ancillary studies
219619233|NCT06438575|DIAGNOSTIC_TEST|Xpert® Xpress MVP test|The Xpert® Xpress MVP is an FDA-cleared point-of-care test for vaginitis diagnosis
219619234|NCT06438575|DIAGNOSTIC_TEST|Usual Care|Usual methods used by the healthcare provider for vaginitis diagnosis
219619235|NCT03362372|BEHAVIORAL|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
219619236|NCT07097441|DRUG|Placebo drug ( normal saline )|At the end of surgery patients will be given placebo ( normal saline ) instead of neostigmine ( reversal agent of atracurium ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
218923092|NCT01377103|DRUG|Placebo|
218923093|NCT06282978|DRUG|Elranatamab (PF-06863135)|The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
218923094|NCT03106311|DIAGNOSTIC_TEST|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
218923095|NCT06383533|DRUG|Disitamab Vedotin Plus Cadonilimab|Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
218923096|NCT02192411|DRUG|Lidocaine|1/4 dose lidocaine
218923097|NCT02200406|DRUG|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
218923098|NCT03318302|OTHER|Survey|Survey of the adult population in Israel
218923099|NCT03766737|DEVICE|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
218923100|NCT03386383|BEHAVIORAL|Intervention|Individual session, physical activity tracker, online intervention
218923101|NCT02528552|DEVICE|LH80 PRO|
218923102|NCT02528552|DEVICE|Sham Device|
218923103|NCT02939443|RADIATION|supine- and prone-position Computed Tomography|
218923104|NCT03071042|DRUG|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
218923105|NCT03071042|DRUG|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
219537188|NCT03948503|PROCEDURE|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
219537189|NCT03948503|PROCEDURE|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
219537190|NCT04123080|DEVICE|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
219537191|NCT03182322|DRUG|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
219537192|NCT03182322|OTHER|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
219537193|NCT03134222|DRUG|Lanraplenib|30 mg tablets administered orally once daily with or without food
219619237|NCT07097441|DRUG|neostigmine (reversal agent)|At the end of surgery patients will be given neostigmine ( reversal agenr ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
219619238|NCT07097220|DRUG|General Anesthesia (GA) group|In the General Anesthesia (GA) group (n = 59), patients received combined intravenous-inhalation general anesthesia. Anesthesia induction was performed using propofol and remifentanil, followed by maintenance with sevoflurane to ensure adequate anesthetic depth and hemodynamic stability throughout the procedure.
218923106|NCT05928962|DRUG|Recombinant Human Adenovirus Type 5 Injection|"1. Recombinant Human Type 5 Adenovirus Injection:~   This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~2. PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
218923107|NCT03329638|DRUG|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
218923108|NCT03329638|DRUG|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
218923109|NCT03329638|DRUG|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
219537194|NCT03134222|DRUG|Filgotinib|200 mg tablets administered orally once daily with or without food
219537195|NCT03134222|DRUG|Lanraplenib placebo|Tablets administered orally once daily with or without food
219537196|NCT03134222|DRUG|Filgotinib placebo|Tablets administered orally once daily with or without food
219537197|NCT04046783|DEVICE|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
219537198|NCT00760825|BIOLOGICAL|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
219537199|NCT00906165|DEVICE|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
219537200|NCT01220362|DRUG|Bupivacain 0.125%|Bupivacain 0.125%
219537201|NCT01220362|DRUG|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
219537202|NCT03482882|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
219537203|NCT00627419|DRUG|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
219537204|NCT01270594|BEHAVIORAL|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
219537205|NCT01270594|BEHAVIORAL|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
219537206|NCT02620891|DEVICE|helium oxygen mixture|
218923110|NCT03329638|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
218923111|NCT05530564|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
218923112|NCT05530564|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
218923113|NCT00565292|DRUG|MK0859|
218923114|NCT00467116|BIOLOGICAL|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
218923115|NCT00467116|DRUG|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes"
218923116|NCT00467116|RADIATION|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions \> 3 days."
218923117|NCT04075032|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
218923118|NCT04075032|OTHER|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
218923119|NCT04808661|PROCEDURE|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
218923120|NCT04808661|DRUG|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
218923121|NCT00751608|DRUG|APL180|
218923122|NCT00751608|DRUG|APL180|
218923123|NCT00751608|DRUG|Placebo|
218923124|NCT05684211|DRUG|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
218923125|NCT05684211|DRUG|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
218923126|NCT05684211|DRUG|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
218923127|NCT05684211|DRUG|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
218923128|NCT02404025|DRUG|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
219537207|NCT06249360|OTHER|Veins with reflux|This group included patients who used only recipient veins with reflux
218923129|NCT02404025|DRUG|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
218923130|NCT02404025|DRUG|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
218923131|NCT05078840|OTHER|Evaluation of first line treatment in patients with stage I and II LBCL|Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
218923132|NCT02061371|OTHER|virtual therapy|
218923133|NCT02061371|OTHER|conventional physiotherapy|
218923134|NCT01574092|DRUG|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
218923135|NCT02871908|DRUG|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8
218923136|NCT02871908|DRUG|Placebo|Placebo
218923137|NCT02199210|OTHER|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
218923138|NCT02289261|DRUG|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
219537208|NCT06249360|OTHER|Reflux-free recipient veins|This group included patients who utilized only reflux-free recipient veins
219537209|NCT02756663|DRUG|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
219537210|NCT02756663|DRUG|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
219537211|NCT02756663|DRUG|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
219537212|NCT05410002|DIETARY_SUPPLEMENT|Dietary Supplement: N-111|Dietary supplement N-111
218923139|NCT02289261|DRUG|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
218923140|NCT03681314|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
219537213|NCT05410002|OTHER|Placebo|Dietary placebo
219537214|NCT01221129|OTHER|Acclimation|11 mg Zn/day as a controlled intake level
218923141|NCT05004441|DRUG|Fruquintinib Combined With mFOLFOX6/FOLFIRI|Fruquintinib (3mg) will be given p.o. daily
218923142|NCT01715740|DRUG|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
218923143|NCT01715740|DRUG|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
218923144|NCT02869880|OTHER|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
218923145|NCT02869880|OTHER|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
218923146|NCT01524796|OTHER|No intervention. Non-interventional study|No intervention. Non-interventional study
218923147|NCT02248519|PROCEDURE|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
218923148|NCT02248519|PROCEDURE|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
218923149|NCT00080535|BIOLOGICAL|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
218923150|NCT02929394|DRUG|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
218923151|NCT01484587|DRUG|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
218923152|NCT01484587|DRUG|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
218923153|NCT01374438|DRUG|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
218923154|NCT01374438|DRUG|Placebo|Placebo capsules given once daily for 90 days
218923155|NCT03938259|DRUG|Fentanyl|identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
219537215|NCT01221129|OTHER|Dietary zinc depletion|\< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
219537216|NCT01221129|OTHER|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
219537217|NCT04904705|OTHER|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
218923156|NCT01595542|BEHAVIORAL|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~1. Cover letter~2. Vaccine promotional flyer~3. Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~4. Improved consent form~5. Note advertising a lottery for free movie tickets for returning the consent form~6. Self-addressed stamped envelope"
219537218|NCT04904705|OTHER|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
219619239|NCT07097220|DRUG|General-Epidural Anesthesia (GEA) group|In the General-Epidural Anesthesia (GEA) group (n = 47), patients received the same general anesthesia protocol as the GA group, in addition to epidural anesthesia. An epidural catheter was placed preoperatively at the T7-T9 vertebral level using a midline approach under strict aseptic conditions. Following successful catheterization and confirmation of proper placement, a continuous intraoperative infusion of 0.25% ropivacaine was administered via the epidural route to provide segmental analgesia and reduce intraoperative opioid requirements.
219619240|NCT07089771|PROCEDURE|Virtual Chromoendoscopy|"High-Definition Virtual Chromoendoscopy (HD-VCE):~Surveillance colonoscopy using high-definition virtual chromoendoscopy enhances mucosal visualization through advanced imaging filters integrated into the colonoscope. This dye-free technique improves detection of dysplasia by increasing contrast and highlighting subtle mucosal patterns during withdrawal. HD-VCE reduces procedure time and eliminates risks related to dye application, offering a practical alternative to dye-based methods. Its efficacy in IBD surveillance requires further validation."
219619241|NCT07089771|PROCEDURE|Dye-Based Chromoendoscopy|"High-Definition Dye-Based Chromoendoscopy (HD-DCE):~Surveillance colonoscopy using high-definition dye-based chromoendoscopy involves segmental application of indigo carmine dye via a spray catheter. The dye enhances mucosal surface patterns, aiding dysplasia detection. HD-DCE is currently considered a gold standard in IBD surveillance due to superior dysplasia detection rates."
219537219|NCT02411903|DRUG|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
219537220|NCT02411903|DRUG|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
219537221|NCT01386853|DRUG|Pitavastatin|2 mg QD
219619242|NCT07112066|DIAGNOSTIC_TEST|FAPI tracer|18F-FAPI-74 PET/CT, cardiac MRI, echocardiography and blood sample for BMP5 serum concetration is performed at baseline and 12-month follow-up.
219537222|NCT01386853|DRUG|Atorvastatin|10 mg QD
219537223|NCT03432663|DRUG|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
219537224|NCT03432663|DRUG|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
219537225|NCT04641702|DRUG|Atropine challenge|Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
219537226|NCT04641702|PROCEDURE|Esophageal muscle biopsy|Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
219537227|NCT04481451|PROCEDURE|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
219537228|NCT04481451|PROCEDURE|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
219537229|NCT04481451|DRUG|Ropivacaine|ropivacaine 0.2% nerve block injection
218923157|NCT02891577|PROCEDURE|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
218923158|NCT00025688|DRUG|carboplatin|
219537230|NCT00913627|DRUG|ibuprofen|
219537231|NCT00913627|DRUG|ibuprofen|
219537232|NCT00913627|DRUG|naproxen|
219537233|NCT00913627|DRUG|Placebo|
218923159|NCT00025688|DRUG|paclitaxel|
219537234|NCT06627998|DIAGNOSTIC_TEST|Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice|Biochemical, clinical and radiological data performed for clinical practice will be retrospectively collected. Osteoporosis and vertebral fractures will be diagnosed through DXA scan and vertebral morphometry.
219537235|NCT03887676|DRUG|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
219537236|NCT03887676|OTHER|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
218923160|NCT04881994|DRUG|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
218923161|NCT01452698|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
218923162|NCT01452698|DRUG|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
218923163|NCT01452698|DRUG|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
219537237|NCT01746238|DRUG|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
219537238|NCT01746238|DRUG|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
219537239|NCT01746238|RADIATION|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
219537240|NCT05847062|PROCEDURE|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
219537241|NCT01110005|OTHER|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
219537242|NCT01110005|OTHER|Lactated Ringer's Solution (LR)|LR IV fluid
219537243|NCT00609830|BEHAVIORAL|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
219537244|NCT00609830|BEHAVIORAL|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
219537245|NCT00609830|BEHAVIORAL|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
219537246|NCT00609830|BEHAVIORAL|No Information|Participants received no informational materials.
219619243|NCT07107646|BEHAVIORAL|vision training system, VTS|Participants in this group will receive individualized visual perceptual learning using the Vision Training System (VTS). The training involves blurred Gabor stimuli presented via a computer-based application. Each participant will complete approximately 20 training sessions over 3 months, with each session lasting 15 to 30 minutes, conducted twice per week. The program is designed to enhance uncorrected visual acuity, contrast sensitivity, and other visual functions by engaging neural mechanisms related to perceptual learning. Training progression is adaptive based on individual performance. The VTS software was developed in collaboration with Bar Ilan University.
218923164|NCT01452698|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
218923165|NCT01907854|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
218923166|NCT01907854|DRUG|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
218923167|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
218923168|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
218923169|NCT02004041|DRUG|VLY-686|
218923170|NCT02004041|DRUG|Placebo|
218923171|NCT05605002|DRUG|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
218923172|NCT05605002|PROCEDURE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
219042821|NCT07018973|OTHER|GAISMA|After the pre-test and randomization, the experimental group will first start the morphological analysis application. After completing a certain period of time, copies of the matrix and suggestion studies will be taken and they will be allowed to use the generative artificial intelligence application. At the end of the application, a post-test will be applied. In addition, an opinion form will be given and their opinions about the morphological analysis method, the use of generative artificial intelligence and the use of artificial intelligence with the morphological analysis method and how it affects them will be taken.
218923173|NCT05605002|PROCEDURE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
218923174|NCT04659876|DIAGNOSTIC_TEST|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
218923175|NCT03378986|PROCEDURE|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
218923176|NCT03378986|PROCEDURE|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
218923177|NCT05950074|BEHAVIORAL|"It´s Up To You program"|The main goal of this program is to prevent substance use and engagement in addictive behaviors through enabling teenagers to make informed and responsible decisions. It seeks to support students in the anticipation of realistic choice situations and problems typically affecting this age group. It is based on social influences, considering the peer group influences (peer pressure) and the affective and cognitive factors that intervene at the time of decision-making and problem-resolution. This program is intended to be delivered by trained teachers in six sessions through six different modules.
218923178|NCT04012957|DRUG|Desidustat Oral Tablet|Desidustat tablet
218923179|NCT04012957|DRUG|Darbepoetin Alfa|Darbepoetin injection
218923180|NCT02215252|DRUG|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
218923181|NCT02215252|DRUG|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
218923182|NCT02215252|DRUG|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
218923183|NCT02215252|DRUG|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
218923184|NCT02633306|DEVICE|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
219537247|NCT01876875|DIETARY_SUPPLEMENT|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
219537248|NCT01876875|DIETARY_SUPPLEMENT|Usual diet|The patients of this group were randomized to continue their usual diet
219537249|NCT05667272|OTHER|No intervention|No intervention
219537250|NCT06347562|GENETIC|Optical Genome Mapping|to evaluate the capability of OGM, its usefulness in clinical diagnosis, and its impact on genetic counseling.
219537251|NCT04843995|PROCEDURE|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
219619244|NCT07113288|DEVICE|Inspire® UAS System|Participants will be implanted with a commercially available Inspire® UAS System. In addition, participants will receive a patient remote which is used to initiate therapy each night.
219619245|NCT07111247|DRUG|Gonadotropin Releasing Hormone Antagonists Relugolix|Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.
218923185|NCT04369573|COMBINATION_PRODUCT|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
218923186|NCT04369573|OTHER|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
218923187|NCT05531292|DEVICE|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
219537252|NCT01998295|DRUG|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
219537253|NCT03391284|DRUG|acetominophen|INTRAVENOUS
219537254|NCT03391284|DRUG|Acetaminophen|ORAL
219619246|NCT07111793|OTHER|Extended phenotyping|Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.
219619247|NCT07111793|OTHER|Blood sample for WES|Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)
218923188|NCT05531292|DEVICE|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
218923189|NCT00956007|BIOLOGICAL|cetuximab|intravenously
218923190|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
218923191|NCT00492492|PROCEDURE|trans-styloid and intrafocal pinning on the one side|
219537255|NCT02110394|OTHER|bendamustine|Routine practice
219537256|NCT02110394|OTHER|rituximab|Routine practice
218923192|NCT00492492|PROCEDURE|volar fixed-angle plating on the other side|
218923193|NCT06217510|DEVICE|Test Brace|Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
218923194|NCT01143376|BEHAVIORAL|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
218923195|NCT01143376|BEHAVIORAL|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
218923196|NCT01143376|BEHAVIORAL|Moderate intensity exercise|
218923197|NCT03774576|DRUG|RO7017773|Single doses of RO7017773
218923198|NCT03774576|DRUG|Itraconazole|Multiple doses of Itraconazole
218923199|NCT05592106|DIAGNOSTIC_TEST|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
218923200|NCT01746901|DRUG|Placebo|Placebo solution + Placebo ALO-02 (intact)
218923201|NCT01746901|DRUG|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
219537257|NCT05621226|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
219537258|NCT04542356|DRUG|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
219537259|NCT04542356|DRUG|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
219537260|NCT01641380|BEHAVIORAL|Text Messaging Intervention|"1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
219537261|NCT03123471|DRUG|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
219619248|NCT07111793|OTHER|Blood sample for PBMC freezing|Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL
219619249|NCT07111793|OTHER|POPC score evaluation|Assessment of POPC score (Pediatric Overall Performance Category)
219619250|NCT07111793|OTHER|Questionnaire completion|"Questionnaires completed by parents or children:~* SDQ~* PedSQL4.0"
219619251|NCT07111156|OTHER|Topical Cream containing 0.1% Pinorox®|"Mode of Usage: Apply a coin size (approximately 1g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
219619252|NCT07111156|OTHER|Topical Cream containing 1% Pinorox®|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
218923202|NCT01746901|DRUG|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
218923203|NCT01746901|DRUG|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
218923204|NCT01746901|DRUG|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
218923205|NCT01746901|DRUG|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
218923206|NCT00742495|DRUG|Forodesine|PK study
218923207|NCT05750849|PROCEDURE|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
218923208|NCT02683577|DRUG|telotristat etiprate|
218923209|NCT06033248|DIAGNOSTIC_TEST|urine sample|urine sample will be collected
218923210|NCT04857476|DIAGNOSTIC_TEST|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
218923211|NCT05029362|BEHAVIORAL|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
218923212|NCT05571605|BEHAVIORAL|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
218923213|NCT05571605|BEHAVIORAL|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
218923214|NCT04851964|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
218923215|NCT04851964|OTHER|Placebo|Placebo subcutaneous injection
219537262|NCT03123471|OTHER|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
219537263|NCT05914454|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
219619253|NCT07111156|OTHER|Placebo (Base Cream)|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
219619254|NCT07113223|DEVICE|Willem™ platform ECG assessment|AI-assisted ECG analysis via the Willem™ platform
218923216|NCT04780477|DIETARY_SUPPLEMENT|High Fiber Diet Featuring Legumes (HLD)|The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (\~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. \~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
218923217|NCT04780477|DIETARY_SUPPLEMENT|Healthy American Diet|The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
218923218|NCT05081180|DRUG|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
218923219|NCT05081180|DRUG|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
218923220|NCT02191735|DEVICE|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
218923221|NCT02191735|DEVICE|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
218923222|NCT04449250|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
218923223|NCT04030910|OTHER|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
218923224|NCT00338845|BEHAVIORAL|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
218923225|NCT00338845|BEHAVIORAL|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
218923226|NCT02726568|DRUG|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
218923227|NCT02726568|RADIATION|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
218923228|NCT02621450|BIOLOGICAL|standart dialysis|dialysate sodium consentration 140 mEq
219537264|NCT03500120|DIAGNOSTIC_TEST|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
219537265|NCT04184518|DRUG|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
219537266|NCT04184518|DRUG|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
219537267|NCT04074603|DEVICE|The needle-free jet injector|Continuous insulin therapy for 2 weeks
219537268|NCT04074603|DEVICE|Conventional insulin pen|Continuous insulin therapy for 2 weeks
219619255|NCT00741507|BEHAVIORAL|Alcohol drinking|Never drinking of alcohol
219619256|NCT00741507|BEHAVIORAL|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
219619257|NCT00741507|BEHAVIORAL|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
219619258|NCT00741507|BEHAVIORAL|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
219619259|NCT00741507|BEHAVIORAL|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
219537269|NCT04406753|OTHER|Manual therapy techniques in C0-1 and C2-3 with cervical exercise|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
219537270|NCT04406753|OTHER|Cervical Exercise|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
219537271|NCT06559254|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
219537272|NCT05792397|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
218923229|NCT02621450|BIOLOGICAL|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
218923230|NCT06198296|GENETIC|21.15.GPC3-CAR T cells|"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2"
218923231|NCT01815970|BEHAVIORAL|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
219537273|NCT00649987|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
219537274|NCT00649987|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
219537275|NCT01115647|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
219537276|NCT01115647|DIETARY_SUPPLEMENT|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
219619260|NCT06581107|PROCEDURE|CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation|During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are recorded. The performance of the research device is evaluated by the radiologists. Postoperative complications of the participants are recorded 7±1 days postoperatively/on the day of discharge based on the postoperative CT scan (whichever comes first).
218923232|NCT00927953|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
218923233|NCT00927953|BIOLOGICAL|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
218923234|NCT05670886|PROCEDURE|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
218923235|NCT02633150|OTHER|Supplementation with red grapes polyphenol|
218923236|NCT06025864|OTHER|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
218923237|NCT01409707|BEHAVIORAL|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
218923238|NCT01409707|BEHAVIORAL|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
219619261|NCT06932094|DRUG|QLS5132|antibody drug conjugate (ADC).
218923239|NCT01409707|BEHAVIORAL|Healthy lifestyles sessions|
218923240|NCT02792686|DRUG|ABX464|Single Administration
218923241|NCT06380621|PROCEDURE|Totally Extra Peritoneal repair (TEP) repair|TEP repair
219537277|NCT01115647|BEHAVIORAL|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
218923242|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁷ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: single intradermal dose of 10⁷ PFU/0.2 ml of vaccinia virus."
218923243|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁶ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: two intradermal doses of 10⁶ PFU/0.2 ml of vaccinia virus (given 28 days apart)."
218923244|NCT05846243|BIOLOGICAL|Live Smallpox Vaccine|"Live smallpox vaccine (Smallpox vaccine) (manufactured by the Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of Russia).~Batch No. Т30 (expiry date: March, 2021). Dosage: Single 1x10⁶ PFU dose administered by multiple-pricking technique on the 30th/60th day after full series of vaccination with VAC∆6."
218923245|NCT05846243|OTHER|Placebo (Sodium chloride bufus, 0.9%)|"Sodium chloride bufus, a 0.9% solvent for the preparation of a dosage form for injections (manufactured by JSC Pharmaceutical manufacturing company Obnovlenie, Russia).~Batch: 391219 (expiry date: January, 2025)."
218923246|NCT04479995|BEHAVIORAL|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
218923247|NCT04479995|BEHAVIORAL|Usual Care|Standard medical visits with additional paper or electronic booklet.
218923248|NCT01658436|DRUG|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
218923249|NCT03077334|DEVICE|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
219537278|NCT00652977|PROCEDURE|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
219537279|NCT00652977|PROCEDURE|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
219537280|NCT03681470|DRUG|Aczone Gel|Aczone Gel 7.5%
219537281|NCT01686477|OTHER|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
219537282|NCT01686477|OTHER|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
219619262|NCT06933459|DRUG|Test Drug|AJU-C714
219619263|NCT06933459|DRUG|Reference Drug|C714R
219619264|NCT06361927|DRUG|SSGJ-707|bispecific antibody
219619265|NCT02107924|PROCEDURE|APPI of TKR-Stimulan|
219619266|NCT06459102|OTHER|Motor Learning|In addition to the conventional physiotherapy program .... per week for 4 weeks Sessions of motor learning exercise will be performed. For the exercise, the participant will sit in a chair with back support, in front of a table, with arms on the table. The participant will wear a glove with an IMU sensor on the upper surface and a pressure sensor on the palm, and a cylinder will be placed in the palm. The participant will be asked to bring the wrist into extension and then back into flexion while grasping the cylinder with maximum force. The participant will be asked to maintain maximum strength during the entire movement. The participant will be given visual feedback on muscle strength and range of motion of the wrist on the monitor in front of them throughout the movement. The same protocol will be applied by keeping the size of the cylinder in the participant's palm the same and changing the weight.
219619267|NCT06459102|OTHER|Control|The control group will receive a conventional physiotherapy program for 4 weeks, 5 days a week. Eccentric training for the extensor carpi radialis brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercises for the ECRB muscle will be given. For eccentric training, the weight that the patients can lift in 10 maximal repetitions will be calculated and they will be asked to work with this weight. The best stretching position for the ECRB tendon is extension of the elbow joint, pronation of the forearm and flexion of the wrist with ulnar deviation. Each participant will be taught to perform each exercise for 10 repetitions and 10 seconds. Patients will perform these exercises in a sitting position. In the control group, daily exercises will be performed under the supervision of a physiotherapist
218923250|NCT00044616|DRUG|Fluoxetine|
218923251|NCT00044616|DRUG|Lithium|
219042822|NCT07018973|OTHER|Control|In the control group, morphological analysis will be applied. Post-tests will be applied at the end of the application. Finally, their opinions about the morphological analysis method and how it affects them will be taken by giving an opinion form.
219537283|NCT01686477|OTHER|Preterm Formula used when there is a shortfall in mother's own milk|
219537284|NCT00836576|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
219537285|NCT00836576|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
219537286|NCT01863030|DEVICE|Phasix mesh implant|
219537287|NCT03851939|COMBINATION_PRODUCT|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
218923252|NCT03798951|OTHER|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
219537288|NCT03153540|DEVICE|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
219619268|NCT03859921|DRUG|Dydrogesterone|Progesterone
219619269|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
219619270|NCT03072420|OTHER|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
219619271|NCT05372614|PROCEDURE|Biopsy Procedure|Undergo biopsy
219619272|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219619273|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
219619274|NCT05372614|PROCEDURE|Echocardiography Test|Undergo echocardiography
219619275|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219619276|NCT05372614|DRUG|Neratinib Maleate|Given PO
219619277|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
218923253|NCT05154786|OTHER|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
218923254|NCT05154786|OTHER|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
218923255|NCT05361707|DRUG|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
219537289|NCT03153540|DEVICE|Sham iTBS|Sham intervention
219537290|NCT02004197|DRUG|Quadruple Allopathic therapy|
219537291|NCT02004197|DRUG|Pylorex plus|
219537292|NCT07007494|OTHER|Nutritional and Inflammatory Marker Evaluation|This is a prospective observational cohort study evaluating whether preoperative immune-nutritional markers-including Prognostic Nutritional Index (PNI), HALP score, Neutrophil-to-Lymphocyte Ratio (NLR), and C-Reactive Protein (CRP)-can predict early postoperative clinical outcomes (complication development, time to oral intake, mobilization, and length of hospital stay) in patients undergoing elective laparoscopic sleeve gastrectomy. No intervention or treatment is administered as part of this study. All data are collected from routine preoperative laboratory tests and standard postoperative clinical follow-up.
219619278|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
219619279|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
219619280|NCT05063981|DRUG|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
219619281|NCT03737695|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
218923256|NCT00464633|DRUG|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
218923257|NCT04418648|DRUG|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
219619282|NCT03737695|OTHER|Medical Chart Review|Undergo clinical information collection
219619283|NCT05916313|DRUG|BI 764532|BI 764532
218923258|NCT02551939|PROCEDURE|Autologous Fat Grafting|Autologous Fat Grafting
218923259|NCT02784548|OTHER|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
218923260|NCT05269459|DRUG|Cannabidiol Administered as Nantheia ATL5|Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
218923261|NCT05269459|DRUG|Placebo|Participants will take 4 matching gel capsules twice daily containing no active drug.
218923262|NCT05799885|OTHER|Neuro-vestibular-ocular group|Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training
219537293|NCT02370719|BEHAVIORAL|Mobile application for diabetes self-management|
219537294|NCT03290781|DRUG|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
219537295|NCT03290781|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
218923263|NCT05799885|OTHER|Myofascial Release group|Manual myofascial release will be applied by the physiotherapist.(30 football players)
218923264|NCT04322526|DRUG|Naltrexone 50 Mg Oral Tablet|Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
218923265|NCT04322526|DRUG|Placebo oral tablet|Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
218923266|NCT00100971|DRUG|autologous tumor cell vaccine|
219537296|NCT04829162|OTHER|Mother with obesity, daughter with obesity|Participants in this group were shown an image of a mother with obesity and a daughter with obesity.
219537297|NCT04829162|OTHER|Mother with obesity, daughter without obesity|Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
219537298|NCT04829162|OTHER|Mother without obesity, daughter with obesity|Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
219537299|NCT04829162|OTHER|Mother without obesity, daughter without obesity|Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
219537300|NCT04829162|OTHER|Mother with obesity, son with obesity|Participants in this group were shown an image of a mother with obesity and a son with obesity.
219537301|NCT04829162|OTHER|Mother with obesity, son without obesity|Participants in this group were shown an image of a mother with obesity and a son without obesity.
219619284|NCT05224102|DRUG|Faricimab|Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
219619285|NCT06792175|DIAGNOSTIC_TEST|Solicue Machine Learning Models|"A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
219619286|NCT06792175|DIAGNOSTIC_TEST|Mercuria Machine Learning Models|"Mercuria is designed to stratify the risk of bipolar disorder in individuals presenting with depressive symptoms. This is a critical clinical need, as misdiagnosis of bipolar disorder as unipolar depression is common and can lead to inappropriate treatment, potentially worsening outcomes. By analyzing speech patterns characteristic of bipolar disorder, Mercuria aims to provide an additional tool for clinicians to differentiate between these conditions more accurately, guiding appropriate treatment decisions.~Mercuria leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
219537302|NCT04829162|OTHER|Mother without obesity, son with obesity|Participants in this group were shown an image of a mother without obesity and a son with obesity.
219619287|NCT02444741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219619288|NCT02444741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218923267|NCT00100971|DRUG|therapeutic autologous dendritic cells|
218923268|NCT00100971|PROCEDURE|tumor cell-derivative vaccine therapy|
218923269|NCT05714410|DIETARY_SUPPLEMENT|PHGG|PHGG
218923270|NCT05105204|DEVICE|ArteVu|The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
218923271|NCT01523756|DEVICE|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
218923272|NCT01523756|DEVICE|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
218923273|NCT00993967|DRUG|idebenone|Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients \> 45 kg
218923274|NCT00533455|DRUG|Gabapentin|
219537303|NCT04829162|OTHER|Mother without obesity, son without obesity|Participants in this group were shown an image of a mother without obesity and a son without obesity.
219537304|NCT04829162|OTHER|Father with obesity, daughter with obesity|Participants in this group were shown an image of a father with obesity and a daughter with obesity.
219537305|NCT04829162|OTHER|Father with obesity, daughter without obesity|Participants in this group were shown an image of a father with obesity and a daughter without obesity.
219537306|NCT04829162|OTHER|Father without obesity, daughter with obesity|Participants in this group were shown an image of a father without obesity and a daughter with obesity.
219537307|NCT04829162|OTHER|Father without obesity, daughter without obesity|Participants in this group were shown an image of a father without obesity and a daughter without obesity.
219537308|NCT04829162|OTHER|Father with obesity, son with obesity|Participants in this group were shown an image of a father with obesity and a son with obesity.
219619289|NCT02444741|OTHER|Laboratory Biomarker Analysis|Correlative studies
218923275|NCT02231359|DRUG|Berodual® Respimat® solution for inhalation|
218923276|NCT01658319|DRUG|fludarabine phosphate|Given IV
218923277|NCT01658319|DRUG|methoxyamine|Given IV
219537309|NCT04829162|OTHER|Father with obesity, son without obesity|Participants in this group were shown an image of a father with obesity and a son without obesity.
219537310|NCT04829162|OTHER|Father without obesity, son with obesity|Participants in this group were shown an image of a father without obesity and a son with obesity.
219537311|NCT04829162|OTHER|Father without obesity, son without obesity|Participants in this group were shown an image of a father without obesity and a son without obesity.
219537312|NCT01788800|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
219537313|NCT02957942|DEVICE|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
219537314|NCT06371807|DRUG|Pembrolizumab injection|(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
219537315|NCT04725708|PROCEDURE|procedure: cerebral oxygenation intervention|During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
219619290|NCT02444741|BIOLOGICAL|Pembrolizumab|Given IV
219619291|NCT02444741|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
219619292|NCT02444741|RADIATION|Radiation Therapy|Undergo low dose radiation therapy
219619293|NCT02444741|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219619294|NCT05065047|DRUG|Belantamab mafodotin|Given by IV
219619295|NCT04068194|DRUG|Avelumab|Given IV
219619296|NCT04068194|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
219619297|NCT04068194|PROCEDURE|Biospecimen Collection|Correlative studies
219619298|NCT04068194|PROCEDURE|Computed Tomography|Undergo CT scan
219619299|NCT04068194|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
218923278|NCT01658319|OTHER|laboratory biomarker analysis|Correlative studies
218923279|NCT01658319|OTHER|pharmacological study|Correlative studies
219537316|NCT05397028|DIETARY_SUPPLEMENT|Meal replacement system|Participants will replace meals with a meal replacement system to assess the efficacy of weight loss leading to remission of diabetes (optimal A1C levels).
219537317|NCT05397028|BEHAVIORAL|Intensive lifestyle Intervention|Participants will sign up with a virtual health program which they will interact with.
219537318|NCT01030848|DEVICE|Total Knee Replacement (LCS rotating platform)|
219537319|NCT01684241|BIOLOGICAL|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
219537320|NCT02000362|BIOLOGICAL|Stem cells|
219537321|NCT04328597|PROCEDURE|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
219619300|NCT04068194|DRUG|Peposertib|Given PO
219619301|NCT05399498|DRUG|Psilocybin|Psilocybin 25mg capsule
219619302|NCT04198350|PROCEDURE|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
218923280|NCT01658319|GENETIC|western blotting|Correlative studies
218923281|NCT01658319|OTHER|mass spectrometry|Correlative studies
218923282|NCT01658319|GENETIC|DNA analysis|Correlative studies
218923283|NCT06584006|DRUG|Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections|Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
218923284|NCT06584006|DRUG|Recombinant Human Interleukin-2 Injections|Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
218923285|NCT01483261|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
218923286|NCT06387121|DRUG|Vincristine|Anti-tumor alkaloids
218923287|NCT06387121|DRUG|Cyclophosphamide|Alkylating agent
218923288|NCT06387121|DRUG|Dexamethasone|Glucocorticoids
218923289|NCT06387121|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
218923290|NCT06387121|DRUG|Inotuzumab ozogamicin|A humanized monoclonal antibody-drug conjugate targeting CD22
218923291|NCT06387121|DRUG|Blinatumomab|Bi-specific anti-CD19/CD3 antibodies
218923292|NCT06387121|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
218923293|NCT06387121|DRUG|Methotrexate|Antifolate antineoplastic drug
218923294|NCT06387121|DRUG|Cytarabine|Pyrimidine antimetabolites
219619303|NCT05753748|PROCEDURE|Endoscopic Eradication Therapy|Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
218923295|NCT06387121|DRUG|Prednisone|Glucocorticoids
218923296|NCT03131024|DIETARY_SUPPLEMENT|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
219537322|NCT05098886|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
219537323|NCT05098886|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
219537324|NCT04383886|OTHER|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
219537325|NCT03452319|OTHER|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
219537326|NCT03452319|OTHER|Usual care|Preoperative information
219537327|NCT00239863|DRUG|FTY720|
218923297|NCT03131024|OTHER|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
219042823|NCT06875908|OTHER|Turkish Validity and Reliability of The GSDS-T in patients with multiple sclerosis|The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis. It has 21 questions. This study will be conducted on patients with multiple sclerosis. In order to evaluate the validity of the GSDS-T, the Pittsburgh Sleep Quality Index (PSQI) which can evaluate sleep quality and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.
219537328|NCT06275061|PROCEDURE|Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
219537329|NCT01242774|DRUG|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
219537330|NCT05755763|OTHER|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
219537331|NCT05081466|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)
219537332|NCT05081466|OTHER|Fruit and vegetable intake|Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire
219537333|NCT05081466|OTHER|Meat intake|Red meat, poultry, processed meat from food frequency questionnaire
219537334|NCT05081466|OTHER|Fish intake|Intake of fish from food frequency questionnaire
219537335|NCT05081466|OTHER|Egg intake|Intake of eggs from food frequency questionnaire
219537336|NCT05081466|OTHER|Dairy intake|Intake of dairy products from food frequency questionnaire
219537337|NCT05081466|OTHER|Tea intake|Intake of tea (drink) from food frequency questionnaire
218923298|NCT00515619|DRUG|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
218923299|NCT02760498|DRUG|cemiplimab|
219537338|NCT05081466|OTHER|Coffee intake|Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire
219537339|NCT05081466|OTHER|Tea and coffee intake|Combined intake of tea and coffee from food frequency questionnaire
219537340|NCT05081466|OTHER|Protein intake|Estimated intake of protein, derived from food frequency questionnaire
218923300|NCT03469947|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
218923301|NCT00891943|OTHER|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
218923302|NCT01784224|PROCEDURE|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
219537341|NCT05081466|OTHER|Calcium intake|Estimated intake of calcium, derived from food frequency questionnaire
218923303|NCT04616989|BEHAVIORAL|Psycho-education|Provide psycho-education to members of the community
219537342|NCT05081466|OTHER|Vitamin D intake|Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
219537343|NCT05401734|DEVICE|Observation and follow up measurement|"The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
219537344|NCT02576730|PROCEDURE|ORIF|surgery for foot and ankle fractures
219537345|NCT00011960|DRUG|cisplatin|
219537346|NCT00011960|DRUG|paclitaxel|
219537347|NCT00011960|PROCEDURE|adjuvant therapy|
218923304|NCT04616989|BEHAVIORAL|Comparator|Distribution of COVID-19 leaflets to members of the community
218923305|NCT04500587|DRUG|ZN-d5|Oral agent; 25 mg or 100 mg formulation
218923306|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
218923307|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
219537348|NCT00011960|RADIATION|radiation therapy|
219537349|NCT01136174|DRUG|Placebo|Placebo BID for cohort 1,2,3
219537350|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
219537351|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
219537352|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
218923308|NCT05035238|BIOLOGICAL|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
218923309|NCT06411262|OTHER|Parkiboks|A non-contact boxing sessions for individuals with Parkinson disease, made-up of 3 sections: a warm-up, a boxing section, a cool-down. Each section is split into a range of exercises. The session is led by a boxing coach with training and expertise in Parkinson disease.
218923310|NCT00896402|DRUG|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
219537353|NCT03727620|DRUG|amoxicillin plus metronidazole|patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
219619304|NCT06345495|DRUG|Ruxolitinib|Given by PO
219619305|NCT06345495|PROCEDURE|Allogeneic Stem Cell Transplantation|Given by Transplant
218923311|NCT00896402|DRUG|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
219537354|NCT03727620|DRUG|Doxycycline|patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
219619306|NCT06345495|DRUG|Levetiracetam|Given by PO
219619307|NCT06345495|DRUG|Eltrombopag|Given by PO
218923312|NCT02410226|PROCEDURE|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
218923313|NCT02410226|RADIATION|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
218923314|NCT02410226|RADIATION|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
219619308|NCT06345495|DRUG|Busulfan|Given by IV
218923315|NCT01590355|RADIATION|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
218923316|NCT01590355|PROCEDURE|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
218923317|NCT03452969|OTHER|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
219537355|NCT04256122|OTHER|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
219537356|NCT00115960|BIOLOGICAL|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
219537357|NCT00115960|BIOLOGICAL|IL-15 DNA adjuvant|Cytokine injection
219619309|NCT06345495|DRUG|Romiplostim|Given by IV
219619310|NCT06345495|DRUG|Fludarabine phosphate|Given by IV
219619311|NCT06345495|DRUG|Cyclophosphamide|Given by IV
219619312|NCT06345495|DRUG|Mesna|Given by IV
219537358|NCT00115960|BIOLOGICAL|IL-12 DNA adjuvant|Cytokine injection
219537359|NCT01107366|PROCEDURE|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
219537360|NCT01107366|PROCEDURE|lupiae technique|"LUPIAE technique~Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:~1. surgical arch reconstruction with a Dacron multibranched surgical prothesis~2. endovascular implantation of a thoracic stent graft"
219537361|NCT02939092|DRUG|Pomegranates peel extract|Pomegranate is antimicrobial
219537362|NCT02939092|DRUG|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
219537363|NCT01074541|RADIATION|UVB|0.375 SED x 4 in a week
219619313|NCT06345495|DRUG|Tacrolimus|Given by IV or PO
218923318|NCT00771758|DRUG|oxycodone IR|maximum daily dose 450 mg
218923319|NCT00771758|DRUG|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
218923320|NCT00771758|DRUG|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
218923321|NCT03067077|PROCEDURE|SMILE|SMILE surgery
218923322|NCT03067077|PROCEDURE|LASIK|LASIK surgery
218923323|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
218923324|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
218923325|NCT02529072|DRUG|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
218923326|NCT02529072|BIOLOGICAL|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
219537364|NCT01074541|RADIATION|UVB|0.75 SED x 4 in a week
219537365|NCT01074541|RADIATION|UVB|1.5 SED x 4 in a week
219537366|NCT01074541|RADIATION|UVB|3.0 SED x 4 in a week
219537367|NCT03557762|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
219537368|NCT03185039|PROCEDURE|Blood and tumor samples|Blood and tumor samples
218923327|NCT01113255|PROCEDURE|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
219537369|NCT02609256|PROCEDURE|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
219537370|NCT02609256|OTHER|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
219537371|NCT03158675|PROCEDURE|fractional carbon dioxide(CO2) laser|-Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
219537372|NCT03158675|DRUG|Topical corticosteroid|Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
219537373|NCT03158675|RADIATION|Ultraviolet B narrow band|Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
219537374|NCT01188850|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
219619314|NCT05199077|DRUG|GM-XANTHO|a topical applied ointment
219619315|NCT06485141|BEHAVIORAL|Safe Storage Intervention|Firearm storage information and secure storage device.
219619316|NCT06485141|BEHAVIORAL|Safe Kids Medication|The Control participants will view a brief medication storage safety video produced by Safe Kids. A Frequently Asked Questions handout on medication safety created by Safe Kids will be available for parents as well.
219619317|NCT05862103|OTHER|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
219619318|NCT03606967|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219619319|NCT03606967|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219619320|NCT03606967|DRUG|Carboplatin|Given IV
218923328|NCT00935584|BEHAVIORAL|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
218923329|NCT03719079|DEVICE|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
218923330|NCT04504825|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
219537375|NCT03331445|DRUG|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
219537376|NCT03238781|DRUG|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
219537377|NCT03238781|DRUG|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
219537378|NCT02593357|DEVICE|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
218923331|NCT04504825|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
219537379|NCT00376285|DRUG|CP-742,033|
219537380|NCT00376285|DRUG|Fenofibrate|
219537381|NCT06873516|DRUG|EVO756|Dose 1
219537382|NCT06873516|DRUG|EVO756|Dose 2
219537383|NCT06873516|DRUG|EVO756|Dose 3
219537384|NCT06873516|DRUG|Placebo control|Placebo control
219537385|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
219537386|NCT07020221|DRUG|VS-7375|VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
219537387|NCT07020221|DRUG|Cetuximab|Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
218923332|NCT04504825|DRUG|cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen|According to institutional standard of care.
218923333|NCT01781546|PROCEDURE|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).
218923334|NCT01781546|PROCEDURE|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).
219537388|NCT07020221|DRUG|Carboplatin + Pemetrexed + Pembrolizumab|A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
219537389|NCT07020221|DRUG|Gemcitabine|A chemotherapy used for the treatment of several types of cancer including advanced or metastatic pancreatic ductal adenocarcinoma.
219537390|NCT07020221|DRUG|Gemcitabine + Nab-paclitaxel|A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.
219537391|NCT07045467|DRUG|Remimazolam Besylate|"This is the first clinical trial evaluating Remimazolam's pharmacokinetics (PK), pharmacodynamics (PD), and safety in renal transplant recipients-a population with unique physiological alterations due to end-stage renal disease and graft reperfusion. Key differentiators include:~Population-Specific Dosing Protocol:~Induction: 6 mg/kg/h until MOAA/S ≤1 (vs. 5-12 mg/kg/h in general surgery).~Maintenance: Titrated (0.5-2 mg/kg/h) to Narcotrend Index 27-60 (lower than typical BIS 40-60 targets), accounting for altered drug metabolism post-transplant.~Transplant-Specific Context:~Administered alongside standard immunosuppressants (methylprednisolone 750 mg + furosemide 60 mg at reperfusion) but prohibits common sedatives (midazolam/propofol) to isolate Remimazolam's effects.~PK/PD sampling accounts for graft function dynamics (e.g., blood draws during reperfusion and post-op days 1-6).~Exploratory Genetic Analysis:~First study linking VDR/"
219537392|NCT07040397|DEVICE|EMMA massage therapy|Expert Manipulative Massage Automation (EMMA) is equipped with sensors to measure muscle stiffness and uses 3D vision technology to measure muscle stiffness and identify pressure points while delivering a massage to patients. Following that, the electronic massager will determine the best course of action for our patients based on the information stored by our Artificial Intelligence and EMMA's robotic arm will perform the massage. EMMA executes massages through soft treatment modules that are warmed to a temperature of between 38℃ and 40℃ to mimic human touch.
219537393|NCT07040397|OTHER|Clinical massage treatment|The direct person clinical massage treatment will be delivered by a clinical licensed massage therapist. The type of massage will follow the EMMA massage in that it will be a deep tissue massage (to mimic the Tuina massage) and generally will be for about 30 minutes to once again mimic the duration of massage therapy of the EMMA.
219537394|NCT06742307|DRUG|Faricimab Injection [Vabysmo]|A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.
219537395|NCT07054411|DEVICE|Radical-7 Pulse CO-Oximeter|Rainbow sensors will be placed on the 4th fingertips of the non-dominant hand of the patients and connected to the Radical-7 Pulse CO-Oximeter device and the initial Hb value will be recorded routinely and recorded hourly during the operation. Hemogram samples will be studied in the laboratory. During the operation, every hour and at the end of the operation, SpHb value, Hb, Hct levels in hemogram will be recorded.
219537396|NCT07062419|DEVICE|endoactivator|activation of irrigant during root canal treatment
219537397|NCT05559892|BEHAVIORAL|DM-CCT|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions).
219537398|NCT05559892|BEHAVIORAL|DM-UCT|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
219537399|NCT06899802|BIOLOGICAL|MVA-BN-WEV|MVA-mBN396 (common name MVA-BN-WEV vaccine), is a highly attenuated, live recombinant virus based on the licensed viral vector MVA-BN, provided as a liquid frozen formulation. It is administered as an intramuscular injection.
219537400|NCT06899802|OTHER|Placebo|Tris-Buffered Saline (TBS) (placebo) is a clear liquid, free from visible extraneous particles. TBS is acceptable for use as a diluent and for intramuscular injection.
219537401|NCT07072975|OTHER|Normobaric hypoxia|Normobaric hypoxia (inspired oxygen fraction of 12.9%) applied between-sets recovery periods
219537402|NCT07072975|OTHER|normoxic condition|Between-sets recovery periods under normoxic condition
219537403|NCT06025747|DRUG|Abemaciclib|Given PO
219537404|NCT06025747|PROCEDURE|Computed Tomography|Undergo CT
218923335|NCT00687193|DRUG|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
218923336|NCT00687193|DRUG|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
218923337|NCT00687193|DRUG|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
219537405|NCT06025747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219537406|NCT06025747|RADIATION|Radiation Therapy|Undergo radiation therapy
219537407|NCT06025747|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
219537408|NCT03996005|PROCEDURE|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
219537409|NCT07076121|DRUG|BMS-986504|Specified dose on specified days
219537410|NCT07076121|DRUG|Gemcitabine|Specified dose on specified days
219619321|NCT03606967|PROCEDURE|Computed Tomography|Undergo CT scan
218923338|NCT00687193|DRUG|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
218923339|NCT00687193|DRUG|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
218923340|NCT00687193|DRUG|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
219537411|NCT07076121|DRUG|Nab-paclitaxel|Specified dose on specified days
219537412|NCT07076121|DRUG|Placebo|Specified dose on specified days
219537413|NCT06750289|COMBINATION_PRODUCT|ICS-LABA|ICS-LABA inhalation
219537414|NCT06750289|COMBINATION_PRODUCT|benralizumab|Benralizumab. SC injection.
219537415|NCT06750289|COMBINATION_PRODUCT|Placebo for Benralizumab|"Placebo for Benralizumab (aka, placebo). SC injection."
219537416|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
219537417|NCT03761173|DEVICE|FlowTriever System|Thrombectomy
219537418|NCT03761173|DRUG|Anticoagulation Agents|Anticoagulation medication
219537419|NCT05849298|DRUG|AAA617|Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
219537420|NCT05849298|DRUG|AAA517|Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
219537421|NCT05849298|DRUG|Piflufolastat F 18|Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
219537422|NCT05849298|DRUG|ARPI|Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
219537423|NCT05849298|DRUG|ADT|as prescribed by the local investigator
219537424|NCT05849298|OTHER|Best supportive care|as prescribed by the local investigator
219537425|NCT06783647|DRUG|LBL-024 for Injection|intravenous infusion.
219537426|NCT06783647|DRUG|Docetaxel Injection|intravenous infusion.
218923341|NCT00529438|DRUG|Bardoxolone methyl|
218923342|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
218923343|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
219537427|NCT06783647|DRUG|Bevacizumab Injection|intravenous infusion.
219537428|NCT06783647|DRUG|Pemetrexed Disodium for Injection|intravenous infusion.
219537429|NCT06783647|DRUG|Paclitaxel Injection|intravenous infusion.
219537430|NCT06783647|DRUG|Carboplatin Injection|intravenous infusion.
219537431|NCT07078604|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
219537432|NCT07078604|DRUG|Cisplatin|Given cisplatin
219537433|NCT07078604|PROCEDURE|Computed Tomography|Undergo CT scans
219619322|NCT03606967|BIOLOGICAL|Durvalumab|Given IV
219619323|NCT03606967|DRUG|Gemcitabine Hydrochloride|Given IV
219619324|NCT03606967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219619325|NCT03606967|DRUG|Nab-paclitaxel|Given IV
219619326|NCT03606967|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Given SC
219619327|NCT03606967|DRUG|Poly ICLC|Given SC
219619328|NCT03606967|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219619329|NCT03606967|BIOLOGICAL|Tremelimumab|Given IV
219537434|NCT07078604|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT-guided biopsy
219537435|NCT07078604|DRUG|Docetaxel|Given docetaxel
219537436|NCT07078604|DRUG|Doxorubicin|Given doxorubicin
219537437|NCT07078604|DRUG|Eribulin|Given eribulin
219537438|NCT07078604|DRUG|Paclitaxel|Given paclitaxel
219537439|NCT07078604|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given liposomal doxorubicin
219537440|NCT07078604|BIOLOGICAL|Sargramostim|Given ID
219537441|NCT07078604|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided biopsy
219537442|NCT07078604|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219537443|NCT07078604|DRUG|Carboplatin|Given carboplatin
219537444|NCT07078604|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
219537445|NCT06834347|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219537446|NCT06834347|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219537447|NCT06834347|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
219537448|NCT07080632|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 300mg CBS per day from day 1 to day 7
219537449|NCT07080632|DRUG|Natural Calculus Bovis(NCB)|Subjects will orally receive 300mg NCB per day from day 1 to day 7
219619330|NCT05858996|BEHAVIORAL|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
219619331|NCT05858996|OTHER|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
219537450|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
219537451|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
219537452|NCT06793358|DRUG|fentanyl and Remimazolam|This is the first dental study that will combine these two sedation drugs
219537453|NCT07084090|BEHAVIORAL|Implementation intention planning|Implementation intention planning to promote patient safety concerns
219537454|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
219537455|NCT07082803|DRUG|TLN-254|Specified dose on specified days.
219537456|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
219619332|NCT02298959|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219537457|NCT07074483|DEVICE|Upper limb rehabilitation wearable device|"The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises.~No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback."
219537458|NCT07080866|DIAGNOSTIC_TEST|MRI|Participants will undergo a 60-minute MRI
219537459|NCT07080866|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
219537460|NCT07086521|BIOLOGICAL|ULSC|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1 x 10\^8 ULSC will be added to into 250 sterile saline for infusion (total volume of 260 mL volume).
219537461|NCT07086521|BIOLOGICAL|Placebo|The Placebo will be 250 ml of sterile saline for IV administration.
219537462|NCT00295113|PROCEDURE|EFR|
219537463|NCT06930625|DRUG|Debio 4126|IM injection, a 12-week extended-release formulation of octreotide
219537464|NCT06930625|DRUG|Placebo|IM injection of mannitol suspension
219537465|NCT06929221|OTHER|use of whiteboard|"Patients will be followed up for 7 days. Routine nursing care will be applied to the control group. The following information will be included on the whiteboard fixed in the patient room for the intervention group.~* Nurse's name~* Doctor's name~* Treatment times during the day~* Nursing interventions and hours for the diagnoses considered for the patient's major problems~* Timing of diagnostic and imaging techniques to be performed on the patient~* Content of appropriate discharge education for the patient~* Points to be considered by the patient before and after treatment~* Dietary considerations for the patient~* Nurse and patient's private note As a result of the data obtained, statistical analyses will be performed and interpreted to determine the effect of whiteboard use on anxiety, depression and satisfaction with nursing care in COPD patients."
219537466|NCT07085767|DRUG|Palazestrant|Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.
219537467|NCT07085767|DRUG|Letrozole-matching placebo|Participants will be treated with letrozole-matching placebo once daily on a 4-week (28 day) cycle
219537468|NCT07085767|DRUG|Ribociclib|Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.
219619333|NCT02298959|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219619334|NCT02298959|PROCEDURE|Computed Tomography|Undergo CT scan
219619335|NCT02298959|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219619336|NCT02298959|BIOLOGICAL|Pembrolizumab|Given IV
219619337|NCT02298959|BIOLOGICAL|Ziv-Aflibercept|Given IV
219619338|NCT03375307|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218923344|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
218923345|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
218923346|NCT05500144|OTHER|Not applicable- no intervention administered|Not applicable- no intervention administered
218923347|NCT03747562|DRUG|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
218923348|NCT03747562|OTHER|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
219537469|NCT07085767|DRUG|Letrozole|Participants will be treated with letrozole 2.5 mg once daily on a 4-week (28-day) cycle
219537470|NCT07085767|DRUG|Palazestrant matching-placebo|Participants will be treated with palazestrant-matching placebo once daily on a 4-week (28-day) cycle
219537471|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
219537472|NCT03725436|DRUG|Paclitaxel|Given IV
219619339|NCT03375307|PROCEDURE|Biospecimen Collection|Undergo blood collection
219619340|NCT03375307|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219619341|NCT03375307|PROCEDURE|Bone Scan|Undergo bone scan
219619342|NCT03375307|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219619343|NCT03375307|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218923349|NCT05225090|OTHER|Smartphone App|"Medisafe is a Med\_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
218923350|NCT06010160|BEHAVIORAL|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
218923351|NCT01394016|DRUG|Abemaciclib|Administered orally.
218923352|NCT01394016|DRUG|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks in Part G only.
218923353|NCT03534804|DRUG|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
218923354|NCT03534804|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
219537473|NCT06888921|DRUG|COM701|COM701 will be administered via intravenous (IV) infusion once every 3 weeks.
219537474|NCT06888921|DRUG|Normal Saline|Saline will be administered via intravenous (IV) infusion once every 3 weeks
219619344|NCT03375307|DRUG|Olaparib|Given PO
219619345|NCT03375307|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219619348|NCT05838768|DRUG|HRO761|Tablet
219619349|NCT05838768|BIOLOGICAL|pembrolizumab|Concentrate for solution for infusion
219619350|NCT05838768|DRUG|irinotecan|Concentrate for solution for infusion
218923355|NCT06313112|OTHER|Observational study|Observational study
219042824|NCT02030860|DRUG|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
219537475|NCT07083947|DIETARY_SUPPLEMENT|CL19183|One capsule taken orally each morning after breakfast with water for 16 weeks
219537476|NCT07083947|DIETARY_SUPPLEMENT|CL24212|One capsule taken orally each morning after breakfast with water for 16 weeks
219537477|NCT07083947|OTHER|Placebo|One capsule taken orally each morning after breakfast with water for 16 weeks
219537478|NCT06620380|DEVICE|Pharmacoscopy 1.0|Pharmacoscopy is currently an academically developed platform. The study is designed to investigate the clinical performance of this academic platform. In the interventional arm, the best candidate agent defined by pharmascopy will be considered to guide the therapeutic decision for each patient.
219619351|NCT06452225|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block.
219619352|NCT06452225|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound guided transversus abdominis plane block.
219619353|NCT01136902|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
219619354|NCT05147415|OTHER|Placebo|Inactive comparator
219619355|NCT05147415|DRUG|Tesomet|Fixed-dose combination
219619356|NCT02844543|DEVICE|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
219537479|NCT06620380|OTHER|Control|The next systemic treatment after surgery will be discussed, with the investigator and at the tumor board, considering also standard histopathological and molecular analysis, including next generation sequencing, molecular profiling analysis and previous treatments received
219537480|NCT06473597|DRUG|Rimegepant|NURTEC ODT 75 mg orally disintegrating tablets
219537481|NCT06473597|DRUG|Rizatriptan Benzoate|Rizatriptan ODT 10mg orally disintegrating tablets
219537482|NCT07088120|DEVICE|Precision-Controlled Ventilation with Real-Time Feedback|Manual ventilation during CPR using a real-time feedback device (EOlife, Archeon Medical) to guide the delivery of tidal volumes (6-8 mL/kg predicted body weight) and ventilation rate (10 breaths per minute). The device measures and displays ventilation parameters in real time, helping providers achieve guideline-recommended targets during resuscitation.
219537483|NCT07088120|OTHER|Standard Manual Ventilation During CPR|Manual ventilation during CPR without real-time feedback, using clinician judgment to guide tidal volume (visible chest rise) and ventilation rate, consistent with American Heart Association guidelines.
219537484|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
219537485|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
219619357|NCT02844543|OTHER|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
218923356|NCT05821127|BEHAVIORAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
218923357|NCT05821127|BEHAVIORAL|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
218923358|NCT05830396|DRUG|Ambroxol Hydrochloride|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
218923359|NCT05830396|DRUG|Placebo|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
218923360|NCT05877924|DRUG|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
218923361|NCT04986904|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
218923362|NCT05835284|DEVICE|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
219537486|NCT06907914|OTHER|Schroth|The Schroth intervention consists of a structured, three-dimensional exercise program based on scoliosis-specific principles. It incorporates corrective postural alignment, rotational breathing techniques, and targeted activation of spinal and scapular stabilizing muscles. The exercises are designed to improve postural control, enhance muscle endurance, and promote neuromuscular re-education for better functional alignment during daily activities.
219537487|NCT05350072|BIOLOGICAL|VAY736|ianalumab s.c.
219537488|NCT05350072|OTHER|Placebo|placebo s.c.
219537489|NCT06907901|BEHAVIORAL|PHAS Assessment|Participants will complete the Postural Habits and Awareness Scale (PHAS) to assess postural awareness and habits. The scale will be administered twice, two weeks apart, to evaluate reliability.
219537490|NCT07089043|DRUG|CST-3056|Administered as an oral solution
219537491|NCT07089043|DRUG|Placebo|Administered as an oral solution
219537492|NCT05940493|DRUG|Abemaciclib|Tablet
219537493|NCT05940493|DRUG|Placebo|Tablet
219537494|NCT04709705|BIOLOGICAL|Human platelets|Platelets given to control bleeding
219537495|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
219537496|NCT05867927|DEVICE|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
219619358|NCT02844543|DEVICE|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
219537497|NCT05867927|DEVICE|Non-da Vinci Surgery|Non-da Vinci Surgery
219537498|NCT07092579|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
219619359|NCT05045443|DRUG|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
219619360|NCT05045443|DIETARY_SUPPLEMENT|Standard of Care|As per institution protocol for Standard of nutritional Care
218923363|NCT02718404|PROCEDURE|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
218923364|NCT02718404|DRUG|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
218923365|NCT02718404|PROCEDURE|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
219537499|NCT07092579|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and optionally at 16 weeks if healing isn't confirmed. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
219537500|NCT07092579|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
219042825|NCT02030860|DRUG|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
219537501|NCT07092579|PROCEDURE|Lower Limb Rehabilitation Exercise Program|A structured exercise program prescribed postoperatively to promote functional recovery after tibial shaft fracture surgery. Exercises target quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent stiffness, and improve circulation. The program includes isometric and dynamic exercises such as: static quadriceps and hamstring contractions, straight leg raises, hip abduction, knee extension, hamstring curls, heel slides, ankle dorsiflexion/plantarflexion, ankle inversion/eversion, ankle circles, toe spreading, and passive ankle stretching using a strap or towel. Exercises are performed in pain-free ranges with gradual progression in repetitions and sets according to the rehabilitation plan. Certain ankle and foot mobility exercises (dorsiflexion/plantarflexion) are also performed hourly during the day to prevent swelling and thrombosis.
219537502|NCT07090746|DEVICE|Clear aligner|Clear aligner
219537503|NCT07090746|DEVICE|Fixed orthodontic appliance|Fixed orthodontic appliance
219619361|NCT03220204|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
219619362|NCT03220204|BEHAVIORAL|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
219619363|NCT01921868|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
219619364|NCT03241862|DEVICE|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
218923366|NCT05313971|OTHER|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
218923367|NCT04214821|DRUG|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
218923368|NCT04214821|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
218923369|NCT00453141|DRUG|dosing of Betamethasone|
218923370|NCT06038110|DIAGNOSTIC_TEST|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
218923371|NCT00174187|DRUG|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
218923372|NCT02000206|DRUG|Propofol|
219042826|NCT02030860|DRUG|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
218923373|NCT02000206|DRUG|Ketamine|
218923374|NCT02000206|DRUG|Alfentanil|
218923375|NCT00344201|DEVICE|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
218923376|NCT05142501|OTHER|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
218923377|NCT01238367|DRUG|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
219537504|NCT07090174|BIOLOGICAL|PDS0101|PDS0101 is an HPV 16-targeted immunotherapy administered as two subcutaneous injections of 0.5 mL each (total 1.0 mL). Each dose contains 3.0 mg of Versamune®, a proprietary cationic lipid nanoparticle adjuvant, and 2.7 mg of HPVmix, a blend of HPV16 E6 and E7 proteins. Versamune® enhances antigen uptake and dendritic cell activation, promoting T-cell priming and memory formation. In preclinical studies, subcutaneous administration resulted in low systemic bioavailability (\<6%) and efficient dendritic cell uptake, consistent with a favorable safety profile. PDS0101 has been studied in a completed Phase I trial in HIV-uninfected women with high-risk HPV and cervical intraepithelial neoplasia (CIN) I. Each participant in this study will receive three doses, spaced 21 days apart (± 7 days) unless there has been Grade 3 or greater toxicity at least possibly related to the study agent.
219619365|NCT01924832|DRUG|dimethyl fumarate|tablet
219619366|NCT02246140|OTHER|Cerebral MRI and MRA|
219619367|NCT04071210|DIETARY_SUPPLEMENT|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
219619368|NCT04071210|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet twice a day for 12 weeks
219619369|NCT01028547|DRUG|dexamethasone|single Bolus dose of dexamethasone 8mg
219619370|NCT01028547|OTHER|normal saline|2 ml 0.9% saline
219537505|NCT07091253|OTHER|HIV+|Participants living with HIV will use a triaxial accelerometer for a week in order to measure the physical activity and sedentary behaviors
219537506|NCT06902480|DIETARY_SUPPLEMENT|WPPC|A chocolate-flavored drink with WPPC added
219537507|NCT06902480|DIETARY_SUPPLEMENT|Whole egg powder|A chocolate-flavored drink with whole egg powder added
219537508|NCT06909136|DRUG|Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)|5-20mg BID (dosage per investigator judgement,JAKi intolerable pts will receive recuded dose of RUX(≥ 5mg BID),and suboptimal JAKi response pts will receive RUX of 15-20 mg BID）
219537509|NCT07096297|DRUG|Luspatercept|Luspatercept will be administered every 3 weeks (21 days) at a starting dose of 1.0 mg/kg (Dose Level 0). Luspatercept will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Participants must have Hgb, blood pressure and weight assessed (changes of body weight of ≤ ± 5% do not require a dose adjustment) prior to each luspatercept dose administration. Subcutaneous injections will be given in the upper arm, thigh, and/or abdomen. Volume for subcutaneous injection will be per institutional standard/guidelines.
219619371|NCT00728260|BIOLOGICAL|None administered in this study|N/A in this study
219619372|NCT03588754|DRUG|Propranolol|Propranolol Extended Release (160mg/day).
219619373|NCT03588754|DRUG|Placebo|Placebo pill administered orally.
219619374|NCT03312387|OTHER|Exercise|Aerobic exercise performed 3/d per week during intervention
219619375|NCT03312387|DIETARY_SUPPLEMENT|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
219619376|NCT03312387|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin ingested throughout intervention
219619377|NCT02220556|PROCEDURE|Blood sampling|
219619378|NCT05414500|DRUG|Mogamulizumab|Administered IV
219619379|NCT05414500|DRUG|Brentuximab vedotin|Administered IV
219619380|NCT04710576|DRUG|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
219619381|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
219619382|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
219619383|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
219619384|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
219619385|NCT01188525|DRUG|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
218923378|NCT04334824|DRUG|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
218923379|NCT04334824|DRUG|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
218923380|NCT03736863|DRUG|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
218923381|NCT03736863|DRUG|Apatinib+ SHR-1316（Adebrelimab）|Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
218923382|NCT03736863|DRUG|SHR-1316（Adebrelimab）+SHR-A2009|SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
218923383|NCT05089825|OTHER|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
218923384|NCT05089825|OTHER|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
218923385|NCT06553937|DRUG|Macitentan and Tadalafil|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
218923386|NCT06553937|DRUG|PrOpsynvi® Film-Coated Tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
218923387|NCT04126135|DRUG|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
218923388|NCT04126135|DRUG|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
218923389|NCT06012916|DRUG|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
218923390|NCT03435211|DEVICE|INVSENSOR00006|Noninvasive pulse oximeter sensor
218923391|NCT04220307|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration
218923392|NCT00759941|DRUG|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
218923393|NCT00759941|DRUG|Placebo eye drops|One drop three times a day in both eyes for 3 months
218923394|NCT00759941|DRUG|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
218923395|NCT04248634|PROCEDURE|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~\- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
218923396|NCT04537624|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219042827|NCT04471168|DEVICE|Cryo-Auriculotherapy|3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
219537510|NCT07096297|DRUG|Darbeopoetin|Darbepoetin alfa will be administered every 3 weeks (21 days), at a starting dose of 300 ug (Dose Level 0). Darbepoetin alfa will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Darbepoetin alfa will be administered as a subcutaneous injection by the site staff in the upper arm, thigh, and/or abdomen per institutional standard/guidelines.
219537511|NCT06908954|DRUG|Palovarotene|A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function
219537512|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)
219537513|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).
219537514|NCT07087340|DEVICE|UBLoop System|"Participants (people living with Type-1-Diabetes) will attend a study visit where the UBLoop system will manage insulin delivery via an insulin pump, using blood glucose values from a continuous glucose meter (CGM). Specialized staff and a remote monitoring system, which is integrated into the UBLoop system, will oversee the participants. The investigational product comprises (1) the BernSHELL App, communicating with the CGM and the insulin pump, (2) the UBLoop algorithm receiving CGM data, processing the control algorithm, calculating insulin dosing, checking the safety of the calculated insulin injections, and transmitting instructions to the insulin pump via BernSHELL, (3) the UBLoop Cloud providing secure storage, analytics support, and data backup, (4) DigiCare, monitoring the safety of the study participants and the system's execution flow in real time.~During the intervention, participants will use the Ypsomed myLife YpsoPump (insulin pump) and the Dexcom G6 or G7 CGM."
219042828|NCT04471168|DEVICE|Sham comparator|3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
219042829|NCT07025278|BEHAVIORAL|Medium difficulty fixed priority group|During the intervention process, participants carried out cognitive and motor tasks simultaneously. They were told to divide attention equally between them and not prioritize one over the other.
219042830|NCT07025278|BEHAVIORAL|Medium difficulty variable priority group|During the intervention process, participants performed medium-difficulty cognitive and motor tasks simultaneously. Participants alter focus between the motor task and the cognitive task every half of the intervention time.
219042831|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
219042832|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
218923397|NCT06104462|DEVICE|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10\*3\*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 \* (Dsitex - Dm1). Therefore, 2.8 \* 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
219537515|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
219537516|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
219537517|NCT07099651|OTHER|tests|neuropsychological tests + Neuroimaging
218923398|NCT04760808|DIAGNOSTIC_TEST|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
218923399|NCT04760808|RADIATION|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
218923400|NCT04760808|DIAGNOSTIC_TEST|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
218923401|NCT04760808|RADIATION|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
218923402|NCT04322890|DRUG|Osimertinib|Osimertinib 80mg, po, qd;
219537518|NCT06779890|DRUG|Sevoflurane|Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
219537519|NCT06779890|DRUG|Desflurane|Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
219537520|NCT06752330|DIETARY_SUPPLEMENT|Use of probiotics during oral hygiene at home|The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
219537521|NCT07099430|DRUG|LBL-024 for Injection|LBL-024 , Intravenous infusion.
219537522|NCT07099430|DRUG|LBL-007 Injection|LBL-007 , intravenous infusion.
219537523|NCT07099430|DRUG|Toripalimab Injection|Toripalimab , intravenous infusion.
219537524|NCT06603246|DRUG|GDC-6988|GDC-6988 will be administered using a dry powder inhalation
219537525|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
219537526|NCT07081555|DRUG|[177Lu]Lu-ABY-271|A single infusion of \[177Lu\]Lu-ABY-271
219537527|NCT07105020|BEHAVIORAL|Interviews|Interviews will be conducted in person, over the phone, or via Zoom.
219537528|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
218923403|NCT04322890|DRUG|Alectinib 150 MG|Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
218923404|NCT04322890|DRUG|Crizotinib 250 MG|Crizotinib 250 MG po bid.
219042833|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
219537529|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
219537530|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
219537531|NCT06914609|DRUG|ION582|ION582 will be administered by IT injection.
219537532|NCT06914609|DRUG|Placebo|ION582 matching placebo will be administered by IT injection.
219537533|NCT05939414|DRUG|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
219537534|NCT07107685|OTHER|Global cohort|All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.
219537535|NCT06779773|DRUG|Avacincaptad pegol (ACP)|intravitreal injection
219537536|NCT05859334|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219537537|NCT05859334|DRUG|Erdafitinib|Given PO
218923405|NCT04322890|DRUG|Savolitinib, Crizotinib.|Savolitinib, 300mg po qd.
218923406|NCT04322890|DRUG|Chemotherapy|500mg, ivgtt, every 21day.
218923407|NCT06339099|OTHER|Conventional physical therapy program|This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
218923408|NCT06339099|OTHER|Loaded gait training|An extra weight was added around the distal legs during gait training in the intervention group. This weight began at 0.5 kg and was gradually increased every two weeks to a maximum of 2 kg
218923409|NCT05398172|DEVICE|MorpheusV Applicator|Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
218923410|NCT04017546|DRUG|CYC065|intravenous infusion
218923411|NCT04017546|DRUG|Venetoclax|oral capsule
218923412|NCT06135805|DRUG|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
218923413|NCT06135805|DRUG|Placebo|Application of placebo oral gel on oral lesions
218923414|NCT04882202|DRUG|Acetaminophen|Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
218923415|NCT04882202|OTHER|Placebo|Normal saline 100 ml (equal amount of acetaminophen) IV every 6 hours
219537538|NCT05859334|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219537539|NCT05859334|PROCEDURE|Optical Coherence Tomography|Undergo OCT
219537540|NCT05653219|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
219537541|NCT05653219|DRUG|Eltrombopag|Film-coated tablet for oral use
219537542|NCT05653219|DRUG|Placebo|Concentrate for solution for infusion for intravenous use.
219537543|NCT06455202|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
219537544|NCT06455202|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
219619386|NCT04796909|BEHAVIORAL|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
219619387|NCT04796909|BEHAVIORAL|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
219619388|NCT05633667|DRUG|Zimberelimab (ZIM)|Administered intravenously
219619389|NCT05633667|DRUG|Domvanalimab (DOM)|Administered intravenously
219619390|NCT05633667|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
219619391|NCT05633667|DRUG|Etrumadenant (ETRUMA)|Administered orally
219619392|NCT05633667|DRUG|Carboplatin|Administered intravenously
219619393|NCT05633667|DRUG|Cisplatin|Administered intravenously
219619394|NCT05633667|DRUG|Pemetrexed|Administered intravenously
219619395|NCT05633667|DRUG|Paclitaxel|Administered intravenously
219619396|NCT05633667|DRUG|Nab-paclitaxel|Administered intravenously
219619397|NCT05633667|DRUG|Docetaxel|Administered intravenously
219619398|NCT05633667|DRUG|Nivolumab|Administered intravenously
219619399|NCT06153836|PROCEDURE|Neurotization Procedure|Undergo placement of nerve graft
219619400|NCT06153836|OTHER|Questionnaire Administration|Ancillary studies
219619401|NCT06153836|PROCEDURE|Subcutaneous Mastectomy|Undergo standard of care NSM
219619402|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
218923416|NCT04806685|BEHAVIORAL|Sleep education|Medical nutrition therapy plus behavior-based sleep education intervention
218923417|NCT04806685|BEHAVIORAL|Diet only|No sleep education
218923418|NCT04006587|DEVICE|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
219537545|NCT06765109|DRUG|Neladalkib (NVL-655)|Oral tablet of Neladalkib (NVL-655)
219537546|NCT06765109|DRUG|Alectinib|Oral capsule of alectinib
219537547|NCT05125302|DRUG|Ubrogepant|Oral Tablet
219537548|NCT05125302|DRUG|Placebo-Matching Ubrogepant|Oral Tablet
219537549|NCT06814509|BEHAVIORAL|Enhanced Standard of Care (ESoC)|Standard recommended nutrition and gestational weight gain counseling; WIC and SNAP enrollment assistance; emergency food referrals
219537550|NCT06814509|BEHAVIORAL|Delivering HOPE|ESoC plus healthy food provision
219537551|NCT06552754|BEHAVIORAL|Motion Reset|virtual reality-based experiential, sensory intervention
219537552|NCT06552754|BEHAVIORAL|Placebo|virtual reality-based experiential, sensory experience without intervention
218923419|NCT01016249|DRUG|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
218923420|NCT01016249|DRUG|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
218923421|NCT01016249|DRUG|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
218923422|NCT03873077|PROCEDURE|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
218923423|NCT03863080|DRUG|RVT-1401|Subcutaneous administration of RVT-1401
218923424|NCT03863080|DRUG|Placebo|Subcutaneous administration of Placebo
219537553|NCT06917781|OTHER|Patients with 18F-PET-PSMA indication|"Blood samples taken on several occasions:~* before the 18F-PSMA PET scan for extension assessment, for all patients.~* at 2nd and 4th treatment cycles (prior to treatment administration), only for patients receiving PLUVICTO® therapy.~During the 1st treatment cycle, samples (optional for the patient) may also be taken at 5 different post-perfusion times.~In addition, all imaging examinations performed during the study (standard 18F-PSMA PET scans) will be collected and centralized by the Sponsor for analysis."
219537554|NCT07111559|DRUG|rt-PA|Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.
219537555|NCT07111559|DRUG|DAPT|Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.
218923425|NCT02220543|OTHER|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
218923426|NCT02220543|OTHER|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
218923427|NCT02368834|BEHAVIORAL|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
218923428|NCT04951024|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
218923429|NCT04951024|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
218923430|NCT04684277|DRUG|antidepressant treatment|depression recieve antidepressant treatment
219537558|NCT07113483|DRUG|Midazolam|"Midazolam:~A commonly used benzodiazepine for sedation, administered intravenously at 0.025-0.05 mg/kg with supplemental doses as required. Known for effective anxiolysis and sedation but with a longer recovery profile compared to remimazolam."
218923431|NCT04684277|OTHER|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
218923432|NCT01342211|BIOLOGICAL|Placebo|Intravenous placebo monthly during treatment phase.
218923433|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
219537559|NCT07113483|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|"Remimazolam:~A novel, ultra-short-acting benzodiazepine used for procedural sedation. Administered intravenously at 5 mg over 1 minute with supplemental dosing as needed. Characterized by rapid onset and quick recovery, with minimal residual sedation."
219537560|NCT07112651|DIETARY_SUPPLEMENT|CL25216|250mg to take one capsule a day after breakfast for 105 days
219537561|NCT07112651|DIETARY_SUPPLEMENT|Placebo|One capsule a day after breakfast for 105 days
219537562|NCT07109297|BIOLOGICAL|Nirsevimab|Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
218923434|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
218923435|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
218923436|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
218923437|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
218923438|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
218923439|NCT01342211|DRUG|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
219537563|NCT07110688|BEHAVIORAL|Virtual human social interaction|The participants will perform a social interaction with the virtual human agent platform to assess mental states.
219537564|NCT07110688|BEHAVIORAL|Cold pressor test|Healthy participants will immerse one hand in cold water for less than 3 minutes, while physiological data will be collected by the new wearable sensor from the other hand.
219537565|NCT06907719|OTHER|Primary Services|Participants receive 40 hours of the Blueprint and 24/7 Dad curricula over the course of ten weeks.
219537566|NCT06863974|OTHER|Blood test|Drawing blood to realize biomarkers of disease course of MOGAD-ADEM and pathophysiology of ADEM (and MOGAD) : cellular and molecular signatures, inflammatory signaling.
218923440|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
218923441|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
218923442|NCT05802212|DRUG|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
218923443|NCT05724277|BEHAVIORAL|Mindfulness Meditation|A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.
218923444|NCT05724277|BEHAVIORAL|Virtual Reality|A 10-minute virtual reality experience will be provided by using virtual reality glasses.
218923445|NCT01851642|PROCEDURE|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
218923446|NCT01851642|PROCEDURE|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
218923447|NCT01851642|PROCEDURE|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
218923448|NCT01851642|DRUG|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
218923449|NCT06543745|BEHAVIORAL|Low-Resistance Training|"The following 6 exercises will be performed in 3 sets of 15-15-15 repetitions, 3 times per week for 12 weeks:~Elbow Flexion, Elbow Extension, Lateral Hip Extensions, Hip Extensions, Knee Extensions, Wall push-ups"
219537567|NCT06824103|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.
219537568|NCT07119489|BEHAVIORAL|Dialectical Behavior Therapy -Skill Training brief intervention|A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness
218923450|NCT05558969|DRUG|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
219537569|NCT07121478|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
218923451|NCT05558969|DRUG|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
218923452|NCT06117605|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
218923453|NCT06117605|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
219537570|NCT06916143|DRUG|LY4100511|Administered orally.
219537571|NCT06916143|DRUG|Rabeprazole|Administered orally.
219619403|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
218923454|NCT01899521|PROCEDURE|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
218923455|NCT01899521|DIETARY_SUPPLEMENT|Zinc sulfate 220 mg once daily|
218923456|NCT01899521|DIETARY_SUPPLEMENT|S-adenosylmethionine 400 mg twice daily|
218923457|NCT01877070|BEHAVIORAL|assessments|
218923458|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
218923459|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
219537572|NCT07122401|DRUG|MT1013|MT1013 + dummy cinacalcet
219537573|NCT07122401|DRUG|Cinacalcet|Cinacalcet + dummy MT1013
219537574|NCT07125378|BEHAVIORAL|Task-oriented resistance exercise|The intervention program includes progressive resistance exercise and daily activity exercise, delivered over a six-week period with an ideal frequency of three sessions per week. Progressive resistance exercise will be provided through a combination of in-person and online sessions, while daily activity exercise will be delivered exclusively in person.
218923460|NCT05595707|OTHER|Expert-Guided Early Tracheostomy|Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
218923461|NCT01367106|PROCEDURE|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
218923462|NCT06214689|OTHER|biomarkers analysis|IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
219537575|NCT07127835|DIAGNOSTIC_TEST|Nurse-led penicillin allergy delabelling service|Patients in this group undergo risk assessment and categorization by nurses to identify low-risk individuals for delabeling. For these patients, nurses will collaborate with allergists in the delabeling process.
218923463|NCT05063058|DRUG|Molecular guided therapy|Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
218923464|NCT06967194|DRUG|Metoprolol (MET)|Administration of metoprolol 25 mg twice daily
219537576|NCT07127835|DIAGNOSTIC_TEST|Allergist-led penicillin allergy delabelling service|Patients assigned to this group will undergo risk assessment and delabeling led by allergists for both low-risk and high-risk cases.
219537577|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
219537578|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
219537579|NCT06933524|DRUG|ATB-320|IV infusion
219537580|NCT06939361|OTHER|Smaller endotracheal tube|"* Inner diameter 7.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 6.5 mm (for patients with a height \< 64 inches)"
219537581|NCT06939361|OTHER|Larger endotracheal tube|"* Inner diameter 8.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 7.5 mm (for patients with a height \< 64 inches)"
218923465|NCT06967194|DRUG|Plcacebo|Administration of matching placebo
218923466|NCT06972121|BEHAVIORAL|Mindset Intervention|The mindset intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. The content introduces meta-mindsets (beliefs about how mindsets shape experiences and outcomes) and reframes non-severe physical symptoms (e.g., muscle soreness, fatigue) as signs of physiological adaptation. Modules cover: (1) what mindsets are and how they affect performance; (2) how to interpret normal training symptoms as positive signals; (3) how to maintain adaptive mindsets during peak training; and (4) race-day mindset preparation. Each module includes brief text, visuals, and reflection questions and takes approximately five minutes to complete.
219537582|NCT06937931|BIOLOGICAL|IPN10200|Study intervention will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
219537583|NCT06937931|OTHER|Placebo|Excipients without active substance will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
219537584|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
219537585|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
219537586|NCT06942949|DEVICE|ELS (Enhanced Lithotripsy System)|ELS (Enhanced Lithotripsy System) utilizes low pressure ultrasound to actuate proprietary microbubbles administered into the urine to pit and fragment urinary stones.
219537587|NCT06940050|PROCEDURE|Coronally advanced flap with a connective tissue graft|The gum at the recession site is detached and reattached higher (combined with a connective tissue graft).
219537588|NCT06940050|PROCEDURE|Tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined with a connective tissue graft).
219537589|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
219537590|NCT06945406|DRUG|LY4057996 SC|Administered SC
219537591|NCT06945406|DRUG|LY4057996 IV|Administered IV
219537592|NCT06945406|DRUG|Placebo SC|Administered SC
219537593|NCT06945406|DRUG|Placebo IV|Administered IV
219537594|NCT06945406|DRUG|Degludec SC|Administered SC
219537595|NCT06945406|DRUG|Lispro SC|Administered SC
219537596|NCT06945406|DRUG|Degludec IV|Administered IV
219537597|NCT06945406|DRUG|Pre-study basal insulin SC|Administered SC
219537598|NCT03778307|BEHAVIORAL|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
219537599|NCT03778307|BEHAVIORAL|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
219537600|NCT07070089|DEVICE|BosSTENT implantation|BosSTENT implantation in the transverse venous sinus
219537601|NCT06955741|DRUG|BMS-986446 IV|Specified dose on specified days was administered intravenously (IV).
219537602|NCT06955741|DRUG|BMS-986446 SC|Specified dose on specified days was administered subcutaneously (SC).
219537603|NCT06955741|DRUG|Acetaminophen|Specified dose on specified days
218923467|NCT06972121|BEHAVIORAL|Marathon Performance Training|The marathon performance training intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. Content is based on publicly available half-marathon training guidance and excludes any mindset-related material. Modules cover: (1) setting race goals and structuring training plans; (2) training tips and best practices (e.g., pacing, injury prevention); (3) navigating peak training periods (e.g., distance increases, rest and recovery); and (4) practical race-day preparation strategies (e.g., pacing, fueling, warm-up routines). Each module includes concise text, visuals, and actionable tips designed to take approximately five minutes to complete.
218923468|NCT06972277|BEHAVIORAL|Commercial weight management program|Participants will receive evidence-based behavioral / lifestyle support from a commercial weight management program.
218923469|NCT05890664|DRUG|Colchicine|"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."
218923470|NCT05890664|DRUG|Placebo|Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
218923471|NCT01582269|DRUG|LY2157299 monohydrate|Orally administered as tablets
218923472|NCT01582269|DRUG|Lomustine|Orally administered as capsules
218923473|NCT01582269|DRUG|Placebo|Orally administered as tablets
218923474|NCT00289042|DRUG|Enoxaparin|
219537604|NCT06955741|DRUG|Loratadine|Specified dose on specified days
219537605|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-poor, plant sterol-poor shake|The first arm is the cholesterol-poor arm, where participants will be given a mixed meal in the form of a cholesterol-poor, plant-sterol-poor shake which provides the lowest cholesterol absorption rate.
219619404|NCT06117150|DEVICE|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
219619405|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
219619406|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
219619407|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
219619408|NCT06557733|PROCEDURE|Biopsy Procedure|Undergo biopsy
219619409|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219537606|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-poor shake|The second arm is the high-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-poor shake, which provides the highest cholesterol absorption rate.
219537607|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-rich shake|The third arm is the moderate-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-rich shake, which provides the moderate cholesterol absorption rate.
219619410|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
219619411|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
219619412|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
219619413|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
219619414|NCT05653687|DEVICE|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
219619415|NCT06581874|OTHER|Clinical assessment by emergency psychiatrist|After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.
219619416|NCT06581874|OTHER|Psychiatric consultation booked through Med@Psy platform|The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
219619417|NCT06375083|BEHAVIORAL|Cognitive Behavioral Therapy|The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
219619418|NCT05252949|DIETARY_SUPPLEMENT|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
219619419|NCT05252949|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
219619420|NCT06513728|OTHER|MPACT Intervention|MPACT has 4 components: accredited training about patient centered, trauma informed methadone treatment, staff education about trauma symptoms with navigation to self screening and treatment or stress management, clinic self assessment tools for trauma informed, patient centered care, and reflective supervision for counselors, case managers and peer staff.
219619421|NCT05512143|DEVICE|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
218923475|NCT06175884|OTHER|Video about pain neuroscience education with enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will show evidence-based communication skills to effectively convey information to patients.
218923476|NCT06175884|OTHER|Video about pain neuroscience education without enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will not show evidence-based communication skills to effectively convey information to patients.
218923477|NCT03626103|BEHAVIORAL|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
218923478|NCT03626103|BEHAVIORAL|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
219537608|NCT07142512|BEHAVIORAL|Step Count tracking and goals|We will provide participants and partners with Fitbits for the duration of the trial. After one week of step counting, the next week target will be to increase by 500 steps/day if baseline \< 5000 steps/day; increase by 750 steps/day if baseline 5000 to 7,500 steps/day; and increase by 1,000 steps/day if baseline \> 7,500 steps/day). Each week thereafter, study staff will pull the step data and apply an algorithm to generate new targets for the next week. In our algorithm, subsequent targets are higher if the participant exceeds prior week targets, and lower/unchanged if below target. This is similar to the algorithm we used in our trial ACTIVE PATIENT GDM (Dasgupta K, Chan D, Bond R, Garfield N, Coolen J, Halperin IJ, Peters TM, et al. Step and weight tracking with targets and coaching interventions in gestational diabetes: A randomized factorial feasibility trial. Diabetes Res Clin Pract. 2025 Jun;224:112241. doi: 10.1016/j.diabres.2025.112241. Epub 2025 May 9. PMID: 40349846.)
219537609|NCT07142512|BEHAVIORAL|Dyadic coping intervention|"Couples will participate in 8 one-hour coaching sessions over 12 weeks (virtual, in-person, or a combination, as preferred). The sessions aim to enhance the couple's understanding of how they influence each other. Both couple members will explore their preferences in terms of ways of communicating and supporting one another's goals. We will use changes in steps as a context to explore how partners can effectively support and coach each other without without eliciting behavioural reactance. We will use are goal setting, action planning, self-monitoring, graded tasks, social environment restructuring, and social support. The coaches will be psychology students. They will receive structured training on the coaching strategy from a licensed mental health professional. We will record the sessions for fidelity and quality assurance purposes. All coaches will meet weekly with the supervising licensed mental health professional."
218923479|NCT04021654|PROCEDURE|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
218923480|NCT04310462|OTHER|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
218923481|NCT05481723|DRUG|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
219537610|NCT07140783|DRUG|0.75% Phentolamine Ophthalmic Solution|Once daily dosing
219537611|NCT07140783|DRUG|Placebo|Once daily dosing
219537612|NCT07147348|BIOLOGICAL|BNT3212|Intravenous infusion
219537613|NCT07147348|BIOLOGICAL|BNT327|Intravenous infusion
219537614|NCT07152327|DRUG|Terbinafine Hydrochloride Cream|Topical antifungal treatment. Terbinafine hydrochloride 1% cream will be applied on an ear pack, inserted into the external auditory canal, and changed every 2 days. Treatment continues for 14 days.
219537615|NCT07151248|DEVICE|Cranial electrical/electrotherapy stimulation (CES)|"Cranial electrical/electrotherapy stimulation (CES) is a non-pharmacological, portable, non-invasive intervention.~Active research units will be locked at the specified amplitude and administer that amplitude of stimulation for 60 minutes therapy."
219537616|NCT07151248|DEVICE|Sham Cranial electrical/electrotherapy stimulation (CES)|Sham research units will be locked into active sham mode which provides stimulation designed to provide the sensation of stimulation for only 5 minutes while continuing to count down for the remaining 55 minutes.
218923482|NCT05481723|PROCEDURE|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
218923483|NCT06482125|DRUG|Dexmedetomidine|Intervention group will receive Total Intravenous Dexmedetomidine as their anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour continued as the sole anesthetic maintenance agent, thereafter.
219537617|NCT07153341|BEHAVIORAL|STEP Decision Support Toolkit|The STEP toolkit includes (1) an educational booklet provided upon admission and annually, (2) condition-specific decision aids addressing common clinical scenarios, and (3) structured phone scripts for staff. STEP empowers residents and care partners to actively engage in decision-making, promotes care aligned with personal values, and supports staff in facilitating advance care planning to reduce unnecessary or complex transitions.
219537618|NCT07154823|OTHER|None - Observational Study|There are no interventions in this observational study.
219537619|NCT06839079|BEHAVIORAL|A Trauma-informed, Paraprofessional Delivered Virtual Cognitive Rehabilitation Program|The intervention will involve 8 proposed individual sessions conducted virtually by a trained bilingual paraprofessional. The intervention will be provided in English or Spanish depending on the participant's preference. The sessions cover psychoeducation about TBI and related symptoms like depression and anxiety, and cognitive activities to address cognitive symptoms (e.g., relaxation strategies and exercises around improving attention, concentration, learning, and memory). Each session covers the topic, real-life examples and practice, and exercises to do outside of the sessions.
219537620|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
219537621|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
218923484|NCT06482125|DRUG|Sevoflurane|Inhalation Sevoflurane will be administered as an anesthetic maintenance agent. Sevoflurane at 2 - 3 Vol% will be administered throughout the operative procedure.
218923485|NCT05353777|DEVICE|Levita Robotic Platform|Levita Robotic Platform
218923486|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
218923487|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
219537622|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
219537623|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
219537624|NCT07146568|OTHER|Pink and Pearl Campaign|This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening.
219537625|NCT07162454|DRUG|Group 1. Complete formula|After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.
219537626|NCT07162454|DRUG|Group 2. Cannabidiol and Urea 10% formula.|After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.
218923488|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
218923489|NCT05667181|DEVICE|Surform|Da Vinci linear cutting stapler
218923490|NCT05979311|DRUG|Dolutegravir|Dolutegravir will be administered once daily.
218923491|NCT05979311|DRUG|Lamivudine|Lamivudine will be administered once daily.
218923492|NCT05979311|DRUG|Bictegravir|Bictegravir will be administered once daily.
218923493|NCT05979311|DRUG|Emtricitabine|Emtricitabine will be administered once daily.
218923494|NCT05979311|DRUG|Tenofovir alafenamide|Tenofovir alafenamide will be administered once daily.
218923495|NCT04809987|OTHER|Virtual Gait|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.
219537627|NCT07162454|DRUG|Group 3. Placebo formula.|Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.
219537628|NCT07166861|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
219537629|NCT07166861|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
219537630|NCT07164859|DRUG|short dual antiplatelet therapy (DAPT) duration|patients will receive DAPT for 7 days (after randomization) followed by P2Y12 inhibitor alone
219537631|NCT07164859|DRUG|Standard DAPT duration|patients will receive DAPT for at least 3 months after randomization or longer and followed by single antiplatelet therapy
219537632|NCT07166601|BIOLOGICAL|M0324|M0324 will be tested at increasing doses as monotherapy to determine dose-toxicity relationship and MTD (if reached) in order to support selection of recommended dose(s) for expansion (RDE).
219537633|NCT07166601|BIOLOGICAL|M0324|M0324 will be further investigated in part 2 and part 3 of the study as combination regimen, in order to determine dose-toxicity relationship in combination and MTD (if reached) in order to support selection of RDE(s) in combination.
219537634|NCT07166601|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously as per standard of care.
219537635|NCT07166601|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered intravenously as per standard of care.
219619422|NCT05493904|PROCEDURE|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~1. By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane \[EEL\] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex\> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~2. By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex\> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
219619423|NCT05493904|PROCEDURE|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
218923496|NCT04809987|OTHER|Physical Exercise|Specific gait exercise was conducted.
218923497|NCT04809987|OTHER|Documental projection|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
218923498|NCT06178055|DRUG|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
218923499|NCT06178055|DRUG|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
219537636|NCT07151573|OTHER|Big Five|"The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Things you do action and how it promotes mental health. The final section presents the five core actions: 1) healthy thinking, 2) meaningful activities, 3) goals and plans, 4) healthy habits, and 5) social connections. Participants are advised to engage in the five daily actions throughout the intervention period. They are also encouraged to fill out a weekly planner and monitor their progress by keeping an overview of the number of daily activities in My Week.The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions."
218923500|NCT06178055|DRUG|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
219537637|NCT07151573|OTHER|Gratitude|The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Gratitude and how it promotes mental health, followed by a short summary on the benefits of gratitude. The final section introduces practical strategies for cultivating gratitude by focusing on five key gratitude activities: 1) keeping a gratitude journal, 2) expressing gratitude to others, 3) finding gratitude in misfortune or difficult situations, 4) appreciating good things and 5) another perspective. The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
219537638|NCT07161999|DRUG|COYA 302|Administered as specified in the treatment arm.
219537639|NCT07161999|DRUG|Placebo|Administered as specified in the treatment arm.
219537640|NCT07170150|DRUG|Trontinemab|Participants will receive IV trontinemab
219537641|NCT07170150|OTHER|Placebo|Participants will receive IV placebo
219537642|NCT07171970|PROCEDURE|IVM-Fresh (No gonadotropin + Fresh embryo transfer)|Patients randomized to this arm will receive estradiol valerate 8 mg/day. IVM will be performed after ≥10 days of estrogen and ET ≥8 mm. From the day of ICSI, they will continue estradiol and start vaginal progesterone 800 mg/day + dydrogesterone (20mg/day). A fresh embryo transfer will subsequently be performed.
219537643|NCT07171970|PROCEDURE|IVF-FET (GnRH-Antagonist - Agonist Trigger - Frozen embryo transfer)|Patients randomized into this group will receive FSH at a dose of 150 IU/day. Oocyte retrieval will be performed once the criteria for triggering are fulfilled, followed by embryo cryopreservation and frozen embryo transfer in the subsequent cycle. Endometrial preparation for frozen embryo transfer will be conducted using an exogenous steroids regimen. Patients will receive estradiol 8 mg/day starting from cycle days 2-3 for 10 days. When the endometrial thickness reaches ≥8 mm, luteal phase support will be initiated with vaginal progesterone 800 mg/day plus dydrogesterone 20 mg/day.
219537644|NCT07179484|DRUG|CT041 autologous CAR T-cell injection|The planned dose of CT041 is 2.5×108 cells. The participants are recommended to receive only a single infusion or multiple infusions (up to 3 infusions) according to the safety and efficacy data of the participants per the investigator. The dose and method of re-infusion are the same as the first infusion. Lymphodepletion pretreatment should be given before re-infusion, and the requirements before lymphodepletion pretreatment and cell infusion should also be met before re-lymphodepletion pretreatment or re-infusion.
218923501|NCT06970093|PROCEDURE|One Anastomosis Gastric Bypass|Participants will undergo One Anastomosis Gastric Bypass (OAGB), a laparoscopic bariatric procedure that creates a long narrow gastric pouch and anastomoses it to a loop of jejunum approximately 150-200 cm from the ligament of Treitz. This bypasses the compressed duodenum to relieve symptoms of SMAS while promoting weight gain or nutritional restoration in undernourished patients.
218923502|NCT06970093|PROCEDURE|Duodenojejunostomy|Participants will undergo Duodenojejunostomy (DJ), a standard surgical procedure to bypass the compressed segment of the duodenum. It involves creating an anastomosis between the duodenum and the jejunum distal to the point of compression, allowing normal food passage and relieving symptoms of Superior Mesenteric Artery Syndrome.
218923503|NCT02828826|OTHER|telephone coaching|
218923504|NCT02582775|DRUG|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
218923505|NCT02582775|DRUG|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
218923506|NCT02582775|DRUG|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
218923507|NCT02582775|RADIATION|Total Body Irradiation|See arm description for dosing.
218923508|NCT02582775|PROCEDURE|Bone marrow infusion|Bone marrow infusion on Day 0
219537645|NCT07179016|BEHAVIORAL|Auricular Point Acupressure (APA) - Self Management (SM)|APA is a noninvasive and needle-free pain management therapy based on the principles of acupuncture. The APA-SM intervention program is aimed to manage chronic musculoskeletal pain leveraging a mobile app containing APA videos and remote vs in-person guidance or coaching to practice APA based on APA study assignment.
219537646|NCT07179016|BEHAVIORAL|Education Control|Education Control group receive an app but the content will be specific to pain and self-management (no APA content) and they practice pain self-management skills (no APA practice).
219537647|NCT07179614|BEHAVIORAL|Overdose Prevention Intervention Package (OPIP)|WJCOIN-II's multi-level 2 X 2 randomized factorial design will examine the effectiveness of OPIP components across four study conditions randomly assigned after baseline data collection (n=75 per condition, 100 per jail site), summarized in Table 7 and described below. In addition to group assignment, outcomes will be assessed as a function of engagement in each intervention component defined as the number of sessions attended (RC and CM conditions) and perceived support, which is a count of the number of types of support provided by the RC and SP (e.g., emotional, financial, etc.).
218923509|NCT02582775|DRUG|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.
218923510|NCT02582775|DRUG|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
218923511|NCT02582775|BIOLOGICAL|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
218923512|NCT02582775|DRUG|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
218923513|NCT01885299|RADIATION|SRS/SBRT|Intervention varies by condition being treated.
218923514|NCT04720183|DRUG|Sulfasalazine|On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
219537648|NCT07184151|DRUG|well root putty ( premixed bioceramic putty) retrograde filling|well root putty ( premixed bioceramic putty) retrograde filling
219537649|NCT07184151|DRUG|MTA retrograde filling|MTA retrograde filling
219537650|NCT07160608|DRUG|Placebo|Participants will receive placebo.
219537651|NCT07160608|DRUG|Tarperprumig|Participants will receive tarperprumig.
219537652|NCT04586660|DRUG|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
219537653|NCT07184619|DRUG|Evenamide 15 mg bid|Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment
219537654|NCT07184619|DRUG|Placebo|Matching placebo capsules bid for a total of 12 weeks of add-on treatment
219537655|NCT07190625|DRUG|fentanyl intravenous|giving intravenous fentanyl
218923515|NCT04720183|DRUG|GLPG3970|On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
218923516|NCT06573879|BEHAVIORAL|Eccentric Exercise|It was investigated whether volleyball athlete participants would develop muscle architecture, muscle strength and performance parameters differently from the control group by performing eccentric exercises in addition to their exercise routines.
219537656|NCT07190625|DRUG|Fentanyl intranasal using atomizer|giving intranasal fentanyl using nasal atomizer
219537657|NCT07190625|DRUG|fentanyl intranasal direct|giving intranasal fentanyl directly into nostrils
219619424|NCT05493904|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
219619425|NCT06522607|DEVICE|rapid palatal expander|Clinical evaluation of the patients who will be treated with rapid palatal expander for about 6 month.
218923517|NCT05964218|BEHAVIORAL|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
219537658|NCT07191353|DRUG|Everolimus|Everolimus 5 mg administered once weekly for 24 weeks
219537659|NCT07191353|DRUG|Placebo|Placebo administered once weekly for 24 weeks
219537660|NCT07191353|OTHER|Resistance training|Resistance training 3 times a week for 24 weeks
219537661|NCT07189416|PROCEDURE|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"
219537662|NCT07200505|OTHER|TR Mixed CORE Exercices|The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalise the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously. he intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance.
219537663|NCT07200505|OTHER|TR Asyncronous CORE Exercices|"The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalize the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously.~The intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance."
219537664|NCT07201298|DEVICE|Ray-Tracing Guided LASIK|A form of LASIK where Ray-Tracing technology is used to create the surgical profile for treating the cornea.
219537665|NCT07201298|DEVICE|Keratorefractive Lenticule Extraction (KLEx)|A form of corneal refractive surgery utilizing a femtosecond laser to create a lens shaped lenticule of corneal tissue that is removed through a small corneal incision.
219537666|NCT07201298|DEVICE|WaveFront Optimized LASIK|A form of LASIK where the corneal treatment profile is modified to decrease induced Spherical Aberration.
219537667|NCT07201298|DEVICE|Topography Guided LASIK|A form of LASIK where a corneal topography of the cornea is used to create the surgical profile for treating the cornea.
219537668|NCT04975698|BIOLOGICAL|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.
219537669|NCT04975698|BIOLOGICAL|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
219537670|NCT07200492|OTHER|Facial serum application|The trained technician will apply the 0.3g-0.4g investigational products on the subject's half face.
219537671|NCT07200492|OTHER|Forearm serum application|The trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm.
219537672|NCT07200700|DIAGNOSTIC_TEST|Knee laxity arthrometer|Inter-reliability analysis of the GNRB arthrometer between two examinors compared to standard KT 1000 arthrometer
219619426|NCT05382442|DRUG|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
219619427|NCT05382442|DRUG|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
219619428|NCT05382442|DRUG|Oxaliplatin|Oxaliplatin via IV infusion
219619429|NCT05382442|DRUG|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
219619430|NCT05382442|DRUG|Irinotecan|Irinotecan via IV infusion
219619431|NCT05382442|DRUG|Leucovorin|Leucovorin via IV infusion
219619432|NCT05382442|DRUG|5-fluorouracil|5-fluorouracil via IV infusion
218923518|NCT02352896|DRUG|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
219537673|NCT07201454|BEHAVIORAL|nursing care|The first stage is the collection of quantitative data. Only quantitative data were collected from patients and caregivers in the experimental and control groups before the implementation of curative care practices based on human caring theory. The second stage includes curative care practices within the scope of the study for the experimental group. Patients and their relatives in the control group will receive routine care services provided at the clinics where the study was conducted, but no interventions will be implemented by the researchers. The third stage is the stage where patient satisfaction, caregiver burden, feelings of entrapment, and satisfaction with caregiving are assessed after the curative care practices. This stage is the final test of quantitative data and the collection of qualitative data. The fourth stage is the evaluation stage. In the final stage, data obtained from all stages will be compared, evaluated, and interpreted.
218923519|NCT06510153|OTHER|Environmental Music Therapy|The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution during approximately 20 minutes.
218923520|NCT06510153|OTHER|Pre-recorded music|The protocol for pre-recorded music is the same as for EMT.
218923521|NCT06510153|OTHER|Standard care only|Standard care in the emergency room waiting room as provided by each hospital without being exposed to EMT or pre-recorded music.
218923522|NCT05104606|OTHER|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~* The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~* The second TEE will be performed at H24 to performed new measurements."
218923523|NCT05104606|OTHER|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
218923524|NCT01588522|DRUG|Compound 31543 Calcitriol 5 μg/mL|5 μg/mL Topical Solution
218923525|NCT01588522|DRUG|Compound 31543 Calcitriol 10 μg/mL|10 μg/mL Topical Solution
218923526|NCT01588522|DRUG|Compound 31543 Calcitriol 20 μg/mL|20 μg/mL Topical Solution
218923527|NCT01588522|DRUG|Compound 31543 Calcitriol 40 μg/mL|40 μg/mL Topical Solution
218923528|NCT01588522|DRUG|Compound 31543 Calcitriol 60 ug/mL|60 ug/mL Topical Solution
218923529|NCT01588522|DRUG|Compound 31543 Calcitriol 80 μg/mL|80 μg/mL Topical Solution
218923530|NCT05500794|OTHER|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~* Guided meditation practices;~* Mindfulness stretching and yoga;~* Reflection and group discussion periods aimed at promoting mindfulness in daily life;~* Practice instructions and opportunity to ask questions;~* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
218923531|NCT05387122|DEVICE|mandibular advancement device (MAD)|mandibular advancement device (MAD) is a removable oral appliance. It is an alternative therapy for patients of Obstructive Sleep Apnea who are non compliant to Continuous positive airway pressure(CPAP) which is the most accepted therapy for Obstructive Sleep Apnea.
219537674|NCT07196904|DEVICE|Ultrasonic Device (Piezosurgery)|Mandibular impacted third molar extraction performed with an ultrasonic surgical device. The piezosurgery device was used exclusively for the osteotomy (bone removal) stage, while conventional rotary instruments were still used for tooth sectioning when required. This selective approach aimed to evaluate whether piezosurgery could reduce surgical trauma compared to full rotary techniques.
219537675|NCT07196904|DEVICE|Conventional rotary instruments|Mandibular impacted third molar extraction performed entirely with conventional rotary instruments. Both bone removal and tooth sectioning were conducted using high-speed rotary instruments under continuous irrigation. This served as the control arm to compare with the ultrasonic-assisted technique.
219537676|NCT07201584|DRUG|Torasemide tablet 10 mg|Tablets by Berlin-Chemie AG (Germany)
219537677|NCT07201584|DRUG|Unat® 10 tablets (Torasemide 10 mg)|Tablets by Viatris Healthcare GmbH (Germany)
219537678|NCT07200271|PROCEDURE|Arthroscopic reconstruction surgery|Arthroscopic reconstruction with allograft, in which a tendon (generally from a tissue bank) is used to reconstruct the ligaments. This technique is performed through small incisions using arthroscopy.
219537679|NCT07200271|PROCEDURE|Open surgery|Open surgery consists of the modified Broström-Gould technique, which allows for the reconstruction of damaged ligaments using the patient's own tissues through an incision on the lateral side of the fibula. This technique has shown satisfactory functional results.
219537680|NCT07201194|OTHER|Holistic acupuncture and acupressure|"The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding.~Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure.~A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes."
218923532|NCT05997225|OTHER|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
218923533|NCT05997225|OTHER|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
218923534|NCT05893485|BEHAVIORAL|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
218923535|NCT05060211|OTHER|Vancouver symptom score for dysfunctional elimination syndroms|Validated questionnaire concerning bladder and bowel symptoms
218923536|NCT05060211|OTHER|Magnetic resonance imaging|Known MRI results of the patient file
218923537|NCT03013998|BIOLOGICAL|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
219204864|NCT06984380|OTHER|Telerehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. BTS TELEREHAB is a platform that allows the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device, that measures movements in real-time, allowing the clinician to remotely monitor the correct execution of the exercises. In addition to the proposed therapeutic exercises, functional assessment tests are also included for patient follow-up. The presence of the inertial sensor supports the clinician in verifying the correct execution of the motor task and in the precise quantification of joint mobility.
219204865|NCT06984380|OTHER|Usual care|Participants will receive a booklet containing information and activities on well- being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
219204866|NCT06665568|DRUG|Intranasal ketamine hydrochloride|Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
219204867|NCT06858527|OTHER|TAU+integrated group CBT|"TAU+integrated group CBT : participants receive a group psychotherapeutic intervention of Integrated CBT lasting eight weekly two-hour sessions, in parallel with their usual individual care. The sessions are led by a psychologist trained and certified in the practice of CBT and a psychiatrist specialized in addiction medicine. The psychotherapeutic intervention follows a fixed structure and is inspired by the CBT manual for the management of ADHD associated with SUDs published by Matthys et al. (2018). This intervention includes modules on planning and organization, time and distraction management, emotional regulation, work on impulsive behaviors and social skills, cognitive work, as well as substance use management and relapse prevention.~The sessions will be punctuated by regular breaks to ensure participants' comfort and the integration of the skills worked on during the sessions.~TAU : participants receive their usual care, in exception of group psychotherapeutic interventions."
219204868|NCT06988228|BIOLOGICAL|15% Dextrose Injection|15% dextrose solution will be administered by injection in three sessions at two-week intervals. It will be applied in combination with conventional exercise therapy.
219204869|NCT06988228|OTHER|izotonic saline injection|Participants will receive isotonic saline solution injections in three sessions at two-week intervals, as a placebo comparator to the 15% dextrose injections. All participants will also receive conventional exercise therapy.
219204870|NCT06988943|DEVICE|Low-dose CT screening|Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination
219204871|NCT06988943|DEVICE|AI full-lung model interpretation system|Using artificial intelligence technology to assist in the interpretation of CT images
219204872|NCT06988943|DEVICE|Digital Health Platform|"Community health centers and streets in Guangzhou use a program called Fei Anxin to manage residents' information in a unified way"
219204873|NCT06996847|BEHAVIORAL|psychoeducational programme to promote a critical attitude towards the symbolic consumption of yoghurt in primary school children|The promotion of critical consumption in children is to be developed in primary school classrooms. Students will spend a total of 7 hours: (2 sessions of 1 hour per week) for 3 consecutive weeks, plus a feedback session (1 hour per week); and there will be another session with parents (1 hour per week). The psychologist tutor will receive a set of six activities related to discriminating between symbolic and critical yoghurt consumption in children, understanding the persuasive intent of yoghurt advertising, awareness of social pressure and critical attitude. Psychological tutors will be trained and provided with support materials and equipment
219537681|NCT07201194|OTHER|Standard medical treatment|Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.
219537682|NCT07202507|OTHER|self-report questionnaires, research interviews|self-report questionnaires and research interviews
219537683|NCT07200622|DRUG|Semaglutide (Rybelsus®)|All subjects will receive oral semaglutide once daily (4-weekly dose escalation from 3 mg to 7 mg and finally 14 mg). This dose escalation schedule is specified in the IMP (Rybelsus) SmPC.
219204874|NCT06997757|BEHAVIORAL|Mobile health|Instructions for brushing twice daily and using interdental cleaning aids via regular mobile phone messages will be sent atleast twice a week.
219537684|NCT07200622|DRUG|Placebo|Matched oral Placebo to be taken once daily.
219537685|NCT07201519|DEVICE|Hepatic Artery Infusion Pump (HAIP)|HAIP will be filled with mixture of FUDR + Dexamethasone, Heparin \& Saline for a 14 day infusion of drugs, followed by a 14 day infusion of Heparin+Saline.
219537686|NCT07201519|PROCEDURE|Standard Treatment|systemic therapy per standard-of-care and institutional standards; visits every two weeks and standard manual HAI dose calculation
219537687|NCT07201519|PROCEDURE|Community Treatment|systemic therapy fill by home infusion based on TO orders. In person visit with CO for systemic chemotherapy with dose recommendations from TO. Locally obtained testing with telehealth visits with TO team.
218923538|NCT03013998|BIOLOGICAL|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
218923539|NCT03013998|OTHER|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
218923540|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
218923541|NCT03013998|DRUG|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
218923542|NCT03013998|DRUG|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
218923543|NCT03013998|DRUG|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
218923544|NCT03013998|DRUG|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
218923545|NCT03013998|DRUG|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
218923546|NCT03013998|DRUG|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
218923547|NCT03013998|DRUG|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
219537688|NCT07201519|DRUG|Systemic Chemotherapy Standard of Care|"Dosing of systemic therapy will be according to established routine practice guidelines. Patients with colon cancer will receive systemic chemotherapy that will consist of either FOLFIRI, FOLFOX, or Irinotecan/oxaliplatin at the discretion of the oncologist.~Patients with intrahepatic cholangiocarcinoma will receive Gemcitabine/Oxaliplatin or Gemcitabine alone, at the discretion of the oncologist."
219537689|NCT07201519|DRUG|Standard Of Care targeting driver mutations|Per current SOC guidelines, EGFR inhibitors targeting driver mutations (e.g., RAS wild-type) will be administered as appropriate (FDA-approved agents such as Panitumumab for EGFR)
219537690|NCT07200531|BEHAVIORAL|Psychotherapy|6-week psychotherapy group intervention
219537691|NCT07202429|DEVICE|MRI|"Multiparametric MRI of adnexal lesions, including conventional sequences, diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) measurement, and dynamic contrast-enhanced (DCE) MRI. Imaging findings were evaluated using the O-RADS MRI scoring system."
219537692|NCT07201441|BEHAVIORAL|Smart Nursing Based on the Health Cloud Platform|On the day of surgery, ensure that the patient or their family members have followed the hospital's official account and bound the patient's information. Through the intelligent cloud platform on the mobile device, they can query the patient's inpatient information, such as examination reports and details of inpatient expenses, and also consult and communicate about the patient's condition.
219537693|NCT07201376|DRUG|Ameluz 10% Topical Gel|One-time topical application of 10% Ameluz gel for up to 1 hour
219537694|NCT07201376|DEVICE|Protoporphyrin IX|Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.
219537695|NCT07200310|OTHER|Non-invasive audiologic and vestibular assessments|standardized, single-session test battery performed in a sound-treated clinical laboratory. Procedures include tympanometry, tympanometry with simple maneuvers (Valsalva/Toynbee) for Eustachian tube function, pure-tone audiometry, otoacoustic emission (OAE) testing, acoustic reflex thresholds, and cervical vestibular evoked myogenic potentials (cVEMP) with EMG monitoring for adequate sternocleidomastoid activation. Testing is non-invasive, takes \~60 minutes, and is conducted under routine clinical practice conditions. No investigational drugs, devices, or biospecimens are used.
218923548|NCT03013998|DRUG|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
218923549|NCT03013998|DRUG|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
218923550|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
218923551|NCT03013998|DRUG|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance \>30 mL/min and \<50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
218923552|NCT03013998|DRUG|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
218923553|NCT03013998|DRUG|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
219619433|NCT06293183|OTHER|Mobile app|Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
219537696|NCT07202442|PROCEDURE|Emergency General surgery patients with robotic approach for the surgery|vPrimary Endpoint: The proportion of procedures performed robotically versus laparoscopically or via laparotomy for selected indications. Secondary Endpoints: A 5% change in perioperative morbidity, laparotomy rate, LOS, critical care admission rate, and operative time. Included Pathologies (for patients eligible for laparoscopy) : Acute cholecystitis with predictors of intraoperative difficulty. Bowel obstruction requiring bowel resection (in presence of CT signs of visceral compromise: poor enhancement of bowel loops, pneumoperitoneum). Complicated acute diverticulitis with perforation and peritonitis. Penetrating abdominal trauma with hemodynamic stability requiring surgery (e.g., bowel resection-anastomosis). Right or left colectomy for other etiologies. Splenectomy in hemodynamically stable or embolized patients.
218923554|NCT03013998|DRUG|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
218923555|NCT03013998|DRUG|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
218923556|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
218923557|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
218923558|NCT03013998|DRUG|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression \[if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored\]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
218923559|NCT03013998|DRUG|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
218923560|NCT03013998|DRUG|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
219204875|NCT06997757|PROCEDURE|Phase I Therapy|Instructions for brushing twice daily and using interdental cleaning aids during appointment only.
219537697|NCT07200349|DRUG|Calcitriol Delivery|Local delivery of Calcitriol (active form of vitamin D3) to one side of the maxillary canine area during orthodontic treatment. The aim is to assess its effect on dental and skeletal changes during canine retraction in a split-mouth design.
219537698|NCT07200791|BEHAVIORAL|Mobile Application|Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.
219537699|NCT07200791|BEHAVIORAL|Usual Care Only|Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.
219537700|NCT07201246|OTHER|Necrotizing Pancreatitis patients' organdysfunction progression|Study the dynamic nature of organ dysfunction
219619434|NCT00813150|DRUG|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
219537701|NCT07202104|DEVICE|Eko digital stethoscopes|Use of the Eko CORE 500 digital stethoscope and 3M Littmann CORE Digital Stethoscope to auscultate and record cardiac phonocardiogram and (when available) electrocardiogram waveforms, as well as heart sounds.
219537702|NCT07201077|DEVICE|Articulating lymph-node grasper (SurgeoFlex Grasp)|Arm 1 - SurgeoFlex Grasp A single-use, low-profile articulating grasper with a 5-millimetre (mm) shaft and a 360-degree (360°) steerable distal tip. During uniportal video-assisted thoracoscopic surgery (UVATS), the device is introduced through the same 3-4-centimetre (cm) utility incision used for the camera and stapler. The flexible neck allows the jaws to approach hilar and mediastinal lymph nodes from multiple angles without repositioning the instrument shaft, thereby reducing instrument collision and chest-wall torque.
219537703|NCT07201077|DEVICE|Arm 2 Intervention Name Traditional rigid endograsper|Arm 2 - Traditional Rigid EndoGrasper A reusable, straight-shafted 5 mm grasper with fixed-angle jaws identical to those used in conventional multi-port video-assisted thoracoscopic surgery (VATS). The instrument is passed through the single 3-4 cm incision in the same fashion as the SurgeoFlex Grasp, but its rigid shaft limits the working angle and often requires external repositioning of the entire instrument to reach deep lymph-node stations.
219537704|NCT07201207|DEVICE|Robotic-assisted total knee arthroplasty|In robotic-assisted total knee arthroplasty, the procedure is performed with the guidance of the robot according to CT-based plan.
219537705|NCT07201207|PROCEDURE|Manual total knee arthroplasty|In manual total knee arthroplasty, the procedure is performed with jig guides according to whole leg weight bearing x-ray planning.
219537706|NCT07202156|DEVICE|10%TXA+2%Reduced Glutathione applied via ultrasound at 5W/cm² in10min|5w/cm² Ultrasound-assisted topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
219537707|NCT07202156|OTHER|10%TXA+2%Reduced Glutathione applied via ultrasound at 0W/cm² 10min|topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
219537708|NCT07201324|OTHER|cranial helmet therapy - observational|"This observational study involves children undergoing cranial helmet therapy. The intervention is not assigned by the investigator. Repeated measurements are performed within participants to evaluate therapy effects. Stage 1 assesses head shape changes to analyze therapy effectiveness. Stage 2 examines factors influencing effectiveness, considering age, deformity type, and sex.~Stage 3 measures body surface temperature using thermal imaging before, during, and after helmet use, with participants analyzed in three age groups: 4-6, 7-9, and 10-12 months. Stage 4 evaluates cervical spine rotation before therapy and after completion, with participants analyzed in the same three age groups."
218923561|NCT03013998|DRUG|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
218923562|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
218923563|NCT03013998|DRUG|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
219537709|NCT07200401|PROCEDURE|Self-swabbing of surgical wound|Participants will perform self-swabbing of their surgical wound under observation by a research nurse via secure video call.
219537710|NCT07200427|BEHAVIORAL|MELIORA Virtual Coach Intervention|Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.
219537711|NCT07200427|OTHER|Control (generic advice)|The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.
219619435|NCT00813150|DRUG|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
219619436|NCT00813150|DRUG|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
219619437|NCT05354388|PROCEDURE|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
219619438|NCT06682741|OTHER|Exercise|supervised exercise training; twice a week for 12 months
218923564|NCT03013998|DRUG|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
218923565|NCT03013998|DRUG|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
218923566|NCT03013998|DRUG|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
219537712|NCT07200661|DEVICE|Experimental A tDCS: Transcranial direct current stimulation.|Group 1: Active tDCS combined with dual-task stepping (Experimental A) Participants in this group will receive anodal tDCS applied over the ipsilesional primary motor cortex (M1) at C3 or C4 (based on the 10-20 EEG system), with the reference electrode positioned over the contralesional supraorbital area. Stimulation will be delivered at an intensity of 2 mA for 20 minutes, During the stimulation period, participants will perform dual-task stepping exercises on unstable surfaces. The stepping program stepping on a foam pad (5 cm thick, 20 cm wide, 12 cm long). Each stepping session lasts 10 minutes and is immediately followed by overground walking at a comfortable speed for 10 meters, while simultaneously performing a cognitive task of counting backwards from 99 to 0. Participants are instructed not to pause or stop while performing the dual task. If they stop for more than 5 seconds, it is considered an error, which will be recorded.
219537713|NCT07200661|DEVICE|Experimental B tDCS: Transcranial direct current stimulation.|Group 2:This group follows the same stepping and dual-task walking program as Group 1 (stepping on foam pad for 10 minutes, followed by overground walking with backward counting for 10 minutes). However, instead of active stimulation, participants receive sham tDCS.
219537714|NCT07200661|DEVICE|Experimental C tDCS: Transcranial direct current stimulation.|Group 3:Participants in this group will receive anodal tDCS only, without any dual-task or stepping training.
219537715|NCT07200921|DRUG|Naoxuekang Dropping Pills|A traditional Chinese medicine. Each pill weighs 35mg. Dosage: 20 pills, three times daily, orally for 90 days.
219537716|NCT07200921|DRUG|Naoxuekang Matching Placebo|A placebo pill matched to Naoxuekang Dropping Pills in appearance, taste , size, and packaging. Dosage: 20 pills, three times daily, orally for 90 days.
219537717|NCT07201389|DEVICE|Scalp Cooling by DigniCap|Scalp cooling with the DigniCap Delta will occur with each chemotherapy dose. The cooling wrap is primed, fitted, and checked for proper contact before a standardized pre-cool phase of 20-30 minutes. Cooling continues during chemotherapy, followed by a post-cool phase of 90-180 minutes based on regimen. The system circulates temperature-controlled coolant through channels in the wrap, with sensors monitoring flow and scalp temperature; a safety sensor ensures scalp temperature never falls below 32°F (0°C). Alerts notify staff of low flow or temperature issues. After cooling, the cap is loosened for 5 minutes to warm before removal, and subjects are given 5 minutes to acclimate before standing.
219619439|NCT04440189|DEVICE|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
219619440|NCT04585984|DIETARY_SUPPLEMENT|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
218923567|NCT03013998|DRUG|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
218923568|NCT03013998|DRUG|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 or days 1 through 14 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
219204876|NCT06997289|DRUG|Group that is receiving treatment.|"Incorporate the following regimen into your daily routine for optimal health benefits:~Chinese Medicine: Take a combination of Modified Xiaoyao Powder (2g), Tianwang Buxin Dan (1.5g), Wendan Decoction (0.5g), Night Jiaoteng (0.5g), and Fushen (0.5g) twice a day for a duration of 1 month. This regimen comes from Keda GMP Pharmaceutical Factory.~Auricular Point Stimulation: Apply small 0.2cm ear magnetic beads on the Shenmen, heart, and brainstem points on both sides of the ear.~Consistency is key to achieving positive results, so make sure to follow this routine diligently.~Two treatment methods are carried out simultaneously"
219204877|NCT06996067|BEHAVIORAL|Essential Coaching Postpartum|Essential Coaching Postpartum consists of one-way, standardized text messages sent to parents from birth to 6-weeks postpartum to provide evidence-based information on newborn care and mental health. Messages are sent twice a day for the first three weeks (10am and 5pm) and then once a day for the following three weeks (10am), starting the second day after birth.
219204878|NCT06996262|OTHER|observational study|The questionnaire consisted of structured questions covering sociodemographic information, health status, dietary habits, and physical activity levels.
219619441|NCT04585984|DIETARY_SUPPLEMENT|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
219619442|NCT06303804|BEHAVIORAL|Educational videos|Participants will be delivered a link to complete demographic information and the initial assessment. Upon completing the (initial) pre-test knowledge assessment, participants will be sent links to the three educational videos staggered across 7 days. Educational videos will determine gaps in knowledge related to opioid use and overdose based on questionnaire responses. Upon the completion of the 7 days, participants will be sent a link to the (final) post-test knowledge assessment to complete.
219204879|NCT06996262|OTHER|observational study|Anthropometric measurements was taken.
219204880|NCT06996262|OTHER|observational study|Biochemical analyses were measured was measured using routine methods.
219204881|NCT06996262|OTHER|observational study|Blood pressure were measured was measured using routine methods.
219204882|NCT06996860|DEVICE|foam roller|fascial therapy for performance effect
219204883|NCT06996860|DEVICE|theragun|fascial therapy for performance effect
219204884|NCT06996860|OTHER|general warm up|fascial therapy for performance effect
218923569|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
218923570|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
218923571|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
218923572|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
218923573|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
218923574|NCT03013998|DRUG|ZE46-0134 (BAML-16-001-S21)|10 mg or 50 mg oral on Days 1-28 of each 28-day cycle for up to 24 cycles. On the first day of Cycle 1, a loading dose of 30 mg to 150 mg will be administered, after which the daily maintenance dose of 10 mg to 100 mg will be administered on days 2-28 of Cycle 1. Maintenance dose continues in subsequence cycles, for up to 24 cycles total.
218923575|NCT04327700|DEVICE|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
218923576|NCT04327700|DRUG|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
218923577|NCT04050735|OTHER|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
218923578|NCT04050735|OTHER|Placebo|Placebo beverage
218923579|NCT04574271|BEHAVIORAL|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
218923580|NCT04574271|BEHAVIORAL|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
218923581|NCT04401813|DRUG|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
218923582|NCT03361761|OTHER|Health education program|formalized/official Health education program
218923583|NCT03361761|OTHER|Health education program|non formalized/official Health education program
218923585|NCT06342037|DRUG|Tiragolumab|600mg every 3 weeks (Q3W)
218923586|NCT06342037|DRUG|Atezolizumab|1200mg every 3 weeks (Q3W)
218923587|NCT06342037|DRUG|Ipilimumab|1 mg/kg, maximum of 4 cycles
218923588|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
219537718|NCT07201467|DRUG|KN060|pharmacokinetic and pharmacodynamic characteristics of KN060 in ESRD on Hemodialysis
218923589|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
218923590|NCT03667378|BEHAVIORAL|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
219537719|NCT07201948|BEHAVIORAL|Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:|"1. : Two distinct groups will be enrolled:~   * Those diagnosed with hypertension: BP \>=140/90, within the last 2 years.~  * Those with BP \>=130/80. Not yet diagnosed with hypertension.~2. . Intervention: Comprehensive and integrated intervention components~   * Implemented by 3 certified experts (Dietician, Fitness Trainer, Cardiologist)~  * Modules: Education, Demonstration, Practical skill development sessions.~3. . Intervention is based on American Hearts Association Life's Simple 7. The nutrition aspect will follow the DASH Diet plan."
219537720|NCT07201649|OTHER|a blood test and urine sample collection.|The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.
219537721|NCT07201675|DRUG|RC48-ADC combined with toripalimab for bladder-sparing therapy|RC48-ADC combined with toripalimab for bladder-sparing therapy
219537722|NCT07200245|OTHER|adrenalectomy|adrenalectomy for pheochromocytoma and non-secreting tumor (incidentaloma)
219537723|NCT07202000|DRUG|Activin ligand-trap biological therapy|Investigational therapy
219537724|NCT07202000|DRUG|Placebo, Normal Saline|Inactive drug
219619443|NCT01683318|PROCEDURE|Thermal Pulsation therapy|
219619444|NCT02832687|DRUG|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
219619445|NCT02832687|DRUG|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
219619446|NCT02408835|DEVICE|PICO™|Negative pressure wound therapy device for closed surgical wounds.
219619447|NCT02154451|DEVICE|Infrared Imaging Device- ALIAS|Infrared Camera
219619448|NCT04380935|BIOLOGICAL|Convalescent plasma|Convalescent plasma of recovered COVID-19 patients (donor)
219619449|NCT04380935|DRUG|Standard of care|"According to national or hospital guidelines COVID-19 Management Protocol"
219619450|NCT01735825|DEVICE|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
219204885|NCT06997367|BIOLOGICAL|MTBVAC|MTBVAC (BBV169) vaccine is a freeze-dried powder containing live attenuated Mycobacterium tuberculosis (M. tb), which is presented as a lyophilized product in a 10- dose vial. After reconstitution with 1.0 mL sterile water for injection, one dose (0.1mL) of vaccine contains 5 x10\^5 CFU live attenuated M. tb. One dose (0.1mL) of the MTBVAC (BBV169) vaccine is to be administered in the right deltoid region via the intradermal route.
219204886|NCT06997367|BIOLOGICAL|BCG Sii|Comparator vaccine: BCG Vaccine (TUBERVAC- Moscow strain), manufactured by Serum Institute of India, is a freeze-dried powder containing an attenuated strain of Bacillus Calmette-Guerin Mycobacterium bovis as a lyophilized product in a 10-dose vial. After reconstitution with 1.0 mL diluent (Sodium chloride) for injection, one dose (0.1mL) of BCG vaccine will be administered in the right deltoid region via the intradermal route.
219537725|NCT07200609|OTHER|Virtual Reality Intervention|"The virtual reality training group will have sessions lasting 40 minutes, 3 days a week for 8 weeks.~* A 30-minute VR-based training session using Kinect Xbox (5 min warm-up, 30 min VR, 5 min cool-down)~* The device has an infrared camera sensor (Kinect sensor) that detects the participant's movement in real time~* Even if the user's movement is not performed correctly in the game settings, the user receives visual and auditory sensory feedback about movement errors.~* All games are provided to engage participants' interest in the topics and require the use of the person's lower extremities.~* Each game will be played for 10 minutes during the 30-minute training session. (A total of 3 games will be played)~* Participants in VR programs typically perform active hip flexion, hip abduction, hip external and internal rotation, knee flexion and extension, ankle dorsiflexion, and plantar flexion while standing.~* Game content: Kinect Sports, Kinect Adventures and Kinect Sports Rivals."
219537726|NCT07200609|OTHER|Home-Based Exercise Intervention|"* Home-based exercise training group will also be given online exercises 3 days a week for 8 weeks.~* Active/passive stretching exercises within pain limits~* Patients will perform exercises at home under a supervised exercise program~* They will perform exercises matching the virtual reality group in terms of exercise sequence, intensity, duration, and mode, incorporating open and closed kinetic chain movements~* A 20-second stretch followed by a 20-second relaxation performed five times per session for each muscle~* Light resistance exercises targeting muscle groups in the lower extremities, with a 5-second contraction followed by a 5-second relaxation, performed five times per session~* Bodyweight exercises~* Balance exercises~* Posture exercises"
219619451|NCT01735825|DEVICE|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
219619452|NCT01735825|DEVICE|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
219619453|NCT01092234|OTHER|Traditional ward|provision of care in a traditional unit/ward.
219619454|NCT01092234|OTHER|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
219619455|NCT02606916|RADIATION|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
219537727|NCT07201051|DRUG|GSK3862995B|Participants will be administered with dose level 1 of GSK3862995B.
218923591|NCT03667378|BEHAVIORAL|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
219619456|NCT02606916|DRUG|DDP|DDP(25 mg/m2.qw) for six weeks.
219619457|NCT02606916|DRUG|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
219619458|NCT00111605|BIOLOGICAL|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
219619459|NCT00111605|BIOLOGICAL|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
219619460|NCT00111605|BIOLOGICAL|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
219619461|NCT00111605|BIOLOGICAL|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
219619462|NCT00976001|OTHER|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
219619463|NCT00976001|OTHER|As the general practitioner wants to do|
219619464|NCT01113437|DRUG|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
218923592|NCT03667378|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
218923593|NCT03667378|BEHAVIORAL|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
218923594|NCT03667378|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
218923595|NCT03667378|BEHAVIORAL|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
218923596|NCT03667378|BEHAVIORAL|visits with a supportive care clinician|Monthly visits with a supportive care clinician
218923597|NCT04504253|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate loose powder
219204887|NCT06997562|OTHER|Greater occipital nerve blockade|Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.
219537728|NCT07201051|DRUG|Placebo|Participants will be administered with matching placebo.
219537729|NCT07202221|OTHER|Participant views Epidural animation before reading gold standard written information|Addition of introductory animation to written OAA epidural information card about labour epidural
219537730|NCT07202221|OTHER|Participant receives current gold standard written information alone|Gold standard OAA (Obstetric Anaesthetists' Association) epidural information card
219537731|NCT07200453|BEHAVIORAL|intervention group 1.1 - e-learning|"The e-learning environment will include text, images, and short videos created using Articulate Rise 360, an easy-to-use e-learning authoring tool, with the following content to improve the different skills of digital health literacy:~1. Evaluating reliability skills: Participants will get to know criteria and indicators for evaluating the content of the information they find and for assessing the trustworthiness of website providers.~2. Improving information skills: Participants will learn simple rules on how to optimize their Google searches.~3. Improving navigation skills: Participants will learn simple rules for navigation; using the back button; using more than one tab; drop-down lists and anchor links are introduced.~4. Additional goals are to raise awareness about various aspects related to online searches, including the exploration of alternative and complementary therapies, and the importance of data protection."
219537732|NCT07200453|BEHAVIORAL|intervention-group 1.2 - e-learning|Participants are also given access to the e-learning environment. However, they will not be taken step-by-step through the content (tunneling). They can choose the order of the content.
218923598|NCT04504253|DRUG|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
218923599|NCT05546879|DRUG|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
218923600|NCT05546879|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
218923601|NCT05546879|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
219619465|NCT01113437|DRUG|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
219619466|NCT04775082|DRUG|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
218923602|NCT03205423|DRUG|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
219204888|NCT06997562|OTHER|Sphenopalatine ganglion blockade|Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.
219204889|NCT06997172|PROCEDURE|TCTR (thread carpal tunnel release)|Percutaneous sonography guided release of carpal tunnel release
219204890|NCT06997172|PROCEDURE|Standard-of-care|Open or endoscopic carpal tunnel release based on patients' and physicians' preferences
219619467|NCT04775082|DRUG|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
219619468|NCT06255223|RADIATION|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
219619469|NCT06255223|RADIATION|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
219619470|NCT06255223|DRUG|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
219619471|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
219619472|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
219537733|NCT07200453|BEHAVIORAL|intervention-group 1.3 - e-learning|Participants are also given access to the e-learning environment, but all rehearsal elements such as quizzes will be removed from the e-learning environment.
219537734|NCT07200453|BEHAVIORAL|intervention-group 2 - PDF|Participants in IG2 will receive the same content as participants in the IG1.1, but not within the interactive learning environment, but in a non-interactive PDF format.
219619473|NCT03904173|DIAGNOSTIC_TEST|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
218923603|NCT04930367|BEHAVIORAL|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
218923604|NCT04930367|BEHAVIORAL|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
218923605|NCT04930367|BEHAVIORAL|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
218923606|NCT04930367|BEHAVIORAL|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
219537735|NCT07201480|BEHAVIORAL|Mortality Salience Prompts|"This intervention implies giving two prompts to participants, in a written format, while asking them to write out answers to the given prompts. The first prompt is: Please briefly describe the emotions that the thought of your death arouses in you. The second prompt is Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead."
219537736|NCT07201480|BEHAVIORAL|Dental Pain Prompts|"This intervention implies giving two prompts to participants, and requesting that participants write out their answers to these prompts. The first prompt is: Please briefly describe the emotions that the thought of dental pain arouses in you. The second prompt is: Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."
219537737|NCT07201740|DEVICE|Leap Motion-based Virtual Reality Therapy|"Arm 1 - Experimental (Leap Motion + Routine Hand Rehabilitation)~Intervention Description: Participants will receive standard postoperative hand rehabilitation plus Leap Motion-based virtual reality training. The VR training will be performed for 20 minutes per day, 5 days per week, for 4 weeks, in addition to routine rehabilitation. The Leap Motion Controller tracks hand and finger movements without physical contact and allows participants to practice functional tasks and grasp patterns in a virtual environment.~Arm 2 - Active Comparator (Routine Hand Rehabilitation Only)~Intervention Description: Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist."
219537738|NCT07201740|OTHER|Active Comparator - Routine Rehabilitation Only|Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist.
219619474|NCT05187390|PROCEDURE|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
219619475|NCT01733550|DEVICE|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
219619476|NCT01733550|DEVICE|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
219619477|NCT01733550|DEVICE|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
219619478|NCT04107324|PROCEDURE|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
219619479|NCT04107324|PROCEDURE|PVE|Portal vein embolisation
219619480|NCT04740450|DEVICE|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm \_ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
219619481|NCT04740450|DEVICE|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
219537739|NCT07200817|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes and Platelets ratio (N/LP)|The Neutrophils to Lymphocytes and Platelets ratio (N/LP) will be measured
219619482|NCT03334435|DRUG|Baricitinib|Administered orally
219619483|NCT03334435|DRUG|Placebo|Administered orally
218923607|NCT04930367|OTHER|Pill Container|A discreet pill container to support ART adherence.
218923608|NCT04930367|OTHER|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
218923609|NCT04930367|OTHER|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
218923610|NCT04930367|OTHER|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
218923611|NCT04930367|OTHER|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
218923612|NCT04930367|BEHAVIORAL|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
219619484|NCT01961050|BEHAVIORAL|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
219619485|NCT01961050|OTHER|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
219537740|NCT07200258|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|"Remote incisions will be performed in the test group. The VISTA technique will be performed as described by Zadeh (Zadeh, 2011).~After administration of local anaesthesia, an access incision will be made in the vestibulum to permit elevation of a broad subperiosteal tunnel. A specialized periosteal elevator will be used to create the tunnel by dissecting beneath the periosteum, extending at least one tooth beyond the recession defects and under each papilla, without surface incisions at the gingival margin. The connective tissue graft will be inserted and positioned beneath the tunnel through the incision. A coronally anchored suturing technique will be used. This technique mean placing a horizontal mattress suture using a 6.0 suture with at approximately 2 to 3 mm apical to the gingival margin of each tooth, covering the width of the tooth. If keratinized gingiva is present, the suture will be placed within the band of keratinized gingiva."
218923613|NCT04930367|BEHAVIORAL|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
218923614|NCT04930367|BEHAVIORAL|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
218923615|NCT04930367|BEHAVIORAL|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
218923616|NCT04930367|BEHAVIORAL|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
218923617|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
218923618|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
218923619|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
218923620|NCT04364867|DRUG|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
218923621|NCT04364867|DRUG|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
218923622|NCT01349608|BEHAVIORAL|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
218923623|NCT03757546|OTHER|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
218923624|NCT02386475|OTHER|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
219537741|NCT07200258|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)|In the MCAT group, the surgical approach will follow the technique described by Aroca et al. (2010). After sulcular incisions made without releasing incisions, a full-thickness muco-periosteal tunnel will be carefully elevated beyond the mucogingival junction and under adjacent papillae using tunneling instruments. The root surfaces will be planed, and a subepithelial connective tissue graft will be harvested from the palatal donor site and inserted into the tunnel. Suspended horizontal mattress sutures will be placed around the contact points to advance and stabilize the flap in a position coronal to the cemento-enamel junction (CEJ) (previous composite at the contact point if necessary). Postoperative care will be identical to that described for the VISTA group.
219537742|NCT03688503|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
219537743|NCT03688503|DIETARY_SUPPLEMENT|placebo|placebo
219537744|NCT02478528|DEVICE|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
219537745|NCT02478528|DEVICE|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
219537746|NCT02478528|OTHER|control condition|No exposure of the subject to any light sources (control condition)
219537747|NCT03523156|DRUG|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
219537748|NCT03523156|DRUG|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
219537749|NCT01079845|BEHAVIORAL|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
219537750|NCT03341013|DRUG|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
219537751|NCT03341013|DRUG|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
219619486|NCT05726201|DIAGNOSTIC_TEST|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
219619487|NCT05628610|DRUG|Tislelizumab|200mg d1, Q3W
218923625|NCT02386475|DRUG|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
218923626|NCT02386475|DRUG|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
218923627|NCT05786651|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
218923628|NCT05097586|DEVICE|active tDCS|2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
218923629|NCT05097586|OTHER|workbook|Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
218923630|NCT05097586|DEVICE|sham tDCS|Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
218923631|NCT05937165|OTHER|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
218923632|NCT05083923|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
218923633|NCT04390763|BIOLOGICAL|NIS793|anti-TGFb antibody. NIS793 2100 mg every 2 weeks by intravenous (i.v.) infusion.
218923634|NCT04390763|BIOLOGICAL|Spartalizumab|anti-PD-1 antibody. spartalizumab 400 mg every 4 weeks by i.v. infusion.
218923635|NCT04390763|DRUG|gemcitabine|SOC chemotherapy. Gemcitabine (1000 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
218923636|NCT04390763|DRUG|nab-paclitaxel|SOC chemotherapy. Nab-paclitaxel (125 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
218923637|NCT05030129|DRUG|5-Hydroxytryptophan|5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
218923638|NCT05030129|DRUG|Ergoloid Mesylates|Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
218923639|NCT05030129|DRUG|Matching placebo for Ergoloid mesylates|Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
218923640|NCT05030129|DRUG|Matching placebo for 5-Hydroxytryptophan|Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
218923641|NCT06651944|DEVICE|Invisalign® System with mandibular advancement featuring occlusal blocks|Class II correction using the Invisalign® System with mandibular advancement featuring occlusal blocks
218923642|NCT06020521|OTHER|Three spectrometry differents technics|"Collection of expired air as follows:~* For online mass spectrometry techniques (PTR-MS and SICRIT)~* For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~* By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~* By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
218923643|NCT06653075|PROCEDURE|mandibular advancement with acrylic splint Herbst Appliance|Mandibular advancement with acrylic splint Herbst Appliance
218923644|NCT04240002|DRUG|gilteritinib|Administered orally.
218923645|NCT04240002|DRUG|fludarabine|Administered by intravenous (IV) infusion
218923646|NCT04240002|DRUG|cytarabine|Administered by intravenous (IV) infusion
218923647|NCT04240002|DRUG|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
218923648|NCT01967849|DIAGNOSTIC_TEST|Oral Glucose tolerance test|
218923649|NCT04115761|BIOLOGICAL|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
218923650|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
218923651|NCT05874791|BEHAVIORAL|Goal Management training|metacognitive group intervention
218923652|NCT06038864|DIAGNOSTIC_TEST|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
218923653|NCT05786924|DRUG|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
218923654|NCT06655376|DRUG|Aspirin|81-100 mg, oral
219619488|NCT05628610|RADIATION|Radiation|Radiotherapy dose: 5,000 c G y / 30f
218923655|NCT06655376|DRUG|Warfarin|Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
218923656|NCT06655168|DEVICE|Video Laryngoscopy|orotracheal intubation by C-Mac ( Video laryngoscopy)
218923657|NCT06655168|DEVICE|Direct Laryngoscopy|Orotracheal intubation using Direct Laryngoscopy
219619489|NCT05628610|DRUG|Paclitaxel|Paclitaxel: 150mg / m2 ,d1, q3w
219619490|NCT05628610|DRUG|Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs|cisplatin, carboplatin, naidaplatin and other platinum drugs
219619491|NCT01742312|RADIATION|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
218923658|NCT06654518|DIAGNOSTIC_TEST|Preoperative CBCT for Bone Density and Ridge Width Measurement|Participants in this arm underwent preoperative Cone Beam Computed Tomography (CBCT) scanning to evaluate bone density and alveolar ridge width. The CBCT scans provide high-resolution, 3D images, which was used to guide the planning and placement of dental implants. The primary goal of the intervention was to assess how well the measurements obtained from CBCT could predict the primary stability of the implants postoperatively.
218923659|NCT05743400|DRUG|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
218923660|NCT05743400|BIOLOGICAL|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~* 1 after each end of perfusion ;~* 1 though concentration before each perfusion ;~* 3 blood samples in 3 different days during the first week;~* 1 weekly for 2 weeks post HSCT."
218923661|NCT06503874|OTHER|Attention Training|The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).
218923662|NCT06503874|OTHER|Music Group|This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.
218923663|NCT06978491|OTHER|Group C|Spinal anesthesia.
218923664|NCT06978491|OTHER|Group T|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied bilaterally between the transversus abdominis and internal oblique muscle.
218923665|NCT06978491|OTHER|Group W|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied to the wound site.
218923666|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
218923667|NCT06589141|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin (500 to 2000 mg orally)
218923668|NCT06589141|DRUG|GlyBURIDE 2.5 MG Oral Tablet|Glyburide (2.5 mg to 20 mg orally)
218923669|NCT06594484|OTHER|Ml Based Algorithm 1|The values in the ML algorithm were selected according to logistic regression analysis and the values used in the other six scores tested. The success rate of the constructed networks correct predictions was considered as the success rate of the algorithm. The usefulness of the test was determined through AUROC analysis. Two algorithms were tested in our study. In the first algorithm (ML1), the dependent variable was erythrocyte suspension (ES) consumption, and the independent variables included patients; demographic data, laboratory data, and operational data
218923670|NCT06594484|OTHER|Ml Based Algroithm 2|is an Ml algorithm created by combining commonly used bleeding scores
218923671|NCT06594484|OTHER|Bleeding Scores|ACTION CRUSCADE TRACK WILL-BLEED PAPWORTH TRUST ACTAPORT skores used to predict ES need
218923672|NCT06597110|BEHAVIORAL|listened to ASMR|ASMR refers to a physiological sensation triggered by specific auditory stimuli.ASMR, characterized by low-frequency human voice and ambient sounds, has garnered significant attention across social media platforms, short and long-form video platforms, and podcasts, owing to its unique pleasurable and stimulating effects. listen to ASMR for 10mins.
218923673|NCT06597227|PROCEDURE|Proximal radical gastrectomy|Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\&#39;s habit.
218923674|NCT06597227|PROCEDURE|Total radical gastrectomy|total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended
218923675|NCT06589076|DIAGNOSTIC_TEST|Clinical and Radiographic assessment + Questionnaires|"* Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression."
218923676|NCT06589349|BEHAVIORAL|Kangaroo Care|Physiological parameters will be measured in the Day (10:00) - Night (22:00) cycle for 3 days, just before being taken into kangaroo care in the experimental group, and when the kangaroo care is terminated, the baby will be measured in the mother's arms. Then, the mother and baby will be placed in kangaroo care for a minimum of 70 minutes
218923677|NCT06595485|BEHAVIORAL|online mindfulness based intervention|We anticipate the online MBI to be 10-20 minutes once daily, at least 5 days per week, for 8 weeks. Online MBI will be available free of charge on iOS and Android platforms. Participants will be instructed to download the app and use for practices. The online MBI group will be introduced to practice including mindful breathing (simple attention to the flow of the breath, inhalations, and exhalations), body scan (attention and awareness of different body parts) and practice of non-judgement of thoughts and emotions and guided meditation (sitting meditation). In addition, we anticipate participants in MBI group will have a group discussion via skype, 30 minute a week for 8 weeks. Moreover, we anticipate participants in MBI group to record how they practice in each day (attendance) as home assignment using online MBI application. For the details of mindfulness practice, we will develop based on data from interview and focus group
218923678|NCT06587438|DEVICE|Sinocare iCan I3 CGM|Real-time Continuous glucose monitoring
218923679|NCT06587438|DEVICE|Sinocare jinzhi+Blood glucose meter|Self-monitoring of blood glucose
219537752|NCT04647760|BEHAVIORAL|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
219537753|NCT04471779|OTHER|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
218923680|NCT06597825|DRUG|root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)|After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
218923681|NCT06598735|DRUG|HRS-4508|HRS-4508
218923682|NCT05464680|OTHER|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
218923683|NCT04139057|DRUG|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
218923684|NCT06603610|OTHER|Intensive geriatric service worker model of care|"Participants in the intervention group will receive care from an intensive geriatric service worker (IGSW), who will help the participant:~(i) Coordinate community resources and actively support participants' instrumental activities of daily living (IADLs) (e.g., linking participants with Meals-on-Wheels, taking participants to appointments) (ii) Advocate for support from home care for completing activities of daily living (ADLs) (iii) Implement patients' prioritized treatment recommendations made by healthcare professionals (e.g., supporting patients to purchase and install home safety equipment because this aligns with their values and preferences)."
218923685|NCT06603610|OTHER|Information brochure and telephone follow-up support|Participants will be e-mailed or mailed a booklet containing information about locally available resources including (1) meal preparation, (2) grocery delivery, (3) housekeeping, (4) pharmacies that deliver medications, (5) home care, and (6) Wheel-Trans. Participants will receive a scripted phone call from the study research coordinator one and three months after study enrolment to see if they have questions about the booklet material.
218923686|NCT06587009|PROCEDURE|Shock wave therapy|Received shock wave therapy 7 times a week and functional exercise therapy intervention
218923687|NCT06587009|PROCEDURE|Conventional conservative treatment|Conventional conservative treatment and functional exercise were given
218923688|NCT06591507|DIETARY_SUPPLEMENT|BCAA Nutritional Intervention|Patients will receive BCAA nutritional supplements. The supplement is taken orally twice daily, with each sachet containing 10g of powder, of which 6g is BCAA, and the remainder consists of preservatives and fruit flavorings to enhance palatability. The morning dose is taken with breakfast, and the second dose is taken as a late evening snack after dinner. For critically ill patients, enteral nutrition is provided instead. During each follow-up visit, patients are required to retain and submit all empty and unused sachets to accurately assess compliance. Dietitians will adjust the type and amount of food for each patient according to the guidelines of the European Society for Parenteral and Enteral Nutrition to ensure a total caloric intake of 35-40 kcal/kg and a protein intake of 1.2-1.5 g/kg (including BCAA supplements).
218923689|NCT06591507|BEHAVIORAL|Muscle Rehabilitation Training|Phase 1: Resistance Training (During Hospital Stay, First Month) Phase 2: Resistance Training (Home-Based, From Hospital Discharge Until 3 Months Post-Surgery) Phase 3: Physical Activity Training (Post-Surgery, After 3 Months)
218923690|NCT06591507|DIETARY_SUPPLEMENT|Standard Nutritional Therapy|Standard Nutritional Therapy
218923691|NCT06589011|OTHER|Pressure Support Ventilation|The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min
218923692|NCT06589011|OTHER|spontaneously assisted breathing|The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
218923693|NCT06595550|DIETARY_SUPPLEMENT|Whey protein|Powder milk
218923694|NCT06595550|DIETARY_SUPPLEMENT|no Whey protein|Powder milk
218923695|NCT06600724|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
218923696|NCT06600724|OTHER|EPIEFFECT|Participants will receive weekly applications of EPIEFFECT and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
218923697|NCT06600724|OTHER|EPIXPRESS|Participants will receive weekly applications of EPIXPRESS and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
219537754|NCT06239688|BEHAVIORAL|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
219537755|NCT06239688|BEHAVIORAL|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
219619492|NCT01742312|PROCEDURE|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
219619493|NCT01742312|OTHER|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
219619494|NCT02383017|DIETARY_SUPPLEMENT|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
218923698|NCT06594653|OTHER|pre treatment assesment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
218923699|NCT06594653|OTHER|post treatment assessment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
218923700|NCT00899132|GENETIC|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
218923701|NCT00899132|GENETIC|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
218923702|NCT00899132|OTHER|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
218923703|NCT04506411|DIETARY_SUPPLEMENT|Turmipure GOLD®|TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
218923704|NCT04506411|DIETARY_SUPPLEMENT|Turmeric rhizome PE 95% curcuminoids|STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
218923705|NCT04506411|DIETARY_SUPPLEMENT|Placebo|Placebo: Maltodextrin - 4 capsules once daily- as prescribed
218923706|NCT06987136|OTHER|Transversus thoracic muscle plane block|Patients will receive a transversus thoracic muscle plane block.
218923707|NCT06987136|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
218923708|NCT06987136|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block.
218923709|NCT06663670|OTHER|Intraneural Facilitation Therapy|"* The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure."
219537756|NCT06194344|BEHAVIORAL|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
219537757|NCT06194344|BEHAVIORAL|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
219537758|NCT05771558|DEVICE|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
219537759|NCT05771558|DEVICE|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
219537760|NCT05700383|BEHAVIORAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
219537761|NCT05700383|BEHAVIORAL|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
219619495|NCT02383017|DIETARY_SUPPLEMENT|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
219619496|NCT02004418|RADIATION|11C-Choline|
219619497|NCT02029118|DRUG|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
219537762|NCT06837220|BEHAVIORAL|Enhanced Courage to Quit|"Participants will engage in a version of the smoking cessation treatment Courage to Quit that has been optimized for implementation in community behavioral health clinics. The group will run over a period of 3 months, where participants will learn behavioral and cognitive skills for smoking cessation and/or reduction. Special attention will be given to the unique needs of the community, such as technology options or more flexible treatment models. The goal of this intervention is to prove that it is feasible to implement, and can create enhanced engagement and smoking outcomes for adults who smoke (AWS) and have fewer socioeconomic resources."
218923710|NCT06663670|OTHER|Nerve Flossing Technique|"Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload."
219537763|NCT01555892|BIOLOGICAL|EBV-specific T cells: A|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
219537764|NCT01555892|BIOLOGICAL|EBV-specific T cells: B|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
219537765|NCT02301975|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
219537766|NCT02301975|DRUG|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
219619498|NCT02029118|DEVICE|acupoint|select acupoint according to traditional Chinese medicine
219619499|NCT02029118|DRUG|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
218923711|NCT04531618|BEHAVIORAL|Emotional Exchange (EE)|These sessions, conducted by a trained study staff member through Zoom, will involve storytelling and discussing emotional experiences with the baby, with prompts like sharing about the pregnancy or reactions to the baby's smiles.
218923712|NCT04531618|OTHER|Newborn Care (NC)|Newborn Care (NC) is a teaching curriculum designed to provide mothers with developmentally appropriate information about newborn care. The curriculum is adapted from previously studied literature that increased maternal knowledge about both medical and developmental concerns.
219204891|NCT06997458|DIAGNOSTIC_TEST|xF Tempus assay|"The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs.~The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021).~The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021)."
219204892|NCT06997796|DRUG|Tranexamic Acid|Tranexamic acid powder intranasally
218923713|NCT06588166|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
219204893|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
219537767|NCT02301975|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
219537768|NCT02301975|DRUG|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
219537769|NCT02301975|DRUG|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
219537770|NCT01038960|BEHAVIORAL|Exercise training|3 months supervised interval training
219537771|NCT02663960|OTHER|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
219537772|NCT02663960|OTHER|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
219619500|NCT03334513|DRUG|Bevacizumab|intravitreal injection of bevacizumab
219619501|NCT03334513|DRUG|Ranibizumab|intravitreal injection of ranibizumab
219619502|NCT02333942|DEVICE|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
219619503|NCT04981418|DEVICE|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
219619504|NCT04981418|OTHER|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
219537773|NCT04086108|DIETARY_SUPPLEMENT|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
219537774|NCT04086108|DIETARY_SUPPLEMENT|GABA supplement|1 gram of GABA dissolved in water.
219537775|NCT04086108|DIETARY_SUPPLEMENT|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
219537776|NCT02186691|OTHER|MRI|
219537777|NCT03091335|OTHER|Music-listening|Patients listen to music on headphones
219537778|NCT05905276|OTHER|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
219537779|NCT05905276|OTHER|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
219537780|NCT06524219|PROCEDURE|unilateral intrafascial resection|Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
219537781|NCT06524219|PROCEDURE|bilateral intrafascial resection|Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
219537782|NCT06524219|PROCEDURE|bilateral extrafascial resection|Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
219537783|NCT05025085|DRUG|AGEN1777|An immunoglobulin gamma (IgG1) antibody
219619505|NCT04981418|OTHER|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat\_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
219619506|NCT01795963|BEHAVIORAL|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
219537784|NCT05025085|DRUG|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
219537785|NCT04509453|DEVICE|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
219537786|NCT04509453|DEVICE|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
219537787|NCT05244213|BIOLOGICAL|Sintilimab|200mg Q3W
219537788|NCT05244213|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
219537789|NCT05244213|DRUG|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
219537790|NCT01882686|OTHER|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
219537791|NCT03787641|DRUG|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
219537792|NCT04842123|DIAGNOSTIC_TEST|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
219537793|NCT02949739|BEHAVIORAL|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
219537794|NCT03999216|DRUG|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
219537795|NCT00004796|DRUG|lactulose|
219619507|NCT01795963|BEHAVIORAL|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz \& Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite \& Fincham, 2007; Braithwaite \& Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
219619508|NCT01109693|DRUG|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
219619509|NCT01109693|DRUG|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
219619510|NCT04505670|DRUG|Donepezil|donepezil orally 5mg
219619511|NCT04505670|DRUG|Placebo oral tablet|Placebo
219619512|NCT04505670|DRUG|Topical Zinc Oxide|Topical Zinc Oxide 20%
219619513|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Plant protein|Pea/lupine protein powder mix
219619514|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Animal protein|Whey protein powder
218923714|NCT06590662|DRUG|Solriamfetol|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period."
218923715|NCT06590662|DRUG|Placebo|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period."
218923716|NCT06587880|DRUG|Chlorhexidine Gluconate|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction, the patient is instructed to pour 10 ml of the mouthwash into a measuring cup, rinse for 1 minute at an alternative time to teeth brushing. Do not eat or drink for 30 min after use.
218923717|NCT06587880|DRUG|Bone Bioactive Liquid|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
218923718|NCT06587880|DRUG|Hyaluronic Acid mouthwash|Prescribed for 7 days period 3-4 times a day starting 24 hours post-extraction, the patient is instructed to pour 20 ml of the mouthwash into a measuring cup and rinse for 1 minute, at an alternative time to teeth brushing. Do not eat or drink for 30 mins after use.
219537796|NCT02742558|BIOLOGICAL|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
218923719|NCT06587880|DRUG|Warm Saline Mouth Rinse|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
218923720|NCT06589882|OTHER|Effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques|Evaluate the effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques practiced in French expert centers over the next 10 years with the rate of technical success (procedure completed) and clinical success (cure) of the digestive pathology presented by the patient who indicated endoscopy without recourse to a new intervention (endoscopic or surgical) within 30 days of the procedure.
218923721|NCT06591065|BEHAVIORAL|Yoga Flow|The study participants were subjected to an intervention comprising hatha yoga sessions conducted twicw weekly over an twelve weeks period, with each session lasting 60 minutes.
218923722|NCT06591065|OTHER|Controlled|The control group did not receive any yoga training
219537797|NCT02742558|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
219537798|NCT02557035|DRUG|Palonosetron|
219537799|NCT02557035|DRUG|Dexamethasone|
219537800|NCT06626724|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma.
219537801|NCT04676503|DIETARY_SUPPLEMENT|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
219537802|NCT05457920|BEHAVIORAL|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
219537803|NCT05457920|BEHAVIORAL|pulse therapy|pulse therapy
219537804|NCT05472311|OTHER|Thermal Ablation|Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
219619515|NCT05848193|OTHER|MyHeadHealth online application|MyHeadHealth is an online application to be accessed through the patients smartphone. The goal of MyHeadHealth is to improve treatment compliance by providing patients with free and convenient access to resources and activities that align with their treatment plan
219619516|NCT05848193|OTHER|Standard of Care|Patients will receive Standard of Care from our concussion clinic as necessary as per the consultation with the physician
218923723|NCT06594731|OTHER|Hip belt squat training|Hip belt squat training performed twice per week for 6 weeks
218923724|NCT06594978|DEVICE|dual-site anodal tDCS over the M1|M1: motor cortex
218923725|NCT06594978|DEVICE|dual-site anodal tDCS over the DLPFC|DLPFC: dorsolateral prefrontal cortex
218923726|NCT06594978|DEVICE|sham tDCS|sham stimulation
218923727|NCT06597578|DEVICE|Extraction tools|The effect of different extraction tools on outcome parameters will be evaluated
219042834|NCT06923553|BEHAVIORAL|NDBIs|Caregivers will meet with clinicians virtually weekly to (a) watch the newly developed NDBI videos that demonstrate the strategy use, (b) discuss how this might be applied to their own child, (c) receive individualized homework planning, (d) record and upload videos of their practice of strategy use with their own child, and (e) review the videos with clinicians to receive individualized feedback on their strategy use. This will occur for 10 weeks. Each session will be video recorded to assess the clinicians' intervention fidelity. After 10 weeks, pre-post tests will be conducted to assess parents' confidence on implementing these strategies, their child's social communication, and satisfaction of providers and caregivers.
219619517|NCT03458078|DRUG|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
219619518|NCT03458078|DRUG|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
218923728|NCT06591754|BEHAVIORAL|ISTDP|Both the individual therapy and the group therapy is based on ISTDP (Intensive Short-Term Dynamic Psychotherapy), an affect-focused psychodynamic therapy method. The therapy focus on the relationship between feelings, anxiety and dysfunctional emotion regulation (i.e. defenses). The purpose is to increase the capacity of anxiety regulation in the patient and to help the patient identify the dysfunctional patterns developed to avoid internal stress and then gradually approach previously warded of feelings. The individual therapy consists of 25 weekly sessions. The group treatment consists of 18 weekly sessions and is structured in three phases. Phase one: Psychoeducation about anxiety and exercises in anxiety regulation. Phase two: patients takes turn to observe their own anxiety and defenses together with a therapist. Phase three: Every session two patients will work with a chosen problem and identify defenses, anxiety and feelings together with a therapist in front of the group.
218923729|NCT06595355|DRUG|bevacizumab with oral curcumin|According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
218923730|NCT06595355|DRUG|bevacizumab with oral placebo|Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
218923731|NCT06596408|OTHER|optical coherence tomography angiography|OCTA will be used to evaluate the macular vascular density and to exclude patients with pathological myopic maculopathy
218923732|NCT06601829|OTHER|abdominal ultrasound|abdominal ulterasound showing multiple cysts in the kidnets and hepatic fibrosis
218923733|NCT06592157|OTHER|NewEpi Plus Liquid Wound Dressing|"1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions."
218923734|NCT06592157|OTHER|standard wound care|The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
218923735|NCT06599060|OTHER|Trinity Amputation and Prosthesis Experience Scale|Participants were administered a questionnaire.
218923736|NCT06588036|DRUG|Prebiotic|. The primary outcome measure will be the mean time from the initiation of treatment to the resolution of diarrhea symptoms. This objective seeks to provide evidence-based insights into the optimal management strategies for childhood diarrhea and inform clinical practice guidelines.
218923737|NCT06588036|OTHER|Duration|every participant is alloted a group based on RCT.
218923738|NCT06588036|DRUG|Smecta|Group 4 will be given smecta scahet
218923739|NCT06591585|RADIATION|Fracture Healing|"A-Clinical evaluation~1. Patients will be recruited for evaluation of documented short / long term complications:~   * subcutaneous haematoma~  * pin tract infection~  * surgical site infection~  * limb length discrepancy~  * arthritis of the hip and spine~  * SI joint pain or fusion~  * scoliosis~2. Visually assisted gait analysis B- Radiographic evaluation~1-Radiographic evaluation of pelvic integrity by plain X-ray ( Antero-posterior . inlet . outlet views) 2- Long film for limb length discrepancy 3- plain x ray whole spine Anterior -posterior \&amp; lateral for scoliosis"
218923740|NCT06602115|OTHER|Observational study, no interventions involved|Observational study, no interventions involved
218923741|NCT06587815|OTHER|musical starry sky projector|Children in intervention group received musical starry sky projector during their sleep time
218923742|NCT06599385|OTHER|Platelet transfusion if platelet count ≤ 10 G/L|Platelet transfusion as soon as platelet count falls ≤ 10 G/L
218923743|NCT06599385|OTHER|Platelet transfusion when platelet count ≤ 20 G/L|Platelet transfusion will be initiated immediately after randomisation
219537805|NCT02466451|OTHER|Questionnaires|"For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
219537806|NCT03607253|OTHER|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
219537807|NCT03606174|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
219537808|NCT03606174|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
219619519|NCT03458078|DRUG|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
219619520|NCT00498147|OTHER|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
218923744|NCT06601283|DRUG|Vitmain C plus herbal medicine|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
218923745|NCT06595745|GENETIC|Wolbachia induced incompatible mating|The intervention will be performed by weekly release of male Aedes aegypti carrying Wolbachia (wAlbB strain) to mate with wild females, resulting in the death of their eggs for birth control. Before release, these males will be irradiated with X-rays to minimize the chance of any residual fertile female releases. The intervention will lead to Ae. aegypti population suppression or even elimination and preventing dengue transmission in release sites.
218923746|NCT06595745|COMBINATION_PRODUCT|Standard traditional chemical mosquito control|Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population
218923747|NCT06587971|PROCEDURE|Standard periodontal treatment protocol|Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.
218923748|NCT06587971|BEHAVIORAL|Oral hygiene education|Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
218923749|NCT06601153|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to characterize coronary atherosclerosis
218923750|NCT05823480|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
218923751|NCT05823480|DRUG|Azacitidine|Given IV
218923752|NCT05823480|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218923753|NCT05823480|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
218923754|NCT05823480|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
218923755|NCT05823480|PROCEDURE|Echocardiography|Undergo ECHO
218923756|NCT05823480|BIOLOGICAL|Magrolimab|Given IV
218923757|NCT05823480|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218923758|NCT05823480|OTHER|Questionnaire Administration|Ancillary studies
218923759|NCT04071990|BEHAVIORAL|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
219537809|NCT03606174|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
219537810|NCT03606174|DRUG|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
219537811|NCT04968821|BEHAVIORAL|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
219619521|NCT03084653|OTHER|Survey|Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
219619522|NCT05405751|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
219619523|NCT01068860|DRUG|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
218923760|NCT04071990|BEHAVIORAL|CBGT|CBGT for OCD patients, without involvement of family members
218923761|NCT04215731|DRUG|Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
218923762|NCT04215731|PROCEDURE|Restaging|Restaging by pelvic magnetic resonance imaging (MRI)
218923763|NCT04215731|RADIATION|Concomitant Chemoradiotherapy|Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
219537812|NCT04968821|OTHER|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
218923764|NCT04215731|PROCEDURE|Surgery|Radical surgery (TME or more extended surgery)
218923765|NCT04215731|RADIATION|Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)|Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
218923766|NCT04215731|DRUG|Induction chemotherpay with FOLFOX|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
218923767|NCT06590844|DRUG|Injectable coenzyme I|On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
219537813|NCT03921879|DRUG|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
219619524|NCT01068860|DRUG|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
219619525|NCT00648791|DRUG|Finasteride Tablets 5 mg|5mg, single dose fasting
218923768|NCT06991829|PROCEDURE|HLA-matched pancreatic endocrine organoids transplantation|Islet cells are isolated from resected pancreatic tissue obtained from patients undergoing surgery, followed by ex vivo expansion and culture. Subsequent procedures include HLA typing, functional assessment of organoid-like structures, and biobanking. After matching for HLA, the cells are administered into patients with type 3c diabetes mellitus (T3cDM) via ultrasound-guided percutaneous transhepatic portal vein catheterization. A 52-week follow-up is conducted to evaluate the safety of the cell therapy and its clinical efficacy in glycemic control.
218923769|NCT06992557|PROCEDURE|Biological drilling osteotomy protocol|"* Osteotomy site preparation through sequential biologic drilling in healed bony site with a pilot drill at 800 rpm with irrigation initiates the drilling process, which is then followed by drills of different sizes and shapes at low speeds at 150rpm without irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
218923770|NCT06992557|PROCEDURE|Conventional drilling osteotomy protocol|"* Preparation for osteotomy site with conventional sequential drilling in healed bony site at 1200 rpm with irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
218923771|NCT06992739|DRUG|Trilaciclib and Sacituzumab Tirumotecan|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to sacituzumab tirumotecan.~Sacituzumab Tirumotecan: 5 mg/kg on days 1 \& 15 of a 28 day cycle via intravenous (IV) infusion until progressive disease or discontinuation."
218923772|NCT06993441|BEHAVIORAL|Experimantal group|Participants in the experimental group listened to MusICure music via speakers for 30 minutes during each radiotherapy session. The intervention was administered concurrently with radiotherapy and aimed to reduce anxiety and emotional distress.
218923773|NCT06993441|BEHAVIORAL|control group|No intervention
218923774|NCT06992570|DIAGNOSTIC_TEST|Quantification of mild trauma brain injury risk|Measure the incidence and severity of mTBI among soldiers engaged in high-risk training activities. (e.g. parachute jumps, high-caliber firearms shooting, artillery fire, explosions). Concentration of brain injury biomarkers (GFAP, UCH-L1) in blood samples collected within 24 hours post-exposure
218923775|NCT06992570|OTHER|Biomechanical Analysis of Head Impact Forces|Evaluate the mechanical forces experienced by soldiers during high-risk activities using wearable accelerometers and high-speed video analysis. Peak head acceleration (g-force) and pressure wave analysis during training activities.
219537814|NCT03921879|DRUG|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
219537815|NCT04807426|OTHER|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
219619526|NCT00648791|DRUG|Proscar Tablets 5 mg|5mg, single dose fasting
219619527|NCT04056260|PROCEDURE|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
219619528|NCT01928264|BEHAVIORAL|Physical activity|
219619529|NCT01615458|BEHAVIORAL|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
219619530|NCT01156779|DRUG|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
219619531|NCT00460603|DRUG|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
219619532|NCT00460603|DRUG|AG-013726|AG-013726 5 mg bid every 2 weeks
219619533|NCT00460603|DRUG|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
219619534|NCT02843321|BIOLOGICAL|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
218923776|NCT06991959|OTHER|Educaton|Family Planning and Sexually Transmitted Diseases Training: The training program used a training module developed by UNFPA based on health belief theory, theory of reason-based behavior, social learning theory and transtheoretical model.
218923777|NCT06991764|DEVICE|Non-Invasive Brain Stimulation (tDCS / tPCS / sham-tPCS)|This is a novel non-invasive brain stimulation technique that we hope to be investigating, and this technique will be compared with an active control (tDCS) and a control (sham-tPCS).
219619535|NCT00317343|DRUG|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
219619536|NCT01956578|OTHER|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
219619537|NCT03176069|OTHER|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
219619538|NCT03176069|OTHER|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~* Kinesiotherapy~* Manual therapy~* Electrotherapy (electric electrostimulation, ultrasound)~* Behavioral therapy"
219619539|NCT00513240|DRUG|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
219537816|NCT04807426|OTHER|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
219619540|NCT00513240|DRUG|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
218923778|NCT06991543|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
218923779|NCT06991543|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)"
218923780|NCT00526812|DRUG|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
218923781|NCT00526812|DRUG|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
218923782|NCT06991777|DEVICE|Precision sedation in intensive care using neurophysiologic and respiratory targets.|Sedation titration using EEG and ventilator parameters
218923783|NCT06992193|DEVICE|Digital Anesthesia|Computer-controlled intraosseous anesthesia system (Dental Hi Tec, France) used to deliver 1.3 mL of 4% articaine with 1:200,000 epinephrine in two stages: gingival and intraosseous injection. The system provides consistent flow and reduced pain perception in children.
218923784|NCT06992193|DRUG|Infiltration Anesthesia|1 mL of 2% lidocaine with epinephrine was delivered via buccal infiltration using a conventional aspirating syringe and 27-gauge short needle. Topical benzocaine gel was applied for 30 seconds prior to injection.
218923785|NCT06992193|DRUG|Mandibular Block|1 mL of lidocaine was administered using the inferior alveolar nerve block technique via a conventional dental syringe and 27-gauge long needle. Negative aspiration was confirmed prior to slow deposition.
218923786|NCT06993051|BEHAVIORAL|Social-HEROES Health-Promotion Program|"Six-month, cluster-level, stakeholder-co-created health-promotion programme delivered in preschool settings. The programme is developed through participatory innovation labs and includes:~* Educator training sessions (monthly)~* Classroom activities on healthy eating, active play and socio-emotional skills (weekly)~* Family workshops and take-home materials promoting 24-hour movement behaviour (diet, physical activity, reduced sedentary time, adequate sleep) (every 4-6 weeks)~* Community engagement events (beginning and end of intervention). Implementation period: 6 months; dosage approx. 20-24 contact hours per child."
219619541|NCT02647710|BEHAVIORAL|PHAT Life Intervention|HIV Prevention behavioral health intervention
219619542|NCT02647710|BEHAVIORAL|Health Promotion Control|Behavioral health intervention control
219619543|NCT00469430|DRUG|cefotaxim and metronidazol|iv administration for at least 24 h
219619544|NCT05263908|DRUG|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
219619545|NCT05973539|OTHER|Diet|Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)
219619546|NCT00279435|DRUG|visilizumab|
219619547|NCT04962295|OTHER|No intervention|No intervention
219619548|NCT00316238|DRUG|olanzapine-RAIM|
219619549|NCT00316238|DRUG|placebo|
219619550|NCT01921608|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
219619551|NCT04711993|OTHER|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
219619552|NCT04711993|OTHER|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
219619553|NCT04588701|PROCEDURE|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
219619554|NCT02340429|DEVICE|DE500 Digital Video Otoscope|
219619555|NCT02129231|DRUG|calcined magnesia|We ensured the patient took the drug at night before meals
219619556|NCT02129231|DRUG|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
219619557|NCT02129231|DRUG|Rosuvastatin|We ensured the patient took the drug at night before meals
218923787|NCT06993012|BEHAVIORAL|Mobile Health Stress Self Management System|FWD has been developed using proprietary machine-learning algorithms to detect physiological markers of stress/PTSD hyperarousal in veterans using a wearable smart watch sensor. Additionally, FWD includes a suite of self-management and monitoring tools through the smartphone app designed through several rounds of human factors design
218923788|NCT06993012|BEHAVIORAL|Intensive Cycling Activity|The Project Hero Ride 2 Recovery is a unique event hosted by Project Hero where veterans participate in a week long cycling challenge where they cycle across the continental US about 50-70 miles per day for a total of over 350 miles within a group of peers.
218923789|NCT06991465|RADIATION|Radiation Therapy|High Dose Hypofractionated Radiotherapy 35 Gy over 5 fractions.
218923790|NCT06991465|DRUG|FOLFOX regimen|Radiosensitizing chemotherapy
218923791|NCT06991465|DRUG|Capecitabine|Radiosensitizing chemotherapy
218923792|NCT06991374|PROCEDURE|combined burst mode|the combined burst mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
218923793|NCT06991374|PROCEDURE|torsional mode|the toesional mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
218923794|NCT04949490|BIOLOGICAL|BNT162b2s01|intramuscular (IM) injection
218923795|NCT04949490|BIOLOGICAL|BNT162b2|IM injection
218923796|NCT06595407|DIAGNOSTIC_TEST|Blood analysis for loss-of-Y chromosome|Analysis for the percentage of circulating leukocytes with loss-of-y chromosome
218923797|NCT06171009|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
218923798|NCT06171009|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
218923799|NCT02086578|DEVICE|Breast MRI|
218923800|NCT02086578|BEHAVIORAL|Breast-Q© questionnaire|
218923801|NCT02086578|RADIATION|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
218923802|NCT05074979|OTHER|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
218923803|NCT05074979|OTHER|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
219619558|NCT01545648|DRUG|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
218923804|NCT05074979|OTHER|informed program|will informed after COVID 19
218923805|NCT05285371|DIAGNOSTIC_TEST|Urinalysis (UA)|Urinalysis will be performed twice daily starting on Postoperative Day 0.
218923806|NCT05285371|DIAGNOSTIC_TEST|Complete Metabolic Panel (CMP)|A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
219042835|NCT06921512|BEHAVIORAL|TCM Daoyin exercise|"Participants will receive a 12-week, group-based TCM Daoyin intervention consisting of two 90-minute sessions per week (total: 24 sessions), led by qualified physicians. Each session integrates movement regulation, breath regulation, and mind regulation, aiming to alleviate anxiety and depression symptoms. Each session includes a 10-minute warm-up and a 10-minute cool-down.~Compliance and Analysis:~Per-protocol analysis will include participants who attend ≥80% of sessions (≥19/24 sessions). Safety analyses will be conducted on all enrolled participants (n=20) following the intention-to-treat (ITT) principle."
219619559|NCT05867030|DRUG|lenalidomide|lenalidomide is administered orally
218923807|NCT05285371|DIAGNOSTIC_TEST|Glucose Stick Test (d-Stick)|A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
218923808|NCT05285371|OTHER|Medical Chart Review|A medical chart review will be performed for all subjects enrolled.
218923809|NCT05712330|OTHER|non invasive ventilation samples|machine samples for bacterial culture will be performed
218923810|NCT05712330|OTHER|patient samples|Patient samples for sputum culture
219042836|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol acetate (HT-Ac)|Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA
219042837|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol eicosapentanoate (HT-EPA)|Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.
219042838|NCT06735222|DIETARY_SUPPLEMENT|Oleacore®|Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA
219042839|NCT06893627|BEHAVIORAL|Body Project|Dissonance-based, online, peed-led eating disorder prevention intervention, consisting of 4 x 1 hour with a week a part.
219042840|NCT06893627|BEHAVIORAL|Expressive writing|Participants are encouraged to write about their body 40 min. per week
219619560|NCT05867030|DRUG|rituximab|rituximab is administered intravenously
218923811|NCT05712330|OTHER|parent questionnaire|parent questionnaire
218923812|NCT03430297|BIOLOGICAL|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
218923813|NCT03430297|DRUG|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = \[body surface area (BSA) x (1000mg/m2)\].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184\* (cm0.725) \* (kg0.425)"
219537817|NCT04807426|OTHER|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
219537818|NCT04422457|OTHER|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
219619561|NCT05867030|DRUG|parsaclisib|parsaclisib is administered orally
219619562|NCT00289848|DRUG|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
219619563|NCT00289848|DRUG|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
219619564|NCT00278057|DRUG|dialysisis with and without glucose in the dialysis|
219619565|NCT00894972|OTHER|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
219537819|NCT02995720|DRUG|Fimasartan/Amlodipine combination drug, Rosuvastatin|
219537820|NCT00247923|PROCEDURE|Hysteroscopic resection of endometrial polyps. (TCRP)|
219619566|NCT05265286|DRUG|FRSW117|"Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117."
219619567|NCT03785522|DRUG|Insulin degludec|Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
219619568|NCT01121614|DEVICE|LOTUS|Device used to seal blood vessel
219619569|NCT01121614|DEVICE|Ethicon Harmonic Scalpel|
219619570|NCT01121614|DEVICE|LigaSure bipolar vessel sealing device|
219619571|NCT00860795|BIOLOGICAL|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
219619572|NCT00860795|DRUG|placebo|placebo 25 ml daily in 2 divided doses for 10 days
219619573|NCT05650112|BIOLOGICAL|FB-001|FB-001 is formulated as a powder in capsule intended for oral administration
219619574|NCT05650112|BIOLOGICAL|Placebo|In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule
219619575|NCT03871543|DEVICE|AquaComfort Plus|Test Lens 1
219619576|NCT03871543|DEVICE|Acuvue Oasys 1-Day|Test Lens 2
219537821|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
219619577|NCT01316081|DIETARY_SUPPLEMENT|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
219619578|NCT05799638|OTHER|Guideline-Directed Medication Treatment (GDMT)|GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
219619579|NCT00194441|OTHER|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
219619580|NCT04294407|OTHER|No intervention|no intervention in this study
219619581|NCT02383979|DEVICE|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
219537822|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
219619582|NCT02383979|DEVICE|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
219619583|NCT01279824|BEHAVIORAL|swallowing therapy|Standardized behavioral swallowing intervention
218923814|NCT02017405|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
218923815|NCT02017405|OTHER|Matching Placebo|
218923816|NCT05383937|OTHER|Speech Therapy INTENS-DYS|During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
219537823|NCT03884894|DIAGNOSTIC_TEST|molecular assay|performed with blood culture simultaneously
219537824|NCT03884894|DIAGNOSTIC_TEST|Blood culture|performed with molecular assay simultaneously
218923817|NCT06107036|DRUG|BI 1015550|BI 1015550
218923818|NCT06107036|DRUG|Moxifloxacin|Moxifloxacin
218923819|NCT06107036|DRUG|Placebo|Placebo-matching BI 101550
219537825|NCT01899989|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
219619584|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
219619585|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
218923820|NCT06590012|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
218923821|NCT06590012|DRUG|Tertinat|Participants will take Tertinat capsules in addition to standard treatment for a year.
218923822|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
218923823|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
219619586|NCT02028897|OTHER|Conventional embryo culture|
219619587|NCT02028897|OTHER|Enclosed embryo culture|
219619588|NCT05496205|DRUG|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
219619589|NCT05496205|DRUG|Placebo|Matching Placebo for each formulations
219619590|NCT03920124|OTHER|Step and walk-based high intensity interval exercise|"Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of \~30 min daily or \~150 min weekly)."
218923824|NCT00811590|DRUG|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
218923825|NCT06882902|BEHAVIORAL|habit formation training|Participants need to perform habit formation exercises for 4 consecutive days. During the exercises, participants will see a picture stimulus and need to learn the corresponding key press. Each day, participants will spend 30 minutes on the training.
218923826|NCT06667687|DRUG|ABBV-291|Intravenous Infusion
218923827|NCT06004739|DRUG|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
218923828|NCT06004739|OTHER|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
218923829|NCT06757530|DIAGNOSTIC_TEST|AI|Using artificial intelligence models to distinguish between patients with lymph node metastasis and those without lymph node metastasis.
218923830|NCT06778434|DRUG|Imipramine|10% imipramine
218923831|NCT06778434|OTHER|Control Vehicle|polyethylene glycol: dimethyl sulfoxide Solution
218923832|NCT04057664|BEHAVIORAL|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
218923833|NCT06867328|PROCEDURE|Platelet-Rich Plasma (PRP) Dressing|"* PRP will be prepared by centrifugation of 20 mL venous blood with an anticoagulant.~* The extracted PRP will be applied twice weekly to the wound.~* A sterile gauze will be placed over the wound after PRP application.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
218923834|NCT06867328|PROCEDURE|Normal Saline Dressing|"Wound will be cleansed with normal saline and covered with sterile gauze.~* Dressing changes will be done twice weekly following wound debridement.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
218923835|NCT06818747|PROCEDURE|Best corrected monocular visual acuity|Assessed with the Monoyer scale and expressed in logMAR at 24 months after corneal transplantation
218923836|NCT06775015|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Serum Raman spectroscopy intelligent diagnostic system Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
218923837|NCT06947408|DRUG|Placebo|Healthy participants and patients with asthma will receive matched placebo.
218923838|NCT06947408|DRUG|IBI3002|Healthy participants and patients with asthma will receive IBI3002 at the corresponding dose and dosing interval.
218923839|NCT05004129|DRUG|Tideglusib|Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.
218923840|NCT03330470|BEHAVIORAL|exercise|participants will be subjected to 4 months supervised exercise intervention
218923841|NCT03330470|DIETARY_SUPPLEMENT|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
218923842|NCT03330470|BEHAVIORAL|stretching|participants will be subjected to 4 months supervised stretching program
218923843|NCT03330470|DIETARY_SUPPLEMENT|supplementation with placebo|participants will be instructed to take placebo 2 times daily
218923844|NCT04402567|OTHER|No Intervention|Not Apply
219537826|NCT01899989|DRUG|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
219537827|NCT03049748|DEVICE|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
218923845|NCT00809718|DRUG|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
218923846|NCT01516541|OTHER|Background care|Guidelines-based medical care
218923847|NCT01516541|DRUG|Placebo|Matching dalcetrapib placebo orally daily
218923848|NCT01516541|DRUG|dalcetrapib|600 mg orally daily
218923849|NCT01933568|RADIATION|SABR|combined CFRT and SABR with concurrent cisplatin
218923850|NCT01933568|DRUG|Cisplatin|combined CFRT and SABR with concurrent cisplatin
219619591|NCT00890383|DRUG|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
219619592|NCT01313897|DRUG|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
219619593|NCT02127151|DRUG|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
219619594|NCT03618693|PROCEDURE|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
219619595|NCT03618693|DEVICE|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
219537828|NCT03049748|OTHER|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
218923851|NCT03572660|BIOLOGICAL|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
219537829|NCT02263703|BIOLOGICAL|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
219537830|NCT03373643|DIAGNOSTIC_TEST|OSA screening|Full night polysomnography
219619596|NCT03618693|OTHER|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
218923852|NCT02559999|OTHER|Painful tonic stimuli|
218923853|NCT02559999|OTHER|non-painful stimuli|
218923854|NCT04430816|PROCEDURE|double mesh modification of chevrel's technique|repair of midline incisional hernia by double mesh modification of chevrel's technique
218923855|NCT04430816|PROCEDURE|on lay mesh hernioplasty|repair of midline incisional hernia by online mesh hernioplasty
218923856|NCT01570946|BEHAVIORAL|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
218923857|NCT02446574|DRUG|Paclitaxel|starting dose 20mg/m2 qw
218923858|NCT02446574|DRUG|Cisplatin|dose 25mg/m2 qw
218923859|NCT02446574|RADIATION|Radiation|60Gy/2Gy/30f
218923860|NCT04775940|PROCEDURE|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
219537831|NCT05367076|BEHAVIORAL|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time"
219537832|NCT04721834|DEVICE|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
219537833|NCT04721834|DEVICE|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
219537834|NCT02645500|BEHAVIORAL|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
219537835|NCT02645500|BEHAVIORAL|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
218923861|NCT04775940|PROCEDURE|Occlusive collagen membrane|Occlusive collagen membrane
218923862|NCT04674423|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
218923863|NCT00110747|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
218923864|NCT00110747|DRUG|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
218923865|NCT06298799|GENETIC|DNA Sequencing and Analysis|DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
218923866|NCT06298799|GENETIC|differential expression analysis with RNA-sequencing (RNA seq) experiments|Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
218923867|NCT02331212|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218923868|NCT02331212|OTHER|Laboratory Biomarker Analysis|Correlative studies
218923869|NCT03903237|OTHER|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
219537836|NCT05212350|PROCEDURE|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
219537837|NCT05212350|PROCEDURE|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
219537838|NCT04855279|OTHER|neutral sodium fluoride|Topically applied
219537839|NCT04855279|OTHER|ACP-CCP gel|Topically applied
218923870|NCT03458104|OTHER|Cone Beam Computed Tomography|Cone Beam CT of the larynx
219537840|NCT04855279|OTHER|nano-hydroxyapatite solution|Topically applied
219537841|NCT04855279|OTHER|glycerine|Topically applied
219537842|NCT05504902|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
219537843|NCT00348543|PROCEDURE|laser treatment|
219537844|NCT04793971|PROCEDURE|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
218923871|NCT03458104|DIAGNOSTIC_TEST|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
218923872|NCT03458104|DIAGNOSTIC_TEST|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
218923873|NCT03666663|DRUG|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
218923874|NCT03666663|DRUG|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
218923875|NCT03666663|DRUG|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
218923876|NCT03666663|DRUG|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
218923877|NCT04822506|PROCEDURE|Routine perioperative management and PEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Preoperation:RN 6 + RN 4 +ST30 + ST 36+ Hegu (bilateral),De qi, electroacupuncture, continuous wave, 5Hz, 30min before surgery at 19:00 PM Inoperatively: LI 4+ PC 6 + ST36 + GB 34 (bilateral) ,Deqi, electroacupuncture with density wave, 2/100Hz, 30 minutes before operation to the end of the operation Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
219537845|NCT04511039|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219537846|NCT04511039|DRUG|Talazoparib Tosylate|Given PO
219537847|NCT01059058|PROCEDURE|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
219537848|NCT01059058|PROCEDURE|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
219537849|NCT01059058|PROCEDURE|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
219537850|NCT01539096|PROCEDURE|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
218923878|NCT04822506|PROCEDURE|Routine perioperative management and postEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
218923879|NCT04490096|DRUG|[11C]-PBR28|"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."
219537851|NCT01539096|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
219537852|NCT01539096|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
219537853|NCT04791813|OTHER|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
219537854|NCT01442558|DRUG|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
219537855|NCT03351296|DRUG|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
219537856|NCT03351296|DRUG|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
219537857|NCT03351296|DRUG|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
219537858|NCT03351296|DRUG|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
219537859|NCT03351296|DRUG|Bevacizumab|bevacizumab 5 mg/kg every 14 days
219537860|NCT02164435|PROCEDURE|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
219537861|NCT02577653|OTHER|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
219619597|NCT04223336|BEHAVIORAL|Brief physical activity and diet intervention|The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
219537862|NCT01814904|DRUG|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
219537863|NCT01814904|DRUG|colestilan-M|BSAeq 6 g/day
219619598|NCT03627117|DRUG|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
219619599|NCT03627117|DRUG|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
219619600|NCT04078594|OTHER|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
219619601|NCT01930162|DRUG|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
219619602|NCT05961046|DEVICE|Vivity IOL|Vivity IOL
219619603|NCT01837901|DEVICE|Transcorneal electrostimulation|
219619604|NCT02865304|DRUG|endostar|
219619605|NCT02814604|OTHER|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
219619606|NCT01229995|DEVICE|dental implants - zirconia abutmetns - prefabricated abutments|
219619607|NCT00004919|DRUG|cisplatin|Given IV
218923880|NCT04730219|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
218923881|NCT04730219|DRUG|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
218923882|NCT01484119|DRUG|ACT-129968|daily tablets
218923883|NCT01484119|DRUG|Placebo|matching placebo tablets and capsules
218923884|NCT01484119|DRUG|Cetirizine|daily capsules
219537864|NCT01814904|DRUG|colestilan-H|BSAeq 9 g/day
219537865|NCT01814904|DRUG|CBPB|
219537866|NCT00611676|DRUG|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
219537867|NCT00470691|PROCEDURE|plaster cast|complete circular plaster cast
219619608|NCT00004919|DRUG|irinotecan hydrochloride|Given IV
219619609|NCT00004919|DRUG|amifostine trihydrate|Given IV
219619610|NCT00004919|OTHER|pharmacological study|Correlative studies
219619611|NCT06189664|DIAGNOSTIC_TEST|Frozen section|Frozen section analysis
219619612|NCT04302415|DRUG|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
218923885|NCT06061302|OTHER|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
218923886|NCT06061302|OTHER|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
219537868|NCT00470691|PROCEDURE|dorsal splint|dorsal plaster splint
219619613|NCT00695461|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
218923887|NCT06229275|DEVICE|Pap smear collection using the Personal Pap Smear (PPS) Device|Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.
218923888|NCT06229275|DEVICE|Active Comparator: Pap smear collection using the Rovers Cervex-Brush|Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.
218923889|NCT00479427|DRUG|GW842166|100 mg once daily
218923890|NCT00479427|DRUG|Placebo|once daily
219204894|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
219619614|NCT00695461|DIETARY_SUPPLEMENT|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
219619615|NCT04237376|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
219537869|NCT00385320|BIOLOGICAL|HRV vaccine|
219537870|NCT01354886|DRUG|FSH-GEX™|single dose
219537871|NCT01354886|DRUG|Gonal-f|150 IU single dose
219537872|NCT01354886|DRUG|Bravelle|150 IU single dose
219537873|NCT01354886|DRUG|Placebo|single dose
219537874|NCT05653934|BEHAVIORAL|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
219537875|NCT05653934|PROCEDURE|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
219619616|NCT04237376|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
219619617|NCT00086229|DRUG|Glucosamine|
219619618|NCT00086229|DRUG|Chondroitin|
219619619|NCT05021393|OTHER|Clinical Pharmacist Intervention|Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
218923891|NCT05991297|OTHER|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~\- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
218923892|NCT05991297|OTHER|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
218923893|NCT00420771|DRUG|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
218923894|NCT00420771|DRUG|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
218923895|NCT01271296|DIETARY_SUPPLEMENT|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
219537876|NCT05653934|BEHAVIORAL|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
219537877|NCT02333123|DRUG|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
219537878|NCT02333123|DRUG|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
219537879|NCT05726838|OTHER|Inclisiran|There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
218923896|NCT01271296|DIETARY_SUPPLEMENT|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
218923897|NCT04333719|OTHER|Type of sedations|Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
218923898|NCT00463567|DRUG|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
218923899|NCT00463567|DRUG|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
219537880|NCT03261323|PROCEDURE|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
219619620|NCT03495557|PROCEDURE|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
219619621|NCT03495557|DEVICE|Experimental|Onlay polypropylene mesh placement (MN mesh)
219619622|NCT04969679|DRUG|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
219619623|NCT04969679|DRUG|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
219619624|NCT00395629|DRUG|Deferasirox (ICL670)|
219619625|NCT01253629|DRUG|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
219619626|NCT01253629|DRUG|Placebo|Placebo medication identical in appearance to active medication was provided
219619627|NCT03534687|BEHAVIORAL|Aerobic Exercise|12-week supervised aerobic exercise
219619628|NCT01474174|BIOLOGICAL|trivalent influenza vaccine|Given IM
219619629|NCT01474174|OTHER|laboratory biomarker analysis|Correlative studies
219619630|NCT02635594|DIETARY_SUPPLEMENT|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
219619631|NCT02635594|OTHER|Placebo|1000mg cellulose + 475mg L-tartaric acid
219619632|NCT02300064|OTHER|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
219619633|NCT02300064|OTHER|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
219619634|NCT02300064|OTHER|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
219619635|NCT02300064|OTHER|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
219619636|NCT02805153|DRUG|PEG-rhG-CSF|
219619637|NCT02805153|DRUG|rhG-CSF|
218923900|NCT00463567|DRUG|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
218923901|NCT00463567|DRUG|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
218923902|NCT00463567|DRUG|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
218923903|NCT03296319|DEVICE|Echocardiography|Echocardiography guided fluid administration
218923904|NCT03063320|OTHER|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
218923905|NCT00186589|DRUG|90Y Ibritumomab tiuxetan|
218923906|NCT01429740|DRUG|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
218923907|NCT01429740|DRUG|Placebo|Placebo oral solution or capsules
218923908|NCT00395668|DEVICE|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
218923909|NCT02432755|BEHAVIORAL|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
218923910|NCT02432755|BEHAVIORAL|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
218923911|NCT02432755|BEHAVIORAL|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
218923912|NCT04289935|PROCEDURE|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
218923913|NCT00029484|BEHAVIORAL|Tai chi chih|
218923914|NCT03077412|DRUG|Filgotinib|Tablet(s) administered orally once daily
218923915|NCT03077412|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
218923916|NCT05117931|DRUG|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (\<80kg) or 1400mg (\>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh \<80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
218923917|NCT06233136|DEVICE|Leg pedalling exercise|Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
218923918|NCT06233136|OTHER|The designed physical therapy program|"It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises"
218923919|NCT04114318|OTHER|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
218923920|NCT05178004|OTHER|Faecal and Urine sample collection|This is an observational study.
218923921|NCT05087004|BEHAVIORAL|Teen Council|Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
218923922|NCT04688008|DRUG|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
219204895|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
219204896|NCT06996652|DRUG|Adalimumab|40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
218923923|NCT02266888|BIOLOGICAL|Rituximab (Rituxan®)|2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
218923924|NCT02266888|BIOLOGICAL|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
218923925|NCT02351856|DRUG|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
218923926|NCT02132988|BIOLOGICAL|OPT-822/OPT-821|
218923927|NCT01458392|BIOLOGICAL|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
218923928|NCT03762993|BEHAVIORAL|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
219204897|NCT06996652|DRUG|Placebo|40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
219537881|NCT03261323|PROCEDURE|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
219619638|NCT06068062|OTHER|modification of OSCE using TBL format|Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
218923929|NCT02202200|DRUG|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
218923930|NCT04698369|DEVICE|Vibration Massage Therapy|WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
219537882|NCT03261323|OTHER|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
218923931|NCT04244292|OTHER|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
218923932|NCT00555698|DEVICE|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
219204898|NCT06997315|OTHER|Time of exercise|The intervention is 1 hour of exercise at 50% between lactate threshold 1 and 2 either in the morning or the evening at the start of the 24 hour sampling period.
219204899|NCT06997315|OTHER|No exercise|The participants will rest for the full 24 hour sampling period.
219619639|NCT03904251|DRUG|Gemtuzumab Ozogamicin|Given IV
219619640|NCT03904251|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219619641|NCT02584101|BEHAVIORAL|ACT|ACT therapy administered in 3 sessions over a 4 week period
219619642|NCT02584101|BEHAVIORAL|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
219619643|NCT04556682|DEVICE|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
219619644|NCT04556682|DEVICE|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
219619645|NCT02309320|BIOLOGICAL|ALX-0171|
219619646|NCT02309320|OTHER|Placebo|
219619647|NCT06453668|BIOLOGICAL|TCD601|Investigational Product
219619648|NCT01293916|OTHER|Spica casting|single versus double leg spica casting
219619649|NCT06121323|OTHER|Sodium lactate infusion|Dosage of sodium-lactate: 0.5 mol/L; 3 mL/kg/time; maximal 300 mL/hour.
219619650|NCT06121323|OTHER|Sodium lactate ingestion|Oral dose is equal to the i.v. dose.
219619651|NCT00606112|DRUG|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
219619652|NCT03068234|DRUG|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
219619653|NCT03068234|DRUG|Placebo oral capsule|Placebo for pirfenidone capsule
219619654|NCT03068234|DRUG|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
219619655|NCT05720741|BEHAVIORAL|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although never formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
219619656|NCT05720741|BEHAVIORAL|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
218923933|NCT01263847|DIETARY_SUPPLEMENT|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
218923934|NCT01193244|DRUG|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
219537883|NCT04827368|OTHER|Breath Test|Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.
219537884|NCT04030429|DRUG|Crizotinib 250 MG|bid orally
219537885|NCT04111965|DRUG|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
219537886|NCT04111965|DRUG|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
219537887|NCT06002230|DRUG|Homeopathic medicines|Globules were administered orally..
218923935|NCT01193244|DRUG|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
219537888|NCT01645995|DIETARY_SUPPLEMENT|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
218923936|NCT01193244|DRUG|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
218923937|NCT04731545|DEVICE|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
218923938|NCT02678026|DEVICE|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
218923939|NCT01129856|DRUG|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
218923940|NCT01129856|DRUG|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
218923941|NCT02909400|DRUG|KH176|
218923942|NCT02909400|DRUG|placebo|
218923943|NCT00689507|BIOLOGICAL|LY2127399|monoclonal antibody
218923944|NCT05324059|DRUG|Pregabalin 75mg/ Tramadol 50 mg|Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
218923945|NCT05324059|DRUG|Pregabalin 75mg|Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
218923946|NCT04605172|OTHER|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
218923947|NCT00384670|BIOLOGICAL|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
218923948|NCT00384670|BIOLOGICAL|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
218923949|NCT01173367|OTHER|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
218923950|NCT01173367|OTHER|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
218923951|NCT05166772|DRUG|Donafenib|200 mg BID，oral administration will start before the first HAIC treatment.
218923952|NCT05166772|DRUG|Sintilimab|200 mg，Q3W，Intravenous infusion will performe before HAIC treatment.
218923953|NCT05166772|OTHER|HAIC|Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
218923954|NCT01394003|DRUG|LY2584702|administered orally
218923955|NCT03839160|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
218923956|NCT03839160|DRUG|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
218923957|NCT03763877|DRUG|PXL770|Oral capsule
218923958|NCT03763877|DRUG|Placebo Oral Capsule|Oral capsule
218923959|NCT03040336|BEHAVIORAL|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
218923960|NCT01262196|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
218923961|NCT01262196|DRUG|Saline|Normal saline (0.9%) solution
218923962|NCT01601548|BEHAVIORAL|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
218923963|NCT01735006|BIOLOGICAL|HPV Vaccine|3 doses at month 0,1 and 6
218923964|NCT01735006|BIOLOGICAL|HEV vaccine|3 doses at month 0,1 and 6
218923965|NCT02026531|OTHER|3-Helium gas|3-Helium gas for MRI contrast
219537889|NCT01645995|DIETARY_SUPPLEMENT|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
219619657|NCT00128635|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
219537890|NCT00905840|DEVICE|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
218923966|NCT03537404|DRUG|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
218923967|NCT03537404|DRUG|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
218923968|NCT03537404|DRUG|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
218923969|NCT03537404|DRUG|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
218923970|NCT03906448|COMBINATION_PRODUCT|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
218923971|NCT01765283|BIOLOGICAL|HepaStem|
219537891|NCT00905840|DEVICE|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
219537892|NCT03496623|DRUG|Inhaled treprostinil solution|Treprostinil inhalation solution
219537893|NCT03496623|DRUG|Placebo solution|Placebo solution
219537894|NCT01334333|DRUG|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
219537895|NCT01334333|DRUG|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
219537896|NCT03326271|PROCEDURE|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
219619658|NCT05183841|DRUG|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
219619659|NCT05183841|OTHER|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
219619660|NCT02945241|DRUG|Vancomycin|Intravenous
218923972|NCT05028543|PROCEDURE|Conventional TLH|"Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached."
219537897|NCT03326271|PROCEDURE|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
219537898|NCT04375384|DRUG|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
219537899|NCT04375384|OTHER|Questionnaire administration|Ancillary studies
219537900|NCT04375384|OTHER|Quality of life assessment|Ancillary studies
219537901|NCT04552418|DRUG|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
219537902|NCT03210480|DRUG|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
219537903|NCT03210480|DRUG|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
219619661|NCT02945241|OTHER|Cystatin C dosing algorithm|Expressed in milliliters per minute
219619662|NCT02945241|OTHER|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
219619663|NCT02256618|OTHER|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
219619664|NCT03113864|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 9 months
219619665|NCT03113864|DIETARY_SUPPLEMENT|Lutein|Daily Supplementation for 9 months
219619666|NCT00105118|DEVICE|Magstim Super Rapid Magnetic Stimulator|
219619667|NCT01057706|OTHER|chiropractic|spinal manipulation and mobilization
219619668|NCT01057706|BEHAVIORAL|exercise|strengthening, stretching, balance
219619669|NCT02780037|BEHAVIORAL|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
219619670|NCT02780037|BEHAVIORAL|Regulatory frame: promotion|Exercise program presented as promoting improvement.
219619671|NCT02780037|BEHAVIORAL|Regulatory frame: not implied|Exercise program presented without implied consequences.
219619672|NCT01967862|PROCEDURE|computed tomography|Undergo CT
219619673|NCT01967862|PROCEDURE|bone scan|Undergo bone scan
219619674|NCT01967862|PROCEDURE|3-Tesla magnetic resonance imaging|Undergo axial MRI
218923973|NCT05028543|PROCEDURE|Clipping of utrine artery at its origin before bginning of TLH|"the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method."
218923974|NCT01175577|DIETARY_SUPPLEMENT|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
219537904|NCT04711980|DRUG|Mudan granule|"Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
218923975|NCT01175577|DIETARY_SUPPLEMENT|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
218923976|NCT01175577|OTHER|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
218923977|NCT01175577|OTHER|Placebo|Safflower oil-filled capsules, one twice daily with meals
218923978|NCT06212336|DRUG|Favipiravir|Interventional Medicinal Product (IMP)
218923979|NCT06212336|DRUG|Ribavirin|Control arm
218923980|NCT06212336|DRUG|Dexamethasone|Interventional Medicinal Product (IMP)
218923981|NCT00001209|DRUG|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
218923982|NCT04226755|DIETARY_SUPPLEMENT|Sodium chloride|1 gram tid (with every meal)
219537905|NCT04711980|DRUG|Placebo|"Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
219537906|NCT01590485|OTHER|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
219619675|NCT01967862|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
218923983|NCT00068692|RADIATION|Radiotherapy|Undergo external beam radiation therapy
219537907|NCT01590485|OTHER|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
219619676|NCT01967862|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
219619677|NCT01967862|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
219619678|NCT01967862|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
219619679|NCT01967862|OTHER|laboratory biomarker analysis|Correlative studies
219619680|NCT02271334|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
219619681|NCT02271334|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
219619682|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
218923984|NCT00068692|DRUG|Fluorouracil|Given IV
218923985|NCT00068692|DRUG|Leucovorin Calcium|Given IV
218923986|NCT00068692|DRUG|Oxaliplatin|Given IV
218923987|NCT00068692|DRUG|Irinotecan|Given IV
218923988|NCT01222689|DRUG|erlotinib hydrochloride|Given PO
218923989|NCT01222689|DRUG|selumetinib|Given PO
218923990|NCT01222689|OTHER|laboratory biomarker analysis|Correlative studies
218923991|NCT03110523|DRUG|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
218923992|NCT04672668|DIAGNOSTIC_TEST|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
218923993|NCT04790916|DRUG|RO7049665|RO7049665, subcutaneous injection, Q2W.
218923994|NCT04790916|OTHER|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
218923995|NCT03854266|DRUG|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
218923996|NCT03854266|DRUG|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
218923997|NCT03854266|DEVICE|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
218923998|NCT03278457|DIAGNOSTIC_TEST|Positron Emission Tomography|Positron Emission Tomography
219619683|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
219619684|NCT02069015|BEHAVIORAL|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
219619685|NCT05302401|BEHAVIORAL|intrapartum uninterrupted midwife support|Prenatal women will be trained about the birth process and psychological and physical support will be provided to women during childbirth. Among these supports, healthy women will be exercised during the labor action, given positions that facilitate childbirth, their hands will be held when they need them, their oral intake will not be restricted, and warm showers will be applied according to their wishes. (These applications can be increased.)
219619686|NCT00031590|DRUG|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
219619687|NCT00031590|DRUG|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
219619688|NCT00031590|DRUG|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
218923999|NCT00248040|DRUG|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
219537908|NCT05126355|BEHAVIORAL|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
218924000|NCT00248040|DRUG|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
218924001|NCT00248040|OTHER|placebo infusion|placebo was volume/schedule matched saline
218924002|NCT03530072|DIAGNOSTIC_TEST|Karius Test|Next Generation Sequencing
218924003|NCT06416124|DIAGNOSTIC_TEST|Anthropometric assessment|A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
218924004|NCT03221153|PROCEDURE|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
218924005|NCT05441748|OTHER|Walnuts|The intervention treatment will contain walnuts.
218924006|NCT05441748|OTHER|Walnut Oil|The intervention treatment will contain walnut oil.
218924007|NCT05441748|OTHER|Control|The control treatment will contain corn oil.
219042841|NCT06894836|BEHAVIORAL|Third wave VR therapy|All participants in this trial will receive the VR intervention which is adapted from third wave CBT protocols (including mindfulness and Acceptance and Commitment Therapy) and focuses on decentering-the ability to step back and view thoughts and emotions as temporary, objective events rather than identifying with them. Decentering has been linked to improved emotional regulation, reduced rumination, and better psychological flexibility, which in turn can lead to improvements in depression and anxiety symptoms. The intervention is clinician-delivered in a clinical setting, one-on-one, over 4-5 sessions (60 min each) across 10-12 weeks. Each session includes psychoeducation, a 15-minute VR experience, and debriefing. Sessions cover three core techniques targeting improvement in decentering ability: 1) arousal reduction via controlled breathing, 2) sitting with discomfort without reacting, and 3) cognitive defusion by changing perception of negative thoughts.
219537909|NCT01739101|BEHAVIORAL|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
219537910|NCT03537872|BEHAVIORAL|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
219537911|NCT03537872|BEHAVIORAL|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
219537912|NCT05342740|OTHER|collect whole blood, urine and stool samples|collect whole blood, urine and stool samples
219537913|NCT00794963|DRUG|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
219537914|NCT00794963|OTHER|As selected by community physician|As selected by community physician
219537915|NCT02420834|OTHER|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
219537916|NCT02420834|OTHER|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
219537917|NCT02420834|OTHER|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
219537918|NCT02420834|OTHER|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
219537919|NCT02681263|DRUG|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
219537920|NCT01932086|DIETARY_SUPPLEMENT|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
219537921|NCT01932086|DIETARY_SUPPLEMENT|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
219619689|NCT00031590|DRUG|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
218924008|NCT05448196|OTHER|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
218924009|NCT00512213|DIETARY_SUPPLEMENT|Immunonutrition for 5 days preoperative|Impact vs Meritene
218924010|NCT00512213|DIETARY_SUPPLEMENT|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
218924011|NCT04724993|OTHER|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
218924012|NCT04724993|OTHER|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
218924013|NCT03481595|DEVICE|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
218924014|NCT01682889|DIETARY_SUPPLEMENT|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
218924015|NCT01682889|DIETARY_SUPPLEMENT|Placebo|NaCl 0.9% intravenously for 24h
218924016|NCT00135824|DRUG|Povidone K25 eye drops (povidone)|
218924017|NCT03252379|PROCEDURE|hepaticojejunostomy|"* Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
218924018|NCT03252379|PROCEDURE|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
218924019|NCT03252379|PROCEDURE|modified hepaticojejunostomy with gastric access loop|"* In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
218924020|NCT05459896|BEHAVIORAL|Physical Activity Training|Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
219042842|NCT06895759|DEVICE|Soda lime|Respiration into a snow air pocket through an experimental rebreathing circuit with the integration of a soda lime canister.
219042843|NCT06895759|DEVICE|Sham|Respiration into a snow air pocket through an experimental rebreathing circuit without the integration of a soda lime canister.
219042844|NCT06897293|PROCEDURE|Modified Broström procedure + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
219537922|NCT01932086|DIETARY_SUPPLEMENT|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
219537923|NCT01932086|DIETARY_SUPPLEMENT|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
219042845|NCT06897293|PROCEDURE|Modified Broström procedure operation|Patients with CLAI and GJL will accept the Modified Broström procedure operation
219537924|NCT01932086|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
219537925|NCT01461421|BEHAVIORAL|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
219537926|NCT01461421|BEHAVIORAL|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
219537927|NCT01461421|BEHAVIORAL|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
219537928|NCT01461421|BEHAVIORAL|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
219537929|NCT01565902|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
219042846|NCT06832813|DEVICE|cTBS|"Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 40s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.~1. Enhanced phase：participants received cTBS treatment for a total of 5 times a week for 2 weeks；~2. Consolidation phase：participants received cTBS treatment for a total of twice a week (at least 24 hours apart) for 8 weeks；~3. Maintenance phase：participants received cTBS treatment for a total of once a week for 8 weeks."
219537930|NCT02118532|DEVICE|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
219537931|NCT03645785|DIETARY_SUPPLEMENT|Normal fluid intake without true lemon|16.9oz water with True Lemon
219537932|NCT03645785|DIETARY_SUPPLEMENT|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
219537933|NCT05261737|PROCEDURE|Corticosteroid Injection|Steroid injection effectiveness will be determined by relief of pain scored by patient using Visual Analogue Scale (VAS). Data will be collected during clinic visit and contacting patients in a determined protocol for the following 6 weeks after steroid injection.After approval of the study, data will collected from participants over a period of 6 weeks follow up; the whole study will be conducted over a total of 2 years.Since the study will not conduct any further test to participants and follow up regimen will only state pain related to the specific condition (De Quervain tenosynovitis) and quick-DASH score, it will not result in any anticipated/unanticipated incidental findings, therefore participants will not be recontacted.
219537934|NCT05663411|DRUG|SHR6508|SHR6508
219537935|NCT05663411|DRUG|SHR6508|SHR6508
219537936|NCT05663411|DRUG|Cinacalcet|Cinacalcet
219537937|NCT00509561|BIOLOGICAL|cetuximab|
219537938|NCT00509561|DRUG|capecitabine|
219537939|NCT00509561|DRUG|cisplatin|
219537940|NCT00509561|RADIATION|radiation therapy|
219537941|NCT02892253|DEVICE|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
219537942|NCT06225076|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
219537943|NCT06225076|PROCEDURE|Stellate ganglion block|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219537944|NCT06225076|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219619690|NCT00031590|DRUG|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
219619691|NCT00031590|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
219042847|NCT06245473|DIAGNOSTIC_TEST|blood sample|During the blood test planned as part of the care an additional blood tube with a volume of 6mL will be takeń in an EDTA tube.
219537945|NCT00905931|DRUG|Lycopene|30 mg oral, daily, for 21 days
219537946|NCT00905931|DRUG|placebo|starch
219537947|NCT01450189|BEHAVIORAL|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
219537948|NCT01450189|BEHAVIORAL|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
219619692|NCT01650480|OTHER|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
219619693|NCT03121846|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
219619694|NCT01780012|BEHAVIORAL|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
219619695|NCT05587322|DRUG|BLI5100|Orally via tablet
219619696|NCT05587322|DRUG|Placebo|Orally via tablet
218924021|NCT05459896|OTHER|Mindfulness-based Intervention|Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
218924022|NCT05459896|OTHER|Energy Conservation Techniques|Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
218924023|NCT06051149|PROCEDURE|caudal adhesolysis using RACZ Catheter|caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy
218924024|NCT06051149|PROCEDURE|caudal adhesiolysis using NAVI Catheter|caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
218924025|NCT00112619|DRUG|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
218924026|NCT04900116|DRUG|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
218924027|NCT04900116|DRUG|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
218924028|NCT04900116|DRUG|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
219537949|NCT01450189|DRUG|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
219537950|NCT01450189|DRUG|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
219537951|NCT01956786|DRUG|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
218924029|NCT04900116|DRUG|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
218924030|NCT01295164|DEVICE|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
219042848|NCT06828419|DEVICE|Domestic single-port laparoscopic surgery system|The minimum distance of the single-port surgical system from the port is 5-7cm to obtain the instrument bending space. The load capacity of surgical tools is increased from 2N to 5N, which greatly improves the structural reliability. At the same time, it can realize 6 degrees of freedom movement。
219537952|NCT01956786|DRUG|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
219537953|NCT01956786|DRUG|Amlodipine|5mg amlodipine,once daily
219537954|NCT06118918|BEHAVIORAL|Phase II comprehensive cardiac rehabilitation program|the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation …etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
219537955|NCT02079194|DRUG|P2Y12 antagonist monotherapy|
219537956|NCT02079194|DRUG|aspirin plus P2Y12 antagonist|
219537957|NCT01151930|DRUG|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
219537958|NCT00043394|DRUG|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
218924031|NCT01295164|DEVICE|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
218924032|NCT03703427|DRUG|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
218924033|NCT03703427|DRUG|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
218924034|NCT04172818|BEHAVIORAL|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
218924035|NCT02001259|DRUG|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
218924036|NCT02001259|DRUG|epidural lidocaine|add into catheter at 48 hr after surgery
218924037|NCT00804921|DRUG|bevacizumab|
218924038|NCT00804921|PROCEDURE|anterior chamber paracentesis|
219537959|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
219537960|NCT00043394|DRUG|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
219537961|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
219537962|NCT00043394|DRUG|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
219537963|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
219537964|NCT00043394|DRUG|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
219537965|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
219537966|NCT03552744|OTHER|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~1. 2-page structured evidence summary on CRC screening and information about Colonoscopy \& FIT (Decision box)~2. patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~3. video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4. 4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~5. individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~6. 2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~7. sample FIT for PCPs who may not be familiar with its contents and use"
219537967|NCT03181594|DEVICE|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
219537968|NCT03945422|DEVICE|AccuTite/FaceTite|Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
219537969|NCT04657965|DRUG|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
219537970|NCT02365012|DRUG|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
219537971|NCT02704585|DEVICE|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
219619697|NCT05046912|BEHAVIORAL|Yoga|8 weeks of online weekly yoga or chair yoga class
219537972|NCT02704585|DEVICE|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
219537973|NCT04327128|DEVICE|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
219619698|NCT05046912|BEHAVIORAL|Mindfulness|8 weeks of online weekly mindfulness class
219619699|NCT03666130|PROCEDURE|endoscopic septoplasty|endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
219537974|NCT03276247|OTHER|observation|observation
219537975|NCT02787876|DRUG|Pegteograstim|
219537976|NCT03282162|DRUG|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
219537977|NCT03282162|DRUG|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
219619700|NCT01714830|DEVICE|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
219619701|NCT01714830|DEVICE|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
219619702|NCT00299325|DRUG|Rimonabant|Tablet, oral administration
219619703|NCT00299325|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219619704|NCT00299325|OTHER|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
219619705|NCT00519857|DRUG|Tibolone|1.25 mg p.o, once daily for 3 years
219619706|NCT00519857|DRUG|Placebo|Tablet p.o, once daily for 3 years
218924039|NCT00804921|DRUG|acetazolamide|
218924040|NCT00804921|DRUG|brimonidine|
218924041|NCT04392180|OTHER|Qualitative Interview|There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
218924042|NCT00193544|DRUG|Arsenic Trioxide|
218924043|NCT00193544|DRUG|Thalidomide|
218924044|NCT01002339|DRUG|Tacrolimus with rapid steroid withdrawal|"* Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
219537978|NCT03426722|DRUG|L-carnitine|"* L-carnitine VS Placebo is randomized (1:1)~* L-carnitine 500mg TID(PO),~* First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given."
219537979|NCT03426722|DRUG|Placebo|Placebo 500mg TID(PO)
219537980|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
219537981|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
219537982|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
219537983|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
219537984|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
219537985|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
219537986|NCT02334644|DIETARY_SUPPLEMENT|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
219619707|NCT04248114|DIAGNOSTIC_TEST|Ultrasound of the Neck|Anatomical measurements were performed on participants during an ultrasound exam
219619708|NCT00485719|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
219619709|NCT05882019|DEVICE|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
219619710|NCT01026519|DRUG|REGN88|Single dose of REGN88 and 43 day follow up.
219619711|NCT01026519|OTHER|Placebo|Placebo to match REGN88 administration
219619712|NCT00516841|DRUG|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
219619713|NCT01120808|PROCEDURE|Paper tape|Paper tape assigned to each participant's randomly selected foot.
219619714|NCT00907543|OTHER|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
219537987|NCT02334644|DIETARY_SUPPLEMENT|Placebo|2 sachets/day x 12 weeks
219537988|NCT01997372|DRUG|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \>1×109/L.
219537989|NCT03610035|DRUG|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
219537990|NCT03610035|DRUG|Placebo|Placebo
219537991|NCT01027923|DRUG|Plerixafor|
219537992|NCT01027923|DRUG|Mitoxantrone|
219537993|NCT01027923|DRUG|Etoposide|
219537994|NCT01027923|DRUG|Cytarabine|
219537995|NCT03837249|DEVICE|Personal Sleep Monitoring|Wearable Sleep Self-Monitoring Device (Actigraphy)
219537996|NCT05901090|OTHER|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
219619715|NCT00907543|OTHER|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
219619716|NCT01282684|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
219619717|NCT01282684|DRUG|Placebo|Matching placebo for PLX5622.
219619718|NCT03051100|DRUG|Bempedoic acid 180mg|bempedoic acid 180 mg
219619719|NCT03051100|DRUG|Ezetimibe 10mg|ezetimibe 10 mg
219619720|NCT03051100|DRUG|Atorvastatin 20mg|atorvastatin 20 mg
219619721|NCT03051100|OTHER|Placebo|placebo
219619722|NCT06292845|DRUG|Topical application of a fluorescent imaging agent|"The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen.~During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system."
219619723|NCT00706459|DEVICE|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
219619724|NCT04636775|DIAGNOSTIC_TEST|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
219619725|NCT04746287|DRUG|CKD-510 single dose|Investigational drug
219619726|NCT04746287|DRUG|CKD-510 food effect|Investigational drug
219619727|NCT04746287|DRUG|CKD-510 multiple dose|Investigational drug
219619728|NCT04746287|DRUG|Placebo|Matching placebo
219619729|NCT05071599|DEVICE|Twin Arch Brackets|Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
219619730|NCT05408299|BIOLOGICAL|Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)|Vaccination
219537997|NCT05901090|OTHER|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
219537998|NCT01527006|DRUG|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
219537999|NCT01409278|PROCEDURE|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
219538000|NCT01409278|PROCEDURE|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
219538001|NCT01409278|PROCEDURE|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
219538002|NCT00367861|DRUG|interruption of Glivec®|interruption of Glivec®
218924045|NCT01002339|DRUG|Tacrolimus with steroids minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
218924046|NCT01002339|DRUG|CsA with steroid minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d"
218924047|NCT04959877|BEHAVIORAL|health education|data collect / Telemedicine
218924048|NCT00002696|DRUG|CAF regimen|
218924049|NCT00002696|DRUG|CMF regimen|
218924050|NCT00002696|DRUG|cyclophosphamide|
218924051|NCT00002696|DRUG|doxorubicin hydrochloride|
219538003|NCT01394497|DRUG|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
219538004|NCT02995005|DRUG|Tenofovir Disoproxil Fumarate|300 mg daily
219538005|NCT03755947|DRUG|Ibrutinib|Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
219538006|NCT03755947|DRUG|Obinutuzumab|Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
219538007|NCT03755947|DRUG|Venetoclax|Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
219538008|NCT00296062|BIOLOGICAL|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
219538009|NCT00296062|DRUG|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
218924052|NCT00002696|DRUG|fluorouracil|
218924053|NCT00002696|DRUG|methotrexate|
218924054|NCT00002696|PROCEDURE|adjuvant therapy|
218924055|NCT00002696|PROCEDURE|conventional surgery|
218924056|NCT00002696|PROCEDURE|neoadjuvant therapy|
218924057|NCT00002696|RADIATION|radiation therapy|
218924058|NCT03708276|OTHER|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
218924059|NCT05573997|DIAGNOSTIC_TEST|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
218924060|NCT05414058|DRUG|Apo-Methylphenidate ER|For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
218924061|NCT03751917|DRUG|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
218924062|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
218924063|NCT04055623|OTHER|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
218924064|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
218924065|NCT04040348|BIOLOGICAL|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
219538010|NCT00296062|DRUG|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
218924066|NCT06483113|DEVICE|Delefilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
219538011|NCT00296062|DRUG|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
219538012|NCT00447577|DRUG|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
219538013|NCT00447577|DRUG|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
219538014|NCT04451837|DRUG|Semaglutide|Ozempic s.c. once weekly for 6 months
219538015|NCT04451837|DRUG|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
219538016|NCT01845376|PROCEDURE|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
219538017|NCT01845376|PROCEDURE|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
219538018|NCT01845376|PROCEDURE|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
219538019|NCT00732082|DRUG|Gemcitabine|
219619731|NCT01160692|DIETARY_SUPPLEMENT|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
219619732|NCT01160692|OTHER|Placebo|Daily oral intake of matching placebo tablets for 3 months
219619733|NCT06012344|OTHER|post facilitation stretch|PFS Post-Facilitation Stretch Participants in this arm received the intervention of post-facilitation stretch technique. Post-facilitation stretch involves the application of manual stretching techniques to the targeted muscles after a facilitation phase, which aims to enhance muscle extensibility. The participants underwent a standardized post-facilitation stretch protocol focusing on the hamstring muscles.
219619734|NCT06012344|OTHER|post isometric relaxation|Participants in this arm of the study received the intervention of post-isometric relaxation technique. Post-isometric relaxation involves the application of isometric contraction followed by a relaxation phase to promote muscle lengthening and improve flexibility. The participants underwent a standardized post-isometric relaxation protocol targeting the hamstring muscles.
218924067|NCT06483113|DEVICE|Delefilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
219619735|NCT06012344|OTHER|hamstring nordic lower|Participants in this arm received the intervention of hamstring Nordic lower exercise. The hamstring Nordic lower exercise is a challenging eccentric exercise that specifically targets the hamstring muscles. Participants performed the exercise under supervision and followed a standardized protocol for the number of repetitions, sets, and rest intervals.
219538020|NCT00732082|BIOLOGICAL|LAG-3|
219538021|NCT02009462|DRUG|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
219538022|NCT02017262|BEHAVIORAL|Self-management group|8 weekly sessions of group self-management
219538023|NCT02017262|BEHAVIORAL|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
218924068|NCT06483113|DEVICE|Delefilcon A multifocal soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with presbyopia
218924069|NCT06408649|DEVICE|Lehfilcon A spherical contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)
218924070|NCT06408649|DEVICE|Lehfilcon A toric contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
219538024|NCT05646381|DRUG|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80mg
219538025|NCT05646381|DRUG|Matching placebo|Matching placebo
218924071|NCT05912257|BEHAVIORAL|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
218924072|NCT05912257|BEHAVIORAL|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
218924073|NCT04190862|DRUG|E-CEL UVEC|Injection of E-CEL UVEC
218924074|NCT02122328|PROCEDURE|Sequential laser photocoagulation of communicating vessels.|
218924075|NCT02122328|PROCEDURE|Selective laser photocoagulation of communicating vessels|
218924076|NCT00661050|PROCEDURE|Alternative Medicine|
218924077|NCT00661050|PROCEDURE|Tai Chi instruction and class participation or walking exercise and sitting meditation|
218924078|NCT00034502|DRUG|ALIMTA|
218924079|NCT00034502|DRUG|irinotecan|
218924080|NCT01087463|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
218924081|NCT01185210|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
218924082|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
219538026|NCT04599439|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
219538027|NCT01051765|DRUG|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
219538028|NCT00885144|DIETARY_SUPPLEMENT|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
219538029|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
218924083|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
218924084|NCT00608374|DRUG|chlorambucil|
218924085|NCT00608374|DRUG|fludarabine phosphate|
218924086|NCT00608374|PROCEDURE|quality-of-life assessment|
218924087|NCT05842902|BEHAVIORAL|mPRISM|PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
219538030|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
219538031|NCT00885144|DIETARY_SUPPLEMENT|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
219538032|NCT03247972|DRUG|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
219538033|NCT06563024|DEVICE|18F-FET PET/CT|The enrolled patients receive the 18F-FET PET/CT.
219538034|NCT05840796|DIETARY_SUPPLEMENT|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
219538035|NCT05840796|DIETARY_SUPPLEMENT|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
218924088|NCT02324348|PROCEDURE|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
218924089|NCT02324348|PROCEDURE|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
218924090|NCT02815501|BIOLOGICAL|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
219538036|NCT03059186|BEHAVIORAL|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
219538037|NCT00593463|DRUG|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
219619736|NCT05986604|BEHAVIORAL|Memory Support Intervention|The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
219619737|NCT05986604|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
219619738|NCT03105908|BEHAVIORAL|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
219619739|NCT03105908|BEHAVIORAL|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
219619740|NCT05370950|DRUG|SHR-1209|SHR-1209，single subcutaneous injection of 450mg
219619741|NCT02059135|BIOLOGICAL|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
219619742|NCT02059135|OTHER|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
218924091|NCT01281800|PROCEDURE|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
218924092|NCT06219408|BEHAVIORAL|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
218924093|NCT03371043|OTHER|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
218924094|NCT02879409|DRUG|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
218924095|NCT02879409|DRUG|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
218924096|NCT02879409|DRUG|Sitagliptin|Oral: 100 mg once daily
218924097|NCT02879409|DRUG|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
218924098|NCT02879409|DRUG|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
219619743|NCT03115437|OTHER|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
219619744|NCT03115437|OTHER|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
219619745|NCT01185678|DRUG|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
218924099|NCT02879409|DRUG|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
219538038|NCT00593463|DRUG|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
219538039|NCT00593463|DRUG|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
219538040|NCT00593463|DRUG|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
219538041|NCT00593463|DRUG|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
219538042|NCT00593463|DRUG|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
218924100|NCT02879409|DRUG|human insulin|insulin dosage and administration according to physician
218924101|NCT00790842|DRUG|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
218924102|NCT00790842|DRUG|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
218924103|NCT00790842|DRUG|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
218924104|NCT06499064|PROCEDURE|mHealth|"Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference."
219538043|NCT00593463|DRUG|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
219538044|NCT00593463|DEVICE|Saline|Saline: I.M. injection may possibly be given
219538045|NCT00593463|DRUG|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
219538046|NCT03682341|GENETIC|endometriosis|patients with or without ovarian endometriosis
219538047|NCT01126203|PROCEDURE|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
219538048|NCT01126203|PROCEDURE|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
219538049|NCT06553664|DRUG|Treat with Vibrabot capsules for at least 7 weeks|Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
219538050|NCT00655590|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
218924105|NCT05462522|DRUG|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
218924106|NCT05462522|DRUG|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
218924107|NCT04022213|DRUG|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
218924108|NCT04022213|RADIATION|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
218924109|NCT00419952|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
218924110|NCT00419952|DRUG|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
219538051|NCT00655590|DRUG|Sildenafil|100 mg daily dosing
219538052|NCT00655590|DRUG|Placebo|Matching placebos
219538053|NCT06406608|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
219538054|NCT03827707|BEHAVIORAL|Noise|Noise applied via headphones during 60 min after meal ingestion
219538055|NCT03827707|BEHAVIORAL|Silence|Headphones without sound applied during 60 min after meal ingestion
219619746|NCT00381862|DRUG|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
219619747|NCT00381862|DRUG|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
218924111|NCT06221306|PROCEDURE|Dental implant: NDI|Placement of narrow diameter implants (NDI) (3.3) in the dentoalveolar ridge
218924112|NCT06221306|PROCEDURE|Dental implant: SDI|Placement of standard diameter implants (SDI) (4.1) in the dentoalveolar ridge with simaltenous bone augmentation
218924113|NCT06400693|OTHER|Endotracheal Intubation|Preparation of all necessary equipment for endotracheal intubation
219538056|NCT01887652|OTHER|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
219538057|NCT01887652|OTHER|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
219619748|NCT00381862|DRUG|fluorouracil|as per institutional standard of care
219619749|NCT00381862|DRUG|irinotecan hydrochloride|as per institutional standard of care
219619750|NCT00381862|DRUG|leucovorin calcium|as per institutional standard of care
219538058|NCT03072433|BEHAVIORAL|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
219538059|NCT03072433|BEHAVIORAL|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
219538060|NCT03368287|DEVICE|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
219538061|NCT01551498|DIETARY_SUPPLEMENT|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
219538062|NCT01551498|DIETARY_SUPPLEMENT|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
219538063|NCT06486298|DEVICE|Vacuum Drain and Passive Drain insertion at abdominoplasty surgery|Compare the subcutaneous collection with Vacuum Drain and Passive Drain insertion at abdominoplasty surgery
219538064|NCT01244022|PROCEDURE|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
219538065|NCT01776190|DEVICE|UVA1 radiation treatment|
219538066|NCT03731234|DRUG|Ibrutinib|Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
219538067|NCT04009486|DEVICE|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
219538068|NCT00123734|DRUG|ThromboView|
219538069|NCT03506763|DRUG|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
219538070|NCT03506763|DRUG|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
219538071|NCT03506763|DRUG|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
219538072|NCT03405688|PROCEDURE|Blood sampling|Extra blood samples taken for laboratory analysis
219538073|NCT02599558|DEVICE|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
219538074|NCT06545890|DRUG|Ketamine|continous infusion during surgery
219538075|NCT06545890|DRUG|Dexmedetomidine|continous infusion during surgery
219538076|NCT01727947|OTHER|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied \> 13% of nuclear area) in each sample will be assessed.
219538077|NCT00404105|PROCEDURE|PRK|
219538078|NCT00404105|PROCEDURE|LASIK|
219538079|NCT01175018|DRUG|Anakinra|Anakinra 100 mg s.c. daily for 14 days
219538080|NCT01175018|DRUG|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
219538081|NCT02926677|BEHAVIORAL|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
219538082|NCT02926677|BEHAVIORAL|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
219538083|NCT02926677|BEHAVIORAL|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
219538084|NCT02926677|DEVICE|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
219538085|NCT00840073|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
219538086|NCT00840073|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
219538087|NCT02486900|DEVICE|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
219538088|NCT04045197|BEHAVIORAL|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
219538089|NCT02775812|DRUG|Cisplatin|Given IV
219538090|NCT02775812|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219538091|NCT02775812|OTHER|Laboratory Biomarker Analysis|Correlative studies
218924114|NCT06400693|OTHER|Supraglottic Airway|Preparation of all necessary equipment for laryngeal mask
218924115|NCT06480201|DRUG|Ketamine|Ketamine infusion amount is dictated by BMI, sex, and age.
219538092|NCT02775812|BIOLOGICAL|Pembrolizumab|Given IV
219538093|NCT00958334|DRUG|Proellex®|25 mg daily (two 12.5 mg capsules)
219538094|NCT03557541|DIETARY_SUPPLEMENT|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
219538095|NCT03557541|DIETARY_SUPPLEMENT|Control|They received a common T2D-preventive diet
219538096|NCT00311441|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
219538097|NCT06038253|DEVICE|Fibroscan|Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients
219538098|NCT03442530|BEHAVIORAL|ToPIC|Expanded tobacco cessation counseling for pregnant women.
219538099|NCT03442530|BEHAVIORAL|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
218924116|NCT06480201|OTHER|Saline|Saline infusion amount is dictated by BMI, sex, and age.
218924117|NCT06184776|OTHER|Lumbar Stiffness Disability Index|The development and evaluation of the Turkish version of the Lumbar Stiffness Disability Index (LSDI) are planned. After ensuring the eligibility of adult participants included in the study, language validity will be established for the Turkish version of LSDI, and internal consistency will be assessed using Cronbach's alpha coefficient. Additionally, the test-retest reliability of the index will be evaluated by reapplying it to participants with a one-week interval. For external structure validity, LSDI scores will be correlated with Oswestry Disability Index, Functional Reach Test, and goniometric measurements. The study will include demographic data and measurements to examine the eligibility of individuals with specific medical conditions for the intervention.
218924118|NCT03126591|DRUG|Olaratumab|Administered IV
218924119|NCT03126591|DRUG|Pembrolizumab (KEYTRUDA®)|Administered IV
219538100|NCT02199873|DRUG|BIIX 1 XX - single rising dose|
218924120|NCT01269021|DRUG|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d
219538101|NCT02199873|DRUG|Placebo|
219538102|NCT04558450|DIAGNOSTIC_TEST|carotid-femoral pulse-wave velocity|early vascular aging tests
218924121|NCT01269021|DRUG|Prednisone in full dose|0.8-1mg/kg/d
219619751|NCT00381862|DRUG|oxaliplatin|as per institutional standard of care
219538103|NCT00028951|DRUG|fibrin sealant|
219538104|NCT00028951|PROCEDURE|surgical wound closure|
219538105|NCT05583721|DRUG|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
219538106|NCT05583721|DRUG|Lexiscan|Given IV prior to PET stress test
219619752|NCT00381862|DRUG|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
219619753|NCT00381862|PROCEDURE|quality-of-life assessment|baseline
219619754|NCT05743829|PROCEDURE|Tissue excision as part of routine clinical care|Tissue excision
218924122|NCT05651061|BIOLOGICAL|SS109|27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
218924123|NCT04277338|DRUG|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
218924124|NCT02158546|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218924125|NCT02158546|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
218924126|NCT03863106|OTHER|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
219619755|NCT05198830|DRUG|Carboplatin|Given IV
219619756|NCT05198830|DRUG|Cisplatin|Given IV
219619757|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
219619758|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
219619759|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
219538107|NCT05583721|DIAGNOSTIC_TEST|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
219538108|NCT06457906|COMBINATION_PRODUCT|Experimental group (SRS/SRT/Hypo-RT)|The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.
219619760|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219619761|NCT05198830|DRUG|Methoxyamine|Given PO
219619762|NCT05198830|DRUG|Pemetrexed|Given IV
219619763|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
219619764|NCT02095548|DRUG|SM04690, 0.03mg/2mL|
218924127|NCT00244569|DRUG|13C-Methacetin|
218924128|NCT00244569|DEVICE|Breath ID Machine|
218924129|NCT02351817|DEVICE|Test A|Ostomy appliance
218924130|NCT02351817|DEVICE|Test B|Ostomy appliance
218924131|NCT02351817|DEVICE|Baseline|Ostomy appliance
218924132|NCT01194856|DRUG|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
218924133|NCT01194856|DRUG|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
218924134|NCT02488915|DEVICE|EmboTrap® Revascularization Device|
218924135|NCT00998361|PROCEDURE|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
219538109|NCT06457906|RADIATION|Controled group (HA-WBRT)|The prescription dose of HA-WBRT is 30Gy in 10 fraction.
219538110|NCT06125678|DIAGNOSTIC_TEST|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
219538111|NCT04814381|DRUG|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
219538112|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner|The hospice and palliative care practitioner will be embedded in one medical intensive care unit for the first half of the study timeframe, after which the practitioner will expand to both medical intensive care units. While active in a medical intensive care unit, the practitioner will proactively trigger palliative care consultations based on clinical criteria and estimated mortality risk, in addition to providing immediate availability for standard-of-care hospice or palliative care consultations.
219619765|NCT02095548|DRUG|SM04690, 0.07mg/2mL|
219619766|NCT02095548|DRUG|SM04690, 0.23mg/2mL|
219619767|NCT02095548|DRUG|Placebo|
218924136|NCT05370638|OTHER|Rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
218924137|NCT06277427|DRUG|PRG-1801 （CAR-T against BCMA）|Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
218924138|NCT01910363|DRUG|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
219538113|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner (Group Effect)|While the hospice and palliative care practitioner is active in one medical intensive care unit with respect to triggering consultations, the other medical intensive care unit can still utilize the practitioner's services for standard-of-care hospice or palliative care consultations.
219538114|NCT06574672|OTHER|None (Historical)|This control arm includes historical patients admitted to the medical intensive care units prior to the study's enrollment timeframe.
219538115|NCT00424619|DRUG|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
219538116|NCT00424619|DRUG|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
219538117|NCT00424619|DRUG|Placebo|Placebo, 1 time bolus dose
219538118|NCT02418637|OTHER|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
219538119|NCT05538052|DRUG|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
219619768|NCT05855135|DEVICE|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
219619769|NCT01182012|BEHAVIORAL|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
219619770|NCT00779935|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
219619771|NCT00598741|OTHER|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
219538120|NCT05538052|DRUG|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
218924139|NCT01910363|DRUG|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
218924140|NCT01477398|DEVICE|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
219538121|NCT04337580|DRUG|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
219538122|NCT04325256|PROCEDURE|Manipal ultrasound scoring system|length of the cervix from the internal to external os, presence or absence of funneling and if present width and length of funneling at internal os were measured. Distance between presenting part to external os will be measured and position of the cervix i.e. whether curved or straight will also noted.
219538123|NCT04325256|PROCEDURE|Levine scoring system|maternal height, parity, body-mass index (BMI) at delivery and the results of modified Bishop's score in calculation of probability of CS
219538124|NCT06057753|BEHAVIORAL|MyStroke|Personalized video-based stroke education platform
219538125|NCT01103713|DRUG|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
219538126|NCT05379972|DRUG|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
219538127|NCT05379972|DRUG|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
219538128|NCT05379972|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
219619772|NCT05176821|DRUG|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
219619773|NCT05176821|DRUG|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
219619774|NCT01664663|RADIATION|Standard radiochemotherapy to 68 Gy|
219619775|NCT01664663|RADIATION|Dose escalated radiochemotherapy up to 84 Gy|
219619776|NCT03055455|DIAGNOSTIC_TEST|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
219619777|NCT01169064|DEVICE|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
218924141|NCT05907863|OTHER|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
218924142|NCT05353270|BEHAVIORAL|Yoga|Yoga sessions will be completed 5 times per week for 4 weeks.
219538129|NCT04601792|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
218924143|NCT05353270|BEHAVIORAL|Waitlist control|Waitlisted participants will maintain their normal exercise and diet for 4 weeks. After follow up testing at week 4, participants will be rerandomized to the yoga condition.
219538130|NCT04601792|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
219538131|NCT04601792|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
219538132|NCT05524701|BEHAVIORAL|Sleep Restriction and Normal Sleep|The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
219538133|NCT02096783|OTHER|informational intervention|Given scripted intervention
219538134|NCT02096783|OTHER|counseling intervention|Given standard counseling
219538135|NCT02096783|OTHER|questionnaire administration|Ancillary studies
219538136|NCT00153530|DRUG|methotrexate|"1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy"
219538137|NCT00153530|RADIATION|radiotherapy|whole-brain irradiation
219538138|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
219538139|NCT02253420|DRUG|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
219538140|NCT02253420|DRUG|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
219538141|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
219538142|NCT01291121|PROCEDURE|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
219538143|NCT05769725|DRUG|Serplulimab|Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
219538144|NCT05769725|DRUG|Docetaxel|40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
219538145|NCT05769725|DRUG|S1|Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
219538146|NCT02499718|DEVICE|BiPAP mode|Noninvasive ventilator
219538147|NCT00852020|DIETARY_SUPPLEMENT|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
219538148|NCT02671526|OTHER|Computerized plasticity-based adaptive cognitive training|
219538149|NCT03786822|PROCEDURE|Cryoballoon Pulmonary Vein Isolation - PVI|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
219538150|NCT01884090|BEHAVIORAL|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
219538151|NCT04011917|BEHAVIORAL|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
219619778|NCT01169064|DEVICE|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
218924144|NCT00264186|DRUG|LPS 2 ng/kg intravenous (IV) bolus|
218924145|NCT00264186|DRUG|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
218924146|NCT00264186|DRUG|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
218924147|NCT00264186|DRUG|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
218924148|NCT00264186|DRUG|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
218924149|NCT04254003|DEVICE|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
218924150|NCT04254003|DEVICE|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
219538152|NCT06462066|PROCEDURE|Experimental medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
219538153|NCT06462066|PROCEDURE|Comparator medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
218924151|NCT02976038|DRUG|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
218924152|NCT06267755|OTHER|Extracorporeal Shockwave therapy|the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
219619779|NCT05651321|OTHER|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
219619780|NCT01750775|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
218924153|NCT06267755|OTHER|Traditional physical therapy|the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
218924154|NCT03632889|BEHAVIORAL|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
219538154|NCT05608447|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
219538155|NCT05608447|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
219538156|NCT00505622|DRUG|Perampanel|
219538157|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
219538158|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
219538159|NCT02354339|DIETARY_SUPPLEMENT|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
219538160|NCT02354339|OTHER|Placebo|Intervention will be administered 30 minutes before meals
218924155|NCT03228550|DIETARY_SUPPLEMENT|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
218924156|NCT03228550|BEHAVIORAL|Aerobic exercise|Static exercise cycle
218924157|NCT03228550|DIETARY_SUPPLEMENT|Placebo multinutrient|Placebo multinutrient supplement
218924158|NCT03755310|DRUG|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
218924159|NCT03755310|DRUG|Placebo|Equivalent dosage, route of administration and dose regimen
219538161|NCT00267592|DRUG|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
219538162|NCT00267592|RADIATION|Radiation Therapy (RT) 5 days a week +|
219538163|NCT00267592|DRUG|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
219538164|NCT00267592|DRUG|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
219538165|NCT00612287|DRUG|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
218924160|NCT01919502|DEVICE|Semi-quantitative urine pregnancy test|
218924161|NCT01046396|DRUG|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
218924162|NCT01046396|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
218924163|NCT04396418|BEHAVIORAL|Education|Randomization between two groups at site level. One cluster with education and one without.
218924164|NCT01208207|DRUG|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
218924165|NCT01208207|DRUG|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
218924166|NCT01208207|DRUG|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
219538166|NCT03978442|BEHAVIORAL|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
219619781|NCT01750775|DRUG|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
219619782|NCT04189978|DIAGNOSTIC_TEST|Clinical evaluation|The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
218924167|NCT01208207|DRUG|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
218924168|NCT01208207|DRUG|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
218924169|NCT01208207|DRUG|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
218924170|NCT01208207|DRUG|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
218924171|NCT01208207|DRUG|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
218924172|NCT01208207|DRUG|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
218924173|NCT01208207|DRUG|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
218924174|NCT01208207|DRUG|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
218924175|NCT01208207|DRUG|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
218924176|NCT02638194|OTHER|Active smoking of Tobacco Hookah for 2 hours|
218924177|NCT02638194|OTHER|Exposure to tobacco hookah second hand smoke|
218924178|NCT02638194|OTHER|Visit a win bar|Participants will visit a wine bar for food and/or drinks
218924179|NCT03086811|BEHAVIORAL|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips."
218924180|NCT01469169|DRUG|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
218924181|NCT00724698|DRUG|Desloratadine|Desloratadine 5 mg once daily
219042849|NCT06897579|DRUG|Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule|Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.
218924182|NCT01928212|DEVICE|Optical coherence tomography|
219538167|NCT03978442|DRUG|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
218924183|NCT04984746|DIETARY_SUPPLEMENT|No Intervention: (control group)|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
218924184|NCT04984746|DIETARY_SUPPLEMENT|Experimental: intervention group|"Molybdenum Iodine group~Lettuces with Iodine and Molybdenum biofortification was assigned to each participant belonging to the intervention group which ate 100gr of each type of lattuce every day for 10 days"
218924185|NCT06371781|DIAGNOSTIC_TEST|Serum Netrin-4, Resistin and Sfrp-5 level measurement|Measurements of the levels of these molecules in the serum samples of the study group will be done with the ELISA kit.
218924186|NCT03193099|OTHER|Brain imaging|Volume, DWS and DTI
218924187|NCT03193099|OTHER|Neurological assessments|UHDRS
218924188|NCT03193099|BEHAVIORAL|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
219538168|NCT03978442|BEHAVIORAL|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
219538169|NCT03978442|BEHAVIORAL|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
219538170|NCT03978442|BEHAVIORAL|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
219538171|NCT04991194|DRUG|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
219538172|NCT01451047|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
219538173|NCT06331247|BEHAVIORAL|General dietary advice|General dietary advice according to the Chinese Dietary Guidelines 2022.
218924189|NCT03193099|BEHAVIORAL|Behavioural assessments|Computerized game
218924190|NCT04458870|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
218924191|NCT04719078|DIAGNOSTIC_TEST|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
218924192|NCT00665652|DRUG|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
218924193|NCT03862326|BEHAVIORAL|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
219538174|NCT06331247|BEHAVIORAL|Localized MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
219538175|NCT06331247|OTHER|Routine medical care|Routine medical care and follow-ups.
219538176|NCT00287963|DRUG|topotecan hydrochloride|
219538177|NCT00287963|DRUG|vinorelbine tartrate|
219538178|NCT04405765|DEVICE|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
219538179|NCT04405765|DEVICE|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
219538180|NCT05220657|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
219538181|NCT05220657|DIAGNOSTIC_TEST|Submaximal exercise test|A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
219538182|NCT01940341|DRUG|TAF|25 mg tablet administered orally once daily
219538183|NCT01940341|DRUG|TDF|300 mg tablet administered orally once daily
219538184|NCT01940341|DRUG|TAF Placebo|Tablet administered orally once daily
219538185|NCT01940341|DRUG|TDF Placebo|Tablet administered orally once daily
219538186|NCT00872092|OTHER|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
219619783|NCT06574685|DIETARY_SUPPLEMENT|Twinkle Eyez Supplementation|The intervention supplement consisted of marigold extract, zeaxanthin, elderberry extract, bilberry extract, lycopene extract, multivitamin, silicon dioxide, inulin, and dextrose monohydrate, all in powder form and packaged in individual sachets (Twinkle Eyez™; Xmegami, Selangor, Malaysia). Each sachet contained 4.6 mg of lutein and zeaxanthin and 15.4 mg of elderberry extract.
219619784|NCT06574685|DIETARY_SUPPLEMENT|Placebo|The placebo supplement was identical in composition but excluded the active ingredients.
219619785|NCT00004656|PROCEDURE|Metabolic assessment with body composition evaluation|
219619786|NCT06575478|DRUG|Fuling Yunhua Granules|Fuling Yunhua Granules
219619787|NCT06575478|DRUG|Fuling Yunhua Granules matched placebo|Fuling Yunhua Granules placebo
218924194|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
218924195|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
219538187|NCT03838276|PROCEDURE|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
219538188|NCT03838276|PROCEDURE|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
219538189|NCT00879918|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
219538190|NCT01205425|OTHER|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
219538191|NCT01205425|PROCEDURE|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
219619788|NCT06575478|DRUG|Dihuang Baoyuan Granules|Dihuang Baoyuan Granules
219619789|NCT06575478|DRUG|Dihuang Baoyuan Granules matched placebo|Dihuang Baoyuan Granules placebo
219619790|NCT05509907|OTHER|Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform|"Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated."
219619791|NCT01367678|DEVICE|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
219619792|NCT01367678|DEVICE|i-Gel extraglottic airway device|Directly measured mucosal pressures
218924196|NCT01749215|DRUG|Topiramate|Experimental study drug
218924197|NCT01749215|DRUG|placebo|Placebo comparator
219538192|NCT04673201|PROCEDURE|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
219619793|NCT02599285|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
219619794|NCT02599285|DEVICE|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
218924198|NCT01749215|BEHAVIORAL|Medical Management|Brief alcohol counseling
218924199|NCT00672321|GENETIC|gene expression analysis|
218924200|NCT00672321|GENETIC|mutation analysis|
218924201|NCT00672321|GENETIC|polymorphism analysis|
218924202|NCT00672321|OTHER|laboratory biomarker analysis|
219538193|NCT02132494|BEHAVIORAL|Physical activity|
219538194|NCT05277363|OTHER|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
219538195|NCT03443986|OTHER|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
219538196|NCT03443986|OTHER|Resistance training associated with vibration sham|"he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown."
219619795|NCT05754892|OTHER|Blood sample|For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
219619796|NCT05754892|OTHER|Urine sample|For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
218924203|NCT00672321|OTHER|questionnaire administration|
218924204|NCT00494793|PROCEDURE|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
218924205|NCT01035801|DRUG|IN-105|Prandial Oral Insulin
218924206|NCT01035801|DRUG|Insulin Lispro Injection|Insulin Lispro Injection
218924207|NCT02556177|PROCEDURE|MRI|MRI scanning
218924208|NCT04579107|COMBINATION_PRODUCT|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
218924209|NCT03739268|DRUG|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
219619797|NCT05754892|OTHER|Tumor sample|For patients with ACC and patients with MPP : tumor sample during surgery
219619798|NCT02179892|DRUG|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
218924210|NCT03739268|DRUG|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
219538197|NCT02613754|BEHAVIORAL|Contingency Management|See arm description.
219538198|NCT02613754|BEHAVIORAL|Treatment as Usual|See arm description
219538199|NCT04808648|DRUG|SH-1028|tablet, oral, 200 mg once daily for day 1 and day 12
219538200|NCT04808648|DRUG|Itraconazole|capsule, oral, 200 mg twice daily for day 8 to day 14
218924211|NCT03262844|BEHAVIORAL|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
218924212|NCT03262844|PROCEDURE|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
218924213|NCT04994288|BIOLOGICAL|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
218924214|NCT04994288|OTHER|placebo injection|placebo injection 0.5ml
219538201|NCT04808648|DRUG|Rifampicin|capsule, oral, 600 mg once daily for day 8 to day 16
218924215|NCT04852926|OTHER|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~* T0 (at inclusion) : before disease + since diagnosis~* C4 (chemotherapy course n°4)~* C6 (chemotherapy course n°6)~* M3 (3 months after chemotherapy)~* M6 (6 months after chemotherapy)~* A1 (1 year after chemotherapy)~* A2 (2 years after chemotherapy)"
218924216|NCT01526577|DRUG|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
218924217|NCT01526577|DRUG|placebo|LC23-1306 placebo
218924218|NCT01526577|DRUG|Ticagrelor|Ticagrelor 90mg
218924219|NCT00951340|OTHER|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
218924220|NCT00951340|BEHAVIORAL|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
218924221|NCT00951340|BEHAVIORAL|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
218924222|NCT03008057|DIETARY_SUPPLEMENT|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
218924223|NCT03008057|DIETARY_SUPPLEMENT|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
218924224|NCT00458263|DRUG|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
218924225|NCT03743181|OTHER|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
218924226|NCT00577304|DRUG|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
219042850|NCT06897579|DRUG|Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection|Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.
219538202|NCT01757392|BIOLOGICAL|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
219538203|NCT01218672|DEVICE|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
219619799|NCT02179892|DRUG|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
219619800|NCT02179892|DRUG|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
219619801|NCT02179892|DRUG|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
219619802|NCT04024969|DIAGNOSTIC_TEST|T2* MRI|Research T2\* weighted MRI sequence
219619803|NCT04024969|DIAGNOSTIC_TEST|Lumbar puncture to test for presence of unmatched oligoclonal bands|Current clinical standard practice
219619804|NCT05480072|DRUG|Palmitoylethanolamide|Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21
219619805|NCT05480072|OTHER|Placebo|Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21
219619806|NCT04903639|DIAGNOSTIC_TEST|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
219619807|NCT05976321|DRUG|TAK-279|TAK-279 capsules.
219619808|NCT05938647|OTHER|Risk factor: group 3|Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
219619809|NCT05938647|OTHER|Risk factor: group 4|Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
219619810|NCT05089513|PROCEDURE|Robotic surgery|Robotoc surgery (Da Vinci) in both donor and recipient
219619811|NCT05644054|DRUG|THC|Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
218924227|NCT00577304|DRUG|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
218924228|NCT00976924|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
218924229|NCT00235274|DRUG|Subcutaneous Secretin|
218924230|NCT02586740|PROCEDURE|Pulmonary artery rehabilitation|
219538204|NCT01218672|DEVICE|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
219538205|NCT03703791|BIOLOGICAL|AR101|AR101 powder
219538206|NCT05572723|DRUG|Remifentanil 2 MG|Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
219538207|NCT05572723|DRUG|dexmedetomidine|"Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability."
219538208|NCT03243487|BEHAVIORAL|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
219538209|NCT03243487|BEHAVIORAL|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
219538210|NCT03708458|DRUG|indomethacin suppository|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
219538211|NCT03708458|DRUG|N-acetylcysteine (NAC)|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
219538212|NCT01676194|OTHER|Intra-arterial administration of DC BeadsR|
219538213|NCT01653951|OTHER|nurse-led care management or peer-led self management|
219538214|NCT05119946|BEHAVIORAL|Suicide prevention video|The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
219538215|NCT05119946|OTHER|Standard suicide treatment|The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
219538216|NCT05332535|BEHAVIORAL|serious game based web application education|serious game based web application education for nursing students
219538217|NCT03840291|DRUG|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
219538218|NCT06558916|DRUG|Dexketoprofen Trometamol|
219538219|NCT06558916|DRUG|Meperidine Injectable Solution|
219619812|NCT05644054|DRUG|Placebo|Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
219619813|NCT06578832|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH, buffering capacity
219619814|NCT06578832|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities
219538220|NCT06558916|DRUG|Paracetamol|
219538221|NCT06558916|DRUG|Fentanyl|Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
219619815|NCT06578832|DIAGNOSTIC_TEST|biochemical tests|urea, calcium, potassium, phosphorus
219619816|NCT06578832|DIAGNOSTIC_TEST|Oral Health Habits|Tooth brushing frequency Dental floss usage Annual dentist visits
219619817|NCT06578832|DIAGNOSTIC_TEST|Oral Findings|"DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries.~DDE Index: Developmental Defects of Enamel index. BAKH Index: Basic Anatomic Keratinization Hierarchy, typically used in specific studies.~DI (Debris Index): Assesses oral hygiene based on the amount of debris on the teeth.~CI (Calculus Index): Measures the amount of calculus (tartar) on the teeth. OHI-S (Simplified Oral Hygiene Index): Assesses oral hygiene based on the presence of debris and calculus.~MGI (Modified Gingival Index): Assesses the severity of gingivitis based on inflammation."
219619818|NCT06578832|DIAGNOSTIC_TEST|Quality of Life Assessment|KINDLR Scale: Used to assess disease-related quality of life from both the child's and the parent's perspectives.
219619819|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
219619820|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
219619821|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
219538222|NCT06234722|DRUG|Very Low Nicotine Cigarette|Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g
219538223|NCT06234722|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.
219619822|NCT03574285|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
219619823|NCT03574285|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
219619824|NCT04795648|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
219619825|NCT04795648|DEVICE|Placebo|Passive emanator with formulated inert ingredients
219619826|NCT06539507|DRUG|BCX17725|BCX17725 for injection
219619827|NCT06539507|DRUG|Placebo|Placebo for injection
219538224|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
219538225|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
219538226|NCT06560749|OTHER|Physical Exercise|Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
219619828|NCT00658723|DRUG|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
219619829|NCT00658723|DEVICE|SURGICEL™|Absorbable hemostat
219619830|NCT02411656|OTHER|Laboratory Biomarker Analysis|Correlative studies
219619831|NCT02411656|BIOLOGICAL|Pembrolizumab|Given IV
218924231|NCT05679752|OTHER|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
218924232|NCT05679752|OTHER|Massage therapy|frictional massage to stimulate the weak muscle groups
219538227|NCT06498700|DRUG|ketamine|0.5 mg/kg/h ketamine infusion
219619832|NCT06481709|DRUG|RLF-OD032|100 mg/mL oral suspension
219538228|NCT06498700|DRUG|dexmedetomidine|0.1 ug/kg/h dexmedetomidine infusion
219538229|NCT00841698|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
219538230|NCT00841698|DRUG|Paxil®|40 mg Film-Coated Tablet
219538231|NCT06555913|OTHER|Maitland Mobilization|"MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain"
219619833|NCT06481709|DRUG|Kuvan|100 mg powder for oral solution
219619834|NCT06576232|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
219619835|NCT03314792|DRUG|Tapentadol|"* Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~* Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
219619836|NCT03314792|DRUG|Oxycodone|"* OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~* OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
218924233|NCT02987686|DRUG|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
219538232|NCT06555913|OTHER|Scapular Stabilization|"Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears"
219538233|NCT06555913|OTHER|Traditional Physical Therapy|ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
219538234|NCT06562049|RADIATION|musculoskeletal ultrasound|musculoskeletal ultrasound on both hands
218924234|NCT02266511|DRUG|Flomax®, Norman II facility|
218924235|NCT02266511|DRUG|Flomax®, Nishine facility|
218924236|NCT05035381|DRUG|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
218924237|NCT03317015|DRUG|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
218924238|NCT03317015|DRUG|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
218924239|NCT03490695|OTHER|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
218924240|NCT03490695|OTHER|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
218924241|NCT06961097|OTHER|Virtual Reality Group|control group
218924242|NCT02900378|DRUG|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
218924243|NCT02900378|DRUG|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
218924244|NCT02900378|DRUG|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
218924245|NCT02900378|DRUG|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
218924246|NCT05201300|DRUG|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
218924247|NCT05201300|DRUG|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
219538235|NCT01481363|BEHAVIORAL|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
219538236|NCT01481363|BEHAVIORAL|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
219538237|NCT00220415|DRUG|SPM 927|
219538238|NCT01417663|DRUG|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
219538239|NCT01417663|BEHAVIORAL|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
219538240|NCT02785887|OTHER|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
219538241|NCT06424457|PROCEDURE|video assisted thoracoscopy (VATS)|the investigators compare the outcomes of intervention by VATS and doing complete decortication or open surgery thoracotomy
219619837|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) delivered using the CE-certified tVNS® device (tVNS Technologies GmbH). Stimulation parameters include a pulse width of 250-500 μs, frequency of 10-25 Hz, and an individually titrated intensity (typically up to 5 mA). The device operates with a 20-50% duty cycle and is used at home.
218924248|NCT05201300|DRUG|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
218924249|NCT01807624|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
219538242|NCT06424457|PROCEDURE|open thoracotomy|the investigators assess the outcomes of intervention by doing complete decortication through open surgery thoracotomy
219538243|NCT05119725|DEVICE|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
218924250|NCT03693924|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
218924251|NCT02868632|DRUG|MEDI4736|anti-PD-L1 human monoclonal antibody
218924252|NCT02868632|DRUG|Tremelimumab|anti-CTLA4 human monoclonal antibody
218924253|NCT02868632|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
218924254|NCT00686413|DRUG|AZD3480|single dose, oral
218924255|NCT00686413|RADIATION|2-[18F]-F-A85380|Single dose, IV
218924256|NCT04653077|OTHER|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
218924257|NCT05021406|DRUG|Carvedilol 12.5 MG|Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
218924258|NCT01773044|DRUG|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
219619838|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Sham stimulation using the same CE-certified tVNS® device. Electrode placement is on the earlobe, which lacks vagus nerve innervation. Stimulation parameters (pulse width, frequency, intensity, duty cycle) mirror those of the active condition, with intensity adjusted to perceptual threshold to mimic the sensation of real stimulation and preserve blinding.
219619839|NCT02874625|PROCEDURE|Dental restoration|Teeth with caries will be restored
218924259|NCT01773044|DRUG|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
218924260|NCT01773044|DRUG|Placebo (for alcalinized lidocaine)|
218924261|NCT00594841|PROCEDURE|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws"
218924262|NCT00594841|OTHER|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
218924263|NCT04014517|OTHER|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
218924264|NCT04014517|DIETARY_SUPPLEMENT|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
219619840|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - including VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
218924265|NCT03769519|BEHAVIORAL|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
218924266|NCT03854097|DEVICE|Active Intermittent Negative Pressure (INP)|Application of -40mmHg negative pressure on the lower limb
219538244|NCT04948905|OTHER|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
219538245|NCT00185458|DRUG|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
219538246|NCT00251979|DRUG|Esomeprazole|
219538247|NCT02618083|DEVICE|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
219538248|NCT01019421|DRUG|Lu AE58054|Add-on treatment to donepezil
219619841|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - without VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
218924267|NCT03854097|DEVICE|Placebo Intermittent Negative Pressure (INP)|Application of -10mmHg negative pressure on the lower limb
218924268|NCT02153749|BEHAVIORAL|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
219538249|NCT01019421|DRUG|Placebo|Add-on treatment to donepezil
218924269|NCT02153749|BEHAVIORAL|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
218924270|NCT02795702|DEVICE|tDCS|Transcranial direct current stimulation
218924271|NCT02795702|BEHAVIORAL|training|Cognitive training
219538250|NCT03567447|DRUG|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
219619842|NCT05303064|DRUG|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
218924272|NCT04588571|PROCEDURE|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
219538251|NCT03567447|OTHER|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
219619843|NCT05303064|DRUG|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
219619846|NCT06968026|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|The eligible participants will undergo an intensity sweep consisting of six stimulation trains over the right dorsolateral prefrontal cortex (DLPFC), with stimulation intensities ranging from 100% to 150% of the individual resting motor threshold (RMT), increasing in 10% increments. Each train will last 60 seconds, comprising 40 seconds of active rTMS at 1 Hz and a 20-second intertrain interval (ITI). Synchronous electrocardiogram (ECG) data will be continuously recorded throughout the entire procedure.
219619847|NCT06966622|PROCEDURE|3D visualization system with coaxial illumination|operation through 3D visualization system with coaxial illumination
219619848|NCT06966622|PROCEDURE|microscope with standard illumination|operation through microscope with standard illumination
219619849|NCT06968286|PROCEDURE|SRP|participants with periodontitis treated with scaling and root planning
219619850|NCT06968286|PROCEDURE|SRP+Injectable platelet rich fibrin|The iPRF will be prepared by the same operator according to the protocol developed by Miron and Choukron in 2017. It involves collecting 10 mL of intravenous blood from the participant using venipuncture of the antecubital vein under sterile conditions. The collected blood is transferred to a plain sterile test tube without anticoagulant and immediately subjected to centrifugation at 70-g force at 700 rpm for 3 minutes. After centrifugation, the blood separates into two parts: the bottom layer consists of a red blood cell compartment, and the top layer is platelet-rich fibrin plasma, which is still in liquid consistency. The top platelet-rich fibrin layer is aspirated into a 2-mL syringe and locally delivered in to the periodontal pocket
219619851|NCT06968286|PROCEDURE|SRP+ciprofloxacine loaded iPRF|"The concentration of the ciprofloxacin drug to be loaded in iPRF will be decided based on the study of Murugan et al., 2024. According to their study, 1 mg/mL of the drug concentration will be found to be biocompatible with maximum efficacy and showed a sustained release of 59% of the loaded drug at the end of the 14-day observation. 1 mg of the drug will be weighed and mixed with 100 μL of deionized water and shaken for 30 seconds to make the drug completely soluble, which will be done just before the blood collection from the participants. Then, 900 μL of the obtained i-PRF will be dispensed in a vial containing a 1-mg/100 μL solution of ciprofloxacin and shaken gently for 10 seconds to obtain a homogenous mix with a final concentration of 1 mg/mL.~This mixture will further immediately loaded in a 1-mL insulin syringe and injected into the periodontal pocket until it filled the pocket"
219619852|NCT06576531|OTHER|Therapeutic exercise|A stepped training intervention designed ad hoc based on a combination of aerobic and strength exercises.
219619853|NCT02651662|DRUG|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
219619854|NCT02651662|DRUG|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
219619855|NCT06546254|DRUG|Lidocaine 1% Injectable Solution|10 cc 1% lidocaine paracervical injection
219538252|NCT06222645|DEVICE|ICG fluorescence imaging technology|Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
219538253|NCT06222645|DEVICE|Imaging photoplethysmography|Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
219538254|NCT00280553|DRUG|bupivicaine|PCA and bupivicaine infusion for up to five days
219538255|NCT00280553|OTHER|Saline infusion|PCA and pump with saline infusion for up to five days
219538256|NCT00909402|DRUG|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
219538257|NCT00909402|DRUG|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
219538258|NCT00909402|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
218924273|NCT04588571|PROCEDURE|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
218924274|NCT00767364|BIOLOGICAL|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
218924275|NCT05201313|DRUG|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
218924276|NCT05201313|DRUG|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
218924277|NCT03429270|DEVICE|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
218924278|NCT01035125|BEHAVIORAL|Self-management program|Participants will receive a one week inpatient self-management program
218924279|NCT00571493|DRUG|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
218924280|NCT00571493|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
218924281|NCT01249261|DRUG|Risedronate|5 mg/day
218924282|NCT01249261|DRUG|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
218924283|NCT04035148|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
218924284|NCT04098718|DRUG|Benralizumab|100mg sub cut once only
218924285|NCT04098718|DRUG|Prednisolone|30mg tablet daily for 5 days
218924286|NCT06462456|DEVICE|Verofilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
218924287|NCT06462456|DEVICE|Verofilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
218924288|NCT00002013|DRUG|Zidovudine|
218924289|NCT00002013|DRUG|AS-101|
218924290|NCT01686399|BEHAVIORAL|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
218924291|NCT04347876|DIAGNOSTIC_TEST|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
218924292|NCT02964143|DEVICE|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
218924293|NCT02964143|DEVICE|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
218924294|NCT02964143|DEVICE|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
218924295|NCT03060096|OTHER|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
219538259|NCT01460147|OTHER|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
219538260|NCT05177588|DRUG|Metformin Hydrochloride|Metformin 2000 mg/day
219538261|NCT06131853|OTHER|survey evaluation|assessment of physical activity, fatigue, fear of movement, and quality of life
219538262|NCT03317548|DIAGNOSTIC_TEST|progesterone|according progesterone level to decide fresh or frozen embryo transfer
219538263|NCT03317548|DIAGNOSTIC_TEST|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
219619856|NCT06546254|OTHER|Capped needle|Tapping the cervicovaginal junction with a capped needle
218924296|NCT03060096|OTHER|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
218924297|NCT03060096|OTHER|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
218924298|NCT03487237|BIOLOGICAL|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
219619857|NCT05584735|BIOLOGICAL|Influenza vaccine|Observe effects of flu vaccine on microbiome
219619858|NCT05584735|BIOLOGICAL|COVID-19 vaccine|Observe effects of COVID-19 vaccine on microbiome
219619859|NCT06441994|DRUG|PSW-1025|PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
219619860|NCT04099966|DRUG|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
219619861|NCT03305848|DRUG|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
219619862|NCT00631592|DRUG|GSK1349572|
219619863|NCT03648229|PROCEDURE|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
219619864|NCT03648229|DRUG|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
219619865|NCT03648229|DRUG|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
218924299|NCT00482053|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
218924300|NCT00482053|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
218924301|NCT00482053|PROCEDURE|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
218924302|NCT00482053|DRUG|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
218924303|NCT00482053|DRUG|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
218924304|NCT00482053|DRUG|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
218924305|NCT00482053|DRUG|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
218924306|NCT00482053|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
218924307|NCT00482053|DRUG|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
218924308|NCT00482053|DRUG|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
218924309|NCT00482053|DRUG|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
218924310|NCT00482053|DRUG|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
218924311|NCT00482053|DRUG|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
218924312|NCT00482053|DRUG|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
218924313|NCT00482053|DRUG|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
218924314|NCT03114683|DRUG|PD1|IBI308 200mg/3 weeks
218924315|NCT02098785|DRUG|Caffeine citrate|Oral solution
218924316|NCT02416336|DEVICE|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
218924317|NCT01967940|DRUG|TAF|25 mg tablet administered orally once daily with food
219619866|NCT00489866|DRUG|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
219619867|NCT00489866|DRUG|Placebo|Same as active drug.
218924318|NCT01967940|DRUG|Placebo|Tablets to match TAF administered orally once daily with food
218924319|NCT01967940|DRUG|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
218924320|NCT01967940|DRUG|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
218924321|NCT01967940|DRUG|ATV|300 mg tablet administered orally once daily.
218924322|NCT01588730|DEVICE|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
218924323|NCT01588730|PROCEDURE|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
218924324|NCT04706455|DEVICE|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
218924325|NCT04706455|DEVICE|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
218924326|NCT02725918|DRUG|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
218924327|NCT02725918|DRUG|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
218924328|NCT00232661|DRUG|ARIMIDEX (anastrazole)|
218924329|NCT00232661|DRUG|NOLVADEX (tamoxifen)|
218924330|NCT04046809|OTHER|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
219619868|NCT06488586|DRUG|Low dose IV Ketamine vs. IN Esketamine|For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
219619869|NCT00864630|BEHAVIORAL|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
219619870|NCT05745818|DRUG|Colchicine Pill|oral pills
219538264|NCT05800652|BEHAVIORAL|Peer Mentoring Program|Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
219619871|NCT04584801|DEVICE|Structured Light Plethysmography|"Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment"
219619872|NCT03939702|DRUG|BMS-986177|An orally administered anticoagulant to prevent and treat thromboembolic events
218924331|NCT04046809|OTHER|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
218924332|NCT00005080|DRUG|nelarabine|Given IV
219619873|NCT03516695|DEVICE|TheraSphere®|Intra-arterial Yttrium-90 glass microspheres
219619874|NCT06320340|OTHER|Exercise|the patients were performed following five exercises for 20 minutes of treatment session two days a week for the 8 weeks.: (1) the swan-dive vol. I, (2) the swan-dive vol II., (3) breast stroke preparation vol. I, (4) breast stroke preparation vol. II, and (5) swimming vol. II. All the exercises were repeated for the 10 times in a session. Before the exercises, patients were taught and instructed about the five key elements (lateral expansion, centralization, positioning the chest, the shoulder girdle, and the head) of clinical pilates that they should pay attention to while performing the exercises. In addition, verbal and tactile feedbacks were given to patients during all the treatment sessions to maintain the good posture and to perform exercises properly.
219538265|NCT00999050|PROCEDURE|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
219538266|NCT01576042|DRUG|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
219538267|NCT01576042|DRUG|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
219538268|NCT01576042|DEVICE|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
219538269|NCT01303549|DRUG|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
219619875|NCT06320340|OTHER|Electrotherapy|Two channels of four-channelled Compex SP Fit-3 (MediCompex SA in Geneva, Switzerland) was used to apply NMES (120 mA, 400 μs, 150 Hz) on lower trapezius and serratus anterior muscles for 20 minutes during exercise.
219619876|NCT03548818|DRUG|Interferon Gamma-1B|Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.
218924333|NCT03651570|DEVICE|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
219538270|NCT01303549|DRUG|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
219538271|NCT02468258|PROCEDURE|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
219538272|NCT03550781|DRUG|Prednisone, cyclophosphamide|Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
219619877|NCT03837054|BIOLOGICAL|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
219538273|NCT01311245|BEHAVIORAL|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
219538274|NCT01311245|BEHAVIORAL|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
219538275|NCT02252133|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
219538276|NCT02252133|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
219538277|NCT01469026|RADIATION|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
219619878|NCT05511870|DRUG|Etripamil Nasal Spray 70mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
219619879|NCT05511870|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
219619880|NCT06476990|BEHAVIORAL|Healthy food box|All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
219619881|NCT01047384|PROCEDURE|acupuncture-moxibustion therapy|
219619882|NCT01047384|PROCEDURE|Regular therapy|
219619883|NCT00789854|DRUG|Quetiapine XR|300 mg once daily (od)
219619884|NCT00789854|DRUG|Lithium carbonate|900 mg once daily (od)
219619885|NCT00789854|DRUG|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
219538278|NCT02981095|PROCEDURE|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
219538279|NCT02981095|DRUG|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
219619886|NCT03972904|DIETARY_SUPPLEMENT|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
219619887|NCT03972904|DIETARY_SUPPLEMENT|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
219619888|NCT05578261|DEVICE|intermittent theta burst stimulation|stimulatory protocol
219619889|NCT00167011|PROCEDURE|CT|
219619890|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
219619891|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
219619892|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
219538280|NCT02981095|DRUG|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
219538281|NCT06562868|OTHER|Bulk-fill Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
218924334|NCT03651570|BEHAVIORAL|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
218924335|NCT01663103|DRUG|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
218924336|NCT01663103|DRUG|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
218924337|NCT05318352|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
218924338|NCT03517397|BEHAVIORAL|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
218924339|NCT03659045|OTHER|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
218924340|NCT04008745|OTHER|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
218924341|NCT05098834|DEVICE|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
218924342|NCT05083169|DRUG|Daratumumab|Daratumumab will be administered SC injection.
218924343|NCT05083169|DRUG|Pomalidomide|Pomalidomide will be administered orally.
218924344|NCT05083169|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
218924345|NCT05083169|DRUG|Bortezomib|Bortezomib will be administered SC injection.
218924346|NCT05083169|DRUG|Teclistamab|Teclistamab will be administered SC injection.
218924347|NCT05094206|BIOLOGICAL|0.75x10^6 cells/kg CAR20.19.22 cells|"Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
218924348|NCT05094206|BIOLOGICAL|1x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
218924349|NCT05094206|BIOLOGICAL|2.5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
219538282|NCT06562868|OTHER|Traditional Posterior Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
219538283|NCT06562868|OTHER|High-filler Flowable Composite|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
219538284|NCT02480322|PROCEDURE|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
219538285|NCT01327222|DRUG|Bevacizumab|1.25 mg intravitreal bevacizumab
219538286|NCT04568785|BEHAVIORAL|Brief Intervention for Influenza vaccine|Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.
219538287|NCT04568785|BEHAVIORAL|Normal advice|In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
219538288|NCT00865592|DRUG|dutogliptin|dutogliptin 400 mg, once daily tablet
219538289|NCT04198844|DRUG|warfarin|warfarin user
219538290|NCT04198844|DRUG|apixaban|apixaban user
219538291|NCT02991378|BEHAVIORAL|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
219538292|NCT02727088|PROCEDURE|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
219538293|NCT02727088|PROCEDURE|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
219538294|NCT00180986|PROCEDURE|Platelet concentrates|
219538295|NCT00280644|DRUG|Leflunomide|
219538296|NCT00182429|DRUG|Metronidazole and Rifampin|
219538297|NCT00925119|DRUG|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
219538298|NCT00752635|DRUG|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
219538299|NCT03914183|DEVICE|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
219538300|NCT03914183|DEVICE|Control|Use of standard of care insulin pen needle
218924350|NCT05094206|BIOLOGICAL|5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
218924351|NCT05094206|BIOLOGICAL|Dose expansion: The maximum tolerated dose of CAR20.19.22 cells|Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
218924352|NCT06540261|DRUG|ONO-7913|Specified dose on specified days
218924353|NCT06540261|DRUG|ONO-4538|Specified dose on specified days
218924354|NCT06540261|DRUG|Fluorouracil|Specified dose on specified days
218924355|NCT06540261|DRUG|Oxaliplatin|Specified dose on specified days
218924356|NCT06540261|DRUG|Levofolinate|Specified dose on specified days
218924357|NCT06540261|DRUG|Bevacizumab|Specified dose on specified days
218924358|NCT06540261|DRUG|Cetuximab|Specified dose on specified days
218924359|NCT06577155|DRUG|Levobupivacaine|Regional anesthesia / analgesia
218924360|NCT06577155|DRUG|Levobupivacaine plus nalbuphine|Regional anesthesia / analgesia
218924361|NCT05395026|OTHER|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
218924362|NCT06201026|OTHER|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
218924363|NCT06201026|OTHER|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
219538301|NCT01904344|DEVICE|Sensor testing and validation|
219619893|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
219619894|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
218924364|NCT04352777|DRUG|Abemaciclib|50 - 150mg tablet BID as prescribed per standard of care
218924365|NCT04352777|DRUG|Fulvestrant|500mg as prescribed per standard of care
218924366|NCT04352777|DRUG|Aromatase Inhibitors|Letrozole, anastrozole as prescribed per standard of care
219538302|NCT02544672|DEVICE|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
219538303|NCT01979861|DEVICE|AEGEA Vapor System(TM)|vapor endometrial ablation
219538304|NCT02502474|OTHER|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
219538305|NCT04024163|DRUG|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
219538306|NCT02193724|OTHER|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
219538307|NCT02193724|OTHER|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
219538308|NCT02189811|BIOLOGICAL|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
218924367|NCT06038136|BEHAVIORAL|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
218924368|NCT04195633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
218924369|NCT04195633|DRUG|Cyclophosphamide|Given IV
218924370|NCT04195633|DRUG|Cyclosporine|Given IV or PO
218924371|NCT04195633|BIOLOGICAL|Filgrastim|Given IV
218924372|NCT04195633|DRUG|Fludarabine|Given IV
218924373|NCT04195633|DRUG|Mycophenolate Mofetil|Given IV or PO
218924374|NCT04195633|DRUG|Mycophenolate Sodium|Given PO
218924375|NCT04195633|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
218924376|NCT04195633|DRUG|Treosulfan|Given IV
218924377|NCT04195633|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218924378|NCT04195633|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218924379|NCT04195633|PROCEDURE|Echocardiography|Undergo echocardiography
218924380|NCT04195633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219538309|NCT02189811|BIOLOGICAL|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
219538310|NCT02189811|BIOLOGICAL|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
219538311|NCT02189811|BIOLOGICAL|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
219619895|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
219619896|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
219619897|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
219619898|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
218924381|NCT04195633|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219538312|NCT02189811|BIOLOGICAL|tOPV|tOPV till 22 weeks of age
218924382|NCT04195633|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218924383|NCT03982355|DEVICE|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
219538313|NCT01247103|DRUG|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
219538314|NCT01247103|DRUG|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
219538315|NCT01247103|OTHER|Placebo|Placebo to match AZD4316
219538316|NCT05980156|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
219538317|NCT05980156|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
219538318|NCT05980156|DRUG|Sulfadoxine pyrimethamine|Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
219538319|NCT02942615|OTHER|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
219538320|NCT01465581|PROCEDURE|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
219538321|NCT03810118|DIAGNOSTIC_TEST|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
219538322|NCT01471041|DEVICE|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
219538323|NCT06202794|DEVICE|Experimental: Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
219538324|NCT06202794|DEVICE|Sham Comparator: Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
219538325|NCT05294783|PROCEDURE|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
219538326|NCT02417298|DRUG|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
219538327|NCT02417298|DRUG|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
219538328|NCT01280149|BIOLOGICAL|substance P|injections of substance P and low dose allergen or placebo
219538329|NCT01280149|BIOLOGICAL|substance P injections|injections of substance P for 8 weeks
219538330|NCT02167659|DEVICE|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
219538331|NCT03202459|DRUG|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
219538332|NCT03202459|DRUG|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
219538333|NCT03202459|DRUG|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
219538334|NCT02233985|DRUG|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
219538335|NCT02233985|DRUG|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
219538336|NCT06016894|PROCEDURE|coronally advanced flap|coronally advanced flap operation
219538337|NCT06016894|OTHER|Nanocrystalline hydroxyapatite loaded in PRF|Nanocrystalline hydroxyapatite loaded in PRF
218924384|NCT03113487|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
219538338|NCT06016894|OTHER|Nanocrystalline tricalcium phosphate loaded in PRF|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
219538339|NCT01504763|PROCEDURE|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
219538340|NCT01249651|DRUG|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
218924385|NCT03113487|BIOLOGICAL|Pembrolizumab|Given IV
219538341|NCT04456881|OTHER|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
218924386|NCT06002269|COMBINATION_PRODUCT|Dietary and Exercise Intervention|Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
219538342|NCT04931563|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
219538343|NCT04931563|DRUG|placebo|Intravenous infusion (IV)
219538344|NCT01849003|DRUG|GS-6615|GS-6615 tablet(s) administered orally
219538345|NCT06033456|PROCEDURE|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
219538346|NCT06033456|PROCEDURE|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
219538347|NCT06033456|PROCEDURE|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
219538348|NCT00808418|DRUG|Elesclomol Sodium|Chemotherapy agent
219538349|NCT00808418|DRUG|Docetaxel|Chemotherapy agent
219538350|NCT04313855|DIAGNOSTIC_TEST|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
219538351|NCT00781794|DRUG|NSA-789 at 2 different doses|
219538352|NCT00053287|DRUG|carboplatin|Carboplatin IV over 24 hours on days 1-5
219538353|NCT00053287|DRUG|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
219538354|NCT00053287|DRUG|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
219538355|NCT00053287|DRUG|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
219538356|NCT01096433|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
219538357|NCT05703438|OTHER|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
219538358|NCT00351676|BEHAVIORAL|Integration of a team based clinical pharmacist|
219538359|NCT00351676|DRUG|Optimizing therapeutic treatments|
219538360|NCT00351676|BEHAVIORAL|Optimizing processes of care|
219538361|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
219538362|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
219538363|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
219538364|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
219538365|NCT02304211|DRUG|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
219538366|NCT05335863|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
219538367|NCT05335863|DIETARY_SUPPLEMENT|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
219538368|NCT00557752|DEVICE|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
219538369|NCT00128167|DRUG|Liquid CAIV-T|
219538370|NCT03886935|DIAGNOSTIC_TEST|Metabolomics|
219538371|NCT02344381|DIETARY_SUPPLEMENT|Sucrose|
219538372|NCT02344381|DIETARY_SUPPLEMENT|Glucose|
219538373|NCT04140877|DEVICE|Visu|An experimental (test) virtual reality display
219538374|NCT01140581|DRUG|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
219538375|NCT04029272|DRUG|Metformin|500 mg tid for 12 weeks
219538376|NCT04029272|DRUG|Exenatide 2 MG|Exenatide injection once weekly for 12 weeks
219538377|NCT04432233|DRUG|Esomeprazole|Proton pump inhibitor
218924387|NCT04473911|DRUG|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
218924388|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
218924389|NCT04473911|RADIATION|TBI|Total body irradiation (TBI) once per cycle.
218924390|NCT04473911|DRUG|Melphalan|Melphalan, infusion, determined dosage, once per cycle
219538378|NCT04432233|DRUG|Metronidazole|antibiotic for H. pylori eradication
219538379|NCT04432233|DRUG|Levofloxacin|antibiotic for H. pylori eradication
218924391|NCT04473911|DRUG|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
218924392|NCT04473911|DRUG|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
218924393|NCT04473911|DRUG|RGI-2001|IV, predetermined dose, weekly to 6 total doses
218924394|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
218924395|NCT01514799|PROCEDURE|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
218924396|NCT04266717|BEHAVIORAL|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
218924397|NCT04266717|BEHAVIORAL|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
218924398|NCT03184168|DRUG|[14C]lorlatinib|Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
218924399|NCT02809001|PROCEDURE|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
218924400|NCT03953352|OTHER|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
218924401|NCT03852056|DRUG|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
218924402|NCT03852056|DRUG|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
218924403|NCT06104826|DRUG|Emicizumab|Emicizumab in Hemophilia A
218924404|NCT00940771|DRUG|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
218924405|NCT04769934|DEVICE|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
218924406|NCT04351334|DRUG|Alectinib|Observational treatment based on physician choice
219538380|NCT01462279|DRUG|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
219538381|NCT02538523|DEVICE|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
219538382|NCT02538523|DEVICE|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
219538383|NCT01300676|DRUG|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
219538384|NCT06295211|OTHER|observational|observational
219538385|NCT04444050|DRUG|BMS-986331|Specified dose on specified days
219538386|NCT04444050|OTHER|Placebo, Matching BMS-986331|Specified dose on specified days
219538387|NCT04044521|OTHER|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 21 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit \& feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will meet with each clinic. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
219538388|NCT02874677|OTHER|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
219538389|NCT01763177|OTHER|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
219538390|NCT06370377|OTHER|the Egyptian code of ethical practice|Nurses' adherence to the Egyptian code of ethical practice
219538391|NCT03475030|OTHER|pre-filled medication trays|
219538392|NCT03475030|OTHER|automated medication reminders|
218924407|NCT00391586|DRUG|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
218924408|NCT00391586|DRUG|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
218924409|NCT00904982|BEHAVIORAL|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
218924410|NCT00904982|DEVICE|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
218924411|NCT03125486|DRUG|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
218924412|NCT04820569|PROCEDURE|Resection and chemotherapy|
218924413|NCT05007769|DRUG|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
218924414|NCT05007769|DRUG|Atezolizumab|Atezolizumab will be commercially available.
219538393|NCT02209428|DRUG|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
218924415|NCT05007769|DRUG|N-803|Will be supplied free of charge to the participants by ImmunityBio
218924416|NCT06473181|OTHER|Core stability exercises|Exercises applied to trunk , pelvis and abdomen to improve ability to stand , walk and balance.
219538394|NCT04975035|DRUG|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
219538395|NCT00811655|PROCEDURE|therapeutic conventional surgery|Surgery of a single brain metastasis.
219538396|NCT00811655|RADIATION|stereotactic radiosurgery|Pre-operative single fraction SRS
218924417|NCT00000996|DRUG|Doxorubicin hydrochloride|
218924418|NCT04906811|DEVICE|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
218924419|NCT04906811|DEVICE|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
219538397|NCT03909945|DIETARY_SUPPLEMENT|Annona muricata|Patients with prehypertension or stage 1 hypertension, in dietary measures, will received daily one tablet of 796 mg of aqueous extracts of Annona muricata leaves. During 60 days
219538398|NCT02769494|DRUG|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
219538399|NCT02769494|DRUG|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
219538400|NCT00813592|DRUG|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
219538401|NCT01673685|DEVICE|Portable Oxygen|
219538402|NCT00494338|DRUG|Docetaxel|
219538403|NCT03682653|DRUG|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
219538404|NCT03682653|DRUG|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
219619899|NCT06560151|BIOLOGICAL|3.75 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
219619900|NCT06560151|BIOLOGICAL|7.5 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
218924420|NCT04355169|DRUG|Naldemedine|Oral tablet
218924421|NCT04355169|DRUG|Placebo|Oral tablet
218924422|NCT05798767|BEHAVIORAL|Neuropsychological tests|"Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium."
218924423|NCT04701827|COMBINATION_PRODUCT|AWARE intervention|Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
219619901|NCT06560151|BIOLOGICAL|15 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
218924424|NCT02420821|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
218924425|NCT02420821|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
218924426|NCT02420821|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
218924427|NCT01798771|PROCEDURE|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
218924428|NCT01798771|PROCEDURE|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
219538405|NCT06064331|DRUG|Lignocaine|IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
219538406|NCT06064331|DRUG|Placebo|IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
219538407|NCT01724372|DRUG|Antidepressant|
219538408|NCT01724372|DRUG|Antipsychotic|
219538409|NCT01367054|DRUG|Metformin|500 mg tablet
219538410|NCT01367054|DRUG|Glifage|500 mg tablet
219619902|NCT05067556|BEHAVIORAL|Acceptance and Commitment Therapy for chronic pain (ACT-CP)|Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
218924429|NCT04488614|PROCEDURE|Breast Concervative or Meastectomy|National treatment guidelines in Norway
219538411|NCT02820350|DEVICE|SCD-F40|CRRT with SCD
219538412|NCT05434364|OTHER|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
219538413|NCT05434364|OTHER|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
219538414|NCT05434364|OTHER|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
219538415|NCT00002939|DRUG|irinotecan hydrochloride|
219538416|NCT00002939|DRUG|paclitaxel|
219538417|NCT05044338|DIAGNOSTIC_TEST|imaging|(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.
219619903|NCT06585176|OTHER|No intervention|This concerns a natural history study. No interventions will be used.
219619904|NCT00923013|DRUG|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour intravenous (i.v.) infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the principal investigator (PI).
219619905|NCT00923013|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenous (i.v.) infusion every week x8, begin day 1 in half of randomized patients and in all hairy cell leukemia variant (HCLv) patients, and then again in all patients at least 6 months later when hairy cell leukemia (HCL) is detected by blood fluorescence-activated cell sorting (FACS).
219619906|NCT00923013|PROCEDURE|BMbx|Baseline and week 5.
218924430|NCT04824339|BEHAVIORAL|Immediate Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
218924431|NCT04824339|BEHAVIORAL|Delayed Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
219538418|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
219619907|NCT00923013|DIAGNOSTIC_TEST|MRI|Baseline and week 5.
219619908|NCT00923013|DIAGNOSTIC_TEST|EKG|Baseline and week 5.
219538419|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
219538420|NCT01937143|BEHAVIORAL|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
219538421|NCT01937143|BEHAVIORAL|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
219538422|NCT01937143|BEHAVIORAL|Control|General information about infant immunizations at birth of a newborn infant
219538423|NCT05369884|DRUG|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
219538424|NCT05369884|DRUG|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
219538425|NCT00979043|BEHAVIORAL|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
219619909|NCT00923013|DIAGNOSTIC_TEST|Echocardiogram|Baseline.
219619910|NCT00923013|DIAGNOSTIC_TEST|Abdominal/splenic ultrasound|Baseline and week 5.
219538426|NCT00979043|BEHAVIORAL|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
219538427|NCT01519258|OTHER|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
219538428|NCT01519258|DEVICE|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
219619911|NCT00923013|PROCEDURE|Stress test|Baseline.
218924432|NCT00686712|DRUG|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
218924433|NCT00686712|DRUG|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
218924434|NCT00686712|DRUG|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
218924435|NCT06086717|OTHER|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
218924436|NCT06086717|OTHER|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
218924437|NCT04291469|DRUG|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
218924438|NCT04291469|DIETARY_SUPPLEMENT|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
218924439|NCT04291469|DIETARY_SUPPLEMENT|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
218924440|NCT05251480|PROCEDURE|Standard of Care|debridement, wound dressings, offloading
218924441|NCT05251480|OTHER|DermGEN™|Decellularized human dermal matrix created from donated human skin
218924442|NCT03987503|DRUG|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
218924443|NCT03987503|DRUG|Standard of care|Standard of HCV care provided by medical care provider
218924444|NCT03987503|DEVICE|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
218924445|NCT05479019|BEHAVIORAL|Visual stimuli|Stimuli will be shown to participants and they will be asked to perform a visual task.
218924446|NCT00059462|DRUG|Interleukin-2 SA|HAART and Bay 50-4798
218924447|NCT00059462|DRUG|HAART|HAART alone
219538429|NCT01391273|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
219538430|NCT01391273|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
219538431|NCT01277835|DRUG|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
219538432|NCT01277835|DRUG|Placebo|Saline Infusion at same rate as experimental arm
219538433|NCT00597454|OTHER|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
219538434|NCT00164684|BEHAVIORAL|Father Friendly Initiative|
219538435|NCT01055795|DRUG|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
219538436|NCT05600699|DEVICE|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
219538437|NCT02818790|BEHAVIORAL|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
219619912|NCT06524739|BIOLOGICAL|IgPro20|IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
218924448|NCT03228823|PROCEDURE|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
219538438|NCT02818790|BEHAVIORAL|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
219619913|NCT06524739|BIOLOGICAL|Placebo|2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
219619914|NCT06585254|DEVICE|Transcutaneous vagus nerve stimulator|A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve
219619915|NCT04512378|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
219538439|NCT06406257|DEVICE|3M™ Bair Hugger™ Warming Unit|Utilizing the 3M Temperature Management Unit to ensure intraoperative body temperature of elderly hip surgery patients remains consistent with their preoperative baseline, while patients in Group C receive no intervention.
218924449|NCT03228823|DRUG|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
218924450|NCT02664896|OTHER|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
218924451|NCT02664896|OTHER|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
218924452|NCT06530147|OTHER|Transversalis Fascia Plane Block|One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
218924453|NCT06530147|OTHER|Transversus Abdominis Plane Block|One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
218924454|NCT01706133|OTHER|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
218924455|NCT04913077|OTHER|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
218924456|NCT01955135|DRUG|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
218924457|NCT01955135|DRUG|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
219042851|NCT05980572|DRUG|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
219042852|NCT05980572|DEVICE|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
219538440|NCT03642808|OTHER|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
219538441|NCT06627478|DRUG|NKF-INS(G)|Single subcutaneous dose of 0.5 IU/kg administered over three periods
219538442|NCT06627478|DRUG|US-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
219619916|NCT05768854|DRUG|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
219042853|NCT05980572|DRUG|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
219042854|NCT06867939|DIETARY_SUPPLEMENT|liposomal curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
219042855|NCT06867939|DIETARY_SUPPLEMENT|Liposomal Curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
219042856|NCT06791850|BEHAVIORAL|HF-FamPALhomeCARE|Participants in HF-FamPALhomeCARE Intervention group receive standard care plus 2 home visits, 3 bi-weekly telephone call on HF home EOLPC care, and follow-up telephone calls at 3, 6, 9, and 12 months.
219042857|NCT06741735|DEVICE|INVU fetal monitoring system|INVU fetal monitoring system allows for at-home non-stress testing as opposed to the typical in-clinic testing
219538443|NCT06627478|DRUG|EU-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
219538444|NCT01099007|BEHAVIORAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
219538445|NCT01099007|BEHAVIORAL|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
219619917|NCT05768854|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
218924458|NCT01955135|DRUG|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
218924459|NCT00655902|DIETARY_SUPPLEMENT|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
218924460|NCT00655902|DIETARY_SUPPLEMENT|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
218924461|NCT01915784|DEVICE|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
218924462|NCT01915784|DEVICE|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
218924463|NCT00168584|DRUG|Vitamin A|
218924464|NCT03678493|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Oral Capsule
218924465|NCT03678493|OTHER|Placebo|Oral Capsule
218924466|NCT03223896|DRUG|Naloxone hydrochloride 20mg/ml|Nasal spray
218924467|NCT01001026|BIOLOGICAL|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
218924468|NCT01001026|BIOLOGICAL|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
218924469|NCT02643914|DRUG|Nicotine|
218924470|NCT02643914|DEVICE|MR Compatible Nicotine Delivery Device|
219538446|NCT06874790|BEHAVIORAL|Catalina|"Catalina transmedia web-based app intervention with 10 story-based videos (including bonus story extender videos) totaling 31 minutes plus the blog of the character, Veronica, which has MH resource links including Veronica's recommendations of at least 3 local Latinx-serving clinics in LA and Orange County ZIP Codes that offer low-cost MH Tx."
219538447|NCT06874790|BEHAVIORAL|Control webpage|Links to informational videos (totaling 31 minutes) on depression and anxiety, listing of the same 3 local Latinx-serving clinics in LA and Orange County ZIP codes that offer low-cost MH Tx, and links to nationally available websites that offer resources (including access to service locators).
219538448|NCT03801707|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
218924471|NCT01093157|DRUG|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
218924472|NCT00656448|DRUG|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
219538449|NCT03801707|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
219538450|NCT00208403|DEVICE|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
219538451|NCT00208403|DEVICE|Palacos R|A high viscosity bone cement for use in total hip replacement
219538452|NCT06698926|DRUG|ABBV-CLS-616|Oral Tablet
219538453|NCT06698926|DRUG|Placebo|Oral Tablet
219538454|NCT06698926|DRUG|Itraconazole|Oral Capsule
219538455|NCT03873272|DEVICE|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
219538456|NCT03873272|DEVICE|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
218924473|NCT03146416|DRUG|Evinacumab|SC or IV administration of Evinacumab
219042858|NCT06777355|OTHER|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
218924474|NCT03146416|DRUG|Placebo|Matching placebo
218924475|NCT04027517|DRUG|JTZ-951|"Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
218924476|NCT04027517|DRUG|Darbepoetin Alfa|"Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
218924477|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
218924478|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
218924479|NCT00335595|DRUG|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
218924480|NCT00335595|DRUG|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
218924481|NCT01929317|DRUG|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
218924482|NCT01929317|DRUG|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
218924483|NCT01929317|DRUG|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
218924484|NCT03791814|DRUG|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
219538457|NCT03873272|DEVICE|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
219538458|NCT07033013|DIETARY_SUPPLEMENT|Placebo|Placebo
219538459|NCT07033013|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary supplement containing EstroG-100 and GABA
219538460|NCT04206462|OTHER|Questionnaire of eating habits|frequency and type of aliments
219538461|NCT00787254|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
219619918|NCT05122052|OTHER|Psychological session|Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
219619919|NCT06620562|DRUG|Naltrexone/Bupropion|Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.
219619920|NCT06620562|DRUG|Placebo|Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.
219619921|NCT06975267|BEHAVIORAL|Norwegian version of Second Step Early Learning|"The interventions is a 28 weeks program divided into five themes. The themes are 1. Skills that promotes learning, 2. Empathy, 3. Managing emotions, 4. Friendship skills and problem solving, and 5. Transitioning to school.~The intervention consists of daily activities. The guidebook is a central part of the program and provides the kindergarten teachers with practical tools and activities to implement the program in everyday settings. The guidebook includes:~28 weekly themes: Each week introduces a new theme with related activities and discussion topics.~Brain-building games: Activities designed to strengthen children's cognitive skills and self-regulation.~Songs and music: Songs that reinforce the learning of social skills. Parent connections: Information sheets and activities to involve parents in their children's social-emotional development.~Puppet theatre: The use of hand puppets Dog and Snail to illustrate and discuss feelings and social situations."
219538462|NCT00787254|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
219538463|NCT02608177|DRUG|Linagliptin|Receives 4 weeks of study drug linagliptin
219538464|NCT02608177|DRUG|Glipizide|Receives 4 weeks of study drug glipizide
219538465|NCT05853328|PROCEDURE|Epley Maneuver|"The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward."
218924485|NCT02382536|DEVICE|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
218924486|NCT02382536|DEVICE|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
218924487|NCT03294252|DRUG|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
218924488|NCT03294252|DRUG|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
218924489|NCT03294252|DRUG|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
218924490|NCT01297829|DRUG|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
218924491|NCT01297829|OTHER|IV Placebo|IV normal saline
218924492|NCT04071717|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
218924493|NCT04071717|BEHAVIORAL|Sham NIRS neurofeedback|Sham NIRS neurofeedback
218924494|NCT01981408|DRUG|[^14C]-LY2801653|Administered orally
218924495|NCT04575389|DIAGNOSTIC_TEST|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
218924496|NCT04586439|DRUG|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
218924497|NCT02877407|PROCEDURE|patient who undergo laparoscopic/robotic-assisted hysteropexy|
218924498|NCT02877407|PROCEDURE|patient who undergo vaginal hysterectomy|
218924499|NCT06166615|DRUG|Ramosetron|Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
218924500|NCT06166615|DRUG|Psyllium|Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
218924501|NCT03616028|DEVICE|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
218924502|NCT04845282|DIETARY_SUPPLEMENT|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
218924503|NCT04845282|DIETARY_SUPPLEMENT|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
218924504|NCT00086632|DRUG|oregovomab|
218924505|NCT00503763|DRUG|Simvastatin|
218924506|NCT02757508|DIETARY_SUPPLEMENT|protein powder supplement|
218924507|NCT02757508|DIETARY_SUPPLEMENT|Vitamins/minerals|
218924508|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
219538466|NCT05853328|PROCEDURE|SemontPLUS maneuver|The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
219538467|NCT03255421|OTHER|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
219538468|NCT07063186|OTHER|Group A - Elastomeric power chain on all bracket wings.|Elastomeric power chain is engaged on all bracket wings
218924509|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
218924510|NCT01457508|BIOLOGICAL|Hib (Hiberix™)|Three doses administered intramuscularly
218924511|NCT01716234|DRUG|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
218924512|NCT01716234|DRUG|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
218924513|NCT01716234|DRUG|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
218924514|NCT01716234|DRUG|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
219538469|NCT07063186|OTHER|Group B - Stainless steel ligatures with elastomeric power chain placed over all bracket wings.|Stainless steel ligatures are used to tie in the archwire on all bracket wings, with an elastomeric power chain placed over the ligatures
219538470|NCT07063186|OTHER|Group C - Elastomeric modules on mesial wings and power chain on distal wings.|Elastomeric modules are placed on the mesial wings of each bracket, while an elastomeric power chain is engaged on the distal wings
218924515|NCT04466319|OTHER|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
218924516|NCT03865901|DIAGNOSTIC_TEST|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
218924517|NCT03401619|COMBINATION_PRODUCT|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
218924518|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
218924519|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
218924520|NCT00702299|DRUG|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
218924521|NCT00702299|DRUG|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
218924522|NCT00702299|DRUG|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
218924523|NCT00702299|OTHER|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
218924524|NCT03901872|DEVICE|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
219042859|NCT07079072|DEVICE|Acupuncture|"The main acupoints include Guanyuan (CV4), Zhongwan (CV12), Shangyintang (EX-HN3), bilateral Tianshu (ST25), bilateral Zusanli (ST36), bilateral Hegu (LI4), and bilateral Taichong (LR3). The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles.~In the experimental group, filiform needles measuring Φ0.30×40mm are inserted into the skin to a depth of 0.5-1 cun, achieving De Qi sensation. Needles are retained for 30 minutes. At each acupoint (except Shangyintang), manual stimulation including lifting, thrusting, twisting, and plucking is performed once every 10 minutes. The participants received 12 acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day."
219042860|NCT07079072|DEVICE|Sham Comparator|The acupoints are same with those in the experimental group. The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles. The control group use dull needles measuring 0.30 × 25 mm, which are inserted vertically through the fixed pad until reaching the skin surface. The needles are gently lifted, twisted, and rotated slightly three times each, without piercing the skin. The needles are retained for 30 minutes, with no manipulation during this period. The participants received 12 sham acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day.
219042861|NCT07079124|BEHAVIORAL|Multi-level Social Participation Intervention|The intervention will span 12 weeks and comprises five core components: (1) a health education manual, (2) a resource information package, (3) a structured library of social activities, (4) a motivational incentive kit, and (5) a training toolkit for staff.
219042862|NCT07079124|BEHAVIORAL|Health Education|Standardized Health Education Materials
219042863|NCT06362590|DRUG|ladiratuzumab vedotin|
219538471|NCT07068321|COMBINATION_PRODUCT|Control Group (transcutaneous electrical nerve stimulation)|Control Group will consist of 20 sessions of 30 min, applied twice per week over a period of 3 months including transcutaneous electrical nerve stimulation, and standardized exercises for LBP through smart phone application.
219538472|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf|Experimental Group will receive 20 sessions of 30 min applied twice per week over a period of 3 months of GDS treatment through smart phone application.
219538473|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf + Cognitive Behavioral Therapy|Experimental Group 2 will receive 20 sessions of 45 min applied twice per week over a period of 3 months of GDS along CBT treatment through smart phone application.
218924525|NCT05581342|DIAGNOSTIC_TEST|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
218924526|NCT02643212|DRUG|Rivaroxaban|
218924527|NCT02643212|DRUG|Placebo|
218924528|NCT03990792|BEHAVIORAL|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
218924529|NCT03990792|OTHER|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
219538474|NCT07068100|BEHAVIORAL|Stage-of-change based physical activity counseling|On the first evaluation day, an individual physical activity program will be created for the participants in the group within the scope of physical activity counseling. A 20-30 minute phone call will be made once a week by a psychologist regarding the stage of change they are in, and a 10-15 minute phone call will be made once a week by a physiotherapist for physical activity counseling.
219538475|NCT07068100|BEHAVIORAL|Giving the group a brochure with recommendations for physical activity and the benefits of physical activity for psychological health|The second group will be given a brochure with recommendations for physical activity and the benefits of physical activity for psychological health.
219538476|NCT07069257|BEHAVIORAL|Oral Motor Therapy|Structured oral motor exercises will be applied to the lips, tongue, cheeks, and jaw. Facial massage and thermal stimulation (warm and cold) will be performed. Intraoral sensory stimulation will be applied using a brush, lemon juice, and a cold metal probe.
219538477|NCT07069257|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Active NMES will be applied bilaterally to the masseter muscles and to the orbicularis oris muscle in addition to oral motor therapy sessions, using a Chattanooga NMES device. Each application will be performed in cycles of 5 seconds of stimulation and 10 seconds of rest. The stimulation parameters will be set to a frequency of 10-15 Hz and a pulse width of 300 microseconds. The current intensity will be gradually increased to a level just above the motor threshold, sufficient to elicit a noticeable pulling sensation without causing discomfort, and will be adjusted according to each participant's tolerance. NMES will be delivered for a total duration of 15 minutes per session. For the electrical stimulation of the orbicularis oris muscle, a pen-type electrode will be used. In this procedure, four regions of the orbicularis oris muscle (upper, lower, right, and left) will be stimulated in two cycles of 45 pulses each.
219538478|NCT07069257|DEVICE|Sham Neuromuscular Electrical Stimulation (Sham NMES)|Simulated neuromuscular electrical stimulation will be applied without delivering active electrical current after oral motor therapy sessions to mimic the treatment experience without producing physiological effects.
219538479|NCT07067970|DRUG|serotonin reuptake inhibitor (SSRI)|"Dapoxetine Group~Dosage: 30 mg dapoxetine, taken orally 1-3 hours before anticipated sexual activity, with a maximum of 3 doses per week.~Administration: Provided in blister packs to ensure compliance. Reference: McMahon et al., 2011."
219538480|NCT07067970|DRUG|Placebo|"Dosage: Placebo tablets identical in appearance and taste to dapoxetine, administered on the same schedule (1-3 hours before sexual activity, maximum 3 doses per week).~Administration: Provided in identical blister packs."
219538481|NCT07067970|OTHER|Acupuncture|"Protocol: Two 30-minute acupuncture sessions per week, targeting standardized points (e.g., CV4, SP6, ST36) known to influence sexual function and autonomic nervous system regulation.~Administration: Performed by licensed acupuncturists following a standardized protocol.~Reference: Sunay et al., 2011."
219538482|NCT07067970|OTHER|Sham|"Sham Acupuncture Group:Protocol: Two 30-minute sessions per week using superficial needle insertion at non-active points to minimize therapeutic effects while maintaining the placebo effect.~Administration: Performed by licensed acupuncturists to ensure consistency with the active acupuncture group"
219538483|NCT07067970|BEHAVIORAL|Exercise|"Kegel Exercises Group:Protocol: Participants will perform pelvic floor muscle exercises consisting of three sets of 10-15 contractions daily, each held for 5-10 seconds followed by relaxation.~Training: Participants will receive initial training from a licensed physiotherapist, with weekly follow-up sessions to ensure proper technique and adherence.~Reference: Pastore et al., 2014."
218924530|NCT03815929|DRUG|Estradiol 100 Micrograms Patch|Standard
218924531|NCT03815929|DRUG|Estradiol Patch|Individualized
218924532|NCT00689039|DRUG|AZD1305|ER tablet, administered as single and repeated doses.
218924533|NCT00689039|DRUG|Placebo|Tablet, administered as single and repeated doses.
218924534|NCT03326713|BEHAVIORAL|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 30-45 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
218924535|NCT03326713|BEHAVIORAL|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
218924536|NCT03326713|OTHER|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
218924537|NCT02612272|DRUG|Ketorolac|intra-articular ketorolac
218924538|NCT02612272|DRUG|Betamethasone|intra-articular betamethasone
218924539|NCT04514861|DEVICE|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
218924540|NCT01624350|DEVICE|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
218924541|NCT00684918|DRUG|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
218924542|NCT00434746|DRUG|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
218924543|NCT01135550|DRUG|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
219538484|NCT07068126|BIOLOGICAL|Mini-Pool IVIG|Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated, closed-system process. Each participant will receive a loading dose of 1 g/kg infused intravenously over 6-8 hours. Maintenance doses of 0.5 g/kg will be given every 2 to 4 weeks for up to five additional doses, with the dosing schedule adjusted based on platelet count. The preparation contains purified IgG and meets safety standards for sterility and viral inactivation.
219538485|NCT03841188|OTHER|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
218924544|NCT01135550|DRUG|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
218924545|NCT00397501|BIOLOGICAL|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
219204900|NCT06997471|BIOLOGICAL|Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes|"Infusion Schedule~1. Primary Infusion: the enriched graft, containing the CD34+ progenitors and depleted naïve T cells, will be infused after the patient has undergone conditioning therapy.~2. In the case of haploidentical donors, an additional NK cell infusion will be administered whenever possible around day 7 post-transplant from a non-mobilized apheresis collection, aiming to enhance graft tolerance and prevente HHV6 disease.~3. Post-Transplant Memory T cell Infusions: beginning on days 15 and 30, and then administered monthly up to a maximum of one year or until the supply is depleted, memory T cells will be infused.~Conditioning Regimen~Prior to HSCT, all patients will undergo a low-intensity conditioning regimen designed to allow engraftment of the donor cells while minimizing toxicity:~1. Total Lymphoid Irradiation (TLI): 8 Gy of total lymphoid irradiation will be administered.~2. Fludarabine: a total dose of 120 mg/m², spread over 4 days (-6 to -3 before transplant), will serv"
219538486|NCT05141097|OTHER|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
219538487|NCT03117257|DRUG|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
219538488|NCT03117257|DRUG|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
219538489|NCT01692717|DRUG|Atorvastatin|10 mg
219538490|NCT01692717|DRUG|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
219538491|NCT01692717|DRUG|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
219538492|NCT01548248|DRUG|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
219538493|NCT01548248|DRUG|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
219538494|NCT03128762|BIOLOGICAL|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
218924546|NCT00397501|DRUG|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
219538495|NCT03429712|DEVICE|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
219538496|NCT04709926|OTHER|Survey|Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
219538497|NCT04709926|OTHER|Interview (optional)|Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
218924547|NCT00397501|DRUG|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
218924548|NCT00397501|DRUG|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
218924549|NCT03645824|DRUG|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
218924550|NCT04978675|DRUG|Fluorine F 18 rhPSMA-7.3|Given IV
218924551|NCT04978675|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
218924552|NCT04978675|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
218924553|NCT06078124|BEHAVIORAL|Sibling Support for Adolescent Girls in Emergencies|"The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls."
218924554|NCT01198977|BEHAVIORAL|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
218924555|NCT01198977|OTHER|Education counseling|Mailed informational video of exercise programs
218924556|NCT02374528|PROCEDURE|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
218924557|NCT02374528|PROCEDURE|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
218924558|NCT01763697|BEHAVIORAL|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
218924559|NCT01763697|BEHAVIORAL|Recorded meal|
218924560|NCT06517160|OTHER|MedBook Portal|"Intervention Group (With MedBook Portal \&amp; MedBook Portal Notice)~1. MedBook Portal Notice in front of the patient home-based medical card~2. Discharge prescriptions are uploaded into MedBook Portal and can be retrieved by doctors \&amp; pharmacists.~MedBook portal (https://aplikasi.jknsarawak.moh.gov.my/medbook) is a webpage that enable sharing of patient medication records among healthcare facilities under Ministry of Health. Sarawak State Health Department owned and managed this portal. All the information is kept under their server. Doctors in the Health Clinics and Study Pharmacists will be given access to this portal whereby each of the healthcare providers shall log in using their Identification Number and the password created by them. Doctor shall log in to MedBook Portal to check on discharge medication list when reviewing the patient at health clinic. MedBook Portal can be accessed both using a smartphone or a computer."
218924561|NCT04080648|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
218924562|NCT04080648|OTHER|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
218924563|NCT05509998|BEHAVIORAL|Screening Method (SM)|All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
218959293|NCT03230305|OTHER|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
219204901|NCT06995911|DEVICE|Virtual Far-sight Reading Device|The Virtual Far-sight Reading Device utilizes a birdbath optical configuration and freeform surface technology to extend the working distance from 30 cm to over 6 meters, thereby simulating distance viewing conditions and maintaining ciliary muscle relaxation. Study participants were required to engage in reading and writing tasks using the device for a cumulative daily duration of at least 1 hour.
219538498|NCT06826755|DIETARY_SUPPLEMENT|Terry Naturally® melatonin 5mg SR|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
219538499|NCT06826755|DIETARY_SUPPLEMENT|Placebo|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
219538500|NCT01763385|DRUG|Erlotinib|
219538501|NCT01763385|RADIATION|concurrent brain radiotherapy|
219538502|NCT01763385|RADIATION|secondary brain radiotherapy|
219538503|NCT04986878|PROCEDURE|single-shot adductor canal block|An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.
219538504|NCT03567668|PROCEDURE|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
218924564|NCT05509998|BEHAVIORAL|Screening and Communication Method (SCM)|Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
218924565|NCT06601803|DRUG|sterile saline solution|The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
218924566|NCT06601803|DRUG|Surgiphor|The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant
218924567|NCT06601803|PROCEDURE|Sample Collection|During the surgical procedure, 4 swabs of the surgical wound will be taken at various times throughout the procedure
218924568|NCT06654908|PROCEDURE|resisted exercise using sand bags,resistance machines and elastic bands|Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
218924569|NCT06655519|BIOLOGICAL|CAR-T（RD140 injection）|"This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once."
218924570|NCT02538510|OTHER|Laboratory Biomarker Analysis|Correlative studies
218924571|NCT02538510|BIOLOGICAL|Pembrolizumab|Given IV
218924572|NCT02538510|DRUG|Vorinostat|Given PO or via PEG
218924573|NCT06604702|PROCEDURE|Autologous Fat Injection for Rectocele|In this procedure, autologous fat is harvested from the patient\&#39;s lower abdomen using a multiport cannula. The fat is then processed via centrifugation to separate the viable fat cells, which are emulsified into nanofat. This nanofat is injected into the submucosal layer of the rectocele through the posterior vaginal wall, using an anoscope for guidance. The procedure is intended to reinforce the rectovaginal fascia, alleviate rectocele symptoms such as obstructive defecation and vaginal bulge, and reduce prolapse recurrence.
218959294|NCT02005198|OTHER|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
218959295|NCT04381338|OTHER|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
218959296|NCT02901665|OTHER|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
218959297|NCT00495079|DRUG|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
219538505|NCT04499729|DEVICE|IntelliCare|IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
219538506|NCT04499729|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual in the Rush Collaborative Care service
219538507|NCT05402553|DRUG|Ondansetron|patients will receive, in addition to standard therapy, ondansetron IV bolus 8 mg BID for 3 days
219538508|NCT05402553|DRUG|Placebo|patients will receive, in addition to standard therapy, normal saline IV bolus BID for 3 days
219538509|NCT00305786|DRUG|gemcitabine hydrochloride|
218959298|NCT02763592|DRUG|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
218959299|NCT02763592|OTHER|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
218959300|NCT02400411|OTHER|Wheat bread|
218959301|NCT02400411|OTHER|margarine|
219538510|NCT00305786|DRUG|oxaliplatin|
218959302|NCT02400411|OTHER|ham|
218959303|NCT02400411|OTHER|soup|
218959304|NCT02400411|OTHER|rye bread|
218959305|NCT00400153|DRUG|Atrovent Respimat (20 mcg)|
219538511|NCT00032396|DRUG|Retisert Implant|
218924574|NCT06596330|BEHAVIORAL|Validation of language model prompts in increasing short-term physical activity|"Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change."
219619922|NCT06975267|BEHAVIORAL|Free play|"Control kindergartens will have additional designated playtime consisting of free play for 28 weeks. The checklist for play conditions is defined as when: Time is set aside in the daily kindergarten routine where (1) it is clearly announced or signaled to the children that it is now free play, (2) it is an absence of requirements for sedentary sitting (unless it is part of the children's play), (3) it is not a situation where children are required to follow instructions (unless it is part of the children's play or general rules in the kindergarten (?)), (4) it is an absence of a pronounced learning outcome or goal with the activities available for the children (beyond what is defined by the children themselves), (5) the children can start and finish activities themselves, and choose what they want to participate in, and (6) adults can join in the game/initiate, but on the children's terms, and the children can choose to leave this game whenever they want."
219619923|NCT04333017|DEVICE|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
219619924|NCT02484716|DRUG|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
218959306|NCT00400153|DRUG|COMBIVENT MDI (36/206 mcg)|
218959307|NCT00400153|DRUG|Combivent Respimat (20 mcg/100 mcg)|
219619925|NCT02484716|DRUG|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
219619926|NCT06485622|PROCEDURE|open bypass group|After heparinization, the target artery is clamped above and below the anastomosis. The target artery is dissected along the anterior wall, calcium portions or mural thrombus are removed. Graft (autologous or prosthetic graft) is cut obliquely and anastomosis suturing starts with distal angle. Next stage is tunnel creating for graft conduction.
219619927|NCT06485622|PROCEDURE|bare metal stent group|Bare metal stent implantation during the index procedure.
219619928|NCT06485622|PROCEDURE|plain old balloon angioplasty group|Only plain old balloon was used during the index procedure.
219619929|NCT06485622|PROCEDURE|drug-coated balloon group|Drug-coated balloon was used during the index procedure.
219619930|NCT06485622|PROCEDURE|directional atherectomy group|Directional atherectomy (with or without drug-coated balloon) during the index procedure.
219619931|NCT06485622|PROCEDURE|hybrid repair group|Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery. Arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological). Endovascular revascularization followed.
219619932|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
219619933|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
219619934|NCT05694260|DRUG|Bempedoic acid|Once daily oral dosing with oral tablets.
219619935|NCT04453436|DRUG|Tenofovir Disoproxil|Genotipic resistance test
219619936|NCT03135717|DIETARY_SUPPLEMENT|Nutritional care|"* Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~* Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~* Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~* Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
219619937|NCT06581354|PROCEDURE|PROVISIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
218959308|NCT00400153|DRUG|Placebo via corresponding inhaler for blinding purposes|
218959309|NCT05364801|OTHER|Survey|Online anonymous survey
218959310|NCT00159562|BEHAVIORAL|individual education|individual sessions of psycho-education
218959311|NCT00159562|BEHAVIORAL|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
218959312|NCT02040727|BEHAVIORAL|Resistance Training|Supervised strength training 3 days per week for 24 weeks
218959313|NCT02040727|BEHAVIORAL|No Resistance Training|No supervised strength training throughout the study
218959314|NCT00393042|DRUG|Dexmethylphenidate|10, 20, 25-30 mg.
218959315|NCT00393042|DRUG|Mixed Amphetamine Salts, ER|10, 20, 25-30
218959316|NCT00393042|DRUG|placebo|randomized placebo week during each 4 week period
218959317|NCT02763969|DRUG|BMS-986202|
218959318|NCT02763969|DRUG|Placebo|
218959319|NCT02763969|DRUG|Interferon alpha-2a recombinant|
218959320|NCT02763969|DRUG|Famotidine|
218959321|NCT02763969|DRUG|Ustekinumab|
218959322|NCT00330161|DRUG|vorinostat|Given orally
219538512|NCT00961168|OTHER|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
218924575|NCT06596330|BEHAVIORAL|Assessment of long-term changes to physical activity and glycemic control|"Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app)."
218924576|NCT06599437|PROCEDURE|laparoscopic cholecystectomy|Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.
218924577|NCT06599437|PROCEDURE|Late laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
218924578|NCT06604507|DEVICE|non-pharmacological app|Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
218924579|NCT06598995|PROCEDURE|Coronary artery bypass grafting or unroofing|Patients had an MB with \&gt;75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \&lt; 5mm (whether deal with these MB with a depth \&lt;5mm depends on the surgeon and the period time of patients received a surgery).
218924580|NCT06587646|DIAGNOSTIC_TEST|Virtual Examination under Anaeastehtic - 3D reconstruction imaging|3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.
218924581|NCT06587646|DIAGNOSTIC_TEST|Standard Care - Written MRI report|A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
218924582|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
218959323|NCT00330161|OTHER|laboratory biomarker analysis|Correlative studies
219538513|NCT00961168|OTHER|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
219538514|NCT04037969|DEVICE|Nesofilcon A|Hydrogel contact lens for daily wear
219204907|NCT06996600|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
219538515|NCT04037969|DEVICE|Delefilcon A|Silicone hydrogel contact lens for daily wear
219538516|NCT01633645|DRUG|Bortezomib|Velcade
219538517|NCT01633645|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
219538518|NCT01633645|DRUG|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
219538519|NCT00808171|DRUG|Livopan|Inhalation of oxygen and nitrous oxide 50%
219538520|NCT00808171|DRUG|Livopan|equimolar mixture of N2O/O2
219538521|NCT00808171|DRUG|EMLA|Lidocaine-prilocain cream
219538522|NCT03406494|OTHER|Early multicomponent physical therapy program|"1. Positioning (upright bed standing; turning, moving on bed).~2. Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~3. Respiratory muscle training (supine abdominal breathing training).~4. Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~5. Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
219538523|NCT05040880|DRUG|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
219538524|NCT05040880|DRUG|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
219538525|NCT00059670|PROCEDURE|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
219538526|NCT04852978|DRUG|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
219538527|NCT04852978|BIOLOGICAL|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
219538528|NCT07201818|DEVICE|Lymphatic Enhancement Technology (LET)|Lymphatic Enhancement Technology (LET) is an FDA-approved electrotherapeutic modality, with indications for addressing local lymphatic and vascular circulation as well as muscle pain and spasm. The Aria LET Elite Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the intervention group.
219538529|NCT07201818|DEVICE|Sham Lymphatic Enhancement Technology (LET)|A separate modified Aria Elite LET Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the sham group. The sham LET device used for the control group will emit a light and sound similar to the true LET device, but will not emit energy waves.
219538530|NCT07202494|OTHER|Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)|Functional MRI (fMRI) Diffusion Tensor Imaging (DTI) Sodium Imaging (23Na-MRI) Phosphorus Imaging (31P-MRI)
219619938|NCT04459936|OTHER|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
219538531|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：42Gy/26Fr.
219538532|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：54Gy/33Fr.
219538533|NCT07201909|DIETARY_SUPPLEMENT|Prebiotic fibre blend|A blend of prebiotic fibres in a powdered supplement form.
219538534|NCT07201909|DIETARY_SUPPLEMENT|Maltodextrin powder|Maltodextrin powder
219538535|NCT07200583|PROCEDURE|Protein A immunoadsorption|Extracorporeal therapy performed prior to haploidentical HSCT to remove donor-specific anti-HLA antibodies (DSA)
219619939|NCT04459936|OTHER|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
219619940|NCT01693016|DEVICE|non-invasive measurement of Hb|
219619941|NCT01693016|PROCEDURE|taking blood samples|
218924583|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice placebo|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
218924584|NCT06090422|DRUG|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
218924585|NCT06090422|DRUG|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
218924586|NCT03397966|DRUG|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
219538536|NCT07200583|DRUG|Rituximab (optional, in some patients)|Anti-CD20 monoclonal antibody occasionally combined with immunoadsorption as part of desensitization strategy
218924587|NCT03397966|DRUG|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
218924588|NCT04983680|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
218924589|NCT05163158|OTHER|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
218924590|NCT06992635|BEHAVIORAL|using non-processing screens|ask subjects to use non-processing screens
218924591|NCT06992635|BEHAVIORAL|using AR screens|ask subjects to use AR screens
218924592|NCT06992635|BEHAVIORAL|using AR+CP screens|ask subjects to use AR+CP screens
218924593|NCT06991452|DIAGNOSTIC_TEST|Liquid biopsy|Serum protein profile, serum metabolic mass spectrometry, plasma cfDNA/cfRNA genomic and epigenomic assays, and serum tumor markers were performed. Patients were followed up for 3 years at a 3-month interval. Collect surgically removed colorectal cancer samples to construct PDX models if necessary.
218924594|NCT03579251|BEHAVIORAL|Black Men's Care|12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
218924595|NCT06070766|DRUG|Ketamine|The use of ketamine in chronic conditions.
218924596|NCT06588543|DEVICE|Endovascular treatment|Endovascular treatment
219538537|NCT07200583|DRUG|Bortezomib (optional, in some patients)|Proteasome inhibitor occasionally used in combination with desensitization therapy.
219538538|NCT07200284|PROCEDURE|Airpolishing device|The authors will assess biochemical and clinical variables
219538539|NCT07200284|PROCEDURE|Manual SRP|Gold standard
219538540|NCT07201779|BEHAVIORAL|REDCHiP|REDCHIP comprises 10 telehealth group sessions for parents of young children with T1D, is grounded in Cognitive Behavioral Therapy (CBT) principles, and is designed to address parents FH, and their avoidant coping behaviors related to FH. Sessions also focus on strengthening parents' coping strategies associated with T1D management and helping them to reduce feelings of diabetes distress.
219538541|NCT07201779|OTHER|Treatment As Usual Control Group|Participants will receive their treatment as usual in medical appointments
219538542|NCT07201714|DRUG|Levocarnitine|Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
219538543|NCT07201857|DIETARY_SUPPLEMENT|nutrition education plus active supplement|Nutrition Group (NUT) Participants will receive standard clinical care combined with nutrition education and protein-enriched soy milk supplementation for approximately 2 weeks before surgery and about 3 weeks after hospital discharge.
219538544|NCT07201857|BEHAVIORAL|Exercise|"Exercise and Nutrition~Participants will receive peri-habilitation exercise training together with nutritional intervention, including carbohydrate plus protein-enriched soy milk supplementation twice daily (before and after exercise), for approximately 2 weeks before surgery and about 3 weeks after hospital discharge."
219538545|NCT07200869|OTHER|No intervention|retrospective observational study. No intervention will be administered; data will be collected from existing medical records of pediatric sickle cell patients at Assiut University Hospital.
219538546|NCT07201701|BIOLOGICAL|Supplementary blood samples for PBMC analysis at V2|Supplementary blood (serum and plasma) and urines samples for bio collection at V3
219538547|NCT07201103|BEHAVIORAL|Conventional PSSE-Schroth|Participants performed conventional Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) for 4 weeks. The program consisted of one 45-minute supervised session per week complemented by home-based exercises. The exercises focused on posture correction, spinal alignment, and corrective breathing techniques according to standard scoliosis rehabilitation protocols.
219538548|NCT07201103|BEHAVIORAL|AR-Assisted PSSE-Schroth|Participants performed Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) enhanced with augmented reality (AR) support for 4 weeks. The intervention included one 45-minute supervised session per week, plus home-based exercises. The AR system provided real-time visual and kinesthetic feedback during exercise sessions to improve body awareness, trunk appearance perception, and adherence.
219538549|NCT07201259|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219619942|NCT03733769|PROCEDURE|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
218959324|NCT05280483|DRUG|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
218959325|NCT05280483|DRUG|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
218959326|NCT03777631|PROCEDURE|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
219619943|NCT00447174|BEHAVIORAL|Dyadic treatment for parental bereavement|
219619944|NCT01416636|DRUG|Treprostinil sodium|
218959327|NCT02655770|DRUG|Liraglutide|
218959328|NCT02655770|DRUG|Placebo|
218924597|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption|Volunteers were asked to consume lupins in brine for 4 weeks.
218924598|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption and dietary suggestion|Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
219619945|NCT01193777|DRUG|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
219619946|NCT01193777|DRUG|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
219619947|NCT02301169|BEHAVIORAL|Heat pain stimuli A|
219619948|NCT02301169|BEHAVIORAL|Video A|
218924599|NCT06591546|DEVICE|Telescoping nail|"The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc."
218924600|NCT06592287|DRUG|Adebrelimab + Apatinib + Lrinotecan liposome|"Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
218924601|NCT06604338|DIAGNOSTIC_TEST|Exome test|An exome will be performed on the participants of RPL group.
219538550|NCT07202403|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. While it's found in various foods, the highest concentrations are in wheat germ, soy, and fermented foods like cheese and miso (Madeo et al. 2018). Spermidine is known for its role in promoting autophagy, a cellular process that helps to clear damaged cells and improve overall cellular function (Eisenberg et al. 2009; Gabandé-Rodríguez, Gómez de Las Heras, and Mittelbrunn 2019). As a result, spermidine has recently attracted significant scientific interest for its potential to enhance lifespan and overall health in laboratory studies.
219619949|NCT02301169|DRUG|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
219619950|NCT02301169|BEHAVIORAL|Heat pain stimuli B|
219619951|NCT02301169|BEHAVIORAL|Video B|
219619952|NCT02301169|DRUG|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
219619953|NCT04553159|BIOLOGICAL|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
219619954|NCT00218023|DRUG|Modafinil|The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
218924602|NCT06604338|DIAGNOSTIC_TEST|Microbiota analysis|A cervical microbiota analysis will be performed in the RPL and control groups.
219538551|NCT07202039|BEHAVIORAL|Brief individual counseling sessions|Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
219538552|NCT07202325|BEHAVIORAL|Resilience Training for Veterans (REST-V)|A 6-week self-help intervention tailored for post-9/11 Veterans offering guidance on cognitive-behavioral self-management coping strategies plus when and how to access recovery support services including mental health treatment. Materials are sent once a week for 6 weeks, and participants can opt to receive weekly reminder text messages or up to 3 brief telephone support calls.
219538553|NCT07202325|OTHER|Usual resources|Standard printed resource/treatment information provided in VHA usual care to post-9/11 Veterans. Covers similar domains as the intervention materials and provides information on a variety of VA and community resources for Veterans. Materials are sent once.
219538554|NCT07201987|DRUG|Vancomycin (local, via calcium sulfate beads)|Patients undergoing spine surgery will receive intraoperative placement of calcium sulfate beads impregnated with vancomycin. The beads are intended to provide local infection prophylaxis.
219538555|NCT07201987|DRUG|Morphine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with morphine. The beads are intended to provide sustained local analgesia.
219538556|NCT07201987|DRUG|Bupivacaine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with bupivacaine. The beads are intended to provide sustained local analgesia.
219538557|NCT00859430|DRUG|Levetiracetam|1000 mg Tablet
219538558|NCT00859430|DRUG|Keppra®|1000 mg Tablet
219538559|NCT06081348|DRUG|Sertraline|Oral capsule (25mg, 50mg, 100mg, 200mg)
219538560|NCT06081348|OTHER|Placebo|Oral placebo capsule
219538561|NCT01889498|DRUG|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~* 250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~* One tablet to take two hours before surgery~* 500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
219538562|NCT06627946|PROCEDURE|TAP group|Local anesthesia 0.25% bupivacine was administered in the TAP plane
219538563|NCT00193245|DRUG|Topotecan|
219538564|NCT00193245|DRUG|Docetaxel|
219538565|NCT03209115|DRUG|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
219538566|NCT03209115|DRUG|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
218924603|NCT06598020|BEHAVIORAL|Supportive Care|Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)
218924604|NCT06597162|BEHAVIORAL|education of patient safety|"For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group."
218924605|NCT06594809|OTHER|PNF|Upper extremity PNF exercise is an exercise method that dynamically stabilizes the scapula and affect scapular muscles activity (Witt et al., 2011). Upper extremity PNF patterns consisted of four diagonal patterns (D1 flexion, D2 flexion, D1 extension, and D2 extension) and six key components manual contact, body position, verbal cues pattern of movement, timing of movement and resistance. Patient will be at sitting position with involved side up, head, spine, and scapula in neutral
218924606|NCT06594809|OTHER|Traditional neck pain treatment|Cervical muscles stretch + Craniocervical retraction ex + Manual therapy
219042864|NCT06898398|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
219538567|NCT05795140|DRUG|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
219538568|NCT06549998|OTHER|Interprofessional Simulation Experience|"Phase 1 (Pre-Brief): Nursing and physical therapy students will have 10 minutes to gather as a group and prepare for the simulation experience.~The students will work together to review the simulated patient's medical chart, which includes a hand off report, physician orders, patient demographic data, disci-pline-specific progress notes, a physical therapy evaluation, and information from lab results posted on a tri-fold board.~Phase 2 (Simulation): After reviewing the chart and establishing a plan as a group for getting the simulated patient out of bed, the interprofessional team of nursing and physical therapy students will enter the simulated hospital room. The goal for the approximately 20-minute encounter is for the interprofessional group to help the simulated patient to get out of bed while closely monitoring the physiological responses to activity.~Phase 3: The simulation will conclude with a 30-minute faculty guided and structured debriefing session."
219538569|NCT06248528|PROCEDURE|Liver resection|Patients in the intervention group received liver resection and postoperative adjuvant therapy
219538570|NCT06248528|PROCEDURE|Locoregional therapy|Patients in the control group received locoregional therapy and systemic therapy
219538571|NCT04026958|DRUG|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
219538572|NCT04026958|DRUG|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
219619955|NCT00218023|DRUG|Levodopa/Carbidopa|Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
219619956|NCT00218023|DRUG|Naltrexone HCl|Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
219042865|NCT06898398|PROCEDURE|Surgery|The surgical plan was based on the tumor size, tumor location, and liver function. We applied Pringle's maneuver with cycles of clamping and unclamping times of 1-10 and 5 min, respectively, and maintained the central venous pressure below 4 mmHg during parenchymal dissection to control intraoperative bleeding.
219538573|NCT03511534|BEHAVIORAL|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
219538574|NCT03511534|OTHER|Pharmacotherapy|Pharmacotherapy by a psychiatrist
219538575|NCT05521867|DEVICE|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
219538576|NCT05521867|DEVICE|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
219538577|NCT05660395|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
219619957|NCT00218023|DRUG|Placebo|Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
219042866|NCT06889545|OTHER|Assessment of frailty using multiple tools|This is an observational study without any intervention. Frailty is assessed using multiple tools and postoperative outcome is compared.
219042867|NCT06853015|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose twice a day.
219042868|NCT06853015|DRUG|Placebo|The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.
218924607|NCT06594809|OTHER|Traditional neck pain treatment + Blackburn scapular stabilization exercises|The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises). Blackburn exercises are one of the ways to treat scapular dyskinesia. Perform 2 sets of 20 repetitions of each exercise each session (3 sessions per week) for four weeks (panse et al .,2018). The exercise load will be 60% of the one-repetition maximum (1-RM) during the first week due to their first exposure to the exercises. The evaluation of one-repetition maximum (1-RM) will be every week for all exercises. From the second evaluation, more weight will be added (compare to the previous evaluation) to maintain the overload.
218924608|NCT06597461|OTHER|Myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
218924609|NCT06597461|OTHER|Placebo myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.
218924610|NCT06603428|DEVICE|internal fixation by plate or screws|\- Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
218924611|NCT06586814|OTHER|Suture|Wound Closure
218924612|NCT06586814|OTHER|Staple|Wound Closure
218924613|NCT06599944|DIAGNOSTIC_TEST|Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale|Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.
219538578|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
219538579|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
219538580|NCT05706870|DRUG|GN-037|GN-037
219538581|NCT05706870|DRUG|Clobetasol 17-propionate|Clobetasol 17-propionate
219538582|NCT05706870|DRUG|Placebo|Placebo
219538583|NCT04318886|BEHAVIORAL|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
219538584|NCT02772367|PROCEDURE|skin punch biopsy|
219538585|NCT06054412|DEVICE|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
219538586|NCT02925884|DEVICE|Gunnar OTC Glasses|Gunnar Over-the-Counter Computer Glasses have optical power of 0.5 diopters for reducing accommodation demands at a typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
219538587|NCT04691973|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
219538588|NCT04691973|OTHER|Usual care|Usual care at ordinary healthcare provider
219538589|NCT03119025|BIOLOGICAL|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
219619958|NCT00218023|BEHAVIORAL|Motivational Interviewing (MI)|The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
219538590|NCT06234358|DEVICE|osteosynthesis|calcaneus osteosynthesis is a surgical fixation of a displaced fracture of the calcaneous bone. The surgery is performed under general or regional anesthesia. A scar is made on the lateral side of the ankle below the lateral malleolus. The bone fragments are repositioned as anatomically as possible. They are fixed by a percutaneous nailing fastener.
219538591|NCT01421264|DRUG|Gabapentin|300mg capsules by mouth
219619959|NCT00218023|BEHAVIORAL|Contingency management (CM)|Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
219538592|NCT04724187|DRUG|Misoprostol|it is prostaglandin E1 .
219538593|NCT04724187|DRUG|Oxytocin|it stimulates uterine contractions
218924614|NCT06589232|OTHER|Food allergy|Threshold dose to pistachio
218924615|NCT06592326|DRUG|9MW2821|9MW2821, 1.25mg/kg, intravenous (IV) infusion
218924616|NCT06592326|DRUG|Toripalimab|Toripalimab, 240mg, intravenous (IV) infusion
218924617|NCT06592326|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, intravenous (IV) infusion
219204908|NCT06879483|PROCEDURE|Thoraco-laparoscopic partial esophagogastrectomy|"1. Laparoscopic Phase:~   * The stomach is mobilized, and a part of it is resected to include the lower esophageal segment.~  * Left gastric nodes, the splenic and common hepatic nodes are dissected.~  * A gastric tube is created using endoscopic staplers for esophageal reconstruction and fixed to the proximal gastrectomy specimen using sutures~2. Thoracoscopic Phase:~   * The patient is positioned in prone position~  * Three small incisions are made in the thorax~  * Further esophageal mobilization through a right thoracoscopy is performed in left lateral decubitus. Periesophageal nodes are retrieved en bloc. Left and right paratracheal and subcarinal lymph nodes are resected separately. The esophagus is transected at the tumor's proximal margin.~3. Reconstruction:~   * An anastomosis (esophagogastric connection) is performed to restore continuity, typically using a circular stapler or hand-sewn technique."
219538594|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
219204909|NCT06865209|DEVICE|Monolithic Zirconia Posterior Single Screw Retained Implant Crowns|Posterior single edentulous sites will be rehabilitated with monolithic zirconia single posterior implant crowns following two different full digital workflows
218924618|NCT06592326|DRUG|Cisplatin/Carboplatin|Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
218924619|NCT06586203|DEVICE|Polygenic Risk Score|The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
218924620|NCT06586749|OTHER|Group B: nurse-led education|Group B: nurse-led education No educational video, will be shown to this group of patients
219204910|NCT06864728|BEHAVIORAL|Video Diabetes Education|Participants will receive a link to a short video explaining their findings. They can use the link as often as they'd like. They will get the results for the CGM and the laboratory findings. They will be linked to their 2 week diet diary
218924621|NCT06586749|OTHER|Group C: nurse-led education and implementation of teleinterventions|Group C: nurse-led education and implementation of teleinterventions An educational video, made for the purposes of the study only, will be shown to them. This is the difference between the two groups
219538595|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
219538596|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
219538597|NCT03733730|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
219619960|NCT00218023|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
219619961|NCT01105364|DRUG|antiangiogenesis therapy|
218924622|NCT06595901|OTHER|Actigraph|Participants will wear an Actigraph hip-worn accelerometer on their non-dominant hip during all waking hours, and on the wrist while sleeping
218924623|NCT06595901|OTHER|Questionnaires|"* Patient Health Questionnaire Anxiety and Depression Scale30 (PHQ-ADS), a validated composite of anxiety and depressive symptoms.~* Self-reported cognition will be assessed by the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog)."
218924624|NCT06595901|OTHER|BrainBaseline application|Objective measures of cognitive function will include those from the BrainBaseline application, a validated research tool developed by Digital Artefacts to remotely measure domains of cognition
218924625|NCT06595901|OTHER|Semi-structured interviews|Semi-structured individual interviews will be conducted with up to 15 healthcare stakeholders and 15-30 patients with breast cancer at any time during the study period, as determined by participant preference.
218924626|NCT06600516|BEHAVIORAL|CBTi: Stimulus Control Core|Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
219619962|NCT01105364|DRUG|stabilized sulphur hexafluoride microbubble-based contrast agent|
219619963|NCT01105364|OTHER|imaging biomarker analysis|
219619964|NCT01105364|OTHER|pharmacological study|
219619965|NCT01105364|PROCEDURE|computed tomography|
219619966|NCT01105364|PROCEDURE|magnetic resonance imaging|
219619967|NCT03389503|PROCEDURE|Radial approach|Approach site for coronary angiography and coronary intervention
219619968|NCT01198470|DEVICE|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
218924627|NCT06600516|BEHAVIORAL|CBTi: Sleep Restriction Core|Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
218924628|NCT06600516|BEHAVIORAL|CBTi: Sleep Compression Core|Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
218924629|NCT06586242|DRUG|Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin|200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
218924630|NCT06595199|OTHER|Online peer support|A closed online peer support group
218924631|NCT06591988|BEHAVIORAL|Lifestyle factors|introduction of environmental risk mitigation policies, from data and evidence from case studies (several European cities) with different levels of exposure to environmental, health, geographic, and socioeconomic factors.
218924632|NCT06589037|OTHER|shock wave treatment control group|The control group, consisting of 24 people, will receive shock wave treatment on the sole of the foot to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
219538598|NCT00685607|DRUG|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
218924633|NCT06589037|OTHER|shock wave treatment experimental group|The experimental group, consisting of 24 people, will receive shockwave treatment on the back of the leg to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
218924634|NCT06599515|PROCEDURE|robotic surgical platform|robot-assisted laparoscopic inguinal hernia repair (rTAR)
219042869|NCT06853015|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
219042870|NCT06853015|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
219042871|NCT06774274|DRUG|Ketamine infusion|"A 10% ketamine solution will be prepared in a 250 cc bag of 0.9% saline (1 mg/cc) using 5 cc from a vial of ketamine that has a concentration of 50 mg/cc. The infusion will be initiated at the time of surgical site closure and will proceed as follows: a bolus of 0.35 cc/kg (equivalent to 0.35 mg/kg) will be administered, followed by a continuous infusion of 0.1 cc/kg/h (equivalent to 0.1 mg/kg/h) for up to 48 hours postoperatively.~Patients in this group will have access to a PCA pump with morphine for analgesic rescue and to monitor daily opioid consumption."
219204911|NCT06864728|BEHAVIORAL|In person or virtual diabetes education|Participants will meet with a nurse to discuss their CGM results and their lab results and get appropriate education.
219538599|NCT00685607|DRUG|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
219538600|NCT01401803|DRUG|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
219619969|NCT03360383|PROCEDURE|percutaneous vertebroplasty|Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
219204912|NCT06860945|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219204913|NCT06997159|DRUG|LXE408|LXE408 film-coated tablets.
219619970|NCT03360383|PROCEDURE|conservative treatment|complete on bed with prevention of complications
219619971|NCT04924387|PROCEDURE|Exercise|All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercises of 2-3 minutes.
219619972|NCT00578045|PROCEDURE|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
219619973|NCT02452606|DRUG|Stalevo®|"* Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
219619974|NCT02500095|OTHER|Fasting|72 hours of fasting
219619975|NCT02500095|DRUG|Saline|Concomitant saline during fasting
219619976|NCT02500095|DRUG|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
219619977|NCT02670226|OTHER|Samples|Blood samples, muscle biopsy
218924635|NCT06993194|DRUG|Haloperidol|Haloperidol will be administered intravenously at a dose of 2.5 milligrams every eight hours over ten minutes. Treatment will begin 48 hours after admission to the intensive care unit and will continue for up to seven days or until delirium and agitation resolve. The need for additional sedation will be addressed with intravenous midazolam and fentanyl as required. The patient's clinical status will be monitored using standardized assessments including the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
218924636|NCT06993194|DRUG|Dexmedetomidine|Dexmedetomidine will be administered by continuous intravenous infusion at a dose of 0.5 micrograms per kilogram. Treatment will begin 48 hours after admission to the intensive care unit and will be repeated every other day for up to seven days or until delirium and agitation resolve. Rescue sedation may be provided with intravenous midazolam and fentanyl as clinically indicated. Delirium and agitation will be assessed regularly using validated tools such as the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
218924637|NCT06145321|DEVICE|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
218924638|NCT06145321|DRUG|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
218924639|NCT06615206|GENETIC|HG204|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
218924640|NCT06992869|BEHAVIORAL|Group-based psychological therapy|Group-based psychological therapy for (1) adjusting to diagnosis; (2) Parkinson's anxiety and/or depression; and (3) Parkinson's-related cognitive decline
218924641|NCT06991907|PROCEDURE|125I seed implantation|125I seed implantation
218924642|NCT06991907|DRUG|PD-1 Inhibitors|PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks. According to the manufacturer's guidelines, the dose is reduced or discontinued based on the severity of adverse effects.
218924643|NCT06992492|PROCEDURE|vojta therapy +conventional chest physical therapy|infants will receive reflex rolling technique along with conventional chest physical therapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. This maneuver includes a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface. A digit pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. Each treatment consists in delivering four stimuli, two to the left half of the chest (stimulations I and II) and two to the right half of the chest (stimulations III and IV). Each stimulus will be consisted of slight pressure, progressively oriented in dorsal, medial and cranial direct
219042872|NCT06774274|DRUG|PCA Ketamine|"A mixture of 5% ketamine and 5% morphine will be prepared in a 100 cc bag of 0.9% saline. This will be achieved by using 1 cc of a ketamine vial (50 mg/cc) and 5 cc of a morphine ampule (10 mg/cc). This results in a final concentration of 0.5 mg of ketamine and 0.5 mg of morphine per cc in the 100 cc saline bag.~The pump settings will be configured as follows:~* PCA (Patient-Controlled Analgesia) dose: 2 cc (which delivers 1 mg of ketamine and 1 mg of morphine)~* Lockout interval: 6 minutes~* Maximum dose limit: 15 doses over a 4-hour period~The pump will be available for patient use for up to 48 hours postoperatively."
219042873|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
219042874|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
219538601|NCT05433857|DRUG|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
219538602|NCT03635320|DEVICE|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
219538603|NCT03635320|DEVICE|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
219538604|NCT04364581|DRUG|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
219042875|NCT06901726|DRUG|Human insulin enteric coated capsules in dose 32mg|Single oral administration of human insulin enteric coated capsules in dose 32mg (16 mg per capsule, two capsules).
219042876|NCT06901726|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU.
219538605|NCT04364581|DRUG|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
219538606|NCT04512781|DEVICE|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
219538607|NCT04512781|DEVICE|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
219538608|NCT06549036|BEHAVIORAL|Veteran Peer Decision Coaching Session for PSA Screening|Veterans in the intervention arm will review the content of the mailed DA, including the values clarification exercise, with the Veteran PDC. Veteran PDC Counseling includes: 1) a structured interview with the patient that focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals and values related to his decision making and 2) role playing exercises to improve SDM skills.
219538609|NCT06628063|OTHER|ultrasound evaluation|Ultrasound scan of fetus in second and third trimestrers
219538610|NCT03448263|PROCEDURE|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
219538611|NCT03448263|PROCEDURE|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
218924644|NCT06992492|PROCEDURE|lung squeezing technique +conventional chest physical therapy|"infants will receive lung squeezing technique along with conventional chest physiotherapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. Lung squeeze technique consists of 3- cumulative chest compressions lasting for 5 seconds, followed by a gentle low release phase, with the chest wall completely released; the second compressions are performed successively for5 minutes on one hemithorax, then 5 minutes on the other hemi thorax. The infant will be in supine position, and without body tilt, for a total of 10 minutes. Use both hands to perform the squeeze on one hemithorax at one time. Place One hand on the posterolateral aspect of the hemi thorax and the other hand covered the anterior chest extending from the lower ribs to above the clavicle of the infant."
218924645|NCT06992492|PROCEDURE|conventional chest physical therapy|Conventional Chest Physical Therapy will be given for both the groups A and B and for group C in isolation manner with medical treatment with special emphasis on whether Surfactant therapy is given or not.it includes postural drainage, vibration, and percussion. Postural drainage will be applied to infants by elevating head of the infant at 30 degrees to prevent gastro esophageal reflex and aspiration. In neonates and infants 'tenting' (using the first three or four fingers of one hand with slight elevation of the middle finger). Chest percussion will be given with motion from the wrist. Vibration of the chest will be done manually by placing the fingers on the chest wall over the segment being drained and the wrist and the elbow remained immobile, isometrically contracting the muscles of the forearm and hand to cause a vibratory motion. The procedure will be performed for 5min. Chest percussion position lying down on the right side and on the left, with 5 min duration on each side
218924646|NCT06992271|BEHAVIORAL|Fast Eccentric|Resistance training done quickly
218924647|NCT06992271|BEHAVIORAL|Slow Eccentric|Resistance training done slowly
218924648|NCT06991634|DRUG|Azvudine tablets|"Phase I: oral administration of 5 mg of Azvudine tablets on an empty stomach, single dose, 5 tablets per dose.~Phase II: oral administration of 5 mg of Azvudine tablets once a day on an empty stomach, 5 tablets once a day, for 7 consecutive days."
218924649|NCT06992921|OTHER|Dietary intervention|Iterventional dietary study using standardised meals with different fat content and carbohydrate quantity and quality or mixed meal tolerance test to predict for an individuals metabolic response.
218924650|NCT06991647|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine at a dose of 2 mcg/kg body weight, diluted in 1 mL of 0.9% NaCl, administered using a 1 mL syringe connected to a Teleflex MAD Nasal device while in the supine position. The soft tip of the device will be gently placed into each nostril without applying pressure. The solution will be sprayed slowly to create a fine mist. The total dose will be divided equally, with 0.5 mL delivered into each nostril, administered approximately 30 minutes before intubation during induction.
218924651|NCT06991647|DRUG|0.9% NaCl solution|Participants will receive 1 ml of 0.9% NaCl solution administered intranasally using a 1 ml syringe connected to a Teleflex MAD nasal device while in the supine position. The soft tip of the Teleflex MAD nasal device is gently placed into each nostril without applying pressure. The solution is slowly sprayed to create a fine mist for patient comfort. The dose is divided equally, delivering 0.5 ml into each nostril, approximately 30 minutes before intubation during induction.
218924652|NCT06991998|PROCEDURE|Autogenous bone graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous bone graft harvested from a secondary intraoral donor site (mandibular ramus or maxillary tuberosity) with a bone scraper. The bone graft is placed into the debrided intraosseous defect, and enamel matrix derivative (EMD) is applied to the root surface. Surgical access is performed using a single flap approach (SFA), and primary closure is achieved with microsurgical sutures.
218924653|NCT06991998|PROCEDURE|Autogenous tooth-derived graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous tooth-derived particulate graft processed from an extracted tooth using a standardized protocol (Bonmaker® device and chemical decontamination), combined with enamel matrix derivative (EMD) applied to the root surface. The surgical site is accessed using a single flap approach (SFA), and graft material is placed into the non-self-contained intraosseous defect after debridement. Primary closure is achieved with microsurgical sutures.
218924654|NCT06992232|DRUG|Intense androgen deprivation therapy|Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.
219204914|NCT06997159|DRUG|Miltefosine 50 MG Oral Capsule [Impavido]|Each capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. Capsules are supplied in packs of 56 capsules sealed in 8 aluminum blister stripes, each containing 7 capsules.
219204915|NCT06997159|DRUG|Placebo to LXE408|Film-coated tablets.
219538612|NCT03448263|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
219538613|NCT00551863|BEHAVIORAL|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
219538614|NCT05003232|DEVICE|Near-infrared spectroscopy (NIRS) and ICM+|The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
219538615|NCT05162105|OTHER|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
219538616|NCT05162105|OTHER|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
219538617|NCT01354626|OTHER|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
219538618|NCT01354626|OTHER|low-protein|The control group will get a diet which is according to healthy eating guidelines.
219538619|NCT00202462|DRUG|Testosterone gel|Testosterone gel 7.5 gm qd
219538620|NCT02111239|DEVICE|CTA|pelvic/abdominal CTA scan
219538621|NCT02111239|DEVICE|MRA|pelvic/abdominal MRA scan
219538622|NCT00835575|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
218924655|NCT06992232|RADIATION|Radiation Therapy|Those allocated radiotherapy received 70Gy/2.8Gy/25f schedule for primary tumor and 70Gy/2.6-2.8Gy/25f or 37.5Gy/7.5Gy/5f for metastatic lymph nodes and bone lesions based on the size and location. Radiation should be finished within 2 years' systemic therapy.
218924656|NCT06992232|PROCEDURE|radical prostatectomy|Those allocated surgery received robot-assisted laparoscopic radical prostaectomy plus extended pelvic lymph node dissection for local treatment. Surgery should be finished within 2 years' systemic therapy.
218924657|NCT06992323|DIETARY_SUPPLEMENT|EPA + HT|Volunteers will consume during 12 weeks 2 g/d of EPA and 15 mg/d of HT, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
218924658|NCT06992323|DIETARY_SUPPLEMENT|EPA|Volunteers will consume during 12 weeks 2 g/d of EPA corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
218924659|NCT06992323|DIETARY_SUPPLEMENT|Sunflower Oil|Volunteers will consume during 12 weeks 2 g/d of Sunflower Oil, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
218924660|NCT06991790|DRUG|Sacituzumab Govitecan (SG)+Toripalimab|"Sacituzumab govitecan (Trodelvy): 10mg/kg, administered by intravenous infusion on day 1 and day 8.~Toripalimab: 240mg, administered by intravenous infusion on day 1."
218924661|NCT06991621|OTHER|Puzzle game|Scenario-based puzzle game sessions (group format)
218924662|NCT06991621|OTHER|Manual Education|Standardized death education manual distribution
218924663|NCT06211361|OTHER|Cardiac rehabilitation|Physical exercise intervention within a cardiac rehabilitation program, lasting 2 months, 3 days per week. The intervention consists of a first part of warm up the large muscle groups, accompanied by breathing exercises, followed by a part of strength and muscular resistance training exercises (upper and lower limbs and abdominal muscles), another part of aerobic exercise part (continuous and interval), using a treadmill or cycle ergometer, and finally a part of stretching exercises and a cool-down phase.
218924664|NCT06602895|OTHER|Intensive short-term functional strength training|All players underwent a rigorous 2-week intensive short-term functional strength training program, with training sessions held for 5 days a week. One group engaged in intensive short-term functional strength training exercises, while the other group focused on balance training. The training regimen was then reversed for the two groups. Each daily training session lasted approximately 2 hours, with 1 hour of either intensive short-term functional strength training or balance training. Every intensive short-term functional strength training session spanned roughly 60 minutes, starting with a 10-minute warm-up followed by dynamic mobility exercises targeting key joints. During the 40-minute core segment of our intensive short-term functional strength training sessions, participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability.
218924665|NCT06602895|OTHER|Balance Training|Participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability ball exercises. This was followed by 15 minutes of multi-joint strength exercises, where athletes performed compound movements like squats, deadlifts, push-ups or bench presses, and pull-ups or lat pull-downs, each for t sets of 8-10 repetitions. The session concluded with 15 minutes of agility and coordination drills, incorporating high-intensity activities such as lateral sprints and rope pulling, specifically designed to improve quickness and neuromuscular coordination, thereby enhancing overall athletic performance. The session concluded with a 10-minute cooldown involving flexibility exercises for the limbs and trunk. Exercise intensity was regulated to correspond with a 6-7 on the repetitions in the reserve-based Rating of Perceived Exertion (RPE) scale, where a s indicates that the exerciser feels they could perform approximately.
218924666|NCT06586775|PROCEDURE|Pulpotomy|complete pulpotomy
218924667|NCT06603376|DRUG|FOLFIRI + Vemurafenib + Cetuximab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
219042877|NCT07087249|BEHAVIORAL|Ultrasound Visual Feedback|Speech therapy using real-time ultrasound imaging to provide visual feedback on tongue placement and movement. Aimed at improving speech accuracy and motor planning in children with Childhood Apraxia of Speech (CAS). The intervention follows principles of motor learning and includes 12 individual sessions over 6 weeks (twice per week). Practice alternates between ultrasound-assisted and non-assisted phases to promote generalization.
219042878|NCT07087249|BEHAVIORAL|Traditional Speech Therapy|Standard speech motor therapy for children with Childhood Apraxia of Speech (CAS), based on evidence-based motor learning approaches. No visual feedback tools are used. Therapy focuses on blocked and random practice, varied feedback, and increasing speech complexity. Delivered in 12 sessions over 6 weeks (twice per week).
219538623|NCT00835575|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
219538624|NCT03923192|DEVICE|Vistacam|device for early proximal caries detection
219538625|NCT03923192|RADIATION|Bitewing radiograph|radiograph for proximal caries detection
219538626|NCT05393050|DRUG|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
219538627|NCT05393050|DRUG|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
219538628|NCT03487081|BEHAVIORAL|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
219538629|NCT03487081|BEHAVIORAL|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
219538630|NCT04618900|PROCEDURE|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
219538631|NCT01858493|BEHAVIORAL|Continence promotion group education workshop|Interactive group education workshop promoting continence
219538632|NCT01858493|BEHAVIORAL|Sham health lecture|Interactive group education workshop about general health
218924668|NCT06603376|DRUG|FOLFIRI ± Bevacizumab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
218924669|NCT06601231|DIAGNOSTIC_TEST|GAAD score|In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).
219619978|NCT03710408|OTHER|Intravenous hydration|"Participants assigned to the intravenous hydration arm will receive their hydration therapy through an intravenous access. This access will be achieved by inserting a BD VenflonTM Pro Safety - 22G in a vein in the dorsal side of the hand or further up the forearm. If the participants is suspected of becoming delirious and at risk of removing the cannula from the hand/forearm, it may be inserted at the dorsal side of the foot. The clinical staff judge this risk and decide site of placement.~Furthermore, a sham subcutaneous access device BD Saf-T-Intima™ Integrated Safety Catheter System will be placed on the abdomen without piercing the skin."
219619979|NCT03710408|OTHER|Subcutaneous hydration|"Participants assigned to the subcutaneous hydration arm will receive their hydration therapy through a subcutaneous access. This access will be achieved by placing a BD Saf-T-Intima™ Integrated Safety Catheter System on the abdomen or, alternatively if the participants is suspected of becoming delirious and at risk of removing the needle, it will be placed on the back at the scapular region.~Furthermore, a sham IV access device BD VenflonTM Pro Safety - 22G will be placed on the dorsal side of the hand without piercing the skin."
219619980|NCT04944043|DRUG|TQ05105 Tablet|TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
219619981|NCT01477346|OTHER|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
219619982|NCT01477346|OTHER|Standard care|Continuing standard General Practitioner led care.
219619983|NCT05375357|PROCEDURE|Application of L-PRF on the donor area|After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF
219619984|NCT05375357|PROCEDURE|Secondary intention healing of the donor area|After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
218924670|NCT06993207|DEVICE|Home Lab|The main goal is to comprehensively assess the cognitive and behavioral status of all participants, regardless of their assigned groups. Validated clinical tests (considered the gold standard) will be used, with measurements taken at participants' homes using a biosignal monitoring kit-the focal tool of the project. Whether in the control or specific groups, all participants will undergo an identical battery of tests in both the laboratory and home settings. The study design includes an introductory session for participants to understand the study's purpose and sign informed consent. Following consent, participants will have three sessions within a 3 to 6-week timeframe: one for autonomous technology use instruction and the other two for cognitive and functional evaluations.
218924671|NCT06590194|DRUG|PH009-1 tablet|PH009-1 will be administered in fasting state
218924672|NCT06604000|BEHAVIORAL|GMT Usual|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks."
219204916|NCT03907982|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
219538633|NCT03747276|OTHER|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
219538634|NCT01312064|DRUG|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
219538635|NCT01312064|DRUG|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
219538636|NCT01916915|DRUG|Tramadol infusion via wound catheter|
219538637|NCT01916915|DRUG|Levobupivacaine|
219619985|NCT02949973|DRUG|voclosporin|
219619986|NCT00063726|DRUG|bortezomib|
219619987|NCT00671112|DRUG|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
219538638|NCT04651036|DRUG|QL0605|a pegfilgrastim biosimilar to US Neulasta.
219619988|NCT00671112|DRUG|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
219619989|NCT02847949|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein
219538639|NCT04651036|DRUG|US Neulasta|US Neulasta
219538640|NCT04383587|OTHER|Serologic testing|COVID19 IgG antibody testing to be performed
219538641|NCT05069688|DRUG|rifampicin|Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
219538642|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
219619990|NCT00716599|DEVICE|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
218924673|NCT06604000|BEHAVIORAL|GMT Cuing|"The participants will receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP; as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends."
218924674|NCT06604000|BEHAVIORAL|GMT Boost|"After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
218924675|NCT06599424|OTHER|Observational|Observational
219538643|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
218924676|NCT04721977|DRUG|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
218924677|NCT04721977|BIOLOGICAL|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
218924678|NCT04721977|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 administered BID via oral tablet
218924679|NCT02864394|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
218924680|NCT02864394|DRUG|Docetaxel|Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
218924681|NCT06766201|DRUG|Metformin|Metformin mixed with propylene glycol
218924682|NCT05609487|OTHER|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
219042879|NCT06902142|DEVICE|Adherence measured by MEMS caps|The methodological choices made in this study are justified by the need to assess the effectiveness of bictegravir, taking into account the varying levels of adherence among PLHIV. The use of electronic antiretroviral caps (MEMS caps: https://aardexgroup.com/medication-event-monitoring-system/ ) and the intra-cellular TAF assay to measure drug concentrations will enable a combined, precise and objective assessment of treatment adherence, and constitute the originality of this research.
219538644|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
219538645|NCT05438433|DEVICE|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
219538646|NCT04665063|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
219619991|NCT01861743|OTHER|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
219619992|NCT01861743|OTHER|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
218924683|NCT05609487|DEVICE|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
218924684|NCT06852313|PROCEDURE|Laparoscopic ovarian cyst surgery|Laparoscopic ovarian cyst surgery is any surgery with the goal of removal or drainage of an ovarian cyst. The exact surgical technique will be predefined by randomization.
218924685|NCT06466590|DIAGNOSTIC_TEST|Use of Measurement Instrument|Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions. The results from both sessions will be compared to assess the instrument's consistency and accuracy
218924686|NCT06929299|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the STSA-1301 on the dates specified in the protocol
218924687|NCT06929299|DRUG|Placebo|Subjects will receive the placebo on the dates specified in the protocol
218924688|NCT04900324|DEVICE|MRI guidance|Injections of botulinum toxin performed using MRI guidance
218924689|NCT04900324|DEVICE|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
219042880|NCT06924047|OTHER|Beautifil Flow Plus X|Shofu's Beautifil Flow Plus X F00 a advanced bioactive injectable composite
219042881|NCT06924047|OTHER|EverX Flow|Short fiber reinforced composite
219042882|NCT06922864|OTHER|thermal stimulation|contact heat stimulation at 54℃
219042883|NCT06922864|OTHER|itch|itch the sole of the foot
219042884|NCT02416882|OTHER|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
219042885|NCT02416882|OTHER|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
219042886|NCT02416882|OTHER|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
219538647|NCT04665063|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
219538648|NCT04665063|PROCEDURE|Leukapheresis|Leukapheresis
219538649|NCT03967223|DRUG|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
219619993|NCT06525350|DRUG|Glumetinib tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
219619994|NCT06525350|DRUG|HB1801 (docetaxel, albumin-bound）|An improved new formulations of docetaxel
219619995|NCT06525350|DRUG|Docetaxel|A chemotherapy drug
219619996|NCT03691519|DRUG|Omega-3 treatment|"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."
218924690|NCT05092100|BEHAVIORAL|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
218924691|NCT05092100|OTHER|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
218924692|NCT05092100|BEHAVIORAL|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
218924693|NCT06526533|OTHER|Liberal RBC Transfusion|Liberal transfusion trigger group (patient receives RBC transfusion if Hb \<90g/L).
218924694|NCT06526533|OTHER|Restrictive RBC Transfusion|Restrictive transfusion trigger group (patient receives RBC transfusion if Hb \<70g/L).
218924695|NCT00777153|DRUG|Cediranib|30 mg/day, oral, until progression
218924696|NCT00777153|DRUG|Cediranib|20 mg/day, oral, until progression
218924697|NCT00777153|DRUG|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
219042887|NCT06924723|PROCEDURE|tear duct probing|"In-office tear duct exploratory surgery was performed on the study participants, and the children were closely monitored for healing after the procedure.~The children were closely monitored for healing afterward, and the patients were also examined at 1 week, 1 month, and 2 months after the start of treatment."
219538650|NCT03967223|DRUG|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
219538651|NCT03967223|DRUG|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
219538652|NCT03283345|PROCEDURE|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
219538653|NCT00567320|DRUG|Varenicline|Varenicline up to 2 mg a day
219538654|NCT00567320|DRUG|Sugar pill or Placebo|Placebo
219538655|NCT03133637|DRUG|ceftriaxone|Eligible infants will receive ceftriaxone as standard of care for sepsis
219538656|NCT06082154|DEVICE|ultrasound|Patient will undergo multiorgan ultrasonography
219538657|NCT06126263|DRUG|Linezolid|Adjunctive antitoxin therapy
219538658|NCT06126263|DRUG|Clindamycin|Adjunctive antitoxin therapy
219538659|NCT01423994|PROCEDURE|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
219538660|NCT01423994|PROCEDURE|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate \<50 bpm, High Heart Rate \>165 bpm, and Pause \> 3 seconds.
219538661|NCT03600467|DRUG|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
219538662|NCT02564965|DEVICE|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
219538663|NCT02564965|DEVICE|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
219538664|NCT03474757|OTHER|Data Collection|Data will be extracted from July 2009 to the last available database extraction
219538665|NCT05510830|PROCEDURE|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT \& HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
219538666|NCT04561063|DRUG|Nitazoxanide|Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
218924698|NCT00777153|DRUG|Placebo Cediranib|Oral, until progression
218924699|NCT04060927|DEVICE|SGRT|Surface Guided Radiation Therapy
218924700|NCT05089786|DEVICE|Exablate Neuro Type 1.0 System with Echo Focusing|MR-Guided Focused Ultrasound
218924701|NCT02472470|DEVICE|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
218924702|NCT02079246|DRUG|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
218924703|NCT06305832|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
218924704|NCT06305832|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
218924705|NCT06305832|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
218924706|NCT00208871|PROCEDURE|Stereoscopic Digital Mammography|screening digital 3D mammogram
218924707|NCT02645669|PROCEDURE|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
218924708|NCT02645669|PROCEDURE|Control site|Only Scaling and Root planing was done.
218924709|NCT05647148|BEHAVIORAL|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
218924710|NCT02751190|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
218924711|NCT02751190|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
218924712|NCT02751190|PROCEDURE|Open anterior mesh repair|
218924713|NCT02751190|PROCEDURE|Open Anterior Non Mesh|
218924714|NCT02751190|PROCEDURE|Combined anterior and posterior repair|
218924715|NCT02751190|PROCEDURE|Open preperitoneal mesh repair|
218924716|NCT02534740|DRUG|tafamidis|relative bioavailability
218924717|NCT02534740|DRUG|tafamidis|fasted
218924718|NCT02534740|DRUG|tafamidis|fed
218924719|NCT02823067|OTHER|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
218924720|NCT04271397|OTHER|Multiple blood samples|Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
218924721|NCT04271397|OTHER|Single blood sample|Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
218924722|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 1g|Ginseng extract 1g, parallel design
218924723|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 3g|Ginseng extract 3g, parallel design
218924724|NCT02763280|DIETARY_SUPPLEMENT|Placebo|placebo, parallel design
218924725|NCT02696967|DRUG|CLR325|CLR325 Concentrate for solution for infusion
218924726|NCT02696967|OTHER|Placebo|Normal saline
218924727|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
218924728|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
218924729|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
218924730|NCT04785534|OTHER|Survey Administration|Complete survey
218924731|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
218924732|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
218924733|NCT00940953|DRUG|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
218924734|NCT04165317|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
218924735|NCT04165317|DRUG|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
218924736|NCT05076162|DIAGNOSTIC_TEST|PAED|Delirium positive or negative
218924737|NCT05581550|RADIATION|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
218924738|NCT05581550|RADIATION|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
218924739|NCT06328335|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
218924740|NCT06328335|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
218924741|NCT00112996|DRUG|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
218924742|NCT00112996|OTHER|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
219204917|NCT03907982|PROCEDURE|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
219204918|NCT03907982|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
218924743|NCT00604487|DEVICE|ARD (Atad Ripener Device)|Atad double balloon ripener device
218924744|NCT00604487|DEVICE|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
218924745|NCT00604487|DEVICE|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
218924746|NCT00712439|DRUG|Gabapentin Extended Release tablets|
218924747|NCT00712439|DRUG|Placebo|
218924748|NCT02812342|DRUG|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
218924749|NCT05612620|DIAGNOSTIC_TEST|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
218924750|NCT02532881|OTHER|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
218924751|NCT02532881|OTHER|Treatment as usual|Treatment as usual
218924752|NCT06118398|DRUG|Intravenous methylprednisolone (IVMP) and Efgartigimod|IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
218924753|NCT06118398|DRUG|IVMP|IVMP 800-1000mg/day for 3-5 days.
218924754|NCT02859571|DRUG|Oxytocin|
218924755|NCT00793897|DRUG|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
218924756|NCT00793897|DRUG|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
218924757|NCT00793897|DRUG|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
218924758|NCT03754621|DIAGNOSTIC_TEST|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
218924759|NCT05813600|DRUG|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
218924760|NCT02131506|DRUG|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
218924761|NCT04415203|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)|Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
218924762|NCT04415203|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)|Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
219538667|NCT04561063|DRUG|Sofosbuvir/Daclatasvir|Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
219204919|NCT06676345|PROCEDURE|Surgical treatment|Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)
219204920|NCT06676345|PROCEDURE|Percutaneous treatment|Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
219204921|NCT05590663|OTHER|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
219538668|NCT06187363|PROCEDURE|Tubularized incised plate procedure|Tubularized incised plate urethroplasty procedure
219538669|NCT06187363|PROCEDURE|Other procedures|Other procedures than tubularized incised plate urethroplasty procedure
219538670|NCT00113386|BIOLOGICAL|filgrastim|Consolidation chemotherapy
219538671|NCT00113386|BIOLOGICAL|pegfilgrastim|Consolidation chemotherapy
219619997|NCT03691519|DIETARY_SUPPLEMENT|Placebo|"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."
219619998|NCT04468425|DRUG|Tofacitinib Citrate|Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.
219538672|NCT00113386|DRUG|cisplatin|
218924763|NCT02955173|PROCEDURE|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
218924764|NCT06456502|DEVICE|Non-invasive neuromodulation|The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
218924765|NCT06456502|OTHER|Placebo|The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
218924766|NCT02549872|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
218924767|NCT03208647|OTHER|AA or not|to study their risk factors
219204922|NCT07002671|PROCEDURE|Appendectomy|Appendectomy (Laparoscopic or conventional open surgery)
219204923|NCT07002671|DIAGNOSTIC_TEST|blood sampling|Blood samples, in the preoperative period, routinely collected from the patients of acute appendicitis cases
219538673|NCT00113386|DRUG|docetaxel|
219538674|NCT00113386|PROCEDURE|adjuvant therapy|
219538675|NCT00113386|PROCEDURE|conventional surgery|
219538676|NCT00113386|PROCEDURE|neoadjuvant therapy|
219538677|NCT00113386|RADIATION|radiation therapy|
219538678|NCT06400355|DRUG|Mannitol|in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
219538679|NCT06400355|DRUG|Ringer's Lactate|similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
219538680|NCT01827566|OTHER|gluten|
218924768|NCT06442878|OTHER|Belly Dance Program|All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
218924769|NCT01707732|DRUG|Enoxaparin|Administration of Enoxaparin
218924770|NCT03317184|PROCEDURE|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
218924771|NCT03317184|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
218924772|NCT05368246|DEVICE|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
218924773|NCT01560663|DRUG|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
218924774|NCT06200662|OTHER|Analgesic strategies during the S visit:|Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.
218924775|NCT06200662|OTHER|Analgesic strategies at visit M|Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
218924776|NCT05812872|DRUG|Toothgraft|Particulate dentin
218924777|NCT05812872|DRUG|Allograft|Mineralized corticocancellous allograft
219204924|NCT05954091|DRUG|OH2 Injection|OH2 injection will be given intratumorally, and Q2W.
219204925|NCT06867653|OTHER|Retraining|Each retraining session begins with a 15-minute comprehensive review, followed by hands-on practice
219538681|NCT01827566|OTHER|gluten free flour|
218924778|NCT05812872|DRUG|Alloplast|Beta tri-calcuim phosphate
218924779|NCT03840018|OTHER|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
218924780|NCT00307710|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
218924781|NCT00918255|BIOLOGICAL|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
219204926|NCT04586244|DRUG|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
219204927|NCT04586244|DRUG|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
219204928|NCT04586244|DRUG|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
219204929|NCT04586244|DRUG|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
219538682|NCT03161717|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
218924782|NCT00918255|DRUG|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
218924783|NCT05264922|DRUG|Tisseel Injectable Product|Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
218924784|NCT05264922|BIOLOGICAL|Stromal Vascular Fraction Cells|Stromal Vascular Fraction cells are autologously harvested, processed and reinjected into the affected shoulder.
218924785|NCT02510521|DEVICE|acute muscle exercise by NMES|
218924786|NCT02510521|DEVICE|daily workout sequence with NMES in one week|
218924787|NCT02510521|OTHER|rest situation|
219538683|NCT03161717|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
219538684|NCT02530333|OTHER|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
219538685|NCT03597711|DEVICE|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
219538686|NCT06381128|RADIATION|Cardiac CT|Computed tomography angiography
219538687|NCT02525211|DRUG|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
219538688|NCT02525211|DRUG|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
219538689|NCT00023361|DRUG|Rifabutin|
219538690|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe assistance|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
219538691|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
219538692|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ|Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
219538693|NCT00247247|DRUG|Comtess®|
218924788|NCT01849991|BIOLOGICAL|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
219619999|NCT00586703|DEVICE|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
218924789|NCT01849991|BIOLOGICAL|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
218924790|NCT00001614|DRUG|Chicken type II collagen|
218924791|NCT02341677|PROCEDURE|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
218924792|NCT02263027|BIOLOGICAL|Vaccine|Licensed trivalent inactivated influenza vaccine
218924793|NCT00722943|OTHER|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
218924794|NCT00722943|OTHER|no intervention|The infant will not be touched by the therapist.
218924795|NCT04766840|DRUG|CAR-T cells|Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
218924796|NCT05442788|BIOLOGICAL|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
218924797|NCT05442788|BIOLOGICAL|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
218924798|NCT05442788|BIOLOGICAL|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
218924799|NCT03900091|DIAGNOSTIC_TEST|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
218924800|NCT03900091|DIAGNOSTIC_TEST|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
218924801|NCT03900091|DIAGNOSTIC_TEST|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
218924802|NCT03900091|OTHER|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
219538694|NCT05074576|OTHER|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
219538695|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
219538696|NCT01480544|OTHER|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
218924803|NCT05791604|DIETARY_SUPPLEMENT|probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG|Take probiotics, 2g each time, twice a day, for 12 weeks
218924804|NCT05791604|DIETARY_SUPPLEMENT|Prebiotics with galactomannan and oligofructose|Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
218924805|NCT01232023|DRUG|Indobufen|Single Oral Dose of
218924806|NCT01982097|DRUG|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
218924807|NCT01686542|PROCEDURE|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
218924808|NCT01686542|PROCEDURE|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
218924809|NCT04570137|DIETARY_SUPPLEMENT|Dietary fiber supplementation|"1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory"
218924810|NCT04500899|DRUG|Mydfrin|A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. BP will be monitored after each bolus of phenylephrine. Subsequent Mydfrin injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
218924811|NCT00637455|DRUG|fexofenadine HCl|
219538697|NCT01480544|OTHER|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
218924812|NCT03557034|DEVICE|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
218924813|NCT04259996|PROCEDURE|PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT|The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
218924814|NCT00692835|PROCEDURE|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
218924815|NCT00692835|PROCEDURE|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
218924816|NCT02494323|DEVICE|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
218924817|NCT01962740|DEVICE|Drug-eluting stent implantation|
218924818|NCT02850926|OTHER|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
218924819|NCT03403283|OTHER|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
218924820|NCT03403283|OTHER|Healthy Controls 15 age matched control subjects|
218924821|NCT04324411|DRUG|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
219365585|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 1|"Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
219538698|NCT05956925|BEHAVIORAL|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
219538699|NCT03399812|DIETARY_SUPPLEMENT|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
219538700|NCT03399812|DIETARY_SUPPLEMENT|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
219538701|NCT04717960|PROCEDURE|nasal submucosal injection of platelet rich plasma|"* The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months"
219538702|NCT04782765|DRUG|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
219538703|NCT02849457|DRUG|Early Vigabatrin|Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
219538704|NCT02849457|DRUG|Delayed Vigabatrin (Placebo)|Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
219538705|NCT00161850|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
219538706|NCT03463850|RADIATION|Dual Energy CT (DECT)|Dual Energy CT (DECT)
219538707|NCT03463850|RADIATION|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
219538708|NCT05374876|OTHER|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
219538709|NCT02257658|DRUG|Doxycycyline|
219538710|NCT02257658|BEHAVIORAL|Incentive|
219538711|NCT00589186|BIOLOGICAL|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
219538712|NCT00589186|DRUG|celecoxib|
219538713|NCT00589186|OTHER|flow cytometry|
219538714|NCT00589186|OTHER|immunoenzyme technique|
219538715|NCT00589186|OTHER|laboratory biomarker analysis|
218924822|NCT00719472|DRUG|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
218924823|NCT00719472|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
218924824|NCT00719472|DRUG|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
218924825|NCT00719472|DRUG|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
218924826|NCT01244893|DEVICE|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
218924827|NCT01244893|DEVICE|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
219042888|NCT06924723|PROCEDURE|Lacrimal sac massage|At the time of the visit, the patient's parents (one of them) were given Standardized tear duct massage (Crigler massage)Teaching and hands-on practice were performed, with the researcher confirming the standardization of movements.Subsequent massages were performed by the family member who received the training, and the child's family swiped the card to access the program.completed by the family member of the child, who scanned the code to enter the small program punch card group, according to the standardized process of massage (the frequency of massage was not less than 3 times/day, each time no less than 4 eight beats)And complete the punch card on time (each punch card interval should be greater than 2 hours).(each clock interval should be more than 2 hours).
219538716|NCT05885594|DRUG|[18F]NOS|\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
219538717|NCT05323916|BEHAVIORAL|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
219538718|NCT05323916|BEHAVIORAL|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
219538719|NCT05323916|BEHAVIORAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
219538720|NCT05323916|BEHAVIORAL|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
219538721|NCT02197481|PROCEDURE|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
219538722|NCT02197481|DEVICE|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
219538723|NCT03673670|DRUG|RPL554 Suspension|A PDE3/4 inhibitor
219538724|NCT03673670|DRUG|Placebo|A placebo solution
219538725|NCT03673670|DRUG|Tiotropium/olodaterol (Respimat)|An anticholinergic/β-agonist combination medication
219538726|NCT00308152|DRUG|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
219538727|NCT04408794|DRUG|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
219538728|NCT01528462|OTHER|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
219538729|NCT00187720|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
219042889|NCT00006028|DRUG|cisplatin|
219042890|NCT00006028|DRUG|gemcitabine hydrochloride|
219042891|NCT06924736|DEVICE|Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter|Randomly assign subjects to the experimental group to treat the lesions with an intravascular shockwave therapy device/disposable coronary artery shockwave catheter.
219538730|NCT06324825|DRUG|Fuzhegn Nizeng Decoction|Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
219538731|NCT06324825|DRUG|Moluodan granules|Subjects taking prepared Moluodan granules 9g twice daily for 6 month.
219538732|NCT01885117|BIOLOGICAL|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
219538733|NCT05336643|DEVICE|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
219538734|NCT04258917|DEVICE|Study withdrawn|Study withdrawn
219538735|NCT04987411|DIAGNOSTIC_TEST|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
219620000|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).
219620001|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.
219620002|NCT04851977|BIOLOGICAL|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).
219620003|NCT05526677|DEVICE|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
218924828|NCT06516380|DEVICE|Combined treatment of Cyberdyne HAL single joint with TecnoBody D-Wall and Walker View 3.0 SCX devices|HAL-SJ sessions were conducted 5 days a week for 3 months and 2 hours a day for a total of 60 sessions. HAL-SJ application was performed in cybernic voluntary control (CVC) mode for 90 minutes. In addition to each HAL-SJ session, balance exercises were performed with TecnoBody D-Wall for 30 minutes net.
218924829|NCT02196948|OTHER|Electrolysis Percutaneous Therapeutic (EPTE)|
218924830|NCT02196948|OTHER|Eccentric exercise|
218924831|NCT00753181|OTHER|Nutritional Formula|nutritional shake daily
218924832|NCT00753181|OTHER|Usual diet|usual dietary habits
218924833|NCT00753181|OTHER|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
219620004|NCT01422213|DRUG|Placebo|capsules; daily; orally
219620005|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
218924834|NCT02740101|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
218924835|NCT02740101|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
218924836|NCT01136083|BEHAVIORAL|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
219620006|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
219620007|NCT04146441|COMBINATION_PRODUCT|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
219620008|NCT04146441|DRUG|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
218924837|NCT01136083|OTHER|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
218924838|NCT00842296|DEVICE|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
218924839|NCT05170997|DIETARY_SUPPLEMENT|Cows' milk|Intervention groups will receive a free 12 week supply of cows' milk equating to a pint a day for study participants. Milk is provided by Lakeland dairies.
218924840|NCT05170997|OTHER|British Dietetic Association Iodine Fact Sheet.|All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
218924841|NCT06311097|OTHER|Fermented dairy|Participants will consume 300g of yogurt daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
218924842|NCT06311097|OTHER|Non-fermented dairy|Participants will consume 300g of milk daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
218924843|NCT03041506|DRUG|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
218924844|NCT03041506|PROCEDURE|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
219620009|NCT01860365|OTHER|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
219620010|NCT01860365|OTHER|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
219620011|NCT00144820|DRUG|Injection of Hyaluronan or Saline|
218924845|NCT03041506|DRUG|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
218924846|NCT03041506|DRUG|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
218924847|NCT04558294|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
218924848|NCT04558294|DRUG|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
218924849|NCT04558294|DRUG|Ketanserin|A dose of 40 mg Ketanserin will be administered.
218924850|NCT02559804|OTHER|survival and late effects|survival and late effects
218924851|NCT05562219|DRUG|QA108 granules|Take the medication as required for 24 weeks
218924852|NCT05562219|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
218924853|NCT00711191|BIOLOGICAL|monoclonal antibody|CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles
218924854|NCT00711191|DRUG|chemotherapy|gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
218924855|NCT00074048|DRUG|BL22|Dosing via IV on Days 1,3, and 5.
218924856|NCT02118961|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
218924857|NCT02118961|BIOLOGICAL|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
218924858|NCT00460083|DRUG|Elidel(R) (pimecrolimus 1%)|
218924859|NCT00460083|DEVICE|EpiCeram(R) -ceramide based barrier repair cream|
218924860|NCT00104923|DRUG|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
218924861|NCT04433988|DRUG|Pentoxifylline|Pentoxifylline 400 mg SR tablet
218924862|NCT04433988|DRUG|Placebo|Placebo tablet
218924863|NCT01599624|BEHAVIORAL|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
219042892|NCT06924736|DEVICE|Non - compliant balloon dilatation catheter|Randomly assign subjects to the control group to treat the lesions with a non - compliant balloon catheter.
219538736|NCT04987411|DIAGNOSTIC_TEST|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
219538737|NCT04987411|DIAGNOSTIC_TEST|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
219538738|NCT04987411|DIAGNOSTIC_TEST|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
219538739|NCT04238754|DRUG|Epidiolex|Epidiolex 100 mg/mL Oral Solution
219538740|NCT04238754|DRUG|Placebo|Cherry syrup oral solution
219538741|NCT02083328|DIETARY_SUPPLEMENT|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
219538742|NCT02083328|DIETARY_SUPPLEMENT|Placebo (Mannitol)|Mannitol filled in gelatine capsules
219538743|NCT02362997|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
219538744|NCT00828698|OTHER|No intervention|
219538745|NCT05256147|DRUG|Ibuprofen|Patient will receive ibuprofen 400 mg before the phototherapy session.
219538746|NCT02505347|OTHER|No splint|Can move arm as tolerated with no restrictions on mobility
219538747|NCT02505347|DEVICE|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
219538748|NCT00392847|BEHAVIORAL|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
219538749|NCT00392847|BEHAVIORAL|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
219538750|NCT06087861|RADIATION|External Beam Radiotherapy|Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
219538751|NCT05963178|BEHAVIORAL|Pre-operative counselling|"A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions."
219538752|NCT04702971|DRUG|Flunarizine|The flunarizine will be given per clinical routine
219042893|NCT06924190|DRUG|Budiair® 200ug/puff inhalation aerosol|The subjects randomly received one puff Budiair®(budesonide inhalation aerosol 200ug/puff )
219538753|NCT04702971|OTHER|healthy control|no intervention for healthy control
219538754|NCT05070572|DEVICE|Accuryn Monitoring System|Utilization of the Accuryn Monitoring System to measure intraabdominal pressure and urine output during laparoscopic inguinal hernia repair surgery.
219620012|NCT00765102|DRUG|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
218924864|NCT01599624|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad \& Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
218924865|NCT05957380|DRUG|DA-2803|All participants are administered one tablet per day for 48 weeks
218924866|NCT05957380|DRUG|DA-2803-R|All participants are administered one tablet per day for 48 weeks
218924867|NCT05957380|DRUG|Placebo of DA-2803|All participants are administered one tablet per day for 48 weeks
218924868|NCT05957380|DRUG|Placebo of DA-2803-R|All participants are administered one tablet per day for 48 weeks
218924869|NCT06401239|OTHER|Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
218924870|NCT06401239|OTHER|Self-efficacy|Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.
218924871|NCT06401239|OTHER|Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
218924872|NCT03605485|DEVICE|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
218924873|NCT05972317|OTHER|Low FODMAP dietary regimen|"intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2."
218924874|NCT06584474|DRUG|Azithromycin neubilization|"nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro"
218924875|NCT06584474|DEVICE|Lung ultrasound|Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
219042894|NCT06924190|DRUG|budesonide 200ug/puff inhalation aerosol|The subjects randomly received one puff budesonide inhalation aerosol(200ug/puff )
219042895|NCT06923475|DRUG|Pembrolizumab|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
219042896|NCT06923475|DRUG|Gemcitabine, Cisplatin|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
219365586|NCT01078805|DRUG|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
219365587|NCT03911726|RADIATION|Single PET/MR-measurement|A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
219365588|NCT05107817|OTHER|Exercise intervention|A ball catching and throwing exercise.
219365589|NCT06419933|OTHER|The SuperKids Program|The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
219365590|NCT02910245|DRUG|Mercaptopurine (Purinethol)|
219365591|NCT02910245|DRUG|Placebo|
219365592|NCT02910245|DRUG|Mesalamine|
219365593|NCT02910245|DRUG|Prednisone|
219365594|NCT05767723|DRUG|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
219365595|NCT05767723|DRUG|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
219365596|NCT04147351|DRUG|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
219365597|NCT02715687|DRUG|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
219365598|NCT02715687|DRUG|Placebo|Will receive 30 days treatment with oral placebo of 200mg
219365599|NCT05558332|BEHAVIORAL|Youth-Nominated Support Teams for CHR|"Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk."
219365600|NCT02474329|OTHER|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.
219365601|NCT02474329|DEVICE|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
219538755|NCT01518972|DRUG|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
219042897|NCT06923059|OTHER|AI-assisted endoscopy recovery assessment|The intervention group will be assessed by the AI model regularly, which will be installed in a smartphone attached to the head of the stretcher once the patient in this group arrives at the recovery room. After the recovery nurse starts the AI application following the standard-of-care baseline assessment of vital signs, the AI application will prompt an automatic voice alarm to wake up the patient by asking if he/she is awake every 10 minutes.
219042898|NCT06923852|BEHAVIORAL|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).
219538756|NCT01518972|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
219538757|NCT04582318|BIOLOGICAL|NGM621|NGM621 will be administered via IV infusion
219538758|NCT04582318|BIOLOGICAL|Placebo|Placebo will be administered via IV infusion
219538759|NCT00189293|DRUG|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
219538760|NCT00189293|OTHER|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
219538761|NCT00803478|PROCEDURE|LASIK|
219538762|NCT05611593|DRUG|FOL100|FOL100 lotion
219538763|NCT05611593|DRUG|Propecia 1Mg Tablet|Oral Finasteride
219538764|NCT02591927|DRUG|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
219538765|NCT02591927|DRUG|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
219538766|NCT05552482|OTHER|Identification of predictive factors|Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
219538767|NCT05742971|DEVICE|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
219538768|NCT04180280|BEHAVIORAL|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
219538769|NCT04180280|BEHAVIORAL|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
219538770|NCT03810950|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
219538771|NCT03810950|BEHAVIORAL|Reading Newspaper|Participants read newspaper
219538772|NCT03810950|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
219538773|NCT01203267|DRUG|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
219538774|NCT06552780|DEVICE|TENs , ultrasound therapy|effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
219538775|NCT04653363|OTHER|assessments|All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
219538776|NCT06196281|OTHER|wooble board proprioceptive training|this includes wooble board proprioceptive training twice a day for four weeks
219538777|NCT06196281|OTHER|multi-station proprioceptive training|this includes multi-station proprioceptive training twice a day for four weeks
219538778|NCT05187923|DIAGNOSTIC_TEST|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
219538779|NCT00057538|BEHAVIORAL|Mantram Repetition|
219538780|NCT05138003|DIAGNOSTIC_TEST|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
219538781|NCT05138003|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
219538782|NCT05138003|DIAGNOSTIC_TEST|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
219538783|NCT05138003|DIAGNOSTIC_TEST|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
219538784|NCT00575159|DRUG|GSK189075|investigational drug
219538785|NCT00575159|DRUG|placebo|placebo comparator
219538786|NCT04374487|DRUG|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
219538787|NCT04374487|OTHER|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
219538788|NCT00006256|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
219538789|NCT00006256|PROCEDURE|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
219538790|NCT00006256|RADIATION|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
219538791|NCT02224742|DEVICE|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
218924876|NCT01807988|BEHAVIORAL|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
219538792|NCT02224742|OTHER|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~* Formal assessment of ulcer and surrounding skin~* Provision of any necessary off-loading~* Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~* Appropriate dressing products~* Appropriate antibiotic therapy~* Nutrition and self care~* Optimal glycaemic control~* Revascularisation if deemed clinically necessary~* Continued close observation"
218924877|NCT00072839|DRUG|ALX-0600|teduglutide
219538793|NCT05841628|DEVICE|532 nm laser treatment|The port wine birthmark will be treated with the DermaV 532 nm laser.
219538794|NCT04470115|OTHER|General anesthesia|Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
219538795|NCT04470115|OTHER|Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks|The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
219538796|NCT01805505|PROCEDURE|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
219538797|NCT01805505|PROCEDURE|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
219620013|NCT00765102|DRUG|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
219620014|NCT06345859|BEHAVIORAL|Heart rate variability biofeedback|This is a Phase 2 parallel intervention design with random assignment. We will randomly assign participants to one of two biofeedback conditions. Both conditions involve completing breathing exercises at home, 30 minutes per day for 10 days, while receiving continuous feedback about parasympathetic activity from the computer.
219620015|NCT05669625|BIOLOGICAL|Investigational live attenuated varicella vaccine|0.5 ml/vial
219620016|NCT05669625|BIOLOGICAL|Placebo of live attenuated varicella vaccine|0.5 ml/vial
219620017|NCT02857816|DEVICE|NURO System PTNM Therapy|
219620018|NCT03197389|DRUG|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
219620019|NCT02940756|DRUG|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
218924878|NCT00072839|DRUG|placebo|placebo solution injected subcutaneously
218924879|NCT00072839|DRUG|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
218924880|NCT00072839|DRUG|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
218924881|NCT00072839|DRUG|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
219042899|NCT06923722|DIETARY_SUPPLEMENT|High-flavonoid grape intervention|High-flavonoid grape powder: 60 g, equivalent to 300 g fresh grapes. Total polyphenols: 437 mg/100g).
218924882|NCT00072839|DRUG|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
218924883|NCT03439228|DEVICE|Lumbar brace|3 months of lumbar brace wear
218924884|NCT06410092|DRUG|FTL001|IV infusion every 2 weeks
218924885|NCT03440164|OTHER|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
219042900|NCT06923722|DIETARY_SUPPLEMENT|Low-flavonoid grape intervention|60 g powder isocaloric-matched control (Total polyphenols: \< 60 mg)
218924886|NCT05969652|OTHER|Heavy slow resistance training|"Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets\*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3\*15 2-3.week 3\*12 4th-5th week 3\*10 6th week 3\*8"
218924887|NCT05969652|OTHER|Eccentric exercise training|"Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week."
219620020|NCT02940756|DRUG|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days."
219620021|NCT02940756|DRUG|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
219620022|NCT06471049|PROCEDURE|Benign Hysterectomy|removal of the uterus
219620023|NCT00053716|DRUG|Liprostin [liposomal Prostaglandin E1]|
219620024|NCT00602251|DRUG|Terbinafine|
219620025|NCT05636696|BEHAVIORAL|Samen Minder Moe (Dutch intervention name)|'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.
219620026|NCT01325363|DEVICE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
219620027|NCT05715411|OTHER|Placebo with light therapy glasses|Placebo
219620028|NCT05715411|OTHER|light therapy with light therapy glasses|light therapy
219620029|NCT02054429|DRUG|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
219620030|NCT04129125|DEVICE|Zoom Reperfusion System|Thrombectomy
219620031|NCT04484142|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
219620032|NCT02547012|DRUG|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
218924888|NCT04341870|DRUG|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
218924889|NCT04341870|DRUG|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
218924890|NCT04341870|DRUG|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
218924891|NCT05125588|DRUG|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
218924892|NCT05125588|DRUG|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
219538798|NCT03538327|DRUG|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
219620033|NCT02547012|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
219620034|NCT06194838|DEVICE|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
218924893|NCT06438653|OTHER|No-intervenyion|No-intervenyion
219042901|NCT05686642|DRUG|LT3001 Drug:high dose|Administered by intravenous infusion.
219042902|NCT05686642|DRUG|Placebo|Administered by intravenous infusion.
219538799|NCT03986801|OTHER|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
219620035|NCT06194838|DEVICE|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
219620036|NCT06809543|DEVICE|Polynucleotides (Tropho Tend)|"Tropho Tend is administered by injecting the solution at level of muscular-tendineal (MJT) or osteo-tendineal junctions (OTJ) using a fine-gauge needle (usually 25-30G).~Before injecting the product, the target area will be disinfected with alcohol or another antiseptic, with the antiseptic removed with physiologic sterile solution.~Total number of treatments will consist in 3 Tropho Tend administrations: at T0 - basal visit;~* T1 - after 2 weeks;~* T3 - after 4 weeks."
219620037|NCT06809543|PROCEDURE|Rehabilitation physiotherapy|Rehabilitation physiotherapy (standard of care)
219620038|NCT03314636|DRUG|Carfilzomib|See in arm description
219620039|NCT03314636|DRUG|Lenalidomide|See in arm description
219620040|NCT03314636|DEVICE|PET-CT|See in arm description
219620041|NCT03314636|DRUG|Dexamethasone|See in arm description
219620042|NCT06973356|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.|Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）.
219620043|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
219620044|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
219620045|NCT06502379|DRUG|AZD8965|AZD8965 will be administered orally.
219620046|NCT06502379|OTHER|Placebo|Placebo will be administered orally.
218924894|NCT04513483|DEVICE|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
218924895|NCT04513483|DEVICE|Placebo|Observation. Treat AF as cardiologist's discretion.
218924896|NCT03809104|OTHER|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
219538800|NCT06121973|BEHAVIORAL|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
219538801|NCT04229225|DRUG|UBX0101|Investigational drug intra-articular (IA) injection
218924897|NCT06266091|DRUG|M701|Intra-peritoneal infusion of M701 combined with system therapy
218924898|NCT06266091|DRUG|paracentesis|paracentesis combined with system therapy
219538802|NCT04229225|OTHER|Placebo|Placebo intra-articular (IA) injection
219538803|NCT03733444|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
219620047|NCT06813703|DEVICE|Using an electrical stimulation device to relieve pain during colonoscopy|In the electrical stimulation group, the device's current intensity will be adjusted to the maximum tolerance below the participant's pain threshold, while in the control group, the current intensity will be set to the minimum.
219620048|NCT01261728|DRUG|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
219620049|NCT06587893|OTHER|echography|performance of ultrasound of the scapular regions to identify and measure the suprascapular notch in our group of healthy adult volunteers.
219538804|NCT03733444|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
219538805|NCT00556322|DRUG|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
219538806|NCT00556322|DRUG|erlotinib [Tarceva]|150mg po daily
219538807|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
219538808|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
219538809|NCT01756326|DRUG|PREOB® Implantation|
219538810|NCT01756326|PROCEDURE|Bone Autograft|
219620050|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
218924899|NCT02968004|DRUG|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
218924900|NCT02968004|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
218924901|NCT04197921|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
219042903|NCT05686642|DRUG|LT3001 Drug:low dose|Administered by intravenous infusion.
219042904|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
219042905|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
219538811|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
219538812|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
219538813|NCT05947591|BEHAVIORAL|foot posture index|the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
219538814|NCT01899755|DRUG|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
218924902|NCT05121064|BEHAVIORAL|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
218924903|NCT05121064|BEHAVIORAL|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
218924904|NCT05121064|BEHAVIORAL|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
218924905|NCT05531201|PROCEDURE|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
218924906|NCT06353893|DEVICE|Anika Integrity Implant System|The implant is a porous, flexible construct knitted using HYAFF® fibers and designed to support cell infiltration and regenerative healing. HYAFF is Anika's proven and proprietary esterified HA technology that resorbs over time as tissue remodels. Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a truly unique and differentiated solution for shoulder surgeons to treat rotator cuff tears.
218924907|NCT05766813|DRUG|Lenrispodun|Lenrispodun 30 mg tablets administered orally, once daily.
218924908|NCT05766813|DRUG|Placebo|Matching tablets administered orally, once daily.
218924909|NCT02115048|DRUG|Letrozole|
218924910|NCT02115048|DRUG|Afatinib|
218924911|NCT05406674|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
218924912|NCT05406674|DRUG|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
218924913|NCT03722238|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
218924914|NCT06132945|DRUG|Cabozantinib|Cabozantinib (40 mg PO daily)
218924915|NCT06132945|DEVICE|Nivolumab|Nivolumab (480 mg IV Day 1)
218924916|NCT06132945|RADIATION|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
218924917|NCT05327296|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
218924918|NCT05327296|DRUG|Propofol|Intravenous infusion of propofol
218924919|NCT02451982|DRUG|Cyclophosphamide|200 mg/m2 IV
219538815|NCT01899755|DRUG|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
219538816|NCT01899755|DRUG|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
219620051|NCT06052813|DRUG|BN104 monotherapy|Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
219620052|NCT06052813|DRUG|BN104 monotherapy|Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)
219620053|NCT06052813|DRUG|BN104 monotherapy - rp2d|receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)
219620054|NCT06824974|BEHAVIORAL|Time-restricted eating plus healthy diet|Subjects will restrict calorie consumption to 8-10 hours during the day plus will follow a healthy plant-based diet.
218924920|NCT02451982|BIOLOGICAL|GVAX pancreatic cancer|5x10\^8 cells intradermal injection
218924921|NCT02451982|DRUG|Nivolumab|480 mg IV
218924922|NCT02451982|DRUG|Urelumab|8 mg IV
218924923|NCT02451982|DRUG|BMS-986253|2400 mg IV
218924924|NCT04417517|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
218924925|NCT04417517|DRUG|azacitidine|Hypomethylating agent (HMA)
219538817|NCT01788423|DEVICE|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
219538818|NCT03637764|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219538819|NCT03637764|DRUG|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219538820|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine|Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
219538821|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine|Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
219620055|NCT05986149|BEHAVIORAL|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
219620056|NCT03181633|DRUG|ACH-0144471|ACH-0144471 will be administered to all participants enrolled in the study.
219620057|NCT06668883|PROCEDURE|Sputum collection for molecular analysis|Sputum collection to be used with syndromic multiplex PCR testing
219620058|NCT06668883|DEVICE|Breath and cough collection for molecular analysis|Breath and cough collection with two proprietary devices to be used with syndromic multiplex PCR testing
218924926|NCT03898544|DEVICE|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
218924927|NCT03898544|DEVICE|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
219620059|NCT06995651|DRUG|Dorzagliatin|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
218924928|NCT02740023|DEVICE|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
218924929|NCT02740023|DEVICE|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
219042906|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
219042907|NCT00567775|DRUG|human insulin|
219538822|NCT03911037|DRUG|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
219620060|NCT06995651|DRUG|Placebo|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
219620061|NCT00665782|OTHER|laboratory biomarker analysis|
219620062|NCT00665782|OTHER|questionnaire administration|
219538823|NCT03911037|DRUG|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
219620063|NCT00665782|OTHER|study of socioeconomic and demographic variables|
219620064|NCT00665782|PROCEDURE|assessment of therapy complications|
219620065|NCT00665782|PROCEDURE|psychosocial assessment and care|
219620066|NCT00665782|PROCEDURE|therapeutic conventional surgery|
219620067|NCT03211676|DEVICE|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
219620068|NCT03211676|DEVICE|Elisio-21H|hemodialysis with Elisio-21H dialyzer
219620069|NCT01838369|DRUG|BI-505|
219620070|NCT05866835|OTHER|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position"
219620071|NCT05866835|OTHER|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
219620072|NCT05866835|OTHER|Evaluation of comfort level:|Collection from participants (self-questionnaire)
219620073|NCT06676917|DRUG|Datopotamab deruxtecan|Trophoblast cell surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody (MAAP-9001a), a GGFG tetra-peptide linker, and a Topo I inhibitor (MAAA-1181a, derived from exatecan). Upon binding to TROP2 on the cell surface, Dato-DXd internalizes into the cells and releases MAAA-1181a in the cytoplasm which inhibits cell replication and promotes cell apoptosis.
219620074|NCT04555317|COMBINATION_PRODUCT|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
219620075|NCT06919536|OTHER|No intervention (observational study)|There is no intervention, this is a observational study,
219042908|NCT00567775|DRUG|inhaled human insulin|
219042909|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
219620076|NCT07005817|BEHAVIORAL|Experimental Health Communication|"Participants view a brief psychoeducational video about the value of connecting in-person with others and receive guided instructions for creating if-then behavioral plans for increasing moments of high-quality social connection. Over the next four weeks, they view messages on a simulated social media platform to encourage in-person, connections with strangers and acquaintances on a platform called Invibe. The Invibe feed will also have approximately 15 background posts each day from users' about their lives, including food, fitness, pets, and travel, common on social media platforms.~During the 4-week Invibe phase, after participants complete each Day Report, they will view the Invibe simulated social media feed. Participant exposure to each target message will be both passive, via that day's feed, and forced, via inclusion on the Day Report. Participants will see 12 social media messages during this 4-week phase, shown in random order within the first 3 daily posts."
219538824|NCT06066047|OTHER|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
219538825|NCT06066047|OTHER|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
219538826|NCT01660945|DRUG|placebo|
219538827|NCT01660945|DRUG|vytorin|
218924930|NCT03754777|PROCEDURE|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
219620077|NCT07005817|BEHAVIORAL|Simulated Social Media Platform Only|To rule out placebo and nonspecific effects, the Keep Social RCT engenders positive expectations in all participants by promoting the use of Invibe as a beta social media platform to build and maintain social ties, a framing that mirrors information-as-usual for wellness through social media connections. Those in the Placebo Control condition receive no further health communication (view no psychoeducational video) and encounter all background content on Invibe (all target messages excluded) with control posts that feature unrelated content.
219620078|NCT07006636|OTHER|Watermelon Juice + liquid meal test at baseline|WMJ will be purchased from a commercially available brand. The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
219620079|NCT07006636|OTHER|Sweetened placebo beverage +liquid meal test at baseline|The placebo beverage made of water and sugar will match the sugar content provided in 355 ml of WMJ (approximately 10-20 g). The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
219538828|NCT06302127|OTHER|Team-based care|The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
219620080|NCT06141655|DRUG|Influenza vaccine|Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
219620081|NCT05421221|DEVICE|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
219620082|NCT06616636|DRUG|Azacitidine|Given by IV
219620083|NCT06616636|DRUG|Rezatapopt|Given orally with food
219620084|NCT02816372|OTHER|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
219620085|NCT04671940|OTHER|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies \& subsequent resections
219620086|NCT04029623|OTHER|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
218924931|NCT00664625|DRUG|BMS-791325|Capsules, Oral, Once Daily, Single Dose
218924932|NCT00664625|DRUG|Placebo|Capsules, Oral, Once Daily, Single Dose
218924933|NCT00093041|DRUG|Zalutumumab|Weekly infusion
218924934|NCT02446522|PROCEDURE|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
218924935|NCT02446522|PROCEDURE|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
218924936|NCT03397069|PROCEDURE|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
219042910|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
219042911|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
219538829|NCT06302127|PROCEDURE|Risk-stratified care pathway|Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
219538830|NCT06302127|BEHAVIORAL|Strengthened health education|The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
219538831|NCT06302127|OTHER|Financial incentives for integration of care|Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
219538832|NCT06302127|OTHER|Supporting health information system|A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.
219620087|NCT04029623|OTHER|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
219620088|NCT06207318|BEHAVIORAL|Acceptance and commitment therapy|The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
219620089|NCT02236039|PROCEDURE|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
219620090|NCT07018180|DEVICE|Use of COVER patchs for continuous glucose monitoring sensor|"The intervention consists of wearing a patch over the continuous glucose monitoring (CGM) sensor typically used by the participant.~The COVER patch is compatible with a wide range of CGM devices on the market, including Freestyle 2 or 3, Dexcom G6/One or G7/One+, and Guardian Sensor 4 or Simplera.~At each sensor change, the participant is required to apply a new COVER PATCH over the CGM sensor. This is done throughout the entire duration of their participation in the study, which lasts for 4 months."
219620091|NCT05303194|BEHAVIORAL|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
219620092|NCT05303194|BEHAVIORAL|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
219620093|NCT06615921|OTHER|No Intervention|This is a non-interventional study.
219042912|NCT02929576|DRUG|Placebo|
219042913|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
219620094|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
219620095|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
219620096|NCT01210560|DRUG|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
219620097|NCT01210560|DRUG|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
219620098|NCT01210560|DRUG|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
219620099|NCT04837196|DRUG|ASP7517|Intravenous (IV)
218924937|NCT03397069|PROCEDURE|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
218924938|NCT03397069|PROCEDURE|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
218924939|NCT05108012|BIOLOGICAL|NK cell therapy|Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
218924940|NCT03408392|DRUG|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
218924941|NCT03408392|DRUG|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
219620100|NCT04837196|DRUG|Pembrolizumab|Intravenous (IV)
218924942|NCT01082068|DRUG|XL147 (SAR245408)|given orally once daily as tablets
218924943|NCT01082068|DRUG|XL765 (SAR245409)|given orally twice daily as capsules
218924944|NCT01082068|DRUG|letrozole (Femara)|given orally once daily as tablets
218924945|NCT04668456|DRUG|Dexmedetomidine|the drug administered either subtenon ot iv
218924946|NCT04668456|DRUG|lidocaine 2%|subtenon injection
218924947|NCT04668456|DRUG|bupivacine 0.5%|subtenon injection
218924948|NCT04668456|DRUG|Normal saline|either subtenon or iv
218924949|NCT06300112|BEHAVIORAL|YOGA|Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
218924950|NCT03303976|BIOLOGICAL|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
218924951|NCT03303976|BIOLOGICAL|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
218924952|NCT00885170|DRUG|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
218924953|NCT00885170|DRUG|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
218924954|NCT00885170|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
219620101|NCT05271175|DEVICE|Active intermittent theta burst stimulation|An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
219620102|NCT05271175|DEVICE|Sham intermittent theta burst stimulation|"An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull."
219620103|NCT00991887|RADIATION|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
219620104|NCT06130566|DRUG|Amlitelimab|Injection solution SC injection
219620105|NCT06130566|DRUG|Placebo|Injection solution SC injection
219620106|NCT07023588|DRUG|Venetoclax|Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.
219620107|NCT06872450|OTHER|informational intervention|informational intervention
219620108|NCT02070705|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
219620109|NCT02070705|DRUG|Ferumoxytol|Given IV
219620110|NCT06699212|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
218924955|NCT00885170|DIETARY_SUPPLEMENT|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
218924956|NCT06204640|DRUG|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
219620111|NCT06699212|BIOLOGICAL|Pembrolizumab|200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
219620112|NCT06699212|DRUG|Carboplatin|Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
219620113|NCT06699212|DRUG|Cisplatin|100 mg/m\^2 IV infusion, Q3W up to 6 cycles
219620114|NCT06699212|DRUG|5-fluorouracil|1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
219620115|NCT06699212|DRUG|Paclitaxel|100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
218924957|NCT03771664|DRUG|SAGE-217|Administered as capsules.
218924958|NCT03771664|DRUG|Placebo|Administered as capsules.
218924959|NCT03703284|OTHER|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
218924960|NCT00783068|DRUG|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
218924961|NCT00783068|DRUG|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
218924962|NCT00783068|DRUG|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
218924963|NCT03276338|BEHAVIORAL|HOLA|To increase condom use and HIV testing
218924964|NCT03207295|DRUG|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
218924965|NCT03207295|DRUG|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
218924966|NCT00561925|DRUG|nevirapine IR|200 mg BID
218924967|NCT00561925|DRUG|nevirapine XR|400 mg QD
218924968|NCT04941209|DEVICE|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
218924969|NCT04941209|DIAGNOSTIC_TEST|(PPA >95%) FDA EUA RT-PCR|Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
218924970|NCT04941209|RADIATION|HR-CT-scan|High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
218924971|NCT00891904|BIOLOGICAL|cetuximab|Given IV
218924972|NCT00891904|RADIATION|stereotactic body radiation therapy|Undergoing Radiotherapy
218924973|NCT04871646|DRUG|CKD-314+SOC|CKD-314 is administered intravenously and standard of care is also performed.
219042914|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
219042915|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
219042916|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
219620116|NCT06699212|DRUG|Docetaxel|75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
219620117|NCT03640338|DEVICE|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
219620118|NCT06880419|DRUG|Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection|"Model-predicted patients at high risk (HR): Recombinant humanized anti-CD25 monoclonal antibody: 50 mg/day when the post-transplant model predicts high risk in the second week post-prediction and 25 mg/day in the fourth and sixth weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at moderate risk (MR): Recombinant anti-CD25 humanized monoclonal antibody: 25 mg/day when the model predicts intermediate risk post-transplantation and at the 2nd, 4th, and 6th weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at low-risk (LR): A conventional aGVHD prevention regimen only was used."
219620119|NCT06691425|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (5 x 8 Gy)
219620120|NCT06691425|DRUG|Chemotherapy|Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
219620121|NCT07112456|DRUG|Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare|\*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
218924974|NCT04871646|DRUG|CKD-314 Placebo+SOC|CKD-314 placebo is administered intravenously and standard of care is also performed..
218924975|NCT00598910|DRUG|Omacor|n-3 PUFA
218924976|NCT00598910|DRUG|Placebo|Placebo
218924977|NCT01544010|BEHAVIORAL|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
218924978|NCT01544010|BEHAVIORAL|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
218924979|NCT01544010|BEHAVIORAL|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
218924980|NCT01544010|BEHAVIORAL|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
218924981|NCT01544010|BEHAVIORAL|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
219538833|NCT00224718|PROCEDURE|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
219538834|NCT00224718|PROCEDURE|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
219538835|NCT03402906|BEHAVIORAL|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
219538836|NCT05836454|OTHER|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
218924982|NCT03006003|DRUG|Raloxifene|Raloxifene tratment more than 4 weeks
218924983|NCT03006003|DRUG|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
218924984|NCT01658033|DRUG|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
218924985|NCT03637738|RADIATION|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
218924986|NCT03637738|RADIATION|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
218924987|NCT05021978|DRUG|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
218924988|NCT05021978|DRUG|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
218924989|NCT05021978|DRUG|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
218924990|NCT04932486|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
218924991|NCT03367988|DRUG|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
218924992|NCT03367988|DRUG|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
218924993|NCT01322620|OTHER|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
218924994|NCT03672708|DIAGNOSTIC_TEST|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
218924995|NCT02769585|BEHAVIORAL|Self-hypnosis|Self-hypnosis
218924996|NCT02769585|BEHAVIORAL|CDE training|standard CDE training for an obese diabetic
218924997|NCT01128634|DRUG|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
218924998|NCT01128634|DRUG|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
219538837|NCT05836454|OTHER|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
219620122|NCT07112456|DRUG|Placebo nebulization (5 mL normal saline) plus standard asthma care|\*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.
218924999|NCT04276896|BIOLOGICAL|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
218925000|NCT03122509|DRUG|durvalumab|1500 mg durvalumab via IV infusion
218925001|NCT03122509|DRUG|tremelimumab|75 mg tremelimumab via IV infusion
218925002|NCT03122509|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
219042917|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
219042918|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
219042919|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
219042920|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
219042921|NCT02242877|DRUG|Telmisartan|
219042922|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
219042923|NCT04722640|DRUG|SKYRIZI|SKYRIZI
219042924|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
219042925|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
219042926|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
219042927|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
219042928|NCT04982029|DRUG|Placebo|Matching placebo
219042929|NCT04962815|DEVICE|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
219042930|NCT05892068|DRUG|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
219042931|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
219042932|NCT05099328|BEHAVIORAL|Recast Therapy|Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
219042933|NCT05099328|BEHAVIORAL|Syntax Stories|Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
219042934|NCT03882606|DEVICE|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
219042935|NCT02882282|OTHER|Laboratory Biomarker Analysis|Correlative studies
219042936|NCT02882282|OTHER|Patient Observation|Undergo observation
219042937|NCT02882282|BIOLOGICAL|Pembrolizumab|Given IV
219042938|NCT05836597|DEVICE|Virtual reality|Virtual reality
219042939|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
219042940|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
219042941|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
219042942|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
219042943|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
219042944|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
218925003|NCT03122509|PROCEDURE|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
218925004|NCT03855488|BEHAVIORAL|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
218925005|NCT03855488|BEHAVIORAL|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
219042945|NCT02252887|DRUG|Gemcitabine|
219042946|NCT02252887|DRUG|Trastuzumab|
219042947|NCT02252887|DRUG|Pertuzumab|
218925006|NCT03855488|BEHAVIORAL|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
218925007|NCT02177032|BIOLOGICAL|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
218925008|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
218925009|NCT02177032|BIOLOGICAL|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
219620123|NCT07113015|DRUG|propranolol|40 mg orally twice daily, titrated up to a maximum of 80 mg/day.
219620124|NCT07113015|DRUG|Amantadine|100 mg orally twice daily, titrated up to a maximum of 200 mg/day.
218925010|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
218925011|NCT00378157|BEHAVIORAL|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
218925012|NCT02692521|DIETARY_SUPPLEMENT|Human Milk|
219538838|NCT05814900|DEVICE|Two photon microscopy imaging|Excised tissues will be imaged with two photon microscopy
219538839|NCT04754217|DEVICE|VAVGJ|Replacement of the aortic valve and ascending aorta
219538840|NCT04754217|DEVICE|CAVGJ|Replacement of the aortic valve and ascending aorta
219620125|NCT07113314|DIETARY_SUPPLEMENT|Lactoferrin Bovine|In addition to standard treatment, a gold-soluble formulation of bovine lactoferrin or bLF (Mosiac®) at the standard dose of 200 mg/day, in single administration, from the start of chemo/radiotherapy treatment and throughout the risk period.
219620126|NCT07037498|DIETARY_SUPPLEMENT|Moringa Oleifera|Participants receive MRJ capsules containing 490 mg of Moringa oleifera leaf extract and 10 mg of royal jelly, taken orally twice per week for 12 months. The capsules are plant-based, produced using locally sourced ingredients, and are part of a food-based supplementation strategy developed as an alternative to iron-folic acid tablets. The intervention is combined with standardized nutrition education via TikTok videos. Adherence is monitored weekly through teacher log sheets and WhatsApp documentation. and Participants receive iron-folic acid (IFA) tablets containing 60 mg of elemental iron and 400 µg of folic acid, taken orally once per week for 12 months in accordance with Indonesia's national supplementation guidelines for adolescent girls. This control intervention is combined with the same standardized nutrition education via TikTok videos. Compliance is tracked weekly through teacher-supervised control sheets and WhatsApp photo submissions.
219620127|NCT05813886|OTHER|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
218925013|NCT02321020|PROCEDURE|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
218925014|NCT02321020|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
219042948|NCT04626518|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
219042949|NCT04626518|BIOLOGICAL|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
219042950|NCT04626518|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
219042951|NCT04626518|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
219538841|NCT06615752|DRUG|green tea and quercetin + docetaxel|green tea and quercetin supplements in combination with docetaxel infusion
219538842|NCT06615752|DRUG|Placebo + docetaxel|Placebo will be given along with docetaxel chemotherapy
219538843|NCT04813354|DEVICE|ELLIPTA|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
219538844|NCT04813354|DEVICE|BREEZHALER|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
219538845|NCT04255147|BIOLOGICAL|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
219538846|NCT06343675|OTHER|There is no intervention|There is no intervention
219538847|NCT02760927|DEVICE|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
219538848|NCT06395792|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
219538849|NCT04521426|OTHER|No other than standard care|No other than standard care.
219538850|NCT02355730|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
219538851|NCT03684330|DIETARY_SUPPLEMENT|Vitamin D|a dose once a week
219538852|NCT03684330|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
219538853|NCT02105272|DRUG|OPC-1085EL ophthalmic solution|
219538854|NCT02105272|DRUG|Latanoprost ophthalmic solution|
219538855|NCT00974558|DEVICE|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
218925015|NCT01312103|BEHAVIORAL|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
218925016|NCT01312103|BEHAVIORAL|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
218925017|NCT04074889|DIETARY_SUPPLEMENT|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
219538856|NCT03603990|PROCEDURE|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
219538857|NCT03603990|PROCEDURE|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
219538858|NCT05363020|DRUG|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
218925018|NCT04074889|OTHER|Placebo|Placebo sachet with no microbial cell preparation
218925019|NCT01259414|OTHER|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
219042952|NCT04626518|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
219538859|NCT05363020|DRUG|Placebo|400 mg identically appearing placebo
219538860|NCT05009212|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (\<5 cm)
219538861|NCT05009212|PROCEDURE|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (\<5 cm)
219538862|NCT04480619|DIAGNOSTIC_TEST|Ga-68-IAC|Clinical management and diagnosis of Metastatic Breast Cancer.
219538863|NCT04085887|DRUG|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
219538864|NCT04085887|DEVICE|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
219538865|NCT04085887|DEVICE|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
219538866|NCT04085887|DEVICE|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
219538867|NCT03418038|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
219538868|NCT03418038|DRUG|Carboplatin|Given IV or PO
219538869|NCT03418038|DRUG|Cisplatin|Given IV or PO
219538870|NCT03418038|DRUG|Cytarabine|Given IV or PO
219538871|NCT03418038|DRUG|Dexamethasone|Given IV or PO
219538872|NCT03418038|DRUG|Etoposide|Given IV or PO
219538873|NCT03418038|DRUG|Gemcitabine Hydrochloride|Given IV or PO
219538874|NCT03418038|DRUG|Ifosfamide|Given IV or PO
219538875|NCT03418038|OTHER|Laboratory Biomarker Analysis|Correlative studies
219538876|NCT03418038|DRUG|Oxaliplatin|Given IV or PO
219538877|NCT03418038|OTHER|Placebo Administration|Given normal saline IV
219538878|NCT03418038|OTHER|Questionnaire Administration|Ancillary studies
219538879|NCT03418038|BIOLOGICAL|Rituximab|Given IV
219538880|NCT03418038|DRUG|Decitabine|Given IV
219538881|NCT03418038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219538882|NCT03418038|PROCEDURE|Core Biopsy|Undergo core needle biopsy
219538883|NCT03418038|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
218925020|NCT01259414|OTHER|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
218925021|NCT01054989|BIOLOGICAL|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
219538884|NCT03418038|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219538885|NCT03418038|PROCEDURE|Echocardiography|Undergo ECHO
219538886|NCT03418038|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219538887|NCT03418038|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219538888|NCT03418038|PROCEDURE|Central Venous Cannula Insertion|Undergo PICC placement
218925022|NCT04069702|BEHAVIORAL|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
218925023|NCT01765933|DIETARY_SUPPLEMENT|DMAA|no placebo
218925024|NCT03597945|PROCEDURE|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
218925025|NCT03597945|PROCEDURE|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
218925026|NCT03597945|PROCEDURE|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
218925027|NCT03702153|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
218925028|NCT04944004|OTHER|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
218925029|NCT04944004|OTHER|Training As Usual (TAU)|Training As Usual (TAU)
219538889|NCT03418038|PROCEDURE|Portacath Placement|Undergo portacath placement
218925030|NCT03096288|DRUG|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
218925031|NCT03096288|OTHER|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
218925032|NCT01644357|OTHER|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
219538890|NCT03418038|PROCEDURE|Computed Tomography|Undergo PET/CT
219538891|NCT03450850|DEVICE|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
219538892|NCT06608537|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
219620128|NCT03274193|BEHAVIORAL|Yoga training program|The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
218925033|NCT00588016|DRUG|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
218925034|NCT03721003|DEVICE|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
218925035|NCT04683484|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
218925036|NCT04683484|BIOLOGICAL|Placebo|0,5 mg Al PO4
218925037|NCT06316050|PROCEDURE|humeral retroversion|REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
218925038|NCT06001073|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
218925039|NCT04958473|DRUG|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
218925040|NCT04958473|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
218925041|NCT03367520|BEHAVIORAL|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
218925042|NCT06116669|DIETARY_SUPPLEMENT|Iron supplementation|Iron supplements as 100 mg oral iron as FeSO4 given daily
218925043|NCT06116669|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
219538893|NCT04503278|BIOLOGICAL|CLDN6 CAR-T|administered as an intravenous (i.v.) infusion.
219538894|NCT04503278|BIOLOGICAL|CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|administered as an i.v. injection at protocol-specified intervals.
218925044|NCT06116669|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
218925045|NCT06116669|OTHER|Placebo|matching placebo capsules given daily
218925046|NCT06116669|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
218925047|NCT02547818|DRUG|ALZT-OP1a|1\) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
218925048|NCT02547818|DRUG|ALZT-OP1b|Anti-inflammatory
218925049|NCT02547818|OTHER|Placebo ALZT-OP1a|Non-active capsules
218925050|NCT02547818|OTHER|Placebo ALZT-OP1b|Non-active tablets
219538895|NCT03190915|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
219538896|NCT03190915|DRUG|Trametinib|Given PO
218925051|NCT01495403|DRUG|Hydroxychloroquine|daily dosing
218925052|NCT02551887|BEHAVIORAL|Automated Reminder|Automated reminder shown to provider
218925053|NCT02551887|BEHAVIORAL|Automated Reminder Plus Script|Provider sees both reminder and script.
218925054|NCT02928614|DRUG|Liraglutide 3 mg (Saxenda)|
218925055|NCT02928614|DRUG|Liraglutide 3 mg placebo|
218925056|NCT03498898|OTHER|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
218925057|NCT02346162|BEHAVIORAL|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.
218925058|NCT02346162|OTHER|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
218925059|NCT00519753|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
218925060|NCT00203099|DRUG|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
218925061|NCT02558296|DRUG|Bexagliflozin|20 mg, tablet
219538897|NCT06525649|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment.
219538898|NCT02964039|BEHAVIORAL|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
219538899|NCT02964039|BEHAVIORAL|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
219538900|NCT02964039|BEHAVIORAL|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
219538901|NCT05107089|DEVICE|Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization
219538902|NCT05751343|DRUG|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
219538903|NCT04454658|DRUG|ABBV-744|Tablet; Oral
219538904|NCT04454658|DRUG|Navitoclax|Tablet; Oral
219538905|NCT04454658|DRUG|Ruxolitinib|Tablet; Oral
219538906|NCT06382636|BEHAVIORAL|Standard Care|This group will utilize standard care with respect to healthcare provider practices.
219538907|NCT06382636|BEHAVIORAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This group will be exposed to the AI enabled healthcare chatbot.
219538908|NCT04850118|BIOLOGICAL|rAAV2tYF-GRK1-hRPGRco|Adeno-associated virus vector expressing a human RPGR gene
219538909|NCT04850118|DRUG|Control|Untreated Control Group 3
219620129|NCT06722651|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|"Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components:~* Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and~* Netrod™ Renal Denervation Radiofrequency Generator The catheter's electrodes deploy into a self-adaptive basket structure, optimizing contact with the vessel wall for effective ablation."
218925062|NCT02558296|DRUG|Placebo|20 mg tablet to match active comparator
218925063|NCT01887457|DRUG|VFEND|voriconazole will be administered in iv form
218925064|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
218925065|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO|Slow-release CHO, alginate encapsulated
218925066|NCT06165393|DIETARY_SUPPLEMENT|CHO|Carbohydrate-only, control
218925067|NCT03183297|DRUG|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
218925068|NCT03183297|DRUG|Naproxen|Naproxen sodium 220mg
218925069|NCT03183297|DRUG|Fexofenadine|Fexofenadine 60mg
218925070|NCT03183297|DRUG|placebo|placebo comparator
218925071|NCT02819804|DRUG|Dasatinib|Given PO
218925072|NCT02819804|OTHER|Laboratory Biomarker Analysis|Correlative studies
218925073|NCT02819804|BIOLOGICAL|Nivolumab|Given IV
218925074|NCT02819804|OTHER|Pharmacological Study|Correlative studies
219538910|NCT06516068|DRUG|HRS-1893|HRS-1893
219538911|NCT01903161|PROCEDURE|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
219538912|NCT01903161|PROCEDURE|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
219538913|NCT04624321|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
219538914|NCT04624321|OTHER|Usual care|Usual care at ordinary healthcare provider
219538915|NCT02042781|DRUG|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
219538916|NCT01172145|DRUG|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
219538917|NCT01172145|DRUG|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
219538918|NCT04256720|BEHAVIORAL|No intervention|No intervention - questionnaire study
219538919|NCT02822326|BIOLOGICAL|CD19-CAR-T2 Cells|
218925075|NCT01512238|OTHER|Pharmaceutical care|Information about medicine, sideeffect, adherence
218925076|NCT01170169|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
218925077|NCT01170169|DRUG|Prilosec|Prilosec® 40 mg of Merck \& Co.Inc.
219042953|NCT04626518|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
219042954|NCT05593653|DRUG|Suvorexant|20mg taken at bedtime for 4 weeks
218925078|NCT01441076|DRUG|Anakinra|Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
218925079|NCT03004937|OTHER|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
219042955|NCT05593653|DRUG|Placebo|placebo taken at bedtime for 4 weeks
219365602|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
219042956|NCT04389216|DEVICE|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
219538920|NCT05669781|DRUG|Metoclopramide 10mg|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
219538921|NCT05669781|COMBINATION_PRODUCT|Gum and metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
219620130|NCT06722651|DEVICE|Sham Procedure|Patients will be remained on the catheterization table for at least 20 min prior to sheath removal.
218925080|NCT00470886|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
219042957|NCT06259409|DEVICE|Regenn® Negative Pressure Therapy System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
219042958|NCT06259409|DEVICE|Prevena™ Incision Management System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
219042959|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
219042960|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
219042961|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
219042962|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
219042963|NCT05436470|DEVICE|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
219042964|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
219042965|NCT00196950|BIOLOGICAL|Meningococcal (vaccine)|
219042966|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
219042967|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
219042968|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
219042969|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
219042970|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
219042971|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
219538922|NCT05669781|OTHER|Gum|One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
219538923|NCT05669781|OTHER|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
219538924|NCT05226923|DRUG|KSP-1007|Single and multiple doses, intravenous administration
219538925|NCT05226923|OTHER|Placebo:0.9% sodium chloride|Single and multiple doses, intravenous administration
219538926|NCT05226923|DRUG|Meropenem|Multiple doses, intravenous administration
219538927|NCT04239833|DRUG|SH-1028 tablets|"The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219620131|NCT00002100|DRUG|Curdlan sulfate|
219365603|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
219365604|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
219365605|NCT05833672|DRUG|Terelizumab|q3w Terelizumab 200mg on day 1 of each cycle
219365606|NCT05833672|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
219365607|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
219365608|NCT06143527|BIOLOGICAL|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
218925081|NCT02947789|PROCEDURE|Emergency surgery|Patients undergoing emergency surgery
219365609|NCT00599495|PROCEDURE|allogeneic HSCT|dose-reduced conditioning regimen
219365610|NCT06028659|OTHER|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
219365611|NCT06028659|OTHER|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
219365612|NCT03570112|DRUG|SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg|sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
219365613|NCT01811147|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
218925082|NCT01385293|DRUG|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
218925083|NCT00346697|DRUG|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
218925084|NCT00346697|DRUG|Placebo|Corn-oil placebo
218925085|NCT05133141|DEVICE|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
218925086|NCT02633904|PROCEDURE|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
218925087|NCT02633904|PROCEDURE|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
218925088|NCT02895893|BEHAVIORAL|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
218925089|NCT04670978|DRUG|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
219042972|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
219042973|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
219042974|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
219042975|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
219042976|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
219042977|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
219042978|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
219042979|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
219042980|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
219042981|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
219042982|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
219042983|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
219042984|NCT01002144|OTHER|blood sampling|
219042985|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
219042986|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
218925090|NCT04186143|OTHER|Closed Cinetic Chain Exercises|Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
218925091|NCT04186143|OTHER|Open Kinetic Chain Exercises|Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
218925092|NCT04186143|OTHER|Control Group|Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
219538928|NCT04239833|DRUG|Placebo SH-1028 tablets|"The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219538929|NCT04239833|DRUG|Gefitinib|"The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets)."
219538930|NCT04239833|DRUG|Placebo Gefitinib|The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
219538931|NCT04138368|BEHAVIORAL|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
219538932|NCT04138368|BEHAVIORAL|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
218925093|NCT00002080|DRUG|Rifabutin|
219538933|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219620132|NCT03271684|OTHER|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
219620133|NCT03271684|OTHER|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
218925094|NCT05380180|OTHER|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
219042987|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
219042988|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
219042989|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
219042990|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
219042991|NCT01086592|OTHER|No intervention|Daily life activities
219042992|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
219042993|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
219042994|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
219042995|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
219042996|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
219042997|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
219042998|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
219042999|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
219538934|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
218925095|NCT05380180|OTHER|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
218925096|NCT03657082|DEVICE|PEP-10|Bottle PEP with a water level of 10 cmH2O
218925097|NCT03657082|DEVICE|PEP-1|Bottle PEP with a water level of 1 cmH2O
219538935|NCT00796653|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
219538936|NCT00796653|DRUG|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
219538937|NCT00018733|DRUG|paroxetine|
219538938|NCT00018733|DRUG|Desipramine|
219538939|NCT03393208|DRUG|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
218925098|NCT03481686|DEVICE|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
218925099|NCT01940796|DRUG|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
219043000|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
219043001|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
219043002|NCT03612167|BEHAVIORAL|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
219043003|NCT03612167|BEHAVIORAL|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
219043004|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
219538940|NCT03393208|DRUG|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
219538941|NCT01459185|DRUG|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
219620134|NCT04910594|DRUG|recombinant human erythropoietin|To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
219043005|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
219043006|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
219538942|NCT00868374|DRUG|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
219538943|NCT00868374|DRUG|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
219538944|NCT01341730|DRUG|Atorvastatin 20mg|20 mg QD for 3 months
219043007|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
219538945|NCT01341730|DRUG|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
219538946|NCT02491905|DRUG|HL tablet|
219538947|NCT02491905|DRUG|Placebo|
219538948|NCT06626867|DIETARY_SUPPLEMENT|Dietary Fiber Supplementation|Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
219538949|NCT06626867|OTHER|Placebo|The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
219538950|NCT01848938|BEHAVIORAL|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
219538951|NCT01498172|BIOLOGICAL|MAGE-A3 ASCI|5 doses every 3 weeks
219043008|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
219043009|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
219043010|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
219043011|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
219043012|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
219043013|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
218925100|NCT02062840|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
218925101|NCT02062840|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
218925102|NCT02062840|DEVICE|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
218925103|NCT02062840|OTHER|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
218925104|NCT03619720|OTHER|Records|Respiratory records, Vocal records Video records Questionnaires
218925105|NCT01680471|DRUG|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
218925106|NCT01680471|DRUG|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
218925107|NCT01680471|DRUG|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
218925108|NCT04454918|DRUG|TAK-906 Oral Capsule|TAK-906 capsule.
218925109|NCT04454918|DRUG|[14C]-TAK-906 Intravenous Infusion|\[14C\]-TAK-906 intravenous infusion.
218925110|NCT04454918|DRUG|[14C]-TAK-906 Oral Solution|\[14C\]-TAK-906 oral solution.
218925111|NCT04497259|OTHER|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
218925112|NCT04497259|OTHER|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
218925113|NCT04497259|OTHER|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
218925114|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
218925115|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
218925116|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
218925117|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
218925118|NCT03271086|BEHAVIORAL|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
218925119|NCT03271086|BEHAVIORAL|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
218925120|NCT03271086|BEHAVIORAL|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
218925121|NCT06082362|OTHER|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
218925122|NCT04868786|DRUG|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
218925123|NCT02415608|DRUG|Ibrutinib|Given orally in 28-day cycles
218925124|NCT02871934|GENETIC|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
218925125|NCT01055197|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
218925126|NCT01055197|RADIATION|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
218925127|NCT02207777|PROCEDURE|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
219538952|NCT01498172|BIOLOGICAL|BCG|1 intravesical dose /week for 6 weeks
219538953|NCT02741895|BEHAVIORAL|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
219538954|NCT06331910|DRUG|insulin eye drops|Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
219538955|NCT01885572|DEVICE|TiLOOP Bra|Titaniferously coated polypropylene mesh
218925128|NCT02207777|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
218925129|NCT00649207|DRUG|ABT-888|Oral Capsules
218925130|NCT00649207|RADIATION|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
218925131|NCT02342028|BIOLOGICAL|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
218925132|NCT04948372|DRUG|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
218925133|NCT04948372|DRUG|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
218925134|NCT00389610|BIOLOGICAL|GVAX pancreas vaccine|Given intradermally
218925135|NCT00840112|DIETARY_SUPPLEMENT|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
218925136|NCT03943654|OTHER|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
218925137|NCT00538902|BIOLOGICAL|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
218925138|NCT00538902|BIOLOGICAL|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
219538956|NCT00539110|DRUG|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
219538957|NCT00539110|DRUG|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
219538958|NCT00066001|DRUG|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
219538959|NCT03244553|DRUG|Prucalopride|5 day treatment
218925139|NCT00538902|BIOLOGICAL|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
219538960|NCT05352789|OTHER|Non validated Survey|Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.
219538961|NCT05357235|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
219538962|NCT03186976|BEHAVIORAL|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2\) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3\) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4\) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5\) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%"
219043014|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
219043015|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
219043016|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
219043017|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
219043018|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
219043019|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
219043020|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
219043021|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
219043022|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
219538963|NCT03186976|OTHER|Standard of Care|Recommendations based on current guidelines
219538964|NCT06324838|PROCEDURE|Standard laparoscopic ileocecal resection|Participants will undergo standard mesocolic sparing resection.
218925140|NCT04324437|OTHER|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
218925141|NCT00860093|OTHER|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
218925142|NCT00860093|DRUG|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
218925143|NCT03739203|DRUG|Cariprazine|Cariprazine supplied in capsules
218925144|NCT03739203|DRUG|Placebo|Placebo supplied in capsules
218925145|NCT03739203|DRUG|Antidepressant Therapy (ADT)|ADT as prescribed by the physician per standard of care in clinical practice.
219043023|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
219204930|NCT06886945|OTHER|Audio-Visual Perceptual Tasks|"Around 75 participants will be recruited for this study (25 per each group), and asked to perform two distinct audiovisual tasks (run via Matlab-based automated routines, and presented using a CRT monitor and a pair of loudspeakers) :~1. TOJ task, in which a white flashing dot, and a basic auditory stimulus, will be presented in close temporal proximity at several stimulus onset asynchronies (SOAs, from 30 to 540 ms in steps of 30 ms), with participants asked to report ( after each trial), which stimulus occurred first (task duration estimate: 25 minutes, 30 trials per each SOA)~2. A modified version of the SIFI (mSIFI), in which the presentation of paired (and temporally close) auditory stimuli will be coupled with the occurrence of either 1 or 2 flashing dots, at several different SOAs (from 30 to 250 ms in steps of 10 ms), with participants asked to report (after each trial), whether they saw 1 vs 2 flashes (task duration estimate: 25 minutes, 30 trials per each SOA)"
219043024|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
219204931|NCT06868953|DRUG|combination of sumatriptan 85 mg and naproxen 500 mg|combination of sumatriptan 85 mg and naproxen 500 mg
219204932|NCT04276779|OTHER|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
219204933|NCT04276779|OTHER|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
219204934|NCT04276779|BEHAVIORAL|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
219204935|NCT04276779|BEHAVIORAL|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
219538965|NCT06324838|PROCEDURE|Extended laparoscopic ileocecal resection|Extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site.
218925146|NCT05056233|OTHER|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
218925147|NCT05647798|OTHER|Blood sugar check every 2 hours|Blood sugar check every 2 hours
219538966|NCT06131086|OTHER|stabilization exercises|this include stabilization exercise thrice a week for six weeks
219538967|NCT06131086|OTHER|stabilization exercises along with pectoralis minor stretching|this include stabilization exercise with pectoralis minor thrice a week for six weeks
218925148|NCT05647798|OTHER|Blood sugar check every 4 hours|Blood sugar check every 4 hours
219043025|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
219043026|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
219043027|NCT01823029|DRUG|erythropoietin|
219043028|NCT01823029|DRUG|enteral nutrition.|
219043029|NCT01823029|DRUG|injection of iron|
219043030|NCT05822869|PROCEDURE|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
219043031|NCT05822869|PROCEDURE|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
219538968|NCT01665209|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
219538969|NCT03782779|OTHER|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
219538970|NCT03782779|OTHER|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
219043032|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
219043033|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
219538971|NCT06455982|DIETARY_SUPPLEMENT|reduced carbohydrate menu combined with ketogenic supplement|Participants will eat a reduced carb menu for 2 months and they will take 15g of MCT in the morning and the evening for a total of 30g per day.
219538972|NCT00697476|DRUG|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
218925149|NCT03405246|BEHAVIORAL|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
218925150|NCT03405246|BEHAVIORAL|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
219538973|NCT02272647|DRUG|IM Saline Placebo (0.25 ml)|
219538974|NCT02272647|DRUG|IM Estradiol valerate (2.5 mg)|
218925151|NCT03131570|DRUG|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
219538975|NCT02272647|DRUG|IM Saline Placebo (0.5 ml)|
219620135|NCT02975947|DEVICE|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
218925152|NCT03131570|DRUG|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
218925153|NCT04425109|BEHAVIORAL|meal test response|soy fermented versus non fermented meal test
218925154|NCT02633098|DRUG|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
218925155|NCT02633098|DRUG|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
219043034|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
218925156|NCT03193957|DRUG|Etanercept|Etanercept PFS and Autoinjector
218925157|NCT03193957|DEVICE|Autoinjector|Autoinjector
218925158|NCT02724891|OTHER|paper form|questionnaires in paper form
218925159|NCT02724891|OTHER|web/smartphone form|questionnaires in web/smartphone
218925160|NCT04043299|DRUG|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
218925161|NCT04043299|DRUG|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
218925162|NCT01782378|DEVICE|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
218925163|NCT01782378|DEVICE|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
218925164|NCT02288741|DRUG|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
219043035|NCT05891548|DRUG|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
219043036|NCT05891548|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
219043037|NCT03186118|BIOLOGICAL|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
219538976|NCT02272647|DRUG|IM Estradiol valerate (5.0 mg)|
219538977|NCT02272647|DRUG|Oral Micronized Progesterone|
219538978|NCT02272647|DRUG|Oral Placebo|
218925165|NCT02288741|DRUG|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
219043038|NCT04718870|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
219043039|NCT04127786|BIOLOGICAL|Purified vero rabies vaccine - serum free - VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
219043040|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
219043041|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
219043042|NCT05149742|BEHAVIORAL|Cognitive and audiometry evaluation|"For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires"
219538979|NCT02272647|DRUG|Ghrelin (0.3 ug/kg)|
219538980|NCT02272647|DRUG|Medroxyprogesterone - Acetate|
219538981|NCT02272647|DRUG|Oral Placebo|(in lieu of Medroxyprogesterone)
219538982|NCT00053963|DRUG|romidepsin|Given IV
218925166|NCT02288741|DRUG|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
218925167|NCT02288741|PROCEDURE|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
218925168|NCT02288741|DRUG|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
218925169|NCT02288741|PROCEDURE|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
218925170|NCT05579613|DEVICE|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
218925171|NCT04569565|DEVICE|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
218925172|NCT00830440|DEVICE|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
218925173|NCT00830440|BEHAVIORAL|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
218925174|NCT04668755|DEVICE|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
218925175|NCT04668755|DEVICE|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
218925176|NCT05338346|DRUG|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
218925177|NCT01935206|DRUG|Naloxone (2 mg/kg)|
218925178|NCT01935206|DRUG|Placebo|
218925179|NCT00130572|DRUG|Pimecrolimus|
218925180|NCT01342861|DIETARY_SUPPLEMENT|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
218925181|NCT02398890|OTHER|routine care|routine care
218925182|NCT04077216|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
219043043|NCT01613781|OTHER|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
219043044|NCT01613781|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
218925183|NCT05513404|DIETARY_SUPPLEMENT|Honeyberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
218925184|NCT05513404|DIETARY_SUPPLEMENT|Cherry|To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
219365614|NCT00891826|DIETARY_SUPPLEMENT|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
218925185|NCT05513404|DIETARY_SUPPLEMENT|Raspberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
218925186|NCT06029829|DRUG|Sintilimab|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
219365615|NCT00891826|DIETARY_SUPPLEMENT|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
219365616|NCT03341676|DRUG|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
219365617|NCT03341676|DRUG|Placebo|Sodium Chloride 0.9% w/v solution for injection
219365618|NCT03847142|OTHER|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
219365619|NCT03847142|OTHER|Outpatient primary care|Usual care delivered through the outpatient primary care setting
219365620|NCT02630160|DRUG|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
219365621|NCT02630160|OTHER|Physiological Saline|Intraarticular infusion physiological serum
219365622|NCT01301430|DRUG|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
219365623|NCT01550497|OTHER|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
219365624|NCT01195337|BEHAVIORAL|PA Prescription Plan|Exercise program and instructions.
219365625|NCT01195337|DEVICE|Pedometer|Step monitor for individual PA progress.
218925187|NCT04381364|DRUG|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
218925188|NCT00588107|OTHER|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
218925189|NCT00588107|BEHAVIORAL|print materials|tailored print materials designed to aid in smoking reduction and cessation
218925190|NCT06131736|OTHER|Tabata Training|This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
218925191|NCT06131736|OTHER|Cluster Training|The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
218925192|NCT00765206|DRUG|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
218925193|NCT00765206|DRUG|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
218925194|NCT02307825|DRUG|Azithromycin|The drug will be taken three times a week for four months.
218925195|NCT02307825|DRUG|Placebo|The placebo will be taken three times a week for four months.
218925196|NCT02416206|DRUG|BeEAM|BeEAM
218925197|NCT00942604|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
218925198|NCT00942604|DRUG|Vehicle gel|two day treatment
218925199|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
218925200|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
218925201|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
218925202|NCT00224822|DRUG|Aripiprazole|
218925203|NCT00212641|DRUG|ONO-5129|
219043045|NCT06241027|OTHER|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
219043046|NCT06241027|OTHER|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
219365626|NCT01195337|BEHAVIORAL|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
219620136|NCT02975947|DEVICE|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
218925204|NCT02846025|DIETARY_SUPPLEMENT|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
218925205|NCT02846025|DIETARY_SUPPLEMENT|Folate and placebo|rich diet aministracao folate and placebo
218925206|NCT02846025|DIETARY_SUPPLEMENT|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
218925207|NCT01143246|DRUG|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
218925208|NCT01143246|DRUG|Placebo|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
218925209|NCT01666028|DEVICE|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
218925210|NCT01666028|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
218925211|NCT04119414|BEHAVIORAL|Spear and Shield (S&S) Program|The S\&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
218925212|NCT04119414|BEHAVIORAL|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
218925213|NCT03842527|DEVICE|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
218925214|NCT01135173|BEHAVIORAL|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
218925215|NCT02506088|BEHAVIORAL|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
218925216|NCT05915910|DIAGNOSTIC_TEST|Specimen Donation|blood donation
218925217|NCT05862077|DEVICE|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
218925218|NCT05862077|BEHAVIORAL|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
218925219|NCT05862077|BEHAVIORAL|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
218925220|NCT05862077|DEVICE|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
218925221|NCT02875236|DRUG|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
218925222|NCT02875236|DRUG|Ringer-acetat|Crystalloid used as standard of care.
218925223|NCT03761992|DIETARY_SUPPLEMENT|Gingko Baloba|Tablets
218925224|NCT03761992|OTHER|Placebo|Tablets
218925225|NCT03150953|DEVICE|MRI-safe bore covering|
219043047|NCT01904604|BIOLOGICAL|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
219043048|NCT01904604|BIOLOGICAL|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
219043049|NCT01904604|BIOLOGICAL|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
219043050|NCT05124665|BEHAVIORAL|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
219538983|NCT05091645|OTHER|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
219538984|NCT05640531|DRUG|WCK 771 IV Infusion|subjects will receive intravenous infusion of WCK 771
219538985|NCT05640531|OTHER|Placebo IV Infusion|subjects will receive matching placebo intravenous infusion
219538986|NCT02970123|BEHAVIORAL|Sit Less, Interact, Move More (SLIMM)|
218925226|NCT03533049|OTHER|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
218925227|NCT03058146|BEHAVIORAL|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
218925228|NCT03058146|BEHAVIORAL|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
218925229|NCT03410706|DRUG|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
218925230|NCT00859196|DRUG|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
219043051|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
219043052|NCT02978287|DRUG|BAVU Solution|Tissue preservation solution for transplantation
219043053|NCT02526069|BEHAVIORAL|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
219538987|NCT00207090|DRUG|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
219538988|NCT00207090|DRUG|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
219538989|NCT00857103|BEHAVIORAL|CHOICE|Use of Choice support system as preparation for patient consultations
219538990|NCT05458635|PROCEDURE|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
219538991|NCT00191490|DRUG|Gemcitabine|
219538992|NCT00191490|DRUG|docetaxel|
219538993|NCT00191490|DRUG|cisplatin|
219538994|NCT06559982|DIETARY_SUPPLEMENT|Brown seaweed and tart cherry blend|Blend of brown seaweed and tart cherry blend taken twice daily
219538995|NCT06559982|OTHER|Placebo|Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
219538996|NCT01552317|OTHER|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
218925231|NCT00859196|DRUG|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
218925232|NCT02354898|DRUG|BBI503|
218925233|NCT02354898|DRUG|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
218925234|NCT02293694|DRUG|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
218925235|NCT05323227|DIAGNOSTIC_TEST|Coronary CTA|Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
218925236|NCT00035243|DRUG|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
218925237|NCT05680402|OTHER|Soft Tissue mobilization|mobilization of soft tissues of body
218925238|NCT05680402|OTHER|Piriformis Syndrome (Piriformis muscle stretching)|Stretching of Piriformis muscle
218925239|NCT03563014|DRUG|Radium-223 (Xofigo, Bay88-8223)|Follow the physician's prescription in routine clinical practice.
218925240|NCT03429114|OTHER|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
218925241|NCT00469599|DRUG|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
218925242|NCT00469599|DRUG|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
219538997|NCT06176534|DRUG|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
219538998|NCT06176534|DRUG|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
218925243|NCT05613140|DRUG|sacubitril/valsartan|Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
218925244|NCT02134496|PROCEDURE|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
218925245|NCT00999102|DRUG|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
218925246|NCT00999102|DRUG|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
218925247|NCT03524508|DRUG|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
218925248|NCT03524508|DRUG|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
218925249|NCT05663658|OTHER|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
218925250|NCT05663658|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
219043054|NCT00107458|DRUG|valproic acid|
218925251|NCT00225316|PROCEDURE|Acupuncture|See Detailed Description.
219043055|NCT02843945|DEVICE|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
219043056|NCT02203812|DRUG|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
219538999|NCT05613686|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
218925252|NCT00746382|DRUG|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
218925253|NCT00746382|DRUG|Placebo cream|Placebo cream
218925254|NCT04436952|DEVICE|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
218925255|NCT04436952|DEVICE|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
219539000|NCT04498806|OTHER|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
219539001|NCT06561373|BEHAVIORAL|Calm & Alert yoga and mindfulness|The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
218925256|NCT04436952|BEHAVIORAL|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
218925257|NCT03056222|DEVICE|Ablation catheter|Ablation of paroxysmal atrial fibrillation
218925258|NCT02871986|DRUG|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
218925259|NCT01455701|DRUG|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
218925260|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 1)|0.5ml/vial
218925261|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 2)|0.5ml/vial
218925262|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 3)|0.5ml/vial
219539002|NCT00545506|DEVICE|conventional bandage|
219539003|NCT00545506|DEVICE|warming bandage|
219539004|NCT01501253|DRUG|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
219539005|NCT01501253|DRUG|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
219539006|NCT01501253|DRUG|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
219539007|NCT00030186|DRUG|CEP-701 60mg|60mg orally 2 times a day for 28 days
219539008|NCT00030186|DRUG|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
219539009|NCT00030186|DRUG|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
219539010|NCT05806957|DEVICE|Fundus Photography|Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT
218925263|NCT01352793|BIOLOGICAL|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
218925264|NCT01352793|BIOLOGICAL|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
218925265|NCT03327662|OTHER|Active CTC Assessment|CTC Counts used to guide treatment switch
218925266|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
218925267|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
218925268|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
218925269|NCT02982980|PROCEDURE|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
218925270|NCT02982980|PROCEDURE|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
219539011|NCT02724605|BIOLOGICAL|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
219539012|NCT02724605|BIOLOGICAL|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
218925271|NCT03075514|OTHER|MKD|Modified ketogenic diet
218925272|NCT03075514|OTHER|MCT|Medium chain triglyceride ketogenic diet
218925273|NCT03203096|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate / Magnesium oxide
218925274|NCT03203096|DIETARY_SUPPLEMENT|Placebo|
219043057|NCT02203812|DRUG|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
219043058|NCT02380651|PROCEDURE|Limb salvage|Local or free flaps
219043059|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
219043060|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
219043061|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
219043062|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
219043063|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
219043064|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
219043065|NCT01347437|BEHAVIORAL|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
219043066|NCT00895466|BIOLOGICAL|PEP-223/CoVaccine HT|
219539013|NCT02571686|DEVICE|Surveyor S4|
219539014|NCT05260697|OTHER|sexual counselling with plissit model|sexual counselling
219539015|NCT05305248|DRUG|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
218925275|NCT03000608|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
218925276|NCT03000608|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
218925277|NCT00100269|DRUG|Menevit anti-oxidant|
218925278|NCT02743052|DRUG|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
218925279|NCT02751853|DEVICE|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
218925280|NCT02480387|DRUG|Ledipasvir/Sofosbuvir FDC|
218925281|NCT01838096|DEVICE|THA using 4th generation CoC|
218925282|NCT02839200|DRUG|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
218925283|NCT02839200|DRUG|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
218925284|NCT02839200|DRUG|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
218925285|NCT02839200|DRUG|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
218925286|NCT02839200|DRUG|Placebo 1|Placebo capsules matching ACT-541468 capsules
218925287|NCT02839200|DRUG|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
219043067|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
219043068|NCT01267396|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
219204936|NCT06303297|OTHER|REFLEXOLOGY|will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.
219204937|NCT06303297|OTHER|GENERALIZED STRETCHING|will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
219539016|NCT05305248|DRUG|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
219539017|NCT06279039|DRUG|Exosome liquid dressing|This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
219539018|NCT00239382|DRUG|Meloxicam ampoule|
219539019|NCT00239382|DRUG|Meloxicam tablet|
219043069|NCT02273843|DRUG|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
218925288|NCT02876432|DEVICE|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
218925289|NCT02876432|DRUG|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
218925290|NCT02876432|OTHER|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
218925291|NCT02633514|DRUG|Cisplatin|25mg/m2,iv gtt,d1-3
218925292|NCT02633514|DRUG|Etoposide|75mg/m2,iv gtt,d1-3
218925293|NCT02633514|RADIATION|radiotherapy|60Gy/30Fx
218925294|NCT00411684|DRUG|CDB-2914|
219043070|NCT02273843|DRUG|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
219043071|NCT01395940|DRUG|KLH-2109|
219043072|NCT01395940|DRUG|KLH-2109|
219043073|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
219043074|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
219043075|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
218925295|NCT01198496|DRUG|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|\<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
218925296|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
218925297|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
218925298|NCT02629900|BEHAVIORAL|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
218925299|NCT00646048|DEVICE|TriVascular Stent-Graft System|TriVascular Stent-Graft System
218925300|NCT01473901|DRUG|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
218925301|NCT01473901|DRUG|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
218925302|NCT04404491|DRUG|Procedural death 1|200mg,d1,15,29,43,57,I.V
218925303|NCT04404491|DRUG|Capecitabine|Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
218925304|NCT04404491|RADIATION|Radiotherapy|radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
218925305|NCT04404491|DRUG|Placebo|placebo: 200mg,d1,15,29,43,57,I.V
218925306|NCT00965861|OTHER|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
219043076|NCT02439112|OTHER|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
219043077|NCT02959281|OTHER|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
219043078|NCT01076985|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
219043079|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
219043080|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
219043081|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
219043082|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
219043083|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
219043084|NCT03606525|PROCEDURE|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
219043085|NCT04145895|OTHER|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
219539020|NCT00819754|DRUG|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
219539021|NCT00702377|OTHER|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
219539022|NCT00702377|OTHER|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
219539023|NCT00304187|DRUG|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
219539024|NCT00304187|DRUG|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
219539025|NCT03807180|OTHER|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
219539026|NCT03353896|DEVICE|Wear novoTTF-200A|Wear novoTTF-200A device
218925307|NCT06112353|DRUG|Neostigmine Injectable Solution|Examine GI-2 recovery
218925308|NCT06112353|DRUG|Sugammadex injection|Examine GI-2 recovery
218925309|NCT01094119|DEVICE|heated blanket|heated blanket
218925310|NCT01094119|DEVICE|heated pad|patients will be warmed with a heated pad during surgery.
218925311|NCT06379204|BEHAVIORAL|the maximum physiological value standardized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and HRR heart rate reserve method, gradually increasing.
218925312|NCT06379204|BEHAVIORAL|the ventilatory threshold individualized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and three zone threshold model, gradually increasing.
218925313|NCT01873872|DIETARY_SUPPLEMENT|Theralac probiotic|
218925314|NCT01873872|DIETARY_SUPPLEMENT|Culturelle probiotic|
218925315|NCT01873872|OTHER|placebo|
218925316|NCT03351725|DEVICE|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
218925317|NCT00684931|OTHER|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
218925318|NCT02779101|DRUG|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
218925319|NCT03533504|OTHER|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
218925320|NCT00516360|DEVICE|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
218925321|NCT02642016|BIOLOGICAL|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
218925322|NCT00201110|BEHAVIORAL|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
218925323|NCT00201110|BEHAVIORAL|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
218925324|NCT03561480|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
218925325|NCT03561480|DRUG|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
218925326|NCT01553890|OTHER|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
218925327|NCT03214848|BEHAVIORAL|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
218925328|NCT05733832|OTHER|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
219043086|NCT02808286|BEHAVIORAL|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
219043087|NCT02808286|BEHAVIORAL|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
219043088|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
219043089|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
219043090|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
219043091|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
219043092|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
219043093|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
219043094|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
219043095|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
219043096|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
219043097|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
219539027|NCT03353896|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
218925329|NCT05509140|OTHER|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
218925330|NCT03352609|DEVICE|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
218925331|NCT03352609|DEVICE|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
218925332|NCT05765578|BIOLOGICAL|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
218925333|NCT05765578|BIOLOGICAL|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
218925334|NCT05765578|BIOLOGICAL|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
218925335|NCT05765578|BIOLOGICAL|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
218925336|NCT05765578|BIOLOGICAL|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
218925337|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
218925338|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
218925339|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
218925340|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
218925341|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
218925342|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
218925343|NCT06373965|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
218925344|NCT01544205|OTHER|fMRI-based neurofeedback|5 sessions lasting one hour each
218925345|NCT05611788|BEHAVIORAL|Structure Learning Training|Participants will undergo 12 sessions of structure learning training lasting about 1 hour each along with 2 testing sessions interspersed within the 12 training sessions. Each session will be conducted in a remote-guided manner with an approximate 1-day gap in between sessions. The entire training will last around two weeks
218925346|NCT05189821|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
218925347|NCT02205736|OTHER|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
219043098|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
219043099|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
219365627|NCT05539846|PROCEDURE|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
219365628|NCT04699604|DRUG|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.
219365629|NCT04699604|DRUG|Placebo|Placebo
219365630|NCT06106594|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
218925348|NCT06188637|DRUG|Ozanimod Oral Capsule|open label ozanimod
218925349|NCT00305188|DRUG|Xaliproden (SR57746A)|oral administration
218925350|NCT00305188|DRUG|Placebo|oral administration
218925351|NCT00305188|DRUG|Oxaliplatin|IV administration
218925352|NCT00305188|DRUG|5-Fluorouracil|IV administration
218925353|NCT00305188|DRUG|Leucovorin|IV administration
218925354|NCT03623165|DEVICE|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
218925355|NCT01071304|DRUG|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
218925356|NCT01071304|DRUG|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
218925357|NCT03458819|DIAGNOSTIC_TEST|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
218925358|NCT02794909|DEVICE|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
218925359|NCT03656289|DRUG|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
218925360|NCT05991271|DEVICE|Venus-Vitae Transcatheter Heart Valve System|The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
218925361|NCT06110026|OTHER|Brunkow Exercise Program|The brunkow exercise program will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
218925362|NCT06110026|OTHER|Lumbar Stabilization Exercises|The lumbar stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
218925363|NCT05674656|DRUG|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
218925364|NCT03957577|OTHER|Prospective observational cohort study|Prospective observational cohort study
218925365|NCT00636298|DRUG|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
218925366|NCT04773535|DEVICE|3D Motion analysis|Motion analysis using DyCare® Lynx system with inertial based sensors as well as an optoelectronic motion analysis system based on infrared cameras (11x Vicon infrared high speed cameras)
218925367|NCT05899426|OTHER|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 2 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
218925368|NCT05899426|OTHER|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
218925369|NCT06046118|DEVICE|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~* 1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~* 2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
218925370|NCT06046118|DEVICE|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
218925371|NCT03777306|OTHER|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
218925372|NCT03777306|OTHER|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
218925373|NCT02898181|DEVICE|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
218925374|NCT03793946|OTHER|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
218925375|NCT06463808|DRUG|Recombinant Human Brain Natriuretic Peptide|we divide our subjects into two groups;one is required to take recombinant human brain natriuretic peptide,the other is not required to take recombinant human brain natriuretic peptide
218925376|NCT00361348|DRUG|Palifermin|
218925377|NCT00361348|DRUG|Heparin|
219539028|NCT04814160|PROCEDURE|mixture of bioactive glass and autogenous bone graft|bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
218925378|NCT03529695|BEHAVIORAL|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
218925379|NCT03529695|BEHAVIORAL|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
218925380|NCT06582381|OTHER|Meal set A|morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
218925381|NCT06582381|OTHER|Meal set B|morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
218925382|NCT06582381|OTHER|Meal set C|morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
218925383|NCT06582381|OTHER|Meal set D|morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
218925384|NCT05394324|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
218925385|NCT02713893|DRUG|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
218925386|NCT02713893|DRUG|Placebo plus Econazole nitrate 1% intravaginal cream|
218925387|NCT02713893|DRUG|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
218925388|NCT02713893|DRUG|Placebo intravaginal cream|
218925389|NCT02864290|DRUG|ASP1235|intravenous (IV) infusion
219539029|NCT04814160|PROCEDURE|autogenous bone graft|bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
218925390|NCT02917096|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
218925391|NCT02917096|DRUG|Fludarabine|Given IV
218925392|NCT02917096|DRUG|Fludarabine Phosphate|Given IV
219539030|NCT05855577|DRUG|Terazosin|Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
218925393|NCT02917096|OTHER|Laboratory Biomarker Analysis|Correlative studies
218925394|NCT02917096|DRUG|Melphalan|Given IV
218925395|NCT02917096|OTHER|Pharmacological Study|Correlative studies
218925396|NCT02917096|DRUG|Ruxolitinib|Given PO
218925397|NCT02917096|DRUG|Ruxolitinib Phosphate|Given PO
219539031|NCT03659565|BEHAVIORAL|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
218925398|NCT02917096|DRUG|Sirolimus|Given PO
218925399|NCT02917096|DRUG|Tacrolimus|Given IV and PO
219043100|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
219043101|NCT04182035|OTHER|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
219539032|NCT03659565|BEHAVIORAL|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
218925400|NCT06125041|DRUG|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
218925401|NCT04040205|DRUG|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily.
218925402|NCT06432296|DRUG|M701|Intra-peritoneal infusion of M701 in experimental group (M701 group\_
218925403|NCT06432296|PROCEDURE|paracentesis|Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
219043102|NCT04182035|OTHER|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
218925404|NCT06333860|DRUG|Risankizumab|Solution for Subcutaneous (SC) injection
218925405|NCT06333860|DRUG|Deucravacitinib|Oral tablet
218925406|NCT06345690|OTHER|VIA Disc NP|VIA Disc NP - Allograft tissue injection
219043103|NCT04182035|OTHER|Education|Education considering neck pain information
219043104|NCT02170584|DRUG|BIBR 953 ZW IV|
219043105|NCT02170584|DRUG|BIBR 1048 MS tablet|
219043106|NCT02170584|DRUG|BIBR 1048 MS oral solution|
219043107|NCT02170584|DRUG|BIBR 953 ZW IV Placebo|
219043108|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
219043109|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
219043110|NCT06355869|OTHER|repeated 3D gait-analysis|An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
219043111|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
219043112|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
219043113|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
219539033|NCT00840606|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
219539034|NCT00840606|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
218925407|NCT05927623|BEHAVIORAL|Multifaceted Virtual Fracture Prevention Program|"* Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Wibbi app (wibbi.com) and monthly virtual exercise consultations.~* Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~* Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
218925408|NCT05927623|BEHAVIORAL|Attention Control|"* Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~* Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~* Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
218925409|NCT06371768|BEHAVIORAL|AYA Educational Information|AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions. Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.
218925410|NCT06371768|BEHAVIORAL|AYA STEPS|The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care. Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques. Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
218925411|NCT00794716|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
218925412|NCT04410367|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
218925413|NCT02835287|OTHER|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
218925414|NCT03227913|OTHER|Two samples of saliva|"1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
218925415|NCT03227913|OTHER|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
218925416|NCT03227913|OTHER|Study of the food bolus|"* Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying"
218925417|NCT05569083|GENETIC|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
218925418|NCT05569083|DIAGNOSTIC_TEST|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
218925419|NCT05569083|DIAGNOSTIC_TEST|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
218925420|NCT05569083|DIAGNOSTIC_TEST|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
218925421|NCT05569083|DIAGNOSTIC_TEST|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
219043114|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
219043115|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
218925422|NCT05569083|DIAGNOSTIC_TEST|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
218925423|NCT05569083|DIAGNOSTIC_TEST|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
218925424|NCT05631587|BEHAVIORAL|WExercise|A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
218925425|NCT05631587|BEHAVIORAL|Control|A control group receiving an information sheet for self-directed exercise.
218925426|NCT06564519|DEVICE|Posture Biofeedback Device|Participants will wear a commercially available posture training device for a two-week tracking period and a two-week training period while performing laparoscopic procedures.
218925427|NCT05818189|DEVICE|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
218925428|NCT05818189|DEVICE|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
218925429|NCT05368753|OTHER|Blood sample|Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA
218925430|NCT05368753|DRUG|Lidocain|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
218925431|NCT05368753|DRUG|ropivacaine|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
218925432|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
218925433|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
218925434|NCT05174416|DRUG|Mavacamten|Mavacamten Capsules
218925435|NCT05174416|DRUG|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
218925436|NCT01648751|DRUG|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
218925437|NCT01648751|DRUG|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
218925438|NCT06575959|DRUG|Enlicitide|Oral tablet
218925439|NCT03111121|DRUG|Sugammadex|receive reversal with sugammadex 4mg/kg
218925440|NCT03111121|DRUG|neostigmine|receive reversal with neostigmine 0.04 mg/kg
218925441|NCT03111121|DRUG|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
218925442|NCT06250049|OTHER|Diabetic foot care protocol|Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
218925443|NCT06250049|OTHER|Group education sessions for patients and/or caregivers|Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
219043116|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
219043117|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
219043118|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
218925444|NCT03604783|DRUG|TP-1287|TP-1287 by oral administration
218925445|NCT05686356|DRUG|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
219043119|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
219043120|NCT00859170|DEVICE|Accordion device|an antiretropulsion device
219043121|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
219204938|NCT06627426|OTHER|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained."
218925446|NCT05686356|DRUG|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
218925447|NCT05686356|DRUG|Pretomanid|Pretomanid will be given at its approved dose
218925448|NCT05686356|DRUG|Bedaquiline|Bedaquiline will be given at its approved dose
218925449|NCT05686356|COMBINATION_PRODUCT|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
218925450|NCT03467750|DRUG|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
218925451|NCT03467750|DRUG|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
218925452|NCT02023463|DRUG|Enzalutamide|Given PO
218925453|NCT02023463|DRUG|Goserelin acetate|Given SC
218925454|NCT02023463|DRUG|Leuprolide acetate|Given IM or SC
218925455|NCT02023463|RADIATION|Radiation therapy|Undergo image-guided radiation therapy
218925456|NCT05673876|DRUG|GDC-8264|GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
218925457|NCT06141226|DRUG|TQB2450 +Anlotinib+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug."
218925458|NCT06141226|DRUG|TQB2450 +Androtinib Placebo+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug."
218925459|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
218925460|NCT04467437|OTHER|Gait Training|Training that targets rehabilitation of walking function
218925461|NCT04467437|DEVICE|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
218925462|NCT05424406|BEHAVIORAL|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
218925463|NCT05424406|BEHAVIORAL|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
218925464|NCT05424406|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
218925465|NCT05424406|BEHAVIORAL|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
219204939|NCT06630169|COMBINATION_PRODUCT|Cryopreserved AURN001|Corneal Endothelial Cells and Y27632
219204940|NCT06694766|PROCEDURE|Blood sample collection|A blood sample collection of 18.5 mL will be required for the immunogenicity component.
219365631|NCT06716905|DRUG|ACT500 tablets|Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1
219365632|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
219365633|NCT06716905|DRUG|ACT500 tablets|Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.
219365634|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
219365635|NCT05084482|OTHER|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
218925466|NCT05562999|DRUG|Rocuronium Bromide|Moderate NMB (TOF 1-2)
218925467|NCT05562999|DRUG|Rocuronium Bromide|Deep NMB (PTC 1-2)
218925468|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in first stage|Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
218925469|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in second stage|Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
218925470|NCT04701762|DEVICE|GlideScope videolaryngoscope (Verathon, Bothell, Washington 98011)|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, Washington 98011) is an FDA-cleared commercially available portable videolaryngoscope.
218925471|NCT04701762|DEVICE|Direct laryngoscopy|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
219539035|NCT04287322|BEHAVIORAL|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
218925472|NCT02749422|DIAGNOSTIC_TEST|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
218925473|NCT04327804|DIAGNOSTIC_TEST|Odd/Even birth year intervention groups|The nostril used and order of testing will be different in each arm.
218925474|NCT04377659|DRUG|Tocilizumab|Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
218925475|NCT06108414|DRUG|low-dose rivaroxaban|Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
218925476|NCT06108414|DRUG|Standard-dose rivaroxaban|Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
218925477|NCT06586840|OTHER|rescue analgesia|. If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia
218925478|NCT06586840|PROCEDURE|Adductor Canal Block|For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.
219043122|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
219043123|NCT05466578|DRUG|abrocitinib|
219043124|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
219043125|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
219043126|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
219043127|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
219043128|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
219043129|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
219043130|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
219043131|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
219043132|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
219043133|NCT02224872|RADIATION|TBI|200 cGy on day -1
219043134|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
219043135|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
219043136|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
219043137|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
219043138|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
219043139|NCT02365636|DRUG|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
219043140|NCT02365636|DRUG|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
219043141|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
219043142|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
219043143|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
219043144|NCT02111252|DRUG|TAK-850|TAK-850 injection
219043145|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
218925479|NCT06586840|PROCEDURE|Adding an IPACK Block to the Adductor Canal Block|For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
218925480|NCT06593561|OTHER|Breast Edema Questionnare|The Breast Edema Questionnaire, developed to evaluate breast edema in women undergoing breast cancer surgery, will be applied.
219539036|NCT04287322|BEHAVIORAL|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
218925481|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
218925482|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
219539037|NCT03589170|DIAGNOSTIC_TEST|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
219539038|NCT06089382|DRUG|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
218925483|NCT06601400|COMBINATION_PRODUCT|Erythropoietin (EPO) with xenograft|After atraumatic extraction of the non-restorable tooth, Implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft and erythropoietin.
219539039|NCT06089382|DRUG|Lenvatinib|8mg orally once a day for 1 year
219539040|NCT06089382|PROCEDURE|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
218925484|NCT06601400|OTHER|Xenograft alone|After atraumatic extraction of the non-restorable tooth, implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft alone.
218925485|NCT06591195|DEVICE|Distraction by use of kaleidoscope|"À kaleidoscope is an optical device consisting of mirrors that reflect images of bits of coloured glass in a symmetrical geometric design through a viewer.~A kaleidoscope was selected as the non-electronic method of distraction, because of its wide availability due to low costs, its evolving and colourful visual stimuli, the fact that is blocks out any visualisations from the environment when used properly, and because it requires active participation (i.e., greater attention) from the subject."
219043146|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
219043147|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
219043148|NCT06382987|DRUG|Deucravacitinib|According to the product label
219043149|NCT06382987|DRUG|Apremilast|According to the product label
219043150|NCT00148603|DRUG|montelukast|
219043151|NCT00072865|DRUG|Pemetrexed|
219043152|NCT00072865|DRUG|Carboplatin|
219043153|NCT05098639|BEHAVIORAL|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
219204941|NCT06687408|PROCEDURE|RATS Group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in robotic-assisted thoracic surgery (RATS) approach, which has been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently.
219204942|NCT06687408|PROCEDURE|VATS group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in video-assisted thoracic surgery (VATS) approach.
219539041|NCT00099047|DRUG|celecoxib|Given PO
219539042|NCT00099047|DRUG|placebo|Given PO
219539043|NCT00099047|OTHER|laboratory biomarker analysis|Correlative studies
219539044|NCT00651820|DRUG|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
219539045|NCT00651820|DRUG|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
218925486|NCT06588309|BEHAVIORAL|Eye movement desensitization and reprocessing (EMDR)|Integrated addiction and traumafocused treatment.
218925487|NCT06588309|BEHAVIORAL|CRA|CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.
218925488|NCT05427422|DIAGNOSTIC_TEST|MRI recording|MRI imaging was performed using a 3 Tesla Siemens Prisma system with a 64-channel head/neck coil (Siemens Medical Systems, Erlangen, Germany). The MRI protocols included as follows: (i) Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes: TR/TE/ TI1/TI2 = 5000/2.98/700/2500 ms, voxel size = 1.0 × 1.0 × 1.0 mm3, FOV = 256 × 240 × 176 mm3; (ii)Gradient-echo EPI: TR 720 ms, TE 33.1 ms, flip angle 52 deg, FOV 208x180 mm, Matrix 104x90, Slice thickness 2.0 mm; 72 slices; 2.0 mm isotropic voxels, Multiband factor 8, Echo spacing 0.58 ms, BW 2290 Hz/Px; (iii) DSI : TR/TE = 3300/73 ms, FOV = 220 × 220 × 60 mm3, voxel size = 2 × 2 × 2 mm3, 128 diffusion direction, b-max = 3000 sec/mm2, AT = 7:22 min); (iv) T2-weighted fluid-attenuated inversion recovery: TR/TE = 9000/84 ms, FOV = 270 × 320 × 22 mm2, voxel size = 0.72 × 0.72 × 6.6 mm3.
218925489|NCT05427422|DIAGNOSTIC_TEST|EEG recording|"EEG was performed using a BrainAmp MR 32 amplifier (BrainProducts GmbH, München, Germany). The EEG protocols included as follows: (i) EEG-fMRI fusion: Sampling rate: 5000 Hz, low cut off-high cut off: DC-1000Hz;(2) EEG-fMRI fusion: Sampling rate: 1000 Hz, low cut off-high cut off: DC-1000Hz.~In (i) an ECG channel would be used to collect artifact of pulse and not used in (ii)."
219043154|NCT05098639|BEHAVIORAL|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
219043155|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
219043156|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
219043157|NCT00003491|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219365636|NCT03475043|BEHAVIORAL|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
219365637|NCT02115230|PROCEDURE|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
219365638|NCT06865170|PROCEDURE|25 gauge needle|This intervention will observe patients post-procedural pain using a 25 gauge needle
219365639|NCT06865170|PROCEDURE|22 gauge needle|This intervention will observe patients post-procedural pain using a 22 gauge needle
219365640|NCT06865170|PROCEDURE|+/- Ethyl Chloride Topical Aerosol Anesthetic|This intervention will observe patients post-procedural pain when using topical ethyl chloride spray. This will be compared to a placebo spray which will utilize isopropyl alcohol.
219365641|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
219365642|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
219365643|NCT01218607|DRUG|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
219365644|NCT01218607|DRUG|Placebo|Placebo will be taken twice daily for 16 weeks
219365645|NCT06916936|OTHER|Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter|"Peanut Butter (PB) Group: Participants in this group will receive a daily snack consisting of a personalized portion of smooth peanut butter (Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). The amount of peanut butter will be limited to 16g per two crackers, but additional crackers will be provided if the personalized portion exceeds this limit"
219365646|NCT06916936|OTHER|Cadbury Milk Chocolate Spread|"Control (CTL) Group: Participants in this group will receive a daily snack consisting of an isocaloric amount of a nut-free, vegetable oil-based chocolate spread (Cadbury Milk Chocolate) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). Similar to the peanut butter group, the chocolate spread will be limited to 16g per two crackers, with additional crackers provided if needed."
219365647|NCT06916442|DIAGNOSTIC_TEST|PET/CT Imaging with GZMB-targeted tracer|Intravenous administration of GZMB-targeted tracer (150-200 MBq), followed by whole-body PET/CT scan 30\~60 minutes post-injection.
219366800|NCT03729882|PROCEDURE|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
218925490|NCT05848752|BEHAVIORAL|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
218925491|NCT06993272|BEHAVIORAL|MIndful Jazz|Mindful Jazz Group: Participants in this group will watch an introduction to jazz appreciation and mindfulness training video, including the use of jazz for pain tolerance prior to the 4-week intervention. Participants in the Mindful Jazz Group will be informed that listening to music they are not comfortable with (i.e., jazz) can enhance long-term pain tolerance.
218925492|NCT06993272|BEHAVIORAL|Reggae Stereotypes|Reggae Stereotype Group: Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks.
218925493|NCT06993272|BEHAVIORAL|Traditional Mindfulness|Participants will listen to a traditional mindfulness practice over the 4 weeks
218925494|NCT06993272|BEHAVIORAL|Pain psychoeducation|Participants listen to an audio recording of the pain psychoeducation video they watch during training over the 4 weeks. Video: https://www.youtube.com/watch?v=azwEQXh5enA
218925495|NCT06991478|DRUG|SK-NK injection|In this stage, two dose groups are preset, namely 20×108 cells and 30×108 cells. Subjects who meet the inclusion criteria will receive intravenous infusion of SK-NK injection once a week for six consecutive times. After completing six consecutive infusions of SK-NK injection, the researchers evaluated that the patient benefited and could continue to receive six consecutive infusions of SK-NK injection. After completing twelve infusions, the decision on whether to continue the treatment subsequently could be made based on the patient's condition
218925496|NCT06991478|DRUG|SK-NK injection|Based on the dose selected from the results of the first stage, the clinical efficacy, safety, tolerability and pharmacokinetic characteristics of RP2D were further verified. The types of cancer and the number of cases enrolled in stage II are to be determined
218925497|NCT06536673|BEHAVIORAL|Intervention to reduce infectious complications of peritoneal dialysis|"* Before catheter placement: The nurse and doctor provide the patient and/or caregiver with a PD simulation.~* Initial training: from the placement of the catheter to the beginning of the technique at home, approximately 4 weeks, 6 and 7 sessions, duration 1-2 hours per session. Individualized learning taking into account learning abilities and education. It includes the explanation of the PD and the display of informational pictograms/capsules.~* Step-by-step teaching: peritoneal exchange, peritoneal orifice care, administration of intraperitoneal medication, recording of constants, detection of complications and risk behaviors.~* Nutritional education and water intake.~* Administration of the Objective Structured Assessment (OSA) checklist.~* Retraining: between the 1st and 3rd month of the start, after an episode of peritonitis and/or hospitalization, risk behaviors, functional/cognitive impairment, passivity/demotivation behaviors, and regularly once the year."
218925498|NCT06536673|BEHAVIORAL|Data collection from the patient's clinical history|Data collection from the patient's clinical history because this new standardized educational intervention was not used.
218925499|NCT06538896|DRUG|Tislelizumab + Nab-Paclitaxel|Tislelizumab, 200mg, intravenous, every 3 weeks
219539046|NCT06561789|OTHER|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
219539047|NCT06561789|OTHER|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
219539048|NCT06561789|OTHER|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
219539049|NCT00005025|BIOLOGICAL|herpes simplex thymidine kinase|
218925500|NCT06538896|OTHER|Rankl inhibitor|RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
218925501|NCT06991400|OTHER|Trans-Amniotic Suture Placement|Trans-Amniotic Suture placement
218925502|NCT06992817|BEHAVIORAL|Hydration-Coach Encouragement|Athletes were encouraged by their coaches to consume fluids during the training session.
219043158|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
219043159|NCT03906669|DRUG|Letrozole|PO daily for 14 days
219043160|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
219043161|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
219043162|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
218925503|NCT06992817|BEHAVIORAL|Short Hydration Informative Session|Athletes were given a brief educational session related to importance of hydration before the exercise session.
219043163|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
219043164|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
219539050|NCT00005025|DRUG|ganciclovir|
219366801|NCT03729882|PROCEDURE|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
219366802|NCT05202145|DRUG|ALXN2050|Oral tablet.
219539051|NCT01312415|DRUG|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
219539052|NCT01312415|DRUG|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
219539053|NCT01911676|DRUG|PF-03463275|
219539054|NCT01911676|DRUG|Placebo|
219539055|NCT01695538|OTHER|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
219539056|NCT01958450|PROCEDURE|Er:YAG laser|acne scar treatment using Er:YAG laser
219539057|NCT01958450|PROCEDURE|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
219539058|NCT04664556|OTHER|observational study|observational study
219539059|NCT03187158|DIAGNOSTIC_TEST|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
219539060|NCT04627467|DRUG|Chloroquine|250mg tablet (150mg base chloroquine)
219366803|NCT05202145|DRUG|Cyclosporine|Oral capsule.
219539061|NCT00773253|DRUG|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
219539062|NCT01878292|DRUG|Placebo|Dose matched placebo tablets, once per day, oral administration.
219539063|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
219539064|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
219539065|NCT06330142|OTHER|Participation in 10 horse-assisted therapy sessions|supporting children and teenagers undergoing radiotherapy with a horse-assisted therapy approach
219539066|NCT06380816|DRUG|UCB4594|Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
219366804|NCT05202145|DRUG|Tacrolimus|Oral capsule.
219366805|NCT05202145|DRUG|MMF|Oral tablet.
219366806|NCT03850197|DEVICE|EarPopper|"The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
218925504|NCT06598215|PROCEDURE|Duckett urethroplasty|hybrid duckett urethroplasty vs modified duckett urethroplasty
218925505|NCT06586671|DRUG|Nemtabrutinib|Oral administration
218925506|NCT06405932|COMBINATION_PRODUCT|Mental Fitness Training Camp|The Mental Fitness Training camp employs and incorporates core learning content derived from Cognitive Behavioral Therapy and Mindfulness. The program comprises nine thought animations, emotional diary, daily breathing exercises, and pleasure lists.
218925507|NCT06590363|OTHER|Listening to zen music|We conducted a quasi-randomized controlled clinical trial with two groups: Intervention Group (I), which corresponded to patients and doctors who underwent the period of musical listening in the office; and the Control Group (C), composed of patients and doctors who did not undergo the period of musical listening.
218925508|NCT06590298|DRUG|Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females|The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
218925509|NCT06587724|OTHER|Questionnaire study|Questionnaire application
218925510|NCT06861504|DEVICE|Femscope Calm Collect Device|The Femscope Calm Collect Device uses a patented brush for cervical cell collection.
218925511|NCT02938299|DRUG|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
218925512|NCT02938299|PROCEDURE|Surgery|Surgical resection of melanoma tumor lesions
218925513|NCT01704209|DRUG|Fibroblast Treatment|
218925514|NCT01704209|PROCEDURE|Vehicle|
218925515|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
218925516|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
218925517|NCT05987930|DEVICE|bone lid technique|group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
219366807|NCT03850197|DEVICE|Tympanometry|The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.
219539067|NCT05391165|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
219620137|NCT06717776|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training.~The occupational problem is defined.~The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model.~Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
218925518|NCT05987930|DEVICE|standard technique|group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
218925519|NCT00755989|OTHER|None available|
219043165|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
219539068|NCT06563206|PROCEDURE|Exergame|Hand Training assisted with Virtual-Reality
219043166|NCT00006219|DRUG|clarithromycin|
219539069|NCT06563206|PROCEDURE|Robotic|Hand Training assisted with Robotic Syrebo
218925520|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
218925521|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
218925522|NCT02786394|BEHAVIORAL|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
218925523|NCT02785549|DRUG|Ibuprofen|600 mg/8hours
219043167|NCT00006219|DRUG|prasterone|
219043168|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
219043169|NCT03431116|RADIATION|ultrasound|to detect the placental site
219043170|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
219043171|NCT06153446|DIAGNOSTIC_TEST|Synovasure® Comprehensive Infection Panel|The Synovasure Comprehensive PJI Test Panel (PJI Panel) is a laboratory-developed test (LDT) panel (CD Laboratories, CLIA Registration No.: 21D0216863) intended to aid the diagnosis of PJI.
219043172|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
219043173|NCT04541875|OTHER|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
219043174|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
219043175|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
219043176|NCT05187416|DIAGNOSTIC_TEST|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
219043177|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
219043178|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
219043179|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
219043180|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
219043181|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
219043182|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
219043183|NCT01782313|DRUG|tivozanib|Given PO
219043184|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
219043185|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
219043186|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
219043187|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
219539070|NCT06563206|PROCEDURE|Conventional|Hand Training with Physical Therapist
219539071|NCT02834026|OTHER|Cicloergometry training|
219539072|NCT02834026|OTHER|No Cicloergometry training|
218925524|NCT02785549|DRUG|Acetaminophen|1 g/8 hours
218925525|NCT02785549|DRUG|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
219539073|NCT04519749|BIOLOGICAL|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
219539074|NCT04045925|OTHER|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
218925526|NCT05348343|BIOLOGICAL|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
218925527|NCT05784493|OTHER|Study group|Washing by heated saline group
218925528|NCT06834945|BEHAVIORAL|AYA SPARK|Intervention includes video conferencing based sessions to cover topics related to fertility-related information needs and concerns among female adult survivors of childhood cancer over a 6-8 week period.
219539075|NCT01960374|DRUG|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
219539076|NCT00222118|BEHAVIORAL|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
219539077|NCT00222118|OTHER|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
219539078|NCT00222118|OTHER|usual care|no intervention
219539079|NCT06432595|OTHER|Instability resistance training and Traditional resistance training|The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.
219539080|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
219539081|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
219539082|NCT01093053|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
219539083|NCT01093053|OTHER|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
219539084|NCT03378492|DEVICE|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
219620138|NCT06717776|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupa
219620139|NCT01406587|DRUG|PP4001|50 mg, 1 dose every 12 hours x 4 doses
219620140|NCT01406587|DRUG|PP4001|100 mg, 1 dose every 12 hours x 4 doses
219620141|NCT01406587|DRUG|PP4001|200 mg, 1 dose every 12 hours x 4 doses
219620142|NCT01406587|DRUG|Placebo|Placebo, 1 dose every 12 hours x 4 doses
218925529|NCT04828343|DRUG|rozanolixizumab|Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
218925530|NCT04828343|OTHER|Placebo|Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
218925531|NCT01341613|DIETARY_SUPPLEMENT|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
218925532|NCT01341613|DIETARY_SUPPLEMENT|Placebo capsule|Twice per day (BID), 9 weeks
219620143|NCT00114660|DRUG|Cocoa butter application|
219620144|NCT03290963|DRUG|Lithium|Lithium will be dosed in units (LI level \> or = 0.4 milliequivalents (mEq)/L)
219620145|NCT03290963|DRUG|Placebo|Placebo tablets, dosed in units
219620146|NCT03290963|DRUG|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
218925533|NCT00538668|DRUG|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
218925534|NCT05150119|DIAGNOSTIC_TEST|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
218925535|NCT01302990|BIOLOGICAL|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
218925536|NCT06094582|OTHER|questionnaire|Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.
218925537|NCT03365089|PROCEDURE|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
218925538|NCT01999257|OTHER|Online pre-test genetic education tool|See Arm Descriptions above.
218925539|NCT05973617|DIAGNOSTIC_TEST|Measurement of corneal biomechanical properties|Measurement of corneal biomechanics
218925540|NCT05217316|BEHAVIORAL|Supervised Virtual Toothbrushing|"A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision."
218925541|NCT05306756|DIAGNOSTIC_TEST|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
219539085|NCT03378492|PROCEDURE|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
219620147|NCT02723344|DIETARY_SUPPLEMENT|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
219620148|NCT02723344|OTHER|Sunflower and medium chain triglyceride oils|Placebo
219620149|NCT03473184|DRUG|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
219620150|NCT01410903|DEVICE|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
218925542|NCT05306756|DIAGNOSTIC_TEST|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
219043188|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
219043189|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
219043190|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
219043191|NCT02093572|OTHER|3 standard meals/day|
219043192|NCT02093572|OTHER|2 meals/day (omit breakfast)|
219043193|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
219043194|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
219043195|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
219043196|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
219043197|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
219043198|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
219620151|NCT04851847|DEVICE|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
219620152|NCT02964247|DRUG|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
218925543|NCT00750503|BEHAVIORAL|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
219539086|NCT01566721|DRUG|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
218925544|NCT01694498|DRUG|A: Desmopressin 25 µg|
218925545|NCT01694498|DRUG|B. Desmopressin 50 µg|
218925546|NCT01694498|DRUG|Placebo|
218925547|NCT04610281|DEVICE|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
218925548|NCT04884464|DEVICE|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
218925549|NCT04884464|DRUG|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
218925550|NCT06611553|PROCEDURE|Biospecimen Collection|Undergo collection of cervical sample by clinician
219620153|NCT02964247|DRUG|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
219620154|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally|Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
218925551|NCT06611553|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
219620155|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
219620156|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)|Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
219620157|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days|Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
218925552|NCT06611553|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
218925553|NCT06611553|OTHER|Electronic Health Record Review|Ancillary studies
218925554|NCT06611553|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
218925555|NCT06611553|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
218925556|NCT06611553|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
218925557|NCT06611553|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal sample and cervical sample
218925558|NCT06611553|OTHER|Questionnaire Administration|Ancillary studies
219043199|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
219043200|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
218925559|NCT06611553|OTHER|Survey Administration|Ancillary studies
218925560|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
218925561|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
218925562|NCT04412512|PROCEDURE|VATS approach|video-assisted thoracic surgery approach
218925563|NCT04412512|PROCEDURE|Thoracotomy approach|
218925564|NCT02789293|DEVICE|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
218925565|NCT01837121|OTHER|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
218925566|NCT02911584|PROCEDURE|Laparoscopic procedure|
219043201|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
219043202|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
219043203|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
218925567|NCT04939714|BEHAVIORAL|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
218925568|NCT01685502|DRUG|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
218925569|NCT04126941|OTHER|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
219043204|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
219043205|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
219539087|NCT00954590|DRUG|Dimebon (latrepirdine)|20 mg orally three times daily
219539088|NCT00954590|DRUG|Placebo|Placebo orally three times daily
219539089|NCT06130436|DEVICE|Sham-Remote Ischemic Conditioning|Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
218925570|NCT04685044|DEVICE|IH 1Tx32Rx Head Array|BrainPET insert
218925571|NCT04899986|OTHER|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
218925572|NCT04899986|OTHER|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
218925573|NCT04262154|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks
218925574|NCT04262154|DRUG|Abiraterone|Abiraterone 1000 mg daily
218925575|NCT04262154|DRUG|Prednisone|Prednisone 5 mg daily
218925576|NCT04262154|DRUG|GnRH analog|Any GnRH analog that is commercially available, injectable, and long acting analog of the native LHRH peptide and is administered to subjects via intramuscular injection. For this study, any GnRH analog can be used and thee manufacturer's instructions for dose and frequency should be followed.
218925577|NCT04262154|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Intensity-modulated, image-guided, ultra-hypofractionated external beam radiotherapy (7.25-7.5 Gy x 5 to prostate and seminal vesicles QOD) will begin around 12 weeks (at Cycle 5 Day 1 (+/-5 days)
218925578|NCT04262154|DRUG|Enzalutamide|160 mg once daily
218925579|NCT04262154|OTHER|Follow up|Subjects who discontinue study treatment for reasons other than progression will be followed every 6 months (+/- 4 weeks) until a documented progression event (i.e., PSA, radiographic, or clinical progression). After a documented progressionevent (whether on treatment or during follow up), subjects will continue to be followed every 6 months (+/- 4 weeks) for overall survival via chart review and/or telephone call.
218925580|NCT06035913|DRUG|Dihydroergot mesylate|take medicine
218925581|NCT03800147|DRUG|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
218925582|NCT03800147|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
218925583|NCT03800147|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
218925584|NCT03800147|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
219620158|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
219620159|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
219620160|NCT02749500|OTHER|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
218925585|NCT00753506|DIETARY_SUPPLEMENT|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
218925586|NCT00753506|DIETARY_SUPPLEMENT|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
218925587|NCT03153943|DEVICE|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
218925588|NCT03153943|OTHER|Workbook support|Printed material support
218925589|NCT02178150|DIETARY_SUPPLEMENT|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
218925590|NCT02178150|DIETARY_SUPPLEMENT|Placebo|
218925591|NCT01791712|PROCEDURE|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
219043206|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
219043207|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
219043208|NCT04338711|DRUG|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
219620161|NCT02749500|DEVICE|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
219620162|NCT01709500|DRUG|LMT (atorvastatin, simvastatin, or rosuvastatin)|
219620163|NCT01709500|DRUG|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
219620164|NCT01709500|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
218925592|NCT01791712|PROCEDURE|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
218925593|NCT03891381|DEVICE|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
218925594|NCT04380285|DEVICE|Custom heel pads and modified soft molded orthotics|
219620165|NCT00197171|BIOLOGICAL|Combined Hepatitis A and B vaccine|
218925595|NCT04380285|DEVICE|Custom hard orthotic|
218925596|NCT04147663|OTHER|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
218925597|NCT03227120|OTHER|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
218925598|NCT05391672|PROCEDURE|we will do ACL augmentation surgery to the patients who have partial ACL tear|we will do ACL augmentation surgery to the patients who have ACL partial tear using hamstring graft and fixation of the graft to the femoral part by adjustable loop and tibial part with Bio or peak screws +\\- staples.
218925599|NCT06431152|BIOLOGICAL|UC-MSC sEV|Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
218925600|NCT04052633|RADIATION|intraoperative cholangiography|success or failure of cholangiography
218925601|NCT03098732|DEVICE|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
218925602|NCT03098732|DEVICE|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
219043209|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
219043210|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
219539090|NCT06130436|DEVICE|Remote Ischemic Conditioning Once Daily|"Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg."
219539091|NCT06130436|DEVICE|Remote Ischemic Conditioning Twice Daily|Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
219539092|NCT01527890|DRUG|Fentanyl|intravenous patient-controlled analgesia
219539093|NCT03286439|OTHER|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
218925603|NCT02117661|DIETARY_SUPPLEMENT|L-carnitine capsules|Oral
218925604|NCT02117661|DIETARY_SUPPLEMENT|Cellulose capsules|oral
219043211|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
219043212|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
219043213|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
219043214|NCT03160963|OTHER|Power Testing|Chair stand, vertical jump, computerized squat
219043215|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
219043216|NCT01802775|DRUG|edoxaban|
218925605|NCT04863469|BEHAVIORAL|B-POC high load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
218925606|NCT04863469|BEHAVIORAL|B-POC low load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
218925607|NCT00357552|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
218925608|NCT00357552|DRUG|Lopinavir/Ritonavir|Twice daily
218925609|NCT04910997|OTHER|Aerobic exercise training|Combination of supervised and home-based aerobic exercise training
218925610|NCT00157989|PROCEDURE|Controlled tidal volume resuscitation|
218925611|NCT05338814|OTHER|scapular corrective exercises|40 minutes each, three times a week for six weeks
218925612|NCT05338814|OTHER|conventional neck exercises|40 minutes each, three times a week for six weeks
218925613|NCT00976404|BIOLOGICAL|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
218925614|NCT00976404|DRUG|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
218925615|NCT00976404|DRUG|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
218925616|NCT00521404|DRUG|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
218925617|NCT00521404|DRUG|gemcitabine|Gemcitabine - 1000mg/meter sq
218925618|NCT00850239|DRUG|dutogliptin|400 mg
218925619|NCT00850239|DRUG|placebo|
218925620|NCT04600661|OTHER|Traditional exercise therapy|Neuromuscular training
218925621|NCT03416543|OTHER|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
218925622|NCT00876551|PROCEDURE|Endoscopic vacuum assisted closure|"1. Endoscopic debridement of wound using a regular biopsy forceps.~2. Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~3. Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson \& Johnson, St-Stevens-Woluwe, Belgium).~4. Trimming of the sponge to the specific wound size.~5. Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~6. Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~7. Sponge exchange twice a week until wound grounds are clean and closed"
218925623|NCT00882557|DRUG|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
218925624|NCT00882557|DRUG|daptomycin|6 mg/kg administered after a hemodialysis session
218925625|NCT00967837|PROCEDURE|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
218925626|NCT00424892|DRUG|Desvenlafaxine Sustained Release|
218925627|NCT04951635|DRUG|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
218925628|NCT04951635|DRUG|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
218925629|NCT02791503|PROCEDURE|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
218925630|NCT02791503|PROCEDURE|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
218925631|NCT04581694|DIAGNOSTIC_TEST|TAVI without contrast|TAVI without contrast
218925632|NCT02282605|DRUG|XF-73 nasal gel|
218925633|NCT02282605|DRUG|Placebo nasal gel|
219043217|NCT01802775|DRUG|Clopidogrel|75mg tablet
219043218|NCT01802775|DRUG|Aspirin|
219043219|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
219043220|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
219043221|NCT00386256|DEVICE|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
219043222|NCT00386256|OTHER|Telephone counseling|
219043223|NCT03019276|DRUG|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
219043224|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
219043225|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
219043226|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
219043227|NCT06189456|DEVICE|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
219043228|NCT06189456|DEVICE|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
219043229|NCT04199429|BEHAVIORAL|Relationship-Based Care|
219043230|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events) and inflammatory mediators
219539094|NCT03374176|DRUG|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
219539095|NCT03374176|DRUG|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
219539096|NCT00398983|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days
219539097|NCT06561568|DIAGNOSTIC_TEST|Conventional physical therapy|Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.
218925634|NCT02282605|OTHER|Chlorhexidine gluconate 2% topical cloths|
218925635|NCT04816552|BEHAVIORAL|CHoBI7 mHealth program Arm|We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
219539098|NCT06561568|OTHER|Kinesiotaping|"Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks."
219539099|NCT02102191|DEVICE|e-cigarette|smoking cigarette without tobacco
219539100|NCT02102191|DEVICE|cigarette|smoking cigarette with tobacco
218925636|NCT04816552|BEHAVIORAL|general message on oral rehydration solution (ORS)|general message on oral rehydration solution (ORS)
218925637|NCT05322473|DRUG|Sonelokimab (M1095)|randomized treatment; parallel-group
218925638|NCT05322473|DRUG|Adalimumab|randomized treatment; parallel-group
219539101|NCT05024682|DEVICE|conventional pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
219539102|NCT05024682|DEVICE|pulse dosed pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
219539103|NCT00699296|DRUG|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
219539104|NCT06055764|DEVICE|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
219539105|NCT01302548|DEVICE|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
218925639|NCT05322473|OTHER|Placebo|randomized treatment; parallel-group
218925640|NCT01908062|DRUG|Extended Release Naltrexone|
219539106|NCT01302548|PROCEDURE|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
219539107|NCT00004786|DRUG|iloprost|
219539108|NCT03537807|DRUG|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
218925641|NCT01908062|OTHER|Treatment As usual|
218925642|NCT03396263|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
218925643|NCT03396263|BEHAVIORAL|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
218925644|NCT03396263|BEHAVIORAL|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
218925645|NCT04823013|OTHER|high power pain threshold ultrasound which the dose was kept constant|Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
218925646|NCT04823013|OTHER|high power pain threshold ultrasound which the dose reduced to one half|Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
218925647|NCT04823013|OTHER|ischemic compression|Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
219043231|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
219539109|NCT00031434|DRUG|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
218925648|NCT00345748|DRUG|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
219043232|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
219043233|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
219043234|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
218925649|NCT00345748|DRUG|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
218925650|NCT01993797|OTHER|Lung US|
218925651|NCT02461277|OTHER|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
218925652|NCT00916331|PROCEDURE|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
218925653|NCT00916331|PROCEDURE|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
218925654|NCT03770767|DRUG|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
218925655|NCT03770767|DRUG|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
218925656|NCT03428035|OTHER|Package Insert|Modified package insert of Ibuprofen given postprocedural as pain medication
218925657|NCT04235751|BEHAVIORAL|Professional Coaching|6 individualized professional coaching sessions via phone
218925658|NCT02086500|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
218925659|NCT02086500|OTHER|Saline control|Saline Control
218925660|NCT03584789|OTHER|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
218925661|NCT03584789|OTHER|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
218925662|NCT00990197|DRUG|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
218925663|NCT02253446|DRUG|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
218925664|NCT02253446|DRUG|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
218925665|NCT05550493|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
218925666|NCT05550493|BEHAVIORAL|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
218925667|NCT05550493|BEHAVIORAL|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
218925668|NCT05550493|BEHAVIORAL|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
218925669|NCT05848999|BIOLOGICAL|UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
219539110|NCT00031434|DRUG|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
218925670|NCT00598676|DEVICE|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
218925671|NCT00598676|DEVICE|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
218925672|NCT00598676|DEVICE|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
218925673|NCT05295069|BEHAVIORAL|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
218925674|NCT02035267|DRUG|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
218925675|NCT02035267|DRUG|Placebo|Phosphate buffered saline placebo for injection.
218925676|NCT05526482|DEVICE|mobile app|preoperative respiratory exercises and thoracic surgery with a mobile application
218925677|NCT00517088|DRUG|IPAQ|
219043235|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
219043236|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
219539111|NCT06287281|OTHER|heel hight shoes|stand upright for 2 hours wearing your own shoes with heels at least 7 cm high
218925678|NCT00808652|OTHER|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~1. Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~2. NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
219539112|NCT03741777|OTHER|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
219539113|NCT03596567|DRUG|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
219539114|NCT03596567|DRUG|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
219539115|NCT03596567|DRUG|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
219539116|NCT02116595|OTHER|high or low acid diet|high or low acid diets
219539117|NCT04118335|OTHER|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
219539118|NCT03905980|PROCEDURE|vaginal delivery|pregnancy ended by vaginal delivery
219539119|NCT03905980|PROCEDURE|Cesarean section|pregnancy ended by cesarean delivery
218925679|NCT05023668|OTHER|No intervention|No intervention
218925680|NCT06103786|BEHAVIORAL|Assigned Interventions|"Ice hockey players did 12 weeks of on-ice high-intensity interval training. Their training included:~Repetitive sprint training Sprint interval training Long-pass tracking drills Chase-the-rabbit tracking drills High-intensity interval training in four types improved college ice hockey players' sports performance in 12 weeks."
218925681|NCT06103786|BEHAVIORAL|Random Interventions|"Ice hockey players did 12 weeks of traditional on-ice training. Their training included:~Varied pacing skating Dribbling and shooting Passing and catching drills 2-on-1 offensive tactics Traditional training in four types improved college ice hockey players' sports performance in 12 weeks.~A 12-week on-ice training program was conducted on college players to observe its effects on their physical fitness, skills, and tactical performance compared to an experimental and control group."
218925682|NCT05053958|OTHER|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
219539120|NCT03398486|DIAGNOSTIC_TEST|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
219539121|NCT03398486|DIAGNOSTIC_TEST|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
219539122|NCT02951858|BEHAVIORAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
219539123|NCT02951858|BEHAVIORAL|Control Group|The participants only receive the materials about the harm of substance use.
219539124|NCT03480880|DEVICE|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
219539125|NCT01237054|DRUG|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
219539126|NCT01237054|OTHER|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
219539127|NCT01237054|DRUG|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
218925683|NCT04509219|DRUG|Methylprednisolone Injection|methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
218925684|NCT04803396|DRUG|DF2755A|"DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14)."
218925685|NCT04803396|OTHER|Placebo|Single oral dose administration on D1
218925686|NCT04827680|DEVICE|Venus Viva MD|The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
219539128|NCT05367986|DEVICE|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
219539129|NCT06503926|OTHER|SARS-COV-2 vaccination|Vaccination
219539130|NCT06527222|DRUG|Ranolazine|500mg twice daily
219539131|NCT06527222|DRUG|Ranolazine|1000 mg twice daily
219539132|NCT06527222|DRUG|Placebo|Ranolazine placebo twice daily
219539133|NCT04815668|OTHER|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
218925687|NCT00614731|BIOLOGICAL|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
218925688|NCT01146717|BEHAVIORAL|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
218925689|NCT01146717|BEHAVIORAL|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
218925690|NCT04755686|PROCEDURE|Fast-tracking|
218925691|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
218925692|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
218925693|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
218925694|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
218925695|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
219539134|NCT04815668|OTHER|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
218925696|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
218925697|NCT01045837|DRUG|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
218925698|NCT01045837|BEHAVIORAL|Gluten free diet|Only gluten free diet will be given in this group
218925699|NCT05457010|BIOLOGICAL|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
218925700|NCT05457010|BIOLOGICAL|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
218925701|NCT04917016|DIAGNOSTIC_TEST|Plasma B-HCG levels|Blood sample
218925702|NCT02037308|DIETARY_SUPPLEMENT|Bread|
218925703|NCT02079961|DIETARY_SUPPLEMENT|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
218925704|NCT02079961|BEHAVIORAL|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
218925705|NCT00602472|DRUG|linagliptin|active
218925706|NCT00602472|DRUG|placebo|placebo to linagliptin 5 mg
218925707|NCT03038880|DRUG|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
218925708|NCT03038880|DRUG|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
218925709|NCT03038880|DRUG|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
218925710|NCT01416324|DRUG|placebo|Vehicle used to dilute the powder for oral administration.
218925711|NCT01416324|DRUG|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925712|NCT01416324|DRUG|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925713|NCT01416324|DRUG|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925714|NCT01416324|DRUG|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925715|NCT01416324|DRUG|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925716|NCT01416324|DRUG|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
219539135|NCT04815668|OTHER|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
219620166|NCT04127773|DEVICE|oro gastric tube|According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
218925717|NCT01416324|DRUG|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
218925718|NCT03678220|DEVICE|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
218925719|NCT04207762|DIAGNOSTIC_TEST|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
218925720|NCT04207762|DIAGNOSTIC_TEST|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
218925721|NCT01718405|OTHER|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
218925722|NCT01718405|GENETIC|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
218925723|NCT01823913|DRUG|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
218925724|NCT01823913|DRUG|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
219204943|NCT05386173|PROCEDURE|Fetal aortic balloon dilatation|Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
219204944|NCT06873477|DIAGNOSTIC_TEST|Gross Motor Function Classification System|Clinical assessment of the outcome of patients with traumatic and hypoxic-ischemic brain injury at least 2 years post-event.
219204945|NCT06873737|OTHER|Blood samples for inflammatory markers|Blood sampling in the first, second, trimester of pregnancy
219204946|NCT06872229|BEHAVIORAL|Autism Spectum Conditions - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
219204947|NCT06872229|BEHAVIORAL|Typical Development - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
218925725|NCT01817803|DRUG|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
218925726|NCT01817803|DRUG|metolazone/no spironolactone|metolazone (add 2.5mg qod)
219043237|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
219539136|NCT03453476|DEVICE|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
219620167|NCT03758417|BIOLOGICAL|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
218925727|NCT01817803|DRUG|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
219043238|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
218925728|NCT01817803|DRUG|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
218925729|NCT03807921|DRUG|Warfarin|Oral anticoagulation
219620168|NCT05768906|OTHER|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
219620169|NCT06956157|DRUG|N-Acetylcysteine Tablets|In addition to participants' existing medication regimens, NAC will be added.
218925730|NCT03807921|DRUG|Aspirin|Antiplatelet treatment
218925731|NCT03746158|DIETARY_SUPPLEMENT|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
218925732|NCT04097964|BEHAVIORAL|brief intervention|1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
218925733|NCT04097964|BEHAVIORAL|treatment as usual|standard care conducted by primary care providers during clinic visits
218925734|NCT02345993|DRUG|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~\+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
218925735|NCT04446104|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
218925736|NCT04446104|DRUG|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
218925737|NCT04446104|DRUG|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
218925738|NCT04446104|DRUG|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
218925739|NCT04446104|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 500mg daily for 42 days
219539137|NCT04009434|DEVICE|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
219539138|NCT04009434|DEVICE|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
219539139|NCT03820427|DIAGNOSTIC_TEST|impulse oscillometry|impulse oscillometry
219204954|NCT05220553|DEVICE|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
219204955|NCT07031726|BEHAVIORAL|Worksite Nutrition and Wellness Program|A structured behavioral intervention combining personalized physical activity and structured physical activity (Zumba classes), personalized nutrition counseling, and mobile app-based self-monitoring.
219204956|NCT07031726|BEHAVIORAL|Standard education|General educational materials on healthy eating and physical activity based on the Ministry of Health guidelines. No tailored or active intervention provided.
219539140|NCT03820427|DIAGNOSTIC_TEST|multiple breath washout test|multiple breath washout test
218925740|NCT00224991|PROCEDURE|Intensive systematic information (osteoporosis school)|
218925741|NCT05097040|BEHAVIORAL|acceptance and commitment therapy (ACT)|The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
218925742|NCT01359085|DRUG|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
218925743|NCT01359085|PROCEDURE|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
218925744|NCT06067217|DRUG|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
219539141|NCT03820427|DIAGNOSTIC_TEST|body plethysmography|body plethysmography
219620170|NCT06956157|DRUG|Placebo Oral Tablet|Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.
219620171|NCT05207865|DRUG|Rimegepant|rimegepant ODT 75mg daily
218925745|NCT06067217|DRUG|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
219539142|NCT00001835|DRUG|Oxaliplatin|
219539143|NCT04817904|DRUG|Rosuvastatin 10mg|The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
219539144|NCT05736718|BEHAVIORAL|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
219539145|NCT05736718|BEHAVIORAL|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
219539146|NCT02619682|DRUG|Ixazomib Citrate|Given PO
219539147|NCT02619682|OTHER|Laboratory Biomarker Analysis|Correlative studies
219539148|NCT02619682|DRUG|Lenalidomide|Given PO
219539149|NCT03835689|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
218925746|NCT04493788|OTHER|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
218925747|NCT00031317|DRUG|Paroxetine|
218925748|NCT00031317|DRUG|Clozapine|
218925749|NCT05337839|PROCEDURE|home exercises|stretching, balance and strengthening exercises
218925750|NCT02724748|BEHAVIORAL|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
218925751|NCT02885025|DIETARY_SUPPLEMENT|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
218925752|NCT02885025|DRUG|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
218925753|NCT02885025|DIETARY_SUPPLEMENT|broccoli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
218925754|NCT02885025|DRUG|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
218925755|NCT03378271|DEVICE|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
218925756|NCT02013271|DEVICE|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
218925757|NCT03522311|PROCEDURE|Vitrectomy|
218925758|NCT00194532|DRUG|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
218925759|NCT00194532|DRUG|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
218925760|NCT01981018|OTHER|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
218925761|NCT02054104|BIOLOGICAL|H1299 cell lysates|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
218925762|NCT02054104|DRUG|Cyclophosphamide|50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
218925763|NCT02054104|DRUG|Celecoxib|400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
218925764|NCT02054104|BIOLOGICAL|Iscomatrix adjuvant|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
218925765|NCT03658590|DRUG|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
218925766|NCT03658590|DRUG|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
219539150|NCT00002831|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
219539151|NCT00002831|DRUG|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
218925767|NCT00823615|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
218925768|NCT00823615|DEVICE|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
218925769|NCT03967613|DEVICE|Functional eletrical stimulation|Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
218925770|NCT05053204|OTHER||
218925771|NCT04989868|PROCEDURE|Trans-Nasal Afferent Loop Decompression|A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (\<3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
218925772|NCT04989868|PROCEDURE|Without Trans-Nasal Afferent Loop Decompression|No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
218925773|NCT02441296|OTHER|Formula with lactose|
218925774|NCT02441296|OTHER|Formula with maltodextrins|
219620172|NCT06336044|DEVICE|Karisma|Intradermal injection
218925775|NCT00955916|DRUG|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
219539152|NCT00002831|DRUG|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
219539153|NCT00002831|DRUG|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
218925776|NCT00955916|DRUG|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
218925777|NCT04834622|BEHAVIORAL|Melodies for Mums|Melodies for Mums (M4M) is an intervention that was developed and tested as part of a collaboration between the Royal College of Music, Imperial College London and University College London from 2015-2017. The programme involved weekly singing classes for mothers and their babies delivered in groups of 8-12 in Children's Centres for 10 weeks. A trained artist delivers 1-hour long singing sessions to mothers with postnatal depression (and their babies) for a period of 10-weeks. The sessions are aimed at the mothers, with songs ranging from sound baths to folk songs and songs created by the mothers themselves. Mothers randomised to the intervention will be prompted via text message, each week before the session, to attend these singing sessions.
218925778|NCT04834622|BEHAVIORAL|Control Community Sessions|Group mother-baby interventions in the community (i.e. baby play, baby reading sessions, baby massage, etc). A list of these activities will be collected from the activities on offer in the community. All the mothers randomised to the control group will be pointed towards these activities, prompted by text messages in line with the prompts received by the mothers in the intervention group. Mothers will be encouraged to attend these non-music based community activities once a week with their babies.
218925779|NCT02600039|OTHER|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
219204957|NCT06876818|OTHER|Evaluation of transcriptomic and cardio-metabolic profiles|The parameters and variables collected in 2006-2007 (T0) will be re-evaluated at the follow-up visit (T1), including demographic, anthropometric, lifestyle data (smoking habit, physical activity, sleep quality) blood pressure, standard biochemical analysis and inflammatory profile. To assess the evolution of glucose tolerance and vascular damage, metabolic (OGTT) and cardiovascular (carotid ecodoppler) profile analyses will be repeated. For gene expression analyses, in addition to messenger RNA from PBMCs (as at T0), RNA from PBMC-derived monocytes will also be extracted and sequenced at T1.
219204958|NCT06879587|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants could take BC99 daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
219204959|NCT06879587|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants could take maltodextrin daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
219204960|NCT06875856|OTHER|Kendall exercises|"1. Positioning supine with the chin tucked in and lifting the head for 2 to 8 sec to strengthen deep cervical flexors.~2. Maintaining a sitting posture, with hands on the occipital region, and flexed spine while moving head downwards to stretch cervical extensors, maintaining an upright posture.~3. Keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula to strengthen retractors of the shoulder.~4. Stretching the pectoralis major and minor while keeping the patient's hands-on the occipital region and standing behind the patient and pulling both elbows backward to target the bilateral pectoralis muscles"
219204961|NCT06875856|OTHER|Cailliet exercises|The intervention of group B will include baseline treatment, followed by maneuvers, including: Neck Cailliet exercise using isometric contractions against the prisoner to the maximum that ends with relaxation and continued with stretching. Each posture was maintained for 30 s and 3 sets of 10 repetitions were performed with 3 sessions per week on alternate days for 4 weeks.
219539154|NCT00002831|DRUG|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
219539155|NCT00002831|DRUG|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
219539156|NCT00002831|DRUG|Methylprednisolone|Given according to clinical grade of GVHD procedures.
219539157|NCT00002831|DRUG|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
219539158|NCT00002831|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
219539159|NCT00002831|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
219539160|NCT00520234|DRUG|Caspofungin|50 mg IV daily
219539161|NCT00520234|DRUG|Normal Saline|100 cc IV daily
219539162|NCT01143311|GENETIC|Arm A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
219539163|NCT03700723|BIOLOGICAL|Resusix|spray-dried solvent/detergent treated plasma (blood product)
219539164|NCT03700723|BIOLOGICAL|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
219539165|NCT04831307|OTHER|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
219539166|NCT05665205|OTHER|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
219539167|NCT05665205|OTHER|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
219539168|NCT01066598|DRUG|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
219539169|NCT06452251|DIAGNOSTIC_TEST|OPG, OC, RANKL, IL-10, IL-1β, Ca, TNF-α and Caspase-1 ELISA|The levels of OPG, OC, RANKL, IL10, IL1β, Ca, TNF-α and Caspase1 in bone and PICF of patients with or without Vitamin D sufficiency were measured by ELISA.
219539170|NCT06452251|DIAGNOSTIC_TEST|Resonance Frequency Analysis|Implant stability was measured by a device (Penguin RFA, Integration Diagnostics, Sweden) based on Resonance Frequency Analysis (RFA) and categorized by Implant Stability Quotient (ISQ) scale.
218925780|NCT02600039|DEVICE|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
218925781|NCT04896515|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
218925782|NCT05842161|BEHAVIORAL|QUIT-AD|An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence
218925783|NCT05842161|OTHER|Enhanced Treatment as Usual|Standard treatment for HIV/TB with one session of psychoeducation.
218925784|NCT00436514|BEHAVIORAL|diet and absorption of ColoPEG|4l of PEG during 2 days
218925785|NCT00436514|PROCEDURE|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
219204962|NCT06878196|DRUG|cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab|Patients with persistent, recurrent, or advanced metastatic cervical cancer who have not received systemic treatment are treated with cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab (treatment dosage: cadonilimab 10 mg/kg, paclitaxel 175 mg/m\^2, cisplatin 50 mg/m\^2, cisplatin AUC 4-5, bevacizumab 7.5-15 mg/kg), once every 3 weeks, for a total of 6 cycles (if the patient continues to benefit, chemotherapy is allowed beyond 6 cycles), followed by maintenance treatment with cadonilab ± bevacizumab.
219204963|NCT06877728|OTHER|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions)|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions) Duration: 10 to 15 repetitions with 3 sets, and 6 sec hold in flexion, extension and side flexion on both right and left.
219204964|NCT06876519|PROCEDURE|Translateral Maxillary Sinus Floor Elevation|Translateral maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
219204965|NCT06876519|PROCEDURE|Hydraulic Transcrestal Maxillary Sinus Floor Elevation|Hydraulic transcrestal maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
219204966|NCT06882226|OTHER|Maslach burnout inventory|Assessing the emotional burden on nursing staff
219204967|NCT06877780|DEVICE|RMR with SME|The RMR will be used in conjunction with slow maxillary expansion
219204968|NCT06877780|DEVICE|BAIMT with RME|The bone-anchored intermaxillary traction will be used with rapid maxillary expansion
219539171|NCT06452251|DIAGNOSTIC_TEST|Periodontal clinical examination|Clinical periodontal indices including plaque index (PI) (Silness and Löe 1964), gingival index (GI) (Löe 1967), probing depth (PD), and bleeding on probing (BOP) (Ainamo and Bay 1975) were recorded using a Williams periodontal probe. The BOP percentage (%) was calculated by dividing the number of bleeding sites by the total number of sites examined.
219539172|NCT06452251|PROCEDURE|Dental implant placement and bone sample collection|All patients were received by a single examiner a bone level implant (standard type and Sandblasted, Large-grit, Acid-etched surface) (Implant Swiss, Yverdon, Switzerland).
219620173|NCT03286387|OTHER|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
219204969|NCT07038330|DRUG|Sucrosomial Iron|Sideral Forte, Italian market formulation of Sucrosomila Iron 30mg per cp
219204970|NCT07037823|OTHER|Modified Yishen Daluo Yin formula|The specific application of the modified Yishen Daluo Yin formula, including the starting point, dosage, and duration of treatment, should be determined based on medical advice, the patient's condition, and their individual preferences.
219204971|NCT06874348|DIAGNOSTIC_TEST|structural and functional MRI|structural and functional MRI
219539173|NCT06452251|PROCEDURE|Gingival Crevicular Fluid Sampling|One month after the healing caps were inserted, peri-implant crevicular fluid (PISF) samples were collected from 6 different sides of each implant. Before sampling, the area was isolated and dried, and paper strips were gently kept in periimplant sulcus for 30 seconds. Strips with blood or saliva contamination were discarded. PISF volumes of each strip were measured by a device (Periotron 8,010, Oraflow Inc, USA). Strips were then pooled, and inserted into tubes. PISF was recovered from paper strips through agitation in phosphate buffer saline (50 mM Tris-HCl, 5 mM CaCl2, 0.2 M NaCl,pH 7.5). All samples were stored at -80C until the day of analysis.
219539174|NCT00268203|BIOLOGICAL|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
219539175|NCT00001035|DRUG|Interferon alfa-2b|
219539176|NCT00001035|DRUG|Zidovudine|
219539177|NCT00001035|DRUG|Zalcitabine|
219539178|NCT00001035|DRUG|Didanosine|
218925786|NCT00436514|PROCEDURE|Standard colonoscopy|1l of PEG the morning just before colonoscopy
219539179|NCT00639028|OTHER|Ankle echography|Ankle echography
219539180|NCT00639028|OTHER|Ankle echography + stress radiography|Ankle echography + stress radiography
219539181|NCT00639028|OTHER|stress radiography|ankle stress radiography
219539182|NCT05396885|BIOLOGICAL|anitocabtagene-autoleucel|Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
219539183|NCT00001865|DRUG|Daclizumab|
219539184|NCT06413186|DRUG|Uteratonic administration|Administer IV 10 IU oxytocin
219539185|NCT06413186|OTHER|cord clamping|delayed cord clamping
218925787|NCT02538393|DRUG|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A
218925788|NCT02538393|DRUG|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
219043239|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
219043240|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
219043241|NCT06145308|DRUG|Cohort 1 (HER2-positive, RC48-ADC)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043242|NCT06145308|DRUG|Cohort 2 (NTRK-fusion or NTRK-mutant)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219539186|NCT06413186|OTHER|delivery of the placenta|Applying controlled core traction
219539187|NCT03197207|PROCEDURE|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
219539188|NCT03197207|PROCEDURE|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
219539189|NCT05213156|DRUG|Oxatrex|0.3% ofloxacin eye drops in single doses
219539190|NCT03327545|DEVICE|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
219539191|NCT03327545|DEVICE|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
219539192|NCT03327545|DEVICE|Control group|Did not receive any treatment.
219539193|NCT03108911|OTHER|Best Practice|Receive standard diet
219539194|NCT03108911|PROCEDURE|Biospecimen Collection|Provide stool sample
219539195|NCT03108911|OTHER|Dietary Intervention|Receive GFD
219539196|NCT03108911|OTHER|Laboratory Biomarker Analysis|Correlative studies
219539197|NCT02316015|DIETARY_SUPPLEMENT|Infatrini® or Infatrini Peptisorb®|
219539198|NCT03186651|DEVICE|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
219539199|NCT02067611|DRUG|X0002|Parallel Assignment
219539200|NCT02067611|DRUG|Placebo|Parallel Assignment
219539201|NCT01852487|DIETARY_SUPPLEMENT|400mg /day during 6 months|
219539202|NCT00491192|DRUG|Diclofenac|
219539203|NCT04571021|OTHER|I-DEPT|Implementation of the novel triage algorithm
219539204|NCT04571021|OTHER|DEPT|Existing triage algorithm
218925789|NCT06383728|DRUG|Osimertinib|Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
218925790|NCT03926611|DRUG|LOU064 Arm 1|10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
218925791|NCT03926611|DRUG|LOU064 Arm 2|35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
218925792|NCT03926611|DRUG|LOU064 Arm 3|100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
218925793|NCT03926611|DRUG|LOU064 Arm 4|10mg bid of LOU064 orally, twice daily from Day 1 to 85
218925794|NCT03926611|DRUG|LOU064 Arm 5|25 mg bid of LOU064 orally, twice daily from Day 1 to 85
218925795|NCT03926611|DRUG|LOU064 Arm 6|100 mg bid of LOU064 orally, twice daily from Day 1 to 85
218925796|NCT03926611|DRUG|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
218925797|NCT05317325|BIOLOGICAL|OCDC vaccine; NeoDC vaccine|OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
218925798|NCT05457439|BEHAVIORAL|Sustainable diet promotion through behavioral change intervention|15 weeks digital intervention to promote sustainable diets through workshops, and behavioral change techniques in a mobile application, to decrease environmental impact of diets and improve health.
218925799|NCT03446196|DEVICE|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV \> 12%
218925800|NCT02025413|DEVICE|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
218925801|NCT01088698|RADIATION|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
219043243|NCT06145308|DRUG|Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043244|NCT06145308|DRUG|TROP2 ADC|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219539205|NCT05710354|DIETARY_SUPPLEMENT|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
219539206|NCT02664961|DRUG|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
219539207|NCT02664961|DRUG|Bevacizumab|Bevacizumab will be dosed every two weeks.
219539208|NCT00394810|DRUG|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
218925802|NCT03134703|DRUG|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
218925803|NCT03134703|DRUG|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
218925804|NCT04295824|DIAGNOSTIC_TEST|Skin imaging and Skin biopsy|"Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed."
218925805|NCT01684865|DRUG|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
218925806|NCT05820906|DRUG|Cadonilimab+Regorafenib+GC|Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8
218925807|NCT03110913|OTHER|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
218925808|NCT02896413|DRUG|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
218925809|NCT02896413|DRUG|Control group|0.9% saline infusion
218925810|NCT00004669|DRUG|hydrocortisone|
218925811|NCT00569517|BEHAVIORAL|CBT|6-CBT based sesions
218925812|NCT00569517|OTHER|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
218925813|NCT00084136|DRUG|Atazanavir|400 mg taken orally daily
218925814|NCT00084136|DRUG|Didanosine (enteric-coated)|400 mg taken orally daily
218925815|NCT00084136|DRUG|Efavirenz|600 mg taken orally daily
218925816|NCT00084136|DRUG|Emtricitabine|200 mg taken orally daily
218925817|NCT00084136|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
218925818|NCT00084136|DRUG|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
218925819|NCT06140862|OTHER|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
218925820|NCT00336596|PROCEDURE|transcranial ultrasound in patients treated with iv t-PA|
218925821|NCT02230670|DRUG|IDN-6556|25 mg BID
218925822|NCT02230670|DRUG|Placebo|
219539209|NCT05385640|OTHER|NO intervention|NO intervention
219539210|NCT02067624|OTHER|Thai massage|
218925823|NCT03543878|DEVICE|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
218925824|NCT05860972|DEVICE|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
218925825|NCT03794336|DRUG|Alogliptin|"Pharmaceutical form: tablet~Route of administration: oral administration"
218925826|NCT03794336|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
218925827|NCT03794336|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral administration"
218925828|NCT03794336|DRUG|Aspirin|"Pharmaceutical form: tablet~Route of administration: oral administration"
218925829|NCT01041755|DRUG|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
218925830|NCT01041755|DRUG|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
218925831|NCT03669497|RADIATION|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
219043245|NCT06145308|DRUG|TKI|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219539211|NCT00445445|OTHER|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
219539212|NCT00445445|OTHER|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
219539213|NCT00445445|PROCEDURE|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
219539214|NCT00445445|PROCEDURE|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
219539215|NCT00445445|PROCEDURE|study of high risk factors|"* Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
218925832|NCT06096571|DRUG|Aterixen|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
218925833|NCT00836693|DRUG|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
218925834|NCT00836693|DRUG|placebo|tablet administered orally once a day for 12 weeks.
218925835|NCT02612779|DRUG|Elotuzumab|
218925836|NCT02612779|DRUG|Pomalidomide|
218925837|NCT02612779|DRUG|Dexamethasone|
218925838|NCT02612779|DRUG|Nivolumab|
218925839|NCT02741739|DRUG|REGN1033|
218925840|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
218925841|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
218925842|NCT06370806|BEHAVIORAL|Weight loss and lifestyle intervention|Interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
218925843|NCT05127733|BEHAVIORAL|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
218925844|NCT05127733|BEHAVIORAL|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
218925845|NCT05127733|BEHAVIORAL|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
218925846|NCT01957306|DIETARY_SUPPLEMENT|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
218925847|NCT00897494|GENETIC|protein expression analysis|Venous blood collection
218925848|NCT00897494|OTHER|laboratory biomarker analysis|Venous blood collection
218925849|NCT00897494|OTHER|mass spectrometry|Venous blood collection
218925850|NCT00897494|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
218925851|NCT06046170|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
218925852|NCT06046170|OTHER|Treatment as Usual|Participants will receive treatment as usual at a community mental health center, including receiving skills training.
218925853|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
218925854|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
218925855|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
218925856|NCT00801177|BIOLOGICAL|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
219204972|NCT06717243|DRUG|Carboplatin/Cisplatin -Etoposide - Atezolizumab|"This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis."
219204973|NCT06718686|DRUG|Rifaximin SSD 40 mg IR tablet|Drug therapy vs placebo
219539216|NCT06368245|PROCEDURE|long-segment posterior TL instrumented fusion|long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.
219539217|NCT05436860|DEVICE|liver ultrasound|"At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group."
218925857|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
218925858|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
218925859|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
218925860|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
218925861|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
218925862|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 4~600 mg I.V."
218925863|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
218925864|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
218925865|NCT01567540|DRUG|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
219539218|NCT06656416|DRUG|ALTO-100|ALTO-100 40 mg tablet BID
218925866|NCT01147510|DRUG|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
218925867|NCT01147510|DRUG|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
218925868|NCT01856959|DRUG|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
218925869|NCT01856959|DRUG|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
218925870|NCT01856959|DRUG|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
218925871|NCT05676177|DIAGNOSTIC_TEST|Ultra Low Dose CT|"* Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD\_DECT\_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)\>30), that is 5 or 10 mAs~* Second scan (ULD\_DECT\_2) 80 kVp - fixed current 20 or 40 mA (if BMI\>30), that is 10 or 20 mAs"
218925872|NCT05676177|DIAGNOSTIC_TEST|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
218925873|NCT02937324|DEVICE|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
219204974|NCT06718686|DRUG|Placebo|Placebo drug
219539219|NCT06656416|DRUG|Placebo|Placebo tablet BID
219539220|NCT06042205|DEVICE|TISSIUM™ Atraumatic Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
219539221|NCT03527485|DIAGNOSTIC_TEST|11UCB-J PET Scan|11UCB-J PET Scan
218925874|NCT02937324|OTHER|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
218925875|NCT02110836|DIETARY_SUPPLEMENT|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
218925876|NCT02110836|DIETARY_SUPPLEMENT|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
219539222|NCT06624267|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
218925877|NCT05532306|DRUG|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
218925878|NCT05532306|DRUG|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
218925879|NCT05538715|PROCEDURE|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
218925880|NCT05538715|PROCEDURE|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
218925881|NCT02538913|BEHAVIORAL|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
218925882|NCT02538913|PROCEDURE|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
218925883|NCT04663659|OTHER|no intervention|no intervention
218925884|NCT06286761|OTHER|endothelial cell collection|Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
218925885|NCT00279487|DRUG|Gabapentin|
218925886|NCT00279487|DRUG|Placebos|
218925887|NCT04264936|DRUG|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
219539223|NCT04930796|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
219539224|NCT06149130|DRUG|Adebrelimab|adebrelimab:1200mg intravenously, Q3W.
219539225|NCT06149130|DRUG|dalpiciclib|dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
219539226|NCT03402503|DRUG|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
219539227|NCT03402503|OTHER|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
219539228|NCT03789019|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
219539229|NCT00613522|OTHER|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale \> 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
219539230|NCT00730691|DRUG|Placebo|Placebo-matching capsules
218925888|NCT01750229|DEVICE|Sham|Frequency Setting - Sham
218925889|NCT01750229|DEVICE|1200 Hz|Frequency Setting - 1200 Hz
218925890|NCT01750229|DEVICE|3030 Hz|Frequency Setting - 3030 Hz
218925891|NCT01750229|DEVICE|5882 Hz|Frequency Setting - 5882 Hz
218925892|NCT02941601|DRUG|Necitumumab|Administered IV
218925893|NCT02941601|DRUG|Gemcitabine|Administered IV
218925894|NCT02941601|DRUG|Carboplatin|Administered IV
218925895|NCT06205628|DRUG|ADX-850|siRNA duplex oligonucleotide
218925896|NCT06205628|DRUG|Placebo|Saline
218925897|NCT05537662|DEVICE|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
218925898|NCT01394796|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
218925899|NCT01394796|DRUG|Placebo|No active treatment is given.
218925900|NCT02372188|OTHER|water|Control
218925901|NCT02372188|DIETARY_SUPPLEMENT|caffeine|
218925902|NCT02372188|DIETARY_SUPPLEMENT|caffein + homoeriodictyol sodium salt|
218925903|NCT02372188|DIETARY_SUPPLEMENT|homoeriodictyol sodium salt|
218925904|NCT00166777|PROCEDURE|exercise training|
218925905|NCT02835248|OTHER|Fall Detection|All participants will wear a device configured to detect falls.
218925906|NCT03430102|DIAGNOSTIC_TEST|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
218925907|NCT02690948|BIOLOGICAL|Pembrolizumab|Given IV
218925908|NCT02690948|DRUG|Vismodegib|Given PO
219620192|NCT06222853|BIOLOGICAL|anti-CD19-CAR-T cells|Three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
219204975|NCT06719076|BEHAVIORAL|Diabetes Healthcare Program (DHCP)|"Training for Type-II Diabetics~The program includes 6 structured training sessions, each session will delivered biweekly and lasting for 1 hour and 20 minutes , covering topics such as:~Week 1: Diabetes Education and Goal Setting Week 3: Nutrition and Meal Planning Week 5: Physical Activity and Exercise Week 7: Medication Management Week 9: Stress Management and Emotional Well-being Week 11: Review and Future Plans Time, Venue, and Interactive Activities Sessions will be held at the Federal General Hospital Basement, on Fridays, from 10:00 am to 11:20 am. Each session includes interactive elements, such as group discussions, practical exercises, and hands-on activities, to ensure participants are fully engaged and equipped to manage their T2DM diabetes."
219204976|NCT07038174|OTHER|Fertility preservation decision aid intervention group|Visited the website containing the web-based decision aid regarding fertility preservation at least once before cancer treatment initiation to independently use the tool in a private setting
219204977|NCT07038720|DRUG|UA026|UA026 will be administered as tablet
219204978|NCT07038720|DRUG|Placebo|Matching placebo will be administered as tablet
219204979|NCT07039162|DRUG|Tislelizumab|"1. ICRT phase -Tislelizumab and CRT regimen Tislelizumab 200 mg IV, C1D1 and C4D1~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )~3. Adjuvant phase-Tislelizumab Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of one year or 17 cycles.)"
219204980|NCT07039162|DRUG|Paclitaxel|"1. ICRT phase -Tislelizumab and CRT regimen Paclitaxel 50 mg/m2 IV, D1, weekly (\* 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Paclitaxel 135 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles.)"
219204981|NCT07039162|DRUG|Cisplatin|"1. ICRT phase -Tislelizumab and CRT regimen Cisplatin 25 mg/m2 IV, D1, weekly ( 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Cisplatin 75 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )"
219539231|NCT00730691|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
219620193|NCT05703685|RADIATION|Lung scan|Immediately after the brain scan
218925909|NCT02254070|DRUG|BIBT 986 BS|
218925910|NCT04551482|DRUG|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
218925911|NCT04551482|DRUG|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
218925912|NCT05324514|PROCEDURE|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
218925913|NCT05324514|DEVICE|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
218925914|NCT05324514|DEVICE|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
219539232|NCT00730691|DRUG|Duloxetine|Overencapsulated duloxetine capsules
219539233|NCT02649647|PROCEDURE|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
219539234|NCT02649647|PROCEDURE|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
219539235|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
219620194|NCT05703685|DRUG|Apremilast|Oral administration of apremilast
219620195|NCT05703685|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
218925915|NCT01411891|DEVICE|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
218925916|NCT02004093|DRUG|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
218925917|NCT02004093|DRUG|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
219620196|NCT01882660|DRUG|Decitabine|
219620197|NCT00899301|OTHER|biologic sample preservation procedure|Tissue, urine and blood collection.
219620198|NCT05022667|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
219620199|NCT06962488|BEHAVIORAL|Regular Care|Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.
218925918|NCT02004093|DRUG|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
218925919|NCT02004093|DRUG|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
218925920|NCT05819151|DIAGNOSTIC_TEST|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
218925921|NCT02868593|OTHER|Pharyngeal swab|
218925922|NCT05498714|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
218925923|NCT05498714|DRUG|CSP＋lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
218925924|NCT01703234|DRUG|Ramipril|ramipril 10 mg/day during 3 months
219204982|NCT07039162|RADIATION|Radiation Therapy|1\. ICRT phase -Tislelizumab and CRT regimen Radiotherapy treatment: IMRT 41-50.4Gy, a dose of 1.8 to 2Gy per day, 5 days per week for 5 weeks during the RT phase.
219204983|NCT07039760|DRUG|Asciminib|Commercially available stock
219204984|NCT07039760|DRUG|Sildenafil|Commercially available stock
219204985|NCT07039760|PROCEDURE|Surgical resection or biopsy|Standard of care
219204986|NCT07030751|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a specific order (stress, sleep, physical activity). Each module will be composed of 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
219204987|NCT07039825|OTHER|Computed tomography angiography|The results of computed tomography angiography on abdominal aortic aneurysm are collected.
219204988|NCT03142009|OTHER|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
219204989|NCT07038564|OTHER|Immune-Nutritional Scoring and Postoperative Sleep Assessment|Routine preoperative laboratory data (hemoglobin, albumin, lymphocyte, platelet) will be used to calculate immune-nutritional scores (HALP, PNI). Postoperative sleep quality will be assessed with the Richards-Campbell Sleep Questionnaire (RCSQ).
219204990|NCT06886425|OTHER|genetic study|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
219204991|NCT06886425|OTHER|Pharmacokinetic study|"Cure 1: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 3: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 6: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase."
218925925|NCT02783807|DEVICE|Eyenez Retinal Camera v200|
219539236|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
219539237|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
219539238|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
219539239|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
219539240|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
219539241|NCT02965859|DRUG|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
218925926|NCT02783807|DEVICE|Volk Pictor Ret 1|
218925927|NCT02445898|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
219539242|NCT02965859|DRUG|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
219539243|NCT05314647|DIETARY_SUPPLEMENT|lutein|daily dose of 5 mg lutein
219539244|NCT05314647|DIETARY_SUPPLEMENT|placebo|daily dose of 0 mg lutein
219539245|NCT00100776|DRUG|Olanzapine|
219539246|NCT00431912|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
219539247|NCT02554890|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
218925928|NCT02445898|DRUG|Isotonic Sodium Chloride|Placebo
219539248|NCT02554890|DRUG|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
219539249|NCT02554890|DRUG|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
219539250|NCT02554890|DRUG|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
219539251|NCT00362596|DRUG|acyclovir|
219539252|NCT03336580|DRUG|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
219539253|NCT00216242|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
219539254|NCT00216242|BIOLOGICAL|Saline placebo|
219539255|NCT03073850|DRUG|Antiplatelet|ASA or clopidogrel
219539256|NCT03073850|DRUG|Low dose oral anticoagulant|Edoxaban of 30mg
218925929|NCT04926987|OTHER|brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders
218925930|NCT00414596|DEVICE|DRX9000™|Device is designed to apply spinal decompressive forces.
218925931|NCT04999540|DRUG|Tucidinostat|30 mg, administered orally twice per week (BIW)
218925932|NCT04999540|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
218925933|NCT02253862|DRUG|Tadalafil|administered days 1, 8 and 16
218925934|NCT02253862|DRUG|Tipranavir|administered days 8-18
218925935|NCT02253862|DRUG|Ritonavir|administered days 8-18
218925936|NCT04592887|RADIATION|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
218925937|NCT04639258|DEVICE|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
218925938|NCT02757209|DEVICE|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
218925939|NCT02757209|DEVICE|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
218925940|NCT02757209|DEVICE|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
218925941|NCT02824341|DEVICE|fMRI|
218925942|NCT00003523|DRUG|aminocamptothecin colloidal dispersion|
218925943|NCT03232697|DIAGNOSTIC_TEST|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
218925944|NCT03232697|DIAGNOSTIC_TEST|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
219539257|NCT03073850|DRUG|Standard dose oral anticoagulant|Edoxaban of 60mg
219539258|NCT03861247|DRUG|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
219539259|NCT03861247|DIETARY_SUPPLEMENT|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
218925945|NCT02135913|DIETARY_SUPPLEMENT|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
219620200|NCT06962488|BEHAVIORAL|SBP PRS Dissemination|Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.
218925946|NCT00126243|DRUG|rituximab|
219204992|NCT06886425|OTHER|Study of phenotypic activity of cytidine deaminase|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
219539260|NCT04093505|DRUG|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
219539261|NCT04093505|DRUG|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
219539262|NCT04093505|DRUG|Glasdegib|Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27
219539263|NCT04093505|DRUG|Placebo Oral Tablet|Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
219539264|NCT06356805|DEVICE|repetitive transcranial magnetic stimulation|Parallel study: Participants are assigned to one of two groups in parallel for 3 months follow up
219539265|NCT05087745|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219539266|NCT02616133|OTHER|chart abstraction|abstraction of breast cancer patients with de-identified data
219620201|NCT06961747|DRUG|Zilucoplan|Dose formulation: Solution for injection. Route of administration: Subcutaneous injection.
218925947|NCT00126243|DRUG|CHOP|
218925948|NCT03930082|OTHER|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
218925949|NCT03566134|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
218925950|NCT03566134|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
218925951|NCT03566134|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
218925952|NCT03566134|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
218925953|NCT03566134|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
218925954|NCT04178668|OTHER|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
218925955|NCT00017576|DIETARY_SUPPLEMENT|calcitriol|
218925956|NCT00017576|DRUG|carboplatin|
218925957|NCT04198558|DRUG|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
218925958|NCT04198558|DRUG|Placebo|Placebo
219539267|NCT03730168|OTHER|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
219539268|NCT04003090|DRUG|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
219539269|NCT05083221|BEHAVIORAL|Hear-Talk-Activity audiological program|The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
219539270|NCT04572139|DIAGNOSTIC_TEST|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
218925959|NCT04320316|DRUG|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
218925960|NCT06960382|DRUG|ALUTARD SQ® Felis domesticus|The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection
218925961|NCT00297258|DRUG|pazopanib|oral tablet
218925962|NCT01502826|DIETARY_SUPPLEMENT|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
218925963|NCT05695378|DRUG|KM-819|Subjects will receive KM-819 400 mg orally daily.
218925964|NCT05695378|DRUG|Placebo|Subjects will receive Placebo orally daily.
218925965|NCT00755053|DRUG|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
219204993|NCT06887725|OTHER|Exercise|The Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) is an innovative exercise approach developed based on the biopsychosocial model. The parameters that form the basis of BETY are function-oriented core stabilization exercises, information management in pain, information management in mood, and information management in sexuality. BETY was shaped by the feedback of individuals with rheumatism who participated in regular exercise sessions for years and was introduced to the literature as a treatment method aiming to create changes in the cognitive structures of patients through exercise.
219539271|NCT05581329|PROCEDURE|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
218925966|NCT00755053|DRUG|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
218925967|NCT02217826|DRUG|DG3173|
218925968|NCT02217826|DRUG|Saline|
219539272|NCT01161615|DRUG|MRX-7EAT|Application of up to two patches for up to 7 days.
219539273|NCT01161615|DRUG|Placebo|Application of up to two patches for up to 7 days.
219539274|NCT04311320|DEVICE|Low-Resource Oxygen Blender|The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
219539275|NCT06721455|OTHER|blood sampling|Discarded blood samples will be taken from routine clinical labs drawn during and after heart surgery.
219539276|NCT02906293|OTHER|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
219539277|NCT04755985|DRUG|AD-213-B|1 tablet administered before the breakfast during 5 days
219539278|NCT04755985|DRUG|AD-2132|1 tablet administered before the breakfast during 5 days
219539279|NCT03649477|DRUG|3.2 mg intranasal carbetocin|three times per day with meals
219539280|NCT03649477|DRUG|9.6 mg intranasal carbetocin|three times per day with meals
219539281|NCT03649477|DRUG|placebo|three times per day with meals
219539282|NCT04142970|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
219539283|NCT04187352|DRUG|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
219539284|NCT04187352|DRUG|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
218925969|NCT02217826|DRUG|Octreotide|
218925970|NCT00485095|BEHAVIORAL|Intake of plant sterols|
218925971|NCT03672968|GENETIC|GS010|
218925972|NCT03405597|DRUG|Commercial Hepatitis B vaccine|Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
218925973|NCT03405597|OTHER|Standard Treatment|HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
218925974|NCT01672580|BEHAVIORAL|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
218925975|NCT01672580|BEHAVIORAL|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
218925976|NCT01672580|BEHAVIORAL|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
218925977|NCT01672580|BEHAVIORAL|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
218925978|NCT02567578|DRUG|YH12852 0.1 mg|
219204994|NCT06703255|DRUG|HX301+/Temozolomide|"Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each."
218925979|NCT02567578|DRUG|YH12852 0.25 mg|
218925980|NCT02567578|DRUG|YH12852 0.5 mg|
218925981|NCT02567578|DRUG|Placebo|
218925982|NCT04182828|DRUG|Lidocaine|both the drugs will be prepared in same volume, color, consistency and appearance
218925983|NCT05851261|DRUG|PA3670|Placebo as control
218925984|NCT04467372|DIETARY_SUPPLEMENT|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
218925985|NCT04467372|DIETARY_SUPPLEMENT|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
218925986|NCT04467372|DIETARY_SUPPLEMENT|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
218925987|NCT04467372|DIETARY_SUPPLEMENT|Capsule placebo|Two placebo capsules daily for 30 days
218925988|NCT03032978|OTHER|Calcium hydroxide|Pulp capping material
218925989|NCT03032978|OTHER|Calcium silicate|Pulp capping material
219043246|NCT06145308|DRUG|Albumin-paclitaxel + platinum|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043247|NCT06145308|DRUG|Albumin-paclitaxel + carboplatin + apatinib + camrelizumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043248|NCT06145308|DRUG|albumin-bound paclitaxel+trastuzumab+pyrotinib|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043249|NCT06145308|DRUG|HER2,trastuzumab deruxtecan± pertuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
218925990|NCT02566421|OTHER|Laboratory Biomarker Analysis|Correlative studies
218925991|NCT02566421|OTHER|Quality-of-Life Assessment|Ancillary studies
218925992|NCT02566421|OTHER|Targeted Therapy|Receive treatment based on genomic sequencing
218925993|NCT05903768|OTHER|Mobilization|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)"
218925994|NCT05903768|OTHER|Cyriax capsular stretching|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times."
218925995|NCT02290249|DEVICE|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
218925996|NCT02290249|DEVICE|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
218925997|NCT04772612|DRUG|sitravatinib|sitravatinib
218925998|NCT03248206|BEHAVIORAL|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
219539285|NCT00952406|OTHER|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
219539286|NCT04655001|BEHAVIORAL|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
218925999|NCT06836063|DRUG|Ropanicant|Tablet dosage form, twice a day
218926000|NCT06836063|DRUG|Placebo|Matching placebo tablets, twice a day
218926001|NCT06516978|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
218926002|NCT06516978|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
218926003|NCT06516978|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219204995|NCT06885840|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
219204996|NCT06885112|DEVICE|FoLix treatment for improving the scalp hair appearance|The study patients will receive 4 FoLix treatment in 4 weeks intervals. the scalp hair improvement will be evaluated by 3 blinded assessors who shall review before and after images, as well as hair count data
219539287|NCT02351024|DRUG|OXP005|
219539288|NCT02351024|DRUG|Naprosyn®|
219539289|NCT05519787|DEVICE|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement…). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
219539290|NCT07056894|BEHAVIORAL|Action-Based Cognitive Remediation|ABCR is a 16 session intervention involving computer-based drills, real-life simulations, and therapist-facilitated discussions intended to promote cognitive strategy monitoring and transfer of cognitive strategies to daily life. The sessions cover the follow key topics: Speed \& Attention, Memory, Executive Functioning, and Social Cognition.
219539291|NCT02430480|DRUG|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
219539292|NCT02430480|DRUG|Enzalutamide|160mg orally, daily for 24 weeks
219539293|NCT02430480|DEVICE|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
218926004|NCT06516978|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
218926005|NCT06516978|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
218926006|NCT06516978|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
218926007|NCT06516978|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
218926008|NCT06516978|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
218926009|NCT06516978|DRUG|Chidamide|Chidamide PO will be administered as per the schedule specified in the respective arm.
218926010|NCT06516978|DRUG|Penpulimab|Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
219043250|NCT06145308|DRUG|AR,darolutamide + goserelin+pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
218926011|NCT06516978|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
218926012|NCT04200599|OTHER|duration of initiation of oxytocin|mode of delivery
218926013|NCT01308437|BIOLOGICAL|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
218926014|NCT01308437|BIOLOGICAL|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
218926015|NCT02676141|OTHER|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
218926016|NCT03236636|DRUG|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
218926017|NCT03236636|DRUG|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
219539294|NCT06746181|BEHAVIORAL|Fraction of inspiration O2(FiO2)|After the patient was admitted to the room, anesthesia induction was performed after pre-oxygenation for 3 minutes. Tracheal intubation was carried out once the medication had fully taken effect. After the surgery began, the inspired oxygen concentration was adjusted for each group. The first lung recruitment maneuver was performed 10 minutes later, and subsequent lung recruitment maneuvers were conducted when pulmonary compliance returned to baseline levels. This process was repeated, with all patients undergoing one final lung recruitment maneuver immediately at the end of the surgery.
218926018|NCT02352155|PROCEDURE|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
218926019|NCT02352155|OTHER|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
218926020|NCT05196295|DRUG|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
218926021|NCT04607538|OTHER|No intervention is made|No intervention is made. This i an observational study.
219620202|NCT06257108|OTHER|Class II Cavity Restorations|The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
218926022|NCT01036048|DEVICE|drug eluting stent|pts with cabg disease treated with drug eluting stent
219539295|NCT02839252|BEHAVIORAL|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
219539296|NCT06139666|DRUG|Exparel Injectable Solution|"Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
219620203|NCT01817517|DEVICE|Medtronic Activa Deep Brain Stimulation System|
219620204|NCT05912010|DIAGNOSTIC_TEST|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
219620205|NCT06061913|BEHAVIORAL|Breast Pump suction pattern|Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.
219620206|NCT05242848|BEHAVIORAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
219620207|NCT00134680|DRUG|Letrozole|Letrozole tablets 2.5 mg by mouth daily
218926023|NCT01036048|DEVICE|bare metal stent|pts with cabg disease treated with bare metal stent
218926024|NCT04522284|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of capecitabine and Ibrutinib for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
219043251|NCT06145308|DRUG|AR,darolutamide +goserelin +docetaxel|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043252|NCT06145308|DRUG|ivonescimab + investigator-choice platinum doublet+|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219204997|NCT06885788|PROCEDURE|To remove the uterine uterine ligament|Both groups underwent laparoscopic inguinal hernia repair. The preservation group retained the uterine round ligament, while the resection group had it removed.
219204998|NCT06884371|OTHER|physical therapy|ultrasound and TENS for the back
218926025|NCT04522284|DRUG|Capecitabine|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. , 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 625mg/m2 twice daily for single agent capecitabine). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
218926026|NCT04522284|DRUG|XELOX|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELOX regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range. The doses of other drug in the XELOX regimen (oxaliplatin) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
219043253|NCT06145308|DRUG|iparomlimab + tuvonralimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043254|NCT06145308|DRUG|cadonilimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043255|NCT06145308|DRUG|CDK4/6 inhibitor+AI or fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043256|NCT06145308|DRUG|alpelisib+fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219539297|NCT06139666|DRUG|Bupivacaine Injectable Solution|"Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
219539298|NCT07067879|OTHER|Lip product|Lip product containing Caulerpa lentillifera extract
219539299|NCT07068490|DRUG|Routine use of P-CAB on DAPT|This group received P-CAB with DAPT after PCI.
219539300|NCT07068490|DRUG|Guideline Directed Medical Therapy|This group received PPI or not with DAPT after PCI according to GI bleeding risk.
219620208|NCT00134680|DRUG|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
219620209|NCT02084810|DRUG|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
219620210|NCT02084810|DRUG|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
219620211|NCT01332669|PROCEDURE|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
219620212|NCT00295581|DRUG|PpPfs25/ISA51 & ScPvs25/ISA51|
219620213|NCT00637312|DEVICE|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
219539301|NCT07067255|BIOLOGICAL|GPC3 CD146 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/GPC3 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~GPC3/CD146 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, GPC3/CD146 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/GPC3 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
218926027|NCT04522284|DRUG|XELIRI|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELIRI regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELIRI regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.~The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care."
218926028|NCT04522284|DRUG|Ibrutinib|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 4-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range.~Maximum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 100% of standard starting dose (i.e. 420 mg once daily for 4 weeks, which constitutes the total of 11760 mg per cycle). Minimum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 50% of the standard starting dose (i.e. 280 mg once daily on alternative days with 140 mg once daily, which constitutes the total of 5880 mg per cycle). The dosing range may be altered to suit the specific circumstances of the participant, thus giving the participant-specific safe dosing range."
218926029|NCT05467306|BEHAVIORAL|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
218926030|NCT00624598|BEHAVIORAL|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
218926031|NCT04067817|DRUG|norepinephrine|patient who was received the treatment of norepinephrine
218926032|NCT04067817|DRUG|Phenylephrine|patient who was received the treatment of phenylephrine
218926033|NCT03745014|DIAGNOSTIC_TEST|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
218926034|NCT03745014|DIAGNOSTIC_TEST|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
218926035|NCT00334048|DRUG|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
218926036|NCT04788329|BEHAVIORAL|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
218926037|NCT04788329|BEHAVIORAL|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
218926038|NCT04800809|OTHER|This study does not entail offering any intervention; all data collected will be based on standard of care.|This study does not entail offering any intervention; all data collected will be based on standard of care.
218926039|NCT06110130|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
218926040|NCT06110130|DRUG|Placebo|Take Placebo 10 mg orally daily for 4 months
219539302|NCT07068399|PROCEDURE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy (ESWT) delivers acoustic energy transmitted through liquid medium to internal body tissues. The intervention group will receive a total of 9 ESWT treatment sessions and 200 shocks will be applied to each ischaemic zone of myocardium for 3 times a week on the three weeks that the patients receive ESWT.
219620214|NCT00637312|DEVICE|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
219620215|NCT05267379|DIAGNOSTIC_TEST|Take blood samples|Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
219204999|NCT06886607|BEHAVIORAL|the Mindfulness and Web-Based Physical Activity Program|"The Mindfulness and Web-Based Physical Activity Program consists of two phases: the Mindfulness Skill Development Program and the Mindful Physical Activity Program. In the first phase of the Program, the Mindfulness Skill Development Program was implemented for two weeks, five days a week, from October 23 to November 3, 2023. The program includes activities for individuals to develop mindfulness skills through videos uploaded on the YouTube channel. In the second phase of the Program, The 12-week Mindful Physical Activity Program, implemented between November 2023 and January 2024, consisted of Mindful Walking and Mindful Physical Activity Day sessions held twice a week (Tuesday and Thursday) and three days a week for 50 minutes. Each session began with a 10-minute warm-up exercise, followed by 40 minutes of endurance and strength training sessions, and ended with 10 minutes of cool-down exercises."
218926041|NCT02030652|PROCEDURE|Intermittent nasal positive pressure positive ventilation.|
219539303|NCT07069075|GENETIC|MMP-2 Gene Polymorphism (rs243865) Analysis|Participants were genotyped for the MMP-2 rs243865 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, CT, or TT) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
218926042|NCT02030652|PROCEDURE|CPAP|Nasal continuous positive airway pressure
218926043|NCT00734539|DRUG|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
218926044|NCT00734539|DRUG|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
218926045|NCT05902247|RADIATION|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer
218926046|NCT05352503|DEVICE|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
219539304|NCT07069075|GENETIC|TIMP-2 Gene Polymorphism (rs8179090) Analysis|Participants were genotyped for the TIMP-2 rs8179090 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, GC, or GG) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
219539305|NCT07069556|DEVICE|ColoSense|multi-target stool RNA test
219539306|NCT07067866|OTHER|Titrated weaning of vasopressin.|The titrated group will follow the vasopressin weaning protocol used in the DOVSS study (reduction of 0.01 U/min per hour).
218926047|NCT04000633|DRUG|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
218926048|NCT04000633|DRUG|Normal saline|Normal saline
218926049|NCT01187355|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
218926050|NCT01187355|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
218926051|NCT01187355|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
218926052|NCT05510388|DEVICE|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
218926053|NCT05510388|DEVICE|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
218926054|NCT02504151|DRUG|Cannabidiol|
218926055|NCT02504151|DRUG|Placebo|
219539307|NCT07067866|OTHER|Abrupt weaning of vasopressin.|The abrupt group will discontinue the vasopressin infusion at the time of randomization, without dose titration.
219539308|NCT07068971|BEHAVIORAL|Online cognitive behavioural therapy for insomnia, bright light therapy, activity|Multimodal intervention
219549905|NCT01958476|DRUG|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
219620216|NCT05270577|OTHER|Prehabilitation|prehabilitation
219620217|NCT05270577|OTHER|Standard care|No intervention
218926056|NCT03005158|OTHER|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
218926057|NCT03005158|OTHER|Randomization Phase|Standard care or HighSTEACS pathway.
218926058|NCT03005158|OTHER|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
218926059|NCT05867238|OTHER|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
218926060|NCT05038982|DRUG|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
218926061|NCT05855707|BIOLOGICAL|WJ-MSC infusion|cellular therapy
218926062|NCT02125669|PROCEDURE|Laser treatment|Pulsed dye laser 595nm
218926063|NCT02125669|DEVICE|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
218926064|NCT01942694|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
218926065|NCT01942694|OTHER|Placebo|Administered as one soft-gel pill daily by mouth
218926066|NCT01774396|DRUG|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
218926067|NCT01774396|DRUG|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
218926068|NCT04530214|OTHER|Blood collection|Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
218926069|NCT04530214|OTHER|Saliva collection|Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
218926070|NCT04530214|OTHER|Electrocardiography (ECG)|Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability
218926071|NCT04530214|BEHAVIORAL|Questionnaires|Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)
218926072|NCT01948596|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
218926073|NCT00472576|DRUG|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
218926074|NCT00472576|DRUG|Placebo|Daily double-blind administration of placebo
218926075|NCT01957007|DRUG|Docetaxel|Docetaxel will be administered IV.
218926076|NCT01957007|DRUG|vantictumab|Vantictumab will be administered intravenously
218926077|NCT04690049|OTHER|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
218926078|NCT04690049|OTHER|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
218926079|NCT01826019|OTHER|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
219043257|NCT06145308|DRUG|PARP inhibitor|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043258|NCT06145308|DRUG|enfortumab vedotin|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043259|NCT06145308|DRUG|HER2, pyrotinib + pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
219043260|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
219043261|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
219043262|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
219043263|NCT03052582|OTHER|Milk type|
219620218|NCT03368092|DRUG|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
218926080|NCT01826019|OTHER|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
218926081|NCT04170608|DEVICE|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
218926082|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
218926083|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
219043264|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
219043265|NCT05550155|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
219539309|NCT07067411|BEHAVIORAL|Education Program Using Gamification on GDM|"The five games planned to be used in the study are; What is Gestational Diabetes?, Nutrition Education, Complication Precautions, Medical Treatment Applications and Physical Activity. The creation and implementation of these games will be done through the Genially platform. The Genially platform is an easy-to-use and free web tool used to create interactive visual content. The platform includes features such as sharing or downloading via website, social media or e-mail by adding animations, effects, sounds and interactive elements. In addition, the performances of the people who share the created content can be tracked and feedback can be obtained. At the beginning of the games planned to be used in the study, an informative video of not more than five minutes on the subject created by the researcher will be shared. National and international guidelines will be taken into consideration in the creation of these videos. One day after the informative video is"
219539310|NCT07068451|PROCEDURE|Greater Occipital Nerve Block (GONB)|A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.
219539311|NCT07068451|PROCEDURE|Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)|Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.
218926084|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
218926085|NCT01046487|PROCEDURE|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
219539312|NCT06129253|OTHER|Urine Sample Collection|When urine is collected as a sample in either CSS or LS, first flow urine samples will be collected
219539313|NCT06129253|OTHER|Self-collected Vaginal Swab|Self-collected Vaginal Swab will be collected by the participant under the supervision of a trained nurse or other health care worker.
219539314|NCT06129253|OTHER|Blood Samples|If funding permits, a blood sample may be collected from participants in LS once during the follow-up period. If blood sample collection was not feasible during a visit, two additional attempts may be made to collect blood samples from LS participants during the subsequent follow-up visits.
219539315|NCT02566928|DRUG|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
219539316|NCT02566928|OTHER|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
219539317|NCT02566928|BEHAVIORAL|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
219539318|NCT03190005|DRUG|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
219539319|NCT03190005|DRUG|Placebos|no medication, healthy subjects.
218926086|NCT04840693|BIOLOGICAL|Biological samples|blood, urine, saliva
218926087|NCT04840693|OTHER|Complications|bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
218926088|NCT01916954|DRUG|3-day artemether-lumefantrine|
219539320|NCT01097577|DRUG|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
219539321|NCT01097577|DRUG|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
219539322|NCT01015300|DRUG|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
219539323|NCT06911203|DRUG|BGM0504|Administered SC
218926089|NCT01916954|DRUG|5-day artemether-lumefantrine|
218926090|NCT02080715|DRUG|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
218926091|NCT02080715|DRUG|Placebo|
219043266|NCT05550155|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
219043267|NCT05771155|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
219043268|NCT03761628|DEVICE|pHyph generation I|A vaginal tablet for the treatment of VVC to be administered every 48 hours
219043269|NCT04515004|DRUG|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
219043270|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
219539324|NCT06911203|DRUG|Tirzepatide|Administered SC
219539325|NCT02616809|OTHER|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
219539326|NCT02616809|OTHER|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
219539327|NCT02616809|OTHER|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
219539328|NCT02616809|OTHER|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
219620219|NCT03368092|DRUG|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
219043271|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
219043272|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
219043273|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
218926092|NCT00993577|OTHER|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
219043274|NCT05235074|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
218926093|NCT00993577|DEVICE|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
219043275|NCT01827657|DRUG|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
219043276|NCT02416427|DRUG|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
219043277|NCT03903627|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
219043278|NCT00007033|DRUG|magnesium gluconate|
219043279|NCT00007033|DRUG|magnesium sulfate|
219043280|NCT01505686|PROCEDURE|MRI scan|MRI scan with a 1,5 T MRI scanner
219043281|NCT01474642|DRUG|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
219043282|NCT01474642|DRUG|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
219043283|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
219043284|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
219043285|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
219043286|NCT03922568|OTHER|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
219043287|NCT03922568|DEVICE|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
219043288|NCT03922568|DEVICE|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
219043289|NCT06308991|OTHER|Yakson touch|Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
219043290|NCT06308991|OTHER|Gentle Human Touch|Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
219043291|NCT06308991|OTHER|Routine care|Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
219043292|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
219043293|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
219043294|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
219043295|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
219043296|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
219539329|NCT02894593|OTHER|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
219620220|NCT03033368|DRUG|Rilpivirine|Rilpivirine 25 mg tablet
219620221|NCT05159375|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
219620222|NCT05159375|OTHER|SMCC|Placebo comparator
219620223|NCT00100607|DRUG|AAE581|
219620224|NCT02024607|DRUG|BBI608|
218926094|NCT00993577|DEVICE|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
218926095|NCT02557139|DRUG|Belumosudil Tablet|
218926096|NCT02557139|DRUG|Belumosudil Capsule|
218926097|NCT00985764|PROCEDURE|cesarean delivery|
218926098|NCT02622126|DRUG|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
218926099|NCT02622126|DRUG|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
219043297|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
219043298|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
219539330|NCT02894593|OTHER|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
219043299|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
219043300|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
219205000|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine and left lateral tilt (LLT) positions. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
219539331|NCT02894593|OTHER|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
219539332|NCT02894593|OTHER|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
219539333|NCT01566396|DEVICE|A3F|A3F fractional RF treatments for facial wrinkles
219043301|NCT06579573|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
219043302|NCT04314089|DRUG|GT103|intravenously (dose depending)
219043303|NCT04321876|BEHAVIORAL|Collaborative Behavioral Health Program|Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
219620225|NCT02024607|DRUG|Fluorouracil|
219620226|NCT02024607|DRUG|Oxaliplatin|
219620227|NCT02024607|DRUG|Leucovorin|
219620228|NCT02024607|DRUG|Irinotecan|
219620229|NCT02024607|DRUG|Bevacizumab|
219620230|NCT02024607|DRUG|Capecitabine|
219620231|NCT02024607|DRUG|Regorafenib|
219620232|NCT06759753|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.
219620233|NCT06759753|DRUG|Placebo|Placebo with the same dosage form, odor and color as Aleeto was administered in the same way and course of treatment.
219620234|NCT05803551|DRUG|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
219620235|NCT05803551|DRUG|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
219620236|NCT04514692|DRUG|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
219620237|NCT03811964|OTHER|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
219620238|NCT06408545|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
219620239|NCT06417099|DRUG|Dihydroartemisinin|dihydroartemisinin 40mg tid po for 90 consecutive days
219620240|NCT03593525|OTHER|SPARK|see above
219620241|NCT04543253|OTHER|MUSE biofeedback|biofeedback through a headband
218926100|NCT02622126|DRUG|Morphine|Sub arachnoid 200 meg morphine
218926101|NCT02622126|DRUG|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
218926102|NCT02622126|DRUG|Ephedrine|If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
218926103|NCT02622126|DRUG|Atropine|Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
218926104|NCT04495023|PROCEDURE|Left elective colectomy|Open or laparoscopic left elective colectomy with colo-rectal anastomosis
219620242|NCT04396873|DRUG|11C-MC1|Injected IV followed by PET scanning
218926105|NCT01378871|DRUG|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
219539334|NCT06594939|DRUG|Polatuzumab Vedotin|A combination of a monoclonal antibody and a chemotherapy drug.
219539335|NCT06594939|DRUG|Mosunetuzumab|A monoclonal antibody.
219539336|NCT06594939|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent.
218926106|NCT03356041|OTHER|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
218926107|NCT01454102|BIOLOGICAL|Nivolumab|
218926108|NCT01454102|DRUG|Gemcitabine|
218926109|NCT01454102|DRUG|Cisplatin|
218926110|NCT01454102|DRUG|Pemetrexed|
218926111|NCT01454102|DRUG|Paclitaxel|
218926112|NCT01454102|DRUG|Carboplatin|
218926113|NCT01454102|DRUG|Bevacizumab|
219043304|NCT04176159|OTHER|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
219043305|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
219539337|NCT06594939|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic.
219539338|NCT06594939|DRUG|Prednisone|Steroid, anti-inflammatory
219539339|NCT06594939|OTHER|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier.
219539340|NCT03569761|BEHAVIORAL|Colorectal Cancer Screening Decision Aid|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
219539341|NCT03569761|BEHAVIORAL|Control Group|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
219539342|NCT03154645|DRUG|Ibuprofen|non-steroidal anti-inflammatory drug
219539343|NCT03154645|DRUG|Acetazolamide|a diuretic
219539344|NCT00748072|DRUG|DDAVP|0.3 mcg/kg subcutaneous
218926114|NCT01454102|DRUG|Erlotinib|
218926115|NCT01454102|BIOLOGICAL|Ipilimumab|
218926116|NCT04892381|DIAGNOSTIC_TEST|Skin Biopsy|"* Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP"
218926117|NCT04355143|DRUG|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
218926118|NCT04355143|OTHER|Current care per UCLA treating physicians|Current care
218926119|NCT02148874|BIOLOGICAL|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
219043306|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
219043307|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
219043308|NCT06456411|OTHER|Cold Stimulation|cold stimulation using ice pack
219539345|NCT00748072|DRUG|saline solution|saline solution 1 ml subcutaneous
219539346|NCT03052309|DEVICE|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
219539347|NCT00316186|DRUG|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
219539348|NCT00316186|DRUG|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
219539349|NCT04086186|PROCEDURE|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
219539350|NCT04086186|PROCEDURE|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
218926120|NCT01287702|DIETARY_SUPPLEMENT|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
218926121|NCT01287702|DIETARY_SUPPLEMENT|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
218926122|NCT01287702|DIETARY_SUPPLEMENT|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
218926123|NCT04647188|OTHER|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
218926124|NCT03559374|OTHER|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
218926125|NCT02592798|DRUG|Abatacept|Abatacept IV administered on Day 1, 15, 29 and then every 28 days
218926126|NCT02592798|OTHER|Normal Saline|Normal Saline administer on Day 1, 15, 29 and then every 28 days
219043309|NCT03118492|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
219539351|NCT06922890|DRUG|STUP-001|in vivo direct cell conversion gene therapy investigational product
219539352|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
218926127|NCT02592798|OTHER|D5W|Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
218926128|NCT03083834|DIAGNOSTIC_TEST|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
219539353|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
219539354|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
218926129|NCT03470389|PROCEDURE|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
218926130|NCT03455595|PROCEDURE|Endoscopic exams|Coloscopy
218926131|NCT05715099|DRUG|Saffron|Dietary Supplement: saffron supplement for IBD
219539355|NCT03145493|DEVICE|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
219539356|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
219539357|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
219539358|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
218926132|NCT05715099|DRUG|Placebo|Dietary Supplement: placebo for IBD
218926133|NCT03699514|DEVICE|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
218926134|NCT02622282|OTHER|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
218926135|NCT02622282|OTHER|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
218926136|NCT02622282|OTHER|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
219043310|NCT03118492|DRUG|Cyclophosphamide|Given IV
219043311|NCT03118492|DRUG|Fludarabine|Given IV
219539359|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
219539360|NCT06944483|PROCEDURE|same-day radioembolization|"On the day of the procedure, angiography is performed, followed by cone-beam CT of the hepatic artery. After injecting 99mTc-MAA into the hepatic artery, the patient is transferred to the nuclear medicine department for a lung shunt scan and lung SPECT/CT. The lung shunt fraction is determined using the planar images.~Using diagnostic CT/MRI and 99mTc-MAA images, the treatment dose is calculated with the multi-compartment MIRD method. The acceptable range for tumor absorbed dose is ≥100 Gy, and the lung dose must be ≤15 Gy. The tumor absorbed dose must be at least 100 Gy and should ideally be within the range of 300 to 600 Gy. There is no upper limit for the tumor absorbed dose."
219539361|NCT06949800|DRUG|EXE-346 Probiotic|Given as a single-dose, powder packet to mix with water
219539362|NCT06949800|DRUG|Placebo|Given as a single-dose, powder packet to mix with water
219539363|NCT06949800|PROCEDURE|Usual Care High Resolution Anoscopy (HRA)|Non-investigational HRA will be performed
218926137|NCT00705016|DRUG|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
218926138|NCT00705016|DRUG|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
218926139|NCT00705016|DRUG|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
218926140|NCT00705016|DRUG|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
218926141|NCT00705016|DRUG|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
219043312|NCT03118492|BIOLOGICAL|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
219043313|NCT03118492|OTHER|Laboratory Biomarker Analysis|Correlative studies
219043314|NCT03118492|DRUG|Melphalan|Given IV
219043315|NCT03118492|DRUG|Mycophenolate Mofetil|Given PO
219043316|NCT03118492|DRUG|Tacrolimus|Given IV or PO
219043317|NCT03118492|RADIATION|Total-Body Irradiation|Undergo TBI
219539364|NCT03985865|DRUG|Intragastric quinine hydrochloride|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
219539365|NCT03985865|DRUG|Intragastric denatonium benzoate|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
219539366|NCT03985865|DRUG|Intragastric placebo|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
219620243|NCT04396873|DRUG|11C-PS13|Injected IV followed by PET scanning
218926142|NCT02233517|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
218926143|NCT02233517|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
218926144|NCT04042948|DRUG|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
219539367|NCT03985865|DRUG|Intraduodenal quinine hydrochloride|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
218926145|NCT05510349|OTHER|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
218926146|NCT00613561|DRUG|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
218926147|NCT05567783|BIOLOGICAL|VIR-2482 (450 mg)|VIR-2482 450mg given by intramuscular injection
219043318|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
219043319|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
218926148|NCT05567783|BIOLOGICAL|VIR-2482 (1200 mg)|VIR-2482 1200 mg given by intramuscular injection
218926149|NCT05567783|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
218926150|NCT06448676|DRUG|Botulinum toxin type A|Head-to-head comparison of all commercially available botulinum neurotoxin type A products
218926151|NCT05411393|OTHER|ADL-enhanced program|The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.
218926152|NCT05411393|OTHER|Usual home health rehabilitation therapy|Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
219043320|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
219043321|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
219043322|NCT01888198|BEHAVIORAL|(EORTC QLQ-C30) questionnaire|
219043323|NCT01888198|BEHAVIORAL|EuroQol EQ-5D 7-item questionnaire|
219043324|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
219043325|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
219043326|NCT04126785|OTHER|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
219539368|NCT03985865|DRUG|Intraduodenal denatonium benzoate|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
219539369|NCT03985865|DRUG|Intraduodenal placebo|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
219539370|NCT04176029|DEVICE|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
219620244|NCT04396873|DRUG|18f-florbetaben|Injected IV followed by PET scanning
219620245|NCT04164082|PROCEDURE|Biopsy Procedure|Undergo bladder biopsy
218926153|NCT04916587|OTHER|Implementation Strategy of ACEs Screenings|We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.
219539371|NCT04845802|OTHER|Inspiratory muscle training(high-IMT group)|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
218926154|NCT04916587|OTHER|Usual Care|"The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services."
218926155|NCT03944577|DRUG|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
218926156|NCT05361668|DRUG|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
218926157|NCT05361668|DRUG|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
218926158|NCT02246790|PROCEDURE|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
218926159|NCT02246790|PROCEDURE|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
218926160|NCT02048670|DEVICE|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
218926161|NCT02787902|BEHAVIORAL|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
218926162|NCT02787902|BEHAVIORAL|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
218926163|NCT03129568|BIOLOGICAL|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
219205001|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
219539372|NCT04845802|OTHER|Inspiratory muscle training(low-IMT group)|Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
219539373|NCT00286702|DEVICE|hand splint|
219539374|NCT04870606|DRUG|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
218926164|NCT00363259|DRUG|Peginterferon alfa-2b|
218926165|NCT00363259|DRUG|Ribavirin|
218926166|NCT05142813|DIAGNOSTIC_TEST|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
218926167|NCT02431637|BIOLOGICAL|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
218926168|NCT02431637|DRUG|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
218926169|NCT01167504|OTHER|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
218926170|NCT03133793|DRUG|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
218926171|NCT03133793|DRUG|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
218926172|NCT03133793|OTHER|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
218926173|NCT03133793|OTHER|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
218926174|NCT05506124|DEVICE|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
219539375|NCT04870606|DRUG|Placebo|Placebo+Standard of care determined by PI and local regulatory
219539376|NCT01498939|DRUG|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
219620246|NCT04164082|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219043327|NCT04126785|OTHER|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
219539377|NCT06438224|OTHER|Extracorporeal shock wave therapy (ESWT)|Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
219539378|NCT06438224|OTHER|sham stimulation|the sham group was treated using an adapter that had the same shape but did not emit any energy
219539379|NCT05152576|DRUG|OnabotulinumtoxinA X|Intramuscular Injection
219539380|NCT05152576|DRUG|Placebo|Intramuscular Injection
219539381|NCT06323239|RADIATION|SBRT|SBRT for metastatic lesions
219539382|NCT06323239|RADIATION|Low-dose Radiotherapy (LDRT)|LDRT for metastatic lesions
219539383|NCT06323239|DRUG|Toripalimab|6 cycles for combined therapy. Toripalimab maintenance for 1 year.
219539384|NCT06323239|DRUG|Gemcitabine|6 cycles for combined therapy.
219539385|NCT06323239|DRUG|Cisplatin|6 cycles for combined therapy.
219539386|NCT06323239|RADIATION|IMRT|IMRT for primary lesion
219539387|NCT06593067|OTHER|Control|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes without a cooling modality.
219539388|NCT06593067|OTHER|Fan|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan as a cooling modality.
219539389|NCT06593067|OTHER|Fan and Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan and water spray as cooling modalities.
219620247|NCT04164082|PROCEDURE|Computed Tomography|Undergo CT
219620248|NCT04164082|PROCEDURE|Cystoscopy|Undergo cystoscopy
219620249|NCT04164082|DRUG|Gemcitabine Hydrochloride|Given intravesically
219620250|NCT04164082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218926175|NCT05506124|DEVICE|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
218926176|NCT02247986|DRUG|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
218926177|NCT05484752|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
218926178|NCT05484752|BEHAVIORAL|Education|Conventional exercise and life style modification
218926179|NCT03192735|DRUG|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
218926180|NCT00036985|DRUG|cyclophosphamide|
218926181|NCT00036985|DRUG|doxorubicin hydrochloride|
218926182|NCT00036985|PROCEDURE|conventional surgery|
218926183|NCT00036985|PROCEDURE|neoadjuvant therapy|
219539390|NCT06593067|OTHER|Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with water spray as a cooling modality.
219539391|NCT05844462|DRUG|Tadalafil|Oral Tadalafil
219539392|NCT05844462|DRUG|Placebo|Oral Placebo
219539393|NCT03183986|DEVICE|Phototherapy|Phototherapy for 24 hours.
219539394|NCT01874561|DRUG|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
219539395|NCT01874561|DRUG|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
219539396|NCT01874561|DRUG|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
219539397|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
219539398|NCT02057835|DRUG|BI 691751 high dose|BI 691751 high dose
219539399|NCT02057835|DRUG|BI 691751 middle dose|BI 691751 middle dose
219539400|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
219539401|NCT02057835|DRUG|BI 691751 low dose 1|BI 691751 low dose 1
218926184|NCT00036985|PROCEDURE|thermal ablation therapy|
219539402|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
219539403|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
219539404|NCT02057835|DRUG|BI 691751 low dose 2|BI 691751 low dose 2
219539405|NCT06626698|OTHER|Static stretching|A passive static stretch of the posterior leg muscles will be performed with the subject in a supine position and knees extended, starting with the ankle at 90º and continuing until reaching the maximum tolerated dorsiflexion.
219620251|NCT04164082|BIOLOGICAL|Pembrolizumab|Given IV
219620252|NCT04164082|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
219620253|NCT06645860|PROCEDURE|SDF+KI+LED Light 20s|After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
219620254|NCT06645860|PROCEDURE|SDF+KI|Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
219620255|NCT04214626|DRUG|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
219620256|NCT04214626|DRUG|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219539406|NCT06626698|DEVICE|Electrical muscle elongation|The intervention will be performed with the subject in a supine position with knees extended. Electrodes will be placed on the gastrocnemius muscles of the leg being assessed. The parameters will be selected. Static stretching will begin until resistance is felt, at which point the intensity of the electrical current will be increased to induce a visible and tolerable contraction. Simultaneously, the subject will be asked to perform an isometric contraction of the antagonist muscles, resisted by the investigator. When the subject feels the stretch again, the intensity of the current will be increased once more until a new movement barrier is reached.
218926185|NCT02936596|DRUG|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
218926186|NCT02936596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid
219539407|NCT02984098|DRUG|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
218926187|NCT02074501|OTHER|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
218926188|NCT03070964|DRUG|plitidepsin|
218926189|NCT00845767|PROCEDURE|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
218926190|NCT05849753|DEVICE|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
218926191|NCT06086769|DEVICE|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
218926192|NCT05228951|DRUG|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
219620257|NCT04214626|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219539408|NCT03425344|DIAGNOSTIC_TEST|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
218926193|NCT02012413|DEVICE|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
218926194|NCT02012413|DEVICE|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
219043328|NCT04126785|OTHER|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
219043329|NCT05279664|OTHER|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
219620258|NCT04214626|DRUG|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219620259|NCT04214626|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219043330|NCT05279664|OTHER|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
219043331|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
219539409|NCT02343926|DRUG|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
219539410|NCT02343926|DRUG|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
219539411|NCT02343926|DRUG|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
219620260|NCT04214626|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219043332|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
219539412|NCT05368480|OTHER|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
219539413|NCT00012818|BEHAVIORAL|relaxation technique|
219539414|NCT00012818|BEHAVIORAL|educational program|
219539415|NCT01601158|BIOLOGICAL|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
219539416|NCT01601158|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
219539417|NCT05878626|OTHER|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
219539418|NCT05954598|DIETARY_SUPPLEMENT|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
219539419|NCT02561845|DRUG|rosuvastatin|5mg, 10mg, 20mg
219539420|NCT05278507|DEVICE|Arrowga+rd Blue Advance Protection PICC Placement|The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
219539421|NCT05278507|DEVICE|Sham Comparator PICC placement|The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
219539422|NCT01095315|OTHER|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
219539423|NCT04438187|OTHER|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
219539424|NCT05349435|DRUG|Fezagepras|Investigational drug
219539425|NCT05349435|DRUG|Sodium phenylbutyrate|Investigational drug
219539426|NCT04278560|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
219539427|NCT04278560|DEVICE|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
219539428|NCT04278560|BEHAVIORAL|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
219620261|NCT04214626|DRUG|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
219620262|NCT06022016|GENETIC|For each person (index case or related) included in this study:|"* an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
219539429|NCT05445739|BEHAVIORAL|The effect of an online exercise course on the increase of elders' regular exercise intention|The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
219539430|NCT02832063|BIOLOGICAL|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
219539431|NCT02832063|BIOLOGICAL|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
219539432|NCT01931722|DIETARY_SUPPLEMENT|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
219539433|NCT01931722|BEHAVIORAL|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
219539434|NCT02303405|DRUG|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
219539435|NCT02303405|DRUG|Pioglitazone|Anti-hyperglycemic agent
219539436|NCT03789565|OTHER|Biomarker test|Diagnostic biomarker study
219539437|NCT01867164|DRUG|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
218926195|NCT03453268|OTHER|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
218926196|NCT03453268|OTHER|Control|usual treatment
218926197|NCT01285557|DRUG|S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
218926198|NCT01285557|DRUG|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
218926199|NCT01781728|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
218926200|NCT05444530|BIOLOGICAL|VAC85135|Participants will receive VAC85135 as IM injection.
218926201|NCT05444530|DRUG|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
218926202|NCT05615922|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
218926203|NCT05615922|BEHAVIORAL|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
218926204|NCT05378672|DRUG|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.
218926205|NCT01655459|PROCEDURE|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
218926206|NCT01047488|DRUG|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
218926207|NCT01047488|DRUG|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
218926208|NCT01047488|DRUG|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
218926209|NCT01047488|DRUG|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
218926210|NCT02315742|BEHAVIORAL|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
218926211|NCT04305691|DRUG|Ixazomib Citrate|Given PO
218926212|NCT04305691|OTHER|Quality-of-Life Assessment|Ancillary studies
218926213|NCT04305691|OTHER|Questionnaire Administration|Ancillary studies
218926214|NCT05589857|DEVICE|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
218926215|NCT05589857|DEVICE|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
218926216|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
219539438|NCT01867164|DRUG|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
219620263|NCT05639946|DRUG|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
219620264|NCT05639946|DRUG|Placebo|Participants will receive placebo drug
219620265|NCT05725681|OTHER|High protein ramen|Participants will be served one portion of high-protein instant ramen noodles \[CHEF WOO Roasted Chicken Flavor Ramen Cup Noodles, Borealis Foods; 71 g\]
219620266|NCT05725681|OTHER|Standard ramen|Participants will be served one portion of standard instant ramen noodles \[RAMEN EXPRESS Chicken Flavor Ramen Cup Noodle Chef Woo, Borealis Foods; 71 g\]
219539439|NCT01880632|DRUG|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
219539440|NCT01531894|DRUG|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
218926217|NCT05686772|DRUG|Antipsychotic use|Use of first/second generation antipsychotics, use of third-generation antipsychotics, use of aripiprazole specifically
218926218|NCT05686772|OTHER|Psychiatric comorbidities|Substance use disorders, cluster B personality disorders, anxiety disorder, major depressive disorder, attention-deficit/hyperactivity disorder, tobacco smoking
219539441|NCT02674880|DRUG|HMW-HA|Aerolized administration b.i.d.
219539442|NCT02674880|OTHER|Placebo|Standard therapy
218926219|NCT05686772|OTHER|Sociodemographics/socioeconomic status|Age, gender identity, ethnicity, highest educational attainment, employment, at school, homelessness, in a relationship
218926220|NCT05686772|OTHER|Gambling history|Non-problematic gambling at the time of admission and/or previous 12 months
218926221|NCT05686772|OTHER|Clinical variables|Main psychiatric diagnosis, history of psychiatric hospitalizations, severity of illness (CGI-S), functioning (SOFAS), concomitant psychotropic medications use
218926222|NCT05030753|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
218926223|NCT05030753|BEHAVIORAL|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
218926224|NCT06969066|BEHAVIORAL|Cognitive Remediation Therapy plus Sleep Hygiene Education (CRT+SHE)|Participants will receive Cognitive Remediation Therapy (CRT) combined with Sleep Hygiene Education (SHE). CRT includes structured training sessions targeting attention, memory, visuospatial skills, calculation ability, logical reasoning, and language abilities. Sessions will be conducted daily for 50 minutes over 6 weeks. Sleep Hygiene Education will cover standard recommendations to improve sleep behaviors.
218926225|NCT06969066|BEHAVIORAL|Sleep Hygiene Education Only (SHE)|Participants will receive Sleep Hygiene Education (SHE) only, including guidance on adjusting sleep schedules, maintaining healthy sleep environments, minimizing stimulant intake, and managing sleep-related behaviors, without any CRT intervention.
218926226|NCT06973486|BEHAVIORAL|psychometric scales|Perceived Stress Scale (PSS) Pain Tolerance Scale (PRS) Surgical Anxiety Scale
218926227|NCT03003325|DRUG|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
218926228|NCT03003325|PROCEDURE|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
218926229|NCT03003325|DRUG|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
218926230|NCT06332521|OTHER|Acoustic signal analysis method|Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.
219539443|NCT04030091|DRUG|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
219539444|NCT04030091|DRUG|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
219620267|NCT06005623|DEVICE|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
219620268|NCT06400147|BEHAVIORAL|Strategy Training|This intervention will use an adapted form of strategy training for people with neglect.
219620269|NCT06400147|BEHAVIORAL|Attention Control|This intervention will use a reflective listening protocol.
219620270|NCT06049849|DEVICE|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
219620271|NCT03568656|DRUG|CCS1477|Capsules, oral
219620272|NCT03568656|DRUG|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
219620273|NCT03568656|DRUG|Enzalutamide|Enzalutamide 40mg capsules/tablets
219620274|NCT03568656|DRUG|Darolutamide|300mg tablets
219620275|NCT03568656|DRUG|Olaparib|150mg tablets
218926231|NCT03173248|DRUG|AG-120|Tablets administered orally
218926232|NCT03173248|DRUG|Placebo|Tablets administered orally
218926233|NCT03173248|DRUG|Azacitidine|Administered SC or IV
218926234|NCT05777187|OTHER|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
218926235|NCT06210724|DIAGNOSTIC_TEST|Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome|Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
218926236|NCT02833233|PROCEDURE|Cryoablation|
218926237|NCT02833233|DRUG|Ipilimumab|
218926238|NCT02833233|DRUG|Nivolumab|
218926239|NCT02991768|DRUG|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
218926240|NCT02991768|DRUG|Placebos|Placebo is matched to the study drug.
218926241|NCT05759026|OTHER|Accompaing cares|"After signing the consent form, the patient will be randomised. The ones randomised in VR groups will choose their preferred environment (e.g. landscapes, animals...).~The participant will be managed during 1 care (one care in control condition (no material used), care with the VR headset, one care with the VR set and the prefered environnent of the patient) for an average of 30 minutes (including the completion of the scales and questionnaires)."
218926242|NCT05202119|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.
218926243|NCT05202119|DEVICE|Sham Transcranial direct current stimulation|To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.
218926244|NCT06096922|OTHER|No intervention|No intervention
218926245|NCT04979546|OTHER|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
218926246|NCT04979546|OTHER|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
218926247|NCT04940585|OTHER|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
218926248|NCT03052829|BEHAVIORAL|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
218926249|NCT03052829|BEHAVIORAL|Usual care|Subjects will undergo their usual care without intervention
218926250|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
218926251|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
218926252|NCT03818854|BIOLOGICAL|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
218926253|NCT03818854|BIOLOGICAL|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
218926254|NCT06515912|OTHER|Ketogenic Diet|A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
218926255|NCT06646185|OTHER|Menstrual Pads|Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
219043333|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
219539445|NCT06282874|DRUG|Lorlatinib|Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
219043334|NCT06513624|DRUG|ETC-159|ETC-159 will be administered orally.
219539446|NCT02744794|DEVICE|Dermal Cooling System|Treatment with cryotherapy.
219539447|NCT03086460|DRUG|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
219539448|NCT03086460|DRUG|Formoterol Inhalation Solution|Active Control
219539449|NCT03086460|DRUG|Placebo pMDI|Matched Placebo
219539450|NCT01831362|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|
219539451|NCT01831362|BEHAVIORAL|Focused Attention (FA)|
219620276|NCT03568656|DRUG|Atezolizumab|840mg/14ml concentrate for solution for infusion vials
219620277|NCT03103087|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
219539452|NCT01831362|BEHAVIORAL|Open- Monitoring|
219539453|NCT02837991|DRUG|CDX-014|
218926256|NCT06646185|OTHER|Menstrual Cups|Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
218926257|NCT06646185|OTHER|Tampons|Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
218926258|NCT04500158|DRUG|Lidocaine|2% Lidocaine with 1:100,000 epi
218926259|NCT04572815|DRUG|Placebo Administration|Given IV and SC
218926260|NCT04572815|OTHER|Quality-of-Life Assessment|Ancillary studies
218926261|NCT04572815|OTHER|Questionnaire Administration|Ancillary studies
218926262|NCT04572815|BIOLOGICAL|Ustekinumab|Given IV and SC
218926263|NCT06193096|DIETARY_SUPPLEMENT|Experimental product|Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.
218926264|NCT06193096|DIETARY_SUPPLEMENT|Control product|"Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks"
218926265|NCT02110069|DRUG|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
218926266|NCT02110069|DRUG|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
218926267|NCT06651684|BEHAVIORAL|CanCEASE with Health Navigator|"CanCEASE is a digital intervention to identify parents who smoke, assess their motivation and willingness to quit, as well as to provide direct linkage to evidence-based smoking interventions, including effective behavioural and pharmacological resources that can be used alone or in combination.~Participants will have the choice to receive CanCEASE at three timepoints (0, 6 and 12 months). CanCEASE will be combined with an offer of support sessions with a Health Navigator.~Health Navigators will be research personnel hired specifically for this study and trained formally in health navigation, tobacco cessation counseling and strategies to address unmet social needs. The investigators will leverage knowledge and experience of two ongoing RCTs of HNs in pediatrics to inform training strategies."
218926268|NCT06651619|OTHER|Water|Prescribed amount of bottled water the evening prior and 2 hours prior to team practice
218926269|NCT06651619|OTHER|Hydration Education|30-60 minutes
218926270|NCT06589063|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with implantation of new-generation balloon-expandable or self-expandable bioprostheses
218926271|NCT06591624|OTHER|Prolonged Mechanical Ventilation|The neurosurgical patients who could extubated within 24 h after surgery
218926272|NCT06591624|OTHER|remain intubation after surgery|could not extubated after surgery and prolong mechanical ventilation for 48 hours
218926273|NCT06653959|DEVICE|active Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.
218926274|NCT06653959|DEVICE|sham Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.
218926275|NCT03583814|BEHAVIORAL|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
219539454|NCT06272266|DEVICE|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
219620278|NCT03103087|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
219620279|NCT03103087|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
218926276|NCT03583814|BEHAVIORAL|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
218926277|NCT06818851|DRUG|Henggliflozin|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.
219043335|NCT06513624|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
219043336|NCT06513624|DRUG|Denosumab / Zoledronic Acid|Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
219043337|NCT03806309|DRUG|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
219043338|NCT03806309|DRUG|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
219043339|NCT04522323|BIOLOGICAL|MEDI5752|MEDI5752
219620280|NCT03103087|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
219539455|NCT06272266|DEVICE|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
218926278|NCT06818851|OTHER|Placebo|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.
218926279|NCT06986551|OTHER|5% NaF fluoride varnish|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It will be dried with air and isolated using cotton rolls.~Package will be unpacked, and the application guide will be used to display the contents and mix to avoid the separation of sodium fluoride components. After isolation, a thin layer of the varnish will coat . The participants will be asked to keep their mouths closed to allow the varnish to set in the presence of saliva. Rinsing or suction was not allowed immediately after the application of the varnish.~The participants will be asked to avoid consumption of rough and viscid food or hot drinks for two hours after application of the varnish. For the rest of that day, participants will be asked to eat soft food and stop tooth brushing (Ezzeldin et al., 2024)."
219043340|NCT04522323|DRUG|Axitinib|INLYTA
219043341|NCT04522323|DRUG|Lenvatinib|LENVIMA
219043342|NCT04388943|OTHER|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
219620281|NCT00413699|DRUG|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
219620282|NCT00413699|DRUG|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
219620283|NCT05524389|RADIATION|Vaginal brachytherapy|"High-dose rate vaginal brachytherapy (VBT) was delivered with a vaginal cylinder.For VBT administered alone, the dose is recommended: 3 fractions of 7 Gy or 5 fractions of 6 Gy or 6 fractions of 5 Gy.~For VBT administered after completion of EBRT: 2-3 fractions of 4-6 Gy."
219620284|NCT05524389|RADIATION|Pelvic external beam radiotherapy|EBRT was delivered to the pelvic area using a total dose of 45-50.4Gy in 25-28 fractions over 5-6 weeks with the intensity-modulated radiotherapy (IMRT) technique, three-dimensional conformal radiotherapy (3D-CRT) modality
219620285|NCT05524389|OTHER|Observation|No radiotherapy is administrated, but active follow-up and quality of life questionnaires is needed after surgery.
219043343|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
219043344|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
219043345|NCT04176003|OTHER|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
219043346|NCT04176003|OTHER|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
219043347|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
219043348|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
219043349|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
219043350|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
219043351|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
219620286|NCT05524389|DRUG|Chemotherapy|Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
219620287|NCT03644641|PROCEDURE|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
218926280|NCT06986551|OTHER|PRG Barrier coat|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It was then dried with air and isolated using cotton rolls.~\| P a g e 13 According to the manufacturer's instructions, the application of PRG barrier coat varnish a drop of the active will be mixed with the base using the attached brush. After isolation with cotton rolls, the brush will be used to smear the WSLs with the mix. I will be undisturbed for at least three seconds, then cured for 10 seconds using the visible-light curing unit (Ezzeldin etal.,2024).~And there will be no post operative instruction to patient after application (light cured resin material)."
218926281|NCT06587828|PROCEDURE|Companion blood samples with procedure|Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.
218926282|NCT06603545|OTHER|Digital education for osteoporosis patients|DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
218926283|NCT06598969|DRUG|Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide|Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
219539456|NCT06272266|DEVICE|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
219539457|NCT06272266|DEVICE|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
219620288|NCT03644641|PROCEDURE|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
219620289|NCT00075816|BIOLOGICAL|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
218926284|NCT06599892|OTHER|Intervention mapping|Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
218926285|NCT06586632|DEVICE|AID technology|Automated insulin delivery system combined with a CGM
218926286|NCT06586632|DEVICE|CGM|CGM alone
218926287|NCT06600828|OTHER|Data collection|Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
219620290|NCT00075816|BIOLOGICAL|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
219620291|NCT04992078|DEVICE|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
219620292|NCT04992078|PROCEDURE|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
218926288|NCT06588985|BEHAVIORAL|Emotion Coaching Parent Training Workshop|Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.
219043352|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
219043353|NCT03307759|DRUG|Pembrolizumab|Pembrolizumab
219043354|NCT03307759|RADIATION|Radiotherapy (SABR)|Radiotherapy
219043355|NCT06050564|OTHER|Treatment recommendations will be based on video documented PBS-Score|Therapeutic recommendations from orthopedic surgeons, will be summarized and described
219043356|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
219043357|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
219043358|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
219205002|NCT06885593|DIAGNOSTIC_TEST|Left Lateral Tilt Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in left lateral tilt (LLT) position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
219205003|NCT06882395|DEVICE|Group 1: FLX aligners for 10 days|FLX aligners worn for 10 days
219620293|NCT05678322|DRUG|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
218926289|NCT06588985|BEHAVIORAL|Waitlist Control|Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
218926290|NCT06592456|BIOLOGICAL|Chickenpox Vaccines|The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
218926291|NCT06604351|DRUG|Sintilimab, Nab-Paclitaxel, and Carboplatin|Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
218926292|NCT02581241|DEVICE|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
218926293|NCT06053671|GENETIC|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
218926294|NCT01704716|DRUG|Vincristine|given during Rapid COJEC and modified N7 therapy
218926295|NCT01704716|DRUG|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
218926296|NCT01704716|DRUG|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
218926297|NCT01704716|DRUG|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
219043359|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
219043360|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
219043361|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
219043362|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219043363|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219043364|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
219043365|NCT06274398|DRUG|TAF/EVG rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
219043366|NCT06274398|DRUG|Matching placebo rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
218926298|NCT01704716|DRUG|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
218926299|NCT01704716|DRUG|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
219043367|NCT06034535|BIOLOGICAL|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
219043368|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
219205004|NCT06882395|DEVICE|Group 3: FLX aligners for 7 days, followed by new FLX aligners for 3 days.|Group 3: FLX aligners worn for 7 days, followed by new FLX aligners for 3 days.
219205005|NCT06882395|DEVICE|Group 2: FLX aligners worn for 7 days, followed by FLX35 aligners for 3 days.|Group 2: FLX aligners for 7 days, followed by FLX35 aligners for 3 days.
218926300|NCT01704716|DRUG|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
218926301|NCT01704716|DRUG|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
218926302|NCT01704716|DRUG|G-CSF|G-CSF is given during Induction Treatment
218926303|NCT01704716|DRUG|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
218926304|NCT01704716|DRUG|Melphalan|Melphalan is given during MAT treatment
218926305|NCT05304195|DIAGNOSTIC_TEST|Glucocerebrosidase|Blood sample (10ml) for GCase activity
218926306|NCT05304195|GENETIC|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
218926307|NCT05304195|DIAGNOSTIC_TEST|Macrophage biomarkers|Blood sample (20ml) for macrophage biomarkers
218926308|NCT06992531|OTHER|Questionnaire and Physical Exam|Standardised participant questionnaires assessing neurological symptoms, including pain (NPSI, DN4, BPI), fatigue (Fatigue Severity Scale), depression and anxiety (PHQ9 and GAD7) and autonomic dysfunction (Malmo PoTS Score and COMPASS-31).
218926309|NCT06992531|DIAGNOSTIC_TEST|Nerve conduction studies|Measures how fast an electrical impulse moves through sensory and motor nerves. The test will be used to identify/rule out large fibre peripheral neuropathy.
218926310|NCT06992531|DIAGNOSTIC_TEST|Microneurography|Electrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction.
218926311|NCT06992531|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Measures psychophysical sensory perception in response to different types of stimuli, such as thermal, mechanical, pressure and vibration. The test will be used to identify/rule out nerve fibre dysfunction, by generating a quantitative sensory profile of different sensory modalities.
218926312|NCT06992531|DIAGNOSTIC_TEST|Skin biopsy|Safe and minimally invasive procedure to quantify intraepidermal nerve fibres density (IENFD). Reduced IENF density is associated with small fibre neuropathy.
218926313|NCT06992531|BIOLOGICAL|Blood Product|A blood sample of a maximum of 120ml will be collected from a superficial upper limb vein. Blood aliquots (50ml tubes) will then be centrifuged to separate serum from the peripheral blood cells.
219043369|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
219043370|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
219043371|NCT05734105|DRUG|Ripretinib|50 mg tablets
219043372|NCT05734105|DRUG|Sunitinib|12.5 mg tablets
219043373|NCT02631811|OTHER|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
219205006|NCT06882044|DEVICE|mHealth|The mobile application contains medication and personalised reminders, the screen where blood pressure and pulse are entered, the lifestyle change recommendations information, and the section that allows users to communicate with the researcher. Also, there is a control panel that allows the application to be controlled remotely, patient information to be viewed, data to be monitored, lifestyle information to be uploaded and viewed in the mHealth, personalised reminders to be sent to patients, and communication with patients.
219620294|NCT05678322|DEVICE|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
219620295|NCT05823285|DRUG|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
219620296|NCT00161226|DEVICE|Levonorgestrel intrauterine system|
219043374|NCT03752619|DEVICE|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
219205007|NCT06882213|OTHER|transcranial direct current stimulation|transcranial direct current stimulation
219205008|NCT06882213|OTHER|core stability exercise.|core stability exercise.
219205009|NCT06881732|BIOLOGICAL|NF54/iGP3|Mosquito-generated sporozoites of the genetically modified, inducible gametocyte-producing parasite line NF54/iGP3, created via CRISPR/Cas9 genetic engineering of the parental wildtype strain Plasmodium falciparum (Pf) NF54 to contain a trimethoprim (TMP)-inducible copy of the Pf gdv1 gene in the dispensable Pf cg6 locus.
219620297|NCT03903289|PROCEDURE|Automated red cell exchange|Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
219620298|NCT03903289|PROCEDURE|Manual red cell exchange|Active Comparator: Manual red cell exchange
219620299|NCT03903289|PROCEDURE|Simple red cell transfusion|Active Comparator: Simple red cell transfusion
219620300|NCT00026988|DRUG|Creatine|
219620301|NCT06048744|PROCEDURE|external oblique intercostal block|U S guided external oblique intercostal block after induction.
219620302|NCT06048744|PROCEDURE|Erector Spine block|US guided erector spine block after induction
219043375|NCT03752619|DEVICE|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
218926314|NCT06992986|OTHER|Investigating differences in the bladder microbiome|"Urine samples and tissue from radical cystectomy specimens will be analyzed for the assessment of the urinary microbiome.~The 16s rRNA gene will be amplified and the resulting amplicons analyzed by Illumina sequencing. To distinguish contaminants, DNA from the sample will be quantified by qPCR and compared to a known urine sample of E. coli. DNA will be extracted using the Quiagen kit and stored at -20 °C until PCR amplification. Bacterial DNA will be amplified with specific primers covering the V1-V3 hypervariable region of the 16S rRNA gene. Libraries will be prepared using the Illumina 16S microbiome sequencing protocol, and their quality will be verified by Bioanalyzer and quantity by qPCR. Sequencing will be performed in paired-end mode on Illumina sequencers. Alpha, beta diversity and species richness will be measured."
219620303|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
218926315|NCT05056415|OTHER|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
218926316|NCT05056415|OTHER|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
218926317|NCT04922216|BEHAVIORAL|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
218926318|NCT04922216|BEHAVIORAL|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
218926319|NCT04922216|BEHAVIORAL|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
218926320|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
218926321|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
218926322|NCT04922216|BEHAVIORAL|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
218926323|NCT04922216|BEHAVIORAL|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
218926324|NCT04922216|BEHAVIORAL|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
218926325|NCT04922216|BEHAVIORAL|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
218926326|NCT04922216|BEHAVIORAL|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
218926327|NCT04922216|BEHAVIORAL|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
218926328|NCT06593080|OTHER|The comprehensive TDA based approach|"The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively.~Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB."
219043376|NCT03752619|OTHER|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
219043377|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
219043378|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
219043379|NCT04565015|BIOLOGICAL|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
219043380|NCT06006559|DRUG|EYU688|EYU688 administered by oral route
219043381|NCT06006559|DRUG|Placebo|Matching placebo administered orally as capsules
219043382|NCT06146166|DIETARY_SUPPLEMENT|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
219205010|NCT06717230|OTHER|EverX Posterior|Restoration
219620304|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
218926329|NCT06603701|DIAGNOSTIC_TEST|Bioimpedancemetry|"2\. Bioimpedancemetry at T1, T2, T3 ; the measurement will be~1. Squeletic mass (total and for each of the 4 limbs)~2. Angle phase (total and for each of the 4 limbs)"
218926330|NCT06603701|OTHER|Dynamometry|Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3
219043383|NCT06146166|DIETARY_SUPPLEMENT|Oral placebo supplement|Oral placebo supplement taken once daily
219620305|NCT06106581|BIOLOGICAL|Control|Nimenrix
219620306|NCT00451373|DEVICE|CVVH and SLED|
218926331|NCT06596681|GENETIC|GA+clozapine|Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
218926332|NCT06590545|DRUG|KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy|A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
218926333|NCT06614881|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
218926334|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
218926335|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
219043384|NCT06959901|BEHAVIORAL|PATHS-UP Mobile Phone Application|Youth in the intervention will be given access to a health-based mobile phone application and a remote bluetooth scale. The app is focused on promoting health education and self-monitoring. For 30 days youth will be asked to engage with content focused on promoting healthy sleep, physical activity, and dietary habits every day. Youth will also be asked to self-monitor health behaviors using the app as it pulls in data on daily steps from the accelerometer embedded within the smartphone, information on weight from daily weigh-ins using the remote scale, sleep via a weekly survey within the app, and caloric intake using a daily food log that is powered through artificial intelligence within the app.
219043385|NCT05430893|OTHER|Botulinum Toxin A|100 UI IM in the adductor longus
219043386|NCT00769847|PROCEDURE|Endoscopic strip craniectomy|Surgery
219539458|NCT03625063|OTHER|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
219043387|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
219539459|NCT03625063|OTHER|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
219539460|NCT04169633|DIAGNOSTIC_TEST|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
219539461|NCT05400694|OTHER|Food|Dairy products with reduced sugar content
219539462|NCT05270135|BEHAVIORAL|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
219539463|NCT01747135|DRUG|VTS-270|
219539464|NCT05674734|BEHAVIORAL|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
219205011|NCT06886035|DRUG|liposomal curcumin|The study group began a regimen of 100 mg oral liposomal curcumin (administered as 50 mg twice daily) one day prior to the procedure. Following surgery, oral liposomal curcumin (50 mg twice daily) was restarted 8 hours postoperatively and maintained for an additional two days. ( A total dose 300 mg)
219205012|NCT06885255|OTHER|Alternate day fasting|Participants are instructed to alternate between consuming 100% of their usual energy intake on one day and only 25% on the following day.
219205013|NCT06885255|OTHER|Time restricted eating|Subjects are instructed to limit their energy intake to 8 hours a day and to fast for the remaining 16 hours.
219620307|NCT00451373|DRUG|Vancomycin|
219620308|NCT00451373|DRUG|Daptomycin|
219620309|NCT00451373|DEVICE|FX60, AV600 (dialyzer)|
219620310|NCT03004274|OTHER|Running sutures|
219620311|NCT03004274|OTHER|Interrupted sutures|
218926336|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
218926337|NCT06614881|DRUG|Normal saline|loading dose of saline was injected 10-min before induction of anesthesia.
218926338|NCT03375788|DRUG|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
218926339|NCT03375788|DRUG|Identical Placebo|Placebo injection daily
218926340|NCT06993454|OTHER|Magnetic Resonance Liver Assessment|Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
219620312|NCT04115319|DRUG|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
219620313|NCT04115319|DRUG|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
219620314|NCT00474890|DRUG|cetericine and pseudoephedrine|
219620315|NCT01864993|DIETARY_SUPPLEMENT|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
218926341|NCT06993454|OTHER|Bike Exercise VO2max|Maximal fitness measured by cycle ergometer.
218926342|NCT06993454|OTHER|DEXA|Measure body composition (fat and lean body mass).
218926343|NCT06992245|DIAGNOSTIC_TEST|DW-MRI|Predict changes in ovarian diffusion using DW-MRI scan
218926344|NCT06992154|DIETARY_SUPPLEMENT|Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule|Probiotic capsule will contain Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, and Bifidobacterium Infantis
219539465|NCT00272519|BEHAVIORAL|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
218926345|NCT06991595|PROCEDURE|cytoreductive resection of adenomyosis, myomectomy, resection of endometriosis|All women chosen for the study will be divided into the groups (AD, UF, DE, ETRS, CTRL) based on the inclusion/exclusion criteria (Table 2).A meticulous concern will be dedicated to patients´ education on advantages and disadvantages (including the eventual risks) of surgical and conservative management of AD and UF. These patients will be allocated into surgical or conservative arm of the study based on their inclinations: either to fertility saving surgical procedure (FSS) with subsequent IVF, or directly to IVF. This phenomenon of the importance of patients´ preferences in controversial clinical situations is the usual part of the management of infertile patients with AD or UF.
218926346|NCT06991595|PROCEDURE|hysteroscopy|Sampling of endometrium (Hysteroscopy) The samples will be collected using hysteroscopy, scheduled into the secretory phase of endometrial cycle. During hysteroscopy, the uterine cavity will be observed and described in the surgical protocol (capacity, symmetry, presence of intrauterine pathologies, internal ostia of the tubes). The 3.2 mm wide hysteroscope will be used. Its usage usually does not require any anaesthesia. The endometrium will be taken using biopsy forceps (7 French / 2.3 mm) and immediately frozen on dry ice and stored at -80 °C until processing. Two pieces of endometrium per patient will be collected - one for isolation of RNA and bulk RNA-Seq and/or RT-qPCR and the second one for isolation of nuclei and snRNA-Seq or validation using snRT-qPCR. If some unexpected findings would be observed during hysteroscopy (especially some interfering with fertility), they would be hysteroscopically removed and endometrial sampling postponed.
219539466|NCT02838160|BEHAVIORAL|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
219043388|NCT03907683|BEHAVIORAL|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
219043389|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
219043390|NCT03400332|DRUG|BMS-986253|Specified dose on specified days
219620316|NCT01864993|DIETARY_SUPPLEMENT|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
219620317|NCT03751033|DEVICE|BSS|Intraoperative aberrometry measurements for BSS will be performed.
219539467|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
219539468|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
219620318|NCT03751033|DEVICE|DiscoVisc|Intraoperative aberrometry measurements for DiscoVisc will be performed.
219043391|NCT03400332|BIOLOGICAL|Nivolumab|Specified dose on specified days
219043392|NCT03400332|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219620319|NCT04231825|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
219043393|NCT03400332|OTHER|Placebo|Specified dose on specified days
219043394|NCT00234988|DRUG|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
219043395|NCT06232421|DRUG|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
219043396|NCT06232421|DRUG|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
219043397|NCT00937417|DRUG|docetaxel|
219043398|NCT00937417|DRUG|vandetanib|
219043399|NCT00937417|GENETIC|proteomic profiling|
219043400|NCT00937417|OTHER|laboratory biomarker analysis|
219043401|NCT00937417|OTHER|pharmacological study|
219043402|NCT06783283|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive electrical stimulation that will be used to stimulate the dorsolateral prefrontal cortex (dlPFC) and temporal cortices and in turn enhance Theta-Gamma Coupling (TGC) and working memory in Mild Cognitive Impairment (MCI). Each participant will receive daily stimulation for 10 days. To deliver the tACS, multiple electrodes embedded in a cap placed on the participant's head. Sham-tACS will follow the same procedure.
219205014|NCT06885255|OTHER|High-intensity interval training|Patients participate in high-intensity interval training.
219539469|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
219539470|NCT04116463|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
219539471|NCT04116463|BEHAVIORAL|Financial Self-Management Program (FSMP)|
219539472|NCT04754035|DRUG|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
219539473|NCT04754035|DRUG|Imbruvica Oral Product|Imbruvica 140 mg
219539474|NCT03057730|BIOLOGICAL|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
219539475|NCT01440803|DRUG|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
219539476|NCT01440803|DRUG|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
218926347|NCT06061003|OTHER|Clinical Anatomical Education with Fractured Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
218926348|NCT06061003|OTHER|Clinical Anatomical Education with Standard Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
218926349|NCT06590155|DRUG|Erythropoietin|the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy
218926350|NCT06588959|OTHER|validity and reliability study|Determination of strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. 6PBRT, which is one of the tests serving this purpose, has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma, but when the literature is reviewed, it is seen that 6PBRT has not been studied in patients with scleroderma. This study was planned as a non-interventional safety study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, the test will be performed 2 times with a 1-hour rest break. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The level of dyspnea and fatigue and baseline values of heart rate will be checked before the second trial to ensure patients are stable. All assessments will be performed by the same physiotherapist.
218926351|NCT05156385|BIOLOGICAL|Blood sample for the determination of antihypertensives or their metabolites.|15 ml of Blood sample for the determination of antihypertensives or their metabolites
218926352|NCT05156385|BEHAVIORAL|Questionnaire on sexual activity|Questionnaire on sexual activity in women
218926353|NCT05156385|BEHAVIORAL|Scale on hospital anxiety and depression|Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
218926354|NCT05156385|BEHAVIORAL|Morisky Questionaire|anti-hypertensive medication compliance questionnaire
218926355|NCT06991985|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum STN and C4 levels were detected
218926356|NCT06527950|OTHER|no intervention|observational study , no intervention
219539477|NCT03004703|DRUG|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
219539478|NCT03004703|DRUG|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
219539479|NCT04762966|DRUG|Metformin|Level of Metformin blood concentration
219539480|NCT01609257|BIOLOGICAL|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
218926357|NCT06585852|DRUG|RGD|Study group main material
218926358|NCT06585852|DRUG|Xenograft|Scaffold material of choice
218926359|NCT06585852|PROCEDURE|Split crest technique|Piezoelectric surgery
218926360|NCT04819542|DEVICE|Bandage|Bandage
219539481|NCT01609257|BIOLOGICAL|Saline Comparator|2 doses IM 28 days apart
218926361|NCT04819542|DEVICE|No bandage|No bandage
218926362|NCT05485896|DRUG|Pembrolizumab plus Lenvatinib|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
218926363|NCT03941236|DRUG|dasiglucagon|Glucagon analog
218926364|NCT05790551|DEVICE|Addinex|Medication dispensing system for Suboxone
219043403|NCT06783283|DEVICE|Sham tACS|During sham-tACS, the device will ramp up to the desired intensity over 60 seconds, and then will immediately ramp down, and the stimulation will be shut off, until the end of the session. At the end of the session, the device will again ramp up for 60 seconds and then ramp down. Sham-tACS will also target dlPFC and temporal cortices (similar to active). Each participant will receive daily sham-tACS for 10 days. To deliver the sham-tACS, multiple electrodes will be embedded in a cap placed on the participant's head.
219043404|NCT05365581|DRUG|ASP2138|Intravenously or Subcutaneously
219043405|NCT05365581|DRUG|Pembrolizumab|Intravenously
219043406|NCT05365581|DRUG|Oxaliplatin|Intravenously
219539482|NCT00761813|DEVICE|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
219539483|NCT00761813|DEVICE|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
219539484|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
219539485|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
219539486|NCT02010918|DRUG|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
219539487|NCT06332170|DRUG|HS-20093|administered as an IV infusion
219539488|NCT06332170|DRUG|Adebrelimab|administered as an IV infusion
218926365|NCT06088069|OTHER|Virtual reality|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
218926366|NCT03278249|OTHER|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
218926367|NCT06601049|DIETARY_SUPPLEMENT|ResArgin|Resveratrol-based supplement
218926368|NCT06594328|BEHAVIORAL|mHealth|participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
218926369|NCT06598111|OTHER|Amplified Benefits|Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.
219539489|NCT06332170|DRUG|Cisplatin/ Carboplatin|administered as an IV infusion
218926370|NCT06598111|OTHER|Amplified Consequences|Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.
218926371|NCT06598111|OTHER|Control|Participants write a brief narrative considering a future free of concern about finances.
218926372|NCT02775786|OTHER|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
218926373|NCT04801420|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
218926374|NCT04801420|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
218926375|NCT04774094|DRUG|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
218926376|NCT07023666|DRUG|Deferoxamine|Deferoxamine is used to reduce excess iron accumulation after monitoring iron levels. Adjustment to therapy will be based on iron burden assessments throughout the study duration.
219539490|NCT06332170|DRUG|Cetuximab|administered as an IV infusion
219539491|NCT06332170|DRUG|Enzalutamide|160mg once daily (QD) orally
219539492|NCT02125461|DRUG|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
219539493|NCT02125461|OTHER|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
219539494|NCT02380976|DRUG|combination drug: DW330SR, DW1030|
219539495|NCT02380976|DRUG|DW340|
219539496|NCT04848987|PROCEDURE|Etching|Etching enamel surface using phosphoric acid
218926377|NCT07023666|DRUG|Deferasirox|Deferasirox is used for iron chelation therapy based on iron burden assessment throughout the study.
219043407|NCT05365581|DRUG|Leucovorin|Intravenously
219043408|NCT05365581|DRUG|Fluorouracil|Intravenously
219539497|NCT01120340|DRUG|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
219539498|NCT01120340|OTHER|placebo|2 pills/day for ten days/month until 24 months
219539499|NCT02247791|PROCEDURE|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
219539500|NCT02247791|PROCEDURE|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
219539501|NCT01602939|DRUG|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
219539502|NCT02266095|DEVICE|Oval-8 Splint|Splinting with Oval-8
219539503|NCT02266095|DEVICE|Tee Pee Splint|Splinting with Tee Pee
219539504|NCT02266095|DEVICE|Forearm Based Splint|Splinting with Forearm based
219539505|NCT02649335|DRUG|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
218926378|NCT07023666|DRUG|Deferiprone|Deferiprone is used for iron chelation therapy used throughout the study.
218926379|NCT07023666|DEVICE|Echocardiography|This device uses ultrasound waves to create images of heart to help evaluate the heart's structure and function. This allows the detection of abnormalities of heart due to iron overload through out the study.
218926380|NCT07023666|DEVICE|Electrocardiogram (ECG)|The Electrocardiogram (ECG) device records the electrical activity of the heart. It is crucial for identifying arrhythmias and conduction abnormalities, which can be exacerbated by iron accumulation in the heart.
218926381|NCT05130528|BEHAVIORAL|Sensorimotor Intervention|Infants in the experimental group will receive 2 sensorimotor intervention sessions in the Neonatal Intensive Care Unit (NICU) and 8 sensorimotor intervention sessions in the home or in a clinic (parent choice) at 1, 3, 5, 8, 11, 15, 20, 26 weeks post NICU discharge. The 2 intervention sessions in the NICU will consist of collaborating with parents to recognize their infant's cues to engage in interaction, readiness for sensory exposures, and anticipatory guidance on the transition to home. The 8 intervention sessions in the home will focus on supporting the parents to read their infant's cues to identify the ideal times for interaction and provide 20 minutes of daily intervention addressing four key principles: encourage 1) self-initiated movement, 2) movement variability, 3) visual and manual object interaction, and 4) social interaction. Parents are encouraged not to impose movement on the infant but to encourage movement through environmental enrichment
219043409|NCT05365581|DRUG|Ramucirumab|Intravenously
219043410|NCT05365581|DRUG|Paclitaxel|Intravenously
219043411|NCT05365581|DRUG|Irinotecan|Intravenously
219539506|NCT02649335|PROCEDURE|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
218926382|NCT06638190|OTHER|100% Orange juice|250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
218926383|NCT06638190|OTHER|50% Orange juice|250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
218926384|NCT06638190|OTHER|0% Orange juice|250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
219539507|NCT05493735|DRUG|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
218926385|NCT06638190|OTHER|Glucose|250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
218926386|NCT06638190|OTHER|100% Orange juice Rep|Repetition of the 100% orange juice intervention
218926387|NCT06638190|OTHER|0% Orange juice Rep|Repetition of the 0% orange juice intervention
218926388|NCT04493008|BEHAVIORAL|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
218926389|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
218926390|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
218926391|NCT04988477|BEHAVIORAL|Study 3: Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 9 months.
218926392|NCT04988477|BEHAVIORAL|Study 2: Pilot trial|Providers trained in brief provider intervention and 1 outreach call over 3 months.
218926393|NCT01582477|DRUG|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
219205015|NCT06725121|BIOLOGICAL|Atezolizumab & Bevacizumab|Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
219539508|NCT05493735|DRUG|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
218926394|NCT01582477|DRUG|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
218926395|NCT04145349|DRUG|Ramucirumab|Administered IV
218926396|NCT04145349|DRUG|Cyclophosphamide|Administered orally
218926397|NCT04145349|DRUG|Vinorelbine|Administered IV
218926398|NCT05531734|DEVICE|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
218926399|NCT05531734|BEHAVIORAL|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
218926400|NCT00002330|DRUG|Ganciclovir|
218926401|NCT03365271|PROCEDURE|drainage|Applying a drain tube during TKA procedure
218926402|NCT03365271|PROCEDURE|non-drainage|No drain tube will be applied during TKA procedure
218926403|NCT04783493|DEVICE|Non-invasive magnetic stimulation of the spinal cord|Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
218926404|NCT04783493|OTHER|Coil will not be connected to the stimulation device|coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
218926405|NCT02553226|DRUG|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
218926406|NCT02553226|DRUG|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
218926407|NCT01035086|DIETARY_SUPPLEMENT|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
218926408|NCT04842812|BIOLOGICAL|TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3|TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
218926409|NCT02061488|OTHER|open-loop night|During the open-loop night the patient is using his insulin pump as usual
218926410|NCT02061488|OTHER|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
219205016|NCT06725121|DRUG|Yttrium-90 (Y-90)|Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
219539509|NCT06093984|PROCEDURE|duostim vs. two antagonist ovarian stimulations|Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
219539510|NCT01830335|DRUG|Indomethacin|
219539511|NCT01830335|DRUG|Placebo|
218926411|NCT02543957|PROCEDURE|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
218926412|NCT00504647|DEVICE|Biventricular Pacemaker|
218926413|NCT01964820|BEHAVIORAL|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
218926414|NCT00942227|OTHER|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
218926415|NCT00942227|OTHER|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
218926416|NCT04279626|PROCEDURE|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
218926417|NCT02306317|OTHER|Standard procedure|FiO2 manually controlled by nursing
218926418|NCT02306317|OTHER|Experimental procedure|FiO2 manually controlled by parents, after training.
218926419|NCT01148979|DRUG|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
218926420|NCT01148979|DRUG|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
219205017|NCT06725121|RADIATION|Stereotactic body radiotherapy (SBRT)|Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
219539512|NCT03084263|PROCEDURE|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
219539513|NCT03084263|PROCEDURE|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
219539514|NCT00714935|BEHAVIORAL|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
219539515|NCT00714935|BEHAVIORAL|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
218926421|NCT05216809|BEHAVIORAL|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.
218926422|NCT05216809|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
218926423|NCT00132470|DRUG|AX200 (G-CSF)|
218926424|NCT04440527|DEVICE|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
218926425|NCT04440527|OTHER|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
218926426|NCT06522100|DRUG|Intravenous administration of Methylprednisolone|Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
218926427|NCT06522100|DRUG|Oral Prednisone|After intravenous administration of Methylprednisolone patients will take by oral Prednisone 1mg/kg per day once a day (with a maximum dose of 90 mg per day for patients weighing \> 90kg) for 1 month, followed with a progressive decrease of 10 mg Prednisone every 15 days until a dose of 10mg per day during 15 days (= stop).
219205018|NCT06725693|DIAGNOSTIC_TEST|18F/68Ga-Exendin 4|Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
219205019|NCT06727409|DRUG|Finerenone|Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy
219205020|NCT06704620|DRUG|Diphenhydramine|Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
219205021|NCT06704620|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d1
219205022|NCT06704620|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
219539516|NCT00994058|DEVICE|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
219539517|NCT01602575|BEHAVIORAL|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
219539518|NCT00835484|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
219205023|NCT06704620|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d1
219539519|NCT00835484|DRUG|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
219539520|NCT01409499|PROCEDURE|hepatic resection|palliative hepatectomy followed by sorafenib
218926428|NCT06522100|DRUG|Perfusion of placebo|Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
218926429|NCT06522100|DRUG|Oral Prednisone placebo|After the perfusion of placebo, patients will take by oral Prednisone placebo once a day for the same duration as that required if the patient was in the investigational medicinal products group (1 month + progressive decrease).
218926430|NCT04147780|PROCEDURE|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
218926431|NCT02132429|DRUG|AMG 333|Oral administration available in varying dose strength.
218926432|NCT02132429|DRUG|Placebo|Placebo containing no active drug
218926433|NCT02506348|DRUG|Diclofenac|
218926434|NCT02506348|DRUG|Nepafenac|
218926435|NCT06022692|DEVICE|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
218926436|NCT06022692|DRUG|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
218926437|NCT04598802|DEVICE|covered stent|atherosclerotic aorto-iliac aneurysm
218926438|NCT04641208|DEVICE|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
218926439|NCT00775190|DRUG|ortho tricyclen|brand name oral contraceptive
218926440|NCT00775190|DRUG|Trinessa|generic oral contraceptive
218926441|NCT00843596|PROCEDURE|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
218926442|NCT05504785|DEVICE|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
218926443|NCT03710200|OTHER|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
218926444|NCT03710200|OTHER|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
218926445|NCT03710200|OTHER|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
218926446|NCT03710200|OTHER|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
218926447|NCT03710200|OTHER|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
218926448|NCT03710200|OTHER|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
219539521|NCT01409499|PROCEDURE|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
218926449|NCT03710200|OTHER|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
219539522|NCT01409499|DRUG|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
219539523|NCT03283358|BEHAVIORAL|Person-centered follow up|
219539524|NCT01888276|OTHER|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop"
218926450|NCT03710200|OTHER|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
218926451|NCT01965678|OTHER|Osteopathic Manipulative Treatment|
218926452|NCT02194478|BEHAVIORAL|Meditation|30 minute, 8 week meditation
218926453|NCT04791163|DEVICE|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
218926454|NCT02476539|DRUG|Hemay022|
219043412|NCT05876182|DRUG|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
219043413|NCT05876182|OTHER|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
219205024|NCT06704620|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d1
219205025|NCT06704620|DRUG|Cisplatin|Cisplatin intravenous infusion 75mg/m2 d1
219539525|NCT02243982|OTHER|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
219539526|NCT05028855|DIAGNOSTIC_TEST|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
218926455|NCT04188561|DRUG|Intra articular injection Group|"Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average."
218926456|NCT04188561|DEVICE|Radiofrequency Group|Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
218926457|NCT03088735|PROCEDURE|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
218926458|NCT03088735|PROCEDURE|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
218926459|NCT00412919|DRUG|Azacitidine|
218926460|NCT02784691|DEVICE|Feeligreen patch|
218926461|NCT01608945|DRUG|Hydrocortisone sodium succinate|100mg/day
218926462|NCT06233396|OTHER|Extra 4DCT scan|Extra 4DCT scan after routine simulation
218926463|NCT02800629|DIETARY_SUPPLEMENT|Modified Citrus Pectin|MCP versus placebo
218926464|NCT02800629|DIETARY_SUPPLEMENT|Placebo|
219539527|NCT01843179|DRUG|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
219539528|NCT01843179|DRUG|Sulindac|Taken orally twice per day at home for 12 months
219539529|NCT03881943|DRUG|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
219539530|NCT03881943|DRUG|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
219539531|NCT03134664|PROCEDURE|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
219539532|NCT03134664|PROCEDURE|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
219539533|NCT05219864|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219539534|NCT05219864|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219539535|NCT04635007|DRUG|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
218926465|NCT00741182|DRUG|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
218926466|NCT00510822|DRUG|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
218926467|NCT00510822|DRUG|Placebo|tablet
218926468|NCT02446119|DEVICE|EndoFLIP|Measurement of pyloric resistance and compliance
218926469|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
218926470|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
218926471|NCT00492635|DRUG|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
218926472|NCT02942459|OTHER|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
218926473|NCT02942459|OTHER|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
218926474|NCT03074552|DIETARY_SUPPLEMENT|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
219539536|NCT04635007|DRUG|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
219539537|NCT04670107|DRUG|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
219539538|NCT03675633|DIAGNOSTIC_TEST|FEUrea|FEUrea in decompansated liver cirrhosis
219205026|NCT07038109|OTHER|Progressive relaxation exercise|The intervention was based on Jacobson's Progressive Muscle Relaxation (PMR) technique. Participants in the experimental group practiced PMR three times per week for four weeks. Each session lasted approximately 45 minutes and was conducted in a quiet environment. In the first session, the researcher provided face-to-face instruction. Subsequent sessions were guided by standardized audio recordings, and the participants were followed through scheduled online video calls. The intervention aimed to reduce depression, anxiety, and stress symptoms and to promote biopsychosocial well-being in nursing students.
219205027|NCT06729723|DEVICE|SAT-001|SAT-001 Treatment Group Participants in this group will use the SAT-001 device for 30 minutes. Before and after using the device, choroidal thickness will be measured using Optical Coherence Tomography (OCT) to assess changes in choroidal thickness.
219205028|NCT06729723|DEVICE|modified SAT-001|"mSAT-001 Treatment Group Participants in this group will use the modified SAT-001 (mSAT-001) device for 15 minutes. Similar to the SAT-001 group, choroidal thickness will be measured using Optical Coherence Tomography (OCT) before and after device usage.~This protocol will help evaluate the effect of the SAT-001 and modified device on choroidal thickness, with measurements taken before and after each usage."
218926475|NCT03074552|OTHER|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
218926476|NCT02482818|DRUG|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
218926477|NCT02482818|DRUG|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
218926478|NCT05611294|DEVICE|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
218926479|NCT05611294|DEVICE|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
218926480|NCT06322654|PROCEDURE|Robotically Assisted Locomotion|"* Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy"
218926481|NCT06322654|PROCEDURE|Robotically Assisted Verticalization|"* Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy"
218926482|NCT04963647|DIAGNOSTIC_TEST|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
218926483|NCT02564003|DRUG|Oxycodone|oxycodone 0,1 mg/kg iv
219205029|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.
218926484|NCT05626868|DEVICE|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
218926485|NCT03689621|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|
218926486|NCT00936767|DRUG|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
218926487|NCT00936767|DRUG|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
218926488|NCT03995602|DIETARY_SUPPLEMENT|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
219205030|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously with levels shown on the participant's phone app in phase B.
219205031|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral immunonutrition formula|Intervention arm will daily receive, for 7 days, a preoperative oral formula with immunonutrients: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, 11 g of lipids, 5.7 g of glutamine, 7 g of arginine, 3.6 g of leucine, 2.7 g of isoleucine, 3.7 g of valine, and 0.35 g of omega 3
219205032|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral Isocaloric and isoproteic polymeric formula|Control arm will daily receive, for 7 days, an isocaloric and isoproteic preoperative oral formula: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, and 11 g of lipids
219539539|NCT03721471|OTHER|Scoring of frailty|"1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer."
219539540|NCT05144451|DIAGNOSTIC_TEST|Transcranial Doppler|"Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7)."
219539541|NCT04001062|PROCEDURE|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
218926489|NCT03995602|DIETARY_SUPPLEMENT|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
218926490|NCT05204004|DEVICE|Sunrise|"Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test."
218926491|NCT05204004|DEVICE|Polygraphy|Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
218926492|NCT01600716|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
218926493|NCT01600716|DRUG|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
218926494|NCT00779155|DEVICE|The Resonator|active magnetic field therapy
218926495|NCT00779155|DEVICE|The Resonator control|inactive magnetic field therapy with placebo fields
219539542|NCT04001062|OTHER|Non-Operative Management|"1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
218926496|NCT05115071|BEHAVIORAL|Childbirth preparation education|"Purpose: The aim of the birth preparation education is to eliminate the fears and concerns of pregnant women about birth and to prepare them for birth during the Covid-19 Pandemic process.~Education hours: The education will be completed in total two weeks and eight hours, consisting of two days and four hours each week.~Method: The education will be given online through the Microsoft Teams application. Each training day will consist of two lessons. Each lesson will last 45 minutes. There will be a 15-minute break between the two lessons. The first lesson will be conducted in the form of a question and answer session with a power-point presentation.In the second lesson, relaxation exercises will be applicated and evaluations will be taken at the end of the lesson.~The group that will receive the education: Healthy pregnant women between 24-34 weeks of gestation will be included in the training. Trainings will continue with closed groups."
218926497|NCT05982418|DEVICE|3D Printed Models (3D printing facilities at GSTT)|3D patient-specific printed models are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D printing.
218926498|NCT05982418|DEVICE|3D Virtual Models (Innersight Labs)|3D patient-specific virtual models loaded into Innersight Labs platform are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D visualisation.
218926499|NCT02601248|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
219539543|NCT03166267|DEVICE|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
218926500|NCT03349034|DRUG|Ropivicaine|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
218926501|NCT03349034|DRUG|Local Saline Infusion|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
218926502|NCT04613037|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
218926503|NCT00658125|PROCEDURE|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
218926504|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
218926505|NCT04922632|BEHAVIORAL|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
218926506|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
218926507|NCT04922632|BEHAVIORAL|Treatment As Usual (TAU)|TAU is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
218926508|NCT05510596|OTHER|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
218926509|NCT05510596|OTHER|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
219539544|NCT00736658|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
219539545|NCT00736658|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
219539546|NCT01934816|OTHER|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
218926510|NCT05510596|OTHER|Neuropsychological tests|Neuropsychological tests
218926511|NCT06081816|OTHER|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
218926512|NCT04359316|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
219205033|NCT06889636|OTHER|Pharmaceutical care in solving drug-related problems in subjects using psychotropic medicines based on standardized protocol..|Pharmacists' interventions were based on Medication Review and Medication Therapy Management evaluations of a subjects' pharmacotherapy to optimize medicine use, improve treatment outcomes and quality of life. The intervention involved the identification of drug-related problems and addressing these issues through pharmacist interventions. The intervention was based on information gathered from the subjects and a list of medicines in use.
219205034|NCT06889636|OTHER|Common pharmacists' practice in Croatia.|Group B participants received pharmaceutical care based on common pharmacists' practice in Croatia during the dispensing of psychotropic drugs.
219205035|NCT06723808|OTHER|Leisure-Time Physical Activity and Occupational Physical Activity|This study does not involve a specific intervention but explores the relationship between leisure-time physical activity (LTPA) and occupational physical activity (OPA) in university staff, with a focus on work ability, musculoskeletal disorders, and quality of life.
219539547|NCT04994535|DRUG|OnabotulinumtoxinA|Injection
219539548|NCT04994535|DRUG|Placebo|Saline injection
219539549|NCT01158118|DRUG|Sargramostim|
219539550|NCT01158118|DRUG|Plerixafor|
219539551|NCT01488435|DIETARY_SUPPLEMENT|Cow's milk|Powdered whole cow's milk
219539552|NCT01488435|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
219539553|NCT04410653|DRUG|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
219539554|NCT01015287|DRUG|Placebo|Administered once orally
219539555|NCT01015287|DRUG|Prasugrel|Administered orally
219539556|NCT06443385|BEHAVIORAL|PDMP Legal Mandate E-mail|E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
219205036|NCT06888752|BIOLOGICAL|Cell injection|LCAR-M61SQ cells intravenous infusion; Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219539557|NCT06443385|BEHAVIORAL|PDMP Clinical Benefit E-mail|E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
219539558|NCT02726360|BEHAVIORAL|survey|The ILR Scale, a non-English language proficiency self-assessment.
219539559|NCT02726360|BEHAVIORAL|Audio record|Audio record the initial visits between patients and their treating physician
219539560|NCT04196062|DEVICE|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
219539561|NCT00469898|DRUG|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"
219539562|NCT00469898|DRUG|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
219539563|NCT05230758|DRUG|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
219539564|NCT05230758|DRUG|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
218926513|NCT04359316|DRUG|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
218926514|NCT02425852|DRUG|Azathioprine|Azathioprine alone versus Azathioprine and IFX
218926515|NCT02425852|DRUG|Infliximab|
218926516|NCT02425852|DRUG|Prednisolone|
218926517|NCT02425852|DRUG|Hydrocortisone|
218926518|NCT06188143|COMBINATION_PRODUCT|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
219539565|NCT05579262|DIETARY_SUPPLEMENT|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
219539566|NCT02739724|PROCEDURE|Adnexal surgery|
219539567|NCT03497858|OTHER|Coconut Water|participants will consume coconut water and complete a simulated basketball game
219539568|NCT03497858|OTHER|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
219539569|NCT03497858|OTHER|Sports drink|participants will consume a sports drink and complete a simulated basketball game
219539570|NCT06248294|DIAGNOSTIC_TEST|CT follow-up|Computed tomography angiography assessment of BAV-related aorthopathy
219539571|NCT00785135|DEVICE|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
219539572|NCT00785135|DEVICE|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
219539573|NCT01452035|OTHER|Exercise|single session of exercise
218926519|NCT00865566|BIOLOGICAL|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
218926520|NCT00865566|BIOLOGICAL|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
218926521|NCT00865566|BIOLOGICAL|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
218926522|NCT00865566|BIOLOGICAL|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
218926523|NCT02905227|DRUG|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
218926524|NCT01898260|DEVICE|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
218926525|NCT01898260|DEVICE|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
218926526|NCT02596932|OTHER|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60mg/dL
219205037|NCT06888037|DRUG|Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）|"CAPOX/SOX (each cycle is 21 days): Oxaliplatin 130mg/m2, ivgtt, D1; Capecitabine 1000 mg/m2, po, bid, D1-14 or S-1: 40-60mg according to BSA, bid, D1-14.~FOLFOX (each cycle is 14 days): Oxaliplatin 85mg/m2, ivgtt, D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours; Leucovorin: 400mg/m2, iv, D1.~PD-1 monoclonal antibody:~Nivolumab 360mg/3 weeks or 240mg /2 weeks, iv, D1; If weight ≥60 kg, Sintilimab 200mg/3 weeks; if weight \< 60 kg, Sintilimab 3mg/kg/3 weeks, iv, D1; Tislelizumab 200mg/3 weeks, iv, D1; Pembrolizumab 200mg/3 weeks, iv, D1;"
219539574|NCT01228539|BEHAVIORAL|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
218926527|NCT02596932|OTHER|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60 mg/dL
219539575|NCT01228539|BEHAVIORAL|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
219539576|NCT04877093|DRUG|Clonidine Pill|The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
219539577|NCT04877093|OTHER|Placebo|Blinded placebo capsules will be provided to participants.
219539578|NCT06219980|COMBINATION_PRODUCT|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
218926528|NCT00815659|DRUG|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
218926529|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
218926530|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
218926531|NCT03847896|DRUG|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
218926532|NCT03847896|DRUG|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
218926533|NCT03847896|OTHER|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
218926534|NCT00936923|DRUG|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
218926535|NCT05224999|DRUG|nivolumab|nivolumab 3mg/kg (every 2 weeks)
219539579|NCT01561807|DRUG|VX-787|
219539580|NCT01561807|DRUG|Placebo|
219539581|NCT03239314|DRUG|Saline Solution|Injected in the adductor canal
219539582|NCT03239314|DRUG|Dexamethasone|Injected in the adductor canal
218926536|NCT01977989|DRUG|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
218926537|NCT05859503|OTHER|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
218926538|NCT05859503|OTHER|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
218926539|NCT01980537|PROCEDURE|Magnetic wire navigation|
218926540|NCT01980537|PROCEDURE|Conventional wire navigation|
218926541|NCT01216826|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
218926542|NCT02978781|DRUG|SAGE-217|SAGE-217 Oral Solution
218926543|NCT02978781|DRUG|SAGE-217|SAGE-217 Capsules
218926544|NCT02978781|DRUG|Placebo|SAGE-217 matching placebo capsules
218926545|NCT01777113|OTHER|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
218926546|NCT01777113|OTHER|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
218926547|NCT01777113|OTHER|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
218926548|NCT03543228|DIAGNOSTIC_TEST|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
219539583|NCT02504138|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
218926549|NCT02763501|PROCEDURE|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
218926550|NCT02763501|PROCEDURE|non-closure of mesenteric defects|Mesenteric defects are left open
218926551|NCT02453321|PROCEDURE|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
219539584|NCT02504138|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
218926552|NCT02453321|PROCEDURE|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
218926553|NCT02453321|PROCEDURE|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
218926554|NCT02453321|DRUG|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
218926555|NCT00025519|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218926556|NCT00025519|DRUG|fludarabine phosphate|
218926557|NCT00025519|DRUG|mycophenolate mofetil|
218926558|NCT00025519|DRUG|tacrolimus|
218926559|NCT00025519|DRUG|thalidomide|
218926560|NCT00025519|PROCEDURE|peripheral blood stem cell transplantation|
218926561|NCT00025519|RADIATION|radiation therapy|
218926562|NCT06047418|PROCEDURE|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
218926563|NCT01887483|DIETARY_SUPPLEMENT|Vetal Laban active|Dairy product with probiotic
218926564|NCT01887483|DIETARY_SUPPLEMENT|Placebo|Dairy product without probiotic
218926565|NCT01796366|DRUG|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
218926566|NCT01796366|DRUG|placebo|S.c placebo administered in combination with insulin 338
218926567|NCT01796366|DRUG|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
218926568|NCT01796366|DRUG|placebo|Oral placebo administered in combination with s.c. insulin glargine
218926569|NCT04527770|DRUG|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
218926570|NCT04527770|DRUG|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
219539585|NCT02442063|DRUG|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
219539586|NCT02442063|DRUG|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
219539587|NCT01493635|OTHER|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
219539588|NCT01493635|OTHER|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
219539589|NCT01370317|DRUG|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
219539590|NCT01370317|DRUG|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
219539591|NCT01688609|DRUG|lapatinib ditosylate|Given PO
219539592|NCT01688609|DRUG|paclitaxel|Given IV
219539593|NCT01688609|BIOLOGICAL|trastuzumab|Given IV
218926571|NCT02497170|BEHAVIORAL|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
218926572|NCT02987790|OTHER|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak\> 100mg / L), with a limit of seven days, if there is clinical improvement.
218926573|NCT01464437|DRUG|AMG 151|Drug: AMG 151 50 mg BID
218926574|NCT01464437|DRUG|Placebo|Placebo
218926575|NCT01464437|DRUG|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
218926576|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg BID
218926577|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg BID
218926578|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg QD
219205038|NCT06888037|DRUG|Maintenance treatment (after 3 months): fruquintinib+PD-1|"After 3 months (12 weeks) of initial treatment with oxaliplatin-based chemotherapy combined with PD-1 monoclonal antibody, those with complete response (CR), partial response (PR) or stable disease (SD) assessed by imaging evaluation continued to receive maintenance treatment with furoquininib and PD-1 monoclonal antibody.~Fruquintinib 3 mg/d, qd po, D1-21, Q4W; PD-1 monoclonal antibody is repeated as initial treatment until the disease progresses or unacceptable toxicity."
219539594|NCT01688609|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
219539595|NCT01688609|OTHER|pharmacological study|Correlative studies
219539596|NCT01688609|OTHER|laboratory biomarker analysis|Correlative studies
219539597|NCT03681080|PROCEDURE|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
219539598|NCT00854711|PROCEDURE|inhaled nitric oxide|80 PPM
219539599|NCT02728674|OTHER|Person in the case is a male.|Person in the case is a male.
219539600|NCT02728674|OTHER|Person in the case is a female.|Person in the case is a female.
219539601|NCT02728674|OTHER|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
219539602|NCT02728674|OTHER|Symptom in the case is pain.|Symptom in the case is pain.
219539603|NCT02717260|DEVICE|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
219539604|NCT05205876|BEHAVIORAL|Eddii mobile application|Participants will use the Eddii mobile application in the intervention arm.
219539605|NCT03341182|PROCEDURE|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
219539606|NCT03341182|PROCEDURE|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
218926579|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg QD
218926580|NCT01464437|DRUG|AMG 151|Drug: AMG 151 400 mg QD
218926581|NCT00445926|DEVICE|deep TMS H-coil|
218926582|NCT05434416|OTHER|mobile app|mobile app self-guided psychological interventions
218926583|NCT00462995|DRUG|Erlotinib|150mg once a day for 28 days
218926584|NCT00462995|DRUG|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
218926585|NCT00566761|DRUG|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
218926586|NCT05488535|DEVICE|cochlear implant headpiece|investigational cochlear implant headpiece
218926587|NCT06521333|DRUG|Resveratrol-Based gel|The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
219539607|NCT04849650|DRUG|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
219539608|NCT04849650|DRUG|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
219539609|NCT02115347|DRUG|Ertugliflozin 15 mg|Tablet
219539610|NCT05982691|RADIATION|Radiation Therapy|Radiation Therapy(General guideline) Patients will receive radiotherapy after induction chemotherapy or right after diagnosis without diagnosis. The dose and fields of radiation will be according to the histology, presence of dissemination, and response to the induction chemotherapy or radiotherapy. Radiation therapy can be administered using either of photons or protons. When induction chemotherapy is administered, radiotherapy is recommended to be started within 6 weeks from the last chemotherapy.
219539611|NCT04630327|OTHER|Beck Depression Inventory-21 (diagnostic survey)|Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
219539612|NCT04630327|OTHER|Beck Anxiety Inventory|Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
219539613|NCT04630327|OTHER|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
219539614|NCT01612091|DEVICE|Monitoring Messenger|Monitoring Messenger prototype device
218926588|NCT06521333|DRUG|Hyaluronic acid gel 0.2%|The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
218926589|NCT06521333|DEVICE|Stent|The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
218926590|NCT03705338|DEVICE|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
218926591|NCT03705338|DRUG|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
218926592|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given weekly
218926593|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given monthly
218926594|NCT00892099|OTHER|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
218926595|NCT06341478|DRUG|various neoadjuvant therapies|Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
218926596|NCT04129567|OTHER|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
218926597|NCT04129567|OTHER|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
218926598|NCT04129567|OTHER|Humidified air|Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
218926599|NCT04129567|OTHER|Dry air|Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
218926600|NCT02376699|DRUG|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
218926601|NCT02376699|DRUG|Pembrolizumab|Given intravenously; schedule is cohort-specific.
218926602|NCT02376699|DRUG|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
218926603|NCT02376699|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
218926604|NCT02376699|DRUG|Nab-paclitaxel|125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
218926605|NCT00217607|DRUG|paclitaxel|
218926606|NCT03352037|DIAGNOSTIC_TEST|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
218926607|NCT00404222|DRUG|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
218926608|NCT00404222|DRUG|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
218926609|NCT00404222|DRUG|Placebo|q 4 hours x 3
218926610|NCT05576454|DRUG|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
218926611|NCT05576454|DRUG|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
218926612|NCT05576454|DRUG|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
218926613|NCT01672671|DRUG|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
219539615|NCT01612091|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
218926614|NCT01657019|DRUG|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
218926615|NCT00041743|BEHAVIORAL|Group Cognitive Behavioral Therapy|
218926616|NCT01367990|DRUG|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
218926617|NCT01167413|DEVICE|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
218926618|NCT01167413|OTHER|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
218926619|NCT00473213|DRUG|Interferon Beta 1|
218926620|NCT06297811|DRUG|Trilaciclib Injection|Experimental: trilaciclib group Intervention: Drug: Trilaciclib Injection \[Cosela\] 240 mg/m\^2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
218926621|NCT06297811|DRUG|Paclitaxel|Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.
218926622|NCT06297811|DRUG|Carboplatin|area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.
218926623|NCT05866952|DIAGNOSTIC_TEST|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
218926624|NCT00030732|DRUG|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
218926625|NCT00030732|DRUG|Gemcitabine alone|Gemcitabine alone
218926626|NCT03339752|DRUG|Rosuvastatin|10 mg tablet
218926627|NCT03339752|DRUG|ACT-541468|25 mg hard capsule
218926628|NCT02518295|OTHER|Positive control|200ml milk containing 18g lactose
218926629|NCT02518295|OTHER|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
218926630|NCT02518295|OTHER|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
218926631|NCT02518295|OTHER|Negative control|200 ml of UHT Lactose free milk
219539616|NCT01526174|DRUG|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
219539617|NCT05651191|DRUG|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
219539618|NCT06354894|DEVICE|Proximal humeral fracture fixation|percutaneous pinning VS plate and screws
219539619|NCT00044135|DRUG|clevudine (drug)|
218926632|NCT05169359|BEHAVIORAL|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
218926633|NCT02713282|DRUG|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
218926634|NCT04144790|DIETARY_SUPPLEMENT|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
218926635|NCT02481661|PROCEDURE|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
218926636|NCT05283811|DEVICE|NEUROPACE RNS SYSTEM|This device is indicated as a therapy in reducing the frequency of seizures in individuals
218926637|NCT05283811|BEHAVIORAL|EMU|Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
218926638|NCT04287036|DEVICE|JJVC Investigational Contact Lens|TEST
218926639|NCT04287036|DEVICE|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
219205039|NCT07038252|DIETARY_SUPPLEMENT|Oral SPM-enriched marine oil (LIPINOVA)|LIPINOVA is an oral dietary supplement provided by Solutex, consisting of marine oil enriched in specialized pro-resolving mediator (SPM) precursors. Each daily dose (3 g/day) includes 1500 mg of omega-3 free fatty acids and a minimum of 520 mcg of SPM precursors (17-HDHA, 18-HEPE, 14-HDHA). The supplement is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) over 12 weeks. It is used to investigate its effect on vascular function and inflammation in patients with obesity-related hypertension. The product is over-the-counter and commonly available in the EU, including France.
219205040|NCT07038252|DIETARY_SUPPLEMENT|Placebo|Placebo capsules provided by Solutex, identical in appearance to LIPINOVA, contain refined olive oil with no active omega-3 fatty acids or SPM precursors. The placebo is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) for 12 weeks, following a randomized, double-blind, crossover design. It serves as a control to evaluate the effects of SPM-enriched marine oil on vascular and inflammatory parameters in patients with obesity-related hypertension.
219366808|NCT03850197|DEVICE|Tubomanometry|"Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
219539620|NCT03621163|PROCEDURE|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
219539621|NCT03621163|PROCEDURE|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
219539622|NCT04430985|DRUG|Oxaliplatin|Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
219539623|NCT04430985|DRUG|5-Fluorouracil|Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
218926640|NCT05252533|DRUG|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
219539624|NCT04430985|DRUG|Leucovorin|Day 1 each cycle: 400 mg/m2 i.v.
219539625|NCT04430985|DRUG|Nivolumab|Day 3 in cycle 3 to 8: 3 mg/kg i.v.
219539626|NCT04430985|DEVICE|Ipilimumab|Day 3 in cycle 3 and 6: 1 mg/kg i.v.
218926641|NCT05802225|DRUG|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
218926642|NCT05802225|DRUG|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
218926643|NCT03352102|PROCEDURE|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
219539627|NCT04548375|DEVICE|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
219539628|NCT00834340|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
219539629|NCT00834340|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
218926644|NCT00998296|DRUG|BIBW 2992|EGFR inhibitor
218926645|NCT00998296|DRUG|BIBF 1120|VEGF inhibitor
218926646|NCT02346721|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
218926647|NCT00892476|DIETARY_SUPPLEMENT|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
218926648|NCT00892476|OTHER|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
218926649|NCT02350296|DRUG|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
218926650|NCT02350296|DRUG|OKi® 80 mg|"OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight)."
218926651|NCT04396639|BIOLOGICAL|Moroctocog-alfa (AF-CC)|Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
218926652|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
218926653|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
218926654|NCT05039983|OTHER|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 30 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
218926655|NCT04285970|OTHER|cycle detection|6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
218926656|NCT04285970|OTHER|detection of effort intensity|6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
218926657|NCT04749004|BEHAVIORAL|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
218926658|NCT01452841|OTHER|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
219366809|NCT05421910|DEVICE|robotic training combined with electrical stimulation|Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
218926659|NCT01452841|OTHER|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
218926660|NCT02229669|PROCEDURE|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
218926661|NCT02229669|PROCEDURE|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
219366810|NCT04747015|DRUG|Oxytocin|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation
219366811|NCT04747015|DRUG|Oxytocin|5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
219366812|NCT04747015|PROCEDURE|cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
219366813|NCT06312891|DRUG|Ivabradine|heart rate lowering therapy
219366814|NCT00330187|DRUG|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
219366815|NCT00330187|BEHAVIORAL|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
219366816|NCT00330187|OTHER|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
219366817|NCT01647737|DIETARY_SUPPLEMENT|MighTeaFlow|4-6 times daily
219366818|NCT01647737|DIETARY_SUPPLEMENT|Xylitol|4-6 times daily
219366819|NCT01303055|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
219366820|NCT01303055|DRUG|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
218926662|NCT02052518|BEHAVIORAL|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
218926663|NCT00965172|OTHER|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
218926664|NCT00965172|OTHER|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
218926665|NCT01544335|OTHER|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
218926666|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
218926667|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
218926668|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
218926669|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
218926670|NCT02231905|DRUG|BI-Sifrol®|
218926671|NCT00297518|DEVICE|PerioWave|
218926672|NCT00297518|PROCEDURE|Scaling and Root Planing|
218926673|NCT05427188|BEHAVIORAL|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
218926674|NCT05427188|BEHAVIORAL|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
218926675|NCT00350415|DRUG|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
218926676|NCT02641782|DRUG|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
218926677|NCT02641782|DRUG|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
218926678|NCT02641782|DRUG|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
218926679|NCT02641782|DRUG|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
218926680|NCT02641782|DRUG|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
218926681|NCT06092593|DEVICE|Upper endoscopy|Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients
219539630|NCT04446676|DEVICE|stabilization with stem|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
219539631|NCT04446676|DEVICE|stabilization with sleeve|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
219539632|NCT03620591|DRUG|Lidocaine|Intraoperative administration of lidocaine
219539633|NCT03620591|DRUG|Placebo|Intraoperative administration of normal saline
218926682|NCT05866315|DRUG|Remimazolam|Administer remimazolam
219539634|NCT01844050|DRUG|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
219539635|NCT01844050|DRUG|Placebo|
219539636|NCT01857167|DIETARY_SUPPLEMENT|Fish Oil Supplementation|
218926683|NCT05866315|DRUG|Desflurane|administer desflurane
218926684|NCT05866315|DRUG|Remifentanil|administer remifentanil
218926685|NCT01752777|BEHAVIORAL|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
218926686|NCT01752777|BEHAVIORAL|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
218926687|NCT03879005|OTHER|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
218926688|NCT03565094|DRUG|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
218926689|NCT03565094|DRUG|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
218926690|NCT05778825|DRUG|Oral Minoxidil|minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
218926691|NCT05778825|OTHER|Placebo|placebo for 4 months
218926692|NCT06169059|DRUG|JLP-2004|administration of JLP-2004(COX-2 inhibitor)
218926693|NCT06169059|DRUG|JC-013|administration of JC-013(COX-2 inhibitor))
218926694|NCT00253318|DRUG|Docetaxel|40 mg/m\^2 IV over 1 hour on Day 1.
218926695|NCT00253318|DRUG|RAD001|30 mg orally on Days 1 and 8.
218926696|NCT00253318|DRUG|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
219539637|NCT01857167|DIETARY_SUPPLEMENT|Flaxseed Oil Supplementation|
219539638|NCT01857167|DIETARY_SUPPLEMENT|placebo|
219539639|NCT03877692|DRUG|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
219205041|NCT06726057|BEHAVIORAL|Imlementation strategies in conjunction with multicomponent hypertension intervention|In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.
219205042|NCT06726057|BEHAVIORAL|Multicomponent hypertension intervention|"The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Hypertension care coordination in primary care facilities for the care of referred patients."
218926697|NCT02694484|OTHER|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
219205043|NCT06726395|DRUG|Penicillin G_1200mg|benzylpenicillin preferred dosing 1gx4
219205044|NCT06726395|DRUG|cloxacillin|cloxacillin 2gx4
218926698|NCT05050227|BEHAVIORAL|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
218926699|NCT05050227|BEHAVIORAL|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
218926700|NCT06344221|DEVICE|Dextrain Manipulandum and haptic feedback device|Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.
218926701|NCT03107871|DRUG|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
219205045|NCT06725719|DIAGNOSTIC_TEST|18F-DPA714/FDPA|Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.
219205046|NCT06725732|DRUG|Tranexamic Acid (TXA)|To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
218926702|NCT03107871|DRUG|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
219205047|NCT06725732|DRUG|Tranexamic Acid|To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
219366821|NCT00271388|DEVICE|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
219366822|NCT03258814|BEHAVIORAL|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
219366823|NCT03258814|BEHAVIORAL|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
219366824|NCT04805086|BIOLOGICAL|MON002|Autologous monocytes
219366825|NCT03681444|OTHER|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
219366826|NCT03681444|OTHER|Clear fluid diet|"Patients will be provided with~* Plain water~* Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~* Soup broth (bouillon or consommé)~* Clear sodas, such as ginger ale and Sprite~* Gelatin (Jell-O)~* Tea or coffee with no cream or milk added~* Sports drinks that don't have color"
219366827|NCT03681444|OTHER|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
219366828|NCT03681444|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
219366829|NCT02817672|BEHAVIORAL|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
219366830|NCT02817672|BEHAVIORAL|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
219366831|NCT01234155|BEHAVIORAL|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
218926703|NCT06526039|OTHER|a novel short regimen|An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
218926704|NCT04135274|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
218926705|NCT05162963|OTHER|fixed implant denture|Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
219205048|NCT06725953|BEHAVIORAL|Social Cognitive Theory-based, Technology-delivered Physical Activity Program|Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
219205049|NCT06733350|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsy
219205050|NCT06733350|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219205051|NCT06733350|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219205052|NCT06733350|OTHER|Patient Observation|Undergo standard AS
219205053|NCT06733350|OTHER|Questionnaire Administration|Ancillary studies
219205054|NCT06733350|DRUG|Therapeutic Testosterone|Given via injection, gel, lotion, or transdermal patch
219539640|NCT03877692|OTHER|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
219539641|NCT02846363|OTHER|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
219539642|NCT05318690|DEVICE|PlayGait|PlayGait is a dynamic energy storing and returning lower-limb exoskeleton.
219539643|NCT05318690|OTHER|Baseline|Baseline condition with no prescribed or intervention lower-limb devices.
219539644|NCT03238183|DRUG|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
219539645|NCT03238183|DEVICE|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
219539646|NCT04553146|PROCEDURE|Immediate implantation in posterior region with alveolar ridge preservation combined with sealing socket abutment|Twenty BLXⓇ Straumann immediate implants were placed flapless. The gap around the implant was filled with xenogeneic biomaterial. An intra-oral scanner was performed and sent to the dental laboratory to digitally design a customized healing abutment. The abutment was then milled from a block of PEEK and placed a couple of hours later in the clinic. Three months after implantation, the abutment was removed and the final monolithic crown based on the initial IOS was placed. The transmucosal design from the SSA was replicated on the final crown.
219539647|NCT04742686|OTHER|Aerobic exercise training|5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
219539648|NCT04588311|DRUG|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
219539649|NCT04588311|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
219539650|NCT01259791|DRUG|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
219205055|NCT06723262|OTHER|Tonotopic cochlear implant fitting FS4T|Comparison of FS4T and FS4noT
219539651|NCT01259791|DRUG|Placebo|Placebo
219539652|NCT00084526|PROCEDURE|computed tomography|
219539653|NCT00084526|PROCEDURE|ultrasound imaging|
219539654|NCT02458625|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|
219539655|NCT02458625|DIETARY_SUPPLEMENT|Iron bisglycinate 60 mg|
219539656|NCT00252967|DRUG|Atorvastatin|80 mg of Atorvastatin
219539657|NCT00252967|DRUG|Placebo|
218926706|NCT05162963|OTHER|removable implant denture|removable implant denture
218926707|NCT05330286|DRUG|LMI070|oral solution
218926708|NCT05330286|DRUG|LMI070|Oral solution
218926709|NCT05330286|DRUG|LMI070|Oral solution given in fasted state
218926710|NCT05330286|DRUG|LMI070|Oral solution given in fed state
218926711|NCT03457896|DRUG|Trastuzumab|Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
218926712|NCT03457896|DRUG|Cetuximab|Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
218926713|NCT03457896|DRUG|Neratinib|240 mg taken by mouth daily until disease progression.
218926714|NCT03457896|DIAGNOSTIC_TEST|Guardant360 Diagnostic Test|Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
218926715|NCT05518097|OTHER|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
218926716|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region."
218926717|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region."
218926718|NCT00363480|DRUG|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
218926719|NCT00363480|DRUG|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
219205056|NCT06732687|OTHER|Calisthenics|"Calisthenics~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks."
219366832|NCT01234155|BEHAVIORAL|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
218926720|NCT00363480|DEVICE|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
218926721|NCT06437041|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days.
218926722|NCT06437041|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
218926723|NCT03365349|OTHER|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
218926724|NCT03365349|OTHER|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
218926725|NCT04636684|DIAGNOSTIC_TEST|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
218926726|NCT05610059|OTHER|Blood Pressure Technology System M|Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
218926727|NCT05610059|OTHER|Blood Pressure Technology System E|Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
218926728|NCT05005182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218926729|NCT05005182|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
218926730|NCT05005182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
218926731|NCT05005182|DRUG|Hydroxyurea|Given PO
218926732|NCT05005182|BIOLOGICAL|Luspatercept|Given SC
218926733|NCT05005182|OTHER|Questionnaire Administration|Ancillary studies
218926734|NCT06800794|BEHAVIORAL|Behavioral Skill Training|7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.
218926735|NCT06800794|OTHER|Meal Provisioning|3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.
219366833|NCT01413958|DRUG|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
219366834|NCT01413958|DRUG|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
219366835|NCT01413958|DRUG|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
219366836|NCT05603429|DIAGNOSTIC_TEST|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
218926736|NCT05863559|BEHAVIORAL|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
218926738|NCT06464991|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
218926739|NCT06464991|DRUG|Daratumumab|"dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1"
218926740|NCT06464991|DRUG|Pomalidomide|dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
218926741|NCT06464991|DRUG|Bortezomib|dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
218926742|NCT06464991|DRUG|Dexamethasone|dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
218926743|NCT04307329|BIOLOGICAL|Monalizumab|Monalizumab 750 mg every two weeks
218926744|NCT04307329|BIOLOGICAL|Trastuzumab|Trastuzumab 4 mg/kg every two weeks
219205057|NCT06732687|OTHER|Plyometrics|Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
219539658|NCT02294786|DRUG|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
219539659|NCT02294786|DRUG|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
218926745|NCT03323346|DRUG|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
218926746|NCT06303388|OTHER|Bruegger,s Exercise|Bruegger's Exercise protocol along with conventional Physiotherapy.
218926747|NCT06303388|OTHER|Egoscue Exercise|Egoscue Exercise along with conventional Physiotherapy.
218926748|NCT04345120|DRUG|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
219539660|NCT02294786|DRUG|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
219539661|NCT02092363|DRUG|OMP-54F28, Paclitaxel and Carboplatin|
219539662|NCT01778010|DRUG|Modafinil 0 mg|Modafinil (0 mg/day)
219539663|NCT01778010|DRUG|Modafinil 200 mg|Modafinil (200 mg/day)
219539664|NCT01778010|DRUG|Modafinil 400 mg|Modafinil (400 mg/day)
219539665|NCT01778010|DRUG|Cocaine 0 mg|Cocaine (0 mg/day)
219539666|NCT01778010|DRUG|Cocaine 12 mg|Cocaine (12 mg/day)
219539667|NCT01778010|DRUG|Cocaine 25 mg|Cocaine (25 mg/day)
219539668|NCT01778010|DRUG|Cocaine 50 mg|Cocaine (50 mg/day)
219539669|NCT05168150|BEHAVIORAL|Experimental: Experimental Group - Intelligent Continuous Expertise Monitoring System group|During each of the practice task they will receive real-time auditory feedback instructed by the intelligent system. After each attempt, a student takes a 5-minute break. They will be shown the errors they made during the task regarding five performance metrics. After seeing each error, they will be shown video demonstration to learn how to expertly perform at each performance metrics. On their 6th attempt they will perform on the realistic scenario without any feedback given.
219205058|NCT06732687|OTHER|Combined( Calisthenics+ Plyometrics)|Description: Both exercises would be performed. First Calisthenics will be performed and then plyometrics will be performed.
219205059|NCT06723717|DRUG|Daily infusion of dornase alfa|Daily infusion of dornase alfa at a dose of 125 microg/kg as an intravenous bolus until day 14 after SAH
219205060|NCT06733051|DRUG|Golidocitinib|150 mg, administered once daily from Day 1 to Day 21 (D1-D21)
219205061|NCT06733051|DRUG|Benmelstobart|1200 mg, administered on Day 1 (D1) of every cycle
218926749|NCT04345120|DRUG|SY-008 matching placebo|SY-008 matching placebo
218926750|NCT02317471|BIOLOGICAL|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
219539670|NCT05168150|BEHAVIORAL|Experimental Group In-person expert-mediated instruction group|During each of the practice task, students will receive verbal feedback from the expert instructor present in the room. After each task, experts will summarize their performance and outline the errors the student made. Based on the student's performance, expert will demonstrate how to expertly perform the task in the simulation, and how to improve their performance in the next attempt. Students will perform the 6th attempt on the realistic scenario without any instruction given.
218926751|NCT02317471|DRUG|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
218926752|NCT01721044|DRUG|Placebo|Administered orally
218926753|NCT01721044|DRUG|Baricitinib|Administered orally
218926754|NCT01721044|DRUG|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
218926755|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
218926756|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
218926757|NCT03824249|DIAGNOSTIC_TEST|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
218926758|NCT02144896|OTHER|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
218926759|NCT00997308|DRUG|AZD1446|Solution, oral, for 4 weeks
218926760|NCT00997308|DRUG|Placebo|
219539671|NCT05279742|DRUG|MANP|Single subcutaneous injection 5 µg/Kg
218926761|NCT04032093|BIOLOGICAL|RSV vaccine|RSV vaccine
219043414|NCT06423053|BEHAVIORAL|Biology Course with Integrated Mindfulness|The intervention, Mindful Physiology, is an undergraduate-level biology course embedded with mindfulness practices. There will be 19 class sessions, each 1 hour and 50 minutes long, over 10 weeks. Students will be taught human physiology through didactic lectures, laboratory activities, and written quizzes typical for a college course. Each class meeting will have \~20 minutes of mindfulness practice in Thích Nhất Hạnh's Plum Village tradition. Students will also be encouraged to practice mindfulness for 15 minutes daily outside the class. Students will complete a daily log of their mindfulness practice and be given credit for each log completion regardless of the minutes of mindfulness practice. Students will be assigned a weekly written reflection on the physiology course content and/or their mindfulness practice. All students in the class are required to attend a 4.5-hour or a two-day (16-hour) on-campus mindfulness retreat.
219043415|NCT05634811|BIOLOGICAL|VLA15|6-valent OspA-based Lyme disease vaccine
219539672|NCT05279742|DRUG|Sacubitril/Valsartan|Oral single dose 97/103 mg
219539673|NCT05279742|DRUG|Oral Placebo|Oral single dose that contains no active ingredient
219539674|NCT05279742|DRUG|Injection Placebo|Single subcutaneous injection that contains no active ingredient
219539675|NCT01667679|DRUG|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
218926762|NCT04032093|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
218926763|NCT01258686|DRUG|Silymarin|700mg thrice daily
218926764|NCT01258686|DRUG|Placebo|Placebo 700mg thrice daily
218926765|NCT03394820|DRUG|Dexamethasone|The intervention is the time when dexamethasone is administered
218926766|NCT00722072|DRUG|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
218926767|NCT00722072|DRUG|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
218926768|NCT00005804|DRUG|cyclophosphamide|
218926769|NCT00005804|PROCEDURE|allogeneic bone marrow transplantation|
219539676|NCT01667679|DRUG|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
219539677|NCT02159183|DEVICE|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
219539678|NCT02159183|DEVICE|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
218926770|NCT00005804|RADIATION|radiation therapy|
218926771|NCT03782246|BEHAVIORAL|MBCT|Mindfulness- based Cognitive Therapy
218926772|NCT03782246|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
218926773|NCT04987333|DRUG|Efavaleukin alfa|Administered as a single dose SC injection.
218926774|NCT04957875|DEVICE|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
218926775|NCT04114760|DEVICE|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
218926776|NCT04114760|DEVICE|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
218926777|NCT00613873|PROCEDURE|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
218926778|NCT04205877|DEVICE|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
218926779|NCT05127954|DRUG|Ubrogepant|Oral Tablet
218926780|NCT02015260|DRUG|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
218926781|NCT02015260|DRUG|Placebo|Placebo
219539679|NCT05329025|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
218926782|NCT05067725|OTHER|CarePath|During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
219043416|NCT05634811|OTHER|Normal Saline|0.9% sodium chloride solution for injection
219043417|NCT01188577|DRUG|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
219043418|NCT01188577|DRUG|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
219043419|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
219043420|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
219043421|NCT00643838|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
219043422|NCT04965792|OTHER|Screening|Blood test
219043423|NCT06700798|DRUG|Orelabrutinib|150mg po
219539680|NCT03570905|OTHER|Sugar Tong Splint|A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
218926783|NCT05679869|OTHER|Masking Sound|Prerecorded environmental noise and masking sounds played from headphones
219043424|NCT06700798|DRUG|rituximab|375mg/m\^2, intravenous
219043425|NCT06700798|DRUG|Cyclophosphamide|750mg/m\^2
219043426|NCT06700798|DRUG|Vincristine|1.4mg/m\^2
219043427|NCT06700798|DRUG|Prednisone tablet|60mg/m\^2
219043428|NCT06050746|OTHER|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
219043429|NCT05847153|BEHAVIORAL|MASC|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
219043430|NCT06138756|DEVICE|Nerivio|Nerivio is a remote electrical neuromodulation (REN) device for the treatment of migraine
219043431|NCT05657470|DRUG|Tenecteplase|intra-arterial tenecteplase
219043432|NCT06846866|DRUG|BMS-986419|Specified dose on specified days
219043433|NCT06846866|DRUG|BMS-986419 Matching Placebo|Specified dose on specified days
219043434|NCT06846866|DRUG|Moxifloxacin|Specified dose on specified days
219043435|NCT06846866|DRUG|Moxifloxacin Matching Placebo|Specified dose on specified days
219620320|NCT05958043|DEVICE|3D- printed Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
218926784|NCT05679869|OTHER|No masking sound|Prerecorded environmental noise but no masking sounds played from headphones
218926785|NCT01457703|DRUG|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
218926786|NCT01457703|DRUG|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
218926787|NCT01457703|DRUG|Recombinant LH|Used to stimulate ovarian function in women.
218926788|NCT01457703|DRUG|Letrozole|An aromatase inhibitor.
218926789|NCT04971434|DEVICE|laser stimulation for acupoints|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
218926790|NCT04971434|OTHER|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
219043436|NCT06846268|DRUG|ADG126|Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).
219366837|NCT01900002|OTHER|Laboratory Biomarker Analysis|Correlative studies
218926791|NCT00949702|DRUG|vemurafenib|960 mg b.i.d. continuous oral dosing
218926792|NCT02271672|DEVICE|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
218926793|NCT02271672|DEVICE|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
218926794|NCT03530982|OTHER|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
218926795|NCT01481844|DRUG|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
218926796|NCT01481844|DRUG|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
218926797|NCT01654302|DRUG|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
218926798|NCT01654302|DRUG|Inactive patch|placebo patch applied once for 12 hours
218926799|NCT00570986|DRUG|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
218926800|NCT00570986|BIOLOGICAL|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
218926801|NCT00570986|BIOLOGICAL|ABT-874|100mg every 12 weeks.
218926802|NCT00828594|DRUG|RAD001|
218926803|NCT00828594|DRUG|RAD001, sorafenib|
219043437|NCT06846268|DRUG|Pembrolizumab|Administered via intravenous infusion on Day 1 and Day 22.
219043438|NCT05100745|DEVICE|Therapeutic Device|This device delivers ultrasound energy to the targeted area of the lower limb.
219043439|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
219043440|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
219043441|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
219043442|NCT06519734|OTHER|Questionnaire|"Questionnaire intended for patients on contraceptive modalities and use of menstrual hygiene products.~Consultation of the medical records of patients who have reported infectious complications linked to the use of intrauterine devices, tampons or menstrual cups."
219366838|NCT01900002|OTHER|Quality-of-Life Assessment|Ancillary studies
219366839|NCT01900002|DRUG|Sorafenib|Given PO
219366840|NCT01900002|DRUG|Sorafenib Tosylate|Given PO
219366841|NCT01900002|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
219366842|NCT00754156|DEVICE|ABRA Abdominal Closure System|ABRA Abdominal Closure System
219366843|NCT00754156|DEVICE|V.A.C. Therapy|V.A.C. Therapy Alone
219366844|NCT00754156|DEVICE|KCI ABThera|KCI ABThera
219366845|NCT04475328|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
219366846|NCT04475328|DRUG|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
219366847|NCT04475328|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
219366848|NCT03262415|DEVICE|LabPatch Continuous Glucose Monitoring (CGM)|"1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~3. A wire that connects the chip to a laptop that continuously captures glucose data."
219366849|NCT04869800|DRUG|CKD-398|Test Drug
219366850|NCT04869800|DRUG|CKD-501, D745|Reference Drug
219366851|NCT01751971|DRUG|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
219366852|NCT01751971|OTHER|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
219366853|NCT06177366|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
219366854|NCT00453401|DRUG|NB-001|
219366855|NCT00167258|BEHAVIORAL|Voucher Reinforcement|
218926804|NCT05397925|BEHAVIORAL|ADSProgram - Self management for substance dependence program|GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
218926805|NCT05397925|BEHAVIORAL|Treatment as usual - Regular nursing consultation on a medication-based program|Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
218926806|NCT00514839|BEHAVIORAL|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
218926807|NCT03136510|DRUG|Apixaban 5 mg|"Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month"
218926808|NCT00043862|DRUG|topotecan|
218926809|NCT00088088|DRUG|Paclitaxel|
218926810|NCT00088088|DRUG|Carboplatin|
218926811|NCT00088088|DRUG|STA 4783|
218926812|NCT06044779|PROCEDURE|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
218926813|NCT06044779|PROCEDURE|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
218926814|NCT04941677|OTHER|no intervention|no intervention in this study
218926815|NCT02203968|DRUG|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
218926816|NCT02203968|DRUG|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
218926817|NCT06177548|PROCEDURE|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
218926818|NCT00434291|DRUG|TG-873870(Nemonoxacin)|
218926819|NCT01771289|DRUG|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
218926820|NCT01771289|RADIATION|Radiation|chemoradiation
218926821|NCT06120400|DRUG|Whole Egg|Whole Large, Grade A Egg
218926822|NCT03257059|OTHER|Breakfast|Glutinous rice (75 grams of available carbohydrate)
218926823|NCT03257059|OTHER|No Breakfast|No food to be served in the morning
218926824|NCT04275362|DEVICE|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
218926825|NCT04275362|DEVICE|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
218926826|NCT04275362|DEVICE|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
218926827|NCT04275362|DEVICE|Control|No total knee replacement
218926828|NCT02765516|OTHER|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
218926829|NCT02765516|OTHER|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
218926830|NCT05506033|PROCEDURE|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
218926831|NCT00651690|BIOLOGICAL|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
218926832|NCT00651690|BIOLOGICAL|Placebo|Saline injection on Day 0
218926833|NCT04477096|DRUG|HS-10234|HS-10234
218926834|NCT04477096|DRUG|Emtricitabine|Emtricitabine
218926835|NCT04002232|DEVICE|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
218926836|NCT01859624|DRUG|Albuterol|Albuterol 4 mg
218926837|NCT05279677|DRUG|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
218926838|NCT02952820|DRUG|lemborexant|
218926839|NCT02952820|DRUG|Placebo|
218926840|NCT04764708|BEHAVIORAL|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
218926841|NCT04764708|BEHAVIORAL|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
218926842|NCT03310918|OTHER|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
218926843|NCT03310918|OTHER|Standard Leukemia care|Standard care per the hospital guideline
219043443|NCT04476017|DRUG|SAGE-718|Oral tablets.
219043444|NCT02704364|BIOLOGICAL|NGM282|
219043445|NCT02704364|OTHER|Placebo|
219043446|NCT06188702|DRUG|S095035|S095035 will be taken orally once daily in 28-day cycles.
219043447|NCT06188702|DRUG|TNG462|TNG462 will be taken orally once daily in 28-day cycles.
219043448|NCT02975934|DRUG|Rucaparib|Rucaparib will be administered daily.
219205062|NCT06733077|DEVICE|gait with cueing wearable device and neuro-ocular performance|"Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home."
219205063|NCT01778686|DRUG|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
219205064|NCT01778686|OTHER|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
219205065|NCT01778686|DIETARY_SUPPLEMENT|Acute tryptophan depletion|
218926844|NCT06237985|PROCEDURE|ProTaper Gold file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.
218926845|NCT06237985|PROCEDURE|OneShape file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.
218926846|NCT06237985|PROCEDURE|TruNatomy file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
218926847|NCT03074240|PROCEDURE|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
219205066|NCT06720675|PROCEDURE|Hypothermic Oxygented Perfusion|HOPE start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid (cold Belzer MPS solution) during back-table preparation. Hepatic perfusion was performed through the vein leads to a pressure of 3-5 mmHg. Organ were treated with continuous HOPE until transplant and the perfusion was continuously monitored and data downloaded in a USB memory.
218926848|NCT03074240|PROCEDURE|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
219205067|NCT06720675|PROCEDURE|Static Cold Storage|Liver grafts are stored in sterile organ bags with cold Belzer or Celsior solution and kept in ice at 4°C.
219205068|NCT06720909|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The standard 8-week MBSR program will be led by certified MBSR instructors from the UCSD Center for Mindfulness. The program content will consist of a variety of mindfulness and meditative techniques, such as sitting meditation, body scans, and mindful yoga. Participants will engage in weekly sessions via Zoom, participation in group discussions, and honing their other mindfulness skills. Throughout the program, participants will be instructed to commit to a daily mindfulness meditation practice lasting approximately 45 minutes, at least 6 days a week.
219366856|NCT00167258|BEHAVIORAL|Extra Counseling Services|
219366857|NCT00167258|BEHAVIORAL|Voucher Reinforcement + Extra Counseling Services|
219366858|NCT06151561|DRUG|AGN-151586|Intramuscular Injection
219366859|NCT06151561|DRUG|Placebo|Intramuscular Injection
219366860|NCT03382509|DRUG|[14C]BI 1467335|Once Daily
219366861|NCT03382509|DRUG|BI 1467335|Twice Daily
218926849|NCT03074240|PROCEDURE|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
218926850|NCT05803239|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
218926851|NCT05803239|PROCEDURE|EBUS-TBMC via a tunnel|Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
218926852|NCT02077452|DRUG|HMS5552|
218926853|NCT02077452|DRUG|Placebo|
219043449|NCT02975934|DRUG|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
219043450|NCT06287203|BEHAVIORAL|Addiction Risk Feedback Program|This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
219043451|NCT02684292|BIOLOGICAL|pembrolizumab|IV infusion
219043452|NCT02684292|BIOLOGICAL|brentuximab vedotin|IV infusion
219366862|NCT04881123|DRUG|SER150|Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
219366863|NCT04881123|DRUG|Placebo|Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
219366864|NCT06002503|DRUG|Venezuelan Equine Encephalitis DNA Vaccine|Venezuelan Equine Encephalitis DNA Vaccine Candidate
219043453|NCT05741125|BEHAVIORAL|DSME + ASE intervention (Centering Appetite)|The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
219043454|NCT03770156|BEHAVIORAL|Questionnaires|Overall Impression of the current state and evolution since the attacks
219043455|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
218926854|NCT04139018|DRUG|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
218926855|NCT04139018|DRUG|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
218926856|NCT03233581|BEHAVIORAL|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
218926857|NCT03233581|BEHAVIORAL|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
218926858|NCT01730482|DRUG|[14C] AT1001|150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
218926859|NCT02243995|OTHER|Physical training|
218926860|NCT02243995|BEHAVIORAL|Physical training|
218926861|NCT02484885|OTHER|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
218926862|NCT00002476|BIOLOGICAL|bleomycin sulfate|
218926863|NCT00002476|DRUG|fluorouracil|
218926864|NCT00002476|DRUG|leucovorin calcium|
218926865|NCT00002476|DRUG|methotrexate|
218926866|NCT00002476|DRUG|vincristine sulfate|
218926867|NCT00002476|RADIATION|low-LET cobalt-60 gamma ray therapy|
218926868|NCT00002476|RADIATION|low-LET photon therapy|
218926869|NCT00002476|RADIATION|radiation therapy|
218926870|NCT03486834|BIOLOGICAL|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
218926871|NCT03486834|DRUG|Placebo|Saline solution administered as a 0.5 mL IM injection
218926872|NCT04476797|DRUG|GC4711 +SBRT|15 minute IV Infusion prior to SBRT
218926873|NCT04476797|DRUG|Placebo +SBRT|15 minute IV infusion prior to SBRT
218926874|NCT00255489|DRUG|Gefitinib|
218926875|NCT00255489|PROCEDURE|palliative thoracic radiotherapy|
218926876|NCT02364570|OTHER|Glucose (100g)|Ingestion of glucose (100g)
218926877|NCT02364570|OTHER|Glucose (75g)|Ingestion of glucose (75g)
218926878|NCT02364570|OTHER|Whole Eggs|Ingestion of 1.5 whole eggs
218926879|NCT02364570|OTHER|Egg Whites|Ingestion of 7 egg whites
218926880|NCT02364570|OTHER|Egg Yolks|Ingestion of 2 egg yolks
218926881|NCT00264732|DRUG|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
218926882|NCT00264732|DRUG|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
218926883|NCT00264732|OTHER|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
218926884|NCT01040910|DRUG|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
218926885|NCT01040910|DRUG|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
218926886|NCT03614156|DRUG|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
219366865|NCT06002503|DEVICE|PharmaJet Stratis Needle-free Injection System|Intramuscular Needle-free Injection System (Jet Injector)
218926887|NCT03614156|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
218926888|NCT02535806|DRUG|Velcade|4 doses of study drug will be given.
218926889|NCT02535806|DRUG|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
218926890|NCT02535806|DRUG|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
218926891|NCT02535806|DRUG|Dexamethasone|Days 1-5 and 15-19
218926892|NCT02535806|DRUG|Mitoxantrone|Days 1 and 2
218926893|NCT02535806|DRUG|Vincristine|Days 1, 8, 15, 22
218926894|NCT02535806|DRUG|Pegaspargase|Days 3 and 17
218926895|NCT00638014|DEVICE|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
218926896|NCT00638014|DEVICE|Conventional wire closure|Conventional wire closure of sternum
218926897|NCT02405832|DIETARY_SUPPLEMENT|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
218926898|NCT02405832|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
218926899|NCT05181436|DIAGNOSTIC_TEST|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
218926900|NCT04287517|DEVICE|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
218926901|NCT01021891|DRUG|Technosphere®/Insulin|
218926902|NCT01786577|OTHER|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
218926903|NCT01786577|BEHAVIORAL|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
218926904|NCT04771117|BEHAVIORAL|Fear of Covid-19 Scale|"The Fear of Covid-19 Scale (FCV-19S) is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. The FVC-19S consists of seven items, such as It makes me uncomfortable to think about coronavirus-19, I am afraid of losing my life because of coronavirus-19, and When watching news and stories about coronavirus-19 on social media, I become nervous or anxious, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19."
218926905|NCT04515472|DRUG|Botnia Clamp|This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.
218926906|NCT04515472|OTHER|Withdrawal of Gender Affirming Hormone Therapy (GAHT)|GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.
218926907|NCT02899468|DEVICE|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
218926908|NCT05808231|DRUG|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
218926909|NCT05808231|DRUG|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
218926910|NCT03420599|PROCEDURE|splenectomy|Traumatic patients who performed total splenectomy
218926911|NCT01131832|DIETARY_SUPPLEMENT|Plant sterol|
218926912|NCT01131832|DIETARY_SUPPLEMENT|Placebo|
218926913|NCT05160181|OTHER|Yogatherapy|Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
218926914|NCT04985123|DEVICE|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
218926915|NCT05024019|DRUG|Nimotuzumab|The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
218926916|NCT01352000|BEHAVIORAL|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
218926917|NCT00002786|BIOLOGICAL|aldesleukin|
218926918|NCT00002786|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
218926919|NCT03612752|DIETARY_SUPPLEMENT|CMI-168|Dietary supplement
218926920|NCT03612752|OTHER|Placebo|Placebo
218926921|NCT00148096|DEVICE|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
218926922|NCT02708186|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
218926923|NCT02708186|DRUG|Placebo|once daily, oral, matching tablets
218926924|NCT00041561|DRUG|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
218926925|NCT00041561|DRUG|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
218926926|NCT02851472|DRUG|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
218926927|NCT02851472|DRUG|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
218926928|NCT00854399|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
218926929|NCT04125472|DRUG|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
219366866|NCT06002503|DEVICE|PharmaJet Tropis Needle-free Injection System|Intradermal Needle-free Injection System (Jet Injector)
218926930|NCT02629263|DIETARY_SUPPLEMENT|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
218926931|NCT03309735|DRUG|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
218926932|NCT03309735|DRUG|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
218926933|NCT03309735|DRUG|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
218926934|NCT05599867|BEHAVIORAL|quality of life|to assess quality among patients with patients with IBD
218926935|NCT01281904|BEHAVIORAL|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
218926936|NCT01281904|BEHAVIORAL|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
218926937|NCT03638037|DIAGNOSTIC_TEST|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
218926938|NCT01020240|BEHAVIORAL|Avolition|\- avolition for cesarean discomforts
218926939|NCT01020240|BEHAVIORAL|Orientation|"* avolition of cesarean discomfort~* physiotherapy orientation"
218926940|NCT01020240|BEHAVIORAL|Guide|"* avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation"
218926941|NCT00834093|BIOLOGICAL|Epstein-Barr Virus Specific Immunotherapy|
218926942|NCT00248768|DEVICE|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
218926943|NCT05914337|BEHAVIORAL|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
218926944|NCT05914337|BIOLOGICAL|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
218926945|NCT05322382|PROCEDURE|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
218926946|NCT02721329|DEVICE|APAP|Automatic Continuous Positive Airway Pressure
218926947|NCT02721329|DEVICE|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
218926948|NCT01587924|DRUG|GSK1278863|tablet
218926949|NCT01587924|DRUG|rhEPO|injection
218926950|NCT00404469|PROCEDURE|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
218926951|NCT00404469|PROCEDURE|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
218926952|NCT00404469|PROCEDURE|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
218926953|NCT05876715|DRUG|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
218926954|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
218926955|NCT00585026|DEVICE|D-28 bifocal lenses and frame|
218926956|NCT00585026|DEVICE|Progressive addition computer lenses and frame|
218926957|NCT04843657|BEHAVIORAL|Observation for symptom distress|Observation for symptom distress
218926958|NCT04833218|DRUG|Propranolol|Test of catecholamines level in moderate traumatic brain injury
218926959|NCT05397158|PROCEDURE|single administration of low dose polyethylene glycol|"Patients in single administration of low dose polyethylene glycol (PEG) group: Take 30ml lactulose and 2L PEG.~Patients in control group: Take 4L PEG."
218926960|NCT05172908|DRUG|Dexamethasone|"5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes.~The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
218926961|NCT05172908|DRUG|Saline|"A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
218926962|NCT03714880|DRUG|Mifepristone 200 MG|Ingestion of study medication vs placebo
218926963|NCT03714880|DRUG|Placebo Oral Tablet|Ingestion of study medication vs placebo
219043456|NCT06283446|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
219043457|NCT06283446|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
219043458|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
219043459|NCT02075840|DRUG|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
219366867|NCT01974609|DRUG|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
218926964|NCT05614596|OTHER|CT guided and Flouroscopic guided injection of corticosteroid and local anathesia|Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
218926965|NCT05103046|DRUG|UCT-03-008|Orally available kinase inhibitor
218926966|NCT03207061|DIAGNOSTIC_TEST|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
218926967|NCT05275504|DRUG|TT-01488|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
219366868|NCT01974609|DRUG|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
219366869|NCT02606578|OTHER|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (\~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
219366870|NCT02022449|BEHAVIORAL|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
219366871|NCT04749069|DIAGNOSTIC_TEST|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
219366872|NCT02820467|DEVICE|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
219366873|NCT02682680|DRUG|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
219366874|NCT02682680|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
219366875|NCT03921996|PROCEDURE|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
219366876|NCT03921996|PROCEDURE|Radical prostatectomy (RP) only|Radical prostatectomy
219366877|NCT01332448|DRUG|Orlistat 120|Orlistat 120mg tid
219366878|NCT01332448|DRUG|Orlistat 60|Orlistat 60mg tid
218926968|NCT00531544|DRUG|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
218926969|NCT02612519|DEVICE|Alfapump|Implantation of Alfapump
218926970|NCT02612519|DEVICE|TIPS|Implantation of TIPS
218926971|NCT01811966|OTHER|Volume|
218926972|NCT01811966|OTHER|Control|
219539681|NCT03570905|OTHER|Clam Shell Splint|A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
218926973|NCT00530972|DRUG|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)
218926974|NCT03507569|DRUG|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
218926975|NCT03507569|OTHER|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
218926976|NCT01050504|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218926977|NCT01050504|OTHER|Laboratory Biomarker Analysis|Correlative studies
218926978|NCT03313037|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
218926979|NCT03313037|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
218926980|NCT03313037|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
218926981|NCT03313037|OTHER|Saline|Placebo
218926982|NCT04664127|DRUG|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
218926983|NCT04664127|DRUG|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
218926984|NCT03806764|DIAGNOSTIC_TEST|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
218926985|NCT06413082|DRUG|Torasemide|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
218926986|NCT06413082|DRUG|Spironolactone|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
219539682|NCT02777580|DRUG|Tenecteplase|Half dose Tenecteplase
219539683|NCT02777580|DRUG|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
219539684|NCT02777580|PROCEDURE|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
219539685|NCT02777580|PROCEDURE|Primary PCI|Primary PCI accoring to local standards
218926987|NCT00000258|DRUG|Nitrous oxide 10% & placebo|
218926988|NCT00000258|DRUG|Nitrous oxide 20% & placebo|
218926989|NCT00000258|DRUG|Nitrous oxide 30% & placebo|
218926990|NCT00000258|DRUG|Nitrous oxide 40% and placebo|
218926991|NCT06503263|DRUG|Zanubrutinib plus Lenalidomide as Maintenance Therapy|Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
218926992|NCT02379091|DRUG|Namilumab|Namilumab subcutaneous injection
218926993|NCT02379091|DRUG|Placebo|Namilumab placebo-matching subcutaneous injection
218926994|NCT02379091|DRUG|Methotrexate|Methotrexate tablets
218926995|NCT02379091|DRUG|Folic/folinic acid|Folic/folinic acid tablets
218926996|NCT05610345|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
219539686|NCT00029263|DRUG|herbals|
219539687|NCT01294917|DEVICE|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
219539688|NCT01294917|DEVICE|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
218926997|NCT05610345|PROCEDURE|Placenta Blood Not Drained|Placenta Blood Not Drained
218926998|NCT04834102|DIAGNOSTIC_TEST|Blood Tests|Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity
218926999|NCT03964831|DEVICE|P200TxE|The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
218927000|NCT03964831|DEVICE|P200DTx|The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
218927001|NCT05056935|DRUG|LB1148|A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
218927002|NCT05056935|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
218927003|NCT00763880|DRUG|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
218927004|NCT00763880|DRUG|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
218927005|NCT04335006|DRUG|Carelizumab|Participants receive SHR-1210 intravenously (IV)
218927006|NCT04335006|DRUG|Nab-paclitaxel|administered intravenously every 4-week cycle
218927007|NCT04335006|DRUG|Apatinib|administered orally every 4-week cycle
218927008|NCT03545958|BEHAVIORAL|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
218927009|NCT03545958|BEHAVIORAL|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
218927010|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
218927011|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
218927012|NCT06234761|DRUG|Dupilumab|Patient who start to take dupilumab will be followed. This study is only observational
218927013|NCT03230461|BEHAVIORAL|Compression depth|
218927014|NCT02951377|OTHER|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
218927015|NCT02951377|DRUG|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
218927016|NCT00252096|DEVICE|Nucleic acid amplification test|
218927017|NCT05826938|DEVICE|Virtual reality technology|Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
218927018|NCT00967070|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
218927019|NCT00967070|DRUG|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
218927020|NCT00040989|DRUG|BAY 56-3722|
218927021|NCT00040989|PROCEDURE|enzyme inhibitor therapy|
219366879|NCT05772637|PROCEDURE|Repeated cystometries with bladder sensations assessment|A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
219539689|NCT01294917|DEVICE|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
218927022|NCT02490865|DRUG|RNS60|RNS60, 4 ml dose nebulized twice daily
218927023|NCT02490865|DRUG|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
218927024|NCT02936804|DEVICE|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
218927025|NCT02529969|DIETARY_SUPPLEMENT|curcumin|
218927026|NCT02529969|DIETARY_SUPPLEMENT|Placebo|
218927027|NCT00437229|DRUG|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
218927028|NCT00437229|DRUG|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
218927029|NCT00437229|DRUG|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
219366880|NCT05804799|DIAGNOSTIC_TEST|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
219539690|NCT04726163|DEVICE|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
219539691|NCT00611364|OTHER|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
219539692|NCT00611364|OTHER|education meetings|This group only participed of education meeting (every fifteen days)
219539693|NCT01193712|PROCEDURE|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
219539694|NCT06562764|OTHER|Counselling by the Trained Pharmacist|The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
219539695|NCT06562764|OTHER|Pictograms Cards and Counselling by the Trained Pharmacist|The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
218927030|NCT01662765|PROCEDURE|Surgery|modified umbilectomy
218927031|NCT01662765|OTHER|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
219539696|NCT02519348|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
218927032|NCT00119184|PROCEDURE|External cephalic version|7.5 mg bupivacaine intrathecally
218927033|NCT00119184|DRUG|spinal anesthesia|spinal anesthesia
218927034|NCT02129699|DRUG|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
218927035|NCT02129699|OTHER|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
218927036|NCT05378191|DRUG|COMIRNATY|One dose of COMIRNATY
218927037|NCT05422898|BEHAVIORAL|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
218927038|NCT05422898|BEHAVIORAL|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
218927039|NCT01607255|DRUG|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
218927040|NCT01607255|PROCEDURE|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
218927041|NCT01607255|PROCEDURE|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
218927042|NCT01607255|PROCEDURE|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
218927043|NCT01173094|DEVICE|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
218927044|NCT01173094|DEVICE|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
218927045|NCT03208829|OTHER|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
218927046|NCT03208829|OTHER|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
218927047|NCT04382352|BIOLOGICAL|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
218927048|NCT03646097|PROCEDURE|Angio-PCI|PCI only with angiography and without OCT findings
218927049|NCT03646097|PROCEDURE|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
218927050|NCT03646097|PROCEDURE|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
218927051|NCT04057417|OTHER|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
218927052|NCT00308490|DRUG|iron sucrose|
218927053|NCT01088724|DRUG|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
218927054|NCT00633113|PROCEDURE|MPPA|\- Medial Parapatellar Arthrotomy
218927055|NCT00633113|PROCEDURE|SV|\- Subvastus Technique
218927056|NCT04516447|DRUG|ZN-c3|Investigational drug
218927057|NCT04516447|DRUG|Carboplatin|Carboplatin is an approved drug
219539697|NCT02519348|BIOLOGICAL|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
219539698|NCT02519348|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
219539699|NCT01444378|DEVICE|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
219539700|NCT00164307|BEHAVIORAL|Parent assisted social skills training|
218927058|NCT04516447|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
218927059|NCT04516447|DRUG|Paclitaxel|Paclitaxel is an approved drug
218927060|NCT04516447|DRUG|Gemcitabine|Gemcitabine is an approved drug
218927061|NCT04516447|BIOLOGICAL|Bevacizumab|Combined with azenosertib
219205069|NCT06720909|OTHER|Open-Label Placebo (OLP)|The placebo pills will be size #1 capsules filled with (1) microcrystalline cellulose, a common inert excipient for pharmaceuticals, and (2) 25 mg riboflavin tracer. Participants will be informed that the placebo pills are inactive substances, like sugar pills, and contain no active medication. Then, they will watch a brief introduction video which will cover four main discussion points: (1) the placebo effect can be powerful and can have beneficial effects for diverse symptoms, (2) the body can respond to taking placebo pills automatically despite the knowledge that it is placebo (e.g., Pavlov's dogs), (3) a positive attitude or expectation can be beneficial but is not necessary, and (4) taking the pills faithfully throughout the intervention period is critical.
219205070|NCT06720909|OTHER|MBSR+OLP|This condition involves a combination of interventions, where participants will receive both MBSR and OLP treatments.
219205071|NCT06721520|BIOLOGICAL|Botulinum Toxin A (Botox )|Patients randomized for intrapyloric Botox injection will undergo the following standard procedure: 100 units of Botox are dissolved in 10 mL normal saline. After identifying the pylorus, the 10 mL of Botox solution is injected intramuscularly at the anterior pyloric ring in 2 separate areas and in 1 area on each side of the pyloric ring.
219205072|NCT06721520|PROCEDURE|Pyloromyotomy|Patients randomized for pyloromyotomy will undergo standard pyloromyotomy as follows: after identifying the pylorus, a 2-cm longitudinal incision is made with Metzenbaum or Mayo scissors on the anterior pylorus, centered on the pyloric ring. The incision extends through the serosa and muscular layers to expose the submucosa and mucosa, which is left intact. The cut muscle is spread apart until the submucosa bulges up to the level of the cut serosa. Care is taken to avoid perforation, and the surgeon confirms no mucosal perforation at the end of the procedure. If a perforation is encountered, it will be repaired primarily.
219205073|NCT06727734|DRUG|Levonorgestrel|Levonorgestrel 1.5 mg
219205074|NCT06727734|DRUG|Piroxicam|Piroxicam 40 mg
219205075|NCT06727734|DRUG|Ulipristal Acetate|Ulipristal 30 mg
219205076|NCT06727734|DRUG|Placebo - LNG|Placebo of levonorgestrel
219205077|NCT06727734|DRUG|Placebo - Piroxicam|Placebo of piroxicam
219205078|NCT06727734|DRUG|Placebo - UPA|Placebo of ulipristal acetate
219205079|NCT06723535|DRUG|BMS-986278|Specified dose on specified days
219205080|NCT06731192|BIOLOGICAL|hUC-MSC|"This group of patients received a total of 2 peripheral intravenous Human umbilical cord mesenchymal stem cells (hUC-MSC) infusions during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days, and the single infusion dose was approximately 2×1000,000 cells/Kg.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
218927062|NCT05720312|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
218927063|NCT00630838|DRUG|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
219205081|NCT06731192|DRUG|Placebo control drug|"This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
219205082|NCT06730763|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.
218927064|NCT00630838|DRUG|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
218927065|NCT05261646|DRUG|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
218927066|NCT05261646|DRUG|Matching placebo|Matching placebo（Stage 1；Stage 2）
218927067|NCT02530515|BIOLOGICAL|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
218927068|NCT02530515|OTHER|Laboratory Biomarker Analysis|Correlative studies
218927069|NCT03723642|DIAGNOSTIC_TEST|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
218927070|NCT03723642|DIAGNOSTIC_TEST|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
218927071|NCT03723642|DIAGNOSTIC_TEST|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
218927072|NCT03723642|DIAGNOSTIC_TEST|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
219205083|NCT06730763|OTHER|Exercise|selected traditional physical therapy program for improve balance and decrease risk of falling
219205084|NCT06888310|PROCEDURE|extra blood sampling|search for biomarkers for the prevention of liver disease
219205085|NCT06888349|PROCEDURE|spinal anesthesia|spinal anesthesia using 15 mg 0.5% hyperbaric bupivacaine in the sitting position at L3-4 or L4-5 intervertebral space.
219205086|NCT06888349|PROCEDURE|Adductor Canal Block|local anesthetic spread around the saphenous nerve in the adductor canal ultrasound guided using 22 Gag spinal needle with injection of 15ml 0.25% bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
218927073|NCT03723642|DIAGNOSTIC_TEST|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
218927074|NCT03723642|DIAGNOSTIC_TEST|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
218927075|NCT03723642|DIAGNOSTIC_TEST|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
218927076|NCT03723642|DIAGNOSTIC_TEST|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
218927077|NCT03723642|DIAGNOSTIC_TEST|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
218927078|NCT03723642|DIAGNOSTIC_TEST|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
218927079|NCT03723642|DIAGNOSTIC_TEST|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
218927080|NCT03723642|DIAGNOSTIC_TEST|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
218927081|NCT06125600|OTHER|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
218927082|NCT06231589|DEVICE|Sperm Selection|Sperm selection using physiological intracytoplasmic sperm injection (PICSI dish) or magnetic-activated cell sorting (MACS) for selecting sperm with high-quality, better morphology and lower DNA fragmentation.
218927083|NCT00222300|BEHAVIORAL|Strength training program|
218927084|NCT05488041|PROCEDURE|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, … AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
218927085|NCT02885701|OTHER|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.
218927086|NCT02885701|OTHER|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
218927087|NCT02885701|OTHER|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
218927088|NCT02689037|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
219366881|NCT01130129|OTHER|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
219366882|NCT00206921|DEVICE|Pulsed dye laser|
218927089|NCT02689037|DRUG|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
218927090|NCT00670748|BIOLOGICAL|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
218927091|NCT00670748|DRUG|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
218927092|NCT00670748|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
218927093|NCT00670748|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219043460|NCT02075840|DRUG|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
219043461|NCT04798352|OTHER|6-minute walk test|6-minute walk test
219043462|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
219043463|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
219043464|NCT00846742|DRUG|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
219366883|NCT00206921|DEVICE|Intense pulsed light|
219366884|NCT02475889|PROCEDURE|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
219366885|NCT02475889|PROCEDURE|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
219366886|NCT04297358|DRUG|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
218927094|NCT00670748|BIOLOGICAL|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
219539701|NCT03946891|DRUG|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
218927095|NCT01424072|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
218927096|NCT01424072|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
218927097|NCT04633265|DEVICE|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
218927098|NCT03307499|OTHER|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
218927099|NCT02283853|DRUG|dimethyl fumarate|administered orally
218927100|NCT02283853|DRUG|Interferon β-1a|administered by intramuscular injection
218927101|NCT05599893|OTHER|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
218927102|NCT05599893|OTHER|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
218927103|NCT06150066|OTHER|Recruiting samples|The GCF, plaque, and saliva samples will recruited from participants.
218927104|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
218927105|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
218927106|NCT05668481|BEHAVIORAL|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
218927107|NCT06653361|PROCEDURE|Green laser|Green Laser
218927108|NCT06978946|PROCEDURE|Deep Cervical Lymphaticovenous Anastomosis(DLVA)|This surgery will enhance the drainage of cerebral lymphatic fluid by surgically establishing a connection between lymphatic vessels and veins in the neck
218927109|NCT04400643|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV is software accessory that automatically adjust ventilation and oxygenation variables to keep the patient within clinician-set target ranges.
218927110|NCT04400643|DEVICE|Non-automated ventilation|In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
219043465|NCT00846742|RADIATION|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
219539702|NCT03946891|DRUG|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
219043466|NCT05159999|OTHER|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
219043467|NCT05159999|DRUG|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
219043468|NCT05225935|DEVICE|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
219205087|NCT06888349|PROCEDURE|interspace between Popliteal artery and capsule of knee (IPACK) block|ultrasound guided Local anesthetic infiltration over the posterior aspect of the femur underneath the popliteal artery targeting the genicular nerves which are the articular branches of tibial and common peroneal nerves, posterior branches of the obturator nerve, and medial genicular nerve using 22Gag spinal needle injecting 20ml 0.25%bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
219539703|NCT02911792|DRUG|Dapagliflozin|SGLT2 inhibitor
219539704|NCT02911792|DRUG|Metformin|Oral diabetes medicine that helps control blood sugar levels.
219539705|NCT02911792|DRUG|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
218927111|NCT04475146|OTHER|video vizualisation|video vizualisation
218927112|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
218927113|NCT06655350|OTHER|MRI|Morphological data on the tendon (appearance) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
218927114|NCT06655350|OTHER|Measure|Morphological data on the tendon (diameter) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
218927115|NCT06654154|DIAGNOSTIC_TEST|variation of serum level vitamine B12|"There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture"
218927116|NCT06588569|DEVICE|Multi-mode tumor treatment system|The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.
218927117|NCT06588569|DEVICE|Radiofrequency ablation therapeutic apparatus|The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.
218927118|NCT06586034|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for both English and Spanish languages and is culturally tailored for Hispanic/Latino/Latinx individuals who smoke. Impacto will be developed for both iOS and Android platforms. The mobile app aims to aid smoking cessation by targeting elevated anxiety sensitivity.
218927119|NCT06594458|PROCEDURE|Observation of newborn with respiratory distress in the delivery room|Newborn manifesting tachypnea or respiratory distress at birth (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians. A clinical evaluation will be carried out every 15 minutes, with the detection of vital parameters. In case of clinical improvement and suspension of oxygen therapy, the newborn will be transferred to the Neonatal Observation Ward to perform multiparameter monitoring of vital signs up to 6 hours of life and then be reunited with the mother. In case of clinical worsening, a bedside thoracic ultrasound will be carried out and depending on the result and the lung ultrasonography score, it will be evaluated whether to continue the observation in the delivery room or to admit the newborn in the Neonatal Care, Neonatal Sub-Intensive Care or Neonatal Intensive care Units
218927120|NCT06600984|DEVICE|whole body vibration|On a vibration platform, the children went into a complete squat. The device was calibrated at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 minutes. After the vibration was turned on, the children were told to stay in the squatting position and to report any discomfort that could occur. The vibration automatically shut off after five minutes. The children then rested for a minute. Next, under the identical conditions as for the squatting position, they were instructed to stand on the vibration platform for five minutes with the therapist\&#39;s assistance. Consequently, WBV was applied for a total of 10 minutes during each session.
218927121|NCT06600984|OTHER|designed physiotherapy program|structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.
219043469|NCT05225935|DEVICE|conventional VT ablation strategy|Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
219043470|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
219043471|NCT05546697|BEHAVIORAL|Online- BA|See arms description
219043472|NCT05563064|DRUG|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
219043473|NCT05237258|BEHAVIORAL|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
219043474|NCT05237258|BEHAVIORAL|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
219205088|NCT06888232|DRUG|Thalidomide|Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.
219205089|NCT06886100|DEVICE|Diode laser|Diode Laser is a semiconductor device similar to a light-emitting diode in which a diode pumped directly with electrical current can create lasing conditions at the diode's junction. It is used in periodontal surgery as melanin depigmentation
218927122|NCT06589336|OTHER|Dietary changes via Instacart vouchers|Instacart will provide consumers with the dignity of choice to shop at preferred retail stores, which is key for our behavioral change strategy. Delivery and service fees will be waived for patients, so 100% of the vouchers will be applied to groceries (all food products excluding alcohol and tobacco). The investigators will use a custom study store front with an integrated website and email option.
218927123|NCT06589336|OTHER|Dietary changes via access to Mid-Ohio Farmacy|Mid-Ohio Farmacy will provide healthy food provisions through a network of food banks with fresh produce and other items.
218927124|NCT06589336|OTHER|Behavior changes via access to Health Impact Ohio Hub|Health Impact Ohio Hub is a regional coordination entity that has connections with community care agencies that employ community health workers to assess social needs and make connections to resources to address social needs. The community health workers will conduct an initial needs assessment, and guide the participant through appropriate care pathways to address social needs.
218927125|NCT06589336|OTHER|Behavioral nutrition counseling|All dietary recommendations will be individualized and informed by existing guidelines to improve diet quality and cardiovascular health through the Mediterranean Diet.
219205090|NCT06886100|DEVICE|Scalpel No 15|The No.15 blade has a small curved cutting edge and is the most popular blade shape ideal for making short and precise incisions.
219205091|NCT06889285|PROCEDURE|Continuos epidural infusion|"This group of parturient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. Similarly, a test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. Infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Bupivacaine 0.1% + Fentanyl 2mcg/ml in 50ml mixture) with the protocol as below: (directly extracted from Malaysia Pain management in Obstetrics and Gynaecology Procedure Guideline 2023)~* Loading dose 10 ml~* Continuous infusion: 10ml/hour"
219205092|NCT06889285|PROCEDURE|Programmed intermittent epidural bolus|"This group patient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. A test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. CADD-Solis infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Ropivacaine 0.05% + Fentanyl 2mcg/ml in 100ml mixture) with the protocol as below:~* Loading dose: 10ml~* Intermittent bolus: 10ml, bolus interval 1 hour, next bolus 1 hour~* PCEA dose: 10ml, lockout interval 10 minutes"
219205093|NCT06889623|PROCEDURE|Immediate postoperative chemotherapy|Systemic chemotherapy with cisplatin/gemcitabine intravenous infusion within 24 hours after TURBT
219205094|NCT01654133|DEVICE|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
219205095|NCT01654133|DEVICE|Endovascular repair of ascending/arch aortic aneurysm using branched stent graft|Repair of ascending/arch aortic aneurysms
219205096|NCT06705387|BIOLOGICAL|Dupilumab|Subcutaneous injection of 300mg per week for 16 weeks.
219205097|NCT06705387|DRUG|Fluticasone|Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
219205098|NCT06732674|DIAGNOSTIC_TEST|A home monitoring strategy with event driven management|Bi-weekly home monitoring with forced vital capacity (FVC), patient reported outcome measures (PROMs), at-home measures of blood oxygen levels (SpO2) during 1-minute-sit-to-stand test (1MSTS) and temperature with algorithm based risk evaluation of deterioration and infection and consecutive event driven management
219205099|NCT01499368|DRUG|Lafutidine|Lafutidine 20mg/day
219205100|NCT01499368|DRUG|Famotidine|Famotidine 40mg/day
219205101|NCT01499368|DRUG|Omeprazole|Omeprazole 20mg/day
219205102|NCT06733389|OTHER|peripheral waveform collection|The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
218927126|NCT06589336|OTHER|Cooking classes|Registered dietician nutritionists will also lead cooking demonstrations every 2 weeks, focused on culinary education and building engagement among SUSTAIN participants.
218927127|NCT06589336|OTHER|Dietary changes to Delivery fees|Delivery fees will be supported for SUSTAIN participants.
219205103|NCT06732115|PROCEDURE|One-step polishing system with nanohybrid resin composite restorations.|one-step polishing system using OneGloss by Shofu
219205104|NCT06732115|PROCEDURE|Multistep system polishing system Super-Snap X-treme (Shofu) with nanohybrid resin composite restorations.|A multi-step polishing system
219205105|NCT06252519|DIETARY_SUPPLEMENT|NAC|1 375 mg capsule containing N-acetyl cysteine
219205106|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC|3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
219205107|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC XS|3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester
219205108|NCT06059443|BEHAVIORAL|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
219205109|NCT07040059|DRUG|AUR103 Calcium|AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
219205110|NCT07040059|DRUG|Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)|Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.
219205111|NCT06721897|OTHER|Prehabilitation Program|"A prehabilitation programme supervised by a physiotherapist in a ward is proposed, with a frequency of 3 sessions/week on alternate days lasting 30-45 min/session, in addition to a daily physical exercise programme at home.~The programme will consist of a warm-up, strength exercises with progressive loads, proprioception, balance, cardiovascular training aimed at functional work and a cool-down.~The home programme will be complementary to the supervised programme, which will consist of daily sessions of 20-30 min of flexibility and proprioception exercises.~The same prehabilitation protocol will be proposed for those patients awaiting total hip and knee replacement surgery."
218927128|NCT06599398|OTHER|Jeroen Pit Huis|The JPH is a unique and innovative Transitional Care Unit (TCU) situated in close proximity of the AUMC. In this TCU, patients and their family reside in separate private home-like apartments. The families can stay while practising in, and adapting to, their new reality until they are ready to transition home. A multidisciplinary team of healthcare experts (nurses, psychosocial care workers, family counsellors, and paediatricians) are gradually guiding parents towards taking on the role of their child's primary caregiver. This process is guided by a newly developed seven phase care path.One condition for staying in the JPH is that one parent is always present. In this form (24/7 parental stay and nursing care directly available under the supervision of pediatricians) the JPH is unique in the Netherlands.
218927129|NCT06603584|RADIATION|Chest x- Rays|prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
219539706|NCT04414891|DEVICE|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
218927130|NCT06600009|DRUG|Secukinumab|Patients had received secukinumab per their dosing regimens prior to this observational study.
219539707|NCT01569269|BEHAVIORAL|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
219539708|NCT01569269|BEHAVIORAL|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
219539709|NCT01569269|BEHAVIORAL|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
219539710|NCT01569269|OTHER|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
219539711|NCT01124305|DEVICE|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
219539712|NCT01124305|DEVICE|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
219539713|NCT01868945|DIETARY_SUPPLEMENT|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
219539714|NCT01868945|DIETARY_SUPPLEMENT|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
219539715|NCT01868945|DIETARY_SUPPLEMENT|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
219539716|NCT01868945|DIETARY_SUPPLEMENT|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
218927131|NCT06600009|DRUG|Adalimumab|Patients had received adalimumab per their dosing regimens prior to this observational study.
219043475|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
219043476|NCT04843852|DRUG|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
219043477|NCT04703218|OTHER|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
219043478|NCT03795610|DRUG|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
219205112|NCT06721897|OTHER|Non prehabilitation Program|The control group (CG) will carry out a post-operative physiotherapy program in addition to a home exercise program that will be shown by the physiotherapist before hospital discharge.
218927132|NCT06596993|OTHER|IMU-based balance training|Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training
218927133|NCT06596993|OTHER|general health education or exercise training|general health education or exercise training
218927134|NCT06589401|DRUG|INP12|Oral paclitaxel
218927135|NCT06597630|OTHER|Tissue specimens were stained by histopathology of hematoxylin-eosin|Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing
218927136|NCT06590259|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.
218927137|NCT06590259|DRUG|Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab|Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
218927138|NCT06602154|OTHER|Resin modified glass ionomer|"The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds."
218927139|NCT06591312|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
218927140|NCT06591312|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
218927141|NCT04791735|PROCEDURE|Laparoscopy|"* Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~* Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~* Use of laparoscopic specific devices:~  * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~ * Use of a laparoscopic camera system with 0° or 30°~ * Use of a dedicated laparoscopic ultrasound probe.~ * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~* Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
218927142|NCT04791735|PROCEDURE|Laparotomy|"* Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~* Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~* Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~* Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
218927143|NCT06589323|PROCEDURE|Coronary artery bypass graft|All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
218927144|NCT06592612|RADIATION|SBRT and second-line systemic therapy|Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
219366887|NCT05721066|DIAGNOSTIC_TEST|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
219366888|NCT05721066|DIAGNOSTIC_TEST|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
219366889|NCT05721066|OTHER|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
219366890|NCT01573910|DRUG|Moxifloxacin ophthalmic solution, 0.5%|
219366891|NCT01573910|DRUG|Ofloxacin ophthalmic solution, 0.3%|
219366892|NCT00000943|BIOLOGICAL|Tetanus Toxoid Vaccine|
219366893|NCT00000943|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
219366894|NCT00000943|BIOLOGICAL|HIV-1 Immunogen|
219366895|NCT00000943|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
219366896|NCT03209219|DRUG|Interferon Alfa-2A|3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
218927145|NCT06592612|DRUG|Second-line systemic therapy|Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
218927146|NCT06587672|DEVICE|Micra AV implantation|Patients received Micra AV implantation
218927147|NCT06603389|OTHER|Psychiatric Non-Suicidal Self-Injury Risk Assessment Scale|sacles or questionnaires
218927148|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 3 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
218927149|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 5 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
218927150|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 7 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
218927151|NCT06600139|BEHAVIORAL|The Collaboration-Screening-Referral (SSH) model|The SSH aims to identify parents in need of mental health support and to strengthen social workers' competence in addressing mental illness. The SSH includes three components: 1) Collaborating - establishing collaboration with local services offering support to adults with mental illness, 2) Screening - using screening instruments for depression (the Patient Health Questionnaire - PHQ-9) and anxiety (GAD-7) to identify symptoms of mental illness among parents, and 3) Referral - Discussing the results of the screening with parents and referring to appropriate services. Techniques from motivational interviewing are included. Social workers receive training and material to administer the screening and refer parents in need of support.
218927152|NCT05156567|DIAGNOSTIC_TEST|Deep Learning System|The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
218927153|NCT06590519|OTHER|Date Seed Extract|"Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules."
218927154|NCT06591416|PROCEDURE|minimally invasive surgical technique|minimally invasive surgical technique
218927155|NCT06591416|PROCEDURE|minimally invasive surgical technique with granulation tissue preservation|minimally invasive surgical technique with granulation tissue preservation
218927156|NCT06591637|BEHAVIORAL|Fertility supportive behavior education based on Watson's Theory of Human Care|In this study, Watson's Theory of Human Caring guided the development of a care framework and nursing intervention for women with infertility. The researchers adapted the theory and focused on six of the ten carative factors : 1) Adopting values of humanity and devotion; 4) Developing supportive care relationships; 6) Using problem-solving methods for informed decisions; 7) Tailoring teaching to individual needs; 8) Creating a comfortable, peaceful environment; 9) Assisting with basic needs. The nursing care program, integrated with IVF treatments (14-18 days), involved four transpersonal interviews lasting 45-90 minutes each. These interviews were recorded in notes, used to individualize future sessions. The approach included active listening, empathy, and support, with participants encouraged to keep diaries for discussion. Communication was maintained in person, by phone, or email.
219043479|NCT06105905|BEHAVIORAL|"Healthy futures (Futuros Saludables)"|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Teens and parent/guardian(s) will complete a 20-minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
219043480|NCT02178163|OTHER|cytology specimen collection procedure|Correlative studies
219043481|NCT02178163|OTHER|laboratory biomarker analysis|Correlative studies
219043482|NCT05452993|DEVICE|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
219043483|NCT05523765|DRUG|Brepocitinib|Oral Brepocitinib
219366897|NCT03209219|DRUG|Cyclosporine Pill|100mg， oral, bid
219366898|NCT03830216|DEVICE|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
219366899|NCT03830216|DEVICE|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
219366900|NCT05888974|DIAGNOSTIC_TEST|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
219539717|NCT02952456|OTHER|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
218927157|NCT06591637|PROCEDURE|Routine nursing care|"Routine nursing care during IVF treatment includes:~Pre-Treatment Counseling: Providing information and addressing patient questions.~Monitoring and Assessment: Regular checks of health, hormone levels, and ovarian function.~Medication Administration: Giving prescribed fertility drugs and other medications.~Assisting with Procedures: Preparing and assisting with egg retrieval and embryo transfer.~Emotional Support: Offering emotional and psychological support. Education: Instructing on medication use, self-care, and recognizing complications.~Follow-Up Care: Scheduling and managing follow-up appointments to monitor progress"
218927158|NCT06591637|DEVICE|"The booklet Fertility-Supporting Health Training"|This booklet was prepared in line with the relevant literature and contained educational content aimed at improving healthy lifestyle behaviours . The training booklet included information on the effects of factors such as obesity, weakness, exposure to environmentally harmful substances, smoking and caffeine use on fertility and the methods of coping with these factors. In addition, information on how to use proper nutrition, develop exercise habits and cope with stress was provided. The booklet was distributed to the women at at the onset of the study.
218927159|NCT06595771|DEVICE|continuous positive airway pressure|continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
218927160|NCT06595771|DEVICE|Polysomnography|"Polysomnography measures Apnea-hypopnea index (Minutes)~Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):~1. Apnea-hypopnea index: 5-14.9 olan; mild OSAS~2. Apnea-hypopnea index: 15-29.9: moderate OSAS~3. Apnea-hypopnea index ≥30: severe OSAS measures duration and percentage of time oxygen saturation dropped below 90% the total minutes of sleep"
218927161|NCT06591832|OTHER|Exercise|Virtual reality based progressive relaxation exercise
218927162|NCT06588023|OTHER|Observational study to evaluate professional practices|"It consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.~The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight)."
218927163|NCT06591325|OTHER|exercise|The RT program was performed in the morning and in groups, three days per week (Mondays, Wednesdays, and Fridays), in the University fitness facility over 12 weeks. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise session) with substantial RT experience to ensure consistent and safe exercise performance. Throughout the intervention period, the RT program was carried out on machines and free weights (Ipiranga Fitness, Presidente Prudente, SP, Brazil). The training program was carried out in groups. Participants performed four exercises for the trunk and upper limbs (chest press, seated row, triceps pushdown, preacher curl) and four exercises for the lower limbs (horizontal leg press, leg extension, lying leg curl, seated calf raise) in three sets of 10-15 repetitions based on previous guidelines (9,22).
218927164|NCT06591325|OTHER|Control|maintaining the daily routine
218927165|NCT06595524|BEHAVIORAL|online mindfulness-based intervention|The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
219043484|NCT03606759|PROCEDURE|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
219043485|NCT03606759|PROCEDURE|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
219539718|NCT03315247|BEHAVIORAL|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
219043486|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
218927166|NCT06591871|OTHER|Self-management educational program for post mastectomy lymphedema women|"The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage)."
218927167|NCT06600893|DEVICE|Low intensity shockwave therapy (LiSWT)|The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment
218927168|NCT06600893|DEVICE|Sham|With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.
218927169|NCT06595797|DRUG|HRS9531|HRS9531
218927170|NCT06595797|DRUG|HRS9531placebo|HRS9531placebo
218927171|NCT05042414|BEHAVIORAL|High intensity interval training|Four times four minutes treadmill interval training
218927172|NCT05042414|BEHAVIORAL|Moderate intensity training|Moderate intensity treadmill training
218927173|NCT05042414|BEHAVIORAL|Resting|No training
218927174|NCT03123731|BEHAVIORAL|Control Arm|Wearing Physical Activity Monitor
218927175|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity Intervention
218927176|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity and Diet Intervention
218927177|NCT06992375|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
218927178|NCT06992375|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
218927179|NCT06992375|OTHER|Exercise|The following exercise will be performed:push-ups
218927180|NCT06857864|DEVICE|Test myopia control lenses (BSL)|Test spectacle lenses will be provided to the subjects throughout the 1 year clinical trial.
218927181|NCT06586983|DRUG|Tenofovir Disoproxil Fumarate|300 mg po OD
218927182|NCT06592625|DRUG|SHR-A1811|SHR-A1811
218927183|NCT06592625|DRUG|Adebrelimab|Adebrelimab
218927184|NCT06603896|OTHER|Aromatherapy|Aromatherapy and placebo patches will be used
218927185|NCT06603857|DRUG|CE Ferulic|CE Ferulic serum regimen combined with laser treatment
219043487|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
219043488|NCT03057639|OTHER|Quality-of-Life Assessment|Ancillary studies
219043489|NCT03057639|OTHER|Questionnaire Administration|Ancillary studies
219043490|NCT02711423|DRUG|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
219043491|NCT02711423|DRUG|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
219043492|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
219043493|NCT06422767|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219043494|NCT06422767|DRUG|Placebo|Placebo will be administered.
219043495|NCT02917083|GENETIC|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."
219043496|NCT04081792|PROCEDURE|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
219043497|NCT06554327|DEVICE|Multiplex PCR|In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
219043498|NCT05748340|PROCEDURE|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
219043499|NCT05904093|DRUG|Fostamatinib|Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
219043500|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
219043501|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
219043502|NCT05329103|DRUG|PEEL-224|Lyophilized powder reconstituted with D5W
218927186|NCT06603857|DRUG|Sham Comparator|Vehicle serum regimen combined with laser treatment
218927187|NCT06603857|DEVICE|1927nm (Clear and Brilliant Perméa®)|non-ablative fractional diode laser
218927188|NCT04515810|OTHER|Internet-Based Intervention|Use smartphone application
218927189|NCT04515810|OTHER|Best Practice|Engage in standard care
218927190|NCT04515810|OTHER|Questionnaire Administration|Ancillary studies
218927191|NCT06613789|BIOLOGICAL|426c.Mod.Core-C4b|self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
218927192|NCT06613789|BIOLOGICAL|3M-052-AF|3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
218927193|NCT06613789|BIOLOGICAL|Aluminum hydroxide suspension (Alum)|Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
218927194|NCT06613789|BIOLOGICAL|Placebo and Diluent|Tris-NaCl buffer.
218927195|NCT06259916|OTHER|Alcohol|Participants in this condition will receive the standard alcohol dose
218927196|NCT06259916|OTHER|Cannabis|Participants in this group will self-administer legal-market flower cannabis
218927197|NCT03837041|OTHER|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
218927198|NCT06543199|PROCEDURE|local application of hyaluronic acid agent to the wound site|Evaluation of the effect of local use of hyaluronic acid agent on wound healing
218927199|NCT06543199|PROCEDURE|Local application of hypericum perforatum L to the wound site|Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi
218927200|NCT06543199|PROCEDURE|wound healing monitoring|Doctor visit on days 3, 7, 14, 21 and 28
219539719|NCT01877317|DEVICE|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
219539720|NCT01244620|DRUG|sitaxentan|sitaxsentan 100 mg QD for 6 days
219539721|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
219539722|NCT01244620|DRUG|sitaxsentan|sitaxsentan 100 mg QD for 6 days
218927201|NCT06602687|DEVICE|PICSI|The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).
218927202|NCT06591130|BEHAVIORAL|Youth culturally adapted manual assisted psychological intervention (Y-CMAP)|YCMAP (Youth culturally adapted manual assisted psychological intervention) is based on CBT principles. It comprises of 8-10 sessions delivered individually over 3 months (weekly for 1 month then fortnightly), lasting for 60 minutes. The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the self-harm attempt using virtual stories of four young people. Therapists and young person choose from a list of techniques those which are most relevant to the young person's problems. Therapy is therefore adapted to fit with the young person's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change. To help determine the most appropriate coping strategy a coping tree is designed. Training in assertiveness and anger management are offered to help the young person to develop resilience to cope with stress.
218927203|NCT06597318|OTHER|Hospitalization|The investigators collect PROMs amongst up to 1000 patients in general internal medicine divisions of all five Swiss university hospitals
218927204|NCT06112509|OTHER|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
218927205|NCT05543330|DRUG|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
218927206|NCT05543330|PROCEDURE|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
218927207|NCT05543330|DRUG|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
218927208|NCT06770543|OTHER|Inclisiran|There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.
219043503|NCT05329103|DRUG|FOLF+B|infusional 5-FU, LV, and bevacizumab
219539723|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
219539724|NCT01244620|DRUG|sitaxsentan|sitaxentan 100 mg QD for 6 days
219539725|NCT01244620|DRUG|sildenafil|sildenafil 20 mg TID for 6 days
219539726|NCT00620711|DEVICE|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
219539727|NCT05379647|DRUG|QN-019a|Experimental Interventional Therapy
219539728|NCT05379647|DRUG|Rituximab|Monoclonal Antibody
218927209|NCT06596278|DEVICE|Memesto|Memesto wearable audio player
218927210|NCT06587425|DRUG|LM-302+Candonilimab+Capecitabine|LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
218927211|NCT06588270|BEHAVIORAL|Virtual Reality Therapy for the Negative Symptoms of Schizophrenia|VRTNSS is a 12-session therapy using psychological intervention principles. Each therapy session will involve engaging with different VR based tasks where participants can experience different activities.
218927212|NCT06588270|BEHAVIORAL|Sham- VR|Patients will attend to VR sessions without the software created activities for treatment (sham-VR).
218927213|NCT06867588|DIAGNOSTIC_TEST|PSMA PET|patients included in the study will perfom a PSMA PET
218927214|NCT06679062|DRUG|Suvorexant|Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
218927215|NCT06679062|OTHER|Placebo|Film coated tablet to match the active drug.
219539729|NCT05379647|DRUG|Cyclophosphamid|Lympho-conditioning Agent
219539730|NCT05379647|DRUG|Fludarabine|Lympho-conditioning Agent
219539731|NCT05379647|DRUG|VP-16|Lympho-conditioning Agent
219539732|NCT00897377|RADIATION|Radiation therapy|
219539733|NCT00897377|DRUG|Temozolomide|
219539734|NCT05430776|RADIATION|Photobimodulation|laser therapy application
219539735|NCT02321098|DRUG|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
218927216|NCT06321263|OTHER|Peripheral Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
218927217|NCT06321263|OTHER|Inspiratory Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
218927218|NCT03012503|DRUG|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
218927219|NCT03012503|DRUG|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
218927220|NCT06586047|DIAGNOSTIC_TEST|PET imaging|Imaging with FDG PET/CT and Pyl PET/CT
219539736|NCT02321098|DRUG|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
219539737|NCT02321098|DRUG|Loceryl NL 15 months|Loceryl once/week for additional 15 months
218927221|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
218927222|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
218927223|NCT06578650|DEVICE|Synthetic Electrospun Fiber Matrix|Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound
218927224|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
218927225|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
218927226|NCT00791505|DRUG|ciprofloxacin|1500 mg a day for 10 days
218927227|NCT00791505|DRUG|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
218927228|NCT02080598|BEHAVIORAL|2 cigarettes in 15 minutes|
218927229|NCT04556799|PROCEDURE|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
218927230|NCT04556799|PROCEDURE|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
218927231|NCT06464822|PROCEDURE|Bariatric Surgery|weight control procedures, including intragastric balloon (IGT) \[5\], laparoscopic adjustable gastric banding (LAGB) \[6\], laparoscopic gastric bypass (LGB) operation and laparoscopic sleeve gastrectomy (LSG)
219043504|NCT05703022|OTHER|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
219043505|NCT04848571|COMBINATION_PRODUCT|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
219043506|NCT02650986|DRUG|Cyclophosphamide|Given IV
219043507|NCT02650986|DRUG|Decitabine|Given IV
219043508|NCT02650986|OTHER|Laboratory Biomarker Analysis|Correlative studies
219043509|NCT02650986|PROCEDURE|Leukapheresis|Undergo leukapheresis
219043510|NCT02650986|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
219043511|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
219043512|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
219043513|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
219043514|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
219043515|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
219043516|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
219043517|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
219043518|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
219043519|NCT06075524|PROCEDURE|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
219043520|NCT06075524|OTHER|Electronic Health Record Review|Medical records are reviewed
219043521|NCT06548412|DRUG|Gemcitabine|Given by IV
219043522|NCT06548412|DRUG|Cisplatin|Given by IV
219043523|NCT06548412|DRUG|Durvalumab|Given by IV
219539738|NCT02493283|DRUG|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
219539739|NCT02493283|DRUG|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
218927232|NCT04285619|OTHER|Positive expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects"
218927233|NCT04285619|OTHER|Neutral expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes."
218927234|NCT01646125|DRUG|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
219539740|NCT02493283|BIOLOGICAL|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
219539741|NCT02493283|BIOLOGICAL|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
219539742|NCT01610245|DRUG|Nitazoxanide|
219539743|NCT01610245|DRUG|Oseltamivir|
218927235|NCT01646125|DRUG|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
218927236|NCT01646125|DRUG|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
218927237|NCT02455830|BIOLOGICAL|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
218927238|NCT05350397|OTHER|How Important Is Acupress Applyıng In Atrıal Fıbrılatıon Treatment?|The acupressure wristband was correctly attached to the Experimental Group and acupressure was applied. The placebo group was fitted with an inverted and loose acupressure wristband. No intervention was applied to the control group.
218927239|NCT01376804|DRUG|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
218927240|NCT02841514|DEVICE|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
218927241|NCT02841514|OTHER|OTC toothpaste and an unoperated Y10 device|
218927242|NCT01691222|DEVICE|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
218927243|NCT00093704|DRUG|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
218927244|NCT03723304|PROCEDURE|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
218927245|NCT03723304|PROCEDURE|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
218927246|NCT00462813|DRUG|oral microencapsulated diindolylmethane|
218927247|NCT00462813|GENETIC|polymerase chain reaction|
218927248|NCT00462813|OTHER|cervical Papanicolaou test|
218927249|NCT00462813|OTHER|cytology specimen collection procedure|
218927250|NCT00462813|PROCEDURE|colposcopic biopsy|
218927251|NCT00959985|DEVICE|Compression Sleeve|Worn for a minimum of 12 hours per day
218927252|NCT00959985|DEVICE|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
219043524|NCT06548412|DRUG|CTX-009|Given by IV
219043525|NCT06003127|DEVICE|Transcranial Magnetic Stimulation-Electroencephalography|Transcranial magnetic stimulation of the cerebral cortex and measurement of TMS-evoked potentials in the EEG.
219043526|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit
219043527|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit.
219539744|NCT01610245|DRUG|Placebo Oral Tablet|
219539745|NCT01610245|DRUG|Placebo Oral Capsule|
219043528|NCT04166487|DRUG|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
219539746|NCT01663233|DRUG|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
219539747|NCT01663233|DRUG|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
219539748|NCT01663233|DRUG|Placebo|Matching placebo to LCZ696
219539749|NCT05947734|DEVICE|"VTS surgical robotic system"|"TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer."
218927253|NCT02005861|PROCEDURE|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
218927254|NCT00256672|DEVICE|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
218927255|NCT00004567|DRUG|Mycophenolate Mofetil|
219043529|NCT04166487|DRUG|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
219043530|NCT04166487|DRUG|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
219539750|NCT01197391|BIOLOGICAL|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
219043531|NCT04166487|DRUG|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
219539751|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose, 1 day
219539752|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
219539753|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
219539754|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
219539755|NCT05192720|DIETARY_SUPPLEMENT|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
219539756|NCT05192720|DIETARY_SUPPLEMENT|Placebo|drinking water with food colour
219539757|NCT04825314|DEVICE|Urethral catheter|All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
219539758|NCT03081481|DRUG|PRX302|Single prostate cancer lesion injected with PRX302
219539759|NCT05878964|OTHER|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
219539760|NCT05878964|OTHER|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
219539761|NCT05878964|OTHER|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
218927256|NCT02606201|OTHER|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
218927257|NCT00904033|DRUG|Calcitriol|Calcitriol tablet taken once per week.
218927258|NCT00904033|BEHAVIORAL|Exercise|Exercise consisting of progressive walking and resistance band training
218927259|NCT00904033|DIETARY_SUPPLEMENT|Multivitamin|
219539762|NCT02220647|DRUG|Linagliptin/Metformin FDC|
219539763|NCT02220647|DRUG|Linagliptin|
219539764|NCT02220647|DRUG|Metformin|
219539765|NCT00859105|DRUG|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
218927260|NCT01357850|DRUG|GSK716155|GSK716155
219539766|NCT00859105|DRUG|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
219539767|NCT00859105|DRUG|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
219539768|NCT00859105|DRUG|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
218927261|NCT01357850|DRUG|Placebo|Placebo
218927262|NCT02626312|OTHER|Laboratory Biomarker Analysis|Correlative studies
218927263|NCT02626312|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
218927264|NCT02626312|RADIATION|Radiation Therapy|Undergo radiation therapy
218927265|NCT02626312|OTHER|Survey Administration|Ancillary studies
218927266|NCT03282396|DRUG|Ibrutinib|Given PO
218927267|NCT05373407|OTHER|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
219539769|NCT02448862|DEVICE|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
219539770|NCT02586935|DRUG|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
219539771|NCT02586935|OTHER|Placebo|Administered orally after dispersion in approximately 100 ml of water
219539772|NCT00064038|DRUG|dexamethasone|Given orally
219539773|NCT00064038|DRUG|lenalidomide|Given orally
219539774|NCT00064038|OTHER|placebo|Given orally
218927268|NCT05940220|OTHER|Acetazolamide|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm
218927269|NCT05940220|OTHER|placebo|placebo
218927270|NCT03531346|OTHER|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
218927271|NCT02528981|DRUG|Probiotic|Lactobacillus GR-1 and RC-14
218927272|NCT02528981|DRUG|Placebo|
218927273|NCT01870518|DEVICE|Bilateral GPi DBS|
218927274|NCT01870518|DEVICE|Bilateral STN DBS|
218927275|NCT03202602|OTHER|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
218927276|NCT03202602|OTHER|Standard care|Office visits and monitoring of CPAP treatment at each visit.
218927277|NCT06119932|PROCEDURE|Evacuation for subdural hematoma by one burrhole|Evacuation for subdural hematoma by one burrhole
218927278|NCT05434286|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
218927279|NCT00090207|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
218927280|NCT00090207|DRUG|Comparator: ondansetron / Duration of Treatment: 4 days|
218927281|NCT02592590|BEHAVIORAL|Group A|"This condition receives three study components:~1. The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~2. The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~3. The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
218927282|NCT02592590|BEHAVIORAL|Group B|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
218927283|NCT02592590|BEHAVIORAL|Group C|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
218927284|NCT02592590|BEHAVIORAL|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
218927285|NCT04510818|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
219539775|NCT06603532|OTHER|low-load blood flow restriction (BFR) training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
218927286|NCT02698553|DRUG|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
218927287|NCT02698553|DRUG|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
218927288|NCT05505617|OTHER|Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.|"Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)"
218927289|NCT02298010|DRUG|Capecitabine, oxaliplatin|
218927290|NCT05447884|OTHER|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
219043532|NCT04166487|DIAGNOSTIC_TEST|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
219043533|NCT03909165|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
219043534|NCT03909165|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
218927291|NCT05447884|OTHER|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
218927292|NCT05447884|OTHER|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
218927293|NCT01748513|OTHER|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
218927294|NCT02565368|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
218927295|NCT02565368|DRUG|CKD-395 0.5/1000mg|single oral administration
218927296|NCT01177397|DRUG|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
218927297|NCT02352389|OTHER|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
218927298|NCT02352389|OTHER|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
218927299|NCT02352389|OTHER|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
219539776|NCT06603532|OTHER|low-load resistance training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
219539777|NCT02349763|DRUG|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
219539778|NCT02349763|DRUG|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
219539779|NCT03359863|DRUG|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
218927300|NCT02352389|OTHER|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
218927301|NCT02352389|OTHER|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
218927302|NCT06129708|OTHER|Aquatic Exercise|The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and
218927303|NCT06129708|OTHER|Aerobic Exercise|The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).
218927304|NCT06299059|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
218927305|NCT06299059|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
219539780|NCT01608360|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
219539781|NCT01608360|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
219539782|NCT06364267|DRUG|Tamoxifen 10 MG|Blinded tamoxifen 10 mg every other day
219539783|NCT06364267|DRUG|Exemestane 25 MG|Blinded exemestane 25 mg every other day
219539784|NCT01747174|DRUG|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
219539785|NCT01747174|DRUG|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
219539786|NCT01747174|PROCEDURE|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
219539787|NCT01875562|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
219539788|NCT04075578|DRUG|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
218927306|NCT05306535|PROCEDURE|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
218927307|NCT02734459|DRUG|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
219539789|NCT04881240|BIOLOGICAL|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
218927308|NCT05985252|PROCEDURE|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
218927309|NCT05985252|PROCEDURE|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
218927310|NCT03261752|DIAGNOSTIC_TEST|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
218927311|NCT01202968|PROCEDURE|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
218927312|NCT04632836|OTHER|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
218927313|NCT01565824|OTHER|web-based support|
218927314|NCT02395471|DEVICE|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
218927315|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
218927316|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
218927317|NCT01090661|DRUG|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
218927318|NCT01090661|DRUG|placebo|placebo intravenous (IV) single dose
218927319|NCT01090661|DRUG|placebo|placebo subcutaneous (SC) single dose
218927320|NCT00118417|DRUG|Clonazepam|Participants will receive clonazepam.
218927321|NCT00118417|DRUG|Sertraline|Participants will receive sertraline.
218927322|NCT00118417|BEHAVIORAL|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
218927323|NCT03891849|DRUG|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
218927324|NCT05353153|OTHER|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
218927325|NCT05353153|OTHER|standart care|no intervention no hypnosis
218927326|NCT05838118|DRUG|Fecal Microbiota Transplantation|Biologically active human fecal fluid (donor stool) is provided in fluid form.
218927327|NCT05838118|OTHER|Standard of Care for Chronic Kidney Disease|Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
219043535|NCT03909165|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
219043536|NCT03909165|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
218927328|NCT03847051|DIAGNOSTIC_TEST|MRI|Brain MRI without intravenous contrast
218927329|NCT00785785|DRUG|Nilotinib (AMN107)|
218927330|NCT00785785|DRUG|imatinib (STI571)|
218927331|NCT04417699|DRUG|TAS 102|Oral medication over Days 1-5
218927332|NCT04417699|DRUG|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
218927333|NCT03894683|DRUG|Melatonin 10 mg|Melatonin tablets (10 mg)
218927334|NCT03894683|DRUG|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
218927335|NCT04268381|OTHER|Biochemical analysis|aMMP-8 is measured by immunofluorometric assay (IFMA).
218927336|NCT06373952|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
218927337|NCT01295437|DEVICE|Vypro II mesh|partly absorbable mesh
218927338|NCT01295437|DEVICE|Premilene LP|lightweight mesh
219539790|NCT04881240|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
219539791|NCT04881240|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
218927339|NCT01295437|DEVICE|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
218927340|NCT00575640|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
218927341|NCT01383356|DRUG|Metformin Single Tablet|Metformin medium doseTablet
218927342|NCT01383356|DRUG|Linagliptin/Metformin Combo|Fixed dose combination
218927343|NCT01383356|DRUG|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
218927344|NCT02796183|DRUG|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
218927345|NCT04250909|DEVICE|Passeo-18|POBA
218927346|NCT04250909|DEVICE|Passeo-18 Lux|DCB
218927347|NCT02154698|OTHER|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
218927348|NCT02154698|OTHER|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
218927349|NCT01926262|BEHAVIORAL|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
218927350|NCT00140582|DRUG|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
218927351|NCT00921375|DRUG|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
218927352|NCT00893438|BEHAVIORAL|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
218927353|NCT00893438|OTHER|Usual care|Usual care treatment for adolescents with CFS
219539792|NCT04881240|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
219539793|NCT04881240|DEVICE|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
219539794|NCT04881240|PROCEDURE|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
218927354|NCT04567992|PROCEDURE|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
218927355|NCT01895556|OTHER|Information|
219539795|NCT06132841|DRUG|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
218927356|NCT01895556|OTHER|Control|
218927357|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
218927358|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
218927359|NCT00584636|DRUG|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
218927360|NCT05432440|BEHAVIORAL|The digital asthma education program|The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
218927361|NCT06238258|BEHAVIORAL|SPECTROM Training|Training regarding treatment of behavioral challenges in adults with intellectual disability
218927362|NCT05488665|DEVICE|Crush technique|Treatment for bifurcation with the Crush technique
218927363|NCT05488665|DEVICE|Culotte technique|Treatment for bifurcation with the culotte technique
218927364|NCT04931368|DRUG|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
218927365|NCT04931368|DRUG|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
218927366|NCT01532986|OTHER|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
218927367|NCT01532986|OTHER|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
218927368|NCT00265603|PROCEDURE|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
218927369|NCT06374563|OTHER|group 1 received topical Bee venom gel|Group 1 received a topical application of Bee Venom gel, 3 times per weeks. The wound dressing changed day after day and was cleaned every time with normal saline.
218927370|NCT06374563|OTHER|Group 2: Phonophoresis of Bee Venom gel|group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per weeks
219539796|NCT06132841|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
219539797|NCT02917525|DIETARY_SUPPLEMENT|Vitamin K2|
219539798|NCT02917525|OTHER|Placebo|
219539799|NCT00393276|BIOLOGICAL|Twinrix|Combined hepatitis A and hepatitis B immunization
219539800|NCT00393276|BIOLOGICAL|Decavac|Diphtheria and tetanus toxoid vaccine
219539801|NCT06444178|DRUG|Aspirin|Oral administration
219539802|NCT06444178|DRUG|REGN9933|Administered intravenous (IV)
219539803|NCT06444178|DRUG|REGN7508|Administered IV
219539804|NCT06444178|DRUG|Rivaroxaban|Oral administration
219539805|NCT05309876|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
219539806|NCT05628233|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
219539807|NCT06092801|OTHER|No intervention|No intervention
219539808|NCT03302039|DRUG|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
219539809|NCT03302039|DRUG|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
219205113|NCT06721351|DIAGNOSTIC_TEST|Diabetic Retinopathy screening Point of Care Artificial Intelligence|Random assignment of participants to intervention and control groups minimizes confounding variables. This ensures that any observed differences in outcomes are likely due to the intervention itself and not pre-existing differences between the groups. Participants of the DRES-POCAI study will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and EyeArt® system, an autonomous AI-based DR screening). The randomization will occur after consenting and completing the surveys, prior to conducting the DR screening process (for those randomized to the intervention group).
219205114|NCT06727526|OTHER|Acupressure|The literature found that acupressure positively affects child health, but no study was found to determine the effect of acupressure on pain and physiological parameters in children undergoing cardiac catheterization. Therefore, this study was designed to determine the effect of acupressure applied before and after cardiac catheterization on infants' pain levels and physiological parameters.
219205115|NCT06727526|OTHER|Placebo acupressure|In health sciences, placebo refers to an inactive intervention used to relax the patient and assess treatment efficacy. It may involve inert substances (e.g., sugar tablets, saline) or non-therapeutic interventions (e.g., artificial electrical stimulation or conversations). Expectancy theory often explains The placebo effect, which suggests that treatment expectations can induce physiological changes. Factors like age, cognitive development, and previous pain experiences influence children's responses to placebo. Parental belief in an intervention's efficacy can reduce a child's pain expectations and positively influence their perception of pain. Although the sample included young children, our study incorporated the placebo group to account for this effect, especially since the parents evaluated pain scores.
219539810|NCT03302039|DRUG|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
218927371|NCT03650231|OTHER|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
218927372|NCT02994446|DEVICE|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
218927373|NCT05204277|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
219205116|NCT06728449|DIETARY_SUPPLEMENT|Cumin tea|The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
219205117|NCT06728449|DIETARY_SUPPLEMENT|Ginger Tea|The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
218927374|NCT05204277|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
219205118|NCT06728449|DIETARY_SUPPLEMENT|Lemon Peel Tea|The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
219539811|NCT03302039|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
219539812|NCT05972174|BIOLOGICAL|mRNA-1018 for H5N8|Sterile liquid for injection
219539813|NCT05972174|BIOLOGICAL|mRNA-1018 for H7N9|Sterile liquid for injection
219539814|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only|Sterile liquid for injection
219539815|NCT05972174|BIOLOGICAL|mRNA-1018 for H7 Only|Sterile liquid for injection
219539816|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
219539817|NCT06696118|DEVICE|Electromagnetic Transduction Therapy (EMTT)|Subjects will be treated with Electromagnetic Transduction Therapy (EMTT) using the Curamedix MAGNETOLITH device. Treatments will be administered twice per week, for four weeks. Each treatment will have the following settings: level 8, 8Hz, and 10,000 pulses andwill take about 15 to 20 minutes. Treatments will be spaced 2-3 days apart.
219539818|NCT05630885|DRUG|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
219539819|NCT05630885|DRUG|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
219539820|NCT05630885|OTHER|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
218927375|NCT05204277|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
218927376|NCT02120898|DRUG|Imiquimod|Cream, generic formulation of the brand product.
218927377|NCT02120898|DRUG|Zyclara®|Cream, brand product.
218927378|NCT02120898|DRUG|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
218927379|NCT03501498|DRUG|Loperamide|Alters intestinal transit time.
218927380|NCT03501498|DRUG|Senna|Alters intestinal transit time.
218927381|NCT06359353|DRUG|Pitavastatin|"Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision."
219539821|NCT05630885|OTHER|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
219539822|NCT05922683|DRUG|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
218927382|NCT05606445|BEHAVIORAL|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
218927383|NCT03913520|OTHER|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
218927384|NCT03218046|BEHAVIORAL|EMDR|Eye Movement Desensitisation and Reprocessing
218927385|NCT05945342|DRUG|Escitalopram|The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
219205119|NCT06728449|DIETARY_SUPPLEMENT|Functional Tea|The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
219205120|NCT06728449|DIETARY_SUPPLEMENT|Conventional therapy|A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
219205121|NCT06728436|BEHAVIORAL|CuidaTEXT|CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.
219205122|NCT03092674|DRUG|Azacitidine|Given SC or IV
219205123|NCT03092674|DRUG|Cytarabine|Given IV
218927386|NCT05945342|OTHER|Interpersonal Psychotherapy for Adolescent|Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
218927387|NCT05945342|OTHER|Escitalopram combined with psychotherapy|The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
219205124|NCT03092674|DRUG|Decitabine|Given IV
219539823|NCT05922683|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
219539824|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
219539825|NCT06852651|PROCEDURE|Superficial Cervical Block (SCB) Group|"Patients in this group will receive a bilateral superficial cervical block under ultrasound guidance after anesthesia induction but before the surgical procedure begins.~The block will be performed using 0.1 mL/kg of 0.25% bupivacaine per side, targeting the superficial branches of the cervical plexus.~The primary goal is to assess its efficacy in postoperative pain management and its impact on recovery parameters."
219539826|NCT01262001|DRUG|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
219539827|NCT01262001|DRUG|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
219205125|NCT03092674|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205126|NCT03092674|DRUG|Midostaurin|Given PO
219205127|NCT03092674|BIOLOGICAL|Nivolumab|Given IV
218927388|NCT05945342|OTHER|Escitalopram combined with rTMS|The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
218927389|NCT05945342|DRUG|Escitalopram combined with sham rTMS|The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
219205128|NCT06735352|OTHER|virtual reality intervention|Evaluated the effect of virtual reality use in elderly people with mild cognitive impairment compared to a control group.
219205129|NCT06735235|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219205130|NCT06735235|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219205131|NCT06735235|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219205132|NCT06735235|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219205133|NCT06734455|OTHER|Robot-Assisted Pyeloplasty|Pyeloplasty in Children using robotic surgery
219205134|NCT06349889|DRUG|Adebrelimab|"Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT"
219205135|NCT06216665|OTHER|Continuous Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test
218927390|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One Placebo capsule to be taken 30 minutes after sachet in the morning."
218927391|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~\- One Placebo capsule to be taken 30 minutes after whey protein in the morning"
218927392|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning"
219539828|NCT04813081|PROCEDURE|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
219539829|NCT01370733|DEVICE|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
219539830|NCT01370733|DEVICE|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
219539831|NCT02866357|OTHER|No intervention|Just collection of nasopharyngeal aspirate for assessment
219539832|NCT05745363|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
219539833|NCT01909024|PROCEDURE|Coil embolisation|transjugular coil embolisation of pelvic veins
219539834|NCT01909024|PROCEDURE|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
219539835|NCT04050943|OTHER|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
219539836|NCT03510208|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
219539837|NCT03510208|BIOLOGICAL|Panitumumab|Given IV
219539838|NCT03510208|DRUG|Panitumumab-IRDye800|Given IV
219539839|NCT03510208|DEVICE|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
219539840|NCT05242705|DIAGNOSTIC_TEST|Serum Cysteine Rich Protein 61|collection of serum samples for chemical analysis
218927393|NCT04295278|DIAGNOSTIC_TEST|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
218927394|NCT01052337|DRUG|anaesthetics: sevofluorane|0.5%of sevofluorane with air
218927395|NCT05060367|DIETARY_SUPPLEMENT|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
218927396|NCT05060367|DIETARY_SUPPLEMENT|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
218927397|NCT00078598|DRUG|Rituximab or Iodine I 131 Tositumomab Therapy|
218927398|NCT06064214|PROCEDURE|u/s guided intermediate cervical plexus block|The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
218927399|NCT04444453|DEVICE|Wearable Pedometer|Pedometer worn on wrist
218927400|NCT00290316|PROCEDURE|Endoscopy ultrasound|
218927401|NCT02454088|OTHER|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
219539841|NCT06539676|DEVICE|Nighttime Aligners|Nighttime aligners worn 10-12 hours per day or night during 2-8 months
219539842|NCT06539676|DEVICE|Daytime Aligners|Daytime aligners worn 20-22 hours per day or night during 2-8 months
219539843|NCT03202238|OTHER|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
219539844|NCT03202238|DEVICE|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
219539845|NCT03202238|DEVICE|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
219539846|NCT00222625|DRUG|rFVIIa + (vit K in AO patients)|
219539847|NCT00222625|DRUG|FFP or aPCC+ vit K in AO treated patients|
219539848|NCT05201833|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
219539849|NCT05201833|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
219539850|NCT05201833|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
219539851|NCT05201833|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
219539852|NCT02181647|BEHAVIORAL|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
219539853|NCT05615909|RADIATION|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
219539854|NCT05615909|RADIATION|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
218927402|NCT02454088|DEVICE|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
218927403|NCT00631072|BIOLOGICAL|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
218927404|NCT00631072|DRUG|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
218927405|NCT06359730|OTHER|LARS score questionnaire|LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life
218927406|NCT05855811|DRUG|Dostarlimab|Dostarlimab should initiated within 6 months after the end of treatment for FPC.
219205136|NCT06216665|OTHER|Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test
219205137|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
219205138|NCT00766948|OTHER|There is no intervention, this is a biorepository.|There are no interventions in this study.
219205139|NCT06704906|DEVICE|Use of Viper Prime/Expedium system with Fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
219205140|NCT06726577|DRUG|TP04HN106|During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
218927407|NCT04916691|PROCEDURE|EPSB for rib fractures|EPSB for rib fractures
218927408|NCT04916691|DRUG|Ropivacaine|Standard of care weight-based optimal Ropivacaine dosing for ESPB
218927409|NCT05689996|DRUG|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
218927410|NCT01584375|OTHER|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~\--------------------------------------------------------------------------------"
218927411|NCT01584375|OTHER|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
218927412|NCT00780312|OTHER|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
218927413|NCT02046577|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol administration
218927414|NCT02046577|DIETARY_SUPPLEMENT|Placebo|Placebo liquid
218927415|NCT03473054|OTHER|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
218927416|NCT00506363|PROCEDURE|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
218927417|NCT03328091|OTHER|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
219205141|NCT06726577|DRUG|Saline|The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
219205142|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
219539855|NCT06443151|PROCEDURE|Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)|The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
219539856|NCT06443151|PROCEDURE|venous occlusion plethysmography|Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.
219539857|NCT06443151|DRUG|Acetylcholine|Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
219205143|NCT03535142|PROCEDURE|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
219205144|NCT06375941|OTHER|Observational|Observational
218927418|NCT03328091|OTHER|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
218927419|NCT02579304|PROCEDURE|transbronchial lung cryobiopsy|bronchoscopic sampling
218927420|NCT01929746|BIOLOGICAL|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
218927421|NCT00589199|PROCEDURE|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
218927422|NCT01042106|DRUG|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
218927423|NCT01042106|DRUG|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
218927424|NCT01907035|BEHAVIORAL|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
218927425|NCT01907035|OTHER|Usual care|
218927426|NCT01412684|PROCEDURE|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
218927427|NCT06256796|OTHER|fresh frozen plasma|repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
218927428|NCT00043979|DRUG|F-18 Fluorodeoxyglucose|
218927429|NCT00043979|BIOLOGICAL|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
218927430|NCT00043979|DRUG|cyclophosphamide|"Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
218927431|NCT00043979|DRUG|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
218927432|NCT00043979|DRUG|doxorubicin hydrochloride|Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
218927433|NCT00043979|DRUG|etoposide|50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
218927434|NCT00043979|DRUG|fludarabine phosphate|"Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
218927435|NCT00043979|DRUG|melphalan|Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
218927436|NCT00043979|DRUG|prednisone|Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
218927437|NCT00043979|DRUG|sirolimus|Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
218927438|NCT00043979|DRUG|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
218927439|NCT00043979|DRUG|vincristine sulfate|Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
218927440|NCT00043979|PROCEDURE|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
218927441|NCT00043979|DRUG|Filgrastim|
218927442|NCT00043979|PROCEDURE|Peripheral Blood Stem Cell donation|
218927443|NCT03904914|OTHER|TOCI|TOCI staging evaluated
218927444|NCT06214273|DEVICE|Low level diode laser|diode laser with a wave length range of 800-980 n m and power less than 500 ml
218927445|NCT06214273|DRUG|Chamomile|Chamomile 3% mucoadhesive gel
218927446|NCT06214273|DRUG|Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel|Topical anti-inflammatory, topical analgesic and topical antifungal
218927447|NCT06286488|DRUG|Vaxigrip|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
218927448|NCT02097264|DRUG|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
218927449|NCT02097264|DRUG|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
218927450|NCT02097264|DRUG|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
218927451|NCT03848026|OTHER|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
218927452|NCT03848026|OTHER|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
218927453|NCT03994848|BEHAVIORAL|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
219205145|NCT06733896|OTHER|trigger point pressure|The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.
219205146|NCT06733896|OTHER|neck exercises|Manual Cervical Traction Technique and others
219205147|NCT06886880|DEVICE|endoscope|findings in upper GIT Endoscopy
218927454|NCT05174403|OTHER|Cerebral and spinal cord magnetic resonance imaging|"Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium).~Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331)."
218927455|NCT04178603|OTHER|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
218927456|NCT02559024|DRUG|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
218927457|NCT05199103|DRUG|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
218927458|NCT04001322|OTHER|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
218927459|NCT04001322|OTHER|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
219205148|NCT06738784|BEHAVIORAL|Perceive, Recall, Plan and Perform (PRPP) evaluation|Passing the PRPP for 2 activities
219205149|NCT06887400|OTHER|Point of care ultrasound (POCUS)|In this study, POCUS was performed by the same emergency medicine physician who had basic and advanced USG training and at least two years of POCUS experience, in accordance with ACEP imaging protocols. A portable USG device with B-Mode, M-Mode, Color Doppler, Power Doppler, Pulsed Wave Doppler modes, and which can be used in all clinical modes with a single probe was used during the protocol application (Butterfly iQ+™, Burlington, United States). Eight abdominal points (epigastric region, right upper quadrant, right side, right lower quadrant, suprapubic region, left lower quadrant, left side and upper quadrant, umbilical region) were scanned with POCUS, the findings were recorded on the previously prepared form, the triage categories of the patients (cl) were updated and the patients were directed to the area where they would be examined with the form.
219205150|NCT06885528|DIAGNOSTIC_TEST|Complete Blood Count with differential|First CBC w/diff test ordered within 12 hours of presentation to ED as part of standard medical care. The MDW result will be used as diagnostic marker to predict the risk of developing sepsis.
219205151|NCT06883396|PROCEDURE|Medial Patellofemoral Ligament (MPFL) Reconstruction|For the purposes of this study, isolated MPFL reconstruction is defined as MPFL reconstruction with a tendon graft, with or without additional soft tissue procedure(s) including lateral retinacular lengthening or release, patellofemoral chondroplasty and/or cartilage restoration. No patient in the study will receive a bony realignment procedure to treat patellar instability.
219205152|NCT06885008|OTHER|Active video game|The participants played the video game using an Xbox 360 Kinect console connected to a 55-inch Full HD television. The video games were planned with the assistance of a physiotherapist, 3 days per week, with 8 repetitions during the first 4 weeks and 12 repetitions during the final 4 weeks. The warm-up and cool-down periods were designed and applicated.
219205153|NCT06885008|OTHER|Aerobic exercise|Aerobic exercise training was performed on a stationary bike, 3 days per week, for 20 minutes per session. The intensity of the aerobic exercise was determined using the Karvonen method. For the first 4 weeks, the intensity was set at 30-50% of the maximum heart rate (MHR), corresponding to light intensity, and was then increased to 50-70% (moderate intensity) for the following 4 weeks. A pulse oximeter (ChoiceMMed, China) was used to monitor the target heart rate. During both the warm-up and cool-down phases of the aerobic exercise, participants performed hip abduction and adduction, hip-knee flexion, heel raises, and mini squats while standing for 3-5 minutes.
219539858|NCT06443151|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
219539859|NCT06443151|DRUG|Ascorbic acid|Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
219539860|NCT06443151|PROCEDURE|venous phlebotomy|Venous blood samples will be collected to measure baseline cardiometabolic characteristics and isolate endothelial cell microvesicles for characterizations and in vitro experiments.
218927460|NCT04001322|OTHER|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
218927461|NCT04001322|OTHER|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
218927462|NCT04001322|OTHER|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
219539861|NCT04311164|OTHER|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
219539862|NCT04311164|OTHER|No intervention given.|No intervention was given.
219539863|NCT04849390|DRUG|ESO-101|Daily administration in the evening at bedtime for 28 days
219539864|NCT04849390|DRUG|Placebo|Daily administration in the evening at bedtime for 28 days
218927463|NCT04001322|OTHER|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
218927464|NCT04001322|OTHER|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
218927465|NCT01544257|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
218927466|NCT01544257|PROCEDURE|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
218927467|NCT04572789|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
218927468|NCT04572789|DIETARY_SUPPLEMENT|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
218927469|NCT00897234|OTHER|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
218927470|NCT05565625|OTHER|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
218927471|NCT05565625|OTHER|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
218927472|NCT05565625|OTHER|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
219539865|NCT03872596|DRUG|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
219539866|NCT03872596|DRUG|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
219539867|NCT03872596|DRUG|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
219539868|NCT03872596|DRUG|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
219539869|NCT03872596|DRUG|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
219539870|NCT03616405|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
219539871|NCT04515095|OTHER|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
219539872|NCT01953185|OTHER|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).
218927473|NCT05565625|OTHER|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
218927474|NCT05565625|OTHER|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
218927475|NCT05565625|OTHER|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
218927476|NCT04614974|DRUG|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
218927477|NCT04614974|OTHER|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
218927478|NCT00076635|DRUG|Interferon gamma-1b|200 mcg, SQ, 3x per week
218927479|NCT01635153|DIETARY_SUPPLEMENT|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
218927480|NCT01635153|DIETARY_SUPPLEMENT|Micronutrient|Dar-vite Multivitamin
218927481|NCT01000792|DRUG|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
218927482|NCT01000792|DRUG|Levocetirizine|Levocetirizine
219539873|NCT01953185|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
219205154|NCT06885008|OTHER|Conventional treatment|Convetional treatment included Hotpack, Transcutaneous Electrical Nerve Stimulation (TENS), and Ultrasound (US) modalities, were applied to the symptomatic knee(s) for a total duration of 30 minutes. Following this, the exercise program outlined below was performed with 3 sets of 10 repetitions each. The session lasted approximately 45 minutes.
219205155|NCT06884228|DEVICE|Vibrating mesh nebulisation|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled
219205156|NCT06884228|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
219539874|NCT02441621|OTHER|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
219539875|NCT02441621|OTHER|premedication|patients receive premedication with midazolam 7.5 mg p.o.
219539876|NCT02441621|OTHER|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
219539877|NCT02441621|OTHER|central venous catheter|a central venous catheter in the right or left internal jugular vein.
219539878|NCT02441621|OTHER|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
219539879|NCT02441621|OTHER|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
219539880|NCT02441621|OTHER|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
219539881|NCT01861535|DRUG|Imiquimod|
219539882|NCT01861535|PROCEDURE|Surgery|
219539883|NCT03122015|OTHER|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
219539884|NCT04345107|DRUG|SY-009|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
219539885|NCT04345107|DRUG|SY-009 matching placebo|SY-009 matching placebo
218927483|NCT02067481|BEHAVIORAL|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
218927484|NCT02231931|DRUG|Digoxin|single dose, fasted
218927485|NCT02231931|DRUG|Rosuvastatin|single dose, fasted
218927486|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
218927487|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
218927488|NCT02231931|DRUG|Metformin hydrochloride|single dose, fasted
218927489|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
218927490|NCT02231931|DRUG|Furosemide|single dose, fasted
218927491|NCT01032122|DRUG|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
218927492|NCT00455182|PROCEDURE|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
218927493|NCT00455182|PROCEDURE|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
218927494|NCT00455182|PROCEDURE|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
218927495|NCT05984576|RADIATION|Reirradiation|Reirradiation recurrent rectal cancer
218927496|NCT02694016|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
219539886|NCT06561607|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
219539887|NCT06561607|DRUG|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle."
219539888|NCT02645409|DRUG|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
219620321|NCT05958043|DEVICE|CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
219620322|NCT05682456|DIETARY_SUPPLEMENT|High-fat shake|The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
218927497|NCT01666041|DRUG|placebo|
218927498|NCT01666041|DRUG|fenofibrate/omega|
218927499|NCT01666041|DRUG|fenofibrate|
218927500|NCT00658359|DRUG|Cyclosporine|Standard of care
219043537|NCT04609020|DEVICE|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
219043538|NCT04609020|DRUG|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
219043539|NCT04609020|DEVICE|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
219539889|NCT02645409|DEVICE|Intraoperative fluorescence imaging system|
219620323|NCT05682456|DIETARY_SUPPLEMENT|Reference shake|The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
219620324|NCT03190993|OTHER|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
219620325|NCT03190993|OTHER|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
219620326|NCT06040515|DRUG|Probiotic Formula|Capsule with 25 billion live strains of Escherichia coli Nissle 1917
219620327|NCT01535417|DRUG|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
219620328|NCT01535417|DRUG|Celebrex|
218927501|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
218927502|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
218927503|NCT06367140|DEVICE|EMG-triggered CIMCT device|The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.
218927504|NCT06367140|DEVICE|general cycling training|The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
218927505|NCT02424877|PROCEDURE|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
218927506|NCT06317740|OTHER|green management intervention program|The program activities focused on integrating green management concepts into both theory and practice learning
218927507|NCT02754440|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
219043540|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
219539890|NCT05747807|DEVICE|Percutaneous intradiscal radiofrequency treatment|using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
218927508|NCT02386540|BEHAVIORAL|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
218927509|NCT03033095|DRUG|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
218927510|NCT02832115|DRUG|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
218927511|NCT02832115|DRUG|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
218927512|NCT03066947|BIOLOGICAL|SV-BR-1-GM|See above
218927513|NCT03066947|DRUG|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
218927514|NCT03066947|BIOLOGICAL|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
218927515|NCT03212781|DRUG|Iron dextran|total dose infusion
218927516|NCT03212781|DRUG|Ferrous Fumarate|oral tablets
218927517|NCT00002127|DRUG|Thalidomide|
218927518|NCT04568616|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
218927519|NCT01364844|DRUG|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
219539891|NCT00886522|PROCEDURE|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
219539892|NCT04440436|DRUG|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
218927520|NCT00445913|BIOLOGICAL|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
218927521|NCT00445913|BIOLOGICAL|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
219043541|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
219043542|NCT00676299|DRUG|JNJ-26483327|
219043543|NCT03804359|DRUG|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
219539893|NCT04407403|BEHAVIORAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
219539894|NCT04407403|BEHAVIORAL|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
219539895|NCT03419403|DRUG|Steroid eye drops|Solution, eye drop
219043544|NCT04339400|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
219043545|NCT03263208|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
219043546|NCT03263208|DRUG|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
219043547|NCT03263208|BIOLOGICAL|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
219539896|NCT03419403|DRUG|Vasoconstrictor eye drops|Solution, eye drop
218927522|NCT02560558|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
218927523|NCT01540552|OTHER|medical chart review|
219205157|NCT06886503|OTHER|Inspiratory Warm-Up - 60% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW60 arm, inspiratory muscle warm-up was performed at 60% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
219205158|NCT06886503|OTHER|Inspiratory Warm-up - 40% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW40 arm, inspiratory muscle warm-up was performed at 40% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
219539897|NCT03419403|OTHER|Cold compress|Cold compress
219539898|NCT03419403|DRUG|Ophthalmic steroid ointment|Ointment
219539899|NCT03419403|DRUG|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
219539900|NCT03419403|DRUG|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
219539901|NCT03419403|RADIATION|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
219539902|NCT04179058|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
219539903|NCT04290858|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
218927524|NCT01540552|PROCEDURE|computed tomography|
218927525|NCT01540552|PROCEDURE|computer-aided detection/diagnosis|
218927526|NCT02245217|DEVICE|PET/CT scan to assess treatment efficacy|
218927527|NCT00176917|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
219043548|NCT00952107|DEVICE|FLARE imaging system|Testing of operation of imaging system
219043549|NCT02018458|BIOLOGICAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
219043550|NCT02018458|BIOLOGICAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
219043551|NCT02857452|OTHER|SLA Questionnaire|
219043552|NCT02857452|OTHER|Lupus Qol Questionnaire|
219043553|NCT02493738|DRUG|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
219043554|NCT02493738|DRUG|Sporanox 100mg|Sporanox 100mg single dose under fed condition
219043555|NCT02107599|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
219043556|NCT06049888|BEHAVIORAL|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
218927528|NCT00176917|DRUG|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
218927529|NCT00533117|DRUG|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
219043557|NCT00779103|DRUG|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
219539904|NCT04825847|DEVICE|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
219539905|NCT04825847|OTHER|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
219539906|NCT02525445|PROCEDURE|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
219539907|NCT02525445|PROCEDURE|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle \[20\]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
219539908|NCT02525445|PROCEDURE|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
219539909|NCT02525445|PROCEDURE|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
219539910|NCT02828449|BEHAVIORAL|therapeutic education program|
219539911|NCT03468764|PROCEDURE|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
219539912|NCT03429725|OTHER|Online prime (statements writing)|Participants to write statements describing themselves or their similarities to their community.
219043558|NCT01407913|PROCEDURE|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
219043559|NCT02509065|DEVICE|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
219043560|NCT02509065|OTHER|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
219043561|NCT06034613|BEHAVIORAL|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
219043562|NCT03509038|OTHER|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
219043563|NCT04364529|OTHER|The pit crew model|The pit crew model
219043564|NCT03382483|DEVICE|Low intensity pulsed ultrasound|bone growth stimulator
219043565|NCT02559869|DRUG|[18F] GE-180|PET Tracer Ligand
219539913|NCT03429725|OTHER|Online prime (circling)|Participants to circle either pronouns denoting themselves or pronouns denoting others.
219043566|NCT02983006|BIOLOGICAL|DS-8273a|"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
219043567|NCT02983006|BIOLOGICAL|Nivolumab|5 mg/kg IV Q 3 weeks
219043568|NCT05409027|DRUG|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
219043569|NCT05409027|DRUG|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
219539914|NCT03429725|OTHER|Online prime (Sumarian Warrior)|Participants read a passage which described the factors that led to his success in a war.
219539915|NCT03429725|OTHER|Online prime (all)|Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
219539916|NCT03466866|BEHAVIORAL|PREVENT|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
219539917|NCT03466866|BEHAVIORAL|EUC (Enhanced Usual Care)|In-home diabetes education with no goal setting or telehealth visits
219539918|NCT00060697|BEHAVIORAL|Adolescent sexual activity education for mothers|
219539919|NCT04926480|PROCEDURE|low and high flow Anesthesia|comparison of hemodynamic changes in low and high flow anesthesia groups
218927530|NCT00533117|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
218927531|NCT00533117|BEHAVIORAL|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
218927532|NCT02910479|DEVICE|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
218927533|NCT02910479|DEVICE|Rectal thermometer|
218927534|NCT02910479|DEVICE|Esophageal thermometer|
218927535|NCT02910479|DEVICE|Vital sense capsule thermometer|
218927536|NCT02037399|DRUG|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
218927537|NCT02037399|DRUG|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
218927538|NCT04926389|OTHER|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
218927539|NCT04926389|OTHER|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
218927540|NCT01263197|DRUG|LY2216684|administered orally
218927541|NCT01263197|DRUG|albuterol|administered orally
218927542|NCT01263197|DRUG|propranolol|administered orally
218927543|NCT01263197|DRUG|placebo for LY2216684|administered orally
218927544|NCT01263197|DRUG|placebo for albuterol|administered orally
218927545|NCT01263197|DRUG|placebo for propranolol|administered orally
218927546|NCT04550884|DIAGNOSTIC_TEST|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
218927547|NCT05445791|DRUG|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
218927548|NCT05445791|OTHER|Placebo|Placebo 500 mg twice daily until disease progression
218927549|NCT06170294|DRUG|TCR-MAGE-A4 T-Cells|"* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells"
218927550|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
218927551|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
218927552|NCT02837770|DRUG|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
219539920|NCT02068820|DEVICE|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
219539921|NCT02068820|DEVICE|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
219539922|NCT02089685|BIOLOGICAL|Pembrolizumab|IV infusion
219539923|NCT02089685|BIOLOGICAL|PegIFN-2b|Subcutaneous infusion
219539924|NCT02089685|BIOLOGICAL|Ipilimumab|IV infusion
218927553|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
218927554|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
218927555|NCT02837770|DRUG|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
218927556|NCT03109496|OTHER|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
218927557|NCT02454517|BEHAVIORAL|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
219620329|NCT01447550|DRUG|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
219620330|NCT04976010|OTHER|No intervention|There will be no intervention in the separate goups, as this is an observational study
218927558|NCT02454517|BEHAVIORAL|Exercise Intervention|Undergo DPP lifestyle intervention
218927559|NCT02454517|OTHER|Informational Intervention|Receive oral and written guidelines and meet with dietician
218927560|NCT02454517|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205159|NCT06886503|OTHER|Sham|In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the sham arm, inspiratory muscle warm-up was performed at 15% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
219205160|NCT06738745|DRUG|HRS-2189|HRS-2189
219205161|NCT06738745|DRUG|HRS-5041|HRS-5041
219205162|NCT06739031|DEVICE|PEF Treatment|PEF Energy ablation of lung tumors
219205163|NCT06738108|DRUG|ECOS|The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE
219205164|NCT06738108|DRUG|Control group|Alteplase IV infusion
219205165|NCT06739382|COMBINATION_PRODUCT|extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.
219620331|NCT03726970|RADIATION|CBCT radiation|CBCT scanning
218927561|NCT02454517|OTHER|Quality-of-Life Assessment|Ancillary studies
218927562|NCT02454517|OTHER|Questionnaire Administration|Ancillary studies
218927563|NCT04641182|OTHER|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
218927564|NCT00809952|PROCEDURE|recombinant FSH|
218927565|NCT06232824|BEHAVIORAL|Tele-rehabilitation|The whole program is constituted of preoperative education and postoperative rehabilitation (in hospital and out of hospital). All the participants received the same preoperative education through the mobile phone application and oral communication. Participants in the intervention group get the multicomponent supervised tele-rehabilitation, while participants in the control group get the home-based self-rehabilitation. All the postoperative rehabilitation programs are presented and executed through the mobile phone application.
218927566|NCT03849508|DRUG|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
218927567|NCT03849508|DRUG|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
218927568|NCT01189032|DRUG|DE-089 ophthalmic solution|
219043570|NCT04098458|BEHAVIORAL|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
219043571|NCT02861950|DRUG|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
219043572|NCT02861950|DRUG|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
219043573|NCT05851729|OTHER|Kegal exercises with postural correction|Kegal exercises with postural correction
219043574|NCT05851729|OTHER|Kegal exercises without postural correction|Kegal exercises without postural correction
219043575|NCT01552239|RADIATION|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
219043576|NCT04033159|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
219043577|NCT02656641|BEHAVIORAL|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
219043578|NCT02656641|BEHAVIORAL|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
219043579|NCT04151602|BEHAVIORAL|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
219043580|NCT00661700|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
219043581|NCT00661700|DRUG|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
219043582|NCT06437210|DIETARY_SUPPLEMENT|Viusid Oral Solution|Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
219043583|NCT06437210|DIETARY_SUPPLEMENT|Placebo|Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
219043584|NCT02845752|DRUG|Stiolto Respimat|Oral inhalation spray
219539925|NCT03965377|BEHAVIORAL|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
218927569|NCT01189032|DRUG|DE-089 ophthalmic solution|
219539926|NCT00318461|DRUG|liraglutide|0.6 mg for s.c. (under the skin) injection.
219539927|NCT00318461|DRUG|metformin|1.5-2.0 g tablets
219539928|NCT00318461|DRUG|glimepiride|4 mg tablets
218927570|NCT01189032|DRUG|Placebo ophthalmic solution|
218927571|NCT03319147|DIETARY_SUPPLEMENT|Active|4g of essential amino acids
218927572|NCT03319147|DIETARY_SUPPLEMENT|Placebo|4g of maltdextrin
218927573|NCT00473382|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
218927574|NCT00473382|DRUG|Sham injection|
219043585|NCT02845752|DRUG|Placebo Respimat|Oral inhalation spray
219043586|NCT00006489|BEHAVIORAL|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
219043587|NCT00006489|DRUG|Naltrexone|Daily dosing 100 mg for 24 weeks
219043588|NCT00006489|DRUG|Placebo|Pill Placebo daily dosing 24 weeks
219043589|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
219043590|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
219043591|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
219043592|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
219043593|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
219043594|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
219043595|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
219205166|NCT06739382|COMBINATION_PRODUCT|two β-lactam antibiotics plus a single non-β-lactam antibiotic|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients
219205167|NCT06739382|OTHER|Control group received standard therapy|Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
219539929|NCT00318461|DRUG|placebo|Glimepiride placebo 1 mg and 2 mg tablets
219539930|NCT00318461|DRUG|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
219205168|NCT06740331|BEHAVIORAL|Analysis of social cognition, memory functioning, and executive functioning processes|Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
219539931|NCT00318461|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
219539932|NCT00318461|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
219539933|NCT00863083|BEHAVIORAL|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
219539934|NCT03372876|DIETARY_SUPPLEMENT|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
219539935|NCT00171886|DRUG|Octreotide|
218927575|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with external ureteral catheter|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.
219043596|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
219043597|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
218927576|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with double J internal ureteral stent|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
218927577|NCT04924881|DRUG|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
218927578|NCT04924881|OTHER|Placebo granules|Placebo granules once daily for 8 weeks
219539936|NCT05134220|DIAGNOSTIC_TEST|Serum Calcium|"* Serum calcium level.~* Serum phosphorus level. will be measured to all study population"
218927579|NCT04365608|PROCEDURE|Direct laryngoscopy|standard laryngoscope with Macintosh blade
218927580|NCT04365608|PROCEDURE|Vie Scope laryngoscopy|Vie Scope with dedicated bougie stylet
218927581|NCT02476461|DRUG|xiapex|
218927582|NCT02476461|PROCEDURE|percutaneous needle fasciotomy|
218927583|NCT01134055|DRUG|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
218927584|NCT01134055|DRUG|placebo|placebo eye drops
218927585|NCT01134055|BIOLOGICAL|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
218927586|NCT00275509|DRUG|Thymoglobulin|
218927587|NCT00275509|DRUG|Daclizumab|
218927588|NCT00275509|OTHER|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
218927589|NCT00275509|DRUG|Mycophenolate mofetil|2 gm/day. Standard of care
218927590|NCT00275509|DRUG|Tacrolimus|To achieve serum level of 8-10 ng/ml.
218927591|NCT00275509|DRUG|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
218927592|NCT00275509|DRUG|Prednisone|Taper over three months to 5 mg daily
218927593|NCT00275509|DRUG|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
218927594|NCT00464776|DRUG|Aliskiren|
219539937|NCT04940494|OTHER|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
219539938|NCT00111098|DRUG|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
219539939|NCT02338583|DEVICE|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
218927595|NCT00464776|DRUG|Aliskiren|
218927596|NCT00464776|DRUG|Aliskiren|
218927597|NCT00464776|DRUG|Aliskiren|
218927598|NCT01585376|GENETIC|mutation analysis|
218927599|NCT01585376|GENETIC|nucleic acid sequencing|
218927600|NCT01585376|OTHER|laboratory biomarker analysis|
219539940|NCT01372345|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
219539941|NCT04134091|DRUG|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
219539942|NCT04134091|DRUG|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
219539943|NCT04134091|DRUG|Placebo|Oral matching placebo capsule administered as BID
219539944|NCT04673721|DIETARY_SUPPLEMENT|Fortified eggs|Average 12 eggs consumed per week
218927601|NCT03308370|BIOLOGICAL|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
218927602|NCT05469659|DRUG|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
218927603|NCT05469659|DRUG|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
218927604|NCT03755349|DEVICE|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
218927605|NCT03755349|OTHER|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
218927606|NCT02874989|DRUG|Dasatinib + Quercetin|
218927607|NCT02874989|DRUG|Placebo|
218927608|NCT04883372|OTHER|continuous glucose monitoring|a continuous glucose monitoring CGM system through the ETAPES telemedicine program
218927609|NCT01967329|DRUG|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
218927610|NCT01967329|DRUG|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
219539945|NCT04673721|BEHAVIORAL|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
219539946|NCT04673721|DIETARY_SUPPLEMENT|Non-egg supplemented|2 or less eggs consumed per week
218927611|NCT01967329|DRUG|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
219539947|NCT04673721|BEHAVIORAL|Usual care diet|Consistency with current diet without consideration of intermittent fasting
218927612|NCT02640534|DRUG|Enzalutamide|Enzalutamide 160 mg od until disease progression
218927613|NCT02640534|DRUG|Metformin|850 mg bid until disease progression
218927614|NCT04846738|DEVICE|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
218927615|NCT04846738|DEVICE|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
218927616|NCT06246461|DRUG|capecitabine|The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
218927617|NCT04876469|PROCEDURE|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
218927618|NCT05064137|DRUG|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
219539948|NCT03206008|DRUG|Magnesium Sulfate|
218927619|NCT05064137|DRUG|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
218927620|NCT05064137|DRUG|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
218927621|NCT01282762|BIOLOGICAL|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
218927622|NCT01282762|BIOLOGICAL|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
218927623|NCT06516016|RADIATION|PET|\[18F\]DPA-714 will be injected intravenously as a 1 minute intravenous bolus injection and dynamic PET acquisition will last 90 min. The aim is the quantification of the neuroimmune reaction during neuroinflammation process.
218927624|NCT06516016|OTHER|MRI 3T|Brain MRI will aim at providing imaging biomarkers which will allow evaluating brain structure, microstructure, iron load, myelin, neurodegeneration of the substantia nigra and locus coeruleus, functional connectivity, brain perfusion and the glymphatic system.
219043598|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
219043599|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
219043600|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
219043601|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
219043602|NCT00654069|DRUG|Placebo|2 tablets every 6 hours for 48 hours
219043603|NCT00654069|DRUG|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
219043604|NCT00654069|DRUG|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
219043605|NCT00737516|BIOLOGICAL|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
219043606|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
219043607|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
219043608|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
219043609|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
219043610|NCT01072695|DRUG|GS-9256|75 mg BID x 28 days
219043611|NCT01072695|DRUG|GS-9190|40 mg BID x 28 days
219043612|NCT01072695|DRUG|Ribavirin|1000-1200 mg/day given BID
219043613|NCT01072695|DRUG|Peginterferon alfa-2a|180 ug q week
219043614|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
219043615|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
219043616|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
219043617|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
219043618|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
219043619|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
219043620|NCT01067404|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
219539949|NCT03206008|DRUG|Normal saline|Placebo
219539950|NCT06177418|PROCEDURE|Transumbilical laparoscopic appendectomy + Glove finger technique|Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.
218927625|NCT06516016|OTHER|Oculomotricity assessment|Recording eye movements in a controlled environment (requiring no specific room or area) in binocular vision at a frequency \> 500Hz, while retaining infrared video footage of eye movements for high-quality clinical monitoring.
218927626|NCT06516016|OTHER|Magnetoencephalography assessment|Recording brain magnetic activity using the Elekta Neuromag® TRIUX Magnetoencephalograph ; The participant will be comfortably seated in an adjustable-height chair. The device is enclosed in a shielded room isolated from external electric and magnetic fields to measure the extremely weak magnetic activities produced by the brain.
219539951|NCT06177418|PROCEDURE|Standard transumbilical laparoscopic appendectomy|Standart transumbilical laparoscopic appendectomy
219366901|NCT01649947|DRUG|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
219366902|NCT01649947|DRUG|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
219366903|NCT01649947|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
219539952|NCT06560853|OTHER|Comprehensive School Health Programme|"Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic."
219539953|NCT06560853|OTHER|Deworming and vitamin A supplementation delivery|Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
219539954|NCT01908556|DRUG|Letrozole|
219539955|NCT01924377|PROCEDURE|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
218927627|NCT06516016|OTHER|Body posture and gait assessment|The acquisition of kinematic gait parameters will be achieved ; markers are positioned on the different segments of members, recognized by a camera system positioned on the walls. Neurophysiologic muscular activity of the lower limbs will also be recorded.
219620332|NCT05770141|PROCEDURE|laser hemorrhoidoplasty|A skin incision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
218927628|NCT06516016|OTHER|Voice recording|Participants will be recorded during a single session at every visit upon baseline with a professional quality head mounted microphone.
218927629|NCT06516016|OTHER|Video-polysomnography|Participants will complete standard sleep questionnaires before the visit and perform neurophysiological tests including cognitive tasks before and after the sleep recording.
219043621|NCT02385799|DRUG|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
219043622|NCT02385799|DRUG|Sertraline|Active medication
219366904|NCT01649947|DRUG|Bevacizumab|"Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
219366905|NCT00124280|DRUG|RAD001|
219043623|NCT02016963|BIOLOGICAL|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
219043624|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
219043625|NCT04688164|DRUG|REL-1017|REL-1017 tablet
219043626|NCT04688164|DRUG|Placebo|Placebo tablet
219043627|NCT04464070|DIETARY_SUPPLEMENT|niacin|induce biosynthesis of PGD2
218927630|NCT06516016|BIOLOGICAL|Blood sampling, skin biopsy, excreta sampling, lumbar puncture|Experimental analyses, genetic and multi-OMIC analyses for biomarker research.
218927631|NCT01963078|DRUG|Oxytocin|
219043628|NCT04464070|DRUG|aspirin|inhibition of cyclooxygenase
219043629|NCT04464070|OTHER|PGD2|labeled precursor
219366906|NCT03295214|DRUG|Acetaminophen|Acetaminophen given for pain relief
219366907|NCT06355882|PROCEDURE|Anesthetic infiltration|Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
219366908|NCT00899340|GENETIC|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
219366909|NCT00899340|GENETIC|microarray analysis|microarray analysis
219366910|NCT00899340|GENETIC|protein expression analysis|protein expression analysis
219366911|NCT00899340|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
218927632|NCT01963078|DRUG|Placebo|
218927633|NCT05679258|DRUG|HLX15|A single dose (8 mg/kg) of HLX15 via intravenous infusion.
218927634|NCT05679258|DRUG|US-sourced DARZALEX®|A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
218927635|NCT05679258|DRUG|CN-sourced DARZALEX®|A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
218927636|NCT05679258|DRUG|EU-sourced DARZALEX®|A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
218927637|NCT03920319|DRUG|Bupropion|Bupropion 150 mg sustained release
218927638|NCT03920319|OTHER|Placebo|
219366912|NCT00899340|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219366913|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
219366914|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
218927639|NCT03388164|DRUG|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
218927640|NCT03388164|DRUG|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
218927641|NCT02359097|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
218927642|NCT02359097|DRUG|Ferumoxytol|Given IV
219366915|NCT05123235|BEHAVIORAL|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
219620333|NCT05770141|PROCEDURE|open surgical hemorrhoidectomy|The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
219366916|NCT01920802|DRUG|olanzapine|5mg BID up to 4 weeks
219366917|NCT01920802|DRUG|iloperidone|6 mg BID up to 4 weeks
218927643|NCT02359097|DRUG|Gadoteridol|Given IV
218927644|NCT02359097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
218927645|NCT04609176|DRUG|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
218927646|NCT04609176|DRUG|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
218927647|NCT02314819|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
219366918|NCT01920802|DRUG|Placebo|BID up to 4 weeks
219620334|NCT05331131|DRUG|Ketamine Topical|Ketamine hydrochloride in mouthwash form
218927648|NCT02314819|DRUG|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
218927649|NCT04587661|BEHAVIORAL|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
218927650|NCT04587661|BEHAVIORAL|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
218927651|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
218927652|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
218927653|NCT00304551|DRUG|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
218927654|NCT00304551|DRUG|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
218927655|NCT00304551|DRUG|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
218927656|NCT03023397|BIOLOGICAL|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
218927657|NCT03705689|OTHER|validation of Bitts|No intervention, observation of photographs of stool
219043630|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
219043631|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
219043632|NCT06724679|OTHER|Utilisability of an immersive VR device in a functional restoration program (FRP) for patients with chronic low back pain.|"Patients participating will engage in three 20-minute VR sessions per week, in addition to the standard FRP program, for a duration of four to five weeks. The sessions will consist of a series of pre-programmed exercises designed to facilitate various trunk movements (flexion, extension, inclination, rotation) through exergames. Each exercise will last an average of 5 to 7 minutes. These exercises have been developed in collaboration between the company providing the VR device and the rehabilitation teams. Patients will be set up by a healthcare provider in a dedicated room for VR use. The provider will configure the device, assist the patient in donning it, and initiate the program, will remain present throughout the session to monitor for any adverse effect~. While the specific exercises may vary, the total duration of the session will be 20 minutes, consisting of various exercises interspersed with breaks. The principal investigator will propose a standardized series of exercises,"
219043633|NCT04415541|BEHAVIORAL|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
219043634|NCT04415541|BEHAVIORAL|Usual Care|Conventional treatment offered in the community.
219043635|NCT00058825|BIOLOGICAL|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
219043636|NCT00058825|DRUG|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
219043637|NCT00058825|PROCEDURE|Stem Cell Transplant|Day 0: Donor stem cells infused.
219043638|NCT00058825|RADIATION|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
219043639|NCT00058825|DRUG|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
219043640|NCT01248858|DRUG|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
218927658|NCT04341246|DEVICE|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
218927659|NCT02387502|DEVICE|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
218927660|NCT02387502|DEVICE|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
218927661|NCT02387502|DEVICE|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
219539956|NCT01924377|PROCEDURE|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
218927662|NCT05805917|DEVICE|Neoviderm Skin Emulsion medical device|Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
218927663|NCT05805917|DRUG|Connettivina 0.2% Cream|Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
218927664|NCT02466893|OTHER|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
218927665|NCT04434443|OTHER|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
218927666|NCT04434443|OTHER|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
218927667|NCT03171961|BEHAVIORAL|online visit group|subjects has online visit with dietitian every 2 weeks+diet
218927668|NCT03171961|BEHAVIORAL|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
218927669|NCT03171961|BEHAVIORAL|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
218927670|NCT04708561|BEHAVIORAL|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1\) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
218927671|NCT03177655|OTHER|Guided Imagery|Guided Imagery meditation
218927672|NCT03177655|OTHER|Journaling|Keeping a journal
219043641|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
219620335|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
219043642|NCT03806920|DIETARY_SUPPLEMENT|Intervention A|
219043643|NCT03806920|DIETARY_SUPPLEMENT|Intervention B|
219043644|NCT03806920|DIETARY_SUPPLEMENT|Intervention C|
219043645|NCT03806920|DIETARY_SUPPLEMENT|Intervention D|
219043646|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
219539957|NCT05790824|OTHER|Spa therapy|"The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~* 54 treatments among the following treatments:~  * Swimming pool, 15 minutes (code 201)~ * Bath with aerobath, 10 minutes (code 205)~ * Bath with immersion shower, 10 minutes (code 206)~ * Cataplasm in multiple local application, 10 minutes (code 408)~* 18 sessions of mobilization pool, 15 minutes (code 601)"
218927673|NCT04601961|DRUG|Propofol|"Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1."
218927674|NCT04601961|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
218927675|NCT01146795|DRUG|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
218927676|NCT01146795|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
218927677|NCT01146795|DRUG|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
218927678|NCT01538095|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
218927679|NCT01538095|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205169|NCT06093438|DRUG|Toripalimab|Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
219205170|NCT06778200|OTHER|client interview|using a data collection form clients voluntarily described services provided by practitioner
219539958|NCT04137575|BEHAVIORAL|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
219539959|NCT04137575|BEHAVIORAL|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
219205171|NCT06778200|OTHER|practitioner responses|completed reflections after each module completion
219205172|NCT06737185|OTHER|EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting|Comparison of FS4T and EAFS4T
219205173|NCT06737133|PROCEDURE|Surgery|Rhinoplasty
219205174|NCT06162052|OTHER|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
219205175|NCT06303544|BEHAVIORAL|Wedge 1|Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
219205176|NCT05591794|OTHER|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
219205177|NCT05591794|DIETARY_SUPPLEMENT|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
219205178|NCT05591794|OTHER|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
219539960|NCT00426621|DRUG|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
219539961|NCT00426621|DRUG|Placebo|4 grams per knee, 4 times per day, for 12 weeks
218927680|NCT01538095|OTHER|Pharmacological Study|Correlative studies
218927681|NCT01538095|BIOLOGICAL|Trebananib|Given IV
218927682|NCT00232752|DEVICE|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
218927683|NCT06239818|DEVICE|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
218927684|NCT06239818|OTHER|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
218927685|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
218927686|NCT06480591|OTHER|Blood Draw|The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
218927687|NCT00385216|DRUG|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
218927688|NCT00385216|OTHER|Placebo|Placebo nasal spray 0mg x 1 before surgery
218927689|NCT06540417|DEVICE|External trigeminal nerve stimulation|The stimulation parameters were set to 120Hz, 250μs, 30s ON-30s OFF, with the intensity adjusted for patient comfort.
218927690|NCT06112093|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
218927691|NCT06112093|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
218927692|NCT06411561|BEHAVIORAL|SLEEP + COG|Combination of SLEEP and COG interventions
218927693|NCT06411561|BEHAVIORAL|COG|Daily 30-minute session of computerized cognitive training
218927694|NCT06411561|BEHAVIORAL|SLEEP|Nighttime use of both ear plugs and eye masks
218927695|NCT06411561|BEHAVIORAL|AC|Educational modules on cognitive and sleep health
218927696|NCT01088178|DEVICE|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
218927697|NCT04431817|DEVICE|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
218927698|NCT06475976|DIAGNOSTIC_TEST|Chest computed tomography (CT) with angiography|A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.
218927699|NCT06475976|DIAGNOSTIC_TEST|Bronchoscopy with bronchoalveolar lavage|During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.
218927700|NCT06475976|DIAGNOSTIC_TEST|Echocardiography|An echo uses sound waves to create computer pictures of the heart.
218927701|NCT06475976|DIAGNOSTIC_TEST|"24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)"|24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
218927702|NCT02745119|DRUG|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
218927703|NCT02973750|PROCEDURE|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
218927704|NCT02973750|PROCEDURE|Tissue Collection|Tissue collection during debulking surgery.
218927705|NCT02973750|PROCEDURE|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
218927706|NCT02444078|OTHER|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
218927707|NCT02444078|OTHER|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
218927708|NCT00432172|DRUG|Epirubicin|
218927709|NCT00432172|DRUG|Cyclophosphamide|
218927710|NCT00432172|DRUG|Docetaxel|
218927711|NCT00432172|DRUG|Exemestane|
218927712|NCT00432172|DRUG|Goserelin|
218927713|NCT00432172|DRUG|Carboplatin|
219205179|NCT06492213|OTHER|No interventions|It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
219205180|NCT06638645|PROCEDURE|VATS/RATS anatomical lung resection|Perioperative care according to the ERAS protocol for lung surgery
218927714|NCT06414629|OTHER|Simulation Based Mentorship Program|"In this program, local level mentors were developed to provide regular mentorship on low-dose high-frequency approach in contrast to one-time coaching in a long gap. This program combined the existing package of the continuum of care along with Helping Babies Survive (HBS) \& Helping Mothers Survive (HMS) guidelines, adopting a simulation-based onsite mentoring and coaching approach. The mentors provided monthly mentorship on following seven modules topics to the nurses of the intervention birthing centers:~1. Infection prevention~2. Antenatal care and counseling~3. Essential care of labor and birth~4. Helping babies breathe~5. Bleeding after birth~6. Essential care of labor and birth~7. Postnatal care and counseling~Every monthly session was followed by four weekly practice sessions. The nurses from intervention birthing centers were also called mentees."
218927715|NCT00460616|DRUG|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
218927716|NCT02791672|BEHAVIORAL|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
218927717|NCT03399188|PROCEDURE|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
218927718|NCT02425943|DEVICE|injectable poly-L-lactic acid Sculptra Aesthetic|
218927719|NCT03810105|DRUG|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
218927720|NCT03810105|DRUG|Durvalumab|Durvalumab 1500mg IV monthly
218927721|NCT06492525|DRUG|Ensartinib|225 mg oral dose on day 1 in period 1 and on day 18 in period 2
218927722|NCT06492525|DRUG|Rifampicin|600 mg QD from day 9 to day 22 in period 2
219043647|NCT03488212|BEHAVIORAL|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
219043648|NCT03488212|BEHAVIORAL|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
219205181|NCT06741384|OTHER|Diaphragmatic breathing exercises|Participants will be directed to position their hands on the rectus abdominis muscle located under the anterior chest wall while resting in a hook position. They will be instructed to inhale slowly and deeply via the nostrils, expanding their abdomen without raising their upper chest, and resting their shoulders. Following the cessation of respiration, the woman will slowly exhale by pursing her lips. A respiratory cycle will consist of a three-second inhalation, a three-second pause, and a six-second exhalation. The diaphragmatic training regimen will consist of doing 3-5 sets of 5-10 deep breaths, with 2-minute intervals of rest in between sets.
219205182|NCT06741384|OTHER|Aerobic training|The women will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
219205183|NCT06742827|OTHER|educational intervention based on information and communication technologies.|will be carried out through a mobile application, which will be installed on each person's device, as well as short text messages will be sent and counseling will be available 24/7. The contents of the application will be educational and will be elaborated framed in the following components: understanding of the disease and the consequences of not adhering (comprehensibility) to the treatment, maintaining a balance between the psychosocial resources that the patient has and the demands that the disease places on them (manageability), and the involvement of the person in decision making and the sense of continuing to adhere to hemodialysis treatment (meaningfulness).
219205184|NCT01242215|DEVICE|ipragliflozin|oral
219205185|NCT01242215|DRUG|Placebo|oral
219205186|NCT01242215|DRUG|Sulfonylurea|oral
219539962|NCT01655654|BEHAVIORAL|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
219539963|NCT01655654|BEHAVIORAL|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
219539964|NCT01655654|OTHER|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
218927723|NCT06492525|DRUG|Itraconazole|200 mg QD from day 9 to day 19 in period 2
218927724|NCT06492525|DRUG|Ensartinib|100 mg oral dose on day 1 in period 1 and on day 12 in period 2
218927725|NCT02790190|OTHER|Radiotherapy dose|
218927726|NCT01106248|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
218927727|NCT02544581|OTHER|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
219539965|NCT06524921|PROCEDURE|dental pulpectomy using metapex|Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
219539966|NCT06524921|PROCEDURE|dental pulpectomy using biodentine|Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
218927728|NCT03725891|DRUG|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
219539967|NCT03612440|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
219539968|NCT03612440|OTHER|normal saline|receive matching placebo (equal volum of normal saline)
219539969|NCT03904329|DRUG|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
219620336|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
219539970|NCT06970028|OTHER|Quantitative Sensory Testing|We will perform QST on the dominant hand and lower back.
218927729|NCT03725891|DRUG|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
218927730|NCT03725891|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
218927731|NCT00357903|BIOLOGICAL|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
218927732|NCT00606593|DRUG|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927733|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927734|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927735|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927736|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927737|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
219539971|NCT06970028|OTHER|Questionnaires regarding pain and quality of life|Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.
219539972|NCT03435835|DEVICE|Control/Sham Treatment|Water at 33ºC was circulated through water-circulating trousers.
219539973|NCT03435835|DEVICE|Heat Therapy (HT)|Water at 42-43ºC was circulated through the water-circulating trousers.
219539974|NCT00179231|DRUG|olanzapine vs. clozapine|
219539975|NCT04793607|OTHER|Pleural procedures|Any pleural procedure that removes fluid
219539976|NCT02278757|OTHER|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
219539977|NCT02278757|OTHER|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
219539978|NCT05912127|DEVICE|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
219539979|NCT02314403|DRUG|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
218927738|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927739|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
219539980|NCT02314403|DRUG|ATG|A T-Cell Depleting Agent
218927740|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
219043649|NCT03488212|BEHAVIORAL|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
219043650|NCT03488212|BEHAVIORAL|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
219539981|NCT02314403|DRUG|Rituximab|B-Cell Depleting Agent
219043651|NCT03488212|BEHAVIORAL|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
219043652|NCT03488212|BEHAVIORAL|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
219043653|NCT05970315|BEHAVIORAL|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
219043654|NCT05970315|BEHAVIORAL|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
219539982|NCT02314403|RADIATION|Total Body Irradiation|
219043655|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
219043656|NCT01401933|DRUG|Rifampin|QD on Days 5-16
219043657|NCT04296981|OTHER|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
219043658|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
219043659|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
218927741|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
218927742|NCT03181529|DRUG|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
219043660|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
218927743|NCT04618107|PROCEDURE|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
218927744|NCT04618107|PROCEDURE|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
218927745|NCT05828329|BEHAVIORAL|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
219043661|NCT00040885|BIOLOGICAL|infliximab|
219043662|NCT00040885|DRUG|docetaxel|
219539983|NCT02314403|RADIATION|Thymic Irradiation|
219539984|NCT02314403|PROCEDURE|Combined Bone Marrow/Kidney Transplantation|
219539985|NCT01929863|DRUG|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]
219539986|NCT01929863|DRUG|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
219539987|NCT01929863|DRUG|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
219539988|NCT00532090|DRUG|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
219539989|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
219539990|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
219539991|NCT05644743|DEVICE|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
219539992|NCT06559514|BEHAVIORAL|Group-based multi-component psychoeducational inventions (GMC-PEIs)|The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
218927746|NCT05828329|BEHAVIORAL|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
218927747|NCT02064257|BEHAVIORAL|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
218927748|NCT02139007|DRUG|Alendronate|
218927749|NCT04968275|BEHAVIORAL|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
218927750|NCT06394141|BEHAVIORAL|Real-time triggers|The first intervention group (n= 30 professional drivers) will receive real-time triggers related to acute stress and sleepiness/fatigue. The real-time feedback involves giving relevant triggers when exceeding some critical stress values or detecting events of \&#39;energy-takers\&#39; based on accurate measurements of mental energy in a fully automated way. The selected triggers will be based on the co-creation workshops with drivers (e.g., auditive, visual) in order to select the most efficient (type or combination of) trigger(s) for the real-time feedback. The warning messages will be tailored to the preferences of the driver (e.g., personalized comfort- and safety-related settings) and aim to generate a warning message/signal meant to alert drivers and prevent they might end up with high stress levels
218927751|NCT06394141|BEHAVIORAL|Personalized tailored feedback|The second intervention group (n= 30 professional drivers) will receive personalized tailored feedback to reduce chronic stress and sleepiness/fatigue. The advice involves personalized (semi-)automatic feedback to drivers about a reduced stress level via the mobile app with automatic reports, as well as post-intervention during the next work break or at the end of the workday, based on the preferences of the driver. The (semi-)automatic feedback is based on the theory of Stages of Change, by which a driver will only receive relevant feedback based on their attitude and willingness during daily life.
218927752|NCT06394141|BEHAVIORAL|Real-time triggers + Personalized tailored feedback|The third intervention group (n= 30 professional drivers) will receive both real-time feedback related to acute stress and sleepiness/fatigue, as well as personalized tailored feedback related to chronic stress and sleepiness/fatigue, similar as in the first and second intervention groups.
218927753|NCT06394141|BEHAVIORAL|App-supported exercise therapy|The fourth intervention group (n= 30 professional drivers) will receive app-supported exercise therapy. The intervention will be based on principles of high-intensity training exercises that focus on the improvement of cardiorespiratory exercise capacity, as well as on the reduction of stress levels during work. Participants will receive instructions via the app to do some short, vigorous exercises adapted to their work environment at regular intervals, e.g., bending-and-stretching exercises with a weight in their hands, walking up and down the stairs of their vehicle for a few minutes, etc.
218927754|NCT06394141|BEHAVIORAL|Conventional intervention|The active control group (n= 20 professional drivers) will get a conventional intervention to reduce stress, e.g., mindfulness.
219043663|NCT00040885|OTHER|placebo|
219043664|NCT01637350|PROCEDURE|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
219043665|NCT00573027|PROCEDURE|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
219043666|NCT05278429|DEVICE|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
219539993|NCT01734265|DRUG|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
219620337|NCT04405492|DEVICE|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
219043667|NCT01806896|DRUG|PF-02545920|"* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days."
219043668|NCT01806896|DRUG|Placebo|"\- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
219043669|NCT01806896|DRUG|PF-02545920|"* 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
219043670|NCT01806896|DRUG|Placebo|"* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
219043671|NCT01574352|BEHAVIORAL|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
219043672|NCT01574352|BEHAVIORAL|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
219539994|NCT01734265|DRUG|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
219539995|NCT05545826|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
218927755|NCT00003439|BIOLOGICAL|recombinant interleukin-12|
218927756|NCT03586557|DEVICE|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
218927757|NCT03586557|DRUG|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
218927758|NCT05803733|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
219539996|NCT06451783|OTHER|Traditional Chinese medicine combined with manipulation treatment|"The specific procedure involves administering the Shengyu Decoction, which consists of the following herbs:~* Shu Di Huang 20 grams~* Bai Shao 15 grams~* Dang Gui 15 grams~* Chuan Xiong 8 grams~* Ren Shen 20 grams~* Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks. Add manipulation of massage：~  * Press and grasp the affected limb three times；~    * Five-finger five-acupoint pressing method；~      * Point pressing on Zusanli (ST36) and Sanyinjiao (SP6)；~        * grasp the interior method to treat the calf three times；~          ⑤ Apply rolling technique around the knee joint；~          ⑥ Knead and straighten the standing tendon (the lateral muscle of the calf)；~          ⑦ Six-finger six-acupoint pressing method；~          ⑧ Push and pull the patella to flex and extend the knee joint；~          ⑨ Knee joint reunion and smooth dispersion method."
218927759|NCT05803733|OTHER|Routine strength training|range of motion exercises and strength training
219539997|NCT06451783|DRUG|Celecoxib capsule|Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
218927760|NCT06042855|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
218927761|NCT06042855|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
218927762|NCT05164991|BEHAVIORAL|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
219043673|NCT04060407|DRUG|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
219043674|NCT04060407|DRUG|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
219043675|NCT04060407|DRUG|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
219043676|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
219043677|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
219043678|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
219043679|NCT01242657|BEHAVIORAL|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
219043680|NCT01242657|BEHAVIORAL|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
219043681|NCT05466149|DRUG|Furmonertinib|240mg QD on a continuous dosing schedule.
219043682|NCT03316872|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219043683|NCT03316872|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
219043684|NCT07018531|PROCEDURE|VST augmentation with TPT|"For TPT group, vertical soft tissue augmentation will be performed simultaneously with implant placement using a 2 mm healing abutment. Than, to ensure tension-free primary closure, mucoperiosteal flaps will be mobilized through vertical releasing incisions. Wound closure will be achieved using horizontal mattress sutures, followed by simple interrupted sutures for optimal tissue adaptation. The healing abutment will act as a mechanical support to maintain space and prevent soft tissue collapse. This tented space is expected to allow blood to accumulate, clot, and gradually reorganize into connective tissue, thereby promoting an increase in vertical soft tissue thickness around the implant.~After 2 months , the initial 2-mm healing abutment will be removed, and a 4 mm healing abutment will be placed by mading a small semilunar incision without touching the bone."
219043685|NCT07018531|PROCEDURE|TPT-PRF|In the PRF group, the same surgical protocol as the TPT group will be followed. However, prior to wound closure, the tented space surrounding the healing abutment will be filled with PRF membranes.
219043686|NCT07018531|PROCEDURE|TPT-PBM|The PBM group will follow the same surgical protocol as the TPT group. In addition, this group will receive photobiomodulation therapy using red-light irradiation at a wavelength of 630 nm, applied to the occlusal site immediately after surgery and repeated after 7 days.
219043687|NCT07018531|PROCEDURE|Group control: implant placement without TPT|The negative control group will consist of patients randomly selected from the recruited population, in accordance with the study's inclusion criteria. Participants in this group will not receive any intervention aimed at VST augmentation during implant placement. This will allow for a clear assessment of the effect of the TPT on VST gain and its impact on MBL. In accordance with ethical guidelines, patients in the control group will undergo VST augmentation at a second stage, prior to the initiation of the prosthetic phase.
219539998|NCT02692547|DEVICE|Hybrid-logic closed loop system|All patients get to wear the pump
219539999|NCT06290284|PROCEDURE|Long Peripheral Catheter|PowerGlide Pro™ Midline Catheter
219620338|NCT00760916|DRUG|UT-15C 1 mg|UT-15C 1 mg
218927763|NCT00485784|OTHER|Blood test|Blood test
218927764|NCT01783691|DRUG|NKTT120|
218927765|NCT01767090|DRUG|ASP1707|Oral
218927766|NCT01767090|DRUG|Placebo|Oral
218927767|NCT01767090|DRUG|Leuprorelin acetate|subcutaneous
219540000|NCT06290284|PROCEDURE|Peripheral Intra-Venous Catheter|Venflon™ Pro Safety Needle Protected IntraVenous Cannula
218927768|NCT02165098|DRUG|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
218927769|NCT02165098|DRUG|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
218927770|NCT02165098|DRUG|Cariprazine capsule|Cariprazine capsule - fasted
219043688|NCT07019402|BEHAVIORAL|Internet-based Mindfulness-Based Stress Reduction (iMBSR)|The iMBSR program is an adaptation of Jon Kabat-Zinn's Mindfulness-Based Stress Reduction (MBSR) to be delivered in an online and asynchronous manner. MBSR was developed by Kabat-Zinn in the 1970s as a method to help individuals manage stress and pain through mindfulness meditation. Mindfulness practice has been linked to numerous benefits such as boosting cognitive control and emotion regulation. MBSR includes practices such as orienting attention to the present moment, often through an object like the breath, nonjudgmental awareness of thoughts and emotions, mindful listening, mindful eating, and body scan meditation.
219043689|NCT07019402|BEHAVIORAL|Internet-based Lifestyle Education (iLifeEd)|iLifeEd is an online and asynchronous lifestyle education program. Participants will be presented with information and activities about healthy aging topics, including physical activity, sedentary behavior, sleep, stress, nutrition and hydration, social support, and cognitively stimulating activities. Stretching and toning exercises will also be included.
219043690|NCT07024667|DEVICE|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)
219043691|NCT07024771|DEVICE|Automated Pupillometer|An automated pupillometer will be used to measure pupil size and calculate NPi in newborns with HIE
219540001|NCT00772161|DRUG|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
219620339|NCT00760916|DRUG|UT-15C 0.25 mg|UT-15C 0.25 mg
219620340|NCT00760916|DRUG|UT-15C 5 mg|UT-15C 5 mg
219620341|NCT00760916|DRUG|Placebo|Placebo
219620342|NCT04751643|OTHER|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
218927771|NCT02165098|DRUG|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
218927772|NCT02165098|DRUG|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
218927773|NCT00231569|DRUG|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
219043692|NCT06769711|PROCEDURE|Surgical procedure using Peroneus Longus for ACL reconstruction.|Surgical procedure using Peroneus Longus for ACL reconstruction.
219043693|NCT06769711|PROCEDURE|Surgical procedure using Hamstring tendons for ACL reconstruction.|Surgical procedure using Hamstring tendons for ACL reconstruction.
219540002|NCT00323882|DRUG|MDX-010|selected dose administered IV every 3 weeks
219540003|NCT02882945|OTHER|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
219620343|NCT04751643|OTHER|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
218927774|NCT00231569|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
218927775|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
218927776|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
218927777|NCT00231569|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
218927778|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
218927779|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
219540004|NCT02882945|OTHER|Group B|200 cases of type 2 DM without complications were enrolled in the study.
219540005|NCT02882945|OTHER|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
218927780|NCT03208946|OTHER|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
219043694|NCT02601287|BIOLOGICAL|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
219043695|NCT06853249|OTHER|liquid meal|An isocaloric amount (500 kcal) of a commercially available liquid meal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
219043696|NCT06853249|OTHER|semi-solid meal|An isocaloric amount (500 kcal) of a commercially available semi-solid oatmeal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
219043697|NCT06853249|OTHER|caloric drink + semi-solid meal|A predefined amount of a caloric drink (= liquid meal) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
219540006|NCT01469351|DRUG|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
219540007|NCT01469351|DRUG|non-active study drug|placebo
218927781|NCT03208946|OTHER|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
218927782|NCT04015544|DIETARY_SUPPLEMENT|Watermelon|Pureed whole (100%) watermelon
218927783|NCT02562677|DEVICE|Transcutaneous Trigeminal Nerve Stimulation|
218927784|NCT00404612|DRUG|Placebo|PO BID
218927785|NCT00404612|DRUG|LX211|0.2 mg/kg, twice a day (BID)
218927786|NCT00404612|DRUG|LX211|0.4 mg/kg, twice a day (BID)
218927787|NCT00404612|DRUG|LX211|0.6 mg/kg, twice a day (BID)
218927788|NCT03210194|BEHAVIORAL|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
218927789|NCT03210194|BEHAVIORAL|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
218927790|NCT02061410|DEVICE|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
218927791|NCT01724099|DRUG|Euiiyin-tang|Korean medicinal herbal drug
218927792|NCT01724099|DRUG|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
218927793|NCT03933007|DRUG|Colchicine,|"the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
218927794|NCT03933007|DRUG|midazolam,|Midazolam 1 mg
218927795|NCT03933007|DRUG|fexofenadine|Fexofenadine 120 mg
218927796|NCT01886053|DRUG|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
218927797|NCT01886053|DRUG|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
218927798|NCT01886053|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
219043698|NCT06853249|OTHER|non-caloric drink + semi-solid meal|A predefined amount of a non-caloric drink (= water, sucralose, flavor) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
219043699|NCT07075354|PROCEDURE|Hydraulic Condensation Root Canal Obturation with BioRoot RCS|Root canal obturation using the hydraulic condensation technique combined with BioRoot RCS, a bioceramic calcium silicate-based sealer. Treatment includes standardized irrigation with sonic activation and drying using a single calibrated paper point without alcohol. The sealer sets hydraulically in the presence of moisture, promotes hard tissue formation, and provides a durable, bioactive seal supporting periapical healing.
219043700|NCT06924684|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.
219043701|NCT06924684|DRUG|Placebo|Placebo caspule
219043702|NCT06923995|OTHER|AI-driven clinical interview|AI-driven clinical interview
219540008|NCT02120547|DRUG|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
219540009|NCT02120547|DRUG|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
219540010|NCT02604420|DRUG|eculizumab|
219540011|NCT02907047|OTHER|tourniquet inflated|
219540012|NCT02907047|OTHER|tourniquet not inflated|
219540013|NCT00096291|OTHER|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
218927799|NCT05433207|DRUG|Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)
219043703|NCT06923813|OTHER|caloric intake measurement|Detailed daily tracking of the enteral feeding provided to each patient, inclusing the type and amount of nutritional formula administered. Apart from the enteral intake, supplemental calories provided by infusion (e.g. glucose) will be recorded to ensure accurate measurement of caloric intake.
219043704|NCT06923813|PROCEDURE|stool sample collection|"* a nonabsorbable blue dye marker will be administered at the start and end of the stool collection period to precisely indentify the stool produced within a specific time frame.~* stool will be collected for three days. Each sample will be collected, weighted and labeled with the date and time, then stored at -20°C.~* only stool samples from the appearance of the first dye marker to the appearance of the second dye marker will be saved and analyzed.~* bomb calorimetry preparation~  * blending and dilution: each stool sample will be put into a blender and mixed with an equal amount of water~ * freeze dying: the diluted stool will be placed into freeze-dye flasks and frozen at -20°C. The next day, the flasks will be placed into a freeze dryer for 48hours.~ * pellet formation: the freeze-dried samples will be formed into 1-gram pellets and stored until calorimetry~ * calorimetry analysis: the Parr 6200 isoperibol calorimeter will be used to measure the energy content of the stool pellets"
219043705|NCT06923813|OTHER|energy expenditure measurement|performing indirect calorimetry to measure the REE of each patient
218927800|NCT04844398|OTHER|Clown visits by RED NOSES Clowndoctors Austria|Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
218927801|NCT02939911|DEVICE|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
218927802|NCT01516021|DIETARY_SUPPLEMENT|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
218927803|NCT00196482|DRUG|changing of fortifier|
218927804|NCT01524575|DRUG|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
218927805|NCT00084071|DRUG|Tifacogin|
218927806|NCT02546388|DRUG|Indium-111 Pentreotide|
218927807|NCT02546388|DRUG|Gallium-68 DOTATATE|
219043706|NCT06922981|BEHAVIORAL|resistance training program|"Thirty-eight male and female patients aged 18-45 years, diagnosed with NSCLBP will be recruited through direct referrals from orthopedic surgeons, based on their availability to participate, thus a sample of convenience will be used, Participants will be randomly assigned as follows:~Group A:~Patients in group (A) (n=19) will receive a periodized resistance exercise program.~Group B:~The patients in group (B) (n=19) will receive a periodized aerobic exercise program"
219205187|NCT06891274|DEVICE|USN before SVN|The group that received ultrasonic rock salt aerosol inhalation therapy followed by small-volume nebulized inhalation therapy.
219540014|NCT00096291|OTHER|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
219540015|NCT03820310|BIOLOGICAL|autologous Tcm cellular immunotherapy|autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
219540016|NCT04131842|OTHER|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
219540017|NCT04131842|OTHER|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
218927808|NCT04546672|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
218927809|NCT04546672|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
218927810|NCT00699114|DRUG|Placebo|Lactose as powder in gelatine capsules, single dose
218927811|NCT00699114|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
218927812|NCT00699114|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
218927813|NCT00699114|DRUG|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
218927814|NCT00699114|DRUG|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
219540018|NCT04131842|OTHER|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
219540019|NCT04131842|OTHER|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
219043707|NCT03632187|DRUG|Abatacept|Subcutaneous abatacept every weeks during 3 months
219043708|NCT03632187|DRUG|Placebos|Subcutaneous placebo every week during 3 months
219043709|NCT06889142|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|The dietary supplement NMN \[1,000mg\] will be taken orally by participants daily for a total of 12 weeks
219043710|NCT06813235|BEHAVIORAL|iDream2Heal|iDream2Heal (iD2H) is an unsupervised, self-guided web-based version of the cognitive behavioural therapy for insomnia (CBT-I).
219043711|NCT06813235|BEHAVIORAL|Easy Exercise|Easy Exercise (eEX) is an unsupervised, self-guided web-based exercise intervention.
219205188|NCT06891274|DEVICE|SVN before USN|The group that received small-volume nebulized inhalation therapy followed by ultrasonic rock salt aerosol inhalation therapy.
219205189|NCT06890858|DRUG|Fasudil Hydrochloride|Exploring whether the study of using Exploring whether the study of using Fasudil Hydrochloride for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors
219205190|NCT04096066|DRUG|Carfilzomib|"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
219205191|NCT04096066|DRUG|Lenalidomide|\- 25 mg orally on days 1-21 of each cycle.
219540020|NCT05978726|DRUG|Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel|Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
219540021|NCT03887910|OTHER|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
218927815|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
218927816|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
218927817|NCT01982656|OTHER|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
218927818|NCT00507780|DRUG|GnRH antagonist|
218927819|NCT04200846|BEHAVIORAL|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
218927820|NCT00387504|DRUG|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
218927821|NCT00387504|OTHER|pharmacological study|samples drawn per protocol
218927822|NCT04257929|DRUG|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
218927823|NCT04257929|DRUG|Placebo oral tablet|Matching placebo tablets
218927824|NCT03710577|BEHAVIORAL|Yoga|1 session
218927825|NCT03710577|BEHAVIORAL|Quiet Rest|1 session
218927826|NCT00525161|DRUG|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
219043712|NCT06813235|BEHAVIORAL|Dream2Heal|Dream2Heal (D2H) is a manualised, multi-component intervention which is grounded with core CBT-I elements of stimulus control, sleep restriction, sleep hygiene, relaxation training, and cognitive restructuring.
219043713|NCT06813235|BEHAVIORAL|iDream2Heal & Easy Exercise|The augmented iDream2Heal \& Easy Exercise (iD2H \& eEX) intervention is a combined, unsupervised, self-guided web-based intervention that covers the content of iD2H and eEX interventions.
219205192|NCT04096066|DRUG|Dexamethasone|"\- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
219366919|NCT00905957|PROCEDURE|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
218927827|NCT00002999|DRUG|cisplatin|
218927828|NCT00002999|DRUG|fluorouracil|
218927829|NCT00002999|RADIATION|radiation therapy|
218927830|NCT02790411|DEVICE|Imaging devices|technological adjustment tests
218927831|NCT02790411|DEVICE|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
218927832|NCT01898559|OTHER|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
218927833|NCT02735811|DEVICE|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
218927834|NCT03250715|OTHER|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
218927835|NCT00516516|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 1g orally, twice daily
218927836|NCT00516516|DIETARY_SUPPLEMENT|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
218927837|NCT02447003|BIOLOGICAL|Pembrolizumab|IV infusion of 200 mg.
218927838|NCT01939418|DRUG|RAD001|Afinitor 5mg qd. po.
218927839|NCT01939418|DRUG|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
218927840|NCT01939418|DRUG|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
219366920|NCT00905957|PROCEDURE|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
219366921|NCT05535647|DRUG|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
219366922|NCT05535647|DRUG|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
219366923|NCT02591264|OTHER|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
219366924|NCT05086042|DIAGNOSTIC_TEST|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
219366925|NCT01286493|BIOLOGICAL|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
219366926|NCT04244370|DEVICE|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
219366927|NCT06072014|OTHER|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
219540022|NCT03887910|OTHER|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
218927841|NCT02677883|OTHER|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
218927842|NCT02677883|OTHER|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
218927843|NCT03848728|OTHER|SEARCH Youth combination intervention|"* Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
218927844|NCT06273995|OTHER|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
218927845|NCT05294549|OTHER|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
218927846|NCT04013477|DRUG|DA-5207|DA-5207 Transdermal Delivery System
219043714|NCT06904885|BEHAVIORAL|Implementation of a guideline-based model of care for hip and knee osteoarthritis|Guideline-based model of care including GLA:D (Good Life with osteoArthritis from Denmark) -program that includes training for physiotherapists and group based education and exercise for patients with hip and knee OA.
219043715|NCT06909344|DEVICE|577 nm Diode laser|All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control
219540023|NCT06562114|DRUG|TML-6 Granules|Administered orally
219620344|NCT06648681|DRUG|Lemborexant 5 mg|"The intervention is the oral administration of a study drug containing lemborexant 5 mg daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge or until the first diagnosis of delirium, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
219043716|NCT06908863|OTHER|Tasks learning and MRI scan|"\- 2-week learning and training phase of motor tasks and oral and facial language (OLF) tasks.~Manual fine motor tasks will correspond to activities requiring increasing precision and different types of grip (crushing a ball, modelling clay with the palm of the hand, sorting round coins with thumb/index pliers).~The OLF praxis tasks will correspond to coordinated movements of different parts of the face (cheeks, lips and tongue).~\- MRI (magnetic resonance imaging) exam, During this exam, the investigator will give to the subject instructions for a task to be carried out. These tasks will correspond to the motor tasks previously trained."
219043717|NCT06908265|DRUG|Toothpaste including mustard extract|"Intervention: Herbal toothpaste containing 0.5% white mustard (Sinapis alba) extract. To assess its effect on plaque index (PI), approximal plaque index (API), gingival index (GI), bleeding on probing (BoP), and bacterial loads of Streptococcus mutans and Lactobacillus spp.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the assigned toothpaste."
219043718|NCT06908265|DRUG|Placebo|"lacebo toothpaste, formulated identically to the experimental toothpaste but without white mustard extract. Serves as a control to compare the antibacterial and clinical effects of the herbal toothpaste.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the placebo toothpaste."
219540024|NCT06562114|DRUG|Placebo|Administered orally
219540025|NCT01094457|DRUG|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
219540026|NCT01094457|DRUG|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
219540027|NCT02911701|DRUG|Acetaminophen|
219540028|NCT02911701|DRUG|Ibuprofen|
219540029|NCT06328829|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
218927847|NCT04013477|DRUG|Donepezil Hydrochloride|donepezil HCl 10mg QD
218927848|NCT06306807|OTHER|Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications|Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
218927849|NCT06306807|OTHER|PNF exercise program|The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
218927850|NCT04161157|BEHAVIORAL|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
218927851|NCT04606602|DRUG|SLN360|SLN360 for subcutaneous (s.c.) injection
218927852|NCT04606602|DRUG|Placebo|Sodium chloride for subcutaneous (s.c.) injection
219620345|NCT06648681|DRUG|Control (placebo) group|"The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following when initiation criteria is met or until their hospital discharge, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
219620346|NCT03924726|PROCEDURE|Micro-osteoperforation (MOP)|Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
219620347|NCT05998187|DRUG|intra-rectal botulinum toxin injections|Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
219620348|NCT02594033|DRUG|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
219620349|NCT06188078|OTHER|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 25 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
219366928|NCT03284450|OTHER|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
219366929|NCT03284450|OTHER|SSRS|The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
219366930|NCT00616135|PROCEDURE|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
219366931|NCT00135629|BIOLOGICAL|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
219366932|NCT00135629|OTHER|Placebo Injection|Placebo Injection
219366933|NCT00135629|PROCEDURE|Venepuncture: 100ml blood sample taken on 12 separate visits|Venepuncture: 100ml blood sample taken on 12 separate visits
219366934|NCT01470677|DRUG|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
219366935|NCT02905734|DRUG|Nicotine patch|Single administration of an active treatment (nicotine patch)
219366936|NCT02905734|OTHER|placebo patch|Single administration of a placebo treatment
219366937|NCT00002948|BIOLOGICAL|filgrastim|
219366938|NCT00002948|DRUG|topotecan hydrochloride|
219366939|NCT00002948|PROCEDURE|bone marrow ablation with stem cell support|
219366940|NCT00002948|PROCEDURE|peripheral blood stem cell transplantation|
219366941|NCT01261559|DEVICE|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
219366942|NCT02935309|DRUG|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
219366943|NCT02935309|DRUG|Capecitabine|Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
219366944|NCT02935309|RADIATION|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
219366945|NCT03869255|PROCEDURE|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
219366946|NCT02773966|RADIATION|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
218927853|NCT03726580|DRUG|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
218927854|NCT02581410|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
218927855|NCT01393392|BEHAVIORAL|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
218927856|NCT01393392|BEHAVIORAL|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
218927857|NCT06268275|PROCEDURE|Scalp block|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
218927858|NCT06268275|DRUG|Esmolol|Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
218927859|NCT00658385|GENETIC|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
218927860|NCT03752567|OTHER|Follow up|like group descriptions
218927861|NCT05589467|OTHER|DASH-FP|Dash diet with only fried potatoes
218927862|NCT05589467|OTHER|DASH-NFP|Dash diet with only non-fried potatoes
218927863|NCT05589467|OTHER|Control|Dash diet with no potatoes
218927864|NCT02390193|PROCEDURE|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
218927865|NCT03172988|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
218927866|NCT03172988|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
218927867|NCT03172988|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
219540030|NCT06328829|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219540031|NCT06328829|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219540032|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
218927868|NCT03172988|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
218927869|NCT05986695|BEHAVIORAL|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
218927870|NCT05986695|BEHAVIORAL|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
218927871|NCT05069948|OTHER|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
218927872|NCT03810924|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
218927873|NCT03810924|BEHAVIORAL|Ergometer|Riding ergometer
219540033|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
218927874|NCT03810924|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
218927875|NCT03810924|BEHAVIORAL|Reading Newspaper|Participants read newspaper
218927876|NCT04854187|DEVICE|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
218927877|NCT06851052|OTHER|sample collection|Samples could include blood, skin biopsy, urine, plucked hair.
218927878|NCT06851052|OTHER|Seeking consent|
218927879|NCT06851052|OTHER|Sample Collection: Surgical|Excess surgical tissue (diseased tissue or tissue being removed for a clinical reason).
218927880|NCT06848491|BEHAVIORAL|AYA WELL Intervention|Behavioral weight management intervention for adolescent and young adult cancer survivors with digital tools, smartphone web app behavioral program, text messages, and expert-guided closed social networking group for peer support.
218927881|NCT06848491|BEHAVIORAL|Self-Guided|Self-guided intervention with digital tools, periodic informational support, and moderated social networking group for peer support.
218927882|NCT04113447|OTHER|observational|observational
218927884|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
218927885|NCT01200771|PROCEDURE|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
218927886|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
218927887|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
218927888|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
218927889|NCT02874521|OTHER|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
218927890|NCT02874521|OTHER|Intra-dialytic cycle training|Cycle training during haemodialysis
219540034|NCT03347487|PROCEDURE|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
218927891|NCT02706106|DEVICE|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
218927892|NCT03976219|OTHER|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
219540035|NCT05852392|OTHER|Adapted PARENT Model|PARENT is a team-based approach to care that utilizes a clinic-based community health worker as part of the WCC team to provide comprehensive and family-centered preventive care services.
219540036|NCT01499602|DRUG|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
218927893|NCT04722419|OTHER|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
218927894|NCT06555549|DRUG|DEH113|tablets
218927895|NCT06555549|DRUG|Placebo|tablets
218927896|NCT03636100|DEVICE|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
218927897|NCT04151303|PROCEDURE|Cervical cerclage|Cervical cerclage and cervical cerclage removal
218927898|NCT01913496|OTHER|ebalance|using the ebalance application for 14 weeks
219043719|NCT06909682|DEVICE|Intervention Group (Device Group - AI-Based Remote Monitoring)|This intervention utilizes a mini-invasive wearable device for continuous remote monitoring of chronic heart failure (CHF) patients. Unlike traditional telemonitoring, it integrates AI-driven predictive analytics to track oxygen saturation (SpO₂), heart rate variability (HRV), electrodermal activity (EDA), temperature, respiratory rate, and sleep quality in real time. The system generates automated alerts for healthcare providers, enabling early detection of CHF exacerbation and proactive intervention through teleconsultations, medication adjustments, or in-person evaluations. Data is securely transmitted to a cloud-based platform, allowing continuous risk assessment and personalized care adjustments. This approach aims to reduce unnecessary hospitalizations, enhance patient monitoring, and optimize heart failure management through advanced AI-based digital health technology.
219540037|NCT01499602|DRUG|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
219540038|NCT01983969|DRUG|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
219540039|NCT01983969|DRUG|Vorinostat|1000 mg by vein on Day -11 through Day -2.
219540040|NCT01983969|DRUG|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
219540041|NCT01983969|DRUG|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
219540042|NCT01983969|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
219540043|NCT01983969|DRUG|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
218927899|NCT06337630|DRUG|PLX038 + Tuvusertib|"Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor."
218927900|NCT05136703|BEHAVIORAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months. Participants receive up to three individually delivered booster sessions through 6 months.
218927901|NCT05136703|BEHAVIORAL|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
218927902|NCT06563102|COMBINATION_PRODUCT|Albuterol/Budesonide|Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation
218927903|NCT06563102|COMBINATION_PRODUCT|Albuterol|Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
218927904|NCT06083506|DEVICE|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
218927905|NCT05037929|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
218927906|NCT05037929|DRUG|Placebo|Participants will receive SC placebo Q2W.
218927907|NCT05934877|BEHAVIORAL|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
218927908|NCT05934877|BEHAVIORAL|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
218927909|NCT05934877|BEHAVIORAL|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
218927910|NCT05269238|OTHER|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
218927911|NCT05269238|OTHER|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
218927912|NCT05403424|OTHER|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
218927913|NCT05403424|DIAGNOSTIC_TEST|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
218927914|NCT05403424|OTHER|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
218927915|NCT05403424|OTHER|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
218927916|NCT03313778|BIOLOGICAL|mRNA-4157|IM injection
218927917|NCT03313778|BIOLOGICAL|Pembrolizumab|Intravenous infusion
218927918|NCT03313778|BIOLOGICAL|SoC Treatment|Intravenous infusion
218927919|NCT06577610|BEHAVIORAL|Feedback from colonoscopy monitoring program|Adenoma detection rate feedback from colonoscopy monitoring programs
218927920|NCT06494826|OTHER|colonoscopy procedure|"Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only ."
218927921|NCT05889546|PROCEDURE|Biospecimen Collection|Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
219043720|NCT06909682|OTHER|Standard Clinical Follow-Up|Participants in this group will receive standard chronic heart failure (CHF) management according to current clinical guidelines. Their follow-up will consist of scheduled in-person visits every three months, during which they will undergo routine laboratory tests (including BNP, NT-proBNP, renal function, and electrolytes), as well as echocardiography and ECG evaluations. Treatment adjustments will be made based on clinical assessments and reported symptoms. Unlike the intervention group, these participants will not use a wearable device, and their condition will be monitored exclusively through traditional hospital visits and self-reported health status.
219043721|NCT06909604|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy
219540044|NCT01983969|OTHER|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
219540045|NCT01983969|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
219540046|NCT01983969|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
219540047|NCT01983969|DRUG|Rituximab|375 mg/m2 by vein on Days -9.
219540048|NCT00436163|DRUG|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
218927922|NCT05609916|BEHAVIORAL|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
218927923|NCT05989217|DEVICE|Occlusal Splint|Occlusion Splint
218927924|NCT05989217|RADIATION|Laser Therapy|Laser Therapy
218927925|NCT05989217|RADIATION|Acupuncture Laser Therapy|Acupuncture Laser Therapy
218927926|NCT04258800|DEVICE|Music during colonoscopy|Music during colonoscopy
218927927|NCT02809235|DIETARY_SUPPLEMENT|coconut oil|3 tablespoons per day of supplemental coconut oil
218927928|NCT04260802|DRUG|OC-001|Administered IV.
218927929|NCT04260802|DRUG|Drug: OC-001 in Combination with Avelumab|Administered IV.
218927930|NCT03529422|DRUG|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
218927931|NCT03529422|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
218927932|NCT02000115|DEVICE|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
218927933|NCT02000115|DEVICE|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
218927934|NCT05704764|BEHAVIORAL|Ending Self Stigma for Persons living with HIV and Use Substances|One-on-one intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
218927935|NCT04815824|BEHAVIORAL|Exercise Mode|Stationary cycling or treadmill walking
218927936|NCT05006573|BIOLOGICAL|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
218927937|NCT05006573|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
218927938|NCT05783037|OTHER|New Organic Infant Formula|New organic infant formula fed daily ad libitum
219043722|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with Enhanced Recovery After Surgery (ERAS) procedure|"This will include at least:~* A one-day hospitalization to visit the surgical unit and to provide therapeutic education to patients and their parents.~* A transition to morphine based treatments per os from intravenous morphine on the second day following surgery~* Phone calls from a surgery unit nurse 2 times a day during 5 days~* A teleconsultation with the surgeon between D3 and D5 following surgery"
219043723|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with standard of care procedure|"Patients in this group will undergo posterior vertebral fusion surgery without the set of procedures for ERAS.~They will have a first consultation with the anesthesist and the surgeon then the surgery will be planned. The discharge from hospital after surgery will not happen early and the standard of care procedures will be followed during and after surgery.~Patients will receive 2 phone calls at D1 and D5 after surgery. The patient will also have 2 appointments at the hospital for post-surgical follow-up at D45 and M12."
219043724|NCT06908772|DRUG|Glumetinib Tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
219043725|NCT06908772|DRUG|Osimertinib Mesylate Tablets|3rd EGFR-TKI
219366947|NCT02773966|RADIATION|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
218927939|NCT05783037|OTHER|Commercial Organic Infant Formula|Commercially available organic infant formula fed daily ad libitum
218927940|NCT05028556|DRUG|Cohort 1 of Y101D|Y101D, 1mg/kg, Q2W, intravenous infusion
218927941|NCT05028556|DRUG|Cohort 2 of Y101D|Y101D, 3mg/kg, Q2W, intravenous infusion
218927942|NCT05028556|DRUG|Cohort 3 of Y101D|Y101D, 10mg/kg, Q2W, intravenous infusion
218927943|NCT05028556|DRUG|Cohort 4 of Y101D|Y101D, 20mg/kg, Q2W, intravenous infusion
218927944|NCT05028556|DRUG|Cohort 5 of Y101D|Y101D, 30mg/kg, Q2W, intravenous infusion
218927945|NCT04353258|BEHAVIORAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
218927946|NCT04353258|BEHAVIORAL|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
218927947|NCT06603792|BEHAVIORAL|EEG-neurofeedback|Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.
218927948|NCT05522153|DRUG|Arista|hemostatic powder
218927949|NCT06597812|PROCEDURE|Sevoflurane|Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).
218927950|NCT06599541|BEHAVIORAL|Hypopressive Exercise|A hypopressive exercise program will be carry out.
218927951|NCT06599541|BEHAVIORAL|Pilates Exercise|A pilates exercise program will be carry out.
218927952|NCT06603922|BEHAVIORAL|Psychological treatment (P-MCT)|Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.
219205193|NCT06744803|BEHAVIORAL|Gamified Neuropathy Management Application on Cancer Behavior|"The study will be conducted in three phases:~Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.~Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.~Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data."
219359877|NCT06074640|OTHER|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
218927953|NCT06603922|BEHAVIORAL|Psychological treatment (MCT)|"Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center."
219043726|NCT06908772|DRUG|Glumetinib Tablets Placebo|Placebo
219043727|NCT06907979|DEVICE|TMS - Sham|Trains consisting of bursts of three stimuli at 50 hertz (Hz) repeated at 5 Hz frequency delivered at 20% of maximum stimulator output (MSO) in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
219043728|NCT06907979|DEVICE|TMS - Active iTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
219043729|NCT06907979|DEVICE|TMS - Active cTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 1 x 40-second train (40 seconds total)
219043730|NCT06908902|PROCEDURE|partial nephrectomy with main or branch renal artery clamping|Robotic-assisted laparoscopic or laparoscopic partial nephrectomy with main or branch renal artery clamping
219043731|NCT06908902|PROCEDURE|partial nephrectomy with zero renal artery clamping|Robotic-assisted laparoscopic partial nephrectomy with zero renal artery clamping
219043732|NCT06909721|DRUG|Misoprostol|to compare Misoprostol and Dinoprostone as regarding to cost-effectiveness and safety in induction of normal Labor
219043733|NCT06908642|DRUG|Hemay005 tablet|Hemay005 is a small molecule PDE4 inhibitor.
219043734|NCT06908642|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
219043735|NCT06909084|PROCEDURE|Myringotomy with ventilation tube|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. A tympanostomy tube (Shepard tube) of appropriate size was placed in the incision and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
219043736|NCT06909084|PROCEDURE|Myringotomy alone|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. NO FURTHER PROCEDURE WAS DONE and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
219043737|NCT06909032|RADIATION|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) will be delivered using Volumetric Modulated Arc Therapy (VMAT). Treatment will be started within 12 weeks of breast conserving surgery and within four weeks of randomisation. Treatment will occur in five (5) once-daily sessions and should be completed within seven (7) days of starting radiotherapy. Two total doses of APBI will be compared: 30 Gy and 26 Gy. The aim is to determine whether quality of life is no worse when a higher dose of APBI is used compared to a slightly lower dose of APBI. The results of this study will help to guide doctors choose the best dose of APBI for patients with early breast cancer in the future.
219620350|NCT06188078|OTHER|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 25 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
218927954|NCT05415072|DRUG|DYP688|Single agent DYP688
218927955|NCT06655259|PROCEDURE|TURP|Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor
218927956|NCT06655259|DRUG|Standard Medical Therapy|Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
218927957|NCT06666218|BEHAVIORAL|Behavioral Intervention|Complete the HOPE intervention workshop
219540049|NCT05615324|BEHAVIORAL|Family Talk Preventive Intervention|This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
219540050|NCT01203215|BEHAVIORAL|2 print based physical activity interventions|physical activity promotion
219540051|NCT05961501|DRUG|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
219540052|NCT05961501|OTHER|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
219540053|NCT06466213|OTHER|single exercise bout about one-leg exercise|cycle exercise includes single leg
219540054|NCT03169985|DRUG|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
219540055|NCT03169985|DRUG|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
219540056|NCT06001762|DRUG|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
219540057|NCT06001762|DRUG|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
219540058|NCT06001762|DRUG|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
219540059|NCT06001762|DRUG|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
219540060|NCT06001762|DRUG|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
219540061|NCT06001762|DRUG|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
219540062|NCT02530905|DRUG|SRP-4045|SRP-4045 solution for IV infusion.
219540063|NCT02530905|DRUG|Placebo|SRP-4045 placebo-matching solution for IV infusion.
219540064|NCT02478047|DRUG|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
219540065|NCT02478047|OTHER|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
219540066|NCT02478047|OTHER|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
219540067|NCT02478047|OTHER|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
218927958|NCT06666218|OTHER|Electronic Health Record Review|Ancillary studies
218927959|NCT06666218|OTHER|Interview|Complete an interview
218927960|NCT06666218|OTHER|Survey Administration|Complete a survey
218927961|NCT06666218|OTHER|Survey Administration|Ancillary studies
218927962|NCT06389955|DRUG|TP 3654|TP 3654 is an investigational orally delivered drug
218927963|NCT03493464|DRUG|BR55|A novel targeted ultrasound contrast agent
218927964|NCT06599229|DIAGNOSTIC_TEST|myocardial contrast echo|Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
218927965|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
218927966|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
218927967|NCT06593782|DRUG|Dolasetron|"1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
218927968|NCT05318313|OTHER|Telerehabilitation|The TR PT evaluation and follow-up visits will be performed via Zoom software
218927969|NCT06603454|RADIATION|Preoperative CT|Preoperative contrast enhanced CT
218927970|NCT06591611|OTHER|PEEK reinforced fixed all-on-four prosthesis|Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK
218927971|NCT06597669|PROCEDURE|Placement of stainless steel crowns on primary molars|Preformed metal crowns have been placed to treat caries in primary molars
218927972|NCT06603480|BEHAVIORAL|Exercise|Aerobic exercise (moderate intensity) at 50-70% of maximum heart rate for 60 minutes, 3 days a week for 12 weeks
218927973|NCT06603480|OTHER|Metformin|Patients who started Metformin 2\*1
218927974|NCT06595667|PROCEDURE|Pulse pressure variation|Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.
218927975|NCT06595667|PROCEDURE|Central venous pressure|Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
218927976|NCT06592131|DRUG|BF844|BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
218927977|NCT06594835|BEHAVIORAL|Better Together|Better Together (BT) is a 90-min, age-appropriate, culturally relevant prevention intervention to prevent substance use among Black youth experiencing household challenges (ages 11-13) by addressing the multilevel influences of substance use.
218927978|NCT06594835|BEHAVIORAL|Youth In the Media (YM)|Delivered in eight in-person, 90-minute sessions concurrently with BT sessions, the YM program was designed to (1) increase participants' awareness of and access to the different types of media and free resources available at the participants local libraries, (2) discuss different types of media that center stories and experiences of Black youth, and (3) expose participants to careers in media.
218927979|NCT06593730|DRUG|NRL001 cream 0.5%w/w|
218927980|NCT06593730|DRUG|NRL001 cream 0.75%w/w|
218927981|NCT06593730|DRUG|NRL001 cream 1.0%w/w|
218927982|NCT06593730|DRUG|NRL001 cream 1.5%w/w|
218927983|NCT06593730|DRUG|NRL001 cream 2.0%w/w|
218927984|NCT06593730|DRUG|NRL001 cream 2.5%w/w|
218927985|NCT06600399|DIAGNOSTIC_TEST|glioblastoma|All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval
218927986|NCT06591000|PROCEDURE|tricuspid valve replacement|Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
219043738|NCT06909370|BEHAVIORAL|peer education|"The training titled The Effect of Peer Education on Human Papillomavirus (HPV) for Students in the Faculty of Health Sciences on Knowledge, Awareness, and Concern Levels includes scientific and up-to-date information about HPV transmission methods, prevention, risk factors, treatment methods, and vaccination. The content of the training aims to provide students with accurate information about HPV, as well as highlight the negative health effects of the virus, particularly its association with serious diseases like cervical cancer. The training seeks to increase students' awareness of HPV and help them manage their levels of concern about the virus. Through the peer education method, students were able to interact with each other, thus providing a more effective learning experience."
219043739|NCT04132492|OTHER|no intervention|there is no intervention
219043740|NCT06908187|OTHER|Opt-In Early Latinx intervention|Participants will access to the Opt-In Early training program website, but will be able to access the Spanish language version as well. Families will fill out a usage diary to record their experience.
219043741|NCT06908187|OTHER|Opt-In Early Rural Intervention|Participants will access to the Opt-In Early training program website. Parents will be able to interact with the rural community-oriented aspects of the program. Families will fill out a usage diary to record their experience.
219366948|NCT03071783|DEVICE|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
219366949|NCT05700266|DRUG|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
219366950|NCT05700266|DRUG|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
219366951|NCT05700266|DRUG|Aspirin|Aspirin (100mg once a day for 1 year)
219366952|NCT05700266|OTHER|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
219366953|NCT04772248|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
219366954|NCT04772248|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
218927987|NCT06591156|PROCEDURE|Root coverage|"Treatment of gingival recession, Miller\&#39;s Class I or Cairo\&#39;s RT1, which is the most predictable group to receive interventions without any impairment or problem for the patients.~After local anesthesia, a horizontal incision was made, delimitating the coronal part of the flap. This horizontal incision of the envelope flap consists of an oblique submarginal incision in the interdental areas that creates a surgical papilla. The incisions continue with the intrasulcular incision in the recession defects and are extended to form an envelope flap between the central and molar. This design facilitates the planned coronal repositioning of the flap tissue on the exposed root surfaces.~The apical gingival tissue at root exposures is raised to a full thickness to provide the critical part of the flap for root coverage with more thickness. Finally, the most apical portion of the flap is elevated in a split-thickness to facilitate coronal displacement of the flap."
218927988|NCT06591156|PROCEDURE|control group|Coronally advanced flap without any graft or biomaterial
218927989|NCT06591247|DEVICE|Double Baloon Catheter|A double Baloon Catheter will be inserted for 12 hours to one of the arms of the study
218927990|NCT06591247|PROCEDURE|Membrane Stripping|Stripping will be considered as 3-5 rotations of separating the amniotic sac from the cervix and will be perfomed twice (every 4-6 hours)
218927991|NCT04895644|OTHER|No Hard Collar|The patient in the intervention arm will not wear a Hard Collar for 12 weeks post injury
218927992|NCT06299475|OTHER|Online counseling and invitation|"Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website"
218927993|NCT06372691|OTHER|Subparaneural Injection (Grup S), Block|Comparison of two different methods in terms of various features
218927994|NCT06372691|OTHER|Interneural Injection (Grup I), Block|Comparison of two different methods in terms of various features
219043742|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~   Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration).~3. Radiotherapy:~Preoperative Radiotherapy:~Positioning: Immobilization with a neck-chest integrated frame, combined CT and MRI positioning with image fusion. Diagnostic MRI images can also be fused simultaneously. CT positioning should be performed with a plain scan, with a slice thickness of 3 mm. MRI positioning should include at least three sequences: T1-enhanced, T2 fat-suppressed, and DWI.~Target and Normal Organ Contouring:~GTVp (Gross Tumor Volume - Primary): Define the breast tumor target area based on MRI, CT, physical examination, and ultrasound"
219043743|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration)."
218927995|NCT06992947|OTHER|Healthy food subsidy: $27/household/week|Participants receive 16 weeks of coupons valued at $27/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
219043744|NCT06909695|OTHER|Blood volume and environmental testing|Testing blood volume measures, iron stores, and physiological responses to acute environmental exposures of heat, cold, and high-altitude (each environment independently)
219043745|NCT06909149|DRUG|Amniotic membrane extract eye drops|Patients received the amniotic membrane extract eye drops once every two hours during waking time as an adjunctive therapy to the specific treatment.
219043746|NCT06909149|DRUG|Specific treatment|Patients received the specific treatment only.
219043747|NCT06908122|DIAGNOSTIC_TEST|laboratory biomarkers in the diagnosis of NAFLD disease|"All included patients will be assessed as follows:~1\. Questionnaire: different questionnaire variables extrapolated from study published by Xin Li, 2024, Bao et al., 2024 (8), (9).The questionnaire will be divided into six parts: First section includes demographic characteristics of patients as (name , age, gender, occupation, educational level and special habits) The second section includes chronic diseases-related questions and drug administration as if a patient were diagnosed with chronic disease, on treatment and drugs used.~The third section for assessment of dietary lifestyle includes:~nutrition adherence to Mediterranean will be assessed by a validated 17-item MedDiet adherence questionnaire, which all participants will answer. A score will be given for each met objective: 1 (compliance) or 0 (non-compliance).~The counseling session will be about the Mediterranean diet program, and a brochure will be given to each patient."
219043748|NCT06908239|OTHER|thermostatic feeding|In the thermostatic feeding group (intervention arm), milk or formula was delivered directly into the stomach via an infusion pump (Model 8713030CN, Shenzhen Shengnuo Medical Equipment Co., Ltd., Shenzhen, Guangdong, China) located within the incubator. The initial temperature of the milk was set at 38°C, and naturally decreased to match that of the incubator, maintaining a stable, thermostatic environment until the completion of feeding, as well as the setting and adjustment of the temperature of incubator according to the Chinese Medical Association guidelines
218927996|NCT06992947|OTHER|Healthy food subsidy: $54/household/week|Participants receive 16 weeks of coupons valued at $54/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
219366955|NCT00224536|PROCEDURE|Intracoronary bone marrow cell transfer|
219366956|NCT06120257|PROCEDURE|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
219366957|NCT06120257|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
218927997|NCT06992947|OTHER|Healthy food subsidy: $81/household/week|Participants receive 16 weeks of coupons valued at $81/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
219366958|NCT06120257|PROCEDURE|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
218927998|NCT06992947|OTHER|Nutrition skill-building|Participants are eligible, but not required, to attend optional nutrition skill-building activities (e.g. cooking and gardening classes).
219366959|NCT03785054|DRUG|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
219366960|NCT03785054|DRUG|Placebo oral capsule|Placebo treatment
219366961|NCT04597476|DIETARY_SUPPLEMENT|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
219366962|NCT04597476|OTHER|Placebo( Potato starch)|Potato starch 4.4gram
219366963|NCT00953394|DRUG|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
219540068|NCT05860686|OTHER|Monoject syringe|monoject syringe is used to clean the wound
218927999|NCT05104112|OTHER|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
218928000|NCT06601361|DEVICE|Fibroscan|Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.
219540069|NCT01083784|DRUG|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
218928001|NCT06598917|DRUG|S-1|"Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request."
219043749|NCT06908239|OTHER|control|In the control arm, standard feeding involved delivering breast milk or formula directly into the stomach using an infusion pump (Model 8713030CN) placed on an infusion stand. The initial temperature of the milk or formula was set at 38°C, and the temperature was allowed to naturally decrease to match the ambient air temperature of the NICU until feeding was completed. For both groups, the feeding volume and speed were managed in accordance with the clinical application guidelines for neonatal nutrition support in China.
219043750|NCT06908200|DEVICE|Radiofrequency therapy|Radiofrequency or myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
219043751|NCT06908200|OTHER|myofascial manual therapy|Myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
219043752|NCT06909656|OTHER|Multimodal electrophysiological recordings|"Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary (tic-like) movement."
219043753|NCT06908356|DRUG|30mg PRAX-628|Once daily oral
219540070|NCT01083784|DRUG|Control group|Control group
219540071|NCT04266405|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
219540072|NCT04266405|DIETARY_SUPPLEMENT|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
219540073|NCT02208128|DRUG|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
219540074|NCT05423197|DRUG|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
219043754|NCT06904781|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
219043755|NCT06904781|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Vitapex/Metapex)
219043756|NCT06909305|DRUG|Ozone|Patients received intraarticular ozone injection.
219540075|NCT05423197|DRUG|Panitumumab|Panitumumab 30mg will be given orally
219540076|NCT05929222|RADIATION|Radiotherapy|Involved-Site Radiation Therapy 24Gy
219540077|NCT05929222|OTHER|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
219540078|NCT04279353|OTHER|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
219540079|NCT00660426|DRUG|Oxaliplatin|
219540080|NCT00660426|DRUG|Gemcitabine|
219540081|NCT00660426|DRUG|Capecitabine|
219540082|NCT00950989|DRUG|Brodalumab|3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
219540083|NCT00950989|DRUG|Placebo|3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
219540084|NCT00950989|DRUG|Methotrexate|Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
219540085|NCT00950989|DIETARY_SUPPLEMENT|folic acid|at least 5 mg per week
219540086|NCT03936556|DRUG|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
218928002|NCT06600256|BEHAVIORAL|Viz HCM ECG Review|Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&amp;#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.
218928003|NCT06600256|BEHAVIORAL|Baseline Effectiveness Cohort|A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.
218928004|NCT06991413|DEVICE|PMS App|The PMS App helps to implement multimodal self help measures in the daily lives of PMS patients through various functions such as symptom diary and interactive exercises.
218928005|NCT06588465|DEVICE|On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
218928006|NCT06588465|DEVICE|low dose On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
218928007|NCT06599294|PROCEDURE|Digital scanning|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
218928008|NCT06599294|PROCEDURE|Two digital impressions will be recorded, one with a conventional intra-oral scanner and another one with an intra-oral photogrammetry scanner.|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
218928009|NCT06614959|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) Therapy|The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
218928010|NCT06073938|DRUG|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
218928011|NCT06993090|DEVICE|Kinesio Tape|A thin, flexible, and elastic therapeutic tape intended for skin application to provide support for muscles and joints. This tape may help decrease pain, swelling, and inflammation while permitting movement. It is commonly utilized to enhance athletic performance and facilitate injury recovery. The tape functions by elevating the skin, which can enhance blood and lymph circulation, and is believed to engage the nervous system through proprioceptive feedback.
218928012|NCT04757168|DEVICE|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
218928013|NCT06673238|DRUG|ABBV-722|Oral Capsule
218928014|NCT06673238|DRUG|Placebo|Oral Capsule
218928015|NCT05455879|OTHER|Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
218928016|NCT06993298|DEVICE|Augmented Reality Ergonomics Training (ARPE)|Participants in this arm will receive an interactive training module using Augmented Reality (AR) delivered via the MAKAR XR app. The module aims to enhance ergonomic knowledge, self-prevention, and self-evaluation related to work-related musculoskeletal disorders (WMSDs)
219043757|NCT06909305|DRUG|Dextrose prolotherapy|Patients received intraarticular dextrose prolotherapy injection.
219043758|NCT06909305|DRUG|Dexmedetomidine|Patients received intraarticular dexmedetomidine injection.
219540087|NCT03936556|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
219540088|NCT03230630|DIAGNOSTIC_TEST|plasma melatonin levels|
219540089|NCT01841554|DEVICE|Cardioband|
219540090|NCT01039961|DRUG|losmapimod 1 mg|IV infusion
219540091|NCT01039961|DRUG|losmapimod|IV infusion (dose to be determined based on PK from first dose)
219540092|NCT01039961|DRUG|losmapimod 15 mg|oral, two 7.5 mg tablets
219540093|NCT02992366|PROCEDURE|implant placement|implant placement
219540094|NCT04486339|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
219540095|NCT01767103|DRUG|Ferriprox®|
219540096|NCT05718284|DEVICE|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
219620351|NCT06188078|OTHER|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies will be bathed under running water 20 minutes after feeding.The bathing process will take 4 minutes in total. After bath, a urine bag will be inserted at the 25th minute of feeding. The success of the transaction and the processing time will be recorded.
218928017|NCT06993298|BEHAVIORAL|Conventional Ergonomics Training|Participants in this arm will receive conventional ergonomic training based on the Department of Occupational Safety and Health (DOSH) guidelines for manual material handling (MMH) workers. The training includes lectures, printed materials, and standard instructional content focused on safe lifting techniques, proper posture, risk factor identification, and strategies to prevent work-related musculoskeletal disorders (WMSDs). This training is delivered in a one-time session with follow-up reminders, simulating current standard practices in workplace safety education.
218928018|NCT06594211|BIOLOGICAL|ACT-001 CAR-NK cell|Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
218928019|NCT06591299|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
218928020|NCT06591299|DRUG|Clopidogrel 75mg|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
218928021|NCT06588452|OTHER|RECTIFIER - a generative artificial intelligence screening tool|RECTIFIER is a large-language model based, generative artificial intelligence-enabled inclusion and exclusion criteria assessment tool.
218928022|NCT06588452|OTHER|Manual clinical trial screening by study staff|The current gold standard - study staff manually review potentially eligible patients through chart review.
218928023|NCT06587373|OTHER|Assessment of the quality of mother-child dyadic relationships|Filling out questionnaires
218928024|NCT06542835|BEHAVIORAL|Video text message|Video text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.
218928025|NCT06542835|BEHAVIORAL|In-clinic CRC screening promotion|Stool-test orders, colonoscopy referrals.
218928026|NCT06542835|BEHAVIORAL|Mailed FIT|Mailed FIT kits.
218928027|NCT06542835|BEHAVIORAL|Social needs navigation|Patient navigation to address social needs.
218928028|NCT06542835|BEHAVIORAL|Reminders|Centralized text and/or telephone reminders for ordered tests.
218928029|NCT06587477|OTHER|Hormonal profile|Blood for FSH, LH, testosterone
219359878|NCT06074640|OTHER|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
219540097|NCT05718284|OTHER|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
219540098|NCT03554577|DEVICE|Hearing Aid without NR|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
219540099|NCT03554577|DEVICE|Hearing Aid with NR_A|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
219620352|NCT05994872|PROCEDURE|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel.
218928030|NCT06587477|OTHER|Semen analysis|Semen analysis
218928031|NCT06587477|OTHER|Questionnaire|The European Male Ageing Study (EMAS) questionnaire
219043759|NCT06568211|DEVICE|Virtual Reality|Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.
218928032|NCT05934565|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
218928033|NCT05514886|DEVICE|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
218928034|NCT07015398|DRUG|NAL ER|Oral tablets
218928035|NCT07015398|DRUG|Pirfenidone|Oral tablets
218928036|NCT07015398|DRUG|Nintedanib|Oral capsules
218928037|NCT05320445|BEHAVIORAL|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
218928038|NCT03075072|RADIATION|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
219359879|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally|coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine
219620353|NCT05994872|PROCEDURE|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel.
219620354|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 60 Hz|Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
219620355|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 130 Hz|Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
218928039|NCT03075072|RADIATION|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
218928040|NCT06474832|OTHER|High-intensity interval training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform HIIT with 5 intervals at 80% heart rate reserve (HRR), each interval lasting 4 minutes, with 3-minute intervals at 40% HRR between each interval.
218928041|NCT06474832|OTHER|Moderate intensity continuous training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform continuous exercise at 59% HRR for 35 minutes.
218928042|NCT06874803|PROCEDURE|Acupuncture and Moxibustion (AM)|Acupuncture and moxibustion group (AM): Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (BL33), and bilateral Weiyang (BL39), combined with moxibustion at Shuifen (CV9) and Zhongliao (BL33).
218928043|NCT06874803|PROCEDURE|Sham Acupuncture and Moxibustion (Sham-AM)|Sham acupuncture and moxibustion group (sham-AM): Acupuncture at non-acuipoints of bilateral Hegu (LI4) and bilateral Zusanli (ST36), with fake moxibustion at Shuifen (CV9) and bilateral Zhongliao (BL33).
218928044|NCT03868995|PROCEDURE|Sham injection|Dextrose water injection to subcutaneous layer at tender point
218928045|NCT03868995|PROCEDURE|Tendon injection|Dextrose water injection to injured tendon
218928046|NCT06592391|OTHER|educational innovation dynamic school day|Schools will form a community of practice, and will be supported with regular workshop to develop a dynamic school day that matches the local context.
218928047|NCT06592391|OTHER|e-learning on a dynamic school day|Schools will form a community of practice, and will develop a dynamic school day that matches their local context using e-learning materials
218928048|NCT06592391|OTHER|expert schools|Schools that have developed a local dynamic school day without additional support
218928049|NCT05625490|DRUG|Ga-68 Galmydar|Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
218928050|NCT05625490|DRUG|13N-ammonia|Two intravenous injections of PET radiotracer \[13N\]Ammonia.
218928051|NCT05755516|DEVICE|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
218928052|NCT05755516|DEVICE|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
218928053|NCT07022353|PROCEDURE|Bilevel erector spinae plane block|Block will be performed unilaterally with the patient in the sitting position leaning forward. The block will be done using a high frequency linear probe (6-13 MHz). The block area will be adequately sterilized and draped, then the ultrasound probe will be placed 2-3 cm laterally from the midline at the level of the T3 spinous process using a sagittal approach to identify the hyperechoic transverse process shadow deep to the trapezius, rhomboid major, and erector spinae muscles. Then, the needle will be inserted craniocaudally in-plane to reach the transverse process deep to the erector spinae muscle. Correct positioning of the needle will be confirmed through real-time visualization of 2-mL saline hydro dissection. After confirmation of needle position, 15 mL of bupivacaine 0.25% will be injected at each level. The same procedure was repeated for the second level T5 spinous process. block failure defined as the presence of full sensation after 30 minutes, patients will be excluded .
218928054|NCT07022353|DRUG|Placebo Oral Capsule|One hour prior to anesthesia induction, the patients will recieve oral placebo capsule that will have the same color, smell, and size as tizanidine.
218928055|NCT07022353|DRUG|tizanidine oral capsule|One hour prior to anesthesia induction, the tizanidine group will receive a 4 mg tizanidine oral capsule.
218928056|NCT04207788|OTHER|HIP-REP|HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.
218928057|NCT04207788|OTHER|Usual care|The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
219043760|NCT06568211|DEVICE|Tablet-Only|PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).
219043761|NCT06915675|BIOLOGICAL|Placental Extract|Participants will receive allografts bone substitutes mixed with flowable human placental derived connective tissue matrix in one extraction socket immediately following tooth extraction.
219043762|NCT06915675|PROCEDURE|Allograft|Participants will receive allografts bone substitutes solely in one extraction socket immediately following tooth extraction.
219043763|NCT06919419|BEHAVIORAL|Multicomponent strategy|dentify patients for HIV/STI testing, engage in discussions around PrEP and navigate patients to PrEP after jail incarceration
219043764|NCT06919159|DIAGNOSTIC_TEST|PSMA PET/CT scan|Different developing agents
219043765|NCT06919159|DIAGNOSTIC_TEST|FDG-PET|Different developing agents
219043766|NCT06923891|DRUG|Xanomeline/Trospium|Xanomeline/Trospium (titrated dose)
219359880|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously|coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
219359881|NCT04445857|OTHER|Normal Saline (NS)|coadministration of normal saline and a single-shot hyperbaric bupivacaine
219359882|NCT01227902|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
219359883|NCT06008574|OTHER|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
219366964|NCT01804231|OTHER|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
218928058|NCT07025317|OTHER|Perceptual-cognitive|"The intervention is to determine the effectiveness of NeuroTracker for treating cognitive deficits associated with a prior history of concussion. NeuroTracker has a virtual cloud-based platform (NeuroTrackerX), which has been validated for use in research. This online platform allows participants to complete the interventions from home and greatly increases the accessibility of the program. Participants will have two 30-minute training sessions per week over the course of the 6-month intervention. Each session will consist of 3 blocks of 20 trials. For each trial in a block, participants sit upright, approximately 20 away from a standard computer or laptop screen, and wear anaglyph 3D glasses while focusing on the center of a standard 20 computer screen."
218928059|NCT04429256|OTHER|data collection|retrospective analysis of perioperative data collected from patient medical charts and from a telephone enquiry
218928060|NCT07024758|BEHAVIORAL|Parent Coached Exposure Therapy|Parent-based cognitive behavioral therapy with guidance from a therapist
218928061|NCT07024758|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
218928062|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
218928063|NCT06705452|OTHER|Additional 4D Flow MRI or additional 4D Flow sequence|Additional 4D Flow MRI or additional 4D Flow sequence
218928064|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket wire in high level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in low level for the treatment of anterior deep bite .
218928065|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket with wire in low level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in high level for the treatment of anterior deep bite .
218928066|NCT02374450|PROCEDURE|Blood collection|For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
218928067|NCT06706999|OTHER|PREVAIL model of care|"Components 1, 2, and 3 are essential components that all participants will receive. Components 4 and 5 are based on the results of either the DAPS tool or the PT consultation call.~1. Screening tool (DAPS) completed at baseline to determine current level of limitation with valued life activities.~2. Recommendation to rheumatology clinician based on screening results to provide exercise resource and/or recommend a PT consult call during routine visit.~3. Exercise resource (PREVAIL website) provided to all participants by their rheumatology clinician at their routine visit.~4. Brief consultation call with a study physical therapist to determine level of priority for PT referral. Only applicable for those with/at risk for limitation with valued life activities.~5. Referral to PT. Only applicable if determined by study physical therapist to meet priority requirements."
218928068|NCT06053775|DEVICE|Transcranial Direct Current Stimulation|tDCS+OCT
218928069|NCT06053775|DEVICE|Transcranial Alternating Current Stimulation|tACS+OCT
218928070|NCT06053775|DEVICE|tES sham|tES sham + OCT
218928071|NCT06053775|DEVICE|Online Cognitive Training|OCT
218928072|NCT03694938|DEVICE|Magnetic resonance imaging|Annually magnetic resonance imaging
218928073|NCT06706687|DIAGNOSTIC_TEST|DISBAND protocol|For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
218928074|NCT00093626|OTHER|Laboratory Biomarker Analysis|Correlative studies
218928075|NCT00093626|DRUG|Sorafenib Tosylate|Given orally
218928076|NCT06286202|BEHAVIORAL|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.
218928077|NCT06286202|BEHAVIORAL|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
218928078|NCT05490927|BEHAVIORAL|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
218928079|NCT05251558|OTHER|Telerehabilitation|The telerehabilitation platform is used to deliver the home exercise program.
218928080|NCT05251558|OTHER|Conventional Education Program|The patient is given education about the points to be considered for the disease and the exercises to be applied.
218928081|NCT04499313|DRUG|Dexamethasone|Injectable solution
218928082|NCT04499313|DRUG|Methylprednisolone|Injectable solution
218928083|NCT05647603|OTHER|data collection|Information about contraception
218928084|NCT04754659|DEVICE|Stentgraft|Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
218928085|NCT05884827|DEVICE|EMG|Measure the electrical activity of the muscle and nerve
219043767|NCT06923176|DRUG|Biejia-Ruangan compound|Biejia-Ruangan compound have the functions of softening hardness, dispersing lumps, removing blood stasis and detoxifying, and nourishing qi and blood. Used for chronic hepatitis B liver fibrosis, as well as early liver cirrhosis characterized by blood stasis obstructing collaterals, qi and blood deficiency with incomplete heat toxicity.
219043768|NCT06923176|OTHER|Routine medical care|Routine medical care
219366965|NCT03680937|OTHER|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
218928086|NCT03202771|DEVICE|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
218928087|NCT03202771|OTHER|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
218928088|NCT02386644|OTHER|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
218928089|NCT02386644|DEVICE|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
218928090|NCT02386644|DEVICE|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
218928091|NCT02386644|OTHER|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
218928092|NCT02386644|OTHER|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
218928093|NCT02653417|DRUG|RAD1901|RAD1901
218928094|NCT02653417|OTHER|Placebo|Placebo
218928095|NCT00804076|BIOLOGICAL|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
218928096|NCT04769388|DRUG|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
218928097|NCT04769388|DRUG|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
218928098|NCT03168776|DEVICE|BuMA Supreme DES|Implant BuMA Supreme stent only
218928099|NCT03168776|DEVICE|Xience or Promus DES|Implant XIENCE family or Promus family only
218928100|NCT03024476|BEHAVIORAL|Behavioral intensification|"Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
218928101|NCT03024476|DRUG|Pharmacological intensification based on olmesartan|"* Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
219359884|NCT06008574|OTHER|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
218928102|NCT03024476|DEVICE|Bluetooth-equipped sphygmomanometer|"* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
218928103|NCT00082225|BIOLOGICAL|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
218928104|NCT00082225|BIOLOGICAL|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
219359885|NCT06008574|OTHER|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
219366966|NCT03680937|OTHER|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
219366967|NCT00963326|OTHER|laboratory biomarker analysis|
218928105|NCT04342533|PROCEDURE|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
218928106|NCT04342533|PROCEDURE|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
218928107|NCT02301416|DRUG|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
218928108|NCT02301416|OTHER|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
218928109|NCT03310853|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
218928110|NCT03310853|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
218928111|NCT01293656|OTHER|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
218928112|NCT06144112|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
218928113|NCT06144112|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
219620356|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) Off (Sham)|Deep Brain Stimulation (DBS) Off (Sham)
219620357|NCT01399775|PROCEDURE|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
219620358|NCT01399775|PROCEDURE|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
219620359|NCT06574581|BIOLOGICAL|ADSC01|The initial 3 subjects will receive low-dose AD-MSC (1x10E6 cells/kg) infusion therapy only once; if no adverse events after 4 weeks, the next 4-7 subjects will receive medium-dose AD-MSC (1x10E6 cells/kg) infusion therapy twice; if no adverse events after 4 weeks of the last infusion, the next 8-10 subjects will receive high-dose AD-MSC (1x10E6 cells/kg) infusion therapy three times.
218928114|NCT01106690|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
218928115|NCT01106690|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
218928116|NCT01106690|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
218928117|NCT01106690|DRUG|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
218928118|NCT01106690|DRUG|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
218928119|NCT00489658|DRUG|Eflornithine plus Nifurtimox combination therapy|
218928120|NCT04028219|DIAGNOSTIC_TEST|Online surveys|Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
218928121|NCT04682054|PROCEDURE|ocular surgery|surgery to remove the pathological eye tissue
218928122|NCT00042315|PROCEDURE|Chemotherapy|
218928123|NCT00042315|DRUG|tariquidar + vinorelbine|
218928124|NCT00042315|DRUG|placebo + vinorelbine|
218928125|NCT05847816|OTHER|Experimental group: infrared vascular imaging|"Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin."
218928126|NCT05933382|OTHER|Corticosteroid Group|Conventional exercise and corticosteroid injection
218928127|NCT05933382|OTHER|Mulligan Group|Conventional exercise and mulligan mobilization
218928128|NCT00031278|DRUG|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
218928129|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
219043769|NCT06923982|OTHER|virtual reality, experimental group|Socio-demographic characteristics form questions were asked to individuals in the intervention group before care. During the care, patients are given virtual reality glasses (VR box 2.0 virtual reality glasses and 6.5 inch) for a total of 15 minutes, ranging from 3 to 10 minutes, and watch videos that the patient wants to watch, such as park, nature and seaside walks, undersea and museum trips, with a music background. and he was shown videos that he could change at any time. After the maintenance, Visual Analog Scale-Pain (VAS-P) scale, General Comfort Level Scale and Satisfaction Evaluation Scale for Virtual Reality Glasses Application questions were applied. 24 hours after the care, VAS-P and General Comfort Level Scale were administered again.
219043770|NCT06923982|OTHER|control group|A socio-demographic questionnaire was administered to the control group before care. During maintenance, no intervention was applied and standard care in routine practice was applied. After the care, Visual Analog Scale-Pain (VAS-P) scale and General Comfort Scale were applied. 24 hours after the treatment, the Visual Analog Scale-Pain (VAS-P) scale and the General Comfort Scale were applied again.
219043771|NCT06924762|DRUG|Placebo intramuscular injection|On the basis of background treatment, intramuscular injection of placebo was added.
219043772|NCT06924762|DRUG|Human interleukin-2 (I) intramuscular injection|On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.
219043773|NCT06924086|DEVICE|Deep Brain Stimulation|Picostim DBS Device
219043774|NCT06924229|DRUG|Hormonal treatment|hormonal treatment for breast cancer
219043775|NCT06924268|BEHAVIORAL|Single Art Therapy Session|Each participant will engage in a 30-60 minute structured art therapy session using pre-drawn coloring sheets featuring themes such as mandalas, nature scenes, and inspirational designs. A variety of coloring tools will be provided, including crayons, colored pencils, markers, gel pens, and watercolor paints. Sessions will be facilitated by the primary investigator, who will provide non-directive prompts and engage in casual conversation to foster comfort and engagement.
219366968|NCT05222633|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
219366969|NCT05222633|DRUG|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
219366970|NCT05222633|DRUG|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
218928130|NCT00031278|DRUG|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
218928131|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
218928132|NCT00031278|DRUG|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
218928133|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
218928134|NCT00031278|DRUG|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
218928135|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
219540100|NCT03554577|DEVICE|Hearing Aid with NR_B|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
219620360|NCT03070236|OTHER|Survey|Select questions will be ask in the survey
218928136|NCT00831181|DRUG|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
218928137|NCT00831181|DRUG|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
218928138|NCT00831181|DRUG|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
218928139|NCT00831181|PROCEDURE|mesorectal excision|mesorectal excision
218928140|NCT01119378|OTHER|Dual isotope technique|Dual isotope technique using stable isotopes
218928141|NCT04085289|DRUG|Galcanezumab|Administered SC
218928142|NCT04085289|DRUG|Placebo|Administered SC
218928143|NCT04648397|OTHER|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
218928144|NCT04648397|OTHER|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
218928145|NCT05302726|DRUG|Estrogen|Transdermal and oral estrogen both as substitution therapy
218928146|NCT01924949|DRUG|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
218928147|NCT03751930|OTHER|Samples|Urinary and faecal samples
218928148|NCT03798353|COMBINATION_PRODUCT|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
218928149|NCT03798353|PROCEDURE|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
218928150|NCT05761548|DIAGNOSTIC_TEST|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
219620361|NCT01710865|OTHER|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
219620362|NCT01710865|OTHER|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
218928151|NCT06096961|BEHAVIORAL|Baby smell|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process.
218928152|NCT03292796|DRUG|Prostaglandins|
218928153|NCT05585450|DEVICE|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
218928154|NCT05585450|DEVICE|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
218928155|NCT01121770|DRUG|fondaparinux sodium injection|1.5mg subcutaneously every day
218928156|NCT04029402|OTHER|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
218928157|NCT04721886|PROCEDURE|Ultrasonsgraphy|Undergo ultrasonography
218928158|NCT04721886|DRUG|Perflutren Lipid Microcpheres|Given IV
218928159|NCT04721886|PROCEDURE|Contrast - Enhanced Ultrasound|Undergo CEUS
218928160|NCT02145377|BIOLOGICAL|PXVX0200 10E8|Oral dose of PXVX0200 10E8
218928161|NCT02145377|BIOLOGICAL|PXVX0200 10E9|Oral dose of PXVX0200 10E9
218928162|NCT02145377|BIOLOGICAL|Placebo|Oral dose of sodium bicarbonate buffer
218928163|NCT02145377|BIOLOGICAL|Shanchol|Licensed comparator
218928164|NCT03863158|OTHER|No intervention|No intervention / medical records only
219620363|NCT03173898|PROCEDURE|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
219620364|NCT02962583|OTHER|Weight loss|
219620365|NCT02962583|DRUG|Probiotic Formula|
219620366|NCT02962583|DRUG|Placebos|
219620367|NCT06338488|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
218928165|NCT02217202|DEVICE|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
218928166|NCT00606606|OTHER|Clinical Decision Support|
218928167|NCT00482248|DRUG|Omalizumab|
218928168|NCT02722993|DIETARY_SUPPLEMENT|Probiotics|
218928169|NCT02722993|DIETARY_SUPPLEMENT|Placebo|
218928170|NCT04193995|BEHAVIORAL|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
219205194|NCT06890910|OTHER|evidence based intervention|"sleep hygiene education. This education focused on four main aspects as follows:~* Personal habits: Women were educated on establishing a regular bedtime routine, engaging in regular exercise, maintaining a healthy diet, avoiding caffeine and nicotine before bedtime, consuming adequate calcium and magnesium, drinking warm milk before sleep, and avoiding gas-producing foods or excessive fluid intake before bed.~* Sleep environment: Women were advised to associate the bedroom only with sleep and intimacy, remove electronic devices, maintain a dark, quiet, and cool environment, ensure mattress and pillows were comfortable, and eliminate noise disturbances such as television.~* Stimulus control: Participants were instructed to use the bed only for sleeping, avoid staying in bed if unable to sleep, and engage in minimally stimulating activities instead of worrying about insomnia.~* Progressive muscle relaxation: Women in the study group received an educational session on the Jacobson's met"
219205195|NCT06891196|OTHER|Long-term Follow-up Surveys|Patients will be given surveys, including validated PRO measures such as the Hip Disability and Osteoarthritis Outcomes Score (HOOS), Short-Form 12 (SF-12), Visual Analog Scale (VAS) for pain, and Marx activity scores.
219205196|NCT06890819|BEHAVIORAL|Assigned Interventions|Behavioral: Structured Feedback, Clinical Decision-Making, Anxiety, Self-Confidence,
219205197|NCT06892470|OTHER|No intervention|No intervention
219205198|NCT06733116|OTHER|Delphi method survey|This intervention involves a Delphi method study, where a panel of experts in isokinetic testing will collaborate to reach a consensus on best practices for standardizing the reporting of isokinetic test data. Unlike other clinical studies, this intervention focuses on gathering expert opinions iteratively to establish a unified framework for data reporting, without direct clinical or experimental treatment. The process includes multiple rounds of feedback, refining key elements related to testing protocols, measurement parameters, and result presentation, ensuring broad expertise from various fields such as medicine, rehabilitation, and biomechanics.
219540101|NCT03554577|DEVICE|Hearing Aid with NR_C|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
219540102|NCT00665145|DRUG|SB-509|Active drug
219205199|NCT06738940|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 48 weeks
219205200|NCT06738979|DRUG|TQF3510 (Semaglutide Injection)|Semaglutide injection is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist.
219205201|NCT06738979|DRUG|Wegovy®|Active Comparator
219205202|NCT06740448|DIETARY_SUPPLEMENT|Green Tea|200 mL Green Tea
219205203|NCT06740448|DIETARY_SUPPLEMENT|Control (Hot Water)|200 mL hot water
219540103|NCT00665145|DRUG|SB-509|Active drug
219540104|NCT00665145|DRUG|Placebo|Placebo
218928171|NCT02196844|BEHAVIORAL|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
218928172|NCT02196844|BEHAVIORAL|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
218928173|NCT02196844|OTHER|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
218928174|NCT01662570|BEHAVIORAL|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
218928175|NCT01662570|OTHER|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
219540105|NCT00665145|DRUG|SB-509|Active drug
219540106|NCT03423485|DEVICE|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
219540107|NCT03804983|DEVICE|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
219540108|NCT03804983|DEVICE|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
219540109|NCT03600376|DRUG|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
218928176|NCT03332706|OTHER|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
218928177|NCT00831480|DRUG|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
218928178|NCT06441240|DIAGNOSTIC_TEST|MRI|Breast MRI
218928179|NCT01312740|OTHER|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
218928180|NCT01312740|OTHER|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
218928181|NCT01531569|OTHER|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
218928182|NCT03674853|DRUG|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
218928183|NCT03674853|DRUG|Oryzanol|take oryzanol in active comparator group for 2 months
218928184|NCT02919995|DRUG|RPL554|RPL554 suspension administered using a nebuliser
218928185|NCT02919995|DRUG|Placebo|Placebo solution administered using a nebuliser
218928186|NCT00560170|DRUG|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
218928187|NCT00560170|DRUG|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
218928188|NCT02717923|OTHER|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
219205204|NCT06739265|DRUG|Golidocitinib plus CHOP|Phase 1: dose escalation phase. Drug Golidocitinib: 2 dose level of 150 mg qod and 150 mg qd; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle. Phase 2: dose expansion phase. Drug Golidocitinib: RP2D established in the phase I study; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle.
219540110|NCT03600376|OTHER|Standard of Care|Body cooling measures and supportive measures
219540111|NCT06248879|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219540112|NCT06248879|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219620368|NCT06338488|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
219620369|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
219620370|NCT05035407|DRUG|IL-2 (Aldesleukin)|dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
219620371|NCT05035407|DRUG|Cyclophosphamide|30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)
219620372|NCT05035407|BIOLOGICAL|KK-LC-1 TCR|1 x 108 transduced KK-LC-1 TCR T cells
219620373|NCT05035407|DRUG|Fludarabine|25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
219620374|NCT05816239|PROCEDURE|Dual Energy CT|Patient will receive Dual Energy CT
218928189|NCT01915589|DRUG|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
218928190|NCT02847052|OTHER|Non interventional study|
218928191|NCT04663009|DEVICE|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
218928192|NCT00070967|PROCEDURE|Acupuncture|
218928193|NCT01059435|DRUG|Romosozumab|Administered subcutaneously or intravenously
218928194|NCT01059435|DRUG|Placebo|Administered subcutaneously or intravenously
218928195|NCT03228225|BEHAVIORAL|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
218928196|NCT01443052|OTHER|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
218928197|NCT03677557|DRUG|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
218928198|NCT02660372|DRUG|Imonogas|Simethicone 120 mg in gel capsules
218928199|NCT02660372|DRUG|Espumisan|Simethicone 40 mg in gel capsules
218928200|NCT04491318|OTHER|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
219043776|NCT06923904|OTHER|Trial group, treated with a 980 nm diode laser and desensitizing topical gel|The study aims to evaluate the actual efficacy of diode lasers in laser desensitization by comparing the topical gel Emoform Actisens, containing 5% potassium nitrate, alone and in combination with a diode laser.
219043777|NCT06924749|DRUG|EGCG|"EGCG (high pressure liquid chromatographic purity~≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day."
218928201|NCT05369741|OTHER|TIME™ at Home|"Components of each 1.5-hour session:~1. Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~2. Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~3. Post-class social time (15 min): Structured and unstructured social interactions~4. Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~5. Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
218928202|NCT03524976|DEVICE|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
218928203|NCT02889952|DEVICE|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
218928204|NCT05103137|OTHER|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
218928205|NCT04943653|DRUG|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
218928206|NCT04640220|PROCEDURE|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
218928207|NCT03196349|DRUG|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
218928208|NCT03196349|DRUG|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
218928209|NCT03196349|DRUG|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
218928210|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel for lip augmentation
218928211|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
218928212|NCT00655200|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
218928213|NCT02210039|DEVICE|SECM Probe|Imaging of the esophagus using SECM probe and system.
219043778|NCT06924242|PROCEDURE|total or partial thyroidectomy|Total thyroidectomy is a surgical procedure that involves the complete removal of the thyroid gland. It is performed to treat conditions such as thyroid cancer, large goiters, or severe hyperthyroidism. The surgery is typically conducted under general anesthesia through an incision in the lower neck. Postoperative management may include hormone replacement therapy with levothyroxine to compensate for the loss of thyroid function. Potential complications include hypocalcemia due to parathyroid gland injury and vocal cord dysfunction from recurrent laryngeal nerve damage.
219043779|NCT06924645|PROCEDURE|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplantation (FMT) is delivered as a single dose of oral microbiota capsules within 72 hours before starting standard therapy.
219043780|NCT06924645|OTHER|Standard Therapy|Standard Therapy Alone
219043781|NCT06923644|OTHER|Optimal Metabotype-specific diet|Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.
219043782|NCT06923644|OTHER|Sub-optimal diet|Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.
219366971|NCT02601573|DRUG|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
218928214|NCT03775135|OTHER|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
219366972|NCT02601573|DRUG|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
219366973|NCT02601573|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
219366974|NCT02601573|DRUG|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
219366975|NCT03527576|DRUG|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
219366976|NCT03527576|DRUG|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
219366977|NCT00001757|DRUG|Voriconazole|
219366978|NCT00746499|DRUG|Raltegravir|400mg raltegravir BID x 7 days
219366979|NCT04968444|OTHER|Physiotherapy|"Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation"
218928215|NCT05242380|OTHER|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
218928216|NCT03441815|DRUG|XC8|
218928217|NCT03441815|DRUG|Placebo|
219043783|NCT06923865|BEHAVIORAL|training group|"Participants in training group are invited to take part in two structured training sessions per week, each lasting 90 minutes:~One session takes place in a larger group setting, where participants engage in physical activities and games together.~The second session is held in a small group format with 1-2 peers-either friends the participant already knows or peers they meet during the larger group session.~Each training session is supervised by a qualified instructor and includes:~Fun, game-based activities~Short workouts aimed at improving fitness~A focus on social interaction, enjoyment, and participation~The sessions are designed to be supportive, engaging, and motivating, with the goal of increasing physical activity in a positive group environment."
219043784|NCT06923579|PROCEDURE|Titanium Mesh Cage|"the Harms cage was adapted for long bone reconstruction due to its structural stability and biocompatibility. The cage provides immediate mechanical support while allowing for bone ingrowth, addressing the limitations of traditional methods.~Advantages of the titanium mesh cage include its ability to maintain bone length, provide immediate stability, and allow for earlier weight-bearing. The porous structure facilitates vascularization and bone integration, potentially leading to improved healing outcomes"
219043785|NCT06923930|DEVICE|External Cueing Device|A portable product that provides movement pattern constraints to ensure improved exercise form, and provides a target zone for exercise effort
219043786|NCT06923930|OTHER|Exercise|"Shoulder stabilization exercise protocol contains 8 exercises (I, Y, T, i, w, alternating arm I/i, n, and supine serratus punch) completed for 8 repetitions each for 3 weeks, and in weeks 4-6 completed at 2 sets of 8 repetitions each."
219043787|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
219043788|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 1 for 84 days
219043789|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 2 for 84 days
219043790|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 3 for 84 days
219540113|NCT06248879|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219043791|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
219540114|NCT00139113|BIOLOGICAL|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
219540115|NCT02152163|DRUG|IV Ibuprofen|
218928218|NCT02542319|DIETARY_SUPPLEMENT|Mablet 360 mg|
218928219|NCT02542319|DIETARY_SUPPLEMENT|Placebo|
218928220|NCT04355039|DRUG|Pomalidomide|4 mg Days 1-21
219043792|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 5 for 84 days
219043793|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 6 for 84 days
219043794|NCT01403038|DRUG|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
219043795|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
219043796|NCT04242108|DIAGNOSTIC_TEST|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
219043797|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
219043798|NCT00178945|DRUG|Botulinum Toxin Type A|
219540116|NCT02152163|DRUG|placebo|
218928221|NCT04355039|DRUG|Dexamethasone|40 mg Days 1, 8, 15 and 22
218928222|NCT04355039|DRUG|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
218928223|NCT04355039|DRUG|INCB053914 65 mg BID|Dose level 1: 65 mg BID
218928224|NCT04355039|DRUG|INCB053914 80 mg BID|Dose level 2: 80 mg BID
218928225|NCT02064101|PROCEDURE|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
218928226|NCT03330301|OTHER|D-tect|"1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
219620375|NCT04733079|OTHER|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
219620376|NCT04733079|OTHER|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
219620377|NCT05249868|OTHER|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for \<5 days is positive on a PRAg test."
219205205|NCT06741358|OTHER|Glialia|Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.
219205206|NCT06741358|OTHER|Placebo|Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.
219205207|NCT06741358|OTHER|Control|Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
219205208|NCT06740916|DRUG|81-mg aspirin once daily|81-mg aspirin once daily
219205209|NCT06740916|DRUG|81-mg aspirin twice daily|81-mg aspirin twice daily
219620378|NCT06265051|DRUG|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
219620379|NCT06265051|DRUG|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
219205210|NCT06736665|DEVICE|Orbital atherectomy|The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
219540117|NCT03480321|DRUG|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
219540118|NCT03480321|DRUG|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
219540119|NCT03480321|DRUG|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
219540120|NCT05191550|BEHAVIORAL|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
219540121|NCT00796562|DRUG|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
219540122|NCT00796562|DRUG|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
219540123|NCT00796562|RADIATION|Total body irradiation|Patients will receive TBI once a day for 4 days.
219540124|NCT01799798|DRUG|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
219620380|NCT03448042|DRUG|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
219540125|NCT00424047|DRUG|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
219620381|NCT03448042|DRUG|Trastuzumab|Trastuzumab will be administered via IV infusion
218928227|NCT02369796|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
219620382|NCT03448042|DRUG|Tocilizumab|Participants will receive IV tocilizumab if needed
219620383|NCT02820857|DRUG|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
219620384|NCT02820857|DRUG|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
219620385|NCT05753618|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
219620386|NCT05753618|DRUG|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
219620387|NCT06315205|DRUG|Letrozole LEBE 75 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
218928228|NCT01821118|BIOLOGICAL|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
219205211|NCT06736665|DEVICE|Intravascular lithotripsy|The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
219043799|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
219043800|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
219205212|NCT06736665|DEVICE|Optical Coherence Tomography (OCT)|"Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure.~These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment."
219540126|NCT00424047|DRUG|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
219540127|NCT05957263|OTHER|Biofeedback training and Osteopathy procedure|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscle. muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, l
219540128|NCT05957263|OTHER|Biofeedback training|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
219620388|NCT06315205|DRUG|Letrozole LEBE 150 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
219620389|NCT06315205|DRUG|Letrozole LEBE 225 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
219043801|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
219043802|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
219043803|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
219205213|NCT06736665|DEVICE|Percutaneous coronary intervention with stent implantation|All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.
219205214|NCT06737666|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang granules were taken 2 bags at a time, 2 times per day at 1h after meal for 4 weeks.
219205215|NCT06737757|DEVICE|Artificial polymer heart valves|The experimental group will use polymer material surgical aortic valves(PoliaValve, Hearthill Medical) for aortic valve replacement
219620390|NCT01034878|DRUG|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
219620391|NCT00271193|BEHAVIORAL|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
218928229|NCT01821118|OTHER|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
218928230|NCT00642083|DEVICE|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
219620392|NCT05687123|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
218928231|NCT05104177|PROCEDURE|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~* Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~* Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~* Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~* Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~* A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
218928232|NCT01605799|BEHAVIORAL|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
218928233|NCT01605799|BEHAVIORAL|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
218928234|NCT03805282|DRUG|Lidocaine|Continuous infusion, variable dose of lidocaine.
218928235|NCT06379815|OTHER|Sodium Lactate|See arm/group description.
218928236|NCT06379815|OTHER|Sodium Chloride|See arm/group description.
218928237|NCT02422667|OTHER|Patient Registry|Orthopedic Data Registry
218928238|NCT04306341|BEHAVIORAL|real time fMRI neurofeedback|Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
218928239|NCT04549129|BEHAVIORAL|Breastfeeding education video|"An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes)."
218928240|NCT04549129|BEHAVIORAL|Breastfeeding website|"The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby)."
218928241|NCT04549129|BEHAVIORAL|Usual breastfeed education|The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
218928242|NCT02202941|OTHER|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
218928243|NCT02202941|OTHER|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
218928244|NCT01099462|DRUG|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
218928245|NCT00345358|BIOLOGICAL|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
218928246|NCT00345358|BIOLOGICAL|Infanrix IPV/Hib|4 intramuscular injections
218928247|NCT05346419|DRUG|Risedronate|Participants received risedronate 35 mg once a week for 6 months.
218928248|NCT05346419|DRUG|Vitamin D|Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
219205216|NCT06737757|DEVICE|Bovine pericardial aortic valve|The control group will undergo aortic valve replacement using bovine pericardial aortic valve
218928249|NCT03903588|DEVICE|Optical Coherence Tomography|Imaging of the Retina
218928250|NCT03917953|DEVICE|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3)."
218928251|NCT02350140|OTHER|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
219205217|NCT06738238|OTHER|ELDOA|"In this, each position will be maintained for 1 minute Level: C0/C1/C2 The patient is side lying with bottom arm folded under the head and maintain the neck in a horizontal position with the spine. the bottom leg is bent to stabilize the torso in a vertical position.~Level: C4/C5 Patient lying in supine position and raise both hand arm towards the roof of the room with extended wrist. Bilateral knee to chest with planter flexion at ankle joint.~Level: C5/C6 Same position as for c4/c5 with the arms will be elevated 120 degree Level C6/C7 Supine position with one arm abducted 90 degree and wrist joint at extension and the other hand abducted 30degrees with wrist joint at extension and one leg knee to chest and one leg raise with knee extension and planter flexion at ankle joint.~Level: T4/T5 Quadruped position with one arm abducted 90degrees with wrist at extension Level: T6/T7. Conventional TX is Hot Pack, Tens for 10min. Patient is assessed through baseline, week 1, week 2 and week 4."
219620393|NCT05687123|PROCEDURE|Computed Tomography|Undergo a CT scan
218928252|NCT02350140|OTHER|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
218928253|NCT02892448|OTHER|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
218928254|NCT06522490|OTHER|Virtual discrete trial training|VDT was given to Experimental group.
219620394|NCT05687123|DRUG|Lutetium Lu 177 Dotatate|Given IV
219620395|NCT05687123|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219620396|NCT05687123|PROCEDURE|Positron Emission Tomography|Undergo a SSR PET/CT scan
218928255|NCT06450483|DEVICE|Auricular vagus nerve stimulation|"Auricular vagal nerve stimulation using TPN dual channel TENS will be used for the study.The device used to stimulate is a conventional TENS. The stimulation is by applying a clip electrode placed on the tragus of the left ear and a second electrode applied on the left upper trapezius of the participant which will then stimulate the vagus nerve.Auricular vagus nerve stimulation session will be applied for 15 minutes. Participant is seated and relaxed.After the first session ended; heart rate will be measured and recorded once again to see the effect of the VNS.~Before the last AVNS session started; heart rate will be measured and recorded. The participants' vagus nerve is then stimulated for 15 minutes."
218928256|NCT00499083|BIOLOGICAL|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
218928257|NCT00499083|DRUG|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
218928258|NCT00499083|DRUG|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
218928259|NCT00499083|DRUG|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
218928260|NCT00499083|DRUG|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
218928261|NCT00499083|DRUG|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
218928262|NCT00499083|GENETIC|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
219620397|NCT05687123|DRUG|Sunitinib Malate|Given PO
219620398|NCT03515512|DRUG|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
218928263|NCT00499083|GENETIC|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
218928264|NCT00499083|GENETIC|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
219043804|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
219043805|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
219043806|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
219043807|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
219043808|NCT02677090|DRUG|Placebo (including Maltodextrin)|
219366980|NCT04968444|OTHER|Back Pain Workshop|Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
219366981|NCT00974220|DRUG|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
219043809|NCT02677090|DRUG|Dose 1 - Promitor®|
219043810|NCT02677090|DRUG|Dose 2 - Promitor®|
219366982|NCT00974220|DRUG|normal saline (placebo)|single dose, 0.9% saline solution
219366983|NCT01052857|PROCEDURE|acupuncture|acupuncture application
219366984|NCT00608855|OTHER|questionnaire administration|
219366985|NCT00608855|PROCEDURE|cryosurgery|
219366986|NCT00608855|PROCEDURE|pain therapy|
219366987|NCT00608855|PROCEDURE|quality-of-life assessment|
219366988|NCT05257512|DRUG|SY-3505|The third-generation ALK TKI
219366989|NCT04569838|DRUG|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
219366990|NCT03135912|DRUG|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
219366991|NCT03135912|DRUG|Placebo|Dosage method of SESC 01, without active ingredients.
219366992|NCT03135912|DRUG|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
219366993|NCT02921425|BEHAVIORAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
219366994|NCT01227967|DRUG|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
219366995|NCT01227967|DRUG|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
218928265|NCT00499083|OTHER|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
218928266|NCT00499083|OTHER|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
218928267|NCT00499083|OTHER|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
218928268|NCT00499083|PROCEDURE|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
218928269|NCT00499083|PROCEDURE|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
218928270|NCT00499083|PROCEDURE|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
218928271|NCT00499083|PROCEDURE|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
218928272|NCT00499083|RADIATION|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
218928273|NCT04239391|DRUG|Triferic|Ferric Pyrophosphate Citrate
218928274|NCT03143062|DIAGNOSTIC_TEST|NEWS|NEWS
218928275|NCT06152393|DIAGNOSTIC_TEST|Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.|"Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118)."
218928276|NCT01902095|DEVICE|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
218928277|NCT01902095|DEVICE|Tooth paste (control)|Active Comparator
218928278|NCT02731235|OTHER|High-intensity training|high intensity training 5 days a week for 12 weeks
218928279|NCT02731235|DRUG|prophylactic stroke medication|Usual care medication for stroke prophylaxis
218928280|NCT02731235|BEHAVIORAL|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
218928281|NCT02094924|DRUG|GSK587323|Single dose of FDC tablet formulation to be taken orally.
218928282|NCT02094924|DRUG|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
219043811|NCT02677090|DRUG|Dose 3 - Promitor®|
219620399|NCT03346096|DRUG|Thiotepa|fixed dose 5mg/kg on days -7-6
219620400|NCT01668615|DRUG|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
219620401|NCT02399137|DRUG|MM-141|
219620402|NCT02399137|DRUG|Placebo|
219620403|NCT02399137|DRUG|Gemcitabine|
219620404|NCT02399137|DRUG|Nab-Paclitaxel|
218928283|NCT03860493|PROCEDURE|Perfusion evaluation with indocyanine green|"1\. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3\. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs."
218928284|NCT04287790|BEHAVIORAL|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
218928285|NCT04287790|DRUG|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
218928286|NCT00704119|DRUG|RhuDex®|"* Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
218928287|NCT01877395|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
219205218|NCT06738238|OTHER|CORRECTIVE EXERCISES|All position will be held for 10 seconds. Initial phase Duration of this phase is 2 weeks. Exercise 1: lying supine on a foam roll with different abduction angles Exercise 2: side lying with external rotation Exercise 3: side lying with forward flexion Exercise 4: standing diagonal flexion Exercise 5: military press Improvement phase. Duration of this phase is 1 week we only add thera- band and dumbbells to the previously mentioned exercises Exercise 1: side lying external rotation with dumbbell Exercise 2: side lying forward flexion with dumbbell Exercise 3: standing diagonal flexion with thera-band Exercise 4: standing external rotation with thera band. Exercise 5: abduction in sitting on training ball. Exercise 6: lying prone on foam ball with different abduction angles Maintenance phase. Duration of this phase is 1 week. Conventional treatment Hot Pack, Tens for 10 minutes Patient is assessed through baseline, week 1, week 2 and week 4.
219205219|NCT06737523|DRUG|CVA|Chiglitazar Sodium in combination with Venetoclax and Azacitidine
219540129|NCT05957263|OTHER|Osteopathy procedure|specific techniques included muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. In addition, there was a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, low amplitude manipulation performed three times a week for 15 minutes each session for 10 weeks.
219205220|NCT06735586|PROCEDURE|neuromuscular control exercise|All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.
219540130|NCT06322420|BEHAVIORAL|Behavioural Activation (BA)|"Behavioural activation treatment delivered in this single arm study. Individual treatment given to all participants in 12 sessions over 11 weeks. All treatment components have been introduced by session 8 that defines minimum amount of treatment in the trial (i.e. 8 session completed).~Behavioral Activation is a psychological treatment for depression focused on gradually re-engaging people with sources of reinforcement and reward in their environment by re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours."
219540131|NCT02485847|PROCEDURE|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
219540132|NCT01019889|DRUG|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
219540133|NCT01019889|DRUG|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
219540134|NCT01019889|DRUG|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
219540135|NCT00312897|DRUG|Omega-3 Fatty Acids|10 wk treatment period
219540136|NCT00312897|DRUG|corn oil|placebo comparator
219540137|NCT03967938|DRUG|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
219540138|NCT04829981|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
219540139|NCT04829981|BEHAVIORAL|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
219540140|NCT02414711|OTHER|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)
219620405|NCT02485093|DEVICE|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
218928288|NCT01877395|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
218928289|NCT00686686|BIOLOGICAL|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
218928290|NCT05741671|OTHER|Questionnaire|Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
218928291|NCT05419778|DEVICE|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
218928292|NCT05419778|DEVICE|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
218928293|NCT00206817|DEVICE|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
218928294|NCT01012440|DEVICE|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
218928295|NCT01012440|DEVICE|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
218928296|NCT03811704|DEVICE|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
218928297|NCT03811704|DRUG|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
218928298|NCT03650283|OTHER|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of \>0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
218928299|NCT06225713|DEVICE|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
218928300|NCT06225713|DEVICE|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
218928301|NCT04100252|OTHER|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
218928302|NCT02198378|DRUG|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
218928303|NCT02198378|DRUG|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
218928304|NCT00594815|DRUG|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
218928305|NCT01278212|RADIATION|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
219540141|NCT02414711|OTHER|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
219620406|NCT02485093|DEVICE|VIP|Ventricular pacing must be less than 10%.
218928306|NCT00515762|DEVICE|elasto-gel cap|scalp cooling cap
218928307|NCT02102178|OTHER|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
218928308|NCT02102178|OTHER|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
219043812|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
219043813|NCT05393375|OTHER|No intervention|No intervention
219043814|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
219043815|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
219043816|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
219043817|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
219043818|NCT00952094|DRUG|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
219043819|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
219043820|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
219043821|NCT04024475|OTHER|Observation|
219043822|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
219540142|NCT06275321|OTHER|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
219540143|NCT06275321|OTHER|Exercise recommendation group|General recommendation about physical exercise. No supervised
219540144|NCT03100344|DRUG|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
218928309|NCT02102178|OTHER|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
218928310|NCT02102178|OTHER|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
218928311|NCT06517589|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|PBT (20 sessions), intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
218928312|NCT06517589|OTHER|Cognitive Behavioral Therapy (CBT)|CBT (20 sessions), intervention planning as usual based on manual.
218928313|NCT01559857|DRUG|Pioglitazone|30mg once daily for 12 weeks
218928314|NCT01559857|DRUG|Sugar Pill|Placebo
218928315|NCT02912689|DEVICE|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
218928316|NCT02912689|DEVICE|Pressure support ventilation|PS during Non-invasive ventilation
218928317|NCT00742261|DRUG|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
218928318|NCT05568303|BEHAVIORAL|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
218928319|NCT00560001|BEHAVIORAL|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
218928320|NCT02900040|OTHER|kidney transplantation|
218928321|NCT04221867|PROCEDURE|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
218928322|NCT04221867|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
218928323|NCT00210743|DRUG|epoetin alfa|
218928324|NCT00071630|BEHAVIORAL|Cognitive Behavioral Therapy|
218928325|NCT00379691|DRUG|phenylephrine|
218928326|NCT03254758|BIOLOGICAL|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
219205221|NCT06735586|PROCEDURE|neuromuscular control exercise and taping|Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
219205222|NCT06741696|PROCEDURE|Surgical extraction|saline irrigation at different temperatures
219205223|NCT06741696|PROCEDURE|saline irrigations|saline irrigation done after 3rd molar surgery
219205224|NCT06742892|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219205225|NCT06742892|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219205226|NCT06742892|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
218928327|NCT03553355|DEVICE|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
219205227|NCT06727396|DRUG|CKD-508 Tablet|Investigational drug
218928328|NCT03553355|DEVICE|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
218928329|NCT02222948|DRUG|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
218928330|NCT02222948|DRUG|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219205228|NCT06727396|DRUG|Placebo Tablet|Placebo
219540145|NCT03100344|DRUG|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
218928331|NCT02112071|BEHAVIORAL|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
218928332|NCT00215839|DRUG|Peginterferon a-2a plus Ribavirin|
218928333|NCT01760252|DRUG|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
219620407|NCT00012792|BEHAVIORAL|Exercise Training|
218928334|NCT00131248|DRUG|Metaclopramide|
219540146|NCT01010503|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
219540147|NCT04984902|DEVICE|Extracorporal therapy|Extracorporal therapy
218928335|NCT00131248|DRUG|Ranitidine|
218928336|NCT00131248|DRUG|placebo|
218928337|NCT04950621|DRUG|remimazolam|Remimazolam will be administered during induction and maintenance for general anesthesia.
218928338|NCT04950621|DRUG|propofol|Propofol will be administered during induction and maintenance for general anesthesia.
219620408|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
218928339|NCT02296645|DRUG|ZuraPrep|Apply topically.
219540148|NCT03173872|PROCEDURE|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
219540149|NCT06986421|OTHER|completion of a structured questionnaire|completion of a structured questionnaire
219540150|NCT01935674|DRUG|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
218928340|NCT02296645|DRUG|ChloraPrep|Apply topically.
218928341|NCT06252688|BEHAVIORAL|Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.|"All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
218928342|NCT04029077|OTHER|NA: intervention is not part of the study|NA: it is not an interventional study
218928343|NCT00342108|BEHAVIORAL|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
218928344|NCT02784899|DRUG|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
219043823|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
219540151|NCT01935674|DRUG|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
219540152|NCT06610227|BIOLOGICAL|SapRNA™-MICA/B Tumor Vaccine|patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively
218928345|NCT02784899|DRUG|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
218928346|NCT02903329|OTHER|Detoxification|Two ways of composing the detoxification protocol
218928347|NCT05418205|OTHER|Families with FGP support|Non-randomized controlled trial with four points of measurement ( in 18 months)
218928348|NCT00593190|DRUG|Gas SF6 (Sulfur Hexafluoride)|ONCE
218928349|NCT06523920|DEVICE|University of Wisconsin solution + cold storage|Preservation of the free flap with UW solution and cold storage during ischemia time
218928350|NCT06523920|OTHER|Unperfused free flap under warm ischemia|Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time
218928351|NCT06198582|OTHER|Virtual Reality Exercises|In addition to conventional treatment, patients in the study group underwent a virtual reality-based task-specific exercise program in a computer-based virtual reality station. Two different virtual reality games that fit the definition of task-specific exercise were selected for our study. In order for the patient to complete the task in the game, the patient was asked to extend the upper extremity and hand to touch the virtual object through the reflection on the screen and to first grasp the object in the virtual environment by making active flexion with all fingers and to move it from one place to another on a certain plane without disturbing the grasping posture of the hand. These virtual reality exercises selected in our study were practiced under the supervision of the researcher 3 days a week for 15 minutes each for a total of 4 weeks. These sessions consisted of three sets of 2.5 minutes each for each game, with 15-second breaks between sets.
218928352|NCT04189887|BEHAVIORAL|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
219540153|NCT04684706|DEVICE|intermittent Theta Burst Stimulation|The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
219540154|NCT02576522|RADIATION|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
219620409|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
219620410|NCT03503604|DRUG|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
219620411|NCT03503604|DRUG|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
219620412|NCT03503604|DRUG|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
219620413|NCT03503604|DRUG|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
219540155|NCT05133817|DRUG|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
218928353|NCT04189887|BEHAVIORAL|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
218928354|NCT01130480|DEVICE|Accu-Chek Integra Glucometer|
218928355|NCT04310371|BEHAVIORAL|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
218928356|NCT02207452|DEVICE|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
219043824|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
219043825|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
219043826|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
219043827|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
219043828|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
219043829|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
219043830|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
219540156|NCT05133817|DRUG|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
219540157|NCT05133817|DRUG|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
219540158|NCT05133817|DRUG|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
219540159|NCT05133817|DRUG|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
219540160|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
218928357|NCT02207452|DRUG|Salbutamol|Salbutamol 5mg nebulised single dose
218928358|NCT02207452|DRUG|Ipratropium|Ipratropium 500mcg nebulised single dose
218928359|NCT02207452|DEVICE|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
218928360|NCT00477386|DRUG|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
219043831|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
219043832|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
219043833|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
219043834|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
219043835|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
219043836|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
219043837|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
219043838|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
219043839|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
219540161|NCT01955200|DRUG|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
219540162|NCT01955200|DRUG|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
219540163|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
219540164|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
219540165|NCT06868056|BEHAVIORAL|Suite of healthy food policies|an online application with a suite of healthy food policies ultra-processed food and beverage taxes, front-of-pack nutrition labeling, and healthy check out regulations that restrict the promotion of ultra-processed products on the checkout page
219620414|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=6 every 3 weeks
219620415|NCT03503604|DRUG|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
218928361|NCT01174719|DRUG|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
218928362|NCT01174719|DRUG|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
219540166|NCT05854602|BEHAVIORAL|Component A|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component A focusses on making parents aware of the process of avoidance in children with anxiety, and helps them to identify situations in which they accommodate to the anxiety of their children. Subsequently, a first step that parents can take to reduce accommodation is discussed."
219540167|NCT05854602|BEHAVIORAL|Component B|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component B tries to increase parents empathetic reactions to their anxious child. This is done by teaching parents to label the emotion of their children, empathize with the emotion, and communicate confidence in the abilities of their child to face the situation."
219540168|NCT05854602|BEHAVIORAL|Component C|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component C consists of cognitive restructuring of parental maladaptive cognitions concerning their child's anxiety. Parents are taught to recognize their own cognitions about the anxiety of their child, challenge this thought and come up with an alternative, helpful thought."
219540169|NCT03923660|OTHER|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
219540170|NCT03923660|OTHER|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
219540171|NCT05048017|DRUG|Regorafenib|Regorafenib, 120 mg, once a day, 3 weeks on/1 week off
219540172|NCT05048017|DRUG|PD-1 inhibitor|"Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks."
219620416|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=4 every 3 weeks
219620417|NCT03503604|DRUG|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
218928363|NCT01174719|DRUG|volume replacement|up 10 50mL/kg/24 hours
218928364|NCT01724632|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
218928365|NCT01254422|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
218928366|NCT01254422|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
218928367|NCT05242120|OTHER|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
218928368|NCT04986514|OTHER|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
218928369|NCT02207088|DRUG|ombitasvir/paritaprevir/ritonavir|tablet
218928370|NCT02207088|DRUG|dasabuvir|tablet
218928371|NCT02207088|DRUG|Ribavirin|tablet
218928372|NCT00450268|PROCEDURE|blood draw, skin shave biopsy|
218928373|NCT01166880|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
218928374|NCT06090136|DRUG|TPN171H|5 mg TPN171H tablets，single dose,oral
218928375|NCT00643162|DRUG|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
218928376|NCT00643162|BEHAVIORAL|Light touch|Light touch twice a week, for 8 weeks
218928377|NCT00643162|BEHAVIORAL|Massage|Massage twice a week, for 8 weeks.
219043840|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
219043841|NCT00460941|DRUG|Placebo|sc weekly
219043842|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
219043843|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
218928378|NCT03551561|DRUG|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
218928379|NCT03551561|DRUG|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
218928380|NCT00724087|OTHER|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
218928381|NCT00724087|OTHER|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
218928382|NCT00046462|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
218928383|NCT00046462|DRUG|Metformin|
218928384|NCT00046462|DRUG|Glyburide|
218928385|NCT00046462|DRUG|Thiazolidinedione|
219043844|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
219043845|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
219540173|NCT02097550|OTHER|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
218928386|NCT02347137|OTHER|step-reduction|reduce daily physical activity to less than 1500 steps per day
218928387|NCT02347137|OTHER|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
218928388|NCT00483769|DRUG|Glargine|
218928389|NCT00382759|PROCEDURE|stem cell transplant|
219540174|NCT02892747|BEHAVIORAL|Educational Program|
218928390|NCT03768934|OTHER|1X airtime incentive|An incentive given in the form of airtime.
219043846|NCT02135224|DRUG|Fentanyl|
219043847|NCT02135224|DRUG|Normal saline|
219043848|NCT00968591|DRUG|Everolimus|
219540175|NCT05814926|DRUG|GP681|GP681, tablet, oral
219540176|NCT01292590|OTHER|High fat meal|40 grams saturated fat
219540177|NCT03427944|DRUG|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
219540178|NCT03427944|DRUG|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
219540179|NCT01521780|PROCEDURE|MRI|Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
219043849|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
219043850|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
219043851|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
219043852|NCT04613180|DRUG|Placebo|placebo containing no active substance
219043853|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
219043854|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
219540180|NCT01521780|PROCEDURE|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
219043855|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
219043856|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
219043857|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
219540181|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
219540182|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
219540183|NCT02259972|DRUG|BI 113823 solution|
219540184|NCT02259972|DRUG|BI 113823 tablet|
219540185|NCT02259972|DRUG|Placebo|
219540186|NCT02259972|OTHER|High fat, high calorie breakfast|only for dose group 5
219540187|NCT01554410|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
219540188|NCT01554410|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
218928391|NCT03768934|OTHER|2X airtime Incentive|An incentive given in the form of airtime.
218928392|NCT03768934|OTHER|Lottery airtime incentive|An incentive given in the form of airtime.
218928393|NCT03798769|OTHER|Supportive Oncology Care at Home|"Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
218928394|NCT02691507|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
218928395|NCT02691507|DRUG|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
218928396|NCT01812252|DRUG|Azacitidine (AZC)|Given IV or SC
219043858|NCT00165971|PROCEDURE|BIS monitoring|
219540189|NCT01554410|DRUG|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
219540190|NCT01788072|DRUG|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
219540191|NCT01788072|DRUG|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
219540192|NCT00048334|DRUG|Depsipeptide, FR901228, FK228|
218928397|NCT01812252|DRUG|Decitabine|Given IV or SC
218928398|NCT01812252|OTHER|Quality-of-Life Assessment|Ancillary studies
219205229|NCT06743763|BEHAVIORAL|fNIRS-based neurofeedback|fNIRS-based neurofeedback is provided during a simulated classroom scenario where the child participants are asked to learn to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
218928399|NCT04603599|DIAGNOSTIC_TEST|serum soluble L1CAM (sL1CAM)|blood sample
218928400|NCT04288726|BIOLOGICAL|CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach an MTD. This will be administered as a single infusion of the full dose for each level, which was already shown to be safe in the first 3 patients treated at dose level 3. Since we have not observed any dose limiting toxicities at the current dose level (Dose Level 3 as of June 2022), we propose to include a new higher dose level (8 × 10\^8).There will be a gap of 4 weeks between the first and second patient, and between the second and the third patient, on each dose level.
218928401|NCT05126953|DEVICE|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
219540193|NCT06059625|PROCEDURE|rotatori cuff repair|rotatori cuff repair
218928402|NCT05126953|DEVICE|Commercially Available B+L Ultra Lenses|Commercially Available B+L Ultra Lenses
218928403|NCT06346769|OTHER|Polyethylene Fiber|In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
218928404|NCT06463249|BEHAVIORAL|CORE Helpline|All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
218928405|NCT06463249|BEHAVIORAL|Extended Helpline|Those who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving all CORE resources including1-on-1 coaching through 1 optional participant-initiated call per month for 6 months.
218928406|NCT06463249|BEHAVIORAL|Enhanced Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 1 optional participant-initiated call/month for 6 months. Additionally, the participants will receive 2 individualized coach-scripted feedback emails per month, and the option to receive daily text message reminders.
218928407|NCT06463249|BEHAVIORAL|Intensive Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 2 scheduled coaching calls/month for 6 months. Additionally, the participants will receive 2 individual coach-scripted feedback emails per month, and the option to receive daily text message reminders.
218928408|NCT06124807|DRUG|LY3305677|Administered SC
218928409|NCT06124807|DRUG|Placebo|Administered SC
218928410|NCT06422819|OTHER|Heart rate variability Biofeedback [HRV-BFB]|"Biofeedback (BFB), sometimes referred to as biological feedback technique, is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population."
218928411|NCT06422819|OTHER|Pseudo HRV-BFB|The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.
218928412|NCT05107336|DRUG|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
218928413|NCT05107336|DRUG|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
218928414|NCT03844399|DEVICE|Ablation|The medical device will passively record image data during the standard care ablation
218928415|NCT03844399|DEVICE|Biopsy|The medical device will passively record image data during the standard care biopsy
218928416|NCT04513509|DRUG|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
218928417|NCT00760032|DRUG|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
218928418|NCT00760032|DRUG|Placebo|Placebo capsules, one capsule per day during four weeks.
218928419|NCT04634253|DRUG|Placebo|Given IV
219043859|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
219043860|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
219205230|NCT06743763|BEHAVIORAL|Virtual Reality Simulated Classroom|A simulated classroom scenario is integrated in VR setting and children are asked to complete academic tasks in the simulated classroom.
219205231|NCT06740201|DRUG|Cipepofol|Adjust plasma target-controlled concentration
219205232|NCT06894004|BEHAVIORAL|Ketogenic Diet|Participants will consume an isocaloric ketogenic diet for 4 weeks with all food provided as packed-out meals.
219205233|NCT06894004|BEHAVIORAL|Control Diet|Participants will consume an isocaloric control diet for 4 weeks with all food provided as packed-out meals.
219540194|NCT05444296|OTHER|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
219540195|NCT05444296|OTHER|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
219540196|NCT00131417|DRUG|ready-to-use therapeutic food|
219620418|NCT04278781|DRUG|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
218928420|NCT04634253|DRUG|LY3462817|Given IV
218928421|NCT03155841|BEHAVIORAL|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
218928422|NCT03155841|BEHAVIORAL|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
218928423|NCT02353975|DRUG|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
218928424|NCT01966016|PROCEDURE|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
218928425|NCT05464342|BEHAVIORAL|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
218928426|NCT05464342|BEHAVIORAL|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
218928427|NCT05464342|BEHAVIORAL|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
218928428|NCT02930512|PROCEDURE|DXA scan|
218928429|NCT02930512|PROCEDURE|pQCT scan|
218928430|NCT05156034|DRUG|SRK-001|Participants will receive IV doses of SRK-001.
219540197|NCT05863962|OTHER|walking and Stretching|Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise
219540198|NCT05863962|OTHER|walking and Jacobsons relaxation technique|Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
219540199|NCT02814877|OTHER|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
218928431|NCT05156034|DRUG|Placebo|Participants will receive IV doses of placebo.
218928432|NCT04580979|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
218928433|NCT01973764|PROCEDURE|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
218928434|NCT01973764|PROCEDURE|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
218928435|NCT03350594|BEHAVIORAL|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
218928436|NCT03350594|BEHAVIORAL|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
218928437|NCT05816447|BEHAVIORAL|interview|Interview patient's perception
218928438|NCT04311021|OTHER|No intervention|No intervention
218928439|NCT04313062|BEHAVIORAL|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
219540200|NCT03973658|DEVICE|Hearing aids|Fitting of hearing aids (for the first time)
219540201|NCT03043872|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
219540202|NCT03043872|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
219540203|NCT03043872|DRUG|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
219540204|NCT03043872|DRUG|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
219540205|NCT03043872|DRUG|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
219540206|NCT05902702|OTHER|Nebulized isotonic saline|The intervention will constitute nebulized isotonic saline.
218928440|NCT05086107|DRUG|BV100|Rifabutin for infusion
218928441|NCT04529902|DRUG|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
218928442|NCT04529902|DRUG|Abatacept|Abatacept claim is used as the exposure group.
218928443|NCT05690802|DRUG|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
218928444|NCT05812066|PROCEDURE|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
218928445|NCT04646421|BEHAVIORAL|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
218928446|NCT01569607|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
218928447|NCT01569607|DEVICE|Sham stimulation|Sham stimulation
218928448|NCT02753504|DRUG|CKD-519|
218928449|NCT02753504|DRUG|placebo|
218928450|NCT02056587|DRUG|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
218928451|NCT03790202|DEVICE|VistaCare®|Controlled atmosphere wound healing device
218928452|NCT01356277|BEHAVIORAL|Action-focused problem-solving|"* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
219043861|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
219043862|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
219043863|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
219043864|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
219540207|NCT05902702|OTHER|Nasal irrigation with isotonic saline|The intervention will constitute isotonic saline administered as nasal drops.
218928453|NCT01356277|DEVICE|Electronic pillbox monitoring, dose reminders, and feedback|"* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders"
218928454|NCT00378365|PROCEDURE|Arsenic trioxide|Arsenic trioxide
219043865|NCT00742313|BIOLOGICAL|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
219043866|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
219043867|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
219043868|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
219043869|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
219043870|NCT00193401|DRUG|Topotecan|
219043871|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
219043872|NCT01436279|DRUG|Mifepristone|200 mg po 20-24 hours prior to the procedure
219043873|NCT01436279|DEVICE|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
219043874|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
218928455|NCT00378365|PROCEDURE|ATRA|ATRA
218928456|NCT01483521|OTHER|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
218928457|NCT03780140|DRUG|Cefiderocol|Cefiderocol for intravenous infusion
218928458|NCT04724109|DRUG|Equfina|Equfina oral tablets.
218928459|NCT00734500|DRUG|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
218928460|NCT04982263|DIAGNOSTIC_TEST|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
218928461|NCT02721966|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
218928462|NCT02721966|DRUG|Secukinumab and Placebo|Placebo matching AIN457
218928463|NCT06037902|DEVICE|CPAP|patients undergo simulation twice, with and without CPAP
219043875|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
219043876|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
219043877|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
219043878|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
219043879|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
219043880|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
219043881|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
219043882|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
219043883|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
219043884|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
219043885|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
219043886|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
219043887|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
219620419|NCT00690911|DRUG|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
218928464|NCT05908019|OTHER|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
218928465|NCT05740501|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218928466|NCT05740501|OTHER|Electronic Health Record Review|Medical records are reviewed
219205234|NCT06894966|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects.
218928467|NCT05740501|OTHER|Questionnaire Administration|Ancillary studies
218928468|NCT03857867|DEVICE|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
218928469|NCT03367637|OTHER|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
218928470|NCT03367637|OTHER|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
218928471|NCT02728167|DEVICE|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
218928472|NCT05702606|OTHER|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
218928473|NCT03522896|OTHER|control|balancing sugars and organic acids
218928474|NCT03522896|OTHER|test meal 1|orange juice plus hesperidin low dose
218928475|NCT03522896|OTHER|test meal 2|orange juice plus hesperidin higher dose
218928476|NCT03522896|OTHER|test meal 3|diluted orange juice plus hesperidin low dose
219205235|NCT06893991|DIETARY_SUPPLEMENT|SYMBIONIC|"Provision of 100 ml symbiotic beverages daygurt per day for 6 weeks, plus standard dietary advice for dyslipidemia"
219205236|NCT06893991|BEHAVIORAL|Dietary advice|Participants get standard dietary advice for dyslipidemia
219620420|NCT02353286|DEVICE|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
219620421|NCT05083026|DIAGNOSTIC_TEST|COVID-19 neutralizing antibody|"This study enrolled persons already who received COVID-19 vaccination under government policy.~1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination~2. isolate serum and store in -80 degree deep freezer~3. measure neutralizing Antibody"
219620422|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
219620423|NCT02597764|BEHAVIORAL|Diaphragmatic Breathing|
218928477|NCT04784572|OTHER|first injection delay and second injection delay|"During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance."
218928478|NCT05612828|BEHAVIORAL|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
218928479|NCT00713518|DRUG|0.5 mg ranibizumab|
218928480|NCT00713518|DRUG|3 mg PF-04523655|
218928481|NCT00713518|DRUG|1 mg PF-04523655|
218928482|NCT04879251|OTHER|No intervention|No intervention
218928483|NCT00121615|DRUG|etanercept|
218928484|NCT00501917|DRUG|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
218928485|NCT02653599|DRUG|TTP273|
218928486|NCT02653599|DRUG|Placebo|
218928487|NCT00176267|RADIATION|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 \& 36 of chemotherapy
218928488|NCT00176267|DRUG|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
218928489|NCT00176267|DRUG|Carboplatin|AUC of 6 on Days 1 \& 22
218928490|NCT00607373|DRUG|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
218928491|NCT00607373|DRUG|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
218928492|NCT04921072|BEHAVIORAL|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
219366996|NCT06078657|DRUG|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
219366997|NCT00564993|DRUG|Dobutamin|10\&20 µg/kg/min
219620424|NCT02597764|BEHAVIORAL|Standard Urotherapy|
219620425|NCT02636218|DRUG|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
219540208|NCT03411148|BEHAVIORAL|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
218928493|NCT04921072|BEHAVIORAL|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
219540209|NCT03411148|BEHAVIORAL|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
219540210|NCT04862572|OTHER|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
219540211|NCT05261945|OTHER|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
219540212|NCT05261945|OTHER|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
219540213|NCT05261945|OTHER|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
219620426|NCT02636218|DRUG|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
218928494|NCT02186418|GENETIC|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
218928495|NCT02765646|DEVICE|Coronary stent procedure (CSP)|
218928496|NCT00243438|DEVICE|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
218928497|NCT00276341|DRUG|EGb 761® (Tanakan®)|
219043888|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
219043889|NCT00033384|DRUG|CI-1040|
218928498|NCT02952404|PROCEDURE|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
219043890|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
219043891|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
219043892|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
219043893|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
219043894|NCT01467076|DRUG|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
219043895|NCT01467076|DRUG|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
219043896|NCT02866838|DRUG|Tranexamic acid|intravenous
219043897|NCT02866838|DRUG|Saline 0.9%|intravenous
219043898|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
219043899|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
219620427|NCT03238521|PROCEDURE|Spinal osteosynthesis with classical pedicle finder|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder
219620428|NCT03238521|PROCEDURE|Spinal osteosynthesis with pedicle finder with impedancemetry|Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
218928499|NCT06402656|DEVICE|Customized facemask|The customized face mask will be fabricated from a 3D digital image of the patient's face obtained by means of a 3D scanner. Such a scanner consists of 6 digital SLR cameras and software capable of processing a 3-D image of the patient's face exportable as an stl file.
218928500|NCT06402656|DEVICE|Standard facemask|The standard facemask is the commercially available Petit standard facemask
218928501|NCT02170077|DRUG|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
218928502|NCT02170077|DRUG|Placebo|Placebo tablets administered orally
218928503|NCT04197596|BIOLOGICAL|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
218928504|NCT03568227|PROCEDURE|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
218928505|NCT03568227|PROCEDURE|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
218928506|NCT05932823|OTHER|Laminary airflow|A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
218928507|NCT05271877|PROCEDURE|Laparoscopy|Diagnostic/operative laparoscopic procedure
218928508|NCT05107726|BEHAVIORAL|TRE Group|This group will practice time-restricted eating
218928509|NCT03171363|BEHAVIORAL|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
218928510|NCT02070536|OTHER|sRAGE|
218928511|NCT01355952|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
218928512|NCT01986426|DRUG|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
218928513|NCT01986426|DRUG|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
218928514|NCT01986426|DRUG|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
218928515|NCT01986426|DRUG|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
218928516|NCT06218966|DEVICE|intracochlear catheter|intracochlear administration of steroids through the intracochlear catheter INCAT
218928517|NCT06008990|DRUG|Buprenorphine|Pregnant mother must be taking Buprenorphine
218928518|NCT06008990|DIAGNOSTIC_TEST|Maternal Brain MRI|Maternal Brain MRI obtained between 24-32 week gestation
218928519|NCT06008990|OTHER|Blood Samples|During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
218928520|NCT06008990|BEHAVIORAL|Questionnaires|Participants will answer questionnaires about their medical history, pregnancy, and substance use.
218928521|NCT04994847|DRUG|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
218928522|NCT01780974|DRUG|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
219043900|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
218928523|NCT01780974|DRUG|Placebo|placebo capsules
218928524|NCT01580163|DRUG|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
218928525|NCT01580163|DRUG|Methadone|Oral Solution，1mg/ml
218928526|NCT01580163|DRUG|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
218928527|NCT03276624|PROCEDURE|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
218928528|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
218928529|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
218928530|NCT06390748|DRUG|esmolol|The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
218928531|NCT01724346|DRUG|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
218928532|NCT01724346|DRUG|Next-line ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
218928533|NCT06071689|DEVICE|screw retained prosthesis|all-on-4 screw-retained prosthesis.
218928534|NCT05120401|DEVICE|presbyopia glasses|fogging for glasses for far and intermediate
218928535|NCT00598793|DRUG|biphasic insulin aspart|
218928536|NCT00598793|DRUG|insulin glargine|
218928537|NCT00598793|DRUG|metformin|
218928538|NCT00598793|DRUG|pioglitazone|
218928539|NCT00397865|BEHAVIORAL|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
218928540|NCT02694289|DRUG|Metformin|Treatment/continuation of metformin therapy during admission
218928541|NCT02694289|DRUG|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
218928542|NCT00996853|OTHER|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
218928543|NCT03237455|DIAGNOSTIC_TEST|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
218928544|NCT03237455|DIAGNOSTIC_TEST|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
218928545|NCT03237455|OTHER|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
219540214|NCT07035119|OTHER|Transcranial magnetic stimulation|Resting motor threshold will be established by first finding the area of the motor cortex associated with visible twitch of the right abductor pollicis brevis (APB). Parameter Estimation by Sequential Testing (PEST) will be conducted to quantify resting motor threshold using visible APB twitch. The left dorsolateral prefrontal cortex (DLPFC) will be located using the Beam F3 method and marked with a felt-tipped marker on the scalp. TMS will be delivered over left DLPFC at 110% of resting motor threshold at 10Hz (5-seconds-on; 10-seconds-off) for 15 minutes per session (3000 pulses), 3 sessions each day (30-minute rest in-between sessions), for 3 days (within 5 consecutive days; a total of 27,000 pulses).
218928546|NCT00332176|DRUG|Celgosivir|400mg qd + standard of care for 12 weeks
219043901|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
219540215|NCT03614845|PROCEDURE|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
219540216|NCT03614845|PROCEDURE|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
219540217|NCT03614845|DIAGNOSTIC_TEST|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
219540218|NCT04235595|OTHER|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
219540219|NCT04235595|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
218928547|NCT00332176|DRUG|Celgosivir|600mg qd + standard of care for 12 weeks
218928548|NCT00332176|DRUG|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
218928549|NCT05880186|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
218928550|NCT03262480|OTHER|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
219043902|NCT00020111|DRUG|arsenic trioxide|
219043903|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
219043904|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
219205237|NCT06893276|BEHAVIORAL|ePSMI|Participants will complete an hour of cognitive behavioral stress management program in person or remote each week for ten weeks. The cognitive behavioral therapy (CBT) skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour. After module completion, participants will have access to modules covered during session.
219620429|NCT03505970|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
218928551|NCT02863120|DRUG|liposomal bupivacaine|
218928552|NCT02863120|DRUG|bupivacaine HCl|
218928553|NCT02863120|DRUG|Ropivacaine|
218928554|NCT02863120|DRUG|Saline|
218928555|NCT01025518|OTHER|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
218928556|NCT01025518|DIETARY_SUPPLEMENT|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
218928557|NCT01025518|DIETARY_SUPPLEMENT|Placebo|Maltodextrine
218928558|NCT02073058|DEVICE|No treatment|
218928559|NCT04416841|BEHAVIORAL|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
218928560|NCT04416841|BEHAVIORAL|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
218928561|NCT04416841|BEHAVIORAL|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
218928562|NCT00131261|DRUG|PXD101|
218928563|NCT00131261|DRUG|Dexamethasone|
218928564|NCT05975203|PROCEDURE|skin-to-skin contact|Immediately after delivery the infant will receive skin-to-skin contact with the mother.
218928565|NCT00569400|DRUG|human insulin|
218928566|NCT06418802|PROCEDURE|STN-DBS surgery|bilateral subthalamic nucleus deep brain stimulation surgery
219043905|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
219540220|NCT05699005|DRUG|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
219043906|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
219043907|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
219540221|NCT06719726|PROCEDURE|PECS I Block|The PECS I block is a regional anesthesia technique performed preoperatively under ultrasound guidance. It involves the injection of 10 mL of 0.5% bupivacaine between the pectoralis major and pectoralis minor muscles to block the medial and lateral pectoral nerves. This procedure targets the right breast in the study to reduce postoperative pain and is compared to local anesthetic infiltration.
219540222|NCT06719726|PROCEDURE|Local Anesthetic Infiltration|Local anesthetic infiltration involves the intraoperative administration of 10 mL of 0.5% bupivacaine under direct visualization into the pectoralis major muscle prior to muscle transection. This procedure targets the left breast in the study for pain management and is compared to the PECS I block.
219205238|NCT06744946|PROCEDURE|thoracoscope|bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
219620430|NCT03505970|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
219620431|NCT00210028|DRUG|Tamoxifen|
219620432|NCT00210028|DRUG|Zarnestra|
218928567|NCT06418802|DEVICE|pulse width|a short pulse width (30s)
218928568|NCT06418802|DEVICE|frequency|frequency parameters of STN-DBS (60,100, and 130HZ)
218928569|NCT02211846|DRUG|Mirabegron|oral
218928570|NCT05689372|DRUG|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
218928571|NCT04494802|BEHAVIORAL|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
218928572|NCT04494802|BEHAVIORAL|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
218928573|NCT02876601|DRUG|Defibrotide|6.25mg/kg bodyweight over 2h infusion
218928574|NCT02876601|DRUG|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
218928575|NCT02876601|DRUG|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
218928576|NCT02876601|DRUG|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
218928577|NCT00256997|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
218928578|NCT00256997|DRUG|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
218928579|NCT02086253|DRUG|BQ-788 and/or BQ-123|
219043908|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
219043909|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
219043910|NCT02285985|DRUG|Placebo|Tablets: 5mg
219043911|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
219043912|NCT05305599|DRUG|Placebo|Placebo
219043913|NCT03199703|DEVICE|Baylis transseptal system group|
219043914|NCT03199703|DEVICE|Standard conventional transseptal group|
219620433|NCT04364893|OTHER|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
219620434|NCT04506034|DRUG|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
218928580|NCT01815697|DEVICE|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
218928581|NCT01065987|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
219540223|NCT05573620|BEHAVIORAL|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
218928582|NCT04673643|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
218928583|NCT04673643|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
219540224|NCT05573620|BEHAVIORAL|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
219540225|NCT05573620|BEHAVIORAL|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
219540226|NCT04647266|PROCEDURE|endoscopic submucosal dissection|endoscopic submucosal dissection
218928584|NCT06486064|DIETARY_SUPPLEMENT|heat-treated Limosilactobacillus fermentum|one capsule daily for 8 weeks
218928585|NCT06486064|DIETARY_SUPPLEMENT|Placebo|one capsule daily for 8 weeks
218928586|NCT01967238|BIOLOGICAL|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
218928587|NCT05992753|OTHER|Questionnaire application|The research data were collected from 455 mothers admitted to the postpartum and lactation unit of a city hospital in Istanbul between September and November 2022. The mothers to be included in the study sample were determined according to the non-probability sampling method, considering the inclusion criteria of the study. The research data were collected by the researchers face-to-face through a questionnaire that lasted about 10-20 minutes.
219043915|NCT02506816|DRUG|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
219043916|NCT04577326|DRUG|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
219043917|NCT04577326|BIOLOGICAL|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
219043918|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
219043919|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
219043920|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
219205239|NCT06744881|PROCEDURE|CAPA-IVM|On days 2-4 of the menstrual cycle, after patients have consented to CAPA-IVM, they will undergo oocyte aspiration anytime thereafter but no later than day 6 of the cycle. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 or day 5 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transfer
219205240|NCT06893926|DIAGNOSTIC_TEST|Prenatal ultrasound examination with blood flow analysis|"For all patients who provide informed consent to participate in the study, an ultrasound examination is performed within 48 hours prior to delivery. This assessment includes:~1. Measurement of fetal anthropometric parameters and estimation of fetal weight.~2. Evaluation of blood flow using the pulsatility index (PI) in the UA, UtA, DV, and MCA."
219205241|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis|A 0.5 mL blood sample is collected from the clamped section of the umbilical cord and immediately sent to the laboratory for cord blood gas analysis, including the determination of pH, base excess (BE), and lactate levels.
219540227|NCT05612204|PROCEDURE|Biopsy under MRI|Biopsy under MRI
219043921|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
219043922|NCT04751591|PROCEDURE|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
219043923|NCT04751591|PROCEDURE|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
219043924|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
219043925|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
218928588|NCT06984354|BEHAVIORAL|Pain education and clinical hypnosis delivered via a mobile app|Pain education and clinical hypnosis will be delivered via a mobile app. The 8-week intervention includes daily sessions on pain education and clinical hypnosis for managing back pain (5 minutes of education, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes). The first six weeks will be semi-standardised, with participants following a set program with the option to repeat sessions. The last two weeks will be flexible, allowing participants to choose a specific program or self-paced continuation of the intervention. Adherence will be monitored by tracking the number of days participants complete sessions, as recorded by the mobile app.
218928589|NCT06984354|BEHAVIORAL|Guideline-informed factsheet|A single guideline-informed factsheet for back pain delivered via a webpage. Participants will be informed that the factsheet intends to provide reassurance for their back pain and encourage reflections on treatments and self-management options.
218928590|NCT06593340|BEHAVIORAL|Messenger 1|The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
218928591|NCT06593340|BEHAVIORAL|Messenger 2|The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
219540228|NCT07060742|DEVICE|Dividat Senso|Participants in the intervention group will receive cognitive-motor training using the Dividat Senso exergame platform, which records body movements and adapts game difficulty in real time. The training targets cognitive and physical functions through interactive games involving steps and weight shifts. It follows a progressive structure, with difficulty increasing over time, and can be personalized by investigators using the Dividat Manager.
219205242|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood S100B protein level|A 1 mL sample of cord blood is collected in a labeled tube, which includes the mother's name, the child's gender, date of birth, and date of collection. The sample is then sent to the laboratory for centrifugation. The resulting serum samples are frozen, and once approximately 80 samples have been collected, they will be thawed and analyzed for S100B protein concentration. Any remaining material after laboratory processing will be properly disposed of.
219205243|NCT06893926|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination is performed to assess for any abnormalities in the newborn.
219205244|NCT06892730|DEVICE|Hybrid TEVAR combined with long bare-metal stent intervention|"\- Primary TEVAR: Primary TEVAR: Employ Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm endograft deployed with ≥2cm proximal landing zone coverage.~Concurrent bare-stenting: Post-TEVAR femoral access deployment of Fabulous® (45-150mm) long bare-metal stent with:~Proximal overlap ≥3cm with TEVAR graft. Distal extension 2-6cm below renal artery plane. Maximum distal limit: above iliac bifurcation.~\- Intraprocedural angiography with spinal reference mapping guides precise stent positioning relative to visceral arteries and infrarenal aorta."
219540229|NCT07060742|OTHER|OTAGO Falls-prevention program|The OTAGO Falls Prevention Program is an evidence-based exercise program designed to reduce falls in older adults. It includes strength and balance training exercises performed at home under the guidance of a physiotherapist. The program aims to improve muscle strength, balance, and mobility, helping to prevent falls and maintain independence.
219540230|NCT06747117|DEVICE|Indigo Aspiration System|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
219540231|NCT07060690|BEHAVIORAL|iCBT with human interaction|The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.
219540232|NCT07060690|BEHAVIORAL|Psychoeducational videos|This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.
219540233|NCT01154231|DRUG|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
219540234|NCT01938339|DEVICE|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
219540235|NCT07059104|PROCEDURE|Breast augmentation|Breast augmentation with an implant
218928592|NCT06593340|BEHAVIORAL|Format 1|The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.
218928593|NCT06593340|BEHAVIORAL|Format 2|The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
218928594|NCT06594965|DRUG|HS-20106|HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
218928595|NCT06592118|OTHER|Different Pathological Types (FTC vs PTC)|Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients
218928596|NCT07033052|BEHAVIORAL|Improvisation + Wellness|Theatrical improvisation exercises, the theatrical art of performance and storytelling without a script, will be combined with wellness techniques
218928597|NCT07033052|BEHAVIORAL|Improvisation|Theatrical improvisation exercises (the theatrical art of performance and storytelling without a script) will be completed in this arm. These exercises will be fairly similar to that from the improvisation + wellness but without the wellness techniques.
218928598|NCT07033052|BEHAVIORAL|Social Craft|Participants assigned to the Social Craft group will engage in arts and crafts projects and activities
218928599|NCT06709222|OTHER|robotic rehabilitation|robotic rehabilitation
218928600|NCT06709222|OTHER|exercise|dual-task exercises
218928601|NCT07040917|DRUG|CAR-T cell|CAR-T cell
218928602|NCT04167878|DEVICE|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
218928603|NCT04167878|DEVICE|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
218928604|NCT06708520|DRUG|Rupatadine|10 mg tablets
218928605|NCT06720220|DRUG|Dexmedetomidine Hydrochloride|"procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3)."
219540236|NCT07059104|PROCEDURE|Breast reconstruction after mastectomy|Breast reconstruction after mastectomy
219540237|NCT07061327|BEHAVIORAL|Online fever management|Online training application will be carried out via Whatsapp
219540238|NCT07060677|PROCEDURE|Inmersive Virtual Reality|Participants will receive a intervention of immersive virtual reality using Meta Quest 3 and the Kinesix XR platform. Sessions will take place twice per week for 8 weeks. The IVR component will focus on balance and mobility through interactive, immersive environments designed to enhance engagement, adherence, and functional outcomes. This multimodal approach aims to reduce fall risk and frailty while improving motivation and quality of life in older adults.
219620435|NCT04506034|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
219620436|NCT04506034|DRUG|IV saline infusion|received i.v. saline infusion.
219620437|NCT03707210|BEHAVIORAL|VR training program|Use VR software to make a training education program.
219620438|NCT02267681|DRUG|Fentanyl|Intravenous fentanyl for sedation/analgesia
219620439|NCT02267681|DRUG|Alfentanil|Intravenous alfentanyl for sedation/analgesia
219620440|NCT02267681|DRUG|Propofol|Intravenous propofol for sedation
219620441|NCT02790164|DRUG|Esmeron|Neuromuscular Blockade
219620442|NCT02790164|DRUG|Saline|Normal Saline
219620443|NCT01075438|BIOLOGICAL|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
219620444|NCT01075438|BIOLOGICAL|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
219620445|NCT06140524|DRUG|Linvoseltamab|Administered per the protocol
219620446|NCT00685217|PROCEDURE|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
219620447|NCT00685217|PROCEDURE|TVT (Gynecare)|Sling procedure for stress urinary incontinence
219620448|NCT03922321|DRUG|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
219620449|NCT01387659|PROCEDURE|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
219620450|NCT02249975|DEVICE|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~* Device malfunctions~* Adverse events~* Patient Pain~* Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
219620451|NCT02832232|OTHER|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
219620452|NCT02832232|OTHER|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
219620453|NCT02832232|OTHER|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
219620454|NCT03632499|OTHER|rehabilitation|rehabilitation
219620455|NCT05169190|PROCEDURE|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
218928606|NCT06720220|OTHER|Nebulization|nebulization session through a face mask nebulizer attached to an oxygen source. The nebulizer chamber was filled with 10 ml of 2% lidocaine (200 mg). The oxygen flow was adjusted at a rate of 8-10 L/min for 10-15 minutes.
218928607|NCT06720220|OTHER|Atomization|"Airway topicalization by atomization (through a modification of McKenzie technique). This modification utilizes a 10-Fr suction catheter instead of 20-gauge cannula. This suction catheter was attached to oxygen tubing with a three-way stopcock. The oxygen tubing was attached to an oxygen source, which delivers a flow of 2-4 L/min. A 10-ml syringe filled with 10 ml of lidocaine 2% was attached to top port of the three-way stopcock.~Local anesthetic was injected via the syringe forming a jet- like spray for topicalization of the nasal and oral mucosa"
218928608|NCT06720220|OTHER|Spray-As-You-Go|airway topicalization method using the fiberoptic bronchoscope itself. The fiberoptic bronchoscope, preloaded with a 6.5 or 7 mm endotracheal tube, was passed under direct vision through the nose into the pharynx. Then 10-ml syringe containing 10 ml Lidocaine 2%, was attached to the working channel, and thus the local anesthetic was sprayed towards the mucosa of postnasal space and back of throat, while advancing the fiberscope. At the level of the epiglottis and around the vocal cords 2-4 ml of lidocaine 2% were sprayed toward these structures as the patient takes a deep breath to achieve sufficient anesthesia to the laryngeal inlet. The patient was asked to take another deep breath as the scope was passed through the vocal cords and 2 ml of lidocaine 2% is sprayed to the trachea and the scope was advanced further until the carina was visualized.
218928609|NCT06877377|BIOLOGICAL|hDNAgr Therapy|A novel investigational therapy that uses fragmented therapeutic double-stranded DNA, designed to correct or replace locally damaged genomic regions in hematopoietic stem cells and elongate telomeres. The hDNAgr therapy is administered according to the study protocol schedule (Visits at Day 0, 14, 28, 60, 90, and 180), with blood draws and safety evaluations at each time point to assess hematological parameters, telomere length, and potential impacts on biological aging.
218928610|NCT06877377|OTHER|Placebo|An inactive formulation identical in appearance to the hDNAgr therapy but lacking the active DNA fragments. It is administered under the same schedule and conditions as the experimental intervention to maintain blinding and enable comparison of safety and efficacy outcomes.
218928611|NCT05715931|DRUG|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
218928612|NCT05715931|DRUG|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
218928613|NCT05715931|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
218928614|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 1 sachet|1 dose day to be absorbed sublingually
218928615|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 2 sachet day|1 sachet two times a day to be sublingually absorbed
218928616|NCT06718452|DIETARY_SUPPLEMENT|Placebo|Same administration of PEA-LUT
219205245|NCT06893835|DRUG|Colistimethate Sodium|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
219205246|NCT06893835|DRUG|Tigecycline|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
219205247|NCT06894238|DIAGNOSTIC_TEST|Sub-hairline EEG Monitoring|Participants will receive standard postoperative care as per institutional protocols, including neuromonitoring, delirium screening, and ICU management. The study will not alter or assign any treatments but will analyze the association between sub-hairline EEG parameters and postoperative delirium (POD) outcomes
219205248|NCT06893718|OTHER|Compressions Stocking Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
219205249|NCT06893718|OTHER|Treadmill Training Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
219205250|NCT06893575|BEHAVIORAL|TTM-Guided Digital Sleep Health Program|This intervention is a TTM-based sleep health improvement program designed for HF patients. It includes three components: (1) Sleep health education sessions (Weeks 1-4) delivered face-to-face and via telehealth, (2) WhatsApp-based sleep hygiene support (Weeks 5-12) with daily reminders, educational messages, and video content, and (3) Follow-up monitoring (Weeks 13-24) with periodic motivational messages. Patients will track their sleep using smartwatches and share data via WhatsApp. The intervention guides behavior change through TTM stages, promoting sustainable sleep hygiene practices.
219540239|NCT07060677|PROCEDURE|Conventional occupational therapy sessions|Participants will receive conventional occupational therapy only, with sessions conducted twice per week for 8 weeks. The intervention will focus on cognitive stimulation, manipulative skill training, and psychomotor exercises, all adapted to the functional level of each participant. Activities aim to maintain or improve autonomy, balance, and coordination, following established occupational therapy guidelines for older adults. No immersive virtual reality or digital technology will be included in this group. This control condition allows for comparison with the experimental group to evaluate the added value of immersive virtual reality in fall risk and frailty reduction.
219540240|NCT01165385|DRUG|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
219540241|NCT01165385|DRUG|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
219540242|NCT07061054|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components: Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and Netrod™ Renal Denervation Radiofrequency Generator. The catheter's electrodes deploy into a self adaptive basket structure, optimizing contact with the vessel wall for effective ablation.
219540243|NCT01305161|OTHER|Blood simple|Single Blood simple at Day 1
219620456|NCT05169190|PROCEDURE|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
219540244|NCT07063485|BEHAVIORAL|Resilience Theory and Satir Model Nursing Skills Training|A structured psychological and nursing intervention program based on resilience theory and the Satir model. It consists of 15 two-hour group sessions during hospitalization, focusing on enhancing resilience, communication, and self-efficacy through themed activities, interactive learning, relaxation techniques, and guided training. The intervention is led by psychologists and psychiatric nurses and includes post-discharge follow-up.
219205251|NCT06892678|DRUG|DFMO|DFMO dose will be calculated based on the BSA measured within 14 days prior to the beginning of each cycle. Tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid.
219205252|NCT06893861|OTHER|Metabolomic profiling|Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.
219540245|NCT07063485|BEHAVIORAL|Routine Nursing Intervention|Standard nursing care for patients with depression, including illness monitoring, daily life guidance, psychological support, and health education on disease management, emotion regulation, and medication.
219540246|NCT07063758|OTHER|Biomarker Analysis|Tumor tissue and serum samples will be collected and analyzed to evaluate the expression of membranous Nectin-4, ADAM10/17, and levels of soluble Nectin-4 (sNectin-4) as predictive biomarkers in patients with advanced urothelial carcinoma receiving standard therapies.
219540247|NCT07063628|DIAGNOSTIC_TEST|TyG-derived index.|"Derived indices included:~* Ty,G×B,M,I = TyG index × body mass index~* TyG×W,C = TyG index × waist circumference~* TyG×WH,tR = TyG index × waist-to-height ratio Quartile-based stratification was applied to each TyG-derived index."
219540248|NCT07063628|DIAGNOSTIC_TEST|Left Ventricular Speckle Tracking|Coronary Angiography and Gensini Scoring: All participants underwent standard diagnostic coronary angiography. CAD was categorized as one-, two-, or three-vessel disease based on the number of vessels with ≥50% stenosis. The severity of CAD was quantified using the Gensini score, which assigns a severity weight to each lesion depending on degree of stenosis and anatomical location. Final scores were calculated by summing weighted values across all coronary segments.
219540249|NCT07068360|COMBINATION_PRODUCT|Strength Training +Postural Correction Exercises + Balance Training +Flexibility Exercises|"Interventions details (Group A) Strength Training Postural Correction Exercises Balance Training Exercises~Flexibility Exercises:"
218928617|NCT06725888|DEVICE|Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:|"Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days"
218928618|NCT07043972|DRUG|Gemcitabine|IV over 30 minutes given on days 1 and 8 of a 21 day cycle
218928619|NCT07043972|DRUG|Carboplatin|IV over 30 minutes given on day 1 of a 21 day cycle
218928620|NCT03672578|OTHER|loss-frame|loss frame label
218928621|NCT03672578|OTHER|gain-frame|gain frame label
218928622|NCT03672578|OTHER|text-only|text-only label
218928623|NCT03672578|OTHER|icon|label with icon and text
218928624|NCT03672578|OTHER|attribution|label with attribution
218928625|NCT03672578|OTHER|no attribution|label with no attribution
218928626|NCT03672578|OTHER|No label|No label
218928627|NCT06704685|DRUG|Butylphthalide|Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.
218928628|NCT06704685|DRUG|Butylphthalide placebo|Butylphthalide placebo
219205253|NCT06738186|OTHER|Video-based exercise program|"The video-based exercise program - Bliib fit -mach mit! focuses on mobilization, muscle strengthening (focus on lower and upper extremities), coordination, balance, and relaxation. Each participant requires the use of a chair for support and to perform exercises in a seated position, if required. The group sessions are supervised by a care professional or registered activation specialist of the residential care facility."
219205254|NCT06738186|OTHER|Caregiver-led activation program|The caregiver-led activation program (DESKK- Demenzspezifisches Kurzzeitpflegekonzept) is instructed and carried out by care professionals (e.g., nursing staff) as optimized standard care conducted individually or in groups.
219205255|NCT06736886|OTHER|Light application|Light application
219540250|NCT07068360|DIAGNOSTIC_TEST|Standard Intervention (Control Group)|"The control group will receive standard physiotherapy for postural hyperkyphosis.~The standard intervention will consist of:~Postural education: Educating participants on proper posture, body mechanics, and ergonomics in daily activities.~Basic stretching exercises targeting the thoracic spine and back muscles. Recommendations for low-impact aerobics activities (e.g., walking or cycling) to promote overall healthThe standard intervention will be delivered over the same 12-week period, with two sessions per week. This group will not receive the integrated multimodal framework with strength training, postural correction, balance training, and flexibility exercises that the experimental group receives. Duration and Frequency"
219540251|NCT07069062|DRUG|Test product HY0001a for injection|HY0010a for injection should be administered at the recommended dosage
219540252|NCT07067476|OTHER|Instant Anti-Redness Emulsion (FLA#2039188 43)|A topical emulsion not yet marketed, developed to relieve skin redness. It contains panthenol and is applied once to the test side of the face after heat-induced redness.
218928629|NCT05232682|DIETARY_SUPPLEMENT|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
218928630|NCT06377033|BEHAVIORAL|Behavioral nudge|Comparison of genetic rates among individuals for whom it may make a difference in their care across study arms.
218928631|NCT06428006|BEHAVIORAL|Cognitive behavioral therapy for insomnia|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
218928632|NCT06428006|BEHAVIORAL|Sleep and lifestyle education|"The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises"
218928633|NCT06891001|DEVICE|Unilateral neutral shoe insert|In the treatment group, subjects will undergo the addition of a neutral shoe insert to the involved lower extremity according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
218928634|NCT06891001|DEVICE|Bilateral Shoe Insert|For subjects placed in the sham group, subjects will undergo the addition of a neutral shoe insert to both lower extremities according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol with guidelines .
218928635|NCT06891001|OTHER|Physical Therapy|For subjects placed in the control group, subjects will undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
218928636|NCT07045363|BEHAVIORAL|Cognitive Intervention|Participants in the intervention arm will receive a personalized one-page Heart Age report based on data from their government-funded annual health check. The report is delivered by trained physicians using a standardized communication script during a routine follow-up visit. The control group receives usual chronic disease care without structured risk communication.
218928637|NCT03002870|OTHER|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
218928638|NCT06743958|OTHER|Exercise intervention|Specific strength and balance training intervention during neoadjuvant chemotherapy, twice per week for 30 min, progression according to individual status
218928639|NCT07051746|BEHAVIORAL|Metacognitive Training (MCT), Traditional Chinese version|The intervention is a culturally adapted version of Metacognitive Training (MCT) for psychiatric populations in Taiwan. The program consists of 8 group sessions over 4 weeks. Each session includes psychoeducation, cognitive exercises, and group discussion to help participants recognize and reduce cognitive biases.
218928640|NCT06845566|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training. The occupational problem is defined. The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model. Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
218928641|NCT06845566|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupational therapy was completed
219043926|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
219043927|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
219043928|NCT02744846|DRUG|Antibiotics exposure|
219540253|NCT07067476|OTHER|Purified Water (Control)|0.3g of water is applied to the control side of the face. Used as placebo comparator to evaluate the redness-relieving efficacy of the test emulsion.
219540254|NCT07068373|DIAGNOSTIC_TEST|Mixed method (Exploratory Sequential)|4-6 Expert SLPs working with Cochlear Implant, A cohort of 100 Urdu speaking children who received cochlear implants
219043929|NCT00418691|DRUG|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
219540255|NCT07068269|OTHER|Self-Management Program|"Week 1: Learn about COPD, practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 reps, 2-3x/day), start 5-10 min light walking, conserve energy with frequent rests.~Week 2: Understand benefits of activity and oxygen use, add seated marches/leg raises, walk 10-15 min, pace activities with rest breaks.~Week 3: Begin strength exercises (sit-to-stand, wall push-ups, 2 sets of 10), increase walking to 15-20 min, practice relaxation for anxiety.~Week 4: Focus on nutrition, walk 20-25 min, continue strength work, recognize flare-up signs, create action plan.~Week 5: Seek social support, walk 25-30 min, add stretching (2-3x/week), track activity daily.~Week 6: Set SMART goals, maintain daily walking 30 min, review coping strategies, add new activities if desired."
219620457|NCT02828293|OTHER|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
219620458|NCT03275493|BIOLOGICAL|CD19 CAR-T cells|Express a Second Generation 4-1BB: CD19 CAR-T cells
219540256|NCT07068269|OTHER|Routine Physical Therapy Exercises|"Week 1: Practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 breaths, 2-3x/day), start walking 5-10 min (3-5x/week), add gentle upper body stretches (20-30 sec holds, 2-3 reps).~Week 2: Continue breathing exercises, increase walking slightly each session, maintain stretches 3-5x/week for flexibility.~Week 3: Keep breathing routines, walk or cycle 15-20 min (4-5x/week), start sit-to-stand strength exercises (2-3 sets of 10-15 reps, 2-3x/week), keep stretching routine.~Week 4: Maintain breathing drills, increase walking/cycling intensity if tolerated, continue strength work and flexibility exercises.~Week 5: Keep up breathing exercises, walk/cycle 20-30 min (5x/week), do sit-to-stand exercises (3 sets of 10-15 reps, 3x/week), maintain upper body stretching.~Week 6: Sustain daily breathing practice, aim for 30 min walking/cycling daily, continue strength and stretch exercises, adjust intensity as needed for long-term progress."
218928642|NCT05298956|OTHER|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
218928643|NCT03387085|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
218928644|NCT03387085|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
218928645|NCT03387085|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
218928646|NCT03387085|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
218928647|NCT03387085|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
218928648|NCT03387085|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
218928649|NCT03387085|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
218928650|NCT03387085|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
218928651|NCT03387085|BIOLOGICAL|haNK for Infusion|NK-92 \[CD16.158V, ER IL-2\]
218928652|NCT03387085|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
218928653|NCT03387085|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
218928654|NCT03387085|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
218928655|NCT03387085|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
218928656|NCT03387085|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
218928657|NCT03387085|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219043930|NCT00418691|DRUG|Modafinil|200 mg PO Once Daily x 4 Weeks
219043931|NCT00418691|DRUG|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
219540257|NCT07068412|COMBINATION_PRODUCT|3D-printed Orthognathic Surgical Simulation|Two standardized 3D-printed anatomical models were created-one representing skeletal Class II and the other skeletal Class III. Simulated osteotomies, including Le Fort I and Bilateral Sagittal Split Osteotomies, were performed on the models to demonstrate surgical movements. These models are used to help patients visualize the procedures planned for their specific cases.
218928658|NCT03387085|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
218928659|NCT03387085|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
218928660|NCT03387085|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
219043932|NCT05052424|DIAGNOSTIC_TEST|Analysis of cytokines and immun cell related markers|blood samples
219043933|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
219043934|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
219043935|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
218928661|NCT07059624|PROCEDURE|"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane (MDNTP-SAOP)"|Patients will have their femoral arterial line inserted using the MDNTP-SAOP technique.
218928662|NCT07059624|PROCEDURE|"Conventional, Short-Axis, Out-Of-Plane (C-SAOP)"|Patients will have their femoral arterial lines inserted using the C-SAOP technique.
218928663|NCT06420999|OTHER|Diaphragmatic ultrasound and data collection|At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
218928664|NCT06132373|BEHAVIORAL|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
219043936|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
219043937|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
218928665|NCT07063862|DRUG|Psilocybin|Participants randomized to the psilocybin microdosing intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of psilocybin daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
218928666|NCT07063862|DRUG|Placebo|Participants randomized to the placebo intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of placebo daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
219540258|NCT07068412|COMBINATION_PRODUCT|2D Visual Representations of Skeletal Movements in Orthognathic Surgery|Two-dimensional images generated from virtual surgical planning-one depicting a Class II skeletal deformity and the other a Class III malocclusion-are used to illustrate the patient's condition and demonstrate the anticipated surgical movements.
218928667|NCT06767319|OTHER|No intervention|The difference in diopters of depth of focus range achieving a threshold of 0.20 logMAR between Trial lens vs. Chart testing method per pre-study IOL group.
218928668|NCT07069101|OTHER|Erector spinae block|Patients will receive continuous ipsilateral erector spinae plane block.
218928669|NCT07069101|OTHER|Edge of lamina block|Patients will receive continuous ipsilateral edge of laminar block.
218928670|NCT07067190|DEVICE|Conventional Bar Attachment|A rigid cast bar attachment fabricated and screwed onto three mandibular implants (placed at the midline and canine areas). The bar connects the implants to provide splinting and retention for a mandibular overdenture without the use of additional retentive components such as OT Caps. The overdenture is adjusted to fit passively over the bar and picked up intraorally.
218928671|NCT07067190|DEVICE|Bar with OT Cap Attachment|A cast bar attachment fitted with two OT Cap attachments, which are designed to improve prosthesis retention and load distribution. This bar system is installed on three mandibular implants (midline and canine regions). The mandibular overdenture is relined to incorporate the female retentive caps that snap onto the OT Caps. This system combines the splinting benefits of the bar with the resilient retention of stud attachments.
218928672|NCT01008540|BIOLOGICAL|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
218928673|NCT07068152|BEHAVIORAL|Preoperative telenursing|The role of Nursing in Telenursing includes Nursing Consultation, Interconsultation, Consulting, Monitoring, Health Education and Reception of Spontaneous Demand mediated by Information and Communication Technologies. In this research, the researcher will make a telephone call the day before surgery to patients scheduled in the surgical map in order to guide them on immediate preoperative care.
218928674|NCT07068347|COMBINATION_PRODUCT|VR + lifestyle modification|"VR + lifestyle modification (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.In lifestyle modification walking at home for 30 min in 3-5 days /week. Dietry habits will be given according to American Institute for cancer Research.~In sleep habits Recommended Sleep Hours 7-9 hours per night,Establish a Consistent Sleep Schedule,Create a Comfortable Sleep Environment,Limit Screen Time Before Bed,Engage in Relaxation Techniques,Limit Caffeine and Alcohol Intake,Manage Nighttime Discomfort,Maintain a Pre-Sleep Routine,Address Emotional Health,Avoid Daytime Naps.Deep breathing exercise for stress management"
219043938|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
219540259|NCT07068464|PROCEDURE|delayed cytoreduction surgery|Delayed cytoreduction surgery is defined as cytoreduction surgery after six cycles of carboplatin and paclitaxel neoadjuvant chemotherapy.
219540260|NCT07068464|PROCEDURE|interval cytoreduction surgery|Interval cytoreduction surgery is defined as cytoreduction surgery after three cycles of carboplatin-paclitaxel neoadjuvant chemotherapy.
219540261|NCT07069114|PROCEDURE|Anterior Cervical Discectomy and Fusion with BAK/C Interbody Fusion|The surgical intervention consisted of anterior cervical discectomy and fusion (ACDF). Patients were placed under general anesthesia in a supine position with slight neck extension. A standard right anterior cervical approach was utilized to expose the affected vertebral levels. Following the removal of the degenerated intervertebral disc and osteophytes, the interbody space was prepared. A Bagby and Kuslich (BAK/C) interbody fusion cage, filled with autogenous bone fragments, was implanted to facilitate fusion. In cases of multi-level surgery, an anterior cervical plate was selectively applied for enhanced stability based on intraoperative assessment. Postoperatively, all patients were required to wear a Philadelphia hard neck brace for a period of 2 months.
219540262|NCT07068828|BEHAVIORAL|Mobilization Encouragement Protocol|This intervention includes a video-based education session delivered before surgery to encourage early mobilization, visual poster reminders in patient rooms on postoperative day 1, and SMS text message reminders sent to patients' phones on postoperative days 1 and 3. Participants will also wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). The goal is to increase physical activity levels, improve recovery quality, and reduce postoperative complications after bariatric surgery.
219540263|NCT07068828|BEHAVIORAL|Smart Watch for Physical Activity Monitoring|Participants in the control group receive standard postoperative care without additional mobilization encouragement. They wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). However, they do not receive video education, posters, or SMS reminders.
219540264|NCT07068698|OTHER|Thumb Manipulation|This intervention consists of chiropractic manipulation techniques applied specifically to the thumb joint. The manipulation will be performed by a trained physiotherapist twice weekly for 4 weeks. The procedure aims to improve thumb joint mobility, hand grip strength, sensory function, and overall hand function. Each session includes standardized manual therapy maneuvers targeting the thumb's range of motion and soft tissue mobility without the use of any devices or medications. The intervention differs from other manual therapies by focusing solely on the thumb region.
219620459|NCT03275493|BIOLOGICAL|CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
218928675|NCT07068347|COMBINATION_PRODUCT|VR only|VR only (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.
219540265|NCT07068750|PROCEDURE|patients received dental implants using single drilling system in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will performed and full thickness mucoperiosteal flap will be reflected to access the site. The implant will be prepared using the new specially designed drill. These drills are available with four drilling lengths (7, 9, 11, 13 mm) characterized by different color codes, and three different diameters (4, 4.5, 5 mm). They allow a single drilling procedure before implant placement in bone with all types. Drilling speed of 1500 RPM and profuse normal saline irrigation will be used throughout the drilling procedure. Tapered implants will be inserted in all patients with insertion torque 30-50Ncm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
219205256|NCT06736639|PROCEDURE|Anchor Suture with Titanium Cable Cerclage|This intervention involves the use of \*\*anchor suture fixation combined with titanium cable cerclage\*\* for the treatment of inferior pole patellar fractures (IPPF). The anchor suture provides stable fixation of fracture fragments by anchoring directly into the bone, while the titanium cable cerclage offers additional reinforcement around the patella to enhance stability and minimize fragment displacement. This method is specifically designed to address the limitations of traditional Kirschner-wire tension band techniques, such as hardware irritation and infection, by using biocompatible and low-profile materials.
219540266|NCT07068750|PROCEDURE|patients received dental implants using Densah burs in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using osseodensification burs (Densah, Versah) at 1200 rpm in the following sequence: (I) pilot (clockwise); (II) WT1828 (counterclockwise), and (III) WT2838 (counterclockwise). These burs have a cutting chisel edge, a tapered shank and non- cutting edges with four or more lands with a negative rake angle. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
219540267|NCT07068750|PROCEDURE|patients received dental implants using conventional drills in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using conventional surgical drills at 1200 rpm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
219043939|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
219043940|NCT06764095|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219043941|NCT06764095|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219043942|NCT06764095|PROCEDURE|Cystectomy|Undergo cytoreductive cystectomy
219043943|NCT06764095|DRUG|Enfortumab Vedotin|Given IV
219043944|NCT06764095|PROCEDURE|Local Therapy|Undergo MDT
219043945|NCT06764095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219043946|NCT06764095|BIOLOGICAL|Pembrolizumab|Given IV
219043947|NCT06764095|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219043948|NCT06764095|OTHER|Questionnaire Administration|Ancillary studies
219043949|NCT06764095|PROCEDURE|Ureterectomy|Undergo ureterectomy
219043950|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase Ib)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
219043951|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase II)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
219043952|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
219043953|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
219043954|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
219043955|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
219043956|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
219043957|NCT03194165|BIOLOGICAL|Darunavir|Dosage
219043958|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
219043959|NCT01718756|DRUG|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
219043960|NCT01718756|DRUG|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
218928676|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy + lifestyle modification|Conventional physical therapy + lifestyle modification In Conventional physical therapy(Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated)
218928677|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy only|Conventional physical therapy only((Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated) ,Trunk lateral flexion with arms in 90 degrees abduction in standing position,Theraband (flexion-extension-abduction, adduction and internal-external rotation),Muscles of upper limb strengthening ,Mobilization for passive glenohumeral joint ,Tissue massage for scars.
218928678|NCT07064915|BEHAVIORAL|Medical-Financial Partnership Support|"The Medical-Financial Partnership (MFP) intervention will include (at minimum):~1. A relationship with a trained MFP intervention team member~2. Establishment of financial and social goals in the initial meeting, with connection to public anti-poverty programs, employment opportunities, and other income supports, among others, as tailored to participant goals~3. Establishment of an action plan to reach short, medium and long-term goals in core MFP domains~4. Co-designing with the participant to identify and refine goals and action steps longitudinally~5. A standard toolkit for access to financial services and public benefits"
218928679|NCT07068386|OTHER|Early intervention with telerehabilitation|"All premature infants aged 3 to 5 months included in the study were assessed for motor development using the General Movements Assessment (GMs) and the Alberta Infant Motor Scale (AIMS), based on videos submitted by their parents. Following the video evaluations, parents were contacted via video call. An intervention program was developed in collaboration with the parents, guided by the video-based assessments.~The intervention program focused on the acquisition of age-appropriate motor development and included components such as massage, positioning, trunk control, movement selectivity, and anti-gravity activities. It was delivered to parents through synchronous. Parents were advised to implement the program for 30 minutes per day, 4 days a week, over a 12-week period. After the intervention, the infants were re-evaluated using the AIMS via video call."
218928680|NCT02819011|DEVICE|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
219540268|NCT06899971|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
218928681|NCT02819011|OTHER|Control|Subjects will be provided with a pair of New Balance 813 shoes
218928682|NCT07069621|BEHAVIORAL|Triple p level parenting program|An evidence-based program with self-agency strategies enhances trust and confidence in managing children's ADHD behaviors
218928683|NCT07071675|DRUG|Calcium Hydroxide Intracanal medication|Treated using calcium hydroxide based material as an intracanal medicament
218928684|NCT07071675|DRUG|bioceramic based intracanal medication|treated using bio-ceramic based material as an intracanal medicament
218928685|NCT07065253|OTHER|blood ponction|blood ponction
218928686|NCT07065253|OTHER|urines collection|urines collection
218928687|NCT07065253|OTHER|hair collection|hair collection
218928688|NCT07065253|OTHER|saliva collection|saliva collection
218928689|NCT07065253|OTHER|stools collection|stools collection
218928690|NCT07069192|BEHAVIORAL|Counselling|Received structured caregiver counseling - weekly sessions for 1 month and biweekly for the next 2 months.
218928691|NCT07069647|OTHER|VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration|VeriSee DR is an AI-assisted diagnosis screening tool for diabetic retinopathy, the software received medical device license approval from the TFDA in 2020 (MOHW-MD-No.006966). VeriSee AMD is an AI-assisted diagnosis screening tool for age-related macular degeneration, the software also received medical device license approval from the TFDA in 2022 (MOHW-MD-No.007652).
219540269|NCT03714685|DRUG|Firibastat|Firibastat (QGC001) 500 mg
219540270|NCT05900635|DRUG|Lactoferrin|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
219540271|NCT05900635|DRUG|Ferrous Glycine Sulfate|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
219540272|NCT06933173|OTHER|Dynamic neural retraining system|"Description: The DNRS program includes the following components: 1) cognitive-behavioural therapy; 2) mindfulness-based cognitive restructuring; 3) emotional restructuring therapy; 4) neural linguistic programming; 5) incremental training; and 6) behaviour modification therapy. DNRS offered in this study includes a 14-hour online course followed by a 12-week online LIVING DNRS group support program. The 14-hour online course includes a variety of exercises, instructional videos, and a workbook. Upon completion, participants are offered a 12-week LIVING DNRS Group Support program which provides individuals with support in how to best implement DNRS into their daily lives with the help of a trained facilitator as well as peer support."
219540273|NCT01963728|DRUG|Insulin, Isophane|daily dosing based on fasting morning glucose levels
219540274|NCT01963728|DRUG|insulin glargine|daily dose based on fasting morning glucose levels
219540275|NCT06738160|DRUG|Narlumosbart|Patients who have not received any systemic therapy will receive narlumosbart and bone target lesion SBRT in combination with first-line treatment immunotherapy and chemotherapy after screening eligible subjects. Narlumosbart, 120mg/time, subcutaneous injection, is administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24Gy/3F is used for spinal metastases, and 30Gy/5F or 35Gy/5F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines. The primary endpoint is to assess the objective response rate of NSCLC patients with bone metastases from narlumosbart combined with SBRT and first-line chemotherapy and immunotherapy. The secondary endpoints include progression-free survival, overall survival and safety. Sample size calculation used the Simon Two-Stage method. 27 subjects will be enrolled in this project, considering the dropout rate of 10%.
219540276|NCT04115293|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
219540277|NCT04115293|DRUG|Placebo|Daily subcutaneous (SC) injection
219540278|NCT03729271|DRUG|Rifaximin|Rifaximin will be given during weeks 2-4
219540279|NCT03729271|DEVICE|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
218928692|NCT07069647|OTHER|Standard fundus photography with physician interpretation|The control group will undergo the fundus photography without AI-functionality, with reports interpreted solely by physicians. Participants must schedule a follow-up visit to receive their results.
218928693|NCT06849037|DRUG|zinacef tretment|prophylactic antibiotic treatment with zinacef
219540280|NCT05137834|OTHER|Exercise|Post-surgical exercise
219540281|NCT00001703|BIOLOGICAL|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
218928694|NCT06849037|OTHER|Placebo|I.V SALINE 100 CC X3/d
218928695|NCT07075796|DEVICE|GLUCUBE system|A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
218928696|NCT07074821|DRUG|Taurolidine citrate 4% and heparin 500|Taurolidine ,citrate 4% and heparin 500 units per ml used as lock solution in tunneled hemodialysis catheter
218928697|NCT07075263|OTHER|Questionnaire|A self-administered structured questionnaire
218928698|NCT07074002|DRUG|BP1.4979|Selective dopamine D3 partial agonist
219540282|NCT00001703|BIOLOGICAL|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
219540283|NCT03242213|BEHAVIORAL|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
218928699|NCT07074002|DRUG|Placebo|Matching placebo of BP1.4979 tablet
218928700|NCT07075250|DRUG|Realgar-Indigo Naturalis Formulation Combined with Anlotinib|"RIF: Oral administration after meals, 6 tablets each time, three times daily (tid), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Anlotinib : Oral administration before breakfast, 10 mg each time, once daily (qd), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Subjects will continue the study treatment until meeting the protocol-defined discontinuation criteria. The total treatment duration should not exceed 18 months."
218928701|NCT07074340|DEVICE|occlusal stabilization splint manufactured with a conventional workflow|Heat-cured acrylic resin occlusal stabilization splint
219540284|NCT01414153|DRUG|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
219540285|NCT01414153|DRUG|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
219540286|NCT01414153|DRUG|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
219540287|NCT01414153|DRUG|sham injection|administered monthly for 4 months
219540288|NCT01117220|DRUG|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
219540289|NCT01117220|DRUG|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
218928702|NCT07074340|DEVICE|occlusal stabilization splint manufactured with Fully-digital workflow|3D printed occlusal stabilization splints
219540290|NCT04259476|DRUG|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
219540291|NCT06081569|DIAGNOSTIC_TEST|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
218928703|NCT07075562|DRUG|Bevacizumab Arterial Perfusion plus TACE|The intervention consists of a combination treatment. Patients undergo transcatheter hepatic artery chemoembolization (TACE), a procedure involving localized delivery of chemotherapy and embolization of the tumor-feeding arteries. This is combined with a targeted arterial perfusion of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF).
218928704|NCT07075562|PROCEDURE|Conventional Therapy|Patients in the control group received conventional therapy, which typically consists of TACE alone for this patient population. This involves the selective catheterization of hepatic arteries supplying the tumor, followed by the infusion of chemotherapeutic agents and an embolic agent to induce tumor necrosis.
218928705|NCT06895031|DRUG|JYP0015|JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.
218928706|NCT07074496|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with ph+ ALL.
219620460|NCT04966871|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
218928707|NCT07074496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
218928708|NCT07074496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
218928709|NCT07074496|DRUG|Olverembatinib|a third-generation TKI
218928710|NCT07075770|DEVICE|Combined iTBS-tACS|The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. iTBS and tACS will be synchronized using a BrainTrigger and SIGNAL Software so that both stimulations will start simultaneously
218928711|NCT07075770|DEVICE|iTBS-sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
218928712|NCT07075770|DEVICE|sham iTBS- sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the iTBS sham condition, stimulation was delivered with the coil angled at 90°, with only the edge of the coil resting on the scalp..~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
218928713|NCT07074210|DEVICE|non invasive ventilation|Non invasive mechanical ventilation pressure support
218928714|NCT07074678|DIAGNOSTIC_TEST|Functional MRI (fMRI)|Research MRI, which will include both structural and functional sequences, will either be collected independently, or in conjunction with clinically-indicated sequences. Functional MRI captures the blood oxygen level dependent (BOLD) signal that reflects brain activity. A subset of the PREDICT study fMRI will include sequences with auditory and/or noxious stimulation. Noxious stimulation will be delivered with an MRI-compatible device that delivers intermittent nailbed pressure under computerized control. Additionally, the BOLD signal will be captured at rest to investigate functional neural networks.
218928715|NCT07074834|DRUG|Metoprolol Succinate Sustained-Release Tablets|Oral administration. Dose was 23.75 mg once daily for the first two weeks, then increased to 47.50 mg once daily.
218928716|NCT07074834|DRUG|Trimetazidine|Oral administration. Dose was one tablet twice daily.
218928717|NCT07074834|DRUG|Routine Drug Therapy|Included oral nitroglycerin tablets (0.5 mg twice daily), aspirin enteric-coated tablets (0.1 g once daily), and rosuvastatin calcium tablets (10 mg three times daily).
218928718|NCT07074652|DRUG|Escitalopram|Participants received 2-3 weeks of escitalopram.
219043961|NCT01718756|DRUG|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
219043962|NCT01970683|DIETARY_SUPPLEMENT|VSL #3 BID|
219540292|NCT06042738|COMBINATION_PRODUCT|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
219540293|NCT04740658|OTHER|No intervention|There is no intervention
219540294|NCT05956561|OTHER|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
219540295|NCT04741893|DEVICE|EndoFLIP|Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
219540296|NCT05547711|DIAGNOSTIC_TEST|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
219540297|NCT01424761|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
219540298|NCT01424761|OTHER|Placebo|Placebo :starch
219540299|NCT03196258|BEHAVIORAL|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
219540300|NCT00378963|DEVICE|ProAdjuster|
219540301|NCT00809250|BIOLOGICAL|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
219540302|NCT01344590|OTHER|Normal Saline|Standard saline procedure will be utilized.
219540303|NCT01344590|OTHER|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
219540304|NCT02267187|PROCEDURE|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
219540305|NCT02267187|DRUG|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
219620461|NCT04966871|BIOLOGICAL|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
218928719|NCT07074652|DRUG|Placebo|Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.
219043963|NCT00951431|DRUG|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
219043964|NCT00951431|DRUG|Placebo|Placebo in the form of study drug
219043965|NCT01307566|DEVICE|Continuous Positive Airway Pressure CPAP|CPAP treatment
219043966|NCT02888899|BEHAVIORAL|Biofeedback|
219620462|NCT04966871|OTHER|Normal Saline|normal saline placebo control
219620463|NCT02508337|DRUG|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
219620464|NCT02508337|DRUG|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
219620465|NCT00618111|DRUG|Granisetron|
219620466|NCT01022840|DRUG|S-Ketamine|drug
219043967|NCT02888899|DRUG|Loperamide|
219620467|NCT01022840|OTHER|Placebo Comparison|saline control
218928720|NCT07074899|OTHER|Multi-component HIV testing and linkage-to-services intervention|"The intervention includes two core components:~1. HIV testing offered at sex-on-premises-venues \[SOPVs\];~2. mHealth-supported linkage to treatment/prevention services (enrollment in a two-way text messaging application adapted from the WelTel platform).~In this trial, the specific format of HIV testing offered will differ according to intervention arm."
218928721|NCT07074717|PROCEDURE|Buccal Mucosal Graft (BMG) Urethroplasty|Urethroplasty using a buccal mucosal graft harvested from the inner cheek. The graft is dorsally onlaid to reconstruct the strictured urethral segment. The procedure is conducted under spinal or general anesthesia.
218928722|NCT07074717|PROCEDURE|Penile Skin Graft (PSG) Urethroplasty|Urethroplasty using a penile skin graft harvested from the ventral surface of the penis. The graft is applied dorsally after excision of the fibrotic urethral segment. The surgery is performed under spinal or general anesthesia.
219540306|NCT02267187|DEVICE|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
219540307|NCT02267187|OTHER|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
218928723|NCT07074587|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises will be taught with an innovative approach based on the principles of finding, feeling, forcing, following and functional training of the pelvic floor muscles. Pelvic floor muscle exercises will be applied as 3 sets in the first 2 weeks, 4 sets in the 3rd and 4th weeks, 5 sets in the 5th and 6th weeks, and finally 6 sets in the 7th and 8th weeks. Individuals will continue their pelvic floor muscle exercises as a home program.
218928724|NCT07074587|BEHAVIORAL|Spinal stabilization exercises focusing on the pelvic floor + Pelvic floor muscle exercises|This program consists of 3 phases: 30 minutes of spinal stabilization exercises focusing on the pelvic floor, 5 minutes of warm-up and 5 minutes of cool-down exercises.The exercises will consist of 3 phases: static, dynamic and functional phases. Individuals will perform static phase exercises for the first 2 weeks, then dynamic phase exercises in the 3rd and 5th weeks and finally functional phase exercise in the 6th and 8th weeks. Individuals will be asked to maintain neutral spine position and abdominal bracing during pelvic floor muscle contraction during all exercises. Individuals will maintain the contraction for 5-10 seconds for 10 repetitions in each position in all phases.
218928725|NCT07075107|PROCEDURE|Blood collection|Blood is collected in order to perform transcriptomic sequencing from blood
218928726|NCT07075107|PROCEDURE|skin biopsy|A biopsy of skin is performed in order to perform transcriptomic sequencing on fibroblasts obtained from the biopsy
218928727|NCT07075211|DEVICE|MARPE (mini-screw assisted rapid palatal expansion)|MARPE (mini-screw assisted rapid palatal expansion) with two min screws in post-pubertal patients
218928728|NCT07075328|OTHER|Drug:5-ALA, Device:Photodynamic system|"\[Phase I part\] Patients will receive 5-ALA administered orally once. After administration of 5-ALA, patients will receive Photodynamic system once.~Dosage of 5-ALA: 10 mg/kg (1st cohort), 20 mg/kg (2nd cohort), 40 mg/kg (3rd cohort), 60 mg/kg (4th cohort) \[Phase II part\] Patients will receive 5-ALA and Photodynamic system once a week for 6 months."
218928729|NCT07075978|BEHAVIORAL|Remote patient monitoring|The usual interprofessional program activities are delivered via remote patient monitoring kits. The kit includes a tablet for virtual visits with the Mobile Health and Wellness Team and access to educational videos, as well as at-home monitoring devices for blood pressure, blood sugar if diabetic, pulse ox if COPD, and/or weight scale.
218928730|NCT07075978|BEHAVIORAL|Telephone|The usual interprofessional program activities are delivered via telephone visits without any at-home monitoring devices.
218928731|NCT07074093|COMBINATION_PRODUCT|app+smartband+education|"Intervention:~Behavioral: Health education~Device: AirVisual App~Device: Amazfit Band 5"
218928732|NCT07074171|BEHAVIORAL|Text message-based education intervention|The intervention consisted of enhanced behavioral and educational text messages, up to three messages each week, providing updates on COVID-19 testing and vaccination. The text messages included digitally delivered intervention content such as a video with low-literacy instructions for administering the rapid antigen tests, guidance if they tested positive (e.g., quarantine, notify contacts, wearing a mask), and other relevant strategies and content focused on increasing COVID-19 testing and vaccination.
218928733|NCT07075393|OTHER|full renal workup|full renal workup (biology and echography)
218928734|NCT07074847|OTHER|Measure QFR|Collect blood samples from 100 patients with normal coronary angiography or stenosis less than 50%, centrifuge and collect plasma, and then send them for further metabolomics testing to analyze the test results.
219540308|NCT06060145|OTHER|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
219540309|NCT06060145|OTHER|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
219540310|NCT04906070|DEVICE|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219540311|NCT04500015|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
219540312|NCT04500015|DRUG|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
219620468|NCT05221944|OTHER|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
219620469|NCT05221944|OTHER|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
219620470|NCT02308150|DEVICE|transcatheter aortic valve replacement|
219620471|NCT04261946|OTHER|Quality of life survey|Unilateral patulous eustachian tube surgically treated were interviewed about our life's quality by a survey
219620472|NCT01607450|DRUG|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
219620473|NCT01607450|DRUG|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
218928735|NCT07074457|DRUG|Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)|"3 cycles of BvC treatment for all enrolled patients.~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;"
218928736|NCT07074457|DRUG|Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)|"Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment).~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;~Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years"
218928737|NCT07074457|DRUG|Maintenance therapy-chidamide|Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years
219540313|NCT03579615|DEVICE|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
218928738|NCT07074509|OTHER|Manual therapy|Patients were treated by manual therapy in the form of nerve gliding, soft tissue release, and carpal bone mobilization, three sessions per week for 4weeks.
218928739|NCT07074509|OTHER|Extracorporeal shock wave therapy|Patients were treated by extracorporeal shock wave therapy. 4 sessions, one week apart, 2000 pulses per session, intensity 1.6 mj/mm, and frequency 8Hz.
219540314|NCT03579615|DEVICE|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
219540315|NCT02427763|DEVICE|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
219540316|NCT02427763|OTHER|collect saliva|the patient spit during 30 seconds in a small bottle
218928740|NCT07074132|BEHAVIORAL|Combined Aerobic and Muscle-Strengthening Training Program|A combined training program including both aerobic and muscle-strengthening physical activities within the same session, conducted over a period of 8 months. Aerobic training is performed at an intensity of 50-70% of heart rate reserve (HRR), and strength training at 60-70% of one-repetition maximum (1-RM). The training is conducted three times per week.
219043968|NCT02888899|DRUG|Stool bulking agent (sterculia or ispaghula husk)|
219540317|NCT02427763|OTHER|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
219540318|NCT02427763|OTHER|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
219540319|NCT05846022|OTHER|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
219540320|NCT05846022|OTHER|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
219540321|NCT03537482|DRUG|APG-2575|APG-2575 will be administered as an oral tablet
219540322|NCT01995227|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine
219540323|NCT01995227|BIOLOGICAL|CRCL|Personalized anti-cancer vaccine
219540324|NCT01995227|BIOLOGICAL|AlloStim|ID injections IV infusion
219540325|NCT06128967|DRUG|Fluvoxamine Maleate 100 MG|Fluvoxamine Maleate 100 mg each pills
219540326|NCT06128967|DRUG|Placebo|Placebo talc pills of same shape, color, weight if compared with active comparator
219540327|NCT06128967|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended release oral tablets of 750 mg each pill
219540328|NCT02392286|DRUG|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
219540329|NCT04974684|DEVICE|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
219540330|NCT04974684|DRUG|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
219540331|NCT01118598|DRUG|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
219540332|NCT01118598|DRUG|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
219540333|NCT02222818|DEVICE|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
219540334|NCT02222818|DEVICE|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
219540335|NCT03717805|OTHER|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
219540336|NCT00444353|DEVICE|DL6049 (injectable poly-L-lactic acid)|
219043969|NCT02888899|OTHER|PTNS|
219540337|NCT00543205|DRUG|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
219540338|NCT03089515|OTHER|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
219540339|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
219540340|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
219540341|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
219540342|NCT01660243|DRUG|Placebo|Placebo (2capsules) once daily for 8 weeks
219540343|NCT02873845|OTHER|Preliminary validation of the COBQoL questionnaire|
218928741|NCT07075575|DRUG|Nicotine Polacrilex Gum (2 mg)|"Participants chew 2 mg nicotine gum according to a tapering 12-week schedule: Weeks 1-6: 1 piece every 1-2 hours; Weeks 7-9: 1 piece every 2-4 hours; Weeks 10-12: 1 piece every 4-8 hours. Max 24 pieces/day. Gum is distributed every 2 weeks during study visits.~Arm(s) Used In:~NRT Gum Only CBGT + NRT Gum"
218928742|NCT07075575|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|"Participants attend six weekly sessions of group-based cognitive behavioral therapy focused on smoking cessation. Sessions include education on cravings, relapse prevention, stress management, and self-efficacy building.~Arm(s) Used In:~CBGT Only CBGT + NRT Gum"
218928743|NCT07075549|OTHER|Maintenance phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema in the maintenance phase of decongestive lymphatic therapy (with compression garments) were included
218928744|NCT07075549|OTHER|Intensive phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema who are treated in the intensive phase of Decongestive Lymphatic Therapy (with multilayer bandages) were included
219540344|NCT00262392|DRUG|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
218928745|NCT07075198|DEVICE|Caesar Foot|The investigators developed a bimodal, passive mechanical prosthetic foot called the Caesar Foot. The Caesar Foot has two modes: one optimized for walking, and one optimized for higher-energy activities like running. It has a switching device that was designed such that when it switches modes, it inherently accounts for the alignment and stiffness differences between walking and running feet (such as the longer length, higher stiffness, and different ground contact points required for running feet). Therefore, it should be largely comparable to a daily use prosthesis / walking foot when in walking mode, and an running specific prosthesis / running blade when in running mode. This foot is attached and aligned to the user's usual prosthetic socket.
218928746|NCT07073573|PROCEDURE|Vital pulp therapy|Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
218928747|NCT07075055|OTHER|Metapaste Calcium Hydroxide|To compare the effect of calcium hydroxide and Bio-C Temp as intra canal medications on postoperative pain via VAS and periapical healing via CBCT
218928748|NCT07075055|OTHER|Bio C-Temp|Bio C-Temp
218928749|NCT07074860|BEHAVIORAL|Peer to peer video to raise awareness about substance use|A total of 4 short, animated videos will be created using design concepts and language created by the VT RAYS. Each video will be \<2 minutes in length and address a specific topic including e-cigarette, cannabis, alcohol and other substance use. These videos will be curated online and shown to study participants during their scheduled primary care visits. The video will be followed by a short online survey available immediately after viewing to collect feedback on the content.
218928750|NCT07075744|OTHER|Intraoperative Heart Rate Monitoring|This is a non-interventional observational analysis of intraoperative heart rate metrics, including minimum, maximum, average, and time-weighted average heart rate recorded during non-cardiac surgery. The study also includes duration-based metrics such as time spent below or above specific heart rate thresholds. These variables were retrospectively analyzed for their association with 30-day postoperative mortality. No clinical intervention or treatment was administered as part of this study.
218928751|NCT07073989|DEVICE|Afferent stimulation|Stimulation applied through mechanical vibration or low-intensity electric currents
218928752|NCT07074418|DRUG|Empagliflozin 10 MG then Placebo|Taking Empagliflozin first
218928753|NCT07074418|DRUG|Placebo then Empagliflozin 10 MG|Taking the Empagliflozin in second
218928754|NCT07075224|DRUG|IMP 08P2002F0|Fixed combination of 0.34 % tropicamide and 2.5 % phenylephrine Hydrochloride (HCl) Eye drop Solution.
219043970|NCT02605668|BEHAVIORAL|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
219540345|NCT02108535|DRUG|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
219540346|NCT02108535|DRUG|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
219540347|NCT06491797|BEHAVIORAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
219043971|NCT02605668|BEHAVIORAL|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
219043972|NCT03172936|DRUG|MIW815|MIW 815 (ADU-S100) is a STING agonist
219540348|NCT01743898|DRUG|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
219540349|NCT01743898|OTHER|no anticoagulation|
219540350|NCT05106114|OTHER|Intensive gait training rehabilitation protocole|6 weeks of intensive gait training : 4 weeks at the center and 2 weeks of home-based telerehabilitation
219540351|NCT04405102|DRUG|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
219540352|NCT04405102|OTHER|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
219540353|NCT03218813|BEHAVIORAL|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
218928755|NCT07075224|DRUG|Mydriasert® insert|0.28 mg tropicamide and 5.4 mg phenylephrine hydrochloride
218928756|NCT07074106|DRUG|Carboplatin and a Taxane|"All patients will receive Carboplatin and a Taxane for 4 cycles.~* Patients who achieve a complete radiological response will proceed directly to surgery.~* Patients without a complete radiological response will receive Doxorubicin and Cyclophosphamide, with or without Pembrolizumab, for an additional 4 cycles before surgery."
218928757|NCT07073937|OTHER|Retrospective chart review|Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.
219620474|NCT01607450|DRUG|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
218928758|NCT07075536|BEHAVIORAL|My Health, My Choice Web-Based Contraceptive Decision Tool|"The My Health My Choice decision tool is a web-based interactive tool designed to educate patients with health conditions about their contraceptive options, elicit their personal preferences and contraceptive concerns, and help them prepare for a contraceptive discussion with their clinician. Patients can compare features of different contraceptive methods side-by-side and grouped by medical risk according to the Center for Disease Control and Prevention U.S. Medical Eligibility Criteria (US MEC). The tool generates an individualized Birth Control Summary for each patient user that records their contraceptive favorites and their questions for the clinician. Clinicians can use the Clinician Version of the tool to review the patient's Birth Control Summary and their medical eligibility for different contraceptive methods per the US MEC guidelines."
219620475|NCT01607450|DRUG|Saline|Normal saline placebo infusion for 12 hours prior to PET study
219620476|NCT00224367|BEHAVIORAL|time to first ambulation|
219620477|NCT05293704|DRUG|Mizoribine|Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight \& gt At 50 kg, the dosage was 100 mg each time.
219620478|NCT05807295|OTHER|Relaxation Program|The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Videos will be sent to caregivers' social media accounts. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications.
219043973|NCT03172936|BIOLOGICAL|PDR001|PDR001 is an anti-PD-1 antibody
219620479|NCT04067050|DEVICE|comfilcon A asphere|Contact Lens
219620480|NCT04067050|DEVICE|Spectacles|Habitual spectacles
219620481|NCT01446341|PROCEDURE|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
219620482|NCT01446341|PROCEDURE|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
219540354|NCT04204395|DEVICE|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
218928759|NCT07075536|BEHAVIORAL|Usual Contraceptive Care|Participants will attend clinic visits per routine. Clinicians proceed with usual contraceptive care. All study activities and incentives for participants in the usual contraceptive care arm are the same as for participants in the intervention arm except for those related to the intervention itself.
219043974|NCT05912699|OTHER|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~* Heat-inactivated L. fermentum K8 Postbiotic.~* Microcrystalline cellulose."
219043975|NCT05912699|OTHER|Placebo|The placebo capsules contain microcrystalline cellulose only.
219043976|NCT05775978|BEHAVIORAL|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
219043977|NCT05775978|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
219043978|NCT05775978|BEHAVIORAL|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
219043979|NCT01617057|DRUG|tiludronic acid|400 mg / day for 3 months
219043980|NCT01617057|DRUG|Placebo|400 mg / day for 3 month
219043981|NCT00403000|DRUG|dutasteride|Oral
219043982|NCT00984581|DRUG|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
219043983|NCT00984581|DRUG|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
219620483|NCT05294679|DRUG|Propofol|All patients completed pre-anaesthesia assessment, signed informed consent, and completed vital signs on the day before surgery, with values as baseline vital signs. On the day of surgery, after routine preparation before colonoscopy (fasting for at least 6h and water restriction for at least 2h before surgery), venous access was established in the left hand. 0.5μg/kg fentanyl was administered intravenously after oxygen inhalation through a nasal catheter (4-6 L/min). About 3 minutes after fentanyl administration, sedation induction was performed with ciprofol or propofol immediately.
219620484|NCT05294679|DRUG|Ciprofol|Ciprofol
219620485|NCT03379337|DIAGNOSTIC_TEST|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
219620486|NCT01588288|PROCEDURE|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
219620487|NCT00659711|DRUG|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
219620488|NCT00659711|DRUG|Placebo|will be placed on a placebo for 12 weeks.
219620489|NCT03160378|BEHAVIORAL|Organizational skills training|10 sessions of parent and child training in a group format.
219043984|NCT00984581|DRUG|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
219043985|NCT03762083|DEVICE|pHyph generation I|A vaginal tablet for the treatment of BV with administration every 48 hours.
219540355|NCT03025087|DRUG|Hydroxychloroquine|Participants will be getting hydroxychloroquine
219620490|NCT03160378|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
219620491|NCT02677753|RADIATION|Fluoroscopy|
219620492|NCT01062425|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
219620493|NCT01062425|DRUG|Cediranib Maleate|Given PO
219620494|NCT01062425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
219620495|NCT01062425|OTHER|Laboratory Biomarker Analysis|Correlative studies
219620496|NCT01062425|OTHER|Placebo Administration|Given PO
219620497|NCT01062425|DRUG|Temozolomide|Given PO
219620498|NCT00498043|DRUG|R-CHOP14 induction regimen|R-CHOP14 induction regimen
219620499|NCT00498043|DRUG|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
219620500|NCT03390608|DRUG|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
219620501|NCT03390608|RADIATION|Radiotherapy|Radiotherapy versus no radiotherapy.
219620502|NCT03390608|DRUG|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
219620503|NCT03390608|DRUG|Chemotherapy|Chemotherapy versus no chemotherapy.
219620504|NCT03390608|PROCEDURE|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
219620505|NCT03390608|OTHER|Age at diagnosis|Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
218928760|NCT07075952|BEHAVIORAL|Food-specific inhibitory control training delivered through the FoodTraining App|"Participants will complete one training session per day for the first week and three sessions per week for the following three weeks (4 weeks in total). Each session lasts about 5 minutes and includes 3 blocks of stimuli presentation. In each block, 32 images (8 low-energy-dense foods, 8 high-energy-dense foods, 16 neutral objects) are presented for 1500ms with a 500ms interstimulus interval. One-hundred ms after the image presentation, a red or green circle appears. Participants will have to tap the image when a green circle appears (go trials) and inhibit a response when a red circle appears (no-go trials). Low-energy-dense foods are always paired with go trials, high-energy-dense foods with no-go trials, and neutral objects with either go or no-go trials. After each block, participants receive feedback on mean accuracy and reaction time. Participants can personalise the training by selecting up to three categories of high-energy-dense foods to include."
218928761|NCT07075952|BEHAVIORAL|Waiting list|Participants allocated to the control condition will not have access to the FoodTraining App during the active phase of the study (8 weeks), but will be offered the opportunity to access the app at the end of the 8-week follow-up period. This ensures that all participants, regardless of group allocation, will have the chance to benefit from the intervention once data collection is complete.
218928762|NCT07075133|OTHER|Antidiabetic diet (control)|Standard antidiabetic diet
219540356|NCT06563297|DRUG|Alfentanil|We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
219540357|NCT01983501|DRUG|Tucatinib (ONT-380)|Given twice per day, orally
219540358|NCT01983501|DRUG|T-DM1|Given intravenously once every 21 days
218928763|NCT07075133|OTHER|eTRE diet|eTRE for a total duration of 12 weeks. During the eTRE, volunteers will have to eat and drink (meals + snacks, medication) exclusively during an 8-hour period which will extend between 6 a.m. (flexible: or 7 a.m. or 8 a.m.) in the morning and 2 p.m. (depending on the chosen start time: or 3 p.m. or 4 p.m.), which corresponds to a fasting period of 16 hours per day
218928764|NCT07075133|OTHER|Physical activity in the morning|Physical exercise will consist of 3 weekly morning sessions that will combine aerobic and resistance exercises
218928765|NCT07075133|OTHER|Physical activity in the afternoon|The physical exercise will consist of 3 weekly afternoon sessions that will combine aerobic and resistance exercises.
218928766|NCT07074561|DRUG|CBZ placebo|Patients received oral administration of one 100 mg placebo tablet three times daily (TID) after meals for four consecutive weeks.
218928767|NCT07074561|DRUG|CBZ|In the EA + CBZ + placebo group, patients received oral carbamazepine (CBZ) at a dosage of 100 mg per tablet three times daily (TID) after meals for 4 consecutive weeks. In the sham EA + CBZ group, patients were administered oral CBZ at 200 mg per dose TID after meals for the same 4-week duration.
219043986|NCT00002524|BIOLOGICAL|Bleomycin Sulfate|
219043987|NCT00002524|BIOLOGICAL|Filgrastim|
219043988|NCT00002524|DRUG|Cisplatin|
219540359|NCT03389113|DEVICE|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
219540360|NCT03389113|OTHER|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
219540361|NCT02940444|DRUG|Heparin|
219540362|NCT01385930|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
219620506|NCT03390608|OTHER|Screen detected tumor|Screening detected tumor (yes, no).
219620507|NCT03390608|OTHER|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
219620508|NCT03390608|OTHER|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
219620509|NCT03390608|OTHER|Estrogen receptor (ER) status|ER-status (positive, negative).
219620510|NCT03390608|OTHER|Tumor grade|Tumor grade (1, 2, 3).
219620511|NCT03390608|OTHER|HER2-status|HER2-status (positive, negative).
219620512|NCT03390608|OTHER|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
219620513|NCT03390608|OTHER|Nodal status|N-status (N0, N1).
219620514|NCT00151879|DRUG|SPM 927|
219620515|NCT02933164|DEVICE|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
219620516|NCT02342678|BEHAVIORAL|Yoga Therapy|
219620517|NCT02342678|BEHAVIORAL|Physical Conditioning|
219620518|NCT02015728|DEVICE|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
219620519|NCT02015728|DRUG|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
219620520|NCT02015728|DRUG|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
219620521|NCT02015728|DRUG|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
219043989|NCT00002524|DRUG|Cyclophosphamide|
218928768|NCT07074561|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
219043990|NCT00002524|DRUG|Cytarabine|
219043991|NCT00002524|DRUG|Doxorubicin Hydrochloride (DOX)|
219043992|NCT00002524|DRUG|Etoposide|
219043993|NCT00002524|DRUG|Fluorouracil|
219043994|NCT00002524|DRUG|Ifosfamide|
219540363|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
219540364|NCT02697682|BIOLOGICAL|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
219540365|NCT03665194|DRUG|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
219540366|NCT03665194|DRUG|Placebo|matching placebo
219540367|NCT03368443|BEHAVIORAL|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
219540368|NCT00864396|DRUG|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
219540369|NCT05731687|OTHER|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
219540370|NCT05731687|OTHER|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
219540371|NCT05794685|PROCEDURE|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
219540372|NCT05794685|PROCEDURE|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
219540373|NCT03423654|OTHER|Spatial Training|Spatial Training using a 5x5 grid
219540374|NCT03423654|OTHER|Letter number matching|Letter number matching
219540375|NCT04210557|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
219540376|NCT03711253|DRUG|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
219540377|NCT03867071|OTHER|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
219540378|NCT03867071|OTHER|placebo injection|Intravenous injection 0,9% saline solution.
219540379|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
219540380|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
219540381|NCT05168787|DRUG|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
219043995|NCT00002524|DRUG|Leucovorin calcium|
219043996|NCT00002524|DRUG|Methotrexate|
219043997|NCT00002524|DRUG|Methylprednisolone|
219043998|NCT00002524|DRUG|Pentamidine|
219043999|NCT00002524|DRUG|Prednisone|
219044000|NCT00002524|DRUG|Trimethoprim-Sulfamethoxazole|
219044001|NCT00002524|DRUG|Vincristine Sulfate|
219044002|NCT00002524|DRUG|Zidovudine (AZT)|
219044003|NCT00002524|RADIATION|Radiation Therapy|
219044004|NCT03584269|DEVICE|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
219044005|NCT03584269|DEVICE|LTOT|Long term oxygenatory tyherapy without NIV
219044006|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
218928769|NCT07074561|PROCEDURE|Sham electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent +GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent +ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
218928770|NCT07074639|OTHER|Personalized, home-based motor-cognitive exergame training|"The simultaneous cognitive-motor training in this study will be delivered using the exergame platform Senso Flex by Dividat (Dividat AG, Schindellegi, Switzerland), which is a pressure-sensitive foldable mat that connects to standard televisions (or any big screen). Games will be allocated across three primary domains: cognition (consisting of five sub-domains), balance (consisting of four sub-domains) and endurance. The five sub-domains of cognition are visuospatial orientation (Cognition A), memory (Cognition B), response inhibition (Cognition C), choice reaction time (Cognition D) and task switching (Cognition E). The four sub-domains of balance are mediolateral weight-shifting (Balance A), multidimensional weight-shifting (Balance B), free walking/stepping (Balance C) and mediolateral stepping (Balance D). The training sessions will be personalized in terms of difficulty level."
219044007|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
219044008|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
219044009|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
219044010|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
219540382|NCT01957059|DRUG|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
219540383|NCT01957059|DRUG|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
219044011|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
219044012|NCT00116558|DEVICE|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
219044013|NCT00116558|DEVICE|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
219540384|NCT01957059|DRUG|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
219540385|NCT01957059|DRUG|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
219540386|NCT01957059|DRUG|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
219540387|NCT03419247|PROCEDURE|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
219540388|NCT03419247|PROCEDURE|Blood draw|Blood will be taken by a needle from a vein.
219540389|NCT03419247|PROCEDURE|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
218928771|NCT07074639|OTHER|Otago Exercise Program|Participants in the CG will receive the evidence-based OEP on fall prevention. The OEP was selected as an active control to mirror usual care in real-world clinical settings and support the pragmatic nature of our study design. The program will be implemented in the form of a booklet, designed to provide a comprehensive guide for improving balance, strength, and overall physical function. Specifically tailored for older adults, the program includes a variety of exercises targeting key areas such as lower limb strength, balance, and flexibility. It features step-by-step instructions, illustrations, and tips to ensure exercises are performed safely and effectively.
219044014|NCT02027844|BEHAVIORAL|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
219044015|NCT02027844|BEHAVIORAL|parental presence|parental presence during inhalational induction of sevoflurane
219044016|NCT05217550|BEHAVIORAL|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
219044017|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
219044018|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
219205257|NCT06736639|PROCEDURE|Kirschner wire tension band + cerclage cable|This intervention uses \*\*Kirschner wire tension band combined with cerclage cable\*\* to treat inferior pole patellar fractures (IPPF). The Kirschner wires are positioned across the fracture site to form a tension band, which transforms tensile forces into compressive forces, promoting fracture stability. The cerclage cable is added to reinforce the fixation by encircling the patella, providing additional stability to comminuted or complex fractures.
219540390|NCT04307680|DEVICE|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
219540391|NCT02589093|DEVICE|Stimulation|
219540392|NCT03155425|DRUG|SHR-1210|A humanized monoclonal immunoglobulin
219540393|NCT03841266|DIAGNOSTIC_TEST|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
219540394|NCT01310647|DRUG|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
219540395|NCT01310647|DRUG|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
219540396|NCT01310647|DRUG|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
219540397|NCT01364493|DRUG|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
219540398|NCT03968172|BEHAVIORAL|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
219620522|NCT02015728|DRUG|Everolimus|Everolimus is an mTOR pathway inhibitor.
219540399|NCT03968172|BEHAVIORAL|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
219540400|NCT04546334|DRUG|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
219540401|NCT04546334|PROCEDURE|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
219540402|NCT04546334|PROCEDURE|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
219540403|NCT04546334|PROCEDURE|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
219540404|NCT00828295|DRUG|palonosetron|palonosetron IV 1 mcg/kg
219540405|NCT00828295|DRUG|palonosetron|palonosetron 3mcg/kg IV
219540406|NCT04949334|DEVICE|Dofin Breathing Strength Builder|"If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O."
219620523|NCT02015728|DRUG|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
219620524|NCT02015728|DRUG|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
219620525|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine|Comparison of each dose of vaccine
218928772|NCT07074405|OTHER|Questionnaire and Physical Exam|This is an online questionnaire that the patients fill in
218928773|NCT07073911|BEHAVIORAL|Exercise|Les Mills Thrive is a 45-minute class that consists of flexibility, strength, and coordination exercises. This program aims to improve sensorimotor control and strength via functional weight-bearing exercises and floor exercises to isolate targeted hip and core muscles. In each class (whether in person or online), a certified Les Mills Thrive instructor will provide options to either increase or decrease the intensity of each exercise to cater to varying fitness levels and fluctuating symptoms. Each exercise has an assisted (using a chair for balance), body weight, and resisted (weight or exercise tubing) option. Participants will have the option to attend group fitness classes or do the classes asynchronously at home using a link to access a recorded class.
218928774|NCT07075172|OTHER|Instrumented-assisted soft tissue mobilization|Instrumented-assisted soft tissue mobilization of the posterior leg and Achilles tendon region
218928775|NCT07074548|DIETARY_SUPPLEMENT|Placebo|Placebo oral capsule identical in appearance to hydroxytyrosol supplement, administered once daily for 4 weeks.
218928776|NCT07074548|DIETARY_SUPPLEMENT|Hydroxytyrosol|Hydroxytyrosol is a natural polyphenol with antioxidant and anti-inflammatory properties, derived from olives. In this study, hydroxytyrosol 10 mg will be administered orally once daily for 4 weeks to assess its effects on blood pressure and inflammatory biomarkers in hypertensive pregnant women.
218928777|NCT07075458|BEHAVIORAL|Magic Rope Trick|Children will be distracted using a magic rope trick during local anesthesia administration.
218928778|NCT07075458|BEHAVIORAL|Magic Thumb Sleeves|Children will be distracted using light-up magic thumb sleeves during local anesthesia administration
218928779|NCT07075458|BEHAVIORAL|Tell-Show-Do (TSD)|Children will receive the conventional Tell-Show-Do behavior management technique during local anesthesia administration
218928780|NCT07074912|OTHER|Prescription for weight-based dosing of antipyretic|The intervention group (n=220) will receive prescription with weight-based dosing for acetaminophen (also prescribed and known as Tylenol) and ibuprofen (also prescribed and known as Motrin).
218928781|NCT07074912|OTHER|Standard discharge instructions|The control group (n=220) will also receive standardized printed discharge instructions but no prescription. The discharge instructions include the appropriate dose of acetaminophen (also known as Tylenol) and ibuprofen (also known as Motrin).
218928782|NCT07074626|OTHER|transrectal ultrasound|"A- Complete history was taking (personal, past, medical, surgical and family history) with careful attention to abdominal examination and suspected cause of pelvic pathology B- Through physical examination (general and abdominal examination). C- Investigations.~* Trans-rectal ultrasound will be conducted to all the virgin patients as the standard US examination to detect the pelvic pathology~* Patient anticipation for pain will be documented before the exam according to pain visual analogue scale (VAS)~* Lidocaine gel will be used on the probe during TRU~* The intensity of pain during trans-rectal US based on the pain visual analogue scale (0-10 ) points and the adverse events like extreme pain, inability to complete the examination and inability to detect the pathology will be reported.A Visual Analogue Scale (VAS) is one of the valided pain rating scales used for the first time in 1921 by Hayes and Patterson."
218928783|NCT07075939|OTHER|No Intervention: Observational Cohort|Observational data collection only
218928784|NCT07075419|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
219044019|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
219044020|NCT05583903|OTHER|Virtual Reality Software|The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
219205258|NCT06737211|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
219540407|NCT02762422|OTHER|Phlebotomy|Removal of 500 cc of blood via forearm vein
219540408|NCT02267408|OTHER|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
219540409|NCT02267408|OTHER|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
219540410|NCT01402050|DRUG|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
219540411|NCT01402050|DEVICE|FOLEY BALLOON|INDUCTION OF LABOR
219540412|NCT06012006|OTHER|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
219540413|NCT03330990|DRUG|Entrectinib|600 mg oral capsule (fasted and fed)
219540414|NCT03330990|DRUG|Midazolam Hydrochloride|2 mg oral syrup (fasted)
219540415|NCT04860349|OTHER|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
219540416|NCT02375477|OTHER|Educational Intervention|Given educational presentation
219620526|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
219620527|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
219540417|NCT05777005|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
219540418|NCT05777005|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
218928785|NCT07075419|DRUG|Penpulimab|Penpulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
219540419|NCT05777005|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
219540420|NCT05777005|BEHAVIORAL|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
219540421|NCT05777005|BEHAVIORAL|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
219620528|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
219620529|NCT02695446|DRUG|Minocycline|Oral extended release minocycline
219620530|NCT01570790|DRUG|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
219620531|NCT01570790|DRUG|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
219620532|NCT01570790|DRUG|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
219620533|NCT05273528|BIOLOGICAL|Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219620534|NCT00179907|PROCEDURE|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors \< 20 mm, 21-25 mm and 26-40 mm respectively
219620535|NCT06349525|DEVICE|telescopic overdenture|Maxillary implant supported telescopic overdenture
219620536|NCT06349525|DEVICE|Locator overdenture|Maxillary implant supported locator overdenture
219620537|NCT03775525|DRUG|GZ17-6.02|Super enhancer Inhibition
218928786|NCT07075003|DEVICE|nociceptive level|remifentanil infusion dose adjustment according to the changes of nociceptive level
218928787|NCT07074808|DEVICE|aiTriage risk score|Risk score generated by AI App aiTriage for chest pain patients
218928788|NCT07076017|BEHAVIORAL|Dry-land strength and conditioning programme|Participants in the experiment group will be asked to complete two supervised gym sessions per week for 10 weeks. Each session will include a variety of plyometric and strength exercises, selected for their relevance to start and turn performance in swimming.
218928789|NCT07076017|BEHAVIORAL|Active control condition|The control group will complete their usual swimming training which comprises of several pool-based session and one land-based session each week.
218928790|NCT07074873|OTHER|Descriptive information form|The age, gender, height, weight, body mass index, age at menarche, time of initial diagnosis, how it was detected (medical history), family history (genealogy), dominant hand use, exercise habits (type of sport and duration), and corset use of individuals participating in the study will be recorded.
219044021|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
219044022|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
219044023|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
219205259|NCT06888622|DRUG|Eculizumab administration|Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks
219540422|NCT02977221|PROCEDURE|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
219540423|NCT01930903|DEVICE|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
219620538|NCT03775525|DRUG|Capecitabine|antimetabolite
219620539|NCT06127342|BEHAVIORAL|Moderate Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 5 minutes, then slowly cycle on a stationary bike for 30 minutes, then cycle on the stationary bike at a slow speed for 5 minutes.
219620540|NCT06127342|BEHAVIORAL|Low Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 40 minutes.
219620541|NCT00941135|OTHER|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
219620542|NCT02154568|DRUG|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
219620543|NCT04287660|DRUG|clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells|"* clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function."
219620544|NCT01454323|OTHER|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
219540424|NCT06625021|PROCEDURE|Chiropractic manipulation|"Chiropractic manipulation: Lower cervical chiropractic manipulation is a technique used to increase mobility and relieve pain in the lower vertebrae of the neck. However, such procedures should only be performed by trained chiropractors; if done incorrectly, they can lead to serious problems. The patient should be placed in a comfortable position. The supine or side-lying position is usually preferred. Contact is established with the transverse processes of the lower cervical vertebrae. High-velocity, Low-amplitude thrust is applied within anatomical limits.~As a graduate of Bahcesehir University Chiropractic Masters Degree, I applied chiropractic twice a week for 3 weeks."
219540425|NCT06625021|PROCEDURE|Exercises to be done for neck pain of mechanical origin|Conservative treatment, which is frequently used in the treatment of mechanical neck pain, was planned. A warm-up period was defined with stretching exercises in all areas of neck movement. Again, isometric exercise should be 10 seconds in all directions. In addition to neck and shoulder mobility exercises, neck region posture exercises were included. It was planned to do these exercises for 4 weeks, 5 days a week, in all 4 groups.
219620545|NCT02162056|DEVICE|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
219620546|NCT01155856|OTHER|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
219620547|NCT02816632|OTHER|mRI|Neural bases of feedbacks' influence on decision making processes
218928791|NCT07074873|OTHER|Health-Related Quality of Life Assessment|The Paediatric Quality of Life Inventory is a valid and reliable health-related quality of life questionnaire used for children. This inventory, which has been adapted into Turkish, consists of two forms for children and families. Both forms include sections on physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (5 items). Scoring is done on a scale of 0-5 for each question (0 = Never causes a problem, 1 = Rarely causes a problem, 2 = Sometimes causes a problem, 3 = Often causes a problem, and 4 = Always causes a problem). The total score of the inventory ranges from 0 to 100 points (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). A high score indicates better health-related quality of life. Since our study population is aged 10-18, the inventories developed for the 8-12 and 13-18 age groups will be used.
218928792|NCT07074873|DIAGNOSTIC_TEST|Trunk rotation angle|The Adam's Forward Bend Test is used as the primary assessment test in the clinical examination of scoliosis patients. In our study, the scoliometer assessment will be performed on the study group while the subjects are standing with equal weight on both feet. Patients will be asked to bend forward so that their shoulder level is aligned with their hip level (body parallel to the ground), and measurements will be taken with the scoliometer, with the highest degree recorded. The Baseline Scoliometer will be used for evaluations.
218928793|NCT07074873|DIAGNOSTIC_TEST|Cobb angle measurement|The Cobb angle allows for the evaluation of deformity in the frontal plane in scoliosis. It is obtained by measuring the lateral flexion angle of scoliosis from a standing spinal X-ray taken in the posterior-anterior direction. The angle between the perpendicular lines connecting the parallel line drawn from the upper edge of the uppermost vertebra (upper vertebra) involved in the curvature and the parallel line drawn from the lower edge of the lowest vertebra (lower vertebra) gives the Cobb angle. In our study, the Cobb angle will be recorded from the spinal X-ray.
218928794|NCT07074873|DIAGNOSTIC_TEST|Pelvic floor muscle activation measurement|The physiotherapist will position the child in a supine position with the knees flexed at 140 degrees, the soles of the feet in contact with the bed, and the thighs and feet approximately 30 centimetres apart. Two surface electrodes will be placed at the 3 and 7 o'clock positions on the perineal region, and a 30×30 mm single-use electrode will be placed on the right thigh as a reference electrode. Children will be taught to contract the correct pelvic floor muscles to move in the ventral and cranial directions. The 'Work-Rest Assessment,' lasting a total of 55 seconds, will be applied to each child using the same device. First, children will be asked to relax their pelvic floor muscles. Then, 5 seconds of contraction (work) and 5 seconds of relaxation (rest) will be performed, and a total of 10 cycles of contraction and relaxation of the pelvic floor muscles will be requested. The device provides a report of the data in graphical and numerical form at the end of the measurement.
218928795|NCT07075692|OTHER|Physiotherapy|Physiotherapy program will include patient education, lifestyle recommendations (fluid intake, diet, correct urination/defecation position, weight control, etc.), breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks
218928796|NCT07075601|BIOLOGICAL|Take 1 ml of blood|Take 1 ml of blood
218928797|NCT07075601|BIOLOGICAL|DNA sequencing|DNA sequencing
219044024|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
219540426|NCT06625021|PROCEDURE|Classic Hand-Wrist Exercises|The participants of this group will be subjected to wrist range of motion (ROM), stretching and strengthening exercises. Measurements will be made in all axes of motion of the wrist, which are extension, flexion, ulnar and radial deviation. ROM exercises and stretching exercises were applied passively to all axes of motion within anatomical limits. At the last angles of the movement, the individual was forced and stretched without causing discomfort and waited at the last angles for a short time. Stretching exercises were performed five times for each movement. Strengthening exercises for all axes of movement of the wrist will be performed using dumbbells weighing 1 and 2 kilograms and an exercise band suitable for the persons endurance and strength. In exercises performed with dumbbells, all movements of the wrist will be performed against gravity. All applications were applied to the classical hand-wrist exercise group for at least half an hour every day for 4 weeks.
219540427|NCT06625021|PROCEDURE|Proprioceptive exercise group|Similar to the classical wrist exercise group, the participants in this group were applied joint range of motion, stretching and strengthening exercises as well as proprioceptive exercises such as joint approximation, traction and mobilization. In addition to all axes of motion of the wrist, active and passive stretching exercises were applied to the forearm flexor and extensor muscles five times each. The resistance and repetition number were gradually increased according to the wrist strength and endurance of the individuals to at least 10 repetitions. Repetitive contraction and rhythmic stabilization techniques were used from proprioceptive neuromuscular facilitation methods. Joint approximation technique and taping of forearm flexor and extensor muscles were used to increase the level of contraction and stimulation of joint receptors. External stabilization and perturbation exercises were performed with an exercise ball against the wall at different angles of the upper extremity.
219540428|NCT03220958|DRUG|Metoclopramide|Metoclopramide 20mg
219540429|NCT03220958|DRUG|Diphenhydramine|Diphenhydramine 25mg
219540430|NCT03220958|DRUG|Normal saline|100ml normal saline
219540431|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
219540432|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
219540433|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
219540434|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
219540435|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
219540436|NCT02393014|PROCEDURE|Simple physical exercises|"1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
219540437|NCT00816413|DRUG|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
219540438|NCT00816413|DRUG|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
219540439|NCT00816413|DRUG|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
219540440|NCT00816413|GENETIC|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
219540441|NCT00816413|GENETIC|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
219540442|NCT00816413|GENETIC|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
219540443|NCT00816413|OTHER|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
219540444|NCT00816413|OTHER|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
219540445|NCT00816413|OTHER|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
219620548|NCT02816632|OTHER|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
219620549|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
219205260|NCT06889064|DRUG|BR1400-1|One tablet administered alone
219205261|NCT06889064|DRUG|BR1400-2|One tablet administered alone
219540446|NCT00816413|OTHER|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
219620550|NCT06858319|DRUG|zigakibart|solution for subcutaneous injection
219205262|NCT06889064|DRUG|BR1400-3|One tablet administered alone
219205263|NCT06888362|DRUG|GZ21T|GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.
219205264|NCT06894901|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
219620551|NCT05708248|DRUG|pentoxifylline|400 mg pentoxifylline tablets twice daily with meals for 6 months
219620552|NCT02962648|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion."
219620553|NCT02702830|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
219620554|NCT02702830|DEVICE|Magnetic Resonance Imaging|Undergo MRI
219620555|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
219620556|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
219620557|NCT06596434|DRUG|Drug: 4-Aminopyridine|Active study drug
219620558|NCT06596434|OTHER|Placebo|Placebo comparator
219620559|NCT06989853|DRUG|Placebo|The effects of placebo will be determined.
219620560|NCT06989853|DRUG|Methamphetamine|Placebo and methamphetamine will be administered intravenously during experimental sessions.
219620561|NCT06989645|DRUG|SYN321|Intra-articular
219620562|NCT06989645|DRUG|Placebo|Intra-articular
219620563|NCT02755285|DEVICE|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
219620564|NCT01597778|BIOLOGICAL|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
219620565|NCT01597778|BIOLOGICAL|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
219620566|NCT00422604|DRUG|salmeterol|
219620567|NCT00422604|DRUG|tiotropium|
219620568|NCT00422604|DRUG|GSK233705|
219620569|NCT06581978|PROCEDURE|Whole-Body Vibration Intervention|Whole-Body Vibration Intervention
219620570|NCT06581978|PROCEDURE|Exercise Intervention Group|Traditional Chinese medical exercises training
219620571|NCT00004883|BIOLOGICAL|trastuzumab|Given IV
219620572|NCT00004883|OTHER|laboratory biomarker analysis|Correlative studies
219620573|NCT01417793|BEHAVIORAL|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
219620574|NCT04831021|PROCEDURE|Dialysis without physical exercise|Hemodialysis control condition
219620575|NCT04831021|PROCEDURE|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
219620576|NCT04831021|PROCEDURE|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
219620577|NCT04383327|BEHAVIORAL|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training during the school term. They will also receive 8 sessions (8 hours) of face-to-face group-based coaching during after the training. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
219620578|NCT04383327|BEHAVIORAL|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including one-day workshop for common stress management and stress management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group that were integrated into the 3 of the 8 PD coaching sessions. A total 3 hours of coaching were included.
218928798|NCT07075601|PROCEDURE|Valve collection (healthcare waste)|Valve collection (healthcare waste)
219540447|NCT00816413|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
218928799|NCT07075601|OTHER|Collection of serious post-operative complications|Collection of serious post-operative complications
219044025|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
219044026|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
219205265|NCT06894472|OTHER|Electromyography biofeedback|Participants in the experimental group will receive surface electromyography (SEMG) feedback training, targeting the Masseter muscle, for 40 minutes per session according to the Evidence-Based practice since longer practice may become counterproductive due to fatigue and loss of focus. The frequency of the sessions will be 3 sessions/week for 4 weeks.
219540448|NCT00816413|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
219540449|NCT00816413|RADIATION|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
219540450|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
219540451|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
219540452|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
219540453|NCT03595436|DIETARY_SUPPLEMENT|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
219540454|NCT03595436|DIETARY_SUPPLEMENT|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
219540455|NCT00364559|DRUG|Rosuvastatin|20 mg 10 days daily
219540456|NCT05710588|OTHER|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
219540457|NCT05710588|OTHER|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
219540458|NCT01376037|DEVICE|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
219540459|NCT01376037|DEVICE|inactive placebo laser device|non-therapeutic light application
219540460|NCT04200833|DRUG|Golimumab|subcutaneous injection
218928800|NCT07075289|DRUG|DLBS1033|Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
218928801|NCT07075289|DRUG|Betahistine Mesylate tablet|Patients would get betahistine mesylate (12 mg, MERTIGO SR tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
218928802|NCT07075120|DRUG|Ipilimumab and Nivolumab|Immunotherapy combination (Ipilimumab and Nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response.
218928803|NCT07075120|RADIATION|Stereotactic Body Radiotherapy (SBRT)|High-dose radiation therapy delivered in 3-5 fractions for local control of tumors in combination with immunotherapy. Radiation dosages are based on the RTOG 1112 trial guidelines to minimize normal tissue exposure.
219044027|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
219540461|NCT06054984|DRUG|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
219540462|NCT00004985|DRUG|Capravirine|
219540463|NCT00004985|DRUG|Nelfinavir mesylate|
219540464|NCT02328040|DRUG|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
218928804|NCT07074028|DIAGNOSTIC_TEST|Medical Research Council sum score (MRC-SS) test|Medical Research Council (MRC)-sumscore evaluates global muscle strength. Manual strength of six muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) is evaluated on both sides using MRC scale
219044028|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
219044029|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
218928805|NCT07074028|DIAGNOSTIC_TEST|Handgrip test combined with surface electromyography (sEMG)|Handgrip test combined with surface electromyography (sEMG) of the flexor digitorum superficialis
219044030|NCT05888168|PROCEDURE|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
219205266|NCT06894472|DRUG|Pharmacotherapy|Pharmacotherapy will be received by all participants in the two groups in the form of multi relaxant (cyclobenzaprine) 10 MG twice daily for 4 weeks \& anti inflammatory (non steroidal anti-inflammatory drugs).
219205267|NCT03032627|PROCEDURE|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
218928806|NCT07074028|DIAGNOSTIC_TEST|Electrical activity during maximal voluntary contraction of the rectus femoris|Surface EMG amplitude (RMS) during maximal voluntary contraction measured by surface electromyography (sEMG) of the rectus femoris
219205268|NCT05166616|PROCEDURE|Biopsy|Correlative studies
218928807|NCT07074028|DEVICE|Musculoskeletal Ultrasound|Measurement of the cross-sectional area (CSA) of the rectus femoris by ultrasound
219044031|NCT00240370|DRUG|Muraglitazar|
219044032|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
219044033|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
219044034|NCT00001839|DRUG|Antithymocyte globulin|
219044035|NCT00001839|DRUG|Cyclosporine|
219044036|NCT03912727|DIETARY_SUPPLEMENT|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
219044037|NCT03912727|OTHER|renal replacement therapy|standard renal replacement therapy
219044038|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
219044039|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
219044040|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
219044041|NCT06216392|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
219044042|NCT06216392|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
219044043|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
219205269|NCT05166616|DRUG|Osimertinib|Given PO
218928808|NCT07074028|DEVICE|Diaphragmatic ultrasound|Diaphragmatic ultrasound is a non-invasive technique that allows for sequential assessment of diaphragm mobility (excursion) and contraction (thickening) in mechanically ventilated patients
219540465|NCT02328040|DRUG|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
218928809|NCT07074028|BIOLOGICAL|blood sampling|Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to: 1) describe the inflammatory profile (plasma measurements of CRP, IL-1, IL-6, TNFα, IL-10, fibrinogen, ferritin, cortisol), 2) assess organ dysfunction and calculate the SOFA score (arterial blood gases, lactate levels, liver function tests, complete blood count, and blood electrolyte panel)
218928810|NCT07074028|DEVICE|Electroneuromyogram|Analysis of peripheral neurogenic and myogenic components involved in intensive care unit-acquired muscle dysfunction through the performance of an electroneuromyogram
219044044|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
219044045|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
219044046|NCT06442501|OTHER|routine care|routine care
219044047|NCT02271308|BEHAVIORAL|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
219044048|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
219044049|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
219205270|NCT05166616|DRUG|Triptolide Analog|Given PO
219205271|NCT06886178|DEVICE|STIL Orthosis|STIL Orthosis, a brace for the arm equipped with passive dampening designed to suppress high-frequency movements.
218928811|NCT07074028|DIAGNOSTIC_TEST|6-minute walk test|The 6-minute walk test (6MWT) is a simple test that requires a quiet, indoor, flat 30-meter course, ideally in a straight rectangular hallway
218928812|NCT07074028|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test and assesses cognitive functions most broadly (attention, concentration, executive functions, memory, language, visual-constructive abilities, abstraction, calculation, orientation).
219540466|NCT01278641|BEHAVIORAL|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
218928813|NCT07074028|BEHAVIORAL|MNA-SF|The MNA-SF (Short Form) is a simplified version that allows us to determine whether the elderly person is well nourished, at risk of malnutrition or malnourished.
218928814|NCT07076043|DRUG|Multiple Product PrEP Program|In the intervention phase, clinics will offer a multi-product PrEP program, which includes daily oral PrEP and other forms of PrEP that are available. To start, the dapivirine vaginal ring will be included among the other forms of PrEP that are available. Others will be added as they become available in Kenya.
218928815|NCT07074600|DEVICE|Electroacupuncture Therapy|Participants in the experimental group will receive daily electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Acupoint selection will target anatomical domains spanning the cranial, upper limb, and lower limb regions.
218928816|NCT07074600|DEVICE|Sham electroacupuncture intervention|Participants in the control group will receive daily sham electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Sham electroacupuncture procedures will target non-acupoint locations outside recognized cranial, upper limb, and lower limb anatomical domains.
218928817|NCT07075809|DEVICE|The laser acupuncture|The intervention group in this study receives laser acupuncture therapy using a laser Micropad GL2+ device with an infrared wavelength of 880 nm. The laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
219044050|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
219540467|NCT01278641|BEHAVIORAL|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
219044051|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
219205272|NCT06886178|DEVICE|Sham|A version of the STIL Orthosis that is visually indistinguishable from original, but which does not have the passive dampening mechanism.
219540468|NCT03199196|DEVICE|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
219540469|NCT03199196|DEVICE|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
219540470|NCT03199196|BEHAVIORAL|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
219540471|NCT03199196|BEHAVIORAL|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
219044052|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
219540472|NCT03199196|BEHAVIORAL|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
219540473|NCT03199196|BEHAVIORAL|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
219540474|NCT06556602|OTHER|MPACT|Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
219540475|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
219540476|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
219540477|NCT03567551|OTHER|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
219540478|NCT03567551|OTHER|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
219540479|NCT03567551|OTHER|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
219540480|NCT02878018|DRUG|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
219540481|NCT02878018|DRUG|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
219540482|NCT04643691|DRUG|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
219540483|NCT00022555|DRUG|bryostatin 1|Given IV
219540484|NCT00022555|DRUG|vincristine sulfate|Given IV
219540485|NCT03135847|DEVICE|Tactor|The tactor is a small robot providing touch and vibration.
219540486|NCT03996837|OTHER|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
219540487|NCT03495011|DIAGNOSTIC_TEST|Breast MRI|Quantitative, multiparametric breast MRI
219540488|NCT03495011|OTHER|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
219540489|NCT01858168|DRUG|Olaparib|Tablets to be taken on an empty stomach twice a day.
219540490|NCT01858168|DRUG|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
219540491|NCT01858168|DRUG|Irinotecan|Administered via IV
219044053|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
219044054|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
219044055|NCT03081416|DRUG|Normal saline|
219044056|NCT03081416|DRUG|Metoclopramide|Standard therapy
219044057|NCT03081416|DRUG|Ketorolac|standard therapy
219044058|NCT03081416|DRUG|Dexamethasone|Standard therapy
219044059|NCT03081416|DRUG|Benadryl|Standard therapy
218928818|NCT07075809|DEVICE|Sham Laser acupuncture|The Control group in this study receives sham laser acupuncture therapy using a laser Micropad GL2+ device with deactivation mode. The sham laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
218928819|NCT07074743|OTHER|community-based PI care bundle|"The PI care bundle follows the aSSKINg model and is delivered in addition to routine care. Key components include:~Assessment Pre-discharge evaluation Ongoing skin, nutrition, and hydration monitoring Caregiver training for home assessment Equipment and Resources~Customized provision of necessary devices based on needs:~Sliding sheets Repositioning cushions Skin barriers Moisturizers Pressure-relieving overlays Alternating air mattresses Implementation Caregivers demonstrate device usage competency Documentation checklist for monitoring Regular follow-up by community nurses Professional Support Community nurses trained by PI specialists Standardized care protocols Regular effectiveness assessment~All participants receive routine care including:~Pre-discharge nutrition assessment Dietician referral if needed Educational materials Basic wound care referrals Hospital-to-home team support for complex cases The intervention provides structured, comprehensive support beyond standard care."
218928820|NCT07074743|OTHER|Wait-list|"During hospitalisation:~Patient's nutritional status assessed. Referred to a dietician before discharge if needed. Nurse assesses caregiver training needs and arranges training if required.~At discharge:~Patients receive PI educational pamphlets (hardcopy or softcopy). Emphasis on regular repositioning, skin inspection, proper nutrition, and hydration.~Patients with PI wounds:~Referred to home nursing or polyclinics for wound care. Only those with complex PI (stage \>3) receive up to two follow-ups by the H2H care team.~H2H team supports general care transition, not PI-specific follow-up alone. Any signs of PI deterioration will be monitored weekly throughout the waiting period for safety and ethical considerations.~If the index PI advances to a higher stage and reports increased pain after a week, the investigator will refer them to a community wound care nurse and record this as a deterioration and will start PI care bundle"
218928821|NCT07074262|DRUG|Ketamine|to compare the effect of Ketamine versus Dexmedetomidine on postoperative cognitive dysfunction and delirium in all cardiac patient undergoing low risk non-cardic surgery.
218928822|NCT07075666|DIAGNOSTIC_TEST|PSA|Prostate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis.
218928823|NCT07075666|DIAGNOSTIC_TEST|DRE|A digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities.
218928824|NCT07075783|DRUG|MgSO4 plus Ropivacaine|1ml 50% MgSO4 added to 0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline for scalp block
218928825|NCT07075783|OTHER|Plain Ropivacaine|0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline and 1 ml of 0.9% NaCl
218928826|NCT07074951|DRUG|Immunosuppressive treatment|"Patients will be able to receive the corticosteroid (CS) monotherapy or CS in combination with other immunosuppressive drugs (e.g. cyclophosphamide, mycophenolic acid) by a decision of treating physician.~CS treatment will start with intravenous or oral induction. In the first case, methylprednisolone will be administered intravenously for 1-3 days at the dosage of 500-1000 mg. Oral prednisolone will be initiated at a dose of 0.5 to 1.0 mg/kg body weight, not exceeded 60 mg/day (week 1) with a rapid decrease by 5 mg each subsequent week until a maintenance dose of 5 mg/day will be reached. Patients will receive maintenance dose for 6 to 12 months."
218928827|NCT07074951|PROCEDURE|Tonsillectomy|Tonsillectomy will be done in accordance with local clinical practice. TE has to be performed no earlier than 12 months before and no later than 12 months after the initiation of IST.
218928828|NCT07074795|PROCEDURE|Inhalation of Nitrous Oxide (N₂O) during Office Operative Hysteroscopy|Inhaled nitrous oxide
218928829|NCT07074795|PROCEDURE|inhalation of ambient air during office hysteroscopy|inhalation of ambient air
218928830|NCT07075965|DRUG|Amlodipine|Evaluating 2 different doses of amlodipine, after an initial titration phase (2.5 mg daily), amlodipine is increased to the target doses of 5 mg and 10 mg
218928831|NCT07075731|OTHER|No intervention|Observational study
219540492|NCT05679921|DRUG|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
219540493|NCT05642312|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
219540494|NCT05642312|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
219620579|NCT07011446|DEVICE|Safer Seat Usability Trial|"Participants will be asked to transfer onto/off of the vehicle seat using their normal method of transfer and then to trial transferring onto/off of a vehicle seat with the Safer Seat 1 one or more times with study personnel. Demographic data will be recorded for all participants to include age, sex, and type of mobility disability. Transfers will be observed by the research personnel and success in transfers will be recorded according to the Physical Mobility Scale.~Usefulness and usability of the Safer Seat transfer experience will be reported by participants via Technology Acceptance Model Surveys; and participants will engage in a brief semi structured interview that will be audio recorded and transcribed via Microsoft Teams."
219540495|NCT03047746|DEVICE|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
219540496|NCT04726345|DRUG|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
219540497|NCT04726345|DRUG|Placebo|Placebo tablet to be taken orally once a day until stent removal.
219540498|NCT04588922|DRUG|SLS009|Solution for injection
219540499|NCT04588922|DRUG|venetoclax|Tablets
219540500|NCT04588922|DRUG|azacitidine|Solution for injection
219620580|NCT06103292|DIAGNOSTIC_TEST|ionized calcium levels|measuring calcium level in trauma patients
218928832|NCT06902766|DEVICE|Active telemonitoring using real-time data from digital inhalers.|"Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI, one for the controller the other for the reliever treatment.~Active telemonitoring using real-time data from digital inhalers.~Investigators will be alerted by email if a child:~1. fails to take his or her controller treatment for 4 continuous days and/or~2. uses \> 4 doses of reliever treatment over 24 hours~3. uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment)~In these cases, investigators will be asked to schedule a teleconsultation within 2 working days with the family and to adapt treatments as needed. They may ask the family to use the portable spirometer and oximeter if necessary.~No systematic consultation will be planned."
218928833|NCT06902766|OTHER|Standard|Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers
218928834|NCT06497543|DRUG|Intrathecal Pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
218928835|NCT02434406|BEHAVIORAL|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
218928836|NCT07074067|PROCEDURE|Laparoscopic surgery|the laparoscopic (LPC) arm, 21 patients will be assigned to conventional LPC and another 21 to robotic surgery, consecutively.
218928837|NCT07074067|PROCEDURE|surgery via v-NOTES|surgery via v-NOTES
218928838|NCT06907446|DIAGNOSTIC_TEST|Comparison of Biopsy Needle Types for Prostate Biopsy|Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle
218928839|NCT01811992|BIOLOGICAL|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
218928840|NCT03422900|DIETARY_SUPPLEMENT|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
218928841|NCT03422900|DIETARY_SUPPLEMENT|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
218928842|NCT06016114|DIAGNOSTIC_TEST|HIV Latency Diagnostic Sampling|This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.
218928843|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
218928844|NCT06910670|OTHER|Standard developed materials|Participants will be given the option to receive different types of results from genomic sequencing. The choices available to them will be explained by research staff following a script that describes what each type of result means. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information
218928845|NCT06910670|OTHER|Genetics Advisor Decision Aid|Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.
218928846|NCT07074665|BIOLOGICAL|5µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. The standard paediatric dose is 5µg R21/50µg Matrix-M.
218928847|NCT07074665|BIOLOGICAL|10µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. 10µg R21/50µg Matrix-M is the standard adult dose.
218928848|NCT07075029|DIAGNOSTIC_TEST|NP swabs|Nasopharyngeal (NP) swabs will be collected from all participants for respiratory pathogen detection using point-of-care testing (POCT) and/or centralized laboratory analysis.
218928849|NCT07074431|PROCEDURE|EYE 1 SURGERY BY CATAPULSE TECHNIC|In arm 2: 1st eye operated by high-frequency pulsed vacuum technology / 2nd eye operated by phacoemulsification
218928850|NCT07074431|PROCEDURE|EYE 2 SURGERY BY CATAPULSE TECHNIC|In arm 1: 1st eye operated by phacoemulsification / 2nd eye operated by high-frequency pulsed vacuum technology
219044060|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
219044061|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
219540501|NCT04516434|DEVICE|Neurometer Neurotron CPT|All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
218928851|NCT05169060|DRUG|Fish Oil Concentrate, 1000 Mg Oral Capsule|Oral capsules, 2 grams or 4 grams per day.
218928852|NCT05169060|DRUG|Salsalate Oral Tablet|Oral tablets, 1.5 gram or 3.0 gram per day.
219540502|NCT04516434|PROCEDURE|Cystometry|After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
219044062|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
219044063|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
219620581|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
219620582|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
219620583|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
219044064|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
219044065|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
218928854|NCT06923618|BIOLOGICAL|Blood samples|Blood samples (5 ml) during surgery
218928855|NCT05585905|DEVICE|Virtual Reality|The VR system will be worn for approximately 5-10 minutes during dental sealant application
218928856|NCT05585905|BEHAVIORAL|Basic Behavior Guidance Techniques|Basic behavior guidance techniques will be used as a distraction technique when the VR system is not used during the dental sealant application
218928857|NCT05228587|DRUG|Indocyanine green|Indocyanine green will be injected in all donor
218928858|NCT05387239|DRUG|VL-PX10 and VL-P22 plus standard care|The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
218928859|NCT05387239|DRUG|Placebo|Saline plus standard care
218928860|NCT06938061|DEVICE|3D Imaging|The Derma Monitor device is a handheld, battery powered camera incorporating polarized LED illumination, a high-resolution CMOS color image sensor and a 3D depth sensor, allowing for the imaging and mapping of a patient's skin.
219540503|NCT04516434|PROCEDURE|Pressure-flow study|A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
219540504|NCT00199758|DRUG|cisplatin|
219540505|NCT00199758|DRUG|Gemcitabine|
219540506|NCT00199758|DRUG|Taxol|
218928861|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
218928862|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
218928863|NCT06002724|OTHER||
218928864|NCT01408173|DRUG|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
218928865|NCT05153694|PROCEDURE|Cystectomy|Removal of the urinary bladder
218928866|NCT01442103|DEVICE|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
218928867|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
219540507|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~\+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
219540508|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~\+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
219540509|NCT03121586|DRUG|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
218928868|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
218928869|NCT06109636|OTHER|Pentacam, Corvis ST and Casia2|scleral and ciliary muscle thickness were obtained by Casia2, biomechanical parameters were obtained by Pentacam and Corvis ST
219540510|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 30/30|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
219540511|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 10/10|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
219620584|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
218928870|NCT03713658|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
218928871|NCT03713658|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
218928872|NCT03713658|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
218928873|NCT03713658|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
218928874|NCT03713658|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
218928875|NCT03713658|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
218928876|NCT03713658|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
218928877|NCT03713658|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
218928878|NCT03713658|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
218928879|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.
218928880|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
218928881|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
218928882|NCT02264236|BIOLOGICAL|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
218928883|NCT01241136|PROCEDURE|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
218928884|NCT01241136|PROCEDURE|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
218928885|NCT02202759|DRUG|MLN0264|MLN0264 IV infusion
218928886|NCT01987453|DRUG|LDV/SOF|Tablet(s) administered orally once daily
218928887|NCT01987453|DRUG|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
218928888|NCT04259099|OTHER|Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)|Administer the questionnaires to 150 participants to classify their status of quality of life.
218928889|NCT00213434|DEVICE|Herbst oral appliance|
218928890|NCT05141890|DIETARY_SUPPLEMENT|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
218928891|NCT04748354|BEHAVIORAL|Otago Exercise Program|An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
218928892|NCT04748354|OTHER|Usual Care|Clinical care provided by a geriatrician.
218928893|NCT00013416|PROCEDURE|Hearing|
218928894|NCT02064582|DRUG|Enzalutamide|160mg by mouth each day
218928895|NCT02064582|DRUG|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
219044066|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
218928896|NCT02064582|RADIATION|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
218928897|NCT00456859|DRUG|Kremezin|
218928898|NCT05868434|PROCEDURE|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
218928899|NCT01937832|DRUG|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
219044067|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
218928900|NCT01937832|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
218928901|NCT05012384|OTHER|Vergence exercises (Orthoptic exercises)|Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)
218928902|NCT05012384|GENETIC|Placebo|Generic management plan with non-visual elements
218928903|NCT01378585|DRUG|DLBS1033|3 x 490 mg DLBS1033 daily
218928904|NCT01378585|DRUG|Placebo|3 x 1 tablet daily
218928905|NCT04953728|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
218928906|NCT00056069|OTHER|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
218928907|NCT02923297|OTHER|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
218928908|NCT04070872|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
218928909|NCT04070872|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
218928910|NCT01512511|PROCEDURE|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
218928911|NCT02554461|OTHER|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
218928912|NCT01685515|DRUG|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
218928913|NCT01685515|DRUG|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
219044068|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
219044069|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
219540512|NCT06326437|OTHER|6-week dyadic intervention|Comprising 6 weekly 60-90min internet-based sessions.
219540513|NCT04120935|OTHER|Observation|Prospective Observation of standard clinical practice.
219540514|NCT05840900|BEHAVIORAL|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
219540515|NCT03456063|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
218928914|NCT05932667|DRUG|Milademetan|The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
218928915|NCT05932667|BEHAVIORAL|Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)|Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
218928916|NCT05536596|PROCEDURE|Orthognathic Surgery|Prognathism/Retrognathism correction through surgical procedures
218928917|NCT05536596|DRUG|Melatonin 10 MG Oral Tablet|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
218928918|NCT05536596|DRUG|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
218928919|NCT05536596|DRUG|Centrum|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneuron). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
218928920|NCT03780296|DEVICE|Real-time action observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
218928921|NCT02105662|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
218928922|NCT00554632|DRUG|Ethinyl estradiol and norgestimate|Oral contraceptive
219540516|NCT03456063|DRUG|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
219540517|NCT03456063|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
219540518|NCT03456063|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
219540519|NCT03456063|DRUG|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
219540520|NCT03456063|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
219540521|NCT03456063|DRUG|Gemcitabine|Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
219540522|NCT01098786|BIOLOGICAL|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
219620585|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
218928923|NCT00554632|DRUG|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
218928924|NCT02118441|DEVICE|Ultrasound-guided Radial Artery Catheter Insertion|
218928925|NCT02118441|DEVICE|Direct Palpation-guided Radial Artery Catheter insertion|
218928926|NCT04695717|BIOLOGICAL|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
219540523|NCT05655494|BEHAVIORAL|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
219540524|NCT05655494|BEHAVIORAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
219540525|NCT05596435|OTHER|No intervention|No intervention
218928927|NCT05813041|DEVICE|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
218928928|NCT02997241|BIOLOGICAL|OncoCare|Personalized monitoring
218928929|NCT02997241|DRUG|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
218928930|NCT01771224|DIETARY_SUPPLEMENT|Palmitoleic acid|Palmitoleic acid and 5-ASA
218928931|NCT01915836|OTHER|web-based video game (Quit IT)|
218928932|NCT01915836|BEHAVIORAL|Questionnaires|
218928933|NCT01915836|BEHAVIORAL|Evaluation Interview|
218928934|NCT06252324|OTHER|Prime taper implant + cover screw|tissue level implant placement with the addition of a cover screw
219540526|NCT03100422|DEVICE|ARMin|arm therapy robot
218928935|NCT06252324|OTHER|Prime taper implant + healing screw|bone level implant placement with the addition of a healing screw
218928936|NCT02334540|DIETARY_SUPPLEMENT|purses|food intake
218928937|NCT02334540|DIETARY_SUPPLEMENT|a calorie/protein matched smoothie|
218928938|NCT00373997|PROCEDURE|Esophageal and Laryngeal biopsies|one day procedure
218928939|NCT00373997|PROCEDURE|egd with biopsy|standard of care procedure with biopsy
218928940|NCT05188833|DEVICE|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
218928941|NCT05188833|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
219540527|NCT03100422|OTHER|Occupational Therapy|bilateral arm training
218928942|NCT02331277|DRUG|BI 655064|subcutaneous injection
218928943|NCT02331277|DRUG|Placebo|Placebo
218928944|NCT03063034|OTHER|PD21864AA|A king size menthol cigarette.
218928945|NCT03063034|OTHER|PD21864AB|A king size menthol cigarette.
218928946|NCT00178776|BEHAVIORAL|Transtheoretical Model Group Therapy|
218928947|NCT00178776|BEHAVIORAL|Education & Advice|
218928948|NCT03978117|DIETARY_SUPPLEMENT|Freeze Dried Watercress Preparation|Freeze dried watercress containing gluconasturtiin, which when added to provided water with flavor powder, will result in a total target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
219044070|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
218928949|NCT03978117|DIETARY_SUPPLEMENT|Placebo Preparation|Maltodextrin added to provided water with flavor powder. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
218928950|NCT04463459|DRUG|Vitamin C, Vitamin E|Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
219044071|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
219540528|NCT05519150|DIAGNOSTIC_TEST|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
219540529|NCT05519150|PROCEDURE|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
219540530|NCT05519150|OTHER|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
218928951|NCT03967353|BEHAVIORAL|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
218928952|NCT00000991|DRUG|Pentamidine isethionate|
218928953|NCT00000991|DRUG|Sulfamethoxazole-Trimethoprim|
218928954|NCT00000991|DRUG|Dapsone|
218928955|NCT00000991|DRUG|Zidovudine|
218928956|NCT02392819|DIETARY_SUPPLEMENT|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
218928957|NCT02392819|DIETARY_SUPPLEMENT|Placebo|
218928958|NCT04922567|DRUG|Lenalidomide|25mg po on day 1-10
218928959|NCT04922567|DRUG|Cyclophosphamide|750mg/m² iv on day1
218928960|NCT04922567|DRUG|Doxorubicin|50mg/m² iv on day 1
218928961|NCT04922567|DRUG|Vincristine|1.4mg/m² iv on day 1
218928962|NCT04922567|DRUG|Prednisone|100mg po on day1-5
218928963|NCT05814172|OTHER|no intervention|no intervention
218928964|NCT00322660|DRUG|Adrenaline|
218928965|NCT02232906|DRUG|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
218928966|NCT05462756|DRUG|Insulin Efsitora Alfa|Administered SC
218928967|NCT05462756|DRUG|Insulin Lispro (U100)|Administered SC
218928968|NCT05462756|DRUG|Insulin Glargine (U100)|Administered SC
218928969|NCT04375085|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
218928970|NCT02336529|DRUG|Bupivacaine|
218928971|NCT02336529|DRUG|NaCl|
218928972|NCT04475887|DRUG|Iron Carboxymaltose|see above
218928973|NCT04475887|DRUG|Placebo|see above
218928974|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
218928975|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
218928976|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
218928977|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
218928978|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
218928979|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
218928980|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
218928981|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
218928982|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
219044072|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
219205273|NCT06746922|DEVICE|Intermittent theta-burst stimulation|"Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows:~Parameters:~Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600"
219044073|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
219044074|NCT03192839|OTHER|Low dose PUFA|Low dose PUFA
219044075|NCT03192839|OTHER|High dose PUFA|High dose PUFA
218928983|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
218928984|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
218928985|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
218928986|NCT01757925|BEHAVIORAL|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
218928987|NCT01757925|OTHER|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
218928988|NCT04090359|DEVICE|Dual Mobility Implant|Patients in this intervention will receive a dual mobility implant
218928989|NCT04090359|DEVICE|Conventional, single-bearing implant|Patients in this intervention will receive a conventional, single-bearing implant
218928990|NCT00089401|DRUG|isolated perfusion|
218928991|NCT00089401|DRUG|melphalan|
218928992|NCT00089401|PROCEDURE|conventional surgery|
218928993|NCT04678219|OTHER|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
218928994|NCT02707822|OTHER|Clinical and genetic factors|
218928995|NCT05519475|DRUG|ALN-HSD|Administered by subcutaneous injection (SC)
218928996|NCT05519475|DRUG|Placebo|Administered by SC injection
218928997|NCT01549418|DRUG|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
218928998|NCT01549418|DRUG|Placebo|
218928999|NCT02259335|DEVICE|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
218929000|NCT00990704|DRUG|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
218929001|NCT00990704|DRUG|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
218929002|NCT04040933|DEVICE|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
219044076|NCT03192839|OTHER|Placebo|Placebo
218929003|NCT04040933|DEVICE|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
218929004|NCT04040933|DEVICE|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
218929005|NCT04040933|DEVICE|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
218929006|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
218929007|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
218929008|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
218929009|NCT02029248|OTHER|Quality of life questionnaire|
218929010|NCT05687669|DRUG|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
219540531|NCT06192303|DIAGNOSTIC_TEST|Bronchoalveolar lavage and pathogen metagenomic sequencing|After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.
218929011|NCT03734380|BEHAVIORAL|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
219540532|NCT05838703|DRUG|tiotropium bromide inhalation powder (Spiriva HandiHaler)|Spiriva HandiHaler is a COPD medication that is available for use.
218929012|NCT03734380|BEHAVIORAL|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
218929013|NCT03734380|BEHAVIORAL|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
218929014|NCT02897440|PROCEDURE|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
218929015|NCT02897440|PROCEDURE|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
219540533|NCT05838703|DRUG|tiotropium bromide (Spiriva Respimat)|Spiriva Respimat is a COPD medication that is available for use.
218929016|NCT03959267|BEHAVIORAL|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
218929017|NCT01079052|DRUG|Famotidine|Tablets
218929018|NCT04422678|DRUG|Imatinib Mesylate|Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
218929019|NCT04422678|DRUG|Standard of Care|Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
218929020|NCT00084513|BIOLOGICAL|trastuzumab|
218929021|NCT00084513|DRUG|imatinib mesylate|
218929022|NCT02409277|OTHER|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
218929023|NCT03204734|DRUG|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
218929024|NCT03204734|DRUG|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
218929025|NCT03307876|OTHER|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
218929026|NCT03993652|BEHAVIORAL|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
218929027|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - single dose
218929028|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - Single dose
218929029|NCT01872390|OTHER|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
218929030|NCT01872390|OTHER|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
218929031|NCT06101589|DIETARY_SUPPLEMENT|25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.|5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
218929032|NCT06101589|DIETARY_SUPPLEMENT|Placebo|Olive oil in 1 ml ethyl oleate with no vitamin D3 content
218929033|NCT04675008|DRUG|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
218929034|NCT00846092|DEVICE|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
218929035|NCT00846092|DEVICE|Near-infrared light (NIR)|"* Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily."
218929036|NCT01071798|DRUG|Rituximab|As prescribed by physician
218929037|NCT04553380|DRUG|basic insulin|"1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night."
218929038|NCT00560196|OTHER|Observation|
218929039|NCT05446818|DIETARY_SUPPLEMENT|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
218929040|NCT05446818|OTHER|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
218929041|NCT03078218|DIAGNOSTIC_TEST|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
218929042|NCT04670367|BEHAVIORAL|Walk 30mins|aerobic exercise
218929043|NCT04670367|BEHAVIORAL|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
218929044|NCT04670367|OTHER|usual care|routine care
218929045|NCT04670367|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
218929046|NCT00641667|DRUG|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
218929047|NCT00538018|DRUG|Telithromycin|
218929048|NCT01235741|DRUG|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
218929049|NCT01235741|DRUG|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
218929050|NCT01794767|DRUG|0,9% NaCl flush|Normal Saline solution
218929051|NCT01794767|DRUG|Heparin 50U/ml|Heparin solution
218929052|NCT00277654|DRUG|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
218929053|NCT03518255|OTHER|Nature video|After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
218929054|NCT03679507|PROCEDURE|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
218929055|NCT03679507|OTHER|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
218929056|NCT03323281|OTHER|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
218929057|NCT05885399|DRUG|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
219044077|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
219044078|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
219044079|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
219044080|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
219044081|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
218929058|NCT04141904|DRUG|Tofacitinib 5 MG [Xeljanz]|Tofacitinib 5mg capsules twice a day for 7-10 days
218929059|NCT04141904|OTHER|Placebo|Placebo capsules twice a day for 7-10 days
218929060|NCT00451633|DRUG|E2007|
218929061|NCT06168448|OTHER|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
218929062|NCT06168448|OTHER|Video information|Explanatory video applied after physician's formal information
218929063|NCT01795170|DIETARY_SUPPLEMENT|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
219044082|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
219044083|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
219044084|NCT02803112|PROCEDURE|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
219044085|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
219044086|NCT02493634|DEVICE|MRWire|
219044087|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
219044088|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
219044089|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
219044090|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
219540534|NCT05838703|DRUG|Hyperpolarized 129XeMRI|Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
219540535|NCT04972864|OTHER|Exercise training group|A regular advanced exercise program was given and followed.
218929064|NCT01795170|DRUG|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
218929065|NCT05758636|BEHAVIORAL|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
218929066|NCT01640392|BEHAVIORAL|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
218929067|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 1|Investigational Reflex Test 1
218929068|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 2|Investigational Reflex Test 2
218929069|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 3|Investigational Reflex Test 3
218929070|NCT01527097|DRUG|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
219540536|NCT04972864|OTHER|Control training group|Basic exercises was given at the beginning and did the same exercises
219540537|NCT04207203|COMBINATION_PRODUCT|sodium zirconium cyclosilicate and healthy diet|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
219540538|NCT06560242|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
219540539|NCT01835860|PROCEDURE|Prostate artery embolization|
219540540|NCT01978730|DRUG|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
219540541|NCT01978730|DRUG|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
218929071|NCT01527097|DRUG|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
218929072|NCT01912170|DIETARY_SUPPLEMENT|Fish oil|
218929073|NCT01912170|DIETARY_SUPPLEMENT|Flaxseed oil|
218929074|NCT03931369|DRUG|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
218929075|NCT04213248|DRUG|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
219540542|NCT01978730|DRUG|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
218929076|NCT01241201|DIETARY_SUPPLEMENT|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
219540543|NCT04910425|DRUG|Fluorine F 18 DCFPyL|Given IV
219540544|NCT04910425|DRUG|Gadobenate Dimeglumine|Given IV
219540545|NCT04910425|DRUG|Gadobutrol|Given IV
219540546|NCT04910425|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219540547|NCT04910425|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
218929077|NCT06088784|DRUG|ATH-399A|Orally administered drug in capsule form.
218929078|NCT06088784|DRUG|Placebo|Orally administered drug in capsule form.
218929079|NCT03992248|BEHAVIORAL|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
218929080|NCT03992248|BEHAVIORAL|Control|Eating for at least 14hrs per day.
218929081|NCT00958906|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
218929082|NCT01528969|DIETARY_SUPPLEMENT|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
218929083|NCT01528969|DIETARY_SUPPLEMENT|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
218929084|NCT01470950|PROCEDURE|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
218929085|NCT01801228|DRUG|Eplerenone|
218929086|NCT00098813|DRUG|romidepsin|Given IV
219540548|NCT04910425|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219540549|NCT04910425|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
219540550|NCT02173834|OTHER|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
219540551|NCT05951049|DRUG|AT02|Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
219540552|NCT02009774|PROCEDURE|NBI Function|
219540553|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after baseline up to 6 months
219540554|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
219540555|NCT03809130|OTHER|Quality-of-Life Assessment|Ancillary studies
219540556|NCT03809130|OTHER|Questionnaire Administration|Ancillary studies
219540557|NCT01959568|PROCEDURE|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
218929087|NCT00098813|OTHER|laboratory biomarker analysis|Correlative studies
218929088|NCT00098813|PROCEDURE|positron emission tomography|Correlative studies
218929089|NCT01588392|BEHAVIORAL|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
218929090|NCT01588392|BEHAVIORAL|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
218929091|NCT02894736|DEVICE|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
218929092|NCT05147090|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
218929093|NCT05147090|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
218929094|NCT04946981|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
218929095|NCT04946981|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
218929096|NCT03727256|OTHER|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
218929097|NCT03727256|OTHER|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
218929098|NCT03123952|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
218929099|NCT05029778|DIETARY_SUPPLEMENT|L-arginine 3g + L-Citruline 2 g|receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
218929100|NCT05029778|DRUG|Placebo|receive placebo 3g PO, for 24 h, until birth.
218929101|NCT02670239|PROCEDURE|normothermic ex vivo lung perfusion|
218929102|NCT05965544|DRUG|Bupivacain (preoperative)|After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
218929103|NCT05965544|DRUG|Bupivacaine-fentanyl|The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
219044091|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
219044092|NCT00786695|DRUG|esomeprazole|esomeprazole (40 mg o d) for 14 days
219044093|NCT00786695|DRUG|Placebo|Identical looking Placebo, same regimen, for 14 days
218929104|NCT05965544|DRUG|Bupivacain (Postoperative)|After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
218929105|NCT04424264|DRUG|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
218929106|NCT04424264|DRUG|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
218929107|NCT04424264|DRUG|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
218929108|NCT02807584|DEVICE|ELECT|
219044094|NCT04262336|DRUG|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
219044095|NCT04262336|DRUG|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
219044096|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
219044097|NCT01103934|DRUG|Placebo|Placebo taken once daily
219044098|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
219540558|NCT03079466|OTHER|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
219540559|NCT06135857|DEVICE|Protocol ECOEMS|Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
218929109|NCT04367623|OTHER|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
218929110|NCT02182752|DRUG|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
218929111|NCT02182752|DRUG|Ropivacaine|Interscalene block using ropivacaine
218929112|NCT00072319|BIOLOGICAL|filgrastim|
218929113|NCT00072319|DRUG|cyclophosphamide|
218929114|NCT00072319|DRUG|epirubicin hydrochloride|
218929115|NCT00072319|DRUG|paclitaxel|
218929116|NCT00072319|PROCEDURE|adjuvant therapy|
218929117|NCT00072319|PROCEDURE|neoadjuvant therapy|
218929118|NCT04287296|BEHAVIORAL|Wakey!|Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
218929119|NCT02538978|BIOLOGICAL|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
218929120|NCT02538978|BIOLOGICAL|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
218929121|NCT02919579|DRUG|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
218929122|NCT02919579|DRUG|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
218929123|NCT02919579|OTHER|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
218929124|NCT02919579|DRUG|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
218929125|NCT05597488|DEVICE|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
218929126|NCT01118000|PROCEDURE|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
218929127|NCT02212951|DRUG|BIOD-531|
218929128|NCT02212951|DRUG|Humalog Mix 75/25|
218929129|NCT02212951|DRUG|Humulin R U-500|
218929130|NCT05048095|OTHER|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
218929131|NCT04562818|DIAGNOSTIC_TEST|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
218929132|NCT04562818|DIAGNOSTIC_TEST|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
219205274|NCT06746922|DEVICE|Sham Intermittent theta-burst stimulation|In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.
219205275|NCT06747806|PROCEDURE|Cardiac Surgery and Procedures|To assess blood and tissue biomarkers of patients undergoing cardiac surgery
219205276|NCT06746935|PROCEDURE|Collagen membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with native collagen membrane.
219205277|NCT06746935|PROCEDURE|Polytetrafluoroethylene membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with polytetrafluoroethylene membrane.
219540560|NCT01379222|DEVICE|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
219540561|NCT00702091|DRUG|Ramipril|10 mg capsule
219540562|NCT06169605|PROCEDURE|removal of primary tumor, neck dissection|removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
219540563|NCT00186251|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
219540564|NCT01521481|OTHER|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
219540565|NCT01521481|OTHER|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
218929133|NCT04562818|DIAGNOSTIC_TEST|Leucocytes|
219540566|NCT01972386|DEVICE|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
218929134|NCT03536416|BEHAVIORAL|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
218929135|NCT05522348|PROCEDURE|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|two patient fitted custom made plates will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
218929136|NCT05522348|PROCEDURE|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|one patient fitted custom made plate will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
218929137|NCT04517175|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
218929138|NCT00220636|DRUG|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
219044099|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
219540567|NCT02124135|BEHAVIORAL|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
219540568|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 \^ 9 CFU/mg
219540569|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 \^ 6 CFU/mg
219540570|NCT04988594|DIETARY_SUPPLEMENT|No culture|No probiotic cultures
219540571|NCT05820360|BEHAVIORAL|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
219540572|NCT00522262|BEHAVIORAL|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
219540573|NCT01137591|DRUG|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
219540574|NCT01137591|DRUG|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
219540575|NCT00601120|PROCEDURE|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
219044100|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
219044101|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
219044102|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
219540576|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
219044103|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
219044104|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
219044105|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
218929139|NCT01119209|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
218929140|NCT01119209|DRUG|Saline|Approved by the Danish Medicines Agency
218929141|NCT03766152|DEVICE|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
218929142|NCT05480267|PROCEDURE|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
218929143|NCT01203969|PROCEDURE|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
218929144|NCT01203969|PROCEDURE|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
219540577|NCT05827991|DRUG|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
218929145|NCT00506974|DRUG|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
218929146|NCT05542719|OTHER|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
218929147|NCT03385980|OTHER|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
218929148|NCT04733859|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
219540578|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
219540579|NCT01987765|DRUG|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
219540580|NCT01314391|GENETIC|mutation analysis|
219540581|NCT01314391|GENETIC|polymerase chain reaction|
218929149|NCT04733859|DIETARY_SUPPLEMENT|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
218929150|NCT00971152|DRUG|menotropins for injection|comparison of different dosages
219540582|NCT01314391|OTHER|laboratory biomarker analysis|
219540583|NCT01499186|OTHER|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
219540584|NCT05315557|DRUG|Terlipressin|1mg/24 hour and titrate according to MAP
219540585|NCT05315557|DRUG|vasopressin|0.03 U/hour and titrate according to MAP
219540586|NCT05294471|DEVICE|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
219540587|NCT00996684|DRUG|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
219540588|NCT00996684|DRUG|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
219540589|NCT03266393|DRUG|Envarsus XR|Once daily sustained-release tacrolimus
219540590|NCT03266393|DRUG|Tacrolimus|Twice daily immediate-release tacrolimus
219540591|NCT04252001|DEVICE|YESS! game|"The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish."
219620586|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
219620587|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
218929151|NCT00971152|DRUG|urofollitropin for injection|comparison of different dosages
218929152|NCT00004114|BIOLOGICAL|filgrastim|
218929153|NCT00004114|DRUG|cyclophosphamide|
218929154|NCT00004114|DRUG|cytarabine|
218929155|NCT00004114|DRUG|fludarabine phosphate|
218929156|NCT00004114|PROCEDURE|peripheral blood stem cell transplantation|
218929157|NCT00218218|DRUG|Transdermal Nicotine Patch|42 mg transdermal nicotine
218929158|NCT00218218|DRUG|21 mg transdermal nicotine|
218929159|NCT00218218|DRUG|placebo patch|
218929160|NCT03348228|DIETARY_SUPPLEMENT|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
218929161|NCT05234697|DRUG|Remifentanil|Remifentanil was used for maintenance of anesthesia.
218929162|NCT02180776|OTHER|Summit 456 TLSO|Thoracolumbarsacral orthosis
218929163|NCT00124514|DRUG|Triptorelin pamoate|IM injection given monthly
218929164|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
218929165|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
218929166|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
218929167|NCT00124514|OTHER|placebo|placebo 0.9% normal saline IM injection
218929168|NCT05615038|PROCEDURE|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
218929169|NCT05615038|PROCEDURE|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
218929170|NCT03292601|DEVICE|NYRC Brace Scoliosis Monitor|Scoliosis Monitor is a system that allows the continuous monitoring of the scoliosis brace use compliance and posture. This product includes a brace wearable that enables the monitoring of the scoliosis brace. The wearable device is able to communicate with a companion mobile application which stores and processes the collected data and is responsible for data synchronization.
218929171|NCT04631250|DRUG|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
218929172|NCT05811286|PROCEDURE|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
218929173|NCT03470610|DRUG|Progesterone|6 mg estradiol and vaginal and rectal progesterone
218929174|NCT01662102|DRUG|Zevalin|Zevalin administered intravenously.
218929175|NCT01662102|DRUG|Rituximab|Rituximab administered intravenously.
219540592|NCT04252001|DEVICE|Snake '97|Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
219540593|NCT04252001|OTHER|Transition-toolkit|The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
219540594|NCT00006468|DRUG|FOLFOX regimen|
219540595|NCT00006468|DRUG|fluorouracil|
219540596|NCT00006468|DRUG|leucovorin calcium|
219540597|NCT00006468|DRUG|oxaliplatin|
219540598|NCT04048096|DIETARY_SUPPLEMENT|Krill Oil|Aker Biomarine Superba Krill Oil
219540599|NCT04048096|DIETARY_SUPPLEMENT|Placebo|Mixed vegetable oil
218929176|NCT01062932|DRUG|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
218929177|NCT01062932|DRUG|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
218929178|NCT01749332|OTHER|Perihepatic Phlebotomy|
218929179|NCT00675272|DRUG|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
218929180|NCT00675272|DRUG|sodium chloride|sodium chloride every 6 hours iv
218929181|NCT03475147|DEVICE|eyeFusion|Smartphone app based flicker fusion test.
218929182|NCT05336591|OTHER|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
218929183|NCT05072236|PROCEDURE|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
218929184|NCT05335226|PROCEDURE|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation|Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation. (HLA 6-10/10, TNC≥1-3×10-7/Kg)
219540600|NCT01528696|DEVICE|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
219540601|NCT01528696|DEVICE|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
219540602|NCT06448221|BEHAVIORAL|a web-based Relationship Teaching(RT)/communication education programs|receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.
219620588|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
218929185|NCT05335226|PROCEDURE|haploidentical hematopoietic stem cell transplantation|Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
218929186|NCT01371357|DRUG|TEST 1|2.4 g/day of guanidinoacetic acid
219620589|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
218929187|NCT01371357|DRUG|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
218929188|NCT01371357|DRUG|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
218929189|NCT01371357|DRUG|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
219540603|NCT06448221|BEHAVIORAL|Helper of Emotional Assessment Relationship Teaching (HEART) program|receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
219540604|NCT02143245|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
218929190|NCT05240027|BEHAVIORAL|Vape use survey|pre \& post test surveys
218929191|NCT03029871|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
218929192|NCT04048356|DRUG|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
218929193|NCT02586298|OTHER|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
219044106|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
219044107|NCT04589403|DRUG|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
219044108|NCT02315768|DRUG|GA101|
219044109|NCT02315768|DRUG|Ibrutinib|
219044110|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
219540605|NCT02143245|DIAGNOSTIC_TEST|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
219540606|NCT03600805|DRUG|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219044111|NCT04237961|PROCEDURE|Injection|Fat injection and botox
219044112|NCT04237961|PROCEDURE|Suture|Suspension suture
219540607|NCT03600805|DRUG|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219540608|NCT03600805|DRUG|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
219540609|NCT03600805|DRUG|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
218929194|NCT02586298|OTHER|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
218929195|NCT05386771|DIETARY_SUPPLEMENT|Whey/collagen protein blend|Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
218929196|NCT05386771|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
218929197|NCT03802292|BIOLOGICAL|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
218929198|NCT03802292|BIOLOGICAL|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
218929199|NCT05682196|DRUG|Rituximab added to standard of care treatment|Rituximab with standard of care treatment
218929200|NCT05682196|DRUG|standard of care treatment alone|Standard of care treatment alone
218929201|NCT00196313|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
218929202|NCT00196313|DRUG|Placebo tablet|1 tablet daily by mouth
218929203|NCT03760042|DRUG|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
219044113|NCT06802757|DRUG|Posaconazole|Posaconazole 120mg/m2 po bid d1-14 q21d
219044114|NCT06802757|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 d1 q21d
219044115|NCT06802757|DRUG|Carboplatin|Carboplatin AUC=6 d1 q21d
219044116|NCT06802757|DRUG|Anthracycline|Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d
219044117|NCT06802757|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg/m2 d1 q21d
219044118|NCT06802757|DRUG|Pembrolizumab|Pembrolizumab 200mg d1 q21d
218929204|NCT03760042|DRUG|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
218929205|NCT03071107|BEHAVIORAL|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
218929206|NCT04485390|OTHER|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
219540610|NCT01948167|BEHAVIORAL|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
219540611|NCT01948167|BEHAVIORAL|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
219540612|NCT01138163|DRUG|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
218929207|NCT01440894|DEVICE|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
218929208|NCT01460693|DRUG|Imatinib|Oral Imatinib 100mg daily
218929209|NCT01460693|DRUG|Dasatinib|Oral Dasatinib 100mg daily
218929210|NCT05824780|OTHER|Exercise training|4-week weightlifting strength training
218929211|NCT00645996|DIETARY_SUPPLEMENT|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
218929212|NCT00645996|DIETARY_SUPPLEMENT|Cornflor|Cornflour 2 gram daily
218929213|NCT03516188|DRUG|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
218929214|NCT03516188|DRUG|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
218929215|NCT04382040|DRUG|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
218929216|NCT04382040|DRUG|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
218929217|NCT00168857|DRUG|telmisartan|
218929218|NCT00168857|DRUG|losartan|
219044119|NCT02877784|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
219044120|NCT02877784|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
219044121|NCT02877784|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
219044122|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
219044123|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
219044124|NCT02287896|DRUG|ROLEDUMAB|See Arm description
218929219|NCT01219881|DRUG|Desflurane|5.4 to 7.4% desflurane
218929220|NCT01219881|DRUG|Sevoflurane|1.4 to 2.5% Sevoflurane
218929221|NCT06054074|BEHAVIORAL|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
219044125|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
219044126|NCT02647034|OTHER|no intervention|no intervention
219044127|NCT05651464|DRUG|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
219044128|NCT05445765|BIOLOGICAL|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219044129|NCT01125215|DRUG|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
219044130|NCT01125215|DRUG|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
219044131|NCT04995016|DRUG|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
219044132|NCT04995016|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
219620590|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
218929222|NCT06054074|BEHAVIORAL|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
218929223|NCT02314559|DRUG|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
218929224|NCT02314559|DRUG|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
218929225|NCT06400381|BEHAVIORAL|Mindfulness|There are many mindfulness-based interventions protocol that can be implemented and practice by healthcare organization. In the current study, the intervention protocol the investigators will use is based on Smiths version of mindfulness meditation (Smith, 2005). This version is compromised of several components includes being mindful of breathing, thought, sounds, taste, body scan, and sitting. The initial educational session by power point presentation will be given to the participant to explain the intervention rationale and procedure of mindfulness in daily life. In addition to giving opportunity for the participant to ask questions during the educational session.
218929226|NCT02590224|DRUG|Ferrous bis-glycinate|
218929227|NCT02590224|DRUG|Ferrous glycine sulphate|
218929228|NCT06356896|BEHAVIORAL|diaphragmatic breathing exercise|Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
218929229|NCT05479357|DRUG|Oxytocin|10 iu will be given intravenously.
218929230|NCT05479357|DRUG|Carbetocin|100 micrograms will be given intravenously.
218929231|NCT01904994|PROCEDURE|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
218929232|NCT01904994|PROCEDURE|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
218929233|NCT01904994|BEHAVIORAL|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
218929234|NCT01904994|BEHAVIORAL|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
219620591|NCT06303141|OTHER|Closed Chain exercises|"Open eyes and closed eyes across arm (3 sets x 60 sec) Lateral step down (3 sets x 6-12 reps) Semi-Squat Exercise (3sets x 6-12 reps) Thera-band isometric (3 sets x 10 -15sec each)"
219620592|NCT06303141|OTHER|Neuromuscular Training|"Neuromuscular Training Exercise:~* Single Leg Raise (3 sec x 30sec each)~* Ankle eversion/inversion (3 sets x 25 reps)~* Double Hopping in place then out of place (3 sets 30 sec)~* Reach with feet (3 sets x 30-60 sec each)~* Reach with hands (3 sets x 30-60 sec each)~* Wobble board Exercise (3sets x 30-60sec each"
219620593|NCT06303141|OTHER|Mobilization with Movement|"Joint mobilization with movement (by Mulligan) refers to manual therapy techniques that are used to modulate pain and treat joint dysfunctions that limit the range of motion (ROM).~(3 sets x 6 oscillation/glide each)"
219620594|NCT00491868|DRUG|R744|100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
219620595|NCT00491868|DRUG|R744|150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
219620596|NCT00491868|DRUG|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
218929235|NCT01904994|OTHER|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
219620597|NCT00491868|DRUG|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
218929236|NCT02670096|DRUG|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
218929237|NCT02988895|RADIATION|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
218929238|NCT02531672|DRUG|11C-choline|
218929239|NCT02531672|DEVICE|PET/CT Scan|
218929240|NCT02700906|DRUG|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
218929241|NCT02700906|DRUG|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
218929242|NCT00491634|DRUG|treosulfan|12 g/m2 x 3 days
218929243|NCT00491634|DRUG|Treosulfan|12 g/m2 x 3
218929244|NCT05133310|DRUG|Simvastatin|Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
218929245|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
218929246|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
218929247|NCT01019083|OTHER|Control|Control will be selected from the Arsenic non contaminated Area
218929248|NCT01019083|DRUG|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
218929249|NCT01019083|DRUG|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
218929250|NCT01019083|OTHER|Arsenic|Participant will be selected from the Arsenic Contaminated Area
218929251|NCT00503815|DRUG|BLI-800|
219205278|NCT06746987|OTHER|Meditation|After the appropriate sample group for the research is created, study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
219540613|NCT00256230|DRUG|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
219540614|NCT00320034|DRUG|R-albuterol, S-albuterol|
219540615|NCT04478435|OTHER|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
219540616|NCT04985019|PROCEDURE|Arm I (Prepectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
219620598|NCT00491868|DRUG|R744 placebo|0 μg/4week for 24 weeks
218929252|NCT00503815|DRUG|Polyethylene glycol 3350 based bowel preparation|
218929253|NCT02196636|DRUG|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
218929254|NCT02196636|DRUG|RO6806127|Administered orally with approximately 240 mL of buffer
218929255|NCT05417919|OTHER|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
218929256|NCT02577718|DRUG|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
218929257|NCT00863226|DEVICE|Resonator Device|Application of Magnetic Fields Using the Resonator Device
218929258|NCT04587427|DRUG|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
218929259|NCT01995838|DRUG|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
218929260|NCT01995838|DRUG|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
218929261|NCT03903406|DRUG|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
218929262|NCT05902806|DIETARY_SUPPLEMENT|Upgraded tube feed|Total duration of study: 4 weeks; 1 week on current tube feed followed by 2 weeks on upgraded tube feed comparable in energy density and fiber content as their current tube feed. The tube feeding regimen is similar to pre study feeding regimen. There will then be a one week follow up period.
218929263|NCT05423561|PROCEDURE|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
218929264|NCT01967576|DRUG|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
218929265|NCT04301804|DRUG|SHR6390|a selective small-molecule CDK4/6 inhibitor
218929266|NCT05237076|DIAGNOSTIC_TEST|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
218929267|NCT00768456|DRUG|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
218929268|NCT00768456|DRUG|Isotonic NaCl|Local Infiltration with NaCl
219205279|NCT06742866|DRUG|Amiodarone Injection|Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
218929269|NCT05611320|OTHER|Awareness campaign - communications campaign|"How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well."
218929270|NCT05611320|OTHER|Online shopping|Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
218929271|NCT04254172|DEVICE|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
218929272|NCT04830319|OTHER|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
218929273|NCT04830319|OTHER|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
218929274|NCT03463928|BIOLOGICAL|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
218929275|NCT05766046|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with LDCT at one or two years interval
218929276|NCT05766046|OTHER|blood test|blood analysis for microRNA and other biomarkers detection
218929277|NCT04151576|OTHER|aromatherapy massage|aromatherapy massage
218929278|NCT05425472|DRUG|HR070803|HR070803
218929279|NCT03186742|DRUG|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
219205280|NCT06742866|DRUG|Sodium Chloride Injection 0.9%|Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
219205281|NCT06742177|PROCEDURE|Group Bi-level ESPB|The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.
219205282|NCT06742177|PROCEDURE|Group M-TAPA block|The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
219540617|NCT04985019|OTHER|Arm II (Subpectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
219540618|NCT04875117|DEVICE|Hearing aid|One or two behind the ear hearing aids provided by the UK National Health Service.
219540619|NCT00378547|DRUG|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
219540620|NCT00378547|DRUG|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
219540621|NCT00378547|DRUG|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
219620599|NCT00491868|DRUG|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
218929280|NCT02550834|OTHER|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
218929281|NCT00212589|DRUG|Capecitabine|
218929282|NCT00212589|DRUG|Fluorouracil + folinic acid|
218929283|NCT04455256|OTHER|x box binding protein|Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
218929284|NCT02633202|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
218929285|NCT02633202|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
218929286|NCT06057467|DRUG|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
219540622|NCT06195579|BEHAVIORAL|Transforming the Intense Child Workbook (Glasser, 2016)|The NHA was delivered in a guided self-help format, using the Transforming the Intense Child workbook (Glasser, 2016) and weekly phone calls.
218929287|NCT02157883|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
218929288|NCT02157883|DRUG|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
218929289|NCT02157883|DRUG|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
218929290|NCT06023017|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
218929291|NCT06023017|BEHAVIORAL|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
218929292|NCT03229785|BIOLOGICAL|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
218929293|NCT04350957|DIAGNOSTIC_TEST|Low-dose Imaging|"We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations."
218929294|NCT00183313|BEHAVIORAL|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
218929295|NCT00183313|BEHAVIORAL|Usual care|Usual care includes standard mental health services.
218929296|NCT02497352|DIETARY_SUPPLEMENT|flaxseed|
219540623|NCT01452802|DEVICE|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
219540624|NCT01452802|DRUG|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
218929297|NCT02497352|BEHAVIORAL|lifestyle modification|
218929298|NCT02460419|DRUG|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
218929299|NCT02460419|OTHER|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
219540625|NCT04535388|DEVICE|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
219540626|NCT02545283|DRUG|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.
219540627|NCT02545283|DRUG|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
219540628|NCT02545283|OTHER|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
218929300|NCT02794532|PROCEDURE|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
218929301|NCT04809480|DIAGNOSTIC_TEST|Fungal rhinosinusitis|Pathology examination
218929302|NCT00888940|DRUG|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
218929303|NCT00888940|DRUG|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
218929304|NCT00327600|DRUG|imexon|
218929305|NCT00327600|DRUG|DTIC|
218929306|NCT05151276|BEHAVIORAL|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
218929307|NCT01202032|DRUG|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
218929308|NCT01578486|DRUG|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
218929309|NCT02751489|OTHER|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
218929310|NCT03931252|DIETARY_SUPPLEMENT|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
218929311|NCT03931252|DIETARY_SUPPLEMENT|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
218929312|NCT05060601|PROCEDURE|Gracey micro-curettes|Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
218929313|NCT05060601|PROCEDURE|Standard Gracey curettes|After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
218929314|NCT02290769|DEVICE|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
218929315|NCT02290769|DEVICE|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
218929316|NCT06330558|PROCEDURE|laparoscopic right adrenalectomy|adrenalectomy
218929317|NCT00101673|DRUG|vildagliptin|
218929318|NCT01915069|DRUG|Cilostazol|
218929319|NCT05704582|OTHER|Avatar Intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
218929320|NCT05704582|OTHER|Addiction supportive intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
218929321|NCT05366062|DRUG|ERC1671|ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
218929322|NCT05366062|DRUG|GM-CSF|Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
218929323|NCT05366062|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
219044133|NCT01561066|PROCEDURE|Autologous platelet-rich fibrin glue (PRFG)|"1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
219540629|NCT00127153|BIOLOGICAL|V110, pneumococcal vaccine polyvalent|
219540630|NCT03609203|OTHER|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
219540631|NCT03609203|OTHER|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
218929324|NCT05366062|DRUG|Pembrolizumab|A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
218929325|NCT05716282|OTHER|Accuracy of neuromuscular recovery estimation|"Accuracy of the estimation of neuromuscular recovery will be measured as:~* Correct attribution of the patients to the groups slow, intermediate or fast recovery~* Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery"
218929326|NCT05601895|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
218929327|NCT05158764|DEVICE|Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification|Etiological treatment of venous disease of the lower limbs stage C6 / C6r
218929328|NCT05254704|OTHER|TEX-Q-F before scheduled surgery|"The TEX-Q-F questionnaire (French version of the breif version of the TEX-Q) contains 15 questions to assess the patient's overall expectations concerning the surgery.~The first 11 questions concern the patient's expectations regarding the postoperative period: pain and functional recovery. The last 4 questions focus on the patient's hopes for the outcome of the surgery. Each item is scored from 0 to 10, according to the intensity of the level of expectation."
218929329|NCT02536963|DEVICE|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
219044134|NCT01561066|DRUG|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
219205283|NCT06742515|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
219205284|NCT01607853|DRUG|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
218929330|NCT02536963|OTHER|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
218929331|NCT05185713|OTHER|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
218929332|NCT05083286|DRUG|OnabotulinumtoxinA|Injection of glabellar rhytids
218929333|NCT05069493|PROCEDURE|simple suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
218929334|NCT05069493|PROCEDURE|mesh|Hiatal hernia repair by tension-free mesh closure
218929335|NCT05451901|PROCEDURE|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
218929336|NCT05451901|PROCEDURE|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
219540632|NCT05570487|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
219540633|NCT00650871|DRUG|GW679769|
218929337|NCT02728687|DRUG|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
218929338|NCT02728687|DRUG|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
218929339|NCT05701501|DRUG|Vitamin B5 Tablets|The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.
218929340|NCT05701501|DRUG|placebo|The control group was given placebo tablets of the same type based on the standard IBD treatment.
218929341|NCT05503823|DEVICE|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
218929342|NCT03586466|DEVICE|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
218929343|NCT03586466|DRUG|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
219044135|NCT01171716|OTHER|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
219044136|NCT04889625|DEVICE|senofilcon A C3|Test Lens
219044137|NCT04889625|DEVICE|Dailies Total 1® Multifocal Contact Lenses|Control Lens
219044138|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
219044139|NCT05052190|BEHAVIORAL|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219044140|NCT05052190|BEHAVIORAL|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
218929344|NCT03586466|OTHER|MEMS|Subjects will receive their medication in a MEMS pill bottle.
219044141|NCT05052190|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
219044142|NCT05052190|BEHAVIORAL|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219540634|NCT00650871|DRUG|Placebo|
219540635|NCT00088192|DRUG|pegaptanib sodium|
218929345|NCT04948359|OTHER|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
219044143|NCT05052190|BEHAVIORAL|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219044144|NCT05052190|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
219540636|NCT01443195|DRUG|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
219540637|NCT01673672|BIOLOGICAL|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
219540638|NCT01673672|BIOLOGICAL|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
219540639|NCT06626581|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
219540640|NCT06626581|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
219620600|NCT07027072|DRUG|KDS2010|KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.
219620601|NCT07027072|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.
219620602|NCT01289678|DRUG|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
219620603|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
218929346|NCT04948359|OTHER|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
218929347|NCT04948359|OTHER|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
218929348|NCT01607684|DEVICE|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
218929349|NCT00012844|DEVICE|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
218929350|NCT00012844|PROCEDURE|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
219044145|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
219044146|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
219044147|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
219540641|NCT02826694|GENETIC|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
219540642|NCT02826694|GENETIC|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
219540643|NCT05913128|PROCEDURE|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
219620604|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
219620605|NCT06878170|BIOLOGICAL|RBM-001|To evaluate the safety and tolerability of the RBM-001 vaccination in healthy adults.
218929351|NCT01070017|OTHER|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
218929352|NCT00904592|DRUG|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
218929353|NCT00904592|DRUG|Placebo Comparator|"Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid"
218929354|NCT02817048|DEVICE|chest tube|
218929355|NCT02817048|PROCEDURE|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
218929356|NCT02817048|PROCEDURE|VATS with chest tube placement|
218929357|NCT02354053|DRUG|Switch to Triumeq|
218929358|NCT02354053|BEHAVIORAL|Adherence support + current ART|
218929359|NCT05404932|DRUG|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
219044148|NCT03578510|DEVICE|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
219044149|NCT03578510|DEVICE|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
219205285|NCT01607853|DRUG|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
219540644|NCT03886129|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
219540645|NCT04581304|DEVICE|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
219540646|NCT04581304|DEVICE|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
219620606|NCT07036081|DIETARY_SUPPLEMENT|Wilbo's Blends+|"A new feeding plan will be developed by the study dietitians. Participants will be transitioned from their current enteral feeding plan to incorporate Wilbo's Blends+. In this new plan Wilbo's Blends+ can provide up to 100% but not lower than 30% of their total daily calorie requirements depending on participant's individual clinical needs, as assessed by the study dietitian.~All participants will be on at least 30% Wilbo's Blends+ for at least 7 days.~If required clinically there is the option to transition participants onto Wilbo's Blends+ over 1-6 days, for children who are deemed particularly sensitive to change in their feeding plan.~Participants or their families/carers will complete an electronic workbook consisting of:~* GI tolerance records for 7 days whilst receiving Wilbo's Blends+~* Compliance records for 7 days whilst receiving Wilbo's Blends+~* Ease of use and palatability questionnaire at the end of the study intervention (after last administration of Wilbo's Blends+"
219620607|NCT07038473|PROCEDURE|Investigational Procedure|"It consists of prospective blood sample collection from children, adolescents and first-degree relatives of T1D probands.~Study without any Investigational Medicinal Product (IMP) administration."
219620608|NCT02996656|DRUG|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
218929360|NCT02668393|DRUG|Docetaxel|
219044150|NCT03663595|OTHER|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
219205286|NCT01607853|DRUG|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
219620609|NCT02996656|DRUG|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
219620610|NCT01132729|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
218929361|NCT02668393|DRUG|Nintedanib|Low Dose
218929362|NCT02668393|DRUG|Nintedanib|Medium dose
218929363|NCT02668393|DRUG|Nintedanib|High dose
218929364|NCT02668393|DRUG|Nintedanib|Continuous high dose
218929365|NCT00309348|OTHER|Weekly measurement of graft flow|
218929366|NCT02763670|OTHER|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
219205287|NCT01607853|DRUG|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
219205288|NCT06739408|DIETARY_SUPPLEMENT|Lean red meat|30g of protein from lean beef.
218929367|NCT02763670|OTHER|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
218929368|NCT00936780|DEVICE|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
218929369|NCT05569278|DRUG|GE200486 0.5M Injection|Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
218929370|NCT06367530|DIAGNOSTIC_TEST|Incidence and survival of trilateral retinoblastoma and the differences globally|The detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.
218929371|NCT01521793|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
218929372|NCT01694797|DRUG|Metoprolol Succinate|
218929373|NCT04433416|DIAGNOSTIC_TEST|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
218929374|NCT03068585|DRUG|Neovasculgen (Cambiogeneplasmid)|treatment
219205289|NCT06739408|DIETARY_SUPPLEMENT|Whey protein|Whey protein to provide 30g protein
218929375|NCT04607018|DEVICE|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
218929376|NCT04256083|BIOLOGICAL|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
218929377|NCT02843516|OTHER|No intervention|No intervention
218929378|NCT04207632|DRUG|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
218929379|NCT03651297|OTHER|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
218929380|NCT03651297|OTHER|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
218929381|NCT03333278|DRUG|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
218929382|NCT03333278|DRUG|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
218929383|NCT03333278|DRUG|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
219044151|NCT03663595|OTHER|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
219044152|NCT04671810|BIOLOGICAL|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
218929384|NCT02141204|BIOLOGICAL|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
218929385|NCT02141204|BIOLOGICAL|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
219044153|NCT06086301|OTHER|PICTURE-THIS|Discharge plans include scheduling post-discharge appointments, community support referrals, transportation arrangements, and addressing identified gaps. Transition care includes 8 check-ins over 3 months post-discharge, focusing on assessing, troubleshooting, and celebrating transition successes, using phone or video. Telehealth-assisted 'warm hand-offs' will connect interventionists with home health and primary care teams during initial visits. '1st touch daytime troubleshooting' offers extra support between check-ins. Problem-solving rehabilitation will be continued from hospital to home, with 7-10 sessions over 3 months, including a home safety survey. A Post-ICU Caregiver Toolkit provides workbooks, training videos, and resources. Lastly, referrals for patient and caregiver social/mental health support are provided.
219044154|NCT06086301|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will receive: (1) Patient and Family Re-sources published by the SCCM for PICS prior to hospital discharge; (2) ongoing assessments on the same schedule as the PICTURE-THIS intervention; (3) referral for urgent or emergent issues identified during assessments. The investigators will not provide the URL for the Post-ICU Caregiving Toolkit but the investigators will not restrict its access either. This control design balances 3 goals: 1) masking participants to group allocation; 2) responding ethically to harm/distress; 3) maintaining group separation to optimize efficacy testing of PICTURE-THIS.
219044155|NCT06086301|BEHAVIORAL|Run-In Phase|All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.
218929386|NCT05695508|DRUG|Teclistamab (Tec)|Subcutaneous administration of Teclistamab
218929387|NCT05695508|DRUG|Daratumumab|Subcutaneous administration of Daratumumab
219205290|NCT06739408|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin, to provide 0g protein but matched isocalorically
218929388|NCT05695508|DRUG|Dexamethasone|administered i.v. or orally
219540647|NCT01619904|PROCEDURE|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
219540648|NCT01619904|PROCEDURE|Standard Therapy|Following standard protocol during peri-operative period
219540649|NCT04715295|DRUG|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
218929389|NCT05695508|DRUG|Lenalidomide|Administration oral
218929390|NCT05695508|DRUG|Bortezomib|Subcutaneous administration
218929391|NCT05695508|DRUG|Talquetamab|Subcutaneous administration of Daratumumab
219044156|NCT06474494|PROCEDURE|Application of one layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
219044157|NCT06474494|PROCEDURE|Application of double layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
219044158|NCT06474494|PROCEDURE|Etch-and-rinse application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
219044159|NCT06474494|PROCEDURE|Selective enamel etching application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
219044160|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
219205291|NCT06741150|BIOLOGICAL|NWRD09 administered by intramuscular injection|Intramuscular injection administration was carried out according to the protocol design.
219540650|NCT04715295|DRUG|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
219540651|NCT04715295|COMBINATION_PRODUCT|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
219540652|NCT00852163|DRUG|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
219540653|NCT05305690|OTHER|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
219540654|NCT05150041|DEVICE|Guardian connect|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
219620611|NCT00468819|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
219620612|NCT07040319|DRUG|Glecaprevir/pibrentasvir|100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg
219620613|NCT06705829|BIOLOGICAL|Prothrombin|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
218929392|NCT05345652|PROCEDURE|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
218929393|NCT00063765|DRUG|Ciliary Neurotrophic Factor Implant NT-501|
218929394|NCT03869697|DRUG|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
218929395|NCT01091220|BIOLOGICAL|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
219044161|NCT00232310|DRUG|CELIVARONE (SSR149744C)|
219044162|NCT03000582|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
219044163|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
219044164|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
219044165|NCT03000582|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
219044166|NCT04765007|OTHER|mindfulness-based stress reduction|"Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application"
219044167|NCT04765007|OTHER|Minimal intervention|A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
219044168|NCT02459977|DRUG|Basiliximab|Basiliximab induction therapy
219044169|NCT02459977|DRUG|No basiliximab|No basiliximab induction therapy
219044170|NCT02459977|PROCEDURE|Kidney transplantation|kidney transplantation
219044171|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
219620614|NCT06724549|DRUG|BN104|This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
218929396|NCT01091220|BIOLOGICAL|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
218929397|NCT06009848|DRUG|Cadonilimab|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
218929398|NCT06042062|DEVICE|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
218929399|NCT06042062|DEVICE|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
218929400|NCT03487705|OTHER|electromyographic essential tremor|"* Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
218929401|NCT01103752|OTHER|no intervention, descriptive study|no intervention, descriptive study
218929402|NCT01918306|DRUG|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~\--------------------------------------------------------------------------------"
218929403|NCT01918306|OTHER|laboratory biomarker analysis|correlative studies
218929404|NCT01918306|OTHER|pharmacological study|correlative studies
218929405|NCT01918306|PROCEDURE|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
218929406|NCT01918306|DRUG|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
218929407|NCT02053376|DRUG|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
218929408|NCT02504593|DEVICE|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
218929409|NCT01673542|DRUG|Lidocaine-Prilocaine 5%|
218929410|NCT01673542|DRUG|DEXERYL|
218929411|NCT02756286|OTHER|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
218929412|NCT04838470|OTHER|cardiac rehabilitation|multidisciplinary disease management program
218929413|NCT01184157|BEHAVIORAL|Home screening|
218929414|NCT01184157|BEHAVIORAL|Clinic screening|
218929415|NCT00344409|DRUG|darbepoetin alfa|
219540655|NCT05150041|DEVICE|iPro2|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
219540656|NCT00951457|DRUG|Bendamustine|
218929416|NCT01017302|DRUG|Placebo|Subcutenaous once weekly for 4 weeks
219540657|NCT00951457|DRUG|Alemtuzumab|
218929417|NCT01017302|DRUG|Placebo|Single subcutaneous dose in week 5
218929418|NCT01017302|DRUG|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
218929419|NCT01017302|DRUG|RO5095932|Single subcutenaous dose in week 5
218929420|NCT05703711|BEHAVIORAL|mHealer|MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
218929421|NCT01958164|DRUG|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
218929422|NCT01958164|DRUG|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
218929423|NCT01958164|DRUG|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
218929424|NCT01958164|DRUG|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
218929425|NCT02930863|OTHER|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
219044172|NCT03746522|DRUG|Placebo|SC injection of placebo
219540658|NCT00447941|DRUG|SCA-136|
219540659|NCT00932841|OTHER|Placebo|One packet PO daily x 8 weeks.
219540660|NCT00932841|DRUG|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
218929426|NCT02930863|BEHAVIORAL|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
218929427|NCT05999357|DRUG|JDQ443|JDQ443 tablets, orally administered
218929428|NCT03830541|OTHER|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
219540661|NCT00932841|DRUG|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
219540662|NCT04057287|OTHER|No intervention|No intervention
219540663|NCT02342535|BEHAVIORAL|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
219540664|NCT02036788|OTHER|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
219540665|NCT02036788|OTHER|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
219620615|NCT07042529|PROCEDURE|OptEx-TAVI|"During TAVI with either self-expanding or balloon-expandable TAVs:~* Pre-dilatation: systematic pre-dilatation with an optimally-sized balloon.~* Post-dilatation: systematic TAV post-dilatation with an optimally-sized balloon.~Optimally-sized balloon:~1. The recommended balloon size used for pre- and post-dilatation is the perimeter-derived mean diameter of the native aortic annulus minus 1 mm and should never exceed the perimeter-derived mean diameter of the native aortic annulus. A smaller-sized balloon should be considered in case of severe left ventricular outflow tract calcium and/or severely calcified leaflets in combination with a shallow sinus of Valsalva.~2. In case of post-dilatation of the Evolut TAV (Medtronic, USA), the instructions for use (IFU) for post-dilatation of the Evolut valve should be respected.~3. Also, a balloon-expandable TAV has to be post-dilated with an optimally-sized balloon in case of randomization to the OptEx-TAVI arm."
219620616|NCT07042529|PROCEDURE|SoC-TAVI|During TAVI with either self-expanding or balloon-expandable TAVs: Pre-dilatation: optional, as per operator preference and post-dilatation: optional, as per operator preference. Operators are only encouraged to post-dilate the implanted TAV in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient. The balloon size used for pre- or post-dilatation is left at the operator's discretion.
219620617|NCT07044323|BEHAVIORAL|Active Virtual Reality Treatment|The self-administered active VR treatment will consist of 8 twice-weekly sessions, each approximately 1 hour in duration, during which subjects will participate in a variety of Virtual Reality active games that require leg movements while receiving high-quality visual feedback of the missing lower leg.
219620618|NCT05247125|COMBINATION_PRODUCT|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
219620619|NCT05247125|DRUG|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
219620620|NCT05247125|DEVICE|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
219620621|NCT05247125|COMBINATION_PRODUCT|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
219620622|NCT04952961|BEHAVIORAL|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
219620623|NCT04030299|DEVICE|Over-the-counter fitting|In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
219620624|NCT06715592|DRUG|Bleomicina|Colposcopically guided ECT following intralesional administration / intravenous Bleomycin or intralesional Cisplatin according to ESOPE recommendations. Reassessment after 30 days by colposcopy and conization with acquisition of histological examination.
219620625|NCT07049536|OTHER|Assessment Group|Allogeneic Stem Cell Transplant recipients will be evaluated with a supervisor physiotherapist for 2 days between the time they are admitted to the stem cell transplantation unit.
219620626|NCT07049536|OTHER|Control Group|Adult healthy group with similar sociodemographic characteristics to the evaluation group.
218929429|NCT04330404|BEHAVIORAL|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
218929430|NCT04330404|BEHAVIORAL|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
218929431|NCT05241990|BEHAVIORAL|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
219540666|NCT05911711|OTHER|Prognostic factor|normal person (no sepsis group)
219044173|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
219044174|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
219044175|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
219044176|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
219540667|NCT00620893|DRUG|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
219044177|NCT05197270|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
219044178|NCT05197270|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
219044179|NCT03716934|DEVICE|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
219540668|NCT00620893|DRUG|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
219205292|NCT06749002|PROCEDURE|Turning based specific training along with functional Muscle training|"Experimental group will receive Turning based specific training protocol for 6 weeks along with functional muscle training, training will be done on alternate days.~Functional muscle training:~Details: Week 1-6: 3 days a week on alternate days.~Hip Abductors:~Side lying leg raises Single leg squatting Standing leg wall press Progressing to Adding resistance bands~Hip adductors:~Side lying adduction Standing Adduction Progress to adding resistance bands~Hip Flexors:~Standing leg lift Straight leg raises Progress to adding resistance bands~Hip Extensors:~Prone lying raises Standing single leg extension Progress to adding resistance bands~Plantarflexors/ DorsiFlexors:~Plantarflexors:~Plantarflexion against resistance Toe raises~Dorsiflexors:~Dorsiflexion against resistance Heel raises~Hip external rotators:~Sitting-externally rotate hip 0-30° Add resistance bands~Hip Internal rotators:~Sitting-internally rotate the hip 0-30° Add resistance bands."
219205293|NCT06749002|PROCEDURE|turning based specific training.|"Week 1:~90 Degrees turns on the spot~Visual cues to follow~Week 2-3:~90 degrees turns on the spot~Figure of 8 walking~Visual cues to follow~Week 4-5:~90 Degrees turns on the spot~Figure of 8 walking~Step across body~Braiding~Week 6:~90 degree turns on the spot~Figure of 8 walking~Step across body~Braiding~Visual cues to follow~Obstacle avoidance"
218929432|NCT05241990|BEHAVIORAL|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
219205294|NCT06750003|PROCEDURE|3D versus 4K laparoscopic bilateral salpingo-oophorectomy|3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
219205295|NCT06748534|DIAGNOSTIC_TEST|Plus Lens Addition (+0.75 D)|Participants in this group were provided with +0.75 D lenses, designed to assist in alleviating strain caused by accommodative infacility by reducing the demand on the eye's focusing mechanism.
219205296|NCT06748534|COMBINATION_PRODUCT|Vision Therapy Using HART Chart|Intervention Details: Participants in this group underwent vision therapy sessions utilizing the HART chart, aimed at enhancing their accommodative flexibility through repetitive focusing exercises.
219205297|NCT06750523|DIAGNOSTIC_TEST|Cord blood sampling|A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.
219205298|NCT06750523|DIAGNOSTIC_TEST|urine sampling|At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.
219205299|NCT06750523|BEHAVIORAL|Life style questionnaire|At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.
219205300|NCT06748833|BEHAVIORAL|SMILE Intervention App|The SMILE app, an iOS and Android compatible smartphone app, is based on effective CBT-based treatment features to help patients manage anxiety symptomology. Access requires a unique login. The SMILE app utilizes three relaxation features: calm breathing, mindfulness meditation, and deep muscle relaxation; one cognitive feature, thought journaling and the challenging of thoughts; one self-monitoring technique; a positive imagery game; and a feature aimed to reduce avoidance behaviour through exposure. The app will be self-guided, with no additional human involvement needed. Participants will be instructed to actively engage with at least one of the app's major functions for a minimum of 3 minutes per day.
219540669|NCT03187925|PROCEDURE|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
219540670|NCT02804724|OTHER|No intervention|
219540671|NCT00538239|DRUG|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
219540672|NCT00538239|DRUG|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
219540673|NCT01834183|DRUG|Tivozanib|
219540674|NCT01834183|DRUG|Gemcitabine|
219540675|NCT03146156|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
219540676|NCT03502811|DEVICE|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
219540677|NCT06331715|DRUG|Palbociclib 125mg|Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products
219540678|NCT00988715|BIOLOGICAL|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
219540679|NCT00988715|DRUG|Cyclosporine|Given IV
219540680|NCT00988715|DRUG|Mycophenolate Mofetil|Given PO
219620627|NCT03765983|DRUG|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
218929433|NCT02019095|OTHER|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
218929434|NCT02453308|DRUG|ACT|"1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days"
219540681|NCT00988715|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
219540682|NCT00988715|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
219540683|NCT00988715|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
219540684|NCT00988715|DRUG|Fludarabine Phosphate|Given IV
219540685|NCT00988715|OTHER|Pharmacological Study|Correlative studies
219540686|NCT00988715|OTHER|Laboratory Biomarker Analysis|Correlative studies
219540687|NCT01022983|DRUG|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
219540688|NCT01022983|DRUG|Placebo|ml/kg/hours - same infusion rate as active comparator
219540689|NCT00694187|DRUG|Zaleplon|
219540690|NCT03333551|DRUG|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
218929435|NCT02453308|DRUG|TACT|"1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
218929436|NCT00066157|DRUG|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
218929437|NCT00066157|DRUG|Medroxyprogesterone|2.5mg tablet daily for 12 months
218929438|NCT00066157|DRUG|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
218929439|NCT00066157|DRUG|Placebo|Placebo tablet daily for 12 months
218929440|NCT02963506|OTHER|Placebo|
218929441|NCT02963506|DRUG|Bimekizumab|Bimekizumab in different dosages.
218929442|NCT03503032|PROCEDURE|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]
218929443|NCT03503032|PROCEDURE|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
218929444|NCT05796934|BEHAVIORAL|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
218929445|NCT06520917|DEVICE|Locator-Positioner (LOPO) Guide Device|Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
218929446|NCT02212782|DRUG|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
219044180|NCT03716934|DRUG|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
219540691|NCT01735994|BEHAVIORAL|Healthy Weight|Eating Disorder Prevention Program for Athletes
219620628|NCT03765983|DRUG|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
218929447|NCT02212782|DRUG|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
218929448|NCT04336917|DRUG|Rhomboid Intercostal and Subserratus Plane Block with local anesthetic|Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
218929449|NCT00905866|OTHER|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
218929450|NCT06204198|OTHER|No intervention|No intervention
218929451|NCT05486806|DRUG|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
218929452|NCT05486806|RADIATION|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
218929453|NCT06514066|DRUG|Cannabidiol Oil|The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.
218929454|NCT02999204|DRUG|Vitamin D3|Two different doses of Vitamin D3
218929455|NCT04258267|PROCEDURE|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
219044181|NCT03716934|DEVICE|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
219044182|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
219044183|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
219540692|NCT01735994|OTHER|Brochure|Brochure on the Female athlete triad
219540693|NCT03850158|DRUG|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
219540694|NCT04425941|OTHER|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
219044184|NCT01550575|DEVICE|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
219540695|NCT03170219|COMBINATION_PRODUCT|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
219540696|NCT03922763|PROCEDURE|Anatomical cut|Surgeon-derived cut based on patient's anatomy
219620629|NCT00218595|BEHAVIORAL|DBT|Dialectical behavior therapy plus opiate replacement medication.
219620630|NCT00218595|BEHAVIORAL|I/GDC|Individual and group drug counseling plus opiate replacement medication.
219620631|NCT05771077|DRUG|Poly(Amidoamine) dendrimer|to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite \& Their Combination on demineralized enamel \& Their Clinical Efficacy on White Spot lesion
219620632|NCT06891794|COMBINATION_PRODUCT|Menstrual disc with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
219620633|NCT06891794|COMBINATION_PRODUCT|Cervical cap with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
219044185|NCT01550575|DEVICE|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
219540697|NCT03922763|PROCEDURE|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
219620634|NCT06169176|OTHER|RAPA-501 Autologous T stem cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T stem cells, (80 x 10EE6 cells per infusion; acceptable dose range of RAPA-501 T stem cells is 20-to-80 x 10EE6 cells per infusion.
219620635|NCT06743009|OTHER|N-lactoyl-phenylalanine|Intravenous infusion of N-lactoyl-phenylalanine (Lac-Phe)
219620636|NCT06743009|OTHER|NaCl|0.9% isotonic NaCl infusion
219620637|NCT06893965|DIAGNOSTIC_TEST|Intra ocular pressure Measure|Measurement of IOP before injection (T0), just after the injection (T1) then 15 (T15), 30 (T30) and 45 (T45) minutes after the injection. Measurement are done with Perkins Tonometer
219044186|NCT06517290|OTHER|Non applicable|Non applicable
219620638|NCT06836141|DIAGNOSTIC_TEST|MRI|MRI during hospitalization and at 12 months post sICH
219620639|NCT06836141|DIAGNOSTIC_TEST|Blood Draw|Will occur during hospitalization and at 3, 6 and 12 months post sICH
219620640|NCT06836141|DIAGNOSTIC_TEST|Cognitive Test|Cognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH
219620641|NCT01553669|BEHAVIORAL|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
219620642|NCT02452437|DRUG|Oxycodone|Controlled release oxycodone 40 mg twice daily
219620643|NCT01005147|DRUG|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
219620644|NCT01005147|OTHER|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
219620645|NCT04433754|OTHER|biochemical analysis|cRP, d-dimer levels and lymphocyte counts will be compared
219620646|NCT05333705|BIOLOGICAL|infusion of natural killer cells|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
219620647|NCT06859645|BEHAVIORAL|Motor imagey training|In addition to the prescribed exercise training, participants in the intervention group will follow a pre-designed motor imagery program for eight weeks, practicing daily. This program will include pre-recorded exercise videos specifically targeting the lumbar region, along with synchronized audio recordings providing detailed explanations of the exercises.
219620648|NCT06859645|BEHAVIORAL|Exercise training|All participants will receive telerehabilitation-based exercise training under the supervision of a physiotherapist for eight weeks. The exercise program will be delivered via videoconferencing as part of a telerehabilitation-based approach. The exercises, conducted under the physiotherapist's supervision, will consist of flexibility and stabilization exercises targeting the lumbar region and will last approximately 25 minutes per session.
219620649|NCT06877546|DEVICE|Lumoral treatment|"Lumoral® Treatment devices are handed over to study participants on the first visit. The treatment is performed first at the clinic under supervision by the researchers. Treatment is then repeated at home twice a week for 12 weeks.~The treatment is started by dissolving one 7 mg Lumorinse® oral tablet in 30 ml amount of pure water. The tablet dissolves in water in one minute, after which the mouthwash is poured into the mouth and swished for 60 seconds. The indocyanine green in the mouthwash adheres to the plaque surface in the teeth and gum line. The mouthwash is then spat out and the mouthpiece of the Lumoral® Treatment device is inserted into the mouth and a light is activated. After 10 minutes, the device turns itself off, after which the mouthpiece is removed from the mouth. Normal oral hygiene routines will then be performed."
219620650|NCT00651274|DRUG|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
219620651|NCT00651274|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
219620652|NCT04616612|BEHAVIORAL|SystemCHANGE (TM)|Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.
219044187|NCT05806216|DEVICE|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
219620653|NCT04616612|OTHER|Attention Control|Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
219620654|NCT04376931|DRUG|Intravenous Solution|Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
219044188|NCT05806216|BEHAVIORAL|Clinically Certain Expert Clinician Diagnosis (CC-ECD)|Diagnosis by an expert clinician using gold standard developmental assessment tools.
219044189|NCT06494384|BEHAVIORAL|Problem Solving Treatment as usual (PST as usual)|PST is a skills-based intervention that teaches clients a 7-step approach in which they 1) select a specific problem and define it in concrete terms,2) select a goal that is feasible to reach before next session, 3) brainstorm various ways to accomplish the goal, 4) evaluate pros and cons of each solution, including the likelihood they can actually implement it, 5) select the best solution, 6) create a plan to implement the solution, and 7) evaluate the plan afterward to ascertain the effectiveness of the solution. Practitioners teach and illustrate the PST process to clients at each session and encourage clients to implement action plans developed using the PST process. Clients are also encouraged to practice the PST process with additional problems between sessions, in order to gain mastery over the PST skills, enhance behavioral activation and as a result improve their belief in their ability to solve problems on their own (self efficacy).
218929456|NCT04258267|PROCEDURE|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
218929457|NCT00710697|DRUG|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218929458|NCT00904137|PROCEDURE|Cast|
218929459|NCT00904137|PROCEDURE|Splint|
218929460|NCT00904137|PROCEDURE|Tape|
218929461|NCT02173899|BIOLOGICAL|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
218929462|NCT02173899|BIOLOGICAL|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
218929463|NCT02173899|BIOLOGICAL|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
218929464|NCT01397968|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
218929465|NCT01397968|DRUG|Placebo|Placebo capsule Placebo tablet
218929466|NCT02716480|BEHAVIORAL|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
218929467|NCT02716480|BEHAVIORAL|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
218929468|NCT01698580|OTHER|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
218929469|NCT01698580|OTHER|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
219620655|NCT03204682|DEVICE|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
219620656|NCT00830973|OTHER|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
218929470|NCT01698580|OTHER|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
218929471|NCT01698580|OTHER|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
219620657|NCT00830973|OTHER|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
219620658|NCT02912182|DRUG|Betamethasone|Betamethasone intravenous
218929472|NCT01698580|OTHER|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
218929473|NCT05043662|DIAGNOSTIC_TEST|UroCAD assay, CTU examination and urine cytology|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
219620659|NCT02912182|DRUG|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
219620660|NCT02912182|DRUG|Prednisolone|Oral tablets
219620661|NCT06737653|DEVICE|Gel containing postbiotics, lactoferrin, aloe barbadensis leaf juice powder and sodium hyaluronate|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
219620662|NCT06737653|DEVICE|Placebo gel|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
218929474|NCT05326490|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively
218929475|NCT05326490|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
218929476|NCT05326490|DRUG|Metformin hydrochloride|The dosage and administration of metformin hydrochloride remain unchanged before screening
218929477|NCT00828204|DEVICE|single-use autoinjector with a prefilled liquid Avonex syringe|
218929478|NCT00828204|DEVICE|Avonex prefilled syringe via manual IM injection|
218929479|NCT00828204|DRUG|BG9418 (interferon beta-1a)|
218929480|NCT03100552|DIAGNOSTIC_TEST|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
218929481|NCT00337480|BEHAVIORAL|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
218929482|NCT02702791|BEHAVIORAL|Telecoaching|Pedeometer based goals and telecoaching support
219540698|NCT03979664|DEVICE|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
218929483|NCT02702791|OTHER|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
218929484|NCT04129463|DEVICE|Subscleral Trabeculectomy (SST) with Iris incarceration|Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
218929485|NCT04129463|DEVICE|Conventional trabeculotomy|Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
218929486|NCT04609670|DRUG|[14C]-ALXN2050|A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
218929487|NCT02641288|DRUG|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
218929488|NCT02641288|DRUG|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
218929489|NCT03254797|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
218929490|NCT03254797|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
218929491|NCT04657393|PROCEDURE|mechanical ventilation|change of ventilation frequency
218929492|NCT00395031|DRUG|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
219540699|NCT03979664|DEVICE|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
219540700|NCT03979664|DRUG|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
219540701|NCT01548053|OTHER|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
218929493|NCT00518765|DRUG|Aliskiren|
218929494|NCT00518765|DRUG|Aliskiren plus placebo|
218929495|NCT00518765|DRUG|Aliskiren|
218929496|NCT00518765|DRUG|Aliskiren plus placebo|
218929497|NCT02792530|OTHER|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
218929498|NCT04431440|OTHER|silver nanoparticles|effect silver nanoparticles will be examined on multidrug resistant bacteria
218929499|NCT00654771|OTHER|urine collection|clean catch urine collection and catheterized urine collection
219540702|NCT00604162|DEVICE|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
219540703|NCT00604162|PROCEDURE|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
219540704|NCT02045667|DRUG|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
219540705|NCT02045667|DRUG|Placebo|Placebo tablets do not contain any active medicinal component.
219540706|NCT02241551|DRUG|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
219540707|NCT02241551|DRUG|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
219540708|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
219540709|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
219540710|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
218929500|NCT02970162|DRUG|Amifampridine Phosphate|
218929501|NCT02970162|DRUG|Placebo Oral Tablet|
218929502|NCT03495089|DIAGNOSTIC_TEST|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
218929503|NCT03495089|DIAGNOSTIC_TEST|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
218929504|NCT03241901|DRUG|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
219540711|NCT02741687|DRUG|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
218929505|NCT03241901|DRUG|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
218929506|NCT03241901|OTHER|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
218929507|NCT06039111|PROCEDURE|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
218929508|NCT00612248|OTHER|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
218929509|NCT02340364|BEHAVIORAL|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
218929510|NCT02340364|BEHAVIORAL|Self-care Education|208 patients randomized to self-care education alone.
218929511|NCT00923572|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
218929512|NCT03760861|DEVICE|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
218929513|NCT00750438|DIETARY_SUPPLEMENT|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
218929514|NCT00750438|DIETARY_SUPPLEMENT|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
218929515|NCT00750438|DIETARY_SUPPLEMENT|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
218929516|NCT03603262|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
218929517|NCT05221957|DRUG|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
218929518|NCT05453591|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
218929519|NCT01926561|OTHER|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
218929521|NCT04845568|BEHAVIORAL|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
218929522|NCT00923793|DEVICE|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
218929523|NCT00923793|DEVICE|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
218929524|NCT06409546|DRUG|Tocopherol and pentoxifilline topical gel|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
218929525|NCT06409546|DRUG|Placebo|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
218929526|NCT02638454|PROCEDURE|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
218929527|NCT04154774|DRUG|Apalutamide|Apalutamide will be administered orally.
218929528|NCT01298986|PROCEDURE|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
219540712|NCT02741687|DRUG|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
218929529|NCT01298986|PROCEDURE|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
218929530|NCT01298986|PROCEDURE|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
219044190|NCT06494384|BEHAVIORAL|Problem Solving Treatment Aid (PST-Aid)|PST-Aid is an internet-based tool to support the delivery of PST. PST-Aid incorporates decision support for the practitioner as well as client and provides PST treatment support functions (i.e., scaffolding), including patient problem lists and session worksheets. PST-Aid was designed to be used during remote sessions, such that practitioners and clients can interact throughout the session while collaboratively viewing and editing worksheets on their own browsers.This system was developed into a prototype that was piloted and found to be acceptable and with adequate usability.
219044191|NCT04811274|BIOLOGICAL|Blood collection|2 to 5 ml
219366998|NCT04671836|DRUG|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
219366999|NCT04671836|DRUG|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
219367000|NCT02627040|DEVICE|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
219367001|NCT02627040|DEVICE|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
219367002|NCT05816681|DRUG|DWJ1230|Daewoong Pharmaceutical
219367003|NCT05816681|DRUG|DWB2001|Daewoong Bio
219367004|NCT04049825|DRUG|OPB-111077|OPB-111077+bendamustine
219367005|NCT04049825|DRUG|OPB-111077|OPB-111077+rituximab+bendamustine
219367006|NCT00430144|DRUG|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
219367007|NCT05064657|PROCEDURE|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
218929531|NCT01298986|PROCEDURE|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
218929532|NCT00354432|DIETARY_SUPPLEMENT|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
218929533|NCT00354432|DRUG|Venlafaxine|Patients receive oral venlafaxine 75mg.
218929534|NCT00354432|DIETARY_SUPPLEMENT|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
218929535|NCT00354432|DRUG|Placebo Pill|Patients receive oral placebo pill.
218929536|NCT02736578|DRUG|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
218929537|NCT02736578|DRUG|Cetuximab|Administered as a 100 mg IV loading dose
218929538|NCT06516536|OTHER|MBI (Mindfulness-Based Intervention)|"Breath-Focused Meditation Approach (5-7 minutes):~They will be guided to observe the flow of air in and out of the nose, noting sensations in the abdomen or chest.~Body scan (7-8 minutes):~Students will be guided through a careful exploration of their body. You'll start with your toes and slowly work your way toward your head, paying attention to the physical sensations in each part of your body.~Simple yoga poses (5-7 minutes):~Students will stand and follow instructions to perform a series of simple poses, such as mountain pose, tree pose, and cat-cow pose."
218929539|NCT02641028|DRUG|CERC-501|CERC-501
218929540|NCT02641028|DRUG|Placebo|Placebo
218929541|NCT04800276|OTHER|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
218929542|NCT04800276|OTHER|global muscle strenghtening|global muscle strenghtening
218929543|NCT05858723|DIAGNOSTIC_TEST|ROAT|Repeated Open Application Test
218929544|NCT01039740|DRUG|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
218929545|NCT06666270|DRUG|SYN818|Patients will orally receive SYN818
218929546|NCT04325321|OTHER|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
218929547|NCT02827877|RADIATION|Copper Cu 64-DOTA-Trastuzumab|Given IV
218929548|NCT02827877|OTHER|Laboratory Biomarker Analysis|Correlative studies
218929549|NCT02827877|BIOLOGICAL|Pertuzumab|Given IV
218929550|NCT02827877|PROCEDURE|Positron Emission Tomography|Undergo PET
218929551|NCT02827877|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218929552|NCT02827877|BIOLOGICAL|Trastuzumab|Given IV
218929553|NCT01685762|DRUG|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
219044192|NCT04811274|BIOLOGICAL|Bronchoalveolar lavage fluid collection|5 to 25 ml
219044193|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
218929554|NCT05206773|DRUG|Venglustat (GZ402671)|Pharmaceutical form: Tablet Route of administration: Oral
218929555|NCT05206773|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
219044194|NCT00132418|DRUG|Enbrel|Enbrel
219044195|NCT00132418|DRUG|Placebo|Placebo
219044196|NCT03653936|DEVICE|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
219044197|NCT02578784|DEVICE|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
219044198|NCT02578784|DEVICE|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
219367008|NCT04840121|DIAGNOSTIC_TEST|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
218929557|NCT06212726|BEHAVIORAL|InjureFree|The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
218929558|NCT04163016|DRUG|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
218929559|NCT05011097|DRUG|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
218929560|NCT06174363|DRUG|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
218929561|NCT06174363|DRUG|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
218929562|NCT06589089|DRUG|autologous hematopoietic stem cell|Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
218929563|NCT02357771|DRUG|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
218929564|NCT02357771|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
218929565|NCT06603688|DRUG|esomeprazole|Esomeprazole 40mg, twice daily for 14 days.
218929566|NCT06603688|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
218929567|NCT06603688|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
218929568|NCT06603688|DRUG|clarithromycin|clarithromycin 500mg, twice daily for 14 days.
218929569|NCT06603688|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
218929570|NCT06603688|DRUG|Minocycline|Minocycline 100 mg, twice daily for 14 days
218929571|NCT06588374|PROCEDURE|lateral internal sphincterotomy|Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
218929572|NCT06597357|PROCEDURE|Arthroscopy &amp; saline irrigation alone|the meniscus scaffold is aimed at replacing partial meniscus defect with a synthetic device.
218929573|NCT06654427|BEHAVIORAL|Obstetric Trauma Informed Care Toolkit|The OB-TIC toolkit will include provider and staff training on trauma- informed care and information on trauma-related perinatal concerns; trauma assessment tools; trauma-informed procedure modifications; clinical language guides; patient-facing resources including birth strategies, referral resources, and education; and clinical language. The OB-TIC intervention will utilize the toolkit to integrate trauma-informed care into clinical practice. Implementation strategies will be assessed to determine the most effective method for integrating OB-TIC content into practice.
218929574|NCT06655597|DIETARY_SUPPLEMENT|REDS Powder|Dietary supplement powder
218929575|NCT03812757|DIAGNOSTIC_TEST|Supraclavicular fossa US scanning|As previously stated.
218929576|NCT06313307|COMBINATION_PRODUCT|topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.
218929577|NCT06313307|DEVICE|Thulium 1927-nm Fractional Laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
218929578|NCT04372381|DEVICE|Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro|Treatment of aortic valve stenosis using transcatheter aortic valve replacement
218929579|NCT06508385|OTHER|Breathing exercise|"Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds)."
218929580|NCT03897777|BEHAVIORAL|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
218929581|NCT06589973|OTHER|Study Cohort|Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.
219044199|NCT06301854|DRUG|TPN171H|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
219044200|NCT01968642|BEHAVIORAL|Educational Intervention|
219044201|NCT05325593|DRUG|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
218929582|NCT06604559|OTHER|Discharge using Apollo application|Discharge using Apollo application
219044202|NCT05325593|DRUG|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
219044203|NCT05634525|DRUG|MRTX849|Given By PO
219367009|NCT00899093|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219367010|NCT00899093|OTHER|Laboratory Biomarker Analysis|Correlative studies
219367011|NCT03403400|BEHAVIORAL|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
219367012|NCT03403400|BEHAVIORAL|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
218929583|NCT06604559|OTHER|Regular discharge|Discharge with the regular process
218929584|NCT06591923|OTHER|No Interventions|No interventions.
218929585|NCT06601023|BEHAVIORAL|Psychosocial intervention|The PM+MiLE is a low-intensity intervention. The intervention will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The problem management ambit will include understanding adversity, managing stress, managing problems, getting going and keep doing, strengthening social support and staying well and looking forward, including positive behaviour modification.The intervention will also incorporate child development and building positive parenting interactions with children.
218929586|NCT05929300|BEHAVIORAL|Yoga|The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.
218929587|NCT05929300|OTHER|Usual Care|"This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
218929588|NCT06597877|RADIATION|CT|Patients with unilateral ear pathology will be randomly assigned to do CT temporal bone, The presence of five variants was determined. These variants were: a high dehiscent jugular bulb, an anteriorly located sigmoid sinus, a deep sinus tympani, an enlarged cochlear aqueduct, and an enlarged internal auditory meatus (IAM). A GE LightSpeed 16, four-slice, helical CT scanner (Fairfield, Connecticut, USA) was used for all patients. The scan parameters were as follows: 1 mm slices, smart Ma (50-250 Ma), 120 kV, 0.8-second rotation time, 0.562:1 pitch factor, and 5.62 mm rotation speed. All scans covered an area from 1 cm inferior to the mastoid tip to 1 cm superior to the petrous temporal bone.
218929589|NCT06593028|BEHAVIORAL|Veggie Vouchers pilot|This intervention aims to increase awareness and use of a Supplemental Nutrition Assistance Program (SNAP) fruit and vegetable incentive program in South Carolina among families with young children experiencing food insecurity. To do so, brief education about this SNAP program is delivered by pediatricians to caregivers during well-child visits. Subsequently, caregivers are given 3 free produce boxes as a free trial of this program to incentivize first time use.
218929590|NCT06591845|DRUG|Ziresovir 125 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
218929591|NCT06591845|DRUG|Ziresovir 500 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
218929592|NCT06591845|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
218929593|NCT06591845|DRUG|Moxifloxacin hydrochloride tablet 400 mg|Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
218929594|NCT06596161|DRUG|Iron sucrose|Receving iron
218929595|NCT06596161|DRUG|Placebo|Placebo
218929596|NCT06593808|PROCEDURE|Weaning from the incubator to open coat at a weight greater than or equal to 1400 grams|They will be dressed in a woolen hat and dress, wrapped in a blanket and placed in crib with preheated mattress.Vital signs will be monitored daily.Axillary temperature will be measured every 3 hours for the first 12 hours, if above or equal to 36.5°C it will be measured every 6 hours for the next 36 hours. If normothermia for 48 hours, the preheated mattress will be turned off and temperature monitoring will be continued every 3 hours for 24 hours.If greater than or equal to 36.5°C, thermal control will be continued every 8 hours for 48 hours, at the end of which time, if normothermic, care will be confirmed.If not it will be placed back in the crib with heated mattress.If temperature still below 36.5°C, an additional blanket will be placed and it will be rechecked after 2 hours.If it remains below 36.5°C, the infant will be placed under a radiant lamp and the temperature will be checked after 3 hours.If hypothermia persists, the infant will be transferred back to the incubator.
218929597|NCT06594861|OTHER|No intervention|No intervention.
218929598|NCT06599905|OTHER|Episodic Migraine (EM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
218929599|NCT06599905|OTHER|Chronic Migraine (CM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
218929600|NCT04370210|BEHAVIORAL|Questionnaires|Child of both groups enrolled, and their parents, must complete online questionnaires
218929601|NCT04852172|DRUG|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
218929602|NCT04852172|OTHER|D5 1/2NS|Saline
218929603|NCT06991504|BEHAVIORAL|Cervical Stabilization Exercises|The main goal of this training is to increase the strength and endurance of the deep cervical flexor and extensor muscles.
218929604|NCT06991504|BEHAVIORAL|vestibular exercises|Vestibular exercises are a training used in individuals with migraine to ensure balance and coordination.
218929605|NCT06991504|BEHAVIORAL|Classic cervical/ neck exercises|Classic cervical neck exercises including stretching and strengthening
219367013|NCT00643149|DRUG|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
219367014|NCT00643149|DRUG|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
219367015|NCT02036229|DRUG|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
219367016|NCT01763164|DRUG|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
219367017|NCT01763164|DRUG|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
219367018|NCT03806244|OTHER|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
218929606|NCT06669845|PROCEDURE|Ultrasonography, Pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
218929607|NCT06993077|OTHER|environment Exposure|No special intervention
218929608|NCT06992479|DEVICE|high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)|"The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.~The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6"
218929609|NCT06992479|DEVICE|NIV routine treatment|Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.
218929610|NCT06518057|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
218929611|NCT06518057|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
218929612|NCT06518057|OTHER|Electronic Health Record Review|Ancillary studies
218929613|NCT06518057|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218929614|NCT06518057|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218929615|NCT06518057|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218929616|NCT06518057|RADIATION|Proton Beam Craniospinal Irradiation|Undergo proton CSI
218929617|NCT06518057|OTHER|Survey Administration|Ancillary studies
218929618|NCT06518057|RADIATION|Volume Modulated Arc Therapy|Undergo photon VMAT CSI
219540713|NCT02741687|DRUG|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
218929619|NCT06518057|PROCEDURE|Hippocampal-Avoidance Craniospinal Irradiation|Undergo HA
218929620|NCT06612788|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
218929621|NCT04574960|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle
218929622|NCT04574960|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle
218929623|NCT04574960|DRUG|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
218929624|NCT06175104|BEHAVIORAL|HeartGPS|"HeartGPS includes three key components:~1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
218929625|NCT06707493|DRUG|Ivosidenib|Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.
218929626|NCT06707493|DRUG|Placebo|Placebo tablets are taken orally.
218929627|NCT06716866|DEVICE|temporally-interfering electric field stimulation|Temporally-interfering electric field stimulation is a candidate non-invasive means to stimulate and modulate the nervous system. We do not know of any other trials of this method in epilepsy patients.
218929628|NCT05560607|DRUG|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
218929629|NCT07046221|DRUG|Tislelizumab|200mg，d1，q3w，1years
218929630|NCT07046221|DRUG|Albumin-Bound Paclitaxel|125mg/m2，d1，d8，q3w，2cycles
218929631|NCT07046221|DRUG|cis-platinum|75mg/m2，d1，q3w，2cycles
218929632|NCT07046221|PROCEDURE|Surgery|Radical resection of esophageal cancer
218929633|NCT07046221|RADIATION|Radiation|50.5Gy/28f
218929634|NCT07046221|DRUG|Nedaplatin|80-100mg/m2，d1，q3w，2cycles
218929635|NCT07046221|DRUG|Carboplatin|AUC=5，d1，q3w，2cycles
218929636|NCT06736262|DRUG|Briquilimab|No additional details needed
218929637|NCT06891417|BIOLOGICAL|Chlamydia mRNA Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration:~Intramuscular injection"
218929638|NCT06891417|OTHER|Placebo|"Pharmaceutical Form:~Solution for injection~Route of Administration:~Intramuscular injection"
219620663|NCT02690038|DRUG|Intravenous immunoglobulin (IVIG)|"Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
219044204|NCT00885833|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
219540714|NCT02741687|DRUG|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
219620664|NCT02690038|DRUG|Normal Saline|"Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
219620665|NCT03203200|BEHAVIORAL|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
219044205|NCT03932396|OTHER|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
219044206|NCT00223106|DEVICE|Vaginal Sling|
219044207|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
219044208|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
219044209|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
219620666|NCT06891612|BEHAVIORAL|Cognitive Assessments|Cognitive Assessments
219620667|NCT06891612|DEVICE|Eye-tracking|measurement of the points of gaze
219620668|NCT06891612|DEVICE|Electroencephalography (EEG)|Electrophysiological monitoring method to record electrical activity of the brain
219620669|NCT06891612|DEVICE|Electrocardiography (ECG)|measurement of the electrical activity of the heart
219620670|NCT05451628|DEVICE|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
219620671|NCT05451628|DEVICE|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
219620672|NCT05134311|DEVICE|PIUR tUS Imaging System|PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
219620673|NCT06741553|DRUG|Lecanemab 10 mg/kg|Lecanemab was administered 10mg/kg every two weeks.
219620674|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
219620675|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
219620676|NCT03481582|DRUG|Nitroglycerin|(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
219620677|NCT03481582|DEVICE|Three dimensional power doppler|Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
219620678|NCT02922127|DRUG|Ulipristal Acetate|Daily use of Ulipristal Acetate
219620679|NCT02922127|DRUG|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
219620680|NCT03817827|OTHER|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
219620681|NCT03817827|DIETARY_SUPPLEMENT|Diet supplementary|Diet supplementary with soy product
219620682|NCT00577603|PROCEDURE|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
219620683|NCT00577603|OTHER|no intervention|
219620684|NCT03196336|OTHER|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
219620685|NCT05446779|DIAGNOSTIC_TEST|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
219620686|NCT05446779|DIAGNOSTIC_TEST|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
219620687|NCT05446779|DIAGNOSTIC_TEST|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
219620688|NCT01595347|DRUG|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
219620689|NCT01595347|OTHER|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
219620690|NCT06007235|DEVICE|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
219620691|NCT06007235|DRUG|Placebo|Saline solution in identical spray bottles
219620692|NCT04740918|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
219620693|NCT04740918|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
219620694|NCT04740918|OTHER|Placebo|Placebo matched to atezolizumab
219620695|NCT03626038|DEVICE|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
218929639|NCT06740747|DEVICE|Intermittent theta-burst stimulation|Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
218929640|NCT06740747|DEVICE|Sham intermittent theta-burst stimulation|Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
218929641|NCT06746116|DRUG|Durvalumab + Chemotherapy phase|Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.
218929642|NCT06746116|DRUG|Durvalumab + Olaparib phase|durvalumab (IV) with olaparib (tablets) every four weeks until progression.
218929643|NCT07054723|BEHAVIORAL|Mobile Daily Diary|This study will include a 14-day daily diary survey in which participants will be expected to complete morning (\~5 minutes) and night (\~10 minutes) assessments using mobile phones provided by the research team.
218929644|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a well-established trauma treatment for children ages 3-17 years that demonstrates improved outcomes relative to other active treatments. Originally developed for treatment of childhood sexual abuse, evidence from numerous randomized clinical trials (RCT) demonstrates that TF-CBT is one of the most effective treatments for children with PTSD and/or depression resulting from many forms of child abuse and neglect as well as other traumatic experiences.TF-CBT is rated by California Evidence-Based Clearinghouse for Child Welfare as highly relevant for child welfare and well-supported in improving children's outcomes, including reduced PTSD symptoms, behavior problems, depression, and shame, and improving parental support related to their children's experiences.
218929645|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) augmented with Socialization (S)|The study will compare standard TF-CBT with TF-CBT augmented with Socialization enhancements. TF-CBT+S includes enhancements to address socioecological stress and trauma and provide coping strategies to support positive socialization.
218929646|NCT07057882|BEHAVIORAL|Health Belief Model-based Education|The intervention is a structured educational program based on the Health Belief Model (HBM), developed to improve health perception and reduce risky behaviors among international university students. The program includes six weekly sessions lasting approximately 45 minutes each, delivered face-to-face in small groups. The training content is tailored to address perceived susceptibility, severity, benefits, barriers, and self-efficacy related to health behaviors. Interactive discussions, visual materials, and culturally sensitive examples are used. Participants in the intervention group receive this training in addition to usual care or routine university services..
218929647|NCT07059637|OTHER|Multidisciplinary clinic evaluation|The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalizations, COPD exacerbations, or mortality. The approach is different than standard of care COPD treatment because it is informed by quantifying muscle mass and strength (through handgrip strength and bio-impedance) and have strong collaborations with nutrition and pulmonary rehabilitation.
218929648|NCT07059637|OTHER|COPD standard of care|Standard COPD care treatment in an ambulatory post-hospital follow up clinic
218929649|NCT07068477|BEHAVIORAL|Values Assessment Tool|The Values Assessment Tool was provided to the participants at baseline and every clinic visit for 3 months
218929650|NCT07068594|DEVICE|Virtual Reality Goggles|A device consisting of glasses placed on the head of patients in the intervention group and earphones attached to the glasses
218929651|NCT07064928|BEHAVIORAL|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 for the Ghanaian context, and among pregnant and/or postpartum women living with HIV
218929652|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
218929653|NCT07063563|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
218929654|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
218929655|NCT07068555|BIOLOGICAL|Immunomodulatory DC vaccines to target prostate cancer|1 to 2 injections, with an interval of one month, of 1\~2x10\^7 DC vaccine administered subcutaneously
218929656|NCT07072611|DRUG|SOF-SKN 0.25%|cream for topical application
218929657|NCT07072611|DRUG|SOF-SKN 0.5%|cream for topical application
218929658|NCT07072611|DRUG|SOF-SKN 1%|cream for topical application
218929659|NCT07072611|DRUG|SOF-SKN 2%|cream for topical application
218929660|NCT07072611|DRUG|Placebo|cream for topical application
218929661|NCT06956040|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year to depict suspicious lung nodules
219540715|NCT02741687|DRUG|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
218929662|NCT05784844|DRUG|Meropenem|Carbapenem antibiotic
218929663|NCT05784844|DRUG|Micafungin|Echinocandin antifungal
218929664|NCT01590888|DRUG|PBT2|250mg capsules administered orally once per day for 26 weeks
218929665|NCT01590888|DRUG|PBT2|100mg capsules administered orally once per day for 26 weeks
218929666|NCT01590888|DRUG|Placebo|Matching capsules administered orally once per day for 26 weeks
218929667|NCT00532610|DRUG|GSK189075|
219540716|NCT02741687|DRUG|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
218929668|NCT00458172|BEHAVIORAL|Assessment of beliefs and attitudes|
218929669|NCT02462135|BEHAVIORAL|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
218929670|NCT02462135|BEHAVIORAL|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
219044210|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
219044211|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
219044212|NCT02051465|DEVICE|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
219044213|NCT02051465|DEVICE|Removal without overtube|Endoscopic removal of polyp without overtube
218929671|NCT01136980|DEVICE|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
218929672|NCT01136980|OTHER|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
218929673|NCT02103673|DRUG|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
218929674|NCT02103673|DRUG|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
218929675|NCT02109185|DRUG|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
218929676|NCT02109185|DRUG|Nasonex® Nasal Spray, 50 μg/actuation|
218929677|NCT02109185|DRUG|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
218929678|NCT02109185|DRUG|Placebo Nasal Spray, 50 μL/actuation|
218929679|NCT03240549|DRUG|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
218929680|NCT02042274|DIETARY_SUPPLEMENT|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
218929681|NCT00124553|BEHAVIORAL|Intensive dietary advice|
218929682|NCT06517004|BIOLOGICAL|JWCAR201|Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
218929683|NCT00145808|DEVICE|Given® Diagnostic System|
218929684|NCT05760469|OTHER|Screening|Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
218929685|NCT02941718|BEHAVIORAL|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
218929686|NCT02941718|BEHAVIORAL|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
218929687|NCT04528966|OTHER|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
218929688|NCT04528966|OTHER|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
218929689|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
218929690|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
218929691|NCT00913952|DRUG|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
218929692|NCT02675673|PROCEDURE|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
218929693|NCT02675673|PROCEDURE|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
218929694|NCT04004195|DRUG|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
218929695|NCT01571687|DIETARY_SUPPLEMENT|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
218929696|NCT01571687|DIETARY_SUPPLEMENT|Placebo|Intake of 6 identically appearing tablets daily containing placebo
218929697|NCT01732718|DRUG|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
218929698|NCT01732718|DRUG|Placebo|Matching placebo tablet by mouth daily for 6 weeks
218929699|NCT02111759|PROCEDURE|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
218929700|NCT02111759|PROCEDURE|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
218929701|NCT02569749|OTHER|Berlin and Epworth questionaries|
218929702|NCT02569749|OTHER|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
218929703|NCT02569749|OTHER|Night polygraph / Polysomnography|
218929704|NCT01734603|PROCEDURE|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
219540717|NCT03413202|DRUG|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
218929705|NCT01734603|PROCEDURE|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
218929706|NCT06405724|DRUG|Liposomal bupivacaine|133mg LB 20mL thoracic paravertebral nerve block
218929707|NCT06405724|DRUG|Ropivacaine|0.5% ropivacaine 20mL thoracic paravertebral nerve block
218929708|NCT04115865|DEVICE|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
218929709|NCT04052152|DRUG|Anlotinib and Sintilimab injection|Patients will be treated with Anlotinib and Sintilimab injection
218929710|NCT02617472|DEVICE|Pelvic floor exerciser|Daily exercise using the study device
218929711|NCT06119139|DRUG|3.6 ml 4% Articaine hydrochloride|3.6 ml 4% articaine buccal infiltration
218929712|NCT06119139|DRUG|1.8 ml 4% Articaine hydrochloride|1.8 ml 4% articaine buccal infiltration
218929713|NCT02561468|DRUG|Nefopam|
218929714|NCT02561468|DRUG|Saline|
218929715|NCT03485872|OTHER|Self-Screening and Referral Information|Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
218929716|NCT03485872|OTHER|Standard Care|Demographic and quality of life questionnaires; standard care provided by participants' GPs
218929717|NCT01041963|DRUG|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
218929718|NCT01041963|DRUG|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
218929719|NCT01041963|DRUG|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
218929720|NCT00809302|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
219540718|NCT03413202|DRUG|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
219540719|NCT03264092|PROCEDURE|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
219540720|NCT00062296|BIOLOGICAL|rituximab|
219540721|NCT00062296|DRUG|epirubicin hydrochloride|
219540722|NCT00440063|DRUG|epoetin beta [NeoRecormon]|
218929721|NCT05494164|OTHER|Nigella sativa nasal oil drops|in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
218929722|NCT05494164|DRUG|standard treatment|intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
219540723|NCT01920334|DRUG|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
219540724|NCT01920334|DRUG|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
218929723|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and Montanide ISA51|
219044214|NCT04374877|DRUG|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
219540725|NCT00253838|PROCEDURE|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
219540726|NCT00253838|PROCEDURE|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
219540727|NCT00429221|BEHAVIORAL|Tailored Medication Messages for Parents|
219540728|NCT01963663|DRUG|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
219540729|NCT01963663|DRUG|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
219540730|NCT01105299|DRUG|CJ anastrozole 1 mg tablet|
219540731|NCT04197908|DEVICE|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
218929724|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and CpG 7909|
218929725|NCT06048640|DIETARY_SUPPLEMENT|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
219540732|NCT05936554|DEVICE|whole body vibration|to improve muscle power and balance.
219540733|NCT05936554|OTHER|Functional strength training|used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
219540734|NCT01205035|DRUG|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
219540735|NCT01044823|OTHER|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
219540736|NCT00443274|OTHER|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
219540737|NCT00443274|DEVICE|410 Arm|Anatomically shaped silicone gel-filled breast implants.
219540738|NCT00443274|DEVICE|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
219540739|NCT04492696|OTHER|Education|Education
219620696|NCT07061899|DIAGNOSTIC_TEST|Anal swap for Chlamydia and Gonorrhoea|"If inflammation is observed on endoscopy up to 35 cm from the anal opening, a swab will be taken during the procedure to test for Chlamydia and Gonorrhoea using standard PCR techniques. If the swab is not taken during the endoscopy, it will be collected during a follow-up outpatient visit. The tests will be analysed immediately at the Department of Microbiology, Aarhus University Hospital.~If positve, the patient will be offered treatment at the department of Venerological diseases."
219044215|NCT04374877|DRUG|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
219044216|NCT04374877|DRUG|Toripalimab|Toripalimab by IV infusion
219044217|NCT03681457|DRUG|LJN452|Dose A single dose
219044218|NCT00323414|DRUG|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
219540740|NCT01774058|DRUG|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
219044219|NCT00323414|DRUG|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
219044220|NCT04087122|DEVICE|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
219044221|NCT05521204|DRUG|Olverembatinib|Given PO
219540741|NCT04672538|PROCEDURE|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
219540742|NCT04672538|PROCEDURE|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
219540743|NCT00109512|DRUG|NBI-56418 (GnRH antagonist)|
219540744|NCT00109512|DRUG|placebo|
219540745|NCT04943549|DRUG|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
219540746|NCT00943033|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
219620697|NCT06275438|OTHER|The delivery being performed via cesarean section surgery rather than natural childbirth|At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
219620698|NCT04784611|BEHAVIORAL|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
219620699|NCT02524847|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
219620700|NCT02524847|PROCEDURE|Extracorporeal Photopheresis (ECP)|
219620701|NCT00254709|DRUG|Sirolimus|
219620702|NCT04352101|DRUG|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
219620703|NCT04352101|DRUG|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
219620704|NCT01943383|GENETIC|iPSC|Single blood draw for the production of induced pluripotent stem cells.
219620705|NCT04016454|PROCEDURE|Intervention|There will be one complete handover
219620706|NCT00782054|OTHER|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
219620707|NCT00782054|OTHER|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
219620708|NCT02692859|BIOLOGICAL|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
219620709|NCT01930682|DRUG|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
219620710|NCT01930682|PROCEDURE|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
219620711|NCT01930682|PROCEDURE|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
219620712|NCT02794727|DEVICE|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
219620713|NCT02794727|DEVICE|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
219620714|NCT00842673|DRUG|ST101|30 mg; administered once/day
219620715|NCT00842673|DRUG|ST101|90 mg; administered once/day
219620716|NCT00842673|DRUG|ST101|180 mg; administered once/day
219620717|NCT00842673|DRUG|Placebo|placebo to match ST101 tablets
219620718|NCT01268527|DRUG|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620719|NCT01268527|DRUG|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620720|NCT01268527|DRUG|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620721|NCT01268527|DRUG|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620722|NCT01268527|DRUG|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620723|NCT01268527|DRUG|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
219620724|NCT01268527|OTHER|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620725|NCT01268527|OTHER|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620726|NCT01268527|OTHER|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620727|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620728|NCT01268527|OTHER|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620729|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
219620730|NCT01268527|DRUG|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
219044222|NCT03628911|DEVICE|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
219044223|NCT03129516|BEHAVIORAL|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
219044224|NCT02552316|DEVICE|NB-UVB Phototherapy|
219044225|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
219044226|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
219620731|NCT03952182|OTHER|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
219620732|NCT03952182|OTHER|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
219620733|NCT05148091|BIOLOGICAL|SCTV01C|A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
219620734|NCT05148091|OTHER|Adjuvant|SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
219620735|NCT05148091|OTHER|Saline|Saline is used as the other control in the trial
219620736|NCT02205463|DRUG|KD019|
219620737|NCT00870844|DRUG|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
219620738|NCT00870844|DRUG|Placebo|Vials with solution for IV infusion
219620739|NCT05484492|BIOLOGICAL|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
219620740|NCT05484492|BIOLOGICAL|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
219620741|NCT03992521|GENETIC|Nucleosome positioning|Stratification of patients based on nucleosome positioning from plasma DNA.
219620742|NCT02279966|DRUG|Vortioxetine 10 mg|
219620743|NCT02279966|DRUG|Paroxetine 20 mg|
219044227|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
219044228|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
219044229|NCT02659020|DRUG|Olaratumab|Administered IV
219044230|NCT02659020|DRUG|Gemcitabine|Administered IV
219044231|NCT02659020|DRUG|Docetaxel|Administered IV
219044232|NCT02659020|DRUG|Placebo|Administered IV
219044233|NCT00222547|DRUG|Vitamin A|
219540747|NCT05634941|DEVICE|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
219620744|NCT02279966|DRUG|Placebo|
219620745|NCT01288079|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
218929726|NCT04198051|DRUG|adjuvant chemotherapy|"Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months."
218929727|NCT01888302|DRUG|Cisplatin|Given IV
218929728|NCT01888302|DRUG|Gemcitabine Hydrochloride|Given IV
218929729|NCT01888302|OTHER|Quality-of-Life Assessment|Ancillary studies
218929730|NCT01888302|DRUG|Sirolimus|Given PO
218929731|NCT00847509|DRUG|[F-18]FLT|The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
218929732|NCT02223702|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
218929733|NCT02223702|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
218929734|NCT02223702|DRUG|Moxifloxacin|400 mg, once in a day for 7 days.
218929735|NCT06333119|DIAGNOSTIC_TEST|modified rankin scale|"Modified Rankin Scale: The functional status of individuals with stroke is determined by this scale.~Modified Ashworth Scale: It allows determining the severity of spasticity. Tinetti Balance and Gait Scale: This scale helps determine the risk of falling by evaluating balance and gait.~Danish Prostatic Symptom Score: It allows to evaluate the storage and urinary functions of the bladder."
218929736|NCT01705509|DRUG|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
219540748|NCT05634941|DEVICE|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
218929737|NCT01227018|DRUG|STA-9090|Given IV
218929738|NCT01227018|RADIATION|Radiologic imaging|radiologic modalities used to evaluate response to treatment
218929739|NCT01227018|PROCEDURE|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
219540749|NCT05173246|DRUG|JS001|JS001 240mg, ivdrip, d1, Q3w
219620746|NCT01288079|DRUG|Duloxetine|Capsule, oral, once daily
219620747|NCT01288079|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
219620748|NCT03696290|DRUG|Aztreonam lysine|Nebulised aztreonam lysine 75mg
218929740|NCT05922800|DEVICE|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
218929741|NCT05922800|DRUG|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
218929742|NCT00190151|DRUG|ciprofloxacin|
218929743|NCT05273671|DRUG|Nalbuphine|will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
218929744|NCT05273671|DRUG|Dexmedetomidine|will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
218929745|NCT05273671|DRUG|normal Saline|will receive with a saline solution 10 min before the end of surgery
219620749|NCT03696290|OTHER|Placebo|Nebulised lactose monohydrate 5mg
219620750|NCT00815464|DEVICE|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
219620751|NCT01530464|DRUG|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
219620752|NCT01530464|DRUG|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
219620753|NCT01530464|DRUG|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
219620754|NCT01132833|OTHER|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
219620755|NCT01132833|OTHER|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
219620756|NCT01132833|OTHER|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
219620757|NCT01036854|DRUG|EUR-1025|orally, 24 mg, daily for 6 days
218929746|NCT03921645|DRUG|aerosol antibiotics|use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
219540750|NCT05173246|DRUG|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
218929747|NCT00921167|DRUG|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
218929748|NCT02164409|PROCEDURE|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
219540751|NCT05173246|DRUG|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
218929749|NCT03613064|OTHER|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
218929750|NCT03511196|DRUG|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
218929751|NCT03511196|DRUG|Abiraterone|Prednisone 5 mg once a day with food.
218929752|NCT03511196|DRUG|Prednisone|Abiraterone 1000 mg daily with empty stomach.
218929753|NCT06957600|PROCEDURE|Preoperative marking|Applying markings prior to uniport VATS wedge resections helps localize small, potentially early-stage lung tumors. After marking, the patients are positioned laterally and receive general anesthesia with single-lung ventilation. The investigators perform VATS wedge resection using uniportal techniques. The utility incision is made in the 5th intercostal space between the anterior and mid-axillary lines. Insufflation is not typically utilized. The lesion is localized, elevated, and confirmed by palpation. The investigators then staple around the lesion using the Endo GIA™ ultra universal stapler with an Articulating Reload featuring Tri-Staple™ Technology in 45 or 60 mm lengths, choosing purple or black loads based on parenchyma thickness. Finally, the investigators close the wound and place one chest drain in the thoracic cavity, set to active suction of 5-10 cm of water.
218929754|NCT06257433|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
218929755|NCT03956654|DRUG|Ribociclib|combination of ribociclib and letrozole
218929756|NCT04068753|DRUG|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
218929757|NCT04068753|DRUG|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
219540752|NCT05173246|DRUG|Carboplatin|Carboplatin AUC 5,d1,Q3w
219540753|NCT06099340|OTHER|muscle-strengthening program|a muscle-strengthening program applied to the ankle muscles (triceps surae and dorsal flexors) in physiotherapy, as a complement to conventional rehabilitation
219540754|NCT05428943|DRUG|OPT101|15-mer peptide derived from the sequence of mouse CD154.
219540755|NCT03904563|DRUG|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
219540756|NCT03904563|RADIATION|chest radiation|split-course chest radiation
219540757|NCT03904563|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
219540758|NCT04665375|DRUG|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
219540759|NCT03949426|DRUG|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
219540760|NCT05180253|DIAGNOSTIC_TEST|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
218929758|NCT03935958|DIETARY_SUPPLEMENT|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
218929759|NCT03935958|OTHER|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
218929760|NCT04858048|PROCEDURE|Anesthesia|2 types of anesthesia (general and WALANT) performed during the surgery
218929761|NCT03227640|PROCEDURE|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
219044234|NCT00222547|DRUG|Albendazole|
219044235|NCT03950518|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
219044236|NCT03950518|DRUG|Arginine hydrochloride|AHC,12mg/d AH,40g/d
219044237|NCT03950518|DRUG|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
219044238|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
219044239|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
219044240|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
219044241|NCT03164967|BIOLOGICAL|Bivigam|
219044242|NCT06406530|PROCEDURE|PRF|Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.
219044243|NCT06406530|PROCEDURE|Natural Healing|After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
219044244|NCT04382911|DRUG|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
219540761|NCT05381688|PROCEDURE|VIM DBS|Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
219540762|NCT03019367|PROCEDURE|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
219540763|NCT03019367|PROCEDURE|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
219540764|NCT00139594|DRUG|licarbazepine|
219540765|NCT02861560|OTHER|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
219620758|NCT01036854|DRUG|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
219620759|NCT01036854|DRUG|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
219620760|NCT01036854|DRUG|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
219620761|NCT04579354|OTHER|virtual reality tour|Patients will be guided via VR on their way through the hospital to the operating theater
218929762|NCT03227640|DEVICE|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
218929763|NCT04245865|DRUG|Fluorouracil|2800 mg/m2 iv
218929764|NCT04245865|DRUG|Calcium folinate|400 mg/m2 iv
218929765|NCT04245865|DRUG|Oxaliplatin|85 mg/m2 iv
219044245|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
219620762|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
219540766|NCT03829397|DIAGNOSTIC_TEST|Questionnaire|Questionnaire
219044246|NCT05996120|PROCEDURE|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
219044247|NCT05996120|PROCEDURE|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
219044248|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
219540767|NCT02957994|DRUG|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
219540768|NCT01269086|BEHAVIORAL|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
219540769|NCT00211263|BEHAVIORAL|Enhanced Clinical Intervention|
219540770|NCT00211263|DRUG|mood stabilizer|
219620763|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
219540771|NCT06223763|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
219540772|NCT06223763|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
218929766|NCT04245865|DRUG|Bevacizumab|5 mg/kg OR 7.5 mg/kg iv
219044249|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
219044250|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
219044251|NCT04059848|COMBINATION_PRODUCT|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
219044252|NCT04059848|COMBINATION_PRODUCT|NMES(Enraf Nonius, Endomed-182, Netherlands)|
219540773|NCT06223763|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
219620764|NCT02806882|DRUG|Ceftaroline fosamil|600mg IV infusion
219620765|NCT04492982|BEHAVIORAL|Yoga|1 hour of group format, guided yoga practice
219620766|NCT04492982|BEHAVIORAL|Distress Tolerance|1 hour didactic group format, to develop distress tolerance skills
219620767|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Treatment Team|The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).
219620768|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Patients|The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.
219620769|NCT06575582|BEHAVIORAL|Training for Digital Navigators|The training takes place in the six study centers and is preferably aimed at medical assistants.
218929767|NCT04245865|DRUG|Capecitabine|2000 mg/m2 orally daily for two weeks
218929768|NCT04245865|DIETARY_SUPPLEMENT|Tocotrienol|300 mg orally x 3 daily
218929769|NCT04245865|OTHER|Placebo|Placebo orally x 3 daily
218929770|NCT00753649|BIOLOGICAL|Infanrix™ hexa|Intramuscular, three doses
218929771|NCT00499616|DRUG|carboplatin|Given IV
218929772|NCT00499616|DRUG|cyclophosphamide|Given IV
218929773|NCT00499616|DRUG|doxorubicin hydrochloride|Given IV
218929774|NCT00499616|DRUG|etoposide|Given orally
218929775|NCT00499616|DRUG|topotecan hydrochloride|Given IV
218929776|NCT00499616|DRUG|Isotretinoin|Given orally
218929777|NCT00499616|PROCEDURE|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
219044253|NCT00006012|BIOLOGICAL|filgrastim|
219044254|NCT00006012|DRUG|amifostine trihydrate|
219044255|NCT00006012|DRUG|cisplatin|
219620770|NCT02205073|DRUG|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
219620771|NCT02205073|DRUG|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
218929778|NCT00499616|DRUG|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
218929779|NCT04531930|PROCEDURE|surgery|Colorectal surgery, mainly total proctocolectomy.
218929780|NCT04531930|PROCEDURE|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
218929781|NCT04531930|OTHER|self choosed methods|A patient chooses a method for himself other than surgery.
218929782|NCT02569788|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
218929783|NCT04233723|OTHER|peripheral blood samples|venous puncture
218929784|NCT00067730|DRUG|Drotrecogin Alfa (activated)|
218929785|NCT00045617|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
218929786|NCT00045617|BIOLOGICAL|monoclonal antibody GD2 anti-idiotype vaccine|
218929787|NCT00045617|DRUG|cisplatin|
218929788|NCT00045617|DRUG|etoposide|
219540774|NCT01342263|BEHAVIORAL|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
218929789|NCT00045617|RADIATION|radiation therapy|
218929790|NCT03108469|DRUG|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
218929791|NCT03108469|OTHER|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
218929792|NCT01189409|DRUG|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
218929793|NCT01189409|DRUG|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
218929794|NCT04150848|BEHAVIORAL|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
218929795|NCT04150848|BEHAVIORAL|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
218929796|NCT01938716|DRUG|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
218929797|NCT00697138|DRUG|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
218929798|NCT06001957|DIAGNOSTIC_TEST|Whole exome sequencing|"Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described.~Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer."
219540775|NCT02297763|DRUG|quetiapine|"patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
219540776|NCT02297763|DRUG|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
218929799|NCT00859911|DIETARY_SUPPLEMENT|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
218929800|NCT02238652|BEHAVIORAL|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
219044256|NCT00006012|DRUG|etoposide|
219044257|NCT00006012|DRUG|paclitaxel|
219044258|NCT00006012|DRUG|topotecan hydrochloride|
218929801|NCT02238652|BEHAVIORAL|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
218929802|NCT02238652|BEHAVIORAL|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
218929803|NCT02238652|BEHAVIORAL|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
218929804|NCT02238652|BEHAVIORAL|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
218929805|NCT00737815|DIETARY_SUPPLEMENT|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
218929806|NCT00737815|OTHER|Placebo|Inactive placebo pill
218929807|NCT05305404|DRUG|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
218929808|NCT05305404|DRUG|Placebo|oral placebo to be administered once at 11:00PM
218929809|NCT04884178|DEVICE|Trifocal Preloaded IOL Delivery System|UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.
219044259|NCT00006012|RADIATION|radiation therapy|
219044260|NCT02827058|DEVICE|G25 pencil point needle|
219044261|NCT02827058|DEVICE|G27 pencil point needle|
219044262|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
219044263|NCT01312584|DIETARY_SUPPLEMENT|Processed High-flavanol|
219044264|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
218929810|NCT05297981|PROCEDURE|Erector spinae plane block|The patient will be placed in lateral decubitus position. A high frequency linear probe of a transportable Fuji M-Turbo ultrasound system will be placed on the spinous process at T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the inplane technique,then 0.5 ml/kg of 0.25% bupivacaine will be injected between the muscle and transverse process. The same procedure will be performed bilaterally.
219044265|NCT05892510|DRUG|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
219540777|NCT01986491|DRUG|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
219540778|NCT01986491|DRUG|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
219540779|NCT01986491|DRUG|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
219540780|NCT01986491|DRUG|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
219540781|NCT01986491|DRUG|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
219540782|NCT04033276|DRUG|Rituximab|IV rituximab
219540783|NCT04033276|DRUG|intravenous immune globulin|iv intravenous immune globulin
219540784|NCT03931460|DRUG|Medical Abortion|Medical Abortion
219540785|NCT00392665|DRUG|Bevacizumab|Given intravenously on day one of each 3 week cycle
219540786|NCT00392665|DRUG|erlotinib|Given orally once a day
219540787|NCT00392665|DRUG|Sulindac|Given orally twice a day
219540788|NCT04677075|PROCEDURE|mastectomy|mastectomy either simple or modified radical
219540789|NCT02283463|DEVICE|Intrauterine device (IUD) insertion|
219540790|NCT02283463|PROCEDURE|Endometrial biopsy|
219540791|NCT05765708|OTHER|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
219540792|NCT05765708|DIAGNOSTIC_TEST|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
219540793|NCT04050254|DEVICE|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
219540794|NCT04050254|DEVICE|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
219540795|NCT04050254|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
219540796|NCT00109265|DRUG|Erlotinib HCl (OSI-774)|
219540797|NCT05514392|DEVICE|HP Cosmos Torqoalizer|Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
219540798|NCT00952250|BEHAVIORAL|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
219540799|NCT00952250|BEHAVIORAL|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
219540800|NCT02856386|DIETARY_SUPPLEMENT|polyphenol supplement|8 mL once daily
219540801|NCT05039112|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
219540802|NCT05039112|DEVICE|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
219620772|NCT02205073|DRUG|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
219044266|NCT05892510|DRUG|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
219044267|NCT04569500|OTHER|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
219540803|NCT04306107|DEVICE|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
219540804|NCT02778321|DEVICE|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
219540805|NCT00927069|DRUG|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
219540806|NCT00927069|DRUG|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
219620773|NCT02603289|DEVICE|Invisalign|
218929811|NCT05297981|PROCEDURE|Quadratus lumborum block|The patient will be placed in the lateral decubitus position. A low frequency curved probe of a transportable Fuji M-Turbo ultrasound system will be placed horizontally in the anterior axillary line midway between the subcostal margin and the iliac crest to identify the triple abdominal muscle layers.A 22-G, 80-mm needle echogenic needle will be inserted in plane relative to the US probe, into the posterior aspect of the QL muscle (between QL and erector spinae muscle); this is known as QLB type 2. Then, 0.5 ml/kg of 0.25% bupivacaine will be injected behind the muscle as a bolus dose. The block will be performed bilaterally.
218929812|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
218929813|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
218929814|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
218929815|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
218929816|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
218929817|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
218929818|NCT00933452|DRUG|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
218929819|NCT00933452|DRUG|duloxetine|15mg, oral administer
218929820|NCT00933452|DRUG|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
218929821|NCT04316819|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
218929822|NCT06514768|BIOLOGICAL|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
219540807|NCT02022254|DRUG|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
218929823|NCT04441086|BEHAVIORAL|eMotion|Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
218929824|NCT04441086|BEHAVIORAL|Healthy Living Active Control|The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
218929825|NCT03683459|DEVICE|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
218929826|NCT00372593|DRUG|asparaginase|Given intramuscularly
218929827|NCT00372593|DRUG|cytarabine|Given IV
218929828|NCT00372593|DRUG|daunorubicin hydrochloride|Given IV over 6 hours
218929829|NCT00372593|DRUG|etoposide|Given IV over 1-4 hours
218929830|NCT00372593|DRUG|gemtuzumab ozogamicin|Given IV over 2 hours
218929831|NCT00372593|DRUG|mitoxantrone hydrochloride|Given IV over 1 hour
218929832|NCT01994824|DRUG|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
218929833|NCT03623529|DRUG|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
218929834|NCT03623529|DRUG|Placebo|Placebo Arm
218929835|NCT00433004|DRUG|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
218929836|NCT03180918|PROCEDURE|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
218929837|NCT03534180|OTHER|Laboratory Biomarker Analysis|Correlative studies
219540808|NCT02022254|DRUG|placebo|Semaglutide placebo will be administered s.c.
218929838|NCT03534180|DRUG|Romidepsin|Given IV
219540809|NCT02022254|DRUG|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
219540810|NCT02022254|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
219620774|NCT04808674|BEHAVIORAL|Cognitive remediation program|Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer
218929839|NCT03534180|DRUG|Venetoclax|Given PO
218929840|NCT01169818|DRUG|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
219620775|NCT03687320|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
219620776|NCT03687320|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
219620777|NCT06275373|DRUG|Teprotumumab Injection [Tepezza]|IGF1 monoclonal antibody
218929841|NCT00330967|DRUG|20% Intralipid|lipid infusion
218929842|NCT00539942|DRUG|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
218929843|NCT00539942|DEVICE|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
219540811|NCT02622737|OTHER|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
219540812|NCT02622737|DEVICE|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
219540813|NCT02622737|DEVICE|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
218929844|NCT01970098|DRUG|KPS-0373, High dose|28 weeks
218929845|NCT01970098|DRUG|KPS-0373, Low dose|28 weeks
218929846|NCT01970098|DRUG|Placebo|28 weeks
218929847|NCT05828485|DRUG|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
218929848|NCT05167643|DRUG|Enituzumab injection+Abesili tablets+Anastrozole tablets|According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
218929849|NCT02616588|BEHAVIORAL|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
218929850|NCT04065737|DRUG|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
218929851|NCT02685332|RADIATION|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30"
218929852|NCT06167733|DEVICE|VERTICA Active device|VERTICA device with a therapeutic RF energy level
218929853|NCT06167733|DEVICE|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
218929854|NCT00751517|DRUG|Methotrexate|
218929855|NCT00751517|DRUG|Cyclophosphamide|
218929856|NCT03745521|OTHER|no intervention|no intervention
218929857|NCT00880919|DRUG|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
218929858|NCT00880919|DRUG|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
218929859|NCT01291732|DRUG|Matching placebo|single dose of matching placebo
218929860|NCT01291732|DRUG|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
218929861|NCT03968562|DRUG|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
218929862|NCT03085602|BEHAVIORAL|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
218929863|NCT03085602|BEHAVIORAL|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
218929864|NCT06255431|DRUG|Ezerra cream|"The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen."
218929865|NCT00578825|DRUG|Lopinavir / Ritonavir plus Ribavirin|
218929866|NCT02578706|DRUG|Clopidogrel|Clopidogrel 75mg
218929867|NCT02578706|DRUG|Aspirin|81 mg
218929868|NCT02578706|DRUG|Placebo|
218929869|NCT00408200|DRUG|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
218929870|NCT00408200|DEVICE|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
219540814|NCT04244877|DRUG|Rifaximin|Drug: Rifaximin tablet
219540815|NCT04459260|BEHAVIORAL|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
219540816|NCT04459260|BEHAVIORAL|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
218929871|NCT03105752|OTHER|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
218929872|NCT03630445|OTHER|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
218929873|NCT03630445|OTHER|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
218929874|NCT03630445|OTHER|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
218929875|NCT03630445|OTHER|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
218929876|NCT03630445|OTHER|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
218929877|NCT05641259|DRUG|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
219044268|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
219044269|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
219044270|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
219044271|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
219540817|NCT04289532|DRUG|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
219540818|NCT02450682|DRUG|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
219540819|NCT02450682|DRUG|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
219540820|NCT00131391|DRUG|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
219540821|NCT00131391|DRUG|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
218929878|NCT05641259|DRUG|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
219044272|NCT01120210|DRUG|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
219044273|NCT01120210|DRUG|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
219044274|NCT01120210|DRUG|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
219044275|NCT01120210|DRUG|Placebo|1-hour infusion of matching placebo on Day 1
219044276|NCT01120210|DRUG|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
219620778|NCT00908544|OTHER|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
219620779|NCT00908544|OTHER|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
219620780|NCT00437567|DIETARY_SUPPLEMENT|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
219620781|NCT00437567|OTHER|Placebo|Similar quantity of sterile water to be added to milk
219620782|NCT02387840|DEVICE|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
219620783|NCT02387840|DEVICE|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
219620784|NCT03170544|DRUG|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
218929879|NCT03646552|DRUG|THX-110|"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."
218929880|NCT01576809|DRUG|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
218929881|NCT02015637|DRUG|Delafloxacin|single dose
219044277|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
219044278|NCT02995291|DRUG|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
219044279|NCT02995291|DRUG|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
219044280|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
219044281|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
219044282|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
219044283|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
219205301|NCT06787794|BEHAVIORAL|Virtual Reality-assisted hypnosis|"The VRH intervention consists of 6 interventional sessions. Every session, first, participants receive hypnotic induction and go through a deepening phase using a hypnotic script and a VR environment designed based on input from individuals suffering from chronic itch. To this end, participants are instructed to close their eyes while they will continue to listen to the recorded hypnotic script developed based on general hypnotic principles as amongst others described by Yapko (2013). Direct antipruritic suggestions are used such as your skin will feel so soft, relaxed and cool, it is fully at ease. After these standardized suggestions, the participants will be alerted again. Home exercises (ca 5 min/day) include guided self-hypnosis records with direct antipruritic suggestions comparable to the ones they listen to during the intervention at location."
219205302|NCT06787560|BIOLOGICAL|CD7 CAR-T cells injection|Each subject receive CD7 CAR T-cells by intravenous infusion
219205303|NCT06787560|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
218929882|NCT02015637|DRUG|Ceftriaxone|single dose
218929883|NCT03644004|OTHER|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
219044284|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
219044285|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
219044286|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
219044287|NCT02694419|DEVICE|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
219044288|NCT04784767|BIOLOGICAL|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
219044289|NCT04784767|DRUG|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
219044290|NCT04784767|BIOLOGICAL|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
218929884|NCT00619814|PROCEDURE|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
219540822|NCT03998605|BEHAVIORAL|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
218929885|NCT03085264|BEHAVIORAL|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
218929886|NCT02961829|DRUG|Maraviroc|antiretroviral intensification
218929887|NCT02961829|DRUG|Dolutegravir|antiretroviral intensification
218929888|NCT02961829|BIOLOGICAL|Dendritic Cell Vaccine|Therapeutic vaccination
219044291|NCT06105528|DRUG|PMN310|60-minute intravenous infusion
219044292|NCT06105528|DRUG|Placebo|60-minute intravenous infusion
219044293|NCT04114435|OTHER|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
218929889|NCT02961829|DRUG|Auranofin|purging
218929890|NCT02961829|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
218929891|NCT05298553|DEVICE|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
219044294|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
219044295|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
219044296|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
219540823|NCT03998605|BEHAVIORAL|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
218929892|NCT05298553|DEVICE|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
218929893|NCT00087867|DRUG|SCIO-469|two 30-mg capsules three times daily
218929894|NCT00087867|DRUG|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
218929895|NCT02354196|PROCEDURE|CCTA|CT of heart to assess coronary disease
218929896|NCT01855061|PROCEDURE|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
218929897|NCT01855061|PROCEDURE|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
218929898|NCT01855061|PROCEDURE|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
219620785|NCT03170544|DRUG|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
219620786|NCT03170544|DRUG|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
219620787|NCT03170544|DRUG|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
219620788|NCT03170544|DRUG|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
219620789|NCT03170544|DRUG|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
219620790|NCT03170544|DRUG|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.
219620791|NCT03170544|DRUG|Placebo to glargine|Placebo to glargine, SC, as a single dose
219620792|NCT03170544|DRUG|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
219620793|NCT03170544|OTHER|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
219620794|NCT03170544|BIOLOGICAL|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
219620795|NCT03745079|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
219620796|NCT03745079|OTHER|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
219620797|NCT03745079|OTHER|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
219620798|NCT03280238|DIAGNOSTIC_TEST|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
219620799|NCT00753038|BIOLOGICAL|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
219620800|NCT00753038|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
219620801|NCT00753038|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
218929899|NCT01855061|PROCEDURE|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
218929900|NCT06186843|BEHAVIORAL|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
218929901|NCT02922647|DEVICE|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
218929902|NCT02922647|DEVICE|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
219540824|NCT02558491|DEVICE|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation."
218929903|NCT01695304|OTHER|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
219620802|NCT04192643|DRUG|Tranexamic Acid 100 MG/ML|1 GR TRANEXAMİC ACİD İN 100 ML SALİNE SOLUTİON GİVEN İN 15 MİNUTES
219620803|NCT04192643|DRUG|Placebos|100 ML SALİNE SOLUTİON
219620804|NCT04273308|DEVICE|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
219620805|NCT02535403|BEHAVIORAL|ICBT|
219620806|NCT01354405|DRUG|Lanreotide|120 mg every 28 days intramuscular
219620807|NCT01689883|DEVICE|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
219620808|NCT03479398|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
219620809|NCT04600947|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
219620810|NCT01156545|DRUG|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
219620811|NCT01156545|DRUG|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
219620812|NCT00226577|DRUG|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
219620813|NCT00226577|DRUG|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
219620814|NCT00226577|PROCEDURE|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
219620815|NCT02162277|DEVICE|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
219620816|NCT01593397|DRUG|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
219620817|NCT01003873|BIOLOGICAL|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
219620818|NCT01003873|PROCEDURE|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
219620819|NCT01003873|BIOLOGICAL|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
219620820|NCT01003873|BEHAVIORAL|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
219620821|NCT01003873|BEHAVIORAL|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
219620822|NCT01003873|BEHAVIORAL|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
219620823|NCT04731727|DRUG|Riboflavin|Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
219620824|NCT01189162|DEVICE|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
219620825|NCT04118491|DEVICE|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
219540825|NCT02558491|OTHER|Usual Care|During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
218929904|NCT05155267|OTHER|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
218929905|NCT04203186|DRUG|atovaquone-proguanil|Malaria standard treatment regimen
218929906|NCT05821062|OTHER|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
218929907|NCT05821062|OTHER|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
218929908|NCT05821062|OTHER|standard ASA therapy|ASA 100 mg daily
218929909|NCT02122003|DRUG|Sorafenib|Sorafenib 400 mg bid
218929910|NCT05590078|DEVICE|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
218929911|NCT05590078|OTHER|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
218929912|NCT05590078|OTHER|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
218929913|NCT05590078|OTHER|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
218929914|NCT01829906|BEHAVIORAL|Multidisciplinary outpatient programme|
218929915|NCT01829906|BEHAVIORAL|Inpatient lifestyle programme|
218929916|NCT02223858|BEHAVIORAL|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
218929917|NCT02223858|BEHAVIORAL|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
219620826|NCT04113473|OTHER|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
219620827|NCT03678246|PROCEDURE|Ramped position|LSFOI glottis view
218929918|NCT04211909|DRUG|SOF/VEL|400/100 mg FDC tablet orally once daily.
218929919|NCT04211909|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
219044297|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
219044298|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
219540826|NCT00746395|DRUG|Lubiprostone|24 mcg oral administration
219540827|NCT00746395|DRUG|Placebo|Oral administration
219540828|NCT00834431|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
219540829|NCT00834431|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
219540830|NCT06627673|DEVICE|Total Knee Arthroplasty|Primary Total Knee Arthroplasty with a PEEK femoral component
219540831|NCT00952939|GENETIC|fluorescence in situ hybridization|At time of surgery
219540832|NCT00952939|OTHER|laboratory biomarker analysis|At time of surgery
219620828|NCT03678246|PROCEDURE|Supine position|LSFOI glottis view
219620829|NCT04143373|PROCEDURE|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
219540833|NCT00952939|PROCEDURE|fine-needle aspiration|At time of surgery
219540834|NCT00952939|PROCEDURE|therapeutic conventional surgery|At time of surgery
218929920|NCT03529591|DEVICE|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
218929921|NCT03529591|PROCEDURE|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
218929922|NCT04936087|OTHER|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
218929923|NCT05676580|PROCEDURE|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
218929924|NCT05676580|OTHER|abstention|No surgery
218929925|NCT04455815|DRUG|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
218929926|NCT03458195|OTHER|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
218929927|NCT06296316|DEVICE|Restorelle Polypropylene Mesh|"The Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse).~Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene."
218929928|NCT02747498|PROCEDURE|Procedure with circumferential pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
218929929|NCT02747498|PROCEDURE|Procedure with linear ablation in addiction to pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
219540835|NCT00952939|OTHER|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
219540836|NCT06124638|DIAGNOSTIC_TEST|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
219540837|NCT06429540|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures."
219540838|NCT06429540|BIOLOGICAL|Xenograft|In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
219620830|NCT03403673|OTHER|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
218929930|NCT04593199|BEHAVIORAL|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
218929931|NCT04593199|BEHAVIORAL|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
219540839|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray|on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
219540840|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray|on-demand or maintenance
218929932|NCT04106206|DRUG|LY3372689|Administered orally
218929933|NCT04106206|DRUG|Placebo|Administered orally
218929934|NCT04063007|OTHER|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
218929935|NCT02106390|BIOLOGICAL|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
218929936|NCT02106390|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
218929937|NCT04516889|PROCEDURE|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
218929938|NCT03198507|DRUG|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
218929939|NCT03198507|DRUG|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
218929940|NCT02980861|PROCEDURE|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
218929941|NCT02980861|PROCEDURE|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
218929942|NCT05436743|DRUG|K-Y Jelly, Topical Gel soaked packs|Topical Gel used as lubricant
218929943|NCT05436743|OTHER|Water soaked packs|Water soaked packs for reduction of postoperative sore throat
218929944|NCT03007693|DRUG|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
219044299|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
219044300|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
219044301|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
219540841|NCT04979663|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
219044302|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
219540842|NCT06293586|PROCEDURE|peribulbar block|"Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes"
219044303|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
219044304|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
218929945|NCT03007693|DRUG|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
218929946|NCT04857632|DRUG|Statin|atorvastatin 20mg per day for 7 days
219044305|NCT05431062|DRUG|Bupivacain|%0.25
219540843|NCT06293586|PROCEDURE|sub-tenon block|Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
219540844|NCT06293586|DRUG|Paracetamol|Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
219540845|NCT01931553|OTHER|Standardized attending morning rounds|
219540846|NCT05248711|BEHAVIORAL|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
219044306|NCT03523377|OTHER|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
219044307|NCT03523377|OTHER|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
219044308|NCT05143177|DRUG|Evogliptin|DA-1229 10 mg, 1 tab
219044309|NCT05143177|DRUG|Placebo|DA-1229 Placebo, 1 tab
219044310|NCT06514521|OTHER|Lutetium vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
219044311|NCT06022510|DEVICE|Fetoscopy Sets for Anterior and Posterior Placentas|Patients who choose to undergo fetoscopic surgery for a complicated monochorionic-diamniotic pregnancy will be offered participation in this study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
219044312|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
219044313|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
219044314|NCT01589302|DRUG|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219044315|NCT01589302|OTHER|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
219044316|NCT01589302|OTHER|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
219044317|NCT01567969|BEHAVIORAL|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
219044318|NCT01567969|BEHAVIORAL|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
219044319|NCT04464681|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
219044320|NCT04464681|DRUG|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
219044321|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
219044322|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
219044323|NCT00020670|BIOLOGICAL|CD 40|
219044324|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
219044325|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
219044326|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
219044327|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
219044328|NCT00157599|PROCEDURE|various diagnostic measures for DVT (e.g., CUS)|
219540847|NCT04936581|PROCEDURE|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
219540848|NCT04936581|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
219540849|NCT04936581|PROCEDURE|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
219540850|NCT04936581|PROCEDURE|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
219540851|NCT01694212|DRUG|Perioperative Diclofenac eye-drops administration|
219540852|NCT01694212|DRUG|placebo|
219540853|NCT04380181|DRUG|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
219540854|NCT03716466|OTHER|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
219540855|NCT03716466|OTHER|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
219540856|NCT01891461|DRUG|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
219540857|NCT03249454|DEVICE|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
218929947|NCT01910935|BEHAVIORAL|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
218929948|NCT00545259|DRUG|AEB071|
218929949|NCT05543642|BIOLOGICAL|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
218929950|NCT05543642|BIOLOGICAL|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
219540858|NCT03249454|DEVICE|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
219540859|NCT03249454|DEVICE|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
219540860|NCT03972683|OTHER|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
219540861|NCT03972683|DRUG|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
219540862|NCT03972683|DRUG|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
219540863|NCT03972683|DRUG|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
219540864|NCT03972683|DRUG|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
219540865|NCT03972683|DRUG|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
218929951|NCT06667141|DRUG|ACR-2316|ACR-2316 is an experimental drug
218929952|NCT05382949|OTHER|SilverBills Financial and Legal Tech Tool for Caregivers|All subjects will be receiving the Silverbills financial and legal tech tool and a pre-post analysis will be conducted.
218929953|NCT04655794|DRUG|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
219540866|NCT04890353|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
219540867|NCT02412085|DRUG|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks"
219540868|NCT01328652|DRUG|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
219540869|NCT01913405|BIOLOGICAL|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
219540870|NCT00754455|BIOLOGICAL|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
219540871|NCT00754455|BIOLOGICAL|Placebo|Placebo as a single injection of 0.5 mL.
219540872|NCT06485908|DRUG|administration of axitinib in combination with etoposide|"1. st stage:~   * Axitinib (Inlyta®) PO, in the morning and in the evening every day~  * Level -1 : Dose 1.2 mg/m²~  * Level 1: Dose 1.6 mg/m²~  * Level 2: Dose 2.0 mg/m²~  * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~   * Axitinib (Inlyta®) dosing as selected at the 1st stage~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)"
219540873|NCT03856320|BEHAVIORAL|Educational Video|An educational video describing obesity treatment options available in the VA.
219540874|NCT02825160|DRUG|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
219540875|NCT05694676|OTHER|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
219540876|NCT05694676|OTHER|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
219540877|NCT05694676|OTHER|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
219540878|NCT03428880|DRUG|Morphine|spinal morphine is done before cesarean section
219540879|NCT03428880|DRUG|Quadratus lumborum block|a US Block QLB is done after surgery
218929954|NCT04781751|DRUG|insulin injection|Carpal tunnel syndrome sonagraphic injection
218929955|NCT06169826|DRUG|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
218929956|NCT06169826|OTHER|Control|Control
218929957|NCT03298906|DRUG|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
218929958|NCT03298906|DRUG|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
218929959|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 8 Gy|
218929960|NCT02811250|RADIATION|Stereotactic radiotherapy 5 x 8 Gy|
218929961|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 10 Gy|
218929962|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 12 Gy|
218929963|NCT01325636|OTHER|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
219540880|NCT06560060|OTHER|No intervention|There are no interventions. The only medical procedure is a blood draw
219540881|NCT03151876|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
219540882|NCT03151876|DRUG|Cladribine|6 mg/m2 intravenously daily for 5 days
219540883|NCT03151876|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
219620831|NCT03202082|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
219620832|NCT01772329|OTHER|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
219620833|NCT01772329|OTHER|Routine Care|Routine Care. No Cognitive Therapy Intervention
219620834|NCT02047474|DRUG|oxaliplatin|Given IV
219620835|NCT02047474|DRUG|leucovorin calcium|Given IV
219620836|NCT02047474|DRUG|irinotecan hydrochloride|Given IV
218929964|NCT05218655|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
218929965|NCT01269190|PROCEDURE|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
218929966|NCT01269190|PROCEDURE|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
218929967|NCT01269190|DRUG|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
218929968|NCT06203847|DRUG|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
219620837|NCT02047474|DRUG|fluorouracil|Given IV
218929969|NCT06203847|DRUG|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
219044329|NCT03298750|PROCEDURE|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
219044330|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
219044331|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
219044332|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
219044333|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
219044334|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
219540884|NCT03151876|DRUG|Busulfan|3.2 mg/kg intravenously daily for 4 days
219540885|NCT03151876|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
219620838|NCT02047474|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219620839|NCT02047474|OTHER|laboratory biomarker analysis|Correlative studies
218929972|NCT06549348|RADIATION|Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance|Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
218929973|NCT04384692|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
218929974|NCT04384692|DRUG|Busulfan|Given IV
218929975|NCT04384692|DRUG|Cyclophosphamide|Given IV
218929976|NCT04384692|DRUG|Fludarabine|Given IV
218929977|NCT04384692|DRUG|Melphalan|Given IV
218929978|NCT04384692|DRUG|Methotrexate|Given IV
218929979|NCT04384692|DRUG|Mycophenolate Mofetil|Given IV or PO
218929980|NCT04384692|DRUG|Ruxolitinib|Given PO
218929981|NCT04384692|DRUG|Tacrolimus|Given IV and PO
218929982|NCT04384692|RADIATION|Total-Body Irradiation|Undergo TBI
218929983|NCT04384692|PROCEDURE|Computed Tomography|Undergo CT scan
218929984|NCT04384692|PROCEDURE|Echocardiography|Undergo echocardiography
218929985|NCT04384692|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
218929986|NCT04384692|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218929987|NCT04384692|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
218929988|NCT06012136|DRUG|VH4004280|VH4004280 will be administered.
218929989|NCT06012136|DRUG|Placebo|Placebo will be administered.
218929990|NCT06012136|DRUG|VH4011499|VH4011499 will be administered.
218929991|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
218929992|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
218929993|NCT03599765|OTHER|Best Practice|Receive routine therapy
219540886|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection|IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
219540887|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo|0.5ml, H. Administer the drug once every 14 days for 64 weeks
219540888|NCT01020474|DRUG|placebo|matching placebo capsules twice daily.
219540889|NCT01020474|DRUG|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
219540890|NCT04964440|DEVICE|Pure-EP|Advanced Signal Acquisition and Processing
219540891|NCT00835146|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
218929994|NCT03599765|PROCEDURE|Local Consolidation Therapy|Receive LCT
218929995|NCT05024968|DRUG|Sintilimab|Given by IV
218929996|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
218929997|NCT05957068|BEHAVIORAL|Control|Usual care group.
218929998|NCT03458247|DRUG|Abiraterone acetate standard dose|1000 mg/day
219540892|NCT00835146|DRUG|COPEGUS™|1 x 200 mg, single-dose fasting
218929999|NCT03458247|DRUG|Abiraterone acetate escalated dose|2000 mg/day
218930000|NCT04007029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
218930001|NCT04007029|DRUG|Cyclophosphamide|Given IV
218930002|NCT04007029|DRUG|Fludarabine Phosphate|Given IV
218930003|NCT04007029|BIOLOGICAL|Tocilizumab|Given IV
218930004|NCT02962063|BIOLOGICAL|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
219540893|NCT00468455|PROCEDURE|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
219540894|NCT03851354|OTHER|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
219540895|NCT05513677|DEVICE|M4D|Coated catheter
218930005|NCT02962063|DRUG|carboplatin AUC 2/paclitaxel|
219540896|NCT05513677|DEVICE|Standard of Care|Standard of Care
219540897|NCT06350240|BEHAVIORAL|Exercise|An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
218930006|NCT02962063|RADIATION|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
218930007|NCT02962063|PROCEDURE|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
219044335|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
219540898|NCT06350240|BEHAVIORAL|Exercise+texture insoles|In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
219540899|NCT06373185|PROCEDURE|Ultrasound-guided sacral erector spinae plane block|Patients were received ultrasound-guided sacral erector spinae plane block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
219044336|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
219540900|NCT06373185|PROCEDURE|Ultrasound-guided caudal block|Patients were received ultrasound-guided caudal block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
219540901|NCT03199963|DRUG|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
219540902|NCT03199963|DRUG|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
219540903|NCT00466167|DRUG|Pramipexol Extended Release|
219540904|NCT00466167|DRUG|Pramipexol Immediate Release|
219540905|NCT00466167|DRUG|Placebo|
219540906|NCT03145623|DRUG|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
219540907|NCT01470976|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%."
219540908|NCT01470976|OTHER|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
219044337|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
219205304|NCT06741215|OTHER|Hand Rehabilitation|"Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week."
219205305|NCT06829186|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|patients will be suplemented during 3 months with longvida, 2 cap /8 hours
219205306|NCT06829186|DRUG|Placebo|one capsules every 8 hours during 12 weeks
219205307|NCT06120608|BEHAVIORAL|Novel dietary approach focused on restricting the intake of highly bioavailable potassium|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
219540909|NCT02784262|DRUG|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
219540910|NCT00727480|PROCEDURE|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
219540911|NCT01144494|DRUG|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
219540912|NCT01144494|DRUG|Artificial tears|Lubricating drops added three times a day for six weeks
219540913|NCT01836380|BEHAVIORAL|Exercise Training|
219620840|NCT03655730|OTHER|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
219620841|NCT03655730|OTHER|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
218930008|NCT02962063|DRUG|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
218930009|NCT01923636|OTHER|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
218930010|NCT00241839|DRUG|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
219540914|NCT04435067|GENETIC|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
219540915|NCT04435067|OTHER|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D\_average, Gray Level Co-occurrence Matrix 3D\_combined, Gray Level Run Length 3D\_average, Gray Level Run Length 3D\_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
218930011|NCT00241839|DRUG|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
218930012|NCT00241839|DRUG|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
219540916|NCT02611440|BEHAVIORAL|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
218930013|NCT00241839|DRUG|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
218930014|NCT04031014|DEVICE|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
218930015|NCT04031014|DEVICE|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
218930016|NCT05865431|DRUG|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
218930017|NCT05598801|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
218930018|NCT03859687|BIOLOGICAL|Vitamin A supplementation|liquid oral vitamin A supplementation
218930019|NCT03859687|BIOLOGICAL|No vitamin A supplementation|No vitamin A supplementation
218930020|NCT05204641|BIOLOGICAL|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
218930021|NCT04394234|DRUG|Direct oral anticoagulant (DOACs)|Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
218930022|NCT04394234|DRUG|Warfarin|Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
219044338|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
219205308|NCT06120608|BEHAVIORAL|Traditional approach|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
218930023|NCT05575830|BIOLOGICAL|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
218930024|NCT06284681|BEHAVIORAL|Weight-focused health coaching|Following the definition of structured lifestyle interventions within the current obesity clinical practice guidelines, the weight-focused health coaching intervention will be delivered as a multi-component behavior change intervention intended to produce clinically-important weight loss through consuming a healthy, energy-restricted diet and increasing physical activity.
218930025|NCT06284681|BEHAVIORAL|Weight-neutral health coaching|Dietary and physical activity prescriptions for the weight-neutral health coaching intervention will be similar to the weight-focused intervention except the diet prescription will be designed to fully meet daily estimated energy requirements rather than creating a negative energy balance and producing weight loss. Health coaches will not emphasize changes in body weight as an explicit goal or as a mediator of improved cardiometabolic health. Rather, health coaches will emphasize achieving diet and exercise behavioral goals as a direct means to improving cardiometabolic health independently of changes in body weight.
219540917|NCT04452786|PROCEDURE|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
218930026|NCT06284681|BEHAVIORAL|Intensify lifestyle approach|Participants identified as non-responders to initial health coaching interventions may be re-randomized to receive a 4-month membership to the local YMCA and health coaches will assist participants in identifying and enrolling in at least 2 weekly group fitness classes at the YMCA.
218930027|NCT06284681|OTHER|Augment with enhanced medical management|Participants identified as non-responders to initial health coaching interventions may be re-randomized to meet with the primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
218930028|NCT03405441|DRUG|JNJ-55375515 Dose Level 1|Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
218930029|NCT03405441|DRUG|JNJ-55375515 Dose Level 2|Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
218930030|NCT03405441|DRUG|JNJ-55375515 Dose Level 3|Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
218930031|NCT03405441|DRUG|JNJ-55375515 Dose Level 4|Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
218930032|NCT03405441|DRUG|JNJ-55375515 Dose Level 5|Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
219205309|NCT06485297|OTHER|questionnary|questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)
219540918|NCT04452786|PROCEDURE|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
219540919|NCT04354363|OTHER|Platelet rich plasma|Giving women PRP before ICSI
219540920|NCT00684697|DIETARY_SUPPLEMENT|iron|High, intermediate and low iron dosage orally for 2 months
218930033|NCT03405441|DRUG|JNJ-55375515 Dose Level 6|Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
219540921|NCT02125760|OTHER|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
218930034|NCT03405441|DRUG|Placebo|All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
218930035|NCT03405441|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
218930036|NCT06113861|DIAGNOSTIC_TEST|Quantiferon Gold|Test for TB infection
218930037|NCT06113861|DIAGNOSTIC_TEST|HIV serology|Test for HIV infection
218930038|NCT06113861|DIAGNOSTIC_TEST|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
218930039|NCT06113861|DIAGNOSTIC_TEST|Chest radiograph|Chest imaging test by traditional X ray
218930040|NCT06113861|DIAGNOSTIC_TEST|Lung ultrasound|Chest imaging test by ultrasound
218930041|NCT06113861|DIAGNOSTIC_TEST|cell free DNA test|Blood test for TB infection
218930042|NCT03852160|DRUG|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
218930043|NCT03852160|DRUG|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
218930044|NCT03852160|DRUG|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
218930045|NCT03852160|DRUG|Placebo|Participants will receive matching placebo as nasal spray.
219540922|NCT02125760|OTHER|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
219540923|NCT03686540|PROCEDURE|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
218930046|NCT03852160|DRUG|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
218930047|NCT03852160|DRUG|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
218930048|NCT03852160|DRUG|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
218930049|NCT03852160|DRUG|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
219540924|NCT02463786|OTHER|No intervention|No intervention
219540925|NCT04942496|DRUG|Chlorhexidine Gluconate|Antimicrobial Skin Wash
219540926|NCT04942496|DEVICE|Hibi Universal Bathing System|Cloths used for patient bathing
219540927|NCT04942496|OTHER|0.1% SLS|Positive control
218930050|NCT03852160|DRUG|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
218930051|NCT03852160|DRUG|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
218930052|NCT03852160|DRUG|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
218930053|NCT04808778|DRUG|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
218930054|NCT04516057|DRUG|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
218930055|NCT04516057|OTHER|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
219540928|NCT04942496|OTHER|Distilled Water|Negative Control
219540929|NCT01039363|DRUG|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
218930056|NCT04288661|PROCEDURE|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered, according to the criteria stated above
219044339|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
219044340|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
219044341|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
219044342|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
219540930|NCT00161785|BIOLOGICAL|FSME-IMMUN 0.5ml|
218930057|NCT01719510|OTHER|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~* one swab for GBS detection by real-time PCR~* the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~2. A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
218930058|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
218930059|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
218930060|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
218930061|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
218930062|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
218930063|NCT06053502|OTHER|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
218930064|NCT01512615|OTHER|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
218930065|NCT01512615|OTHER|Control group|Usual care, clinical control as provided by treating heart centre
218930066|NCT00860860|DRUG|TF2|TF2: 75-300 mg
218930067|NCT00860860|DRUG|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
219540931|NCT02278809|BEHAVIORAL|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
219540932|NCT03559907|BEHAVIORAL|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
219540933|NCT03559907|BEHAVIORAL|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
219620842|NCT01436240|BEHAVIORAL|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
219620843|NCT03888469|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
218930068|NCT02465827|DRUG|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
218930069|NCT02465827|DRUG|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
218930070|NCT02465827|DRUG|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
218930071|NCT05245617|DEVICE|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
218930072|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
218930073|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
218930074|NCT01635296|DRUG|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
218930075|NCT01635296|DRUG|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
218930076|NCT00872443|OTHER|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
218930077|NCT00629070|OTHER|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
219044343|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
219044344|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
218930078|NCT00629070|OTHER|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
219540934|NCT06558500|PROCEDURE|Uterocervical angle|"With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form."
219540935|NCT04958915|DIAGNOSTIC_TEST|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
218930079|NCT02877589|OTHER|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
218930080|NCT02282098|DRUG|Colchicine|Colchicine 0.6mg twice daily
218930081|NCT02282098|DRUG|Placebo|Placebo Colchicine
218930082|NCT02863419|DRUG|semaglutide|Oral semaglutide once-daily.
218930083|NCT02863419|DRUG|liraglutide|Subcutaneous (s.c.) injection once-daily.
219540936|NCT06412861|DRUG|Ketamine|0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
219540937|NCT06412861|DRUG|Fentanyl|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
219540938|NCT05799677|OTHER|Reflexology|Additive reflexology treatment
219540939|NCT04725747|DRUG|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
219540940|NCT04725747|DRUG|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
219540941|NCT04725747|DRUG|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
219540942|NCT05997797|OTHER|FAAM|The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
219540943|NCT01101620|DRUG|Levosimendan|
219540944|NCT06626165|DRUG|Mirikizumab|Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.
219540945|NCT06626165|DRUG|Vedolizumab|Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
219540946|NCT00900094|GENETIC|fluorescence in situ hybridization|
219044345|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
219044346|NCT05051254|OTHER|Esogastric pressure measurement|"Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function."
219044347|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
219044348|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
219044349|NCT03337100|BEHAVIORAL|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
219044350|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
219540947|NCT00900094|GENETIC|polymerase chain reaction|
219540948|NCT00900094|GENETIC|protein expression analysis|
219540949|NCT00900094|OTHER|immunohistochemistry staining method|
219540950|NCT00900094|OTHER|laboratory biomarker analysis|
219540951|NCT00900094|OTHER|mass spectrometry|
219540952|NCT02189226|DEVICE|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
218930084|NCT02863419|DRUG|placebo|Placebo once-daily.
218930085|NCT05846854|OTHER|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
219540953|NCT06289738|OTHER|ICF|Matching the answers given to the question set consisting of 6 open-ended questions with ICF
219540954|NCT00599820|DRUG|Intravitreal Bevacizumab|
219540955|NCT02465125|BIOLOGICAL|red blood cell transfusion|
219540956|NCT04775004|OTHER|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
219540957|NCT04775004|OTHER|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
218930086|NCT03645720|DEVICE|Plastic cannula|puncture using plastic cannula
218930087|NCT03805152|DRUG|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
218930088|NCT03805152|DRUG|Dysport (R)|Intramuscular injection
219044351|NCT05970224|DRUG|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
219044352|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
219044353|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
219044354|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
219044355|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
219044356|NCT04970758|OTHER||no intervention
219044357|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
219540958|NCT00616863|DRUG|Oxcarbazepine|
219540959|NCT06208358|DEVICE|tACS|We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
219540960|NCT01002963|DRUG|PF-04418948|solution, 30 mg, single
218930089|NCT00004428|DRUG|CPX|
218930090|NCT05357248|DEVICE|BT-NCBT-00X|the intervention group will consist of 20 patients to receive the BT-NCBT-00X treatment for 90 days. They will receive a baseline MRI-PDFF, Fibroscan and have the tests repeated at 90 days.
218930091|NCT03311243|PROCEDURE|Non surgical periodontal therapy|
218930092|NCT03311243|DRUG|Chemical plaque control|
218930093|NCT02559375|OTHER|Survey|
218930094|NCT01437566|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
218930095|NCT01437566|DRUG|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
219540961|NCT01002963|DRUG|PF-04418948|solution, 100 mg, single
219540962|NCT01002963|DRUG|PF-04418948|solution, 300 mg, single
219540963|NCT01002963|DRUG|PF-04418948|solution, 1000 mg, single
219540964|NCT01002963|DRUG|PF-04418948|solution, 3000 mg, single
219540965|NCT01002963|DRUG|PF-04418948|solution, 4500 mg, single
219540966|NCT01002963|DRUG|PF-04418948|solution, 6000 mg, single
219540967|NCT00818558|BIOLOGICAL|ISET Methode|Sampling of blood - ISET Methode
218930096|NCT01437566|DRUG|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
219540968|NCT02927639|OTHER|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
219540969|NCT03516539|DEVICE|Group ML|Mcgrath videolaryngoscope
218930097|NCT01437566|DRUG|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
218930098|NCT01437566|DRUG|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
218930099|NCT05119361|OTHER|Early Dry protocol|"After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours."
218930100|NCT03449667|DEVICE|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
218930101|NCT03449667|DEVICE|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
219540970|NCT03516539|DEVICE|Group DL|Macintosh laryngoscope
218930102|NCT00409734|BEHAVIORAL|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
219540971|NCT04987216|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
219044358|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
219540972|NCT01309763|BIOLOGICAL|AFFITOPE AD03|s.c. injection
219540973|NCT01309763|BIOLOGICAL|AFFITOPE AD03 + Alum|s.c. injection
219540974|NCT04342663|DRUG|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
219540975|NCT04342663|DRUG|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
219540976|NCT00404963|DRUG|placebo|
219540977|NCT00404963|DRUG|GSK376501|
219540978|NCT00346190|DRUG|Alendronate|
219540979|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
219540980|NCT03643250|OTHER|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
219540981|NCT03643250|OTHER|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
219540982|NCT03643250|OTHER|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
219540983|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
219540984|NCT03264521|OTHER|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
219540985|NCT04661007|DRUG|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
219540986|NCT04661007|DRUG|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
219540987|NCT04661007|DRUG|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
219620844|NCT03888469|DEVICE|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
219620845|NCT04845867|DEVICE|ISAR-M THYRO|A diagnostic device for early detection of haemorrhage following thyroid surgery
219620846|NCT04947592|DRUG|Fluconazole 150 mg|fluconazole 150 MG once daily for 14 days
219620847|NCT04993001|OTHER|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
218930103|NCT00409734|BEHAVIORAL|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
218930104|NCT06035757|DRUG|Bridion 200 MG in 2 ML Injection|Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
218930105|NCT06035757|DRUG|Pyridostigmine Bromide 5 MG/ML|Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
218930106|NCT03515330|OTHER|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
219540988|NCT04661007|DRUG|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
218930107|NCT05654818|DRUG|Vitamin D|100,000 UI
218930108|NCT05654818|DRUG|Placebo|The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
219540989|NCT03986294|DRUG|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
219540990|NCT03986294|DRUG|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
219540991|NCT02825680|OTHER|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
219540992|NCT02825680|OTHER|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
219540993|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
219540994|NCT06219317|DRUG|Placebo|standard saline solution
219044359|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
219044360|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
219540995|NCT04258735|DIAGNOSTIC_TEST|Genomic analysis|WES, RNASeq, ctDNA, Exosome
219540996|NCT02805166|DRUG|PEG-rhG-CSF|
219540997|NCT00284791|DRUG|Lamotrigine (drug)|
219540998|NCT00284791|DRUG|Fluoxetine (drug)|
219540999|NCT00284791|DRUG|sertraline (drug)|
219044361|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
219541000|NCT06106958|BEHAVIORAL|Home Exercise Program|"Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily."
219541001|NCT06106958|BEHAVIORAL|Minimalist Shoes|"Participants will receive a pair of minimalist shoes. They will wear them for an allotted amount of time per day each week, in order to allow for a slow adjustment into the shoes. The protocol is as follows:~* Week 1: 1 hour per day~* Week 2: 2 hours per day~* Week 3: 4 hours per day~* Week 4: 6 hours per day~* Week 5: 8 hours per day~* Week 6: 8 hours per day~* Week 7: 8 hours per day~* Week 8: 8 hours per day"
219541002|NCT01978925|OTHER|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
218930109|NCT04084691|OTHER|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
219044362|NCT00477672|DRUG|Placebo|tablet, once daily by mouth, 6 weeks
219541003|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
219541004|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
219044363|NCT06223594|OTHER|Intravenous Fluid Therapy|Evaluate the safety and efficacy of the Dallas acute pancreatitis protocol(DAPP) order set on Acute pancreatitis(AP) patients receiving aggressive, goal-directed Intravenous fluid(IVF )therapy.
219044364|NCT05981638|OTHER|group WM|Patients were given 5ml/kg dose of water and patients were mobilized.
219044365|NCT05981638|OTHER|group WR|Patients were given 5ml/kg dose of water and patients were rest.
219205310|NCT06807801|BEHAVIORAL|Baby swimming|Participants in the treatment group will be contacted by a researcher and invited to an introductory meeting at the swimming facility, where they will receive information about the baby swimming course from the instructor. The course will take place twice a week for five weeks, totaling 10 sessions of 30 minutes each. During the sessions, mothers will be encouraged to engage in physical contact, maintain eye contact, and respond to their baby's signals. The course will also include water safety exercises.
219205311|NCT06747793|OTHER|Virtual Reality|The intervention will consist of relaxing virtual reality stimulation, which will be started after obtaining informed consent. Immersive 360-degree videos (nature environments) will be played inside a head-mounted display, with the video sound played inside headphones. Each virtual reality video will last 30 minutes. The stimulation will be provided two times per day, morning and evening, every day until the patient ICU discharge, or the maximum of 7 days will be reached. The intervention group will also receive standard intensive care unit care, same as in the control group.
219205312|NCT01105091|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
219541005|NCT00563264|BEHAVIORAL|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
219541006|NCT06030583|OTHER|Scales and Forms|This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
218930110|NCT04084691|OTHER|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
218930111|NCT04084691|OTHER|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
219205313|NCT01105091|DRUG|Flolan®|Per Prescribing Information
218930112|NCT04084691|OTHER|Normal meal|\- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
218930113|NCT04084691|OTHER|Normalized meal|"\- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
218930114|NCT04084691|OTHER|Fasting|non meal in the hour before exercise
218930115|NCT04981990|PROCEDURE|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
218930116|NCT04981990|PROCEDURE|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
218930117|NCT00580307|PROCEDURE|Septoplasty|Surgical straightening of nasal septum
218930118|NCT00580307|PROCEDURE|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
218930119|NCT05267522|OTHER|Egg diet|30% fat \[6% saturated fat\], 20% protein, 40% carbohydrate, 600 mg cholesterol
218930120|NCT05267522|OTHER|Egg-free Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 300 mg cholesterol
218930121|NCT05267522|OTHER|Control Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 600 mg cholesterol
218930122|NCT05711212|DIETARY_SUPPLEMENT|micellar solubilized Xanthohumol|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
218930123|NCT05711212|DIETARY_SUPPLEMENT|Placebo|single administration of 4 soft gelatine capsules containing only micelles
218930124|NCT00647959|DRUG|Doxycycline Tablets, 150mg|150mg, single dose fasting
218930125|NCT00647959|DRUG|Adoxa Tablets 150 mg|150mg, single dose fasting
218930126|NCT05744817|BEHAVIORAL|Inspiratory muscle strength training|30 breaths/day against a set resistance
218930127|NCT02324101|DEVICE|Hsp90|Detect plasma Hsp90α concentration
218930128|NCT00210951|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
218930129|NCT04786717|OTHER|core muscle training|The intervention of this group will focus on training the endurance of the core muscle.
218930130|NCT04786717|OTHER|movement control training|Based from the initial test, the subjects will receive either lumbar flexion control exercise or lumbar extension control exercise. They will perform each lumbar movement control exercise in different position. Starting from the lying position, then progressing to sitting, standing with support, and the last level will be standing without support. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
218930131|NCT04786717|OTHER|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, so the subjects will not have any real movement, and the last 7 times they will perform the lumbar motor control exercise literally. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
218930132|NCT02135796|OTHER|Echocardiography|
218930133|NCT04522232|PROCEDURE|conventional Total laparoscopic hysterectomy|"the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached."
218930134|NCT04522232|PROCEDURE|Total laparoscopic hysterectomy with prior uterine artery ligation at its origin|"the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy"
218930135|NCT01574469|OTHER|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
218930136|NCT01574469|OTHER|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
219044366|NCT05981638|OTHER|Group AR|Patients were given 5ml/kg dose of apple juice and patients were rest.
219541007|NCT06302114|OTHER|Assessment of overhead athletes|Assessment of medicine ball forward throw, Y balance test, Range of motion of the shoulder (internal and external rotation), strength of internal and external rotator muscles.
219541008|NCT02552758|BIOLOGICAL|omega-3 fatty acid|omega-3 fatty acid
218930137|NCT02516137|PROCEDURE|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
218930138|NCT02516137|PROCEDURE|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
219541009|NCT02552758|BIOLOGICAL|placebo|placebo
218930139|NCT02516137|PROCEDURE|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
218930140|NCT02516137|OTHER|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
218930141|NCT04058964|BIOLOGICAL|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
218930142|NCT04058964|BIOLOGICAL|Pembrolizumab|Given IV
218930143|NCT03859934|DRUG|Melatonin|Melatonin treatment
218930144|NCT03859934|DRUG|Placebo Oral Tablet|Placebo treatment
218930145|NCT02644655|BIOLOGICAL|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
218930146|NCT02864784|DRUG|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
218930147|NCT02864784|OTHER|Placebo|microcrystalline cellulose
219044367|NCT05981638|OTHER|Group AM|Patients were given 5ml/kg dose of apple juice and patients were mobilized.
219044368|NCT04427969|BEHAVIORAL|prone position|to lay in prone position at least 12 hour in a day at ICU
219044369|NCT00006125|DRUG|doxorubicin hydrochloride|
219044370|NCT00006125|DRUG|topotecan hydrochloride|
219044371|NCT00838565|DRUG|Placebo|intravenous infusion on three consecutive months
219044372|NCT00838565|DRUG|dose level 1|intravenous infusion on three consecutive months
219044373|NCT00838565|DRUG|dose level 2|intravenous infusion on three consecutive months
219044374|NCT00838565|DRUG|dose level 3|intravenous infusion on three consecutive months
219541010|NCT02552758|DEVICE|positron emission tomography (PET)|
219541011|NCT04215328|DIETARY_SUPPLEMENT|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
219541012|NCT04215328|DIETARY_SUPPLEMENT|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
219541013|NCT01208935|DRUG|Nicotine Patch|
219541014|NCT01208935|DRUG|Nicotine Gum|
218930148|NCT01736995|BEHAVIORAL|Functional Family Therapy|
219044375|NCT00838565|DRUG|dose level 4|intravenous infusion on 3 consecutive months
219044376|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
219044377|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
219044378|NCT06368544|OTHER|lower-body positive-pressure|By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
219044379|NCT05431088|DRUG|Osivelotor|Tablets which contain drug substance
219044380|NCT03841058|DRUG|Abaloparatide|80 mcg delivered SC by a pen
219044381|NCT03841058|DRUG|Placebo|A pen to deliver a SC dose of placebo
219044382|NCT02460770|DRUG|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
219541015|NCT03011294|DEVICE|Continuous positive airway pressure (CPAP)|Standard treatment for sleep apnea
219044383|NCT02800148|DRUG|Azelaic acid foam|
219044384|NCT02800148|DRUG|Azelaic acid foam|
219044385|NCT02800148|DRUG|Azelaic acid foam - Placebo|
219541016|NCT03011294|DEVICE|Nasal strip|Placebo
218930149|NCT01736995|BEHAVIORAL|Motivational Enhancement Tx/Cognitive Behavioral Tx|
218930150|NCT01736995|BEHAVIORAL|Contingency Management|
218930151|NCT01553968|OTHER|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
218930152|NCT06361069|OTHER|distraction cards, kaleidoscope and finger puppet|"A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions."
219044386|NCT06451042|DIAGNOSTIC_TEST|FET-PET/MRI|Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
219044387|NCT06361823|DRUG|Semaglutide|Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
219044388|NCT06361823|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet (max 1200 kcal/day)
219205314|NCT06346379|BEHAVIORAL|Baduanjin exercise|Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
219205315|NCT06836193|OTHER|Emotional intervention|Negative emotional intervention
219205316|NCT06836193|OTHER|Emotional intervention|Positive emotional intervention
219205317|NCT06804590|DRUG|9MW0311|9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
219205318|NCT06804590|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
219205319|NCT06860789|DRUG|AK135|IV infusion, specified dose with specified treatment frequency
219541017|NCT04521218|OTHER|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
219541018|NCT04521218|OTHER|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
219541019|NCT03323008|OTHER|Prototype|Usability testing and System Usability Scale
219541020|NCT00471133|BIOLOGICAL|Xenogeneic Tyrosinase DNA Vaccine|
219044389|NCT02372851|DEVICE|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
219044390|NCT02420028|DEVICE|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
219044391|NCT02420028|DEVICE|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
218930153|NCT00424684|PROCEDURE|collection of blood sample|
219044392|NCT06244862|DRUG|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
219541021|NCT00471133|DEVICE|TriGrid Delivery System for Intramuscular Electroporation|
219541022|NCT05922696|DRUG|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
219541023|NCT05131113|OTHER|Physical exercise|Physical exercise
219541024|NCT02969616|BIOLOGICAL|Trinity Elite|cell based allograft
218930154|NCT05099952|PROCEDURE|Biospecimen Collection|Undergo collection of cheek cell and blood samples
218930155|NCT05099952|OTHER|Counseling|Meet with therapist
218930156|NCT05099952|OTHER|Educational Intervention|Participate in BBT-CI sessions
218930157|NCT05099952|OTHER|Electronic Health Record Review|Medical records are reviewed
218930158|NCT05099952|OTHER|Medical Device Usage and Evaluation|Wear actigraphy watch
218930159|NCT05099952|OTHER|Questionnaire Administration|Ancillary studies
218930160|NCT03511937|BEHAVIORAL|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
218930161|NCT03511937|OTHER|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
218930162|NCT01339143|DRUG|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
218930163|NCT01339143|DRUG|pioglitazone|15mg, QD, PO, 16 weeks
219541025|NCT03332485|DRUG|ECP Colon Prep Kit|ECP Colon Prep Kit
219541026|NCT03332485|DRUG|MoviPrep®|MoviPrep®
218930164|NCT01249079|OTHER|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
218930165|NCT00060840|DRUG|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
218930166|NCT00060840|DRUG|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
219541027|NCT03184389|BEHAVIORAL|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
219541028|NCT00966589|PROCEDURE|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
218930167|NCT02768857|BEHAVIORAL|Sensorimotor reeducation programs|
218930168|NCT04148846|DRUG|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
219044393|NCT01455012|DRUG|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
219541029|NCT00621491|DRUG|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
219541030|NCT04584294|BEHAVIORAL|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
218930169|NCT04148846|PROCEDURE|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
218930170|NCT04148846|DRUG|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
219044394|NCT01455012|DRUG|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
219044395|NCT01121692|BEHAVIORAL|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
219205320|NCT06860555|DEVICE|Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)|Imaging with the MHRC and optical coherence tomography (OCT).
218930171|NCT04148846|DRUG|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
218930172|NCT04148846|DRUG|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
218930173|NCT04148846|DRUG|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
218930174|NCT04148846|DIETARY_SUPPLEMENT|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
218930175|NCT02284243|DRUG|Intranasal Dexmedetomidine|
218930176|NCT02284243|DRUG|Intranasal Placebo|
218930177|NCT03783832|OTHER|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
218930178|NCT01655485|OTHER|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
218930179|NCT00553891|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
218930180|NCT00553891|DRUG|placebo nasal spray|One spray in each nostril once daily for 3 months.
219620848|NCT04993001|OTHER|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
218930181|NCT03570099|DRUG|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
218930182|NCT03570099|OTHER|Historical control cohort|Historical data will be retrieved from quality registries.
218930183|NCT01227993|DRUG|Finasteride|
218930184|NCT00843219|PROCEDURE|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
218930185|NCT05637580|DRUG|Timing of drug administration|The effect of drug administration timing on tumor and lymph node responses was observed.
218930186|NCT00338585|DRUG|alfimeprase|
218930187|NCT03702283|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
218930188|NCT03532204|RADIATION|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
218930189|NCT03532204|DRUG|Chemotherapy|At investigator's discretion
218930190|NCT04615052|OTHER|Exercise training|A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
218930191|NCT00541385|DRUG|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
218930192|NCT00541385|DRUG|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
218930193|NCT06344962|DEVICE|Absorbable Suture|3-0 V-Loc
219044396|NCT01121692|BEHAVIORAL|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
219044397|NCT01121692|BEHAVIORAL|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
219044398|NCT04488965|OTHER|Autologous transplant|Autologous transplant obtained from cortical biopsy
219044399|NCT02550847|DEVICE|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
219044400|NCT04110483|PROCEDURE|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
219044401|NCT04110483|PROCEDURE|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
219044402|NCT02178384|PROCEDURE|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
219620849|NCT04680169|DEVICE|Bronchoscopic intubation through AuraGain LMA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
219620850|NCT04680169|DEVICE|Bronchoscopic intubation through I-gel SGA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
218930194|NCT06344962|DEVICE|Non-absorbable Suture|3-0 Prolene
218930195|NCT04542837|BIOLOGICAL|KN046|Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
219541031|NCT04410263|DIAGNOSTIC_TEST|Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)|"Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy"
218930196|NCT04542837|DRUG|Lenvatinib|Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW\<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
218930197|NCT04717219|OTHER|Blood drawing|Blood will be drawn after inclusion of the participants.
218930198|NCT06237504|DEVICE|SaCoVLM™|Patients will receive general anesthesia with their airways maintained with the SaCoVLM, which is a newer supraglottic airway device with a video port to directly visualize the upper airway.
218930199|NCT06237504|DEVICE|Ambu®Auragain™|Patients will receive general anesthesia with their airways maintained with the Ambu Auragain, which is a conventional 2nd generation supraglottic airway device.
218930200|NCT04387604|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF\>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
218930201|NCT01099332|OTHER|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
218930202|NCT01099332|OTHER|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
218930203|NCT03468140|DRUG|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
218930204|NCT03468140|OTHER|No intervention|Historical control arm
218930205|NCT05882708|DRUG|Ivabradine|After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
218930206|NCT03313622|BEHAVIORAL|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
218930207|NCT03313622|BEHAVIORAL|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
218930208|NCT03674047|DRUG|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
218930209|NCT06800092|DRUG|Sildenafil|Sildenafil, 50mg, daily
219044403|NCT02178384|DEVICE|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
219044404|NCT02178384|PROCEDURE|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
219044405|NCT02643654|DRUG|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
219205321|NCT06866158|BIOLOGICAL|Dendritic cell immunotherapy|DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2. The number of cells given depends on individual yields.
219541032|NCT00429416|DRUG|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
219541033|NCT00429416|DRUG|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
219620851|NCT00452244|DRUG|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
219620852|NCT00452244|DRUG|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
219620853|NCT00999986|DRUG|cyclophosphamide|50 mg oral per day for 7 days
218930210|NCT05197504|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
218930211|NCT04139798|DRUG|NOV03|100% Perfluorohexyloctane
219541034|NCT00429416|DRUG|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
219541035|NCT00429416|DRUG|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
218930212|NCT04139798|DRUG|Placebo|Saline solution (0.6% sodium chloride solution)
218930213|NCT05293197|DEVICE|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
218930214|NCT04187781|DEVICE|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
218930215|NCT02869464|OTHER|Imaging-Ultrasound|Abdominal Ultrasound
218930216|NCT02869464|OTHER|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
218930217|NCT02869464|GENETIC|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
218930218|NCT03381638|DEVICE|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
218930219|NCT03838432|DEVICE|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
218930220|NCT05286775|OTHER|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~1. 3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~2. 5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~3. \*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~   For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~4. Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~5. Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~6. Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~   * Four weekly applications."
218930221|NCT05286775|OTHER|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
218930222|NCT06292078|BEHAVIORAL|Instructional Skill-Building Learning Approach (ISLA)|The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
218930223|NCT05414084|DIETARY_SUPPLEMENT|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
218930224|NCT06193356|OTHER|Learning tool|Video based learning tool about detection of endoscopic resection scars and recurrence.
218930225|NCT04269889|DRUG|Eltrombopag|"Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
218930226|NCT05766800|DRUG|Serplulimab|Specified dose on specified days
218930227|NCT05766800|DRUG|Carboplatin|Specified dose on specified days
218930228|NCT05766800|DRUG|Pemetrexed|Specified dose on specified days
218930229|NCT05766800|DRUG|Nab-paclitaxel|Specified dose on specified days
218930230|NCT05766800|DRUG|Liposomal paclitaxel|Specified dose on specified days
218930231|NCT05766800|PROCEDURE|Surgery|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
219205322|NCT06877494|DIETARY_SUPPLEMENT|fish oil|Twice a day, with one dose of DHA 300mg: EPA 60mg, for a continuous intervention of 90 days
219541036|NCT00429416|DRUG|Tacrolimus|Tacrolimus given before and after HSCT infusion
219541037|NCT00429416|DRUG|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
219541038|NCT00429416|BIOLOGICAL|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
219541039|NCT00429416|PROCEDURE|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
219541040|NCT03141840|DEVICE|ABL01|Experimental medical device
219541041|NCT03141840|DEVICE|Placebo|ABL01 lacking active component
219541042|NCT01349218|OTHER|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
219541043|NCT01349218|OTHER|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
219541044|NCT04360161|DEVICE|swept-source optical coherence tomography|Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of \<10 μm.
218930232|NCT05766800|RADIATION|Radiotherapy|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
218930233|NCT03841279|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
218930234|NCT05599945|DRUG|NNC0581-0001|Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
218930235|NCT05599945|DRUG|Placebo (NNC0581-0001)|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
219541045|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
219541046|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
219541047|NCT01055041|DRUG|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
219541048|NCT00322439|DRUG|Etanercept|Observational study - no drug administered
218930236|NCT02981446|DRUG|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
218930237|NCT02981446|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
218930238|NCT00095888|DRUG|triapine|Given IV
218930239|NCT00095888|DRUG|gemcitabine hydrochloride|Given IV
218930240|NCT00095888|OTHER|laboratory biomarker analysis|Correlative studies
218930241|NCT00095888|OTHER|pharmacological study|Correlative studies
218930242|NCT04072900|DRUG|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
218930243|NCT04072900|DRUG|Anti-PD-1|3mg/kg, ivgtt, Q2w
218930244|NCT04072900|DRUG|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
218930245|NCT04072900|DRUG|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
218930246|NCT02826317|PROCEDURE|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS \>0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS \>0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
218930247|NCT02572908|OTHER|Sourdough wheat bread|
218930248|NCT02572908|OTHER|Regular yeast baked toast bread|
218930249|NCT02572908|OTHER|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
218930250|NCT00120302|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
218930251|NCT00120302|DRUG|Placebo|Matching vehicle cream
218930252|NCT01281514|DRUG|everolimus|Given PO
219541049|NCT02280733|OTHER|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
219541050|NCT03769922|PROCEDURE|Extensive mesenteric resection|The mesentery is resected avoiding the root region.
219541051|NCT03769922|PROCEDURE|Limited mesenteric excision|The mesentery is retained.
219541052|NCT03644888|OTHER|Cycle ergometer training|Already in arm/group descriptions
219541053|NCT03644888|OTHER|Airway clearance program|Already in arm/group descriptions
219541054|NCT03644888|DEVICE|Vibration therapy|Already in arm/group descriptions
219541055|NCT03644888|DEVICE|Sham vibration therapy|Already in arm/group descriptions
219541056|NCT06738966|DRUG|BL0175|"BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue."
218930253|NCT01281514|DRUG|carboplatin|Given IV
218930254|NCT01281514|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
218930255|NCT01281514|OTHER|laboratory biomarker analysis|Correlative studies
218930256|NCT00042822|DRUG|romidepsin|
218930257|NCT03102437|DEVICE|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
218930258|NCT03265314|BEHAVIORAL|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
219205323|NCT06882135|DRUG|HW071021 Tablets|Administered orally at pre-specified doses once or twice daily.
219541057|NCT05206344|OTHER|clowns|presence or absence of clowns during the performance of a painful act, on pain
219541058|NCT04891744|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
219541059|NCT04891744|DRUG|Thalidomide|100mg/d, Po. on day1-28
219541060|NCT04891744|DRUG|Dexamethasone|20 mg/d Po. on day 1, 2,8,9,15,16,22,23
219541061|NCT01278953|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
219620854|NCT05623423|OTHER|(Admira Fusion, Voco GmbH, Germany)|cavity margins will be extended to the proximal area, incisal edge, facial and lingual surfaces All enamel margins will be beveled at a 45° angle to the external cavosurface.(approximately 0.5-2.0 mm) An impression for the upper anterior teeth will be taken to produce a silicon palatal index The proximal margins of the restorations will be achieved using the Unica anterior matrix teeth will be etched using 37% phosphoric acid gel for 30 s then rinsed with air water for 20 s A single coat of universal bond cured using and LED light curing unit for 10 s Using the chosen enamel shade of the ORMOCER Resin Composite a thin layer (0.5-1 mm) Unica matrix will used to produce the proximal margins of the restorations Contouring, finishing and polishing of the restoration will be done Dental floss and finishing strips will be used Rubber dam will then be removed and occlusion will be checked using an articulating paper
219541062|NCT05778110|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
219541063|NCT04097483|BEHAVIORAL|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
219541064|NCT01966484|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
219541065|NCT01966484|DRUG|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
219541066|NCT02885909|DEVICE|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
219620855|NCT05623423|OTHER|Methacrylate Based Composite|The exact same steps as in the intervention will be done but using the chosen shades of Methacrylate Based Composite Resin. (Ceram.X Spectra ST, Dentsply Sirona, UK)
219620856|NCT02135523|RADIATION|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
219620857|NCT03539302|DRUG|Flecainide Acetate|Oral inhalation form using a nebulizer
219620858|NCT01585090|OTHER|doing strengthening exercises of pelvic floor muscles|
219620859|NCT03784638|PROCEDURE|lingually-based triangle flap design|A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
219620860|NCT03784638|OTHER|buccally based triangular flap design|A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
219620861|NCT05533619|DRUG|Proton pump inhibitor|Inpatients using proton pump inhibitor
219620862|NCT06582238|OTHER|Dentists in Clinical Practice|Experience in managing Dentine Hypersensitivity
219620863|NCT02585908|BIOLOGICAL|CIK|CIK cells will be used against tumor cells.
219620864|NCT02585908|BIOLOGICAL|γδ T|γδ T cells will be used against tumor cells.
219620865|NCT02585908|BIOLOGICAL|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
218930259|NCT03265314|BEHAVIORAL|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
218930260|NCT04308291|DEVICE|MiniMed™ 780G System|Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.
218930261|NCT02134158|DEVICE|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
219620866|NCT05802628|DRUG|Cetylpyridinium Chloride Buccal Tablets|Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
219620867|NCT06357897|DRUG|Local PEG4000|PEG-Chula is developed from PEG 4000 used at King Chulalongkorn Memorial Hospital with added sweetener and flavours. Children will be given PEG-Chula at a dose of 0.5 - 1 g/kg/day.
218930262|NCT05533736|OTHER|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
219541067|NCT02885909|PROCEDURE|Insulin protocal|Using insulin protocal based on glucose monitor
218930263|NCT01499355|BIOLOGICAL|BIIB023|
218930264|NCT01499355|BIOLOGICAL|Placebo|
218930265|NCT01499355|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
219541068|NCT01083719|PROCEDURE|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
219541069|NCT04633564|BIOLOGICAL|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
218930266|NCT01499355|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
218930267|NCT01526733|DRUG|Sham Injection|
218930268|NCT01526733|DRUG|Recombinant human hyaluronidase PH20|
219541070|NCT04633564|BIOLOGICAL|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
219541071|NCT01472263|DRUG|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
219541072|NCT01472263|DRUG|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
219541073|NCT02684747|OTHER|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
219541074|NCT02684747|OTHER|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
219541075|NCT06559410|OTHER|Electroencephalogram (EEG), CT Brain, Echocardiogram|analyze the etiology, electroencephalographic (EEG) findings, neuroimaging, and neurological sequalae of newborns with congenital heart disease who were presented with seizures
219541076|NCT05103514|OTHER|Online Survey|There are no interventions planned for this study. This is an observational study only.
219541077|NCT03612232|DRUG|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
219541078|NCT06321653|RADIATION|Hypofractionated radiotherapy scheme|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
219541079|NCT02665715|OTHER|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
219620868|NCT06357897|DRUG|Commercial PEG4000|For commercial PEG, We use Forlax as the control group. Children will be given Forlax at a dose of 0.5 - 1 g/kg/day.
219620869|NCT01506505|DRUG|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
219620870|NCT01927120|DRUG|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
219620871|NCT01927120|DRUG|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
219620872|NCT01927120|DRUG|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
219620873|NCT02298127|OTHER|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
219620874|NCT04127227|DRUG|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy"
219620875|NCT00107627|OTHER|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
219620876|NCT00107627|OTHER|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
219620877|NCT00107627|OTHER|Skin staples;|Skin staples;
218930269|NCT01526733|DRUG|Insulin aspart|
218930270|NCT01526733|DRUG|Insulin lispro|
218930271|NCT06508190|BEHAVIORAL|continuous positive airway pressure|continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night
218930272|NCT06508190|BEHAVIORAL|free walking exercise and continuous positive airway pressure|patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
219044406|NCT02643654|DRUG|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
219044407|NCT02294877|DRUG|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
219541080|NCT02665715|OTHER|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
219541081|NCT01771939|PROCEDURE|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
219541082|NCT01771939|PROCEDURE|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
219541083|NCT07068061|DEVICE|PDO suture|A biodegradable polymer used in dissolvable sutures and lifting threads, stimulating collagen production as it degrades.
219541084|NCT06701240|BEHAVIORAL|ParentChild+|92-session early literacy focused intervention
219541085|NCT06701240|BEHAVIORAL|FamilyNutrition+|92-session active control focused on child nutrition
218930273|NCT04202601|DRUG|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
218930274|NCT04202601|DRUG|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
218930275|NCT01523912|DEVICE|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
218930276|NCT00281242|OTHER|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
218930277|NCT01812863|PROCEDURE|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
218930278|NCT05924217|OTHER|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
218930279|NCT06459206|DEVICE|Pulse oximeter|Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
218930280|NCT01970293|OTHER|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
218930281|NCT05064215|PROCEDURE|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
218930282|NCT01795053|BEHAVIORAL|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
218930283|NCT01795053|BEHAVIORAL|Placebo open play session|
218930284|NCT02080806|DEVICE|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
219541086|NCT06899022|OTHER|Normal therapeutic DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and current over approximately 20 min.
219620878|NCT01614873|DEVICE|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
219044408|NCT06016634|DRUG|Alendronate Sodium|Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
219044409|NCT03634553|OTHER|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
219541087|NCT06899022|OTHER|Reduced current DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and reduced (50%) current over approximately 20 minutes.
219541088|NCT06899022|OTHER|Reduced frequency DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic current and reduced (4 Hz) frequency over approximately 20 min.
219620879|NCT03493191|DRUG|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
219620880|NCT03493191|DRUG|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
219620881|NCT03493191|DRUG|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
218930285|NCT04343742|DRUG|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
219620882|NCT03493191|DRUG|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
218930286|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
218930287|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
218930288|NCT01840982|DIETARY_SUPPLEMENT|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
218930289|NCT01840982|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
218930290|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
218930291|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
218930292|NCT02911844|DRUG|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
218930293|NCT04772274|DRUG|Ustekinumab|45 mg, single-dose
218930294|NCT03754998|BEHAVIORAL|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
218930295|NCT05653869|DRUG|APS03118|Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
218930296|NCT03052062|DIETARY_SUPPLEMENT|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
218930297|NCT06276829|DIAGNOSTIC_TEST|LDH/albumin ratio|LDH/Albumin ratios of patient and control groups were recorded.
218930298|NCT04539795|DRUG|Alvelestat|oral tablet
218930299|NCT04539795|DRUG|Placebo|oral tablet
218930300|NCT06007950|BEHAVIORAL|Time-restricted eating 10-hr|Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
218930301|NCT00454324|DRUG|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
218930302|NCT00454324|DRUG|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
218930303|NCT01875094|OTHER|Self-Management / MTM using Health IT|
218930304|NCT02699749|DRUG|TAK-931|TAK-931 oral capsules.
218930305|NCT04613648|DIAGNOSTIC_TEST|Imaging|Ultrasonographic imaging of the shoulder
218930306|NCT01577888|DEVICE|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
218930307|NCT00065078|PROCEDURE|Home dispensing of contraception|
218930308|NCT03121053|DRUG|sodium bicarbonate|
218930309|NCT03121053|DRUG|hypotone saline|
218930310|NCT01626469|DRUG|Captopril|25mg Captopril
218930311|NCT01626469|DRUG|placebo|placebo
218930312|NCT01871935|DRUG|Remifentanil|Anaesthesia with remifentanil/propofol.
218930313|NCT01871935|DRUG|Sufentanil|Anaesthesia with sufentanil/propofol
218930314|NCT03549182|DRUG|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
219620883|NCT03493191|DRUG|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
218930315|NCT03549182|DRUG|placebo treatment|oral administration of placebo (102.3g)
218930316|NCT01599637|DRUG|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
218930317|NCT01599637|DRUG|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
218930318|NCT03460249|OTHER|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
218930319|NCT02565108|DRUG|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
218930320|NCT02565108|DRUG|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219620884|NCT03493191|DRUG|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
219620885|NCT00127114|DRUG|Amantadine|
219620886|NCT00127114|DRUG|Placebo|
219620887|NCT05579964|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
218930321|NCT02565108|DRUG|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
219541089|NCT04786353|OTHER|LongCOVIDkidsDK|Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
219541090|NCT07067957|OTHER|Arabic Dysfunctional Voiding Symptom Score Questionnaire (DVSS)|A validated Arabic version of the Dysfunctional Voiding Symptom Score Questionnaire (DVSS) questionnaire will be used to screen children for symptoms of lower urinary tract dysfunction. It includes 10 items assessing urinary and bowel habits.
218930322|NCT05755321|OTHER|Skin biopsy|Skin biopsy performed during surgery.
219620888|NCT05579964|DRUG|Placebo|Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
219620889|NCT01796678|DRUG|Arginine|
219620890|NCT01796678|DRUG|Placebo|Saline or Sugar pill was given as placebo
218930323|NCT02874378|DRUG|Dexmedetomidine|
218930324|NCT02874378|DRUG|0.9%NaCl solution|
218930325|NCT00453219|PROCEDURE|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
218930326|NCT00453219|PROCEDURE|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
218930327|NCT00453219|GENETIC|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
218930328|NCT00453219|PROCEDURE|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
218930329|NCT00453219|PROCEDURE|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
218930330|NCT04763369|BIOLOGICAL|Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
218930331|NCT04763369|BIOLOGICAL|Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa|Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
219044410|NCT03634553|OTHER|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
219044411|NCT03409432|DRUG|Brentuximab Vedotin|Given IV
219044412|NCT03409432|OTHER|Laboratory Biomarker Analysis|Correlative studies
219044413|NCT03409432|DRUG|Lenalidomide|Given PO
219044414|NCT05328830|OTHER|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
219044415|NCT05328830|OTHER|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
219044416|NCT01938274|OTHER|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
219044417|NCT00110058|BIOLOGICAL|recombinant interferon alfa|
219044418|NCT00110058|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219044419|NCT00110058|DRUG|cyclosporine|
219044420|NCT00110058|DRUG|fludarabine phosphate|
219044421|NCT00110058|DRUG|imatinib mesylate|
219044422|NCT00110058|DRUG|mycophenolate mofetil|
219044423|NCT00110058|PROCEDURE|peripheral blood stem cell transplantation|
219044424|NCT00110058|RADIATION|radiation therapy|
219541091|NCT07068035|BEHAVIORAL|Temporary abstinence and expressive writing|This brief, self-administered intervention combined both temporary gaming abstinence and gaming-focused expressive writing to mitigate gaming problems
219620891|NCT00944060|OTHER|lifestyle intervention|
219620892|NCT02107131|DRUG|Intravitreal ranibizumab 0.3mg|
219620893|NCT04707573|DRUG|Vadadustat|oral capsules
219620894|NCT03123744|DRUG|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
219620895|NCT05227391|PROCEDURE|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
219620896|NCT05227391|PROCEDURE|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
219541092|NCT07068035|BEHAVIORAL|Gaming as per usual and control writing|Participants continued with their usual gaming routine and engaged in control writing exercises for 15 minutes every other day for a total of 4 sessions
218930332|NCT00973635|OTHER|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
218930333|NCT06125717|BIOLOGICAL|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
218930334|NCT02873416|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
218930335|NCT02873416|BIOLOGICAL|Precision Cells|Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
218930336|NCT02640287|BIOLOGICAL|Blood or bone marrow samples|
219044425|NCT01215227|DRUG|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
219044426|NCT01215227|DRUG|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
219044427|NCT01215227|DRUG|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
219541093|NCT02202486|OTHER|Brain MRI|Brain MRI with gadolinium contrast
219541094|NCT05625022|DRUG|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
219620897|NCT06059287|DRUG|Henagliflozin|Henagliflozin 10mg qd po
219620898|NCT06059287|DRUG|Metformin|Metformin 1000mg bid po
219620899|NCT06452017|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
219044428|NCT01215227|DRUG|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
219620900|NCT06452017|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
219620901|NCT04773340|BEHAVIORAL|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
219620902|NCT00246194|DRUG|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
219620903|NCT04527133|DRUG|Aprotinin|Intravenous or inhalation
218930337|NCT01887535|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
218930338|NCT01887535|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
218930339|NCT01887535|DRUG|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
218930340|NCT01887535|DRUG|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
218930341|NCT01887535|DRUG|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
218930342|NCT01887535|DRUG|Placebo|Matching placebo will be administered as an oral suspension formulation.
218930343|NCT05021861|DRUG|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
218930344|NCT05021861|DIAGNOSTIC_TEST|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
218930345|NCT05021861|DIAGNOSTIC_TEST|Control group|SYSTEMICALLY HEALTHY FEMALES
219044429|NCT03419728|BEHAVIORAL|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
219044430|NCT00925483|PROCEDURE|dialysis|different dialysis schedules for each arm
219044431|NCT02253810|DRUG|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
219044432|NCT02253810|DRUG|Placebo|Saline solution
219044433|NCT06165796|DEVICE|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
219044434|NCT00605046|DRUG|SPECT scan|AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
219044435|NCT04925063|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
219044436|NCT02787473|DRUG|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
219044437|NCT02787473|DRUG|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
219044438|NCT02787473|RADIATION|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
219541095|NCT02433977|DIETARY_SUPPLEMENT|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
219541096|NCT02433977|DRUG|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
219541097|NCT02433977|DRUG|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
218930346|NCT02963285|OTHER|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
218930347|NCT06150391|DEVICE|Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks|Visionary exercises are computer gammified activities that run on a computer with internet connection to facilitate home therapy. Patient must wear anaglyph glasses. Visual stimuli consists in dichoptic Gabor Patches presented to the amblyopic eye. Frequency is adjusted to actual patient visual acuity, and contrast to actual patient performance (contrast sensitivity). A band-filtered noise mask at the same frequency than the Gabor patch is presented to the fellow eye in certain ocassions.
218930348|NCT06150391|DEVICE|Patching|PEDIG (Pediatric Eye Disease Investigator Group) recommended amblyopia treatment. Consist on covering a child's better-seeing eye with a patch for 2 hours per day for mild and moderate amblyopia or 6 hours per day for severe amblyopia
218930349|NCT00405600|PROCEDURE|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
218930350|NCT03698877|DIAGNOSTIC_TEST|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
218930351|NCT04869826|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD\_2020 universal protocol.
218930352|NCT01310075|DEVICE|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
218930353|NCT01310075|DEVICE|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
218930354|NCT03382444|PROCEDURE|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
218930355|NCT03382444|DIAGNOSTIC_TEST|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
219541098|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
219541099|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
219541100|NCT01199562|PROCEDURE|infection prophylaxis and management|Undergo infection prophylaxis and management
219541101|NCT01199562|OTHER|laboratory biomarker analysis|Correlative studies
219620904|NCT06789523|BEHAVIORAL|Friendship Bench|"The Friendship Bench model comprises 6 weekly, individual sessions with trained peer workers in addition to the usual care. Peer workers will help participants identify problems, outline potential solutions, and implement selected solutions.~The adaptation of Friendship Bench for Vietnamese methadone patients made revisions, such as removing the 'Belief in supernatural powers' section, replacing the Shona Symptom Questionnaire with DASS-21, and adding meth use. But this adaptation removed women-focused content on pregnancy and postpartum depression that we plan to include."
219044439|NCT02787473|DRUG|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
219044440|NCT00882258|DRUG|12.5 mg Proellex|12.5 mg Proellex administered orally daily
219541102|NCT01199562|OTHER|flow cytometry|Correlative studies
219620905|NCT06789523|BEHAVIORAL|Usual psychiatric care|Usual care includes monthly check-ups by peer workers, referral to hospital-based psychiatric services or other available mental health services if needed. This usual care might surpass standard psychiatric care in other provinces given that peer workers in Haiphong have been well trained on case management skills.
219620906|NCT06792955|DRUG|HRS9531 injection|Multi-dose pen of HRS9531 injection solution.
219620907|NCT06792955|DRUG|HRS9531 injection|Single-dose pen of HRS9531 injection solution.
219620908|NCT06655493|OTHER|No treatment given|Participants will continue their normal care and will not get any treatment as part of this study.
219620909|NCT07078175|PROCEDURE|Xingnao Kaiqiao Acupuncture|"Acupuncture procedure developed by Prof. Shi Xuemin. Key acupoints include DU26, PC6, SP6, LI4, and GV20, applied with rapid and penetrating stimulation.~Arm(s): Xingnao Kaiqiao Acupuncture"
219044441|NCT00882258|DRUG|25 mg Proellex|25 mg Proellex administered orally daily
219044442|NCT00882258|DRUG|Placebo|Administered orally daily
219044443|NCT06431893|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
219044444|NCT05132764|PROCEDURE|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
219044445|NCT04854915|BEHAVIORAL|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
219044446|NCT04854915|BEHAVIORAL|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
219620910|NCT07078175|PROCEDURE|Electroacupuncture|Routine electroacupuncture using standard acupoints for hemiplegic upper limb rehabilitation, including LI15, LI11, SJ5, and LI4, with low-frequency electrical stimulation.
218930356|NCT03154411|DRUG|ABY-029|A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
218930357|NCT05349071|DRUG|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
218930358|NCT05349071|DRUG|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
218930359|NCT01377337|DRUG|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
218930360|NCT03052075|OTHER|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
218930361|NCT02124785|PROCEDURE|Blood sampling|At Years 21 to 25 after their second vaccine dose.
218930362|NCT02778789|DRUG|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
218930363|NCT02778789|DRUG|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
218930364|NCT03450122|BIOLOGICAL|Aldesleukin|Given SC
218930365|NCT03450122|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
218930366|NCT03450122|DRUG|Cyclophosphamide|Given IV
218930367|NCT03450122|BIOLOGICAL|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
218930368|NCT00770172|BIOLOGICAL|filgrastim|Given subcutaneously
218930369|NCT04617704|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
218930370|NCT02395081|DIETARY_SUPPLEMENT|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
218930371|NCT02395081|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
218930372|NCT02395081|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
218930373|NCT01123902|DEVICE|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
218930374|NCT01123902|DEVICE|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
218930375|NCT01876017|BIOLOGICAL|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
219044447|NCT03585452|DRUG|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
219044448|NCT03585452|DRUG|Propofol based general anesthesia|Patients with typical anaesthetic regimens
219044449|NCT01995799|DEVICE|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
219044450|NCT02453958|DEVICE|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
219044451|NCT01977586|OTHER|Magnetic Resonance Imaging (MRI)|
218930376|NCT03835806|OTHER|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
218930377|NCT03835806|OTHER|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
218930378|NCT05807620|OTHER|Gentle Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
218930379|NCT05807620|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen (morning and evening, 2x daily).
218930380|NCT05807620|OTHER|Sunscreen SPF 30|"Neutrogena Ultra Sheer Dry Touch SPF 30. Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an over the counter"
218930381|NCT02099955|DRUG|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
218930382|NCT04097574|DRUG|NPO-13: l-menthol|20 mL/site
218930383|NCT04171843|GENETIC|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
219044452|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
219044453|NCT03437122|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
219044454|NCT01742793|DRUG|lenalidomide (Revlimid) and romidepsin (Istodax)|
219044455|NCT01076829|OTHER|Spice polyphenols|spice
219044456|NCT05534763|BEHAVIORAL|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
219541103|NCT01199562|GENETIC|DNA analysis|Correlative studies
219541104|NCT01199562|GENETIC|RNA analysis|Correlative studies
218930384|NCT04171843|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
218930385|NCT04171843|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
218930386|NCT04171843|DRUG|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
218930387|NCT00926861|DEVICE|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
218930388|NCT00926861|DEVICE|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
218930389|NCT01223781|BEHAVIORAL|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
219541105|NCT01199562|PROCEDURE|management of therapy complications|undergo infection prophylaxis and management
218930390|NCT02779946|DEVICE|Fibro Scan|
218930391|NCT02779946|GENETIC|PNPLA3|
218930392|NCT02991040|DEVICE|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
219044457|NCT05534763|OTHER|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
219044458|NCT02825836|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
219541106|NCT01199562|DRUG|ganciclovir|Given IV
219541107|NCT01199562|DRUG|valganciclovir|Given orally
219541108|NCT01199562|DRUG|foscarnet sodium|Given orally
219541109|NCT01199562|PROCEDURE|antiviral therapy|undergo infection prophylaxis and management
219541110|NCT01199562|GENETIC|polymerase chain reaction|Correlative studies
219541111|NCT01199562|GENETIC|protein expression analysis|Correlative studies
219541112|NCT03603808|DEVICE|Electroporation|Undergo electroporation
219541113|NCT03603808|BIOLOGICAL|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
219541114|NCT03603808|OTHER|Laboratory Biomarker Analysis|Correlative studies
218930393|NCT02991040|DEVICE|Revanesse Ultra|Comparator without lidocaine
218930394|NCT00102817|DRUG|somatropin|
218930395|NCT02395159|DEVICE|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
218930396|NCT02395159|OTHER|sterile plaster dressings|standard wound management method of sterile plaster dressings
218930397|NCT04615026|DIAGNOSTIC_TEST|duplex sonography|all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
218930398|NCT03829202|DEVICE|Own mechanical knee|Daily use of own mechanical knee
218930399|NCT03829202|DEVICE|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
218930400|NCT02295618|DEVICE|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
219541115|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
219541116|NCT04025229|BEHAVIORAL|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
218930401|NCT02295618|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
218930402|NCT05147259|DRUG|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
218930403|NCT06190704|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
218930404|NCT05303311|DRUG|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
218930405|NCT05303311|DRUG|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
218930406|NCT01869764|DRUG|omega-3 fatty acid|Given PO
218930407|NCT01869764|OTHER|placebo|Given PO
218930408|NCT01869764|OTHER|laboratory biomarker analysis|Correlative studies
219044459|NCT02825836|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
219044460|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
218930409|NCT00380783|DRUG|AGN 203818|
218930410|NCT01286480|BEHAVIORAL|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
218930411|NCT01312532|DEVICE|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
219044461|NCT05248516|DIETARY_SUPPLEMENT|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
219044462|NCT05248516|DIETARY_SUPPLEMENT|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
219044463|NCT05248516|DIETARY_SUPPLEMENT|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
219541117|NCT05292339|DRUG|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
219541118|NCT05292339|DRUG|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
219541119|NCT06834607|DEVICE|Physician Modified Aortic Endograft repair for complex aortic aneurysm|To assess the use of the Physician-Modified Endovascular Grafts to repair juxtarenal aneurysms in high-risk subjects considered to be unsuitable candidates for open surgical repair, have limited or no other options for treatment, and having appropriate anatomy.
219541120|NCT05355883|BEHAVIORAL|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
218930412|NCT01312532|DEVICE|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
218930413|NCT01626872|DRUG|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
218930414|NCT01626872|DRUG|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
218930415|NCT01626872|DRUG|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
219541121|NCT05355883|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
218930416|NCT01626872|DRUG|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
218930417|NCT05724537|PROCEDURE|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
218930418|NCT02979548|DRUG|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
218930419|NCT02979548|DRUG|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
218930420|NCT02979548|DRUG|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
219044464|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
219541122|NCT05355883|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
219541123|NCT05355883|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
219541124|NCT05355883|BEHAVIORAL|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
219541125|NCT02571907|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
219541126|NCT02571907|DEVICE|Atrium iCAST™|Implantation of Atrium iCAST
219541127|NCT02571907|DEVICE|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
219541128|NCT01512823|BEHAVIORAL|Education|"Interactive educational intervention:~* 4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~* Emailed notes from second session~* Telephonic/email follow-up (reminders)~Didactic educational intervention:~\- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
219541129|NCT06649110|DRUG|LTP|LTP001
219541130|NCT06649110|DRUG|Placebo|Placebo
219541131|NCT06191094|DRUG|Faricimab Injection|Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.
219541132|NCT06191094|DRUG|sham treatment|Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
219541133|NCT03666026|BEHAVIORAL|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
218930421|NCT05275283|OTHER|PEEP|6 cmH2O of PEEP
218930422|NCT00960999|RADIATION|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
218930423|NCT00960999|RADIATION|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
218930424|NCT01696188|DEVICE|interscalene nerve catheter|
218930425|NCT05114252|DEVICE|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
218930426|NCT05114252|BEHAVIORAL|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
218930427|NCT00302367|DRUG|OROS methylphenidate hydrochloride|
219044465|NCT02196272|BEHAVIORAL|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~\- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
218930428|NCT00302367|DRUG|immediate release methylphenidate hydrochloride|
219044466|NCT01147185|DEVICE|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
219044467|NCT01147185|DEVICE|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
219044468|NCT00256919|DRUG|GW856553|
219044469|NCT04566796|DRUG|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
219044470|NCT04566796|DRUG|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
219044471|NCT02856542|DRUG|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
219044472|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
219044473|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
219044474|NCT00739752|BEHAVIORAL|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
219044475|NCT00739752|BEHAVIORAL|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
219620911|NCT06736158|GENETIC|Genetic testing for inherited bleeding disorders|Gene panel for bleeding: This analysis will look at a list of genes known to be associated with rare coagulation, platelet, connective tissue, and bleeding disorders. There are currently 318 genes on the panel however this list may be updated throughout the study. Genes of study include those on the the International Society of Thrombosis and Haemostasis (ISTH) TIER-1 (the first group of genes are the diagnostic-grade) and TIER-2 gene list, as well as additional genes identified in published research.
219620912|NCT07081438|BEHAVIORAL|icbt|12-Week Therapist-Based iCBT for OCD (Adapted Version of OCD Net: https://therapistguide.webcbt.se/index.html)
219620913|NCT07081100|DIETARY_SUPPLEMENT|Probiotic group|Participants took a freeze-dried probiotic powder every day, half an hour after a meal.
219620914|NCT07089706|BIOLOGICAL|mRNA-1283 Variant-containing Formulation|Sterile liquid for injection
219620915|NCT06861231|DEVICE|Transcraneal Direct Current Stimulation (tDCS)- Active|The stimulation will use a neoprene cap with carbon rubber electrodes and sponges soaked in saline solution (5x5 cm). The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC), and the cathode over the right supraorbital area (rSO). Constant current intensity of 2mA and a stimulation time of 20 minutes per day for 12 days will be applied, with an initial and final ramp of 30 seconds.
219620916|NCT06861231|DEVICE|Transcranial Direct Current Stimulation (tDCS)- Sham|Participants assigned to the sham tDCS group will also receive 12 home-based sessions of 20 minutes each. However, to mimic the sensation of active stimulation without delivering therapeutic current, the stimulator will only apply current during the initial and final 30-second ramp periods. The device will remain on for 20 minutes, but no current will be applied after the first ramp, simulating an active procedure without physiological effect.
219620917|NCT06861231|BEHAVIORAL|Cognitive Training (CT)|All participants will complete 12 home-based cognitive training sessions, each lasting 50 minutes. The training will include structured tasks focused on executive function and memory, such as categorization, problem-solving, autobiographical recall, planning, and schedule analysis. Instructions will be provided at the start of each session, and participants will work independently or with caregiver support.
219620918|NCT07096713|DRUG|Intervention 1: Brolucizumab|Intravitreal injection of Brolucizumab (6 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
219620919|NCT07096713|DRUG|Intervention 2: Aflibercept|Intravitreal injection of Aflibercept (2 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
218930429|NCT01024413|DRUG|erlotinib|study arm.erlotinib 150 mg oral till disease progression
218930430|NCT01024413|DRUG|gefitinib|study arm.gefitinib 250 mg oral till disease progression
218930431|NCT01267500|PROCEDURE|Non surgical therapy|patching or fusion exercises
218930432|NCT00601393|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
218930433|NCT00601393|OTHER|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
218930434|NCT04087850|BEHAVIORAL|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
219044476|NCT00739752|BEHAVIORAL|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
219044477|NCT00739752|BEHAVIORAL|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
219044478|NCT00739752|BEHAVIORAL|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
219044479|NCT00739752|BEHAVIORAL|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
218930435|NCT04239014|DRUG|Olaparib|Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
218930436|NCT04239014|DRUG|Ceralasertib|Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
219541134|NCT03666026|BEHAVIORAL|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
219541135|NCT03666026|BEHAVIORAL|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
219541136|NCT02286739|DEVICE|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA pre-market submission (510K) clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
219541137|NCT02286739|PROCEDURE|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
219620920|NCT07097519|OTHER|Immersive Virtual Reality (IVR)|This intervention involves the use of a high-end immersive virtual reality (IVR) application through the Oculus Quest 2 headset. Nurses participate in a rhythm-based exergame, Beat Saber, for at least 10 minutes per session, during 8-16 clinical shifts over an 8-week period. The game engages users in physical movement to music, requiring whole-body coordination and providing visual, auditory, and haptic feedback. The intervention aims to reduce stress and anxiety and enhance job performance among ICU nurses by providing an immersive, engaging, and therapeutic experience within the clinical environment.
218930437|NCT04239014|DRUG|Placebo to match olaparib|Per olaparib
218930438|NCT04960657|DRUG|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
218930439|NCT04960657|DRUG|PACAP38|PACAP38 infusion
218930440|NCT05002296|PROCEDURE|upper cervical manipulation|rotatory upper cervical manipulation to both sides. The treatment program was conducted for twelve sessions (three sessions per week). Assessment procedures were performed before and after treatment through visual analogue scale (VAS)
218930441|NCT04139213|DRUG|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
218930442|NCT04139213|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
219044480|NCT00153400|BEHAVIORAL|Enhanced Lifestyle Intervention|Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.
219044481|NCT01434290|RADIATION|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
219044482|NCT01434290|RADIATION|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
219044483|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
219620921|NCT07096999|OTHER|Non-Interventional Study|Non-interventional study
219541138|NCT05572281|DRUG|Tasimelteon Oral Capsule|No additional information
219541139|NCT05572281|DRUG|Tasimelteon Oral Suspension|No additional information
219541140|NCT04071652|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
219541141|NCT06035250|DRUG|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
219541142|NCT03447353|DRUG|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
218930443|NCT04139213|OTHER|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
218930444|NCT04139213|DRUG|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
219044484|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
219541143|NCT03447353|DRUG|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
219541144|NCT03447353|DRUG|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
219541145|NCT03913676|BEHAVIORAL|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
219620922|NCT07097688|BIOLOGICAL|Sodium Hexametaphosphate (SHMP) Inorganic polyphosphates (poly[P]) are linear polymers of orthophosphate (Pi) residues linked by energy-rich phosphoranhydride bonds, Ithas multiple physiological funct|The study will be with two parallel arms (1:1 allocation ratio). The sample size per group will be calculated according to the following equation for binary outcomes; N = (Zα/2 + Zβ) 2 ×p1(1 - p1) + p2(1 - p2)/δ 2 so the minimal sample size for an equal size clinical trial is 27teeth in each group. We will recruit 30 teeth in each group for possible attrition
218930445|NCT02753452|BEHAVIORAL|Residential Immersive Life Skills programming|
218930446|NCT02753452|BEHAVIORAL|Non-residential life skills programming|
218930447|NCT01173237|PROCEDURE|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
218930448|NCT01173237|PROCEDURE|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
218930449|NCT01260402|DEVICE|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
218930450|NCT01260402|DEVICE|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
218930451|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
218930452|NCT02284035|DRUG|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
219541146|NCT01343004|DRUG|Placebo|Placebo 0 mcg subcutaneous daily
219541147|NCT01343004|DRUG|BA058 80 mcg|BA058 80 mcg subcutaneous daily
219620923|NCT04563715|DIAGNOSTIC_TEST|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
219620924|NCT04563715|BEHAVIORAL|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
219620925|NCT07095569|DEVICE|(Shoulder individual nerves TRF (thermal radio frequency): Patients will receive shoulder individual nerves Thermal RF.|Shoulder individual nerves thermal RF technique: The patient will be put in the sitting position, monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. after disinfection A high-frequency linear transducer (10-15 Hz) will be placed parallel and cephalad to the spine of the scapula. The probe will be moved from cephalad to caudad until the trapezius and supraspinatus muscles were identified. The suprascapular nerve will be identified as a hyperechogenic structure in the suprascapular fossa deep to the superior transverse scapular ligament. A 10 cm radiofrequency needle, with a 10 mm active tip, will be inserted in plane with the ultrasound beam and advanced to reach the proximity to the nerve. A nerve stimulator was used as an additional nerve-finding modality.
219620926|NCT07095569|DRUG|conservative treatment|Patients will receive conservative treatment Acetaminophen (paracetamol 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.
218930453|NCT02284035|DRUG|EFV/TDF/FTC|standard combination therapy
218930454|NCT02284035|DRUG|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
218930455|NCT02284035|DRUG|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
218930456|NCT02284035|DRUG|EFV plus ABC/3TC or RPV/TDF/FTC|
218930457|NCT02284035|DRUG|ATV/r plus ABC/3TC|
218930458|NCT02284035|DRUG|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
218930459|NCT02284035|DRUG|RAL plus ABC/3TC|
219541148|NCT01343004|DRUG|teriparatide|teriparatide 20 mcg subcutaneous daily
219541149|NCT00313794|DRUG|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
219541150|NCT01660789|BEHAVIORAL|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
219541151|NCT03110848|DRUG|Atorvastatin|Atorvastatin 20 mg daily
219541152|NCT03110848|DRUG|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
218930460|NCT02284035|DRUG|Other ART regimens|
218930461|NCT04832997|DIAGNOSTIC_TEST|Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)|Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS \>= 3 and PRI-MUS \>= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
219044485|NCT04625751|OTHER|CO2-enriched air|To assess cardiovascular reactivity
219044486|NCT04625751|OTHER|Meal response test|Meal response test to assess changes in splanchnic blood flow.
219541153|NCT05635448|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
219541154|NCT05635448|BEHAVIORAL|No intervention - waitlist control|No intervention - waitlist control
219541155|NCT05217472|DRUG|Ravaglimab|Intravenous Injection
218930462|NCT04501770|DRUG|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
218930463|NCT04501770|DRUG|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
218930464|NCT04501770|DRUG|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
218930465|NCT04501770|DRUG|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
218930466|NCT04501770|DRUG|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
218930467|NCT04501770|DRUG|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
218930468|NCT04501770|DRUG|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
218930469|NCT04501770|DRUG|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
218930470|NCT00928408|DRUG|Cinacalcet|
218930471|NCT00776074|DRUG|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
218930472|NCT00776074|DRUG|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
218930473|NCT01930006|DRUG|MGCD265|
218930474|NCT00787644|DRUG|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
218930475|NCT00787644|DRUG|Placebo|Matching placebo (inert tablet)
218930476|NCT04078425|DRUG|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
218930477|NCT00536744|DEVICE|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
218930478|NCT00536744|OTHER|Sham|Non-energized (inactive - Sham) application + standard of care
218930479|NCT01619280|DRUG|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
219541156|NCT05217472|DRUG|Ravagalimab|Subcutaneous Injection
219541157|NCT05217472|DRUG|Placebo|Intravenous Injection
219541158|NCT05217472|DRUG|Placebo|Subcutaneous Injection
219620927|NCT07104721|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3×10⁶ STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
218930480|NCT02177565|BIOLOGICAL|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
218930481|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
219044487|NCT05289609|PROCEDURE|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
219541159|NCT02399423|BEHAVIORAL|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
219541160|NCT02399423|BEHAVIORAL|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
219620928|NCT07100249|DRUG|HDM2012|HDM2012 will be administered via IV infusion.
219620929|NCT05043480|DEVICE|PEMF|Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.
219541161|NCT04504617|BEHAVIORAL|Nutrition education intervention to enhance complementary feeding practices|The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
219620930|NCT03304301|BEHAVIORAL|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
219620931|NCT02562573|DRUG|PBI4050|
219620932|NCT07110766|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
218930482|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
218930483|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
218930484|NCT05528315|DRUG|ABX-002|ABX-002
218930485|NCT05528315|DRUG|Placebo|Placebo
219044488|NCT03821012|OTHER|in-hospital process optimization|
219620933|NCT07110766|DRUG|Placebo|Administered orally placebo
219620934|NCT07112248|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219620935|NCT07112248|DIETARY_SUPPLEMENT|inulin|Inulin is a kind of soluble dietary fiber.
219620936|NCT07111026|BEHAVIORAL|Sisters of Heart|"The intervention consists of ten weekly, 60-75-minute in-person peer support group sessions led by trained community health workers/promotoras (CHWs/Ps), with 6-10 participants per group. Sessions will be semi-structured, covering AHA Life's Essential 8 (LE8), stress management, and individualized topics based on participant priorities and social needs identified through surveys or group discussions. Each session includes stress management, core educational content, and time for addressing participant-driven issues. CHWs/Ps will also provide individualized support outside the sessions through direct community resource navigation, including phone or in-person warm handoffs to needed services."
219620937|NCT07111026|BEHAVIORAL|Basic intervention|The Basic intervention will include assessment of AHA LE8, provision to participants of results of 1) their baseline AHA LE8 assessments, including lab results, 2) written/online information with pertinent AHA LE8 health education content, 3) stress management educational materials, and 4) written information about the Ellenton Migrant Farm Worker Clinic and a community resource list
219620938|NCT07111312|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
219620939|NCT07111312|OTHER|Placebo control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
219620940|NCT07112963|DRUG|Fluoride Varnish|"Application of fluoride varnish to proximal surfaces of primary molars following standard clinical protocols to promote remineralization and arrest early carious lesions.~Application of resin infiltrant material to proximal non-cavitated carious lesions in primary molars, performed according to manufacturer instructions to arrest lesion progression.~Sequential application of resin infiltration followed by fluoride varnish on proximal surfaces of primary molars to maximize caries arrest and remineralization effects."
219620941|NCT07111819|BEHAVIORAL|Self-sampling acceptance|Cervical self-sampling devices will be distributed among the study participants followed by survey on the devices acceptance
219620942|NCT07113119|OTHER|Exercise intervention|Patients that will be randomly assigned in the group A will be invited to attent 1-year exercise sessions, with frequency 3 sessions per week. The program included 30 minutes of Pilates exercises, strengthening, balance and flexibility exercises, which are performed with rubber bands, mobility sticks and balls.
219044489|NCT03821012|OTHER|PPCI hospital-based regional STEMI transfer network construction|
219044490|NCT03821012|OTHER|the whole-city STEMI care network construction|
219044491|NCT02839616|PROCEDURE|orthotopic liver transplantation|
219044492|NCT03501095|DIAGNOSTIC_TEST|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
218930486|NCT01642589|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
218930487|NCT01642589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
218930488|NCT00359645|PROCEDURE|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
219541162|NCT03306030|DRUG|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
219541163|NCT03306030|DRUG|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
218930489|NCT01703767|BEHAVIORAL|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
218930490|NCT06498076|DRUG|Norepinephrine|injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
218930491|NCT06498076|DRUG|Ephedrine|injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
218930492|NCT02119377|OTHER|questionnaire|
219541164|NCT03374605|DEVICE|active tDCS|15 minutes of active (2mA) high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
218930493|NCT01334450|DEVICE|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
218930494|NCT00298558|BEHAVIORAL|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
218930495|NCT04302077|OTHER|virtual doctor visit|interactive live-video feed at home through EPIC
218930496|NCT04302077|OTHER|Standard care doctor's visit|In person visit as per standard of care
218930497|NCT06266143|DRUG|Y101D|Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
218930498|NCT04002102|OTHER|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
219541165|NCT03374605|DEVICE|sham tDCS|15 minutes of sham high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
219541166|NCT05343676|DEVICE|ultrasonography|"* For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~* For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~* Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
219541167|NCT05468879|DRUG|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
219541168|NCT05468879|DRUG|Amaryl®|Amaryl®
219541169|NCT04196907|DEVICE|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
219541170|NCT04102085|OTHER|no intervention|no intervention
219541171|NCT00526188|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
219541172|NCT02529709|OTHER|High-Protein Condition|The participants will be fed a high-protein meal
219541173|NCT02529709|OTHER|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
218930499|NCT04002102|OTHER|Usual care|Remain in standard care after randomization and educational materials.
218930500|NCT04002102|OTHER|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
218930501|NCT06383481|OTHER|Mobile based education|"Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided."
218930502|NCT00057720|DRUG|TLK286 HCl for injection|
218930503|NCT00057720|DRUG|topotecan hydrochloride for injection|
218930504|NCT00057720|DRUG|doxorubicin HCl liposome injection|
218930505|NCT00752778|OTHER|pet-scan FDG-F18|
219541174|NCT00211653|DRUG|N-Acetylcysteine|
219541175|NCT02642653|DRUG|Lovastatin|Once per day dosing
219541176|NCT02642653|OTHER|Placebo|Once per day dosing
219620943|NCT07113418|DIAGNOSTIC_TEST|ELISA|Enzyme-Linked Immunosorbent Assay. It's a lab technique used to detect and measure specific proteins like antibodies or antigens in a biological sample using enzyme-linked antibodies. When a substrate is added, the enzyme causes a color change, which makes it easy to measure the result accurately.
218930506|NCT01538758|OTHER|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
218930507|NCT01538758|OTHER|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
218930508|NCT01073111|DEVICE|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
218930509|NCT01073111|DEVICE|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
218930510|NCT01073111|DEVICE|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
219541177|NCT02942563|DRUG|FOLFOXIRI|"Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
218930511|NCT06128759|OTHER|Focusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
219044493|NCT02012595|OTHER|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
219541178|NCT00893685|DEVICE|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
219541179|NCT06558734|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
219541180|NCT06558734|PROCEDURE|Cementation|Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
219541181|NCT00834717|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
219541182|NCT00834717|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
219541183|NCT05488158|OTHER|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
219541184|NCT05936645|PROCEDURE|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
219541185|NCT05936645|PROCEDURE|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
219541186|NCT00217503|BIOLOGICAL|bevacizumab|
218930512|NCT02908672|DRUG|Atezolizumab|Will be administered as per the schedule described in individual arm.
218930513|NCT02908672|DRUG|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
218930514|NCT02908672|DRUG|Cobimetinib|Will be administered as per the schedule described in individual arm.
218930515|NCT02908672|DRUG|Vemurafenib|Will be administered as per the schedule described in individual arm.
219044494|NCT05952622|DEVICE|Continuous passive motion therapy|Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
219044495|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
219541187|NCT00217503|BIOLOGICAL|filgrastim|
219541188|NCT00217503|BIOLOGICAL|pegfilgrastim|
219541189|NCT00217503|DRUG|bortezomib|
219541190|NCT00217503|DRUG|cyclophosphamide|
219541191|NCT00217503|DRUG|doxorubicin hydrochloride|
219541192|NCT00217503|DRUG|etoposide|
219541193|NCT00217503|DRUG|ganciclovir|
219541194|NCT00217503|DRUG|valganciclovir|
219541195|NCT00217503|DRUG|zidovudine|
219541196|NCT03821675|DEVICE|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
219541197|NCT03821675|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
218930516|NCT02908672|DRUG|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
218930517|NCT05127863|BEHAVIORAL|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
218930518|NCT01342016|DRUG|tacrolimus capsule|oral
218930519|NCT01342016|DRUG|tacrolimus placebo|oral
218930520|NCT01342016|DRUG|leflunomide tablet|oral
218930521|NCT01342016|DRUG|leflunomide placebo|oral
218930522|NCT01342016|DRUG|prednisone|oral
218930523|NCT04740372|OTHER|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
219541198|NCT05826119|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
219541199|NCT05826119|DRUG|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
219541200|NCT00508651|BIOLOGICAL|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
218930524|NCT05952882|DRUG|Liraglutide + Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks
218930525|NCT05952882|DRUG|Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
218930526|NCT03767413|PROCEDURE|PNF|proprioceptive neuromuscular facilitation training
218930527|NCT03767413|PROCEDURE|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
218930528|NCT00005618|DRUG|arsenic trioxide|
219044496|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
219044497|NCT03761732|BEHAVIORAL|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
219044498|NCT04657497|DRUG|FOY-305|Specified Dosage and Duration of Treatment
219044499|NCT04657497|DRUG|Placebo|Specified Dosage and Duration of Treatment
219541201|NCT00508651|BIOLOGICAL|Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
219541202|NCT05693623|OTHER|cold application|cold application
219541203|NCT01669980|DRUG|Ceftaroline fosamil|"* Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
219541204|NCT01669980|DRUG|IV Ceftriaxone and Vancomycin|"* IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
219620944|NCT07111000|PROCEDURE|Epley Maneuver|The patient's head is turned 45 degrees towards the side that caused the most nystagmus or reproduced their initial symptoms. The patient is then laid down with their head hanging over the edge of the bed. After that, the head will be rotated 90 degrees in the opposite direction, with the head remaining in a dependent position. The patient is then asked to roll onto their side with their head facing downward. They are then brought back to a sitting position and the head is moved forward 45 degrees. Each position is held until the vertigo and/or nystagmus subsides or for at least 30 seconds
218930529|NCT01880138|OTHER|watching animated cartoon before general anesthesia|
218930530|NCT01880138|OTHER|not watching animated cartoon beofre general anaesthesia|
218930531|NCT02606513|OTHER|MR Urography; CT Urography|
218930532|NCT04819607|OTHER|model of care|Multidisciplinary model of care for BMFS patients.
218930533|NCT03452657|DRUG|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
218930534|NCT03452657|PROCEDURE|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
218930535|NCT06315582|PROCEDURE|Removal of uterine septum with hysteroscopic scissors without electrosurgery.|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
218930536|NCT06315582|PROCEDURE|Hysteroscopic septoplasty utilizing bipolar electrosurgery|Hysteroscopic septoplasty utilizing bipolar electrosurgery
218930537|NCT06521398|OTHER|Doula Support|Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
218930538|NCT07074522|PROCEDURE|Single-layer closure|Patients who underwent single-layer closure of the transverse lower segment during cesarean section.
218930539|NCT07074522|PROCEDURE|Double-layer closure|Patients who underwent double-layer closure of the transverse lower segment during cesarean section.
218930540|NCT07075913|OTHER|Subcostal transverse abdominis plane block|Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
218930541|NCT07075913|OTHER|Erector spinae plane block|Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
218930542|NCT07074925|OTHER|Video assisted informed consent|The 2-minute video (available in English or Spanish) will use animation to explain the neonatal LP procedure, benefits, and risks.
218930543|NCT07074925|OTHER|Standard consent|The standard consent group will receive usual procedure description and consent.
218930544|NCT07074119|DEVICE|wearable-based adjustment therapy|"* Patients will wear the BWS for 7 days prior to each of the visit : baseline (V1) at week 0, V2 at week 4 (phone call at 1 month), V3 at week 12 (3 months visit) and V4 at week 24 (6 months).~* Data extracted from each session of monitoring with the BWS will be made available to the neurologist (only in the experimental group) prior to V1 (W0), V2 (W4), V3 (W12) and V4 (W24) respectively~* Treatment adjustment will be guided by the current consensus guidelines for treatment adjustment for motor fluctuations in PD using reports from BWS data. Reports will be screened by neurologists before the patient's visit so the groups blinding is correctly observed"
218930545|NCT07074613|DEVICE|Traditional Treadmill Walking|Participants walked on a traditional treadmill with standard time, speed, and distance tracking, no AR features.
218930546|NCT07074613|DEVICE|JOHNSON 8.1T treadmill with Passport AR system|Participants walked on an AR-integrated treadmill with immersive virtual environments and real-time feedback.
218930547|NCT07075042|DEVICE|Training with PRC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
218930548|NCT07075042|DEVICE|Training with DC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
218930549|NCT07075042|DEVICE|PRC Device use in community and home|After the training sessions, all subjects will use the PRC device in their homes, just in a different order.
218930550|NCT07075042|DEVICE|DC Device use in community and home|After the training sessions, all subjects will use the DC device in their homes, just in a different order
218930551|NCT07074574|OTHER|Present odors to participants while recording brain activity using fMRI|Present odors to participants while recording brain activity using fMRI
218930552|NCT04379414|BEHAVIORAL|YES portal|A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.
218930553|NCT02692638|PROCEDURE|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
218930554|NCT02692638|PROCEDURE|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
218930555|NCT00124436|DRUG|alitretinoin|
218930556|NCT04952948|OTHER|PILATES Training|During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
218930557|NCT00326430|BEHAVIORAL|Cognitive Therapy, Interpersonal Therapy|
218930558|NCT04652219|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
218930559|NCT01678404|DRUG|131I-rituximab|
219044500|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
219044501|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
219044502|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
219044503|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
219044504|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
219044505|NCT06391788|PROCEDURE|thoracoscopic Morrow surgery|minimally invasive trans-mitral Morrow septal myectomy
219044506|NCT06391788|PROCEDURE|modified Morrow surgery|median open modified enlarged Morrow septal myectomy
218930560|NCT04986319|DIAGNOSTIC_TEST|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
218930561|NCT04475302|BIOLOGICAL|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
218930562|NCT05857475|DEVICE|CPAP therapy|Continous positive airway pressure therapy
218930563|NCT05857475|OTHER|Control|No CPAP
218930564|NCT00123422|BEHAVIORAL|Breathing retraining|exercise training with computerized training program
218930565|NCT00123422|BEHAVIORAL|Heliox|exercise training with a helium oxygen combination
219044507|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
219044508|NCT01828372|OTHER|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
219620945|NCT07111000|PROCEDURE|Sham maneuver|This control maneuver will involve coordinated movements of the hands and legs, while excluding any head movement. Patients will be at first in a sitting position with both feet on the ground and both hands placed on the thighs and then they will be asked to lift both hands off the thighs, keeping the arms extended. They will then be asked to return to their initial upright sitting position. Patients will then raise their right foot off the ground while keeping the left one planted on the ground. It will be an alternating movement between lifting the right and left feet while maintaining a smooth and well- controlled rhythm for 90 seconds.
219620946|NCT07110831|DRUG|Fluoxetine|Participants in the intervention arm will receive oral fluoxetine capsules starting with 20mg daily for 12 weeks. The dose of the fluoxetine may be adjusted during follow-up by titrating the dose against the participants' response..
219620947|NCT07110831|BEHAVIORAL|Cognitive-behavioral therapy|Participants with HAM-D score of between 8 and 13 (mild depression) will receive sessions of Cognitive Behavioural Therapy (CBT) as per standard routine care. Participants in the intervention arm will also receive sessions of CBT as per standard routine care.
219620948|NCT07110935|DRUG|intravenous iron|intravenous iron dextran
219620949|NCT07110935|DRUG|oral iron|oral iron(ferrous Sulphate)
219620950|NCT07113158|DRUG|Aspirin + Acid folic|Aspirin 100 mg/day and Acid Folic 5 mg/day + gold standard treatment
219620951|NCT07113158|DRUG|Placebo Aspirin + Placebo Acid folic|The Placebo Aspirin 100 mg/j + Placebo folic acid 5 mg/j + reference treatment
219620952|NCT07105514|DIETARY_SUPPLEMENT|Indole-3-propionic acid (IPA)|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Active capsules are taken orally and contain 250 mg of IPA each.
219620953|NCT07105514|DIETARY_SUPPLEMENT|Placebo|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Placebo capsules are taken orally and contain maltodextrin.
219620954|NCT07112235|BIOLOGICAL|Rhinovirus-A16|Nasal inoculation with a dose equivalent to 100 TCID50 of rhinovirus-A16 inoculum will be administered to all participants in the study
219620955|NCT07112716|PROCEDURE|Empirical superior vena cava isolation|Empirical superior vena cava isolation with radiofrequency ablation
219620956|NCT07112716|PROCEDURE|Ablation without empirical superior vena cava isolation|No ablation or ablation of other arrhythmic foci wuthout empirical superior vena cava isolation
219620957|NCT07113301|PROCEDURE|incisional or core-needle biopsy for tumor diagnosis|incisional or core-needle biopsy for tumor diagnosis
219620958|NCT07111715|DEVICE|Small bowel Video Capsule Endoscopy (VCE) using an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC),|Small bowel Video Capsule Endoscopy (VCE) will be performed using the an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC), which is able to automatically select suspected lesions thus creating a very short video constituted only by selected images.
219620959|NCT07112144|BIOLOGICAL|DTacP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml；Injection；
218930566|NCT00123422|BEHAVIORAL|Exercise|exercise training
219620960|NCT07112144|BIOLOGICAL|DTaP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml.Injection
219620961|NCT07112144|BIOLOGICAL|DTacP-IPV/Hib|Administer 1 dose at 2 months, 4 months, 6 months and 18 months of age respectively, with each injection dose being 0.5 ml.Injection
219620962|NCT07111767|DIETARY_SUPPLEMENT|Low-Cost Post-Bariatric Diet|"Low-Cost Post-Bariatric Diet (Experimental):~Based on the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines.~Uses affordable, locally available foods (e.g., eggs, lentils, local dairy products) to meet protein and micronutrient needs.~Designed to be cost-effective and accessible for patients from low-income or rural areas."
219620963|NCT07111767|DIETARY_SUPPLEMENT|Standard High-cost Post-Bariatric Diet|"Standard Post-Bariatric Diet (Active Comparator):~The conventional high-cost diet currently followed at the study hospital. Includes imported or expensive protein supplements such as whey protein and cottage cheese, along with nutritional products not easily accessible in rural or low-resource settings."
219620964|NCT07111832|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
219620965|NCT07111832|DRUG|SHR-1316 Injection|SHR-1316 injection.
218930567|NCT05452343|BIOLOGICAL|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
219044509|NCT01677091|OTHER|Cervical vibration|Vibration of neck muscles during 10 minutes
219044510|NCT01677091|OTHER|Prism adaptation|Prism adaptation during 10 minutes
219044511|NCT01677091|OTHER|Conventional rehabilitation|conventional rehabilitation
219044512|NCT00558103|DRUG|lapatinib|Oral administration
219044513|NCT00558103|DRUG|Pazopanib|Oral administration
219044514|NCT04947332|PROCEDURE|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
219044515|NCT05886959|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
219044516|NCT05886959|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219044517|NCT05886959|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
219044518|NCT05886959|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219541205|NCT04718025|DRUG|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
219541206|NCT04718025|DRUG|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
219541207|NCT04718025|DRUG|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
219541208|NCT01665690|OTHER|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
219620966|NCT07111832|DRUG|Toripalimab Injection|Toripalimab injection.
219620967|NCT07111832|DRUG|Paclitaxel for Injection|Paclitaxel for injection.
219044519|NCT05886959|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
219044520|NCT05886959|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219541209|NCT01665690|BEHAVIORAL|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
219541210|NCT02028221|DRUG|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
219541211|NCT02028221|DRUG|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
219541212|NCT03757195|PROCEDURE|Augmentation|combination product
219541213|NCT03581097|OTHER|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
219541214|NCT06374134|BEHAVIORAL|Community Engagement Practice|Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.
219541215|NCT06374134|BEHAVIORAL|Patient-Centric Protocol Element|Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.
219541216|NCT00721435|PROCEDURE|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
219541217|NCT01092455|DRUG|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
219541218|NCT04857138|DRUG|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
218930568|NCT03089281|DEVICE|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
218930569|NCT02796313|BEHAVIORAL|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
218930570|NCT02796313|BEHAVIORAL|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
218930571|NCT01506804|OTHER|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
218930572|NCT00430404|OTHER|Collaborative care (Intervention)|Structured shared care with treatment protocol \& support
218930573|NCT01255436|OTHER|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
218930574|NCT01255436|OTHER|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
218930575|NCT02927561|OTHER|Diabetic Retinopathy screening|Diabetic Retinopathy screening
218930576|NCT00826462|DRUG|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
219541219|NCT04857138|DRUG|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
219541220|NCT04604262|DEVICE|Waterpik|Waterpik dental water jet
219541221|NCT05850676|DIAGNOSTIC_TEST|Sleep study|Participants will spend two nights in the Penn Sleep Center
219541222|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
219541223|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
218930577|NCT00826462|DRUG|Placebo|Injection with sodium chloride at start and at 3 weeks
218930578|NCT00826462|DRUG|Lidocaine|10 mg of lidocaine at start and at 3 weeks
218930579|NCT00826462|OTHER|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
218930580|NCT00826462|DRUG|Naproxen|Naproxen 500 mg bid for 14 days
218930581|NCT06521931|DRUG|PN20|Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
218930582|NCT06287099|DRUG|BRL-101|Subjects will receive a single infusion of BRL-101.
218930583|NCT03016494|DRUG|Co-administration of DWC20155 and DWC20156|
219044521|NCT05886959|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
219541224|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
219541225|NCT05735145|DRUG|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
219541226|NCT00744679|DRUG|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
219541227|NCT05644184|BIOLOGICAL|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
219541228|NCT05644184|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
219541229|NCT06563115|DRUG|(PEG)-BHD1028 Single Ascending Dose|4, 8, 16, 32, and 64 μg/Kg
219541230|NCT06563115|DRUG|(PEG)-BHD1028 Multiple Ascending Dose|8, 16, and 32 μg/Kg
219541231|NCT06563115|OTHER|Placebo|Diluent
219541232|NCT05276635|BEHAVIORAL|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
218930584|NCT03016494|DRUG|DWJ1386 Tab.|
218930585|NCT02955043|BEHAVIORAL|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
218930586|NCT05876000|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for mechanical circulatory support
218930587|NCT01081106|PROCEDURE|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
218930588|NCT00004366|PROCEDURE|Physical therapy|
218930589|NCT02817568|OTHER|Drawing Blood|Drawing Blood for genetic analysis
218930590|NCT04395742|OTHER|Data collection|Only data collection
218930591|NCT00426244|OTHER|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
218930592|NCT00426244|OTHER|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
218930593|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
218930594|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
218930595|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
218930596|NCT00184301|BEHAVIORAL|inpatient treatment|inpatient treatment during 1 year
218930597|NCT00184301|BEHAVIORAL|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
218930598|NCT01908803|DRUG|AL-60371/AL-817 otic suspension|
218930599|NCT01908803|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
218930600|NCT04791306|OTHER|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
218930601|NCT04791306|OTHER|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
218930602|NCT00867815|DRUG|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
218930603|NCT01305993|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
218930604|NCT00245752|DEVICE|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
218930605|NCT05326269|DRUG|Terbutaline|Subcutaneous injection
219044522|NCT05886959|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
219541233|NCT05276635|BEHAVIORAL|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
219541234|NCT04137835|DEVICE|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
218930606|NCT02840591|DRUG|Ramelteon|
218930607|NCT02840591|DRUG|Citicoline|
219620968|NCT07112729|OTHER|Active SMS Invitation|Participants in this group will receive a text message inviting them to participate in the free FOBT program. The SMS message will include a brief explanation of the program, instructions on how to obtain a screening kit, and a contact number for inquiries. A reminder SMS message will be sent one week after the initial message.
219620969|NCT07113262|DRUG|IBI311|Teprotumumab N01 injection (code name IBI311)
218930608|NCT00120419|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
218930609|NCT04980144|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
218930610|NCT04980144|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
218930611|NCT03383016|OTHER|Lifestyle questionnaires|
218930612|NCT03383016|DIAGNOSTIC_TEST|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
218930613|NCT03136848|DRUG|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
218930614|NCT05190497|DEVICE|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
218930615|NCT01043367|DIETARY_SUPPLEMENT|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
218930616|NCT01043367|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
219044523|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
219620970|NCT07113262|DRUG|Placebo|Placebo
219620971|NCT07112586|DRUG|Plasma derived exosomes|Exosomes derived from patients' plasma, centrifuged at high speeds multiple times
219620972|NCT07103369|DRUG|SM17 for injection|SM17 monoclonal antibody for intravenous infusion use
219620973|NCT07103369|OTHER|SM17 placebo for injection|placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein
218930617|NCT04441918|COMBINATION_PRODUCT|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
218930618|NCT00306319|DRUG|moxifloxacin|
218930619|NCT01864603|OTHER|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
218930620|NCT01864603|OTHER|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
218930621|NCT01864603|OTHER|Targeted PrEP and Targeted testing interventions|
218930622|NCT01864603|OTHER|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
218930623|NCT01956929|DRUG|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
218930624|NCT01956929|DRUG|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
218930625|NCT06186193|BEHAVIORAL|MyP|see above: attention exercise based on phone app
218930626|NCT05653076|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract|Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
218930627|NCT00529867|DRUG|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
218930628|NCT00529867|DRUG|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
218930629|NCT05113069|DRUG|SHR-A1912|SHR-A1912, dose escalation and expansion.
218930630|NCT05832229|DRUG|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
218930631|NCT01610778|DIETARY_SUPPLEMENT|Placebo|
218930632|NCT01610778|DIETARY_SUPPLEMENT|5-aminolevulinic acid phosphate|
218930633|NCT00003518|DRUG|gemcitabine hydrochloride|
218930634|NCT00003518|DRUG|paclitaxel|
218930635|NCT03743857|PROCEDURE|Manual Therapy|AP ankle mobilization
218930636|NCT00710580|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
219620974|NCT07109453|OTHER|18 Test Products along with positive and negative control|1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
219620975|NCT07110779|BEHAVIORAL|Telenursing consultation|Telenursing consultations, which will be carried out via telephone calls, video calls, or messaging platforms, will be held between one, three, and five months after the first consultation. The North American Nursing Diagnosis Association (NANDA-I), the Nursing Outcomes Classification (NOC), and the Nursing Interventions Classification (NIC) taxonomies will be used to structure these consultations.
218930637|NCT00710580|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
218930638|NCT00710580|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
218930639|NCT04946279|OTHER|Best Practice|Receive usual/standard of care
218930640|NCT04946279|OTHER|Informational Intervention|Receive conversation tool
218930641|NCT04946279|OTHER|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
218930642|NCT03893942|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
218930643|NCT03893942|OTHER|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
218930644|NCT03893942|OTHER|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
218930645|NCT03893942|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
218930646|NCT03893942|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
218930647|NCT03893942|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
218930648|NCT03893942|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
218930649|NCT03893942|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
218930650|NCT05408442|OTHER|No intervention|No intervention
218930651|NCT01501877|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
218930652|NCT01501877|BEHAVIORAL|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
218930653|NCT01432925|PROCEDURE|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
218930654|NCT00001213|DRUG|Cysteamine|
219541235|NCT05438550|DRUG|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
219541236|NCT02255149|DEVICE|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
219541237|NCT00308906|DRUG|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
219541238|NCT00506376|BEHAVIORAL|Interview|Interview that will take about 20 minutes to complete.
219541239|NCT03098485|DRUG|Levofloxacin|5 days of levofloxacin administration
218930655|NCT06522126|BEHAVIORAL|progressive relaxation exercise|One of the techniques employed to mitigate the prevalence of PMS complaints in women during this period is progressive relaxation exercises (PRE). It is one of the most preferred options due to its simplicity, cost-effectiveness, and reliability. Over the course of numerous years of research, progressive relaxation has been validated as an efficacious approach for regulating muscle tension. These exercises are performed to facilitate the distinction between tension and looseness in the body and to enable the individual to relax on her own in daily life. PRE involves the voluntary, systematic tension and relaxation of large muscle groups in the human body. PRE reduces anxiety levels by reducing muscle tension. It also provides the individual with a sense of profound rest, renewal, and rebirth.
218930656|NCT00149318|OTHER|Biochemical analyses.|Biochemical analyses.
218930657|NCT00509483|RADIATION|Radioactive iodine|Radioactive iodine preceded by rhTSH
218930658|NCT05801341|DEVICE|Lollipop|An oral lollipop swab will be obtained by placing a flocked swab into the mouth and sucking on the swab for 20 seconds as one would suck on a lollipop
218930659|NCT00908843|OTHER|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
218930660|NCT00908843|OTHER|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
219541240|NCT03098485|DRUG|Azithromycin|5 days of azithromycin administration
219541241|NCT03098485|DRUG|Cefpodoxime|5 days of cefpodoxime administration
219541242|NCT02508870|DRUG|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
219541243|NCT02508870|DRUG|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
218930661|NCT04583774|OTHER|Prediction error tasks|The intervention involves two tasks, one that involves taste stimuli and another that involves monetary stimuli, and test their impact o brain response in electro encephalography (EEG) and functional magnetic resonance imaging (fMRI)
218930662|NCT01554241|DIETARY_SUPPLEMENT|D3 2000 IU/day|2000 IU/day D3
218930663|NCT01554241|DIETARY_SUPPLEMENT|D3 4000 IU/day|vitamin D3 4000 IU/day
218930664|NCT01554241|DIETARY_SUPPLEMENT|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
218930665|NCT01554241|DIETARY_SUPPLEMENT|vitamin D3 800 IU/day|vitamin D3 800 IU/day
218930666|NCT04673019|BEHAVIORAL|Nurse AMIE (Addressing Metastatic Individuals Every day)|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
218930667|NCT06104436|BEHAVIORAL|Individualized music playlist|Individualized music playlist composed of preferred music genres sequenced according to the ISO-Principle. It will be played at the state of agitation.
218930668|NCT06104436|BEHAVIORAL|Preferred music|Preferred music is composed of the genres selected by the participants, and to be played at random sequence.
218930669|NCT06104436|BEHAVIORAL|Usual care|Usual technique for calming agitated older adults with dementia
218930670|NCT03404752|DRUG|Peg-Filgrastim|
218930671|NCT05272501|BEHAVIORAL|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
219541244|NCT03866265|DIETARY_SUPPLEMENT|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
219541245|NCT03866265|OTHER|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
219541246|NCT00238615|DRUG|Docetaxel|20 mg/m2, 75 mg/m2 infusion
219541247|NCT00238615|DRUG|Carboplatin|AUC of 2 and 6 infusion
219541248|NCT00238615|PROCEDURE|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
219541249|NCT00238615|PROCEDURE|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
219541250|NCT05710718|DEVICE|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC is connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
218930672|NCT04599413|OTHER|SURVEY|Pain survey on pianists
219541251|NCT05710718|DEVICE|Hollister® Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence. It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
219541252|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
219541253|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
219541254|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541255|NCT02404701|DIETARY_SUPPLEMENT|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541256|NCT02404701|DIETARY_SUPPLEMENT|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541257|NCT02404701|DIETARY_SUPPLEMENT|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541258|NCT02404701|DIETARY_SUPPLEMENT|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541259|NCT02404701|DIETARY_SUPPLEMENT|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541260|NCT02404701|DIETARY_SUPPLEMENT|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219620976|NCT07113379|BIOLOGICAL|Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.|Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
218930673|NCT04030117|PROCEDURE|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
218930674|NCT04030117|PROCEDURE|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
218930675|NCT00077415|DRUG|gemcitabine hydrochloride|
218930676|NCT00077415|DRUG|triapine|
218930677|NCT00273494|PROCEDURE|Surgery|
218930678|NCT05591313|BEHAVIORAL|LI-40|Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
218930679|NCT05591313|BEHAVIORAL|MI-30|Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
218930680|NCT05591313|BEHAVIORAL|HI-16|Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
218930681|NCT02074410|DRUG|OMS643762|
219541261|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
219541262|NCT02310386|DEVICE|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
218930682|NCT02074410|DRUG|Placebo|
218930683|NCT02306902|DRUG|fenofibrate|130mg, Capsules
218930684|NCT02306902|DRUG|ANTARA® (fenofibrate)|130mg, Capsules
219541263|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
219541264|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
219541265|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
219541266|NCT04757298|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
219541267|NCT04757298|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
219541268|NCT04757298|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
219541269|NCT04757298|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
218930685|NCT03835832|OTHER|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
218930686|NCT03314129|BEHAVIORAL|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
218930687|NCT03314129|BEHAVIORAL|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
219044524|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
218930688|NCT03314129|BEHAVIORAL|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
218930689|NCT03314129|BEHAVIORAL|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
218930690|NCT06288100|OTHER|Observation|"1. Measure changes in tibial slope after medial opening wedge High tibial osteotomy in Skeletally mature patient with unicompartmental osteoarthitis and genuvarus knee~2. Evaluate the effect of tibial slope angle change on the clinical outcome at 1 year ."
219044525|NCT03759067|DRUG|clopidogrel 75mg|clopidogrel once daily 75mg
219044526|NCT03759067|DRUG|Clopidogrel 300 mg|clopidogrel 300mg reloading
219044527|NCT03759067|DRUG|clopidogrel 600mg|clopidogrel 600mg loading
219044528|NCT01266213|DRUG|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
219044529|NCT01266213|DRUG|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
219044530|NCT01266213|DRUG|Goserelin|Goserelin s.c.
219541270|NCT06313034|BEHAVIORAL|Breastfeeding education based on motivational interviewing technique|"Breastfeeding education based on motivational interviewing technique; Breast milk properties, benefits to mother and baby, breastfeeding positions, the relationship between breastfeeding and attachment, signs of hunger in the newborn, Breastfeeding frequency, duration and termination, Breast milk expressing methods, Expressions showing that the newborn has enough milk, Breast milk storage will cover the topics. These topics will be given based on motivational interviewing technique.~According to the motivational interviewing technique, the mother's intention, importance and confidence-sufficiency regarding breastfeeding will be determined and firstly, an agenda will be created on issues related to breastfeeding with the mother. Each session will be conducted by following the open-ended questioning, verification, reflective listening and summarizing approaches of the motivational interviewing technique."
219541271|NCT04870320|BEHAVIORAL|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
219541272|NCT04870320|BEHAVIORAL|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
218930691|NCT01614392|BEHAVIORAL|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
219541273|NCT04870320|OTHER|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
219541274|NCT01421901|DRUG|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
219541275|NCT01421901|PROCEDURE|appendectomy|
219541276|NCT06366815|OTHER|Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy|clinical and functional data collection of non ambulant patients with Duchenne muscular dystrophy
218930692|NCT01614392|BEHAVIORAL|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
218930693|NCT00779350|DRUG|sertraline 100 mg tablets|
218930694|NCT01657240|DRUG|PRO-118|instill one drop in each eye once a day for 21 days
218930695|NCT01657240|DRUG|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
218930696|NCT05283941|DIETARY_SUPPLEMENT|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
218930697|NCT01993121|OTHER|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
218930698|NCT02980393|BEHAVIORAL|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
218930699|NCT01380821|RADIATION|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
218930700|NCT01744080|OTHER|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
218930701|NCT01744080|OTHER|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
218930702|NCT04786535|PROCEDURE|Expanded Hemodialysis|"* Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
218930703|NCT04786535|PROCEDURE|High-flux Conventional Hemodialysis|"* Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
218930704|NCT04786535|PROCEDURE|Hemodiafiltration|"* Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
219541277|NCT04066088|OTHER|Placebo|Placebo will be administered same times as GXR
219541278|NCT04066088|DRUG|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
219541279|NCT00310271|BIOLOGICAL|pPJV7630 with pPJV2012 administered by PMED|
219541280|NCT01441297|DRUG|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
219541281|NCT03720691|DEVICE|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
219541282|NCT03720691|DEVICE|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
219541283|NCT00446966|DRUG|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
219541284|NCT06501222|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219541285|NCT00376493|DRUG|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
219541286|NCT02975765|PROCEDURE|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
219541287|NCT06235723|DEVICE|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
219541288|NCT05646823|DIETARY_SUPPLEMENT|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
219541289|NCT05646823|DIETARY_SUPPLEMENT|Placebo|vehicle only - Maltodextrin gluten free
219541290|NCT00100464|DRUG|Paroxetine|
219541291|NCT00100464|DRUG|5HTP|
219541292|NCT01261663|OTHER|oral nutritional energy and protein enriched supplement (NOS)|
219620977|NCT07110961|PROCEDURE|A suggested immobilization test (SIT)|The Suggested Immobilization Test (SIT) is a provocative test. RLS symptoms (urge to move the leg and leg paresthesia) are primarily observed during wakefulness, especially at rest, in the evening, and/or during the night. During the test, the patient remains in a bed (or a reclining chair), at a 45° angle with legs outstretched. Originally, the SIT only quantified leg motor activity. Since 2002, it also includes the assessment of leg discomfort, which is estimated by the patient every 5 min, on a 100-mm horizontal visual analogue scale. Leg movements are quantified using surface electromyography (EMG) from bilateral anterior tibialis muscles. Using these pathological thresholds, the clinical RLS/WED diagnosis is correctly predicted in 88% of subjects with a sensitivity of 82% and a specificity of 100%.
219620978|NCT07105254|DRUG|Roflumilast topical 0.3% foam|Roflumilast 0.3% topical foam
218930705|NCT03353519|OTHER|Primary care model|"Specifically, the intervention will comprise the following components:~1. Structured review of patient needs;~2. A self-management programme (MLAS) for stroke survivors and their carers;~3. A direct point of contact for stroke survivors and carers at the GP surgery;~4. Optimised communication between General Practice staff and specialist services;~5. Service mapping for stroke related needs;~6. Training for General Practice staff."
218930706|NCT06465407|DIETARY_SUPPLEMENT|Collagen|Participants will consume two 30-g amount of collagen peptides derived from bovine hide (commercially available as Vital Proteins or Peptan) mixed in 300 ml of orange gatorade zero.
218930707|NCT06465407|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume two 30-g amount of pure maltodextrin mixed in 300 ml of orange gatorade zero.
218930708|NCT01719497|DRUG|[C-11]OMAR|PET radioligand
219044531|NCT01547416|DRUG|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
219620979|NCT07112508|BEHAVIORAL|PRISM dashboard is a data report|The PRISM dashboard captures a clinicians activity relative to their peers. It provides social norms feedback on an array of clinical interventions that an FCP makes.
219044532|NCT01547416|DRUG|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
219541293|NCT00443651|DRUG|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
219620980|NCT07112508|OTHER|THe usual care intervention is a first contact physiotherapy service.|usual care
219541294|NCT00443651|DRUG|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
219620981|NCT07111143|OTHER|nursing intervention|medication only
219620982|NCT07111169|DEVICE|intermittent theta burst stimulation (iTBS) intervention|iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.
219541295|NCT01988376|DEVICE|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
219541296|NCT01988376|DEVICE|Conventional Pap smear|Conventional Pap smear
219541297|NCT02855853|OTHER|serious game et virtual reality|
219541298|NCT02855853|OTHER|Nintendo Wii|
219541299|NCT00859521|DRUG|Levetiracetam|1000 mg Tablet
219541300|NCT00859521|DRUG|Keppra®|1000 mg Tablet
219541301|NCT02275143|RADIATION|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
219541302|NCT03168126|DEVICE|Pro-AQT|Use of the device for advanced hemodynamic monitoring
219541303|NCT03934281|DEVICE|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
218930709|NCT00892983|BEHAVIORAL|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
219541304|NCT03934281|DEVICE|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
219044533|NCT01458327|DRUG|Midomafetamine|125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
219044534|NCT01458327|BEHAVIORAL|Therapy|Non-directive therapy
219044535|NCT06420154|BIOLOGICAL|anti-CD19-CAR-T cells|"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"
219044536|NCT04999046|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
219044537|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
219541305|NCT03631628|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
219541306|NCT03631628|BEHAVIORAL|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
219541307|NCT03631628|BEHAVIORAL|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
219541308|NCT03631628|BEHAVIORAL|Conventional Rehabilitation Program|Standardized upper limb training
219541309|NCT06118697|PROCEDURE|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
219541310|NCT00834132|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
219541311|NCT00834132|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
219620983|NCT07110753|BEHAVIORAL|combined lifestyle intervention focusing on various lifestyle components, delivered by a lifestyle coach and oncology nurse|The combined lifestyle intervention focuses on various lifestyle components, including nutrition, physical activity, sleep, stress and sense of purpose, and is structured around the process of behaviour change. It is delivered by a lifestyle coach in collaboration with an oncology nurse.
219620984|NCT07110753|BEHAVIORAL|short online lifestyle intervention by lifestyle coach and educational materials after 6 months|The control group receives 4 online group sessions from a lifestyle coach and all educational materials after 6 months of intervention
218930710|NCT00892983|BEHAVIORAL|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
218930711|NCT06108232|DRUG|Obinutuzumab|Given by IV (vein)
218930712|NCT06108232|DRUG|CC-99282|Given by PO
219541312|NCT02380794|DRUG|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
219541313|NCT02380794|DRUG|Placebo|
219541314|NCT01515891|DRUG|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
219541315|NCT06447948|BEHAVIORAL|Keep Exercising and Stay Steady|"Digital Health, home exercise intervention containing a digital NHS approved falls prevention exercise App (Keep On Keep Up), fitness watches, telephone and/or social media communication, and behavior change techniques.~Currently (date, 13 May 2024) the intervention has not been developed with the community of practice group. Further details of the phase 1 and phase 2 interventions will be provided after the community of practice events."
219620985|NCT07111845|BEHAVIORAL|Medical Consultation|Participants will be randomly assigned to receive medical consultation about urinary stone disease from one of five sources: a real urologist (in-person) or one of four AI chatbots (ChatGPT, Gemini, Perplexity, or Microsoft Copilot). Each participant will be instructed to ask all their questions related to urinary stone disease and continue the consultation until they feel adequately informed. The consultation format (human vs. AI) will depend on group assignment. After the session, participants will complete a validated satisfaction questionnaire (CSQ-8) to assess their experience.
219620986|NCT04240626|DRUG|Neurontin|600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
218930713|NCT01977872|BEHAVIORAL|A worksite activity-diet intervention|
218930714|NCT03448913|PROCEDURE|PECS block|It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
218930715|NCT06211959|BEHAVIORAL|Approach Bias Modification with Implementation Intentions|Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
218930716|NCT02370108|DEVICE|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
218930717|NCT05466864|DEVICE|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
218930718|NCT00257257|DRUG|Rimonabant (SR141716)|
218930719|NCT01149668|DRUG|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
218930720|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid|2.8mg
219044538|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
219541316|NCT04456972|DIAGNOSTIC_TEST|One arm only|Samples of plasma to analyze ctDNA
219541317|NCT02768701|DRUG|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
219541318|NCT02768701|DRUG|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
219541319|NCT03683667|DRUG|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
219541320|NCT03683667|DRUG|Placebos|Contain inert excipients only
219620987|NCT04240626|DRUG|Dilaudid Injectable Product|.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
218930721|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
218930722|NCT03680846|DEVICE|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
218930723|NCT03680846|OTHER|CMM|Conventional Medical Management
218930724|NCT02029300|OTHER|Fiberoptic Intubation through the nasal route|
218930725|NCT02029300|OTHER|Fiberoptic intubation through the oral route|
218930726|NCT05045378|DRUG|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
218930727|NCT05045378|DRUG|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
218930728|NCT05045378|DRUG|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
219620988|NCT04240626|DRUG|Marcaine Injectable Product|0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
219620989|NCT04240626|DRUG|Oxycodone Hydrochloride|1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
219620990|NCT04240626|DRUG|Hycet 7.5Mg-325Mg/15Ml Solution|Dosage: 10-15ml q4h prn for pain control
219541321|NCT03683667|DIETARY_SUPPLEMENT|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
219541322|NCT03683667|DIETARY_SUPPLEMENT|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
218930729|NCT05835687|DRUG|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
219541323|NCT03683667|DIETARY_SUPPLEMENT|Egg|Egg provided daily to infants from 6-12 months of age
218930730|NCT06249867|DRUG|Darifenacin 7.5 MG Extended Release Oral Tablet|During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.
219541324|NCT03683667|BEHAVIORAL|Nutrition Education|Monthly messaging on infant and young child feeding
219541325|NCT00014768|DRUG|glucose|
219620991|NCT04240626|DRUG|Zofran Injection|4 mg IV for nausea control while inpatient, prn
218930731|NCT06249867|DRUG|Placebo|During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
218930732|NCT05752760|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
219044539|NCT04035304|OTHER|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
219044540|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
219044541|NCT03993938|DEVICE|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
219044542|NCT03164798|PROCEDURE|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
219044543|NCT04466475|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
219044544|NCT04466475|DRUG|Melphalan|Given via infusion
219044545|NCT04466475|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
219541326|NCT00014768|DRUG|insulin|
218930733|NCT05752760|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
218930734|NCT01858025|RADIATION|Pencil Beam scanning Radiation|
218930735|NCT01858025|DRUG|5-fluorouracil|
218930736|NCT01858025|DRUG|Mitomycin-C|
218930737|NCT05035706|PROCEDURE|Biopsy|Undergo biopsy
219541327|NCT00014768|DRUG|leucine|
219541328|NCT01847495|DRUG|Irinotecan|40mg/m2 x 3-5 days
219541329|NCT01847495|RADIATION|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
219541330|NCT01350986|BEHAVIORAL|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006)."
219620992|NCT04240626|DRUG|Scopolamine patch|Topical application patch for nausea control, used with/without Ativan.
219620993|NCT04240626|DRUG|Ativan|0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
219620994|NCT04240626|DRUG|Flexeril Oral Product|5 mg orally q8h prn for muscle spasms.
219620995|NCT04240626|DRUG|Tylenol Suspension|1000 mg q6h PRN for pain control.
219620996|NCT06932562|DRUG|Linvoseltamab|Administered per the protocol
219620997|NCT06932562|DRUG|Daratumumab|Administered per the protocol
219620998|NCT06932562|DRUG|Lenalidomide|Administered per the protocol
218930738|NCT05035706|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
218930739|NCT05035706|OTHER|Electronic Health Record Review|Medical records reviewed
218930740|NCT05035706|OTHER|Photography|Photographs taken
219620999|NCT06932562|DRUG|Dexamethasone|Administered per the protocol
218930741|NCT04533529|DRUG|Seltorexant|Seltorexant tablet will be administered orally once daily.
219541331|NCT01350986|BEHAVIORAL|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
219541332|NCT02718963|DEVICE|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219541333|NCT03254225|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
219541334|NCT02188563|OTHER|Comprehensive smoking cessation intervention|
219541335|NCT02188563|BEHAVIORAL|Enhanced usual care|
219541336|NCT01547286|BIOLOGICAL|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
219541337|NCT01547286|RADIATION|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
219541338|NCT01547286|DRUG|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
218930742|NCT04533529|DRUG|Placebo|Matching placebo tablet will be administered orally once daily.
218930743|NCT05592002|DEVICE|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
218930744|NCT05084833|BEHAVIORAL|Control|Electronic educational materials
218930745|NCT05084833|BEHAVIORAL|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
218930746|NCT05084833|BEHAVIORAL|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
218930747|NCT03014544|DEVICE|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
218930748|NCT03014544|DEVICE|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
219541339|NCT02376114|DRUG|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
219541340|NCT02376114|DRUG|Placebo to Ginkgo biloba|
219541341|NCT03541538|DEVICE|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
219621000|NCT06925932|BEHAVIORAL|Dietary advice - Sweet taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are sweet but have no or low amounts of free sugars, e.g., sweet no- or low-free sugar foods, fruit, and no- or low-calorie sweeteners.
218930749|NCT03612531|PROCEDURE|Manual Therapy|Receive manual therapy
218930750|NCT05201014|DIAGNOSTIC_TEST|NT-pro-BNP|Blood draw
218930751|NCT05201014|DIAGNOSTIC_TEST|Electrocardiogram|electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart
218930752|NCT05201014|DIAGNOSTIC_TEST|Echocardiogram|medical imaging of the heart
218930753|NCT05816850|DIAGNOSTIC_TEST|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
219044546|NCT04116645|OTHER|genital and rectal swab|6\. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
219541342|NCT03541538|DEVICE|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
218930754|NCT05816850|DIAGNOSTIC_TEST|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
219044547|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
219044548|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
219044549|NCT00371943|PROCEDURE|band ligation|
219044550|NCT06468709|DRUG|Glucocorticoids|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
219044551|NCT06468709|DRUG|Glucocorticoids+MMF|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
219044552|NCT02069522|OTHER|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
219044553|NCT02069522|OTHER|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
219044554|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
219044555|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
219044556|NCT03470337|OTHER|Placebo|
219044557|NCT04784286|OTHER|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
219044558|NCT04784286|OTHER|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
219044559|NCT03301324|DEVICE|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
219044560|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
219541343|NCT00540995|DRUG|busulfan|Given IV
219541344|NCT00540995|DRUG|etoposide|Given IV
219541345|NCT00540995|RADIATION|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
219621001|NCT06925932|BEHAVIORAL|Dietary advice - Taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet but are full of tasty flavours, e.g., non-sweet foods and drinks with nuts, herbs or spices.
219621002|NCT06925932|BEHAVIORAL|Dietary advice - No taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet and have no strong flavours, e.g., non-sweet plain foods and drinks.
219621003|NCT06932107|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
219621004|NCT06932107|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds
219621005|NCT05696444|DEVICE|RAS Prostatectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.
219621006|NCT05696444|DEVICE|RAS Cystectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have the RAS surgery using the Medtronic Hugo RAS system.
219621007|NCT05696444|DEVICE|RAS Nephrectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have the RAS surgery using the Medtronic Hugo RAS system.
219621008|NCT05673577|DRUG|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
218930755|NCT06315010|DRUG|Repotrectinib|"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."
218930756|NCT01950130|PROCEDURE|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
218930757|NCT05868239|DEVICE|Aerosol box|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
219541346|NCT00540995|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
219621009|NCT01609790|BIOLOGICAL|Bevacizumab|Given IV
219621010|NCT01609790|OTHER|Laboratory Biomarker Analysis|Correlative studies
218930758|NCT06784063|DEVICE|Clareon Vivity Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
219044561|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
219044562|NCT02419118|DRUG|Daratumumab|Treatment of myeloma patients with Daratumumab
219621011|NCT01609790|OTHER|Pharmacological Study|Correlative studies
219621012|NCT01609790|OTHER|Placebo Administration|Given IV
219621013|NCT01609790|BIOLOGICAL|Trebananib|Given IV
219621014|NCT06940973|GENETIC|Parental samples|"On fertilization, following the conventional ICSI/IVF procedure, samples from cumulus cells (obtained during the routine oocyte denudation process) and surplus sperm cells present in seminal plasma will be retrieved. These samples will be stored frozen at -20°C until they are sent to Igenomix. There, they will be used to perform the genetic analysis required to achieve the study's objectives, provided the patient consents to participate. If the patient ultimately chooses not to participate, these samples will be destroyed.~Parents may be asked to provide a saliva sample for the same purpose in cases where obtaining the samples during fertilization was not possible or if the collected samples were unsuitable for processing in the laboratory. The saliva sample may be collected at the clinic during one of the scheduled visits for reproductive treatment or, alternatively, by the parents at home using a kit provided by the clinic."
219044563|NCT02419118|DRUG|Lenalidomide|Treatment of myeloma patients
219044564|NCT02419118|DRUG|Dexamethasone|Treatment of myeloma patients
219621015|NCT06940973|DIAGNOSTIC_TEST|PGT-A|On day 3 of development, assisted hatching will be performed to facilitate biopsy at the blastocyst stage. Each embryo will be biopsied in the laboratory using conventional trophectoderm (TE) biopsy techniques on day +5, +6, or +7 of development, depending on when they reach the appropriate blastocyst stage. After biopsy, blastocyst will be vitrified following the clinical routine protocol and store until the genetic results are available. The biopsy samples will be placed in a PCR tube labeled with its corresponding study-specific code and stored in a cold rack at 4°C before being transferred to a freezer at -20°C. Finally, the samples will be sent to the Igenomix for preimplantation genetic testing for aneuploidy.
219621016|NCT06940973|GENETIC|TE rebiopsies and spent blastocyst media collection|"After obtaining the PGT-A results, any embryo not genetically confirmed as euploid and without ploidy abnormalities will be thawed, washed, and cultured for rebiopsy. A complementary analysis using next-generation sequencing (NGS) techniques will be performed to confirm the diagnosis and determine the origin of the abnormalities. For this additional analysis, in addition to the new biopsies, the individual culture medium of each embryo will be aspirated after an incubation period of 8 to 24 hours. The collected medium will be placed in PCR tubes and stored in a freezer at -20°C before being sent to the laboratory.~Regardless the result of these complementary analysis, no rebiopsied blastocyst will be considered for clinical purposes."
219621017|NCT06940011|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily
219621018|NCT06940011|OTHER|Placebo|4 capsules once daily OR 2 capsules twice daily
219621019|NCT06941233|BEHAVIORAL|Our Peers - Empowerment and Navigational Support - Community Living (OP-ENS - CL)|Op-ENS - CL is a 12-month, remote delivered peer navigator intervention. Participants will meet with a trained peer navigator who mentors nad supports them through a manualized process of collaborative conversations, barrier identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
219621020|NCT06940128|PROCEDURE|Direct Ischemic Conditioning A|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.
219044565|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
219541347|NCT00540995|PROCEDURE|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
219541348|NCT00540995|PROCEDURE|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
218930759|NCT06783686|DRUG|NV701|eye drop
218930760|NCT06783686|DRUG|Pilocarpine 1.25% Eye drop|eye drop
218930761|NCT03438461|DRUG|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
218930762|NCT03438461|DRUG|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
218930763|NCT05658913|DRUG|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
219044566|NCT01243346|DRUG|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
219541349|NCT00540995|RADIATION|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
219541350|NCT01464450|DRUG|Rivaroxaban|Single 20 mg-dose
219541351|NCT04176835|DRUG|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
219044567|NCT03880851|RADIATION|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
219044568|NCT04044417|PROCEDURE|currettage|open flap debridement
219044569|NCT04044417|DRUG|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
219044570|NCT04044417|DRUG|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
219044571|NCT01926795|PROCEDURE|Short leg cast|
219044572|NCT01926795|PROCEDURE|No Immobilization|
219541352|NCT04176835|DRUG|Placebo|
218930764|NCT05460000|DRUG|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
218930765|NCT05460000|DRUG|6 cycles chemotherapy|Standard chemotherapy as comparator
218930766|NCT05661409|DRUG|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
218930767|NCT05661409|DRUG|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
218930768|NCT05753046|DRUG|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
218930769|NCT05753046|DRUG|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
218930770|NCT05132608|OTHER|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
218930771|NCT02229344|OTHER|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
218930772|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
218930773|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
218930774|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
218930775|NCT06016270|DRUG|hSTC810 400 mg + Paclitaxel|"hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion"
218930776|NCT06016270|DRUG|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
218930777|NCT05316948|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
218930778|NCT04439136|DRUG|Afatinib Dimaleate|Given PO
218930779|NCT02429245|OTHER|Retrospective study|
218930780|NCT06236048|PROCEDURE|MRI scan|7 Tesla MRI scan
218930781|NCT06236048|PROCEDURE|PET-MR scan|18F-fluorodeoxyglucose PET-MR scan
218930782|NCT05350878|OTHER|Implementation Intervention|Virtual and in-person implementation support
219621021|NCT06940128|PROCEDURE|Direct Ischemic Conditioning B|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.
219621022|NCT06940128|PROCEDURE|Direct Ischemic Conditioning C|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.
219621023|NCT06940999|OTHER|Traditional physical therapy|Application of laser three times per week in addition to applying deep friction massage, stretching exercises along with the uses of pressure garment.
219621024|NCT06945107|DRUG|Picankibart|"The participants in picankibart treatment group will receive picankibart 200mg SC at Weeks 0, 4, 8, 20 and 32.~The participants in IL-17 mAb continued treatment group will receive picankibart 200mg SC at Weeks 16, 20, 24 and 36."
219541353|NCT05931458|PROCEDURE|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
218930783|NCT06563804|DRUG|S227928|For administration via intravenous (IV) infusion
218930784|NCT06563804|DRUG|Venetoclax|For oral administration
218930785|NCT04129008|DRUG|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
218930786|NCT04129008|DRUG|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
218930787|NCT00433082|BEHAVIORAL|Ramadan Fasting|
218930788|NCT06840262|OTHER|Questionnaire Administration|Ancillary studies
218930789|NCT06840262|PROCEDURE|Regenerative Peripheral Nerve Interface Surgery|Undergo regenerative peripheral nerve interface surgery
218930790|NCT06840262|PROCEDURE|Targeted Muscle Reinnervation|Undergo targeted muscle reinnervation
219541354|NCT05931458|DRUG|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
219541355|NCT06152458|DRUG|Vitamin C|Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
219541356|NCT03006835|DRUG|Clopidogrel|
219541357|NCT00258024|DRUG|IPT-sulphadoxinepyrimethamine|
219541358|NCT05453422|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
219044573|NCT06975176|BEHAVIORAL|Stigma reduction intervention|"Care providers will complete the Stigma Reduction Intervention curriculum. The intervention is a multi-day stigma reduction training program for providers.~Content design is greatly informed by materials developed in our pilot R34 study, and which may be modified prior to the intervention if the team gains new insights from the baseline round of unannounced visits and each of the two CABs. Briefly, the intervention consists of both didactic and experiential learning components. Didactic sessions include instruction on syphilis epidemiology, clinical management, and public health significance. Experiential sessions include discussion sessions that are facilitated by pre-recorded videos, followed by role play with trained SPs."
219044574|NCT04219865|DRUG|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
219044575|NCT04219865|DRUG|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
219044576|NCT04219865|DRUG|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
219044577|NCT04219865|DRUG|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
219044578|NCT04219865|DRUG|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
219044579|NCT05982535|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
219044580|NCT02922270|OTHER|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
219044581|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
219044582|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
219541359|NCT03257735|DIAGNOSTIC_TEST|next-generation sequencing|"1. Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~2. Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~3. Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
219621025|NCT06945107|DRUG|Secukinumab|The participants in IL-17 mAb continued treatment group who have received secukinumab before enrollment, will receive secukinumab 300mg SC at Weeks 0, 4, 8 and 12.
218930791|NCT04333576|DRUG|Elagolix|Tablet:Oral
218930792|NCT04333576|DRUG|Placebo|Tablet:Oral
218930793|NCT04333576|DRUG|Combined Oral Contraceptive|Tablet:Oral
218930794|NCT06789172|DRUG|OKN4395|OKN4395 oral dosing twice per day
218930795|NCT06789172|COMBINATION_PRODUCT|Pembrolizumab|200 mg IV every 3 weeks
218930796|NCT06789172|OTHER|Fasting|Fasting before first dose of OKN4395
218930797|NCT06789172|OTHER|Fed|Food provided to patient before first OKN4395 dose
218930798|NCT06789172|DRUG|H2 Receptor Antagonist|Famotidine 20 mg IV (as a slow push over 2 minutes) administered 3 hours prior to OKN4395
218930799|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will be provided food to meet the ketogenic diet prescription for the 6-week weight maintenance phase.
218930800|NCT06736028|BEHAVIORAL|Calorie Restriction|Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.
218930801|NCT06736028|BEHAVIORAL|Behavioral Support|Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.
218930802|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will have food provided to meet the standard low-fat diet prescription for the 6-week weight maintenance phase.
218930803|NCT03249402|DRUG|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
218930804|NCT03249402|DRUG|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
218930805|NCT06551116|DIAGNOSTIC_TEST|CE-10-IVD|Leftover tumor tissue from a routine biopsy will be sent for analysis.
218930806|NCT06628830|DEVICE|VamosJuntxs App|"Psychoeducational materials (videos, information and interactive exercises) about depression, anxiety and social support~Skills training through information and activities based on the principles of cognitive behavioral therapy (cognitive restructuring, behavioral activation, emotional regulation, problem solving and exposure)"
218930807|NCT06628830|OTHER|Web Conciencia Saludable|mental health psychoeducational campaign (https://concienciasaludable.uchile.cl/)
218930808|NCT06157892|DRUG|disitamab vedotin|Given into the vein (IV; intravenous)
218930809|NCT06157892|DRUG|tucatinib|300mg given twice daily by mouth (orally)
218930810|NCT02363452|DRUG|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
218930811|NCT04329806|DRUG|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
218930812|NCT04329806|DRUG|Amlodipine 5 MG|Amlodipine 5 MG twice daily
218930813|NCT05017571|DRUG|Colchicine|Colchicine 1 capsule (0.6 mg) per day
218930814|NCT05017571|DRUG|Placebo|Placebo 1 capsule per day
218930815|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
218930816|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
219541360|NCT03415308|OTHER|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
218930817|NCT05258656|BEHAVIORAL|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
218930818|NCT05258656|BEHAVIORAL|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
218930819|NCT04604301|DEVICE|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
218930820|NCT02862431|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
218930821|NCT02862431|DRUG|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
218930822|NCT02997228|DRUG|Atezolizumab|Given IV
218930823|NCT02997228|BIOLOGICAL|Bevacizumab|Given IV
219044583|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
219044584|NCT00245765|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use"
219541361|NCT03415308|OTHER|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
218930824|NCT02997228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218930825|NCT02997228|PROCEDURE|Computed Tomography|Undergo CT or CT/PET
218930826|NCT02997228|DRUG|Fluorouracil|Given IV
218930827|NCT02997228|DRUG|Leucovorin|Given IV
218930828|NCT02997228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218930829|NCT02997228|DRUG|Oxaliplatin|Given IV
218930830|NCT02997228|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
218930831|NCT02997228|OTHER|Quality-of-Life Assessment|Ancillary studies
218930832|NCT02997228|OTHER|Questionnaire Administration|Ancillary studies
218930833|NCT05361551|PROCEDURE|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
218930834|NCT02636595|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
218930835|NCT01897688|BIOLOGICAL|Islet Cell Transplant|
218930836|NCT03772158|DRUG|Cetirizine 10mg|Chewable tablet
218930837|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
218930838|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
219541362|NCT03415308|OTHER|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
218930839|NCT00099333|DRUG|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
218930840|NCT00099333|DRUG|Insulin|Insulin will be taken according to the subject's current regimen
218930841|NCT05393921|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
218930842|NCT03147937|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
218930843|NCT04373720|PROCEDURE|Magnetic Resonance Elastography|Undergo MRE
219044585|NCT00245765|OTHER|Placebo|Matching Placebo to Certolizumab Pegol
219044586|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
219044587|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
219205324|NCT06887361|BEHAVIORAL|MOON Program|The MOON Program aims to contribute to the primary prevention of sexual violence among young university students. The program aims to achieve this goal by promoting bystander attitudes and behaviors through psychoeducation and skills training that enable participants to be active agents in this process. During the sessions, beliefs that legitimize violence will be deconstructed and skills such as communication about consent and empathy will be promoted. The MOON program consists of five online sessions, which are intended to be completed autonomously on a weekly basis. Throughout the sessions, participants will learn on the following topics: SV and consent, gender stereotypes, SV myths and bystander attitudes and behaviors.
219205325|NCT06740643|PROCEDURE|intracanal reinforcement using short composite post|after pupectomy is done flowable composite will be applied 3mm intacanal to make a short compsite post before zircon crown aplicaction
219541363|NCT01804608|OTHER|Strength|
219205326|NCT06740643|PROCEDURE|no intracanal reinforcement|no intracanal reinforcement using resin modified glass ionmer before zircon crown application
219205327|NCT06891872|BIOLOGICAL|Vaicella Vaccine+DTaP on Day 0, MMR on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection~MMR: lyophilized powder, subcutaneous injection"
219205328|NCT06891872|BIOLOGICAL|Varicella vaccine+MMR on Day 0，DTaP on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~MMR: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection"
219205329|NCT06891872|BIOLOGICAL|Varicella Vaccine|lyophilized powder, subcutaneous injection
219205330|NCT06747598|DIAGNOSTIC_TEST|pregnancy test|POC pregnancy testing using peripheral serum
219621026|NCT06945107|DRUG|Placebo|"The participants in picankibart treatment group will receive placebo SC at Weeks 12, 16, 24 and 36.~The participants in IL-17 mAb continued treatment group will receive placebo SC at Week 32."
219541364|NCT01804608|OTHER|Sensorimotor|
219541365|NCT04754984|BEHAVIORAL|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
219541366|NCT05651243|DIETARY_SUPPLEMENT|Ketone Ester Supplement|Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
219541367|NCT05651243|OTHER|Placebo|Oral ingestion of cellulose combined with a flavoring agent and diluted in water
219541368|NCT05946486|DRUG|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
218930844|NCT04373720|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
218930845|NCT04006132|DEVICE|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
219044588|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
219044589|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
219044590|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
219044591|NCT00660348|DRUG|morphine sulfate|This is morphine given in the traditional methods.
219044592|NCT00660348|DEVICE|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
219044593|NCT01703793|DRUG|Test Product 49778|
219044594|NCT01703793|DRUG|Test Product 10156|
219044595|NCT01703793|DRUG|Vehicle (placebo)|
219044596|NCT03346122|DRUG|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
219044597|NCT03346122|DRUG|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
219541369|NCT05608642|OTHER|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
219541370|NCT05608642|OTHER|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
219541371|NCT05608642|OTHER|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
219621027|NCT06945107|DRUG|Ixekizumab|The participants in IL-17 mAb continued treatment group who have received ixekizumab before enrollment, will receive ixekizumab 80mg SC at Weeks 0, 4, 8 and 12.
218930846|NCT06006884|PROCEDURE|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
218930847|NCT06006884|DIAGNOSTIC_TEST|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
218930848|NCT06006884|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
218930849|NCT06006884|DIAGNOSTIC_TEST|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
218930850|NCT06006884|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
218930851|NCT05244135|PROCEDURE|Pulmonary rehabilitation|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
218930852|NCT05492682|DRUG|PeptiCRAd-1|All patients will receive PeptiCRAd-1.
218930853|NCT05492682|DRUG|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
219044598|NCT03346122|DRUG|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
219044599|NCT03346122|DRUG|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
219044600|NCT03346122|DRUG|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
219044601|NCT03346122|DRUG|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
219044602|NCT03346122|DRUG|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
219044603|NCT03346122|DRUG|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
219044604|NCT03346122|DRUG|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
218930854|NCT05492682|DRUG|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
218930855|NCT00921518|DRUG|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
218930856|NCT00921518|DRUG|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
218930857|NCT06487494|PROCEDURE|Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures|2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.
218930858|NCT06487494|PROCEDURE|Circumcision wound closure using continuous sutuing|Continuous suturing is the standard following circumcision for wound closure.
219044605|NCT03346122|DRUG|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
219044606|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
219044607|NCT02581774|OTHER|normal delivery tracking|normal delivery tracking
219044608|NCT01617603|OTHER|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
218930859|NCT04806555|DIAGNOSTIC_TEST|Compression ultrasound examination|After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
218930860|NCT05377801|BEHAVIORAL|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
218930861|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
218930862|NCT06246448|PROCEDURE|Robotic-assisted radical cholecystectomy|Procedure will be performed robotic-assisted
218930863|NCT06246448|PROCEDURE|Open radical cholecystectomy|Procedure will be open
218930864|NCT04624074|BEHAVIORAL|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
218930865|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
218930866|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
219367019|NCT01396369|DRUG|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
219541372|NCT02601963|DRUG|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
218930867|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
219044609|NCT00873548|DEVICE|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device"
219044610|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
219541373|NCT02601963|DRUG|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
219541374|NCT02601963|DRUG|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
218930868|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
219044611|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
219044612|NCT06854081|COMBINATION_PRODUCT|EluPro Antibiotic-Eluting BioEnvelope|Utilization of an EluPro Antibiotic-Eluting BioEnvelope with the CIED during the participant's CIED implant procedure.
219044613|NCT06863701|DRUG|Etoricoxib + Betamethasone fixed dose|One tablet of 90 mg / 0.25 mg a day
219044614|NCT06863701|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
219541375|NCT03563833|OTHER|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
219541376|NCT03563833|OTHER|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
219541377|NCT02225405|DRUG|Cisplatin|Given IV
219541378|NCT02225405|DRUG|Docetaxel|Given IV
219541379|NCT02225405|OTHER|Laboratory Biomarker Analysis|Correlative studies
218930869|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
218930870|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
219044615|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
219541380|NCT02225405|DRUG|Nintedanib|Given PO
219541381|NCT03911583|BEHAVIORAL|Control Group (CG)|The control group does not receive these notifications (PUSH)
218930871|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
219541382|NCT03911583|BEHAVIORAL|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
218930872|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
218930873|NCT01465919|DRUG|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
218930874|NCT01465919|OTHER|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
218930875|NCT00055913|BIOLOGICAL|bevacizumab|Given IV
218930876|NCT00055913|DRUG|erlotinib hydrochloride|Given orally
218930877|NCT00055913|OTHER|laboratory biomarker analysis|Correlative studies
218930878|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
219044616|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
219044617|NCT06137950|DRUG|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
218930879|NCT04423302|DIETARY_SUPPLEMENT|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
218930880|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
219621028|NCT06795035|DIAGNOSTIC_TEST|Continuous Saline Thermodilution|Continuous saline thermodilution for determination of microvascular resistance reserve (MRR) is a novel operator-independent method to assess coronary microvascular function. CST has been studied in the setting of angina with nonobstructive coronary arteries (ANOCA), but not in the setting of acute MI. In contrast, bolus thermodilution, used to determine the index of microcirculatory resistance (IMR), has been shown in the setting of STEMI to predict extent of myocardial injury and long-term clinical outcomes (e.g., heart failure, mortality, nonfatal MI, and ischemic stroke). In contrast to bolus thermodilution techniques, CST does not require the use of active medications (e.g., papaverine or adenosine) -- only a small volume of normal saline.
219621029|NCT03212235|RADIATION|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
219621030|NCT06941298|BEHAVIORAL|Neuroimaging Investigation|Participants will undergo fMRI neuroimaging at two timepoints, at the start of the study and at the 1 year follow up. The fMRI is one hour in duration. During the fMRI, participants will complete two tasks investigating diverse aspects of reward circuitry activity. After this is completed, participants will be followed up for another year clinically.
218930881|NCT03682770|DRUG|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
218930882|NCT03682770|DRUG|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
218930883|NCT03682770|DRUG|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
218930884|NCT02362282|BEHAVIORAL|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
219621031|NCT04388852|BIOLOGICAL|Ipilimumab|Given IV
219621032|NCT04388852|DRUG|Valemetostat|Given PO
219044618|NCT06137950|DRUG|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
219541383|NCT03911583|BEHAVIORAL|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
219541384|NCT00787553|DRUG|cefazolin|2.0 g, IV, 2 hours before surgery
219541385|NCT00787553|DRUG|tinidazole|2.0 g orally, 12 hours before surgery
219541386|NCT00787553|DRUG|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
219541387|NCT01471353|DRUG|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
219541388|NCT00836472|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
219541389|NCT00836472|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
219621033|NCT03886025|OTHER|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
219621034|NCT03886025|BEHAVIORAL|Cognitive training|Iowa Gambling Task will be used for cognitive training
219621035|NCT03886025|OTHER|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
219541390|NCT06627712|DRUG|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
219044619|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
219541391|NCT06627712|DRUG|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
219541392|NCT03519139|OTHER|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
219541393|NCT00486187|DRUG|rosiglitazone|
219541394|NCT00486187|DRUG|metformin or sulfonylurea|
219541395|NCT00907387|DRUG|RT001|Dose A RT001
219541396|NCT00907387|DRUG|RT001|Dose B RT001
219621036|NCT06946641|DRUG|QLS12010|QLS12010 oral capsule(s)
219621037|NCT06946641|DRUG|Placebo|Matching placebo oral capsule(s)
219621038|NCT03376724|OTHER|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
219621039|NCT03376724|OTHER|Minimal|Analgesic use when necessary and a single back scholl class
219621040|NCT03460002|BIOLOGICAL|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
219621041|NCT03460002|BIOLOGICAL|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
219621042|NCT03427242|DRUG|Apatinib|oral apatinib 750mg qd
219621043|NCT00518700|OTHER|new MPS|
219621044|NCT00518700|OTHER|RepleniSH|
219621045|NCT04941820|OTHER|clinical pharmacist intervention|clinical pharmacist intervention
219621046|NCT00980694|DIETARY_SUPPLEMENT|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
219621047|NCT06950957|DEVICE|Video Laryngeal Mask Airway (VLMA)|A second-generation supraglottic airway device with an integrated video camera, used for airway management in adult patients undergoing elective septoplasty. The device allows real-time visualization of the glottic inlet to identify blood infiltration or anatomical challenges. Prior to removal, a fiberoptic bronchoscope will be introduced through the device's lumen to assess the distal trachea for blood contamination. Parameters such as airway insertion time, ventilation mechanics, hemodynamic data, analgesic requirements, and postoperative recovery scores (e.g., Aldrete score, sore throat incidence) will be recorded and analyzed.
219621048|NCT06950957|DEVICE|Endotracheal Tube (ETT)|A standard cuffed endotracheal tube inserted using direct laryngoscopy, employed for airway management during elective septoplasty. At the end of surgery, a fiberoptic bronchoscope will be passed through the ETT to evaluate the distal trachea for blood contamination. Airway insertion time, ventilation parameters, intraoperative hemodynamics, analgesic use, and postoperative outcomes (including sore throat and recovery scores) will be documented and compared with the VLMA group to assess differences in airway safety and clinical performance.
219621049|NCT05671588|PROCEDURE|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
219621050|NCT05671588|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
219621051|NCT06955520|DRUG|Vonoprazan|a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.
219621052|NCT06955520|DRUG|Esomeprazole 40mg|It is a proton pump inhibitor which reduces the excessive acid secretion in the stomach and it heals grade B esophagitis (\>5mm ulcer between two mucosal folds in esophagus)
219621053|NCT06949228|DRUG|tenecteplase|Patients treated with standard of care mechanical thrombectomy (MT) that achieved mTICI 2b or higher revascularization. Patients will be randomized into one of two arms: IA TNK or control.
219621054|NCT06954493|DRUG|Ibrexafungerp|Ibrexafungerp Oral Tablet
219621055|NCT06951581|DIETARY_SUPPLEMENT|Short Chain Fatty Acid|Participants in this arm will receive an oral formulation of short-chain fatty acids (SCFAs) daily for 12 weeks. SCFAs are administered as a dietary supplement to investigate their potential impact on the systemic and urinary metabolome in kidney transplant recipients.
219621056|NCT06951581|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Oral capsules with sacharosa (200 mg) matching SCFA appearance, administered once a day.
219621057|NCT03862430|DRUG|NanO2TM|0.1 mL/kg NanO2 infusion
219621058|NCT03862430|DRUG|Placebo Saline Infusion|Saline Infusion
219621059|NCT07112001|BEHAVIORAL|PositiveLinks with Counseling|A community health worker delivered, specialized counseling intervention through video call on the PositiveLinks app
219621060|NCT07112001|BEHAVIORAL|Standard of Care (SOC)|This intervention includes the use of the unmodified PositiveLinks app and the standard of care for addressing anxiety and depression in the HIV clinic
219621061|NCT05776953|DRUG|Ketorolac|IV Ketorolac for pain
219621062|NCT03570827|DRUG|Androgen Suppression|Given androgen suppression therapy
219621063|NCT03570827|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219621064|NCT03570827|OTHER|Quality-of-Life Assessment|Ancillary studies
219621065|NCT03570827|OTHER|Questionnaire Administration|Ancillary studies
219541397|NCT00907387|OTHER|Placebo|Dose C Placebo
219541398|NCT02013882|PROCEDURE|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
219541399|NCT04858126|DEVICE|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
219541400|NCT02518360|OTHER|Osteopathic|Body adjustment in three sessions (20 minutes/session).
219541401|NCT02518360|OTHER|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
218930885|NCT02362282|BEHAVIORAL|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
218930886|NCT02362282|BEHAVIORAL|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
218930887|NCT01755182|DRUG|approved pharmacologic therapy|
218930888|NCT01755182|PROCEDURE|TAE|after randomization, and after 3 months
218930889|NCT01447459|BEHAVIORAL|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
218930890|NCT05974124|DEVICE|Povidone-Iodine 0.66%|Povidone-iodine 0.66% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
218930891|NCT05974124|DEVICE|Chlorhexidine 0.02%|Chlorhexidine 0.02% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
218930892|NCT00500513|PROCEDURE|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
218930893|NCT00500513|PROCEDURE|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
218930894|NCT00500513|RADIATION|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
218930895|NCT06208280|DRUG|After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.|"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)"
218930896|NCT01278225|BEHAVIORAL|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
218930897|NCT01278225|BEHAVIORAL|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
218930898|NCT01278225|BEHAVIORAL|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
219044620|NCT07010094|DEVICE|BM shockwave devices|Use the BM shockwave devices for pre-treatment of coronary calcification lesions.
219541402|NCT04998526|OTHER|Experimental group|The cold gel pack will be applied to the nape.
219541403|NCT04998526|OTHER|Placebo group|The gel pack kept at room temperature will be applied to the nape.
219541404|NCT03172286|DEVICE|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
219541405|NCT04733755|DIETARY_SUPPLEMENT|Beauty Image|1.97g/package; 2 packages one day for 8 weeks
219541406|NCT04733755|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
219541407|NCT01695239|DRUG|Ixekizumab|Administered SC
219541408|NCT01695239|DRUG|Placebo|Administered SC
219541409|NCT01695239|DRUG|Adalimumab|Administered SC
219541410|NCT02007863|PROCEDURE|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
219541411|NCT02007863|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
219541412|NCT02007863|DRUG|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
219541413|NCT02007863|DRUG|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
218930899|NCT01470326|DRUG|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
218930900|NCT01980667|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
218930901|NCT01980667|DRUG|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
218930902|NCT05153096|DRUG|NBL-015|NBL-015 by intravenous infusion
218930903|NCT01166282|BIOLOGICAL|adalimumab|Adalimumab solution for subcutaneous injection.
219541414|NCT03781102|BEHAVIORAL|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
219541415|NCT00004213|DRUG|triapine|
219541416|NCT04865003|OTHER|treatment of infection|
219541417|NCT06627543|DIAGNOSTIC_TEST|echo|echocardiographic
218930904|NCT01166282|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
218930905|NCT06081270|OTHER|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
218930906|NCT02849899|DRUG|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
219541418|NCT04631393|DRUG|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
219541419|NCT05629728|BEHAVIORAL|Tai Chi exercise|Sun-style Tai Chi (21 forms)
219541420|NCT04353362|DRUG|Ofloxacin|400 mg, 1 time per day for 5 days
219541421|NCT04353362|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
219541422|NCT04353362|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
219541423|NCT00767260|DRUG|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
219541424|NCT00767260|DRUG|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
219541425|NCT00767260|DEVICE|HOT|Hyperbaric Oxygen Therapy
219541426|NCT00767260|DRUG|SMT|hypoglycemic drugs or exogenous insulin
219541427|NCT03168763|BEHAVIORAL|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
219541428|NCT03168763|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
219541429|NCT00735540|OTHER|Observational|Data summary only
219541430|NCT04472039|DEVICE|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
219541431|NCT02173886|DRUG|Bupropion SR and XL|
219541432|NCT00078039|DRUG|Paliperidone ER|
219541433|NCT05239195|OTHER|Video Laryngoscope|Laryngoscope with a camera and a video screen
219541434|NCT05239195|OTHER|Direct Laryngoscope|Laryngoscope without a camera or a video screen
219541435|NCT06626841|DIAGNOSTIC_TEST|Pelvic floor muscles contractile capacity and activation|"An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis)."
219541436|NCT00069758|DRUG|SDX-105|
219541437|NCT05502835|DEVICE|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
219541438|NCT05502835|OTHER|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
219541439|NCT06033417|OTHER|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
218930907|NCT02849899|DRUG|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
218930908|NCT00787358|DRUG|ZT-031|80 ul subcutaneous injection per day
218930909|NCT00787358|OTHER|placebo|80 ul daily subcutaneous injection of vehicle only
218930910|NCT03588884|DRUG|Calcifediol Oral Capsule|Capsule, daily
218930911|NCT03588884|DRUG|Calcifediol Oral Product|Capsule, once a month
218930912|NCT03588884|DRUG|Cholecalciferol|Capsule, once a month
218930913|NCT03588884|DRUG|Paricalcitol Oral Capsule|Capsule, daily
218930914|NCT04666220|OTHER|VETC evaluation|We will evaluate VETC presence on tissue specimens
218930915|NCT00992472|DRUG|Prochlorperazine suppositories, 25mg|
218930916|NCT00992472|DRUG|Compazine® suppositories, 25mg|
218930917|NCT00400972|DEVICE|GlideScope videolaryngoscope|
218930918|NCT06012552|DRUG|Tianeptine|Tianesal 12,5mg
218930919|NCT06012552|DRUG|Placebo|application as in the control group
218930920|NCT02902289|DRUG|Ibuprofen 200 mg/5 mL oral suspension|
218930921|NCT02902289|DRUG|MOMENT 200 mg coated tablet|
218930922|NCT00132704|RADIATION|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
219541440|NCT06033417|OTHER|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
218930923|NCT00132704|RADIATION|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
218930924|NCT06284135|OTHER|Michl-stitch|In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
219541441|NCT01591564|BEHAVIORAL|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
219044621|NCT06873139|BEHAVIORAL|text messages|There will be two arms for the texting intervention: high and low. Both arms will receive text messages, but the frequency of the messages will vary by arm. Text intervention messaging will be sent through an automated text messaging service programmed by the CM Research Informatics team, which has been approved by the institution.
219541442|NCT03552484|BEHAVIORAL|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
219541443|NCT03552484|BEHAVIORAL|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
219541444|NCT01654484|DRUG|DE-117|Ophthalmic Solution, QD, 28 Days
219541445|NCT01654484|DRUG|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
219541446|NCT01654484|DRUG|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
219541447|NCT01654484|DRUG|Placebo|Ophthalmic Solution, QD, 28 days
219541448|NCT05636254|DIAGNOSTIC_TEST|MRI Brain and spine|"* MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)"
218930925|NCT05465577|OTHER|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
218930926|NCT01302249|DRUG|Latanoprost 0.005%|q.d.
218930927|NCT01302249|DRUG|AR-12286 Ophthalmic Solution 0.5%|
218930928|NCT01302249|DRUG|Timolol maleate ophthalmic solution 0.5%|
218930929|NCT04651062|DEVICE|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
218930930|NCT04651062|PROCEDURE|no endocuff|colonoscopy is performed without endocuff.
218930931|NCT03135964|DEVICE|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
218930932|NCT02760953|PROCEDURE|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
218930933|NCT02760953|DRUG|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
218930934|NCT03444636|DRUG|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
218930935|NCT03444636|DRUG|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
218930936|NCT00380367|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
218930937|NCT00473096|BEHAVIORAL|Informed breast cancer surgical treatment|
218930938|NCT03281200|DRUG|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
218930939|NCT03281200|DRUG|L01 - Antineoplastic agents|L01 - Antineoplastic agents
219541449|NCT05636254|DIAGNOSTIC_TEST|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
218930940|NCT03281200|DRUG|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
218930941|NCT03281200|DRUG|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
219541450|NCT05146076|OTHER|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
219541451|NCT05146076|OTHER|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
218930942|NCT03281200|DRUG|L01XE31 - Nintedanib|L01XE31 - Nintedanib
218930943|NCT00133068|BEHAVIORAL|Computer|Computer intervention only
218930944|NCT00133068|BEHAVIORAL|Reduction in financial barrier|Copay only
218930945|NCT00133068|BEHAVIORAL|Computer intervention & reduction of financial barrier|computer intervention \& copay
218930946|NCT00133068|BEHAVIORAL|Control|No intervention
218930947|NCT00225732|OTHER|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
218930948|NCT00225732|DRUG|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
219621066|NCT06954714|PROCEDURE|Drug-eluting stent implantation|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DES group, latest second-generation DES will be used in accordance with standard practice guideline."
218930949|NCT00392769|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
218930950|NCT04601649|BEHAVIORAL|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
218930951|NCT05109143|DRUG|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
218930952|NCT05109143|OTHER|Standard Medical Treatment|Standard Medical Treatment
218930953|NCT01155518|DRUG|testosterone|intramuscular every 2 weeks
218930954|NCT01155518|DRUG|clomiphene|thrice a week
218930955|NCT01155518|DRUG|placebo|intramuscular saline injections every 2 weeks
218930956|NCT01155518|DRUG|placebo|oral
218930957|NCT01641185|PROCEDURE|radiation|radiation with protons or carbon ions
218930958|NCT00326859|DRUG|remifentanil|
218930959|NCT00439517|DRUG|UFOX + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
218930960|NCT00439517|DRUG|FOLFOX4 + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16"
218930961|NCT01684813|DRUG|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
218930962|NCT01684813|DRUG|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
218930963|NCT00988728|DRUG|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
218930964|NCT00988728|DRUG|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
218930965|NCT00988728|DRUG|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
218930966|NCT02058303|DRUG|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
219541452|NCT06430632|DEVICE|Robotic Gait Training|Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
219541453|NCT06430632|OTHER|Usual Care Gait Training|Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
219541454|NCT05959187|DIAGNOSTIC_TEST|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
219541455|NCT03280953|DIAGNOSTIC_TEST|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
218930967|NCT02058303|DRUG|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
218930968|NCT06003894|OTHER|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
218930969|NCT06003894|OTHER|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
218930970|NCT03171571|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
219541456|NCT02248051|DRUG|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
219541457|NCT00261391|DRUG|Marimastat|
218930971|NCT03244839|PROCEDURE|bariatric surgery|bariatric surgery
219044622|NCT07019285|BEHAVIORAL|High intensity interval walking training|High intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 90 to 110% of 6MWTdistance. The frequency of the training is three times a week
219541458|NCT03570060|BIOLOGICAL|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
219541459|NCT03570060|PROCEDURE|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
219541460|NCT03570060|PROCEDURE|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
219541461|NCT01411462|DEVICE|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
219541462|NCT05891522|PROCEDURE|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
219044623|NCT07019285|BEHAVIORAL|Moderate-intensity interval walking training|Moderate intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is three times a week
219044624|NCT06316063|DEVICE|Apnoeic oxygenation with high-flow nasal oxygen|The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
219044625|NCT06316063|OTHER|Mechanical ventilation|Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
219044626|NCT07024147|BIOLOGICAL|JWCAR239|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20
219044627|NCT07024147|DRUG|Fludarabine|Administered according to package insert
219044628|NCT07024147|DRUG|Cyclophosphamide|Administered according to package insert
219541463|NCT05891522|PROCEDURE|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
219541464|NCT03416673|PROCEDURE|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
219541465|NCT03416673|PROCEDURE|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
219541466|NCT04808362|BIOLOGICAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
219541467|NCT03256396|PROCEDURE|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
219541468|NCT04162899|DRUG|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
219541469|NCT04621617|DRUG|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
219541470|NCT04621617|DRUG|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
219541471|NCT04621617|DRUG|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
219541472|NCT04982523|BEHAVIORAL|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
219621067|NCT06954714|PROCEDURE|Drug-coated balloon angioplasty|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds."
218930972|NCT03644472|DRUG|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
218930973|NCT03644472|DRUG|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
218930974|NCT04526769|DIAGNOSTIC_TEST|Tear Collection|"A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored."
218930975|NCT02304367|BIOLOGICAL|Burosumab|Solution for subcutaneous injection
218930976|NCT01185665|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulator
218930977|NCT01185665|DEVICE|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
218930978|NCT00554489|BEHAVIORAL|exercise intervention|participation in physical activity intervention program weeks 2 through 5
218930979|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
218930980|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
219044629|NCT07024004|BEHAVIORAL|Exergame-Based Exercise + Conventional Physical Therapy|"Participants in this group will engage in a combined intervention consisting of:~Multicomponent physical exercise (aerobic, strength, balance, and flexibility), delivered twice per week for 12 weeks.~Exergames training using the Nintendo Switch console and Ring Fit Adventure game. Sessions include warm-up, gameplay involving full-body movements (e.g., squats, running, balance tasks), and cooldown.~Sessions are adapted to individual physical capacities and supervised by a trained kinesiologist.~The intensity is monitored using the Borg Scale, following ACSM guidelines."
219044630|NCT07024004|BEHAVIORAL|Conventional Physical Therapy|"Participants in this group will receive a standard multicomponent physical exercise program consisting of:~Exercises for aerobic capacity, strength, balance, and flexibility.~Delivered in-person twice per week for 12 weeks at senior care centers.~Sessions include warm-up (5-10 min), main activity (30-40 min), and cooldown (5-10 min).~Intensity is controlled using the Borg Scale and monitored by a supervising kinesiologist."
219621068|NCT02813291|DEVICE|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
219621069|NCT02813291|DEVICE|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
219367020|NCT01396369|DRUG|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
218930981|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
218930982|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
218930983|NCT04462614|DRUG|Decrease per-dialytic heparin therapy|Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
218930984|NCT03544177|OTHER|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
219621070|NCT03861117|PROCEDURE|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
218930985|NCT03544177|OTHER|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
218930986|NCT00199212|DRUG|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
218930987|NCT02403648|DRUG|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
218930988|NCT02403648|DRUG|Lilly Glucagon|
218930989|NCT02403648|DRUG|Novo Glucagon|
218930990|NCT00526071|DRUG|migalastat HCl|
218930991|NCT04767984|DRUG|Atorvastatin Calcium|Given PO
218930992|NCT04767984|PROCEDURE|Biopsy of Colon|Undergo colonoscopy with biopsy
218930993|NCT04767984|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218930994|NCT04767984|DRUG|Placebo Administration|Given PO
218930995|NCT04767984|OTHER|Questionnaire Administration|Ancillary studies
218930996|NCT00272311|DRUG|Aspirin|Dosage
218930997|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
218930998|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
218930999|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
218931000|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
218931001|NCT01168037|DEVICE|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
218931002|NCT01168037|PROCEDURE|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
218931003|NCT05996133|DRUG|Bupivacaine Hcl 0.25% Inj|30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.
219367021|NCT00016458|DRUG|anti-thymocyte globulin|
219367022|NCT00016458|DRUG|cyclophosphamide|
219367023|NCT03883269|DRUG|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
219367024|NCT03883269|DRUG|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
218931004|NCT05996133|OTHER|Normal saline|3 mL normal saline
218931005|NCT03409016|OTHER|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
218931006|NCT04229537|BIOLOGICAL|SCT-I10A|200 mg intravenous (IV) on Day 1 of Q3W.
218931007|NCT04229537|BIOLOGICAL|SCT200|6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
219367025|NCT03883269|DRUG|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
219367026|NCT05158855|DIETARY_SUPPLEMENT|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
219367027|NCT03458169|DEVICE|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
219367028|NCT03458169|DEVICE|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
219367029|NCT03458169|DEVICE|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
219367030|NCT04358757|PROCEDURE|Elective cesarean delivery|scheduled cesarean delivery for maternal / obstetric indications
219367031|NCT00526201|BEHAVIORAL|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
219367032|NCT00526201|BEHAVIORAL|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
218931008|NCT04229537|OTHER|Chemotherapy|Capecitabine and Oxaliplatin.
218931009|NCT04319588|PROCEDURE|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
218931010|NCT04319588|PROCEDURE|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
218931011|NCT04251130|DRUG|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
218931012|NCT03387878|DEVICE|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
218931013|NCT04169074|DRUG|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
218931014|NCT03397810|RADIATION|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
218931015|NCT05884541|OTHER|TipsbyText Messages|Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
218931016|NCT04529018|COMBINATION_PRODUCT|[18F]CETO|\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
218931017|NCT06850623|COMBINATION_PRODUCT|Acoustic Cluster Therapy|Drug: PS101; Device: Ultrasound
218931018|NCT06850623|DRUG|Modified FOLFIRINOX|Chemotherapy
218931019|NCT05021068|OTHER|Postural Assessment|Spinal mouse measurement
218931020|NCT06254885|PROCEDURE|Equi-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.
218931021|NCT06254885|PROCEDURE|Sub-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
218931022|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with analogic guide|coDiagnostix9® planning software
218931023|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with CAD-CAM surgical guide|coDiagnostix9® planning software
218931024|NCT00973804|DRUG|EPOCH-F/R|
218931025|NCT00973804|DRUG|FLAG|
218931026|NCT00973804|DRUG|Transplant Preparative Regimen (Flu/Cy/Mes)|
218931027|NCT00973804|DRUG|GVHD Prophylaxis (tacrolimus and sirolimus)|
218931028|NCT00973804|PROCEDURE|Double Cord Blood Transplantation|
219541473|NCT06627023|DEVICE|Implant Placement with Conical or Butt-Joint Connection|Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
219541474|NCT04145635|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
219541475|NCT02538549|BEHAVIORAL|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
219541476|NCT02663349|BEHAVIORAL|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
219541477|NCT05391594|DEVICE|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
219541478|NCT04865471|PROCEDURE|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
219541479|NCT05882526|DEVICE|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
218931029|NCT02546206|DIETARY_SUPPLEMENT|Probiotic Yoghurt|Probiotic yoghurt consumption
218931030|NCT02546206|DIETARY_SUPPLEMENT|Natural Yoghurt|Natural yoghurt consumption
218931031|NCT01184963|DIETARY_SUPPLEMENT|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
218931032|NCT01184963|DIETARY_SUPPLEMENT|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
218931033|NCT05866809|DRUG|HK-660S|Administered orally
218931034|NCT05866809|DRUG|Placebo|Administered orally
218931035|NCT00318643|DRUG|Mitomycin C|intravesical administration
218931036|NCT00318643|DRUG|Chemophase|intravesical administration
218931037|NCT02601846|OTHER|No intervention|This is an observational study, without any specific intervention.
218931038|NCT00867672|DRUG|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
218931039|NCT00867672|DRUG|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
218931040|NCT00867672|DRUG|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
218931041|NCT01702649|DRUG|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
218931042|NCT01702649|DRUG|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
219541480|NCT02847624|DRUG|tolvaptan|
218931043|NCT00406484|BEHAVIORAL|Standard drug counseling|Individual drug counseling
218931044|NCT00406484|BEHAVIORAL|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
218931045|NCT02778737|BEHAVIORAL|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
218931046|NCT02778737|BEHAVIORAL|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
218931047|NCT00002002|DRUG|Trimethoprim|
218931048|NCT00002002|DRUG|Sulfamethoxazole|
218931049|NCT00002002|DRUG|Leucovorin calcium|
218931050|NCT02503761|DRUG|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
218931051|NCT03417154|DRUG|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
218931052|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
218931053|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
218931054|NCT05429957|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~* MET of the Iliopsoas~* MET of Piriformis muscle~* MET of Quadratus Lumborum muscle~* MET of Erector Spinae muscle"
218931055|NCT05429957|OTHER|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~* Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~* Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~* Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
218931056|NCT01850654|GENETIC|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
219541481|NCT04280224|BIOLOGICAL|NK Cells|twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
219044631|NCT07024264|OTHER|Total energy requirement calculated by predictive equation|Critically ill patients are highly susceptible to malnutrition, making accurate caloric estimation essential to prevent both underfeeding and overfeeding during the acute phase in the ICU. Although predictive equations (PE) are widely used to estimate energy requirement, indirect calorimetry (IC) remains the gold standard. This study aimed to compare energy requirements estimated by PE and IC across different BMI categories.
219044632|NCT07024459|DEVICE|Monitoring|Participants will be monitored with secondary monitor collecting data from parameters under evaluation
219044633|NCT07023887|OTHER|6-12-25 Training Regimen|A conditioning regimen involving three exercises performed consecutively with minimal rest. Includes 4-6 repetitions at 4-0-1-0 tempo, 10-12 repetitions at 3-0-1-0 tempo, and 20-25 repetitions at 2-0-1-0 tempo.
219044634|NCT07023887|OTHER|8x8 Training Regimen|A conditioning regimen optimizing high volume with short rest periods. Six exercises are performed consecutively with a 2-0-1-0 tempo and no rest between sets.
219044635|NCT07023887|OTHER|5/5/5 Cluster Set Training Regimen|A hypertrophy regimen where an individual performs 5 repetitions at a tempo of 4 seconds during the eccentric movement of the exercise, while performing the concentric motion in 1 second then resting for 20 seconds and repeating the sequence two additional times to total three clusters of 5 repetitions.
219044636|NCT07023887|OTHER|Double Training Regimen|A hypertrophy regimen adding an additional set of lesser repetitions for a specified exercise at the end of a tri-set of exercises.
219367033|NCT01124825|DEVICE|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
219367034|NCT01124825|DEVICE|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
219367035|NCT03119012|DRUG|Clopidogrel|75mg/day
219367036|NCT03119012|DRUG|Ticagrelor|120mg/day
219367037|NCT03119012|DRUG|Aspirin|100mg/day
219367038|NCT04205435|BIOLOGICAL|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
219367039|NCT01975168|DEVICE|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
219367040|NCT01273064|DRUG|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
219367041|NCT01273064|DRUG|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
219367042|NCT01273064|DRUG|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
218931057|NCT01850654|GENETIC|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~* CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~* CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~* CRC study participants diagnosed with CRC \<50 years, regardless of tumor studies or family history~* CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
218931058|NCT01850654|BEHAVIORAL|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
218931059|NCT01850654|OTHER|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
218931060|NCT01850654|BEHAVIORAL|Questionnaire|
218931061|NCT02036814|BEHAVIORAL|Program Health Education|
218931062|NCT02426203|PROCEDURE|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
218931063|NCT03327207|OTHER|Non Interventional|Non Interventional
218931064|NCT01885598|DRUG|Apixaban|
218931065|NCT03585738|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
218931066|NCT03585738|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
218931067|NCT02864459|OTHER|Muscular ultrasound|Muscular ultrasound is done before extubation
218931068|NCT05322395|DIAGNOSTIC_TEST|ESC 0/1 hour troponin pathway|randomisation to 0/1 versus 0/3 hour pathway
218931069|NCT04204889|DRUG|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
218931070|NCT05644158|PROCEDURE|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
218931071|NCT05644158|OTHER|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
218931072|NCT02500797|BIOLOGICAL|Ipilimumab|Given IV
218931073|NCT02500797|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931074|NCT02500797|BIOLOGICAL|Nivolumab|Given IV
218931075|NCT02500797|OTHER|Quality-of-Life Assessment|Ancillary studies
218931076|NCT01342159|PROCEDURE|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
218931077|NCT02611583|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation
218931078|NCT06440681|OTHER|Providing nutritional counselling|"Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks."
219367043|NCT01273064|DRUG|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
219367044|NCT05789095|OTHER|Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)|"Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation."
219367045|NCT02906072|BEHAVIORAL|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
219367046|NCT02906072|BEHAVIORAL|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
219367047|NCT00291551|DEVICE|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
219367048|NCT00855114|DRUG|everolimus|5 mg/day x 7 days by mouth
219367049|NCT00855114|PROCEDURE|therapeutic conventional surgery|Definitive excision of breast cancer tissue
219367050|NCT00702078|BEHAVIORAL|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
219367051|NCT00702078|BEHAVIORAL|usual care|follow-up according to todays best practice
219367052|NCT01897480|BIOLOGICAL|LY2875358|Administered IV
219367053|NCT01897480|DRUG|Erlotinib|Administered Orally
218931079|NCT06440681|OTHER|counseling on physical activity|"Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)"
218931080|NCT04803552|DEVICE|Overnight sleep study with Sleepiz One and a respiratory polygraphy|"Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~* Thoracic respiratory effort: respiration frequency (BR), respiration curve~* Airflow: respiration frequency (BR), respiration curve~* Body movement: body position~* Blood oxygen saturation (SpO2)~* Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions"
218931081|NCT01328132|DRUG|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
218931082|NCT01328132|DRUG|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
219621071|NCT03861117|PROCEDURE|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
219621072|NCT06004661|DRUG|AAA617|Administered intravenously once every cycles (1 cycle = 6 weeks)
219621073|NCT06004661|DRUG|68Ga-PSMA-11|Single intravenous dose of approximately 150 MBq
218931083|NCT02382432|DRUG|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
218931084|NCT02382432|DRUG|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
218931085|NCT05950815|DRUG|CD73 Antigen|subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.
218931086|NCT05744934|DEVICE|LUX-Dx™|Placement of LUX-Dx at the time of stage 1 palliation
218931087|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
218931088|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
218931089|NCT02346058|DRUG|Esarin Gel|
219367054|NCT01238692|DRUG|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
219367055|NCT01238692|DRUG|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
218931090|NCT01684293|BEHAVIORAL|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
218931091|NCT01684293|BEHAVIORAL|Psychoeducation/games|Psychoeducation/games
218931092|NCT01647347|DRUG|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
218931093|NCT01647347|OTHER|Water|
218931094|NCT01673737|DRUG|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
218931095|NCT01673737|DRUG|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
218931096|NCT00088764|BEHAVIORAL|Coping skills training|8 sessions of pain and stress coping skills training
219367056|NCT06215833|DRUG|Propofol|All children will undergo anesthesia via Propofol bolus injection in induction then Propofol infusion in maintenance of anesthesia and will be given after total recovery, Cetal suppositories as postoperative analgesia
219367057|NCT06215833|DRUG|Sevoflurane|All children will undergo anesthesia via Sevoflurane will be given during induction then through maintenance of anesthesia and will be given after total recovery, Cetal suppositories as post operative analgesia
219367058|NCT02658812|OTHER|Laboratory Biomarker Analysis|Correlative studies
219367059|NCT02658812|BIOLOGICAL|Talimogene Laherparepvec|Given IT
219367060|NCT01512264|DEVICE|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
219367061|NCT06335056|BEHAVIORAL|ProudMe|"ProudMe Tech: Regular human/computer interaction (3-5 times per week) to engage in SMART goal-setting, behavior monitoring, and self-reflection as assisted by AI-enabled feedback.~ProudMe Physical Education \[PE\]: 12 lessons to acquire knowledge, skill, and dispositions to improve physical activity, diet, screen-based sedentary behaviors.~ProudMe Cafeteria: Purposely enabling policy and environmental changes in school cafeteria (recognize areas of strengths and weaknesses; set goals and action plans; make changes to improve scores assessed by the Smarter Lunchroom Scorecard).~ProudMe Training: 4-hour implementation training + regular check-in and support (via motivational interviewing techniques)"
219367062|NCT06335056|BEHAVIORAL|Waitlist Control|The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the overall importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
218931097|NCT00088764|BEHAVIORAL|Written emotional disclosure|4 sessions of writing about stress
218931098|NCT00088764|BEHAVIORAL|Arthritis education|8 sessions of learning about rheumatoid arthritis
218931099|NCT00088764|BEHAVIORAL|Health behavior writing|4 sessions of writing about various health behaviors
219621074|NCT05618834|BEHAVIORAL|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
219621075|NCT05618834|BEHAVIORAL|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
219621076|NCT06142565|DEVICE|Nose plug|Participants will complete olfactory training with scented nose plugs.
219621077|NCT06142565|OTHER|Regular olfactory training|Participants will complete olfactory training with regular odors found in their home.
218931100|NCT02289157|DEVICE|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
218931101|NCT03275649|OTHER|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
218931102|NCT04782479|PROCEDURE|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
218931103|NCT00463515|DRUG|carboplatin/gemcitabine|
218931104|NCT00463515|PROCEDURE|cisplatin/radiation therapy|
218931105|NCT00561509|DRUG|SSRIs|Use within normal clinical practice
218931106|NCT00561509|DRUG|Dual antidepressants|Use within clinical practice
218931107|NCT04378543|BIOLOGICAL|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
218931108|NCT04016766|BEHAVIORAL|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
218931109|NCT04033016|BEHAVIORAL|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
218931110|NCT04033016|BEHAVIORAL|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
219367063|NCT04433507|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
219367064|NCT04433507|PROCEDURE|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
219367065|NCT02758158|DEVICE|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
219367066|NCT02314507|OTHER|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
219367067|NCT02314507|OTHER|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
219367068|NCT02025296|DEVICE|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
219367069|NCT00217165|DRUG|taurine|taurine 2mg BID po
218931111|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
218931112|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
218931113|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
218931114|NCT04923282|BIOLOGICAL|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
218931115|NCT04923282|BIOLOGICAL|Placebo|Intravenous infusion
218931116|NCT05080335|OTHER|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~1. TRANS- vs CIS-gender female instructors~2. With or without short videos of transgender youth embedded into the didactic \[TV or CV\]; for the group with no embedded videos \[NV\], the same videos will be shown AFTER completion of the post measures)~3. No-intervention control, in which TV will be delivered \*after\* collection of pre/post measures."
218931117|NCT02627976|DEVICE|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
218931118|NCT02983552|OTHER|iPad®|Binocular therapy using a Dig Rush application on an iPad®
218931119|NCT02983552|OTHER|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
218931120|NCT00694642|BIOLOGICAL|Selected CD 133+ cells|Endothelial progenitor cell CD 133
218931121|NCT02740452|DEVICE|ligamys technique|Ligamys technique (device) or standard technique
218931122|NCT02740452|OTHER|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
218931123|NCT00163683|BEHAVIORAL|Dietary Therapy|
218931124|NCT06353555|DRUG|Euthyrox|Upon discovering low T3 or low T4 levels, administer oral levothyroxine sodium tablets daily. If accompanied by a decrease in TSH, the regimen is 100μg qd (for individuals weighing \<75kg) or 150μg qd (for individuals weighing \>75kg). If not accompanied by a decrease in TSH, the regimen is 50μg qd. However, if thyroid function does not significantly improve within 3 days of medication, the regimen is adjusted to 100μg qd. Treatment should continue until transfer out of the NICU or discharge, with a minimum duration of 7 days.
218931125|NCT06353555|DRUG|Euthyrox|Patient will not receive the oral levothyroxine sodium tablets.
218931126|NCT00691834|BIOLOGICAL|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
218931127|NCT00691834|BIOLOGICAL|Placebo|Plasma and culture medium (10 ml)
218931128|NCT00623142|DRUG|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
218931129|NCT04178785|DRUG|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
218931130|NCT03339843|DRUG|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
218931131|NCT00357006|DRUG|Estradiol|100 mcg adjunctive transdermal estradiol
218931132|NCT00357006|DRUG|Estradiol|200 mcg adjunctive transdermal estradiol
219044637|NCT06876441|BEHAVIORAL|HDTC training program|Participants will receive usual care plus HDTC training program, including four parts: (1)30-minute educational seminar via Tencent: provide disease knowledge, propose strategies to replace sedentary behavior, and introduce Tai Chi. (2)1-hour online nurse-lead dyadic coaching session: introduce dyadic Tai Chi, clarify the roles and responsibilities, and establish a shared goal among dyads. (3)1-hour preliminary Tai Chi training session: face-to-face, introduce online Tai Chi learning, demonstrations on using heart rate monitor, and suggestions for safe home environment. (4)12-week Tai Chi training: Dyads learn Tai Chi following Tai Chi master online. Each session will last 30 minutes in week 2, increase to 40 minutes in week 3, and reach 50 minutes in week 4. The dyads' mastery of Tai Chi will then be assessed either onsite or online. Subsequently, they will practice Tai Chi with the master once a week and follow instructional videos twice a week, with each session lasting 50 minutes.
219044638|NCT06876441|OTHER|Usual Care Group|HF-caregiver dyads in the control group will receive the usual care, including a 30-min online comprehensive education and nurse-led support through telephone consultations in the aspects of symptom management, medication, dietary and exercise suggestions, psychosocial support, and regular monthly follow-up every month.
219044639|NCT06718413|DRUG|hyaluronidase plus saline|Injection of study drug with saline
219044640|NCT06718413|DRUG|saline|injection of normal saline and no study drug
219044641|NCT04074317|DRUG|PRAM9|SC injection
218931133|NCT00357006|OTHER|placebo|adjunctive transdermal placebo
218931134|NCT05380817|OTHER|Remote Monitoring Program|Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
218931135|NCT05724888|BEHAVIORAL|Peer mentorship and physical activity|Participants will be asked to participate for 12 weeks, attending 3 sessions per week (if in the intervention arm). Session 1 will be a group session that will be about 90 minutes, session 2 will be an individual session with a peer mentor for 20-30 minutes, and session 3 will be a virtual check in with the peer mentor about 15 minutes. The intervention will focus on increasing physical activity through the circle of courage.
218931136|NCT02293317|BIOLOGICAL|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
218931137|NCT02293317|DRUG|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
218931138|NCT02293317|OTHER|Saline|Placebo
218931139|NCT00976560|DRUG|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
218931140|NCT00976560|OTHER|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
218931141|NCT04152941|DRUG|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
218931142|NCT03710161|DRUG|Vitamin D|Vitamin D taken in two different dosages daily for six months.
219044642|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
219044643|NCT04074317|DRUG|Regular Insulin|SC injection
218931143|NCT02356861|DEVICE|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
218931144|NCT05130515|DRUG|Niraparib|Niraparib 200mg po QD, day1\~21
219541482|NCT06802471|DEVICE|electroacupuncture|"The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device.~The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40.~Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6.~The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm, Φ0.30×50mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
218931145|NCT05130515|DRUG|Anlotinib|Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle
218931146|NCT02132026|DRUG|Denosumab|
218931147|NCT02132026|DRUG|Alendronic Acid|
218931148|NCT02132026|DRUG|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
219621078|NCT03717311|OTHER|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
218931149|NCT02132026|DRUG|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
218931150|NCT00889161|DRUG|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
218931151|NCT00171561|DRUG|valsartan/hydrochlorothiazide|
218931152|NCT04844411|DRUG|JNJ-67835989|JNJ-67835989 will be administered orally.
218931153|NCT04844411|DRUG|Placebo|Matching placebo will be administered orally.
218931154|NCT02842489|PROCEDURE|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
218931155|NCT02842489|PROCEDURE|left lateral horizontal position|patients will be horizontally positioned on their left side
218931156|NCT01216189|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
218931157|NCT05459883|PROCEDURE|splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation
218931158|NCT00888732|DRUG|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
219621079|NCT02862275|DRUG|Atezolizumab|Given IV
219621080|NCT02862275|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219621081|NCT02862275|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219621082|NCT02862275|PROCEDURE|Computed Tomography|Undergo CT scan
219621083|NCT02862275|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621084|NCT02862275|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621085|NCT06293456|OTHER|Dignity Therapy|A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.
219621086|NCT03150329|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931159|NCT03829644|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
218931160|NCT03210337|DRUG|A-101 Topical Solution|A-101 Topical Solution
218931161|NCT03210337|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
218931162|NCT05633758|DRUG|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
218931163|NCT05633758|DRUG|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
219541483|NCT06802471|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable non-insertive sham control needles (Φ0.3mm×40mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
218931164|NCT04536558|DRUG|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
219205331|NCT06749938|OTHER|Holistic Intervention|"* Aerobic Exercise Prescription. Each participant will be given instruction on an exercise program to progress to perform a total of 150 minutes/wk of moderate-vigorous aerobic activity (including any yoga practice they choose to do) with two days of strengthening exercises using exercise bands.~* Yoga Protocol and Meditation Exercise. Participants will be asked to practice three 75-min session days per week. The program will focus on developing breath and body awareness/control (pranayama), focused concentration, meditation, muscular strength, muscular endurance, and mobility (flexibility) training that involves the mind body spirit connection.~* Diet Intervention. Coaching for diet modification will be incorporated into the psychosocial support messaging.~* Psychosocial Support. Motivational strategies to enhance exercise compliance comprise of electronic messaging using the BlueJay Mobile-Health, (Livermore, CA). This tele-health HIPPA compliant allows private communication."
219205332|NCT06747975|DRUG|Dexamethasone and Ondansetron|patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
218931165|NCT04536558|DRUG|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
219044644|NCT06757413|OTHER|Enhanced Virtual reality|"This study evaluates a 4-week multidisciplinary intervention for patients with chronic non-specific low back pain, combining physiotherapy and psychological approaches. Both components leverage virtual reality (VR) technology to address physical and psychological aspects of pain management, operating in parallel to maximize patient outcomes. The physiotherapy intervention consists of a therapeutic exercise program based on the principles of the Back School. Over 8 sessions (2 per week), patients perform VR-guided exercises where visual-proprioceptive information is manipulated.~The psychological positive body image-based intervention consists of 4 sessions approaching 5 different clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. 2 sessions (Body Awareness and Pain Acceptancce) will include virtual reality environments to enhance the clinical outcomes."
219044645|NCT06757413|OTHER|Active Comparator: Treatment as usual|Participants will receive the usual treatment applied at the hospital
219205333|NCT06747975|DRUG|Bupivacaine + saline|patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
219205334|NCT06754865|DRUG|Xiyanping injection+ antibiotic|Xiyanping injection+ antibiotic
219205335|NCT06754865|DRUG|Antibiotic|Antibiotic
219621087|NCT03150329|BIOLOGICAL|Pembrolizumab|Given IV
219621088|NCT03150329|DRUG|Vorinostat|Given PO
219621089|NCT06848075|DRUG|Elismetrep (K-304) Dose Level 1|Administered orally
219621090|NCT06848075|DRUG|Elismetrep (K-304) Dose level 2|Administered orally
219621091|NCT06848075|DRUG|Elismetrep (K-304) Dose level 3|Administered orally
219541484|NCT05639933|DRUG|HT-001 2% Topical Gel|Topical gel, 2% active
219541485|NCT05639933|DRUG|HT-001 1% Topical Gel|Topical gel, 1% active
219541486|NCT05639933|DRUG|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
219541487|NCT05639933|DRUG|HT-001 Placebo|Topical gel, vehicle gel
219621092|NCT06848075|DRUG|Elismetrep (K-304) Dose level 4|Administered orally
219621093|NCT06848075|DRUG|Placebo|Administered orally
219621094|NCT02853214|GENETIC|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
219621095|NCT03284385|DRUG|Adavosertib|Given PO
219621096|NCT04860453|GENETIC|WES via Illumina NextSeq 550 sequencing system|Sequencing will be performed on an Illumina sequencing system
219621097|NCT04860453|DIAGNOSTIC_TEST|Blood Draw|Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
219621098|NCT04860453|DIAGNOSTIC_TEST|Skin biopsy|Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
219621099|NCT04860453|DIAGNOSTIC_TEST|Saliva Sample|Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
219621100|NCT06565195|DRUG|LY3962681|IT injection
218931166|NCT00125164|DRUG|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
218931167|NCT05005117|PROCEDURE|Laparoscopic operation|Operation
218931168|NCT05005117|PROCEDURE|Open operation|Operation
218931169|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
218931170|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
218931171|NCT00518102|DRUG|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
218931172|NCT00518102|OTHER|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
218931173|NCT02127697|DRUG|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
218931174|NCT02127697|DRUG|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
219541488|NCT01690780|DRUG|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
219541489|NCT01690780|DRUG|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
218931175|NCT02127697|DRUG|salbutamol/ albuterol|Taken as rescue medication
218931176|NCT03773276|DRUG|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses."
219044646|NCT07068308|BEHAVIORAL|web-based FRAIL-SM program|The 8-week web-based FRAIL-SM includes family involvement, self-regulation, autonomy support, information sharing and linkage.
219044647|NCT06775964|BIOLOGICAL|adMSC|IV-infusion of autologous, adipose-derived, Mesenchymal Stem Cells (adMSCs), of approximately 2x10(8) adMSCs in 250mL saline.
219044648|NCT06782295|DEVICE|Constrained Condylar bearing|Patients in this intervention will receive a CCK bearing component
219044649|NCT06782295|DEVICE|posterior stabilized bearing|Patients in this intervention will receive a PS bearing component
219044650|NCT07086170|OTHER|Psychological First Aid Training|Structured training based on psychological first aid principles. Delivered in six 60-minute sessions over three weeks. Includes theoretical content, interactive methods, and case-based exercises to build disaster response competencies.
219044651|NCT07086898|OTHER|Integrated Neuromuscular Inhibition Technique|Patients will receive integrated neuromuscular inhibition technique in the form of intermittent ischemic compression, strain counterstrain, and muscle energy technique plus postural correction exercises
219044652|NCT07086898|OTHER|Postural Correction Exercise|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
219044653|NCT03968822|DRUG|Lidocaine 2%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
219044654|NCT03968822|DRUG|Lidocaine 1%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
219541490|NCT06517979|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
219541491|NCT00488774|OTHER|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
218931177|NCT02528812|DEVICE|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
218931178|NCT02528812|OTHER|Manual Massage|A massage therapist massaged the participant
218931179|NCT02869568|OTHER|Data collection|
218931180|NCT01339052|DRUG|BKM120|
219541492|NCT00488774|DRUG|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
219541493|NCT00488774|DRUG|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
219541494|NCT00488774|DRUG|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
219541495|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
219541496|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
219541497|NCT01110473|DRUG|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
218931181|NCT01339052|PROCEDURE|Surgery|Surgery
218931182|NCT02501577|DEVICE|SAD 1|Placement and fiberoptic control
219541498|NCT01110473|DRUG|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
218931183|NCT02501577|DEVICE|SAD 2|Placement and fiberoptic control
218931184|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
218931185|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
218931186|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
218931187|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
218931188|NCT00513916|DIETARY_SUPPLEMENT|soy isoflavones|High or low dose of soy isoflavones in the diet.
219541499|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
219541500|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
219541501|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
218931189|NCT03339219|DRUG|Cabozantinib|Cabozantinib tablets
218931190|NCT04623632|DRUG|Transversus abdominus plane block|transversus abdominus plane block using 40 ml of bupivacaine 0.25%
218931191|NCT04623632|DRUG|Transversus abdominus plane placebo|injection of 40 ml of normal saline in the transversus abdominus plane
218931192|NCT05179356|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg given once daily for three months
218931193|NCT05179356|DRUG|Placebo|Matching placebo
218931194|NCT02015962|DRUG|Intravenous potassium chloride|
219044655|NCT03968822|DRUG|Bupivacaine 0.25%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
219044656|NCT03968822|DRUG|Bupivacaine 0.5%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
219044657|NCT03968822|DRUG|Intralipid, 20% Intravenous|a 250ml bag administered intravenously
219044658|NCT03968822|OTHER|Saline intravenously|a 250ml bag administered intravenously
219044659|NCT03968822|OTHER|Saline|3 mL of test solution to a skin area on the thigh, 2cm in diameter
219541502|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
219541503|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
219541504|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
219541505|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
219541506|NCT02993380|DIETARY_SUPPLEMENT|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
218931195|NCT02015962|DRUG|Oral potassium chloride|
218931196|NCT05349799|DEVICE|TEOSYAL RHA® 1|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment."
218931197|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
218931198|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
218931199|NCT02955849|DEVICE|SLT laser|Patients will be offered initial SLT laser by doctors
218931200|NCT01917630|DRUG|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
218931201|NCT01917630|DRUG|placebo|
218931202|NCT00034580|DRUG|olanzapine|
218931203|NCT00034580|DRUG|risperidone|
218931204|NCT04472832|DRUG|Placebo for Treatment A|6 tablets matched to mitapivat tablet
218931205|NCT04472832|DRUG|Mitapivat 100 mg|Two 50-mg tablets
218931206|NCT04472832|DRUG|Placebo for Treatment B|4 tablets matched to mitapivat tablet
218931207|NCT04472832|DRUG|Mitapivat 300 mg|Six 50-mg tablets
218931208|NCT04472832|DRUG|Placebo for Treatment C|4 tablets matched to mitapivat tablet
218931209|NCT04473677|DIAGNOSTIC_TEST|The new qFIT and colonoscopy with pathological examination|Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
218931210|NCT01497496|DRUG|High Dose Methylprednisolone (HDMP)|1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
219205336|NCT06745193|DRUG|chidamide+Camrelizumab+Apatinib|chidamide+Camrelizumab+Apatinib
219205337|NCT06745193|DRUG|Irinotecan or Docetaxel or Paclitaxel|Irinotecan Docetaxel Paclitaxel
219541507|NCT02993380|DIETARY_SUPPLEMENT|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
219541508|NCT04244760|BEHAVIORAL|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
219541509|NCT04244760|BEHAVIORAL|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
219541510|NCT03382925|PROCEDURE|cervical interlaminar with lidocaine|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.
218931211|NCT01497496|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
218931212|NCT01497496|DRUG|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
218931213|NCT05726708|BEHAVIORAL|E-Learning|On line modules of coaching for parents
218931214|NCT06255613|DEVICE|Belun Ring|The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.
218931215|NCT06255613|DEVICE|Belun Cor|"The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts."
218931216|NCT02124993|OTHER|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
218931217|NCT00485810|DRUG|Olanzapine Hydrochloride|
218931218|NCT03330249|DRUG|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
218931219|NCT03330249|DRUG|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
218931220|NCT03330249|RADIATION|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
218931221|NCT00675610|BEHAVIORAL|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
219044660|NCT06908434|DRUG|GenSci128 tablets|GenSci128 tablets have three specifications, including 50mg, 200mg, 500mg, and are taken in combination with the doctor's advice in different dose levels. GenSci128 will be orally administrated daily (except single dose in Cycle 0) with no interruptions until occurrence of unacceptable toxicity, or progressive disease, or withdrawal of consent, or death, or contact lost, or starting a new anticancer therapy, etc. (whichever occurs first).
219541511|NCT03382925|PROCEDURE|cervical interlaminar with normal saline|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
219541512|NCT03382925|DRUG|Lidocaine|2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
219541513|NCT03382925|DRUG|Triamcinolone Acetonide|2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
219541514|NCT03382925|DRUG|Normal saline|2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
218931222|NCT04900727|OTHER|No intervention|No intervention
218931223|NCT01469377|DRUG|Placebo|Placebo was supplied in capsules
218931224|NCT01469377|DRUG|Cariprazine|Cariprazine was supplied in capsules.
218931225|NCT05330299|BEHAVIORAL|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
218931226|NCT01733680|DRUG|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
218931227|NCT01733680|BEHAVIORAL|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
218931228|NCT02681978|DRUG|Ivabradine|Ivabradine 5 mg twice daily
218931229|NCT02681978|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
218931230|NCT06520293|OTHER|Sweet Beverage|A beverage containing different sweet ingredients.
218931231|NCT05208099|BIOLOGICAL|Blood tests|"For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
218931232|NCT05208099|PROCEDURE|exeresis|"For patients, it will be performed:~\- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
218931233|NCT05208099|PROCEDURE|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin"
218931234|NCT04903613|DRUG|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
218931235|NCT00080236|DRUG|IDN-6556|
218931236|NCT00080236|DRUG|Placebo|
218931237|NCT05966688|DRUG|SPR720|Multiple oral doses of SPR720 capsules.
218931238|NCT05966688|DRUG|Azithromycin|Multiple oral doses of azithromycin.
218931239|NCT05966688|DRUG|Ethambutol|Multiple oral doses of ethambutol.
218931240|NCT02666625|PROCEDURE|saliva samples|
218931241|NCT02666625|PROCEDURE|blood samples|
219621101|NCT06565195|OTHER|Placebo (aCSF)|IT injection
219621102|NCT06565260|OTHER|Exercise Intervention|Participate in exercise program
219621103|NCT06565260|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
219621104|NCT06565260|OTHER|Nutritional Intervention|Participate in nutrition program
219621105|NCT06565260|OTHER|Physical Performance Testing|Ancillary studies
219621106|NCT06565260|OTHER|Questionnaire Administration|Ancillary studies
219621107|NCT05702229|DRUG|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
219621108|NCT05702229|DRUG|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
219621109|NCT05702229|DRUG|FOLFOX|5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
219621110|NCT05702229|DRUG|XELOX|capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
218931242|NCT01792752|BEHAVIORAL|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
218931243|NCT01792752|BEHAVIORAL|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
219205338|NCT06755905|PROCEDURE|ICGL-guided treatment|Indocyanine green lymphography guided resection combined with sclerotherapy
219541515|NCT01560767|DRUG|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
219541516|NCT01560767|DRUG|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
219541517|NCT03128723|DEVICE|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
219541518|NCT04069286|DRUG|Oral Aroeira|Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.
219541519|NCT04069286|DRUG|Omeprazole 20Mg Capsule|Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
219541520|NCT03059615|DRUG|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
219541521|NCT03059615|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
219541522|NCT00061061|BEHAVIORAL|Behavior Therapy|
219541523|NCT05836545|DRUG|Remimazolam|The patient with remimazolam
219541524|NCT05836545|DRUG|Midazolam|The patient with midazolam
219541525|NCT00020605|DRUG|naloxone hydrochloride|
219541526|NCT04030286|OTHER|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
219541527|NCT00673660|BEHAVIORAL|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
219541528|NCT01674491|DIETARY_SUPPLEMENT|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
219541529|NCT01741948|DRUG|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
219541530|NCT00004801|DRUG|monoclonal factor IX replacement therapy|
219541531|NCT02924363|DIAGNOSTIC_TEST|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
219541532|NCT02924363|DIAGNOSTIC_TEST|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
219541533|NCT00245063|DRUG|cediranib maleate|Given PO
219541534|NCT00245063|OTHER|laboratory biomarker analysis|Correlative studies
219541535|NCT00245063|OTHER|pharmacogenomic studies|Optional correlative studies
219541536|NCT05174741|OTHER|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
219541537|NCT05174741|OTHER|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
219541538|NCT03917147|PROCEDURE|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
219541539|NCT01370369|DRUG|Testosterone gel (FE 99903)|
219541540|NCT02471820|DRUG|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
219541541|NCT02471820|DRUG|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
219541542|NCT02471820|DRUG|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
219205339|NCT06755905|PROCEDURE|Conventional Treatment group|Resection with sclerotherapy
219541543|NCT05099380|DEVICE|senofilcon A C3|TEST Lens
219541544|NCT05099380|DEVICE|senofilcon A|CONTROL Lens
218931244|NCT01792752|BEHAVIORAL|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
218931245|NCT01792752|BEHAVIORAL|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
218931246|NCT01792752|BEHAVIORAL|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
218931247|NCT00776516|DRUG|mirabegron|oral
218931248|NCT00776516|DRUG|rifampin|oral
218931249|NCT04176484|OTHER|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
219541545|NCT03789994|BEHAVIORAL|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
219541546|NCT03789994|OTHER|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
219621111|NCT05702229|DRUG|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
218931250|NCT06581549|OTHER|Translation analysis|Bulk GEP analysis, Spatial whole transcriptome analysis, mIF analysis of tumors
218931251|NCT03942120|DRUG|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
218931252|NCT05441813|DRUG|Virgin Coconut Oil|Standard of care with the addition of virgin coconut oil mouth rinse
219044661|NCT06909513|DEVICE|U-shaped Travel Neck Pillow|Participants in the intervention group will receive a U-shaped travel neck pillow immediately after surgery upon arrival to the ward. The pillow will be used only during rest (supine or semi-Fowler's position) for the first 24 hours postoperatively and removed before mobilization begins. After removal, assessments will include cervical comfort using the Visual Analog Scale (VAS), pain scores during neck movements (flexion, rotation, lateral flexion-excluding extension) via VAS, the McGill Pain Questionnaire for pain localization and severity, and cervical range of motion using a universal goniometer. This intervention aims to evaluate the pillow's effectiveness in reducing neck pain, stiffness, and discomfort, and improving mobility after thyroidectomy.
219044662|NCT06909266|OTHER|OT Hope 0 - 5 ans Therapeutic tool|OT Hope 0 - 5 ans Therapeutic tool for self determination of pediatric goals in occupational therapy
219044663|NCT06909266|OTHER|Qualitative interviews with parents|qualitative interviews to understand how vestibular impairments affect their child's daily life activities, challenges encountered, and strategies used to support participation.
219044664|NCT06908915|DEVICE|Nd:YAG laser 1064 nm|The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.
219205340|NCT06753890|DRUG|Changkang granules|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
218931253|NCT06358313|DRUG|Atorvastatin 40mg|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
219205341|NCT06753890|DRUG|Changkang Granules placebo|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
219205342|NCT06753643|OTHER|The IMPACTFrail programme|The IMPACTFrail programme
219205343|NCT06755346|DRUG|Cannabis plant (THC 20mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
219205344|NCT06755346|DRUG|Cannabis (0%/ THC / 0% CBD)|THC (0%) / CBD (0%) - Placebo marijuana
219541547|NCT01281891|DRUG|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
219541548|NCT01281891|DRUG|I/T morphine|Morphine special 0.1 mg injected intrathecally
219541549|NCT03753230|DEVICE|Electroencephalography|Cerebral measurements from electroencephalography devices while music is presented to the participant
219541550|NCT02295163|PROCEDURE|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
219541551|NCT02295163|PROCEDURE|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
219541552|NCT02405481|BEHAVIORAL|SEPA III|
219621112|NCT05702229|DRUG|AZD0901|an anti Claudin18.2 ADC; IV infusion
219621113|NCT05702229|DRUG|5-Fluorouracil|5-FU, IV infusion, Q3W
219621114|NCT05702229|DRUG|Capecitabine|Oral take, Q3W
219621115|NCT05580666|DRUG|Azithromycin Oral Tablet|Antimicrobial therapy
219621116|NCT05580666|DRUG|Placebo oral tablet|Inert ingredients
219541553|NCT01354418|DRUG|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
219541554|NCT01354418|DRUG|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
219541555|NCT01972490|DRUG|avastin|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
219541556|NCT01972490|DRUG|mFOLFOX6|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
219541557|NCT01839279|DRUG|Tizanidine|
219541558|NCT01839279|DRUG|Placebo|
218931254|NCT06358313|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
218931255|NCT05745493|BEHAVIORAL|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
218931256|NCT05670301|DIAGNOSTIC_TEST|cytokine and lipidomic profiling|"* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~* Serum amyloid A~* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~* Lipidomics"
218931257|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo electroacupuncture therapy
218931258|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
218931259|NCT02754752|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931260|NCT02754752|OTHER|Quality-of-Life Assessment|Ancillary studies
218931261|NCT02754752|OTHER|Questionnaire Administration|Ancillary studies
218931262|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
218931263|NCT02812420|BIOLOGICAL|Durvalumab|Given IV
218931264|NCT02812420|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
218931265|NCT02812420|BIOLOGICAL|Tremelimumab|Given IV
218931266|NCT06463457|DRUG|Darolutamide|Androgen receptor antagonist, tablet taken orally per protocol.
218931267|NCT06463457|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.
219044665|NCT06909669|BEHAVIORAL|Group brief transdiagnostic cognitive-behavioral therapy|Eight-session treatment based on Barlow's Unified Protocol. These sessions include: improving motivation and commitment to treatment, understanding the functioning of emotions, emotional awareness training, developing more flexible and adaptive thinking patterns, reduction of emotional avoidance and emotion-driven behaviors; awareness and tolerance of physical sensations; interoceptive and situational emotional exposure; achievement, maintenance and relapse prevention.
219621117|NCT03321643|DRUG|Atezolizumab|Given IV
219621118|NCT03321643|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621119|NCT03321643|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219621120|NCT03321643|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218931268|NCT05313945|PROCEDURE|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
218931269|NCT05313945|PROCEDURE|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
218931270|NCT06479213|BEHAVIORAL|REACH Peer Coaching Program|The REACH Peer Coaching Program consists of weekly coaching calls conducted over video teleconference. Coaches will use motivational interviewing to help participants formulate and work towards movement goals.
219044666|NCT06909669|BEHAVIORAL|Group relaxation|The participants in this group will receive basic training in Jacobson's progressive relaxation with a similar periodicity to the ultra-brief intervention.
219205345|NCT06755346|DRUG|Cannabis plant (THC 40mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
219541559|NCT01839279|DRUG|Moxifloxacin|
219541560|NCT05198947|DRUG|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
219541561|NCT05198947|DRUG|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
219541562|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
219541563|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
219541564|NCT05170594|DRUG|Bevacizumab|Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
219541565|NCT05170594|DRUG|chemotherapy|The non-platinum chemotherapy regimen will be determined by the investigator.
219541566|NCT05170594|DRUG|Fluzoparib|Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
219541567|NCT05569629|PROCEDURE|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
219621121|NCT03321643|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
219621122|NCT03321643|DRUG|Gemcitabine|Given IV
219621123|NCT03321643|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218931271|NCT06479213|BEHAVIORAL|REACH Mobile Health Application|Participants will use the the REACH mobile health application to set weekly movement goals and log physical activity.
219541568|NCT03092466|PROCEDURE|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
218931272|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
218931273|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
218931274|NCT05699538|BEHAVIORAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
218931275|NCT04030507|DEVICE|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
218931276|NCT03916913|RADIATION|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
218931277|NCT02275234|OTHER|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
218931278|NCT04230031|DRUG|Daratumumab|Experimental
218931279|NCT02302339|DRUG|glembatumumab vedotin|
218931280|NCT02302339|DRUG|glembatumumab vedotin and varlilumab|
218931281|NCT02302339|DRUG|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
218931282|NCT02302339|DRUG|glembatumumab vedotin and CDX-301|
218931283|NCT01568242|DEVICE|Phacoemlsification|Transurgical measurement of temperature
218931284|NCT01651637|DRUG|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
219205346|NCT06768073|DEVICE|Sham (No Treatment)|The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
219205347|NCT06768281|DIAGNOSTIC_TEST|Headache Impact Test-6 (HIT-6)|Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
219205348|NCT06768281|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
219541569|NCT03092466|DRUG|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
219541570|NCT03092466|DRUG|control group|infusion of saline solution (15ml) in femoral catheter
219541571|NCT04518631|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
219621124|NCT03321643|DRUG|Oxaliplatin|Given IV
219621125|NCT03321643|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
218931285|NCT02460237|PROCEDURE|Disease Screening|Complete HPV self-test
218931286|NCT02460237|OTHER|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
218931287|NCT02460237|OTHER|Informational Intervention|Receive standard instructions and information sheet
218931288|NCT02460237|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931289|NCT02460237|OTHER|Survey Administration|Ancillary studies
218931290|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
218931291|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) Dim light-therapy|\<100 lux for 30 minutes
218931292|NCT04017195|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
218931293|NCT04017195|DRUG|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
219205349|NCT06768281|DIAGNOSTIC_TEST|Visual Analogue Score (VAS)|Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.
219541572|NCT00671320|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
218931294|NCT06159777|DRUG|Polyethylene Glycol 3350|\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
218931295|NCT04270266|OTHER|Educational Intervention|Attend educational sessions
218931296|NCT04270266|OTHER|Meditation Therapy|Attend meditation sessions
218931297|NCT04270266|OTHER|Questionnaire Administration|Ancillary studies
219541573|NCT00671320|DRUG|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
219541574|NCT02831920|OTHER|CEUS and targeted biopsies|
219541575|NCT02831920|OTHER|MRI and targeted biopsies|
219541576|NCT04834440|DRUG|Ropivacaine|all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations
219621126|NCT03321643|BIOLOGICAL|Rituximab|Given IV
219621127|NCT04438824|DRUG|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
219621128|NCT04438824|DRUG|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
218931298|NCT04264026|DRUG|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
218931299|NCT05667493|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
218931300|NCT05519982|BEHAVIORAL|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
218931301|NCT05519982|BEHAVIORAL|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
218931302|NCT02824614|DIETARY_SUPPLEMENT|E967-Xylitol|
218931303|NCT02824614|DIETARY_SUPPLEMENT|E968-Erythritol|
218931304|NCT03978546|DIAGNOSTIC_TEST|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
218931305|NCT03978546|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
218931306|NCT03978546|DIAGNOSTIC_TEST|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
218931307|NCT00645346|BIOLOGICAL|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
218931308|NCT00645346|BIOLOGICAL|Placebo|Subjects will receive one dose of placebo
218931309|NCT01185080|DRUG|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
218931310|NCT01185080|DRUG|Placebo|Nasal spray solution, intranasal, three times weekly for one month
218931311|NCT01185080|DRUG|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
218931312|NCT04545580|DRUG|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
218931313|NCT04545580|DRUG|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
218931314|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered.
218931315|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered at RP2D regimen.
218931316|NCT02876562|PROCEDURE|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
218931317|NCT03959176|DRUG|Brimonidine|2 drops administered once in the left eye in both study arms
218931318|NCT03959176|DRUG|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
218931319|NCT03959176|DRUG|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
218931320|NCT02739061|BEHAVIORAL|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
218931321|NCT02739061|DRUG|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
218931322|NCT02739061|OTHER|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
218931323|NCT00002150|DRUG|Celgosivir hydrochloride|
218931324|NCT02808598|BEHAVIORAL|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
218931325|NCT05395975|DEVICE|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
218931326|NCT05287620|DEVICE|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
218931327|NCT00567099|DRUG|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
218931328|NCT04640610|OTHER|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
218931329|NCT05012917|OTHER|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
219541577|NCT06161350|COMBINATION_PRODUCT|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
218931330|NCT05012917|OTHER|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
218931331|NCT06491485|DRUG|Group M (lidocaine with Magnesium sulfate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
218931332|NCT06491485|DRUG|Group B (lidocaine with Sodium bicarbonate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
219541578|NCT03730363|DRUG|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
219541579|NCT03465163|DEVICE|Deep Brain Stimulation|The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
218931333|NCT06491485|DRUG|Group C (lidocaine with saline)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
218931334|NCT05504707|BIOLOGICAL|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
218931335|NCT05504707|BIOLOGICAL|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
218931336|NCT05557110|DRUG|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
219044667|NCT06909669|BEHAVIORAL|Group ultra-brief transdiagnostic cognitive-behavioral therapy|This is a reduction to four sessions of the brief transdiagnostic treatment (Experimental group 1). For this reduction, sessions 1 and 2 of the brief transdiagnostic treatment will be combined, sessions 3 and 6 will be eliminated, and sessions 7 and 8 will be combined. As in experimental group 1, the treatment groups will consist of 8-10 people. Each session will have a duration of 1.5 hours and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
219044668|NCT06909669|BEHAVIORAL|Individual ultra-brief transdiagnostic cognitive-behavioral treatment format|Participants of this group, wil receive the same treatment than group 2 (ultra-brief transdiagnostic cognitive-behavioraltreatment in group format) but individual format. Each session will have a duration of 1 hour and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
219044669|NCT06923449|OTHER|Multidisciplinary Tumor Board|Institution of Multidisciplinary Tumor Board for Gastric Cancer at Fondazione Policlinico Gemelli in november 2019
219044670|NCT06923787|DRUG|Lidocaine|intravenous infusion of lidocaine
219044671|NCT06923787|DRUG|Dexamethasone|intravenous infusion of dexamethasone
219044672|NCT06923787|DRUG|Placebo|saline solution intravenous infusion
219044673|NCT06924671|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
219205350|NCT06768281|OTHER|Masseter muscle injection|1 ml of insulin needle with a 27-gauge ½ inch 13 mm needle tip will be injected into up to 4 trigger points in the taut bands that cause the most pain in the masseter muscle. Injections were done at most 3 times. As the control group, the first group was injected with isotonic saline; the second group was injected with 2% lidocaine without vasoconstrictor; the third group with ozone gas; and the fourth group with ozonated isotonic saline.
219205351|NCT06768112|DEVICE|Non-Invasive Vagus Nerve Stimulation|Using non-invasive vagus nerve stimulation at the ear to stimulate the adrenergic and serum hormone pathways, activating the frontal lobe system, sensory-motor nervous system, and cerebellum, to investigate the effects and neural mechanisms of dynamic posture training and learning.
219205352|NCT06768112|BEHAVIORAL|balance training|Participants will be asked to stand on a soft-platform and hit on blaze-pod LED within 60 seconds.
219541580|NCT03129763|BEHAVIORAL|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
218931337|NCT06654375|PROCEDURE|Endovascular Thrombectomy|"Endovascular thrombectomy (EVT) in this clinical trial involves the mechanical removal of a thrombus from a blocked large cerebral artery using specialized devices like stent retrievers or aspiration catheters. Key distinguishing features of this EVT protocol include:~* Extended Time Window: Unlike standard EVT, which is typically performed within 24 hours after symptom onset, this intervention targets patients presenting beyond 24 hours.~* Collateral Circulation Assessment: Multi-phase CT angiography (CTA) is employed to evaluate collateral flow, prioritizing patients with favorable collateral grades. This selection process helps ensure the identification of patients most likely to benefit from EVT despite the late presentation."
219541581|NCT03129763|BEHAVIORAL|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
218931338|NCT06654570|DRUG|Intravaginal estrogen during adjuvant letrozole|Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
219541582|NCT03129763|BEHAVIORAL|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
219541583|NCT03129763|BEHAVIORAL|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
219541584|NCT03129763|BEHAVIORAL|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
219541585|NCT03998150|PROCEDURE|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
219541586|NCT03998150|PROCEDURE|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
219541587|NCT05925010|DIETARY_SUPPLEMENT|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
219541588|NCT05408169|BEHAVIORAL|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible."
219541589|NCT05408169|BEHAVIORAL|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
219541590|NCT01350908|OTHER|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
219541591|NCT00564408|DRUG|Carbachol|3 microgram per kg bodyweight infused intravenously
219541592|NCT03902548|DRUG|[18F]P16-129|Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
219541593|NCT01717339|OTHER|Sleep Study|
219541594|NCT02157623|DRUG|Levulan|Levulan application followed by Red or Blue light PDT
219541595|NCT02157623|OTHER|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
219541596|NCT02157623|OTHER|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
219541597|NCT06196307|COMBINATION_PRODUCT|Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization|"Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)"
219541598|NCT02096185|RADIATION|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
219541599|NCT02096185|RADIATION|2 dimensional digital imaging|
219541600|NCT01746056|DEVICE|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
219541601|NCT04070547|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
219541602|NCT04070547|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
219621129|NCT00739882|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
219621130|NCT00739882|DRUG|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
219621131|NCT06360198|OTHER|No intervention|No intervention was applied to the group.
218931339|NCT04462627|DIAGNOSTIC_TEST|Blood group determination|Determination of the blood group (ABO/LE)
218931340|NCT04462627|DIAGNOSTIC_TEST|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
219205353|NCT06768112|BEHAVIORAL|Mini-Mental State Examination|The mini-mental state examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
219205354|NCT06759857|DRUG|FHND9041|FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
219541603|NCT00316277|BEHAVIORAL|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
219541604|NCT00316277|BEHAVIORAL|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
219541605|NCT01400984|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
219541606|NCT00388531|DRUG|Depocyte®|Depocyte® is a cytostatic drug
219541607|NCT01180322|DRUG|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (\>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
219541608|NCT01180322|DRUG|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
219541609|NCT01180322|DRUG|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
219205355|NCT06759857|DRUG|Afatinib|Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
218931341|NCT04462627|DIETARY_SUPPLEMENT|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
218931342|NCT05903950|DEVICE|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
218931343|NCT05903950|DEVICE|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
219205356|NCT06759675|OTHER|group based exercise with Cognitive functional therapy|"1. Cognitive functional therapy CFT A cognitive functional therapy is the behavioral approach which is used to treat low back pain. This approach has 3 components Making sense of pain Exposure with control Lifestyle changes~2. Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation"
219205357|NCT06759675|OTHER|Group based exercise|Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation
219205358|NCT05680298|DRUG|Dupilumab|solution for injection, Subcutaneous injection
219205359|NCT06763874|DEVICE|EMG-based FES device|One session of one hour to execute task-oriented exercises with the upper limb while wearing the EMG-based FES device. Submission of questionnaires related to usability, acceptance and satisfaction of the device.
218931344|NCT06593548|DRUG|Ivosidenib (AK112)|Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
218931345|NCT06137495|DIAGNOSTIC_TEST|Sensitization to House dust mites|The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
218931346|NCT01104311|PROCEDURE|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
218931347|NCT01104311|PROCEDURE|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
218931348|NCT06609577|DEVICE|Diaphragm Ultrasound-Guided External Diaphragm Pacing|This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
218931349|NCT05788770|OTHER|FEops HEARTGuide|FEops HEARTGuide added to routine preoperative CT imaging. Results of the computer modelling will be discussed with TAVR implanting team prior to and during the procedure.
218931350|NCT03760718|DRUG|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
218931351|NCT03760718|DRUG|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
218931352|NCT03760718|DRUG|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
218931353|NCT05968560|BEHAVIORAL|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
219205360|NCT06341062|OTHER|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge
219541610|NCT01180322|DRUG|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
219541611|NCT01180322|DRUG|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count \> 0.5 x 109/l."
219541612|NCT04514939|OTHER|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
219541613|NCT06366048|DIAGNOSTIC_TEST|the different definitions of PHLF according to 50-50 criteria and ISGLS criteria|Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
219541614|NCT00429286|BEHAVIORAL|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
218931354|NCT05968560|BEHAVIORAL|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
218931355|NCT05968560|BEHAVIORAL|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
218931356|NCT05758194|OTHER|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
218931357|NCT05758194|OTHER|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
218931358|NCT07074080|OTHER|Performing chest compressions on a mannequin using the foot|Performing chest compressions on a mannequin using the foot
219541615|NCT04694963|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
219541616|NCT04694963|PROCEDURE|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
219541617|NCT04694963|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
219541618|NCT02514382|DRUG|Bortezomib|Given SC or IV
219541619|NCT02514382|DRUG|Dexamethasone|Given PO, IV, or IM
219541620|NCT02514382|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931359|NCT07074080|OTHER|Performance of standard chest compressions with the upper limbs.|Performance of standard chest compressions with the upper limbs.
218931360|NCT07074691|DRUG|Regional Dexamethasone|Patients were generally anesthetized, then a supraclavicular block is given (0.5% bupivacaine + dexamethasone 8 mg regionally), total volume = 20 mL (18 mL 0.5% bupivacaine + 2 mL dexamethasone).
218931361|NCT07074691|DRUG|Intravenous Dexamethasone|Patients were generally anesthetized, and then a supraclavicular block was administered (0.5% bupivacaine), with a total volume of 20 mL (18 mL of 0.5% bupivacaine and 2 mL of normal saline).
219541621|NCT02514382|OTHER|Pharmacological Study|Correlative studies
219541622|NCT02514382|BIOLOGICAL|Wild-type Reovirus|Given IV
219541623|NCT03058003|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext\_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
219541624|NCT03058003|OTHER|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
219205361|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
219205362|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
219541625|NCT02836821|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
219541626|NCT02836821|DRUG|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
219541627|NCT06562621|BIOLOGICAL|ON-01|ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
218931362|NCT07075614|BEHAVIORAL|Parent Training Program|"Parent Training Programs are complementary interventions to special education, implemented by parents to support the social, cognitive, and behavioral development of children with autism and other developmental disorders.~Throughout the program, key developmental skills that children are expected to acquire-such as social skills (eye contact, joint attention, play, imitation), language, cognitive, motor, and self-care abilities-are explained using sample photos and simple instructions.~Additionally, the program provides guidance on how to foster secure attachment between parent and child and how to support social-communicative skills through warm, responsive interactions in daily life."
218931363|NCT07074470|DRUG|Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|2 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally, W1，60mg，W2，40mg biw，W3，cycle 1； 40mg， biw，cycle 2
218931364|NCT07074470|PROCEDURE|Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning|"TB preconditioning:~Thiotepa intravenous drip 300mg/m2 d-6-d-5; Busulfan: intravenous drip, 0.8mg/kg q6h d-4--d2; followed by autologous peripheral stem cells infusion at day 0"
218931365|NCT07074470|DRUG|Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|4 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally biw, cycle 3-6；
218931366|NCT07074470|RADIATION|Consolidation therapy-whole brain radiation therapy|whole brain radiotherapy: CTV1: 20-30Gy/10fractions GTVp: 25-40Gy/10fractions
218931367|NCT07074470|DRUG|Maintenance treatment-PD-1 monoclonal antibody|PD-1 monoclonal antibody for up to 2 years intravenous infusion, 200mg d1 (21days per cycle)
218931368|NCT07075757|DRUG|Single in situ intra-arterial injection of bevacizumab|3 Escalating doses of an in situ intra-arterial injection of Bevacizumab (5 mg/kg, 7.5 mg/kg, 10 mg/kg)
218931369|NCT07075653|OTHER|Survey using a questionnaire.|Participants fill out a brief survey in which they answer questions about vegetarian diets.
218931370|NCT06927973|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound
219541628|NCT06562621|DRUG|ONF|ONF is an extended-release formulation of flucytosine.
219541629|NCT00835263|DRUG|Lamotrigine|200 mg Tablet
219541630|NCT00835263|DRUG|Lamictal®|200 mg Tablet
218931371|NCT07074223|PROCEDURE|Fascial wrapping the site of tendon repair|wrapping the tendon repair site by Pelnac or Fascial graft
219541631|NCT05281861|OTHER|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
219541632|NCT05281861|OTHER|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
219541633|NCT01910753|PROCEDURE|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
219541634|NCT05172947|DRUG|Resveratrol|This group received resveratrol with the conventional therapy
218931372|NCT07074223|PROCEDURE|Modified Kestler tendon repair|Modified Kestler tendon repair
218931373|NCT07074223|PROCEDURE|ADM (Pelnac) wrapping of repaired tendon|Modifed kestler tendon repair wrapped by ADM ( Pelnac)
218931374|NCT07074366|BEHAVIORAL|Splint Therapy with Structured Communication|All participants received a stabilization splint for the management of TMDs, combined with a structured counseling protocol delivered by the assigned dentist.
218931375|NCT04510961|OTHER|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
218931376|NCT06932796|BEHAVIORAL|Health Care Provider Stigma Training and Clinic-Based Messaging Campaign|Providers in 10 HIV clinics participated in a 5 session anti-stigma health facility training focused on: 1) raising awareness about stigma and discrimination at the facility; and 2) changing attitudes and behaviors towards women who use drugs and/or trade sex; and 3) building a stigma-free clinic. Each of these clinics also received anti-stigma messaging materials (i.e., pamphlets, posters) to display in their clinics over a 6 month period. Providers received text-based message twice a month during this time to reinforce skills learned during trainings and to empower providers to be stigma change agents. Providers completed pre/post survey assessments.
219541635|NCT05172947|DRUG|Placebo|This group received placebo with the conventional therapy
219541636|NCT05172947|OTHER|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
219541637|NCT05172947|OTHER|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
218931377|NCT06482450|OTHER|LetsTalkShots (patient-facing CDS)|LetsTalkShots is a website which provides patients/parents with tailored videos addressing vaccine concerns.
218931378|NCT06482450|OTHER|LetsTalkShots (provider-facing CDS)|The provider-facing CDS component will propagate patient concerns obtained from LetsTalkShots (and the appropriate talking points to address the talking points) into the electronic health record (EHR) for the provider at the point of care.
219621132|NCT03995537|BIOLOGICAL|blood sample|"Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 4 mL Heparin sample and one 2.5 mL PAXgene® sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~* between inclusion and LT in case of major clinical change~* During the pre-transplant follow-up 3 months after inclusion, for patients who have not been transplanted within 3 months after inclusion~* at day 1 after LT~* 2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times."
219621133|NCT04033861|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
218931379|NCT06482450|OTHER|Appointment Reminder Message|"The regular text message and e-mail appointment reminder includes a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
218931380|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
218931381|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
218931382|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
218931383|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
219205363|NCT03008382|OTHER|No intervention- observational sub-study|Participants did not receive placebo or metoprolol during the entire duration of the study.
219541638|NCT04376190|RADIATION|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
219621134|NCT04033861|DRUG|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
219621135|NCT03793114|DIAGNOSTIC_TEST|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
219621136|NCT03793114|DIAGNOSTIC_TEST|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
219621137|NCT03793114|DEVICE|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
219621138|NCT03793114|OTHER|Blood test|Cardiovascular and inflammatory biomarker profiles
219621139|NCT03808155|DRUG|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
219621140|NCT03808155|DRUG|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
219621141|NCT06734156|OTHER|No intervention: observational study|No intervention: observational study
219621142|NCT06843226|OTHER|No Intervention|This is a non-interventional study.
219621143|NCT06154915|OTHER|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
219621144|NCT05469009|DRUG|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening
219621145|NCT05469009|DEVICE|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.
219621146|NCT05469009|DRUG|Lecanemab|Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
219621148|NCT06962852|GENETIC|BI 3720931|BI 3720931
219621149|NCT03907254|OTHER|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
219621150|NCT06644924|COMBINATION_PRODUCT|Intervention: AS MDI|Drug Treatment: (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)
219621151|NCT06644924|COMBINATION_PRODUCT|Intervention: Ventolin Evohaler|Drug: Treatment (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)
219621152|NCT06644924|COMBINATION_PRODUCT|Intervention: Placebo matching AS MDI|Drug: Treatment (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)
219621153|NCT04441307|BEHAVIORAL|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
218931384|NCT05255289|PROCEDURE|Urodynamic investigations before and after an Solyx sling protocol.|Urodynamic investigations (stated above.)
218931385|NCT04195841|PROCEDURE|Z shaped incision|"After local anaesthesia, a mucoperiosteal flap will be elevated at the edentulous ridge with two horizontal incisions placed with a no MB 69 blade, 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. The extend of the incisions should be up to the proximal line angles of the adjacent teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles. A periosteal elevator is used to elevate a full thickness mucoperiosteal flap buccally and lingually to the level of the mucogingival junction, exposing the alveolar ridge of the implant surgical sites.~Endosseous implant placement is done followed by simple interrupted resorbable sutures"
218931386|NCT04195841|PROCEDURE|H shaped incision|"After local anaesthesia, a mucoperiosteal flap is elelevated by placing sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles using a MB 69 blade.~Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth. A full thickness mucoperiosteal flap will be elevated buccally and lingually to the level of the mucogingival junction to expose the alveolar ridge of the implant surgical sites using a periosteal elevator.~Endosseous implant will be placed, followed by simple interrupted resorbable sutures."
218931387|NCT05358353|DEVICE|Bare Temporary Spur Stent System|Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
218931388|NCT01731431|OTHER|Insulin|
218931389|NCT01731431|DRUG|Glyburide|
218931390|NCT04894331|OTHER|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris \& Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
218931391|NCT04894331|OTHER|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
218931392|NCT00384046|DRUG|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
218931393|NCT00384046|DRUG|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
218931394|NCT03776006|PROCEDURE|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
218931395|NCT02997306|PROCEDURE|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
218931396|NCT02997306|PROCEDURE|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
218931397|NCT03748004|BEHAVIORAL|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
218931398|NCT03748004|BEHAVIORAL|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
218931399|NCT03965390|BEHAVIORAL|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
218931400|NCT03290599|OTHER|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
219541639|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
219541640|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
219541641|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
218931401|NCT03207763|DEVICE|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
218931402|NCT03207763|DEVICE|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
218931403|NCT05582083|DRUG|Momelotinib|Momelitinib available as tablets.
218931404|NCT04856813|OTHER|Manual therapy active|massage or ischemic compression with active contraction, tha will be isometric or concentric.
218931405|NCT04856813|OTHER|Manual therapy|massage or isquemic compression without contraction
218931406|NCT02605122|DRUG|Solithromycin|
218931407|NCT02605122|DRUG|Standard of Care|Age- and weight-based dosing as appropriate per sites standard of care.
218931408|NCT06220942|DRUG|Phenylephrine|Pregnant female presented for C.S. after receiving spinal anesthesia, recording the vital data, phenylephrine will be given in a dose of 50 µg IV immediately if the heart rate increases ≥ 20 % of baseline
218931409|NCT02945579|RADIATION|Undergo EBRT|Undergo EBRT
218931410|NCT02945579|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931411|NCT02945579|OTHER|Quality-of-Life Assessment|Ancillary studies
218931412|NCT02945579|OTHER|Questionnaire Administration|Ancillary studies
218931413|NCT02945579|RADIATION|Partial Breast Irradiation|Undergo partial breast irradiation
218931414|NCT01560182|GENETIC|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
218931415|NCT03283605|RADIATION|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
218931416|NCT03283605|DRUG|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
218931417|NCT03283605|DRUG|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
219205364|NCT06833567|BEHAVIORAL|Brief mentalization-based group psychotherapy|"The intervention is an adaptation for anxiety and depression profiles of the introductory group program to Mentalization-Based Treatment for personality disorders.~Sessions program:~* Session 1: Building epistemic trust.~* Session 2: Introduction to mentalization.~* Session 3: Mentalization problems.~* Session 4: Emotions.~* Session 5: Mentalizing emotions.~* Session 6: Attachment relationships.~* Session 7: Attachment and mentalization.~* Session 8: Interpersonal relationships. Mentalizing relationships in the group.~* Session 9: Anxiety, attachment and mentalization.~* Session 10: Depression, attachment and mentalization.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
219541642|NCT04776798|OTHER|Taping|Tape applications will repeat twice per week, for 4 weeks.
219541643|NCT05723393|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound
218931418|NCT02479308|DRUG|Moxifloxacin|Single administration
218931419|NCT02479308|DRUG|ALKS 5461|Daily administration for a total of 12 dosing days
218931420|NCT02479308|DRUG|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
218931421|NCT04603027|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
219541644|NCT00350389|BEHAVIORAL|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
219541645|NCT00372086|DRUG|Rosiglitazone|
219541646|NCT04684186|PROCEDURE|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
219541647|NCT04684186|PROCEDURE|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
219621154|NCT04441307|BEHAVIORAL|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
218931422|NCT04603027|DRUG|Placebo|Placebo oral capsule
218931423|NCT02831101|DRUG|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
219541648|NCT01490567|DRUG|Donepezil|5 mg/day
219541649|NCT01490567|DRUG|placebo|placebo 5mg/d
218931424|NCT02831101|DRUG|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
218931425|NCT02248246|DEVICE|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)"
218931426|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
219044674|NCT07172503|DRUG|68Ga-NOTA-GPA33 nanobody|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed colorectal cancer, gastric cancer, pancreatic cancer and other malignant tumors with high GPA33 expression and healthy volunteers, using specific positron imaging agents target GPA33(in the case of \[68Ga\]Ga-NOTA-GPA33 nanobody) , to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
219205365|NCT06833567|BEHAVIORAL|Acceptance and Commitment Therapy group intervention|"The intervention includes 12 sessions based on Acceptance and Commitment Therapy. Sessions program:~* Session 1: Presentation.~* Session 2: Cognitive defusion~* Session 3: Uncontrollability of thought, emotions and behavior.~* Session 4: Creative Hopelessness.~* Session 5: Mindfulness and acceptance.~* Session 6: Values.~* Session 7: Values and action.~* Session 8: Vital goals.~* Session 9: Goal achievement plan.~* Session 10: Implementation.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
219205366|NCT06759623|DRUG|Different drug type for conduction of general anesthesia|Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
219541650|NCT05241639|DIAGNOSTIC_TEST|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
219541651|NCT02070458|DRUG|ixazomib|Given PO
219541652|NCT02070458|DRUG|mitoxantrone hydrochloride|Given IV
219541653|NCT02070458|DRUG|etoposide|Given IV
219541654|NCT02070458|DRUG|cytarabine|Given IV
219541655|NCT03600363|DRUG|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
219541656|NCT03600363|DRUG|Placebos|oral placebos as a maintenance therapy
219541657|NCT04853563|OTHER|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
219621155|NCT03262259|BEHAVIORAL|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
219621156|NCT04090398|PROCEDURE|Biospecimen Collection|Correlative studies
219621157|NCT04090398|PROCEDURE|Bone Scan|Undergo bone scan
219621158|NCT04090398|PROCEDURE|Computed Tomography|Undergo CT scan
219621159|NCT04090398|OTHER|Electronic Health Record Review|Ancillary studies
219621160|NCT04090398|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219541658|NCT06319495|BEHAVIORAL|Rehabilitation therapy|"During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
219621161|NCT04090398|DRUG|Paclitaxel|Given IV
218931427|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
218931428|NCT00807001|DRUG|IDX184|oral dose, active or placebo
218931429|NCT00170859|DRUG|Everolimus|
218931430|NCT03542786|DIETARY_SUPPLEMENT|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Lactobacillus plantarum CECT7484~* Lactobacillus plantarum CECT7485~* Pediococcus acidilactici CECT7483"
218931431|NCT03542786|DIETARY_SUPPLEMENT|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Partially Hydrolyzed Guar Gum (PHGG)~* Inulin HPD~* Oat Beta-Glucans~* Pectin~* Inulin Low Protein Diet (LPD)~* Polydextrose~* Maltrodextrins"
219621162|NCT04090398|RADIATION|Radium Ra 223 Dichloride|Given IV
219621163|NCT04090398|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
219621164|NCT05618028|DRUG|ABBV-525|Oral; Tablet
219621165|NCT06497699|DRUG|Dexycu|single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
219621166|NCT04214067|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219621167|NCT04214067|RADIATION|Brachytherapy|Undergo vaginal brachytherapy
219621168|NCT04214067|PROCEDURE|Computed Tomography|Undergo CT
219621169|NCT04214067|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219621170|NCT04214067|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621171|NCT04214067|BIOLOGICAL|Pembrolizumab|Given IV
219621172|NCT04214067|OTHER|Quality-of-Life Assessment|Ancillary studies
219621173|NCT04214067|OTHER|Questionnaire Administration|Ancillary studies
218931432|NCT03542786|DIETARY_SUPPLEMENT|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
218931433|NCT00854113|DRUG|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
218931434|NCT00854113|DRUG|Placebo|Placebo to match EGT0001474
218931435|NCT02724618|DRUG|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
218931436|NCT02724618|RADIATION|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
219044675|NCT07171814|DRUG|Honghua Xiaoyao tablets|The non-exposed group (patients who did not receive Honghua Xiaoyao Tablets or other targeted drug treatments) only received routine clinical observation, and no drug intervention was applied after obtaining informed consent. If patients need to withdraw from the study due to their condition during the study period, on the premise that the patients have given full informed consent, doctors shall recommend other treatment regimens in accordance with clinical standards (when necessary, first-line drugs such as selective serotonin reuptake inhibitors (SSRIs) may be selected for intervention).
219205367|NCT06760962|BEHAVIORAL|Reflective Mindfulness and Emotional Regulation training|The RMERT program consisted of six weekly 90-minute sessions facilitated by researchers trained in cognitive behavioral therapy (CBT) and transactional analysis (TA). The training employed the ABC model of CBT (Activating events, Beliefs, and Consequences) to address maladaptive cognitive patterns, along with TA techniques such as empathic inquiry and reflection. Relaxation strategies, including diaphragmatic breathing and progressive muscle relaxation, were also integrated. The sessions focused on enabling students to reflect on their mental and emotional states, process their feelings, and apply cognitive reappraisal-a healthy emotional regulation strategy-instead of relying on expressive suppression, which is maladaptive.
219541659|NCT06319495|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219621174|NCT04214067|PROCEDURE|X-Ray Imaging|Undergo x-rays
218931437|NCT02724618|DRUG|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
218931438|NCT04001530|DRUG|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
218931439|NCT04001530|DRUG|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
219205368|NCT06762262|COMBINATION_PRODUCT|Moderate-Intensity continuous training|refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
218931440|NCT03206229|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
218931441|NCT03206229|DRUG|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
219205369|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
219044676|NCT07172113|DEVICE|CBT + VR|This CBT intervention is conducted in VR using Embodied AI technology. A virtual therapist will present in a virtual therapy room. Participants can freely talk to and interactive with the virtual therapist.
219205370|NCT06740292|DEVICE|conventional miniplates|conventional miniplates in double configuration
219621175|NCT04645589|DRUG|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
219621176|NCT04596774|PROCEDURE|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
219621177|NCT04596774|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
219621178|NCT01236508|RADIATION|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
218931442|NCT02121119|DRUG|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
218931443|NCT02121119|DRUG|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
218931444|NCT03284307|DRUG|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
218931445|NCT03284307|DRUG|Ketamine|20 participants will be administered Ketamine.
218931446|NCT03284307|DRUG|Propofol|20 participants will be administered Propofol.
218931447|NCT03284307|DRUG|Midazolam|20 participants will be administered Midazolam.
218931448|NCT03807856|DRUG|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
219044677|NCT07173751|DRUG|Pumitamig|Solution for intravenous (IV) infusion
219044678|NCT07173751|DRUG|Nab-paclitaxel/Paclitaxel|IV infusion
218931449|NCT03807856|OTHER|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
218931450|NCT06444841|BEHAVIORAL|Digital - Google Calendar|"Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm)."
219044679|NCT07173751|DRUG|Gemcitabine|IV infusion
219044680|NCT07173751|DRUG|Carboplatin|IV infusion
219541660|NCT06319495|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219541661|NCT06319495|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219541662|NCT00663481|DRUG|CoFactor|
219541663|NCT00663481|DRUG|Leucovorin|
219541664|NCT05365308|BEHAVIORAL|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
219541665|NCT03004118|DIETARY_SUPPLEMENT|Nutridrink|Liquid meal of 200ml
219541666|NCT03004118|DEVICE|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
219541667|NCT03004118|DEVICE|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
219541668|NCT03004118|DRUG|Placebo Oral Tablet|4 week oral intake (daily)
219541669|NCT03004118|DRUG|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
219541670|NCT03004118|DEVICE|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
219541671|NCT03004118|PROCEDURE|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
219621179|NCT06578208|OTHER|Spinal Manipulation|The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction (Fagundes Loss et al., 2020).
219621180|NCT05679947|OTHER|Mobilization protocol|The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) \>30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
219621181|NCT00612274|DRUG|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
219044681|NCT07173751|DRUG|Eribulin|IV infusion
219044682|NCT07173751|DRUG|Matching placebo|IV infusion
219205371|NCT06740292|DEVICE|InterFlex plates|InterFlex plates in configuration
219044687|NCT07174206|DEVICE|Smartwatch - all data|Single-lead ECG, blood pressure (BP), oxygen saturation (SpO2), and continuous heart rate (HR).
219044688|NCT07174206|DEVICE|Portable holter system|continuous ECG monitoring for 14 days for comparison with the data from the smartwatch
219044689|NCT07174206|PROCEDURE|Telemonitoring|Remote consultations triggered by critical alerts based on predefined thresholds.
219205372|NCT06758271|DRUG|Avacopan|oral administration
219205373|NCT06782308|OTHER|Survey using a questionnaire.|patients preferences survey
219541672|NCT03004118|PROCEDURE|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
219541673|NCT06627218|DRUG|Prothrombin Complex Concentrate|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
219541674|NCT05502679|OTHER|Weight bearing as tolerated|Bearing weight on lower limb extremity
219541675|NCT05502679|OTHER|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
219541676|NCT04374864|DRUG|Trelagliptin|Anti diabetic
219541677|NCT05637333|DIAGNOSTIC_TEST|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
219541678|NCT02341846|OTHER|Qualitative interviews|
219541679|NCT06429592|OTHER|education|nursing care practice
218931451|NCT06444841|BEHAVIORAL|Paper-based - Memory Support System|The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
218931452|NCT01680029|DEVICE|PBASE-system 2.0|
219541680|NCT01901263|BEHAVIORAL|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
218931453|NCT04909918|DRUG|Dexamethasone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
218931454|NCT04909918|DRUG|Methylprednisolone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
219044690|NCT07174206|OTHER|AI Model Development|Data analysis using artificial intelligence for prioritization of patients based on health data collected from wearables.
219044691|NCT07174206|DEVICE|Smartwatch - ECG and HR|Single-lead ECG and continuous heart rate (HR)
219044692|NCT07172841|DEVICE|"Intervention group Virtual OFF"|"Patients randomized to shunt setting Virtual Off at the three month follow-up visit. After 5-7 days, the setting will be restored to the previous setting."
219044693|NCT07172841|DEVICE|Control group (no change in shunt setting)|Patients randomized to continue their shunt setting unchanged
219044694|NCT07172633|OTHER|scenario-based simulation teaching with virtual technology|5-week scenario-based simulation teaching with a virtual coach acting as an older adult with dementia in addition to regular dementia care lectures
219541681|NCT01789463|OTHER|Self rehabilitation|
219541682|NCT01789463|OTHER|Self rehabilitation plus physiotherapy|
219541683|NCT02528279|DRUG|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
219541684|NCT03251755|BEHAVIORAL|Yoga|Exercise promotion using Chinese Yoga
218931455|NCT04683887|DEVICE|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
218931456|NCT02273596|DRUG|ALXN1840|Individualized oral doses of ALXN1840.
218931457|NCT02113137|DRUG|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
218931458|NCT02113137|DEVICE|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
218931459|NCT00468962|DRUG|FACOS (functional food)|
218931460|NCT04153396|DRUG|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
219044695|NCT07172633|OTHER|traditional dementia case discussions|5-week traditional dementia case discussions in addition to regular dementia care lectures
219044696|NCT07172854|OTHER|Pelvic Floor Muscle Training|Supervised PFMT with biofeedback, 3 times per week for 12 weeks, plus home exercises.
219044697|NCT07172854|OTHER|Aerobic Exercise|Treadmill walking, moderate intensity (Borg 4-6), 60 minutes/session, 3 times per week for 12 weeks.
219044698|NCT07172854|OTHER|Relaxation Training|Guided breathing, imagery, and meditation, once weekly for 12 weeks, in addition to home practice.
219044699|NCT07172854|OTHER|Patient Education|Standardized education on urinary incontinence, pelvic anatomy, lifestyle modification, and stress management.
219044700|NCT03548584|DRUG|Brexpiprazole|Oral tablets
219044701|NCT03548584|OTHER|Placebo|Oral tablets
219541685|NCT06308484|DEVICE|Transcutaneous vagus nerve stimulation|Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
219541686|NCT06308484|DEVICE|Closed-loop AM-tACS|Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
219541687|NCT03927300|DEVICE|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
219541688|NCT04972578|DEVICE|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
219541689|NCT03069183|DRUG|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
219541690|NCT03069183|DRUG|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
219541691|NCT02183311|DRUG|BI 1356 BS - single rising dose|
218931461|NCT04153396|DRUG|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
218931462|NCT02604160|DRUG|LY3113593|Administered by slow intravenous (IV) infusion.
219541692|NCT02183311|DRUG|BI 1356 BS - multiple rising dose|
219541693|NCT02183311|DRUG|Placebo|
219541694|NCT05834751|DRUG|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
219541695|NCT05834751|DRUG|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
219541696|NCT02476045|DRUG|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
219541697|NCT02476045|DRUG|panitumumab|Maintenance treatment (ARM B)
219541698|NCT02476045|DRUG|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
219541699|NCT03388905|DEVICE|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
219541700|NCT00345696|DRUG|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
219541701|NCT00345696|DRUG|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
219541702|NCT00345696|DRUG|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
219541703|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
219541704|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
218931463|NCT02604160|DRUG|Placebo|Administered by slow intravenous (IV) infusion.
219541705|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
219541706|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
218931464|NCT02427997|BEHAVIORAL|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
219044702|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
219205374|NCT06751511|OTHER|General warm-up|The General Warm-up (Control) protocol will consist of activities such as running and dynamic, active, and passive movements, adapted to suit the varied sports disciplines included in the study. These exercises will align with the principles of elevation, activation, and mobilization, aiming to enhance mobility across key muscle groups, from the arms and shoulders to the lower back and legs. Each session will include clear demonstrations to ensure proper technique and pacing, with participants performing a standardized number of repetitions. Researchers will supervise participants closely to verify accurate form and consistent execution during the intervention.
219541707|NCT00120887|DRUG|Atorvastatin|
219541708|NCT03669861|DRUG|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
219541709|NCT01804244|DRUG|TMC278|1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
219541710|NCT05049291|BEHAVIORAL|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
219541711|NCT03169062|DEVICE|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
219541712|NCT00374231|DRUG|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
219541713|NCT00374231|DRUG|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
219541714|NCT00374231|DRUG|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
219541715|NCT06541327|DRUG|Chimeric Antigen Receptor|CAR-T
219541716|NCT04200586|DRUG|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
219541717|NCT01604941|DRUG|SPD602|50 mg/kg/day orally twice daily for 24 weeks
219541718|NCT06627114|BEHAVIORAL|nutrition education program|"Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress."
219541719|NCT06627114|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
219541720|NCT06627114|OTHER|control group|receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
219541721|NCT05248308|DEVICE|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
219621182|NCT00612274|DRUG|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
219621183|NCT00612274|DRUG|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
219621184|NCT04406181|BEHAVIORAL|HADS|Hospital Anxiety and Depression Scale
219621185|NCT04406181|BEHAVIORAL|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
219621186|NCT02772211|DRUG|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
218931465|NCT02427997|BEHAVIORAL|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
218931466|NCT00785642|DRUG|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
218931467|NCT01596062|DRUG|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
218931468|NCT01596062|DRUG|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
218931469|NCT01596062|DRUG|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
218931470|NCT01596062|DRUG|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
218931471|NCT01596062|DRUG|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
218931472|NCT04643717|OTHER|Electronic pupillometer analysis|Electronic pupillometer analysis
218931473|NCT02611596|DRUG|Ranolazine|24 weeks of the assigned medication
218931474|NCT02611596|DRUG|Placebo|Placebo for 24 weeks
218931475|NCT02284698|OTHER|Health Education|Heath education will be given through awareness creation \& pamphlet distribution
218931476|NCT02139592|DRUG|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
218931477|NCT01864382|OTHER|Core stability|Core stability 5 days a week during 5 weeks
218931478|NCT01864382|OTHER|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
218931479|NCT00171262|DRUG|Fluvastatin|
218931480|NCT04805099|DRUG|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
219621187|NCT02772211|DRUG|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
219621188|NCT02772211|DRUG|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
219621189|NCT05904834|OTHER|Flexibility training|Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
219621190|NCT02735681|PROCEDURE|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
219621191|NCT02735681|PROCEDURE|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
218931481|NCT05404672|OTHER|Aerobic Training|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
218931482|NCT05404672|OTHER|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
218931483|NCT03060980|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
218931484|NCT03060980|DRUG|Empagliflozin (oral)|10 mg/day and 25 mg/day
218931485|NCT03060980|DRUG|Glimepiride (oral)|1-6 mg/day
218931486|NCT03278054|OTHER|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
218931487|NCT03278054|OTHER|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
218931488|NCT03278054|OTHER|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
218931489|NCT03180840|BIOLOGICAL|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
218931490|NCT02648256|OTHER|Polymerase Chain Reaction on Oropharyngeal rinse|
219541722|NCT06626984|DRUG|Imatinib|Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
219541723|NCT06626984|DRUG|Compound sodium lactate solution|Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
219621192|NCT06626477|DEVICE|Intra nasal mechanical stimulation treatment (INMEST)|The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.
218931491|NCT06464237|BEHAVIORAL|Mio-App|The Mio-App aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and motor skills to reduce cognitive and physical long-term sequelae after cancer during adolescence.
218931492|NCT02429180|OTHER|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
218931493|NCT04085900|BIOLOGICAL|Blood and saliva|Collect blood and saliva samples from participants
218931494|NCT04085900|DIAGNOSTIC_TEST|P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA|Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
218931495|NCT04085900|DIAGNOSTIC_TEST|Fiberoptic endoscopy and biopsy|Screening participants will refer to fiberoptic endoscopy and biospy
218931496|NCT04264481|PROCEDURE|Adductor Canal Block|Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
218931497|NCT04264481|PROCEDURE|Intra-Articular Steroid and Lignocaine Injection|Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
218931498|NCT06000774|OTHER|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
218931499|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
218931500|NCT06004427|OTHER|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
218931501|NCT06004427|OTHER|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
218931502|NCT05492578|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
218931503|NCT05492578|DRUG|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
218931504|NCT05492578|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
218931505|NCT05492578|DRUG|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
219044703|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
219541724|NCT05859984|DRUG|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
219541725|NCT05069480|DEVICE|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
218931506|NCT03497195|DIAGNOSTIC_TEST|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
218931507|NCT06833580|OTHER|The intervention group, who will receive the health belief model-based fall prevention education program|Each participant in this group will receive two in-person individual educational sessions based on the health belief model (HBM).
218931508|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
218931509|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
218931510|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
218931511|NCT00337623|DRUG|Prednisolone|
218931512|NCT06160843|DRUG|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
218931513|NCT02338271|OTHER|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
218931514|NCT05742711|DEVICE|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
218931515|NCT05742711|DEVICE|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
219541726|NCT05069480|OTHER|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
219621193|NCT06626477|DEVICE|Sham (No Treatment)|A modified Walther System not delivering active treatment manufactured by Abilion Medical Systems AB.
219541727|NCT03545022|PROCEDURE|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
218931516|NCT05240391|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
219541728|NCT01826838|DRUG|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
218931517|NCT05240391|DRUG|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
219541729|NCT02764853|BEHAVIORAL|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
218931518|NCT05246358|DEVICE|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
219541730|NCT02764853|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
218931519|NCT02427308|DRUG|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
218931520|NCT04149756|OTHER|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
218931521|NCT03269396|PROCEDURE|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
218931522|NCT04530383|DRUG|Metformin Hydrochloride|500-1000 mg twice daily
218931523|NCT04633005|DRUG|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
218931524|NCT04633005|DRUG|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
218931525|NCT04110288|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
219044704|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
219044705|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
219044706|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
219044707|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
219044708|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
219044709|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
219044710|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
219044711|NCT00965068|OTHER|Cholesterol|
219044712|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
219044713|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
219044714|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
219044715|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
219044716|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
219044717|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
219044718|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
218931526|NCT04110288|DEVICE|Non-drug coated Device Treatment|
218931527|NCT03249116|OTHER|animal-assisted intervention|Interaction with a therapy dog
218931528|NCT03249116|OTHER|active control|Interaction with a stuffed dog
218931529|NCT00766662|DRUG|Sulfadoxine pyrimethamine|
218931530|NCT04299789|OTHER|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
218931531|NCT00221117|DEVICE|Neuroprosthesis-FES Therapy|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
218931532|NCT00221117|OTHER|Conventional Ocupational Therapy (COT)|Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
219044719|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
219541731|NCT04593160|DRUG|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
219541732|NCT04593160|DRUG|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
219541733|NCT04593160|DRUG|Placebo|Preoperative single dose of placebo
219541734|NCT01448096|DRUG|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
219541735|NCT01448096|PROCEDURE|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
219541736|NCT01736007|DEVICE|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
219541737|NCT01736007|DEVICE|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
218931533|NCT03405532|DIAGNOSTIC_TEST|DM-ECC|Diabetes mellitus CPB
219044720|NCT00004917|BIOLOGICAL|epoetin alfa|
219541738|NCT04185857|DRUG|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
219541739|NCT04185857|DRUG|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
219541740|NCT00625222|PROCEDURE|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
219541741|NCT04041713|DRUG|Rett-T|antioxidant cocktail
219541742|NCT04041713|OTHER|Placebo|Placebo
219541743|NCT06822374|DRUG|Normosol-R|Standard of care isotonic fluid.
218931534|NCT02217358|DEVICE|NBI endoscopy|"see in detail description of the study part of the protocol"
218931535|NCT03952975|OTHER|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
219044721|NCT00004917|DRUG|cisplatin|
219541744|NCT06822374|DRUG|buffered 2% hypertonic saline|"A solution containing 2% sodium chloride (NaCl) that is buffered by the addition of another salt like sodium acetate."
219541745|NCT00235027|OTHER|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
219541746|NCT04525027|DIAGNOSTIC_TEST|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
219541747|NCT05479058|DRUG|Filgotinib|Administered orally once daily
219541748|NCT05479058|DRUG|Placebo|Administered orally once daily
219541749|NCT03279250|DRUG|Abiraterone Acetate|Given PO
219541750|NCT03279250|DRUG|Apalutamide|Given PO
219044722|NCT00004917|RADIATION|radiation therapy|
219044723|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
219541751|NCT03279250|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given IM
218931536|NCT03007225|DRUG|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
219044724|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
219044725|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
219541752|NCT03279250|DRUG|Prednisone|Given PO
219541753|NCT03279250|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219541754|NCT02890069|BIOLOGICAL|PDR001|anti-PD1 antibody
219541755|NCT02890069|DRUG|LCL161|
219541756|NCT02890069|DRUG|Everolimus|
219541757|NCT02890069|DRUG|Panobinostat|
219541758|NCT02890069|DRUG|QBM076|
219541759|NCT02890069|DRUG|HDM201|
219541760|NCT01157130|OTHER|Exercise Regimen|Exercise instruction
219541761|NCT05301218|PROCEDURE|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
219621200|NCT06581224|OTHER|Primary Hospital Provider Team|The PHP team aims to enhance continuity during hospital readmissions with a consistent cohort of seven hospital medicine physicians and two advanced practice providers (APPs). To improve care transitions, the team will have an integrated case manager who will continue following PHP patients during subsequent hospitalizations. Physicians will follow a standard seven-day service schedule, with the two APPs alternating five-to-seven-day periods. Daily huddles between physicians and APPs will further promote continuity. During the index admission, the PHP team will create a care plan in consultation with the patient to improve standardization of inpatient care and transition to outpatient settings. Communication will be a core tenet of the team, with scheduled monthly team meetings of physicians, APPs, case manager, dyad partner, and representatives from nursing and therapy services to revise individualized care plans for PHP patients and brainstorm solutions for complex challenges.
219621201|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
219541762|NCT04153877|OTHER|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
219541763|NCT06353139|DEVICE|Modified olfactory training device|Conduct olfactory training in patients with olfactory disorders
219541764|NCT05457452|DEVICE|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
219541765|NCT05721794|OTHER|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
219541766|NCT02532439|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
219541767|NCT02532439|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
219541768|NCT02532439|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
219541769|NCT01640197|DIETARY_SUPPLEMENT|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
219541770|NCT01640197|OTHER|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
219541771|NCT05799313|OTHER|At home removal|Removal of PNE lead at home
219541772|NCT05799313|OTHER|In office removal|Removal of PNE lead in the office
219541773|NCT02256943|DRUG|Amitriptyline|100 mg single dose
219541774|NCT02256943|DRUG|Tolterodine|Placebo 1 mg single dose
218931537|NCT03007225|DRUG|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
218931538|NCT03482596|BEHAVIORAL|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
218931539|NCT03970317|DEVICE|Broad Band Light|Broad Band Light Device
218931540|NCT01413204|DRUG|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
218931541|NCT01413204|DRUG|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
218931542|NCT01413204|DRUG|Placebo|The patients will receive Placebo orally for 24 weeks.
218931543|NCT00851058|BEHAVIORAL|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
218931544|NCT00851058|BEHAVIORAL|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
218931545|NCT00851058|BEHAVIORAL|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
219541775|NCT05569512|DRUG|Uproleselan|Administered by intravenous infusion
219541776|NCT05569512|DRUG|Fludarabine|Administered by intravenous infusion
219541777|NCT05569512|DRUG|Clofarabine|Administered by intravenous infusion
219541778|NCT05569512|DRUG|Busulfan|Administered by intravenous infusion
219541779|NCT06352138|BIOLOGICAL|Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.|comparison vs the reference product to demonstrate biological similarity
219541780|NCT06352138|BIOLOGICAL|Active comparator: European Union licenced epoetin alfa|comparison vs. the test product to demonstrate biological similarity
219541781|NCT06559969|DRUG|Intravenous administered opioid|Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
219541782|NCT06559969|DRUG|Epidural administered opioid|Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
219541783|NCT06560528|DRUG|combination with Disitamab Vedotin and with Tislelizumab and Capecitabine|"Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W."
219541784|NCT02317263|DRUG|testosterone|
219541785|NCT02317263|DRUG|placebo gel|
219541786|NCT03910231|DRUG|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
219541787|NCT00604474|DEVICE|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
219541788|NCT00000915|BEHAVIORAL|Vaccine preparedness|
219541789|NCT01090687|RADIATION|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
219541790|NCT01090687|DEVICE|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
218931546|NCT00851058|BEHAVIORAL|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
219541791|NCT04078022|BIOLOGICAL|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
219541792|NCT04078022|OTHER|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
219541793|NCT04078022|BIOLOGICAL|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
219541794|NCT00463684|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
218931547|NCT04922541|DRUG|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
218931548|NCT00000369|BEHAVIORAL|Individual psychotherapy|
218931549|NCT00000369|DRUG|Lithium carbonate|
219541795|NCT00463684|BIOLOGICAL|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
219541796|NCT00990535|DRUG|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
219541797|NCT04948619|BIOLOGICAL|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
219541798|NCT00191815|DRUG|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
219541799|NCT00191815|DRUG|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
219621202|NCT05423093|BEHAVIORAL|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
219621203|NCT03112408|BEHAVIORAL|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
218931550|NCT06165315|BEHAVIORAL|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
219541800|NCT01075282|DRUG|Insulin Glargine|
218931551|NCT00487656|DRUG|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
219541801|NCT01075282|DRUG|LY2189265|
219541802|NCT01075282|DRUG|Metformin|
219541803|NCT01075282|DRUG|Glimepiride|
219541804|NCT04454229|OTHER|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
219541805|NCT04454229|OTHER|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
219541806|NCT00926835|DRUG|paroxetine|6 weeks, 20-50mg/day
218931552|NCT00487656|DRUG|placebo|6 mg/ml ampule solution for injection at .01mg/kg
218931553|NCT04490876|PROCEDURE|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
218931554|NCT03101332|BEHAVIORAL|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
218931555|NCT00818701|DRUG|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
218931556|NCT00818701|DRUG|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
218931557|NCT05793268|OTHER|Nuc Discontinuation|Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.
218931558|NCT05793268|DRUG|Entecavir or Tenofovir|Continuation of either entecavir or tenofovir treatment for 3 years
218931559|NCT02901392|PROCEDURE|AMS-800|Artificial urianry sphincter
218931560|NCT02901392|PROCEDURE|ADVANCE/ADVANCEXP|Male sling
218931561|NCT02901392|PROCEDURE|VIRTUE|Male sling
218931562|NCT02901392|PROCEDURE|INVANCE|Male sling
218931563|NCT03370900|OTHER|Testing|Participants either received 20 case testing with or without feedback
218931564|NCT01852409|DRUG|bevacizumab|
218931565|NCT00861562|DRUG|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
218931566|NCT00861562|DRUG|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
218931567|NCT00659737|DRUG|Aprepitant|40mg tablet
218931568|NCT00659737|DRUG|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
218931569|NCT04579939|DIAGNOSTIC_TEST|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
218931570|NCT00475956|DRUG|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
218931571|NCT00475956|DRUG|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
218931572|NCT02291458|DRUG|L-arginine|9 gram L-arginine / day for 6 weeks
218931573|NCT02291458|DRUG|Placebo|9 gram placebo / day for 6 weeks
218931574|NCT05593068|PROCEDURE|MRI|Pancreatic MRI
218931575|NCT02506803|DRUG|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
219541807|NCT00926835|DRUG|Escitalopram|10-20mg/day for 6 weeks
219541808|NCT00926835|DRUG|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
219541809|NCT00926835|DRUG|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
219541810|NCT00926835|DRUG|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
219541811|NCT00926835|DRUG|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
219541812|NCT00926835|DRUG|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
218931576|NCT03677453|OTHER|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
219541813|NCT00926835|DRUG|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
219541814|NCT00926835|DRUG|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
219541815|NCT00831103|DRUG|EPB-348|Treated over seven days
219541816|NCT00831103|DRUG|Valacyclovir|Treated over seven days
218931577|NCT05865119|DEVICE|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
219044726|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
219205375|NCT06751511|OTHER|Inspiratory muscle warm-up (Placebo - %15)|The placebo inspiratory muscle warm-up protocol will utilize the POWERbreathe® device at 15% of maximal inspiratory pressure (MIP). This placebo protocol will consist of two sets of 30 breaths, separated by a 60-second rest interval, with participants seated and wearing a nose clip. Proper technique will be taught during a prior familiarization session, and participants will be closely monitored during testing to ensure accurate execution. This protocol is designed to function as a placebo, effectively concealing the study's true objective to improve data validity and reliability.
219205376|NCT06751511|OTHER|Inspiratory muscle warm-up (%40 IMW)|This study will implement a respiratory muscle warm-up protocol at 40% of maximal inspiratory pressure (MIP) using the POWERbreathe® device, as this intensity is considered optimal for effectively stimulating respiratory muscles. The protocol will consist of two sets of 30 breaths, with a 60-second rest period between sets, conducted while participants are seated and wearing a nose clip. Training for proper technique will be provided during the familiarization session, and participants will be closely monitored throughout the tests to ensure correct and consistent execution.
219541817|NCT01360333|OTHER|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
219044727|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
218931578|NCT05865119|PROCEDURE|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
219044728|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
219044729|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
219044730|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
219044731|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
219044732|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
219044733|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
219044734|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
219044735|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
219044736|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
219044737|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
219044738|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
219541818|NCT05997108|DIAGNOSTIC_TEST|CBC|Platelet and red blood cell volume indices
219541819|NCT05269069|OTHER|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
219541820|NCT05277402|DRUG|ADG116|IV infusion
219541821|NCT05418374|PROCEDURE|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
219541822|NCT00002562|DRUG|paclitaxel|
219541823|NCT05439707|DEVICE|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
218931579|NCT01046838|DRUG|Sildenafil|40 mg three times daily for 9 weeks
218931580|NCT01046838|DRUG|Placebo|tablet 3 times daily for 9 weeks
218931581|NCT01107158|BIOLOGICAL|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
219541824|NCT05439707|DEVICE|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
219541825|NCT01501448|DRUG|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
219541826|NCT01501448|DRUG|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
218931582|NCT04259918|PROCEDURE|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
219541827|NCT03893123|OTHER|Observational study, prostate cancer is outcome of interest|Observational study
219044739|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
219044740|NCT03950284|DEVICE|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
219044741|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
219044742|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
219044743|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
219621204|NCT03112408|BEHAVIORAL|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
218931583|NCT01713101|DRUG|Early intravenous tranexamic acid administration|Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.
218931584|NCT01713101|DRUG|placebo|
218931585|NCT01627730|OTHER|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
218931586|NCT06325592|PROCEDURE|surgical timing and operation path|surgical timing; laparoscopic hysterectomy or abdominal hysterectomy
219044744|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
219044745|NCT01701466|OTHER|Aveeno cream|Twice a day
219044746|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
219044747|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
219541828|NCT00003470|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218931587|NCT00811915|DRUG|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
218931588|NCT03588585|PROCEDURE|Tension|Tension applied to catheter and taped firmly to leg.
218931589|NCT03588585|PROCEDURE|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
218931590|NCT06016777|PROCEDURE|Ultrasound-guided paraspinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided paraspinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
219541829|NCT04437199|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
219044748|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
219541830|NCT04437199|DRUG|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
219541831|NCT04342559|OTHER|Belamy (vaginal moisturizer)|"The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period"
219541832|NCT05801484|OTHER|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
219541833|NCT02687126|DEVICE|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
219541834|NCT02598323|DEVICE|ultrasound|
219044749|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
219541835|NCT04415515|BEHAVIORAL|RN case management|A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, \& to develop a case management plan that focuses on improving medication adherence \& reconciliation, condition-based measures \& outcomes, addressing psycho-social needs, \& intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, \& support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment \& coordinate services).
219541836|NCT04415515|BEHAVIORAL|Community Health Worker Case Management|In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).
219541837|NCT04415515|BEHAVIORAL|RN Standard care coordination and disease management|RN Standard care coordination and disease management
219541838|NCT00210587|DRUG|epoetin alfa|
219541839|NCT05229133|DEVICE|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
219541840|NCT04371133|DIAGNOSTIC_TEST|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
219541841|NCT01794845|DRUG|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
219541842|NCT01794845|DRUG|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
219541843|NCT01794845|RADIATION|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
219541844|NCT02662933|OTHER|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
219541845|NCT02139826|DRUG|IX-01|
219541846|NCT02261389|OTHER|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
219541847|NCT04802694|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart."
219541848|NCT04802694|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale . Since the hydrocolloid barrier tape can stay on the skin for 7 days and be transparent, the assessment of skin condition will be realized for 7 days and noted down to the chart."
219541849|NCT04802694|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart."
219541850|NCT03507491|DRUG|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
219621205|NCT03112408|BEHAVIORAL|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
218931591|NCT06016777|PROCEDURE|Ultrasound-guided erector spinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided erector spinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
218931592|NCT06016777|PROCEDURE|Patient-controlled intravenous analgesia pump|Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
219044750|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
219541851|NCT03507491|DRUG|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
219541852|NCT00830349|DRUG|Risperidone|1 mg Tablet
219541853|NCT00830349|DRUG|Risperidone|1 mg Tablets
219541854|NCT05867862|OTHER|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
219541855|NCT03913065|DIAGNOSTIC_TEST|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
219541856|NCT05235581|OTHER|Intervention A : virtual environment with avatar|30-second right and left unipodal static and dynamic balance test with avatar only
219541857|NCT05235581|OTHER|Intervention B : virtual environment with reinforced visual signal|30-second right and left unipodal static and dynamic balance test with reinforced visual signal only
219541858|NCT05235581|OTHER|Intervention C : virtual environment with avatar and reinforced visual signal|30-second right and left unipodal static and dynamic balance test with avatar and reinforced visual signal
219541859|NCT05235581|OTHER|Intervention D : real environment|30-second right and left unipodal static and dynamic balance test in real environment
219541860|NCT05728541|DRUG|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
219541861|NCT03725969|DIETARY_SUPPLEMENT|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
219541862|NCT03725969|DIETARY_SUPPLEMENT|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
219541863|NCT01747694|BEHAVIORAL|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
218931593|NCT00946621|DRUG|Ramipril 10 mg Capsule (Sandoz)|
218931594|NCT00946621|DRUG|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
218931595|NCT05008965|BIOLOGICAL|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
218931596|NCT05008965|OTHER|Placebo|Formulation buffer
219541864|NCT01422291|DRUG|paracetamol|1 gr
219541865|NCT01422291|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
218931597|NCT02974543|DEVICE|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
218931598|NCT02974543|DEVICE|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
218931601|NCT00742235|DRUG|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
218931602|NCT03079843|OTHER|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
218931603|NCT03079843|OTHER|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
218931604|NCT04509661|DRUG|LABA/LAMA or Placebo inhalation|Inhaled LABA/LAMA for one year.
219044751|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
219541866|NCT01422291|DRUG|Dexketoprofen|50 mg
219541867|NCT01422291|DRUG|Paracetamole|1 gr
219541868|NCT04308785|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
219541869|NCT04308785|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
219621206|NCT03112408|BEHAVIORAL|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
218931605|NCT06437743|DEVICE|Nociception Level (NoL) Monitor|The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.
218931606|NCT00133003|DRUG|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
218931607|NCT00133003|DRUG|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
218931608|NCT05459844|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
218931609|NCT05459844|DRUG|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
219541870|NCT04308785|OTHER|Placebo|Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
219541871|NCT01456221|DIETARY_SUPPLEMENT|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
219621207|NCT05364931|DRUG|Cotadutide|Cotadutide administered subcutaneously once daily
219621208|NCT05364931|DRUG|Placebo|Placebo administered subcutaneously once daily
219621209|NCT02833961|DEVICE|Magnetic resonance imaging|
219621210|NCT06800144|BEHAVIORAL|Heart rate synchronized motor imagery music therapy|Participants included in this group will listen a metronome sound in a rhythm synchronized with their heart rate.
219621211|NCT06800144|BEHAVIORAL|Heart rate synchronized music therapy|Participants included in this group will listen to soothing/relaxing music without lyrics in a rhythm synchronized with their heart rate.
218931610|NCT01237899|DRUG|LY2623091|Administered orally.
218931611|NCT01237899|DRUG|Placebo|Administered orally.
219044752|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
219044753|NCT04485559|DRUG|Everolimus|Given PO
219541872|NCT01456221|DIETARY_SUPPLEMENT|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
219541873|NCT03066050|OTHER|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
219541874|NCT03066050|OTHER|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
219541875|NCT03066050|OTHER|CABG|Participants underwent coronary artery bypass grafting
219541876|NCT01616550|OTHER|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
219541877|NCT01616550|OTHER|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
219541878|NCT01616550|OTHER|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
219541879|NCT01616550|OTHER|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
219541880|NCT04416386|OTHER|Vitamin C|Pre and post-operative blood plasma levels of vitamin C will be investigated
219541881|NCT06561191|OTHER|Hemodialysis mode, dialyzer type|Change of hemodialysis mode and dialyzer type
219541882|NCT00130377|BIOLOGICAL|cell therapy|autologous or allogeneic cells
219541883|NCT02709018|DRUG|losartan|Angiotensin receptor blocker (ARB)
219541884|NCT02709018|DRUG|Placebo|Placebo
219541885|NCT04173273|DRUG|Etrasimod|Dose A taken by mouth, once daily.
219541886|NCT04173273|DRUG|Etrasimod|Dose B taken by mouth, once daily.
219541887|NCT04173273|DRUG|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
219541888|NCT06538181|DRUG|Pacritinib|Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
219541889|NCT05271383|DEVICE|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
219541890|NCT05486338|DEVICE|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
219541891|NCT06647173|BEHAVIORAL|Blued+ Service Platform|During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
219541892|NCT06415045|DRUG|BI 1015550|BI 1015550
219541893|NCT05497804|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219541894|NCT05497804|DRUG|Carfilzomib|Given IV
219541895|NCT05497804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219541896|NCT05497804|BIOLOGICAL|Daratumumab|Given SC
219541897|NCT05497804|DRUG|Dexamethasone|Given IV/PO
218931612|NCT01237899|DRUG|Eplerenone|Administered orally.
219044754|NCT04485559|DRUG|Trametinib|Given PO
219044755|NCT06784167|OTHER|Non-Interventional Study|Non-interventional study
219541898|NCT05497804|DRUG|Lenalidomide|Given PO
219541899|NCT05497804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219541900|NCT05497804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219541901|NCT05497804|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219541902|NCT05497804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219541903|NCT05497804|PROCEDURE|Echocardiography|Undergo ECHO
219541904|NCT05497804|PROCEDURE|Chest Radiography|Undergo chest x-ray
219541905|NCT01473953|DRUG|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
219541906|NCT01473953|DRUG|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
219541907|NCT00772239|DEVICE|Rotation thromboelastometry (ROTEM)|Coagulation measurement
219541908|NCT00772239|PROCEDURE|Standard coagulation managment procedure|Standard coagulation managment procedure
219541909|NCT01327391|PROCEDURE|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
218931619|NCT05357950|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
218931620|NCT05357950|DRUG|Placebo|Placebo matches active drug in size, color and taste
218931621|NCT05035420|DEVICE|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
218931622|NCT05035420|DEVICE|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
219044756|NCT05181033|DRUG|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
219541910|NCT01327391|PROCEDURE|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
219541911|NCT06269952|OTHER|No intervention|No intervention. The participants are asked questions from and questionnaire and later also interviewed guide by an interview-guide
219541912|NCT01348438|DEVICE|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
219541913|NCT00570609|OTHER|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
219541914|NCT05662163|PROCEDURE|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
219541915|NCT05662163|PROCEDURE|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
219541916|NCT05821647|OTHER|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
219541917|NCT02819947|OTHER|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
219541918|NCT06819787|OTHER|Electronic Heath Record Platform to Support Pharmacists in Delivering Contraceptive Services|An electronic health record (EHR) platform specifically designed to support community pharmacists in delivering contraceptive services. The platform streamlines clinical workflows, provides clinical decision support, and promotes adherence to the US Medical Eligibility Criteria (USMEC) guidelines and state regulatory requirements.
219541919|NCT01923753|DEVICE|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
219541920|NCT01923753|DEVICE|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
219541921|NCT01923753|DEVICE|Sham Aerosure|Deactivated but identical Aerosure HFAO device
219541922|NCT05487547|DEVICE|IPL_RF_MGX|intense pulsed light followed by Radiofrequency followed by meibomian gland expression
219541923|NCT02745054|OTHER|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
219541924|NCT06986954|DEVICE|Beacon Tip Catheters|Indicated for use in angiographic procedures by physicians trained and experienced in angiographic techniques. Standard techniques for placement of vascular access sheaths, angiographic catheters, and wire guides should be employed. Beacon Tip Sizing Catheters have marker bands that can be used for anatomical measurements.
219541925|NCT03887884|DRUG|CVT-301|Levodopa Inhalation Powder
219541926|NCT03887884|DRUG|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
219541927|NCT05033678|DEVICE|Diagnostic algorithms|Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
219541928|NCT03633214|OTHER|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
219541929|NCT01494532|DRUG|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
218931623|NCT05035420|DEVICE|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
218931624|NCT05035420|DEVICE|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
218931625|NCT05035420|DEVICE|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
219541930|NCT01494532|DRUG|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
219541931|NCT06861790|BEHAVIORAL|tVNS|Though we will be utilizing a tVNS (Transcutaneous Vegus Nerve Stimulation) device this study is not a device study. The device being used is being done so under its approved usage. The intervention utilizes a non-invasive process to stimulate the Vagus nerve using very small electrical currents. This intervention is completed daily for one month.
219541932|NCT06861790|PROCEDURE|Complete Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
219541933|NCT06861790|PROCEDURE|Anterior Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
219541934|NCT05865769|OTHER|Balance|measuring pulmonary and vestibular functions in all subjects
219541935|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Tibial Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the tibial nerve on one leg, with electrodes above the malleolus and on the bottom of the foot"
218931626|NCT05035420|DEVICE|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
218931627|NCT05842174|DRUG|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
218931628|NCT05842174|DRUG|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
218931629|NCT05842174|DRUG|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
218931630|NCT06380270|DIETARY_SUPPLEMENT|Oral probiotic Streptococcus salivarius eK12|Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)
218931631|NCT06380270|OTHER|Placebo|Orally dissolving placebo tablets
218931632|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
218931633|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218931634|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
218931635|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
218931636|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
218931637|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
218931638|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219541936|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Genital Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the genital nerve, with electrodes on either side of the clitoris."
218931639|NCT04553757|OTHER|Survey Administration|Complete survey
218931640|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
218931641|NCT06847724|BIOLOGICAL|CYB704|Intravenous Infusion
218931642|NCT06847724|BIOLOGICAL|Ocrevus-EU|Intravenous Infusion
219621212|NCT05551000|OTHER|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
219621213|NCT04550494|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621214|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219621215|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
218931643|NCT06847724|BIOLOGICAL|Ocrevus-US|Intravenous Infusion
218931644|NCT06843759|OTHER|mat pilates|Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises
218931645|NCT06843759|OTHER|reformer pilates|Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star
218931646|NCT04576104|PROCEDURE|Biopsy Procedure|Undergo biopsy
218931647|NCT04576104|DRUG|Extended Release Metformin Hydrochloride|Given PO
218931648|NCT04576104|DRUG|Megestrol Acetate|Given PO
218931649|NCT04576104|OTHER|Questionnaire Administration|Ancillary studies
218931650|NCT06232876|DEVICE|Blinded continuous vital sign monitoring|Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
218931651|NCT06232876|DEVICE|Unblinded continuous vital sign monitoring|Continuous ward monitoring with vital signs available to clinicians and investigators.
218931652|NCT04077047|BEHAVIORAL|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
218931653|NCT04730271|DEVICE|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
218931654|NCT00461370|DRUG|SRX251|
218931655|NCT01025726|BEHAVIORAL|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
218931656|NCT01025726|BEHAVIORAL|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
219621216|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621217|NCT04550494|DRUG|Talazoparib|Given PO
218931657|NCT01025726|BEHAVIORAL|General Health Education|Host community events for chronic disease education
218931658|NCT03933085|BEHAVIORAL|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
218931659|NCT01917162|DEVICE|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
218931660|NCT01917162|DEVICE|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
218931661|NCT00891670|DRUG|cilostazol|100mg twice daily for at least 1 month
218931662|NCT00891670|DRUG|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
218931663|NCT00891670|DRUG|aspirin|aspirin 100mg
218931664|NCT04336501|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
219044757|NCT05181033|DRUG|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
219541937|NCT06999265|BEHAVIORAL|Neutral and Erotic Film Clip Alternation|During the testing period, participants will first view a 5-minute neutral film depicting nature scenes to allow blood flow levels to stabilize. This will be followed by a 10-minute period while the subject watches an erotic film clip for assessment of arousal responses without electrical stimulation. A 10-minute clip of the same neutral film will follow, to allow blood flow levels to return to baseline. Five minutes into this film, electrical stimulation will be resumed at the previously determined amplitude. Finally, the subject will view another 10-minute erotic film clip depicting similar sexually explicit material as the first while electrical stimulation remains on as the last sequence in the testing. Physiological arousal will be assessed with a vaginal photoplethysmography probe, yielding vaginal pulse amplitude (VPA) for analysis. Subjective arousal will be assessed with a subjective arousal questionnaire.
219541938|NCT04564053|DRUG|LNA043|Single intra-articular injection on Day 1
219541939|NCT04564053|DRUG|Placebo|Single intra-articular injection on Day 1
219541940|NCT02217293|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
219541941|NCT00641134|OTHER|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
219541942|NCT00209625|DRUG|irinotecan|
219541943|NCT00209625|DRUG|leucovorin|
219621218|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
218931665|NCT03617198|BIOLOGICAL|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
218931666|NCT05350774|DRUG|IV normal saline|IV normal saline 250ml for 5 days
218931667|NCT05350774|DRUG|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
218931668|NCT05782179|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
218931669|NCT05782179|BIOLOGICAL|Placebo|Normal Saline 0.9 %
218931670|NCT06053567|BEHAVIORAL|Aerobic Exercise|Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
219044758|NCT04612179|DEVICE|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
219541944|NCT00209625|DRUG|fluorouracil|
219541945|NCT05672030|OTHER|Non-Interventional|No intervention.
219541946|NCT04018482|OTHER|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
219541947|NCT04018482|OTHER|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
219541948|NCT02827266|DRUG|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
219541949|NCT06016361|OTHER|VS-200Cr|Topical cream with moisturizing factors.
219541950|NCT06016361|OTHER|Standard of care|AAD recommended course of care.
219541951|NCT01845298|DRUG|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
219541952|NCT02220049|DRUG|Bortezomib|
219541953|NCT01939080|PROCEDURE|Exercise training with supervised sessions|
219541954|NCT04241757|DIAGNOSTIC_TEST|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
219541955|NCT02744287|BIOLOGICAL|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
219541956|NCT02744287|DRUG|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
218931671|NCT06053567|BEHAVIORAL|Counseling|Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
218931672|NCT06053567|DRUG|Nicotine patch|On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
218931673|NCT03564379|DRUG|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
218931674|NCT03564379|DRUG|Placebo|Matching placebo tablet will be administered orally.
218931675|NCT06580951|PROCEDURE|Regenerative Peripheral Nerve Interface|The RPNI portion of the case will consist of blunt dissection of the cut sensory branches of the intercostal nerves at the T3 and/or T4 levels, with creation of a peripheral nerve interface using a small cuff of dissected pectoralis muscle and 3-0 Monocryl suture. The breast reconstruction will otherwise be performed as per standard protocol.
218931676|NCT06510686|OTHER|İnspiratory muscle training|exercises to strengthen inspiratory muscles
218931677|NCT06510686|OTHER|Core training|exercises to strengthen inspiratory and core muscles
218931678|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
218931679|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time bilateral intracochlear administration using the Akouos Delivery Device.
218931680|NCT01731561|DRUG|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
218931681|NCT01731561|DRUG|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
218931682|NCT04894006|BEHAVIORAL|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
219541957|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
219541958|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
219541959|NCT05652257|DRUG|[14C]-brensocatib|Oral solution.
219541960|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
219541961|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
219541962|NCT01616225|DRUG|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
219541963|NCT03755050|OTHER|general and specific data|General and specific data collected
219541964|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
218931683|NCT04894006|BEHAVIORAL|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
218931684|NCT04894006|BEHAVIORAL|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
218931685|NCT05963438|PROCEDURE|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
219541965|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
219541966|NCT03580915|BEHAVIORAL|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
218931686|NCT05970289|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
218931687|NCT05970289|DRUG|BRII-835|BRII-835 will be given via subcutaneous injection
218931688|NCT01630876|PROCEDURE|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
218931689|NCT01630876|PROCEDURE|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
218931690|NCT06008691|DRUG|"novel MAB (alone or in combination)"|"novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy"
219205377|NCT06763497|OTHER|Systematic Oral Feeding Education Program|The experimental group will receive 11 intervention sessions during the study period. The first intervention will occur immediately after the pretest and will involve a systematic oral feeding education program, including guided feeding techniques and practical feeding demonstrations. During the feeding session, caregivers' practices will be recorded on video. These recordings will then be reviewed with the caregiver to identify areas for improvement.The remaining 10 intervention sessions will take place daily on days 2-4, 6-9, and 11-13, during which the researcher will observe the primary caregiver's feeding practices, provide assistance, and offer tailored suggestions. On the 14th day, the experimental group will complete the same posttest assessments as the control group.
219205378|NCT06769035|DIETARY_SUPPLEMENT|Cocoa, amaranth seed and ginger|Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks
219205379|NCT06769035|DIETARY_SUPPLEMENT|Amaranth seed|Sachet with 10g of amaranth seed one dose per day for 12 weeks
219541967|NCT03580915|BEHAVIORAL|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
219541968|NCT07067645|PROCEDURE|Horizontal Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive horizontal closure of the vaginal cuff. After removal of the uterus, the vaginal cuff is closed in a transverse (right-to-left) direction using standard absorbable sutures. The technique aims to maintain or optimize the anatomical axis and preserve vaginal length in the horizontal plane. The entire procedure is performed under general or regional anesthesia by an experienced surgical team.
219541969|NCT07067645|PROCEDURE|Vertical Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive vertical closure of the vaginal cuff. After the uterus is removed, the vaginal cuff is closed in a cranio-caudal (top-to-bottom) orientation using absorbable sutures. This technique is hypothesized to better support apical structures and reduce tissue tension. Procedures are performed under general or regional anesthesia with standardized operative technique.
219541970|NCT02761512|DRUG|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
219205380|NCT06769035|DIETARY_SUPPLEMENT|Cocoa|Sachet with 20gr of cocoa one dose per day for 12 weeks
219205381|NCT06769035|DIETARY_SUPPLEMENT|Placebo|Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
219205382|NCT02030964|DRUG|DFMO|
219205383|NCT02030964|DRUG|Celecoxib|
219205384|NCT02030964|DRUG|Cyclophosphamide|
219205385|NCT02030964|DRUG|Topotecan|
219205386|NCT06857565|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247|CRISPACT® (Lactobacillus crispatus M247), Pharmextracta, S.p.A
219205387|NCT06857565|DIETARY_SUPPLEMENT|iNatal-duo® (containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3)|iNatal-duo®, PharmExtracta S.p.A
218931691|NCT04814004|DRUG|hCD19.IL15.CAR-iNKT|Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
218931692|NCT05377255|COMBINATION_PRODUCT|16 mg naloxone AP003|4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
218931693|NCT05377255|COMBINATION_PRODUCT|8 mg naloxone NARCAN Nasal Spray|2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
218931694|NCT01907711|DEVICE|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
218931695|NCT00179192|PROCEDURE|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
218931696|NCT00179192|PROCEDURE|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
218931697|NCT03599089|DRUG|CA-008|single-dose wound infiltration prior to surgical incision closure
218931698|NCT03599089|DRUG|Placebo|single-dose wound infiltration prior to surgical incision closure
218931699|NCT03599089|DRUG|Ketorolac|30mg IV administered intraoperatively
219044759|NCT04861402|DEVICE|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
219541971|NCT02761512|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
219541972|NCT02761512|DRUG|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
219541973|NCT06947993|DRUG|GHZ339|GHZ339 administered at dose A, B, C and D
219541974|NCT06947993|DRUG|Placebo|Matching placebo
219541975|NCT06954870|OTHER|Ozone therapy|As detailed in the research arms, major ozone application and local ozone application will be performed.
219541976|NCT05607420|BIOLOGICAL|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
218931700|NCT03599089|DRUG|Acetaminophen|1000mg IV administered intraoperatively
218931701|NCT03599089|DRUG|Oxycodone|5mg PO prn post-surgery
218931702|NCT03599089|DRUG|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
218931703|NCT03214666|DRUG|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day"
218931704|NCT03214666|DRUG|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
218931705|NCT00470275|DRUG|cytarabine|Given IV
218931706|NCT00499148|OTHER|herbal extract; root of woody shrub grown in India/Sri-Lanka|
218931707|NCT04399785|OTHER|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
218931708|NCT05274893|DRUG|SYHX2011 and Abraxane®|IV infusion, 260 mg/m\^2
218931709|NCT06214091|PROCEDURE|Gastrointestinal decompression|Gastric tube is inserted within 24-hour severe ischemic stroke attack; gastrointestinal decompression is performed for 48 hours.
219044760|NCT06096324|BEHAVIORAL|Job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.|Participants will receive job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.
219044761|NCT06096324|BEHAVIORAL|Job announcements|Participants will receive job announcements only.
219541977|NCT05607420|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
218931710|NCT06214091|PROCEDURE|Control|Gastric tube is inserted within 24-hour severe ischemic stroke attack.
218931711|NCT03916900|PROCEDURE|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
218931712|NCT03916900|PROCEDURE|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
218931713|NCT02893397|DEVICE|Activity Monitor|Wear a fitbit
218931714|NCT02893397|BEHAVIORAL|Exercise Intervention|Undergo supervised exercise sessions
219541978|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
219541979|NCT03859089|OTHER|Medical Cannabis|N/A - Observational Cohort Study
219541980|NCT01373593|DRUG|lidocaine|
219541981|NCT01373593|DRUG|Placebo|
218931715|NCT06453889|DEVICE|Multimode thermal therapy|The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
218931716|NCT02442297|BIOLOGICAL|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
218931717|NCT06841887|DIAGNOSTIC_TEST|US acquisitions|US acquisition from two anatomical regions i.e., the non-dominant arm and the neck.
218931718|NCT01177371|DRUG|busulfan|Given orally
218931719|NCT01177371|DRUG|cyclophosphamide|Given IV
218931720|NCT01177371|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
218931721|NCT01177371|DRUG|methylprednisolone|Given IV or orally
218931722|NCT01177371|DRUG|methotrexate|Given IV
218931723|NCT01177371|DRUG|cyclosporine|Given IV or orally
218931724|NCT04616456|DRUG|[F-18]PBR06|PET radiopharmaceutical
218931725|NCT04616456|DRUG|Verdiperstat|verdiperstat targets microglial inflammation in the brain
218931726|NCT02071394|DRUG|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
218931727|NCT02071394|OTHER|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
218931728|NCT01519921|DRUG|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
218931729|NCT03915093|OTHER|Educational nursing protocol|It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
218931730|NCT03915093|OTHER|Routine hospital care|The routine care given by physicians and nurses after thoracoscopic surgery
218931731|NCT06561165|DEVICE|Standard HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
218931732|NCT06561165|DEVICE|Multifocal network targeted HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
218931733|NCT06561165|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will have an MRI before or after having HD-tDCS intervention.
218931734|NCT04268667|OTHER|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
219541982|NCT02570477|PROCEDURE|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
218931735|NCT05120921|OTHER|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
218931736|NCT05120921|OTHER|Self-management|Providing rehabilitative exercises to patients to do at home
218931737|NCT05120921|OTHER|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
218931738|NCT05120921|OTHER|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
218931739|NCT00845117|PROCEDURE|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
218931740|NCT00925457|OTHER|No Intervention|Neither current domperidone nor current PPI
218931741|NCT00925457|DRUG|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
218931742|NCT00925457|DRUG|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
218931743|NCT05777252|OTHER|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
218931744|NCT01956838|DIETARY_SUPPLEMENT|umami|intraduodenal infusion of umami tastant
218931745|NCT01956838|DIETARY_SUPPLEMENT|bitter|intraduodenal infusion of bitter tastant
219541983|NCT02570477|DRUG|Vancomycin|125mg Vancomycin four times per day
219541984|NCT03914105|PROCEDURE|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
218931746|NCT01956838|DIETARY_SUPPLEMENT|sweet|intraduodenal infusion of sweet tastant
218931747|NCT04670471|DRUG|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
218931748|NCT04670471|DRUG|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
218931749|NCT02902861|DRUG|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
218931750|NCT02902861|DRUG|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
218931751|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
218931752|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
218931753|NCT01288261|DRUG|paclitaxel|Given IV
218931754|NCT01288261|BIOLOGICAL|bavituximab|Given IV
218931755|NCT01288261|OTHER|laboratory biomarker analysis|Correlative studies
218931756|NCT01288261|OTHER|pharmacological study|Correlative study
218931757|NCT01415882|DRUG|Cyclophosphamide|Given PO
218931758|NCT01415882|BIOLOGICAL|Daratumumab|Given IV
218931759|NCT01415882|DRUG|Dexamethasone|Given PO or IV
218931760|NCT01415882|DRUG|Ixazomib Citrate|Given PO
218931761|NCT01415882|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931762|NCT02390505|DRUG|Vitamin C|
218931763|NCT02390505|DRUG|Placebo|
218931764|NCT00533936|BIOLOGICAL|trastuzumab|
219044762|NCT04988503|DEVICE|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
219541985|NCT03914105|PROCEDURE|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
219541986|NCT00106223|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
219541987|NCT02881541|PROCEDURE|Enhanced support|
219541988|NCT02881541|PROCEDURE|Usual care|
219541989|NCT04693611|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
219541990|NCT04693611|PROCEDURE|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
219541991|NCT00503919|PROCEDURE|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
219541992|NCT04480086|DRUG|Mivebresib|Tablet: Oral
219541993|NCT04480086|DRUG|Navitoclax|Tablet; Oral
219541994|NCT04480086|DRUG|Ruxolitinib|Tablet; Oral
219621219|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
219621220|NCT04673149|BIOLOGICAL|GLS-5310|GLS-5310 DNA plasmid vaccine
219541995|NCT04712045|OTHER|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
218931765|NCT00533936|DRUG|cyclophosphamide|
218931766|NCT00533936|DRUG|doxorubicin hydrochloride|
218931767|NCT00533936|DRUG|fluorouracil|
218931768|NCT00533936|DRUG|paclitaxel|
218931769|NCT00533936|PROCEDURE|adjuvant therapy|
218931770|NCT00533936|PROCEDURE|conventional surgery|
218931771|NCT00533936|PROCEDURE|neoadjuvant therapy|
218931772|NCT06056479|PROCEDURE|external oblique intercostal block|20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
218931773|NCT01932437|BIOLOGICAL|ETI-204|monoclonal antibody
218931774|NCT01932437|OTHER|Placebo|Placebo for ETI-204
218931775|NCT00074490|DRUG|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
218931776|NCT00074490|DRUG|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
218931777|NCT00074490|DRUG|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
218931778|NCT00074490|DRUG|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
218931779|NCT00074490|DRUG|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
218931780|NCT00074490|DRUG|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
219044763|NCT05308901|DRUG|Pembrolizumab|200 mg IV every 3 weeks for a maximum of 2 years.
219044764|NCT05308901|DRUG|Lenvatinib|20 mg daily for a maximum of 2 years.
219044765|NCT03621631|BEHAVIORAL|Optimized Tai Chi intervention|Optimized Tai Chi intervention
219044766|NCT03621631|BEHAVIORAL|Traditional Tai Chi intervention|Traditional Tai Chi intervention
219541996|NCT04712045|OTHER|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
219541997|NCT01319383|DRUG|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
219541998|NCT01031394|OTHER|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
219541999|NCT00772603|DRUG|Placebo|Non-active tablet identical to study drug tablets
219542000|NCT00772603|DRUG|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
219542001|NCT00772603|DRUG|1200mg SPN-804|two active tablets and two non-active tablets, all identical
219542002|NCT02489461|DRUG|VM-1500|VM-1500 up to 96 weeks
219542003|NCT02489461|DRUG|Efavirenz|Efavirenz up to 48 weeks
219542004|NCT02489461|DRUG|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
219542005|NCT00938509|DRUG|ibuprofen suppositories|5-10 mg/kg/day-suppositories
219621221|NCT04673149|BIOLOGICAL|Placebo|Placebo
219621222|NCT06489834|OTHER|Group Drumming|Weekly group drumming for 8 weeks
219621223|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
219621224|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
219205388|NCT06867679|OTHER|Recreational Soccer Training (Boys Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
219542006|NCT05452785|DRUG|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
219542007|NCT05452785|DRUG|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
219542008|NCT05452785|DRUG|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
219542009|NCT01639911|DRUG|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
219542010|NCT01639911|DRUG|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
219542011|NCT02882776|DIETARY_SUPPLEMENT|Ginger drink|Ginger powder dissolved in water
219542012|NCT00836004|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
219621225|NCT03662776|BEHAVIORAL|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
219621226|NCT03662776|BEHAVIORAL|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
219621227|NCT02160015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219621228|NCT02160015|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219621229|NCT02160015|PROCEDURE|Computed Tomography|Undergo CT
218931781|NCT00074490|PROCEDURE|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
218931782|NCT00074490|GENETIC|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
219542013|NCT00836004|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
218931783|NCT00074490|DRUG|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
218931784|NCT00074490|PROCEDURE|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
219621230|NCT02160015|PROCEDURE|Electrocardiogram|Undergo ECG
219621231|NCT02160015|DRUG|Ibrutinib|Given PO
219621232|NCT02160015|DRUG|Lenalidomide|Given PO
219621233|NCT02160015|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621234|NCT02160015|BIOLOGICAL|Rituximab|Given IV
219621235|NCT06346119|OTHER|this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day|Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
219621236|NCT01955499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218931785|NCT00074490|DRUG|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
218931786|NCT00074490|GENETIC|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
218931787|NCT02722499|BEHAVIORAL|High Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65."
219542014|NCT04548635|DEVICE|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
219542015|NCT03548363|DIETARY_SUPPLEMENT|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
219621237|NCT01955499|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219621238|NCT01955499|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219621239|NCT01955499|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219621240|NCT01955499|DRUG|Ibrutinib|Given PO
219542016|NCT03548363|DIETARY_SUPPLEMENT|Placebo|200 mg/d maltodextrin
219542017|NCT01004562|OTHER|informational intervention|
219542018|NCT01767363|OTHER|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
219542019|NCT01767363|OTHER|Alpha-blockers|Use of alpha-blockers over the study period.
218931788|NCT02722499|BEHAVIORAL|Moderate Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85"
218931789|NCT02722499|BEHAVIORAL|Low Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150."
218931790|NCT03810911|DRUG|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
218931791|NCT03935763|OTHER|observational disease study|observation of routine clinical practices in mCRC
218931792|NCT05567718|BEHAVIORAL|Paediatric Anaesthesia Emergence Delirium scale|measure emergence delirium in children
218931793|NCT03973060|DEVICE|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
218931794|NCT03973060|GENETIC|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
218931795|NCT00448643|RADIATION|Vaginal Brachytherapy|High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
218931796|NCT00448643|DRUG|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
218931797|NCT00448643|RADIATION|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
218931798|NCT02668536|DRUG|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
218931799|NCT02668536|DEVICE|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
218931800|NCT04794569|DRUG|tinzaparin|low molecular weight heparin
219205389|NCT06867679|OTHER|Recreational Soccer Training (Girls Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
219205390|NCT06866990|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|The investigational product is a probiotic containing Lactobacillus johnsonii. It is recommended to be stored under refrigerated conditions at approximately 4°C. Participants are instructed to take one sachet twice daily, dissolved in warm water, with a total daily oral dose exceeding 1×10¹¹ colony-forming units (CFU).
219205391|NCT06866990|OTHER|Placebo|The placebo product contains the same excipients as the investigational product, except for the absence of Lactobacillus johnsonii. It is identical to the investigational product in appearance, color, weight, and taste. It is recommended to be stored under refrigerated conditions at approximately 4°C. The administration method is the same as that of the experimental group.
219205392|NCT06693986|BIOLOGICAL|Replicative Adenovirus Vector (RGDCRAdCOX2F)|"RGDCRAdcox2F (RGD) is a local product and is provided through this study."
219205393|NCT06870890|DIAGNOSTIC_TEST|muscle evaluation|The investigators will evaluate the muscle mass and muscle strenght for all patients included
218931801|NCT04794569|DRUG|Rivaroxaban|direct oral anticoagulant
218931802|NCT04141436|BEHAVIORAL|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
218931803|NCT04141436|OTHER|Routine clinical procedure|Routine clinical procedure
219205394|NCT06870890|BIOLOGICAL|Dosage|Evaluation of the cinetic of biomarkers during exercise
219205395|NCT06870890|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|CPET
219205396|NCT06870890|COMBINATION_PRODUCT|Questionnaire and Physical Exam|Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
219205397|NCT06889077|OTHER|QR Code Group|Students will receive support in their clinical practice through QR Code-supported perioperative education materials.
219205398|NCT06757166|PROCEDURE|endotracheal intubation|endotracheal intubation for invasive mechanical ventilation
219542020|NCT01855035|OTHER|prolonged ECG monitoring|10-day Holter ECG measurement
219542021|NCT01855035|OTHER|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
219621241|NCT01955499|DRUG|Lenalidomide|Given PO
219621242|NCT01955499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621243|NCT01955499|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219621244|NCT05904171|BEHAVIORAL|Tangotherapy|"Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks."
218931804|NCT03111628|DRUG|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
218931805|NCT02321176|DRUG|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
218931806|NCT02506413|OTHER|MamaToto Package|"The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers."
218931807|NCT01620216|OTHER|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
218931808|NCT01620216|DRUG|Dasatinib|Given PO
218931809|NCT01620216|DRUG|Idelalisib|Given PO
218931810|NCT01620216|OTHER|Laboratory Biomarker Analysis|Correlative studies
218931811|NCT01620216|DRUG|Pacritinib|Given PO
218931812|NCT01620216|OTHER|Pharmacological Study|Correlative studies
218931813|NCT01620216|DRUG|Ponatinib|Given PO
218931814|NCT01620216|DRUG|Ponatinib Hydrochloride|Given PO
218931815|NCT01620216|DRUG|Ruxolitinib|Given PO
218931816|NCT01620216|DRUG|Sorafenib|Given PO
218931817|NCT01620216|DRUG|Sorafenib Tosylate|Given PO
218931818|NCT01620216|DRUG|Sunitinib|Given PO
218931819|NCT01620216|DRUG|Sunitinib Malate|Given PO
218931820|NCT06109662|DIAGNOSTIC_TEST|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
218931821|NCT06109662|OTHER|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
218931822|NCT06218797|OTHER|a routine sedation protocol|In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.
218931823|NCT06218797|DRUG|Nebulized with dexmedetomidine|Patients will be received nebulisation with dexmedetomidine 2mcg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
218931824|NCT06959849|DEVICE|Use of robot surgical system|
218931825|NCT06095128|DRUG|Vedolizumab|Vedolizumab IV infusions
218931826|NCT06095128|DRUG|Tofacitinib|Tofacitinib Tablets
218931827|NCT03937999|DRUG|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
218931828|NCT04638660|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
218931829|NCT04638660|DRUG|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
218931830|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
218931831|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
218931832|NCT05222269|DRUG|68Ga-PTF|68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
218931833|NCT01182506|BEHAVIORAL|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
218931834|NCT06276946|RADIATION|standard radiotherapy|radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.
219205399|NCT06761248|DEVICE|Fluorescent Starch Nanoparticles Caries Detection Rinse|The fluorescent starch nanoparticles caries detection rinse is an innovative diagnostic tool designed to enhance the early detection of active dental caries. It contains proprietary fluorescent starch nanoparticles that infiltrate the porous enamel of active caries lesions. Upon illumination with a standard dental curing light, the nanoparticles fluoresce, allowing clinicians to differentiate active caries from inactive lesions and other enamel conditions. This rinse is evaluated as a non-invasive, highly sensitive, and specific diagnostic device.
219621245|NCT05904171|BEHAVIORAL|Physical activity|Walking and stretching in group twice a week (1h each session), for 6 weeks.
218931835|NCT06276946|RADIATION|experimental radiotherapy|radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
219621246|NCT05636748|DIAGNOSTIC_TEST|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
219621247|NCT05636748|DIAGNOSTIC_TEST|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
219621248|NCT05636748|DIAGNOSTIC_TEST|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
218931836|NCT01651585|DRUG|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
219621249|NCT05636748|DIAGNOSTIC_TEST|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
219621250|NCT03837626|DRUG|Placebo - Cap|6 months of 1 pill a day
219621251|NCT03837626|DRUG|Amiloride Pill|Max dose of 5 mg a day for 6 months
219621252|NCT06345443|DIETARY_SUPPLEMENT|Nicotinamide Riboside Malate|Active supplement.
219621253|NCT06345443|OTHER|Placebo|Placebo
219621254|NCT05019716|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219621255|NCT05019716|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621256|NCT05019716|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219621257|NCT05019716|PROCEDURE|Chest Radiography|Undergo chest x-ray
219621258|NCT05019716|DRUG|Cisplatin|Given IV
218931837|NCT06224933|DEVICE|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
219542022|NCT01056484|BEHAVIORAL|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
219542023|NCT01056484|OTHER|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
219542024|NCT02435160|BIOLOGICAL|Fecal Microbiota Transplantation|
218931838|NCT06444256|DRUG|SUVO|Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
218931839|NCT06444256|DRUG|TAU|Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
218931840|NCT05025059|PROCEDURE|Discussion|Participate in coaching sessions
219205400|NCT06930443|OTHER|Oxygen consumption measurement|After arrival to the ICU, prior to cessation of iv anaesthetics and extubation, indirect calorimetry will be performed by connecting a metabolic monitor to the ventilator during a minimum of 20 minutes.
219542025|NCT00033917|DRUG|indomethacin|an anti-inflammatory drug
219542026|NCT00033917|DRUG|placebo|saline
219542027|NCT02185144|BEHAVIORAL|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
219542028|NCT02185144|BEHAVIORAL|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
219542029|NCT04018404|OTHER|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
219621259|NCT05019716|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
219621260|NCT05019716|DRUG|Etoposide|Given IV
219621261|NCT05019716|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
219621262|NCT05019716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621263|NCT05019716|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219621264|NCT06410196|BEHAVIORAL|Mood modulation|Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events
218931841|NCT05025059|OTHER|Exercise Intervention|Perform walking exercise
219621265|NCT05120635|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
218931842|NCT05025059|OTHER|Exercise Intervention|Perform strength exercises
218931843|NCT05025059|OTHER|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
219621266|NCT05302583|OTHER|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
219621267|NCT00932412|DRUG|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
218931844|NCT05025059|OTHER|Informational Intervention|Maintain exercise log
218931845|NCT05025059|OTHER|Medical Device Usage and Evaluation|Wear fitness tracker
219621268|NCT00932412|DRUG|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
219621269|NCT01875601|BIOLOGICAL|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
218931846|NCT05025059|OTHER|Quality-of-Life Assessment|Complete questionnaires
218931847|NCT05025059|OTHER|Questionnaire Administration|Complete questionnaires
218931848|NCT04879329|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
218931849|NCT04879329|DRUG|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
218931850|NCT01617161|RADIATION|Proton Beam Therapy|5 days per week up to 9 weeks
218931851|NCT01617161|RADIATION|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
218931852|NCT05505955|DRUG|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
218931853|NCT05505955|DRUG|Placebo|Subjects took Placebo in Part 1 and Part 2.
218931854|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
219205401|NCT06924281|BEHAVIORAL|Brief motivational interviewing with personalized feedback|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The enhanced (experimental) group receives personalized feedback, i.e., a summary of self-reported drinking patterns and results of liver imaging with Fibroscan®, i.e., steatosis (liver fat) and fibrosis (liver scaring) scores. The feedback is used to develop discrepancies between a goal of halting or reversing health risks associated with consuming alcohol versus continuing to drink. The sessions are matched in duration and interventionist skill level with the standard (control) group.
218931855|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
218931856|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
218931857|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
218931858|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
218931859|NCT05787002|DRUG|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
218931860|NCT05787002|DRUG|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
218931861|NCT03587376|DRUG|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
219205402|NCT06924281|BEHAVIORAL|Brief motivational interviewing with standard health information|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The standard (control) group does not receive personalized feedback. The sessions are matched in duration and interventionist skill level with the enhanced (experimental) group.
219205403|NCT06878573|DRUG|Intravitreal Aflibercept Injection|After instillation of topical anesthesia (0.4% oxybuprocaine hydrochloride and lidocain; own production), sterilization of the eyelid (Betaisodona solution 11% povidone-iodine, Mundipharma, Limburg, Germany), and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) will be injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions.
219542030|NCT04403672|DEVICE|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
219542031|NCT01686386|DRUG|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
218931862|NCT01648686|PROCEDURE|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
219542032|NCT01686386|DRUG|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
219542033|NCT01686386|DRUG|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
219542034|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
219542035|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
219542036|NCT00598052|DRUG|Escitalopram|10mg/day
219542037|NCT01564394|BEHAVIORAL|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
219542038|NCT01564394|BEHAVIORAL|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
219621270|NCT01875601|BIOLOGICAL|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
219621271|NCT05879978|DRUG|Obrixtamig|Obrixtamig
219621272|NCT05879978|DRUG|Ezabenlimab|Ezabenlimab
219621273|NCT05541653|OTHER|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
219621274|NCT05541653|OTHER|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
219621275|NCT06202443|OTHER|Early PT|Physical therapy delivered within the first three months after surgery.
219621276|NCT06202443|OTHER|Delayed PT|Physical therapy delivered greater than 3 months after surgery.
218931863|NCT05539898|DEVICE|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
218931864|NCT05942833|PROCEDURE|Sigmoid resection|Timing of sigmoid resection
219542039|NCT02663921|OTHER|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure."
219542040|NCT02663921|OTHER|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry"
219621277|NCT06348238|BEHAVIORAL|Self-Affirmation|Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
219621278|NCT04316546|DRUG|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
219621279|NCT03505801|DEVICE|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
219621280|NCT05437705|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
219621281|NCT05828082|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621282|NCT05828082|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219621283|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
219621284|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621285|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
219621286|NCT05828082|DRUG|Tuvusertib|Given PO
219621287|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
219621288|NCT03504397|DRUG|zolbetuximab|Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
218931865|NCT04713241|PROCEDURE|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
218931866|NCT04713241|OTHER|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
218931867|NCT01434199|PROCEDURE|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
218931868|NCT00612144|DRUG|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
218931869|NCT00612144|DRUG|Metformin HCl|"Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
218931870|NCT04184700|DIETARY_SUPPLEMENT|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
218931871|NCT04184700|DIETARY_SUPPLEMENT|RHF|Rice hydrolysed formula
218931872|NCT04184700|DIETARY_SUPPLEMENT|SF|Soy formula
218931873|NCT04184700|DIETARY_SUPPLEMENT|EHWF|extensively hydrolysed whey formula
218931874|NCT04184700|DIETARY_SUPPLEMENT|AAF|amino acid based formula
219542041|NCT06619184|PROCEDURE|NCEHFORSCS transplantation|One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
219542042|NCT06619184|PROCEDURE|MPG procedure|"Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match"
219542043|NCT04273971|OTHER|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
219542044|NCT04367766|PROCEDURE|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
219542045|NCT04606550|DEVICE|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
219542046|NCT02305732|BIOLOGICAL|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
219542047|NCT02888756|BIOLOGICAL|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
219542048|NCT02888756|BIOLOGICAL|TriMix|Therapeutic vaccination, followed by treatment interruption
219542049|NCT02888756|BIOLOGICAL|Placebo|Therapeutic vaccination, followed by treatment interruption
219542050|NCT05058430|DEVICE|Electrical salivary stimulator system assigned to subjects with xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
219542051|NCT05058430|DEVICE|No Electrical salivary stimulator system assigned to subjects without xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
219542052|NCT05470153|DEVICE|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
219542053|NCT03548194|DRUG|BNC210|BNC210 300 mg b.i.d
219542054|NCT03548194|DRUG|Placebo|Placebo b.i.d.
219542055|NCT03214523|BEHAVIORAL|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
219542056|NCT01465113|DRUG|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
219621289|NCT03504397|DRUG|placebo|Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
219621290|NCT03504397|DRUG|oxaliplatin|Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
218931875|NCT02643446|BIOLOGICAL|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
218931876|NCT02643446|BIOLOGICAL|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
218931877|NCT00003469|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
219542057|NCT01465113|DRUG|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
219542058|NCT01465113|DRUG|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
218931878|NCT04718155|DRUG|Atorvastatin|will receive 40 mg atrorvastatin 2 days
218931879|NCT04718155|OTHER|placebo|will receive 40 mg placebo 2 days
218931880|NCT03610269|DEVICE|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
218931881|NCT01138449|DRUG|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
218931882|NCT00523302|DEVICE|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
218931883|NCT00523302|DEVICE|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
218931884|NCT03387618|DIAGNOSTIC_TEST|Digital PET/CT imaging|Next generation PET/CT imaging
218931885|NCT04411667|DRUG|Octagam|Standard of Care plus Octagam infusion for 3 days.
218931886|NCT00682123|DIETARY_SUPPLEMENT|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
218931887|NCT01065727|OTHER|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
218931888|NCT01065727|OTHER|natalizumab|monthly natalizumab during 3 years
219542059|NCT01465113|PROCEDURE|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
219044767|NCT06956339|PROCEDURE|Early anterior cruciate ligament surgery|Participants randomised to early anterior cruciate ligament reconstruction surgery (ACLR) will be referred to a study orthopaedic surgeon. Participants will have surgery within 8 weeks of randomisation. The ACLR will reflect usual care for each surgeon. Participants will undergo routine preoperative care, including an anaesthetic consultation to assess fitness for surgery and general anaesthesia. Surgeons will choose their preferred surgical technique and graft, and treat concomitant injuries surgically if indicated and aligned with their usual practice. Participants will follow the surgeon's standard recommendations regarding post-operative care and appointments. Participants will be provided with 15 funded physiotherapy consultations within 12 months of surgery and undertake a physiotherapist-supervised goal-oriented exercise-based rehabilitation program.
219542060|NCT01465113|DRUG|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
218931889|NCT01406782|BIOLOGICAL|rituximab|
218931890|NCT01406782|GENETIC|DNA analysis|
218931891|NCT01406782|GENETIC|gene expression analysis|
218931892|NCT01406782|GENETIC|polymerase chain reaction|
218931893|NCT01406782|OTHER|laboratory biomarker analysis|
218931894|NCT04326803|BIOLOGICAL|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
219542061|NCT04322513|DIAGNOSTIC_TEST|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
219542062|NCT05726162|DEVICE|biofeedback-based music program|The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.
219621291|NCT03504397|DRUG|folinic acid|Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
219621292|NCT03504397|DRUG|fluorouracil|Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
219621293|NCT03431714|DRUG|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
219621294|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
218931895|NCT00067002|PROCEDURE|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
218931896|NCT00067002|PROCEDURE|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
218931897|NCT00067002|DRUG|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
218931898|NCT00067002|DRUG|Melphalan|140 mg/m2 by vein on Day -8.
218931899|NCT00067002|DRUG|Thiotepa|5 mg/Kg by vein on Day -7.
218931900|NCT00067002|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
218931901|NCT00067002|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6.
219621295|NCT04629495|DRUG|Rapamycin|RAPA will be administered orally 1mg daily
219621296|NCT04629495|OTHER|Placebo|Placebo will be administered orally once daily
218931902|NCT00067002|DRUG|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
218931903|NCT00067002|RADIATION|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
218931904|NCT03483857|BEHAVIORAL|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
218931905|NCT01017198|DRUG|BIIB021 and Food|Assessing the effect of food use on BIIB021
218931906|NCT01017198|DRUG|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
218931907|NCT03315663|OTHER|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
218931908|NCT03315663|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
219542063|NCT05726162|OTHER|Control|The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
218931909|NCT00522808|DRUG|A-831|
218931910|NCT02733640|DRUG|Pantoprazole|pantoprazole 40 mg once-daily
218931911|NCT02733640|DRUG|Ranitidine|ranitidine 150 mg twice-daily
218931912|NCT02039141|OTHER|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
218931913|NCT02481219|DEVICE|PillCam® COLON 2 procedure-CONTROL|
218931914|NCT02481219|DRUG|Senna tablets|
218931915|NCT02481219|DRUG|PEG|
218931916|NCT02481219|DRUG|Metoclopramide|
218931917|NCT02481219|DRUG|Erythromycin|
218931918|NCT02481219|DRUG|SUPREP oral sulfate solution|
218931919|NCT02481219|DRUG|Bisacodyl|
218931920|NCT02481219|DRUG|SUPREP oral sulfate solution with Gastrografin|
218931921|NCT00843700|BEHAVIORAL|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
218931922|NCT00843700|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
218931923|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
218931924|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
218931925|NCT01444040|DEVICE|iStent inject|Implantation of two iStent inject devices
218931926|NCT01444040|DRUG|Travoprost|Travoprost drops
218931927|NCT02064023|DEVICE|insulin pump|subjects in the experimental arm will administer insulin using a pump
218931928|NCT02064023|OTHER|multiple daily insulin injection|Subjects will continue with usual insulin injections
218931929|NCT01354314|DRUG|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
218931930|NCT01354314|DRUG|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
218931931|NCT01354314|DRUG|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
218931932|NCT01354314|DRUG|Placebo|One capsule in the morning, three capsules in the evening
218931933|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
218931934|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
219542064|NCT02695797|OTHER|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
219542065|NCT02695797|DRUG|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
219542066|NCT05823766|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
219542067|NCT05823766|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
219542068|NCT05823766|BEHAVIORAL|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
219542069|NCT05823766|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
219542070|NCT05823766|PROCEDURE|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
219542071|NCT05823766|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
219542072|NCT03784937|DIAGNOSTIC_TEST|Doppler ultrasound|Each patient received Doppler ultrasound for research of DVT, no matter the risk stratification.
219542073|NCT03344055|DEVICE|Endocuff Vision (ECV) second generation|"Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope"
219542074|NCT04643197|DEVICE|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
218931935|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
218931936|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
218931937|NCT02665390|PROCEDURE|Percutaneous cryoablation|Percutaneous cryoablation
218931938|NCT03406312|DIAGNOSTIC_TEST|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
218931939|NCT05445271|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
218931940|NCT04930471|DRUG|Metformin|Treatment with Metformin as prescribed by the treating physician.
218931941|NCT03807206|BEHAVIORAL|Questionnaire|Patient questionnaire
218931942|NCT02797938|DEVICE|Taper guard tube|Taper guard tube was intubated
218931943|NCT02797938|DEVICE|Cylindrical tube|Cylindrical tube was intubated
218931944|NCT00414336|DRUG|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
218931945|NCT03619382|RADIATION|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
218931946|NCT03619382|RADIATION|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
218931947|NCT03553303|DRUG|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
218931948|NCT00389038|BEHAVIORAL|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
218931949|NCT00389038|BEHAVIORAL|Headache Education|Behavioral Treatment 2 (headache education)
218931950|NCT00389038|DRUG|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
218931951|NCT02978976|DRUG|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
218931952|NCT02978976|DRUG|saline|saline placebo injection in the same regimen.
218931953|NCT04588584|OTHER|Survey and Interviews|Survey and Interviews
218931954|NCT01094847|DRUG|DWJ1252|tablet(oral) administration following the schedule of each arm
219621297|NCT02767557|DRUG|Tocilizumab|Intravenous infusion
219621298|NCT02767557|DRUG|Gemcitabine|Intravenous infusion
219621299|NCT02767557|DRUG|nab-Paclitaxel|Intravenous infusion,
219621300|NCT06513078|OTHER|Static cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes.
219621301|NCT06513078|OTHER|Static sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
219621302|NCT06513078|OTHER|Dynamic cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes.
219621303|NCT06513078|OTHER|Dynamic sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
219621304|NCT01989585|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621305|NCT01989585|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219621306|NCT01989585|PROCEDURE|Computed Tomography|Undergo CT
219621307|NCT01989585|DRUG|Dabrafenib|Given PO
219621308|NCT01989585|PROCEDURE|Echocardiography Test|Undergo echocardiography
219621309|NCT01989585|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621310|NCT01989585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621311|NCT01989585|PROCEDURE|Multigated Acquisition Scan|Undergo multigated acquisition scan
219621312|NCT01989585|BIOLOGICAL|Navitoclax|Given PO
219621313|NCT01989585|OTHER|Pharmacological Study|Correlative studies
219621314|NCT01989585|DRUG|Trametinib|Given PO
219621315|NCT02653963|DRUG|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
219621316|NCT00804310|DRUG|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
219621317|NCT00804310|DRUG|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
219621318|NCT05549843|OTHER|Manual therapy|Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
219621319|NCT00961675|DRUG|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4 gtt BID (twice a day)
219621320|NCT00961675|DRUG|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID (twice a day)
219621321|NCT00323375|DRUG|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
219621322|NCT00323375|DRUG|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
219621323|NCT04111289|DRUG|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"* After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
219542075|NCT04643197|DEVICE|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
218931955|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
218931956|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
218931957|NCT05365425|DRUG|Choline fenofibrate|choline fenofibrate 178.8mg (135mg as fenofibric acid)
218931958|NCT05365425|DRUG|Policosanol|policosanol 10mg
218931959|NCT06331143|DEVICE|Ultrasound-Guided Mid-Transverse Process to Pleura (MTP) Block|Patients will receive MTP block after induction of anesthesia.
218931960|NCT06331143|DRUG|Morphine|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
218931961|NCT01010646|DRUG|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
218931962|NCT01010646|DRUG|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
218931963|NCT01010646|DRUG|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
219044768|NCT06956339|OTHER|Novel bracing protocol|"Participants will undertake the Cross Bracing Protocol under the supervision of a study physiotherapist (23 funded physiotherapy sessions within 12 months). Medical oversight and venous thromboembolism prophylaxis will be provided by the study sports and exercise medicine physician.~A specialised knee brace will be fitted within 21 days of ACL injury. The knee is kept at 90° flexion in the brace at all times for the first four weeks. The brace is then adjusted weekly by the physiotherapist to allow progressive increases in knee range (60-90° flexion at 5 weeks, 45-90° flexion at 6 weeks, 30° to full flexion at 7 weeks, 20° to full flexion at 8 weeks, 10° to full flexion at 9 weeks, unrestricted range at 10 weeks, brace off at 12 weeks). Whilst braced and after brace removal, the participant will undertake physiotherapist-supervised goal-oriented exercise-based rehabilitation within the available knee range."
219044769|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
219542076|NCT03125473|BIOLOGICAL|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
219542077|NCT00311974|DRUG|Dihydralazine|
219542078|NCT00974740|DRUG|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
219542079|NCT00974740|DRUG|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
219542080|NCT05230563|DEVICE|Ti-LUNG|"Participating clinicians will perform two image interpretations on all cases. One period the clinicians only will perform lung nodule detection on chest CT images, and the other period will perform lung nodule detection on chest CT images with the aid of Taihao lung CT decision support system. In each interpretation, all lung nodule is marked by each radiologist. This test collects chest computerized tomography cases for computer analysis, and evaluates whether the TaiHao lung CT decision support system helps doctors make more accurate diagnoses."
219542081|NCT04777734|BIOLOGICAL|efgartigimod|an intravenous infusion of efgartigimod
219542082|NCT04941586|OTHER|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
219542083|NCT04941586|OTHER|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
219542084|NCT02682238|DRUG|BBI-4000, 15%|
218931964|NCT03239106|DRUG|Apremilast|Apremilast 30 mg BID daily
219542085|NCT02682238|OTHER|Vehicle gel|
218931965|NCT00402402|PROCEDURE|Tuberculin skin test|
218931966|NCT00402402|PROCEDURE|Quantiferon-TB Gold assay|
218931967|NCT06217484|BEHAVIORAL|delayed feedback|participants learn through either immediate or delayed feedback during a computer task
219044770|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
219044771|NCT06465329|DRUG|REGN7075|IV infusion
219542086|NCT02909907|DRUG|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
219542087|NCT02909907|OTHER|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
219542088|NCT00075478|PROCEDURE|Total-Body Irradiation|Undergo TBI
219542089|NCT00075478|DRUG|Fludarabine Phosphate|Given IV
219542090|NCT00075478|DRUG|Mycophenolate Mofetil|Given PO
219542091|NCT00075478|DRUG|Cyclosporine|Given PO
218931968|NCT04591808|DRUG|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
219542092|NCT00075478|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
219542093|NCT03270462|DRUG|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
219542094|NCT02700776|OTHER|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
219542095|NCT02700776|PROCEDURE|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
219542096|NCT03158467|OTHER|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
219542097|NCT02075463|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
218931969|NCT04591808|DRUG|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
218931970|NCT04591808|DRUG|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
218931971|NCT00981110|DEVICE|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
218931972|NCT00981110|DEVICE|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
218931973|NCT05481086|OTHER|No Interventions|There is no interventions in this study
218931974|NCT06405191|BEHAVIORAL|Web based education|The link to the web page was shared with the students in the experimental group (https://inonuhemsirelikesaslari.com, the expired page cannot be accessed at the moment). Theoretical training and application process steps video for IV catheterization and IM injection skills were taken to the students in the experimental group and uploaded to the web page. The students in the experimental group were given a username-password with which they could access the web page, and the access status of the students was followed by the researcher. The researcher was able to see the frequency of each student watching the videos and their scores in online tests. The student who did not watch the videos or did not take the test was interviewed and feedback was given about watching them. Students were able to access the web page as often as they wanted for two weeks.
219542098|NCT02075463|DRUG|Placebo|Matching placebo tablet for GSK1278863
218931975|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
218931976|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
218931977|NCT00107913|DRUG|Doxil|
218931978|NCT02149043|DEVICE|Thermography|Thermographic imaging of the patient's abdomen surface
218931979|NCT02149043|PROCEDURE|Colonoscopy|Endoscopic examination of the colon
219542099|NCT00804180|BEHAVIORAL|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
219621324|NCT04689191|BIOLOGICAL|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
218931980|NCT01004991|BIOLOGICAL|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
218931981|NCT01004991|DRUG|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
218931982|NCT01004991|DRUG|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
218931983|NCT01004991|DRUG|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
218931984|NCT01004991|DRUG|prednisone|100 mg PO days 8-12 of each of 6 cycles
219044772|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 100 million|LSCs grown from autologous trans-bronchial biopsy specimens
219044773|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 200 million|LSCs grown from autologous trans-bronchial biopsy specimens
219044774|NCT04386967|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
219044775|NCT04386967|DRUG|Keytruda|Anti-PD-1 antibody
219621325|NCT04689191|BIOLOGICAL|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
219621326|NCT01239810|DRUG|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
219621327|NCT05736757|DRUG|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
218931985|NCT01004991|DRUG|azacytidine|Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
218931986|NCT05847946|OTHER|Kinesio tape application and Core stabilization home program|Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.
218931987|NCT05847946|OTHER|Core stabilization home program|Core stabilization exercises will be given to the participants as a home exercise program.
219044776|NCT03968744|DRUG|Safinamide|Safinamide taken per Os for 12 weeks
219044777|NCT05427500|DRUG|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
219044778|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
218931988|NCT02904278|OTHER|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
218931989|NCT02904278|OTHER|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
218931990|NCT03537521|PROCEDURE|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
218931991|NCT01740648|DRUG|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
218931992|NCT01740648|DRUG|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
218931993|NCT01740648|RADIATION|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
218931994|NCT04677088|BIOLOGICAL|TCR-T cells|Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
218931995|NCT03780166|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
218931996|NCT01872416|DEVICE|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
218931997|NCT01804400|DRUG|QAW039|
218931998|NCT01804400|DRUG|Montelukast|
219621328|NCT06370637|OTHER|Barrier Cream|Patients in the control arm will be treated with a 15% zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
219621329|NCT06370637|OTHER|Dermategrity Everyday Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
219621330|NCT02646995|DIETARY_SUPPLEMENT|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
219621331|NCT02646995|DIETARY_SUPPLEMENT|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
219621332|NCT03444181|BEHAVIORAL|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
219621333|NCT03444181|BEHAVIORAL|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
219621334|NCT03558802|OTHER|questionnaire|questionnaire
219621335|NCT01820143|DRUG|Ilaprazole|
219621336|NCT01820143|DRUG|Esomeprazole|
219621337|NCT02445248|BIOLOGICAL|Tisagenlecleucel|The target dose of CTL019 transduced cells for adult patients consisted of a single infusion of 5 x 10\^8 viable CTL019 transduced cells, which was administered via intravenous infusion. The acceptable dose range was 1 - 5x10\^8 viable CTL019 transduced cells.
219621338|NCT02445248|DRUG|Lymphodepleting chemotherapy|Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle was planned. The use of any additional bridging therapy prior to the recommended lymphodepleting chemotherapy was at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy was started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The lymphodepleting regimen was: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) and cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).
219621339|NCT01554670|PROCEDURE|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
219621340|NCT01563042|DRUG|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
219621341|NCT01563042|DRUG|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
219621342|NCT04320225|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
219621343|NCT04968535|DEVICE|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
218931999|NCT01804400|DRUG|Placebo|
219205404|NCT06878573|DEVICE|Laser speckle flowgraphy|"The RetFlow consists of a fundus camera equipped with a diode laser at a wavelength of 830 nm and a digital charge-coupled device camera (750 x 360 pixels). A total of 118 images are acquired at a rate of 30 frames per second over a 4-second measurement period. The main output parameter of LSFG, mean blur rate (MBR), is calculated from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. MBR was calculated for the total ONH area, defined by a ellipsoid region of interest (ROI). By using the on-board software, the MBR will be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) and the tissue area containing the microvasculature (ONH-MT, mean MBR of tissue area)"
219205405|NCT06879275|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|2 self administered questionnaire for diagnosis of dismorphophobia will be administered
219205406|NCT06738472|OTHER|home based exercises|given exercises to the participants
219205407|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
219205408|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
219205409|NCT06190600|OTHER|High Intensity Interval Training (HIIT)|HIIT training twice a week throughout the chemotherapy: treadmill, elliptical, stationary bicycle and indoor rower. The intensity of physical activity will be increasing during consecutive mesocycles. Each training session will begin with a 10-min. wole-body warm-up session at 50-60% hear rate (HR) max. Mesocycle 1 - one month with 4 sets of 1 min. 45 sec. of exercise at a maximal intensity of 75% HR max. Mesocycle 2 with exercises at 80% to 90% HR max divided into 3 periods: 1/ one month, session of 5 sets 1 min. 30 sec. each; 2/ two months, sessions of 5 sets 1 min. 45 sec. each; 3/ two months, sessions of 5 sets 2 min. each. Moreover patients will be instructed to individually perform- a 45-min. aerobic training session (e.g.: walking, jogging, roller skating, swimming) once a week, in patient's own time.
219542100|NCT03324594|DEVICE|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"1. WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~2. WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~3. The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
218932000|NCT01809340|DRUG|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
219542101|NCT00462228|DRUG|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
219621344|NCT02596971|DRUG|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
219621345|NCT02596971|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
219621346|NCT02596971|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
219621347|NCT02596971|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
219205410|NCT06190600|DRUG|neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)|Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
219205411|NCT06190600|OTHER|Standard Supportive Care|Patients will be asked to perform 150-300 min. of moderate-intensity aerobic activity or 75-150 min. of vigorous aerobic activity. Each participant will be monitored by an activity watch worn at all times by the patient.
219621348|NCT02596971|DRUG|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
218932001|NCT01809340|DRUG|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
218932002|NCT01809340|DRUG|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
218932003|NCT02331888|DEVICE|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
218932004|NCT00714870|BEHAVIORAL|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
218932005|NCT05474157|OTHER|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
219542102|NCT00462228|DRUG|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
218932006|NCT01591525|BEHAVIORAL|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
218932007|NCT01591525|BEHAVIORAL|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
218932008|NCT01591525|BEHAVIORAL|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
218932009|NCT04379895|DEVICE|Radiofrequency ablation|Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
218932010|NCT01463449|PROCEDURE|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
219044779|NCT04644224|OTHER|Educational Activity|Attend health coaching session
219044780|NCT04644224|OTHER|Educational Intervention|Attend resource navigation session
219044781|NCT04644224|OTHER|Informational Intervention|Receive handbook
219044782|NCT04644224|OTHER|Questionnaire Administration|Ancillary studies
219044783|NCT04644224|PROCEDURE|Support Group Therapy|Attend support group
219044784|NCT03348761|DEVICE|rTMS group|
219044785|NCT06029322|PROCEDURE|Socket seal after alveolar ridge preservation|Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
219044786|NCT04482179|DEVICE|Active TMS|Active TMS will be delivered at 100% motor threshold
219044787|NCT04482179|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
219044788|NCT04482179|DEVICE|Sham TMS|Sham TMS will be administered
219044789|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
219044790|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
219044791|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
219044792|NCT06032780|OTHER|Eccentric Resistive Training + Aerobic training Group|"Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
219044793|NCT06032780|OTHER|Resistance Training + Aerobic training Group|"Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
219205412|NCT05897047|COMBINATION_PRODUCT|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
219542103|NCT00466401|DRUG|Simvastatin|
219542104|NCT00466401|DRUG|Ezetimibe|
219542105|NCT05235386|DEVICE|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
219205413|NCT05968703|DEVICE|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
218932011|NCT00389259|DRUG|Placebo|IV placebo q4h
218932012|NCT04563949|OTHER|Repeat Testing|Repeat Testing with the PLA will be conducted
218932013|NCT03895749|DIETARY_SUPPLEMENT|NEO40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
218932014|NCT03399552|DRUG|Avelumab|10mg/kg delivered by IV infusion
218932015|NCT03399552|RADIATION|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
218932016|NCT00544297|DRUG|PEP005 gel|Two day application, 0.05%
219044794|NCT06032780|OTHER|Aerobic training Group|Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
219205414|NCT06480994|DIAGNOSTIC_TEST|Routine Assays on fresh plasma|"Routine coagulation tests using STA-R Max analyzer :~Prothrombin Time (PT) activated Partial Thromboplastin Time (aPTT Thrombin Time (TT) Fibrinogen Anti-Xa activity"
219542106|NCT01383486|DRUG|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
219542107|NCT01383486|DRUG|Advil|Commercially available Advil; oral caplet upon incidence of pain
219542108|NCT06197009|DRUG|SCT650C|Administered SC
219542109|NCT02437747|DRUG|SRP + Aloe|Scaling and root planing along with aloe vera application was done
219542110|NCT02437747|PROCEDURE|SRP|Scaling and root planing was done
219542111|NCT03726892|DEVICE|PCI|Coronary Intervention
219621349|NCT02596971|DRUG|Prednisone|Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
219621350|NCT02596971|DRUG|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
219542112|NCT03498794|PROCEDURE|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
219621351|NCT02596971|DRUG|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.
219621352|NCT02779920|PROCEDURE|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
219542113|NCT04643067|DRUG|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
219542114|NCT04643067|DRUG|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
219621353|NCT01899482|OTHER|Manual Lymphatic Drainage|
218932017|NCT01696539|BEHAVIORAL|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
218932018|NCT01696539|OTHER|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
218932019|NCT00493129|DRUG|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
218932020|NCT04691076|DRUG|Propofol|Propofol is administered by target-controlled infusion
218932021|NCT04691076|DRUG|Esketamine|Esketamine is intravenously administrated
218932022|NCT04691076|DRUG|Fentanyl|Fentanyl is intravenously administrated
218932023|NCT03918564|DEVICE|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
218932024|NCT00783107|DRUG|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
218932025|NCT00783107|DRUG|Placebo|
218932026|NCT02357368|DRUG|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
218932027|NCT02357368|DEVICE|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
218932028|NCT02357368|DEVICE|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
219044795|NCT06268613|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
219044796|NCT06268613|DRUG|EU sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
219542115|NCT04643067|DRUG|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
219542116|NCT04643067|DRUG|Placebo|This is the comparative arm.
218932029|NCT02357368|DEVICE|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
218932030|NCT01573689|BEHAVIORAL|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
218932031|NCT00194428|BEHAVIORAL|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
218932032|NCT00194428|BEHAVIORAL|Low fat caloric diet|Low fat caloric diet
218932033|NCT03626909|OTHER|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
218932034|NCT03626909|OTHER|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
218932035|NCT03626909|OTHER|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
218932036|NCT03626909|OTHER|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
218932037|NCT01162642|DIETARY_SUPPLEMENT|Green Tea|Green Tea 4 cups daily
218932038|NCT01162642|OTHER|Placebo|4 cups placebo tea for 6 weeks
218932039|NCT00002496|DRUG|chemotherapy|
218932040|NCT00002496|DRUG|cisplatin|
218932041|NCT00002496|DRUG|fluorouracil|
218932042|NCT00002496|PROCEDURE|conventional surgery|
218932043|NCT00002496|RADIATION|low-LET cobalt-60 gamma ray therapy|
218932044|NCT00002496|RADIATION|low-LET electron therapy|
218932045|NCT00002496|RADIATION|low-LET photon therapy|
218932046|NCT02894684|DRUG|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
218932047|NCT02894684|DRUG|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
219621354|NCT01899482|BEHAVIORAL|Education|Behavioral education.
219621355|NCT00595920|BIOLOGICAL|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
218932048|NCT04082793|COMBINATION_PRODUCT|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
218932049|NCT04082793|COMBINATION_PRODUCT|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
218932050|NCT05370677|GENETIC|ARMS|amplification refractory mutation system
219044797|NCT06268613|DRUG|US sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
219044798|NCT00004238|DRUG|pralatrexate|
219542117|NCT05137821|DEVICE|Er: YSGG laser|Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
219542118|NCT05137821|OTHER|no therapy|new sealed implant without any surface treatment
219542119|NCT01042665|DRUG|latanoprost 0.005%|Active comparator
219542120|NCT01042665|DRUG|Placebo|Placebo comparator
219542121|NCT00651131|DRUG|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
219542122|NCT04028180|OTHER|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
219621356|NCT00351468|DRUG|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
219621357|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
219542123|NCT04028180|OTHER|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
219542124|NCT01398163|OTHER|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
219542125|NCT01398163|OTHER|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
219542126|NCT04034290|BIOLOGICAL|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
219542127|NCT04034290|OTHER|Placebo|Placebo
218932051|NCT02682043|DEVICE|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
218932052|NCT05935670|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
218932053|NCT04843462|DEVICE|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time."
218932054|NCT04843462|DRUG|Esketamine nasal spray|All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
218932055|NCT03831750|OTHER|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
218932056|NCT02639221|DRUG|PXT002331|
218932057|NCT02172885|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
218932058|NCT02377817|DEVICE|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
218932059|NCT02377817|DEVICE|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
218932060|NCT01734616|BEHAVIORAL|Old Exercise|
218932061|NCT01734616|DIETARY_SUPPLEMENT|Old Acute Cocoa|
218932062|NCT01734616|DIETARY_SUPPLEMENT|Old 7 Day Cocoa|
219542128|NCT00498654|BIOLOGICAL|Ty800 (Salmonella typhi) Oral Vaccine|
219542129|NCT04364126|DEVICE|Home blood pressure apparatus|Target \<125/80 mmHg
219542130|NCT04364126|OTHER|Clinic blood pressure|Target \<130/80 mmHg
219542131|NCT03437265|DRUG|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
219542132|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
219542133|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
219542134|NCT03113708|DRUG|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
219542135|NCT01160666|DRUG|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
219542136|NCT04435847|BIOLOGICAL|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
219542137|NCT04435847|OTHER|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
219542138|NCT05462327|PROCEDURE|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
219542139|NCT05462327|PROCEDURE|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
219542140|NCT03302780|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
219542141|NCT03302780|DEVICE|tDCS active|tDCS will be applied for 20 minutes.
219542142|NCT03302780|DEVICE|tDCS sham|
218932063|NCT05169008|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular injection
218932064|NCT05169008|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
218932065|NCT03895840|DRUG|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
218932066|NCT05552989|OTHER|this is a non-interventional study|this is a non-interventional study
218932067|NCT05342714|DEVICE|Remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
218932068|NCT01931566|DRUG|Pioglitazone|Pioglitazone SR tablets
218932069|NCT01931566|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets
218932070|NCT03382353|DIETARY_SUPPLEMENT|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
218932071|NCT03382353|BEHAVIORAL|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
218932072|NCT03382353|BEHAVIORAL|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
219044799|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
219044800|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
219044801|NCT03323489|RADIATION|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
219542143|NCT04131621|BIOLOGICAL|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
219542144|NCT03517085|GENETIC|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
219542145|NCT03517085|DRUG|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
219542146|NCT00137254|DRUG|Insulin|IV insulin
219542147|NCT00137254|DRUG|Stable Isotopes|IV administration of stable isotopes
219542148|NCT00137254|DRUG|Indocyanine Green|IV administration of ICG
219542149|NCT04306783|OTHER|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
219542150|NCT05148273|BEHAVIORAL|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
219542151|NCT00840476|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
219542152|NCT00840476|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
218932073|NCT03382353|BEHAVIORAL|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
218932074|NCT03382353|BEHAVIORAL|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
218932075|NCT04569487|PROCEDURE|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
218932076|NCT02622178|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
219044802|NCT00152217|DRUG|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
219044803|NCT00152217|PROCEDURE|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
219542153|NCT05580692|PROCEDURE|Biospecimen Collection|Biospecimen Sample Collection
219542154|NCT06210984|DRUG|Low caffeine dose|2 mg/kg dose of caffeine in pill form
219542155|NCT06210984|DRUG|Moderate caffeine dose|5 mg/kg dose of caffeine in pill form
219542156|NCT06210984|DRUG|Placebo|5 mg/kg dose of maltodextrin in pill form
219542157|NCT03192163|OTHER|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
219542158|NCT01220635|BEHAVIORAL|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
219542159|NCT01220635|BEHAVIORAL|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
219542160|NCT01714895|OTHER|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
218932077|NCT02622178|DIAGNOSTIC_TEST|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
218932078|NCT03306316|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic experimental group
218932079|NCT03306316|DIETARY_SUPPLEMENT|Dextrose Control|Dextrose Control
218932080|NCT00659789|DRUG|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
218932081|NCT00659789|DRUG|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
218932082|NCT06416384|OTHER|Hand Massage Group|The patients in the hand massage application group were asked by the researcher; Hand massage with olive oil was applied 12 times in total, three times a week for four weeks. No application was made to the side with fistula.
218932083|NCT06416384|OTHER|Control Group|Patients in the control group received routine nursing care in the clinic for four weeks.
218932084|NCT01290770|OTHER|blood sample|blood sample at inclusion and 1 month after inclusion
218932085|NCT03348059|DRUG|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
218932086|NCT00760617|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
218932087|NCT00760617|BIOLOGICAL|Fluarix|Intramuscular (IM) administration, 1 dose
218932088|NCT01764906|DEVICE|Novosis|
218932089|NCT01764906|PROCEDURE|Iliac crest bone graft|
218932090|NCT00002630|BIOLOGICAL|filgrastim|
218932091|NCT00002630|DRUG|cyclophosphamide|
218932092|NCT00002630|DRUG|melphalan|
218932093|NCT00002630|PROCEDURE|peripheral blood stem cell transplantation|
218932094|NCT00002630|RADIATION|low-LET cobalt-60 gamma ray therapy|
218932095|NCT00002630|RADIATION|low-LET photon therapy|
218932096|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
218932097|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
219542161|NCT01714895|OTHER|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
218932098|NCT02421835|DIETARY_SUPPLEMENT|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
218932099|NCT02421835|DIETARY_SUPPLEMENT|Placebo|700 mg Maltodextrin per day
219542162|NCT03664063|DRUG|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
219542163|NCT03664063|DRUG|Albendazole|"Single dose of Albendazole weight based dosing~\- 400mg"
219542164|NCT03664063|DRUG|Ivermectin|Ivermectin weight based dosing - max 21mg
218932100|NCT00662441|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
218932101|NCT01032252|OTHER|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
218932102|NCT01147874|PROCEDURE|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
218932103|NCT02109497|DRUG|PBT2|PBT2 250 mg administered
219044804|NCT06021067|BIOLOGICAL|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
219542165|NCT03664063|DRUG|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
219542166|NCT00848536|DRUG|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
218932104|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
218932105|NCT04625101|DRUG|Placebo|Non-active dosage form.
218932106|NCT00082797|DRUG|leucovorin calcium|
218932107|NCT00082797|DRUG|methotrexate|
218932108|NCT01436435|DEVICE|Jetstream Atherectomy System|Atherectomy
218932109|NCT04150861|DRUG|Follitropin Delta|Solution for Injection, subcutaneous administration
219542167|NCT00848536|DRUG|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
218932110|NCT02360878|DEVICE|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
218932111|NCT01206725|OTHER|Exercise|"1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
218932112|NCT00000288|DRUG|Cotinine fumarate|
218932113|NCT01149018|DRUG|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
218932114|NCT01149018|DRUG|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
218932115|NCT03197896|OTHER|Educational Intervention|Review prostate cancer information
218932116|NCT00251732|DRUG|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
218932117|NCT00251732|DRUG|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
219542168|NCT02748707|DRUG|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
218932118|NCT00251732|DRUG|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
218932119|NCT06400043|OTHER|Cognitive dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.
218932120|NCT06400043|OTHER|Motor dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
219621358|NCT03088072|DRUG|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl \>50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow \<5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
218932121|NCT01879098|DIETARY_SUPPLEMENT|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
218932122|NCT01879098|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
219542169|NCT02748707|DRUG|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
219542170|NCT02748707|DRUG|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
219542171|NCT02748707|OTHER|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
219621359|NCT03088072|DEVICE|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
219621360|NCT03088072|DRUG|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
218932123|NCT01879098|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
218932124|NCT01879098|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
218932125|NCT00434785|DRUG|AGG-523|
218932126|NCT00467753|DRUG|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
218932127|NCT00467753|OTHER|Placebo/sugar pill|Dosage similar to active drug
219044805|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
219044806|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
219044807|NCT05418452|DRUG|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
219044808|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
219044809|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
219044810|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
219044811|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
218932128|NCT04798404|OTHER|Multimodal exercise intervention|The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
218932129|NCT02175030|DRUG|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
218932130|NCT02175030|DRUG|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
219044812|NCT00004091|OTHER|Papanicolaou test|
218932131|NCT05255315|BEHAVIORAL|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
218932132|NCT01637441|PROCEDURE|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
218932133|NCT01637441|PROCEDURE|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
218932134|NCT01521403|DRUG|Metronidazole|3x500 mg/day for 10 days
218932135|NCT01521403|DRUG|Placebo|3x1 tablet per day for 10 days
218932136|NCT03734913|DRUG|ZSP1602|ZSP1602 capsules for oral administration
219542172|NCT01131637|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
219542173|NCT01131637|DRUG|placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
219542174|NCT01009229|DIETARY_SUPPLEMENT|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
219542175|NCT00151593|OTHER|Celsior®|Graft preservation solution
219542176|NCT00489177|DEVICE|A|QuickOpt intra-cardiac electrogram optimization
219542177|NCT00489177|DEVICE|B|Single optimization in initial month post-implant
219542178|NCT03036748|DIETARY_SUPPLEMENT|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
219542179|NCT03036748|DRUG|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
218932137|NCT02440841|DRUG|fedovapagon|
218932138|NCT02440841|DRUG|Itraconazole|
218932139|NCT02440841|DRUG|rifampicin|
219044813|NCT00004091|OTHER|cytology specimen collection procedure|
219044814|NCT00004091|OTHER|fluorescent antibody technique|
219044815|NCT00004091|PROCEDURE|colposcopic biopsy|
219044816|NCT00004091|PROCEDURE|study of high risk factors|
219044817|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
219044818|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
219044819|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
219044820|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
219044821|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
219044822|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
219044823|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
219044824|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
219044825|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
219044826|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
219044827|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
219044828|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
219044829|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
219044830|NCT06066151|DIETARY_SUPPLEMENT|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
219205415|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on fresh plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
219542180|NCT05896995|OTHER|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
219542181|NCT05896995|OTHER|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
219542182|NCT05882630|DRUG|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
219542183|NCT05887427|OTHER|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
219542184|NCT05887427|OTHER|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
219542185|NCT03432182|DIAGNOSTIC_TEST|electroencephalography|Sleep states definition by electroencephalograpy
219542186|NCT01293591|OTHER|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
219621361|NCT03088072|DRUG|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
218932140|NCT05442476|OTHER|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
218932141|NCT05442476|OTHER|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
218932142|NCT05442476|OTHER|conventional physiotherapy|conventional physiotherapy
219621362|NCT00508014|OTHER|Usual Care|Usual Care with primary care provider during time period
218932143|NCT04235621|OTHER|FSGS/TR-MCD|This is a non-interventional study
218932144|NCT04235621|OTHER|Diabetic Nephropathy (DN)|This is a non-interventional study
218932145|NCT01072643|DRUG|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
218932146|NCT05136014|OTHER|Collection of surgical waste|collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed
218932147|NCT01075542|DEVICE|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
218932148|NCT01075542|DEVICE|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
218932149|NCT02817464|DRUG|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
219542187|NCT01293591|OTHER|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
219621363|NCT00508014|BEHAVIORAL|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
219542188|NCT03987191|DRUG|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219542189|NCT06562231|OTHER|quality of life scale|This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
219542190|NCT01065740|OTHER|Patient education|
219542191|NCT01148186|BEHAVIORAL|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
219542192|NCT03261167|DRUG|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
219542193|NCT03261167|DRUG|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
219542194|NCT05464563|DEVICE|Electroencephalogram|An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
219621364|NCT04457908|DIAGNOSTIC_TEST|intelligent assessment|intelligent neurological function assessment
219621365|NCT00611923|DRUG|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
218932150|NCT02817464|DRUG|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
218932151|NCT00885534|DRUG|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
218932152|NCT00540085|DRUG|Rocuronium|0.6 mg/kg given intravenously before intubation
218932153|NCT04919798|DEVICE|Non-invasive bladder emptying device|The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
218932154|NCT00507143|DRUG|irinotecan|
218932155|NCT02453711|DRUG|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
218932156|NCT02453711|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
218932157|NCT02453711|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
218932158|NCT00343096|DRUG|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
219542195|NCT01425086|DEVICE|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
219542196|NCT06446479|DRUG|Dronabinol Pill|Dronabinol 20 mg
219542197|NCT06446479|DRUG|Placebo|placebo
219542198|NCT05086003|COMBINATION_PRODUCT|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
218932159|NCT05940090|DEVICE|SkinIO|The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
218932160|NCT01867177|OTHER|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
218932161|NCT01867177|OTHER|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
218932162|NCT01867177|BEHAVIORAL|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
218932163|NCT01033799|OTHER|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
218932164|NCT01033799|OTHER|Non fermented dairy product (control)|
219044831|NCT05366660|OTHER|Interrogation/programming|As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
219044832|NCT05339932|OTHER|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
219044833|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
219044834|NCT03924492|DRUG|ZULRESSO (brexanolone) injection|ZULRESSO
219044835|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
219044836|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
219044837|NCT03739775|PROCEDURE|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
219044838|NCT06631287|DRUG|Baricitinib|4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
219044839|NCT06631287|OTHER|Placebo|Matched placebo capsule, PO once daily for 24 weeks.
219044840|NCT04706013|DRUG|Pyridoxal Phosphate|Oral tablets 50 mg
219044841|NCT06106373|DEVICE|iotaSOFT Insertion System|robotic assistive technology for cochlear implant electrode insertion
219044842|NCT06442462|DRUG|SPG302|small synthetic molecule
219044843|NCT06442462|DRUG|Placebo|Placebo
219044844|NCT04988295|DRUG|Lazertinib|Lazertinib will be administered orally.
219044845|NCT04988295|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion.
219044846|NCT04988295|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion.
219044847|NCT04988295|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
219542199|NCT01198964|PROCEDURE|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
219542200|NCT04763733|OTHER|laparoscopic splenectomy|surgical
219542201|NCT03037554|DEVICE|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
219542202|NCT03037554|DEVICE|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
219542203|NCT01572662|DRUG|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
219044848|NCT05013554|DRUG|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
219044849|NCT05013554|DRUG|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
219542204|NCT01572662|DRUG|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
219542205|NCT01572662|PROCEDURE|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
219542206|NCT01572662|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
219542207|NCT01572662|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
219542208|NCT01572662|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
218932165|NCT04071288|PROCEDURE|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
218932166|NCT03008369|OTHER|Laboratory Biomarker Analysis|Correlative studies
218932167|NCT03008369|DRUG|Lenvatinib|Given PO
218932168|NCT03008369|OTHER|Quality-of-Life Assessment|Ancillary studies
218932169|NCT02774629|OTHER|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
219542209|NCT03364192|BEHAVIORAL|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
219542210|NCT03563274|DEVICE|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
219542211|NCT04266340|DRUG|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
219542212|NCT04266340|DRUG|midazolam|0.5mg/kg oral midazolam
219542213|NCT04266340|DRUG|midazolam|0.05mg/kg intravenous injection midazolam
219542214|NCT04266340|DRUG|Saline|no premedication
219542215|NCT01065857|DRUG|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
219542216|NCT01065857|DRUG|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
219542217|NCT02919540|OTHER|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
219542218|NCT04450069|COMBINATION_PRODUCT|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
219542219|NCT05984303|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
219542220|NCT02939703|OTHER|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
219542221|NCT06361407|BEHAVIORAL|Illusion task|The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
219542222|NCT01093833|DEVICE|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
219542223|NCT01093833|DEVICE|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
219542224|NCT01093833|DEVICE|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
219542225|NCT05105607|DRUG|D-4517.2|Subcutaneous (SC) injection
218932170|NCT06462599|GENETIC|Gene polymorphism from blood samples|"Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation"
218932171|NCT03873142|BEHAVIORAL|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
218932172|NCT01578876|DEVICE|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
218932173|NCT02964091|DRUG|sofosbuvir/ledipasvir|
218932174|NCT00089869|DRUG|olanzapine|
219205416|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on frozen plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
218932175|NCT00089869|DRUG|atomoxetine|
218932176|NCT00089869|DRUG|placebo|
218932177|NCT01292629|DEVICE|iSert 251 intraocular lens|aphakic intraocular lens
219542226|NCT06626893|BIOLOGICAL|Functional tests|Functional analyses will be performed on primary sample from each enrolled patient. Isolated blast cells are cultered and incubated with a specific library of drugs (175 drugs) at four different concentrations for 72 hours.
219542227|NCT06626893|GENETIC|Next Generation Sequencing analysis|For each patient, sequencing analyses will be performed on blast cells (for somatic mutations) and on epithelial cells from buccal swab (for germline mutations)
219542228|NCT06626893|BIOLOGICAL|Microvesicles analysis|Analyses on microvesicles isolated from both Bone Marrow samples and Peripheral Blood Samples will be performed to investigate the microenvironment of the disease.
219542229|NCT04499677|DRUG|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
219542230|NCT04499677|DRUG|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
219542231|NCT04499677|OTHER|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
219542232|NCT04499677|OTHER|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
219542233|NCT03094598|OTHER|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
218932178|NCT03172416|DRUG|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
219044850|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
219044852|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
219044853|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
219542234|NCT03094598|OTHER|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
219542235|NCT03094598|OTHER|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
219542236|NCT00918645|DRUG|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
219542237|NCT01747668|DIETARY_SUPPLEMENT|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
219542238|NCT01747668|DIETARY_SUPPLEMENT|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
218932179|NCT03172416|DRUG|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
219044854|NCT04934306|OTHER|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
219044855|NCT03328273|DRUG|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
219044856|NCT03328273|DRUG|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
219044857|NCT04083976|DRUG|Erdafitinib|Participants will receive erdafitinib oral tablets.
219044858|NCT06332404|DEVICE|Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)|Hypoglossal nerve stimulation therapy
219044859|NCT05359211|DRUG|Cyclophosphamide|Given IV
219044860|NCT05359211|DRUG|Fludarabine|Given IV
219044861|NCT05359211|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219044862|NCT05359211|DRUG|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Given IV
219044863|NCT05359211|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219044864|NCT05359211|PROCEDURE|Echocardiography|Undergo ECHO
219044865|NCT05359211|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219044866|NCT05359211|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219044867|NCT05359211|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219044868|NCT05359211|PROCEDURE|Lumbar Puncture|Undergo LP
219044869|NCT05359211|PROCEDURE|Computed Tomography|Undergo PET/CT
219044870|NCT05359211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218932180|NCT04241562|OTHER|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
219044871|NCT05359211|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219044872|NCT05359211|PROCEDURE|Biopsy|Undergo tissue biopsy
219044873|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
219044874|NCT05027139|DRUG|Evorpacept|Administered IV
218932181|NCT03863769|OTHER|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
218932182|NCT02064777|DRUG|Tacrolimus|
219044875|NCT05448846|PROCEDURE|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
219205417|NCT05443555|DRUG|Gabapentin|Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
219205418|NCT05443555|DRUG|Placebo|Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
219205419|NCT05038150|DRUG|SGN1|The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
219542239|NCT05752552|DRUG|DO-2|Deuterated MET kinase inhibitor
218932183|NCT00704236|DRUG|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
218932184|NCT00704236|DRUG|Placebo|
218932185|NCT01579136|BEHAVIORAL|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
218932186|NCT03229980|DRUG|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
218932187|NCT03229980|DRUG|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
219542240|NCT06560827|BIOLOGICAL|CT011 CAR-GPC3 T Cells Injection|The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
219542241|NCT00729976|DRUG|Ibuprofen suppository|5-10mg/Kg of ibuprofen
219542242|NCT00729976|DRUG|Ibuprofen Suspension|5-10mg/Kg
218932188|NCT04292899|DRUG|Remdesivir|Administered as an intravenous infusion
219542243|NCT04479527|DRUG|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
219542244|NCT06491420|OTHER|fixation with arthroscopy|the pipkin fracture is fixed with the help of arthroscopy and percutaneous methods.
219621366|NCT00611923|DRUG|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
219621367|NCT04740710|BEHAVIORAL|Breathing and Attention Training|A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
218932189|NCT04292899|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
218932190|NCT03016052|BEHAVIORAL|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
218932191|NCT01578369|OTHER|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
218932192|NCT01947140|DRUG|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
218932193|NCT01947140|DRUG|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
219205420|NCT04224246|DRUG|Gamma Hydroxybutyrate|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
219205421|NCT06281795|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 8 weeks.
219542245|NCT02742194|DIETARY_SUPPLEMENT|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
219542246|NCT02742194|DIETARY_SUPPLEMENT|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
218932194|NCT05053802|COMBINATION_PRODUCT|Microwave ablation plus Camrelizumab|Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
218932195|NCT05053802|DEVICE|Microwave ablation|Tumor received treatment of microwave ablation
218932196|NCT00992797|DRUG|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.
218932197|NCT00992797|OTHER|Orange juice|Orange juice at randomization day and at week 5.
218932198|NCT03695367|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
218932199|NCT03695367|DEVICE|Luer lock applicator|Applicator for instillation.
218932200|NCT03695367|DEVICE|Vial access device|Device for withdrawal of drug product.
218932201|NCT03695367|DRUG|Ibuprofen|Ibuprofen, 600 mg.
218932202|NCT03695367|DRUG|Acetaminophen|Acetaminophen, 1 g.
218932203|NCT03695367|DRUG|Ketorolac|Intraoperative IV ketorolac.
218932204|NCT00559819|DRUG|placebo|Placebo (orange juice), same volume as alcohol
218932205|NCT00559819|DRUG|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
218932206|NCT00536419|DRUG|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
218932207|NCT00536419|OTHER|Placebo|Placebo, daily dose, 4 days, oral administration
219542247|NCT00001991|DRUG|Atovaquone|
219542248|NCT04366544|OTHER|Part A1: Survey|Online
219621368|NCT03588910|DRUG|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
219621369|NCT03588910|DRUG|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
218932208|NCT01678495|OTHER|Sulfur hexafluoride + ultrasounds|
218932209|NCT01678495|DRUG|Recombinant tissue plasminogen activator|
218932210|NCT05574413|OTHER|Moderate intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
218932211|NCT05574413|OTHER|High intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
218932212|NCT05574413|OTHER|High intensity interval exercise|Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
218932213|NCT05574413|OTHER|Resting (no exercise) control|Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.
218932214|NCT02189733|BIOLOGICAL|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
218932215|NCT05824195|OTHER|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
218932216|NCT02984605|DIETARY_SUPPLEMENT|nutritional meal replacement|1 times a day with bags of nutritional meal replacement + individualized exercise prescription
218932217|NCT03204864|DEVICE|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
218932218|NCT03204864|DEVICE|Conventional CS lead placement|Clinical Practice
218932219|NCT01707199|DRUG|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
218932220|NCT03990727|DIAGNOSTIC_TEST|Retina Analysis-mosaic|Fundus retina pattern study
219542249|NCT04366544|OTHER|Part A2: Sample collection|Blood and Stool
219542250|NCT04366544|OTHER|Part B:|EEG and fMRI
219542251|NCT05133180|DRUG|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
219542252|NCT05133180|OTHER|Vehicle|Vehicle will be instilled with the same scheme of the test product
219044876|NCT05448846|BEHAVIORAL|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~* Chair sit to stand exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~* Seated curl to press exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~* Monopodal balance \| 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
219542253|NCT03446768|OTHER|Peer support|Access to educational and informational support by a trained peer coach
219621370|NCT03588910|DRUG|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
219621371|NCT05260567|BEHAVIORAL|Exercise and Lifestyle Change|"Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%."
218932221|NCT03990727|DIAGNOSTIC_TEST|Autofluorescence|Fundus reflectance-functionality
218932222|NCT03990727|DIAGNOSTIC_TEST|OCT- 1 micra|Fine tomography fundus retina
218932223|NCT03990727|PROCEDURE|Genotype analysis|Molecular target retina dystrophy analysis
218932224|NCT06140810|OTHER|Lung Recruitment|Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
218932225|NCT02353624|BEHAVIORAL|Cycling|Cycling distance of 2880 km in 14 days
218932226|NCT02964169|BEHAVIORAL|Family Planning Support|
218932227|NCT01117363|OTHER|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
218932228|NCT00986037|DRUG|ABT-308|Single IV doses
219542254|NCT03446768|OTHER|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
219542255|NCT03446768|OTHER|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
219621372|NCT00838903|BIOLOGICAL|albiglutide|albiglutide
219621373|NCT00838903|DRUG|sitagliptin|sitagliptin
219621374|NCT00838903|DRUG|glimepiride|Glimepiride
219621375|NCT00838903|DRUG|metformin|Metformin
219621376|NCT00838903|BIOLOGICAL|placebo albiglutide|placebo to match albiglutide
219621377|NCT00838903|DRUG|placebo sitagliptin|placebo to match sitagliptin
219621378|NCT00838903|DRUG|placebo glimepiride|placebo to match glimepiride
219621379|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
219542256|NCT04154592|OTHER|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
218932229|NCT00986037|DRUG|ABT-308|Multiple SC doses x 3
218932230|NCT00986037|DRUG|Placebo|Single IV dose
218932231|NCT00986037|DRUG|Placebo|Multiple SC doses x 3
218932232|NCT03494998|DIAGNOSTIC_TEST|PAT-POPS|Emergency Department-specific screening tool
218932233|NCT01497561|DRUG|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
218932234|NCT01497561|DRUG|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
218932235|NCT02967783|DEVICE|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
218932236|NCT02967783|DEVICE|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
218932237|NCT02967783|DEVICE|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
218932238|NCT04610593|BEHAVIORAL|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
218932239|NCT00136097|DEVICE|Placement of a silver impregnated central venous catheter|
219542257|NCT04154592|OTHER|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
219542258|NCT02821676|PROCEDURE|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
219542259|NCT02821676|PROCEDURE|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
219542260|NCT00004148|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
219542261|NCT04913974|PROCEDURE|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
219542262|NCT02036086|DRUG|Vemurafenib|Drug
219542263|NCT02036086|DRUG|Cobimetinib|Drug
219542264|NCT01535222|DRUG|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
219542265|NCT01535222|DRUG|Placebo|Commercially available NaCl
219621380|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
219621381|NCT02734966|DRUG|Tiopronin Injection|Tiopronin Injection 200mg OD
219621382|NCT04565145|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
219621383|NCT04565145|DRUG|Placebo|Participants will be given three placebo capsules per day for one week
219621384|NCT04122963|PROCEDURE|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
219621385|NCT04122963|PROCEDURE|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
218932240|NCT02469870|BEHAVIORAL|Autism Parent Trainer (APT)|Experimental condition
219621386|NCT05661539|DEVICE|Transvaginal Ultrasonography|The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
218932241|NCT02469870|BEHAVIORAL|Teaching Routines (Control)|Content comparison group.
218932242|NCT01600170|DRUG|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
218932243|NCT01600170|DRUG|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
218932244|NCT01974635|DEVICE|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
218932245|NCT04972617|DIAGNOSTIC_TEST|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
218932246|NCT03401814|OTHER|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
219542266|NCT05119504|BEHAVIORAL|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
219542267|NCT05119504|BEHAVIORAL|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
219542268|NCT00370539|DRUG|verteporfin, bevacizumab, triamcinolone acetonide|
219542269|NCT00935012|DRUG|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
219542270|NCT00819312|DRUG|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
219542271|NCT00433719|DRUG|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
219542272|NCT03808519|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
218932247|NCT05242198|PROCEDURE|Robotic prostatectomy|patients who will undergo robotic prostatectomy
218932248|NCT03846492|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
218932249|NCT04961684|DEVICE|Solver Pen|One application per day for 3 months
219205422|NCT06532097|BEHAVIORAL|Physical and behavioral smartwatch-based activation|We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
219205423|NCT05025774|OTHER|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
219542273|NCT03808519|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
219621387|NCT04293939|DIAGNOSTIC_TEST|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (\~15 cm area) with a soft brush at a velocity of \~5 cm/s Stimulus blocks will last for \~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (\~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
219621388|NCT00002234|DRUG|Efavirenz|
219621389|NCT00002234|DRUG|Adefovir dipivoxil|
219621390|NCT00002234|DRUG|Lamivudine|
218932250|NCT04961684|DRUG|Loceryl 5%|One application per week for 3 months
218932251|NCT06802198|PROCEDURE|total hysterectomy|Total hysterectomy (TH) involves the complete removal of the uterus including the cervix
218932252|NCT06802198|PROCEDURE|subtotal hysterectomy|subtotal hysterectomy (STH) preserves the cervix while removing the upper part of the uterus
218932253|NCT04818372|DRUG|CM313-Dose escalation|Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
219205424|NCT03512405|BIOLOGICAL|Blinatumomab|Given IV
219205425|NCT03512405|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205426|NCT03512405|BIOLOGICAL|Pembrolizumab|Given IV
219621391|NCT00002234|DRUG|Didanosine|
218932254|NCT04818372|DRUG|CM313|Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
218932255|NCT04818372|DRUG|Dexamethasone|dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
219542274|NCT01442155|DRUG|Capecitabine|Administered according to the Summary of Product Characteristics.
219542275|NCT01442155|BIOLOGICAL|Oxaliplatin|Administered according to the Summary of Product Characteristics.
219542276|NCT04906538|PROCEDURE|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
219542277|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
219542278|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
219621392|NCT04632186|DEVICE|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
219621393|NCT00516022|DRUG|Mistletoe extract|The drug will be administered 3 times a week at home.
219621394|NCT01850238|BIOLOGICAL|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
219621395|NCT01850238|OTHER|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
219542279|NCT02226432|PROCEDURE|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified"
219542280|NCT02226432|DEVICE|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
219621396|NCT00683618|DRUG|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
219621397|NCT00683618|DRUG|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
219621398|NCT04570670|DRUG|monomethyl fumarate 190 mg|
219621399|NCT04570670|DRUG|dimethyl fumarate 240 mg|
219621400|NCT02746718|OTHER|Blood sample|A blood sample for CPK dosage and pompe disease test
219621401|NCT06536361|OTHER|Virtual Reality-Based Learning Tool|The intervention involves the use of a virtual reality-based learning tool to teach thorax and lung physical examination skills. The tool uses Oculus Meta Quest 3 VR headset to provide immersive simulation experiences. The VR tool includes high-quality graphics and interactive scenarios to facilitate skill development.
219621402|NCT06536361|OTHER|Traditional Small Group Training|The intervention involves traditional small group training conducted in the Nursing Principles Skills Laboratory. This training includes hands-on practice with physical examination techniques using simulation mannequins and feedback from instructors. The approach is designed to provide practical experience without the use of virtual reality technology.
219621403|NCT02062060|DRUG|Abametapir Lotion 0.74% w/w|
219621404|NCT02062060|DRUG|Vehicle Lotion|
219621405|NCT03557619|DRUG|Venetoclax|tablet; oral
219621406|NCT03557619|DRUG|ethinyl estradiol/levonorgestrel|tablet; oral
219621407|NCT06574074|BEHAVIORAL|Gain-Life (Give informAtIoN to transform Life)|The Gain Life intervention comprises four components: (i) information about depression, (ii) awareness of available services, (iii) stigma reduction through dispelling myths and facts about depression, and (iv) a life transformation story. The first module aims to raise awareness about depression, with a particular focus on its causes, manifestations, and the potential negative consequences of untreated depression. The second component includes the types of services offered, costs, distance to service providers, and operating hours. The third component address stigma and misconceptions surrounding depression by addressing the root causes of stigma, dispelling myths, and providing accurate information about depression. The final module of the Gain Life intervention features recovery stories of individuals who have overcome depression. This module includes two 8-minute video stories of individuals who successfully recovered from depression.
219621408|NCT02129166|DRUG|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
219621409|NCT02129166|DRUG|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
219205427|NCT06020261|BEHAVIORAL|Parent Management Training|developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
219542281|NCT02226432|OTHER|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
219542282|NCT05628545|BIOLOGICAL|GDKM-100 injection|Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
219621410|NCT00002772|BIOLOGICAL|filgrastim|
219621411|NCT00002772|DRUG|carboplatin|
219621412|NCT00002772|DRUG|carmustine|
219621413|NCT00002772|DRUG|cisplatin|
219621414|NCT00002772|DRUG|cyclophosphamide|
219621415|NCT00002772|DRUG|doxorubicin hydrochloride|
219621416|NCT00002772|DRUG|paclitaxel|
218932256|NCT04818372|DRUG|Lenalidomide|25 mg/day lenalidomide 21 of 28 days cycle
218932257|NCT05775276|PROCEDURE|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
218932258|NCT05943067|BIOLOGICAL|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
219205428|NCT02720068|BIOLOGICAL|Favezelimab|IV infusion
219205429|NCT02720068|BIOLOGICAL|Pembrolizumab|IV infusion
218932259|NCT06594432|DRUG|R-CHOP+Z+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
218932260|NCT06594432|DRUG|R-CHOP+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
218932261|NCT04798768|DEVICE|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
218932262|NCT03688594|DIAGNOSTIC_TEST|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
218932263|NCT04352036|OTHER|no interventional study|no interventional study
218932264|NCT04643652|BEHAVIORAL|Noise Reduction Bundle|"Implementation of a bundle of noise reducing interventions. This concerns among other things:~reduction of alarms, phone calls/pagers/ beepers, introduction of a defined period in which there is a reduction of controllable sound (quiet time), etc"
218932265|NCT06067360|DEVICE|IFIS sleeve|IFIS sleeve will be inserted to prevent iris prolapse
218932266|NCT05259280|OTHER|Wellinks|Digital health and virtual care program for COPD management.
218932267|NCT03470844|BEHAVIORAL|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
218932268|NCT03470844|BEHAVIORAL|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
218932269|NCT03470844|OTHER|fMRI|Brain volume, chemical markers, functional outcome
218932270|NCT03470844|BEHAVIORAL|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
218932271|NCT04267913|DRUG|Dexamethasone|Given IV
219205430|NCT02720068|DRUG|Oxaliplatin|IV infusion
219542283|NCT01637376|DRUG|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
219621417|NCT00002772|DRUG|tamoxifen citrate|
218932272|NCT04267913|DRUG|Docetaxel|Given IV
218932273|NCT04267913|BIOLOGICAL|Ramucirumab|Given IV
218932274|NCT04267913|DRUG|Sapanisertib|Given PO
218932275|NCT05960721|DRUG|Rivaroxaban 15mg|QD
218932276|NCT05960721|DRUG|Aspirin 100mg|QD
218932277|NCT05960721|DRUG|Clopidogrel 75mg|QD
218932278|NCT05960721|DRUG|Rivaroxaban 10mg|QD
218932279|NCT05960721|DRUG|Rivaroxaban 2.5mg|B.I.D
218932280|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
218932281|NCT01192802|DRUG|albendazole|single 1 tablet of 400 mg of albendazole
218932282|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
218932283|NCT02185859|DRUG|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
219205431|NCT02720068|DRUG|Irinotecan|IV infusion
218932284|NCT02185859|DRUG|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
219205432|NCT02720068|DRUG|Leucovorin (Calcium Folinate)|IV infusion
219205433|NCT02720068|DRUG|Fluorouracil [5-FU]|IV infusion
219205434|NCT02720068|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
219205435|NCT02720068|DRUG|Lenvatinib|Oral
219542284|NCT05770076|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
219542285|NCT05770076|DIETARY_SUPPLEMENT|Placebo|Placebo
219542286|NCT00429962|DRUG|intravitreal ranibizumab|intraocular injection
219542287|NCT00429962|DRUG|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
219542288|NCT00705666|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
219621418|NCT00002772|DRUG|thiotepa|
219621419|NCT00002772|PROCEDURE|autologous bone marrow transplantation|
219621420|NCT00002772|PROCEDURE|peripheral blood stem cell transplantation|
219621421|NCT00002772|RADIATION|radiation therapy|
219542289|NCT00705666|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
218932285|NCT02185859|DRUG|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
218932286|NCT02525770|DEVICE|radiostereometric analysis (RSA)|
218932287|NCT02687191|BIOLOGICAL|PF-05230907|PF-05230907 IV bolus injection
218932288|NCT05218291|OTHER|Yoga Practice|In this study, the yoga initiative to be made for the caregivers in the experimental group consists of breathing, meditation and yoga poses.
218932289|NCT05218291|OTHER|Ongoing caregivers|Caregivers included in the control group, who did not apply any yoga intervention, will be observed as caregivers.
218932290|NCT00022022|DRUG|docetaxel|
218932291|NCT00022022|PROCEDURE|quality-of-life assessment|
218932292|NCT03093571|DEVICE|Auricular stimulation|Auricular stimulation with indwelling fixed needles
218932293|NCT03093571|BEHAVIORAL|Relaxation|Progressive muscle relaxation
218932294|NCT02230514|DRUG|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
218932295|NCT02230514|OTHER|autologous iliac crest|Autologous iliac crest in association with surgery
218932296|NCT02230514|PROCEDURE|Surgery|Standard surgery for non-union fractures
218932297|NCT05647161|DEVICE|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
218932298|NCT05647161|DEVICE|No Intervention|Control Group
218932299|NCT03536117|BIOLOGICAL|MTBVAC|Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
218932300|NCT03536117|BIOLOGICAL|BCG|Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
218932301|NCT00865410|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
218932302|NCT00865410|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
218932303|NCT00790140|DIETARY_SUPPLEMENT|Prosure|This is an enteral tube feed with 125 kcals \& 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
218932304|NCT00790140|DIETARY_SUPPLEMENT|Ensure Plus|This is a standard enteral tube feed with 150 kcals \& 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
218932305|NCT01278472|DEVICE|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
219044877|NCT05149950|BEHAVIORAL|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
219044878|NCT06504719|DRUG|Antibody-Drug Conjugates|Patients with advanced breast cancer treated with ADCs
219044879|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about acceptance
218932306|NCT01278472|DEVICE|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
218932307|NCT02052076|BEHAVIORAL|Meal pattern|
218932308|NCT04254328|DEVICE|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
218932309|NCT04254328|DEVICE|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
218932310|NCT05633316|DEVICE|Investigational device named ICSIA|Oocytes will undergo intracytoplasmic sperm injection using the ICSIA (the investigational) device.
218932311|NCT05633316|DEVICE|Manual ICSI|Oocytes will undergo intracytoplasmic sperm injection using the ICSI manual protocol
218932312|NCT03940768|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
218932313|NCT03940768|DIETARY_SUPPLEMENT|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
219542290|NCT03115957|OTHER|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
219542291|NCT03521973|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
219542292|NCT03521973|OTHER|Normal Saline|0.9% Sodium chloride
218932314|NCT00752440|OTHER|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
218932315|NCT04860544|PROCEDURE|RED BLOOD CELLS TRANFUSION|
219542293|NCT04570748|PROCEDURE|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
218932316|NCT01571544|DEVICE|Thermal suit|Thermal suit
218932317|NCT01571544|OTHER|Conventional clothing|Conventional clothing
218932318|NCT01343641|DRUG|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
218932319|NCT01343641|DRUG|Placebo|Inactive Pill used as a comparator
218932320|NCT01305590|OTHER|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
218932321|NCT01819818|DRUG|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
218932322|NCT06073145|DEVICE|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
218932323|NCT04461067|DIAGNOSTIC_TEST|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
218932324|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
218932325|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
219044880|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about refusal
219044881|NCT04861506|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and mechanical thrombectomy device (MTD) and/or pharmacomechanical thrombectomy (PMT）and/or percutaneous aspiration thrombectom (PAT) and/or CDT(catheter-directed thrombolysis) and/or percutaneous aspiration thrombectom (PAT) thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
219044882|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
219044883|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
219044884|NCT05544344|BEHAVIORAL|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
219044885|NCT05544344|OTHER|Services as Usual|Subjects receive mental health services as usual.
219542294|NCT04570748|PROCEDURE|capsulectomy|capsulectomy without repair
219542295|NCT05187065|OTHER|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
219621422|NCT05138705|BIOLOGICAL|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
219621423|NCT05795543|PROCEDURE|Subtalar Arthrodesis by Screws|Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
219621424|NCT05080075|BIOLOGICAL|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
219621425|NCT03444428|OTHER|Non Invasive Ventilation|Assessments for those participants who are being set up onto NIV
219621426|NCT03444428|OTHER|Without Non Invasive Ventilation|Assessments for those participants who are not being set up onto NIV
219621427|NCT00525681|DRUG|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
219621428|NCT00525681|DRUG|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
219621429|NCT03003962|DRUG|Durvalumab (MEDI4736)|Anti-PD-L1 monoclonal Antibody monotherapy
218932326|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
218932327|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
218932328|NCT01774656|DRUG|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
219621430|NCT03003962|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
219621431|NCT03003962|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
218932329|NCT05795608|DEVICE|respiratory exercise with incentive spirometry|Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
218932330|NCT06025968|BEHAVIORAL|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
218932331|NCT06025968|BEHAVIORAL|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
218932332|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
218932333|NCT06003686|BEHAVIORAL|PVA Consumer Guide|"Subject's will receive education on the PVA consumer guide 3 times over the course of the study.~Each session will be approximately 10-15 minutes and will consist of a general review of the nutrition, exercise, and general healthy living guidelines content included."
218932334|NCT06003686|BEHAVIORAL|WebMD|Subject's will receive education on how to navigate the WebMD site and find information on health, exercise and nutrition 3 times over the course of the study. Each session will be approximately 10-15 minutes and will consist of a general review of the health and wellness content available on the website. At study completion, subjects in this group will be provided with the PVA guide and a brief orientation of the nutrition, exercise, and general healthy living guidelines content included in the guide.
218932335|NCT03520855|OTHER|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
218932336|NCT03520855|BEHAVIORAL|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
219044886|NCT05049785|OTHER|Counseling|Attend nutrition counseling sessions
219044887|NCT05049785|BEHAVIORAL|Exercise Intervention|Complete PA sessions
219044888|NCT05049785|OTHER|Informational Intervention|Receive nutrition handouts
219044889|NCT05049785|DIETARY_SUPPLEMENT|Nutritional Intervention|Attend tasting sessions
219044890|NCT05049785|OTHER|Questionnaire Administration|Ancillary studies
219044891|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
219044892|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
219044893|NCT06836180|DEVICE|Near infrared light therapy|Once a day, once 30 minutes of near-infrared light treatment, 6 times a week for 96 weeks
219044894|NCT03567213|DEVICE|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
219542296|NCT03259139|BEHAVIORAL|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
219044895|NCT00118807|DRUG|Amodiaquine plus artesunate (AQ/AS)|
219044896|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
219044897|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
219542297|NCT05180422|DRUG|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
219044898|NCT05922332|DIETARY_SUPPLEMENT|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
219044899|NCT05922332|DIETARY_SUPPLEMENT|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
219542298|NCT05180422|DRUG|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
219621432|NCT03003962|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
219044900|NCT06618287|DRUG|BMS-986507|Specified dose on specified days
219044901|NCT06618287|DRUG|Osimertinib|Specified dose on specified days
219044902|NCT06618287|DRUG|Pembrolizumab|Specified dose on specified days
219044903|NCT06618287|DRUG|Nivolumab|Specified dose on specified days
219044904|NCT05516628|PROCEDURE|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
219621433|NCT03003962|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
219044905|NCT05516628|DRUG|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for two years following resection of hepatocellular carcinoma tumour.
219044906|NCT02504372|BIOLOGICAL|Pembrolizumab|IV infusion
219621434|NCT03003962|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
219621435|NCT03162250|DRUG|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
219621436|NCT03162250|DRUG|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
218932337|NCT06047015|COMBINATION_PRODUCT|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
218932338|NCT06047015|COMBINATION_PRODUCT|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
218932339|NCT00214890|DRUG|Tenofovir|300 mg once daily
218932340|NCT00214890|DRUG|Abacavir|600 mg once daily
218932341|NCT01450332|DEVICE|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
218932342|NCT02584010|OTHER|Silicon-based aerosol|Apply twice a day over the postoperative scar
218932343|NCT02584010|OTHER|Silicon-based gel|Apply twice a day over the postoperative scar
218932344|NCT04160754|BEHAVIORAL|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
218932345|NCT04160754|BEHAVIORAL|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
218932346|NCT02225002|DRUG|CP-870,893|
218932347|NCT02873702|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
218932348|NCT02873702|DRUG|Lansoprazole|Lansoprazole capsules.
218932349|NCT02873702|DRUG|Placebo|Dexlansoprazole placebo-matching capsules.
218932350|NCT03164239|BEHAVIORAL|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
218932351|NCT01180582|DEVICE|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
219044907|NCT02504372|OTHER|Placebo|IV infusion
219044908|NCT05620940|DRUG|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
219621437|NCT03162250|DRUG|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
219621438|NCT02242812|DRUG|Telmisartan|
218932352|NCT00583895|DRUG|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
218932353|NCT00583895|DRUG|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
218932354|NCT00426413|DRUG|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
218932355|NCT03638765|BIOLOGICAL|DCVax-Direct|activated, autologous dendritic cells
218932356|NCT06385626|DIETARY_SUPPLEMENT|Raspberry leaf tea|10 g of raspberry leaf tea
218932357|NCT03762317|DRUG|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
218932358|NCT03762317|DRUG|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
218932359|NCT00713167|DRUG|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
218932360|NCT00713167|DRUG|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
218932361|NCT03443570|DRUG|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
218932362|NCT03443570|DRUG|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
218932363|NCT01171482|DRUG|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
218932364|NCT01171482|DRUG|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
219044909|NCT05620940|DRUG|IVL3004|Naltrexone Long-Acting Injection
219044910|NCT05620940|DRUG|IVL4002|Naltrexone Long-Acting Injection
219044911|NCT03901963|DRUG|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
219044912|NCT03901963|DRUG|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
219621439|NCT02242812|DRUG|Metoprolol succinate|
219621440|NCT02242812|DRUG|Placebo|
218932365|NCT01171482|DRUG|sorafenib|400 mg BID every 28 days
219205436|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
219205437|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
219205438|NCT06752109|OTHER|Antipronation Taping|Before applying the tape, its length was measured by passing it over the areas on the foot where it would be applied. The tape was first attached to the medial side of the big toe, with tension in the direction of flexion and abduction of the toe. The ankle was then positioned in full plantar flexion. The tape was applied from the medial side of the foot towards the heel, wrapping around it, and then directed towards the sole. While the foot was in an inversion position at the navicular level, the tape was applied with maximum tension from medial to lateral and brought back to the sole. The remainder of the tape, with maximum tension, was applied from the sole to the dorsal side of the ankle, ending without tension at the proximal and lateral side of the leg. A second strip of tape, with maximum tension, was applied to support the medial longitudinal arch. The ends of the tape were placed over the malleoli without tension, aiming to reduce excessive pronation.
219205439|NCT06752109|OTHER|Sham|In the sham taping application, the length of the tape was measured by passing it over the areas where it would be applied. The tape was applied to the medial side of the big toe, but without tension, simply placed. Then, the tape was directed towards the sole of the foot, passing over the heel. At the navicular level, the tape was applied from medial to lateral, returning to the sole without tension. A second strip of tape was applied to the sole without tension. The ends of the tape were placed over the malleoli without stretching. Since no tension was applied, this application was only placed and has a limited effect on reducing excessive pronation.
218932366|NCT05475756|DEVICE|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
218932367|NCT05475756|DEVICE|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
218932368|NCT06318013|DIAGNOSTIC_TEST|vitality test|A vitality test will be performed using a vitalometer to check if the drowsiness is gone
218932369|NCT01318239|PROCEDURE|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
218932370|NCT04445896|OTHER|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
218932371|NCT05542030|DIAGNOSTIC_TEST|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
219205440|NCT05583344|DRUG|GSK4532990|GSK4532990 will be administered.
219205441|NCT05583344|DRUG|Placebo|Placebo will be administered.
219205442|NCT05227417|BEHAVIORAL|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
219205443|NCT01243814|DEVICE|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
219542299|NCT02284867|OTHER|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
219542300|NCT00553124|DRUG|selenium|
219542301|NCT00553124|DRUG|vitamin E|
219542302|NCT00553124|PROCEDURE|biopsy|
219542303|NCT00553124|PROCEDURE|chemoprevention|
219542304|NCT00553124|PROCEDURE|cryopreservation|
219542305|NCT00553124|PROCEDURE|cytology specimen collection procedure|
219542306|NCT00553124|PROCEDURE|diagnostic procedure|
219621441|NCT04261803|BIOLOGICAL|salivary sample|spit of saliva in a tube
218932372|NCT05542030|DIAGNOSTIC_TEST|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
219205444|NCT01243814|DEVICE|placebo injection|joint injection with saline solution for placebo
219542307|NCT00553124|PROCEDURE|gene expression analysis|
219542308|NCT00553124|PROCEDURE|immunohistochemistry staining method|
219542309|NCT00553124|PROCEDURE|laboratory biomarker analysis|
219542310|NCT00553124|PROCEDURE|medical chart review|
219542311|NCT00553124|PROCEDURE|mutation analysis|
219542312|NCT00553124|PROCEDURE|polymerase chain reaction|
219542313|NCT00553124|PROCEDURE|quality-of-life assessment|
219542314|NCT00553124|PROCEDURE|questionnaire administration|
219542315|NCT00553124|PROCEDURE|study of socioeconomic and demographic variables|
219542316|NCT03931616|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
219621442|NCT04261803|BIOLOGICAL|blood test|2millilitter blood test
218932373|NCT05542030|DIAGNOSTIC_TEST|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
218932374|NCT02749084|BIOLOGICAL|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
218932375|NCT01039376|BIOLOGICAL|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
218932376|NCT01039376|OTHER|Observation|Observation/Safety Evaluation
218932377|NCT03828071|PROCEDURE|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
218932378|NCT00120497|DRUG|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
218932379|NCT02695563|DRUG|Lactoferrin|
218932380|NCT06210217|DRUG|Dobutamine hydrochloride, Injectable|In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.
218932381|NCT06210217|DRUG|0.9% normal saline|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
218932382|NCT03252925|DRUG|N-Acetylcysteine|50mg/Kg.d, oral
218932383|NCT03252925|DRUG|Placebo Oral Tablet|50mg/Kg.d, oral
218932384|NCT04409080|DRUG|REGN7257|Administered by intravenous (IV) infusion, in Part A and B.
218932385|NCT04555616|BEHAVIORAL|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
218932386|NCT04555616|BEHAVIORAL|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
218932387|NCT04555616|BEHAVIORAL|Placebo|Participants' caregivers will receive a set script of placebo modifications.
219044913|NCT06829017|OTHER|Postoperative Hypothermia Management Care Bundle|"The postoperative hypothermia care bundle consists of three main parameters, Diagnose hypothermia, Maintain/maintain normothermia and Monitor body temperature at regular intervals, and eight sub-parameters of these parameters. For this purpose, this study evaluates the pilot implementation and effectiveness of the postoperative hypothermia management care bundle developed within the scope of the research."
219044914|NCT01683279|BIOLOGICAL|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
219044915|NCT06559995|DIETARY_SUPPLEMENT|"ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,"|ketone supplement
219044916|NCT06559995|DIAGNOSTIC_TEST|magnetic resonance imaging session|1.5 hour magnetic resonance imaging session
218932388|NCT03419923|DRUG|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
218932389|NCT03419923|DRUG|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
218932390|NCT00409552|BEHAVIORAL|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
219044917|NCT06559995|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
219044918|NCT02102256|DEVICE|Auditory Brainstem Implant|
219044919|NCT03032796|BEHAVIORAL|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
218932391|NCT00409552|BEHAVIORAL|VR with flat projection display|VR with flat projection display
218932392|NCT00409552|BEHAVIORAL|non-interactive video with head display|non-interactive video with head display
219542317|NCT03931616|PROCEDURE|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
219542318|NCT01590563|DEVICE|IUD|Insertion of a spherical IUD, one year follow-up
219542319|NCT02990286|DRUG|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
219542320|NCT02990286|DRUG|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
219542321|NCT02990286|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
219542322|NCT03256695|DRUG|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
218932393|NCT00409552|BEHAVIORAL|non-interactive video with with flat projection display|non-interactive video with with flat projection display
218932394|NCT04816669|BIOLOGICAL|BNT162b2|Intramuscular injection
218932395|NCT01229267|BIOLOGICAL|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
218932396|NCT01229267|BIOLOGICAL|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
218932397|NCT04913935|DIAGNOSTIC_TEST|Muscle-Skeleton Ultrasonography|postero-anterior radiography
218932398|NCT00919321|BIOLOGICAL|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
218932399|NCT03057483|BIOLOGICAL|Seasonal Influenza vaccine|Seasonal Influenza vaccine
218932400|NCT03578952|DEVICE|TAVR with Evolut R valve|TAVR with Evolut R valve
218932401|NCT02873494|DEVICE|PHYSIOFLOW - PF05 Lab1TM|
218932402|NCT06441916|DRUG|Dabigatran Etexilate Capsules 150 mg|Dabigatran Etexilate
218932403|NCT04655352|DIETARY_SUPPLEMENT|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
219542323|NCT05204979|OTHER|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
218932404|NCT03181737|BEHAVIORAL|Covivio/Relaxio|Informations already included in arm/group descriptions.
218932405|NCT03498404|RADIATION|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
218932406|NCT03498404|OTHER|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
218932407|NCT06109961|DRUG|Oxygen Gas for Inhalation|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
218932408|NCT06109961|OTHER|Standard of care|The accepted standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission.
219542324|NCT04313764|DRUG|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
219542325|NCT04313764|DRUG|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
219542326|NCT00582179|PROCEDURE|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
219621443|NCT02521883|DEVICE|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
219621444|NCT02521883|DEVICE|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
218932409|NCT03408704|OTHER|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~1. The Swedish guidelines~2. Example of cases~3. Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
218932410|NCT05676021|BEHAVIORAL|motivational interview|motivational interview-based health education
218932411|NCT04312659|DRUG|Infliximab|Participants will be observed who were treated with Infliximab.
218932412|NCT00163813|PROCEDURE|Early jejunal feeding (using frictional NJ tube)|
218932413|NCT00163813|PROCEDURE|Standard feeding (using nasogastric [NG] tube)|
218932414|NCT01765972|DEVICE|etafilcon A with Lacreon|contact lens with Lacreon
218932415|NCT01765972|DEVICE|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
218932416|NCT01765972|DEVICE|etafilcon A with print|contact lens with print
219542327|NCT00582179|DEVICE|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
218932417|NCT01765972|DEVICE|Spectacles (habitual)|Spectacles
218932418|NCT04326283|DRUG|Trametinib (0.5 mg)|0.5 mg/day
218932419|NCT04326283|DRUG|Trametinib (1 mg)|1 mg/day
218932420|NCT04326283|DRUG|Riluzole (100 mg)|100 mg/day (50 mg twice)
218932421|NCT01900717|DRUG|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
218932422|NCT01900717|DRUG|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
218932423|NCT02446899|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
218932424|NCT02446899|DRUG|Placebo|Intravenous infusion (IV)
218932425|NCT03652285|DEVICE|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
218932426|NCT03652285|DEVICE|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
219542328|NCT02308059|OTHER|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
219542329|NCT02308059|OTHER|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
219542330|NCT05347459|DRUG|Dapagliflozin|usual and customary doses for type 2 diabetes management
219542331|NCT05347459|DRUG|Empagliflozin|usual and customary doses for type 2 diabetes management
219542332|NCT05347459|DRUG|Canagliflozin|usual and customary doses for type 2 diabetes management
219542333|NCT05347459|DRUG|Sitagliptin|usual and customary doses for type 2 diabetes management
219542334|NCT05347459|DRUG|Saxagliptin|usual and customary doses for type 2 diabetes management
219542335|NCT05347459|DRUG|Linagliptin|usual and customary doses for type 2 diabetes management
219542336|NCT05347459|DRUG|Vildagliptin|usual and customary doses for type 2 diabetes management
219542337|NCT03930732|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219542338|NCT03930732|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
219542339|NCT03930732|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
219542340|NCT03930732|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
218932427|NCT02192281|OTHER|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
218932428|NCT04050202|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC) Intervention|ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
218932429|NCT01615913|DRUG|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
218932430|NCT01615913|DRUG|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
219542341|NCT03930732|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219542342|NCT05025137|OTHER|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
219542343|NCT05025137|OTHER|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
219542344|NCT03406156|DRUG|Obinutuzumab|Administered via intravenous infusion
219542345|NCT03406156|DRUG|Bendamustine|Administered via intravenous infusion
218932431|NCT01615913|DRUG|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
219044920|NCT03032796|BEHAVIORAL|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
219044921|NCT03032796|BEHAVIORAL|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
219542346|NCT03406156|DRUG|Venetoclax|The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
219542347|NCT03515707|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219542348|NCT03515707|DRUG|Busulfan|Given IV or oral
219542349|NCT03515707|DRUG|Etoposide|Given IV
219542350|NCT03515707|OTHER|Laboratory Biomarker Analysis|Correlative studies
219542351|NCT01923545|DRUG|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
219542352|NCT01923545|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
219542353|NCT00187928|DRUG|Topiramate|
219542354|NCT00387933|DRUG|hydroxyurea|
219542355|NCT00387933|DRUG|imatinib mesylate|
219542356|NCT00387933|DRUG|vatalanib|
219542357|NCT04708028|OTHER|Dog Therapy|The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
219542358|NCT06557551|OTHER|Thin catheter surfactant|Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
219542359|NCT00625560|DRUG|Entecavir|entecavir 1.0 mg QD
219542360|NCT00625560|DRUG|Lamivudine|lamivudine 100 mg QD
219542361|NCT03342846|DEVICE|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
219542362|NCT01904162|DRUG|400 mg finafloxacin (2 x 200 mg tablets)|
219542363|NCT05124444|GENETIC|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
219542364|NCT06468839|BEHAVIORAL|digital addiction management model|The experimental group will implement a digital addiction model. No intervention will be made to the control group.
219542365|NCT04654182|DRUG|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
219542366|NCT02942823|OTHER|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
219542367|NCT04099758|BEHAVIORAL|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
219542368|NCT04099758|BEHAVIORAL|Audio-recording control|10 minute non-fiction audio-recording delivered online
219542369|NCT06133101|DRUG|Standard Soy Milk|Consumption of commercially available soy milk
219542370|NCT06133101|DRUG|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
219542371|NCT01679327|DRUG|Oxaliplatin|
219542372|NCT01679327|DRUG|Xeloda|
219542373|NCT01679327|DRUG|Calcium folinate (CF)|
219542374|NCT01679327|DRUG|5-FU|
219542375|NCT01679327|DRUG|Bevacizumab|
219542376|NCT04366960|DRUG|Enoxaparin|Subcutaneous enoxaparin
219542377|NCT03366792|DEVICE|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
219542378|NCT06042231|BEHAVIORAL|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
219542379|NCT06042231|BEHAVIORAL|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
219542380|NCT01530048|DRUG|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
219542381|NCT04471922|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
219542382|NCT04471922|DRUG|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
219542383|NCT04471922|DRUG|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
219542384|NCT03013530|PROCEDURE|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
218932432|NCT04303676|OTHER|Virtual Practice Facilitation with e-Learning|"Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
218932433|NCT04303676|OTHER|Virtual Practice Facilitation without e-Learning|"Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
218932434|NCT01742117|DRUG|Clopidogrel|One 75 mg tablet per day by mouth for one year
218932435|NCT01742117|DRUG|Ticagrelor|One 90 mg tablet twice per day by mouth for one year
218932436|NCT04623853|DEVICE|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
218932437|NCT03925779|DRUG|Dexmedetomidine|dexmedetomidine sedation
218932438|NCT03925779|DRUG|Propofol|propofol sedation
218932439|NCT03925779|DRUG|Remifentanil|Remifentanil sedation
218932440|NCT00674713|OTHER|Acupuncture|
218932441|NCT00674713|DRUG|Ondansetron|
218932442|NCT00674713|DRUG|Physiological saline solution|
218932443|NCT00674713|OTHER|Sham acupuncture|
218932444|NCT00674713|DRUG|Ondansetron|
218932445|NCT00674713|OTHER|Acupuncture at P6 point|
218932446|NCT00674713|DRUG|Physiological saline solution|
218932447|NCT00674713|OTHER|Sham acupuncture|
218932448|NCT05733117|DRUG|Vitamin D|cholecalciferol
218932449|NCT02730780|DIETARY_SUPPLEMENT|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
218932450|NCT02730780|DIETARY_SUPPLEMENT|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
218932451|NCT05540587|DRUG|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
218932452|NCT05540587|DRUG|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
218932453|NCT00673738|DRUG|Cetuximab|"* Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
218932454|NCT00673738|RADIATION|Conformal Thoracic Radiotherapy (CTRT)|"* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \>1,000 and platelets \>75,000) required. Patient may be delayed for a max. of 2 weeks. If \> 2 week delay occurs, patient will come off study."
218932455|NCT02705066|DIETARY_SUPPLEMENT|Citicoline supplement|
218932456|NCT02705066|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
218932457|NCT05486624|OTHER|Reiki|Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
218932458|NCT02814552|OTHER|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
218932459|NCT02814552|OTHER|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
218932460|NCT01499277|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
218932461|NCT01499277|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
219044922|NCT03032796|BEHAVIORAL|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
219542385|NCT02450539|DRUG|Abemaciclib|Administered orally
219542386|NCT02450539|DRUG|Docetaxel|Administered IV
219542387|NCT06438640|BEHAVIORAL|My Anesthesia Choice-HF Model|Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
219542388|NCT06154096|OTHER|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
219542389|NCT02699463|DEVICE|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
219044923|NCT04833348|OTHER|Motor function measurement using inertial sensors|"Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~* Free motor skills in the supine position~* Motricity in the supine position stimulated by a play frame~* Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~* Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control"
219044924|NCT06095102|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
219542390|NCT02699463|OTHER|Control Group|Standard sleep hygiene counseling as per published guidelines
219542391|NCT06627686|DIAGNOSTIC_TEST|Air way occlusion pressure|Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
219542392|NCT04387786|DRUG|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
219621445|NCT04243889|DEVICE|NEOX Cord 1K|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
219044925|NCT06095102|DRUG|Placebo|Placebo will be administered orally.
219542393|NCT05606458|BEHAVIORAL|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
219542394|NCT02587663|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
219542395|NCT02587663|PROCEDURE|Mammography|Undergo bilateral mammography
219621446|NCT03802825|BEHAVIORAL|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
219621447|NCT03802825|OTHER|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
219621448|NCT01699009|OTHER|Plant based diet|
219621449|NCT01699009|OTHER|an unrestricted diet|
219621450|NCT03673969|PROCEDURE|Gastric bypass|Surgical method of gastric bypass
219621451|NCT06575322|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219621452|NCT06575322|DRUG|Paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219621453|NCT06575322|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219621454|NCT06575322|PROCEDURE|Surgical resection|Standard of care
219621455|NCT04614519|PROCEDURE|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
219621456|NCT04614519|PROCEDURE|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
219621457|NCT00407134|PROCEDURE|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
219621458|NCT05875402|DRUG|Chimeric antigen receptor T cell preparation targeting GCC|Chimeric antigen receptor T cell preparation targeting GCC
219621459|NCT02926443|OTHER|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
219621460|NCT02926443|OTHER|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
219621461|NCT04383561|OTHER|Non-surgical periodontal treatment|Scaling and root planing (SRP), in four clinical visits
219621462|NCT04383561|OTHER|Oral hygiene instructions|Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
219542396|NCT02587663|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast conserving surgery
219542397|NCT02587663|PROCEDURE|Ultrasonography|Undergo bilateral whole-breast ultrasound
219542398|NCT02587663|PROCEDURE|Ultrasonography|Undergo targeted breast ultrasound
219542399|NCT02587663|OTHER|Gadolinium|Contrast agent used in MRI
219542400|NCT02647463|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|
219542401|NCT04242823|DIAGNOSTIC_TEST|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
219542402|NCT05164354|OTHER|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
219542403|NCT05164354|OTHER|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
218932462|NCT01499277|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
219542404|NCT03151577|PROCEDURE|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
219621463|NCT01468337|DRUG|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
218932463|NCT01423747|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
219621464|NCT00850057|BIOLOGICAL|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
219621465|NCT00861640|DRUG|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
218932464|NCT01423747|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
219621466|NCT00861640|DRUG|Oral Rabeprazole|Oral Rabeprazole 1 bid
219621467|NCT00000468|DRUG|tissue plasminogen activator|
218932465|NCT01423747|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
219621468|NCT02034734|DRUG|ASP3652|oral
219621469|NCT02162134|OTHER|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
219621470|NCT02162134|OTHER|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
219621471|NCT02162134|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
219621472|NCT02162134|DRUG|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
219621473|NCT02162134|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
219621474|NCT02162134|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
219621475|NCT02162134|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
219621476|NCT02162134|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
219621477|NCT02162134|DRUG|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
219621478|NCT02162134|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
219621479|NCT01675934|PROCEDURE|Retroflexion with the adult colonoscope.|
219621480|NCT01675934|PROCEDURE|Retroflexion with the pediatric colonoscope.|
219621481|NCT03428152|PROCEDURE|superior hypogastric block|superior hypogastric blockade during surgery
219621482|NCT05339373|DRUG|Aceclofenac film-coated tablet 100 mg|Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
219621483|NCT05339373|DRUG|Airtal® film-coated tablet 100 mg|"Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac."
219621484|NCT03662087|COMBINATION_PRODUCT|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
219621485|NCT03662087|BIOLOGICAL|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
219621486|NCT03908996|BEHAVIORAL|Profile by Sanford weight management plan|The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
219621487|NCT00486746|BEHAVIORAL|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
218932466|NCT01423747|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
218932467|NCT01423747|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
218932468|NCT01423747|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
218932469|NCT01423747|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
218932470|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment."
218932471|NCT04195373|BIOLOGICAL|TMV-018 + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC."
218932472|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC."
218932473|NCT05118659|PROCEDURE|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
218932474|NCT05118659|PROCEDURE|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
218932475|NCT03493217|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
218932476|NCT00605787|DRUG|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
218932477|NCT05593978|BEHAVIORAL|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
218932478|NCT05593978|BEHAVIORAL|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
218932479|NCT03585751|PROCEDURE|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
218932480|NCT03585751|PROCEDURE|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
218932481|NCT03585751|PROCEDURE|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
218932482|NCT00604799|DEVICE|Talent Thoracic Stent Graft|TEVAR
218932483|NCT02532738|DRUG|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
218932484|NCT02532738|BIOLOGICAL|MSC treatment 01|Injection of 3×10E6/kg of MSC
218932485|NCT02532738|BIOLOGICAL|MSC treatment 02|Injection of 6×10E6/kg of MSC
218932486|NCT02532738|OTHER|NS|Injection of NS
218932487|NCT02804152|BEHAVIORAL|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
219044926|NCT04519528|OTHER|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
219542405|NCT05811793|DRUG|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
219542406|NCT03219853|DIETARY_SUPPLEMENT|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
219542407|NCT03219853|DIETARY_SUPPLEMENT|Conventional parsnips|Parsnips which have been grown in a conventional environment
219542408|NCT01108445|DRUG|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
218932488|NCT01051518|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
218932489|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
218932490|NCT04566926|DRUG|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
218932491|NCT04566926|DRUG|Placebo|Participant will receive matching placebo.
218932492|NCT02141438|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
218932493|NCT04300621|DRUG|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
219542409|NCT01108445|DRUG|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
219542410|NCT01943045|BIOLOGICAL|NGM282|
219542411|NCT01943045|OTHER|Placebo|
219542412|NCT04188392|DRUG|Pimavanserin|pimavanserin tablet
219542413|NCT06370104|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention|see arm description
219621488|NCT00486746|BEHAVIORAL|General information on healthy lifestyle habits|A single session
218932494|NCT04300621|DRUG|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
218932495|NCT04300621|DRUG|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
218932496|NCT04300621|DRUG|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
218932497|NCT00792168|DRUG|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
218932498|NCT00792168|OTHER|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
218932499|NCT02968108|DRUG|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
218932500|NCT04620070|PROCEDURE|ECPR|Application of prehospital ECPR
218932501|NCT05575167|DRUG|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
218932502|NCT05483309|DIAGNOSTIC_TEST|CT scan|Patients receive a CT scan
218932503|NCT05483309|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia
218932504|NCT06531551|OTHER|The group to which Acupressure will be applied in each fraction|Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
219044927|NCT04519528|OTHER|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
219621489|NCT05002634|DIETARY_SUPPLEMENT|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
219621490|NCT02570308|DRUG|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
218932505|NCT06371001|OTHER|disease|Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
218932506|NCT04033458|DRUG|JNJ-64140284|Participants will receive JNJ-64140284 orally.
218932507|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
218932508|NCT06640023|BEHAVIORAL|Z-drug Default Quantity|For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
218932509|NCT06640023|BEHAVIORAL|Redirection + Accountable Justification|"For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the Encounter Report.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display."
218932510|NCT03255174|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
219044928|NCT05429203|DEVICE|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
218932511|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
218932512|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
218932513|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
218932514|NCT04954833|DEVICE|EMO-200|TEST Lens
218932515|NCT04954833|DEVICE|EMO-118|CONTROL Lens
218932516|NCT04339036|DRUG|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
218932517|NCT04339036|DRUG|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
218932518|NCT04339036|COMBINATION_PRODUCT|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
218932519|NCT04023019|BIOLOGICAL|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
219044929|NCT05429203|DEVICE|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
219044930|NCT04731610|OTHER|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
219044931|NCT04731610|OTHER|Surveillance after resection|Surveillance after tumour resection
219044932|NCT03944499|DRUG|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
219044933|NCT05441332|OTHER|EOS Radiation|One EOS exam of lower extremities
219044934|NCT05441332|BEHAVIORAL|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
219542414|NCT06370104|BEHAVIORAL|Living under control|see arm description
219621491|NCT04269369|DRUG|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
219621492|NCT00629356|GENETIC|dengue fever|
218932520|NCT04023019|BIOLOGICAL|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
219044935|NCT05074186|DEVICE|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
219621493|NCT00140868|DEVICE|Luminal stents|
219621494|NCT00140868|PROCEDURE|Minimally Invasive Surgical Bowel Diversion|
218932521|NCT04023019|BIOLOGICAL|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
218932522|NCT04023019|BIOLOGICAL|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
219542415|NCT00585286|DEVICE|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
218932523|NCT04023019|BIOLOGICAL|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
219542416|NCT02066038|DRUG|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
219542417|NCT02541227|DRUG|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
219542418|NCT06455332|OTHER|Optic nerve MRI sequence|Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
219542419|NCT01937182|DRUG|Citalopram|Citalopram 10-40 mg per day administered orally
219542420|NCT01937182|DRUG|Placebo|1/2-2 tablets per day with no intrinsic drug activity
218932524|NCT04023019|BIOLOGICAL|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
219044936|NCT05176561|BEHAVIORAL|Auditory-Cognitive Training|"Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search)."
219044937|NCT05176561|BEHAVIORAL|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
219044938|NCT06553794|OTHER|Gastroscopy with duodenal mucosal tissue biopsies|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
219044939|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
219044940|NCT00433654|DEVICE|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
219044941|NCT00433654|OTHER|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
219044942|NCT06471920|BEHAVIORAL|Standardized Education|Patients randomized to the standardized education group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
219044943|NCT06471920|BEHAVIORAL|Telerehabilitation|Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
219044944|NCT04158297|PROCEDURE|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
219044945|NCT06095947|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
219044946|NCT06028932|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
219044947|NCT06050395|BEHAVIORAL|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
219044948|NCT06050395|BEHAVIORAL|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
218932525|NCT01854450|OTHER|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
218932526|NCT01854450|OTHER|control|usual obstetrical care
218932527|NCT06137365|DRUG|Cannabis|Cannabis gummy product will be prepared using cannabis flower extract.
218932528|NCT06137365|DRUG|Placebo|Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
218932529|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
218932530|NCT04239248|DIETARY_SUPPLEMENT|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy."
218932531|NCT04239248|DIETARY_SUPPLEMENT|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
218932532|NCT03208296|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
218932533|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
219542421|NCT04685291|PROCEDURE|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
218932534|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
218932535|NCT03810651|OTHER|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
218932536|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
218932537|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
218932538|NCT05180383|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
218932539|NCT06440421|BEHAVIORAL|MTL Labels|The MTL label developed by the United Kingdom (UK) Food Standards Agency (FSA) includes per serving size information and grades each nutrient i.e., energy, sugar, fat, saturated fat, and sodium separately based on recommended thresholds. Green signifies a healthy amount of that nutrient; red signifies an unhealthy amount, and amber signifies that the nutrient levels fall between healthy and unhealthy amounts. Additionally, the label also shows how much of a person's daily allowance for a particular nutrient is met by consuming one serving of the product. Lastly, MTL includes the absolute values of each nutrient per serving of a product and the percentage of an adult's daily reference intake that is met by consuming a serving of this product. These will be displayed on all food and beverage products shown on this version of Bahrain e-Mart.
219044949|NCT06050395|BEHAVIORAL|Educational Handouts|Participants will receive educational handouts on diet.
219044950|NCT06050395|BEHAVIORAL|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
219621495|NCT03841864|OTHER|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
219621496|NCT00482768|BEHAVIORAL|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
218932540|NCT05202756|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
218932541|NCT05202756|BEHAVIORAL|EMA Monitoring Only|Safety Planning Intervention; ecological momentary assessment only
218932542|NCT05335915|OTHER|Nicotine|Nicotine pouches will be self-administered
218932543|NCT05335915|OTHER|Cigarette|Cigarette will be smoked
218932544|NCT03603353|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
219621497|NCT00917748|DRUG|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
219621498|NCT00917748|DRUG|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
219621499|NCT00917748|DRUG|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
218932545|NCT03603353|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
218932546|NCT03675321|DEVICE|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
218932547|NCT03675321|DEVICE|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
218932548|NCT00936286|DEVICE|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
219542422|NCT04685291|DRUG|Conventional pain management|"* oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
219542423|NCT03592420|BEHAVIORAL|Interdisciplinary multicomponent interventions|
219542424|NCT03592420|BEHAVIORAL|Usual care|standard care
219542425|NCT05411887|DRUG|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
219542426|NCT00113958|DRUG|Cinacalcet|
219542427|NCT02332967|OTHER|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
219542428|NCT02332967|OTHER|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
219542429|NCT02332967|OTHER|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
219542430|NCT03750357|DEVICE|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
219621500|NCT04242498|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
218932549|NCT00910416|DRUG|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
218932550|NCT00910416|DRUG|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
218932551|NCT00910416|DEVICE|EEG monitoring|simultaneous monitoring with Bis and Neurosense
218932552|NCT04422158|DIETARY_SUPPLEMENT|Nuun electrolyte tablet|Each table contains 2 grams of carbohydrate and a combination of electrolytes. calcium (13mg, 1%DV), sodium (300mg, 13%DV), potassium (150mg, 3%DV), magnesium (25mg, 6%DV), and chloride (40mg, 2%DV).
218932553|NCT04422158|OTHER|water|water
218932554|NCT01487343|BEHAVIORAL|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
218932555|NCT04442802|PROCEDURE|Percutaneous transluminal angioplasty|Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
219542431|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- anodal group|2mA/20mins/session;
219542432|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- sham group|0mA/20mins/session
219542433|NCT06562504|DEVICE|transcranial alternating current stimulation (tACS)-tACS group|1.5 mA/20 min/session; 6HZ, theta
219542434|NCT02913924|DRUG|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
219542435|NCT02913924|DRUG|Placebo|
219542436|NCT05173350|OTHER|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
219621501|NCT04242498|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
219621502|NCT06133387|DEVICE|Endoscopic submucosal dissection using the ELS System|All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
219621503|NCT05715281|BIOLOGICAL|Atezolizumab|Given IV
219621504|NCT05715281|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219621505|NCT05715281|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219621506|NCT05715281|PROCEDURE|Computed Tomography|Undergo CT scan
219621507|NCT05715281|PROCEDURE|Echocardiography Test|Undergo ECHO
219621508|NCT05715281|DRUG|Tiragolumab|Given IV
218932556|NCT04284228|BIOLOGICAL|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
218932557|NCT05095948|PROCEDURE|Discussion|Undergo audio recording of clinic conversations
218932558|NCT05095948|OTHER|Electronic Health Record Review|Review of medical records
218932559|NCT05095948|OTHER|Questionnaire Administration|Complete questionnaires
218932560|NCT00825487|DRUG|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
218932561|NCT00343460|DRUG|APF530|Given subcutanously
218932562|NCT00343460|DRUG|dexamethasone|Given IV and orally
218932563|NCT00343460|DRUG|Palonosetron Hydrochloride|Given IV
218932564|NCT00343460|OTHER|placebo|Given subcutanously or IV
218932565|NCT05853991|OTHER|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
218932566|NCT05853991|OTHER|Active comparator|Application of affective touch
218932567|NCT05853991|OTHER|Placebo|Application of static touch
218932568|NCT05938400|DEVICE|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
218932569|NCT01318460|DRUG|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
219542437|NCT05173350|OTHER|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
219542438|NCT03157193|DRUG|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
218932570|NCT01318460|DRUG|Placebo infusion|Twenty-four hour administration of placebo
218932571|NCT06457750|BEHAVIORAL|Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application|Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
218932572|NCT01397214|DRUG|Megace F|Megace F oral suspension
218932573|NCT01397214|DRUG|Megace OS|Megace oral suspension
218932574|NCT00006340|DRUG|arginine butyrate|
218932575|NCT00006340|DRUG|ganciclovir|
218932576|NCT02688777|BEHAVIORAL|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
218932577|NCT04073108|DIAGNOSTIC_TEST|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
218932578|NCT06138496|DRUG|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
218932579|NCT02549365|DRUG|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
218932580|NCT02549365|PROCEDURE|Surveillance (nasal swabbing) during influenza season|
218932581|NCT02718144|DRUG|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
218932582|NCT04315740|OTHER|Particles from candles|Generating fine and ultrafine particles from lit candles
218932583|NCT04315740|OTHER|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
219044951|NCT06050395|BEHAVIORAL|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
219044952|NCT06050395|BEHAVIORAL|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
219542439|NCT03157193|DRUG|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
219542440|NCT03222557|PROCEDURE|Electroacupuncture|Refer to arm description
219542441|NCT03222557|PROCEDURE|Sham Acupuncture|Refer to arm description
219542442|NCT03222557|DEVICE|Electroacupuncture|Refer to arm description
219542443|NCT03222557|DEVICE|Sham Acupuncture|Refer to arm description
219542444|NCT02947945|DRUG|Reslizumab|All subjects will receive Reslizumab
219542445|NCT04208724|OTHER|Training|Participate in the training program
219542446|NCT04208724|OTHER|Cancer Screening intervention|Receive cancer screening intervention
219044953|NCT06050395|BEHAVIORAL|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
219044954|NCT03100227|OTHER|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
219044955|NCT03100227|OTHER|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
219044956|NCT04984551|OTHER|Extension of Community Health (ECHO) Telementoring Clinic|Participate in ECHO clinics presenting cases for guidance and feedback
219044957|NCT04984551|OTHER|In-Country Workshops|In-Country Workshops Participate in hands-on training and workshops
219542447|NCT04208724|OTHER|Survey Administration|Ancillary studies
219542448|NCT02448160|DEVICE|alfapump|Implantation of alfapump
219542449|NCT02448160|DRUG|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
219542450|NCT02225314|BEHAVIORAL|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
219542451|NCT02225314|BEHAVIORAL|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
219542452|NCT02225314|BEHAVIORAL|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
219542453|NCT04178122|GENETIC|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
218932584|NCT04315740|OTHER|Clean Air|Nothing but clean air
218932585|NCT00194506|BEHAVIORAL|Internet co-management module|
218932586|NCT02614599|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
218932587|NCT02614599|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
218932588|NCT02865213|DEVICE|OBA|"The intrusion of posterior teeth using removable appliance OBA."
218932589|NCT02865213|DEVICE|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
218932590|NCT02865213|DEVICE|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
218932591|NCT04366817|BEHAVIORAL|psychological assessment|psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
219621509|NCT01108718|OTHER|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
219621510|NCT01108718|OTHER|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
219621511|NCT05095844|BIOLOGICAL|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
219621512|NCT03380429|DRUG|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
219621513|NCT03380429|DRUG|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
219621514|NCT03380429|DEVICE|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
219621515|NCT03380429|DEVICE|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
219621516|NCT03380429|DEVICE|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
219621517|NCT00432926|BEHAVIORAL|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
219621518|NCT00432926|BEHAVIORAL|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
219621519|NCT00432926|BEHAVIORAL|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
219621520|NCT04535141|DRUG|Olanzapine 5 MG|It will be a de-identified pill created by investigational drug services at University of North Carolina
219621521|NCT04535141|DRUG|Placebo|It will be a de-identified pill created by investigational drug services at University of North Carolina
219621522|NCT01014546|DRUG|Arsenic Trioxide|Given PO
219621523|NCT01014546|DIETARY_SUPPLEMENT|Ascorbic Acid|Given PO
219621524|NCT01014546|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621525|NCT01014546|OTHER|Pharmacological Study|Correlative studies
219621526|NCT06258538|DEVICE|Robots can aid in distal UE rehabilitation through exoskeleton (EXO)|Exoskeleton robot-assisted therapy Each EXO robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Hand of Hope (HOH) robotic hand system . HOH is an exoskeleton type of robot that is worn on the dorsal side of the impaired hand with 2 surface EMG sensors attached to the extensor digitorum and flexor digitorum superficialis.
219621527|NCT06258538|DEVICE|End-effector robot-assisted therapy (EE)|Each EE robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Amadeo robotic system. Amadeo is an end-effector robot with 5 finger slides, which are attached to the fingertips and the thumb via magnetic finger pads. The integrated sensor for each finger allows the robot system to provide patients with real-time visual feedback of finger strengths and range of motion
219621528|NCT06258538|BEHAVIORAL|Unilateral task-oriented therapy|The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
218932592|NCT01153334|DRUG|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1\. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
218932593|NCT06511141|DEVICE|Axonics SNM System|To assess clinical outcomes of the Axonics SNM System in the male OAB population.
219044958|NCT04984551|OTHER|Professional Oncology Educations Programs|Receive 5 core online lectures
219542454|NCT05892081|BIOLOGICAL|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
219542455|NCT05892081|BIOLOGICAL|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
219542456|NCT02431000|PROCEDURE|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
219542457|NCT04421716|DRUG|Ursolic Acid|Ursolic Acid 150mg
219542458|NCT04421716|DRUG|Curcumin|Curcumin 600mg
219542459|NCT06003335|BEHAVIORAL|Regular message delivery|Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.
219542460|NCT06003335|BEHAVIORAL|Chat-type support message delivery|Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
219542461|NCT03447535|OTHER|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
219542462|NCT03447535|OTHER|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
219542463|NCT04819386|OTHER|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
219044959|NCT04984551|OTHER|Medical Chart Review|Medical charts are reviewed for data collection
219044960|NCT04984551|OTHER|Questionnaire Administration|Complete questionnaire(s)
219542464|NCT00918684|DRUG|Escitalopram|10mg tab daily
219542465|NCT05250323|OTHER|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
219542466|NCT05226390|BIOLOGICAL|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
219542467|NCT06559605|PROCEDURE|zirconia barrier|barrier membrane used for guided bone regeneration and augmentation of ridge defect
219542468|NCT06559605|PROCEDURE|titanium mesh|barrier membrane used for guided bone regeneration
219542469|NCT00484679|DRUG|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
219542470|NCT00402103|DRUG|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
219542471|NCT00402103|DRUG|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
219542472|NCT00402103|DRUG|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
219621529|NCT06258538|BEHAVIORAL|Bilateral task-oriented therapy|The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
218932594|NCT06684704|OTHER|minimal and high flow anesthesia|Low-flow anesthesia technique is a technique based on the re-breathing of at least half of the gas exhaled in semi-closed systems by returning at least half of the exhaled gas to the patient in the next inspiration.
218932595|NCT02999672|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
218932596|NCT03565497|BEHAVIORAL|Wellness Education Control Condition|As per arm of the same name
218932597|NCT03565497|BEHAVIORAL|Mindfulness Training|As per arm of the same name
218932598|NCT03565497|BEHAVIORAL|Mindfulness Training Plus IE|As per arm of the same name
218932599|NCT03731676|DEVICE|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
219044961|NCT06484855|DRUG|IBI355|IBI355 IV. Q4W
219621530|NCT05220852|COMBINATION_PRODUCT|Dry needling with exercise|"At the initial session, dry needling will be given to their upper trapezius muscles' hyperactive trigger sites, and EX will continue for a minimum of three times per week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
218932600|NCT03731676|DEVICE|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
218932601|NCT04765891|OTHER|Positional release therapy|Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
218932602|NCT04765891|OTHER|Therapeutic Massage|Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
218932603|NCT03103334|OTHER|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
218932604|NCT03103334|DRUG|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
218932605|NCT01075685|BEHAVIORAL|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
219044962|NCT06484855|DRUG|IBI355 placebo|IBI355 placebo IV. Q4W
219044963|NCT05480956|BEHAVIORAL|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
219044964|NCT05480956|BEHAVIORAL|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
219542473|NCT06558708|DRUG|GZR101 Injection|Once daily
219542474|NCT06558708|DRUG|GZR33 Injection|Once daily
219542475|NCT06558708|DRUG|Insulin aspart|Once daily
219542476|NCT02128308|DRUG|Levofloxacin and Streptomycin added|
219542477|NCT02128308|DRUG|Moxifloxacin and Kanamycin added|
219542478|NCT06545474|DEVICE|bilateral theta burst stimulation|Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
219542479|NCT06545474|DRUG|SSRI treatment|Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
219542480|NCT04828538|DIETARY_SUPPLEMENT|Vitamin D|Daily 4000 IU Vitamin D for 60 days
219044965|NCT05480956|BEHAVIORAL|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
219044966|NCT05432336|DIAGNOSTIC_TEST|NGS for endohtalmitis / Multiplex PCR for keratitis|"For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples"
219044967|NCT06345742|OTHER|No parental participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Diaper care will be performed by the primary nurse.~4. Premature Infant Comfort Scale will be evaluated during and after the diaper care application."
219044968|NCT06345742|OTHER|Mother participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Mothers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Mothers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the mothers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
219044969|NCT06345742|OTHER|Father participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Fathers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Fathers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the fathers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
219044970|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
219044971|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219044972|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
219044973|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
218932606|NCT01075685|BEHAVIORAL|Minimum information|"This intervention includes:~* information about hazardous drinking~* an alcohol diary"
218932607|NCT00531661|DEVICE|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
218932608|NCT03516630|DRUG|Trazodone 20 mg|Oral drops
218932609|NCT03516630|DRUG|Trazodone 60 mg|Oral drops
218932610|NCT03516630|DRUG|Trazodone 140 mg|Oral drops
218932611|NCT03516630|DRUG|Placebo|Oral drops
218932612|NCT03516630|DRUG|Moxifloxacin 400mg|Tablet
218932613|NCT02037685|BEHAVIORAL|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~* Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~* Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
218932614|NCT02037685|OTHER|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
218932615|NCT03470298|PROCEDURE|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
218932616|NCT01255683|DRUG|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
218932617|NCT02812862|DRUG|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
219044974|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
219044975|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
219542481|NCT04828538|DIETARY_SUPPLEMENT|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
219542482|NCT04828538|DIETARY_SUPPLEMENT|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
218932618|NCT01814267|OTHER|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed"
218932619|NCT01814267|OTHER|conventional|"conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed"
219542483|NCT04828538|OTHER|Placebo|Placebo
219542484|NCT04451746|DRUG|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
219542485|NCT00835692|DRUG|Clarithromycin|500 mg Tablet
218932620|NCT02633709|DRUG|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
218932621|NCT02633709|OTHER|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
218932622|NCT02633709|DRUG|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
218932623|NCT04986761|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
218932624|NCT05860309|OTHER|quadratous lumborum block|The patient will be placed in the lateral position, after sterilization.. QLB will be done using ultrasound, The probe will be positioned superior to the iliac crest, in the transverse orientation, at the posterior axillary line. The Shamrock sign will be identified at the L4 level, and the insulated nerve block needle will be advanced from posterior to anterior, through the QL muscle, until the needle tip is visualized in the interfascial plane between the QL muscle and psoas muscle. As the correct needle placement is confirmed with 2-3 mL of saline, 20 mL of 0.25% bupivacaine will be injected ensuring that the psoas muscle will be pushed deeply.
218932625|NCT01347619|OTHER|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
218932626|NCT01347619|OTHER|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
218932627|NCT01347619|OTHER|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
218932628|NCT04570319|DIETARY_SUPPLEMENT|Probiotic Bths-08|A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
218932629|NCT04570319|DIETARY_SUPPLEMENT|Placebo|A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
218932630|NCT05361148|OTHER|no interventions will be used|This is a cohort study with no interventions.
219044976|NCT06564532|BEHAVIORAL|Evaluatively conditioning participant to like partner|The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
219542486|NCT00835692|DRUG|Biaxin®|500 mg Tablet
219542487|NCT01360138|PROCEDURE|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
219542488|NCT05395052|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
218932631|NCT02858362|DRUG|Ezutromid|Administered orally.
218932632|NCT00586417|OTHER|punch biopsy|skin biopsies
218932633|NCT04945928|PROCEDURE|Surgery|Participants having been evaluated as operable after receiving first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) will receive surgery.
219044977|NCT06564532|BEHAVIORAL|Evaluatively conditioning partner to like participant|The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
219044978|NCT06561685|DRUG|LY4050784|Oral
219044979|NCT06561685|DRUG|Pembrolizumab|Administered IV.
219044980|NCT06561685|DRUG|Cisplatin|Administered IV.
219044981|NCT06561685|DRUG|Carboplatin|Administered IV.
219044982|NCT06561685|DRUG|Pemetrexed|Administered IV.
219044983|NCT06561685|DRUG|Paclitaxel|Administered IV.
219044984|NCT06561685|DRUG|Nab paclitaxel|Administered IV.
219542489|NCT05395052|DRUG|Cyclophosphamide|Lympho-conditioning agent
219542490|NCT05395052|DRUG|Fludarabine|Lympho-conditioning agent
219542491|NCT05395052|DRUG|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
219542492|NCT05395052|COMBINATION_PRODUCT|Avelumab|Monoclonal antibody
219542493|NCT05395052|COMBINATION_PRODUCT|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
219542494|NCT05395052|COMBINATION_PRODUCT|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
219542495|NCT05395052|COMBINATION_PRODUCT|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
219542496|NCT05395052|COMBINATION_PRODUCT|Trastuzumab|Monoclonal antibody
219542497|NCT05395052|COMBINATION_PRODUCT|Cetuximab|Monoclonal antibody
219542498|NCT05395052|COMBINATION_PRODUCT|Amivantamab|Monoclonal antibody
219542499|NCT05395052|DRUG|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
218932634|NCT04693624|OTHER|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
218932635|NCT04301505|OTHER|Intervention 1|Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
218932636|NCT04301505|OTHER|Intervention 2|The same checklist will be delivered at the beginning of the study and repeated after 6 months.
218932637|NCT02194985|DRUG|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
218932638|NCT01131689|DRUG|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
218932639|NCT00018083|DRUG|rifabutin|
218932640|NCT00018083|DRUG|isoniazid|
218932641|NCT00018083|DRUG|efavirenz|
218932642|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
218932643|NCT01775618|BIOLOGICAL|BAY94-9027|Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
218932644|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
218932645|NCT02561832|DRUG|Olaparib|tablets taken orally twice daily
218932646|NCT02561832|DRUG|Carboplatin|intravenous injections on day one of each cycle
218932647|NCT02561832|DRUG|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
219205445|NCT02056236|DRUG|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
219205446|NCT02056236|OTHER|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
218932648|NCT02561832|DRUG|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
218932649|NCT05635253|OTHER|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
218932650|NCT05635253|OTHER|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
218932651|NCT02280343|OTHER|evaluated lung function|lung function tests
218932652|NCT03077841|OTHER|Laboratory Biomarker Analysis|Correlative studies
218932653|NCT03077841|RADIATION|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
218932654|NCT03077841|OTHER|Questionnaire Administration|Ancillary studies
218932655|NCT06480084|DIAGNOSTIC_TEST|Continuous Laryngoscopy during Exercise Test (CLE test)|A flexible fiberoptic laryngoscope (Olympus, Tokyo, Japan) is introduced directly through the nose or via a slightly modified Hans Rudolph facemask, and into the pharyngeal space. A modified Bruce protocol with a 60-second incremental intensity step is used (Appendix A) and heart rate is monitored. During the CLE test participants perform incremental exercise on a treadmill until symptom-limiting distress or exhaustion. Forced expiratory flow-volume loops are measured before, during and after the CLE test.
218932656|NCT04103749|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
218932657|NCT02615639|BIOLOGICAL|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
218932658|NCT02615639|DRUG|Entecavir|0.5mg tablet every night by mouth
218932659|NCT02615639|DRUG|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
218932660|NCT02615639|DRUG|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
219044985|NCT03413423|BEHAVIORAL|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
218932661|NCT02615639|DRUG|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
218932662|NCT02615639|DRUG|Telbivudine|Telbivudine 600mg tablet every day by mouth
218932663|NCT01070485|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
219044986|NCT03413423|BEHAVIORAL|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
219044987|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
219044988|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
219044989|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
219044990|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
219044991|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
219044992|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
219044993|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
219044994|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
219044995|NCT06428019|DRUG|Venetoclax|Oral: Tablet
219044996|NCT06428019|DRUG|Acalabrutinib|Oral: Tablet
219044997|NCT06428019|DRUG|Obinutuzumab|Intravenous Infusion
219044998|NCT04590885|BEHAVIORAL|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
219205447|NCT06460441|DIAGNOSTIC_TEST|SUNRISE© device|"The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician."
218932664|NCT03284580|OTHER|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
218932665|NCT03284580|OTHER|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
218932666|NCT03284580|OTHER|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
218932667|NCT00768313|DEVICE|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
218932668|NCT00768313|DEVICE|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
218932669|NCT01262989|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
218932670|NCT01262989|DRUG|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
219044999|NCT04590885|BEHAVIORAL|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
219045000|NCT03852797|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
219045001|NCT03852797|DRUG|Ketamine|Ketamine in solution, 10-4M to 10-7M
219045002|NCT03852797|DRUG|Propofol|Propofol in solution, 10-4M to 10-7M
219045003|NCT03852797|DRUG|Etomidate|Etomidate in solution, 10-4M to 10-7M
219045004|NCT05179421|DRUG|Low dose oxytocin|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
219045005|NCT05179421|DRUG|High dose oxytocin|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
219045006|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
219045007|NCT06803680|DRUG|BGB-B455|Planned doses administered on specified days per protocol.
219205448|NCT04299113|DRUG|Vinorelbine|Given IV
219045008|NCT06803680|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219045009|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
219045010|NCT06372249|DRUG|Inulin|Soluble tapioca starch from Ingredion.
219205449|NCT04299113|DRUG|Mocetinostat|Given PO
218932671|NCT01564576|DRUG|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
218932672|NCT04108637|PROCEDURE|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
218932673|NCT06835933|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is most commonly performed bariatric/metabolic surgery. LSG is performed in patients with obesity and/or obesity-related comorbidities. During LSG, the stomach was resected from 5 cm proximal to the pylorus to the angle of His, guided by a 36-French bougie. In patients with hiatal hernia, concomitant HHR was also performed with LSG using non-absorbable sutures. Routine oral potassium-competitive acid blocker (PCAB) was prescribed for 3 months after surgery and the discontinuation of PCAB was determined based on GERD symptoms at the 3-month visit.
218932674|NCT02557880|BEHAVIORAL|Sleep Application Diary|Tool used to document sleep hygiene.
218932675|NCT02557880|BEHAVIORAL|Treatment As Usual|Sleep hygiene counseling
218932676|NCT06003270|DRUG|Quercetin 1000 mg|Active comparator
218932677|NCT06003270|DRUG|Quercetin 500 MG|Active comparator
218932678|NCT06003270|DRUG|Placebo|Placebo comparator
218932679|NCT04551534|DRUG|DNL201|Oral dose(s)
218932680|NCT04551534|DRUG|Placebo|Oral dose(s)
219205450|NCT06136260|OTHER|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will text and/or call the parent after receiving the referral; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, subsequent calls or texts from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
218932681|NCT03358524|DRUG|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
218932682|NCT03358524|DRUG|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
218932683|NCT03048578|DRUG|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
218932684|NCT03048578|DRUG|Placebo|Subcutaneous Saline Solution
218932685|NCT01096459|PROCEDURE|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
218932686|NCT02961738|BEHAVIORAL|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
218932687|NCT00552435|DEVICE|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
218932688|NCT01052701|DRUG|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)"
218932689|NCT01052701|DRUG|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
219045011|NCT04917146|OTHER|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
219045012|NCT05927792|DEVICE|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
219045013|NCT05927792|DEVICE|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
219205451|NCT06136260|OTHER|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a link to a webpage with a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
219205452|NCT03466476|DEVICE|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
219205453|NCT04493476|DRUG|Chinese herbal formula|Chinese herbal formula
218932690|NCT05529797|OTHER|Veovita-VR|Veovita-VR is a VR intervention with positive emotional stimuli and positive behavioral activation designed to reduce depressive symptoms in people with at least moderate depressive symptoms. In the VR session, the participants stay in a beautiful environment (island, sandy beach, beautiful scenery). They can engage in activities that are perceived as positive (climbing, treasure hunting, listening to music, building sandcastles). The session has a length of approx. 30 minutes. Participants are free to continue to engage with any treatment they require during the duration of the study.
219045014|NCT06175221|BIOLOGICAL|Tumor lysate, particle only (TLPO) vaccine|A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
219045015|NCT03058133|OTHER|fMRI study|Functional brain activations of face-voice processing during a gender task
218932691|NCT04243616|DRUG|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
218932692|NCT04243616|DRUG|Paclitaxel|80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
218932693|NCT04243616|DRUG|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
219045016|NCT04893954|DIAGNOSTIC_TEST|Full Spine Radiography|Full Spine Radiography
219045017|NCT04893954|DIAGNOSTIC_TEST|Lumbar spine MRI|Lumbar spine MRI
219045018|NCT03473743|DRUG|Erdafitinib|Participants will receive erdafitinib orally.
219045019|NCT03473743|DRUG|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
219045020|NCT03473743|DRUG|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
219045021|NCT03473743|DRUG|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
219045022|NCT02433314|DRUG|SAGE-547|
219045023|NCT04521166|DEVICE|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
219045024|NCT06431061|DEVICE|Lens A (omafilcon B)|15 minutes of daily wear.
219045025|NCT06431061|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
219045026|NCT02614547|DRUG|SAGE-547|Administered as intravenous infusion.
218932694|NCT04243616|DRUG|Doxorubicin|60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
218932695|NCT04243616|DRUG|Cyclophosphamide|600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
219045027|NCT02614547|DRUG|Placebo|Administered as intravenous infusion.
219045028|NCT06418256|OTHER|Spleen, blood and plasma collection|Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
219045029|NCT06484075|DRUG|Placebo|The placebo will be a tablet, but only containing inert inactive ingredients.
219045030|NCT06484075|DRUG|Suvorexant|Drug approved for improving sleep
218932696|NCT00287378|DRUG|omalizumab|omalizumab as per weight and IgE
218932697|NCT05290285|DIETARY_SUPPLEMENT|Amino-Ther Pro|Food supplements
219045031|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
219045032|NCT06348719|PROCEDURE|Robot-assisted laparoscopy|The experimental procedure corresponds to robot-assisted laparoscopy.
219045033|NCT06348719|PROCEDURE|conventional laparoscopy|"The control procedure corresponds to conventional laparoscopy."
219045034|NCT06348719|OTHER|Prospective cohort study|A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
219045035|NCT06348719|OTHER|Retrospective cohort study|Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.
219045036|NCT06348719|OTHER|information and consent|information and consent
219045037|NCT06348719|OTHER|randomization|Randomization
219045038|NCT06348719|OTHER|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
218932698|NCT05290285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
218932699|NCT01723319|DEVICE|HBLPADD coil deep TMS|20 daily deep TMS treatment
218932700|NCT01723319|DEVICE|Sham|inactive treatment
219045039|NCT06348719|OTHER|Surgical data collection|Surgical data collection at Day 0
219045040|NCT06348719|OTHER|Biological data collection|Biological data collection at Day 1
219045041|NCT06348719|OTHER|Collection of histological data from the surgical specimen|Collection of histological data from the surgical specimen et Day 42
219045042|NCT06348719|OTHER|Phone calls|Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
218932701|NCT02459834|OTHER|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
218932702|NCT02459834|OTHER|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
218932703|NCT02459834|OTHER|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
218932704|NCT03161444|OTHER|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
218932705|NCT00235365|BEHAVIORAL|meta-cognitive therapy|Meta-cognitive therapy
218932706|NCT00235365|OTHER|waiting list|waiting list control
218932707|NCT00996333|DRUG|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
218932708|NCT04749056|BEHAVIORAL|EPAS (electronic psycho-oncological adapative screening program)|"Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested."
218932709|NCT04885777|DRUG|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
218932710|NCT04885777|OTHER|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
218932711|NCT03746119|OTHER|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
218932712|NCT03746119|OTHER|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
218932713|NCT03705143|BEHAVIORAL|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
218932714|NCT03705143|BEHAVIORAL|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
218932715|NCT01420952|DRUG|[11C]LY2428703|
218932716|NCT01271985|DRUG|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
219045043|NCT06348719|OTHER|Pain assessment|Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
218932717|NCT01271985|OTHER|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
219045044|NCT06348719|OTHER|Collect of data on non-reimbursed transport|Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
219045045|NCT06348719|OTHER|Collect of everyday help|Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
219045046|NCT06348719|OTHER|Collection of the business resumption date|Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
219045047|NCT06348719|OTHER|SF36 questionnaire|SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
219045048|NCT06348719|OTHER|Questionnaire EQ5D-5L|Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
219045049|NCT06348719|OTHER|FIGO Stadium|FIGO Stadium at inclusion and Day 42
219045050|NCT06348719|OTHER|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
219045051|NCT06348719|OTHER|Collection of adjuvant treatments|Collection of adjuvant treatments at month 6
219045052|NCT06348719|OTHER|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
219045053|NCT06348719|OTHER|Collection of data|Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used
219045054|NCT05783505|OTHER|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
218932718|NCT04655807|DRUG|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
219045055|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
219045056|NCT05598047|BEHAVIORAL|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
219542500|NCT06562387|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
219542501|NCT06562387|OTHER|cognitive stimulation|This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
219542502|NCT06562387|DEVICE|sham transcranial direct current stimulation|Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.
219542503|NCT06562309|OTHER|take feces and blood samples from patients|this study does not involve any intervention
218932719|NCT04655807|DRUG|Placebo|Matching placebo will be administered as SC injection.
218932720|NCT04655807|DRUG|Adalimumab|Adalimumab will be administered as SOC biological therapy.
218932721|NCT04655807|DRUG|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
218932722|NCT05063773|DEVICE|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
218932723|NCT01348516|DRUG|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
219045057|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
219045058|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
218932724|NCT01348516|DRUG|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
218932725|NCT03572595|DIAGNOSTIC_TEST|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
218932726|NCT03557060|DRUG|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
218932727|NCT05428397|DIAGNOSTIC_TEST|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
218932728|NCT04112212|DRUG|Fluorescence molecular imaging procedure using vedolizumab-800CW|First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
218932729|NCT04112212|OTHER|Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW|Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.
219045059|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
219045060|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
219045061|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
219045062|NCT05619692|DRUG|SAGE-718|Softgel lipid capsules.
219045063|NCT05619692|DRUG|SAGE-718-matching Placebo|Softgel lipid capsules.
219205454|NCT06386419|DRUG|inclisiran|Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
218932730|NCT04112212|COMBINATION_PRODUCT|Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab|Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
219542504|NCT03526757|OTHER|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
219542505|NCT03526757|OTHER|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
219542506|NCT01149733|DRUG|Tamsulosin|Test 0.4 mg Capsule
219542507|NCT01149733|DRUG|Tamsulosin|Reference Listed 0.4 Capsule
219542508|NCT05456594|OTHER|Conventional bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).
219542509|NCT05456594|OTHER|Bounceless bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).
219542510|NCT05456594|OTHER|Shefit bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
219542511|NCT04665596|DEVICE|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
219542512|NCT03260153|DRUG|Deproteinised Calf Blood Serum Injection|
218932731|NCT06103253|DIETARY_SUPPLEMENT|a Bla80 group|the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
218932732|NCT00003897|BIOLOGICAL|gp100 antigen|
218932733|NCT00003897|BIOLOGICAL|sargramostim|
218932734|NCT03300596|BEHAVIORAL|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
218932735|NCT03300596|BEHAVIORAL|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
218932736|NCT03566485|DRUG|Atezolizumab|Given by IV
218932737|NCT03566485|DRUG|Cobimetinib|Given by mouth
218932738|NCT03566485|DRUG|Idasanutlin|Given by mouth
218932739|NCT03641586|DRUG|BGB-283|
218932740|NCT03115788|OTHER|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
218932741|NCT03115788|OTHER|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
218932742|NCT03115788|OTHER|iPad|
218932743|NCT04999852|DEVICE|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
219542513|NCT03260153|DRUG|Placebo (Sodium Chloride)|
219542514|NCT00217763|DRUG|3APS|
219542515|NCT02632864|RADIATION|Proton arm|Proton beam therapy
219542516|NCT04345653|DRUG|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
219542517|NCT00360763|DRUG|candesartan cilexetil|
219542518|NCT03964935|DRUG|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
219542519|NCT03964935|DRUG|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
219542520|NCT03964935|OTHER|Distilled water|Used to irrigate periodontal pockets after SRP
219542521|NCT03823924|PROCEDURE|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
219542522|NCT00412503|DRUG|Topotecan, Temozolomide|
219045064|NCT06205849|DRUG|IRE + intratumoral mitazalimab (CD40 antibody) injection|Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.
219045065|NCT06205849|DEVICE|NanoKnife|Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
219542523|NCT01798719|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
219542524|NCT01798719|BEHAVIORAL|General Advice|Only general advice about diet
219542525|NCT00304538|DRUG|very low dose (VLD) glucagon|
219542526|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment A|
219542527|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment B|
219542528|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment C|
219542529|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment D|Placebo
219542530|NCT01895335|DRUG|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
219542531|NCT00418938|DRUG|Panitumumab|6mg/kg IV
219542532|NCT00418938|DRUG|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
219045066|NCT05201469|DRUG|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
219542533|NCT00418938|DRUG|Leucovorin|400mg/m\^2 IV (in the vein)
219542534|NCT00418938|DRUG|Irinotecan|180mg/m\^2 IV (in the vein)
219542535|NCT00418938|DRUG|5-Fluorouracil|400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
219045067|NCT05201469|DRUG|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
219045068|NCT05402397|DRUG|Losartan Potassium|Patients will receive losartan potassium for 30 days.
219045069|NCT05909085|DEVICE|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
219045070|NCT05909085|DEVICE|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
219045071|NCT06165354|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
219045072|NCT06165354|COMBINATION_PRODUCT|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
219542536|NCT00082147|PROCEDURE|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
219542537|NCT04952857|DRUG|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
219542538|NCT00115063|BEHAVIORAL|group sessions|group sessions lead by a trained primary care clinic employee
219542539|NCT00115063|DRUG|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
219542540|NCT00115063|BEHAVIORAL|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
219542541|NCT00115063|OTHER|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
218932744|NCT04999852|BEHAVIORAL|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
218932745|NCT06102525|DRUG|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
219045073|NCT01246791|DRUG|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
219045074|NCT06580197|OTHER|Auricular Acupoint Therapy|Ear point diagnosis and treatment is one of acupuncture and moxibustion methods, which originates from the theory of acupuncture and moxibustion meridians and is the product of the combination of modern Chinese medicine and western medicine, including two parts: auricular acupoint diagnosis and auriculotherapy. Ear point diagnosis refers to the determination of auricle positive reaction points through vision, touch, pressure and other methods to diagnose diseases in some parts of the body on the basis of ear point theory. Ear point treatment refers to the use of certain therapeutic devices on ear points to achieve the purpose of prevention and treatment of diseases by stimulating ear points, which are often carried out simultaneously in clinical practice.
219045075|NCT00989820|DRUG|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
219045076|NCT05267054|DRUG|Ociperlimab|administered intravenously
218932746|NCT06102525|COMBINATION_PRODUCT|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
218932747|NCT06122415|DIAGNOSTIC_TEST|Plasma Amyloid Probability Score 2 (APS 2) score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
219045077|NCT05267054|DRUG|Tislelizumab|Administered intravenously once every 3 weeks
219045078|NCT05267054|DRUG|Rituximab|Administered intravenously once every 3 weeks
219045079|NCT06255028|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
219542542|NCT00115063|OTHER|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
219045080|NCT06255028|BIOLOGICAL|IL-2|IL-2 subcutaneous (SC) injection
219542543|NCT05125900|OTHER|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
219542544|NCT05949853|OTHER|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
219542545|NCT01857947|OTHER|AECOPD Mr proADM|
219542546|NCT00789308|DRUG|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
219542547|NCT00789308|DRUG|Heparin|Anticoagulation
219542548|NCT00789308|DRUG|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
219542549|NCT00789308|DRUG|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
219542550|NCT00789308|DRUG|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
219542551|NCT00789308|DRUG|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
219542552|NCT00789308|DRUG|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
219542553|NCT00789308|DRUG|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
219542554|NCT00789308|DRUG|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
219542555|NCT03072030|BIOLOGICAL|GamEvac-Combi (vaccine)|vaccination
219542556|NCT03072030|BIOLOGICAL|Placebo|vaccination
219542557|NCT01349257|DRUG|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
218932748|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217/nptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218932749|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
219045081|NCT06255028|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
219045082|NCT02134301|DRUG|Oritavancin|
219045083|NCT06031844|DRUG|DFV890|oral film-coated tablets
219045084|NCT06031844|DRUG|Placebo|oral film-coated tablets
219045085|NCT02276430|OTHER|Vena punction|Once 90 ml
219045086|NCT04729348|DRUG|Pembrolizumab|Oral, daily, dosage per protocol
219045087|NCT04729348|DRUG|Lenvatinib|Oral, daily, dosage per protocol
219045088|NCT05843084|PROCEDURE|7T MRI network analysis for deep brain stimulation in Parkinson's disease|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in PD patients.
219542558|NCT02982577|DRUG|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
219542559|NCT02982577|OTHER|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
219542560|NCT01776138|OTHER|Collect Blood and Survey Instruments|
219542561|NCT03808376|DEVICE|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
219542562|NCT06571734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219542563|NCT06571734|PROCEDURE|Computed Tomography|Undergo CT
219542564|NCT06571734|PROCEDURE|Echocardiography|Undergo ECHO
219542565|NCT06571734|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219542566|NCT06571734|DRUG|Zanzalintinib|Given PO
219542567|NCT04953520|PROCEDURE|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
219045089|NCT05503173|BEHAVIORAL|MCBMAP|MCBMAP integrates motivational interviewing (MI) and cognitive-behavioral skill training interventions for unhealthy drinking with cognitive-behavioral and self- management approaches for chronic pain. The intervention is delivered through internet-based videoconferencing and supplemented with web-based content to support the intervention. The initial treatment session provides a rationale for addressing alcohol and pain together in the context of HIV management, and initiates MI related to alcohol use. Participants receive 6 additional treatment sessions over the subsequent weeks.
218932750|NCT06122415|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218932751|NCT06122415|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218932752|NCT05901558|BEHAVIORAL|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
218932753|NCT05901558|BEHAVIORAL|Community intervention|Regular community intervention
218932754|NCT04965597|DRUG|Treosulfan|Given IV
218932755|NCT04965597|DRUG|Fludarabine Phosphate|Given IV
219045090|NCT05503173|OTHER|Brief Advice and Information|Through videoconferencing an interventionist will provide participants psychoeducation about the effects of alcohol and pain on HIV symptoms, advice/recommendations to reduce alcohol use, and a list of local treatment resources for alcohol and chronic pain.
219045091|NCT04332653|DRUG|NT-I7|Administered by intramuscular (IM) injection
219045092|NCT04332653|DRUG|pembrolizumab (KEYTRUDA®)|Administered by intravenous (IV) injection
219045093|NCT04049760|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
219045094|NCT05841758|DRUG|Hydroxychloroquine|Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
219045095|NCT05841758|DRUG|Placebo|Placebo during a 12 months double blind placebo-controlled period
219045096|NCT05626049|OTHER|Primary Spine Provider Model|Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.
219045097|NCT05626049|OTHER|Usual Care|Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
219542568|NCT04953520|PROCEDURE|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
219542569|NCT01718704|DEVICE|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
219045098|NCT04989608|OTHER|Neuroimaging|realization of a neuroimaging 1 and 3 years after the transient ischemic accident
219045099|NCT06441201|DIAGNOSTIC_TEST|Pulse flowmeter|Measures peripheral pulse volumes by an electrode applied non-invasively to the lower extremity (left or right) at the beginning of the endoscopic evaluation for the duration of the procedure, and up to 2 hours after the completion of the procedure.
219045100|NCT05541783|PROCEDURE|laparoscopy-assisted distal gastrectomy Group|LADG
219542570|NCT03644550|DRUG|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
219542571|NCT03644550|BIOLOGICAL|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
219542572|NCT01731457|DRUG|etanercept|adding appropriate dose of etanercept to the perfusion fluid
219542573|NCT03563872|OTHER|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
219542574|NCT03563872|OTHER|Active Comparator|Usual, team-based care
218932756|NCT04965597|DRUG|Tacrolimus|Given IV and PO
218932757|NCT04965597|DRUG|Methotrexate|Given IV
218932758|NCT04965597|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
218932759|NCT04965597|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
218932760|NCT04965597|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo bone marrow transplant
218932761|NCT04965597|OTHER|Quality-of-Life Assessment|Ancillary studies
218932762|NCT04965597|PROCEDURE|Echocardiography|Undergo ECHO
218932763|NCT04965597|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218932764|NCT04965597|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
218932765|NCT04965597|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
218932766|NCT04965597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218932767|NCT04965597|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
218932768|NCT04965597|PROCEDURE|Computed Tomography|Undergo chest CT
218932769|NCT04991389|DRUG|129-Xe|Inhaled contrast for MRI
218932770|NCT06045754|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
218932771|NCT06045754|DRUG|Adalimumab|Adalimumab subcutaneous injection.
218932772|NCT06045754|DRUG|Ustekinumab|Ustekinumab intravenous infusion.
218932773|NCT06045754|DRUG|Ustekinumab|Ustekinumab subcutaneous injection.
218932774|NCT02343237|PROCEDURE|Osteopathic treatment|osteopathic sessions of 20 minutes
219045101|NCT05541783|PROCEDURE|Totally laparoscopic distal gastrectomy|TLDG
219045102|NCT05407324|DRUG|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
218932775|NCT02343237|PROCEDURE|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
218932776|NCT06637852|BEHAVIORAL|SUFICS-PACT|SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
218932777|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
218932778|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
218932779|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
219542575|NCT01712906|BIOLOGICAL|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
219542576|NCT01712906|BIOLOGICAL|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
218932780|NCT05645016|BEHAVIORAL|COEST|Adapted version of our COEST training, targeting Black church members.
218932781|NCT05566561|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
218932782|NCT06375499|DEVICE|T2769|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
218932783|NCT06375499|DEVICE|Hylo-Forte®|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
218932784|NCT04729322|PROCEDURE|Biopsy|Undergo biopsy
218932785|NCT04729322|PROCEDURE|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
218932786|NCT04729322|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
218932787|NCT04729322|DRUG|Metronidazole|Given PO
219542577|NCT01712906|BIOLOGICAL|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
218932788|NCT04729322|DRUG|Neomycin|Given PO
218932789|NCT04729322|BIOLOGICAL|Nivolumab|Given IV
218932790|NCT04729322|BIOLOGICAL|Pembrolizumab|Given IV
218932791|NCT04729322|OTHER|Questionnaire Administration|Ancillary studies
219045103|NCT05407324|DRUG|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
219045104|NCT05407324|OTHER|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
219205455|NCT05362006|DEVICE|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
219542578|NCT01712906|BIOLOGICAL|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
219542579|NCT01712906|BIOLOGICAL|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
219542580|NCT04863560|OTHER|Auditory Cueing|Metronome beat to step in time with
219542581|NCT04863560|OTHER|Visual Cueing|Lines on the floor to step over
218932792|NCT04729322|DRUG|Vancomycin|Given PO
218932793|NCT05489523|DRUG|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
218932794|NCT06009393|DRUG|SHR-1918|Three administration
219542582|NCT04863560|OTHER|tactile Cueing|Vibration to step in time with (metronome like)
218932795|NCT04042337|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
218932796|NCT06196164|PROCEDURE|EUS-BD|We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
219542583|NCT03734861|DEVICE|BreatheSmart System|"* BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence"
219542584|NCT03734861|OTHER|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
218932797|NCT06196164|PROCEDURE|ERCP-BD|We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
218932798|NCT06308718|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
218932799|NCT04120493|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
218932800|NCT04120493|OTHER|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
219205456|NCT05362006|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
218932802|NCT04030455|DRUG|Carboplatin|Given IV
218932803|NCT04030455|DRUG|Cisplatin|Given IV
218932804|NCT04030455|DRUG|Docetaxel|Given IV
218932805|NCT04030455|BIOLOGICAL|Pembrolizumab|Given IV
218932806|NCT06420297|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
218932807|NCT05889845|DRUG|Candin, Intradermal Solution|Injection at the base of the selected wart
218932808|NCT05889845|DRUG|Placebo|Injection at the base of the selected wart
218932809|NCT06215677|DRUG|Camrelizumab|Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
218932810|NCT06364774|BIOLOGICAL|ALS20|novel lentiviral vector ALS20
218932811|NCT06228066|DRUG|Lurbinectedin|Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
218932812|NCT06228066|DRUG|Avelumab|Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
218932813|NCT06453265|DRUG|Cebranopadol- 600 ug|"Dose ascending cohorts~\- Cebranopadol 600 ug single dose"
218932814|NCT06453265|DRUG|Cebranopadol- 800ug|"Dose ascending cohorts~\- Cebraopadol 800 ug single dose"
219542585|NCT04173858|DRUG|Naloxegol|25 mg oral naloxegol once daily.
219542586|NCT01506622|DRUG|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
219542587|NCT01506622|DRUG|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
219542588|NCT01506622|DRUG|Administration of saline|Saline will be administered to control group at the end of anesthesia.
218932815|NCT06453265|DRUG|Cebranopadol- 1000ug|"Dose ascending cohorts~\- Cebranopadol 1000 ug single dose"
218932816|NCT06453265|DRUG|Treatment A:|Cebranopadol, dose determined in Part A
218932817|NCT06453265|DRUG|Treatment B|Oxycodone HCl IR 40 mg
218932818|NCT06453265|DRUG|Treatment C|Placebo
218932819|NCT06453265|DRUG|Qualification|Oxycodone 40mg
218932820|NCT06453265|DRUG|Qualification|Matching Placebo
218932821|NCT03664687|DRUG|Zoledronate|Administered intravenously (IV)
218932822|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
218932823|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
218932824|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
218932825|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
218932826|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
218932827|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
218932828|NCT04939415|DRUG|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
218932829|NCT04939415|DRUG|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
218932830|NCT06344403|DRUG|analgesic|Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.
218932831|NCT06344403|BEHAVIORAL|Tender point infiltration|Lidocaine mixed with diprospan injected into tender points.
218932832|NCT04216524|DRUG|Cyclophosphamide|Given IV
218932833|NCT04216524|DRUG|Cytarabine|Given IT or IV
219542589|NCT04067739|OTHER|non interventional study|non interventional study
219542590|NCT04626154|DIAGNOSTIC_TEST|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
219542591|NCT01447511|DRUG|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
219542592|NCT01447511|DRUG|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
219542593|NCT01447511|DRUG|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
219621531|NCT05220852|OTHER|Exercise|"patients in this group are going to have onley neck exercise for 2 weeks minimum 3 times a week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
218932834|NCT04216524|DRUG|Dexamethasone|Given PO or IV
218932835|NCT04216524|DRUG|Doxorubicin|Given IV
218932836|NCT04216524|DRUG|Mercaptopurine|Given PO
218932837|NCT04216524|DRUG|Methotrexate|Given IT, IV, or PO
218932838|NCT04216524|DRUG|Methylprednisolone|Given IV
219045105|NCT06120855|DRUG|Regulated cannabis from authorized pharmacies|"The intervention group is allowed to purchase regulated cannabis in authorized pharmacies. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles.~Study participants can choose between different cannabis-containing products such as dried cannabis flowers, cannabis concentrates (colloquially called hashish or hash), e-liquids and oral cannabis. Besides the cannabis products, participants can buy vaping or vaporizing electronic devices at the pharmacy (they are not considered as study products)."
219045106|NCT06120855|DRUG|Cannabis from the illicit market|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
219045107|NCT05929495|DRUG|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
219045108|NCT06491342|DIETARY_SUPPLEMENT|Probiotic|Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
219045109|NCT06491342|DIETARY_SUPPLEMENT|Placebo|placebo
219045110|NCT02457598|DRUG|Tirabrutinib|Capsules or tablets administered orally
219045111|NCT02457598|DRUG|Idelalisib|Tablets administered orally twice daily
219045112|NCT02457598|DRUG|Entospletinib|Tablets administered orally
219045113|NCT02457598|DRUG|Obinutuzumab|Administered intravenously
219045114|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
219045115|NCT05349591|BIOLOGICAL|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
219045116|NCT02312102|DRUG|Lenalidomide|Chemotherapy
219045117|NCT02312102|DRUG|Velcade|Chemotherapy
219542594|NCT04738448|BEHAVIORAL|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
219542595|NCT06151691|OTHER|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test|"Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test."
219542596|NCT01067833|DRUG|K201 Tablet|oral tablet, x28 days
219621532|NCT06258928|DIAGNOSTIC_TEST|Functional examination|Compared to nonoperated limb, after 6 months of early rehabilitation.
218932839|NCT04216524|DRUG|Prednisone|Given PO
218932840|NCT04216524|BIOLOGICAL|Rituximab|Given IV
218932841|NCT04216524|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219542597|NCT01067833|DRUG|Placebo Tablet|oral tablet, x28 days
219542598|NCT01316055|DRUG|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
219621533|NCT03502733|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219621534|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218932842|NCT04216524|DRUG|Venetoclax|Given PO
218932843|NCT04216524|DRUG|Vincristine|Given IV
218932844|NCT02629809|DRUG|Cyclophosphamide|Given IV
218932845|NCT02629809|DRUG|Fludarabine Phosphate|Given IV
218932846|NCT02629809|DRUG|Ibrutinib|Given PO
218932847|NCT02629809|BIOLOGICAL|Obinutuzumab|Given IV
219045118|NCT06272344|OTHER|Teleconsultation|Teleconsultation at 6 months
219045119|NCT01403974|DRUG|BI 836845|Intravenous infusion once every week
219045120|NCT06411678|DRUG|68GA-DOTA-dPNE|Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
219045123|NCT05147272|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 in combination with gemcitabine
219621535|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
219621536|NCT03502733|DRUG|Copanlisib|Given IV
219621537|NCT03502733|PROCEDURE|Echocardiography Test|Undergo ECHO
219621538|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
219621539|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621540|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
219621541|NCT06194448|DRUG|Osimertinib|80 mg daily (or 40 mg daily for dose reduction)
218932848|NCT06233747|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by licensed nursing assistants or other non-specialist clinicians who provide one-on-one safety supervision during boarding. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy. Given that one-on-one safety supervision is the current standard of care during boarding, I-CARE requires minimal additional resources beyond those already available in acute care hospitals and builds on well established research demonstrating the effectiveness of task-sharing, the redistribution of tasks within the workforce, to address the shortage of mental health professionals.
218932849|NCT05130580|OTHER|Enhanced Consultation|Attend an enhanced consultation with decision aid
218932850|NCT05130580|OTHER|Standard of Care Consultation|Attend standard of care consultation
218932851|NCT05130580|PROCEDURE|Conventional Imaging|Undergo 2D and 3D torso imaging
218932852|NCT05130580|OTHER|Educational Intervention|Receive educational materials
218932853|NCT05130580|OTHER|Questionnaire Administration|Ancillary studies
218932854|NCT06564792|BEHAVIORAL|Contingency management|Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
218932855|NCT02425293|BEHAVIORAL|asthma patient education|
218932856|NCT05569239|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1.
218932857|NCT05569239|BIOLOGICAL|Saline Solution|One single administration intramuscularly at Day 1.
218932858|NCT03612934|PROCEDURE|Specialist Palliative Care|In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
218932859|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
218932860|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
218932861|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
218932862|NCT03715348|DRUG|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
218932863|NCT03715348|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
218932864|NCT02034864|OTHER|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
218932865|NCT02034864|OTHER|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
218932866|NCT01276210|DRUG|sorafenib tosylate|Given PO
218932867|NCT01276210|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
218932868|NCT01276210|OTHER|laboratory biomarker analysis|Correlative studies
219205457|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
218932869|NCT05577299|DEVICE|PET/CT|18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
218932870|NCT06053658|DRUG|Tivozanib|Given by PO
219621542|NCT06194448|DRUG|Cisplatin or Carboplatin; Pemetrexed or Paclitaxel|Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
218932871|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
218932872|NCT02239419|PROCEDURE|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
219205458|NCT02231749|BIOLOGICAL|Nivolumab|
219205459|NCT02231749|BIOLOGICAL|Ipilimumab|
219205460|NCT02231749|DRUG|Sunitinib|
219205461|NCT04838301|DRUG|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
219205462|NCT04838301|OTHER|Placebo|Normal saline solution IV via 30-minute infusion, once per week
218932873|NCT02239419|PROCEDURE|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
218932874|NCT03525795|DRUG|CPI-1205|Administered orally
218932875|NCT03525795|DRUG|ipilimumab|Administered intravenously
218932876|NCT00135551|DRUG|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
218932877|NCT00135551|DRUG|β-blockers|benidipine+β-blockers, titlation scheme
218932878|NCT00135551|DRUG|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
218932879|NCT02057185|BEHAVIORAL|Study questionnaire|Questionnaire based on work situation of enrolled patients.
218932880|NCT02057185|BEHAVIORAL|SF-36 Questionnaire|Version 1.6
218932881|NCT00679900|DRUG|eplivanserin (SR46349)|5 mg/day
218932882|NCT00679900|DRUG|lormetazepam|1 mg/day
218932883|NCT05717543|DEVICE|Retro-illuminator|The device Retro-illuminator will be used to photograph the eyes.
218932884|NCT01314586|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
218932885|NCT00798993|OTHER|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
218932886|NCT00798993|DRUG|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
218932887|NCT00798993|OTHER|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
218932888|NCT00478023|DRUG|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
218932889|NCT00478023|DRUG|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
218932890|NCT00478023|DRUG|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
219542599|NCT01188863|DRUG|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
219542600|NCT01188863|DRUG|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
219542601|NCT01188863|DRUG|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
219542602|NCT02919462|DRUG|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
218932891|NCT00478023|DRUG|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
218932892|NCT00478023|DRUG|Placebo|4 - 6 hourly; Total 72 hours
218932893|NCT06045156|DRUG|Tirofiban|Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
218932894|NCT06045156|DRUG|Tirofiban simulant|Tirofiban simulant is placebo packed the same style as tirofiban
218932895|NCT04198688|BEHAVIORAL|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
218932896|NCT03899922|DRUG|Drugs inducing uveitis|Drugs susceptible to induce uveitis
218932897|NCT01209325|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
218932898|NCT01209325|OTHER|laboratory biomarker analysis|
219045124|NCT06272097|BEHAVIORAL|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
219045125|NCT06272097|BEHAVIORAL|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
219542603|NCT02919462|DRUG|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
219542604|NCT02919462|DRUG|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
219542605|NCT02919462|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
219542606|NCT02919462|DRUG|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
219542607|NCT02919462|DRUG|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
219542608|NCT02915445|BIOLOGICAL|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
219542609|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
219542610|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
218932899|NCT02454842|DRUG|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
218932900|NCT04061330|DRUG|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
218932901|NCT04061330|DRUG|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
218932902|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
218932903|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
218932904|NCT01523041|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
218932905|NCT01638871|BEHAVIORAL|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
218932906|NCT00396253|DRUG|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
218932907|NCT01280708|OTHER|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
218932908|NCT05425940|DRUG|XL092|Supplied as tablets; administered orally daily
218932909|NCT05425940|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
218932910|NCT05425940|DRUG|Regorafenib|Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
218932911|NCT02282514|BIOLOGICAL|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
218932912|NCT02282514|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
218932913|NCT02282514|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
218932914|NCT02282514|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
218932915|NCT02282514|DRUG|Methylprednisolone|Steroid
218932916|NCT02282514|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
218932917|NCT02282514|DRUG|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
218932918|NCT01093235|BIOLOGICAL|bevacizumab|
218932919|NCT01093235|DRUG|cyclophosphamide|
219045126|NCT05750667|BEHAVIORAL|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
219045127|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
219045128|NCT06367361|DRUG|Oxfendazole|Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
219045129|NCT06367361|DRUG|Triclabendazole|The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
219045130|NCT03205618|OTHER|Non-Interventional|Non-Interventional
219621543|NCT06194448|DRUG|Radiation|"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
218932920|NCT01093235|DRUG|docetaxel|
218932921|NCT01093235|DRUG|epirubicin hydrochloride|
218932922|NCT01093235|DRUG|fluorouracil|
218932923|NCT01093235|PROCEDURE|assessment of therapy complications|
218932924|NCT01093235|PROCEDURE|neoadjuvant therapy|
218932925|NCT01093235|PROCEDURE|quality-of-life assessment|
218932926|NCT01093235|PROCEDURE|therapeutic conventional surgery|
218932927|NCT05340478|BEHAVIORAL|Adjunctive Family - Cognitive Behavioral Therapy|AF-CBT provides family members psychoeducation on anxiety and teaches skills to facilitate the recovery of Veterans in the process of completing anxiety treatment.
218932928|NCT01594216|DRUG|Ruxolitinib|
218932929|NCT01594216|DRUG|Exemestane|
218932930|NCT01809119|PROCEDURE|Partial nephrectomy|
218932931|NCT04460001|DRUG|Ranibizumab|Intravitreal
218932932|NCT04460001|DRUG|Ranibizumab|Intravitreal
218932933|NCT04460001|DRUG|triamcinolone acetate|intravitreal
218932934|NCT02149901|DRUG|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
218932935|NCT02149901|DRUG|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
218932936|NCT02149901|OTHER|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
218932937|NCT02149901|OTHER|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
218932938|NCT05846737|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
219045131|NCT01436812|PROCEDURE|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
219045132|NCT01436812|PROCEDURE|positive end expiratory pressure|PEEP 0 cmH2O
218932939|NCT02550405|BEHAVIORAL|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
218932940|NCT02575586|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
218932941|NCT02575586|DEVICE|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
218932942|NCT02506244|DEVICE|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
218932943|NCT02506244|DEVICE|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
218932944|NCT00092443|BIOLOGICAL|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
218932945|NCT00092443|BIOLOGICAL|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
218932946|NCT01160822|BIOLOGICAL|Canakinumab|Intra-articular injection
218932947|NCT01160822|DRUG|Placebo to canakinumab|Intra-articular injection
218932948|NCT01160822|DRUG|Naproxen|Tablets for oral administration
218932949|NCT01160822|DRUG|Placebo to Naproxen|Tablets for oral administration
218932950|NCT01962350|DEVICE|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
218932951|NCT03651024|DEVICE|ED surgery|The surgical implant for ED treatment
218932952|NCT04772560|DEVICE|Precision1 for Astigmatism|Daily disposable soft toric contact lens
218932953|NCT04772560|DEVICE|Precision1 Sphere|Daily disposable soft spherical contact lens
218932954|NCT02441595|BEHAVIORAL|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
218932955|NCT02441595|BEHAVIORAL|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
218932956|NCT01319552|PROCEDURE|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
218932957|NCT01319552|PROCEDURE|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
218932958|NCT01493167|OTHER|limb casting/splinting|ankle and arm cast
218932959|NCT04717336|OTHER|Sodium Chloride|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
218932960|NCT04717336|OTHER|Placebo|placebo capsules
218932961|NCT03962062|DRUG|Moxidectin|2 mg tablets
218932962|NCT04521725|DEVICE|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
218932963|NCT04521725|DEVICE|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
218932964|NCT00492258|DRUG|sorafenib tosylate|
218932965|NCT00492258|PROCEDURE|adjuvant therapy|
218932966|NCT02665832|DRUG|DWJ1351|
218932967|NCT02665832|DRUG|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
218932968|NCT01075490|DRUG|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
218932969|NCT01075490|DRUG|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
218932970|NCT01698398|DEVICE|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
218932971|NCT06079112|DRUG|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
218932972|NCT06079112|DRUG|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
218932973|NCT04883827|OTHER|Blood collection|20-40 mL of blood to extract cell free DNA
218932974|NCT04883827|OTHER|Urine collection|up to 15 mL of urine to extract cell free DNA
218932975|NCT06273215|DRUG|The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
218932976|NCT04005131|DEVICE|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
218932977|NCT04005131|DEVICE|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
218932978|NCT01951963|DRUG|Ketamine|
218932979|NCT01951963|DRUG|Morphine|
218932980|NCT03632850|OTHER|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
218932981|NCT03523988|DRUG|Acetaminophen|Acetaminophen gel capsule
218932982|NCT03523988|DRUG|Ibuprofen|Ibuprofen gel capsule
219621544|NCT01175993|OTHER|Elliptical exercise|Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
218932983|NCT05922917|DEVICE|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
218932984|NCT05285046|OTHER|No intervention|No intervention
218932985|NCT02550639|OTHER|BIOMARKER- elispot test|ELISPOT TEST
218932986|NCT02951000|PROCEDURE|platysma suture|
219045133|NCT00260754|BEHAVIORAL|Community-Popular Opinion Leader Model|
219045134|NCT00260754|BEHAVIORAL|Diffusion of Innovations|
219045135|NCT03784573|BEHAVIORAL|Dog + handler|Dog + handler
219045136|NCT03784573|BEHAVIORAL|No dog|No dog
219045137|NCT05251246|BEHAVIORAL|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
219045138|NCT05164783|COMBINATION_PRODUCT|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
219045139|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
219045140|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
219045141|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
219045142|NCT01526889|DRUG|LFG316|LFG316 administered intravitreally (IVT)
219045143|NCT01526889|DRUG|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
219542611|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
219542612|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
219621545|NCT02043457|OTHER|phenotyping|
219621546|NCT06981832|BEHAVIORAL|Personalised support (advanced practice nurse and adapted physical activity teacher)|Personalised support (advanced practice nurse and adapted physical activity teacher)
219621547|NCT06981832|BEHAVIORAL|Standard support (advanced practice nurse)|Standard support (advanced practice nurse)
219621550|NCT05211882|OTHER|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
219621551|NCT05211882|OTHER|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
218932987|NCT02951000|PROCEDURE|no platysma suture|
218932988|NCT03141827|DRUG|Insulin|Insulin 40 IU, nasal spray, single dose
218932989|NCT03141827|DRUG|Placebo|Placebo, nasal spray, single dose
218932990|NCT02926885|DEVICE|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
218932991|NCT02926885|DEVICE|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
218932992|NCT02926885|PROCEDURE|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
218932993|NCT00105781|BEHAVIORAL|Exercise counseling|
219045144|NCT05928910|DEVICE|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
219045145|NCT05928910|OTHER|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
219045146|NCT01391975|PROCEDURE|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
219205463|NCT05249842|DIAGNOSTIC_TEST|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
219205464|NCT05249842|DIAGNOSTIC_TEST|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
219205465|NCT05249842|DIAGNOSTIC_TEST|6MWT|6 minute walk test
219542613|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
219542614|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
218932994|NCT00654550|DRUG|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
219045147|NCT03438890|DEVICE|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
219045148|NCT03438890|DEVICE|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
219045149|NCT03438890|DEVICE|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
219621552|NCT04272788|DRUG|Infliximab|The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
219621553|NCT05872789|DRUG|Diazepam 1% oral gel|Diazepam 1% used with topic oral gel on tongue and palate twice daily.
218932995|NCT00928239|PROCEDURE|laparoscopic sacropexy with mid vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
218932996|NCT00928239|PROCEDURE|laparoscopic sacropexy with caudal vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
218932997|NCT04163211|PROCEDURE|Abdominal drain|A latex-free drain (size 20F)
218932998|NCT05825378|DRUG|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
218932999|NCT05825378|DRUG|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
218933000|NCT02772458|OTHER|Dodecanoate acid and saline|Test drink
218933001|NCT05079308|DEVICE|Peripheral sealing device for surgical mask or filtering face piece|The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
218933002|NCT05079308|DEVICE|IIR Surgical mask with Filtering face piece|The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
218933003|NCT02116205|BIOLOGICAL|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
218933004|NCT02116205|BIOLOGICAL|Placebo|0.9% sodium chloride
218933005|NCT02116205|DEVICE|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
219045150|NCT06325384|DEVICE|Lifelight|Contactless Vital Signs Measurement via RPPG
219045151|NCT06325384|DEVICE|Blood Pressure Cuff|Standard Blood Pressure Cuff Digital
219045152|NCT05550051|PROCEDURE|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
219621554|NCT05872789|DRUG|Placebo|Placebo oral gel used on tongue and palate twice daily.
219621555|NCT06463990|OTHER|TyG index|association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia
219621556|NCT01827111|DRUG|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
219621557|NCT01827111|DRUG|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
219621558|NCT01827111|BEHAVIORAL|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
219621559|NCT03016884|BIOLOGICAL|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
219621560|NCT02169271|DRUG|Aspirin|Given PO
218933006|NCT01234389|DEVICE|Electrochemical H. pylori detection method|Determination of H. pylori infection.
218933007|NCT01234389|DEVICE|IHC|Determination of H. pylori infection.
218933008|NCT01234389|DEVICE|C13-urea breath test|Determination of H. pylori infection.
218933009|NCT01234389|DEVICE|HUT|Determination of H. pylori infection.
218933010|NCT00569959|OTHER|fasting 12+ hours|fasting 12+ hours
218933011|NCT00569959|OTHER|Non-fasting|Non-fasting
218933012|NCT05006638|DRUG|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
218933013|NCT05006638|DRUG|Atropine|a drug used as an antidote for some types of pesticides
218933014|NCT05006638|DRUG|Toxogonin|a drug used as an antidote for some types of pesticides
218933015|NCT05006638|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
218933016|NCT00069615|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
218933017|NCT00069615|DEVICE|Continuous Glucose Monitoring System™ (CGMS)|
218933018|NCT00241436|DRUG|Anastrozole (ARIMIDEX™)|
218933019|NCT02510508|BEHAVIORAL|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
218933020|NCT02510508|BEHAVIORAL|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
218933021|NCT02510508|OTHER|Non-intervention|Non-intervention
218933022|NCT02219425|PROCEDURE|endometrial biopsy|
219045153|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
219045154|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
219045155|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
219045156|NCT01192971|DRUG|Apatinib|apatinib p.o. once daily for 4 weeks
219045157|NCT01990677|DRUG|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
219045158|NCT01990677|DRUG|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
219542615|NCT04807595|OTHER|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
219542616|NCT00161551|DEVICE|Vitatron T70 DR|
219542617|NCT05251155|DIAGNOSTIC_TEST|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
219542618|NCT06182449|DEVICE|Virtual Reality Distraction|In a private NICU room, mothers will wear a head-mounted VR device when they will initiate the expression of their maternal milk. The video within the VR system will provide a calm forest environment with waterfalls, animals, and birdsong (INSPIRE® Program). The baby may or may not be present in the room during the intervention. This will be documented.
219542619|NCT06182449|OTHER|Standard Protocol|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby. Use of any co-interventions for anxiety management (e.g. music) durign this sequence will be documented.
218933023|NCT02541604|DRUG|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
218933024|NCT01065883|BEHAVIORAL|community health worker|community health workers will provide education in the home
218933025|NCT01065883|BEHAVIORAL|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
219045159|NCT00273728|DRUG|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
219045160|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
218933026|NCT02406534|BEHAVIORAL|HRQoL surveys|
218933027|NCT00034268|DRUG|LY900003|
218933028|NCT04245683|PROCEDURE|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
218933029|NCT04245683|OTHER|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
218933030|NCT02373683|DEVICE|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
218933031|NCT05785442|DRUG|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
218933032|NCT05785442|DRUG|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
218933033|NCT05932862|DRUG|XL309|XL309 will be administered orally per assigned schedule.
218933034|NCT05932862|DRUG|Olaparib|Olaparib will be administered orally per assigned schedule.
218933035|NCT05095376|DRUG|Lomustine|Given PO
218933036|NCT05095376|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218933037|NCT05095376|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
218933038|NCT05095376|OTHER|Questionnaire Administration|Ancillary studies
218933039|NCT05095376|DRUG|Temozolomide|Given PO
219621561|NCT02169271|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621562|NCT02169271|OTHER|Placebo|Given PO
219621563|NCT05289739|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
219542620|NCT06562062|PROCEDURE|Extra-articular Lateral Column Lengthening Procedure|Lateral column lengthening (LCL), originally described by Evans, is an established procedure to correct stage II adult acquired flatfoot deformity (AAFD). However, the relative position between the facets is violated, and other problems may include nonunion, malunion, and calcaneocuboid (CC) joint subluxation. Herein, we report a modified extra-articular technique of LCL with hockey-stick osteotomy, which preserves the subtalar joint as a whole, increases bony apposition to enhance healing ability, and preserves the insertion of the calcaneofibular ligament to stabilize the posterior fragment to promote adduction of the forefoot
219542621|NCT01348789|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
219542622|NCT05450653|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
219542623|NCT06562478|BEHAVIORAL|Zazen Meditation|The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
219542624|NCT05168735|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
219542625|NCT05168735|BEHAVIORAL|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
219542626|NCT05168735|BEHAVIORAL|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
219542627|NCT03503318|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
219542628|NCT03503318|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
219542629|NCT00165685|DRUG|Sibutramine Hydrochloride Monohydrate|
219542630|NCT01668602|DEVICE|Fast Walking with Fast Functional Electrical Stimulation (FES) Training|Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
219542631|NCT01668602|OTHER|Fast Walking|Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
219542632|NCT01468272|DRUG|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
219542633|NCT01468272|DRUG|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
219542634|NCT04815759|OTHER|routine dental restorative procedures|pulp and restorative therapy
219542635|NCT00067535|DRUG|Cocaine-Related Disorders|
219542636|NCT02319824|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
219542637|NCT02319824|OTHER|Laboratory Biomarker Analysis|Correlative studies
219542638|NCT02319824|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
219542639|NCT05802485|OTHER|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
219542640|NCT05801315|DEVICE|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
219542641|NCT05801315|DEVICE|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
219542642|NCT00200187|PROCEDURE|low venous pressure general anesthesia|
219542643|NCT00200187|PROCEDURE|combined spinal-epidural anesthesia|
219542644|NCT06099652|DRUG|611 300 mg Q2W|611 subcutaneous (SC) injection
219542645|NCT06099652|DRUG|611 450 mg Q2W|611 subcutaneous (SC) injection
219542646|NCT06099652|DRUG|Matching placebo|placebo subcutaneous (SC) injection
219542647|NCT02374385|BIOLOGICAL|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
219542648|NCT02374385|OTHER|Placebo|Normal saline
219542649|NCT01636661|DEVICE|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
219542650|NCT01445691|DRUG|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
219542651|NCT03311594|DRUG|Low Alcohol|Low Alcohol Consumption
219542652|NCT03311594|DRUG|Moderate Alcohol|Moderate Alcohol Consumption
219542653|NCT03311594|DRUG|Placebo Alcohol|Placebo Alcohol Consumption
219542654|NCT03311594|OTHER|Pain Induction|10% capsaicin solution placed on forearm and heat induction
219542655|NCT03311594|OTHER|No Pain Induction|Water placed on forearm
219542656|NCT04350723|PROCEDURE|Awake Proning|The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
219542657|NCT05405881|OTHER|Proprioception measurement tool|No intervention, as it is a psychometric properties study
219542658|NCT06187441|DRUG|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
219542659|NCT06187441|DRUG|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
218933040|NCT02472028|OTHER|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
218933041|NCT02472028|OTHER|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
218933042|NCT02846519|DRUG|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
219542660|NCT06187441|DRUG|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
218933043|NCT02846519|DRUG|Rifampin|2 capsules (300 mg each) of rifampin.
218933044|NCT04133792|DRUG|Simvastatin 40mg|40 mg orally daily for 5 years.
218933045|NCT04133792|DRUG|Placebo oral tablet|40 mg orally daily for 5 years.
218933046|NCT03604835|OTHER|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
219045161|NCT04852744|OTHER|Brain MRI|"Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups."
219045162|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
219542661|NCT05336422|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
219542662|NCT04275479|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
219542663|NCT04275479|OTHER|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
219542664|NCT04275479|OTHER|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
219542665|NCT04275479|DEVICE|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
219542666|NCT04275479|OTHER|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
219542667|NCT04275479|OTHER|Medical History Questionnaires|The participant will be asked to provide detailed medical history
219542668|NCT04496349|DRUG|APG-115|QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
218933047|NCT06416306|BEHAVIORAL|Speech Intervention|The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.
218933048|NCT05760339|BEHAVIORAL|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
219542669|NCT04496349|DRUG|APG-2575|APG-2575 given orally each day in cycle, in repeated 21-day cycles
219542670|NCT06025279|OTHER|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
219542671|NCT01825798|DRUG|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
219621564|NCT06606990|PROCEDURE|Biopsy Procedure|Undergo biopsy
219621565|NCT06606990|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219542672|NCT01825798|DRUG|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
218933049|NCT05760339|DIETARY_SUPPLEMENT|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
218933050|NCT03196453|DIETARY_SUPPLEMENT|Probiotic|probiotic and/or placebo intervention in toddlers
218933051|NCT05760573|BEHAVIORAL|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
218933052|NCT02272205|OTHER|Retrospective analysis of records|
218933053|NCT03150693|DRUG|Allopurinol|Given PO
218933054|NCT03150693|DRUG|Cytarabine|Given IT, IV, SC
218933055|NCT03150693|DRUG|Daunorubicin Hydrochloride|Given IV
218933056|NCT03150693|DRUG|Vincristine Sulfate|Given IV
218933057|NCT03150693|DRUG|Dexamethasone|Given PO or IV
218933058|NCT03150693|DRUG|Pegylated L-Asparaginase|Given IV
218933059|NCT03150693|DRUG|Methotrexate|Given IT, IV, PO
219045163|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
218933060|NCT03150693|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
218933061|NCT03150693|DRUG|Cyclophosphamide|Given IV
219542673|NCT03874143|OTHER|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
219542674|NCT03867838|DEVICE|compliant support|Participants will be given compliant arm support and their reachable workspace measured
218933062|NCT03150693|DRUG|Mercaptopurine|Given PO
218933063|NCT03150693|BIOLOGICAL|Rituximab|Given IV
218933064|NCT03150693|DRUG|Doxorubicin|Given IV
218933065|NCT03150693|DRUG|Thioguanine|Given PO
218933066|NCT03150693|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
218933067|NCT03150693|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621566|NCT06606990|PROCEDURE|Computed Tomography|Undergo CT
218933068|NCT01369888|DRUG|Cyclophosphamide|60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
218933069|NCT01369888|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
218933070|NCT01369888|BIOLOGICAL|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
219542675|NCT02982161|DRUG|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
219542676|NCT02982161|DRUG|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
219542677|NCT02982161|DRUG|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
219621567|NCT06606990|PROCEDURE|Echocardiography Test|Undergo ECHO
219621568|NCT06606990|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219621569|NCT06606990|BIOLOGICAL|Pidnarulex|Given IV
219621570|NCT06409611|DEVICE|neuromuscular electrical stimulation|Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
218933071|NCT01369888|DRUG|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
218933072|NCT06005207|DRUG|progesterone vaginal sustained-release gel|90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
218933073|NCT02752165|OTHER|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
218933074|NCT02752165|OTHER|Enhanced Usual Care|Report of symptoms to primary care physician
218933075|NCT02820493|DRUG|vedolizumab|
218933076|NCT04131647|OTHER|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
218933077|NCT04131647|OTHER|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
218933078|NCT04765683|OTHER|questionnaire|Survey of views on outpatient consultation format
219045164|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
219045165|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
219045166|NCT01125111|PROCEDURE|surgery(robot versus laparoscopy)|
219542678|NCT01441349|DRUG|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days"
219621571|NCT06602739|DRUG|REGN5713|Administered per protocol
219621572|NCT06602739|DRUG|REGN5715|Administered per protocol
219621573|NCT06602739|DRUG|Placebo|Administered per protocol
219621574|NCT06595563|DRUG|Trastuzumab emtansine|T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
218933079|NCT05530512|OTHER|electroacupuncture|acupuncture needling and stimulation are applied for 30 min
218933080|NCT06483100|DRUG|Elrantamab|"\- Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15"
219045167|NCT03507556|PROCEDURE|Triple paste and induced bleeding|
219542679|NCT01441349|DRUG|IP chemotherapy plus simvastatin|"* Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1"
219542680|NCT01745679|DRUG|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
219542681|NCT00834873|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
219542682|NCT00834873|DRUG|COREG® 25 mg tablets|1 x 25 mg
219542683|NCT03262051|DIAGNOSTIC_TEST|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
219542684|NCT05272813|DRUG|MS-553|MS-553
219542685|NCT01633281|PROCEDURE|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
219542688|NCT01125163|DIETARY_SUPPLEMENT|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
219542689|NCT01125163|DIETARY_SUPPLEMENT|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
219621575|NCT06609096|BEHAVIORAL|Sexual counseling based on the PLISSIT model|Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.
219542690|NCT06103812|DEVICE|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
219542691|NCT03227276|DIETARY_SUPPLEMENT|Litramine|2 tablets to be taken 3 times a day after meals
219621576|NCT06609096|BEHAVIORAL|Sexual counseling based on the BETTER model|A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
218933081|NCT06483100|DEVICE|clonoSEQ|FDA approved MRD testing
218933082|NCT04618653|OTHER|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
218933083|NCT05220436|OTHER|DISCOVER workshop programme|See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance \& Commitment Therapy principles.
218933084|NCT01704599|DRUG|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
218933085|NCT05788159|DRUG|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
219542692|NCT03227276|DIETARY_SUPPLEMENT|Placebo tablet|2 tablets to be taken 3 times a day after meals
218933086|NCT05788159|DRUG|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
218933087|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
218933088|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
218933089|NCT02932852|PROCEDURE|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
218933090|NCT02932852|PROCEDURE|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
219621577|NCT05541016|PROCEDURE|Biospecimen Collection|Undergo blood and saliva specimen collection for NavDx testing
219621578|NCT05541016|DRUG|Cisplatin|Given IV
219621579|NCT05541016|PROCEDURE|Computed Tomography|Undergo CT scan
218933091|NCT04812652|BEHAVIORAL|Digitally distributed yoga|Yoga distributed through internet.
219045168|NCT03507556|DRUG|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
219045169|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
219045170|NCT00966238|BIOLOGICAL|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
219045171|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
219045172|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
219045173|NCT02927457|DRUG|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
218933092|NCT06212128|COMBINATION_PRODUCT|RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol (Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol)
219621580|NCT05541016|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
219621581|NCT05541016|DRUG|Docetaxel|Given IV
219621582|NCT05541016|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
219621583|NCT05541016|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219621584|NCT05541016|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218933093|NCT06212128|COMBINATION_PRODUCT|LCRT|LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine
218933094|NCT00996398|OTHER|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
218933095|NCT02840461|DRUG|Ivermectin Cream, 1%|
218933096|NCT02840461|DRUG|Placebo/Vehicle cream|
218933097|NCT02469311|OTHER|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
218933098|NCT02469311|OTHER|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
218933099|NCT06648044|OTHER|Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie|
218933100|NCT03983356|OTHER|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
218933101|NCT04162678|PROCEDURE|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
218933102|NCT04162678|OTHER|Laboratory Biomarker Analysis|Correlative studies
218933103|NCT04162678|PROCEDURE|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
218933104|NCT04162678|OTHER|Medical Chart Review|Review of medical chart
218933105|NCT05823467|DRUG|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
218933106|NCT05823467|DEVICE|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
218933107|NCT03657693|DIAGNOSTIC_TEST|NICU MRI|MRI device that is not FDA approved.
218933108|NCT03657693|DIAGNOSTIC_TEST|Polysomnography|Polysomnography to better determine obstruction index in the airway.
218933109|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
219621585|NCT05541016|PROCEDURE|Modified Barium Swallow Study|Undergo MBSS
218933110|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
218933111|NCT01737502|DRUG|Auranofin|Given PO
218933112|NCT01737502|DRUG|Sirolimus|Given PO
218933113|NCT01737502|OTHER|Laboratory Biomarker Analysis|Correlative studies
218933114|NCT01737502|OTHER|Pharmacological Study|Correlative studies
218933115|NCT04835857|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
218933116|NCT04835857|DEVICE|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
218933117|NCT04835857|DEVICE|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
218933118|NCT03741673|OTHER|Quality-of-Life Assessment|Ancillary studies
218933119|NCT03741673|OTHER|Questionnaire Administration|Ancillary studies
218933120|NCT03741673|RADIATION|Stereotactic Radiosurgery|Undergo SRS
218933121|NCT03819985|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
219621586|NCT05541016|OTHER|Observation|Undergo observation
219621587|NCT05541016|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219621588|NCT05541016|OTHER|Quality-of-Life Assessment|Ancillary studies
219621589|NCT05541016|OTHER|Questionnaire|Ancillary studies
219621590|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
218933122|NCT03819985|OTHER|Quality-of-Life Assessment|Ancillary studies
218933123|NCT03819985|OTHER|Questionnaire Administration|Ancillary studies
218933124|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
218933125|NCT06262516|PROCEDURE|Nephroureterectomy|Participants will undergo standard-of-care nephroureterectomy for UTUC.
218933126|NCT06262516|PROCEDURE|Lymph Node Dissection|Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
219621591|NCT06661720|DRUG|Tivozanib|Given orally
219621592|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219621593|NCT06661720|PROCEDURE|MRI|Undergo MRI
219621594|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
219621595|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
219621596|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
219621597|NCT06986434|GENETIC|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg."
219621598|NCT06986434|DRUG|fludarabine and cyclophosphamide|"Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells."
218933127|NCT05307965|DEVICE|Retriever Thrombectomy|The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.
218933128|NCT05307965|PROCEDURE|Percutaneous Coronary Intervention|Standard of care
218933129|NCT05307965|PROCEDURE|Thrombus Aspiration|Standard of care treatment with manual thrombectomy catheter
218933130|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
218933131|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
218933132|NCT05411952|OTHER|No intervention|Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
218933133|NCT05820191|DRUG|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
218933134|NCT04672655|BEHAVIORAL|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
219045174|NCT02927457|DRUG|Placebo|Subjects will receive matching Placebo topically.
219045175|NCT00127140|DRUG|vorinostat|
219045176|NCT01068938|DEVICE|three different perimeters: HFA, Octopus, MATRIX|visual fields
219045177|NCT05393518|BEHAVIORAL|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
219045178|NCT05393518|BEHAVIORAL|Neuropsychiatric assessment|Screening for depression and anxiety
219045179|NCT04270916|DIAGNOSTIC_TEST|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
219045180|NCT00804336|DRUG|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
219045181|NCT00804336|DRUG|RAD001|Given orally once a day
219045182|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
219045183|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
219045184|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
219045185|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
219542693|NCT02183727|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
219045186|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
219542694|NCT02183727|PROCEDURE|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
218933135|NCT03224000|PROCEDURE|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
219045187|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
219045188|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
219045189|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
219045190|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
219045191|NCT00225836|DEVICE|OVA (TENS apparatus)|
219045192|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
219045193|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
219542695|NCT02197741|DRUG|opiate with bolus|
219045194|NCT04505891|BEHAVIORAL|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
218933136|NCT03224000|BEHAVIORAL|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
219045195|NCT04505891|BEHAVIORAL|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
219045196|NCT00356551|BEHAVIORAL|Family Spirit curriculum|
219045197|NCT01105507|DRUG|canakinumab (company code: ACZ885D)|
219045198|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
219205466|NCT03582592|BEHAVIORAL|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
219205467|NCT05080413|DEVICE|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
219205468|NCT05080413|DEVICE|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
219205469|NCT05727332|BEHAVIORAL|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
219205470|NCT06647303|BEHAVIORAL|Training on communication framework|Surgeons will receive training on the Better Conversations framework
218933137|NCT03224000|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
218933138|NCT03224000|PROCEDURE|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
218933139|NCT03224000|PROCEDURE|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
218933140|NCT03224000|PROCEDURE|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
219205471|NCT06647303|OTHER|Focus Group|Participants will attend a focus group to discuss the survey instruments used in this study which will help with future study design
218933141|NCT03224000|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
218933142|NCT04526418|DEVICE|24/7 EEG™ SubQ system|Electrographic seizure recording sensitivity of an ipsilaterally implanted 24/7 EEG™ SubQ system: proportion of identified ipsilateral seizures as compared to ipsilateral video-EEG during admission to the Epilepsy Monitoring Unit
219045199|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
219045200|NCT05374265|OTHER|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
219045201|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
219045202|NCT04334460|DRUG|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
219045203|NCT00000403|DRUG|Doxycycline|
219045204|NCT02133729|OTHER|Blood sampling and OGTT|
219045205|NCT03395314|DRUG|Ketamine|1 single dose of IV ketamine
219045206|NCT03395314|DRUG|Midazolam|1 single dose of IV midazolam
219045207|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
219045208|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
219045209|NCT00547703|DRUG|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
219045210|NCT00547703|DRUG|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
219045211|NCT00210314|DRUG|high dose methotrexate|
219045212|NCT00210314|DRUG|high dose cytarabine|
219205472|NCT06647303|OTHER|Surveys|Participants will complete surveys regarding the surgeon's communication skills
219205473|NCT05541926|BEHAVIORAL|e-Connect|Implementation of the e-Connect system
219542696|NCT02354560|DRUG|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
219542697|NCT04518956|PROCEDURE|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
219542698|NCT04518956|PROCEDURE|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
219542699|NCT04518956|PROCEDURE|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
219542700|NCT03575585|BEHAVIORAL|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
218933143|NCT05237947|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
219542701|NCT03575585|BEHAVIORAL|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
219542702|NCT03575585|BEHAVIORAL|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
219542703|NCT03575585|BEHAVIORAL|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
218933144|NCT05237947|OTHER|Questionnaire Administration|Ancillary studies
219542704|NCT02358538|DRUG|Ganaxolone|oral suspension or capsules
219542705|NCT00669721|DRUG|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
219621599|NCT06984094|BIOLOGICAL|SCB-1019T|SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).
219621600|NCT06984094|BIOLOGICAL|SCB-1022|SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).
219621601|NCT06984094|BIOLOGICAL|SCB-1033|SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).
218933145|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
218933146|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
218933147|NCT05741840|BEHAVIORAL|PBT-A|PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
219045213|NCT00210314|RADIATION|radiotherapy|
219542706|NCT00669721|DRUG|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
219542707|NCT03155672|BEHAVIORAL|Art therapy|Art Therapy
219542708|NCT01322321|DRUG|ACZ885|
219542709|NCT01322321|DRUG|Placebo|
219542710|NCT06611579|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve using a transcatheter approach
219542711|NCT06991608|OTHER|Collection of patient data|This non-interventional study and will not influence treatment decisions
219621602|NCT06860178|OTHER|Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months|in the intenvention arm, the children will get the vaccine R21 Matrix M together with the CPS
219621603|NCT06990321|DRUG|Intermediate-dose Cytarabine in Combination with Venetoclax|Elderly patients with Middle- and High-risk Acute Myeloid Leukemia who received the Intermediate-dose Cytarabine in Combination with Venetoclax at the First Hospital of Jilin University from March 1, 2024 to December 31, 2026.
219621604|NCT04846400|DEVICE|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
219621605|NCT04252651|OTHER|Blood Draw|This study will involve blood draws to test for specific cytokines
219621606|NCT02641093|DRUG|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
218933148|NCT05741840|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
218933149|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
218933150|NCT00494676|DEVICE|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
218933151|NCT00494676|DEVICE|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
219045214|NCT04062916|OTHER|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
219045215|NCT01583010|DEVICE|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
219045216|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
219045217|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
219045218|NCT00358462|DRUG|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
219045219|NCT00358462|DRUG|Doxycycline|one 100mg capsule administered twice daily for seven days
219542712|NCT04802655|OTHER|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
219621607|NCT02641093|PROCEDURE|Surgery|gross total surgical resection
219621608|NCT02641093|RADIATION|Radiation Therapy|60-66 Gy over 6 weeks
219621609|NCT02641093|DRUG|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
218933152|NCT05816421|BEHAVIORAL|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
218933153|NCT05816421|BEHAVIORAL|Non-Affinity KEEP|Non-Affinity KEEP
218933154|NCT06806709|DEVICE|PIVO-Pro needle-free blood collection device|The PIVO™ Pro Needle-free Blood Collection Device advances a flexible flow tube through the intravenous catheter to access optimal blood draw conditions, overcoming traditional hurdles to collect high-quality, reliable blood samples.
218933155|NCT06451406|DRUG|Selective serotonin re-uptake inhibitor|Patients received selective serotonin re-uptake inhibitor as medical treatment for treatment of premature ejaculate.
219045220|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
219045221|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
219045222|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
219542713|NCT04802655|OTHER|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
219542714|NCT03221543|DEVICE|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
219542715|NCT06615726|BEHAVIORAL|Regular physical exercise|Best medical treatment plus regular physical exercise. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.
219542716|NCT06615726|OTHER|Control group|Best medical treatment
219621610|NCT04805905|OTHER|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
219621611|NCT00659191|DRUG|GSK1265744|
219621612|NCT06576973|DRUG|Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.
219045223|NCT03758911|OTHER|Semi-structured Interview|
219045224|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
219045225|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
218933156|NCT06451406|DRUG|Hyaluronic acid|Patients received injection of glans penis with hyaluronic acid
218933157|NCT04250493|BIOLOGICAL|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
218933158|NCT04250493|BEHAVIORAL|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
218933159|NCT04250493|BEHAVIORAL|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
218933160|NCT04250493|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
219045226|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
219045227|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
218933161|NCT04250493|BIOLOGICAL|Blood sampling|Optional blood sampling for the constitution of a biological collection
219542717|NCT01261039|RADIATION|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
219542718|NCT04492540|OTHER|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
219542719|NCT04492540|OTHER|MIND diet program|control group will receive diet program for 12 weeks
218933162|NCT07075497|OTHER|Neuromuscular electrical stimulation (NMES)|NMES is applied during each 10-second isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator delivering biphasic, symmetric rectangular pulses at 50 Hz with a 250 µs pulse width. Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one approximately two finger-breadths below the gluteal fold and the other over the distal third of the muscle belly. Stimulation intensity is individually titrated to each participant's maximal motor threshold-eliciting a strong, yet painless, contraction-and the exact milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs NMES intensity and cues the timing of the 10 s contraction and ensuing 30 s passive stretch.
218933163|NCT07075497|OTHER|Sham Neuromuscular electrical stimulation (NMES)|Sham NMES is delivered during each 10 s isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator with biphasic, symmetric rectangular pulses (50 Hz, 250 µs pulse width). Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one two finger-breadths below the gluteal fold and one over the distal third of the muscle belly. Intensity is individually set to the sensory threshold, defined as the minimal current producing a slight tingling without any visible muscle response; this milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and full knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs the NMES intensity and cues the 10 s contraction timing.
218933164|NCT07075497|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 30 seconds, followed by a 10-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
218933165|NCT07074938|DRUG|Jianmin Daopeng Angong Niuhuang Wan|An Gong Niu Huang Wan comes from JianMin Dapeng.
218933166|NCT07074938|DRUG|Tongrentang Angong Niuhuang Wan|Angong Niuhuang Wan comes from Tongrentang.
218933167|NCT06923488|DRUG|Leflunomide 10mg|Leflunomide 10mg tablet
219045228|NCT03995953|BEHAVIORAL|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for caregivers to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
219045229|NCT03995953|OTHER|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
219205474|NCT06498258|OTHER|Pozitif Psikoterapi Denge Modeli Temelli Psikoeğitim|In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
219205475|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
219205476|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
219542720|NCT04544995|DRUG|Niraparib (Tablet for oral suspension)|Niraparib will be administered as TfOS (Tablet for oral suspension)
219542721|NCT04544995|DRUG|Dostarlimab|Dostarlimab will be administered as IV infusion
219542722|NCT04544995|DRUG|Niraparib (Tablet)|Niraparib will be administered as tablet
219542723|NCT06918002|DRUG|Elranatamab|Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms
219542724|NCT06918002|DRUG|Lenalidomide (Revlimid®)|In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), in monotherapy (Arm C)
219542725|NCT06918002|DRUG|Daratumumab SC (Darzalex)|Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A
219542726|NCT06918002|PROCEDURE|Autologous Stem Cell Transplantation|ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD
219542727|NCT06918002|DRUG|Bortezomib (Velcade®)|Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A
219542728|NCT06918002|DRUG|Dexamethasone|Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A
219621613|NCT06576973|PROCEDURE|Esophagectomy|Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
218933168|NCT06923488|DRUG|Leflunomide 20mg|Leflunomide 20mg tablet
218933169|NCT06923488|DRUG|Decitabine|Decitabine dose of 20 mg/m2
218933170|NCT06938581|OTHER|ERAS Protocol|"The ERAS protocol consists of:~* Day before surgery: Oral carbohydrate drink (evening), Acetaminophen 1000mg (evening), Celecoxib 200mg (morning and evening)~* Morning of surgery: Oral carbohydrate drink (2-4 hours before surgery), Celecoxib 200mg, Acetaminophen 1000mg Additionally, optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed."
218933171|NCT06938581|OTHER|Standard Perioperative Care|Standard perioperative care without ERAS protocol components. Includes routine preoperative instructions and omission of oral carbohydrate drink, celecoxib, and preoperative acetaminophen. Optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed.
218933172|NCT05102253|PROCEDURE|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
219205477|NCT02828150|DIETARY_SUPPLEMENT|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI \>30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
219205478|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
219205479|NCT05781438|BEHAVIORAL|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
219205480|NCT06495099|OTHER|Russian electrical stimulation|Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
219205481|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
219205482|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
219205483|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
219205484|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
219205485|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
219205486|NCT05453084|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
219205487|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
219205488|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
219205489|NCT06323512|DEVICE|Pulmonary artery denervation (PADN)|Combining invasive angiography with pulmonary artery CTA is frequently employed to determine the final size of the PADN catheter, aiming for an expected ratio of distal ring/vessel diameter between 1.1 and 1.2. The PADN system comprises a radiofrequency generator, connecting tubing and control handle, and the PADN catheter. The main interface of the radiofrequency generator offers multiple language options and displays parameters such as temperature, impedance, energy, and ablation time. The generator features three control modes: temperature control, power control, and a combination of both.
219205490|NCT06442579|OTHER|Walking on a treadmill|Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.
219205491|NCT04554121|BEHAVIORAL|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
219205492|NCT04554121|BEHAVIORAL|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
219542729|NCT01216566|DEVICE|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
219542730|NCT00609557|DRUG|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
218933173|NCT05102253|PROCEDURE|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
219542731|NCT00848653|DEVICE|CRT device|market approved CRT device
219542732|NCT05526183|BIOLOGICAL|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
219542733|NCT06623084|OTHER|Platelets characterization|To identify platelet features that correlate with liver disease progression and to study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.
218933174|NCT05102253|OTHER|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
218933175|NCT04508491|OTHER|Rhythm control|Rhythm control with medications or any procedure
218933176|NCT04508491|OTHER|Rate control|Rate control
218933177|NCT02516540|BEHAVIORAL|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
218933178|NCT00381290|BEHAVIORAL|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
218933179|NCT00381290|BEHAVIORAL|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
218933180|NCT03089164|DIAGNOSTIC_TEST|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
219542734|NCT07004322|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219621614|NCT06576973|OTHER|Collecting samples from participant|Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
219621615|NCT02852174|BEHAVIORAL|Mindfulness meditation training|Mindfulness meditation training
218933181|NCT04797624|PROCEDURE|Gastric cancer surgery|Appropriate gastric cancer surgery types for the convenient patients
218933182|NCT05189041|OTHER|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
218933183|NCT06131476|DRUG|Blink® Tears eye drops|Control Drops
218933184|NCT06131476|DRUG|Investigational lipid eye drops|Test Drops
218933185|NCT05680532|DIETARY_SUPPLEMENT|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
219205493|NCT06649435|PROCEDURE|PPG measurement|"PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart."
219542735|NCT07004322|DRUG|Placebo|Placebo matched to NNC0519-0130 will be administered subcutaneously.
219542736|NCT06246786|DRUG|Cyclosporin A|Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
219542737|NCT05350137|PROCEDURE|100% oxygen|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
219621616|NCT03307980|BIOLOGICAL|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
219621617|NCT06671834|DRUG|PF-07905428|Topical solution of PF-07905428 0.08% or PF-07905428 0.24%
219621618|NCT06671834|DRUG|Placebo|Topical solution of placebo
218933186|NCT05680532|OTHER|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
218933187|NCT02736890|DRUG|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
219205494|NCT06474754|DIAGNOSTIC_TEST|High-sensitivity troponin, serum|A serum derived measure of myocardial injury. Threshold value of 14ng/L.
218933188|NCT02736890|DRUG|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
218933189|NCT04748198|PROCEDURE|Intracorneal ring segment implantation|Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
218933190|NCT02904954|DRUG|Durvalumab|Intravenously
218933191|NCT02904954|OTHER|Durvalumab plus SBRT|Intravenously plus radiotherapy
218933192|NCT05819827|OTHER|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
218933193|NCT04520646|DRUG|Empagliflozin|empagliflozin of 10mg/day is added on the basis of primary care
218933194|NCT02295670|DEVICE|Vividtrac|video-laryngoscopy
218933195|NCT02295670|DEVICE|MIL|direct-laryngoscopy
218933196|NCT01851759|DRUG|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
218933197|NCT01851759|DRUG|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
218933198|NCT04541459|DEVICE|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
218933199|NCT04541459|DEVICE|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
218933200|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
218933201|NCT06055439|BIOLOGICAL|CHM-2101 CAR-T cells|Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
219045230|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
218933202|NCT05761886|OTHER|telehealth-based clinical pharmacy intervention|The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity
218933203|NCT04751006|OTHER|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
218933204|NCT04751006|OTHER|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
219621619|NCT06517602|DIETARY_SUPPLEMENT|Supplementation of Moringa oleifera leaf powder|Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
219621620|NCT03139851|DRUG|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219045231|NCT03279939|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
218933205|NCT03230370|OTHER|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
218933206|NCT03230370|OTHER|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
218933207|NCT05155514|PROCEDURE|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
218933208|NCT01491607|BIOLOGICAL|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
218933209|NCT01708785|BEHAVIORAL|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
218933210|NCT01708785|BEHAVIORAL|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
218933211|NCT01708785|BEHAVIORAL|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
218933212|NCT01708785|BEHAVIORAL|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
218933213|NCT01317277|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
218933214|NCT01317277|BEHAVIORAL|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
218933215|NCT00774566|PROCEDURE|PV-Isolation RF|Radiofrequency
218933216|NCT00774566|PROCEDURE|PV-Isolation Cryo|Cryo-Balloon
218933217|NCT02074683|PROCEDURE|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
218933218|NCT02074683|PROCEDURE|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
218933219|NCT00852852|BEHAVIORAL|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
218933220|NCT00912795|BEHAVIORAL|SMS Turkey|"6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
218933221|NCT04595981|DRUG|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
218933222|NCT00232726|DRUG|CP-4055 (ELACYT)|
218933223|NCT06266832|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
218933224|NCT06266832|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1, Q3W
218933225|NCT06266832|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W
218933226|NCT06266832|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
218933227|NCT06266832|PROCEDURE|Biopsy|local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
218933228|NCT00735267|DRUG|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
219045232|NCT03279939|DEVICE|Color Fundus Photography|Non-contact white light photography.
218933229|NCT03842189|DRUG|M281|Participants will receive once weekly intravenous (IV) infusions of M281
218933230|NCT03061006|DRUG|Dabigatran Etexilate|150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.
218933231|NCT03061006|DRUG|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
218933232|NCT01391052|DRUG|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
218933233|NCT01391052|OTHER|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
219045233|NCT03279939|DEVICE|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
219045234|NCT03279939|DEVICE|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
219045235|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
219045236|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
218933234|NCT04738461|OTHER|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
219542738|NCT05350137|PROCEDURE|Carbon dioxide|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
219542739|NCT00794456|DRUG|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
219542740|NCT00794456|DRUG|Valeriana|1 tablet PO twice a day
219542741|NCT01367145|DRUG|OMACOR|4 capsules OMACOR 1g per day
219542742|NCT01367145|DRUG|Placebo|4 capsules placebo per day
219542743|NCT00256165|DEVICE|Tissue valve|Aortic valve replacement
218933235|NCT04738461|OTHER|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
218933236|NCT04738461|OTHER|Home Exercise Group|The same exercise program applied to telerehabilitation group.
218933237|NCT02991976|PROCEDURE|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
218933238|NCT03346980|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
218933239|NCT03008200|DEVICE|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
218933240|NCT03698097|OTHER|patient satisfaction survey|Patient survey completed in a paper or survey monkey based internet version accessible via a QR code or link
218933241|NCT06232200|OTHER|ACUPUNCTURE|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
218933242|NCT03021343|DRUG|Colchicine|colchicine given as per trial protocol
218933243|NCT03259503|DRUG|Busulfan|Given IV
218933244|NCT03259503|DRUG|Gemcitabine|Given IV
218933245|NCT03259503|DRUG|Melphalan|Given IV
218933246|NCT03259503|DRUG|Olaparib|Given PO
218933247|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
219542744|NCT00761163|OTHER|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
219542745|NCT00761163|OTHER|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
219542746|NCT00761163|OTHER|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
219542747|NCT07016230|DRUG|Tarlatamab|Patients enrolled in both cohorts will receive treatment with tarlatamab at the dose of 1 mg on D1, 10 mg on D8 and D15 and Q2W thereafter in a 28-day cycle. Tarlatamab will be administrated in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal.
219542748|NCT03500094|DRUG|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
219542749|NCT04323683|GENETIC|Microarray|High throughput technique for determining global gene expression of the condition of interest
218933248|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
218933249|NCT03259503|BIOLOGICAL|Rituximab|Given IV
218933250|NCT03259503|DRUG|Vorinostat|Given PO
219045237|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
218933251|NCT02273804|DRUG|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
218933252|NCT02273804|DRUG|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
218933253|NCT05688722|PROCEDURE|Supine position|Patients preoxygenated in supine position before endotracheal intubation
218933254|NCT05688722|PROCEDURE|20 degree head elevation position|Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
218933255|NCT05688722|PROCEDURE|30 degree head elevation position|Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
218933256|NCT05688722|PROCEDURE|45 degree head elevation position|Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
218933257|NCT02689440|DRUG|Dasatinib|Given PO
218933258|NCT02689440|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205495|NCT06474754|DIAGNOSTIC_TEST|Submaximal Cardiopulmonary Exercise Testing|FDA-approved device uses breath by breath sampling during calibration and exercise challenge. Analysis is performed using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO2 and a paramagnetic sensor for O2 measurements. Automated calibration using a calibration gas mixture (15.6% O2/5% CO2) is performed at regular intervals. The Shape II calculations used to differentiate causes of exertional dyspnea are Artificial Intelligence (AI) based algorithms and measurements have been previously validated to conventional cardiopulmonary exercise testing methods. Brief smCPET is comprised of a 2-minute calibration phase, 3 minutes of graded exercise using a stair-step and a 1 minute recovery phase for a total of 6 minutes. An instant report is then generated.
218933259|NCT02689440|DRUG|Venetoclax|Given PO
218933260|NCT02922049|OTHER|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
219205496|NCT06474754|DIAGNOSTIC_TEST|Duke Activity Status Index|A validated measure of preoperative functional capacity which will be utilized to cross-validate smCPET peak VO2. Low DASI score has been found to estimate peak oxygen uptake (VO2), predict MINS, myocardial infarction, and inducible myocardial ischemia on myocardial perfusion scintigraphy.
219205497|NCT03678350|DEVICE|Light Dosimetry for Intranoperative Therapy|Undergo IO-PDT
218933261|NCT03835949|DRUG|TJ004309|Antibody to CD73
218933262|NCT03835949|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
218933263|NCT02877992|PROCEDURE|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
218933264|NCT05355246|OTHER|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
219045238|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
219045239|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
219045240|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
219045241|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
219045242|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
219045243|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
219045244|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
219045245|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
219045246|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
219045247|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
219045248|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
219045249|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
219045250|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
219045251|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
219045252|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
219045253|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
219045254|NCT00397995|PROCEDURE|above- or under elbow cast|
219045255|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
219045256|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
219205498|NCT03678350|PROCEDURE|Photodynamic Therapy|Undergo IO-PDT
219205499|NCT03678350|DRUG|Porfimer Sodium|Given IV
219205500|NCT04033822|PROCEDURE|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
219205501|NCT05696704|OTHER|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
219205502|NCT05696704|OTHER|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
219205503|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
218933265|NCT05355246|OTHER|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
218933266|NCT04904393|DEVICE|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
218933267|NCT03858309|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
218933268|NCT03858309|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
218933269|NCT02813577|DEVICE|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
218933270|NCT00663091|DRUG|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
219045257|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
219045258|NCT00325806|DRUG|Ramipril|
219045259|NCT04707534|DRUG|Dexamethasone|Dexamethasone
219045260|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
219045261|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
219045262|NCT04951622|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
219045263|NCT04951622|DRUG|Placebo|Matching placebo will be administered as an IV infusion.
219045264|NCT04951622|DRUG|Nipocalimab SC-LIV|Nipocalimab will be administered subcutaneously.
219045265|NCT04531943|DRUG|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
219045266|NCT04531943|DRUG|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
219542750|NCT03565926|OTHER|Manual Therapy|"1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
219045267|NCT05675371|BEHAVIORAL|Assessment by Expert Clinician During Behavioral Intervention (ABA or similar)|Assessment (e.g., responder vs. non-responder status) utilizing gold-standard clinical reference assessments performed by expert clinicians as the subject undergoes Applied Behavioral Analysis (ABA) or similar intervention for autism spectrum disorder and related developmental delays
219045268|NCT05675371|DEVICE|Assessment by the EarliPoint Assessment For Autism Spectrum Disorder|Assessment by The EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), a medical device which employs Dynamic Quantification of Social-Visual Engagement (DQSVE) to aid clinicians in the diagnosis, assessment, and treatment monitoring of ASD related developmental delays, is a diagnostic tool which measures an individual's visual preferential attention to social information in the environment relative to normative age-specific benchmarks.
219045269|NCT05718258|DRUG|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
219205504|NCT03957252|DIAGNOSTIC_TEST|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
219205505|NCT04899479|DRUG|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
219205506|NCT04899479|OTHER|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
219542751|NCT03565926|OTHER|Hypopressive exercises|Protocol 5 Hypopressive exercises
219542752|NCT04342650|DRUG|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
219542753|NCT04342650|DRUG|Placebo oral tablet|150mg placebo tablets
219542754|NCT03605030|DEVICE|Novel Lead Based Armboard|Novel Lead Based Armboard
219542755|NCT03605030|DEVICE|Standard Armboard|Standard Armboard (without lead)
219621621|NCT03139851|DRUG|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
219045270|NCT06640556|BEHAVIORAL|watching animation show|The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
219045271|NCT06322602|PROCEDURE|Intracranial Catheter Placement|Undergo Ommaya reservoir placement
219542756|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Written Emotional Disclosure|A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
219542757|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Healthy Habits Disclosure|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
219542758|NCT05513274|BEHAVIORAL|Health Behavior Control + Written Emotional Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
219621622|NCT02537561|DRUG|Cisplatin|
218933271|NCT00663091|DRUG|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
218933272|NCT00663091|DRUG|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
218933273|NCT06132815|DEVICE|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
219045272|NCT06322602|PROCEDURE|Lumbar Puncture|Undergo LP
219045273|NCT06322602|PROCEDURE|Biopsy|Undergo biopsy
219045274|NCT06322602|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
219045275|NCT06322602|PROCEDURE|Computed Tomography|Undergo CT
219045276|NCT06322602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219045277|NCT04108208|DRUG|Apalutamide|Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
219045278|NCT04108208|DRUG|Placebo|Matching placebo will be administered orally.
219045279|NCT04108208|DRUG|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
219045280|NCT03463889|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
219045281|NCT03463889|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI in combination with PET
219045282|NCT03463889|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
219045283|NCT01753089|BIOLOGICAL|WDVAX|
219045284|NCT06731816|OTHER|Neck and stabilization exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. In addition to neck stretching, range of motion, and isometric exercises applied in the neck exercise group, they will also apply spinal and cervical region stabilization exercises.
219045285|NCT06731816|OTHER|Neck exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. They will perform neck stretching, range of motion and isometric exercises.
219045286|NCT05831592|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound assessment (sensitivity, specificity) in undernutrition in patients
219045287|NCT05520034|BEHAVIORAL|Health Education|The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
219621623|NCT02537561|DRUG|Gemcitabine|
219621624|NCT02537561|DRUG|Talazoparib|
219621625|NCT04132973|BEHAVIORAL|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
219621626|NCT02841137|DRUG|Progesterone|comparison of different dosages of drug towards the active comparator
219621627|NCT07009080|OTHER|motor imagery|The researcher will explain to the players what MI is and how it works. Following the explanation, players will seated in a comfortable armchair facing the researcher, will ask to minimize distracting thoughts, and to be as mindful as possible without speaking for five minutes, and to imagine themselves executing the correct angles during a landing.
219542759|NCT05513274|BEHAVIORAL|Health Behavior Control + Healthy Habits Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
219542760|NCT07035925|DEVICE|ECMT-100|Colloidal hydrogel
219542761|NCT06703346|DRUG|Experimental: Letetresgene autoleucel|Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
219542762|NCT04981262|DIETARY_SUPPLEMENT|Stimulance|Intervention with Prebiotic supplement
219542763|NCT05469997|BEHAVIORAL|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
219542764|NCT05469997|DIETARY_SUPPLEMENT|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
219542765|NCT07057193|DRUG|Dexmedetomidine group (D group)|patients will receive intravenous dexmedetomidine (0.25 μg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
219542766|NCT07057193|DRUG|Ketamine group (K group)|patients will receive intravenous ketamine (0.25mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
219542767|NCT07057193|DRUG|Midazolam group (M group)|patients will receive intravenous midazolam (0.05 mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
219542768|NCT07057193|OTHER|5ml of normal saline|patients will receive 5ml of normal saline intravenous10 min before the end of the surgical procedure as placebo.
219542769|NCT06563141|OTHER|traction and mobilization|The patient undergoes a 15-minute infrared therapy session, followed by flexibility and stretching exercises targeting the trunk and four extremities muscles. Land manipulation techniques are used for cervical, dorsal, and lumbar spine to assess and treat spinal dysfunctions. Deep breathing exercises with rib mobilization are also performed to promote respiratory function and thoracic flexibility. The session aims to improve overall health.
219542770|NCT06563141|OTHER|active exercise therapy|Patients with adolescent idiopathic scoliosis will receive exercise programs from seven major schools under SOSORT, focusing on realigning the spine, rib cage, shoulders, and pelvis to normal anatomical postures.
219542771|NCT07051252|DRUG|HBS-201|On Days 1-7, participants will take HBS-201 17.8 mg per day (one 17.8 mg tablet) and on Days 8-14, participants will take HBS-201 35.6 mg per day (two 17.8 mg tablets).
219542772|NCT07067268|DRUG|Adjuvant therapy|Tislelizumab: 200 mg IV on day 1, every 3 weeks Capecitabine: 1000 mg/m² orally twice daily on days 1-14，every 3 weeks Treatment duration: 8 cycles
219542773|NCT07067502|DEVICE|Biphasic cuirass ventilator which is a type of negative pressure ventilator will be applied to patients on the intervention arm|As opposed to patients being placed on Non invasive ventilation (CPAP or BiPAP) the intervention arm patients will be placed on the Biphasic cuirass ventilator which is a form of negative pressure ventilator.
219542774|NCT07067450|DRUG|Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)|The immune checkpoint inhibitors used for adjuvant therapy after surgery were consistent with those used during the neoadjuvant treatment before surgery, including pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab.
219542775|NCT07067450|OTHER|Observation|Postoperative observation is conducted without the use of any anti-tumor treatment.
219542776|NCT07068906|DRUG|CAR-T cells chimenric antigen receptor T cells|CT1194C cells infusion
218933274|NCT06132815|OTHER|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
219045288|NCT06279312|DIETARY_SUPPLEMENT|Placebo drink|consume 1 drink per day for 4 weeks
219045289|NCT06279312|DIETARY_SUPPLEMENT|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
219045290|NCT00283933|DRUG|migalastat HCl|
219045291|NCT05397665|DRUG|AT-007|AT-007, aldose reductase inhibitor
219045292|NCT05397665|DRUG|Placebo|Liquid oral suspension
219045293|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
219045294|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
219045295|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
219621628|NCT05913336|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
218933275|NCT06132815|OTHER|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
218933276|NCT06132815|OTHER|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
218933277|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
218933278|NCT01446055|DEVICE|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
218933279|NCT01446055|DEVICE|Ficoll conventional cell processing method|Comparison of different cell processing methods
218933280|NCT00668889|DRUG|Lactic acid (Dermacid)|
218933281|NCT06360120|DRUG|Atorvastatin 40 Mg Oral Tablet|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
218933282|NCT06360120|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
218933283|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
218933284|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
219045296|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
219205507|NCT06054295|OTHER|Biospecimen collection|Collection of both blood and saliva samples from participants at the time of study enrollment
219205508|NCT06054295|OTHER|Questionnaire Administration|The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
219542777|NCT07067528|BEHAVIORAL|A novel PTLD clinical diagnostic algorithm|A clinical diagnostic algorithm designed to help TB clinicians identify patients at risk of post-tuberculosis lung disease (PTLD) at the end of TB treatment. The algorithm is implemented as a visual aid and structured questionnaire integrated into routine care. Clinicians use it to screen TB survivors and refer suspected PTLD cases to a post-TB clinic for confirmatory evaluation and management.
219542778|NCT07069283|BEHAVIORAL|Self-Compassion Program|Program includes four basic practices: breathing meditation, walking meditation, body scan, and mindful movement. Consciously focusing on what is happening allows people to observe and accept what they are experiencing in their bodies, minds, and the world around them at that moment. Mindfulness practices are an 8-week practice consisting of 2-2.5 hour sessions per week by a trained instructor, mindfulness meditation practices, yoga practices, examining the psychological and physiological aspects of stress, and recently including the concept of self-compassion. In addition, daily practices are given to participants, and a suitable day is determined as a retreat day. The aim is to enable individuals to reveal and experience their thoughts, emotions, and bodily sensations and to increase emotional tolerance by revealing avoidance behaviors. Individuals learn to return to and accept intense bodily sensations and emotional discomfort with mindfulness.
219205509|NCT05123261|BEHAVIORAL|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
218933285|NCT02780752|DRUG|hymecromone|Oral Hymecromone
218933286|NCT00573300|PROCEDURE|Phlebotomy|Single blood draw
218933287|NCT04931706|OTHER|Magnetics Assisted by Singe port|Use of magnet for assistance through the surgery, and a novel approach as it is single port
218933288|NCT00160901|DRUG|two complex naturopathic add-on therapies, leaflet 5-a-day|
219045297|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
219045298|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
219045299|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
218933289|NCT05066932|OTHER|Additionnal blood samples|Additionnal blood samples
218933290|NCT02131649|DEVICE|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
219045300|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
219205510|NCT02591433|OTHER|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
219205511|NCT02591433|OTHER|Support Group Therapy|Undergo JeffQuit group therapy
219205512|NCT02591433|OTHER|Quality-of-Life Assessment|Ancillary studies
218933291|NCT02627261|BIOLOGICAL|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
218933292|NCT06519851|OTHER|suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%|postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
218933293|NCT06519851|OTHER|Interscalene block with 20 ml bupivacaine 0.25%|postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
218933294|NCT03370978|BEHAVIORAL|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
218933295|NCT04413006|BEHAVIORAL|Self-Compassion for Chronic Pain Virtual Group Treatment Program|6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
218933296|NCT02921841|BEHAVIORAL|D*STAR|
218933297|NCT02921841|BEHAVIORAL|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
218933298|NCT01526304|OTHER|no intervention|No intervention, only observational study
218933299|NCT02233361|BEHAVIORAL|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
218933300|NCT05936697|DEVICE|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
218933301|NCT05936697|DEVICE|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
218933302|NCT05936697|OTHER|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
218933303|NCT04238897|DEVICE|soft contact lens|
219045301|NCT03802448|COMBINATION_PRODUCT|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
219045302|NCT03802448|DEVICE|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
219045303|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
219045304|NCT04865432|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
219045305|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
219045306|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
219045307|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
219045308|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
219045309|NCT01408186|DRUG|Rabeprazole|Rabeprazole 20 mg daily
219045310|NCT01408186|DRUG|Famotidine|Famotidine 40mg daily
219045311|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
219045312|NCT02946060|OTHER|Audiobooks|iPods with audiobooks
219045313|NCT02946060|OTHER|Tempo-pace synchronized playlists|Playlists with or without RAS
219045314|NCT02946060|OTHER|Usual Care|iPods containing either a silent track or white noise
219045315|NCT02558998|OTHER|Survey|
219045316|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
219045317|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
219045318|NCT04649034|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
219542779|NCT07069205|BEHAVIORAL|Tele-nursing supported respiratory exercises|This intervention consists of a structured tele-nursing supported respiratory exercise program including abdominal breathing, pursed-lip breathing, and effective coughing techniques. The training is delivered through educational booklets and videos over a 12-week period, aiming to improve respiratory function and patient self-management in tuberculosis patients.
219542780|NCT07068945|BEHAVIORAL|Group of 17-year-old patients living in Nice and receiving psychiatric care|Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.
219542781|NCT07067905|DRUG|68Ga-XT771|68Ga-XT771 is injected intravenously with a dose of 4-8 mCi
219045319|NCT04649034|DIAGNOSTIC_TEST|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
219045320|NCT04649034|DIAGNOSTIC_TEST|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
219045321|NCT04649034|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
219045322|NCT04649034|DIAGNOSTIC_TEST|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
219045323|NCT05939206|PROCEDURE|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
219542782|NCT07068854|OTHER|HPP mango juice group|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
219542783|NCT07068854|OTHER|control juice|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
219542784|NCT07068087|PROCEDURE|Preoperative sioldosin to facilitate ureteric access sheath insertion in RIRS|group A (study group) that included 21 patients who received silodosin 'one capsule 8 mg per day for 1 week preoperatively
219542785|NCT07068087|PROCEDURE|ureteric access sheath insertion in RIRS without silodosin (Placebo)|group B (study group) that included 21 patients who received Placebo'one capsule per day for 1 week preoperatively
219542786|NCT07066046|PROCEDURE|Colonoscopy|"This single-center, randomized, open-label clinical trial will assess the effectiveness of artificial intelligence (AI)-assisted colonoscopy versus standard high-definition colonoscopy in detecting and characterizing colorectal lesions. Conducted over 12 months in São Paulo, Brazil, the study will include 100 adult patients undergoing elective colonoscopy.~Participants will be stratified by age and randomized (1:1) after sedation. All lesions will be resected, recorded, and analyzed histologically. The intervention group will also include AI output data (CAD EYE).~The primary goals are to evaluate adenoma detection rate (ADR) and AI diagnostic accuracy. Given the global burden of colorectal cancer (CRC), particularly in developing countries, this study aims to provide real-world data on the impact of AI in CRC screening."
219542787|NCT07067840|DEVICE|Treated with the triple branched stent graft system|Participants treated with the triple branched stent graft system
219542788|NCT07069465|DIAGNOSTIC_TEST|flotufolastat F 18|PSMA-PET scan with Posluma agent (x2)
219542789|NCT07069465|DRUG|Relugolix 120 MG|Administration of oral ADT for 3 and 6 weeks
219542790|NCT07069465|DIAGNOSTIC_TEST|Serum PSA and Testosterone|Serum PSA and testosterone at study initiation and again at 3 and 6 weeks after initiation of ADT
219542791|NCT07067372|DEVICE|FireMagic™ Magbot Ablation Catheter|All patients signed informed consent forms, enrolled in the trial, underwent surgical treatment for rapid arrhythmia using XX, and were discharged after follow-up data collection. The total duration for each subject is estimated to be approximately 7 days.
219542792|NCT07069504|OTHER|AI-based role play|Participants will role play informed consent scenarios with a generative AI-driven patient simulation designed to mimic a realistic consent discussion for an endoscopic procedure.
219542793|NCT07069504|OTHER|Peer role play|Participants will role play informed consent discussions with a peer (i.e., another participant randomized to this group)
219045324|NCT04568057|DEVICE|NIR Transcranial phototherapy device|1068 nm NIR helmet
219045325|NCT04568057|DEVICE|Placebo Transcranial Device|The placebo device looks like the active device.
219045326|NCT02350309|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablet.
219045327|NCT02350309|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablet.
219045328|NCT02350309|DRUG|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
219045329|NCT02350309|DRUG|Flurazepam 30 mg|Flurazepam 30 mg capsule.
219045330|NCT03033407|OTHER|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
218933304|NCT05266170|DEVICE|aerobic and anaerobic exercises|"\[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1\. Fitness exercise program with EX1"
218933305|NCT00555516|OTHER|EW02|"1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
218933306|NCT04730232|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
218933307|NCT04730232|DRUG|Nab-paclitaxel|Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
218933308|NCT01782391|DEVICE|Stimulation|
218933309|NCT01782391|DEVICE|SHAM|no stimulation
218933310|NCT00111852|DRUG|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
219045331|NCT03414346|OTHER|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
219542794|NCT07067541|DRUG|Control lidocaine cream|lidocaine cream alone
219542795|NCT07067541|DRUG|Experimental lidocaine cream + moisturizer cream|lidocaine cream + moisturizer cream
218933311|NCT00111852|DRUG|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
218933312|NCT00111852|DRUG|Placebo|Dose-Match Placebo, intravenous administration.
218933313|NCT01470118|DRUG|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
218933314|NCT01470118|DRUG|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
219542796|NCT07067606|DEVICE|ultrasound contrast|All participants will be subjected to full history taking, full clinical examination, laboratory investigations (complete blood count, erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\], blood urea, serum creatinine, serum glutamic-oxaloacetic transaminase \[SGOT\], serum glutamate-pyruvate transaminase \[SGPT\], immunological tests (antinuclear and anti-DNA antibodies and C3 and C4 levels), urine analysis, and 24-h urinary protein). SLE disease activity index (SELDAI) will be also calculated for every patient. (8) Musculoskeletal examination with power Doppler, the ultrasound examination will be performed at the musculoskeletal ultrasonography unit at the rheumatology division of the internal medicine department. Bilateral musculoskeletal US examinations of hands and wrists with power Doppler (PD) evaluation will be done for all patients. US examinations were performed using the standardized scanning technique according to EULAR guidelines for musculoskeletal US in rheumatolog
218933315|NCT01470118|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
218933316|NCT00785382|DRUG|Placebo|Lactulose Placebo
218933317|NCT00785382|DRUG|Pregabalin 150 mg|150 mg Q12H x 2 doses
218933318|NCT05475080|DRUG|Antiplatelet Drug|Any antiplatelet drug or combination
218933319|NCT05475080|DRUG|Anticoagulant|Any anticoagulante
218933320|NCT05475080|PROCEDURE|Endovascular|Angioplasty +- stent
218933321|NCT05475080|PROCEDURE|Surgery|Endarterectomy
218933322|NCT00285623|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
218933323|NCT02458326|OTHER|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
218933324|NCT02458326|OTHER|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
218933325|NCT01009216|DRUG|ABT-384|Doses will be administered daily for 5 days.
218933326|NCT04036396|BEHAVIORAL|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
218933327|NCT04036396|BEHAVIORAL|Usual Care plus Customized Referrals|Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
218933328|NCT00606437|PROCEDURE|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
218933329|NCT03212313|DRUG|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
218933330|NCT00782847|BEHAVIORAL|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
219542797|NCT07068815|DEVICE|Fu's Subcutaneous Needling|Participants were seated while the practitioner identified affected muscles (sternocleidomastoid, scalene, splenius capitis, and upper trapezius) via sliding palpation. After routine disinfection, a disposable FSN needle (Nanjing Paifu Medical Technology Co., Ltd., Jiangsu, China) was inserted parallel to the subcutaneous loose connective tissue surrounding the affected muscle. Once fully inserted, the soft tube stand was secured in the slot. After confirming no pain, the practitioner performed smooth, gentle, fan-shaped swaying movements (120° angle, \~100 times/min) with the index and ring fingers. This was accompanied by reperfusion activities-resistance-based contraction and relaxation of the affected muscles, performed collaboratively by the practitioner and participant. Each set comprised 20 swaying movements and 10 seconds of reperfusion, repeated three times per muscle.
219542798|NCT07068815|DRUG|Flunarizine Hydrochloride|Participants in the drug group were administered 5 mg flunarizine hydrochloride capsules nightly before sleep for 4 weeks.
218933331|NCT03097809|OTHER|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
218933332|NCT03839797|BEHAVIORAL|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
218933333|NCT03839797|BEHAVIORAL|Standard Health Education|Standard Health Education
218933334|NCT00643903|BEHAVIORAL|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
218933335|NCT00643903|BEHAVIORAL|Standard care|Participants will receive standard of care for HIV infections.
219045332|NCT03414346|OTHER|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
219045333|NCT03414346|OTHER|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
219045334|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
219045335|NCT00861211|DRUG|Placebo|Placebo comparator
218933336|NCT00643903|BEHAVIORAL|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
218933337|NCT00156468|BEHAVIORAL|Provider Prompt|
218933338|NCT05083117|DRUG|XW001|It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
218933339|NCT05083117|DRUG|Placebo|It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
218933340|NCT02902237|BIOLOGICAL|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
218933341|NCT02004678|DRUG|DS-1150b|
218933342|NCT02004678|OTHER|Placebo|
218933343|NCT03983811|DRUG|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
218933344|NCT03983811|DRUG|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
218933345|NCT03983811|OTHER|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
218933346|NCT01301027|DRUG|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
218933347|NCT01301027|DRUG|Placebo|1 pill a day for 26 weeks
218933348|NCT03088956|OTHER|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
219045336|NCT06419335|DRUG|CoQ10|The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
219045337|NCT00003585|BIOLOGICAL|aldesleukin|
219045338|NCT00003585|BIOLOGICAL|recombinant interferon alfa|
218933349|NCT04919200|DIAGNOSTIC_TEST|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
218933350|NCT00277732|PROCEDURE|Pharmaceutical care at baseline and follow-up visits over 6 months|
218933351|NCT01279785|DRUG|123I-MIP-1072|Single IV dose
219045339|NCT00003585|DRUG|fluorouracil|
219045340|NCT00003585|DRUG|isotretinoin|
219045341|NCT00003585|PROCEDURE|surgical procedure|
219045342|NCT03026621|DIETARY_SUPPLEMENT|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
218933352|NCT02023697|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
218933353|NCT04293822|DRUG|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
218933354|NCT04293822|DRUG|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
219045343|NCT03026621|OTHER|Herbal tea|This is an herbal tea that will look like the control
219205513|NCT05486793|BEHAVIORAL|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
219542799|NCT07067307|DRUG|melatonin|melatonin 20 mg tablet once daily at bedtime
219542800|NCT07067307|DRUG|Placebo|Placebo once daily at bedtime
219542801|NCT07067437|RADIATION|single-fraction very accelerated partial breast irradiation|Adjuvant accelerated partial breast brachytherapy, with interstitial multicatheter technique, in one fraction.
219542802|NCT07069036|DRUG|SEP-631|Oral, tablet
219542803|NCT07069036|OTHER|Placebo|Oral, tablet
219542804|NCT07067515|COMBINATION_PRODUCT|non surgical with PUFA injection|The hyperpigmented gingiva in the canine/1st premolar region to the contralateral comparable tooth region in the maxillary aesthetic areas will be the target area for this procedure. A local anesthesia will be used to numb the area. Using an insulin and plastic syringe (needle: 30-gauge, 8 mm length), 1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva at approximately the epithelial connective tissue interface until the tissue blanche, 2-3 mm apart. The insulin syringe, bevel facing upward, will be inserted into the corresponding gingival tissues. For four weeks, this dosage of omega-3 (PUFAs) will be administered once a week. Furthermore, patients will take 2 capsules. Each capsule contains 1 gram of Omega3(PUFAs) as an additional food supplement (up to 3 gram daily for the period of injection except the day of injection. the patients will receive a packet containing required number of capsules have to be taken every week.
219542805|NCT07067515|PROCEDURE|surgical treatment|Patients with gingival hyperpigmentation of oral mucosa. For the scalpel technique, following the administration of a local anesthetic solution, a partial split thickness flap was raised with the help of blade no. 15 with the Bard Parker handle to scrape the epithelium in maxillary anterior area from canine to canine in the other side; will be surgical removal of pigmentation using the scalpel in 45 degrees to remove the superficial layer. Bleeding Will be controlled using a pressure pack with sterile gauze. Care was taken that excessive tissue was not removed thereby avoiding any bone exposure. This will be followed by careful examination of the exposed connective tissue surface, and the wound will be irrigated with saline. Bleeding will be controlled using a pressure pack, and once hemostasis is achieved, the site will be covered by a periodontal dressing for a period of one week. patients will be advised to stop eating hard, acidic, spicy, and colored foods before surgery. All patie
219542806|NCT07069049|OTHER|electroacupuncture|Sterile acupuncture needles (Huatuo brand, specification: 0.25mm\*40mm) were applied to Hegu (Li4), Neiguan (PC 6), Guanyuan (CV 4) and Sanyinjiao (SP 6) by twidling, rotating, lifting and thrusting for 30 seconds. After getting qi (a feeling of acid, numbness, weight and swelling), the electronic acupuncture instrument (SDZ-II type, Huatuo brand) was connected, and the continuous wave was 50HZ. The current intensity was 1-5mA (preferably as much as the patient could tolerate without pain).
219542807|NCT07069049|OTHER|Sham-electroacupunture|Sham electroacupuncture was applied at the non-meridian and non-acupoint sites 3mm apart from the acupoints in the experimental group. The acupuncture method was shallow acupuncture, only 1-4mm through the skin.
219542808|NCT07069582|DRUG|Standard dose rifampicin|Single-dose rifampicin at 10 mg/kg body weight
219542809|NCT07069582|DRUG|High dose rifampicin|Single-dose rifampicin at 20 mg/kg body weight
219542810|NCT07069582|DRUG|Standard dose isoniazid|Single-dose isoniazid at 5 mg/kg body weight
219542811|NCT07069582|DRUG|Standard dose levofloxacin|Single-dose levofloxacin at 10-15 mg/kg body weight
219542812|NCT07069582|DRUG|Standard dose rifapentine|Single-dose rifapentine at 10 mg/kg body weight
219542813|NCT07069582|DRUG|Standard dose bedaquiline|Single-dose bedaquiline at 400 mg
219542814|NCT07067424|OTHER|Lavender Aromatherapy|Participants will inhale lavender essential oil via cotton pads placed near the nose for 20 minutes prior to colonoscopy. The application will take place in a pre-procedure waiting area under nurse supervision.
219205514|NCT05486793|BEHAVIORAL|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
219542815|NCT07067424|OTHER|Bergamot Aromatherapy|Participants will inhale bergamot essential oil through cotton pads placed near the nose for 20 minutes before the colonoscopy procedure, under the supervision of clinical staff.
219542816|NCT07067424|OTHER|Placebo Inhalation|Participants will inhale an odorless substance (distilled water) using the same method and duration as the intervention groups, to simulate the aromatherapy procedure.
219542817|NCT07067359|DIETARY_SUPPLEMENT|Enteral Nutrition|This study selected patients with esophageal cancer undergoing neoadjuvant therapy as the research subjects. All enrolled patients underwent comprehensive nutritional risk screening and malnutrition assessment prior to enrollment. After the completion of nutritional risk screening and assessment, patients identified with nutritional risk were randomly assigned to two groups: the Standard Nutrition Therapy group (SNT) and the Intensive Nutrition Therapy group (INT). Patients in the SNT group received a conventional nutritional support regimen during hospitalization, which included dietary guidance and necessary nutritional supplements. In addition to the standard regimen, patients in the INT group continued to receive ongoing nutritional counseling and nutritional supplement support after discharge to ensure sustained nutritional support.
219542818|NCT07067281|PROCEDURE|Lichtenstein Tension-Free Mesh Hernioplasty|Open surgical repair of inguinal hernia using a tension-free mesh technique. A standard polypropylene mesh is placed over the posterior wall of the inguinal canal and fixed with non-absorbable sutures under spinal or local anesthesia. This is a conventional method widely used in open hernia surgery.
219542819|NCT07067281|PROCEDURE|Laparoscopic Transabdominal Preperitoneal (TAPP) Repair|Laparoscopic approach to inguinal hernia repair performed under general anesthesia. Three ports are used to access the abdominal cavity, and a peritoneal flap is created to place a large polypropylene mesh in the preperitoneal space. The mesh is fixed with tacks or glue, and the peritoneal flap is closed. This minimally invasive method is designed to reduce postoperative pain and enhance recovery.
219542820|NCT07067177|DRUG|Paracetamol (drug)|IV prophylactic paracetamol will be given prior to detection of PDA starting from 6 hours of age. It will be used to measure wethere this intervention reduces the risk of having persistant PDA, HsPDA, or any of their complications.
219542821|NCT04887480|DEVICE|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
219542822|NCT04887480|DRUG|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
219542823|NCT06948773|DEVICE|Helix Surgical System|A handheld device to viscodilate up to 360 degrees of Schlemm's canal and collector channels that also enables intracanalicular scaffolding procedure to restore the aqueous outflow system of a glaucomatous eye.
219542824|NCT03114891|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
219542825|NCT03114891|BEHAVIORAL|Task|Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
219542826|NCT03114891|PROCEDURE|fMRI-guided TMS target|Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
218933355|NCT04153552|DIETARY_SUPPLEMENT|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
219542827|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
219542828|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
219542829|NCT05376800|DRUG|BI 907828 (Brigimadlin)|BI 907828 (Brigimadlin)
219542830|NCT01718301|DRUG|boceprevir|
219542831|NCT01718301|DRUG|Ribavirin|
219542832|NCT01718301|DRUG|Peginterferon alfa-2a|
218933356|NCT02483962|OTHER|Gelatine capsule|Gelatine capsules containing no active ingredients.
218933357|NCT02483962|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
218933358|NCT03667456|PROCEDURE|Self-rehabilitation by digital support|Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
218933359|NCT03346694|DEVICE|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
218933360|NCT03346694|DEVICE|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
218933361|NCT03346694|DEVICE|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
219542833|NCT01718301|DRUG|Peginterferon alfa-2b|
219542834|NCT04464200|DRUG|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
219542835|NCT06152302|OTHER|Mobility study in dry conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.
219542836|NCT06152302|OTHER|Mobility study in water conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
219542837|NCT06703840|DRUG|LIB-01|LIB-01 oral suspension
218933362|NCT00915616|DRUG|Melatonin|
218933363|NCT00636493|DEVICE|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
218933364|NCT00845897|DRUG|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
219542838|NCT06703840|DRUG|LIB-01 Placebo|LIB-01 Placebo oral suspension
219542839|NCT06437119|DIETARY_SUPPLEMENT|Compound plant nutrients|The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate.
219542840|NCT06437119|DIETARY_SUPPLEMENT|placebo|A placebo with an indistinguishable appearance and color.
219045344|NCT01054638|DRUG|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
219045345|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
219045346|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
219045347|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
219542841|NCT04727359|OTHER|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
219542842|NCT06385184|OTHER|No Intervention|Observational study with no intervention
219542843|NCT05763589|OTHER|No intervention is involved|No intervention is involved
219542844|NCT06785389|DIAGNOSTIC_TEST|Fear of anesthesia, surgery and hospitals scale|The day before surgery, patients will be interviewed using the scales of Fear of anesthesia, surgery and hospitals.
219542845|NCT06785389|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|The day before surgery, patients will be interviewed using the State-Trait Anxiety Inventory
219542846|NCT06785389|DIAGNOSTIC_TEST|Nummerical Rating Scale for postoperative pain|In the first postoperative day, patients will be monitored using the Nummerical Rating Scale, which will assess postoperative pain.
219542847|NCT05630950|DEVICE|Smoking cessation mobile application|Mobile application for smoking cessation.
219542848|NCT05630950|BEHAVIORAL|Written material for smoking cessation|Written material for smoking cessation
219542849|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
219542850|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
219542851|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
219045348|NCT01736696|DRUG|tofacitinib|5 mg BID For 13 days and once on Day 14
219045349|NCT01736696|DRUG|tofacitinib|10 mg BID for 13 days and once on Day 14\*
219542852|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
219542853|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
218933365|NCT00845897|DRUG|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
218933366|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
218933367|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219045350|NCT01736696|DRUG|tofacitinib|20 mg BID for 13 days and once on Day 14
219045351|NCT01736696|DRUG|tofacitinib|30 mg BID for 13 days and once on Day 14
219045352|NCT01736696|DRUG|tofacitinib|60 mg tablet once a day (QD) for 14 days
218933368|NCT00629889|DRUG|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
219045353|NCT01736696|DRUG|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
219045354|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
219045355|NCT01701661|OTHER|conservative treatment|Compression stockings class II
219045356|NCT05756322|DRUG|LBS-007|Open Label.
219045357|NCT02114879|BEHAVIORAL|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
218933369|NCT00629889|DRUG|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
218933370|NCT03113461|DEVICE|CPAP|non-invasive positive airway pressure applied using an oronasal mask
218933371|NCT05791019|OTHER|Paleolithic diet effect on patients|Efficacy of paleolithic diet in control of blood level of glucose in type 2 DM patients
219045358|NCT02114879|BEHAVIORAL|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
219045359|NCT05954325|PROCEDURE|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
218933372|NCT04387084|DRUG|Atezolizumab|Given IV
218933373|NCT04387084|DRUG|Avelumab|Given IV
218933374|NCT04387084|BIOLOGICAL|Cemiplimab|Given IV
219205515|NCT04876339|DEVICE|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
218933375|NCT04387084|BIOLOGICAL|Durvalumab|Given IV
219205516|NCT04876339|OTHER|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
219205517|NCT04791943|DRUG|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
219205518|NCT04791943|DRUG|Lactose pill|3 lactose pills will be provided to the control arm
219205519|NCT06103201|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
219205520|NCT06463951|OTHER|Psychotherapy - Gestalt psychotherapy|Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
219205521|NCT06251050|DRUG|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.30 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
219205522|NCT06251050|DRUG|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
218933376|NCT04387084|BIOLOGICAL|Nivolumab|Given IV
218933377|NCT04387084|BIOLOGICAL|Pembrolizumab|Given IV
218933378|NCT04387084|OTHER|Quality-of-Life Assessment|Ancillary studies
218933379|NCT04387084|OTHER|Short-Term Fasting|Undergo STF
218933380|NCT04387084|BIOLOGICAL|Dostarlimab|Given IV
218933381|NCT04387084|BIOLOGICAL|Retifanlimab|Given IV
218933382|NCT04387084|BIOLOGICAL|Toripalimab|Given IV
218933383|NCT04387084|BIOLOGICAL|Tislelizumab|Given IV
218933384|NCT05013541|OTHER|No intervention|Observational study, standard record of need to void during cystometry
218933385|NCT05838482|DEVICE|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
218933386|NCT00887211|DEVICE|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
218933387|NCT00887211|DEVICE|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
219045360|NCT05189457|DRUG|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
219045361|NCT05189457|DRUG|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
219045362|NCT05189457|DRUG|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
219045363|NCT05189457|DRUG|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
218933388|NCT04685889|PROCEDURE|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
219045364|NCT01485523|OTHER|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
219045365|NCT06414057|OTHER|Offering opportunistic HPV vaccine during routine sexual health clinic visits|Investigators will offer Gardasil-9 and HPV self-swab screening to up to 500 individuals across the three study sites, aiming to recruit 120-180 individuals within each of the three participating health boards over a 6-9 month timeframe. Participants will be asked to provide a vaginal swab sample for baseline HPV testing.
219542854|NCT06834308|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS (100 Hz, 60 ms pulse width) will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to produce strong paresthesia without pain. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
218933389|NCT03841201|DRUG|Lenvatinib|oral
219045366|NCT06259331|DRUG|SPN-812 (600mg, QD)|Viloxazine ER
219045367|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
219045368|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
219045369|NCT01625247|PROCEDURE|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
219045370|NCT01248299|DRUG|FU-CDDP|"every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]"
219045371|NCT01248299|DRUG|LV5FU2-CDDP|"every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]"
219045372|NCT01248299|DRUG|FOLFOX|"every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]"
219045373|NCT01248299|DRUG|TPF|"every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]"
219045374|NCT01248299|OTHER|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
218933390|NCT03841201|DRUG|Nivolumab|iv infusion
219205523|NCT06251050|DRUG|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
219205524|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
219205525|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
219205526|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
219205527|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
219205528|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
219205529|NCT04430309|BEHAVIORAL|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
218933391|NCT04312724|DEVICE|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
218933392|NCT02472067|BEHAVIORAL|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
218933393|NCT01009619|DRUG|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
219542855|NCT06834308|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|The participants will be able to see the same parameters as the conventional TENS (100 Hz, 60 ms pulse width) on the screen, but there will be no actual stimulation. Sham TENS will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to 4Hz for all participants in the Sham arm. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
219542856|NCT06119477|OTHER|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
219542857|NCT06119477|OTHER|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
219542858|NCT06119477|OTHER|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
219542859|NCT06790394|DRUG|Florbetaben F18|Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
219542860|NCT02068794|OTHER|Laboratory Biomarker Analysis|Correlative studies
219542861|NCT02068794|PROCEDURE|Mesenchymal Stem Cell Transplantation|Given IP
219542862|NCT02068794|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
219542863|NCT02068794|PROCEDURE|Echocardiography|Undergo ECHO
219542864|NCT02068794|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219542865|NCT02068794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219542866|NCT02068794|PROCEDURE|Chest Radiography|Undergo chest X-ray
219542867|NCT02068794|PROCEDURE|Single Photon Tomography and Computed Tomography Scan|Undergo SPECT/CT
219542868|NCT02068794|PROCEDURE|Computed Tomography|Undergo CT
219542869|NCT02068794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219542870|NCT04748796|OTHER|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
219542871|NCT04748796|DRUG|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
219542872|NCT04359407|OTHER|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
219542873|NCT06514014|DIETARY_SUPPLEMENT|Preterm Infant Formula|Transition from donor human milk to preterm infant formula
219542874|NCT02316548|RADIATION|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
219542875|NCT06182436|DEVICE|Virtual Reality Distraction|For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.
218933394|NCT01009619|DRUG|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
219542876|NCT06182436|OTHER|Standard Treatment|"Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention.~Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented"
218933395|NCT01324037|OTHER|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
218933396|NCT01172717|DRUG|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
218933397|NCT01419652|OTHER|hold hypoglycemic meds|continue versus hold hypoglycemic medications
219542877|NCT06788431|DRUG|IMC-001 and Optimal medical treatment|Subjects receive IMC-001 administered by injection once a week for 13 weeks and also receive optimal medical treatment.
218933398|NCT06511401|OTHER|Pharmacogenomic (PGx) results.|These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
219205530|NCT04430309|BEHAVIORAL|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
218933399|NCT04796090|OTHER|Clinical assessment|FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
218933400|NCT04676399|DRUG|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
218933401|NCT04676399|DRUG|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
219542878|NCT06788431|DRUG|IMC-001 placebo and optimal medical treatment|Subjects receive IMC-001 placebo administered by injection once a week for 13 weeks and also receive optimal medical treatment.
219542879|NCT01958294|DEVICE|MICHI Neuroprotection System|
219542880|NCT05679115|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
219542881|NCT05605522|DRUG|[225]-FPI-2059|"\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation."
219542882|NCT05605522|DRUG|[111In]-FPI-2058|\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
219542883|NCT05747950|OTHER|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
219542884|NCT05747950|OTHER|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
219542885|NCT05747950|OTHER|Conventional Therapy|Conventional exercises
219542886|NCT02252250|PROCEDURE|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
218933402|NCT04593537|OTHER|No intervention|This is an observational study, no intervention is involved
218933403|NCT00721383|BEHAVIORAL|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
218933404|NCT00721383|BEHAVIORAL|CSBI|Caregiver skill-building
218933405|NCT00140608|DEVICE|Seprapack Sinus Dressing|
218933406|NCT02888600|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
219205531|NCT03740867|OTHER|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
219542887|NCT02252250|PROCEDURE|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
219542888|NCT04982614|BIOLOGICAL|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
219542889|NCT05546138|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
219542890|NCT05546138|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
219542891|NCT05546138|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
219542892|NCT05546138|DIAGNOSTIC_TEST|Corneal confocal Microscopy|Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
219542893|NCT05546138|DIAGNOSTIC_TEST|MRI|Functional and structural MRI pictures of peripheral nerves and CNS
219542894|NCT05546138|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of Sural nerve
219542895|NCT05546138|OTHER|Composite scores and questionnaires|Composite scores and questionnaires
218933407|NCT02888600|BEHAVIORAL|Health Education|Guided health education and stress management training
218933408|NCT04117516|PROCEDURE|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
218933409|NCT04117516|PROCEDURE|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
218933410|NCT04283227|GENETIC|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
218933411|NCT05623917|BEHAVIORAL|Tele-supervised diaphragmatic respiratory exercise|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
218933412|NCT02084407|OTHER|Clinical examination, skin biopsy, blood and urine sampling|
219542896|NCT03707171|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
218933413|NCT06411314|COMBINATION_PRODUCT|Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
218933414|NCT06411314|DRUG|Lactulose 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
218933415|NCT06411314|DRUG|Pimafucin® (natamycin) 100 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
218933416|NCT04040387|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
218933417|NCT04040387|DEVICE|Sham NightWare|NightWare device not providing interventions
218933418|NCT05824104|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
218933419|NCT03286517|BIOLOGICAL|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
218933420|NCT02188888|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
218933421|NCT05546632|DIAGNOSTIC_TEST|Blood sampling|Patients will have one blood sampling using one EDTA tube and one Cyto-Chex BCT tube, one after the other
218933422|NCT00611026|DRUG|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
218933423|NCT00611026|DRUG|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
218933424|NCT00611026|DRUG|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
218933425|NCT05019521|DRUG|Danicopan|Oral tablet.
218933426|NCT05019521|DRUG|Placebo|Oral tablet.
219045375|NCT06966063|PROCEDURE|4-7-8 breathing along with standard management.|"For 4-7-8 breathing, Patient is asked sit in comfortable position. Patient is asked place the tip of your tongue up against the back of your front teeth. Keep it there through the entire breathing process. Instruct the patient to breathe in silently through your nose to the count of four (4sec) and Hold your breath to the count of seven (7sec). Exhale through your mouth to the count of eight (8sec), making an audible whoosh sound. That completes one full breath. Repeat the cycle another three time, and gradually in increase the cycle four time.~Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. Week 01 and 02 Frequenc: 01 session/day Intensity: Start with comfortable duration. Time: 10 minutes Week 03 and 04 Frequecy: 02 sessions/day Intensity: 4 sec inhale, 7 sec hold and 8 sec exhale Time: 15 minutes"
219045376|NCT06966063|PROCEDURE|Control Group|"Patients will recieve medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity.~Total 4 weeks protocol. Before and after 4 weeks pre and post interventional values will be taken.~Week 01 and 02 Patients will receive medications prescribed by pulmonologist. Week 03 and 04 Patients will receive medications prescribed by pulmonologist."
219542897|NCT03707171|DRUG|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
219542898|NCT02324660|OTHER|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
219542899|NCT02508662|OTHER|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
219542900|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
219542901|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
219542902|NCT02286050|OTHER|CF Nursing Program|
219542903|NCT04205266|DRUG|Ferumoxytol|IV iron infusion
219542904|NCT04205266|DRUG|Ferrous Sulfate|oral iron therapy
219542905|NCT01093989|DIETARY_SUPPLEMENT|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
219542906|NCT02566850|DEVICE|Ekso|powered lower extremity exoskeleton
219542907|NCT02486081|DEVICE|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
219542908|NCT00465621|DRUG|Xalatan|
219542909|NCT00089011|DRUG|fludarabine phosphate|Given IV
218933427|NCT01481818|DRUG|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
218933428|NCT02881606|DEVICE|Naso-alveolar molding (NAM)|
218933429|NCT02881606|DEVICE|Computer aided design NAM (CAD/NAM)|
218933430|NCT05477667|DIAGNOSTIC_TEST|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
218933431|NCT01732289|GENETIC|genes|Draw blood for genetic screening
218933432|NCT01129596|DRUG|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
218933433|NCT05895812|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
218933434|NCT00575731|BEHAVIORAL|Weight management strategies|
218933435|NCT05577117|DRUG|Dexmedetomidine|drugs are injected with induction of general anesthesia
218933436|NCT05173753|OTHER|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
218933437|NCT02615899|OTHER|Matched: Targeted (specific) balance exercise interventions|
218933438|NCT02615899|OTHER|Mismatched: Untargeted (non-specific) balance exercise interventions|
219542910|NCT00089011|RADIATION|total-body irradiation|Undergo radiotherapy
219542911|NCT00089011|DRUG|mycophenolate mofetil|Given IV or PO
219542912|NCT00089011|DRUG|tacrolimus|Given IV or PO
219542913|NCT00089011|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
219542914|NCT00089011|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
219542915|NCT00089011|OTHER|laboratory biomarker analysis|Correlative studies
218933439|NCT03613519|BEHAVIORAL|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
218933440|NCT03613519|BEHAVIORAL|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
219045377|NCT05721274|BEHAVIORAL|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
219045378|NCT00001731|DRUG|Cyclosporin A|
219045379|NCT04581642|DEVICE|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
219542916|NCT06627062|PROCEDURE|moderate and severe subluxated lens extraction|A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
219542917|NCT03307577|DRUG|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
219542918|NCT03307577|OTHER|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
219542919|NCT03647254|BEHAVIORAL|Patient education group|Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
219542920|NCT00372983|DRUG|NOV-205|
219542921|NCT05305092|DEVICE|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
219542922|NCT00830258|DRUG|Pravastatin sodium 80 mg tablets|1 x 80 mg
219542923|NCT00830258|DRUG|Pravachol® 80 mg tablets|1 x 80 mg
219542924|NCT03909607|DRUG|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
219542925|NCT03909607|DRUG|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
219542926|NCT03909607|DRUG|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
219621629|NCT07005960|OTHER|Art Therapy for Anxiety in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, and the State-Trait Anxiety Inventory prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
219542927|NCT01497587|DRUG|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
219045380|NCT05164237|OTHER|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
219542928|NCT00682461|DRUG|Nicotine|Marketed nicotine replacement therapy formulation
219542929|NCT00682461|DRUG|Nicotine|Nicotine prototype
219542930|NCT00954460|DRUG|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
219542931|NCT02798458|DEVICE|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
219542932|NCT02798458|PROCEDURE|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
219542933|NCT04035187|DRUG|fast itraconazole tablet|100mg dose
219542934|NCT04035187|DRUG|medium itraconazole tablet|100mg dose
219542935|NCT04035187|DRUG|slow itraconazole tablet|100mg dose
219542936|NCT04035187|DRUG|oral itraconazole solution|100mg dose
219542937|NCT01429870|DRUG|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
218933441|NCT03613519|BEHAVIORAL|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
218933442|NCT05918913|DRUG|Revumenib|Revumenib administered orally every 12 hours.
218933443|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
219045381|NCT05164237|OTHER|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
219045382|NCT05164237|OTHER|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
219045383|NCT03794037|DRUG|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
219045384|NCT03794037|COMBINATION_PRODUCT|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
219045385|NCT04106310|DEVICE|High-flux dialyzer|a dialyzer meeting the definition of high-flux
219045386|NCT04106310|DEVICE|Theranova dialyzer|a middle cut-off dialyzer
219045387|NCT06017089|DEVICE|AI-based Advisor system|Tandem t:slim X2 with Control-IQ and t:connect mobile application and Dexcom G6 or G7 system, connected to UVA cloud-based Physician Dashboard with insulin pump parameters driven by an AI-based Advisor system.
219205532|NCT06099548|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
219205533|NCT05492201|DRUG|LY3873862|Administered orally.
219205534|NCT05492201|DRUG|Placebo|Administered orally.
219205535|NCT05133076|BIOLOGICAL|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
219045388|NCT06481202|BIOLOGICAL|Complarate®|The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
219045389|NCT06481202|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
219045390|NCT06477029|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
219045391|NCT06477029|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
219205536|NCT05133076|BIOLOGICAL|Placebo|Placebo
219205537|NCT04315571|DEVICE|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
218933444|NCT03131609|OTHER|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
218933445|NCT03131609|OTHER|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
218933446|NCT03131609|OTHER|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
219045392|NCT02776228|DRUG|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
219045393|NCT02776228|DRUG|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
219205538|NCT04315571|PROCEDURE|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
218933447|NCT03131609|OTHER|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
219205539|NCT05641207|DEVICE|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung"
219542938|NCT06402799|BEHAVIORAL|Home-based E-biking|The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised. Heart rate will be monitored as well as power in Watt at each session.
219542939|NCT05638490|OTHER||no intervention
219542940|NCT01116739|DEVICE|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
219542941|NCT01116739|BEHAVIORAL|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
219542942|NCT01116739|OTHER|Dental services delivered by the Indian Health Service.|
219542943|NCT00973219|DRUG|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
219542944|NCT04917991|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
218933448|NCT02394587|BEHAVIORAL|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
218933449|NCT04434456|DEVICE|CGuard stent implantation|CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
218933450|NCT01543048|OTHER|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
218933451|NCT02533453|BIOLOGICAL|Bydureon|exenatide once weekly
218933452|NCT01732237|DRUG|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
219045394|NCT05994716|OTHER|Telemonitoring|"A) Monthly completion data on the web platform: 1) SCCAI for Ulcerative colitis and Harvey-Bradshaw index for Crohn disease. 2) IBD disk questionnaire to evaluate disease dynamics. 3) General blood test.~B) Possibility of online consultation with a gastroenterologist upon request via chat or phone call.~C) Access to educational information about IBD, necessary lifestyle changes, dietary recommendations;~D) monthly phone call will be made to each patient from the intervention group to answer any questions or concerns they may have and to interview them according to the checklist."
219045395|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
219045396|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
219045397|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
219045398|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
219205540|NCT06265506|BEHAVIORAL|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
219542945|NCT04917991|DIETARY_SUPPLEMENT|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
218933453|NCT01732237|DRUG|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
218933454|NCT01732237|DRUG|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
218933455|NCT01579929|DRUG|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
218933456|NCT05866523|BEHAVIORAL|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
219542946|NCT04935580|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
219542947|NCT05511935|OTHER|professional development training for CHWs on dental health (GRIN)|multi module online training
218933457|NCT05866523|BEHAVIORAL|Standard of Care|Subject admitted and seen by routine inpatient medical service.
219542948|NCT06405243|DRUG|Myoinositol|Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
219542949|NCT06405243|DRUG|Chromium|chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
219542950|NCT06405243|DRUG|l-arginine|new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
219542951|NCT06405243|DRUG|Letrozole 2.5mg|selective aromatase inhibitor
219542952|NCT03966027|OTHER|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
219542953|NCT03966027|OTHER|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
219542954|NCT01361633|DRUG|d-cycloserine|single oral administration of 250 mg d-cycloserine
218933458|NCT05438212|PROCEDURE|Brain Surgery|Undergo surgery per standard of care
219045399|NCT02635191|DRUG|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
219542955|NCT01361633|DRUG|Sugar Pill|Single oral administration 250 mg Sugar Pill
219542956|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED)|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
219542957|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED) Spanish|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day in Spanish.
219542958|NCT02677558|OTHER|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
219542959|NCT02108639|DRUG|DCV 3DAA FDC|
219542960|NCT02108639|DRUG|BMS-791325|
219542961|NCT06006754|OTHER|Observational study|No intervention: observational study
219542962|NCT05874596|BEHAVIORAL|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
218933459|NCT05438212|OTHER|Quality-of-Life Assessment|Ancillary studies
218933460|NCT05438212|OTHER|Questionnaire Administration|Ancillary studies
218933461|NCT05438212|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
218933462|NCT05773001|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
219045400|NCT02635191|DRUG|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
219045401|NCT03367377|DRUG|LY3209590|Administered SC
219045402|NCT03367377|DRUG|Insulin Glargine|Administered SC
219045403|NCT00368589|DRUG|atorvastatin|
219045404|NCT02340533|PROCEDURE|hysteroscopic endo-myometrial biopsy|
219045405|NCT02340533|DEVICE|ultrasound|two dimensional trans-vaginal ultrasonography
219045406|NCT00755066|DRUG|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
219045407|NCT00755066|DRUG|Placebo|Placebo intranasal spray
219542963|NCT06468514|OTHER|neural tensioning technique on radial nerve|the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
219542964|NCT06468514|OTHER|Sliding technique on radial nerve|The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
219542965|NCT04505826|DRUG|OP-1250|Complete Estrogen Receptor ANtagonist (CERAN)
219542966|NCT06127238|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
218933463|NCT00602017|DRUG|Amlodipine|
218933464|NCT03635073|DRUG|Soticlestat|Soticlestat tablets or mini-tablets.
218933465|NCT03404180|PROCEDURE|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
218933466|NCT03404180|DRUG|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
218933467|NCT03404180|PROCEDURE|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
219045408|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
219045409|NCT02112825|BEHAVIORAL|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
219045410|NCT03320681|DEVICE|Electrical Stimulation|Percutaneous electrical nerve stimulation
219045411|NCT03320681|OTHER|Dry Needling Stimulation|Percutaneous nerve stimulation
219542967|NCT06383988|OTHER|Support for Caregiver - Generic List|Receive a generic resource list
219542968|NCT06383988|OTHER|Support for Caregiver - Personalized List|Receive personalized resource list
219542969|NCT06383988|OTHER|Internet-Based Intervention - CONNECT|Receive access to CONNECT tool
219542970|NCT06383988|BEHAVIORAL|Patient Navigation|Complete calls with caregiver navigator
219542971|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|"Participants randomized to the MTT/antibiotic arm of PART A will be administered oral MTT capsules over the course of 28 days.~Participant enrolled on PART B will be administered oral MTT capsules over the course of 28 days."
219205541|NCT06265506|BEHAVIORAL|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
219542972|NCT05695261|DRUG|Antibiotic|"Participants randomized to the MTT/antibiotic arm of PART A will receive oral antibiotics for 7 days prior to the MTT administration visit.~Participant enrolled on PART B will receive oral antibiotics for 7 days prior to the MTT administration visit."
219542973|NCT05695261|OTHER|Placebo (in place of MTT)|Participants randomized to the placebo arm of PART A will be administered oral placebo capsules in place of MTT over the course of 28 days.
218933468|NCT03404180|PROCEDURE|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
219045412|NCT04130295|OTHER|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
219045413|NCT06267612|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
219045414|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
219045415|NCT01437228|DRUG|placebo|NO İNTERVENTİON
219045416|NCT04165668|OTHER|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
219045417|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
219205542|NCT05763251|OTHER|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
219205543|NCT04696523|DRUG|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
219045418|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
219045419|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
219045420|NCT02153866|BIOLOGICAL|rotavirus vaccine|3ml/dose, oral
219205544|NCT04696523|DRUG|air/oxygen|Control group will be treated with air/oxygen
219542974|NCT05695261|OTHER|Placebo (in place of antibiotics)|Participants randomized to the placebo arm of PART A will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
219045421|NCT02153866|BIOLOGICAL|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
219542975|NCT05695261|OTHER|Oral Immunotherapy (OIT)|Participant enrolled on PART B will be on maintenance peanut oral immunotherapy (OIT) for their clinical care.
219542976|NCT04966169|DEVICE|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
219542977|NCT05665361|DRUG|Sasanlimab|Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
219542978|NCT05665361|DRUG|Palbocicilib|Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
219542979|NCT06073691|BEHAVIORAL|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
219542980|NCT06073691|OTHER|Placebo|Placebo
219542981|NCT02138539|OTHER|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
219542982|NCT02138539|DRUG|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
219045422|NCT02153866|BIOLOGICAL|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
219045423|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
219045424|NCT04623333|DRUG|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
219205545|NCT06853275|BEHAVIORAL|Experimental: External Focus|Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1-repetition maximum). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will receive visual feedback from a linear position transducer for each repetition, indicating the speed of the last repetition/movement.
219205546|NCT06853275|BEHAVIORAL|Other: Internal Focus|Arm Description: Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1RM). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will NOT receive visual feedback for each repetition. This is the control condition.
219542983|NCT01818024|DRUG|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
219542984|NCT01818024|DRUG|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
219542985|NCT01818024|DRUG|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
218933469|NCT00732537|DRUG|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
218933470|NCT00732537|DRUG|Oxygen (>90% by hood) - standard therapy|"Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
218933471|NCT04752904|DEVICE|ClearSight System|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem
218933472|NCT00068419|DRUG|tamoxifen citrate|Given orally
218933473|NCT00068419|DRUG|sulindac|Given orally
218933474|NCT00068419|OTHER|laboratory biomarker analysis|Correlative studies
218933475|NCT03519711|DRUG|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
218933476|NCT01475617|DIETARY_SUPPLEMENT|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
218933477|NCT01475617|DIETARY_SUPPLEMENT|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
218933478|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
219045425|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
219542986|NCT01818024|DRUG|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
219542987|NCT01818024|DRUG|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
219542988|NCT01818024|DRUG|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
219542989|NCT01818024|DRUG|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
219542990|NCT01818024|DRUG|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
219542991|NCT03756441|BEHAVIORAL|Mindfulness meditation|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
219045426|NCT01941446|DRUG|Eravacyline, Moxifloxacin, and placebo|
219045427|NCT00712296|DRUG|ASHMI 4|4 capsules orally twice a day
219045428|NCT00712296|DRUG|ASHMI 12|12 capsules orally twice a day
219045429|NCT00712296|DRUG|Placebo|Placebo 6 capsules twice a day
219045430|NCT05605665|DRUG|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
219045431|NCT05605665|DRUG|rapamycin|Rapamycin 0.5ml was taken orally once per day
219045432|NCT03904706|OTHER|Audits only|Formalized audit teams with monthly meetings at each facility.
219045433|NCT03904706|OTHER|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
219045434|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
219542992|NCT03756441|BEHAVIORAL|Psychotherapy group|Caregivers will learn the technique of group problem solving
219542993|NCT00023881|DRUG|bortezomib|
219542994|NCT03723044|OTHER|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
218933479|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
219542995|NCT03243786|BEHAVIORAL|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
219045435|NCT05411796|DEVICE|Tampax menstrual cup|regular flow size
219045436|NCT05411796|DEVICE|Other menstrual cup|size 1
219045437|NCT04212468|OTHER|no intervention|no intervention
218933480|NCT01475617|DIETARY_SUPPLEMENT|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
219542996|NCT01510938|DIETARY_SUPPLEMENT|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
218933481|NCT01475617|DIETARY_SUPPLEMENT|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
219621630|NCT07005960|OTHER|Art Therapy for Resilience in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, the Brief Resilience Scale, prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
219621631|NCT03446430|DEVICE|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
219045438|NCT05687019|COMBINATION_PRODUCT|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
219542997|NCT01510938|DIETARY_SUPPLEMENT|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
218933482|NCT03951662|OTHER|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level \>3mg/dL and AST level\>50U/L
218933483|NCT03951662|OTHER|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
218933484|NCT01366157|GENETIC|microarray analysis|
218933485|NCT01366157|GENETIC|protein expression analysis|
218933486|NCT01366157|OTHER|immunohistochemistry staining method|
219621632|NCT06550947|GENETIC|Immunohistochemistry|Immunohistochemical expression of ALDOA in bladder urothelial carcinoma
219621633|NCT07011420|DEVICE|Experimental socket with 4 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 4 channels will be active during this condition.
219621634|NCT07011420|DEVICE|Experimental socket with 8 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 8 channels will be active during this condition.
219045439|NCT05958212|BEHAVIORAL|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
219045440|NCT05958212|BEHAVIORAL|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
219045441|NCT02741115|DRUG|Udenafil|Active drug
219045442|NCT02741115|DRUG|Placebo|Matching Placebo
219045443|NCT04912921|DIETARY_SUPPLEMENT|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
219621635|NCT07011420|DEVICE|Experimental socket with up to 16 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. All16 channels (or the maximum number of channels based on limb size) will be active during this condition.
218933487|NCT01366157|OTHER|laboratory biomarker analysis|
218933488|NCT04788706|OTHER|Low level Laser Therapy and Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
218933489|NCT04788706|OTHER|Placebo Laser and Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
218933490|NCT04788706|OTHER|Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
218933491|NCT04788706|OTHER|Placebo Laser and Placebo Laser plus Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
218933492|NCT03135496|OTHER|Study of endothelial function biological markers|Study of endothelial function biological markers
218933493|NCT04674761|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
218933494|NCT04674761|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
218933495|NCT05490888|DRUG|PHIN-214 Subcutaneous injection|subcutaneous injection(s) with PHIN-214 terlipressin derivative
218933496|NCT01567267|BEHAVIORAL|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
218933497|NCT01567267|BEHAVIORAL|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
219542998|NCT02921958|BEHAVIORAL|occupational therapy|Family-centered occupational therapy services
219542999|NCT04084639|DIETARY_SUPPLEMENT|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
219543000|NCT03913377|DEVICE|Spectacles|Subjects' own habitual spectacles
219543001|NCT03913377|DEVICE|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
219543002|NCT02730533|DRUG|Esomeprazole|Proton pump inhibitor
218933498|NCT05289895|OTHER|No intervention|This study was an observational trial without any intervention
218933499|NCT01808105|OTHER|Control Formula|Feeding ad libitum
218933500|NCT01808105|OTHER|Experimental Formula 1|Feeding ad libitum
219045444|NCT04912921|DIETARY_SUPPLEMENT|Placebo|4 tablets taken daily (2 in am and 2 in pm)
219045445|NCT04912921|DIETARY_SUPPLEMENT|Curcumin|500 mg HydroCurc® twice a day
219045446|NCT04912921|DIETARY_SUPPLEMENT|Control (microcrystalline cellulose)|2 tablets taken daily
219045447|NCT04106479|DEVICE|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
219045448|NCT06476587|OTHER|Assessment of postural stability and active motion perception|"This assessment, designed to evaluate the impact of the vestibular deficit on everyday tasks, will include questionnaires and standardised clinical tests.~The questionnaires are the Fall Efficacy Scale; the Dizziness Handicap Inventory; the Oscillopsia Severity Questionnaire; the Hospital Anxiety and Depression Scale; the Hamilton Anxiety Scale; the Global Physical Activity Questionnaire; the Motion Sickness Susceptibility Questionnaire part B; and the Cambridge Depersonalization Scale.~In addition, three standardised clinical tests will be carried out: Five Times Sit to Stand Test; Tandem walking test; and Fukuda step test (50 steps).~Five specific clinical tests will also be carried out: Sit-to-stand-with-walk-and-turn; Perception of active body rotation; Perception of walking distance; Triangle Completion Task; and Gait assessment."
219045449|NCT06476587|OTHER|Cognitive tests|Four cognitive tests from the French Focus Group on Executive Functions Assessment (GREFEX) battery will be carried out: the Stroop test; the Trail Making Test; the Baddeley's dual task; and a test of Corsi's Blocks.
219045450|NCT06476587|OTHER|Eccentric axis rotation|This test, also known as the unilateral centrifugation test, provides a quantitative assessment of unilateral utricular otolith function, whereas the tests currently used (vestibular evoked myogenic potential, VEMP) only provide a qualitative assessment.
219045451|NCT06476587|OTHER|Osteodensitometry|To assess the participants' bone mineral density, the reference technique of densitometry using two-photon absorptiometry will be used.
219045452|NCT06476587|OTHER|Posturography|Participants' ability to maintain their balance will be assessed using measurements taken on the Synapsys platform. To standardise their position, they will have to stand on the platform with their feet apart, arms at their sides and look straight ahead. Volunteers will be asked to sit down between each trial. The surface area and length of the centre of pressure will be measured under open-eye balance conditions with and without image reading/exploration and dynamics. During this test, 9 balance assessment situations lasting approximately 1 minute each will be performed.
219045453|NCT06476587|OTHER|Vestibulo-sympathetic regulation test|"Participants will be seated on a rotating chair in the dark. Using a virtual reality headset, three visual stimuli will be presented: (A) no visual stimulus (darkness), (B) visual stimulus corresponding to a displacement of the participant along a cylindrical trajectory, (C) visual stimulus corresponding to a displacement of the participant along a conical trajectory. These 3 types of visual stimuli will be presented alone or during an Off-Vertical Axis Rotation (OVAR) with the chair axis inclined at an angle of 10° to the vertical and a rotation speed of 60°/s.~During each sequence, blood pressure, heart rate and end-tidal carbon dioxide (CO2) will be continuously recorded using standard medical equipment."
219205547|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
219621636|NCT07011420|DEVICE|Experimental socket with 8 targeted channels active|Participants will utilize the experimental socket made with targeted EMG channels. This socket will follow Coapt's clinical instructions for targeted site location to identify and mark locations for 8 targeted EMG channels.
218933501|NCT01808105|OTHER|Experimental Formula 2|Feeding ad libitum
218933502|NCT01808105|OTHER|Human Milk|Feeding ad libitum
218933503|NCT04466670|DRUG|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
218933504|NCT04466670|DRUG|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
219205548|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
219205549|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
219205550|NCT05875701|BIOLOGICAL|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
219543003|NCT02730533|DRUG|No PPI treatment|No PPI treatment before ESD procedure
219543004|NCT01260805|DRUG|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
219543005|NCT01260805|DRUG|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
219543006|NCT03499353|DRUG|TALAZOPARIB|Talazoparib 1mg/day
219543007|NCT00868660|DRUG|ZP1848|sc. bolus
219543008|NCT02179294|DRUG|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
219543009|NCT02179294|DRUG|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
219543010|NCT03448094|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
219543011|NCT03448094|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of three months.
219543012|NCT05701384|DRUG|Lazertinib|160mg po qd
219543013|NCT01675115|DRUG|BNG-1|BNG-1 3 grams TID for 4 weeks
219543014|NCT01675115|DRUG|Aspirin|Aspirin 100 mg QD for 4 weeks
219543015|NCT03956420|BEHAVIORAL|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
219543016|NCT03956420|DIETARY_SUPPLEMENT|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
219543017|NCT03956420|DRUG|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
218933505|NCT02354430|BEHAVIORAL|Water-exercise|"1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises."
218933506|NCT06327880|DRUG|PF-07054894 or placebo|multiple oral doses of PF-07054894 for 14 days
218933507|NCT06406179|BIOLOGICAL|dd-cfDNA-guided|"In groups I and II, the blood sample for dd-cfDNA assay will be taken on D0, just prior to transplantation, for all patients.~in addition, for patients following a dd-cf DNA-guided strategy based on dd-cf DNA ; samples for dd-cf DNA assay will be taken at M3 and M12 visits and at visits for clinical indication (5 maximum) and the blood will be sent to the PARCC technical platform of INSERM UMR 970. By combining the dd-cfDNA level and relevant medical data, an integration report will be sent to the centers to stratify patients into high-risk or low-risk rejection profiles.~If the patient is classified in the low risk of rejection subgroup, he may decide not to perform the biopsy. If the patient is classified in the high risk of rejection subgroup, he may decide to perform the biopsy within 15 days of the sample being taken. the decision to perform the biopsy is left to the discretion of the physician."
218933508|NCT03692104|DIAGNOSTIC_TEST|transrectal ultrasound|Use of US for post implant quality assessment
218933509|NCT00707941|DRUG|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
218933510|NCT00707941|DRUG|Placebo|"Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
218933511|NCT00314795|DRUG|Peginesatide|Peginesatide injection
218933512|NCT03871218|BIOLOGICAL|Hyaluronic acid group|Applicaton of topical Hyaluronic acid
218933513|NCT03200080|DRUG|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
218933514|NCT03200080|DRUG|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
218933515|NCT03200080|DRUG|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
218933516|NCT03200080|DRUG|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
218933517|NCT04053803|DRUG|IMR-687|Oral administration of once daily IMR-687
218933518|NCT04497623|DEVICE|Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours|Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
218933519|NCT00209612|DRUG|Taxol|Day1,15 X mg/m2, IV (in the vein)
219045454|NCT06476587|OTHER|Sleep quality assessment|"Participants will have to complete five standardised clinical questionnaires: Pittsburgh Sleep Quality Index; Spiegel questionnaire assessing sleep quality; Morningness-Eveningness questionnaire; Insomnia Severity Scale; and Epworth Sleepiness Scale.~Moreover, the activity/rest rhythm will be measured continuously by actimetry over a period of 11 days.~The volunteer will also have to wear a Somno-Art® bracelet all night long during the eleven days of monitoring to collect the volunteer's actimetry and heart rate in order to specify which sleep stage the volunteer is in and thus monitor changes in sleep stages over the course of the night.~Finally, participants will have to complete a sleep diary."
219543018|NCT03956420|OTHER|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
219543019|NCT03956420|OTHER|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
219543020|NCT03956420|DRUG|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
219543021|NCT03956420|DRUG|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
219543022|NCT03956420|DRUG|Intraoperative period|Sevoflurane 1.5 MAC higher in patients \< 60 years old
219543023|NCT03956420|DRUG|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
219543024|NCT03956420|DRUG|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
218933520|NCT00209612|DRUG|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
218933521|NCT06804005|BEHAVIORAL|Music group|Music will be sung continuously in an area equipped with a sound system so that subjects can listen comfortably without headphones, and will be performed with the participation of students and peer support. Each intervention activity will last approximately 60 minutes.
219543025|NCT00002890|BIOLOGICAL|lintuzumab|
219543026|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543027|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
218933522|NCT06804005|BEHAVIORAL|mandala group|In the mandala coloring activity, they will be asked to choose the picture they want from the mandala coloring booklets and color it however they want. This activity will take approximately 60 minutes.
219543028|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219621637|NCT07011420|DEVICE|Coapt EMG Cuff|This device is the commercially available Coapt EMG Cuff. This armband cuff with electrodes can be strapped onto the user's arm to connect with the Coapt app and play virtual games with their EMG signals.
218933523|NCT01500720|DRUG|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
218933524|NCT01500720|DRUG|Topotecan|Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
218933525|NCT06044077|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
218933526|NCT06044077|BIOLOGICAL|control pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp
218933527|NCT02439437|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
218933528|NCT02527421|DRUG|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
218933529|NCT05624970|BEHAVIORAL|aerobic training , tobacco cessation and nutritional advices|"1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months"
218933530|NCT05624970|BEHAVIORAL|tobacco cessation and nutritional advices|Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
218933531|NCT02281513|OTHER|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
218933532|NCT02281513|OTHER|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
218933533|NCT02281513|OTHER|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
218933534|NCT02447523|PROCEDURE|Elective abdominal surgery|
218933535|NCT05557188|OTHER|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
218933536|NCT05557188|OTHER|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
218933537|NCT05700019|BEHAVIORAL|Pinkwashed Advertisements|Real advertisements from alcoholic beverage companies' social media accounts that contain messaging or other features that associate the alcohol company with breast cancer awareness or research.
218933538|NCT05700019|BEHAVIORAL|Control - Standard Advertisements|Real advertisements from the same alcoholic beverage companies' social media accounts that do not contain messaging or other features associated with breast cancer awareness or research.
218933539|NCT04927169|DRUG|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
218933540|NCT04927169|DRUG|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
218933541|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
219045455|NCT06476587|OTHER|Representation of space and time assessment|"* Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity."
219543029|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543030|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543031|NCT01117623|DRUG|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543032|NCT01117623|DRUG|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543033|NCT01117623|DRUG|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
219543034|NCT05947409|DRUG|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
219621638|NCT06870344|DRUG|Dihydroartemisinin piperaquine|Taken orally. 11 kg to less than 17 kg 1 tablet per day for 3 days 40 mg 320 mg 17 kg to less than 25 kg 1½ tablets per day for 3 days 60 mg 480 mg 25 kg to less than 36 kg 2 tablets per day for 3 days 80 mg 640 mg 36 kg to less than 60 kg 3 tablets per day for 3 days 120 mg 960 mg 60 kg to less than 80 kg 4 tablets per day for 3 days 160 mg 1280 mg 80 kg or more 5 tablets per day for 3 days 200 mg 1600 mg For patients weighing less than 11 kg, alternative formulations supplying lower amounts of active substance should be preferred
218933542|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
218933543|NCT00806819|DRUG|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
218933544|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
218933545|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
218933546|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
218933547|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
218933548|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
218933549|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
218933550|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
218933551|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
218933552|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
218933553|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
218933554|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
218933555|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
218933556|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
218933557|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
218933558|NCT03564678|DRUG|Vitamin B Complex|Given PO
218933559|NCT03028337|RADIATION|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
218933560|NCT03028337|BEHAVIORAL|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
218933561|NCT03367702|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218933562|NCT03367702|OTHER|Quality-of-Life Assessment|Ancillary studies
218933563|NCT03367702|OTHER|Questionnaire Administration|Ancillary studies
219543035|NCT05915858|OTHER|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~* The angle of hip flexion should not exceed 60 degree.~* The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
219543036|NCT05915858|OTHER|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~* The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~* The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~* The process is repeated 3-5 times with a 30"
219543037|NCT02395809|PROCEDURE|lateral internal sphincterotomy|
219543038|NCT02395809|PROCEDURE|TENS|
219543039|NCT00862563|DRUG|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
218933564|NCT03367702|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219543040|NCT00862563|DRUG|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
219543041|NCT00862563|DRUG|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
219543042|NCT00862563|DRUG|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
219543043|NCT03822754|BIOLOGICAL|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
219543044|NCT03822754|BIOLOGICAL|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
219621639|NCT06870344|COMBINATION_PRODUCT|Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis|Study staff will provide adult participant with LLIN(s), DP and with an 8-oz packet of Bti, a pair of latex gloves, a teaspoon, and a tracking form. A staff member will then survey an area (50 m radius) around the house and demonstrate appropriate application in up to 5 potential breeding sites.
219621640|NCT06870344|OTHER|Long-lasting Insecticidal Net|Distribution of Long-lasting Insecticidal Net to all households on the study.
219621641|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally once daily
219621642|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
218933565|NCT06487533|DEVICE|EmbracePlus Smartwatch|"The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
219045456|NCT06476587|OTHER|Influence of vestibular information on the bodily self-consciousness|"Participants will wear a virtual reality headset which allows them to be immersed in a virtual room similar in appearance to the one they are in. They will sit on a stool and hold a joystick in their hand. An avatar seen from behind, also sitting on a stool, will be presented in the centre of the virtual room approximately 2 m from them. The experimenter will touch several areas of the participant's back, over his clothes, with the end of the joystick. This movement will be reproduced by the virtual joystick in contact with the avatar's back, in two conditions: the synchronous condition, and the asynchronous condition.~After 2 min of stimulation, participants will perform a mental imagery task: a ball in the background of the virtual scene will roll towards them. After 3'', a black screen will appear and participants will have to imagine that the ball keeps moving towards them at the same speed. They will have to press the trigger when they think the ball has reached their level."
219205551|NCT05875701|BIOLOGICAL|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
219543045|NCT00685464|DRUG|Abciximab|Intravenous.
219543046|NCT00685464|DRUG|Abciximab|Intracoronary
219543047|NCT04633863|DEVICE|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
219621643|NCT06625775|DRUG|Fulvestrant|Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
219621644|NCT06625775|DRUG|Ribociclib|Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
219621645|NCT06625775|DRUG|FOLFOX|Patients will receive FOLFOX as infusion every 14 days
219621646|NCT06625775|DRUG|Bevacizumab|Patients will receive bevacizumab as infusion every 28 days
219621647|NCT07013539|DIETARY_SUPPLEMENT|plant extract|hard shell capsule containing plant extract
218933566|NCT06487533|DEVICE|Corti Sensor|"The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
218933567|NCT05449548|DRUG|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
218933568|NCT05988632|DRUG|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
218933569|NCT05988632|DRUG|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
219543048|NCT03584308|DIETARY_SUPPLEMENT|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
219543049|NCT03584308|DIETARY_SUPPLEMENT|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
219543050|NCT03584308|DIETARY_SUPPLEMENT|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
219543051|NCT03584308|DIETARY_SUPPLEMENT|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
219543052|NCT01187823|DEVICE|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
219543053|NCT01187823|DEVICE|Nocturnal oxygen|Nocturnal use of oxygen
219543054|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
219543055|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
219543056|NCT01139216|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
219543057|NCT05330533|RADIATION|scrotal duplex|Scrotal colour doppler ultrasonography
218933570|NCT04067830|OTHER|Best Practice|Receive usual care
218933571|NCT04067830|PROCEDURE|Laparoscopic Surgery|Undergo laparoscopic surgery
219205552|NCT04548830|PROCEDURE|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
219543058|NCT02285491|DRUG|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
218933572|NCT04067830|OTHER|Quality-of-Life Assessment|Ancillary studies
218933573|NCT04067830|OTHER|Questionnaire Administration|Ancillary studies
218933574|NCT04067830|DEVICE|Respiratory Muscle Training Device|Use power lung device to complete RMT
218933575|NCT04067830|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo video-assisted thoracic surgery
219543059|NCT02285491|DRUG|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
219543060|NCT00190541|PROCEDURE|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
219543061|NCT00190541|PROCEDURE|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
219543062|NCT04337658|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219543063|NCT04337658|DRUG|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219543064|NCT04337658|DRUG|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
219543065|NCT04337658|DRUG|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219543066|NCT00736190|DRUG|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
219543067|NCT03246503|DEVICE|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
219543068|NCT04121507|DRUG|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
219543069|NCT04121507|PROCEDURE|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
219543070|NCT04121507|DIAGNOSTIC_TEST|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
219543071|NCT04121507|DIAGNOSTIC_TEST|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
219543072|NCT01556906|DRUG|Lomitapide|Oral administration with escalating doses administered once daily
219543073|NCT00004162|BIOLOGICAL|sargramostim|
219543074|NCT00004162|DRUG|methotrexate|
219543075|NCT00004162|DRUG|pegylated liposomal doxorubicin hydrochloride|
218933576|NCT06374602|DRUG|Pembrolizumab + Lenvatinib|Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
218933577|NCT05055050|DRUG|UGN-201|Intravesical 200 mg /50 ml x 1 dose
218933578|NCT05869708|DEVICE|Active RS-EFP|A minimum of 10 and up to 15 active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
218933579|NCT05869708|DEVICE|Sham RS-EFP|a minimum of 10 and up to 15 sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
218933580|NCT02987712|OTHER|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
218933581|NCT04016623|DEVICE|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
218933582|NCT04016623|DEVICE|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
218933583|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
218933584|NCT05555069|OTHER|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
218933585|NCT05555069|OTHER|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
218933586|NCT00823693|DRUG|Bimosiamose Cream|
219543076|NCT00004162|DRUG|vincristine sulfate|
219543077|NCT03005834|OTHER|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
219543078|NCT01896934|DRUG|Sertraline|50-200mg daily
219543079|NCT05521919|BEHAVIORAL|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
219543080|NCT05521919|BEHAVIORAL|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
219543081|NCT03920449|DRUG|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
219543082|NCT03920449|PROCEDURE|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
219543083|NCT02095522|DRUG|Colchicine|Colchicine 1mg per day for one month
219543084|NCT02095522|DRUG|Placebo|Placebo
219543085|NCT05991362|DRUG|GFH312 100 mg|Participants receive single dose of GFH312 100 mg orally
219543086|NCT05991362|DRUG|GFH312 200 mg|Participants receive single dose of GFH312 200 mg orally
218933587|NCT00823693|DRUG|Placebo Cream|
218933588|NCT02285946|PROCEDURE|major spine surgery|
219205553|NCT04799119|BEHAVIORAL|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
219205554|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
219205555|NCT05667610|OTHER|Standard care|Standard care: Peanut or nut free diet
219205556|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
219205557|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
219205558|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
219205559|NCT06449482|DRUG|Selinexor|three dosage groups were set up, selinexor 60mg QW, 40mg BIW, or 60mg BIW
219543087|NCT05991362|DRUG|GFH312 120mg|Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
219543088|NCT05991362|OTHER|Placebo|Participants receive placebo matching with GFH312
219543089|NCT01492439|BEHAVIORAL|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
219621648|NCT07013539|DIETARY_SUPPLEMENT|Placebo|hard shell capsule containing maltodextrine
219621649|NCT06689852|DEVICE|Enriched|To be used twice a day
219621650|NCT06689852|DRUG|Loceryl 5%|To be used once a week
219621651|NCT01904695|DRUG|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
219621652|NCT01904695|DRUG|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
218933589|NCT05231122|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
218933590|NCT05231122|BIOLOGICAL|Bevacizumab|Given IV
218933591|NCT05231122|BIOLOGICAL|Pembrolizumab|Given IV
218933592|NCT05231122|OTHER|Quality-of-Life Assessment|Ancillary studies
219045457|NCT06476587|OTHER|3 Tesla MRI|"The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal."
219045458|NCT03723655|DRUG|mavacamten|mavacamten capsules
219045459|NCT06642818|OTHER|protocolized interview and prevention messages|This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
219045460|NCT06855160|BIOLOGICAL|Candidate varicella vaccine|Investigational varicella vaccine administered intramuscularly.
219045461|NCT06855160|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
218933593|NCT05231122|OTHER|Questionnaire Administration|Ancillary studies
218933594|NCT00148083|DRUG|Risperdal Consta (drug)|
218933595|NCT00148083|BEHAVIORAL|Social Skills Training|
218933596|NCT02464696|DRUG|Methylprednisolone|IPS cohort only
218933597|NCT02464696|PROCEDURE|Oxygen Therapy|Receive high flow oxygen therapy
219045462|NCT06855160|BIOLOGICAL|MMR vaccine|MMR vaccine administered subcutaneously or intramuscularly.
219045463|NCT06855160|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
219045464|NCT06855160|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219045465|NCT06855160|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219045466|NCT06855160|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
219543090|NCT01492439|BEHAVIORAL|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
218933598|NCT02464696|DEVICE|Positive Air Pressure Device|Undergo NIPPV
218933599|NCT05842044|DRUG|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
219045467|NCT04761185|DRUG|Raltitrexed|The RTX-HIPEC protocol used a modified Fibonacci dose escalation method with 7 dose levels (3, 4, 5, 6, 7, 8, 9 mg/m2)
219045468|NCT03553875|DRUG|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
219045469|NCT03553875|DRUG|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
219045470|NCT06981234|DRUG|Acetazolamide|Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
219045471|NCT06981234|DRUG|Placebo|Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.
219045472|NCT04961034|PROCEDURE|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
219543091|NCT00716625|DRUG|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
219543092|NCT03891095|DRUG|Oxytocin|intranasally administrated
219543093|NCT03891095|DRUG|L-DOPA|orally administered
218933600|NCT05842044|DRUG|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
218933601|NCT05842044|DRUG|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
218933602|NCT05842044|DRUG|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
218933603|NCT05842044|DRUG|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
218933604|NCT05776823|BEHAVIORAL|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
218933605|NCT05776823|BEHAVIORAL|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
218933606|NCT05776823|BEHAVIORAL|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
219543094|NCT03891095|DRUG|Placebos|intranasally administrated and orally administered
218933607|NCT05776823|BEHAVIORAL|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
218933608|NCT05268003|DRUG|Ponatinib|Given by PO
218933609|NCT05268003|DRUG|Venetoclax|Given by PO
218933610|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
218933611|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
218933612|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
218933613|NCT05834569|DRUG|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
218933614|NCT05834569|DRUG|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
219045473|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
219045474|NCT05972044|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
219045475|NCT05972044|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
219205560|NCT06449482|DRUG|Venetoclax|cycle 1 100mg d1 200mg d2 400mg d3-28 cycle 2-4 400mg d1-d28
219543095|NCT02349022|RADIATION|[89Zr]Df-IAB2M|
219543096|NCT01924286|DRUG|Prednisone|
218933615|NCT04671693|OTHER|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
218933616|NCT02971748|BIOLOGICAL|Pembrolizumab|Given IV
218933617|NCT06193616|DRUG|Octreotide|All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
219045476|NCT05972044|DRUG|Placebo|Placebo tablets, taken once daily
219205561|NCT06449482|DRUG|Azacitidine|75mg/m2 d1-d7 28d/cycle 4 cycles
219205562|NCT06965868|DRUG|Metformin|The Metformin intervention will be self-administred capsules, taken during a 12-week period: Four weeks of dose increase; first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks.
219543097|NCT01924286|DRUG|Placebo|
219543098|NCT00967148|DRUG|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
219543099|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
219543100|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
219543101|NCT04589546|DRUG|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
219543102|NCT04589546|DRUG|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
219543103|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
219543104|NCT01327781|DRUG|Endoxifen Hydrochloride|Given PO
218933618|NCT05819801|OTHER|Non-fasting|Instructing patients to eat before their local-only procedure
218933619|NCT05819801|OTHER|Fasting|Instructing patients to fast before their local-only procedure
218933620|NCT04755153|OTHER|Practice Facilitation|Tailored interventions provided by a trained Practice Facilitator
219045477|NCT05433389|BEHAVIORAL|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
219045478|NCT05433389|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
219045479|NCT05433389|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
219045480|NCT05433389|BEHAVIORAL|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
219045481|NCT05433389|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
219205563|NCT06965868|DRUG|Placebo|This intervention will be self-administered placebo capsules
219543105|NCT01327781|OTHER|Laboratory Biomarker Analysis|Correlative studies
219543106|NCT01327781|OTHER|Pharmacological Study|Correlative studies
219543107|NCT01327781|OTHER|Questionnaire Administration|Ancillary studies
219621653|NCT06874426|PROCEDURE|Endoscopic endonasal skull base surgery|This intervention will be performed as part of the standard-of-care for patients scheduled for endoscopic endonasal skull base surgery for lesions in the (para)sellar region
218933621|NCT04755153|OTHER|Non-Practice Facilitation|Implementation support without using Practice Facilitation
218933622|NCT05342883|DEVICE|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
218933623|NCT01189643|DRUG|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
218933624|NCT03137199|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
218933625|NCT02389309|DRUG|Cyclophosphamide|Given PO
218933626|NCT02389309|DRUG|Dasatinib|Given PO
218933627|NCT02389309|OTHER|Laboratory Biomarker Analysis|Correlative studies
218933628|NCT02389309|DRUG|Temsirolimus|Given IV
219543108|NCT05990504|DEVICE|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
219543109|NCT05990504|DEVICE|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
219543110|NCT02042560|OTHER|Blood samples|
219543111|NCT02042560|OTHER|Spleen samples|
219543112|NCT01165060|DRUG|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
219543113|NCT02786160|DIETARY_SUPPLEMENT|HMO|
219543114|NCT02786160|DIETARY_SUPPLEMENT|Dextropur|
219543115|NCT01251068|DEVICE|near infrared spectroscopy: invos 5100|duration:six hours
219543116|NCT01251068|DEVICE|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
218933629|NCT06265012|BIOLOGICAL|PHV01|Marburg virus vaccine
219543117|NCT01251068|DEVICE|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
219543118|NCT06024980|PROCEDURE|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
219621654|NCT04030338|DRUG|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
219621655|NCT04030338|DRUG|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
219621656|NCT04030338|DIAGNOSTIC_TEST|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
218933630|NCT06265012|BIOLOGICAL|Placebo|Lactated Ringer's Solution
218933631|NCT01746836|OTHER|Laboratory Biomarker Analysis|Blood draws.
218933632|NCT01746836|DRUG|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
218933633|NCT01746836|OTHER|Quality-of-Life Assessment|Surveys completed.
218933634|NCT05030883|BEHAVIORAL|Source of news|The main intervention was the source of the news that was shown to participants
218933635|NCT04901715|DRUG|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
218933636|NCT04901715|DIAGNOSTIC_TEST|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 microcurie (µCi) deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive three quarters of the adult dose to account for the smaller lung volume.
218933637|NCT04013542|BIOLOGICAL|Ipilimumab|Given IV
218933638|NCT04013542|BIOLOGICAL|Nivolumab|Given IV
218933639|NCT04013542|RADIATION|Radiation Therapy|Undergo radiation therapy
218933640|NCT04105166|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
218933641|NCT06567860|BIOLOGICAL|Influenza Fluzone vaccine|Fluzone vaccine administered in both May-June and in September-October for each participant.
218933642|NCT03404193|DRUG|Decitabine|Given IV
218933643|NCT03404193|OTHER|Laboratory Biomarker Analysis|Correlative studies
218933644|NCT03404193|DRUG|Venetoclax|Given PO
218933645|NCT06966804|DRUG|Terazosin|Subject will complete 14-day course of Terazosin
218933646|NCT06966804|DRUG|Tamsulosin|Subject will complete 14-day course of Tamsulosin
218933647|NCT06125028|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PTF i.v. injection
218933648|NCT06125028|DRUG|[18F]Fluorodeoxyglucose|\[18F\]FDG i.v. injection.
219045482|NCT06864013|DRUG|Experimental|The experimental group will receive neoadjuvant short-course radiotherapy (dose 25Gy/5f), followed by CAPEOX+Iparomlimab and Tuvonralimab (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w; Iparomlimab and Tuvonralimab 5mg/kg iv d1, q3w) for 4 cycles. Patients who undergo surgery will receive CAPEOX combined with Iparomlimab and Tuvonralimab for 4 cycles, followed by sequential treatment with Iparomlimab and Tuvonralimab for up to 1 year.
219205564|NCT06964919|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
219543119|NCT06024980|PROCEDURE|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd)."
219543120|NCT04374799|DRUG|Heparin|two doses of heparin
219543121|NCT04374799|DRUG|Placebos|placebo
219543122|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
219543123|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
219543124|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
219543125|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
219543126|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
219543127|NCT04065646|OTHER|Mobile|
219543128|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
218933649|NCT00580385|OTHER|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
219205565|NCT06964919|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
219205566|NCT06966414|BEHAVIORAL|Morning exercise|Participants performed bodyweight exercise in the morning between 08:00 to 11:00 AM.
219205567|NCT06966414|BEHAVIORAL|Evening exercise|Participants performed bodyweight exercise in the morning between 18:00 to 21:00 PM.
219205568|NCT06965543|PROCEDURE|Immediate G-POEM|Gastric POEM (G-POEM) performed under general anesthesia. A submucosal tunnel will be created along the greater curvature of the stomach to access the pyloric muscle under endoscopic vision. The pylorus will be incised at two locations with a dual myotomy between the 5 and 8 o'clock positions on the clock face
219543129|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
219543130|NCT02836574|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC).
219621657|NCT06694480|DRUG|FID-022|Advanced solid tumors
218933650|NCT05359926|OTHER|Experimental|Early urethral foley removal after the surgery
218933651|NCT05359926|OTHER|Active comparator|Delayed urethral foley removal after the surgery
218933652|NCT04022499|BEHAVIORAL|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
218933653|NCT04022499|BEHAVIORAL|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
218933654|NCT04988009|OTHER|Electronic Health Record Review|Review of medical chart
218933655|NCT04988009|OTHER|Survey Administration|Complete survey
219543131|NCT02836574|PROCEDURE|Renal Biopsy|a procedure in which a small sample of kidney tissue is removed
218933656|NCT06096467|BEHAVIORAL|Comprehension Exercise Training|Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
219045483|NCT06864013|DRUG|Control|The control group will receive neoadjuvant short-course radiotherapy,followed by CAPEOX (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w) for 4 cycles. Patients who undergo sugery will receive CAPEOX for 4 cycles.
219045484|NCT02863835|OTHER|EIT|All participants will have continuous monitoring of EIT whilst self venting
219543132|NCT04803162|DIAGNOSTIC_TEST|High-resolution manometry|The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
219543133|NCT04803162|DIAGNOSTIC_TEST|Serum biomarkers|The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
219543134|NCT04803162|DIAGNOSTIC_TEST|Gastrointestinal Quality of Life index|The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
219621658|NCT07022717|BEHAVIORAL|Brief youth overdose prevention education|Providers in the intervention group will inform youth participants about: the risk factors for overdose, how to stay safe and prevent overdose, how to recognize an overdose, and how to respond to an overdose.
218933657|NCT06096467|DIETARY_SUPPLEMENT|Placebo milk|Placebo milk: 8 g. protein for each serving and provided immediately after the CET session
218933658|NCT06096467|DIETARY_SUPPLEMENT|Protein Supplement|Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
219543135|NCT04803162|DRUG|Omeprazole 20 MG Oral Tablet|The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
219543136|NCT05231824|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
219543137|NCT05231824|BEHAVIORAL|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
219543138|NCT06244485|DRUG|Valemetostat tosylate|Administered orally once daily
219543139|NCT06244485|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
219543140|NCT06244485|DRUG|Dato-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle.
219543141|NCT00002601|BIOLOGICAL|filgrastim|5 ug/kg daily following stem cell reinfusion
218933659|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q14 day schedule
218933660|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q21 day schedule
218933661|NCT04593862|OTHER|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
218933662|NCT02844868|DEVICE|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
218933663|NCT02844868|DEVICE|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
219543142|NCT00002601|DRUG|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
219543143|NCT00002601|DRUG|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
219621659|NCT07022717|OTHER|Information about Naloxone|Providers in the intervention group will inform youth participants how to use naloxone and offered a kit to take home.
219621660|NCT07022717|OTHER|Usual standard of care|Participants will be provided usual care by providers in the control group.
218933664|NCT02324387|PROCEDURE|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
218933665|NCT02324387|DRUG|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
218933666|NCT05575401|PROCEDURE|Lateral pharyngoplasty|Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.
218933667|NCT05575401|PROCEDURE|Tonsillectomy|Extracapsular tonsillectomy
218933668|NCT04466007|DRUG|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
218933669|NCT04466007|DRUG|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
219045485|NCT02863835|OTHER|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
219045486|NCT05124782|OTHER|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
219543144|NCT00002601|DRUG|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
219543145|NCT00002601|DRUG|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
219543146|NCT00002601|PROCEDURE|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
219543147|NCT05451914|OTHER|My Diabetes Care|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
219543148|NCT04343001|DRUG|Aspirin|Aspirin 150mg
219543149|NCT04343001|DRUG|Losartan|Losartan 100mg
219543150|NCT04343001|DRUG|Simvastatin|Simvastatin 80mg
219543151|NCT05917925|DIETARY_SUPPLEMENT|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
219543152|NCT05917925|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
219543153|NCT05610033|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
219543154|NCT04852393|PROCEDURE|Block|cervical medial branch block
219543155|NCT04156230|DRUG|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
219543156|NCT02259244|BEHAVIORAL|Weight reduction program|
219621661|NCT00226499|BIOLOGICAL|Priorix-tetra™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
219621662|NCT00226499|BIOLOGICAL|Priorix™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
218933670|NCT04466007|DRUG|Placebos|0,9% physiological saline
218933671|NCT06127303|DRUG|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
219543157|NCT05836896|GENETIC|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
218933672|NCT06127303|OTHER|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
218933673|NCT05750732|BEHAVIORAL|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
218933674|NCT04637867|OTHER|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample"
218933675|NCT03164460|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
218933676|NCT03164460|RADIATION|Proton Radiation|Undergo IMRT/IMPT
218933677|NCT03164460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218933678|NCT05985655|DRUG|GTAEXS617|Administered as specified in the treatment arm.
218933679|NCT05985655|DRUG|SoC|Participants will receive either fulvestrant (breast cancers) or paclitaxel + bevacizumab (HGSOC) as specified in the treatment arm.
218933680|NCT00433043|DRUG|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
218933681|NCT00433043|PROCEDURE|CRT (cardiac resynchronization therapy)|Both arms
218933682|NCT06947018|BEHAVIORAL|Adolescent Girls' and Boys' Empowerment Program|"The program was developed based on a social behavioural change (SBC) approach in order to change attitudes and behaviours of the participants, consisting of the following main activities on a 6 - 8 week cycle.~* Girls' Empowerment Training: Workshops comprise six sessions of approximately 80 minutes each, held separately with girls aged 12-15 and 16-18 years in groups of approximately 12-20 adolescents on a range of life skill themes.~* Boys' Awareness Raising Training: Similar to the girls' training, four workshops are organized for boys aged 12-15 and 16-18 years, in separate sessions, with similar length and group size.~* Awareness Raising Seminars to Caregivers: Caregivers (e.g., mothers, fathers) are invited to a one-time seminar focused on the negative outcomes of child marriage and role of caregivers in preventing child marriage, lasting approximately one hour and conducted separately for fathers and mothers to eventually influence social norms in the family and communities."
218933683|NCT06946836|DRUG|AK104|Eligible patients will be randomly assigned in a 1:1 ratio to either the PD-1 combined with chemotherapy group or the AK104 monotherapy group. Treatment will be administered every 3 weeks, with patients undergoing three preoperative treatment cycles before surgery.
218933684|NCT04598074|OTHER|Opioid Package Prototype (OPP)|The Opioid Package Prototype (OPP) is a child-resistant/senior-friendly, calendar-blister packaging of limited pill counts with flat readable billboard space for medication labeling.
218933685|NCT04598074|OTHER|Usual Care (standard amber vial)|The standard amber vial (orange bottle) is the container that medication is normally dispensed in outside of the study.
218933686|NCT03843541|DRUG|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
218933687|NCT03843541|DRUG|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
218933688|NCT03843541|OTHER|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
218933689|NCT03896269|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219543158|NCT00824291|DRUG|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
218933690|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
218933691|NCT05070416|DEVICE|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
218933692|NCT05208450|OTHER|Practice support And Community Engagement (PACE)|A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
218933693|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
218933694|NCT04617925|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
219045487|NCT02626065|BIOLOGICAL|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
219045488|NCT02626065|DRUG|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
219045489|NCT03331692|OTHER|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
219045490|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
219543159|NCT00824291|GENETIC|Genotyping|CYP2D6 genotyping at randomization
219621663|NCT00226499|BIOLOGICAL|Varilrix™|1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
218933695|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.~SSD: NNC0442-0344 A will be administered subcutaneously."
219543160|NCT00933686|DRUG|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
219543161|NCT00933686|DRUG|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
219543162|NCT01330576|PROCEDURE|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
219543163|NCT01330576|PROCEDURE|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
219543164|NCT04108572|BEHAVIORAL|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
219543165|NCT03656367|DIETARY_SUPPLEMENT|Cheddar cheese|The reference product is a commercial matured cheddar cheese
219543166|NCT03656367|DIETARY_SUPPLEMENT|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
219543167|NCT03656367|DIETARY_SUPPLEMENT|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
219543168|NCT03656367|DIETARY_SUPPLEMENT|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
219543169|NCT02184845|DEVICE|Implant NobelActive 3.0|
219543170|NCT01505933|DRUG|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
219543171|NCT01505933|DRUG|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
219543172|NCT06562322|DEVICE|Placebo|Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
219543173|NCT06562322|DEVICE|300 J|Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
219543174|NCT06562322|DEVICE|600 J|Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
218933696|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.~SSD: Placebo will be administered subcutaneously."
218933697|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
218933698|NCT06345794|DRUG|Itraconazole|Administered orally.
219543175|NCT06562322|DEVICE|1260 J|Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
219543176|NCT00395694|DRUG|lamictal|anti-epileptic drug
219543177|NCT01648582|DRUG|Dulaglutide|Administered SC
219543178|NCT01648582|DRUG|Insulin glargine|Administered SC per dosing titration schedule
219543179|NCT01648582|DRUG|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
218933699|NCT06345794|DRUG|Fluconazole|Administered orally.
219543180|NCT01648582|DRUG|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
218933700|NCT06345794|DRUG|Carbamazepine|Administered orally.
218933701|NCT03400371|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
218933702|NCT03400371|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
218933703|NCT04858035|BEHAVIORAL|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
219045491|NCT06670625|BEHAVIORAL|IDAC+|Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.
219045492|NCT06997445|OTHER|Interventional group: Jacobson's progressive muscle relaxation technique with aerobic exercise|Jacobaon's progressive muscle relaxation technique for 15 minutes Total duration: 45 minutes
219543181|NCT03142165|DRUG|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
219543182|NCT03142165|OTHER|Placebo|Placebo
218933704|NCT04858035|BEHAVIORAL|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
218933705|NCT06274788|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
218933706|NCT05307692|DRUG|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
218933707|NCT05307692|DRUG|Placebo|Matching placebo will be administered orally as a tablet.
219205569|NCT06965543|PROCEDURE|Delayed G-POEM|Participants will receive standard medical treatment, including prokinetic agents, antiemetics (ondansetron 8 mg twice daily), nutritional support, and dietary counseling. Laxative treatments will be prescribed as needed. After three months, participants will undergo G-POEM as described above
218933708|NCT06621017|DRUG|ROSE-010 99 mcg|Sub-cutaneous injection of ROSE-010 solution
219205570|NCT06834425|DRUG|Peritendinous NSAID injection|Peritendinous NSAID (parecoxib) injection
219205571|NCT06834425|DRUG|Control group (placebo)|Normal saline mixed with local anesthetics injection
219205572|NCT02989662|DRUG|Mifepristone|Participants receive 6 doses.
219205573|NCT02989662|DRUG|Placebo - Cap|Participants receive 6 doses
218933709|NCT06621017|DRUG|Placebo|Sub-cutaneous injection of saline solution
219205574|NCT06280235|DRUG|BI 1569912|BI 1569912
219205575|NCT06280235|DRUG|Placebo|Placebo matching BI 1569912
219205576|NCT06541522|DEVICE|EIT|Two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height (2nd intercostal space or 5th intercostal space). The order will be drawn at random.
219205577|NCT03819101|DRUG|Acetylsalicylic acid|100mg
219205578|NCT03819101|DRUG|Atorvastatin|80 mg
219205579|NCT04527094|DIAGNOSTIC_TEST|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
219205580|NCT06752993|DEVICE|Expiratory Muscle Strength Training (EMST-150)|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) used to exhale against a same-pressure load every exhalation for strengthening primarily the core muscles. The device pressure is adjusted according to PEmax and reliability/reproducibility has been demonstrated.
219205581|NCT06752993|DEVICE|Sham Training|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) without physiological load. The sham device closely resembled the EMST device, with the only difference being that the pressure release valve was rendered nonfunctional by removing the spring. As a result, it exerted minimal to no physiological load on the targeted muscles.
219205582|NCT05515978|DRUG|Metformin|Metformin is a medication used to treat type 2 diabetes, gestational diabetes, and prediabetes. In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
219205583|NCT05515978|BEHAVIORAL|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
218933710|NCT06621017|DRUG|ROSE-010 150 mcg|Sub-cutaneous injection of ROSE-010 solution
218933711|NCT05376566|DRUG|Hydrochloric Acid (2 M)|Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
219205584|NCT00328783|DEVICE|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
219205585|NCT00328783|RADIATION|Radiation Therapy|
219543183|NCT03142165|DRUG|Diphenhydramine|50 mg intravenous administration
219543184|NCT03142165|DRUG|Famotidine|20 mg intravenous administration
219543185|NCT05994066|OTHER|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
218933712|NCT05376566|DRUG|Normal saline|Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
218933713|NCT05413135|DRUG|ARO-APOC3|ARO-APOC3 Injection
218933714|NCT05209074|DRUG|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
218933715|NCT05209074|DRUG|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
218933716|NCT04550442|DRUG|Azacitidine|Given IV or SC
218933717|NCT04550442|DRUG|Venetoclax|Given PO
218933718|NCT03151486|DRUG|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
218933719|NCT03151486|DRUG|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
218933720|NCT03151486|DRUG|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
218933721|NCT03151486|DRUG|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
218933722|NCT03151486|DRUG|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
219543186|NCT02699866|DEVICE|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
219543187|NCT01384591|DRUG|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
219205586|NCT01054092|DRUG|ipragliflozin|oral
219543188|NCT01384591|DRUG|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
219543189|NCT01384591|DRUG|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
218933723|NCT03151486|DRUG|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
218933724|NCT03151486|DRUG|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
218933725|NCT03151486|DRUG|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
218933726|NCT03151486|DRUG|Placebo|Participants will receive matching placebo in all cohorts.
219543190|NCT01384591|DRUG|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
218933727|NCT06523387|BEHAVIORAL|Pivotal Response Treatment Online (PRT-O) Course|Pivotal Response Treatment - Parent Training
218933728|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
218933729|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
218933730|NCT05660954|DRUG|Cabozantinib|"* All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose."
218933731|NCT06852768|BIOLOGICAL|d-MAPPS|Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.
218933732|NCT06852768|BIOLOGICAL|Placebo|Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.
218933733|NCT06852768|OTHER|PI and Patient Masked|Both the PI and the participant are masked on the drug administered.
219205587|NCT04323488|BEHAVIORAL|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
219205588|NCT04909697|DRUG|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
219205589|NCT04909697|DRUG|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
219205590|NCT01242202|DRUG|ipragliflozin|oral
219205591|NCT01242202|DRUG|alpha glucosidase inhibitor|oral
219543191|NCT01959672|PROCEDURE|4-Dimensional Computed Tomography|Correlative studies
219543192|NCT01959672|DRUG|Fluorouracil|Given IV
219543193|NCT01959672|DRUG|Gemcitabine Hydrochloride|Given IV
219543194|NCT01959672|OTHER|Laboratory Biomarker Analysis|Correlative studies
219543195|NCT01959672|DRUG|Leucovorin Calcium|Given IV
219543196|NCT01959672|DRUG|Nelfinavir Mesylate|Given PO
219543197|NCT01959672|BIOLOGICAL|Oregovomab|Given IV
219543198|NCT01959672|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218933734|NCT04693468|DRUG|Axitinib|Given PO
218933735|NCT04693468|DRUG|Crizotinib|Given PO
218933736|NCT04693468|DRUG|Palbociclib Isethionate|Given PO
218933737|NCT04693468|DRUG|Talazoparib Tosylate|Given PO
218933738|NCT04488055|BEHAVIORAL|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
218933739|NCT04488055|BEHAVIORAL|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
218933740|NCT05112289|DIAGNOSTIC_TEST|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
219205592|NCT04599010|OTHER|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
219543199|NCT01959672|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219543200|NCT03593512|PROCEDURE|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
219543201|NCT06560710|OTHER|vitrectimy|Clinical characteristics and surgical outcomes
219543202|NCT00840216|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
219543203|NCT00840216|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
219543204|NCT02526121|PROCEDURE|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
219543205|NCT02526121|BEHAVIORAL|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
219543206|NCT00682500|DRUG|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
219205593|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
219205594|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
218933741|NCT02568267|DRUG|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
218933742|NCT04903080|BIOLOGICAL|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
218933743|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
219045493|NCT06997445|OTHER|Aerobic Exercise|"Participants in this group will only be provided aerobic exercise for 4 weeks supervised by physiotherapist.~Aerobic Exercise include the following:~* Warm up exercises for 5 minutes.~* Brisk walking on treadmill for 25 minutes which include warm up period for 10 minutes then 14 minutes brisk walk and cool down period included 1 minute walk.~* Stepper for 5 minutes.~* Static cycling for 5 minutes.~* Cool down for 5 minutes.~Week 03 and Week 04:~Frequency: 5 days per week Intensity: 60-80% Target heart rate Time: 45 minutes~Week 01 and Week 02:~Frequency: 5 days per week Intensity: 50-60 % Target heart rate Time: 45 minutes"
219205595|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
219543207|NCT00682500|DRUG|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
219543208|NCT04530656|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
219543209|NCT04530656|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
219543210|NCT04530656|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
219543211|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Two doses of placebo (0.5ml) at the schedule of day 0, 28
219543212|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（high-dose group）|Two doses of placebo (1.0ml) at the schedule of day 0, 28
219543213|NCT04530656|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）|Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
219543214|NCT05527561|BEHAVIORAL|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
219543215|NCT05527561|BEHAVIORAL|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
219543216|NCT06356766|OTHER|Telerehabilitation|Modified Duran Protocol via Telerehabilitation
219045494|NCT06339736|OTHER|Questionnaires administered to all study participants|Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
219543217|NCT06356766|OTHER|Face-to-face rehabilitation|Modified Duran Protocol
219045495|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via posterior approach|Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.
219045496|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via anterior approach|Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.
219045497|NCT07003997|DRUG|Baricitinib|This small molecule, orally bioavailable agent is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases (JAK). These enzymes play an important role in the processes of inflammation. Patients will receive a dose of 2 mg oral daily.
219205596|NCT05524844|OTHER|Sample Collection|Saliva, gastric aspirate, and esophageal brushings and biopsies.
219543218|NCT04924920|DIAGNOSTIC_TEST|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
219543219|NCT04924920|DIAGNOSTIC_TEST|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
219543220|NCT04924920|DIAGNOSTIC_TEST|Fluid challenge|Bolus of fluids of 4 ml/kg given within 10 minutes
219543221|NCT05857774|OTHER|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
219543222|NCT05857774|OTHER|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
218933744|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
218933745|NCT01604330|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
218933746|NCT01604330|DRUG|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
218933747|NCT05735951|DRUG|STIRIPENTOL oral administration|"Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
218933748|NCT04194437|DEVICE|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
218933749|NCT05382299|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
218933750|NCT05382299|DRUG|Paclitaxel|Administered intravenously
218933751|NCT05382299|DRUG|nab-Paclitaxel|Administered intravenously
218933752|NCT05382299|DRUG|Gemcitabine|Administered intravenously
218933753|NCT05382299|DRUG|Carboplatin|Administered intravenously
219543223|NCT05857774|OTHER|Biological measurements|Skeletal troponin-I
219543224|NCT01322880|BEHAVIORAL|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
218933754|NCT05065008|OTHER|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
218933755|NCT05065008|OTHER|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
219045498|NCT07003997|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
219045499|NCT07003620|DRUG|Neoadjuvant immunochemotherapy|All patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1/PD-L1 inhibitor therapy, followed by open radical hysterectomy and pelvic lymphadenectomy. Postoperative adjuvant therapy (chemotherapy, chemoradiation, or maintenance immunotherapy) will be determined based on pathological assessment. Tumor tissue samples will be collected during treatment for single-cell sequencing analysis.
219045500|NCT06672523|DRUG|BMS-986504|Specified dose on specified days
219045501|NCT06672523|DRUG|[14C]-BMS-986504|Specified dose on specified days
219045502|NCT06924034|OTHER|Phase I and Phase II Cardiac Rehabilitation Program|The program consisted of two stages: an inpatient phase lasting until discharge, followed by an outpatient-supervised Phase II lasting eight weeks. In the intervention group, the participants in the inpatient phase received active-participatory lower extremity movements and progressive walking training (i.e., progressive walking in the room-corridor-hospital) to prepare them for discharge. The inpatient phase I was conducted with supervision following the American Heart Association recommendations. Participants in the intervention group were then administered phase II of the supervised CR program. Phase II CR was performed 3 non-consecutive days a week for 8 weeks as an aerobic exercise program.
219045503|NCT06541795|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.
219045504|NCT06920147|DRUG|Ertapenem|Participants will receive a single dose of IV ertapenem (1g) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
219621677|NCT05584618|OTHER|Education|education
219621678|NCT05327400|OTHER|Pathological|The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
218933756|NCT04816513|DRUG|Ustekinumab|Ustekinumab will be administered as SC injection.
218933757|NCT04920578|DRUG|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
218933758|NCT04920578|OTHER|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
219543225|NCT01322880|BEHAVIORAL|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
219543226|NCT01058668|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219543227|NCT01058668|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
219543228|NCT02406560|DRUG|tafamidis|fasted
219543229|NCT02406560|DRUG|tafamidis|high fat meal
218933759|NCT06677905|BEHAVIORAL|web-based spinal cord injury self-management program|"Peer health coaches will be recruited from the United Spinal Connecticut Chapter and SCI BC. They will be at least 5 years post-SCI and will be certified in brief action planning and in Mental Health First Aid.~Online coaching sessions are expected to cover a health-related topic (eg. bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression etc) and a self-management skill topic (eg.action planning, goal setting, problem-solving, mood management, navigating the health care system, communicating with health care providers). To ensure we meet the unique needs of participants, the coach and participant will determine jointly how many sessions to spend on a topic. In addition, coaches will be able to link relevant information and resources contained in the resource library to each session."
218933760|NCT06677905|BEHAVIORAL|Peer support|Existing peer support program from the United Spinal Connecticut Chapter or SCI BC
218933761|NCT03374475|DRUG|JNJ-42847922 20mg|Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
218933762|NCT03374475|DRUG|JNJ-42847922 40mg|Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
218933763|NCT03374475|DRUG|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
218933764|NCT05991154|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
218933765|NCT05938322|OTHER|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates \< 30g/day, 1.2g-1.5g protein/kg/day and lipids \> 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
218933766|NCT05938322|OTHER|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
218933767|NCT02978612|DRUG|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
218933768|NCT05344313|DIETARY_SUPPLEMENT|Ensure Plus Advance|as in the arm description of the intervention
218933769|NCT04817163|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
219045505|NCT06920147|DRUG|Cefazolin and Metronidazole.|Participants will receive a single dose of a combination of IV cefazolin (re-dosed during the case every 4 hours and/or after every 1,500 mL of blood loss) and IV metronidazole (single dose 500 mg) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
219205597|NCT05524844|OTHER|Endoscopy results|Results from standard of care endoscopy (scheduled separate of study)
219543230|NCT02406560|DRUG|tafamidis|
219543231|NCT04543682|DRUG|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
219543232|NCT04543682|DRUG|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
219543233|NCT04543682|PROCEDURE|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
219543234|NCT03695692|BEHAVIORAL|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
219543235|NCT03695692|BEHAVIORAL|pelvic floor exercise|The exercise program is performed every day for 6 weeks
219543236|NCT00817440|OTHER|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
219205598|NCT05524844|OTHER|Dietary questionnaire|Diet History Questionnaire (II)
219543237|NCT00817440|OTHER|Fasting|3 days of fasting and then the same as arm 1
219543238|NCT00365430|BEHAVIORAL|safety program|Education, patient involvement, tailored implementation and a computerized registration system
219543239|NCT04322292|DRUG|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
219543240|NCT03876639|OTHER|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
218933770|NCT04817163|BEHAVIORAL|Professionally-administered booster face-to-face CBT-I sessions|"Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment."
218933771|NCT02003924|DRUG|Enzalutamide|160 mg by mouth once daily
219543241|NCT03876639|PROCEDURE|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
219543242|NCT03876639|PROCEDURE|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
219543243|NCT05955534|DEVICE|TPUG|Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.
219543244|NCT05955534|PROCEDURE|PEG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
219543245|NCT05955534|PROCEDURE|PRG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
218933772|NCT02003924|DRUG|Placebo|Sugar pill to mimic enzalutamide
218933773|NCT01711554|BIOLOGICAL|Dinutuximab|Given IV
218933774|NCT01711554|DRUG|Isotretinoin|Given PO
218933775|NCT01711554|OTHER|Laboratory Biomarker Analysis|Correlative studies
219045508|NCT07005141|DEVICE|Endovascular Iliac Branch Stent-Graft Implantation|Implantation of a self-expanding dual-lumen iliac branch stent-graft designed to treat iliac artery aneurysms while preserving perfusion to the internal iliac artery. The device enables connection to bridging stent-grafts directed to both the internal and external iliac arteries. It is compatible with previously implanted or concurrently implanted bifurcated aortic stent-grafts with branch diameters between 14 and 16 mm. The stent-graft is delivered endovascularly using a low-profile catheter-based system under fluoroscopic guidance. Once in position, the device is deployed via a controlled pull-back release mechanism. Radiopaque markers assist in precise alignment and facilitate the placement of bridging components.
219045509|NCT06868277|BIOLOGICAL|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
219045510|NCT06868277|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
219045511|NCT06864403|DRUG|Mirikizumab - Intravenous (IV)|300 mg mirikizumab at Weeks 0, 4, and 8
219045512|NCT06864403|DRUG|Mirikizumab - Subcutaneous (SC)|Pre-filled syringes administered at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
219045513|NCT03377712|DEVICE|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
219543246|NCT01068821|OTHER|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
219543247|NCT01068821|OTHER|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
219543248|NCT03772821|OTHER|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
219543249|NCT03772821|OTHER|Incision/scar measurement|Between D0 and D90
219543250|NCT04859517|DRUG|ADG20|Single dose of ADG20
219543251|NCT04859517|DRUG|Placebo|Single dose of placebo
219543252|NCT01906918|PROCEDURE|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
219621679|NCT00583765|DRUG|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
218933776|NCT01711554|DRUG|Lenalidomide|Given PO
218933777|NCT01711554|OTHER|Pharmacological Study|Correlative studies
218933778|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
218933779|NCT04232228|OTHER|No intervention|No intervention was used in this study.
218933780|NCT06371755|DEVICE|Ultrasound examination with REMS technology|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
218933781|NCT05696717|DRUG|Ampreloxetine|Oral tablet, QD
218933782|NCT05696717|DRUG|Placebo|Oral tablet, QD
219045514|NCT03377712|DEVICE|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
219045515|NCT03377712|DEVICE|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
219543253|NCT04730466|OTHER|Neuropsychological rehabilitation|The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
218933783|NCT03870672|DEVICE|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
218933784|NCT03870672|DEVICE|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
218933785|NCT03870672|DEVICE|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
218933786|NCT03870672|DEVICE|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
218933787|NCT04595474|DEVICE|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
218933788|NCT04693767|DEVICE|Mechanical thrombectomy|"1. Clot specimen collection~2. Extracranial blood collection"
218933789|NCT04693767|OTHER|Minimally invasive surgery|"1. Clot specimen collection~2. Arterial blood collection"
218933790|NCT00065572|DRUG|ZD6126|
218933791|NCT00065572|DRUG|Placebo|
218933792|NCT05023486|DRUG|NP-G2-044 Monotherapy|1600 mg QD, 2000mg QD, and 2100 mg QD
219045516|NCT03377712|DEVICE|Pain evaluation|by means of questionnaires
219543254|NCT05928156|OTHER|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
219543255|NCT05928156|OTHER|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
219543256|NCT03953287|DRUG|Paracetamol|A randomized, cross over design
219543257|NCT04652856|DEVICE|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
218933793|NCT05023486|DRUG|Anti-PD-1 Therapy|previously initiated per standard of care, at a dose and frequency in accordance with the package insert
218933794|NCT05023486|DRUG|NP-G2-044 Combination therapy|1600 mg QD or 2100 mg QD
218933795|NCT04033497|DEVICE|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
218933796|NCT05754281|DEVICE|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
218933797|NCT03023345|DEVICE|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
219045517|NCT03377712|DEVICE|Evaluation of the function|through questionnaires
219045518|NCT03377712|DEVICE|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
219045519|NCT03377712|DEVICE|Quality of life assessment|through questionnaire
219045520|NCT07009132|DEVICE|Dual cholate clearance assay|Study participants are administered labeled oral and intravenous cholate, and then two blood samples are taken over 60-minutes. Serum cholate levels are measured by blood draws.
219045521|NCT07009132|RADIATION|MRI|Unsedated non contrast cardiac magnetic resonance imaging (MRI)
219045522|NCT07133178|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine
219543258|NCT04652856|DEVICE|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
219543259|NCT01112761|DEVICE|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
218933798|NCT03181048|PROCEDURE|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
218933799|NCT03181048|PROCEDURE|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
219543260|NCT05041361|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
219543261|NCT05041361|DEVICE|Whole-Body Hyperthermia (WBH)|Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
219543262|NCT00000261|DRUG|30% Nitrous oxide|
219543263|NCT00000261|OTHER|Placebo|No drug (100% oxygen)
219543264|NCT00000261|DRUG|0.2% sevoflurane|
219543265|NCT00000261|DRUG|0.4% sevoflurane|
219543266|NCT00000261|DRUG|0.6% sevoflurane|
219543267|NCT05675033|DRUG|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
218933800|NCT05579847|OTHER|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
218933801|NCT05579847|BEHAVIORAL|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
219045523|NCT07133178|BIOLOGICAL|Control|Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization
219045524|NCT07008118|DRUG|INCA035784|INCA035784 will be administered at protocol defined dose.
219543268|NCT01642277|DRUG|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
219543269|NCT00924547|DIETARY_SUPPLEMENT|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
219543270|NCT00924547|DIETARY_SUPPLEMENT|Placebo|Placebo identical to active treatment.
219543271|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using allograft|Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.
219543272|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using xenograft|Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.
219543273|NCT06627829|DEVICE|Usual care|Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
219621680|NCT07032467|OTHER|Psychosocial and Behavioral Assessment|Participants completed validated self-report questionnaires to assess levels of social media addiction and compulsive exercise behaviors. No therapeutic or experimental intervention was administered. Data were collected through surveys for observational analysis.
219621681|NCT07137117|OTHER|Behavioral Treatment|"Patients in the experimental group will be administered a Patient Information Form on the morning of surgery. Standard discharge education will be provided within 72 hours after surgery. After discharge, patients will be contacted at 1, 2, 3 weeks, and 2, 4, and 5 months for informational purposes only; no assessment will be administered. During this period, regular follow-up and support will be provided to enhance patient compliance with post-surgical care. The Interview Information Collection Form will be used during telephone interviews with patients to collect and evaluate current health data. This practice will ensure systematic and accurate recording of patients' current conditions. Patients will be contacted at 1, 3, and 6 months to complete the Medication Adherence Scale and the Nutrition and Exercise Attitude Scale, collecting data on medication adherence and behavioral attitudes. These assessments will be used as a systematic approach to monitoring patient adherence t"
219621682|NCT07137572|OTHER|Art Prescription|Any of the art interventions (theatre, dance, visual arts, music or cinema)
219621683|NCT00450593|GENETIC|gene expression analysis|
219621684|NCT00450593|GENETIC|microarray analysis|
219621685|NCT00450593|GENETIC|molecular genetic technique|
219621686|NCT00450593|GENETIC|mutation analysis|
218933802|NCT05579847|BEHAVIORAL|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
218933803|NCT05579847|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
218933804|NCT05579847|BEHAVIORAL|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
218933805|NCT01315652|BEHAVIORAL|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
219543274|NCT02906540|PROCEDURE|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
219543275|NCT02906540|PROCEDURE|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
218933806|NCT01315652|BEHAVIORAL|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
218933807|NCT04253691|DEVICE|Virtual Reality Mediated Relaxation|Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
219045525|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
219045526|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
219045527|NCT06619457|OTHER|Mitopure (Urolithin A) Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
219045528|NCT06619457|OTHER|Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
219045529|NCT06504251|DIAGNOSTIC_TEST|Delirium Diagnostic Tool-Provisional ( DDT-Pro )|The Delirium Diagnostic Tool-Provisional (DDT-Pro) is another tool created to assist in the diagnosis of delirium. It does not require specialist expertise. It can assess the main symptoms of acute confusion, including cognitive ability (Cognition), higher-level thinking skills (Higher level thinking), and the sleep-wake cycle (Sleep-wake cycle).
219045530|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
219045531|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
219045532|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
219543276|NCT04178850|BIOLOGICAL|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
219621687|NCT00450593|OTHER|laboratory biomarker analysis|
219621688|NCT00450593|PROCEDURE|mutation carrier screening|
219045533|NCT06120283|DRUG|Elacestrant|Standard dose administered orally as a tablet.
219045534|NCT07010705|DEVICE|ActiGraph LEAP|The ActiGraph LEAP has received 510(k) clearance from the US FDA and offers extensive sensor collections, providing continuous digital measures of activity, sleep, mobility, and additional vital signs, including heart rate and variability, oxygen saturation, and skin temperature, in a single fit-for-purpose device.
219045535|NCT07010705|DEVICE|Axivity AX6|The Axivity AX6 is a data logger capable of recording raw data from a suite of integrated sensors. It features a state of the art 6-Axis movement sensor measuring linear acceleration and angular velocity at high precision. All sensor locations and Orientations are identical to the AX3 for maximum compatibility. All data is stored in its raw, unaltered format on the embedded flash memory.
219045536|NCT06625593|DRUG|BG-C137|Administered intravenously
219045537|NCT05875246|BEHAVIORAL|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
219621689|NCT00450593|PROCEDURE|study of high risk factors|
219621690|NCT05369754|BIOLOGICAL|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
219621691|NCT06725030|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
219621692|NCT07052084|DRUG|Vasopressin administration|Low dose of vasopressin (0.02ui /min), maximum 5 days
219621693|NCT07052084|DRUG|Sodium chloride administration|NaCl 0.9 %, maximum 5 days
219543277|NCT04178850|BIOLOGICAL|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
219543278|NCT02523963|OTHER|family work shop|"1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
219543279|NCT00147563|DRUG|Eplerenone|
218933808|NCT06655779|DIAGNOSTIC_TEST|Acoustic Detection of Blood Flow|Subject will have the acoustic device scoring performed prior to a Coronary CTA. No treatment decisions will be based upon the acoustic device score.
218933809|NCT06980948|GENETIC|ST-503|Genomic Medicine
219543280|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
219543281|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
219543282|NCT05111223|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
219543283|NCT02091713|OTHER|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
219543284|NCT02545803|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
219543285|NCT06356103|DIETARY_SUPPLEMENT|Whey-Based Partially Hydrolyzed Formula|Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
219543286|NCT06356103|DIETARY_SUPPLEMENT|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines|protein and micronutrient requirements according to the recommended dietary allowance (RDA)
219543287|NCT03605342|DRUG|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
219543288|NCT03605342|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
219543289|NCT03605342|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
219543290|NCT05234788|PROCEDURE|Transfemoral Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via femoral artery access
219543291|NCT05234788|PROCEDURE|Transradial Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via radial artery access
218933810|NCT06980948|PROCEDURE|Sham (No Treatment)|Sham Procedure
218933811|NCT06597123|BEHAVIORAL|Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training|Basic participants will participate in two motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool (Real-time Evaluation of Dialogue in Motivational Interviewing), and both the spirit of MI and presence of bias as measured by Dougall GPT.
219045538|NCT06117397|OTHER|Text Messaging Intervention|A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
219045539|NCT07015190|DRUG|Darovasertib|Dosed orally, twice daily (28-day/ cycle
219045540|NCT07015190|PROCEDURE|Primary Local Therapy|Plaque Brachytherapy or Enucleation
219045541|NCT02285504|DRUG|SAGE-547|Intravenous injection
219543292|NCT04254887|PROCEDURE|EPBD|Small incision of the duodenal nipple + EPBD
219543293|NCT04254887|PROCEDURE|EST|Large incision of the duodenal nipple + EPBD
219543294|NCT05734677|BEHAVIORAL|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
219543295|NCT04649593|DIETARY_SUPPLEMENT|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
219543296|NCT06216561|DRUG|CRS-HIPEC + LSTA1|LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
219543297|NCT06216561|PROCEDURE|CRS-HIPEC alone|Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
219543298|NCT02281994|DEVICE|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
219045542|NCT06686771|RADIATION|SBRT|Please refer to the current NCCN NSCLC guidelines for possible treatment options
219045543|NCT06686771|OTHER|Second-line standard of care therapy|Please refer to the current NCCN NSCLC guidelines for possible treatment options.
219045544|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
219045545|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
219045546|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219045547|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219543299|NCT02086214|DEVICE|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
219543300|NCT02086214|DEVICE|Control|LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
218933812|NCT06597123|BEHAVIORAL|Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training|Plus participants will participate in four motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool, and both the spirit of MI and presence of bias as measured by Dougall GPT.
219543301|NCT00440167|DRUG|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
219543302|NCT00440167|DRUG|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
219543303|NCT00440167|DRUG|Erlotinib|Erlotinib 150 mg/d oral, daily without break
219543304|NCT05028608|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
219543305|NCT05028608|DRUG|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
219543306|NCT05028608|DRUG|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
219543307|NCT05840133|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
219543308|NCT05572437|DEVICE|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
218933813|NCT06590649|BEHAVIORAL|Household-level effects|At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). The household participants will be analyzed side by side with the index participants.
218933814|NCT04626362|OTHER|Cranberry juice|Cranberry juice cocktail is a product of Ocean Spray Cranberries, Inc.
218933815|NCT05044468|DRUG|Lidocaine|Given via injection
218933816|NCT05044468|DRUG|Liposomal Bupivacaine|Given via injection
219205599|NCT05769634|BEHAVIORAL|Stereoelectroencephalography|Computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
219205600|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
219205601|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
218933817|NCT05044468|OTHER|Questionnaire Administration|Ancillary studies
219045548|NCT04656600|DRUG|Cerezyme® / Imiglucerase|Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
219045549|NCT07018765|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of eight weekly sessions, each lasting 60-90 minutes. The first session will be delivered face-to-face in the hospital, and the remaining sessions will be conducted online via Zoom. The program content includes mindful breathing, body scanning, stress management, emotional regulation, and interpersonal mindfulness exercises.
219045550|NCT07018752|DRUG|roginolisib|Roginolisib daily intake
219045551|NCT07018752|DRUG|golcadomide|Golcadomide daily intake
219045552|NCT07018752|DRUG|azacitidine|oral 5-azacitidine daily intake
219205602|NCT04715139|DEVICE|Products listed in Group/Cohort Description|Depending on approved indication per product
219543309|NCT02557347|BEHAVIORAL|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
219543310|NCT00908128|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
219543311|NCT00908128|DRUG|CellCept®|CellCept® Tablets, 500 mg
219543312|NCT00796328|DRUG|Phenylephrine infusion|Up-down, biased coin design
219543313|NCT02842853|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219543314|NCT02842853|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219543315|NCT03595800|PROCEDURE|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
219543316|NCT04089553|DRUG|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
219543317|NCT04089553|DRUG|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
219621694|NCT07051798|OTHER|It is a qualitative type of study that will be conducted through face-to-face interviews.|It is a qualitative type of study that will be conducted through face-to-face interviews.
219205603|NCT04821765|DRUG|PD-1 antibody|200mg, d1, q3W
219543318|NCT04089553|DRUG|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
219543319|NCT02873832|BIOLOGICAL|Blood sample|
219543320|NCT02873832|OTHER|Flow cytometry|
219543321|NCT02873832|OTHER|western blot|
219543322|NCT04594577|DEVICE|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
219543323|NCT01798264|DRUG|ITCA 650 (exenatide in DUROS)|
219543324|NCT00121901|DRUG|glyceryl nitrate|
219543325|NCT01064960|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
219543326|NCT02045849|DRUG|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
219621695|NCT03719027|DIAGNOSTIC_TEST|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
219621696|NCT00946920|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
218933818|NCT06812312|OTHER|PCR Trainning|A two-hour training intervention was conducted by a CPR-B instructor. The first 30 minutes were dedicated to explaining how to recognize a cardiopulmonary arrest, the correct technique for chest compressions, ventilations, and AED use. The remaining 90 minutes were for practical application of the intervention. This was conducted with five CPR-B training torsos (Little Anne QCPR training mannequin, Laerdal) and a simulated AED for CPR training (AED Practi-Trainer - Bilingual, WNL). Both theoretical and practical training were provided by a basic life support instructor from the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC), instructing participants under the 2021 European Resuscitation Council (ERC) recommendations.
218933819|NCT06654453|PROCEDURE|Thrombectomy|Manual thrombectomy followed by Percutaneous Coronary Intervention (PCI), a procedure involving mechanical removal of thrombus before stent placement in coronary arteries to restore blood flow in STEM
218933820|NCT06654453|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.
218933821|NCT06655506|COMBINATION_PRODUCT|ERAS group|This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
219045553|NCT04918303|DEVICE|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
219045554|NCT04154111|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; double blinded
219045555|NCT04154111|DEVICE|Sham TBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
219045556|NCT04154111|DEVICE|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system (double blinded).
219045557|NCT04154111|DEVICE|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
219205604|NCT04821765|RADIATION|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
219205605|NCT04821765|DRUG|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
219205606|NCT04821765|DRUG|Cisplatin|75mg/m2, d1, q3W
219543327|NCT02045849|DRUG|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
219543328|NCT02045849|DRUG|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
219543329|NCT02471027|PROCEDURE|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
219543330|NCT04145427|BEHAVIORAL|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
219543331|NCT04145427|BEHAVIORAL|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
219543332|NCT04018768|OTHER|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
219543333|NCT04018768|OTHER|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
219543334|NCT03682601|DRUG|5% sinecatechins ointment|Topical 5% sinecatechins ointment will be applied once daily.
219543335|NCT03682601|DRUG|Placebo|Aquaphor/vehicle
219543336|NCT03682601|DRUG|10% sinecatechins ointment|Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
219543337|NCT02817867|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
219543338|NCT02817867|DEVICE|TMS|Transcranial magnetic stimulation
219543339|NCT02817867|DEVICE|tDCS + TMS|Association between tDCS and TMS.
219543340|NCT03572868|OTHER|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the second or the third trimester of pregnancy.
219543341|NCT03714594|DRUG|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
219543342|NCT03714594|DRUG|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
219543343|NCT03714594|DRUG|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
219543344|NCT03153462|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
219543345|NCT01403194|DEVICE|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
219543346|NCT05224531|DRUG|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
219543347|NCT06627465|DEVICE|MS Sherpa|The MS Sherpa application is a CE-certified smartphone application (installed on the mobile phone of the patient) that collects digital biomarkers using tests (\~six minutes/test: self-monitoring questionnaires, smartphone 2-MWT, and a smartphone SDMT) once per week in the home environment of the patient.
219543348|NCT06627465|DEVICE|Neurokeys|The NeuroKeys application is a CE-certified application (installed on the mobile phone of the patient) that passively and continuously monitors keystroke dynamics of everyday typing as a digital biomarker.
219543349|NCT04328935|BEHAVIORAL|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
219543350|NCT01366963|BEHAVIORAL|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
219543351|NCT01366963|BEHAVIORAL|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
219543352|NCT01366963|BEHAVIORAL|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
219543353|NCT05181969|DEVICE|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
219543354|NCT05181969|DEVICE|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
219543355|NCT05181969|DEVICE|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
219543356|NCT05181969|DEVICE|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
219543357|NCT00452920|DRUG|docetaxel|
218933822|NCT06655506|COMBINATION_PRODUCT|Control group|This group will include patients that do not follow the predetermined criteria of ERAS protocols
218933823|NCT04301193|DEVICE|Quantra Analyzer|Subject's blood samples will be manipulated in the lab and will be tested with the Quantra Analyzer. After obtaining blood from each patient, the blood was diluted to varying dilutions to obtain different fibrinogen concentrations. This way, 89 samples were prepared from the blood from 13 patients. Each sample was analyzed for fibrinogen concentration in the lab using conventional technology. Additionally each sample was used to measure Quantra variables such as clot stiffness (CS), and fibrinogen contribution to clot stiffness (FCS).
218933824|NCT05723276|DRUG|Psilocybin|Psilocybin 25mg PO
218933825|NCT06817239|DRUG|Esketamine|Esketamine (1mg/ml) will be administered at a loading dose of 0.2 mg/kg, namely at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with a formulation consisting of esketamine 50mg and sufentanil 200 μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
219205607|NCT04002505|OTHER|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
219205608|NCT06439693|DRUG|Nab-Paclitaxel|Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.
219205609|NCT06439693|DRUG|Paclitaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
219205610|NCT06439693|DRUG|Docetaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
219543358|NCT00452920|RADIATION|cesium Cs 137|
219543359|NCT00452920|RADIATION|radiation therapy|
219543360|NCT04624360|DRUG|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
219543361|NCT04624360|OTHER|Placebo|2cc 0.9% Saline
219543362|NCT03317444|DRUG|TRC101|Oral suspension
219543363|NCT03317444|DRUG|Placebo|Oral suspension
219543364|NCT02589301|BIOLOGICAL|Pegfilgrastim|
219543365|NCT02944617|OTHER|Laboratory Biomarker Analysis|Correlative studies
219543366|NCT02944617|DIETARY_SUPPLEMENT|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
219543367|NCT02944617|DRUG|VEGF-TKI|Must be received as standard of care chemotherapy
219543368|NCT06130215|OTHER|Simple meal management|"* Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
219543369|NCT06130215|OTHER|Precise meal management|precise carbohydrate counting for each meal
219543370|NCT05091151|DRUG|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
219543371|NCT05238428|BEHAVIORAL|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
219543372|NCT04602754|DRUG|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
218933826|NCT06817239|DRUG|Normal saline|Normal saline will be administered at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with sufentanil 200μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
218933827|NCT00560352|DRUG|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
218933828|NCT00560352|DRUG|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD
218933829|NCT00560352|DRUG|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
218933830|NCT05301790|DEVICE|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
218933831|NCT01916044|OTHER|Ultrasound|Measure of Uterine Segment by Ultrasound
219543373|NCT04602754|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
219543374|NCT04602754|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
219543375|NCT04602754|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
219543376|NCT04602754|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
218933832|NCT05987007|DEVICE|Acoustic slow-wave activity enhancement|The acoustic enhancement of slow-wave activity will be conducted using the Dreem2 headband. This device utilizes five dry-EEG electrodes (O1, O2, FpZ, F7, and F8), a 3D accelerometer, and a pulse oximeter to detect slow-wave activity and generates acoustic stimulation of slow-waves to augment slow-wave sleep.
218933833|NCT05987007|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia (CBTI) is a well-established first-line or complimentary treatment for insomnia which consists of cognitive and behavioral modifications, including addressing maladaptive sleep-related behaviors, controlling sleep environment, and limiting time spent in bed.
218933834|NCT06824727|OTHER|Baseline cell blood counts|Obtain one peripheral blood sample from participants who have severe thrombocytopenia defined as 30,000 platelets/mcl or less
219045558|NCT06698497|BEHAVIORAL|Communication Campaign|A social media vaccine communications campaign is deployed once increasing amounts of SARS-CoV-2 RNA are identified in the New York State wastewater surveillance network. The social media campaigns on Facebook, Instagram, and NextDoor social media platforms will run for 11 weeks. The campaign disseminates information about the wastewater surveillance network and vaccination (not COVID-19 specific) to residents in intervention counties. These social media platforms not only allow for quick and cost-effective exposure, but also allow for participation and interaction with participants. The campaign ads include a call-to-action link to the New York State wastewater surveillance network webpage which has information and links regarding vaccines for respiratory transmitted pathogens (COVID-19, influenza, and RSV) and how to schedule an appointment.
219205611|NCT06439693|DRUG|Phesgo|Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.
218933835|NCT05458219|DRUG|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
218933836|NCT04777175|DRUG|immunity therapy|The patient receives immunotherapy
218933837|NCT02847338|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
218933838|NCT02847338|DRUG|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
218933839|NCT02847338|DRUG|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
218933840|NCT02847338|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
219205612|NCT06439693|DRUG|T-DM1|HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.
219205613|NCT06439693|DRUG|Pertuzumab|Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
219205614|NCT06439693|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.
219205615|NCT06439693|DRUG|Trastuzumab Subcutaneous Subcutaneous|Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.
219205616|NCT06439693|DRUG|Tucatinib|Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.
219543377|NCT04602754|OTHER|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
219543378|NCT02793245|OTHER|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
219543379|NCT02793245|OTHER|Simplified pulmonary function test|
219543380|NCT05463848|DRUG|Pembrolizumab|Intravenous infusion
219543381|NCT05463848|DRUG|Olaparib|Pill taken by mouth
219543382|NCT05463848|DRUG|Temozolomide|Pill taken by mouth
219543383|NCT04698473|OTHER|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
219543384|NCT04698473|OTHER|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
219543385|NCT03110627|DEVICE|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
219543386|NCT03110627|DEVICE|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
219543387|NCT03090880|DRUG|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
219543388|NCT00586989|PROCEDURE|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
218933841|NCT03384134|OTHER|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
218933842|NCT06595875|OTHER|m-tapa block|Patients in Group M were placed in the supine position. After skin antisepsis with 5% povidone-iodine, a sterile drape was placed. The high-frequency (8-13 MHz) linear ultrasound (USG) probe was covered with a sterile sheath, and the transversus abdominis, internal oblique, and external oblique muscles were identified at the 10th costal margin in the sagittal plane at the costochondral angle. The probe was angled sagittally to visualize the costochondral angle at the edge of the 10th rib and to display the posterior surface of the rib cartilage in the midline. Using an in-plane technique, a 22-gauge, 100-millimeter (mm) Stimuplex A peripheral nerve block needle was advanced cranially, and the needle tip was directed towards the posterior surface of the 10th costal cartilage. After negative aspiration, 20 mL of 0.25% bupivacaine was injected under the lower surface of the costal cartilage. The same procedure was repeated on the opposite side.
218933843|NCT06065345|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
219045559|NCT07034976|DEVICE|Active Radiofrequency (Capenergy C500 UpGradeC200)|"Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events.~In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health."
219205617|NCT06439693|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
219205618|NCT05699525|BEHAVIORAL|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
219543389|NCT00107991|DRUG|etanercept|etanercept 50 mg/week subcutaneous injection
219543390|NCT00636129|BEHAVIORAL|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
219543391|NCT00015691|DRUG|Metformin hydrochloride|
219543392|NCT00015691|DRUG|Rosiglitazone maleate|
219543393|NCT01942122|DRUG|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
219543394|NCT01942122|DRUG|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
219543395|NCT01942122|DRUG|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
219543396|NCT03781622|DEVICE|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
219543397|NCT02479763|PROCEDURE|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
219205619|NCT05699525|BEHAVIORAL|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
219205620|NCT02295072|BEHAVIORAL|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
219205621|NCT04490356|BEHAVIORAL|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
219543398|NCT05764096|OTHER|No intervention|No intervention
219543399|NCT05635812|OTHER|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
219543400|NCT05635812|OTHER|EEG experimentation|duration: 1 hour
219543401|NCT05635812|OTHER|Oculometry experimentation|duration: 30 minutes
219543402|NCT03745963|BEHAVIORAL|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
219543403|NCT03745963|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
219543404|NCT02754089|DRUG|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
219543405|NCT02754089|DRUG|Placebo|500 mg twice daily after meals for 6 weeks
219543406|NCT04626414|DRUG|Ferric maltol capsule|single dose of 30 mg capsule
219543407|NCT04626414|DRUG|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
219543408|NCT02538627|DRUG|MM-151|MM-151
219543409|NCT02538627|DRUG|MM-121|MM-121
219543410|NCT02538627|DRUG|MM-141|MM-141
219621697|NCT00946920|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
219543411|NCT02538627|DRUG|trametinib|trametininb
219543412|NCT00506831|DRUG|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
219205622|NCT03733626|COMBINATION_PRODUCT|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
219205623|NCT03733626|COMBINATION_PRODUCT|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
219205624|NCT06653244|DRUG|Injection|dexmedimidine infusion
219543413|NCT03933592|PROCEDURE|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
219543414|NCT03933592|PROCEDURE|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
219543415|NCT03958396|DRUG|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
219543416|NCT02451163|DIETARY_SUPPLEMENT|wheat polysaccharides|Consumed once daily for 12 weeks.
219543417|NCT02451163|DIETARY_SUPPLEMENT|maltodextrin|Consumed once daily for 12 weeks.
219543418|NCT03865563|DRUG|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
219543419|NCT01770223|DRUG|boceprevir|
219543420|NCT01770223|BIOLOGICAL|PegIFN-2b|
219543421|NCT01770223|DRUG|RBV|
219543422|NCT01462708|DRUG|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
219543423|NCT00499759|BEHAVIORAL|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
219543424|NCT00499759|BEHAVIORAL|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
219543425|NCT00499759|BEHAVIORAL|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
219543426|NCT00499759|BEHAVIORAL|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
219543427|NCT00499759|BEHAVIORAL|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
219543428|NCT00499759|BEHAVIORAL|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
219543429|NCT03253354|DEVICE|repetitive magnetic stimulation|Neurostimulation
218933844|NCT06361303|DEVICE|SNOO Bassinet|This is a non-interventional, prospective observational and descriptive active surveillance study of a cohort of individuals who have purchased or rented a SNOO for use with their infant.
218933845|NCT02607709|PROCEDURE|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
218933846|NCT02607709|PROCEDURE|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
218933847|NCT06603805|PROCEDURE|MAST group|
218933848|NCT06603805|PROCEDURE|breast-conserving surgery plus adjuvant radiotherapy|Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
218933849|NCT06589115|OTHER|Blood Flow Restriction Cuff|The standardized exercises will be performed while wearing a blood flow restriction cuff.
218933850|NCT06589115|OTHER|Physical Therapy|Standard physical therapy
218933851|NCT05287906|OTHER|Water|Each subject will receive one control and three treatments in the crossover design. The control contains water only.
218933852|NCT05287906|OTHER|Glucose|Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
218933853|NCT05287906|OTHER|Steviol Glycosides|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
218933854|NCT05287906|OTHER|Steviol Glycosides plus glucose|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
218933855|NCT05287906|OTHER|Rebaudioside A|A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
218933856|NCT02279706|OTHER|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
218933857|NCT06841198|DEVICE|spinal cord transcutaneous stimulation|"Stimulation, using the Neostim-5 (Cosyma Ltd.), a 5-channel electrical stimulator, will be administered throughout the study period, beginning shortly after the injury and continuing at regular intervals until one year post-spinal cord injury. It will be performed in two settings:~1. During seated mapping to identify stimulation sites (potentially T7/8, T11/12, L1/2, and S1/2) and determine stimulation parameters (e.g., frequency, pulse wave, amplitude) that elevate systolic blood pressure (SBP) and maintain it within the target range of 110-120 mmHg.~2. During 70-degree tilt tests to elicit an orthostatic response (a drop in blood pressure accompanied by symptoms)."
218933858|NCT00487461|DRUG|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
218933859|NCT00487461|DRUG|Placebo|Placebo tablet
218933860|NCT00487461|DRUG|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
218933861|NCT06821178|BEHAVIORAL|Acute stress manipulation|Youth will be randomly assigned to the HS (high stress) or LS (low stress) TSST-M condition. The objective activities will be identical in the HS and LS conditions but the context will vary. The HS condition will be highly evaluative. The researcher will tell youth that they are being videotaped in order to code their behaviors later. The observers will maintain neutral expressions, provide instructions in a neutral tone, and avoid eye contact. In the LS condition, evaluative components are removed \[31, 53\]. Observers will be introduced as new, and the videotaping will be explained as a check to ensure that the observers follow instructions. The observers will appear disorganized while giving instructions, smile, and maintain an open body posture and eye contact.
218933862|NCT06609499|DEVICE|Flexible-tip Bougie|The device is used for intubation and then the manikin is ventilated
218933863|NCT06609499|DEVICE|Gum-elastic Bougie|The device is used for intubation and then the manikin is ventilated
218933864|NCT06855277|DRUG|AAA817|AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.
218933865|NCT06855277|DRUG|ARPI|Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.
219045560|NCT07034976|DEVICE|Sham Radiofrequency (Capenergy C500 UpGrade C200 - Placebo Mode)|"Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated delivered energy value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health."
219543430|NCT01094054|PROCEDURE|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
219543431|NCT01094054|BEHAVIORAL|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
219543432|NCT02464657|DRUG|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
219543433|NCT02464657|DRUG|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
219543434|NCT02464657|DRUG|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
218933866|NCT06855277|DRUG|Standard of Care|Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel.
218933867|NCT06601790|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
218933868|NCT06601790|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
218933869|NCT05767749|DRUG|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
219543435|NCT02464657|DRUG|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
219543436|NCT02464657|DRUG|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
219543437|NCT00287131|PROCEDURE|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
219543438|NCT06499844|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
219543439|NCT05331534|BEHAVIORAL|Eye-tracking assisted attention control training (ACTo)|"ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement."
219543440|NCT05331534|BEHAVIORAL|Attention control training (ACT)|Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
219543441|NCT06230094|OTHER|moderate intensity|Arm Circles, Leg Swings, Lunges, brisk walk
219543442|NCT06230094|OTHER|high intensity|Arm circles, Leg swings, Lunges, skipping rope
219543443|NCT04322344|DRUG|Escin|treatment with escin or escinate sodium
219543444|NCT04322344|DRUG|standard therapy|antiviral drugs
218933870|NCT05767749|DRUG|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
218933871|NCT05767749|DRUG|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
218933872|NCT02968212|DRUG|Clofazimine|All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
218933873|NCT02968212|OTHER|sugar pill|All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
218933874|NCT00563472|DRUG|estetrol|10 mg orally per day for 28 days
219045561|NCT07030894|DRUG|"Nefecon®,Ambrisentan"|"Subjects who meet the screening criteria will be treated with Budesonide in combination with Ambrisentan.~Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally. Ambrisentan , 5mg/d for 36 weeks, taken orally."
219045562|NCT06876779|BEHAVIORAL|VR intervention|The intervention comprises six sessions of 60 minutes each. There are six VR scenarios such as a café, MTR, school scene, and classroom. The difficulty levels of these scenarios are determined by several factors: (1) the density and proximity of individuals present, as observed in a café or MTR setting, (2) the presence of familiar individuals, such as acquaintances or classmates who may be encountered and greeted in a school environment, and (3) the level of interaction required, such as engaging in a group discussion within a classroom. Participants have the flexibility to choose a different scenario for each session or repeat a previously selected one.
219543445|NCT05464186|BEHAVIORAL|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
218933875|NCT00563472|DRUG|estetrol|20 mg orally per day for 28 days
218933876|NCT00563472|DRUG|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
218933877|NCT00563472|DRUG|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
218933878|NCT02141828|DRUG|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
218933879|NCT06611956|OTHER|No intervention (observational study)|No intervention (observational study)
219543446|NCT05464186|BEHAVIORAL|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
219621698|NCT03482973|DRUG|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
219621699|NCT03482973|OTHER|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
219621700|NCT05008874|OTHER|Natural History Observation|Data collection on progression of disease
218933880|NCT04756232|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
218933881|NCT04756232|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
219045563|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
219045564|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
219045565|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
219543447|NCT04786496|BEHAVIORAL|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
219543448|NCT04786496|BEHAVIORAL|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
219543449|NCT04786496|BEHAVIORAL|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
219543450|NCT04379739|DRUG|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
219543451|NCT01429363|PROCEDURE|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
219543452|NCT04537663|DRUG|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
219543453|NCT04537663|DRUG|Placebo|Intradermal injection of sterile 0.9% NaCl.
219543454|NCT02222064|BEHAVIORAL|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
219543455|NCT04710290|DIETARY_SUPPLEMENT|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
219543456|NCT04710290|DIETARY_SUPPLEMENT|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
219543457|NCT04710290|DIETARY_SUPPLEMENT|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
219543458|NCT04710290|DIETARY_SUPPLEMENT|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
219543459|NCT02853643|DRUG|ASN002|Single dose study with food effect
219543460|NCT02937935|BIOLOGICAL|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
219543461|NCT02937935|BIOLOGICAL|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
219543462|NCT01808651|DRUG|Fluoxetine|Administered orally
219543463|NCT00644137|DRUG|pregabalin|Help stop smoking
219543464|NCT00644137|OTHER|cigarettes|help stop smoking with study medication
219543465|NCT00932763|DRUG|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
219543466|NCT00932763|DRUG|Norvasc|10 mg dose (Pfizer, USA)
219543467|NCT06219031|OTHER|no intervention|no intervention
219543468|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
219543469|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
219543470|NCT01028586|DRUG|Placebo|matching placebo tablets
219543471|NCT02488239|DEVICE|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
219543472|NCT04854460|DRUG|Revemact|1 tablet contains 6 mg Ivermecin
219543473|NCT04854460|DRUG|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
219543474|NCT04854460|DRUG|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
219621701|NCT03666273|DRUG|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
219621702|NCT03666273|DRUG|Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
219621703|NCT07055594|DRUG|SOA101|Participants will receive SOA101. The RP2D will be determined based on the results of the Phase I study. During the dose expansion phase, participants will receive SOA101 at the RP2D regimen.
219045566|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
219045567|NCT06749964|BEHAVIORAL|Internet-delivered, therapist-assisted, pain-focused CBT based on the psychological flexibility model for chronic pain|8-session intervention, twice weekly for the first 3 weeks and once weekly for the final 2 weeks (45-60 min each session) aimed at promoting psychological flexibility. Treatment involves a mixture of video and audiotaped presentations and homework activities for the participant.
219543475|NCT05297227|PROCEDURE|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
219543476|NCT05031260|DEVICE|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
219543477|NCT03283982|DEVICE|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
219543478|NCT03283982|DEVICE|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
219543479|NCT04254198|BEHAVIORAL|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
219543480|NCT04254198|BEHAVIORAL|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
219543481|NCT06141486|DRUG|Frexalimab|SAR441344 Solution for IV infusion
219543482|NCT06141486|DRUG|Placebo|Solution for IV infusion
218933882|NCT06591338|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
218933883|NCT06591338|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
218933884|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
218933885|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
218933886|NCT07001943|OTHER|enteral nutrition|We'll use an enteral nutrition intervention with intact protein formulations. Initiate nasogastric tube feeding at 20ml/h and continue for 24 hours. Adjust feeding strategies based on patients' SMA blood flow reactivity.
218933887|NCT04708067|DRUG|Bintrafusp Alfa|Given IV
218933888|NCT04708067|PROCEDURE|Biopsy|Undergo biopsy
218933889|NCT04708067|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
218933890|NCT07007182|DRUG|SOX regimen|"The SOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral S-1 (tegafur/gimeracil/oteracil) 40-60 mg twice daily, taken on days 1-14 followed by 7 days off, in a 21-day cycle.~Experimental arm: 3 cycles before surgery, 5 cycles after surgery. Control arm: up to 8 cycles as standard systemic therapy."
218933891|NCT07007182|DRUG|CAPEOX regimen|"The CAPEOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral capecitabine 1000 mg/m² twice daily on days 1-14, repeated every 3 weeks (q3w), up to 8 cycles.~Used as a standard chemotherapy option in the control arm, with or without PD-1 inhibitor according to PD-L1 CPS score."
219045568|NCT00323154|DRUG|Nalbuphine|
219045569|NCT06545955|DRUG|Nadofaragene Firadenovec|vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
219543483|NCT06141486|DRUG|MRI contrast-enhancing agents|IV, as per respective label
219045570|NCT06545955|DRUG|Gemcitabine|Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
219543484|NCT04325659|DEVICE|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
219543485|NCT04325659|DRUG|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
219045571|NCT06545955|DRUG|Docetaxel|Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
219045572|NCT06545955|DRUG|Pembrolizumab|Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
219045573|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
218933892|NCT07007182|DRUG|PD-1 inhibitor|"A PD-1 inhibitor is administered intravenously at a fixed dose of 200 mg every 3 weeks.~It is combined with SOX in the experimental arm (CPS ≥1 patients) during conversion and adjuvant phases, and with CAPEOX or SOX in the control arm (CPS ≥1 patients).~Maintenance PD-1 inhibitor continues for up to 1 year or until disease progression or unacceptable toxicity."
219045574|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
218933893|NCT07007182|RADIATION|Para-aortic lymph node radiotherapy (IMRT to station 16)|"Intensity-modulated radiotherapy (IMRT) is delivered postoperatively to the para-aortic (station 16) nodal basin.~Elective nodal basin: 45-50 Gy in 25 fractions Positive nodes: 56-60 Gy in 25 fractions Radiotherapy is given concurrently with oral capecitabine or S-1 as radiosensitizers."
218933894|NCT07007182|DRUG|Capecitabine / S-1 (radiosensitizer during IMRT)|"During para-aortic IMRT, patients receive concurrent oral capecitabine 825 mg/m² twice daily on radiation days, or oral S-1 dosed according to body surface area.~These agents are used as radiosensitizers during postoperative radiotherapy."
219543486|NCT04325659|DRUG|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
219543487|NCT04325659|DEVICE|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
219543488|NCT06426225|OTHER|General Anesthesia|General Anesthesia Applied Group 2 Patients.
219543489|NCT06426225|OTHER|Spinal Aneshtesia|Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
219543490|NCT06559657|DEVICE|eKare Insight, imitoMeasure Mobile App, Visitrak|The wound size of the patients was measured with three different methods. Wound depth was measured using manual method and three-dimensional imaging devices.
219543491|NCT03130335|PROCEDURE|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
218933895|NCT05002218|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
218933896|NCT05002218|BEHAVIORAL|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
218933897|NCT06868537|BEHAVIORAL|Launching! to adulthood group therapy|Participants will be in a 12-week therapy program that includes weekly group sessions and individual coaching.
218933898|NCT06868537|BEHAVIORAL|standard of care|Participants will receive a list of resources
218933899|NCT06619080|DRUG|Genicular nerve block with bupivacaine and corticosteroids|"\- GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
218933900|NCT06619080|DRUG|Genicular nerve block with bupivacaine|"\- GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
219621704|NCT07057999|BEHAVIORAL|MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay)|The MIND diet consists of 15 components. While the first 10 of the components are considered healthy for the brain, the last 5 are considered unhealthy. The MIND diet portion and consumption frequency recommendations are as follows; olive oil consumption ≥ 48 g/day; oil seeds and nuts ≥ 5 servings/week; green leafy vegetables ≥1 serving/day; cooked vegetables ≥1 serving/day; whole grains ≥3 servings/day; legumes 3 servings/week; red fruits such as blueberries and strawberries ≥2 servings/week; poultry ≥2 servings/week; fish and seafood ≥1 serving week; red wine 1 glass/day; red meat ≤4 servings/week; butter ≤10 g/day; bakery products \<5 servings/week; fast food \<1 serving/week. Patients assigned to this group will be given a diet program based on isocaloric, MIND diet principles, which they will be asked to follow for 12 weeks.
219621705|NCT07057999|BEHAVIORAL|Traditional healthy nutrition program specific to Turkey|There are no prohibited foods in the traditional Türkiye-specific nutrition recommendations included in the TÜBER 2022 report, but there are foods that are recommended to be restricted or increased. According to the healthy nutrition program, 3 portions/day from the milk and dairy products (milk, yogurt, kefir, cheese) group; 2.5-3 portions/day from the meat, chicken, fish, eggs, legumes, oilseeds and nuts group; 2.5-4 portions/day from the vegetable group; 2-3 portions/day from the fruit group; 3-7 portions/day from the bread and cereal group; 3-4 portions/day from the fat group and finally, simple sugar consumption is recommended as a maximum of 10% of total energy. An isocaloric diet will be prepared according to the body composition and eating habits of the patients and they will be asked to follow it for 12 weeks.
218933901|NCT06619080|DRUG|Genicular nerve block with saline|"\- GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
219621706|NCT04401215|BEHAVIORAL|Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)|This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
219543492|NCT03130335|BIOLOGICAL|BMA|Bone marrow will be aspirated from the iliac crest.
219543493|NCT03702218|DRUG|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
219543494|NCT02589366|DRUG|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
219543495|NCT04690985|BEHAVIORAL|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
219543496|NCT04690985|OTHER|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
218933902|NCT06874439|OTHER|WHO QualityRights program|"The WHO's QualityRights program involves an assessment, called observation, of mental health care services by an ephemeral multidisciplinary team, which provides feedback and recommendations for improving care practices. The observation team, trained in the QualityRights (QR) methodology, includes mental health professionals, researchers, legal experts, and management staff from mental health organizations. Each team always incorporates at least one expert by experience and one informal caregiver or family member. Participation in the program is voluntary and initiated at the request of healthcare facilities.~The observation is structured into three stages:~1. Site preparation~2. On-site observation~3. Restitution of observation report and follow-up"
218933906|NCT07037238|DRUG|Everolimus 10mg daily|An oral mTOR inhibitor
218933907|NCT06705686|DRUG|(R)-9bMS|(R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
218933908|NCT07042100|BIOLOGICAL|Dose level (DL)1|Administered IV every 3 weeks
218933909|NCT07042100|BIOLOGICAL|DL2|Administered IV every 3 weeks
218933910|NCT07042100|BIOLOGICAL|DL3|Administered IV every 3 weeks
219543497|NCT00759317|DRUG|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
219543498|NCT04528784|DEVICE|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
219543499|NCT00038363|PROCEDURE|Rehabilitation|
219543500|NCT00038363|PROCEDURE|Subacute care|
219543501|NCT01644253|BIOLOGICAL|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
219543502|NCT01644253|BIOLOGICAL|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
219543503|NCT01644253|BIOLOGICAL|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
219543504|NCT01644253|BIOLOGICAL|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
219543505|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
219543506|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
219543507|NCT02889380|DRUG|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
219543508|NCT04012892|COMBINATION_PRODUCT|CD19 CART|CD19 CART
219543509|NCT03429361|OTHER|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
219543510|NCT03313323|BIOLOGICAL|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
219543511|NCT04537481|OTHER|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
219543512|NCT03621995|OTHER|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
218933911|NCT07042100|BIOLOGICAL|DL4|Administered IV every 3 weeks
219543513|NCT06012812|DRUG|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
218933912|NCT07042100|BIOLOGICAL|DL5|Administered IV every 3 weeks
218933913|NCT06721507|DRUG|tirzepatide|Participants will be educated on dietary and lifestyle changes. Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary. Dose escalation will proceed per package directions if instructed by study team at follow up visits.
218933914|NCT06721507|BEHAVIORAL|Standard of Care|Participants will be educated on dietary and lifestyle changes
218933915|NCT07038356|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
219543514|NCT03352362|DRUG|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
219543515|NCT03352362|DRUG|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
219543516|NCT03352362|DRUG|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
218933916|NCT07038356|DRUG|Placebo|Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
218933917|NCT06369233|DEVICE|MegaShield®-SP|MegaShield®-SP application Lumbar discectomy or laminectomy
218933918|NCT06369233|DEVICE|Guardix-SP Plus|Guardix-SP Plus application Lumbar discectomy or laminectomy
218933919|NCT04962412|OTHER|"Standard care bundle"|"The management for AKI patients were performed by implementing a standard care bundle suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline."
219543517|NCT00700739|DEVICE|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
219543518|NCT00700739|DEVICE|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
219543519|NCT06394973|DRUG|T4090 0.2%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
219543520|NCT06394973|DRUG|T4090 0.3%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
219543521|NCT06394973|DRUG|Rhopressa®|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
219543522|NCT04828616|DRUG|DP303c injection|DP303c injection, every 3 weeks (Q3W)
219543523|NCT03552003|OTHER|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
219543524|NCT00532077|DRUG|rhPTH(1-34)|
219543525|NCT00532077|DRUG|SB-751689 100 mg|
219045575|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
219045576|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
219045577|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
219045578|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
219045579|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
219045580|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
219045581|NCT02520024|BEHAVIORAL|self-directed care|
219045582|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
219045583|NCT04453852|BIOLOGICAL|Saline|Saline control
219045584|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
219045585|NCT01167712|BIOLOGICAL|Bevacizumab|Given IV
219045586|NCT01167712|DRUG|Carboplatin|Given IV
219045587|NCT01167712|PROCEDURE|Computed Tomography|Correlative studies
219045588|NCT01167712|DRUG|Paclitaxel|Given IV
219045589|NCT01167712|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219045590|NCT03633396|BIOLOGICAL|Imsidolimab|Administered by subcutaneous injection once a month
219045591|NCT03633396|DRUG|Placebo|Administered by subcutaneous injection once a month
219045592|NCT01012817|OTHER|Laboratory Biomarker Analysis|Correlative studies
219045593|NCT01012817|OTHER|Pharmacogenomic Study|Correlative studies
219045594|NCT01012817|OTHER|Pharmacological Study|Correlative studies
219045595|NCT01012817|DRUG|Topotecan Hydrochloride|Given IV
219045596|NCT01012817|DRUG|Veliparib|Given PO
219045597|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
219045598|NCT05683171|DRUG|Rituximab|Given by IV (vein)
219045599|NCT05683171|DRUG|Lenalidomide|Given by PO
219045600|NCT05683171|DRUG|Valemetostat|Given by PO
219045601|NCT05797792|DRUG|Intraarterial alteplase|See arm/group descriptions.
219045602|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
219543526|NCT00532077|DRUG|SB-751689 400 mg|
219543527|NCT05990127|DRUG|AK104|AK104 IV, q3w
219543528|NCT05990127|DRUG|Tislelizumab|Tislelizumab IV, q3w
219543529|NCT05990127|DRUG|carboplatin|carboplatin IV, q3w
219543530|NCT05990127|DRUG|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
219543531|NCT05990127|DRUG|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
219543532|NCT01299662|DRUG|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
219543533|NCT01426568|BEHAVIORAL|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
219543534|NCT02336074|DRUG|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
219621707|NCT06424197|OTHER|Racial group-targeted messages|Colorectal cancer screening messages targeted towards participants racial group.
218933920|NCT06887634|OTHER|Rebozo and Maternal Procedures|"Combination of FLI and side-lying release SLR and Rebozo technique in a pre-specified order:~1\) FLI for 30 seconds repeated for 3 subconsequent contractions; 2) SLR for 30 seconds repeated for 3 consequent contractions; 3) Rest with free maternal postures for 15 minutes; 4) 15 minutes of Rebozo on maternal pelvis (women on hands and knees); 5) Rest with free maternal postures for 15 minutes; 6) 15 minutes of Rebozo on the side of the fetal spine (supine women).~Duration of the intervention ranges between 90 and 105 minutes. The intervention will start within thirty minutes after randomization; it can be interrupted at any time if needed. It will be considered performed when the proposed sequence is completed. After completion of the sequence, women will be allowed to move freely and adopt different postures. No FLI or SLR procedures or the Rebozo technique will be further allowed until sonographic assessment of the fetal head is performed at 3 hour and thirty after randomization"
218933921|NCT06887634|OTHER|Control|Standard of care, including upright, semi-recumbent, lateral recumbent, and hands-and-knees position. They will not receive forward-leaning inversion (FLI) and side-lying release (SLR) and Rebozo technique. the control group will continue to adopt maternal postures with no possibility of performing the FLI or SLR procedures or the Rebozo technique until sonographic assessment of fetal head position is completed at 3 hours and thirty after randomization.
219045603|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
219045604|NCT05592912|DRUG|HydroLenz Injection|The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
219045605|NCT05592912|OTHER|No HydroLenz Injection|No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
219543535|NCT02336074|DRUG|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
219543536|NCT02336074|DRUG|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
219045606|NCT04581460|OTHER|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
219543537|NCT02336074|BIOLOGICAL|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
219543538|NCT02336074|BIOLOGICAL|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
219543539|NCT05129176|DRUG|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
219543540|NCT05129176|DRUG|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
219543541|NCT04548141|OTHER|Questionnaire|Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
219543542|NCT02679729|DRUG|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
219543543|NCT02679729|DRUG|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
219543544|NCT02679729|OTHER|Placebo|inactive substance
219543545|NCT05213663|OTHER|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
219543546|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
219543547|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
219543548|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
219543549|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
219543550|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
219543551|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
219543552|NCT00111787|DRUG|Lapatinib|Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
219543553|NCT00111787|DRUG|Paclitaxel|Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
219543554|NCT01246687|BEHAVIORAL|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
219543555|NCT00284518|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
219543556|NCT00284518|DRUG|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
219543557|NCT05475964|DEVICE|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
219543558|NCT03488108|OTHER|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
219543559|NCT03488108|DRUG|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
219543560|NCT06322485|BEHAVIORAL|Internet-based self-management intervention|An internet-based cognitive-behavioral therapy with six modules.
218933922|NCT07048041|OTHER|Functional Assessment Battery|Participants completed a series of validated patient-reported outcome questionnaires (Oxford Hip Score, WOMAC, SF-12) and physical performance tests (Timed Up and Go, Four Square Step Test, 4-Meter Gait Speed Test) during a single outpatient assessment session. No therapeutic or invasive interventions were performed.
218933923|NCT06053684|DEVICE|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
218933924|NCT06053684|DEVICE|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
218933925|NCT06727500|BEHAVIORAL|HIIT plus plyometric training|"The HIIT plus plyometric training will perform two weeks of exercise adaptation involving 25 minutes of MICT at 65% of maximal heart rate (HRmax) and 5 minutes of jumps in place at 5 - 6 of the EPinfant scale of Perceived exertion. The HIIT plus plyometric training will perform 15 minutes of HIIT and 5 minutes of jumps each session. The HIIT phase will be performed in a work recovery intensity at 85 and 50% of the HRmax. The work phase of jumps will be performed all out, and the recovery phase will be performed at 5 - 6 of the EPinfant scale of perceived exertion. The work: recovery bouts will be progressed from 1:4 (15 seconds: 60 seconds) at weeks 3-6, to 1:3 (15 seconds: 45 seconds) at weeks 7-9, and to 1:3 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured."
219621708|NCT06424197|OTHER|Explicit Commitment|Indicate explicit commitment to return at home screening kit.
219621709|NCT06762873|DIAGNOSTIC_TEST|Drug Induced Sleep Endoscopy with PNS|Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.
219621710|NCT01184430|DEVICE|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
219621711|NCT01597973|DRUG|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
219621712|NCT01597973|DRUG|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
219621713|NCT01414673|DRUG|HCG|5000 IU
219621714|NCT00333294|DRUG|Gefitinib|
219621715|NCT00333294|PROCEDURE|Radiation therapy|
219621716|NCT00333294|DRUG|Cisplatin|
219621717|NCT00333294|DRUG|Vinorelbine|
219621718|NCT03499444|DRUG|Rucaparib|Rucaparib will be administered twice daily
219045607|NCT05991037|BIOLOGICAL|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
219045608|NCT06771128|DRUG|Ginkgo Biloba oral tablet|patients receive Ginkgo Biloba oral tablet 120 mg once daily
219543561|NCT03774537|DRUG|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
219543562|NCT03774537|DRUG|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
219543563|NCT06185088|DEVICE|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
219543564|NCT06185088|DEVICE|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
219543565|NCT01450592|OTHER|No drug|Diabetic Population
219621719|NCT06058819|DIAGNOSTIC_TEST|Newborns suspected of Infections|This study will include NICU newborns of at least 7 days of life with suggestive signs of neonatal sepsis. The results will be extrapolated to this same population.
219621720|NCT02166567|PROCEDURE|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
219621721|NCT02166567|PROCEDURE|Swim-up|Semen processing will be carried out with the conventional swim-up method.
219045609|NCT06771128|DRUG|Desmopressin Acetate 0.2 mg Tablets|patient receives desmopressin 0.2 mg oral tablet once daily
219045610|NCT06771128|DRUG|Placebo|patients receive Placebo oral tablet once daily
219045611|NCT05492773|DEVICE|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
219045612|NCT05492773|DEVICE|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
219045613|NCT06109870|BEHAVIORAL|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
219045614|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
219045615|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
219045616|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
218933926|NCT06727500|BEHAVIORAL|HIIT|The HIIT group will perform two weeks of exercise adaptation involving 30 minutes of moderate-intensity continuous training (MICT) at 65% of the maximal heart rate (HRmax) reached in the maximal oxygen consumption test. The HIIT group will perform 20 minutes of HIIT each session, with a work: recovery intensity at 85% and 50% of HRmax, respectively. The work: recovery bouts will be progressed from 1:4 (15 seconds:60 seconds) at weeks 3-6, to 1:3 (15 seconds:45 seconds) at weeks 7-9, and to 1:2 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured.
219543566|NCT01450592|OTHER|No drug|Non-Diabetic Population
219543567|NCT00752466|DRUG|Topiramate; flunarizine|
219543568|NCT05412576|DRUG|Lidocaine Hydrochloride 2% Injection Solution|Injectable
219543569|NCT05412576|DRUG|0.9% NaCl|Injectable
219543570|NCT02348281|DRUG|Bicalutamide|150mg, po, qd, d1-28
219543571|NCT05108467|DIAGNOSTIC_TEST|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
219543572|NCT01619241|OTHER|PET/CT|F-18 FLT PET/CT
219543573|NCT03810703|DRUG|Placebo oral capsule|Placebo oral capsule
219543574|NCT03810703|DRUG|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
219543575|NCT03810703|DRUG|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
218933927|NCT03516617|DRUG|Acalabrutinib|Given PO
219045617|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
219543576|NCT03530852|DEVICE|Relizorb|Tube feeds run across device to digest fats.
219045618|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
219045619|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
219543577|NCT06558942|DEVICE|incisional negative pressure wound technology|Negative pressure device used directly on closed or sutured incisions
219621722|NCT06410482|PROCEDURE|US guided caudal block|"After placing the patient in the left lateral position (hips and knees flexed) following monitoring and induction of anaesthesia, the field will be sterilized with 70% alcohol in 2% chlorhexidine.~Initial scanning in the transverse plane allows for visualization of the midline and identification of the sacrococcygeal ligament between the 2 sacral cornua. The 2 cornua resemble the 2 eyes of a frog and thus are collectively called the frog-eye sign. The US probe is then rotated 90 degrees to acquire a longitudinal view. The needle is then advanced at a 20-degree angle with needle tip and length visualization Once the needle is confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood.~A slow injection of the local anaesthetic can then be performed, dose of (0.2 mL/kg 0.25% bupivacaine and 1 μg/kg of dexmedetomidine"
219543578|NCT00748722|DEVICE|CT Angiography|Injection of contrast material (iodine)
219543579|NCT00429481|BIOLOGICAL|Rotarix|
219543580|NCT02632968|PROCEDURE|Pinhole surgery with and without buttons|
219543581|NCT03602339|DRUG|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
219543582|NCT03602339|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
218933928|NCT03516617|OTHER|Laboratory Biomarker Analysis|Correlative studies
219045620|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
219045621|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
219045622|NCT04661124|DEVICE|SPECTRALIS|ophthalmic imaging device with head and chinrest
219543583|NCT02946424|DRUG|Placebo Oral Capsule|12 month course of daily placebo
219543584|NCT02946424|DRUG|Simvastatin|12 month course of daily simvastatin
219543585|NCT00006258|BIOLOGICAL|filgrastim|
219543586|NCT00006258|DRUG|cisplatin|
219543587|NCT00006258|DRUG|cyclophosphamide|
219543588|NCT00006258|DRUG|etoposide|
219543589|NCT00006258|DRUG|methotrexate|
219543590|NCT00006258|DRUG|vincristine sulfate|
219543591|NCT00006258|PROCEDURE|adjuvant therapy|
219543592|NCT00006258|RADIATION|radiation therapy|
218933929|NCT03516617|BIOLOGICAL|Obinutuzumab|Given IV
218933930|NCT03516617|OTHER|Patient Observation|Undergo observation
218933931|NCT03516617|OTHER|Quality-of-Life Assessment|Ancillary studies
218933932|NCT05603312|GENETIC|AAV-GAD Low Dose|Bilateral infusion of AAV-GAD low dose
218933933|NCT05603312|GENETIC|AAV-GAD High Dose|Bilateral infusion of AAV-GAD high dose
218933934|NCT05603312|PROCEDURE|Sham Surgery|Sham infusion
219045623|NCT04661124|DEVICE|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
219543593|NCT04366635|PROCEDURE|Impacted third molar surgery|Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
219543594|NCT04366635|PROCEDURE|Application of mineralised plasmatic matrix|After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
219543595|NCT04366635|PROCEDURE|Application of β-tricalcium phosphate|After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
218933935|NCT05289947|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
218933936|NCT05289947|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
219045624|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. It includes first an intermittent theta burst (iTBS) protocol at a frequency of 5 Hz with 1800 pulses to the left DLPFC at 90% motor threshold, followed by a continuous theta burst (cTBS) protocol at a frequency of 5 Hz with 600 pulses to the right DLPFC at 80% motor threshold.
219543596|NCT04600635|PROCEDURE|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
219543597|NCT01901783|PROCEDURE|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
219543598|NCT01901783|PROCEDURE|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
219543599|NCT00395980|DEVICE|surgical table pressure mat|
219543600|NCT02316054|DEVICE|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
219543601|NCT05187208|DRUG|Niraparib|"Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
219543602|NCT02849093|OTHER|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
219543603|NCT02543632|DEVICE|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
219543604|NCT06625502|BEHAVIORAL|Culturally-Affirming Racial Equity Framework|The CARE framework is a process-focused, protocol- based, and modular approach to promote mental health equity. It focuses on cultivating the therapeutic alliance across patient-provider differences in the first 3-4 treatment sessions, the critical window for engaging patients in care. Target processes include transparent communication, client-centeredness, client activation, and an affirming and comprehensive approach to assessment and treatment planning. Case conceptualization and treatment planning is collaborative, and guided by the individual clinician based on evidence-based treatments. The therapist receives ongoing biweekly supervision in Alliance-Focused Training and consultation sessions with a group-specific expert.
219543605|NCT05852626|OTHER|Redistribution of diabetes care between nurses and physicians|It will be proposed that nurses and physician share the clinical care of patients with type 2 diabetes, with complementing actions
219543606|NCT05852626|OTHER|Individualized glycemic target|Define the target of individualized glycemic treatment for patients with the support of a tool on the website, which will encourage the intensification and de-intensification of treatment when appropriate
219543607|NCT05852626|OTHER|Minimum care recomendations|It will be proposed to carry out the minimum necessary assessments that, annually, nurses and physicians must do to ensure the adequacy of quality indicators in the care of diabetes in the PHC
219543608|NCT05852626|OTHER|No intervention|Primary care health teams will follow their rotine care of type 2 diabetes
219543609|NCT04231422|COMBINATION_PRODUCT|Platelet-rich plasma|12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
219621723|NCT06410482|PROCEDURE|Dorsal penile nerve block|"after general anesthesia induction. With the patient in the supine position. After skin sterilization the US linear probe will be transversely placed on the root of the penis. After placing the penis in gentle traction, a50 mm block needle will be inserted from the lateral part of the penis root towards the dorsal section of the penis with the in-plane technique, It will be advanced through Dartos fascia until resistance to the needle disappeared.~Once the superficial sheath will be passed, the tip of the needle will be advanced into Buck's fascia and then positioned between Buck's fascia and tunica albuginea, lateral to the dorsal artery. After making sure there will be no blood with negative aspiration, half of the total 0.2 mL/kg dose of 0.25% bupivacaine will be administered while observing its distribution with US. The same procedure will be then repeated on the other side of the penis."
219621724|NCT01573182|BIOLOGICAL|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
218933937|NCT06739941|OTHER|Oat fiber (BG-OS)|Beta-glucan oligosaccharide (BG-OS) is beta-glucan predominant, dietary fiber obtained by extracting oat fiber from oat grain and applying a food-grade depolymerization process to shorten the polysaccharide chain length of the fiber. BG-OS retains the fiber structure of oat fiber but has a shorter chain length, which makes it water soluble and easily formulated into any food.
218933938|NCT06743243|DRUG|Tegoprazan|Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.
218933939|NCT06743243|DRUG|Famotidine|Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
218933940|NCT06743243|DRUG|Placebo|Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.
218933941|NCT07053826|DEVICE|Penile Traction Device|Patients will be randomized into one of two groups: penile traction therapy 30 min 3x/day x 3 months, or control (no treatment). Preoperative erectile function surveys will be recorded in the EMR per standard of care. Following randomization, patients allocated to the treatment arm will be instructed how to use the device properly. Patients in the treatment arm will record a daily journal of use of the device (Appendix 1). After a minimum of 3 months, patients in the treatment arm will return for their scheduled procedure. Control arm patients will be scheduled directly for an OR date.
219543610|NCT00613145|DRUG|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
219543611|NCT00613145|DRUG|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
219543612|NCT03087747|PROCEDURE|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
219543613|NCT02723721|DRUG|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
219543614|NCT03379883|PROCEDURE|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V"
219543615|NCT03379883|PROCEDURE|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
219543616|NCT04254718|BEHAVIORAL|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
219543617|NCT01658774|DRUG|Albendazole|Single 400mg dose
218933942|NCT07053826|PROCEDURE|Inflatable Penile Prosthesis Implantation|Implantation of a three-component inflatable penile prosthesis.
218933943|NCT05372354|DRUG|CC-92480|Specified dose on specified days
218933944|NCT05372354|DRUG|Tazemetostat|Specified dose on specified days
218933945|NCT05372354|DRUG|BMS-986158|Specified dose on specified days
218933946|NCT05372354|DRUG|Trametinib|Specified dose on specified days
218933947|NCT05372354|DRUG|Dexamethasone|Specified dose on specified days
218933948|NCT07055438|PROCEDURE|Ultrasound guided Rectus sheath block|After receiving general anesthesia, bilateral ultrasound guided rectus sheath block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
218933949|NCT07055438|PROCEDURE|ultrasound guided external oblique intercostal plane block|After receiving general anesthesia, bilateral ultrasound guided external oblique intercostal plane block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
218933950|NCT07057908|PROCEDURE|Video Laryngoscope Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngoscope under general anesthesia. After induction, a standard bougie will be advanced through the vocal cords under video guidance, and the endotracheal tube will be railroaded over the bougie into the trachea.~The primary outcome will be intubation time, measured from insertion of the device until confirmation of successful tracheal intubation. Additional parameters such as intubation success rate, ease of insertion, and complications (e.g., desaturation, airway trauma, failed attempts) will also be recorded. No extra procedures will be performed beyond routine airway management."
219045625|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. One session will consist of a high frequency (5 Hz) intermittent theta burst (iTBS) of 1800 pulses at 90% motor threshold to the left DLPFC followed by a pseudo continuous theta burst (cTBS) of 600 pulses at 5 Hz frequency at 80% motor threshold to the right DLPFC. The sham cTBS treatment will be applied by placing the coil at a 45-degree angle to the application site.
219045626|NCT05825469|BEHAVIORAL|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
219543618|NCT01658774|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C
219543619|NCT04666116|DIETARY_SUPPLEMENT|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
219543620|NCT02951247|DEVICE|Hearing Aid|Successor of Phonak Virto V90-10 NW O
219543621|NCT03342339|OTHER|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
219543622|NCT03342339|OTHER|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
219543623|NCT03342339|OTHER|Iowa Gambling Task|Test of Iowa Gambling Task
219543624|NCT01885949|DRUG|Tivozanib|Oral
219543625|NCT01885949|DRUG|Enzalutamide|oral
219543626|NCT04827394|DEVICE|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
219543627|NCT04827394|DEVICE|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
219543628|NCT07025954|PROCEDURE|Cesarean delivery|"All patients were delivered via cesarean section with standardized perioperative management, including preoperative preparation (e.g., autologous bloodreserve, corticosteroid administration for foetal lungmaturation, etc.), surgical approach, and postoperative care.~Conservative management (intentional placental retention in situ with local resection and pelvic devascularization) was primarily employed, while peripartum hysterectomy was reserved for those with extensive invasion or failed conservative treatment."
218933951|NCT07057908|PROCEDURE|Video Laryngeal Mask Airway (SaCoVLM) Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngeal mask airway (SaCoVLM) under general anesthesia. After successful placement of the device, a standard bougie will be inserted through the SaCoVLM's dedicated lumen, and an endotracheal tube will be advanced over the bougie into the trachea under video guidance.~The primary outcome will be intubation time, defined as the duration from device insertion to confirmation of successful intubation. Secondary outcomes include intubation success rate, ease of insertion, and complications such as desaturation, trauma, or failed attempts. As both techniques are part of routine practice, no additional risks will be introduced."
219045627|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
219543629|NCT07027306|PROCEDURE|Posterior stabilization (pedicle screws)|"* Any other type of solely vertebral augmentation (stents, etc.), specify~* Posterior stabilization (pedicle screws)~* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with screw augmentation~* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)~* Combined posterior and anterior stabilization"
219543630|NCT03786172|BEHAVIORAL|Smoking cessation Intervention|"* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
219045628|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
219045629|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219543631|NCT03786172|BEHAVIORAL|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
219543632|NCT05047536|DRUG|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
219543633|NCT00834275|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
219543634|NCT00834275|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
219543635|NCT05680935|DIAGNOSTIC_TEST|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
219543636|NCT05680935|DIAGNOSTIC_TEST|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
219543637|NCT05680935|DIAGNOSTIC_TEST|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
219543638|NCT05680935|DIAGNOSTIC_TEST|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
219543639|NCT06891313|DEVICE|Piezo Surgery.|Using bone cutting inserts.
219543640|NCT06891313|PROCEDURE|Bone Discs|Selected bone discs diameters mounted on contra angled hand piece and external irrigation hand piece at gear ratio 1:1.
219543641|NCT03100019|DIETARY_SUPPLEMENT|Resveratrol|
219543642|NCT03100019|DRUG|Placebo|
219543643|NCT07062315|BEHAVIORAL|Chronotype-matched time-restricted eating|A 12 weeks time-restricted eating intervention that match participants' chronotype
219543644|NCT07062315|BEHAVIORAL|Chronotype-unmatched time-restricted eating|A 12 weeks time-restricted eating intervention that not match participants' chronotype
219543645|NCT07068113|OTHER|DANCE GROUP|home exercise program + 50 min/week brisk walking + 100 min/week dance
219543646|NCT07068113|OTHER|EXERCISE GROUP|home exercise program + 150 min/week brisk walking
219543647|NCT07067996|PROCEDURE|erector spinae plane block|erector spinae plane block will be given as intraoperive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
219543648|NCT07067996|DRUG|Nalbuphine|Nalbuphine will be given as intraopertive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
219543649|NCT07069322|BEHAVIORAL|Richards-Campbell Sleep Questionnaire (RCSQ)|\- Score 0 = Very poor sleep, 100 = Very good sleep
219543650|NCT06089239|OTHER|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
219543651|NCT06089239|OTHER|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
219543652|NCT07067489|BEHAVIORAL|Balneotherapy|Participants receive 20-minute balneotherapy sessions involving full-body immersion in thermal-mineral spring water at a therapeutic spa facility. Sessions are conducted five days per week over a three-week period. Water temperature and mineral content are standardized according to institutional protocols. The intervention is designed to provide analgesic, anti-inflammatory, and muscle-relaxant effects through thermally induced vasodilation and neuromuscular modulation.
219543653|NCT07067489|BEHAVIORAL|Whole-Body Vibration Exercise|"Participants perform whole-body vibration (WBV) exercises using the Compex Winplate platform (Uniphy Elektromedizin GmbH \& CoKG), certified under ISO 9001:2000 and DIN EN ISO 13485:2003. The exercise protocol includes static squats, dynamic squats, bridge exercises, dynamic weight shifting, and toe raises. Vibration is applied at a frequency of 30-40 Hz and amplitude of 2-4 mm for 40-60 seconds per set, with two sets per session and a 3-minute rest between sets. WBV is applied following a standardized exercise program, and the full intervention is delivered five days per week for three weeks."
218933952|NCT07057791|DRUG|Ivonescimab 10 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 10 mg/kg intravenous (IV) on Day 1 followed by carboplatin area under the curve (AUC) 5 IV on Day 1 and etoposide 100 milligrams per square meter (mg/m²) IV on Day 1, 2 and 3 followed by maintenance ivonescimab 10 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
218933953|NCT07057791|DRUG|Ivonescimab 20 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 20 mg/kg IV on Day 1 followed by carboplatin AUC 5 IV on Day 1 and etoposide 100 mg/m² IV on Day 1, 2 and 3 followed by maintenance ivonescimab 20 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
218933954|NCT07051733|BEHAVIORAL|Health Information Literacy Enhancement|"Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows:~1. Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory: ① Strengthening skills related to Health Information Literacy; ② Training on Medication Management Skills; ③ Practice of Self-Monitoring Skills; ④ Education on Diet and Exercise Management Knowledge.~2. Health Behavior Motivation Management Based on the Health Empowerment Theory: ① Personalized Goal Setting; ② Behavioral Incentives and Feedback; ③ Construction of Peer Support Networks; ④ Demonstration Effect of Role Models.~3. Health Management Support System Based on the Health Empowerment Theory: ① Online Dynamic Monitoring; ② Family-Community Collaborative Support; ③ Digital Monitoring Platform; ④ Continuous Supply of Resources."
218933955|NCT07053059|DRUG|Obecabtagene autoleucel|given by Infusion
218933956|NCT07076849|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum 299v|Probiotic
218933957|NCT07076849|OTHER|Placebo Capsule(s)|Placebo control
218933958|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
218933959|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
218933960|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
218933961|NCT07090213|OTHER|Survey using a questionnaire|Eighty women, determined by the number of questions times the rule of 10, will be asked to fill out the Pelvi-Perineal Surgery Sexuality Questionnaire - PPSSQ and Female Sexual Function Index (FSFI) questionnaires and will be asked to fill out the PPSSQ again 7 days later for test-retest reliability.
218933962|NCT06927635|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
218933963|NCT06927635|OTHER|Systemic therapy|Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
218933964|NCT04985565|OTHER|Dietary Intervention|Participate in Mediterranean diet
218933965|NCT04985565|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
218933966|NCT07103382|DIETARY_SUPPLEMENT|Attapulgite|Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.
218933967|NCT07103382|DIETARY_SUPPLEMENT|Placebo|Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.
219205625|NCT06868693|DRUG|Neoadjuvant Chemotherapy (NAT) Group|This cohort includes elderly patients (≥70 years) with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy (NAT). The NAT regimens include 5-FluoroUracil, Irinotecan, Oxaliplatin (FOLFIRINOX), gemcitabine/nab-paclitaxel (GnP), and other standard chemotherapy protocols. The study aims to evaluate the impact of NAT on overall survival (OS), progression-free survival (PFS), R0 resection rates, and postoperative outcomes, as well as the toxicity profile of different NAT regimens.
219205626|NCT04983199|DEVICE|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
219205627|NCT04894864|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
219543654|NCT07068282|DRUG|Cholecalciferol (vitaminD3)|Vitamin D3 mouthwash was prepared for COVID-19 participants, to compare between the saliva only (control group), and with the use of mouthwash in saliva after the participants swish for 60 seconds (experimental group) and compare the effect of vitamin D over the virus in saliva, from both groups by testing via RAT and R-PCR.
218933971|NCT06882317|OTHER|Long Term Follow-Up|No intervention is administered on this study. Subjects who have received CLBR001 autologous CAR-T cells in a primary Calibr treatment trial will be followed long term in line with FDA guidance.
218933972|NCT07132281|BEHAVIORAL|Language activities active inference|Participants will join reading or writing activities and come up with their own inference about wording or plots.
218933973|NCT07132281|BEHAVIORAL|Language activities passive|Participants will join reading or writing activities and will be given step-by-step explanations about the wording and plots.
218933974|NCT07132281|BEHAVIORAL|Board Games|Participants will play board games with each other.
218933975|NCT07141225|PROCEDURE|Off-Clamp Sutureless Technique|During the procedure, the renal artery and its branches are not clamped. The tumor is completely resected with a gross margin of 0.5-1 cm from its edge. Monopolar or bipolar electrocautery is used for hemostasis during resection. Following tumor removal, the renal resection bed is subjected to meticulous hemostasis, followed by the application of hemostatic agents without suture closure.
219205628|NCT04894864|DRUG|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
219205629|NCT06875713|BEHAVIORAL|Parenting for Lifelong Health Program (DAYEM)|This intervention consists of the Parenting for Lifelong Health (PLH) program, delivered through eight in-person sessions, supplemented by a digital parenting program (ParentApp). The intervention aims to enhance positive parenting behaviors and reduce child maltreatment.
219205630|NCT06875713|BEHAVIORAL|Adult nutrition|The control group will receive education on adult nutrition over the same period.
219543655|NCT07068620|DEVICE|Home-based cognitive training|"All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD.~Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months."
219543656|NCT07069231|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
219543657|NCT07067320|BEHAVIORAL|Bibliotherapy combined with games to overcome fear of the dark|Bibliotherapy combined with games, applied by parents at home. Treatment based on cognitive-behavioural techniques. Duration: 4-5 weeks. Experimental group recived this bibliotherapeutic intervention.
219543658|NCT07067931|OTHER|Exercise stroboscopic|In this study, balance and plyometric exercises will be performed by one group using stroboscopic glasses.
219543659|NCT07067931|OTHER|training|routine training program
218933976|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
218933977|NCT07145255|DRUG|ADC|MBRC-201 ADC
218933978|NCT07145502|BIOLOGICAL|Allogeneic MSC infusions (IV)|Optional T-reg therapy (experimental/compassionate-use basis)
219045630|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
219045631|NCT05782686|PROCEDURE|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
219045632|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
219543660|NCT07067931|OTHER|Exercise|balance and plyometric exercises
219543661|NCT07069296|DIAGNOSTIC_TEST|blood samples were collected from participants|Blood samples obtained
219543662|NCT07069296|DIAGNOSTIC_TEST|blood samples|Blood sampling
219543663|NCT07067463|DRUG|Orelabrutinib|Orally
219543664|NCT07067463|DRUG|Placebo|Orally
219543665|NCT07067619|BEHAVIORAL|Pain-acceptance intervention|"The intervention start with a conversation and inquiry about the participant's pain while continuously validating his experience and creating a shared understanding of their struggles and difficulties due to the pain.~Next, the experimenter explain the relations between distress, pain and suffering, emphasizing that in many cases trying to control our pain, emotions and thoughts leads us to undesirable results through emotional avoidance, anger and escape. This explanation will be accompanied with commonly used metaphors to enhance participants' understanding. Afterwards, participants are familiarized with the strategy of emotional acceptance of pain. The strategy will be comprehensively explained and participants will practice it with the experimenter twice: Firstly, by practicing with the mental exercise of STOP (i.e. Stop, Take a step back, Observe, Procced Mindfully); Secondly by practicing the pain acceptance strategy while feeling moderate pain, and discuss their experience."
219543666|NCT07068724|COMBINATION_PRODUCT|Gluma Desensitizer and ER:CR;YSGG laser combination|Participants in this group received both treatments: Gluma was applied using the same method as in Gluma, followed by Er,Cr:YSGG laser therapy using the same parameters and technique as in laser.
219543667|NCT07068724|DEVICE|Er,Cr:YSGG laser|Participants received Er,Cr:YSGG laser treatment (Water-Lase iPlusTM; Biolase® Technology Inc., Irvine, CA, USA). Laser parameters were set as follows: 2780 nm wavelength, 0.25 W power, 20 Hz frequency, 140 μs pulse duration, and 30 seconds exposure time. The MZ6 tip (660 μm diameter, 6 mm length, 1 mm spot size) was used in non-contact mode from a 1 mm distance, perpendicular to the dentin surface, with 0% water and 10% air spray. All laser applications followed international safety standards and protocols.
219543668|NCT07069270|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab , 240mg, D1, subcutaneous injection, Q4W.
218933979|NCT07139795|BEHAVIORAL|Mindful eating and movement|Group mindful eating sessions will be conducted once per week, one hour per session, for eight weeks. Participants will be encouraged to attend at least two, 45-minute yoga sessions per week.
219543669|NCT07069270|DRUG|Adebrelimab|Adebrelimab, 1200 mg, D1, intravenous drip, Q3W
219543670|NCT07069270|DRUG|Chemotherapy|Etoposide, 100mg /m², D1-3, IV, Q3W. Carboplatin, AUC 5, D1, IV, Q3W
219543671|NCT01030133|DEVICE|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
218933980|NCT07144748|OTHER|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
218933981|NCT07144215|DRUG|Dexmedetomidine 3 mcg|Patient received spinal injection of dexmedetomidine 3 mcg.
219045633|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
219045634|NCT06394570|DRUG|Enfortumab vedotin|Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
219045635|NCT05351255|DEVICE|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
219045636|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
219045637|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
218933982|NCT07144215|DRUG|Dexmedetomidine 4 mcg|Patient received spinal injection of dexmedetomidine 4 mcg.
218933983|NCT07144215|DRUG|Dexmedetomidine 5 mcg|Patient received spinal injection of dexmedetomidine 5 mcg.
219543672|NCT01030133|DEVICE|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
219543673|NCT01030133|DEVICE|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
219543674|NCT01030133|DEVICE|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
219543675|NCT01030133|DEVICE|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
219543676|NCT07068243|DRUG|1.0% lidocaine with epinephrine (1:100,000)|"The block will be performed by advancing the needle into the posterior rectus sheath compartment, with the local anesthetic deposited posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath.~Drug: 20 mL injection of 1.0% lidocaine with epinephrine (1:100,000) on each side (40mL total/subject)"
219543677|NCT07068568|DRUG|Sonidegib|Sonidegib was administered orally at a dose of 200 mg once daily as per approved guidelines. The intervention was applied in a real-world clinical setting to patients with histologically confirmed, locally advanced periocular basal cell carcinoma (laBCC) deemed unsuitable for surgical resection or radiotherapy due to the tumor's extent or proximity to critical ocular structures. A flexible, individualized dose modulation strategy was implemented to manage adverse effects and optimize patient adherence. Modifications included temporary treatment interruptions or reduced dosing frequency, tailored to each patient's clinical status and tolerance. The goal of the intervention was to achieve local tumor control while preserving ocular structures, visual function, and cosmetic appearance. All patients received regular multidisciplinary follow-up, including ophthalmologic and dermatologic assessments.
219543678|NCT07067853|DEVICE|Lidocaine 2 % Pharmacopuncture|Injection of 0.5mL Lidocaine 2% solution into GB20 acupuncture point, both sides every week for 4 week
219543679|NCT07067853|DRUG|propranolol 20mg|Propranolol 20mg, twice daily for 28 day / 4 week
219543680|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy|Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.
218933984|NCT07144215|DRUG|Dexmedetomidine 6 mcg|Patient received spinal injection of dexmedetomidine 6 mcg.
218933985|NCT07144215|DRUG|Bupivacain hyperbaric 0.5% 12.5 mg|Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg
218933986|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
219045638|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
219045639|NCT05341544|DEVICE|Parasym device|The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
219045640|NCT05341544|DEVICE|Sham device|Sham device
219045641|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
219045642|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
219205631|NCT06870032|OTHER|standard medical care|standard medical care
218933987|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Not Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
218933988|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
218933989|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
218933990|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
219205632|NCT06870032|OTHER|structured pulmonary rehabilitation|"structured pulmonary rehabilitation program including:~* Physical Therapy: Breathing exercises, airway clearance techniques, inspiratory muscle training.~* Pediatrics \& Chest Medicine: Medical supervision, optimization of pharmacological treatment.~* Physiology: Monitoring pulmonary function and physiological responses to exercise.~* Public Health: Evaluating program feasibility and its impact on healthcare utilization."
219543681|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy + FAKTR|"Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.~FAKTR Functional and Kinematic Treatment with Rehabilitation) technique:~The FAKTR (Functional and Kinematic Treatment with Rehabilitation) technique applied is a modified IASTM technique in the pain-provocative position (incorporating static positions, motions, functional movements, resistance, and proprioceptive positions)."
219543682|NCT07067983|DIAGNOSTIC_TEST|Results following systematic screening|The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy
219543683|NCT07069023|OTHER|breathing exercise group|Oncology patients with nausea, vomiting and fatigue were given breathing exercises throughout the treatment.
219205633|NCT05588505|BEHAVIORAL|Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD|The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
219205634|NCT06186414|DRUG|SIM0237|Several dose levels of SIM0237 will be administered as a single agent for evaluation
219205635|NCT06186414|DRUG|SIM0237 and BCG|Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
219205636|NCT06186414|DRUG|SIM0237|RD level of SIM0237 will be administered as a single agent for evaluation
219543684|NCT07069023|OTHER|reiki group|Oncology patients with nausea, vomiting and fatigue received reiki throughout the treatment.
219621725|NCT05744167|BEHAVIORAL|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
219621726|NCT05744167|BEHAVIORAL|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
219621727|NCT05981690|BEHAVIORAL|Therapist guided, parent-led CBT for preadolescent children with OCD|This treatment was adapted from an existing evidence based therapist guided parent-led CBT intervention for preadolescent children with anxiety difficulties. It consists of 6 to 8 treatment individual treatment sessions where parents learn CBT techniques to apply at home with their child
219621728|NCT00043303|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
219621729|NCT06528379|BEHAVIORAL|Physical Activity|"The exercise programme is a 6-month progressive tailored-based exercise regime comprising~* aerobic exercises (40-60%)~* resistance exercises (20-40%)~* balance with resistance exercises (20%) .~This is peformed 3 times weekly, it is tailored to each individual but delivered in a small group-based manner. Two sessions are supervised by physiotherapist /exercise scientist and one session is unsupervised, home-based."
219621730|NCT02164045|DRUG|BMS-663068|BMS-663068
219621731|NCT01755533|OTHER|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
218933991|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Not Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
219543685|NCT01944761|BEHAVIORAL|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
219543686|NCT04368624|OTHER|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
219543687|NCT04368624|DIAGNOSTIC_TEST|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
219543688|NCT01654458|BEHAVIORAL|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
219543689|NCT06664931|OTHER|Group (A) Muscle Energy Technique (MET)|"MET will be applied to three key muscles commonly associated with neck pain:~upper trapezius, levator scapulae, and anterior scalenus."
219543690|NCT06664931|OTHER|Group (B) Mulligan Mobilizations Techniques (MMT).|Participants in Group (B) will receive MMT alongside the traditional treatment. MMT utilizes a specific technique called Sustained Natural Apophyseal Glides (SNAGs) to improve joint mobilization.
219543691|NCT03886961|DEVICE|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
219045643|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
219045644|NCT01368575|PROCEDURE|CABG|CABG
219543692|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
219543693|NCT03331289|DRUG|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
219543694|NCT03331289|DRUG|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
219045645|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
219543695|NCT03331289|DRUG|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
219543696|NCT03331289|DRUG|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
219543697|NCT06938295|DIAGNOSTIC_TEST|Comparative Use of High-End and Mid-End Intestinal Ultrasound Devices for IBD Disease activity assessment|This study compares two intestinal ultrasound (IUS) devices-a high-end machine (Samsung RS85) and a mid-end machine (Siemens ACUSON S2000)-for assessing ileocolonic inflammation in IBD patients. The high-end device offers advanced imaging features, including high-resolution, speckle reduction, and extended field of view, allowing for detailed visualization of the bowel wall and vascularity. The mid-end device, while more basic, provides essential IUS functions for examining bowel wall thickness, structure, and inflammation markers. Both devices are used in a single clinical session, with results compared against tandem ileo-colonoscopy as the reference standard. This unique dual approach enables evaluation of the diagnostic performance of each device type. If comparable, the mid-end device may offer a cost-effective solution, increasing access to routine IUS in various healthcare settings, especially where high-end technology is limited.
219543698|NCT06943924|PROCEDURE|Frailty assessment|This study aims to investigate the accuracy and clinical utility of these scoring systems in predicting mortality in individuals aged 65 and older undergoing emergency surgery.
219543699|NCT00477594|DRUG|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
219045646|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
219543700|NCT06945042|OTHER|Arm A|The intervention will consist of systematic financial navigation with consistent screening and intervention on any financial related issues. All patients randomized to the financial navigational group will be contacted by clinical trial staff assigned to the study to screen for financial needs. Based on the results of this assessment, the clinical trials staff will refer to the appropriate services for personalized recommendations and assistance provided by Atrium Health personnel including financial navigators, nurse navigators. All the resources provided to the patient, including counseling, will be free of charge. Assessment will be performed once per month for 6 months.
219045647|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
219045648|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
219045649|NCT02321865|DRUG|NPC-02|
219045650|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
219045651|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
219045652|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
219045653|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
219045654|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
219543701|NCT06945042|OTHER|Arm B|All patients randomized to the Standard of Care arm will have access to the financial distress resources (Financial Navigation and Nurse Navigation) as per current clinical policy which is per patient or clinician request. Utilization of these resources will be tracked to assess and describe the per-protocol population. All the resources provided to the patient, including counseling, will be free of charge as per institutional policy.
219543702|NCT03011476|DRUG|Donepezil|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
219543703|NCT03011476|DRUG|Placebos|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
219543704|NCT06939803|OTHER|Risk model-driven CDS|"The CDS intervention will use an automated risk model called VTE-AI to add EHR-based prompts in the form of alerts targeting those encounters on which 1) VTE-AI risk is above 5% predicted risk (found to be high risk in prior analyses), 2) no active DVT prophylaxis pharmacologic order is present, 3) no contraindication has been documented in the current admission"
219543705|NCT00712777|DRUG|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
219543706|NCT06517056|DEVICE|Emovi Knee Kinesiography|All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
219543707|NCT05261802|OTHER|Descriptive Intervention|A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
219543708|NCT06224803|DIETARY_SUPPLEMENT|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
219543709|NCT06224803|DIETARY_SUPPLEMENT|Indigestible dextrin|Indigestible dextrin as placebo intervention
219543710|NCT05117489|DRUG|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
219543711|NCT05117489|DRUG|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
219621732|NCT01755533|OTHER|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
219205637|NCT06186414|DRUG|SIM0237 and BCG|RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
219205638|NCT05574036|DRUG|Febuxostat 80 MG Oral Tablet|Febuxostat used as 80 mg oral tablet once daily for 6 months
219205639|NCT05574036|DRUG|vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
219205640|NCT02333162|DRUG|Fludarabine Phosphate|Given IV
219205641|NCT02333162|DRUG|Melphalan|Given IV
219543712|NCT05117489|DRUG|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
219543713|NCT05117489|DRUG|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
219543714|NCT06495138|DEVICE|StableEyes|"Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit."
219543715|NCT05714865|DRUG|Surfactant|Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP
219543716|NCT04517604|DEVICE|Magventure MagProx100 with MagOption|The Magventure C-B60 butterfly coil will be used for single-pulse TMS to determine motor threshold. iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B65 Butterfly coils) or active-only Cool-B65 Butterfly (figure 8) coil. Only the active setting will be used.
219543717|NCT06954233|DIAGNOSTIC_TEST|Uroflowmetry and questionnaires|Uroflowmetry - urine flow assessment Questionnaires: IPSS, ICIQ-MLUTS, IIEF-5, MSHQ-EjD, EQ-5D-5L
219543718|NCT01753375|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
219543719|NCT01753375|DIETARY_SUPPLEMENT|Placebo|Placebo to be given orally on weekly basis
219543720|NCT02635750|DRUG|BI 409306|
219543721|NCT02635750|DRUG|Donepezil|
219543722|NCT04821349|DEVICE|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
219205642|NCT02333162|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMTMI
219205643|NCT02333162|RADIATION|Total Marrow Irradiation|Undergo IMTMI
219205644|NCT02333162|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
219205645|NCT02333162|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219205646|NCT02333162|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
219205647|NCT02333162|DRUG|Tacrolimus|Given IV or PO
219205648|NCT02333162|DRUG|Mycophenolate Mofetil|Given IV or PO
219205649|NCT02333162|OTHER|Laboratory Biomarker Analysis|Correlative studies
219205650|NCT02831283|DRUG|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
219205651|NCT02831283|DRUG|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
219205652|NCT02831283|PROCEDURE|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
218933992|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
218933993|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
218933994|NCT07144033|DIETARY_SUPPLEMENT|Butyrate and Taurine|This dose of butyrate is chosen to maximize any treatment effect in postoperative pain. Butyrate was reported to be safe at this dose for a prolonged period of 8 weeks. The dose of taurine is considered safe according to the European Food Safety Authority and was used in previous human perioperative trials. A human pharmacokinetic study showed that after taking 4g taurine (32 mmol) orally, plasma taurine levels reached a peak level of 86 mg/L (or 0.7 mmol/L) at 1.5 hours, exceeding the physiological plasma taurine level (0.01-0.1 mmol/L), which is needed to exert its pharmacological benefits.
219543723|NCT00805779|DEVICE|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
219543724|NCT05383807|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
219543725|NCT02468518|DRUG|Vitamin E capsule|Capsules will be distributed to each participant free of cost
219543726|NCT04053153|DEVICE|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
219543727|NCT04830462|DRUG|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
219543728|NCT04830462|DRUG|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
219543729|NCT05471596|DEVICE|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
219543730|NCT04449315|OTHER|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
219543731|NCT04377087|DRUG|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
219543732|NCT06183788|BEHAVIORAL|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
219543733|NCT06450145|DRUG|interferon α-2b|Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
219543734|NCT04247945|BIOLOGICAL|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
219621733|NCT04777227|DRUG|Lidocaine injection|2% (20mg/ml) lidocaine solution
219621734|NCT04777227|DRUG|Physiological water injection|0.9% sterile sodium chloride water
218933995|NCT07144033|OTHER|Placebo|indistinguishable placebo capsules will be administered orally after enrolment on the day before surgery, followed by daily administration for three months after surgery.
218933996|NCT07146958|OTHER|Chia seeds|Chia seeds will be added to soup and bread recipes.
219543735|NCT01524185|BEHAVIORAL|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
219543736|NCT01524185|BEHAVIORAL|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
219543737|NCT02484404|DRUG|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
219543738|NCT02484404|DRUG|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
219543739|NCT02484404|DRUG|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
219543740|NCT03133260|DIAGNOSTIC_TEST|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
219543741|NCT03133260|DRUG|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
219543742|NCT03133260|DRUG|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
218933997|NCT07146958|OTHER|Hemp seeds|Hemp seeds will be added to soup and bread recipes.
218933998|NCT07146958|OTHER|Placebo|The placebo will be food items that are not enriched with the intervention products.
218933999|NCT06947161|DRUG|Gengigel|Throat pack will be soaked with gengigel, and post operatively, will see if there is any presence of sore throat, severity of sore throat. 10 mlm of gengigel, in liquid form will be used to soak the throat pack. 30 patients will receive gengigel spray soaked throat pack, and control group will receive normal saline soaked throat pack
218934000|NCT07148934|DIAGNOSTIC_TEST|Smartphone seismographic recording and Bed Based Ballistocardiographic recordings|A short recording of heart rhythm using a smartphone and bed-based ballistocardiogram.
219543743|NCT02875392|OTHER|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
219543744|NCT02875392|OTHER|placebo pills|taking placebo pills as if patients are under treatment.
219543745|NCT01975116|DRUG|azurin-derived cell-penetrating peptide p28|Given IV
218934001|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin|Participants received Whole wheat muffin once a day
219543746|NCT06555458|DRUG|Dexmedetomidine|Patient group to be given dexmedetomidine
219543747|NCT06555458|DRUG|Saline|Patient group to be given salin
219543748|NCT06339645|PROCEDURE|PRP|Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection
219621735|NCT04777227|PROCEDURE|Debridement|A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
219621736|NCT04777227|PROCEDURE|Needle insertion|A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
219621737|NCT00537173|PROCEDURE|Core Biopsy|biopsy
219621738|NCT00537173|PROCEDURE|Blood Collection|Blood/serum sample
219621739|NCT00537173|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
218934002|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)
218934003|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)
218934004|NCT07142044|DRUG|EC5026 oral tablet|Oral soluble epoxide hydrolase inhibitor
218934005|NCT07142044|DRUG|Placebo|Matching oral placebo
218934006|NCT07147296|PROCEDURE|ARC-IM System Implantation|Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
218934007|NCT07147296|DEVICE|ARC-IM Therapy (active)|The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
218934008|NCT07147296|DEVICE|ARC-IM Therapy (sham)|The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation (after 3 months of sham stimulation) at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
218934009|NCT06955468|BEHAVIORAL|Priming Survey|13-item priming survey assessing patients' goals, treatment preferences, and disease understanding.
218934010|NCT07144839|OTHER|Data Collection Throughout Pregnancy and Delivery|Participants will receive monitoring by ultrasound and blood tests at three time points during pregnancy, and delivery and neonatal data will be collected.
219543749|NCT04742543|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
219543750|NCT05491187|DRUG|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
219543751|NCT05491187|DRUG|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
219543752|NCT03599193|DRUG|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
219543753|NCT03599193|DRUG|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
219543754|NCT00789386|DRUG|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
219543755|NCT00789386|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
219543756|NCT04722198|DIETARY_SUPPLEMENT|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
219621740|NCT00537173|DRUG|Avastin|Avastin 10 mg/kg IV, day 1 and 15
219621741|NCT00185289|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
219543757|NCT00394303|DRUG|Intraoperative continuous insulin infusion|Nomogram specified in appendix
219543758|NCT00394303|OTHER|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
219543759|NCT05213052|OTHER|Topical cream|Topical cream applied to painful joint or muscle
219543760|NCT00018213|DRUG|Naltrexone Hydrochloride|
218934011|NCT07146763|BEHAVIORAL|Prescribing Feedback|Automated prescribing feedback messages are delivered to clinician prescribers in participating emergency departments. Messages are based on Geriatric Emergency Medication Safety Recommendations (GEMS-Rx) recommendations and include aspirational norms and benchmark comparisons. Depending on study arm, feedback is sent either from a credible peer messenger or through an anonymous messenger system.
219543761|NCT00018213|DRUG|Transdermal Nicotine|
219543762|NCT00571935|DRUG|insulin aspart|
219543763|NCT00571935|DRUG|soluble human insulin|
219543764|NCT01310998|BEHAVIORAL|High intensity exercise|4x4 intervals
219543765|NCT01949805|DRUG|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
219543766|NCT01949805|DRUG|Hydroxyurea|Hydroyurea capsules taken daily po
219543767|NCT00835705|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
219543768|NCT00835705|DRUG|Augmentin®|400 mg-57 mg chewable tablet
219543769|NCT03417076|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
219543770|NCT03049631|DIETARY_SUPPLEMENT|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
219543771|NCT03049631|DIETARY_SUPPLEMENT|Raspberry|Red raspberries (1 cup equivalent)
218934012|NCT07150585|DEVICE|Ultrasonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the Ultra X device (Eighteeth) with ultrasonic tips.
218934013|NCT07150585|DEVICE|Sonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using an EDDY sonic activation tip (VDW, Munich, Germany)
218934014|NCT07150585|DEVICE|Laser Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the LightWalker (Fotona, Ljubljana, Slovenia) Er:YAG laser device in SWEEPS mood
218934015|NCT07152912|DRUG|Isoflurane|Patients will receive general anesthesia and maintenance by isoflurane.
218934016|NCT07152912|DRUG|Sevoflurane|Patients will receive general anesthesia and maintenance by sevoflurane.
218934017|NCT07154875|PROCEDURE|Assisted Hatching|Laser-assisted zona drilling performed either on Day-3 or Day-5 of culture, depending on randomization arm.
218934022|NCT07157072|OTHER|Corrective rigid taping|Rigid taping used to correct pelvic torsion in patients with CAI
218934023|NCT07158333|DEVICE|Mobile Cardiac Telemetry (MCT System)|MCT System without data transmission
218934024|NCT07156162|OTHER|Videos: Taste vs Health|Participants in this intervention will watch taste and health focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
218934025|NCT07156162|OTHER|Health vs. Taste|Participants in this intervention will watch health and taste focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
219543772|NCT01706094|OTHER|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
219543773|NCT01750294|DRUG|Chlorthalidone|
219543774|NCT05360394|DEVICE|Paclitaxel Coated Balloon|CAS treated with PCB only
219543775|NCT05360394|DEVICE|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
219543776|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
219543777|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention without Mutual Gaze|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, social sensory routines, and naturalistic developmental behavioral strategies described in the program manual. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
219621742|NCT04382729|OTHER|Neuromuscular Electrical Stimulation|The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
219621743|NCT04382729|OTHER|Physical Therapy Exercise|The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
218934026|NCT07157592|OTHER|Ventrogluteal IM Injection tecnique|"Ventrogluteal IM injection technique:~During IM injection into the ventrogluteal region:~* The entrance angle of the needle is 90º.~* The 25-gauge (1-inch) syringe is held with the active hand as if holding a pen, and no hand change is made during the injection.~* The needle is rapidly inserted into the skin and withdrawn at the same angle 5 seconds after the injection.~* The drug is injected for 5 seconds/mL without blood aspiration during injection.~* Light pressure is applied to the area after injection, with no massage performed.~To evaluate the appropriateness of the application ventrogluteal IM injection technique, the opinions were obtained of five experts in nursing principles and child health and disease nursing."
218934027|NCT07156175|DRUG|SAR444336|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
218934028|NCT07156175|DRUG|Placebo|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
218934029|NCT07158268|DRUG|HSK47388|HSK47388 tablets will be administered orally, once a day
219205653|NCT03661255|BEHAVIORAL|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
219045655|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
219045656|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
219543778|NCT04410380|BEHAVIORAL|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
219543779|NCT05539157|DRUG|JCXH-211|JCXH-211 administered once every 28 days
219543780|NCT00665925|DRUG|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
219543781|NCT00665925|DRUG|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
219543782|NCT00665925|DRUG|Placebo|Placebo, orally, either once a day, or twice a day
219045657|NCT02191488|DRUG|5-aminolevulinic acid|
219045658|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
219543783|NCT00580541|BEHAVIORAL|variety|variety and nonvariety
219543784|NCT00687206|DRUG|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
218934030|NCT07157501|BEHAVIORAL|Accupressure|Acupressure will be applied by pressing in circular movements on the acupoint with the thumb finger first in clock wise and then anti-clock wise direction. The finger must remain at the same point on the skin and be moved in small circles
219543785|NCT02832960|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
219543786|NCT02832960|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
219543787|NCT06059755|OTHER|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
218934031|NCT07157501|OTHER|Aromatherapy inhaler|The lavender inhalation application will be explained to the children and their mothers. Two drops of 100% pure organic lavender oil will poured on a cotton. The cotton will have fixed by the child at 5 cm distance from his or her nose and will asked to breathe slowly for 10-15 minutes
218934032|NCT07156981|BEHAVIORAL|Physiotherapy|The treatment program will include patient education, lifestyle recommendations, breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks.
219045659|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
219045660|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
219045661|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
219045662|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
219045663|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
219543788|NCT06059755|OTHER|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
219543789|NCT03625973|BEHAVIORAL|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
219543790|NCT03625973|BEHAVIORAL|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
219543791|NCT01173835|BEHAVIORAL|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
218934033|NCT07156487|DEVICE|Digital Anesthesia with SleeperOne 5|For both maxillary and mandibular teeth, 1.7 mL of Ultracaine D-S Fort carpule (4% articaine with 1:200,000 epinephrine) was administered in two stages (gingival and intraosseous injection) using a computer-controlled intraosseous anesthesia system with a 30-gauge, 9 mm Effitec needle.
218934034|NCT07156487|DEVICE|Infiltration Anesthesia with a Metal Cartridge Syringe|For maxillary teeth, buccal infiltration is performed using a metal carpule syringe and a 30G, 16 mm Effitec needle (Dental Hi Tec, France); after aspiration, Ultracaine D-S Fort is slowly injected over 1 minute.
218934035|NCT07156487|DEVICE|Mandibular Block Anesthesia with a Metal Cartridge Syringe|For mandibular teeth, the injection site is dried, and a 27G, 35 mm Effitec needle (Dental Hi Tec, France) is inserted between the pterygomandibular raphe and internal oblique ridge, aligned with contralateral molars. After aspiration, Ultracaine D-S Fort is slowly injected over 1 minute using a traditional metal carpule syringe, following the standard mandibular block technique.
219205654|NCT04174560|BIOLOGICAL|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
219205655|NCT06627920|DEVICE|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
219205656|NCT06626958|BEHAVIORAL|Stress Ball|Stress Ball app
219205657|NCT06872008|BEHAVIORAL|Hand Massage|"Hand massage to elderly people Hand massage application consists of five basic classical massages including efflorage, petrissage, friction, tapotman and vibration.~It is a massage that includes manipulation and is performed with western technique.~The researcher will collaborate with the institution's physiotherapist throughout the application. Hand massage in the literature Although there is no standard duration for how long the massage should be applied, studies have shown that the massage is applied for an average of 5-10 times, and in this study the massage application time was It was determined as 10 minutes in total, 5 minutes for each hand. Hand massage with baby oil will be performed 3 times a week for 4 weeks, for a total of 12 sessions."
218934036|NCT07157891|BIOLOGICAL|MSC-Derived Secretome|The secretome will be collected from cultured MSCs under sterile, GMP-compliant conditions and concentrated to retain bioactive molecules. It will be injected into the affected knee under ultrasound guidance.
218934037|NCT07157891|BIOLOGICAL|MSC-Derived Secretome + Autologous PRGF|MSC-derived secretome will be collected from mesenchymal stem cell cultures under sterile, GMP-compliant conditions. Autologous PRP will be prepared from the participant's own peripheral blood using a standardized single-spin centrifugation method and combined with 10% calcium chloride to activate growth factors. Both components will be mixed and administered into the affected joint under ultrasound guidance.
218934038|NCT07157059|BEHAVIORAL|Doula Care|Participants assigned to the Doula care group received care from the doula pre, during, and post delivery.
218934039|NCT07157436|OTHER|Non-interventional study|observational study. non-interventional
218934040|NCT07157124|OTHER|Dynamic Visual Noise (DVN)|DVN is a brief visual array of patterns of flickering black and white dots. In alignment with prior literature, the DVN array will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares that will change at a rate of 640 frames per second. The DVN will be 30 seconds in duration, though participants will be able to keep watching for as long as desired by restarting the video of the array.
218934041|NCT07157124|OTHER|Static Visual Noise (SVN)|SVN is similar to DVN, but refers to a static (or still) image of an array of black and white squares. The SVN will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares. SVN has been used in previous working memory-loading studies as a control for DVN. Similar to the DVN, participants in the control group will view the SVN for at least 30 seconds (but they will be able to keep viewing it for as long as desired).
219205658|NCT06868602|OTHER|psychoeducation|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study,Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
219543792|NCT03690349|OTHER|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
218934042|NCT07157371|OTHER|Supervised structured aerobic exercise training|Supervised structured aerobic exercise plan will be conducted in gym by the physiotherapist
219621744|NCT04435873|OTHER|"Survey using Your Home Dialysis Care Experience tool."|Validation of a new survey instrument to capture the experience of care by home dialysis patients.
219621745|NCT05129774|PROCEDURE|Radical surgery with PALND|sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
218934043|NCT07157371|OTHER|Walk|Females with PCOS will be instructed to do a walk at home with medications
218934044|NCT07156617|PROCEDURE|Interventional therapy|Interventional therapy
219205659|NCT06868602|OTHER|Exercise|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study, Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
219205660|NCT06870903|PROCEDURE|Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy|The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).
219205661|NCT06870903|PROCEDURE|Transperitoneal lymphadenectomy|In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.
218934045|NCT07156617|DRUG|Systemic therapy|Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab
219205662|NCT06874608|DIETARY_SUPPLEMENT|complete, polymeric formula, fiber, lactose and gluten free|The dietary intervention attempts to induce remission in the first 4-week treatment without any change in the pharmaceutical therapy. In case of worsening or not reaching the outcomes, the patient will be defined as a failure and start rescue therapy with the standard of care.
219543793|NCT06182462|DEVICE|Virtual Reality Distraction|"The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded."
219543794|NCT06182462|DEVICE|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
219543795|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
219543796|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
219621746|NCT05129774|PROCEDURE|Radical surgery without PALND|surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
219621747|NCT02353182|DRUG|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
219621748|NCT02353182|DRUG|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
219621749|NCT02353182|DRUG|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
219621750|NCT02353182|DRUG|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
218934046|NCT07156214|OTHER|Assessment of markers of oxidative stress in peripheral blood samples|Participants will perform serial blood samples at interval of 12 months to compare levels of markers of oxidative stress
218934047|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
219205663|NCT06875349|OTHER|foot reflexology|Foot reflexology is a complementary therapy that involves applying pressure to specific points on the feet, which are believed to correspond to different organs and systems in the body. This technique aims to promote healing by improving blood circulation, reducing stress, and supporting overall well-being. Reflexology is often used to help with issues such as constipation, stress, sleep disorders, and pain management.
218934048|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
218934049|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
218934050|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
218934051|NCT07156747|OTHER|Visual Analog Scale|The Visual Analog Scale (VAS) is a linear instrument employed to measure perceived pain intensity, spanning from 0 (indicating no pain) to 10 (representing the most severe pain), where patients indicate the level that most accurately represents their experience.
218934052|NCT07156747|OTHER|State-Trait Anxiety Inventory|The STAI is a self-administered questionnaire with two parts: STAI-1 measures state anxiety, representing a transient emotional state triggered by a particular circumstance, while STAI-2 examines trait anxiety, denoting a consistent predisposition to experience anxiety across diverse situations.
219543797|NCT05231460|DRUG|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
219543798|NCT05231460|DRUG|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
219543799|NCT05231460|DRUG|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
218934053|NCT07156747|OTHER|Video|watching video on Digital Platfrom (for example, Youtube)
218934054|NCT07156747|OTHER|Image|Prostate biopsy information with images
218934055|NCT07156968|DRUG|Bupivacaine-fentanyl|A peripheral intravenous (IV) catheter will be inserted, and a 7 mL kg-1 crystalloid infusion will be initiated. The patients will be premedicated with 0.03 mg kg-1 midazolam IV. Heart rate and peripheral oxygen saturation (SpO2) will be monitored continuously; systolic, diastolic, and mean arterial pressure (MAP) will be measured noninvasively at 5 min intervals during the procedure and at 15 min intervals during the post anesthesia care unit (PACU) stay. The baseline values will be recorded. Nasal oxygen 2 L min-1 will be administered during the whole procedure
219543800|NCT05231460|DRUG|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
219543801|NCT05256160|OTHER|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
219543802|NCT05256160|OTHER|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
219543803|NCT06960915|DEVICE|immersive virtual reality|The research procedure will be the realization of reminiscence workshops in immersive virtual reality. The residents will be equipped with a virtual reality headset where they will enjoy 360° panoramas that will immerse them in the heart of villages in the Amiens basin and in particular their village based on 3 to 5 images per village: church square, village square, town hall, emblematic places, etc.
219543804|NCT06960915|DEVICE|classic reminiscence workshops|It will be compared to classic reminiscence workshops in which the organizer will propose to discuss memories and past experiences using photographs, objects or music in the control arm.
218934056|NCT07157462|DIETARY_SUPPLEMENT|Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species)|The probiotic powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
218934057|NCT07157462|DIETARY_SUPPLEMENT|Placebo Powder for Oral Solution|The placebo powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
219045664|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
219045665|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
219045666|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
219045667|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
219205664|NCT06875349|OTHER|abdominal massage|Abdominal massage is a therapeutic technique that involves applying gentle pressure and circular motions to the abdominal area to stimulate digestion, improve bowel movements, and relieve discomfort. It is commonly used to help with issues such as constipation, bloating, and digestive disorders by promoting intestinal motility and blood circulation. This technique can be performed manually or with the help of tools and is often incorporated into holistic and nursing care practices.
219045668|NCT06445374|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
219045669|NCT04820283|BEHAVIORAL|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
219045670|NCT04820283|BEHAVIORAL|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
218934058|NCT07158008|PROCEDURE|Nissen-Sleeve Gastrectomy (N-SG)|Laparoscopic Nissen-Sleeve Gastrectomy is a modification of standard sleeve gastrectomy that incorporates an anti-reflux procedure. The greater curvature of the stomach is mobilized and short gastric vessels are divided. A segment of the gastric fundus is preserved and passed behind the distal esophagus to create a 360-degree wrap (Nissen fundoplication) around the lower esophageal sphincter. The crura of the diaphragm are approximated if necessary. Following fundoplication, the remainder of the stomach is resected longitudinally over a 40 French bougie using a linear stapling device, creating a tubular gastric conduit. This approach aims to achieve weight loss while providing a functional anti-reflux barrier and maintaining gastrointestinal continuity.
218934059|NCT07158008|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Laparoscopic Roux-en-Y Gastric Bypass is a standard bariatric procedure that combines gastric restriction with intestinal bypass. A small proximal gastric pouch is created using linear staplers, completely separating it from the gastric remnant. A 100 cm alimentary (Roux) limb of jejunum is measured from the ligament of Treitz and anastomosed to the gastric pouch (gastrojejunostomy) using a linear stapler. A jejunojejunostomy is then performed 150 cm distal to the gastrojejunostomy to connect the biliopancreatic limb to the alimentary limb, restoring intestinal continuity. The mesenteric defects are closed to reduce the risk of internal hernia. This procedure promotes weight loss and has established effectiveness in reducing gastroesophageal reflux symptoms.
219205665|NCT06263686|OTHER|Pasteurised yoghurt|Pasteurised (heat treated) natural yoghurt containing \<15 CFU/g of Lactobacillus delbrueckii bulgacirus and \<15 CFU/g of Streptococcus thermophilus.
219543805|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
219543806|NCT06549465|BIOLOGICAL|45 kBq/kg Ac-225 rosopatamab tetraxetan|45 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
219543807|NCT06549465|BIOLOGICAL|55 kBq/kg Ac-225 rosopatamab tetraxetan|55 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
219543808|NCT06549465|BIOLOGICAL|60 kBq/kg Ac-225 rosopatamab tetraxetan|60 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
219543809|NCT00849030|DRUG|Anastozole (Arimidex)|1mg, orally, once daily
219543810|NCT00849030|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
219543811|NCT00849030|DRUG|Anastozole (Arimidex) placebo|1mg, orally, once daily
219543812|NCT00849030|DRUG|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
219543813|NCT00271492|DRUG|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
219543814|NCT00271492|DRUG|Atrasentan|1 10mg capsule per day for the 6 month study period.
219543815|NCT00271492|DRUG|atrasentan|One 10 mg capsule per day for 6 month study period
219205666|NCT06263686|OTHER|Fresh yoghurt|containing ≥ 108 CFU/g of Lactobacillus delbrueckii bulgacirus and ≥ 108 CFU/g of Streptococcus thermophilus
219205667|NCT06263686|OTHER|Sterilised yoghurt|Not containing viable bacteria
219205668|NCT06631729|BEHAVIORAL|HRV-bio|participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
219543816|NCT06635135|DRUG|Aticaprant|Aticaprant will be administered orally.
219543817|NCT06635135|OTHER|Placebo|Placebo will be administered orally.
219543818|NCT04797663|DEVICE|Nd-YAG laser|laser hair removal device
219543819|NCT04797663|DRUG|TCA 20%|chemical peel
219543820|NCT06196047|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
219543821|NCT06196047|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
219543822|NCT02624297|OTHER|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
219543823|NCT06081634|BEHAVIORAL|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
219543824|NCT06081634|OTHER|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
219543825|NCT06626620|DRUG|Magnesium Sulphate infusion|Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
219543826|NCT06626620|DRUG|Terbutaline Infusion|Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
219621751|NCT05192239|DRUG|THC 5|5 milligrams of THC in gummy form
219621752|NCT05192239|DRUG|Placebo|Commercially available non-THC fruit snack
219621753|NCT01654640|DRUG|Metformin|metformin 500mg p.o. bid for 24 weeks
219621754|NCT01654640|DRUG|Placebo (for metformin)|placebo 1T bid
219621755|NCT04108286|DEVICE|1-DAY ACUVUE MOIST|TEST
219621756|NCT04108286|DEVICE|DAILIES AQUA COMFORT PLUS|CONTROL
219621757|NCT00054795|DRUG|Motexafin Gadolinium|
219621758|NCT04133012|OTHER|Samplings|"* blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample"
219621759|NCT02735902|DRUG|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
219543827|NCT02570958|DRUG|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
219543828|NCT05106803|DRUG|ciprofloxacin|Antibiotics used in vitro n the study
219621760|NCT02735902|DRUG|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
218934060|NCT07158008|PROCEDURE|Sleeve Gastrectomy (SG)|Laparoscopic Sleeve Gastrectomy is a restrictive bariatric procedure involving longitudinal resection of the stomach to create a tubular gastric conduit. The greater curvature is mobilized and short gastric vessels are divided. Using a bougie as a guide, the stomach is divided with a linear stapling device from the antrum to the angle of His, removing approximately 75-80% of gastric volume, including most of the fundus. This reduces stomach capacity and ghrelin production, promoting weight loss while maintaining gastrointestinal continuity.
218934061|NCT07156578|DRUG|Bivamelagon|daily dose of oral bivamelagon
218934062|NCT07157748|DRUG|Fufang E'jiao Jiang|Oral solution; 20 mL TID for 90 days;
218934063|NCT07157748|DRUG|Matching Placebo|Oral solution; 20 mL TID for 90 days;
218934064|NCT00892346|PROCEDURE|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
218934065|NCT06355180|DRUG|Esketamine|The experimental group will receive intravenous esketamine hydrochloride. Participants will be asked to fast for 8 hours prior to administration. On treatment days, esketamine will be administered at a dose of 0.2 mg/kg, diluted in 0.9% sodium chloride solution. The infusion rate will be controlled with an infusion pump or syringe pump to ensure a minimum administration duration of 40 minutes. Treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks, totaling six sessions. For participants demonstrating intolerance to either the dose of 0.2 mg/kg or the six-session regimen, investigators could modify the treatment protocol based on efficacy and safety assessments.
219621761|NCT03223350|DRUG|Capsaicin 0.1% Cream|Topical application
219621762|NCT03223350|DRUG|Placebos|placebo cream
219621763|NCT02983019|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
219621764|NCT04098341|DIAGNOSTIC_TEST|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
219621765|NCT03402295|DRUG|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
219621766|NCT05117216|BEHAVIORAL|Parental Vigilant Care (Parental training)|
219621767|NCT05117216|BEHAVIORAL|Technological Parental Monitoring|
219621768|NCT05405816|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy for obesity
219621769|NCT02627690|OTHER|islet transplanted|islet transplantation
219621770|NCT02627690|OTHER|non islet transplanted|no islet transplantation (for a non nephrologic reason)
219621771|NCT00993538|PROCEDURE|Blood sampling|
219621772|NCT00993538|PROCEDURE|Bone marrow aspiration|
219621773|NCT03398564|PROCEDURE|Erector Spinae Plan Block|The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
219621774|NCT03398564|PROCEDURE|Oblique subcostal TAP|ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
219621775|NCT02172443|DRUG|tiotropium inhalation powder capsules|
219621776|NCT02172443|DRUG|Atrovent|
219621777|NCT02172443|DRUG|placebo to Atrovent|
219621778|NCT02172443|DRUG|placebo to tiotropium inhalation capsules|
219621779|NCT03883321|OTHER|Cognitive behavioral stress management|Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
219621780|NCT00203333|DEVICE|Medtronic REVEAL|
219621781|NCT03477006|BIOLOGICAL|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
219621782|NCT02251483|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|
219621783|NCT02251483|OTHER|Placebo|
219621784|NCT05683704|DRUG|AK105，Anrotinib hydrochloride|AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles
219621785|NCT06797505|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
219621786|NCT06797505|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
219621787|NCT02174627|DRUG|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
219543829|NCT02670161|DRUG|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
219543830|NCT01791062|DEVICE|HYTOP®|HYTOP® will be implanted once during surgery.
219543831|NCT06562959|BEHAVIORAL|Fluid Restriction Program|In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.
219543832|NCT06562959|OTHER|Intervention Bundle (Fluid Restriction Program and Auricular Acupressure|the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
219543833|NCT02491099|DRUG|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
219543834|NCT01592240|DRUG|PBO|Placebo Q28d
219543835|NCT01592240|DRUG|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
219543836|NCT01592240|DRUG|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
219543837|NCT01592240|DRUG|PBO|Placebo, Q14d
219543838|NCT01592240|DRUG|PF-04950615|PF-04950615 50mg, Q14d
219543839|NCT01592240|DRUG|PF-04950615|PF-04950615 100 mg, Q14d
219543840|NCT01592240|DRUG|PF-04950615|PF-04950615 150mg, Q14d
219543841|NCT03181620|OTHER|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
219543842|NCT00465218|PROCEDURE|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
219543843|NCT04816773|DEVICE|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
219543844|NCT03704103|OTHER|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
219543845|NCT04166162|BEHAVIORAL|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
219543846|NCT04166162|BEHAVIORAL|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
219543847|NCT04166162|BEHAVIORAL|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
219543848|NCT04166162|BEHAVIORAL|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
219543849|NCT01909713|DRUG|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
219543850|NCT01011413|DRUG|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
219543851|NCT01011413|DRUG|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
219543852|NCT03207152|BIOLOGICAL|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
219543853|NCT06393530|DRUG|0.9%sodium chloride|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
219543854|NCT06393530|DRUG|0.2% ropivacaine|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
219543855|NCT05374850|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
219621788|NCT02174627|DRUG|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
219621789|NCT05579431|DRUG|VX-634|Suspension for oral administration.
219621790|NCT05579431|DRUG|Placebo|Suspension for oral administration.
219621791|NCT04542473|DRUG|Pancreatic Enzyme|CREON micro 5000
219621792|NCT04542473|DRUG|Ursodeoxycholic acid|Ursodiol C24H40O4 suspension
218934066|NCT06355180|DEVICE|Electroconvulsive therapy|The control group will receive ECT. Prior to each session, participants will undergo safety evaluations and concomitant medication adjustments. Following an 8-hour fast and bladder evacuation, other preoperative preparations include intravenous administration of anticholinergic agents, short-acting anesthetics, and muscle relaxants. Electrodes will be placed unilaterally on the non-dominant hemisphere, with the seizure threshold determined via titration. The treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks (six sessions in total). The protocol permitted regimen modifications for participants unable to tolerate the full course, based on efficacy and safety assessments.
219543856|NCT04835116|DRUG|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
219543857|NCT04835116|DRUG|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
219543858|NCT04763031|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
219543859|NCT04082741|DRUG|BMS-986318|Specified dose on specified days
219543860|NCT04082741|OTHER|Placebo|Placebo Matching BMS-986318
219543861|NCT05089903|BEHAVIORAL|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
219543862|NCT05089903|BEHAVIORAL|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
219543863|NCT05089903|BEHAVIORAL|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
219543864|NCT05089903|BEHAVIORAL|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
219543865|NCT05089903|BEHAVIORAL|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
219543866|NCT02994836|BIOLOGICAL|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
219543867|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
219543868|NCT02994836|BIOLOGICAL|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
219543869|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
219543870|NCT01216020|DRUG|cetuximab|"* Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
219543871|NCT01216020|DRUG|cisplatin (associated to radiotherapy)|"* CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
219543872|NCT02751424|DRUG|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
219543873|NCT02751424|DRUG|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
219543874|NCT01448434|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
219543875|NCT01448434|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
219543876|NCT02197416|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
219621793|NCT04542473|OTHER|Pancreatic Enzyme placebo|Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
219543877|NCT03206749|DRUG|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
219543878|NCT03206749|DRUG|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
219621794|NCT04542473|OTHER|Ursodeoxycholic acid placebo|Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
219543879|NCT03206749|DRUG|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
219543880|NCT01363817|DRUG|BMS-906024|
219543881|NCT01363817|DRUG|Dexamethasone|
219543882|NCT06026267|BIOLOGICAL|20% High Dose Albumin|"A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
219621795|NCT05050565|BEHAVIORAL|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
219543883|NCT06026267|OTHER|Standard Medical Treatment|Standard Medical Treatment
218934067|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
218934068|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
218934069|NCT01077050|DEVICE|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
219045671|NCT06533969|PROCEDURE|Epidural Spinal Cord Stimulation|"This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days"
219045672|NCT06533969|DEVICE|Electrocorticographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
219045673|NCT06533969|DEVICE|Electroencephalographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
219045674|NCT05576025|OTHER|Lifestyle intervention (cold exposure)|Participants will undergo two cold exposures with different shivering intensities. Mild shivering is defined as energy expenditure increased by 1.5-fold compared to the resting metabolic rate. Moderate shivering is 2.5-fold increase in metabolic rate.
219543884|NCT06026267|BIOLOGICAL|20% Reduced Dose Albumin|"B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
219543885|NCT01298609|DEVICE|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
219543886|NCT03302949|DIETARY_SUPPLEMENT|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
219543887|NCT02870686|PROCEDURE|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
219543888|NCT02870686|PROCEDURE|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
219543889|NCT05572996|DRUG|Inhaled Treprostinil|
219621796|NCT00392691|DRUG|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients \> 80kg) for imaging.
219543890|NCT03900013|PROCEDURE|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
219543891|NCT03900013|PROCEDURE|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
219621797|NCT00392691|DRUG|rituximab|250 mg/m2
219621798|NCT00392691|DRUG|melphalan|"* Dose level 1: 100 mg/m2~* Dose level 2: 140 mg/m2~* Dose level 3: 170 mg/m2~* Dose level 4: 200 mg/m2"
219621799|NCT00392691|DRUG|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
219621800|NCT00392691|PROCEDURE|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils \> 0.5x109/l for at least 2 consecutive days."
219621801|NCT06564818|DRUG|CYB003|CYB003 is a Deuterated Psilocin Analog.
219621802|NCT06564818|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
219621803|NCT06564818|DRUG|Placebo|Placebo
219045675|NCT04817254|DRUG|TMZ|150 mg/m2 on days 1-5 of cycles 1-6
219045676|NCT04817254|DRUG|ipilimumab 3mg/kg|3 mg/kg q 4 weeks for cycles 1-4
219045677|NCT04817254|DRUG|Nivolumab|1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
219045678|NCT04817254|DRUG|ipilimumab 1mg/kg|1 mg/kg q 4 weeks for cycles 1-4
219205669|NCT06631729|BEHAVIORAL|ED-JITAI|"participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels."
219543892|NCT02451696|DRUG|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
219543893|NCT00967395|OTHER|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
219543894|NCT00967395|OTHER|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
219543895|NCT03348527|DRUG|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
219543896|NCT02803827|OTHER|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
219543897|NCT02803827|BIOLOGICAL|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
219543898|NCT02803827|OTHER|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
219543899|NCT03332082|PROCEDURE|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
219543900|NCT03531060|DRUG|IRL790|IRL790 capsule 10 mg
219543901|NCT03531060|DRUG|Placebo|Placebo capsule
219543902|NCT04891276|OTHER|Data collection|Data collection on the national PMSI database
219543903|NCT01846091|OTHER|Laboratory Biomarker Analysis|Correlative studies
219621804|NCT04564092|DRUG|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
219543904|NCT01846091|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
219543905|NCT06498024|OTHER|Kellogg's - rice krispies (control)|One serving size (140g) of whole white rice cereal will be provided. Preparation will be consistently maintained throughout.
219543906|NCT06498024|OTHER|Kellogg's - rice krispies (control) + 125ml milk|One serving size (140g) of whole white rice cereal with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
219543907|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
219543908|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) will be provided. Preparation will be consistently maintained throughout.
219621805|NCT02026050|PROCEDURE|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
219621806|NCT02026050|PROCEDURE|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
219621807|NCT02026050|PROCEDURE|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
219621808|NCT03667040|BEHAVIORAL|JOOL app|Participants will use the JOOL app for 30 days
218934070|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
219045679|NCT06273488|OTHER|Auriculotherapy|Treatment of pain, drug addictions, or other ailments by stimulating the various points on the external ear (EAR AURICLES). It is based on the ancient Chinese practices of EAR ACUPUNCTURE, but sometimes magnets and other modes of stimulation are used.
219543909|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with a 10% added purple powder (sweet potato) will be provided. Preparation will be consistently maintained throughout.
219543910|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 50% fava bean blend) and 10% purple powder (sweet potato) with 125 ml milk. Preparation will be consistently maintained throughout.
219543911|NCT05690152|DEVICE|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
219543912|NCT04345640|OTHER|no intervention|no intervention
219543913|NCT05014828|DRUG|lenvatinib|Administered at the dose of 20 mg orally, once daily.
219543914|NCT05014828|DRUG|Tislelizumab|400 mg administered intravenously on Day 1 of each 42-day cycle
219543915|NCT00721162|BIOLOGICAL|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
219543916|NCT05006690|OTHER|Clinical Pilates-Based Exercise Training|Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
219543917|NCT06238570|DEVICE|Gavi, Merck® (automated vitrification instrument)|"This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.~The oocytes will be stored in closed cassettes in liquid nitrogen"
219543918|NCT06238570|DEVICE|Vitrolife system|The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
219543919|NCT04186260|BEHAVIORAL|NAFLD-specific weight loss intervention|This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.
219543920|NCT04186260|OTHER|Wait-list control|Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
219543921|NCT02987985|DRUG|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
219543922|NCT02987985|DRUG|Acetaminophen|acetaminophen 15 mg/kg
219621809|NCT03165812|PROCEDURE|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
219543923|NCT02987985|DRUG|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
219621810|NCT03165812|PROCEDURE|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
219543924|NCT02987985|DRUG|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
219543925|NCT02987985|DRUG|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
219543926|NCT02987985|DRUG|Sevoflurane|Sevoflurane (dose titrated to effect)
219543927|NCT02987985|DRUG|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
219621811|NCT05344495|DRUG|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
219621812|NCT05344495|DRUG|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
219621813|NCT00071110|PROCEDURE|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
219543928|NCT04364087|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
219543929|NCT05523895|DRUG|Pimavanserin|Pimavanserin
219543930|NCT05523895|DRUG|Placebo|Pimavanserin matching placebo
219543931|NCT03674892|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|TrueTear™ intranasal neurostimulator (ITN)
219543932|NCT05404594|BEHAVIORAL|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
219543933|NCT02241863|BEHAVIORAL|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
219543934|NCT02241863|BEHAVIORAL|Routine counseling|
219543935|NCT06414733|BIOLOGICAL|Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
219045680|NCT04147312|DRUG|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
219045681|NCT04147312|DRUG|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
219045682|NCT04992221|PROCEDURE|arterial line|arterial line inserted for invasice mointroing and sampling
219045683|NCT06843980|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
219543936|NCT05554419|DRUG|Azacitidine|Given IV or SC
219543937|NCT05554419|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219543938|NCT05554419|DRUG|Cytarabine|Given IV
219543939|NCT05554419|PROCEDURE|Echocardiography Test|Undergo ECHO
219543940|NCT05554419|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219543941|NCT05554419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219543942|NCT05554419|DRUG|Venetoclax|Given PO
219543943|NCT00848146|PROCEDURE|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
219543944|NCT05644587|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
219543945|NCT01907607|DRUG|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
219543946|NCT02478983|DEVICE|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
219045684|NCT06843980|OTHER|Non-Surgical Treatment|The non-surgical arm includes assist devices, physical conditioning, prescription or nonprescription medications, creams, vitamins, or supplements, intra-articular Injections, physical therapy and weight loss.
219045685|NCT04067362|OTHER|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
219543947|NCT02478983|DEVICE|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
219543948|NCT01932177|DRUG|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
219543949|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
218934071|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
218934072|NCT02759718|BIOLOGICAL|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
218934073|NCT00880243|DRUG|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
218934074|NCT03253861|OTHER|No intervention|No intervention
218934075|NCT03696459|DRUG|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
218934076|NCT03696459|DRUG|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
219045686|NCT02871128|DIETARY_SUPPLEMENT|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
219045687|NCT02871128|DIETARY_SUPPLEMENT|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
219543950|NCT01932177|DRUG|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
219543951|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
219543952|NCT05664087|DRUG|Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
219543953|NCT03136627|DRUG|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
219543954|NCT03136627|DRUG|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
219621814|NCT00071110|PROCEDURE|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
219621815|NCT00512681|DRUG|Irinotecan, Oxaliplatin, TS-1|"* S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~* Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
219621816|NCT00200564|DRUG|ketamine|
219621817|NCT01759602|DRUG|C1-esterase inhibitor (Cinryze)|
218934077|NCT03696459|DRUG|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
219543955|NCT03077880|PROCEDURE|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
218934078|NCT03696459|DRUG|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
219543956|NCT05373173|BEHAVIORAL|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
219621818|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
219621819|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
219621820|NCT01473264|DRUG|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
218934079|NCT03696459|DRUG|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
218934080|NCT03696459|DRUG|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
218934081|NCT03696459|DRUG|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
218934082|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
219045688|NCT02871128|DRUG|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
219045689|NCT01453842|DIETARY_SUPPLEMENT|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
219045690|NCT01453842|DIETARY_SUPPLEMENT|Olive oil|Carrot and olive oil and 1½ g of paracetamol
219045691|NCT01453842|DIETARY_SUPPLEMENT|Carrot|Carrot and 1½ g of paracetamol
219045692|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
219045693|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
218934083|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
218934084|NCT01214096|DRUG|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
218934085|NCT01214096|DRUG|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
218934086|NCT00003182|DRUG|cisplatin|
218934087|NCT00003182|DRUG|gemcitabine hydrochloride|
218934088|NCT05426603|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
219045694|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
219045695|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
219045696|NCT04076969|BEHAVIORAL|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
219205670|NCT06871527|DRUG|fruquintinib + tislelizumab + FOLFOX|"phase Ib: fruquintinib (3+3 dose escalation design): L1: 3 mg/d, L2: 4 mg/d, L3: 5 mg/d, qd po, D1-14, Q3W; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin : 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W.~phase II: fruquintinib: RP2D; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin: 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W."
219205671|NCT06872242|DIAGNOSTIC_TEST|Polysomnography|Polysomnography after enrollment for suspected obstructive sleep apnea
219205672|NCT06875115|DEVICE|laser acupuncture|laser acupuncture on acupoints
219205673|NCT05931393|DRUG|Cabozantinib 80 MG|cabozantinib 80mg daily
219205674|NCT06296394|OTHER|Parenthood|The intervention group will consist of participants who became first time parents to children under 5 years of age.
219205675|NCT01487928|DIETARY_SUPPLEMENT|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
219205676|NCT04732416|DRUG|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
218934089|NCT05426603|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
218934090|NCT03198624|DRUG|HTL0018318|Part A single dose Part B five doses
218934091|NCT03198624|DRUG|Placebo oral capsule|Part B only
219205677|NCT05454241|DRUG|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
219205678|NCT05424718|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
219205679|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
219205680|NCT06697587|BEHAVIORAL|Enhanced Cognitive Reappraisal and Emotion Awareness Training (eCREAT)|"eCREAT features psychoeducational content on anger management, practical exercises, and homework assignments, all supported by an online therapist who provides text-based feedback. The protocol builds on a previously evaluated protocol for maladaptive anger (ClinicalTrials.gov; ID: NCT03858296) with added focus on anger inhibition.~eCREAT is based on the two-stage model of maladaptive anger inhibition (Burns et al., 2008), which posits that suppressed anger may rebound and return as angry fantasies and ruminations. To address these core mechanisms, the treatment includes training on adaptive anger processing and expression and strategies for disrupting anger ruminations. These added treatment components are based on established protocols for depressive rumination, and assertive expression of emotion, adapted for an anger context. Additionally, the treatment also focuses on how to flexibly shift between different emotion regulation strategies depending on contextual demands."
219205681|NCT06696521|BEHAVIORAL|Intervention A- Telephone|For intervention A: Once a patient is randomized to telephone (Intervention A), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
219543957|NCT05373173|BEHAVIORAL|Tele-assessment only|Consented families will complete home-based tele-assessment via Zoom that includes the TAP-Preschool. Each participant will have recent data available from comprehensive evaluation tools (ADOS-2, cognitive functioning, adaptive skills). After the session, participating caregivers will provide information about acceptability and challenges.
219543958|NCT04269642|DRUG|PT320 2.0mg Placebo|PT320 2.0mg Placebo
219543959|NCT04269642|DRUG|PT320 2.0 mg|Exenatide slowly released formulation
219543960|NCT04269642|DRUG|PT320 2.5 mg|Exenatide slowly released formulation
219543961|NCT04398056|DRUG|Chemotherapy plus radiotherapy and Toripalimab|"1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
219543962|NCT03779334|DRUG|Risdiplam|Risdiplam will be administered orally.
219543963|NCT02649179|DRUG|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
219543964|NCT02649179|DRUG|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
219543965|NCT06101771|DIAGNOSTIC_TEST|echoCARDIOGRAPHY|Assessment of epicardial fat thickness in children with familial dyslipidemia
218934092|NCT06519721|DRUG|Lenvatinib Combined with VIC-1911|"Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months."
218934093|NCT00006118|DRUG|cisplatin|
219543966|NCT06515405|DRUG|Hydrocortisone|"Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023)."
218934094|NCT00006118|DRUG|gemcitabine hydrochloride|
218934095|NCT00006118|DRUG|paclitaxel|
218934096|NCT05040113|DRUG|CBP-307|CBP-307 capsules oral administration
218934097|NCT00684060|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
218934098|NCT00684060|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
218934099|NCT04917341|DIAGNOSTIC_TEST|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
218934100|NCT06523101|DRUG|PJ009|Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.
218934101|NCT06523101|DRUG|Placebo|Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.
218934102|NCT03708783|PROCEDURE|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
218934103|NCT00702715|DRUG|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
218934104|NCT03340324|BIOLOGICAL|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
218934105|NCT02641561|DRUG|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
219543967|NCT06465927|OTHER|Clinical data collection|Clinical data of elderly acute appendicitis patients with an appendicolith who underwent emergency appendectomy were collected and analyzed.
219543968|NCT03388853|DRUG|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
219543969|NCT03388853|OTHER|Placebo|Placebo once daily for four weeks.
219543970|NCT03934476|BEHAVIORAL|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
219621821|NCT03447587|OTHER|Electroacupuncture|Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.
219045697|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
219045698|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
219045699|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
219045700|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
219045701|NCT02881996|DRUG|IV tylenol|IV tylenol given scheduled in addition to standard PCA
219045702|NCT02881996|DRUG|No IV tylenol|No additional IV Tylenol given
219543971|NCT03934476|BEHAVIORAL|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
218934106|NCT02641561|DRUG|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
219045703|NCT02881996|DRUG|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
219543972|NCT05183191|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
219543973|NCT00797160|DRUG|propofol|2mg/Kg IV in bolus before tracheal intubation
219543974|NCT02275962|DRUG|K-877|
219543975|NCT02275962|DRUG|Rifampin|
219543976|NCT01660594|OTHER|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
219543977|NCT01684774|DRUG|Bupivacaine|
219543978|NCT03246763|BEHAVIORAL|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
219543979|NCT03508011|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
219543980|NCT06560593|DRUG|NTQ5082|single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
219543981|NCT06560593|DRUG|Placebo|multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
219543982|NCT05735795|OTHER|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
219543983|NCT05512104|PROCEDURE|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
219543984|NCT04836494|DRUG|BBP-671|BBP-671, oral suspension
219543985|NCT04836494|DRUG|Placebo|Placebo matching BBP-671
219543986|NCT04836494|DRUG|BBP-671|BBP-671, tablet
219543987|NCT01175135|DRUG|PF-02545920|5 mg tablet every 12 hours for 28 days
219543988|NCT01175135|DRUG|PF-02545920|15 mg tablet every 12 hours for 28 days
219543989|NCT01175135|DRUG|Placebo|One tablet/capsule every 12 hours for 28 days
219543990|NCT01175135|DRUG|Risperidone|3 mg capsule every 12 hours for 28 days
219543991|NCT00529464|PROCEDURE|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
219543992|NCT00529464|PROCEDURE|Colposcopy|A standard colposcopy will be performed.
219543993|NCT00529464|PROCEDURE|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
219543994|NCT02364258|DRUG|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
219543995|NCT02364258|DRUG|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
219543996|NCT00003725|DRUG|valrubicin|
219543997|NCT00003725|PROCEDURE|conventional surgery|
219543998|NCT01886222|OTHER|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
219543999|NCT01886222|OTHER|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
219544000|NCT06319976|OTHER|open chain exercises for rotator cuff muscles|open chain exercises for rotator cuff muscles, three times per week for six weeks.
219544001|NCT06319976|OTHER|Advices for postural correction|Advices for postural correction like neutral position of head and neck, aliening the shoulder and hip and using a foot stool to rest the feet.
218934107|NCT02641561|DRUG|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
218934108|NCT02641561|DRUG|Placebo|Placebo would be a suppository 50 mg x 2
219045704|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
219045705|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
219045706|NCT03422341|DEVICE|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
218934109|NCT04314297|DRUG|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
219544002|NCT04194476|DIAGNOSTIC_TEST|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
219544003|NCT02100917|DRUG|DMB-3111|
219544004|NCT02100917|DRUG|trastuzumab|
219544005|NCT04692155|DRUG|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
219544006|NCT04692155|DRUG|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
219544007|NCT01438203|PROCEDURE|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
219621822|NCT03447587|OTHER|Sham acupuncture|Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
218934110|NCT01827423|DEVICE|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
218934111|NCT06831825|COMBINATION_PRODUCT|YAP101 (AAV9-Sav-shRNA)|YAP101 delivered using YAPCATH-101
218934112|NCT03751657|DRUG|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
218934113|NCT03751657|DRUG|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
218934114|NCT03751657|DRUG|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
218934115|NCT03751657|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
218934116|NCT03751657|DRUG|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
218934117|NCT03751657|DRUG|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
218934118|NCT03162913|DIETARY_SUPPLEMENT|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
219045707|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
219045708|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
219045709|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
219045710|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
219045711|NCT06424054|OTHER|eChemoCoach|the eChemoCoach is an electronic questionnaire which is accessible for patients via the secured electronic health portal (EHP) of the EHR, which is CE-certified. By utilizing the eChemoCoach, patients (for this project we focus on breast cancer patients) have the ability to complete a questionnaire on a daily basis, when experiencing side effects. The eChemoCoach has the potential to evaluate the severity of adverse effects based on the CTCAE criteria and triage them, mimicking the decision-making process of a HCP through computer adaptive testing (CAT). Upon completing the questionnaire, the eChemoCoach translates the responses for each specific side effect into corresponding CTCAE grades. The tool then promptly offers patients personalized advice, tailored to their individual condition.
219544008|NCT01438203|PROCEDURE|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
219544009|NCT02579733|DRUG|Azathioprine|
219544010|NCT02579733|DRUG|Placebo|
219544011|NCT00940563|DRUG|Imatinib|
219544012|NCT00776763|DRUG|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
219544013|NCT00934323|DRUG|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
219544014|NCT00934323|DRUG|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
219544015|NCT02485951|PROCEDURE|Central air injection|Air was injected inside the trephination site in the central injection group.
219544016|NCT02485951|PROCEDURE|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
219544017|NCT02114788|OTHER|Internet-based|
219544018|NCT04398147|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
219544019|NCT04398147|BIOLOGICAL|Placebo|Intramuscular administration
219544020|NCT05235854|DRUG|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
219544021|NCT01165047|DRUG|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
219544022|NCT01934205|DRUG|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
219544023|NCT01934205|DRUG|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
219544024|NCT04221347|OTHER|blood sampling|blood samples will be taken in specified time points
219544025|NCT00747305|DRUG|sunitinib malate|
219544026|NCT00747305|GENETIC|gene expression analysis|
219544027|NCT00747305|GENETIC|reverse transcriptase-polymerase chain reaction|
219544028|NCT00747305|GENETIC|western blotting|
219544029|NCT00747305|OTHER|immunohistochemistry staining method|
219544030|NCT00747305|OTHER|laboratory biomarker analysis|
219544031|NCT00747305|PROCEDURE|adjuvant therapy|
219544032|NCT00747305|PROCEDURE|neoadjuvant therapy|
219544033|NCT00747305|PROCEDURE|therapeutic conventional surgery|
219544034|NCT02120677|DRUG|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
219544035|NCT00967135|DRUG|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
219544036|NCT00967135|DRUG|Placebo|Matching oral placebo twice daily for 5 consecutive days.
219544037|NCT01945450|DRUG|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
219544038|NCT01945450|DRUG|Ampicillin|
218934119|NCT03162913|OTHER|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
218934120|NCT04466709|OTHER|none intervention type|This is an observational study, no intervention
219045712|NCT04101266|OTHER|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
219045713|NCT04101266|OTHER|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
219544039|NCT01945450|DRUG|Gentamycin|
219045714|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
219045715|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
219544040|NCT01945450|DRUG|Clindamycin|
219045716|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
219544041|NCT06225362|DEVICE|Quatera 700|Phacoemulsification device
219544042|NCT06225362|DEVICE|Centurion|Phacoemulsification device
219544043|NCT04474990|DRUG|Tradipitant|NK-1 Receptor antagonist
219544044|NCT05714930|OTHER|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
219544045|NCT05915559|PROCEDURE|Tonsillectomy|Tonsillectomy
219544046|NCT05915559|OTHER|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
219544047|NCT03206086|DRUG|Eltrombopag|Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
219544048|NCT04113109|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
219544049|NCT04113109|DRUG|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
219544050|NCT04113109|DRUG|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
219544051|NCT04113109|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
219544052|NCT04113109|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
219544053|NCT06627127|DEVICE|Target stimulation (HGN, AC, GG, Strap muscles)|Stimulation of the HGN or GG along with AC or strap muscles.
219544054|NCT06140082|GENETIC|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
219544055|NCT04516460|DEVICE|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
219544056|NCT03591276|DRUG|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
219544057|NCT03957551|DRUG|Cabozantinib|"Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle."
219544058|NCT03957551|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
219544059|NCT05283148|OTHER|Dual-energy X-ray absorptiometry|Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body
219544060|NCT05283148|OTHER|Vertebral fracture analysis|Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA
219544061|NCT05283148|OTHER|Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire|Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
219544062|NCT00292929|DRUG|Intravenous artesunate|
219544063|NCT00095784|DRUG|Decitabine|Given SC
219544064|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
219544065|NCT05207878|OTHER|STEGA-MRI|Precision drawing task (movement assessment)
219544066|NCT04131413|DRUG|pNGVL4aCRTE6E7L2|The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
219544067|NCT00000666|DRUG|Pyrimethamine|
219544068|NCT03071562|OTHER|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
219544069|NCT06124339|BEHAVIORAL|Physical Activity|There will be three sessions a week over the course of 16 weeks.
219544070|NCT06124339|BEHAVIORAL|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
219544071|NCT06124339|BEHAVIORAL|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
219045717|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
219045718|NCT02789176|OTHER|Surveys|Regarding development, epilepsy, and family impact
219544072|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
219544073|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
219544074|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
219544075|NCT05169931|BIOLOGICAL|RegenerEyes|Biologic eye drop
219544076|NCT01161420|DEVICE|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
219045719|NCT02789176|OTHER|EEG|
219045720|NCT02473068|DEVICE|CPAP|
219544077|NCT04435574|DRUG|Lactoferrin|Bovine Lactoferrin 100mg sachets.
219544078|NCT04435574|DRUG|Ferrous Sulfate|6mg/kg of ferrous sulfate.
219544079|NCT00064831|DRUG|Black Cohosh Extract (BCE)|
219621823|NCT03213808|OTHER|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
219045721|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
219045722|NCT03393221|BEHAVIORAL|SBWC|
219045723|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
219045724|NCT00772096|DRUG|n-3 fatty acids|
219544080|NCT02145273|BEHAVIORAL|Interpersonal Psychotherapy for Depression -Group|
219544081|NCT05947474|DRUG|ORB-011|Drug: ORB-011 is dosed via IV infusion
219045725|NCT05194020|OTHER|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
219544082|NCT04378751|BEHAVIORAL|Decision aid video|Decision aid video
219544083|NCT04378751|BEHAVIORAL|Genetic counseling informational brochure|Genetic counseling informational brochure
218934121|NCT01452932|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
218934122|NCT01452932|OTHER|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
218934123|NCT03055130|OTHER|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
218934124|NCT02310204|BEHAVIORAL|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
218934125|NCT02310204|OTHER|standard psoriasis care alone|
218934126|NCT03894813|DRUG|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
218934127|NCT03894813|DRUG|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
219045726|NCT06381921|BEHAVIORAL|IBS-PPSM intervention|IBS-PPSM intervention includes 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting.
218934128|NCT00080444|DRUG|aprepitant|aprepitant capsules
218934129|NCT00080444|DRUG|ondansetron|ondansetron IV preparation
218934130|NCT00080444|DRUG|dexamethasone|dexamethasone tablets
218934131|NCT00080444|DRUG|placebo to aprepitant|Matching placebo to aprepitant capsules
219544084|NCT04378309|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
218934132|NCT00080444|DRUG|placebo to dexamethasone|Matching placebo to dexamethasone tablets
219045727|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
219045728|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
219544085|NCT05920629|BEHAVIORAL|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 3 months. We will perform a first echocardiography at randomization and a second at 3 months' follow-up.
219544086|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
219544087|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
219045729|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
219045730|NCT00596011|DRUG|Placebo|Matching placebo BID
219045731|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
219544088|NCT03218150|PROCEDURE|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
219544089|NCT04149691|DRUG|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
218934133|NCT00080444|DRUG|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
218934134|NCT05523778|PROCEDURE|placement of pancreatic duct stents before enucleation surgery|Advance placement of pancreatic stents endoscopically
218934135|NCT05523778|PROCEDURE|Direct enucleation surgery|Patients will receive direct enucleation surgery
218934136|NCT04002492|BEHAVIORAL|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
218934137|NCT01619969|DRUG|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
218934138|NCT01619969|DRUG|placebo|Capsules of identical appearance containing starch
218934139|NCT01213199|DRUG|Adapalene|Adapalene Gel 0.3%
219045732|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
219045733|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
219045734|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
218934140|NCT03083873|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
218934141|NCT03083873|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
218934142|NCT06125080|DRUG|Utidelone|Utidelone (30 mg/m2, days 1-5, every 3 weeks)
218934143|NCT06125080|DRUG|Tirelizumab|Tirelizumab（200mg, day1, every 3 weeks）
218934144|NCT06125080|DRUG|Bevacizumab|Bevacizumab(7.5mg/kg, day1, every 3 weeks)
218934145|NCT01677377|DRUG|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
218934146|NCT01677377|DRUG|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
218934147|NCT05250388|PROCEDURE|Arthroscopic Bankart repair|Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
218934148|NCT00296699|DRUG|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~\* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
218934149|NCT03975478|PROCEDURE|Gastric bypass|The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.
218934150|NCT03975478|PROCEDURE|Sleeve gastrectomy|The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
218934151|NCT02932371|DEVICE|ECOM™.|
218934152|NCT02932371|DEVICE|Trans-esophageal echography|
218934153|NCT01284335|DRUG|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218934154|NCT01284335|DRUG|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218934155|NCT01284335|DRUG|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218934156|NCT01284335|DRUG|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218934157|NCT01284335|DRUG|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
218934158|NCT01284335|DRUG|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
219544090|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (single-shot)|30 mL of 0.25% bupivacaine will be injected as single-shot block 20 mins prior to surgery
218934159|NCT02656693|BEHAVIORAL|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
218934160|NCT02656693|BEHAVIORAL|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
218934161|NCT00994968|DRUG|cyclophosphamide|
218934162|NCT00994968|DRUG|docetaxel|
218934163|NCT00994968|DRUG|doxorubicin hydrochloride|
218934164|NCT00994968|DRUG|tegafur-gimeracil-oteracil potassium|
218934165|NCT00994968|PROCEDURE|neoadjuvant therapy|
218934166|NCT00994968|PROCEDURE|therapeutic conventional surgery|
218934167|NCT00842751|DRUG|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
218934168|NCT00842751|OTHER|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
218934169|NCT00842751|DRUG|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
218934170|NCT00842751|DRUG|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
218934171|NCT00842751|OTHER|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
218934172|NCT01403597|DEVICE|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
219045739|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
219544091|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (catheter)|In addition to administration of 30 mL of 0.25% bupivacaine prior to surgery, a catheter will be placed in the area to administer bolus of 1 mg/kg of 0.25% bupivacaine every 8 hours postoperatively.
218934173|NCT00693901|BEHAVIORAL|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
218934174|NCT00693901|BEHAVIORAL|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
219045740|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
219045741|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
219045742|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
219045743|NCT01588002|DRUG|danoprevir|multiple oral doses
219045744|NCT01588002|DRUG|efavirenz|multiple oral doses
219045745|NCT01588002|DRUG|ritonavir|multiple oral doses
219045746|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
219045747|NCT04583813|DRUG|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
219045748|NCT04583813|OTHER|Placebo|Empagliflozin matching placebo, once daily, for 24 months
219045749|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
219544092|NCT06389448|DEVICE|pCLE-gastr|After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
219544093|NCT06452030|BEHAVIORAL|Specific sensorimotor control training|Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
219544094|NCT06452030|BEHAVIORAL|Aspecific extension training|Participants allocated to the aspecific group will receive spinal extension exercises.
219544095|NCT06452030|BEHAVIORAL|Fascia training|Participants allocated to the fascia group will receive general movement exercises.
219544096|NCT06847074|BEHAVIORAL|Multimodal Exercise|Each 60-minute class will include a 10-minute warm-up (i.e., stretches for the major muscles and walking on the spot), 40 minutes of training, and a 10-minute cool down (i.e., stretches and relaxation techniques).Instructors will use heart rate monitors to continuously track intensity during and across all sessions.
218934175|NCT03319758|PROCEDURE|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
218934176|NCT01628666|DRUG|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
219045750|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
219045751|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
219045752|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
219544097|NCT06847074|BEHAVIORAL|Cognitve and Social Activities|Each 60-minute class will include 30 minutes of cognitive enrichment activities and 30 minutes of activities that promote social interactions.
219544098|NCT00608322|DRUG|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
219544099|NCT00608322|OTHER|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
218934177|NCT01628666|DRUG|Conventional|Cefazolin preoperative
218934178|NCT04535778|BEHAVIORAL|COMPASS|An 11 module, therapist-supported online CBT program.
218934179|NCT04535778|BEHAVIORAL|Standard charity resources|Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
219045753|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
219544100|NCT03396939|DEVICE|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
219544101|NCT04228822|OTHER|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
218934180|NCT02269267|DRUG|Imatinib (Stopping their TKI)|Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
218934181|NCT02269267|DRUG|Dasatinib (Stopping their TKI)|Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
219045754|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
219621824|NCT04507464|BEHAVIORAL|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
219621825|NCT05810532|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
219621826|NCT05810532|OTHER|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
219621827|NCT02433132|OTHER|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
218934182|NCT02269267|DRUG|Nilotinib (Stopping their TKI)|Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
219045755|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
219045756|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
219045757|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
219544102|NCT05846139|COMBINATION_PRODUCT|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
219544103|NCT05846139|COMBINATION_PRODUCT|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
219544104|NCT06157905|DRUG|Oral Tofacitinib citrate|oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
219544105|NCT04491422|COMBINATION_PRODUCT|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
219544106|NCT00587730|DEVICE|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
219544107|NCT02761525|OTHER|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
219045758|NCT00796965|DRUG|Placebo|
219045759|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
219544108|NCT02761525|OTHER|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
219544109|NCT03023449|DRUG|Nitric Oxide|Inhaled Nitric Oxide gas
219544110|NCT06072339|OTHER|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
219544111|NCT06072339|PROCEDURE|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
219621828|NCT02686307|PROCEDURE|ICD Implant|Implantation of an implantable cardioverter/defibrillator
218934183|NCT02269267|DRUG|Bosutinib (Stopping their TKI)|Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
219544112|NCT06072339|BIOLOGICAL|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
218934184|NCT03016000|DRUG|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
219544113|NCT06072339|OTHER|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
218934185|NCT03016000|OTHER|Observation|Just observation
218934186|NCT00482066|DRUG|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
218934187|NCT03620877|BEHAVIORAL|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
218934188|NCT03053167|DRUG|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
218934189|NCT03053167|DRUG|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
218934190|NCT03773796|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
218934191|NCT01158599|BIOLOGICAL|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
218934192|NCT05906290|OTHER|Multigenerational eHealth Intervention for Grandparents and Grandchildren|Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
218934193|NCT04161703|PROCEDURE|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
218934194|NCT04161703|PROCEDURE|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A \& B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
218934195|NCT00590772|DRUG|montelukast|10 mg po each day (compared to placebo for 2 weeks)
218934196|NCT00590772|DRUG|placebo|placebo for 2 weeks
218934197|NCT03993067|PROCEDURE|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
219045760|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
219621829|NCT03896698|DEVICE|Transcranial Ultrasound Stimulation|TUS activate the brain cells
218934198|NCT03993067|PROCEDURE|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
218934199|NCT02543424|BEHAVIORAL|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
218934200|NCT06182956|DEVICE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
218934201|NCT06182956|DEVICE|Nasal high-flow oxygen therapy|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
218934202|NCT06182956|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
218934203|NCT03360318|DEVICE|elbow cast|elbow cast
218934204|NCT03360318|DEVICE|Removable elbow brace|Removable elbow brace
219544114|NCT05877339|DIAGNOSTIC_TEST|Survey|Survey
219045761|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
219045762|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
219045763|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
219045764|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
219045765|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
219621830|NCT00856882|DIETARY_SUPPLEMENT|soy protein|
219045766|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
219544115|NCT03614039|DIETARY_SUPPLEMENT|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
219544116|NCT03614039|DIETARY_SUPPLEMENT|Placebo|
219621831|NCT00856882|DIETARY_SUPPLEMENT|isoflavones|
219621832|NCT00856882|DIETARY_SUPPLEMENT|milk protein|
218934205|NCT01173289|RADIATION|External Beam Radiotherapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~* Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~* Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~* Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~* The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
218934206|NCT01833156|DEVICE|MoistureMeterD|measuring erythema size and the dielectric constant values
218934207|NCT03243292|OTHER|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
218934208|NCT03805659|DEVICE|HD-tDCS|High-Dose transcranial Direct Current Stimulation
218934209|NCT03805659|DEVICE|Sham|Sham sessions (no electric current)
218934210|NCT02082119|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
218934211|NCT01350401|GENETIC|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
218934212|NCT03263663|DRUG|targeted substance according to the avatar model|individualized second line treatment
218934213|NCT03188497|DRUG|Lobaplatin|Lobaplatin for Injection
218934214|NCT03188497|DEVICE|linear accelerator|Medical linear accelerator
218934215|NCT02228837|DIETARY_SUPPLEMENT|Pear|
219544117|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
218934216|NCT02228837|DIETARY_SUPPLEMENT|Placebo|
218934217|NCT04099264|OTHER|Personalized music|Patients in the intervention group will listen to personalized music from the Musicare application
218934218|NCT04099264|OTHER|Audio Books|Patients in the active comparator group will listen to audio books
218934219|NCT04800172|DRUG|Roflumilast|administration of roflumilast 500 mcg tablet once daily for 3 months.
218934220|NCT04800172|DRUG|placebo|administration of placebo tablet once daily for 3 months.
218934221|NCT01773759|BEHAVIORAL|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
218934222|NCT03768648|OTHER|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
218934223|NCT03768648|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
218934224|NCT03768648|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
218934225|NCT03768648|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
218934226|NCT03768648|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
219544118|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
219544119|NCT05606120|DEVICE|CL TRAUMA femoral stem|Hip arthroplasty according to the instruction for use.
218934227|NCT02869737|DEVICE|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
218934228|NCT01047605|DRUG|Neurapas balance|6 tablets single dose
218934229|NCT01047605|DRUG|Pascoflair 425 mg|3 tablets , single dose
218934230|NCT01047605|DRUG|P-Tabletten weiß|3 tablets, single dose
218934231|NCT00796419|DRUG|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
218934232|NCT00796419|DRUG|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
218934233|NCT01250145|DRUG|LY333334|Transdermal patch
218934234|NCT01250145|DRUG|Placebo|Transdermal patch
218934235|NCT05345340|OTHER|Telemedicine|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days)."
218934236|NCT05345340|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
218934237|NCT04491513|DIAGNOSTIC_TEST|Computed tomography angiography|Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
218934238|NCT00082862|BIOLOGICAL|recombinant interferon alfa|
218934239|NCT00082862|DRUG|cisplatin|
218934240|NCT00082862|DRUG|gemcitabine hydrochloride|
218934241|NCT00082862|PROCEDURE|hyperthermia treatment|
218934242|NCT02513927|DRUG|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
218934243|NCT02513927|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
218934244|NCT04455464|DRUG|Midodrine Oral Tablet|Midodrine will be given 10 mg for one time only.
218934245|NCT02964013|BIOLOGICAL|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
218934246|NCT02964013|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
218934247|NCT02964013|DRUG|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
218934248|NCT02964013|DRUG|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
219544120|NCT05331482|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
219544121|NCT05331482|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
219544122|NCT06192368|DEVICE|INSPIRE|Virtual reality application for relaxing.
219544123|NCT06192368|DEVICE|Tablet|Gaming tablet
219544124|NCT06145412|DRUG|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
219544125|NCT06145412|DRUG|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
219544126|NCT06145412|RADIATION|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
219544127|NCT05776420|BEHAVIORAL|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
219544128|NCT06389591|BIOLOGICAL|pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
219544129|NCT06389591|BIOLOGICAL|RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)|personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
219544130|NCT05614765|DRUG|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
219544131|NCT05817110|OTHER|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
219544132|NCT06161506|DEVICE|Elidah Device|The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
218934249|NCT02964013|BIOLOGICAL|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
218934250|NCT02964013|DRUG|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
219544133|NCT00834444|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
219544134|NCT00834444|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
219544135|NCT01321567|DRUG|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
219544136|NCT06559644|BIOLOGICAL|Hema-NeoTIL01|Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
219544137|NCT00473772|DEVICE|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
219544138|NCT05866263|OTHER|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
219544139|NCT05485064|DRUG|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
219544140|NCT05485064|PROCEDURE|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
219544141|NCT05485064|DRUG|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
218934251|NCT02964013|DRUG|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
218934252|NCT01404936|DRUG|Interferon-2A|4 (x106 IU/m\^2) subcutaneously on days 1-4.
218934253|NCT01404936|DRUG|Adriamycin|25 mg/m\^2 by vein on day 4.
218934254|NCT01404936|DRUG|Bleomycin|10 mg/m\^2 by vein on day 4.
219365716|NCT05682014|BEHAVIORAL|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
218934255|NCT01404936|DRUG|Velban|6 mg/m\^2 by vein on day 4.
219544142|NCT05485064|DRUG|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
219621833|NCT04430062|PROCEDURE|Surgical procedures performed under general anesthesia|Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
218934256|NCT01404936|DRUG|Dacarbazine|375 mg/m\^2 by vein on day 4.
218934257|NCT00156676|DEVICE|Body-weight supported treadmill|
218934258|NCT00156676|DEVICE|Lokomat|
218934259|NCT00156676|DEVICE|Body-weight supported treadmill|
218934260|NCT00156676|DEVICE|Lokomat|
218934261|NCT01398306|OTHER|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
219205682|NCT06696521|BEHAVIORAL|Intervention B- Televideo|For intervention B: Once a patient is randomized to televideo (Intervention B), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
219205683|NCT06696573|DRUG|Prophylactic NSAID Administration|Participants in this arm will receive a prophylactic dose of a non-steroidal anti-inflammatory drug (NSAID) prior to the onset of pain during medical abortion procedures for pregnancies between 13 and 22 weeks. The intervention aims to reduce pain intensity throughout the process. The NSAID administration involves a specific dosage and schedule, adhering to safety guidelines and monitored for potential side effects.
219544143|NCT06321016|OTHER|Physical exercise program|At least two sessions a week for a 6-month supervised and individualized physical exercise program that will have two phases: one that will be carried out in person in the hospital environment taking advantage of medical visits, and a second phase that will allow the patient to carry out the exercise sessions from home with live virtual supervision.
219544144|NCT06321016|OTHER|Type of the physical exercise program|Two types of intervention are proposed depending on the age of the patients: Exercise intervention for adolescents (12 to 18 years): training will be based on strength training (2 - 3 sets of 8 - 12 repetitions) with elastic bands, weights, weights, medicine balls or body weight and aerobic work on a stationary bike, treadmill or other aerobic exercises. Sessions will last about 30-60 minutes (depending on the patient's situation). Exercise intervention for children (4 to 11 years old): The aim will be to work on basic motor skills through play, thus trying to avoid the delay in motor development, and to indirectly work on their physical condition to better cope with the effects of the treatments. Music, games that require movement and materials such as balls, hoops, etc., will be used to motivate the child to move while enjoying themselves. This will be done in sessions of 20 - 40 minutes.
219205684|NCT06696573|DRUG|On-Demand NSAID Administration|Participants in this group will receive a non-steroidal anti-inflammatory drug (NSAID), such as Ibuprofen, in oral tablet form at a dose of 400 mg. The drug will be administered as needed when participants report experiencing pain during the medical abortion process for pregnancies between 13 and 22 weeks. The goal of this intervention is to provide pain relief in response to individual needs, with administration and dosage adjusted as clinically indicated. Monitoring will occur to assess the efficacy, safety, and patient response to the on-demand approach.
219544145|NCT05288972|DEVICE|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
219544146|NCT05288972|DEVICE|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
219544147|NCT02022150|BEHAVIORAL|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
219544148|NCT02129140|DEVICE|Hernia graft/mesh|observational group
219544149|NCT03855579|DRUG|Levosimendan|Intraoperative infusion of Levosimendan
219544150|NCT03855579|DRUG|Milrinone|Intraoperative infusion of Milrinone
219544151|NCT05105633|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
219205685|NCT05198765|BEHAVIORAL|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
219205686|NCT04552119|DEVICE|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
219205687|NCT04552119|DEVICE|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
219205688|NCT06226948|DEVICE|CGM|Participants will wear CGM monitors for 10 days.
219205689|NCT06226948|DIAGNOSTIC_TEST|Visualization|Enriched visualization of SCORE2 CVD risk.
219205690|NCT06501924|DIETARY_SUPPLEMENT|DA-005|Oral Botanical Supplement HIF-1a inhibitor
219205691|NCT06501924|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
219205692|NCT06501924|DRUG|DA-002|Topical Alpha 1 Agonist (GRAS)
219205693|NCT06501924|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Placebo Oral Tablet
219205694|NCT06501924|OTHER|Placebo Topical Solution|Placebo Topical Solution
219205695|NCT04046549|DRUG|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
219205696|NCT04046549|DRUG|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
219544152|NCT05105633|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
219544153|NCT04293653|OTHER|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
219544154|NCT05498857|DRUG|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
219544155|NCT05498857|DRUG|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
219544156|NCT05887934|DEVICE|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
219544157|NCT03926650|DEVICE|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
219544158|NCT05442034|BIOLOGICAL|growth factors to help in regeneration|regenerative therapy
219544159|NCT05299463|DIAGNOSTIC_TEST|Exercise Testing|"* Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG)."
219544160|NCT04884841|OTHER|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
219544161|NCT04884841|OTHER|Patients without postoperative complications|Patients without postoperative complications
219544162|NCT00045786|DRUG|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
219544163|NCT06621784|OTHER|Core stabilization exercises|In most studies, exercises focused on the extremities have been researched. We believe that the positive effects of the core region on walking and postural stability will play a significant role in the treatment of knee osteoarthritis.
219544164|NCT06621784|OTHER|Classical exercise therapy|In the first group of our study, we prescribed exercises that have been proven effective in many studies, are frequently prescribed, and focus on joint range of motion and quadriceps strengthening
219544165|NCT00835614|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
219544166|NCT00835614|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
219544167|NCT00606281|DRUG|Aripiprazole|oral, 24mg/day
219544168|NCT00606281|DRUG|placebo|oral, 0mg(4tablets)/day
219544169|NCT02294981|DEVICE|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
219544170|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
219544171|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
219544172|NCT02875314|DRUG|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
219544173|NCT02875314|DRUG|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
219544174|NCT02875314|DRUG|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
219544175|NCT02927210|DRUG|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
219544176|NCT02927210|DRUG|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
219544177|NCT00525746|BEHAVIORAL|Interview|Interview lasting about 50 minutes.
219544178|NCT06300216|DRUG|Octreotide microspheres|20mg/30mg Q4W
219544179|NCT00617396|DRUG|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
219544180|NCT06013150|DRUG|Epinephrine|Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
219544181|NCT06013150|DRUG|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
219544182|NCT00003980|DRUG|BIBX 1382|
219621834|NCT03257540|DEVICE|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
219621835|NCT02696291|DRUG|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
219621836|NCT02696291|DRUG|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
219205697|NCT04046549|DRUG|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
219365717|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic retrosigmoid minimally invasive vestibular neurectomy
219365718|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic tenotomy of middle ear muscles
219365719|NCT00483327|DRUG|Megestrol Acetate|
219365720|NCT00239031|DRUG|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
219365721|NCT02087332|DRUG|Prolonged release Torasemide (Britomar)|
219365722|NCT02087332|DRUG|Torasemide (Diuver)|
219365723|NCT04217343|DIAGNOSTIC_TEST|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
219365724|NCT01746251|DRUG|Afatinib|
219365725|NCT04120558|OTHER|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
219365726|NCT04120558|OTHER|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
219365727|NCT01184690|PROCEDURE|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
219365728|NCT01184690|PROCEDURE|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
219365729|NCT00249574|DRUG|Buprenorphine/naloxone|Human subjects HIV, HCV
219365730|NCT00249574|DRUG|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
219365731|NCT00670007|BIOLOGICAL|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
219365732|NCT00618722|DRUG|Deoxycholic Acid Injection|
219365733|NCT00618722|DRUG|Placebo|
219365734|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
219365735|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
219365736|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
219365737|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
219365738|NCT05825248|OTHER|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
219365739|NCT05825248|OTHER|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
219365740|NCT05949008|DRUG|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
219365741|NCT05949008|DRUG|Placebo|Matching placebo will be provided as 1000 mg capsules
219365742|NCT00624221|PROCEDURE|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
219365743|NCT00200057|DEVICE|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
219544183|NCT05749887|PROCEDURE|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~1. No parametrial involvement, extrafascial hysterectomy;~2. There is parametrial involvement, extensive hysterectomy(Q-MC);~3. Only bladder invasion, anterior pelvic exenteration;~4. Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~5. Invasion of bladder and rectum, total exenteration.~6. The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
219205698|NCT04046549|DRUG|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
219621837|NCT02696291|DRUG|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
219621838|NCT02696291|DRUG|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
218934262|NCT01368328|DIETARY_SUPPLEMENT|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
218934263|NCT06278441|OTHER|Kangaroo care and White noise|CG newborns underwent routine heel lancing, and no intervention was performed.
218934264|NCT01886599|DRUG|Asunaprevir|
218934265|NCT01137201|PROCEDURE|Suturing of mesenteric defects|
218934266|NCT01460043|DRUG|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
219045767|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
219045768|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
219045769|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
219205699|NCT06700187|OTHER|Interrupting sitting with walking breaks|Participants will engage in 27 minutes walking in different frequencies, including short breaks (walk 1 minute every 10 minutes), moderate breaks (walk 3 minutes every 30 minutes), and long breaks (walk 27 minutes in one time during the intervention).
219205700|NCT06632379|DRUG|Atorvastatin 10 mg|Participants will be assigned to 10 mg Atorvastatin
219621839|NCT02696291|DRUG|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
219621840|NCT02696291|DRUG|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
219621841|NCT06358768|OTHER|teamwork job improvement overall|increase of teamwork capacities and skills improvement
219621842|NCT06358768|OTHER|teamwork job improvement in actor scenario vs mannequin scenario|increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
219621843|NCT02312167|DEVICE|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
218934267|NCT01460043|DRUG|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
218934268|NCT01014351|DRUG|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
218934269|NCT01014351|DRUG|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
218934270|NCT01014351|DRUG|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
218934271|NCT01069900|DRUG|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
218934272|NCT01069900|DRUG|Ertapenem|For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
218934273|NCT01069900|DRUG|Amoxicillin/Clavulanate|Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
218934274|NCT01069900|DRUG|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
219205701|NCT06632379|DRUG|Placebo|Participants will be assigned to identical appearing placebo
219205702|NCT00638898|DRUG|busulfan|Given IV
219045770|NCT02821962|BEHAVIORAL|Sedentary prompts from a VTAP device|
219045771|NCT02399150|OTHER|No intervention as observational study|
218934275|NCT01069900|DRUG|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
218934276|NCT01069900|DRUG|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
218934277|NCT06343480|DRUG|Labour Induction|the use of misoprostol sublingual for labour induction compared with oxytocin titration in parturients with prelabour membrane rupture at term.
219045772|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
219205703|NCT00638898|DRUG|melphalan|Given IV
219205704|NCT00638898|DRUG|topotecan hydrochloride|Given IV
219205705|NCT00638898|OTHER|laboratory biomarker analysis|Correlative studies
219205706|NCT00638898|BIOLOGICAL|filgrastim|Given IV or subcutaneously
219205707|NCT00638898|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transplantation
219205708|NCT00638898|OTHER|pharmacological study|Correlative studies
219205709|NCT00638898|PROCEDURE|autologous bone marrow transplantation|Undergo transplantation
219205710|NCT06875570|OTHER|Pliometric Training|The full intervention program will cover 12 weeks in the season. Prior to training, players will be instructed to warm-up for ten minutes with general running exercises and dynamic stretching. The plyometric training intervention will consist of 5 exercises performed in the following order: Leap forward and backward on the line, leap sideways on the line, double leg knee to chest, split squat jump, and squat jump (Bavli, 2012). A volleyball coach will monitor the whole training.
219205711|NCT06875570|OTHER|Jump Rope Training|The entire intervention program will last for 12 weeks during the season. Before training, players will be instructed to warm up with general running exercises and dynamic stretching for ten minutes. The jump rope intervention will consist of 5 exercises performed in the following order: basic jump step, double leg double jump, double leg jump left and right, double leg jump forward and backward, and scissor steps (Trecroci et al., 2015). Each exercise will be performed by all participants using a jump rope with the same characteristics in terms of weight (e.g. 230g), length (e.g. shoulder size) and material (e.g. PVC, Polyvinyl Chloride). A metronome speed of 120 beats per minute will be used to ensure equal exercise intensity in both exercise programs Furthermore, a volleyball coach will monitor the entire workout.
219205712|NCT06875570|OTHER|Small Sided Games|More complex, skill-based conditioning exercises for volleyball are small-sided games (2v2, 3v3) and competition drills (6v6). Although the duration of each rally in these drills is not controlled by the coach, the total duration of the drill will be recorded to aid in-session and inter-session planning. Total repetitions will be easily measured by adding up the total points played in the rally and then multiplying by the number of rallies per point. The coach will create an emotionally intense environment by applying a scoring system (e.g. team winning 2 out of 3 rallies gets 1 big point, 5 seconds rest) and encouraging the players (Trajkovic et al., 2012).
219205713|NCT06873061|OTHER|telenursing|This study aims to examine the impact of telemedicine training on nursing students. The training content is designed specifically for nursing students and includes various techniques such as simulations.
219205714|NCT03501836|DEVICE|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
219205715|NCT03965234|DRUG|Cisplatin|Given via infusion
219205716|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
219205717|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
219205718|NCT07029945|DRUG|BRX011|Subjects will ingest BRX011 orally, as capsules.
219205719|NCT07029945|DRUG|Placebo|Subjects will ingest Placebo orally, as capsules.
219205720|NCT06694337|DIETARY_SUPPLEMENT|300 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
219205721|NCT06694337|DIETARY_SUPPLEMENT|450 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
219205722|NCT06694337|OTHER|Control group|Placebo
219205723|NCT06694935|DRUG|QX1206|QX1206 will be administered orally before bedtime
219205724|NCT06874400|OTHER|Dairy|The dairy products that participants will be required to consume include: 1) Trial 1: 2% cow's milk; 2) Trial 2: dairy yogurt; 3) Trial 3: 2% cottage cheese; 4) Trial 4: 2% cow's milk; and 5) Trial 5: isolated whey protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 dairy product in that trial.
219365744|NCT01533727|DRUG|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
219365745|NCT01533727|DRUG|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
219045773|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
219045774|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
219544184|NCT02893735|OTHER|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
219205725|NCT06874400|OTHER|Plant-based alternative|The plant-based products that participants will be required to consume include: 1) Trial 1: soy beverage; 2) Trial 2: plant-based yogurt; 3) Trial 3: tofu; 4) Trial 4: 2% simulated milk; and 5) Trial 5: isolated soy protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 plant-based alternative product in that trial.
219544185|NCT02893735|OTHER|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
219544186|NCT03556618|BEHAVIORAL|Whole Person Care (WPC) Reentry Program - Pre & Post Release services|Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
219544187|NCT06558890|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation
219544188|NCT04522258|DIETARY_SUPPLEMENT|Dietary fiber|Fermentable cereal bran
219544189|NCT04522258|DIETARY_SUPPLEMENT|Placebo|Refined cereal flour
219544190|NCT02213263|BIOLOGICAL|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
219544191|NCT02213263|BIOLOGICAL|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
219544192|NCT06559085|PROCEDURE|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
219544193|NCT06559085|PROCEDURE|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
219544194|NCT05752721|BEHAVIORAL|Transition to Online Ordering|The intervention food pantry will transition to online ordering at least once.
219544195|NCT03492320|OTHER|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
219544196|NCT03006757|OTHER|titanium dioxide denture base|
219621844|NCT00218712|BEHAVIORAL|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
219045775|NCT01569529|BEHAVIORAL|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
219045776|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
219045777|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
219045778|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
219045779|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
219045780|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
219205726|NCT06289153|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
219205727|NCT06289153|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
219205728|NCT07030049|DEVICE|Postero-stabilized total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a postero-stabilized total knee replacement. The postero-stabilized TKA consists of a femoral component with a build-in cam mechanism and a tibial component with a post-mechanism.
219544197|NCT01188681|DRUG|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
219045781|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
219045782|NCT03325166|DRUG|Ferumoxytol|Given IV
219045783|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
219045784|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219045785|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
219205729|NCT07030049|DEVICE|Cruciate-retaining total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a cruciate-retaining total knee replacement. The cruciate-retaining TKA consists of a femoral component and a tibial component that leaves the posterior cruciate ligament intact.
219205730|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
219544198|NCT01188681|DRUG|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
219544199|NCT01188681|DRUG|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
219544200|NCT01188681|DRUG|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
219544201|NCT02087553|BIOLOGICAL|Transfusion of red blood cells|(non-experimental) PRBC transfusion
219544202|NCT02087553|BIOLOGICAL|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
219544203|NCT06446869|DIETARY_SUPPLEMENT|Gyntima Menopause|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
219544204|NCT06446869|OTHER|Placebo|Placebo comparator
219544205|NCT02937948|OTHER|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
219544206|NCT02937948|RADIATION|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
219544207|NCT03853005|OTHER|HVHDF|Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
219544208|NCT03853005|OTHER|controlled|Patients will receive the usual care
219544209|NCT06397339|OTHER|INTACT Program|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
219544210|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
219544211|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
219544212|NCT03060863|BEHAVIORAL|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
218934278|NCT02642315|DRUG|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
219045786|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
219045787|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
219544213|NCT03060863|BEHAVIORAL|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
219544214|NCT03060863|BEHAVIORAL|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
219544215|NCT03060863|BEHAVIORAL|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
219544216|NCT03829670|DIAGNOSTIC_TEST|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
219544217|NCT04516915|DRUG|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
219544218|NCT04516915|DRUG|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
219544219|NCT05444647|PROCEDURE|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
219544220|NCT05333107|DRUG|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
219045788|NCT06263335|OTHER|Mindfulness Based Stress Reduction Intervention|During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
219544221|NCT05333107|DRUG|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
219544222|NCT05333107|DRUG|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
219544223|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
219045789|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
219621845|NCT00218712|BEHAVIORAL|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
218934279|NCT01760785|DRUG|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
219205731|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
219205732|NCT06879834|DEVICE|taking fundus photos using non-mydriatic fundus camera|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
219205733|NCT07031349|DEVICE|MARPE|Adult patients with maxillary constriction underwent maxillary expansion using a miniscrew-assisted rapid palatal expander (MARPE).
219205734|NCT07032714|DRUG|Talquetamab|Talquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).
219544224|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
219544225|NCT03637556|DRUG|DST-0509|Novel iron chelator with improved absorption characteristics
219544226|NCT03637556|DRUG|Jadenu|Commercial iron chelator with standard absorption characteristics
219544227|NCT03637556|DRUG|Exjade|Commercial iron chelator with standard absorption characteristics
219544228|NCT01326494|DRUG|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
219544229|NCT00299871|DRUG|LIXISENATIDE (AVE0010)|
219621846|NCT05761314|DIAGNOSTIC_TEST|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
219621847|NCT02350023|DRUG|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
219621848|NCT02350023|DRUG|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
218934280|NCT01760785|DRUG|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
218934281|NCT04870489|COMBINATION_PRODUCT|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
218934282|NCT04870489|DEVICE|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
218934283|NCT03771170|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
219045790|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
219544230|NCT03668015|OTHER|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
219544231|NCT03668015|OTHER|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
219544232|NCT00263588|DRUG|lapatinib|tyrosine kinase inhibitor
219544233|NCT01943877|PROCEDURE|scaling root planing|scaling root planing
219544234|NCT01943877|DRUG|Propolis|experimental
219544235|NCT05630612|DRUG|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
219544236|NCT03848507|DRUG|albumin 20%|Intravenous administration of 20% albumin during cystectomy
219544237|NCT05053230|BEHAVIORAL|IM@Home|Participants in the IM@Home group will receive a 12-week virtual, synchronous, mind-body and fitness program. The Classes will be conducted via Zoom video conferencing platform. Patients will choose from a variety of weekly classes, occurring one to four times per week. An Integrative Medicine Service (IMS) clinical therapist (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting will lead each session. Activities range from more movement-based (fitness, yoga, dance therapy, or tai chi) to meditative-based classes (meditation, guided meditation, or music therapy). All clinicians will provide an overview of the session, 25 to 40 minutes of content, and five minutes for feedback and discussion. Each class lasts 30 to 45 minutes with optional audio or video participant participation and group chat.
219544238|NCT05053230|BEHAVIORAL|Enhanced usual care|Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation audio or video recordings for meditation, guided imagery, and relaxation.
219544239|NCT04532879|DEVICE|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
219544240|NCT02622386|DRUG|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
218934284|NCT03771170|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
219045791|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
219544241|NCT02622386|OTHER|Placebo|Matching placebo capsule taken daily for 12 weeks.
219544242|NCT01183910|DIETARY_SUPPLEMENT|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
219544243|NCT01183910|DIETARY_SUPPLEMENT|Calcium Carbonate|Oral Tablet Taken Twice a Day
219544244|NCT02760732|DEVICE|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
219544245|NCT02760732|DEVICE|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
219544246|NCT01277276|DEVICE|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
219544247|NCT05621694|BEHAVIORAL|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
219544248|NCT03236311|DRUG|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
219544249|NCT03236311|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
219544250|NCT03236311|DRUG|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219544251|NCT03236311|DRUG|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
218934285|NCT06421103|DRUG|Indocyanine Green (ICG)|Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
218934286|NCT00248963|DRUG|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
218934287|NCT04044170|DRUG|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
218934288|NCT05768022|OTHER|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
218934289|NCT05768022|OTHER|placebo|placebo taping
218934290|NCT00662675|DRUG|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
219205735|NCT07032714|DRUG|Mezigdomide|Administered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).
219544252|NCT03236311|DRUG|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219544253|NCT03236311|DRUG|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
219544254|NCT02074020|DRUG|Blisibimod|Administered via subcutaneous injection once per week
219544255|NCT02074020|DRUG|Placebo|Administered via subcutaneous injection once per week
219544256|NCT00044434|DRUG|bupropion (Wellbutrin)|
219544257|NCT02331563|DRUG|Dexmedetomidine|ultrasound guided transvers abdominis plane block
219544258|NCT02331563|DRUG|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
219544259|NCT02462681|DRUG|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
219544260|NCT00887419|BEHAVIORAL|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
219544261|NCT00887419|BEHAVIORAL|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
219544262|NCT01098591|OTHER|cell therapy|
219621849|NCT06871254|OTHER|Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)|TIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.
219621850|NCT02773147|DRUG|Cyanocobalamin|
219621851|NCT02773147|DRUG|Folate|
218934291|NCT00662675|DRUG|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
218934292|NCT04986436|DRUG|HS-10360|Single or multiple dose(s) of HS-10360
218934293|NCT04986436|DRUG|Placebo|Single or multiple dose(s) of Placebo
218934294|NCT04330729|DRUG|Acetylsalicylic acid|Se arm description
219045792|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
219045793|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
219544263|NCT01701323|BIOLOGICAL|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
219544264|NCT01701323|DRUG|Cytarabine|Given IV
219544265|NCT01701323|DRUG|Filgrastim|Given SC or IV
219544266|NCT01701323|DRUG|Fludarabine Phosphate|Given IV
219544267|NCT04554290|DIAGNOSTIC_TEST|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
219544268|NCT06244043|OTHER|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
219544269|NCT06244043|OTHER|Email Support|Email-based support throughout study period
219544270|NCT06244043|OTHER|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
219544271|NCT00480038|OTHER|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
219544272|NCT01718873|DRUG|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
219621852|NCT02773147|DRUG|Pyridoxine|
218934295|NCT05971576|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
219544273|NCT01718873|DRUG|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
219544274|NCT01718873|DRUG|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
219544275|NCT01718873|DRUG|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
219621853|NCT06751238|BIOLOGICAL|Secukinumab|Intravenous secukinumab
219621854|NCT03845660|BEHAVIORAL|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
218934296|NCT03717870|PROCEDURE|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
219045794|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
219045795|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
219544276|NCT01718873|DRUG|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
219544277|NCT05521360|BEHAVIORAL|Autonomic Modulation Training|AMT is a six week online behavioral intervention comprised of two components. The first component is an adapted (to online format) version of an established and publicly available HRVBF protocol (Lehrer et al, 2013, Biofeedback).The second is the integration of meta-cognitive coping skills and autonomic modulation breathing techniques into the HRVBF protocol (Arpaia \& Andersen, 2019 Frontiers in Psychiatry; Andersen, Arpaia \& Gustafsberg, 2021 Int J Emerg Ment Health and Human Resilience).
219544278|NCT05633862|DRUG|BI 1015550|BI 1015550
219544279|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
219621855|NCT01452880|DRUG|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
219621856|NCT01452880|DRUG|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
218934297|NCT03717870|PROCEDURE|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
218934298|NCT03717870|PROCEDURE|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
218934299|NCT06220760|DIAGNOSTIC_TEST|Ultrasound|The use of US to calculate placenta accreta index
218934300|NCT03867370|DRUG|Toripalimab (JS001 )|Given IV
218934301|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
218934302|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
218934303|NCT04475042|DRUG|Dapagliflozin|10mg od
218934304|NCT04475042|DRUG|Placebo|Placebo
218934305|NCT05143372|DEVICE|Vibrolung|Vibroacoustic respiratory therapy
219045796|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
219544280|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
218934306|NCT00522236|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
219621857|NCT05255731|RADIATION|Low frequency laser activated photobiomodulation|"Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal."
218934307|NCT03310489|BEHAVIORAL|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
218934308|NCT03310489|BEHAVIORAL|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
218934309|NCT00176956|PROCEDURE|Skin Biopsy|Skin biopsy.
218934310|NCT00422864|DRUG|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
218934311|NCT00422864|DRUG|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
218934312|NCT00422864|DRUG|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
218934313|NCT00422864|PROCEDURE|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
219045797|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
219544281|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
219544282|NCT02630797|DIETARY_SUPPLEMENT|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
219544283|NCT03142152|DEVICE|Carillon Mitral Contour System|The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
219544284|NCT03142152|OTHER|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
219544285|NCT03334058|DRUG|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
219544286|NCT06307639|DIAGNOSTIC_TEST|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
219544287|NCT00194363|BEHAVIORAL|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
219544288|NCT00318188|PROCEDURE|standardized reeducation and readaptation program|
219544289|NCT00174551|DRUG|prazosin|
219544290|NCT01103843|DRUG|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
219544291|NCT01103843|DRUG|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
219621858|NCT05255731|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
219621859|NCT01025882|DRUG|gemcitabine hydrochloride|Given IV
219621860|NCT01025882|RADIATION|stereotactic body radiation therapy|Given as a single fraction
219621861|NCT00180531|DEVICE|Renewal TR2|
219544292|NCT05485662|OTHER|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
219544293|NCT05485662|OTHER|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
219544294|NCT00343213|PROCEDURE|colposcopy|
219544295|NCT01539564|DRUG|Minocycline HCl Microspheres|
219544296|NCT04423380|DRUG|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
219544297|NCT06102148|OTHER|PNF Group|Exercise training and PNF training
219544298|NCT06102148|OTHER|Control Group|Exercise training
219544299|NCT00367133|PROCEDURE|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
219544300|NCT00367133|DRUG|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
218934314|NCT03353337|BEHAVIORAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
218934315|NCT03353337|BEHAVIORAL|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
218934316|NCT02447224|DRUG|1 gm IV ertapenem at enrollment|
218934317|NCT02447224|DRUG|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
218934318|NCT02447224|PROCEDURE|Appendectomy|
219045798|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
219045799|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
219045800|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
219544301|NCT00367133|DRUG|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
219544302|NCT00836758|DEVICE|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
219544303|NCT00906399|DRUG|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
219544304|NCT00906399|DRUG|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
219544305|NCT04225364|DRUG|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
219544306|NCT04225364|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
219544307|NCT04225364|DRUG|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
219544308|NCT01408654|BEHAVIORAL|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
219544309|NCT05173298|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
219544310|NCT04892420|DRUG|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
219544311|NCT04892420|DRUG|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
219544312|NCT04892420|DRUG|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
219544313|NCT04892420|DRUG|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
219544314|NCT04020796|DIETARY_SUPPLEMENT|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
219544315|NCT01212276|DRUG|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
219621862|NCT05460767|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
219621863|NCT02259010|DRUG|Alisertib|Alisertib tablets
218934319|NCT00927914|DRUG|Ranirestat|Ranirestat 40 mg tablets
219045801|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
219045802|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
219045803|NCT00054561|DRUG|isotretinoin|
219045804|NCT00054561|PROCEDURE|adjuvant therapy|
219621864|NCT02259010|DRUG|Itraconazole|Itraconazole oral solution
219621865|NCT05718414|DEVICE|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
218934320|NCT00927914|DRUG|Placebo|Placebo tablets
219045805|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
219045806|NCT03435549|BEHAVIORAL|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
219544316|NCT05498662|DEVICE|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
219544317|NCT06550869|PROCEDURE|Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision|The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.
219544318|NCT06550869|PROCEDURE|Local infiltration anesthesia|The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
219205736|NCT07032714|DRUG|Dexamethasone|Administered orally once per day, at the schedule outlined in the Arm Descriptions.
219205737|NCT06696326|DIAGNOSTIC_TEST|standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
219205738|NCT06882382|OTHER|conventional physiotherapy|normal joint movements, chest physiotherapy, and mobilization for 40 min
219205739|NCT06882382|OTHER|Virtual reality|normal joint movements, chest physiotherapy, and mobilization for 40 min and 20 min virtual reality
218934321|NCT01089517|DRUG|E10030 plus Lucentis|once a month intravitreal injection
218934322|NCT01089517|DRUG|Lucentis|10 mg/mL intravitreal injection monthly
219045807|NCT03435549|BEHAVIORAL|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
219544319|NCT03265860|DEVICE|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
219544320|NCT02618460|DEVICE|Non contrast-enhanced magnetic resonance imaging|
218934323|NCT00272896|DRUG|Vasoactive intestinal peptide|
219045808|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
219045809|NCT02694224|DRUG|vismodegib|Smo inhibitor
219045810|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
219045811|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
219045812|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
219045813|NCT00701129|BIOLOGICAL|Alglucosidase Alfa|Administered as IV infusion.
219045814|NCT00701129|DRUG|Methotrexate|Administered subcutaneously.
219045815|NCT00701129|DRUG|Rituximab|Administered as IV infusion.
219045816|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
219045817|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
219045818|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
219045819|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
219045820|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
219045821|NCT06388551|DRUG|LY03017|single dose, administered orally
219045822|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
219045823|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
219045824|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
219045825|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
219045826|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
219544321|NCT03103360|DEVICE|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
218934324|NCT04196387|DIAGNOSTIC_TEST|urine culture|urine culture and antibiotic susceptibility test
218934325|NCT01456624|DRUG|Megace|800mg
218934326|NCT01456624|DRUG|DW-ES(B)|625mg
218934327|NCT05002244|DRUG|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
218934328|NCT05002244|DRUG|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
219205740|NCT06684327|DRUG|Albumin-paclitaxel Injection|Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.
219544322|NCT03103360|PROCEDURE|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
219544323|NCT05163691|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
219544324|NCT05163691|DRUG|Placebo|GH001 Placebo administered via inhalation
219621866|NCT06582576|DIAGNOSTIC_TEST|Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.|Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.
219621867|NCT01138202|DRUG|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
218934329|NCT05002244|DRUG|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
218934330|NCT03543787|COMBINATION_PRODUCT|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
218934331|NCT01675544|PROCEDURE|Electrocardiogram|EKG voltage changes between admission and discharge
218934332|NCT01675544|PROCEDURE|Six minute walk test|
218934333|NCT03118661|OTHER|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
218934334|NCT03118661|PROCEDURE|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
219045827|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
219045828|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
219045829|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
219045830|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
219544325|NCT00353457|DRUG|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
219544326|NCT00353457|RADIATION|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
219544327|NCT05957146|DEVICE|Routine hemodialysis|"* Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin."
219544328|NCT01124786|DRUG|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
219544329|NCT01124786|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
219544330|NCT00544492|DEVICE|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
219544331|NCT04739735|PROCEDURE|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
219544332|NCT01129986|DEVICE|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
219544333|NCT01665508|DRUG|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
219544334|NCT00750243|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
219544335|NCT00750243|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
219621868|NCT03961737|PROCEDURE|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
219621869|NCT03521011|DEVICE|MSCT|Non enhanced MSCT Abdomen
219621870|NCT06634420|BIOLOGICAL|NTLA-2002|CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
219045831|NCT01872572|DRUG|Placebo|Placebo
219045832|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
219045833|NCT00770120|DRUG|everolimus|
219045834|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
219045835|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
219045836|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
219045837|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
219045838|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
219045839|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
219544336|NCT03946787|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
218934335|NCT05317091|OTHER|Laughter yoga practiced|"In this study, 8 sessions of laughter yoga were applied to the nurses in the experimental group as an intervention, twice a week for 4 weeks. Due to the Covid-19 pandemic; Laughter Yoga sessions were held on the web through the 'ZOOM' program.~For this reason, it is recommended that the laughter yoga sessions be done with a group and that the group should consist of at least five people in order to provide group dynamics. Sessions are planned according to the days and hours that nurses can attend. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday-Saturday between 20:00-21:00. The nurses were constantly contacted (whatsapp, phone) to ensure that they attend the sessions regularly and that there is no interruption in the sessions. No experiment was performed on the control group during the study. However, after the research, a 4-week laughter yoga was given to the nurses who wanted it."
218934336|NCT04206280|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
218934337|NCT04206280|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
218934338|NCT00502411|DRUG|Doxorubicin|17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
218934339|NCT00502411|RADIATION|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
218934340|NCT00921895|DEVICE|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
218934341|NCT04502940|DIAGNOSTIC_TEST|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
218934342|NCT04882345|DRUG|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
218934343|NCT00618345|DRUG|everolimus|
218934344|NCT00618345|GENETIC|DNA analysis|
219045840|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
219045841|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
219045842|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
219205741|NCT06719180|DRUG|Bupivacain|Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area
219205742|NCT06719180|OTHER|Saline (NaCl 0,9 %) (placebo)|A saline placebo
219205743|NCT06875245|DRUG|Faricimab Injection|Intravitreal Injection
219205744|NCT06299514|DEVICE|Pace and Ablate|Conduction System Pacing (CSP) followed by AtrioVentricular Node Ablation (AVNA)
218934345|NCT00618345|GENETIC|protein analysis|
218934346|NCT00618345|GENETIC|western blotting|
218934347|NCT00618345|OTHER|flow cytometry|
218934348|NCT00618345|OTHER|laboratory biomarker analysis|
218934349|NCT00618345|PROCEDURE|biopsy|
218934350|NCT00581880|BEHAVIORAL|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
218934351|NCT00108875|BIOLOGICAL|Survivin peptide vaccine|
218934352|NCT01658644|OTHER|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
218934353|NCT02296372|DEVICE|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
218934354|NCT00689260|DEVICE|easypod|Subjects is aware that the device records injection information that can be viewed by user
219045843|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
219045844|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
219045845|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
219205745|NCT06299514|DRUG|Medication|Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
219544337|NCT03946787|OTHER|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
219544338|NCT03272685|DRUG|Very Low Nicotine Content Cigarettes|0.4 mg nicotine/g tobacco; 9 mg tar
218934355|NCT00689260|DEVICE|easypod|Subjects is not aware that the device records injection information that can be viewed by user
218934356|NCT06466018|DIAGNOSTIC_TEST|Schirmer test paper|"This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved."
219045846|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
219544339|NCT03272685|DRUG|Normal Nicotine Content Cigarettes|15.8 mg nicotine/g tobacco; 9 mg tar
219544340|NCT02555137|OTHER|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
219544341|NCT02355847|OTHER|Lectures|Lectures
219544342|NCT06039735|OTHER|Chemotherapy and/or autologous hematopoietic stem cell transplantation|Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
219544343|NCT01278095|DRUG|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
219544344|NCT01278095|DRUG|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
219544345|NCT04468867|DIAGNOSTIC_TEST|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
218934357|NCT05780424|BIOLOGICAL|BRII-196|BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
218934358|NCT05780424|BIOLOGICAL|BRII-198|BRII-198 is a fully human IgG-1 mAb derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
218934359|NCT05780424|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
218934360|NCT05780424|BIOLOGICAL|Remdesivir|Antiviral agent
218934361|NCT06359444|OTHER|Combined aerobic + strength training|"Participants will follow a combination of endurance and strength training for 14 weeks.~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
218934362|NCT06359444|OTHER|Combined strength + HIIT training|"6 weeks of endurance training and strength training, 8 weeks of strength training and HIIT.~Participants will follow the same combination of endurance and strength training for the first six weeks, to build up to a baseline level of physical fitness. They will then switch to eight weeks of a combination of strength training and High Intensity Interval Training (HIIT).~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
218934363|NCT02537158|DRUG|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
218934364|NCT02537158|PROCEDURE|TACE|TACE group patients will accept TACE therapy once at a month after resection.
219045847|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
219045848|NCT00222495|DRUG|quetiapine|
219045849|NCT00222495|DRUG|olanzapine|
219045850|NCT00222495|DRUG|risperidone|
219045851|NCT06161792|DRUG|0.8 mg RCN3028|Oral
219205746|NCT05975736|BEHAVIORAL|Search only for masses|Participants search the simulated mammogram for simulated masses.
219544346|NCT04468867|DIAGNOSTIC_TEST|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
219544347|NCT03490058|DRUG|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
219544348|NCT03105947|OTHER|Coconut oil|50g extravirgin coconut oil daily for four weeks
219544349|NCT03105947|OTHER|Butter|50g butter daily for four weeks
219544350|NCT03105947|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
219544351|NCT04583657|OTHER|Eggs|Consumption of two eggs (control or test) per day during three months
219045852|NCT06161792|DRUG|Placebo|Oral
219544352|NCT06559631|BEHAVIORAL|Indigenously Adapted CRA|Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
219544353|NCT01218360|DRUG|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
219544354|NCT04172480|OTHER|Blood sampling|Peripheral blood sampling on EDTA
219544355|NCT00858780|DRUG|Etanercept|50 mg etanercept once weekly + methotrexate
219544356|NCT00858780|DRUG|Etanercept|25mg etanercept once weekly + methotrexate
219544357|NCT00858780|DRUG|Placebo|Placebo comparator once weekly + methotrexate
219544358|NCT00863330|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
219544359|NCT02929472|BEHAVIORAL|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
218934365|NCT00264758|DEVICE|Conventional hemodialysis|Three times per week in-center hemodialysis
218934366|NCT00264758|DEVICE|Frequent hemodialysis|Six times per week in-center hemodialysis
218934367|NCT00662298|DRUG|prednisolone|40mg of prednisolone once a day for 14 days
218934368|NCT02975232|BEHAVIORAL|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
218934369|NCT02975232|BEHAVIORAL|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
218934370|NCT01528202|DIETARY_SUPPLEMENT|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
219045853|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
219045854|NCT02886585|DRUG|Pembrolizumab|
219045855|NCT02886585|RADIATION|MRI|
219045856|NCT02886585|RADIATION|PET/CT|
219045857|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
218934371|NCT01528202|DIETARY_SUPPLEMENT|Fruit juice cordial|fruit flavoured juice concentrate
218934372|NCT04854447|DEVICE|Single-Vision Spectacles|Spectacle correction for myopia treatment
218934373|NCT02862353|BIOLOGICAL|blood sample|15 ml of blood
219045858|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
219045859|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
219045860|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
219045861|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
219045862|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
219045863|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
219045864|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
219045865|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
219045866|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
219045867|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
219205747|NCT05975736|BEHAVIORAL|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
218934374|NCT04877951|BEHAVIORAL|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
219045868|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
219045869|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
219045870|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
219045871|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
219045872|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
219045873|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
219045874|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
219205748|NCT05975736|BEHAVIORAL|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
219205749|NCT05975736|BEHAVIORAL|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
219365746|NCT02243384|PROCEDURE|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
219544360|NCT02929472|BEHAVIORAL|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
219544361|NCT04353986|DRUG|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
219544362|NCT03947658|PROCEDURE|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
219544363|NCT01283763|DRUG|Topical Imiquimod|16 weeks
219544364|NCT01283763|PROCEDURE|Conization|Large loop excision of the transformation zone
219544365|NCT05214716|DIAGNOSTIC_TEST|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
219621871|NCT06634420|BIOLOGICAL|Normal Saline IV Administration|The administration of intravenous (IV) normal saline
219621872|NCT07065149|OTHER|1)0.1% Pinorox® Cream 2)1% Pinorox® Cream 3)Base cream 4)Positive control 5)Negative control|0.04 gm of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through finn chamber patch.
219365747|NCT02243384|PROCEDURE|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
219365748|NCT04968418|DEVICE|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
219621873|NCT00463372|DRUG|PF-02545920|
218934375|NCT01862692|BEHAVIORAL|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
218934376|NCT01862692|BEHAVIORAL|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
219045875|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
219621874|NCT01805063|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
219621875|NCT01805063|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
219621876|NCT06031090|DRUG|Clonidine Injection|intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
218934377|NCT01168219|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
219045876|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
219045877|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
219045878|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
219045879|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
219045880|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
219045881|NCT05130411|DIETARY_SUPPLEMENT|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
219045882|NCT00006475|DRUG|imatinib mesylate|
219045883|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
219045884|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
219045885|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
219045886|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
219365749|NCT00227201|BEHAVIORAL|Self-affirmation intervention|
219365750|NCT06122402|OTHER|SECURE Care Bundle|The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including CHG dressing and silicone based remover.
219365751|NCT06122402|PROCEDURE|Standart Care|It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
219365752|NCT00061711|DRUG|Hormone Replacement Therapy|
218934378|NCT01168219|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
218934379|NCT01168219|DRUG|Azacitidine|Given SC or IV
218934380|NCT01168219|DRUG|Busulfan|Given IV
218934381|NCT01168219|DRUG|Fludarabine Phosphate|Given IV
218934382|NCT01168219|OTHER|Laboratory Biomarker Analysis|Correlative studies
218934383|NCT01168219|DRUG|Methotrexate|Given IV
218934384|NCT01168219|OTHER|Pharmacological Study|Correlative studies
218934385|NCT01168219|DRUG|Tacrolimus|Given PO or IV
218934386|NCT05584319|DRUG|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
219045887|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
219621877|NCT06031090|DRUG|Granisetron Injection|intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
219621878|NCT06031090|DRUG|Normal Saline 10 mL Injection|intravenous 10 ml normal saline 20 minutes before spinal anesthesia
218934387|NCT03546868|DRUG|[18F]FSPG|Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
218934388|NCT01292824|DRUG|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
218934389|NCT01368224|DIETARY_SUPPLEMENT|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
218934390|NCT00874926|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
218934391|NCT04992858|DRUG|CT053PTSA|CT053PTSA will be administered orally once a day
218934392|NCT03209739|OTHER|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
218934393|NCT06455046|DRUG|AK104|PD-1/CTLA-4 bispecific antibody
218934394|NCT06455046|DRUG|Recombinant Human Adenovirus 5 Injection|Recombinant Human Adenovirus 5 Injection
218934395|NCT00506636|BEHAVIORAL|Tissue engineering for hair follicle regeneration|
218934396|NCT04740138|BEHAVIORAL|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
219621879|NCT02433184|DRUG|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
218934397|NCT02785796|OTHER|CV4|
219045888|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
219621880|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
218934398|NCT02785796|OTHER|SHAM TECHNIQUE|
218934399|NCT02600819|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
218934400|NCT02600819|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
218934401|NCT05165693|OTHER|Experimental Formula|Diabetes-specific study formula
219045889|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
218934402|NCT05165693|OTHER|Test Meal|Instant oatmeal
218934403|NCT05055492|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
218934404|NCT00994344|DRUG|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
218934405|NCT00994344|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
218934406|NCT00347373|DRUG|Tonalin Conjugated linoleic acid (dietary supplement)|
218934407|NCT01097031|OTHER|Infusion Intermittent|
218934408|NCT02465554|PROCEDURE|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
218934409|NCT03712423|DRUG|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
219045890|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
219365753|NCT00061711|DRUG|Cimicifuga racemosa (Black Cohosh)|
219365754|NCT00061711|DRUG|Multibotanical phytoestrogen formula|
219365755|NCT03752125|DIETARY_SUPPLEMENT|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
219365756|NCT03752125|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
219365757|NCT02151825|DIETARY_SUPPLEMENT|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
219365758|NCT02151825|OTHER|Placebo|3 capsules of Maltodextrin per day
219365759|NCT05148026|DRUG|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
219365760|NCT05148026|DRUG|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
219365761|NCT03198143|DRUG|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
219365762|NCT03198143|DRUG|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
218934410|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
218934411|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
218934412|NCT02490020|BIOLOGICAL|mesenchymal stem cell|
218934413|NCT03089762|BIOLOGICAL|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
218934414|NCT06260722|DRUG|Retatrutide|Administered SC.
218934415|NCT06260722|DRUG|Semaglutide|Administered SC.
218934416|NCT05585944|DIAGNOSTIC_TEST|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
218934417|NCT04797559|PROCEDURE|SZMN Block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
218934418|NCT02631590|DRUG|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
218934419|NCT02631590|DRUG|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
218934420|NCT02631590|DRUG|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
218934421|NCT04657094|DRUG|Acalabrutinib|Given PO
218934422|NCT01857817|DRUG|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
218934423|NCT01857817|DRUG|Placebo|The placebo capsules will be prepared to match the active drug.
219045891|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
219045892|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
219045893|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
218934424|NCT02383212|DRUG|Cemiplimab|
218934425|NCT02383212|RADIATION|Hypofractionated radiotherapy|
218934426|NCT02383212|DRUG|Cyclophosphamide|
219045894|NCT03364049|DRUG|MK-7162|oral tablets
219045895|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
219045896|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
218934427|NCT02383212|DRUG|Docetaxel|
219045897|NCT00934206|BEHAVIORAL|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
219045898|NCT03009240|DRUG|Decitabine|Given IV
219045899|NCT03009240|OTHER|Laboratory Biomarker Analysis|Correlative studies
219045900|NCT03009240|DRUG|Pevonedistat|Given IV
218934428|NCT02383212|DRUG|Carboplatin|
218934429|NCT02383212|DRUG|GM-CSF|
218934430|NCT02383212|DRUG|Paclitaxel|
218934431|NCT02383212|DRUG|Pemetrexed|
218934432|NCT05393102|OTHER|No interventions|No interventions
218934433|NCT05097963|DEVICE|Endoscopic Ultrasound Shear Wave Elastography|Software to determine stiffness of liver for evaluating liver fibrosis.
218934434|NCT03888417|DEVICE|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
218934435|NCT02146534|DRUG|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
218934436|NCT02146534|DRUG|Placebo|placebo will be taken PO BID
218934437|NCT02817009|BEHAVIORAL|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
219045901|NCT03009240|OTHER|Pharmacological Study|Correlative studies
219045902|NCT04606693|OTHER|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
219045903|NCT03366350|PROCEDURE|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
219045904|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
219365763|NCT03840876|DEVICE|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
219365764|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
218934438|NCT02817009|BEHAVIORAL|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
218934439|NCT02817009|BEHAVIORAL|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
219205750|NCT06883994|OTHER|Fermented vegetable intervention|"Participants will be provided with reduced-sodium fermented vegetables developed by Dr. Ilenys Pérez-Díaz at the USDA-ARS Food Science and Market Quality and Handling Research Unit. The fermented, refrigerated vegetables have been shown to have Lactiplantibacillus spp. content \>10\^7 CFU/mL at 21 days shelf-life.~Products are prepared in a Good Manufacturing Practices Facility at North Carolina State University, Department of Food, Bioprocessing, and Nutrition Sciences.~The fermented vegetables will be shipped in coolers on cold packs with temperature indicators to the WHNRC. Participants will be asked to consume two pre-packaged 50g servings of fermented vegetables a day, for a total daily serving of 100g, not to heat the fermented vegetables prior to consumption, to log their consumption and to rate the acceptability of the fermented vegetables. They will be advised to avoid other fermented foods and to otherwise maintain their habitual diet."
218934440|NCT00578149|DRUG|Bevacizumab|
218934441|NCT00578149|DRUG|Carboplatin|
218934442|NCT00578149|DRUG|Paclitaxel|
218934443|NCT02948634|DEVICE|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
218934444|NCT02948634|DEVICE|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
218934445|NCT05773170|DRUG|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
218934446|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
219205751|NCT06884124|BEHAVIORAL|Experimental|Micro teaching method will be applied for ventrogluteal injection training. Students will be trained with short learning units, multimedia content and feedback sessions.
219544366|NCT02324452|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
219544367|NCT01299935|BEHAVIORAL|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
219544368|NCT01299935|BEHAVIORAL|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
219544369|NCT02615249|BIOLOGICAL|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
219544370|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
219544371|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
219544372|NCT02504333|DRUG|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
219544373|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
219544374|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
219544375|NCT00242554|DRUG|Zoledronic acid|
219544376|NCT04056585|PROCEDURE|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
219544377|NCT04056585|PROCEDURE|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
219544378|NCT00741780|DRUG|Placebo|
219544379|NCT00741780|DRUG|plerixafor|
219544380|NCT00741780|DRUG|granulocyte colony-stimulating factor (G-CSF)|
219544381|NCT01192932|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
219544382|NCT02254005|DRUG|bivatuzumab mertansine|
219544383|NCT05226533|DRUG|DWRX2003|Intramuscular injection of DWRX2003
219544384|NCT05226533|DRUG|Placebo|Intramuscular injection of placebo
219544385|NCT00574847|DRUG|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
219544386|NCT00574847|DRUG|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
218934447|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
218934448|NCT02956200|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
218934449|NCT02787629|PROCEDURE|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
218934450|NCT02787629|PROCEDURE|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
219544387|NCT00070148|DRUG|Megestrol Acetate|Megace by mouth for 12 weeks
219621881|NCT02433184|DRUG|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
219621882|NCT02433184|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
218934451|NCT03261427|DRUG|Lyrica 150Mg Capsule|150 mg oral administered (BID)
219621883|NCT02433184|DRUG|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
218934452|NCT03261427|DRUG|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
218934453|NCT02225691|DEVICE|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
218934454|NCT05282602|OTHER|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
218934455|NCT05282602|OTHER|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
218934456|NCT05697185|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
219205752|NCT06884124|BEHAVIORAL|Control|Routine lectures and practice will be done on the model
219205753|NCT06884163|GENETIC|comprhensive spatial transcriptomic profile on lesional skin biopsies|Spatial transcriptomics (Visium, 10X Genomics) will be used to analyze gene expression of chronic eczema derived from lesional skin biopsies
219205754|NCT06883890|DRUG|Recombinant LH (Luveris)|In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will be administered.
219205755|NCT06883890|DRUG|No Treatment Added|In the control group, women will not receive any therapy and will be followed up with the same schedule as women in the treatment group
219205756|NCT07038057|DIETARY_SUPPLEMENT|Short peptide enteral nutrition|Short peptide formula enteral nutrition was initiated within 48 hours after admission to the ICU. For patients with poor swallowing function or no consciousness, nasogastric tubes were placed. Starting from low-calorie or nourishing feeding, 70% of the target energy should be achieved within 7 days, and the protein should be 1.2-1.5 g/kg/d. Due to the large individual differences in energy expenditure among patients with sepsis, the indirect calorimetry (IC) method was used to determine energy expenditure. If the IC method is not feasible, the calculation formula based on body weight: 20-25 kcal/kg/d should be applied for calculation. If the patient is not transferred out of the ICU after 7 days, continue to gradually increase to the target energy and protein requirements under tolerable conditions, and gradually transition to whole protein nutrition after 7 days.
219544388|NCT00070148|DRUG|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
219544389|NCT05108948|BEHAVIORAL|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
219544390|NCT05108948|PROCEDURE|Radiography|Spinal radiography : full, face, profile
219621884|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
219621885|NCT01238159|RADIATION|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
218934457|NCT05069272|OTHER|Bakuchiol and Ethyl Linoleate|A synergistic combination of Bakuchiol and Ethyl Linoleate
218934458|NCT05069272|OTHER|Vehicle|No actives
218934459|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
218934460|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
218934461|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
218934462|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
218934463|NCT03830892|OTHER|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
218934464|NCT03830892|OTHER|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
218934465|NCT04661579|BIOLOGICAL|Malaria Vaccine RTS,S/AS01E|RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.
218934466|NCT04661579|BIOLOGICAL|Abhayrab rabies vaccine|Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.
218934467|NCT04661579|DRUG|Dihydroartemisinin-piperaquine (DHA/Pip)|"Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites."
219045905|NCT05114291|OTHER|Explorations are planned as part of the one-day hospitalization|"* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~* Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~* Standardized blood pressure measurement :~  * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~* Hemodynamic parameters :~  * Sphygmocor® : measure of the central blood pressure and pulse wave velocity~ * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~ * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~* Others : if indicated (echocardiography, ABPM)"
219544391|NCT06432751|OTHER|Post Operative Acute Kidney Injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
219544392|NCT00452218|DRUG|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
219621886|NCT04968730|OTHER|Postoperative rehabilitation nursing|Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
219621887|NCT02817763|PROCEDURE|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
219621888|NCT02817763|PROCEDURE|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
219621889|NCT02817763|DRUG|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
219544393|NCT00833300|DRUG|Haloperidol|"* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
219621890|NCT02724319|DEVICE|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
219621891|NCT06778551|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A therapeutic exercise protocol will be carried out, consisting of 2 sessions per week for 8 weeks, supervised and guided by a physiotherapist. The objective is to improve thoracic mobility, as well as the strength and motor control of the scapular retractor and protractor muscles (middle and lower trapezius, rhomboids, and serratus anterior) and the rotator cuff.
219621892|NCT06778551|OTHER|Control (Standard treatment)|The protocol will include the application of therapeutic ultrasound. For this application, ultrasound gel will be used to reduce friction and improve the transmission of waves. Using a 5 cm² transducer, pulsed ultrasound will be applied at a frequency of 3 MHz and an intensity of 1 W/cm² for 10 minutes. Patients will be informed that they should not feel any sensation during the procedure, and if they do, the intensity will be reduced. Finally, kinesitherapy will be applied through classic shoulder mobility exercises.
219621893|NCT00496717|DEVICE|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
219621894|NCT02389829|DRUG|Hydromorphone|
219621895|NCT02389829|DRUG|Prochlorperazine|
219621896|NCT02389829|DRUG|Diphenhydramine|
219621897|NCT01950468|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
219621898|NCT01950468|DRUG|DaTscan|A single intravenous dose of 3 to 5 mCi
219621899|NCT02165163|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
219621900|NCT02362360|DEVICE|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
219621901|NCT02362360|DEVICE|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
219045906|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
219045907|NCT02953821|DRUG|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
219045908|NCT02953821|DRUG|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
219621902|NCT07067827|OTHER|Self-administered questionnaire|The self-administered questionnaire was previously prepared by the research team for another project. It includes 14 questions addressing the dentition, fractures, joint hypermobility, height, and eye abnormalities present in the participants or their relatives. This questionnaire covers the clinical manifestations of rare bone diseases such as osteogenesis imperfecta, pycnodysostosis, hypophosphatasia, and osteopetrosis. This self-administered questionnaire will be filled online by participant. Average completion time of 20 minutes.
219544394|NCT00833300|DRUG|Olanzapine|"* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
219544395|NCT03937557|DIAGNOSTIC_TEST|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
219544396|NCT02811003|DEVICE|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
218934468|NCT04661579|DRUG|Artemether / Lumefantrine|"Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy."
218934469|NCT04661579|DRUG|Primaquine|One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
218934470|NCT01743859|DRUG|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
218934471|NCT01743859|DRUG|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
218934472|NCT01743859|OTHER|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
218934473|NCT03752437|DIAGNOSTIC_TEST|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
218934474|NCT03752437|DRUG|Heparin|300 IU of heparin
219544397|NCT01732224|DRUG|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
219544398|NCT01732224|DRUG|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
219544399|NCT04391270|BEHAVIORAL|blended intervention|A blended intervention group combining the web-based components with face-to-face workshops and posters
219544400|NCT04391270|BEHAVIORAL|web-based intervention|A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
219544401|NCT02055547|DRUG|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
218934475|NCT00337675|DRUG|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
218934476|NCT00337675|DRUG|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
218934477|NCT00337675|DRUG|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
218934478|NCT00859456|DRUG|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
218934479|NCT04518189|DRUG|lidocaine patch|lidocaine patch applied 3 hours before the procedure
218934480|NCT04518189|DRUG|Sham patch|Sham patch applied 3 hours before the procedure
218934481|NCT04633044|DIETARY_SUPPLEMENT|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
218934482|NCT04633044|DIETARY_SUPPLEMENT|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
219544402|NCT02055547|DRUG|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
219544403|NCT02055547|DRUG|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
219544404|NCT02055547|DRUG|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
219544405|NCT02055547|DRUG|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
219544406|NCT02055547|DRUG|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
219544407|NCT02055547|DRUG|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
219544408|NCT02055547|DRUG|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
219544409|NCT02055547|DRUG|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
219544410|NCT02055547|DRUG|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
219544411|NCT02055547|DRUG|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
218934483|NCT05521399|DIAGNOSTIC_TEST|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
218934484|NCT05521399|DIAGNOSTIC_TEST|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
218934485|NCT05521399|DIAGNOSTIC_TEST|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
218934486|NCT06845501|DIETARY_SUPPLEMENT|purine-rich diet|diet to achieve a purine intake of 160mg/d
218934487|NCT01890603|OTHER|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
218934488|NCT01890603|OTHER|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
219544412|NCT02055547|DRUG|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
218934489|NCT05140720|BIOLOGICAL|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval \> 1 month Group 3: 2 doses, dose interval \> 2 months"
218934490|NCT04141839|BEHAVIORAL|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
219205757|NCT07038057|DIETARY_SUPPLEMENT|Whole protein enteral nutrition|The whole protein formula enteral nutrition was initiated within 48 hours of admission to the ICU, and the rest were same.
219205758|NCT06881810|DRUG|Oxytocin nasal spray|Syntocinon® nasal spray is applied according to description in arms section
219205759|NCT06881810|OTHER|Placebo|Placebo nasal spray is applied according to description in arms section
219205760|NCT06720389|RADIATION|peri implant bone loss was assessed by CBCT|using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)
219205761|NCT06720389|OTHER|posterior ridge resorption was assessed by CBCT|posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
219205762|NCT06720610|DRUG|Vonoprazan 20 mg|Vonoprazan PO, 20mg, once a day, 14 days.
219205763|NCT06720610|DRUG|Esomeprazole|Esomeprazole PO, 40mg, once a day, 14 days
219205764|NCT06729645|OTHER|radiotherapy|External beam radiotherapy and endorectal brachytherapy
219205765|NCT06728267|OTHER|Core stabilization training|Exercise training will be given for 6 weeks, 3 days a week, 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks.
219205766|NCT06728267|OTHER|Training|Routine training sessions conducted by coaches specific to the sport of underwater rugby.
219205767|NCT06729801|DEVICE|IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS)|The IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a novel device designed to enable real-time monitoring of intrarenal pressure (IRP) during retrograde intrarenal surgery (RIRS). It incorporates a pressure-sensing port connected to a gas conduit embedded in the sheath, which allows the surgeon to adjust irrigation flow and suction pressure based on real-time IRP readings, thereby optimizing stone retrieval efficiency while ensuring safety by maintaining a safe IRP range. The device improves surgical outcomes, particularly in complex cases involving larger renal stones, by reducing operative time and minimizing the risk of complications.
219365765|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
219365766|NCT01891643|DRUG|Lenalidomide|
219365767|NCT01891643|DRUG|Dexamethasone|
219365768|NCT01891643|BIOLOGICAL|Elotuzumab|
219365769|NCT00004165|BIOLOGICAL|filgrastim|
219365770|NCT00004165|DRUG|melphalan|
219365771|NCT00004165|PROCEDURE|peripheral blood stem cell transplantation|
219365772|NCT06956638|OTHER|Non-interventional|Non-interventional study
219365773|NCT03983681|BEHAVIORAL|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
219365774|NCT03983681|BEHAVIORAL|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
219365775|NCT04494009|DRUG|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
219365776|NCT04751396|OTHER|Best Practice|Receive standard educational information
219365777|NCT04751396|OTHER|Educational Intervention|Navigate educational tool
219365778|NCT04751396|OTHER|Interview|Participate in interview
219365779|NCT04751396|OTHER|Questionnaire Administration|Complete questionnaire
219365780|NCT04751396|OTHER|Survey Administration|Complete surveys
219365781|NCT06208488|DRUG|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
219365782|NCT06208488|DRUG|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
219365783|NCT03347149|DEVICE|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
219365784|NCT01429571|OTHER|No intervention|No intervention
219365785|NCT05330208|DRUG|SHR-1816|SHR-1816
219365786|NCT05330208|DRUG|Placebo|Placebo
219365787|NCT02965716|BIOLOGICAL|Pembrolizumab|Given IV
219365788|NCT02965716|BIOLOGICAL|Talimogene Laherparepvec|Given IL
219365789|NCT05197803|DEVICE|Hearing aid|Participants will complete testing aided and unaided. The hearing aids have been fit to compensate for their hearing loss.
219365790|NCT01567098|PROCEDURE|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
219365791|NCT02592889|DEVICE|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
219365792|NCT01081756|DRUG|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
219365793|NCT01081756|DRUG|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
219365794|NCT04552171|BEHAVIORAL|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
219365795|NCT02613208|DRUG|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
219365796|NCT02613208|DRUG|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
219365797|NCT01208129|DRUG|NAB001|nail lacquer, once daily, 52 weeks
219365798|NCT01208129|DRUG|Placebo control|nail lacquer, once daily, 52 weeks
219365799|NCT02663895|DRUG|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
219365800|NCT00247104|DRUG|Cranberries - Vaccinium macrocarpon|
219544413|NCT04615741|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
219205768|NCT06729801|DEVICE|Conventional FANS|The Conventional Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a standard device used in retrograde intrarenal surgery (RIRS) for stone retrieval. Unlike the IRP-monitoring version, this device does not provide real-time monitoring of intrarenal pressure (IRP). Irrigation flow and suction pressure are pre-set and adjusted based on clinical protocols. It facilitates the removal of renal stones through a flexible and navigable design, but without the added capability of monitoring and adjusting IRP during the procedure.
219205769|NCT04207931|DRUG|Topical steroid class I-II|applied once daily - 18 month duration of the study
219544414|NCT04615741|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
219544415|NCT05098743|BEHAVIORAL|Medisafe smartphone mobile application|The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.
219544416|NCT05098743|BEHAVIORAL|Printed medication list|Patients will receive a printed out medication list from their electronic medical record.
219544417|NCT04309773|DRUG|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
219544418|NCT04309773|DRUG|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
219544419|NCT01372930|DRUG|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
219544420|NCT01372930|DRUG|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
219544421|NCT00756171|DRUG|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
219544422|NCT00756171|DRUG|placebo|2 times 3 625mg tablets daily
219544423|NCT03257228|GENETIC|comparative semiquantitative immunohistochemistry|
219544424|NCT03396354|PROCEDURE|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
219544425|NCT03396354|PROCEDURE|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
219544426|NCT02480660|BEHAVIORAL|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
219544427|NCT03858933|DEVICE|eBrainFit Platform|Alpha/Theta regulation with eyes open
219544428|NCT03858933|DEVICE|eBrainFit Platform|Amygdala regulation with eyes open
219544429|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
219544430|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
219544431|NCT04276064|DEVICE|Sham stimulation|Sham stimulation
219544432|NCT03719040|DEVICE|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
219544433|NCT01345539|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
219544434|NCT01345539|DRUG|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
219544435|NCT03769532|DRUG|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
219621903|NCT07067827|OTHER|Family tree|For the family tree, this step is done by a telephone interview lasting a maximum of 45 minutes, depending on the size of the participant's family. The researcher will be able to reconstruct the family history with the index case. The family tree will then contain the family history up to the second degree of kinship with respect to the index cases. The information collected through the index cases when creating the family tree must include, for each relative, biological sex, as well as information on the presence or absence of a rare or genetic bone disease and clinical signs associated with these diseases, such as short stature, bone deformities, deafness, eye problems, etc.
219544436|NCT03769532|DRUG|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
219544437|NCT06973265|DEVICE|TENS|After the surgery, 2 TENS electrodes will be placed on the inner part of the upper arm of the patient's arm on the side where surgery was performed, and the frequency will be 100 Hz, the pulse duration will be 100 µs and the amplitude will be adjusted so as not to cause muscle contraction, and a 20-minute TENS application will be performed.
218934491|NCT01053780|OTHER|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
218934492|NCT01053780|BEHAVIORAL|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
218934493|NCT01516086|DRUG|Fluticasone Propionate (FP)|FP Inhalation BID
218934494|NCT06458478|OTHER|Hyper-oxygenated gel|Novox drop is a medical device (CE certified, class II b, non-invasive) based on oxygen-enriched olive oil (Excipients: Mint essential oil (2%), Stevia extract (1%)). Mechanism of action: facilitate the healing process by creating, thanks to the release of reactive oxygen species (ROS), a microenvironment favorable to the activation of the microcirculation and at the same time unfavorable to the proliferation of pathogens. Furthermore, it has a film-forming, protective, barrier and soothing action thanks to its oily nature.
218934495|NCT06458478|OTHER|glycerin based gel|The placebo consists of a viscous, colorless and transparent gel, based on glycerin (Conformity:FUI).
219205770|NCT04207931|DRUG|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
219205771|NCT04207931|DRUG|Doxycyline|oral antibiotic twice daily for 6 months
219544438|NCT02923349|DRUG|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
219544439|NCT06200363|DRUG|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
219544440|NCT06200363|DRUG|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
219544441|NCT01902719|BEHAVIORAL|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
219621904|NCT00133016|PROCEDURE|Amniotomy|
219045909|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
219045910|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
219045911|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
219045912|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
219045913|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
219045914|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
219045915|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
219045916|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
219045917|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
219045918|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
219045919|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
219205772|NCT04207931|DRUG|Minoxidil|5% solution or foam started after month 8
219205773|NCT05355441|DRUG|Paracetamol|Routine clinical practice treatments recommended by the medical team involved
219544442|NCT01902719|BEHAVIORAL|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
219544443|NCT01902719|BEHAVIORAL|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
219544444|NCT05683561|BIOLOGICAL|CoronaVac|D0; intramuscular injection
219544445|NCT05683561|BIOLOGICAL|SCTV01E|D0; intramuscular injection
219544446|NCT00567463|DEVICE|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
219544447|NCT03759704|DRUG|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
219621905|NCT04748562|DRUG|Progesterone|Taking prontogest vaginally
219621906|NCT02084225|PROCEDURE|ultrasound guided regional nerve block|participants were the physicians performing the procedure
218934496|NCT00531791|DRUG|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
219205774|NCT05355441|DRUG|Ibuprofen 600 mg|Routine clinical practice treatments recommended by the medical team involved
219544448|NCT01189747|BIOLOGICAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
218934497|NCT00531791|DRUG|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
218934498|NCT00775593|DRUG|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.~Induction therapy~\- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
218934499|NCT00775593|DRUG|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.~Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.~Induction therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.~Maintenance therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
218934500|NCT02067676|BIOLOGICAL|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
218934501|NCT02067676|DRUG|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
218934502|NCT04440865|OTHER|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
218934503|NCT04440865|OTHER|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
218934504|NCT04712630|PROCEDURE|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
219544449|NCT01189747|DRUG|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
219544450|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
218934505|NCT04712630|PROCEDURE|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
219045920|NCT05908097|DEVICE|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting.
219621907|NCT06582654|DEVICE|Sampling|"Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study)."
219045921|NCT05908097|DEVICE|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
219045922|NCT00976898|RADIATION|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
219045923|NCT05107128|DRUG|SAGE-718|Oral capsules.
219045924|NCT05107128|DRUG|Placebo|SAGE-718-matching oral capsules.
219621908|NCT01738347|DRUG|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
219621909|NCT06701591|OTHER|Kinesiotaping|Participants will be seated on a chair, KT will be applied bilaterally at the end of the expiration on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension. In order to stimulate the muscle and support the function, the stimulation technique is usually applied from the origin to the insertion of the muscle with the recommended stretching of 25 to 50%.
219621910|NCT06701591|OTHER|chest physical therapy|The chest physical therapy program is consisted of deep breathing exercises, postural drainage, and cough.
219621914|NCT05491317|BIOLOGICAL|GEN1042|Intravenous
219045925|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
219045926|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
219045927|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
219045928|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
219045929|NCT03977571|PROCEDURE|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
219621915|NCT05491317|DRUG|Pembrolizumab|Intravenous
219621916|NCT05491317|RADIATION|Radiotherapy|Radiotherapy
219621917|NCT06370676|DIAGNOSTIC_TEST|Oesophageal temperature measurement|Oesophageal temperature measurement
219621918|NCT05639465|BEHAVIORAL|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
219621919|NCT05639465|BEHAVIORAL|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
219621920|NCT07074145|BEHAVIORAL|Heart Health and Nutrition for Life (HHNL)|The CHW-led educational intervention will draw on two evidence-based programs, Healthy for Life (American Heart Association) and Your Heart, Your Life (NHLBI). Both curricula are designed to be facilitated by community health workers/promotores de salud and have been tested in both English and Spanish. Study-adapted curricular elements will include 12 core educational activities, delivered in six, two-hour, in-person sessions. In the context of expected family and work obligations alongside limited resources of FNCH patients, the investigators anticipate structuring sessions over, at most, 2 months with a class size of approximately 5-15 patients. In the CHW-led educational intervention, participants will learn about topics such as understanding risk for heart disease, the importance of physical activity, affordable healthy eating, and how family members can support health.
219621921|NCT07074145|BEHAVIORAL|Self-Measured Blood Pressure|Self-measured blood pressure (SMBP) is a proven, cost-effective strategy to improve blood pressure control by promoting patient engagement and medication adherence. All study participants will receive the same validated BP monitor, with cuff sizes adjusted as needed, selected from the US Blood Pressure Validated Device Listing. Patients will be trained using the AMA's 7-Step SMBP Quick Guide, consistent with FNCH clinical education practices. They will be asked to record baseline BP readings and complete at least one SMBP cycle per month during the 12-month study. Each cycle includes at least three consecutive days of morning and evening BP measurements.
219205775|NCT05355441|DRUG|Tramadol|Routine clinical practice treatments recommended by the medical team involved
219544451|NCT06081972|DIETARY_SUPPLEMENT|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
219544452|NCT06081972|DIETARY_SUPPLEMENT|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
219544453|NCT06081972|DIETARY_SUPPLEMENT|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
219544454|NCT04063878|DEVICE|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
219544455|NCT07130877|DIETARY_SUPPLEMENT|WHO F100|WHO F1OO
219544456|NCT07130877|DIETARY_SUPPLEMENT|WHO RECIPE BASED F100|Recipe-made formula will be given after initial stabilization, starting from 150 kcal per kg per day to a maximum of 220 kcal per kg per day at 4-hourly intervals, and intakes and vitals will be monitored.
219621922|NCT04052555|DRUG|Berzosertib|Given IV
219045930|NCT03977571|OTHER|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
219621923|NCT04052555|PROCEDURE|Biospecimen Collection|Correlative studies
219621924|NCT04052555|OTHER|Quality-of-Life Assessment|Ancillary studies
219621925|NCT04052555|OTHER|Questionnaire Administration|Ancillary studies
219621926|NCT04052555|RADIATION|Radiation Therapy|Undergo RT
219045931|NCT06447116|DEVICE|CGuard Prime™ Carotid Stent System|CGuard Prime™ Carotid Stent System
219045932|NCT01452308|BIOLOGICAL|Simtuzumab|
219045933|NCT01679275|OTHER|measuring cerebral oxygenation|
219045934|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
219045935|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
219045936|NCT05916586|DRUG|Prednisone|Prednisone 40 mg orally once a day for 7 days
219045937|NCT03816358|BIOLOGICAL|Anetumab Ravtansine|Given IV
219045938|NCT03816358|PROCEDURE|Biopsy Procedure|Undergo biopsy
219045939|NCT03816358|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219045940|NCT03816358|DRUG|Gemcitabine Hydrochloride|Given IV
219045941|NCT03816358|BIOLOGICAL|Ipilimumab|Given IV
219045942|NCT03816358|BIOLOGICAL|Nivolumab|Given IV
219045943|NCT04182100|DRUG|P1101|P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
219045944|NCT04182100|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
219045945|NCT04182100|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
219045946|NCT06285981|DEVICE|Chimaera Long Nail|The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
219045947|NCT06124976|DRUG|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
219045948|NCT04397263|DRUG|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
219544457|NCT04469959|DRUG|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
219544458|NCT04469959|DRUG|Placebo|Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
219544459|NCT07127094|DRUG|Test Product (Glimcoza)|Tablet formulation
219544460|NCT07127094|DRUG|Reference (R) Twymeeg®|Tablet formulation
219544461|NCT02751827|OTHER|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
219544462|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
219544463|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
219544464|NCT07130656|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
219544465|NCT03568838|DRUG|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
219544466|NCT02097160|OTHER|Vitamin D fortified yogurt and cheese products|
219544467|NCT02097160|OTHER|Control Group 1|
219544468|NCT07038447|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
219621927|NCT06930495|DRUG|Weight loss SOC Treatment with second generation anti-diabetic medications|To determine the best incretin-based drug for the treatment \[done as part of regular standard of care (SOC) treatment\], participants will go to UTSW weight wellness clinic and undergo a comprehensive history and physical exam to evaluate their overall health. This information is used to create an individualized approach to the participants weight loss regimen. As part of the regimen, participants will receive guidance on initiating lifestyle modifications including diet and exercise and may be referred to a clinical psychologist for evaluation and management of factors like stress, anxiety and depression, and exercise which may influence their health behaviors and body weight.
219621928|NCT03798028|BIOLOGICAL|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.
219544469|NCT07038447|DRUG|Fludarabine|Administered intravenously
219544470|NCT07038447|DRUG|Cyclophosphamide|Administered intravenously
219544471|NCT06544811|OTHER|Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.
219544472|NCT06544811|OTHER|Cultural Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
219544473|NCT07046910|DIAGNOSTIC_TEST|Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy|Hyperpolarized Xenon-129 MRI twice with navigational bronchoscopy twice
219544474|NCT07046910|DRUG|Hyperpolarized Xenon129|Lung transplant recipient with hyperpolarized Xe129 in MRI as an inhalation contrast agent
219544475|NCT07046949|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Ultrasound-guided anterior QL block performed preoperatively
219544476|NCT07046949|DRUG|Parenteral administration of analgesics|Intravenous opioids or NSAIDs used perioperatively.
219544477|NCT07046949|PROCEDURE|General Anesthesia (GA)|Standard general anesthesia per continious 1% propofol infusion and propofol bolus administration, atracurium and fentanyl administration.
219544478|NCT07061847|DRUG|Lidocaine (drug)|"The study intervention involves the use of 1% cardiac preservative-free lidocaine. Lidocaine is a local anesthetic commonly used in medical procedures to numb a specific area of the body. In this case, the lidocaine is formulated at a concentration of 1% and will be diluted to 50 mL with normal saline.~This treatment is an intra-arterial bilateral lidocaine infusion into the middle meningeal artery (i.e. this is a lidocaine infusion into the brain blood vessels to turn off the pain receptors responsible for causing chronic headaches). Lidocaine is an FDA approved anesthetic (i.e. pain killer) used in common medical practice. Lidocaine, however, has not yet been approved by the FDA for this particular use. For this reason, the use of lidocaine in this study is considered investigational."
219544479|NCT07061847|PROCEDURE|Lidocaine Procedure|All patient who meet eligibility criteria at their baseline visit will be scheduled for the Liocaine procedure.
218934506|NCT02164708|BEHAVIORAL|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
218934507|NCT01243580|DRUG|Ortho-Cyclen|Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
218934508|NCT01243580|DRUG|AG200-15|AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
218934509|NCT02689362|DRUG|Evogliptin|1 tablet per day
218934510|NCT02689362|DRUG|Sitagliptin|1 tablet per day
219205776|NCT05355441|DRUG|Morphine|Routine clinical practice treatments recommended by the medical team involved
219365801|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
219544480|NCT06760312|PROCEDURE|Root canal shaping with Continuous Rotation|The root canal shaping is conducted with a continuous rotation kinematic.
218934511|NCT02689362|DRUG|Placebo Evogliptin|1 tablet per day
218934512|NCT02689362|DRUG|Placebo Sitagliptin|1 tablet per day
218934513|NCT00000400|DRUG|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
218934514|NCT00000400|DRUG|alendronate|70 mg/week by oral route
218934515|NCT03372681|PROCEDURE|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
218934516|NCT03372681|PROCEDURE|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
218934517|NCT03159039|OTHER|Conventional Physiotherapy|
218934518|NCT03159039|OTHER|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
218934519|NCT02039024|DRUG|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
218934520|NCT03655249|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
218934521|NCT03655249|DRUG|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
219365802|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
219365803|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
219365804|NCT05529563|PROCEDURE|LSG|LSG
219365805|NCT05636631|DEVICE|Chest ultrasound|chest ultrasound as a non invasive, low cost \& bedside device for differentiation \& follow up of lung congestion \& pneumonia
219365806|NCT00237679|BEHAVIORAL|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
219365807|NCT00237679|BEHAVIORAL|Unstimulated|No current is generated.
219365808|NCT05855304|OTHER|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
219365809|NCT05855304|OTHER|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
219365810|NCT03805126|BEHAVIORAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
219365811|NCT03805126|BEHAVIORAL|Usual Care|Usual care includes consultation with a social worker and a community health worker.
219365812|NCT05335889|DEVICE|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
219544481|NCT06760312|PROCEDURE|Root canal shaping with Apical Reverse|The root canal shaping is conducted with a apical reverse kinematic.
219544482|NCT06760312|PROCEDURE|Root canal shaping is conducted with Apical slow-down kinematic.|The root canal shaping is conducted with a apical slow-down kinematic.
219544483|NCT06765291|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
219544484|NCT06765291|BEHAVIORAL|This is Quitting (TIQ)|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
219544485|NCT06752707|DEVICE|MiGo Tracker|Perform home exercise sessions while wearing MiGo Tracker device that logs exercise data.
219544486|NCT06752707|OTHER|Conventional home exercise program|Exercise following printed sheets or booklet
219544487|NCT07060924|BEHAVIORAL|Game-Based Learning (GBL)|Participants in this group received practical training in peripheral intravenous cannulation (PIVC) using a game-based learning (GBL) simulation platform called 3D Medsim. The platform offered a scenario-based training environment that included a structured sequence of pre-test, simulated procedural performance, and post-test. Students were required to perform virtual tasks such as preparing the patient, selecting the correct equipment, identifying the puncture site, and performing cannulation. The simulation provided interactive feedback and scoring. The application was accessible via PC, tablet, or smartphone, allowing students to practice flexibly. Training was conducted under the supervision of an anesthesiologist.
219544488|NCT07060924|BEHAVIORAL|Model Arm Practice|Participants in this group practiced PIVC using a high-fidelity model arm simulator designed to replicate human anatomy and venous access. The training model included artificial veins (basilic, cephalic, median cubital, and metacarpal) with realistic skin layers and a circulation system that mimicked blood flow. Students practiced cannulation techniques including vein localization, needle insertion, and catheter placement. The hands-on training provided tactile and visual feedback, and all procedures were supervised by an anesthesiologist. This method aimed to develop psychomotor skills and confidence through realistic simulation.
219544489|NCT07068646|PROCEDURE|CT myocardial thickness map guided PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system. A pre-procedural cardiac CT scan will be used to generate an atrial myocardial thickness map. In this group, atrial segments with wall thickness \>2.5 mm identified on the CT map will receive additional PFA applications (up to 8 per PV) to ensure transmural lesion formation. All other segments will receive the standard minimum of 8 applications per vein. The ablation catheter will remain stationary to allow lesion stacking when needed.
219544490|NCT07068646|PROCEDURE|Empirical PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system according to a standardized empirical protocol. Each pulmonary vein will receive a minimum of 8 PFA applications without adjustment based on anatomical or CT-based parameters. Additional applications may be delivered at the operator's discretion based on procedural findings, but no wall thickness mapping will be used.
219544491|NCT07068165|DRUG|5mg lenalidomide|Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
219621929|NCT07084389|BEHAVIORAL|FinSoc|Financial Social Work intervention (FinSoc) The FinSoc intervention is a structured financial social work program designed for families experiencing complex financial difficulties. It consists of five modules, each delivered in a one-on-one session with a trained social worker. The modules focus on key areas such as budgeting, emotional and relational aspects of money, financial decision making, building long-term financial capability. The intervention aims to reduce financial anxiety, strengthen economic self-efficacy, and support overall wellbeing. Motivational interviewing techniques and client-centred approaches are used throughout to encourage active participation and goal-setting.
219621930|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain)
219621931|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands
218934522|NCT04660565|DRUG|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
219621932|NCT07097129|PROCEDURE|Mask Ventilation|Mask ventilation with mechanical ventilator set to pressure controlled ventilation, 15 cmH20 peak pressure, 10 respiratory rates per minute
218934523|NCT04660565|DRUG|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
218934524|NCT02177071|DRUG|INFLIXIMAB|
218934525|NCT02177071|DRUG|AZATHIOPRINE|
218934526|NCT02177071|DRUG|MERCAPTOPURINE|
218934527|NCT02177071|DRUG|Methotrexate|
218934528|NCT02730013|BEHAVIORAL|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
218934529|NCT01048034|DRUG|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
218934530|NCT01048034|DRUG|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
219544492|NCT07068165|DRUG|10mg lenalidomide|Lenalidomide 10mg/ day combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/ day for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
219621933|NCT07095218|DEVICE|Application of Tacs|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (40 Hz, 80 Hz, individual gamma frequency) and in a theta-gamma coupling range (6-80 Hz). A sham stimulation group will also be included. The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4). Pre- and post-stimulation cognitive performance will be assessed using neuropsychological tests, while EEG will be used to evaluate theta-gamma phase-amplitude coupling and oscillatory changes.
219621934|NCT07094919|DEVICE|Corheart 6 left ventricular assist system|Corheart 6 left ventricular assist system provides circulatory support for patients with advanced left heart failure.
218934531|NCT03238495|DRUG|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
218934532|NCT03238495|DRUG|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
218934533|NCT06403345|BEHAVIORAL|Green Activity Program|See arm description.
218934534|NCT03283514|OTHER|Complete denture|questionnaire
218934535|NCT04853017|DRUG|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
218934536|NCT03460262|DEVICE|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
219544493|NCT07068165|DRUG|Prednisone monotherapy|The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).
219544494|NCT07068074|PROCEDURE|Wide local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue.
219544495|NCT07068074|PROCEDURE|Sentinel Lymph Node and Wide Local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well.
219544496|NCT07067203|DEVICE|Lafayette hand held dynamometer|"Muscle Strength Measurement:~The strength of the quadriceps (knee extensors) and hamstrings (knee flexors) of the amputated limb will be measured using a handheld digital dynamometer (Nicholas MMT, Lafayette Instruments). Measurements will be taken with the prosthesis in place. Quadriceps strength will be assessed in a supine position with the knee at 30° flexion, while hamstring strength will be assessed in a prone position with the knee at 20° flexion. Each participant will perform three maximal effort trials after a practice attempt. The highest value will be scaled to body mass for analysis."
219544497|NCT07067203|DIAGNOSTIC_TEST|Timed up and Go test|"Timed Up and Go (TUG) Test:~Participants will complete a standardized 3-meter TUG assessment to evaluate functional mobility. The test will be broken down into five components: standing, walking, turning, returning, and sitting. After one practice run, two timed trials will be conducted, and the average of both will be used for analysis. All procedures will be conducted by trained physical therapists following a standardized protocol."
219544498|NCT07068984|OTHER|Differences between lower limb balances were assessed by the Y-Balance test|The Y-Balance test was used to evaluate bilateral anterior difference, composite score, lateral and posterior balance, symmetry ratio and bilateral difference
218934537|NCT03460262|DEVICE|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
218934538|NCT05569070|OTHER|Guided Young United Parents! Website Intervention|Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.
219045949|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
219045950|NCT02142530|DRUG|Carfilzomib|
219045951|NCT02142530|DRUG|Belinostat|
219045952|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
219045953|NCT06371222|DRUG|Beta blocker|controlled group
219045954|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
219544499|NCT07068802|BEHAVIORAL|Message framing|Participants provided electronic informed consent with voluntary withdraw options. Randomization was implemented through a 1:1:1:1 allocation ratio to four conditions: Control group (Group 1, n=154) receiving a standard statement of HPV risks (In mainland China, HPV vaccines are currently approved only for female use. However, in other countries, they are also available for males. HPV can cause cancers throughout the body, from the head to the reproductive system. Thus, HPV vaccination can protect against many cancer types. Annually, over 120,000 Chinese are diagnosed with HPV-related cancers, with about 50,000 dying from them.); Intervention 1 (Group 2, n=152) adding male-specific health risks; Intervention 2 (Group 3, n=153) adding risk to female partners; Intervention 3 (Group 4, n=153) adding both personal risk and risk to female partners. The protocol involved sequential completion of pre-exposure questionnaires, timed 120-second message exposure, and immediate post-exposure asses
219544500|NCT07067814|DRUG|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
219544501|NCT07067814|PROCEDURE|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
219544502|NCT07068542|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan: 4mg/kg, IV, Q6W, D1, D15, D22
219544503|NCT07068542|DRUG|Tislelizumab|Tislelizumab: 400mg, IV, Q6W, D1
219544504|NCT07067918|OTHER|Upper Body Plyometric Training|"Upper Body Plyometric Training - Intervention Description:~A 12-week upper-body plyometric training protocol designed to enhance explosive upper-extremity power in elite male kickboxers. Exercises included medicine ball chest passes, overhead throws, plyometric push-ups, clap push-ups, and rotational medicine ball throws. Training was performed three times per week (20-30 minutes per session) in addition to regular kickboxing practice."
219544505|NCT07067918|OTHER|Lower Body Plyometric Training|"Lower Body Plyometric Training - Intervention Description:~A 12-week lower-body plyometric training program targeting explosive leg strength and anaerobic performance in elite male kickboxers. The program included countermovement jumps, squat jumps, lateral hurdle jumps, plyometric bounding, tuck jumps, and depth jumps. Sessions were conducted three times per week (20-30 minutes each), alongside regular kickboxing training."
219544506|NCT07069413|BEHAVIORAL|tele-ImPACT|Participants will receive 12 weeks of Project ImPACT intervention as delivered via Telehealth
219544507|NCT07068958|DRUG|0.25% RCI001 Ophthalmic Solution|0.25% RCI001 Ophthalmic Solution
219544508|NCT07068958|DRUG|Placebo Ophthalmic Solution (vehicle)|Placebo Ophthalmic Solution (vehicle)
219544509|NCT07067086|OTHER|Test Cream|A facial cream (Formula# 899675 44A, 30 mL) was applied once by participants under supervision. 1g of cream was spread over the entire face and neck, followed by targeted massage on wrinkle-prone areas including forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical and photo-based evaluations were conducted at baseline (T0), 10 hours (T10h), and 24 hours (T24h) after application.
219544510|NCT07069439|BEHAVIORAL|Turkish Version of the P-DrHy-Q|Participants will complete the Turkish-translated version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), which includes 12 items assessing psychosocial burden in two domains: mental health and social activity. A subgroup of participants (n ≈ 20) will complete the same questionnaire again after 14 days to assess test-retest reliability
219544511|NCT07067164|OTHER|Bulk fill resin composite restorative material|Both restorative materials were applied in a clinical setting following standard infection control protocols and material-specific preparation techniques. The interventions were performed by the same calibrated operator to ensure consistency, and evaluated using modified USPHS criteria by two blinded, independent assessors at 1 week (baseline), 6 months, and 12 months. The study employed a split-mouth design to allow direct intra-individual comparison between the two materials under similar oral conditions.
219544512|NCT07069335|DRUG|Olaparib 150 MG|Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration
219544513|NCT07067294|DEVICE|Low-Level Light Therapy|"The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Group, Italy), which delivers low-level polychromatic red and near-infrared light (600-1200 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after cataract surgery.~The treatment is designed to stimulate meibomian gland activity, improve tear film stability, reduce ocular surface inflammation.~This protocol is unique compared to standard treatments for dry eye because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications."
219621937|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
219621938|NCT06926205|DRUG|Mosunetuzumab (IV)|6 cycle of Mosunetuzumab+CHOP and then 11 cycles more of mosunetuzumab on mnotherapy
219621939|NCT01047254|DRUG|Elontril|flexible dose of Bupropion 150-300 mg
219621940|NCT01047254|DRUG|placebo|
219621941|NCT00346983|DRUG|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
219621942|NCT00346983|DRUG|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
219045955|NCT05132127|DRUG|sutimlimab|Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
219045956|NCT04677491|DRUG|Ospemifene 60 mg|Ospemifene vs placebo
219045957|NCT04677491|BEHAVIORAL|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
219045958|NCT05386043|DRUG|FET F-18|PET scan with FET prior to biopsy
219045959|NCT05386043|DRUG|O-15 Radioisotope|PET scan with O-15 Water prior to biopsy
219621943|NCT07095790|DRUG|Tirofiban+Oral Dual Antiplatelet Therapy|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)
219621944|NCT07095790|DRUG|Oral Dual Antiplatelet Therapy|Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)
219621945|NCT07096895|PROCEDURE|EDEE (EUS-directed transenteric ERCP)|Technical aspects of EUS-guided anastomosis and ERCP via LAMS (Lumen apposing metal stent)
219045960|NCT05386043|PROCEDURE|CT scan|CT scan prior to biopsy
219045961|NCT05386043|PROCEDURE|MRI with gadolinium-based contrast|MRI prior to biopsy
219544514|NCT07067294|DEVICE|Sham (No Treatment)|"Sham-treated controls underwent the same procedural setup as the active treatment group, using the Eye-light® device (Espansione Group, Italy). However, instead of delivering therapeutic levels of light energy, the device operated in demo light mode, emitting less than 30% of the full treatment power. This setting simulated the visual and sensory experience of a low-level light therapy (LLLT) session without delivering biologically effective photobiomodulation.~The sham intervention included two 15-minute sessions: one administered 7 days before cataract surgery and one 7 days after. This approach allowed for masking of participants and investigators to minimize bias, while ensuring that patients in the control group received no active therapeutic exposure."
219544515|NCT05028569|DRUG|BOTOX|Intramuscular Injection
219544516|NCT05028569|DRUG|Placebo|Intramuscular Injection
219544517|NCT06253182|BEHAVIORAL|Self-Guided PEPP Intervention Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
219544518|NCT06253182|BEHAVIORAL|Self-Guided PEPP Education Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
219621946|NCT07095946|DEVICE|Electronic Syringe Intraligament Technique|Use of an electronic syringe device to deliver local anesthesia using the periodontal ligament (PDL) technique in pediatric dental patients
219621947|NCT07095946|DEVICE|Electronic syringe IANB Technique|Use of an electronic syringe device to deliver local anesthesia via the Inferior Alveolar Nerve Block Technique in pediatric dental patients
219621948|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
219621949|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
219045962|NCT05386043|PROCEDURE|Biopsy Collection|Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
219045963|NCT06322719|DEVICE|Hyperangulated blade videolaryngoscope|For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
219045964|NCT06322719|DEVICE|Macintosh blade videolaryngoscope|For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
219045965|NCT05472623|DRUG|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
219045966|NCT05472623|COMBINATION_PRODUCT|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
219045967|NCT04592003|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
219621950|NCT07101900|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
219045968|NCT06521476|DRUG|Acetazolamide|Oral acetazolamide 250 mg daily for 7 days
219045969|NCT06521476|DRUG|Placebo|Oral placebo daily for 7 days
219045970|NCT01589757|OTHER|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
219045971|NCT01589757|OTHER|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
219045972|NCT05971849|DRUG|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
219045973|NCT05086731|OTHER|Best Practice|Receive standard of care
219045974|NCT05086731|OTHER|Informational Intervention|Receive reminders
219045975|NCT05086731|OTHER|Medical Device Usage and Evaluation|Receive a SMRxT smart pill bottle
219045976|NCT05086731|OTHER|Quality-of-Life Assessment|Ancillary studies
219045977|NCT05086731|OTHER|Survey Administration|Ancillary studies
219205777|NCT06724796|OTHER|Y4BI|"The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly."
218934539|NCT05569070|OTHER|Nutrition Website|Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
218934540|NCT05985369|OTHER|Controlled diet and resistance exercise|Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
218934541|NCT04411732|DEVICE|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
218934542|NCT04411732|DIAGNOSTIC_TEST|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
218934543|NCT04411732|DIAGNOSTIC_TEST|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
219045978|NCT05153382|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
219205778|NCT06724796|OTHER|ACTIVE|The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
219205779|NCT06722560|OTHER|GLP-1 hormone|s.c. continuous infusion for 72 hours using an insulin pump
219205780|NCT06722560|OTHER|Placebo|s.c. continuous infusion for 72 hours using an insulin pump
219205781|NCT06723418|OTHER|Malnutriton Screening Tool (PYMS)|In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
219544519|NCT06455969|DRUG|Goserelin 3.6 MG|Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
219544520|NCT06455969|OTHER|Multi-Stressor Training|A 4-week physical training program that mimics military training.
219544521|NCT06455969|DRUG|Testosterone gel (AndroGel 5g)|Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
219544522|NCT06455969|DRUG|Testosterone gel (AndroGel 1.25g)|Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
219544523|NCT06455969|DRUG|Estradiol / Levonorgestrel Transdermal System [Climara Pro]|Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
219544524|NCT06455969|DRUG|Placebo Patch|Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
219544525|NCT06067919|OTHER|decision tree for the choice of intraoperative antibiotic prophylaxis|Presentation of a decision tree to anaesthetists to guide the choice of intraoperative antibiotic prophylaxis
219544526|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
219544527|NCT05893342|DIAGNOSTIC_TEST|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
219544528|NCT05427708|DEVICE|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
219544529|NCT05427708|BEHAVIORAL|Psycho-Education|See: Arm/group descriptions
219544530|NCT06840509|DEVICE|CorSky ICD or CRT-D|Subjects with an indication for an ICD or CRT-D device will be implanted with a CorSky device of the CorSky ICD family according to standard implantation procedures. Device programming will be done according to the medical needs of the subjects.
219544531|NCT06257355|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
219045979|NCT03604692|DRUG|axatilimab|axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
219544532|NCT02256722|DRUG|KUC 7483 CL|
219544533|NCT02256722|DRUG|Bisoprolol|
219544534|NCT02256722|DRUG|Propranolol|
219544535|NCT02256722|DRUG|Acipimox|
219544536|NCT02256722|DRUG|Salmeterol|
219544537|NCT06163001|BEHAVIORAL|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
219544538|NCT06163001|DIETARY_SUPPLEMENT|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
219544539|NCT01195038|BIOLOGICAL|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
219544540|NCT06626932|RADIATION|18 FDG (Fludeoxyglucose 18F)|18-f FDG
219544541|NCT02376881|DRUG|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
219045980|NCT06133426|DEVICE|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
219045981|NCT02171481|DRUG|Dabigatran etexilate polymorph II|
219621951|NCT07104695|BEHAVIORAL|Solomiya App - CBT-based self-help intervention|"Solomiya App - CBT-based self-help intervention~The Solomiya app is a mobile-based self-help intervention designed to reduce and cope with depressive symptoms and improve sleep in individuals exposed to chronic stress. It has been created within the Solomiya project and is based on preliminary work in other international health settings (Böge 2022) where it has shown to improve depressive symptoms as part of a Stepped Care and Collaborative Model (SCCM). It includes psychoeducational multimedia modules on stress management and sleep problems, along with cognitive behavioral therapy (CBT)-based tools such as guided relaxation exercises, mindfulness practices, and behavioral activation strategies. The app also offers symptom tracking using the PHQ-9 to support user self-monitoring. Participants are instructed to engage with the app regularly over a 4 week period. The intervention is entirely self-guided and does not involve therapist support. App usage and adherence data will be collect"
219621952|NCT03578367|DRUG|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
219045982|NCT02171481|DRUG|Dabigatran etexilate polymorph I|
219045983|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
219045984|NCT02321696|DEVICE|Acupuncture|
219544542|NCT02376881|OTHER|placebo|100 ml normal saline in 2 hr for 3 successive days
219544543|NCT06150703|DRUG|Ovulation induction with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
219544544|NCT06150703|DRUG|Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
219544545|NCT03932045|DEVICE|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
219544546|NCT03932045|DEVICE|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
219544547|NCT04790526|OTHER|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
219544548|NCT03407209|OTHER|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
219544549|NCT01896713|OTHER|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
219544550|NCT00073580|DRUG|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) \>300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
219544551|NCT05561166|OTHER|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
219544552|NCT00592969|DRUG|metformin|
219544553|NCT00592969|DRUG|biphasic insulin aspart|
219621953|NCT03578367|DRUG|Imatinib|Imatinib 400 mg taken orally once daily
219045985|NCT02321696|OTHER|Physiotherapy and eccentric exercise|
219045986|NCT02321696|OTHER|Watchful waiting and eccentric exercise|
219045987|NCT02321696|OTHER|eccentric exercise|
219045988|NCT00041431|DRUG|Hormone Replacement Therapy|
219045989|NCT06423898|DRUG|Ampicillin plus ceftriaxone in continuous infusion|Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis
219045990|NCT06423898|DRUG|Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed|"Ampicillin plus ceftriaxone as an intermittent infusion for a minimum of 14 days. After, if the patient is discharged from the hospital, the following treatments, until the 42-day treatment period is completed:~1. Intravenous treatment according to the following regimens:~   Ampicillin plus ceftriaxone as an intermittent infusion, teicoplanin, daptomycin, dalbavancin or linezolid.~2. Oral treatment according to the following regimens: amoxicillin plus moxifloxacin, amoxicillin plus linezolid, amoxicillin plus rifampin, linezolid plus moxifloxacin or linezolid plus rifampin."
219621954|NCT03578367|DRUG|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
219621955|NCT04685512|DRUG|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
219621956|NCT02729025|DRUG|Evolocumab|Administered subcutaneously once a month using an autoinjector/pen.
219544554|NCT02490072|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
219544555|NCT02490072|DRUG|normal saline(Saline 0.9%)|
219544556|NCT04939571|OTHER|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
219045991|NCT01274624|BIOLOGICAL|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
219045992|NCT01274624|DRUG|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
219045993|NCT01274624|DRUG|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
219045994|NCT01274624|DRUG|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
219045995|NCT01274624|DRUG|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
219045996|NCT03929965|DRUG|Anlotinib|Anlotinib
219544557|NCT00582387|GENETIC|specimen samples|blood, urine and tissue
219544558|NCT00582387|BEHAVIORAL|questionnaires|
219544559|NCT02452619|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
219621957|NCT02729025|DRUG|Placebo|Administered subcutaneously once a month using an autoinjector/pen.
219045997|NCT01438320|DIETARY_SUPPLEMENT|Quercetin|Bioflavonoid
219045998|NCT02703636|DRUG|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
219045999|NCT01505127|DRUG|TAK-438|
219544560|NCT00889486|DRUG|TZP-102|
219544561|NCT00889486|DRUG|Placebo|
219621958|NCT01267019|BEHAVIORAL|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
219621959|NCT01267019|BEHAVIORAL|social cognitive training|30 sessions of social cognitive training without in vivo exercises
219544562|NCT04423835|PROCEDURE|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
219621960|NCT01267019|BEHAVIORAL|non-social skills training|30 sessions of skills training that has no specific social content
219621961|NCT07111923|OTHER|Balance Assesment|The study design was a single-group repeated measures design. Nineteen individuals meeting the inclusion criteria were included. The assessments were conducted individually in a quiet environment, isolated from other athletes and external factors. Athletes were instructed to refrain from intense exercise and training, avoid caffeine consumption, and attend the assessment in sportswear within the last 24 hours. Upon arrival for the assessments, athletes were seated to rest while demographic information was collected. Each test was explained verbally and visually, and participants were allowed to perform a trial. A crossover design method was used in the study, with the order of tests (hands on hips or hands free) determined randomly. Retest measurements were conducted 24 hours after the initial test at the same time of day. The tests performed are described below.
219621962|NCT07113431|DIETARY_SUPPLEMENT|IBD-AID diet combined with Kate Farms Peptide 1.5|Combining standardized-IBD diet developed by the University of Minnesota (IBD-AID) with commercially available pea protein plant-based enteral nutrition formula (Kate Farms Peptide 1.5)
219621963|NCT07113431|OTHER|IBD-AID diet|Standardized IBD diet developed by the University of Massachusetts Medical School (IBD-AID)
219046000|NCT01505127|DRUG|Lansoprazole|
219046001|NCT01505127|DRUG|Amoxicillin|
219046002|NCT01505127|DRUG|Clarithromycin|
219621964|NCT07110740|DRUG|UI009|inhale UI009 twice a day on Day 1 and Day 8.
219621965|NCT07110740|DRUG|UIC202005|inhale UIC202005 twice a day on Day 1 and Day 8.
219621966|NCT07112417|DEVICE|Augmented Reality|Participants in this group will undergo mini-screw placement assisted by augmented reality (AR) technology. A customized AR system will guide the clinician in real-time to ensure optimal screw positioning, improve accuracy, and minimize placement errors.
219046003|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
219046004|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
219046005|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
219046006|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
219046007|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219046008|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
219544563|NCT06556017|DIAGNOSTIC_TEST|Diagnosis of SSI|Comparison of the manual system and ChatGPT for SSI diagnosis in colorectal surgery procedures enrolled in the SSI surveillance programme.
218934544|NCT04411732|DIAGNOSTIC_TEST|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
218934545|NCT03293368|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
218934546|NCT03293368|DRUG|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
218934547|NCT00505349|BEHAVIORAL|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
219544564|NCT01608984|PROCEDURE|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
219544565|NCT01608984|PROCEDURE|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
219544566|NCT01608984|PROCEDURE|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
219544567|NCT04584541|BIOLOGICAL|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
219544568|NCT04584541|BIOLOGICAL|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
219544569|NCT04584541|BIOLOGICAL|Stools|SarS-Cov-2 viral load assessment
219544570|NCT06561542|DRUG|LX22001 for Injeciton|single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
219544571|NCT06561542|DRUG|Tegoprazan tablet|50mg,oral,single dose
219544572|NCT06561542|DRUG|Esomeprazole sodium for injection|80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
219621967|NCT07112417|PROCEDURE|Conventional screw placement|Participants in this group will receive mini-screw placement using the conventional freehand method without augmented reality assistance. The screws will be placed according to standard clinical protocols based on anatomical landmarks and clinician experience
218934548|NCT01802138|BIOLOGICAL|Activated T lymphocyte|intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
218934549|NCT03393988|DRUG|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
218934550|NCT03393988|PROCEDURE|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
219544573|NCT00615667|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
219544574|NCT03375957|DRUG|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
219544575|NCT03375957|DRUG|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
219544576|NCT00767481|DRUG|Travoprost/Brinzolamide|Eye drop suspension, once daily
219544577|NCT00767481|DRUG|Cosopt|Eye drop solution, one drop BID
219544578|NCT05405023|OTHER|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
219544579|NCT05405023|OTHER|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
219544580|NCT02864836|PROCEDURE|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
219544581|NCT02770690|DRUG|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
219544582|NCT02770690|DRUG|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
219544583|NCT02770690|DRUG|placebo|apply normal saline before propofol iv injection
219544584|NCT06335927|DRUG|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
219544585|NCT00265226|BIOLOGICAL|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
219544586|NCT01881763|DRUG|Ketamine|Ketamine 1-2 mgr/ kg IV
219544587|NCT01881763|DRUG|Methohexital|Methohexital 0.5-1mg/kg IV
219544588|NCT06558968|OTHER|aesthetic functional space maintainers|evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
219544589|NCT01624233|DRUG|80 mg ixekizumab|Administered SC
218934551|NCT03393988|DRUG|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
219544590|NCT05281354|OTHER|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
219544591|NCT02203539|OTHER|exposure to normal light|exposure for 60 minutes in duration
219544592|NCT02203539|OTHER|exposure to bright light|exposure to bright light for 60 minutes of duration
219544593|NCT02203539|OTHER|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
218934552|NCT02009280|DRUG|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
218934553|NCT02009280|DRUG|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
218934554|NCT03904693|DRUG|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
219544594|NCT01877122|DEVICE|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
219544595|NCT01877122|DEVICE|Marlex® Mesh Implant|
219544596|NCT05488795|BEHAVIORAL|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
219621968|NCT07111676|BEHAVIORAL|The Solution-focused Intervention for Mental health (SIM)|SIM is a manual-based program delivered to upper secondary school students in mentor groups by a specially trained teacher. It consists of group-based, solution-focused coaching set within a normative frame of mental well-being. By co-creating perceptions and meaning through language and dialogue, focusing on resources for approaching a preferred future, students increase their solution-building capability, thereby acquiring skills to become agents in their own life, more aware of and prone to invest in mental health. For a detailed description, see Söderqvist et al. https://doi.org/10.1016/j.ssmmh.2025.100493.
218934555|NCT03904693|DRUG|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
218934556|NCT03904693|DRUG|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
219046009|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
219046010|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
219046011|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
219046012|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
219046013|NCT00159523|BIOLOGICAL|placebo|
218934557|NCT03904693|DRUG|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
218934558|NCT03904693|DRUG|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
218934559|NCT03904693|DRUG|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
219046014|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
219046015|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
219046016|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
219046017|NCT01851005|DRUG|Normal saline|Use as placebo
219046018|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
219046019|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
219046020|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
219046021|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
219046022|NCT03495882|DRUG|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
219544597|NCT03215641|DEVICE|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
219544598|NCT00063687|DRUG|Oxypurinol|
219544599|NCT02757287|DRUG|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~\- Quality of Life questionnaire the day after the bolus"
219544600|NCT04511156|OTHER|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
219544601|NCT06122155|DEVICE|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
219544602|NCT06122155|DEVICE|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
219544603|NCT00079495|DRUG|NBI-5788|
219544604|NCT00778453|OTHER|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
219544605|NCT00778453|OTHER|Hospital-based BIT|bilateral symmetric, repetitive arm training
218934560|NCT04223349|DRUG|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
218934561|NCT04223349|DRUG|Placebo|Matching placebo in capsule will be administered orally.
218934562|NCT05796141|BEHAVIORAL|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
218934563|NCT05796141|BEHAVIORAL|Dyadic Action Planning|Participants will develop dyadic action plans together.
219544606|NCT00778453|OTHER|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
219544607|NCT00778453|OTHER|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
219544608|NCT00778453|OTHER|Home-based BAT|bilateral symmetric, repetitive arm training
219544609|NCT00778453|OTHER|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
219544610|NCT05025033|DRUG|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
219544611|NCT04372238|BEHAVIORAL|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
219544612|NCT04372238|BEHAVIORAL|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
219544613|NCT03278041|PROCEDURE|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
219544614|NCT03278041|DEVICE|maxillary obturator|immediate surgical obturator
219544615|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
219544616|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
219544617|NCT04778878|DEVICE|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
218934564|NCT05796141|BEHAVIORAL|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
218934565|NCT05796141|BEHAVIORAL|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
218934566|NCT05796141|BEHAVIORAL|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
218934567|NCT03959878|DEVICE|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
219621969|NCT07110974|BEHAVIORAL|Diabetes Distress scale 17 and Quality Of Life Instrument|questionnaire that assesses the distress resulting from being diabetic patient type 1 and another questionnaire that assesses the quality of life among type 1 diabetic Sohag University students
218934568|NCT02858505|DRUG|27 mg elemental iron|
218934569|NCT02858505|DRUG|54 mg elemental iron|
218934570|NCT04793022|DRUG|TIVA with Propofol|Total intravenous anesthesia with propofol
218934571|NCT04793022|DRUG|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
218934572|NCT03099278|DRUG|Ezetimibe|Ezetimibe 20 mg oral daily
218934573|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
218934574|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
218934575|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
218934576|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
219544618|NCT04837105|OTHER|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
219544619|NCT04837105|OTHER|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
219544620|NCT05676294|DRUG|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
219621970|NCT07113340|DEVICE|Carina™ Surgical Platform, developed by Ronovo Surgical, Inc|A modular surgical robot that offers greater flexibility in the number of instrument arms and surgical layout options.
219544621|NCT05676294|DRUG|Placebo|oral matched placebo one hour prior to ambulatory surgery
219544622|NCT03656536|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
219544623|NCT03656536|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
219544624|NCT03656536|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
219544625|NCT06384495|PROCEDURE|REAL-A|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
219544626|NCT06384495|PROCEDURE|REAL-C|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
219544627|NCT06384495|PROCEDURE|SHAM|one session of sham tDCS for 20 minutes to the right ventro-lateral cerebellum.
218934577|NCT06398509|BEHAVIORAL|Control|The control intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The control intervention focuses on home safety, home management of common childhood illnesses, and promotion of language development.
218934578|NCT06398509|BEHAVIORAL|Futuros Fuertes 2.0|The Futuros Fuertes 2.0 intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The Futuros Fuertes 2.0 intervention focuses on optimal infant feeding, screen time, and sleep practices.
219544628|NCT06013527|OTHER|Supervised Training|"Two different classes over alternate weeks twice per week :~1. 60-minute step aerobics class (Given week 1,3,5,7)~2. 60 minutes circuit training class (Given week 2,4,6,8)~Each class will include warm-up and cool-down periods both lasting 10-15 min. The exercise period of 30 minutes the maximum target RPE would be set at 14-16 on a 20-point BORG scale, a level of exercise that feels somewhat hard or hard and coincides with about 86-92% of maximal heart rate, 76-85% of maximal VO 2 and 5-7 metabolic equivalents (METs) ideal for improving the related domains of QoL and Cardiovascular endurance (12). During the first 3 weeks, the participants would exercise at a lower level of RPE (approximately 11-13), to adapt to the training and so that newly recruited participants could also join the group without difficulty."
219544629|NCT06013527|OTHER|Individually tailored home program|The type of home training would mainly consist of endurance training such as walking, Nordic walking, or aerobic training, but it would also include jumps and leaps like step aerobics to promote bone health. The Participants will be asked to perform these thrice per week.
219544630|NCT00334815|BIOLOGICAL|Bevacizumab|Given IV
219544631|NCT00334815|DRUG|Cisplatin|Given IV
219544632|NCT00334815|DRUG|Docetaxel|Given IV
219544633|NCT00334815|DRUG|Etoposide|Given IV
219544634|NCT00334815|BIOLOGICAL|Filgrastim|Given SC
219544635|NCT00334815|BIOLOGICAL|Pegfilgrastim|Given SC
219544636|NCT00334815|RADIATION|Radiation Therapy|Undergo thoracic radiotherapy
218934579|NCT05677568|DEVICE|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
218934580|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
218934581|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
218934582|NCT02765750|BEHAVIORAL|No message|The headphones will be placed on patient's ears but no message will be played.
219544637|NCT03862911|RADIATION|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
218934583|NCT06474026|DEVICE|ExAblate 4000 Type 2.1|"In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments."
219046023|NCT02151526|DRUG|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
219544638|NCT03862911|RADIATION|Stereotactic ablative radiotherapy|"Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily"
219544639|NCT06458023|DEVICE|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
219544640|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
219544641|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
219621971|NCT07112950|DEVICE|Press Needle Acupuncture and standart therapy|The patient will have a press needle applied, which will be removed on the seventh day.
219621972|NCT07112092|BEHAVIORAL|Tell-Show-Do|Standard behavioral management technique where the dental procedure is explained to the child, demonstrated, and then performed.
219621973|NCT07112092|BEHAVIORAL|Music Therapy|Participants listen to calming music during the dental extraction procedure to reduce anxiety and pain perception.
219621974|NCT07112092|BEHAVIORAL|Therapeutic Play Therapy|Use of structured play activities designed to reduce dental anxiety and improve cooperation during tooth extraction.
219205783|NCT06731699|DRUG|FD-001|"The initial dose was 0.4mg, and subsequent doses of 0.8mg, 1.6mg, 2.4mg, 3.2mg, and 4.0mg were proposed to be administered in a progressive manner using the rapid titration method combined with the traditional 3+3 experimental design. The trial process consists of three periods: screening period, treatment period, and follow-up period. The screening period lasted from D-28 to D-1 for treatment (DLT observation period): during this time frame, there was a single administration period (C0D1-C0D4) where oral administration occurred on day one followed by safety observations on days two to four; as well as multiple administration period one (C1D1-C1D28) where oral administration took place on days one to two and seven to nine with rest periods in between. The drug is available in capsule form."
219205784|NCT06884644|DIAGNOSTIC_TEST|Death by Airsquat|Increasing number of squats have to be completed every minute (EMOM principle).
219544642|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
219544643|NCT06390943|OTHER|Facility-based feeding support package plus (FB-FSP+)|Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
219544644|NCT06390943|OTHER|Transition-to-home feeding support package plus (TTH-FSP+)|Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
219544645|NCT06204991|BIOLOGICAL|ADP-TILIL7|Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement
219544646|NCT06204991|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
219544647|NCT06204991|DRUG|Fludarabine Phosphate|Lymphodepleting Chemotherapy
219544648|NCT06204991|DRUG|Proleukin|IL-2
219544649|NCT06359847|DRUG|ST-1898 tablets|Tablets: 5 mg and 40 mg
219544650|NCT05181982|OTHER|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
219544651|NCT03414450|DRUG|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
219544652|NCT03414450|DRUG|dasatinib|dasatinib tablets at 140 mg will be dosed every day
219544653|NCT05457413|PROCEDURE|Sleeve gastrectomy|Bariatric surgery
219544654|NCT00944294|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
219544655|NCT00944294|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
219621975|NCT07111221|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt performed prior to liver transplantation in patients with increased risk of intraoperative blood loss
219621976|NCT07111221|DRUG|Non-selective beta-blockers|Non-selective beta-blockers for lowering portal hypertension
218934584|NCT00690781|DIETARY_SUPPLEMENT|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
218934585|NCT00690781|DIETARY_SUPPLEMENT|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
219046024|NCT05929482|BEHAVIORAL|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
219046025|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
219621977|NCT07112105|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 30 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
219621978|NCT07112105|DEVICE|Sham rTMS|Subjects randomized to sham rTMS will undergo the same procedures on the same equipment as subjects assigned to active rTMS, but no active magnetic stimulation will be delivered.
219046026|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
219046027|NCT06052618|DRUG|Pacritinib|Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
219046028|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
219046029|NCT04698356|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
219046030|NCT00531843|DRUG|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
218934586|NCT00690781|DIETARY_SUPPLEMENT|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
218934587|NCT00690781|DIETARY_SUPPLEMENT|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
219046031|NCT00531843|DEVICE|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
219046032|NCT00375843|DRUG|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
219046033|NCT00375843|DRUG|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
219046034|NCT00136292|DRUG|daptomycin|
219046035|NCT05427435|DEVICE|Marshall ethanolisation|Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
219046036|NCT05265611|BEHAVIORAL|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
219544656|NCT01966666|DRUG|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
219544657|NCT01966666|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
219544658|NCT01966666|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
219544659|NCT01966666|DRUG|Placebo|500mL 0.9% sodium chloride.
219544660|NCT05889143|DRUG|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
218934588|NCT00369265|DRUG|Lansoprazole|Lansoprazole 30mg twice daily
219046037|NCT05265611|BEHAVIORAL|Tutoring|Young adults will be trained to tutor students in elementary school.
219046038|NCT03037788|DRUG|WO3979|Application of cream to each axilla
219046039|NCT03037788|DRUG|WO3970|Application of cream to each axilla
219046040|NCT03037788|DRUG|WO3992|Application of cream to each axilla
218934589|NCT00369265|DIETARY_SUPPLEMENT|Sugar pill|placebo twice daily
219046041|NCT03037788|DRUG|Placebo (WO3988)|Application of cream to each axilla
219046042|NCT05454501|OTHER|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
219544661|NCT04325139|OTHER|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
219544662|NCT04723134|COMBINATION_PRODUCT|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
219544663|NCT00003003|BIOLOGICAL|sargramostim|
219544664|NCT00003003|DRUG|mitomycin C|
219544665|NCT00003003|DRUG|mitoxantrone hydrochloride|
219544666|NCT06463041|OTHER|Experimental, comparator and control|How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
219544667|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
219544668|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
219544669|NCT01815320|PROCEDURE|Contrast-enhanced ultrasound (CE-US)|
219046043|NCT05454501|OTHER|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
219046044|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
219046045|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
219544670|NCT01815320|DEVICE|SonoVue|
219544671|NCT04304066|OTHER|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
219544672|NCT05322967|OTHER|Time of ordinary antihypertensive medication intake|Time of ordinary antihypertensive medication intake
219544673|NCT02543489|DEVICE|Flex IM rod|
219544674|NCT03767374|PROCEDURE|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
219544675|NCT03767374|PROCEDURE|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
219621979|NCT07111897|PROCEDURE|percutaneous cannulated screw fixation|fixation of calcaneal fractures by cannulated screws inserted percutaneously
219621980|NCT07111897|PROCEDURE|Plate fixation|Fixation of calcaneal fracture by plate.
219621981|NCT07111806|DRUG|Tirofiban|Tirofiban is administered as a loading dose and continuous intravenous infusion as soon as possible after the randomization.
218934590|NCT06174415|DEVICE|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
218934591|NCT02736318|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
218934592|NCT01140126|DRUG|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
218934593|NCT00078546|BIOLOGICAL|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
218934594|NCT00078546|BIOLOGICAL|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
218934595|NCT04859933|PROCEDURE|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
218934596|NCT04859933|PROCEDURE|AV-node ablation|Right sided ablation of the AV-node
218934597|NCT01847027|DRUG|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
219544676|NCT03767374|PROCEDURE|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
218934598|NCT01847027|DRUG|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
218934599|NCT01320917|DEVICE|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
218934600|NCT01320917|DEVICE|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
219046046|NCT06120491|DRUG|Saruparib|Oral
219046047|NCT06120491|DRUG|Placebo|Oral
219046048|NCT06120491|DRUG|Abiraterone Acetate|Oral
219544677|NCT03767374|OTHER|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
219544678|NCT05586880|OTHER|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
219544679|NCT05586880|OTHER|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
219544680|NCT05869721|OTHER|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
219621982|NCT07111806|DRUG|Placebo|Matched placebo will be infused in a similar fashion.
219621983|NCT07112287|DEVICE|MyeloGen Gene Panel|The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.
219621984|NCT07113275|RADIATION|Short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy.
219621985|NCT07113275|RADIATION|Long-course radiotherapy|Long-course radiotherapy (LCRT, 50.4 Gy administered in 28 fractions) will be delivered concurrently with oral capecitabine.
219621986|NCT07113275|DRUG|Capecitabine|1000mg/m2, bid, po, d1-14,q3w
219621987|NCT07113275|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1,q3w
219621988|NCT07113275|DRUG|Camrelizumab|200mg, ivgtt, q3w
219621989|NCT07113275|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
218934601|NCT00986765|DRUG|Lovenox® (enoxaparin)|Injectable solution 4000 UI
218934602|NCT00986765|DRUG|Aspegic ® (Aspirin)|100 mg/day
218934603|NCT05022576|DIAGNOSTIC_TEST|Robotic arm assisted PSMA PET/CT guided prostate biopsy|The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
218934604|NCT04667221|DEVICE|Active transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.
218934605|NCT04667221|DEVICE|Sham transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
218934606|NCT02181088|BIOLOGICAL|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10\^9 vp
218934607|NCT02181088|BIOLOGICAL|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10\^10 vp
218934608|NCT02181088|BIOLOGICAL|MVA RH5 low dose|MVA RH5 at 1 x 10\^8 pfu
218934609|NCT02181088|BIOLOGICAL|MVA RH5 full dose|MVA RH5 at 2 x 10\^8 pfu
218934610|NCT03278171|BEHAVIORAL|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
218934611|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
218934612|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2.5mg po daily
219046049|NCT06120491|DRUG|Darolutamide|Oral
219046050|NCT06120491|DRUG|Enzalutamide|Oral
219046051|NCT03664609|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
219544681|NCT06258421|OTHER|No Intervention|Observatory Study
219544682|NCT05124366|PROCEDURE|dental prophylaxis + oral hygiene instructions|Follow up: 2 weeks and 4 weeks
218934613|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
218934614|NCT00030914|DRUG|medroxyprogesterone|
219046052|NCT06049420|BEHAVIORAL|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
218934615|NCT00030914|DRUG|venlafaxine|
218934616|NCT03054532|DRUG|Durvalumab|Durvalumab intravenous 1500 mg
219046053|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
218934617|NCT03054532|DRUG|Lenali|Lenalidomide oral 20 mg/day
218934618|NCT03854279|DEVICE|tonsillar dissection|The tonsils will be removed by bizact device
219046054|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
219046055|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
219046056|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
219046057|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
219046058|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
219046059|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
219046060|NCT03536039|DRUG|Prednisone|75 mg
219544683|NCT04193241|PROCEDURE|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
219544684|NCT01246258|OTHER|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
219544685|NCT01246258|OTHER|Utricular centrifugation test|Standard test of balance function
219544686|NCT05543135|DIAGNOSTIC_TEST|basic audiological evaluation|pure tone audiometry\&immitancemetry
219046061|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
219046062|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
219046063|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
219046064|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
219046065|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
219544687|NCT02645253|DRUG|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
219544688|NCT02645253|DRUG|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
219544689|NCT02645253|DRUG|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
219544690|NCT02645253|DRUG|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
219544691|NCT02645253|DRUG|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
219544692|NCT00000458|DRUG|sertraline (Zoloft)|
219544693|NCT00000458|BEHAVIORAL|cognitive behavior therapy|
219544694|NCT01016782|DRUG|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
218934619|NCT06351007|OTHER|Nutritional education and psychological intervention|"In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting"
218934620|NCT06351007|OTHER|Standard care|"The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml"
219046066|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
219046067|NCT05719428|OTHER|DRUID AI Program|Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
219046068|NCT05188170|DRUG|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
219046069|NCT04748146|OTHER|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
219046070|NCT06390033|DEVICE|Prosthetic foot|Experimental prosthetic foot.
219046071|NCT02681302|DRUG|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
219046072|NCT02681302|DRUG|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
219365813|NCT05335889|DEVICE|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
219046073|NCT06033144|DIAGNOSTIC_TEST|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography"
219046074|NCT05256069|DRUG|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
219046075|NCT05256069|DRUG|Placebo|Participants will receive a placebo in pill form.
219046076|NCT02942017|DRUG|Placebo|Intravenous infusion of matching placebo for SAGE-547.
219046077|NCT02942017|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
219046078|NCT05149755|DEVICE|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
219046079|NCT04126291|BEHAVIORAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
219046080|NCT04685304|GENETIC|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
219365814|NCT05030714|DIAGNOSTIC_TEST|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
219365815|NCT04222829|PROCEDURE|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
219365816|NCT02235506|PROCEDURE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
219365817|NCT02235506|PROCEDURE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
219365818|NCT02235506|DEVICE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
219544695|NCT05334875|DIAGNOSTIC_TEST|Electroretinogram (ERG)|Applying electrodes to assess retinal function
219544696|NCT05334875|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
218934621|NCT06116370|PROCEDURE|Rezum procedure|In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.
219046081|NCT04685304|OTHER|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
219359886|NCT06785168|OTHER|Machine-based Resistance Training|The participants will receive HF treatment as prescribed by cardiologists. If participants have any additional medical conditions, their existing medications or treatments should continue. They are also asked to maintain their usual physical activity, exercise routines, and dietary habits, without making changes outside of the study intervention. At the beginning, patients participating in resistance training should complete a pretest of one-repetition maximum (1-RM) to assess muscle strength, which will be used by a professional physical therapist to develop an individualized prescription. The specific movements are as follows: (1) leg press and (2) calf raise by Proxomed Compass 540 (Germany); (3) leg curl, (4) chest press, (5) push up, (6) seated row by HUR machine (US). During the 8 weeks, subjects will train 3 non-consecutive days/week with intensity 30%1-RM to 60% 1-RM, 3 sets/one excercise with 8-12 repetitions.
219544697|NCT05490563|DRUG|SLS-005|SLS-005
219544698|NCT05490563|DRUG|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
219544699|NCT04197492|RADIATION|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
219544700|NCT04197492|DRUG|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
219621990|NCT01276860|DEVICE|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
219621991|NCT07111754|BEHAVIORAL|Behavioural Message|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed. This can be delivered to participants via a QR code, or a warning message on the packet."
219621992|NCT07111754|BEHAVIORAL|Behavioural message + positive framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a positive manner. This can be delivered to participants via a QR code, or a warning message on the packet."
218934622|NCT06116370|PROCEDURE|B-TURP procedure|In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
218934623|NCT03937622|OTHER|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
218934624|NCT05463484|DRUG|Test composition Saliactive® (olive product, betaine and xylitol)|Fluoridated toothpaste with Saliactive®.
218934625|NCT05463484|DRUG|Placebo|Fluoridated toothpaste without Saliactive®.
218934626|NCT05463484|DRUG|Control|Commercial Fluoridated toothpaste for gingivitis with zinc citrate.
218934627|NCT02873377|DRUG|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
218934628|NCT02873377|DRUG|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
218934629|NCT02873377|OTHER|Smoking Quitline Referral|Fax referral to the State smoking Quitline
218934630|NCT02873377|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
218934631|NCT04951609|DRUG|Seltorexant|Participants will receive a single oral dose of seltorexant.
219046082|NCT04685304|OTHER|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
219046083|NCT06513286|BIOLOGICAL|TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
219046084|NCT06513286|BIOLOGICAL|TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
219544701|NCT04313751|BEHAVIORAL|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
219544702|NCT04313751|OTHER|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
219544703|NCT03679091|DRUG|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
219544704|NCT03679091|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
219544705|NCT03135301|DRUG|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
219544706|NCT03135301|DRUG|letrozole|letrozole 5 milligram tablets
219544707|NCT05613972|OTHER|Brief Suicide and Trauma Therapy|12-week trauma therapy
219544708|NCT03325881|DRUG|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
219544709|NCT03325881|DRUG|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
219544710|NCT03676634|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
219544711|NCT02121067|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
218934632|NCT04951609|DRUG|Placebo|Participants will receive matching placebo orally.
218934633|NCT01773213|PROCEDURE|Ice-water-test|
219544712|NCT03060486|DEVICE|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
218934634|NCT01586572|DRUG|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
218934635|NCT01586572|DRUG|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
219046085|NCT05033028|OTHER|Smartphone app|SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
219205785|NCT06886594|OTHER|breast cancer education program training|"The first researcher conducted the breast cancer education program for the experimental group, and the researcher completed her doctorate in Obstetrics, Gynecology and Diseases Nursing. The content of the education given to the experimental group was prepared in accordance with the Breast Cancer Prevention, Screening, Diagnosis, Treatment and Follow-up Clinical Guide 2020 (Version 1.0) of the Ministry of Health of the Republic of Turkey. Each woman in the experimental group was given face-to-face individual education in accordance with the education material prepared by the first researcher, and their questions were answered at the end of the education. After the theoretical education was completed, each woman in the experimental group was given BSE practical education using the Wearable Breast Examination Simulator by the first researcher using the demonstration method in accordance with the steps in the Breast Self-Examination brochure by the Cancer Early Diagnosis, Screening"
219544713|NCT02730650|OTHER|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
219544714|NCT02551640|OTHER|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
219544715|NCT02933658|DRUG|Telmisartan|
219544716|NCT02933658|DRUG|Amlodipine|
218934636|NCT04573582|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
219205786|NCT06707194|BIOLOGICAL|Etanercept|Prefilled syringe, 25mg of hypodermic injection, twice a week
219205787|NCT06707194|DRUG|Benzathine Penicillin|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks
219205788|NCT06707194|OTHER|Placebo|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, intramuscular injection, once every two weeks
218934637|NCT02925299|DEVICE|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
218934638|NCT02925299|DEVICE|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
219205789|NCT06733480|DEVICE|Band Connect|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
219205790|NCT07039201|BIOLOGICAL|CG-102-12C|Chimeric Antigen Receptor Autologous T-cell
219544717|NCT02933658|DRUG|Rosuvastatin|
219544718|NCT04873063|DRUG|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
219544719|NCT03799874|DRUG|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
219544720|NCT03799874|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
219544721|NCT05446519|BEHAVIORAL|Survey|Survey is proposed to all pilots who are members of the National Union of Airline Pilots
219544722|NCT02216981|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|
219046086|NCT06145009|BEHAVIORAL|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
219046087|NCT00457197|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
218934639|NCT03313167|OTHER|Non-interventional|Non-interventional
218934640|NCT03980704|DRUG|IMPACT|Administration of oral immunostimulating oral supplement
218934641|NCT03980704|DRUG|resource protein|Administration of oral high-protein oral supplement
219046088|NCT00457197|DRUG|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
219046089|NCT00193882|DRUG|Cisplatin|80mg/m2 IV day 1
219046090|NCT00193882|RADIATION|Radiotherapy|35 Gy in 15 fractions
219046091|NCT00193882|DRUG|5-Fluorouracil|800mg/m2/day IV days 1 - 4
219046092|NCT00123188|PROCEDURE|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
219544723|NCT05152745|OTHER|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
219621993|NCT07111754|BEHAVIORAL|Behavioural message + negative framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a negative manner. This can be delivered to participants via a QR code, or a warning message on the packet."
218934642|NCT02610114|OTHER|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
218934643|NCT02610114|OTHER|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
218934644|NCT02376153|DEVICE|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
218934645|NCT02376153|DEVICE|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
218934646|NCT04496583|OTHER|Fluid depletion strategy|The fluid depletion strategy will be individualized depending on the response to the standardized furosemide test (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) with a urinary output (UO) cutoff of 200 ml at 2 hours. The desired depletion endpoint will be targeted by using diuretics (40 mg q6h iv initially, adjusting dose by UO) or ultrafiltration (UF) if UO \<200 ml/2h
218934647|NCT02407600|DRUG|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
218934648|NCT02407600|DRUG|Placebo|
218934649|NCT05955781|PROCEDURE|Spinal Mobilization With Leg Movement|spinal mobilization with leg movement is the intervention given to experimental group. This technique involves applying pressure to the relevant spinous process while the patient moves their limb through the previously restricted range of motion. It is assumed that the restriction of movement is due to a spinal issue but it does not always indicate nerve damage as spinal movement is necessary for limb movement beyond a certain point. The goal is to address any spinal mechanical limitations and there may also be potential effects on the nerves.
218934650|NCT05955781|PROCEDURE|Spinal Mobilization|The patients will be given Spinal mobilization transverse glide(kaltenborn glide) on the effected spinous process. The total time duration will be 25-30 minutes.
218934651|NCT05955781|PROCEDURE|Conventional treatment|Participants will be given Hot pack for 15 minutes, TENS for 10 minutes
218934652|NCT06347120|PROCEDURE|nasogastric tube|nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.
218934653|NCT06347120|OTHER|NOM without NGT insertion|intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h
218934654|NCT02129127|DEVICE|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
218934655|NCT01817270|BIOLOGICAL|Live Attenuated Varicella Vaccine|
218934656|NCT04044001|DRUG|BTZ-043|BTZ-043 (250mg per tablet)
218934657|NCT04044001|DRUG|Rifafour e-275®|Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
218934658|NCT04044001|DRUG|Probe Drug Cocktail|"A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg"
218934659|NCT04044001|DRUG|Dolutegravir 50mg Tab|1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
219046093|NCT03080103|PROCEDURE|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
219046094|NCT03080103|DRUG|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
219046095|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
219046096|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
219046097|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
219046098|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
219046099|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
218934660|NCT06091683|PROCEDURE|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
218934661|NCT05244252|DRUG|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
218934662|NCT05244252|DRUG|Bupivacaine|bupivacaine
218934663|NCT02185482|BEHAVIORAL|Physician Supported Care|
218934664|NCT02185482|OTHER|Usual care|
218934665|NCT06370429|OTHER|Progressive Relaxation Exercises, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
218934666|NCT03929497|DRUG|Lu AF11167|Lu AF11167 - 2 or 4 mg/day; tablets, orally
218934667|NCT05115149|DEVICE|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
218934668|NCT05115149|PROCEDURE|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
218934669|NCT05115149|PROCEDURE|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
219046100|NCT05059600|DRUG|ZULRESSO®|Intravenous infusion of ZULRESSO®.
219046101|NCT05091424|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab
219205791|NCT05146297|BEHAVIORAL|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
219205792|NCT05146297|BEHAVIORAL|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
219205793|NCT06734312|DEVICE|Gastric Fundal Mucosal Ablation (GFMA)|Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy
219544724|NCT05152745|OTHER|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
219046102|NCT05091424|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
219046103|NCT05091424|DRUG|Venetoclax|Participants will receive daily oral venetoclax
219046104|NCT05390801|OTHER|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
219046105|NCT02152995|PROCEDURE|Computed Tomography|Undergo iodine I-124 PET/CT
219046106|NCT02152995|OTHER|Iodine I 124|Undergo iodine I-124 PET/CT
219046107|NCT02152995|RADIATION|Iodine I-131|Given PO
219046108|NCT02152995|OTHER|Laboratory Biomarker Analysis|Correlative studies
219046109|NCT02152995|OTHER|Pharmacodynamic Study|Correlative studies
219046110|NCT02152995|PROCEDURE|Positron Emission Tomography|Undergo iodine I-124 PET/CT
219046111|NCT02152995|DRUG|Trametinib|Given PO
219205794|NCT06736496|DRUG|Nalbuphine|patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
219205795|NCT06736496|DRUG|Dexmedetomidine|patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
218934670|NCT05115149|DEVICE|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
218934671|NCT05115149|PROCEDURE|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
218934672|NCT04041167|DRUG|alpha lipoic acid|alpha lipoic acid treatment
218934673|NCT04041167|DRUG|Saline|No alpha lipoic acid treatment
218934674|NCT02037230|DRUG|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
218934675|NCT02037230|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
218934676|NCT02037230|RADIATION|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
218934677|NCT05000255|BEHAVIORAL|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
218934678|NCT05000255|BEHAVIORAL|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
218934679|NCT00218842|BEHAVIORAL|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
218934680|NCT01448980|PROCEDURE|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
218934681|NCT01448980|PROCEDURE|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
218934682|NCT03771313|DRUG|Ceftaroline|Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
218934683|NCT04336878|BEHAVIORAL|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
218934684|NCT06403332|BEHAVIORAL|brief intervention|The intervention for cohort A (intervention arm) based on brief intervention on alcohol consumption performed by a psycologist, medical visit peformed by an hepatologist including assessment of underlying liver disease with non invasive test (i.e Fibroscan and lab work).
218934685|NCT01339572|DRUG|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~1. Pre-apheresis peripheral blood CD34+ count \<20 cells/μL on day 5.~2. Estimated CD34+ cell collection is \< 25% of target cell dose after 1 day of apheresis.~3. Estimated CD34+ cell collection is \< 50% of target cell dose after 2 days of apheresis."
218934686|NCT01339572|DRUG|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID."
219046112|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
218934687|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
219046113|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
219046114|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
219046115|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
219205796|NCT06736015|DIETARY_SUPPLEMENT|Myo-Inositol 600 mg + Selenium 83 mcg|Myo-Inositol 600 mg + Selenium 83 mcg: 1 tablet once a day for 6 months
219359887|NCT01473797|DRUG|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
219359888|NCT05280756|DEVICE|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
219365819|NCT02235506|DEVICE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
218934688|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
219544725|NCT03713866|DIAGNOSTIC_TEST|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
219544726|NCT05950919|OTHER|TASKPEN|"The package of integrated HIV/NCD services:~1. Integrated non-communicable/HIV care (one stop shop for services)~2. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~3. Access to cardio-metabolic condition screening \& laboratory monitoring~4. Non-communicable disease-focused electronic medical record module~5. Strengthened NCD medication supply chain"
219544727|NCT03104231|OTHER|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
219544728|NCT04837469|PROCEDURE|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
219544729|NCT04367519|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
219544730|NCT01724463|OTHER|Severe Sepsis Management Bundle|"Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels"
219544731|NCT05780463|DRUG|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
219544732|NCT05780463|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
219544733|NCT05780463|BIOLOGICAL|Remdesivir|Antiviral agent
219544734|NCT05921981|BEHAVIORAL|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
219544735|NCT05921981|BEHAVIORAL|White Noise|White Noise
218934689|NCT00553371|OTHER|biomarker analysis|
218934690|NCT00553371|PROCEDURE|computed tomography|
218934691|NCT06139367|DRUG|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
219544736|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
218934692|NCT02864056|OTHER|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
219544737|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
219544738|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
218934693|NCT00793013|DEVICE|Volume-Cycled Assist-Control (AC) mode|"1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40%~2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~4. Inspiratory to Expiratory ratio set at 1:1 to 1:3~5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol~7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
219365860|NCT06959875|BEHAVIORAL|High-Fidelity Simulation-Based Therapeutic Communication Training|This intervention involves a structured, high-fidelity simulation scenario in a clinical skills lab setting using mannequins and standardized patients. The scenario focuses on communication with a patient experiencing perinatal loss. The session includes pre-briefing, simulation, and debriefing components.
219365861|NCT06959875|BEHAVIORAL|Paper-Pencil Simulation-Based Therapeutic Communication Training|This intervention utilizes a written clinical case scenario related to perinatal loss. Students read the scenario and write appropriate therapeutic communication responses, followed by group discussion and instructor feedback. The focus is on reflection and theoretical integration.
219365862|NCT06960837|BEHAVIORAL|ultrasound simulation training case-based workshop during resident sim days|Using the CAE Vimedix ultrasound simulator or standardized patient, a patient stem will be read or video shown to an individual participant. The participant will have 10 minutes to discuss the scenario and scan the simulator/patient. Participants will verbalize their findings and receive additional information, including diagnostic tests or point-of-care ultrasound (POCUS) videos, as they proceed through the case. They will be scored using a standardized rubric. For Objective Structured Clinical Exam (OSCE) testing, two independent raters, both with ultrasound fellowship training, one known to the participants and one unknown to the participants, will observe and rate the participant on a simulated POCUS case using the already published OSCE tool. The rater will read a brief standardized stem, and the participant will have 10 minutes to complete the station.
219544739|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
219544740|NCT01146223|OTHER|laboratory biomarker analysis|Correlative studies
219544741|NCT00540423|DRUG|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
219544742|NCT00540423|DRUG|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
219544743|NCT00540423|DRUG|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
219544744|NCT00540423|DRUG|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
219544745|NCT01969123|DRUG|Drug: EVP-6124|
219544746|NCT01969123|DRUG|Placebo|
219544747|NCT05968638|OTHER|Regular Diet|Regular Diet
219544748|NCT05968638|OTHER|Ketogenic Diet|Ketogenic Diet
219544749|NCT04077645|BEHAVIORAL|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
219544750|NCT04077645|BEHAVIORAL|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
219544751|NCT04077645|BEHAVIORAL|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
219544752|NCT06497972|OTHER|White bread (control, 32 grams, 14.4 grams of carbohydrate)|32 grams of white bread, providing 14.4 grams of carbohydrate, which was incorrectly dosed and matched only half the carbohydrate in the rice cakes.
219544753|NCT06497972|OTHER|Brown rice cake|A 40g rice cake made of 100% brown rice (providing 31 grams of carbohydrate)
219544754|NCT06497972|OTHER|Wild rice (25%) and brown rice (75%) cake|A 40g rice cake made of a blend of 25% wild rice and 75% brown rice (providing 31 grams of carbohydrate)
219544755|NCT06497972|OTHER|White bread (control, 66 grams, 31 grams of carbohydrate)|66 grams of white bread, providing 31 grams of carbohydrate, this arm was added after the mistake in the first control dosing was discovered, so this arm was not randomized and was completed after the first three.
219544756|NCT01214590|DEVICE|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
219544757|NCT02223585|OTHER|Animal-based protein diet|
219544758|NCT02223585|OTHER|Vegan-based protein diet|
219544759|NCT01053585|DRUG|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
218934694|NCT00793013|DEVICE|Airway Pressure Release Ventilation (APRV) mode|"1. Ventilation uses Drager Model X1~2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~3. Time periods for the high \& low pressure levels can be set independently~4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min~7. If spontaneous breathing is achieved,level of sedation will be decreased~8. If spontaneous respirations are \>20 breaths/min, sedation will be increased~9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
219544760|NCT01053585|DRUG|Placebo|Placebo single 'dose' 90 minutes prior to study
219544761|NCT00360607|DRUG|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
219544762|NCT00360607|DRUG|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
219544763|NCT00360607|DRUG|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
218934695|NCT01850758|PROCEDURE|Regenexx SD|stem cell treatment
218934696|NCT01850758|OTHER|Exercise Therapy|exercise therapy control
218934697|NCT05109195|OTHER|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
219544764|NCT00360607|DRUG|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
219544765|NCT05837832|DIETARY_SUPPLEMENT|Milk-based phospholipids|Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
219544766|NCT00196963|BIOLOGICAL|Meningococcal (vaccine)|
219544767|NCT06559878|DIAGNOSTIC_TEST|13C-α-Ketoisocaproic Acid Breath Test|13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).
219544768|NCT06559878|DIETARY_SUPPLEMENT|Ethanol|6% ethanol soluted in normal saline is given intravenously during one metabolic visit.
219544769|NCT06559878|DIETARY_SUPPLEMENT|Lipid Emulsion|Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.
219544770|NCT06559878|OTHER|Normal Saline|Normal saline is given intravenously during one metabolic visit.
219544771|NCT02277093|DRUG|Pacritinib|
219544772|NCT01995162|DEVICE|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
219544773|NCT02903407|DRUG|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
219544774|NCT02903407|DRUG|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
219544775|NCT02903407|DRUG|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
219544776|NCT00525213|DRUG|Rob 803|two capsules per day during 12 weeks
219544777|NCT00525213|DRUG|Placebo|two capsules per day during 12 weeks
219544778|NCT05143047|BEHAVIORAL|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
218934698|NCT04083768|DEVICE|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
218934699|NCT04628325|DRUG|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
218934700|NCT02210494|DRUG|Secretrol|
218934701|NCT03950297|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
219544779|NCT04801654|DIAGNOSTIC_TEST|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
219544780|NCT04168398|DRUG|Combination drug|Anticoagulation
219544781|NCT00154739|DRUG|Gemcitabine|
219544782|NCT00154739|DRUG|Cisplatin|
219544783|NCT00154739|DRUG|Epirubicin|
219544784|NCT06562465|PROCEDURE|dietary and exercise management|Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
218934702|NCT01286051|DRUG|Follistim administration|adminstation of FSH for ovulation induction
219544785|NCT06562465|PROCEDURE|no dietary and exercise management|NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
219544786|NCT00615823|DRUG|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
219544787|NCT00615823|DRUG|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
219544788|NCT00216736|DRUG|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
219544789|NCT00216736|DRUG|placebo|Single dose oral placebo at ED discharge
219544790|NCT04960917|BEHAVIORAL|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
219544791|NCT03916861|DEVICE|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
219544792|NCT03916861|PROCEDURE|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
219544793|NCT06063460|DIAGNOSTIC_TEST|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
218934703|NCT01286051|DRUG|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
218934704|NCT06380413|OTHER|Tai Chi Chuan Plus Walking|Participants perform a 12-week program with two weekly sessions on non-consecutive days. The sessions last 75 min (5 min of warm-up, 45 min of Tai Chi Chuan (TCC), 20 min of walking, and 5 min of cool-down). The intervention occurs at the School of Physical Education, Federal University of Pelotas. The TCC section occurs in a mirrored dance studio, while walking occurs on an indoor sports court. The TCC sections are based on the simplified Yang 16-movement form. Over the 12 weeks, participants learn the fundamentals and basic principles of TCC and practice the 16 movements. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
219046116|NCT04971850|OTHER|Sleep study|"Procedures added by research during PSG :~* SDB screening questionnaires~* Electromyography (EMG) of accessory and abdominal muscles~* Cerebral oxygenation~* Mandibular movements~* Sleep headband (pre-teens and teens) or other connected device~* Automatic PSG analyzes~* Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG."
218934705|NCT06380413|OTHER|Walking|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. The sessions last 30 minutes (5 minutes of warm-up, 20 minutes of walking, and 5 minutes of cool-down) throughout the intervention period. The intervention occurs in an indoor sports court at the School of Physical Education, Federal University of Pelotas. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
218934706|NCT03820895|DIAGNOSTIC_TEST|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
218934707|NCT02967224|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218934708|NCT02967224|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218934709|NCT02967224|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218934710|NCT02967224|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218934711|NCT02967224|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
218934712|NCT02062619|BEHAVIORAL|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
218934713|NCT02062619|OTHER|Real tDCS|Real tDCS 20 minutes per session, three times per week
218934714|NCT02062619|OTHER|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
218934715|NCT01497223|DRUG|MGCD290|1 Oral Dose Administration
218934716|NCT01939769|OTHER|Exercise - Low-intensity exercise|
218934717|NCT01939769|OTHER|Exercise - High-intensity exercise|
218934718|NCT01420211|DRUG|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
218934719|NCT01420211|DEVICE|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
218934720|NCT04473469|DEVICE|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
218934721|NCT01809743|DRUG|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
218934722|NCT01809743|DRUG|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
219365863|NCT02983487|PROCEDURE|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
219365864|NCT02983487|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
219365865|NCT00896467|OTHER|questionnaire administration|
219365866|NCT00896467|PROCEDURE|psychosocial assessment and care|
219365867|NCT00896467|PROCEDURE|quality-of-life assessment|
219365868|NCT03129308|DIAGNOSTIC_TEST|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
219365869|NCT00437216|DRUG|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
219365870|NCT00437216|DRUG|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
219365871|NCT00891514|BEHAVIORAL|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
219365872|NCT00891514|BEHAVIORAL|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
219365873|NCT04782167|BEHAVIORAL|BRACE|"Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1\) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
219365874|NCT04782167|BEHAVIORAL|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
219365875|NCT00360347|DRUG|C.E.R.A.|
219365876|NCT01249235|PROCEDURE|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
219365877|NCT03775707|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219365878|NCT03775707|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
218934723|NCT01809743|DRUG|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
218934724|NCT01809743|DRUG|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
218934725|NCT01809743|DRUG|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
218934726|NCT00004101|BIOLOGICAL|apolizumab|
218934727|NCT00060619|BEHAVIORAL|thermal biofeedback|
219621994|NCT07111780|OTHER|"Coordinative-Based Physical Activity Practices training group"|In the first session, participants were asked to fill in an information form, including demographic information. They were asked to complete the Brunel Mood Scale and the International Physical Activity Questionnaire (IPAQ). participants' height and body weight were measured. Participants' height was measured with a portable statiometer. Body weight was measured with a digital scale witha precision of 0.1 kg. In the second session, Go/No-Go and mental rotation tests, which are used to evaluate the cognitive functions of the participants, were administered to the participants. The KTK3+ motor competence test was used to determine the motor competence of the participants.The tests were administered to the participants in the same order and by the same researchers. Before the assessment of KTK3+ test of 5 minutes of running and 5 minutes of dynamic stretching was performed. Coordination-based physical activity applied to the exercise group continued for 25-30 minutes twice for 8 weeks.
219621995|NCT06921382|BEHAVIORAL|Peer counseling|Participants in the intervention condition will be matched with Spanish-speaking peer counselors who will visit mothers at home regularly (weekly at the beginning of the study, monthly at the end of the study).
219621996|NCT06921382|BEHAVIORAL|Additional funds|In Month 1, mothers can choose to receive a $150 gift card or an electric breast pump. In Months 2-5, if infants are signed up for the WIC exclusive breastfeeding package, infants will receive $100 and mothers will receive $50. If infants are signed up for the WIC partial breastfeeding package, infants will receive $50 and mothers will receive $30.
219621997|NCT07111351|OTHER|Without intervention|Without intervention
219621998|NCT07111273|DIAGNOSTIC_TEST|FC and FIT TEST at WEEK0 2 4|FC and FIT TEST at WEEK0 2 4
219621999|NCT07112131|BEHAVIORAL|Non-Diet Nutrition Education Program|The intervention is an 8-week online nutrition education program based on non-diet approaches, including intuitive eating, rejecting diet mentality, honoring hunger, body acceptance, and well-being. Each weekly session is 60 minutes long and involves interactive discussions and home practices.
218934728|NCT00060619|BEHAVIORAL|relaxation training|
218934729|NCT00060619|BEHAVIORAL|cognitive coping skills|
218934730|NCT00060619|BEHAVIORAL|parent education|
218934731|NCT04485351|OTHER|no intervention|no intervention
218934732|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
218934733|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
218934734|NCT00973232|DRUG|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
218934735|NCT00973232|DRUG|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
218934736|NCT00973232|DRUG|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
219365879|NCT01451593|DRUG|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
219365880|NCT01451593|DRUG|Placebo|placebo identical in appearance to active IMP (phenytoin)
219365881|NCT06250387|PROCEDURE|Endobronchial ultrasound transbronchial cryobiopsy|"Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy"
219365882|NCT04925492|RADIATION|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
219365883|NCT04925492|DRUG|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
219365884|NCT05364411|RADIATION|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
219365885|NCT05364411|RADIATION|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
219365886|NCT05063812|OTHER|Observational|All these patients have been enrolled in the COVID-19 remote patient monitoring program
219365887|NCT00788905|DEVICE|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
219365888|NCT01718184|PROCEDURE|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
219365889|NCT01718184|PROCEDURE|Sulcoflex intraocular lens implantation|
219365890|NCT03169426|DRUG|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
219365891|NCT02720757|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
219544794|NCT06063460|OTHER|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
219544795|NCT06063460|OTHER|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
219544796|NCT06063460|OTHER|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
219544797|NCT06063460|OTHER|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
219544798|NCT00193960|PROCEDURE|1) Intraocular pressure 2) visual acuity|
219544799|NCT02273492|DRUG|Asasantin ER|
219544800|NCT02273492|OTHER|Standardized breakfast|
219544801|NCT01406080|DRUG|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
219544802|NCT01406080|DRUG|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
219544803|NCT00857038|DRUG|Doxycycline|Doxycycline tablets, 100mg daily
219544804|NCT00857038|DRUG|Placebo|Placebo tablets 100mg
219544805|NCT03632031|DEVICE|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
219544806|NCT03774303|OTHER|Mobile application|A mobile application that will be used to prepare families for day surgery
219544807|NCT03774303|OTHER|current practice|the current practice used to prepare families for day surgery
219641852|NCT06959329|OTHER|Active and passive physical therapy without intensified sensory stimulation|"Intervention: Passive and active therapy without high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes):~• Stroking and rubbing techniques from classic massage applied in the area of arm forearm and hand with low force and frequency upper limb massage - 15 minutes per limb~Active therapy (30 minutes): upper limb muscle strengthening exercises (without globalized vibration); difficulty level individually adjusted to meet participants' current potential, so that in the last sets/reps little manual assistance from the therapist is needed:~* Supine pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing push-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing elbow extensions - 3 sets of 8 reps, \~45 seconds rest between sets"
218934737|NCT00973232|DRUG|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
218934738|NCT00973232|DRUG|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
218934739|NCT05283772|BEHAVIORAL|Development of eye tracker for simulation training in nursing|"Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks."
219544808|NCT05527639|BEHAVIORAL|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
219544809|NCT05198622|PROCEDURE|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
219544810|NCT05198622|PROCEDURE|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
219544811|NCT00035139|DRUG|methylphenidate|
219544812|NCT01961947|BIOLOGICAL|ASP7374|subcutaneous
219544813|NCT01961947|BIOLOGICAL|approved egg-derived TIV|subcutaneous
219544814|NCT06386354|DIAGNOSTIC_TEST|Train-of-four|Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
219544815|NCT04378621|DRUG|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
219544816|NCT04378621|OTHER|Hand training|Physical hand training 10 min twice daily while on stable treatment
219544817|NCT06559904|OTHER|Mediterranean diet|"The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face."
219544818|NCT02943538|DEVICE|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
219544819|NCT02943538|DEVICE|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
219544820|NCT02943538|OTHER|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
219622000|NCT07110727|BEHAVIORAL|Two days, role play, adult interactive capacity building sessions of healthcare workers on PTSD screening and management. Pre/posttest and change in practice in screening will be used for evaluation|"Intervention~1\. Capacity Building of Healthcare workers on PTSD Management For training, the three purposefully selected health facilities selected for the study were written on small pieces of paper. The papers were twisted and thrown on a table. Then, a child was asked to pick up any paper. The one picked was the intervention health facility (Buea Regional Hospital). Healthcare workers at the BRH who provide care to RTI survivors at risk of PTSD 1 month after RTI from our health units of interest in the BRH, will be selected for training (mostly unit heads and front-line staff in trauma/injury will be trained) in two role-play, adult training, interactive sessions on the screening of PTSD using the DSM-5 tool and on timely management of RTI patients with regard to PTSD, linkage to care to psychotherapists, and referrals. Pre/post knowledge evaluation on the use of the DSM-5 tool and management of PTSD will be done, and results compared."
219622001|NCT07112196|DRUG|Visugromab (CTL-002)|IV infusion
219622002|NCT07112196|DRUG|Placebo|IV infusion
219622003|NCT06512935|OTHER|Increase in the PEEP followed by decrease in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
218934740|NCT02565667|DEVICE|KOL|KOL staple was used for rectal anastomosis
219544821|NCT00909753|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
219544822|NCT00909753|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
219544823|NCT03222921|PROCEDURE|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
219544824|NCT05600894|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
219544825|NCT05600894|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219544826|NCT05600894|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219544827|NCT05600894|DRUG|Decitabine and Cedazuridine|Given PO
219544828|NCT05600894|DRUG|Venetoclax|Given PO
219622004|NCT06512935|OTHER|Decrease in the PEEP followed by increase in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
219544829|NCT02351700|DRUG|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
219544830|NCT02351700|DRUG|IV Placebo|IV Placebo intraoperatively and postoperatively
219544831|NCT06563037|OTHER|No intervention|This is an observational study
219544832|NCT00418145|DRUG|megadose oral methylprednisolone|1400 mg qd/5 days
219544833|NCT00418145|DRUG|IV methylprednisolone|1000 mg/qd/5 days
218934741|NCT02565667|DEVICE|traditional staple|traditional staple was used for rectal anastomosis
219544834|NCT06469645|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
219544835|NCT02421822|OTHER|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
219544836|NCT00706277|DRUG|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
219544837|NCT00706277|DRUG|propofol|propofol 2mg
219544838|NCT00706277|DRUG|remifentanil|remifentanil 0,25mcg/kg/hour
219544839|NCT00706277|DRUG|fentanyl|fentanyl 100mcg
218934742|NCT01030926|DRUG|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
218934743|NCT01030926|DRUG|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
219544840|NCT00706277|DRUG|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
219544841|NCT02307994|DRUG|75IU uFSH|
219544842|NCT01714622|PROCEDURE|subtotal gastrectomy with gastroduodenostomy|
219544843|NCT01714622|PROCEDURE|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
219544844|NCT01714622|PROCEDURE|total gastrectomy with Rou-en-Y esophagojejunostomy|
219544845|NCT04494607|DIETARY_SUPPLEMENT|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
219544846|NCT03214588|DRUG|TAK-831|TAK-831 tablets
219544847|NCT03214588|DRUG|TAK-831 Placebo|TAK-831 placebo matching tablets
219544848|NCT03406598|OTHER|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
219544849|NCT00896688|PROCEDURE|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
219544850|NCT02856308|DEVICE|Hairstetics hair implant device|
219544851|NCT01449981|BEHAVIORAL|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
219544852|NCT01449981|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
219544853|NCT03498235|DRUG|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
219544854|NCT03498235|DRUG|Propofol|In Team Propofol ,anesthesia is maintained with propofol
219544855|NCT01910038|DRUG|corticoids+ tocilizumab 8mg/Kg/4 weeks|
219544856|NCT05806853|DRUG|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
219544857|NCT05806853|DRUG|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
219544858|NCT00845637|DRUG|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
219544859|NCT00845637|DRUG|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
219544860|NCT04026815|OTHER|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
219544861|NCT04124315|OTHER|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
219544862|NCT04124315|OTHER|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
218934744|NCT02985528|OTHER|further diagnostic|further diagnostic procedures - mainly CHEST CT -
218934745|NCT01627288|RADIATION|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
219544863|NCT02211924|DRUG|BI 44847|
219544864|NCT02211924|DRUG|Placebo|
219544865|NCT02206893|BEHAVIORAL|Self-monitoring via Smartphone|
219544866|NCT02206893|BEHAVIORAL|Peer support via Smartphone|
218934746|NCT02773576|DRUG|Risperidone implant|
219544867|NCT02206893|BEHAVIORAL|Professional support via Smartphone|
219544868|NCT02206893|BEHAVIORAL|Self-monitoring via Web (Static)|
219544869|NCT06627361|DEVICE|PRO-FLEX PIVOT Foot evaluation|The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
219544870|NCT06627361|DEVICE|Class III ESAR Foot evaluation|The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
219544871|NCT03270254|DEVICE|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
219544872|NCT02061553|BEHAVIORAL|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
219544873|NCT02061553|BEHAVIORAL|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
219544874|NCT02061553|BEHAVIORAL|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
219544875|NCT01798628|DRUG|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
219544876|NCT01798628|DRUG|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
219544877|NCT01798628|DRUG|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
219544878|NCT01631552|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
218934747|NCT01804127|DRUG|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
219544879|NCT03480763|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
219544880|NCT03480763|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
219544881|NCT03480763|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
219622005|NCT06933342|BEHAVIORAL|Habituation to dental examination|"The habituation will be performed by dental hygenists working in the public dental service in Rogaland or Vestland counties. The dental hygenists have completed a 2-day educational course consisting of both theoretical and practical information specifically adressing dental examination of children with autism spectrum disorder. The habituation will be done at the dental office.~The intervention consists of five structured habituation sessions with the trained dental hygienist where the different elements of a clinical dental examination will be introduced stepwise in a controlled manner. Parents/guardians will also receive a toolbox with visual aids and a dental examination mirror with instructions for use during home preparations prior to the habituation sessions."
219622006|NCT06933342|BEHAVIORAL|Preparations at home|"Participants in the augmented control group will receive a toolbox with visual aids and a dental examination mirror. The parents/guardians of these participants will receive written information on how to use these tools at home to prepare for a clinical dental examination."
219622007|NCT06853353|OTHER|Heart Failure Specialist Nurses consultations|Heart Failure Specialist Nurses consultations
219622008|NCT06002009|RADIATION|MRI|MRI of shoulder
218934748|NCT01237197|DRUG|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
219622009|NCT06002009|OTHER|Nerve conduction study|Nerve conduction study
219622010|NCT06508710|DRUG|Ketamine|Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
219622011|NCT06508710|DRUG|Placebo|Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
219622012|NCT05652153|OTHER|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
218934749|NCT01237197|DRUG|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
218934750|NCT02374749|BEHAVIORAL|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
218934751|NCT02374749|BEHAVIORAL|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
218934752|NCT01032889|DRUG|Deoxycholic acid injection|
218934753|NCT01032889|DRUG|Placebo|Phosphate buffered saline placebo for injection
218934754|NCT02410564|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
218934755|NCT02410564|BEHAVIORAL|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
219622013|NCT06939972|DIETARY_SUPPLEMENT|Topical Analgesic with Camphor and Menthol|Participants will apply the product directly to the lower abdomen or back during menstrual cycles, following specific application instructions. The product provides analgesic and cooling effects to reduce discomfort.
219622014|NCT06953934|DRUG|ABBV-932|Oral Capsule
219622015|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
218934756|NCT01439828|DRUG|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
218934757|NCT00000596|DRUG|prednisone|
218934758|NCT00000596|DRUG|cyclophosphamide|
218934759|NCT00000596|DRUG|dapsone|
218934760|NCT04910841|DEVICE|CGM GUARDIAN 2|continuous blood glucose monitoring system
218934761|NCT02039843|OTHER|Emotional Support Dogs|Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized.
218934762|NCT02039843|OTHER|Service Dogs|Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, \& behind).
219046117|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
219544882|NCT04481958|BEHAVIORAL|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
219544883|NCT05592574|OTHER|Blood sample|Blood samples required to performe IL-17 Dosage
219544884|NCT04034277|OTHER|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
219544885|NCT04034277|OTHER|Conventional Treatment|"speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
219544886|NCT05364177|DRUG|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
219622016|NCT05966584|DRUG|Benralizumab|Benralizumab 30mg subcutaneously on day -1.
218934763|NCT04130503|DEVICE|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
218934764|NCT04130503|BEHAVIORAL|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
218934765|NCT02015910|DRUG|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
218934766|NCT02015910|DRUG|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
218934767|NCT00909298|DRUG|TTP889|300 mg
218934768|NCT00909298|DRUG|Placebo|Placebo
219046118|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
219046119|NCT04802174|DRUG|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
219046120|NCT04802174|DRUG|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
219046121|NCT00872846|DEVICE|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
219544887|NCT05364177|DRUG|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
219544888|NCT01895764|DRUG|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
219544889|NCT01895764|DRUG|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
219622017|NCT05966584|DRUG|fulvestrant or AIs) and PI3K inhibition (alpelisib)|SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
219622018|NCT05759182|DEVICE|Powered Exoskeleton Gait Training|A trained medical professional will adjust the exoskeleton to fit each participant and tailor the program(sit to stand, stand to sit, standing balance and weight shift, walk in place, walk forward) according to their physical condition and specific needs. Based on each participant's walking ability, appropriate safety devices (such as crutches, canes, or a harness) will be used during the intervention.
218934769|NCT00792220|PROCEDURE|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
218934770|NCT00792220|PROCEDURE|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
218934771|NCT04615377|BEHAVIORAL|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
219046122|NCT04804462|DEVICE|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
219046123|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
219046124|NCT03334006|DRUG|Pentaglobin®/Standard of Care|Standard-of-Care treatment + Pentaglobin®
219046125|NCT00106782|PROCEDURE|Transcranial Electrical Polarization (TEP)|
219046126|NCT03384121|DRUG|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
219544890|NCT04509167|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
219544891|NCT01440179|DRUG|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
219544892|NCT04682951|PROCEDURE|Decompressive Craniectomy|
219544893|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
219544894|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
219046127|NCT02155023|DRUG|Insulin dosing|
219046128|NCT02155023|DEVICE|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
219544895|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
219544896|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
219544897|NCT03828708|OTHER|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
219544898|NCT01782053|BEHAVIORAL|Picture warning|Warning contains picture proposed for each text statement by FDA
219544899|NCT01782053|BEHAVIORAL|Control|
219544900|NCT03629054|DRUG|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
219544901|NCT03629054|DRUG|Empagliflozin|single dose
219544902|NCT03629054|DRUG|Linagliptin|single dose
219544903|NCT03629054|DRUG|Metformin HCl|single dose
219544904|NCT06136039|PROCEDURE|Arm I (Sarcopenia)|Same as standard treatment
219544905|NCT06136039|PROCEDURE|Arm II(Normal)|Same as standard treatment
219544906|NCT05591105|DRUG|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
219544907|NCT05591105|DRUG|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
219544908|NCT03703154|DRUG|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
219544909|NCT03703154|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
219544910|NCT01503957|DEVICE|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
219544911|NCT01503957|DEVICE|Saline solution|Nasal spray, 2 sprays in each nostril
219622019|NCT03967522|DRUG|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
219544912|NCT00851305|DEVICE|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
219205797|NCT06885502|DEVICE|RGS|The standardized intervention schedule consists of 20-30-minute daily training sessions (including weekends) for 6 weeks, in addition to the prescribed conventional therapy (Standard of Care, SoC). Each session includes 4 to 6 exercises, each lasting approximately 5 minutes. To promote variability and engagement, at least one exercise will be replaced every week based on the participant's progress. Participants are encouraged to train more than the prescribed duration if desired. The RGSapp training will take place at home, and patients will use a smartphone. An optional wearable device (smartwatch) will be used to remotely monitor the use of the paretic upper arm for the duration of the trial. Regular check-ins by clinicians will monitor adherence, adjust the intervention if needed, and ensure the participants' safety.
219205798|NCT06738680|DIAGNOSTIC_TEST|LAFOV system (an innovative, latest-generation system) scan|To collect data from the LAFOV system (an innovative, latest-generation system) during the PET scan planned as part of your treatment.
218934772|NCT04615377|OTHER|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
218934773|NCT05211843|OTHER|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
218934774|NCT05211843|OTHER|Apple juice|apple juice
218934775|NCT00954226|DRUG|Erlotinib Hydrochloride|Given PO
219544913|NCT00851305|DEVICE|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
219544914|NCT00205777|DRUG|Bazedoxifene Acetate|BZA 20mg, daily, oral
219544915|NCT00205777|OTHER|Placebo|Placebo, daily, oral
219544916|NCT02588144|PROCEDURE|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
218934776|NCT00954226|OTHER|Laboratory Biomarker Analysis|Correlative studies
219544917|NCT02588144|PROCEDURE|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
219544918|NCT01824940|BEHAVIORAL|Standard care|"Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system"
219046129|NCT03546751|DEVICE|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
219046130|NCT03546751|OTHER|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
218934777|NCT06376331|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
218934778|NCT00857688|DRUG|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
218934779|NCT00857688|OTHER|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
218934780|NCT05925868|BEHAVIORAL|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
218934781|NCT00983658|DRUG|huMAb OX40L|Intravenous repeating dose
218934782|NCT00983658|DRUG|placebo|Intravenous repeating dose
219046131|NCT04488120|DEVICE|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
219046132|NCT06561217|OTHER|Chart review|Chart review
219205799|NCT06741033|DIAGNOSTIC_TEST|Conventional physiotherapy|Conventional physiotherapy of medial knee osteoarthritis patients: Isometric exercises, strengthening exercises, stretching exercises and electrotherapy.
219205800|NCT06741033|COMBINATION_PRODUCT|Toe-in gait modification|A specific alteration in walking pattern where the toes are directed inward during walking. This modification should be clearly defined, including the degree of inward rotation of the foot and how it is taught and monitored in participants. Toe-in gait modification basically includes decrease foot progression angle from baseline through internal foot rotation. Participants are instructed to increase the Toe-in angle of their study limb by 5 degree and walk at least 5-10 minutes (progressed to 15-20 min after 4 week) with this progression angle.
219544919|NCT01824940|OTHER|WASH|"WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
218934783|NCT05408546|DRUG|TS23|Monoclonal antibody to a2-antiplasmin
218934784|NCT05408546|DRUG|Placebo|Placebo
218934785|NCT03830307|DEVICE|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
218934786|NCT02624986|DRUG|Idasanutlin|Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
218934787|NCT02624986|DRUG|Obinutuzumab|Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
218934788|NCT02624986|DRUG|Rituximab|Participants received a fixed dose of rituximab, 375 mg/m\^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m\^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
218934789|NCT03056196|DIAGNOSTIC_TEST|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
218934790|NCT04254185|PROCEDURE|Simple decompression|Surgical technique
218934791|NCT04254185|PROCEDURE|Subcutaneous anterior transposition|Surgical technique
218934792|NCT02181244|OTHER|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
218934793|NCT02181244|OTHER|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
218934794|NCT00740857|DRUG|placebo|2 placebo gels capsules delivered as a single dose.
218934795|NCT00740857|DRUG|ibuprofen Formulation 1|2 marketed ibuprofen gels
218934796|NCT00740857|DRUG|ibuprofen Formulation 2|2 marketed ibuprofen gels
218934797|NCT05809297|DEVICE|Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®|According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
218934798|NCT05809297|DRUG|Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer|The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
218934799|NCT03227419|DRUG|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
218934800|NCT03227419|DRUG|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection."
218934801|NCT03433040|DRUG|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
218934802|NCT03532451|DRUG|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
218934803|NCT03532451|DRUG|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
218934804|NCT01879358|DEVICE|Drug-eluting stent|
218934805|NCT00466596|DRUG|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
218934806|NCT06343987|BEHAVIORAL|Physical Activity|12-week physical activity program with training 3 times a week. The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
218934807|NCT06186765|DEVICE|Axonics SNM System (Model 4101)|Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
218934808|NCT04123938|OTHER|Pea Protein|Soluble pea protein
218934809|NCT04123938|OTHER|Whey Protein|Whey protein concentrate
218934810|NCT04123938|OTHER|Maltodextrin|Non-protein isocaloric comparator
218934811|NCT05555108|BEHAVIORAL|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
218934812|NCT05555108|BEHAVIORAL|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
218934813|NCT01552434|BIOLOGICAL|Bevacizumab|Given IV
218934814|NCT01552434|BIOLOGICAL|Cetuximab|Given IV
218934815|NCT01552434|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218934816|NCT01552434|OTHER|Pharmacological Study|Optional correlative studies
218934817|NCT01552434|DRUG|Temsirolimus|Given IV
218934818|NCT01552434|DRUG|Valproic Acid|Given PO
218934819|NCT03217071|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
218934820|NCT03217071|RADIATION|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
218934821|NCT03217071|PROCEDURE|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
218934822|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
218934823|NCT03214510|DRUG|Bupivacaine|Given via thoracic epidural catheter or TAP block
218934824|NCT03214510|DRUG|Fentanyl|Given via thoracic epidural catheter
218934825|NCT03214510|DRUG|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
218934826|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of thoracic epidural catheter
218934827|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
218934828|NCT03214510|DRUG|Liposomal Bupivacaine|Given via TAP block
218934829|NCT03214510|BEHAVIORAL|Questionnaire|Ancillary studies
219544920|NCT01824940|DIETARY_SUPPLEMENT|Infant and young child feeding|"IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
218934830|NCT02212535|DRUG|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
218934831|NCT05764642|DRUG|Definity|Ultrasound contrast agent administered intravenously
219205801|NCT06736782|BEHAVIORAL|Self-Empowerment Care Intervention Group|"The intervention emphasizes four key principles: hydration, exercise, dietary support, and defecation care. Each component is designed to address fundamental needs and promote independence in activities of daily living (ADLs).~Individualized care plans will be developed in collaboration with healthcare professionals and caregivers to ensure alignment with participants' functional capabilities and personal goals."
219205802|NCT06736782|BEHAVIORAL|Control Group|"Standard caregiving practices without emphasis on structured hydration, exercise, or dietary programs.~General assistance with ADLs as per existing care routines in the respective facilities."
219544921|NCT01824940|OTHER|WASH and Nutrition|"WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions"
219544922|NCT02401906|OTHER|MRI|
219544923|NCT04110236|BEHAVIORAL|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
219622020|NCT04760990|OTHER|data collection|clinical data collection regarding COVID-19 suggestive symptoms or confirmed SARS-CoV-2-infections (medical events), recorded comorbidities (concomitant diseases relevant to MS and COVID-19) and recorded vaccinations (other treatments). This information is systematically collected during the routine clinical visits of the patient within the SMSC every 6-12 months.
219622021|NCT04760990|OTHER|analysis of blood samples|analysis of archived serum samples collected every 6-12 months within the SMSC for measurement of anti-SARS-CoV-2 antibodies in pre-pandemic reference samples and prospectively determine the anti-SARS-CoV-2-serostatus during the study period.
219622022|NCT03796988|DEVICE|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
219622023|NCT06068101|DIAGNOSTIC_TEST|Secreening test for primary aldosteronism and Confirmatory Testing|Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL
218934832|NCT05764642|DIAGNOSTIC_TEST|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
218934833|NCT05186805|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
218934834|NCT07115121|DRUG|Intravenous Ferric Carboxymaltose|Patients were given ferric carboxymaltose as a maximum single dose of 1000 mg diluted in 250 mL of sterile 0.9% normal saline as a slow infusion over 45 minutes.
218934835|NCT07115121|DRUG|Intravenous Iron Sucrose|Patients received intravenous injections of iron sucrose complex, which contained 200 mg of elemental iron (equivalent to 2 ampoules of 5 ml), mixed in 100 ml of 0.9% normal saline and infused over a period of 30 minutes every other day for up to 5 doses.
218934836|NCT05014256|BEHAVIORAL|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
218934837|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
219205803|NCT06549933|OTHER|Criostymulation|"Method: Cryosauna. Temperature: -160°C. Duration: 5 days. Session Timing: 9:00 a.m.~Session Length: 3 minutes per day"
219205804|NCT05317364|DRUG|Estradiol 0.01% Vag Cream|1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy
219205805|NCT05317364|DRUG|Placebo vaginal cream|Placebo cream
219622027|NCT06705205|OTHER|SAS video|The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.
219622028|NCT01611844|DEVICE|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
219622029|NCT01611844|DEVICE|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
219622030|NCT06335017|DIETARY_SUPPLEMENT|Induction of labor|In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
219622031|NCT06957249|DRUG|Optic White 5%HP ActivShine Toothpaste|0.76% MFP toothpaste
218934838|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
218934839|NCT00427765|DRUG|Busulfan|Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
218934840|NCT00427765|DRUG|Melphalan|70 mg/m\^2 IV for 2 Days
218934841|NCT06590584|OTHER|Patients with obesity|Six-Minute Pegboard and Ring Test: It will be used to evaluate upper extremity exercise capacity. There are 20 rings on 4 iron bars on the board used and patients will be asked to attach the rings with both hands, first from top to bottom and then from bottom to top. At the end of the six minutes, the total number of rings attached will be recorded. Heart rate, blood pressure, respiratory rate, dyspnea and fatigue will be evaluated according to the Modified Borg Scale before and after the test.
218934842|NCT06883305|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218934843|NCT06883305|OTHER|Placebo|Placebo subcutaneous injection
218934844|NCT05904028|DRUG|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
218934845|NCT05904028|DEVICE|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
218934846|NCT06813781|DRUG|AZD5004|Dose 1
218934847|NCT06654245|BEHAVIORAL|Telephone based interview|Receive SHAREDCare navigator calls
218934848|NCT06654245|OTHER|Survey using a questionnaire.|Ancillary studies
218934849|NCT06654245|OTHER|Electronic health record review|Ancillary studies
218934850|NCT06654245|OTHER|Referral|Receive standard of care automated referrals
218934851|NCT06775301|DIAGNOSTIC_TEST|Hyfe Cough Monitoring System|Smartwatch-based cough monitoring
218934852|NCT07074301|BEHAVIORAL|Caregiver Training Program|The intervention consists of a two-month structured education program including two face-to-face sessions and a mobile application. The training content covers PEG care, stoma and tube management, enteral nutrition, drug administration via tube, and troubleshooting complications.
218934853|NCT05016505|BEHAVIORAL|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
218934854|NCT05016505|BEHAVIORAL|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
219365892|NCT04324645|OTHER|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
219365893|NCT02606552|DRUG|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
219365894|NCT02606552|DRUG|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
219365895|NCT02606552|DEVICE|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
219365896|NCT02048345|DRUG|Suspension Fasted State|
219365897|NCT02048345|DRUG|Suspension Fed State|
219365898|NCT02048345|DRUG|Solution Fasted State|
219365899|NCT02048345|DRUG|Solution Fed State|
219365900|NCT00531193|DRUG|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
219365901|NCT00531193|OTHER|[11C]SCH442416|11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
219365902|NCT00883493|DRUG|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
219365903|NCT00883493|DRUG|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
219365904|NCT04324177|OTHER|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
219365905|NCT05959473|DEVICE|Idylla EGFR_IUO/3.20 Mutation Test|Clinical Performance Study Protocol for Idylla EGFR\_IUO/3.20 Mutation Test The EGFR\_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.
218934855|NCT06101797|OTHER|Remote supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised by video call. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
219544924|NCT04110236|BEHAVIORAL|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
219544925|NCT04840927|DRUG|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
219544926|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
219544927|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
219544928|NCT04644068|DRUG|AZD5305|Oral PARP inhibitor
219544929|NCT04644068|DRUG|Paclitaxel|IV Anti-microtubule agent
219544930|NCT04644068|DRUG|Carboplatin|IV Platinum chemotherapeutic
219544931|NCT04644068|DRUG|T- Dxd|IV Antibody-drug conjugate
219544932|NCT04644068|DRUG|Dato-DXd|IV Antibody-drug conjugate
219544933|NCT04644068|DRUG|Camizestrant|Oral SERD Molecule
219544934|NCT03610386|OTHER|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
219544935|NCT03610386|OTHER|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
219544936|NCT06459258|OTHER|Motion-triggered NMES training protocol|Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball
219544937|NCT06459258|OTHER|Non-Motion-triggered NMES training protocol|Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
219544938|NCT00013390|PROCEDURE|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
219622032|NCT06957249|DRUG|Crest3DWhite Advanced Radiant Mint Toothpaste|0.243% NaF toothpaste
218934856|NCT06101797|OTHER|In-person supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised at a physiotherapy clinic. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
219622033|NCT06524544|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622034|NCT06524544|PROCEDURE|Computed Tomography|Undergo CT
219622035|NCT06524544|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622036|NCT06524544|BIOLOGICAL|Pembrolizumab|Given IV
219622037|NCT06524544|OTHER|Questionnaire Administration|Ancillary studies
219622038|NCT06524544|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219622039|NCT05930106|OTHER|Intraoperative fluid ratio|This ratio is calculated by dividing the sum of procedure subcutaneous infiltration and intravenous fluid by the total aspirate volume during surgery
218934857|NCT06904664|OTHER|Individualized temperature health risk early warning and risk factor management|Receive individualized temperature health risk warning and prevention risk factor management information for stroke through the application
218934858|NCT06904664|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
219544939|NCT00013390|PROCEDURE|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
219544940|NCT02336308|DRUG|Ketamine|
219544941|NCT02336308|DRUG|Placebo, Normal Saline|
219544942|NCT05377164|BEHAVIORAL|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
219544943|NCT02253329|PROCEDURE|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
219544944|NCT02253329|PROCEDURE|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
219544945|NCT00351039|DRUG|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
219544946|NCT00351039|DRUG|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
219544947|NCT00351039|DRUG|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
219544948|NCT03873363|DEVICE|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
219544949|NCT03873363|DEVICE|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
219544950|NCT00834353|DRUG|ATT|
219544951|NCT00512811|DRUG|furosemide|
219544952|NCT02363764|PROCEDURE|Nasal swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
219544953|NCT02363764|PROCEDURE|Cough swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
219544954|NCT02363764|PROCEDURE|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~\- Expectorating CF patients"
219622040|NCT05930106|DEVICE|Carotid Artery Doppler Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
218934859|NCT06904664|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
218934860|NCT04274530|BEHAVIORAL|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
218934861|NCT02153229|RADIATION|Photodynamic Therapy|
218934862|NCT02153229|PROCEDURE|Radical Pleurectomy|
218934863|NCT02153229|RADIATION|Chemotherapy|
218934864|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
219544955|NCT02363764|PROCEDURE|Induced sputum|"Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients"
219544956|NCT02363764|PROCEDURE|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~\- Bronchoscopy CF patients"
219544957|NCT02363764|OTHER|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
219544958|NCT03703258|BEHAVIORAL|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
219544959|NCT03033810|DEVICE|Fractional flow reserve and instantaneous wave-free ratio|"1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance."
219544960|NCT03045536|DEVICE|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
219544961|NCT06464926|DEVICE|Enterra Therapy System|"The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options."
219544962|NCT01159899|PROCEDURE|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
219544963|NCT03349632|DEVICE|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
219046133|NCT04294134|BEHAVIORAL|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
219544964|NCT03349632|DEVICE|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
219544965|NCT03349632|DEVICE|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
219544966|NCT03349632|DEVICE|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
219544967|NCT00842309|DRUG|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
219544968|NCT00842309|DRUG|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
219544969|NCT01468688|DRUG|STI571|
219544970|NCT01468688|DRUG|BKM120|BKM120 combination therapy
219544971|NCT00427154|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
219544972|NCT00427154|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
219544973|NCT00427154|DRUG|metformin|Tablets, 2000 mg/day.
219544974|NCT00427154|DRUG|glimepiride|Tablets, 8 mg/day.
219205806|NCT06739733|DIAGNOSTIC_TEST|SRG|Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.
219544975|NCT00893945|DRUG|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
219544976|NCT00893945|DRUG|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
219544977|NCT00893945|DRUG|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
219544978|NCT03221205|DEVICE|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
219544979|NCT03221205|DEVICE|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
219544980|NCT02997345|OTHER|There is no intervention associated with this study.|There is no intervention associated with this study.
219544981|NCT00000205|DRUG|Buprenorphine|
219544982|NCT03646409|OTHER|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
219544983|NCT01444053|DEVICE|No Intervention|No Intervention
219544984|NCT01376596|BEHAVIORAL|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
219544985|NCT01376596|BEHAVIORAL|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
219544986|NCT00870558|DRUG|ethiodized oil|Given as an intra-arterial infusion
219544987|NCT00870558|RADIATION|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
219622041|NCT03008642|OTHER|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
219622042|NCT05770349|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass grafting
219622043|NCT04442971|BEHAVIORAL|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
219622044|NCT04442971|BEHAVIORAL|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
218934865|NCT04806464|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
218934866|NCT07098143|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
218934867|NCT06904326|OTHER|Postoperative dynamic radiography|Participants will perform a dynamic radiography 3 months after lumbar decompression surgery under UBE to study vertebral instability
218934868|NCT03995134|COMBINATION_PRODUCT|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
218934869|NCT07100522|DEVICE|Hearing aid in spectacle frame form factor|"eyewear frames embedded with groundbreaking technology which seamlessly integrate an air conduction hearing aid (over-the-counter OTC, in the United States) intended to amplify sound for adult users (18yrs and older) with a perceived mild to moderate hearing impairment. Nuance Audio Glasses may, if necessary, be used in association with prescription lenses for those adults who also require correction of visual defects. Nuance Audio Glasses can be worn all day and can be easily configured via the App to adapt to any situation, from business meetings to family time."
218934870|NCT07100522|DEVICE|hearing aid|Hearing aid in spectacle frame form factor
218934871|NCT07100587|BEHAVIORAL|Ketogenic diet|A structured, equicaloric ketogenic diet providing approximately 1200 kcal/day, consisting of high fat (70-80 g/day), moderate protein (80-90 g/day), and very low carbohydrate intake (20-30 g/day), primarily from non-starchy vegetables. The diet is administered for 3 consecutive weeks to induce nutritional ketosis. A sugar-free multivitamin supplement is provided throughout the intervention.
218934872|NCT07100587|BEHAVIORAL|Mediterranean diet|A structured Mediterranean diet administered for 3 weeks following a 2-week transition phase. The diet provides approximately 1200 kcal/day and emphasizes plant-based foods, extra virgin olive oil as the main fat source, moderate consumption of fish, dairy products, and whole grains, with limited red meat and processed foods.
218934873|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste +ozone therapy application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Periodontal paste (Coe-pak) will be applied to the area left for secondary healing after ozone therapy (activated oxygen (Cure 09 Active Oxygen))
219622045|NCT04442971|BEHAVIORAL|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
219622046|NCT05060939|DIAGNOSTIC_TEST|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
219622047|NCT05688514|DEVICE|Innovalve MR system|Innovalve MR system
219365906|NCT01699139|DEVICE|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
219365907|NCT01699139|DEVICE|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
219365908|NCT02932787|DEVICE|Height-adjustable workstation|
219365909|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
219365910|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
219365911|NCT01084551|DRUG|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
219365912|NCT00423059|DRUG|bevacizumab|
219365913|NCT01583478|BIOLOGICAL|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
219365914|NCT02556567|OTHER|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
219365915|NCT01944709|BIOLOGICAL|Dendritic cell application|
219365916|NCT04688294|DRUG|Sacubitril-Valsartan|30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
219365917|NCT04688294|DRUG|Valsartan|30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
219365918|NCT05674474|DRUG|Vorasidenib|Administered orally as tablets.
219365919|NCT06228612|DEVICE|vacuum therapy|vacuum therapy :all patients were informed about initial suction sensation and possible appearance of bruising at the application site. Basic vacuum therapy equipment (cangexia, China) was utilized including a manual suction pump, plastic cups of 40 mm diameter with rolled edge, and anti-septic tools.
219365920|NCT06228612|DEVICE|maxillary stabilization splint (MSS)|maxillary stabilization splint (MSS): was constructed for each patient from hard, heat-cured clear acrylic resin and fitted to the maxillary teeth. On the mounted master casts, the vertical dimension was adjusted to provide 3 mm of vertical space between the closest opposing cusps of the maxillary and mandibular teeth.
219365921|NCT06228612|DEVICE|vacuum therapy VT and maxillary stabilization splint (MSS)|vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
219365922|NCT00215007|DRUG|Levofloxacin|
218934874|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Only periodontal paste will be applied after the surgery.
218934875|NCT07103967|BEHAVIORAL|Calorie information manipulation|The intervention will be administered by changing the information presenting to participants at point-of-choice when ordering alcoholic drinks and bar snacks. When alcohol calorie information is present, participants will see the calorie content of alcohol products on menus and at other point-of-choice locations. When it is not present, this information will be absent.
218934876|NCT07103967|BEHAVIORAL|Serving size manipulation|The intervention will be administered by changing the availability of alcoholic drinks. When serving sizes are reduced, participants will only be able to order 2/3 pint of 1/2 servings of beer, and 125 ml servings of wine. When serving sizes are not reduced, participants will be able to order 1 pint servings or 1/2 servings of beer, and 175 ml or 125 ml servings of wine.
218934877|NCT07110116|OTHER|Alternate nostril breathing with Incentive Spirometery|Participants in experimental group were instructed to close their left nostril by left index finger and inhale through their right nostril for six seconds, then closing the right nostril and holding breath for six seconds. Afterward, they exhaled through the left nostril slowly for six seconds. Next, they inhaled through left nostril, keeping the right nostril closed for six seconds then hold the breath by closing both nostrils for six seconds subsequently, and then exhaled through the right nostril, keeping the left closed for six seconds repeating these steps several times for 10 minutes
219544988|NCT04752605|BEHAVIORAL|Finnish ENGAGE together|Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
219622048|NCT02369718|OTHER|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
219622049|NCT02369718|OTHER|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
219622050|NCT03927833|DEVICE|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
219622051|NCT05906602|DEVICE|Real Ischemic Conditioning|10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.
219622052|NCT05906602|DEVICE|Sham Ischemic Conditioning|Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
219622053|NCT04242446|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219622054|NCT04242446|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
219622055|NCT06783491|DRUG|Mitomycin (MM)|Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
219622056|NCT06783491|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC \>1.5x109/L and platelets \>75x109/L should be ensured prior to Day 1 of each 14-day cycle.
219622057|NCT06783491|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
219622058|NCT06790563|DEVICE|Neuromodulation|Neuromodulation by UCon
219622059|NCT05826808|DIAGNOSTIC_TEST|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
219622060|NCT04708418|PROCEDURE|Biopsy Procedure|Undergo biopsy
219622061|NCT04708418|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219622062|NCT04708418|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219622063|NCT04708418|BIOLOGICAL|Pembrolizumab|Given IV
219622064|NCT04708418|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219205807|NCT06739733|DIAGNOSTIC_TEST|EMS|"Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals."
219205808|NCT06734481|DRUG|Sodium bicarbonate pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days. For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage.Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days.
219205809|NCT06734481|DRUG|Saline pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of saline in 7days For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage. Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days..
218934878|NCT07110116|OTHER|Incentive spirometery|The control group participants were asked to do breathing exercise with incentive spirometry. The subject is asked to create a tight seal around the mouthpiece and asked to inhale deeply and slowly and the subject would observe the flow meter for visual feedback of his/her effort. At the end of the inspiration the subject is asked to sustain the inhalation 2-3 seconds to facilitate the Inspiratory hold. Subject relaxes the seal around the mouthpiece and exhales. Normal breathing is taken, then the exhalation phase in the incentive spirometry is done and the whole cycle is repeated 5 - 10 times thrice a day over a period 6 weeks
218934879|NCT07143903|OTHER|artificial application|The conceptual framework for this study proposes that an AI-powered labor monitoring application, designed to track contractions, analyze symptoms, provide educational resources, and utilize predictive analytics, will enhance maternal experience by increasing perceived control, reducing anxiety, and boosting confidence during the first stage of labor. These improvements in maternal experience are expected to mediate positive outcomes, including higher maternal satisfaction, lower stress levels, and timely interventions when necessary, ultimately leading to better fetal outcomes, such as higher Apgar scores and reduced NICU admissions. The framework hypothesizes that expectant mothers using the AI application will have a more empowered labor experience compared to those receiving traditional monitoring, with measurable benefits for both mothers and their newborns.
218934880|NCT07147114|DRUG|Combination therapy|Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
218934881|NCT07147114|DRUG|Monotherapy|Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
218934882|NCT07156227|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218934883|NCT07156227|DRUG|Camonsertib|Given PO
218934884|NCT07156227|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219205810|NCT06735378|OTHER|Intradialytic Cycling|The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
219205811|NCT06734013|DIAGNOSTIC_TEST|Molecular diagnostic|RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
219205812|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 14 day
219622065|NCT04708418|PROCEDURE|Surgical Procedure|Undergo surgery
219205813|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + low dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 2 times/day, oral, for 14 day
219622066|NCT04708418|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC or intratumorally
219622067|NCT04821856|DRUG|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
219622068|NCT04821856|DRUG|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
219622069|NCT01947023|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219622070|NCT01947023|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622071|NCT01947023|PROCEDURE|Computed Tomography|Undergo CT
219622072|NCT01947023|DRUG|Dabrafenib|Given PO
219622073|NCT01947023|DRUG|Dabrafenib Mesylate|Given PO
219622074|NCT01947023|PROCEDURE|Echocardiography Test|Undergo ECHO
218934885|NCT07156227|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218934886|NCT07156227|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218934887|NCT07156604|DRUG|Vebreltinib Enteric Capsules|treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery.
219205814|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 10 day
219205815|NCT06736106|OTHER|screening|Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
219205816|NCT06091540|BEHAVIORAL|Feasibility and Efficacy of Individual SH+ Intervention|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
219544989|NCT02597374|DEVICE|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
219544990|NCT03285438|DRUG|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
219544991|NCT03285438|DRUG|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
219544992|NCT05271890|PROCEDURE|Immediate non-surgical periodontal treatment and oral hygiene instructions|
219544993|NCT04054258|DEVICE|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
219544994|NCT06339437|OTHER|ERAS Protocol|Ehanced recovery after surgery protocols were applied
219622075|NCT01947023|DRUG|Lapatinib|Given PO
219544995|NCT05326880|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
219544996|NCT05326880|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
219622076|NCT01947023|DRUG|Lapatinib Ditosylate|Given PO
219622077|NCT01947023|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622078|NCT01947023|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219622079|NCT01947023|PROCEDURE|Positron Emission Tomography|Undergo PET
219622080|NCT05420064|BEHAVIORAL|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
219622081|NCT05420064|BEHAVIORAL|MyGene Portal|Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
219622082|NCT05420064|BEHAVIORAL|Standard of Care|Participants will received appropriate clinical care as outline by standard of care guidelines
218934888|NCT07156383|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first line treatment for Insomnia. Participants will receive weekly CBT-I during which they will receive the tools to improve their sleep.
218934889|NCT07157293|BEHAVIORAL|Online Motivation Enhancing Intervention|This is a online intervention that will ask participants to review and complete 30 minutes of material each week.
218934890|NCT07157423|DRUG|Eptacog alfa (NovoSeven)|Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)
218934891|NCT07157098|DEVICE|asymmetrical high-flow nasal cannula|high-flow nasal oxygen therapy via asymmetrical nasal prongs
218934892|NCT07157098|DEVICE|non-invasive ventilation with standard mask|non-invasive ventilation with standard oronasal mask, clinically used in the participting site
218934893|NCT07157098|DEVICE|non-invasive ventilation with a new mask|non-invasive ventilation with a new mask design, with under-nose, bridge-free design
218934894|NCT07156266|PROCEDURE|Kegal Exercise|"Dead Bugs:Participants will begin by lying on their backs with their arms extended overhead and legs bent at a 90-degree angle. While engaging their core muscles, they will gradually lower their arms and legs toward the floor, then return to the starting position.~Bridging Exercise: Lying on their backs with knees bent and feet flat on the ground, participants will gently raise their hips upward while activating the pelvic floor muscles, then slowly lower them back to the starting position."
218934895|NCT07156266|PROCEDURE|Squats Exercise|"Sumo Squats: Participants will stand with their feet placed wider than shoulder-width apart and toes pointing outward. They will then squat down, keeping their backs straight and their weight on their heels, pause briefly at the bottom, and return to a standing position.~Narrow Squats: With their feet set shoulder-width apart and toes pointing forward or slightly outward, participants will lower their bodies into a squat position while keeping their backs straight and their weight centered in the heels. After a brief pause, they will return to a standing position."
218934896|NCT07158190|BIOLOGICAL|Vaccine|Vaccine TAK003 administration
219544997|NCT03218787|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
219544998|NCT03218787|DRUG|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
219544999|NCT02878148|DEVICE|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
218934897|NCT07158398|DRUG|Vimseltinib|Administered orally
218934898|NCT07158398|DRUG|Rosuvastatin|Administered orally
218934899|NCT07156903|OTHER|Interview|Patients and their care-givers will be asked to participate in interviews
218934900|NCT07157358|BEHAVIORAL|standardized audio hypnosis recordings for healthy children at primary school|8 different audio hypnosis recordings hat chidlren will listen too at a daily basis (one recording per day)
218934901|NCT07158411|DRUG|Vimseltinib|Administered orally
218934902|NCT07158411|DRUG|Metformin|Administered orally
218934903|NCT07158203|DEVICE|CADx simultaneously|The investigators showed the CADx suggestion during the 15-second playback of the video
219545000|NCT01112462|DRUG|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
219545001|NCT01112462|DRUG|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
219545002|NCT00246662|DRUG|Vosaroxin|All patients receive vosaroxin Injection
219545003|NCT02144844|BEHAVIORAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
219545004|NCT01129258|DRUG|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
219545005|NCT01129258|DRUG|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
218934904|NCT07158203|BEHAVIORAL|CADx delayed|During the 15-seconds polyp video the CADx suggestion appear only in the last 3 seconds of the video
218934905|NCT07157306|DRUG|Gecacitinib Combined With Donafenib and PD-1 Inhibitor|Subjects were enrolled and started receiving treatment with Gecacitinib (100mg, Bid, po) for 7 consecutive days; thereafter, they were treated with PD-1 antibody (Q3W, iv) and Donafenib (200mg, Bid, po), counting the day of infusion of PD-1 monoclonal antibodies as C1D1, with each cycle lasting 3 weeks. Subsequent treatments involved administering Gecacitinib for 1 week before each infusion of PD-1.
218934906|NCT07157722|DRUG|Iron chelating intervention|JADENU is indicated for the treatment of chronic iron overload due to blood transfusions.
218934907|NCT07157722|DRUG|N Acetyl cysteine 600mg|N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.
219545006|NCT03653299|DEVICE|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
219545007|NCT05432115|DRUG|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
219545008|NCT02264977|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
219545009|NCT03573544|DRUG|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
218934908|NCT07157722|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha lipoic acid (ALA) 600 mg will be administered orally once daily for 12 weeks.
218934909|NCT07158164|DRUG|Fluorouracil injection|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
218934910|NCT07158164|DRUG|Xeloda|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
218934911|NCT07158437|BIOLOGICAL|SL-325|DR3 blocking antibody
218934912|NCT07158437|OTHER|Placebo (Normal Saline)|Normal saline
219545010|NCT03573544|DRUG|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
218934913|NCT07151508|DEVICE|Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age|"Secukinumab was administered in a weight-adapted dosing regimen equivalent to that used in clinical trials for psoriasis: 75 mg for less than 25 kg,150 mg for 25 to 50 kg, and 300 mg for greater than 50 kg at baseline and weeks1,2,3, and 4 and monthly there after.~Dupilumab was administered at a dose dependent on the patient's weight and age in accordance with the instructions."
218934914|NCT07158489|DRUG|Gemcitabine + Ivonescimab|"The trial combines two Investigational Medicinal Products (IMPs):~* Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC).~* Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation."
218934915|NCT07156422|PROCEDURE|A scalp biopsy using a 4 mm punch in the retroauricular hair zone|a scalp biopsy using a 4 mm punch in the retroauricular hair zone under local anesthesia
219545011|NCT03573544|DEVICE|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
219545012|NCT00246792|BEHAVIORAL|Group treatment|
219545013|NCT02736019|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
219545014|NCT02736019|DRUG|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
219545015|NCT02736019|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
218934916|NCT07156422|OTHER|a general health questionnaire|a general health questionnaire : demographics, history, treatment, smoking, alcohol consumption, phototype.
218934917|NCT07156422|OTHER|Questionnaires concerning their sensitive scalp|"* The characteristics of a sensitive scalp (location, chronicity, triggering and soothing factors, use of cosmetics, etc.)~* Sensitive Scalp Score (3S)~* Impact on quality of life: BoSS questionnaire~* Impact of pruritus on quality of life (ItchyQol)"
218934918|NCT07157956|DRUG|CVL006 combined with pemetrexed and carboplatin|CVL006 combined with pemetrexed and carboplatin
218934919|NCT07157956|DRUG|CVL006 in combination with SKB264|CVL006 in combination with SKB264
218934920|NCT07157956|DRUG|CVL006 in combination with DS-8201|CVL006 in combination with DS-8201
218934921|NCT07157956|DRUG|CVL006 in combination with Enfortumab Vedotin|CVL006 in combination with Enfortumab Vedotin
219205817|NCT06048263|BEHAVIORAL|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
219545016|NCT02736019|DRUG|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
219545017|NCT04443998|DEVICE|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
219545018|NCT03846193|BIOLOGICAL|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
219545019|NCT03846193|DEVICE|GT005 / Device: Orbit™ Subretinal Delivery System|"GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).~A single dose of GT005 was administered with subretinal injection via suprachoroidal cannulation approach.~Device: Orbit™ Subretinal Delivery System"
219545020|NCT03476226|OTHER|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
219545021|NCT03856580|BEHAVIORAL|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
219545022|NCT03856580|BEHAVIORAL|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
219545023|NCT06276556|DRUG|ABP-671|"Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study."
219545024|NCT06276556|DRUG|Allopurinol|Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
219545025|NCT03463460|OTHER|Laboratory Biomarker Analysis|Correlative studies
219545026|NCT03463460|BIOLOGICAL|Pembrolizumab|Given IV
219545027|NCT03463460|DRUG|Sunitinib Malate|Given PO
219545028|NCT02389595|OTHER|HIV positive subjects|This group will provide a blood sample.
219205818|NCT06048263|DRUG|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
219545029|NCT02389595|OTHER|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
219545030|NCT01847235|DRUG|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
219545031|NCT06809140|DRUG|Enfortumab vedotin|1.25 mg/kg (maximum dose 125 mg)
219545032|NCT06809140|DRUG|Pembrolizumab|200 mg
219545033|NCT07125664|BIOLOGICAL|alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion)|IV Prolastin administered once at 120 mg per kilogram of body weight
219545034|NCT07125664|DRUG|Placebo|\+ IV administration of 0.9% sodium chloride
219545035|NCT03047564|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
219545036|NCT03047564|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
219545037|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
219545038|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
219545039|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
218934922|NCT07156942|BEHAVIORAL|Story-Based Digital Game|Participants in this arm played a story-based digital game during their regular hemodialysis sessions. The game was administered once per week, with each session lasting approximately 10 to 15 minutes, over a 4-week period. The game was accessed via an online platform and designed to educate patients on dietary choices, fluid management, and dialysis self-care through interactive storytelling and decision-making tasks.
218934923|NCT07156799|DRUG|Kaempferol Gel|Local topical application of Kaempferol gel into the implant site during one-stage delayed implant placement to enhance peri-implant bone healing and osseointegration.
218934924|NCT07156565|DRUG|[Ac 225]RTX-2358|\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group (3 total) will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it is appropriate to allow the next group to proceed.
218934925|NCT07156565|DIAGNOSTIC_TEST|[Cu64]LNTH-1363S|\[Cu64\]LNTH-1363S is a investigational radioactive diagnostic imaging agent to demonstrate that the tumor expresses Fibroblast Activation Protein. An imaging test is performed after a single injection with \[Cu64\]LNTH-1363S 13-35 days before the first administration of study drug \[AC225\]RTX-2358 to confirm that the sarcoma has FAP expression.
219205819|NCT06173102|DEVICE|Cranial Orthosis|Early versus usual reception of orthosis.
219205820|NCT06307002|OTHER|Playing a contraception education videogame|"The WMM game is divided into three parts- a reproductive anatomy quiz (Parts), an interactive tool for education about each individual birth control method (Methods), and a section in which players help avatar couples choose the most effective method for them."
219205821|NCT06742983|OTHER|Isobutyl cyanoacrylate|Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution
219205822|NCT06742983|OTHER|Chlorhexidine (0.2%)|Chlorhexidine Digluconate 0.2%
219205823|NCT06742983|OTHER|Normal Saline (0.9% NaCl)|Sodium chloride 0.9%
219545040|NCT04681534|DEVICE|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
219545041|NCT02377778|DRUG|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
219545042|NCT02377778|DRUG|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
219545043|NCT01513434|PROCEDURE|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
219545044|NCT01513434|PROCEDURE|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
219545045|NCT01513434|PROCEDURE|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
219545046|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
219205824|NCT03696433|DIETARY_SUPPLEMENT|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
219205825|NCT03696433|DIETARY_SUPPLEMENT|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
219205826|NCT06742554|DRUG|Buprenorphine transdermal patch|"Buprenorphine Transdermal Patch (10 mg): Applied once before surgery for continuous pain control.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
219205827|NCT06742554|DRUG|Tramadol|"Tramadol: Administered orally or intravenously at a standard dose of 100 mg every 8 hours, based on patient-reported pain levels.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
219205828|NCT03950076|DRUG|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
219205829|NCT03950076|OTHER|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
219205830|NCT06888973|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
219545047|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
219046134|NCT04294134|BEHAVIORAL|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based…model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
219046135|NCT06447844|DEVICE|OsteoGen Plug|OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
219205831|NCT06888973|OTHER|Placebo|0.9% Saline as placebo
219205832|NCT06891573|BEHAVIORAL|Lifestyle Management|For 16 weeks, participants will receive exercise, cognitive training, nutrition education, and disease education through a smartphone app, and the content and intensity of the intervention will be adjusted every four weeks through an assessment of frailty symptoms through the app.
219205833|NCT06891326|DEVICE|sham transcranial Alternating Current Stimulation|we use fade-in, short-stimulation, fade-out (FSF) stimulation pattern, with 60s-long fade-in/out periods, 2.0mA peak current at the beginning and the end of stimulation session
219205834|NCT06891326|DEVICE|active tACS|The active tACS protocol lasted for 40 min of continuous sine-wave stimulation with the frequency of 10Hz and an amplitude ranging from 1.5mA to 2.0mA, adjusted according to the tolerability among individuals.
219545048|NCT00147498|DRUG|CP-690,550|30 mg BID for 6 weeks
219046136|NCT06447844|DEVICE|BioGide|BioGide is a resorbable collagen membrane
219046137|NCT04278144|DRUG|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
219046138|NCT04278144|DRUG|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
219545049|NCT00147498|OTHER|Placebo|Placebo tablets
219545050|NCT02368639|DEVICE|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
219545051|NCT06209983|PROCEDURE|ERAS|"1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
219046139|NCT01059370|PROCEDURE|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
219046140|NCT04048642|BEHAVIORAL|DASH|7 days of a DASH diet
219046141|NCT04048642|BEHAVIORAL|Whole-Food, Plant-Based|7 days of a WFPB diet
219545052|NCT06209983|PROCEDURE|Conventional care|"1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
219545053|NCT03281135|OTHER|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
219545054|NCT01139970|OTHER|Laboratory Biomarker Analysis|Correlative studies
219545055|NCT01139970|OTHER|Pharmacological Study|Correlative studies
219545056|NCT01139970|DRUG|Temozolomide|Given PO
219545057|NCT01139970|DRUG|Veliparib|Given PO
219545058|NCT01838681|DRUG|Placebo|Once daily, tablets, orally
219545059|NCT01838681|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
219545060|NCT01838681|DRUG|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
219545061|NCT00246922|DRUG|Roflumilast|
219545062|NCT03129373|DEVICE|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
219545063|NCT05816564|BEHAVIORAL|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
219545064|NCT05816564|BEHAVIORAL|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
219545065|NCT01065610|DRUG|Oxytocin|
219545066|NCT01065610|DRUG|Placebo|
219545067|NCT03579394|PROCEDURE|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
219545068|NCT03579394|PROCEDURE|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
219545069|NCT05909358|BIOLOGICAL|CAd3|CAd3 candidate vaccine which is one of the investigational products
219545070|NCT05909358|BIOLOGICAL|ChAdox1|ChAdox1 candidate vaccine which is one of the investigational products
219545071|NCT05909358|BIOLOGICAL|rVSV-SUDV|rVSV-SUDV candidate vaccine which is one of the investigational products
219046142|NCT05548023|DEVICE|The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent|The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
219046143|NCT04552587|BEHAVIORAL|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
219046144|NCT02440386|BEHAVIORAL|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
219545072|NCT05909358|OTHER|Control|Placebo
219545073|NCT00298415|DRUG|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
219545074|NCT00298415|DRUG|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
219545075|NCT04964973|DEVICE|Control|Post-surgical physiotherapeutic activity.
219545076|NCT04964973|DEVICE|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
219545077|NCT04964973|DEVICE|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
219545078|NCT04945252|DIAGNOSTIC_TEST|Signpost caries|Identify carious lesion according to ICCMS visual criteria
219545079|NCT06366386|BEHAVIORAL|Screening and treatment of hypertension among PLHIV in DSD models for HIV|In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
219205835|NCT06890663|OTHER|Nonspecific Hypnotherapy for Relaxation|A therapeutic technique that uses hypnosis for relaxation.
219205836|NCT06890663|OTHER|Gut-Directed Hypnotherapy (GDH)|A therapeutic technique that uses hypnosis and relaxation to help with gastrointestinal (GI) disorders.
219046145|NCT06146530|DEVICE|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
219046146|NCT02660320|DEVICE|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
219046147|NCT02660320|DEVICE|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
219046148|NCT04116164|DRUG|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
219046149|NCT03072134|BIOLOGICAL|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
219046150|NCT03678155|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
219046151|NCT06967584|OTHER|Kinesio Taping|"The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region to facilitate the respiratory muscles. Anteriorly, an I-shaped Kinesio tape will be applied with the base anchored on the xiphoid process, stretched to 50-75% tension, applied only to the linea alba. The ends of the tape will be applied without tension toward the subcostal curvature. Posteriorly, a second I-shaped Kinesio tape will be applied. The base of the tape will be anchored on the spinous process of the 12th thoracic vertebra with 50-75% tension, and the tails will be applied without tension toward the ribs"
219046152|NCT06967584|OTHER|Sham Kinesio Taping|The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region but without tension
219046153|NCT04907032|DRUG|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
219046154|NCT04907032|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
219046155|NCT03326011|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
219205837|NCT06890663|OTHER|3-month Follow-Up|A 3-month follow is completed after both intervention phases (general hypnotherapy and Gut Directed Hypnotherapy) are completed for each participant.
219205838|NCT06745271|DRUG|[14C]-tebapivat|Oral Capsule
219205839|NCT06745271|DRUG|[13C2,15N3]-tebapivat|Intravenous Solution
219205840|NCT05578651|DEVICE|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
219205841|NCT06892392|PROCEDURE|ICG administration|"For the administration of ICG, it is necessary to perform a gastroscopy by the Digestive Service of each center, with sedation 24 h before surgery. For this, the lesion is located by gastroscopy, after which it is injected in 4 quadrants in the submucosa, with a total volume of 2 ml.~To prepare the ICG, 0.5 ml (containing 0.625 mg of ICG) is dissolved in 1.25 mg/dl of sterile water"
219545080|NCT01502696|BIOLOGICAL|PEG IFN alfa-2b|3µg/kg weekly injections
219545081|NCT05826327|DRUG|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
219545082|NCT05826327|DRUG|Sufentanil|Sufentanil for labour analgesia in the control group
219545083|NCT00104910|RADIATION|Internal Radiation Therapy|
219545084|NCT00104910|RADIATION|3-Dimensional Conformal Radiation Therapy|
219545085|NCT00104910|BIOLOGICAL|Cetuximab|Given IV
219545086|NCT00104910|DRUG|Cisplatin|Given IV
219545087|NCT00815087|DEVICE|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
219545088|NCT00815087|BEHAVIORAL|Exercise home program|Daily exercise training
219545089|NCT01229150|DRUG|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
219622085|NCT05457790|BEHAVIORAL|ACT Intervention|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
219205842|NCT06891391|OTHER|Dynamic Neuromuscular Stabilization exercises|DNS is a method used to enhance muscle stability. It is a manual and rehabilitative approach based on developmental kinesiology to optimize the movement system. These exercises optimize internal muscle forces on each spinal segment.
219545090|NCT01229150|DRUG|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
219545091|NCT01229150|DRUG|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
219545092|NCT00805402|OTHER|flow cytometry|flow cytometry
219545093|NCT06460272|OTHER|Medically Tailored Meals|Meals culturally tailored to provide essential nutrition
219545094|NCT04914351|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
219545095|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through peripheral veins|Umbilical cord-mesenchymal stem cells injected through peripheral veins
219545096|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through hepatic artery|Umbilical cord-mesenchymal stem cells injected through hepatic artery
219205843|NCT06891391|OTHER|Deep Cervical Muscle exercises|Deep cervical muscle exercises are isometric exercises that strengthen weak muscles without causing discomfort to pain-sensitive structures like ligaments, tendons, or neck joints. This involves contracting specific muscles without changing muscle length or impeding joint movement.
219205844|NCT06739213|DRUG|SYHA1813|The starting dose of SYHA1813 is 20mg QD
219205845|NCT06739213|DRUG|Investigator's Choice Treatment|Investigator's Choice Treatment
219205846|NCT06737965|OTHER|Medical abortion|"Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory."
219205847|NCT06737965|OTHER|Foetopathology exam|"Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution."
219205848|NCT06737965|OTHER|Outcomes mesurement|"* From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone."
219205849|NCT06880068|DIAGNOSTIC_TEST|Dual Task Impact on Daily-living Activities Questionnaire|This questionnaire makes us assess dual-task performance while performing daily-living activities.
219205850|NCT06739694|BEHAVIORAL|PNE|A manual therapy(Mulligan´s Mobilization with Movement) and 4 sessions of strenght exercises program was administered for both groups. In addition, a pain neuroscience education protocol was administered for the experimental group for a whole period of 4 weeks (1 session/week, 75mins per session).
219205851|NCT06739694|PROCEDURE|Manual therapy|5 sessions of Mulligan´s Mobilization with Movement and 4 sessions of strenght exercises
219205852|NCT06736730|BEHAVIORAL|Hospital-Linked Violence Intervention Program|Activation of Operation Good, our community partner with a history of direct violence interruption in the streets and longitudinal health and wellness services to firearm injured patient (i.e. linking and aiding those who have suffered from violent injury to mental healthcare, job services, educational services)
219205853|NCT06736730|BEHAVIORAL|Mobile Community Event Support|A menu of services provided to the community in an activated cluster where funding will be provided to assist that community in holding events that support overall health and wellness (community clean-up, legal advisory services, pop-up clinic for blood pressure checks).
219205854|NCT06736730|BEHAVIORAL|Unrestricted Cash Assistance|A participant in an activated cluster after firearm injury will receive two disbursements of 500$. One at the time of initial hospital evaluation and a second disbursement \~1 month later to offset the financial burden associated with firearm injury on the individual.
219205855|NCT06869304|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Preoperative and postoperative MoCA test scores
219205856|NCT06251245|PROCEDURE|Oral Injector|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
219545097|NCT06982027|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
219545098|NCT06982027|PROCEDURE|Peripheral nerve block|An injection of numbing medicine near a specific nerve or group of nerves to numb the part of the body undergoing surgery.
219545099|NCT06817265|DRUG|TNTL|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
219545100|NCT06817265|DRUG|TNTL simulation preparation|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
219545101|NCT04492553|DRUG|AndroGel|Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
219545102|NCT01032213|DRUG|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
219545103|NCT01032213|DRUG|normal saline|Group S received the same volume of isotonic saline as same method.
219545104|NCT01954277|DEVICE|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
219545105|NCT01954277|DEVICE|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
219205857|NCT06251245|PROCEDURE|Spoon|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
219205858|NCT06734715|OTHER|Conservative oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
219205859|NCT06734715|OTHER|Liberal oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
219205860|NCT06736197|PROCEDURE|Group TVB|Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.
219545106|NCT06022588|DRUG|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
219205861|NCT06736197|PROCEDURE|Group PSV|Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
219545107|NCT06022588|DRUG|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
219545108|NCT06022588|DIAGNOSTIC_TEST|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
219545109|NCT06022588|DIAGNOSTIC_TEST|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
219545110|NCT04917419|OTHER|Luminotherapy and /or Psychoeducation Program|TO complete
219545111|NCT02995135|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)"
219545112|NCT02995135|DRUG|SFP Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219545113|NCT05768334|DRUG|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
219205862|NCT06736197|PROCEDURE|Group PSV+PEEP|At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
219205863|NCT06735495|DRUG|CD19&CD22 bispecific CAR-T cells|Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
219205864|NCT06734598|DRUG|Echo-guided Botox injection|Echo-guided Botox injection to the masticatory muscles
219545114|NCT01381653|OTHER|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
219205865|NCT06734598|PROCEDURE|echo-guided normal saline injection|echo-guided normal saline injection
219205866|NCT06734572|DRUG|18F-FAPIBiotin|The dose will be 148-296 MBq given intravenously.
219359889|NCT05280756|DEVICE|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
219359890|NCT04787965|DRUG|Opicapone|Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
219622086|NCT05457790|BEHAVIORAL|Waitlist|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
219622087|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
219622088|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
219622089|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
219622090|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
219622091|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219622092|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219622093|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
219622094|NCT05633511|PROCEDURE|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
219545115|NCT01186835|PROCEDURE|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
219545116|NCT01186835|PROCEDURE|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
219545117|NCT02011945|DRUG|Dasatinib|
219545118|NCT02011945|DRUG|Nivolumab|
219545119|NCT05492162|OTHER|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~* Well-being (Workshops)~* Smoking prevention (Conference)~* Balanced diet (Workshop)~* Optimal organization for daily healthy living (Conference)"
219545120|NCT00902538|DRUG|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
219545121|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
219545122|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
219622095|NCT04665765|DRUG|Carboplatin|Given IV
219622096|NCT04665765|DRUG|Etoposide|Given IV
219622097|NCT04665765|DRUG|Ifosfamide|Given IV
219622098|NCT04665765|DRUG|Polatuzumab Vedotin|Given IV
219205867|NCT06735794|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-c (active comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-c, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
219359891|NCT05724550|DRUG|Sugammadex|"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
219359892|NCT05724550|DRUG|Neostigmine|"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
219359893|NCT00836355|DRUG|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
219359894|NCT00836355|DRUG|Minocycline|200 mg orally once daily for 5 days
219359895|NCT02939157|OTHER|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
219545123|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
219545124|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
219545125|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
219622099|NCT04665765|BIOLOGICAL|Rituximab|Given IV
219622100|NCT06519149|DEVICE|Slow Wave UASD|An oral appliance for the treatment of OSA and snoring
219545126|NCT03531827|DRUG|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
219622101|NCT02593279|GENETIC|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
219622102|NCT02593279|GENETIC|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
219622103|NCT05325177|DRUG|Standard Dose Ibuprofen|(10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
219622104|NCT05325177|DRUG|High Dose Ibuprofen|(20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
219622105|NCT00780377|DRUG|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
219622106|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
219622107|NCT04941651|BEHAVIORAL|OBE-COACH program|"OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program.~The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses.~To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals.~The intensity level of the program is selected by the user at any time."
219545127|NCT03531827|DRUG|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
219622108|NCT04941651|DEVICE|Connected devices|"Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight."
219622109|NCT04941651|DEVICE|Connected Activity Tracer|The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.
219622110|NCT04941651|BEHAVIORAL|e-learning program|e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
219622111|NCT00183404|DRUG|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
219622112|NCT03356938|BEHAVIORAL|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
218934926|NCT07157813|BEHAVIORAL|Structured Health Dialogue|"Health Screening (Approx. 15-20 minutes):~Measurement of height, weight, BMI, and waist-to-hip ratio Blood pressure recording Collection of fasting blood samples to assess glucose, cholesterol, and triglyceride levels~Health and Lifestyle Questionnaire:~Self-reported assessment of physical activity, dietary habits, alcohol and tobacco use, psychosocial stress, and family history of cardiovascular disease~Creation of an Individualized Health Curve:~Visual summary of the patient's current cardiovascular risk factors, showing how these factors interact and where improvement is needed~Structured Health Dialogue (60-90 minutes):~A one-on-one conversation between the participant and a trained nurse using principles of motivational interviewing Focused on identifying personal health goals, enhancing motivation for lifestyle change, and discussing possible support strategies Tailored Health"
218934927|NCT07158320|BEHAVIORAL|Relaxation training|In Jacobson's progressive muscle relaxation method, the first step is to make various muscle groups contract, to realize what it feels like to contract in this body area; The second step is to release these contracted muscle groups and notice how a relaxed muscle feels as the contraction subsides. During the exercise, the contraction is continued for 5 seconds. After the contraction, the muscles are relaxed for 10-15 seconds and in the meantime, rest is provided. Before starting the training, the person is taught the correct breathing technique and is asked to use the correct breathing technique throughout the practice. The practice should be done calmly without haste. During the practice, people should choose clothes that they can feel comfortable in. The practice should be applied in a quiet, dim environment where people can feel comfortable. It can also be performed with the eyes closed.
218934928|NCT07156305|BEHAVIORAL|Protective Behavioral Strategies|Participants receive psychoeducation about protective behavioral strategies and are asked to choose three strategies that they do not already engage in regularly but would be willing to start using more.
218934929|NCT07156305|BEHAVIORAL|Goal-Setting|Participants receive psychoeducation about protective behavioral strategies and goal-setting. They are asked to choose three strategies that they do not already engage in regularly and identify two goals related to each strategy.
219359896|NCT05366283|BIOLOGICAL|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
218934930|NCT07156253|DRUG|SYN818 and Olaparib will be administered|Patients will orally receive SYN818 and Olaparib
218934931|NCT07157150|BEHAVIORAL|Free Play SSG|Other current and former name(s) or alias(es), if any, different from the Intervention Name(s), that the sponsor has used publicly to identify the intervention(s), including, but not limited to, past or present names such as brand name(s), or serial numbers
218934932|NCT07157150|BEHAVIORAL|Controlled Pass|Participants train in 3v3 and 4v4 football games under Controlled Pass rules for 8 weeks.
218934933|NCT07157683|OTHER|Biospecimen collection|"If a blood sample is drawn as part of standard care, up to six additional EDTA tubes (42 mL max) will be collected for research.~In addition, the following optional samples may be collected, depending on investigator assessment and/or patient preference:~* Saliva sample (if no blood draw is performed)~* Urine sample~* Stool sample"
218934934|NCT07156994|OTHER|No Intervention: Observational Cohort|Participants will be followed digitally using the LCC app. They will complete questionnaires about their health status and do voice recordings on their own rhythm during the entire study duration.
219359897|NCT02527707|DRUG|lonafarnib|antiviral farnesyltransferase inhibitor
219359898|NCT02527707|DRUG|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
219622113|NCT03356938|BEHAVIORAL|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
219622114|NCT00485732|BIOLOGICAL|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
219622115|NCT00485732|BIOLOGICAL|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
219622116|NCT00803790|DRUG|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
219622117|NCT00803790|DRUG|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
219622118|NCT00803790|DIETARY_SUPPLEMENT|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
219622119|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
219622120|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
219622121|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
219622122|NCT04183348|BEHAVIORAL|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
219622123|NCT04183348|BEHAVIORAL|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
219622124|NCT06342700|DRUG|Rilzabrutinib crystalline form|Pharmaceutical form:Film coated tablet Route of administration:Oral
219622125|NCT06342700|DRUG|Rilzabrutinib amorphous form|Pharmaceutical form:Film coated tablet Route of administration:Oral
219622126|NCT05773092|DRUG|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
219359899|NCT06217315|OTHER|No Intervention|There is no intervention.
219359900|NCT00234312|DRUG|escitalopram and sertraline|
219359901|NCT00060255|DRUG|busulfan|iv
219359902|NCT00060255|DRUG|carboplatin|iv
219359903|NCT00060255|DRUG|carmustine|iv
219359904|NCT00060255|DRUG|cyclophosphamide|iv
219359905|NCT00060255|DRUG|etoposide|iv
219359906|NCT00060255|DRUG|melphalan|oral
219359907|NCT00060255|DRUG|thiotepa|iv
219359908|NCT00060255|PROCEDURE|autologous bone marrow transplantation|iv
219359909|NCT00060255|PROCEDURE|bone marrow ablation with stem cell support|iv
219359910|NCT00060255|PROCEDURE|peripheral blood stem cell transplantation|iv
219359911|NCT00060255|RADIATION|radiation therapy|body x-ray
219359912|NCT00930059|DRUG|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
219359913|NCT00930059|DRUG|Placebo|matching placebo tablets, every 12 hours for 12 wks
219359914|NCT01636466|DRUG|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
219359915|NCT05236803|BEHAVIORAL|Testing of general motor skills, fine motor skills and occulomotricity|"Recording of participant's performance during eye, fine motor and gross motor tests; Children's gross motor skills will be assessed through a biomechanical analysis.~Eye movements will be recorded using the eye-tracking system (Tobii Pro TX300). The technique used is the corneal reflection technique."
219359916|NCT05236803|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires.
219359917|NCT04002310|DRUG|BI 754132|One single injection
219359918|NCT00542997|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
219359919|NCT05301387|PROCEDURE|Ganglion Sphenopalatine Block|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl
219359920|NCT06538506|DEVICE|RehUp BCI Intervention|Participants will be seated wearing a cap on their head containing surface electrodes connected to a computer/laptop. The laptop employs machine learning algorithms and uses the scalp electroencephalogram (EEG) signals from the scalp's surface to control a robotic arm which supports the patient's stroke-affected arm. The machine learning algorithms rapidly interpret EEG signals and adjust the outgoing movement commands to the robot based on an individual's responses to stimuli. The participant will be wearing a VR headset. The VR displays visual stimulus in time with the robotic arm. Based on information from the EEG, the participant is able to animate their robotic arm and receive visual task-based feedback in the VR.
219545128|NCT04745234|DRUG|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
219545129|NCT06820970|DEVICE|chronic remote ischemic conditioning|Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is squeezed for 6 minutes per cycle and the rest is 4 minutes, for a total of 4 cycles per cycle.
219545130|NCT06820970|BEHAVIORAL|Mindfulness Therapy|Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.
219545131|NCT06820970|OTHER|sham CRIC|The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as those of the CIRC group.
219545132|NCT06820970|BEHAVIORAL|sham MFT|Sham MFT: Health Education + Relaxation (HER): A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation (music or simple muscle loosening), excluding mindfulness-specific techniques (no present-moment/nonjudgmental awareness training, no breath-focused meditation, no open monitoring).
219545133|NCT06277492|DRUG|Single ascending doses SUL-238|PART 1: SUL-238 single ascending doses
219545134|NCT06277492|DRUG|Single dose Placebo|PART 1: Placebo single dose
219545135|NCT06277492|DRUG|Single dose SUL-238|PART 2: SUL-238 single dose for pharmacokinetics
219545136|NCT06277492|DRUG|Multiple ascending doses SUL-238|PART 3: SUL-238 multiple ascending doses
219545137|NCT06277492|DRUG|Multiple doses Placebo|PART 3: Placebo multiple doses
219545138|NCT06277492|DRUG|2000 mg SUL-238 single dose for pharmacokinetics (food effect)|PART 2B: 2000 mg single dose of SUL-238
219545139|NCT06277492|DRUG|Single dose placebo (food effect)|PART 2B: Placebo single dose
219545140|NCT06359860|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
219545141|NCT05032742|BEHAVIORAL|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
219545142|NCT06601439|OTHER|Observational Study|Observational Study
219545143|NCT06603103|PROCEDURE|SPHERIKA prosthesis|total knee arthroplasty with kinematic alignement with SPHERIKA prosthesis
219545144|NCT06603103|PROCEDURE|ORIGIN prosthesis|total knee arthroplasty with kinematic alignement with ORIGIN prosthesis
219545145|NCT06598956|DRUG|TQ05105|TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
219545146|NCT06979856|BEHAVIORAL|Short animated video|The short animated video (approximately 2 minutes) draws a parallel between cigarette addiction and smartphone addiction.
219622127|NCT01857037|OTHER|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
218934935|NCT07157709|OTHER|non-pharmacological interventions|Care staff collaborate with residents to select the most suitable non-pharmacological intervention from the designated toolkit to reduce pain. It is imperative to pay attention to the resident's preferences and to ascertain which intervention they would like to attempt.
218934936|NCT07156292|OTHER|Observational study, not interventional|Observational study, not interventional
218934937|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
218934938|NCT02685267|DRUG|Docetaxel|
218934939|NCT02685267|DRUG|Enzalutamide|
218934940|NCT02685267|DRUG|Prednisone|
218934941|NCT02042872|DRUG|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
218934942|NCT05203900|DIETARY_SUPPLEMENT|Infant formula with Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
218934943|NCT05203900|DIETARY_SUPPLEMENT|Infant formula without Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
218934944|NCT06155396|DRUG|Disitamab Vedotin|2.0 mg/kg IV every 2 weeks
218934945|NCT06155396|DRUG|Zimberelimab|240mg IV every 2 weeks
219545147|NCT06979856|BEHAVIORAL|Informational Control|A short fact sheet presenting written information and statistics about smartphone usage.
219545148|NCT06609278|BEHAVIORAL|harm reduction intervention|Each participant will complete a pre-test at Study Visit 1 prior to the intervention, participate in the intervention, then complete a post-test. After the intervention, participants will participate in a recorded focus group. Participants will be offered FTS, Narcan, first aid supplies at the study visit.
219545149|NCT06987708|OTHER|The Multimodal Lifestyle Intervention|The multimodal lifestyle intervention has six foci: positive cognition, exercise/movement, stress reduction, social connection, emotional well-being, and nutrition
219622128|NCT05775900|DRUG|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
219622129|NCT05775900|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
219622130|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
219622131|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
219622132|NCT05454735|PROCEDURE|coronary artery bypass surgery|coronary artery bypass surgery
219622133|NCT05454735|PROCEDURE|aortic valve replacement surgery|aortic valve replacement surgery
219545150|NCT05649683|BIOLOGICAL|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
219545151|NCT00849797|DRUG|Oxcarbazepine|600 mg Tablet
218934946|NCT00696917|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
218934947|NCT00696917|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
218934948|NCT04730661|DIAGNOSTIC_TEST|Sit to stand test|"The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~* If SpO2 \<90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~* SpO2 \<90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~* SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge."
218934949|NCT00667108|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
218934950|NCT00667108|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
218934951|NCT00667108|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
218934952|NCT04384133|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
218934953|NCT04384133|DIAGNOSTIC_TEST|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
218934954|NCT04384133|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
218934955|NCT04384133|DIAGNOSTIC_TEST|Thorax Computed Tomography|Computed tomography is a radiological examination.
218934956|NCT04384133|DIAGNOSTIC_TEST|Chest X Ray|Chest X ray is a radiological examination.
218934957|NCT04384133|DIAGNOSTIC_TEST|Blood eosinophil level|A tube of blood will be drawn from the participant.
218934958|NCT04384133|OTHER|CAT|It consists of 8 questions.
218934959|NCT04384133|OTHER|mMRC|It is the scale used to measure the severity of shortness of breath.
218934960|NCT00544700|BIOLOGICAL|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
218934961|NCT00544700|OTHER|no maintenance|No treatment until progression
218934962|NCT05339867|BEHAVIORAL|Prevent Maternal Mortality using Mobile technology (PM3)|"PM3: The app will include:~1. integrated self-management and tailored health messaging feature~2. support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~3. multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~4. a feature that will update women on maternal and reproductive health policies that impact women."
218934963|NCT00943072|BIOLOGICAL|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
219205868|NCT06735794|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-s (experimental study intervention), which will be delivered unilaterally to the left motor cortex. Following iTBS-s, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
219545152|NCT00849797|DRUG|Trileptal®|600 mg Tablet
219545153|NCT02955901|OTHER|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
219545154|NCT02955901|OTHER|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
219545155|NCT03115697|DRUG|Lactulose|Lactulose 20 mL
219545156|NCT03115697|DRUG|Rifaximin|Rifaximin 550 BD
219545157|NCT03115697|BIOLOGICAL|Plasmapheresis|Plasmapheresis 8 hrly duration
219545158|NCT03986463|OTHER|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
219545159|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
219545160|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
219545161|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
219545162|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
219545163|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219545164|NCT06661915|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
219545165|NCT06661915|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219545166|NCT06661915|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219545167|NCT06661915|DRUG|Decitabine and Cedazuridine|Given PO
219545168|NCT06661915|DRUG|Iadademstat|Given PO
219545169|NCT06996782|DRUG|Rilvegostomig|Rilvegostomig will be administered as an intravenous (IV) infusion.
219545170|NCT06996782|DRUG|AB248|AB248 will be administered via syringe or an IV bag.
219545171|NCT06996782|DRUG|Cisplatin|Cisplatin will be administered as SoC as an IV infusion.
219545172|NCT06996782|DRUG|Carboplatin|Carboplatin will be administered as SoC as an IV infusion.
219545173|NCT06996782|DRUG|Pemetrexed|Pemetrexed will be administered as SoC as an IV infusion.
219545174|NCT06996782|DRUG|Paclitaxel|Paclitaxel will be administered as SoC as an IV infusion.
219545175|NCT06996782|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as SoC as an IV infusion.
219545176|NCT06996782|DRUG|Ramucirumab|Ramucirumab will be administered as an IV infusion.
219545177|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
219545178|NCT03631056|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)|
219545179|NCT03022643|BEHAVIORAL|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
219545180|NCT03022643|OTHER|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
219545181|NCT02901379|DRUG|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
219545182|NCT02901379|DRUG|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
219545183|NCT00679081|DEVICE|CelTx|Single application; split-mouth design
219545184|NCT00679081|OTHER|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
219545185|NCT01366781|OTHER|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
219545186|NCT06602362|OTHER|Partnered sex involving choking|When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
219359921|NCT06538506|OTHER|Control Therapy|The study therapist will focus on 3 activities (\~15 minutes each/session): passive range of motion exercises, motor imagery, and mirror therapy. These activities were chosen as they are all passive activities that are commonly used in a patient with severe impairment of the post-stroke arm and hand. Each session will last \~1hour including set up and switching between activities.
219359922|NCT04788940|PROCEDURE|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
219359923|NCT04857099|OTHER|Data extraction from medical files|Data extraction from medical files
219359924|NCT05835947|OTHER|Dual Pathology|Women with both genital HSIL/SCC and Anal HSIL/SCC
219545187|NCT06602362|OTHER|Partnered sex not involving choking|When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
219545188|NCT06999798|PROCEDURE|Diagnostic Mammography|Undergo mammography
219545189|NCT06999798|PROCEDURE|Resection|Undergo surgical resection of the lymph node as part of standard care.
219545190|NCT06999798|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging. Ultrasound images will be evaluated for presence and visibility/conspicuity of the twinkling marker.
219545191|NCT06999798|DEVICE|Twinkling Marker Placement|Undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement.
219545192|NCT07001124|DIAGNOSTIC_TEST|duochrome test and +1 blur test|"The participant is seated at a standard testing distance (typically 6 meters or 20 feet). A duochrome chart with black letters on a split red-green background is presented.~After determining the subjective refraction, a +1.00 diopter (DS) lens is added to the final prescription. The participant is asked to read the distance visual acuity (VA) chart. The expectation is that the visual acuity should drop to 4 lines on Snellen chart (6/24) when the +1.00 DS lens is added. If VA reduces to 6/24: Indicates that the refraction is not over-minused or over-plussed (proper end point of refraction). If VA remains better than 6/24: Suggests the patient was still accommodating, possibly leading to over-minus (in myopes) or under-plus (in hyperopes) and the refraction should be re-evaluated."
218934964|NCT00943072|DRUG|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
218934965|NCT00030459|DRUG|cisplatin|
218934966|NCT00030459|DRUG|mitomycin C|
218934967|NCT00030459|DRUG|vinblastine sulfate|
218934968|NCT00030459|DRUG|vinorelbine tartrate|
218934969|NCT04930341|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
218934970|NCT05815875|COMBINATION_PRODUCT|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
218934971|NCT05815875|OTHER|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
218934972|NCT04976907|DEVICE|Contactless vital sign information collection|Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
218934973|NCT03774056|DRUG|HC-1119|oral
219545193|NCT04478370|BIOLOGICAL|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
219622134|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
219622135|NCT03629977|DEVICE|CRRT|Continuous Renal Replacement Therapy
219622136|NCT01251874|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219622137|NCT01251874|DRUG|Carboplatin|Given IV
219622138|NCT01251874|PROCEDURE|Computed Tomography|Undergo PET/CT
219622139|NCT01251874|OTHER|Fluorothymidine F-18|Given FLT
219622140|NCT01251874|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218934974|NCT00552188|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
218934975|NCT00552188|DRUG|Placebo|oral dosing, 1 time daily for 24 weeks
218934976|NCT05008900|RADIATION|Salvage radiotherapy|Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.
218934977|NCT03887702|OTHER|Best Practice|Receive best practice
218934978|NCT03887702|DRUG|Entecavir|Given PO
218934979|NCT03887702|DRUG|Tenofovir Alafenamide|Given PO
218934980|NCT03887702|DRUG|Tenofovir Disoproxil Fumarate|Given PO
218934981|NCT01193257|DRUG|Orteronel|Orteronel tablets
218934982|NCT01193257|DRUG|Prednisone|Prednisone tablets
218934983|NCT01193257|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
218934984|NCT00732407|DRUG|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
218934985|NCT00732407|DRUG|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
218934986|NCT03347292|DRUG|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
218934987|NCT03347292|DRUG|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
218934988|NCT02789267|OTHER|Regular dietary support|Systematic and regular dietary support after radiotherapy
218934989|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing stretching
218934990|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing Ai Chi
218934991|NCT05272345|PROCEDURE|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
218934992|NCT05224167|DRUG|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
218934993|NCT05224167|DRUG|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
218934994|NCT00899496|OTHER|immunological diagnostic method|
219622141|NCT01251874|DRUG|Veliparib|Given PO
218934995|NCT00899496|OTHER|physiologic testing|
218934996|NCT03393247|DRUG|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
218934997|NCT03393247|DRUG|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
218934998|NCT01870934|DEVICE|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
218934999|NCT04381546|OTHER|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
218935000|NCT04988360|DEVICE|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
218935001|NCT04988360|DEVICE|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
218935002|NCT01934647|DRUG|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
218935003|NCT04049409|DRUG|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
218935004|NCT04049409|DRUG|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
219622142|NCT06801665|COMBINATION_PRODUCT|FMT+QL1706+Bevacizumab+XELOX|Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.
219622143|NCT06509009|DRUG|Nimotuzumab|nimotuzumab, toripalimab, gemcitabine, cisplatin
219622144|NCT06382168|DRUG|DFP-10917|DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.
219622145|NCT06382168|DRUG|Venetoclax|Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
219622146|NCT05230628|DEVICE|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
219622147|NCT05230628|DEVICE|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
219622148|NCT05172245|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219622149|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622150|NCT05172245|DRUG|Cisplatin|Given IV
219622151|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219622152|NCT05172245|DRUG|Ipatasertib|Given PO
218935005|NCT04321135|BEHAVIORAL|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
218935006|NCT04321135|BEHAVIORAL|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
218935007|NCT04385693|PROCEDURE|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
219046156|NCT04677556|OTHER|Esogastric pressures measurement|"Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued."
219046157|NCT02895958|DRUG|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
219046158|NCT04721249|DIETARY_SUPPLEMENT|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
219046159|NCT04721249|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
219046160|NCT06267625|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
219046161|NCT00613509|BIOLOGICAL|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
219046162|NCT00613509|BIOLOGICAL|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
219046163|NCT02906774|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
219359925|NCT00001357|DRUG|Interleukin-2|
219359926|NCT01746771|DRUG|HM781-36B(Poziotinib)|QD\*2weeks/3weeks
219359927|NCT01746771|DRUG|Paclitaxel|175mg/m2
219359928|NCT01746771|DRUG|Trastuzumab|8mg/kg
219359929|NCT03303911|DRUG|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
219359930|NCT02949128|BIOLOGICAL|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
219359931|NCT02050412|OTHER|Cat fur scratch test|
219359932|NCT05340920|DIAGNOSTIC_TEST|Oral Food Challenge|diagnostic values of skin prick test and specific IgE for allergy confirmed by oral food challenge (routine, not an intervention)
219359933|NCT02388568|DRUG|Lorcaserin|Lorcaserin plus Lifestyle Modification
219359934|NCT02388568|DRUG|Placebo|Placebo plus Lifestyle Modification
219359935|NCT02788500|OTHER|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
219622153|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622154|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219622155|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
219545194|NCT06999720|DRUG|HX15001 (SAD)|Part A (Single Ascending Dose), participants will receive a single intravenous dose of HX15001 at escalating dose levels in sequential cohorts (Cohorts 1-7).
219545195|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 1-7 of the study.
219622156|NCT03985800|OTHER|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
218935008|NCT04385693|PROCEDURE|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
218935009|NCT02044107|BEHAVIORAL|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
218935010|NCT02058745|BEHAVIORAL|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
218935011|NCT02058745|BEHAVIORAL|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
218935012|NCT02058745|BEHAVIORAL|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
218935013|NCT05710445|OTHER|Augmented Reality|Mixed reality smart glasses will be used to view a virtual monitor which mirrors the ultrasound screen in real-time.
218935014|NCT02816827|DIETARY_SUPPLEMENT|AG-01|Product to increase mental alertness
218935015|NCT02816827|DIETARY_SUPPLEMENT|AG-05|Product to increase mental alertness
218935016|NCT02816827|DIETARY_SUPPLEMENT|AG-06|Product to increase mental alertness
218935017|NCT02816827|DIETARY_SUPPLEMENT|AG-07|Product to increase mental alertness
218935018|NCT00514748|PROCEDURE|DIEP|flap survival, operation time, flap complications, donor site morbidity.
218935019|NCT00514748|PROCEDURE|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
218935020|NCT01949467|DRUG|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
218935021|NCT02836639|DRUG|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
218935022|NCT02836639|DRUG|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
218935023|NCT02836639|DRUG|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
218935024|NCT04473742|BIOLOGICAL|Blood collection|4 EDTA tubes for 24 mL blood collection
218935025|NCT04473742|BIOLOGICAL|Blood sample|2 drying tubes for 12 mL blood collection
218935026|NCT04473742|BIOLOGICAL|Blood sample|1 drying tube for 6 mL blood collection
219545196|NCT06999720|DRUG|HX15001 (MAD)|In Part B (Multiple Ascending Dose), participants will receive multiple intravenous doses of HX15001 in cohorts 8 and 9 to assess safety, tolerability, and pharmacokinetics.
219545197|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 8-9 of the study.
219545198|NCT03756272|PROCEDURE|Bupivacaine block|stellate ganglion bupivacaine injection
219545199|NCT03756272|PROCEDURE|Placebo ganglion block|stellate ganglion sodium chloride injection
218935027|NCT06476639|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound monitoring|Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
219359936|NCT04799041|DRUG|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
219359937|NCT04799041|DRUG|Placebo|There were 15 patients in this group. Each one received only one treatment.
219359938|NCT05812677|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
219359939|NCT03897738|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
219359940|NCT03897738|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
219359941|NCT03897738|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
219359942|NCT04473417|DRUG|Forxiga|single dose administration after 10hr fasting
219359943|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
219359944|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
219359945|NCT04473417|DRUG|DA-2811|single dose administration after high fat and calorie fed diet
219545200|NCT01369368|DRUG|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
219545201|NCT03835767|OTHER|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
219545202|NCT03835767|OTHER|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
219545203|NCT03835767|OTHER|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
219545204|NCT03835767|OTHER|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
219545205|NCT01318369|DRUG|Namisol|Single dose delta-9-tetrahydrocannabinol
219545206|NCT01318369|DRUG|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
219545207|NCT01125072|OTHER|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
219545208|NCT00725322|DRUG|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
219545209|NCT00725322|DRUG|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
219545210|NCT07128082|DRUG|Tirzepatide|The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
219545211|NCT07128082|DRUG|Placebo|Participants in the control group will receive a placebo instead of active study medication for a 12 month period.
219545212|NCT06867822|DRUG|ProAgio|ProAgio is a pegylated protein with a single pegylated site. The 12,131 Dalton protein is produced in E. coli and is composed of 105 amino acids with no disulfide bonds. The structure of the polyethylene glycol moiety is Methoxy PEG maleimide 30000.
219545213|NCT06867822|DRUG|FOLFIRI|FOLFIRI is a combination of three drugs: (leucovorian, fluorouracil, and irinotecan) used to treat advanced metastatic colorectal cancer. FOLFIRI is commercially available will be administered using standard dosing regimen as per institutional guidelines.
219545214|NCT06867822|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab is commercially available and will be administered using standard dosing regimen as per institutional guidelines.
219545215|NCT02818842|OTHER|Primary Health Insurance Fund data|"Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date"
219545216|NCT02818842|OTHER|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
219046164|NCT01877629|DRUG|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
219545217|NCT02818842|OTHER|Mother and child protection data collection|"Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)"
219545218|NCT02818842|OTHER|Medicalisation Program of Information Systems data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)"
219545219|NCT06036134|BEHAVIORAL|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
219545220|NCT06036134|BEHAVIORAL|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
219545221|NCT06036134|BEHAVIORAL|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
219545222|NCT05096286|DEVICE|Ethos Therapy|FDA-approved treatment planning system
219545223|NCT06620939|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
219622157|NCT03985800|OTHER|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
219046165|NCT01877629|DRUG|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
219046166|NCT06383663|PROCEDURE|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
219046167|NCT06383663|RADIATION|radiotherapy|Patients in the control group received only standard radiation therapy.
219205869|NCT06735794|DEVICE|Sham iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-sh (sham comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-sh, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
219046168|NCT06144736|PROCEDURE|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
219205870|NCT06734650|OTHER|peripheral waveform collection|The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
219205871|NCT06735521|DIAGNOSTIC_TEST|Cardiac magnetic resonance stress-perfusion|"Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium.~Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest."
219205872|NCT06734117|DIAGNOSTIC_TEST|Elecsys® Troponin T hs Gen 6|It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.
219205873|NCT06734117|PROCEDURE|Blood sample collection|Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.
219545224|NCT06623591|DEVICE|active Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
219205874|NCT06742099|PROCEDURE|Intercostal chest tube|the use of chest tubes to drain malignant pleural effusion
219205875|NCT06742099|COMBINATION_PRODUCT|Pleurodesis|the injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis
219205876|NCT06743048|PROCEDURE|Tissue Sparing Laser Implantation|A penile implant will be implanted using the cavernosal sparing technique and assisted by a laser fibre optic
219205877|NCT06744205|BIOLOGICAL|Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
219545225|NCT06623591|DEVICE|sham Transcutaneous auricular vagus nerve stimulation|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
219545226|NCT06869057|BEHAVIORAL|REDDCAT2 Post-Discharge Navigation|Those in the REDDCAT2 intervention group will be partnered with a patient navigator whose role will be to review the results of the screening survey completed at the beginning of the study. The patient navigator will help coordinate the participant's care before leaving the hospital and for 90 days after. Together, the participant and navigator will form an action plan intended to help address personal, social, or community factors affecting the participant's health. The navigator is expected to contact the participant every 2 weeks, though this can be adjusted based on their preference.
219046169|NCT06144736|DRUG|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
219046170|NCT04022135|DIETARY_SUPPLEMENT|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
219046171|NCT04022135|DIETARY_SUPPLEMENT|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
219046172|NCT01955057|BEHAVIORAL|Research interviews|
219205878|NCT06744205|BIOLOGICAL|TIV mRNA-neuraminidase (NA)|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
219205879|NCT06744205|BIOLOGICAL|TIV mRNA-HA Vaccine 2|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
219205880|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
219046173|NCT01955057|BEHAVIORAL|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
219046174|NCT01955057|BEHAVIORAL|Projective methods (Thematic apperception Test, Rorschach)|
219046175|NCT01955057|BEHAVIORAL|Carbon monoxide test|
219545227|NCT06869057|OTHER|Treatment as Usual (TAU)|"TAU participants will receive standard care from the UMass Memorial Healthcare (UMMH) hospitalist team as appropriate. Participants will receive a printed list of community resources. No study-related patient navigation support will be provided.~In 2024, Centers for Medicare and Medicaid Services mandated social determinants of health (SDOH) screening for inpatients. UMMH will use a checklist social needs screener. It will be up to the hospitalist teams to act on SDOH screening results. The UMMH hospitalist teams may consult endocrinology and/or inpatient social services to provide support and consultation for all patients regardless of study participation or group assignment. If medically appropriate, the endocrinology service may manage medications and provide referrals for continued treatment post discharge. All services that are normally provided by hospital care teams will remain available."
218935028|NCT03104660|DEVICE|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
218935029|NCT05767879|DRUG|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
219545228|NCT06679582|DRUG|Luveltamab tazevibulin|"Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.~Other Names:~* STRO-002~* Luvelta"
219545229|NCT01350557|OTHER|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
218935030|NCT04619160|DRUG|Propofol|TCI 4 µg/mL start until BIS-value of 50
218935031|NCT04619160|DRUG|Sevoflurane|start 1 MAC, until BIS-value of 50
218935032|NCT01638442|DRUG|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
218935033|NCT01638442|DRUG|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~\--------------------------------------------------------------------------------"
218935034|NCT04768608|DRUG|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
218935035|NCT05296395|OTHER|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
218935036|NCT05296395|OTHER|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
219046176|NCT04692337|PROCEDURE|Intra-operative Ommaya Reservoir placement|An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
219046177|NCT06418386|PROCEDURE|manual saline IA|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution, All carious tissue will be removed by hight speed handpiece, distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min ,The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium),using manual k file starting with #15 and irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
219545230|NCT01350557|OTHER|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
219622164|NCT05799378|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
219622165|NCT05799378|DRUG|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
218935037|NCT03437590|DRUG|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
218935038|NCT03437590|DRUG|[18F]-JNJ-64413739|\[18F\]-JNJ-64413739 fluid for injection administered intravenously.
218935039|NCT04059315|OTHER|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
218935040|NCT05862168|DRUG|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
218935041|NCT05862168|DRUG|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
218935042|NCT05862168|DRUG|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
218935043|NCT05862168|DRUG|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
218935044|NCT05284526|OTHER|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
218935045|NCT01903980|OTHER|No intervention. It is a retrospective study|No intervention. It is a retrospective study
218935046|NCT05433844|DRUG|Reference Drug or Test Drug|"Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
218935047|NCT02606149|BEHAVIORAL|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
218935048|NCT02606149|BEHAVIORAL|Standard of information|
218935049|NCT01828151|DEVICE|Noninvasive ventilation mask|
219545231|NCT05331508|BEHAVIORAL|gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)|Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
218935050|NCT04625517|PROCEDURE|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
219545232|NCT00905528|DRUG|Telmisartan 80 mg/d|
219545233|NCT00905528|DRUG|Ramipril 10 mg/d|
219545234|NCT06223932|DRUG|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
219545235|NCT04774705|OTHER|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
219545236|NCT04774705|OTHER|Placebo group|For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
219545237|NCT03010098|DEVICE|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
219545238|NCT03010098|DEVICE|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
219545239|NCT03651219|DRUG|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
219545240|NCT03651219|DRUG|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
219545241|NCT05811689|DIAGNOSTIC_TEST|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). \[10\] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
219545242|NCT02252120|DEVICE|Supreme|
219545243|NCT02252120|DEVICE|Laryngeal Tube|
219545244|NCT01126463|DRUG|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
219545245|NCT06683846|DRUG|Ivocizumab|Administered via intravenous (IV) infusion
219545246|NCT05288686|PROCEDURE|sentinel lymph node biopsy procedure|Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
219622166|NCT05559580|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
219622167|NCT05559580|DRUG|Placebo|Placebo
219622168|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
219622169|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
219622170|NCT05632484|BIOLOGICAL|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
219622171|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
219622172|NCT04324606|BIOLOGICAL|MenACWY|Standard single dose of MenACWY vaccine delivered intramuscularly
219622173|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 full boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
219622174|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 half boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
218935051|NCT04625517|DRUG|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
219622175|NCT04324606|BIOLOGICAL|MenACWY boost|A standard dose of MenACWY followed by a boost dose of MenACWY
219622176|NCT04324606|DRUG|Paracetamol|1g every 6 hours for 24 hours
219622177|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
219622178|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
219622179|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
219622180|NCT05773404|OTHER|Passive Neurodynamics and Passive axial hip mobilisation/distraction|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
219622181|NCT05773404|OTHER|Active therapy|Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
219622182|NCT05773404|OTHER|2.5.3. Combined therapy|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
218935052|NCT00441064|DRUG|Aliskiren|
219205881|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Vaccine High Dose|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
219545247|NCT07015086|BEHAVIORAL|Guided Imagery and Positive Birth Experience Sharing|The positive experience will be shared by one of the researchers and the pregnant women's questions will be answered after the sharing. The mental imagery techniques prepared by Rossman (2015) to facilitate birth will be used for the mental imagery application. After the training, the mental imagery instructions will be given to the pregnant women as an audio recording in mp3 format. The pregnant women will be asked to do the mental imagery once or twice a day for at least 8 weeks. The mental imagery application takes approximately 20 minutes. The pregnant women will be reminded to do the application every day via the Whatsapp® application. The pregnant women will be asked to mark whether they do the application every day or not on the weekly follow-up chart.
219545248|NCT06415903|DRUG|TQB3117 tablets|TQB3117 is a protein inhibitor.
219046178|NCT06418386|PROCEDURE|manual neem IB|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by high speed hand piece~  , distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with neem leaf extract 100%~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
219545249|NCT00880139|PROCEDURE|Blood sampling|Determination of cytokine plasma levels (ELISA)
219545250|NCT00880139|PROCEDURE|Noninvasive measurement of systemic hemodynamics|performed once
219545251|NCT00880139|PROCEDURE|Visual acuity assessment|ETDRS charts
219545252|NCT00880139|DEVICE|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
219545253|NCT00880139|PROCEDURE|Ophthalmic examination and fundus photography|7 + 1 standard fields
219545254|NCT00880139|DEVICE|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
219545255|NCT00880139|DEVICE|High resolution optical coherence tomography (OCT)|performed once
219545256|NCT00926887|DEVICE|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
219545257|NCT00926887|DEVICE|Placebo Laser|Inactive light
219046179|NCT06418386|PROCEDURE|manual sodium hypochlorite IC|"* adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by hight speed hand piece~* distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
219046180|NCT06418386|PROCEDURE|rotary saline IIA|"* shaping and cleaning done with using AF baby fanta files open file:#17 taper 08,then #20 taper 04 ,yellow then #25 taper 04 red , then #30 taper 04 blue . the files activated with torque 2 and speed 350 . Irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then restored with glass inomar and stainless steel crown"
219046181|NCT06418386|PROCEDURE|rotary neem IIB|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by high speed hand piece ,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS METION BEFORE ,and irrigation with 100%neem extract~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
219046182|NCT06418386|PROCEDURE|rotary sodoium hypochlorite IIC|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by hight speed hand piece,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS MENTION BEFORE , and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
219046183|NCT04954742|DRUG|Riociguat|Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
219046184|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
219205882|NCT06739629|OTHER|Insect porridge|Yellow mealworm porridge
219545258|NCT00440934|DEVICE|Amplitude-modulated electromagnetic fields|
219545259|NCT04454307|DRUG|Tramadol|tramadol 100 mg twice daily for 10 days
219545260|NCT04454307|OTHER|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
219545261|NCT02584608|DRUG|ACTIMMUNE|
219545262|NCT04198363|DRUG|Vonoprazan|Vonoprazan Tablets
219545263|NCT04198363|DRUG|Amoxicillin|Amoxicillin Capsules
219545264|NCT04198363|DRUG|Clarithromycin|Clarithromycin Tablets
219545265|NCT04198363|DRUG|Bismuth Potassium citrate|Bismuth Potassium citrate
219545266|NCT04198363|DRUG|Esomeprazole|Esomeprazole Tablets
219545267|NCT04534790|RADIATION|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
219545268|NCT04893408|OTHER|observational study|
219545269|NCT05204368|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
219545270|NCT05204368|DRUG|Meropenem|Meropenem 1g for injection
219545271|NCT04739358|DRUG|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
219545272|NCT05344118|OTHER|Survey|REDCap survey
219622183|NCT05867849|DRUG|Cannabidiol|Cannabinoid
219622184|NCT05867849|OTHER|Placebo|Inactive substance
219622185|NCT05904626|DRUG|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
219622186|NCT05904626|DRUG|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
219622187|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
219622188|NCT06320938|OTHER|Neuroscience-Based Pain Education Combined with Home Exercise Program|Neuroscience-Based Pain Education and Home Exercises will be applied.
219622189|NCT06320938|OTHER|Myofascial Induction Techniques Combined with Home Exercise Program|Myofascial Induction Techniques and Home Exercises will be applied.
219046185|NCT06329102|PROCEDURE|Surgical access|Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
219046186|NCT02549508|DEVICE|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
219545273|NCT00004398|DRUG|heme arginate|
219046187|NCT02549508|DEVICE|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
219046188|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
219205883|NCT06739629|OTHER|Maize Porridge|Maize porridge
219545274|NCT00004398|DRUG|tin mesoporphyrin|
219545275|NCT03067987|DEVICE|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
219545276|NCT03442322|OTHER|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
219545277|NCT03442322|OTHER|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
219545278|NCT05713058|BEHAVIORAL|eTRC diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
219545279|NCT05713058|BEHAVIORAL|Control diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
219545280|NCT02082808|DRUG|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
219545281|NCT02082808|DRUG|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
219545282|NCT06022146|DRUG|Rifampin and Isoniazid|3HR regimen of isoniazid and rifampicin once daily for three months
219545283|NCT06022146|DRUG|isoniazid and rifapentine|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
219545284|NCT01439451|PROCEDURE|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
219545285|NCT05238857|OTHER|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
219622190|NCT06320938|OTHER|Home Exercises Group|Home Exercises wiil be applied
219622191|NCT06484660|PROCEDURE|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
219545286|NCT07064603|PROCEDURE|TCAF|tunnel coronal advanced flap
219545287|NCT07067099|BIOLOGICAL|Plasma with neutralizing autoantibodies to Type I Interferons|Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies
219545288|NCT07067216|OTHER|Designed scapular stabilization using pressure biofeedback|Patients will attend 1-hour physical therapy sessions twice weekly for 6 weeks. The program will include posterior capsule mobilization, scapular stabilization using pressure biofeedback (targeting lower trapezius, latissimus dorsi, pectoralis major, deep cervical flexors, and scapular retractors), and strengthening exercises using therabands: external rotation, shoulder diagonals, rows, and extensions. Additional training will involve physioball scapular exercises (up/down \& side/side), prone scapular strengthening (e.g., TYI, superman), and scapular-clock drills to improve mobility, proprioception, and stability.
219545289|NCT07067216|OTHER|Designed physical therapy program|Patients will receive cryotherapy and perform stretching exercises for the pectoralis minor and posterior capsule. Strengthening exercises using theraband will target the rotator cuff (especially external rotators) and scapular depressors/retractors. Scapular stabilization will be trained through prone exercises on a ball (T, Y, W) and on a plinth, including rowing, horizontal abduction, extension, superman, and TYI exercises. Additionally, patients will perform the scapular-clock exercise to enhance mobility, control, and proprioception.
219545290|NCT07067658|DEVICE|Installation of Heartfelt Device|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
219545291|NCT07067658|OTHER|Enhanced Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation. At the start of the study, they will be reminded (or told) about the importance of self-checks and will be handed a patient booklet (from the British Heart Foundation) to standardise patients' knowledge.
219545292|NCT07067658|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
219545293|NCT07067658|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts on the active comparator arm to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
219545294|NCT07067710|OTHER|Motor imagery combined with action observation|To observe and imaging one action with a video resource. Not virtual reality.
219545295|NCT07068022|OTHER|Organ dysfunction score adjusted to obstetric patients (SOFA-OBS)|The obstetric SOFA (SOFA-OBS) adjusts renal and cardiovascular variables to physiological changes of pregnancy. Moreover, it simplifies respiratory evaluation, in terms of replacing arterial blood gases (ABG) for peripheral oxygen saturation/fraction of inspired oxygen (spO2/FiO2), when ABGs were not available. Variables unchanged during pregnancy (neurologic, hepatic and platelets), won't be modified.
219545296|NCT07067944|DRUG|Ephedrine|The parturient will receive ephedrine infusion immediately before intrathecal injection till delivery of the baby at a dose of 4mg /min.
219545297|NCT07067944|DRUG|Noradrenaline|The parturient will receive noradrenaline infusion immediately before intrathecal injection till delivery of the baby at a dose of 4 microgram/minute.
219545298|NCT06900933|PROCEDURE|Onlay bone block covered with collagen membrane|Onlay bone block covered with collagen membrane
219545299|NCT06900933|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block covered without collagen membrane
219545300|NCT07068737|BEHAVIORAL|bathing care package|Participants receive a bathing care package that includes a swaddled immersion bath. Room temperature is maintained at 26-27°C with 40-60% humidity. Bath water temperature is controlled at 37-38°C. The infant is swaddled and immersed in water up to the shoulders while the head remains above water. The bath lasts no longer than 5 minutes. After bathing, the infant is gently dried without rubbing, wrapped in a towel, and placed in a pre-warmed incubator (31-34°C) for 10 minutes.
219545301|NCT07068737|BEHAVIORAL|routine bath|Participants receive routine bathing care according to NICU standards. This includes hand hygiene before the procedure, preparing necessary materials, placing the infant in a mesh sling in the bath, washing the body from clean to dirty areas with soft sponges and hospital-provided cleansing agents. The bath lasts up to 10 minutes. After bathing, the infant is quickly dried without rubbing and then diapered.
219545302|NCT07068659|OTHER|Circuit Aerobic Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute aerobic portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 3 - 4, participants will complete two circuits of walking for 4 1/2 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 5 - 6, participants will complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 5 minutes, and walking backward and forward for 10 meters for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. The intensity of the aerobic exercises will be maintained at 9 - 15 on the rating of
219549906|NCT01958476|DRUG|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally \>8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
218935053|NCT00903188|DRUG|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
219205884|NCT06737068|PROCEDURE|Low pressure pneumoperitoneum (8-10mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with low pressure pneumoperitoneum (8-10mmHg) with AirSeal device
219545303|NCT07068659|OTHER|Circuit Resistance Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute resistance portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 3 - 4, participants will complete two circuits of hamstring curl with ankle weight on each leg for 4 1/2 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 5 - 6, participants will complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 5 minutes, and modified squats with weights for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. Ch
218935054|NCT00903188|DRUG|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
218935055|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
218935056|NCT00953056|BIOLOGICAL|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
218935057|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
218935058|NCT00953056|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
218935059|NCT01842217|PROCEDURE|FES-PET|
218935060|NCT03962504|BEHAVIORAL|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
218935061|NCT02943434|OTHER|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
218935062|NCT01646229|OTHER|Polymyxin-B hemoperfusion|
218935063|NCT01646229|OTHER|Control|
218935064|NCT00889720|DRUG|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
218935065|NCT01327482|DRUG|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
218935066|NCT00476229|DRUG|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
219545304|NCT07068009|BEHAVIORAL|Training and Support Programme on Data-driven Quality Development|"The training and support program uses a train-the-trainer strategy.~The research team:~* develop training and support materials~* organize an e-mail helpdesk support~* organize and conduct the scientific examination~The external training providers:~\- train the management representatives and the quality leaders.~The quality leader and the manager:~* elaborate and test a quality development project based on one MQI with PDCA cycle~* animate interprofessional meetings~* organize a collective workshop with residents and relatives~* engage residents and relatives in individual conversations by testing a brochure"
218935067|NCT00476229|RADIATION|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
218935068|NCT00476229|PROCEDURE|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
218935069|NCT00476229|DRUG|Rituximab|375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
218935070|NCT06338969|OTHER|Carbohydrate Restriction after a Gastric Bypass|"All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates."
218935071|NCT04680182|PROCEDURE|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
218935072|NCT01776216|OTHER|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
218935073|NCT01776216|OTHER|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
218935074|NCT00019201|OTHER|cytology specimen collection procedure|
219545305|NCT07068256|DRUG|Terbinafine|Terbinafine will be given at a dose of 62.5 mg in patients with a body weight \< 20 kg, 125 mg from 20 to 40 kg, and 250 mg in \> 40 kg for a period of 4 weeks.
219545306|NCT07068256|DRUG|Itraconazole|Itraconazole will be given at a dose of 5 mg/kg/day for 7 days and then 14 days off. Three such pulses will be given to the patients.
218935075|NCT00019201|OTHER|immunohistochemistry staining method|
218935076|NCT00019201|OTHER|sputum cytology|
218935077|NCT00019201|PROCEDURE|bronchoscopic and lung imaging studies|
218935078|NCT00019201|PROCEDURE|bronchoscopy|
218935079|NCT00019201|PROCEDURE|comparison of screening methods|
218935080|NCT00019201|PROCEDURE|endoscopic biopsy|
218935081|NCT02164461|BIOLOGICAL|Axalimogene filolisbac|
218935082|NCT06160648|OTHER|Management according to Mechanical Diagnosis and Therapy|MDT management is based on the patient response to repeated end range movements.
218935083|NCT06160648|OTHER|Management according to the Cervical Spine Clinical Practice Guidelines|CPG management is based on clinical research regarding management of people with neck pain.
218935084|NCT00078897|DRUG|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
219205885|NCT06737068|PROCEDURE|Standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
219205886|NCT06740604|DEVICE|BSD-10CH|The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
219205887|NCT06740604|DEVICE|Sham BSD-10CH|The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
219205888|NCT06738992|DRUG|Aspirin|Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
219545307|NCT07069491|DEVICE|Sphygmomanometer|Blood pressure measurement by Sphygmomanometer
219545308|NCT07069387|BEHAVIORAL|CARE-TB digital adherence package|CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients.
219545309|NCT07069387|BEHAVIORAL|Standard Care|Directly observed therapy at any government healthcare facility (by nurses) or at home (by caretaker)
219545310|NCT07068789|PROCEDURE|balloon angioplasty|endovascular angioplasty of infrapopliteal arteries performed using standard balloon catheters under fluroscopic guidance to restore blood flow to the ischemic area
219622192|NCT06253104|DIAGNOSTIC_TEST|BodyMetrix Body Composition Ultrasound|We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
219622193|NCT03317392|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219622194|NCT03317392|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218935085|NCT03865381|DEVICE|Onduo App|The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
219205889|NCT06738992|DRUG|Warfarin|Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
219205890|NCT06735313|DIAGNOSTIC_TEST|Periodontal examination and saliva collection|Before the periodontal examination, saliva samples are collected from each patient participating in the study and periodontal measurements are made.
219205891|NCT06736145|OTHER|Traditional Physical Therapy|"Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
219622195|NCT03317392|PROCEDURE|Computed Tomography|Undergo CT
219622196|NCT03317392|OTHER|Laboratory Biomarker Analysis|Correlative studies
219622197|NCT03317392|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622198|NCT03317392|DRUG|Olaparib|Given PO
219622199|NCT03317392|OTHER|Quality-of-Life Assessment|Ancillary studies
219622200|NCT03317392|RADIATION|Radium Ra 223 Dichloride|Given IV
219622201|NCT04199676|DIAGNOSTIC_TEST|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
219622202|NCT03753490|OTHER|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
218935086|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
218935087|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
218935088|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
218935089|NCT03824145|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
219205892|NCT06736145|OTHER|Mulligan Glides|"Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.~Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
219545311|NCT06716424|DRUG|iGlarLixi (insulin glargine/lixisenatide)|iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
219545312|NCT07068516|DRUG|Tislelizumab|Received tislelizumab combined with investigator's choice of chemotherapy
219545313|NCT07068516|DRUG|SOX or CAPOX regimen|chemotherapy (SOX or CAPOX regimen)
219545314|NCT07069530|BEHAVIORAL|Receptive Music Therapy|Participants received six 30-minute sessions of receptive music therapy delivered by live solo piano performance over two weeks. The same playlist was performed in a fixed order at each session, held one hour before dinner. The intervention was designed to reduce depressive symptoms in dementia patients and alleviate caregiver burden using a structured, low-cost, non-pharmacological approach.
219545315|NCT07068841|DRUG|sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3|"Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.~Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3."
219545316|NCT07069543|PROCEDURE|Adenotonsillectomy|the adenotonsillectomy group children, indicated for immediate adenotonsillectomy
219205893|NCT06735157|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (intermittent theta burst stimulation) will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby iTBS will be delivered three times during the same study session. Each iTBS session will deliver 600 pulses in 50 Hz bursts of 3 pulses for a total of 1800 pulses delivered each day. iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
219205894|NCT06735157|BEHAVIORAL|Augmented reality vestibular rehabilitation therapy|Participants will complete the vestibular training through Nreal Air AR Glasses (Nreal, China). The vestibular training task was custom-made in Unity V2021.3.14fI software using C+ script language. Participants will be standing upright for the AR training, with a safety bar positioned directly in front of them should they need to hold onto something. A large cross-shaped target will be positioned approximately 3 feet in front of the participant's head with its vertical center aligned with the participant's midline. This will act as a visual starting point. The training is adapted from clinical vestibular rehabilitation training methods used in PCD. The vestibular training task consists of locating and tracking a series of moving 3-dimensional balls presented at random within the participant's field of view.
219205895|NCT06735157|DEVICE|SHAM repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be delivered using a Magstim Rapid 2 sham stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of sham stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby sham iTBS will be delivered three times during the same study session. Each sham iTBS session will sound and feel identical to real iTBS delivery, but will not deliver a stimulating current. Sham iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Sham stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of sham iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
219205896|NCT06734663|PROCEDURE|Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision|Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.
219205897|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft suturing|pterygium is surgically removed, and a conjuctival graft is placed on bare sclera using sutures to surrounding conjuctiva.
219205898|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft placement by autologous blood|pterygium is surgically removed and a conjuctival graft is placed on bare sclera on which the patient's blood remains. the graft is left without sutures, adhering only by autologous blood.
219545317|NCT07069543|PROCEDURE|Rapid maxillary expansion|expansion group children with a narrow palate and posterior crossbite, with indication for rapid maxillary expansion
219545318|NCT07068217|OTHER|Exercise|"Sample size was determined via G\*Power analysis: two groups (n=13 each), total n=26. Participants will be randomized using Random.org into the Rhythmic Exercise Group (REG) or the Exercise Group (EG).~Both groups will receive a supervised home-based exercise program, overseen via telerehabilitation. Exercises will be performed 3 times per week for 45-60 minutes each session, over 4 weeks (12 sessions total). Progression to the next week's program will require an 80% success rate; otherwise, the same week's program will be repeated. Online supervision will monitor weekly performance."
219622203|NCT03753490|OTHER|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
219205899|NCT06306534|OTHER|Auditory Nerve Acute (ANA) Electrode Array|To measure eABRs when stimulating the human auditory nerve
219545319|NCT07068048|DRUG|Dexametasone|"Intra-operatively, all participants recruited must have the recurrent laryngeal nerve identify and confirm with Intraoperative Nerve Monitoring (IONM) device.~After removal of thyroid gland, 8mg of dexamethasone will be diluted in 100cc of irrigation water and irrigate the operative field for 1 minute for the intervention group."
219205900|NCT06741800|DRUG|ACARIZAX®️|ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
219205901|NCT06743438|DRUG|Tenofovir Amibufenamide（TMF）|Once-daily oral dose of 25 mg TMF were maintained in all participants
219545320|NCT07068048|DRUG|Water for injection|For the placebo group, they will received water irrigation over the operative field only which is the current standard of practice at the moment.
219622204|NCT04643015|DIAGNOSTIC_TEST|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
219622205|NCT06325020|OTHER|The assessment of patients with possible angina using the ORACLE pathway|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
219205902|NCT06743139|DIAGNOSTIC_TEST|Echography|Simultaneous performance of an echocardiogram (part of the follow-up assessment for sickle cell heart disease) at rest and then during the cardiorespiratory stress test, and an ear capillary lactatemia analysis (already routinely performed to ensure the safety of the cardiorespiratory stress test) during the cardiorespiratory stress test routinely performed at Mondor University Hospital prior to cardiovascular rehabilitation programs.
219545321|NCT07067125|BEHAVIORAL|AR-Supported Scoliosis-Specific Physiotherapy|This intervention consists of scoliosis-specific physiotherapy supported by AR technology. Participants will engage in postural correction exercises delivered by licensed physiotherapists using an AR system that provides real-time avatar feedback, movement guidance, and gamified motivation. The intervention aims to improve body awareness, adherence, and motivation among adolescents diagnosed with AIS. Each participant will complete at least four weeks of structured AR-supported sessions.
219545322|NCT07068685|OTHER|Suicide risk prediction algorithm|Use of a suicide risk prediction algorithm, developed by the Mental Health Research Network (MHRN), will be used to prompt additional mental health monitoring. Mental health monitoring will include asking patients about suicidal thoughts (via the ninth question of the Patient Health Questionnaire-9, PHQ-9), followed by suicide risk assessment (via use of a brief self-administered version of the Columbia Suicide Risk Severity Rating Scale, C-SSRS), followed by Safety Planning with a designated member of the primary care team.
219545323|NCT07068178|DRUG|ICI-HIPET|Patients received the following interventions: On Day 0, intravenous administration of tislelizumab (an anti-PD-1 immune checkpoint inhibitor) was initiated within 3 hours post-HIPEC. Tumor tissue samples were collected before HIPEC, at 30 minutes, 60 minutes, and 90 minutes (end of HIPEC). Serum samples were collected pre- and post-HIPEC. On Day 1, additional serum samples were collected 24 hours after HIPEC-ICI completion. From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy, with serum sampling repeated at 48 hours post-HIPEC-ICI. On Days 21 and 42, the second and third cycles of neoadjuvant chemotherapy (tislelizumab + paclitaxel + carboplatin) were administered intravenously.
219545324|NCT07067385|BIOLOGICAL|Neoantigen Personalized Cancer Vaccine|Cohort 1: subjects will receive neoantigen tumor vaccine combination with Sintilimab. Cohort 2: subjects will receive neoantigen tumor vaccine combination with Sintilimab and chemotherapy .
219545325|NCT07067333|DEVICE|intramedullary nails for group A|fixation of the shaft femure fracture in this group by intramedullary nails
219545326|NCT07067333|DEVICE|plate for group B|fixation of the shaft femure fracture in the group b by plates
219545327|NCT07069478|OTHER|Stress Intervention|Experimental Stress: Behavioral induction of acute psychosocial and physiological stress. First, participants will be provided with a speech topic and given 4 minutes to prepare a speech that they subsequently deliver in front of evaluators and a video recorder. Then, participants will complete a mental arithmetic task in front of the evaluators for 8 minutes. Then, participants will complete a cold pressor task in which they submerge their hand in ice water for 90 seconds.
219545328|NCT07067580|OTHER|respiratory exercise|The experimental group will be trained on respiratory exercises by the researcher the day before the surgery. The patients will be asked to perform the post-operative respiratory exercises as 1 set (4 breaths) per hour. The patient's vital signs will be monitored before and after the respiratory exercise. Patients will not have difficulty during the respiratory exercise, they will be asked to do it gradually.
219545329|NCT07069608|DIETARY_SUPPLEMENT|Cheers Restore|Cheers Restore contains a formulation of antioxidants, electrolytes, and plant-based compounds designed to support physiological resilience and sleep recovery after alcohol consumption. This study is structured to evaluate Cheers Restore in a real-world setting without introducing investigational or therapeutic claims.
219545330|NCT04284319|PROCEDURE|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
219545331|NCT06891261|DEVICE|Piezo Surgery.|Piezotome woodpecker®: Surgic touch.
219545332|NCT06891261|PROCEDURE|Bone Discs.|bone discs mounted on staight hand piece and contra angled 1:1 gear ratio.
219205903|NCT06743113|DEVICE|Hemanext ONE System|Hypoxic red blood cells
219205904|NCT06743113|DEVICE|Conventional RBCs|Conventional red blood cells
219545333|NCT06930794|DRUG|Vebreltinib combined with platinum-based doublet chemotherapy.|"Vebreltinib: Each cycle is 3 weeks (21 days). It is administered orally twice a day (BID), and the dosage level depends on the cohort assignment.~Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment."
219545334|NCT06930794|DRUG|platinum-based doublet chemotherapy.|Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment.
219545335|NCT02111694|BEHAVIORAL|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
219549907|NCT00085501|DRUG|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
219549908|NCT00085501|DRUG|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
219549909|NCT00085501|DRUG|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
219205905|NCT06353334|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
219549910|NCT00290927|DRUG|insulin glulisine|
219545336|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
219545337|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
219545338|NCT06882018|OTHER|Repeated practice guided by peers|"This approach involves repeated, peer-guided practice. Each session will involve two participants, who will support each other using the feedback grid from the first section of the Neonatal Mask Ventilation Competency Assessment Tool developed by DiLabio et al. (2018) to provide feedback on practicing technical skills."
219545339|NCT06882018|OTHER|Instructor-guided deliberate practice|In this group, practice is deliberate (PD) and is led by an instructor. Each session will be supervised by an instructor for two to four participants, and the latter will use the same feedback grid as that used in the intervention group to provide feedback.
219545340|NCT01404988|BEHAVIORAL|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
219545341|NCT01404988|BEHAVIORAL|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
219545342|NCT01404988|OTHER|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
219545343|NCT06911567|DRUG|TEV-56286 Test|Administered orally
219545344|NCT06911567|DRUG|TEV-56286 Reference|Administered orally
219549911|NCT03647722|OTHER|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
219549912|NCT04915339|BEHAVIORAL|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
218935090|NCT03824145|BEHAVIORAL|Attention Control|"The attention control participants will receive a home/work organization intervention:~Following completion of the attention control home/work organization program and 16-week assessment, women will receive the lifestyle program."
218935091|NCT02606084|DRUG|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
218935092|NCT05268497|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
218935093|NCT05268497|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
218935094|NCT05268497|DRUG|Antidepressant|Antidepressant will be administered orally.
218935095|NCT04003038|PROCEDURE|Negative Pressure Wound Therapy|Receive wound care with NPWT
218935096|NCT04003038|PROCEDURE|Wound Care Management|Receive wound care with a standard dressing (bandage)
219549913|NCT04915339|BEHAVIORAL|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
219549914|NCT04915339|BEHAVIORAL|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
218935097|NCT04338802|DRUG|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
218935098|NCT04338802|OTHER|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
218935099|NCT02196662|DRUG|IBD98-M:|single adiministration
218935100|NCT02196662|DRUG|IBD98-M without HA|single adiministration
218935101|NCT02196662|DRUG|Delzicol|single adiministration
218935102|NCT05079243|BIOLOGICAL|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
219046189|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
219545345|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
219549915|NCT01691612|BIOLOGICAL|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
219549916|NCT02152618|OTHER|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
219549917|NCT03563443|DIAGNOSTIC_TEST|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
219549918|NCT03010605|DEVICE|Measuring Every Day Device|
219622206|NCT04815083|DRUG|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
219622207|NCT04815083|DEVICE|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
218935103|NCT04422483|OTHER|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
218935104|NCT00666016|DRUG|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
218935105|NCT03174730|BEHAVIORAL|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
219549919|NCT03010605|OTHER|Physical Therapy|
218935106|NCT03174730|BEHAVIORAL|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
218935107|NCT01214733|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
218935108|NCT00249899|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
218935109|NCT00249899|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
218935110|NCT02785523|DRUG|Ganoderma Spore Lipids|
218935111|NCT02785523|DRUG|Placebo|
218935112|NCT02785523|DRUG|Chemotherapy|
218935113|NCT05744843|BEHAVIORAL|exercise|cardiovascular and lower limb strengthening exercise programme
218935114|NCT05744843|PROCEDURE|Deep venous stenting|Planned surgical intervention
218935115|NCT05045495|DIAGNOSTIC_TEST|Sucrose Hydrogen Methane Breath Test|Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
218935116|NCT00135499|DRUG|Rituximab|375 mg/m², D1, 4 cycles
218935117|NCT00135499|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
218935118|NCT00135499|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
218935119|NCT00135499|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
218935120|NCT00135499|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
218935121|NCT00135499|DRUG|Prednisone|60 mg, D1-D5, 4 cycles
218935122|NCT00135499|DRUG|Prednisone|40 mg, D1-D5, 4 cycles
218935123|NCT00135499|DRUG|Doxorubicin|50 mg/m², D1, 4 cycles
219046190|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
219046191|NCT02448875|DEVICE|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
219046192|NCT02448875|DEVICE|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
219549920|NCT03588260|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
219549921|NCT00002160|DRUG|Ziconotide|
219549922|NCT02032927|DRUG|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
219205906|NCT06353334|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
219205907|NCT04403438|OTHER|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
219545346|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
219545347|NCT00681161|OTHER|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
219545348|NCT06425302|DRUG|Golcadomide|Specified dose on specified days
219545349|NCT06425302|DRUG|Rituximab|Specified dose on specified days
219545350|NCT06425302|DRUG|Cyclophosphamide|Specified dose on specified days
219545351|NCT06425302|DRUG|Doxorubicin|Specified dose on specified days
219545352|NCT06425302|DRUG|Vincristine|Specified dose on specified days
219545353|NCT06425302|DRUG|Prednisone|Specified dose on specified days
219545354|NCT06425302|DRUG|Bendamustine|Specified dose on specified days
219545355|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
219545356|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
219545357|NCT04594252|DRUG|ALXN1840|Administered orally as tablets.
219545358|NCT01677754|DRUG|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
219545359|NCT01677754|DRUG|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
219622208|NCT04815083|DRUG|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
219622209|NCT06023069|OTHER|Number of steps recorded by mobile phone as a proxy for physical activity|This cohort is likely to have patients with many steps/day (high activity) and few steps/day (low activity)
219622210|NCT06251323|OTHER|iPATH implementation approach|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.
219622211|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
219622212|NCT04465409|DEVICE|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
218935124|NCT00135499|DRUG|Cyclophosphamide|750 mg/m², D1, 4 cycles
218935125|NCT00135499|DRUG|Vincristine|1.4 mg/m², D1, 4 cycles
218935126|NCT00618228|DRUG|Balsalazide|
218935127|NCT02094157|DRUG|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
218935128|NCT02094157|DRUG|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
218935129|NCT01055431|OTHER|Control bread|Control bread
218935130|NCT01055431|OTHER|Teff Bread|Teff bread
218935131|NCT03846908|OTHER|MCT|patients will receive fat load with MCT
218935132|NCT03846908|OTHER|SFA|patients will receive fat load with SFA
218935133|NCT03846908|OTHER|MUFA|patients will receive fat load with MUFA
218935134|NCT01519167|DRUG|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
218935135|NCT01519167|DRUG|Midazolam|0.025 - 2 mg/kg IV
218935136|NCT01519167|DRUG|Fentanyl|0.5 - 3 mcg/kg IV
218935137|NCT05744674|DRUG|HR18034|HR18034 228mg/342mg/456mg
218935138|NCT05744674|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
218935139|NCT01175499|DEVICE|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
219205908|NCT05862636|BEHAVIORAL|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
219545360|NCT01677754|DRUG|Donepezil|Stable dose as background medication
219545361|NCT01677754|DRUG|Memantine|Stable dose as background medication in combination with AChEIs
219545362|NCT01677754|DRUG|Rivastigmine|Stable dose as background medication
219545363|NCT01677754|DRUG|Galantamine|Stable dose as background medication
219545364|NCT03922490|DEVICE|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
219545365|NCT03922490|PROCEDURE|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
219545366|NCT02794584|DRUG|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
219545367|NCT02794584|PROCEDURE|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
219545368|NCT02794584|PROCEDURE|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
219545369|NCT03705117|BIOLOGICAL|V565|Capsules for oral administration
219545370|NCT04935554|OTHER|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
219545371|NCT03191305|DRUG|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
219545372|NCT03191305|DRUG|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
218935140|NCT01175499|DEVICE|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
218935141|NCT02654769|DRUG|Ingenol Mebutate (Picato®)|Brand product
218935142|NCT02654769|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
218935143|NCT02654769|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
218935144|NCT00557713|DRUG|bevacizumab|"1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
218935145|NCT02602210|DRUG|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
218935146|NCT02602210|DRUG|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
218935147|NCT00556504|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
218935148|NCT00556504|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
218935149|NCT00556504|DRUG|Ribavirin|conventional treatment of Hepatitis C
218935150|NCT00556504|DRUG|Placebo|Placebo, without acting ingredient.
218935151|NCT02932241|BEHAVIORAL|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
218935152|NCT00158496|DRUG|pegylated interferon alpha2a|
218935153|NCT00158496|DRUG|ribavirin|
218935154|NCT00565188|DRUG|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
218935155|NCT05808543|OTHER|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
219046193|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
219046194|NCT04989946|DRUG|Degarelix|standard Gonadotropin-releasing hormone (GnRH) antagonist
219046195|NCT04989946|BIOLOGICAL|pTVG-AR|DNA vaccine encoding androgen receptor ligand-binding domain
219545373|NCT01802645|DRUG|Cetuximab|
219545374|NCT01802645|DRUG|Bevacizumab|
219545375|NCT01802645|DRUG|Irinotecan|
219545376|NCT01802645|DRUG|Oxaliplatin|
219545377|NCT01802645|DRUG|5-FU|
219545378|NCT01802645|DRUG|Folinic Acid|
219545379|NCT06503666|BEHAVIORAL|ZAIMARA|"The ZAIMARA curriculum focuses on strengthening communication between adolescent girls and young women (AGYW) and their mother figures (MF) to make healthy sexual decisions, to learn more about HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP). The topics in the curriculum focus on effective communication, mothers talking to daughters on sex, HIV, STIs and PrEP. The intervention consists of participants attending a two day workshops with their MF.~Other names:~ZAIMARA"
219545380|NCT06503666|BEHAVIORAL|Health Promotion|"The health promotion (HP) curriculum focuses on healthy living by encouraging good nutrition, improving knowledge on violence recognition, management and support/resources, exercise, informed consumer behavior, alcohol and substance use.The intervention consists of participants attending a two day workshops with their MF.~Other names:~HP"
219545381|NCT01513044|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
219545382|NCT01513044|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
219545383|NCT04547179|DRUG|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
219545384|NCT04547179|DEVICE|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
219545385|NCT04547179|OTHER|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
218935156|NCT05808543|OTHER|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
219545386|NCT03597724|OTHER|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
219545387|NCT05226741|DEVICE|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
219545388|NCT01361334|DRUG|Pazopanib|800 mg QD p.o.
219545389|NCT03578809|BIOLOGICAL|MEDI6012|MEDI6012
219545390|NCT03578809|OTHER|Placebo|Placebo
219622213|NCT06072274|OTHER|The virtual reality educational modules|The experimental group will participate in a dementia education program combining VR lasting approximately 2-3 hours. The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
218935157|NCT02546518|DEVICE|Moniri Otovent|Please see Arm Description.
218935158|NCT02546518|DEVICE|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
218935159|NCT02401789|DEVICE|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
218935160|NCT04711226|DRUG|AT-1501|AT-1501 IV infusion
218935161|NCT04297527|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
218935162|NCT04297527|PROCEDURE|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
218935163|NCT05486377|DRUG|Remimazolam besylate|Remimazolam besylate TIVA
218935164|NCT02561338|DRUG|HMS5552|75mgQD
218935165|NCT02561338|DRUG|HMS5552|100mgQD
218935166|NCT02561338|DRUG|HMS5552|50mgBID
218935167|NCT02561338|DRUG|HMS5552|75mgBID
218935168|NCT02561338|OTHER|Placebo|QD/BID
218935169|NCT01039883|DRUG|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
218935170|NCT01039883|DRUG|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
219545391|NCT02753985|OTHER|Survey|
219545392|NCT02577133|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
219545393|NCT02577133|DIETARY_SUPPLEMENT|Placebo|The placebo consisted of an identical bottle with distilled water
219545394|NCT02867085|OTHER|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
219545395|NCT04746976|DRUG|Diroximel Fumarate|As described in the arm.
219545396|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
219545397|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
219545398|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
219545399|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
219545400|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
219545401|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
219545402|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
219545403|NCT01279109|BEHAVIORAL|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
219545404|NCT01279109|BEHAVIORAL|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
219545405|NCT01705483|DRUG|ASP9853|oral
219545406|NCT01705483|DRUG|Docetaxel|intravenous (IV)
219545407|NCT01705483|DRUG|Paclitaxel|Taxol
219545408|NCT06018818|DEVICE|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
219545409|NCT06039605|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
219545410|NCT05276479|OTHER|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
219545411|NCT06461988|DRUG|Talquetamab|"Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3: 60 mcg/kg C1D5: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13"
219545412|NCT06461988|DRUG|Talquetamab and Lenalidomide|Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)
219545413|NCT06830993|BEHAVIORAL|"Move More Personalized Exercise Program"|"Move More - a personalized exercise program involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aims to get participants to move more, by any means necessary."
219545414|NCT06830993|BEHAVIORAL|Intradialytic Exercise Program|"Those in the intradialytic exercise group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)."
219545415|NCT06191276|BEHAVIORAL|STEP@Home Intervention|STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.
218935171|NCT00882817|OTHER|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
218935172|NCT02978599|DRUG|AVL-3288|daily for 5 days
218935173|NCT02978599|DRUG|Placebo|daily for 5 days
218935174|NCT00533676|DRUG|MK0524A, /Duration of Treatment : 8 Weeks|
218935175|NCT00533676|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
218935176|NCT03384862|DIETARY_SUPPLEMENT|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
218935177|NCT03384862|DIETARY_SUPPLEMENT|Placebo|Placebo pills, with same appearance as intervention pills.
218935178|NCT03384862|DIETARY_SUPPLEMENT|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
218935179|NCT02411097|PROCEDURE|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
218935180|NCT01849731|OTHER|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
218935181|NCT01849731|OTHER|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
218935182|NCT04236609|DEVICE|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
218935183|NCT04236609|DEVICE|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
218935184|NCT04200352|DRUG|TEV-50717|Oral tablets are 6, 9, and 12 mg.
218935185|NCT02135926|DEVICE|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
218935186|NCT02135926|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
218935187|NCT00474591|DRUG|Fondaparinux|
219046196|NCT04989946|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
219046197|NCT04989946|DRUG|Cemiplimab|Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
219046198|NCT04989946|DRUG|Fianlimab|Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
219545416|NCT06191276|BEHAVIORAL|Usual care|Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
219545417|NCT02158741|BEHAVIORAL|Home Visits and Lifestyle Education Support|
219545418|NCT01002287|DEVICE|SprayShield Adhesion Barrier System|Adhesion Barrier Device
219545419|NCT01002287|PROCEDURE|Good Surgical Technique Alone|Good Surgical Technique Alone
219545420|NCT03163160|PROCEDURE|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
219545421|NCT03163160|PROCEDURE|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
219545422|NCT05330780|OTHER|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
219545423|NCT02997176|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
219545424|NCT04273386|OTHER|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
219545425|NCT04595669|BEHAVIORAL|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
219545426|NCT02396888|DRUG|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
219545427|NCT02396888|DRUG|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
219545428|NCT04158128|OTHER|non-intervention|non-interventional, prospective cohort study
219545429|NCT00373256|DRUG|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
219545430|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
219545431|NCT00373256|DRUG|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
219545432|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
219622214|NCT04151186|BIOLOGICAL|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
219622215|NCT02611895|BIOLOGICAL|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
219622216|NCT00003624|DRUG|amifostine trihydrate|
219046199|NCT04989946|DRUG|FLT PET/CT|Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
219622217|NCT00003624|DRUG|cisplatin|
219046200|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
219046201|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
219046202|NCT00204256|DRUG|Iron sucrose|
219046203|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
219046204|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
219545433|NCT02867358|DRUG|KT07 Capsule|
219545434|NCT02867358|OTHER|Placebo|
219545435|NCT00327457|BEHAVIORAL|Help with physician office and patient management|
219545436|NCT00327457|BEHAVIORAL|Tailored physician recommendation letter|
219545437|NCT02987634|OTHER|PeriActive|mouthwash
219545438|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
219622218|NCT00003624|DRUG|paclitaxel|
219622219|NCT04417010|PROCEDURE|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
219205909|NCT06892873|DEVICE|Comfort-In|Application of Comfort-in Jet Injection Method Comfort-in jet injection method was used for palatal anesthesia of the primary molars. The device was placed 5 mm below the palatal gingival margin, close to the free gingiva, and with a steep angle. 0.2 ml of anesthetic solution was administered by pressing the jet injection system button. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine was used as a local anesthetic agent in the injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
219545439|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
219545440|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
219622220|NCT02863185|DRUG|Pitavastatin|
219046205|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
219046206|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
219046207|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
219046208|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
219046209|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
219046210|NCT06391879|GENETIC|Single cell sequencing, whole genome and metabolomic sequencing|The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
219046211|NCT06425458|BEHAVIORAL|Co-Designed Strengths-Based Leadership Program|Please see arm description.
219046212|NCT05483790|BEHAVIORAL|the multimodal intervention|"The in-person training course included 25 minutescognitive training activities were conducted for , followed by a 15-minute healthy lifestyle education. After a 10-minute break, physical exercise training was administered for 15 minutes. Finally, 15 minutes wrap-up session.~The cognitive training encompassed memory-related training and attention-related training. The physical exercise included finger exercises, elastic band exercises, Tai Chi/ Baduanjin with guidance. The healthy lifestyle education included guidance on nutrition, sleep, stress management, and mood adjustment by teaching problem-solving skills. Additionally, the intervention provided information and support to facilitate lifestyle changes and included discussions and practical exercises, such as tools for assessing dietary behavior."
219046213|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
219545441|NCT04241458|DRUG|BI 703621|BI 703621
219545442|NCT04241458|DRUG|Placebo|Placebo
219545443|NCT04241458|DRUG|Midazolam|Midazolam
219622221|NCT02863185|DRUG|Atorvastatin|
219545444|NCT03836040|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
219545445|NCT03836040|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
219545446|NCT03836040|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
219545447|NCT03836040|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
219545448|NCT05625399|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
219545449|NCT05625399|DRUG|rHuPH20|Specified dose on specified days
219545450|NCT05985525|DEVICE|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
219545451|NCT05989412|OTHER|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
219545452|NCT06144424|DRUG|Oral EP262|Once daily
219545453|NCT06144424|DRUG|Placebo|Once Daily
219622222|NCT05092958|DRUG|Avelumab|Given IV
219622223|NCT05092958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219622224|NCT05092958|PROCEDURE|Bone Scan|Undergo bone scan
219545454|NCT05539469|DEVICE|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
219545455|NCT05539469|OTHER|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
219545456|NCT06471413|OTHER|The Prevention Toolbox : BOAT®|The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
219046214|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
219046215|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
219545457|NCT05829915|DEVICE|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
219545458|NCT05829915|OTHER|No exercise program|The control group did not received the physical exercise program
219545459|NCT05526391|DRUG|TAK-341|TAK-341 IV infusion
219545460|NCT05526391|DRUG|Placebo|TAK-341 placebo-matching IV infusion
219545461|NCT06492876|GENETIC|FT-003|Administered via intraocular injection.
219545462|NCT03463226|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
219545463|NCT03463226|DIAGNOSTIC_TEST|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
219545464|NCT03463226|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
219622225|NCT05092958|DRUG|Cabozantinib S-malate|Given PO
219046216|NCT05663515|DRUG|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
219046217|NCT05663515|DRUG|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
219046218|NCT04466891|DRUG|ZW25 (Zanidatamab)|Administered intravenously
219046219|NCT06984861|DIAGNOSTIC_TEST|18F-FMISO PET/CT Scan|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. Subjects will undergo 18F-FMISO scan (only 1 injection) occurs at 8-10 treatment days\* into chemoradiation. Each patient will have a baseline staging FDG PET scan which is used to localize the tumor at the primary site and all suspicious cervical neck nodes (\> 1 cm in short axis diameter with focal abnormal increased FDG avidity). These lesions are then assessed on the respective 18F-FMISO PET/CT.
219046220|NCT06984861|COMBINATION_PRODUCT|Chemoradiation|Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks and when downstaged to T1-2 and \< N3, the patient is eligible to receive concurrent chemoradiation per protocol.A total radiation therapy of 30Gy will be delivered to the oropharynx and neck at 2Gy per fraction per day over 15 days for patients who exhibited no evidence of hypoxia on the intra-treatment 18F-FMISO PET/CT. Concurrent chemotherapy (2 cycles) will be given. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks)
219046221|NCT06984861|OTHER|Questionnaires|EQ-5D-5L, MDADI-HN, COST-FACIT
219046222|NCT06978621|BIOLOGICAL|Inactivated hepatitis A vaccine (I-HAV)|"A formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain)~Dose and administration: 0.5 mL intramuscular injection for participants age \<=18 years, and 1.0 mL intramuscular injection for participants age 19 years and above."
219046223|NCT02620098|OTHER|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
219046224|NCT00004078|DRUG|irinotecan hydrochloride|Given IV
219046225|NCT00445328|DRUG|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
219046226|NCT00445328|DRUG|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
219622226|NCT05092958|PROCEDURE|Computed Tomography|Undergo CT
219622227|NCT05092958|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622228|NCT05092958|OTHER|Quality-of-Life Assessment|Ancillary studies
219622229|NCT05092958|OTHER|Questionnaire Administration|Ancillary studies
219622230|NCT05356013|DRUG|Caplyta|Atypical antipsychotic
219622231|NCT05356013|DRUG|Placebo|Pill that contains no medicine.
219545465|NCT03463226|DIAGNOSTIC_TEST|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
219046227|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
219046228|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
219046229|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
219545466|NCT03463226|DIAGNOSTIC_TEST|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
219545467|NCT03463226|DIAGNOSTIC_TEST|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
219545468|NCT05812118|BEHAVIORAL|Physical active learning|The intervention will last for 8-10 weeks. The ALPHYL intervention will be conducted in physical education (PE) and non-PE lessons by teachers. In addition to the PE lessons, at least three physically active activities in subjects other than PE will be conducted every day (5 days per week), with a total duration of approximately 30 minutes of light and moderate-to-vigorous physical activity per day. The weekly dose of physically active learning will thus be 100-150 minutes, so that a volume of 800-1200 minutes is foreseen during the 8-10 weeks. The PE classes will also be conducted in a mix of cooperative learning, non-linear pedagogy and health-based PE.
218935188|NCT04690452|BEHAVIORAL|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
218935189|NCT04371393|BIOLOGICAL|Remestemcel-L|administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
218935190|NCT04371393|DRUG|Placebo|administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
219046230|NCT04246970|OTHER|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
219545469|NCT03001596|PROCEDURE|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
219545470|NCT03001596|PROCEDURE|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
219545471|NCT03001596|PROCEDURE|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
219545472|NCT05415891|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
219545473|NCT05415891|DEVICE|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
219545474|NCT02727192|DEVICE|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
219545475|NCT03050866|DRUG|Cabazitaxel|25mg/m2 q3w
219545476|NCT03050866|OTHER|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
219545477|NCT03050866|OTHER|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
219545478|NCT03050866|OTHER|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
219545479|NCT03050866|OTHER|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
219545480|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID|vaccination
219545481|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
219622232|NCT05541835|DIAGNOSTIC_TEST|sampling|venous sampling of patient
219622233|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
219622234|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
219622235|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
219622236|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
219622237|NCT01517945|BEHAVIORAL|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
219622238|NCT06569316|PROCEDURE|Biospecimen Collection|Undergo blood or saliva and leftover tissue sample collection
219622239|NCT06569316|OTHER|Communication Intervention|Receive care plan recommendations
219622240|NCT06569316|OTHER|Genetic Testing|Undergo genetic testing
219622241|NCT06569316|OTHER|Survey Administration|Ancillary studies
219622242|NCT06325566|DRUG|Rexlemestrocel-L + HA mixture|Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
219622243|NCT06325566|DRUG|Saline|Saline solution injection adjacent to the index disc.
219046231|NCT04246970|OTHER|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
219046232|NCT02254278|DRUG|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
219046233|NCT02254278|RADIATION|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
219046234|NCT02254278|RADIATION|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
219046235|NCT04669457|DRUG|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
219046236|NCT04669457|DRUG|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
219622244|NCT06216366|DRUG|Sodium Chloride 0.9% Inj pre-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
219622245|NCT06216366|DRUG|Sodium Chloride 0.9% Inj post-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
219622246|NCT06216366|DRUG|Recombinant human plasma gelsolin pre-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
219046237|NCT05403710|DRUG|Botulinum toxin|Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
219545482|NCT00928057|DEVICE|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
219545483|NCT00928057|DEVICE|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
219545484|NCT00928057|DEVICE|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
219545485|NCT03543735|BEHAVIORAL|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
219545486|NCT03543735|OTHER|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
219545487|NCT03461341|OTHER|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
219545488|NCT05278403|OTHER|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
219622247|NCT06216366|DRUG|Recombinant human plasma gelsolin post-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
219622248|NCT06216366|OTHER|Hyperbaric chamber|High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
219622249|NCT05388760|DRUG|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
219622250|NCT05036109|DRUG|Aspirin|by mouth every day for up to 90 days
219046238|NCT02710682|PROCEDURE|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure."
219046239|NCT02710682|DEVICE|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged."
219046240|NCT06033638|OTHER|Score assessment|PBS Score
219046241|NCT05114005|BEHAVIORAL|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
219046242|NCT05114005|BEHAVIORAL|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hour training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
219046243|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
219046244|NCT01852448|GENETIC|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
219046245|NCT05514405|DRUG|Remimazolam (Byfavo)|Remimazolam is continuously infused based on bispectral index (within 40-60).
219545489|NCT05278403|OTHER|Neurological physiotherapy|Application of conventional physical therapy techniques.
219545490|NCT01897064|BEHAVIORAL|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
219545491|NCT01897064|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
219545492|NCT02331108|DRUG|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
219545493|NCT04544618|DEVICE|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
219545494|NCT04532996|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
219545495|NCT05592808|DEVICE|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
219622251|NCT05036109|DRUG|Vitamin D|by mouth every day for up to 90 days
219622252|NCT05036109|DIETARY_SUPPLEMENT|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
219622253|NCT05036109|OTHER|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
219046246|NCT05514405|DRUG|Propofol|Propofol is continuously infused based on bispectral index (within 40-60).
219545496|NCT05592808|OTHER|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
219545497|NCT05592808|OTHER|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
219545498|NCT00845130|BIOLOGICAL|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
219622254|NCT05036109|BEHAVIORAL|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
219622255|NCT06274658|BEHAVIORAL|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
219545499|NCT05497557|DRUG|Omeprazole|Omeprazole will be administered as an oral capsule.
219545500|NCT05497557|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
219545501|NCT04292691|DRUG|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
219545502|NCT04292691|DRUG|40ml of Ringer's Lactate|already outlined in the arm/group description
219545503|NCT03513224|OTHER|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
219545504|NCT05274724|DIAGNOSTIC_TEST|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
219545505|NCT05274724|DIAGNOSTIC_TEST|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
219622256|NCT06463782|DRUG|68Ga-LNC1007 Injection|The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
219622257|NCT04289441|DIETARY_SUPPLEMENT|Bifiasthm|Subjects will be instructed to take an active or placebo sachet twice daily for eight weeks, and subsequent intake of one dose daily for a further eight weeks.
219622258|NCT04289441|DIETARY_SUPPLEMENT|Placebo|Placebo
219622259|NCT00191581|DRUG|Humalog Mix 50|
219622260|NCT00191581|DRUG|Human Insulin Mix 50:50|
219622261|NCT04992650|PROCEDURE|Fat grafting|Fat grafting
219622262|NCT01419756|DEVICE|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
219622263|NCT00001298|DRUG|carboxypeptidase-G2|
219622264|NCT00127231|BEHAVIORAL|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
219622265|NCT00127231|BEHAVIORAL|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
218935191|NCT03800940|PROCEDURE|Fistulography and trans-drain occlusion|"1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
218935192|NCT03800940|PROCEDURE|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
219545506|NCT04425096|OTHER|Skin to skin contact|Skin to skin contact
219545507|NCT03151824|OTHER|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
219545508|NCT06316336|DRUG|Alfuzosin Hydrochloride 10 mg|Alfuzosin Hydrochloride 10 mg (test durg)
219545509|NCT06316336|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (reference drug)
219545510|NCT05762458|DRUG|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
219545511|NCT05762458|DRUG|Placebo|placebo to Ammoxetine.
219622266|NCT02029066|DRUG|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.
219622267|NCT03096314|DRUG|Vitamin D3|540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube
219622268|NCT03096314|DRUG|Placebo|A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
219622269|NCT05884385|OTHER|Simulated exercises|as detailed in arm description
219622270|NCT05884385|OTHER|Mental Visualisation|as detailed in arm description
218935193|NCT01147913|BEHAVIORAL|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
219046247|NCT05074290|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
219046248|NCT05074290|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
219046249|NCT06600620|DEVICE|Monitoring patients heart rythms with a wireless patch device|The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
219046250|NCT02284503|DRUG|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
219046251|NCT06601309|DRUG|Serplulimab|Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
219046252|NCT06601309|DRUG|Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
219046253|NCT06601309|DRUG|Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
219046254|NCT06601309|RADIATION|Radiotherapy|Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
219046255|NCT00316199|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
219046256|NCT00316199|DRUG|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
219046257|NCT03203902|OTHER|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
219046258|NCT05742451|OTHER|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
219046259|NCT02801318|PROCEDURE|Polysomnography|
219046260|NCT00333684|DEVICE|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
219046261|NCT00590954|DRUG|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
219046262|NCT06325540|PROCEDURE|indirect pulp capping with theracal pt|indirect pulp capping using the theracal pt material
219046263|NCT06325540|PROCEDURE|indirect pulp capping with therabase|indirect pulp capping using the therabase material
219622271|NCT00010335|PROCEDURE|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
218935194|NCT01147913|BEHAVIORAL|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
218935195|NCT05689580|DIETARY_SUPPLEMENT|Ketogenic diet|The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
219622272|NCT00010335|DEVICE|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
218935196|NCT05689580|DIETARY_SUPPLEMENT|Balanced diet|Balanced diet
218935197|NCT00993148|DRUG|maraviroc|150 mg tab by mouth once daily for 96 weeks
218935198|NCT00993148|DRUG|darunavir|800 mg tab by mouth once daily for 96 weeks
219622273|NCT04167319|OTHER|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
219545512|NCT03081897|DRUG|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
219545513|NCT03081897|DRUG|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
219545514|NCT03681977|DEVICE|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
219545515|NCT03681977|DEVICE|Zimmer Persona Knee-PS|Persona the personalized knee system
219545516|NCT03013036|DEVICE|Ultrasonography|
219046264|NCT06325540|PROCEDURE|indirect pulp capping with biodentine|indirect pulp capping using the biodentine material
219046265|NCT05733351|DRUG|Abiraterone|Given PO
219046266|NCT05733351|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219046267|NCT05733351|PROCEDURE|Bone Scan|Undergo bone scan
219046268|NCT05733351|PROCEDURE|Computed Tomography|Undergo CT
219545517|NCT03013036|DRUG|Sevoflurane|
219545518|NCT03013036|DRUG|intravenous midazolam|
219545519|NCT03013036|DRUG|Propofol|
219622274|NCT04323410|PROCEDURE|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
219622275|NCT04323410|PROCEDURE|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
219622276|NCT06396117|OTHER|mTESE (microscopic testicular sperm extraction)|"Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method"
219622277|NCT06071364|DIAGNOSTIC_TEST|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
219622278|NCT04382495|OTHER|survey|online survey
219622279|NCT05472025|OTHER||
219046269|NCT05733351|DRUG|Docetaxel|Given IV
219046270|NCT05733351|DRUG|Enzalutamide|Given PO
219046271|NCT05733351|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
219046272|NCT05733351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219046273|NCT05733351|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
219046274|NCT05733351|DRUG|Vudalimab|Given IV
219545520|NCT03013036|DRUG|fentanyl and rocuronium|
219545521|NCT02752074|DRUG|pembrolizumab + epacadostat|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
219046275|NCT06858111|BIOLOGICAL|Fertilo|Fertilo is an engineered line of ovarian support cells that aid egg maturation.
219046276|NCT06858111|DEVICE|Medicult IVM|MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.
219046277|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
219046278|NCT06670443|DEVICE|experimental group|Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
219046279|NCT06670443|DEVICE|control group|Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
219046280|NCT02313025|OTHER|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
219046281|NCT02313025|OTHER|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
219046282|NCT04222179|DEVICE|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
219545522|NCT02752074|DRUG|pembrolizumab + placebo|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)"
219545523|NCT05101382|OTHER|Observation|Retrospective Observation of standard clinical practice
219545524|NCT06160804|PROCEDURE|Skeletal traction|A pin through the bone with weights attached
219545525|NCT06160804|PROCEDURE|Femoral shaft splinting|A splint of the broken thigh bone
219545526|NCT04017494|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
219545527|NCT04017494|DIAGNOSTIC_TEST|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
219545528|NCT04017494|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
219545529|NCT04017494|DIAGNOSTIC_TEST|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
219545530|NCT04017494|DIAGNOSTIC_TEST|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
219622280|NCT01997788|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
218935199|NCT00993148|DRUG|ritonavir|100 mg capsule by mouth once daily for 96 weeks
218935200|NCT00452972|DRUG|Spinal Anesthesia|
218935201|NCT06471348|DRUG|Bupivacaine liposome injectable suspension|EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.
218935202|NCT06471348|DRUG|Bupivacaine Hydrochloride and Epinephrine Injection|Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).
218935203|NCT02905890|DRUG|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
219046283|NCT03869138|BEHAVIORAL|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
219046284|NCT06669403|DRUG|OPT101|OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
219046285|NCT06669403|OTHER|Placebo|0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
219046286|NCT06669897|OTHER|Questionnaire|Chronic cough questionnaire
219046287|NCT06994897|DRUG|PF-07985631|Experimental Pfizer compound which will be SC or IV
219046288|NCT06994897|DRUG|Placebo|Placebo which will be SC or IV
219046289|NCT04853667|OTHER|Interview|Semi-structured interview, lasting a maximum of one hour
219545531|NCT02169063|RADIATION|carbon-11 acetate|Given IV
219545532|NCT02169063|RADIATION|fluorine F 18 sodium fluoride|Given IV
219545533|NCT02169063|PROCEDURE|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
218935204|NCT02905890|DEVICE|Condoms|Latex male condoms
218935205|NCT01318980|DRUG|GSK2190915 100mg milled tablet|Taken orally
218935206|NCT01318980|DRUG|[14C] radiolabelled GSK2190915 solution|Microtracer solution
218935207|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
218935208|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
218935209|NCT01318980|DRUG|GSK2190915 100mg enteric-coated tablet.|Taken orally
218935210|NCT04558840|PROCEDURE|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
219046290|NCT05903131|BEHAVIORAL|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
219046291|NCT05903131|DRUG|Progestin|Released via the levonorgestrel-releasing IUD.
219046292|NCT05903131|BEHAVIORAL|Enhanced usual care|1-3 page handouts
219046293|NCT05903131|DRUG|Levonorgestrel-releasing IUD.|Standard of care
219545534|NCT02169063|OTHER|laboratory biomarker analysis|Correlative studies
219545535|NCT03692663|DRUG|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
219545536|NCT03692663|BIOLOGICAL|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
219545537|NCT03692663|BIOLOGICAL|fludarabine|Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
219545538|NCT00041392|DRUG|Magnesium|100 mg/kg
219545539|NCT00041392|DRUG|0.9% saline|Placebo
219545540|NCT05262985|DRUG|Durvalumab|In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
219545541|NCT04908852|OTHER|Blood Sample Collection - Observational Study|Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.
219545542|NCT04908852|OTHER|Symptom questionnaires - Observational Study|Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
219545543|NCT02574377|DRUG|A: myDC vaccination|
219622281|NCT01997788|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
219622282|NCT01997788|DRUG|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
219622283|NCT05727839|DRUG|JCXH-211 Injection|JCXH-211 administered once every 28 days
219622284|NCT03205722|OTHER|Non-Interventional|Non-Interventional
219622285|NCT00083382|DRUG|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
219622286|NCT00083382|DRUG|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
219622287|NCT00083382|DRUG|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
219622288|NCT02852135|DEVICE|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
218935211|NCT03816293|DEVICE|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
218935212|NCT06307197|DEVICE|HAAL platform|"The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices.~The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors."
219046294|NCT01811121|DRUG|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
219545544|NCT02574377|DRUG|B: pDC vaccination|
219545545|NCT02574377|DRUG|C: combined myDC/pDC vaccination|
219046295|NCT01811121|DRUG|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
219046296|NCT06856590|DIETARY_SUPPLEMENT|Zinc Supplementation|Participants assigned to zinc-containing arms will receive oral zinc gluconate supplementation (78 mg twice daily) for 8 weeks. This intervention aims to evaluate the effect of zinc in preventing and reducing the severity of regorafenib-induced hand-foot skin reaction (HFSR).
219046297|NCT06856590|DRUG|Clobetasol Propionate 0.05% Cream|Participants assigned to clobetasol-containing arms will receive topical clobetasol propionate 0.05% cream, applied twice daily to the palms and soles for 8 weeks. This intervention aims to assess the efficacy of clobetasol in preventing regorafenib-induced HFSR.
219046298|NCT06592820|DEVICE|Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation Imaging|EUS combines ultrasound technology with endoscopy to gain an internal vantage point to obtain higher resolution ultrasound images. Shear Wave is a software option on the ultrasound system EUS that provides an advanced measure and dynamic display of tissue stiffness which is being evaluated for use in assessing liver fibrosis. Attenuation Imaging (ATI) is a novel application that provides the capability to quantify and color-code the changes in attenuation coefficient of the liver that may arise with changes in liver composition (e.g., increased fat levels).
219046299|NCT06592820|DEVICE|FibroScan|A small ultrasound probe to measure the velocity of a sound wave passing through the liver. This is converted into kilopascals (kPa), which is used to assess liver fibrosis.
219046300|NCT06592820|DEVICE|Liver biopsy|"A biopsy of liver tissue could be obtained under endoscopic ultrasound guidance, interventional radiology (percutaneously), or surgically.~Endoscopic Ultrasound-guided liver biopsy provides high resolution images of left lobe of the liver and a good portion of the right lobe of the liver. This, coupled with Doppler capability, allows the physician to direct the biopsy needle safely into the liver for sampling under real time image guidance."
219046301|NCT07007234|BEHAVIORAL|Physical activity intervention|The INTERVENTION group will participate in a 4-month goal-setting intervention aimed to replace mentally passive sedentary behaviors with mentally active sedentary behaviors, light physical activity, or moderate-to-vigorous activity.
219545546|NCT01369927|BIOLOGICAL|Shigella Sonnei O-SPC/rBRU|
219545547|NCT03266380|DIAGNOSTIC_TEST|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
219545548|NCT00170729|DRUG|Prednisolone acetate|
219545549|NCT01160796|DRUG|placebo|1x14-day course of treatment during 4 cycles
219545550|NCT01160796|DRUG|Lcr35®|1x14-day course of treatment during 4 cycles
219545551|NCT02392195|OTHER|Non-interventional|Observational
219545552|NCT00907907|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
219622289|NCT02852135|DEVICE|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
219622290|NCT05995574|BEHAVIORAL|avatar communication training|Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
219622291|NCT00959114|BIOLOGICAL|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
219545553|NCT00907907|DRUG|CellCept® Tablets|CellCept® Tablets, 500 mg
219545554|NCT05898607|OTHER|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
219545555|NCT05898607|OTHER|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
219545556|NCT05351892|DRUG|Elinzanetant (BAY3427080)|Soft gel capsule, oral
219545557|NCT00006376|DRUG|chemotherapy|
218935213|NCT06328413|DEVICE|photobiomodulation|Photobiomodulation application at different extraoral and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
219545558|NCT00006376|DRUG|tipifarnib|
219545559|NCT05026294|OTHER|plyometric exercises|Exercises for strength and flexibility
219545560|NCT05026294|OTHER|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
219545561|NCT06164860|OTHER|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
219545562|NCT06164860|OTHER|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
219545563|NCT01561391|DRUG|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
219545564|NCT01561391|DRUG|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
219545565|NCT01561391|OTHER|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
219545566|NCT01561391|DRUG|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
219545567|NCT01783366|DEVICE|TUBE EXCHANGER|
219545568|NCT00545792|DRUG|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
219545569|NCT03265574|DRUG|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
219545570|NCT03991273|OTHER|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
218935214|NCT06328413|OTHER|Leukocyte and Platelet Rich Fibrin|Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
218935215|NCT00233064|BIOLOGICAL|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
218935216|NCT00233064|BIOLOGICAL|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
218935217|NCT03508908|DIAGNOSTIC_TEST|HIV-1 RNA testing|During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
218935218|NCT03456310|DIAGNOSTIC_TEST|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
218935219|NCT04251403|DIAGNOSTIC_TEST|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
218935220|NCT06120361|DIAGNOSTIC_TEST|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218935221|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218935222|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218935223|NCT06120361|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218935224|NCT06120361|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
218935225|NCT06120361|DIAGNOSTIC_TEST|MRI and CT of the brain|Structural brain imaging
218935226|NCT06120361|DIAGNOSTIC_TEST|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
218935227|NCT03263559|PROCEDURE|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
218935228|NCT03263559|DRUG|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
218935229|NCT03263559|DRUG|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
219545571|NCT03991273|OTHER|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
218935230|NCT03263559|DRUG|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
218935231|NCT03263559|DRUG|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
219545572|NCT02891863|DEVICE|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
219545573|NCT01771263|DEVICE|iControl-RP|
219545574|NCT01307124|DRUG|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg"
219545575|NCT00599079|DRUG|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
219545576|NCT04991610|RADIATION|computed tomography|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
219545577|NCT03253510|OTHER|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
219545578|NCT03253510|OTHER|Poly-methyl methacrylate|Gold standard denture base material
219545579|NCT04550702|DRUG|Mirabegron 25mg|Mirabegron 25 mg per day
219545580|NCT03057210|OTHER|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
219545581|NCT03057210|OTHER|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
219545582|NCT00445796|DRUG|Artesunate|
219545583|NCT00445796|DRUG|Amodiaquine|
219545584|NCT02812121|DRUG|umbilical cord blood mesenchymal stem cells|
219545585|NCT05126485|DEVICE|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
219622292|NCT00959114|BIOLOGICAL|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
218935232|NCT03263559|DRUG|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
218935233|NCT03263559|RADIATION|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
218935234|NCT03263559|DRUG|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
218935235|NCT05444257|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
219622293|NCT00578019|PROCEDURE|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith \& Nephew supracondylar nail.
219622294|NCT00578019|PROCEDURE|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
218935236|NCT06019000|COMBINATION_PRODUCT|CYR-064|CYR-064 is a nasal solution.
218935237|NCT01881828|DRUG|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
218935238|NCT01881828|OTHER|oral placebo|
218935239|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
218935240|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
219545586|NCT01711632|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
219545587|NCT03325387|DRUG|LY3305677|Administered SC
219622295|NCT05650684|OTHER|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
219046302|NCT07007234|BEHAVIORAL|Standard of care|The CONTROL group also will participate of 4 face-to-face individual sessions during the experimental period, lasting \~15-30 minutes, however they will receive general instructions related to WHO guidelines for physical activity
219622296|NCT00975117|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
219622297|NCT00975117|DIETARY_SUPPLEMENT|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
219622298|NCT03779217|OTHER|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
219622299|NCT03779217|PROCEDURE|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
219622300|NCT04370171|OTHER|care modalities|For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
219622301|NCT04370171|OTHER|Teleconsultation either by phone or by computer consultation|Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
219622302|NCT01059422|DRUG|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
219622303|NCT03775265|DRUG|Atezolizumab|Given IV
219622304|NCT03775265|PROCEDURE|Biopsy of Bladder|Undergo a bladder biopsy
219622305|NCT03775265|DRUG|Cisplatin|Given IV
219622306|NCT03775265|PROCEDURE|Computed Tomography|Undergo CT or MRI
219622307|NCT03775265|PROCEDURE|Cystoscopy|Undergo a cystoscopy
219622308|NCT03775265|DRUG|Fluorouracil|Given IV
219622309|NCT03775265|DRUG|Gemcitabine|Given IV
219046303|NCT06619561|DRUG|Vimseltinib|Administered orally
219545588|NCT03325387|DRUG|Placebo|Administered SC
219545589|NCT05163847|BIOLOGICAL|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
219545590|NCT05163847|BIOLOGICAL|Fluzone HD IIV|Administered intramuscularly on Day 1
219545591|NCT05163847|OTHER|IN Placebo|Administered intranasally on Day 1
219046304|NCT04413929|DRUG|Ergoferon|Oral administration
219545592|NCT05163847|OTHER|IM Placebo|Administered intramuscularly on Day 1
219545593|NCT03679598|DRUG|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
219622310|NCT03775265|PROCEDURE|Magnetic Resonance Imaging|Undergo CT or MRI
219622311|NCT03775265|DRUG|Mitomycin|Given IV
219622312|NCT03775265|OTHER|Quality-of-Life Assessment|Ancillary studies
219622313|NCT03775265|RADIATION|Radiation Therapy|Undergo 3DCRT or IMRT
218935253|NCT04638543|DRUG|ABP-671|ABP-671 Tablet
218935254|NCT04638543|DRUG|Placebo|Placebo
218935255|NCT03388710|RADIATION|XRay|Xray to confirm the location of the endotracheal tube
218935256|NCT04915612|DRUG|Gemtuzumab Ozogamicin|Given IV
218935257|NCT04915612|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219622314|NCT03775265|OTHER|Survey Administration|Ancillary studies
219622315|NCT03775265|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo a TURBT
219622316|NCT04335123|DRUG|Losartan|25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
219622317|NCT05079945|PROCEDURE|Spinal cord Tractography in order to differentiate spinal tracts.|Spinal cord tractography using DTI MRI sequences of the brain and spinal cord, in order to differentiate tracts at the spinal cord level; and by performing a stitching process between Brain and Spinal cord DTI sequences.
219622318|NCT01643577|PROCEDURE|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
219622319|NCT01643577|PROCEDURE|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
219622320|NCT02506868|DRUG|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
219622321|NCT00076726|DRUG|Infliximab|
219622322|NCT05029791|OTHER|Tumor biopsy|2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
219622323|NCT05029791|OTHER|Blood sample|1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
219545594|NCT03679598|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
219545595|NCT04244630|COMBINATION_PRODUCT|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
219545596|NCT05437848|DRUG|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
219545597|NCT05437848|OTHER|Placebo|Placebo subcutaneous injection
219545598|NCT00629122|DRUG|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
219622324|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
219622325|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
219622326|NCT06963996|BEHAVIORAL|Sleep health education|"The intervention consists of three structured sessions delivered over three weeks, with additional online follow-ups. Each session lasts 1.5 hours and takes place in the evening, with a one-week interval between sessions.~Session 1 focuses on providing fundamental knowledge about sleep health. Session 2 introduces behavioral strategies to improve sleep health and asks participants to implement behavior change intentions.~Session 3 reviews the implementation of the intention, the changes made or not, and addresses the relationship between stress and sleep, along with coping strategies."
219622327|NCT05025358|DRUG|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
218935258|NCT01120964|DRUG|Intravenous L-Citrulline|
218935259|NCT01120964|DRUG|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
218935260|NCT01003769|DRUG|Lenalidomide|Given PO
218935261|NCT01003769|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
218935262|NCT01003769|OTHER|Laboratory Biomarker Analysis|Correlative studies
218935263|NCT03747861|DEVICE|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
218935264|NCT00826202|DRUG|D-serine|60 mg/kg/day
218935265|NCT00826202|OTHER|Placebo|Inert Placebo
218935266|NCT01440777|BEHAVIORAL|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~* Daily articles~* Daily activities to help get the sleep you need~* Daily sleep improvement recommendations~* Audio recorded relaxation exercises~* Daily e-mails from your program coach~* Personal progress charts~* An online sleep log and daily sleep score"
218935267|NCT04045028|DRUG|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
218935268|NCT04045028|DRUG|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
218935269|NCT04045028|DRUG|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
219046305|NCT07009665|OTHER|Personalized SV-guided resuscitation|Participants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours.
219046306|NCT07009665|OTHER|Standard Care Resuscitation|In the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign).
219046307|NCT02782949|DRUG|Curcumin|Given PO
219046308|NCT02782949|OTHER|Laboratory Biomarker Analysis|Correlative studies
219046309|NCT02782949|OTHER|Placebo Administration|Given PO
219046310|NCT02782949|OTHER|Quality-of-Life Assessment|Ancillary studies
219046311|NCT04850612|OTHER|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
219046312|NCT07010432|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219046313|NCT07010432|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219046314|NCT07010432|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
219046315|NCT07010432|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
218935270|NCT04045028|DRUG|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
218935271|NCT02545088|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
218935272|NCT02545088|OTHER|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
218935273|NCT02545088|OTHER|2nd control group|The 2nd control group will not receive an intervention.
219545599|NCT00629122|DRUG|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
219545600|NCT00629122|DRUG|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
219545601|NCT00629122|DRUG|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
219545602|NCT06395246|BEHAVIORAL|Active Comparator: Continuous calorie restriction|Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
219545603|NCT06395246|BEHAVIORAL|eTRE|early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
219545604|NCT05467111|OTHER|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
219545605|NCT00002764|BIOLOGICAL|filgrastim|
219545606|NCT00002764|DRUG|doxorubicin hydrochloride|
219545607|NCT00002764|DRUG|ifosfamide|
219545608|NCT00002764|PROCEDURE|conventional surgery|
219622330|NCT06305728|DIAGNOSTIC_TEST|89Zr-DFO-HuMab-5B1 immunoPET|Participants who choose to will undergo immunoPET before surgery.
219622331|NCT06305728|DIAGNOSTIC_TEST|HP MRI|Participants who choose to will undergo HP MRI before surgery.
219046316|NCT06691269|DEVICE|Photobiomodulation|Photomodulation (PBM) is a promising non-tissue penetrating (i.e. minimally invasive) approach for achieving tooth and soft tissue anesthesia/analgesia in dental patients. A patent pending near-infrared laser technology that aims to provide dental analgesia will be used for PBM. This intra-oral PBM device comes with a tip comprising of a series of photonic emitters with specific wavelengths that can go through the tooth structure and bone, blocking the nerve conduction like local anesthetics. Research has shown that one burst of light application (for about 20 second) can provide up to 15-20 minutes of pain relief. Based on existing research PBM does not present a serious risk to health, safety, or welfare of a subject.
219622332|NCT06305728|COMBINATION_PRODUCT|Blood assay|Will be drawn within 6 weeks of surgery and annually as post operative care
219046317|NCT06691269|DRUG|Topical Benzocaine|Topical Benzocaine at injection site to reduce discomfort of local infiltration
219046318|NCT06691269|DRUG|Local Anesthesia|Local infiltration using local anesthetics with epinephrine
219046319|NCT07019766|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
219046320|NCT07021144|BEHAVIORAL|"VA|PREVENTION web application (digital intervention)"|"VA\|PREVENTION web app, a digital intervention incorporating behaviour change techniques delivered by a Virtual Human Coach (VHC), educational content and progress tracking via a dashboard."
219545609|NCT06078501|DRUG|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
219545610|NCT06078501|DRUG|Placebo|Placebo buccal administration 2-3 hours prior to procedure
219545611|NCT04728542|DEVICE|ORIGIN PS System|70 surgeries with the ORIGIN PS System
219545612|NCT04728542|DEVICE|VANGUARD PS System|70 surgeries with the VANGUARD System
219545613|NCT03155503|DRUG|SUVN-911|Oral Tablet
219545614|NCT03155503|DRUG|Placebo|Oral Tablet
219545615|NCT00197353|DRUG|Epidural bupivacaine (dose/concentration/volume ranging)|
219545616|NCT01380782|DRUG|BIBF 1120|200 mg BID oral for 28 day cycle
219545617|NCT05747469|DRUG|local anaesthetic injection|Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
219545618|NCT05747469|PROCEDURE|Human Adipose Allograft|Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
219622333|NCT06317987|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
219622334|NCT06381154|PROCEDURE|Biopsy|Undergo biopsy
219622335|NCT06381154|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622336|NCT06381154|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219622337|NCT06381154|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
218935274|NCT04932408|OTHER|Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.|A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
219545619|NCT06627868|DIETARY_SUPPLEMENT|NAD+ precursor|NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
219545620|NCT06627868|OTHER|Placebo|Oral placebo daily intake for 6 months
219545621|NCT01839344|DIETARY_SUPPLEMENT|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
219545622|NCT01839344|DRUG|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
218935275|NCT02831972|DRUG|AG120|
218935276|NCT02831972|DRUG|Itraconazole|
218935277|NCT04690023|PROCEDURE|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
219046321|NCT07021144|BEHAVIORAL|Type 2 Diabetes Guidebook|T2D prevention guidebook, an educational material that include standard guidelines on healthy eating and the importance of regular physical activity and reduction of sedentary behaviour.
219046322|NCT07019038|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-AIHA will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
219046323|NCT07019116|OTHER|Standard gatekeeping|Human evaluators (mostly physicians) review referrals and determine, based on established protocols, whether they should be authorized.
219046324|NCT07019116|OTHER|AI algorithm|An AI algorithm was developed to perform the first evaluation (triaging) of the referrals inserted in the electronic referral system from the Rio Grande do Sul Health Department.
219046325|NCT07019116|OTHER|Subsequent interactions between primary care and regulation system|After the first evaluation of a referral, several subsequent rounds of interaction between gatekeepers and primary care physicians can be conducted to further detail patient needs and urgency.
219545623|NCT01839344|DRUG|placebo|An oral single dose of a solid, colored empty capsule.
219545624|NCT03676946|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
219545625|NCT03676946|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
219545626|NCT03676946|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
219545627|NCT03125447|OTHER|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
219545628|NCT04580784|RADIATION|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
219622338|NCT06381154|DRUG|Fluorouracil|Given IV
219622339|NCT06381154|DRUG|Irinotecan|Given IV
219622340|NCT06381154|DRUG|Leucovorin|Given IV
219622341|NCT06381154|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
219622342|NCT06381154|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219622343|NCT06381154|DRUG|Oxaliplatin|Given IV
219622344|NCT06381154|BIOLOGICAL|Pembrolizumab|Given IV
219545629|NCT02369822|DIETARY_SUPPLEMENT|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
219545630|NCT06556849|DEVICE|Defocus Incorporated Multiple Segments (DIMS)|To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
219545631|NCT05967286|DRUG|Alpelisib|Given PO
219545632|NCT05967286|PROCEDURE|Biopsy|Undergo biopsy
219545633|NCT05967286|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219545634|NCT05967286|PROCEDURE|Bone Scan|Undergo bone scans
219545635|NCT05967286|PROCEDURE|Computed Tomography|Undergo CT
219545636|NCT05967286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219545637|NCT05967286|DRUG|Olaparib|Given PO
219545638|NCT05967286|PROCEDURE|Positron Emission Tomography|Undergo PET
219545639|NCT03965286|DRUG|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
219205910|NCT06892873|OTHER|Traditional dental injection|Application of Traditional Dental Injection Method Palatal injection; It was applied 5-10 mm below the palatal gingival margin\*, on the attached gum, and with a 45-degree needle angle. After needle entry, 0.2 mL of anesthetic solution was stored when bone contact was removed. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine and a 27 G dental needle were used as local anesthetic agents for injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
219545640|NCT05264363|DEVICE|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
219545641|NCT00003035|BIOLOGICAL|filgrastim|
219545642|NCT00003035|DRUG|doxorubicin hydrochloride|
219545643|NCT00003035|DRUG|paclitaxel|
219545644|NCT00003035|DRUG|tamoxifen citrate|
219545645|NCT00003035|PROCEDURE|surgical procedure|
219545646|NCT00003035|RADIATION|radiation therapy|
219545647|NCT05039996|BEHAVIORAL|education and relaxation program|randomized controlled trial
219545648|NCT01447017|DRUG|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
219545649|NCT01447017|DRUG|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
219545650|NCT03877939|DIAGNOSTIC_TEST|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
219545651|NCT01701063|DRUG|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
219545652|NCT01701063|DRUG|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
219205911|NCT06893744|DEVICE|occlusal splint|
219205912|NCT06892860|DRUG|Avelumab|Avelumab treatment will be given up to a maximum of 2 years from the end of chemotherapy
219545653|NCT01701063|DRUG|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
219545654|NCT02365363|OTHER|Control|Non pulse ingredient bagel
219545655|NCT02365363|OTHER|Pea flour|Pulse ingredient bagel
219545656|NCT02365363|OTHER|Pea fibre|Pulse ingredient bagel
219545657|NCT02365363|OTHER|Pea flour and pea fibre|Pulse ingredient bagel
219545658|NCT02365363|OTHER|Pea flour and pea protein|Pulse ingredient bagel
219545659|NCT02365363|OTHER|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
219545660|NCT05387408|BEHAVIORAL|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
219545661|NCT01154712|DEVICE|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
219545662|NCT01154712|DEVICE|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
219545663|NCT01773408|DRUG|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
219545664|NCT01773408|DRUG|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
219545665|NCT01773408|DRUG|Idarubicin|Idarubicin will be administered as per standard clinical practice.
218935278|NCT04690023|PROCEDURE|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
219205913|NCT06737887|OTHER|Stoma simulation|Patients who will undergo stoma surgery will have an intervention one day before the surgery. The adapter will be cut to an estimated stoma size, heated by rubbing with hands and adapted to the skin by applying stoma paste. The patient will be asked to place their hand on the adapter and apply pressure. Then, the stoma bag filled with tissues and water and the adapter will be combined. The patient will be informed that they should not hesitate to do any activity that they will spend 24 hours with the stoma bag. The patient will be provided with the opportunity to go to the toilet, eat, sleep and experience all their daily activities with the stoma. It allows patients to experience the stoma bag by putting it on 24 hours before the surgery. In this way, patients know that they will not encounter any surprises after the surgery.
219205914|NCT06736392|PROCEDURE|Ultrasound guided Pericapsular Nerve Group Block|"With the patient in the supine position and the leg slightly abducted, a curvilinear transducer (2.5-7.5 MHz) is prepared with sterile conduction gel and covered with a sterile probe cover. The transducer is placed transversely over the anterior superior iliac spine (ASIS), then aligned with the pubic ramus and rotated approximately 45° parallel to the inguinal crease. The probe is slid medially to identify key landmarks: the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas tendon, femoral artery, and femoral nerve. Sliding the probe distally or tilting caudally exposes the femoral head.~A 20-22 gauge echogenic needle (100 mm) is inserted in-plane from lateral to medial, targeting the plane between the psoas tendon and the pubic ramus. the anesthetic agent is deposited to lift the psoas tendon while avoiding tendon puncture."
219205915|NCT06736392|DRUG|Isobaric Bupivacaine 0. 25%|group c will receive PENG block with only 20ml isobaric bupivacaine 0.25%
219205916|NCT06736392|DRUG|20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine|group D will receive PENG block with 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine
219205917|NCT06736392|DEVICE|the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)|the two groups will receive the PENG block under ultrasound guidance
219205918|NCT06736392|DEVICE|a standard echogenic 20-22 gauge 100mm needle|the two groups will receive the PENG block using a standard echogenic 20-22 gauge 100mm needle
219205919|NCT06894030|BEHAVIORAL|Gait Training Video|Personalized gait training videos featuring cued and non-cued gait for participants
219205920|NCT06894030|BEHAVIORAL|Cognitive Cue|A verbal cue to be mentally rehearsed by each participant
218935279|NCT04690023|DRUG|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
218935280|NCT04690023|DRUG|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
219046326|NCT07018895|DRUG|Sham treatment|ambient air (FiO2 = 21%) will be delivered for 3 days 1 time a day for 45 minutes
219046327|NCT07018895|DRUG|FiO2 reduced by 20% alternating with 34% FiO2|FiO2 reduced by 20% alternating with 34% FiO2
219046328|NCT07020117|DRUG|[225Ac]Ac-AKY-1189 (therapeutic)|\[225Ac\]Ac-AKY-1189 Injection
219046329|NCT07020117|DRUG|[64Cu]Cu-AKY-1189 (imaging)|\[64Cu\]Cu-AKY-1189 Injection
219046330|NCT07021209|BIOLOGICAL|GT719 Injection|GT719 Injection
219046331|NCT07019818|DRUG|Esmolol Hcl 10Mg/Ml Inj|Esmolol is an injectable cardioselective beta-blocker, preferentially inhibiting beta-1 adrenergic receptors, while avoiding an increase in peripheral vascular resistance.
219046332|NCT07019818|DRUG|Sufentanil 5 mcg|Sufentanil is a synthetic opioid with the pharmacological properties of a µ-receptor agonist.
219205921|NCT06893172|OTHER|Warm acupuncture and Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks, combined with warm acupuncture at the Ashi point, EX-B2, LI4, TE6, PC5 and SP6, five times a week for 4 weeks.
219545666|NCT01773408|DRUG|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
219545667|NCT01773408|DRUG|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
219622345|NCT06381154|DRUG|Photodynamic Therapy|Undergo intratumoral photoradiation
219622346|NCT06381154|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and PET/MRI
219622347|NCT06381154|OTHER|Questionnaire Administration|Ancillary studies
219622348|NCT06381154|DRUG|Verteporfin|Given IV
219622349|NCT04968184|DRUG|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
218935281|NCT04237116|BIOLOGICAL|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
218935282|NCT04237116|BIOLOGICAL|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
219046333|NCT07018323|DRUG|IMVT-1402|Dose 1 for 26 weeks
219046334|NCT07018323|DRUG|IMVT-1402|Dose 2 for 26 weeks
219046335|NCT07018323|DRUG|Placebo|For 26 weeks
219046336|NCT07019792|OTHER|Protaper ultimate|Using Protaper Ultimate file system for canal preperation
219046337|NCT07019792|OTHER|Truanatomy file system|Using Truanatomy file system for canal preperation
219046338|NCT07019792|OTHER|Hyflex EDM|Using Hyflex file system for canal preperation
219046339|NCT07019792|OTHER|Xp shaper rise|Using XPshaper rise system for canal preperation
219046340|NCT07024329|OTHER|Remote Symptom Monitoring and Management|A study nurse will digitally monitor symptom complexity and provide symptom management between clinic visits. This will increase the frequency of collection and use of electronic PROs to provide responsive symptom management. Electronic PROs are collected digitally, and a complexity algorithm is used to flag patients with high symptom complexity. This will allow the study nurse to proactively manage symptoms in a timelier way.
219205922|NCT06893172|DRUG|Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks
219205923|NCT06892626|PROCEDURE|RIRS|RIRS performed in lithotomy position for which guide wire pass to the kidney, then passing ureteral dilators up to 14F and ureteral access sheath. Dusting stones by RIRS and holmium laser Fiber 200 mm, at the end of operation DJ was fixed.
219205924|NCT06892626|PROCEDURE|PNL|PNL performed in prone position, after passing guide wire and ureteric catheter in lithotomy position. Puncture to the kidney, passing 2 wires, then using renal dilators and access sheath to enter kidney by nephroscopy, fragment stones by pneumatic and remove stones, then place nelaton 28F at end of operation
219205925|NCT06892808|PROCEDURE|Non-Surgical Periodontal Therapy|"Under local anesthesia, full-mouth debridement (supragingival and subgingival scaling and root planing, FM-SRP) was performed by an experienced periodontist, initiated within 48 hours post-atrial fibrillation ablation and completed in two sessions within 48 hours. Polishing was performed using a rubber cup with prophylaxis paste. The procedure utilized Gracey curettes and piezoelectric ultrasonic tips combined with a force-controlled system.~Postoperative Care Immediate Care: Local Adjunctive Therapy: 2% minocycline gel was injected into deep periodontal pockets (PD ≥5mm). Antimicrobial Rinse: 0.12% chlorhexidine solution (15 mL, 30-second rinse twice daily) for 14 days.~Follow-Up Intervention At the 6-month follow-up, additional oral debridement was performed in the intervention group if indicated by the presence of bleeding points and/or increased probing pocket depth (PPD)."
219205926|NCT06892808|PROCEDURE|Background Periodontal Care|All study participants received oral hygiene instruction using the modified Bass technique. At baseline, supragingival deposits (dental plaque and calculus) were removed with an ultrasonic scaler or rubber cup with prophylaxis paste. To maintain blinding, simulated subgingival instrumentation sounds were played during the procedure for control group participants.
219205927|NCT06894186|OTHER|Gaenial universal injectable|GC Gaenial universal injectable advanced injectable composite with nano sized filler that merge the adaptation of flowable composite and mechanical properties of hybird composite
219205928|NCT06736925|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|DHA+EPA capsules contain purified deep-sea fish oil, made from 100% wild-caught sardines and anchovies with a 3-year shelf life. The capsule shell is made from bovine limed bone with a size of 20 oblongs. Each soft gel capsule contains 480 mg of DHA, 205 mg of EPA, 145 mg of other omega-3 FA, and 10 mg of vitamin E. Participants in the DHA+EPA group will ingest 5 capsules daily \[a total of 3.4 g/d: DHA (2.4 g), EPA (1.0 g)\].
218935283|NCT00619710|DRUG|Meropenem|Intravenous
219205929|NCT06736925|DIETARY_SUPPLEMENT|Organic soybean oil|We will use organic soybean oil pills ) as a placebo condition for the DHA+EPA group. One capsule contains 485 mg of organic soybean oil, including negligible amounts of DHA (1.1 mg), EPA (1.7 mg), and vitamin E (10 mg). Participants will ingest 5 capsules daily. Soybean oil is one of the most widely used vegetable oils in the world. Soybean oil contains polyunsaturated fats and 18-carbon omega-3 FA (total omega-3 FA of 73.9 mg per capsule), but very low levels of DHA and EPA, which makes it an excellent placebo counterpart when evaluating the effects of DHA/EPA. The placebo capsule's shelf life, composition, shape, size as the DHA+EPA active comparator.
219205930|NCT06736925|OTHER|Soccer Heading Model|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer (G-force tracker) embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 30 mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
219205931|NCT06737835|DEVICE|18 FDG|18 flurodeoxy glucose PET/CT
219205932|NCT06738875|DEVICE|manometre|Increases in peak and mean airway pressures of ETT cuff pressures will be monitored in patients undergoing laparoscopic bariatric surgery
219205933|NCT06739564|PROCEDURE|ICE PACKING|ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.
219545668|NCT06559917|OTHER|life review|"After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed."
219545669|NCT03657550|DRUG|Levamlodipine, Amlodipine|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
219622350|NCT04968184|DRUG|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
219622351|NCT04057729|DRUG|IMP4297|10mg/capsule.
219622352|NCT01163201|BIOLOGICAL|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)
219622353|NCT01163201|BIOLOGICAL|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
219622354|NCT01163201|DRUG|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour
218935284|NCT00619710|DRUG|Imipenem-cilastatin|Intravenous
218935285|NCT06428968|DRUG|160 units nasal insulin spray|Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.
219545670|NCT03657550|DRUG|Amlodipine, Levamlodipine|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
219545671|NCT05571449|PROCEDURE|Open reduction and internal fixation|Internal fixation of the fracture
219545672|NCT05571449|PROCEDURE|Standard osteosynthesis planning|Plain radiograph and CT images are used
219545673|NCT05571449|PROCEDURE|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
219545674|NCT02695472|DRUG|80 Milligrams NSI-189|Orally Administered
219545675|NCT02695472|DRUG|Placebo|Orally administered
219545676|NCT02695472|DRUG|40 Milligrams NSI-189|Orally Administered
219545677|NCT05963750|OTHER|virtual reality|virtual reality
219545678|NCT03428750|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
219545679|NCT03428750|BIOLOGICAL|Placebo|Placebo
219545680|NCT01787565|OTHER|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
219545681|NCT01787565|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
218935286|NCT00472030|DRUG|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
218935287|NCT00472030|DRUG|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
219046341|NCT07024329|OTHER|Clinic Team Huddle|Support will be provided to clinic teams to implement a team huddle (team planning session) one week prior to clinics, to assess how additional electronic PROs data for patients participating in RESPONd impacts their ability to identify stable patients with low symptom complexity who could receive virtual care or Registered Nurse (RN) led clinic care.
219046342|NCT07024225|PROCEDURE|Endoscope|Lower endoscopy
219046343|NCT07018986|OTHER|MIND Diet|a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.
219046344|NCT07018986|OTHER|Usual Diet|Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.
219046345|NCT07023601|OTHER|Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma|All patients will undergo a local tumor radical excision and unilateral (if medial border \> 1 cm from midline) or bilateral (medial border \< or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .
219046346|NCT07023744|DRUG|Placebo|Placebo arm: participants will receive Placebo MPL-012 oil only through the trial participation. MPL-012 is produced by MediPharm Labs, each mL contains 0mg CBD and 0mg THC.
219046347|NCT07023744|DRUG|CBD Isolate|CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.
219046348|NCT07023744|DRUG|CBD CHE|CBD-CHE arm: MPL -016 is a CBD-enriched cannabis herbal extract, produced by MediPharm Labs, each mL contains 100mg of CBD and 3mg of THC.
219205934|NCT06739564|PROCEDURE|DRY NEEDLING|DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
218935288|NCT03690297|DEVICE|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
218935289|NCT00829504|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
219046349|NCT06097845|DIAGNOSTIC_TEST|Transcranial Ultrasound|Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
219545682|NCT03957226|DEVICE|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
219545683|NCT00000330|DRUG|Opioid-Related Disorders|
219549923|NCT02032927|DRUG|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
219549924|NCT02539628|DRUG|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
218935290|NCT00829504|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg
218935291|NCT03212144|OTHER|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
219549925|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
219549926|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
219549927|NCT00895050|OTHER|Review of clinical records|
219545684|NCT05668689|OTHER|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
219545685|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
219545686|NCT00243425|PROCEDURE|Standard Quality Improvement|
219545687|NCT00243425|PROCEDURE|Patient-centered Intervention|
219545688|NCT06396286|PROCEDURE|single rod|surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
218935292|NCT03212144|OTHER|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
218935293|NCT02841904|DEVICE|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
218935294|NCT06052319|DEVICE|Care4Today® Connect CAD-PAD Mobile Application|Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
219545689|NCT01078350|PROCEDURE|tumor tissue aspiration|
219545690|NCT01078350|PROCEDURE|phlebotomy|
219545691|NCT03058614|DRUG|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
218935295|NCT02668978|DEVICE|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
218935296|NCT02668978|PROCEDURE|Standard surgical technique|Lung resuturing or restapling
218935297|NCT05949021|DRUG|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
219622355|NCT01163201|DRUG|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
218935298|NCT05462379|PROCEDURE|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
218935299|NCT03882255|DRUG|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
218935300|NCT03882255|DRUG|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
218935301|NCT03882255|DRUG|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
218935302|NCT02838394|PROCEDURE|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
218935303|NCT02838394|OTHER|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
219046350|NCT06879457|BEHAVIORAL|PCC-based mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, using a person-centred care (PCC) approach.
219046351|NCT06879457|BEHAVIORAL|Provider-led mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, based on the conventional provider-led model.
219046352|NCT06695845|DRUG|Zanidatamab|Administered by intravenous (IV) infusion
219046353|NCT06900985|BEHAVIORAL|8-sessions CBT + App|It will consist of 8 one-hour sessions applied in group format once a week and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The smoking cessation treatment follows a cognitive-behavioral approach with components for anhedonia reduction, increased physical activity and positive social support, being a modified, multidisciplinary, and extended version of the original smoking cessation program (Becoña, 2007; Becoña et al., 2017). The treatment will be complemented with an App with active therapeutic components that participants will use during treatment and the one-year follow-up period.
219205935|NCT06889948|DRUG|Daratumumab|All patients will receive either fixed-dose daratumumab as a single agent therapy or fixed-dose daratumumab combined with stem cell transplantation.
219545692|NCT03058614|DIAGNOSTIC_TEST|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
219622356|NCT01163201|RADIATION|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
219622357|NCT01163201|BIOLOGICAL|Umbilical cord blood transplantation|Infusion given on day 0
219545693|NCT03058614|DIAGNOSTIC_TEST|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
219205936|NCT06668077|DEVICE|iTBS of the left DLPFC|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the DLPFC of the left hemisphere while not performing any other task
218935304|NCT06849258|DEVICE|FloStent|Flexible cystoscopy to deploy medical device used to treat BPH
218935305|NCT06849258|DEVICE|Sham (Control)|Flexible Cystoscopy without deployment of medical device used to treat BPH
219205937|NCT06668077|DEVICE|iTBS of the vertex|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the vertex while not performing any other task
219545694|NCT01919112|DEVICE|tDCS|Anodal tDCS will be administered with swallowing exercises
219545695|NCT00027664|BIOLOGICAL|recombinant interferon alfa|
219545696|NCT00027664|DRUG|thalidomide|
219545697|NCT02095379|OTHER|oligosecretary|not abvailable
219545698|NCT04263506|OTHER|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
219545699|NCT04467151|DRUG|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
219545700|NCT04467151|OTHER|Placebo|Administration of placebo (albumin 5%)
219545701|NCT02554877|DRUG|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
219545702|NCT02554877|DRUG|Placebo|oral tablet
219545703|NCT01601405|DRUG|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
219545704|NCT01601405|DRUG|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
219545705|NCT00274651|DRUG|belinostat|
219545706|NCT04474405|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
219545707|NCT04474405|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
219545708|NCT04474405|PROCEDURE|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
219545709|NCT04474405|DRUG|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
219545710|NCT04474405|PROCEDURE|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
219545711|NCT05571462|OTHER|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
218935306|NCT03532828|OTHER|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
218935307|NCT06451757|DRUG|Sonlicromanol|Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks
218935308|NCT06451757|DRUG|Placebo|Oral administration of 100 mg placebo twice daily during 52 weeks
218935309|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
218935310|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
218935311|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
219545712|NCT03659994|DIETARY_SUPPLEMENT|Multivitamin|Vitabeard
219545713|NCT03659994|DIETARY_SUPPLEMENT|Placebo|Placebo
219545714|NCT00635648|DRUG|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
219545715|NCT02956525|DRUG|Dexibuprofen|Dexibuprofen 200 mg
219545716|NCT04547192|OTHER|Improving initial care of the injured|Improvement in Care Processes
219545717|NCT06182722|DIAGNOSTIC_TEST|Mental assessments|Patients will receive psychiatric rating scales evaluation every visit.
219545718|NCT03720444|OTHER|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
219545719|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
219549928|NCT02901730|PROCEDURE|532nm laser group|LPI with 532nm laser.
219549929|NCT02901730|PROCEDURE|561nm laser group|LPI with 561nm laser.
219549930|NCT00006453|DRUG|carboplatin|
219549931|NCT00006453|DRUG|gemcitabine hydrochloride|
219549932|NCT04358367|DRUG|Dexmedetomidine Injectable Product|Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
219549933|NCT04358367|DRUG|Saline|Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
219545720|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
219545721|NCT04194801|DRUG|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
219545722|NCT05213286|DIAGNOSTIC_TEST|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
219545723|NCT04981704|DRUG|Poziotinib|Poziotinib Tablets
219545724|NCT04981704|DRUG|Itraconazole|Itraconazole Oral solution
219545725|NCT04981704|DRUG|Phenytoin|Phenytoin Capsules
219545726|NCT04981704|DRUG|Paroxetine|Paroxetine Tablets
218935312|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
218935313|NCT01422343|PROCEDURE|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
218935314|NCT02267837|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
218935315|NCT01209533|DRUG|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
218935316|NCT02178137|DRUG|Diacerien|
218935317|NCT02178137|DRUG|Glucosamine/Chondroitin|
218935318|NCT02178137|DRUG|Placebo|
218935319|NCT06073561|OTHER|learning curve of Underwater mucosectomy|Patients will be submitted to underwater mucosectomy (U-EMR)
218935320|NCT03461588|RADIATION|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
219046354|NCT06900985|BEHAVIORAL|4-sessions CBT+App|It will consist of 4 one-hour sessions applied in group format every two-weeks (8 weeks total duration) and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The 4 sessions will have the following content: 1) explanation of treatment rationale and components available in the App; 2) participants' progress monitoring, reinforcement of achieved goals, and analysis of difficulties; 3) cessation planning support; and 4) relapse prevention support. The treatment sessions will be protocolized in a treatment manual. The treatment will be complemented with the same App that the other conditions
219046355|NCT06900985|BEHAVIORAL|Smoking cessation App|It will consist in the same App than the other two conditions. No therapeutic contact will be avaliable.
219046356|NCT07075094|PROCEDURE|Bladder stimulation|This stimulation consists of two stages. In the first maneuver, the bladder is stimulated by gentle tapping of the suprapubic area for 30 seconds. In the second maneuver, the paravertebral area is massaged in a circular motion for 30 seconds. The two stimulation maneuvers are repeated sequentially for 5 minutes.
219046357|NCT07075094|PROCEDURE|Subrapubic cutaneous stimulation|Circular rubbing movements will be made on the baby's suprapubic area with gauze soaked in cold salt water until micturition begins.
219046358|NCT07125261|DRUG|BHV-700|75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)
219046359|NCT06665100|DRUG|PUL-042|Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution
219046360|NCT06665100|DRUG|Placebo|Sterile Saline for Inhalation
219046361|NCT03290456|DRUG|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
219046362|NCT03290456|DRUG|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
219046363|NCT07087210|OTHER|Positron Emission Tomography (PET)|18F-TPP+ PET/CT imaging
219046364|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
219046365|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
219545727|NCT01942239|DEVICE|real time continuous glucose monitoring|
219545728|NCT01923740|DEVICE|XIENCE V EECSS|Subjects receiving XIENCE V
219545729|NCT01923740|DEVICE|Absorb BVS System|Subjects receiving Absorb BVS System
219545730|NCT00005040|DRUG|arsenic trioxide|
219545731|NCT06433388|DEVICE|MRI|Magnetic Resonance Imaging (MRI) is a non-invasive imaging technology that produces three dimensional detailed anatomical images. Patients will be subjected to MRI scans and imaging of the kidneys and liver
219545732|NCT04723693|OTHER|Qualitative Interview|A single one hour semi structured qualitative interview
219545733|NCT03953703|DRUG|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
219545734|NCT03953703|DRUG|Placebo|Placebo 1000 mg twice per day for 6 weeks
219545735|NCT03969628|DIAGNOSTIC_TEST|ICCMS|Risk caries assessment will consider ICCMS criteria
219545736|NCT01468623|OTHER|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
219545737|NCT01468623|OTHER|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
219545738|NCT02922569|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
219545739|NCT02922569|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
219545740|NCT02922569|OTHER|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
219545741|NCT02922569|OTHER|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
219549934|NCT01148069|PROCEDURE|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
219549935|NCT05919901|OTHER|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
219549936|NCT02248714|DIETARY_SUPPLEMENT|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
219545742|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
219545743|NCT01410227|BIOLOGICAL|Recombinant von Willebrand factor (rVWF)|Intravenous administration
219545744|NCT01410227|DRUG|Placebo|Syringe supplied with physiologic saline solution for infusion
219545745|NCT01410227|BIOLOGICAL|Recombinant factor VIIII (rFVIII)|Intravenous administration
219545746|NCT04571294|PROCEDURE|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
219545747|NCT04037722|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
219545748|NCT04037722|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
219545749|NCT04692558|BIOLOGICAL|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
219545750|NCT04692558|PROCEDURE|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
219622358|NCT03943693|DEVICE|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
219622359|NCT03943693|DEVICE|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
219622360|NCT03103438|BIOLOGICAL|BCD-089|
219622361|NCT05809869|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
218935321|NCT03461588|RADIATION|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
218935322|NCT00912197|DIETARY_SUPPLEMENT|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
218935323|NCT00912197|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
218935324|NCT01006993|DEVICE|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
218935325|NCT04373252|BIOLOGICAL|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
219046366|NCT06805318|BEHAVIORAL|Vocational Rehabilitation intervention for pwMS|"The VR intervention will cover three areas of intervention:~* Rehabilitation Area: this intervention has the goal of managing the work performance from a rehabilitative point of view.~* Reasonable accommodation area: this intervention has the goal of assessing the needs of reasonable accommodations, such has workspace modification, change in organization of the activities, management of work time, etc.., and propose it to the employer.~* Educational and Formative Area: this area is responsible for the implementation of educational intervention for the employees and the employers about multiple sclerosis and its impact on work performance, the rights and obligations of the employer and employee about disability management on the workplace."
219545751|NCT06467513|DRUG|Esketamine hydrochloride injection|The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
219622362|NCT05809869|DRUG|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
219622363|NCT05809869|RADIATION|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
219545752|NCT03954808|OTHER|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
219545753|NCT03954808|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
219545754|NCT03319108|OTHER|Exercise|Pulmonary Rehabilitation Program for 8 weeks
219205938|NCT06668077|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation after the iTBS, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, otherwise 1 point will be lost. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
219205939|NCT01553149|DRUG|Lenalidomide|Given PO
219205940|NCT01553149|OTHER|Pharmacological Study|Correlative studies
219545755|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
219545756|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
219545757|NCT02188628|DEVICE|H-Man|H-man is a portable end-effector planar upper limb robot.
219545758|NCT02188628|OTHER|Additional Conventional Therapy|Repetitive goals based arm therapy
219545759|NCT06258746|DRUG|[14C]HSK31679|A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
219545760|NCT00002220|DRUG|Indinavir sulfate|
219205941|NCT04386746|DRUG|Gemcitabine|1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
218935326|NCT03422094|BIOLOGICAL|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
218935327|NCT03422094|BIOLOGICAL|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
219205942|NCT04386746|DRUG|Docetaxel|37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
219545761|NCT00002220|DRUG|Efavirenz|
219545762|NCT00002220|DRUG|Levocarnitine|
219205943|NCT06747026|DRUG|initial Sequential iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days."
219545763|NCT00002220|DRUG|Adefovir dipivoxil|
219545764|NCT02890992|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
219545765|NCT02890992|DRUG|statins|Pharmaceutical form: tablet Route of administration: oral
219545766|NCT02890992|DRUG|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
218935328|NCT03422094|BIOLOGICAL|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
219545767|NCT02890992|DRUG|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
219545768|NCT02890992|DRUG|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
219545769|NCT02890992|DRUG|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
219545770|NCT02890992|DRUG|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
219545771|NCT06562374|DEVICE|Low Frequency Ultrasound Therapy|The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
219545772|NCT01522820|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
219545773|NCT01522820|OTHER|Laboratory Biomarker Analysis|Correlative studies
218935329|NCT03422094|PROCEDURE|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
219545774|NCT01522820|OTHER|Pharmacological Study|Correlative studies
219545775|NCT01522820|DRUG|Sirolimus|Given PO or PEG
219545776|NCT06157268|OTHER|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
219545777|NCT02287844|OTHER|XOS|5 g of XOS everyday for 4 weeks.
219545778|NCT02287844|OTHER|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
219545779|NCT02287844|OTHER|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
219545780|NCT02799992|PROCEDURE|689 nm Laser Treatment of the Macula|
219545781|NCT02799992|PROCEDURE|Half Dose Photodynamic Therapy|
219545782|NCT00669162|DRUG|Docetaxel|20mg/m2 IV weekly for 7 weeks
219545783|NCT00669162|RADIATION|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
219545784|NCT00669162|DRUG|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
219545785|NCT02680444|BEHAVIORAL|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
219545786|NCT02680444|BEHAVIORAL|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
219545787|NCT02680444|BEHAVIORAL|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
219545788|NCT01528163|DRUG|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
219545789|NCT01528163|DRUG|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
218935330|NCT03422094|PROCEDURE|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
218935331|NCT04288284|PROCEDURE|Curative resection of colorectal cancer|
218935332|NCT06268977|DRUG|SGLT2 inhibitor|a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
219205944|NCT06747026|DRUG|initial Concurrent iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT."
219545790|NCT05779943|DRUG|Furosemide|Given IV
219545791|NCT05779943|OTHER|F18-rhPSMA-7.3|Given IV
219545792|NCT05779943|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219545793|NCT05779943|PROCEDURE|Computed Tomography|Undergo PET/CT scan
218935333|NCT02538354|DIETARY_SUPPLEMENT|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
219545794|NCT05548465|DRUG|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
218935334|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
218935335|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
218935336|NCT03801044|DIAGNOSTIC_TEST|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
218935337|NCT03801044|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
219205945|NCT06747026|DRUG|RT with maintenance of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
219205946|NCT06747026|DRUG|RT after discontinuation of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
219545795|NCT05548465|DRUG|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
219545796|NCT00911274|DRUG|Mycophenolate Mofetil|250 mg Capsule
219545797|NCT00911274|DRUG|CellCept®|250 mg Capsule
219545798|NCT00807495|DRUG|Alisertib|Alisertib capsules
219545799|NCT05877274|OTHER|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
219545800|NCT00870662|DEVICE|AFS System|AFS System with patient specific flow rate
219545801|NCT04393818|BEHAVIORAL|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
219545802|NCT04376203|PROCEDURE|Thyroidectomy|Typical Thyroidectomy
219545803|NCT03198923|BIOLOGICAL|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
219545804|NCT03822130|DRUG|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
219545805|NCT03822130|DRUG|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
219545806|NCT03822130|DRUG|Systemic Chemotherapy|Systemic Chemotherapy
219545807|NCT03822130|DRUG|Oral Chemotherapy|Oral Chemotherapy
219545808|NCT02719665|DIETARY_SUPPLEMENT|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
219545809|NCT02719665|DIETARY_SUPPLEMENT|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
219545810|NCT02719665|DIETARY_SUPPLEMENT|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
219545811|NCT02412852|DRUG|Sodium nitrite|Sustained release formulation of sodium nitrite
219545812|NCT02412852|DRUG|Placebo|Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
219545813|NCT04737863|PROCEDURE|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
219545814|NCT03142022|OTHER|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
219545815|NCT04880616|DRUG|NBI-827104|Capsules for oral administration
219545816|NCT04880616|DRUG|Placebo|Capsules matching NBI-827104 for oral administration
219545817|NCT01174186|DRUG|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
219545818|NCT05274763|OTHER|Quality-of-Life Assessment|Ancillary studies
219545819|NCT05274763|OTHER|Questionnaire Administration|Ancillary studies
219545820|NCT05274763|PROCEDURE|Spiritual Therapy|Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
219545821|NCT06241963|DEVICE|Active Comparator: Unilateral real High definition transcranial direct current stimulation|Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
219545822|NCT06241963|DEVICE|Active Comparator: Bilateral real High definition transcranial direct current stimulation|Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
219046367|NCT06888609|OTHER|Back Extensor Strengthening Exercises|"1. Superman Exercise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~2. Prone Arm and Leg Raise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~3. Seated Row (Resistance Band) Sets/Reps: 2 sets × 12-15 reps, hold 3-5 sec~4. Wall Angels Sets/Reps: 2 sets × 10-12 reps, 3-5 sec per cycle"
219046368|NCT06888609|OTHER|Core Stability Exercises|"1. Side Plank Sets/Reps: 3 sets, hold 10-60 sec per side~2. Dead Bug Exercise Sets/Reps: 3 sets × 6-15 reps per side~3. Bridging Exercise Sets/Reps: 3 sets × 10-20 reps, hold 2-5 sec~4. Bird-Dog Exercise Sets/Reps: 3 sets × 8-15 reps per side, hold 2-5 sec"
219545823|NCT06241963|DEVICE|Sham Comparator: Sham High definition transcranial direct current stimulation|The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
219545824|NCT01237691|BEHAVIORAL|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
219545825|NCT01237691|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
219545826|NCT00250263|DRUG|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
219545827|NCT00250263|DRUG|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
219545828|NCT01555086|PROCEDURE|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
219622364|NCT03749876|OTHER|Unfiltered Cigarettes|Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
219622365|NCT03749876|OTHER|Filtered Cigarettes|Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
219545829|NCT01555086|PROCEDURE|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
219545830|NCT02960295|DEVICE|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
219545831|NCT02960295|DEVICE|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
219545832|NCT02960295|DEVICE|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
219545833|NCT02960295|DEVICE|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
219545834|NCT02960295|PROCEDURE|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
219545835|NCT03165669|DEVICE|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
219545836|NCT03165669|OTHER|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
219545837|NCT03601403|DEVICE|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
218935338|NCT03801044|RADIATION|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
218935339|NCT03801044|DIAGNOSTIC_TEST|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
218935340|NCT03801044|DIAGNOSTIC_TEST|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
218935341|NCT05687500|DRUG|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
218935342|NCT05687500|BIOLOGICAL|Pharmacokinetics study|"* For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);~* For subsequent patients included during phase II:~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment~* 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.~* In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution."
218935343|NCT05687500|BIOLOGICAL|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized
218935344|NCT05687500|BIOLOGICAL|Routine biological monitoring|"If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.~Transaminases and hemostasis will be done only in case of clinical indication before the first administration."
219046369|NCT07096102|BEHAVIORAL|ENRICH Group|Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows: (1) Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory:①Strengthening skills related to Health Information Literacy; ②Training on Medication Management Skills;③ Practice of Self-Monitoring Skills;④Education on Diet and Exercise Management Knowledge. (2) Health Behavior Motivation Management Based on the Health Empowerment Theory:① Personalized Goal Setting;②Behavioral Incentives and Feedback;③Construction of Peer Support Networks;④Demonstration Effect of Role Models. (3) Health Management Support System Based on the Health Empowerment Theory:①Online Dynamic Monitoring;②Family-Community Collaborative Support;③Digital Monitoring Platform;④Continuous Supply of Resources.
219545838|NCT06354023|DRUG|Recombinant human growth hormone|All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
219545839|NCT00003223|DRUG|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
219545840|NCT06143202|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor|Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
219545841|NCT05921864|OTHER|Passive heat exposure|Participants will be exposed to heat in a chamber.
219545842|NCT05921864|OTHER|Active heat exposure|Participants will participate to a 6-hour run.
219545843|NCT01066858|DRUG|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
219545844|NCT01844843|DEVICE|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
219545845|NCT05578443|DRUG|10g Astragalus|Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
219545846|NCT05578443|BEHAVIORAL|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
219545847|NCT05578443|DRUG|20g Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
219545848|NCT05726669|OTHER|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
219545849|NCT01306838|DIETARY_SUPPLEMENT|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
219545850|NCT01306838|OTHER|Routine care|Routine care
218935345|NCT01615029|DRUG|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
218935346|NCT01615029|DRUG|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
218935347|NCT01615029|DRUG|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
219046370|NCT07096102|BEHAVIORAL|Routine Care Group|①Distribute 3-5 push publics on screening health information and health disinformation in the first week；②Distribute 3-5 push publics on medicine knowledge in the second week；③Distribute 3-5 push publics on self-monitoring knowledge in the third week；④Distribute 3-5 publics on exercise knowledge in week 4；⑤Distribute 3-5 push publics on dietary knowledge in week 5 and week 6.
219046371|NCT06916039|OTHER|immediate verbal memory after high GI breakfast|Difference in immediate verbal memory after high GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
219046372|NCT06916039|OTHER|immediate verbal memory after low glycemic index breakfast|Difference in immediate verbal memory after low GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
219046373|NCT07172659|DRUG|Dovramilast|Dovramilast
219046374|NCT07172659|DRUG|Prednisolone|Standard of care
219046375|NCT07172659|DRUG|Thalidomide|Standard of care (US only)
219046376|NCT07172945|OTHER|Blood, fecal, saliva|Blood, fecal and saliva samples
219046377|NCT07172945|OTHER|intestinal content samples and biopsies|intestinal content samples and biopsies obtained per upper or lower gastrointestinal tract endoscopy
219046378|NCT07174063|DRUG|JSB462|300 mg or 100 mg once a day (QD) with food
219046379|NCT07174349|DRUG|Uroselective alpha-1-adrenergic receptor antagonist|Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
219046380|NCT07174349|OTHER|Placebo|Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
219046381|NCT07173894|PROCEDURE|Shoulder Field Block by Orthopedic Surgeon|"For Shoulder Field Block intervention:~This intervention involves a regional anesthesia technique targeting the sensory nerves of the shoulder surgical field: the suprascapular, axillary, and lateral pectoral nerves. The block is performed intraoperatively by the orthopedic surgeon using anatomical landmarks after induction of general anesthesia. A mixture of lidocaine with epinephrine, bupivacaine, and saline is injected into the shoulder area to provide local anesthesia and prolonged postoperative analgesia. This technique aims to spare the phrenic nerve, potentially reducing respiratory complications associated with traditional blocks."
219545851|NCT06306404|DRUG|Estrogens and Progestogens|"Menopausal Hormone Therapy, formerly known as Hormone Replacement Therapy (HRT), is a medical treatment that involves the use of hormones to relieve the symptoms of menopause and to reduce the risk of certain long-term health conditions associated with menopause. Menopause is a natural biological process that occurs when a women's ovaries stop producing effects, and her estrogen and progesteron hormone levels subsequently decrease. MHT typically involves administration of a combination of sec steroids.~In this study MHT consists of estradiol transdermal patches (50 mcg (Systen), which provide a stable release of estradiol and lead to more stable blood levels. This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT guidelines."
219545852|NCT06306404|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy|"CBTi is a guided, internet-based cognitive behavioral therapy program for insomnia, containing information and exercises on sleep. It consists of five online sessions:~1. Psycho-education on sleep, disordered sleep and sleep hygiene (i.e. general guidelines about health and environmental factors influencing sleep),~2. Sleep restriction (i.e. restrict time in bed to the average sleep time) and stimulus control training (i.e. reinforce association of bed with sleeping),~3. Rumination and relaxation techniques,~4. Cognitive restructuring (i.e. changing misconceptions about sleep),~5. Relapse prevention."
219545853|NCT01242098|DRUG|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
218935348|NCT01615029|DRUG|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
218935349|NCT03194230|OTHER|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
218935350|NCT05285605|DRUG|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
218935351|NCT01326104|BIOLOGICAL|TTRNA-xALT|TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.
218935352|NCT01326104|BIOLOGICAL|TTRNA-DCs|TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.
218935353|NCT04794816|OTHER|Questionnaire Administration|Complete questionnaire
218935354|NCT01745458|DRUG|SB-659032|
218935355|NCT01745458|DRUG|Placebo|Matched placebo
218935356|NCT00735488|OTHER|Observational|Summary of data
218935357|NCT01287741|DRUG|Rituximab|Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
218935358|NCT01287741|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
218935359|NCT01287741|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
219046382|NCT07173894|PROCEDURE|Interscalene brachial plexus block and superficial cervical plexus block|This intervention involves a standard interscalene brachial plexus block performed preoperatively by an anesthesiologist under ultrasound guidance. It anesthetizes the upper roots (C5-C7) of the brachial plexus to provide effective analgesia for shoulder surgery. While effective, it carries risks such as hemi-diaphragmatic paralysis, Horner's syndrome, and motor weakness of the ipsilateral arm due to spread to adjacent nerves.
219046383|NCT07172100|DRUG|Carica Papaya Leaf Extract Group|Carica papaya leaf extract syrup will be administered orally at a dose of 10 mL three times daily (TID) for a total of 3 days. Each 10 mL dose contains 1000 mg of papaya leaf extract. This intervention will be given in addition to standard supportive therapy for dengue fever
219046384|NCT07172100|OTHER|standard treatment|patients in this group will receive only the standard treatment for dengue fever
219046385|NCT07170332|DEVICE|ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
219046386|NCT07174167|DRUG|Genicular nerve block with prilocaine|ultrasound guided genicular nerve block (GNB) injecting 6 mL of 2% prilocaine to the genicular nerves
219046387|NCT07174167|DRUG|genicular nerve block with prilocaine and triamcinolone|ultrasound guided genicular nerve block (GNB) injecting 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone to the genicular nerves
219046388|NCT07174167|DRUG|Sham injection|placebo injection using 6 mL of 0.9% saline to knee region other than genicular nerves
219046389|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 14%.
219046390|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 20%.
219046391|NCT07164742|BEHAVIORAL|8 week (short arm) Intervention - pulmonary rehabilitation|8 weeks (short arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
219046392|NCT07164742|BEHAVIORAL|24 week (long arm) Intervention - pulmonary rehabilitation|24 weeks (extended arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
219046393|NCT07174141|OTHER|Ophthalmological examination|at inclusion, at 3 months and 6 months; OCT-A retina
219046394|NCT07174141|BIOLOGICAL|Blood sample|Collection of a 2 mL blood sample at inclusion
219545854|NCT01242098|DRUG|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
218935360|NCT01287741|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
219205947|NCT06746818|BEHAVIORAL|Heart Math interventions|". The key components of Heart Math interventions include:~1. Heart Rate Variability (HRV) Training: This involves biofeedback techniques to help individuals learn how to control their heart rate and promote emotional balance.~2. Quick Coherence Technique: Participants are guided through a series of steps to shift their emotional state from stress to calmness, facilitating a sense of peace and emotional clarity.~3. Focus on Positive Emotions: Encouraging individuals to cultivate feelings like gratitude and compassion can enhance resilience and overall mental well-being.~4. Mindfulness Practices: Incorporating mindfulness helps individuals become more aware of their thoughts and feelings, allowing them to respond to stressors more effectively."
219205948|NCT06747754|OTHER|Establishment of a Database of HIV Patients|Establishment of a database that allows for systematic and continuous collection of data relating to clinical, laboratory and treatment characteristics of patients with HIV-1 for research purposes.
219545855|NCT01395628|DRUG|in vitro sensitivity-directed chemotherapy|
219545856|NCT01395628|OTHER|cell proliferation assay|
219545857|NCT01395628|OTHER|fluorescence activated cell sorting|
219545858|NCT01395628|OTHER|laboratory biomarker analysis|
219545859|NCT01395628|OTHER|microscopy|
219545860|NCT03608228|OTHER|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
219545861|NCT01876667|OTHER|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
219545862|NCT01876667|OTHER|Placebo|Usual Care
219545863|NCT01647828|DRUG|OMP-59R5|OMP-59R5 administered intravenously
219545864|NCT01647828|DRUG|Gemcitabine|administered intravenously
219545865|NCT01647828|DRUG|Placebo|administered IV
219545866|NCT01647828|DRUG|Nab-Paclitaxel|administered intravenously
219545867|NCT01906372|DRUG|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
218935361|NCT01287741|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
219205949|NCT06743087|DIAGNOSTIC_TEST|Jamar handheld dynamometer|Jamar handheld dynamometer
219545868|NCT01169753|DRUG|Placebo|Oral tablet every morning for 2 weeks
218935362|NCT01287741|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
218935363|NCT02773316|DRUG|MR902|
218935364|NCT02773316|DRUG|IR morphine sulphate|
219205950|NCT06741943|DEVICE|insulin pump (model: AR-B200A)|USE insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
219205951|NCT06741371|PROCEDURE|Monocryl|Closure of the uterine scar by monofilament suture material
219205952|NCT06741787|DRUG|Patients desensitized by sublingual spray|Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
219205953|NCT06749808|DIETARY_SUPPLEMENT|Carotenoid Nutritional Supplement|Carotenoid Nutritional Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 10 mg Lutein, 2 mg Zeaxanthin, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
219205954|NCT06749808|DIETARY_SUPPLEMENT|Placebo|Placebo Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
219205955|NCT06748755|RADIATION|Group 1|To determine the sensitivity of ultrasound in detecting HCC
219205956|NCT06751095|OTHER|Maitland's Mobilization in End range|End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint .(0-135 degree)
219205957|NCT06751095|OTHER|Maitland's mobilization in Mid range|Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint
219545869|NCT01169753|DRUG|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
219545870|NCT00755677|OTHER|Pulses|subjects consume 1 pulse food daily for eight weeks
219545871|NCT00170677|DRUG|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
219545872|NCT00170677|DRUG|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
219545873|NCT01261949|DEVICE|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
219545874|NCT01261949|DEVICE|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
219545875|NCT03641001|BEHAVIORAL|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
219549937|NCT05412121|DEVICE|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
219205958|NCT06749795|DRUG|LIV001|Orally administered for 8 weeks
219205959|NCT06749795|DRUG|Placebo|Orally administered for 8 weeks
219205960|NCT05066503|DIETARY_SUPPLEMENT|260279 active study product|The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.
218935365|NCT02861885|OTHER|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
218935366|NCT04421027|DRUG|Baricitinib|Given orally
219046395|NCT07173907|PROCEDURE|CuRV CXL|A two-part transepithelial isotonic riboflavin system (ParaCel™ Part 1 and Part 2) was used. Part 1 was applied with a surgical spear and repeated drops, followed by Part 2 instillation for 6 minutes. After rinsing with balanced salt solution, UVA irradiation was performed using the Mosaic® device with Boost Goggles™ delivering supplemental oxygen. Pulsed UVA (365 nm, 30 mW/cm²) was applied in a personalized, three-zone pattern (15 J/cm² to the cone apex, 10 J/cm² to an intermediate annulus, and 7.2 J/cm² to the periphery), guided by Pentacam tomography. A bandage contact lens was placed at the end of the procedure.
219545876|NCT04125407|OTHER|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, …) focusing on the flatfoot deformity.
219622366|NCT04186793|BEHAVIORAL|Guided Grocery Shopping (GGS)|"The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
218935367|NCT04421027|DRUG|Placebo|Given orally
218935368|NCT03756324|DRUG|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
219205961|NCT06780826|DRUG|Atezolizumab|Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
219205962|NCT06780826|DRUG|Etoposide|Etoposide,intravenous infusion, 100mg/m,21 days per cycle
219205963|NCT06780826|DRUG|Carboplatin|carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
219205964|NCT06745089|DEVICE|Intense pulsed light|Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.
219046396|NCT07173907|PROCEDURE|Accelerated CXL Procedure (aCXL)|The subjects underwent the aCXL procedure was performed under topical anesthesia after tailored epithelial removal, leaving a small island over the thinnest corneal area. Riboflavin-dextran solution was applied for 30 minutes, followed by UVA irradiation (9 mW/cm², total 5.4 J/cm²) using the KXL device. The cornea was rinsed with Ringer's solution during treatment, and a bandage contact lens was placed afterward.
219046397|NCT07171983|DRUG|BMS-986454|Specified dose on specified days
219046398|NCT07171983|OTHER|Placebo|Specified dose on specified days
219205965|NCT06745089|DEVICE|thermal pulsation therapy|Thermal pulsation therapy utilizes local heating and massage on the eyelids.
219046399|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Pinaverium Bromide|A figure-of-eight coil is used to apply active low-frequency (1 Hz) rTMS to the corresponding representation area of the prefrontal cortex (mPFC). The treatment is administered for 20 minutes daily for a total of 2 weeks.
219205966|NCT06745089|DRUG|Ocular lubricant|Ocular lubricants moisturize the ocular surface.
219205967|NCT05951452|OTHER|Blood samples for testosterone and SHBG measurements|"Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
219205968|NCT05951452|OTHER|Saliva samples for oxytocin measurements|"Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
219205969|NCT04258189|DRUG|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
219545877|NCT02482922|OTHER|Exercise & Dietary Supplement|
219545878|NCT06843252|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
219545879|NCT06843252|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
219545880|NCT01439620|DEVICE|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
219545881|NCT00627796|DRUG|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
219545882|NCT02035163|PROCEDURE|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
219545883|NCT02182713|DRUG|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
219545884|NCT02182713|DRUG|Salbutamol|Salbutamol 100 mcg per puff
219545885|NCT04882254|PROCEDURE|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
219545886|NCT02484807|OTHER|no intervention, only observation of different groups|
219545887|NCT03340545|OTHER|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
219545888|NCT00137735|DRUG|Gabapentin|300mg tds
219545889|NCT00137735|OTHER|placebo|tds
219545890|NCT05802563|DEVICE|fitness tracker|Study subjects will wear a Fitbit fitness tracker
219545891|NCT06077786|DRUG|Lu AG06474|Oral solution
219545892|NCT06077786|DRUG|Placebo to Lu AG06474|Oral solution
219046400|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Bifidobacterium|Bifidobacterium animalis subsp. lactis BB-12, provided in capsule form. Each capsule contains a minimum of 5 billion colony-forming units (CFU). Administered orally at a dosage of one capsule twice per day, with meals, for a duration of 2 weeks. The product will be stored refrigerated as per manufacturer's instructions.
219046401|NCT07172139|COMBINATION_PRODUCT|Sham Comparator: Sham rTMS + Pinaverium Bromide|Pinaverium Bromide 50 mg film-coated tablets. Administered orally at a dosage of 50 mg (one tablet) three times daily, 30 minutes before meals, for a duration of 2 weeks.
219046402|NCT07172139|COMBINATION_PRODUCT|Placebo Comparator: Sham rTMS + Bifidobacterium|Description: Sham stimulation is delivered using a placebo coil that mimics the sound and sensation of active rTMS but does not deliver the full magnetic field. Parameters identical to active arm.
219046403|NCT07174323|DIETARY_SUPPLEMENT|Peptide derived from collagen protein|Peptide derived from collagen protein
219046404|NCT07174323|DIETARY_SUPPLEMENT|Whey protein isolate|Whey protein isolate
219046405|NCT07174076|DRUG|cordyceps sinesis capsule|cordyceps sinesis capsule 4 capsules tid po for 12 months
219046406|NCT07174076|DRUG|cordyceps sinesis capsule placebo|cordyceps sinesis capsule placebo 4 capsules tid po for 12 months
219046407|NCT07172347|DRUG|VC005 tablets|VC005 groups repeat administration for 52 weeks
219046408|NCT07172347|DRUG|VC005 Tablets Placebo|VC005 Placebo groups repeat administration for 52 weeks
219046409|NCT07172126|DRUG|TQB3201 tablets|TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to AR and the other end to a ligand of E3 ligase (CRBN) via a linker. This product is effective against anti-androgen drugs (such as abiraterone, enzalutamide, etc.) resistance mutations, including AR amplification, point mutations (L702H, H875Y, T878A mutations, etc.), and can target the degradation of wild-type AR and AR ligand-binding domain mutants, especially L702H mutations, which is a new generation of AR-PROTAC.
219046410|NCT07173075|DIAGNOSTIC_TEST|impedancemetry|impedancemetry by the InBody S10 device, during a visit, after stabilization of the patient's blood volume, within a limit of 7 days after inclusion
219046411|NCT07171827|DRUG|Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine|Patients received Brentuximab Vedotin (BV)+ Doxorubicin, Vinblastine, and Dacarbazine (AVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
219046412|NCT07171827|DRUG|Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine|Patients received Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
219046413|NCT07173933|GENETIC|GC310|GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene
219046414|NCT07174284|OTHER|No Intervention: Observational Cohort|No intervention was applied to the patients within the scope of this study.
219046415|NCT06085313|BEHAVIORAL|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
219046416|NCT06085313|BEHAVIORAL|CAPA|Web App-based information and coaching/support program for cancer pain management
219046417|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
219046418|NCT04519632|OTHER|Qualitative study|Qualitative interviews
219046419|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
219545893|NCT06077786|DRUG|Ibuprofen|Capsule
219545894|NCT06077786|DRUG|Pregabalin|Capsule
219545895|NCT06077786|DRUG|Placebo|Capsule
219545896|NCT00624286|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219545897|NCT00624286|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219545898|NCT02054819|OTHER|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
219545899|NCT02054819|OTHER|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
219545900|NCT00075608|BIOLOGICAL|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
219545901|NCT00075608|DRUG|melphalan|140-200 mcg/kg IV over two days
219545902|NCT00075608|PROCEDURE|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
219545903|NCT00075608|PROCEDURE|stem cell infusion|infusion of previously collected stem cells on Day 0
219545904|NCT01676064|DRUG|ringer lactate solution|
219545905|NCT01676064|OTHER|restrictive fluid regime|
219545906|NCT05845723|DRUG|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
219545907|NCT05845723|DRUG|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
219545908|NCT05845723|DRUG|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
219545909|NCT02177617|DRUG|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
219545910|NCT02177617|BEHAVIORAL|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
219545911|NCT02177617|PROCEDURE|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
219545912|NCT03046550|DRUG|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
219545913|NCT03046550|DRUG|Placebo|placebo
219545914|NCT03221049|DIAGNOSTIC_TEST|radiomics|
218935369|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
218935370|NCT03756324|BEHAVIORAL|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
218935371|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
218935372|NCT05374603|DRUG|Savolitinib|Savolitinib combine with Durvalumab
218935373|NCT05374603|DRUG|Durvalumab|savolitinib plus durvalumab
218935374|NCT05036733|DRUG|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
219046420|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
219046421|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
219046422|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
219046423|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
219046424|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
219046425|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
219545915|NCT04800718|OTHER|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
219545916|NCT01956318|BEHAVIORAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
219545917|NCT03921918|DEVICE|Breast Pump|Hydraulic Breast pump
219545918|NCT06563219|OTHER|Glasgow coma scale|The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
219046426|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
219545919|NCT06563219|OTHER|Hunt-Hess scale|"The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance."
219046427|NCT01786408|DEVICE|TAP20-C|
219046428|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
219046429|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
219046430|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
219046431|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
219046432|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
219046433|NCT05766891|BEHAVIORAL|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
219046434|NCT05766891|BEHAVIORAL|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
219046435|NCT05766891|BEHAVIORAL|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
219545920|NCT06563219|OTHER|World Federation of Neurological Surgeons (WFNS) scale|"The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit"
219545921|NCT06563219|OTHER|modified Fisher scale|"The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH."
219545922|NCT06563219|OTHER|VASOGRADE scale|"The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score."
219622367|NCT04186793|OTHER|Diet Provision Group|"This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
219622368|NCT05377463|BEHAVIORAL|Peer support to promote uptake and persistence of medication assisted treatment (MAT)|Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
218935375|NCT06946810|BEHAVIORAL|Combined visits-based transition|In this arm, patients experience a gradual transition involving joint consultations where both pediatric and adult gastroenterologists are present. This includes at least one combined visit at the pediatric clinic and one at the adult clinic, allowing for collaborative care and direct communication between all parties during the transition process.
218935376|NCT06946810|BEHAVIORAL|Letter-based transition|In this arm, patients are transitioned from pediatric to adult gastroenterology care through a referral system where the pediatrician prepares a comprehensive clinical report that accompanies the patient to their first adult gastroenterology appointment. The transition occurs without joint visits between pediatric and adult specialists.
218935377|NCT06164795|DRUG|Zoledronate|intravenous infusion
218935378|NCT06164795|DRUG|Denosumab|subcutaneous injection
218935379|NCT06164795|DRUG|Teriparatide|subcutaneous injection
218935380|NCT06164795|DRUG|Romosozumab|subcutaneous injection
218935381|NCT06164795|DRUG|Abaloparatide Injection (80 mcg)|daily subcutaneous injection
218935382|NCT05978713|DRUG|Tirzepatide|Administered SC
218935383|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
218935384|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
218935385|NCT04223193|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
218935386|NCT04223193|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
218935387|NCT05407064|DRUG|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
218935388|NCT05407064|OTHER|Placebo|A substance that is designed to have no therapeutic value.
218935389|NCT05989204|BIOLOGICAL|TmCD19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
218935390|NCT05994261|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
219046436|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
219046437|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
219046438|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
219046439|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
219545923|NCT06563219|OTHER|Ogilvy and Carter scale|"The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size \>10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)"
219545924|NCT04090021|DRUG|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
219545925|NCT04090021|DRUG|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
218935391|NCT05684172|DRUG|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
218935392|NCT05684172|OTHER|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
219046440|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
219545926|NCT04090021|DRUG|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
219046441|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
219545927|NCT04090021|DRUG|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
219545928|NCT04090021|DRUG|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
219545929|NCT04090021|DRUG|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
219545930|NCT00675779|DRUG|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
219545931|NCT00675779|DRUG|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
219545932|NCT00841659|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
219545933|NCT00841659|DRUG|Paxil®|40 mg Film-Coated Tablet
219046442|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
219545934|NCT04026243|PROCEDURE|QL block|U/S guided Transmuscular Quadratus Lumborum Block
219046443|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
219545935|NCT04026243|PROCEDURE|TF block|U/S guided Transversalis Fascia Plane Block
219545936|NCT01988636|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
218935393|NCT02405702|OTHER|restrospective study|
218935394|NCT06209580|DRUG|AMT-253 for injection|Administered intravenously
218935395|NCT06015022|DRUG|Epigallocatechin gallate (EGCG)|EGCG is a green tea-derived catechin
219046444|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
218935396|NCT06015022|OTHER|Placebo|Placebo in the same capsule with the experimental agent (EGCG).
218935397|NCT02498691|BIOLOGICAL|Biological collection|Blood and saliva samples, placenta and cord blood collection
218935398|NCT02022124|DRUG|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
218935399|NCT03071419|BEHAVIORAL|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
218935400|NCT00930033|PROCEDURE|Nephrectomy|Current surgery
218935401|NCT00930033|OTHER|Sunitinib alone|Sunitinib alone without nephrectomy
219046445|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
219046446|NCT04702633|OTHER|Results obtained by biopsy and MRI results.|Results obtained by biopsy and MRI results.
219046447|NCT04702633|OTHER|Clinical data|Clinical data
219046448|NCT04071457|DRUG|Lenalidomide|Commercially available intervention
219046449|NCT04071457|DRUG|Daratumumab/rHuPH20|SWOG-Held IND
219046450|NCT05301270|DIAGNOSTIC_TEST|EMG Evaluation|Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
219046451|NCT03940508|BEHAVIORAL|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
219046452|NCT03940508|BEHAVIORAL|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
219545937|NCT01988636|DRUG|Placebo|Placebo
219549938|NCT05545436|DRUG|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
219549939|NCT02942810|DRUG|WCK 5222|IV infusion over a period of 60 minutes
218935402|NCT06044727|PROCEDURE|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
219549940|NCT01832922|DRUG|Bendamustine|
219549941|NCT01832922|DRUG|Rituximab|
219545938|NCT05458687|OTHER|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"* Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
219545939|NCT04272437|DRUG|Concentrated herbal extract granules TRA|Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
219545940|NCT04272437|DRUG|Placebo|Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
219545941|NCT03810937|OTHER|head position|head positioning in sniffing or flat position
219545942|NCT05836311|DEVICE|One Perclose Proglide Suture|One Perclose Proglide Suture
219545943|NCT05836311|DEVICE|Two Perclose Proglide Suture|One Perclose Proglide Suture
219545944|NCT02054715|BEHAVIORAL|print educational intervention|print educational intervention
219545945|NCT02054715|BEHAVIORAL|multimedia psychoeducational intervention|multimedia psychoeducational intervention
219545946|NCT04207528|BEHAVIORAL|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
219545947|NCT03444883|DRUG|Ilaprazole|10mgx2 tablet once daily for weeks
219545948|NCT02331511|DRUG|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
219545949|NCT02331511|DRUG|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
219545950|NCT02331511|DRUG|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
219545951|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
219545952|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
219545953|NCT05492032|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
219545954|NCT05492032|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
219622369|NCT05377463|BEHAVIORAL|Behavioral Activation Treatment (BAT) to reduce depression|Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.
219622370|NCT05377463|BEHAVIORAL|No Intervention Components|Participants not assigned to components 1 and 2
219622371|NCT03173118|PROCEDURE|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
219622372|NCT03842917|OTHER|Biological samples|Urine and blood samples
219622373|NCT03842917|OTHER|Blood pressure measurement|Home blood pressure self-measurement and hospital blood pressure measurement
218935403|NCT06044727|PROCEDURE|Conventional subgingival instrumentation|Conventional subgingival instrumentation
218935404|NCT03012399|BEHAVIORAL|Hypnosedation|Undergo hypnosedation
219046453|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
219046454|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
219622374|NCT02620293|DEVICE|Eczema Repair Emollient|An Emollient
218935405|NCT03012399|OTHER|Questionnaire Administration|Ancillary studies
218935406|NCT03012399|BEHAVIORAL|Verbal Support|Speak with min-body specialist
218935407|NCT06555601|DRUG|UCB3101|Study participants will receive UCB3101 as prespecified in each cohort.
218935408|NCT06555601|DRUG|Placebo|Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
219545955|NCT05492032|BEHAVIORAL|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
219545956|NCT04298151|DRUG|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
219545957|NCT04298151|DRUG|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
219545958|NCT03612154|DRUG|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
219545959|NCT05730920|DRUG|Methadone|IV Methadone
219545960|NCT05730920|DRUG|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
219545961|NCT01293097|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
219545962|NCT01293097|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
219545963|NCT04138251|DRUG|Empagliflozin|oral administration of Empagliflozin
219545964|NCT06562998|DRUG|Pentoxifylline|Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
219545965|NCT05913245|DIETARY_SUPPLEMENT|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
219545966|NCT05913245|OTHER|Water|Preoperative water
219545967|NCT01159145|DRUG|D961H|Oral, capsule
219545968|NCT01159145|DRUG|Omeprazole|Oral, tablet
219622375|NCT03396653|BEHAVIORAL|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
218935409|NCT07120295|DEVICE|Dragonfly™ Digital Pancreaticobiliary System|Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.
218935410|NCT06653179|PROCEDURE|Sacral Erector Spinae Plane Block|The patient is placed in the prone positionon a procedure table. The sacral region is exposed, and the area is prepped with antiseptic solution under sterile conditions. The ultrasound high-frequency linear transducer is placed transversely over the sacrum. The sacral cornua are typically seen as bony structures adjacent to the sacral hiatus, appearing as two hyperechoic structures. Rotate the ultrasound probe to a sagittal position over the sacrum to align with the fourth and fifth sacral vertebrae. Under continuous ultrasound guidance, block needle is inserted in-plane with the ultrasound probe. Direct the needle through the soft tissue towards the plane between the erector spinae muscle and the sacrum. After confirming needle placement, the injectate mixture of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is administered. A total volume of 10 mL is injected, and real-time ultrasound is used to observe the spread of the injectate within the target tissue plane.
219046455|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
219046456|NCT05132075|DRUG|JDQ443|JDQ443 tablets, orally administered
219046457|NCT05132075|DRUG|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
219545973|NCT03993145|BEHAVIORAL|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
219545974|NCT04010045|DEVICE|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
219545975|NCT06102850|BEHAVIORAL|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
219545976|NCT06319625|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
219545977|NCT06319625|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219549942|NCT01624272|DEVICE|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
219549943|NCT01624272|OTHER|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
219046458|NCT05978700|DEVICE|Video-game|The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
219549944|NCT02319850|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
219549945|NCT06416449|OTHER|kinesiotape application|"In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
219549946|NCT03300687|DRUG|FX-322|intratympanic injection
218935411|NCT06653179|PROCEDURE|Caudal Epidural Injection|The patient is positioned in the prone position on the procedure table, and the sacral region is exposed and prepped with antiseptic solution under sterile conditions. The fluoroscope is positioned laterally to visualize the sacral hiatus. Under fluoroscopic guidance, the block needle is inserted through the skin and advanced toward the sacral hiatus. Continuous fluoroscopy is used to ensure correct needle placement, typically visualized at the level of the sacral canal. After confirming the appropriate position with contrast media, the injectate consisting of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is slowly administered, with a total volume of 10 mL. During injection, careful monitoring of the needle position is performed to avoid intravascular injection. After the procedure, patients are monitored for potential complications such as hypotension and allergic reactions.
219046459|NCT05978700|BEHAVIORAL|Conventional therapy|The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
219046460|NCT02307578|DRUG|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
219046461|NCT04253171|DEVICE|Lithoplasty|"The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions."
219549947|NCT03300687|DRUG|Placebo|intratympanic injection
218935412|NCT03000660|DRUG|Venetoclax|Venetoclax at one of four escalating doses
218935413|NCT03000660|DRUG|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
219046462|NCT04253171|DEVICE|Conventional|Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
219545978|NCT06319625|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219545979|NCT06319625|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219545980|NCT04890418|DRUG|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
219046463|NCT06056063|DEVICE|Halcyon 4.0|This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
219545981|NCT04890418|OTHER|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
219545982|NCT02627235|BEHAVIORAL|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
219545983|NCT02627235|BEHAVIORAL|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
219545984|NCT00205686|DRUG|DHEA|
219545985|NCT00205686|BEHAVIORAL|exercise|
219545986|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|an acute dose of spirulina up to 5 g
219545987|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
219545988|NCT00151489|DRUG|pregabalin|
219545989|NCT00151489|DRUG|placebo|
219545990|NCT02463981|DEVICE|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
219622376|NCT03396653|BEHAVIORAL|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
219622377|NCT06362746|DRUG|Non-immunogenic recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
219622378|NCT06362746|DRUG|Placebo|15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
218935414|NCT05091372|DRUG|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
219545991|NCT04296994|BIOLOGICAL|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
218935415|NCT05091372|DRUG|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
219545992|NCT06056414|OTHER|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
219622379|NCT01293695|BEHAVIORAL|Hypnosis|Hypnosis relaxation in five weekly sessions
218935416|NCT06655844|DEVICE|Sana Pain Reliever|The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).
219545993|NCT00568672|DRUG|Olanzapine|Olanzapine 5 mg / day for 6 months
219545994|NCT00883233|DRUG|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
219622380|NCT01293695|OTHER|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
219622381|NCT05457023|OTHER|Plasma Neurofilament Light (NF-L)|Plasma NF-L is a biomarker of axonal brain injury following sports-related head impacts.
219622382|NCT05457023|OTHER|Omega-3 Index|Omega-3 Index is the omega-3 fatty acid content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) within the erythrocyte cell membrane. It is expressed as EPA+DHA as a percent of total identified fatty acids.
219622383|NCT05457023|OTHER|HeadCount Questionnaire|HeadCount is a web-based, structured, self-administered questionnaire to assess longer-term heading exposure during competitive play and is administered bi-weekly.
219545995|NCT00883233|DRUG|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
219545996|NCT00883233|DRUG|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
219545997|NCT00883233|DRUG|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
219545998|NCT05748535|DEVICE|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
219545999|NCT02355418|PROCEDURE|Mitral valve repair|Standard mitral valve repair surgery
219546000|NCT03227991|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
219546001|NCT03227991|BEHAVIORAL|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
219546002|NCT05633745|DRUG|NEU-723|Oral Doses
219546003|NCT05633745|DRUG|Placebo|Oral Doses
219546004|NCT00495222|PROCEDURE|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
219546005|NCT00495222|DEVICE|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
219546006|NCT00495222|DEVICE|Tissue Plication|Tissue plication for GJ stoma reduction
219546007|NCT00073307|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
219546008|NCT00073307|DRUG|Placebo|Placebo
219546009|NCT06187142|BEHAVIORAL|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
219046464|NCT06352177|OTHER|Noom Weight Application|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
219046465|NCT04026503|OTHER|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
219046466|NCT05970575|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
219046467|NCT04373902|PROCEDURE|Physiological-based cord clamping|See 'Arm'
219046468|NCT05787587|DRUG|IDE-161|Oral Medication
219046469|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
219046470|NCT05757817|PROCEDURE|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
219046471|NCT05893654|DRUG|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
219546010|NCT06187142|BEHAVIORAL|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
219546011|NCT06187142|BEHAVIORAL|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
219546012|NCT06187142|BEHAVIORAL|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
219546013|NCT06187142|BEHAVIORAL|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
219546014|NCT06187142|BEHAVIORAL|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
219546015|NCT06187142|BEHAVIORAL|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
219546016|NCT01375309|DIETARY_SUPPLEMENT|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
219546017|NCT01375309|DIETARY_SUPPLEMENT|Placebo contains dextrin|0.5 of dextrin
219546018|NCT06560437|OTHER|Chinese Jingjin Manual Therapy|Chinese Jingjin therapy is a form of manual therapy that utilizes the principles of Chinese Jingjin Theory (also known as Chinese Sinew Channel Theory) to alleviate nodular lesions in sinew channels caused by Jingjin injuries and to realign skeletal joints. Chinese Jingjin manual therapy is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
219546019|NCT01438060|DRUG|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
219046472|NCT05893654|RADIATION|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
219046473|NCT03366077|DIETARY_SUPPLEMENT|Probiotic|Probiotic
219046474|NCT06043297|DRUG|Apixaban 5MG|Each film-coated tablet contains 5 mg apixaban
219046475|NCT06043297|DRUG|Eliquis 5 mg|Each film-coated tablet contains 5 mg apixaban
219046476|NCT01666340|OTHER|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
219046477|NCT01666340|OTHER|Exercise intervention|High intensity exercise
219046478|NCT02885363|OTHER|Clinical examination|
219046479|NCT02885363|OTHER|Blood sample|
219046480|NCT02885363|PROCEDURE|Echocardiography|
219046481|NCT01163383|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
219046482|NCT01163383|DRUG|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
219046483|NCT06361888|DRUG|Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
219046484|NCT06361888|DRUG|Nab-paclitaxel Plus Gemcitabine|"Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
219046485|NCT06361888|DRUG|Surufatinib with Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
219046486|NCT06219551|OTHER|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
219046487|NCT05041803|DRUG|CTP-543|Twice daily dosing
219046488|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
219546020|NCT01438060|DRUG|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
219546021|NCT02725580|GENETIC|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
219046489|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
219549948|NCT03369132|DEVICE|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
219046490|NCT03440970|DRUG|Lysine Chloride|Patients will receive the study drug thrice daily for 5 days.
219549949|NCT03369132|DEVICE|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
219549950|NCT03102385|BEHAVIORAL|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
219549951|NCT03102385|BEHAVIORAL|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
219549952|NCT01231737|DRUG|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
219549953|NCT05563207|OTHER|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
219549954|NCT05563207|OTHER|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
219546022|NCT06166862|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
219546023|NCT06166862|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
219546024|NCT01215760|OTHER|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
219546025|NCT01215760|OTHER|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
219546026|NCT00177580|DRUG|Pravastatin|
219546027|NCT05948072|DRUG|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
219546028|NCT05948072|DRUG|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
219546029|NCT05136469|OTHER|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
219546030|NCT05136469|OTHER|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
219546031|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
219546032|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
219546033|NCT01442376|DRUG|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
219546034|NCT01442376|DRUG|Placebo to Ondansetron|
219546035|NCT01442376|DRUG|Placebo to Ondansetron|
219546036|NCT01442376|DRUG|Placebo to Palonosetron|
219046491|NCT03440970|OTHER|Placebo|Patients will receive the placebo thrice daily for 5 days.
219046492|NCT05709002|BEHAVIORAL|MASP+|mHealth (mobile app) for smoking cessation
219046493|NCT05709002|BEHAVIORAL|Control|A mobile app designed to assist the general population with smoking cessation.
219046494|NCT06529705|DEVICE|EkiYou V2|Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
219046495|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
219046496|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
219046497|NCT06520566|BEHAVIORAL|Holistic care partner perinatal nurse navigation|The nurse navigators assess patient medical, social, and structural needs at enrollment, 20-, 28-, and 36-weeks gestation; and at 1-week, and 3, 6, and 9 months postpartum. They provide coordination, support, and referrals, and enhanced communication with or escalate concerns to the primary physician as indicated. The nurse navigator tailors additional visits to the individual needs of the patients (for example, managing comorbidities, social isolation, breastfeeding support). Participants also have access to a Black woman-led support group during pregnancy and the first postpartum year, and access to Black woman-led childbirth and lactation classes.
219046498|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
219046499|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
219046500|NCT01433263|DRUG|BYM338 active drug|
219046501|NCT01433263|DRUG|Placebo|
219046502|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
219046503|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
219046504|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
219046505|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
219046506|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
219546037|NCT04143880|DRUG|Progesterone|intramuscular injection intranasal administration
219546038|NCT04143880|OTHER|saline|intramuscular injection intranasal administration
219546039|NCT06070480|OTHER|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
219546040|NCT06070480|OTHER|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
219546041|NCT06070480|OTHER|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
219546042|NCT05237830|PROCEDURE|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
219546043|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
219546044|NCT03499873|DRUG|Placebos|Placebo
219546045|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
219046507|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
219046508|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
219205970|NCT06793514|DRUG|Probiotic|The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles) alongside with fructooligosaccharide (FOS), which is prepared in the concentration of 109 cfu by Bisot Khimr and is in the form of an edible sachet that can be dissolved in cold water, which is consumed once a day for one month. Sachets should be stored at a temperature of 2 to 8 degrees Celsius (in the refrigerator), which increases the useful life of probiotic bacteria and makes them more effective.
219205971|NCT06793514|DRUG|Placebo Drug|The placebo is also prepared in the form of probiotic supplement in the form of sachets with similar packaging by the bio-fermenting pharmaceutical company.
219205972|NCT06839820|OTHER|Infusion rate of infliximab|Infusion reactions of infliximab is compared between 30 and 60 minutes infliximab infusion-rates.
219205973|NCT06840626|OTHER|Series of breathing exercises|During the intervention, participants perform respiratory exercises, including deep breathing, belly breathing, exhalation with vocalization, and forced exhalation. Each exercise is repeated five times, three times per day: twice in the morning and once in the afternoon. The exercises are conducted in a seated, corrected position, guided by rehabilitation specialists or special needs teachers who provide instructions and demonstrations. Teachers are provided with the exact protocol for the breathing exercises series. Each breathing exercise focuses on maintaining a specific rhythm, with inhalation lasting approximately 3-4 seconds, holding for 1-2 seconds, and exhalation for 5-6 seconds. Forced exhalation is facilitated using playful motivational tools such as windmills and balloon blowing. The protocol includes instructions for the breathing exercises in first-person singular. The entire session lasts approximately 5 minutes, resulting in a total of 15 minutes of training per day.
219046509|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
219046510|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
219046511|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
219205974|NCT06837064|DEVICE|Chatbot supporting system|"The intervention tool is the automated chatbot supporting system, which contains:~A) educational information (therapeutic education and psychoeducation); B) symptom monitoring (stool quality and frequency, assessment of mood, sleep quality, physical activity, and dietary adherence on a scale of 0 to 10); C) behavioral distraction techniques, and body tension reduction techniques."
219205975|NCT04476953|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient.
219546046|NCT03616691|DRUG|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
219546047|NCT03616691|DRUG|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
219546048|NCT01717950|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
219546049|NCT01717950|BIOLOGICAL|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
219546050|NCT03646175|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
219546051|NCT03646175|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
219546052|NCT04269122|OTHER|No Intervention|No intervention
219546053|NCT03456544|DRUG|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
219546054|NCT02711644|BEHAVIORAL|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
219549955|NCT05563207|OTHER|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
219549956|NCT05563207|OTHER|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
219622384|NCT05013710|OTHER|Complete Clinical Interaction|The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
219622385|NCT01832064|BEHAVIORAL|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
219622386|NCT03915132|DRUG|Nimotuzumab|Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
219622387|NCT03915132|RADIATION|VMAT|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
219622388|NCT04977375|DRUG|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
219622389|NCT04977375|RADIATION|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
219622390|NCT04977375|PROCEDURE|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
219622391|NCT00319137|DRUG|GW274150|
219622392|NCT03669380|OTHER||
219622393|NCT04703972|BEHAVIORAL|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
219622394|NCT04439929|BIOLOGICAL|TUR01|Administered as a single 40 mg, subcutaneous dose
219622395|NCT04439929|BIOLOGICAL|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
219622396|NCT04046887|DRUG|Lonsurf|Lonsurf will be administered orally twice a day on days 2-6 and 16-20 of every 28-day cycle at a dose of 25 mg/m2, 20 mg/m2 or 30 mg/m2 depending on cohort assignment.
218935417|NCT06655844|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
218935418|NCT06655662|OTHER|β-globin restored autologous hematopoietic stem cells|Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
218935419|NCT06654180|DEVICE|Orthokeratology|Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.
219622397|NCT04046887|DRUG|Gemcitabine|Gemcitabine will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 800 mg/m2, 600 mg/m2 or 1000 mg/m2 depending on cohort assignment.
219622398|NCT04046887|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 100 mg/m2, 75 mg/m2 or 125 mg/m2 depending on cohort assignment.
219622399|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
219622400|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
219622401|NCT01935609|BEHAVIORAL|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
219622402|NCT00957801|DRUG|Testosterone injection|100 mg single IM injection
219622403|NCT00957801|DRUG|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
219622404|NCT00957801|DRUG|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
218935420|NCT06654180|DEVICE|defocus-incorporated multiple segment lenses (DIMS) spectacles|It is the special lenses with peripheral lots of tiny segments of plus lenses around the center
218935421|NCT06654180|DEVICE|DISK|SVS
218935422|NCT06654180|DEVICE|Single-focus spectacles|Myopic Glasses with mono-focus in each eye
218935423|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
218935424|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
218935425|NCT05902715|DEVICE|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
219046512|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
219046513|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
219546055|NCT02711644|BEHAVIORAL|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
219622405|NCT05098522|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
219546056|NCT06428539|DIAGNOSTIC_TEST|T-reg cells|laboratory test
219546057|NCT04404725|DEVICE|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
219546058|NCT04404725|DEVICE|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
219546059|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
219546060|NCT06202755|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219546061|NCT06202755|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219622406|NCT05098522|DRUG|Placebo|Matching placebo for IRL201104
219622407|NCT01146639|RADIATION|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
219622408|NCT01146639|DRUG|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
219622409|NCT00448266|DRUG|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
219622410|NCT00448266|DRUG|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
219622411|NCT00002303|DRUG|Epoetin alfa|
219622412|NCT02124655|DRUG|Essential oils|
219622413|NCT02124655|DRUG|0.2% chlorhexidine|
218935426|NCT06586710|OTHER|Assessment activation of interferon pathway|"* Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed."
219046514|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
219622414|NCT02124655|DRUG|Sterile water|
219622415|NCT01283464|DRUG|Retinol|1.0% cream
219622416|NCT01283464|DRUG|Tretinoin|0.02% cream
219622417|NCT00225615|DRUG|sapropterin dihydrochloride|
219622418|NCT04024670|OTHER|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
219622419|NCT06534762|BIOLOGICAL|Mirabegron|To explore the efficacy and safety of milaberon combined with standard treatment in advanced solid tumors
219622420|NCT06122792|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
219046515|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
219046516|NCT06840782|RADIATION|Radical local treatment|"RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).~The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB."
219046517|NCT06840782|DRUG|SoC-based immunotherapy (+/- chemotherapy)|"Current French SoC will be used. Main SoC-based immunotherapy includes:~* Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.~* Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).~Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.~Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...)."
219046518|NCT06062056|OTHER|EHR alert|An EHR alert will be fired if a behavioral health patient is missing a COVID-19 or influenza vaccine.
219046519|NCT06062056|BEHAVIORAL|Motivational Interviewing|In response to the alert and using support tools in the EHR, the behavioral health clinician will integrate motivational interviewing into the counseling session to discuss vaccine hesitancy (if it is deemed appropriate based on patient needs and clinical judgment).
219205976|NCT04476953|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
219205977|NCT06646549|OTHER|No intervention|No intervention
219546062|NCT05128396|BEHAVIORAL|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
219546063|NCT05128396|BEHAVIORAL|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
219549957|NCT05563207|OTHER|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
219549958|NCT05563207|OTHER|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
219549959|NCT02119637|DEVICE|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
219549960|NCT02119637|DEVICE|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
219549961|NCT00651651|DRUG|budesonide/formoterol|
219549962|NCT00651651|DRUG|budesonide|
218935427|NCT06982716|DEVICE|Lexie Lumen Hearing Aids|The Lexie Lumens (Lexie Hearing) are self-fitting wireless air conduction hearing aids consisting of 16 channels, wide-dynamic-range compression technology, feedback reduction, Bluetooth connectivity and programming, digital noise reduction, and a directional microphone array. These hearing aids will be sourced at a cost of $240 USD per pair as this study will be conducted in low-income settings. The hearing aids allow for Bluetooth in-situ hearing aid fitting using the Lexie proprietary fitting algorithm that is based on the NAL/NL2 algorithm from a smartphone application (Lexie Hearing) based on the four hearing thresholds tested. These digital hearing aids were designed for use by adults over the age of 18 years with known or self-perceived mild-to-moderate hearing loss. The Lexie Lumens are behind-the-ear (BTE) hearing aids powered by replaceable batteries. Individuals can conduct an in-situ hearing test via the hearing aids for customized amplification or select a minimal gain.
218935428|NCT06982716|DEVICE|Go Ultra Hearing Aids|Go Ultras (GoHearing) are rechargeable, BTE pre-set hearing aids with advanced audio features, digital sound processing and Bluetooth-streaming capabilities. Designed for adults with mild-to-moderate hearing loss, these hearing aids have four unique programs that the user can manually change to ensure optimal listening comfort. These devices have both program and volume memory functions, as well as noise and wind noise reduction. Go Ultras will be sourced at a cost of less than $130 USD per pair, as this study will be conducted in low-income settings.
218935429|NCT04973683|DRUG|AL101|Given IV
219046520|NCT06062056|BEHAVIORAL|Warm hand off to nurse|For patients interested in vaccination following motivational interviewing, the behavioral health clinician will do a warm hand off to a nurse for vaccination
219046521|NCT05684770|OTHER|4G tablet|Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
219549963|NCT00651651|DRUG|formoterol|
218935430|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219046522|NCT05426174|BIOLOGICAL|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219046523|NCT05426174|BIOLOGICAL|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219046524|NCT06375798|PROCEDURE|radiotherapy|If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
219046525|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
219205978|NCT06734520|DRUG|super-transplantation in 3 severe β -thalassemia pediatric patients.|Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
219205979|NCT06748430|OTHER|Grape variety control|Reference grape variety
219205980|NCT06748430|OTHER|Grape variety 1|First grape variety to evaluate
219549964|NCT03576053|DRUG|Lidocaine|Lidocaine intradermal injection
219549965|NCT03576053|OTHER|Histamine|Skin Prick Test with Histamine
219549966|NCT03576053|OTHER|Cowhage|Manually skin insertion of cowhage spicules
219546064|NCT05128396|BEHAVIORAL|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
219546065|NCT05128396|BEHAVIORAL|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
219546066|NCT05871463|BIOLOGICAL|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
219546067|NCT00834405|DRUG|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
219546068|NCT00834405|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
219546069|NCT00264134|DRUG|Docetaxel|
219546070|NCT00264134|DRUG|Irinotecan|
219546071|NCT00264134|DRUG|Carboplatin|
219622421|NCT06122792|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic injection of tissue adhesives will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new endoscopic injection of tissue adhesives will be performed."
219622422|NCT05008744|PROCEDURE|Fetoscopic laser ablation|"Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.~The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope."
219622423|NCT01171144|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
219622424|NCT01171144|OTHER|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
219622425|NCT01171144|OTHER|Hospital discharge records|Reviewing the hospital discharge records
219622426|NCT01692860|OTHER|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
219622427|NCT00256074|PROCEDURE|Enteral feeding formula|
219622428|NCT02626026|DRUG|Tirabrutinib|Capsules administered orally.
219622429|NCT02626026|DRUG|Placebo|Capsules administered orally.
219622430|NCT00687726|BEHAVIORAL|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
219622431|NCT00687726|BEHAVIORAL|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
219622432|NCT02450201|DRUG|Pyruvate|
218935431|NCT02987387|DEVICE|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
218935432|NCT06600087|BEHAVIORAL|Questionnaire|Standardized self-administered questionnaire specifically designed for this study.
219622433|NCT04289025|OTHER|Exercise|A set of exercises are provided to each patient.
219622434|NCT01778855|OTHER|IV t-PA and normothermia|
219622435|NCT01778855|DEVICE|IV-tPA and hypothermia|
219622436|NCT02079623|PROCEDURE|Electroporation/ Nano knife treatment|
219622437|NCT02079623|DEVICE|NanoKnife|
219622438|NCT06415708|DRUG|Obinutuzumab Combined With Bendamustine|"The treatment is divided into two phases: induction therapy and maintenance therapy Induction therapy: 6 cycles of obinutuzumab (1000 mg, IV) on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6 (28 days/cycle). Bendamustine (90 mg/m2, IV) on Days 1 and 2 of Cycles 1-6.~Maintenance therapy: Patients who achieved at least a partial response after 6 months of induction therapy were eligible to enter the maintenance phase, during which obinutuzumab (1000 mg, IV) was administered every 2 months for 2 years."
219622439|NCT06578000|DRUG|Magnesium sulfate|Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).
219622440|NCT06578000|OTHER|conventional therapy|conventional therapy (Splint + Stretch + strength) twice a week for six weeks
219622441|NCT03563599|DRUG|Telacebec (Q203)|High, Mid, Low dose of telacebec
219622442|NCT03563599|DRUG|Rifafour e-275|RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
219622443|NCT00879307|DRUG|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
219622444|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Text|Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.
218935433|NCT06589024|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
218935434|NCT06589024|OTHER|Sleep Hygiene Education|Access to sleep hygiene education materials
219046526|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
219205981|NCT06748430|OTHER|Grape variety 2|Second grape variety to evaluate
219205982|NCT06891768|DIAGNOSTIC_TEST|Blood culture|Blood culture for bacteriological profile and antibiotic sensitivity
219546072|NCT02252016|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
219546073|NCT02252016|DRUG|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
219546074|NCT00840281|DRUG|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
219546075|NCT00840281|DRUG|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
219546076|NCT06212492|DRUG|NMBAs|Early and systematic use of NMBAs
219546077|NCT06212492|OTHER|Prone positioning|Early and systematic use of prone positioning
219546078|NCT06227858|DIETARY_SUPPLEMENT|Safr'Inside supplement (Activ'Inside, SAS)|Dietary supplementation will be taken in addition to habitual diet of the patients
219546079|NCT06227858|OTHER|Plcebo|Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
219546080|NCT00944190|BEHAVIORAL|Self-management intervention|Brief counseling technique, self-management,
219546081|NCT00944190|BEHAVIORAL|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
219546082|NCT00509990|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
219546083|NCT04941638|PROCEDURE|Distal radial access|Vascular access for primary PCI in patients with STEMI
219546084|NCT05492279|DIETARY_SUPPLEMENT|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
219546085|NCT05492279|DIETARY_SUPPLEMENT|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
219546086|NCT05080387|OTHER|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
219546087|NCT06627387|OTHER|Balance Training Using Augmented Reality|"The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6)."
219546088|NCT04706637|DRUG|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
219546089|NCT04706637|DRUG|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
219546090|NCT03170622|DIAGNOSTIC_TEST|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
219546091|NCT00794547|DRUG|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
219546092|NCT00794547|DRUG|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
219546093|NCT06561984|BEHAVIORAL|antenatal education|Giving educational sessions to the intervention group regarding modes of delivery
218935435|NCT06654609|COMBINATION_PRODUCT|Insoles for Foot|Assess the condition of foot ulcers in patients, beginning with creating a cast of the affected foot. After the initial rectification, necessary modifications are made to prepare the rough insole. The size and fit of the insole are then carefully checked against the patient's foot. I use local silicone materials, secured with lady socks or stockinette to ensure the insole stays in place and provides durability.
219546094|NCT02632253|PROCEDURE|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
219546095|NCT02632253|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
219546096|NCT00109954|DRUG|cisplatin|
219546097|NCT00109954|RADIATION|brachytherapy|
219546098|NCT00109954|RADIATION|yttrium Y 90 glass microspheres|
219546099|NCT02064153|PROCEDURE|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
219205983|NCT06046898|DEVICE|non-invasive ventilation with or without resistance|non-invasive ventilation with or without resistance.
219546100|NCT02064153|PROCEDURE|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
219546101|NCT04762251|OTHER|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
219546102|NCT04762251|OTHER|Current Best Practice|Best practice guidelines to improve diet quality
219546103|NCT06559761|PROCEDURE|Hepatectomy|According to guideline recommended procedure of hepatectomy
219546104|NCT04033705|DEVICE|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
219546105|NCT00685477|DRUG|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
219546106|NCT00685477|DRUG|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
219546107|NCT00685477|DRUG|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
219546108|NCT00685477|DRUG|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
219546109|NCT00685477|DRUG|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
219546110|NCT00685477|DRUG|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
219205984|NCT06742645|BEHAVIORAL|Brief Motivational Interviewing|"Brief Motivational Interviewing (BMI), the object of the training and of the present research study, is an interview methodology that includes the intervention on the motivation to change of subjects with risky behaviors for their health, in order to obtain changes in their lifestyle and maintain correct behaviors for health over time (1). The BMI is mainly based on the Transtheoretical Model of Change by Di Clemente CC. and Prochaska JO (2).~In particular, the BMI has been defined by its creators, Miller and Rollnick, as a collaborative style of conversation aimed at strengthening motivation and commitment to change (3), both through defined attitudes, strategies and techniques, and through the exploration of ambivalence or internal fracture, which together with availability and a sense of self-efficacy (4) provides a framework of personal motivation."
219546111|NCT02050685|OTHER|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
219205985|NCT06742645|BEHAVIORAL|Standard of Care (SOC)|Standard of Care (SOC) - The health workers of the Navile Community House carry out the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire
219546112|NCT04631562|DRUG|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
218935436|NCT02930018|DRUG|Nerinetide (NA-1), 2.6 mg/kg|Single intravenous infusion of nerinetide over 10 ± 1 minutes
218935437|NCT02930018|DRUG|Placebo|Placebo Comparator: Placebo
218935438|NCT06646731|DEVICE|cryoneurolysis|Peripheral nerve cryoneurolysis of the foot
218935439|NCT06646731|DEVICE|sham cryoneurolysis|a sham probe will be placed percutaneously proximal to target nerves. No cryoneurolysis will be given.
218935440|NCT06813963|DRUG|Topical Minoxidil（5%） to the scalp.|The patient will apply 5% Minoxidil topical solution to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
218935441|NCT06813963|DRUG|Placebo|The patient will apply placebo to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
219546113|NCT04631562|DRUG|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
219546114|NCT04631562|DRUG|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
218935442|NCT04746183|DRUG|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
218935443|NCT04746183|DRUG|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
218935444|NCT04746183|DRUG|Nitazoxanide|"CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
218935445|NCT04746183|DRUG|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
218935446|NCT04746183|DRUG|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
219546115|NCT04631562|DRUG|Placebo IV|Placebo IV will be administered as an IV infusion.
219546116|NCT05313217|DIAGNOSTIC_TEST|Knee extension angle|"Knee Extension Angle (KEA):~* This test will be administered with an ankle-foot orthosis (AFO) maintaining the participants ankle in neutral.~* The participant will lie supine on the examination table with the contralateral lower extremity (LE) stabilized on the support surface using a mobilization strap.~* The hip of the lower being examined will be flexed to 90 degrees.~* The participant will then actively straighten their lower leg while maintaining upper leg in same position~* Once the participant feels they are at maximal knee extension (patient instructed to straighten leg as far as what is comfortable), the angle will be measured with iPhone Inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
219546117|NCT05313217|DIAGNOSTIC_TEST|Straight Leg Raise|"Straight Leg Raise (SLR):~* Position the participant in supine on the plinth with knees extended and L LE strapped to the plinth~* The participant will keep the AFO donned on the R distal ankle to keep the ankle in neutral position.~* A researcher will passively lift the participant's right leg moving at a slow but consistent pace of approximately 15 degrees per second, while keeping it straight until a significant resistance is detected or the participant reports a production of symptoms, whichever occurs first.~* Measurement of the SLR angle will be assessed with iPhone inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
219546118|NCT05313217|DIAGNOSTIC_TEST|Slump Test|"Slump Test Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant will sequentially flex trunk, look down at the floor~* Participant will extend R knee until symptoms are felt. Measure of angle with iPhone inclinometer placed at superior aspect of medial malleolus~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
219546119|NCT05313217|DIAGNOSTIC_TEST|Extended slump test|"Extended Slump Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant is asked to arch their lower back into maximal extension in sitting, stabilized to research bench to maintain hyper-lordosis posture.~* The participant is asked first flex cervical spine, then to extend their knee until it reaches full ROM or symptoms are felt that limit ROM.~* Knee extension ROM is assessed with iPhone inclinometer at superior aspect of medial malleolus.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
219546120|NCT04306952|BEHAVIORAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
219549967|NCT03576053|OTHER|Heat stimulation|Short heat stimulation
219546121|NCT04306952|BEHAVIORAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
219546122|NCT04306952|BEHAVIORAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
219546123|NCT06431321|BEHAVIORAL|Tabudira Parenting Intervention for Early Childhood Development|2 session programme delivered weekly over 2 weeks using group-based delivery aimed at reducing child maltreatment, improving parenting behaviours and parent's mental health.
219546124|NCT06431321|OTHER|Nutritional guide for younger children|2 session programme delivered weekly over 2 weeks aimed at providing parents with nutritional education to help provide maximum nutrition to the growing child
219546125|NCT01001403|DRUG|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
219546126|NCT01001403|DRUG|Normal saline|10 ml of normal saline
219546127|NCT05315063|OTHER|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
219546128|NCT05315063|OTHER|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
219546129|NCT04142918|OTHER|Immunostaining|Immunostaining of oral mucosa/gingiva samples
219546130|NCT02537457|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
219546131|NCT02537457|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
219546132|NCT05351957|PROCEDURE|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
219546133|NCT01944072|OTHER|Aerobic exercise training intensity|
219546134|NCT01190865|BIOLOGICAL|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
219546135|NCT06516354|DEVICE|Portable sleep apnea screening|Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
219546136|NCT06516172|OTHER|Comprehensive disease-specific rehabilitation|"Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes."
219546137|NCT00326872|DRUG|Cediranib Maleate|
219546138|NCT05374057|OTHER|Chiropractic spinal manipulative therapy (CSMT)|See study arm.
219546139|NCT05374057|OTHER|CSMT sham manipulation|See study arm.
219546140|NCT05374057|DRUG|Ibuprofen|See study arm.
219546141|NCT05374057|DRUG|Placebo medication|See study arm.
219546142|NCT02651506|PROCEDURE|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
219546143|NCT02651506|PROCEDURE|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
219546144|NCT01902394|OTHER|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
219549968|NCT03576053|OTHER|Pre-heating|Mild skin pre-heating
219549969|NCT03576053|OTHER|Serotonin|Serotonin electrophoresis
218935447|NCT04746183|DRUG|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
218935448|NCT04746183|DRUG|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
218935449|NCT04746183|DRUG|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
218935450|NCT04746183|DRUG|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
218935451|NCT04746183|DRUG|ALG-097558|ALG-097558 600 mg Twice a day (BD) for 5 days
219546145|NCT01902394|OTHER|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
219546146|NCT01045681|DRUG|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
219546147|NCT06627621|PROCEDURE|Alveolar Ridge Reconstruction|scaffold guided alveolar bone regeneration
219546148|NCT04171115|DRUG|G03-52-01|G03-52-01 administered intramuscularly
219546149|NCT04171115|DRUG|Placebo|Placebo administered intramuscularly
219546150|NCT02436200|DEVICE|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
219546151|NCT03157115|DEVICE|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
219546152|NCT02471807|DEVICE|Edwards FORMA Tricuspid Transcatheter Repair System|
219546153|NCT00143364|DRUG|varenicline (CP-526,555)|
219546154|NCT00957021|DEVICE|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
219546155|NCT00746421|DRUG|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
219546156|NCT00746421|DRUG|Placebo|200mg, 300mg or 400mg
219546157|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
219546158|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
219546159|NCT00108043|PROCEDURE|FES-evoked functional upright gait|
219546160|NCT05327777|DRUG|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
219546161|NCT05327777|BEHAVIORAL|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
219546162|NCT01822119|DEVICE|Baha Attract System|
219546163|NCT06596889|PROCEDURE|Successful airway management|"* Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient."
219546164|NCT05510141|OTHER|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
219546165|NCT05510141|DRUG|Nitrous oxide|Standard procedure
219546166|NCT02000388|DRUG|Ketorolac Tromethamine|
219546167|NCT02000388|OTHER|Standard of Care|
219546168|NCT04386577|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
219546169|NCT04386577|DRUG|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
219546170|NCT02294305|DRUG|Vortioxetine|
219546171|NCT02294305|DRUG|Placebo|
219546172|NCT00932477|DRUG|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
219546173|NCT00932477|DRUG|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
219546174|NCT00932477|DRUG|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
219546175|NCT03031795|DRUG|Ketorolac|Oral Tablet
219546176|NCT03031795|DRUG|Placebo|Oral Tablet
219549970|NCT04507698|OTHER|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
219549971|NCT00051805|BEHAVIORAL|Promotion of adherence to ARV medications|
219549972|NCT01611506|BIOLOGICAL|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
219549973|NCT01611506|DRUG|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
219546177|NCT02184715|OTHER|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
219546178|NCT00961376|BIOLOGICAL|PBMC re-infusion|Autologous PBMC re-infusion
218935452|NCT04746183|DRUG|ALG-097558 and Remdesivir|ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.
219546179|NCT00961376|BIOLOGICAL|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
219622445|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Video|Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
219622446|NCT00191477|DRUG|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
219622447|NCT00191477|DRUG|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
219622448|NCT06047730|PROCEDURE|operation ways|nothing
219622449|NCT00916084|DEVICE|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
219546180|NCT02174926|PROCEDURE|Elective laparoscopic sigmoid resection|
218935453|NCT04746183|DRUG|NHS standard of care as per COVID-19 treatment guidelines|NHS standard of care as per COVID-19 treatment guidelines
219546181|NCT02174926|DIETARY_SUPPLEMENT|Conservative treatment|Written lifestyle guidance and fiber supplements
219546182|NCT00205621|DEVICE|Positron Emission Tomography|
219546183|NCT01483820|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
219546184|NCT00867360|DRUG|Mifepristone (RU-486)|
219546185|NCT00867360|DRUG|Placebo|Placebo medication
219546186|NCT04673825|OTHER|Patient initiated care + telemonitoring|See arm/group descriptions.
219546187|NCT02763488|DEVICE|DelfiPTS tourniquet system|
219546188|NCT02763488|OTHER|Standard physical therapy|
219546189|NCT03493178|DIETARY_SUPPLEMENT|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
219546190|NCT03493178|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
219546191|NCT03493178|DIETARY_SUPPLEMENT|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
218935454|NCT06289907|DIETARY_SUPPLEMENT|Bonafide-HF3.0|Take 2 capsules once daily in the mornings with food
218935455|NCT06289907|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
218935456|NCT02471937|BIOLOGICAL|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
218935457|NCT06526793|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
218935458|NCT06123741|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
218935459|NCT06123741|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
218935460|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
218935461|NCT06593743|DRUG|Perianal NRL001 Gel 3 strengths|A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.
218935462|NCT06593743|DRUG|Intraanal NRL001 Gel 2 strengths|A single application of 3.0% or 1.0% Gel
218935463|NCT06593743|DRUG|Intrarectal NRL001 Gel|A single application of 1.0% Gel
218935464|NCT06593743|DRUG|NRL001: 10mg suppository|NRL001 10mg suppository applied to rectum.
218935465|NCT06601595|DRUG|TNF inhibitors|tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
218935466|NCT06601595|DRUG|conventional ibd medical treatment|Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
218935467|NCT01857492|DEVICE|tDCS|
218935468|NCT01857492|BEHAVIORAL|Meditation|Both Active and SHAM groups will receive Meditation.
218935469|NCT06170411|DEVICE|Elexir (program1)|The Elexir is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as Trigeminal Nerve Stimulation. The Elexir will deliver trigeminal nerve stimulation.
218935470|NCT06170411|DEVICE|sham device|The sham device will deliver sham trigeminal nerve stimulation.
218935471|NCT06667011|BEHAVIORAL|Feedback|learning conversation between trainee and teacher lasting 5 to 10 minutes at the end of each working day
219546192|NCT05604209|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered intramuscularly (IM) at Day 0
219546193|NCT05604209|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered intramuscularly (IM) at Day 0
219546194|NCT05604209|BIOLOGICAL|MVA.tHIVconsv4|Administered intramuscularly (IM) at Day 28
219546195|NCT05604209|BIOLOGICAL|MVA.tHIVconsv3|Administered intramuscularly (IM) at Day 28
219546196|NCT05604209|OTHER|Placebo|Administered at intramuscularly (IM) Day 0 and Day 28
219546197|NCT05812625|OTHER|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
219546198|NCT05812625|OTHER|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
219546199|NCT02986256|BEHAVIORAL|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
219546200|NCT02986256|BEHAVIORAL|Visit at home|Home visit by the referring nurse every 15 days
219546201|NCT00112437|DRUG|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
219546202|NCT00112437|DRUG|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
219546203|NCT00112437|DRUG|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
219546204|NCT00112437|DRUG|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
219546205|NCT00112437|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
219546206|NCT00112437|DIETARY_SUPPLEMENT|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
219546207|NCT00112437|DRUG|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
219546208|NCT04783337|DIAGNOSTIC_TEST|HR-pQCT (high resolution computertomograph)|In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
219546209|NCT04783337|DIAGNOSTIC_TEST|Blood withdrawal|Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
219546210|NCT00531128|BEHAVIORAL|High/Low Sitosterol|
219546211|NCT02011828|DRUG|Ergocalciferol|50,000 IU/week
219546212|NCT02011828|DRUG|Placebo|Placebo tablet
219546213|NCT02440997|OTHER|aromatherapy|
219546214|NCT02440997|OTHER|foot bath|
219546215|NCT03541252|DRUG|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
219546216|NCT03076437|COMBINATION_PRODUCT|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
219546217|NCT02577458|DRUG|CM082|CM082 tablets taken orally once a day on 28-day cycles
219546218|NCT02577458|DRUG|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
219546219|NCT00207662|DRUG|infliximab or placebo|
219546220|NCT04371224|DRUG|Irinotecan Liposomal Injection [Onivyde]|both arm
219546221|NCT04371224|DRUG|Capecitabine|NaliCap
219546222|NCT04371224|DRUG|5-fluorouracil|NAPOLI
219546223|NCT04371224|DRUG|Leucovorin|NAPOLI
219549974|NCT01611506|DRUG|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
219549975|NCT00537095|DRUG|Vandetanib|300 mg oral once daily oral dose
219549976|NCT00537095|OTHER|Placebo|
219549977|NCT06505005|DEVICE|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
219549978|NCT06505005|DEVICE|Sham Patch without haptic vibrotactile trigger technology (VTT)|Sham Patch without haptic vibrotactile trigger technology (VTT)
219549979|NCT03227939|PROCEDURE|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
219549980|NCT03227939|PROCEDURE|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
219549981|NCT01370122|OTHER|Survey|
219549982|NCT00349765|BEHAVIORAL|higher fat, high polyunsaturated fat diet|
219549983|NCT00349765|BEHAVIORAL|higher fat, high saturated and trans fat diet|
219549984|NCT00349765|BEHAVIORAL|lower fat diet|
218935472|NCT06609694|DEVICE|Portable oxygen concentrator Inogen G5 model|The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
219046527|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
219046528|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
219546224|NCT04584749|DRUG|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
219046529|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
219046530|NCT06184516|PROCEDURE|Reproductive organ sparing radical cystectomy|"Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool."
219546225|NCT04979143|PROCEDURE|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
219546226|NCT00227370|DRUG|valganciclovir|valgan 900mg QD x 9 months post lung transplant
219546227|NCT00227370|OTHER|Placebo|
219546228|NCT04693429|DRUG|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
219546229|NCT05114512|OTHER|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
219546230|NCT04778501|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
219546231|NCT01476969|DEVICE|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
219546232|NCT02337322|DRUG|Dolutegravir|
219546233|NCT02337322|DRUG|Darunavir/r|
219546234|NCT03517319|DRUG|Normal Saline 0.9% 1.2 ml|
219622450|NCT00916084|DEVICE|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
219046531|NCT06184516|PROCEDURE|Radical cystectomy|"Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool."
219046532|NCT05723770|DRUG|instillation of NOV03|This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
219046533|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
219046534|NCT01171898|DRUG|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
219546235|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
219546236|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
218935473|NCT06984952|PROCEDURE|ERAS protocol|The ERAS protocol includes pre-admission patient education through audiovisual materials; reduction of perioperative fasting duration with preoperative carbohydrate loading and early postoperative oral intake; multimodal prophylaxis for postoperative nausea and vomiting; early removal of surgical drains and intravenous lines; early mobilization; and multimodal analgesia aimed at minimizing postoperative opioid use. The detailed protocol used in this study has been published previously \[https://doi.org/10.5230/jgc.2025.25.e27\].
219046535|NCT01171898|DRUG|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
219046536|NCT01659112|OTHER|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
219046537|NCT01659112|OTHER|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
219046538|NCT02150564|DEVICE|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
219546237|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
219546238|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
218935474|NCT06011551|DEVICE|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
219546239|NCT07135102|DRUG|225Ac-PSMA-XT|Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.
219546240|NCT02612298|DRUG|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
219546241|NCT02612298|DRUG|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
219546242|NCT04013841|OTHER|Oral-agents/Enema|"1. Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~2. Enema for mechanical bowel preparation prior to left-side colorectal resection"
219546243|NCT06874764|OTHER|Wireless Lighting Reaction System Training(Agility plus Cognitive)|Agility training and Cognitive trainings(cognitive trainings ready within the device: Eye for detail, Hawk eye, Juggle Factor)
219546244|NCT02588339|DRUG|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
219546245|NCT02588339|DRUG|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
219546246|NCT02588339|DRUG|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
219546247|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
219546248|NCT03927495|RADIATION|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
219546249|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
219546250|NCT06408636|OTHER|Cardiac MRI|All selected patients completed a cardiac magnetic resonance examination without other interventions.
219546251|NCT01952691|DEVICE|kinesiotaping|correction method was used to align hallux.
219546252|NCT02955004|PROCEDURE|Electrical cardioversion|Transthoracic direct current electrical cardioversion
219546253|NCT00199901|BIOLOGICAL|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
219546254|NCT00199901|BIOLOGICAL|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
218935475|NCT06011551|OTHER|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
219546255|NCT06335186|DIAGNOSTIC_TEST|upper endoscopy|to detect esophageal or gastric varices
219546256|NCT05546398|DRUG|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
219546257|NCT05546398|OTHER|No study drug|No study drug was administered during this study.
219546258|NCT05403268|DEVICE|DeltaScan|Twice daily DeltaScan observations
218935476|NCT04917757|DIAGNOSTIC_TEST|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
218935479|NCT06591403|OTHER|the index and middle fingers of each participant&amp;#39;s active hand|A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
219546259|NCT06678399|DRUG|KELI-101|KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
219546260|NCT06678399|OTHER|Vehicle (placebo)|Plasmalyte
219546261|NCT02845791|BEHAVIORAL|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
219546262|NCT05776901|DEVICE|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
219549985|NCT03201276|DRUG|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
219549986|NCT00799162|OTHER|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
219549987|NCT00566722|BIOLOGICAL|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
218935480|NCT06595680|DRUG|Medialipide 20% perfusion|Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
219549988|NCT01875107|DRUG|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
219205986|NCT06752044|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
219046539|NCT02150564|PROCEDURE|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
219205987|NCT06752044|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
219205988|NCT06752044|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219205989|NCT06752408|DRUG|Aumolertinib|Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
219205990|NCT06752408|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
219205991|NCT06752343|DRUG|Photodynamic Therapy|Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de
219205992|NCT06752343|DRUG|Clobetasol|"The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration"
219546263|NCT05911919|DEVICE|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
219546264|NCT00917735|DRUG|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
219546265|NCT00917735|OTHER|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
219546266|NCT04080999|DEVICE|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
219546267|NCT04080999|DEVICE|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
219546268|NCT03681587|OTHER|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
219546269|NCT03681587|OTHER|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
219546270|NCT03581994|DIAGNOSTIC_TEST|DDI Test Report|Test results of simulated patients
219546271|NCT01964872|DRUG|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
219546272|NCT01964872|DRUG|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
219546273|NCT01964872|DRUG|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
219622451|NCT02962492|DRUG|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
219622452|NCT02962492|DRUG|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
219205993|NCT06749756|DRUG|vitamin B6+ Vitamin B12 +vitamin C|In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
219205994|NCT06749756|DRUG|vitamin B6+ Vitamin B12|In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
219205995|NCT06749756|DRUG|vitamin C|On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
219205996|NCT06749756|DRUG|0.9%Nacl|The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
219205997|NCT06753565|DRUG|Carnitine|"It is a nutritional supplement with trade name  Carnitol® in Egypt."
219205998|NCT06753565|DRUG|Disease-modifying anti-rheumatic drugs|They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
219205999|NCT06754605|BIOLOGICAL|SCTV02|Participants will receive a singe dose of SCTV02 on Day 0.
219546274|NCT01964872|DRUG|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
219546275|NCT01964872|DRUG|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
219546276|NCT01964872|DRUG|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
219546277|NCT01964872|DRUG|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
219546278|NCT03561558|DRUG|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
219546279|NCT03561558|DRUG|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
219546280|NCT03342235|PROCEDURE|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
219546281|NCT03342235|OTHER|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
219546282|NCT03342235|DEVICE|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
219546283|NCT01215903|DIETARY_SUPPLEMENT|Fish gelatin and omega-3 polyunsaturated fatty acid|
219546284|NCT01215903|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|
219546285|NCT00954603|DRUG|quetiapine|25-100 mg
219546286|NCT00954603|DRUG|haloperidol|0.5-2 mg
219546287|NCT03232541|OTHER|Standard care|A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
219546288|NCT03232541|DEVICE|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
219546289|NCT03232541|DEVICE|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
219546290|NCT01139606|OTHER|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
219546291|NCT03263793|BEHAVIORAL|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
219546292|NCT03980301|DIAGNOSTIC_TEST|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
219546293|NCT05124522|BEHAVIORAL|MSPA eClass|An 8-week MS-HAPA Internet-based intervention
219546294|NCT03197818|DRUG|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
219546295|NCT03197818|DRUG|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
219549989|NCT04305470|DRUG|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
219206000|NCT06754605|BIOLOGICAL|Placebo|Participants will receive a singe dose of Placebo on Day 0.
219206001|NCT06756061|DRUG|Prednisone + Jakavi(ruxolitinib)|"The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)"
219206002|NCT06756061|DRUG|Prednisone|"The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease."
219549990|NCT02671058|DRUG|Cortenema|Hydrocortisone Administered as a Liquid Enema
219549991|NCT02671058|DRUG|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
219549992|NCT01167335|DRUG|BGG492|
219549993|NCT01167335|DRUG|Placebo|
219546296|NCT06056115|DRUG|Tislelizumab,Platinum|"1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
219206003|NCT06752447|DRUG|LNF2007|"LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first."
219546297|NCT04733456|BEHAVIORAL|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
219206004|NCT06755138|OTHER|Observational Assessment|This study includes the use of surface electromyography (sEMG), video analysis, and questionnaires to assess trunk compensation patterns and their relationship with scoliosis, functional, quality-of-life, and pain parameters
219546298|NCT04733456|DEVICE|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
219546299|NCT04733456|OTHER|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
219546300|NCT04733456|OTHER|Blood and urine collection|for inflammatory markers and metabolomic \[IMC\] analysis
219546301|NCT00000950|DRUG|Ethambutol hydrochloride|
219546302|NCT00000950|DRUG|Isoniazid|
219546303|NCT00000950|DRUG|Pyrazinamide|
219546304|NCT00000950|DRUG|Pyridoxine hydrochloride|
219546305|NCT00000950|DRUG|Rifampin|
219546306|NCT02604641|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
219546307|NCT02604641|DIETARY_SUPPLEMENT|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
219546308|NCT02604641|DIETARY_SUPPLEMENT|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
219546309|NCT01074424|GENETIC|proteomic profiling|
219546310|NCT01074424|OTHER|laboratory biomarker analysis|
219546311|NCT04487184|OTHER|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
219206005|NCT06753929|DEVICE|wireless wearable thermal anisotropy measurement device|non-invasive device used for assessing CSF shunt flow via thermal anisotropy measurements in a routine outpatient clinic setting
219206006|NCT06755385|OTHER|Pleuropulmonary ultrasound|pleuropulmonary ultrasounds performed at D0, between D2 and D5 during hospitalization and at D-1 on discharge
219206007|NCT06738810|DIAGNOSTIC_TEST|Fibrotest-actitest/NASHtest|A blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest and to calculate the NAFLD fibrosis score
219546312|NCT04384224|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
219546313|NCT00197249|BIOLOGICAL|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
219546314|NCT03187821|PROCEDURE|Laser peripheral iridotomy|location of laser peripheral iridotomy
219546315|NCT02305134|DRUG|Tipepidine Hibenzate|
219546316|NCT02305134|DRUG|Placebo|
219546317|NCT04946708|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
219546318|NCT05786118|OTHER|No intervention|There is no intervention in this study
219546319|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
219546320|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
219546321|NCT03995849|DIAGNOSTIC_TEST|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
219546322|NCT04231643|DRUG|Dronabinol|one-time oral administration of 5 mg dronabinol
219546323|NCT04231643|DRUG|Epidiolex|one-time oral administration of 600 mg Epidiolex
219546324|NCT04231643|DRUG|Placebos|one-time oral administration of placebo
219622453|NCT02962492|DRUG|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
219622454|NCT03992963|DEVICE|Hearing Aid without frequency lowering enabled|Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
219546325|NCT03017729|BIOLOGICAL|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
219546326|NCT01374646|BEHAVIORAL|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
219546327|NCT01208194|DRUG|MGN1703|solution, 60 mg, twice a week, until progression
219546328|NCT01208194|DRUG|Placebo|solution, 60 mg, twice a week, until progression
219546329|NCT02658214|DRUG|paclitaxel + carboplatin|IV infusion
219546330|NCT02658214|DRUG|carboplatin + etoposide|IV infusion
219546331|NCT02658214|DRUG|gemcitabine + carboplatin|IV infusion
219546332|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
219546333|NCT02658214|DRUG|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
219622455|NCT03992963|DEVICE|Hearing Aid with frequency lowering enabled|Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
219622456|NCT03589417|OTHER|Assessments with Biodex Balance System®|Postural Stability, limits of stability and fall risk tests will be applied with the Biodex Balance System®
219622457|NCT02825017|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79\_Y73-161)
219622458|NCT01571219|BIOLOGICAL|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
219622459|NCT06424613|DRUG|Lithium Carbonate|Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.
218935481|NCT06595680|DRUG|NaCl 0,9%|Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
218935482|NCT06595680|BIOLOGICAL|Blood sample|Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.
219046540|NCT06845891|DEVICE|CONNECTED SMART CAP|The intervention in this study consists of attaching a smart cap to the insulin pen of individuals with type 1 diabetes who use flash glucose monitoring and experience a time above range (TAR \>180 mg/dL) for more than 25% of the time. This metric has been associated with diabetes-related complications, and the objective of this study is to determine whether this simple device could help reduce this underexplored parameter.
219546334|NCT02658214|BIOLOGICAL|durvalumab|IV infusion
219622460|NCT06424613|DRUG|Non-lithium medication|No history of lithium use within the past year
219622461|NCT00272077|DRUG|Insuline glargine|
219622462|NCT02455206|BEHAVIORAL|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
218935483|NCT06860867|DEVICE|PerQdisc|PerQdisc Artificial Implant
218935484|NCT06861049|DIETARY_SUPPLEMENT|Psychobiotic Supplement|Lactobacillus helveticus R0052 Bifidobacterium bifidum R0071 Bifidobacterium longum R0175
218935485|NCT06861049|DIETARY_SUPPLEMENT|Placebo Supplement|Maltodextrin
219046541|NCT06221696|DIETARY_SUPPLEMENT|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
219046542|NCT06221696|OTHER|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
219046543|NCT01359592|BIOLOGICAL|rituximab|
219046544|NCT01359592|DRUG|cyclophosphamide|
219046545|NCT01359592|DRUG|doxorubicin hydrochloride|
219046546|NCT01359592|DRUG|prednisone|
219046547|NCT01359592|DRUG|vincristine sulfate|
219546335|NCT02658214|BIOLOGICAL|tremelimumab|IV infusion
219622463|NCT02455206|BEHAVIORAL|Usual care|
219546336|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
219546337|NCT02658214|DRUG|cisplatin + 5-fluorouracil (5FU)|IV infusion
219546338|NCT06205264|OTHER|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
219546339|NCT04130464|DRUG|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
219546340|NCT04130464|DRUG|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
219546341|NCT04130464|DRUG|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
219546342|NCT01360086|BIOLOGICAL|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
219546343|NCT01360086|DRUG|cisplatin|Cisplatine (50mg/m²)
219546344|NCT01360086|DRUG|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
219546345|NCT01360086|DRUG|leucovorin calcium|
219546346|NCT01360086|PROCEDURE|adjuvant therapy|
219546347|NCT01360086|PROCEDURE|neoadjuvant therapy|
219546348|NCT01360086|PROCEDURE|quality-of-life assessment|
219546349|NCT01360086|PROCEDURE|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
219546350|NCT02509286|DRUG|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
219546351|NCT02509286|DRUG|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
219546352|NCT02509286|DRUG|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
219546353|NCT02509286|DRUG|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
219546354|NCT02509286|DRUG|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
219546355|NCT02509286|DRUG|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
219546356|NCT02509286|RADIATION|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
219546357|NCT00754507|DRUG|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
219546358|NCT00754507|DRUG|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
219622464|NCT06576804|BEHAVIORAL|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
218935486|NCT06862206|OTHER|benralizumab|non-interventional
218935487|NCT06858904|DIETARY_SUPPLEMENT|Placebo|Non- calorically sweetened Water
218935488|NCT06858904|DIETARY_SUPPLEMENT|ConcenTrace|1.25 milliliter of concentrace per liter
218935489|NCT06858904|DIETARY_SUPPLEMENT|ZeroLyte|Beverage with 1 pack of ZeroLyte per 500 milliliter of water
218935490|NCT03708003|DRUG|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
218935491|NCT03708003|DRUG|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
218935492|NCT04434937|DRUG|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
218935493|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
218935494|NCT06993233|DRUG|CIT-013 high dose|subcutaneous injection
218935495|NCT06993233|DRUG|CIT-013 medium dose|subcutaneous injection
218935496|NCT06993233|DRUG|Placebo|subcutaneous injection
219546359|NCT04132115|DRUG|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546360|NCT04132115|DRUG|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546361|NCT04132115|DRUG|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546362|NCT04132115|DRUG|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546363|NCT04132115|DRUG|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546364|NCT04132115|DRUG|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
219546365|NCT04132115|DRUG|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
218935497|NCT06993831|BEHAVIORAL|Virtual Reality-based psychotherapy|"A manualized, modularized, Virtual Reality-based intervention comprising 10 sessions of 1 hour each. The VR therapy aims at enhancing anticipatory pleasure and positive emotions by amplifying exposure and reactivity towards social environments and rewarding activities using a highly elaborate VR software. The VR exposure comprises several different virtual social environments (e.g., a bus, a café, a park etc.) In a tailored treatment approach, therapists will guide participants to train focusing on positive stimuli, engage in activities, experience social rewards, and practice expressing emotions through body language.~The therapy focuses on increasing the awareness of positive outcomes that may influence motivation. The therapy deploys activity appraisal/re-appraisal intended to enhance the salience of future opportunities for reward and desire for such rewards, thus targeting reward anticipation processes and promoting enjoyable daily-life activities."
219546366|NCT04132115|DRUG|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
219546367|NCT04132115|DRUG|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546368|NCT04132115|DRUG|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
219546369|NCT04132115|DRUG|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
219546370|NCT02483195|DRUG|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
219546371|NCT02483195|DRUG|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
218935498|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
218935499|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
218935500|NCT06995924|OTHER|Educational Intervention|Complete self-directed interactive education
218935501|NCT06995924|OTHER|Electronic Health Record Review|Ancillary studies
219546372|NCT02483195|DRUG|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
219546373|NCT02483195|OTHER|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
219546374|NCT05706415|DIAGNOSTIC_TEST|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
219546375|NCT01379313|PROCEDURE|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
219546376|NCT01379313|PROCEDURE|1:1 ratio|I:E ratio of 1:1 is applied.
218935502|NCT06995924|OTHER|Internet-Based Intervention|Receive access to CTAC
218935503|NCT06995924|BEHAVIORAL|Patient Navigation|Receive patient navigation services
218935504|NCT06995924|OTHER|Survey Administration|Ancillary studies
218935505|NCT06863220|OTHER|Intravesical Ozone Therapy|Patients received 50 mL ozonated saline (20-40 µg/mL) intravesically twice weekly for 3 weeks.
219046548|NCT01359592|OTHER|R-CHOP regimen|
219046549|NCT01359592|OTHER|laboratory biomarker analysis|
219046550|NCT01359592|RADIATION|fludeoxyglucose F 18|
219046551|NCT01359592|RADIATION|selective external radiation therapy|
219046552|NCT01359592|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219046553|NCT01422499|DRUG|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
219046554|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
219046555|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
219046556|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
219046557|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
219622465|NCT06576804|BEHAVIORAL|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
219046558|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
219046559|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
219046560|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
219546377|NCT01379313|PROCEDURE|2:1 group|Inverse I:E ratio of 2:1 is applied.
219546378|NCT01379313|PROCEDURE|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
219546379|NCT00365053|DRUG|belinostat|Given IV
219546380|NCT00365053|OTHER|laboratory biomarker analysis|Correlative studies
219546381|NCT02488057|DRUG|Liraglutide|Active comparator. See arm descriptions.
219546382|NCT02488057|BEHAVIORAL|Weight loss|Active comparator. See arm descriptions.
218935506|NCT06863220|OTHER|Placebo (Normal Saline)|Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.
219546383|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
219546384|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
219546385|NCT03318757|DRUG|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
219546386|NCT03318757|DRUG|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
219546387|NCT01951209|DRUG|Rifaximin|550mg orally twice daily for 12 weeks
219546388|NCT01951209|DRUG|Placebo|Matched placebo
219546389|NCT00564031|DRUG|Femanest|2mg/day
219546390|NCT00564031|DRUG|gestapuran|5mg/day
219546391|NCT00564031|DRUG|placebo|daily
219546392|NCT00564031|DRUG|Femanest plus Gestapuran|combined daily
218935507|NCT06863220|OTHER|Control|Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.
218935508|NCT00114517|DRUG|17B-estradiol|Oral 17B-estradiol 1 mg daily
218935509|NCT00114517|OTHER|Placebo|Matching oral 17B-estradiol placebo daily
218935510|NCT03669341|OTHER|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
219046561|NCT03854916|OTHER|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
219046562|NCT03854916|OTHER|World Walking App|A mobile app that encourages users to walk.
219046563|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
219046564|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
219046565|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
219046566|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
219046567|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
219046568|NCT06178874|DRUG|Insulin regular|hyperglycemic control
219046569|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
219046570|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
219546393|NCT06312462|BEHAVIORAL|health education|In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
219546394|NCT04089462|BEHAVIORAL|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
219546395|NCT04089462|BEHAVIORAL|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
219546396|NCT04544800|DEVICE|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
218935511|NCT03669341|OTHER|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
219546397|NCT00510393|DEVICE|XIENCE V everolimus eluting coronary stent system|
219546398|NCT00510393|DEVICE|MULTILINK VISION coronary stent system|
219546399|NCT06482606|OTHER|Flickering Checkerboard Stimulation|This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
219546400|NCT00660660|DRUG|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
219546401|NCT00660660|DRUG|Placebo|once daily
219546402|NCT02941939|OTHER|Hyperbaric chamber|
219546403|NCT02941939|OTHER|Ambient pressure|
219546404|NCT04581122|PROCEDURE|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
219546405|NCT00566657|BIOLOGICAL|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
219546406|NCT00566657|BIOLOGICAL|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
218935512|NCT02544100|OTHER|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
218935513|NCT02587637|DEVICE|Dorsal root ganglion (DRG) stimulation|The role the DRG plays in the development and maintenance of chronic pain, we have developed a neurostimulator system for the management of chronic intractable pain by electrically stimulating the DRG
218935514|NCT06602947|OTHER|Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation|"1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
218935515|NCT07000357|DRUG|AZD0780|Participants will receive oral AZD0780 once daily
219546407|NCT00347048|DRUG|tacrolimus|oral
219546408|NCT00347048|DRUG|Placebo|oral
219546409|NCT04750681|DIETARY_SUPPLEMENT|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
219546410|NCT04750681|DIETARY_SUPPLEMENT|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
219546411|NCT01025141|DEVICE|Skeletal anchorage (MINISCREW)|Skeletal anchorage
219546412|NCT01025141|DEVICE|dental anchorage|dental anchorage (reference)
218935516|NCT07000357|DRUG|Placebo|Participants will receive oral placebo once daily
218935517|NCT06602726|DRUG|REGN1908|Administered per the protocol
218935518|NCT06602726|DRUG|REGN1909|Administered per the protocol
218935519|NCT06602726|DRUG|Placebo|Administered per the protocol
218935520|NCT06599918|DRUG|Nicotinamide|Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
218935521|NCT06599918|DRUG|Placebo|Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
219546413|NCT05270499|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
219546414|NCT01986725|BEHAVIORAL|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
219549994|NCT01939535|OTHER|No intervention|Evaluation of an imaging technique ic MRI
219549995|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
219549996|NCT03649763|DRUG|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
218935522|NCT06599281|OTHER|Physiotherapy|The physical therapy program was applied for 3 months, 6 days a week, 2 sessions per day, and an average session duration of 45 minutes. Each neurodevelopmental exercise and proprioceptive exercise was applied for 10 minutes, and stretching exercises were applied for 45 seconds and 3 repetitions. The exercises included functional rotation, sitting with or without arm support, crawling, kneeling, half kneeling, standing up by holding on, and sequencing exercises. Stretching exercises were mostly positional stretches aimed at lateral flexion of the spine.
218935523|NCT04528303|GENETIC|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
218935524|NCT04528303|GENETIC|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
219046571|NCT00749775|DRUG|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
219046572|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
219546415|NCT01986725|BEHAVIORAL|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
219622466|NCT00674648|BIOLOGICAL|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
219622467|NCT06008652|DRUG|DR-0201|DR-0201 is a bi-specific antibody
219622468|NCT06008652|DRUG|Placebo|Placebo
219622469|NCT01286467|DRUG|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
219622470|NCT05428774|OTHER|Test product 1|Participants will receive TP1 during one experimental visit.
219546416|NCT05538858|PROCEDURE|Mechanical Ventilation|Positive pressure mechanical ventilation
219546417|NCT03590119|DRUG|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
219546418|NCT03594617|BEHAVIORAL|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
219546419|NCT04534985|BEHAVIORAL|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
219546420|NCT03414151|OTHER|Observation|No intervention administered.
219546421|NCT02282124|BEHAVIORAL|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
219622471|NCT05428774|OTHER|Test product 2|Participants will receive TP2 during one experimental visit.
219622472|NCT05428774|OTHER|Placebo|Participants will receive placebo during one experimental visit.
219622473|NCT01058642|DRUG|ADL5747|
219622474|NCT01058642|DRUG|Placebo|
219622475|NCT01058642|DRUG|Pregabalin|
219622476|NCT01994408|OTHER|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
219046573|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
219046574|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
219046575|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
219046576|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
219046577|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
219546422|NCT02282124|BEHAVIORAL|Usual Care, containing one session|Session takes place within the first three months after transplantation
219546423|NCT06520904|DRUG|PCSK9 inhibitor|PCSK9 inhibitors combined with moderate-intensity statin therapy
219546424|NCT06520904|DRUG|Statin|Intensive statin therapy
219546425|NCT01866124|OTHER|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
219046578|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
219546426|NCT01569113|DRUG|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
219546427|NCT01569113|DRUG|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
219546428|NCT01232049|DRUG|Multiple Oral Dose of|Pitavastatin 4mg
219546429|NCT01232049|DRUG|Multiple Oral Dose of|Valsartan 320mg
219622477|NCT03825796|DRUG|Enasidenib Mesylate|Given PO
219622478|NCT03825796|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219622479|NCT01136057|BIOLOGICAL|Collection of Anti-Influenza A Immune Plasma|
219046579|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
219046580|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
219046581|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
219046582|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
219546430|NCT06677749|PROCEDURE|Eccentric resistance-exercise|Each participant will complete 300 repetitions of eccentric knee extensions using an isokinetic dynamometer after a baseline skeletal muscle biopsy is taken. Three hours following this, a second muscle biopsy will be taken to evaluate the changes in the dependent variables being measured (myokines).
219206008|NCT06763354|RADIATION|Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection|On the examination bed, the patient was placed in the lying truncated position, the perineum was disinfected with a towel, and a double-lumen urinary catheter was inserted via the perineum.Inject 50ml saline to clean the bladder once, open the drainage bag to drain.1mci SGC8 was dissolved in 50ml physiological saline. The drainage bag was clamped shut and 50ml of developer was injected into the bladder through the catheter, followed by 10ml of gas or saline (all developer in the ureter was injected into the bladder. The catheter was closed for 1 hour, during which time the patient was placed in the flat position, left lateral position, right lateral position, and supine position changing positions every 15 minutes.After 1 hour, the drainage bag was opened, the bladder was emptied with radioactive fluid, and the urine bag was replaced.
219622480|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
219206009|NCT06762145|DRUG|Methylprednisolone (Corticosteroid)|Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR
219206010|NCT06762145|DRUG|Placebo|Placebo for 3 days started from the day on TAVR
219206011|NCT03875001|DRUG|Placebo|For each dose group a placebo group was given matching placebo tablets, participants were randomized within each dose group in a 3:1 ratio (active drug:placebo), tablets taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
219206012|NCT03875001|DRUG|Dose group 1 - 50 mg BI 1358894|2 film-coated tablets of 25 milligram (mg) BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
219206013|NCT03875001|DRUG|Dose group 2 - 100 mg BI 1358894|1 film-coated tablet of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
219546431|NCT02428348|OTHER|Interview about prototype EEG-cap|
219546432|NCT00680940|DRUG|Paclitaxel & Cisplatin|Chemotherapeutic agent
219546433|NCT00680940|BIOLOGICAL|Mycobacterium w.|Immunomodulator
219546434|NCT03420092|DRUG|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
219046583|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
219546435|NCT03420092|DRUG|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
219046584|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
219046585|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
219046586|NCT06193135|DRUG|Corifolitropin Alfa|Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.
219046587|NCT06193135|DRUG|Folitropin Beta|Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
219046588|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
219046589|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
219046590|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
219546436|NCT03420092|DRUG|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
219546437|NCT03420092|DRUG|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
219546438|NCT03420092|DRUG|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
219046591|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
219046592|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
219046593|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
219046594|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
219046595|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
219046596|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
219546439|NCT03420092|DRUG|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
219546440|NCT02132910|OTHER|RESTORE Intervention|
219622481|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
219622482|NCT02593838|OTHER|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
219622483|NCT02137213|DRUG|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
219546441|NCT04857333|DIAGNOSTIC_TEST|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
219546442|NCT04857333|DRUG|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
219546443|NCT04857333|PROCEDURE|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
219546444|NCT04823533|DIETARY_SUPPLEMENT|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
219546445|NCT05385835|OTHER|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
219546446|NCT06137846|DEVICE|Air-Polish|Dental implant will be cleaned with an airpolishing device
219546447|NCT06137846|DEVICE|Ultrasonic|Dental implant will be cleaned with an ultrasonic device with a plastic tip
219546448|NCT03375749|BEHAVIORAL|Standing desk intervention|Standing desk converter
219546449|NCT03375749|BEHAVIORAL|Waitlist control|Control
219546450|NCT05909241|DRUG|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
219546451|NCT03523650|DRUG|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
219546452|NCT03523650|DRUG|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
219546453|NCT03256227|BEHAVIORAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
219546454|NCT03256227|BEHAVIORAL|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
219546455|NCT06660121|PROCEDURE|Electrochemotherapy with bleomycin|Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
219546456|NCT02088931|BIOLOGICAL|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
219546457|NCT04404439|DRUG|Nortriptyline + topiramate|Treatment group 1
219546458|NCT04404439|DRUG|Verapamil + paroxetine|Treatment group 2
219546459|NCT04404439|OTHER|Placebo|Placebo comparator
219546460|NCT01899352|PROCEDURE|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
219546461|NCT02895802|BEHAVIORAL|Verbal instructions with picture diagram|verbal instructions and picture diagram
219546462|NCT02895802|BEHAVIORAL|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
219546463|NCT02895802|BEHAVIORAL|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
219546464|NCT02895802|BEHAVIORAL|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
219546465|NCT04180969|DRUG|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
219546466|NCT04180969|DEVICE|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
219546467|NCT04180969|DRUG|Placebo oral tablet|placebo stressor
219546468|NCT04180969|DEVICE|sham rTMS|sham mPFC rTMS
219546469|NCT01487720|DRUG|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
219546470|NCT02043392|DEVICE|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
219546471|NCT05285865|OTHER|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
219206014|NCT03875001|DRUG|Dose group 3 - 200 mg BI 1358894|2 film-coated tablets of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
219206015|NCT06761287|PROCEDURE|Endoscopic resection|Eligible patients will undergo endoscopic submucosal dissection (ESD) or endoscopic intermuscular dissection (EID) after two to eight weeks of nCRT completion, depending on the used neo-adjuvant regimen. Procedures will be performed using the GIF EZ-1500 endoscope (Olympus America, Center Valley, PA, USA) and an electrosurgical unit (VIO 300 D; Erbe, Germany) to power the electrosurgical knife (1.5-mm DualKnife J, Olympus America). For mucosal incision, Endocut or Drycut mode will be used, while Precise, Swift or Spray Coagulation modes will support submucosal dissection and hemostasis. An initial submucosal lift will be created by Glycéol Gel injection. The ERBE Flushing Pump (Erbe, Germany) will supply further submucosal lift during dissection through foot pedal-controlled, pressurized injections of methylene blue and saline solution delivered via the DualKnife J's ceramic-tipped tubing.
219046597|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
219046598|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
219206016|NCT06761287|BEHAVIORAL|Short interval restaging|"Close follow-up and endoscopic re-evaluation four to eight weeks after the initial evaluation\*.~\*Defined as the first endoscopic evaluation after completion of the neoadjuvant treatment"
219546472|NCT05285865|OTHER|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
219046599|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
219046600|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
219046601|NCT03732898|DEVICE|Novel Programming (nDBS)|The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.
219046602|NCT03732898|DEVICE|Conventional Programming (cDBS)|The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
219046603|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
219046604|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
219046605|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
219046606|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
219046607|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
219046608|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
219046609|NCT04181346|DRUG|Pregabalin|antipsychotic
219046610|NCT04181346|DRUG|Placebo|Placebo
219046611|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
219046612|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
219046613|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
219046614|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
219046615|NCT04537806|DRUG|Placebo|Administered as IV infusion.
219046616|NCT02111486|OTHER|breakfast|
219046617|NCT03019627|DRUG|NGF|Eye Drop 20 μg/mL
219046618|NCT03019627|OTHER|Vehicle|Vehicle Eye Drop
219046619|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
219046620|NCT01433224|GENETIC|DNA methylation analysis|
219046621|NCT01433224|GENETIC|RNA analysis|
219046622|NCT01433224|GENETIC|mutation analysis|
219046623|NCT01433224|GENETIC|nucleic acid sequencing|
219046624|NCT01433224|GENETIC|polymerase chain reaction|
219046625|NCT01433224|GENETIC|polymorphism analysis|
219046626|NCT01433224|OTHER|laboratory biomarker analysis|
219046627|NCT01433224|OTHER|medical chart review|
219046628|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
219546473|NCT00664196|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
219546474|NCT05282693|DIETARY_SUPPLEMENT|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
219546475|NCT05282693|DIETARY_SUPPLEMENT|Placebo|Lemon flavored liquid
219546476|NCT00595140|DRUG|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
219546477|NCT00595140|DRUG|combination with somatostatin analogue octreotide|s.c., 100µg, one time
219546478|NCT00595140|DRUG|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
219546479|NCT06000579|OTHER|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
219546480|NCT03531450|BEHAVIORAL|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
219546481|NCT01566851|OTHER|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
219546482|NCT00881634|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
219622484|NCT02137213|DRUG|Placebo|Normal saline will be added to oral methadone preparations as placebo.
219622485|NCT03876743|OTHER|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
219622486|NCT03876743|OTHER|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
219622487|NCT03876743|OTHER|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
219622488|NCT03876743|OTHER|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
219622489|NCT04973150|BEHAVIORAL|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
219622490|NCT00092118|DRUG|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
219622491|NCT00092118|DRUG|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
219622492|NCT00123760|PROCEDURE|Positron Emission Tomography (PET) scan|
219622493|NCT01139125|DRUG|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
219046629|NCT06133543|PROCEDURE|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
219046630|NCT00479908|DRUG|Sildenafil citrate|
219046631|NCT00479908|DRUG|Glyceryl trinitrate|
219046632|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
219046633|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
219546483|NCT00881634|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
219546484|NCT04701216|DRUG|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
219546485|NCT05795621|BIOLOGICAL|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
219546486|NCT05795621|BIOLOGICAL|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
219546487|NCT03915600|OTHER|Quinoa|Personalized diet added with quinoa
219546488|NCT03915600|OTHER|Flaxseed|personalized diet added with flaxseed
219546489|NCT03915600|OTHER|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
219546490|NCT06562647|DRUG|SY001|PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
219546491|NCT00294047|BIOLOGICAL|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219546492|NCT00294047|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219622494|NCT04768816|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
219622495|NCT04768816|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
219546493|NCT01689077|OTHER|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
219546494|NCT04418297|DRUG|CT-G20|oral tablet
219546495|NCT04418297|DRUG|Placebo|oral tablet
219546496|NCT00080392|DRUG|DNA Plasmid Vector|
219546497|NCT00080392|DRUG|EW-A-401 DNA Plasmid Vector|
219546498|NCT02157974|DRUG|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
219546499|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
219546500|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
219546501|NCT00538031|DRUG|cyclophosphamide|Given orally
219546502|NCT00538031|DRUG|celecoxib|Given orally
219546503|NCT03444792|PROCEDURE|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~\- If failed the surgeon will use artery forceps to dilate cervix"
219546504|NCT01862601|DEVICE|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
219546505|NCT03356691|OTHER|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy."
219622496|NCT03751098|DRUG|Tropicamide/Phenylephrine ophthalmic solution (TR/PE)|Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
219546506|NCT03356691|OTHER|Prayer|Individuals will receive prayer during 1 to 2 minutes.
219546507|NCT03356691|OTHER|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
219546508|NCT03356691|OTHER|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
219546509|NCT03356691|OTHER|Fluid therapy.|Individuals will receive fluid therapy.
219046634|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
219046635|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
219046636|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
219046637|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
219046638|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
219046639|NCT01947530|PROCEDURE|Standard Bronchoscopy|
219206017|NCT06761287|PROCEDURE|Total mesorectal excision|This technique consists of the surgical complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum).
219546510|NCT03356691|OTHER|No-fluid therapy.|Individuals will receive no-fluid therapy.
219546511|NCT04411576|DIAGNOSTIC_TEST|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
219546512|NCT04411576|DIAGNOSTIC_TEST|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
219546513|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
219546514|NCT02063139|DRUG|Flutiform 50/5 ug (2 puffs bid) pMDI|
219546515|NCT02063139|DRUG|Fluticasone 50 ug (2puffs bid) pMDI|
219546516|NCT02063139|DRUG|Beclometasone Autohaler 50 ug (2 puffs bid)|
219546517|NCT02393144|DEVICE|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
219546518|NCT02393144|DEVICE|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
219546519|NCT02393144|OTHER|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
219546520|NCT02393144|DRUG|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
219546521|NCT02393144|DRUG|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
219546522|NCT02393144|DRUG|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
219546523|NCT02393144|DRUG|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
219546524|NCT00876967|DEVICE|metallic single use blade|metallic single use blade
219546525|NCT00876967|DEVICE|plastic single use blade|plastic single use blade
219546526|NCT00876967|DEVICE|metallic reusable blade|metallic reusable blade
219546527|NCT04862767|DRUG|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
219546528|NCT04862767|COMBINATION_PRODUCT|Aldesleukin|SC, Bid
219546529|NCT00535912|PROCEDURE|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
219622497|NCT03751098|DRUG|Placebo|Eyewash administered with the Optejet microdose dispenser
219622498|NCT01908075|DRUG|FP/SAL|
219622499|NCT01908075|DRUG|BDP/FOR|
218935525|NCT06614790|DRUG|Niraparib 200/300 MG|"We expect to enroll approximately 300 patients from about 10 sites. Treatment part of study.~Part I- looking retrospectively at the time period JAN 2021-MAR 2023. The retrospective data will include patients who are enrolled in niraparib treatment:~* under the EAP (started in JAN 2021, in continuation)~* under the B.50 drug program, which began in January 2022 Of note, the retrospective multi-center observational study will involve about 30 patients treated with niraparib in EAP (FIGO III R0 after PDS included) and patients who were treated with niraparib before starting RWE (about 120 pts) (JAN 2021- MAR 2023) by the drug program B.50 which has been started to adapt on 1st of Jan, 2022.~FIGO III PDS to R0 patients are included to this study. Part II- looking prospectively at the time period APR 2023 to DEC 2025. The prospective data will include patients who are enrolled in niraparib treatment under the B.50 drug program.~The prospective multi-center observational study will i"
219546530|NCT01665495|PROCEDURE|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
219546531|NCT05275699|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
219546532|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
219546533|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
219546534|NCT06649006|DRUG|Blinatumomab|IV infusion
219546535|NCT03407963|PROCEDURE|Embolization|Embolization by microparticles (300-500 microns)
219546536|NCT04862039|DEVICE|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
219546537|NCT03497130|OTHER|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
219546538|NCT05372744|OTHER|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
219546539|NCT06020430|RADIATION|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
219546540|NCT04002648|PROCEDURE|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
219546541|NCT04002648|PROCEDURE|Sternotomy|Longitudinal resection of the sternum
219622500|NCT04798911|OTHER|Phase 1 Observational Interviews|Qualitative interviews with patients with SS
219622501|NCT04970147|OTHER|Gastrostomy care bundle|Gastrostomy care bundle
219622502|NCT06005272|OTHER|Questionnaire|Interviewer assisted completion of questionnaire.
219622503|NCT02608216|DRUG|[18F]FLT|\[18F\]FLT PET/CT scan, imaging tracer
219206018|NCT06765694|DRUG|Botulinum toxin injection|first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
219546542|NCT03694015|RADIATION|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
219622504|NCT02608216|DEVICE|PET/CT|\[18F\]FLT PET/CT scan
219622505|NCT02608216|DRUG|ribociclib|therapeutic
219622506|NCT02608216|DRUG|paclitaxel|therapeutic
219622507|NCT06742840|DRUG|HRS-2129|HRS-2129.
219622508|NCT06742840|DRUG|HRS-2129 placebo|HRS-2129 placebo.
219622509|NCT06292065|DIAGNOSTIC_TEST|Point-of-care gastric ultrasound|Using ultrasound to visualise the gastric antrum in supine position and right lateral decubitus.
219622510|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
219546543|NCT03694015|RADIATION|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
219546544|NCT04130022|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
219546545|NCT05515796|DRUG|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
219546546|NCT05515796|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
219622511|NCT03045016|DRUG|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
219622512|NCT05387473|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly CBT-I. This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
219546547|NCT05515796|DRUG|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
219546548|NCT05515796|RADIATION|Radiotherapy|25 Gy/5 fractions
219546549|NCT04676529|DRUG|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
219546550|NCT02143258|PROCEDURE|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
219546551|NCT02147379|DRUG|Lurasidone|
219206019|NCT06771154|DRUG|Adebelimab Combined with Apatinib|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
219206020|NCT06771154|DRUG|Adebelimab|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
219206021|NCT06772766|DRUG|9MW3011|Ascending IV doses administered per protocol
219206022|NCT06772766|DRUG|9MW3011 placebo|Ascending IV doses administered per protocol
219546552|NCT00393250|OTHER|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
219206023|NCT06773143|DRUG|Esketamine at low dose|After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.
219206024|NCT06773143|OTHER|Normal Saline (0.9% NaCl)|After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.
219206025|NCT06773260|DIAGNOSTIC_TEST|Liver and Spleen stiffness measurement.|The use of spleen stiffness measurement to reduce unnecessary upper digestive endoscopies has never been evaluated in this patient setting.
219206026|NCT05062057|DEVICE|Adhesive ambulatory ECG recording patches|All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
219546553|NCT00393250|OTHER|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
219546554|NCT04474587|OTHER|Indirect calorimetry|Measurements of REE by indirect calorimetry
219546555|NCT04707963|DIETARY_SUPPLEMENT|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
219206027|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.
219206028|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.
219206029|NCT06827431|DRUG|Placebo|Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.
219206030|NCT06827431|DRUG|Sertraline|Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.
219546556|NCT04707963|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
219546557|NCT06474936|BEHAVIORAL|Food education|During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
219546558|NCT05758623|DEVICE|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
219546559|NCT02319655|PROCEDURE|Air tamponade|Air tamponade
219546560|NCT02319655|PROCEDURE|Balanced salt solution filling|BSS filling
219546561|NCT05213624|DRUG|BI 764198|BI 764198
219546562|NCT05213624|DRUG|Placebo|Placebo matching BI 764198
219546563|NCT01339247|DRUG|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
219549997|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
219206031|NCT06492057|DEVICE|Electromyostimulation (EMS)|EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
219206032|NCT06492057|DEVICE|Myoton|The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
219206033|NCT06492057|DIAGNOSTIC_TEST|Electromyography (EMG)|As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only
219206034|NCT06492057|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only
219206035|NCT06492057|DIAGNOSTIC_TEST|Dynamometry|Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
219206036|NCT06018701|DEVICE|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
219206037|NCT06596733|DEVICE|Vit-A-Vision|Participants will apply Vit-A-Vision ointment on a daily basis, up to 3 times daily per eye, for at least 30 days.
219546564|NCT01339247|DRUG|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
218935526|NCT06530394|DIETARY_SUPPLEMENT|Greek yogurt|Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.
218935527|NCT05799872|BEHAVIORAL|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.
218935528|NCT05799872|BEHAVIORAL|Psychoeducational and Behavioral Therapy (PBT)|The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
218935529|NCT05748600|DRUG|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
218935530|NCT05748600|DRUG|Placebo|administration of placebo tablet
218935531|NCT00024622|DRUG|18F-Fluoro-L-dopa|
218935532|NCT00024622|DRUG|O-15 Water|
219206038|NCT06746649|PROCEDURE|Combined training|12-week long time specific combined training 2 times a week
219206039|NCT06754735|DEVICE|Topical Wound Oxygen Therapy|The active intervention is the application of the Topical Wound Oxygen device that supplies cyclical oxygen pressure directly to the wound site within a sealed environment.
219206040|NCT06754735|DEVICE|Sham Control Topical Wound Oxygen|The sham control intervention is the application of Topical Wound Oxygen device that supplies topical room air to the wound site within a sealed environment.
219206041|NCT06749587|DEVICE|TEOSYAL RHA® 1|"Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin"
219206042|NCT06752785|DRUG|CAR-T Therapy|CD19/CD22 CAR-T cell therapy
219206043|NCT06754111|BEHAVIORAL|ideal birth environment|"ideal birth room While designing a single room without unnecessary medical equipment, your own bed linen, bed linen, It will be a pillow case, a photo frame, he will be able to listen to the music he wants, he will be able to make a photo of his own choice.~There will be a companion, a birthing ball and chair, and the room will allow freedom of movement.~It will be designed to allow"
219206044|NCT06758089|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
219206045|NCT06758089|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
219206046|NCT06758349|OTHER|General questionnaire|Demographic, medical history, and musical activity data will be collected using a specifically designed questionnaire
219206047|NCT06758349|OTHER|Pain Questionnaire|"Questionnaire that evaluate pain and functional limitation during last week, last six months e during the carrier.~The impact of painful symptoms on professional and non-professional activities , during the last week, will be assessed using the QuickDASH scale for the upper limb, the Modified Oswestry Low Back Disability Index for low back pain, and the Neck Disability Index questionnaire for cervico-dorsalgia"
219546565|NCT06267339|DEVICE|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
219546566|NCT06267339|DEVICE|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
219546567|NCT02180321|DRUG|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
218935533|NCT06678269|DRUG|Abemaciclib|The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
218935534|NCT06678269|RADIATION|Radiation Therapy|27Gy in 3 daily fractions or 30Gy in 5 daily fractions completed entirely within 28 days of simulation via stereotactic body radiotherapy (SBRT).
218935535|NCT07134738|DRUG|Dimolegin|Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily.
219206048|NCT06758349|OTHER|Postural assessment without musical instrument in sitting position|Postural assessment without the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
218935536|NCT07134660|PROCEDURE|Liposomal Bupivacaine intercostal nerve block|Ultrasound-guided intercostal nerve block with liposomal bupivacaine 266 mg (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
218935537|NCT07134660|PROCEDURE|Bupivacaine Hydrochloride intercostal nerve block|Ultrasound-guided intercostal nerve block with 0.25% bupivacaine hydrochloride (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
218935538|NCT07134660|OTHER|Standard Postoperative Analgesia|No intercostal nerve block. Patients receive standard postoperative analgesia consisting of an intravenous patient-controlled opioid pump per institutional protocol.
218935539|NCT07127432|DEVICE|The Storytelling Caterpillar|The Storytelling Caterpillar is a plastic toy measuring 19.5 × 5.5 × 25.5 cm and is recommended for use in children aged 1-6 years. It is designed in the form of a storybook and includes interactive f
218935542|NCT06866691|DRUG|levetiracetam|levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days
219546568|NCT02180321|DRUG|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
219546569|NCT04159285|BEHAVIORAL|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
218935543|NCT06866691|DRUG|lacosamide|lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days
218935544|NCT06675643|OTHER|Non-Interventional Study|Non-Interventional study
218935545|NCT07008469|DRUG|Del-desiran (AOC 1001)|Del-desiran will be administered by intravenous (IV) infusion.
218935546|NCT04077879|DRUG|ASP1617|Oral
218935547|NCT04077879|DRUG|Placebo|Oral
218935548|NCT07129811|PROCEDURE|Stellate Ganglion Block|The stellate ganglion is located in front of the anterior tubercle of the C6 vertebra. An ultrasound-guided intervention will be performed from the affected side and 2 cc of 1% lidocaine will be injected.
218935549|NCT06347926|PROCEDURE|Questionnaires given before and after photobiomodulation|Questionnaires given at 1 month, 6 months and 12 months
218935550|NCT06592209|BEHAVIORAL|Sedentary Breaks|Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
218935551|NCT06681402|DRUG|FLAMOD|FLAMOD (GMP-grade flagellin) inhalation
218935552|NCT06681402|DRUG|Placebo|Placebo inhalation
218935553|NCT06625034|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218935554|NCT06625034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218935555|NCT06625034|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
218935556|NCT06625034|PROCEDURE|Positron Emission Tomography|Undergo PET
218935557|NCT06625034|OTHER|Questionnaire Administration|Ancillary studies
218935558|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive human-driven treatment planning
218935559|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive RapidPlan treatment planning
218935560|NCT05038098|PROCEDURE|Gastrectomy|Undergo surgery
218935561|NCT05038098|DRUG|Indocyanine Green|Given peritumorally
218935562|NCT05038098|OTHER|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
219546570|NCT04159285|OTHER|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
219546571|NCT05452707|OTHER|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
218935563|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
219546572|NCT06626607|DRUG|CCB use|Postoperative antihypertensive medication includes CCB
219546573|NCT06626607|DRUG|non-CCB use|Postoperative antihypertensive medication does not include CCB
219546574|NCT02889107|OTHER|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
219206049|NCT06758349|OTHER|Postural assessment with the instrument in sitting position.|Postural assessment with the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
219206050|NCT06760234|DIAGNOSTIC_TEST|No Interventions|The high-throughput extraction of quantitative image features from medical images
219206051|NCT06760234|DIAGNOSTIC_TEST|No Interventions|Immunohistochemical analysis
219206052|NCT06760078|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.
219206053|NCT06760078|DRUG|Placebo|An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
219206054|NCT06759987|BEHAVIORAL|self-care behavior intervention|The intervention group received the self-care behavior intervention program based on the interaction model of health behavior
219546575|NCT01883713|DEVICE|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
219546576|NCT06023433|DEVICE|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
218935564|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
218935565|NCT03644511|DRUG|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
219046640|NCT06421142|PROCEDURE|imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI|"FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg.~MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis."
218935566|NCT03644511|DRUG|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
218935567|NCT03578783|DRUG|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
218935568|NCT03578783|DRUG|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
218935569|NCT06556810|DRUG|Atibuclimab (IC14)|Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
219046641|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
219046642|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
219046643|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
219046644|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
219046645|NCT06246643|DRUG|Regorafenib (Stivarga, BAY73-4506)|Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
218935570|NCT06398444|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
218935571|NCT02226731|DEVICE|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
218935572|NCT02226731|DEVICE|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
219046646|NCT06637371|DRUG|AMG 691|Subcutaneous (SC) injection
219046647|NCT06637371|DRUG|Placebo|SC injection
219046648|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
219046649|NCT05980676|BEHAVIORAL|Personalized Two-Week Email-Based Program|Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
219046650|NCT06232629|DEVICE|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
219046651|NCT06232629|DEVICE|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
219046652|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
219046653|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
219046654|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
219546577|NCT02897375|DRUG|Carboplatin|Given IV
219546578|NCT02897375|DRUG|Cisplatin|Given IV
219546579|NCT02897375|DRUG|Palbociclib|Given PO
219546580|NCT05941065|OTHER|Balancing gel cream|Skin balancing gel cream will be applied onto clean skin morning and night
219546581|NCT05389722|DRUG|CC-92480|Specified dose on specified days
219546582|NCT05389722|DRUG|Rifampin|Specified dose on specified days
219546583|NCT05389722|DRUG|Itraconazole|Specified dose on specified days
219546584|NCT05389722|DRUG|Digoxin|Specified dose on specified days
219546585|NCT05389722|DRUG|Rosuvastatin|Specified dose on specified days
219546586|NCT05507801|OTHER|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
219546587|NCT05507801|OTHER|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
219546588|NCT01543360|PROCEDURE|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
219546589|NCT01543360|PROCEDURE|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
219546590|NCT01792726|RADIATION|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
219546591|NCT06097819|OTHER|Mobile app-based game group|Mobile app based game therapy+Occupational therapy+Sensor-based game therapy
218935573|NCT06690905|DRUG|Piperacillin-tazobactam administered in a prolonged infusion|For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.
218935574|NCT06690905|DRUG|Piperacillin-tazobactam administered in a standard infusion|For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
218935575|NCT07018492|DRUG|BPN14770|Administered as specified in the treatment arm.
218935576|NCT07012005|DRUG|BPN14770|BPN14770 will be administered per schedule specified in the arm description.
218935577|NCT04549298|OTHER|No interventions|No interventions - observational study
218935578|NCT03543917|COMBINATION_PRODUCT|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
219046655|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
219046656|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
219546592|NCT06097819|OTHER|Supervised combined sensor-based game group|Occupational therapy+Sensor-based game therapy
219546593|NCT06097819|OTHER|Individualized occupational therapy group|Occupational therapy
219546594|NCT00193804|RADIATION|IMRT|IMRT in cervical cancers
219546595|NCT01837914|PROCEDURE|Maxillary expansion|
219546596|NCT01837914|PROCEDURE|Adenotonsillectomy|
219546597|NCT03195595|DEVICE|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
219546598|NCT03195595|DEVICE|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
219546599|NCT03811418|DRUG|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
219546600|NCT03811418|DRUG|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
219546601|NCT03811418|DRUG|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
219546602|NCT03811418|DRUG|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
218935579|NCT06248996|RADIATION|Hyperfractionated radiotherpy|83.0 Gy in 68 fractions, 1.22 Gy per fraction, two daily fractions, five days per week to the primary tumour volume (GTVT\_83.0). To the primary tumour with an added margin (PTVT\_74.8) and to neck node metastases (PTVN\_74.8) the prescribed dose will be 74.8 Gy in 68 fractions, 1.10 Gy per fraction twice daily. To elective neck nodes (PTV 54.4) the prescribed dose will be 54.4 Gy in 68 fractions, 0.80 Gy per fraction twice daily.
219546603|NCT03125408|DIAGNOSTIC_TEST|HCV Assay|Molecular diagnostic test to detect Hepatitus C
219546604|NCT01496495|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
219546605|NCT06628076|DIAGNOSTIC_TEST|Culture specific antibiotic therapy|Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
219546606|NCT06628076|DIAGNOSTIC_TEST|Antibiotic|Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\&#39;s disc diffusion method on Mueller Hinton Agar.
219546607|NCT06628076|DIAGNOSTIC_TEST|Biofilm assessment|The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
219546608|NCT06628076|DIAGNOSTIC_TEST|nanoparticle zinc oxide|Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
219546609|NCT06628076|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
219546610|NCT03158727|BIOLOGICAL|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
219546611|NCT03158727|OTHER|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
219622513|NCT05387473|BEHAVIORAL|Best-evidence usual care (UC) plus information sessions|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly general information sessions (general education sessions in line with recommendations from best-practice guidelines and recent evidence). This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
219622514|NCT06013969|DRUG|Spesolimab|Spesolimab intravenous (i.v.) infusion
219622515|NCT06973603|OTHER|Blood samples|24mL blood sample (3 dry tubes with 8mL)
219046657|NCT02755272|DRUG|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
219046658|NCT02755272|DRUG|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
219046659|NCT02755272|DRUG|Gemcitabine|IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.
219046660|NCT06322121|OTHER|MRI|Assessment of vascular reactivity and CAA/SVD MRI markers
219206055|NCT06749275|DEVICE|5,000 ppm fluoride toothpaste|In group 1, toothbrushing with toothpaste of 5,000 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
219546612|NCT00264966|DRUG|ASM8|
218935580|NCT06248996|RADIATION|Control group|68.0 Gy in 34 fractions, 2.00 Gy per fraction per day, five or six days per week to tumour volumes and 54.4 Gy in 34 fractions, 1.60 Gy per fraction to elective neck nodes.
218935581|NCT07013747|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: suspension for injection Route of administration: intramuscular
218935582|NCT07013747|OTHER|Placebo|Pharmaceutical form: liquid solution for injection Route of administration: intramuscular
219546613|NCT01706757|DEVICE|go-cart|conducts exercises with the help of a go-cart
219546614|NCT00223457|BEHAVIORAL|Factors that influence compliance|
219546615|NCT02284750|PROCEDURE|Percutaneous coronary intervention|
219546616|NCT00127985|DRUG|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
219546617|NCT03110874|DRUG|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
219546618|NCT03110874|DRUG|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
219546619|NCT00985439|DRUG|Diclofenac Test (lower dose)|18-mg Single dose
219546620|NCT00985439|DRUG|Diclofenac Test (upper dose)|35-mg Single dose
219546621|NCT00985439|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
219546622|NCT00985439|DRUG|Placebo|Capsules 2 Single-dose
219546623|NCT00110604|BEHAVIORAL|folic acid (0.8 mg)|
219546624|NCT02330939|OTHER|Low fat- Low glycemic index meal|
219546625|NCT02330939|OTHER|MUFA- Low glycemic index meal|
219546626|NCT02330939|OTHER|SAFA- Low glycemic index meal|
219546627|NCT02330939|OTHER|Low fat- High glycemic index meal|
219546628|NCT02330939|OTHER|MUFA- High glycemic index meal|
219546629|NCT02330939|OTHER|SAFA- High glycemic index meal|
219546630|NCT02044731|BEHAVIORAL|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
219546631|NCT03030664|DIETARY_SUPPLEMENT|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
219546632|NCT03030664|DRUG|Placebo|Same formulation as study product, without probiotics.
219546633|NCT01051349|BIOLOGICAL|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
218935583|NCT00924027|RADIATION|High Dose Radiation (HDR) Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
218935584|NCT00924027|DIAGNOSTIC_TEST|MRI|When deemed necessary.
218935585|NCT00924027|DIAGNOSTIC_TEST|CT|Obtained based on the sites of target, as clinical situation dictates and at each follow-up to determine local control.
219546634|NCT01051349|BIOLOGICAL|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
219546635|NCT05724784|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
219546636|NCT06129084|GENETIC|FGFR Testing|Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
219546637|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
219546638|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
219546639|NCT03262103|BIOLOGICAL|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
219546640|NCT03262103|PROCEDURE|Radical Prostatectomy|as per standard care
219546641|NCT06476977|PROCEDURE|Dorsal webspace combined corticosteroid and anesthetic injection|The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
219546642|NCT06476977|PROCEDURE|Palmar combined corticosteroid and anesthetic injection|The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
219546643|NCT00583999|OTHER|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
219046661|NCT03912753|BEHAVIORAL|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
219046662|NCT03912753|OTHER|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
219046663|NCT04009330|DIAGNOSTIC_TEST|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
219046664|NCT04530552|DRUG|Apalutamide|Given PO
219046665|NCT04530552|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219046666|NCT04530552|OTHER|Quality-of-Life Assessment|Ancillary studies
219046667|NCT04575025|DRUG|Tabrecta tablets|There was no treatment allocation. Patients administered Tabrecta by prescription that had started before inclusion of the patient into the study were enrolled.
219046668|NCT06297122|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
219046669|NCT05431699|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
219046670|NCT05431699|DIAGNOSTIC_TEST|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
219046671|NCT05431699|PROCEDURE|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
219206056|NCT06749275|DEVICE|22,600 ppm fluoride varnish|The application protocol of 5% fluoride varnish will be used together with the 1,450 ppm paste with the same protocol of the group 1: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
219546644|NCT00841542|DRUG|Amlodipine Besylate|10 mg Tablet
219546645|NCT00841542|DRUG|Norvasc®|10 mg Tablet
219546646|NCT03847688|DEVICE|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
219546647|NCT01554007|OTHER|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
219546648|NCT03730272|DRUG|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
219641853|NCT06959329|OTHER|Active and passive physical therapy with intensified sensory stimulation|"Intervention: Passive and active therapy incorporating high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes): stimulation of joint receptors, muscle spindles, and tactile pathways:~* High-frequency soft tissue mobilisations~* Localised high-amplitude vibration (30-50 Hz; Galileo Mano 30, Novotec Medical GmbH)~* Deep pressure techniques - Wilbarger brushing protocol followed by joint compressions Active therapy (30 minutes): upper limb and shoulder girdle muscle strengthening exercises with globalized vibration using Redcord Stimula (30-50 Hz; Redcord AS, Norway); difficulty level individually adjusted to meet participants' current potential. Excercises the same as in the control group."
218935586|NCT00924027|DIAGNOSTIC_TEST|PET Scan|When deemed necessary.
218935587|NCT05458713|DEVICE|Laser acupuncture|Irradiate acupoints with low power laser
218935588|NCT06628206|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
218935589|NCT06628206|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
219046672|NCT05431699|PROCEDURE|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
219046673|NCT05431699|PROCEDURE|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
219046674|NCT05552716|OTHER|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
219046675|NCT05379166|DRUG|Azacitidine|Given IV
219046676|NCT05379166|OTHER|Quality-of-Life Assessment|Ancillary studies
219046677|NCT05379166|OTHER|Questionnaire Administration|Ancillary studies
219046678|NCT05379166|DRUG|Venetoclax|Given PO
219046679|NCT03456336|OTHER|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
219046680|NCT03456336|OTHER|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
219046681|NCT06505031|DRUG|TAK-861|Oral tablet.
219046682|NCT06505031|DRUG|Placebo|TAK-861-matching placebo tablet.
219046683|NCT06034496|DEVICE|Active CES|Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4\~6 weeks), 20 minutes per day.
219046684|NCT06034496|DEVICE|Sham CES|Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
219046685|NCT01351961|BIOLOGICAL|blood sampling|take a sample of blood, 46 ml
219046686|NCT01351961|PROCEDURE|brain MRI and TEP cerebral|magnetic resonance imaging
219546649|NCT00849823|BEHAVIORAL|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
219546650|NCT00849823|BEHAVIORAL|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
219546651|NCT04811235|DEVICE|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
218935590|NCT06623292|OTHER|Motivational interviewing-based breastfeeding education|This program includes breastfeeding motivational interviewing consisting of a total of 4 sessions and breastfeeding education consisting of one session.
218935591|NCT06691035|DRUG|Elacestrant|"345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)"
219046687|NCT01351961|OTHER|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
219046688|NCT01351961|OTHER|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
219046689|NCT01351961|PROCEDURE|Vascular explorations|Pulse wave velocity, VWF, IMT
219046690|NCT01351961|BIOLOGICAL|Urine sample|
219046691|NCT06075147|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
218935592|NCT06691035|BIOLOGICAL|DC1 native/mutated ESR1|"2.0-5.0 x 10 (20-50 million) cells (Injections in groin nodes (or accessible breast tumor if available) weekly with DC1 for eight consecutive weeks, alternating between native ESR1 DC1s and mutated ESR1 DC1s.~Mutated ESR1 DC1s on week 1 followed by native ESR1 DC1s on week 2, alternating during the initial vaccination series and the subsequent booster phase.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses."
218935593|NCT06203132|DRUG|Doravirine + tenofovir DF + lamivudine|Oral administration
218935594|NCT06203132|DRUG|Dolutegravir + tenofovir DF + lamivudine or emtricitabine|Oral administration
218935595|NCT07022743|DRUG|Imatinib|Imatinib is a first-line tyrosine kinase inhibitor which is used in the management of chronic myeloid leukaemia. It will be used by all the patients in the 3 arms of the study (Groups A, B and C)
218935596|NCT07022743|DRUG|Artesunate|Artesunate has been established to reverse resistance to some chemotherapeutic agents. patients in 2 arms of the study (Groups B and C) will be given artesunate at 4mg/kg (not exceeding 200mg daily) in combination with imatinib
218935597|NCT07022275|DIETARY_SUPPLEMENT|Hemp protein powder|Agoge Universal Hemp Protein Powder - A certified cannabinoid-free hemp protein powder.
218935598|NCT06325813|DEVICE|Active repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.
219046692|NCT05752955|OTHER|SMARThealth Pregnancy|"At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
219046693|NCT06577987|DRUG|CID-078 Monotherapy|Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
219046694|NCT04961047|BEHAVIORAL|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
219046695|NCT04961047|BEHAVIORAL|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
219046696|NCT06184750|PROCEDURE|Biopsy Procedure|Undergo biopsy
219046697|NCT06184750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219046698|NCT06184750|PROCEDURE|Mammography|Undergo mammography
219046699|NCT06184750|OTHER|Questionnaire Administration|Ancillary studies
219046700|NCT06184750|DRUG|Tamoxifen|Given PO
219046701|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
219046702|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
219046703|NCT03277261|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
219046704|NCT03277261|DRUG|Teriflunomide|Film-coated tablets administered orally.
219046705|NCT03277261|DRUG|Oral Placebo|Administered orally.
219046706|NCT03277261|DRUG|IV Placebo|Administered as an IV infusion.
219046707|NCT02597010|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
218935599|NCT06325813|DEVICE|Sham repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
218935600|NCT06223373|DEVICE|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
219046708|NCT02597010|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219046709|NCT05944250|DEVICE|Spincare matrix|The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
219046710|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
219546652|NCT03564587|BEHAVIORAL|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
219546653|NCT05149209|PROCEDURE|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
219546654|NCT05770388|DEVICE|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
219546655|NCT05770388|BEHAVIORAL|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
219546656|NCT04461964|DEVICE|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
219546657|NCT02027337|DRUG|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
219546658|NCT02027337|DRUG|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
219622516|NCT06055790|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin) PET/CT|"PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\]."
218935601|NCT06223373|DEVICE|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
218935602|NCT03632473|DIAGNOSTIC_TEST|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
218935603|NCT06872775|OTHER|Blood draws to assess RNA expression levels|None. Standard of Care (SOC) only.
218935604|NCT06874205|DRUG|11C-JMJ-129|Injected IV followed by PET scanning
218935605|NCT06217640|DIAGNOSTIC_TEST|Dual X Ray Absorptiometry|"* Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength"
218935606|NCT05283031|DIAGNOSTIC_TEST|Modified Diurnal Tension Curve|The modified diurnal tension curve (mDTC), an alternative that involves IOP measurements every 2 or 3 hours during office hours, is more feasible and may provide better information regarding the IOP profile than single IOP measurements.
219046711|NCT00499603|DRUG|Paclitaxel|80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
219046712|NCT00499603|DRUG|5-Fluorouracil|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
219046713|NCT00499603|DRUG|Epirubicin|100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
219046714|NCT00499603|DRUG|Cyclophosphamide|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
219046715|NCT00499603|DRUG|RAD001|30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
219046716|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
219046717|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
219046718|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
219046719|NCT03444714|DRUG|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
219046720|NCT05658562|DRUG|MT-2111|i.v. infusion
219046721|NCT00006279|DRUG|Nevirapine|
219046722|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
219046723|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
219546659|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
219546660|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
219546661|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
219546662|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
219546663|NCT06043388|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
218935607|NCT04087109|OTHER|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
219046724|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219046725|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
219046726|NCT05277896|DRUG|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
219046727|NCT05277896|DRUG|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
219046728|NCT04863703|DRUG|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
219046729|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
219046730|NCT05297903|DRUG|XmAb20717|10mg/kg IV
219046731|NCT06505590|DEVICE|Educational content|Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).
219046732|NCT06505590|DEVICE|Educational material plus self-management program - self-administered version|Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
219046733|NCT06505590|DEVICE|Educational material plus self-management program - guided version with mental health professional|Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
219046734|NCT05744427|DRUG|JSKN003|JSKN003 should be administered intravenously on the first day of each 3-week cycle.
219546664|NCT06043388|BIOLOGICAL|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
219546665|NCT00472212|DEVICE|Spectacles|Hyperopic spectacle lenses
219622517|NCT06321133|OTHER|High flow nasal cannula immediate ending|High flow is immediately ended
218935608|NCT07031557|DEVICE|EchoStation Implementing REMS Technology|Ultrasound-based densitometry used for the prevention, diagnosis, and monitoring of bone health status and fracture risk at reference anatomical sites (femur and spine), including all patient categories.
218935609|NCT07031557|OTHER|Nutritional and Fracture Risk Assessment Questionnaires|Questionnaires regarding Calcium Intake, dietary habits assessment (Predimed), and Algorithm for Fracture Risk in Women of Childbearing Age (AFEF) developed by the Fragility Fracture Observatory (OFF)
219046735|NCT01351870|RADIATION|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
219046736|NCT01351870|RADIATION|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
219046737|NCT06388720|DRUG|Mitomycin-C|Intravesical instillation of Mitomycin-c 40 mg in 20 ml as the first agent in sequential treatment.
219046738|NCT06388720|DRUG|gemcitabine|Intravesical instillation of Gemcitabine 2000 mg in 50 ml following Mitomycin-c administration.
219046739|NCT04836429|DRUG|Porfimer Sodium|Given IV
219046740|NCT04836429|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
219046741|NCT04836429|DRUG|Photodynamic Therapy|Undergo photodynamic therapy
219046742|NCT04836429|DEVICE|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
219046743|NCT04697628|DRUG|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
219046744|NCT04697628|DRUG|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
219046745|NCT04697628|DRUG|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
219046746|NCT04697628|DRUG|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
219546666|NCT00472212|DEVICE|Control|Plano (no power, control) spectacle lenses
219546667|NCT04879537|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
219622518|NCT06321133|OTHER|High flow nasal cannula weaning|High flow is gradually weaned by reducing the flow rate
219622519|NCT05836584|BIOLOGICAL|Atezolizumab|Given IV
219622520|NCT05836584|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219546668|NCT06512909|OTHER|Virtual Reality Glasses Application|A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
219546669|NCT06512909|OTHER|Stress Ball Application|One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
219546670|NCT03098901|DIAGNOSTIC_TEST|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
219546671|NCT05059028|OTHER|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
219546672|NCT01111448|DRUG|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
219546673|NCT01043952|DRUG|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
219046747|NCT04697628|DRUG|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
219046748|NCT04697628|DRUG|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
219046749|NCT04943874|DEVICE|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
219046750|NCT04943874|DEVICE|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
219046751|NCT05994378|DRUG|SHR7280；Ganirelix Acetate Injection simulant|SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;
219546674|NCT01043952|DRUG|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
219046752|NCT05994378|DRUG|SHR7280 simulant； Ganirelix Acetate Injection|SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
219046753|NCT01946204|DRUG|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
219046754|NCT01946204|DRUG|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
219046755|NCT00524446|DIETARY_SUPPLEMENT|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
219046756|NCT00524446|DIETARY_SUPPLEMENT|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
219046757|NCT00524446|DIETARY_SUPPLEMENT|Maize-soy flour|Counseling + Vitamin A as for ST\_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
219046758|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
219046759|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
219046760|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
219046761|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
219046762|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
219046763|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
219046764|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
219046765|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
219046766|NCT03789201|DEVICE|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
219046767|NCT03789201|DEVICE|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
219046768|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
219046769|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
219046770|NCT04932590|OTHER|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
219046771|NCT03778931|DRUG|Elacestrant|400 mg/day once daily oral dosing
219046772|NCT03778931|DRUG|Standard of Care|"* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~* Anastrozole 1 mg/day on a continuous dosing schedule~* Letrozole: 2.5 mg/day on a continuous dosing schedule~* Exemestane: 25 mg/day on a continuous dosing schedule"
219206057|NCT06749275|DEVICE|38% SDF|The application protocol of 38% SDF annually will be used together with the 1,450 ppm paste with the same protocol of the group 2: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
219206058|NCT06439160|OTHER|Participants will be asked to complete a series of questionnaires at t0, t1 and t2|"Individuals will be people who voluntarily will take part in a residential three to six weeks multidisciplinary inpatient intensive rehabilitation treatment targeting the improvement of psychological well-being, body image, and psychopathology for anorexia nervosa.~Therefore, at T0 (at the beginning of the treatment) and T1 (at the end of the rehabilitation programme), participants will fill out some self-report questionnaires to evaluate the effect of the multidisciplinary inpatient intensive rehabilitation treatment on different outcomes (i.e. psychological well-being, eating pathology, body image, and comorbidities), among which their social components/skills. Moreover, we will ask participants to complete 3 months after discharge the questionnaires related to the social components/skills only. Participants will be contacted by email, within the email participants will find a link to click on for the completion of the questionnaires."
219206059|NCT05934227|DRUG|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
219206060|NCT05934227|OTHER|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
219206061|NCT06788847|PROCEDURE|Ultrasound guided needle knife dissection|"This procedure involves a minimally invasive dissection of the fibrous cords in Dupuytren's Contracture using a needle knife guided by ultrasound imaging. Local anesthesia using 3-5 ml of 1% Lidocaine and 0.25% bupivacaine is administered for patient comfort. The technique aims to improve precision, minimize complications and reduce recurrence.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
219546675|NCT01043952|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
219546676|NCT03475251|BIOLOGICAL|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
219546677|NCT03475251|BIOLOGICAL|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
219546678|NCT03475251|DRUG|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
219546679|NCT05347953|DEVICE|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
219546680|NCT06557954|DIAGNOSTIC_TEST|human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)|PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
219546681|NCT01534845|DRUG|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
219546682|NCT05074745|DIAGNOSTIC_TEST|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
219546683|NCT02945618|DEVICE|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
219546684|NCT02945618|OTHER|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
219546685|NCT02729987|BEHAVIORAL|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
219546686|NCT01669460|OTHER|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
219546687|NCT05450107|PROCEDURE|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
219546688|NCT05450107|PROCEDURE|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
218935610|NCT07031765|BIOLOGICAL|exHSC|Ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) at a targeted dose of 2.5 x 106 cells/kg (or maximal achievable dose, with a minimum deliverable dose of 1/10 target dose; max dose 1.0 x 108 total cells for patients ≥40kg).
219622521|NCT05836584|DRUG|Capecitabine|Given PO
219622522|NCT05836584|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219622523|NCT05836584|DRUG|Docetaxel|Given IV
219622524|NCT05836584|PROCEDURE|Echocardiography Test|Undergo ECHO
219622525|NCT05836584|DRUG|Fluorouracil|Given IV
219622526|NCT05836584|DRUG|Leucovorin Calcium|Given IV
219622527|NCT05836584|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
219622528|NCT05836584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622529|NCT05836584|DRUG|Oxaliplatin|Given IV
219622530|NCT05836584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219546689|NCT01403363|DRUG|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
219546690|NCT02266407|PROCEDURE|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
219546691|NCT02281539|DEVICE|Neuromotus|
219546692|NCT02462837|DRUG|Mirabegron|
219546693|NCT02462837|DRUG|Placebo|
219546694|NCT00159458|DRUG|Gemcitabine and oxaliplatin|
219546695|NCT05199064|OTHER|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
219546696|NCT04428307|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
219546697|NCT04428307|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
219546698|NCT05351567|OTHER|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
219546699|NCT02163382|DEVICE|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
219546700|NCT02163382|DEVICE|Neurovent Monitor XIII|RIP jacket installation
219546701|NCT02163382|DEVICE|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
219546702|NCT02163382|DEVICE|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
219546703|NCT02163382|DEVICE|Neurovent Monitor XIII|Second period with conventional NIV settings
219546704|NCT05291195|DEVICE|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
219546705|NCT05291195|DRUG|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
219546706|NCT05291195|DRUG|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
219546707|NCT05025527|DIAGNOSTIC_TEST|biparametric MRI (bpMRI)|Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
219546708|NCT05025527|DIAGNOSTIC_TEST|Prostate cancer antigen (PSA)|Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
219546709|NCT01891773|BEHAVIORAL|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
219546710|NCT03418753|DIAGNOSTIC_TEST|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
219546711|NCT06345235|DIAGNOSTIC_TEST|blood test|Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
219546712|NCT03899935|PROCEDURE|Laparoscopy|Laparoscopy for endometriosis
219546713|NCT04405479|BEHAVIORAL|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
219546714|NCT02623257|OTHER|mutation detection|
219546715|NCT02623257|OTHER|ARMS|
219546716|NCT02623257|GENETIC|ctDNA analysis|
219546717|NCT03783663|BEHAVIORAL|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
219546718|NCT03701945|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
219546719|NCT03556813|OTHER|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
219546720|NCT04332445|OTHER|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
219206062|NCT06795854|OTHER|Aerobic training|Sessions will be conducted 3 times per week. Each 40-minute session will include a 5-minute warm-up involving fast walking, slow running, and stretching, followed by an active phase of continuous running. The running period will start at 15 minutes and increase by 2 minutes every two sessions until reaching 30 minutes. The session will conclude with a 5-minute cool-down of slow running and stretching. Exercise intensity will be maintained at 13-15 on the Borg Rate of Perceived Exertion, with continuous walking performed on a treadmill.
219622531|NCT05836584|PROCEDURE|Surgical Procedure|Undergo surgery
219622532|NCT06238128|BEHAVIORAL|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
219546721|NCT04562935|OTHER|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
219546722|NCT03302832|OTHER|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
219546723|NCT03302832|OTHER|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
219546724|NCT04432636|OTHER|Data collection of environmental factors|\- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
219546725|NCT04432636|OTHER|Collection of maternal feces|\- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
219546726|NCT04432636|OTHER|Collection of infant feces|\- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
219546727|NCT04432636|OTHER|food questionnaire|\- A food questionnaire completed by the mother the week after delivery,
219546728|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
219546729|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
219622533|NCT06238128|BEHAVIORAL|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
219622534|NCT05586321|BIOLOGICAL|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
219546730|NCT04432636|OTHER|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
219546731|NCT04432636|OTHER|The 'Ages and Stages Questionnaire' ASQ|\- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
218935611|NCT07031765|DRUG|Nivolumab|Nivolumab 3mg/kg once every 2 weeks, max dose 240mg. Nivolumab will be administered on day 1 and day 15 of each cycle for a total of 10 cycles. Nivolumab may continue for a total two years of therapy, at the discretion of the treating team.
219546732|NCT05582967|OTHER|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
219546733|NCT00241020|DRUG|Octreotide|
218935612|NCT07031765|PROCEDURE|Resection or biopsy|Patients must be candidates for standard of care surgical resection or biopsy.
218935613|NCT06715670|DRUG|Zibotentan|Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
219046773|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
219046774|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
219046775|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
219046776|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
219546734|NCT04029545|DEVICE|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
219622535|NCT04424719|OTHER|Blood test|"High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression)."
219622536|NCT02861417|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
219622537|NCT02861417|DRUG|Busulfan|Given IV
219622538|NCT02861417|DRUG|Cyclophosphamide|Given IV
219622539|NCT02861417|DRUG|Fludarabine|Given IV
219622540|NCT02861417|DRUG|Fludarabine Phosphate|Given IV
219546735|NCT02458664|GENETIC|Genetic analysis on tumor kept in tumor bank|
219546736|NCT05372250|OTHER|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
219546737|NCT01802112|DIETARY_SUPPLEMENT|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
219546738|NCT01802112|OTHER|placebo|15gr placebo
219546739|NCT02722187|PROCEDURE|subinguinal microscopic varicocelectomy|
219546740|NCT02722187|PROCEDURE|laparoscopic varicocelectomy|
219546741|NCT03482180|DRUG|KI1106 4g, QD|KI1106 4 Capsules
219546742|NCT03482180|DRUG|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
219622541|NCT02861417|OTHER|Laboratory Biomarker Analysis|Correlative studies
219622542|NCT02861417|DRUG|Mycophenolate Mofetil|Given PO
219622543|NCT02861417|OTHER|Pharmacological Study|Correlative studies
219622544|NCT02861417|DRUG|Tacrolimus|Given IV or PO
219622545|NCT02861417|DRUG|Thiotepa|Given IV
219046777|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
219046778|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
219046779|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
219046780|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
219046781|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
219046782|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
219546743|NCT00691782|OTHER|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
219546744|NCT01715922|DRUG|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
219546745|NCT01715922|DRUG|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
219546746|NCT01715922|PROCEDURE|lumbar punctures|lumbar punctures to control intracranial pressure
219546747|NCT01756807|DEVICE|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
219622546|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
219622547|NCT02415101|PROCEDURE|Resective surgery|
219622548|NCT04426006|OTHER|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire"
219622549|NCT06778330|DRUG|Dapagliflozin (DAPA)|Control group: receive dapagliflozin in addition to standard therapy
219622550|NCT06778330|DRUG|Sildenafil|Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy
219622551|NCT06041204|DRUG|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
219622552|NCT06041204|DRUG|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
219622553|NCT05280470|DRUG|Ifinatamab Deruxtecan (I-DXd)|I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
219622554|NCT05548062|OTHER|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
219046783|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
219206063|NCT06795854|OTHER|Relaxation techniques|Relaxation techniques will include slow deep breathing and mindfulness meditation exercises. The breathing exercise will involve six cycles per minute, with a 4-second inhalation and a 6-second exhalation, repeated for 30 minutes, three sessions per week. Mindfulness meditation will include a stress and pain management program with sessions starting at 10-15 minutes and gradually increasing to 20-30 minutes, three times per week. Sessions will be conducted in a quiet, comfortable space, focusing on breath awareness, body scanning, thought observation, and optional loving-kindness meditation, concluding with a reflection period.
219206064|NCT06795854|OTHER|Low fodmap diet|All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
219206065|NCT04506255|DEVICE|Silicone tape|Medical grade tape with silicone adhesive
219206066|NCT06754969|PROCEDURE|Peripheral Nerve Regenerative Interface (RPNI) and Nerve/Muscle Biopsy|RPNI is a surgical technique which wraps denervated muscle targets around severed nerve ends.
219206067|NCT06754969|PROCEDURE|Biopsy Alone|Sural nerve and muscle biopsy performed in the standard fashion.
219206068|NCT06755593|PROCEDURE|Electroacupuncture|We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)
219546748|NCT03928405|OTHER|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
219546749|NCT01749553|OTHER|Sleeper Stretch|Posterior shoulder stretch technique
219546750|NCT00779519|DRUG|TTP435|
219546751|NCT00779519|DRUG|Placebo|
219546752|NCT06476093|DRUG|Anlotinib hydrochloride|Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
219546753|NCT06451653|BEHAVIORAL|Men in Maternity Health (MiM) Intervention|The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
219046784|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
219046785|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
219046786|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
219046787|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
219046788|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
219046789|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
219546754|NCT03277963|DEVICE|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
219546755|NCT00924638|DEVICE|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
219546756|NCT00051779|DRUG|CAL|
219546757|NCT05314257|DRUG|Granisetron Hydrochloride|IV granisetron 1mg
219546758|NCT05314257|OTHER|0.9% normal saline|IV 5ml of 0.9% normal saline
219546759|NCT05248230|BIOLOGICAL|4D-710|4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
219546760|NCT04218435|DRUG|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
219046790|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
219046791|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
219046792|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
219046793|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
219046794|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
219046795|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
219546761|NCT00847535|BIOLOGICAL|autologous muscle cell injection|Injection of autologous muscle cells
219546762|NCT04603703|OTHER|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
219046796|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
219046797|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
219546763|NCT04603703|OTHER|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
219546764|NCT04237415|PROCEDURE|EMG biofeedback training|
219546765|NCT01463579|OTHER|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
219546766|NCT01463579|OTHER|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
219546767|NCT04560231|DRUG|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
219546768|NCT03835468|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
219546769|NCT03835468|DIETARY_SUPPLEMENT|Maltodextrin|sugar based placebo
219546770|NCT01057368|BEHAVIORAL|Day of intensive meditation practice|Long-term meditators practice for \~6 hours of meditation at each time point
219546771|NCT01057368|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
219622555|NCT05548062|OTHER|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
219622556|NCT04666740|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
219622557|NCT04666740|DRUG|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
219622558|NCT06332014|DRUG|Prolia|Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.
219622559|NCT03266627|DRUG|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
219622560|NCT03745209|DEVICE|Ultrasound|Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
218935614|NCT07039136|OTHER|Virtual Reality Mirror Therapy|"Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. Data from participants' right forearms will be collected using Leap Motion tracking. In the virtual reality environment, both the original and mirrored forearms will be displayed within the participants' field of view.~The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement."
219046798|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
219046799|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
219046800|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
219622561|NCT05352750|BIOLOGICAL|SON-1010|SON-1010 multiple ascending dose
219546772|NCT01057368|BEHAVIORAL|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
219546773|NCT01252953|DRUG|Anacetrapib|tablet, 100mg daily
219546774|NCT01252953|DRUG|Placebo anacetrapib|tablet, 1 tablet daily
219546775|NCT03954431|DIAGNOSTIC_TEST|Dedicated breast CT(BCT)|The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
219622562|NCT05671341|DIAGNOSTIC_TEST|Assessment|Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS
218935615|NCT07039136|OTHER|Conventional Mirror Therapy|Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement.
219622563|NCT03028428|BIOLOGICAL|Placenta Derived Mesenchymal Stem Cell|1ml 1\*10\^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
219622564|NCT03028428|DRUG|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
218935616|NCT07039136|OTHER|Sham Virtual Reality|Participants will experience pre-recorded virtual environments while seated and wearing a virtual reality headset, without interacting with the environment. The virtual reality application will be used for 10 minutes at the end of each session of conventional mirror therapy.
218935617|NCT07039591|DEVICE|Pro-type IVR|Women will test three non-medicated IVRs on two one-day clinic visits (two on the first day, one on the second day) by manipulating them, vaginally inserting each ring and then performing a controlled set of tasks simulating routine daily activities with the ring in the vagina.
218935618|NCT06722118|DRUG|Dexamethasone IV|IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
219046801|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
219046802|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
219046803|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
219046804|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
219046805|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
219206069|NCT06755593|DEVICE|Intravenous laser|We use intravenous laser with the iBIO-ILIB He-Ne laser device Mini-630 with 635 nm wavelength manufactured by Vietnam Laser Technology Center.
219206070|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|Bacillus coagulans JBI-YZ6.3 (BC4U)
219206071|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|An escalating dose cross-over design: Participants are fed 0 mg, 100 mg, 200 mg, and 400 mg on different clinic visits.
219622565|NCT03268083|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
219622566|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
219622567|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
219622568|NCT06403176|OTHER|No intervention|No intervention
219622569|NCT02828579|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
219622570|NCT03982290|OTHER|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
219622571|NCT03982290|OTHER|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
219622572|NCT05111782|OTHER|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
219622573|NCT03694080|COMBINATION_PRODUCT|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
219622574|NCT03215212|OTHER|eye mask|eye mask administered from 10 pm to 7 am
219622575|NCT03215212|OTHER|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
219622576|NCT03215212|OTHER|ear plug|ear plug administered from 10 pm to 7 am
219546776|NCT01007994|DRUG|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"
219546777|NCT05620862|DRUG|Mitoxantrone Hydrochloride Liposome|In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
219546778|NCT05620862|DRUG|Irinotecan|50mg/ m2，d1-5, 21 days per cycle
219546779|NCT05620862|DRUG|Vincristine|Vincristine 1.5mg/ m2，d1 , 21 days per cycle
219546780|NCT05073380|BEHAVIORAL|Intervention Group - PRO-ECO Intervention|The PRO-ECO intervention will be tailored to individual sites. Through collection of focus group and baseline data, the intervention will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective interventions outlined in the literature have informed the development of the intervention foundation and potential tailoring.
219546781|NCT05073380|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO intervention.
219546782|NCT00064090|DRUG|cytarabine|
219546783|NCT00064090|DRUG|triapine|
219546784|NCT00380679|BIOLOGICAL|Influenza vaccination|
219546785|NCT00380679|BIOLOGICAL|Pneumococcal polysaccharide vaccination|
219546786|NCT03595462|OTHER|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
219546787|NCT03595462|OTHER|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
219546788|NCT03367260|OTHER|Preference Elicitation|Survey of patient preferences for treatment
219622577|NCT04633317|DEVICE|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
219622578|NCT04633317|DEVICE|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
219622579|NCT05717972|OTHER|Kombucha|"Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste."
219622580|NCT01739205|BEHAVIORAL|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
219206072|NCT06765785|DIAGNOSTIC_TEST|CTCA|Screening CTCA will be performed in the experimental arm after 1:1 randomisation using sealed envelope technique
219546789|NCT00018460|DRUG|Vitamin B|
219546790|NCT06441591|DRUG|Vinpocetine|Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
219546791|NCT06441591|DRUG|Standard Therapy|Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
219546792|NCT06441591|OTHER|Placebo|Starch-filled capsules, matching those of the intervention
219546793|NCT02516189|OTHER|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
219546794|NCT01710748|DEVICE|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
219046806|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
219546795|NCT01710748|DEVICE|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
219546796|NCT06627348|DEVICE|Hilotherm ChemoCare|Hilotherapy
219546797|NCT00283764|DRUG|Xalatan|
219546798|NCT01519830|DRUG|Iron carboxymaltose (Ferinject)|Intravenous iron
219546799|NCT01519830|DRUG|Placebo|0.9% NaCl solution
219546800|NCT00966485|DRUG|80 mg ASA dosing|
219546801|NCT00966485|DRUG|500 mg ASA dosing|
219546802|NCT04444063|PROCEDURE|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
219546803|NCT00408616|BIOLOGICAL|Grazax-R|Grass tablet, 75.000 SQ per day for one year
219546804|NCT00408616|BIOLOGICAL|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
219046807|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
219622581|NCT06317389|OTHER|Questionnaires|Patients will benefit of supervision by the ONCORAL team in the usual way and their intervention will be limited to completing questionnaires.
219622582|NCT04760626|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
219622583|NCT04760626|DRUG|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
219046808|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
219622584|NCT04760626|DRUG|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
219622585|NCT04760626|DRUG|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
219046809|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
219046810|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
219046811|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
219046812|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
219046813|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
219046814|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
219046815|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
219046816|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
219206073|NCT06840353|OTHER|Experimental group (Pecha Kucha training)|Ventrogluteal injection training given to students using the Pecha Kucha training method
219206074|NCT06295952|DRUG|Pasireotide|Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
219206075|NCT06295952|OTHER|SF-36 and HADS|Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
219206076|NCT05495945|DEVICE|Low-intensity focused ultrasound pulsation (LIFUP)|LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.
219546805|NCT06628141|OTHER|Nutritional support tool|Nutritional support tool
219546806|NCT00958724|DRUG|Neratinib|
219546807|NCT00958724|DRUG|Vinorelbine|
219546808|NCT05604014|BEHAVIORAL|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
219622586|NCT02452944|DEVICE|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
219622587|NCT02452944|DEVICE|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
219622588|NCT03762265|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
219622589|NCT03762265|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
219549998|NCT02976064|BEHAVIORAL|PreHabilitation|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
219622590|NCT01805089|DRUG|Melatonin 3 mg|Melatonin vs. Placebo
219622591|NCT04423991|DEVICE|COViage|Machine learning intervention
219622592|NCT00197782|BIOLOGICAL|Hib conjugate vaccine|
219622593|NCT00688350|BEHAVIORAL|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
219622594|NCT00806403|DRUG|reteplase 10+10 U|comparison to primary PCI
219622595|NCT00806403|PROCEDURE|primary PCI|comparison to thrombolysis
219622596|NCT01882985|DRUG|Docetaxel|Given IV
218935619|NCT06722118|OTHER|Placebo|Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
218935620|NCT06712797|BEHAVIORAL|Physical Activity (PA)|"Participants will receive a Fitbit (Inspire 3, Google LLC, Mountain View, CA, USA) to encourage and self-monitor Physical Activity (PA) using active minutes, which approximate moderate-to-vigorous PA.~Fitbits will be synced to a HIPAA-compliant platform created by Moffitt's Biostatistics and Bioinformatics Shared Resource (BBSR).~Study personnel will view active minutes to provide individualized feedback and encourage progression. Weekly feedback will encourage participants to increase active minutes by 10% until achieving ≥ 150 minutes to meet cancer prevention recommendations.~Participants who reach ≥ 150 active minutes will be encouraged to maintain or exceed recommendations."
218935621|NCT06712797|BEHAVIORAL|Nutrition (N)|"Participants will undergo counseling at baseline (T0) to address nutritional symptoms and provide targets for daily calories and protein following a Mediterranean diet. This diet includes a high intake of vegetables, legumes, fruits, and unsaturated fatty acids, low intake of saturated fatty acids, and a moderately high intake of fish.~Total caloric intake will be calculated. A standard breakdown of 40% carbohydrates, 30% fats and 30% protein will be used. Individuals will review this calculation during their office encounters and follow these values using the FitBit, application, which will adjust to their daily energy expenditure.~Additional counseling (in-person or via Zoom) will occur at baseline (T0) + 12 weeks to gauge progress toward calorie and protein targets, monitor weight change, and guide dietary changes.~Participants will log daily food intake and self-monitor progress toward calorie and protein goals."
218935622|NCT06726148|DRUG|ECI830|Experimental
218935623|NCT06726148|DRUG|ribociclib|Approved medication
218935624|NCT06726148|DRUG|fulvestrant|Approved medication
218935625|NCT06466421|DRUG|Fexofenadine|Fexofenadine 60 mg orally once daily for 3 months
218935626|NCT06466421|DRUG|Gabapentin|100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
218935627|NCT06883344|DEVICE|Automated insulin delivery (AID) system|An AID system incorporates data from a continuous glucose monitor (CGM) to automatically adjust the amount of insulin delivered by an insulin pump via an algorithm that incorporates multiple factors, including predicted glucose level in the next 30-60 minutes, target glucose level, and recent insulin delivery.
218935628|NCT06883344|OTHER|Intravenous (IV) insulin|Variable rate IV insulin infusions are used in most labor/delivery units as the standard of care for glycemic management for pregnant people with T1D. A continuous rate of IV insulin is infused, with manual rate adjustments made based on current glucose level and hospital-specific protocols.
218935629|NCT05122455|DRUG|ASA|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
219046817|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
219046818|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
219046819|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
219046820|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
219046821|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
219046822|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
219046823|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
219046824|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
219046825|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
219622597|NCT01882985|DIETARY_SUPPLEMENT|Lycopene|Given PO
219546809|NCT01026402|DRUG|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
219546810|NCT03922555|DRUG|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
219546811|NCT02010463|OTHER|Exercise|
219546812|NCT05159921|OTHER|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
219046826|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
219546813|NCT01080703|OTHER|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
219546814|NCT03616379|BEHAVIORAL|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
219046827|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
219046828|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
219046829|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
219046830|NCT05481619|DRUG|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
219046831|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
219046832|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
219046833|NCT06960096|OTHER|DBS combined with fMRI|Participants will undergo fMRI scanning while their DBS device is either turned OFF or ON. BOLD (blood oxygen level dependent) changes in response to DBS will be evaluated across PD participants. These scans and DBS procedure will be used for research purposes only and are not for treatment or diagnostic purposes.
219046834|NCT06444646|OTHER|Adipose tissue biopsy|From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.
219046835|NCT06444646|OTHER|Blood sampling|From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.
219046836|NCT06444646|OTHER|Questionnaire|Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.
219046837|NCT06444646|OTHER|Patient phenotyping|Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.
219046838|NCT06644040|DRUG|TeriQ Patch|"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"
219046839|NCT06644040|DRUG|Teribone Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
219046840|NCT06644040|DRUG|Forteo Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
219046841|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
219046842|NCT04601688|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
219046843|NCT04601688|DRUG|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
219046844|NCT04181827|DRUG|Cilta-cel|Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
219046845|NCT04181827|DRUG|Pomalidomide|Pomalidomide 4 mg will be administered orally.
219046846|NCT04181827|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
219046847|NCT04181827|DRUG|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
219046848|NCT04181827|DRUG|Daratumumab|Daratumumab 1800 mg will be administered SC.
219046849|NCT01857063|DRUG|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
219546815|NCT03616379|BEHAVIORAL|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
219546816|NCT03616379|BEHAVIORAL|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
219546817|NCT05657587|DEVICE|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
219546818|NCT04056338|OTHER|No intervention|No intervention.
219546819|NCT02959879|DRUG|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
219546820|NCT02959879|DRUG|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
219546821|NCT02959879|PROCEDURE|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
219546822|NCT02959879|DRUG|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
219546823|NCT02959879|DRUG|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
219546824|NCT00840203|DRUG|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
219546825|NCT00840203|DRUG|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
219546826|NCT02121184|DRUG|Routine oxytocin|per regular oxytocin protocols
219546827|NCT02121184|DRUG|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
219546828|NCT02943343|OTHER|No intervention|
219546829|NCT02042859|DEVICE|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
219546830|NCT04892615|DEVICE|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
218935630|NCT05122455|DRUG|Clopidogrel|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
218935631|NCT05122455|DRUG|Edoxaban|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
218935632|NCT06890312|PROCEDURE|Administration of heparin after sheath insertion|Administration of heparin after sheath insertion
218935633|NCT06890312|PROCEDURE|Administration of heparin prior to sheath insertion|Administration of heparin prior to sheath insertion
218935634|NCT07054333|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
218935635|NCT05185661|BEHAVIORAL|eHealth education|"eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education"
219546831|NCT04892615|DEVICE|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
219546832|NCT06433232|PROCEDURE|ROOT CANAL TREATMENT|ROOT CANAL TREATMENT
219546833|NCT01438593|PROCEDURE|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
219546834|NCT02966782|DRUG|venetoclax|Tablet
219546835|NCT02966782|DRUG|azacitidine|Powder for injection, subcutaneously or intravenous
219546836|NCT03999645|PROCEDURE|Early laparoscopic cholecystectomy|within 72h from symptom onset
219546837|NCT03999645|PROCEDURE|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
219622598|NCT06337149|OTHER|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)
219622599|NCT03786848|OTHER|MiniPDX Group|Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
219622600|NCT06101966|RADIATION|external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)|Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
219546838|NCT01889407|DRUG|Idarubicin|8 mg/m2, iv drip on days 1-3
219546839|NCT01325909|BEHAVIORAL|Exercise programme|
219546840|NCT06560671|OTHER|novel type of health education|animation video based health education
219546841|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
219546842|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
219622601|NCT00051051|DRUG|CI-1033|
219206077|NCT05495945|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) using Propofol|Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
219206078|NCT06019728|DRUG|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
219546843|NCT05562011|DEVICE|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
219546844|NCT02491853|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
219546845|NCT06271005|DIETARY_SUPPLEMENT|NeuroTears|Over-the-counter supplement
219546846|NCT06271005|DIETARY_SUPPLEMENT|Placebo|Oral placebo pill
219546847|NCT03393754|BIOLOGICAL|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
219546848|NCT06196554|DRUG|Oxaliplatin|"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."
218935636|NCT07068295|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
218935637|NCT07068295|DRUG|Insulin Aspart|Insulin aspart will be administered subcutaneously.
218935638|NCT02415621|DRUG|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
218935639|NCT06843772|OTHER|ergonomic training|will receive ergonomic training.
218935640|NCT06843772|OTHER|exercise|People who will receive an exercise program. Participants will receive ergonomic training along with the exercise program.
218935641|NCT07074769|DEVICE|Evaluation of speech-in-noise intelligibility and listening effort|The speech in noise testing will be performed in lab settings; the listening effort evaluated trough a standardized questionnaire
218935642|NCT06823180|DRUG|Hydromorphone hydrochloride low dose|15min before the end of the operation, 0.1mg hydromorphone hydrochloride was injected into the epidural space in the low-dose group for preemptive analgesia.
218935643|NCT06823180|DRUG|Hydromorphone hydrochloride high dose|15min before the end of the operation, 0.3mg hydromorphone hydrochloride was injected into the epidural space in the high-dose group for preemptive analgesia.
218935644|NCT06823180|DRUG|0.9% sodium chloride|15min before the end of the operation, 0.9% sodium chloride injection was given in the control group.
218935645|NCT06762444|BEHAVIORAL|Speech-language pathologist (SLP) protocol|The SLP intervention protocol consists of six components, all of which will be implemented by the treating speech-language pathologist
218935646|NCT06585410|DRUG|Cemiplimab|Administered per protocol
218935647|NCT06585410|PROCEDURE|Standard of care|Primary surgery
218935648|NCT04888988|OTHER|Best Practice|Receive standard of care
218935649|NCT04888988|OTHER|Exercise Counseling|Meet with certified exercise instructor
218935650|NCT04888988|OTHER|Exercise Intervention|Participate in the EXCAP program
218935651|NCT04888988|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218935652|NCT04888988|OTHER|Neuropathy Assessment|Undergo tactile sensitivity test
218935653|NCT04888988|OTHER|Questionnaire Administration|Ancillary studies
218935654|NCT03460977|DRUG|Mervometostat (PF-06821497)|Oral continuous
218935655|NCT03460977|DRUG|Enzalutamide|Oral continuous
218935656|NCT07082816|DRUG|Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution|Investigational ophthalmic solution
218935657|NCT07082816|DRUG|Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution|Commercially available ophthalmic solution
218935658|NCT07087314|DRUG|SG301 Subcutaneous injection|Subcutaneous injection every weeks (QW\*6),subsequently, administer it once every two weeks for a total of three times (Q2W\*3). The total number of doses is nine.
218935659|NCT03487432|DEVICE|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
218935660|NCT03487432|DEVICE|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
218935661|NCT06901700|OTHER|Experimental Group|Total 40\~60 minutes, 3 sessions per week in alternate day for 8 weeks, total 24 sessions 5 min warm up and 5 min cool down Power training (using body weight as resistance): hip flexor, hip extensor, hip adductor, hip abductor, knee flexor, ankle plantarflexor, hip external rotator, hip internal rotator, knee extensor, ankle dorsiflexor, ankle invertor, ankle evertor
218935662|NCT06901700|OTHER|control group|Health education
218935663|NCT06905197|DRUG|DZD6008|Daily dose of DZD6008
218935664|NCT05693649|BEHAVIORAL|No Direct Patient Outreach|Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
218935665|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Colonoscopy Only|Patient will receive direct outreach including an order to schedule and complete colonoscopy.
218935666|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Sequential Choice|Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
218935667|NCT05693649|BEHAVIORAL|Visit-Based Nudge/Text|Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
218935668|NCT05693649|BEHAVIORAL|No Nudge/Text|Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
218935669|NCT01805076|PROCEDURE|Breast surgery|
218935670|NCT01805076|PROCEDURE|Magnetic resonance imaging|
218935671|NCT01805076|PROCEDURE|Mammography|
218935672|NCT05943106|BIOLOGICAL|Durvalumab|Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
219046850|NCT01857063|DRUG|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
219046851|NCT04911166|COMBINATION_PRODUCT|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
219046852|NCT05221853|DIAGNOSTIC_TEST|cardiovascular magnetic resonance|CMR scan at 3 Tesla
219046853|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
219046854|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
219046855|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
219046856|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
219046857|NCT04973605|DRUG|Sonrotoclax|Administered orally daily
219046858|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
219046859|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
219046860|NCT04973605|DRUG|Daratumumab|Administered subcutaneously weekly
219046861|NCT04973605|DRUG|Pomalidomide|Administered orally daily
219046862|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
219046863|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
219046864|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
219046865|NCT02121340|BEHAVIORAL|Behavioral Activation|
219206079|NCT06019728|DRUG|Acetaminophen|Tablet or solution; Oral
219206080|NCT06019728|DRUG|Diphenhydramine|Tablet or solution; Oral
219546849|NCT03721653|DRUG|Bevacizumab|5 mg/kg iv over 30 minutes day 1
219546850|NCT03721653|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes day 1
219546851|NCT03721653|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
219546852|NCT03721653|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
219546853|NCT03721653|DRUG|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
219546854|NCT03721653|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
219546855|NCT04352205|DRUG|Bortezomib|Given SC
219546856|NCT04352205|BIOLOGICAL|Daratumumab|Given IV
219546857|NCT04352205|DRUG|Dexamethasone|Given PO and IV
219546858|NCT04352205|DRUG|Lenalidomide|Given PO
219546859|NCT04352205|DRUG|Thalidomide|Given PO
219546860|NCT05751447|DIAGNOSTIC_TEST|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
219546861|NCT03119077|DRUG|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
219546862|NCT03119077|DRUG|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
219546863|NCT03119077|DRUG|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
219546864|NCT03097445|DRUG|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
219546865|NCT03811145|BIOLOGICAL|Tendoncel|Platelet lysate gel
219546866|NCT03811145|OTHER|Placebo control gel|Placebo control gel
219046866|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
219046867|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
219046868|NCT06506461|DRUG|Plerixafor|Given Subcutaneous (under the skin)
219046869|NCT06506461|DRUG|Busulfan|Given Intravenous (IV)
219046870|NCT06506461|BIOLOGICAL|Gene-modified CD34+ cells|Given Intravenous (IV)
219046871|NCT06506461|DRUG|Motixafortide|Given Subcutaneous (under the skin)
219046872|NCT02115282|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tissue samples
219546867|NCT03296956|DIETARY_SUPPLEMENT|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
219546868|NCT03296956|OTHER|Placebo|Matching placebo for appearance, taste
219546869|NCT01446770|DEVICE|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
219546870|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
219546871|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
219206081|NCT06019728|DRUG|Dexamethasone|Tablet or solution; Oral
219622602|NCT02946463|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
219622603|NCT02946463|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
219622604|NCT06577246|PROCEDURE|scaling root planing|periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.
219622605|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video1-2)|"The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)"
218935673|NCT05943106|BIOLOGICAL|BCG|Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
218935674|NCT06901466|DRUG|Experimental: Rivaroxaban monotherapy|Rivaroxaban monotherapy
218935675|NCT06901466|DRUG|Active Comparator: Rivaroxaban+Aspirin|Rivaroxaban+Aspirin
218935676|NCT07097428|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
218935677|NCT07092670|DRUG|Dabrafenib + Trametinib|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
219046873|NCT02115282|PROCEDURE|Computed Tomography|Undergo CT
219046874|NCT02115282|DRUG|Entinostat|Given PO
219046875|NCT02115282|DRUG|Exemestane|Given PO
219046876|NCT02115282|DRUG|Goserelin|Given PO
219046877|NCT02115282|DRUG|Goserelin Acetate|Given SC
219046878|NCT02115282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219046879|NCT02115282|OTHER|Placebo Administration|Given PO
219046880|NCT02115282|OTHER|Quality-of-Life Assessment|Ancillary studies
219046881|NCT06468111|BEHAVIORAL|Animal Assisted Therapy|Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
219046882|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
219046883|NCT01686646|DRUG|paracetamol|paracetamol
219622606|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video 3)|iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups.
218935678|NCT07092670|DRUG|Pembrolizumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
218935679|NCT07092670|DRUG|Nivolumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
218935680|NCT07092670|OTHER|Observation|Patients who will not initiate adjuvant therapy, but will undergo observation (due to refusal, comorbidities, other reasons).
218935681|NCT04347629|BEHAVIORAL|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
218935682|NCT04044872|DIAGNOSTIC_TEST|[1-13C]pyruvate along with MRI imaging|\[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
218935683|NCT07113990|PROCEDURE|Active EA|Participants will receive electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable sterile needles will be inserted at standardized acupoints to achieve de qi, then connected to an electroacupuncture device for 30 minutes per session.
218935684|NCT07113990|PROCEDURE|Sham EA|Participants will receive sham electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable blunt needles will be placed at the same acupoints without skin penetration or electrical stimulation, with the electroacupuncture device turned on but delivering no current, for 30 minutes per session.
218935685|NCT07113990|DEVICE|Active rTMS|Participants will receive high-frequency rTMS to the ipsilesional M1 area once daily for 2 consecutive weeks (total 10 sessions). Stimulation will be delivered with a MagPro R30 stimulator at 10 Hz, 1600 pulses per session, 4-second trains with 41-second inter-train intervals.
218935686|NCT06922617|BEHAVIORAL|Switching to E-Cigarette|Participants will receive twelve weeks of e-cigarette products with instructions to switch completely at switch date
218935687|NCT06922617|DRUG|Quitting using Medication|Participants will receive twelve weeks of FDA approved medication, combination NRT, with instructions to quit smoking cigarettes at quit date
219546872|NCT03349567|BEHAVIORAL|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
219546873|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
219546874|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
219046884|NCT02319538|PROCEDURE|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
219206082|NCT06019728|DRUG|Montelukast|Tablet or chewable tablet or oral granules; Oral
219206083|NCT06019728|DRUG|Loratadine|Tablet or chewable tablet; Oral
219206084|NCT06019728|DRUG|Cetirizine|Tablet or oral solution; Oral
219546875|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
219546876|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
219546877|NCT03066544|DRUG|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
219546878|NCT03066544|DRUG|Naratriptan Pill|one pill will be administered twice each day for 5 days
219546879|NCT03066544|DRUG|Dexamethasone|one tablet will be administered twice each day for 3 days
219622607|NCT06577246|BEHAVIORAL|Periodontal Disease Prediction (PDP)|The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years. These projections were presented to the patients in three dimensions with PDP visualisation.
219622608|NCT02491840|PROCEDURE|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
219622609|NCT06307795|DRUG|ANS014004|Varying doses of ANS014004
219622610|NCT06022406|BIOLOGICAL|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
219622611|NCT06022406|BIOLOGICAL|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
219622612|NCT04737889|DRUG|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
219046885|NCT01220271|DRUG|LY2157299|Administered orally
219046886|NCT01220271|DRUG|Radiation|Administered as approved
219046887|NCT01220271|DRUG|Temozolomide|Administered orally
219046888|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
219046889|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
219046890|NCT06362148|DIAGNOSTIC_TEST|Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
219046891|NCT06362148|DIAGNOSTIC_TEST|18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)|FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
219046892|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
219046893|NCT02296814|DRUG|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
219046894|NCT02296814|DRUG|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
219046895|NCT03941730|PROCEDURE|Biopsy|Undergo tissue biopsy
219046896|NCT03941730|PROCEDURE|Computed Tomography|Undergo CT
219046897|NCT03941730|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219046898|NCT03941730|PROCEDURE|Positron Emission Tomography|Undergo PET
219046899|NCT03941730|BIOLOGICAL|Therapeutic Estradiol|Given PO
219046900|NCT01449578|DRUG|Dexpramipexole|Oral Tablet at varying doses
219046901|NCT01449578|DRUG|Dexpramipexole Placebo|Oral tablet at varying doses
219046902|NCT04275596|DRUG|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
219046903|NCT04275596|DRUG|Placebo|Application of topical placebo on the anal wound until complete wound healing
219206085|NCT06019728|DRUG|Fexofenadine|Tablet or oral suspension; Oral
219546880|NCT03066544|DRUG|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
219546881|NCT01728480|DRUG|entolimod|Given SC
218935688|NCT06922617|BEHAVIORAL|Counseling|Participants will recieve brief weekly counseling to support their quit or switch attempt from cigarettes.
219546882|NCT01728480|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219546883|NCT01728480|DRUG|cisplatin|Given IV
219546884|NCT01728480|OTHER|pharmacological study|Correlative studies
219546885|NCT01728480|OTHER|laboratory biomarker analysis|Correlative studies
219546886|NCT05294276|OTHER|no intervention related|no intervention related
219622613|NCT04737889|DRUG|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
219622614|NCT04737889|DRUG|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
219622615|NCT04737889|DRUG|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
219622616|NCT03399045|PROCEDURE|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
219622617|NCT03399045|PROCEDURE|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
218935689|NCT06557798|DEVICE|Any commercially available transcatheter aortic valve|Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
218935690|NCT06557798|PROCEDURE|Surgical explantation and aortic valve replacement|Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
218935691|NCT06557798|OTHER|Conservative management|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
218935692|NCT04695977|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
218935693|NCT04695977|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
218935694|NCT06922591|DRUG|TNG462|MTA cooperative PRMT5 inhibitor
218935695|NCT06922591|DRUG|RMC-9805|RAS(ON) G12D selective covalent inhibitor
218935696|NCT06922591|DRUG|RMC-6236|RAS(ON) multi-selective inhibitor
218935697|NCT05756855|BEHAVIORAL|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
218935698|NCT06932458|PROCEDURE|Retroperitoneal Lymph Node Dissection|Open bilateral nerve-sparing RPLND.
218935699|NCT06931158|DRUG|Open-label Placebo|Open-label placebo pill for 21 days at 2 per day
218935700|NCT06931158|BEHAVIORAL|Standard Rationale|Scientific rationale about the placebo effect
219046904|NCT03254238|OTHER|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
219046905|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
219546887|NCT04411680|DRUG|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
219546888|NCT04411680|DRUG|Standard of care|Standard of care for COVID-19
219546889|NCT05595980|DIETARY_SUPPLEMENT|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
219546890|NCT05595980|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
219546891|NCT00690027|PROCEDURE|Emergency portacaval shunt|
219546892|NCT00690027|PROCEDURE|Emergency and long-term endoscopic sclerotherapy|
219546893|NCT06430294|OTHER|Spinal mobilisation|Application of a force on pediatric manikins.
219622618|NCT01932333|DRUG|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
219622619|NCT01932333|DRUG|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
219622620|NCT01932333|DRUG|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
218935701|NCT06931158|BEHAVIORAL|Mindfulness|Mindfulness based rationale
218935702|NCT06931158|BEHAVIORAL|Control Rationale|Basic epidemiological information about chronic pain to achieve structural equivalence for the control groups
218935703|NCT05020184|DRUG|Cimetidine|Oral Cimetidine 800mg twice daily.
218935704|NCT05020184|DRUG|Placebo|Placebo twice daily
219046906|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
219546894|NCT01166529|PROCEDURE|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
219046907|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
219546895|NCT05661591|DRUG|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
219546896|NCT05661591|DRUG|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
219546897|NCT06556329|OTHER|Robot (Intervention)|The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
219546898|NCT00748566|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
219546899|NCT02349672|PROCEDURE|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
219546900|NCT03018990|OTHER|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
219546901|NCT04471116|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
219546902|NCT02182596|DRUG|Mylotarg|Dose level study
219546903|NCT05001958|BEHAVIORAL|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
219546904|NCT06346535|DIAGNOSTIC_TEST|Cognitive Testing|Digital Cognitive Testing performed at home.
219546905|NCT04658225|PROCEDURE|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
219546906|NCT02353936|DRUG|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
219546907|NCT06103097|OTHER|No interventions done (obervational)|Observational study
219546908|NCT00366639|OTHER|Acute Decompensated Heart Failure|Treatment \& outcomes during hospital admission for Acute DHF
219546909|NCT04937439|OTHER|Traditional Physical Therapy program|"1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting"
219206086|NCT05477589|DRUG|busulfan, cyclophosphamide and melphalan, BuCyMel|a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
219206087|NCT05477589|DRUG|clofarabine, fludarabine and busulfan, CloFluBu|combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
219546910|NCT04937439|OTHER|Segmental trunk training A|Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
219546911|NCT04937439|OTHER|Segmental trunk training B|Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
219546912|NCT04937439|OTHER|Segmental trunk training C|Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
219622621|NCT03929523|DEVICE|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
219546913|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
219546914|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
219546915|NCT02888964|DRUG|Add-on therapy|Pioglitazone therapy
219546916|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
219546917|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
219546918|NCT02227238|DRUG|DTG|DTG is supplied as 50 mg tablets
219546919|NCT02227238|DRUG|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
219622622|NCT03929523|DEVICE|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
218935705|NCT03105713|OTHER|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
218935706|NCT06935422|DEVICE|Ultrasound|Measuring cerebroplacental ratio discordance in monochorionic twins at 16-20 Weeks of gestation
218935707|NCT02844309|DRUG|Thalidomide|thalidomide 50-150 mg per night
219206088|NCT05309577|BEHAVIORAL|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
218935709|NCT04193189|BIOLOGICAL|HEPLISAV-B|Administered by IM injection
218935710|NCT04193189|BIOLOGICAL|ENGERIX-B|Administered by IM injection
218935711|NCT07145034|DRUG|Prosman|Prosman, the study drug is prepared from the gummy extract (pygeum) from the Indian plum tree Prunus domestica and is available in various dosage forms. Originally, pygeum, was obtained from the African prune tree bark (Prunus africanum) and was used for the treatment of various urinary problems.
218935712|NCT07145034|OTHER|Placebo|Placebo matched to the Prosman
218935713|NCT01650597|DRUG|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
218935714|NCT01650597|DRUG|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
218935715|NCT01650597|DRUG|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
218935716|NCT00108199|BEHAVIORAL|Problem-Solving Training|
218935717|NCT00108199|BEHAVIORAL|Work-Related Social Skills Training|
218935718|NCT06947252|DIAGNOSTIC_TEST|Oral food challenge test|Oral food challenge test at home or in the hospital
218935719|NCT06947915|OTHER|Co-design workshop|Co-design workshops to develop the implementation model
218935720|NCT06947915|OTHER|Survey|Survey of care staff knowledge and confidence
218935721|NCT06947915|OTHER|Interview|Interview to explore care staff experience of the falls management support
218935722|NCT06947785|OTHER|Combined Neural Mobilization with Manual myofascial Release|Combined neural mobilization with manual myofascial release will be provided to each subject.
218935723|NCT06947785|OTHER|Neural Mobilization|neural mobilization will be provided to each subject.
218935724|NCT06947785|OTHER|Manual Myofascial Release|Manual myofascial release will be provided to each subject.
218935725|NCT06945965|PROCEDURE|Injectable platelet-rich fibrin (i-PRF) scaffold|The separated plasma and platelets form a light-yellow-colored layer, which is situated at the top of the tube. This is then aspirated using a syringe with a needle (partially active injectable form).
218935726|NCT06945965|PROCEDURE|platelet-rich fibrin (PRF)scaffold|The fibrin clot was removed from the test tube with sterile tweezers, then cut into fragments, then placed incrementally in the canal space below the CEJ using hand pluggers (without prior induction of apical bleeding).
219206089|NCT06759454|DRUG|Glutaraldehyde-Based Desensetizing Agent|A glutaraldehyde-based desensitizing agent applied to the cervical area of affected teeth using a micro-brush, left undisturbed for 30 seconds, and air-dried. Both interventions aim to reduce pain associated with dentinal hypersensitivity by either occluding dentinal tubules or reducing nerve excitability
219546920|NCT02227238|DRUG|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
219546921|NCT03306238|PROCEDURE|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
218935727|NCT06945965|PROCEDURE|blood clot (BC) scaffold|A sterile saline-soaked cotton pellet was placed into the canal 2 mm below the orifice for 15 minutes to form a blood clot.
219546922|NCT03306238|PROCEDURE|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
219546923|NCT03354338|DRUG|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
219546924|NCT03354338|OTHER|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
219546925|NCT04025021|DIETARY_SUPPLEMENT|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
219546926|NCT04025021|DEVICE|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
219546927|NCT05172687|BEHAVIORAL|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
219546928|NCT05172687|BEHAVIORAL|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
219546929|NCT02375815|OTHER|Statin Choice Implementation|
219546930|NCT02751437|DIETARY_SUPPLEMENT|Arginine|
219622623|NCT07121179|BEHAVIORAL|Beighton Scoring system|The Beighton Scoring system is commonly used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring system includes the following assessments: passive dorsiflexion of the fifth metacarpophalangeal joint, passive hyperextension of the elbow, passive hyperextension of the knee, passive apposition of the thumb to the flexor aspect of the forearm, and forward flexion of the trunk. A Developmental Physiotherapy and Pediatric Rehabilitation specialist will evaluate the joint hypermobility assessment of infants.
219622624|NCT07121179|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
218935728|NCT06953466|DRUG|QRX003, 4% Lotion|QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)
218935729|NCT00387985|DRUG|MOA-728|
219046908|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
219546931|NCT03601585|DEVICE|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
219546932|NCT02075333|DIETARY_SUPPLEMENT|Ingestion of solution|Participants will ingest the solution
219546933|NCT02075333|DIETARY_SUPPLEMENT|Rinising of solution|Participants rinse the solution in the oral cavity
219546934|NCT03725345|BEHAVIORAL|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
219546935|NCT06076109|OTHER|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
219546936|NCT06076109|OTHER|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
219622625|NCT05292001|DRUG|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
218935730|NCT07150455|OTHER|Echocardiographic Assessment (2D Speckle Tracking)|All participants will undergo standardized 2D echocardiographic examination including Global Longitudinal Strain (GLS) measurement. No drug or device intervention is applied.
218935731|NCT07156448|BEHAVIORAL|Multicomponent Exercise Program|Participants in the intervention group received a structured, multicomponent exercise program consisting of resistance training, stretching, and walking. The program began on the second day of hospitalization and continued until discharge, with a frequency of five sessions per week. Each session lasted approximately 30 minutes, including about 20 minutes of resistance and stretching exercises targeting major muscle groups through functional movements (e.g., sit-to-stand, leg flexion-extension) and flexibility exercises for the upper arms, back, and posterior legs, performed in 2 to 3 sets of 8 to 12 repetitions. Each session also incorporated approximately 10 minutes of walking, with intensity adjusted according to individual tolerance.
218935732|NCT07156513|PROCEDURE|Epidural Pulsed Radiofrequency|Pulsed radiofrequency applied via a guidable epidural catheter electrode (Cosman RCE-E401519-P), advanced through the sacral hiatus to the target lumbar or sacral root (L5 and/or S1) under fluoroscopic guidance. Parameters: 45 V, 2 Hz, 20 ms pulses, applied at a single location with continuous temperature monitoring (≤42°C). Procedure performed with Cosman C4 generator.
218935733|NCT07156513|DRUG|Betamethasone (Epidural Corticosteroid Injection)|Epidural injection of 12 mg betamethasone diluted in 8 ml sterile saline, administered via the sacral hiatus under fluoroscopic guidance.
218935734|NCT07158424|PROCEDURE|Serious games|Participants in the experimental groups engage in daily sessions of serious games from the Vana Vital Platform (Super Surfer, Hungry Woo, Paddle Waddle, Woo's Wonderful World Adventure). Each child will for 30 minutes per day over 10 training days.
218935735|NCT07158424|PROCEDURE|Intensive rehabilitation|"Participants receive their intensive rehabilitation program, which includes:~30 minutes of physical therapy (PT) 20 minutes of occupational therapy 5 minutes of spinal manipulative therapy 60 minutes of full-body massage with reflexotherapy 15 minutes of joint mobilization 15 minutes of treadmill gait training (with or without suspension) 15 minutes of strength training 30 minutes of group rhythmic gymnastics"
218935736|NCT07158424|PROCEDURE|Physical therapy|Participants receive an additional 30 minutes of physical therapy (PT)
219546937|NCT01608906|DRUG|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
219546938|NCT01608906|DRUG|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
219546939|NCT00327847|DRUG|Oral Vitamin D Supplementation|
219546940|NCT03966911|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
219546941|NCT05635630|OTHER|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
219546942|NCT05635630|OTHER|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
219546943|NCT02408653|DEVICE|EEG|
219546944|NCT01158053|DEVICE|FFR and VH-IVUS|"* Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) \>48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~* No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~* FFR followed by VH-IVUS of study lesion(s)~* Any additional PCI based on routine clinical practice and FFR/IVUS data?~* If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~* If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
219546945|NCT01158053|DEVICE|IVUS and FFR|
219546946|NCT06414200|OTHER|multidisciplinary structured tailored made nutritional advice|The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
219546947|NCT00868998|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
219546948|NCT02047305|DEVICE|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
219546949|NCT06426290|BEHAVIORAL|post-surgery psychological evaluation|"Following questionnaires will be done :~Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor Eating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire (EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)"
219546950|NCT04212845|DRUG|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
219546951|NCT04212845|DEVICE|Fluoroscopy|Fluoroscopy-guided transforaminal injection
219546952|NCT04212845|DEVICE|Ultrasound|Ultrasound-guided erector spinae plane block
219546953|NCT01986647|BEHAVIORAL|On the Move exercise - exercise leader|exercise physiologists
219546954|NCT01986647|BEHAVIORAL|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
219546955|NCT01986647|BEHAVIORAL|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
219546956|NCT01986647|BEHAVIORAL|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
219622626|NCT05292001|OTHER|Saline Placebo|Normal saline
219046909|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
219046910|NCT00180375|DEVICE|Prizm, Vitality, Renewal|Follow-up during 2 years
219046911|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
219046912|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
219046913|NCT06331793|DEVICE|Active AlgoCare|Device that emits Pulsed Electromagnetic Fields
219546957|NCT05240417|PROCEDURE|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
219546958|NCT05240417|PROCEDURE|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
219622627|NCT07135115|BEHAVIORAL|Digikost report baseline only|The Digikost report will be made available for the participant immediately after completing of the Digikost questionnaire at baseline.
219622628|NCT07135115|BEHAVIORAL|Digikost report intensive with individual counselling and webinars|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months. Additionally, the participant is offered an individual lifestyle counselling meeting by telephone at baseline and invited to inspirational webinars on cancer preventive lifestyle every 6 months.
219622629|NCT07135115|BEHAVIORAL|Digikost report intensive|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months.
219622630|NCT05881863|OTHER|No intervention|This is an observational study
219622631|NCT06812884|OTHER|Education|The mobile application will be introduced to the group to be trained and the application will be downloaded to their phones, tablets or computers.
219622632|NCT06979505|DRUG|GV101|GV101 suspension
219622633|NCT06979505|DRUG|GV101 placebo|GV101 placebo suspension
219622634|NCT03155620|PROCEDURE|Biopsy Procedure|Undergo biopsy
219046914|NCT06331793|DEVICE|Non-active AlgoCare|Device that doesn't emit Pulsed Electromagnetic Fields
219546959|NCT02905435|DEVICE|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
219546960|NCT02086474|DRUG|Hyaluronan|Intra-articular injection
219546961|NCT02086474|DRUG|Bupivacaine|Extra-capsular injection
219546962|NCT01885819|BIOLOGICAL|Autologous stromal vascular fraction cells|
219546963|NCT01442051|PROCEDURE|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
219546964|NCT06034483|OTHER|Pelvic floor exercise training|"* Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
219546965|NCT06034483|OTHER|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
219546966|NCT06259630|DRUG|Nicotine|Participant receives oral dose of nicotine
219546967|NCT06259630|DRUG|Placebo oral capsule|Participant receives oral dose of placebo
219546968|NCT03459339|DEVICE|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
219546969|NCT00595153|DRUG|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
219546970|NCT06179173|OTHER|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
219546971|NCT06179173|OTHER|Conventional physiotherapy|Conventional physiotherapy
219546972|NCT06204367|DIAGNOSTIC_TEST|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
219546973|NCT03166527|DRUG|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
219546974|NCT03498560|DEVICE|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
219546975|NCT05204420|PROCEDURE|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
219546976|NCT02195544|DRUG|Synvisc®|
219546977|NCT06431776|DRUG|Molgramostim|Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
219546978|NCT02178891|DEVICE|extra short implant|
219546979|NCT02392689|OTHER|Procalcitonin|Procalcitonin guided antibiotic therapy
219546980|NCT01507662|BEHAVIORAL|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
219546981|NCT04008680|OTHER|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
219046915|NCT03464864|DRUG|Treprostinil Inhalation Powder|Single ascending dose
219046916|NCT01723228|DRUG|Rasagiline|
219546982|NCT05341180|DRUG|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
219622635|NCT03155620|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622636|NCT03155620|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow and/or biopsy
219622637|NCT03155620|PROCEDURE|Bone Scan|Undergo a bone scan
219622638|NCT03155620|PROCEDURE|Computed Tomography|Undergo CT, PET/Ct, and/or CT/MRI
219622639|NCT03155620|DRUG|Ensartinib|Given PO
219622640|NCT03155620|DRUG|Erdafitinib|Given PO
219046917|NCT01723228|DRUG|Placebo|
219622641|NCT03155620|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
219622642|NCT03155620|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
219206090|NCT06759454|DEVICE|Low Level Laser Therapy|Low-level laser therapy (LLLT) using a diode laser set to a low power level (e.g., 100 mW, continuous wave mode). Each affected tooth will be treated for three minutes, targeting apical, cervical, and middle points
219206091|NCT06769113|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219546983|NCT05341180|DRUG|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
219622643|NCT03155620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
219622644|NCT03155620|PROCEDURE|Mutation Carrier Screening|Undergo tumor tissue mutation screening
219046918|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
219046919|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
219046920|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
219046921|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
219046922|NCT00862784|BIOLOGICAL|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
219546984|NCT01627431|DRUG|Acetylsalicylic acid|100 mg once per day
219546985|NCT01627431|DRUG|Clopidogrel|75 mg once per day
219546986|NCT00197873|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
219546987|NCT00197873|OTHER|Placebo administration.|Placebo is administered during chemotherapy.
219622645|NCT03155620|DRUG|Olaparib|Given PO
219622646|NCT03155620|DRUG|Palbociclib|Given PO
219046923|NCT00862784|DRUG|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
219046924|NCT00862784|DRUG|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
219622647|NCT03155620|OTHER|Pharmacological Study|Correlative studies
219622648|NCT03155620|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
219622649|NCT03155620|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
219046925|NCT00862784|DRUG|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
219622650|NCT03155620|DRUG|Samotolisib|Given PO
219622651|NCT03155620|DRUG|Selpercatinib|Given PO
219046926|NCT00862784|DRUG|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
219046927|NCT06972732|DRUG|Metformin|The dosage and dose frequency are maintained as they were before the screening.
219046928|NCT06972732|DRUG|Dapagliflozin/Pioglitazone|Dapagliflozin 10mg/Pioglitazone 30mg QD
219046929|NCT06972732|DRUG|Dapagliflozin/Sitagliptin|Dapagliflozin 10mg/Sitagliptin 100mg QD
219046930|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
219206092|NCT06769113|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219206093|NCT06769113|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219206094|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with semitendinosus tendon autograft
219206095|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with peroneus longus autograft
219206096|NCT06892613|BEHAVIORAL|Emotion-Focused Couples Therapy (EFCT)|EFCT is a structured approach to couples therapy that focuses on helping partners understand and express their emotions, address attachment insecurities, and strengthen their emotional connection.
219206097|NCT06892613|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT is a form of therapy that aims to improve relationship satisfaction through behavioral change, communication training, and problem-solving techniques.
219622652|NCT03155620|DRUG|Selumetinib Sulfate|Given PO
219622653|NCT03155620|DRUG|Tazemetostat|Given PO
219622654|NCT03155620|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
219622655|NCT03155620|DRUG|Ulixertinib|Receive PO
219622656|NCT03155620|DRUG|Vemurafenib|Given PO
219622657|NCT03155620|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219622658|NCT04750954|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219622659|NCT04750954|PROCEDURE|Computed Tomography|Undergo CT
219622660|NCT04750954|DRUG|Lutetium Lu 177 Dotatate|Given IV
219046931|NCT06296303|OTHER|Pulsed electromagnetic therapy|Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
219046932|NCT06296303|OTHER|Ultrasound phonophoresis|Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
219622661|NCT04750954|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622662|NCT04750954|DRUG|Peposertib|Given PO
219622663|NCT06982222|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219546988|NCT04541173|OTHER|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
219546989|NCT04541173|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
219546990|NCT04541173|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
219546991|NCT05121194|BEHAVIORAL|Cognitive Behaviour Therapy|Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
219546992|NCT02666482|BEHAVIORAL|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
219546993|NCT05366231|DRUG|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
219546994|NCT05366231|DRUG|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
219546995|NCT03587129|DRUG|Apatinib|An anti-tumor Targeted drug
219546996|NCT04805840|DEVICE|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
219546997|NCT03985657|DEVICE|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
219546998|NCT05373576|BEHAVIORAL|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
219546999|NCT05423873|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
219547000|NCT00192257|BIOLOGICAL|CAIV-T and TIV|
219547001|NCT01710722|DRUG|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
219547002|NCT01710722|DRUG|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
219547003|NCT01710722|DRUG|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
219547004|NCT03449225|OTHER|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
219547005|NCT00028925|BIOLOGICAL|filgrastim|
219046933|NCT06296303|OTHER|Conventional physical therapy|"Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises"
219046934|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
219046935|NCT06108817|OTHER|No Intervention|These practices do not receive information material
219046936|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
219547006|NCT00028925|DRUG|carboplatin|
219547007|NCT00028925|DRUG|topotecan hydrochloride|
219547008|NCT00028925|RADIATION|WBRT|
219547009|NCT04348422|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
219547010|NCT04348422|DIAGNOSTIC_TEST|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
219622664|NCT06982222|PROCEDURE|Bone Scan|Undergo technetium TC-99m bone scan
219206098|NCT06739850|COMBINATION_PRODUCT|Identification of Risk Phenotypes of Sarcopenia|Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.
219206099|NCT06736912|DRUG|IN-114199 2.5mg or placebo|IN-114199 2.5mg or placebo (1 Tablet, QD)
219206100|NCT06736912|DRUG|IN-114199 10mg or placebo|IN-114199 10mg or placebo (1 Tablet, QD)
219206101|NCT06736912|DRUG|IN-114199 20mg or placebo|IN-114199 10mg or placebo (2 Tablets, QD)
219206102|NCT06736912|DRUG|IN-114199 40mg or placebo|IN-114199 10mg or placebo (4 Tablets, QD)
219206103|NCT06736912|DRUG|IN-114199 5mg or placebo|IN-114199 2.5mg or placebo (2 Tablets, QD)
219547011|NCT04348422|OTHER|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
219547012|NCT04074707|DIETARY_SUPPLEMENT|Labeled iron solution (60mg and 120mg Ferrous Fumarate)|3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
219547013|NCT00643305|BEHAVIORAL|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
219547014|NCT00643305|BEHAVIORAL|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
219622665|NCT06982222|PROCEDURE|Computed Tomography|Undergo PET/CT, SPECT/CT and PSMA PET/CT
219622666|NCT06982222|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219622667|NCT06982222|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
219622668|NCT06982222|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219046937|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
219046938|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
219046939|NCT01313429|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
219046940|NCT01313429|BIOLOGICAL|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
219046941|NCT01313429|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
219046942|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
219046943|NCT03196752|OTHER|simple palpation|conventional
219046944|NCT02170246|DRUG|Telmisartan|
219622669|NCT06982222|RADIATION|Technetium TC-99m|Undergo technetium TC-99m bone scan
219206104|NCT06739538|DIAGNOSTIC_TEST|Bobath exercises|Bobath concept, are therapeutic techniques designed to improve motor control and function in individuals with neurological conditions, particularly those with cerebral palsy. These exercises focus on facilitating normal movement patterns, enhancing postural stability, and reducing muscle spasticity. The approach emphasizes individualized treatment, utilizing hands-on techniques to promote movement awareness and encourage the development of functional skills. By reinforcing weak movements and inhibiting overactive ones, Bobath exercises aim to enhance overall motor abilities and improve the quality of life for affected individuals.
219206105|NCT06739538|COMBINATION_PRODUCT|Gasotransmitters|such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small gaseous signaling molecules that play key roles in various physiological functions, including the regulation of muscle tone and neuroinflammation. In the context of spastic diplegic cerebral palsy (CP), gasotransmitters may help reduce spasticity and pain. Gasotransmitters help reduce spasticity and pain in children with spastic diplegic cerebral palsy through multiple mechanisms: Muscle relaxation and improved blood flow reduce muscle tightness, Anti-inflammatory and neuroprotective properties help minimize the damage that exacerbates spasticity.They also modulate pain pathways, both centrally and peripherally, reducing pain perception.
219206106|NCT06739473|BEHAVIORAL|Movies|Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.
219206107|NCT06739473|BEHAVIORAL|Cold|Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.
219622670|NCT06982222|RADIATION|Tin Sn 117m Pentetate|Given IV
219622671|NCT06574906|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
219622672|NCT06656143|OTHER|Traditional Physical therapy|"The exercise program included the strengthening of the deep cervical flexor and shoulder retractor muscles and also stretching of the pectoralis and cervical extensor muscles.~(3 sets of 12 repetitions) Strengthening Deep Cervical Flexors Lying chin tuck Lying chin tuck with head lift. Strengthening Shoulder Retractors Standing shoulder pull back with elastic Shoulder pull back with weight Stretch Cervical Extensors Chin drop Stretch Pectoralis Muscle Bilateral Pectoral stretch"
219641854|NCT06958120|PROCEDURE|superficial parasternal intercostal Plane block|A high-frequency linear transducer was used to guide the insertion of a needle 2 cm lateral to the sternum. After identifying key anatomical structures, the needle was advanced in-plane into the pectointercostal fascial plane between the pectoralis major and internal intercostal muscle. Correct placement was confirmed with a saline injection, and then a local anesthetic (0.4 ml/kg of a 1:1 mix of bupivacaine 0.25% and lidocaine 1%) was injected bilaterally at the second and fourth ribs.
218935737|NCT07157826|DEVICE|Guided Imagery Application|"Guided Imagery Intervention:~Scenario-based guided imagery, one of the guided imagery techniques, will be utilized. The scenario will be developed with input from experts to promote functional recovery. Expert opinions will be obtained from a psychologist and a psychiatric nurse. The scenario will begin with breathing exercises and continue with the safe place technique. Patients will be instructed to listen to the audio recording using headphones in an environment free from disturbances, to set their phones to airplane mode, and to inform their relatives not to interrupt them before starting the session. Headphones will be provided by the researcher for each patient. After the content of the audio recordings is created during the initial session, it will be recorded via phone and transferred as a file to the patients' phones, with instructions on how to use it. The audio recording will last approximately 15 to 20 minutes and will include relaxing, soft background music."
219046945|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
219046946|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
219046947|NCT05093426|OTHER|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
219046948|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
219046949|NCT00085943|DRUG|LEXIVA (GW433908)|
219046950|NCT00085943|DRUG|Ritonavir|
219046951|NCT00085943|DRUG|KALETRA|
219046952|NCT00085943|DRUG|EPIVIR|
219046953|NCT00085943|DRUG|Ziagen|
219046954|NCT00085943|DRUG|Abacavir/Lamivudine|
219046955|NCT00085943|DRUG|Fosamprenavir|
219046956|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
219046957|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
219046958|NCT06561347|DRUG|Zanubrutinib|A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor
219046959|NCT06561347|DRUG|Bendamustine|Alkylating agent
219046960|NCT06561347|DRUG|Rituximab|Monoclonal antibody
219046961|NCT01895738|BEHAVIORAL|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
219046962|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
219046963|NCT00243516|DEVICE|PREtest Consult|
219046964|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
219046965|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
219046966|NCT02084628|DRUG|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
219046967|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
219046968|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
219046969|NCT00494572|DRUG|Montelukast|10 mg rapid dissolving granule in sterile water orally once
219046970|NCT00494572|OTHER|sterile water|sterile water
219046971|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
219046972|NCT06265402|PROCEDURE|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
219046973|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
219547015|NCT01004510|DRUG|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
219547016|NCT03145987|DIETARY_SUPPLEMENT|Vitis vinifera extract|
219547017|NCT03145987|OTHER|Placebo|
219547018|NCT04194333|PROCEDURE|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
219547019|NCT01790685|DRUG|dexamethasone implant|
219547020|NCT04273295|OTHER|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
219547021|NCT01654419|DEVICE|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
219547022|NCT01654419|DEVICE|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
219547023|NCT04255433|DRUG|Tirzepatide|Administered SC
219547024|NCT04255433|DRUG|Dulaglutide|Administered SC
219547025|NCT01960296|DRUG|Clopidogrel|Continue home dose of clopidogrel into surgery
219547026|NCT01960296|DRUG|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
219547027|NCT02003391|DRUG|Beta-blocker monotherapy|Per participant's current prescribed therapy
219547028|NCT02003391|DRUG|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
219547029|NCT04894630|OTHER|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
219547030|NCT02272803|DRUG|Lenalidomide|
219547031|NCT02272803|DRUG|Dexamethasone|
219547032|NCT02272803|BIOLOGICAL|Elotuzumab (BMS-901608)|
219547033|NCT06463119|OTHER|Collection of data in a registry|The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
219547034|NCT00464763|DRUG|Dexmedetomidine|
219547035|NCT00464763|DRUG|Placebo|
219547036|NCT03051945|DRUG|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
219547037|NCT03051945|OTHER|Normal saline|Placebo
219547038|NCT07113821|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion from type II to type IV
219547039|NCT07113821|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion from type II to type IV
219547040|NCT01406353|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
219547041|NCT00357461|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
219547042|NCT00357461|BIOLOGICAL|gp100:280-288(288V) peptide vaccine|
219206108|NCT06739473|DRUG|Hyperinsulinemic euglycemic clamp|Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.
219206109|NCT06739473|RADIATION|H2[15O]O PET/CT|H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.
219547043|NCT00357461|BIOLOGICAL|incomplete Freund's adjuvant|
219547044|NCT00357461|BIOLOGICAL|ipilimumab|
218935738|NCT07156812|DEVICE|Custome made 3D PEEK plate|Custome made 3D PEEK plate
218935739|NCT07156812|DEVICE|3D Titanium plate|Pre-bent 3D Titanium plate
219206110|NCT06739473|RADIATION|[18F]FDG PET/CT|Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq
219547045|NCT05579548|DRUG|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
219547046|NCT01023113|PROCEDURE|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
219547047|NCT01023113|PROCEDURE|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
219547048|NCT04460716|PROCEDURE|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
219547049|NCT06562088|DRUG|HDM1002 and rifampicin|Administered orally
219547050|NCT06562088|DRUG|HDM1002 and itraconazole|Administered orally
219547051|NCT06687057|BEHAVIORAL|HRV Biofeedback Training|The intervention involves 5 training sessions lasting 45 minutes (specifically, 5-minute baseline and 5 HRV biofeedback trials lasting 5 minutes each) according to the protocol published by Lehrer et al. (2013). Physiological signals (ECG and respiratory rate) will be recorded during all sessions. During the training, participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing. They will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle in order to maximize the difference between the maximum and minimum heart rate within each respiratory cycle \[i.e., respiratory sinus arrhythmia (RSA), an index of vagal modulation on the heart\] (Lehrer et al., 2003; Lehrer et al., 2000).
219641855|NCT06958120|PROCEDURE|Erecto spinea plane block|Using ultrasound, a needle is inserted near the T5 vertebra into the plane beneath the erector spinae muscle. After confirming correct positioning with saline, a local anesthetic mixture is injected in the fascial plane.
219641856|NCT03016130|OTHER|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
219641857|NCT04437225|DIETARY_SUPPLEMENT|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
219641858|NCT04437225|OTHER|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
219641859|NCT04437225|OTHER|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
219641860|NCT04437225|OTHER|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
219547052|NCT06687057|OTHER|Placebo Training|The Placebo procedure requires participants to attend 5 sessions lasting 45 minutes during which they perform a task. Physiological signals (ECG and respiration rate) will be recorded during all sessions. Participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing but these will not directly reflect the subject's cardiorespiratory activity. Participants in the control group will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle, but the feedback on the screen will not reflect that subject's RSA changes.
219547053|NCT05124600|DEVICE|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
219206111|NCT06739473|DRUG|CEUS or Contrast enhanced Ultrasound|Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
219547054|NCT07026864|RADIATION|MR-guided Radiation Therapy|MR-guided Radiation Therapy
219547055|NCT07032389|COMBINATION_PRODUCT|Polypill|The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.
219547056|NCT07138209|DRUG|QLS32015|QLS32015 will be administered subcutaneously.
219547057|NCT07138209|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219547058|NCT07138209|DRUG|Selinexor|Selinexor will be administered orally.
219547059|NCT07138209|DRUG|Dexamethasone|Dexamethasone will be administered orally
219547060|NCT06791096|DIAGNOSTIC_TEST|AI-assisted auscultation|The study begins with non-blinded staff collecting medical histories and specialist physicians conducting face-to-face auscultations and assessments. Then, primary care doctors will conduct face-to-face auscultations and first assessments, and use AI-assisted stethoscopes to collect heart sounds following a set protocol. The AI model will analyze the data in real-time and provides an immediate diagnostic result, which is relayed back to the primary care physicians. Based on this, they will make a secondary assessment. All participants will undergo echocardiography.
219547061|NCT06791096|DIAGNOSTIC_TEST|Independent auscultation|It includes medical history collection by non-blinded independent personnel, face-to-face auscultation and evaluations conducted by specialist physicians and primary care doctors separately. All participants will undergo echocardiography.
219622673|NCT06656143|OTHER|Diaphragmatic Myofascial Release|To release the diaphragm, the patient was positioned in the supine position. The therapist stood at the head of the patient. The therapist made manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist was gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist deepened hand contacts towards the inner costal margins Exercise Program (3 sets of 12 reps) Strengthening deep cervical flexors Strengthening shoulder retractors Stretching Cervical Extensors Stretching Pectoralis Muscle
219206112|NCT06891963|OTHER|Acupuncture-like TENS|"The first experimental group will receive 20-minute sessions of TENS, where participants adjust the amplitude to achieve strong muscle twitching beneath the electrodes at an intensity below the pain threshold. Acupuncture-like TENS uses high-frequency pulsed currents at two trains per second with an internal pulse frequency of 100 pps. The pulse pattern is set to burst, with an asymmetrical biphasic waveform and a pulse duration of 200 µs. Minor fluctuations in pulse rate between 100 and 104 pps were noted using a cathode ray oscilloscope before the experiment."
219206113|NCT06891963|OTHER|Dry needling|The second experimental group will receive 20-minute sessions of dry needling. Patients will be positioned in a prone, relaxed position, and the overlying skin will be cleaned with alcohol. The muscle will be palpated to locate the trigger point (MTrP), with the muscle grasped between the thumb, index, and middle fingers. A solid filiform needle within a guide tube will be inserted into the MTrP using a tapping motion at an oblique angle. The upper trapezius muscle will be palpated for trigger points, with needle insertion depths ranging from 10-15mm. After obtaining a local twitch response, the needle will be moved vertically 3-5mm until no more twitch responses occur. This group will also receive 20 minutes of conventional physical therapy.
219206114|NCT06891963|OTHER|Conventional treatment|All participants in the three groups will receive conventional treatment in the form of hot pack treatment followed by active range of movement (AROM) exercises. A hot pack will be placed on the patients cervical, paraspinal, and upper thoracic areas (including the upper trapezius muscle with aMTrP) for 20 minutes. This will be followed by AROM exercise for cervical spine joints. Participants were asked to actively flex the neck so that the head dropped toward the contralateral trapezius muscles. Patients then rotated the head toward ipsilateral side. This exercise will be repeated five times.
219206115|NCT06892535|DRUG|Albumin infusion, 2g/L of ascitic fluid aspiration.|Albumin infusion lower than the standard dose, either 2g/L or 4g/L of ascitic fluid aspiration is termed as low dose.
219547062|NCT02324335|DRUG|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
219547063|NCT02324335|OTHER|Placebo|
219547064|NCT02302716|DRUG|LY2963016|Administered SC
219547065|NCT02302716|DRUG|LANTUS®|Administered SC
219622674|NCT06692192|DRUG|Psilocybin|25mg of psilocybin
219547066|NCT02302716|DRUG|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
219547067|NCT06215196|DIETARY_SUPPLEMENT|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
219547068|NCT06215196|OTHER|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
219547069|NCT01770002|PROCEDURE|Everted suture technique|
219547070|NCT01770002|PROCEDURE|Non-everted suture technique|
218935740|NCT07156864|DRUG|1/10 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/10 therapeutic dose of the study drug (parenteral administration).
219547071|NCT04336332|COMBINATION_PRODUCT|Hydroxychloroquine Sulfate + Azithromycin|Given PO
219547072|NCT04336332|DRUG|Hydroxychloroquine Sulfate|Given PO
219622675|NCT06692192|DRUG|Psilocybin|1mg of psilocybin
219622676|NCT06692192|DRUG|Midazolam|The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.
219622677|NCT06692192|DRUG|Saline|Saline will be administered as a placebo for midazolam
219547073|NCT04735887|OTHER|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
219547074|NCT02780063|OTHER|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
219547075|NCT01619956|DEVICE|SLA dental implants|Dental implant with surface modification.
219547076|NCT01619956|PROCEDURE|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
219547077|NCT01619956|PROCEDURE|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
219547078|NCT00792207|OTHER|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
219547079|NCT00792207|OTHER|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
219547080|NCT00557245|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
219547081|NCT00557245|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
219547082|NCT00557245|DRUG|Placebo|Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
219547083|NCT03627598|DEVICE|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
219547084|NCT03627598|DEVICE|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
219547085|NCT01527838|BIOLOGICAL|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
219547086|NCT04569058|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
219547087|NCT04472858|DRUG|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
219547088|NCT04472858|DRUG|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
219547089|NCT00851409|DRUG|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
219622678|NCT06986174|DRUG|Pacritinib|Kinase inhibitor, capsule, taken orally per protocol.
219547090|NCT03432091|DRUG|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
219547091|NCT02225106|DRUG|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
219547092|NCT05608486|DEVICE|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
219547093|NCT00229021|DRUG|doripenum|
219547094|NCT06628115|DEVICE|cerament V or G|Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
219547095|NCT02623647|RADIATION|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
219547096|NCT06209749|OTHER|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
219547097|NCT01768260|DEVICE|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
219547098|NCT01768260|DRUG|Aspirin|Standard drug therapy
219547099|NCT04796480|DIETARY_SUPPLEMENT|YOGURT|Group 1 was given yogurt
219547100|NCT04796480|DIETARY_SUPPLEMENT|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
219622685|NCT06467760|DEVICE|InDx CMC Implant|The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
219547101|NCT01418573|OTHER|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
219547102|NCT01418573|OTHER|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
219046974|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
219547103|NCT01418573|OTHER|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
219547104|NCT02225782|DRUG|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
219547105|NCT05243251|DRUG|Olanzapine 5 MG|, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
219547106|NCT05243251|DRUG|Placebo|Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
219547107|NCT02464254|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
219547108|NCT02464254|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
219547109|NCT05644106|DEVICE|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
219547110|NCT01127087|DRUG|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
219547111|NCT01933282|DRUG|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
219547112|NCT01933282|DRUG|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
219547113|NCT02986555|DEVICE|Existing Biofeedback|Using relaxing assisted biofeedback approach
219547114|NCT02986555|DEVICE|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
219547115|NCT02316223|BEHAVIORAL|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
219547116|NCT01929187|DRUG|Phytonail|
219547117|NCT01929187|DRUG|Loceryl|
219547118|NCT06043349|COMBINATION_PRODUCT|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
219547119|NCT06043349|DRUG|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
219547120|NCT04020458|PROCEDURE|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
218935741|NCT07156864|DRUG|1/2 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/2 therapeutic dose of the study drug (parenteral administration).
218935742|NCT07156864|DRUG|full therapeutic dose|15 volunteers + 3 replacement volunteers will recieve full therapeutic dose of the study drug (parenteral administration).
218935743|NCT07156864|DRUG|Patients with a verified diagnosis of COVID-19|10 volunteers with a verified diagnosis of COVID-19 will recieve full therapeutic dose of the study drug (parenteral administration).
218935744|NCT07156877|PROCEDURE|Pulsed Field Ablation (PFA) with VOLT Catheter|Participants in this arm will undergo pulmonary vein isolation (PVI) using the VOLT catheter, a novel single-shot ablation device that delivers pulsed field energy (a non-thermal ablation method). The catheter features a balloon-in-basket design and enables electro-anatomical mapping. The procedure is performed under conscious sedation or general anesthesia and follows standard PVI protocols adapted for the PFA technology.
218935745|NCT07156877|PROCEDURE|Thermal Ablation (Radiofrequency or Cryoablation)|"Participants in this arm will receive PVI using established thermal ablation techniques, either:~* Radiofrequency ablation, a point-by-point technique using heat delivered through a catheter tip guided by mapping systems, or~* Cryoballoon ablation, which uses freezing energy delivered via a balloon catheter.~The choice between RF and cryoablation is at the discretion of the treating physician, in line with standard care."
218935746|NCT07157345|DRUG|PDR001|This drug was packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus
219046975|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
219046976|NCT02282696|OTHER|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
219046977|NCT05390203|DIAGNOSTIC_TEST|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
219547121|NCT04277793|BEHAVIORAL|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
219547122|NCT06274762|OTHER|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
219547123|NCT05465863|BIOLOGICAL|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
219547124|NCT02988258|GENETIC|CMV-TCR transduced donor-derived T cells|Dose escalation
219547125|NCT04483921|OTHER|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
219046978|NCT04001569|DRUG|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
219046979|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
219046980|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
219046981|NCT06347081|PROCEDURE|Nd- YAG laser at 532nm wavelength|Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
219046982|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
219046983|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
219046984|NCT00279565|DRUG|buprenorphine|
219046985|NCT00279565|DRUG|methadone|
219046986|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
219046987|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
219046988|NCT04936958|OTHER|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
219046989|NCT00064246|BIOLOGICAL|rituximab|Given IV
219046990|NCT00064246|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
219046991|NCT00064246|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219046992|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
219046993|NCT00682019|DRUG|Placebo|matching placebo
219046994|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
219547126|NCT01275664|PROCEDURE|Adjuvant Therapy|Ancillary studies
219547127|NCT01275664|DRUG|Aprepitant|Given IV and PO
219547128|NCT01275664|DRUG|Carboplatin|Given IP
219547129|NCT01275664|DRUG|Cisplatin|Given IP
219547130|NCT01275664|DRUG|Dexamethasone|Given PO
219547131|NCT01275664|DRUG|Granisetron Transdermal Patch|Apply one patch to upper arm
219547132|NCT01275664|PROCEDURE|Management of Therapy Complications|Ancillary studies
219547133|NCT01275664|OTHER|Questionnaire Administration|Ancillary studies
219547134|NCT06270745|DRUG|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
219547135|NCT06416241|DRUG|EYLEA 2 MG in 0.05 ML Injection|Intravitreal injection
219547136|NCT00529763|DRUG|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
219547137|NCT02260063|DRUG|Epinastine syrup|
219547138|NCT02260063|DRUG|Epinastine tablets|
219046995|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
219046996|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
219046997|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
219046998|NCT00019474|BIOLOGICAL|filgrastim|
219046999|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
219047000|NCT00019474|DRUG|fluorouracil|
219047001|NCT00019474|DRUG|hydroxyurea|
219047002|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
219547139|NCT03669250|DRUG|CVN058|CVN058 will be given at two doses, a low does and a high dose
219547140|NCT03669250|OTHER|Placebo comparator|inactive placebo
218935747|NCT07157657|BIOLOGICAL|Surgical implantation with standard (DRM) or photosynthetic dermal regeneration matrices (PDRM) in same patient.|Under sterile conditions and appropriate anesthesia, standard dermal regeneration matrices (DRMs) and photosynthetic dermal regeneration matrices (PDRMs), containing live photosynthetic microalgae, are implanted in separate wound areas or in anatomically distinct wounds on the same patient. Each site is then covered with a transparent adhesive dressing. In the experimental (PDRM) area, a light-emitting dressing is applied to stimulate photosynthesis and promote localized oxygen production.
219547141|NCT00469885|DRUG|Nicotine replacement|For reduction
219547142|NCT00469885|BEHAVIORAL|Motivational counseling|No drugs
219547143|NCT00828321|DRUG|Ramipril 10 mg capsule|1 x 10 mg
219547144|NCT00828321|DRUG|Altace® 10 mg capsule|1 x 10 mg
219547145|NCT02131220|DRUG|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
219547146|NCT02131220|DRUG|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
219547147|NCT02131220|DRUG|normal saline|intracoronary bolus infusion using selective catheter during PCI
219547148|NCT04879381|OTHER|Sputum samples|During consultation, one expectoration will be performed.
219547149|NCT04920695|DRUG|Nitric Oxide|Pulmonary vasodilator (gas).
219547150|NCT04920695|DRUG|Placebo|medical grade normoxic gas (FiO2 = 0.21)
219547151|NCT03119896|OTHER|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
219547152|NCT01742403|RADIATION|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
219547153|NCT04020016|DRUG|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
219547154|NCT04020016|DRUG|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
218935748|NCT07157657|PROCEDURE|Autologous split-thickness skin grafting over implanted matrices|Approximately 21 days after the initial intervention, and once the wound bed meets predefined grafting criteria based on clinical evaluation, an autologous dermo-epidermal skin graft is performed.
218935749|NCT07156656|PROCEDURE|Conventional treatment|Beside the using of Sivelestat Sodium or placebo, all postoperative care will adhere to each center's standard protocols for type A aortic dissection.
219047003|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
219047004|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
219047005|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
219047006|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
219047007|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
219047008|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
219047009|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
219047010|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
219047011|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
219047012|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
219047013|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
219547155|NCT03326167|OTHER|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
219547156|NCT05483608|OTHER|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
219547157|NCT05483608|OTHER|Recumbent cycling|Exercise using a recumbent cycle ergometer
219547158|NCT04523480|DRUG|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
219547159|NCT04523480|DRUG|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
219547160|NCT04523480|DRUG|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
219547161|NCT06432140|GENETIC|VGN-R09b injection|Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
219547162|NCT05774522|OTHER|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
219547163|NCT05774522|OTHER|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
219047014|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
219047015|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
218935750|NCT07156656|DRUG|Sivelestat sodium|The daily dose (4.8 mg/kg) is diluted in 48 mL of 0.9 % saline and administered as a continuous intravenous infusion over 24 hours at 2 mL/h (equivalent to 0.2 mg/kg/h) for 72 consecutive hours.
218935751|NCT07156656|DRUG|Placebo|An equal volume of placebo-containing only the excipients of sivelestat sodium and diluted to 48 mL with 0.9 % saline-will be infused at 2 mL/h for 72 consecutive hours.
218935752|NCT07157579|DIAGNOSTIC_TEST|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.
218935753|NCT07157033|DRUG|XER-001|XER-001 (Amifostine for nasoduodenal delivery)
219047016|NCT06518668|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
219047017|NCT06518668|DRUG|Cyclophosphamide LD|"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"
219047018|NCT05950581|DEVICE|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
219047019|NCT05950581|DEVICE|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
219047020|NCT04325828|DRUG|Apalutamide|Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
219047021|NCT04325828|DRUG|GnRH Agonist|A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
219047022|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
219047023|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
219047024|NCT06428500|DRUG|QTX3046|QTX3046 will be administered at protocol defined dose.
219047025|NCT06428500|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
219047026|NCT06731218|BIOLOGICAL|RGB-5088|Transplantation under the anterior rectus sheath
218935754|NCT07156682|DRUG|QL1706|neoadjuvant administered at a dose of 5 mg/kg, intravenous infusion, every three weeks (Q3W), on day 1 of each cycle, 4 cycles
218935755|NCT07156682|DRUG|XELOX|Oxaliplatin 130 mg/m² by intravenous infusion on Day 1; Capecitabine 850-1000 mg/m² orally twice daily (morning and evening) from Day 1 to Day 14; 4 Cycles in total.
219047027|NCT06079164|DRUG|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
219047028|NCT06079164|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
219047029|NCT06079164|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
219047030|NCT03889119|RADIATION|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
219047031|NCT05122897|DEVICE|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
219047032|NCT05122897|DEVICE|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
219047033|NCT04753840|OTHER|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
219047034|NCT04753840|OTHER|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
219047035|NCT04753840|BEHAVIORAL|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
219047036|NCT05754684|BIOLOGICAL|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
219047037|NCT05754684|DRUG|Dinutuximab beta|Dinutuximab beta iv for 5 days
218935756|NCT07158138|OTHER|Digital yoga intervention|Digital yoga intervention
219047038|NCT05754684|DRUG|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
219047039|NCT05754684|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
219047040|NCT05754684|DRUG|Spironolactone|Spironolactone po three time daily
219047041|NCT05754684|DRUG|Naxitamab|Naxitamab iv for 4 days (as alternative for dinutuximab)
219547164|NCT05774522|OTHER|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
219547165|NCT00114322|DEVICE|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
219547166|NCT00721916|DRUG|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
218935757|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
218935758|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
219547167|NCT00721916|DRUG|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
219047042|NCT04209946|PROCEDURE|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
219047043|NCT04209946|PROCEDURE|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
219047044|NCT04175210|RADIATION|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
219047045|NCT04175210|RADIATION|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
219047046|NCT04436640|DRUG|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
219047047|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|Intramuscular injection
219047048|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed|Intramuscular injection
219047049|NCT05091619|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|Intramuscular injection
219047050|NCT04635241|DRUG|Unfractionated heparin|Inhaled nebulised 6 hourly
219047051|NCT03726177|DRUG|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
219047052|NCT03726177|DRUG|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
219547168|NCT04733508|DRUG|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
219547169|NCT04733508|DRUG|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
219547170|NCT05688358|DIAGNOSTIC_TEST|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
219547171|NCT02189603|BIOLOGICAL|Recombinant (E. Coli) Hepatitis E Vaccine|
219547172|NCT04410705|OTHER|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
218935759|NCT07158177|DEVICE|Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.|both of the patient's eyes will be implanted: 1 CPO and the other APO
218935760|NCT07158177|DEVICE|Clareon Panoptix|both of the patient's eyes will be implanted: 1 CPO and the other APO
218935761|NCT07158385|OTHER|Standard test meal (SM)|Participants were given a standard breakfast meal with a fat and protein content similar to their daily intake. Insulin was administered according to their individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
218935762|NCT07158385|OTHER|High fat high protein meal-carbohydrate counting (HFHP)|On the high-fat, high-protein meal-carbohydrate counting test day (HFHP), participants were given a high-fat and high-protein breakfast. Insulin was administered according to the individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
218935763|NCT07158385|OTHER|High fat high protein meal-fat counting (HFHP-a)|On the high-fat, high-protein meal-fat-counting test day (HFHP-a), participants were given a high-fat and protein breakfast. In addition to their individual carbohydrate/insulin ratio, insulin was administered based on fat counting (1 unit for every 15 g of fat after the first 15 g of fat in the meal). In this method, the insulin dose calculated based on their individual carbohydrate/insulin ratio was delivered via insulin pump as a standard bolus, while the insulin dose calculated based on their fat count was delivered as a 4 hour extended bolus.
219047053|NCT03726177|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
219547173|NCT04410705|OTHER|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
219547174|NCT04410705|OTHER|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
219547175|NCT02244554|DEVICE|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
219547176|NCT01221649|DEVICE|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
219547177|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
219547178|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering \[MSK\]).
219547179|NCT04241341|OTHER|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
219547180|NCT04241341|OTHER|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
219547181|NCT03815409|OTHER|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
219547182|NCT03815409|OTHER|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
219547183|NCT06043375|DIETARY_SUPPLEMENT|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
219547184|NCT01182519|BEHAVIORAL|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
219547185|NCT03121079|DRUG|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
219547186|NCT06819735|DRUG|DT-7012|Intravenous infusion
219547187|NCT06819735|DRUG|Immune checkpoint inhibitor|Intravenous infusion
219547188|NCT06395883|DRUG|Glucocorticoid Effect|Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
219547189|NCT02064673|DRUG|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
219547190|NCT02064673|DRUG|placebo|placebo orally twice a day
219547191|NCT06002126|DIAGNOSTIC_TEST|Xpert HPV|The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV 16, HPV 18/45, HPV 31/33/35/52/58, HPV 51/59, HPV 39/68/56/66 all with a corresponding cycle threshold.
219547192|NCT06002126|DIAGNOSTIC_TEST|QIAsure Methylation Test|The Qiagen QIAsure assay is a multiplex real-time PCR test that amplifies the methylated promoter regions of the tumor suppressor genes, FAM19A4 and has-mir124-2, as well as a methylation-unspecific fragment of the ACTB reference gene. Hypermethylation of the host genes FAM19A4 and has-mir124-2 has been shown to detect high-grade cervical lesions and cancer.
219547193|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
219547194|NCT04509596|DRUG|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
219547195|NCT00834964|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
219547196|NCT00834964|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
219547197|NCT05095181|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219547198|NCT04101396|DIETARY_SUPPLEMENT|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
219547199|NCT01147939|DRUG|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
219547200|NCT01147939|DRUG|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
219547201|NCT05937841|DRUG|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
219547202|NCT02440607|OTHER|Electronic Cognitive Aid|
219547203|NCT02440607|OTHER|Static Cognitive Aid|
219547204|NCT02722239|DRUG|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
219547205|NCT02722239|DRUG|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
219547206|NCT02722239|DRUG|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
219547207|NCT06618339|BEHAVIORAL|Mindfulness-based intervention|8 Session Mindfulness-based intervention
219547208|NCT06356636|BEHAVIORAL|Financial Inclusion Improves Sanitation and Health|This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
219547209|NCT05411276|DRUG|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
219547210|NCT01664767|OTHER|Sulfur Thermal water|
218935764|NCT07158385|OTHER|High fat high protein meal-fat and protein counting (HFHP-b)|On the high-fat, high-protein meal-fat and protein counting test day (HFHP-b), participants were given a high-fat and protein breakfast. In addition to the individual carbohydrate/insulin ratio, insulin was administered according to the adapted Pankowska Algorithm (1 FPU for every 100 kcal after the first 200 kcal of the meal). In this method, the insulin dose calculated based on the individual carbohydrate/insulin ratio was delivered as a standard bolus by an insulin pump, while the insulin dose calculated based on the fat and protein count was delivered as a spread over 4 hours.
218935765|NCT07157410|OTHER|Machinable lithium-disilicate ceramic onlay (IPS e.max CAD)|Single indirect onlay restoration milled from an IPS e.max CAD block and crystallized according to the manufacturer's Instructions for Use, then adhesively luted on a randomized molar under.
218935766|NCT07157410|OTHER|Pressed lithium-disilicate ceramic onlay (IPS e.max Press)|Single indirect onlay restoration heat-pressed from an IPS e.max Press ingot and then adhesively luted on a randomized molar under rubber-dam isolation.
218935767|NCT07157410|OTHER|Machinable composite onlay (BRILLIANT Crios)|Single indirect onlay restoration milled from a BRILLIANT Crios block and then adhesively luted on a randomized molar under rubber-dam isolation.
218935768|NCT07156734|DEVICE|Neuromuscular Electrical Stimulation|Studies in healthy individuals have demonstrated that NMES applied to the quadriceps of one limb induces short-term increases in strength and neural drive in the contralateral homologous muscle. Since these effects have only been observed in healthy individuals, it is essential to investigate whether similar responses occur in ACL patients.
218935769|NCT07158372|DIAGNOSTIC_TEST|AI-assisted Intraoperative Anatomy Analysis|This is a prospective study on patients aged 18 years or more diagnosed with laparoscopic cholecystectomy. We will collect information such as laparoscopic cholecystectomy videos and procedure type, excluding patients who did not undergo surgery at the original hospital or whose videos were blurry.
218935770|NCT07157007|DRUG|Ratutrelvir (83-0060) non-randomised|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
218935771|NCT07157007|DRUG|Paxlovid|Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)
218935772|NCT07157007|DRUG|Ratutrelvir (83-0060)|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
218935773|NCT07157488|BEHAVIORAL|Conventional Physical Therapy With Dual Task Training|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Conventional PT (20 min): Wide leg squatting, hip flexion/extension, hip abduction/adduction, knee extension/flexion with ankle weights (Uysal et al., 2024).~Dual Task Training (20 min): Balance activities (semi-tandem stance, tiptoe, heel stance, one-leg stance, line walking) with cognitive activities (verbal fluency, simple math, memory recall, daily routine recall)."
219047054|NCT04791748|DIAGNOSTIC_TEST|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
219047055|NCT04791748|OTHER|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
219047056|NCT05160337|DIAGNOSTIC_TEST|Biomarker based IVD tests|Biomarker based IVD tests
219047057|NCT04602624|DRUG|SAGE-718|SAGE-718 oral tablets.
219547211|NCT01664767|OTHER|Placebo|
219547212|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
219547213|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
219547214|NCT00000653|DRUG|Zalcitabine|
219547215|NCT06371703|RADIATION|automated system in reducing radiation exposure|evaluate the effectiveness of the automated system in reducing radiation exposure for radiographers involved in PET/CT procedures.
219547216|NCT04925791|DIAGNOSTIC_TEST|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
219547217|NCT04925791|DIAGNOSTIC_TEST|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
219547218|NCT01876992|DRUG|Metformin|
219547219|NCT04911218|DEVICE|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
219547220|NCT04911218|DEVICE|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
219547221|NCT05098223|BEHAVIORAL|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
219547222|NCT03371186|OTHER|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
219547223|NCT03371186|OTHER|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
219547224|NCT03371186|OTHER|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
219547225|NCT03371186|OTHER|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
219547226|NCT03371186|OTHER|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
219547227|NCT02270697|DEVICE|Array|Applications of oligonucleotide array in diagnosis.
219547228|NCT06507176|PROCEDURE|flexible ureteroscopic lithotripsy|This group of patients underwent flexible ureteroscopic lithotripsy.
218935774|NCT07157488|BEHAVIORAL|Dual Task Training With Vestibular Stimulation|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Dual Task Training (20 min): Same as Intervention 1 (balance + cognitive tasks).~Vestibular Stimulation (20 min): Sliding activity on physio roll (10 repetitions) and vertical bouncing on physio roll for 10 minutes (Parashar et al., 2017)."
218935775|NCT07157384|DIETARY_SUPPLEMENT|Low calorie meal replacement plan|intervention provided to both arms in 2 out of the 3 study phases: Phase 1 (total dietary replacement) and Phase 2 (food re-introduction)
219547229|NCT06507176|PROCEDURE|percutaneous nephrolithotomy|This group of patients underwent percutaneous nephrolithotomy.
219547230|NCT05366582|DEVICE|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
219622686|NCT06818045|PROCEDURE|Non Surgical Periodontal Treatment|This procedure will be applied to all patients. All patients received nonsurgical periodontal treatment. Scaling root planing and subgingival debridement were performed.
219622687|NCT06818045|OTHER|Periodontal measurements will be performed|Periodontal measurements will be performed on all patients (plaque index, gingival index, bleeding on probing, periodontal pocket depth, clinical attachment loss).
219622688|NCT06818045|OTHER|biochemical measurements|Serum and gingival crevicular fluid (GCF) samples will be collected from patients for biochemical evaluations.
219622689|NCT06818045|OTHER|No medication will be administered to patients.|No medication will be administered to patients.
218935776|NCT07157384|BEHAVIORAL|Diabetes self management education|intervention provided to both arms throughout study conducted as in-person session and telephone sessions
218935777|NCT07157384|DEVICE|Intermittently scanned continuous glucose monitoring|intervention provided to the intervention arm only: isCGM + LCMR + DSME
218935778|NCT07157384|DEVICE|capillary blood glucose monitoring|intervention provided to the control arm only: CBG + LCMR + DSME
218935779|NCT07157969|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
218935780|NCT07157969|DRUG|Pembrolizumab|200 mg intravenously every three weeks
218935781|NCT07157969|DRUG|Atezolizumab|1200 mg intravenously every three weeks
218935782|NCT07157969|DRUG|Bevacizumab|15mg/kg intravenously every three weeks
218935783|NCT07157969|DRUG|Camrelizumab|200 mg intravenously every three weeks
218935784|NCT07157969|DRUG|Apatinib|250mg once daily
218935785|NCT07157969|PROCEDURE|TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
218935786|NCT07157969|PROCEDURE|HAIC|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
219622690|NCT04064827|DRUG|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
219547231|NCT05366582|DEVICE|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
218935787|NCT07157969|PROCEDURE|DEB-TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
218935788|NCT07156279|BEHAVIORAL|EFT(Emotional Freedom Technique)|EFT is a behavioral intervention in which participants tap with their fingertips on specific acupressure points while focusing on a target issue. The technique is non-invasive, painless, and simple to apply. Sessions also include the use of positive affirmations during tapping.
219547232|NCT00491738|DRUG|bevacizumab|Intravenous repeating dose
219547233|NCT00491738|DRUG|sunitinib|Oral repeating dose
219547234|NCT00491738|DRUG|placebo|Intravenous repeating dose
219547235|NCT00942838|DRUG|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
219547236|NCT00942838|RADIATION|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
219547237|NCT05293106|BIOLOGICAL|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
219547238|NCT05869136|PROCEDURE|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
219622691|NCT06980038|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
218935789|NCT07158099|DRUG|Methylconalamin Injection(WP205)|25 mg intramuscular injection in the upper-arm deltoid
218935790|NCT07158099|DRUG|Methylconalamin for Injection|25 mg intramuscular injection in the upper-arm deltoid
218935791|NCT07158294|OTHER|Peripheral blood withdrawal for BCR::ABL1 mutations testing|Peripheral blood samples taken from patients treated according to clinical practice with resistance to imatinib or 2GTKI therapy according to the ELN recommendations will be shipped to one of the reference laboratories and analyzed by ddPCR using Bio-Rad ADS assays and reagents. Samples will be analyzed in batches of suitable size. ddPCR results will be compared with NGS results. In patients positive for mutations below 20% by ddPCR (low level mutations) peripheral blood sample(s) will be collected every 3 months at subsequent follow-up visits to monitor the kinetics of mutations in relation to therapy continuation or change.
218935792|NCT07156344|DIAGNOSTIC_TEST|Progression and Outcome of Intracranial Atherosclerosis|"Progression and Outcome of Intracranial Atherosclerosis is the primary endpoint; all others are secondary endpoints. Stroke defined as any stroke and new ipsilateral stroke (including ischemic and hemorrhagic stroke) associated with vascular stenosis."
218935793|NCT07158021|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218935794|NCT07158021|OTHER|Electronic Health Record Review|Ancillary studies
218935795|NCT07158021|DRUG|Goserelin|Given SC
218935796|NCT07158021|DRUG|Leuprolide|Given IM
219547239|NCT05869136|PROCEDURE|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
219547240|NCT02694536|DRUG|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
219547241|NCT02694536|DRUG|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
219622692|NCT06980038|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219622693|NCT06980038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622694|NCT06980038|BIOLOGICAL|Cemiplimab|Given IV
219622695|NCT06980038|PROCEDURE|Computed Tomography|Undergo CT scan
219622696|NCT06980038|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219622697|NCT06980038|PROCEDURE|Tumor Resection|Undergo resection surgery
219622698|NCT05562466|DRUG|QMF149|QMF149 75/40 μg o.d via Breezhaler
219622699|NCT05562466|DRUG|Budesonide|Budesonide 200 μg o.d via Breezhaler
219622700|NCT01041924|OTHER|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
219622701|NCT01041924|OTHER|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
219622702|NCT02092870|DRUG|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
219641861|NCT06005285|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model focuses on teaching inside children's play and care activities, carried out within a joint activity structure. Adults follow children's leads into activities, embed teaching objectives inside the play, use the play as the reward, and build targeted skills following developmental science and ABA principles.
219206116|NCT06759909|DRUG|Dapagliflozin (DAPA)|"We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E/'e).~After enrollment, the patients will be treated with dapagliflozin (10 mg/d) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period."
219547242|NCT03368209|DEVICE|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
219547243|NCT06307288|DRUG|minocycline|The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
219547244|NCT06307288|DRUG|tranilast|The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
219547245|NCT05912335|DRUG|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
219547246|NCT00470379|DRUG|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
219547247|NCT04852133|OTHER|Burn subjects|see eligibility criteria
219547248|NCT03515473|DEVICE|cochlear implant|cochlear implant surgery
219206117|NCT06761950|DEVICE|Low Level laser therapy|The patient received low-level laser therapy three times per week for four weeks, with immobilization maintained. The Mustang 2000 Laser device was used with an infrared laser probe to accelerate tendon healing. The device's specifications include peak power output of 15W, power density of 15W/cm2, wave length of 890nm, pulse frequency of 100Hz, spherical size of 0.002cm2, pulse duration of 130 ns, exposure duration of 60 sec, and energy density of 5.85J/cm2.
219547249|NCT00325182|DRUG|Levetiracetam|
219547250|NCT00325182|OTHER|Historical controls|
219547251|NCT00235560|DRUG|rapamycin|sirolimus
219547252|NCT04199494|OTHER|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
219547253|NCT01426360|OTHER|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
219547254|NCT01426360|OTHER|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
219547255|NCT01911429|DRUG|Lurasidone 40 mg|Lurasidone 40 mg once daily
219622703|NCT06490224|BEHAVIORAL|Relevant Patient Reported Outcome Measures (PROMs)|Depending on the participant's complaint: Hip disability and osteoarthritis outcome score JR (HOOS JR), Knee disability and osteoarthritis outcome score JR (KOOS JR), Quick Disabilities of the Arm, Shoulder, and Hand, Quick Disabilities of the Arm, Shoulder, and Hand (QUICKDASH), Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder-7 (GAD7), Patient Self-Efficacy Questionnaire (PSEQ-2), Patient-Reported Outcomes Measurement Information System (PROMIS Global 10)
219622704|NCT06490224|OTHER|My Whole Health Map|Short visual map of responses to 10 questions of subjective measures.
219547256|NCT01911429|DRUG|Lurasidone 80 mg|Lurasidone 80 mg once daily
219641862|NCT06005285|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|Treatment as usual provided by community-based autism agencies
219641863|NCT06431555|DEVICE|MRI|Non-contrast, free-breathing MRI scan
218935797|NCT07158021|OTHER|Questionnaire Administration|Ancillary studies
219547257|NCT01911429|DRUG|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
219547258|NCT00529191|DRUG|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
219547259|NCT00529191|OTHER|Placebo|One out of three subjects will receive a placebo.
219547260|NCT06563284|OTHER|AURORA Mobile App|"Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety."
219547261|NCT03695354|DEVICE|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
219547262|NCT03695354|PROCEDURE|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
219547263|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 1|
219547264|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 2|
219547265|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 3|
219547266|NCT01252758|OTHER|Placebo|
219547267|NCT01252758|DRUG|Albuterol|
219547268|NCT01252758|DRUG|Albuterol|
219547269|NCT03171194|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
219547270|NCT03864094|DRUG|Ephedrine|0,1 mg/kg
219547271|NCT03864094|DRUG|Phenylephrine|1 microg/kg
219547272|NCT03864094|DRUG|Norepinephrine|0,1 microg/kg
219547273|NCT03864094|DRUG|Sodium chloride|0,1 ml/kg
218935798|NCT07156695|PROCEDURE|Deep Marginal Elevation (DME)|Deep Marginal Elevation (DME) is performed by elevating the deep margin of Class II cavities using resin-modified glass ionomer cement (RMGIC), followed by adhesive bonding and placement of a nanofilled composite resin restoration. This procedure improves accessibility of the restorative margin, enhances marginal sealing, and facilitates plaque control.
218935799|NCT07158502|DRUG|TauroPace Cohort|"After sterile opening of the vial, the entire content of TauroPace™ will be poured into single-use sterile trays. Following skin incision, the surgical site will be irrigated with 5 mL of TauroPace™ solution.~The leads, device generator, and fixation sutures will then be thoroughly wiped using sterile gauze soaked in the solution. Once the leads are connected to the generator, the entire system will be treated again with TauroPace™ before being inserted into the pocket.~At the end of the procedure, the final surgical site will be irrigated once more with an additional 5 mL of TauroPace™ using a sterile syringe. A full 100 mL vial of the solution will be used for each patient, ensuring continuous antimicrobial coverage throughout the procedure.~Excess solution will be gently removed prior to surgical wound closure."
219547274|NCT03864094|DRUG|Propofol|2 mg/kg
219547275|NCT03864094|DRUG|Remifentanil|1,7 microg/kg
219547276|NCT01662960|BEHAVIORAL|Mirror therapy|A home-based therapy involving mirrored visual feedback
218935800|NCT07157020|PROCEDURE|ommaya capsule implantation technique|Intervention criteria: Low-threshold intervention group and high--threshold intervention group
218935801|NCT07158034|DEVICE|Lenire Device|The Lenire device is a non-invasive stimulation system designed to reduce the symptoms of chronic subjective tinnitus. It includes a controller that is connected to headphones for sound delivery to the ears and a mouthpiece that provides mild electrical stimulation to the surface of the tongue. Users are recommended to use the device for 60 minutes daily, either in two consecutive 30-minute sessions or at different times throughout the day, for a minimum of 36 hours.
218935802|NCT07154186|OTHER|Coronary Angiographic Assessment|Coronary angiographic assessment will be performed for all patients.
218935803|NCT07157943|OTHER|Abridge AI Scribe|"Users will have access to the Abridge AI scribe software, either integrated into Epic Haiku (Abridge Inside) or via standalone app that send information back to Epic (Abridge Integrated)."
218935804|NCT07157943|OTHER|DAX Copilot|Users will have access to DAX Copilot integrated into Epic Haiku or via standalone app.
218935805|NCT07156773|DRUG|XJN010 Nasal Spray|"In the XJN010 Nasal Spray group, subjects will receive XJN010 Nasal Spray，Based on the frequency of the off periods experienced by Parkinson's patients."
219547277|NCT01662960|BEHAVIORAL|Divider therapy|A home-based therapy involving removed visual feedback.
219547278|NCT06144060|DRUG|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
219547279|NCT06144060|DRUG|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
219547280|NCT00433745|DRUG|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
219547281|NCT00327145|DRUG|valsartan|
219547282|NCT00327145|DRUG|hydrochlorothiazide|
219547283|NCT00327145|DRUG|amlodipine|
219547284|NCT01509391|DRUG|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
219547285|NCT02967926|PROCEDURE|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
219547286|NCT05783089|BIOLOGICAL|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
219547287|NCT02207582|DEVICE|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
218935806|NCT07156773|DRUG|Placebo|"In the XJN010 Nasal Spray blank preparation group, subjects will receive XJN010 Nasal Spray blank preparation, Based on the frequency of the off periods experienced by Parkinson's patients ."
219206118|NCT06761950|DEVICE|Placebo low level laser therapy|Same as in the study group except turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect 3 sessions per week for 4 weeks.
219206119|NCT06761950|OTHER|medical treatment|the patients received their drugs from their treating physicians
219547288|NCT02207582|DEVICE|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
219547289|NCT00625157|DRUG|ASF 1096 0.5 % cream|
219622705|NCT04010565|DIETARY_SUPPLEMENT|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
219622706|NCT04010565|DIETARY_SUPPLEMENT|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
219622707|NCT04817124|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
219622708|NCT04817124|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
219622709|NCT04817124|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
219622710|NCT02621359|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily
219622711|NCT02621359|DRUG|Levofloxacin|Levofloxacin 500 mg once daily
219622712|NCT02621359|DRUG|Doxycyclin|Doxycyclin 100 mg twice daily
219206120|NCT06761950|OTHER|physical therapy program|patients received the traditional program after flexor tendon repair involving isometric exercise, stretching and mobilizations
219206121|NCT06761274|OTHER|peripheral blood sampling|"It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:~* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).~* newly diagnosed (stage II b, III or IV, Ann Arbor Classification)."
219206122|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
219206123|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
219206124|NCT06767371|PROCEDURE|Teeth with irreversible pulpitis|Teeth with irreversible pulpitis to be treated with conventional root canal treatment
219367070|NCT02427347|OTHER|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
219547290|NCT00625157|DRUG|ASF 1096 placebo cream|
219547291|NCT04448730|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
219622713|NCT02621359|DRUG|Omeprazole|Omeprazole 40 mg twice daily
219622714|NCT00779896|DRUG|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
219622715|NCT01383174|BEHAVIORAL|Peer Support Program|"* Work with a trained counselor who is a breast cancer survivor~* Meet 8 times in-person over the 8 week program with the counselor~* Counselor helps participant develop a personalized support program to help her improve her quality of life~* Receives information on breast cancer, its treatments, and stress management"
219622716|NCT01946750|BIOLOGICAL|Serum|
219547292|NCT00422045|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
219547293|NCT02791958|DRUG|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
219547294|NCT02791958|DRUG|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
219622717|NCT01946750|BIOLOGICAL|Stools|
219622718|NCT01946750|BIOLOGICAL|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
219622719|NCT01946750|BIOLOGICAL|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
219622720|NCT04181619|DIETARY_SUPPLEMENT|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session
219622721|NCT04181619|OTHER|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
219622722|NCT01787292|BEHAVIORAL|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
219622723|NCT01787292|BEHAVIORAL|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
219622724|NCT01787292|BEHAVIORAL|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
219047058|NCT04832477|BEHAVIORAL|Stigma counseling for PrEP use|This counseling consists of a single-session (45 minute) delivered by trained peer counselors. The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care. This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health. (2) Evaluating concerns around discussing PrEP with health care providers. The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP. (3) Promoting resiliency beliefs and positive adaptation. For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
219047059|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
219047060|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
219047061|NCT03527420|OTHER|Exercise training|Twelve weeks of aerobic exercise training
219047062|NCT06368492|DRUG|Psilocybin|Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
219047063|NCT06368492|BEHAVIORAL|Hypnosis script|All participants will receive a brief hypnotic induction aimed at producing analgesia before the second administration of CPT
219047064|NCT05182385|DRUG|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
219047065|NCT05182385|DRUG|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
219367071|NCT02427347|OTHER|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
219367072|NCT00002162|DRUG|Saquinavir|
219367073|NCT00002162|DRUG|Lamivudine|
219367074|NCT00002162|DRUG|Stavudine|
219367075|NCT00002162|DRUG|Zidovudine|
219367076|NCT00002162|DRUG|Zalcitabine|
219367077|NCT00002162|DRUG|Didanosine|
219622725|NCT06129448|DIAGNOSTIC_TEST|transthoracic echocardiography|All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
219367078|NCT01966549|DRUG|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
219622726|NCT00828217|OTHER|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
219367079|NCT01966549|DRUG|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
219367080|NCT01232699|BEHAVIORAL|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
219547295|NCT02791958|DRUG|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
219547296|NCT02684331|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
219547297|NCT02684331|OTHER|Echocardiography|Standard measurements and strain.
219547298|NCT02684331|OTHER|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
219206125|NCT06769737|DRUG|Interventional group#1|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) + 3 mcg of Dexmedetomidine HCL, Demexa®, 4mcg/ml (0.75 ml) total volume = 3.55 ml.~The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision. The Bromage score is a clinical scale used to determine motor block during regional anesthesia by evaluating lower limb movement: Grade 0: Full movement of hips, knees, and ankles (no block). Grade 1: Unable to lift the leg but can move knees and ankles (partial block). Grade 2: Unable to bend the knee but can move ankles (near-complete block). Grade 3: No movement in hips, knees, or ankles (complete block). Dermatomal coverage will be assessed simultaneously till it reaches the L1-L2 level. Also, The Ramsay Sedation Scale (RSS) will be used to evaluate the sedation depth, if any."
219206126|NCT06769737|DRUG|Interventional group#2|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) total volume = 2.8 ml.~The intravascular mixture consists of 0.5 mcg/kg of Dexmedetomidine HCL, Demexa®, and a maximum of 30 mcg diluted to 4 mcg/ml. According to body weight, the total volume is 7.5 ml or less and given using a syringe pump over 30 minutes. The anesthesiologist will start the infusion once the patient is positioned supine post-spinal anesthesia and has stable hemodynamics. The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision reaches grade 3: No movement in hips, knees, or ankles (complete block). The anesthesiologist will assess dermatomal coverage until it reaches the L1-L2 and calculate the Ramsay Sedation Scale (RSS) of the depth of sedation aiming for level 2: Patient is cooperative, oriented, and calm"
219206127|NCT06765265|DRUG|Rosuvastatin 20 mg/day|Rosuvastatin 20 mg / Day for 24 weeks
219547299|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
219547300|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
219547301|NCT02659462|OTHER|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
219547302|NCT04662476|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplement
219547303|NCT04125394|DEVICE|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
219547304|NCT00171015|DRUG|valsartan plus hydrochlorothiazide|
219547305|NCT01503658|DRUG|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
219547306|NCT05006131|OTHER|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
219547307|NCT03458845|DIAGNOSTIC_TEST|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
219547308|NCT03534076|OTHER|Cohort Observational study|Cohort Observational study - there is no intervention
219547309|NCT02024230|DRUG|Rivaroxaban or Warfarin|a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
219547310|NCT03810586|DEVICE|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
219547311|NCT02043132|DRUG|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
219547312|NCT02043132|DRUG|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
219547313|NCT00012974|BEHAVIORAL|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
219547314|NCT00012974|PROCEDURE|Provider education, computer reminders, nurse case management|
219622727|NCT06149975|OTHER|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
219622728|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
219622729|NCT02250898|OTHER|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
219547315|NCT03827395|BIOLOGICAL|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
218935807|NCT07156643|DRUG|Anlotinib and bempegaldesleukin|"Subjects will receive concurrent anlotinib, bempegaldesleukin, and radiotherapy, followed by maintenance therapy with anlotinib, bempegaldesleukin, and chemotherapy.~Concurrent Radiotherapy Phase:~Anlotinib: 10 mg orally once daily on days 1-14, every 3 weeks (q3w), for 2 cycles during radiotherapy.~Bempegaldesleukin: 1200 mg IV on day 1, q3w, for 2 cycles during radiotherapy. Radiotherapy: Delivered once daily, with a total biological effective dose (BED) of 36-100 Gy. Techniques may include conventional fractionation or stereotactic body radiotherapy (SBRT), as determined by the investigator.~Maintenance Phase:~Chemotherapy: Doxorubicin 40 mg/m² IV day 1 + ifosfamide 1.2-2.4 g/m² IV days 1-5 per 21-day cycle for 4-6 cycles.~Anlotinib: 10 mg orally once daily on days 1-14, q3w. Bempegaldesleukin: 1200 mg IV on day 1, q3w."
218935808|NCT07158359|BEHAVIORAL|chewing gum mastication|chewing gum mastication
218935809|NCT07156357|DIAGNOSTIC_TEST|Surface Electromyography|Tests performed to evaluate swallowing function
218935810|NCT07156357|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|Assessment of swallowing function
218935811|NCT07157761|BEHAVIORAL|Buit in de klas|The program is taught by a trusted teacher of the students (for example, their mentor). The program consists of a lesson of about one hour. It includes a short film and an interactive chat box that allows students to chat with the main character of the film. In addition, there is a guideline for discussing the topic in the classroom and information on where to find help.
218935812|NCT07156240|BEHAVIORAL|Experimental I (SDT)|SDT-based course aiming to inmprove professionals operational interpersonal qualities
218935813|NCT07156240|BEHAVIORAL|Experimental II (Hedonic)|Hedonic-based course aiming to inmprove professionals operational interpersonal qualities
218935814|NCT07156240|OTHER|Control group|FITT-VP bases course aiming to improve exercise prescription
218935815|NCT03474965|DRUG|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
218935816|NCT07157332|PROCEDURE|Bariatric Sleeve Surgery|Participants undergo a restrictive bariatric procedure called sleeve gastrectomy, performed by experienced surgeons. This procedure involves surgical reduction of the stomach size to aid in weight loss. The study observes outcomes related to iron metabolism, body composition, and biochemical markers over six months post-surgery. No additional interventions or treatments are applied as part of the study protocol; the surgery is part of routine clinical care.
218935817|NCT03229941|PROCEDURE|Blood Transfusion|Blood Transfusion
218935818|NCT06303063|DEVICE|SINOMED IAS Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
218935819|NCT06303063|DEVICE|Neuroform Atlas Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
218935820|NCT03847428|DRUG|Durvalumab|Durvalumab IV (intravenous)
218935821|NCT03847428|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
218935822|NCT03847428|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
218935823|NCT04951947|DRUG|JS201 combine with Lenvatinib|JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
218935824|NCT01671917|OTHER|Educational and exercise program|"* 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour"
219547316|NCT03827395|OTHER|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
218935825|NCT01671917|OTHER|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
218935826|NCT03270579|DRUG|[18F]JNJ-64511070|An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
218935827|NCT02832362|DRUG|Carbomer 980|Test product containing 0.5% carbomer 980 gel
219047066|NCT03508219|DEVICE|BiOSS LIM C|"The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems."
219047067|NCT06974565|DRUG|AZD2389|AZD2389 will be administered orally.
219047068|NCT06974565|DRUG|Quinidine|Quinidine will be administered orally.
218935828|NCT02832362|OTHER|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
218935829|NCT00229385|DRUG|Ziprasidone|40-80 mg BID
218935830|NCT03795246|PROCEDURE|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
218935831|NCT03795246|BIOLOGICAL|Biological Test|"Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL"
218935832|NCT03795246|PROCEDURE|Pelvic Ultrasound|Antral Follicles Count
218935833|NCT04800770|DIAGNOSTIC_TEST|4C mortality score|4C mortality score and phosphate levels
218935834|NCT03007641|BEHAVIORAL|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
219047069|NCT03878199|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
219047070|NCT03878199|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219547317|NCT04267692|OTHER|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
219547318|NCT05324033|RADIATION|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
219547319|NCT05324033|PROCEDURE|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
219547320|NCT04150133|OTHER|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
219547321|NCT05866588|BEHAVIORAL|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"1. Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~2. Follow-up: Providing education and counseling for childbirth.~3. Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~4. Follow-up: To provide counseling on the issues needed with the approaching of the birth.~5. Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~6. Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~7. Follow-up: To evaluate the transition to motherhood.~8. Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
219547322|NCT01112722|BIOLOGICAL|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
219547323|NCT01112722|BIOLOGICAL|histamine|imitates pain and erythema of honeybee venom
219547324|NCT00158925|DEVICE|EASYTRAK EPI lead|EASYTRAK EPI lead
219547325|NCT04257838|DRUG|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
219547326|NCT03431636|OTHER|immersion|cold water immersion
219547327|NCT03431636|OTHER|ice pack|ice packs through the body
219547328|NCT03431636|OTHER|rest|seated rest
219547329|NCT01484912|DRUG|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
219547330|NCT01484912|DRUG|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
219547331|NCT00773149|DRUG|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
219547332|NCT00796341|PROCEDURE|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
219547333|NCT01150422|OTHER|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
219547334|NCT00921674|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
219547335|NCT05154890|DRUG|Pegtarviliase IV|Administered IV
219547336|NCT05154890|DRUG|Pegtarviliase SC|Administered SC
219547337|NCT04165252|DIAGNOSTIC_TEST|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
219547338|NCT03129685|PROCEDURE|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
219547339|NCT02584907|OTHER|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
219047071|NCT03878199|DRUG|Ruxolitinib|Given PO
219547340|NCT03089983|DRUG|Methadone|Participants will receive daily or weekly doses of oral methadone.
219047072|NCT05711927|DEVICE|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
219047073|NCT05711927|DEVICE|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
218935835|NCT03007641|BEHAVIORAL|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
218935836|NCT00094484|DRUG|Cinacalcet HCl|
218935837|NCT04136015|DRUG|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
219047074|NCT06310707|DEVICE|ePatch ® Extended Wear Holter (EWH)|"Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied"
219047075|NCT06635876|BEHAVIORAL|Coaching Sessions|"The coach will use motivational interviewing techniques to:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT"
219047076|NCT05526989|DRUG|Dostarlimab|300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
219047077|NCT05526989|DRUG|Niraparib|200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
219047078|NCT04563884|OTHER|Questionnaires|"Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart."
219047079|NCT02696551|OTHER|Medical education|
219047080|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
219047081|NCT05480566|OTHER|Functional strength training|Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.
219047082|NCT05480566|DEVICE|NMES|For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
219047083|NCT05480566|DRUG|Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)|Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
219047084|NCT05480566|OTHER|Routine physiotherapy|Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
219047085|NCT07130058|DIETARY_SUPPLEMENT|GI Product Form - Control|Participants will use their GI Health Product Form - Control as directed for a period of 6 weeks
219047086|NCT07130058|DIETARY_SUPPLEMENT|GI Health Product Form - Active|Participants will use their GI Health Product Form - Active as directed for a period of 6 weeks
219047087|NCT06343363|BEHAVIORAL|Early discharge protocol|Patients admitted for transcatheter edge-to-edge repair to either mitral or tricuspid valve and then discharged within 36 hours
219047088|NCT03069378|DRUG|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
218935838|NCT04900532|DIETARY_SUPPLEMENT|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
219047089|NCT03069378|DRUG|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
219047090|NCT06977451|DRUG|nL-CHCHD-001|Personalized Antisense Oligonucleotide
219047091|NCT06979180|DIETARY_SUPPLEMENT|Papillex®|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
219047092|NCT06979180|OTHER|Placebo|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
219047093|NCT06842836|OTHER|Study intervention|From the date of study authorization, the principal investigator, together with his specially identified collaborators, will proceed to identify patients who meet the inclusion criteria. Then, during the first follow-up visit, the principal investigator, or one of his co-investigators, will deliver the informed consent to the parent(s) of the minor subject candidate for enrollment in the study, explaining all the characteristics and evaluations stipulated in the protocol and answering any questions. After the informed consent is signed, patients will be enrolled and the data required to conduct the study will be collected, and a fecal sample will be requested specifically for the conduct of the study. At the same time, completion of the KIDMED (Mediterranean Diet Quality Index in children and adolescents) questionnaire will be requested.
219047094|NCT02598180|DEVICE|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
219047095|NCT05849467|DRUG|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
218935839|NCT04900532|DIETARY_SUPPLEMENT|Placebo|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
218935840|NCT01027806|DRUG|Montelukast|1 pill per day for 4 months
218935841|NCT06231771|DRUG|Allogeneic mesenchymal stem cells (MSCs)|Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
219547341|NCT03089983|DRUG|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
219547342|NCT03089983|DRUG|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
219547343|NCT05992454|DEVICE|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
219547344|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
219547345|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
219047096|NCT06592274|BIOLOGICAL|HB0017|300mg Q12W
219047097|NCT06592274|BIOLOGICAL|HB0017|300mg Q8W
219547346|NCT04403347|DIETARY_SUPPLEMENT|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
219547347|NCT04403347|DRUG|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
219547348|NCT02287480|BIOLOGICAL|VSV-ZEBOV|See arm/group descriptions.
219547349|NCT02728999|PROCEDURE|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
219547350|NCT02728999|PROCEDURE|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
219547351|NCT05289440|DRUG|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
219547352|NCT05289440|DRUG|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
219547353|NCT05289440|DRUG|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
219547354|NCT04501848|PROCEDURE|adenotonsillectomy|adenotonsillectomy surgery
219622730|NCT02250898|OTHER|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
219622731|NCT04421560|DRUG|Ibrutinib|Capsule, taken by mouth daily
219622732|NCT04421560|DRUG|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
219622733|NCT04421560|DRUG|Rituximab|Given as infusion into a vein (intravenous, IV)
219622734|NCT06605105|DRUG|CYB003|CYB003 is a deuterated psilocin analog
219622735|NCT03142737|OTHER|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
219622736|NCT03142737|OTHER|Eggs intake|Each participant will consume 2 cooked large eggs.
219622737|NCT03142737|OTHER|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
219547355|NCT05497063|DRUG|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
219547356|NCT05497063|DRUG|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
219622738|NCT03142737|OTHER|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
219547357|NCT06272617|DEVICE|verum acupuncture|a type of acupuncture which is useful
219547358|NCT06272617|DEVICE|sham acupuncture|a type of acupuncture which is useless
219622739|NCT03142737|OTHER|Intact beef intake|Each participant will consume 2 ounces of intact beef.
219622740|NCT06988553|DRUG|AZD5004|AZD5004 will be administered as an oral tablet once daily.
219622741|NCT06988553|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
219622742|NCT06613438|DEVICE|eGERD device|"The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user."
219622743|NCT06613438|DEVICE|eGERD_Sham|The eGERD\_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD\_Sham is identical to the eGERD device.
219622744|NCT01924689|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
219622745|NCT04585958|PROCEDURE|Biopsy Procedure|Undergo biopsy
219047098|NCT06592274|BIOLOGICAL|HB0017|150mg Q4W
219047099|NCT05764564|DIAGNOSTIC_TEST|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
219047100|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
219047101|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
219047102|NCT06095115|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
219047103|NCT06095115|DRUG|Placebo|Placebo will be administered orally
219206128|NCT06765265|DRUG|Atorvastatin 40 mg|Atorvastatin 40mg / Day for 24 weeks
219547359|NCT02235922|OTHER|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
219547360|NCT02235922|OTHER|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
219547361|NCT04967469|DRUG|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
219547362|NCT04967469|DRUG|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
219547363|NCT02991196|DRUG|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
219547364|NCT03198663|BEHAVIORAL|POSSE|Popular-opinion leader
219547365|NCT00293878|DRUG|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
219547366|NCT00979147|PROCEDURE|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
219547367|NCT00979147|PROCEDURE|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
219547368|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
219547369|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
219547370|NCT02674711|BEHAVIORAL|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
219547371|NCT04567329|DRUG|NOV03|100% perfluorohexyloctane
219547372|NCT04567329|DRUG|Saline Solution|0.6% sodium chloride solution
219547373|NCT00137644|BEHAVIORAL|Preventing AIDS Through Live Movement and Sound (PALMS)|
219547374|NCT04637360|DRUG|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
219547375|NCT04637360|DRUG|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
219547376|NCT00211562|DRUG|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
219547377|NCT06311929|DRUG|PD-1 monoclonal antibody and lenvatinib|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
219622746|NCT04585958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219622747|NCT04585958|PROCEDURE|Computed Tomography|Undergo CT
219547378|NCT06311929|DRUG|PD-1 monoclonal antibody|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
219547379|NCT02399462|DRUG|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
219622748|NCT04585958|PROCEDURE|Echocardiography Test|Undergo echocardiography
219547380|NCT02373462|DRUG|Olmesartan|
219547381|NCT02373462|DRUG|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
219547382|NCT00339157|DRUG|Anakinra|
219547383|NCT00339157|BIOLOGICAL|Pneumo23|
219547384|NCT04249765|OTHER|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3\. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
219547385|NCT00185757|DRUG|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
219547386|NCT01659073|PROCEDURE|Caloric Vestibular Stimulation|
219622749|NCT04585958|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219622750|NCT04585958|DRUG|Olaparib|Given PO
219622751|NCT04585958|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219622752|NCT05326750|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
219622753|NCT05793164|OTHER|no intervention|no intervention
219622754|NCT01790074|OTHER|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
219622755|NCT01790074|OTHER|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
219622756|NCT00063011|BEHAVIORAL|Calcium rich diet|
219622757|NCT00063011|BEHAVIORAL|Weight bearing exercise|
219622758|NCT03267212|DEVICE|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
219622759|NCT03267212|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
219622760|NCT03267212|OTHER|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
219622761|NCT01560975|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
219547387|NCT05576831|PROCEDURE|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
219547388|NCT01323491|DRUG|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
219547389|NCT05174390|DIAGNOSTIC_TEST|Coala Heart Monitor Pro|thumb- and chest-ECG
218935842|NCT06231771|DRUG|Normal Saline|Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
218935843|NCT00295386|BEHAVIORAL|Cognitive behavior therapy (CBT)|
219547390|NCT01003938|DRUG|Topotecan|
219547391|NCT01003938|DRUG|Erlotinib|
219547392|NCT03583398|PROCEDURE|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
219547393|NCT05860777|OTHER|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
219547394|NCT00674128|DEVICE|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
219547395|NCT00674128|DEVICE|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
219622762|NCT05481632|OTHER|Endoangel assisted the process of colonoscopy|Endoangel assisted doctors to detect polyps
219622763|NCT05481632|OTHER|Colonoscopy was performed without endoangel assistance|Polyps were detected without ENDOANGEL assistance
218935844|NCT00295386|DRUG|Zopiclone|
218935845|NCT01186172|DRUG|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
218935846|NCT01186172|DRUG|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
218935847|NCT00409669|DEVICE|Barraquer tonometer|barraquer tonometer
218935848|NCT01264705|DRUG|bavituximab (0.3 mg/kg) and sorafenib|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
219547396|NCT01512628|DRUG|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
219547397|NCT04224753|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
219547398|NCT05614453|DRUG|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
219547399|NCT05614453|DRUG|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
219547400|NCT01572051|BEHAVIORAL|Educational Course|2 Educational courses
219547401|NCT01572051|BEHAVIORAL|Phone Calls|Phone Calls
219547402|NCT01572051|BEHAVIORAL|Printed Material|Printed Material
219547403|NCT03147053|DRUG|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
219547404|NCT03147053|DRUG|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
219547405|NCT03209505|DEVICE|Acuvue Oasys|FDA approved contact lens, fit for daily wear
219547406|NCT03209505|DEVICE|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
219547407|NCT04431505|OTHER|apoptosis|study of apoptotic changes due to anaesthesia
219547408|NCT06562920|DRUG|adebrelimab and chemotherapy|3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
219547409|NCT04285268|DRUG|Bortezomib|Given IV or SC
219547410|NCT04285268|BIOLOGICAL|Rituximab|Given IV
219547411|NCT04285268|DRUG|Venetoclax|Given PO
219547412|NCT01791751|DRUG|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
219547413|NCT02412358|DEVICE|toothbrush|
219547414|NCT03717701|DRUG|metformin|Patients will take metformin single dose of 1000 mg orally once a day
219547415|NCT03717701|DRUG|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
219547416|NCT03717701|DRUG|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
219547417|NCT04987554|DIETARY_SUPPLEMENT|glycophosphopeptical AM3|3 g/day of AM3
219547418|NCT04987554|OTHER|Placebo|3 g/day of placebo
219622764|NCT04106427|DEVICE|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
219622765|NCT04106427|DEVICE|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
219622766|NCT04106427|BEHAVIORAL|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
219622767|NCT04106427|BEHAVIORAL|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
219547419|NCT04888767|OTHER|Interval Training Hight Intensity Program|"* Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
219547420|NCT00829452|DRUG|Ramipril 10 mg capsule|1 x 10 mg
219547421|NCT00829452|DRUG|Altace® 10 mg capsule|1 x 10 mg
219547422|NCT05239585|DEVICE|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
219547423|NCT00991796|DRUG|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
219547424|NCT00991796|DRUG|Placebo|Placebo
219547425|NCT00991796|DRUG|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
219047104|NCT06808828|BEHAVIORAL|Health and coping skills|An occupational therapist and occupational therapy graduate capstone student will lead in-person sessions. Subjects will participate in an occupational therapy program that meets 2x/week x 4 weeks for eight sessions. Topics will include sleep hygiene, physical activity, healthy cooking, self-management, coping skills, self-esteem, mindfulness, and goal setting. Subjects will receive education as well as actively engage in activities related to the topic. Subjects will be provided with a personal journal to complete homework involving reflections on the topics discussed in the sessions.
219547426|NCT00991796|DRUG|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
219547427|NCT00740896|BEHAVIORAL|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
219547428|NCT00740896|BEHAVIORAL|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
219547429|NCT06561308|DRUG|Pucotenlimab|Pucotenlimab is administered at 200mg, q3w，intravenous infusion
219622768|NCT04208100|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
219622769|NCT05575973|DRUG|Mitoxantrone Hydrochloride Liposome|Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
219622770|NCT05575973|DRUG|Rituximab|Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
219047105|NCT04331158|OTHER|Dry cupping therapy|Dry cupping therapy application on the patient's skin
219047106|NCT06806267|DEVICE|Virtual reality exposure therapy|Exposure therapy applied through virtual reality goggles, controlled by a clinician
219047107|NCT06806267|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied to the vmpfc, 2mA
219047108|NCT06806267|BEHAVIORAL|Imaginal exposure therapy|Imaginal exposure therapy
219047109|NCT06581263|DEVICE|Meta Quest 3|Meta Quest 3 is a virtual reality headset device
219047110|NCT06807190|DRUG|Insulin Icodec|Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.
219047111|NCT03841149|OTHER|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
219047112|NCT06807411|OTHER|Conventional exercise|Participants in the conventional exercise group will receive a total of 24 sessions of conventional therapy over 8 weeks (3 days per week, 30-minute sessions).
219547430|NCT06561308|DRUG|Carboplatin|AUC=4-6，q3w，intravenous infusion
219547431|NCT06561308|DRUG|Paclitaxel|175 mg/m2，q3w，intravenous infusion, administered over 30min.
219622771|NCT05575973|DRUG|Lenalidomide|Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.
219622772|NCT07008599|OTHER|Pulpal Blood Sample|Biochemical markers were measured in blood samples using enzyme-linked immunosorbent assay (ELISA).
219047113|NCT06807411|OTHER|Video game based exercise|The video-based game exercise group will undergo the same conventional therapy, with an additional video game-based exercise program using the Becure Extremity ROM device under physiotherapist supervision. The program will include KinectPong, KinectBalloon, ArmRotate, and Uball games. Balance, joint position sense, ROM, functionality, and quality of life parameters will be assessed before and after treatment.
219047114|NCT06683729|DEVICE|Trans-septal (TS) Mitral Valve Replacement (TSMVR) Valve system|Trans-catheter, trans-septal mitral valve replacement.
219047115|NCT06084013|OTHER|Non-Interventional Study|Non-interventional study
219047116|NCT07024212|DRUG|DR10624 Injection|Drug: DR10624 injection
219047117|NCT07024212|DRUG|Placebo|Drug: Placebo
219547432|NCT06561308|PROCEDURE|Surgery|Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection
219547433|NCT04431518|DRUG|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
219547434|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
219547435|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
219547436|NCT05841654|DRUG|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
219206129|NCT06766682|BEHAVIORAL|The Skill Development Program for Emotion Regulation|The Skill Development Program for Emotion Regulation to be carried out with the intervention group was planned as 6 sessions. The aim of this study was to investigate The Skill Development Program for Emotion Regulation Program on oncology nurses' emotion regulation difficulties, emotion regulation skills, experiential avoidance, and compassion fatigue.
219206130|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 1|Intervention: need support, two-month face-to-face and web-based need-supportive intervention program for PE teachers.
219206131|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 2|Intervention: autonomy or competence or relatedness support, one-month face-to-face and web-based need-supportive intervention program for PE teachers.
219547437|NCT04070898|PROCEDURE|Remove urinary catheter after surgery|Remove bladder catheter after surgery
219547438|NCT03331458|BEHAVIORAL|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
219547439|NCT05854563|OTHER|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
219547440|NCT02705716|OTHER|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
219547441|NCT02705716|OTHER|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
219547442|NCT06057558|BIOLOGICAL|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
219547443|NCT01457196|DIAGNOSTIC_TEST|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
219547444|NCT02364986|DRUG|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
219547445|NCT02364986|DRUG|Avonex|Avonex 30µg (day 1 and 8) i.m.
219547446|NCT00006516|BEHAVIORAL|Infant stimulation|
219547447|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
219622777|NCT06411223|BEHAVIORAL|Collaborative drug therapy management model|CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
219622778|NCT06411223|DRUG|Cabotegravir/Rilpivirine|Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
218935849|NCT01264705|DRUG|bavituximab (1.0 mg/kg ) and sorafenib|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
218935850|NCT01264705|DRUG|bavituximab (3.0 mg/kg) and sorafenib|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
218935851|NCT04096599|OTHER|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
218935852|NCT04096599|OTHER|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
218935853|NCT00367614|DRUG|pantoprazole|
219547448|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
219547449|NCT03485118|DRUG|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
219547450|NCT02517424|DRUG|High THC/Low CBD Cannabis|Dried cannabis
219547451|NCT02517424|DRUG|High THC/High CBD Cannabis|Dried cannabis
218935854|NCT00068861|DRUG|metformin XR|
218935855|NCT00068861|DRUG|clomiphene citrate|
219206132|NCT06769321|DEVICE|Automatic Thermo-mechanical Massage Bed|The MASTER V6 (Master series, CGM MB-1701, CERAGEM Co. Ltd., Cheonan, Korea) used in this study is a commercially available automated thermo-mechanical therapy device that combines mechanical spinal stimulation with far-infrared (FIR) heat treatment.
219547452|NCT02517424|DRUG|Low THC/Low CBD Cannabis|Dried cannabis
219622779|NCT04444440|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic.
219622780|NCT04444440|OTHER|Placebo Pill|Placebo Pill
219622781|NCT06873009|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Smoking Cessation|"A structured three-session group intervention (1.5 hours per session over three weeks) using cognitive-behavioral and motivational strategies to enhance motivation, manage cravings, and prevent relapse.~Associated Arm: CBT Group"
219622782|NCT06873009|OTHER|Health Education Session on Tobacco Use|"A single-session group intervention (1 hour) providing information on the health risks of tobacco use, addiction mechanisms, and the long-term benefits of quitting smoking.~Associated Arm: Health Education Group"
219622783|NCT07013630|DIETARY_SUPPLEMENT|Clarity Placebo Control|Participants will use their Clarity Placebo Control as directed for a period of 6 weeks.
219622784|NCT07013630|DIETARY_SUPPLEMENT|Clarity Active Product|Participants will use their Clarity Active Product as directed for a period of 6 weeks.
219547453|NCT04677517|DEVICE|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
219547454|NCT04677517|BEHAVIORAL|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
219547455|NCT04677517|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
219547456|NCT04677517|BEHAVIORAL|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
219547457|NCT04677517|BEHAVIORAL|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
219622785|NCT06683534|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
219622786|NCT06683534|DRUG|Placebo|Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
219622787|NCT00156403|DRUG|amlodipine (drug)|
219047118|NCT07024498|OTHER|care coordination implementation strategies|The intervention will be a bundle of implementation strategies developed during a prior study and informed by the multi-team systems framework. Core implementation strategies are expected to include a standardized ED substance use navigator note (with education and billing support), a mechanism for sharing PHI information across ED-clinic pairs that use different electronic health record systems, an improved ability for patients to directly contact EDs and clinics, ensuring ED and outpatient teams mutually understand each other roles, implementing procedures to increase capacity for same-day outpatient buprenorphine refills, and interactive problem solving with an external facilitation team. Strategies will be adapted to local contexts at each site.
219047119|NCT07024628|OTHER|Heat adaptation digital messaging|Digital messages to equip and prepare patients for extreme heat events. The first message will to encourage patients to prepare by creating a heat safety plan, and to form Check-in Companion groups among friends, neighbours, and relatives as well as to connect patients with existing key infrastructure that can be vital during heat events (ex: cooling stations and public facilities with air conditioning). When a heat-advisory is announced, additional messages will be sent to alert patients in the Treated group to activate their heat safety plans.
219047120|NCT07024628|OTHER|Non-heat-related digital messaging|Digital health promotion messages not related to heatwaves
219047121|NCT04745689|DRUG|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
219047122|NCT04745689|DRUG|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
219047123|NCT04745689|DRUG|Carboplatin|IV infusions through induction phase if chosen by Investigator.
219047124|NCT04745689|DRUG|Cisplatin|IV infusions through induction phase if chosen by Investigator.
219047125|NCT04745689|DRUG|Etoposide|IV infusions through induction phase.
219047126|NCT07025200|DRUG|Dupilumab|Clinical assessment, lung function, CT-scans and Bronchoscopy prior to and 22 weeks after initiation of Dupilumab.
219206133|NCT06831981|OTHER|Hyperthermia|Additional hyperthermia to radiochemotherapy regime in Arm 1 and radiochemotherapy without additional hyperthermia in Arm 2.
219206134|NCT06831981|RADIATION|Radiotherapy|Radiotherapy of the pelvis
219206135|NCT06831981|DRUG|Chemotherapy with 5-fluorouracil|Chemotherapy with 5-flurouracil is given in parallel to radiotherapy
219547458|NCT06627881|OTHER|Continuous aerobic kayak training program|Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
219622788|NCT03212274|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219622789|NCT03212274|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622790|NCT03212274|PROCEDURE|Computed Tomography|Undergo a CT scan
219622791|NCT03212274|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
219622792|NCT03212274|DRUG|Olaparib|Given PO
219622793|NCT04123431|DEVICE|Total Hip Replacement|Primary elective total hip replacement
219622794|NCT06681181|DRUG|GSK4528287|GSK4528287 will be administered.
219622795|NCT06681181|DRUG|Placebo|Placebo will be administered.
219206136|NCT06831981|DRUG|Consolidation chemotherapy with FOLFOX|Consolidation chemotherapy with 5-fluorouracil and oxaliplatin
219206137|NCT06757556|OTHER|Non-starchy vegetables will be provided to the participants as an intervention.|Intervention will consist of provision of vegetables (based on WHO criteria of 2-3 servings) to overweight and obese adults fo weight loss purpose.
219206138|NCT06757699|OTHER|Walking|"Participants will perform 30 minutes of walking and cycling exercises. During the cycling and walking exercises, heart rate will be calculated using the Karvonen formula based on heart rate reserve.~HRmax (maximum heart rate)=220-age HRR (%)(heart rate reserve)= (HR-HRrest)/(HRmax-HRrest)\*100~Blood samples will be collected from participants before starting the exercise, at the end of the 30-minute exercise session, and twice more at 30-minute intervals. The same participants will perform the cycling exercise half an hour later, and the same procedures will be applied."
219206139|NCT06757699|OTHER|Cycling|Cycling
219206140|NCT06755749|BEHAVIORAL|Family Planning Education|"Stage 1 (Day 1, 10-15 min): The education content for Session 1 in the FP Education Booklet prepared by the researchers was provided to the participants using the face-to-face interview method. After making an appointment for Stage 2 (Day 3) to be carried out at the FHC, the first stage of the data collection process was complete.~Stage 2 (Day 3, 10-15 min): The education content for Session 2 in the FP Education Booklet was provided to the participants who arrived at the FHC on their predetermined appointment days using the face-to-face interview method. After making an appointment for Stage 3 (Day 7) to be carried out at the FHC, the second stage of the data collection process was complete.~Stage 3 (Day 7, 1-5 min): The data collection forms were administered again to the participants who arrived at the FHC on their appointment days assigned at Stage 2, and the data collection process was complete."
219206141|NCT06757088|DEVICE|M1 Stimulation Group|For M1, the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
219206142|NCT06757088|DEVICE|Cerebellar Stimulation Group (CbSG)|For the Cerebellar Stimulation Group, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below the inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle
219547459|NCT06627881|OTHER|Aerobic Endurance Circuit Program|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
219047127|NCT07023770|BEHAVIORAL|specific lateropulsion rehabilitation program (exoskeleton + specific physiotherapy orientation rehabilitation)|"5 times a week during 30 minutes sessions = 15 Physiotherapy sessions, focused on the active vertical body orientation in the frontal plane and comprising exoskeleton-assisted balance and gait exercises.~\+ 5 times a week during 30 minutes sessions = 15 conventional physiotherapy without exercises dedicated to lateropulsion or verticality representation alleviation The intervention description is more extensive in the study description section"
219047128|NCT07023770|BEHAVIORAL|Conventional physiotherapy without without exercises dedicated to lateropulsion or verticality representation alleviation|10 times a week, during 30-minutes
219047129|NCT03738410|BEHAVIORAL|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
219047130|NCT03738410|OTHER|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
219047131|NCT07024810|OTHER|remote ischemic preconditioning|Participants randomized to the PIR intervention group will receive a hand-held blood pressure device (Welch Allyn DuraShock™ DS45, NY, USA) to self-administer PIR. The cuff will be placed around the upper arm and inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, and this cycle will be repeated another three times. This process will be performed 5 days a week for 3 months. The arm on which participants will apply the PIR is the left arm. Participants will be supervised during their first PIR session and every 15 days to ensure that it is performed correctly and, they will be free to perform the PIR at any time during the day and will record it in a diary to monitor compliance. Participants will be instructed to follow their normal routine and refrain from engaging in any new physical activity or changing their eating habits.
219047132|NCT07025499|BEHAVIORAL|Group ICT Intervention|Participants will be given access to a tablet. With this technology, participants will be invited to set personal goals related to using this technology to foster social connection and community participation. Participants will attend a group led by two occupational therapy students and an occupational therapist focused on digital literacy and how to use technology to meet their goals. In the group, participants will learn how to use their device and how to safely access various online resources and tools to support their recovery. Participants will keep their provided devices upon conclusion of the group sessions. Participants will complete quantitative outcome measures at the start and end of the group intervention. Participants will be invited to attend a semi-structured interview one month after the completion of the group about their experiences with the program.
219047133|NCT07024511|OTHER|Auricular acupuncture|Auricular acupuncture
219047134|NCT07024511|OTHER|Acupuncture|Acupuncture
219047135|NCT06714513|BIOLOGICAL|QTP101|QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
219047136|NCT06714513|BIOLOGICAL|Placebo|Sterile 0.9% normal saline
219047137|NCT06878677|OTHER|Data-driven exercise|"The result from the Statistical Parametric Mapping 1D (SPM1D) analysis will be used to identify the magnitude of deviation from normal gait patterns in reference to healthy subjects for each lower limb joint. Thereby, the targeted action and joint position can be identified. Training will focus on the specific movement where the steepest gradients are observed.~The targeted exercises will be selected based on the five largest deviations observed during the swing or stance phase. Open-chain exercises will be applied to address deviations in the swing phase, while closed-chain exercises will be applied to address deviation in the stance phase. Each exercise will be performed for approximately 80-100 repetitions, with a total duration of 10 minutes per exercise, including rest periods."
219047138|NCT06878677|BEHAVIORAL|Standardized exercises|The participants will perform dose match standardised exericse program.
219047139|NCT06711965|PROCEDURE|Standard of care reconstruction|Participants will receive standard of care reconstruction
219047140|NCT06711965|PROCEDURE|Surgery, Breast Mold|Participants will undergo surgery. The surgeon may utilize the custom breast mold in shaping the autologous tissue flap for particiapnts.
219047141|NCT06881472|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|GIP
219047142|NCT06881472|DRUG|alanine|Alanine
219206143|NCT06757088|COMBINATION_PRODUCT|M1 + Cerebellar Stimulation Group|In M1, the anodal electrode will be placed over the M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region whereas simultaneously for the CbSG, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle.
219206144|NCT06757088|DEVICE|Sham Stimulation Group|In Sham stimulation, Electrodes will be placed according to M1 Stimulation i.e., the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
219622796|NCT06680258|DRUG|TPST-1120|TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
219047143|NCT06881472|DRUG|Saline (NaCl 0,9 %) (placebo)|Placebo
219047144|NCT06719219|BIOLOGICAL|LTB-SA7|LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.
219047145|NCT06719219|BIOLOGICAL|Placebo|Sodium Phosphate with Sodium Chloride
219047146|NCT06728293|OTHER|Liver Link|Support Program
219047147|NCT07042672|DRUG|GLP-1|Subcutaneous GLP-1 receptor agonist prescribed for weight management according to routine clinical practice. Acceptable agents include liraglutide (up-titrated to ≤ 3.0 mg daily), semaglutide (≤ 2.4 mg weekly), or tirzepatide (≤ 15 mg weekly). Dose escalation and maintenance follow approved product labels and treating-physician judgment. Planned treatment duration: 12 months or longer.
219047148|NCT07042672|BEHAVIORAL|CBTe Group Therapy|Ten weekly 2-hour group sessions based on Cognitive Behavioral Therapy-Enhanced (CBT-E) plus individualized lifestyle consultations every 4 months over a 12-month period. Content targets eating patterns, weight-management behaviors, and emotion-regulation skills. Delivered by trained multidisciplinary staff at the Obesity Centre.
219047149|NCT06885177|DEVICE|Experimental|Participants will receive treatment with Abbott's Coronary IVL System followed by stenting.
219622797|NCT06680258|BIOLOGICAL|Atezolizumab|Atezolizumab is an IV administered biologic.
219622798|NCT06680258|BIOLOGICAL|Bevacizumab|Bevacizumab is an IV administered biologic.
219622799|NCT06874322|OTHER|Voiceitt|Participants will use Voiceitt App
219047150|NCT06310031|DEVICE|BrioVAD System|Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
219047151|NCT06310031|DEVICE|HeartMate 3|Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
219047152|NCT06889857|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|This study will involve informed consent, a 12-week observation period, a 12-week study drug administration period, and a 4-week follow-up period.
219047153|NCT06890026|DRUG|Faricimab Injection [Vabysmo]|The procedures were carried out according to the local standard protocol, which involved applying 2-3 drops of topical tetracaine anesthesia, using an eye speculum, disinfecting with 5% povidone-iodine, employing a 33G needle, marking the injection site 3.5 mm posterior to the limbus with calipers in either the superotemporal or inferotemporal quadrant, applying a sterile cotton tip for tamponade after needle removal, and omitting post-procedure antibiotics.
219206145|NCT06776991|BEHAVIORAL|Positive Affect Treatment - Behavioral (PAT-B)|8 therapy sessions conducted individually with a therapist. Focuses on improving reward processing to increase positive emotional experience. Specific techniques include psychoeducation on mood cycle and positive emotions, mood monitoring, behavioral activation, and imaginal recounting and savoring of behavioral activation events. Intervention includes between-session practice.
219206146|NCT06776991|BEHAVIORAL|Relaxation Treatment|8 therapy sessions conducted individually with a therapist. Focuses on mindfulness and relaxation skills. Specific techniques include mindfulness approaches from dialectical behavior therapy, diaphragmatic breathing, and progressive muscle relaxation. Intervention includes between-session practice.
219367081|NCT01232699|BEHAVIORAL|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
219367082|NCT01232699|BEHAVIORAL|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
219367083|NCT03190408|OTHER|Fluids|Fluids Administered in Shock
219367084|NCT02893345|BEHAVIORAL|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
219367085|NCT02893345|OTHER|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
219622800|NCT05691712|DRUG|Tirzepatide|Administered SC
219622801|NCT05691712|DRUG|Placebo|Administered SC
219622802|NCT05199701|DEVICE|Mammography|All subjects who are indicated for a screening or diagnostic mammogram or breast biopsy will undergo an investigational exam in a new mammography device.
219622803|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
219622804|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
219622805|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
219622806|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
219622807|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
219622808|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
219206147|NCT06776991|BEHAVIORAL|Exposure Therapy|8 therapy sessions conducted individually with a therapist using the inhibitory retrieval model of exposure therapy. Sessions are designed to include four exposures each (32 exposures total). Each exposure is a public speech delivered to an audience. Goal of this treatment is to reduce public speaking anxiety. Principles of exposure therapy that will be incorporated are maximizing prediction error, maintaining attention to the situation/stimuli that are perceived predictors of the feared outcome (e.g., social rejection), removing safety signals, variability, engaging in post-exposure rehearsal/consolidation, deepened extinction, and positive occasion setter extinction. Intervention does not include between-session practice.
219206148|NCT06775314|DRUG|Cleanser|Cleanser consist of Triethyl citrate and Pyruvic acid, will be given to subjects to be applied every morning, evening and night in group 2
219206149|NCT06775314|DRUG|Combination cream|combination cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic acid will be given to subjects to be applied every morning, evening and night in group 2
219206150|NCT06775314|DRUG|spot cream|spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2
219206151|NCT06775314|DRUG|Adapalene 0,1% cream|adapalene 0.1% cream will be given to subjects to be applied every night in group 1 and 2
219206152|NCT06775314|DRUG|placebo cleanser|placebo cleanser will be given to subjects to be applied every morning, evening and night in group 1
219206153|NCT06775314|DRUG|placebo cream combination|placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1
218935856|NCT00942097|DRUG|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
219206154|NCT06775314|DRUG|placebo spot cream|placebo spot cream will be given to subjects to be applied every morning and evening in group 1
218935857|NCT00942097|DRUG|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
219206155|NCT06777225|OTHER|breathing exercises|"This study is to examine the effects of breathing exercises on nausea, vomiting and anxiety levels in patients with gynecological cancer.~1 Exercise:~* Find a quiet, calm and comfortable place for yourself.~* Lie on your back in a comfortable place (flat surface, bed or couch) and bend your knees or sit in a comfortable place (chair or armchair).~* Close your eyes.~* Place your left hand on your belly and your right hand on your chest.~* Take a deep breath through your nose for 4 seconds.~* Feel your hand on your belly rise and your belly swell as you breathe in.~* Make sure your chest is not swollen.~* Hold your breath for 4 seconds. Breathe out in 4 seconds.~* Do this 10 times every day, morning and evening, 3 times."
219367086|NCT02135380|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
219367087|NCT02135380|BIOLOGICAL|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
219367088|NCT02135380|OTHER|Control|Standard Therapy
219367089|NCT03082560|DIAGNOSTIC_TEST|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
219367090|NCT02411747|BEHAVIORAL|Testing|
219367091|NCT02411747|BEHAVIORAL|Directed self-regulated simulation training|
219367092|NCT01950832|OTHER|Investigating clinically normal patients with optic coherence tomography|
219367093|NCT02363075|DRUG|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
219367094|NCT02363075|DRUG|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
219367095|NCT02104284|PROCEDURE|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
219367096|NCT05401266|PROCEDURE|mild hypercapnia|Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
219367097|NCT03891147|OTHER|Electro-acupuncture|
219367098|NCT04178980|DRUG|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
219367099|NCT01896960|DRUG|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
219367100|NCT00996203|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
219367101|NCT00996203|DRUG|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
219367102|NCT00622895|DRUG|fludarabine phosphate|Given IV
219367103|NCT00622895|DRUG|Mycophenolic Acid|Given PO
219367104|NCT00622895|DRUG|tacrolimus|Given PO
219367105|NCT00622895|RADIATION|total-body irradiation|Undergo TBI
219367106|NCT00622895|PROCEDURE|bone marrow transplantation|Undergo transplantation
219547460|NCT06627881|OTHER|High intensity interval program with rope|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
219547461|NCT02610881|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
219547462|NCT02610881|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
219547463|NCT02610881|BEHAVIORAL|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
219547464|NCT02454595|BEHAVIORAL|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
219547465|NCT01622764|RADIATION|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
219547466|NCT00562718|DRUG|capecitabine|
219547467|NCT00562718|PROCEDURE|adjuvant therapy|
219547468|NCT00562718|RADIATION|radiation therapy|
219547469|NCT01868243|DRUG|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
219547470|NCT01868243|DRUG|Warfarin|Warfarin adjusted-dose
219547471|NCT01200186|DRUG|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
219547472|NCT01200186|DRUG|Progestin Only Pills|At the discretion of the attending physician
219547473|NCT02000258|PROCEDURE|Double-bundle ACL reconstruction|
219547474|NCT02000258|DEVICE|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
219547475|NCT05325268|PROCEDURE|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
219547476|NCT03505996|BIOLOGICAL|CS1001|Monoclonal antibody
219547477|NCT02195401|OTHER|Cleanroom|Cleanroom with air the quality of the pre-industrial age
219547478|NCT03010657|OTHER|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
219547479|NCT00627744|DRUG|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
219547480|NCT00220844|DRUG|Desipramine|
219547481|NCT00220844|DRUG|Amitriptyline|
219547482|NCT02230267|OTHER|High intensity exercise and balance training|
219547483|NCT02230267|OTHER|Usual care arm exercise|
219547484|NCT01395017|DRUG|dasatinib|GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219547485|NCT01395017|DRUG|Placebo|Matching Placebo
219547486|NCT03086434|OTHER|Culturally Tailored Intervention|School-based substance use prevention
219547487|NCT03086434|OTHER|Standard Substance Abuse Education|Class room program
219547488|NCT01808716|DEVICE|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
219547489|NCT04737239|OTHER|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
219547490|NCT03985124|BEHAVIORAL|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
219547491|NCT04604938|DRUG|Losartan|administration of losartan (50 mg) (oral)
219547492|NCT04604938|DRUG|Placebo oral tablet|administration of placebo (oral)
219547493|NCT05480423|BEHAVIORAL|Mindfulness-based intervention|1\. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
219547494|NCT06209255|PROCEDURE|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
219547495|NCT03911206|BEHAVIORAL|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
219547496|NCT03911206|BEHAVIORAL|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
219547497|NCT03911206|BEHAVIORAL|IMT and Exercise|Combining IMT training and exercise
219547498|NCT06485518|BEHAVIORAL|The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.|The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
219047154|NCT06737718|OTHER|Eye tracking|"The eye-tracking session will take place in the Pediatric Radiology department of Necker Hospital. The child will be seated in front of a computer screen. Films and images with social and/or non-social content will be shown to the children. The session will be unique, will last approximately 15 minutes and will not involve any constraints for the child.~Eye tracking allows to measure where and how a person looks. An infrared light is emitted towards the subject's eye. It is reflected there and a camera records the reflections generated, allowing a real-time calculation of the position of the gaze. The technique is harmless and non-invasive."
219047155|NCT06737718|OTHER|Data collection from patients' medical files|"Data collection from patients' medical files:~* Brain imaging data if this examination was carried out as part of the patient's care,~* Angelman syndrome genotypes."
219547499|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
219547500|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
219547501|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
219547502|NCT01757379|DIETARY_SUPPLEMENT|Inulin|15 g of inulin dissolved in 200 ml of water
219547503|NCT02285049|OTHER|Urticaria Control Test|"* The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
219547504|NCT01782937|DRUG|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
219547505|NCT04814628|PROCEDURE|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
219622809|NCT02603588|PROCEDURE|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
219622810|NCT02603588|PROCEDURE|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
219622812|NCT06687421|OTHER|High-risk treatment SOC|radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)
219622813|NCT06687421|OTHER|Active monitoring|Followed with PSA measurements
219622814|NCT06687421|PROCEDURE|Radical prostatectomy|Radical prostatectomy
219622815|NCT06687421|RADIATION|Radiotherapy|Radiotherapy
219622816|NCT06687421|DRUG|Androgen deprivation therapy|GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
219047156|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
219047157|NCT06893380|DRUG|Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.|Tislelizumab: IV 200mg on Day 1 of every 3-week cycle Nab-paclitaxel: IV 75mg/m2 on Days 1 and 8 of every 3-week cycle (up to 16 cycles) Gemcitabine: IV 800mg/m2 on Days 1 and 8 of every 3-week cycle Cisplatin: IV 25mg/m2 on Days 1 and 8 of every 3-week cycle (up to 8 cycles)
219367107|NCT00622895|PROCEDURE|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
219367108|NCT00622895|PROCEDURE|quality-of-life assessment|Ancillary studies
219367109|NCT00622895|OTHER|laboratory biomarker analysis|Correlative studies
219367110|NCT00622895|OTHER|flow cytometry|Correlative studies
219367111|NCT00622895|PROCEDURE|biopsy|Punch biopsy of skin involved with scleroderma
219367112|NCT01745809|PROCEDURE|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
219367113|NCT06454526|BEHAVIORAL|Mindfulness Based Program|Mindfulness Based Program is an 8-week program with a total of 25 hours. The program, which consists of lectures, meditation and sharing areas, consists of the following topics: Six Senses and Pleasure, Mindfulness and Mind, Get Out of the Head and Enter the Body, Compassion, Meeting Challenges, Stress Reactions and Healing, Retreat Silence Day, Neuroplasticity and the Changing Brain and Wise Living.
219367114|NCT03686969|DRUG|Octanorm|Octanorm 0.5g/kg/week
219367115|NCT03686969|OTHER|Placebo|Placebo
219367116|NCT01044563|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
219367117|NCT01044563|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
219547506|NCT04814628|PROCEDURE|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
218935858|NCT04037696|BEHAVIORAL|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
219547507|NCT04814628|PROCEDURE|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
219622817|NCT06689163|DRUG|HRS-1167 tablets|HRS-1167 tablets
219622818|NCT06689163|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
219622819|NCT06689163|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
218935859|NCT04037696|BEHAVIORAL|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
218935860|NCT02682862|DRUG|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
218935861|NCT02682862|DRUG|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
219047158|NCT07056140|PROCEDURE|Epidural Simulation Training|The group will have access to a epidural simulator and would have possibility to freely experiment and improve their skill on the phantom before their residency period in the obstetric unit
218935862|NCT03823313|BEHAVIORAL|SCAI (Spiritual Care Assessment and Intervention)|4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
218935863|NCT02981615|DRUG|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
218935864|NCT02981615|DRUG|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
219047159|NCT07056140|PROCEDURE|Standard Clinical Training|Participants will receive a standard clinical training based on frontal lessons regarding indications , controindications to epidural analgesia and the technique will be explained also with the use of video material
219047160|NCT07057323|DEVICE|Coronary Sinus Reducer|Subjects will have the Coronary Sinus Reducer implanted in their coronary sinus during a right heart catheterization procedure.
219047161|NCT06747091|PROCEDURE|Catheter Ablation|This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
219047162|NCT07049068|DRUG|Oral Nicotinamide|"Participants from group 1 received 120 capsules of 500 mg nicotinamide and a tube of placebo cream at each visit. . All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
219622820|NCT06696131|DRUG|TNK|TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.
218935865|NCT06434142|PROCEDURE|implant overdenture|Following the two-stage surgical protocol, two dental implant fixtures with a length of 10 mm and a diameter of 3.7 mm were inserted at the canine area of the mandibular alveolar ridge.
218935866|NCT00539864|BIOLOGICAL|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
218935867|NCT00539864|BIOLOGICAL|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
218935868|NCT05593263|PROCEDURE|surgical correction of astigmatism with cataract|The Steep meridian will be identified and marked, relaxing limbal / corneal incisions will be designed according to it.
218935869|NCT02840799|DRUG|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
219622821|NCT07026981|DRUG|[Ga-68]MTP220 PET/CT Scan|Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.
219622822|NCT00697632|DRUG|MGCD265|Oral daily administration without interruption
219547508|NCT04814628|PROCEDURE|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
219622823|NCT03479580|OTHER|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
219047163|NCT07049068|DRUG|topical nicotinamide|"Participants from group 2 received a tube of 5% nicotinamide cream and 120 placebo capsules. All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
219547509|NCT05662605|DEVICE|W-PPMA|"W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot."
219547510|NCT06144398|DEVICE|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
219547511|NCT06144398|DEVICE|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
219547512|NCT06402227|OTHER|gamified instruction|"At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win."
219547513|NCT06402227|OTHER|conventional lesson lecture|The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
219547514|NCT03677960|DRUG|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
219547515|NCT05021276|DRUG|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
219547516|NCT02115776|DRUG|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
219547517|NCT02115776|DRUG|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
219547518|NCT02115776|DRUG|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
219622824|NCT06216275|BEHAVIORAL|Integrated Snoezelen-Aromatherapy-Personal Item Therapy|"Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized"
218935870|NCT02840799|DRUG|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
218935871|NCT02586558|OTHER|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
218935872|NCT02586558|OTHER|Reference group|Ready-to-feed infant formula to be fed ad libitum
218935873|NCT02565784|DEVICE|Restylane|Facial tissue augmentation
218935874|NCT02565784|DEVICE|Perlane|Facial tissue augmentation
218935875|NCT02267876|DEVICE|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
218935876|NCT02267876|PROCEDURE|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
218935877|NCT03160235|RADIATION|Magnetic resonance imaging|
218935878|NCT03160235|DEVICE|EEG|
218935879|NCT03160235|DEVICE|NIRS|
218935880|NCT03439384|DEVICE|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
218935881|NCT00578734|DRUG|Lucinactant|Slow intra-tracheal instillation
218935882|NCT00578734|OTHER|Sham Comparator|Slow intra-tracheal instillation
219547519|NCT01116791|PROCEDURE|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS"
219547520|NCT02082327|DRUG|IV migalastat HCl|
219622825|NCT07028294|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
218935883|NCT04990804|DRUG|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
219547521|NCT02082327|DRUG|IV placebo|
219622826|NCT00352742|DRUG|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
219622827|NCT05828498|DIETARY_SUPPLEMENT|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
219622828|NCT03161353|DRUG|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
219622829|NCT03161353|DRUG|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
219622830|NCT03161353|DRUG|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
218935884|NCT04990804|DRUG|Opioid-Free Postoperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
218935885|NCT02417506|OTHER|E-OA-07 (Lanconone)|
218935886|NCT02417506|DRUG|Ibuprofen|
218935887|NCT00580528|BEHAVIORAL|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
218935888|NCT00580528|BEHAVIORAL|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
218935889|NCT01326338|DRUG|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
218935890|NCT06146283|COMBINATION_PRODUCT|Jamar Hydraulic Hand Dynamometer|"This device measures hand grip strength. The individual should be in an upright sitting position. There should be no arm support on the sitting surface. ...~The knee angle should be 90 degrees. Elbow angle should be 90 degrees. The wrist should be held without deviation. The measurement should be performed 3 times with an interval of 10 seconds."
218935891|NCT05083858|OTHER|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
218935892|NCT05083858|OTHER|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
219547522|NCT02082327|DRUG|oral migalastat HCl|
219547523|NCT02096692|DEVICE|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
219547524|NCT02096692|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
219547525|NCT01783392|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|
219547526|NCT02002130|DRUG|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
219547527|NCT02002130|DRUG|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
219547528|NCT02002130|DRUG|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
219622831|NCT03161353|DRUG|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
219622832|NCT03161353|DRUG|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
219547529|NCT06471725|OTHER|combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound|The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
219547530|NCT03294122|RADIATION|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
219547531|NCT03294122|RADIATION|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
219547532|NCT04306601|DEVICE|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
219547533|NCT01063244|DEVICE|foley balloon only|place foley balloon only in cervix
219547534|NCT01063244|DEVICE|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
219547535|NCT00473616|DRUG|AZD7762|intravenous infusion
219547536|NCT00473616|DRUG|Irinotecan|intravenous injection
219547537|NCT00827840|DRUG|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
218935893|NCT05083858|OTHER|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
218935894|NCT04611399|BEHAVIORAL|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
218935895|NCT04611399|OTHER|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
219547538|NCT00827840|DRUG|Risperidone|1 to 6 mg of risperidone once or twice a day
219547539|NCT00001864|DRUG|Atropine|
219547540|NCT00001864|DEVICE|Patch|
219547541|NCT04482816|DEVICE|Physiological pacing|Pacing of the his bundle or the left bundle branch
219547542|NCT04482816|DEVICE|Right ventricular pacing|Conventional pacing; right ventricular pacing
219547543|NCT02028416|DRUG|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
219547544|NCT06042296|OTHER|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
219547545|NCT04775316|DEVICE|Leukomed T / Tplus skin sensitive treatment|Application of sterile wound dressing.
219547546|NCT04392596|DEVICE|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure."
219622833|NCT03161353|DRUG|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
219622834|NCT02851017|OTHER|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
219622835|NCT06694805|DRUG|CAB LA + RPV LA|Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
219622836|NCT06694805|DRUG|Oral ART|Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
218935896|NCT00536445|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
218935897|NCT01745822|DRUG|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
218935898|NCT01745822|DRUG|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
219547547|NCT06562010|BEHAVIORAL|iCT-SAD-PK|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
219622837|NCT06686342|OTHER|No intervention|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
218935899|NCT04202419|DEVICE|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
219547548|NCT03275623|DRUG|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
219547549|NCT03275623|OTHER|Standard Prenatal Care|Continued surveillance of urinary cultures
219547550|NCT05108935|DRUG|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
219547551|NCT05108935|DRUG|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
219547552|NCT05108935|DRUG|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
219047164|NCT06743204|OTHER|Self-Reported Risk Screening for PrEP and Diagnostic STI testing|The intervention arm will include: 1) Standard-of-care STI symptom screening: The investigators will ask participants if any STI symptoms 2) PrEP screening (if HIV- only): PrEP eligibility screening will be done using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP 3) STI laboratory diagnostic testing: Regardless of HIV serostatus, vaginal swabs will be collected to test for chlamydia, gonorrhea, trichomonas, and human papilloma virus. Syphilis testing will be performed using blood samples participants provided in the Rakai Community Cohort Study. Participants who test positive for a curable sexually transmitted infection (chlamydia, gonorrhea, trichomonas, or syphilis) OR who screen eligible for PrEP using the Ministry of Health SRST AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for an STI will be provided with free treatment, as will the partner(s).
219547553|NCT04966403|OTHER|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
219547554|NCT04966403|OTHER|trampoline-based stretch-shortening cycle exercises|muscle strength
219547555|NCT00999687|DRUG|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
219547556|NCT00999687|OTHER|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
219547557|NCT02940652|RADIATION|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
219547558|NCT01126606|DRUG|Dermacid Silver (Lactic acid)|Liquid soap, daily use
219547559|NCT01126606|DRUG|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
218935900|NCT00251043|BEHAVIORAL|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
218935901|NCT00251043|BEHAVIORAL|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
219206156|NCT06777225|OTHER|scale|The patient received standard nursing care and the scale was applied after the intervention. The 21-question inventory developed by Dr. Aaron T. Beck was used. The reliability and validity of the Beck Depression Inventory (BDI), which is used to measure the severity of depression, was performed in our country by N. Hisli in 1989. (Cronbach's alpha value was calculated as 0.85). Each question takes a value between 0-3 points. When evaluating the results; 0-10 points are normal; 11-16 points are mild mood disorder; 17-20 points are borderline clinical depression; 21-30 points are moderate depression; 31-40 points are severe depression and over 40 points are very severe depression (Çiçekçe et al, 2023).
219547560|NCT00940433|PROCEDURE|open properitoneal hernia repair|suprapubic retro-inguinal approach
219547561|NCT00940433|PROCEDURE|Lechtestien hernia repair|onlay mesh repair
219547562|NCT00940433|PROCEDURE|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
219547563|NCT00940433|PROCEDURE|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
219547564|NCT04599842|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
219547565|NCT04175587|DRUG|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
219622838|NCT06686342|OTHER|No Intervention: Observational Cohort|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
219622839|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
219622840|NCT07035158|DIAGNOSTIC_TEST|Libra Oral Solution|EVOC Probe
218935902|NCT00407056|DRUG|Difluprednate Ophthalmic Emulsion|
219547566|NCT05583409|RADIATION|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
219547567|NCT05583409|DRUG|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
219547568|NCT01965093|PROCEDURE|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
219547569|NCT01965093|PROCEDURE|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
219547570|NCT00474188|DRUG|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
219547571|NCT00474188|DRUG|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
219622841|NCT07032935|BEHAVIORAL|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION
219622842|NCT06707844|OTHER|Conventional treatment|"Conventional treatment will include:~* Stretching exercises (5Reps with 15sec hold): Gastrocnemius-soleus stretch, TA stretch.~* Strengthening exercises (5Sets, 5Reps, 5sec hold): Weight-bearing lunges, Short-foot exercise.~* Maitland mobilization Grade 2 \& 3 (3 Sets, 20Reps) at Talonavicular joint."
218935903|NCT03550352|DRUG|TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)|Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
218935904|NCT03550352|DRUG|TN-C200M2 oral capsules (CBD 200 mg)|Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
218935905|NCT02325869|DEVICE|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
218935906|NCT04534816|DIAGNOSTIC_TEST|Indocyanine Green|Perfusion assessments
218935907|NCT04432727|DEVICE|Flexitouch Plus with Cellular Connectivity (FT-CC)|Daily use of FT-CC
218935908|NCT01617226|DRUG|Azacitidine|Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
219622843|NCT06707844|OTHER|Myofascial release|"* Myofascial release is a manual therapy applying sustained pressure on the calf muscles to release fascial restrictions.~* Protocol: 3 sets of 2-minute pressure applications with a 1-minute break between sets~* Performed twice weekly for 3 weeks"
218935909|NCT01617226|DRUG|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
218935910|NCT00107640|BEHAVIORAL|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
218935911|NCT01643421|OTHER|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
218935912|NCT03708354|DRUG|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
218935913|NCT03708354|DRUG|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
218935914|NCT03059355|BIOLOGICAL|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
218935915|NCT03059355|BIOLOGICAL|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
218935916|NCT03059355|OTHER|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
218935917|NCT04966663|DRUG|Nivolumab|Antineoplastic agent
218935918|NCT04966663|DRUG|Pemetrexed|Antineoplastic agent
218935919|NCT04966663|DRUG|Gemcitabine|Antineoplastic agent
218935920|NCT04966663|DRUG|Cisplatin|Antineoplastic agent
218935921|NCT04966663|DRUG|Carboplatin|Antineoplastic agent
218935922|NCT04966663|PROCEDURE|ctDNA blood test|Blood will be collected for ctDNA testing
219547572|NCT00260715|BEHAVIORAL|Community-Popular Opinion Leader Model|
219547573|NCT00260715|BEHAVIORAL|Diffusion of Innovations|
219547574|NCT05198505|DRUG|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
219547575|NCT00493727|DRUG|N-acetylcysteine(Mucomyst)|
218935923|NCT03032302|DIETARY_SUPPLEMENT|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
218935924|NCT03032302|DIETARY_SUPPLEMENT|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
218935925|NCT01595022|DRUG|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
218935926|NCT01595022|DRUG|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
218935927|NCT01595022|DRUG|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
218935928|NCT01204008|PROCEDURE|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
219547576|NCT00223093|DRUG|TAIZ|
219547577|NCT02683291|DRUG|sirolimus|
219547578|NCT02683291|DRUG|tacrolimus|
219547579|NCT02683291|DRUG|mycophenolate|
219547580|NCT02683291|DRUG|Prednisone|Prednisone 30mg/day
219547581|NCT02683291|DRUG|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
219547582|NCT02683291|DRUG|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
219547583|NCT02125981|DRUG|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
219547584|NCT02125981|DRUG|Placebo|taking placebo drug
219547585|NCT04417439|OTHER|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
219622844|NCT06707844|OTHER|Tissue flossing|"Tissue flossing involves wrapping a latex band around the calf muscles with 50-75% elongation, followed by active ankle movements (dorsiflexion, plantarflexion, circles, heel raises).~Protocol: 4 sets of 8 repetitions, 10-second rest between sets Performed twice weekly for 3 weeks."
219622845|NCT07135687|DRUG|Losartan|Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
219622846|NCT07135687|OTHER|Placebo|The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.
219206157|NCT06777225|OTHER|scala|The scale was developed by Rhodes and McDaniel (1999), and its Turkish validity and reliability were carried out by Fatma Genç and Mehtap Tan. The scale, which evaluates the number and severity of nausea-vomiting-retching episodes in the last 24 hours, consists of eight items. The scale has three sub-dimensions: Symptom Experience, Symptom Formation, and Symptom Distress. The responses to the items on the five-point Likert-type scale are scored as 0 = minimum 22 distress level, 4 = maximum distress level. When evaluating the scores, items 1, 3, 6, and 7 are reversed. The highest score that can be obtained from the scale is 32, and higher scores mean that nausea-vomiting symptoms have increased in patients (Odabaşı et al, 2021).
219622847|NCT06715735|BEHAVIORAL|Theory-based health behaviour change intervention|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
219206158|NCT06769503|OTHER|aromatherapy|Lavender oil dropped on gauze will be smelled for approximately 3-5 minutes.
219206159|NCT06770205|OTHER|traditional physical therapy|hot pack and TENS for 10 minutes and massage that will as 3 sessions per week for 4 weeks.
219547586|NCT04919616|DRUG|TILs（Tumor Infiltrating Lymphocytes）|10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
219547587|NCT01803594|DIETARY_SUPPLEMENT|Krill Oil|Neptune Krill Oil Gold
219547588|NCT01803594|DIETARY_SUPPLEMENT|Lutein|Jarrow Formulas
219547589|NCT01803594|DIETARY_SUPPLEMENT|Nicotinic acid|Natures Way
219547590|NCT01803594|DIETARY_SUPPLEMENT|Dairy phospholipids|PC700 manufactured by Fonterra
219547591|NCT01803594|OTHER|Control|Control shake without dietary supplements
219547592|NCT05384457|OTHER|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
219547593|NCT05384457|OTHER|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
219547594|NCT01949324|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
218935929|NCT01204008|PROCEDURE|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
218935930|NCT00458224|BEHAVIORAL|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
218935931|NCT03137264|DRUG|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
218935932|NCT04188444|BIOLOGICAL|Blood test|20 ml of blood, three times
218935933|NCT02817932|DRUG|Ranolazine|
218935934|NCT05178368|PROCEDURE|Surgical/ Transcatheter aortic valve replacement|The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
218935935|NCT04561726|OTHER|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
218935936|NCT04561726|OTHER|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
218935937|NCT00215176|DRUG|modafinil|
218935938|NCT03332680|BIOLOGICAL|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
218935939|NCT03332680|BIOLOGICAL|Standard control medium|Embryos placed in this medium prior to transfer
218935940|NCT00947440|DRUG|ABT-072|See arm description for more information
218935941|NCT00484848|DEVICE|Vortex port and Celsite port|
218935942|NCT05917678|OTHER|Repositioning Therapy|Caregivers will be instructed how to increase tummy time activities and reshape their infant's heads using at-home methods to direct their attention to the non-preferred side.
219547595|NCT01949324|PROCEDURE|Sham procedure|Sham surgery for Sham arm
219547596|NCT01949324|DEVICE|NT-501 Implant|NT-501 encapsulated cell implant
219547597|NCT01949324|PROCEDURE|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
219547598|NCT00001058|DRUG|Indinavir sulfate|
219622848|NCT07035990|DRUG|SION-451|"* Pharmaceutical form: tablet~* Route of administration: oral"
218935943|NCT05917678|DEVICE|Cranial Remolding Orthosis|A custom cranial remolding orthosis (FDA Class II device) will be made to fit affected infants. this should be worn 23 hours per day and the Orthotist needs to be seen regularly for adjustments until the head shape is resolved.
218935944|NCT03227783|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
218935945|NCT00476008|DRUG|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
218935946|NCT00476008|DRUG|Placebo|One tablet placebo morning and evening (BID) for 12 months
218935947|NCT03970044|DRUG|Exenatide 2 MG|Glucagon-like peptide-1 receptor
218935948|NCT03970044|DRUG|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
218935949|NCT01170247|DRUG|Ketamine|Intranasal Ketamine (100 mg/mL)
218935950|NCT01170247|DRUG|Ketamine|Intramuscular Ketamine
218935951|NCT01901796|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
218935952|NCT01075308|DRUG|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
218935953|NCT05576545|DEVICE|The Breast Cancer Self-Care App|The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
218935954|NCT05061043|OTHER|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
218935955|NCT05061043|OTHER|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
218935956|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
219547599|NCT00001058|DRUG|Ritonavir|
219547600|NCT00001058|DRUG|Ethambutol hydrochloride|
219547601|NCT00001058|DRUG|Clarithromycin|
219547602|NCT00001058|DRUG|Rifabutin|
219547603|NCT04364191|BEHAVIORAL|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
219547604|NCT04364191|BEHAVIORAL|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
219547605|NCT04495543|BEHAVIORAL|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
219547606|NCT03961204|OTHER|Data Collection|No study treatment was administered as part of this study
219547607|NCT05173792|DRUG|AK119|Subjects will receive AK119 intravenously.
219547608|NCT05787678|BIOLOGICAL|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
219547609|NCT04363554|OTHER|Fluid intake|The participants will intake fluid
219547610|NCT04363554|OTHER|Thirsting|The participants will thirst
219547611|NCT00707330|DRUG|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
219547612|NCT02016274|OTHER|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
219547613|NCT06561490|RADIATION|sonographic assesment of placental thickness and volume|sonographic assesment of placental thickness and volume
219547614|NCT04318808|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
219547615|NCT01670643|BEHAVIORAL|Video camera magnifier|reading with video camera magnifier
219622849|NCT07035990|DRUG|SION-2222|"* Pharmaceutical form: capsule~* Route of administration: oral"
219622850|NCT07035990|DRUG|SION-109|"* Pharmaceutical form: tablet~* Route of administration: oral"
219622851|NCT07035990|DRUG|Placebo SION-451|Placebo matched to SION-451
219622852|NCT07035990|DRUG|Placebo SION-2222|Placebo matched to SION-2222
219622853|NCT07035990|DRUG|Placebo SION-109|Placebo matched to SION-109
219622854|NCT07040033|OTHER|There will be no intervention|There will be no intervention
219622855|NCT07040033|BEHAVIORAL|There will be no intervention|There will be no intervention
219622856|NCT01288963|DRUG|IL-2|Observation only
219622857|NCT06703437|DRUG|Dehydrated alcohol|Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
219622858|NCT06703437|DRUG|Lidocaine IV|By periprostatic injection, 2mL
219547616|NCT02913287|DIETARY_SUPPLEMENT|Aquamin/Aquamin MG|Marine-based nutraceutical
219622859|NCT02556229|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
219622860|NCT07047703|DRUG|Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers|Participants in Part A will receive a single dose of GRWD0715 on Day 1 only.
219547617|NCT02913287|OTHER|Maltodextrin Placebo|Maltodextrin Placebo
219547618|NCT00675142|PROCEDURE|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
219547619|NCT04116957|DEVICE|RTLS current tag|Validate location system performance against manual observation of nursing activity
219547620|NCT04116957|DEVICE|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
219622861|NCT07047703|DRUG|Part B - Multiple Ascending Dose (MAD) in participants with axSpA|Participants in Part B will receive GRWD0715 for 28 days
219622862|NCT07047703|DRUG|Part C - Safety expansion cohort in participants with axSpA|Participants in Part C will receive GRWD0715 for 12 weeks
218935957|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
219547621|NCT01165450|DRUG|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
219547622|NCT01165450|DRUG|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
219547623|NCT03586219|BEHAVIORAL|Opioid-specific educational patient pamphlets|See prior description
218935958|NCT02746224|PROCEDURE|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
218935959|NCT02746224|PROCEDURE|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
218935960|NCT01916291|DRUG|Propess insertion group|
219547624|NCT01957280|DRUG|patritumab|
219547625|NCT04934098|DEVICE|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
219547626|NCT04934098|DEVICE|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
219547627|NCT02865824|DRUG|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
219622863|NCT07047703|DRUG|Part D - Randomised, placebo-controlled, expansion cohort in participants with axSpA|Participants in Part D will receive GRWD0715 or placebo-to-match for 12 weeks
219622864|NCT07047183|DRUG|VEN (Venetoclax)|Enrolled patients will receive: Venetoclax: 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. Azacitidine: 75 mg/m² on Days 1-7. Cycle duration: 28 days Total cycles: 1 to 2 cycles
219622865|NCT07044479|DRUG|Enlicitide|Single dose of enlicitide is administered orally on day 1 of each testing period
219622866|NCT03910400|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|"After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR."
219622867|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light at different times of day
219622868|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light for 2h30 at different times of day with sleep
219622869|NCT05232383|DEVICE|red light|Application of red light at different times of day
219622870|NCT05232383|DEVICE|red light|Application of red light at different times of day with sleep
219622871|NCT05232383|DEVICE|green light|Application of green light at different times of day
219622872|NCT05232383|DEVICE|green light|Application of green light at different times of day with sleep
219622873|NCT07067736|OTHER|Cefazolin antibiotic prophylaxis|Determination of cerebrospinal fluid concentration
219547628|NCT02865824|DRUG|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
219622874|NCT07068139|OTHER|AI-Based Predictive Modeling|This is not a therapeutic or diagnostic intervention. The study uses a retrospective dataset of radiologic and pathological records to train and validate a deep learning model designed to predict tumor stage and survival in patients with non-small cell lung cancer (NSCLC). No experimental procedure is applied to participants.
219622875|NCT00181727|DRUG|divalproex sodium extended release|
219547629|NCT05964049|DEVICE|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
219622876|NCT03764774|DRUG|LY3463251|Administered SC
219622877|NCT03764774|DRUG|Placebo|Administered SC
219547630|NCT05964049|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219547631|NCT00664053|DIETARY_SUPPLEMENT|DHEA|50mg daily for 6 months
219547632|NCT00664053|BEHAVIORAL|Yoga|2 sessions per week for 6 months
219547633|NCT00664053|DIETARY_SUPPLEMENT|Placebo|Placebo supplement every day for 6 months
219547634|NCT00664053|BEHAVIORAL|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
219622878|NCT01467297|DRUG|ceftidoren|ceftidoren 200 mg bid for 5 days
219622879|NCT01467297|DRUG|levofloxacin|levofloxacin 500 mg once daily for 7 days
219622880|NCT06650150|DIAGNOSTIC_TEST|maximal inspiratory pressure|maximal inspiratory pressure (mip) will be measured with a specific device
219622881|NCT06650150|DIAGNOSTIC_TEST|maximal expiratory pressure|MEP will be measured with a specific device
219622882|NCT06650150|DIAGNOSTIC_TEST|6 minute walk test|6mwt will be done by a phsyotherapist
219622883|NCT06065098|BEHAVIORAL|Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
219622884|NCT03854474|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219622885|NCT03854474|PROCEDURE|Computed Tomography|Undergo CT
219622886|NCT03854474|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219622887|NCT03854474|BIOLOGICAL|Pembrolizumab|Given IV
219622888|NCT03854474|DRUG|Tazemetostat|Given PO
219622889|NCT02208362|BIOLOGICAL|Arm 1: IL13Ra2-specific CAR Tcm cells|Given via intratumoral catheter
219622890|NCT02208362|BIOLOGICAL|Arm 2: IL13Ra2-specific CAR Tcm cells|Given via intratumoral/intracavitary catheter
219622891|NCT02208362|BIOLOGICAL|Arm 3: IL13Ra2-specific CAR Tcm cells|Given via intraventricular catheter
219622892|NCT02208362|BIOLOGICAL|Arm 4: IL13Ra2-specific CAR Tcm cells|Given via intratumoral or intracavitary, and via intraventricular catheter
219547635|NCT00879164|DRUG|bupivacaine hydrochloride|
219547636|NCT00879164|OTHER|questionnaire administration|
219547637|NCT06050239|DRUG|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
219622893|NCT02208362|BIOLOGICAL|Arm 5: IL13Ra2-specific CAR Tn/mem cells|Given via intratumoral or intracavitary, and via intraventricular catheter
219622894|NCT02208362|OTHER|Laboratory Biomarker Analysis|Correlative studies
219622895|NCT02208362|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
219622896|NCT02208362|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Correlative studies
219622897|NCT02208362|OTHER|Quality-of-Life Assessment|Ancillary studies
219622898|NCT06046066|DRUG|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
219547638|NCT00170469|BIOLOGICAL|AVA|
219547639|NCT00170469|BIOLOGICAL|rPA vaccine containing alhydrogel|
219622899|NCT07077174|OTHER|Permissive lung-protective ventilation|The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline in which the target RR is estimated by combining the baseline RR with the results of arterial blood gas analysis (ABG), determined by the highest acceptable partial pressure of carbon dioxide (PaCO2) of ≤ 8.5 kPa (64 mmHg) but limited by the lowest acceptable arterial pH (pHa) of \> 7.20. The RR is gradually decreased, in steps of 2 breaths every 10 minutes, based on continuous end-tidal CO2 monitoring. To ensure that the pHa does not fall below 7.20, following randomization, ABGs are repeated every hour until the target RR is reached, for at least 6 hours. Thereafter, blood gas analyses are repeated at least every 8 hours (at the start of every nursing shift). Down-titration of RR stops at a rate of 4 breaths per minute. This approach continues until the switch to spontaneous breathing. Of note, when the pHa is \> 7.50, this must first be decreased to ≤ 7.50 based on local protocol.
219622900|NCT07077174|OTHER|Conventional lung-protective ventilation|Following randomization, which should happen within 1 hour after start of ventilation in the ICU, the RR is set according to standard of care, based on continuous end-tidal CO2 monitoring, to target a normal PaCO2 (4.7-6.4 kPa or 35-48 mmHg) combined with a pHa within the range of 7.35 to 7.45. Following randomization, blood gas analyses are repeated every hour for at least 6 hours, and thereafter at least every 8 hours (at the start of every nursing shift). This approach continues until the weaning phase.
219622901|NCT05319574|RADIATION|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
219622902|NCT05319574|DRUG|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
219547640|NCT01710696|DRUG|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
219547641|NCT01710696|DRUG|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
219622903|NCT03746431|DRUG|[111In]-FPI-1547 Injection|\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
219047165|NCT06743204|OTHER|Self-reported risk screening for PrEP and syndromic management for STIs|This active comparator (control) arm will receive the following: 1) Standard-of-care STI symptom screening: Regardless of HIV serostatus, participants will be asked if any STI symptoms 2) Syphilis testing for pregnant participants: Regardless of HIV serostatus, syphilis testing will be performed using blood samples provided in the Rakai Community Cohort Study. 3) PrEP screening (if HIV- only): Participants will be screened for PrEP eligibility using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP. Participants who screen eligible for PrEP using the Ministry of Health SRST OR pregnant participant's who test positive for syphilis AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for syphilis will be provided with free treatment, as will the partner(s).
219047166|NCT06895499|DRUG|HB0043|Low dose
219547642|NCT01566435|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219047167|NCT06895499|DRUG|HB0043|Medium dose
219547643|NCT01566435|DRUG|Cisplatin|
219547644|NCT01566435|DRUG|Fluorouracil|
219206160|NCT06770205|OTHER|kendall Exercise Group A|"The group B will receive Proprioceptive Neuromuscular Facilitation technique for stretching and rhythmic stabilization technique for strengthening. Proprioceptive Neuromuscular Facilitation (PNF) is a stretching technique utilized to improve muscle elasticity and has been shown to have a positive effect on active and passive range of motions. The PNF group performed the intervention for 30 minutes a day, six times a week, a total of 24 times. (13) In this group, two types of PNF techniques were given:~1. first is strengthening technique included rhythmic stabilization that is characterized by alternating isometric contractions against resistance, no motion intended to apply for the weak muscles of upper cross syndrome included deep neck flexors specifically lower trapezius and serratus anterior.~2. Second is stretching technique included contract relax that is resisted isotonic contractions of the restricting muscles (antagonists) followed by relaxation and movement"
219206161|NCT06777953|OTHER|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
219206162|NCT06777953|OTHER|Popliteal Sciatic Nerve Block|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
219206163|NCT05073510|DEVICE|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
219547645|NCT01566435|RADIATION|Intensity modulated radiation therapy|
219547646|NCT01566435|DRUG|Cetuximab|
219206164|NCT06377124|BEHAVIORAL|3S intervention|"The 3S intervention includes information and support related to self-management of lung cancer, including~1. an individual 3S session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
219547647|NCT01566435|PROCEDURE|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
219547648|NCT03999008|DRUG|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
219547649|NCT03999008|DRUG|Placebos|Apple Sauce 5 mL+ 1 mL saline
218935961|NCT04596436|OTHER|no intervention|no intervention
218935962|NCT06531889|OTHER|classical physiotherapy program|Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
218935963|NCT06531889|OTHER|Core Stabilization Exercises|The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
218935964|NCT03758300|OTHER|Radiofrequency|See previous page
219047168|NCT06895499|DRUG|HB0043|High dose
219047169|NCT06083519|BEHAVIORAL|White Noise|This is the control condition. Listening to white noise -- participants listen to white noise for 24 minutes
219047170|NCT06083519|BEHAVIORAL|Music and Auditory Beat Stimulation|Listening to music and auditory beat stimulation. The VIBE app (LUCID) incorporates theta-band (4 Hz) auditory beat stimulation and an auditory music recommendation system. Participants will listen to this music with theta auditory beat stimulation for 24 minutes.
219047171|NCT03091192|DRUG|Savolitinib|600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
219547650|NCT06547177|OTHER|fruit juice|During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
219547651|NCT03684928|DEVICE|Comfilcon A (test)|Daily wear contact lenses
219547652|NCT03684928|DEVICE|Senofilcon C (control)|Daily wear contact lenses
219547653|NCT05804786|DEVICE|Guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
219547654|NCT05278520|PROCEDURE|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
219547655|NCT00135850|GENETIC|VEGF-A165 plasmid|
219547656|NCT04632550|PROCEDURE|Circumferential pulmonary vein isolation(CPVI) group|"1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
219547657|NCT04632550|PROCEDURE|Posterior box isolation(POBI) group|"1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
219622904|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection multi-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
219622905|NCT03746431|BIOLOGICAL|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
219622906|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection single-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
219622907|NCT06929312|OTHER|Tabletop simulation based teaching|a pre tested and validated questionnaire was used as a tabletop simulation method on Cholera outbreak.
219622908|NCT06929312|OTHER|conventional class room teaching|conventional class room lecture using power point was delivered on Cholera outbreak.
219622909|NCT06618222|DEVICE|Wingspan stent system|All patients had received Percutaneous transluminal angioplasty and stenting with Wingspan stent system.
219206165|NCT06377124|BEHAVIORAL|GH information|"The GH information includes information related to general health, including~1. an individual GH session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
219206166|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
219206167|NCT06862583|PROCEDURE|surgery|Open heart surgery
219206168|NCT06862583|PROCEDURE|endovascular intervention|Aortic endovascular intervention
219206169|NCT06892236|GENETIC|iPSC generation|Base editing
219622910|NCT07079683|OTHER|Toothpaste Product|BioFresh toothpaste containing a blend of alpha-amylase and gluco-amylase enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
219622911|NCT07079683|OTHER|Toothpaste Product|Placebo toothpaste containing no enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
219622912|NCT06903793|OTHER|cervical manipulation|Cervical upglide/rotation manipulation targeted to C5/C6 on the dominant shoulder side
219622913|NCT06181630|DIAGNOSTIC_TEST|Breast milk, plasma, and blood samples|Although this study is non- interventional regarding treatment with ozanimod, the study is considered interventional due to the collection of breast milk and plasma from the lactating women and blood samples from their breastfed infants and the additional diagnostic and monitoring procedures required for the study.
219622914|NCT04423627|DRUG|Clonidine|Clonidine 0.2 mg/day oral tablet
219206170|NCT06111885|DRUG|Indapamide 2.5 MG|1 indapamide 2.5 mg capsule per day for 28 days
219206171|NCT06111885|DRUG|Hydrochlorothiazide 50Mg|1 hydrochlorothiazide 50 mg capsule per day for 28 days
219206172|NCT06111885|DRUG|Chlorthalidone 25mg|1 chlorthalidone 25 mg capsule per day for 28 days
219206173|NCT06411522|DEVICE|Mouthwash containing 0.12% CHX (Chlorhexidine)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.2% CHX mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
219622915|NCT04423627|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 37.5 mg/day oral tablet
219622916|NCT04423627|DRUG|Placebo|Placebo
219622917|NCT06905093|OTHER|Standard care|Standard care including rehabilitation sessions three times per week.
219622918|NCT06905093|OTHER|Eccentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Eccentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
219622919|NCT06905093|OTHER|Concentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Concentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
219047172|NCT03091192|DRUG|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
219047173|NCT07061275|BEHAVIORAL|Telehealth-Supervised Resistance Training|"The exercise protocol will incorporate a variety of exercise modalities adapted for home use in limited space environments. Elastic resistance bands will be used for lower-limb strength exercises such as leg presses, hip abduction, and ankle dorsiflexion, while sandbag-style leg weights will be employed for activities including knee extensions, seated marches, and standing squats. To target balance, low-cost tools such as foam pads, balance cushions, or step platforms will be used for tasks including static standing, single-leg stance, and step-up exercises designed to challenge postural control in a safe, progressive manner.~Sessions will be delivered through a secure live-streaming platform accessible on smartphones. The streaming platform supports background audio, allowing exercise sessions to be accompanied by music, which may help increase motivation and enjoyment for participating children. Each session will be led by trained instructors from the Hunan Normal University."
219047174|NCT07060573|BEHAVIORAL|Parental Oral Stimulation Protocol|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by parents, previously trained and supervised in the neonatal unit.
219047175|NCT07060573|BEHAVIORAL|Physiotherapist-led Oral Stimulation|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by a licensed physiotherapist.
219047176|NCT07059728|DEVICE|Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)|Intervention group: Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)
219047177|NCT07059728|DEVICE|Oxygen therapy during sedation delivered via nasal cannulae at 5L/min|Control group: Oxygen therapy during sedation delivered via nasal cannulae at 5L/min
219047178|NCT05026554|GENETIC|Tape stripping|Optional genetic analysis for chronic hand eczema
219047179|NCT05262023|DRUG|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
219047180|NCT05262023|DRUG|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
219047181|NCT06143891|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
219047182|NCT06143891|DRUG|Placebo|Pharmaceutical form:Table-Route of administration:oral
219047183|NCT06143891|DRUG|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
219047184|NCT06143891|DRUG|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
219047185|NCT05677360|BEHAVIORAL|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
219047186|NCT05677360|BEHAVIORAL|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
219047187|NCT05677360|BEHAVIORAL|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
219047188|NCT06787222|DRUG|tretinoin 0.025% + Z. officinale patch|Material used for patch formulation were 3,15 grams of polyvinyl alcohol, 4,2 grams of polyvinyl pyrrolidone, 12,6 ml distilled water, and 1,05 grams of Z. officinale extract.
219047189|NCT06787222|DRUG|tretinoin 0.025% cream|no Z. officinale patch applied after tretinoin 0.025% application
219047190|NCT06767514|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab as an IV injection
219047191|NCT06767514|BIOLOGICAL|Pembrolizumab Injection|Subject will receive Pembrolizumab as an IV injection
219047192|NCT06747156|DRUG|ABO2203 Injection|Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager
219047193|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
219047194|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
219047195|NCT06811116|PROCEDURE|Biospecimen Collection|Undergo blood collection
219047196|NCT06811116|DRUG|Cabozantinib S-malate|Given PO
219047197|NCT06811116|PROCEDURE|Imaging Procedure|Undergo imaging scans
219047198|NCT06811116|DRUG|Sapanisertib|Given orally (PO)
219547658|NCT04632550|PROCEDURE|POBI+Anterior linear ablation(AL) group|"1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
219547659|NCT05167474|OTHER|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
219622920|NCT06909006|DRUG|Semaglutide 2.4mg|The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator
219622921|NCT06909006|DRUG|Semaglutide placebo|Visually identical and same label as the active comparator intervention
219622922|NCT05223400|DRUG|Clindamycin Injection|it is a clindamycin use evaluation study
219547660|NCT04221113|PROCEDURE|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
219547661|NCT01222234|DRUG|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
219547662|NCT01222234|DEVICE|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
219547663|NCT01222234|DRUG|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
219547664|NCT06628232|OTHER|pacifier with breast milk|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk
219547665|NCT06628232|OTHER|heel heating|swaddling in the mother\&#39;s lap together with local dry heat application
219547666|NCT06628232|OTHER|interventions combined|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk and heel heating
219622923|NCT06480240|DRUG|OBI-992|OBI-992 is an antibody-drug conjugate
219047199|NCT07069751|DIETARY_SUPPLEMENT|diet rich in fiber|Enrolled and eligible patients will be encouraged to consume a balanced diet rich in fiber for the entire duration of the trial (i.e., 12 weeks). Patients will also be encouraged to prolong plant-based diets beyond week 12. Free outpatient medical visit will be performed at enrollment and at week 12, and nutritional counseling will be given at the time of enrollment, one month later and on demand. Dietary measurements will be conducted along the entire duration of the nutritional regimen by questionnaires. In particular, the patient will write for each day of the trial the number associated to the chosen diet plan or food.
219047200|NCT06848868|PROCEDURE|Ambulatory flexible ureterorenoscopy|Ambulatory flexible ureterorenoscopy (experimental)
219047201|NCT06540144|DRUG|rozanolixizumab|rozanolixizumab solution for injection
219047202|NCT06901570|DRUG|Kuangxiong Aerosol|Patients in the intervention group will receive Kuangxiong Aerosol for eight weeks, in addition to guideline-recommended medications. The aerosol will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
219547667|NCT06628232|OTHER|Control|swaddling the baby in the mother\&#39;s lap
219547668|NCT06691243|DRUG|Semaglutide|The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
219547669|NCT06691243|DRUG|Placebo|Patients randomized to placebo arm will receive placebo injection every week.
219547670|NCT06878989|BEHAVIORAL|Caloric restriction diet|Dietary intervention consisting on a meal plan designed to induce an 8-10% weight loss over a 12-16 week period.
219547671|NCT06878989|BEHAVIORAL|Weight maintenance diet|Dietary intervention consisting on a meal plan designed to maintain a stable body weight for up to 16 weeks.
219547672|NCT06555640|DRUG|DR10624 Injection|Drug: DR10624 injection
219547673|NCT06555640|DRUG|Placebo|Drug: placebo
219547674|NCT05829460|DRUG|Semaglutide|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
219547675|NCT05829460|DRUG|Placebo|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
219547676|NCT05829460|DRUG|LNG-IUD (Progestin)|Released via the levonorgestrel-releasing IUD.
219547677|NCT05829460|BEHAVIORAL|Telemedicine behavioral weight program|Optional to attend.
219547678|NCT00003885|DRUG|arsenic trioxide|
219547679|NCT02230605|OTHER|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
219547680|NCT02230605|OTHER|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
219622924|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
219622925|NCT07095595|OTHER|Patient Safety Educational Program based on WHO Curriculum|This study involves a structured 5-day educational program targeting nursing leaders and educators, with each day comprising 2 to 3 hours of instructional sessions. it will will include a combination of lectures, videos, group discussions, and case study analyses to enhance engagement and practical learning
219622926|NCT06876415|OTHER|P0.1 and delta Poeso integration into the decanulation decision|P0.1 and delta Poeso integration into the decanulation decision
219622927|NCT04960592|DEVICE|Spinal Cord Stimulation|Temporary implantation of a clinical available neurostimulator.
219622928|NCT02836691|DEVICE|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
219622929|NCT02996227|PROCEDURE|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
219622930|NCT02996227|PROCEDURE|Epidural analgesia|Epidural catheters will be inserted preoperatively.
219547681|NCT02230605|OTHER|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
219547682|NCT02230605|OTHER|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
219547683|NCT02230605|OTHER|Short Form 36 Health Survey|To be completed at the Screening Visit
219547684|NCT02230605|OTHER|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
219547685|NCT02230605|OTHER|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
219547686|NCT02230605|OTHER|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
219547687|NCT01620840|DRUG|Lacosamide 10mg/ml|intravenous administration up to 10 days
219547688|NCT05920447|DEVICE|LMA|Monitor the ventilatory parameter and incidence of complications
219547689|NCT00531180|PROCEDURE|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
219547690|NCT00531180|PROCEDURE|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
219547691|NCT05404789|OTHER|Centrifugation|Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
219547692|NCT06722027|BEHAVIORAL|Compassion Centered Spiritual Health Team Intervention (CCSH-TI)|"Delivered to healthcare teams by spiritual health clinicians proficient in group facilitation. It is composed of 4 sessions delivered every other week and lasting 60 minutes each.~CCSH-TI sessions teach participants to attune to their interpersonal relationships; acknowledge and allow difficult emotions; and access compassion. It also provides psychoeducation about skillful coping strategies. Each session consists of didactic material about team norms and safety, a feeling check-in, facilitated group discussions about social connection and professional team building, and meditations to promote mindfulness, to cultivate a feeling of being nurtured, and to access compassion for self and others. CCSH-TI is delivered to healthcare teams by spiritual health clinicians proficient in group facilitation."
219547693|NCT06722027|BEHAVIORAL|Treatment as Usual|TAU refers to the current buffet of wellness and professional development activities that are available to employees at the Winship Cancer Institute.
219622931|NCT02996227|DRUG|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
219622932|NCT02996227|DRUG|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
219047203|NCT06901570|DRUG|Placebo Drug|Patients in the control group will receive a placebo version of Kuangxiong Aerosol for eight weeks, alongside guideline-recommended medications. The placebo will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
219047204|NCT06903442|BEHAVIORAL|Co-designed cardiovascular brief intervention|Patients will be randomised to a brief intervention where they will be informed of their high-sensitivity cardiac troponin value and cardiovascular risk.
219047205|NCT06903650|PROCEDURE|bilateral salpingectomy, ovarian arter doppler ultrasonography|The effect of salpingectomy operation on ovarian reserve
219047206|NCT06928506|DEVICE|Hi-OxSR device|The Hi-OxSR device consists of the Hi-Ox mask connected to a portable oxygen concentrator, with added tubing serving as a reservoir for rebreathed exhaled breath.
219047207|NCT06928506|DEVICE|Hi-Ox device|The Hi-Ox mask is connected to a portable oxygen concentrator.
219047208|NCT07085429|BIOLOGICAL|Blood and tissue sampling|"Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected:~* before any therapeutic intervention (T1) for a total volume of 36mL,~* prior to surgery (T-Surg) for a total volume of 24mL,~* at each progression (T2a, b, c…) for a total volume of 24mL,~* at the end of follow-up (T3) for a total volume of 24mL."
219047209|NCT07084844|DEVICE|WaveLigh Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
219547694|NCT06716580|DEVICE|Circulating Tumor DNA (ctDNA) Assay|Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
219622933|NCT07098234|DRUG|Vitamin D3|Neonates were given vitamin D3 (cholecalciferol) in an oral drops formulation (400 IU/drop), at a dose of 400 IU once a day until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours as an adjuvant therapy to phototherapy.
219622934|NCT07098234|PROCEDURE|Phototherapy|Neonates received only phototherapy until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours.
219641864|NCT04342767|DEVICE|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
219047210|NCT07085286|DEVICE|Continous IAP measurement|Continuous IAP measurement via existing Foley bladder catheter - allowing continuous APP, MPP and RPP calculation
219547695|NCT03733145|DRUG|Angiotensin II|Participants in the ACE inhibitors, angiotensin-receptor blockers (ARBs), and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
219547696|NCT06725160|BEHAVIORAL|Parent Coaching|Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
219547697|NCT06725160|BEHAVIORAL|Active Control|General parent support and psychoeducation based on components of standard PCIT.
219547698|NCT00457067|DRUG|Ranibizumab|
219547699|NCT03512483|BEHAVIORAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
219547700|NCT03317067|DRUG|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
219547701|NCT03317067|OTHER|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
218935965|NCT03820700|BEHAVIORAL|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
218935966|NCT03820700|BEHAVIORAL|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
218935967|NCT03820700|BEHAVIORAL|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
218935968|NCT02847676|PROCEDURE|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
218935969|NCT04193072|BEHAVIORAL|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
218935970|NCT02727439|OTHER|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
218935971|NCT01385397|OTHER|Preceptorship and virtual community|
218935972|NCT02799251|OTHER|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
218935973|NCT00620932|BEHAVIORAL|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
218935974|NCT06138860|OTHER|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
219047211|NCT06923046|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
219047212|NCT06923046|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In additionto time with their clinician, they will also have groupactivities that address relevant topics.
219047213|NCT07078812|BEHAVIORAL|Mirror Therapy|Mirror Therapy involves placing a mirror in the patient's midsagittal plane to reflect movements of the unaffected upper limb, creating a visual illusion of movement in the paretic limb. Patients perform bilateral symmetrical movements while focusing on the mirror reflection, helping to stimulate motor cortex activation and promote neuroplasticity. Sessions last 30 minutes, 5 days per week, for 6 weeks. This intervention is delivered in addition to standard stroke rehabilitation.
219047214|NCT07078812|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy consists of observing video demonstrations of functional upper limb movements, followed by the patient imitating the observed actions. Each session includes 15 minutes of watching goal-directed tasks and 15 minutes of active execution. This therapy aims to activate the mirror neuron system and enhance motor recovery. The protocol is administered 5 days per week for 6 weeks and is combined with routine stroke rehabilitation practices.
219047215|NCT07085143|DRUG|Compound Ciwujia Granules|Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; Continue concomitant SSRI medication therapy throughout the treatment period;
219047216|NCT07085143|DRUG|placebo|"1. Take placebo twice daily for 8 weeks;~2. Continue concomitant SSRI medication therapy throughout the treatment period;"
218935975|NCT06138860|OTHER|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
219047217|NCT07086365|DEVICE|Immersive virtual reality|Virtual reality with hand tracking and immersive environment
219047218|NCT07086365|DEVICE|Immersive Virtual Reality|Immersive virtual reality is a digital therapeutic approach to enhance neuroplasticity using virtual environment and hand tracking for functional motion in upper extremity
219547702|NCT07061821|OTHER|accelerated cardiac cine-MRI sequence|Addition of an accelerated cardiac cine-MRI sequence with deep learning-based image reconstruction to the standard cardiac MRI protocol, performed during the same session
219547703|NCT07128485|OTHER|Fentanyl test strips|Fentanyl test strips (FTS) are small strips of paper that can detect the presence of fentanyl in illicit drugs.
219547704|NCT07128485|BEHAVIORAL|Fentanyl test strip education|Developed in the R61 phase, the educational intervention will provide participants with knowledge about how to correctly use fentanyl strips.
219547705|NCT07128602|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes of anodal tDCS over the primary motor cortex contralateral to the participants surgical limb during a quadriceps torque matching task
219547706|NCT07128602|DEVICE|sham transcranial direct current stimulation (tDCS)|Participants receive sham tDCS in which the device only delivers current during the first and last 30 seconds while participants perform a quadriceps torque matching task
219547707|NCT07075822|OTHER|20g of FiberSMART®|20g of FiberSMART® dissolved in 250g of water
219547708|NCT07075822|OTHER|20g of Dextose|20g of dextrose dissolved in 250g of water
219547709|NCT07075822|OTHER|Water Control|250g of water
219547710|NCT05309135|DRUG|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
219547711|NCT06140355|BEHAVIORAL|Qigong|a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
219547712|NCT06140355|BEHAVIORAL|Daily 2 min pain management survey|Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
219547713|NCT05880082|DRUG|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
219547714|NCT06675175|DRUG|AZD4144|Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
219547715|NCT06675175|OTHER|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
219547716|NCT06904378|DRUG|Ontegimod|Per assigned dose level.
219622935|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
218935976|NCT05300438|DRUG|TSN084|Oral tablets
218935977|NCT00792571|DRUG|Beraprost Sodium Modified Release|
218935978|NCT00593476|OTHER|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
218935979|NCT00593476|OTHER|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
219641865|NCT00836888|BIOLOGICAL|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
219047219|NCT07086014|BEHAVIORAL|Cognitive Reappraisal|an emotion-regulation strategy while being asked to complete cognitive tasks.
219547717|NCT06904378|DRUG|Gemcitabine|The dose of gemcitabine is 1000 mg/m\^2.
219547718|NCT06904378|DRUG|Nab paclitaxel|The dose of nab-paclitaxel is 125 mg/m\^2.
219641866|NCT06049966|DRUG|Atezolizumab|TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
219547719|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
219547720|NCT07089992|DRUG|Pembrolizumab|Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses
219547721|NCT02287961|PROCEDURE|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
219547722|NCT02287961|PROCEDURE|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
219547723|NCT02287961|PROCEDURE|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
219547724|NCT02287961|PROCEDURE|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
218935980|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
218935981|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
218935982|NCT02490969|PROCEDURE|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
219047220|NCT05570409|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 1g bid for 6 months
219047221|NCT05570409|DRUG|Prednisolone|initially 1mg/kg in a step-down regime for 6 months
219047222|NCT05570409|DRUG|Mycophenolate Mofetil Placebo|MMF matching Placebo
219047223|NCT05570409|DRUG|Prednisolone Placebo|Prednisolone matching placebo
219547725|NCT06912295|DRUG|HL-1186|HL-1186 tablet for oral administration.
219547726|NCT06912295|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
219547727|NCT00025935|DRUG|Lithium|
219547728|NCT06495450|DEVICE|Omnidirectional Virtual Reality and Treadmill Training|Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
219547729|NCT06495450|BEHAVIORAL|Traditional Exercise|A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
219547730|NCT04981925|BEHAVIORAL|MBSR treatment|"Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up."
219547731|NCT03031821|DRUG|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
219547732|NCT03031821|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
219547733|NCT07112040|BEHAVIORAL|Behavioral - ASSYST-VS Protocol|"The ASSYST-SV protocol consists of three sessions, each lasting approximately 90 minutes, ideally delivered once per week over a three-week period.~The intervention includes:~Session 1: Psychoeducation: Explanation of typical responses to sexual trauma, providing information about the recovery process, and establishing a strong therapeutic alliance between the client and therapist.~Sessions 1-3: Emotional self-regulation using trauma-sensitive yoga exercises adapted for survivors of sexual violence.~Sessions 2-3: Trauma desensitization using EMDR-informed techniques, including bilateral stimulation and self-applied tools such as the Butterfly Hug.~Safety procedures and closure are included in all sessions to ensure emotional containment and promote participant well-being.~The intervention is delivered by trained professionals in specialized support services for victims of gender-based violence."
219547734|NCT05121844|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
219547735|NCT06912945|PROCEDURE|using diode laser 980nm wavelength in benign laryngeal lesions|using diode laser 980nm wavelength in treatment of benign laryngeal lesions
219547736|NCT06912945|PROCEDURE|using diode laser 450nm wavelength in benign laryngeal lesions|using diode laser 450nm wavelength in treatment of benign laryngeal lesions
219547737|NCT06912945|PROCEDURE|using traditional cold instrumentations in benign laryngeal lesions|using traditional cold instrumentations in treatment of benign laryngeal lesions
219547738|NCT00667212|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
219047224|NCT07161115|RADIATION|Reduced-field short-course radiotherapy|A dose of 25 Gy in 5 fractions was delivered as short-course radiotherapy, with one fraction per day, completing treatment within one week. The target volume was delineated using both CT and MRI. Compared to conventional radiotherapy fields, the irradiated volume was significantly reduced to include only the primary tumor and any metastatic lymph nodes as identified on MRI and CT.
219047225|NCT07161115|DRUG|Immunotherapy combined with chemotherapy|After completion of radiotherapy, chemotherapy with the XELOX regimen (oxaliplatin 130 mg/m² on day 1 plus capecitabine 1500 mg/m² on days 1-14, every 3 weeks) was initiated in combination with sintilimab immunotherapy (200 mg every 3 weeks) for 4 cycles.
219047226|NCT07161115|RADIATION|Standard short-course radiotherapy|"Patients in the standard short-course radiotherapy group will receive 25 Gy in 5 fractions, once daily. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas."
219047227|NCT07161115|RADIATION|Standard long-course radiotherapy|Patients in the standard long-course radiotherapy group will receive 50 Gy in 25 fractions, once daily, five days per week, with concurrent oral capecitabine chemotherapy. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas.
219047228|NCT07161115|DRUG|Chemotherapy|Two weeks after the completion of radiotherapy, patients will receive four cycles of CAPOX chemotherapy.
219047229|NCT07160101|OTHER|Eggshell derived nano hydroxyapatite|Eggshell derived nano hydroxyapatite has high solubility and allows faster integration \& replaces with osseous tissue
219047230|NCT07160101|OTHER|Hydroxyapatite|Hydroxyapatite has similar chemical composition with crystalline structure of native bone
219047231|NCT07163546|BEHAVIORAL|Lifestyle intervention|"A lifestyle intervention is an occupational therapy intervention program that aims to help individuals change their lifestyle by encouraging greater engagement in meaningful activities. This program aims to help participants develop healthy routines and habits. It offers a perspective that combines various approaches such as patient education, occupational self-analysis, problem-solving, and building motivation to prevent and manage chronic health problems. Participants gain self-analysis and problem-solving skills while experiencing positive lifestyle changes and developing healthy routines.~The lifestyle intervention was planned as a total of 8 sessions, 2 sessions per week."
219047232|NCT07160036|DEVICE|RLRL(Model RS-200-2A, Eyerising; Suzhou Xuanjia Optoelectronic Technology Co., Ltd., Suzhou, China))|use RLRL twice a day
219047235|NCT07166640|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg is titrated if insertion is unsuccessful.
219047236|NCT07167810|PROCEDURE|bone cement|chest wall reconstruction using polymethyl methacrylate PMMA bone cement
219047237|NCT07167810|PROCEDURE|steel wires|chest wall reconstruction using no 05 stainless sternal steel wires
219047238|NCT07167199|PROCEDURE|Subcuticular monocryl suture|Under the skin suture placed by hand
219547739|NCT00667212|BEHAVIORAL|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
219547740|NCT06238843|DRUG|Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）|"Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles.~Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)."
219547741|NCT06238843|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .
219547742|NCT06921967|DEVICE|Rose K2|Corneal RGP lens with flexible parameters.
219547743|NCT06921967|DEVICE|Onefit MED|Scleral RGP lens with flexible parameters.
219547744|NCT07110207|BIOLOGICAL|Blood test|Metabolic measurements and measurements of hormones related to food intake
219547745|NCT07110207|OTHER|Interrogation of the subject|Collection of socio-demographic data, medical and family history, medication
219547746|NCT07110207|OTHER|Cognitive assessment|MMSE and MoCA cognitive tests
219547747|NCT07110207|OTHER|Nutritional assessment|Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)
219547748|NCT07110207|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution (prepared beforehand)
219547749|NCT07110207|OTHER|Sucrose taste detection test|Triangular test
219547750|NCT06916221|BEHAVIORAL|Long Term Memory|Tablet computer game designed to stimulate environmental enrichment via an adaptive and immersive experience learning virtual neighborhoods and errands in order to complete assigned errands.
219547751|NCT06916221|BEHAVIORAL|Worder|Tablet computer game designed to stimulate interest in solving word puzzles, much like the Boggle game.
219547752|NCT07116681|DRUG|Inhaled treprostinil|Inhaled treprostinil is an inhaled prostacyclin analog which triggers pulmonary arterial dilation. This is the only intervention in this trial.
219547753|NCT07114796|DIETARY_SUPPLEMENT|Standard Commercial Lactose-Free Formula|"COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration: 7 days"
219547754|NCT07114796|DIETARY_SUPPLEMENT|Rice based recipe method feeding formula|"Rice based recipe method feeding formula Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Rice-Based Lactose-Free Therapeutic Formula~Description: A locally prepared rice-based formula developed as an alternative to F-75, using puffed rice, sugar, oil, and micronutrient mix. It is lactose-free and used for feeding well-nourished children with persistent diarrhea.~Route: Oral/Nasogastric~Dosage: As per WHO feeding schedule - 130 ml/kg/day in 2-hourly feeds.~Duration: 7 days during the stabilization phase~For Arm: COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration:"
219547755|NCT06907017|DEVICE|LVAS|Implantation and use of the CorWave LVAS to evaluate the safety and effectiveness of the CorWave LVAD to treat advanced left ventricular heart failure.
219547756|NCT06920992|BEHAVIORAL|Working memory and set-switching tasks|A behavioral task that requires subjects to switch between stimulus- response contingencies based on a colored contextual cue. In addition, a behavioral task that requires subjects to memorize a set of visual stimuli. Subjects will then be presented with a test set and will be asked to indicate whether any stimulus therein is not part of original memorized set.
219547757|NCT06923033|BEHAVIORAL|Smartphone App|Participants will download a study app that will allow them to track smoking urges and abstinence. Access to augmented reality will become available after 48 hours of self-reported abstinence.
219547758|NCT07121972|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo Magnetic resonance (MR) imaging
219547759|NCT07121972|DEVICE|Artificial Intelligence (AI)|AI applied to MRI images
219547760|NCT07131072|OTHER|daiphragm mobility by ultrsound|fibrosis score, alveolitis score by CT Chest
219547761|NCT07131072|OTHER|spirometry ,DLCo|FEV1, FVC, FEV1/FVC, DLCo
219547762|NCT07129980|DEVICE|ARGOS Biometer|The ARGOS biometer uses swept-source optical coherence tomography (SS-OCT) with a 1060 nm tunable laser to capture high-resolution B-scan images of the entire eye. This technology enables sum-of-segments (S-O-S) biometry, measuring each ocular component-corneal thickness, aqueous depth, lens thickness, and vitreous length-individually and summing these values to determine total axial length. SS-OCT provides deep tissue penetration while simultaneously capturing keratometry, white-to-white, and pupillometry data in a single scan. For keratometry measurements, the ARGOS uniquely employes SS-OCT-based telecentric keratometry, which involves projection of 16 infrared LEDs in a wider 3.0 mm ring pattern onto the cornea and calculates curvature from those reflections.
219547763|NCT07139080|BEHAVIORAL|Mobile education|It consists of participants who will download the mobile patient education and breathing exercise reminder program and apply it for 10 weeks.
219547764|NCT07140367|PROCEDURE|Transarterial Microembolization|Identification of the hypervascularization of the knee. Selective and super-selective catheterization of pathological genicular arterial branches, through the use of micro-catheters. - Injection of embolizing material (Nexsphere-F - Kardia) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
219547765|NCT07139392|BIOLOGICAL|Albumin (5% serum-protein solution containing immunoglobulins)|"* Preoperative Phase:~  * Oral hygiene instruction~ * Phase I periodontal therapy~ * Initial photography and papillary height measurements using digital calipers or customized stents~* Surgical Technique:~  * Local anesthesia~ * Intrasulcular incision around target teeth~ * Papilla preservation flap~ * Harvesting CTG from the palate~ * Injection of liquid Bio-PRF at the papillary base (test group)~ * CTG positioned in the papilla region~ * Suturing with microsurgical technique~* Postoperative Protocol:~  * Analgesics (e.g., ibuprofen 400 mg)~ * Chlorhexidine 0.12% mouth rinse for 2 weeks~ * Suture removal at 10-14 days~ * Follow-up at 1 month, 3 months, and 6 months"
219547766|NCT07139392|BIOLOGICAL|connective tissue graft|Local anesthesia. Intrasulcular incision around target teeth. Papilla preservation flap. Harvesting CTG from the palate
219547767|NCT07138729|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT|"For 68Ga-FAPI PET/CT scan，each patient was injected with 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) body weight of 68Ga-FAPI. PET/CT from skull to feet was performed 60±5 min post-injection.~For 99mTc-CTR-FAPI SPECT scan:each patient was injected with 10-20mCi 99mTc-CTR-FAPI . Planar SPECT scan and SPECT/CT were performed 60±5 min post-injection."
219622936|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
219547768|NCT07139119|BEHAVIORAL|Health Belief Model-Based Educational Program for Skin Cancer Prevention Among Female Healthcare Workers|"This blended educational intervention employs the Health Belief Model (HBM) to promote skin cancer preventive behaviors in female healthcare workers in Ahvaz, Iran. The 7-session program (each 45 minutes) combines in-person training with WhatsApp-based follow-ups.~Participant Components:~* Structured sessions targeting knowledge and HBM constructs such as perceived susceptibility, severity, benefits, barriers, self-efficacy, and cues to action.~* Use of multimedia tools including videos, pamphlets, and interactive discussions.~* Motivational messaging, stress management clips, and role-modeling techniques to build self-efficacy.~* Visual cues such as posters placed in healthcare workplaces.~* Daily reminder messages to reinforce behavior change.~Unique aspects distinguishing this intervention include its specific tailoring for female healthcare workers in a high UV-exposure region, the combined digital and face-to-face delivery approach, and comprehensive focus on all HBM construc"
219547769|NCT07140107|BEHAVIORAL|AI-generated PLS|Reading AI-generated Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
219547770|NCT07140107|BEHAVIORAL|Original PLS|Reading original Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
219547771|NCT07139639|DRUG|Guanxinning Tablets|"Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* NMPA Approval No. Z20150028~* Administration: 4 tablets orally, three times daily for 6 months"
219547772|NCT07139639|DRUG|Matching Placebo for Guanxinning|"Matching Placebo for Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* Drug Product Certificate of Analysis Approval No.YF-R-C037A-2024104-A~* Administration: 4 tablets orally, three times daily for 6 months"
219547773|NCT07140302|PROCEDURE|deep brain stimulation|"Stereotactic implantation of DBS electrodes with chronic electrical stimulation of target nuclei for dystonia.~or Stereotactic radiofrequency ablation of dystonia-related target nuclei."
219622937|NCT06865053|OTHER|Heart failure screening pathway|Heart failure screening pathway in general medicine consultations (questionnaire, NT-proBNP level, echocardiographic examination)
219622938|NCT07101263|DIETARY_SUPPLEMENT|Standard whey|A typical whey protein is given that differs in chemical structure from the atypical whey protein used in the experimental group
219622939|NCT07101263|DIETARY_SUPPLEMENT|Hydrolyzed whey|This type of whey has different chemical structure from typical wheys such as that used in this nstudy's control group
219547774|NCT07138859|DEVICE|Robot assisted radical right hemicolectomy (D3 lymph node dissection)|RRH (Robotic Right Hemicolectomy) group: Experimental group: Performing robotic radical right hemicolectomy (D3 lymph node dissection)
219622940|NCT07103070|DEVICE|Arch supports|Set of 3 arch supports supplied by Good Feet
219622941|NCT02970487|DEVICE|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
219622942|NCT07104929|DIETARY_SUPPLEMENT|Beta Glucan|12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500
219622943|NCT06208306|DRUG|Itepekimab (SAR440340)|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
219622944|NCT06208306|DRUG|Placebo|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
219622945|NCT01956201|DRUG|Atorvastatin 20mg|\[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
219622946|NCT01956201|DRUG|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
219622947|NCT01956201|OTHER|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
219622948|NCT07112326|BEHAVIORAL|Community Gardening Program|Participants will take part in a 26-week community gardening program with Ecosource, which involves cooking classes, as well as nutrition and type 2 diabetes education. These weekly sessions will be led by Ecosource and take place in community gardens across different sites in Mississauga and at Ecosource's teaching kitchens. Diabetes education sessions will take place once per month (6 times/program) and will be led by subject matter experts including dietitians/diabetes educators. The delivery format for these sessions may be virtual or in-person depending on the topic covered and participant availability. Participants will be invited to a WhatsApp Community Chat to stay motivated and engaged with the study over the 26-week period.
219622949|NCT07112430|DRUG|Fentanyl Citrate (Intranasal)|Fentanyl citrate will be administered intranasally at a dose of 2 mcg/kg via a mucosal atomization device, 5 minutes prior to ROP screening. Used in conjunction with standard non-pharmacologic comfort strategies.
219047239|NCT07167199|DEVICE|Subcuticular absorbable staple using Insorb device|Under the skin stapling device that delivers absorbable staples
219047240|NCT07170566|DEVICE|innovaMatrix AC|"nnovaMatrix® AC consists of ECM derived from porcine placental material. The device is supplied in a variety of sterile sheet configurations. It is packaged in double peel-open packages and is intended for single use only. The device is terminally sterilised using E-Beam sterilisation and is for licensed healthcare practitioner use only.~InnovaMatrix® AC is composed of collagen, elastin, laminin, fibronectin, hyaluronic acid and sulphated glycosaminoglycans. The wound dressing is provided in sheets that are approximately 40-100 microns thick in sizes ranging from 1 x 1cm to 5 x 5cm. They are provided as single-use, sterile wound coverings.~InnovaMatrix® AC received Food and Drug Administration (FDA) clearance under K193552 on October 21, 2020. InnovaMatrix® AC has an FDA classification of KGN, which designates it as a collagen wound dressing."
219047241|NCT07164261|OTHER|progressive muscle relaxation training|Progressive muscle relaxation training will be performed twice a week, each session lasting 20-30 minutes, for a total of 12 sessions over 6 weeks.
219547775|NCT07138859|DEVICE|Laparoscopic assisted radical right hemicolectomy (D3 lymph node dissection)|LRH (Laparoscopic Right Hemicolectomy) group: control group: underwent laparoscopic radical right hemicolectomy (D3 lymph node dissection)
219622950|NCT07112430|DRUG|Normal Saline (Placebo, Intranasal)|An equivalent volume of intranasal normal saline will be administered using a mucosal atomization device, 5 minutes prior to ROP screening.
219641867|NCT06049966|DRUG|Carboplatin|SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
219206174|NCT06411522|DEVICE|Mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.05% CHX + 0.05% CPC mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
219206175|NCT06844825|OTHER|Tele rehabilitation|The experimental group will receive the treatment remotely by ZOOM platform and phone call
219641868|NCT06049966|DRUG|Etoposide|ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
219206176|NCT06844825|OTHER|usual care only|in-person usual care provided by the physical therapist
219206177|NCT06754657|PROCEDURE|Continuous perineural infusion|infusion rate 4 ml/h, with 5 ml boluses (30-minute lockout). The PCA button disabled
219206178|NCT06754657|PROCEDURE|Single injection|infusion rate 0 ml/h, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration
219206179|NCT05457725|BEHAVIORAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
219206180|NCT05457725|BEHAVIORAL|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
218935983|NCT02975362|OTHER|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
219206181|NCT06089551|DRUG|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
219206182|NCT06875037|DEVICE|Electric stimulation removable appliance|The device will be used with the fixed appliance to accelerate orthodontic tooth movement (i.e., canine retraction).
219206183|NCT06875037|PROCEDURE|Traditional orthodontic fixed appliance without accleration|The traditional method of canine retraction will be employed using fixed appliances. No additional appliances will be used to activate orthodontic tooth movement.
219206184|NCT06782815|DEVICE|Acupuncture|acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
219206185|NCT06782815|DEVICE|Acupuncture|（1）Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; （2）Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.
219547776|NCT07139288|BEHAVIORAL|therapeutic exercise program|Each subject completes four dynamic tasks, including ankle resistance exercises, resistance kinematic chain exercises, heel raise exercises, and BOSU ball exercises at 3 times per week for 4 weeks
219547777|NCT07139288|DEVICE|Extra corporeal shock wave therapy|"The extracorporeal shock waves will be delivered with 2,500 shockwave impulses (6 Hz), The intensity of extracorporeal shock waves is adjusted according to the patients' degree of tolerance to the pain. In the experimental group, the extracorporeal shockwave will apply to the anterior talofibular ligament, posterior talofibular ligament, calcaneofibular ligament, and tibialis anterior muscle.~twice per week for 4 weeks"
219547778|NCT07139288|DEVICE|photobiomodulation Therapy|Photobiomodulation therapy will be performed with a laser an 810 nm wavelength, 0 \~ 500 mW adjustable and continuous power output, and a 0.4 cm beam diameter was used. The subjects in the group C will be treated with the laser at a dose of 239 J/cm2 (power: 100 mW; intensity: 796 mW/cm2; irradiation time: 5 min/point, 20 min in total) at 3 times per week for 4 weeks
219547779|NCT07139366|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219547780|NCT07139366|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 1 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219547781|NCT07139366|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
219547782|NCT07139366|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
219547783|NCT07139366|DRUG|Saccharomyces Boulardii Oral Powder|Saccharomyces boulardii combined with Bismuth-containing quadruple therapy:given for 14 days at a dose of Saccharomyces boulardii powder 250 mg 2 packets BID#bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219547784|NCT07139470|DRUG|Sacituzumab Tirumotecan + anlotinib|"Phase I part: 3 prespecified doses (sac-TMT 4mg/kg Q2W +anlotinib 8mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib10mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib12 mg Q3W).~Phase II part: sac-TMT patients Q2W +anlotinib RP2D Q3W."
219547785|NCT07139249|OTHER|The high intensity interval training|The training program for students in groups 1 and 2 involves high intensity interval training exercises, conducted three times per week for six weeks. The sessions include a 10-minute warm-up at 40% Heart Rate Reserve, four high-intensity work periods at 85-95% Heart Rate Reserve, three low-intensity work periods at 60-70% Heart Rate Reserve, and a 5- 10 minute cool down at 30% Heart Rate Reserve.
219206186|NCT06782698|BEHAVIORAL|Home-based exercise program|"The home-based program follows the National recommendations on Physical Exercise for Cancer Patients \[Bruno RC, 2023\]. It is logbook-guided and technology-enabled.~It consists of:~* Two initial supervised explanatory sessions, in the Physic and Rehabilitation Medicine Gym of our institution.~* Followed by 2 muscular training sessions + 3 additional periods of aerobic exercise per week in their home environment until the end of neoadjuvant treatment. Patients are given a logbook with instructions and a sports bracelet for heart rate monitoring.~The training sessions will be monitored by smartwatch heart rate measurements and self-notion of effort according to Borg Categorization \[Borg GA, 1982\] and recorded by the participants in the Mi Fitness application or an Exercise Diary.\[Nilsen TS, 2018\]"
219206187|NCT06782698|BEHAVIORAL|Promotion of Healthy Physical Activity|"The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist."
219206188|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.25mg, s.c.,day 1 single dose .
219206189|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.5mg, s.c.,day 1 single dose .
219206190|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,1mg, s.c.,day 1 single dose .
219206191|NCT06749860|DRUG|Disitamab Vedotin + tislelizumab + bevacizumab|"Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use."
219206192|NCT06761417|DRUG|Mitoxantrone liposome|Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
219206193|NCT06761417|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
219206194|NCT06761417|DRUG|Anlotinib|Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
219206195|NCT06760871|OTHER|nebulised distilled water|After the surgery, the patients will be admitted to the ward and taken to the bed, and their care and treatment will be applied by the nurse. Afterwards, the researcher will apply cold vapour as an inhaler for 15 minutes. For this application, the stand to which the ultrasonic nebuliser device is connected will be positioned close to the patient's bed. 200 ml of distilled water will be placed in the liquid reservoir of the device. The patient will be given a comfortable position and the device will be adjusted so that the steam hose covers the patient's mouth and nose and the patient will be allowed to inhale the steam through the mouth and nose. After the electrical connection of the device is provided, the device will be started and cold steam application will begin. In the 1st hour, inhaler cold water vapour application will be performed for 15 minutes.
219206196|NCT06737679|BEHAVIORAL|Body Scan|"Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online."
219206197|NCT06737081|DRUG|SAL-0951 tablets 4mg|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
219206198|NCT06737081|DRUG|SAL-0951 tablets 5mg|initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
219622951|NCT07110857|PROCEDURE|Cervical plexus block with 0.2 % Naropeine|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.2 % ropivacaine (Naropeine) uni- or bilateral depending on the surgical incision
219641869|NCT00001810|DRUG|Voriconazole|
219641870|NCT00887523|BEHAVIORAL|radiation in prone position|radiation in prone position
218935984|NCT02975362|OTHER|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
219641871|NCT00887523|BEHAVIORAL|radiation in supine position|radiation in supine position
218935985|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
218935986|NCT06395337|DRUG|[111In]In-DOTA-ANTI-CEA antibody injection|tracer injection
218935987|NCT06395337|RADIATION|SPECT/CT scan|abdominal and thoracic SPECT/CT scan
218935988|NCT06395337|PROCEDURE|Resection surgery|oncological resection surgery will be performed extended with the use of dual-modality imaging.
218935989|NCT05709093|DRUG|Lemzoparlimab+Azacitidine (AZA)|"1. Lemzoparlimab is administered by intravenous (IV) infusion once a week at a dose of 30 mg/kg in 28-day treatment cycles~2. Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles."
218935990|NCT05709093|DRUG|Azacitidine (AZA)|AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.
218935991|NCT05400382|BEHAVIORAL|Mindfulness|Meditation training to help reduce stress and reactivity to pain and other stressors.
218935992|NCT05033704|DRUG|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
219547786|NCT07139249|OTHER|The study moderate continuous training|All students in groups 3\&4 will receive moderate continuous training 3 times per week for 6 weeks. Each session 40 to 50 minutes included a 5 to 10 minute warm-up, fo followed by 30 minutes of moderate aerobic exercise (treadmill walking exercise) with constant intensity at 60% to 70% Heart Rate Reserve and 5 to 10 minutes cool-down
219547787|NCT07138521|DRUG|Linezolid (IV and PO)|No dose change and continued linezolid 600 mg every 12 hours.
219547788|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 300 mg every 12 hours.
219547789|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 600 mg every 24 hours.
219547790|NCT07139002|OTHER|Bobath Therapy|The group will repeat 10 exercises (facilitated rolling, sitting balance exercises, weight shifting in standing, functional sit-to-stand, stepping practice, reaching activities, wall slides, therapeutic ball exercises, stair climbing practice, and breathing and relaxation techniques) for 8 weeks.
219547791|NCT07139002|OTHER|Sensory Training|The group will repeat 9 exercises (texture discrimination, shape, size, and discrimination, tactile recognition, proprioception training, temperature differentiation, tactile localization, sensory mapping, sensory training through functional activities, and tabletop sensory exercises) for 8 weeks.
219547792|NCT05885568|BIOLOGICAL|blood sampling|Blood sampling from healthy volunteers
219547793|NCT05885568|OTHER|drone transportation|drone transportation
219547794|NCT05885568|OTHER|car transportation|car transportation
219622952|NCT07110857|PROCEDURE|Cervical plexus block with saline placebo|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.9 % saline uni- or bilateral depending on the surgical incision
218935993|NCT01615536|PROCEDURE|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
218935994|NCT01615536|PROCEDURE|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
218935995|NCT01088048|DRUG|Idelalisib|Idelalisib tablet administered orally
218935996|NCT01088048|DRUG|Rituximab|Rituximab administered intravenously
218935997|NCT01088048|DRUG|Bendamustine|Bendamustine administered intravenously
219206199|NCT06739395|DRUG|Olaparib tablet|Usage and dosage: The recommended dosage is 200mg, twice a day, equivalent to a total daily dose of 400mg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided(from the I-PREDICT study).
219547795|NCT00469521|DRUG|Refresh Tears, 9582X|
219547796|NCT02347111|DRUG|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
219547797|NCT02347111|DRUG|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
219547798|NCT05984290|DEVICE|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
219547799|NCT07140042|OTHER|Survey|Survey
219547800|NCT07139028|OTHER|Tibialis Anterior resistance training and ladder drills|19 participants will be in experimental group A, they will perform tibialis anterior resistance training exercises with ladder drills (3 times/ week for 6 weeks) along with traditional training
219547801|NCT07139028|OTHER|Traditional training|19 participants will be in control group B,they will perform only traditional training (guided by coach)
219547802|NCT07138612|BEHAVIORAL|Peer education group|Students will learn urinary catheterization through peer education.
219547803|NCT07140510|DRUG|Dinalbuphine Sebacate|Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA
219547804|NCT07140510|DRUG|Normal Saline|Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block
219547805|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
219547806|NCT04725513|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
219547807|NCT04725513|DEVICE|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
219547808|NCT04725513|OTHER|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
219547809|NCT07138742|DRUG|Steroid eye drops|steroid eye drops will be used in control group as usual regimen in treatment of vernal keratoconjunctivitis
219547810|NCT07138742|DRUG|Tacrolimus eye drops|Compound Tacrolimus eye drops in 2 different concentrations will be assessed in treatment of vernal keratoconjunctivitis in terms of efficacy and safety being compared with steroid eye drops
219622953|NCT07113041|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
219622954|NCT07113041|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training (dose matched to the experimental group) administered by the Physical therapist.
219622955|NCT07113353|DEVICE|Brain4Care|Non-invasive intracranial pressure monitor
219641872|NCT00355225|PROCEDURE|ITN distribution channel|
219641873|NCT04803422|DRUG|Antibiotic|The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
218935998|NCT01088048|DRUG|Ofatumumab|Ofatumumab administered intravenously
218935999|NCT01088048|DRUG|Fludarabine|Fludarabine administered orally
218936000|NCT01088048|DRUG|Everolimus|Everolimus administered orally twice daily until disease progression
219206200|NCT06739395|DRUG|Temozolomide capsule|Administration method and dosage: 75mg/m2, orally administered for 7 consecutive days, with a treatment cycle of every 21 days.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206201|NCT06739395|DRUG|Anlotinib|Usage, dosage, and administration method: Take orally once a day before breakfast. Take the medication continuously for 2 weeks and stop taking it for 1 week, that is, 3 weeks (21 days) is one course of treatment. Until disease progression or intolerable toxic side effects occur.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206202|NCT06739395|DRUG|Trametinib tablet|Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206203|NCT06739395|DRUG|Dabrafenib|Usage and dosage: Take 150mg orally twice a day, with an interval of about 12 hours.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. When this product is used in combination with trametinib, it should be taken once a day at the same time, along with this product administered in the morning or evening.The dosage for combined use will be adaptively adjusted by the researcher.
219206204|NCT06739395|DRUG|Vebreltinib Enteric Capsules|Usage and dosage: The recommended starting dose is 200 mg/time, taken orally twice a day (once in the morning and once in the evening), until disease progression or intolerable toxicity occurs.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206205|NCT06739395|DRUG|Alpelisib Pill|Usage and dosage: The recommended dosage is 300mg (two 150mg film tablets), taken once a day with food; Continue treatment until the disease worsens or unacceptable toxicity occurs.Administration method: Patients should take aspirin at approximately the same time every day and swallow the entire aspirin tablet (the tablet should not be chewed, crushed, or separated before swallowing).The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206206|NCT06739395|DRUG|Sacituzumab Govitecan-Hziy 180 MG|Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219547811|NCT07140523|DRUG|SRSD107|SRSD107 is an investigational siRNA product for anticoagulants.
219547812|NCT07140523|DRUG|enoxaparin|Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
219547813|NCT07138599|DEVICE|Virtual Reality ECMO Simulation Training|The intervention is a virtual reality simulation of an ECMO system, whereby the user is guided through the steps of how to perform an 11 step ECMO circuit check, and specific indicators of abnormal functioning are highlighted. The simulation is produced in Unreal Engine 4.23, and it simulates a virtual ICU and a virtual patient.
219622956|NCT07112027|OTHER|Behavioral and MR scanning|After enrollment, participants will be screened on the basis of the inclusion and exclusion criteria. Subsequently, during the single study, participants will be administered a series of questionnaires (Edinburgh Handedness Inventory - Short Form; Evaluation of social related abilities, competences, and traits: Autism Quotient Test, DASS-21, SIAS, DERS, Ekman test; SET; I-TIPI, and conceptual ratings on semantic dimensions (moral, social, political). Then, an MR acquisition without contrast will be performed. Specifically, we will acquire structural, resting state and functional (BOLD) sequences, in the latter case during the administration of a semantic categorization task. The task is aimed to ascertain participants' responses time and accuracy in processing abstract concepts. Participants will be required to indicate the category of each of the visually presented words by means of button press. The study visit will last 3 hours in total.
218936001|NCT01088048|DRUG|Bortezomib|Bortezomib administered as a subcutaneous injection
218936002|NCT01088048|DRUG|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
218936003|NCT01088048|DRUG|Lenalidomide|Lenalidomide administered orally
219547814|NCT07138599|OTHER|Instructional Video of Certified Perfusionists on Performing a Circuit Check|This intervention is a seven minute narrated high definition video in which a two certified perfusionist describe how to perform the identical eleven step circuit check on a primed Cardiohelp circuit, what to look for in terms of pathology or abnormal function, and . Participants will view the clip once on a laptop with headphones in a quiet room and may ask questions or receive clarification from the study coordinator, and this will be demonstrated on the physical ECMO machine and/or circuit present. The video conveys the checklist at reduced speed and explaining the purpose of each step and has been reviewed by the expert panel for accuracy and completeness.
219547815|NCT07138846|DRUG|MRG004A plus best supportive care|MRG004A will be administrated as specified in the protocol.
219547816|NCT07138846|DRUG|Placebo plus best supportive care|Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.
219547817|NCT07139964|DIETARY_SUPPLEMENT|Vitamin D3|Participants receive oral vitamin D3 (cholecalciferol) 10,000 IU daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. Vitamin D3 is provided in identical-appearing capsules. Compliance is monitored using the MMAS-8 adherence scale.
219547818|NCT07139964|OTHER|Placebo|Participants receive an oral placebo capsule daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. The placebo is identical in appearance to the vitamin D3 capsule. Compliance is monitored using the MMAS-8 adherence scale.
219206207|NCT06739395|DRUG|Lenvatinib Capsules|Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219547819|NCT07138950|OTHER|Mulligan Bent Leg Raise (BLR) Technique|The Mulligan bent leg raise technique involves isometric contraction followed by stretches applied to the hamstring muscle in specific directions. The aim is to increase hamstring flexibility and active knee extension range of motion. The participant lay supine on an elevated bed, while the physiotherapist sat lateral to the leg to be stretched, placing the popliteal fossa of the participant's knee on their shoulder. The hip and knee of the leg to be stretched were flexed to 90°. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with their leg and then relax. At this point of relaxation, the physiotherapist pushed the flexed knee as far forward as possible in the direction of hip flexion within a painless range. This position was held for 5 seconds at the end of the movement. Then, the neutral position was returned, and the procedure was repeated three times
219547820|NCT07138950|OTHER|Static Stretching|Participants lay supine on a stretcher with their backs straight. With the knee fully extended, the physical therapist placed the participant's leg on their shoulder and supported the ankle
219547821|NCT07139600|BIOLOGICAL|CD7 CAR-T cells infusion|Autologous T cells are collected by leukapheresis, activated, and transduced with a retroviral vector encoding a CD7-specific CAR. Following fludarabine/cyclophosphamide lymphodepletion, CD7-CAR-T cells (3 × 10\^6/kg) are infused intravenously. This intervention is distinguished by its CD7 target, aiming to suppress aberrant T-cell-mediated marrow destruction and restore hematopoiesis in aplastic anemia.
219547822|NCT07139769|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' needs and preferences for psychosocial intervention.
219547823|NCT02836262|DEVICE|HIT Hip Replacement System|HIT Hip Replacement System
219206208|NCT06739395|DRUG|Pazopanib Pill|"Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided."
219206209|NCT06739395|DRUG|Palbociclib Pill|Usage, dosage, and administration method: 100mg, orally administered once daily for 21 consecutive days, followed by a 7-day discontinuation; Every 28 days is a treatment cycle.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219547824|NCT05499728|OTHER|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
219547825|NCT02179593|OTHER|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
219547826|NCT02179593|OTHER|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
219547827|NCT04903340|PROCEDURE|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
219547828|NCT00808717|DRUG|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
219547829|NCT00798603|BIOLOGICAL|bevacizumab|
219547830|NCT00798603|DRUG|carboplatin|
219547831|NCT00798603|DRUG|pemetrexed disodium|
219547832|NCT02435264|OTHER|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
219547833|NCT05387109|DRUG|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
219206210|NCT06739395|DRUG|Chidamide|Usage and dosage: It is recommended to take 30mg (6 tablets) each time, twice a week, with an interval of no less than 3 days between each dose (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). It should be taken 30 minutes after breakfast.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
218936004|NCT01621802|BIOLOGICAL|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
218936005|NCT01621802|BIOLOGICAL|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
218936006|NCT01621802|BIOLOGICAL|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
219206211|NCT06739395|DRUG|PD-1/PD-L1/PD-1&CTLA4 inhibitor|Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219547834|NCT03501511|BEHAVIORAL|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
219547835|NCT03501511|BEHAVIORAL|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
219547836|NCT05325515|DRUG|Conventional alendronate|Conventional alendronate 70mg weekly
219547837|NCT05325515|DRUG|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
219547838|NCT00966160|DRUG|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
219547839|NCT00966160|DRUG|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
219547840|NCT05496920|DIAGNOSTIC_TEST|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
219547841|NCT05496920|DIAGNOSTIC_TEST|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
219547842|NCT01283503|DRUG|BKM120|
219547843|NCT04069936|BIOLOGICAL|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
219547844|NCT04069936|BIOLOGICAL|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
219547845|NCT04069936|DRUG|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
219547846|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
219547847|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
219547848|NCT04534621|OTHER|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
219547849|NCT00008060|DRUG|FOLFIRI regimen|
219547850|NCT00008060|DRUG|FOLFOX regimen|
219547851|NCT00008060|DRUG|fluorouracil|
219547852|NCT00008060|DRUG|irinotecan hydrochloride|
219547853|NCT00008060|DRUG|leucovorin calcium|
219547854|NCT00008060|DRUG|oxaliplatin|
219547855|NCT01538160|DRUG|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
219547856|NCT00405860|DRUG|CellCept (mycophenolate mofetil)|
219547857|NCT01074827|OTHER|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
219547858|NCT06203080|DRUG|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
219547859|NCT06203080|DRUG|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
219547860|NCT03904095|PROCEDURE|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219622957|NCT07112560|DIAGNOSTIC_TEST|Standard screening procedure for amblyopia|"The standard examination for amblyopia screening consists of three steps:~A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask.~A cover/uncover test, during which the child is required to fixate on an image A Lang I stereopsis test performed under binocular vision."
219641874|NCT04606823|PROCEDURE|Minimally invasive surgery|The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
219641875|NCT04606823|OTHER|Glasgow Benefit Inventory (GBI)|A quality of life-questionnaire is to be completed by the subjects at one occasion.
219206212|NCT06739395|DRUG|Target Gene|Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
219206213|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
219206214|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
219547861|NCT03904095|PROCEDURE|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219547862|NCT03904095|PROCEDURE|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219547863|NCT03234907|DRUG|Vedolizumab IV|Vedolizumab IV infusion
219547864|NCT03234907|DRUG|Placebo|Vedolizumab placebo-matching
219547865|NCT00642993|DRUG|SCH 497079|100 mg capsule administered orally
218936007|NCT01621802|BIOLOGICAL|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
219206215|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in self-etch mode|Resin composite restoration bonded using universal adhesive in self-etch mode
219206216|NCT06770153|PROCEDURE|Tensor|balancing will be carried out using the TEMIS DePuy tensioner and carrying out any releases according to the gap-balancing technique
219206217|NCT06770153|PROCEDURE|standard|primary TKA implantation with ligament balancing without use of the tensioner
219206218|NCT06901167|OTHER|Residential In-Reach Program|All enrolled residential aged care homes will be able to access the residential-in-reach (RIR) program intervention. The RIR program provides a consultation service from a central hospital to an aged care facility in the Grampians region in the state of Victoria, Australia. Aged care staff will make a telehealth referral to central hub, where a nurse practitioner will triage the patient and make recommendations (for example, monitor resident condition, more examples: comprehensive assessment for unwell residents, liaison with the General Practitioners for diagnosis and treatment plan, provide education and support to staff) or further referrals (for example, refer to geriatrician or call an ambulance).
219206219|NCT05154669|OTHER|Financial counseling|The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.
219547866|NCT00642993|DRUG|Placebo|Placebo capsules matching SCH 497079 administered orally
219547867|NCT02664415|BIOLOGICAL|VRC01|40 mg/kg; administered IV
219547868|NCT02664415|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
219547869|NCT00128219|BIOLOGICAL|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
219547870|NCT00128219|BIOLOGICAL|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
219547871|NCT01188590|DEVICE|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
219547872|NCT04224584|DRUG|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
219547873|NCT04224584|DRUG|Placebo oral tablet|Placebo will act as a control for duloxetine.
219547874|NCT05878132|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
219547875|NCT05878132|OTHER|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
219547876|NCT03968328|OTHER|Interview|Take part in interview
219547877|NCT03968328|OTHER|Survey Administration|Respond to survey
219547878|NCT04885751|DRUG|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
219547879|NCT04885751|DRUG|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
219547880|NCT03611387|DEVICE|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
219547881|NCT04341883|DRUG|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
219547882|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
219547883|NCT01020825|DRUG|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
219547884|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
219622958|NCT07112560|DIAGNOSTIC_TEST|New amblyopia screening method using a virtual reality headset.|The examination with the virtual reality headset consists of three main steps: A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask. The eye-tracking system analyzes fixation and the visual response of the stimulated eye. A cover/uncover test, during which the child is required to fixate on an image projected inside the headset. Eye movements are tracked to detect any deviations or abnormalities in ocular coordination. A Lang I stereopsis test performed under binocular vision, in which the child must identify three-dimensional images hidden within a virtual board. The eye-tracking system detects fixation on the images and allows evaluation of depth perception
218936008|NCT03236376|OTHER|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
219547885|NCT04039022|DRUG|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
219547886|NCT02986139|DRUG|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
219547887|NCT02986139|DRUG|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
219547888|NCT02235558|DRUG|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
219547889|NCT05474651|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
219547890|NCT00414726|DRUG|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
219547891|NCT00414726|DRUG|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
219547892|NCT05496192|DRUG|Nivolumab/rHuPH20|Specified dose on specified days
219547893|NCT05496192|DRUG|Nivolumab|Specified dose on specified days
219547894|NCT00136448|DRUG|cytosine arabinoside (ara-C)|
219547895|NCT00136448|DRUG|daunomycin|
219547896|NCT00136448|DRUG|interleukin-2|
219547897|NCT02107196|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
219547898|NCT02107196|DRUG|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
219547899|NCT01661517|BEHAVIORAL|Motivational interviewing and referral to treatment|
219547900|NCT04898998|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
219547901|NCT04898998|OTHER|routine care|routine care
219547902|NCT04000945|DEVICE|BTL-899|Treatment with BTL-899 device, 3 therapies
219547903|NCT04000945|DEVICE|Sham|Sham treatment with BTL-899 device, 3 visits
218936009|NCT03236376|OTHER|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
218936010|NCT05762068|OTHER|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
218936011|NCT02850913|DRUG|Doxycycline|"* 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
218936012|NCT02850913|OTHER|Placebo|\- Placebo (matching capsules containing no active ingredients)
218936013|NCT04857320|COMBINATION_PRODUCT|Human insulin|Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
218936014|NCT00452816|BEHAVIORAL|Workplace Solutions Consulting approach|"Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation"
218936015|NCT00452816|BEHAVIORAL|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
219547904|NCT00516295|DRUG|topotecan hydrochloride|Given IV
219547905|NCT00516295|DRUG|vincristine sulfate|Given IV
219547906|NCT00516295|DRUG|cyclophosphamide|Given IV
219547907|NCT00516295|BIOLOGICAL|bevacizumab|Given IV
219547908|NCT00195754|DRUG|divalproex sodium|
218936016|NCT03260751|DIETARY_SUPPLEMENT|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
218936017|NCT03260751|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
218936018|NCT05909657|OTHER|questionnaires (surveys)|Mixed-methods study. Both the qualitative interview guides and the questionnaire surveys are adapted from the Sickle Cell Disease Implementation Consortium (SCDIC) project which is a multicentre study occurring in the United States.
218936019|NCT03713346|OTHER|Lactose free milk|Single dose of lactose free milk
218936020|NCT03713346|OTHER|Jersey milk|Single dose of jersey milk
219547909|NCT05475548|DEVICE|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
219547910|NCT05503992|OTHER|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
219547911|NCT06160180|DRUG|Dexamethasone|Submucosal application
219547912|NCT04921696|OTHER|RBC transfusion|RBC was transfused to the infants.
219547913|NCT04921696|OTHER|no-RBC transfusion|RBC was not transfused to the infants.
219547914|NCT04738968|DEVICE|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
219547915|NCT03416049|DEVICE|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
219547916|NCT03416049|DEVICE|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
219547917|NCT03416049|DEVICE|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
219547918|NCT03416049|DEVICE|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
219547919|NCT02034513|DRUG|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
219547920|NCT02034513|DRUG|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
219547921|NCT02034513|DRUG|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
219547922|NCT01969760|BEHAVIORAL|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
219547923|NCT00913276|DRUG|Propofol|
219206220|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Patches|24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
219206221|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Lozenges|"General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated"
219547924|NCT00913276|DRUG|Sevoflurane|
219547925|NCT00481169|DRUG|Bazedoxifene Acetate (TSE-424)|
219547926|NCT05270044|DRUG|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
219547927|NCT05270044|DRUG|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
219547928|NCT03622229|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
219547929|NCT00686868|OTHER|placebo|placebo
219547930|NCT00686868|DRUG|ofatumumab|fully human anti-CD20 monoclonal antibody
219547931|NCT03735706|RADIATION|Radiation dose reduction|The radiation dose is is different between groups
219547932|NCT03735706|OTHER|Contrast media volume reduction|Contrast media volume is different between groups
219547933|NCT03735706|RADIATION|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
219547934|NCT03735706|DIAGNOSTIC_TEST|Weight|A weighing scale is used to measure a patients body weight right before the scan.
219547935|NCT04097444|BIOLOGICAL|Bevacizumab|Given IV
219547936|NCT04097444|DRUG|5-fluorouracil|Given IV
219547937|NCT04097444|DRUG|Leucovorin calcium|Given IV
219547938|NCT04097444|DRUG|Irinotecan hydrochloride|Given IV
219547939|NCT04097444|DRUG|Oxaliplatin|Given IV
219547940|NCT04097444|DRUG|Capecitabine|Given PO
219547941|NCT02985749|DRUG|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
219641876|NCT04606823|OTHER|Additional follow-up visits after surgery|There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
219641877|NCT06622993|OTHER|Psychotherapy|The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.
219641878|NCT03864731|DEVICE|Bone conduction device (ADHEAR)|adhesive bone conduction device
218936021|NCT03713346|OTHER|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
219547942|NCT05315791|PROCEDURE|different methods for maxillary sinus floor elevation|a: 0\~3mm+ground into pieces; b: 0\~3mm+replace the bone; c: 0\~3mm+turn inward to hold up the membrane; d: 3\~5mm+ground into pieces; e: 3\~5mm+replace the bone; f: 3\~5mm+turn inward to hold up the membrane
219547943|NCT03318289|BEHAVIORAL|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
219547944|NCT03119662|DRUG|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
219547945|NCT03119662|DRUG|Placebos|100 mL saline, followed by a 10 mL saline flush.
219547946|NCT05434091|DRUG|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
219547947|NCT05434091|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
219547948|NCT00836862|OTHER|Biologic specimens|Banking of serum, DNA and tissue
219547949|NCT05963269|OTHER|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
219547950|NCT05436626|PROCEDURE|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
219547951|NCT05436626|PROCEDURE|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
219547952|NCT05436626|PROCEDURE|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
219547953|NCT01682187|DRUG|LY2157299|Administered orally
219547954|NCT01682187|DRUG|Lomustine|Administered orally
219547955|NCT00031954|DRUG|carboplatin|
219547956|NCT00031954|DRUG|gemcitabine hydrochloride|
219547957|NCT00031954|DRUG|paclitaxel|
219547958|NCT05452213|DRUG|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
219547959|NCT02465892|BEHAVIORAL|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
219547960|NCT05397977|DEVICE|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
219547961|NCT05397977|OTHER|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
219547962|NCT04146090|OTHER|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
219547963|NCT04146090|OTHER|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
219547964|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
219547965|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
219547966|NCT04823936|OTHER|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
218936022|NCT03713346|OTHER|High A2 β-casein milk|Single dose of A2 β-casein milk
219206222|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Gum|Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
219547967|NCT03143049|DRUG|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
219547968|NCT03143049|DRUG|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
219622959|NCT07112183|DRUG|Oral treprostinil (UT-15C) sustained release tablets|30 patients with symptomatic primary or secondary Raynaud's phenomenon (RP) resistant to standard vasodilatory therapy will be enrolled. Prior to treatment, subjects will record each day for 42 days the number of RP attacks as well as the duration of each RP attack, considered to be baseline data. After the 6-week baseline run in, all subjects will receive oral treprostinil sustained release tablets. Dose escalations can occur every 48 hours in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 3mg three times daily over a 6-week period. Titration can be done as quickly as tolerated. Once at goal dose subjects will enter the 26-week treatment phase. Throughout the study (6-week titration - 26-week treatment phase) subjects will record each day the number of RP attacks.
219622960|NCT07111429|DIAGNOSTIC_TEST|Novel severity grading system of stoma-related complication in cancer patients|Over 5000 stoma patients treated at 26 centers between 2022 and 2023 were classified according to SITI-CD Classification.
219622961|NCT07113080|DRUG|lavender essential oil inhaled using face mask|participants will inhale lavender essential oil via nebulizer before local anesthesia administration
219547969|NCT01600313|DIETARY_SUPPLEMENT|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
219547970|NCT04469400|DIETARY_SUPPLEMENT|Low fat diet intensive intervention|education and Compound protein solid beverage
219047242|NCT07163117|OTHER|lumbar stabilization exercises|The participants required to be in a prone position with pillow under abdomen, first raise one leg then the other leg, raise one arm then the other arm, after that raise two legs together, then raise two arms together, raise right arm with left leg then left arm with right leg, then raise both arms and both legs together, every position hold for 20 seconds. Then they required to be in a half kneeling on standing for right leg hold for 20 second and repeat for other leg, do it again but their knees doesn't touch the ground. Finally they required to lie on their backs, and bend their knees at around a 90 degree angle. Place their hands to their sides and their feet flat on the floor at about shoulder width and asked to raise their hips off the floor, hold 20 second.
219047243|NCT07163117|OTHER|endurance training|"1. Back extensor endurance training exercise:~   The participants lay prone over the end of a treatment table with the anterior superior iliac spine supported on the bench edge. Their ankles were fixed by the researcher. They maintained the horizontal position for as long as possible, beginning timing when the horizontal unsupported position was achieved and ending when they dropped below the horizontal plane. The duration of holding was measured in seconds.~2. Back flexor endurance training exercise:~The participants asked to sit on the table with your arms crossed against their chest and their back against the wedge. Fix them to the table with a belt across the feet. They asked to remove the wedge from their back using the timing device to record how much time is accumulated until the original position can no longer be maintained."
219547971|NCT04469400|OTHER|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
219547972|NCT02528045|PROCEDURE|Vitrectomy with scleral shortening|
219547973|NCT05341453|PROCEDURE|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
219622962|NCT07113080|DRUG|lemongrass essential oil inhaled using face mask|participants will inhale lemongrass essential oil via nebulizer before the local anesthesia administration
219622963|NCT07112664|DEVICE|Fully Guided Dental Implant Placement Using Surgical Guide|All participants will undergo fully guided dental implant placement using a 3D-printed surgical guide (tooth-supported or mucosa-supported). The surgical guide is designed and fabricated based on preoperative CBCT and intraoral scan data. Implant site preparation and fixture insertion are performed entirely through the guide using manufacturer-specific guided surgery kits.
219047244|NCT07163117|OTHER|Home based program|General and similar exercises for back muscles introduced for this group. They instructed to do knee to chest stretch, lower back rotational stretch, bridge exercise. The required measure data were obtained from the selected cases in this group before and after the end of rehabilitation program.
219622964|NCT07110792|OTHER|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|"The MBCT-L (Bernard, Cullen \& Kuyken, 2017) intervention is an 8-week group intervention, comprising a pre-course orientation session, eight 2-hour sessions, and a half-day silent session.~MBCT-L was delivered synchronously online. MBCT-L group were led by one MBCT-L instructor"
219622965|NCT07111299|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
219641879|NCT03652636|DRUG|Sulfur Hexafluoride Microspheres|2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
219641880|NCT06554522|DRUG|Surfactant|Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)
219547974|NCT05341453|PROCEDURE|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
219547975|NCT05341453|PROCEDURE|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
219547976|NCT05141474|BIOLOGICAL|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
219547977|NCT05141474|DRUG|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
219547978|NCT05141474|DRUG|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
219622966|NCT07111299|OTHER|Placebo Control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
219622967|NCT07113002|BEHAVIORAL|Emotional Freedom Technique (EFT)|Emotional Freedom Technique (EFT) is a psychological intervention that uses tapping on acupuncture points combined with cognitive techniques to reduce stress and anxiety. Participants received EFT sessions for 4 weeks.
219047245|NCT07161830|DEVICE|Omeza® Complete Matrix|OCM Application, Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
219622968|NCT07112261|OTHER|Avatar Therapy|The Avatar Intervention will take place over 10 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars. The goal of the therapy is to develop strategies to improve mood and promote the fulfillment of social functioning.
219622969|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in Invasive Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities~Hyperspectral imaging (HSI):~HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma.~Point-wise Raman spectroscopy (RS):~RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens confirming the possible presence of positive margins~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed."
218936023|NCT02405377|PROCEDURE|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
218936024|NCT02405377|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
218936025|NCT02405377|DRUG|0.9% sodium chloride ﬂuid administration|
218936026|NCT02405377|DEVICE|5-French catheter|
219047246|NCT07161830|OTHER|Standard of Care|Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
219047247|NCT07164950|DEVICE|Medical-grade compression stocking|A knee-high compression stocking providing 20-30 mmHg pressure will be applied to the assigned foot during the ADC treatment period to prevent chemotherapy-induced peripheral neuropathy (CIPN). Stockings will be worn daily, except during bathing.
219047248|NCT07171099|DRUG|Rengalin|Solution for oral administration
219047249|NCT07171099|DRUG|Placebo|Solution for oral administration
219047250|NCT07168863|DEVICE|EUS-guided FNB|EUS-guided FNB from the lesions in the pancreatobiliary tract
219047251|NCT07163429|DRUG|Flurbiprofen 8.75 MG|Topical administration of flurbiprofen 8.75 mg spray applied directly to the tracheal and bronchial cuffs of the double-lumen endobronchial tube before intubation. A total of three sprays will be applied: one spray to the bronchial cuff and two sprays to the tracheal cuff, immediately before intubation.
219047252|NCT07163429|DRUG|Saline spray|Topical administration of placebo spray (0.9% normal saline) applied in the same manner as the active intervention, with one spray to the bronchial cuff and two sprays to the tracheal cuff of the double-lumen tube before intubation.
219547979|NCT05285319|RADIATION|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
219547980|NCT05285319|RADIATION|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
219547981|NCT00425841|DRUG|gemcitabine hydrochloride|
219547982|NCT00425841|DRUG|oxaliplatin|
219547983|NCT00425841|PROCEDURE|adjuvant therapy|
219547984|NCT00425841|PROCEDURE|neoadjuvant therapy|
219547985|NCT00425841|RADIATION|hypofractionated radiation therapy|
219547986|NCT00425841|RADIATION|stereotactic radiosurgery|
219547987|NCT02218541|DEVICE|abutment margin 0.5 mm subgingival|
219547988|NCT02218541|DEVICE|abutment margin 1.5 mm subgingival|
219547989|NCT01338090|DRUG|89Zr-bevacizumab|Intravenous injection 120 MBq
219547990|NCT01338090|DRUG|Everolimus|Oral use, 10 mg per day
219547991|NCT03134053|DEVICE|extracorporeal shock-wave|to treat painful and retracting scars
219547992|NCT03134053|OTHER|massage|to treat painful and retracting scars
219547993|NCT00657254|DRUG|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
219547994|NCT02646488|BEHAVIORAL|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
219547995|NCT02646488|BEHAVIORAL|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
219547996|NCT02646488|BEHAVIORAL|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
219547997|NCT02646488|BEHAVIORAL|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
219547998|NCT02646488|BEHAVIORAL|Standard Care Regimen 9 Months|
219547999|NCT02646488|BEHAVIORAL|Standard Care Regimen 12 Months|
219548000|NCT02646488|BEHAVIORAL|Standard Care Regimen 15 Months|
219548001|NCT02646488|BEHAVIORAL|Standard Care Regimen 18 Months|
219548002|NCT02646488|BEHAVIORAL|Standard Care Regimen 21 Months|
219548003|NCT02646488|BEHAVIORAL|Standard Care Regimen 24 Months|
219047253|NCT07163559|BEHAVIORAL|coping skills training|"CST aims to improve physical/mental health in chronic headache patients by reducing pain intensity, migraine attacks, and medication use. The program includes 8 sessions (2/week) covering:~Client-centered problem-solving \& migraine education (COPM-based), Activity pacing, stress management, and healthy habits, Energy conservation techniques, Social participation, Program evaluation. Session durations: Session 1 (45 min), Sessions 2-6 (60-75 min), Sessions 7-8 (60 min)."
219047254|NCT07163858|PROCEDURE|passive leg raising for hemodynamic management during open-heart coronary bypass grafting|Passive leg raising will be used in the experimental group in order to manage hemodynamics: legs will be raised to an angle of approx. 45°
219047255|NCT07163858|PROCEDURE|Use of Noradrenaline only in control group|Noradrenaline will be used for hemodynamic management. Passive leg raising will not be used in this group
219047256|NCT07168616|DIAGNOSTIC_TEST|Ga-68 PSMA11 PET/CT|delayed (120-minute) Ga-68 PSMA PET/CT and will be evaluated by using Istanbul PSMA PET/CT Criteria (IPPC)
219548004|NCT02646488|BEHAVIORAL|Standard Care Regimen 27 Months|
219548005|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 21 Months|
219548006|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 24 Months|
219548007|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 27 Months|
219548008|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 30 Months|
219548009|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 33 Months|
219548010|NCT02826395|DRUG|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
219548011|NCT03789487|DEVICE|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
219548012|NCT03819088|DIETARY_SUPPLEMENT|Zinc|Given PO
219548013|NCT03212651|DRUG|Pembrolizumab|Pembrolizumab 200mg IV infusion
219548014|NCT01732328|DIETARY_SUPPLEMENT|Calcium plus vitamin D|
219548015|NCT02767804|DRUG|X-396 (ensartinib)|oral ALK inhibitor
219548016|NCT02767804|DRUG|crizotinib|oral ALK inhibitor
219548017|NCT04584138|BEHAVIORAL|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
219548018|NCT02582190|DRUG|Colchicine group|antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
219548019|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
219548020|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
219548021|NCT00385736|BIOLOGICAL|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
219548022|NCT06298123|DRUG|Anti-PD-1 monoclonal antibody|The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
219548023|NCT03002935|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
219548024|NCT04381871|DIETARY_SUPPLEMENT|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
219548025|NCT04381871|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
219548026|NCT02341690|OTHER|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
219548027|NCT02341690|OTHER|control|Standard care at the promotion centre in the municipality
219548028|NCT00213590|DRUG|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
219548029|NCT00901524|DRUG|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
219548030|NCT01557751|GENETIC|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
219548031|NCT04323527|DRUG|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
219548032|NCT02573662|BIOLOGICAL|Blood and Urine sampling|Blood and Urine Sampling
219548033|NCT02573662|RADIATION|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
219548034|NCT02573662|BIOLOGICAL|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
219548035|NCT05356091|DRUG|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
219548036|NCT05356091|DRUG|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
219548037|NCT02997891|DIAGNOSTIC_TEST|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
219548038|NCT02997891|DIAGNOSTIC_TEST|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
219548039|NCT05361252|PROCEDURE|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
219548040|NCT04220606|DRUG|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
219548041|NCT01531790|DRUG|Carboplatin|d1, AUC 5, i.v.
219548042|NCT01531790|DRUG|Pemetrexed|d1, 500 mg/m2, i.v.
219548043|NCT01531790|DRUG|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
219548044|NCT01531790|DRUG|Centrum|1 tablet/day
219548045|NCT01949922|PROCEDURE|Injection of autologous muscle fibers into the anal sphincter.|
219548046|NCT01949922|PROCEDURE|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
219548047|NCT01949922|BEHAVIORAL|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
219548048|NCT01949922|DRUG|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
219548049|NCT05461716|DEVICE|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
219548050|NCT00835666|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
219548051|NCT00835666|DRUG|PROSCAR®|1 x 5 mg, single dose fasting
219548052|NCT03599362|DRUG|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
219548053|NCT03599362|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
219548054|NCT06150963|DEVICE|Virtual Reality|Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.
219548055|NCT06150963|PROCEDURE|Standard Procedure Thyroid Biopsy|In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
219206223|NCT06853158|BEHAVIORAL|Music therapy|Participants in the 2 experimental MT conditions (In person MT (InMT) or hybrid (inperson.virtual (HybMT) will receive 6 MT sessions over 6 weeks. Each MT session will last no longer than one hour. This 6-week treatment period may be extended to up to 8 weeks if a scheduling conflict prevents a participant from receiving the 6 MT sessions over 6 consecutive weeks.
219548056|NCT06150963|PROCEDURE|Standard Procedure PICC Placement|In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.
219548057|NCT04823169|OTHER|podobarometry|podobarometric measures on day 7 and day 30
219548058|NCT00197938|PROCEDURE|Measurement of rectal lactic acid.|
219548059|NCT00007423|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219548060|NCT00007423|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219548061|NCT04533620|RADIATION|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
219548062|NCT04533620|RADIATION|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
219548063|NCT03707587|DRUG|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
219548064|NCT05476588|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
219548065|NCT02312154|DEVICE|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
219548066|NCT00603499|DIETARY_SUPPLEMENT|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
219548067|NCT00603499|OTHER|Placebo|Subjects in the control group received inert placebo once per day during 4 months
219548068|NCT05581407|BIOLOGICAL|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
219548069|NCT06468254|DRUG|Statin|Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
219548070|NCT06468254|DRUG|Sugar pill|Control Group: Conventional chemotherapy and maintenance therapy alone.
219548071|NCT04413266|DIETARY_SUPPLEMENT|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
219548072|NCT02871076|DEVICE|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
219548073|NCT01044537|DRUG|Placebo|Placebo to match PF-04937319 will be provided.
219548074|NCT01044537|DRUG|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
219548075|NCT04732325|DEVICE|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
219548076|NCT06622330|OTHER|Positioning|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
219548077|NCT00383916|DRUG|pantoprazole|
219548078|NCT01649921|DRUG|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
219548079|NCT01649921|OTHER|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
218936027|NCT03790696|DEVICE|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
218936028|NCT04743986|BIOLOGICAL|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
218936029|NCT04743986|DRUG|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
219548080|NCT04442503|DRUG|SAGE-217|SAGE-217 oral capsules.
219548081|NCT04442503|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
219548082|NCT00614861|OTHER|Non-cancer pain management survey|Non-cancer pain management survey
219548083|NCT03552328|OTHER|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
219548084|NCT03552328|OTHER|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
219548085|NCT02570828|DEVICE|Thermal Imaging|FLIR ONE attachment to an iPhone
219622970|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in DCIS Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens and using a special needle probe 2 mm below the tissue surface thus confirming the possible presence of positive margins.~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed"
219622971|NCT07112677|DIAGNOSTIC_TEST|Brucella Antibody Testing (ELISA)|Serological testing for Brucella antibodies using the SERION ELISA classic Brucella IgG/IgM/IgA kit (Institut Virion\\Serion GmbH, Würzburg, Germany). The test detects Brucella-specific IgG, IgM, and IgA antibodies in serum samples to assess current or past exposure. All samples were processed and interpreted according to the manufacturer's instructions. This diagnostic intervention was used for both the low back pain group and the control group.
219548086|NCT04332198|OTHER|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
219622972|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose(0.25mg)|SC Injection in deltoid of Low dose (LD; 0.25 mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
219622973|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®|SC injection in deltoid of LD (0.25 mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
219622974|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg)|SC injectionin deltoid of High dose (HD; 1mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
219622975|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®|SC injection in deltoid of HD (1mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
219548087|NCT03769428|PROCEDURE|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
219548088|NCT03769428|PROCEDURE|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
219548089|NCT03124511|PROCEDURE|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
219548090|NCT04469751|DIAGNOSTIC_TEST|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
219548091|NCT05411653|OTHER|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
219548092|NCT05411653|OTHER|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
219548093|NCT00387153|DRUG|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
219047257|NCT07167992|PROCEDURE|Pleurodesis|Talc slurry pleurodesis is a chemical technique for managing recurrent pleural effusions and pneumothoraces. The procedure involves instilling a suspension of talc (4-5 grams) in sterile saline (50-100 mL) into the pleural space via a chest tube. This induces an inflammatory reaction, leading to fibrosis and fusion of pleural surfaces. The technique demonstrates 70-90% success rates in malignant pleural effusions and pneumothoraces, with efficacy comparable to talc poudrage. While generally safe, potential complications include pain, fever, and rarely, pneumonitis or empyema. Use of large-particle, asbestos-free talc and standardized protocols has improved its safety profile.
219047258|NCT07167992|PROCEDURE|pleurodesis|Talc insufflation, is a pleurodesis technique involving direct insufflation of dry talc powder into the pleural cavity during thoracoscopy. It allows visual inspection of the pleural space and concurrent diagnostic procedures. Success rates range from 85% to 93% for malignant pleural effusions and pneumothoraces, with efficacy comparable or potentially superior to talc slurry in some studies. The procedure typically requires general anesthesia and is more invasive than talc slurry. Common side effects include chest pain, fever, and dyspnea. The risk of severe respiratory complications has decreased with large-particle, asbestos-free talc. While effective, the choice between insufflation and slurry depends on patient factors, institutional expertise, and resource availability.
219047259|NCT07168551|DIAGNOSTIC_TEST|*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .|Lab methods
219622976|NCT07112157|DRUG|Oliceridine|After entering the room, the patient was intravenously injected with oselidine at a dose of 0.08mg/kg during anesthesia induction
219622977|NCT07112157|DRUG|Sulfentanil|After the patient entered the room, sufentanil was injected intravenously during anesthesia induction with a dose of 0.4 μ g/kg
219622978|NCT07110870|PROCEDURE|Cognitive Physical Dual task training|"Randomized Control Group (A)/ Cognitive Physical Dual Task Training Participants in control group will perform cognitive physical dual task training to improve working memory, attention and executive function in elderly with mild cognitive impairment. Dual-task training involved eight programs consist from simple dual-task to more complex dual-task tasks.~Cognitive task involves verbal fluency, attention, Forward digit span task, backward digit span task, calculation tasks and memory, aerobic exercise including performing actions like dragging the foot and placing it on floor markers (Marked from 1 to 5), Drawing any letters with their feet while seated, range of motion exercise while standing, forward walking, backward walking, tandem walking and stair climbing and strengthening exercise consisting of Thera-band with low intensity training by arms and by legs and passing/throwing a ball (0.1kg, 0.4kg) will be used for physical tasks. Eight programs will be repeated thrice, resultin"
219047260|NCT07168551|RADIATION|*Imaging Studies:* 1- Ultrasound 2 - FibroScan|Imaging
219047261|NCT07168551|DEVICE|Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.|Instrument
219548094|NCT03292705|BEHAVIORAL|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
219622979|NCT07110870|PROCEDURE|Binaural Beats and Cognitive physical dual task training|"In experimental group, Binaural beats will be given 03 min before performing a dual task.~Participants will be in a quiet room and two tones of different frequencies will be generated through the Audacity Program (Version 3.4.2) via stereo headphones presenting a different tone to each ear.~Phase-I: A warm-up at the beginning of each session (05 min) with supervised walking exercises on a flat surface.~Phase II: Binaural beats will be induced thrice a week, for 08 weeks. Alpha, and gamma waves, over 30 min, split into two sub-sessions lasting 12 min each. Participants will be allowed to take a 6-minute rest between sub-sessions. Alpha BB (10 Hz), (R: 410 Hz, L: 400 Hz) and gamma BB (30 Hz) (R: 430 Hz, L: 400 Hz) will be provided.~Phase-III: Return to calm (05 min) with relaxation and breathing exercises, lying on the floor.~The stimulus volume, played through stereo headphones will be set by the participants at the start of the session to a comfortably loud level."
219622980|NCT07111442|DIAGNOSTIC_TEST|renal artery fractional flow reserve measurement|Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).
219622981|NCT07111442|DRUG|dopamine|Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.
219622982|NCT07111442|DEVICE|renal artery stent|Stent will be treated for the stenotic renal artery for patients randomized to stenting group
218936030|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%"
218936031|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
218936032|NCT03353506|BIOLOGICAL|LFMT|Lyophilized fecal microbiota transplant
218936033|NCT03353506|BIOLOGICAL|LSFF|Lyophilized sterile fecal filtrate
218936034|NCT03599219|BIOLOGICAL|sample|confirmation of platelet dysfunction
218936035|NCT02595489|DIETARY_SUPPLEMENT|vitamin D3|Daily oral supplement provided by study investigators
218936036|NCT03436082|DEVICE|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
218936037|NCT02449148|OTHER|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
218936038|NCT04867304|OTHER|Patient education about chronic pancreatitis.|"Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters."
219047262|NCT07152938|BEHAVIORAL|AVR Group (Chemotherapy + AVR)|the intervention group received AVR before they started treatment and during the session. The researcher administered the posttest questionnaire The questionnaire assessed immediately after finishing AVR. Participants informed not to discuss AVR with each other's, as the researcher explained to the participants the purpose of the study and their participation will not affect their care or treatment
219047263|NCT07141641|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|
219047264|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material from pleural cavity and thick fibrous entrapping peel over the lung resulting in full expansion of lung.
219047265|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material and thick fibrinous entrapping peel over the lung
219047266|NCT07168369|DIETARY_SUPPLEMENT|protein and energy-rich supplement|The nutritional supplements were provided in the form of ready-to-drink liquid solutions rich in protein and energy. Patients without diabetes received one 235 ml bottle per day of Ensure® Protéine Max (Abbott Nutrition, Montreal, Canada), which contained 350 kcal, 20 g of protein, 11 g of fat, 44 g of carbohydrates, 1.5 g of calcium-HMB and other essential micronutrients. Patients diagnosed with diabetes prior to LT received one 237 ml bottle per day of Boost® Diabetic (Nestlé, Montreal, Canada), which provided 190 kcal, 16 g of protein, 7 g of fat, 17 g of carbohydrates, and other essential micronutrients. Patients were instructed to consume the supplement in four equal doses of \~60 ml each, taken daily with breakfast, lunch, dinner, and as a bedtime snack, totaling one full bottle per day. The supplementation lasted for 12 weeks, beginning once solid oral feeding was initiated.
219047267|NCT07174050|DEVICE|King Vision Channeled Video Laryngoscope|King Vision Videolaryngoscope (KVVL) is one of the new indirect laryngoscopes with disposable (either with channeled or non-channeled) blades .Both designs include an anti-fog lens coating . The channelled KVVL has a rigid blade with an integrated channel for introducing the endotracheal tube. The height and width of the standard non-channeled and channeled blades are 13 mm and 26 mm vs 18 mm and 29 mm, respectively. The KVVL has a unique design and high-quality image . It has a camera that enables a clear view of the glottis. It is a solid, portable, battery-operated device with an organic LED display for video laryngoscopy . It allows better glottis visualization and Cormack Lehane score than DL. Compared with Airtraq, the KVVL has wide field of view (160° vs 80° respectively) and potentially shortens the time to tracheal intubation .
219047268|NCT07174050|DEVICE|Macintosh Laryngoscopy|In clinical practice, direct laryngoscopy (DL) with either a curved (Macintosh) or straight (Miller) blade is a well-known and reliable technique in the hands of an experienced operator.
219047269|NCT07173738|DRUG|BIA 5-1058|During treatment period 1, a single oral dose of BIA 5-1058 (400 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
219047270|NCT07173738|DRUG|Furosemide|During treatment period 2, a single oral dose of furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
219047271|NCT07173738|DRUG|BIA 5-1058 and Furosemide|During treatment period 3, a single oral dose of both investigational medicinal product (IMPs) BIA 5-1058 (400 mg) concomitantly with furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
219047272|NCT07172776|BEHAVIORAL|oral cancer communication tool|The overall goal is to determine if the OPC communication tool has potential to enhance Black-men's and dentists' comfort discussing oral and pharyngeal cancers in clinical-like settings. This communication tool will ideally help dentists communicate with their patients about oral cancer risk and treatment. The oral cancer screenings will occur in person. Participants will complete a pre-survey either on paper or online, engage with a dentist or dental student, then complete a post-survey
219047273|NCT07172802|DRUG|GI-108|Dose level will be escalated from 0.1mg/kg to 0.6 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 years)
219047274|NCT07173309|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
219047275|NCT07172516|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
219047276|NCT07172516|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
219047277|NCT07173374|RADIATION|SCART Dose Escalation Arm|Patients will receive SCART with escalating dose cohorts (10 Gy, 13 Gy, 16 Gy, and 19 Gy per fraction within the SCART region) using a standard 3+3 design. All patients will also receive background SBRT (25 Gy in 5 fractions) to the gross tumor volume and margin.
219548095|NCT03292705|BEHAVIORAL|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
219548096|NCT00003953|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
219548097|NCT00003953|DRUG|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
219548098|NCT00003953|DRUG|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
219548099|NCT00003953|DRUG|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
219548100|NCT00003953|DRUG|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
219548101|NCT00003953|PROCEDURE|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
219548102|NCT00003953|PROCEDURE|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
219622983|NCT07111442|OTHER|sham stenting|For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.
219622984|NCT03257280|OTHER|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
219622985|NCT03775174|DRUG|Mepsevii|
219548103|NCT00003953|RADIATION|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
219622986|NCT06364488|DEVICE|TrueBlue App|The use of the TrueBlue App, to generate automated measures of mood that can be assessed for agreement with validated clinical scales eg. PHQ9.
219622987|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
219622988|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219622989|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
219622990|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
219622991|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219548104|NCT01567553|OTHER|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
219548105|NCT05766553|OTHER|Virtual reality pod|The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
219548106|NCT05766553|OTHER|nicotine patches and chewing gum|Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
219548107|NCT00000956|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219548108|NCT02940457|DEVICE|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
219548109|NCT02940457|DEVICE|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
219548110|NCT06558812|DEVICE|prefabricated space maintainer|"i. Prefabricated band will be selected for the abutment tooth by measuring the mesiodistal diameter of the abutment tooth with a caliper and will be adjusted with the internal diameter of the prefabricated band.~ii. The loop will be selected based on the available mesiodistal space and buccolingual width of the abutment tooth, excessive length with be cut by cutting plier and will then place inside the band's tube by using a HOWE pliers.~iii. Cotton roll isolation will use, then will be cemented with glass ionomer,"
219622992|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
219622993|NCT03267433|BIOLOGICAL|Rituximab|Given IV
219622994|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219622995|NCT04756063|DRUG|Ascorbic acid|Intravenous vitamin C
219622996|NCT04756063|OTHER|Placebo|Normal Saline
218936039|NCT04043858|DRUG|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
218936040|NCT01079299|DEVICE|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
218936041|NCT03145870|OTHER|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
218936042|NCT06168916|DIAGNOSTIC_TEST|PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.
218936043|NCT01851603|DEVICE|AVL-3288|Drug
218936044|NCT01851603|DRUG|Placebo|Identical diluent to that used for AVL-3288
218936045|NCT03473509|OTHER|CKD Registry|Health Service intervention
218936046|NCT01818011|DRUG|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
218936047|NCT01818011|DRUG|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
218936048|NCT01818011|DRUG|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
218936049|NCT01818011|DRUG|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
218936050|NCT01818011|DRUG|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
218936051|NCT01818011|DRUG|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
218936052|NCT01818011|DRUG|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
218936053|NCT03791957|OTHER|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
218936054|NCT03498937|DEVICE|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
218936055|NCT03498937|DEVICE|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
218936056|NCT02049593|DRUG|PARP inhibitor BMN-673|Given PO
218936057|NCT02049593|DRUG|temozolomide|Given PO
218936058|NCT02049593|DRUG|irinotecan hydrochloride|Given IV
218936059|NCT02049593|OTHER|pharmacological study|Correlative studies
218936060|NCT02049593|OTHER|laboratory biomarker analysis|Correlative studies
218936061|NCT01931319|DRUG|Intravenous baclofen|
218936062|NCT02637492|OTHER|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
218936063|NCT00950859|DRUG|GSK1349572 (Cohort I)|50 mg once daily
219548111|NCT06558812|DEVICE|conventional space maintainer|"i. A full arch Impressions will be taken with alginate material. ii. Impressions will be poured up using dental stone within 30 min of the impression taking.~iii. The children will be given an appointment for space maintainer insertion. iv. In the second visit , Cotton roll isolation will use, cementation will be performed with glass ionomer ."
219548112|NCT02933060|OTHER|Normal saline (1000 mL)|
219548113|NCT02933060|OTHER|Control|
219548114|NCT01945580|PROCEDURE|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
219548115|NCT04540094|DRUG|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
219548116|NCT04540094|DRUG|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
218936064|NCT00950859|DRUG|GSK1349572 (Cohort II)|50 mg twice daily
219047278|NCT07172178|BIOLOGICAL|γδ T-PD-1 Ab cells|Patients will receive 6 cycles of ex-vivo expanded γδ T-PD-1 Ab cells treatments,at two-weeks' intervals.γδ T-PD-1 Ab cells are injected through the Ommaya device in a typical 3+3 dose-escalation design(Dose escalation, 1×10\^7, 3×10\^7, 1×10\^8).
219047279|NCT07174024|DEVICE|Narrow Band UVB Treatment|type of phototherapy
219548117|NCT04635020|PROCEDURE|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
219548118|NCT04635020|PROCEDURE|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
219548119|NCT04635020|PROCEDURE|Cataract surgery|Conventional cataract surgery
219548120|NCT05034874|DRUG|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
219548121|NCT05034874|OTHER|Placebo|Saline
218936065|NCT04896086|DRUG|VRC-GENADJ0110-AP-NV (Adjuplex)|Adjuplex is a sterile, pyrogen-free adjuvant solution produced by the VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline. Adjuplex adjuvant was mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B.
218936066|NCT04896086|BIOLOGICAL|Flucelvax|Flucelvax is an inactivated influenza vaccine licensed for the 2020-2021 season.
218936067|NCT04896086|DRUG|VRC-FLUMOS0111-00-VP (FluMos-v1)|FluMos-v1 investigational vaccine is composed of engineered pentameric promoters based on C. albicans lumazine synthase assembled with 20 trimeric promoters displaying HA ectodomains. It contains hemagglutinin (HA) proteins from the following 4 influenza strains: A/Idaho/07/2018, A/Perth/1008/2019, B/Colorado/06/2017 and B/Phuket/3073/2013.
218936068|NCT02917642|DEVICE|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
218936069|NCT02917642|DEVICE|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
218936070|NCT00475696|DRUG|Duloxetine|
218936071|NCT03398083|DRUG|THC|THC capsule
218936072|NCT03398083|DRUG|Alprazolam|Alpraxolam capsule
218936073|NCT03398083|DRUG|Placebo oral capsule|Sugar pill capsule
219047280|NCT07174024|DEVICE|blue light emitting diode|type of diode
219622997|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
218936074|NCT03398083|DRUG|CBD|CBD capsule
218936075|NCT02249832|DEVICE|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
218936076|NCT00458978|DRUG|Cediranib Maleate|Given orally
218936077|NCT00458978|OTHER|Laboratory Biomarker Analysis|Correlative studies
219047281|NCT07173946|OTHER|Standard of Care Anti-tumor Therapy|This is an observational cohort study. There is no intervention assigned by the study protocol. Treatment strategies (including but not limited to chemotherapy, immunotherapy, radiotherapy, and local interventional therapy) are determined solely by the treating physician based on clinical practice guidelines and individual patient circumstances.Patients will receive real-world anti-tumor treatments as prescribed by their physicians. Common treatments for extensive-stage small cell lung cancer (ES-SCLC) may include platinum-etoposide chemotherapy, immune checkpoint inhibitors (such as anti-PD-L1/PD-1 antibodies), radiotherapy, and other therapies per standard clinical practice. The study will observe and record these treatments and their outcomes.
219548122|NCT05132426|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
219548123|NCT00003357|BIOLOGICAL|GM2-KLH vaccine|
219548124|NCT00003357|BIOLOGICAL|QS21|
219047282|NCT07173582|DIAGNOSTIC_TEST|Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.|"All patients will be subjected to:~A- Complete medical history:~including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations.~B- Clinical examination:~* General and local rheumatologic examination.~* Local chest examination (inspection, palpation, percussion, auscultation).~* Assessment of RA disease activity using DAS 28 ESR.~C- Laboratory investigations:~CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status.~D- Radiology and PFT:~PFTs and HRCT chest patterns will be done for patients.~E- MMP measurement:~MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.~F. The capillaroscopy procedure"
219548125|NCT05729048|DEVICE|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
219548126|NCT00989950|DRUG|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
219548127|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
219622998|NCT06087445|DEVICE|NeuroLife EMG-FES Sleeve System|Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
219622999|NCT03777215|DRUG|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
219623000|NCT03777215|DRUG|Saline|Saline will be used as the placebo comparator.
219641881|NCT01729338|DRUG|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \[10,12,14, etc.\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
218936078|NCT05576636|BEHAVIORAL|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
218936079|NCT05576636|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
218936080|NCT03357588|OTHER|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
218936081|NCT03357588|OTHER|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
218936082|NCT04396561|DRUG|Paravertebral group (group P):|"In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels."
219548128|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
219548129|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
219548130|NCT00387530|DRUG|oral sodium phenylbutyrate|
219548131|NCT00387530|DRUG|valganciclovir|
219548132|NCT00387530|GENETIC|polymerase chain reaction|
219548133|NCT00387530|GENETIC|protein expression analysis|
219548134|NCT00387530|PROCEDURE|biopsy|
219548135|NCT02863822|BEHAVIORAL|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
219548136|NCT02863822|BEHAVIORAL|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
219548137|NCT05966922|PROCEDURE|Transcutaneous Electrical Stimulation|Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
219548138|NCT00101439|DRUG|ezetimibe|
219623001|NCT06792981|OTHER|Universal primary prevention program based on ICTs|"The intervention adopts a multicomponent approach, addressing three agents in the prevention and management of eating disorders: parents, teachers and students.~1. Intervention with parents:~   Parents will receive specific materials, including an informative guide on early identification of warning signs, promoting healthy lifestyle habits, and fostering effective communication with their children.~2. Intervention with teachers:~   A two-hour in-person session will train teachers on platform use and provide tools for eating disorder prevention through role-playing techniques. Online resources will complement the training, while researchers ensure adherence via weekly follow-ups and parent reminders.~3. e-Preta program: The intervention for minors is delivered through an online platform, structured into 9 sessions of 45 minutes each, over 3 months. Weekly, platform-guided activities are proposed for classroom use with minimal teacher interaction, along with voluntary at-home activities."
219623002|NCT04563754|DIAGNOSTIC_TEST|mHRME (Mobile High resolution microendoscope)|"Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging."
219623003|NCT04563754|DRUG|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
219623004|NCT04563754|DIAGNOSTIC_TEST|High resolution anoscopy|Standard of care (SOC) HRA with Lugol's iodine will be performed.
219623005|NCT06313970|DRUG|QL1706|QL1706 5mg/kg，IV，D1, Q3W
219548139|NCT00101439|DRUG|Comparator: placebo|
219548140|NCT05801822|DIAGNOSTIC_TEST|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
219548141|NCT04830540|DEVICE|OOFOS Recovery Footwear|The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
219548142|NCT01851772|DEVICE|Treatment with Electronic Brachytherapy|
219623006|NCT06313970|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W
219623007|NCT06313970|DRUG|Gemcitabine|gemcitabine，1000mg/m2，IV，D1、8；Q3W.
219623008|NCT06313970|DRUG|Bevacizumab|bevacizumab, 7.5mg/kg，IV，D1；Q3W.
219623009|NCT04023396|DRUG|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
219623010|NCT06452940|OTHER|Exercise|A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
219548143|NCT00500201|DRUG|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
219548144|NCT00500201|DRUG|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
219548145|NCT00500201|DRUG|Placebo|Placebo tablets will be administered orally by subjects.
219548146|NCT03415867|DRUG|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
219548147|NCT03245658|DRUG|THC and CBD Mixture|Individually titrated doses on daily basis
219548148|NCT01679158|DEVICE|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
219548149|NCT00633672|DRUG|Esomeprazole|20mg Oral tablet once daily
219548150|NCT00633672|DRUG|Ranitidine|150mg oral twice daily
219548151|NCT00633672|DRUG|Esomeprazole|40mg oral tablet once daily
219548152|NCT05988840|OTHER|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
219548153|NCT05934695|OTHER|Lymphedema severity stratification|"Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds"
219548154|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
219548155|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
219548156|NCT06452758|OTHER|2000 meter ergometer test|Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
219548157|NCT00840658|BEHAVIORAL|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
219623011|NCT06500845|OTHER|Bevel marginal design endocrown for endodontically treated teeth|Bevel marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
219548158|NCT00840658|BEHAVIORAL|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
219548159|NCT00840658|BEHAVIORAL|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
219548160|NCT00840658|BEHAVIORAL|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
219548161|NCT02956096|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
219548162|NCT02956096|DEVICE|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
219548163|NCT05710458|DEVICE|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
219548164|NCT05710458|DEVICE|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
219548165|NCT01867658|DEVICE|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
219548166|NCT00474058|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
219548167|NCT00474058|OTHER|Placebo|Placebo transdermal patches
219548168|NCT03101358|DRUG|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
219548169|NCT06114836|DRUG|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
219548170|NCT06114836|OTHER|AR formula|Added rice formula will be ordered for 4 weeks.
219548171|NCT02386358|DRUG|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
219548172|NCT02386358|DRUG|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
219548173|NCT01430533|DRUG|azelaic acid pre foam formulation|
219548174|NCT01430533|DRUG|Vehicle pre foam formulation|
219548175|NCT01430533|DRUG|Water|
219548176|NCT02024048|OTHER|OCT|Optical coherence tomography in enhanced depth imaging mode
219548177|NCT04598763|OTHER|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
219548178|NCT05616728|DRUG|EDP-235|capsule
219548179|NCT05616728|DRUG|Placebo|capsule
219623012|NCT06500845|OTHER|Butt marginal design endocrown for endodontically treated teeth|Butt marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
219548180|NCT00690495|DRUG|Propofol|Propofol (drug), intravenous, induction of anesthesia
219548181|NCT00690495|DRUG|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
219548182|NCT03958812|DIAGNOSTIC_TEST|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
219623013|NCT05127226|DRUG|ION582|ION582 will be administered by IT injection.
219548183|NCT01572623|DRUG|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
219548184|NCT01572623|DRUG|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
219548185|NCT01024855|DEVICE|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
219548186|NCT02757703|DRUG|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
219548187|NCT02757703|DRUG|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
219548188|NCT02757703|DRUG|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
219548189|NCT02757703|DEVICE|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
219548190|NCT00076622|DRUG|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
219548191|NCT00076622|DRUG|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
219548192|NCT05210647|DEVICE|robotic surgery|by da Vinci Xi
219623014|NCT03140748|OTHER|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
219548193|NCT03306277|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
218936083|NCT04437134|OTHER|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
219047283|NCT07171918|DRUG|Antibiotics, Vasopressors|Both groups are scored on REMS and NEWS2, and then observed closely for the period of hospital stay with regard to ICU stay duration, ventilator days, vasopressor dependent days and total hospital duration
219548194|NCT05603351|DIAGNOSTIC_TEST|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
219548195|NCT05603351|DIAGNOSTIC_TEST|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
219548196|NCT05603351|PROCEDURE|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
219548197|NCT05283954|DRUG|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
219548198|NCT05283954|DRUG|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
219548199|NCT03574805|DRUG|PRS-060|Study drug
219548200|NCT03574805|DRUG|Placebo|Inhalant designed to mimic PRS-060
219548201|NCT04046705|PROCEDURE|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
219548202|NCT04046705|OTHER|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
218936084|NCT04437134|OTHER|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
218936085|NCT02765581|DEVICE|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
219548203|NCT04058977|OTHER|Power training|Progressive exercise protocol with focus on velocity of movement
219548204|NCT03097198|OTHER|Plum-blossom Needle|"* acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
219548205|NCT03097198|DRUG|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
219548206|NCT00253305|DRUG|Organogel of naftifine, 2%|
219548207|NCT00253305|DRUG|Organogel of terbinafine, 2%|
219548208|NCT00253305|DRUG|Organogel of naftifine, 6%|
219548209|NCT00253305|DRUG|Organogel of terbinafine, 6%|
219548210|NCT06007729|DRUG|HS-20093|Participants in all subjucts will receive HS-20093 at 10mg/kg
219548211|NCT03459235|OTHER|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
219206224|NCT06853158|OTHER|Health education|The content for the HybHE control was adapted from Project PEEP: Patients Empowered and Educated Providers. The Sickle Cell Community Consortium developed Project PEEP with a grant from Global Blood Therapeutics. Project PEEP addresses unmet needs directly identified and prioritized by a collective of patients with SCD, caregivers, and community-based organizations. The objective is to provide the tools and resources to improve communication and increase positive patient-provider interactions to receive quality, timely care. For the proposed study, we will use modules from the curriculum developed for patients living with SCD.
219206225|NCT06703281|PROCEDURE|Interscalene Nerve Block|Patients assigned to the Interscalene Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
219206226|NCT06703281|PROCEDURE|Superior trunk block|Patients assigned to the Superior Trunk Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
219548212|NCT04432558|DIAGNOSTIC_TEST|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
219623015|NCT04075825|OTHER|Placebo|Darvadstrocel placebo-matching eASCs intralesional injection received in previous ADMIRE-CD II study. No drug administration in this study.
219548213|NCT04432558|OTHER|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
219548214|NCT04432558|DRUG|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
219548215|NCT05623592|DRUG|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
219548216|NCT05623592|DRUG|Sodium chloride|Sodium chloride subcutaneously
219548217|NCT01425840|DRUG|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
219548218|NCT02495207|DEVICE|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
219548219|NCT05945472|OTHER|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
219548220|NCT05945472|OTHER|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
219623016|NCT04075825|BIOLOGICAL|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
219548221|NCT06560034|DEVICE|VicorderCS|"1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis"
218936086|NCT02765581|DEVICE|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
219623017|NCT04428554|RADIATION|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
219623018|NCT05972018|DRUG|Liposomal bupivacaine|Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
219623019|NCT05972018|DRUG|Ropivacaine|Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
219623020|NCT05972018|DRUG|Bupivacain|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
219623021|NCT04907097|DIETARY_SUPPLEMENT|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
218936087|NCT02765581|BEHAVIORAL|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
218936088|NCT02664571|DEVICE|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
218936089|NCT02664571|DEVICE|MRI scan|Subjects will have an MRI scan at inclusion.
218936090|NCT02664571|BIOLOGICAL|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
218936091|NCT01635426|DRUG|Aspirin|Aspirin 75 mg daily for 2 months after meals
218936092|NCT01635426|DRUG|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
218936093|NCT05212818|DRUG|TF0023|Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
218936094|NCT03765034|BEHAVIORAL|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
218936095|NCT03765034|BEHAVIORAL|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
219548222|NCT01371617|DRUG|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
219548223|NCT05264896|DRUG|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
219623022|NCT04907097|OTHER|Placebo|Placebo capsuled will be used as a comparator.
219623023|NCT01820117|OTHER|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
219623024|NCT01820117|OTHER|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
219623025|NCT01820117|OTHER|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
219623026|NCT01820117|OTHER|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
219623027|NCT01820117|OTHER|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
219623028|NCT01820117|OTHER|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
219623029|NCT01820117|OTHER|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
219623030|NCT01820117|OTHER|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
219623031|NCT01820117|PROCEDURE|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
218936096|NCT05799248|DRUG|rhPSMA-7.3 (18F)|Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
218936097|NCT06529926|OTHER|Observational|Only classical physiotherapy application for 4 weeks.
218936098|NCT06529926|OTHER|IASTM Technique Application|IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
218936099|NCT00229567|DRUG|Lidocaine infusion plus ketamine injection|
218936100|NCT02516969|RADIATION|Stereotactic Body Radiotherapy|Radiation
218936101|NCT03398499|DEVICE|VIOFOR (Med & Life)|Device: VIOFOR (Med \& Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
218936102|NCT01804738|OTHER|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
218936103|NCT01804738|OTHER|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
218936104|NCT00717704|DRUG|ixabepilone|by vein once every 3 weeks
218936105|NCT00717704|DRUG|Dasatinib|by mouth once daily
218936106|NCT04000854|DRUG|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
218936107|NCT01588418|DRUG|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
218936108|NCT01588418|DRUG|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
218936109|NCT00701883|DRUG|Placebo|2 capsules, once a day for 8 weeks
218936110|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
218936111|NCT00701883|DRUG|MBX-8025|2 capsule, once daily for 8 weeks
218936112|NCT00701883|DRUG|Atorvastatin|2 capsules, once daily for 8 weeks
218936113|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
218936114|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
218936115|NCT04216264|BEHAVIORAL|Standard response|Parents pick from a menu of behavior changes
218936116|NCT04216264|BEHAVIORAL|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
218936117|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
219548224|NCT05264896|DRUG|XELOX|XELOX 8 cycles post radical gastrectomy
219548225|NCT04339634|OTHER|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
219548226|NCT03082586|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
219548227|NCT03082586|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
219548228|NCT03082586|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
219548229|NCT03082586|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
219548230|NCT03082586|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
219548231|NCT03082586|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
219623032|NCT01820117|OTHER|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
219623033|NCT00351624|BEHAVIORAL|DHA|
219623034|NCT00351624|BEHAVIORAL|placebo|
219623035|NCT04021914|DEVICE|EnChroma glasses|Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
219623036|NCT01506037|DRUG|Desloratadine|Desloratadine ODT 5 mg
219623037|NCT04969406|OTHER|Brillouin Spectroscopy via BOSS System|Biomechanical Imaging of the Cornea and Lens
219623038|NCT03349060|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
219623039|NCT03349060|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
218936118|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
218936119|NCT01111799|PROCEDURE|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
218936120|NCT04073979|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
218936121|NCT04320589|DRUG|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
218936122|NCT04320589|DRUG|General anesthetic|1\) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
218936123|NCT00967421|DRUG|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
219623040|NCT03349060|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
219623041|NCT04137081|BEHAVIORAL|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
219623042|NCT02861586|BIOLOGICAL|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
218936124|NCT00967421|DRUG|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
218936125|NCT00967421|OTHER|Placebo drink|Placebo drink containing no alcohol + placebo pill
219548232|NCT05448235|OTHER|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
219623043|NCT02861586|BIOLOGICAL|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
219623044|NCT02861586|BIOLOGICAL|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
219206227|NCT06627790|DRUG|Mouthwash preparation|Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
219206228|NCT06868979|OTHER|Clinical assessment|Clinical examination including Medical history, developmental trajectory, epilepsy history, ASD symptoms, clinical examination at the inclusion visit by a neuropediatrist
219548233|NCT05448235|OTHER|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
219548234|NCT01296841|DEVICE|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
219548235|NCT03340623|DEVICE|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
219548236|NCT03168659|DEVICE|HeartLight|HeartLight Endoscopic Ablation System
219548237|NCT03168659|PROCEDURE|Ablation|Pulmonary vein isolation ablation
219548238|NCT06089395|DRUG|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
219548239|NCT06089395|DRUG|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
219548240|NCT01412827|RADIATION|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
219548241|NCT04758208|DIAGNOSTIC_TEST|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
219548242|NCT00919737|DRUG|NPC-08|Polifeprosan 20 with Carmustine 3.85%
219548243|NCT02849106|PROCEDURE|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
219548244|NCT00975754|DRUG|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
219548245|NCT00975754|DRUG|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
219623045|NCT02861586|BIOLOGICAL|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
219548246|NCT00975754|DRUG|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
219548247|NCT00975754|DRUG|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
219548248|NCT04342936|DRUG|Camrelizumab|A humanized monoclonal immunoglobulin
219548249|NCT04342936|DRUG|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
219548250|NCT06251349|RADIATION|Radiation|Single dose radiation with 7-8 Gy
219548251|NCT06251349|DRUG|Diclofenac|postoperative treatment with diclofenac to prevent HO
219623046|NCT00955409|BIOLOGICAL|ACC-001(3µg) + QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
219623047|NCT00955409|BIOLOGICAL|ACC-001(10µg) + QS21|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
219623048|NCT00955409|BIOLOGICAL|ACC-001(30µg) + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
219623049|NCT01894308|DRUG|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
219623050|NCT01894308|DEVICE|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
219623051|NCT06577389|OTHER|Enhanced recovery after surgery|The ERAS program for lumbar fusion surgery will be implemented.
218936126|NCT00970996|DRUG|Temozolomide|250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
218936127|NCT00970996|DRUG|Abraxane|100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
218936128|NCT00970996|DRUG|Cisplatin|20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
218936129|NCT00970996|BIOLOGICAL|Interleukin-2|9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
218936130|NCT00970996|BIOLOGICAL|Interferon alpha 2b|5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
218936131|NCT02495519|DRUG|Imatinib|Imatinib 400 mg/day until disease progression
219548252|NCT01174849|DRUG|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
219548253|NCT01174849|DRUG|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
219548254|NCT01174849|DRUG|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
219623052|NCT06552416|DRUG|MT-401-OTS|MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.
219623053|NCT03109067|OTHER|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
219623054|NCT06554652|PROCEDURE|Lymph node tracer navigated selective neck dissection|Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).
219623055|NCT06554652|PROCEDURE|Modified neck dissection|Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
219623056|NCT05597943|BEHAVIORAL|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
219623057|NCT06131788|BEHAVIORAL|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
219623058|NCT03457948|PROCEDURE|Arterial Embolization|Undergo TAE
219623059|NCT03457948|BIOLOGICAL|Pembrolizumab|Given IV
218936132|NCT04212962|BEHAVIORAL|Transitional care model (TCM)|Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient
218936133|NCT04212962|BEHAVIORAL|Usual care|usual hospital discharge and post-discharge care
219206229|NCT06868979|OTHER|Parental questionnaires|Parental questionnaires including Vineland-2, ABC, CBCL, PPD-MRS, SRS-2 and BRIEF completed at the inclusion visit
219206230|NCT06868979|OTHER|Cognitive assessment|Cognitive assessment including Leiter-3, PPVT 5, EVT 3 completed at the inclusion visit
219206231|NCT06868979|OTHER|Reasoning assessment|Simple reasoning tasks on tablets performed at the inclusion visit.
219206232|NCT06868979|DEVICE|fNIRS assessement|Imaging session using fNIRS (NIRSport 8x8, NIRx Medical Technologies LLC, Berlin, Germany) performed at the inclusion visit.
219206233|NCT06756295|BIOLOGICAL|individualized tumor FAST vaccine combination (including adjuvant)|Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.
219206234|NCT06860074|BEHAVIORAL|Sustainable Environmental Health Programs|"* Sustainable Future: Environment, Ecological Balance and Health,~* Ecological Balance and Pollution: Protecting Environmental Health~* Ecological Balance and Environmental Health~* A New Life for Waste: A Sustainable Future with Recycling~* Environmental Behaviors~* Recycling for Street Animals: A Shed Construction Project"
219548255|NCT00981838|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
219548256|NCT00881751|BIOLOGICAL|bevacizumab|Given IV
219548257|NCT00881751|DRUG|erlotinib hydrochloride|Given orally
219548258|NCT00881751|DRUG|sorafenib tosylate|Given orally
219623060|NCT03457948|BIOLOGICAL|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
219623061|NCT03457948|DEVICE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
219623062|NCT04522336|DRUG|Docetaxel|Given IV
219623063|NCT04522336|DRUG|Fluorouracil|Given IV
219623064|NCT04522336|DRUG|Oxaliplatin|Given IV
219623065|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
219623066|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
219623067|NCT06801002|DRUG|JBZ-001|JBZ-001 Oral Capsule
219548259|NCT02784236|DEVICE|telemedicine|The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
219548260|NCT05406518|OTHER|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
219548261|NCT05252377|OTHER|Breathing Exercise|"1. The patient will be asked to close their eyes~2. He will be asked to relax his head and neck in a semi-sitting position in bed~3. The patient will be asked to breathe through the nose for 3 seconds by counting~4. Then he will be told to hold his breath for 3 seconds~5. As the last step, he will be asked to breathe out again in 3 seconds."
219623068|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
219548262|NCT01492556|DRUG|Etoposide|Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
219548263|NCT03633721|DRUG|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
218936134|NCT02563067|DRUG|QAW039|QAW039 150 mg once daily
219548264|NCT03633721|OTHER|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
219548265|NCT00209690|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219548266|NCT00209690|DRUG|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
218936135|NCT02563067|DRUG|QAW039|QAW039 450 mg once daily
218936136|NCT02563067|DRUG|Placebo|Placebo once daily
218936137|NCT03873818|BIOLOGICAL|Ipilimumab|Given IV
218936138|NCT03873818|BIOLOGICAL|Pembrolizumab|Given IV
218936139|NCT00839319|DRUG|Acyline|300 ug/kg subcutaneous injections on Day 1.
218936140|NCT00839319|OTHER|placebo hCG (no active ingredient)|placebo hCG
218936141|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
218936142|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
218936143|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
218936144|NCT00839319|DRUG|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
218936145|NCT04014868|DEVICE|Nasal high-flow|See arm description.
218936146|NCT04014868|OTHER|Sham nasal high-flow|See arm description.
218936147|NCT02444767|DRUG|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
218936148|NCT03544333|DEVICE|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
218936149|NCT00774267|DRUG|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
218936150|NCT00774267|DRUG|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
218936151|NCT00774267|DRUG|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
218936152|NCT00774267|DRUG|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
218936153|NCT02335788|DEVICE|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
218936154|NCT05631613|PROCEDURE|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
218936155|NCT03363490|BEHAVIORAL|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
218936156|NCT03363490|BEHAVIORAL|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
219047284|NCT07173270|OTHER|Oral health support|The intervention group will receive examination and treatment by a dental hygienist every 3 months starting 6 months after completion of RT/CRT up to 3 years. During visits to the dental hygienist, they will be asked about oral hygiene habits, fluoride use, dry mouth problems, and dietary habits (including intake of easily degradable carbohydrates). Oral dryness will be assessed using the Clinical Oral Dryness Scale. The stimulated salivary secretion and buffering capacity will be assessed, and the ability to open the mouth, cariological and periodontal status and registered plaque. Based on the results of the clinical examination, the patient will get individually tailored advice and recommendations on oral hygiene, fluoride use, dry mouth relief, and support in reducing the intake of food items and drinks with high sugar content. Professional oral care will be given, and fluoride applications when indicated.
219047285|NCT07172789|OTHER|head down position|the patient is positioned at a -20° Trendelenburg
219047286|NCT07173647|DEVICE|Electrical Muscle Stimulation (EMS)|Electrical Muscle Stimulation (EMS) will be applied to the quadriceps muscles of children with cerebral palsy during stationary cycling sessions as part of the Pediatric Endurance and Limb Strengthening (PEDAL) program. EMS will be delivered using clinically approved portable stimulators at parameters appropriate for muscle strengthening and endurance training (frequency 35-50 Hz, pulse width 200-400 μs, duty cycle on/off as tolerated). EMS will be administered simultaneously with cycling to enhance muscle activation and improve motor outcome
219047287|NCT07173647|BEHAVIORAL|Pediatric Endurance and Limb Strengthening (PEDAL) Program|The PEDAL program is a structured exercise intervention designed for children with cerebral palsy. It includes 60-minute sessions of stationary cycling, warm-up, endurance and limb strengthening exercises, and cool-down stretching. Sessions are conducted three times per week for four weeks under therapist supervision. This program is used in both arms of the trial, with or without adjunct Electrical Muscle Stimulation (EMS).
219047288|NCT07173699|PROCEDURE|root canal treatment|Standardized root canal treatment performed on asymptomatic mandibular molars. Procedures include local anesthesia, rubber dam isolation, access cavity preparation, cleaning and shaping with rotary instruments, irrigation with NaOCl and EDTA, and obturation using a standardized protocol. Saliva samples are collected prior to treatment for melatonin analysis. Postoperative pain and sleep quality are assessed using validated questionnaires.
219047289|NCT07173595|DRUG|QLS2309|initial dose - MTD; QW; intravenous infusion
219047290|NCT07173881|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
219047291|NCT07173452|OTHER|vaginal examination|pelvic dimensions measured via vaginal examination.
219047292|NCT07173452|OTHER|physical body measurements|Anthrometric measurements of the participants were made
219047293|NCT07173452|DIAGNOSTIC_TEST|transvaginal ultrasonographic|intrapartum pelvic evaluations were performed by transvaginal ultrasonography
219047294|NCT07174245|DEVICE|continuous glucose monitor|All participants who wear CGM
219047295|NCT07172893|BIOLOGICAL|DermaBind TL|Full-Thickness Dehydrated Placental Allograft
219047296|NCT07172087|OTHER|Baduanjin for patients with enterostomy|Modified Baduanjin exercise: a standardized, low-to-moderate intensity qigong regimen consisting of eight sequential movements combined with diaphragmatic breathing. The program excludes any additional resistance or aerobic training and is compared with routine walking exercise only.
219047297|NCT07174193|DEVICE|Piezosurgery|Initially introduced in the field of implantology, piezosurgery has gained increasing popularity in orthognathic surgery in recent years (7-9). This technique utilizes ultrasonic vibrations ranging from 60-210 μm/s at frequencies between 24-29 kHz to cut bone, thereby minimizing trauma to surrounding soft tissue (10). Although numerous studies have been conducted, many clinical investigations have been limited by small sample sizes and insufficiently described methodologies (17, 18). Furthermore, the lack of standardized assessment tools hinders reliable comparisons of outcomes across studies (19). While surgeons increasingly recommend the use of piezosurqical instruments in orthognathic surgery, robust evidence from the literature remains insufficient to support the change in surgical technique.
219047298|NCT07174193|DEVICE|Conventional techniques|In the control group a Lindemann burr will be used to perform the horizontal and vertical osteotomies and the cut at the lower border of the mandible. A reciprocal saw will then be used to connect the horizontal and vertical osteotomies in the sagittal plane.
219047299|NCT07172555|OTHER|Virtual Dietetic First-Appointment Webinar for Coeliac Disease|This intervention is a dietitian-led, pre-recorded on-demand webinar specifically designed for adults who have been newly diagnosed with coeliac disease. It acts as a patient's first formal dietetic appointment after diagnosis and provides comprehensive education about coeliac disease and the strict gluten-free diet required for its management. Unlike traditional approaches, which rely on face-to-face or telephone appointments with a dietitian-and which often involve significant waiting times-the webinar is available immediately online, allowing patients to access trusted, specialist information at their own pace and convenience, including the opportunity to re-watch as needed
219206235|NCT04653740|PROCEDURE|specimen sample collection|"Before and during treatment, and at progression, collection of :~* Blood~* Exhaled air~* Saliva~* Sweat~* Tears~* Urine"
219206236|NCT06889337|OTHER|head elevated laryngoscopy position by Oxford pillow|ramped position, also known as head elevated laryngoscopy position,
219206237|NCT06882486|PROCEDURE|nephrectomy|Nephrectomy scheduled within 3 months of inclusion. Patients may continue their systemic treatment at the usual rate until D-5 prior to surgery. Treatment will not be resumed after surgery. Surgery may consist of partial or enlarged nephrectomy, with or without associated lymph node dissection, depending on technical possibilities and at the surgeon's discretion.
219206238|NCT06787976|DRUG|Dolutegravir (DTG)|Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
219206239|NCT06787976|DRUG|Darunavir/Cobicistat (FDC)|Darunavir Cobicistat + TDF/FTC
219548267|NCT00209690|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219548268|NCT00827164|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
219548269|NCT00827164|BEHAVIORAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
219548270|NCT04031690|OTHER|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
219548271|NCT04031690|OTHER|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
219548272|NCT04879719|BEHAVIORAL|Ego-depletion|The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.
219548273|NCT04879719|BEHAVIORAL|Control|The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
219548274|NCT03354858|PROCEDURE|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
219548275|NCT02245503|DRUG|Tamsulosin|
218936157|NCT03363490|BEHAVIORAL|Health education|All four groups of patient will receive two times of health education in the first week.
219548276|NCT01852799|DRUG|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
218936158|NCT04021641|DIAGNOSTIC_TEST|Speech recognition in noise|Measurement of speech recognition performance in noise
218936159|NCT02110043|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
219206240|NCT06523556|BIOLOGICAL|Axatilimab|Given IV
219548277|NCT02385708|DRUG|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
219548278|NCT02385708|DRUG|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
219548279|NCT05561088|OTHER|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
219548280|NCT05561088|OTHER|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
219548281|NCT05453487|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
219548282|NCT05453487|BIOLOGICAL|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
219548283|NCT05453487|BIOLOGICAL|rabies vaccine|received three dose of rabies vaccine
219548284|NCT03162159|OTHER|Collection of growth and bone maturation data|
219548285|NCT00178178|DEVICE|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
219548286|NCT00178178|DRUG|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
219548287|NCT00178178|DRUG|Placebo|Drug: Placebo
218936160|NCT02110043|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
218936161|NCT01039519|DRUG|Ganetespib|Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
218936162|NCT05844007|BEHAVIORAL|Trauma-Informed Yoga|Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
219206241|NCT06523556|DRUG|Azacitidine|Given IV or SC
219548288|NCT05032807|DRUG|Standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
219548289|NCT05032807|DRUG|Novel formulation|Cannabidiol 1000mg with lipid matrix, single dose, oral
219548290|NCT01559363|DRUG|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
219548291|NCT03810963|COMBINATION_PRODUCT|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
219548292|NCT03810963|OTHER|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
219548293|NCT00672984|DRUG|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
219548294|NCT00672984|DRUG|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
219548295|NCT00672984|DRUG|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
219623069|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
219548296|NCT05022979|OTHER|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
219623070|NCT02466191|DRUG|Memantine|
219623071|NCT02466191|DRUG|Gabapentin|
219047300|NCT07172555|OTHER|Standard Dietetic Consultation (Face-to-Face or Telephone)|Participants in this group are allocated to receive the existing standard of care: an individual appointment with a specialist dietitian, delivered either in person (face-to-face) or by telephone. During the appointment, the dietitian provides a comprehensive overview of the gluten-free diet, strategies for avoiding cross-contamination, and advice on nutritional adequacy. As in the experimental arm, baseline assessment and validated questionnaires are administered pre- and post-intervention, with follow-up at 6 months to collect clinical, adherence, satisfaction, and quality of life data for direct comparison with the on-demand webinar intervention.
219047301|NCT07173725|DRUG|Octenidine dihydrochloride 0.1%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
219047302|NCT07173725|DRUG|Chlorhexidine 2%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
219047303|NCT07173049|BEHAVIORAL|AAC Speech supplementation|The speech supplementation intervention involves learning to point to pictures, words, or letters on a communication board while simultaneously producing speech. Children will spend up to 30 minutes learning to use the strategy in one- on-one interaction with a speech therapist and demonstrate mastery by using the strategy successfully on a series of test stimuli.
219047304|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
219548297|NCT00645853|DRUG|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
219548298|NCT00645853|DRUG|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
219548299|NCT01746472|BEHAVIORAL|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
219047305|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
219623072|NCT01880554|DEVICE|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
219623073|NCT03315390|OTHER|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
219047306|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
219548300|NCT01746472|BEHAVIORAL|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
219548301|NCT01746472|BEHAVIORAL|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
219548302|NCT01746472|BEHAVIORAL|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
219623074|NCT03315390|OTHER|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
219623075|NCT03981796|BIOLOGICAL|Dostarlimab|Participants will be administered dostarlimab
219623076|NCT03981796|DRUG|Placebo matching dostarlimab|Participants will be administered placebo matching dostarlimab
219623077|NCT03981796|DRUG|Carboplatin|Participants will be administered carboplatin
219623078|NCT03981796|DRUG|Paclitaxel|Participants will be administered paclitaxel
219623079|NCT03981796|DRUG|Niraparib|Participants will be administered niraparib
219047307|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
219047308|NCT04414384|OTHER|Step Counter|step counter to track steps
219047309|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
219047310|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
219047311|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
219047312|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
219047313|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
219623080|NCT03981796|DRUG|Placebo matching Niraparib|Participants will be administered placebo matching Niraparib
219623081|NCT05161481|DRUG|Avenciguat (BI 685509)|Participants received Avenciguat twice daily (BID) throughout the study. Up-titration depended on the assigned dose group. At Visit 2 (Week 1), each dose included one 1 mg Avenciguat tablet. At Visit 3 (Week 2), the dose was increased to one 2 mg Avenciguat tablet per dose. From Visit 4 onward (Week 3+), participants received one 3 mg Avenciguat tablet per dose. This regimen continued for 24 weeks, with all doses taken with water, with or without food.
219047314|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
219047315|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
219047316|NCT00881309|DRUG|Tripterygium|TW 90mg/d
219047317|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
219548303|NCT02327559|BEHAVIORAL|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
219548304|NCT02327559|BEHAVIORAL|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
219548305|NCT06410638|DIAGNOSTIC_TEST|Six Minute Walking Test|It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
219548306|NCT06410638|DIAGNOSTIC_TEST|Shuttle walking test|Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
219548307|NCT06563232|DEVICE|FNA group|Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
219548308|NCT06563232|DEVICE|Adapt FNB group|Fine-needle-biopsy (22G Adapt Aspiration)
219548309|NCT05409651|BEHAVIORAL|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
219548310|NCT01717352|BEHAVIORAL|Weight Loss Education|
219548311|NCT01717352|BEHAVIORAL|Sleep and Eating Routine|
219548312|NCT03168503|DIETARY_SUPPLEMENT|LGG+Promitor™|synbiotic
219548313|NCT03168503|DIETARY_SUPPLEMENT|Promitor™|Soluble Corn Fiber
219548314|NCT03168503|DIETARY_SUPPLEMENT|LGG-PB12+Promitor™|synbiotic
219548315|NCT03168503|DIETARY_SUPPLEMENT|Maltodextrin|Control
219548316|NCT04736303|DEVICE|BIS|The implementation of BIS monitoring
219548317|NCT00870116|RADIATION|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
219548318|NCT00870116|RADIATION|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
219548319|NCT00870116|RADIATION|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
219548320|NCT04060251|DEVICE|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
219548321|NCT04060251|OTHER|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
219548322|NCT03118063|DIAGNOSTIC_TEST|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
219548323|NCT06188663|DIETARY_SUPPLEMENT|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
219548324|NCT03260686|OTHER|experimental|video guide for upper limb exercise
219047318|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
219047319|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
219206242|NCT06523556|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219548325|NCT02550535|GENETIC|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
219623082|NCT05161481|DRUG|Placebo matching Avenciguat (BI 685509)|Participants received matching placebo twice daily (BID) throughout the study. At Visit 2 (Week 1), each dose included one 1 mg and one 2 mg placebo tablet (four tablets daily). A pseudo up-titration was applied at Visit 3 (Week 2), maintaining the same tablet composition to preserve blinding. From Visit 4 (Week 3) onward, a second pseudo up-titration adjusted each dose to one 2 mg and one 3 mg placebo tablet (four tablets daily). All doses were taken with water, with or without food.
218936163|NCT04901780|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
219047320|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
219206243|NCT06523556|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
219548326|NCT03678363|OTHER|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
219548327|NCT01983735|DRUG|TELMINUVO Tab. (80/2.5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."
219548328|NCT01983735|DRUG|TELMINUVO Tab. (80/5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."
219548329|NCT01983735|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."
219548330|NCT01983735|DRUG|S-amlodipine 5mg|"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."
219548331|NCT03605641|OTHER|JUUL|JUUL Virginia Tobacco
219548332|NCT03605641|OTHER|VUSE Solo|VUSE SOLO Original
219548333|NCT03605641|OTHER|Conventional Cigarette|Subject preferred conventional cigarette
219548334|NCT05858333|OTHER|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
219548335|NCT00064324|DRUG|perifosine|Given orally
218936164|NCT04901780|OTHER|cross body stretch|crossbody stretch performed by an individual
218936165|NCT03046862|DRUG|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
218936166|NCT03046862|DRUG|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
218936167|NCT03046862|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks
218936168|NCT03046862|DRUG|Cisplatin|Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
218936169|NCT03419559|BIOLOGICAL|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
218936170|NCT03419559|DRUG|Durvalumab|PD-L1 antagonist monoclonal antibody
218936171|NCT04323657|DRUG|TC-110 T Cells|TC-110 T Cells
218936172|NCT04323657|DRUG|Fludarabine|Flu/Cy Lymphodepletion
218936173|NCT04323657|DRUG|Cyclophosphamide|Flu/Cy Lymphodepletion
218936174|NCT05070715|OTHER|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
218936175|NCT03062540|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
218936176|NCT03062540|DRUG|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
218936177|NCT01994096|DRUG|Caspofungin|
218936178|NCT05112952|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
218936179|NCT05231512|OTHER|Respiratory Music Therapy Protocol|Participants will engage in eight (8) 45-minute virtual music therapy groups containing up to 6 participants over the course of 8 weeks. Within these groups, participants will be invited to use instruments provided including a Yamaha recorder and a Grover Trophy slide whistle. 45 minute virtual music therapy sessions facilitated by board-certified music therapy will consist of music-assisted relaxation through music visualization, followed by gentle pulmonary exercise via wind instrumental playing, and concluding with group singing.
219047321|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
219047322|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
219047323|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
219206244|NCT06523556|OTHER|Survey Administration|Ancillary study
219548336|NCT00064324|OTHER|laboratory biomarker analysis|Correlative studies
219548337|NCT00064324|OTHER|pharmacological study|Correlative studies
219548338|NCT01079858|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
219548339|NCT05206851|OTHER|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
219548340|NCT05206851|OTHER|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
219623083|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
219548341|NCT02575456|BIOLOGICAL|Ebola Vaccine|
219548342|NCT02575456|BIOLOGICAL|Placebo|control
219548343|NCT05870215|OTHER|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
219548344|NCT05870215|OTHER|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
219548345|NCT05870215|OTHER|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
219548346|NCT05870215|OTHER|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
219548347|NCT05870215|OTHER|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
219548348|NCT05870215|OTHER|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
219548349|NCT05870215|OTHER|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
219548350|NCT04193150|DIAGNOSTIC_TEST|Full pulmonary specialist assessment|Please see description for the intervention arm.
219548351|NCT00487435|DRUG|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
219548352|NCT02426450|PROCEDURE|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
219548353|NCT02426450|DRUG|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
219548354|NCT02426450|DRUG|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
219548355|NCT01355835|DEVICE|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
219548356|NCT02581527|DRUG|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
219548357|NCT02581527|DRUG|Isoniazid|Isoniazid 75mg - all arms
219548358|NCT02581527|DRUG|Ethambutol|Ethambutol 275mg - all arms
219623084|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
219548359|NCT02581527|DRUG|Pyrazinamide|Pyrazinamide 400mg - all arms
219623085|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
219623086|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
219623087|NCT06033547|DRUG|Cabotegravir Formulation F|Cabotegravir Formulation F will be administered
219623088|NCT06033547|DRUG|Cabotegravir Formulation G|Cabotegravir Formulation G will be administered
219623089|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
219548360|NCT06627634|PROCEDURE|Metastatectomia and standard treatment for resectable disease.|Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
219548361|NCT01663662|DRUG|Tolvaptan|
219548362|NCT01663662|DRUG|placebo|
219548363|NCT03135080|OTHER|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
219047324|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
219548364|NCT03135080|OTHER|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
219548365|NCT04672603|PROCEDURE|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
219548366|NCT02117830|DRUG|Androxal 25 mg capsules|
219548367|NCT02117830|DRUG|Androxal 250 Capsules|
219548368|NCT02117830|DRUG|Placebo Capsules|
219548369|NCT02117830|DRUG|Moxifloxacin 400 mg|
219548370|NCT01159873|DRUG|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
219548371|NCT01159873|DRUG|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
219548372|NCT01237444|DRUG|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
219548373|NCT01237444|DRUG|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
219548374|NCT05798884|DEVICE|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
219548375|NCT05798884|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
219548376|NCT04015024|DRUG|SKLB1028 150mg bid|150mg oral administration twice a day
219548377|NCT04015024|DRUG|SKLB1028 200mg bid|200mg oral administration twice a day
219548378|NCT04015024|DRUG|SKLB1028 300mg qd|300mg oral administration once a day
219548379|NCT05212987|DRUG|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
219548380|NCT04971512|DRUG|EDP-721|Oral administration (Part 1)
219623090|NCT01536808|OTHER|Analysis telomere|Analysis telomere
218936180|NCT01374503|BIOLOGICAL|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
218936181|NCT01374503|BIOLOGICAL|Placebo|single or multiple i.v. administration
219548381|NCT04971512|DRUG|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
219548382|NCT04971512|DRUG|EDP-721 (Part 2)|Oral administration (Part 2)
219548383|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
219548384|NCT04971512|DRUG|EDP-514|Oral administration
219548385|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-514
219548386|NCT00452738|BEHAVIORAL|Therapy dog|
219548387|NCT00452738|BEHAVIORAL|Costumed character|
219548388|NCT00452738|BEHAVIORAL|Parents-only|
219548389|NCT02734511|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
219548390|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
219548391|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
219548392|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
219623091|NCT01536808|OTHER|Stress test|Stress test
219623092|NCT01536808|OTHER|echocardiography|echocardiography
218936182|NCT06520410|DEVICE|Pars plana vitrectomy with a 18 mm short vitrector|Using the shorter 18 mm vitrector for various pediatric vitreoretinal surgeries
218936183|NCT03859583|DIETARY_SUPPLEMENT|Capsaicin|4 tsp of cayenne in a breakfast omelette
218936184|NCT03859583|DIETARY_SUPPLEMENT|Control|breakfast omelette without cayenne pepper
218936185|NCT03847506|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
219623093|NCT05762172|OTHER|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
219047325|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
219047326|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
219548393|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
219548394|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
219548395|NCT00838162|DRUG|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
219548396|NCT00838162|DRUG|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
219548397|NCT00838162|DRUG|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
219548398|NCT00838162|DRUG|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
219548399|NCT00838162|DRUG|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
219548400|NCT00838162|DRUG|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
219548401|NCT05262322|DRUG|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
219548402|NCT05262322|DRUG|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
219548403|NCT05262322|DRUG|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
219548404|NCT04627844|DIETARY_SUPPLEMENT|Immediate Feeding|Standard tube feeds begun at an earlier time point
219548405|NCT04627844|DIETARY_SUPPLEMENT|Delayed Feeding|Standard tube feeds begun at delayed time point
219548406|NCT02350257|BEHAVIORAL|Internet-based CBT|12 weeks of internet-based CBT
219548407|NCT00408304|DRUG|omega-3 fatty acid|
219548408|NCT01529164|DRUG|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
219623094|NCT06527365|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
219623095|NCT02742506|OTHER|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
219623096|NCT05674812|DIAGNOSTIC_TEST|Multimodal pre-extubation risk assessment in elderly surgical patients|This observational cohort study evaluates risk factors for extubation failure in elderly surgical patients. All participants receive standard pre-extubation clinical assessments per institutional protocol, including LUS、DE and oxygenation index (PaO₂/FiO₂), arterial blood gas analysis, and the patients'laboratory results before and after surgery. The association between these parameters and extubation failure will be analyzed.
219623097|NCT04214262|DRUG|Atezolizumab|Given IV
219623098|NCT04214262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623099|NCT04214262|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219623100|NCT04214262|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
219623101|NCT04214262|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219623102|NCT04214262|OTHER|Quality-of-Life Assessment|Ancillary studies
219623103|NCT04214262|OTHER|Questionnaire Administration|Ancillary studies
219623104|NCT04214262|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219623105|NCT06514495|OTHER|Therapy|Cognitive behavioral psychotherapy with exposure
219047327|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
219047328|NCT02188368|DRUG|POM|
219047329|NCT02188368|DRUG|Steroids|
219047330|NCT02188368|DRUG|PLD|
219047331|NCT02188368|DRUG|CFZ|
219047332|NCT02188368|DRUG|BTZ|
219047333|NCT02188368|DRUG|CLA|
219047334|NCT02188368|DRUG|CY|
219047335|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
219047336|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
219047337|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
219047338|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
219047339|NCT00072345|DRUG|lomustine|
219047340|NCT00072345|DRUG|temozolomide|
219047341|NCT00072345|DRUG|thalidomide|
219548409|NCT01529164|DRUG|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
219548410|NCT01529164|DRUG|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
219548411|NCT01529164|DRUG|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
219623106|NCT05733312|DEVICE|InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system|Focused ultrasound which targets energy to a specific area in the brain based on imaging and disrupts the blood brain barrier which keeps certain drugs and other molecules out of the brain.
219623107|NCT02978625|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219623108|NCT02978625|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623109|NCT02978625|PROCEDURE|Computed Tomography|Undergo CT
219623110|NCT02978625|OTHER|Laboratory Biomarker Analysis|Correlative studies
219623111|NCT02978625|BIOLOGICAL|Nivolumab|Given IV
219623112|NCT02978625|PROCEDURE|Positron Emission Mammography|Undergo PET/CT
219623113|NCT02978625|BIOLOGICAL|Talimogene Laherparepvec|Given IT
219623118|NCT06039358|DIETARY_SUPPLEMENT|Caffeine.|Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
219623119|NCT06039358|DRUG|Cellulose.|Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
219047342|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
219623120|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg QD hard capsules
219623121|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg BID hard capsules
219623122|NCT03874858|DRUG|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
219047343|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
219206245|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
219206246|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
219206247|NCT03215706|BIOLOGICAL|Ipilimumab|Specified dose on specified day
219206248|NCT03215706|BIOLOGICAL|Nivolumab|Specified dose on specified day
219548412|NCT00712816|DEVICE|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
219548413|NCT00712816|OTHER|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
219548414|NCT06013163|DRUG|Xenical® vs EMP 22|Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
219548415|NCT06013163|DRUG|EMP 22 vs Xenical®|Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
219548416|NCT06013163|DRUG|EMP 16 vs Xenical®|Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
219548417|NCT01451541|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
219548418|NCT01451541|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
219548419|NCT01451541|DRUG|Placebo|Placebo - one dose per nostril
219548420|NCT04003363|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
219548421|NCT04712838|DRUG|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
219548422|NCT04712838|DRUG|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
219548423|NCT04712838|DRUG|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
219548424|NCT04712838|DRUG|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
219548425|NCT04712838|DRUG|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
219548426|NCT04712838|DRUG|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
219548427|NCT04872608|DRUG|Letrozole|Letrozole will be given daily on days 1-28.
219548428|NCT04872608|DRUG|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
219548429|NCT04872608|DRUG|Onapristone ER|Onapristone will be given daily on days 1-28.
219548430|NCT01780350|DEVICE|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
219548431|NCT00017550|BIOLOGICAL|anti-thymocyte globulin|
219548432|NCT03155867|OTHER|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
219548433|NCT00796796|DRUG|Temsirolimus|
219548434|NCT00796796|RADIATION|Radiation therapy|
219548435|NCT03844334|DEVICE|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
219548436|NCT07009093|OTHER|Mighty Pro Application|Access to Mighty Pro Application
219548437|NCT00052221|BIOLOGICAL|Epoetin alfa|
219548438|NCT00052221|OTHER|Placebo|
219548439|NCT01621945|BIOLOGICAL|MenBvac|Blood test
219548440|NCT02153645|DRUG|240mg Amantadine HCl ER tablets|
219548441|NCT02153645|DRUG|Placebo tablets|
219548442|NCT02153645|DRUG|320mg Amantadine HCl ER tablets|
219548443|NCT00754858|DRUG|belotecan hydrochloride|
219548444|NCT00754858|DRUG|cisplatin|
219623123|NCT05279651|DRUG|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
219623124|NCT05279651|DRUG|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
219623125|NCT06308614|DRUG|20 mg estetrol monohydrate|Active treatment
219623126|NCT06308614|OTHER|Placebo|Matching Placebo to E4
219623127|NCT06682871|PROCEDURE|Analgesia|Postoperatively, patients will be given analgesia
218936186|NCT03847506|DRUG|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
218936187|NCT03847506|DRUG|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
218936188|NCT01571518|DRUG|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
219623132|NCT05599581|BEHAVIORAL|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being."
218936189|NCT01571518|DRUG|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
218936190|NCT05669261|PROCEDURE|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
219047344|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
219047345|NCT05924464|OTHER|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
219047346|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
219047347|NCT04798274|DEVICE|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
219047348|NCT00208429|DEVICE|Pinnacle Acetabular System|
219047349|NCT06477315|OTHER|survey|telephone surveys
219047350|NCT06335329|BEHAVIORAL|Discussion of point-of-care ultrasound lung findings|"The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. \>3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present"
219047351|NCT05141591|OTHER|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
219047352|NCT04789239|DRUG|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
219623133|NCT04772131|DEVICE|Desara® One Single Incision Sling|Single incision sling
219623134|NCT04772131|DEVICE|Desara® Blue Transobturator Sling|Standard mid-urethral sling
218936191|NCT05669261|BIOLOGICAL|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
218936192|NCT05428657|OTHER|EC Brain After-school Program|"* Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet"
219623135|NCT06057038|BIOLOGICAL|GEN1042|Intravenous
218936193|NCT05428657|OTHER|conventional intervention|Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
219623136|NCT06057038|DRUG|Pembrolizumab|Intravenous
219623137|NCT06057038|DRUG|Cisplatin|Intravenous
219623138|NCT06057038|DRUG|Carboplatin|Intravenous
219623139|NCT06057038|DRUG|5-Fluorouracil|Intravenous
219623140|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
219623141|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
219623142|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
219623143|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
219623144|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
219623145|NCT04514484|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623146|NCT04514484|DRUG|Cabozantinib S-malate|Given PO
219623147|NCT04514484|PROCEDURE|Computed Tomography|Undergo CT
219623148|NCT04514484|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623149|NCT04514484|BIOLOGICAL|Nivolumab|Given IV
219623150|NCT05063656|DRUG|Gabapentin|8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
219623151|NCT06211673|OTHER|Semi-structured interviews|"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."
219641882|NCT01729338|DRUG|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
219641883|NCT01729338|DRUG|Revlimid|"Lenalidomide (odd cycles \[9,11,13, etc.\]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
218936194|NCT05346666|DRUG|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
218936195|NCT06241391|DIAGNOSTIC_TEST|PSMA PET-CT|Prostate Specific Membrane Antigen PET-CT
218936196|NCT02644603|PROCEDURE|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
218936197|NCT00385437|BEHAVIORAL|Driving Simulator Testing|
218936198|NCT00385437|DRUG|Mirtazapine Treatment|
218936199|NCT05453669|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
219047353|NCT04789239|OTHER|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
219206249|NCT03215706|DRUG|Carboplatin|Specified dose on specified day
219623152|NCT06211673|OTHER|Heteroquestionnaires|7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
219623153|NCT06355531|DRUG|FNP-223|Oral tablets
219623154|NCT06355531|DRUG|Placebo|Oral tablets
219623155|NCT05411016|DRUG|Placebo|Placebo is administered single dose or multiple dose by IV or SC injection
219623156|NCT05411016|DRUG|KK4277|KK4277 is administered single dose or multiple dose by IV or SC injection
219623157|NCT05439005|DRUG|Dexmedetomidine|Dexmedetomidine+Lidocaine
219623158|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
219623159|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
219623160|NCT05782400|RADIATION|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
219623161|NCT05782400|BIOLOGICAL|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
219623162|NCT04357769|OTHER|PSS (Perceived Stress Scale)|Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
219623163|NCT04357769|OTHER|GAD-7 (7-item Generalized Anxiety Disorder)|Self-administered scale for the evaluation of anxiety symptoms in the last weeks
219623164|NCT04357769|OTHER|PHQ-9 (9-item Patient Health Questionnaire)|Self-administered scale for the evaluation of depressive symptoms in the last weeks
219623165|NCT04357769|OTHER|SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
219623166|NCT04357769|OTHER|Zaritt Burden Interview|Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
218936200|NCT02089893|DEVICE|Fundus photography|Non-mydriatic fundus photographs
218936201|NCT00594243|BEHAVIORAL|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
218936202|NCT00594243|OTHER|Wait-list control|No treatment given.
219047354|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
219047355|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
219047356|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
219047357|NCT04342832|PROCEDURE|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
219047358|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
219047359|NCT02870907|OTHER|Observation|no post operative chemotherapy
218936203|NCT00351052|DRUG|Pimecrolimus|Pimecroliums cream 1 % bid.
218936204|NCT00351052|DRUG|Placebo|Vehicle control (placebo) bid.
218936205|NCT00808080|BIOLOGICAL|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
218936206|NCT00429728|DRUG|GW876008|
218936207|NCT02935439|OTHER|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
219047360|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
218936208|NCT01330108|DRUG|ambrisentan|ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
218936209|NCT05545540|OTHER|Musical Neurostimulation|Daily exposure to musical composition found to have antiseizure properties
219047361|NCT02870907|DRUG|Vincristine|1, 5 mg/m²/d, IV at D1.
219047362|NCT02870907|RADIATION|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
219047363|NCT02870907|DRUG|Carboplatin|160 mg/m²/d, IV from D1 to D5.
219047364|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d, IV at D22 and D26
219548445|NCT02224586|DEVICE|light treatment|clinical routine treatment according to the doctor's advice
219047365|NCT02870907|DRUG|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
219047366|NCT02870907|DRUG|Carboplatin|560 mg/m²/d, IV at D1.
219047367|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV from D1 to D5
219047368|NCT02870907|DRUG|Carboplatin|160 mg/m²/d,IV from D1 to D5
219047369|NCT02870907|DRUG|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
219047370|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d), IV at D22
219548446|NCT04820829|OTHER|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
219548447|NCT04820829|OTHER|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
219548448|NCT04820829|OTHER|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
219548449|NCT00704639|DRUG|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
219548450|NCT00704639|DRUG|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
219047371|NCT02870907|DRUG|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
219206250|NCT03215706|DRUG|Paclitaxel|Specified dose on specified day
219548451|NCT00704639|RADIATION|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
219548452|NCT02438735|PROCEDURE|laparoscopic endometrioma excision|
219548453|NCT02438735|OTHER|Conservative follow up|
219548454|NCT04823832|PROCEDURE|pancreaticoduodenectomy|resection of the head of pancreas and the duodenum followed by triple anastomosis
219548455|NCT00414180|DRUG|Bupropion SR|
219548456|NCT03857828|OTHER|semen sample|• seminal sample for measuring clusterin level.
219548457|NCT05941390|DEVICE|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
219548458|NCT05941390|DEVICE|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
219548459|NCT03746795|DEVICE|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
219548460|NCT03746795|DEVICE|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
219548461|NCT00860938|DRUG|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
219548462|NCT04023981|DEVICE|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
219548463|NCT02992964|DRUG|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
219548464|NCT01600963|DRUG|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
219548465|NCT01600963|DRUG|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
219548466|NCT01600963|DRUG|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
219548467|NCT01600963|DRUG|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
219548468|NCT00412464|DRUG|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
219548469|NCT02469363|DEVICE|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
219548470|NCT02469363|DEVICE|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
219548471|NCT02469363|DEVICE|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
219548472|NCT02469363|DEVICE|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
219548473|NCT01296607|DRUG|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
219548474|NCT01296607|DRUG|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
219623167|NCT00998504|DIETARY_SUPPLEMENT|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
219623168|NCT00998504|DIETARY_SUPPLEMENT|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
219623169|NCT01078935|DIETARY_SUPPLEMENT|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
219047372|NCT02870907|PROCEDURE|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
219623170|NCT01078935|DIETARY_SUPPLEMENT|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
219623171|NCT05627245|DRUG|Belinostat|Given IV
219047373|NCT02870907|DRUG|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
219047374|NCT02870907|DRUG|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
219047375|NCT02870907|DRUG|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
219047376|NCT02870907|PROCEDURE|Peripheral bood stem cell transplantation|at D0
219047377|NCT04229134|BEHAVIORAL|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
219047378|NCT05668923|BEHAVIORAL|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
219047379|NCT06128265|BEHAVIORAL|Sleep Extension|Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
218936210|NCT05545540|OTHER|Placebo Musical Neurostimuloation|Daily exposure to musical composition found NOT to have antiseizure properties
218936211|NCT03072108|DIETARY_SUPPLEMENT|Bonolive|2 caps per day of Bonolive
218936212|NCT03072108|DIETARY_SUPPLEMENT|Placebo|2 caps per day of Placebo
218936213|NCT05844488|DEVICE|PrecivityAD|Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
218936214|NCT00243269|BEHAVIORAL|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
218936215|NCT00004802|DRUG|dichlorphenamide|
219047380|NCT06128265|BEHAVIORAL|Sleep Regularity|Consistent bedtimes (within 30min)
219047381|NCT02143414|PROCEDURE|Biopsy Procedure|Undergo a biopsy
219623172|NCT05627245|PROCEDURE|Biopsy Procedure|Undergo biopsy
218936216|NCT02437708|PROCEDURE|REP with L-PRF|
218936217|NCT02437708|PROCEDURE|REP|
218936218|NCT02437708|BIOLOGICAL|stem and progenitor cells|
218936219|NCT01897818|DEVICE|communication system P300 Speller|
218936220|NCT04909073|DRUG|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
218936221|NCT03664596|DIETARY_SUPPLEMENT|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
218936222|NCT03664596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
218936223|NCT01474252|DRUG|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
218936224|NCT05344404|DIETARY_SUPPLEMENT|Nicotinamide Riboside|3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
218936225|NCT05344404|DIETARY_SUPPLEMENT|Placebo|Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
218936226|NCT01936441|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
218936227|NCT01936441|BEHAVIORAL|Menopause Education Control (MEC)|See Experimental Arm Description
218936228|NCT05062499|DEVICE|Active TENS|electrical stimulation
219047382|NCT02143414|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
219047383|NCT02143414|BIOLOGICAL|Blinatumomab|Given IV
219047384|NCT02143414|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
219047385|NCT02143414|PROCEDURE|Computed Tomography|Undergo a CT scan
219047386|NCT02143414|DRUG|Dasatinib|Given PO
219047387|NCT02143414|PROCEDURE|Echocardiography Test|Undergo ECHO
219047388|NCT02143414|PROCEDURE|Lumbar Puncture|Undergo a lumbar puncture
219047389|NCT02143414|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219047390|NCT02143414|DRUG|Mercaptopurine|Given PO
219047391|NCT02143414|DRUG|Methotrexate|Given PO
219047392|NCT02143414|DRUG|Methotrexate Sodium|Given PO
219047393|NCT02143414|DRUG|Prednisone|Given PO
219047394|NCT02143414|DRUG|Vincristine|Given IV
219047395|NCT02143414|DRUG|Vincristine Sulfate|Given IV
219047396|NCT02143414|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219047397|NCT06342713|DRUG|BGB-45035|Administered orally
219047398|NCT06342713|DRUG|Placebo|Administered orally
219047399|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
219623173|NCT05627245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219548475|NCT01730846|DRUG|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
219623174|NCT05627245|PROCEDURE|Computed Tomography|Undergo CT scan
219623175|NCT05627245|OTHER|Pharmacokinetic Study|Pharmacokinetic study
219623176|NCT05627245|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
219623177|NCT05627245|DRUG|Tazemetostat|Given PO
219548476|NCT01730846|DRUG|Placebo|Placebo
219623178|NCT01038986|BIOLOGICAL|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
219623179|NCT02348736|DEVICE|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
219623180|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
219548477|NCT01730846|DRUG|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
219548478|NCT03587545|OTHER|Probiotic nasal spray|Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
219548479|NCT03587545|OTHER|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
219623181|NCT03761108|DRUG|Linvoseltamab|Administered per the protocol
219623182|NCT05785910|DIAGNOSTIC_TEST|IUDS|a battery of neuropsychological test
219623183|NCT05961033|DEVICE|Virtual Reality based exercises|Play VR games
219623184|NCT03266861|DIAGNOSTIC_TEST|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
219623185|NCT03800199|OTHER|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
219623186|NCT03984448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623187|NCT03984448|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218936229|NCT05062499|DEVICE|Sham TENS|no stimulation
218936230|NCT03128125|OTHER|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
218936231|NCT03128125|OTHER|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
218936232|NCT03128125|OTHER|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
218936233|NCT03052400|DRUG|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
218936234|NCT03052400|DRUG|Placebo|Matching placebo
218936235|NCT00555061|DRUG|Retapamulin Ointment, 1%|1% Ointment
218936236|NCT01873534|DRUG|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
218936237|NCT03929380|OTHER|Squat protocol|60% of 1RM weight for 100 squat reps
218936238|NCT02309905|DEVICE|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
218936239|NCT03548181|BEHAVIORAL|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
218936240|NCT00951613|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
218936241|NCT02527603|PROCEDURE|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
218936242|NCT02527603|PROCEDURE|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
219548480|NCT01812993|DEVICE|Non-invasive ventilatory treatment with auto-BPAP|
219548481|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
219548482|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
219548483|NCT01018862|DRUG|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
219548484|NCT01968031|DRUG|Istradefylline 40 mg|Istradefylline 40 mg and placebo
219548485|NCT01968031|DRUG|Istradefylline 20 mg|Istradefylline 20 mg and placebo
219548486|NCT01968031|DRUG|Placebo|Placebo
219623188|NCT03984448|PROCEDURE|Computed Tomography|Undergo CT scan
219623189|NCT03984448|DRUG|Cyclophosphamide|Given IV
219623190|NCT03984448|DRUG|Doxorubicin Hydrochloride|Given IV
219623191|NCT03984448|DRUG|Etoposide|Given IV
219623192|NCT03984448|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219623193|NCT03984448|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219623194|NCT03984448|DRUG|Prednisone|Given PO
219623195|NCT03984448|BIOLOGICAL|Rituximab|Given IV
219623196|NCT03984448|DRUG|Venetoclax|Given PO
219623197|NCT03984448|DRUG|Vincristine Sulfate|Given IV
219548487|NCT06626971|DRUG|ARA290|4 mg subcutaneous injections of ARA290 over an 84 day period
219548488|NCT02119988|PROCEDURE|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
219548489|NCT02119988|PROCEDURE|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
219548490|NCT04440150|PROCEDURE|Appendectomy|Open or Laparascopic Surgery
219548491|NCT07025330|DRUG|Efgartigimod|efgartigimod 1000 mg subcutaneous injection given once weekly
219548492|NCT00840879|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
219548493|NCT00840879|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
219548494|NCT07024199|OTHER|The initial pain assessment|The initial pain assessment will be carried out according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
219623198|NCT00152061|DRUG|3TC and FTC|
219623199|NCT02284074|OTHER|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
219623200|NCT02284074|OTHER|Experimental: Nasal LPS spray 1µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
219623201|NCT02284074|OTHER|Experimental: Nasal LPS spray 10 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
219623202|NCT02284074|OTHER|Experimental: Nasal LPS spray 30 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
218936243|NCT02527603|DRUG|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
218936244|NCT03291964|DIAGNOSTIC_TEST|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
219623203|NCT02284074|OTHER|Experimental: Nasal LPS spray 100 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
218936245|NCT05145218|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
219623204|NCT01817868|OTHER|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
219623205|NCT01220843|DRUG|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
219623206|NCT01220843|DRUG|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
219623207|NCT04225715|DRUG|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
219623208|NCT04225715|DRUG|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
219623209|NCT04225715|DRUG|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
219623210|NCT04225715|DRUG|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
218936246|NCT05145218|DRUG|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
218936247|NCT05145218|DRUG|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
218936248|NCT05776095|PROCEDURE|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
219548495|NCT07024199|DRUG|Drug administration according to protocol (paracetamol + ibuprofen OR paracetamol + metamizol)|"Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi intravenously 10 mg/kg body weight (maximum 400 mg/dose).~Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin intravenously 15 mg/kg body weight (maximum 100 mg/dose)."
219548496|NCT07024199|OTHER|The effectiveness of the treatment|The effectiveness of the treatment will be assessed 60 minutes after the start of the intervention according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
219623211|NCT04225715|DRUG|PEG-IFN|PEG-IFN will be administered subcutaneously
219623212|NCT04225715|DRUG|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
219623213|NCT03152773|PROCEDURE|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
219623214|NCT02936297|DIETARY_SUPPLEMENT|High dose Gluten|
219623215|NCT02936297|DIETARY_SUPPLEMENT|Low dose Gluten|
219623216|NCT02936297|DIETARY_SUPPLEMENT|Lactose free placebo|
219623217|NCT05662072|BEHAVIORAL|Motor imagery|Mental imagery of respiratory exercises
219623218|NCT05662072|BEHAVIORAL|Action observation|Action observation of respiratory exercises
219623219|NCT05662072|OTHER|Placebo Intervention|Placebo observation
219548497|NCT05800899|BEHAVIORAL|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
219047400|NCT04295538|DRUG|Elezanumab|Solution for infusion; Intravenous (IV)
219047401|NCT04295538|DRUG|Placebo|Solution for infusion; Intravenous (IV)
219047402|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
219047403|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
219047404|NCT05679791|DEVICE|Dynamometer|to assses hand grip
219047405|NCT04605757|OTHER|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
219047406|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
219047407|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
219047408|NCT02293785|DRUG|Oxycodone-Naloxone|
219047409|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
219047410|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
219047411|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
219047412|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
219047413|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
219047414|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
219047415|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
219047416|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
219047417|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
219047418|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
219047419|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
219047420|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
219047421|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
219047422|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
219047423|NCT01728155|DRUG|chemotherapy|
219047424|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
219047425|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
219047426|NCT01014494|DEVICE|Adaprev|Class III Medical Device
219047427|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
219047428|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
219047429|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
219047430|NCT00178958|DEVICE|Holter Monitor|
219047431|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
219206251|NCT03215706|DRUG|Pemetrexed|Specified dose on specified day
219206252|NCT03215706|DRUG|Cisplatin|Specified dose on specified day
219206253|NCT06759116|PROCEDURE|Control group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)
219548498|NCT05800899|BEHAVIORAL|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
219548499|NCT06705192|DRUG|VES001|"VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg."
219623220|NCT05131841|DRUG|Cipterbin Combined With Vinorelbine|"1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
219548500|NCT07138495|DEVICE|AI-personalized virtual reality rehabilitation system for unsupervised home-based stroke therapy|The personalized RGS app rehabilitation is a home-based, virtual reality therapy platform for motor and cognitive stroke recovery. Therapy tasks are gamified, task-specific, and adapt in difficulty based on real-time performance. An AI-driven clinical decision support system personalizes and updates exercise prescriptions after each session, with optional clinician adjustments. Integrated wearable sensors (RGSwear) track real-world activity and adherence. Data are securely uploaded to a cloud-based platform for remote monitoring. This is the first multicenter, international RCT to test AI-personalized VR rehabilitation at home with up to 12-month follow-up, combined with cost-effectiveness and usability evaluation.
219548501|NCT07129837|DIAGNOSTIC_TEST|Clinical evaluation, disease activity and disability scoring, and laboratory testing including RF, anti-CCP, and serum anti-PCOLCE antibody measurement by ELISA.|"For rheumatoid arthritis (RA) patients: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, assessment of disease activity using DAS-28 score, functional disability evaluation by modified Health Assessment Questionnaire (mHAQ), and laboratory investigations including CBC, ESR, CRP, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibodies measured by ELISA.~For healthy controls: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, and laboratory testing limited to serum anti-PCOLCE antibodies measured by ELISA."
219548502|NCT03864380|DIAGNOSTIC_TEST|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
219548503|NCT03864380|DIAGNOSTIC_TEST|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
219548504|NCT03864380|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
219623221|NCT00887575|DRUG|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
219623222|NCT00887575|DRUG|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
219623223|NCT00887575|DRUG|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
219623224|NCT05014659|DIETARY_SUPPLEMENT|Creatine monohydrate|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
219623225|NCT05014659|DIETARY_SUPPLEMENT|Placebo|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
219623226|NCT04934813|OTHER|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
219641884|NCT03933579|DIAGNOSTIC_TEST|Deep phenotyping|Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
219641885|NCT02041143|DIETARY_SUPPLEMENT|Milk protein|Study product will provide 25 g of protein to subjects.
219641886|NCT02041143|DIETARY_SUPPLEMENT|Placebo|Product with no protein
219548505|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
219548506|NCT01263353|DRUG|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
219641887|NCT06206551|OTHER|Spiritual Needs Questionnaire|This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
219548507|NCT01263353|DRUG|Everolimus followed by Pasireotide LAR + Everolimus|
219548508|NCT07054554|OTHER|NTRI-MH|NTRI-MH intervention will use evidence-based instructional strategies for adult professional development (i.e., lecture, discussion, case studies, role-playing). NTRI-MH training includes 20 hours of didactic and interactive sessions (5 sessions of 4 hours each) covering the following areas specific to MH needs in young children at-risk: 1) benefits and barriers (professional and family) to early intervention for children with MH concerns, 2) approaches for empowering caregivers, 3) supporting strategies to assist families through early MH access and service engagement , 4) use of the dashboard to track and monitor the course of clinical, functional, and behavioral outcomes, 5) evidence-based working alliances with PCPs and teachers (including a 2 hour session with the child's teacher), and 6) MH resources, treatments and services, and strategies to support parental management of young child behaviors.
219548509|NCT07059403|BIOLOGICAL|SN2001|100 µg, for subcutaneous (SC) injection
219548510|NCT07059403|BIOLOGICAL|SN2001|200 µg, for subcutaneous (SC) injection
219548511|NCT07059403|BIOLOGICAL|SN2001|300 µg, for subcutaneous (SC) injection
218936249|NCT05776095|DEVICE|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
218936250|NCT00485134|BIOLOGICAL|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
219548512|NCT07058662|GENETIC|Single dose intravenous of BBM-D101|BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.The administration is completed by a single intravenous infusion.
219548513|NCT06764680|DRUG|Trifluorouracil tepidopyrimidine|30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w
219548514|NCT06764680|DRUG|Bevacizumab|5mg/kg. ivgtt. d1 and d15. q4w
219548515|NCT06764680|DRUG|Sindilizumab|200mg. ivgtt. d1. q4w
219548516|NCT06764680|RADIATION|IMRT|In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.
219641888|NCT00177840|PROCEDURE|acupuncture|
219641889|NCT05550909|DRUG|Artesunate-amodiaquine combination|Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
219548517|NCT04236596|DEVICE|Participants received a Neurostimulator, which was used to map the pudendal nerve|Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
219623227|NCT05251337|DRUG|Essential oils|Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.
219623228|NCT05251337|DRUG|Placebo|Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
219623229|NCT01715532|DRUG|Huachansu|
219548518|NCT07064538|DIETARY_SUPPLEMENT|Neuralli® MP|Neuralli® MP containing 60 billion CFU (administered as two capsules per day)
219623230|NCT01715532|OTHER|TACE|
219623231|NCT02011685|BEHAVIORAL|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
219623232|NCT02011685|BEHAVIORAL|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
219623233|NCT06509737|BEHAVIORAL|Face to face group|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase by providing Life with Food Allergy Training based on the Health Promotion Model with face-to-face training in parents of children diagnosed with food allergy.
219623234|NCT06509737|BEHAVIORAL|social mediagroup|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase in parents of children diagnosed with food allergy by providing Life with Food Allergy Education based on the Health Promotion Model through social media.
219623235|NCT03684707|DRUG|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
219623236|NCT03684707|OTHER|starch tablet|starch tablets
219623237|NCT01044407|DEVICE|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
219623238|NCT06362083|OTHER|Questionnaires and data collection|It is a non-interventional, single-center, non-randomized, prospective observational study obtaining data and patient-reported outcomes.
219623239|NCT03318861|GENETIC|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
218936251|NCT00485134|BIOLOGICAL|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
218936252|NCT00485134|BIOLOGICAL|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
218936253|NCT00485134|OTHER|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
219206254|NCT06759116|PROCEDURE|Fentanyl group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)
219548519|NCT07064161|DRUG|Mupirocin (drug)|Wounds were dressed with gauze impregnated with mupirocin ointment covered by a transparent dressing (Tegaderm)
218936254|NCT00002213|DRUG|Abacavir sulfate|
218936255|NCT00002213|DRUG|Amprenavir|
218936256|NCT00002213|DRUG|Efavirenz|
219548520|NCT07064161|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|Wounds were dressed with a 1-inch size Duoderm Control Gel Formula hydrocolloid dressing
219548521|NCT07065357|DRUG|Empagliflozin (oral)|Participants received Empagliflozin 10 mg orally once daily for six months.
219548522|NCT07065357|OTHER|Matching placebo|Participants received matching placebo orally once daily for six months.
219548523|NCT07075146|DRUG|DOR/3TC/TDF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100/300/300 mg
219548524|NCT07075146|DRUG|BIC/FTC/TAF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
219623240|NCT03318861|DRUG|Cyclophosphamide|Administered intravenously
219623241|NCT03318861|DRUG|Fludarabine|Administered intravenously
219623242|NCT02741661|OTHER|No intervention. Observational study|No intervention
219623243|NCT00917852|DEVICE|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
219623244|NCT02623933|RADIATION|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
219623245|NCT02932488|DRUG|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
219623246|NCT02059655|DRUG|Bimatoprost|
219623247|NCT02059655|DRUG|Eye drop solution|Artificial tear drops
219623248|NCT03285516|BEHAVIORAL|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
219548525|NCT04428281|DRUG|RO7248824|In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
219623249|NCT00471081|BIOLOGICAL|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
219623250|NCT04386655|BEHAVIORAL|Brain Injur Coping Skills - Telemedicine|"BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals"
219623251|NCT05776784|PROCEDURE|dental procedure|questionnaire for patient with dental procedure
219623252|NCT01265108|DRUG|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
219623253|NCT01265108|DRUG|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
219623254|NCT01131364|DRUG|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
219623255|NCT03768908|DRUG|Artemether-lumefantrine|Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
219623256|NCT03768908|DRUG|Artesunate + Amodiaquine|Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
219623257|NCT04145050|OTHER|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
219623258|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
219623259|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
219623260|NCT00277238|DRUG|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
219623261|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
219623262|NCT00123838|DEVICE|Calypso® 4D Localization System|Localization of prostate irradiation.
219623263|NCT02844933|DRUG|Cannabidiol|Oral solution
219623264|NCT02844933|DRUG|Placebo|Matching oral solution
219623265|NCT06134284|DRUG|Orelabrutinib combined with rituximab|This is a single-arm trial. Patients with relapsed/refractory marginal zone lymphoma will be treated with the OR regimen. The treatment plan is as follows: Orelabrutinib 150mg oral administration once a day, Day 1-21; Rituximab 375mg/m² intravenous infusion, Day 1. Each cycle is 21 days. PET-CT evaluation will be conducted after 4 cycles. If a partial response (PR) or better is achieved, the patient will receive further treatment with the OR regimen for an additional 4 cycles before transitioning to single-agent maintenance therapy with either rituximab or obinutuzumab. If a PR or better is not achieved after 4 cycles, the patient will discontinue from the trial.
219623266|NCT04503148|DRUG|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
219623267|NCT04503148|DRUG|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
218936257|NCT00473304|DEVICE|Johnson&Johnson Acuevue daily disposable lenses|
218936258|NCT01780064|BEHAVIORAL|interviews with a psychologist|interviews with a psychologist
219623268|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|subcutaneous depot medroxyprogesterone acetate
218936259|NCT01780064|BEHAVIORAL|Questionnaires|Questionnaires
219623269|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|intramuscular depot medroxyprogesterone acetate
219623270|NCT00094731|PROCEDURE|Memory Training|
219623271|NCT02865967|OTHER|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
219623272|NCT02865967|OTHER|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
219623273|NCT06142604|DRUG|Flecainide|Single 300mg dose of oral flecainide
219623274|NCT03638804|DIAGNOSTIC_TEST|89Zr-KN035|Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
219641890|NCT05550909|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
219641891|NCT05550909|DRUG|Artemether-lumefantrine|Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
219047432|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
219623275|NCT06348069|BEHAVIORAL|Pharmacy-based PrEP refill and gift voucher|The intervention arm of this study introduces the opportunity for a pharmacy-based PrEP refill system for sex workers, coupled with financial incentives to increase adherence. Participants receive PrEP medications from selected pharmacies, a strategy designed to improve PrEP access and enhance privacy/discretion. Additionally, participants in the intervention are awarded escalating gift card values for each successful refill collection at study pharmacies, aiming to incentivize continued PrEP use for effective HIV prevention. The intervention seeks to enhance convenience and motivate adherence through financial rewards.
219623276|NCT06348069|BEHAVIORAL|Control (Standard of care)|For sex workers in the control group, PrEP refill pick-up will be available through CESHHAR's existing network of clinical sites. There is no gift card incentive and no pick-up at private pharmacies.
219623277|NCT03922308|OTHER|Placebo|Participants will receive injection of placebo matched to SHP655.
219623278|NCT03922308|DRUG|SHP655|Participants will receive injection of SHP655.
219623279|NCT03922308|OTHER|Standard of Care|Participants will receive PEX as Standard of Care (SOC).
219623280|NCT06354036|PROCEDURE|the Transhiatal Tunnel Valvuloplasty technique|The ThTV esophagogastrostomy procedure involved placing a lengthy gastric tube into the lower mediastinum, firmly bound to the esophagus.
219623281|NCT02809729|DRUG|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
219623282|NCT02809729|DRUG|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
219623283|NCT02809729|PROCEDURE|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
219623284|NCT02809729|OTHER|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
219623285|NCT03779230|DRUG|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
219623286|NCT03340597|DRUG|F901318|F901318 tablet
219623287|NCT01659983|PROCEDURE|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
219623288|NCT01256450|DRUG|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
219623289|NCT01256450|DRUG|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
219623290|NCT06468085|PROCEDURE|premixed Bioceramic NeoPUTTY®|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
219623291|NCT06468085|PROCEDURE|Biodentine™|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic or Biodentine™ according to the corresponding group then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
219623292|NCT06468085|PROCEDURE|Root canal treatment|Root canal treatment will be performed to the control group followed by composite restoration. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
219623293|NCT04915313|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
219623294|NCT04915313|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
219623295|NCT06255119|DEVICE|3D Therapy Thrive|A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
219623296|NCT03426618|OTHER|Non-interventional|Non-interventional
219623297|NCT03376789|DRUG|MYL-1501D product using manufacture process V|MYL-1501D product using manufacture process V
219623298|NCT03376789|DRUG|MYL-1501D product using manufacture process VI|MYL-1501D product using manufacture process VI
219623299|NCT04787913|BEHAVIORAL|herdimm|In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
219047433|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
219047434|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
219623300|NCT04787913|BEHAVIORAL|guardianmeasles|A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
219623301|NCT04787913|BEHAVIORAL|theotheredmundmeasles|A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
219623302|NCT04787913|BEHAVIORAL|sbsnewsgeneric|A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
219623303|NCT04787913|BEHAVIORAL|publichealthagencycanadaflu|A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
219623304|NCT04787913|BEHAVIORAL|robertkochgeneric|A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
219623305|NCT01118741|DRUG|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
219623306|NCT05214690|DRUG|DW1809-T2|pelubiprofen 25mg
219623307|NCT05214690|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
218936260|NCT03620864|OTHER|Motor Control Exercises|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
218936261|NCT03620864|OTHER|Motor Control Exercise Plus Neurodynamic Intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
218936262|NCT00970684|BIOLOGICAL|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
218936263|NCT00970684|DRUG|docetaxel|75 mg/m2 on day 1
218936264|NCT00970684|DRUG|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
218936265|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
218936266|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
218936267|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
218936268|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
219206255|NCT06759116|PROCEDURE|Dexmedetomidine group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )
219623308|NCT00965211|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
219047435|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
219623309|NCT03732937|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography with biometry and TCD measurement
219623310|NCT03889418|BEHAVIORAL|Electronic medical recorded clinical decision support [EMR CDS]|The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD \>=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD \>=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
219047436|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
219047437|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
219047438|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
219047439|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
219047440|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
219047441|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
219641892|NCT05550909|DRUG|Amodiaquine|Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
219641893|NCT00593710|DRUG|Losartan|Losartan (25mg OD)
219641894|NCT00593710|DRUG|Atenolol|Atenolol (25-50mg OD)
218936269|NCT01146327|DRUG|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
218936270|NCT05432089|DRUG|Intranasal Oxytocin|24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
219047442|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
218936271|NCT03257319|DRUG|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
218936272|NCT03257319|DRUG|IV placebo|Patient in arm A will receive 1 to 6 injection
218936273|NCT03257319|DEVICE|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
219047443|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
219047444|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
218936274|NCT03257319|DRUG|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
219641895|NCT04842617|DRUG|SHR6390|SHR6390 combined with endocrine therapy
218936275|NCT03777748|DEVICE|dental implants and stud attachments|
218936276|NCT01123551|DRUG|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
218936277|NCT01123551|DRUG|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
218936278|NCT03030976|DRUG|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
218936279|NCT03030976|DRUG|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6\~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
218936280|NCT05631483|DEVICE|DAISe|Use of the DAISe Thrombectomy Device
218936281|NCT03574012|DEVICE|Monitoring Device|Use Fitbit tracker
218936282|NCT03574012|OTHER|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
218936283|NCT03574012|OTHER|Informational Intervention|Receive general health and fitness information from clinician
219047445|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
219047446|NCT05757570|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
219047447|NCT06271655|DEVICE|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
219047448|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
219047449|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
219047450|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
219047451|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
219047452|NCT05035745|DRUG|Talazoparib|Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
219047453|NCT05035745|DRUG|Selinexor|Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
219047454|NCT03587935|OTHER|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
219047455|NCT03587935|OTHER|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
218936284|NCT03574012|OTHER|Questionnaire Administration|Ancillary studies
218936285|NCT02888678|BEHAVIORAL|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
218936286|NCT02888678|BEHAVIORAL|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
218936287|NCT00481091|DRUG|ABT-263|Tablet; Oral
218936288|NCT00006119|DRUG|hydroxyurea|
218936289|NCT04294680|DEVICE|Cryotherapy|see opiate sparing description
219047456|NCT04270825|BEHAVIORAL|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
219047457|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
219641896|NCT04842617|DRUG|placebo|placebo combined with endocrine therapy
219641897|NCT04611867|OTHER|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
219206256|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
219206257|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
219548526|NCT05291819|OTHER|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
219047458|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
219047459|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
219548527|NCT05291819|OTHER|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
219548528|NCT07097493|DRUG|Liposomal Bupivacaine|10 ml of 0.25% bupivacaine expanded with 133 mg (10 ml volume) of liposomal bupivacaine into both the adductor canal and iPACK blocks (total of 40 ml)
219623311|NCT03889418|BEHAVIORAL|Stepped opioid collaborative care model [CCM]|The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
219623312|NCT00350090|DRUG|Epoetin Alfa|
219623313|NCT00210418|DIETARY_SUPPLEMENT|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
219623314|NCT00210418|BEHAVIORAL|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
219623315|NCT04459325|BIOLOGICAL|Tigerase® and best available care|Nebulised dornase alfa \[2.5 mg BID\] for 7 days
219623316|NCT04459325|OTHER|Best available care|Patients will receive the usual care in accordance with good practice.
218936290|NCT03975244|BEHAVIORAL|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
219047460|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
219623317|NCT05984901|DEVICE|The continuous ambulatory vestibular assessment (CAVA) system|"The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).~The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.~The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS."
219548529|NCT07097493|DRUG|Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination|20 ml of solution consisting of 0.25% bupivacaine, 1.667mcg/ml of clonidine, 1:400,000 epinephrine, 0.15 mg total of buprenorphine, and 2 mg total of preservative free dexamethasone which will be used in both the adductor canal block and iPACK block (total of 40 ml)
219623318|NCT06187012|OTHER|Hypertensive pregnancy|Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
219623320|NCT04889443|PROCEDURE|Surgical cartilage repair procedure requiring harvest procedure or Autologous Stromal Cell Implantation|Any surgical cartilage repair procedure of the knee that requires a harvest biopsy of knee cartilage, which will leave a controlled small cartilage injury
219623321|NCT04418167|DRUG|JSI-1187|JSI-1187 capsules for oral administration
219623322|NCT04418167|DRUG|Dabrafenib|Dabrafenib capsules for oral administration
219548530|NCT05543720|DEVICE|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
219623323|NCT06818669|BEHAVIORAL|CVD-FIT|The structured incentive will include monthly supplemental income plus weekly reimbursement for the purchase of healthy food options. Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
219623324|NCT06818669|BEHAVIORAL|Enhanced Usual Care|Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
219623325|NCT06965114|PROCEDURE|Biospecimen Collection|Undergo blood sample and buccal swab collection
219623326|NCT06965114|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219623327|NCT06965114|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219623328|NCT06965114|DRUG|Cladribine|Given IV
219623329|NCT06965114|PROCEDURE|Computed Tomography|Undergo CT
219623330|NCT06965114|BIOLOGICAL|Rituximab|Given IV
219623331|NCT06965114|DRUG|Tovorafenib|Given PO
219623332|NCT00328497|DRUG|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
219623333|NCT06643299|DRUG|Probiotic Agent|BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
219047461|NCT06126757|DEVICE|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
219047462|NCT06126757|OTHER|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
219047463|NCT04180215|DRUG|HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
219548531|NCT02957331|DRUG|Propranolol|
219548532|NCT07127861|OTHER|Treadmill gait training|Participants will undergo a 15-minute treadmill gait training session using a safety harness and under the continuous supervision of a physiotherapist to ensure patient safety. The study will be carried out for 12 weeks with a frequency of two weekly sessions. During them, the participants will receive treadmill training. All participants will walk at a speed exceeding 2.5 km/h. The speed will be individually adjusted to provide a challenging yet appropriate intensity based on each participant's capabilities.
219548533|NCT07138976|OTHER|sampling tissue|EUS- and US- guided pancreatic biopsy
219623334|NCT06643299|OTHER|Placebo|Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
219641898|NCT06222060|OTHER|Questionnaire about Shaken Baby Syndrome|Knowledge assessment questionnaire completed in the maternity ward by both parents
219047464|NCT04180215|DRUG|HB-202 intravenous administration alternating with HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
219623335|NCT02172664|PROCEDURE|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
219623336|NCT02172664|PROCEDURE|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
219548534|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the knee then ankle|"Procedure/Surgery: Procedure/Surgery: Kinesio Taping (KT) applied to the knee or ankle Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
219623337|NCT02172664|DEVICE|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
219623338|NCT03608631|DRUG|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
219623339|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
219623340|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
219623341|NCT06105632|DRUG|Everolimus|Active Comparator
219623342|NCT06105632|DRUG|Exemestane|Active Comparator
219623343|NCT06169124|PROCEDURE|Biospecimen Collection|Undergo archived tissue and blood sample collection
219623344|NCT06169124|PROCEDURE|Chest Radiography|Undergo chest x-ray
219623345|NCT06169124|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219623346|NCT06169124|DRUG|Darolutamide|Given PO
219623347|NCT06169124|DRUG|Exemestane|Given PO
219623348|NCT06169124|DRUG|Leuprolide Acetate|Given IM
219623349|NCT06169124|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623350|NCT06169124|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219047465|NCT04180215|DRUG|HB-201 intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
219047466|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + pembrolizumab.|Dose Expansion
219047467|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
219047468|NCT04180215|DRUG|HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)|Dose escalation; 10 patients
219623351|NCT05840224|BIOLOGICAL|GS-4528|Administered intravenously
219623352|NCT05840224|DRUG|Zimberelimab|Administered intravenously.
219623353|NCT06175325|PROCEDURE|Trans-radial embolisation of haemorrhoids|"Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluoroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic."
219623354|NCT06703996|OTHER|Discussion|Participate in check-in/goal-setting discussions
219047469|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
219047470|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
219047471|NCT04447716|DRUG|Venetoclax|Given PO
219623355|NCT06703996|OTHER|Medical Device Usage and Evaluation|Wear the InBody Band 3 fitness tracker
219623356|NCT06703996|OTHER|Questionnaire Administration|Ancillary studies
219623357|NCT06596460|DIAGNOSTIC_TEST|TAVI planning CT (adapted)|TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
219623358|NCT06325085|OTHER|compensatory and restorative rehabilitation techniques|"compensatory and restorative rehabilitation techniques Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
219623359|NCT06325085|OTHER|Traditional cognitive rehabilitation training|"Naming words ( ask patient to name food, states, family members) Counting numbers backwards, backward counting of days and months) Spell the word backwards, remembering a piece of information Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
219623360|NCT02638142|DRUG|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
219623361|NCT02638142|DRUG|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
219623362|NCT06798948|DIETARY_SUPPLEMENT|Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra|Oral combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
219623363|NCT06798948|OTHER|Placebo maltodextrin|The patient takes two tablets of the placebo maltodextrin every day
219047472|NCT04447716|DRUG|Lenalidomide|Given PO
219047473|NCT04447716|BIOLOGICAL|Rituximab|Given IV
219047474|NCT04447716|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219047475|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
219047476|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
219047477|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
218936291|NCT05198440|DEVICE|non-invasive neuromodulation|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
219623364|NCT06948929|DIETARY_SUPPLEMENT|SCV09|SCV09 consists of a blend of four probiotic species from the Bifidobacterium and Lactobacillus genera (20 billion CFU in 1 sachet per day), prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides and inulin, vitamin B6, B9, B12 and vitamin D.
219623365|NCT05849493|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
219047478|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
219047479|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
219548535|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the ankle then knee|"Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
219548536|NCT07138560|DRUG|CREXONT ER|exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods
219623366|NCT05849493|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
219623367|NCT06333171|DRUG|4-Aminopyridine|Active study drug
219623368|NCT06333171|OTHER|Placebo|Placebo comparator
219623369|NCT05816785|DRUG|Cetuximab|Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
219623370|NCT05816785|DRUG|Imatinib|400 mg orally daily
219623371|NCT06974773|DEVICE|NettleEndo|The NettleEndo device is a portable, home-use transcranial direct current stimulation (tDCS) system designed to deliver low-intensity electrical stimulation to targeted brain regions. The device delivers a constant current of 2 mA in the active stimulation group, targeting the left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC) through pre-set electrode positioning.
219623372|NCT06974773|DEVICE|Sham NettleEndo Device|The sham version of the NettleEndo device is visually identical to the active device and is used under the same schedule. The device is pre-programmed to deliver a brief 2 mA current for 20 seconds at the beginning of each session to mimic the initial skin sensations of active stimulation, after which no current is delivered for the remainder of the session. This allows participants to remain blinded to their group assignment. The device is used with the same electrode positioning as the active version.
219623373|NCT06838767|OTHER|Conventional treatment|"10 min moist heat pack Self-assisted anterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self-assisted posterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self -assisted inferior capsule stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Codman's pendular exercises 10 reps Muscle strengthening exercises (after 4 weeks)~* Internal rotators and External rotators isometrics Hold for 5-8 seconds and repeat 10 times~* chair press According to FIIT protocol 10 reps progressing to 20 and 30 repetitions in 5th and 6th week with two session in a day, three days per week for six consecutive weeks"
219623374|NCT06838767|OTHER|Kinetic chain approach|Kinetic chain approach Shoulder flexion with ipsilateral anterior step-up, Shoulder-dump exercise Starting position with Body weight is on the contralateral-side leg with trunk flexion and rotation. Finishing position. With Body weight is on the ipsilateral-side leg with thoracic extension. Modified shoulder-dump Exercise Sternal-lift starting position with head and trunk flexed forward. Finishing position with emphasizing thoracic extension. Tubing fencing exercise starting position with body weight on the ipsilateral leg. Elbow is at the hip; thoracic extension and scapular retraction are encouraged, Athletic stance during ball-stabilization exercise. Axially loaded wall-slide exercise. Motion at the hips and trunk complements the sliding pattern of the hand.Perform each exercise for 3 Days (twice a day) a week for 6 weeks. 10 reps ,2 sets According to FITT protocol, 10 reps, two sessions per day, and three days per week for 6 consecutive weeks.
219623375|NCT06852248|PROCEDURE|Ureteric stenting|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will have conventional ureteric stenting (temporary tubes placed in the ureters)
219623376|NCT06852248|PROCEDURE|Indocyanine green (ICG) dye|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will receive indocyanine green (ICG) dye injected into the ureters to make them visible under a special light.
219623377|NCT06573294|DRUG|GEN1057|Intravenous (IV) infusion
219623378|NCT06573294|DRUG|Premedication|IV infusion/orally by mouth.
219548537|NCT07139535|DRUG|RAY1225|Administered SC
219548538|NCT07139535|DRUG|placebo|Administered SC
218936292|NCT05198440|DEVICE|electroencephalography|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
218936293|NCT05198440|DEVICE|anatomical MRI|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
219047480|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
218936294|NCT01453985|PROCEDURE|Full-Thickness-Gastroplication|
218936295|NCT01296672|DRUG|Finasteride|Finasteride 5mg every day by mouth for 3 months
218936296|NCT01296672|DRUG|Placebo|Placebo every day by mouth for 3 months
218936297|NCT02812251|DRUG|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
218936298|NCT02812251|DRUG|Placebo|Matching placebo will be administered.
218936299|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
218936300|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
218936301|NCT03383341|DIETARY_SUPPLEMENT|Cricket Protein Powder|Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
218936302|NCT03383341|OTHER|Placebo control|Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
218936303|NCT04027608|OTHER|Reinforcing value of HED and LED foods in response to snack food monotony|Each child will be asked to eat two different snack foods over the course of two weeks each. The RRV of that food (vs alternative reinforcer) will be tested and baseline and post exposure. Increases in RRv for food after monotony will be considered sensitization to that food. All children will be followed to observe weight change over time for 2 years each.
219047481|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
219047482|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
219548539|NCT07140458|OTHER|Buteyko Breathing|"Buteyko Breathing is a technique focusing on controlled, reduced breathing to improve oxygen uptake and reduce hyperventilation-related symptoms using Air hunger.~Procedure:-~After gaining proper relaxation:~1. Exhale slowly, and then hold that breath.~2. Use the index finger and thumb to plug the nose.~3. Hold that breath until there is an urge to breathe, and then inhale.~4. Breathe normally for at least 10 seconds.~5. Repeat several times."
219548540|NCT07140458|OTHER|Box breathing|"Box Breathing (4-4-4-4 Technique) - Box Breathing exercises boosts lung function by optimizing oxygen flow and activating relaxation responses.Each exercise Sessions included 20 cycles of Box Breathing.~The procedure of the box breathing cycle includes:~1. inhale for 4 seconds~2. Hold the breath for 4 seconds~3. Exhale for 4 seconds~4. Hold the breath for 4 seconds, and repeat."
219548541|NCT07139834|DRUG|SSRI (escitalopram or sertraline)|11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
219548542|NCT07139834|DRUG|Extended-Release Memantine|6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
219548543|NCT07139834|DRUG|Placebo|6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment
219548544|NCT07138963|DIAGNOSTIC_TEST|Genetic Testing and Muscle Biopsy|Comprehensive diagnostic assessment including clinical examination, electromyography (EMG), muscle biopsy for histopathological evaluation, and genetic testing to determine phenotype-genotype correlation in congenital myopathies and muscular dystrophies.
219548545|NCT07140263|BEHAVIORAL|CARE MI|"The intervention consists of four sessions, each lasting between 60 and 90 minutes, ideally delivered on consecutive weeks. It integrates psychoeducation on trauma and moral injury, emotional regulation strategies, and incorporates elements from several evidence-based approaches. These include the EMDR-IGTP-OTS group protocol, acceptance and values-based work from ACT, and self-compassion-focused interventions.~In the Waiting List arm, CARE-MI will be delivered after the initial assessment period of the Experimental arm."
219548546|NCT07140263|BEHAVIORAL|TAU: Treatment as usual|During the waiting period, Waiting list group will receive usual institutional support.
219206261|NCT00945724|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
219548547|NCT07139496|DEVICE|Spinal Cord Stimulator|"After the implantation of the spinal cord stimulator, the study will begin with 3 phases:~For the first phase, SCS over lumbrosacral spinal cord will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the second phase, SCS over lumbrosacral spinal cord will be stopped. SCS over the injury site will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the third phase, SCS over both lumbrosacral spinal cord and injury site of spinal cord will be activated for another 3 months with appropriate stimulation of lower limb muscles for walking~During all the phrases, physiotherapy of individual muscle groups for walking will be arranged. Exoskeleton training will also be arranged for 4 to 5 hours per week."
219548548|NCT07138872|PROCEDURE|Prone Position Percutaneous Nephrolithotomy|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the prone position. The procedure begins with ureteral catheter placement in lithotomy position, followed by prone positioning for renal access under C-arm fluoroscopic guidance. Stone fragmentation will be performed using pneumatic or ultrasonic lithotripters, and nephrostomy placement will be completed according to standard protocol.
219623379|NCT06574373|OTHER|Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention|Blood will be collected from patients with indolent IPMN, invasive IPMN, and IPMN associated with pancreatic cancer, depending on their clinical course. Patients with indolent IPMN will be monitored by the gastroenterology units of their respective institutions, which will inform the patient. Patients with invasive IPMN and/or associated with cancer will undergo surgical resection as part of their standard clinical care, and blood will be collected after informed consent is obtained by the surgical teams at each institution.
219623380|NCT06079359|DRUG|ALXN1850|Participants will receive a ALXN1850 via subcutaneous (SC) injection.
218936304|NCT06230237|BEHAVIORAL|Smiling is fun + professional support|"Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.~While they do the online program, they will receive periodically professional support. The professional support will be contacts of 20 minutes long, will take place every two weeks and will last 3 months."
218936305|NCT06230237|BEHAVIORAL|Smiling is fun|Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.
219206262|NCT06953622|DRUG|Conservative treatment|Receive no antipaletet drug treatment and surgery
219206263|NCT06953622|DRUG|Antipaletet drug|Use of antipaletet drugs.
219206264|NCT06953622|PROCEDURE|Patent Foramen Ovale Closure|Receive the surgery of Patent Foramen Ovale
219206265|NCT06952673|BEHAVIORAL|Multiple speed increments from 3km/h to 8km/h on a treadmill|Healthy participants will undergo a fixed experimental protocol of multi-stage treadmill speed walking/running wearing microsensors and a respiratory/metabolic testing mask.
219206266|NCT06114069|PROCEDURE|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
218936306|NCT03176537|DRUG|Testosterone gel|Androgel (50mg testosterone), gel, daily
218936307|NCT03176537|DRUG|Placebos|Placebo, gel, daily
218936308|NCT02950467|DRUG|Psilocybin|One individual oral psilocybin treatment session
219206267|NCT03109873|RADIATION|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
219206268|NCT03109873|DRUG|Metformin Hydrochloride|Given orally
219206269|NCT03109873|OTHER|Placebo|Given orally
219206270|NCT06294678|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
219206271|NCT00994643|BIOLOGICAL|Rituximab|Given IV
219206272|NCT00994643|BIOLOGICAL|Interleukin-2|Given SC
219206273|NCT05994508|OTHER|Pickleball program|The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
219548549|NCT07138872|PROCEDURE|Supine Position Percutaneous Nephrolithotomy (Galdakao-modified Valdivia)|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the Galdakao-modified Valdivia supine position. Following general anesthesia, the ipsilateral side will be elevated 20-30°, with the ipsilateral leg extended and the contralateral leg abducted. Ureteral catheter placement will be followed by renal access under C-arm fluoroscopy. Stone fragmentation and removal will be performed using the same standardized lithotripsy and irrigation protocols as in the prone group.
219623381|NCT06079359|DRUG|Placebo|Participants will receive placebo via SC injection.
219623382|NCT06616584|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623383|NCT06616584|BIOLOGICAL|Cemiplimab|Given IV
219623384|NCT06616584|PROCEDURE|Computed Tomography|Undergo CT
219623385|NCT06616584|DRUG|Dexamethasone|Given PO
219548550|NCT07139444|OTHER|One time Physical Therapy Evaluation|"A physical therapist will perform an evaluation which will consist of history taking and assessing the following: strength, endurance, range of motion, sitting/standing balance, sensory testing, and skin integrity. Following these assessments, the physical therapist will assess participant's functional mobility which involves assessing how you get out of bed, standing up, and walking. The physical therapist will also assess the participant on three tests which help determine your balance and assistance required with functional mobility. The tests that will be performed in no particular order are PASS, MSAS, AM-PAC 6-Clicks, OPS, MRS, and FCI. Data for the AM-PAC daily activity and applied cognition domains will be obtained from the patient's chart from the Occupational Therapy evaluation. Discharge destination information will be obtained from the PT evaluation and the discharge destinations will be acute/inpatient rehab, SAR, SNF, Home with or without home PT, and outpatient PT."
219548551|NCT07139340|OTHER|HA gel|Hyaluronic Acid gel 0.8% 1 mL
219548552|NCT07140406|OTHER|conventional rehabilitation training|The rehabilitation training is designed based on the specific functional conditions of the patient's limbs. The specific training methods include proper limb positioning, exercise therapy such as passive movement, anti-spasticity training, scapular girdle muscle training, joint extension training, forearm pronation and supination training, occupational therapy, joint movement training, roller treatment, and fine motor skill training, etc. The treatment is conducted once a day and five times a week. The treatment lasts for 4 consecutive weeks.
219623386|NCT06616584|DRUG|Docetaxel|Given IV
219623387|NCT06616584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623388|NCT06616584|BIOLOGICAL|Ramucirumab|Given IV
219623389|NCT06513091|DEVICE|OCS Lung|The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
219623390|NCT02593292|BEHAVIORAL|PROSPERO|"The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
219623391|NCT02593292|OTHER|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
219623392|NCT01841047|RADIATION|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
218936309|NCT02950467|BEHAVIORAL|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
218936310|NCT06208475|OTHER|Resistance exercise|Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
218936311|NCT02592057|DRUG|SOF|SOF tablets administered orally once daily based on approved prescribing information
218936312|NCT04651842|DEVICE|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
219206274|NCT01761968|DRUG|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
219206275|NCT06048978|OTHER|Commercial native starch without processing|A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
219623393|NCT06180122|DIAGNOSTIC_TEST|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
219623394|NCT00357981|DRUG|ORTHO EVRA, the contraceptive patch|
219623395|NCT01770769|DEVICE|Hemi - arthroplasty|modular hemiarthroplasty
219623396|NCT01770769|DEVICE|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
218936313|NCT02921178|OTHER|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
218936314|NCT03565328|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
218936315|NCT03897517|DIETARY_SUPPLEMENT|Proprietary Botanical Blend|Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
218936316|NCT03897517|DIETARY_SUPPLEMENT|Placebo|Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
219206276|NCT06048978|OTHER|Modified starch with extrusion processing|A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
219206277|NCT06046820|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
219623397|NCT03447925|DRUG|Medicinal Plant|Medicinal Plant Extract with vaseline cream
219623398|NCT03447925|DRUG|Salicylate|Salicylate 10% with vaseline cream
219623399|NCT03447925|DRUG|Vaseline|Vaseline cream
219623400|NCT00473317|BEHAVIORAL|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
218936317|NCT05494424|BEHAVIORAL|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
218936318|NCT05255809|OTHER|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
218936319|NCT05255809|OTHER|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
218936320|NCT00025480|DRUG|carboplatin|
218936321|NCT00025480|DRUG|paclitaxel|
218936322|NCT00025480|DRUG|tipifarnib|
218936323|NCT00025480|RADIATION|radiation therapy|
218936324|NCT02285608|OTHER|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
218936325|NCT05466617|BEHAVIORAL|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
218936326|NCT01490905|OTHER|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
218936327|NCT01490905|DRUG|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
218936328|NCT01490905|DRUG|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
218936329|NCT01338454|DRUG|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
218936330|NCT02560077|OTHER|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
218936331|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
218936332|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
218936333|NCT05156021|DRUG|anti-VEGF|To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
218936334|NCT04207541|BEHAVIORAL|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
218936335|NCT04119830|BIOLOGICAL|Pembrolizumab|Given IV
218936336|NCT04119830|OTHER|Questionnaire Administration|Ancillary studies
218936337|NCT04119830|DRUG|Rintatolimod|Given IV
218936338|NCT02682225|DRUG|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
218936339|NCT02682225|DRUG|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
218936340|NCT02682225|DRUG|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
218936341|NCT02682225|DRUG|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
218936342|NCT02682225|DRUG|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
218936343|NCT01396447|DRUG|Placebo|Placebo was supplied in capsules.
218936344|NCT01396447|DRUG|Cariprazine|Cariprazine was supplied in capsules.
218936345|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
218936346|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
218936347|NCT03080896|DEVICE|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
218936348|NCT03080896|DEVICE|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
218936349|NCT00476853|DRUG|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
218936350|NCT03868813|BEHAVIORAL|Semi-structured Interview|One-on-one semi-structured interviews
218936351|NCT02453347|DEVICE|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
219548553|NCT07140406|OTHER|conventional acupuncture|Conventional acupuncture treatment involves needling at acupoints on the upper limbs of patients to improve their upper limb function. The treatment is administered once a day, five times a week, for a continuous period of four weeks.
219623401|NCT05488340|DRUG|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
219623402|NCT05488340|DRUG|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
219623403|NCT05488340|DRUG|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
219548554|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on flexor muscle groups|The acupuncture points of the milli-needle fire-puncture device are located in the flexor muscle groups of the upper limbs, including the biceps brachii and the flexor muscle group of the forearm.
219548555|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on extensor muscle groups|The acupuncture points for the milli-needle fire-puncture device are located in the extensor muscle groups of the upper limbs, including the triceps brachii and the extensor muscles of the forearm.
219623404|NCT05488340|DRUG|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
219623405|NCT05488340|DRUG|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
219548556|NCT07140406|OTHER|Conventional needle puncture with a fire needle|The acupuncture points for milli-needle fire-puncture are commonly used ones on the upper limbs.
219548557|NCT07138989|DRUG|Valganciclovir Hydrochloride Tablets|Valganciclovir hydrochloride tablets will be administered at 900 mg twice daily from day 1 to day 14, followed by 450 mg twice daily from day 15 to day 20, for a total of 3 cycles.
219623406|NCT05488340|DRUG|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
219548558|NCT07138989|DRUG|gemcitabine, cisplatin, and PD-1 antibody|"Gemcitabine 1000 mg/m² will be administered intravenously on days 1 and 8; cisplatin 80 mg/m² intravenously on day 1; and PD-1 antibody intravenously on day 1. Each cycle is 21 days in duration, and treatment will be administered for a total of 4 to 6 cycles.~Following completion of the 4 to 6 cycles, patients will continue PD-1 antibody maintenance therapy (every 3 weeks) for up to two years or until disease progression, unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of informed consent, or death."
219206278|NCT06046820|DRUG|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
218936352|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
219548559|NCT07139561|BEHAVIORAL|Oral Health in Hands - Parent Digital Program|"The 16-week parent-focused digital intervention aims to improve oral health practices in children aged 6-10 by empowering parents through structured, engaging, and cost-effective activities. Parents receive daily reminders, including two brushing cues and one snack tip, to reinforce healthy routines. Weekly quizzes with 3-5 questions enhance knowledge retention, while interactive photo or video tasks such as Show your foam smile or Healthy lunchbox challenge promote family involvement and fun. Gamification strategies include awarding digital badges for streaks, such as the 7-day brushing badge and snack swap champion, to maintain motivation. Parents track brushing, flossing, and snack swaps using a simple 1-tap tracker, ensuring easy and consistent reporting. An optional moderated WhatsApp group provides a platform for sharing tips, photos, and encouragement, fostering a supportive peer community. The intervention combines education, habit formation, and social support to sustainab"
219548560|NCT07139093|DEVICE|DBS-coupled tACS|tACS will be applied in a phase-coupled manner, so that tACS and DBS are synchronized
219548561|NCT07139678|OTHER|SUMAC|Participant will complete tasks given in SUMAC.
219548562|NCT07140471|PROCEDURE|Onlay Mesh Repair|Polypropylene mesh is placed over the anterior rectus sheath and fixed with Prolene sutures after hernia sac reduction.
219548563|NCT07140471|PROCEDURE|Sublay Mesh Repair|Polypropylene mesh placed in the retrorectus space and fixed with Prolene sutures after Rectus Sheath Dissection
219548564|NCT07140185|BEHAVIORAL|Regular Weekly Physical Activity Program|Structured physical activity sessions three times per week, 50 minutes each, over 8 weeks. Includes aerobic exercises, supervised by trained instructors. Goal is to distribute the recommended weekly activity evenly.
219548565|NCT07140185|BEHAVIORAL|Weekend Warrior Physical Activity Program|Same total weekly activity as Arm 1, but concentrated in 2 weekend sessions of 75 minutes each. Includes aerobic exercises, supervised by the same trained instructors.
219623416|NCT06982365|DIETARY_SUPPLEMENT|Enovita® (Grape Seed Extract)|Enovita® is a standardized grape seed extract containing polyphenols, known for their antioxidant and vasodilatory properties. Participants in this group will take 150 mg of Enovita® orally, twice daily (total daily dose: 300 mg) for 8 weeks.
218936353|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
218936354|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
219047483|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
219206279|NCT06953648|BEHAVIORAL|High Intensity Interval Training|The intervention will consist of three 30-minute training sessions/week, each starting with a five-minute warm-up, followed by 20 minutes of interval training, and ending with a five-minute cool-down. The interval training will consist of 10 alternating high- and low-intensity intervals, with a 1:1 work-to-rest ratio (one minute of high intensity followed by one minute of low-moderate intensity). As participants' fitness improves, the interval intensity will increase accordingly.
219206280|NCT06104670|DIETARY_SUPPLEMENT|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
219206281|NCT06104670|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
219206282|NCT06952933|BEHAVIORAL|Other|Surveys will be distributed for data collection. A subset of patients will participate in diagnostic clinician interviews. No interventions will be tested.
219623417|NCT06982365|OTHER|Placebo Capsule|Participants in this group will receive a matching placebo capsule identical in appearance to the Enovita® capsule, taken orally, twice daily for 8 weeks.
219206283|NCT06670404|DEVICE|Vertebroplasty|Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
219206284|NCT06390059|DEVICE|Tumor Treating Fields|"The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit."
219206285|NCT06390059|DRUG|Atezolizumab|"Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
219206286|NCT06390059|DRUG|Gemcitabine|"Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
219206287|NCT06390059|DRUG|nab-paclitaxel|"Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
219548566|NCT07138885|PROCEDURE|HAI-FOLFOX + bevacizumab + QL1706|"Arm 1:~HAI-FOLFOX Administration (Day 1 of Each Cycle) Super-selective insertion the arterial catheter into the tumor-feeding artery, then infusion: Oxaliplatin: 85 mg/m², Leucovorin: 400 mg/m², 5-FU: 2500 mg/m²~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via arterial infusion.~Then QL1706 (5 mg/kg, IV infusion, Q3W).~Treatment Schedule: Repeat HAI-FOLFOX + arterial bevacizumab every 3 weeks (max 6 cycles), followed by QL1706 maintenance (Q3W)."
219548567|NCT07138885|PROCEDURE|TACE + bevacizumab + TAS-102 + QL1706|"Arm 2:~On-Demand TACE (Lipiodol: ≤10 mL, mixed with platinum + doxorubicin agent, each ≤50 mg) to form an emulsion. Repeat TACE until TACE resistance develops (typically \~4 sessions).~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via intra-arterial route.~After first TACE, begin TAS-102 (15 mg/m² po BID) once liver function recovers to acceptable levels.~Then QL1706 (5 mg/kg, IV infusion, Q3W)."
219623418|NCT03993626|DRUG|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
219623419|NCT07001410|OTHER|Age group|Observation of the outcomes by age groups.
219623420|NCT06676098|PROCEDURE|IANBD 3D guided approach|The IANBD will be used to administer the dental anesthetic 2mm medial to the lingula
219623421|NCT01555749|DRUG|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
219623422|NCT01555749|DRUG|placebo|One injection administered subcutaneously (s.c., under the skin)
219623423|NCT06589570|DEVICE|Removable Partial Denture|A removable partial denture (RPD) is a dental prosthesis designed to replace one or more missing teeth in the mouth. Unlike full dentures, which are used when all teeth are missing, an RPD is specifically made for patients who still have some of their natural teeth remaining. It restores both function and aesthetics, allowing patients to chew, speak, and smile with greater confidence.
219623424|NCT04300062|PROCEDURE|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
218936355|NCT00613275|OTHER|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
219623425|NCT06686979|OTHER|No Intervention: Observational Cohort|The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
219623426|NCT07025824|DRUG|Treosulfan (Treo)|10 g/m2 intravenous
219623427|NCT07025824|DRUG|Melphalan (Mel)|140 mg/m2 intravenous
219623428|NCT07025824|DRUG|Fludarabine (Flud)|30 mg/m2 intravenous
218936356|NCT00201513|BEHAVIORAL|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
219047484|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
219047485|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
219047486|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
219047487|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
219548568|NCT07140588|PROCEDURE|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
219548569|NCT07138820|PROCEDURE|Parathyroidectomy|Imaging with 18-F-choline-PET-CT
219548570|NCT07139782|DEVICE|Riancorp LTU-904 Laser and Handycure® (Medical Quant)|"Riancorp: At the first intervention session the therapist will apply the device for 60 secs each at 14 - 25 points on the face and neck. Most patients will need application of the device at 15 to 20 points The Riancorp runs for 60 seconds, providing 1.5 j/cm2 in 60 seconds.~Handycure: used by patients at home once/day on the prescribed days (Wks 1-6 3x/wk; Wks 7-10 x2/wk; Wks 11-12 x1/wk) 1. Patients will apply the device for 5 minutes at each point as instructed by the physiotherapist."
219548571|NCT07138625|BIOLOGICAL|Nebulized normal saline|Eligible patients with moderate bronchiolitis who met the inclusion criteria were randomly assigned in a 1:1 ratio to either the hypertonic saline (3%) group or the normal saline (0.9%) group. Randomization was performed using a computer-generated random number sequence prepared by an independent statistician not involved in patient recruitment or treatment. Allocation concealment was ensured through the use of sequentially numbered, opaque, sealed envelopes, which were opened only after patient enrollment and completion of baseline assessments.
219548572|NCT07139379|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
219548573|NCT07139379|OTHER|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy using goggle
219548574|NCT07139379|OTHER|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy using goggle
219623429|NCT03171376|PROCEDURE|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
219623430|NCT06719440|RADIATION|Radiotherapy (CTV=10mm)|Radiotherapy with reduced irradiation volume CTV=10mm
219047488|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
219623431|NCT06719440|RADIATION|Radiotherapy (CTV=15mm)|Radiotherapy with standard irradiation volume CTV=15mm
219623432|NCT07038746|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
219623433|NCT06724614|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
219623434|NCT06724614|DRUG|Placebo|Placebo
219623435|NCT07048288|OTHER|Multi-angle isometrics|Multi angle exercises include cervical flexion training, Cervical extension training, and Cervical lateral flexion training
219623436|NCT07048288|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique used in rehabilitation to support muscles and joints without restricting movement.
219623437|NCT07048288|OTHER|Dynamic exercise|The dynamic exercise program included dynamic cervical flexion, dynamic cervical extension, and dynamic lateral flexion.
219623438|NCT07048288|OTHER|Conventional Physiotherapy|Conventional physiotherapy included transcutaneous electrical nerve stimulation
218936357|NCT00201513|BEHAVIORAL|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
218936358|NCT00201513|BEHAVIORAL|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
219047489|NCT04776395|DRUG|Dexamethasone|Given PO
219047490|NCT04776395|DRUG|Iberdomide Hydrochloride|Given PO
219623439|NCT04636788|PROCEDURE|Venous sampling|venous sampling of 12ml
219548580|NCT07139808|DEVICE|GK5 CGKM|Wear for a consecutive 15 days
219548581|NCT07140055|DRUG|BLX-7006|BLX-7006 Single or Multiple doses administered orally as a tablet
218936359|NCT04860388|PROCEDURE|closed eruption technique|The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
218936360|NCT00986011|OTHER|questionnaire administration|
218936361|NCT00986011|OTHER|study of socioeconomic and demographic variables|
218936362|NCT00986011|OTHER|survey administration|
218936363|NCT00986011|PROCEDURE|study of high risk factors|
218936364|NCT00207285|BEHAVIORAL|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
218936365|NCT00207285|PROCEDURE|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
218936366|NCT01386970|DRUG|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
218936367|NCT04330313|PROCEDURE|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
218936368|NCT04330313|PROCEDURE|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
219047491|NCT04776395|OTHER|Quality-of-Life Assessment|Ancillary studies
219047492|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
219047493|NCT05057416|BEHAVIORAL|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
219047494|NCT02267629|DRUG|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
219047495|NCT05883982|PROCEDURE|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
219047496|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
219047497|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
219047498|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
219548582|NCT07140055|DRUG|Placebo|Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
219548583|NCT07138508|DRUG|Nicorandil 20mg|Oral nicorandil 20mg
219548584|NCT07140250|OTHER|Education with AI Technology|Shared decision making (SDM) about sinusitis treatment will be facilitated by AI technology via ChatGPT
219548585|NCT07140250|OTHER|Education using Traditional Internet Search Engines|Participant Education in Sinusitis using Traditional Internet Search Engines through Google
219548586|NCT07139184|DIAGNOSTIC_TEST|Diagnosis of Charcot foot disease|Diagnosis of Charcot foot disease will be obtained from the results of physical examination and according to x-ray examination of foot which was performed at the Radiology Department of Assiut University Hospital. The Eichenholtz classification system, developed by Sidney N. Eichenholtz in 1966, categorizes Charcot arthropathy (also known as Charcot foot) into three stages based on clinical and radiographic findings. These stages are development, coalescence, and reconstruction
219623440|NCT05756595|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
219623441|NCT06891443|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
219623442|NCT06891443|OTHER|Placebo IVT|Placebo with identical appearance to sepofarsen
219623443|NCT06741683|BIOLOGICAL|TDV|TDV SC injection.
219623444|NCT06741683|OTHER|Placebo|Placebo SC injection.
219623445|NCT07053800|BIOLOGICAL|Obecabtagene autoleucel|Obecabtagene autoleucel (obe-cel) given as a single infusion
218936369|NCT04330313|PROCEDURE|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
219047499|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
218936370|NCT04330313|PROCEDURE|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
219047500|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
219548587|NCT07139184|DIAGNOSTIC_TEST|Hematologic and biochemical parameters,|"Hematologic and biochemical parameters, including lymphocyte, monocyte, neutrophil, and platelet counts, as well as glucose, HbA1c, triglyceride (TG), HDL, and LDL levels, will be extracted from patient records.~NLR=absolute neutrophil count (109/L)/absolute lymphocyte count (109/L), PLR=platelet count (109/L)/absolute lymphocyte count (109/L), LMR=absolute lymphocyte count (109/L)/absolute monocyte count (109/L), GLR=glucose (mg/dL)/absolute lymphocyte ratio (109/L), TGR=triglyceride (mg/dL)/glucose ratio (mg/dL), THR=triglyceride (mg/dL)/HDL ratio (mg/dL), SIRI = absolute neutrophil count (109/L) × absolute monocyte count (109/L)/ absolute lymphocyte count (109/L), SII = platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L), TyG index = fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2, PIV =absolute neutrophil count (109/L) × platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L)."
218936371|NCT04881942|OTHER|e-Vapor Product A|e-Vapor product XL25F
218936372|NCT04881942|OTHER|e-Vapor Product B|e-Vapor product XL40CB
218936373|NCT04881942|OTHER|e-Vapor Product C|e-Vapor product XL35WM
218936374|NCT04881942|OTHER|e-Vapor Product D|e-Vapor product XL40MB
218936375|NCT01049542|DRUG|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
219548588|NCT07139184|DIAGNOSTIC_TEST|ELIZA Assay|For each patient, 2 ml of blood will be obtained. The serum levels of IL-10, TNF-α will be assessed by using (ELISA) kit obtained from (Biodiagnostic company, Egypt) according to the manufacturer protocol.
219548589|NCT07139756|DIAGNOSTIC_TEST|Lower body negative pressure|LBNP is a technique that redistributes blood from the upper body to the dependent regions of the legs, thus reducing central venous pressure and venous return and thereby activating the sympathetic nervous system (SNS). The subject is placed in a cylindrical airtight tank, which is sealed at the level of the iliac crests, and sub-atmospheric pressure is produced using a vacuum pump. It can be used to characterize the cardiovascular responses to orthostatic stress
219548590|NCT07139509|DRUG|allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells|dosage form: UCAR-T cell injection Route of Administration: Single intravenous injection Participants will receive lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) from Day -5 to -3, prior to UCAR-T cell infusion on Day 0.
219548591|NCT07139015|OTHER|CONSTRAINT-INDUCED MOVEMENT THERAPY|Constraint-Induced Movement Therapy (CIMT) involves restricting the unaffected arm to promote use of the affected limb through task-specific exercises. It is delivered 5 days a week for 6 weeks, with sessions lasting 60-90 minutes, focusing on improving strength, dexterity, and function.
218936376|NCT01224951|DRUG|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
218936377|NCT02939807|DRUG|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
218936378|NCT00097656|OTHER|multi-center, randomized, controled periodontal therapy|periodontal therapy
218936379|NCT06395467|BEHAVIORAL|InTEGRA|"Session topics are as follows: Parent Info Session - Informational and Q\&A format; Motivation Building- Addressing AA/NA Expectancies and Experiences; AA/NA Expectancies and Treatment Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management (AA/NA and Hungry, Angry, Lonely, Tired HALT; Effective Communication (Sharing at AA/NA meetings; getting a sponsor); Depression Management; Using AA/NA for enhancing Social Support and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse"
218936380|NCT06395467|BEHAVIORAL|MET/CBT|Session topics are as follows: Motivation Building Session; Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management; Effective Communication; Depression Management; Enhancing the Social Support Network and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse
218936381|NCT04230252|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
218936382|NCT05227170|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
218936383|NCT05227170|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
218936384|NCT05741164|PROCEDURE|Biopsy|Undergo tumor biopsy
218936385|NCT05741164|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218936386|NCT05741164|PROCEDURE|Computed Tomography|Undergo CT scan
218936387|NCT05741164|BIOLOGICAL|Pembrolizumab|Given IV
218936388|NCT05741164|DRUG|Propranolol|Given PO
218936389|NCT05741164|OTHER|Questionnaire Administration|Ancillary studies
219206290|NCT06378619|DIAGNOSTIC_TEST|Tapping Test|For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
219206291|NCT06378619|DIAGNOSTIC_TEST|Archimedes Spiral|For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.
219206292|NCT06784843|DRUG|Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block|Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
219206293|NCT06784843|DRUG|Midazolam as an adjuvant to local anesthesia for peribulbar block|Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
219206294|NCT05550571|DEVICE|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
219206295|NCT04875754|GENETIC|ICM-203|Intra-articular injection
219548592|NCT07139015|OTHER|MIRROR THERAPY|"Mirror Therapy (MT) uses a mirror to reflect movements of the unaffected limb, creating the illusion of movement in the affected limb.~Participants will do 60-90 minute sessions, 5 days a week for 6 weeks.~Exercises include hand opening/closing, finger movements, and simple object tasks to improve motor function and coordination through visual feedback."
219548593|NCT07140432|OTHER|Bone scintigraphy|A bone scintigraphy exam will be performed in addition of the already performed scanner in the current practice
219548594|NCT07140315|DRUG|[18F]DK222 radiotracer|\[18F\]DK222 is an investigational radiotracer used detect non-small cell lung cancer (NSCLC) or Urothelial Cancer (UC) tissue in the body when used with positron emission tomography/computed tomography. Participants will undergo a PET-CT scan after \[18F\]DK222 is injected into the participant's vein an intravenous line.
219548595|NCT07138898|DRUG|Methotrexate|Continue throughout perioperative period
219548596|NCT07138898|DRUG|Sulfasalazine|Continue throughout perioperative period
219548597|NCT07138898|DRUG|Hydroxychloroquine|Continue throughout perioperative period
219548598|NCT07138898|DRUG|Leflunomide|Continue throughout perioperative period
219548599|NCT07138898|DRUG|Azathioprine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
219548600|NCT07138898|DRUG|Mycophenolate|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
219548601|NCT07138898|DRUG|Cyclosporine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
219548602|NCT07138898|DRUG|Tacrolimus|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
219548603|NCT07138898|DRUG|Etanercept|Control group: Schedule surgery 2 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
219548604|NCT07138898|DRUG|Adalimumab|Control group: Schedule surgery 3 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
219548605|NCT07138898|DRUG|Golimumab|"Control group: Schedule surgery 5 weeks after last administered 4-week subcutaneous dose or 9 weeks after last administered 8-week intravenous dose.~Intervention group: Schedule surgery 2 weeks after last administered 4-week subcutaneous dose or 4 weeks after last administered 8-week intravenous dose."
219047501|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
219047502|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
219047503|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
219047504|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
219047505|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
219047506|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
219047507|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
219047508|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
219047509|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
219047510|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
219047511|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
219623446|NCT06896578|PROCEDURE|Lateral lymph node dissection|Removal of lateral lymph nodes in the obturator and internal iliac compartment including fatty tissue, but excluding vascular and nervous tissue
219623447|NCT02225431|DRUG|sodium chloride infusion|
219623448|NCT06793800|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|TAVSS is an application system that uses an electrical transcutaneous stimulation device placed on the concha or tragus of the ear. Functional Magnetic Resonance Imaging studies have shown that stimulation of these areas activates the ipsilateral nucleus tractus solitarius (NTS) via vagal projections to the brainstem and forebrain. Unlike cervical vagus nerve stimulation, TAVSS utilizes a physiological pathway to activate the NTS and the dorsal motor nucleus, which subsequently sends impulses bilaterally to the heart surface via efferent cervical vagus nerves. Therefore, this technique eliminates the possibility of directly and asymmetrically stimulating cardiac motor efferent fibers, which could lead to adverse cardiac events. TAVSS combines advantageous qualities such as being non-invasive, cost-effective, convenient, and efficient.
219623449|NCT05063552|BIOLOGICAL|Atezolizumab|Given IV
219548606|NCT07138898|DRUG|Certolizumab|Control group: Schedule surgery 5 weeks after last administered dose. Intervention group: Schedule surgery 2 weeks after last administered dose.
219548607|NCT07138898|DRUG|Infliximab|"Control group: Schedule surgery 9 weeks after last administered intravenous dose.~Intervention group: Schedule surgery 4 weeks after last administered dose."
219623450|NCT05063552|BIOLOGICAL|Bevacizumab|Given IV
219623451|NCT05063552|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623452|NCT05063552|DRUG|Carboplatin|Given IV
219623453|NCT05063552|BIOLOGICAL|Cetuximab|Given IV
219623454|NCT05063552|DRUG|Cisplatin|Given IV
219623455|NCT05063552|PROCEDURE|Computed Tomography|Undergo CT scan
219623456|NCT05063552|DRUG|Docetaxel|Given IV
219548608|NCT07138898|BIOLOGICAL|Rituximab|Control: Schedule 7 months after last administered dose. Intervention group: Schedule 3 months after last administered dose.
219548609|NCT07138898|BIOLOGICAL|Belimumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
219548610|NCT07138898|BIOLOGICAL|Tocilizumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
219548611|NCT07138898|BIOLOGICAL|Anakinra|Control group: Schedule surgery 2 days after last administered daily dose. Experimental group: Schedule surgery 1 day after last administered daily dose.
219548612|NCT07138898|BIOLOGICAL|Canakinumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
219548613|NCT07138898|BIOLOGICAL|Abatacept|"Control group: Schedule surgery 2 weeks after last administered weekly subcutaneous dose or 5 weeks after last administered monthly intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly subcutaneous dose or 2 weeks after last administered monthly intravenous dose."
219548614|NCT07138898|BIOLOGICAL|Secukinumab|"Control group: Schedule surgery 5 weeks after last administered subcutaneous dose.~Intervention group: Schedule surgery 2 weeks after last administered subcutaneous dose."
219548615|NCT07138898|BIOLOGICAL|Ixekizumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
219548616|NCT07138898|BIOLOGICAL|Bimekizumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4 weeks after last administered 8-week dose
219548617|NCT07138898|BIOLOGICAL|Ustekinumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6 weeks after last administered 12-week dose.
219548618|NCT07138898|BIOLOGICAL|Guselkumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4.5 weeks after last administered 8-week dose.
219548619|NCT07138898|BIOLOGICAL|Risankizumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6-7 weeks after last administered 12-week dose.
219623457|NCT05063552|PROCEDURE|Echocardiography Test|Undergo ECHO
219623458|NCT05063552|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623459|NCT05063552|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219206296|NCT04875754|DRUG|Placebo|Intra-articular injection
219548620|NCT07138898|DRUG|Tofacitinib|Control group: Schedule surgery 4 days after last administered daily dose. Intervention group: Schedule surgery 2 days after last administered daily dose.
219548621|NCT07138898|DRUG|Upadacitinib|Control group: Withhold 4 days prior to surgery Intervention group: Withhold 2 days prior to surgery
219623460|NCT03640494|DEVICE|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
219623461|NCT05142280|OTHER|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
219623462|NCT05142280|OTHER|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
219623463|NCT01422980|OTHER|1- Test dairy product containing specific ingredients|
219623464|NCT01422980|OTHER|2- Control dairy product without specific ingredients|
219623465|NCT01223391|OTHER|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
219623466|NCT01223391|OTHER|No abdominal binder|Standing without abdominal binder for 3 minutes
219623467|NCT00656552|DRUG|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
219623468|NCT05928312|DRUG|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1\. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
219548622|NCT07140198|PROCEDURE|Hyperbaric Oxygen Therapy|HBOT will be administered in five sessions (1 on Day 0, 2 on Day 1, 2 on Day 2), beginning immediately after the lipofilling. Each session consists of 100% oxygen inhalation at 2.5 ATA for 90 minutes. Postoperative MRI will be performed six months after each AFT session to assess the volume of retained graft.
219548623|NCT07140198|OTHER|Control|Patients in the control group will undergo standard follow-up after the lipofilling without HBOT.
219548624|NCT07139977|DRUG|Enfortumab Vedotin|Enfortumab vedotin is an ADC comprised of a fully human IgG1Κ antibody conjugated to the microtubule-disrupting agent MMAE via a protease-cleavable linker. Enfortumab vedotin is thought to induce anti-tumor activity by binding to the nectin-4 protein on the surface of cancer cells, leading to internalization, proteolytic cleavage of the linker, and intracellular release of MMAE that subsequently disrupts tubulin polymerization and leads to mitotic arrest and apoptosis of the tumor cell.
219548625|NCT07138547|DRUG|Eliglustat, CD30 target immunotherapy|"Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week.~CD30 target immunotherapy：Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy."
219548626|NCT07140536|OTHER|Environmental temperature|The office is day is spent in 19 or 23°C room temperature from 08:30AM to 04:30PM.
219548627|NCT07140536|BEHAVIORAL|Physical activity|From 08:30AM to 04:30PM, the office is day is spent either fully sedentary or interspersed with light walking on a treadmill (60 min at 10:00AM, 15 min at 01:00PM, 15 min at 02:00PM, 15 min at 03:00PM, 15 min at 04:00PM).
219623469|NCT00003627|DRUG|cisplatin|
219623470|NCT00003627|DRUG|fluorouracil|
219623471|NCT00003627|RADIATION|radiation therapy|
219623472|NCT04071834|DIAGNOSTIC_TEST|ELISA|Detection of blood orphanin and norepinephrine in patients
218936390|NCT02333617|OTHER|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
219047512|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
219548628|NCT07139405|DRUG|Metformin XR 1000mg|Arm 1: Metformin XR 1000mg Monotherapy (taken AM)
219548629|NCT07139405|DRUG|Valsartan 80mg Tablet|Arm 2: Valsartan 80mg (taken PM)
219548630|NCT07139405|DRUG|Valsartan 160mg tablet|Arm 3: Valsartan 160mg (taken PM)
219548631|NCT07139405|DRUG|Celecoxib (Celebrex®) 100mg|Arm 2: Celecoxib 100mg (taken AM)
219623473|NCT06157008|DRUG|General Anesthetics|General anesthetics used in spinal cord electrical stimulator insertion surgery
219623474|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
219623475|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions BID over 14 days
219548632|NCT07139405|DRUG|Celecoxib (Celebrex®) 200mg|Arm 3: Celecoxib (taken AM)
219548633|NCT07139405|DRUG|Metformin XR 500 mg|Arm 2: Metformin 500mg (taken AM)
219548634|NCT03834077|OTHER|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
219548635|NCT03834077|OTHER|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
219623476|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
219623477|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
219623478|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every QD over 14 days
219623479|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
219623480|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
219623481|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
219623482|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
219623483|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
219623484|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
219623485|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
218936391|NCT02333617|OTHER|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
219548636|NCT02293486|DIETARY_SUPPLEMENT|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
219548637|NCT05541198|OTHER|Pressure Injury Prevention Care Bundle|"1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
219548638|NCT06933602|OTHER|relaxin|"Progressive Muscle Relaxation (PMR) exercises help alleviate symptoms in patients with COPD by reducing the effects of anxiety and stress, distracting attention from pain, and relieving muscle tension and spasms.~These exercises are beneficial in managing:~Tension headaches Back pain Tension and pain in jaw muscles Tension and pain around the eye muscles Muscle spasms Insomnia Stress-related muscle tension The required content of the exercises for relieving stress-related tension will be provided in a booklet. The booklet will be given to the patients following the training session."
219548639|NCT07135921|BEHAVIORAL|Sleep Hygiene Education|This intervention consists of a nurse-led sleep hygiene education program delivered through a 30-minute PowerPoint presentation. Participants in the intervention group will also receive twice-daily reminder messages via WhatsApp for four weeks to reinforce healthy sleep habits. The program aims to improve sleep quality and disease management in individuals with cardiovascular disease. After the study, the educational materials will also be shared with the control group.
219548640|NCT07138911|OTHER|Intervention group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Activity plan is calendar on mobile health app. Mobile placed in pocket or bag before starting walk and mark activity on calendar.
219623486|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
219623487|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
219623488|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
219623489|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
219623490|NCT05807490|DRUG|PF-07328948|Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
219623491|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
219623492|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
218936392|NCT02333617|OTHER|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
219623493|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
219623494|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
219623495|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
219623496|NCT00204490|DIETARY_SUPPLEMENT|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
219623497|NCT00204490|DIETARY_SUPPLEMENT|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
219623498|NCT02901938|PROCEDURE|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
219623499|NCT02901938|DEVICE|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
219623500|NCT06551493|OTHER|Observation of postnatal wound assessment|Observation of postnatal wound assessment
218936393|NCT02333617|OTHER|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
218936394|NCT02905851|OTHER|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
218936395|NCT02905851|OTHER|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
218936396|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
219623501|NCT06551493|OTHER|Interview|Interview to elicit individual perspectives of wound assessment
219623502|NCT01497028|PROCEDURE|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
219623503|NCT04214977|PROCEDURE|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
219623504|NCT04214977|PROCEDURE|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
219623505|NCT01582776|DRUG|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
219623506|NCT06325826|DIAGNOSTIC_TEST|General Evaluation Score (GES)|According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)
219623507|NCT00238966|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219623508|NCT05460338|DRUG|Cholecalciferol|native form of Vitamin D.
219623509|NCT02397512|DRUG|application of lactulose|Subjects will ingest 50g of lactulose once
219623510|NCT02397512|OTHER|application of sucrose|Subjects will ingest 50g of sucrose once
219623511|NCT02257710|DEVICE|Orsiro|
219623512|NCT05952102|DRUG|Nigella Sativa Oil capsule|Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
219623513|NCT00146302|BIOLOGICAL|Bacille Calmette Guerin (BCG)|
219623514|NCT04073537|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
219623515|NCT04073537|DRUG|Placebos|Anlotinib blank analog capsule.
219623516|NCT04073537|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
219623517|NCT04073537|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
219623518|NCT00480337|PROCEDURE|In Vitro Maturation of immature oocytes|
219623519|NCT01853215|DEVICE|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
219623520|NCT02166333|DIETARY_SUPPLEMENT|200 IU/d cholecalciferol|
219623521|NCT02166333|DIETARY_SUPPLEMENT|1000 IU/d cholecalciferol|
219623522|NCT02166333|DIETARY_SUPPLEMENT|2000 IU/d cholecalciferol|
219623523|NCT02166333|DIETARY_SUPPLEMENT|4000 IU/d cholecalciferol|
219623524|NCT03221647|OTHER|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
219623525|NCT03901677|OTHER|Tai-chi training|Group exercise apply with physiotherapist
219623526|NCT00503698|DRUG|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
219623527|NCT00503698|DRUG|placebo|Placebo injected s.c (under the skin)
219623528|NCT03523520|DRUG|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
219623529|NCT03523520|DRUG|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
218936397|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
218936398|NCT03828201|DRUG|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
219623530|NCT03523520|DRUG|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
219623531|NCT03083327|DIETARY_SUPPLEMENT|Parenteral nutrition.|Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
219623532|NCT03083327|OTHER|Pragmatic standard care.|Nutrition support will be provided as per usual care.
219623533|NCT04389229|DRUG|cyclophosphamide|600mg/m2/day for 3 days ( on day -5, -4, -3)
219623534|NCT04389229|DRUG|fludarabine|30mg/m2/day for 3 days ( on day -5, -4, -3)
219623535|NCT04389229|DRUG|IL-2 (Proleukin)|Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion
219623536|NCT04389229|GENETIC|Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)|Single dose at 5 x 10\^9 - 5 x 10\^10
219623537|NCT04389229|GENETIC|Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)|Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)
219623538|NCT00868920|OTHER|patient control of pump|Patient controls sedation pump during colonoscopy.
219623539|NCT00868920|OTHER|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
219623540|NCT00495573|DRUG|acyclovir|400 mg acyclovir, orally three times a day for 5 days
219623541|NCT05895448|DRUG|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
219623542|NCT02604095|DIETARY_SUPPLEMENT|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
219623543|NCT00682786|DRUG|5FU|
219623544|NCT00682786|RADIATION|Radiation|
219623545|NCT00682786|PROCEDURE|Surgery of resectable lesions|
219623546|NCT00682786|DRUG|Irinotecan|
219623547|NCT02252835|DRUG|Arhalofenate|800 mg once daily orally for four weeks
219623548|NCT02252835|DRUG|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
219623549|NCT02252835|DRUG|Arhalofenate|600 mg once daily orally for four weeks
219623550|NCT02252835|DRUG|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
219623551|NCT02252835|DRUG|Colchicine|0.6 mg daily
219548641|NCT07138911|OTHER|Control group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Manual record of walking and date.
219548642|NCT07140627|DRUG|Bupivacain|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants had received 1 mL/kg 0.25% bupivacaine. Post operative pain was assessed.
219548643|NCT07140627|DRUG|Dexmedetomidine & Bupivacaine.|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants were included and administered 1 mL/kg 0.25% bupivacaine and 1 μg/kg dexmedetomidine. Post operative pain was assessed.
219548644|NCT07140393|DRUG|HRS-4508+ Capecitabine|HRS-4508+ Capecitabine
219548645|NCT07140393|DRUG|HRS-4508+ Trastuzumab|HRS-4508+ Trastuzumab
219548646|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Pertuzumab|HRS-4508+ Trastuzumab+ Pertuzumab
219548647|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Capecitabine|HRS-4508+ Trastuzumab+ Capecitabine
219548648|NCT07140393|DRUG|Trastuzumab+ Capecitabine|Trastuzumab+ Capecitabine
219548649|NCT07140393|DRUG|HRS-4508+A1811|HRS-4508+A1811
219548650|NCT07138924|OTHER|Graston Technique|Firstly, apply a moisturizer or gel to affected part. Then gentle strokes are applied from proximal to distal direction to assess trigger point or taut band. After knowing the exact area, apply strokes gently with minimum force in all directions by keeping tool in 30- 60-degree angle. Total Application time will be between 40-120 seconds. conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
218936399|NCT03828201|DRUG|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
218936400|NCT03828201|DRUG|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
218936401|NCT03828201|DRUG|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
218936402|NCT03828201|DRUG|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
218936403|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
219047513|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
219047514|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
219047515|NCT03912233|DRUG|VX-121|Tablets for oral administration.
219047516|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
219047517|NCT03912233|DRUG|VX-561|Tablets for oral administration.
219047518|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
219047519|NCT03912233|DRUG|IVA|Tablets for oral administration.
219047520|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
219047521|NCT04135638|PROCEDURE|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
219047522|NCT04135638|PROCEDURE|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
219047523|NCT01464320|DRUG|ABT-614|Active
219047524|NCT01464320|DRUG|Placebo Comparator|Placebo
219047525|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
219047526|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
219047527|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
219047528|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
219548651|NCT07138924|OTHER|Dynamic Oscillatory Stretch Technique|Passively stretch that is at the first point of stretch sensation. The next component to DOS, 2-sec, passive stretch with slow oscillation. Total 10 reps x 2 sec hold oscillations x 3 sets.conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
219548652|NCT07140562|DEVICE|Tricuspid Annular Therapy System|A transcatheter device designed for tricuspid valve repair.
219548653|NCT07139548|DRUG|RAY1225|Administered SC
219206297|NCT06182423|BEHAVIORAL|STEPS-CI (Support, Training, and Education for Pain Self-management- Cognitively Inclusive version)|This intervention is a community health worker (CHW)-led chronic pain self-management program designed for older adults with chronic pain and mild to moderate cognitive impairment. It is a 7-week intervention that includes two primary components: a website that includes brief instructional videos on pain management skills as well as testimonials from individuals living with the two target health conditions; and weekly telephone sessions with a CHW to support and motivate participants in setting goals related to pain management. Reminder strategies and content addressing pain management challenges related to cognitive impairment are incorporated throughout. Participants may choose to work with a care partner during intervention activities.
219206298|NCT06286670|PROCEDURE|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
219206299|NCT06286670|PROCEDURE|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
219623552|NCT05667090|OTHER|Vitamin D|Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks
219623553|NCT05667090|OTHER|Placebo|Oral supplementaiton of placebo once a week for 4 weeks
219206300|NCT06493461|BIOLOGICAL|HS135|HS135 is dosed subcutaneously
219206301|NCT05412004|DRUG|Tirzepatide|Administered SC
219206302|NCT05412004|DRUG|Placebo|Administered SC
219206303|NCT05448833|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
219206304|NCT06797050|DEVICE|Training in reordering figurative stories with a social robot through the Learning by Teaching approach|A test session of the 'picture sequencing' task with the social robot is planned. The selected children will undergo an initial neuropsychological, motor and school learning assessment and will be divided into Group 1 and Group 2: Group 1 (Experimental) will be offered training with the social robot, while Group 2 (Control) will continue standard care. Both groups will be re-evaluated after approximately about 4 months. After which Group 2 will be able to start treatment. After about 4 months, the children in both groups will again undergo the planned assessments. During the training, the child will be asked to help the social robot to reorder sequences of pictures from figurative stories in order to create a story that respects temporal or causal links, or motor actions of increasing complexity, according to the Learning by Teaching paradigm.
219548654|NCT07139548|DRUG|Semaglutide|Administered SC
219548655|NCT07140549|OTHER|Survey using a questionnaire.|"A monocentric experimental study conducted as a survey, including patients enrolled in our fertility preservation program between May 2005 and May 2020.~Participants were asked about their current reproductive health status, their experience with the fertility preservation process, and their overall satisfaction with the care they received."
219548656|NCT07139613|OTHER|Control group(PS)Planer occlusal scheme with rounded shoulder finish line|Control group (PS) will have planer occlusal scheme with rounded shoulder finish line.
219548657|NCT07139613|PROCEDURE|First intervention group(FF) flat occlusal scheme with feather edge finish line|First intervention group we will have flat occlusal scheme with feather edge finish line
219548658|NCT07139613|PROCEDURE|Second intervention group(FS) flat occlusal with rounded shoulder finish line design|Second intervention will have flat occlusal scheme with rounded shoulder finish line design
219548659|NCT07140575|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|twice daily rTMS, intermittent theta burst stimulation targeting the left dorsolateral prefrontal cortex with a figure-8 coil
219548660|NCT07139912|DEVICE|Thoracic Aortic Multi-Branch Stent Graft System|The Thoracic Aortic Multi-Branch Stent Graft Systemm consists of the Single-Branch Aortic Stent-Graft System, the aortic extension stent graft system and the branch stent system.
219548661|NCT07139730|DRUG|Lignocaine 2% concentration solution|the effect of preoperative nebulized lidocaine on the stress response to intubation, monitored by rise in serum cortisol level post intubation
219548662|NCT07139275|OTHER|aerobic exercise|exercise protocol was applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
219548663|NCT07139275|BEHAVIORAL|added sugar elimination|specialized programme of eliminating all kinds of added sugar (all kinds of sugars that are not naturally occurring in natural foods
219548664|NCT07139275|COMBINATION_PRODUCT|aerobic exercise and added sugar elimination|a specialized program of combining added sugar elimination protocols ( elimination of all kinds of added sugars and allowing only sugars naturally occurring in foods) combined with the same aerobic exercise protocol that applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
219548665|NCT07140003|PROCEDURE|pleural biopsy|To assess whether pleural tissue culture can improve the identification of causative organisms in pleural infections (using the pleural fluid culture), which can aid in selecting appropriate antimicrobial therapy and improve treatment outcomes, thus may provide valuable insights into the utility of pleural tissue culture in managing pleural infection and may guide clinicians in selecting the most appropriate diagnostic approach.
219548666|NCT07140094|BEHAVIORAL|Structured mindfulness intervention|The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. The mindfulness recordings are between two and twenty minutes long and are accessed online.
219548667|NCT07140081|DRUG|BLX-0871|BLX-0871 Single or Multiple doses administered orally as a tablet
219548668|NCT07140081|DRUG|Placebo|Participants will receive matching placebo of BLX-0871 for each of the oral cohorts.
219548669|NCT07138755|DRUG|Experimental|Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous） Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma） Radiation:Adaptive radiotherapy with V20\<20%: 1.PGTV60-66Gy/2.0-2.2Gy/30F;PTV54Gy/1.8Gy/30F;2.PGTV54-66Gy/2.0-2.2Gy/30F；3.PGTV50Gy/2.0Gy/25F
219623554|NCT03551990|PROCEDURE|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
219623555|NCT02381847|PROCEDURE|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
219623556|NCT02673177|PROCEDURE|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
219623557|NCT02673177|PROCEDURE|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
219623558|NCT05684874|RADIATION|Neoadjuvant RT|"Dosimetric CT scan with contrast injection for treatment planning. Radiation therapy at a dose of 50Gy in 25 fractions, 5 fractions per week. Daily pre-treatment positioning tomographic imaging (either high energy (MVCT) or cone beam computed tomography (CBCT)).~Delineation of the tumor volume and evaluation of its evolution. In case of change of volume and if medically relevant, new dosimetric scan and collection of the tumor volume."
219623559|NCT05684874|OTHER|Pre-radiotherapy mpMRI|"Performed less than 14 days before the dosimetric scan. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
219623560|NCT05684874|OTHER|Post-radiotherapy mpMRI|"Performed 4 to 6 weeks after the end of the radiotherapy. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
219623561|NCT05684874|PROCEDURE|Tumor resection|Performed 6 to 8 weeks after the end of radiotherapy. An anatomopathological observation of the surgical specimen will be performed.
219623562|NCT01611727|DRUG|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
219623563|NCT01294774|DRUG|KRP203 - 1.2mg|
219623564|NCT01294774|DRUG|Placebo to KRP203 - 1.2 mg|
219623565|NCT03099031|DRUG|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
219623566|NCT05383131|DRUG|HEC585|Mulltiple doses of HEC585 for up to 10 days
219623567|NCT05383131|DRUG|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
219623568|NCT05383131|DRUG|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
219623569|NCT00396682|DRUG|Cyclophosphamide|150 - 250 - 350 mg
219623570|NCT07062380|PROCEDURE|Curative liver resection|Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.
219623571|NCT07062380|PROCEDURE|Real-world multimodal therapy|Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.
219623572|NCT03026634|BEHAVIORAL|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
219623573|NCT00359424|DRUG|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
219623574|NCT00359424|OTHER|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
219623575|NCT01210534|OTHER|No intervention|No intervention
219623576|NCT05828381|DRUG|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
219047529|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
219047530|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
219047531|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
219623577|NCT05828381|DRUG|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
219623578|NCT05828381|DRUG|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
219623579|NCT00762710|DRUG|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
219623580|NCT00762710|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
219047532|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
219047533|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
219047534|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
219047535|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
219548670|NCT06948747|DRUG|AZD5004|"Participants will receive oral tablets of AZD5004 as single dose on the following days, (i) Day 7, Day 14, Day 21, Day 28, Day 35, Day 42 and Day 55 in Part A. (ii) Day 9 to Day15, Day 16, Day 17 to Day 23, Day 24 to Day 30, Day 31 to Day 37, Day 38 to Day 41 and Day 42 in Part B.~(iii) Day 3 to Day 9, Day 10 to Day 25, Day 26 to Day 33, and Day 34 in Part C."
219548671|NCT06948747|DRUG|Rosuvastatin|Participants will receive single oral tablets of rosuvastatin 10mg on Days 1, 7, 14, 21, 28, and 35.
219548672|NCT06948747|DRUG|Erythromycin|Participants will receive oral doses of erythromycin 500 mg, twice a day from Day 49 to Day 54; and a single dose of 500 mg on Day 55.
219548673|NCT06948747|DRUG|Atorvastatin|Participants will receive single oral doses of 40 mg atorvastatin on Days 4, 8, 16, 38, and 42.
218936404|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
218936405|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
218936406|NCT01349959|DRUG|Azacitidine|Given SC
218936407|NCT01349959|DRUG|Entinostat|Given PO
218936408|NCT01349959|OTHER|Laboratory Biomarker Analysis|Correlative studies
218936409|NCT01349959|OTHER|Pharmacological Study|Correlative studies
218936410|NCT02675634|DEVICE|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
218936411|NCT02675634|DEVICE|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
218936412|NCT02675634|DEVICE|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
218936413|NCT01652534|DRUG|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
218936414|NCT01652534|DRUG|Placebo|Sugar Pill
218936415|NCT03965481|RADIATION|Dynamic Enhanced CT|Undergo standard CECT
219047536|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
219047537|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
219047538|NCT02206113|BEHAVIORAL|Standing workstation|
219047539|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
219047540|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
219047541|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
219047542|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
219047543|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
219047544|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219047545|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
219047546|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
219047547|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
219047548|NCT05921994|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
219047549|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
219047550|NCT04163289|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
219047551|NCT06528405|DRUG|dapagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
219047552|NCT06528405|OTHER|Other anti-diabetic drug or no anti-diabetic drug|"Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist."
219047553|NCT06528405|DRUG|empagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
219047554|NCT06528405|DRUG|canagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
219047555|NCT04938362|OTHER|FDG-PET|\[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
219047556|NCT04938362|OTHER|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
219047557|NCT04355000|PROCEDURE|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
219047558|NCT04355000|PROCEDURE|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
218936416|NCT03965481|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI scan
218936417|NCT03965481|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI scan
218936418|NCT00261820|DRUG|tacrolimus|
218936419|NCT00261820|DRUG|mycophenolate mofetil|
218936420|NCT00261820|DRUG|methylprednisolone|
218936421|NCT00261820|DRUG|prednisolone|
218936422|NCT00261820|DRUG|sirolimus|
219548674|NCT06948747|DRUG|Simvastatin|Participants will receive single oral doses of 20 mg simvastatin on Days 1 and 31.
219548675|NCT06948747|DRUG|Repaglinide|Participants will receive single oral doses of 0.5 mg repaglinide on Days 1, 10, 26, and 34.
218936423|NCT01085994|OTHER|Literature search|Literature search followed by systematic review and meta-analysis
218936424|NCT00731302|DRUG|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
218936425|NCT02663401|BEHAVIORAL|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
218936426|NCT03082625|DRUG|Transdermal Magnesium|Magnesium
218936427|NCT03082625|DRUG|Placebo|
218936428|NCT05997303|OTHER|Continuous norepinephrine infusion via an infusion pump|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
218936429|NCT05997303|OTHER|Manual bolus norepinephrine administration|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
218936430|NCT04140513|RADIATION|Fludeoxyglucose F-18|Given via injection
218936431|NCT04140513|PROCEDURE|Positron Emission Tomography|Undergo dPET
218936432|NCT03067714|OTHER|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
218936433|NCT03067714|OTHER|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
219548676|NCT03366948|OTHER|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
219548677|NCT06894199|OTHER|The Work Shop|Employment intervention consists of 2 days (about 5 hours each) of interactive educational content focused on a variety of topics.
219548678|NCT06949410|DRUG|HER2 Vaccine|MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines
219548679|NCT07138833|DRUG|Dimethyl Fumarate Enteric-coated Capsules|Eligible 50 RMS patients will orally take dimethyl fumarate enteric-coated capsules during treatment, with an initial dose of 120 mg twice daily for 7 days, followed by a maintenance dose of 240 mg twice daily for 48 weeks
219548680|NCT07139522|DRUG|Bupivacaine|Patients will receive 20 ml of 0.25% isobaric bupivacaine.
219548681|NCT07139522|DRUG|Dexamethasone|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 4mg of dexamethasone).
219548682|NCT07139522|DRUG|Magnesium sulphate|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 200mg of magnesium sulphate).
219548683|NCT07139353|DRUG|Linperlisib|Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II)
219548684|NCT07139353|DRUG|Chidamide|Chidamide: 20mg, po, biw
219548685|NCT07139210|OTHER|perceptual motor training|"Perceptual -motor training program:~1. Balance exercises~2. Awareness training exercises~3. Spatial awareness exercises~4. Training of shape perception exercises~5. Visual perception training exercises~6. Auditory perception training~7. Touch-kinetic perception training~8. Coordination of eye and hand, eye and leg, subtle motor actions"
219548686|NCT07139899|COMBINATION_PRODUCT|Hyperpolarized Xenon 129|Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent
219623581|NCT02569879|OTHER|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
219623582|NCT02462603|DRUG|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
218936434|NCT00905801|OTHER|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
218936435|NCT00201188|BEHAVIORAL|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
218936436|NCT05163626|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
218936437|NCT02757716|OTHER|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
218936438|NCT02328638|BEHAVIORAL|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
218936439|NCT02328638|BEHAVIORAL|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
218936440|NCT03860259|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
219623583|NCT02218138|BEHAVIORAL|Learning 2 BREATHE|Mindfulness-based group program
219623584|NCT02218138|BEHAVIORAL|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
219623585|NCT03309137|DEVICE|Chlorhexidine flush|"1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~   After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~2. Discard the syringe and device in biohazard waste.~3. Blue Cap the IV as per routine practice."
219623586|NCT00907361|DEVICE|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
219623587|NCT03160937|OTHER|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
219623588|NCT00720551|OTHER|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
219623589|NCT01235754|DRUG|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
219623590|NCT01235754|DRUG|placebo gel|once daily transdermal placebo gel
219623591|NCT07059793|DEVICE|MITRIS RESILIA Mitral Valve|Surgical replacement of native or prosthetic mitral valve.
219623592|NCT07063823|DRUG|HB-2121|HB-2121 taken once orally.
219623593|NCT01370629|DRUG|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
219623594|NCT00025025|OTHER|sample testing|
219623595|NCT01461837|DRUG|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
219623596|NCT05160922|DRUG|crizotinib|crizotinib oral treatment
219623597|NCT06498648|DRUG|Abemaciclib|Given PO
219623598|NCT06498648|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219623599|NCT06498648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623600|NCT06498648|PROCEDURE|Computed Tomography|Undergo PET/CT
219047559|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
219047560|NCT03916146|BEHAVIORAL|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
219047561|NCT05624112|DRUG|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
219047562|NCT04771208|BEHAVIORAL|"I kua na'u Let Me Carry Out Your Last Wishes"|A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
219047563|NCT01351896|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219047564|NCT01351896|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219047565|NCT01351896|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219047566|NCT01351896|PROCEDURE|Computed Tomography|Undergo CT
219623601|NCT06498648|DRUG|Docetaxel|Given IV
219623602|NCT06498648|OTHER|Fluorothymidine F-18|Given IV
219623603|NCT06498648|DRUG|Gemcitabine|Given IV
219623604|NCT06498648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219623605|NCT03067727|DRUG|Dinoprostone|The DVI contains 10 mg Dinoprostone
219623606|NCT03067727|DRUG|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
219623607|NCT02092376|DRUG|Cholecalciferol|
219623608|NCT02092376|DRUG|Placebo|
219623609|NCT02805920|DRUG|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
219623610|NCT05888220|OTHER|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
219623611|NCT00004330|DRUG|luteinizing hormone-releasing factor|
219047567|NCT01351896|DRUG|Lenalidomide|Given PO
219047568|NCT01351896|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
219047569|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
219047570|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
219623612|NCT01626001|PROCEDURE|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
219623613|NCT05774067|DRUG|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
219623614|NCT05774067|DRUG|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
219623615|NCT05774067|DRUG|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
219623616|NCT03312244|DRUG|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
219623617|NCT03312244|DRUG|Placebo|Placebo
219623618|NCT00304850|BEHAVIORAL|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
219623619|NCT00304850|DRUG|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
219623620|NCT01591096|DRUG|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
219623621|NCT05079672|DRUG|Dexmedetomidine|Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
219623622|NCT05079672|DRUG|0,9% Saline|Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
219623623|NCT05479786|OTHER|Expectant management|Follow-up with beta-HCG dosages and transvaginal ultrasound scans
219623624|NCT05479786|PROCEDURE|Salpingectomy|Removal of the affected Fallopian tube by laparoscopy
219623625|NCT05479786|PROCEDURE|Salpingostomy|Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
219623626|NCT02044263|BEHAVIORAL|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
219623627|NCT02044263|BEHAVIORAL|face-to-face CBT-i|
219623628|NCT02227563|DEVICE|Active tDCS|repetitive daily tDCS sessions for a period of one week
219623629|NCT02227563|DEVICE|control|
219623630|NCT01831635|OTHER|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
219623631|NCT01831635|OTHER|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
219623632|NCT01831635|OTHER|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
218936441|NCT03860259|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
218936442|NCT05482100|DIAGNOSTIC_TEST|Patients monitored with OmniGraf testing|This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
218936443|NCT05512156|OTHER|Supervised Toothbrushing|"* Recruitment, consent, and Questionnaires (Behaviors, Quality of Live, Cost Analysis) distribution.~* Inclusion \& Exclusion Criteria Applied~* Baseline Dental examination~* Toothbrushes \& Toothpastes Home and school use packs delivery-Colgate (six pack per child a year- child soft toothbrush with a1450ppm fluoridated toothpaste))~* Supervised teachers training~* Three months intervals monitoring visits~* 12months Follow up and Questionnaires (Behaviours) distribution~* Endpoint dental Examination and Questionnaires (Behaviours, Quality of Live, Cost Analysis) distribution"
218936444|NCT00811018|DRUG|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
218936445|NCT03792906|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
218936446|NCT03792906|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
218936447|NCT03792906|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
218936448|NCT03792906|DRUG|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
218936449|NCT00162019|DRUG|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
218936450|NCT04420104|PROCEDURE|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
219623633|NCT05790395|OTHER|Theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
218936451|NCT04420104|DRUG|iv analgesia|iv contromal
219047571|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
219047572|NCT05952037|DRUG|Sonrotoclax|Administered orally as a tablet.
219047573|NCT05952037|DRUG|Zanubrutinib|Administered orally as a capsule.
219047574|NCT00215046|DRUG|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
219047575|NCT00215046|DRUG|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
219623634|NCT05790395|OTHER|health-risk behaviors|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
219623635|NCT02716714|DRUG|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
219623636|NCT02716714|DRUG|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
219623637|NCT06065163|OTHER|Diuretic de/escalation based on ultrasound findings (VExUS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
219623638|NCT06065163|OTHER|Diuretic de/escalation based on clinical findings (CCS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
219623639|NCT00240708|DRUG|risperidone|
219623640|NCT01163838|BIOLOGICAL|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219047576|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
219047577|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
219623641|NCT01163838|BIOLOGICAL|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623642|NCT01163838|BIOLOGICAL|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623643|NCT01163838|BIOLOGICAL|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623644|NCT01163838|BIOLOGICAL|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623645|NCT01163838|BIOLOGICAL|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623646|NCT01163838|BIOLOGICAL|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
219623647|NCT03059017|DRUG|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
219623648|NCT03059017|DRUG|Niosomes|Niosomes
219047578|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
219047579|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
219047580|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
219047581|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
219047582|NCT02786485|BIOLOGICAL|rivogenlecleucel|T cells transduced with iCasp safety switch
219047583|NCT02786485|DRUG|Rimiducid|administered to treat GVHD
219047584|NCT06214208|OTHER|Transcutaneous Spinal Stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
219047585|NCT02983071|DRUG|G1T38|
219047586|NCT02983071|DRUG|Fulvestrant|
219047587|NCT00015275|BEHAVIORAL|Cocaine-Related Disorders|
219047588|NCT05385939|OTHER|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
219548687|NCT07139145|BEHAVIORAL|Progressive Muscle Relaxation + Standard Physiotherapy|Standard physiotherapy exercises plus PMR sessions. PMR is gradually transitioned from therapist-guided to self-directed practice across the 6 weeks.
219548688|NCT07139145|BEHAVIORAL|Standard Physiotherapy|Participants receive a 6-week standard physiotherapy program delivered twice weekly. Sessions include warm-up, weight-bearing training, balance exercises, gait training, and functional activities. The protocol focuses on improving mobility, weight-bearing capacity, balance, and functional independence. No Progressive Muscle Relaxation or additional behavioral techniques are included.
219548689|NCT07139951|PROCEDURE|Biopsy Procedure|Undergo laparoscopy with biopsy
219548690|NCT07139951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219548691|NCT07139951|DRUG|Cisplatin|Given IP
219548692|NCT07139951|PROCEDURE|Computed Tomography|Undergo PET/CT
219548693|NCT07139951|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Given p-HIPEC
219548694|NCT07139951|PROCEDURE|Laparoscopy|Undergo laparoscopy with biopsy
219548695|NCT07139951|PROCEDURE|Lymphadenectomy|Undergo D2 lymphadenectomy
219548696|NCT07139951|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219548697|NCT07139951|DRUG|Paclitaxel|Given IP
219548698|NCT07139951|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
219548699|NCT07139951|PROCEDURE|Surgical Procedure|Undergo gastrectomy and reconstruction
219548700|NCT07139847|DRUG|Magnesium Sulfate Infusion|Magnesium Sulfate (Experimental Group) Intravenous bolus of magnesium sulfate 30 mg/kg administered over 15 minutes immediately after induction of general anesthesia, followed by continuous infusion at 10 mg/kg/h until the end of surgery. Solutions were prepared in identical syringes and infusion bags by an anesthesia technician not involved in patient care. The preparation and administration protocol ensured blinding of participants, anesthesia providers, and outcome assessors.
219548701|NCT07139847|DRUG|0.9% Saline Infusion|ntravenous bolus and continuous infusion of 0.9% sodium chloride solution in the same volume, infusion rate, and duration as the magnesium sulfate group. Solutions were indistinguishable in appearance and prepared under the same blinding procedures.
219548702|NCT07138638|DEVICE|High-Frequency QRS|All enrolled patients underwent HF-QRS assessment, with subsequent recording of MACE to evaluate the predictive value of HF-QRS parameters for clinical outcomes
219548703|NCT07138664|BEHAVIORAL|Super Skills for Life program|Study-Skills program will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
219548704|NCT07138664|BEHAVIORAL|Study-Skills program|Study-Skills program will be used as a comparator intervention, which will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
219623649|NCT05969184|DRUG|CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)|CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data
219623650|NCT01801943|BEHAVIORAL|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
219623651|NCT01801943|BEHAVIORAL|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
219623652|NCT01801943|BEHAVIORAL|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
219623653|NCT01801943|BEHAVIORAL|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
219623654|NCT00310999|DEVICE|Shikani Optical Stylet|
219623655|NCT03690700|OTHER|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
219623656|NCT03830333|DRUG|Ceftolozane/Tazobactam|Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
219623657|NCT03830333|DRUG|Metronidazole|Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
219623658|NCT03830333|DRUG|Meropenem|Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
219623659|NCT03830333|DRUG|Placebo|Saline by IV infusion every 8 hours for 4 to 14 days.
219623660|NCT03077477|DRUG|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
219623661|NCT03077477|DRUG|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
219623662|NCT00131612|DRUG|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
219623663|NCT03805412|DEVICE|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
219623664|NCT02816346|BIOLOGICAL|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
219623665|NCT00160823|PROCEDURE|Self-administered leaflet|
219623666|NCT04231617|DRUG|glibenclamide|Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
219623667|NCT04231617|DRUG|CGRP infusion|CGRP infusion
219623668|NCT04231617|DRUG|Placebo|placebo
219047589|NCT03909009|DEVICE|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
219047590|NCT04977323|OTHER|TICK-B group|These interventions will use as distraction techniques.
219548705|NCT07140354|DEVICE|cervical transcutaneous spinal cord stimulation|Cervical transcutaneous spinal cord stimulation (tSCS) delivers electrical currents over the cervical spinal cord to modulate neural circuits controlling the upper extremities. This approach has been shown to facilitate motor output, improve hand and arm function, and promote neuroplasticity in individuals with cervical spinal cord injury.
219548706|NCT07139704|BEHAVIORAL|Mindfulness-Based Sexual Counseling (MBSR-BA)|A MBSR-based sexual counseling program applied to women after episiotomy, 2 sessions per week for 4 weeks, 8 sessions in total.
219548707|NCT07138703|BEHAVIORAL|Mobile based intervention program|The participants in this group will be using the mobile application
219548708|NCT00023166|DRUG|PEG-paclitaxel|
219548709|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -0.75mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
219548710|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -1.5mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
219548711|NCT07140328|DRUG|HSK39004 Inhalation Suspension -3mg BID|HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day； And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ；
219548712|NCT07140328|DRUG|HSK39004 Placebo|HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
219548713|NCT05738421|DIAGNOSTIC_TEST|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
219548714|NCT04247243|DEVICE|Rapid testing|Abbott ID NOW Strep A testing
219548715|NCT04247243|DIAGNOSTIC_TEST|Reference testing|Culture-based testing
219548716|NCT06358963|DRUG|Receive 30 mg of Coq10|Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
219548717|NCT06358963|DRUG|Non-Medicare Drugs|and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
219548718|NCT01016340|DRUG|MCS|MCS-5 Softgel 5 mg
219548719|NCT00605150|RADIATION|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
219548720|NCT06361550|OTHER|VENREDI group|Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
219623669|NCT01974518|DRUG|Rituximab and Cyclophosphamide IV|
219623670|NCT05454319|DEVICE|Biofeedback|Home-based biofeedback with medical device
219623671|NCT05488743|BEHAVIORAL|educational intervention|The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
219623672|NCT00824200|BEHAVIORAL|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.
219623673|NCT00824200|DRUG|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
219623674|NCT00824200|DRUG|placebo|tamsulosin placebo
219623675|NCT00824200|BEHAVIORAL|placebo|placebo behavioral intervention
219623676|NCT05164770|DRUG|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
219623677|NCT05164770|DRUG|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
219623678|NCT03695783|OTHER|Online decision aid called IBD&me|Patients randomized to IBD\&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
219623679|NCT03695783|OTHER|Standardized educational material|Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
218936452|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
218936453|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
218936454|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
218936455|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
218936456|NCT04978298|OTHER|Placebo|Placebo
218936457|NCT04978298|DRUG|Rasigiline|Rasigiline
218936458|NCT04978298|DRUG|Phenelzine|Phenelzine
218936459|NCT04978298|DRUG|Ozanimod|Ozanimod
218936460|NCT04495920|DRUG|CGB-S-100|Alcohol and choline geranate
218936461|NCT00272532|DRUG|Thiocolchicoside|
218936462|NCT01662609|PROCEDURE|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
218936463|NCT00271453|DRUG|Durogesic® (fentanyl transdermal drug delivery system)|
218936464|NCT01976091|GENETIC|SRP-9004|Isolated Limb Infusion (ILI)
218936465|NCT03042819|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
218936466|NCT03042819|DRUG|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
218936467|NCT01802996|DRUG|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
218936468|NCT04565639|DEVICE|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
219047591|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
219623680|NCT04107545|BEHAVIORAL|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
219623681|NCT01992627|DEVICE|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
219623682|NCT01769573|BIOLOGICAL|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
219623683|NCT01769573|DRUG|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
219623684|NCT05402189|DRUG|Ketodex, Fentanyl|"The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline."
219623685|NCT03441412|DRUG|Ticagrelor 90mg|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
219623686|NCT03441412|DRUG|Epinephrine|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
219623687|NCT03441412|DRUG|Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
219623688|NCT01886677|BEHAVIORAL|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
219623689|NCT01886677|BEHAVIORAL|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
219623690|NCT02413905|BIOLOGICAL|Stool samples|Stool samples
219623691|NCT06436976|DRUG|LT-002 (Lactobacillus reuteri ATG-F4|The group that will be consuming probiotics for 12 weeks.
219623692|NCT07071441|DRUG|Indomethacin 100 MG|All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure
219623693|NCT07071441|DRUG|Diclofenac 100mg|All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure
219623694|NCT01188031|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
219047592|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
219047593|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
219047594|NCT02365597|DRUG|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
219047595|NCT02365597|DRUG|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
219047596|NCT02365597|DRUG|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
219047597|NCT03409471|DEVICE|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
219047598|NCT03409471|DEVICE|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
219047599|NCT03409471|DIAGNOSTIC_TEST|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
219047600|NCT00262548|DRUG|Rosuvastatin; improvement of lipid profile|
219047601|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
219047602|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
219047603|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
219047604|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
219047605|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
219047606|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
219623695|NCT01188031|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
219623696|NCT06765733|DRUG|Aleeto|"Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection."
219623697|NCT05057130|DRUG|Doxorubicin, Cisplatin, Methotrexate|IV
219623698|NCT05057130|DRUG|Doxorubicin, Cisplatin|IV
219623699|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in clinic
219623700|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in home
219623701|NCT07073794|OTHER|Health Care Delivery|Receive in home cancer treatment with CCBW
219623702|NCT07073794|OTHER|Questionnaire Administration|Ancillary studies
219623703|NCT07071714|DRUG|SHR-8068 Injection|SHR-8068 injection.
219623704|NCT07071714|DRUG|Adebrelimab Injection|Adebrelimab injection.
219623705|NCT07071714|DRUG|Bevacizumab Injection|Bevacizumab injection.
219623706|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
219623707|NCT03878095|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
219623708|NCT03878095|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219623709|NCT03878095|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219623710|NCT03878095|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219623711|NCT03878095|DRUG|Ceralasertib|Given PO
219623712|NCT03878095|PROCEDURE|Computed Tomography|Undergo CT scans
219623713|NCT03878095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
219623714|NCT03878095|DRUG|Olaparib|Given PO
219623715|NCT06560463|DEVICE|Access to Dexcom G7 CGM Data|Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
219623716|NCT04517409|PROCEDURE|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
219623717|NCT04517409|PROCEDURE|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
219623718|NCT05615727|DRUG|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
219623719|NCT05615727|DRUG|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
219623720|NCT05615727|OTHER|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
219623721|NCT02298777|PROCEDURE|- Skin biopsy - Urine sample - Blood sample|
219623722|NCT00809562|DRUG|Placebo|po daily for 10 days
219623723|NCT00809562|DRUG|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
219623724|NCT06564311|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
219623725|NCT06564311|DRUG|Placebo|Placebo
218936469|NCT05500404|DIAGNOSTIC_TEST|Ultrasound measurment of placental thickness|The maximum placental thickness in the lower uterine segment will obtained using trans-abdominal ultrasound scan. For the image to be deemed suitable, a midline sagittal section of the lower uterine segment (with the implanted placenta) and the cervical canal, with the intervening urinary bladder will be required (Bhide et al., 2019). The measurement will be performed by a researcher who will be blinded to the final diagnosis.
218936470|NCT00934362|DRUG|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
218936471|NCT00934362|DRUG|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
218936472|NCT02906176|DRUG|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
218936473|NCT02906176|DRUG|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
218936474|NCT00679796|PROCEDURE|Varicella (chickenpox) lesion sampling|
219623726|NCT05505591|DRUG|Cangrelor|Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
219623727|NCT00435331|DRUG|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
219623728|NCT06447662|DRUG|PF-07934040|panKRAS inhibitor
219623729|NCT06447662|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
219623730|NCT06447662|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
219623731|NCT06447662|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
219623732|NCT06447662|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
219623733|NCT06447662|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
219623734|NCT06447662|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
219623735|NCT06447662|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
219623736|NCT06447662|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor)
219623737|NCT06447662|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
218936475|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
218936476|NCT00006205|DRUG|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
218936477|NCT00006205|DRUG|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
219548721|NCT06361550|OTHER|Health education|Health education on Mediterranean diet
219548722|NCT06024031|DRUG|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
219548723|NCT00325312|DRUG|carbon dioxide, subcutaneous application|
219548724|NCT02760355|DRUG|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
219548725|NCT02760355|DRUG|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
219548726|NCT00107016|DRUG|RAD001, Letrozole 2.5mg|
219548727|NCT00107016|DRUG|Letrozole 2.5mg|
219548728|NCT04067193|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
218936478|NCT00006205|DRUG|Placebo + cognitive behavioral therapy|placebo
218936479|NCT00006205|DRUG|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
218936480|NCT05910190|DRUG|Use of buprenorphine with FAO > 30 OME|Patients will receive buprenorphine with concurrent FAO \>30 OME and be assessed for withdrawal, pain, and other symptoms.
218936481|NCT05910190|BEHAVIORAL|CPM Rx application use|The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
218936482|NCT02415478|OTHER|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
218936483|NCT03527732|DRUG|Albendazole|Monotherapy of albendazole (400 mg)
219548729|NCT06467097|RADIATION|SBRT(Stereotatic Body Radiation Therapy)|Patients will receive treatment for one to two weeks, one to five times per region.
219548730|NCT05356481|DEVICE|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
218936484|NCT03527732|DRUG|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
219548731|NCT03224143|BEHAVIORAL|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
219548732|NCT03224143|BEHAVIORAL|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
219548733|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|Concentration-controlled
219548734|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|1g po bid
219548735|NCT00337493|DRUG|Cyclosporine or tacrolimus|Reduced
219548736|NCT00337493|DRUG|Cyclosporine or tacrolimus|Standard, as prescribed
219548737|NCT01872676|OTHER|Spine manipulation|
219548738|NCT01872676|OTHER|Manipulation sham|
219548739|NCT04852627|BEHAVIORAL|Brisk walking|Walking
219548740|NCT04899934|BEHAVIORAL|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
219548741|NCT04899934|OTHER|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
219548742|NCT06174558|DEVICE|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
219548743|NCT04388358|DRUG|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
219548744|NCT01939990|DRUG|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
219548745|NCT01939990|DRUG|Nebivolol|5 to 10mg per day
219548746|NCT00400452|BEHAVIORAL|wheelchair skills training|
219548747|NCT02779400|DEVICE|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
219548748|NCT00483743|DRUG|TPI 1020|250 mcg/caps 2 caps BID x 42 days
219548749|NCT00483743|DRUG|Budesonide|400mcg mcg capsules- 2 capsules BID
219548750|NCT00483743|DRUG|Placebo|2 caps BID x42 days
219548751|NCT06314633|OTHER|Hair cut|Hair locks and follicles will be cut twice in winter and spring
219548752|NCT06314633|OTHER|Socio-economic questionnaires|Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
219548753|NCT00533156|DEVICE|Vascular access site closure (7F Ensure)|
219548754|NCT05183451|PROCEDURE|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
219548755|NCT05183451|PROCEDURE|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
219548756|NCT04218487|DRUG|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
219548757|NCT04218487|DRUG|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
219548758|NCT04218487|OTHER|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
219548759|NCT01216865|BIOLOGICAL|umbilical cord mesenchymal stem cells|5\*10/7 per ischemic limb
219548760|NCT01216865|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
219548761|NCT02772822|DRUG|SCT400 plus CHOP|
219548762|NCT02772822|DRUG|Rituximab plus CHOP|
219548763|NCT05946239|OTHER|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
219548764|NCT00015925|DRUG|entinostat|
219548765|NCT01030796|BEHAVIORAL|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
219548766|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
219623738|NCT06447662|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
219623739|NCT06447662|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
219623740|NCT06447662|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
219623741|NCT07079826|DEVICE|Sparrow Link (Active tAN)|Participants will receive the Sparrow Link device with active transcutaneous auricular neurostimulation (tAN) in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
219623742|NCT07079826|DEVICE|Sparrow Link (Sham tAN)|Participants will receive the Sparrow Link device with sham (non-active) stimulation in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
219623743|NCT06830629|DRUG|MZE829|Capsules for oral administration
219623744|NCT06889168|DRUG|Imatimib Mesylate|Participants will take Imatinib mesylate (imatinib), an FDA approved drug for leukemia, orally 400 mg (twice daily)
219623745|NCT06889168|DRUG|Placebo|Placebo will be administered in the same dosage and manner as the study drug. The placebo looks like the study drug but contains no active ingredients.
219623746|NCT07122986|DRUG|E coli vaccine 1 Dose A|Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
219623747|NCT07122986|DRUG|E coli vaccine 1 Dose B|Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
219623748|NCT07122986|DRUG|E coli vaccine 2|Candidate E coli vaccine 2, administered according to a 0, 6-month interval
219623749|NCT07122986|DRUG|E coli vaccine 3|Candidate E coli vaccine 3, administered according to a 0, 6-month interval
219623750|NCT07122986|DRUG|E coli Vaccine 4 Dose A|Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
219623751|NCT07122986|DRUG|E coli Vaccine 4 Dose B|Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
218936485|NCT05241548|PROCEDURE|BMAC on PCL Scaffold|Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
218936486|NCT00509613|DRUG|Sorafenib|
218936487|NCT00509613|DRUG|Sirolimus|
218936488|NCT02280408|OTHER|Placebo|Normal saline placebo.
218936489|NCT02280408|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
218936490|NCT06134024|PROCEDURE|Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections|During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
218936491|NCT06134024|PROCEDURE|Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only|During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
218936492|NCT00629369|DEVICE|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
218936493|NCT01092117|DEVICE|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
218936494|NCT04482452|PROCEDURE|Colonoscopy|Diagnostic colonoscopy will be performed
219623752|NCT07122986|DRUG|E coli Vaccine 4 Dose C|Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
219623753|NCT07122986|DRUG|E coli Vaccine 5 Dose A|Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
219623754|NCT07122986|DRUG|E coli Vaccine 5 Dose B|Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
219623755|NCT07122986|DRUG|Placebo|Placebo administered according to a 0, 6-month interval
219623756|NCT07085507|DRUG|VT7208|a small synthetic molecule capsule, oral
219623757|NCT07085507|DRUG|Placebo|capsule, oral
219623758|NCT06902389|BIOLOGICAL|Super Hi-TCR-T cells|"Intravenous infusion of 3.0×10⁶ cells/kg of Super Hi-TCR-T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP.~The expression levels of Nectin4, NKG2DL, TROP2, B7H3, GPC3 and FAP were detected by immunohistochemistry. Meanwhile, 20ml peripheral blood was extracted to evaluate the quality of T cells. Patients with positive expression rates of at least 2 targets (excluding FAP) \>10% and qualified T cell quality could be considered for inclusion.~Peripheral blood lymphocytes were collected and Hi-TCR-T cells targeting three targets (including FAP) were prepared. After pretreatment with fludarabine + cyclophosphamide chemotherapy (FC regimen), the prepared Hi-TCR-T cells were transfused back, in which the dose of Hi-TCR-T cells at each target was 3.0x106 cells/kg body weight (the dose was the extended therapeutic dose obtained in the previous clinical trial), and the drug was administered by peripheral intravenous infusion."
219623759|NCT05467501|DEVICE|Theraputic ultrasound|Therapeutic ultrasound
219623760|NCT05044117|DRUG|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
219623761|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* 2 cervical takings~* 2 sampling of blood before and after the total hysterectomy"
219623762|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the cervical conization~* 2 sampling of blood before and after the intervention"
218936495|NCT02827929|BEHAVIORAL|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
219047607|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
219623763|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation~* 2 sampling of blood before and after the intervention"
219623764|NCT01073085|BEHAVIORAL|"Web-based automated coaching by e-mails"|
219623765|NCT01073085|BEHAVIORAL|Self-help guide|
219623766|NCT05412953|OTHER|Questionnaire Administration|Complete questionnaire
219623767|NCT05412953|BEHAVIORAL|Tonation Breathing Technique|Participate in tonation breathing techniques
219623768|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
219623769|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
219623770|NCT07080476|OTHER|Decongestive lymphatic therapy|"Decongestive lymphatic therapy (DLT) is the current standard of care for lymphoedema management as recommended by the International Society of Lymphology (ISL). It consists of manual lymphatic drainage (MLD), skin care (education), compression therapy using a properly fitted compression bra, and supervised exercise therapy. Sessions last 45 minutes and are delivered two times per week for a period of four weeks.~On non-treatment days, participants are encouraged to perform home exercises and document self-care practices in a diary."
219623771|NCT07080476|OTHER|Kinesio tape|"Kinesio tape will be applied by trained physiotherapists twice a week. The kinesio tape remains in place for three consecutive days and is replaced once a week. After six days of continuous use, patients will have one rest day without kinesio tape to allow the skin to recover. This cycle will be repeated for the duration of the intervention period.~The kinesio tape will be applied using a standardised fan-cut technique to ensure consistent application across all study sites. Tape length will be individually tailored. Each application will consist of three fan-shaped strips:~1. Breast: Anchored at the ipsilateral axilla and directed vertically over the affected breast.~2. Ventral anastomosis: Originating from the contralateral axilla and applied horizontally over the chest.~3. Dorsal anastomosis: Also anchored at the healthy axilla and applied horizontally over the back.~Patients will be instructed in safe self-application for potential use during follow-up."
219623772|NCT07080476|OTHER|Compression bra (sub-study)|In a subset of participants, different types of commercially available compression bras are tested for pressure and comfort. Each bra is worn for a period of one week without compromising the outcomes of the primary objective. The pressure exerted by the garment is measured using the PicoPress device on the first day of wear. The wearing comfort is evaluated using an adjusted version of the ICC compression questionnaire after one week of wearing the compression bra.
219623773|NCT04545112|DEVICE|CABG|"Elective, coronary artery bypass (CABG) surgery. Each study subject will receive an left internal mammary artery (LIMA) conduit to the left anterior descending (LAD) coronary artery. Patients with uncompromised saphenous veins will receive a SVG to the LCX or RCA and the XABG to the remaining territory. Patients with compromised arterial and/or saphenous veins, (i.e., no-vein patients), will receive one XABG to the LCX or RCA to achieve incomplete revascularization."
219623774|NCT06850662|OTHER|Backward walking observation training|Backward treadmill training after watching a video of backward walking.
219623775|NCT06850662|OTHER|Non-motor observational backward walking training|Backward treadmill training after watching a video of landscape without any movements.
219623777|NCT06775886|OTHER|myPACE+ algorithm|myPACE+ algorithm with mono-fractional exponent
219623778|NCT04117074|DRUG|Liposomal bupivacaine|Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
219623779|NCT04117074|OTHER|Thoracic epidural analgesia (bupivacaine)|Perioperative bupivacaine based thoracic epidural placed preoperatively.
219623780|NCT07087587|DEVICE|CPAP|CPAP will be randomized 2 weeks on 2 weeks off for 12 weeks total
219623781|NCT02321033|DIETARY_SUPPLEMENT|soft drinks|soft drinks with palatinose and maltodextrin
219623782|NCT04521881|DRUG|Tranexamic Acid 500 MG|given once as an intramuscular injection
219047608|NCT05244629|DEVICE|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
219047609|NCT00000781|DRUG|Nevirapine|
219047610|NCT00000781|DRUG|Zidovudine|
219047611|NCT00000781|DRUG|Zalcitabine|
219047612|NCT00000781|DRUG|Didanosine|
219047613|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
219047614|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
219047615|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
219047616|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
219206305|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
219206306|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
219623783|NCT02051582|PROCEDURE|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
219623784|NCT02051582|PROCEDURE|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
219623785|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
219623786|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
219623787|NCT04092270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623788|NCT04092270|PROCEDURE|Computed Tomography|Undergo CT scan
219623789|NCT04092270|PROCEDURE|Echocardiography Test|Undergo ECHO
219623790|NCT04092270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623791|NCT04092270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219623792|NCT04092270|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219623793|NCT04092270|DRUG|Peposertib|Given PO
219623794|NCT04751370|PROCEDURE|Computed Tomography|Undergo CT
219623795|NCT04751370|BIOLOGICAL|Ipilimumab|Given IV
219623796|NCT04751370|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623797|NCT04751370|BIOLOGICAL|Nivolumab|Given IV
219623798|NCT04751370|RADIATION|Radiation Therapy|Undergo short-course radiation therapy
219206307|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
219623799|NCT04751370|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219623800|NCT04751370|PROCEDURE|Total Mesorectal Excision|Undergo TME
219623801|NCT06349512|PROCEDURE|68Ga-FAPI-46 PET/CT imaging|The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
219623802|NCT07091357|DRUG|SHR-1819 Injection|SHR-1819 injection.
219623803|NCT07091357|DRUG|SHR-1819 Injection Placebo|SHR-1819 injection placebo.
219623804|NCT06193603|OTHER|True dry cupping therapy|In the intervention group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. The therapist will perform 5 minutes of dry cupping therapy, moving the cups up and down using both hands. Participants will also receive routine physiotherapy, including a 20-minute session of transcutaneous electrical stimulation with a frequency of 100 pulses per second and a duration of 60 microseconds. The stimulation intensity will be adjusted for sensory stimulus. Stabilization exercises like abdominal hollowing and bridging will be included. The treatment will consist of 10 sessions, three times per week.
218936496|NCT01081964|DRUG|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
218936497|NCT01081964|DRUG|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
218936498|NCT01081964|DRUG|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
218936499|NCT03072004|DEVICE|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
218936500|NCT03072004|DEVICE|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
218936501|NCT03710083|DEVICE|Guardian™ Sensor (3)|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
218936502|NCT04155580|DRUG|ASTX660|Capsule for oral administration
218936503|NCT04155580|DRUG|ASTX727|Tablet for oral administration
218936504|NCT03993106|DRUG|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
218936505|NCT05300763|DEVICE|senofilcon A prototype|Test
218936506|NCT05300763|DEVICE|Dailies Total 1|Control
218936507|NCT02170415|DRUG|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
218936508|NCT02170415|OTHER|Pain education|Participant will receive a pain education leaflet
218936509|NCT02170415|BEHAVIORAL|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
218936510|NCT02170415|PROCEDURE|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
219623805|NCT06193603|OTHER|Sham cupping therapy|In the control group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. However, unlike the intervention group, the cups in the control group will not be moved and will remain stationary for 5 minutes. The cups will have small holes (\<2mm in diameter) to release negative pressure quickly. Double-sided tapes will be used to secure the cups and maintain contact with the skin.
219623806|NCT05514873|DRUG|zilucoplan (RA101495)|Subcutaneous injection
219623807|NCT06193902|BIOLOGICAL|LEU011|Immunotherapy
219623808|NCT06908681|PROCEDURE|Bilateral Intertransverse Process Block (ITPB)|A bilateral intertransverse process block (ITPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine per side prior to coronary artery bypass grafting. The block targets the dorsal rami of thoracic spinal nerves to provide postoperative analgesia.
219623809|NCT06908681|PROCEDURE|placebo saline injection|A bilateral placebo injection (20 mL of 0.9% saline per side) will be administered at the same anatomical site under ultrasound guidance prior to coronary artery bypass grafting, mimicking the ITPB procedure without active drug.
219623810|NCT03625037|BIOLOGICAL|Epcoritamab|Administered as specified in the treatment arm.
219623811|NCT06098144|DRUG|Nicorette|"Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
219623812|NCT06098144|BEHAVIORAL|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
219623813|NCT06098144|BEHAVIORAL|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
219623814|NCT06098144|BEHAVIORAL|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
219623815|NCT05425927|DEVICE|SyMRI 15 (3D)|Neurological MRI image collection
219623816|NCT07098351|DRUG|Remitch|Nalfurafine 2.5μg daily for 2 weeks. Afterwards, the dose can be increased to 5μg daily if necessary (maximum dose not exceeding 5μg daily), continued for another 2 weeks.
219623817|NCT07094984|OTHER|Fecal microbiota transplantation (FMT)|FMT administered after antibiotic pre-treatment and bowel cleansing. Delivered either in capsule form or via colonoscopy to restore healthy gut microbiota and support decolonization of ARB.
219623818|NCT07094984|DIETARY_SUPPLEMENT|Probiotic Therapy|Oral administration of a high-dose multistrain probiotic containing Lactobacillus, Bifidobacterium, and Streptococcus strains for 20 days following bowel cleansing.
219623819|NCT07094984|OTHER|Gut Microbiota Boosting Diet|A structured 38-day diet designed to promote eubiosis and support spontaneous ARB decolonization. Meals are tailored and delivered to patients based on clinical nutrition protocols.
219623820|NCT05636267|DRUG|AK119|AK119 IV every 3 weeks.
219623821|NCT05636267|DRUG|AK112|AK112 IV every 3 weeks.
219623822|NCT05636267|DRUG|Pemetrexed|Pemetrexed IV every 3 weeks.
219623823|NCT05636267|DRUG|Carboplatin|Carboplatin IV every 3 weeks.
219623824|NCT07097818|BEHAVIORAL|T1D team, structured education, peer support , and diabetes technologies|Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
219623825|NCT07097818|BEHAVIORAL|Routine Management|Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.
219623826|NCT03488082|BEHAVIORAL|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
219623827|NCT04982848|DRUG|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
218936511|NCT02170415|OTHER|Daily visits from pain team whilst in hospital|
219623828|NCT07103356|BEHAVIORAL|Water Pitcher Filtration System|Table-top water pitcher filtration system
219623829|NCT07106580|OTHER|lyophilized FMT capsules|A total of 18 capsules made from the initial 80 g of donor stool given through 3 days (three capsules twice daily)
219623830|NCT07106580|OTHER|Placebo capsules|18 capsules of identical appearance and weight given in the same way as FMT capsules
219623831|NCT06873659|DRUG|SON-DP|Solution for IV administration
219623832|NCT04708054|DRUG|Busulfan|Given IV
219623833|NCT04708054|DRUG|Cladribine|Given IV
219623834|NCT04708054|DRUG|Fludarabine Phosphate|Given IV
219623835|NCT04708054|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplantation
219623836|NCT04708054|DRUG|Thiotepa|Given IV
219623837|NCT04708054|DRUG|Venetoclax|Given PO
219623838|NCT07112274|DRUG|Empagliflozin 10 MG|Treatment group will receive empagliflozin 10 mg tablet once daily
219623839|NCT07112274|OTHER|Placebo Tablet|control group will receive placebo tablet.
218936512|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
218936513|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
218936514|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
218936515|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
219623840|NCT07111091|OTHER|GAIT AND BALANCE EVALUATION|"In our study, participants' walking assessments were made with GAITRite electronic walking path (CIR System INC. Clifton. NJ. USA.).~In the postural balance assessments of the participants, the Bertec Balance Check Screener™ BP5050 20x20 inch (Bertec Comporation Columbus, OH, USA) force platform was used. The Bertec force platform is a three-component balance platform that is based on objectively measuring instantaneous changes in vertical force and center of pressure (CoP). Bertec was designed to evaluate the ability to maintain balance while standing.~The assessments were made in all participants without an orthosis, with unilateral AFO and with bilateral AFO. In our study, participants were given a 10-minute rest period between assessments."
219623841|NCT07112820|OTHER|perfusion ultrasound|"During the examination, the power of the probe will be increased in order to assess myocardial perfusion.~The contrast agent bubbles are destroyed by applying a 'flash', i.e. a temporary increase in the power of the ultrasound beam. Systole after systole, on a recorded loop, the filling velocity of the myocardium, which depends on myocardial blood flow, is analysed. The assessment of perfusion is visual and qualitative."
219623842|NCT07111520|DRUG|BNT326|intravenous (IV) infusion
219623843|NCT07111520|DRUG|BNT327|IV infusion
219623844|NCT07111520|DRUG|Pembrolizumab|IV infusion
219623845|NCT07111520|DRUG|SoC|IV infusion. Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin). Chemotherapy will be selected according to the indication.
219623846|NCT07112898|PROCEDURE|Platelet-Rich Plasma (PRP)|Autologous PRP (approximately 4-6 mL) will be prepared using a double centrifugation technique and activated with 10% calcium gluconate. It will be administered by injecting 0.1-0.2 mL/cm² subdermally into the recipient bed and intradermally into the graft prior to placement.
219623847|NCT07112898|PROCEDURE|Standard Skin Grafting|Grafts will be placed on a clean, vascularized wound bed, secured with nonabsorbable sutures, and covered with standard postoperative dressings. No PRP will be applied.
219623848|NCT07111208|BEHAVIORAL|Green Space Activity Group - Daily Physical Activity|Participants in this group will be instructed to take a brisk 30-minute walk each day in designated urban green spaces (e.g., parks, forested areas). Physical activity will be monitored using Fitbit Alta wristband sensors to track duration, intensity, and steps.
219623849|NCT07111208|BEHAVIORAL|Mediterranean Diet Group - Dietary Intervention|Participants in this group will follow the principles of the Mediterranean diet, including increased consumption of fruits, vegetables, whole grains, legumes, nuts, and olive oil, and reduced intake of red meat and processed foods. They will receive dietary guidance and support for meal planning throughout the 7-day intervention.
219623850|NCT07113145|DRUG|Oral intake of medication|● Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered).
219623851|NCT07113145|DRUG|Oral intake of medication|● Group B: Received Silodosin 4mg, administered orally once daily.
219623852|NCT07113145|DRUG|Oral intake of medication|● Group C: Received Dapoxetine hydrochloride 30 mg, taken 2 hours before intercourse, on-demand, minimum of 8 times/month for 3 months.
219623853|NCT07113145|DRUG|Oral intake of medication|● Group D: Received Dapoxetine hydrochloride 30 mg, administered daily.
219623854|NCT07112703|OTHER|Incentive spirometer exercises|The study group was instructed to use an incentive spirometer, which should be held upright, sealed around the mouthpiece, and taken slowly and deep breaths. They will be motivated to achieve a preset volume through visual feedback. The child will hold their breath for 2-3 seconds at full inspiration and, after each set of 10 breaths, cough to clear mucus from the lungs. The exercise duration is 15 minutes.
218936516|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
218936517|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
219047617|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
219047618|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
219047619|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
219047620|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
219623855|NCT07112703|OTHER|Diaphragmatic breathing|The child will lie on their back, place one hand on their belly and one on their chest, and use a balloon or doll to fill both belly and chest up like a balloon. Inhale deeply, let the hands on the belly rise, then exhale slowly, making the belly down. The exercise will last for 10 minutes.
219623856|NCT07112703|OTHER|Pursed lip breathing:|Sit in a seated position with crossed legs or knees. Inhale slowly through the nose for three seconds, then exhale through pursed lips, similar to blowing out birthday candles.
218936518|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
218936519|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
218936520|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
218936521|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
218936522|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
218936523|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
218936524|NCT05008406|OTHER|Satisfaction|Students Satisfaction
218936525|NCT04344561|OTHER|Postural Positioning|Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
218936526|NCT01914341|OTHER|Music|Live music played on the pentatonically tuned children's harp
219047621|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
219047622|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
219047623|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
219047624|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
219623857|NCT07112703|OTHER|Costal breathing exercises|The study involves conducting Costal breathing exercises for children. The exercises involve placing hands on the apical region of the lung, turning the child's head, relaxing the shoulder and neck muscles, taking a deep breath, pushing the hand out, holding, and exhaling slowly. The hands provide pressure and resistance after initiation of inspiration, and the children rest for 2 minutes between exercises. The duration of the exercise varies between the control and study groups.
219623858|NCT07113470|DEVICE|The Salvia PRIMUS implantable neurostimulator System|The Salvia PRIMUS implantable neurostimulator System is designed to provide subcutaneous neurostimulation to the V1 branches of the Trigeminal nerves (supra-orbital and supra-trochlear nerves) and the branches of the Greater Occipital Nerves. It is intended to modulate headaches' neural networks by utilizing mild electrical pulses. There are 2 stimulation waveforms options: the Salvia burst waveform providing paresthesia-free stimulation and Tonic waveform, providing paresthesia-provoking stimulation. The PRIMUS System comprises a 25 cm (forehead) and a 17cm (back of the head) subcutaneous implant, a MySalvia device, a programmer, and surgical tooling.
219623859|NCT07112638|OTHER|immersive technology-based intergenerational intervention to improve movement patterns in older adults|Intervention group The intervention consists of 60-minute supervised sessions conducted once per week for 12 weeks. Each session begins with a 10-minute warm-up, followed by 15 minutes of strength training. Four structured session types (A, B, C, and D) were designed and are being rotated throughout the 12-week period. These sessions incorporate upper and lower body exercises performed using body weight and/or resistance bands, adapted to each participant's physical function.
219623860|NCT07111689|BEHAVIORAL|Conventional Occupational Therapy Interventiın|1-2. Week: Occupation-based interventions for visual skills 3-6. Week: Social Skills Training 7-8. Week: Interventions for participation problems in ADLs
219623861|NCT07111689|BEHAVIORAL|Virtual Reality İntervention|In this study, the Xbox 360 gaming console and Kinect sensor were utilized for the virtual reality (VR) intervention. The Xbox 360 functions as an interactive gaming platform, while the Kinect sensor is a motion-detection device that captures users' positions and movements through an integrated camera and sensors. The selection of games for the VR intervention was conducted in collaboration with experts from various disciplines. The evaluation process considered the cognitive and functional demands required for successful gameplay, the potential skills each game could enhance, and the overall therapeutic purpose of the selected games. Following an independent assessment of each game, nine games were identified as suitable for the intervention. Given that all selected games shared similar functional requirements, participants were provided access to the full set of games to optimize engagement and motivation.
219623862|NCT07113184|DEVICE|dual sr|Dual Stentriever
219623863|NCT07113184|DEVICE|single sr|Single Stentriever
219623864|NCT07110883|DRUG|SYS6023|SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
219623865|NCT07113197|RADIATION|conventional angiography|"* Peak systolic velocity (PSV)~* Velocity ratios~* Segment visualization quality~* Degree of stenosis"
219623866|NCT07113405|DIETARY_SUPPLEMENT|Protein and Polyphenols|Participants in this group will receive 10 times a recovery drink containing protein and polyphenols.
219623867|NCT07113405|DIETARY_SUPPLEMENT|Protein|Participants of this group will receive ten times a recovery drink containing only protein without polyphenols.
219623868|NCT07113405|DIETARY_SUPPLEMENT|Placebo|Participants of this group will receive 10 times a placebo containing no protein nor polyphenols.
219623869|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
218936527|NCT03563183|OTHER|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
219623870|NCT07110909|OTHER|HPV Education|HPV Education
219623871|NCT07112833|DRUG|Induction stage：Adebrelimab+TC；Treatment stage: TC/PF+ radiation therapy；Maintenance stage: Adebrelimab|"Induction stage：Adebrelimab+TC： Adebrelimab : 1200mg d1, iv, q3w ； TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv，carboplatin AUC=5, d1, iv, q3w，2 cycles.~Treatment stage: TC/PF+ radiation therapy:~PET-CT responders (SUV (PETr) reduction ≥35%)：~TC/PF+ radiation therapy:~TC : paclitaxel 50mg/m2, nab-paclitaxel paclitaxel 60mg/m2, d1, iv; carboplatin AUC=2, d1, iv, qw，5 cycles.~PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.~Radiation therapy: 50.4Gy-60Gy/28-33f.~PET-CT non-responders (SUV (PETr) reduction \<35%)：(switch to a different chemotherapy drug which not used during the earlier induction phase)~PF/TC+ radiation therapy:~dose same as above.~Maintenance stage: Adebrelimab:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs（Up to one year）."
219623872|NCT07111468|DRUG|YHP2401|Total 7 days of treatment and The daily dose is tid.(YHP2401 + Placebo of YHR2402 + Placebo of YHR2403)
219047625|NCT05998109|DEVICE|PheCheck™|"Quantitative, single-use, rapid test Intended for home-based self-testing and monitoring of PKU.~1 fingerstick specimen collected at each study visit"
219047626|NCT05998109|DIAGNOSTIC_TEST|HPLC Amino Acid Analyzer|1 venous specimen collected at each study visit
218936528|NCT02296983|BIOLOGICAL|VSV-ZEBOV|VSV-ZEBOV
218936529|NCT06204835|DRUG|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
218936530|NCT03801031|DRUG|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
218936531|NCT03801031|DRUG|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
219623873|NCT07111468|DRUG|YHR2402|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + YHR2402 + Placebo of YHR2403)
219623874|NCT07111468|DRUG|YHR2403|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + Placebo of YHR2402 + YHR2403)
219623875|NCT07111988|DRUG|Valbenazine|Selective vesicular monoamine transporter 2 (VMAT2) inhibitor
219623876|NCT07111988|DRUG|Placebo|Pill that contains no medicine
219623877|NCT07106970|PROCEDURE|Linear ablation|Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.
219623878|NCT07106970|PROCEDURE|PVI alone|Undergo PVI with the study device
219623879|NCT07109518|BIOLOGICAL|uCD7 CART|Subjects screened to meet the requirements for uCD7 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine (Flu) and cyclophosphamide (CTX) based preconditioning should be performed within 1 week prior to uCD7 CART infusion: Flu 30mg/m2 ×3 days; CTX 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and etoposide. Infusion of uCD7 CART must be performed 24 hours after completion of chemotherapy preconditioning. uCD7 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
219623880|NCT07116915|DRUG|HRS-9821 Powder for Inhalation.|HRS-9821 Powder for Inhalation.
219623881|NCT07116915|DRUG|HRS-9821 Powder for Inhalation placebo|HRS-9821 Powder for Inhalation placebo
218936532|NCT06159218|DEVICE|CEST - coiled oesophageal string test|All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
219623882|NCT07116915|DRUG|Moxifloxacin Hydrochloride Tablets|Moxifloxacin Hydrochloride Tablets
219623883|NCT06925737|DRUG|Ifinatamab deruxtecan|Administered via intravenous (IV) infusion every 3 weeks (q3W) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
219623884|NCT06925737|DRUG|Docetaxel|Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
219623885|NCT06925737|DRUG|Prednisone|Oral tablet administered once per day or per approved product label
219623886|NCT06931327|DRUG|Test Drug|AJU-C711
219623887|NCT06931327|DRUG|Reference Drug|C711R
219623888|NCT03923647|DEVICE|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
219623889|NCT07140289|DIAGNOSTIC_TEST|Ultrasound of gastric contents|An ultrasound examination of the abdomen to observe and measure gastric contents
219623890|NCT07142356|DRUG|RTN-001|A potent and selective PDE5 inhibitor.
219623891|NCT07142356|DRUG|Matching placebo control|The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.
219047627|NCT05998109|DIAGNOSTIC_TEST|Dried Blood Spot Cards|capillary blood specimen collected at each study visit
219047628|NCT06022939|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Given IV
218936533|NCT05068882|DIETARY_SUPPLEMENT|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
218936534|NCT05068882|DIETARY_SUPPLEMENT|High-protein nutrition|Oral nutrition with high-protein content
218936535|NCT05068882|DIETARY_SUPPLEMENT|Standard nutrition|Oral nutrition with standard ingredients
218936536|NCT05865041|DRUG|Farudodstat|Farudodstat tablets administered orally
218936537|NCT05865041|DRUG|Placebo|Placebo tablets administered orally
219047629|NCT06022939|PROCEDURE|Biopsy|Undergo fat pad biopsy
219047630|NCT06022939|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
219047631|NCT06022939|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219047632|NCT06022939|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219047633|NCT06022939|DRUG|Bortezomib|Given SC
219047634|NCT06022939|PROCEDURE|Computed Tomography|Undergo CT scan
219047635|NCT06022939|DRUG|Cyclophosphamide|Given PO or IV
219047636|NCT06022939|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
219047637|NCT06022939|DRUG|Dexamethasone|Given PO or IV
219047638|NCT06022939|PROCEDURE|Echocardiography|Undergo echocardiography
219047639|NCT06022939|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219047640|NCT06022939|DRUG|Melphalan|Given IV
219047641|NCT06022939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219047642|NCT06022939|PROCEDURE|Stem Cell Isolation|Undergo stem cell collection
219047643|NCT06022939|OTHER|Survey Administration|Ancillary study
219623892|NCT07142369|PROCEDURE|Synovial Fluid withdrawal at the preoperative clinic visit|Synovial Fluid withdrawal at the preoperative clinic visit
219623893|NCT07142369|PROCEDURE|Platelet-Rich Plasma (PRP) preparation and injection|Platelet-Rich Plasma (PRP) preparation and injection
219623894|NCT07142369|PROCEDURE|Synovial fluid withdrawal at the time of surgery|Synovial fluid withdrawal at the time of surgery
219623895|NCT07142369|PROCEDURE|3mL synovial fluid withdrawn at the preoperative visit|3mL synovial fluid withdrawn at the preoperative visit
219623896|NCT07142148|DIAGNOSTIC_TEST|CDAT - phase 1|"The English version of the Celiac Dietary Adherence Test (CDAT) will be translated into Polish using the forward-backwards-forward translation model, with the author's consent (already obtained by the applicants). The Polish translation will be performed by two native bilingual speakers of Polish and English. Both translations will be compared and standardised. The Polish version will then be translated into English by two native bilingual speakers of English who are unfamiliar with the original English version. The translation and original will be compared to clarify discrepancies and ensure conceptual equivalence between the versions. The agreed-upon translation will be culturally adapted, if necessary. The items will be reviewed by five experts, and an I-CVI of at least 0.78 will be considered satisfactory content validity."
219623897|NCT07142148|OTHER|CDAT - phase 2|"In the next step, 10 coeliac disease (CD) patients aged 10 years and older and 10 caregivers/parents of CD patients under 10 years of age will be asked to rate the clarity of each statement on a Likert scale \[1 = unclear to 5 = very clear\]. Questions with a mean score \<4.0 will be rephrased and re-evaluated.~Internal consistency analysis using Cronbach's alpha and the mean inter-item correlation (AIC) will be used to assess reliability. Convergent validity will be assessed by comparing scale scores with serological marker levels. Confirmatory factor analysis (CFA) will be conducted, taking into account the SRMR fit index."
218936538|NCT03679520|OTHER|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care"
218936539|NCT03679520|OTHER|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood"
219623898|NCT07141992|OTHER|Active Neural Mobilzations|Participants in this group will receive active neural mobilization in the form of neural flossing techniques. These involve controlled, repeated movements performed actively by the patient to mobilize peripheral nerves without placing them under excessive tension. The goal is to restore neural mobility, reduce mechanosensitivity, and relieve neuropathic symptoms such as burning pain.
219623899|NCT07141992|OTHER|Passive Neural Mobilzations|Participants in this group will receive passive neural mobilization using neural tensioning techniques. These techniques involve therapist-applied passive limb movements that place a controlled tensile load on the neural structures. The objective is to improve neural gliding, reduce nerve compression, and decrease neuropathic pain, particularly in cases of restricted neural tissue mobility.
219623900|NCT06930300|OTHER|Hypertonic 3% saline|Participants receive 10 ml/kg body weight of 3% saline infused over 1 hour. The aim is to stimulate copeptin release.
219623901|NCT06930300|OTHER|Water|Participants ingest 20 ml/kg water over 1h. The aim is to suppress copeptin release.
219623902|NCT06942143|BIOLOGICAL|Super1 TCR-T|All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.
219623903|NCT06940349|DRUG|Palbociclib|Palbociclib and Sunitinib
219623904|NCT06940349|DRUG|Sunitinib|Palbociclib and Sunitinib
219623905|NCT02496663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219623906|NCT02496663|PROCEDURE|Computed Tomography|Undergo CT scan
219623907|NCT02496663|PROCEDURE|Echocardiography Test|Undergo ECHO
218936540|NCT01419288|OTHER|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
219623908|NCT02496663|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219623909|NCT02496663|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219623910|NCT02496663|BIOLOGICAL|Necitumumab|Given IV
219623911|NCT02496663|DRUG|Osimertinib|Given PO
218936541|NCT02880436|OTHER|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
218936542|NCT00922012|DEVICE|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
219047644|NCT06425562|OTHER|Full lung function|This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
219047645|NCT06425562|OTHER|Multiple breath nitrogen washout|Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
219047646|NCT06425562|OTHER|Impulse oscillometry|Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
219047647|NCT01552226|DEVICE|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
219047648|NCT01552226|DEVICE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
218936543|NCT01409811|DRUG|zoledronic acid|Given IV
218936544|NCT01409811|OTHER|laboratory biomarker analysis|Correlative studies
218936545|NCT01409811|PROCEDURE|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
219047649|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
219047650|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
219206308|NCT00968149|DRUG|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
219206309|NCT00968149|DRUG|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
219623912|NCT06941025|OTHER|Not applicable- observational study|Not applicable - observational study
219623913|NCT07141147|RADIATION|Radiation|"1. Technique:Linear accelerator with volumetric modulated arc therapy for irradiation.~2. Target Volume Delineation (Two-phase irradiation):~Clinical Target Volume 1 (CTV1):Encompasses tumor bed (preoperative MRI/CT-defined ACC extent) + regional lymphatics (ipsilateral para-aortic nodes).~Clinical Target Volume 2 (CTV2):Tumor bed only (preoperative MRI/CT-defined ACC extent).~Planning Target Volume (PTV):PTV1: CTV1 + 0.6 cm margin.PTV2: CTV2 + 0.6 cm margin.~4.Organs at Risk (OARs):Stomach, liver, bilateral kidneys, pancreas, spinal cord, and bowel/colon within radiation fields.~5.Prescription Dose: Phase 1: PTV1 → 45 Gy in 25 fractions (1.8 Gy/fraction), 5 fractions/week. Phase 2: PTV2 → 10 Gy in 5 fractions (2.0 Gy/fraction), 5 fractions/week."
219623914|NCT07141472|DIETARY_SUPPLEMENT|GB|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
219623915|NCT07141472|DIETARY_SUPPLEMENT|Placebo|Placebo is a product that resemble active GB but does not contain any of the active ingredients
219623916|NCT07148791|BIOLOGICAL|Anti-BCMA-CD19 CAR-T cells|Anti-BCMA-CD19 CAR-T cell injection is an autologous, dual-target chimeric antigen receptor T-cell therapy designed to target CD19 and BCMA antigens. Peripheral blood mononuclear cells (PBMCs) are collected from each participant and modified ex vivo using lentiviral transduction to express the CAR construct. Lymphodepletion with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) is administered for 3 days (Day -5 to Day -3). The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's clinical condition. CAR-T cells are infused intravenously on Day 0 at one of three dose levels (1x10\^6, 2x10\^6, or 3x10\^6 CAR+ T cells/kg, ±20%). This product is being investigated in patients with relapsed or refractory IgG4-related disease (IgG4-RD) to assess safety and preliminary efficacy.
219623917|NCT02702128|DRUG|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
219623918|NCT02702128|DRUG|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
219623919|NCT06952348|BEHAVIORAL|Stair and brisk walking combined|See arms.
219623920|NCT06952348|BEHAVIORAL|Brisk walking|See arms.
218936546|NCT01942733|DRUG|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
219623921|NCT06952348|BEHAVIORAL|Standard care|See arms.
219623922|NCT07142031|OTHER|BioHPP|Onlay restorations fabricated from BioHPP polymer will be applied to 20 patients. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
218936547|NCT04506099|DEVICE|TINS Active protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
219623923|NCT07142031|OTHER|Lithium Disilicate|Onlay restorations fabricated from lithium disilicate will be applied to 20 patients and will serve as the control group for comparison with the BioHPP onlay restorations. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
219623924|NCT07143630|DEVICE|Neuromuscular Electrical Stimulation|NMES will be applied to the abdominal muscles using a multichannel stimulator. Each session will last approximately 20 minutes, administered 5 times per week for a total of 15 sessions, in addition to core stabilization exercise program performed with the same frequency.
219623925|NCT07143630|BEHAVIORAL|Core Stabilization Exercises|Participants will perform a structured core stabilization exercise program. The program will be administered 5 times per week for a total of 15 sessions.
219047651|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
219047652|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
219047653|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
219047654|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
219047655|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
219047656|NCT05812053|PROCEDURE|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
219623926|NCT07142278|BIOLOGICAL|DUVAX 200 µg|Intramuscular injection of 200 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
219623927|NCT07142278|BIOLOGICAL|DUVAX 400 µg|Intramuscular injection of 400 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
219623928|NCT07142278|BIOLOGICAL|Placebo (Adjuvant only)|Intramuscular injection of placebo consisting of Adjuvant formulation in phosphate-buffered saline without active antigen, administered at Weeks 0, 4, and 22
219623929|NCT07149246|OTHER|Nutrition intervention|Frequent follow-up from a dietitian during ICU and hospital stay, and after discharge, up to 6 months after ICU admission.
219623930|NCT07091916|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
219047657|NCT05812053|RADIATION|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 12 months follow-up periods.
219047658|NCT05091528|DRUG|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
219047659|NCT05091528|DRUG|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
219047660|NCT05091528|DRUG|tucatinib|300 mg by mouth (PO) twice daily (BID)
219047661|NCT05091528|DRUG|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
219047662|NCT05091528|DRUG|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
219047663|NCT05091528|DRUG|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
219047664|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
219047665|NCT01026051|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
219047666|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
219047667|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
219047668|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
219047669|NCT03023488|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
219047670|NCT03023488|DEVICE|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
219623931|NCT07101250|DRUG|Acetazolamide 500 MG Extended Release Oral Capsule|Active Drug
219623932|NCT07101250|DRUG|Placebo|Inactive Drug
219047671|NCT03023488|DEVICE|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
219047672|NCT03640676|DEVICE|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
219047673|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
219047674|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
219047675|NCT05435885|OTHER|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
219047676|NCT05435885|OTHER|Control (Education)|Usual care with only one educational session.
219047677|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
219047678|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
219047679|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
219047680|NCT02610855|PROCEDURE|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
219047681|NCT02610855|OTHER|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
219047682|NCT02610855|DEVICE|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
219206310|NCT05266417|DRUG|INS-GSH|Intranasal INS-GSH Twice Daily
219206311|NCT05266417|DRUG|Matched Placebos|Intranasal Matched Placebos Twice Daily
219623933|NCT07151170|OTHER|Telerehabilitation Pelvic Floor Muscle Training (TR-PFMT) Group|The program will be delivered online in small groups by a physiotherapist. The program includes diaphragmatic breathing, pelvic mobility (pelvic tilts, hip circles, cat-cow), stretching (butterfly, child pose, deep squat), and progressive strengthening of phasic and tonic fibers through stationary PFMT (10-sec moderate-hold + 3 quick flicks, 8 sets in weeks 1-3, 10 sets in weeks 4-6, 10-sec rest) and home-based PFMT (10 fast contractions and 10 moderate-hold contractions, 2 sets in weeks 1-2 with weekly set increases, 10-sec rest), performed in prone lying, supine hook-lying, butterfly, sitting, and standing positions. All sessions will be recorded, and participants will submit weekly exercise diaries.
219623934|NCT07151170|OTHER|Supervised Pelvic Floor Muscle Training (S-PFMT) Group|In the supervised group, the protocol will be delivered by a physiotherapist in a clinical environment by face-to-face. The standardized Pelvic Floor Muscle Training protocol will be monitored exactly the same as Telerehabilitation group (TR-PFMT).
218936548|NCT04506099|DEVICE|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
219623935|NCT07153289|BIOLOGICAL|CD318-CAR-T cells|Autologous T cells collected by leukapheresis, genetically modified using a GMP-manufactured lentiviral vector encoding a fully human CD318-specific chimeric antigen receptor (CAR), and expanded on the CliniMACS Prodigy system. After lymphodepleting chemotherapy (fludarabine/cyclophosphamide), participants receive (Phase I) a single CAR-T infusion per BOIN dose-escalation to determine MTD/RP2D; (Phase IIa) an expansion at RP2D with a predefined dual-dosing schedule (two infusions) separated by a protocol-defined interval.
219623936|NCT07152054|DEVICE|virtual forest bathing|"Virtual reality (VR) is an advanced computer technology and a novel technique used in healthcare to alleviate pain and provide patient comfort. It enables individuals to interact with a 360-degree virtual environment through a headset device. It has been observed that painful or emotionally stressful stimuli from the external world are diminished within the VR environment, with the individual's attention redirected and focused on this immersive setting.~In our study, a 20-minute VR video will be used, providing the sensation of walking through a calming 360-degree virtual forest environment accompanied by natural sounds, viewed through VR headsets. Unlike some commercially available VR headsets, the Oculus Quest 2 model will be utilized, as it serves as both the computer and display system, eliminating the need for a smartphone. This device is preferred for its ability to deliver high-quality video without interruptions that might negatively affect the VR experience.~After explaining"
219623937|NCT07112170|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
219623938|NCT07151144|OTHER|Massage|During the active phase of labor (cervical dilation of 4-7 cm), participants received 15-minute sessions of light-pressure massage to the lower back, sacrum, and lumbar area at regular intervals.
218936549|NCT00634101|DEVICE|nelfilcon A|contact lens
219623939|NCT07151144|OTHER|Shower|During the same phase, participants were assisted to take a warm shower for approximately 20 minutes.
218936550|NCT00634101|DEVICE|narafilcon A|contact lens
218936551|NCT01594528|OTHER|pain tests|pain induction with pressure application or ischemia on the arm
218936552|NCT04004871|DRUG|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
218936553|NCT04004871|RADIATION|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
218936554|NCT04588454|OTHER|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
218936555|NCT04154527|OTHER|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
218936556|NCT02575157|OTHER|No intervention|No intervention
218936557|NCT01077076|DRUG|Zegerid|Zegerid taken once daily for 11 days.
218936558|NCT01077076|DRUG|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
218936559|NCT01077076|OTHER|Placebo|Placebo taken once daily for 11 days.
218936560|NCT06134804|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
218936561|NCT06134804|BIOLOGICAL|Placebo|Placebo will be administered as an IM injection.
218936562|NCT06134804|BIOLOGICAL|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
218936563|NCT06170099|RADIATION|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
218936564|NCT06170099|DEVICE|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
218936565|NCT05699694|DIETARY_SUPPLEMENT|StemRegen product|"Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible:~Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance."
219206312|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
219206313|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
219623940|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%) and Sodium Fluoride Varnish (NaF, 5%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). In addition, a 5% sodium fluoride varnish (NaF) is applied to all teeth at 3-month intervals (months 3, 9, 15, 21). Applications are performed by a dentist using standard microbrush or applicator techniques, ensuring lesions coverage for SDF and full dentition coverage for NaF varnish. This alternating protocol evaluates whether combining periodic SDF with regular fluoride varnish enhances caries arrest in primary teeth compared to semiannual SDF alone.
219623941|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). Applications are performed by a dentist using a microbrush to directly cover the lesion surface until fully saturated. No additional fluoride varnish is provided in this arm. The protocol evaluates the effectiveness of semiannual SDF application alone for arresting active caries in primary teeth of young, uncooperative pediatric patients.
219206314|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
219206315|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
219623942|NCT07152119|DRUG|Litfulo|as provided in real world practice.
219623943|NCT03525678|DRUG|Belantamab mafodotin frozen liquid|Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
218936566|NCT03126513|PROCEDURE|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
218936567|NCT01814241|DRUG|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
218936568|NCT04510441|OTHER|Nil intervention|Nil intervention; retrospective cohort study
218936569|NCT02100696|DRUG|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
218936570|NCT02100696|DRUG|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
218936571|NCT05867498|BEHAVIORAL|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
218936572|NCT05867498|BEHAVIORAL|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
218936573|NCT05343728|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
218936574|NCT05343728|DIAGNOSTIC_TEST|Standard coagulation profile laboratory examination|Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
218936575|NCT04713007|BEHAVIORAL|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
218936576|NCT04713007|BEHAVIORAL|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
218936577|NCT04451187|DRUG|Seltorexant Dose 1|Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
219623944|NCT03525678|DRUG|Belantamab mafodotin lyophilized powder|Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
219623945|NCT02747108|BEHAVIORAL|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
218936578|NCT04451187|DRUG|Seltorexant Dose 2|Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
218936579|NCT04451187|DRUG|Placebo|Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
218936580|NCT04451187|DRUG|Zopiclone|Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
218936581|NCT04565119|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
218936582|NCT01989494|DEVICE|Pedometer|All groups will receive a pedometer to measure their daily steps
218936583|NCT06262178|BEHAVIORAL|Parenting-STAIR Modular (PSTAIR-M)|12-16 PSTAIR-M treatment sessions (approximately 12-16 weeks).
219206316|NCT05383352|DRUG|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle
219206317|NCT05383352|DRUG|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
219206318|NCT05901727|OTHER|No intervention|Observational data collection only.
219206319|NCT01688765|OTHER|Observational|
219623946|NCT02747108|BEHAVIORAL|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
219623947|NCT06066749|OTHER|Filtration of all PM and VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM) and volatile organic compounds (VOC's) will be removed using commercially available P100/VOC respirator filters (3M cartridge; 60925 or equivalent)."
219623948|NCT06066749|OTHER|Filtration of VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM)will be removed using commercially available P100 respirator filters (DM; cat. # 2097)."
219623949|NCT06401421|DIAGNOSTIC_TEST|ctDNA MRD test|Blood and tissue samples will be collected for the ctDNA MRD test
219623950|NCT06299592|COMBINATION_PRODUCT|PET/MRI using [18F]FEPPA tracer|PET/MRI scans with \[18F\]FEPPA radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia
219623951|NCT05585606|DRUG|Placebo|Volume Matched Placebo
219623952|NCT05585606|DRUG|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 1.9 mg/kg"
219623953|NCT05585606|DRUG|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 3.8 mg/kg"
219623954|NCT05585606|DRUG|scp776 (4.8 mg/kg)|Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg
219623955|NCT05585606|DRUG|scp776 (all dose levels)|A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.
219623956|NCT01205815|OTHER|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
218936584|NCT06262178|BEHAVIORAL|Treatment as Usual (TAU)|Weekly treatment sessions of an established EBT. The total number of sessions/weeks will be determined by the EBT and clinic protocols.
218936585|NCT07084168|BEHAVIORAL|Educational videos|Educational videos about genetic testing will be provided. Subjects will be asked to view one of three videos (an endometrial cancer/Lynch Syndrome video or a longer or shorter version of an ovarian cancer video) relevant to their cancer diagnosis and genetic testing.
218936586|NCT07084168|BEHAVIORAL|Survey|Subjects will be asked to complete a brief satisfaction survey.
218936587|NCT07142395|PROCEDURE|Immediate skin closure|After laparotomy wounds will be closed primarily using no. 1 vicryl suture
218936588|NCT07142395|PROCEDURE|Delayed primary closure|Deeper layers of wound will be closed after surgery and loose mattress sutures will be applied to skin with prolene. After three to five days of daily dressing with bactericidal solution, the skin will be closed
218936589|NCT06938464|DIETARY_SUPPLEMENT|Probiotics|Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid
218936590|NCT06938464|DIETARY_SUPPLEMENT|Placebo|placebo with similar appearance and smell but not containing probiotics
218936591|NCT06940778|OTHER|No Interventions|no interventions
218936592|NCT02713464|BEHAVIORAL|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
218936593|NCT07144163|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth
218936594|NCT07144163|DRUG|Placebo|Placebo, tablets, once daily by mouth
218936595|NCT07141251|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
218936596|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
218936597|NCT07157085|OTHER|Comprehensive treatment|Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
219206320|NCT05180838|DEVICE|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
219206321|NCT05354323|BIOLOGICAL|NECVAX-NEO1|Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes
219623957|NCT05763407|DEVICE|NORM™ System|NORM™ System
219623958|NCT05590988|OTHER|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
218936598|NCT07157241|DIETARY_SUPPLEMENT|Intervention|omega-3 capsules with a concentration of 1000 mg/day for three months (NOW Foods- Ultra omega-3 500 EPA/250 DHA).
218936599|NCT07157241|DIETARY_SUPPLEMENT|Control group (placebo)|corn oil capsule /day for 3 months
218936600|NCT07157397|BEHAVIORAL|Plant-Focused Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics to guide patients to consume a diet emphasising plant-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
218936601|NCT07157397|BEHAVIORAL|Standard Renal Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics based on current guideline recommendations, to guide patients to consume a diet emphasising animal-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
219206322|NCT05468827|PROCEDURE|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
219206323|NCT03217461|PROCEDURE|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera and cornea by sutured femtosecond laser-assisted limbal autograft.
219206324|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
219206325|NCT03934931|OTHER|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
219206326|NCT03934931|OTHER|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
219206327|NCT03934931|OTHER|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
219206328|NCT03934931|OTHER|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
219206329|NCT03934931|OTHER|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
219206330|NCT03934931|OTHER|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
219206331|NCT06158152|DIETARY_SUPPLEMENT|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
219206332|NCT06158152|DIETARY_SUPPLEMENT|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
219623959|NCT05590988|OTHER|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
219206333|NCT06158152|DIETARY_SUPPLEMENT|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
219206334|NCT04232085|DRUG|Alemtuzumab|Preparative regimen
219623960|NCT04559139|DRUG|Cisplatin|Given IV
218936602|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version A|Qualia Iron Version A manufactured by Qualia Life Sciences
218936603|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version B|Qualia Iron Version B manufactured by Qualia Life Sciences
218936604|NCT07156526|DIETARY_SUPPLEMENT|Placebo|Rice powder
219206335|NCT04232085|DRUG|Fludarabine|Preparative regimen
219206336|NCT04232085|DRUG|Melphalan|Preparative regimen
219206337|NCT04232085|RADIATION|Low Dose Total Body Irradiation|Preparative regimen
219206338|NCT04232085|DRUG|Cyclophosphamide|GVHD prophylaxis
219206339|NCT04232085|DRUG|Tacrolimus|GVHD prophylaxis
219206340|NCT04232085|DRUG|Mycophenolate Mofetil|GVHD prophylaxis
219206341|NCT06465420|BIOLOGICAL|Haemophilus influenzae type a (Hia) glycoconjugate vaccine|0.5 mL intramuscular injection, given on days 0 and 28
219206342|NCT04801797|DRUG|Cytarabine|Intravenous infusion
218936605|NCT07156318|BEHAVIORAL|2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome|Drumming lessons consisting of how to use hands to drum on djembe drum, using alternating hands to drum, drumming to a metronome and to music.
218936606|NCT07156318|BEHAVIORAL|Lessons after measurement|Receiving lessons after the two lab visits should still offer any possible positive effects to participants while still allowing us to compare the Control group children's behaviors to those of the Experimental group.
218936607|NCT07156539|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
219206343|NCT04801797|DRUG|Idarubicin|Intravenous infusion
219206344|NCT04801797|DRUG|Daunorubicin|Intravenous infusion
219206345|NCT04801797|DRUG|Liposomal daunorubicin and cytarabine|Intravenous infusion
219206346|NCT04801797|DRUG|Venetoclax|Orally by mouth
219623961|NCT04559139|DRUG|Gemcitabine Hydrochloride|Given IV
218936608|NCT07156539|DRUG|Dulaglutide Injection|Dulaglutide injected subcutaneously once weekly
218936609|NCT07158255|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
219206347|NCT04801797|DRUG|Azacitidine|Intravenous infusion
219206348|NCT04115007|RADIATION|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
219206349|NCT04115007|DRUG|Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
219206350|NCT05441280|DRUG|pimavanserin|pimavanserin 34mg PO at bedtime
219206351|NCT05441280|OTHER|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
219206352|NCT05734495|DRUG|Pirtobrutinib|Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
219623962|NCT04559139|PROCEDURE|Lymphadenectomy|Undergo portal lymphadenectomy
219623963|NCT04559139|PROCEDURE|Partial Hepatectomy|Undergo partial hepatectomy
219623964|NCT04763915|OTHER|Correlative Studies (Survey)|Administer surveys
219623965|NCT04763915|OTHER|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
219623966|NCT04763915|BEHAVIORAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
219623967|NCT04763915|BEHAVIORAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
219623968|NCT04763915|BEHAVIORAL|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
219623969|NCT04763915|OTHER|Access to Education Materials|Receive access to VUS educational materials
219623970|NCT05679674|RADIATION|Stereotactic Ablative Body Radiation (SABR)|50 Gy in 5 fractions, once per day for 5 days
218936610|NCT07158255|OTHER|Exercise training|In addition to electrotherapy, the patients in the study group will receive 15 sessions (45 minutes, 5 days a week, for 3 weeks) of exercise training consistent with the literature. Exercise training includes programs to increase joint range of motion and mobility at the pain threshold and to restore functionality. Following electrotherapy, upper extremity normal range of motion exercises, anterior and posterior capsule stretching exercises, pendulum exercises, wand exercises, isometric training in 3 planes, and isotonic strengthening exercises will be applied. Five exercises will be selected each day, performed under the supervision of a physiotherapist. A 2-minute rest period will be provided after each exercise, followed by a transition to the next exercise. Care will be taken to perform the exercises within the pain threshold and to ensure that the pain does not exceed a VAS score of 2.
218936611|NCT07156838|OTHER|bioflex crown|A preformed bioflex crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area, bioflex crown fitting and proper occlusion will be checked then it will be cemented using type-I glass ionomer cement, Any excess cement will be removed.
219047683|NCT02610855|OTHER|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
219047684|NCT06457373|PROCEDURE|Demineralized Dentin Allograft|20 sockets are randomly allocated to receive the Demineralized Dentin Allograft (split-mouth study)
219047685|NCT06457373|PROCEDURE|Demineralized Dentin Autograft|20 sockets are randomly allocated to receive the Demineralized Dentin Autograft (split-mouth study)
219047686|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
219047687|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
219047688|NCT04515459|OTHER|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~* 2 OTE will be performed before the surgery,~* 6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
219047689|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
219047690|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
219047691|NCT02886052|OTHER|Active control|
219047692|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L\_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
219206353|NCT05734495|DRUG|Venetoclax|Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
219206354|NCT04864652|DEVICE|CHILLS Procedure|CHILLS Cryotherapy procedure
219206355|NCT02454283|DRUG|Vanoxerine HCl|
219206356|NCT02454283|DRUG|Placebo|
219623971|NCT05679674|DEVICE|Tumor Treating Fields (TTF)|Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
219623972|NCT05053191|BEHAVIORAL|Partnership, Assessment, Care and Transition training intervention|Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
219623973|NCT06148246|BEHAVIORAL|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 12 weeks, working to increase their moderate- to vigorous-intensity physical activity.
219623974|NCT04871542|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219623975|NCT04871542|OTHER|Questionnaire Administration|Complete questionnaires
219623976|NCT06637293|DEVICE|DeepECG plateform diagnosis & recommendations|EchoNeXT\& ECG-AI algorithm
219623977|NCT03425838|DRUG|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
219623978|NCT03425838|DRUG|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
219623979|NCT03425838|DRUG|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
219623980|NCT02511028|DRUG|Ferumoxytol|510mg (17mL) IV
219623981|NCT03589261|DEVICE|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
218936612|NCT07156838|OTHER|zerconia crown|"Occlusal reduction will be done by 1-1.5 mm using coarse football shaped diamond bur following the natural occlusal anatomy.~Interproximal contacts will be opened with a tapered fissure bur. The proximal space should be enough to permit the chosen crown to fit passively.~The molar will be trimmed down circumferentially 0.5-1.25 mm as needed with the use of tapered diamond burs.~•About 1 to 2 mm subgingival preparation will be done to achieve a feather-edge finish line.~Prepared tooth should be free from any blood or saliva. Try-in will be done using the pink crowns, to check the occlusion and Passive fit of the crown.~The zirconia crown will be luted with type I glass ionemer cement. Consistent firm finger pressure will be applied during cementation, Any excess cement will be removed, and proper occlusion will be verified"
218936613|NCT07156838|OTHER|stainless steel crown|"An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement.~Any excess cement will be removed, and proper occlusion will be verified"
218936614|NCT07158346|DRUG|L03RD1|1 tablet of L03RD1
218936615|NCT07158346|DRUG|L03RD2|2 tablets of L03RD2
218936616|NCT07158346|DRUG|CT-L03|1 tablet of CT-L03
219206357|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
219623982|NCT04975152|DRUG|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
219623983|NCT05801029|DRUG|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
218936617|NCT07156552|BEHAVIORAL|Resistance exercise training and protein supplementation|"The intervention consists of two components:~1. Resistance Exercise Training Participants will engage in a 24-week resistance training program. This program includes one supervised session per week supervised by a qualified kinesiologist, complemented by two to three additional unsupervised sessions per week performed at home.~2. Protein Supplementation~Participants will receive daily protein supplements for a total duration of 12 weeks. The dosage will be progressively increased:~* 20 grams per day during weeks 1-4~* 40 grams per day during weeks 5-8~* 60 grams per day during weeks 9-12 After the 12-week supplementation period, participants will receive additional dietary counseling sessions with a dietitian. These sessions aim to support the maintenance of adequate protein intake through dietary intake."
218936618|NCT07157631|DRUG|tranexamic acid|In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
218936619|NCT07157631|DRUG|0.9 % saline|In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
218936620|NCT07156591|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention during esophagogastroduodenoscopy
218936621|NCT07156396|DEVICE|SleeperOne®, dental Hitec, France|SleeperOne® is a computerized local anesthetic delivery system used to deliver 3% mepivacaine following application of 20% benzocaine topical gel. It is designed to reduce injection pain and improve comfort during pediatric dental procedures.
219623984|NCT05801029|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
219623985|NCT04327063|DRUG|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
219623986|NCT04327063|DRUG|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
219623987|NCT05926661|OTHER|NCC Support Toolkit|"Pre-discharge intervention-~* Set expectations for parents/caregivers to spend time bedside and attend rounds~* iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~* Download Nemours App and teach them how to use it~* Education materials- to ease the use of medications, Oxygen and feeding~* Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding."
219047693|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
219047694|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
219047695|NCT04583761|BEHAVIORAL|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
219047696|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
219047697|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
219206358|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
219206359|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
219206360|NCT04861558|DRUG|5Fluorouracil|Injection of 250-850 mg/m2.
219047698|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
219047699|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
219047700|NCT06541457|DRUG|HRS-7249 injection|6 subjects for HRS-7249 injection
219047701|NCT06541457|DRUG|Placebo|2 subjects for placebo
219047702|NCT06540066|DRUG|BGB-B3227|Administered intravenously.
219047703|NCT06540066|DRUG|Tislelizumab|Administered intravenously.
219047704|NCT06540066|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
219047707|NCT05518045|DRUG|LM-108|Administered intravenously
219047708|NCT05518045|DRUG|Toripalimab|Administered intravenously
219047709|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219047710|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
219047711|NCT06015880|DRUG|Lenalidomide|Given PO
219047712|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
219047713|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
219047714|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219047715|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
219206361|NCT04861558|DRUG|Irinotecan|Injection of 360 mg/m2
219206362|NCT04861558|DRUG|Oxaliplatin|Injection of 460 mg/m2
219206363|NCT02467270|DRUG|Ponatinib|Tablet, taken orally once daily.
219206364|NCT05779839|BEHAVIORAL|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
219206365|NCT05779839|BEHAVIORAL|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
219206366|NCT04319549|OTHER|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
219206367|NCT04319549|OTHER|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
219206368|NCT02932761|DRUG|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
219206369|NCT02932761|PROCEDURE|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
219206370|NCT05438992|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
219206371|NCT05980559|DRUG|Xeomin|50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
219206372|NCT03311516|OTHER|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
219206373|NCT03311516|OTHER|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
219206374|NCT04914403|BIOLOGICAL|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
219206375|NCT00448552|DRUG|capecitabine|
219623988|NCT05681767|BEHAVIORAL|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
218936622|NCT07156396|PROCEDURE|Conventional Infiltration|Local anesthetic (3% mepivacaine) will be administered using a conventional dental syringe after the application of 20% benzocaine topical anesthetic.
219206376|NCT00448552|DRUG|oxaliplatin|
219206377|NCT03890848|BEHAVIORAL|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
219206378|NCT03890848|BEHAVIORAL|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
219206379|NCT06403995|BEHAVIORAL|Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
219206380|NCT06403995|BEHAVIORAL|Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
219206381|NCT06403995|BEHAVIORAL|Recommended, directed Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
219206382|NCT06539715|DIAGNOSTIC_TEST|Visual field assessment|Automated perimetry
219206383|NCT05220943|BEHAVIORAL|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
219623989|NCT05681767|OTHER|Treatment as usual|Treatment as usual
219623990|NCT06414590|DRUG|Tebentafusp-Tebn|Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
219623991|NCT06951477|PROCEDURE|Revision Total Knee Arthroplasty|Study participants must be scheduled to receive a revision TKA.
219623992|NCT04898634|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
219206384|NCT04632394|DIAGNOSTIC_TEST|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
219206385|NCT04632394|PROCEDURE|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
219206386|NCT03554889|BIOLOGICAL|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
219623993|NCT05721755|DRUG|Carboplatin|Given IV
219206387|NCT03554889|DRUG|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
219206388|NCT02438059|BEHAVIORAL|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
219206389|NCT00995631|PROCEDURE|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
219623994|NCT05721755|DRUG|Cisplatin|Given IV
219623995|NCT05721755|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219623996|NCT05721755|DRUG|Fluorouracil|Given IV
219623997|NCT05721755|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219623998|NCT05721755|DRUG|Paclitaxel|Given IV
219206390|NCT06274775|OTHER|Educational Video|Educational video about the nail biopsy procedure
219623999|NCT05721755|BIOLOGICAL|Pembrolizumab|Given IV
219624000|NCT05721755|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218936623|NCT07157995|BEHAVIORAL|BALANCE Building Active LIving and Addressing Needs for Caregiver Empowerment|The Balance intervention will include individual visits by a Caregiver Navigator and group sessions with other participants, led by the caregiver navigator. The focus will be on future planning, resources for unmet needs and support and socialization.
218936624|NCT07156435|DRUG|Vyxeos 44 MG / 100 MG Liposome Injection|Vyxeos®/CPX-351 will be infused in 90 minutes on day 1, 3 and 5 only, 3 hours after the end of clofarabine (if administered on the same day).
218936625|NCT07156435|DRUG|Clofarabine|Clofarabine infusion will be given according to the assigned dose level, over 2 hours IV, daily on day 2-6 (for 5 consecutive days).
218936626|NCT07156669|DEVICE|Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG)|Patients will receive ECLS treatment using the Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG) during ground-based inter-hospital patient transport and/ or stationary treatment according to their intended use and local standards/ requirements.
218936627|NCT07157475|DRUG|Treatment with SGLT2 inhibitors (flozins)|Patients received SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as part of their routine clinical care during the 12-month follow-up period after elective or urgent lower limb revascularization procedures. The study does not assign treatment; medication use occurred independently of the study protocol.
218936628|NCT07157735|DRUG|dapansutrile|Dapansutrile tablets administered for 26 weeks, starting at 1,000 mg daily (500 mg twice daily) for 4 weeks, escalated to 2,000 mg daily (1,000 mg twice daily) thereafter.
218936629|NCT07157735|DRUG|placebo|Matched placebo tablets administered for 26 weeks, admistered as per the active treatment.
218936630|NCT07156409|DEVICE|Peripheral Embolization Coil System|Primarily used to block or reduce the blood flow velocity in the peripheral vascular system
218936631|NCT05170919|DRUG|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
219206391|NCT03426800|OTHER|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
219206392|NCT02297919|BEHAVIORAL|Effectiveness of Internet Based Obesity Control Programme|
219206393|NCT04852315|DIETARY_SUPPLEMENT|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
219624001|NCT05721755|OTHER|Quality-of-Life Assessment|Ancillary studies
219624002|NCT05721755|RADIATION|Radiation Therapy|Undergo radiation therapy
219624003|NCT06557876|PROCEDURE|Pulmonary vein isolation by pulse field ablation|Pulse Field Ablation (PFA) is a non-thermal energy based on high voltage, ultra-short energy pulses applied selectively to cardiomyocytes.
219624004|NCT06557876|PROCEDURE|Pulmonary vein isolation by cryoablation|Cryoablation is a conventional thermal energy, also delivered with a single-shot cryoballoon device.
219624005|NCT05974774|DRUG|iMAB|no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.
219624006|NCT05974774|DRUG|cMAB|LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
219624007|NCT02818595|DEVICE|electroencephalogram (HR-EEG)|
219624008|NCT02818595|DEVICE|Near Infra Red Spectroscopy (NIRS)|
219624009|NCT05404737|OTHER|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
219624010|NCT05404737|OTHER|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
219624011|NCT02615600|DEVICE|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
219624012|NCT01727388|PROCEDURE|lateral decubitus|
219624013|NCT01727388|PROCEDURE|supine decubitus|
219624014|NCT06475859|OTHER|Montreal Imaging Stress Test|A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.
219624015|NCT06475859|OTHER|Relaxation breathing|3 short sessions (4 minutes) of relaxation breathing
219624016|NCT05389449|DRUG|Danicopan|Oral tablet
219624017|NCT06055361|DRUG|BxC-I17e (primed iMSC derived Extracellular vesicles(EV))|Pharmaceutical form : solution for injection
219624018|NCT06055361|DRUG|Placebo|Pharmaceutical form : solution for injection
219624019|NCT05796479|DRUG|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
219624020|NCT05796479|DRUG|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
219624021|NCT03294954|GENETIC|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9"
219624022|NCT03294954|BIOLOGICAL|GINAKIT cells + Etanercept|"Four dose levels of GINAKIT cells in combination of Etanercept will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Combination Dose level 1: 3 x 10\^6 + Etanercept\*~* Combination Dose level 2: 1 x 10\^7 + Etanercept\*~* Combination Dose level 3: 3 x 10\^7 + Etanercept\*~* Combination Dose level 4: 1 x 10\^8 + Etanercept"
219624023|NCT03289520|DRUG|Clopidogrel|
219624024|NCT03289520|DRUG|Placebo|
219624025|NCT03787784|OTHER|AI presentation|Automatic diagnosis information of AI is visible to endoscopist
219047716|NCT06113419|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
219047717|NCT06969196|OTHER|Written Communicatoin|ICU clinicians will be asked to edit AI-generated written summaries for content and clarity before they are delivered to families
219047718|NCT05774899|DRUG|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
219047719|NCT05774899|DRUG|Abemaciclib|CDK4/6 inhibitor, tablet taken orally.
219047720|NCT05774899|DRUG|Lenvatinib|Per standard care, capsule taken orally.
219047721|NCT01716728|OTHER|enzyme analysis|
219624026|NCT01822639|DRUG|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
219624027|NCT01822639|DRUG|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
219624028|NCT01822639|DRUG|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
219624029|NCT04446338|DIAGNOSTIC_TEST|Antibody Test|Presence and Titer of Anti-Sars-CoV-2 Antbodies
219624030|NCT01256489|DRUG|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
219624031|NCT04851028|BEHAVIORAL|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
219624032|NCT02863055|DRUG|Nintedanib|Nintedanib 200 mg administered twice daily
219624033|NCT02863055|DRUG|Placebo|Matching placebo administered twice daily
219624034|NCT02467738|RADIATION|Brachytherapy|Undergo brachytherapy with Cesium-131
219624035|NCT02467738|DRUG|Cesium-131|Undergo brachytherapy with Cesium-131
219624036|NCT02467738|PROCEDURE|Conventional surgery|Undergo surgical resection
219624037|NCT04050163|BIOLOGICAL|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
219624038|NCT06273514|OTHER|TECAR|"TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM."
219047722|NCT00945022|DEVICE|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
219047723|NCT03351764|DEVICE|Sham TMS|Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.
219047724|NCT03351764|DEVICE|TMS|non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
219047725|NCT00003694|DRUG|omacetaxine mepesuccinate|Given IV
219047726|NCT00003694|DRUG|cytarabine|Given IV
219206394|NCT04852315|DIETARY_SUPPLEMENT|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
219624039|NCT06273514|OTHER|Dry needling|"Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe."
219624040|NCT00858455|DRUG|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
219624041|NCT00858455|DRUG|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
219624042|NCT00858455|DRUG|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
219624043|NCT00858455|DRUG|GSK1349572|A single dose of GSK1349572
219624044|NCT00980239|DRUG|Irinotecan|Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
219624045|NCT00980239|DRUG|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
219624046|NCT00980239|DRUG|Oxaliplatin|Starting dose 60 mg/m\^2 by vein over 2 hours on Days 1 and 15 of every cycle.
219624047|NCT00980239|DRUG|Cetuximab|500 mg/m\^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
219624048|NCT03091543|DRUG|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
219624049|NCT03091543|DRUG|Placebo|2 capsules of placebo
219624050|NCT03091543|DRUG|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
218936632|NCT05170919|DRUG|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
218936633|NCT06030752|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
219624051|NCT03091543|DRUG|BIA 6-512 50 mg dose|2 capsules of 25 mg
219624052|NCT03091543|DRUG|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
219624053|NCT03091543|DRUG|BIA 6-512 200 mg dose|2 capsules of 100 mg
218936634|NCT05106426|BEHAVIORAL|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
218936635|NCT05106426|BEHAVIORAL|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
218936636|NCT01111578|DEVICE|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
218936637|NCT04199130|BEHAVIORAL|BrainHQ|"BrainHQ is a web-based brain-training program. The investigators will assign participants to attention specific modules that they will complete at home with the goal of restoring attentional functions lost through injury via repetitive tasks of graded difficulty."
218936638|NCT04199130|BEHAVIORAL|Goal Management Training|"This is a manualized, interactive, metacognitive-strategy training designed to promote a mindful approach to complex real-life tasks and reduce lapses in attention via implementation of compensatory mechanisms for monitoring tasks."
218936639|NCT05751564|BIOLOGICAL|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw \& inject MSC intra-articular therapy
218936640|NCT05751564|BIOLOGICAL|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
218936641|NCT02260180|DRUG|A-101|Topical Solution
219624054|NCT03132935|PROCEDURE|Telemedical support|Telemedical support by a physician in a telemedicine centre
219624055|NCT02393950|DRUG|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
219624056|NCT02393950|DRUG|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
219624057|NCT04423211|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
219624058|NCT04423211|DRUG|Apalutamide|Given PO
218936642|NCT02460796|OTHER|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
218936643|NCT04319692|DIETARY_SUPPLEMENT|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
218936644|NCT04319692|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks.
218936645|NCT01043289|OTHER|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
218936646|NCT00611403|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
218936647|NCT00611403|DRUG|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
218936648|NCT03945604|DRUG|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
219624059|NCT04423211|PROCEDURE|Computed Tomography|Undergo PET/CT
219624060|NCT04423211|DRUG|Degarelix|Given SC
219624061|NCT04423211|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219624062|NCT04423211|OTHER|Fluciclovine F18|Given IV
219624063|NCT04423211|DRUG|Goserelin Acetate|Given SC
219624064|NCT04423211|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
219624065|NCT04423211|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219624066|NCT04423211|DRUG|Leuprolide Acetate|Given IM
218936649|NCT05127746|DRUG|Aricept 5mg Tablet|1 tablet once daily
218936650|NCT05127746|DRUG|Aricept 10mg Tablet|1 tablet once daily
218936651|NCT05127746|DRUG|DA-5207 A|1 patch once weekly
218936652|NCT05127746|DRUG|DA-5207 B|1 patch once weekly
218936653|NCT01812668|DRUG|cabozantinib-s-malate|Given PO
218936654|NCT01812668|RADIATION|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
218936655|NCT01812668|PROCEDURE|positron emission tomography|Undergo 18F PET/FMAU PET scan
218936656|NCT01812668|OTHER|pharmacological study|Correlative studies
218936657|NCT01812668|OTHER|laboratory biomarker analysis|Correlative studies
218936658|NCT01710540|OTHER|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
218936659|NCT01710540|OTHER|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
218936660|NCT02439359|DRUG|CF-301|Dose escalation
218936661|NCT02439359|DRUG|Placebo|
218936662|NCT00129844|DRUG|Motexafin Gadolinium|
218936663|NCT03817047|BEHAVIORAL|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
218936664|NCT03817047|BEHAVIORAL|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
218936665|NCT03817047|BEHAVIORAL|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
218936666|NCT03817047|BEHAVIORAL|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
218936667|NCT00632788|OTHER|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
218936668|NCT03636464|OTHER|Blood collection|Pharmacokinetics
218936669|NCT06348290|DRUG|JMKX001899|Oral
218936670|NCT06348290|DRUG|Itraconazole|Oral
218936671|NCT06348290|DRUG|Midazolam|Oral
218936672|NCT06348290|DRUG|Rifampin|Oral
218936673|NCT06348290|DRUG|dextromethorphan|Oral
218936674|NCT06348290|DRUG|Rosuvastatin|Oral
218936675|NCT06348290|DRUG|digoxin|Oral
218936676|NCT02375061|BEHAVIORAL|e-BPS|
218936677|NCT02375061|BEHAVIORAL|Daily Activities|
218936678|NCT03860818|OTHER|Health services delivery|Technology-enabled pharmacist intervention
218936679|NCT03126344|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
218936680|NCT03126344|DEVICE|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
218936681|NCT03126344|DEVICE|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
218936682|NCT01811056|DRUG|Mifepristone|Mifepristone use outside of the center
218936683|NCT01139008|DRUG|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
218936684|NCT01139008|DRUG|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
219624067|NCT04423211|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
219624068|NCT04423211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
218936685|NCT04546984|DRUG|HEC96719|Part 2：Mulltiple doses up to 10 days
219624069|NCT04423211|OTHER|Quality-of-Life Assessment|Ancillary studies
219624070|NCT04423211|OTHER|Questionnaire Administration|Ancillary studies
219624071|NCT04423211|DRUG|Relugolix|Given PO
219624072|NCT04423211|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219624073|NCT04423211|DRUG|Triptorelin|Given IM
219624074|NCT04423211|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
219624075|NCT04884815|GENETIC|UX701|Nonreplicating, recombinant gene transfer vector
219624076|NCT04884815|DRUG|Standard of Care (SOC)|SOC treatment (i.e., copper chelators and/or zinc) administered according to standard regimens.
219624077|NCT02909777|DRUG|CUDC-907|
219624078|NCT06343090|DRUG|CD19 CAR T-cell|Murine-derived CD19 CAR T cells
219624079|NCT06343090|DRUG|CD22 CAR T cells|humanized CD22 CAR T cells
219624080|NCT06343090|PROCEDURE|hematopoietic stem-cell transplantation|allo-HSCT
219624081|NCT04290988|DEVICE|EEG Neurofeedback|Active EEG neurofeedback
219624082|NCT04290988|DEVICE|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
219624083|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
219624084|NCT03971071|DRUG|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
219624085|NCT03971071|DRUG|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
219624086|NCT03971071|DRUG|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
219624087|NCT03697148|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
219624088|NCT02185196|DRUG|Vitamin D3|20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
219624089|NCT02185196|DRUG|Placebo|20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
219624090|NCT00443690|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
218936686|NCT03154229|OTHER|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
218936687|NCT03154229|OTHER|Paper-based decision-support|WHO guidelines presented on paper
218936688|NCT03154229|OTHER|Pre-Assessment of practices|Observation of baseline clinical practice.
218936689|NCT00347620|DEVICE|spectacles|
218936690|NCT00347620|PROCEDURE|Cataract Surgery|
218936691|NCT04567901|OTHER|Death|Mortality group
218936692|NCT04567901|OTHER|Survive|Survival group
219047727|NCT00003694|OTHER|laboratory biomarker analysis|Correlative studies
219047728|NCT03791658|OTHER|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
219047729|NCT03791658|OTHER|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
219047730|NCT03791658|OTHER|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
219047731|NCT03791658|OTHER|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
219047732|NCT04725461|DEVICE|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
219047733|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
219047734|NCT05012813|OTHER|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
219047735|NCT01159964|BIOLOGICAL|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
219047736|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
219047737|NCT05984277|DRUG|Volrustomig|Volrustomig
219047738|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
219047739|NCT05984277|DRUG|Carboplatin|Carboplatin
219047740|NCT05984277|DRUG|Paclitaxel|Paclitaxel
219047741|NCT05984277|DRUG|Pemetrexed|Pemetrexed
219047742|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
219047743|NCT00448422|DRUG|prulifloxacin|Tablet
219047744|NCT05896839|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219047745|NCT05896839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219047746|NCT05896839|PROCEDURE|Computed Tomography|Undergo CT scan
219047747|NCT05896839|BIOLOGICAL|Ipilimumab|Given IV
219047748|NCT05896839|PROCEDURE|Kidney Biopsy|Undergo kidney biopsy
219047749|NCT05896839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219047750|NCT05896839|BIOLOGICAL|Nivolumab|Given IV
219047751|NCT05896839|DRUG|Prednisone|Given PO
219047752|NCT05896839|DRUG|Sirolimus|Given PO
219047753|NCT02171598|DRUG|Clopidogrel|
219047754|NCT02171598|DRUG|Dabigatran high dose|
219047755|NCT02171598|DRUG|Dabigatran low dose|
219047756|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
219624091|NCT00443690|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
219624092|NCT03209271|DRUG|Ringer's Acetate (warm)|Body temperature fluid
219624093|NCT03209271|DRUG|Ringer's Acetate (cold)|Room temperature fluid
219624094|NCT04827095|OTHER|Web-Based Support and Education Program 1|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
219624095|NCT04827095|OTHER|Web-Based Support and Education Program 2|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
219624096|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624097|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624098|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624099|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
219624100|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
219624101|NCT00728455|DRUG|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624102|NCT00728455|DRUG|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624103|NCT00728455|DRUG|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
219624104|NCT00728455|DRUG|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
219624105|NCT00728455|DRUG|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
219624106|NCT04403724|DRUG|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
219624107|NCT02845024|DRUG|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
219624108|NCT02845024|DRUG|placebo Group|Oral placebo was taken within 15 days
218936693|NCT04951661|DEVICE|Virtual Reality|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
219624109|NCT03781908|DRUG|Silver Nitrate|First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
219624110|NCT03781908|DEVICE|Indwelling Pleural Catheter|"First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture."
218936694|NCT03968939|DRUG|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
219624111|NCT04682808|DRUG|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
219624112|NCT04977804|OTHER|Exercise|The interventions are a form or exercise, specifically resistance exercise.
219624113|NCT04977804|OTHER|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
219624114|NCT05053633|PROCEDURE|Combined spinal epidural anesthesia|The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.
219624115|NCT04815070|PROCEDURE|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
218936695|NCT03968939|DIETARY_SUPPLEMENT|Melatonin|Oral Melatonin, 3 mg
218936696|NCT03968939|BEHAVIORAL|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
219624116|NCT00922077|BEHAVIORAL|standard physical therapy program with emphasis on dynamic balance exercises|
219624117|NCT00000292|PROCEDURE|Cocaine|
219624118|NCT04678518|DIAGNOSTIC_TEST|Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF|1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
219624119|NCT03439241|DEVICE|Coloplast ostomy device|the test product is a newly developed Coloplast ostomy device
218936697|NCT00505778|DRUG|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
219624120|NCT00626002|DRUG|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
219624121|NCT02881853|DRUG|XmAb7195|
219624122|NCT02881853|DRUG|Placebo|
218936698|NCT00505778|DRUG|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
218936699|NCT00116298|DRUG|stavudine, efavirenz, lamivudine|
218936700|NCT03414892|DRUG|Globalagliatin Hydrochloride|once daily, oral
218936701|NCT03414892|DRUG|Placebo|once daily, oral
218936702|NCT01785173|PROCEDURE|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
218936703|NCT01785173|PROCEDURE|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
218936704|NCT01373671|DEVICE|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
218936705|NCT04249232|DRUG|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
218936706|NCT04249232|DRUG|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
218936707|NCT05204303|DIAGNOSTIC_TEST|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
218936708|NCT05204303|OTHER|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
218936709|NCT05204303|OTHER|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
218936710|NCT05367492|DRUG|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
218936711|NCT05367492|DRUG|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
218936712|NCT05367492|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
218936713|NCT05367492|BEHAVIORAL|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
219624123|NCT04719572|OTHER|Basic treatment group|A total of 60 subjects were recruited in the group.
218936714|NCT00344578|DEVICE|Restor IOL|
218936715|NCT00995293|DRUG|DOCETAXEL|Intravenous
218936716|NCT00995293|DRUG|CISPLATIN|Intravenous
218936717|NCT00995293|DRUG|5-FLUOROURACIL|Intravenous
218936718|NCT00551278|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
218936719|NCT00772317|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
219624124|NCT04719572|OTHER|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
219624125|NCT04719572|OTHER|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
218936720|NCT00333762|DEVICE|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
218936721|NCT00333762|DEVICE|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
219047757|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
218936722|NCT02744404|DEVICE|POC EID|
218936723|NCT01022528|DRUG|Dexamethasone (0.1 mg/kg)|
218936724|NCT01022528|DRUG|Dexamethasone (0.2 mg/kg)|
218936725|NCT01022528|OTHER|Saline|
218936726|NCT02583737|PROCEDURE|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
219624126|NCT04830631|DEVICE|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
219624127|NCT00338416|DRUG|Epoetin alfa|
219624128|NCT02544438|DRUG|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
219624129|NCT02629315|OTHER|Carnoy's solution|
219624130|NCT02629315|OTHER|10% neutral buffered formaldehyde|
219624131|NCT04578301|OTHER|No Intervention|No Intervention
219624132|NCT01211834|DRUG|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
219624133|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
219206395|NCT01894074|BEHAVIORAL|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
219206396|NCT01894074|BEHAVIORAL|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
219206397|NCT05353894|DRUG|GNS561 oral tablets and capsules|Two formulations and Two dosage will be compared
219206398|NCT03479411|DRUG|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
219206399|NCT03479411|DRUG|Itraconazole 200 mg|Sporanox® Oral Solution
219624134|NCT01211834|DRUG|Placebo|intravenously over 1 hour infusion every 4weeks
219624135|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
219624136|NCT00803608|DEVICE|TrueContour® Insole|Novel designed insole
219624137|NCT00803608|DEVICE|Current standard of care insole|Current Medicare approved A5513 insole
219624138|NCT04656821|DRUG|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
219624139|NCT04656821|PROCEDURE|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
219624140|NCT04656821|PROCEDURE|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
219624141|NCT04537078|DRUG|Duphaston|will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.
219624142|NCT04537078|DRUG|Gonadotropin|will be used for controlled ovarian hyperstimulation in both arms
219624143|NCT04537078|DRUG|Cetrotide Injectable Product|will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
219624144|NCT04537078|DRUG|Decapeptyl|will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter in the first cycle only.
219624145|NCT04537078|DRUG|Chorionic Gonadotropin|will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle \>18 mm in diameter.
219624146|NCT04537078|DRUG|Combined Oral Contraceptive|luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .
219624147|NCT04537078|DRUG|Cyclo-Progynova|Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.
219624148|NCT04537078|DRUG|progesterone|in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
219624149|NCT02154607|DEVICE|CO2-Laser Treatment|
219624150|NCT00357292|DRUG|Azithromycin (T1225)|
219624151|NCT03068377|DIETARY_SUPPLEMENT|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
219624152|NCT03068377|DIETARY_SUPPLEMENT|Placebo|soft gel capsules without test material
218936727|NCT02583737|PROCEDURE|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
218936728|NCT01847326|DRUG|carboplatin|Given IV
219206400|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
219206401|NCT05566067|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
219206402|NCT02988193|DEVICE|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
218936729|NCT01847326|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
218936730|NCT01847326|DRUG|fluorouracil|Given IV
218936731|NCT01847326|DRUG|hydroxyurea|Given PO
219206403|NCT06030648|BIOLOGICAL|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
219206404|NCT05521386|DRUG|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
219206405|NCT05521386|DRUG|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
219206406|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
219206407|NCT02299349|DRUG|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
219206408|NCT02299349|DRUG|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
219624153|NCT03892798|OTHER|No interventions are planned|No interventions are planned
219624154|NCT04886843|OTHER|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
219624155|NCT04886843|DEVICE|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
219624156|NCT00121914|PROCEDURE|percutaneous ethanol instillation (PEI)|
219624157|NCT01033903|DRUG|misoprostol|800 micrograms intravaginally ONCE
219624158|NCT04298970|DIETARY_SUPPLEMENT|Intervention|Freeze-dried Brassica oleracea var. acephala
219624159|NCT04298970|DIETARY_SUPPLEMENT|Placebo|Placebo product
219047758|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
219047759|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
219624160|NCT06577311|COMBINATION_PRODUCT|Aminolevulinic acid hydrochloride 10% topical gel with Red Light|Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.
219624161|NCT05682209|DRUG|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
219624162|NCT05682209|OTHER|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
219624163|NCT02479451|DRUG|Theophylline|The study medication will be provided by Foundation Care.
219624164|NCT04940273|DRUG|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
219624165|NCT02044120|DRUG|niraparib|
219624166|NCT02044120|DRUG|Temozolomide|
219624167|NCT02044120|DRUG|Irinotecan|
219624168|NCT02525120|DEVICE|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
219624169|NCT02525120|PROCEDURE|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
219047760|NCT05083481|DRUG|ASP1570|Oral tablet
219047761|NCT05083481|DRUG|pembrolizumab|Intravenous Infusion
219047762|NCT05083481|DRUG|Trifluridine + Tipiracil|Oral Administration
219047763|NCT05083481|DRUG|Bevacizumab|Intravenous Infusion
219047764|NCT05083481|DRUG|Docetaxel|Intravenous Infusion
219624170|NCT01762644|DRUG|Oral Cyclosporine and Oral Omeprazole|
219624171|NCT01762644|DRUG|Oral Omeprazole|
219624172|NCT06070467|OTHER|Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools|"A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~1. Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~2. For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~1. Semi-directive interviews,~2. Focus groups,~3. Field observation."
219624173|NCT01568892|DRUG|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
219624174|NCT01568892|DRUG|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
219624175|NCT01427348|PROCEDURE|with assistant|head extension by an assistant during direct laryngoscopy
219624176|NCT01427348|PROCEDURE|without assistant|without head extension by an assistant during direct laryngoscopy
219624177|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
219047765|NCT05388669|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
219047766|NCT05388669|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection.
219047767|NCT05388669|DRUG|Amivantamab Intravenous|Amivantamab will be administered by IV infusion.
219047768|NCT06585137|OTHER|Web-Based Mind-Body Awareness Program|The program has been developed in line with peer-reviewed literature and expert opinions. It will incorporate a nursing approach based on the Meleis transition theory, education, mind-body awareness practices, and messages specific to women's health. Participants will be involved in an awareness program consisting of 3 sessions over an average of 2 weeks. Participants will be asked to complete their first final test one day after the egg retrieval (OPU) procedure, i.e., an average of 8-12 days after ovulation induction. There will be no intervention between the embryo transfer and the pregnancy test day. During this time period, interactive sessions between the researcher and participants will be conducted, and nursing care will be provided according to Meleis. The implementation phase of the study will be completed with 39 participants after the second final test following the pregnancy test.
219047769|NCT01952522|BEHAVIORAL|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
219047770|NCT01952522|BEHAVIORAL|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
219047771|NCT05452447|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
219047772|NCT05452447|DEVICE|Placebo|Passive emanator with formulated inert ingredients
219206409|NCT00787969|BIOLOGICAL|rituximab|Give IV
219206410|NCT00787969|DRUG|cladribine|Give IV
219206411|NCT00787969|DRUG|temsirolimus|Give IV
219206412|NCT00787969|BIOLOGICAL|Filgrastim|Give SC
219624178|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
219047773|NCT04102371|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
219047774|NCT04102371|DRUG|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
219047775|NCT04102371|DRUG|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
219047776|NCT04944017|DRUG|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
219047777|NCT04944017|OTHER|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
219047778|NCT02166489|BIOLOGICAL|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
219047779|NCT01591473|DRUG|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
219047780|NCT01591473|DRUG|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
219047781|NCT01591473|DRUG|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
219047782|NCT01591473|DRUG|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
219047783|NCT01591473|DRUG|Placebo|Placebo; 3 doses; nasal administration every 28 days
219624179|NCT01567774|DRUG|Atorvastatin|os, 20 mg, once per day, for 30 days
219624180|NCT01567774|DRUG|Rosuvastatin|os, 10 mg, once per day, for 30 days
219624181|NCT02182492|DRUG|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
219624182|NCT02182492|DRUG|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
218936732|NCT01847326|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
218936733|NCT01847326|RADIATION|radiation therapy|Undergo radiation therapy
218936734|NCT01847326|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
218936735|NCT01847326|OTHER|laboratory biomarker analysis|Correlative studies
218936736|NCT00423917|BIOLOGICAL|bevacizumab|
218936737|NCT00423917|DRUG|fulvestrant|
218936738|NCT05555420|DEVICE|SRP+Laser|Non-surgical periodontal therapy in combination with Laser
218936739|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counseling A|Krill powder capsules
218936740|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counselling B|Placebo capsules
218936741|NCT00927004|DRUG|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
218936742|NCT00927004|DRUG|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
218936743|NCT04466579|OTHER|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
218936744|NCT04466579|OTHER|Standard care|Standard anesthesiology care according to the protocol of the study
218936745|NCT03848182|DRUG|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
218936746|NCT03848182|BIOLOGICAL|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
218936747|NCT02936648|OTHER|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
218936748|NCT03479164|OTHER|Ultra Low-Dose CT|Ultra Low-Dose CT
218936749|NCT00549068|DRUG|Risedronate Sodium (Actonel)|
218936750|NCT05067699|DIAGNOSTIC_TEST|Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)|The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
218936751|NCT04981535|DEVICE|Head box during upper gastrointestinal endoscopy|"็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy."
218936752|NCT04192383|RADIATION|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
218936753|NCT00126334|PROCEDURE|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
219047784|NCT01591473|DRUG|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
219047785|NCT01133184|BIOLOGICAL|Sci B vac|Sci B vac
219047786|NCT00480779|BEHAVIORAL|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
219047787|NCT00480779|BEHAVIORAL|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
219047788|NCT01763775|DEVICE|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
219047789|NCT01763775|DEVICE|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
219047790|NCT05682131|DRUG|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
219047791|NCT05682131|COMBINATION_PRODUCT|Conventional chemotherapy|conventional chemotherapy
219047792|NCT06971224|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|2000 mg NR daily.
219047793|NCT06971224|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
219047794|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
219047795|NCT00876304|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
219047796|NCT00876304|DRUG|Placebo|Placebo capsules every 12 hours for 10 days
219047797|NCT06974110|DRUG|MOMA-341|MOMA-341 administered orally
219206413|NCT00787969|BIOLOGICAL|Pegfilgrastim|
219206414|NCT04129164|DRUG|VIB4920|Intravenous Dose 1.
219624183|NCT01836731|BEHAVIORAL|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
219624184|NCT01836731|BEHAVIORAL|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
219206415|NCT04129164|DRUG|Placebo|Intravenous dose matched to VIB4920.
219206416|NCT03868930|BEHAVIORAL|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
219206417|NCT03868930|BEHAVIORAL|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
219206418|NCT04304768|BIOLOGICAL|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
219206419|NCT06199635|DEVICE|Self-Forming Magnetic Anastomosis Device and Delivery System|Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
219624185|NCT02199431|DRUG|Lu AF11167|
219624186|NCT02199431|DRUG|Itraconazole|
219624187|NCT00873392|DRUG|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
219624188|NCT00873392|OTHER|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
219624189|NCT03027635|DEVICE|PleurX, peritoneal tunnelated catheter|A permanent catheter
219624190|NCT03027635|DEVICE|Large Volume Paracentesis|Short time drainage
219624191|NCT03027635|DRUG|Ciprofloxacin 500Mg Tablet|SBP prophylaxis
219624192|NCT01616836|OTHER|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
219624193|NCT01616836|OTHER|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
219624194|NCT01616836|OTHER|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
219624195|NCT03549078|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
219624196|NCT02964520|BEHAVIORAL|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
218936754|NCT05941195|OTHER|Psychoeducation|"In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included."
218936755|NCT03870243|DEVICE|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
218936756|NCT03870243|DEVICE|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
218936757|NCT03504176|OTHER|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
218936758|NCT02165267|BIOLOGICAL|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
218936759|NCT02165267|BIOLOGICAL|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
219624197|NCT02964520|BEHAVIORAL|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
219047798|NCT06974110|DRUG|Irinotecan|Irinotecan administered by IV infusion
219047799|NCT06974110|DRUG|Immunotherapy|Immunotherapy administered by IV infusion
219624198|NCT03657420|DRUG|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
219047800|NCT02445027|DEVICE|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
219047801|NCT03549247|BEHAVIORAL|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
219047802|NCT03127891|BEHAVIORAL|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
219047803|NCT03127891|OTHER|control group|no intervention should be given to patients allocated to this group
219047804|NCT05735561|DIAGNOSTIC_TEST|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
219047805|NCT01946399|DRUG|Ozurdex implant|Intravitreal injection of Dexamethasone implant
219047806|NCT01341886|DRUG|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
219047807|NCT04738916|DEVICE|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
219047808|NCT03179176|OTHER|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
219047809|NCT02325011|DRUG|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
219047810|NCT02325011|DRUG|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
219047811|NCT03037528|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
219047812|NCT03037528|BEHAVIORAL|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
219047813|NCT03037528|BEHAVIORAL|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
219047814|NCT03037528|BEHAVIORAL|dietary tracking|Participants will be asked to track their diet consistently.
219624199|NCT03657420|DRUG|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
219624200|NCT03657420|DRUG|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
218936760|NCT02165267|BIOLOGICAL|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
218936761|NCT03893461|RADIATION|x|Stereotactic body radiation therapy for localized NSCLC
218936762|NCT02137915|BIOLOGICAL|Human Central Nervous System Stem Cells|
218936763|NCT01576900|BEHAVIORAL|SyBeMeP (Systemized Behavioural Modification education Program)|"* Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
218936764|NCT03622918|DRUG|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
218936765|NCT03622918|DRUG|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
218936766|NCT01923272|DEVICE|AlphaCore Device|Active stimulation to the vagal nerve
218936767|NCT01923272|DEVICE|AlphaCore|Active AlphaCore treatment
218936768|NCT05202340|OTHER|No intervention|No intervention
218936769|NCT01757353|BEHAVIORAL|BASICS motivational interview|
218936770|NCT01757353|BEHAVIORAL|BASICS plus normative enhancement motivational interview|
218936771|NCT01757353|BEHAVIORAL|Self-directed: Information only|
219624201|NCT00249301|DRUG|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
219624202|NCT00582101|BEHAVIORAL|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
219206420|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
219624203|NCT00582101|BEHAVIORAL|General Health Promotion|7 hour one-day workshop on general health promotion topics
219624204|NCT03005704|DRUG|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
219624205|NCT03432104|DIETARY_SUPPLEMENT|Oxxynea®|Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.
219624206|NCT03432104|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
219624207|NCT04268225|PROCEDURE|US guided dynamic needle tip positioning peripheral intravenous cannulation|Catheterizations will be performed by one of three pediatric intensivists with vast experience in both traditional and US guided DNTP techniques for peripheral intravenous access. The operator will be allowed to independently choose which peripheral vein to cannulate. If necessary, patients will be given supplemental dose of sedation and analgesia in addition to the already given continuous infusions for invasive mechanical ventilation. Before puncture, the limb will be taped and maintained in an optimal position. A tourniquet will be placed proximal to the planned cannulation site. The site of puncture will be disinfected with Chlorhexidine gluconate 0.5% w/v, Alcohol 70% v/v. The choice of catheter will be left to the discretion of the operator. Available PIV cannulas include : 14 GA, 2X45 mm; 17 GA, 1.4X45 mm; 18 GA 1.2X45 mm; 20 GA 1X32mm BD Venflon™ and 24 GA, 0.7X19 mm; 26 GA 0.6X19 mm BD Neoflon™ (Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden).
219624208|NCT04268225|PROCEDURE|Traditional peripheral intravenous cannulation|For traditional insertion technique insertion attempt will be blind or tactile.
218936772|NCT05106699|RADIATION|proton plus carbon ion radiation|All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
218936773|NCT04660097|DRUG|Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer|This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
218936774|NCT05114642|DEVICE|Skeletal Class III Malocclusion Treatment with Face Mask Group|Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
218936775|NCT01067092|BEHAVIORAL|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
219206421|NCT04755439|PROCEDURE|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
219206422|NCT05441449|DEVICE|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
219206423|NCT05494762|DRUG|BGB-B167|Intravenous administration
219206424|NCT05494762|DRUG|Tislelizumab|Intravenous administration
219206425|NCT03443999|DEVICE|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
219206426|NCT05791708|DRUG|Sutimlimab|CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
219624209|NCT01894386|DRUG|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
219624210|NCT01894386|DRUG|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
219624211|NCT01894386|DRUG|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
219624212|NCT01894386|DRUG|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
219624213|NCT06577324|BEHAVIORAL|Live group music therapy|The intervention will involve the use of live music in a group of patients during their quimiotherapy session. The intervention will last approximately forty minutes and will be organized into three stages: Opening (10 min), Body Awareness and Movement (7-10 minutes), Intervention Development (20 minutes). Genres and songs are performed based on the group's preferences and suggestions. The instruments used for the group intervention are the same as those mentioned earlier; participants are provided with percussion instruments, accompanied by the music therapist's voice and the participants' voices. The intervention encourages active participation, with users playing the instruments, singing, engaging in dialogue, and/or reflecting between songs.
219624214|NCT02538575|OTHER|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
219624215|NCT03489642|BEHAVIORAL|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
219624216|NCT06081842|OTHER|Contraceptive counseling strengthening intervention package|Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
219624217|NCT01775111|BEHAVIORAL|Cognitive Training|
219624218|NCT01775111|BEHAVIORAL|Strength Training|
219624219|NCT01775111|DIETARY_SUPPLEMENT|FortiFit|
219624220|NCT04261829|PROCEDURE|Autologous Fat Transfer|Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
219624221|NCT05396027|OTHER|Audio-guided deep breathing|2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
219624222|NCT04089631|DRUG|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
219624223|NCT05602844|PROCEDURE|PSI Lapidus|Design of PSI: DICOM files will be imported into the Model Intestinal Microflora in Computer Simulation (MIMICS 21.0) 3D image processing software (Materialize, Belgium) for 3D rendering. The segmented bone images will be used for design of the computer-aided modelling (CAM) surgical jigs. 3D printing of PSI jig. PSI-assisted Lapidus Surgery.
219624224|NCT05602844|PROCEDURE|Conventional Lapidus|exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws
219624225|NCT01697748|DEVICE|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
219624226|NCT01697748|DEVICE|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
219624227|NCT03512769|DEVICE|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
219624228|NCT02694172|OTHER|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
219624229|NCT04412967|DEVICE|Dynamic ultrasound-guided short-axis needle tip navigation|placement of peripheral venous catheters using ultrasound guided technique
219624230|NCT04412967|OTHER|Standard technique of placing a PVC|Standard technique with palpation or Visual inspection of the pvc placement site
219624231|NCT00553839|DRUG|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
219206427|NCT06960018|DEVICE|Ennovate® Cervical, open surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using an open surgical technique"
219206428|NCT06960018|DEVICE|Ennovate® Cervical, minimal invasive surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using a minimally invasive technique."
219206429|NCT04227899|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
219206430|NCT04227899|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
219624232|NCT02684864|OTHER|Non-interventional|
219624233|NCT01898507|OTHER|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
219624234|NCT02245399|BEHAVIORAL|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
219206431|NCT06562218|PROCEDURE|isokinetic strengthening exercise|"Participants' isokinetic strength measurements will be assessed using the Cybex II Humac Norm isokinetic dynamometer. A strengthening programme will be performed for a total of 12 sessions, 3 days a week for 4 weeks, at 20 degrees of flexion, 20 degrees of extension, 60-90 and 180 degrees/s speed.~At the beginning and end of the 12th session, isokinetic and isometric muscle performance tests will be performed on the healthy wrist, and isometric wrist flexor and extensor strength measurements will be performed in neutral position 1 week after removal of the cast on the fractured wrist."
219206432|NCT06562218|PROCEDURE|conventional exercise programm|The immobilised limb was given finger grip exercises.
219206433|NCT04353492|BIOLOGICAL|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
219047815|NCT05222113|DRUG|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
219206434|NCT04617587|BEHAVIORAL|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
219206435|NCT01198431|BEHAVIORAL|Sleep duration|Duration of sleep per night
219206436|NCT03694262|DRUG|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
219206437|NCT03694262|DRUG|Bevacizumab|15mg/kg IV on day 1 of every cycle
219206438|NCT03694262|DRUG|Atezolizumab|1,200mg IV on day 1 of every cycle
219047816|NCT03958240|OTHER|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
219206439|NCT06799052|DEVICE|Transcervical single-balloon catheter|A single-balloon (Foley) catheter will be placed through the cervix and filled to 30cc of water or saline. The balloon will remain in the participant until their procedure, usually 3-4 hours, or earlier if it falls out on its own.
219206440|NCT06799052|DEVICE|Synthetic osmotic dilators|Dilators will be maintained in the cervix between 3-4 hours, during which each dilator rod will swell several times its initial dried diameter.
219206441|NCT01401231|BEHAVIORAL|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
219206442|NCT01401231|OTHER|Usual care|Continued usual care (could include referral for medication or psychotherapy)
219206443|NCT01773993|DRUG|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
219206444|NCT02332850|BIOLOGICAL|Isatuximab|Given IV
219206445|NCT02332850|DRUG|Carfilzomib|Given IV
219206446|NCT02332850|DRUG|Dexamethasone|Given IV or PO
219206447|NCT05010746|DEVICE|Innovalve TMVR system|Innovalve TMVR system
219206448|NCT04664881|DEVICE|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
219206449|NCT04153994|PROCEDURE|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
219206450|NCT04400071|BEHAVIORAL|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
218936776|NCT01067092|BEHAVIORAL|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
218936777|NCT01175083|BIOLOGICAL|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
218936778|NCT01175083|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
218936779|NCT01175083|BIOLOGICAL|Polio Sabin|4 oral doses
218936780|NCT02467686|BEHAVIORAL|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
218936781|NCT02467686|BEHAVIORAL|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
218936782|NCT02467686|BEHAVIORAL|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
219624235|NCT02245399|BEHAVIORAL|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
219624236|NCT00259870|DRUG|SB-773812|
219624237|NCT00259870|DRUG|Olanzapine|
219624238|NCT01965756|DRUG|Metformin|
218936783|NCT02467686|DRUG|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
218936784|NCT02467686|DRUG|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
218936785|NCT02467686|DRUG|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
218936786|NCT05855148|PROCEDURE|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
219047817|NCT00607282|DRUG|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
219047818|NCT00253578|DRUG|sorafenib tosylate|Given PO
219047819|NCT00253578|OTHER|laboratory biomarker analysis|Correlative studies
219047820|NCT04519619|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
219047821|NCT01188603|DRUG|flibanserin 100 mg dose every evening|all subjects receive flibanserin
219047822|NCT06193681|OTHER|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
219047823|NCT06193681|OTHER|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
219047824|NCT02257736|DRUG|Apalutamide|Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
219047825|NCT02257736|DRUG|Abiraterone acetate|Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
219047826|NCT02257736|DRUG|Prednisone|Participants will receive 5 mg tablet of prednisone twice daily orally.
219047827|NCT02257736|DRUG|Placebo|Participants will receive matching placebo to apalutamide once daily orally.
219047828|NCT03655678|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
219047829|NCT01664013|DRUG|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
219047830|NCT04029363|DEVICE|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
219047831|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
219624239|NCT01965756|DRUG|Placebos|
219624240|NCT00425932|BIOLOGICAL|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
219624241|NCT03247231|DEVICE|Endoscopic band ligation without resection|Endoscopic treatment of subepithelial tumors: autoamputation by endoscopic band ligation without resection.
219624242|NCT03247231|PROCEDURE|SINK|To obtain sample tissue biopsies after the endoscopic band ligation without resection, performing a single-incision with a needle-knife.
219624243|NCT05915663|OTHER|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
219624244|NCT05915663|OTHER|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
219624245|NCT06283381|DRUG|Esomeprazole|oral administration, tablets, 40 mg
219624246|NCT03886610|OTHER|Healthy controls|individuals without spinal cord injury
219624247|NCT03886610|OTHER|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
219624248|NCT03886610|OTHER|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
219624249|NCT01704495|DRUG|AZD5069|AZD5069 oral capsules self-administered twice daily.
219624250|NCT01704495|DRUG|Placebo|Placebo oral capsules self-administered twice daily.
219624251|NCT04735523|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure group
219624252|NCT04735523|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
219624253|NCT02338323|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
218936787|NCT00267813|DRUG|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
218936788|NCT02637830|OTHER|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
218936789|NCT02637830|OTHER|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
218936790|NCT02637830|OTHER|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
218936791|NCT00475306|DRUG|metoclopramide 10 mg|an anti-emetic medication
218936792|NCT00475306|DRUG|Diphenhydramine 25 mg|used for prophylaxis against akathisia
218936793|NCT00475306|DRUG|Placebo|placebo
218936794|NCT00475306|DRUG|Metoclopramide 20 mg|Metoclopramide 20 mg
218936795|NCT04407949|OTHER|CPAP Treatment|Comparing events from the CPAP device with the events scored in PSG
218936796|NCT00985361|DIETARY_SUPPLEMENT|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
218936797|NCT00985361|DIETARY_SUPPLEMENT|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
218936798|NCT01716052|DRUG|placebo|Lactulose
218936799|NCT01716052|DRUG|Ibuprofen|
218936800|NCT01042041|DRUG|sorafenib tosylate|Given orally
219206451|NCT04400071|BEHAVIORAL|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
219624254|NCT02338323|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
219624255|NCT01009450|PROCEDURE|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
219624256|NCT01009450|PROCEDURE|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
219624257|NCT04369144|OTHER|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
219624258|NCT05533593|DRUG|Aminoglycoside|Inpatients using aminoglycoside
219624259|NCT05936060|BIOLOGICAL|INMUNOCEM|Mesenchymal Stromal Cell suspension intraarticularly injected
219624260|NCT05936060|DRUG|PLACEBO COMPARATOR|Administration of plasmalyte as a vehicle for MSC
219624261|NCT01967966|DRUG|GDC-0032|Single oral dose
219624262|NCT01967966|DRUG|GDC-0032|Single IV dose
219624263|NCT00802230|DRUG|Terbutaline Infusion|
219624264|NCT05780125|DRUG|FibCLOT|30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
219624265|NCT05780125|DRUG|RiaSTAP|30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
219624266|NCT03866512|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
218936801|NCT01042041|DRUG|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
219624267|NCT06254118|DRUG|Polyunsaturated Fatty Acids|1000mg omega-3 fatty acids taken once daily with meals for 12 months
219624268|NCT06254118|DIETARY_SUPPLEMENT|olive oil|1000mg olive oil taken once daily with meals for 12 months
219624269|NCT02328313|BEHAVIORAL|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
219624270|NCT03328507|DRUG|BLI4900|BLI4900 Bowel Preparation
219624271|NCT03328507|DRUG|PEG Control|Polyethylene glycol-based bowel preparation
218936802|NCT01042041|DRUG|cisplatin|Given via transarterial/hepatic chemoembolization
218936803|NCT01042041|DRUG|mitomycin C|Given via transarterial/hepatic chemoembolization
218936804|NCT01042041|PROCEDURE|transarterial chemoembolization|
218936805|NCT01042041|PROCEDURE|hepatic artery embolization|
218936806|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
218936807|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
218936808|NCT05437497|DRUG|Remimazolam Injection|The experimental group was sedated with remimazolam
218936809|NCT05437497|DRUG|Propofol Injection|The control group was sedated with propofol
218936810|NCT04056832|PROCEDURE|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
219206452|NCT06014528|DRUG|IN10018|100mg QD orally (PO)
219624272|NCT02262715|DRUG|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
219624273|NCT02262715|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
219624274|NCT02262715|OTHER|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
218936811|NCT04056832|PROCEDURE|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
218936812|NCT03742752|OTHER|Enteral nutrition|administration of enteral nutrition
218936813|NCT03742752|OTHER|Parenteral nutrition|administration of parenteral nutrition
219206453|NCT06014528|DRUG|Placebo of IN10018|100mg QD orally (PO)
219624275|NCT00997373|DRUG|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
219624276|NCT06155929|BEHAVIORAL|Flight|The participants are flying to turkey and back home. The flights are the intervention.
219624277|NCT05209867|DRUG|CBD oil|"* Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc \~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~* The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
218936814|NCT05048511|BIOLOGICAL|vitamin D estimation|Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
219624278|NCT01129063|DRUG|Clopidogrel|"Pharmaceutical form : tablet~Route of administration: oral"
219624279|NCT02183324|DRUG|Low dose of BI 1356 BS|
219624280|NCT02183324|DRUG|Medium dose of BI 1356 BS|
219624281|NCT02183324|DRUG|High dose of BI 1356 BS|
219624282|NCT02183324|DRUG|Placebo|
219624283|NCT00566241|DRUG|recombinant human IGF-1|rhIGF-1
219624284|NCT00566241|DRUG|Placebo|Placebo
219624285|NCT00323453|DEVICE|Open appendectomy using Alexis Wound Retractor followed by standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
219624286|NCT00323453|PROCEDURE|Open appendectomy with standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
218936815|NCT04790565|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
218936816|NCT04342507|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
218936817|NCT04342507|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
218936818|NCT03521778|OTHER|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~1. Triggerbands - therapist put a pressure by the thumb along the presented pathway.~2. Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~3. Folding Distortions - therapist conduct traction or compression of the affected joint.~4. Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~5. Cylinder Distortions - therapist compress and stretch by the hands affected area.~6. Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
218936819|NCT03521778|OTHER|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
218936820|NCT03521778|OTHER|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
218936821|NCT02405442|DRUG|Andecaliximab|Andecaliximab administered via subcutaneous (SC) injection
218936822|NCT02405442|DRUG|Placebo|Placebo to match andecaliximab administered via SC injection
218936823|NCT06014398|DIAGNOSTIC_TEST|Dynamic testing of Pituitary Function|"Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1\].~Dynamic testing of pituitary function:~* Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~* Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency."
218936824|NCT00551057|BEHAVIORAL|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
219047832|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
219047833|NCT00816868|DRUG|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
219624287|NCT01867125|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
219624288|NCT01867125|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
219624289|NCT04812041|OTHER|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
219624290|NCT04812041|OTHER|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
219624291|NCT00529503|DRUG|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
219624292|NCT00529503|DRUG|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
219624293|NCT00529503|DRUG|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
219624294|NCT00529503|DRUG|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
219624295|NCT00529503|DRUG|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
219624296|NCT00529503|DRUG|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
219624297|NCT05188261|DRUG|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
219624298|NCT05188261|DRUG|Placebo|A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
219624299|NCT04051671|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
219624300|NCT03690128|BEHAVIORAL|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
219624301|NCT03690128|BEHAVIORAL|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
219624302|NCT04501237|BEHAVIORAL|Bruxers with sleep hygiene instructions|the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
219624303|NCT06575283|OTHER|No intervention will be performed in this cohort study|Deep learning classification models will be used for automatic prediction of cerebral palsy. Machines will be used to assist doctors in cerebral palsy risk evaluation.
219624304|NCT05966077|OTHER|IMPACT OF SENDING AN SMS|"Each subject of the experimental group will receive, in addition to the usual procedure of the VigilanS Lorraine device, an SMS 48 hours before the telephone call for evaluation at 3 months, warning him of this call.~The time of this SMS has been set at 1:00 p.m. for all the people included in this group.~At the end of this evaluation call, the caller will pass a satisfaction questionnaire to the subject in relation to the sending of the SMS"
219624305|NCT04177095|DIAGNOSTIC_TEST|Allosure|Monthly monitoring of dd-cfDNA levels in blood
218936825|NCT05349565|OTHER|CONVENTIONAL PHYSICAL THERAPY|"High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes"
218936826|NCT05349565|OTHER|MUSCLE ENERGY TECHNIQUE|"Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes"
219624306|NCT04177095|DRUG|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
219624307|NCT04177095|DIAGNOSTIC_TEST|Trugraf|Monthly monitoring of Trugraf result
219047834|NCT00308711|DRUG|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
219624308|NCT03693638|DRUG|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
219624309|NCT03693638|DRUG|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
218936827|NCT02223845|OTHER|Music|Self-selected music played via headphones
219047835|NCT00308711|DRUG|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
219047836|NCT00308711|DRUG|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
219047837|NCT02311751|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
219047838|NCT02167256|DRUG|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
219624310|NCT03280524|OTHER|reflexology|
219624311|NCT03280524|OTHER|self-care guidelines with feet|
219624312|NCT02810041|DIETARY_SUPPLEMENT|yoghurts enriched with XXS|
219624313|NCT02810041|DIETARY_SUPPLEMENT|yoghurts non enriched with XXS|
219624314|NCT04171336|BEHAVIORAL|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
219624315|NCT00777296|DRUG|ARIKACE™|Study start date is before Jan 18, 2017.
219624316|NCT00777296|DRUG|Placebo|Study start date is before Jan 18, 2017.
219624317|NCT01731132|DRUG|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
219624318|NCT00228436|DRUG|peginesatide|
219624319|NCT04973267|BEHAVIORAL|Game Plan for PrEP|See arm description.
219624320|NCT04973267|BEHAVIORAL|Attention-Matched Control Lifestyle Habits Videos|Web-based videos providing information on sleep hygiene and proper diet.
219624321|NCT06258941|BEHAVIORAL|MF-HIIT|Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
218936828|NCT03476590|PROCEDURE|new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine|"The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations."
218936829|NCT00093379|DRUG|Capecitabine|825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
219624322|NCT06258941|BEHAVIORAL|HIIT-only|Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
219624323|NCT06258941|BEHAVIORAL|MF-only|Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
219624324|NCT06258941|BEHAVIORAL|Sedentary activity|Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
219624325|NCT04082923|OTHER|Liquid meal|Four-hour liquid mixed meal test
219624326|NCT04082923|OTHER|Solid meal|Four-hour solid mixed meal test
219624327|NCT05382819|DRUG|FRTX-02 Capsule|DYRK-1A Inhibitor
219624328|NCT05382819|DRUG|Placebo|Matching Placebo
219624329|NCT04665219|BEHAVIORAL|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
219624330|NCT04665219|BEHAVIORAL|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
219624331|NCT00590213|DRUG|Casodex 150mg|
219624332|NCT00590213|PROCEDURE|Radiotherapy|
219624333|NCT00590213|PROCEDURE|Haematology|
219624334|NCT02967315|PROCEDURE|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
219624335|NCT02967315|PROCEDURE|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
219624336|NCT02967315|PROCEDURE|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (\< 1% risk) after central line placement.
219624337|NCT02967315|PROCEDURE|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
219624338|NCT02967315|PROCEDURE|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
219624339|NCT02967315|PROCEDURE|Pregnancy test|A urine pregnancy test will be performed in female subjects.
219624340|NCT02967315|PROCEDURE|Electrocardiogram|12 lead ECG
219624341|NCT00206271|BEHAVIORAL|neck collar; advice to act-as-usual; active mobilisation|
219624342|NCT01644071|DRUG|cipralex|one time 10 mg, tablet
219624343|NCT03437863|DEVICE|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
219624344|NCT04282941|DRUG|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
218936830|NCT00093379|DRUG|Oxaliplatin|50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
218936831|NCT00093379|RADIATION|Radiation Therapy (XRT)|Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
218936832|NCT05546580|DRUG|Iadademstat|iadademstat oral solution
218936833|NCT05546580|DRUG|Gilteritinib Oral Tablet|120 mg Gilteritinib
218936834|NCT00267787|OTHER|genetic analysis|standard of care
218936835|NCT01171560|PROCEDURE|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
218936836|NCT03275350|DRUG|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
218936837|NCT03275350|OTHER|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
218936838|NCT06251882|OTHER|injection|10ml D5W injection for MP patients
218936839|NCT05753696|DRUG|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
218936840|NCT05753696|DRUG|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
218936841|NCT00400270|PROCEDURE|Breathing and relaxation exercises: the Papworth Method|
218936842|NCT04254770|DEVICE|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
218936843|NCT04254770|DEVICE|Marketed Power Toothbrush|Marketed Power Toothbrush
219624345|NCT04282941|DRUG|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
219624346|NCT06364917|DRUG|Pembrolizumab|The dosing regimens for Pembrolizumab (200 mg Q3W), are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
219624347|NCT06364917|DRUG|Carboplatin|The combination therapy dosages for Carboplatin are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
219624348|NCT06364917|DRUG|Paclitaxel|The combination therapy dosages for Paclitaxel are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
219624349|NCT06364917|DRUG|Pemetrexed|The combination therapy dosages for Pemetrexed are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
219624350|NCT06364917|DRUG|Nivolumab|The dosing regimens for Nivolumab (360 mg Q3W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
219624351|NCT06364917|DRUG|Ipilimumab|The dosing regimens for Ipilimumab (1 mg/kg Q6W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
219624352|NCT05113550|OTHER|Surgical remove|liver hydatid cyst (LHC) treated by total or partial pericystectomy
219624353|NCT00672724|DRUG|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
219624354|NCT00672724|DRUG|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
219624355|NCT00952835|OTHER|regular treatment|regular treatment
219624356|NCT04494490|BEHAVIORAL|Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback|The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
219624357|NCT02472106|DEVICE|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
219624358|NCT05989256|DIAGNOSTIC_TEST|EndoTool|EndoTool is a vendor based glucose management software
219624359|NCT05989256|OTHER|glucose management team|comparison group will be services that have not yet implemented EndoTool
219624360|NCT05989256|OTHER|standard of care glucose management|providers adjusting insulin and consulting the Glucose Management Team at their discretion
218936844|NCT05262049|OTHER|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
218936845|NCT05262049|OTHER|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
218936846|NCT05262049|OTHER|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
218936847|NCT01707576|BEHAVIORAL|consultation 10 days later|new depression screening
218936848|NCT06426589|OTHER|Resistence training and mediterranean diet|"Resistance training. Subjects assigned to the experimental group participated in resistance program twice a week (on Tuesdays and Thursdays) for a period of 12 weeks, totaling 24 sessions of 60 minutes each. Each session during this time was divided into three clearly differentiated parts: i) 5-minute warm-up comprised of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise.~Mediterranean Diet. In addition to the resistance intervention, the experimental group received a Mediterranean diet protocol based on the study by Ismail et al. \[34\] with the following meal plan: i) carbohydrates constituted 50% of daily intake; ii) fats repre-sented 35%; and iii) proteins accounted for 15%."
218936849|NCT01668862|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
218936850|NCT01668862|DRUG|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
219206454|NCT06014528|DRUG|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
219206455|NCT06414434|DRUG|BTX-A51|Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
219206456|NCT06100939|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
219206457|NCT06100939|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
219206458|NCT06550232|DRUG|Papaverine|Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline
219206459|NCT06550232|OTHER|placebo|I.V Sallne
219624361|NCT04835662|BEHAVIORAL|Complementary feeding promotion|The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
219624362|NCT03819972|DIETARY_SUPPLEMENT|Dose response of Capolac®|Capolac® (milk minerals high in calcium) dose is manipulated
219624363|NCT00287534|DRUG|Anastrozole|oral
219624364|NCT00287534|DRUG|Tamoxifen|oral
219624365|NCT01592786|DRUG|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
219624366|NCT06234839|DIETARY_SUPPLEMENT|L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets|Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
219624367|NCT00108264|BIOLOGICAL|Tumor RNA transfected dendritic cells|
219624368|NCT02183558|OTHER|OGTT by randomization|
219624369|NCT02183558|OTHER|OGTT by indication|
219624370|NCT06308458|OTHER|Breather Exerciser Trainer|Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks
218936851|NCT02817529|DEVICE|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
219206460|NCT02263274|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
219206461|NCT01380743|DRUG|duvoglustat|Single oral dose
219206462|NCT01380743|DRUG|rhGAA|Single intravenous infusion
219206463|NCT06494605|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is an early naturalistic and behavioural intervention for children with initial signs of neurodivergence or on the autism spectrum between the ages of 12-48 months. This early intervention aims to increase the rates of development in several domains and to decrease the characteristics of autism conditions that hinder children's ability to learn from everyday experiences and interactions.
219206464|NCT05876078|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
219206465|NCT05542082|DEVICE|CHILLS Procedure|Cryotherapy
219624371|NCT06308458|OTHER|Conventional Breathing Exercise|Diaphragmatic breathing; place one hand on upper chest and the other on belly. Patient Breathe in slowly through nose, letting the air in deeply towards lower belly then patient is asked to tighten abdominal muscles and let them fall inward during exhalation through pursed lips Pursed-up breathing; by inhales through nose and exhales over 4 and 6 seconds in a whistling position Exercise connected with respiration; repetitive bilateral shoulder flexion then repetitive bilateral shoulder abduction, synchronized with breathing
219624372|NCT02483221|DRUG|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
219624373|NCT02483221|DRUG|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
219624374|NCT04349228|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200mg/day
219624375|NCT04349228|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine (HCQ) without any active substance
218936852|NCT02817529|DEVICE|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
218936853|NCT00504946|DRUG|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
218936854|NCT00504946|DRUG|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
219624376|NCT03827993|BEHAVIORAL|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
219624377|NCT00061997|DIETARY_SUPPLEMENT|inositol|
219624378|NCT03034447|OTHER|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
219624379|NCT03034447|OTHER|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
219624380|NCT03034447|OTHER|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
219624381|NCT00597662|DEVICE|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
218936855|NCT00504946|DRUG|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
218936856|NCT00504946|DRUG|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
219047839|NCT02167256|DRUG|AZD0530 125mg daily|Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
219047840|NCT02167256|DRUG|Placebo|50% of patients will receive placebo treatment for the duration of the study.
219047841|NCT06082102|DRUG|Orelabrutinib|Orelabrutinib Tablets
219047842|NCT06082102|DRUG|Rituximab|Rituximab Injection
219047843|NCT06082102|DRUG|Lenalidomide|Lenalidomide Capsules
219047844|NCT06082102|DRUG|Rituximab|Rituximab Injection
219047845|NCT03389711|COMBINATION_PRODUCT|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
219047846|NCT01420081|DRUG|PF-05212384|154mg IV weekly
219047847|NCT01420081|DRUG|PF-05212384|154mg IV weekly
219047848|NCT01420081|DRUG|PF-05212384|154mg IV weekly
219047849|NCT04203550|PROCEDURE|Intraoperative irrigation|Operation with irrigation
219047850|NCT04203550|PROCEDURE|No irrigation|Operation without irrigation
219047851|NCT04295603|OTHER|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
219047852|NCT04295603|OTHER|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
219624382|NCT00597662|DEVICE|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
218936857|NCT00504946|DRUG|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
218936858|NCT05216744|DRUG|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
219206466|NCT05368467|COMBINATION_PRODUCT|The clinical course and disease management|The clinical course and disease management of pulmonary hypertension patients
219206467|NCT06448091|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
219206468|NCT05260047|BEHAVIORAL|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
219206469|NCT05260047|BEHAVIORAL|Telehealth MAT|Describe what is the Telehealth MAT briefly
219206470|NCT05260047|BEHAVIORAL|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
218936859|NCT05216744|DRUG|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
218936860|NCT00114790|RADIATION|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
218936861|NCT05279573|DIETARY_SUPPLEMENT|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
218936862|NCT05279573|OTHER|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
218936863|NCT05367635|DRUG|SKB315 for injection|SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
218936864|NCT01900418|BEHAVIORAL|Walk with Ease|An evidence-based walking program
218936865|NCT05461508|BIOLOGICAL|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
218936866|NCT05461508|OTHER|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
218936867|NCT02214394|OTHER|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
218936868|NCT02214394|DEVICE|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
219624383|NCT06089564|BEHAVIORAL|Skit video, Pictorial, Sign language|Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
219624384|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
219624385|NCT04202120|OTHER|Age-related stereotyping priming|The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
219624386|NCT04202120|OTHER|Non age-related stereotype priming|he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
219624387|NCT04908774|BEHAVIORAL|Fasting Mimicking Diet|"The mobile application Salufast provides standardised fasting packages for 5 days of approx. 500 kcal and accompanies the participants during all fasting days."
219624388|NCT00607074|DRUG|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
219624389|NCT00607074|DRUG|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
219624390|NCT00607074|DRUG|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
219624391|NCT02659410|OTHER|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
219624392|NCT02659410|OTHER|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
219624393|NCT02659410|OTHER|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
219624394|NCT02659410|OTHER|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
219624395|NCT02659410|OTHER|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
218936869|NCT00578292|DRUG|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
218936870|NCT00578292|DRUG|Fludarabine|30mg/m2 Day -5 through Day -2
218936871|NCT00578292|DRUG|Campath 1H|Per institutional guidelines Days -5 through -2
218936872|NCT00578292|DRUG|Cyclophosphamide|50 mg/kg Days -5 through -2
218936873|NCT00578292|DRUG|MESNA|10 mg/kg x 5 Days -5 through -2
218936874|NCT01756170|DRUG|paclitaxel|
218936875|NCT01756170|DRUG|cisplatin|
219624396|NCT02659410|OTHER|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
219624397|NCT02659410|OTHER|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
219624398|NCT02659410|OTHER|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
219624399|NCT02659410|OTHER|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
219624400|NCT02659410|OTHER|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
219624401|NCT02659410|OTHER|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
219624402|NCT02659410|OTHER|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
219624403|NCT02659410|OTHER|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
219624404|NCT02659410|OTHER|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
219624405|NCT02659410|OTHER|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
219624406|NCT03966417|OTHER|Exercise training|Continuous exercise training 2 times per week for a period of 12 weeks.
219624407|NCT03061136|DRUG|Clonazepam|
219624408|NCT03061136|DRUG|Placebo|
219624409|NCT05342194|DRUG|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
219624410|NCT05342194|DRUG|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
218936876|NCT01756170|RADIATION|Radiotherapy|
219206471|NCT04242589|RADIATION|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
218936878|NCT04726969|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
218936879|NCT04726969|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
219206472|NCT04242589|PROCEDURE|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
219624411|NCT05342194|DRUG|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
219624412|NCT05342194|DRUG|Oral placebo|Oral placebo po QD continuously
219624413|NCT05342194|DRUG|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
219624414|NCT05342194|DRUG|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
219624415|NCT05342194|DRUG|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
219624416|NCT04598009|DRUG|Binimetinib|Taken orally (PO) twice a day (BID)
219624417|NCT04598009|DRUG|Imatinib|Taken orally (PO) once a day (QD)
219624418|NCT05538897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219624419|NCT05538897|PROCEDURE|Computed Tomography|Undergo CT scan
219624420|NCT05538897|DRUG|Ipatasertib|Given PO
219624421|NCT05538897|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219624422|NCT05538897|DRUG|Megestrol Acetate|Given PO
219624423|NCT02393157|DRUG|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
219624424|NCT02393157|DRUG|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
219624425|NCT02393157|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
219624426|NCT02393157|DRUG|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
219624427|NCT02393157|DRUG|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
219624428|NCT05050136|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
219624429|NCT05050136|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
219624430|NCT05697809|DRUG|OXU-001|Suprachoroidal sustained release dexamethasone acetate
219624431|NCT05697809|DEVICE|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
219624432|NCT05697809|DRUG|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
219624433|NCT05182632|BEHAVIORAL|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
219206473|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
219206474|NCT02224729|DRUG|Bendamustine hydrochloride|Given IV
219206475|NCT02224729|DRUG|Bortezomib|Given SC
219206476|NCT02224729|DRUG|Dexamethasone|Given PO
219624434|NCT02199964|DRUG|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
219206477|NCT06620952|PROCEDURE|O-ring technique|"O-ring technique. consists on a different arrangement of fibrin-glue on a polymethilmetacrylate cranioplasty, with the aim to create a gasket to prevent CSF leakage"
219206478|NCT05078879|DRUG|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
219206479|NCT05281744|BEHAVIORAL|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
219206480|NCT01248624|BEHAVIORAL|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
219206481|NCT03984318|PROCEDURE|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
219624435|NCT02199964|DRUG|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
219624436|NCT01664637|DRUG|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
219206482|NCT06507371|RADIATION|node-sparing modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
219206483|NCT06507371|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
219206484|NCT06507371|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
219206485|NCT06507371|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219206486|NCT06507371|RADIATION|standard short-course radiotherapy|radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
219624437|NCT01664637|DRUG|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
219624438|NCT04381143|DRUG|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablet daily
219624439|NCT04381143|DRUG|Matching Placebo|Matching Placebo 1 pill daily
219624440|NCT05029037|DRUG|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
219206487|NCT05110261|DRUG|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
219206488|NCT05110261|DRUG|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
219206489|NCT05708534|DRUG|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
219206490|NCT06130826|PROCEDURE|Biopsy|Undergo tissue biopsy
219206491|NCT06130826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219206492|NCT06130826|PROCEDURE|Bone Scan|Undergo bone scan
219206493|NCT06130826|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219206494|NCT06130826|DRUG|Immunotherapy|Receive M5A-IL2 ICK SC
219206495|NCT06130826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219206496|NCT06130826|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219206497|NCT06130826|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219206498|NCT06966154|DRUG|tislezumab|Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W).
219624441|NCT05029037|DRUG|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
219624442|NCT02749188|OTHER|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
219624443|NCT05821933|DRUG|RC108|RC108 plus Furmonertinib and/or Toripalimab
219624444|NCT06087848|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
219624445|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
219624446|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
219624447|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
219624448|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
219624449|NCT06097364|DRUG|Vincristine|Administered by IV infusion
219624450|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
219624451|NCT06271785|DIAGNOSTIC_TEST|HR-EEG recording|All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
219624452|NCT05946590|PROCEDURE|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
219624453|NCT05000788|BEHAVIORAL|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
219624454|NCT05000788|BEHAVIORAL|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
219624455|NCT03964285|OTHER|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
219624456|NCT03964285|OTHER|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
219624457|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
219624458|NCT04400838|BIOLOGICAL|MenACWY vaccine|Standard single dose of MenACWY vaccine
219624459|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
219624460|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
219624461|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR
219624462|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)
218936880|NCT04726969|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
218936881|NCT02933684|DRUG|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
218936882|NCT02933684|BEHAVIORAL|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
218936883|NCT02933684|DRUG|Placebo|Administered in pill form.
219047853|NCT04590495|DRUG|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
219047854|NCT04590495|DRUG|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
219047855|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
219047856|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
219047857|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
219206499|NCT06966154|DRUG|golidocitinib|"Golidocitinib: Dose-escalating oral regimens:~Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD)."
219624463|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
219624464|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
219624465|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
219624466|NCT05574101|DRUG|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
219624467|NCT05574101|RADIATION|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
219047858|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
218936884|NCT02977962|BEHAVIORAL|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
219624468|NCT06061809|DRUG|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
219624469|NCT06061809|DRUG|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
219624470|NCT06061809|DRUG|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
219624471|NCT06061809|DEVICE|Tumor Treating Fields (TTFields, 200 kHz)|"TTFields (OPTUNE Gio®), for the treatment of newly diagnosed and/or recurrent GBM, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body/brain. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells. TTFields is comprised of two main components: (1) an Electric Field Generator and (2) INE Insulated Transducer Arrays (the transducer arrays). Patients carry the device in an over-the-shoulder bag or backpack and receive continuous treatment without changing their daily routine."
219047859|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
219624472|NCT05755438|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
219624473|NCT05755438|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
219047860|NCT00414388|DRUG|Sorafenib|400mg twice daily
219047861|NCT02153775|BEHAVIORAL|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
219624474|NCT06455137|DEVICE|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
219624475|NCT05981989|DEVICE|Epidural electrical stimulation (EES)|Subjects will undergo a surgical procedure to implant a system that provides epidural electrical stimulation (EES) of the cervical spinal cord. After surgery, subjects will undergo a structured physical rehabilitation program and electrical stimulation.
219047862|NCT05098535|OTHER|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
219047863|NCT05098535|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
219047864|NCT01997268|DRUG|Placebo|Corn Oil
219047865|NCT01997268|DRUG|SC401B 2 capsules|
219047866|NCT01997268|DRUG|SC401B 4 capsules|
219047867|NCT01997268|DRUG|SC401B 6 capsules|
219047868|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
219047869|NCT00411619|DRUG|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
219047870|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
219047871|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
219047872|NCT00000102|DRUG|Nifedipine|
219047873|NCT03591575|DRUG|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
219047874|NCT03591575|DRUG|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
219047875|NCT03130322|OTHER|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
219047876|NCT03130322|OTHER|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
219047877|NCT03130322|OTHER|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
219047878|NCT03130322|OTHER|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
219047879|NCT03130322|OTHER|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
219047880|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
219047881|NCT03945981|DRUG|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
219047882|NCT06980636|DRUG|Shengmai Liquid|The Shengmaiyin treatment group will be given the traditional Chinese medicine Shengmaiyin oral liquid (produced by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with the approval number Z41021384. Ingredients: Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, excipients: sucrose, sodium benzoate, ethylparaben, specification 10m1/bottle), taken orally at a dose of 10ml per time, three times a day
219624476|NCT06622850|OTHER|Acupressure|"In acupressure, cun is used as the unit of measurement to determine the points to be applied. In order to find the acupressure points correctly, measurements should be made using the individual\&#39;s own fingers. The thumb widths of the individuals participating in the study will be measured and converted as centimeter 1 cun unit. The points to be used in acupressure will be Shen Men (HT7) located in the transverse wrist crease, in the small depression between the pisiform and ulna bones, (LI11) located at the end of the crease when the elbow is bent, and Hegu (LI4) located in the space between the thumb and index finger will be marked by the certified researcher (GB) with an acetate pen in the patients in the study group. And the application will be performed by the certified researcher (GB)."
219624477|NCT06972901|BIOLOGICAL|Early faecal calprotectin dosage|An early dosage of faecal calprotectin will be done for the active arm group.
219624478|NCT05781295|DEVICE|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
219624479|NCT05781295|DEVICE|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
219624480|NCT00832702|PROCEDURE|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
219624481|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
219624482|NCT05534009|OTHER|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
219624483|NCT05279027|DRUG|Zirconium Zr 89 Crefmirlimab Berdoxa|Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
219624484|NCT05832671|PROCEDURE|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
219624485|NCT05832671|PROCEDURE|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
218936885|NCT02977962|OTHER|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
219047883|NCT06980636|OTHER|Placebo|A simulated Shengmaiyin oral liquid (provided by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with main ingredients water, brown sugar, flavoring agents, etc., specification 10m/bottle), 10ml per time, three times a day. The treatment course for Shengmaiyin or placebo will be 8 weeks (56 days), with follow-up continuing until 30 days after the end of the treatment course.
219206500|NCT06966154|DRUG|Selinexor|Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.
219206501|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Digital jaw relation group|implant supported maxillary overdenture constructed using electronic facebow to record maxillo-mandibular relation.
218936886|NCT00856518|DEVICE|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
218936887|NCT00856518|DEVICE|Sham|The same device just like the EMST but does not provide a load on the target muscle group
218936888|NCT04849559|DRUG|Tradipitant|Tradipitant Capsule
218936889|NCT04849559|DRUG|Placebo|Placebo Capsule
218936890|NCT00947193|DRUG|Ataluren|Oral powder
219206502|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Static jaw relation group|implant supported maxillary overdenture constructed using the conventional jaw relation method.
219206503|NCT06965088|BIOLOGICAL|Combined Intra-operative platelet-rich plasma with corticosteroid injection|Combined Intra-operative platelet-rich plasma with corticosteroid injection was administered around the surgical wound. Each patient had 10 ml of blood collected into a RegenKit A-PRP tube. The blood-filled tube was then placed into a RegenLab PRP centrifuge and spun for approximately 5 minutes to obtain platelet-rich plasma (PRP), yielding around 5 ml of injectable PRP. Once prepared, the PRP was stored in the collection tube and used within 4 hours from the time of blood draw to the time of injection. After the keloid excision and wound closure were completed, the PRP was aseptically aspirated from the tube using a sterile needle and injected into the intradermal layer along the wound edges using a 30G needle. The injection was performed in a sterile manner, with a dosage of 0.5 ml of PRP per 1 centimeter of wound length. For corticosteroid administration, triamcinolone acetonide (40 mg/ml) was used. The medication was injected into the intradermal layer using a 30G needle along the
219047884|NCT03665038|DRUG|Brexanolone|Administered as IV infusion.
219047885|NCT06984536|DRUG|Reduced ATG plus mini PTCy|The conditioning protocol comprises cytarabine (Ara-C) (4 g/m2/day, days -9), busulfan (Bu) (3.2 mg/kg/day, days -8 to -6), cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4), simustine (250 mg/m2, day -3) and r-ATG (total 7.5mg/kg ,from days -5 to -2). Mini PTCy 14.5mg/kg/day will be given on day +3 and +4.
219047886|NCT06658847|OTHER|Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.
219047887|NCT06658847|OTHER|No Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.
219047888|NCT06861439|DRUG|Tirzepatide|Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.
219047889|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
219047890|NCT01686412|DEVICE|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
219047891|NCT07000994|DRUG|Dobutamine|In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
219047892|NCT07000994|OTHER|Routine care|In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
219047893|NCT06998407|DRUG|AVZO-021|AVZO-021 is an oral selective CDK2 inhibitor
219047894|NCT06998407|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
219047895|NCT06998407|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
219047896|NCT06998407|DRUG|AVZO-023|AVZO-023 is an oral selective CDK4 inhibitor
219047897|NCT07001644|DEVICE|microneedling|microneedling with topical application of PRP on one side of abdomen and microneedling only on the other side.
219047898|NCT07001644|DEVICE|Carboxytherapy|carboxytherapy with intradermal injection of PRP on one side of abdomen and carboxytherapy only on the other side.
219047899|NCT04579679|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
219047900|NCT06678438|PROCEDURE|Ultrasound-guided brachial plexus block|The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
219047901|NCT06678438|PROCEDURE|Haematoma Block|Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
219047902|NCT06630832|OTHER|Simulated work in the heat with no cooling during rest breaks|Young and older adults will not undergo cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
219047903|NCT06630832|OTHER|Simulated work in the heat with partial cooling during rest breaks|Young and older adults will not undergo partial cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
219047904|NCT06630832|OTHER|Simulated work in the heat with full cooling during rest breaks|Young and older adults will not undergo full cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
219047905|NCT07024030|DRUG|0.02mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
219047906|NCT07024030|DRUG|0.04mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
219047907|NCT07025473|DIAGNOSTIC_TEST|Smartphone-enabled otoscopy|Belle AI for ear image assessment
219047908|NCT07024927|PROCEDURE|AF ablation|Catheter ablation will be performed under general anesthesia or local anesthesia. Pulmonary vein isolation (PVI) was performed in all patients. Beyond this mandatory step, the specific ablation strategy/protocol and ablation parameters/settings will be determined at the discretion of the operating physicians at each participating center.
219624486|NCT04579848|DRUG|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
219206504|NCT06965088|DRUG|Intra-operative corticosteroid injection|Intra-operative corticosteroid injection alone was administered around the surgical wound using triamcinolone acetonide (40 mg/ml). The injection was performed into the intradermal layer using a 30G needle, immediately after keloid excision and wound closure. The medication was injected along the wound edges following the suture line, at a dosage of 0.1 ml per 1 centimeter of wound length.
219206505|NCT06505889|OTHER|Local anesthesia methods|Local pain control method before arterial blood sampling procedure
219206506|NCT01102673|DRUG|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
219206507|NCT01102673|DRUG|Placebo|Placebo to match PF-04991532 will be provided
219206508|NCT01181154|DRUG|rituximab (Mabthera®)|1000 mg at day 1 and day 15
219624487|NCT04579848|DRUG|Placebo|Placebo capsule
219624488|NCT04579848|DRUG|Folic Acid 1 MG|Folic acid
219624489|NCT04556890|DEVICE|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
219624490|NCT04556890|DEVICE|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
219624491|NCT05267236|OTHER|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
219624492|NCT05267236|OTHER|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
219624493|NCT06976242|PROCEDURE|Elastic Resistance Training|The type of resistance exercises in which the participants use the Thera Band of yellow and red colours (weight about 2-2.5 kg with full elongation) for resistance training
219206509|NCT01181154|DRUG|Placebo|equivalent volume total
219206510|NCT05324683|OTHER|No intervention planned|No intervention planned; study is observational
219624494|NCT06976242|PROCEDURE|Free Weight Exercises|The type of resistance exercises in which the participants use weight cuffs (weight 2-2.5 kg) tied to their lower leg for resistance training
219624495|NCT06976242|PROCEDURE|Conventional Training|The conventional training includes side-lying hip abductions, standing weighted abductions, and lateral step-ups exercises.
219624496|NCT06974656|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of n 0.3-0.5 μg/kg/h.
219624497|NCT06974656|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5-2 mg/kg/h.
219624498|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
218936891|NCT00805337|DEVICE|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
218936892|NCT05765513|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
218936893|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
218936894|NCT02663544|OTHER|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
218936895|NCT02663544|OTHER|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
219206511|NCT06755411|OTHER|OHFCP2|The proposed intervention consists of a two-phase approach for implementing guidelines and evidence-based recommendations: educating healthcare professionals and enhancing clinical activity.
219206512|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
219206513|NCT04457843|OTHER|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
219624499|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
219624500|NCT06572384|BIOLOGICAL|Belimumab|Belimumab will be administered.
219624501|NCT06572384|OTHER|Placebo|Placebo will be administered.
219624502|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
219624503|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
219624504|NCT05815511|DIETARY_SUPPLEMENT|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
219624505|NCT05815511|DIETARY_SUPPLEMENT|Placebo|Oral capsule consumption once a day for 12 weeks
219624506|NCT04318977|DEVICE|high-frequency rTMS|repetitive transcranial magnetic stimulation
219624507|NCT04318977|DEVICE|TBS|theta burst stimulation
219624508|NCT04318977|DEVICE|placebo|placebo transcranial magnetic stimulation
219624509|NCT03210714|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219624510|NCT03210714|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
219624511|NCT03210714|PROCEDURE|Bone Scan|Undergo a bone scan
219624512|NCT03210714|PROCEDURE|Computed Tomography|Undergo a CT scan
219624513|NCT03210714|DRUG|Erdafitinib|Given PO
219624514|NCT03210714|OTHER|Laboratory Biomarker Analysis|Correlative studies
219624515|NCT03210714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218936896|NCT02663544|OTHER|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
219624516|NCT03210714|OTHER|Pharmacological Study|Correlative studies
219624517|NCT03210714|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219624518|NCT03210714|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
219624519|NCT03210714|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219624520|NCT05691166|BEHAVIORAL|High-intensity progressive resistance training|Supervised high-intensity progressive resistance training twice per week for 12 months
219624521|NCT05691166|OTHER|General practitioner care|Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
219624522|NCT06807463|DRUG|TEV-53408|Solution for subcutaneous (sc) injection
219624523|NCT06807463|DRUG|Placebo|Solution for subcutaneous (sc) injection
219047909|NCT07024927|PROCEDURE|VT ablation|For patients with hemodynamically stable VT, comprehensive chamber mapping (including activation mapping, substrate mapping, and entrainment mapping) is recommended. This aims to elucidate the VT activation sequence and identify the critical isthmus. Precise ablation targeting the isthmus should be performed to terminate the VT. For patients with hemodynamically unstable VT, substrate mapping during sinus rhythm can be performed first. This includes identification of low-voltage zones and abnormal electrograms (e.g., late potentials, local abnormal ventricular activities - LAVAs). Targeted substrate modification ablation should then be conducted based on the mapping findings. For all patients, complete substrate mapping is recommended after VT termination.
219624524|NCT01909934|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
219624525|NCT03969004|DRUG|Cemiplimab|Intravenous (IV) infusion over 30 minutes
219624526|NCT03969004|DRUG|Placebo|Intravenous (IV) infusion over 30 minutes
219624527|NCT06090097|DEVICE|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
219624528|NCT06090097|OTHER|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
219624529|NCT05907161|DEVICE|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
219624530|NCT05907161|DEVICE|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
219624531|NCT05907161|DEVICE|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
219624532|NCT02795663|DEVICE|NIRS EEG HR recording|NIRS EEG HR recording
219624533|NCT05671172|DRUG|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
219624534|NCT05671172|DRUG|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
219624535|NCT06443502|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
219624536|NCT06443502|DRUG|Concomitant Antibiotic Therapy|Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
219624537|NCT06730555|BEHAVIORAL|ACCESS Intervention|Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.
219624538|NCT06730555|BEHAVIORAL|Control Group|Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.
219624539|NCT05064709|DEVICE|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
218936897|NCT00926029|DRUG|Fluoride|Brush twice daily
218936898|NCT00926029|DRUG|Triclosan, fluoride|Brush twice daily
218936899|NCT00926029|OTHER|Metal salt|Brush twice daily
218936900|NCT00635258|DRUG|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
218936901|NCT00635258|DRUG|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
218936902|NCT06317129|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted.
218936903|NCT05106153|DRUG|Suvorexant|Suvorexant will be administered orally as per assigned treatment sequence.
218936904|NCT05106153|DRUG|Zolpidem|Zolpidem will be administered orally as per assigned treatment sequence.
218936905|NCT05106153|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
218936906|NCT05106153|DRUG|Placebo|Placebo will be administered orally as per assigned treatment sequence.
218936907|NCT04553042|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
218936908|NCT04601467|DRUG|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
218936909|NCT04601467|DRUG|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
218936910|NCT06311617|DIAGNOSTIC_TEST|Optical coherence tomography|Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
218936911|NCT00971815|DRUG|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
218936912|NCT00971815|DRUG|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
218936913|NCT02105961|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
218936914|NCT02105961|DRUG|Placebo|Sterile 0.9percent sodium chloride solution
218936915|NCT00005062|RADIATION|radiation therapy|
218936916|NCT05613465|DRUG|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
218936917|NCT05613465|DRUG|Placebo|Placebo is packaged in the same package as the drug
218936918|NCT05618691|DRUG|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
218936919|NCT05618691|OTHER|Placebo|Placebo will be administered to subjects in the placebo group
219548767|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
219548768|NCT06103383|DRUG|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
218936920|NCT03031080|DEVICE|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
218936921|NCT02385643|BEHAVIORAL|SmartPhone Support System|
218936922|NCT02522663|OTHER|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
218936923|NCT02541396|DRUG|Wafermine|35 or 70 mg ketamine in a sublingual wafer
218936924|NCT02541396|DRUG|Oxycodone|5 mg oxycodone capsule
218936925|NCT02541396|DRUG|Placebo|Placebo capsule or placebo wafer
218936926|NCT02966444|OTHER|MUFA-rich HF Meal|
218936927|NCT02966444|OTHER|PUFA-rich HF Meal|
218936928|NCT02966444|OTHER|SFA-rich HF Meal|
218936929|NCT06518408|DRUG|Cabotegravir Injectable Product|long-acting regimen dosed every 2-months
218936930|NCT06518408|DRUG|Rilpivirine Injectable Product|long-acting regimen dosed every 2-months
218936931|NCT01347411|PROCEDURE|CPAP|Treatment with CPAP
218936932|NCT00540852|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
218936933|NCT04937465|OTHER|No intervention done|No intervention was done. This was an observational study.
218936934|NCT02566369|DRUG|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
218936935|NCT02566369|DRUG|Placebo cream|Placebo cream applied once daily for 12 weeks
218936936|NCT03472261|DRUG|Botulinum toxin type A|Dysport
218936937|NCT03472261|OTHER|Upper extremity orthoses|Twister
218936938|NCT03472261|OTHER|Home exercise program|Specific exercises for pronation deformity
218936939|NCT00558649|BIOLOGICAL|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
218936940|NCT06193668|BEHAVIORAL|High-fat overnutrition|Overnutrition: 40% higher lipid consumption per day than required
218936941|NCT06193668|BEHAVIORAL|Normocaloric macronutrient-balanced nutrition|"Normocaloric, macronutrient-balanced nutrition:~Calories requirement for weight maintenance \[(kcal/d) 55% carbohydrates, 15% proteins, 30% fat\]"
219548769|NCT06103383|PROCEDURE|Oocyte pick up|Surgical oocyte pick up without triggering
219548770|NCT06103383|PROCEDURE|Oocyte in vitro maturation|In vitro maturation procedure
219548771|NCT06103383|PROCEDURE|Oocyte in vitro activation|In vitro oocyte activation procedure
219548772|NCT01851876|DEVICE|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
219548773|NCT01151280|DEVICE|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
219548774|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
219548775|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
219548776|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
219206514|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
219206515|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
219624540|NCT05064709|DEVICE|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
219624541|NCT06023602|DRUG|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
219624542|NCT06023602|DRUG|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
219624543|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
219624544|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
219047910|NCT07024992|BEHAVIORAL|ESCAPE app + NRT|ESCAPE is a mobile intervention that targets anxiety sensitivity among Black adults who smoke cigarettes and have HIV. This intervention is framed within the cultural context of interoceptive stress among Black adults who smoke, which is supported by theory, empirical evidence, and characteristics of this group. The intervention employs a variety of features to educate users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. ESCAPE also utilizes Ecological Momentary Assessments (EMAs) to gather information and provide personalized messages to users in real time. All participants will receive free nicotine replacement therapy (NRT).
219047911|NCT07024992|BEHAVIORAL|quiSTART app + NRT|quitSTART is a smartphone-based National Cancer Institute (NCI) intervention for standard mobile smoking cessation treatment. The intervention contains features that allow its' users to better understand their smoking patterns, and build skills needed to become and stay smoke free. The app allows users to track cravings and delivers motivational messages to users for each craving they track. All participants will receive free nicotine replacement therapy (NRT).
219047912|NCT07024992|BEHAVIORAL|Control (CTRL)|The CTRL group will complete the same baseline survey, follow-up surveys, and ecological momentary assessments as the ESCAPE app + NRT and the quitSTART app + NRT group. All participants will receive free nicotine replacement therapy (NRT). They will not receive additional intervention content.
219047913|NCT07024277|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219047914|NCT07025603|BEHAVIORAL|The social ABCs|"The Social ABCs, a parent-mediated intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD), originally developed in Canada (Brian et al., 2016). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behavioural Analysis). The two main goals of the intervention: early functional verbal communication and positive affect sharing in the context of play and caregiving activities.~The current study follows the Group Social ABCs protocol, a 6-week parent-mediated intervention designed to support early social communication in young children with autism. The program is delivered at two research sites: Soroka and Hebrew University of Jerusalem. Each week, parents participate in: One group session via Zoom, led by a trained Social ABCs coach, with 3-5 parents per group. These sessions introduce strategies and provide peer support, and one to two individual face-to-face coach (See #17-745 for more information)."
219047915|NCT07025356|DRUG|Implantation of a trigeminal Vagus cervical nerve stimulator system|The NS 100 is a medical device used for the treatment of diabetic neuropathy pain. Routine observational monitoring will be performed
219206516|NCT00357682|DRUG|Esomeprazole|20mg per day
219206517|NCT00357682|DRUG|Esomeprazole|80mg per day
218936942|NCT04154189|DRUG|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
219047916|NCT07025356|DEVICE|Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation|The medium term outcomes of neurostimulation will be assessed on diabetic neuropathy pain, glucose and drug usage
219047917|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
219047918|NCT07023900|OTHER|Manual traction|The pacemaker or ICD lead extraction with manually.
219047919|NCT07025057|BEHAVIORAL|Provider training|The study will address patient-provider interactions through actionable, experiential provider trainings focused on communication provider, cultural relevance, and awareness of and referrals to community care services including Community Health Workers (CHW) and home visiting, for both clinical and community settings. Trainings are rooted in both history and in current research about how to address maternal mortality disparities, and will include self-learning, didactics, reflection, discussion, and identifying ways to tailor trainees settings to better hear, respect, and meet the needs of perinatal Black and Hispanic women.
219047920|NCT07023549|PROCEDURE|ABC|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
219047921|NCT07023549|PROCEDURE|ACB|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
219047922|NCT07023549|PROCEDURE|BAC|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
219047923|NCT07023549|PROCEDURE|BCA|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
219047924|NCT07023549|PROCEDURE|CAB|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
219206518|NCT00357682|DRUG|Aspirin|300mg per day
218936943|NCT04154189|DRUG|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
219047925|NCT07023549|PROCEDURE|CBA|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
219047926|NCT07023835|DRUG|50 mg Usnoflast|50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)
219047927|NCT07023835|DRUG|75 mg Usnoflast|75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)
219047928|NCT07023835|DRUG|Placebo|Matching placebo of 25 mg and 50 mg
219047929|NCT06633302|OTHER|Simulated multi-day heatwave exposure|Older adults exposed to a multi-day simulated heat wave exposure
219206519|NCT04878094|DIAGNOSTIC_TEST|Intravenous Indocyanine Green/ICG injection|Intravenous Indocyanine Green/ICG injection will be administered for visualization
219548777|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
219548778|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
219548779|NCT04956289|DRUG|Viltolarsen|Received during weekly intravenous infusions
219548780|NCT02579226|DRUG|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
219548781|NCT04210544|DIETARY_SUPPLEMENT|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
219548782|NCT04210544|DIETARY_SUPPLEMENT|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
219548783|NCT04210544|DIETARY_SUPPLEMENT|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
219548784|NCT03123874|DEVICE|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
219548785|NCT03123874|DEVICE|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
219548786|NCT01780467|BEHAVIORAL|Role of dopamine|
219548787|NCT01816789|DRUG|rFSH|
219548788|NCT01816789|DRUG|buserelin|
219548789|NCT01626339|DRUG|Intravitreal Ranibizumab|
219548790|NCT01626339|DRUG|Intravitreal bevacizumab|
219548791|NCT00057226|DRUG|Radafaxine|
219548792|NCT03007706|PROCEDURE|Women undergo cesarean section delivery|
219548793|NCT06504355|BEHAVIORAL|Training program incorporating video aerobic exercise, action video game and resistive action video game|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
219548794|NCT00844350|DRUG|letrozole , oxytocin,hCG,clomiphene citrate|
219548795|NCT03544242|OTHER|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
219548796|NCT03544242|DRUG|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
219548797|NCT03544242|DRUG|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
219624545|NCT05273788|DEVICE|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
219624546|NCT05112705|DIAGNOSTIC_TEST|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
219624547|NCT05700942|DEVICE|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
219624548|NCT05700942|DEVICE|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
219624549|NCT03670615|OTHER|tDCS|All study participants randomized to tDCS will receive active tDCS.
219624550|NCT03670615|OTHER|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
219624551|NCT03670615|OTHER|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
219624552|NCT03670615|OTHER|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
219624553|NCT02883816|OTHER|assessment of lung function|measurement of lung volumes and flow rates of bronchial
219624554|NCT05445102|PROCEDURE|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
219624555|NCT00592306|DRUG|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
219624556|NCT00592306|DRUG|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
219624557|NCT03732664|DRUG|Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab|One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
218936944|NCT04154189|DRUG|Etoposide|Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
218936945|NCT04154189|DRUG|Lenvatinib|Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
218936946|NCT02050893|DRUG|sedatives(Midazolam and Propofol)|
218936947|NCT04609462|PROCEDURE|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
218936948|NCT04609462|PROCEDURE|High flow nasal cannula|Breathing support with High-flow nasal cannula
218936949|NCT04048772|BEHAVIORAL|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
218936950|NCT04048772|OTHER|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
218936951|NCT04727372|OTHER|Questionnaire|A structured questionnaire will be served to each participant of study after getting the verbal consent from him for inclusion into the study
218936952|NCT06268756|OTHER|Data collection|Data collection
218936953|NCT00748904|DRUG|Rifaximin|400 mg orally
218936954|NCT00748904|DRUG|Lactulose|20 grams titrate to 2-3 bowel movements in one day
218936955|NCT02170103|PROCEDURE|percutaneous intervention (PCI)|Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
218936956|NCT02170103|DRUG|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
218936957|NCT02170103|PROCEDURE|Ultrasound|Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
218936958|NCT03680326|DEVICE|OCT|only OCT
218936959|NCT04079309|BEHAVIORAL|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
218936960|NCT01287312|PROCEDURE|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
218936961|NCT00631943|DRUG|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
218936962|NCT04980092|OTHER|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
219624558|NCT00826969|DRUG|Ciclesonide|320µg Ciclesonide versus Placebo
219624559|NCT00826969|DRUG|Placebo|Placebo
218936963|NCT04223219|DRUG|Fentanyl|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
219624560|NCT04091516|BEHAVIORAL|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
219624561|NCT03696134|OTHER|questionnaire|questionnaire
219624562|NCT01442597|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
219624563|NCT01442597|BEHAVIORAL|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
219624564|NCT01442597|BEHAVIORAL|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
219624565|NCT04230928|OTHER|Very low carbohydrate diet|Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 \& 10. Participants will learn to track carbohydrate intake
219624566|NCT04230928|OTHER|Standard DPP-GLB diet|Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, \& 10
219624567|NCT04230928|BEHAVIORAL|Standard DPP-GLB program modules|Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
219624568|NCT06483009|DEVICE|Cryoablation|Cryoablation: For subjects assessed as stable disease (SD) after two cycles of medication, one session is performed under local anesthesia after assessment. The multidisciplinary team, including investigators and radiologists, evaluates the feasibility of tumor ablation based on the size, location, and proximity to major blood vessels. Criteria for eligible lesions include a maximum diameter \<5cm, relatively isolated lesion location, and not adjacent to major blood vessels or vital structures. Cryoablation is performed using a 17G IceRod Plus 1.5 cryoablation needle, guided by CT, and avoiding nearby anatomical structures using the Visual-ICE cryoablation system.
219624569|NCT03751176|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
218936964|NCT04223219|DRUG|Fentanyl, Propofol|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
219047930|NCT07024537|DRUG|FOLFOXIRI-HAIP+Fuquinitinib|All patients received oral fruquintinib at an initial dose of 4 mg once daily from day 1 to day 21 of each 28-day cycle, and FOLFOXIRI-HAIP chemotherapy with Oxaliplatin 85 mg/m² and Leucovorin 400 mg/m² infused via arterial pump over 2 hours on day 1, Irinotecan 150 mg/m² infused via arterial pump over 90 minutes on day 1,and 5-Fluorouracil 2400 mg/m² infused via arterial pump over 46 hours, repeated biweekly until disease progression, patient's refusal, unacceptable toxic effects, or withdrawal of consent.
219047931|NCT07023874|PROCEDURE|Bupivacaine group|Participants will receive bilateral ultrasound-guided pecto-intercostal fascial plane block
219624570|NCT03751176|DRUG|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
219624571|NCT03751176|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
219624572|NCT03751176|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
219624573|NCT02816736|DRUG|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
219624574|NCT02816736|DRUG|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
219624575|NCT02816736|DRUG|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
219624576|NCT02816736|DRUG|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
219624577|NCT03835923|BEHAVIORAL|lifestyle intervention|"intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback."
219624578|NCT03835923|BEHAVIORAL|usual care|Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
219624579|NCT05863663|OTHER|questionnaire|cross sectional questionnaire
219624580|NCT01139775|DRUG|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
219624581|NCT01139775|DRUG|Cisplatin|Administered intravenously as a continuous 1-hour infusion
219624582|NCT01139775|DRUG|LY2603618|Administered intravenously as a continuous 1-hour infusion
219624583|NCT02774941|DEVICE|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
218936965|NCT04223219|DRUG|Dexmedetomidine, Ketamine, Magnesium sulfate|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
218936966|NCT01526759|DIETARY_SUPPLEMENT|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
218936967|NCT01526759|DIETARY_SUPPLEMENT|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
218936968|NCT05911685|DEVICE|SeaLA™ left atrial appendage occluder|"1. Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~2. Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~3. Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~4. Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
218936969|NCT04133688|DEVICE|ASC|mobile app
218936970|NCT03367078|DEVICE|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
218936971|NCT03367078|OTHER|Usual care|Usual care of DOC patients
218936972|NCT02138448|BEHAVIORAL|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
219047932|NCT07023874|PROCEDURE|bupivacaine + dexmedetomidine group|Participants will receive bilateral ultrasound-guided pecto intercostal fascial plane block using 30 mL of 0.25% bupivacaine with one µg/kg dexmedetomidine in each side
219206520|NCT04878094|DIAGNOSTIC_TEST|PINPOINT endoscopic fluorescence imaging system|After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.
219624584|NCT02774941|DEVICE|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
219624585|NCT01542242|DRUG|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
219624586|NCT04752852|DRUG|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
219624587|NCT04752852|DRUG|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
219624588|NCT06583174|BEHAVIORAL|Breastfeeding Attitudes|Relationship between Breastfeeding Attitudes and Nutrition Knowledge Levels
219624589|NCT02050386|OTHER|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
219624590|NCT02050386|OTHER|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
219624591|NCT04083638|DIAGNOSTIC_TEST|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
219624592|NCT05047692|BIOLOGICAL|AdCLD-CoV19-1|Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
219624593|NCT05784233|BEHAVIORAL|Relevance (Likelihood Salient Item is Target)|The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
219624594|NCT01753310|BIOLOGICAL|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
219624595|NCT01753310|DRUG|Placebo|Up to 2mL
219624596|NCT03193853|DRUG|Tak-228 & Tak-117|Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
219624597|NCT03193853|DRUG|Cisplatin & Nab Paclitaxel|following Tak-228 \& Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
219624598|NCT04079647|DRUG|Immunotherapy|Patients receive immunotherapy for cancer treatment
219624599|NCT06318416|DIAGNOSTIC_TEST|urine spectrophotometry for rifampin absorbance|All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
219624600|NCT04886219|OTHER|Eye examination|"* Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~* orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~* ocular biometry~* corneal topography~* monocular photographs in photopic and scotopic condition"
219624601|NCT06482853|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
219624602|NCT06482853|DRUG|Saline|Saline will be used as the placebo comparator.
219624603|NCT06684951|DRUG|hCG|observe hCG effect on endometrial receptivity
219624604|NCT05797519|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
219624605|NCT05581641|BIOLOGICAL|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection.
219624606|NCT05581641|OTHER|Placebo|Placebo matched to RNA vaccine administered as intramuscular injection.
219624607|NCT04935879|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
219624608|NCT04935879|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
219624609|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218936973|NCT03005899|DRUG|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
218936974|NCT03005899|DRUG|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
219624610|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219624611|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218936975|NCT02474069|DRUG|Secukinumab|
218936976|NCT04173494|DRUG|Momelotinib|Momelotinib tablets will be self-administered orally once daily
219624612|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
219624613|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219624614|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
219624615|NCT06644781|DRUG|Ifinatamab deruxtecan|Intravenous administration
219624616|NCT06644781|DRUG|Docetaxel|Intravenous administration
218936977|NCT04173494|DRUG|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
218936978|NCT04173494|DRUG|Danazol|Danazol capsules will be self-administered orally twice daily
218936979|NCT04173494|DRUG|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
218936980|NCT04300166|DEVICE|Telemedicine & Humidification|Wireless control of CPAP usage, adherence, leakage and humidifier usage
218936981|NCT04078256|OTHER|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
218936982|NCT04078256|OTHER|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
218936983|NCT03656380|DRUG|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
218936984|NCT03656380|DRUG|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
218936985|NCT03656380|OTHER|Placebo|Saline subcutaneous injection
218936986|NCT04518579|PROCEDURE|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
218936987|NCT01623050|DEVICE|SinuSys Dilation System|Sinuplasty
219206521|NCT04878094|DIAGNOSTIC_TEST|Endoscopy|Standard technique and assessment of anastomosis without the use of NIR angiography
219624617|NCT06644781|DRUG|Paclitaxel|Intravenous administration
219624618|NCT06644781|DRUG|Irinotecan hydrochloride (HCl)|Intravenous administration
219624619|NCT05112185|BEHAVIORAL|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
219624620|NCT06842667|BEHAVIORAL|Papageno video|"The intervention will be a video (14 min 13 sec in length) of a series of clips from the Papageno interviews developed during the pilot phase of this project. The decision to combine the videos and shorten the total length of the video was based on the feedback we received during the acceptability and feasibility phase of this study. Interviewees were asked questions about a time in their life when they came close to suicide but found non-suicide alternatives (their Papageno story)."
219624621|NCT06842667|BEHAVIORAL|Control video|The control condition will involve viewing a mental health education video (12 min 14 sec in length) created by our team. It is a simple informational video, aimed at psychoeducation about suicide and safety promotion. It includes a list of mental health and crisis resources. Both videos are interview-style.
219624622|NCT06882876|DRUG|JS014 Combined With Toripalimab and TACE|JS014 (60μg/kg,QW)+Toripalimab (240mg , Q3W)+ dTACE (60mg/m2)
219624623|NCT06983730|DIETARY_SUPPLEMENT|Vitamin B3|1000mg once a day orally for two days, once the day before the exercise session, and once the day of the exercise session.
219624624|NCT05976386|DRUG|Dupilumab (SAR231893)|Injection solution Subcutaneous
219624625|NCT06657144|DRUG|CHS-114|Solution for infusion
219624626|NCT06657144|DRUG|Toripalimab|Solution for infusion
218936988|NCT02133690|BIOLOGICAL|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
218936989|NCT02133690|OTHER|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
219624627|NCT06657144|DRUG|5 Fluorouracil|Solution for infusion
218936990|NCT04316091|DRUG|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
219624628|NCT06657144|DRUG|Cisplatin|Solution for infusion
219624629|NCT06983223|DIETARY_SUPPLEMENT|Sucrosomial® Vitamin B12|Sucrosomial® B12 is an advanced oral vitamin B12 supplement formulated with Sucrosomial® technology to enhance absorption. Participants in this group will receive 1,000 mcg of Sucrosomial® B12 (single sachet of orally dissolving powder) once daily for 4 weeks.
219624630|NCT06983223|OTHER|Placebo (Oral)|Participants in the placebo group will receive an identical powder that matches the Sucrosomial® B12 in appearance, packaging, and administration. The placebo will be administered once daily for 4 weeks.
219624631|NCT06985706|PROCEDURE|Subthreshold Micropulse Laser (SML)|SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.
219047933|NCT07024485|DEVICE|AR animations and 5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The intervention group received a tutorial that incorporated Augmented Reality (AR) animations alongside conventional teaching materials. In addition to watching four real-life smoker scenario videos and reading corresponding case texts, students used their smartphones to interact with AR animations that visualized the physiological effects of smoking (e.g., lung cancer, vascular disease, aging). These animations were used during group discussions and role-play sessions, helping students to assess smokers' knowledge, illustrate health risks, and tailor counseling plans using the 5As model. The AR experience was designed to enhance learning engagement, emotional connection, and self-efficacy in delivering smoking cessation counseling.
219047934|NCT07024485|DEVICE|5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The control group, received a conventional tutorial without the use of AR technology. They watched the same four smoker scenario videos and read the same case texts, then engaged in small group discussions and role-play activities to develop quit plans using the 5As counseling model. However, unlike the intervention group, their learning process relied solely on textual and video materials, without the immersive or interactive elements provided by AR. This approach represents standard smoking cessation training methods commonly used in nursing education.
219047935|NCT06885034|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
219206522|NCT06966349|DRUG|Systane Complete Preservative-Free|"One drop of Systane Complete Preservative Free will be instilled in each eye.~Higher order aberrations assessed before and after instillation."
219624632|NCT06985706|DRUG|Anti-VEGF Monotherapy (standard care)|Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).
219624633|NCT06982573|DEVICE|Effects of applying magnetic stimulation|The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients with End-Stage Renal Disease (ESRD)
218936991|NCT04316091|DRUG|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
218936992|NCT00244543|DRUG|R89674 (generic name not yet established)|
218936993|NCT00158964|DEVICE|EASYTRAK 4 STEERABLE LV lead|
218936994|NCT02411890|PROCEDURE|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
218936995|NCT02411890|PROCEDURE|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
218936996|NCT02411890|PROCEDURE|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
219624634|NCT06983184|OTHER|MC-synced NTP|Menstrual cycle-synced neuromuscular training program
219624635|NCT06983184|OTHER|Blinded NTP|Blinded neuromuscular training program
219624636|NCT06820099|DRUG|HRS-7535 tablet|HRS-7535 tablet.
219624637|NCT06820099|DRUG|HRS-7535 tablet placebo|HRS-7535 tablet placebo.
219624638|NCT01956773|OTHER|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
219624639|NCT03440229|OTHER|Emulsifier-containing diet|CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
219624640|NCT00126750|BEHAVIORAL|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
218936997|NCT02411890|PROCEDURE|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
218936998|NCT02283827|DRUG|BIA 2-093|
218936999|NCT02283827|DRUG|Phenytoin|
218937000|NCT02861001|DEVICE|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
218937001|NCT02861001|DEVICE|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
218937002|NCT02193503|OTHER|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
218937003|NCT03733886|DEVICE|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
218937004|NCT05724095|OTHER|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
218937005|NCT05724095|OTHER|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
218937006|NCT05724095|OTHER|electrodes attached|electrodes are attached to area of acupoints
218937007|NCT02147561|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
218937008|NCT04799093|DIAGNOSTIC_TEST|EyeBOX|Eye-Tracking based diagnostic
218937009|NCT04287270|OTHER|Assesment|Evaluations which explained in the arms section will be made as described.
218937010|NCT01599988|DIETARY_SUPPLEMENT|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
218937011|NCT01599988|DIETARY_SUPPLEMENT|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
218937012|NCT02952443|BEHAVIORAL|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
219047936|NCT06886230|DRUG|Placebo (Normal Saline)|Patients in this group will receive an intravenous (IV) injection of normal saline before surgery. This serves as a control group to compare the efficacy of active treatment groups in preventing postoperative nausea and vomiting.
219047937|NCT06886230|DRUG|Ondansetron (Zofran)|Patients in this group will receive a single intravenous (IV) dose of Ondansetron 4 mg before surgery. Ondansetron is a selective 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting associated with anesthesia and surgery.
219047938|NCT06886230|DRUG|Dexamethasone|Patients in this group will receive a single intravenous (IV) dose of Dexamethasone 8 mg before surgery. Dexamethasone is a corticosteroid with anti-inflammatory properties that has been shown to reduce the incidence of PONV by modulating inflammatory pathways and neuroreceptor activity.
219047939|NCT06889246|DIETARY_SUPPLEMENT|Anvitra Gastric Suspension|Anvitra Gastric Suspension is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in patients. The intervention involves administering 1 packet (15 ml) per dose three times daily, taken orally 30 minutes after meals, for a duration of 14 days. The supplement is intended to alleviate symptoms of GERD (heartburn, regurgitation, and dyspepsia). Anvitra Gastric Suspension has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in GERD treament.
218937013|NCT02952443|BEHAVIORAL|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
218937014|NCT06222788|DEVICE|Convertible Plasma Jet|NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
218937015|NCT05818969|BEHAVIORAL|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
218937016|NCT00262626|DRUG|Intraocular pressure reduction|
218937017|NCT00262626|PROCEDURE|Argon laser trabeculoplasty|
218937018|NCT00262626|PROCEDURE|Trabeculectomy|
218937019|NCT02829567|BEHAVIORAL|Motivational interviewing|
218937020|NCT05727852|DIAGNOSTIC_TEST|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
218937021|NCT05727852|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
218937022|NCT05727852|DIAGNOSTIC_TEST|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
218937023|NCT03691194|DIETARY_SUPPLEMENT|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
219624641|NCT01400490|DIETARY_SUPPLEMENT|EPA-DHA Study|6 weeks of dietary supplementation
219624642|NCT00450437|BIOLOGICAL|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
219624643|NCT00450437|BIOLOGICAL|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
219624644|NCT01087125|DRUG|No Interventions|No Interventions
218937024|NCT03691194|DIETARY_SUPPLEMENT|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
218937025|NCT00528593|DRUG|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
218937026|NCT04635540|BEHAVIORAL|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
218937027|NCT05263778|DRUG|Bempedoic Acid / Ezetimibe Oral Tablet|Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
218937028|NCT05263778|DRUG|Placebo|Matching placebo by mouth once daily for 12 weeks
218937029|NCT04578236|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
219047940|NCT07042997|PROCEDURE|Evaluation of Anatomical Accuracy in Targeting Forearm Extensor Muscles with Blind Dry Needling in Patients with Lateral Epicondylitis Using Ultrasound Guidance|"Using a high-resolution linear probe (5-12 MHz) , the muscle in which the needle tip is located is monitored in real time in the transverse and longitudinal planes. Whether the needle is in the targeted muscle is recorded as correct or incorrect."
219047941|NCT06724965|BEHAVIORAL|Trans STAIR|Skills Training in Affect and Interpersonal Regulation (STAIR) is a transdiagnostic evidenced-based mental health treatment for individuals who have experienced multiple traumas. STAIR is based in cognitive-behavioral principles and delivered in a flexible manner over 8 group sessions, with demonstrated efficacy for the treatment of PTSD and other mental health symptoms. This trial will adapt and pilot test the STAIR intervention to be culturally appropriate and acceptable for TGD persons, adding content related to TGD health and wellness, coping with minority stress, responding to stigma and microaggressions, social support, and community connectedness, self-compassion, celebrating trans joy, trans advocacy, sexual health and PrEP use.
219047942|NCT06724965|BEHAVIORAL|PrEP Well|"This pilot trial will leverage PrEP Well, a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care)"
219047943|NCT06888895|OTHER|Passive-active stretching (PAS)|Passive-active stretching (PAS) combines conventional passive stretching with active exercises designed to activate muscles that promote hamstring elongation. On the other hand, passive stretching (PS) is a commonly administered intervention to improve hamstring flexibility.
219047944|NCT06888895|OTHER|Passive hamstring stretching|Participants will receive one minute of passive hamstring stretching applied three times for each lower limb, with a 30-second rest time between stretches.
219047945|NCT07045168|OTHER|risk-scoring model|This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.
219206523|NCT06966349|DEVICE|Senofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
219206524|NCT06966349|DEVICE|Somofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
219624645|NCT00486785|DRUG|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
219624646|NCT05880875|BEHAVIORAL|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series designed to train and support directors and education coordinators supervising state pre-kindergarten classrooms in using a reflective supervision approach with their staff.
218937030|NCT04578236|DRUG|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219624647|NCT05694793|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
218937031|NCT01191762|DRUG|sevelamer carbonate|2400 mg with each meal for 4 weeks
218937032|NCT01191762|DRUG|placebo|3 tablets with each meal
218937033|NCT03336112|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
218937034|NCT03336112|OTHER|Information program|Information program delivered by the Internet during 5 weeks.
219624648|NCT05694793|DEVICE|Glean Urodynamics System|Wireless and catheter free urodynamics system
219624649|NCT06824688|PROCEDURE|Single-port robotic total mesorectal excision|Single-port robotic total mesorectal excision
219624650|NCT06824688|PROCEDURE|Multi-port robotic total mesorectal excision|Multi-port robotic total mesorectal excision
219206525|NCT06965790|DRUG|contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume|Calculation of the standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg) and calculation of the specific blood volume using the established Nadler formula for male and female. Adjustment of the contrast agent according to the ratio of the blood volumes. The amount of saved contrast agent is replaced 1:1 by NaCl.
219206526|NCT03228719|BEHAVIORAL|Standardize PT after TKR with a Physical Activity Intervention|Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.
219624651|NCT05963191|DEVICE|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
219624652|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of unilateral versus bilateral hypoglossal nerve stimulation on upper airway collapsibility during drug-induced sleep endoscopy
219624653|NCT06859918|BEHAVIORAL|TUNE In: Training to Understand and Navigate Emotions and Interactions|A cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, and social skills.
219624654|NCT05238298|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
219624655|NCT03585569|BIOLOGICAL|Abobotulinumtoxin A|Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)
219624656|NCT03839069|PROCEDURE|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
219624657|NCT06478498|BIOLOGICAL|Necator americanus L3 larvae|Necator americanus L3 larvae
219624658|NCT00097097|PROCEDURE|Neonatal Resuscitation|
219624659|NCT04899180|DRUG|99mTc-PYP|Radioisotope used by SPECT/CT imaging
219624660|NCT03811691|DIAGNOSTIC_TEST|MRI exam|Pacing system safety and stability under MRI scan environment
219624661|NCT06162598|OTHER|Ventriloquist Puppet|one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
219624662|NCT05114889|BIOLOGICAL|BSI-045B|BSI-045B will be administered weekly, subcutaneously
219624663|NCT06669780|DEVICE|AMMO PTH DTx|An online cognitive behavioral therapy program accessed through a online program.
219624664|NCT06669780|DEVICE|AMMO SHAM|Online activities not including CBT in the AMMO online program.
219624665|NCT05263245|OTHER|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
219624666|NCT06994338|DRUG|Tirzepatide|Tirzepatide (sc)
219624667|NCT06994338|DRUG|Placebo injections|Placebo injections
219624668|NCT06864585|DRUG|Avibactam sodium/Ceftazidime hydrate|The recommended adult dosage is 2.5 g (0.5 g of avibactam and 2 g of ceftazidime) administered by intravenous infusion over a period of 2 hours 3 times daily. For peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess, Zavicefta should be co-administered with a metronidazole injection.
219624669|NCT06864351|OTHER|OptiThyDose|"OptiThyDose is an iterative mathematical model applied at each patient visit, consisting of three components: (i) a disease-specific pharmacometrics (PMX) model, (ii) an empirical Bayesian estimation (EBE) component, and (iii) an optimal control theory (OCT) component. It calculates the optimal LT4 or CMZ/MMZ dose to maintain Free Thyroxine (FT4) levels within the upper half of the age-specific reference range, integrating past clinical and lab data.~Dosing follows international guidelines, with physicians able to consult OptiThyDose for individualized dosing within recommended ranges. At each outpatient visit, the physician can either (A) prescribe a dose within OptiThyDose's suggested range or (B) choose a dose based on personal experience."
219624670|NCT01502657|DEVICE|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
219624671|NCT05382793|DIETARY_SUPPLEMENT|Control|No iodine
219624672|NCT05382793|DIETARY_SUPPLEMENT|Iodide (150 μg/day)|A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
219624673|NCT05382793|DIETARY_SUPPLEMENT|Iodine (300 μg/day)|Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
219624674|NCT05429372|GENETIC|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
219624675|NCT05137119|DRUG|Cefazolin|Cefazolin
219624676|NCT05137119|DRUG|Penicillin|benzylpenicillin
219624677|NCT05137119|DRUG|Clindamycin|Clindamycin
219624678|NCT05137119|DRUG|Vancomycin|Vancomycin or Daptomycin
219624679|NCT05137119|OTHER|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
219624680|NCT05137119|RADIATION|Whole body FDG PET/CT Imaging|Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
219624681|NCT04524533|BEHAVIORAL|Experimental smoking cessation video|Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.
219624682|NCT04524533|BEHAVIORAL|Control video|Participants randomized to the control group will watch a 10 minute video.
219624683|NCT04524533|OTHER|Brochure of smoking cessation EBTs|All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.
219624684|NCT04524533|BEHAVIORAL|Tailored text message program|Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.
219624685|NCT04524533|OTHER|Assessment text messages|Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
219624686|NCT02792010|DEVICE|Hip cartilage MRI|Hip cartilage MRI
219624687|NCT07003295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219624688|NCT07003295|PROCEDURE|Computed Tomography|Undergo PET/CT
219624689|NCT07003295|BIOLOGICAL|Glofitamab|Given IV
219624690|NCT07003295|BIOLOGICAL|Obinutuzumab|Given IV
219624691|NCT07003295|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219624692|NCT07004556|DIAGNOSTIC_TEST|Preoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.
219624693|NCT07004556|DIAGNOSTIC_TEST|Postoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.
219624694|NCT02583451|DRUG|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
219624695|NCT02583451|DRUG|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
219624696|NCT02583451|DRUG|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
219624697|NCT02583451|DRUG|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
218937035|NCT02874976|DEVICE|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
219047946|NCT06744465|DEVICE|NearWave monitoring|NearWave optical molecular monitoring
219047947|NCT07052786|BEHAVIORAL|Infants will receive group care based on individualized developmental care according to the guide.|A guide to implementing group care based on individualized developmental care will be developed, and nurses working in the NICU will be trained in group care practices and how to use the guide.
219047948|NCT07052786|BEHAVIORAL|Standard care|Nurses working in the NICU will continue to provide standard care. After the study is completed, nurses in the control group will also receive the same training as the other group.
218937036|NCT02874976|DEVICE|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
219047949|NCT07053566|BEHAVIORAL|Rotator Cuff Strengthening Exercises|Progressive exercise program focused on rotator cuff muscles
219047950|NCT07053566|BEHAVIORAL|Latissimus Dorsi Strengthening Exercises|Progressive exercise program targeting the latissimus dorsi muscle
219047951|NCT06787066|DRUG|Propranolol Hydrochloride|Examine how IV propranolol impacts sympathetic transduction
219624698|NCT02583451|DRUG|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
219624699|NCT02583451|DRUG|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
219624700|NCT07007793|DRUG|Baxdrostat|Baxdrostat tablet administered orally, once daily (QD).
219624701|NCT07007793|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
219624702|NCT05556772|PROCEDURE|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
219624703|NCT05556772|OTHER|Interview|Attend interview
219624704|NCT06864780|OTHER|Posture Correction Exercises|This intervention focuses on improving forward head posture (FHP) through a series of corrective exercises aimed at enhancing cervical alignment, reducing muscle strain, and reinforcing proper posture habits. The exercises include chin tucks, cervical retraction with resistance bands, shoulder blade squeeze, and wall posture alignment. Participants will receive hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. These exercises target deep cervical flexors and postural stabilizers to help retrain the neck and upper back muscles, promoting long-term postural correction. The intervention will be performed 3 times per week for 6 weeks under supervision, with a focus on maintaining correct postural alignment during daily activities.
219624705|NCT06864780|OTHER|Strengthening and Stretching Exercises|This intervention aims to address muscle imbalances associated with forward head posture (FHP) by incorporating stretching of tight muscles (upper trapezius, levator scapulae) and strengthening of weak postural muscles (deep neck flexors, scapular stabilizers). The exercises include upper trapezius stretch, levator scapulae stretch, deep neck flexor strengthening, and scapular retraction with resistance bands. Participants will undergo hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. The stretching exercises will help release tension in overactive muscles, while strengthening exercises will restore muscular balance, improving posture and reducing neck discomfort. The intervention will be conducted 3 times per week for 6 weeks with supervised sessions to ensure proper technique and progressive improvement in flexibility and strength.
219624706|NCT05111561|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219624707|NCT05111561|DRUG|Binimetinib|Given PO
219624708|NCT05111561|PROCEDURE|Biopsy Procedure|Undergo biopsy
219624709|NCT05111561|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219624710|NCT05111561|PROCEDURE|Computed Tomography|Undergo CT
219624711|NCT05111561|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219624712|NCT01019343|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
219624713|NCT01019343|DEVICE|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
219624714|NCT01019343|DEVICE|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
219624715|NCT01019343|OTHER|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
219624716|NCT01019343|OTHER|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
219624717|NCT01019343|DEVICE|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
219624718|NCT01019343|DEVICE|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
219624719|NCT01019343|DIAGNOSTIC_TEST|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
219624720|NCT01019343|DEVICE|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
219624721|NCT01019343|PROCEDURE|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
219624722|NCT01019343|OTHER|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
219624723|NCT01019343|PROCEDURE|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
219624724|NCT01019343|PROCEDURE|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
219047952|NCT06787066|DRUG|Phentolamine Injection|Examine how IV phentolamine impacts sympathetic transduction
219624725|NCT01019343|PROCEDURE|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
219624726|NCT01019343|PROCEDURE|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
219624727|NCT01019343|PROCEDURE|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
219624728|NCT01019343|PROCEDURE|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
219624729|NCT01019343|PROCEDURE|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
219624730|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
219624731|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
219624732|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
219624733|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
219047953|NCT06836609|DRUG|ALN-CIDEB|Administered per the protocol
219047954|NCT06836609|DRUG|Placebo|Administered per the protocol
219047955|NCT06885931|DEVICE|Pudendal neuromodulation|In this feasibility study, all subjects will receive the Amber UI system.
219047956|NCT06773845|DEVICE|TheraSphere|The multicompartment MIRD model (a.k.a. partition model) based on diagnostic CT/MRI and 99mTc-MAA SPECT-CT will be used to plan a targeted dose of 700 Gy (± 50%) to the tumor. Given the high tumor burden, a scheduled second radioembolization within 120 days from the initial treatment will be permitted at the discretion of the operators provided the cumulative lung dose remains below 50 Gy. A scheduled second radioembolization may be considered when the largest tumor diameter exceeds 8 cm, or the estimated lung dose reaches 30 Gy while the tumor absorbed dose remains below the target dose of 700 Gy. The radioactive microsphere delivery device used will be glass-based (TheraSphere; Boston Scientific, MA, USA), in which Y90 is an integral constituent of the biocompatible glass matrix. Dosimetry planning will be made by personalized dosimetry software (Simplicit90y; Boston Scientific).
219047957|NCT07064785|BEHAVIORAL|Video-based ART adherence counseling|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Two one-hour video-based sessions with associated activities at 0 and 12 weeks~* Enhanced/Intensive adherence counselling with video component between 24-35 weeks for those with high viral load"
219047958|NCT07064785|BEHAVIORAL|Standard of Care (SOC)|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Basic adherence counselling between 24-35 weeks for those with high viral load"
219047959|NCT07066722|DRUG|VH4524184|VH4524184 will be administered.
219047960|NCT07066722|DRUG|Itraconazole|Itraconazole will be administered.
219047961|NCT07066722|DRUG|Rifabutin|Rifabutin will be administered.
219047962|NCT07066722|DRUG|Phenytoin|Extended phenytoin sodium will be administered.
219047963|NCT07066722|DRUG|Metformin|Metformin will be administered.
219047964|NCT07064109|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|Colchicine 0.5 MG Oral Tablet Once Daily
219047965|NCT04953442|BEHAVIORAL|Fit 24|This 12-week goal-setting intervention will test the feasibility of using a Fitbit watch and motivational text messaging to improve physical activity and sleep in Hispanic youth (14-16 years of age) with obesity. Youth will be prompted to set weekly steps per day and hours of sleep per night goals. Text messages will be grounded in the Self-Determination Theory and will provide evidence-based strategies, support, and motivation to encourage youth to meet their goals.
219047966|NCT06767345|DRUG|statins, ezetimibe|Rosuvastatin 20mg once daily
219047967|NCT06767345|DRUG|Combination therapy|Rosuvastatin 10mg + Ezetimibe 10mg
219047968|NCT06606847|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
219047969|NCT06606847|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219047970|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
219624734|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
219047971|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
219047972|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
219624735|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
219624736|NCT07036523|DRUG|BI 765423|BI 765423
219624737|NCT07036523|DRUG|Placebo|Placebo to BI 765423
219624738|NCT06708936|BIOLOGICAL|KSD-201|Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
219624739|NCT06882746|DRUG|BI 765049|BI 765049
219624740|NCT06886009|DRUG|Spevigo®|Intravenous
219624741|NCT06707766|OTHER|Oculomotor Exercise along with conventional Therapy|"Oculomotor Exercises: Saccadic eye movement, Smooth pursuit, Adaptation X1, Adaptation X2.~Time duration will be 2 minutes for each exercise.~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
219047973|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
219624742|NCT06707766|OTHER|sub-occipital muscle energy technique along with Conventional Therapy|"Sub-occipital muscle energy technique (PIR) 3 rep \* 1 set with 20 sec hold~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle~strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
219624743|NCT06884202|DEVICE|Delefilcon A contact lenses with different base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
219624744|NCT06884202|DEVICE|Delefilcon A contact lenses with standard base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
219624745|NCT06888323|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
219624746|NCT06888323|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219047974|NCT03596645|DRUG|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
219047975|NCT03596645|DRUG|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
219047976|NCT07086833|OTHER|Low Cysteine Diet|A diet low in cysteine, about 1.4 g/1000 kcal.
219047977|NCT07086833|OTHER|High Cysteine Diet|A diet high in cysteine, about 3 g/1000 kcal.
219624747|NCT06888323|PROCEDURE|Buccal Swab|Undergo buccal swab
219047978|NCT07087028|DEVICE|SleeperOne™|Computerized intraosseous anesthesia was delivered using the SleeperOne™ (Dental HiTec, France) device with a 30 G × 9 mm Effitec needle at a 15° angle to the mucosa. A total of 2 mL 2% articaine with 1:100,000 epinephrine was administered per site.
219206527|NCT03228719|OTHER|Standardized PT after TKR|Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
219624748|NCT06888323|PROCEDURE|Computed Tomography|Undergo SPECT/CT
219624749|NCT06888323|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219624750|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 5 mg QW|IIb：Efsubaglutide Alfa 5 mg QW
219624751|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 10 mg QW|Efsubaglutide Alfa 10 mg QW
219624752|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
219624753|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg Q2W|Efsubaglutide Alfa 20 mg Q2W
219624754|NCT06921486|DRUG|Phase IIb：Placebo|Placebo
219624755|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose High Dose|The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
219624756|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose Low Dose|The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
219624757|NCT06921486|DRUG|Phase III：Placebo|Placebo
219624758|NCT02492867|RADIATION|Response-driven Adaptive Radiation Therapy|
219624759|NCT02492867|DRUG|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
219047979|NCT07087028|OTHER|Conventional Infiltration Anesthesia|The intervention for the Conventional Infiltration Anesthesia involves the manual administration of a local anesthetic using a standard dental syringe with a fine-gauge needle.
219047980|NCT07085078|BEHAVIORAL|progressive relaxation exercises|Participants with menopausal symptoms received progressive relaxation exercise training, led by the responsible researcher who assigned them to the experimental group.
219047981|NCT07085871|OTHER|Fish Powder|This RCT aims to test the effectiveness of fish powder (produced from dried fish from Lake Malawi - Lake Malawi sardine) used to fortify school meals. The intervention meal will be the normal school meal, however substituing 3-5g of ingredients (such as soya flour, maize flour or groundnut flour) for 3-5g of fish powder.
219047982|NCT07087106|DRUG|[F-18]FDG|PET radiopharmaceutical
219047983|NCT07086209|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplement|Oral BCAA blend (leucine, isoleucine, valine), 10 g/day divided into two doses, pre- and post-training, for 6 weeks.
219624760|NCT02492867|DRUG|Paclitaxel|40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV
219624761|NCT02492867|DEVICE|FDG-PET|
219624762|NCT02492867|DEVICE|V/Q SPECT|
219624763|NCT02492867|DRUG|Durvalumab|10 mg/kg during consolidation. Given IV
219624764|NCT03296527|DRUG|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
219624765|NCT03296527|DRUG|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
219624766|NCT05366166|BIOLOGICAL|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
219624767|NCT05366166|DRUG|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
219624768|NCT05366166|DRUG|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
219624769|NCT05366166|RADIATION|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
219624770|NCT04987151|OTHER|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
219624771|NCT04987151|OTHER|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
219624772|NCT04987151|OTHER|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
219624773|NCT00122382|DRUG|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
219047984|NCT07086209|BEHAVIORAL|Therapeutic Exercise Program|6-week structured program including isometric, eccentric, plyometric, and sprint-specific exercises.
219047985|NCT07085156|DRUG|Fludarabine; melphalan; busulfan|The conditioning regimen includes fludarabine, busulfan, and melphalan, with a transplant conditioning intensity of 3.0. The RIC is used in the allo-HCT in the MDS patients.
219047986|NCT07085897|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE) for allied health practicum trainees|The intervention is structured into three video-and-exercise sessions. Part one focuses on students' mindsets in coping with practicum-related challenges and their attitudes towards setbacks, encouraging them to shift from a 'fear-of-failure' mindset to a 'failure-is-enhancing' mindset. Part two introduces the nature and concept of neuroplasticity to promote students' understanding of effective learning. Part three centers on providing guidance for students on strategies to cope with stress and emotional turbulence with growth mindset regarding emotion.
219206528|NCT04868656|OTHER|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
219624774|NCT00122382|DRUG|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
219624775|NCT00122382|DRUG|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
219624776|NCT05243160|OTHER|medication review|The intervention consist of a medication review by a clinical pharmacologist.
219624777|NCT01099592|DRUG|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not \< 8, the dose will increase to 40 mg.
219624778|NCT02588963|OTHER|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
219624779|NCT02588963|OTHER|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
219624780|NCT02588963|OTHER|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
219624781|NCT02748746|DEVICE|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
219624782|NCT02748746|DEVICE|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
219624783|NCT00708890|BEHAVIORAL|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
219624784|NCT02890602|DRUG|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
219624785|NCT02890602|DRUG|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
219624786|NCT01702064|DRUG|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
219624787|NCT01702064|DRUG|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
219624788|NCT04042506|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
219624789|NCT04042506|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
219624790|NCT02463370|OTHER|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
219624791|NCT02463370|OTHER|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
219624792|NCT02463370|OTHER|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
219624793|NCT02463370|OTHER|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
219624794|NCT02873793|GENETIC|Extraction of total RNA from healthy and tumour tissues|
218937037|NCT02874976|DEVICE|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
219624795|NCT05850611|DRUG|Methylene Blue|The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
219624796|NCT05850611|OTHER|Milk (control)|Group B will receive 200 ml of milk for 4 weeks.
219624797|NCT05850611|DRUG|Methylene Blue and Platelet-Rich Plasma-Fibrin Glue|Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
219624798|NCT05850611|OTHER|Milk and Platelet-Rich Plasma-Fibrin Glue (control)|Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks.
219047987|NCT06903468|PROCEDURE|Novel cavity marking technique|A novel cavity marking technique will be performed on all participants during their breast conservation surgery. For this technique, cavity marking will be in a clockwise fashion per breast starting with the superior margin of the tumor bed. The superior margin of the left breast will be marked with a single large clip, followed by a double clip for the lateral margin, a triple clip for the inferior margin, and a quadruple clip for the medial margin. The superior margin of the right breast will be marked with a single large clip, followed by a double clip for the medial margin, a triple clip for the inferior margin and a quadruple clip for the lateral margin. Margins with multiple clips will always have one large clip with the remaining clips standard medium size.
219047988|NCT07085455|DIETARY_SUPPLEMENT|Early Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 4 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by protocol
219047989|NCT07085455|DIETARY_SUPPLEMENT|Late Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 8 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by the same protocol as in the early SPN group.
219047990|NCT07086443|OTHER|Activate™ Matrix|Participants will receive weekly applications of Activate™ Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219047991|NCT07086443|OTHER|AmnioDefend™ FT Matrix|Participants will receive weekly applications of AmnioDefend™ FT Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219047992|NCT07086443|OTHER|Palisade™ DM Matrix|Participants will receive weekly applications of Palisade™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219047993|NCT07086443|OTHER|Enclose™ TL Matrix|Participants will receive weekly applications of Enclose™ TL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219624799|NCT02040805|BEHAVIORAL|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
219624800|NCT02040805|BEHAVIORAL|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
219624801|NCT01008605|OTHER|delivery system|syringe
219624802|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity|Cohort A: Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab (Keynote 189, EmpowerLung 3) for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity
219624803|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity|"Cohort B:~Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab (CheckMate9LA) for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity"
219624804|NCT02884362|OTHER|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
219624805|NCT02582229|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
219624806|NCT01213966|DRUG|OZ439|po, single dose
219624807|NCT06817304|BEHAVIORAL|Tiny Heroes|This is a four modules online intervention based on cognitive behavioral therapy directed at parets of anxious children 3-6 years
219624808|NCT05354167|OTHER|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
219624809|NCT05354167|OTHER|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
219624810|NCT00405561|DRUG|AMT2003|
219624811|NCT06301074|DRUG|HS-10509|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
219624812|NCT06301074|DRUG|Placebo|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
219624813|NCT04145765|OTHER|correlation|the subjects completed the questionnaires
219624814|NCT03591874|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
219624815|NCT03591874|DRUG|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
219624816|NCT05157412|DRUG|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
219624817|NCT05157412|DRUG|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
219624818|NCT05278312|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
218937038|NCT02874976|DEVICE|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
219624819|NCT05106179|DRUG|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
219624820|NCT05106179|DRUG|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
219624821|NCT00980252|BEHAVIORAL|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
219624822|NCT03046732|OTHER|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
219624823|NCT04390607|DIAGNOSTIC_TEST|leukocyte esterase electrochemical assay|A sample of blood drawn for routine standard of care laboratory assessments will be used to also test the new electrochemical assay. This is a validation study and the results of the electrochemical assay will not be used to treat patients
219624824|NCT06196437|OTHER|Acupuncture|Participants will receive acupuncture.
219624825|NCT06196437|OTHER|Sham Acupuncture|Participants will receive sham acupuncture.
219624826|NCT01729273|OTHER|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
219624827|NCT03958929|OTHER|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
219624828|NCT01228682|DRUG|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
219624829|NCT00318773|DRUG|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
219624830|NCT02245516|DRUG|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
219624831|NCT02245516|DRUG|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
219624832|NCT04163003|BEHAVIORAL|Targeted Approaches for Promoting Adolescent Sleep (TAPAS)|The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
219624833|NCT04163003|BEHAVIORAL|Sleep Monitoring Only|Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
219624834|NCT04147364|OTHER|no intervention|only retrospective reviews for medical records
219624835|NCT03644342|DRUG|Nirapaib|(see treatment regimen and method of treatment assignment)
219624836|NCT03718988|BEHAVIORAL|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
219624837|NCT03718988|BEHAVIORAL|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
219624838|NCT00839488|DRUG|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
219624839|NCT00839488|DRUG|famotidine 20 mg iv|famotidine 20 mg q12h
219624840|NCT04667637|DRUG|edaravone dexborneol|Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
219624841|NCT00548678|DRUG|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
219624842|NCT00548678|DRUG|ketorolac|intravenous ketorolac
219624843|NCT00548678|DRUG|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
218937039|NCT02679118|DEVICE|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
218937040|NCT00005035|DRUG|oxaliplatin|
218937041|NCT03554564|BEHAVIORAL|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
218937042|NCT03554564|OTHER|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
218937043|NCT00984997|PROCEDURE|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
218937044|NCT00984997|RADIATION|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
218937045|NCT00984997|DRUG|Cisplatin|50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
219047994|NCT07086443|OTHER|Sentry™ SL Matrix|Participants will receive weekly applications of Sentry™ SL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219624844|NCT00548678|DRUG|aspirin|oral aspirin
219624845|NCT05782933|DRUG|Rituximab|Rituximab combined with or without cyclosporine
219624846|NCT05782933|DRUG|Modified Ponticelli regimen|Corticosteroid and cyclophosphamide
219624847|NCT04083547|DIAGNOSTIC_TEST|iCellate|New method of circulating tumour cell detection and capture.
219624848|NCT04290364|OTHER|Palliative care|The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
219624849|NCT02282540|PROCEDURE|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
219624850|NCT05359744|DIAGNOSTIC_TEST|Performance testing|Performance testing on a bicycle ergometer.
219624851|NCT02380586|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
219624852|NCT01845441|DRUG|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
219624853|NCT01845441|DRUG|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
219624854|NCT01845441|DRUG|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
219624855|NCT06284369|BEHAVIORAL|Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign|To explore how smokers reacted to the gain-framed and loss-framed video ad
219624856|NCT06284369|BEHAVIORAL|Health Message Framing|Gain- framed messages in health communication are constructed by framing a particular outcome as either a benefit or a cost, relative to a specific reference poin
219624857|NCT00648882|DRUG|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
218937046|NCT00984997|DRUG|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
218937047|NCT00984997|RADIATION|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
218937048|NCT00505401|BIOLOGICAL|recombinant HIV-1 Tat protein|
218937049|NCT00746057|BIOLOGICAL|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
218937050|NCT06227793|BEHAVIORAL|pharmaceutical intervention|Individuals randomized to the intervention group will undergo monthly pharmaceutical consultations for health education, initiated after randomization. There will be three in-person consultations, starting in month 1 with monthly spacing, scheduled by the pharmacist in the office, except for the first consultation, which will be scheduled by the pharmacist over the phone after randomization. These consultations will be part of the intervention study's educational process and will take place between the initial and final assessments. The educational process scripts for each consultation include a pharmaceutical follow-up form and an inhalation technique assessment form. Once the consultation is completed, the patient will also receive, via WhatsApp and/or email according to their preference, an educational video demonstrating the step-by-step inhalation technique based on their prescribed treatment.
218937051|NCT06384118|BEHAVIORAL|Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study|Based on IMB health education theory Questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; hypoglycemia knowledge promotion on the second day; Peer experience sharing on the third day; access to WeChat group and knowledge pushing on the fourth day; hypoglycemia-related lectures and practical teaching on the fifth day, face-to-face teaching and development of blood glucose management plan. Hypoglycemia knowledge contest on the day before discharge; One week, two weeks and three weeks after discharge for WeChat push or phone call; WeChat push, phone call and questionnaire.
218937052|NCT02003599|DEVICE|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
218937053|NCT02003599|DEVICE|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
218937054|NCT04518267|BEHAVIORAL|Structured clinical interview|A structured clinical interview will be performed at enrollment.
218937055|NCT04518267|BEHAVIORAL|Psychological questionnaires|Several psychological questionnaires will be performed at enrollment.
218937056|NCT02279264|DEVICE|RightSpot Infant pH Indicator|pH indicator
218937057|NCT06193226|OTHER|Cryotherapy|"Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure.~The spray's nozzle of the Cryogun spray -50 ◦C was situated 1 cm away from the skin's surface and applied on the oral lesion for 30 seconds. Each freezing cycle lasted 10 to 30 seconds, with the subsequent 60-second thaw interval lasting twice as long as the freezing time. The ice ball that formed during freezing was totally melted before the subsequent freezing process could begin.~The application process should went from the core out to the edges. The management of lesions that are too big to be frozen by a single spray requires many overlapping treatments of liquid nitrogen. Mucoceles and erosive lichen planus took 30 to 50 seconds to freeze, whereas fibromas and leukoplakia took 60 to 70 seconds."
218937058|NCT03898557|BEHAVIORAL|Provision of HIV self-test with Commitment and planning prompts|The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
218937059|NCT03898557|BEHAVIORAL|Provision of HIV self-test|This arm will receive a HIV self-test
218937060|NCT04456855|PROCEDURE|Locoregional surgery|Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
218937061|NCT06245980|DRUG|SGLT2 inhibitor|According to whether SGLT2i was used
219047995|NCT07086443|OTHER|Shelter™ DM Matrix + SOC|Participants will receive weekly applications of Shelter™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219047996|NCT07086508|BEHAVIORAL|e-CHECKUP TO GO (eCTG)|A brief, web-based program designed by San Diego State University to reduce high-risk drinking by providing personalized normative feedback regarding alcohol use, risk factors, and risks associated with drinking and accurate information about alcohol.
219047997|NCT07086508|BEHAVIORAL|e-Parent Intervention and eCTG (eCTG+)|The eCTG+ is a combination of the eCTG and the e-Parent Intervention, which is an electronic handbook developed by Rob Turrisi to guide parents in discussing drinking, behaviors, and consequences with their teens.
219624858|NCT00648882|DRUG|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
219624859|NCT04321746|DRUG|Ketamine|ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
219624860|NCT04321746|OTHER|Placebo|the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
219624861|NCT00000377|DRUG|Nortriptyline|
219624862|NCT02822937|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
219624863|NCT02822937|DRUG|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
219624864|NCT02822937|OTHER|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
219624865|NCT02822937|DRUG|Placebo|Sugar pill
219624866|NCT03451253|OTHER|amino acid mixture beverage|commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
219624867|NCT03451253|OTHER|glucose-based sports drink|Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
219624868|NCT02573051|DRUG|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
219047998|NCT07084896|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219624869|NCT02573051|DRUG|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
219624870|NCT02573051|OTHER|placebo|
219624871|NCT05563454|DRUG|BAY2395840|Administration of dosage form 1 under diet 1 condition
219624872|NCT04382547|BIOLOGICAL|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
219624873|NCT04382547|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
219624874|NCT03875053|DIAGNOSTIC_TEST|Monitoring Device|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
219624875|NCT03875053|OTHER|Quality-of-Life Assessment|Ancillary studies
219624876|NCT03875053|OTHER|Questionnaire Administration|Ancillary studies
219624877|NCT05106140|OTHER|Magnetic Resonance Imaging (MRI)|A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.
219624878|NCT05106140|DEVICE|Kinarm Robotic Exoskeleton Assessment|"The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours."
219624879|NCT05106140|OTHER|Clinical Assessment|The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
219624880|NCT01445730|DIETARY_SUPPLEMENT|Fructose|3 month fructose diet 75 g/day
219624881|NCT00520065|OTHER|enteral nutritional formula|Meal glucose tolerance test
219624882|NCT00520065|OTHER|Diabetes specific enteral product|Meal Glucose tolerance test
219624883|NCT05507073|PROCEDURE|Manual Total Hip Replacement|Implantation of a hip Device to alleviate pain and recover range of movement
219624884|NCT05507073|PROCEDURE|Robot-Assisted Total Hip Replacement|Robot assisted Implantation of a hip Device to alleviate pain and recover range of movement
219624885|NCT01167140|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
219624886|NCT07118878|DRUG|AGMB-129|AGMB-129
219624887|NCT07118878|OTHER|Placebo|Placebo
219047999|NCT07084896|DRUG|Nirogacestat|Nirogacestat will be administered.
219048000|NCT07086729|OTHER|CT-Based Morphologic and Attenuation Scoring|Retrospective analysis of CT images to extract morphological and Hounsfield Unit (HU) parameters for development of a predictive scoring model (TSMAS). No clinical or therapeutic intervention was performed.
219048001|NCT07087262|DRUG|SNH-119014|study drug
219624888|NCT07126522|OTHER|Discussion|Ancillary studies
219624889|NCT07126522|OTHER|Internet-Based Intervention|Use the HERCaRE app
219624890|NCT07126522|OTHER|Interview|Ancillary studies
219624891|NCT07126522|OTHER|Survey Administration|Ancillary studies
219624892|NCT02147977|DIETARY_SUPPLEMENT|dietary supplement: n-3 PUFA|
219624893|NCT02147977|DIETARY_SUPPLEMENT|olive oil|
219624894|NCT06356688|DRUG|Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab|Paclitaxel Polymeric Micelles for Injection:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 10mg/kg, IV drip, d3, q3w;
219624895|NCT06946823|DEVICE|Just-In-Time Adaptive Intervention for Adolescent Anxiety|A JITAI smartphone app to reduce anxiety levels among rural adolescents by delivering somatic-based activity recommendations
219624896|NCT03825354|BEHAVIORAL|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
219624897|NCT03834155|OTHER|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
219624898|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
219624899|NCT03834155|OTHER|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
219048002|NCT07087262|DRUG|Placebo|placebo
219048003|NCT07085624|DRUG|ceftazidime|ceftazidime loading dose and maintenance dose
219048004|NCT07085624|BIOLOGICAL|plasma ceftazidime dosage|"plasma ceftazidime dosage kinetics will be performed according to an optimal D- sampling plan (4 measurements per subject: T0+5min, T0+3h, T0+6h, T0+24h, PFIM software).~T0 corresponds to the time to administer the ceftazidime loading dose."
219048005|NCT07085663|OTHER|Exergame-assisted simultaneous motor-cognitive training|Exergame-assisted simultaneous motor-cognitive training
219048006|NCT07085598|DIETARY_SUPPLEMENT|Vitamin D|15 male epileptic patients with hypovitaminosis D will be enrolled. They will be supplemented with Vitamin D orally 50,000 IU/week for 8 weeks
219624900|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
219624901|NCT04783428|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as part of this DMP
219624902|NCT05542381|DRUG|Loteprednol Etabonate Ophthalmic Gel [Lotemax]|Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
219624903|NCT05542381|OTHER|Refresh Lubricant Eye Drops [Artificial Tears]|REFRESH® Brand Lubricant Eye Drops are artificial tears. In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
219624904|NCT06242080|BEHAVIORAL|Mindfulness|Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.
219624905|NCT05673200|PROCEDURE|Biopsy Procedure|Undergo biopsy
219624906|NCT05673200|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219624907|NCT05673200|PROCEDURE|Computed Tomography|Undergo CT
219624908|NCT05673200|DRUG|Decitabine and Cedazuridine|Given PO
219624909|NCT05673200|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219624910|NCT05673200|DRUG|Paclitaxel|Given IV
219624911|NCT05673200|BIOLOGICAL|Pembrolizumab|Given IV
218937062|NCT02519985|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
218937063|NCT03238430|DRUG|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
218937064|NCT03238430|DRUG|Morphine PCA|a postoperative Morphine PCA
219624912|NCT05881759|BEHAVIORAL|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
219624913|NCT04857372|DRUG|IAG933|Capsule
219624914|NCT04660344|DRUG|Atezolizumab|ctDNA positive participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
219624915|NCT04660344|OTHER|Placebo|ctDNA positive participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
219624916|NCT04660344|DEVICE|Signatera|Signatera will be used to evaluate whether circulating tumor DNA (ctDNA) is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter follow-up.
219624917|NCT06833970|OTHER|Colgate use|An evaluation of Colgate total toothpaste currently in use will be provided.
219624918|NCT06833970|OTHER|Curaprox use|An evaluation of Curaprox toothpaste currently in use will be provided.
219624919|NCT06833970|OTHER|ROCS use|An evaluation of ROCS toothpaste currently in use will be provided.
219624920|NCT06833970|DEVICE|Fixed orthodontic treatment|For standard fixed orthodontic treatment, orthodontic brackets and mechanics will be applied.
219624921|NCT06064929|DRUG|Felzartamab|Administered IV
219624922|NCT01015417|DRUG|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
219624923|NCT01015417|OTHER|No medication|no postoperative antibiotics
219624924|NCT04829136|DIETARY_SUPPLEMENT|Kate Farms 1.0|Given enteral nutrition via nasoenteric feeding
219624925|NCT04829136|DIETARY_SUPPLEMENT|Standard of Care Nutritional Support|Given standard of care, which may be parenteral nutrition
219624926|NCT04829136|OTHER|Survey Administration|Ancillary studies
219624927|NCT04829136|DIETARY_SUPPLEMENT|Dietary Supplement|Receive fiber supplementation orally or enterally
219624928|NCT04829136|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
219624929|NCT04829136|OTHER|Electronic Health Record Review|Ancillary studies
219624930|NCT04829136|OTHER|Fiber and Dietary Assessments|Ancillary studies
219624931|NCT02908061|PROCEDURE|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
219624932|NCT02908061|PROCEDURE|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
219624933|NCT04069299|DRUG|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
219624934|NCT04069299|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
219624935|NCT06708351|OTHER|Best Practice|Receive standard care
219624936|NCT06708351|OTHER|Health Promotion and Education|Receive instructions on how to use HPV self-testing kit
219048007|NCT07085884|BEHAVIORAL|The Static-Dynamic Balance Training Combined with Reminiscence Therapy|The intervention group received a 12-week SDBT-RT program, conducted twice weekly: 40-minute reminiscence therapy plus 50-minute balance training in odd weeks, and 50-minute balance training alone in even week.
219048008|NCT07087301|OTHER|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
219048009|NCT07087301|DRUG|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
219624937|NCT06708351|PROCEDURE|HPV Self-Collection|Undergo HPV self-collection
219624938|NCT06708351|OTHER|Text Message-Based Navigation Intervention|Receive text messages for HPV testing results and triage and treatment reminders
219624939|NCT01339195|BEHAVIORAL|French adaptation of NINDS-Canadian Stroke Network battery|"* clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI"
219624940|NCT05680805|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
219624941|NCT04417660|DRUG|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
219624942|NCT03339128|DRUG|Eluxadoline|Oral tablets
219624943|NCT03339128|DRUG|Placebo|Oral tablets
219624944|NCT06467357|DRUG|Gemcitabine|Standard of care chemotherapy by intravenous infusion
219048010|NCT07085481|DRUG|room temperature Bupivacaine|bupivacaine will be on a sterile shelf in the operating room at 23°C. The empty syringes and needles will be also on the same shelf before their use.
219048011|NCT07085481|DRUG|warm Bupivacaine|bupivacaine will be warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature for at least 2 hours before initiating the block.
219624945|NCT06467357|DRUG|Cisplatin|Standard of care chemotherapy by intravenous infusion
219624946|NCT06467357|DRUG|Durvalumab|Standard of care immunotherapy by intravenous infusion
219624947|NCT06467357|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
219624948|NCT06467357|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
219624949|NCT06467357|DIAGNOSTIC_TEST|Agilent HercepTest™ mAb pharmDx|"A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis)."
219624950|NCT06467357|DIAGNOSTIC_TEST|Ventana PD-L1 SP263 assay|A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
219624951|NCT04486118|DRUG|Lisinopril Pills|Tablets will be taken by oral administration daily, based on titration
219624952|NCT04486118|DRUG|Benazepril Pill|Tablets will be taken by oral administration daily, based on titration
219624953|NCT05865054|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
219624954|NCT06291376|DRUG|Ravulizumab|Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
219624955|NCT06291376|DRUG|Placebo|Participants will receive placebo via weight-based IV infusion.
219624956|NCT03555162|OTHER|fMRI|Imaging examination
219624957|NCT05774691|DRUG|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
219624958|NCT05774691|DRUG|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
219624959|NCT04103762|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
219624960|NCT04103762|DIAGNOSTIC_TEST|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
219624961|NCT06632457|DRUG|Survodutide|Subcutaneous injection
219624962|NCT06632457|DRUG|Placebo matching survodutide|Subcutaneous injection
219624963|NCT04059822|OTHER|Slow and deep breathing|Please see arm description
219624964|NCT04355572|DRUG|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
219624965|NCT04355572|DRUG|Placebo|Randomized to placebo daily
219624966|NCT06144684|DRUG|GUB014295|GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
219624967|NCT06144684|DRUG|GUB014295-PLACEBO|GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
219624968|NCT05880706|DRUG|BL-B01D1|Administration by intravenous infusion
219624969|NCT05880706|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
219624970|NCT06230796|DEVICE|FES-cycling|30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
218937065|NCT03238430|DRUG|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
218937066|NCT01829152|DEVICE|CHM|
218937067|NCT02507700|PROCEDURE|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
218937068|NCT02507700|DRUG|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
219048012|NCT07086950|DEVICE|Body Brain Trainer software|Patients will engage in cognitive and physical exercises with the training software Body Brain Training (BBT) for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
219624971|NCT06230796|DEVICE|SHAM-cycling|30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
218937069|NCT02507700|DEVICE|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
218937070|NCT02507700|OTHER|Plaster cover|Plaster cover will be used to control group for sham procedure
218937071|NCT02507700|DRUG|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
218937072|NCT02507700|OTHER|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
218937073|NCT02364635|DRUG|icosabutate|Single dose at each dose levet
218937074|NCT02743104|DRUG|Ketamine|
218937075|NCT02743104|DRUG|Propofol|
218937076|NCT02743104|DRUG|midazolam and atropine|
218937077|NCT02743104|DRUG|Lidocaine|
219624972|NCT06417684|DRUG|Amitriptyline|25 mg prescribed to be taken once daily for 90 days each evening.
219624973|NCT06417684|BEHAVIORAL|Lifestyle Modification|Written and video instructions to instruct the participant to improve restful sleep, exercise, avoidance of dietary triggers, and mealtime regularity.
219624974|NCT04445649|DIAGNOSTIC_TEST|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
219624975|NCT03896503|DRUG|Berzosertib|Given IV
219624976|NCT03896503|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
219624977|NCT03896503|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219624978|NCT03896503|PROCEDURE|Computed Tomography|Undergo a CT scan
219624979|NCT03896503|DRUG|Topotecan Hydrochloride|Given IV
219624980|NCT05067868|BIOLOGICAL|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
219624981|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
219624982|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
219624983|NCT06058585|DRUG|Finerenone|Finerenone 10mg or 20mg tablets, oral, once daily
219624984|NCT06058585|DRUG|Placebo Finerenone|Finerenone matched placebo tablets, oral, once daily
219624985|NCT06392841|DRUG|Androgen Deprivation Therapy (ADT)|Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)
219624986|NCT06392841|DRUG|Niraparib/Abiraterone Acetate DAT|Niraparib 200 mg/ Abiraterone acetate 1000 mg orally
219624987|NCT06392841|DRUG|Abiraterone Acetate|1000 mg orally
219624988|NCT06392841|DRUG|Prednisone|5 mg orally
219624989|NCT06392841|DRUG|Docetaxel|75 mg/m2 IV
219624990|NCT04597359|DRUG|Placebo Administration|Given PO
219624991|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
219624992|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
219624993|NCT04597359|DRUG|Sinecatechins|Given PO
219624994|NCT04433234|DRUG|DS-5141b|Administered via subcutaneous injection once weekly
219624995|NCT06830395|BIOLOGICAL|CM313|CM313(SC) injection
219624996|NCT06830395|DRUG|Placebo|Matched placebo
219624997|NCT01815541|DRUG|teicoplanin|
219624998|NCT06310746|DRUG|GARP/TGF-β1 monoclonal antibody|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
219624999|NCT06310746|DRUG|Placebo|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
219625000|NCT05380531|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
219625001|NCT06514261|DRUG|Azacitidine|Given IV or SC
219625002|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219625003|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219625004|NCT06514261|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219625005|NCT06514261|PROCEDURE|Buccal Swab|Undergo buccal swab
218937078|NCT03331640|DRUG|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
218937079|NCT03331640|DRUG|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
218937080|NCT02349217|BEHAVIORAL|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
218937081|NCT02349217|BEHAVIORAL|Self-Help Materials|Participants and partner receive self-help materials.
218937082|NCT02349217|BEHAVIORAL|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
219625006|NCT06514261|DRUG|Iadademstat|Given PO
219625007|NCT06514261|DRUG|Venetoclax|Given PO
219625008|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
219625009|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
219625010|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
219625011|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
219625012|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
219625013|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
219625014|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
219625015|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
219625016|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
219625017|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
219625018|NCT05437159|BEHAVIORAL|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
219625019|NCT05437159|DEVICE|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
219625020|NCT05437159|DEVICE|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
219625021|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
219625022|NCT05952726|OTHER|Expiratory cycling change at different levels of pressure support ventilation|"Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow."
219625023|NCT05579314|DRUG|XW014|Oral tablets
219625024|NCT05579314|DRUG|Placebo|Matched oral placebo tablets
219625025|NCT05579314|DRUG|XW014|Oral capsules
219625026|NCT05579314|DRUG|Placebo|Matched oral placebo capsules
219625027|NCT06328608|DRUG|PRX-102 1 mg/kg every two weeks|Drug: PRX-102 1 mg/kg every two weeks
219625028|NCT06639451|DEVICE|RANGER™ Paclitaxel Coated Balloon Catheter|A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
219625029|NCT06644417|DRUG|TQA3605 tablets plus NAs|TQA3605 tablets is core protein regulator
219625030|NCT06644417|DRUG|TQA3605 Placebo plus NAs|Placebo without drug substance
219625031|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
219625032|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
219625033|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
219625034|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
219625035|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
219625036|NCT04137757|OTHER|Lower Body Negative Pressure|Lower body negative pressure will be applied.
219625037|NCT04137757|OTHER|Sham Pressure|Noise will be turned on but no pressure will be applied.
219625038|NCT02899819|OTHER|meconium|The meconium will be sampled in the first 2 days of life
219625039|NCT03773770|DRUG|Triheptanoin|Liquid for oral (PO) or enteral tube administration
219625040|NCT04877691|DRUG|Medi-546|Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
219625041|NCT04877691|DRUG|Placebo|Solution for injection in aPFS
219625042|NCT03492372|OTHER|Waste tissues are collected at the time of spinal surgery.|This is a single visit study. Waste tissues are collected at the time of spinal surgery.
219625043|NCT05734157|DEVICE|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
219625044|NCT00979238|GENETIC|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
219625045|NCT00979238|DRUG|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
219625046|NCT06377852|DRUG|Palbociclib 125mg|Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
219625047|NCT06377852|DRUG|Ribociclib 600mg|Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
219625048|NCT06377852|DRUG|Ribociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
219625049|NCT06377852|DRUG|Palbociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
219625050|NCT03298893|DRUG|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
219625051|NCT03298893|DRUG|Cisplatin|40 mg/m2, once a week during radiotherapy
219625052|NCT03298893|RADIATION|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
219625053|NCT06636435|DRUG|CBA-1205 Part 1|CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
219625054|NCT06636435|DRUG|CBA-1205 Part 2|CBA-1205: 20 mg/kg and 30 mg/kg (Intravenous solution)
219625055|NCT06636435|DRUG|CBA-1205 Part 3|CBA-1205: 30 mg/kg (Intravenous solution)
219625056|NCT06636435|DRUG|CBA-1205 Part 4|CBA-1205: 20 mg/kg (Intravenous solution)
219625057|NCT06636435|DRUG|CBA-1205 Part 5|CBA-1205: 10 mg/kg (The initial cohort, Intravenous solution)
219625058|NCT06026046|OTHER|Adapted sport program based on fencing|"This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters."
219625059|NCT05486637|BEHAVIORAL|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
219625060|NCT05486637|BEHAVIORAL|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
219625061|NCT02895750|DRUG|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
219625062|NCT03026062|BIOLOGICAL|Durvalumab|Given IV
219625063|NCT03026062|BIOLOGICAL|Tremelimumab|Given IV
219625064|NCT04449666|DIAGNOSTIC_TEST|Neuropsychological assessment and structural MRI|Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
218937083|NCT02349217|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
218937084|NCT02349217|BEHAVIORAL|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
218937085|NCT02349217|PROCEDURE|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
219625065|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
219625066|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
219625067|NCT06335966|DEVICE|Screening with swallowable esophageal cell-collection devices (SECD)|All participants who enroll in this study and provide their consent will undergo screening with an FDA approved swallowable esophageal cell-collection device (SECD)
219625068|NCT02972060|DRUG|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
219625069|NCT02972060|DRUG|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
219625070|NCT06334705|OTHER|blood test, food collection, hair collection, calcium scan, etc.|everything is specified during the phone call and in the consent form to be signed
219625071|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Erector Spinae block|Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
219625072|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Paravertebral block|Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
219625073|NCT02563327|DRUG|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
219625074|NCT02563327|DRUG|Moxifloxacin|A fluoroquinolone
219625075|NCT02563327|DRUG|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
219625076|NCT02563327|DRUG|Isoniazid|An anti-tuberculosis agent
219625077|NCT02563327|DRUG|Pyrazinamide|An anti-tuberculosis agent
219625078|NCT02563327|DRUG|Ethambutol|An anti-tuberculosis agent
219625079|NCT02563327|DIETARY_SUPPLEMENT|Pyridoxine|An essential vitamin
219625080|NCT05301192|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
219625081|NCT05301192|DRUG|Saline|Saline will be used as the placebo comparator.
219625082|NCT05338489|DRUG|Selpercatinib|Administered orally.
219625083|NCT05338489|DRUG|Itraconazole|Administered orally.
219625084|NCT05338489|DRUG|Rifampin|Administered orally.
219625085|NCT05546866|DRUG|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
219625086|NCT03915366|DRUG|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
219625087|NCT03915366|DRUG|Tuberculostatic Agents|Treatment for tuberculosis
219625088|NCT04700631|DIAGNOSTIC_TEST|urinary extracellular vesicle concentration|urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients
219625089|NCT04700631|DIAGNOSTIC_TEST|blood sample|blood sample in order to determine creatin level
219625090|NCT06100289|DRUG|Vedolizumab IV|Vedolizumab IV injection.
219625091|NCT06100289|DRUG|Vedolizumab SC|Vedolizumab SC injection.
219625092|NCT02979587|DEVICE|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
219625093|NCT01539967|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
219625094|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
219625095|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
219625096|NCT06084364|DRUG|Injection of triamcinolone acetonide into the CMC-1 joint|intraarticular injection with triamcinolone acetonide
219625097|NCT06084364|BEHAVIORAL|Multimodal Occupational therapy for CMC-1 joint OA|Patient education, instructions about hand exercises, orthosis and training
219625098|NCT06084364|DRUG|Placebo|Intraarticular injection with saline
219625099|NCT05814549|DIAGNOSTIC_TEST|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
219625100|NCT05795101|DRUG|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
219625101|NCT05795101|DRUG|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
219625102|NCT00210210|DRUG|Ketamine|
219625103|NCT00210210|DRUG|Saline solution|
219625104|NCT03433170|PROCEDURE|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
219625105|NCT03433170|PROCEDURE|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
219625106|NCT04026490|BEHAVIORAL|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
219625107|NCT04026490|BEHAVIORAL|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
219625108|NCT03096418|DRUG|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
219625109|NCT02932956|GENETIC|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219625110|NCT02932956|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
219625111|NCT02932956|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
219625112|NCT06578481|OTHER|Exercises|Individuals in the first group underwent cervical stabilization (CS) exercises and additional scapular and lumbopelvic stabilization (SLPS) exercises three times a week for 6 weeks. The second group was treated with only CS exercises for the same period. In addition, stretching exercises and a 20-minute hot pack were applied to the muscles around the neck of all patients.
219625113|NCT04367181|DEVICE|Diffuse Correlation Spectroscopy (DCS)|Diffuse correlation spectroscopy uses light in the near infrared spectral region to quantify non-invasively cerebral blood flow. The DCS device will be use to monitor blood flow changes over time in all ELGA enrolled babies
219625114|NCT04367181|DEVICE|Amplitude Integrated Electroencephalography (aEEG)|Amplitude Integrated Electroencephalography like EEG it is used clinically to monitor brain function in intensive care settings over longer periods of time. aEEG data will be correlated with CBF variation over time
219625115|NCT03354351|BEHAVIORAL|Stepped-care model|The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
219625116|NCT01506115|DRUG|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
219625117|NCT04741750|OTHER|Simplified HCV care within a mobile medical unit|Delivers guideline-based care for HCV in a stream-lined manner on a mobile medical unit
219625118|NCT03019861|BEHAVIORAL|Ayurvedic nutritional counseling|
219625119|NCT03019861|BEHAVIORAL|Conventional nutritional counseling|
219625120|NCT05872854|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
219625121|NCT05872854|OTHER|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
219625122|NCT03476889|OTHER|Infant formula|Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
219625123|NCT02004366|DRUG|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
219625124|NCT02004366|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
219625125|NCT02004366|DRUG|Linagliptin|Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
219625126|NCT02004366|DRUG|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
219625127|NCT02004366|DRUG|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
219625128|NCT03158038|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.
219625129|NCT03158038|OTHER|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
219625130|NCT01130376|BIOLOGICAL|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
219625131|NCT01130376|DRUG|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
219625132|NCT01130376|DRUG|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
219625133|NCT01130376|DRUG|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
219625134|NCT05980624|DIETARY_SUPPLEMENT|oral nutrition supplement|patients receive ONS 300kcal in daily basis
219625135|NCT01219426|OTHER|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
219625136|NCT02275546|DRUG|Placebo vaginal ring|Drug-free placebo vaginal ring
219625137|NCT02275546|DEVICE|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
219625138|NCT02527746|DRUG|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
219625139|NCT02527746|DRUG|EC regimen|Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
219625140|NCT01962012|DEVICE|AcceleDent Aura|
219625141|NCT01962012|DEVICE|Sham Device|
219625142|NCT02955355|BIOLOGICAL|HYQVIA|Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
218937086|NCT02349217|BEHAVIORAL|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
219625143|NCT02612623|DRUG|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
219625144|NCT02612623|DRUG|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
219625145|NCT05891093|DRUG|Fluzoparib|Fluzoparib 50mg bid orally for 1 year.
219625146|NCT05891093|DRUG|Anastrozole|1mg, qd orally
219625147|NCT05891093|DRUG|Letrozole|2.5mg, qd orally
219625148|NCT05891093|DRUG|Exemestane|25mg, qd orally
219625149|NCT05891093|DRUG|Tamoxifen|10mg, bid orally
219625150|NCT05891093|DRUG|Toremifene|60mg, qd orally
219625151|NCT05891093|DRUG|Abemaciclib|150mg/100mg/50mg, bid orally for 2 years
219625152|NCT05891093|DRUG|LHRH agonist|Leuprorelin acetate, goserelin acetate
219625153|NCT04831411|PROCEDURE|Total Knee Arthroplasty|The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
219625154|NCT04831411|OTHER|Whole Body Vibration|Whole Body Vibration
219625155|NCT04831411|OTHER|Progressive Resistance Training|Progressive Resistance Training
219625156|NCT05043974|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
219625157|NCT05177484|DRUG|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
219625158|NCT04446013|OTHER|Optic Nerve Sheath Diameter Measurement|The change in intracranial pressure via optic nerve sheath diameter measurement
219625159|NCT04947384|DIAGNOSTIC_TEST|To discern micro-RNA specific for right and left heart induced PH|While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.
219625160|NCT03426124|DEVICE|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
219625161|NCT01129440|DEVICE|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
219625162|NCT01129440|DEVICE|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
219625163|NCT06056037|BEHAVIORAL|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
219625164|NCT06056037|BEHAVIORAL|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
219625165|NCT05079035|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
219625166|NCT05079035|BIOLOGICAL|Saline|2 mL Sterile, preservative free 0.9% NaCl
219625167|NCT05085548|DRUG|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
219625168|NCT05085548|DRUG|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
219625169|NCT05085548|DRUG|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
219625170|NCT00001258|DRUG|Oxygen-15 Water|
219625171|NCT06234384|OTHER|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
219625172|NCT05216861|OTHER|Demand and ability protocol|"The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified."
219625173|NCT05216861|OTHER|Collaborative interventions as usual|The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
219048013|NCT07086950|DEVICE|RehaCom software|Patients will engage in exercises with the cognitive training software RehaCom (Hasomed®), which is a proxy to the standard of care, for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
219625174|NCT02849145|BIOLOGICAL|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
219048014|NCT07086755|DRUG|Vadadustat 900mg|Participants will receive 900mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
219048015|NCT07086755|DRUG|Vadadustat 1200mg|Participants will receive 1200mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
219625175|NCT04213885|COMBINATION_PRODUCT|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
219625176|NCT05486091|BEHAVIORAL|App-Enhanced Brief Cognitive-Behavioral Therapy|BCBT is a cognitive-behavioral intervention designed to target core skills deficits among suicidal individuals. App-enhanced BCBT incorporates the use of a SmartPhone app during the therapy sessions.
219625177|NCT06686485|DEVICE|FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems|"The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath.~The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium."
219625178|NCT05929664|BIOLOGICAL|Cemiplimab|Given IV
219625179|NCT05929664|PROCEDURE|Computed Tomography|Undergo CT scan
219625180|NCT05929664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219625181|NCT05929664|OTHER|Quality-of-Life Assessment|Ancillary studies
219625182|NCT05929664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219625183|NCT05929664|PROCEDURE|Biopsy|Undergo biopsy
219625184|NCT06112860|DEVICE|Over the counter hearing aid|An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.
219625185|NCT06112860|BEHAVIORAL|Communication Strategies Information/Counseling|Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
219625186|NCT05766267|DRUG|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
219625187|NCT05766267|DRUG|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
219625188|NCT05766267|DRUG|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
219625189|NCT05766267|DRUG|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
219625190|NCT05766267|DRUG|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
219625191|NCT05766267|DRUG|Isoniazid|Isoniazid is part of control regimen (HRZE).
219625192|NCT05766267|DRUG|Rifampin|Rifampin is part of control regimen (HRZE).
219625193|NCT05766267|DRUG|Ethambutol|Ethambutol is part of control regimen (HRZE).
219625194|NCT05889650|PROCEDURE|External Lumbar drainage|ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
219625195|NCT06188715|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
219625196|NCT06188715|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
219625197|NCT06188715|DRUG|Placebo Moxidectin|Placebo tablets for moxidectin
219625198|NCT06188715|DRUG|Placebo Albendazole|Placebo tablets for albendazole
219625199|NCT03389932|BEHAVIORAL|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
219625200|NCT02290756|BEHAVIORAL|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
219625201|NCT02290756|BEHAVIORAL|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
219625202|NCT03658785|BIOLOGICAL|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
219625203|NCT03658785|DRUG|Aldesleukin|IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
219625204|NCT03658785|DRUG|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
219625205|NCT03658785|DRUG|Fludarabine|Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
219625206|NCT01654185|DRUG|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
219625207|NCT01654185|DRUG|Aromatase Inhibitor|1 tablet per day
219625208|NCT02992353|PROCEDURE|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
219625209|NCT02992353|PROCEDURE|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
219625210|NCT03817853|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
219625211|NCT03817853|DRUG|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
219048016|NCT07086755|DRUG|Placebo|Participants will matching placebo (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
219625212|NCT03817853|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
219625213|NCT03817853|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
219625214|NCT03817853|DRUG|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
219048017|NCT06773936|DRUG|Induction Phase|Asciminib, Dasatinib, Prednisone, and Methotrexate
219048018|NCT06773936|DRUG|Re-Induction Phase|Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
219048019|NCT06773936|DRUG|Post-Remission|Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
219048020|NCT06773936|DRUG|Maintenance|Asciminib, Dasatinib, Prednisone, and Methotrexate
219625215|NCT03817853|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
219625216|NCT04760977|DRUG|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
219625217|NCT04760977|DEVICE|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
219625218|NCT04760977|BIOLOGICAL|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
219625219|NCT04760977|OTHER|Prehospital management|Stay and play strategy vs scoop and run
219625220|NCT04760977|DEVICE|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
219625221|NCT03035383|PROCEDURE|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
219625222|NCT03035383|PROCEDURE|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
219625223|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
219625224|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
219625225|NCT03902262|PROCEDURE|appendicectomy|
219625226|NCT06189196|DEVICE|BLOW BOTTLE|Blow Bottle PEP' is the cost-effective device comparative to other PEP devices. Treatment (CPT) along with BBPEP twice a day. Therapist made a cost-effective BBPEP which generates 10 cm of H2O PEP and it was given for 10 breaths, 3 sets with 5 second hold.
219625227|NCT06189196|OTHER|ACBT|Active cycle of breathing technique (ACBT) is an alternative airway clearance technique. A typical ACBT cycle consists of breathing control, three to four thoracic expansion exercises, and a forced expiratory technique (huffing). ACBT has been shown to improve short-term secretion clearance in patients with chronic lung disease. It is also flexible, tolerated, and accepted well by patients. Although ACBT is widely used in patients with respiratory conditions characterized by chronic sputum production.
219625228|NCT05477264|DRUG|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
219625229|NCT04756882|DRUG|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
219048021|NCT05637775|OTHER|EEG-based BCI system for (hands) Motor Imagery training|For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
219048022|NCT05637775|OTHER|Control - MI intervention|Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
219625230|NCT05990374|DRUG|Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc|The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
219625231|NCT06193317|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
219625232|NCT06492759|RADIATION|Radiation Therapy|Undergo radiation therapy
219625233|NCT06492759|BIOLOGICAL|Pembrolizumab|Given IV
219625234|NCT06492759|DRUG|Nab-paclitaxel|Given IV
219625235|NCT06492759|DRUG|Paclitaxel|Given IV
219625236|NCT06492759|DRUG|Carboplatin|Given IV
219625237|NCT06492759|DRUG|Gemcitabine|Given IV
219625238|NCT06492759|PROCEDURE|Biopsy|Undergo biopsy
219048023|NCT07085195|GENETIC|gene therapy|Six participants are planned to be divided into three dose groups in the dose escalation principle. The dose escalation principle is as follows: After the first sentinel subject receives 1×10¹² vg virus vectors, the research team will evaluate the safety, tolerability, and efficacy of the current drug dose after 4 weeks. If this sentinel does not experience dose-limiting toxicity, another sentinel subject will receive a 2×10¹² vg dose; if this sentinel develops dose-limiting toxicity (DLT), this dose will be defined as an intolerable dose, and the Data Review Committee will determine whether to select a lower dose for exploration or terminate dose escalation based on the existing data. If this sentinel subject doesn't experience dose-limiting toxicity, another participant will receive a 4×10¹² vg dose as a new sentinel subject. If this sentinel subject doesn't experience DLT, all of the next three subjects will receive a 4×10¹² vg dose.
219625239|NCT06492759|PROCEDURE|Computed Tomography|Undergo CT
219625240|NCT06492759|PROCEDURE|Bone Scan|Undergo bone scan
219625241|NCT06492759|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219625242|NCT06492759|OTHER|Medical Chart Review|Ancillary studies
219625243|NCT03390023|BEHAVIORAL|Focus Group|Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
219625244|NCT01146119|BIOLOGICAL|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
219625245|NCT01146119|BIOLOGICAL|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
219625246|NCT01146119|BIOLOGICAL|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
219625247|NCT01146119|BIOLOGICAL|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
219625248|NCT03415932|BEHAVIORAL|health education|Health information by a multimodal team
219625249|NCT04652115|DRUG|Defibrotide|Deibrotide via IV
219625250|NCT00314340|BEHAVIORAL|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
219625251|NCT00314340|DRUG|ER Morphine|
219625252|NCT00314340|DRUG|hydrocodone plus acetaminophen|
219625253|NCT00314340|DRUG|placebo|
219625254|NCT03227289|OTHER|Stayed in NRDS|The neonates with NRDS are stayed in NRDS.
219625255|NCT03227289|OTHER|Converted to ARDS|The neonates with NRDS are converted to ARDS.
219625256|NCT00607620|BEHAVIORAL|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
219625257|NCT01620138|DRUG|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
219625258|NCT01620138|DRUG|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
219048024|NCT07085195|DRUG|clozapine|Clozapine ramp-up will be performed four weeks after neurosurgery, when the participants have recovered, and the participants will be treated orally with clozapine. Clozapine is 25mg per tablet, and the oral dose is 1/32, 1/16, and 1/8 tablet twice a day, in the morning and at noon, respectively, with each dose repeated for 3 days for a total of 9 days. If no DLT develops during this time, the participants will continue to take 1/8 pill orally twice a day as a maintenance dose, and they will be monitored for 12 months.
219625259|NCT04025099|OTHER|Internal Cues|"The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT."
219625260|NCT04025099|OTHER|External Cues|"The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity."
219625261|NCT06150937|BEHAVIORAL|AEGIDA intervention arm|The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting \~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.
219625262|NCT06150937|BEHAVIORAL|AEGIDA control arm|The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting \~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
219625263|NCT05316207|OTHER|Telenursing|From the end of the first week after discharge to the end of the first month, patients were counseled over the phone during the home process. Complications were followed up.
219625264|NCT03602378|DIAGNOSTIC_TEST|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
219625265|NCT03602378|DEVICE|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
219625266|NCT03602378|DEVICE|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
219625267|NCT03602378|DEVICE|AGE reader|for measuring Advanced Glycation End products (AGEs)
219625268|NCT04273347|OTHER|standard of care for patient with brain trauma and spinal cord injury|neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
219625269|NCT01982513|DEVICE|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
219625270|NCT00141492|DRUG|Androgel (testosterone gel)|
219625271|NCT00279071|DEVICE|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
219625272|NCT02551562|OTHER|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
219625273|NCT02551562|OTHER|Placebo|Basic skin care regimen
219625274|NCT06309992|DRUG|Survodutide|Survodutide
219625275|NCT06309992|DRUG|Placebo|Placebo matching survodutide
219625276|NCT00629252|DRUG|Sertindole|oral 12-20 mg/day
219625277|NCT00629252|DRUG|Risperidone|oral 2-6mg / day
219625278|NCT05739383|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Subcutaneous injection in pre-filled syringe.
219625279|NCT05739383|DRUG|Placebo in 1.5ml|Matching placebo in 1.5ml solution for injection
219625280|NCT04969328|OTHER|ParTNer-STEPs|"The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~1. an informative website available for parents from recruitment until follow-up.~2. online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~3. transfer consultations across the paediatric and adult department. The transition consultations consist of:~   * a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~  * a farewell consultation with the paediatric nurse (0-3 months before transfer).~  * a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~  * a welcoming consultation with the nurse from the adult care (0-3 months after transfer)."
219625281|NCT05509894|DRUG|Ngenla|As provided in real world practice
219625282|NCT02933385|BEHAVIORAL|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
219625283|NCT02933385|BEHAVIORAL|Web-based health discussions|Create interactions between the employees.
219625284|NCT02933385|BEHAVIORAL|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
219625285|NCT02933385|BEHAVIORAL|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
219625286|NCT02933385|BEHAVIORAL|Closing events|these aim to motivate the employees to continue into the program.
219625287|NCT02933385|BEHAVIORAL|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
219625288|NCT02933385|BEHAVIORAL|Social Health platform|
219625289|NCT02933385|BEHAVIORAL|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
219625290|NCT05916937|DRUG|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
219625291|NCT05916937|DRUG|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
219625292|NCT03252535|BIOLOGICAL|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
219625293|NCT03252535|BIOLOGICAL|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
219625294|NCT03252535|OTHER|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
219625295|NCT05900388|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
219625296|NCT05900388|DRUG|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
219625297|NCT06966479|DRUG|Verekitug|Verekitug subcutaneous injection.
219625298|NCT06966479|DRUG|Placebo|Verekitug matching placebo.
219625299|NCT05583617|DRUG|Cevostamab|"Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles."
219625300|NCT05583617|DRUG|Lenalidomide|Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
219625301|NCT05583617|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
219625302|NCT05583617|DRUG|Iberdomide|Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
219625303|NCT05583617|DRUG|Dexamethasone|Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
219625304|NCT06967610|DRUG|Pirtobrutinib|Given PO 200mg daily
219625305|NCT06967610|DRUG|Venetoclax|Given PO daily
219625306|NCT06967610|DRUG|Obinutuzumab|Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
219625307|NCT06529822|BIOLOGICAL|Synthetic long peptide personalized cancer vaccine|Neoantigen vaccines will be provided on a patient-specific basis
219625308|NCT06529822|DRUG|Poly ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
219625309|NCT06529822|DEVICE|Signatera assay|Signatera is a clinically validated, personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS) based clinical trial assay targeting 16 tumor-specific mutations. It is intended for the detection of ctDNA isolated from anticoagulated peripheral whole blood from post-surgical patients previously diagnosed with localized or advanced solid tumors to aid physician assessment and treatment decision-making, together with other clinical factors
219625310|NCT05323409|BEHAVIORAL|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
218937087|NCT05676840|PROCEDURE|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
218937088|NCT00299169|BEHAVIORAL|N of 1 Trials|N of 1 Trials of statin therapy
218937089|NCT05252091|DRUG|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
218937090|NCT02970903|DEVICE|VitalPAD|VitalPAD prototype device
218937091|NCT02970903|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
218937092|NCT04306861|DIAGNOSTIC_TEST|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
218937093|NCT00075257|DRUG|DVS-233 SR|
218937094|NCT01790997|DRUG|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
218937095|NCT01790997|DRUG|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
218937096|NCT01790997|DRUG|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
218937097|NCT02428725|OTHER|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
218937098|NCT01492335|BEHAVIORAL|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
218937099|NCT01492335|BEHAVIORAL|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
218937100|NCT02096640|PROCEDURE|Type of surgical teqnique for tracheostomy|
218937101|NCT00000903|DRUG|Indinavir sulfate|
218937102|NCT00000903|DRUG|Lamivudine/Zidovudine|
218937103|NCT00000903|DRUG|Nelfinavir mesylate|
218937104|NCT00000903|DRUG|Efavirenz|
218937105|NCT01995188|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
218937106|NCT01995188|DRUG|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
218937107|NCT01995188|DRUG|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
218937108|NCT04988243|OTHER|All aortic valve products on the market|"1. Subjects with severe aortic valve stenosis~2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~4. Be able to contact the subjects or their legal guardians / relatives;~5. The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
218937109|NCT02471599|PROCEDURE|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
219625311|NCT06852677|OTHER|Deep Squat position|"Participants assigned to the deep squat group will perform a cumulative total of 20 minutes of deep squatting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture with heels on the ground, feet shoulder-width apart, and knees aligned with toes. They will be encouraged to gradually increase their squat duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper squat form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
219625312|NCT06852677|OTHER|Cross-legged Sitting|"Participants assigned to the cross-legged sitting group will perform a cumulative total of 20 minutes of cross-legged sitting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture while sitting. They will be encouraged to gradually increase their cross-legged sitting duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper sitting form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
219625313|NCT06184204|DRUG|Trombix® (Rivaroxaban)|20mg or 15 mg as per the doctor's prescription
219625314|NCT04144894|DIAGNOSTIC_TEST|Shear Wave Elastography|Advanced ultrasound technique
219625315|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
219048025|NCT07085936|BEHAVIORAL|Video-based orientation program|The intervention group will receive a structured video-based orientation program developed for first-degree relatives of psychiatric inpatients. The program consists of four sessions (each 45-60 minutes) delivered over one week by psychiatric nurses. Topics include an introduction to the psychiatric unit, understanding stigma, basic information on mental illnesses, and strategies for coping with stigma. Educational videos support learning and discussion. Unlike the control group, this intervention emphasizes stigma awareness and emotional support. Pre- and post-tests are used to assess perceived stress and stigma.
219625316|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
219625317|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
219625318|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
219625319|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
219625320|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
219625321|NCT04248452|DRUG|Capecitabine|Given PO
219625322|NCT04248452|DRUG|Fluorouracil|Given IV
219048026|NCT07086924|DRUG|Methotrexate|Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.
219625323|NCT04248452|DRUG|Leucovorin|Given IV
219625324|NCT04248452|DRUG|Leucovorin Calcium|Given IV
219625325|NCT04248452|DRUG|Oxaliplatin|Given IV
219625326|NCT04248452|RADIATION|Radiation Therapy|Undergo radiation therapy
219625327|NCT02683993|DEVICE|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
219625328|NCT06496451|OTHER|Spinal tap for CSF collection|"A spinal tap will be done on you by your choice of bedside or in the interventional radiology (IR) suite in the Shands (Neuromedicine) hospital. This procedure will be done by trained technicians under medical supervision or the principal investigator. Local anesthesia will be used to numb the site of injection on your back. We plan to collect about 4 tablespoons of spinal fluid."
219625329|NCT06496451|OTHER|Venipuncture for blood sample|a sample of blood (approximately 4-5 tablespoonfuls) will be collected
219625330|NCT06668558|DRUG|Azacitidine (AZA)|"Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
219625331|NCT06668558|DRUG|Venetoclax|"Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
219625332|NCT04712474|BEHAVIORAL|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
219625333|NCT04876157|DIAGNOSTIC_TEST|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
219625334|NCT05883293|DRUG|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
219625335|NCT05691491|PROCEDURE|Biopsy Procedure|Undergo biopsy
219625336|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219625337|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
219625338|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219625339|NCT05691491|DRUG|Temozolomide|Given orally (PO)
219625340|NCT05691491|DRUG|Tuvusertib|Given PO
219625341|NCT05600283|DIAGNOSTIC_TEST|Swab kit (COBAS HPV 4800 Assay -Evalyn brush)|Patient self-sampling swab kit to collect a vaginal sample for HPV testing
219625342|NCT05600283|DIAGNOSTIC_TEST|Clinician-collection of cervical sample for HPV testing|Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing (Evalyn brush)
219625343|NCT06463886|BEHAVIORAL|STEP-AD|This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
219625344|NCT06463886|BEHAVIORAL|Enhanced treatment as usual (E-TAU)|Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
219625345|NCT06509763|DEVICE|ECGI system during LBBP implant|ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
219625346|NCT06877702|DRUG|BMS-986460|Specified dose on specified days.
219625347|NCT06880562|DEVICE|Splanchnic Nerve Denervation|Catheter-based endovascular denervation (CDN) of renal arteries and splanchnic nerves (celiac + SMA) using radiofrequency ablation
219625348|NCT06880562|DEVICE|Renal Denervation Only|Catheter-based endovascular denervation (CDN) of renal arteries only, without splanchnic nerve denervation
219625349|NCT06881823|DRUG|AAA602|\[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.
219625350|NCT06881823|DRUG|AAA802|\[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion
219625351|NCT06881823|DRUG|Gallium (68Ga) gozetotide|Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.
219625352|NCT06881823|DRUG|Piflufolastat (18F)|Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.
219625353|NCT06881823|DRUG|Flotufolastat F 18|Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.
219625354|NCT06881823|DRUG|18F-PSMA-1007|Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.
219625355|NCT07038343|DRUG|AVZO-1418|Specific dose in protocol specified schedule
219625356|NCT07038343|DRUG|Combination Agent 1|Per label based on combination agent used
219625357|NCT07038343|DRUG|Combination Agent 2|Per label based on combination agent used
219625358|NCT07039708|BEHAVIORAL|E-MinD Life Semantic|The E-MinD Life programme is designed to teach semantic memory strategies. The memory strategies are applied to 12 common daily activities required for community living, e.g. meal preparation, laundry activities, and built into the E-MinD Life programme on a computer-based platform. The intervention runs over 9 weeks with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week. During the home sessions, participants will complete the same activities as those learnt during the healthcare-professional-led sessions. Family members or carers will be invited to join the healthcare-professional-led sessions as observers and support the participants in the home sessions if needed.
219625359|NCT07039708|BEHAVIORAL|Cognitive stimulation|Participants will receive stimulation for visual attention and memory through activities such as playing a game that requires them to find missing pieces, and auditory attention and memory through activities such as remembering a song. The intervention will adopt a similar structure as the E-MinD Life Semantic group, with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week for 9 weeks.
219625360|NCT06719245|PROCEDURE|Targeted Muscle Reinnervation (TMR)|In short: each transected nerve is identified after amputation and is dissected proximally for length. A nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby amputated nerve.
219625361|NCT06719245|PROCEDURE|Standard neurectomy|During the amputation a standard neurectomy will be performed based on the surgeons preference. Standard neurectomy will include cutting of the nerve, with or without traction, with or without coagulation, and with or without infiltration with a local anesthetic (i.e., ropivacaine) or phenol. Ligation of the nerve will not be allowed.
219625362|NCT06716801|DRUG|Cenobamate|Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications.
219625363|NCT03907488|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
219625364|NCT03907488|DRUG|Brentuximab Vedotin|Given IV
219625365|NCT03907488|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
219625366|NCT03907488|DRUG|Dacarbazine|Given IV
219625367|NCT03907488|DRUG|Doxorubicin Hydrochloride|Given IV
219625368|NCT03907488|BIOLOGICAL|Filgrastim|Given SC or IV
219625369|NCT03907488|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219625370|NCT03907488|BIOLOGICAL|Nivolumab|Given IV
219625371|NCT03907488|BIOLOGICAL|Pegfilgrastim|Given SC
219625372|NCT03907488|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219625373|NCT03907488|OTHER|Quality-of-Life Assessment|Ancillary studies
219625374|NCT03907488|OTHER|Questionnaire Administration|Ancillary studies
219625375|NCT03907488|RADIATION|Radiation Therapy|Receive radiation therapy
219625376|NCT03907488|DRUG|Vinblastine Sulfate|Given IV
219625377|NCT05585476|DEVICE|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
219625378|NCT05585476|COMBINATION_PRODUCT|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
219625379|NCT07042412|BEHAVIORAL|Ta'am Mustadam Intervention|"The Ta'am Mustadam intervention, guided by the BCW and BCT, will be implemented over six weeks with a four-week follow-up among adults in the CMHS canteen.~The intervention will consist of the following elements:~1. Education: The educational messages will be shared via WhatsApp on Fridays \&Tuesdays, with additional dietary tips on Wednesdays, timed before main meal. Moreover, weekly video recipes will be shared on Saturdays~2. Behavioral Practice: This component engages participants withs sustainable eating habits through biweekly cooking competitions and hands-on meal preparation activities held on Thursdays.~3. The environmental restructuring component aims to promote sustainable food choices at CMHS canteen by enhancing healthy food availability, appeal, and visibility through local produce, improved dish palatability, and visual/nutritional cues via QR codes, tray mats, and banners.~The evaluation of Ta'am Mustadam intervention will be guided by RE-AIM framework."
219625380|NCT06705946|BEHAVIORAL|Aqua vest group|Participants in this group will perform Dynamic Stability Training (DST) sessions twice a week for 12 weeks while wearing an aqua vest. Each session will focus on dynamic stability exercises aimed at improving balance, lower limb joint moment distribution, and gait. Each session will last for 50 minutes
219625381|NCT06705946|BEHAVIORAL|Weight vest group|Participants in this group will perform the same Dynamic Stability Training (DST) sessions twice a week for 12 weeks, but with a weight vest instead of an aqua vest. Each session will focus on balance, lower limb joint moment distribution, and gait, lasting for 50 minutes
219625382|NCT02858999|DRUG|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
219625383|NCT06925750|BIOLOGICAL|Sotatercept|SC injection administered every 3 weeks
219625384|NCT06925750|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
219625385|NCT06885671|RADIATION|Multiple Fraction PBI|Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.
219625386|NCT06885671|RADIATION|Single Fraction PBI|Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.
219625387|NCT06736691|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
219625388|NCT06736691|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
219625389|NCT06736691|DRUG|Mebendazole|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
219625390|NCT06736691|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
219625391|NCT06643598|BEHAVIORAL|Abecedarian Approach|The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
219625392|NCT03283384|DRUG|Letrozole|Letrozole 2.5 mg daily.
219625393|NCT03283384|DRUG|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
219625394|NCT03283384|DRUG|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
219625395|NCT06741410|DRUG|Ephedrine|Intravenous boluses of ephedrine
219625396|NCT06741410|DRUG|Phenylephrine|Intravenous continuous infusion of phenylephrine
219625397|NCT06614712|OTHER|Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)|"Incident renal disease patients in this cohort are defined as those that newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the start date of this cohort study period, the 1st August 2020 and until the 1 st February 2023 (DAPA\_CKD P\&R date in Spain). The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-1 of this study cohort.~At the index date-1, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines.~Patients will be followed up from the index date-1 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall observation period."
219625398|NCT06614712|OTHER|Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)|We define the post-P\&R cohort including all incident renal disease patients observed in the dapagliflozin-CKD post-pricing and reimbursement period. Patients in this cohort newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the 1 st February 2023 (DAPA\_CKD P\&R date in Spain) and until the end of the study observation period. The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-2 of this study cohort. At the index date-2, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines. Patients will be followed up from the index date-2 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall study period
219625410|NCT07053891|DRUG|Voclosporin (LUPKYNIS)|In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.
219625411|NCT06780306|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
219625412|NCT06780306|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|300 mL Sterile, preservative free 0.9% NaCl
219625413|NCT06264531|DRUG|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
219625414|NCT06264531|DRUG|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
219625415|NCT03875781|DRUG|Chemotherapy|"Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
219625416|NCT03875781|DRUG|Radiochemotherapy|"Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
219625417|NCT06750809|DEVICE|PermeaDerm Biosynthetic Wound Matrix|Study participants randomized (1:1) to this arm will receive PermeaDerm Biosynthetic Wound Matrix prior to skin graft.
219625418|NCT06750809|DEVICE|Frozen Human Cadaveric Allograft (FHCA)|Study participant randomized (1:1) to this arm will receive Frozen Human Cadaveric Allograft (FHCA) prior to skin graft.
219625419|NCT07058883|DEVICE|Juläine|Juläine is a sterile injectable implant containing poly-L-lactic acid microspheres, intended for intradermal use to improve skin depressions from acne scars.
219625420|NCT07058883|OTHER|Sterile Saline (Placebo)|Sterile saline solution used as a placebo control, administered in the same volume and schedule as Juläine.
219625421|NCT05516862|OTHER|Dragons acupuncture|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles."
219625422|NCT05516862|OTHER|Dragons acupressure|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles."
218937110|NCT02471599|OTHER|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
219048027|NCT07085520|DRUG|Microneedle with 0.24mg Denosumab|This intervention uses microneedle patches loaded with 0.24mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
219048028|NCT07085520|DRUG|Saline Microneedle Patch|This intervention involves the use of a microneedle patch loaded with saline. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It serves as a control to assess the skin safety of the microneedle patch without the active drug. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
218937111|NCT01572285|PROCEDURE|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
218937112|NCT01572285|PROCEDURE|Sham|Sham procedure using a non-penetrating needle
218937113|NCT03173183|DRUG|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
219625423|NCT05516862|OTHER|Dragons placebo|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles."
219625424|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
219625425|NCT02269098|OTHER|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
219625426|NCT01766076|OTHER|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
219625427|NCT01766076|DRUG|Placebo|PBMC collected for immune activation assays using flowcytometry
219625428|NCT02155127|BEHAVIORAL|walking|
219625429|NCT00893880|DRUG|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
219625430|NCT04848155|OTHER|socially assistive robot|"The intervention group will work with the ReMIND-system. This ReMIND-system consists of:~1. An existing socially assistive robot called James® that will be adapted based on the needs of the older adults and the robot's own functionality. For example, exercise videos and games to stimulate physical and cognitive activity will be developed and made available on the robot. The robot has to be programmed by the researcher using the ZBOS Control© application on a separate tablet that is connected to the robot.~2. The Keosity-app, an application specifically designed to support people in telling, documenting and sharing their life stories with others. This application will be available on the robot."
219625431|NCT04211688|BEHAVIORAL|Group Schema therapy|Bimonthly outpatient psychotherapy delivered in individual setting
219625432|NCT04211688|BEHAVIORAL|Individual Schema therapy|weekly outpatient psychotherapy delivered in group setting
219625433|NCT04903431|BEHAVIORAL|Crisis Response Planning for Suicide Risk|Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
219625434|NCT02075567|PROCEDURE|Experimental|
219048029|NCT07085520|DRUG|Microneedle with 1.2mg Denosumab|This intervention uses microneedle patches loaded with 1.2mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
219048030|NCT07085520|DRUG|Microneedle with 6mg Denosumab|This intervention uses microneedle patches loaded with 6mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
219625435|NCT02201004|DRUG|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
219625436|NCT02201004|DRUG|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
219625437|NCT02201004|DRUG|placebo|Pharmaceutical form:tablet Route of administration: oral
219048031|NCT06619379|OTHER|Retention time of speculum|"According to the randomization, the speculum can be extracted :~1. just after the transfer catheter is withdrawn~2. 60 seconds after the transfer catheter is withdrawn~3. 420 second (7 minutes) after the catheter is withdrawn"
219048032|NCT06906614|BEHAVIORAL|Simulation-Based Communication Training|"In our study, the intervention is more of an experimental situation - a scenario.~High-fidelity scenarios include patients played by real actors displaying anxiety, aggression, silence, and emotional distress in various clinical situations such as delivering serious news or frustration for waiting for physicians. The average time of each simulation is 12 minutes."
219048033|NCT06902779|OTHER|Support of the hospital pharmacist for the medication management at hospital discharge|1\) The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns.
219048034|NCT07092150|OTHER|School meals|Daily mid-day meals sourced locally and supplemented by school gardens.
219048035|NCT07092150|OTHER|School gardens|A school vegetable garden to grow green leafy vegetables on school grounds.
219625438|NCT06250296|OTHER|New model of psychiatric inpatient care|"The intervention envisages major structural changes in wards, in particular the reorganization of clinical discussion and decision-making spaces, as well as the medical and nursing referral system, and the inclusion of relatives in care:~* Treatment planning involving the patient, with a focus on his or her needs and resources.~* Care by referral teams, present every day of the week, to ensure continuity and consistency of care.~* As few decisions as possible made without the patient, and transparency in decision-making.~* Emphasis on the subjective meaning of illness, beyond symptoms.~* Greater visibility of care planning for patients, who will benefit from weekly agendas~* Closer collaboration with relatives, through open invitations to all clinical discussions, telephone hotlines and meeting times.~* Openness to the network and community care, by promoting communication and exchanges between all stakeholders, and the development of early warning tools such as the joint crisis plan."
219625439|NCT02028663|DRUG|CJ-12420|Once daily, Oral administration
219625440|NCT02028663|DRUG|Esomeprazole|Once daily, Oral administration
219625441|NCT05341219|PROCEDURE|Light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
219625442|NCT05341219|PROCEDURE|Sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
219625443|NCT06414941|DRUG|Dexmedetomidine administration|atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
219625444|NCT06414941|DRUG|Dexmedetomidine plus low-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
219625445|NCT06414941|DRUG|Dexmedetomidine plus high-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
219625446|NCT04088812|OTHER|Placebo meat derivative + Placebo satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
219625447|NCT04088812|OTHER|Placebo meat derivative + Satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
219625448|NCT04088812|OTHER|Experimental meat derivative + Placebo satiating control|Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
219625449|NCT05521581|OTHER|Hand massage|Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
219625450|NCT00170781|DRUG|Lumiracoxib|
219625451|NCT03205319|DEVICE|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
219625452|NCT05011838|OTHER|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
219625453|NCT05011838|OTHER|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
219625454|NCT05011838|OTHER|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
219625455|NCT02371538|DIETARY_SUPPLEMENT|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
219625456|NCT03514732|DRUG|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
219625457|NCT03695900|OTHER|Targeting SpO2 at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours
219625458|NCT03695900|OTHER|Targeting SpO2 at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
219625459|NCT03194542|DRUG|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
219625460|NCT03047187|DIAGNOSTIC_TEST|ACLR|"* quadriceps and hamstring isometric muscles test~* single hop for distance~* IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
219625461|NCT04274933|DRUG|Venetoclax|Tablet; Oral
219625462|NCT04274933|DRUG|Capecitabine|Tablet; Oral
219625463|NCT01381211|DRUG|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
219625464|NCT01381211|DRUG|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
219625465|NCT00155597|BEHAVIORAL|home physical therapy|
219625466|NCT02540382|DEVICE|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions\* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
219625467|NCT02540382|DEVICE|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
219625468|NCT04762160|DRUG|Tazemetostat|Study Drug
219625469|NCT04762160|COMBINATION_PRODUCT|Rituximab|Partner Drug
219625470|NCT00056927|BEHAVIORAL|Anti-smoking Socialization Program|
219625471|NCT04366492|OTHER|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
219625472|NCT02475473|OTHER|Exercise Training|Chronic High-Intensity Resistance Training
219625473|NCT02976129|DRUG|V565|Daily dosing of V565 three times a day orally for 6 weeks
219625474|NCT02976129|DRUG|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
219625475|NCT06244329|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.
219625476|NCT04924192|DRUG|TQB3616 capsules|A CDK4/6 kinase inhibitor
219625477|NCT04924192|DRUG|Anlotinib Hydrochloride capsules|A multi-target receptor tyrosine kinase inhibitor
219625478|NCT04924192|DRUG|Irinotecan Hydrochloride for Injection|An inhibitor of DNA topoisomerase Ⅰ
219625479|NCT04823065|DRUG|Loperamide Pill|4 mg Imodium, per os
219625480|NCT04823065|DRUG|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
219625481|NCT04872686|DRUG|0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|"Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software."
219625482|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|"Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software"
219625483|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to healthy volunteer|"Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software"
219625484|NCT04872686|OTHER|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
218937114|NCT00947687|DRUG|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
219625485|NCT03113812|DRUG|ABvac40|
219625486|NCT03113812|DRUG|Placebo|
219625487|NCT01875523|DRUG|Serelaxin|
219625488|NCT04417452|OTHER|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
219625489|NCT04417452|OTHER|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
219625490|NCT04417452|BEHAVIORAL|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
219625491|NCT04417452|DIAGNOSTIC_TEST|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
219625492|NCT04302870|DRUG|Memantine Hydrochloride Oral Solution|Memantine hydrocholoride taken once daily
219625493|NCT04302870|DRUG|Trazodone Hydrochloride oral solution|Trazodone Hydrochloride taken once daily
219625494|NCT04302870|DRUG|Placebo oral solution|Placebo taken once daily
219625495|NCT04302870|DRUG|Amantadine Hydrochloride Oral Solution|Amantadine Hydrochloride taken once daily
219625496|NCT04302870|DRUG|Tacrolimus 1Mg Cap|Tacrolimus 1Mg overencapsulated tablet taken once daily
219625497|NCT04302870|DRUG|Placebo capsule|Placebo taken once daily
219625498|NCT02772133|PROCEDURE|Primary PCI|
219625499|NCT03531775|DIAGNOSTIC_TEST|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
219625500|NCT00677937|BEHAVIORAL|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
219625501|NCT02206854|DRUG|R-flurbiprofen|200 mg gelatine capsule once orally
219625502|NCT05669105|DIAGNOSTIC_TEST|Specimen sample|Participants will have up to 100 mL of whole blood collected.
219625503|NCT03655405|OTHER|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
219625504|NCT03936205|DRUG|Dexmedetomidine|Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
219625505|NCT00019773|DRUG|capecitabine|
219625506|NCT00019773|DRUG|oxaliplatin|
219625507|NCT04988269|DIAGNOSTIC_TEST|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
219625508|NCT04988269|DIAGNOSTIC_TEST|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
219625509|NCT02641795|DEVICE|Minimally invasive robotic cochlear implantation|
219625510|NCT01657838|DRUG|Isavuconazole|oral
219625511|NCT01657838|DRUG|Ketoconazole|oral
219625512|NCT03601013|OTHER|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
219625513|NCT05523102|DRUG|Paracetamol|Intravenous paracetamol/acetaminophen
219625514|NCT05523102|DRUG|Ketorolac|Intravenous ketorolac/NSAID
219625515|NCT02045264|DRUG|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
219625516|NCT01991743|DRUG|Group 2.5|Administration of bupivacaine 2.5 mg.
219625517|NCT01991743|DRUG|Group 5|Administration of 5 mg bupivacaine
219625518|NCT01991743|DRUG|Group 7.5|Administration of 7.5 mg bupivacaine
219625519|NCT01991743|DRUG|Group 10|Administration of 10mg bupivacaine.
219625520|NCT02288403|BEHAVIORAL|Aerobic interval training|
219625521|NCT02288403|BEHAVIORAL|Continuous training|
219625522|NCT03218995|DRUG|Eteplirsen|Infusion for intravenous use.
219625523|NCT00450879|DRUG|Pazopanib Hydrochloride|Given PO
219625524|NCT00450879|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
219625525|NCT00450879|OTHER|Pharmacological Study|Correlative studies
218937115|NCT00947687|DRUG|Placebo|
218937116|NCT02052388|DRUG|Daptomycin|Active Comparator
218937117|NCT02052388|DRUG|Brilacidin|Experimental Drug
219625526|NCT00450879|OTHER|Laboratory Biomarker Analysis|Correlative studies
219625527|NCT03440242|DEVICE|JJVC Contact Lens|etafilcon A with PVP DD
219625528|NCT03440242|DEVICE|Marketed Contact Lens|nelfilcon A DD
219625529|NCT00039559|OTHER|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
219625530|NCT00108459|BEHAVIORAL|Low Carbohydrate Diet|
219625531|NCT00147875|DRUG|Prednisone|
219625532|NCT00147875|DRUG|Vinblastine|
219625533|NCT00147875|DRUG|Doxorubicin (Adriamycin)|
219625534|NCT00147875|DRUG|Gemcitabine|
219625535|NCT00616837|OTHER|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
219625536|NCT00616837|OTHER|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
219625537|NCT05643937|BEHAVIORAL|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
219048036|NCT07092150|DIETARY_SUPPLEMENT|IFA and Deworming|Weekly iron and folic acid supplements and annual deworming.
219048037|NCT07092150|BEHAVIORAL|Nutrition education|Nutrition education, led by trained teachers, that will cover health, agriculture, and WASH topics.
219048038|NCT07092150|BEHAVIORAL|Women's workshops|Community workshops that will engage mothers or female guardians in gardening, nutrition, and entrepreneurship, offering support and training for small businesses and homestead gardens.
219048039|NCT07090018|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
219048040|NCT06594159|DRUG|LY4065967|Administered orally
219048041|NCT06594159|DRUG|Placebo|Administered orally
219048042|NCT06594159|DRUG|Rosuvastatin|Administered orally
219048043|NCT06302296|DEVICE|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
219048044|NCT06302296|BEHAVIORAL|Placebo injection|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
219048045|NCT06748274|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.
219048046|NCT06748274|DEVICE|High-definition transcranial direct current stimulation (HD-tDCS)|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low-intensity electrical current to specific areas of the scalp. The electric current induces alterations in the membrane potentials of underlying neuronal networks. The application of tDCS with concentric ring electrodes is a more targeted form of tDCS, allowing for more precise modulation of cortical activity compared to traditional tDCS methods.
219048047|NCT07093489|BIOLOGICAL|LC16m8|LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.
219048048|NCT06908655|OTHER|MRI|The procedure to be investigated will be to perform a diffusion tensor sequence during the MRI indicated as part of the treatment. The diffusion tensor sequence takes 10 minutes to acquire, for a total examination time of 30 minutes instead of 20 minutes, including set-up.
219048049|NCT06909045|OTHER|Adaptive DBS|The Medtronic Percept device will be activated with the aDBS functionality. Participant will receive adaptive DBS.
219048050|NCT06909045|OTHER|Continue DBS|The Medtronic Percept device will be equipped with aDBS functionality (to maintain the blinding of the allocation), but this functionality will remain inactive. Participant will receive continue DBS.
219048051|NCT06903754|DRUG|With ISGLT2|Patients for whom we will prescribe ISGLT2
219048052|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
219048053|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
219048054|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
219625538|NCT05643937|BEHAVIORAL|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
219625539|NCT05794100|OTHER|Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator|One pack of each product (1 to 10) will be consumed on a separate occasion
219625540|NCT00546533|DRUG|Etanercept|
219625541|NCT02859337|DRUG|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
219625542|NCT02859337|DRUG|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
219625543|NCT02871154|OTHER|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
219625544|NCT03277287|RADIATION|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
219625545|NCT01622647|OTHER|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
219625546|NCT05135065|OTHER|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
219048055|NCT06912165|DRUG|Placebo|Participants will receive placebo QD from Week 0 through Week 16.
219048056|NCT06904547|OTHER|No intervention administered|No intervention administered
219048057|NCT06904547|OTHER|Non Interventional Study|Non Interventional Study
219048058|NCT06909890|BEHAVIORAL|Chios mastic beverage|Participants of this intervention arm will be provided with a sparkling beverage enriched with the natural mastic aqueous extract (0.2%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
219625547|NCT03134144|DEVICE|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
219625548|NCT02680704|OTHER|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
219625549|NCT04494386|BIOLOGICAL|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
219625550|NCT04494386|OTHER|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
219625551|NCT01465412|DRUG|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
219625552|NCT06301763|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
219625553|NCT06301763|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
219625554|NCT05814263|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
219625555|NCT05814263|DEVICE|LV pacing|LV lead in a CS branch
219625556|NCT03241849|PROCEDURE|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
219625557|NCT06416943|OTHER|3D printed educational model|Slide-based presention plus 3D printed port-A catheter model
219625558|NCT02913118|DRUG|Andrographolid Sulfonate Injection (AS Injection)|
219625559|NCT02913118|DRUG|Cephalosporin|
219625560|NCT02913118|DRUG|Azithromycin, Minocycline or Doxycycline|
219625561|NCT02913118|DRUG|Amoxicillin-clavulantic acid|
219625562|NCT02913118|DRUG|Fluoroquinolones|
219625563|NCT02913118|DRUG|Placebo|
219625564|NCT05951413|DRUG|Sildenafil Citrate|a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5),
219625565|NCT05951413|DRUG|estradiol|estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
219625566|NCT04390113|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
219625567|NCT04390113|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
219625568|NCT05605418|BEHAVIORAL|CHESS intervention|The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
219625569|NCT07061951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219625570|NCT07061951|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219625571|NCT07061951|PROCEDURE|Computed Tomography|Undergo CT
219625572|NCT07061951|PROCEDURE|Echocardiography Test|Undergo echocardiography
219625573|NCT07061951|DRUG|Mirdametinib|Given PO
219625574|NCT01351649|BEHAVIORAL|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
219625575|NCT05607784|BEHAVIORAL|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
219625576|NCT05607784|BEHAVIORAL|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
219625577|NCT04020666|DRUG|Urinary Kallidinogenase|
219625578|NCT00195143|GENETIC|Surgical infusion of AAV-GAD into the subthalamic nucleus|
219625579|NCT04750499|PROCEDURE|Adipose tissue injection associated with endorectal advancement flap.|"Injection of adipose tissue will be associated with endorectal advancement flap technique. In blind fistulas and special cases, in which the flap is not indicated, alternative techniques will be used. In all cases, autologous, micro-fragmented and minimally manipulated adipose tissue, obtained with a standardized procedure, previously validated and authorized, will be injected. This procedure uses the Lipogems ® device (Lipogems International SpA, Milan, Italy), with which a well-characterized adipose tissue is obtained with the maximum safety guarantees."
219625580|NCT03815500|BEHAVIORAL|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
219625581|NCT01611883|DRUG|Ezetimibe|10 mg oral dose once daily for 24 weeks
219625582|NCT01611883|DRUG|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
219625583|NCT00396071|DRUG|vildagliptin|vildagliptin 100 mg
219625584|NCT00396071|DRUG|Placebo|matching placebo
219625585|NCT04628247|DEVICE|Spring gravity bar|"1. contain two wooden board length (160 cm) and width (15 cm)~2. contain pair of spring at every end of board~3. two wooden board connect in the middle"
219625586|NCT06469905|DEVICE|Erector Spina Plan Block|ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.
219625587|NCT06469905|OTHER|Stabilization exercises|Stabilization exercises will be practiced to control group
219625588|NCT07067567|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
219625589|NCT04125147|DEVICE|Experimental: Montage Bone Hemostat|Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
219625590|NCT03242473|OTHER|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
219625591|NCT04044989|DEVICE|Laser|Diode laser device was used for photobiomodulation
219625592|NCT04044989|DEVICE|light-emitting diode (LED)|LED device was used for photobiomodulation
219625593|NCT04044989|DEVICE|Placebo|Diode laser device was used for placebo effect
219625594|NCT01170429|DRUG|Procaterol hydrochloride|25µg BID for 8 weeks
219625595|NCT01170429|DRUG|Meptin placebo|25µg BID for 8 weeks
218937118|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
218937119|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
218937120|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
218937121|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
218937122|NCT02453204|BEHAVIORAL|Sitting|
218937123|NCT02453204|BEHAVIORAL|Standing|
219625596|NCT01598272|DIETARY_SUPPLEMENT|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
219625597|NCT01598272|DIETARY_SUPPLEMENT|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
219625598|NCT00052572|DRUG|ixabepilone|
219625599|NCT00030901|DRUG|L-selenomethionine|Randomization between active L-selenomethionine and placebo
219625600|NCT00030901|DRUG|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
219625601|NCT03126968|DRUG|Topical epinephrine|Prophylactic topical epinephrine
219625602|NCT03126968|DRUG|Placebos|Topical placebo (normal saline)
219625603|NCT05897281|PROCEDURE|SHOOT exercise group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
219625604|NCT05897281|PROCEDURE|routine training group|The control group will continue their routine training
219625605|NCT00369954|DRUG|carboplatin|
218937124|NCT02453204|BEHAVIORAL|Walking|
218937125|NCT04098484|OTHER|Control Trial|Participants will abstain from exercise throughout a 3-month period
218937126|NCT04098484|OTHER|Exercise Trial|Participants will execute a 3-month exercise training program
219625606|NCT00369954|DRUG|gemcitabine hydrochloride|
219625607|NCT05632861|DRUG|HuHuangLianzonggan capsule|HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
219625608|NCT05632861|DRUG|HuHuangLianzonggan capsule placebo|HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
219625609|NCT05290883|DIETARY_SUPPLEMENT|Novel yoghurt drink containing Polar Lipids|Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
219625610|NCT02153177|PROCEDURE|Rotator cuff repair|Arthroscopic procedure
219625611|NCT02153177|DRUG|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
219625612|NCT02153177|DRUG|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
219625613|NCT01955928|BEHAVIORAL|Online Cognitive behavioral treatment for insomnia|
219625614|NCT03550677|PROCEDURE|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
219625615|NCT03550677|PROCEDURE|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
219625616|NCT06545851|OTHER|Oxygen therapy - constant oxygen flow|During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow
219625617|NCT06545851|OTHER|Oxygen therapy - automatic titrating oxygen flow|During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
219625618|NCT04014205|DRUG|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
219625619|NCT02576847|DRUG|Omiganan|Topical gel
219625620|NCT01724697|OTHER|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
219625621|NCT01724697|OTHER|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
219625622|NCT01806051|DRUG|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
218937127|NCT05080699|DIETARY_SUPPLEMENT|Peptamen Intense VHP, Nestlé Health Science, Switzerland|An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
218937128|NCT00038818|BIOLOGICAL|CD8 Depleted Donor Lymphocyte|
218937129|NCT01328067|DEVICE|Exablate 2100|MRgFUS
218937130|NCT01328067|PROCEDURE|Myomectomy|Non-Hysteroscopic Myomectomy
218937131|NCT00710541|DEVICE|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
219048059|NCT06909890|BEHAVIORAL|Placebo beverage|Participants of this intervention arm will be provided with a placebo sparkling beverage (same organoleptic characteristics with experimental beverage but no active ingredients) and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
219048060|NCT06909877|DRUG|HH2853 Tablets|25mg, 100mg and 200 mg BID oral administration
219048061|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
219048062|NCT07096232|DIAGNOSTIC_TEST|Multi-Agent AI Diagnostic Workflow (AEYE)|This intervention consists of an orchestrated diagnostic workflow utilizing multiple specialized artificial intelligence (AI) agents to analyze patient data and ophthalmic imaging for the diagnosis of refractive errors and keratoconus. The workflow, named Automated Evaluation for Your Eye (AEYE), integrates various AI modules designed for data extraction, image interpretation, and decision support. Each patient's clinical information, corneal topography, tomography, and other relevant imaging are processed sequentially through these AI agents, with results synthesized into a diagnostic recommendation. The system operates independently of clinician input, and outputs are blinded prior to comparison with consultant ophthalmologist assessments. The intervention is intended to assess diagnostic accuracy, efficiency, and concordance with expert clinical decision-making.
219048063|NCT06181786|DRUG|NAV-240|Intravenous administration of NAV-240
219048064|NCT06181786|DRUG|Placebo|Intravenous administration of matching placebo for NAV-240
219048065|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
219048066|NCT07095829|OTHER|No intervention|Evaluation of natural history of the disease
219048067|NCT06909448|DEVICE|abdominal belt|40 postpartum women will only wear abdominal belt for 14 weeks.
219048068|NCT06909448|DEVICE|TECAR therapy|will wear the same abdominal belt for 6 weeks then participating in TECAR therapy 3 sessions /week for 8 weeks.
219048069|NCT06909383|DRUG|Nanocrystalline megestrol acetate|Nanocrystalline megestrol acetate
219048070|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
219048071|NCT06909331|DIETARY_SUPPLEMENT|Exogenous ketone salt|Exogenous ketone salt supplement will be taken once to determine acute circulating levels of beta-hydroxybuyrate and acetoacetate compared to a control supplement.
219548798|NCT01517919|BEHAVIORAL|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
219548799|NCT05263713|OTHER|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
219548800|NCT02308241|DRUG|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
219548801|NCT04381741|BIOLOGICAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
219548802|NCT01756313|PROCEDURE|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
219548803|NCT04383249|DIAGNOSTIC_TEST|Pathology result|Pathology result of the hernia sac
219548804|NCT00494741|DRUG|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
219548805|NCT00494741|DRUG|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
219548806|NCT01269645|BEHAVIORAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
219548807|NCT00916045|DRUG|Thiotepa|
219548808|NCT00916045|DRUG|Fludarabine|
219548809|NCT00916045|DRUG|Intravenous busulphan|
219548810|NCT00916045|DRUG|Thymoglobulin|
219548811|NCT00916045|DRUG|Ciclosporin|
219548812|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
219548813|NCT00916045|DRUG|Fludarabine|
219548814|NCT00916045|DRUG|Cyclophosphamide|
219548815|NCT00916045|RADIATION|Radiotherapy|
219548816|NCT00916045|DRUG|Thymoglobulin|
219548817|NCT00916045|DRUG|Ciclosporin|
219548818|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
219548819|NCT00916045|DRUG|Fludarabine|
219548820|NCT00916045|DRUG|Melphalan|
219548821|NCT00916045|DRUG|Thymoglobulin|
219548822|NCT00916045|DRUG|Ciclosporin|
219548823|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
219548824|NCT04133116|DRUG|LY3471851|Administered SC
219548825|NCT04133116|DRUG|Placebo|Administered SC
219548826|NCT01630616|DRUG|Odanacatib|single oral dose, tablets, 10 or 50 mg
219548827|NCT01630616|DRUG|Placebo|single oral dose, tablets
219048072|NCT06909331|DIETARY_SUPPLEMENT|Placebo drink solution|Participants consumed a placebo drink that was flavor, color and calorie matched to the experimental drink.
219048073|NCT07086469|DRUG|Neoadjuvant immunochemotherapy|Albumin-bound paclitaxel 260 mg/m² on day 1, cisplatin 25 mg/m² on days 1-3, and toripalimab 240 mg on day 1 of each 3-week cycle (q3w), for a total of 2 cycles.
219625632|NCT03945227|DRUG|standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001|drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
219625633|NCT03945227|DRUG|PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001|drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
219625634|NCT01205776|DEVICE|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
219625635|NCT01205776|PROCEDURE|CABG|Those patients receiving CABG
219625636|NCT00000162|PROCEDURE|Macular Argon Laser Photocoagulation|
219625637|NCT00000162|PROCEDURE|Peripheral Scatter Argon Laser Photocoagulation|
219625638|NCT00000162|PROCEDURE|Scatter Argon Laser Photocoagulation|
219625639|NCT03268980|OTHER|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
219625640|NCT03268980|OTHER|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
219625641|NCT04191174|OTHER|Hyperpolarized 129Xe MRI|Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity
219625642|NCT04191174|OTHER|Technegas V SPECT|Technegas V SPECT to evaluate ventilation heterogeneity
219625643|NCT04191174|OTHER|Sputum Induction|Sputum induction to evaluate luminal cellular inflammation
219625644|NCT05159531|DRUG|PrEP|Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
219625645|NCT05159531|OTHER|mHealth Model of Care|Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.
219625646|NCT05159531|OTHER|Standard of Care|Delivery of PrEP care through the local standard of care
219625647|NCT04853082|DRUG|Limonene capsule|All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
219625648|NCT04853082|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
219625649|NCT00964574|DRUG|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
219625650|NCT00964574|DRUG|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
219625651|NCT00734994|DEVICE|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
219625652|NCT00734994|DRUG|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
219625653|NCT02596360|DRUG|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
219625654|NCT02596360|DRUG|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
219625655|NCT02081027|DRUG|Riluzole|
219625656|NCT02081027|OTHER|placebo|
219625657|NCT01358929|DRUG|Placebo|Placebo to RO6807952
219625658|NCT01358929|DRUG|RO6807952|Escalating subcutaneous dose
219625659|NCT02021929|DRUG|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~* Unresectable hepatocellular carcinoma~* Advanced renal cell carcinoma~* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
219625660|NCT02021929|DRUG|Placebo|
219048074|NCT07086469|DRUG|Surufatinib Administration|Surufatinib 200 mg orally once daily (po, qd) on days 1-14, administered concurrently with immunochemotherapy. During radiotherapy, surufatinib will be administered at the start of each radiotherapy phase.
219625661|NCT05925647|DRUG|Messenchymal stem cell secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
219625662|NCT05925647|DRUG|Placebo|NaCl 0,9% infusion
219625663|NCT06780007|DIETARY_SUPPLEMENT|Probiotic|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
219625664|NCT06780007|DIETARY_SUPPLEMENT|Placebo|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
219625665|NCT01199627|DRUG|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
219625666|NCT01199627|DRUG|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
219625667|NCT01199627|DRUG|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
219625668|NCT06854783|DRUG|Cannabidiol|Cannabidiol
219625669|NCT06897358|DRUG|Leniolisib|Planned dose will range from 10 mg twice daily to 70 mg twice daily
219625670|NCT07071649|OTHER|blood withdrawal|blood withdrawal
219625671|NCT07068204|DEVICE|2% Calcium Hypophosphite Toothpaste|Oral hygiene instruction and regular application of the 2% Calcium Hypophosphite Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
219625672|NCT07068204|DEVICE|Sodium Fluoride Toothpaste (1450 ppm F)|Oral hygiene instruction and regular application of the Sodium Fluoride Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
219625673|NCT03989128|OTHER|Medical Chart Review|Undergo medical chart review
219625674|NCT03989128|OTHER|Survey Administration|Complete survey
219625675|NCT02985580|DIETARY_SUPPLEMENT|Blueberry|
219625676|NCT02985580|DIETARY_SUPPLEMENT|Placebo|
219625677|NCT06897748|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study
219625678|NCT06897748|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study
219625679|NCT06900413|PROCEDURE|Group ESP|"Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes.~A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic."
219625680|NCT06900413|PROCEDURE|Group EXORA|Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound.
219625681|NCT03153163|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
219625682|NCT07071974|DRUG|BI 456906 formulation A|BI 456906 formulation A
219625683|NCT07071974|DRUG|BI 456906 formulation B2|BI 456906 formulation B2
219625684|NCT06848530|OTHER|Prescribed Medications|participant's movement disorders medications, prescribed by their treating physician
219625685|NCT06848530|OTHER|Deep brain stimulation adjustment|Deep brain stimulator parameters may be adjusted within normal clinical limits
219625686|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
219625687|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
219625688|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
219625689|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
219625690|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
219625691|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
218937132|NCT00393861|DRUG|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
219625692|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
219625693|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
219625694|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
219625695|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
219048075|NCT07086469|DRUG|Concurrent Chemotherapy|Toripalimab 240 mg on day 1 of each 3-week cycle (q3w), starting one day prior to the initiation of radiotherapy. Weekly administration of albumin-bound paclitaxel 50 mg/m² and cisplatin 25 mg/m² on day 1 during the radiotherapy course.
219625696|NCT07129785|BEHAVIORAL|Dynamic Surface Exercise Training (DSET)|DSET involves performing multi-planar trunk activation, postural control, and balance exercises on unstable surfaces such as Swiss/gym balls, bolsters, trampolines, and platform swings. Each session lasts 60 minutes, four times per week, for six weeks. Activities include optimal arousal (bouncing), high sitting with one- and two-hand reaching, sit-to-stand transitions, and lateral weight-shifting. The unstable surface provides postural perturbations that stimulate vestibular, proprioceptive, and visual systems to improve gross motor function and balance in children with spastic diplegic cerebral palsy.
219625697|NCT07129785|BEHAVIORAL|Static Surface Exercise Training (SSET)|SSET consists of functional strength, posture, and balance exercises performed on stable surfaces such as mats, benches, or stools. Each session lasts 60 minutes, four times per week, for six weeks. Activities include transfers between sitting and quadruped, high sitting with functional reaching, static and dynamic standing balance, ball-catching and kicking, and trunk activation tasks. Exercises aim to enhance gross motor function and balance through controlled, stable postural activities in children with spastic diplegic cerebral palsy.
219048076|NCT07086469|RADIATION|Radiotherapy|All patients will undergo thoracic intensity-modulated radiotherapy (IMRT), delivered once daily, 5 days per week, at a total prescribed dose of 50 Gy.
219048077|NCT05054686|OTHER|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
219048078|NCT05054686|OTHER|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
219625698|NCT04093310|DEVICE|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
219625699|NCT04093310|PROCEDURE|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
219625700|NCT06568016|OTHER|Best Practice|Receive clinical care consistent with current practice
219625701|NCT06568016|OTHER|Communication Intervention|Receive standardized communication from FIT QI champion
219625702|NCT06568016|OTHER|Communication Intervention|Receive coordination from GI liaisons
219625703|NCT06568016|OTHER|Coordination|Receive enhanced GI care coordination
219625704|NCT06568016|OTHER|Educational Intervention|Watch pre-colonoscopy educational video
219625705|NCT06568016|OTHER|Electronic Health Record Review|Undergo FIT result review by Primary Care FIT Tracker
219625706|NCT06568016|OTHER|Electronic Health Record Review|Ancillary studies
219625707|NCT06568016|OTHER|Informational Intervention|Undergo generation and review of GI FIT Tracker report
219625708|NCT06568016|OTHER|Informational Intervention|Receive informational sheet
219625709|NCT06568016|OTHER|Interview|Ancillary studies
219625710|NCT06568016|BEHAVIORAL|Patient Navigation|Receive navigation from GI liaisons
219625711|NCT06568016|OTHER|Referral|Receive referral
219625712|NCT06568016|OTHER|Referral|Receive referral per standardized template
219625713|NCT06568016|OTHER|Text Message-Based Navigation Intervention|Receive follow-up text message
219625714|NCT06899282|BEHAVIORAL|Jigsaw method|"Jigsaw/puzzle method is one of the collaborative learning techniques. The Jigsaw technique requires each student to focus on a particular aspect of the topic, become an expert on that topic and teach it to their peers. Once the students have learned the topic in their expert group, they return to the original group and teach what they have learned back to them as if solving a jigsaw puzzle (Geiselman et al., 2024). For the application of the technique, the Jigsaw Technique Application Directive was prepared as a training material to be delivered to the students."
219625715|NCT06899282|BEHAVIORAL|The theoretical training|The theoretical training will be conducted in 2 sessions. The first session will cover the definition, prevalence and importance of pressure ulcers, etiology and classification, risk assessment and pressure ulcers in special patient groups. The second session will cover prevention and treatment of pressure ulcers.
219625716|NCT06676943|PROCEDURE|XEOS AURA 10 specimen PET-CT scan of tumour specimens|Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
218937133|NCT04571567|DRUG|Secukinumab|Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
218937134|NCT02796261|DRUG|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
218937135|NCT02796261|DRUG|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
218937136|NCT02796261|DRUG|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
218937137|NCT04968769|OTHER|ischemic compression|manual therapy
218937138|NCT04968769|OTHER|kinesio taping|elastic therapeutic taping
218937139|NCT04968769|OTHER|exercise|posture exercises
218937140|NCT00617968|DRUG|DOCETAXEL|
218937141|NCT04202172|PROCEDURE|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography"
218937142|NCT00459186|DRUG|RAD001|Daily for two weeks
218937143|NCT00459186|DRUG|Docetaxel|Infusion once per cycle
218937144|NCT00459186|DRUG|Prednisone|Prednisone 5 mg by mouth twice daily
218937145|NCT06061757|DEVICE|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
219625717|NCT05609630|DRUG|Upadacitinib|Oral tablet or Oral solution
219625718|NCT05609630|DRUG|Tocilizumab|Subcutaneous injection or Intravenous infusion
219625719|NCT03817190|DRUG|DS107|DS107 Capsule
219625720|NCT03817190|DRUG|Placebo|Placebo capsule
219625721|NCT01622673|DRUG|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
219625722|NCT01622673|DRUG|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
219625723|NCT01622673|DRUG|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
219625724|NCT01358461|BIOLOGICAL|Blood sampling|Blood sampling
219625725|NCT01358461|OTHER|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
219625726|NCT04146012|DEVICE|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
219625727|NCT03757312|DIAGNOSTIC_TEST|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
219625728|NCT04351958|BEHAVIORAL|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
219625729|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
219625730|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
219048079|NCT05054686|OTHER|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
219048080|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
219625731|NCT07137728|DEVICE|Dual Frequency Low-Level Laser Therapy|DF-LLLT (830 nm, 100 mW/cm², 9.12 Hz, 5 J/cm²) applied over each identified trigger point for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
219625732|NCT07137728|DEVICE|Sham Laser|Inactive laser device identical in appearance and sound to the active laser but without light emission, applied for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
219625733|NCT07137728|OTHER|Conventional Therapy (Stretching and Strengthening Program)|A standardized physiotherapy program including stretching and strengthening exercises for the cervical and shoulder muscles. The program is performed under physiotherapist supervision twice weekly for 4 weeks. Exercises are identical across both study arms and include stretching of the upper trapezius and strengthening of the neck and scapular stabilizer muscles.
219048081|NCT04708470|DRUG|Bintrafusp Alfa|"Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
219048082|NCT04708470|DRUG|PDS01ADC|PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
219625734|NCT06906042|RADIATION|Imaging examinations|"* Cardiovascular MRI~* Hepatic MRI~* Hepatic ultrasound"
219625735|NCT06906042|OTHER|Paramedical examinations|"* Urinary pregnancy test for women of childbearing age.~* Blood sample for cardiometabolism profiling~* Blood samples for biobanking (according to the information and consent form)~* Impedancemetry~* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device."
219625736|NCT06906042|OTHER|Medical examination|"* Review of risk factors~* Review of previous history~* Recording of current medication (dci, dose, start date)~* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)"
219625737|NCT06906042|OTHER|Echocardiography|Echocardiography including: 12-lead digital ECG
219625738|NCT05649943|DRUG|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
219625739|NCT05649943|PROCEDURE|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
219625740|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
219048083|NCT04708470|DRUG|Entinostat|The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
219048084|NCT06361095|BEHAVIORAL|Traditional Attention Bias Modification|Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
219048085|NCT06361095|BEHAVIORAL|Gamified Attention Bias Modification|Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
219048086|NCT06361095|BEHAVIORAL|Sham Attention Bias Modification|Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
219048087|NCT04638894|PROCEDURE|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
219048088|NCT07107061|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
219048089|NCT07107061|OTHER|Pilates exercises|Pilates exercises are characterized as muscle strengthening and stretching.
219048090|NCT07107061|OTHER|Aerobic exercise|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
219048091|NCT06860230|DEVICE|Philips FAST SpO2 with Nellcor Pulse Oximetry Sensors|Noninvasive pulse oximeter
219048092|NCT05684510|DEVICE|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
219206529|NCT04868656|OTHER|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
219625741|NCT06909071|DEVICE|Hybrid Closed-Loop Artificial Pancreas System|The total daily insulin requirement is calculated as 0.3 - 0.6 U/(kg·d) according to patient's weight. The system automatically adjusts the basal rate during operation. Nurses enter bolus dose orders in AAPS software as directed by physicians. Blood glucose is monitored via continuous glucose monitoring and 4 daily fingerstick measurements (fasting and 2 hours after each meal).
219625742|NCT07102641|DRUG|Acetaminophen|Acetaminophen 1000 mg q6H
219625743|NCT07102641|DRUG|NSAID (Ketorolac/Ibuprofen)|NSAID (ketorolac 30 mg q6H for first 24 hours post-op followed by ibuprofen 600 mg q6H)
219625744|NCT06911749|DIAGNOSTIC_TEST|MSOT with ICG|Application of Multispectral Optoacoustic Tomography (MSOT) in combination with the oral contrast agent Indocyanine Green (ICG) to measure gastrointestinal transit time
219625745|NCT06911749|DIAGNOSTIC_TEST|MRI|Non-invasive MRI imaging technique will be employed to assess the peristalsis of intestinal segments
219625746|NCT06439836|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219625747|NCT06439836|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219625748|NCT06439836|PROCEDURE|Computed Tomography|Undergo CT
219625749|NCT06439836|BIOLOGICAL|Emavusertib|Given PO
219625750|NCT06439836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219625751|NCT06439836|BIOLOGICAL|Pembrolizumab|Given IV
219625752|NCT06439836|PROCEDURE|Positron Emission Tomography|Undergo PET
219625753|NCT07111117|PROCEDURE|18F-MFBG PET/CT imaging|Participants will receive the 18F-MFBG tracer and undergo a PET/CT imaging.
219625754|NCT00109174|DEVICE|3T and 7T device|3T and 7T device
219625755|NCT06922630|BEHAVIORAL|WIN|Weight-neutral health intervention
219625756|NCT07113509|PROCEDURE|mechanical polishing|mechanical polishing of implant resin crowns with polishing paste and discs
219625757|NCT07113509|PROCEDURE|glazing|glaze liquid application followed by light-curing of the resin implant crowns
219625758|NCT07114900|BEHAVIORAL|PA4Health app physical activity intervention|PA4Health app intervention Arm Description: During the app intervention consists of six components: 1) Goal setting and monitoring, 2) Tailored motivational messages based on survey data on barriers and facilitators of physical activity, 3) Education, which consists of twenty-two physical activity (PA) related topics, 4) a semi-structured chatroom where 3-5 participants per chatroom interact with one another to receive and provide peer support for PA, 5) Locator, which provides information about community resources (e.g., community parks, museums) based on participant's zip code, and 6) Steps, which allow participant to monitor their daily level of exercise. Participants wear a Fitbit tracker during the program
219625759|NCT07114900|BEHAVIORAL|Wellness Text Messaging Program|Participants set goal for PA and are encouraged to monitor their level of physical throughout the program. They receive a daily wellness related message during the program as a contact control. They also wear Fitbit tracker during the program.
219048093|NCT05684510|DEVICE|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
219048094|NCT05527184|DRUG|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
219048095|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
219048096|NCT07106814|DRUG|Metabolically Armed TIL cells|Each subject receive metabolically armed TIL cells by intravenous infusion.
219048097|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219625760|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
219625761|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
219625762|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
219625763|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
219625764|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
219625765|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
219625766|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
219625767|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
219625768|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
219625769|NCT07120152|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Subcutaneous infliximab
219625770|NCT06932302|DEVICE|Electrical Stimulation|Electrical stimulation of the dorsal genital nerve will be accomplished using the UCon system and patch electrodes developed by InnoCon. The UCon system includes a programmable control unit; leads that connect to the control unit and electrodes; a silicone surface electrode; a reference electrode; and a remote control for quick on and off toggling of stimulation.
219625771|NCT06932302|DEVICE|Smart vibrator|Subjects will use a smart vibrator at home twice a week during the study. The Lioness smart vibrator records physiological responses during use.
219625772|NCT06936527|BIOLOGICAL|Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
219625773|NCT06936527|BIOLOGICAL|Drug: XS-03|XS-03 orally
219625774|NCT06936527|BIOLOGICAL|Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
219625775|NCT06946290|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume of study medication.
219625776|NCT06946290|PROCEDURE|Sham block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
219625777|NCT06955104|DRUG|JW0108 + C2407|JW0108 + C2407
219625778|NCT06955104|DRUG|JW0108 + C2407 placebo|JW0108 + C2407 placebo
219625779|NCT07141862|DIAGNOSTIC_TEST|RT-qPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR
219625780|NCT07141862|DIAGNOSTIC_TEST|ddPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR
219048098|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 1|Participants will use their Radicle Revive Active Study Product 1 as directed for a period of 6 weeks.
219048099|NCT06923826|DRUG|Sacituzumab govitecan|Day 1 and Day 8: Sacituzumab Govitecan will be administered at the dose of 10 mg/kg via intravenous infusion.
219625781|NCT07151482|DIETARY_SUPPLEMENT|Collagendep|The purpose of this study is to evaluate the improvement of quality of life, vulvovaginal atrophy (VVA) and of initial Urinary Incontinence (UI) in menopausal women with GSM symptoms following oral administration of a food supplement treatment containing 2.5 g of BCP® and other functional ingredients taken once daily over a period of 16 weeks.
219625782|NCT07151313|DEVICE|Bee Venom Phonophoresis|Ultrasound therapy device
219625783|NCT07151313|DRUG|Standard Care (oral decongestants + saline nasal irrigation)|(oral decongestants + saline nasal irrigation)
219625784|NCT07151313|BIOLOGICAL|Bee Venom Phonophoresis|bee venom extract prepared for topical use)
219048100|NCT07119307|PROCEDURE|Entire Papilla Preservation Technique|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD) plus bone mineral derived xenograph (BMDX)
219048101|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone|Entire Papilla Preservation Surgical Technique (EPPT) alone
219625785|NCT07151768|DIAGNOSTIC_TEST|Observational Study|"* assignment of PVD-B65 score derived from standard of care testing~* no therapeutic intervention or other treatment"
219625786|NCT07152977|OTHER|Radiological evolution of ano-perineal lesions by MRI|Patients selected retrospectively will have benefited from an MRI at diagnosis and a control MRI during follow-up. They will be selected during a follow-up consultation or a biotherapy injection in a day hospital. Patients selected consecutively are monitored at the Rouen University Hospital for perineal Cohn's disease, treated with Biotherapy: Infliximab, Adalimumab, Ustekinumab, Vedolizumab.
219625787|NCT07152665|BEHAVIORAL|Video-Based Education|Parents of children in the intervention group were informed that the educational videos used in the study aimed to reduce the child's pain, fear, and anxiety.
219625788|NCT07151430|DEVICE|Service Package Group|patients receive comprehensive multimorbidity management service package (digital tools, MDT decision support, lifestyle interventions, long-term management tools).
219625789|NCT07151898|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two and/or four cycles of Trop2-ADC therapy.
219625790|NCT07151677|DEVICE|tDCS (active)|The investigators will administer active tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For active tDCS, the current will slowly be increased to 2mA and applied for 20 minutes.
219625791|NCT07151677|BEHAVIORAL|Attention-focused sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. Participants will receive 10 sessions of this treatment.
219625792|NCT07151677|BEHAVIORAL|Sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on improving auditory comprehension . Participants will receive 10 sessions of this treatment.
219625793|NCT07151677|DEVICE|tDCS (sham)|The investigators will administer sham tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For sham tDCS, the current will slowly be increased to 2mA over the course of 30 seconds and then immediately ramped back down to zero.
219625794|NCT07152990|OTHER|Transcutaneous Oxy-Capnography|Patients will be monitored using transcutaneous oxy-capnography to evaluate the prevalence of nocturnal alveolar hypoventilation in these population. Nocturnal alveolar hypoventilation is defined with PTcCO2 \> 49 mmHg more than 10% of the time of capnographic recording.
219625795|NCT07152990|OTHER|Quality of life questionnaires|"Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and the Patient-Reported Hypoventilation Questionnaire."
219625796|NCT07152990|OTHER|Arterial gasometry|Arterial blood gas analysis will be performed only in patients presenting nocturnal hypoventilation.
219625797|NCT07152990|OTHER|Body plethysmography|Plethysmography will be performed only in patients presenting nocturnal hypoventilation. It will be used to measure lung volume and assess pulmonary function. This non-invasive procedure involves the patient breathing into a device that measures changes in pressure within a sealed chamber.
219625798|NCT07152990|OTHER|Spirometry with reversibility test|The intervention will be performed only in patients presenting nocturnal hypoventilation. Spirometry with a reversibility test will be performed to assess lung function and evaluate the response to bronchodilators. The procedure involves measuring forced expiratory volume and forced vital capacity before and after the administration of a bronchodilator.
219625799|NCT07152990|OTHER|Clinical examination|Clinical exam will be performed only in patients presenting nocturnal hypoventilation. It will consists of standard interview/clinical examination: vital signs, cardiological, pulmonary, abdominal, neurological examination, search for clinical signs of nocturnal hypoventilation, search for signs of hypoxia/hypercapnia, pulmonary auscultation.
219625800|NCT07152483|DIETARY_SUPPLEMENT|High resistant starch staple foods|Participants in the intervention group will intake high resistant starch staple foods (achieving daily intake of ≥28g resistant starch)
219625801|NCT07152483|DIETARY_SUPPLEMENT|Regular starch staple foods|Participants in the control group will intake isocaloric regular starch staple foods
219625802|NCT07152314|DIAGNOSTIC_TEST|Digital plaque quantification using intraoral scanner|Participants will undergo three-dimensional intraoral scanning at three time points during a single session: initial scanning (T0), after biofilm disclosure with plaque disclosing solution (T1), and after supervised toothbrushing (T2).
219625803|NCT07152275|DEVICE|Percussive Therapy|"Percussive therapy will be administered using the Hypervolt Go 2 Black, a massage gun commonly used in clinical and athletic settings.~Participants will lie in a prone position on a treatment table. To promote hamstring muscle relaxation, a support roll will be placed under the ankle. The intervention will be delivered by the same researcher for all participants to ensure consistency. Using the round head attachment, percussive therapy will be applied longitudinally along the hamstring muscle group (from proximal to distal) for a total of 120 seconds per leg. Specifically, 60 seconds will be applied to the semitendinosus and semimembranosus, and 60 seconds to the biceps femoris. The same procedure will then be repeated on the opposite leg."
219625804|NCT07152145|DEVICE|Active stimulation tSCS|Active transcutaneous spinal cord stimulation (tSCS) delivered with the SCONE™ device. Electrical currents are applied non-invasively through surface electrodes placed on the skin over the spine. Sessions are combined with standardized upper limb rehabilitation therapy. Participants receive stimulation twice per week for 12 weeks.
219625805|NCT07152145|DEVICE|Sham: stimulations using a non-active electric stimulation|Sham stimulation delivered with the SCONE™ device, using identical setup and procedures as the active intervention but without effective current. This procedure is designed to mimic the sensation and experience of active stimulation while delivering no therapeutic neuromodulation. Participants also perform standardized upper limb rehabilitation therapy twice per week for 12 weeks.Transcutaneous Spinal Cord Stimulation (tSCS) - Sham (SCONE™)
219625806|NCT07152145|BEHAVIORAL|Occupational/Upper Limb Rehabilitation Therapy|Standardized occupational therapy program focused on upper limb function. Sessions are delivered in combination with either active or sham transcutaneous spinal cord stimulation.
219625807|NCT07152574|DEVICE|TAVR using a tele-operated Robot|TAVR procedure with TAVIPILOT tele-operated robot by Caranx Medical enhancing the precision of transcatheter aortic valve positioning during TAVR.
219625808|NCT07152769|DRUG|Iparomlimab and Tuvonralimab + GC|Iparomlimab and Tuvonralimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w
219048102|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)
219048103|NCT07118124|DEVICE|Zio monitor|Evaluate analyzable time of the Zio monitor over the wear duration of up to 14 days in a pediatric population.
219625809|NCT07152769|DRUG|Sintilimab + GC|Sintilimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w.
219625810|NCT07151326|DRUG|Cabozantinib|All patients will be treated with cabozantinib at 60 mg once daily.
219625811|NCT07152236|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
219048104|NCT03195478|DRUG|Nivolumab|Specified dose on specified days
219625812|NCT07152522|OTHER|cross sectional observational|the therapist measured ROM in six directions: flexion, extension, right and left side bending, and right and left rotation to investigate the association between NDI and ROM of cervical spine
219625813|NCT07152925|DEVICE|Beta-frequency transcranial alternating current stimulation|Active beta-frequency transcranial alternating current stimulation: 20 Hz tACS delivered through a 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak, 100 % intensity, gradually ramped up over 30 s, maintained for 20 min, then ramped down over 30 s; two sessions per day with at least 4 h between sessions, repeated for 7 consecutive days (14 total sessions).
219625814|NCT07152925|DEVICE|sham beta-frequency transcranial alternating current stimulation|Sham transcranial alternating current stimulation: identical 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak current ramped up over 30 s and immediately ramped down to 0 mA, followed by 19.5 min of no stimulation to match the 20-min session duration of active tACS; delivered twice daily (≥4 h apart) for 7 consecutive days (14 total sessions).
219625815|NCT07152509|OTHER|Observational Assessment|The demographic, clinical, and personal characteristics of the individuals will be collected and recorded through a questionnaire. For all participants, body fat percentage (%), skeletal muscle mass percentage (%), visceral fat percentage (%), and resting metabolic rate (kcal), measured using the Omron Body Composition Monitor, will be recorded. Waist and hip circumference will be measured with a tape measure; lower extremity muscle strength (M. Quadriceps) will be assessed with a muscle hand-held dynamometer; grip strength will be assessed with a hand grip dynamometer; physical activity level will be evaluated using the International Physical Activity Questionnaire-Short Form (IPAQ-SF); functional capacity will be measured with the 6-Minute Walk Test (6MWT); postural stability and balance will be assessed with the Biodex Balance System; clinical balance will be assessed with the Berg Balance Scale; quality of life will be evaluated using the Nottingham Health Profile (NHP)
219625816|NCT07152873|DRUG|AD-117|AD-117 1Tab., Per Oral
219625817|NCT07152873|DRUG|AD-117A|AD-117A 1Tab., Per Oral
219625818|NCT07152457|OTHER|No intervention|None intervention
219625819|NCT07151690|DRUG|anti-BCMA/CD3 bispecific antibody|CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3. In this study, CM336 is administered subcutaneously with a step-up dosing strategy in Cycle 1 (3 mg Day 1, 20 mg Day 4, 40 mg Day 8 and onwards weekly). Patients who achieve ≥VGPR by Cycle 4 may switch to 80 mg every two weeks from Cycle 5. The total treatment duration is up to 12 cycles (28 days per cycle), with follow-up for safety and efficacy endpoints including hematologic and organ response.
219625820|NCT07152171|BEHAVIORAL|Pain Neuroscience Education During Aerobic Exercise|Participants will cycle on an ergometer for 20-30 minutes at light intensity (Borg CR10 = 3; 40-50% HRmax). During cycling, they will receive interactive pain neuroscience education delivered by a therapist, including neurobiology of pain, central sensitization, and self-management strategies. Visual aids and metaphors will be used to facilitate understanding.
219048105|NCT03195478|DRUG|Ipilimumab|Specified dose on specified days
219048106|NCT06915766|DRUG|Bezuclastinib|Drug: Bezuclastinib Tablets
219048107|NCT07134881|BEHAVIORAL|Careverse|Careverse is a digital psychoeducational website designed to assist caregivers and patients to clarify their values, end-of-life preferences, enable surrogates to further their understanding of the patient's wishes, and prepare surrogates for the role and responsibilities of a medical decision maker. The intervention consists of values elicitation tools, educational materials, and testimonies. The participants will receive guides on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and clinicians.
219048108|NCT07134881|OTHER|Usual Care|Caregivers in the comparator arm will receive a digital version of standard advanced care planning education material prepared by Agency of Integrated Care. The ACP Workbook is created by AIC to help individuals explore their values, care preferences, and end-of-life goals in a structured, reflective way.
219048109|NCT07134725|BIOLOGICAL|SpiN-Tec MCTI UFMG|Chimeric recombinant protein (SpiN) adjuvanted with CTVad1
219048110|NCT07134725|OTHER|Active Comparator: Covishield® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
219625821|NCT07152171|BEHAVIORAL|Aerobic Exercise Alone|Participants will perform 20-30 minutes of supervised cycling on an ergometer at light intensity (Borg CR10 = 3; 40-50% HRmax). No educational content will be provided. Sessions will include warm-up, main phase, and cool-down, matched in duration and intensity to the experimental group.
219625822|NCT07151495|DIAGNOSTIC_TEST|Speckle tracking and 2D echocardiography|The study will involve only the collection of data obtained from routine clinical procedures and a telephone follow-up. Preoperative echocardiographic data and pre-operative left atrial speckle tracking data will be retrieved
219625823|NCT07152444|DRUG|QLS1410 (CYP11B2 inhibitor)|QLS1410 tablets
219625824|NCT07152444|DRUG|placebo|Matching placebo tablets
219625825|NCT07152405|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219625826|NCT07152405|DRUG|Investigator's choice of chemotherapy|Administration by intravenous infusion for a cycle of 2 or 3 or 4 weeks.
219625827|NCT07152899|OTHER|Unilateral anodal tDCS|Evaluates the effects of unilateral, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia
219625828|NCT07152899|OTHER|Bihemispheric anodal tDCS|Evaluates the effects of bihemispheric, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
219625829|NCT07152899|OTHER|Sham tDCS|Evaluates the effects of Sham tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
219625830|NCT07152899|OTHER|NMES + swallowing therapy|Examines the effects of NMES therapy on swallowing function in both post-stroke and Parkinson's disease patients
219625831|NCT07152899|OTHER|Sham NMES + swallowing therapy|Examines the effects of Sham therapy on swallowing function in both post-stroke and Parkinson's disease patients
219625832|NCT07151560|DRUG|6 cycle RC48 and JS001|Different medication cycles
219625833|NCT07151560|DRUG|12 cycle RC48 and JS001|Different medication cycles
219625834|NCT07152587|DRUG|Low dose steroids|Receive 0.5mg/kg Methylprednisolone
219625835|NCT07152587|DRUG|Moderate dose steroids|Receive 1.0mg/kg Methylprednisolone
219625836|NCT07152587|DRUG|Saline (0.9% NaCl)|Saline 100ml
219625837|NCT07151664|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life
219625838|NCT07152366|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
219625839|NCT07152366|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
219625840|NCT07151404|PROCEDURE|Acupuncture at LU7 (Lieque) + Electroacupuncture|Participants will receive filiform needle acupuncture at Lieque (LU7) combined with electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11). Sterile disposable filiform needles (0.3 × 25 mm) will be inserted at LU7 using standard manual acupuncture technique. Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
219625841|NCT07151404|PROCEDURE|Electroacupuncture Only|Participants will receive electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11), without acupuncture at Lieque (LU7). Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
219625842|NCT07152210|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
219625843|NCT07153133|BIOLOGICAL|albumin platelet rich fibrin|sixteen teeth extraction socket filled by albumin platelet rich fibrin
219625844|NCT07151976|DEVICE|PCI|PCI with athero-thrombotic aspiration and subsequent pathological analysis: Pathologic Characteristics of Athero-Thrombotic AsPirated Material of OCT-Verified Culprit Lesion in Acute Coronary Syndrome
219625845|NCT07152756|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention and the endoscopic mucosal visibility score during esophagogastroduodenoscopy
219625846|NCT07182747|BEHAVIORAL|Nursing students' intervention programme|12-week intervention programme conducted by nursing students and students trained in Sciences of Physical Activity and Sport (CAFYD). Participants will receive weekly three sessions of 45-60 minutes. It will include physical exercise and occupational therapy sessions aimed at improving frailty and other related outcomes in the participating older adults through interdisciplinary collaboration and ongoing monitoring. Nursing students will implement personalised intervention programmes designed by a multidisciplinary team comprising CAFYD students, an occupational therapist, and nurses experienced in the care of older adults.
219048111|NCT07134725|OTHER|Active Comparator: Comirnaty® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
219625847|NCT07182747|BEHAVIORAL|Standard care from Public Andalusian Health Service|They will receive the standard care provided by the Andalusian Health Service as part of its portfolio of services offered to older adults residing in institutions, as well as the standard care provided by the institutions in which they live. As part of these services, older adults receive support such as accommodation, laundry, health promotion activities, health monitoring, assistance with activities of daily living, individual, group, and community social care, as well as means of communication with the outside world. The action plans or protocols established in care processes for older adults living in nursing homes do not include externally delivered multidisciplinary intervention programmes.
219625848|NCT07184424|DRUG|lenalidomide|For patients with hepatocellular carcinoma who have experienced disease progression after receiving standard clinical treatment with lenvatinib in combination with PD-1 inhibitors, the addition of lenalidomide capsules to the three-drug combination therapy was followed by a 2-month follow-up liver imaging examination to observe changes in the target lesion and whether new lesions had developed in other areas.
219625849|NCT07182240|DEVICE|LC-OCT Imaging|handheld imaging device will take high resolution images of lesion
219048112|NCT07140380|DRUG|IVW-1001 Ophthalmic Eyelid Wipe|Dry eye treatment
219625850|NCT07184489|OTHER|implementation strategies|"1. Analysis of barrier factors: A focus group interview will be conducted. Purposive sampling was used to include senior nurses in the ward, members of the evidence-based group, and doctors for the analysis of barrier factors. Then the CFIR-ERIC matching tool will be used to develop implementation strategies based on the barrier factors.~2. The best - worst scaling method will be used to generate relatively reliable and valid preference evidence of stakeholders for implementation strategies from CFIR-ERIC matching tool.~3. The implementation strategies will be developed specifically by an expert group. This group includes nursing managers and experts in evidence-based practice.~4. Implement the strategies."
219625851|NCT07183345|OTHER|Dynamic Pain Assessment and Management System|Personalized nursing education was adopted. These measures include the use of preoperative analgesic drugs, postoperative Traditional Chinese Medicine (TCM) fumigation, and wrist-ankle acupuncture for pain relief.
219625852|NCT07183345|DRUG|Routine drug analgesia|adopted routine drug analgesia and conventional nursing education
219625853|NCT07182500|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
219625854|NCT07182500|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
219625855|NCT07184099|DRUG|Phloroglucinol|Phloroglucinol was administered as intravenous stat infusion with Ringer Lactate infusion.
219625856|NCT07183930|PROCEDURE|Tubeless Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a double-J stent is placed; no nephrostomy tube is inserted.
219625857|NCT07183930|PROCEDURE|Standard Tube Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a 14 Fr nephrostomy tube and a double-J stent are placed.
219625858|NCT07182942|DRUG|Xiqing|oral intervention of Xiqing
219625859|NCT07182942|DRUG|probiotics|oral intervention of probiotics
219625860|NCT07183631|OTHER|Platelet rich fibrin|Platelet-rich fibrin (PRF) was prepared according to the manufacturer's instructions. A blood sample was collected from the cubital vein in 10 ml tubes without anticoagulant and centrifuged at 3000 rpm for 10 minutes using a GLO GT416 table centrifuge (GLO Glotech Co. Ltd, Korea) and GLO PRP collection kit (GLO PRP-Kit, Glotech Co, Asan Choong-nam, Korea/ Glofinn, Finland).
219625861|NCT07183631|OTHER|Enamel matrix derivate|"In the control group, the root surface was conditioned with 24% ethylenediaminetetraacetic acid (EDTA) gel for two minutes, washed with physiological saline solution, dried, and treated with enamel matrix derivative (EMD), (Emdogain, Straumann, Switzerland) per manufacturer recommendations."
219625862|NCT07182734|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot and RehabCoach|"During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a therapist or researcher. Minimally-supervised therapy means that participants try to perform therapy independently with the device, while the supervisor is present to provide assistance only if problems occur or if participants have questions.~A few days after the study begins, participants are introduced to the RehabCoach application, which provides conversational support, reminders, and educational content throughout the intervention.~During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. In each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes."
219625863|NCT07182734|DEVICE|Unsupervised Therapy with ReHandyBot and RehabCoach|"After the familiarization phase, participants continue training without direct supervision at the clinic until discharge and then at home for six weeks. If the therapist considers the participant capable of training safely and effectively with the device, the participant will keep training with the ReHandyBot unsupervised, both at the clinic and at home, while supported by the RehabCoach application. RehabCoach provides reminders, motivational support, and educational material to guide the home-based therapy.~If participants are not considered ready for unsupervised therapy with the device, they will not proceed to the unsupervised phase."
219625864|NCT07182968|OTHER|Questionnaire study|Questionnaire application
219625865|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
219625866|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
219548828|NCT01156441|PROCEDURE|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
219625867|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
219625868|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
219625869|NCT06141902|OTHER|Jing Si Herbal Drink|Jing Si Herbal Drink
219625870|NCT06776848|OTHER|Observation phase|Start of the observation phase for all patients for a period of 6 months. Group B: continuation of the observation phase for a further 6 months
219625871|NCT06776848|DRUG|Lithium treatment|The daily dose of lithium will be increased until the target lithiaemia is reached, while monitoring tolerance and possible adverse effects.
219625872|NCT06776848|BIOLOGICAL|biological monitoring|"The blood level of lithium will be monitored by regular blood tests~\- every 4 days until a targeted blood level is obtained"
219625873|NCT05372640|DRUG|Abemaciclib|Given PO
219625874|NCT05372640|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219625875|NCT05372640|PROCEDURE|Biopsy Procedure|Undergo biopsy
219625876|NCT05372640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219625877|NCT05372640|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging evaluation
219625878|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
219625879|NCT04219254|DRUG|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
219625880|NCT05681039|DRUG|Tiragolumab|Given by IV (vein)
219625881|NCT05681039|DRUG|Atezolizumab|Given by IV (vein)
219625882|NCT05681039|BEHAVIORAL|Standard of Care|after care from surgery
219625883|NCT05681039|BEHAVIORAL|Questionnaires|Quality of life
219625884|NCT05681039|RADIATION|Cisplatin|Given by IV (vein)
219625885|NCT05681039|RADIATION|Carboplatin|Given by IV (vein)
219625886|NCT06015529|DIAGNOSTIC_TEST|4PEPS strategy|"Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~1. based only on clinical data (very low CP: PEPS \< 0),~2. based on a D-dimer level \< 1000 μg/L (low CP: PEPS ≥ 0 and \< 5),~3. based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and \<12), or~4. the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)"
219625887|NCT01176578|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
219625888|NCT05738174|DEVICE|high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
219625889|NCT05738174|DEVICE|sham high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
219625890|NCT05452642|BEHAVIORAL|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
219625891|NCT05452642|BEHAVIORAL|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
219625892|NCT06437444|BEHAVIORAL|The implementation strategy to encourage the adoption of the Care Pathway|"1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Integration of information and communication tools into electronic health records to facilitate the recording and the standardized implementation of recommended practice.~3. Audit \& Feedback (A\&F) data reports, sent monthly, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~4. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~5. Distribution of reminder posters in paediatrics consultations, PEDs and health centers."
219625893|NCT06528353|DIAGNOSTIC_TEST|HPV16-E6 serology and HPV ctDNA|"In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance."
219625894|NCT04971980|DRUG|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
219048113|NCT06938724|OTHER|Omission of local therapies|"Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion.~This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered."
219625895|NCT05282394|PROCEDURE|Abdominal massage|abdominal massage
219625896|NCT05282394|OTHER|Reading|guidance given to parents about reading with baby
219625897|NCT02710448|DRUG|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
219625898|NCT06077864|DRUG|survodutide|once weekly subcutaneous injection
219625899|NCT06077864|DRUG|Placebo|once weekly subcutaneous injection
219625900|NCT06787690|DEVICE|Cohealyx|Cohealyx application, followed by autologous split-thickness skin graft
219625901|NCT05104736|DRUG|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
219625902|NCT06955221|PROCEDURE|Ultrasound-guided aspiration and alcohol sclerotherapy|Ultrasound-guided puncture and alcohol sclerotherapy
219625903|NCT06226610|DRUG|Dupilumab|injection every two weeks while on study
219625904|NCT06226610|OTHER|Placebo|injection every two weeks while on study
219625905|NCT05510128|OTHER|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~* Completion of the acute cystitis symptoms score (ACSS) questionnaire.~* Measure the temperature.~* Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
219625906|NCT01812031|OTHER|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
219625907|NCT06449144|OTHER|Mindfulness education|The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
219625908|NCT06270485|PROCEDURE|PEEP|Application of different PEEP-Levels during invasive mechanical ventilation
219625909|NCT03576326|BEHAVIORAL|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
219625910|NCT05830266|BEHAVIORAL|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
219625911|NCT05830266|BEHAVIORAL|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
219625912|NCT03357536|PROCEDURE|Human biological samples|"* Blood sample~* Skin biopsy~* Saliva"
219625913|NCT06963710|DRUG|ALG-000184|300 mg tablet
219625914|NCT06963710|DRUG|TDF|300 mg tablet
219625915|NCT05740280|DRUG|iCP-NI|20 mg/mL iCP-NI solution for intravenous injection
219625916|NCT05740280|DRUG|Placebo|Placebo solution for intravenous injection
219625917|NCT06011434|BEHAVIORAL|Mammography Screening Conversation Aid|"Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points."
219625918|NCT05142722|DRUG|Placebo|placebo tablet made to resemble active
219625919|NCT05142722|DRUG|Obicetrapib|10mg obicetrapib tablet
219625920|NCT04222010|DRUG|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
219625921|NCT04222010|DRUG|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
219625922|NCT04222010|DRUG|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
219625923|NCT06215716|DRUG|Efruxifermin|Administered by subcutaneous injection
219625924|NCT06215716|DRUG|Placebo|Administered by subcutaneous injection
219625925|NCT06388733|DRUG|Niraparib|Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
219625926|NCT06388733|DRUG|Temozolomide|Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
219625927|NCT06548542|DRUG|Risankizumab|Subcutaneous Injection
219625928|NCT06548542|DRUG|Lutikizumab|Subcutaneous Injection
219625929|NCT06548542|DRUG|ABBV-382|Intravenous Infusion
219625930|NCT06548542|DRUG|Risankizumab|Intravenous Infusion
219625931|NCT06548542|DRUG|ABBV-382|Subcutaneous Injection
219625934|NCT04252950|BEHAVIORAL|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
219625935|NCT04252950|PROCEDURE|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
219625936|NCT05582122|BIOLOGICAL|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
219625937|NCT06326255|BEHAVIORAL|laughter yoga|each class, including warm-up exercises, laughter yoga exercises, breathing and a relaxation session and sharing
219625938|NCT05506254|DRUG|hLB-001|hLB-001 gene therapy
219625939|NCT06843434|DRUG|Balstilimab|Balstilimab is a fully human monoclonal IgG4 antibody designed to block PD-1 binding to PD-L1 and PD-L2
219625940|NCT06843434|DRUG|Botensilimab|Botensilimab is a novel fully human fragment crystallizable (Fc)-engineered immunoglobulin 1 kappa (IgG1κ) anti-CTLA-4 immunoglobulin G1 (IgG1) antagonist antibody that is designed to optimally promote fragment-crystallizable gamma receptor (FcγR) effector functions that are important for enhancing T cell priming and regulatory T cell (Treg) depletion.
219625941|NCT06205784|OTHER|Prehabilitative exercise|3-4 weeks of heavy resistance exercise
219625942|NCT03461900|OTHER|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
219625943|NCT03461900|OTHER|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
219625944|NCT06846476|OTHER|Insole|"The production process of the insoles will be produced by Computer Aided Design and Computer Aided Manufacturing (CAD-CAM) method by making plantar pressure analysis and physical evaluation of the individual.~The insoles will be designed to reduce the load in areas where the pressure is high with off loading technique. The design of the insoles to be produced individually will be made by the researcher (expert orthotist). The materials to be used in the production of insoles will be determined according to the needs of the participant and materials suitable for diabetic individuals will be preferred. In this context; mostly Ethyl Vinyl Acetate (EVA) and materials with cellular air permeability on the upper surface will be used."
219625945|NCT06846476|OTHER|Demographic Information and Anamnesis Form|Demographic information and anamnesis form; demographic information of the participant, disease history, physical condition of the foot, skin condition, medications used, allergic status, surgical history, presence of edema, discolouration and temperature increase.
218937146|NCT03715049|PROCEDURE|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
218937147|NCT02516852|OTHER|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
218937148|NCT04681976|BEHAVIORAL|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
218937149|NCT03386916|PROCEDURE|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
218937150|NCT01632124|OTHER|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
218937151|NCT02928016|OTHER|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
218937152|NCT02928016|OTHER|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
219625946|NCT06846476|OTHER|Pedobarographic analysis|"Pedobarographic analysis and evaluation of postural balance are widely used by clinicians and researchers to examine the foot structure and to determine the loading patterns of the foot. The data are obtained with electronic sensors placed on the platform where the gait takes place. The sensors are directly connected to the platforms and the computer system programmed to perform foot analysis. With the pedobarography device, pressure distribution data in the foot are obtained in both static and dynamic conditions.~Foot plantar pressure analysis and postural balance will be performed using the EsCoSCAN® static and dynamic pedobarographic assessment device.~During the analysis, the individual will be made to stand without moving while looking straight ahead in the standing position for static analysis. This evaluation will be performed before and 3 months after the use of insoles."
219625947|NCT06846476|OTHER|Postural balance|Postural balance assessment in the study will be performed with 'Becure Balance System (Becure Global GmbH)'. Individuals will be evaluated for balance on the device with eyes open-closed, single foot-double foot. This evaluation will be performed before and 3 months after the use of insoles.
219625948|NCT06846476|OTHER|The Foot Functional Index (FFI)|"The Foot Functional Index (FFI) consists of pain, disability and activity limitation and contains a total of 23 items. Pain and disability titles consist of 9 questions each. The pain item measures the severity of foot pain in different situations. The 9 items in the inability heading assess the severity of the difficulty in performing functional activities due to the person's foot problems.~The activity limitation heading consists of 5 items and measures the activity limitations of the person due to foot problems. AFI is a self-completed scale. Individuals answer the questions with a Visual Analogue Scale (VAS), taking into account their foot condition one week ago. A high score indicates more pain, inability and activity limitation. This evaluation will be performed before and 3 months after the use of insoles."
219625949|NCT06846476|OTHER|Sensory Evaluation|"Diabetic foot ulcer (DFU), which is one of the microvascular complications of diabetes, frequently occurs in association with loss of protective sensation due to peripheral neuropathy, ischaemia due to peripheral arterial insufficiency, poor foot care and infection. Loss of pressure sensation caused by peripheral nerve damage will be evaluated with 'Semmes Weinstein' monoflaments. The 5.07 nylon monoflament used in the test was produced to bend when 10 g force was applied. This pressure is applied to specific points on the plantar and dorsal aspect of the foot.~This evaluation will be performed before and 3 months after the use of insoles."
219206530|NCT05810025|BEHAVIORAL|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
219206531|NCT03603730|DEVICE|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
219206532|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
218937153|NCT02928016|OTHER|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
218937154|NCT02928016|OTHER|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
218937155|NCT02928016|OTHER|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
218937156|NCT02928016|OTHER|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
218937157|NCT04316988|DIAGNOSTIC_TEST|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
218937158|NCT03812276|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
218937159|NCT01043913|DRUG|Guarana extract|Guarana extract 50mg q12 hours for 21 days
218937160|NCT01485172|DRUG|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
218937161|NCT01485172|DRUG|placebo monotherapy|placebo as monotherapy in Parkinson's disease
218937162|NCT00002751|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
218937163|NCT06131060|OTHER|Progressive eccentric exercises|This include progressive eccentric exercises thrice a week for 6 weeks.
218937164|NCT06131060|OTHER|Bodyweight exercises|This include bodyweight exercises thrice a week for 6 weeks
218937165|NCT01614691|DRUG|SPARC1203|Active
218937166|NCT01614691|DRUG|Placebo|Placebo
218937167|NCT01384149|DEVICE|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
218937168|NCT01384149|DEVICE|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
218937169|NCT02549924|DRUG|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
219625950|NCT06846476|OTHER|Orthotic Satisfaction Questionnaire- Q-YTKMD (QUEST 2.0)|It is a standardised and widely used questionnaire developed to examine the satisfaction of individuals using orthotics with the device they use. In 2020, a Turkish validity and reliability study was conducted. QUEST 2.0 consists of 12 items. Of these, 8 items question the assistive device and 4 items question service satisfaction. Scale scoring is calculated with a 5-point Likert scale (1=Not satisfied at all, 5=Very satisfied). This evaluation will be performed after the use of insoles.
219625951|NCT06846476|OTHER|6 Minute Walk Test (6MWT)|Participants will walk for 6 minutes at a speed of their choice in a flat and suitable area of 30 metres. The distance walked in 6 minutes will be recorded in metres.
219625952|NCT06846476|OTHER|Pulse Oximeter Heart Rate and Oxygen Saturation|Heart rate and oxygen saturation (SpO2) will be recorded by pulse oximetry before and after the 6MWT. The pulse oximeter is a non-invasive device that attaches to a person's fingertip.
219625953|NCT03932786|PROCEDURE|Biospecimen collection|Collection of tissue and saliva samples
219625954|NCT03932786|OTHER|Vision assessment|Undergo vision assessment
219625955|NCT03932786|OTHER|Questionnaire administration|Complete questionnaires
219625956|NCT03932786|OTHER|Quality of life assessment|Complete questionnaires
219625957|NCT03932786|OTHER|Laboratory Biomarker Analysis|Correlative studies
219625958|NCT04026477|BEHAVIORAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
219625959|NCT04026477|BEHAVIORAL|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
219625960|NCT03982836|DIETARY_SUPPLEMENT|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
219625961|NCT05731700|DEVICE|Drug Eluting Balloon|PCI of in-stent restenosis
219625962|NCT06423573|DRUG|Filsuvez|Topical gel
219625963|NCT06434935|COMBINATION_PRODUCT|CABA|Coronary Bypass
219625964|NCT05735080|DRUG|INX-315|Oral administration
219625965|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
219625966|NCT05735080|DRUG|Abemaciclib|Abemaciclib will be combined with INX-315
219625967|NCT05094297|BEHAVIORAL|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
219625968|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
219625969|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
219625970|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
219625971|NCT06385678|DRUG|HRS-4642|administrated per dose level in which the patients are assigned
219625972|NCT06385678|DRUG|Adebrelimab|administrated per dose level in which the patients are assigned
218937170|NCT02549924|DRUG|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
218937171|NCT00974480|OTHER|Redermic|Cosmetic cream formulation 609637 43.
218937172|NCT00974480|DRUG|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
218937173|NCT02283762|DRUG|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
218937174|NCT02283762|DRUG|Placebo|Sham-titration
218937175|NCT05037799|DRUG|Rb-82 Radioisotope|Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
218937176|NCT04372940|DRUG|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
218937177|NCT04372940|OTHER|Saline Irrigation|Saline will serve as the control.
218937178|NCT00050362|DRUG|Rofecoxib and Bupivacaine|
218937179|NCT02501395|OTHER|No intervention, observational|
218937180|NCT05998057|OTHER|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~* Standing Hip Out 3 sets of 30sec~* 90-90 Hip Stretch 3 sets of 30 seconds~* World's Greatest Stretch 3 sets of 30 seconds~* Star Excursion 3 sets of 5 reps~* Side Jumps+ Balance 3 sets of 10 reps~* Forward Hops + Balance 3 sets of 10 reps~* Squat 3 sets of 10 reps~* Squat Jump 3 sets of 10 reps~* Jumping Spider Push-up 3 sets of 10 reps~* Double Leg Vertical Jump 3 sets of 10 reps~* Broad Jumps 3 sets of 10 reps~* Lateral Box Shuffles 3 sets of 10 reps~* Plank 3 sets of 30 seconds~* Side Plank 3 sets of 30 seconds~* Bird Dog 3 sets of 10 reps~* Glute Bridge 3 sets of 10 reps~* Single Leg Glute Bridge 3 sets of 10 reps~* Single Toe Raises 3 sets of 30sec~* Nordic Hamstrings 3 sets of 10 reps~* Monster Walk 3 sets of 10 reps"
218937181|NCT05998057|OTHER|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
218937182|NCT00540332|DRUG|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
218937183|NCT00540332|DRUG|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
219625973|NCT06385678|DRUG|SHR-9839|administrated per dose level in which the patients are assigned
219625974|NCT06385678|DRUG|Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection|administered as prescribed by the investigator.
219625975|NCT06385678|DRUG|Cetuximab Solution for Infusion|administrated per dose level in which the patients are assigned
219625976|NCT02422017|DRUG|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
219625977|NCT02422017|OTHER|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
219625978|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
219625979|NCT06572657|OTHER|physical exercise|physical exercise
219548829|NCT05435833|PROCEDURE|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
219548830|NCT02331628|DEVICE|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine."
219548831|NCT00691704|DRUG|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
219548832|NCT00691704|DRUG|Sequential Maintenance Therapy|"Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
219548833|NCT05959486|DRUG|BR6002A|One tablet administered alone
219548834|NCT05959486|DRUG|BR6002B|One tablet administered alone
219548835|NCT05959486|DRUG|BR6002|One capsule administered alone
219548836|NCT01993186|DRUG|UX007|oral liquid
219548837|NCT01993186|DRUG|Placebo|oral liquid
219548838|NCT05267444|PROCEDURE|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
219548839|NCT03390257|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
219548840|NCT04661202|OTHER|multimodal exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction."
219548841|NCT02578290|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
219548842|NCT05919199|OTHER|No intervention|No intervention
219548843|NCT05998980|PROCEDURE|Componeer prefabricated veneers|Individual Randomized Clinical Trial
219548844|NCT05998980|PROCEDURE|Essentia resin composite veneers|Individual Randomized Clinical Trial
219548845|NCT01861249|DRUG|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
219548846|NCT06676813|BEHAVIORAL|Alternate day fasting|Alternate day fasting
219548847|NCT05306496|DEVICE|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
219548848|NCT00758797|OTHER|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
219548849|NCT02313558|DRUG|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
219548850|NCT02313558|DRUG|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
219548851|NCT02015832|DEVICE|Coronary stent|
219548852|NCT02015832|RADIATION|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
219548853|NCT02015832|DEVICE|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
219548854|NCT02015832|DEVICE|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
219548855|NCT02015832|DEVICE|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
219548856|NCT02131077|BIOLOGICAL|ALLO-ASC-TI|
219548857|NCT02131077|DRUG|Placebo|
219625980|NCT05365295|OTHER|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
219625981|NCT06571383|DRUG|Semaglutide|Participants will receive semaglutide s.c(under the skin) once weekly.
219625982|NCT04910269|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
219625983|NCT04910269|OTHER|Placebo|Infusion of 35 milliliters standard isotonic saline
219625984|NCT06534918|OTHER|Fitbit|Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
219625985|NCT06534918|BEHAVIORAL|Nutrition Course: Group Sessions|The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
219625986|NCT06534918|BEHAVIORAL|Physical Activity Program: Group Sessions|The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
219625987|NCT06534918|BEHAVIORAL|Nutrition Course: One on One Sessions with Registered Dietitian|Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
219048114|NCT07146802|BEHAVIORAL|Metacognitive Training (MCT) for psychosis|MCT for psychosis is based on the theoretical foundations of the cognitive-behavioral model of schizophrenia, but it employs a somewhat different therapeutic approach. The program is comprised of ten modules targeting common cognitive errors, problem-solving biases as well as emotional problems in schizophrenia. These errors and biases may, on their own or in combination, culminate in the establishment of false beliefs to the point of delusions. The aim of the sessions is to raise the participants' awareness of these distortions and to prompt them to critically reflect on, expand upon, and change their current repertoire of problem solving. In addition to the sessions, the program includes homework tasks to reinforce the skills learned between sessions.
219206533|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
219625988|NCT06534918|BEHAVIORAL|Physical Activity Program: One on One Sessions with an Exercise Physiologist|Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
219625989|NCT06534918|BEHAVIORAL|Nutrition and Physical Activity Prescription|Participants will receive a lifestyle medicine prescription pad, developed by the investigators, which serves as a checklist to assist participants in effectively monitoring their dietary habits and physical activity routines. Participants will also receive an 8-week text messages program which will direct participants to a webpage with nutrition and physical activity content.
219625990|NCT05943964|BEHAVIORAL|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
219625991|NCT06369025|BEHAVIORAL|Interaction Competencies with Children|"Interaction Competencies with Children - for Teachers (ICC-T) Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~Interaction Competencies with Children - for Parents (ICC-P) Core training components include parents-child interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the home"
219625992|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
219625993|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
219625994|NCT05530525|DIAGNOSTIC_TEST|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
219625995|NCT05530525|DIAGNOSTIC_TEST|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
219625996|NCT05530525|DIAGNOSTIC_TEST|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
219625997|NCT05208931|PROCEDURE|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
219625998|NCT04010760|DIAGNOSTIC_TEST|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
218937184|NCT02302014|OTHER|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
218937185|NCT05525481|DRUG|Tamoxifen|Hormone therapy
218937186|NCT05237089|OTHER|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
218937187|NCT05237089|OTHER|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
218937188|NCT05237089|OTHER|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
218937189|NCT00299390|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
218937190|NCT03233984|BEHAVIORAL|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
218937191|NCT01901913|DEVICE|MD-bolus calculator for pre-meal bolus|
218937192|NCT01901913|DEVICE|No MD-bolus calculator for pre-meal bolus|
218937193|NCT00709865|DRUG|tonapofylline|IV
218937194|NCT00709865|DRUG|Placebo|IV
218937195|NCT00495014|DRUG|GSK376501|
218937196|NCT00495014|DRUG|Placebo|
218937197|NCT03311698|BEHAVIORAL|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
218937198|NCT06316024|DIETARY_SUPPLEMENT|water|The participants drink 240 mL of water approximately 6-8 hours after surgery
218937199|NCT06316024|DIETARY_SUPPLEMENT|juice/sport drink group|The participants drink 240 mL of juice/sport drink approximately 6-8 hours after surgery
218937200|NCT06316024|DIETARY_SUPPLEMENT|Chewing gum group|The participants eat chewing gum approximately 6-8 hours after surgery
218937201|NCT02920242|DRUG|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
218937202|NCT02920242|DRUG|Rifaximin (Xifaxan)|200 mg tablet administered orally
218937203|NCT02920242|DRUG|Placebo|Matching Placebo tablet administered orally
218937204|NCT04659213|DEVICE|esolution catheter|esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
218937205|NCT03565419|DEVICE|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
219206534|NCT06964958|DRUG|177Lu-PSMA-617|A radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
219625999|NCT03906760|OTHER|Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
219626000|NCT06585514|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
219626001|NCT05745831|OTHER|Therapeutic decision tool|A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
219626002|NCT05388227|OTHER|Pole walking|The intervention will consist of group sessions held at the participating communities, 2-3 times per week, for 20-60 minutes per session, over a 12-week period. Pole walking exercises are tailored for participants and progressive in nature. Sessions will be led by trained peer, staff, or student instructors and conducted outdoors (indoors if weather conditions do not permit).
219048115|NCT07147036|PROCEDURE|Biodentine - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Mixing of Biodentine (Septodont, France) in an amalgamator (30 seconds at 4000 rpm)~Placement of Biodentine into the prepared cavity using an amalgam carrier and condensation~After 1 week: Placement of self-cure GIC (Fuji, Japan) as a base~Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
219626003|NCT06120166|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
219626004|NCT06798623|BIOLOGICAL|Autologous Mesenchymal Stromal Cells|Autologous mesenchymal stromal/stem cells extracted from the subject during a routine standard of care ACL reconstruction surgery and reintroduced in one clinic visit approximately 21 days after completion of the surgery. After being removed from the patient, the cells will be cultured, modified, and harvested to become the final investigational product. Each subject will receive 1.5 ml of the investigative drug. This will contain 5x10\^7 (50 million) autologous MSCs.
219626005|NCT00437021|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
219626006|NCT00437021|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
219626007|NCT00437021|OTHER|Placebo|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
219626008|NCT00437021|OTHER|Placebo|Physiologic normal saline for injection.
219626009|NCT02194842|DRUG|Ra223|
219626010|NCT02194842|DRUG|Enzalutamide|
219048116|NCT07147036|PROCEDURE|Calcium Hydroxide - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Cavity dried with cotton pellet~Placement of a 0.5 mm layer of Calcium Hydroxide (Dycal)~After 2-3 minutes (setting time): Placement of self-cure GIC (Fuji, Japan)~After 1 week: Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
219048117|NCT06952426|OTHER|No intervention|Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).
219048118|NCT06952426|OTHER|Other treatment|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.
219206535|NCT04811027|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
219206536|NCT04811027|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
219626011|NCT05381532|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
219626012|NCT05791812|DEVICE|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
219626013|NCT03936361|DRUG|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
219626014|NCT04594551|BIOLOGICAL|Purified vero rabies vaccine - serum free|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
219626015|NCT04594551|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
219626016|NCT04594551|BIOLOGICAL|Human rabies immunoglobulins|Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
219626017|NCT06585774|DRUG|INCA034176|IV infusion
219626018|NCT06585774|DRUG|Placebo|IV infusion
219626019|NCT06585774|DRUG|Corticosteroids|Oral/IV Infusion
219626020|NCT06835387|DRUG|Nanoliposomal irinotecan|Nanoliposomal Irinotecan 50 mg/m2 will be administered over 90 minutes (± 10 minutes) IV. All subjects must be pre-medicated prior to nanoliposomal irinotecan infusion with standard doses of dexamethasone and a 5-HT3 antagonist, or equivalent other anti-emetics (according to standard institutional practices).
219626021|NCT06835387|DRUG|Oxaliplatin|Oxaliplatin 60 mg/m2 will be administered over 120 minutes (± 10 minutes) IV. Institutional standards may be used for all aspects of oxaliplatin administration including premedication administration.
219626022|NCT06835387|DRUG|5 fluorouracil|5-FU will be administered as a continuous infusion over 46 hours. Subjects will go home with an infusion pump and return to clinic at the end of infusion for removal of the pump or, if possible, the pump may be removed at the subject's home (except on Cycle 1 Day 3).
219626023|NCT06835387|DRUG|Leucovorin|Leucovorin 400 mg/m2 will be administered over 30 minutes IV.
219626024|NCT03083548|DIAGNOSTIC_TEST|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
219626025|NCT03083548|DIAGNOSTIC_TEST|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
219626026|NCT03083548|DIAGNOSTIC_TEST|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
219626027|NCT05557292|DRUG|RMC-5552|Given IV
219048119|NCT06952426|OTHER|Iptacopan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.
219048120|NCT06952426|OTHER|Atrasentan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.
219048121|NCT04683679|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
219048122|NCT04683679|DRUG|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
219626028|NCT05897775|DEVICE|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
219626029|NCT05918835|DEVICE|High-frequency repetitive transcranial magnetic stimulation (active rTMS)|HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).
219626030|NCT05918835|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
219626031|NCT04874454|DIAGNOSTIC_TEST|ultrasound|evaluate the vocal cord movement among the stroke patients
219626032|NCT06634524|DRUG|Dexmeditomidine|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
219626033|NCT06634524|DRUG|Normal saline|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
219626034|NCT06351800|BEHAVIORAL|Predictplusprevent intervention|The intervention is based on validated risk algorithms to predict depression and anxiety and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps participants to develop their own personalized plans to prevent (PPP) depression and/or anxiety; 3) eight intervention modules (the core of the system) including activities to prevent depression and anxiety, to be proposed and monitoring by the DSS. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6, 9 and 12 months.
219626035|NCT06351800|OTHER|Psychoeducational intervention|To know the level of risk of experiencing depression and/or anxiety in the next 12 months. In addition, participants assigned to this intervention will have free access to the 24 self-help pamphlets for preventing depression and anxiety.
219626036|NCT01104805|BEHAVIORAL|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
219626037|NCT01104805|BEHAVIORAL|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
219626038|NCT03876535|OTHER|Nanomix eLab® System molecular diagnostic test (non-interventional)|This is not an interventional study. It involves performance equivalence demonstration of a point of care diagnostic system to FDA cleared predicate devices currently used in sepsis and SIRS diagnosis.
219626039|NCT01734135|OTHER|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
219206537|NCT06649747|DRUG|AFA-281|A small molecule, orally available
219626040|NCT04462406|BIOLOGICAL|Ipilimumab|Given IV
219626041|NCT04462406|BIOLOGICAL|Nivolumab|Given IV
219626042|NCT04462406|OTHER|Patient Observation|Undergo active surveillance
219626043|NCT04462406|BIOLOGICAL|Pembrolizumab|Given IV
219626044|NCT06454240|DRUG|lunsekimig|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
219048123|NCT04683679|RADIATION|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
219048124|NCT07148986|DIETARY_SUPPLEMENT|Clarity Active Product 1|Participants will use their Clarity Active Product 1 as directed for a period of 6 weeks.
219048125|NCT07148986|DIETARY_SUPPLEMENT|Clarity Product Placebo Control|Participants will use their Clarity Product Placebo Control as directed for a period of 6 weeks.
219206538|NCT05677230|PROCEDURE|Balloon occluded/plug assisted retrograde transvenous obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
219626045|NCT06454240|DRUG|placebo|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
219626046|NCT05743595|BIOLOGICAL|Personalized Neoantigen DNA vaccine|The sites of immunization may be rotated for each of the immunizations.
219626047|NCT05743595|BIOLOGICAL|Retifanlimab|Retifanlimab will be supplied by Incyte.
219626048|NCT05743595|DEVICE|TDS-IM v 2.0 electroporation device|Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
219626049|NCT00236340|DEVICE|Syringe aspiration|It consists of performing successive aspirations using a 50ml syringe connected to the needle by a flexible tube.
219626050|NCT00236340|DEVICE|Wall suction|The tubing is connected to the centralized suction system by continuous vacuum, the value of the applied vacuum is 250mmHg
219206539|NCT05677230|PROCEDURE|Endoscopic Variceal Obturation|Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
219626051|NCT06205706|DRUG|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
219626052|NCT06205706|DRUG|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
219626053|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
219626054|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
219626055|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
219626056|NCT06515145|PROCEDURE|High Volume Therapeutic Plasma Exchange|Experimental- High Volume Therapeutic Plasma Exchange at (8 - 9 litres of plasma would be exchanged in each patient over 6 - 8 hours)
219626057|NCT06515145|PROCEDURE|Standard volume therapeutic plasma exchange|Active Comparator - The standard volume strategy would be performed centrifugation technique with Plasma volume varying from 1.5 - 2.5 times the plasma - volume along with Standard Medical Treatment.
219626058|NCT05523544|BEHAVIORAL|schematherapy|psychotherapy
219626059|NCT03682081|DEVICE|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
219626060|NCT03682081|DEVICE|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
219626061|NCT01368094|PROCEDURE|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
219626062|NCT01368094|PROCEDURE|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
219626063|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
219626064|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
219626065|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
219048126|NCT07124351|DRUG|CYTALUX™ (pafolacianine)|All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.
219048127|NCT07138677|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
219048128|NCT07152184|DRUG|Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup|"Biological A blood sample of up to 5 mL will be taken at visits V0, V5, and V14, for a maximum total volume of 15 mL for the study.~Behavioral Quality of life and disease assessment questionnaires will need to be completed by the patient and their caregiver."
219048129|NCT07153081|DEVICE|Actigraphy watch intervention|Participants in this group only will be given an Actigraphy watch to track their physical activity levels.
219048130|NCT07156721|DEVICE|Phototherapy with White Reflective Drape|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; a double-layer white reflective drape (125 × 105 cm) was placed around three sides and overhead, with a white sheet under the infant.
219048131|NCT07156721|DEVICE|Standard Phototherapy|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; no reflective drape or additional reflective material used.
219048132|NCT07164001|OTHER|Twin-Specific Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using twin-specific growth charts. These charts account for twin gestation norms and may influence clinical decision-making regarding growth restriction and perinatal management. The intervention does not involve any direct physical procedure or device but rather a change in the interpretation framework of routinely collected ultrasound data.
219048133|NCT07164001|OTHER|Singleton-Based Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using singleton-based growth charts. These charts are commonly used in standard practice but may overestimate growth restriction in twin pregnancies. The intervention does not involve any direct physical procedure or device but alters the interpretation framework for standard prenatal ultrasound findings.
219626066|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
219626067|NCT02770235|OTHER|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
219626068|NCT02770235|OTHER|AGE measurement|By AGE-ReaderTM
219626069|NCT01467713|DRUG|Ramelteon SL|Ramelteon sublingual (SL) tablets
219626070|NCT01467713|DRUG|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
219626071|NCT04580810|BEHAVIORAL|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
219626072|NCT04451057|DEVICE|high flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
219626073|NCT04451057|DEVICE|low flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
219626074|NCT05340088|PROCEDURE|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
219626075|NCT05560568|OTHER|Sleep parameters data collection|Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).
219626076|NCT03532425|DRUG|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
219626077|NCT03532425|DRUG|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
219626078|NCT03532425|DRUG|B/F/TAF Placebo|Tablet taken orally once daily
219626079|NCT03532425|DRUG|Atripla Placebo|Tablet taken orally once daily
219626080|NCT04148586|OTHER|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
219626081|NCT01100086|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
219626082|NCT01100086|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
219626083|NCT04967924|OTHER|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
219048134|NCT07173023|PROCEDURE|Transnasal Puncture with Mitomycin C application|"* Performed under general anesthesia.~* Nasal cavities decongested with oxymetazoline.~* Atretic plate perforated using serial dilators under direct visualization.~* Additional removal of bony/membranous tissue including the posterior nasal septum as possible.~* Topical mitomycin C (0.5 mg/mL) applied to the edges of the newly created choana for 2 minutes using cotton pledget in a transparent tube , followed by irrigation with saline.~* syndromatic patients and patients requiring less time UGA will be included in this group"
219626084|NCT04967924|OTHER|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
219626085|NCT03090334|DIAGNOSTIC_TEST|De-escalation|Antifungal therapy will be stopped according with BG results
219626086|NCT01707810|PROCEDURE|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
218937206|NCT00202878|DRUG|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
218937207|NCT00202878|DRUG|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
218937208|NCT00202878|DRUG|Placebo for simvastatin 40 mg|one or two tablets orally daily
218937209|NCT00202878|DRUG|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
219626087|NCT01707810|PROCEDURE|conventional method|
219626088|NCT03600961|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
219626089|NCT05413213|PROCEDURE|Ambulatory rehabilitation program|Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
219626090|NCT06296771|OTHER|Dietary energy restriction group (D)|"The participants allocated to the dietary energy restriction group will receive instructions to change their usual dietary intake and maintain their regular physical activity routine for the duration of eight weeks.~The dietary energy restriction depends on a total calorie deficit of 5000 kcal per week, achieved by the consumption of reduced meal portions. This deficit is computed by subtracting the participants\&#39; energy expenditure, as measured by ActiheartTM, rather than relying on reported energy intake. This approach is employed to reduce potential difficulties arising from participants under-reporting their food consumption. The energy deficit is calculated by multiplying the weight of each food item recorded over a 5-day period by an individual factor obtained from energy expenditure data. This calculation enables the determination of the required energy intake for the intervention period."
218937210|NCT03338738|DIAGNOSTIC_TEST|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
218937211|NCT04815148|DRUG|MH004 Ia(0.1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
218937212|NCT04815148|DRUG|MH004 Ia(0.3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
219626091|NCT06296771|OTHER|Dietary energy restriction and exercise group (D+E)|"The individuals within the dietary energy restriction and exercise group will be instructed to reduce their habitual energy intake by 5,000 kcal per week while taking part in physical exercise with a frequency of three sessions per week of HIIT and two sessions per week of resistance exercise throughout a duration of 8 weeks. Sessions can be performed in any order, but we will recommend alternating HIIT and resistance training days and taking the two rest days separately to allow for recovery.~The exercise programme will start the session by participating in a gentle stretching routine with the objective of reducing the effects of exercise-induced shoulder discomfort. The treatment focuses on the four main muscle groups in the upper body: the latissimus dorsi, the triceps, the rhomboid, the pectoral, and the upper trapezius. Each pose is held in the stretched position for a length of 15 seconds throughout each set, for a total of 4 sets."
219626092|NCT04986345|OTHER|High-intensity interval training (HIIT)-4|4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.
219626093|NCT04986345|OTHER|High-intensity interval training (HIIT)-10|10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.
219626094|NCT04986345|OTHER|Rest|Participants are to stay seated for 30 minutes while reading or watching television.
219626095|NCT05448274|BIOLOGICAL|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
219626096|NCT05448274|BIOLOGICAL|Ruminococcus torques|10\^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
219626097|NCT01611935|DRUG|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
219626098|NCT01853813|DRUG|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
219626099|NCT04875221|COMBINATION_PRODUCT|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
219626100|NCT00162110|DRUG|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
219626101|NCT05172284|OTHER|Questionnaires|This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.
219626102|NCT03215290|PROCEDURE|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
219626103|NCT04558801|DEVICE|Mobile application-based lifestyle change program|Usage of the Mobile application-based lifestyle change program
219626104|NCT00277225|DRUG|Abatacept|
219626105|NCT06413628|OTHER|screw tapered appliance|The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.
219626106|NCT03469856|DRUG|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
219626107|NCT06574113|DEVICE|Perin Health Patch|The Perin Health Patch (PHP)is a multimodal wearable health patch, which combines auscultation, electrocardiography (ECG), pulse oximetry via photoplethysmography (PPG), bioimpedance (BioZ), skin temperature, and motion and tilt sensors. The PHP integrates multiwavelength PPG (MWPPG) with blue, green, red, and IR LEDs, allowing for precise calculation of PTT, PWV, and related unique parameters, that are used for the calculation of cuffless blood pressure.
219626108|NCT03446027|DEVICE|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
219626109|NCT05939960|DIAGNOSTIC_TEST|CGT test|GCT、PRP-CT、PPP-CT monitor
219626110|NCT05687396|DEVICE|virtual reality|virtual reality designed as cycling in the forest
219626111|NCT05687396|OTHER|conventional pulmonary rehabilitation|pulmonary rehabilitation
219626112|NCT03097341|DRUG|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
219626113|NCT03097341|DRUG|xisomab 3G3-Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
219626114|NCT03097341|DRUG|xisomab 3G3-Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
219626115|NCT03097341|DRUG|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
219626116|NCT03097341|OTHER|Placebo|Participants will receive a single intravenous dose of placebo.
219626117|NCT01209949|DRUG|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
219626118|NCT05736016|DEVICE|medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)|All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
219626119|NCT01798810|PROCEDURE|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
219626120|NCT06685003|BEHAVIORAL|Digital Tutorial overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 7 weeks and revisited over 6 months.
219626121|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months.
219626122|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials plus feedback and Coaching|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months. Plus group coaching and feedback on audio recordings of CRAFT procedures used in sessions
219626123|NCT04428697|PROCEDURE|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
219626124|NCT00729612|DRUG|carboplatin|
219626125|NCT00729612|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219626126|NCT00729612|GENETIC|protein expression analysis|
219626127|NCT00729612|OTHER|immunoenzyme technique|
219626128|NCT00729612|OTHER|immunohistochemistry staining method|
219626129|NCT00729612|OTHER|laboratory biomarker analysis|
219626130|NCT02483039|BEHAVIORAL|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
219626131|NCT01125241|DRUG|wuling capsule|orally, three tablets each time,three times a day
219626132|NCT01125241|DRUG|placebo of wuling capsule|orally, three tablets each time and three times a day
219626133|NCT05649839|OTHER|garment|patient randomized in the experimental arm will wear the specially designed garment
219626134|NCT01414582|DEVICE|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
219626135|NCT01414582|OTHER|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
219626136|NCT00003909|DRUG|motexafin gadolinium|Given IV
219626137|NCT00003909|RADIATION|radiation therapy|Undergo radiation therapy
219626138|NCT00003909|OTHER|pharmacological study|Correlatives studies
219048135|NCT07173023|PROCEDURE|Endoscopic Crossover Flap Repair|"* Performed under general anesthesia using a 0° 4 mm endoscope.~* Elevation of mucosal crossover flaps to cover exposed bone following resection of the atretic plate where one flap is inferiorly based and the other is superiorly based.~* Precise removal of the posterior vomer and lateral bony plates as needed using cold steel instruments and possible nasal drill.~* Flaps will be repositioned to minimize exposed bone and promote mucosal healing preventing restenosis."
219048136|NCT07171788|OTHER|low level laser therapy|patients will receive LLT. The LLLT system used in the study (ASA LASER M6) delivered 1.0 W in continuous wave at a wave length in the near infrared of 808 nm. The incident power density will be 670 mW/cm2.The probe head will held with light pressure in contact with the skin over the course of median nerve on the dysfunctional limb for 15 minutes. Protective goggles will be used to prevent direct eye contact of the laser beam. plus selected phyiscal therapy program
219048137|NCT07171788|OTHER|selected physical therapy program|patient will receive standard physical therapy program for wrist flexors spasticity post-stroke typically includes the following components: Passive stretching: Passive static or dynamic stretching of the wrist flexorss is the mainstay to reduce spasticity and Physical therapy exercises in form of specific techniques of proprioceptive facilitation, relaxation techniques, passive and self-passive motions, and proper limb positioning. plus sham low level laser therapy
219048138|NCT07173608|BEHAVIORAL|Inner Engineering Program|"The intervention is a comprehensive secular training called Inner Engineering (IE), offered by the international non-profit Isha Foundation. This program combines cognitive reappraisal and emotion regulation strategies, breath-based meditation and simple yoga practices. The training provides precise, step by step and easy to follow instructions on how to perform the practices. No previous experience of yoga and meditation is required. By fostering health, exuberance and awareness, one can engineer their inner climate the way they want it to lead a joyful, fulfilling life. Previous research shows improved wellbeing, mindfulness, joy, sleep, relationships, psychological capital, and work engagement, compassion, and parent-child relationships. Evidence suggest it may promote enhanced Heart Rate Variability and Sympathovagal balance."
219048139|NCT07174011|DRUG|Roflumilast|Phosphodiesterase-4 (PDE4) inhibitor assigned to arm A
219048140|NCT07174011|DRUG|intralesional steroid|intralesional injection of corticosteroid
219048141|NCT07171996|OTHER|Dual-Simulation TPS + Biomechanical Planning|Combines TG-43-based TPS with a patient-specific FE biomechanical model to optimize needle paths and seed placement considering OAR limits, fracture risk, needle stability, and seed migration risk.
219048142|NCT07171996|OTHER|Conventional TPS Planning|Conventional TPS-driven plan per institutional practice; no biomechanical modeling.
219048143|NCT07172321|DRUG|PF-08049820 MR1|Administered orally
219626139|NCT00006339|DRUG|Indinavir sulfate|
219626140|NCT00006339|DRUG|Ritonavir|
219626141|NCT00006339|DRUG|Hydroxyurea|
219626142|NCT00006339|DRUG|Stavudine|
219626143|NCT00006339|DRUG|Didanosine|
219626144|NCT03204786|DRUG|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
219626145|NCT03204786|DRUG|Placebo|Placebo Nasal Spray
219626146|NCT03029403|DRUG|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
219626147|NCT03029403|BIOLOGICAL|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
219626148|NCT03029403|DRUG|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
219626149|NCT04167540|BIOLOGICAL|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
219626150|NCT05464524|OTHER|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
219626151|NCT05464524|OTHER|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
219626152|NCT06123286|DRUG|Tart Cherry|1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
219626153|NCT06123286|DRUG|Omega 3 FA (Fish Oil)|2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks
219048144|NCT07172321|DRUG|PF-08049820 MR2|Administered orally
219626154|NCT06200545|OTHER|PrEP eligibility assessment|PrEP eligibility assessment
219626155|NCT06200545|DIAGNOSTIC_TEST|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
219626156|NCT06200545|OTHER|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
219626157|NCT06200545|BEHAVIORAL|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
219048145|NCT07172321|DRUG|PF-08049820 IR|Administered orally
219048146|NCT07171905|DRUG|investigating the role of CAIX as target in VHL disease and in VHL-/- tumors.|Participants VHL disease and in VHL-/- tumors, will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently undergo imaging with a hybrid PET/CT scanner.
219048147|NCT07173127|DRUG|Ryeqo treatment|Ryeqo treatment will be administered and hemostasis markers will be measured at T0 and T1
219048148|NCT07173777|DEVICE|Cardiac Waveform Generator|A pacing device that allows for programmable pulse waveforms to generate a predefined set of anodal biphasic waveforms. It possesses a battery-powered floating point gate array (FPGA) using software that allows flexibility in waveform configuration.
219048149|NCT07173283|OTHER|MenTOras: Peer Mentorship Program for Newly Graduated Occupational Therapists|The MenTOras intervention is a structured peer mentorship program designed for newly graduated occupational therapists in Aragón, Spain. The program pairs early-career occupational therapists (mentees, graduated within the past two years) with experienced colleagues (mentors, with at least five years of practice). Over approximately three months, each mentor-mentee pair participates in at least six structured sessions (online or in person). Sessions follow three phases-initiation, development, and closure-focusing on professional identity, reflective practice, emotional support, and skill integration. Mentors receive orientation and guidance to ensure program consistency. COPTOA also offers topic-specific training to address emerging professional needs. The intervention aims to foster professional integration, enhance self-confidence, and promote well-being among new occupational therapists, while strengthening professional cohesion and retention.
219048150|NCT07172165|DIAGNOSTIC_TEST|Expert double-blind evaluation|Expert reading will be using TCDPlayer and will be blinded to clinical data, source information, and other assessments. They will manually annotate six predefined signal features: characteristic audible signal increase, characteristic wave-like of raw Doppler signals, Emboli-to-Background Ratio, Emboli-to-Mirror Ratio, signal duration, and average velocity of maximum intensity. Analysis will be completed within 90 days.
219626158|NCT06200545|OTHER|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
219626159|NCT06200545|OTHER|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
219626160|NCT06200545|OTHER|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
219626161|NCT06088290|DRUG|Lurbinectedin|IV Infusion
219626162|NCT06088290|DRUG|Doxorubicin|Short IV push or bolus (according to label)
219626163|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
219626164|NCT04293393|DRUG|Doxorubicin|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
219626165|NCT04293393|DRUG|Cyclophosphamide|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
219626166|NCT04293393|DRUG|Taxane|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
219626167|NCT04293393|DRUG|Letrozole|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
219626168|NCT04293393|DRUG|Abemaciclib|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
219626169|NCT04293393|DRUG|LHRH Analogue|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
219626170|NCT02075203|BIOLOGICAL|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
219626171|NCT02075203|DRUG|Placebo|Saline
219626172|NCT02075203|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
219626173|NCT01365871|PROCEDURE|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
219626174|NCT04077593|DEVICE|RRate Mobile app|Test respiratory rate with RRate application
219626175|NCT00843765|OTHER|acupuncture, massage and basic TCM treatment|"1. During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~2. After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
219626176|NCT00843765|OTHER|rehabilitation and WM basic treatment|"there two steps:~1. during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~2. After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
219626177|NCT05849532|DEVICE|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
219626178|NCT03596957|DRUG|Tolvaptan|At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
219626179|NCT05344560|DEVICE|soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore|TEST Lens
219626180|NCT05344560|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|CONTROL Lens
219626181|NCT03096860|OTHER|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
219626182|NCT03096860|OTHER|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
219626183|NCT06573684|DIAGNOSTIC_TEST|Electromyography|All of groups will have assessment of electromyography result
219626184|NCT04714424|DEVICE|Virtual Reality Headset|Virtual reality (VR) - a 3-D reality right in a headset
219626185|NCT04689035|DRUG|AVLX-144|Test drug
219626186|NCT04689035|DRUG|Placebo|Placebo
219626187|NCT03197480|DRUG|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
219626188|NCT05244057|DRUG|Hepalatide|6.3mg, s.c., qd for 48 weeks
219626189|NCT05244057|DRUG|Placebo of Hepalatide|s.c., qd for 48 weeks
219626190|NCT05244057|DRUG|Tenofovir Alafenamide Tablets|25mg, p.o., qd for 48 weeks
219626191|NCT05244057|DRUG|Pegylated Interferon alfa 2a|90ug, s.c., qw for 48 weeks
219626192|NCT05565248|COMBINATION_PRODUCT|VCTX211|CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
219626193|NCT00360282|DRUG|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
219626194|NCT00360282|OTHER|Placebo|In an unlabeled pill given once on one of two visits.
219626195|NCT01481948|BEHAVIORAL|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
219626196|NCT03035825|DIETARY_SUPPLEMENT|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
219626197|NCT03035825|OTHER|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
219626198|NCT03634969|DRUG|BMS-986224|Specified dose on specified days
219626199|NCT06058546|DRUG|Jiuweihuaban Pill placebo|Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
219626200|NCT06058546|DRUG|low dose Jiuweihuaban Pill|Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
219626201|NCT06058546|DRUG|high dose Jiuweihuaban Pill|High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
218937213|NCT04815148|DRUG|MH004 Ia(1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
219626202|NCT01380912|DRUG|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
219626203|NCT01207024|OTHER|knee MRI|knee MRI before surgery (inclusion) and one year after
219626204|NCT03264183|DIAGNOSTIC_TEST|Transesophageal Echocardiography|TEE measures of right ventricular function
219626205|NCT03264183|DIAGNOSTIC_TEST|Transthoracic Echocardiography|TTE measures of right ventricular function
219626206|NCT04727905|DIETARY_SUPPLEMENT|energy drink|The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
219626207|NCT02544620|OTHER|Does fulfil of discharge criteria on the day of the surgery|
219626208|NCT02544620|OTHER|Does not fulfil of discharge criteria on the day of the surgery|
219626209|NCT00563693|DEVICE|ASV|Adaptive servo ventilator
219626210|NCT00563693|OTHER|without Autoset CS2|without Autoset CS2
219626211|NCT04121819|DRUG|Cytarabine|cytarabine 100mg/m2 d1-5 subcutaneous
219626212|NCT06563453|DEVICE|transcranial alternating current stimulation|Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.
219626213|NCT00916669|DRUG|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
219626214|NCT00916669|DRUG|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
219626215|NCT00916669|DRUG|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
219626216|NCT01444664|PROCEDURE|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
219626217|NCT02647008|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
219626218|NCT05487443|DRUG|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
219626219|NCT04268771|BIOLOGICAL|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
219626220|NCT04268771|BIOLOGICAL|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
219626221|NCT00483015|BEHAVIORAL|smoking|
219626222|NCT01237574|OTHER|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
219626223|NCT00006429|PROCEDURE|body weight-supported treadmill training|
219626224|NCT03970629|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
219626225|NCT02491866|OTHER|to develop and validate a Computerized Adaptative Testing|"* Elaboration of a pool of items, based on literature review and interview with patients.~* Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~* Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~* Metrological validation of the CAT.~* Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
219626226|NCT00133848|DRUG|SB-275833 ointment, 1%|
219626227|NCT00449865|DRUG|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
219626228|NCT00449865|OTHER|placebo|an inactive substance
219626229|NCT04197466|OTHER|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
219626230|NCT04197466|OTHER|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
219626231|NCT04197466|OTHER|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
219626232|NCT04412031|OTHER|non applicable|non applicable
219626233|NCT00444535|DRUG|lapatinib|1500 mg oral lapatinib (once daily)
219626234|NCT00444535|DRUG|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
219626235|NCT03898453|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
219626236|NCT03898453|BEHAVIORAL|support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
219626237|NCT01354652|DRUG|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
219626238|NCT02613832|OTHER|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
219626239|NCT02613832|OTHER|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
219626240|NCT00558467|DRUG|pramipexole immediate release (IR)|
219626241|NCT00558467|DRUG|Placebo|
219626242|NCT06311916|DRUG|HAIC + Tirelizumab +lenvatinib +liver resection|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
219626243|NCT06311916|PROCEDURE|liver resection|Direct liver resection or laparoscopic liver resection depending on tumor status.
219626244|NCT01549587|DRUG|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
219626245|NCT01549587|DEVICE|toothbrush|brush thoroughly twice daily
219626246|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
219626247|NCT01549587|DRUG|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
219626248|NCT01549587|DEVICE|toothbrush|twice daily brush thoroughly for 2 minutes
219626249|NCT01549587|DRUG|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
219626250|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
219048151|NCT07172698|OTHER|multicomponent training with an emphasis on muscle power|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility. Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds.
219048152|NCT07172698|OTHER|traditional multicomponent training|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility
219626251|NCT01532856|DRUG|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
219626252|NCT01532856|DRUG|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
219626253|NCT01532856|DRUG|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
219626254|NCT02025725|DRUG|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
219626255|NCT02025725|DRUG|Placebo Nasal Spray|nasal spray formulation with vehicle only
219626256|NCT06504914|BEHAVIORAL|Assigned Interventions|Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
219626257|NCT05708118|DIAGNOSTIC_TEST|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
219626258|NCT05708118|DIAGNOSTIC_TEST|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
219626259|NCT06374238|BEHAVIORAL|CBT+ Health coach|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in CBT w/ Health coach group will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. In addition participants will have weekly contact with a peer health coach.
219626260|NCT06374238|BEHAVIORAL|CBT w/o Health Coach ( self-guided)|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants CBT w/o Health coach groups will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool.
219626261|NCT06374238|BEHAVIORAL|Usual Care|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in the UC group will be asked to engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
219626262|NCT01513005|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
219626263|NCT05900336|DRUG|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
219626264|NCT05900336|DRUG|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
219626265|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
219626266|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
219626267|NCT05004051|DEVICE|ViTAA Analysis|Imaging Analysis Software
219626268|NCT05958121|BIOLOGICAL|IMA402 (Phase Ia)|Intravenous infusions in escalating dose levels
219626269|NCT05958121|BIOLOGICAL|IMA402 (Phase Ib)|Treatment at MTD and/or RDE (Phase Ib)
219626270|NCT05958121|BIOLOGICAL|IMA402 (Phase II)|Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
219626271|NCT02867592|DRUG|Cabozantinib|Given PO
219626272|NCT02867592|DRUG|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
219626273|NCT02867592|OTHER|Pharmacological Study|Correlative studies
219626274|NCT04821635|DEVICE|Rower assisted by electrostimulation (FES-ROW)|"1. Pre-inclusion visit~2. Inclusion visit~3. Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~   Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~4. Interim assessment visit at Month 3 (M3)~5. Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~   Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~6. Final assessment visit at Month 6 (M6)~7. End of clinical research visit, 3 months after the end of training (Month 9, M9)"
219626275|NCT02655614|DRUG|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
219626276|NCT02655614|DRUG|Placebo|Placebo matching to GDC-0134
219626277|NCT02655614|DRUG|Rabeprazole|Rabeprazole 20 mg twice daily orally
219626278|NCT02655614|DRUG|Midazolam|2mg of liquid formulation of midazolam orally
219626279|NCT02655614|DRUG|Caffeine|100 mg tablet or solution of caffeine orally
219626280|NCT00519116|DRUG|Rapamune® (Sirolimus)|
219626281|NCT00519116|DRUG|Tacrolimus|
219626282|NCT00519116|DRUG|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
219626283|NCT06209190|RADIATION|total marrow and total lymphoid irradiation|doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
219626284|NCT02992041|DRUG|VVZ-149 Injections|IV infusion of 900 or 1100 mg of VVZ-149
219626285|NCT02992041|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
219626286|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
219626287|NCT06323421|BEHAVIORAL|Mindfulness|Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
219626288|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
219626289|NCT04341597|OTHER|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
219626290|NCT05445609|DRUG|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
219626291|NCT05445609|BIOLOGICAL|Nivolumab|Given IV
219626292|NCT03831932|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219626293|NCT03831932|PROCEDURE|Computed Tomography|Undergo CT scan
219626294|NCT03831932|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219626295|NCT03831932|DRUG|Osimertinib|Given PO
219626296|NCT03831932|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219626297|NCT03831932|DRUG|Telaglenastat Hydrochloride|Given PO
219626298|NCT03831932|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219626299|NCT06820957|PROCEDURE|Biopsy Procedure|Undergo bone marrow aspiration and biopsy
219626300|NCT06820957|PROCEDURE|Biospecimen Collection|Undergo tissue and/or blood sample collection
219626301|NCT06820957|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219626302|NCT06820957|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219626303|NCT06820957|PROCEDURE|Computed Tomography|Undergo CT
219626304|NCT06820957|DRUG|Cyclophosphamide|Given IV
219048153|NCT07173062|DIETARY_SUPPLEMENT|Spirulina Arthrospira platensis (microalgae)|Spirulina Arthrospira platensis (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
219048154|NCT07173062|DIETARY_SUPPLEMENT|Gelidium corneum|Gelidium corneum (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
219048155|NCT07173062|OTHER|Placebo|Microcrystalline cellulose, silicon dioxide and dicalcium phosphate (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
219626305|NCT06820957|DRUG|Doxorubicin Hydrochloride|Given IV
219626306|NCT06820957|PROCEDURE|Echocardiography Test|Undergo echocardiography
219626307|NCT06820957|DRUG|Etoposide|Given IV
219626308|NCT06820957|OTHER|Fludeoxyglucose F-18|Given FDG
219626309|NCT06820957|DRUG|Ifosfamide|Given IV
219626310|NCT06820957|DRUG|Irinotecan Hydrochloride|Given IV
219626311|NCT06820957|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219626312|NCT06820957|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
219626313|NCT06820957|OTHER|Questionnaire Administration|Ancillary studies
219626314|NCT06820957|RADIATION|Radiation Therapy|Undergo radiation
219626315|NCT06820957|DRUG|Regorafenib|Given PO
219626316|NCT06820957|PROCEDURE|Surgical Procedure|Undergo surgery
219626317|NCT06820957|DRUG|Vincristine Sulfate|Given IV
219626318|NCT06982235|DEVICE|Ureteroscope system|LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring
219626319|NCT06982235|DEVICE|Laser system|Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology
219626320|NCT01815775|OTHER|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
219626321|NCT06600412|DRUG|R3R01|R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.
219626322|NCT06600412|DRUG|Placebo|Please refer to arm/group description for further information.
219626323|NCT06594848|DIETARY_SUPPLEMENT|Black rice extract|Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects
219626324|NCT06594848|OTHER|Placebo|The placebo for this study is composed by maltodextrin and food colorant
219626325|NCT06595498|DIAGNOSTIC_TEST|Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).
219626326|NCT06595498|DIAGNOSTIC_TEST|cobas® EGFR Mutation Test v2 (Roche)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
219626327|NCT02839473|DEVICE|Castalie water spray|
219626328|NCT02839473|DEVICE|Hydrogel Hydrosorb®|
219626329|NCT05188183|DEVICE|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
219626330|NCT05188183|BEHAVIORAL|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
219626331|NCT05188183|OTHER|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
219626332|NCT06980688|PROCEDURE|Propofol titration|Induction starts with propofol target-controlled Infusion (TCI) (Schnider model) at target effect-site drug concentration (Cet) 0.5-1.0 µg/mL and remifentanil TCI (Minto model) at Cet 0.5 ng/mL. If loss of consciousness (LOC) is not reached, propofol Cet is increased in 0.5-1.0 µg/mL steps. For intubation, remifentanil Cet increases up to 6.0 ng/mL.
219626333|NCT06980688|PROCEDURE|Conventional propofol induction|Induction starts with propofol TCI at Cet 4-8 µg/mL and remifentanil TCI at Cet 2.5-3.5 ng/mL.
219626334|NCT05604066|DIAGNOSTIC_TEST|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
219626335|NCT05604066|DIAGNOSTIC_TEST|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
219626336|NCT03945240|PROCEDURE|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
219626337|NCT03945240|PROCEDURE|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
219206540|NCT06214793|DRUG|Taletrectinib|Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
219626338|NCT03945240|PROCEDURE|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
219626339|NCT04048239|PROCEDURE|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
219626340|NCT04048239|OTHER|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
219626341|NCT04048239|OTHER|electromyograph|electromyographic verification of the facial nerve
219626342|NCT05754190|DEVICE|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
219626343|NCT06860594|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219626344|NCT06860594|PROCEDURE|Computed Tomography|Undergo CT
219626345|NCT06860594|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219626346|NCT06860594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219626347|NCT06860594|DRUG|Triapine|Given PO
219626348|NCT06998680|OTHER|VitaGreen Capsule A+VitaGreen Tonic|VitaGreen Capsule A+VitaGreen Tonic,use 24 weeks
219626349|NCT06998680|OTHER|VitaGreen Capsule B+VitaGreen Tonic|VitaGreen Capsule B+VitaGreen Tonic,use 24 weeks
219626350|NCT06998680|OTHER|Capsule Placebo+VitaGreen Tonic|Capsule Placebo+VitaGreen Tonic,use 24 weeks
219626351|NCT06998680|OTHER|Capsule Placebo+Tonic Placebo|Capsule Placebo+Tonic Placebo,use 24 weeks
219626352|NCT04933721|DRUG|berotralstat|BCX7353 capsules or granules administered orally once daily
219626353|NCT07004998|PROCEDURE|Cricoid Pressure (30 N)|Manual application of posterior pressure on the cricoid cartilage at a standardized force of 30 newtons. The pressure is applied by a trained operator using one or two fingers, with the goal of compressing the esophagus against the cervical spine. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
219626354|NCT07004998|PROCEDURE|Left Paratracheal Pressure (30 N)|Manual application of pressure to the left paratracheal region, lateral to the trachea and inferior to the thyroid cartilage, at a standardized force of 30 newtons. The pressure is applied by a trained operator using the thumb or fingers. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
219626355|NCT07000123|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
219626356|NCT07000123|DRUG|Placebo|Participants will receive daily oral dose of placebo
219626357|NCT04204655|DIAGNOSTIC_TEST|BIA|Bioelectrical Impedance Analysis
219626358|NCT06588348|DRUG|Steroid treatment|All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.
219626359|NCT06588348|PROCEDURE|Esophageal Manometry|On the final day of Prednisone use, all subjects will undergo esophageal manometry testing to assess for treatment response.
219626360|NCT06588348|OTHER|Survey|All enrolled subjects will be asked to complete follow-up Eckardt and BEDQ surveys.
219626361|NCT06593678|OTHER|Telerehabilitation Program|Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
219626362|NCT06593678|OTHER|Booklet-based rehabilitation program|Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
219626363|NCT06674733|PROCEDURE|Botox administration|Treatment for bruxism
219626364|NCT06674733|PROCEDURE|Aromatherapy|treatment for stress-bruxism
219626365|NCT06674733|PROCEDURE|Clinical evaluation|Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered
219626366|NCT06674733|PROCEDURE|Imaging Time|Ultrasonography and shear wave elastography examination will be performed before the procedure, one month after, and three months after the procedure.
219626367|NCT06679946|DRUG|Vutrisiran|Vutrisiran administered SC q3M
219626368|NCT06871072|OTHER|Telerehabilitation|EG performed using an artificial intelli-gence (AI) application called RehBody, which detects body segments, assists in cor-recting the technique and monitoring the exercise, number of sets and repetitions done, and the adherence percentage
219626369|NCT06871072|OTHER|Exercise program|CG participants followed the exercise program and trained at home with images and videos as support.
219626370|NCT06866964|DRUG|Low-dose ASA|81 mg by mouth daily for 26 weeks
219626371|NCT07010354|DEVICE|Stenting|Endovascular treatment of stenosed or occluded iliac arteries: Permanent intraluminal placement of a covered stent
219626372|NCT06095505|DRUG|Alisertib|Alisertib enteric-coated tablets
219626373|NCT07011056|DRUG|Purinostat Mesylate for Injection|"The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle lasts for 21 days, and the total treatment cycle is 6 cycles.~After 6 cycles, the investigator will assess whether the subjects can continue to benefit, whether they can sustain the treatment with the investigational drug, and adjust the frequency of continuous administration based on the evaluation results of the efficacy over these 6 cycles."
219626374|NCT07011056|DRUG|Selinexor Tablets|The recommended dose of selinexor tablets is 60 mg per administration, taken orally on the 1st and 3rd day of each week (for example, Monday and Wednesday, or Tuesday and Thursday), with a 4-week course as one treatment cycle. Patients who achieve partial response (judged by the investigator as the best expected response for the subject) or have better efficacy can switch to maintenance treatment, with a maintenance dose of 60 mg taken orally once a week.
219626375|NCT05666726|OTHER|Pain|Thermal pain
219048156|NCT07173920|DEVICE|repetitive Transcranial Magnetic Stimulation|"Patients will receive rTMS treatment for a total of 14 days. Prior to treatment, patients will undergo an MRI scan; the images will be preprocessed to construct a structural network, and precise localization of the pre-SMA (preSupplementary Motor Area) region and the SCAN (Somatosensory-Cognitive-Action Network) will be performed based on coordinates.~Participants will receive two treatment sessions per day, with an interval of at least 1 hour between each session. Each treatment session consists of 3 cTBS (Continuous theta-Burst Stimulation) treatments, and the interval between each cTBS treatment is at least 15 minutes. Each cTBS treatment lasts 40 seconds, comprising 3 pulses at 50 Hz, repeated every 200 ms (equivalent to 5 Hz), totaling 600 pulses per cTBS treatment. Accordingly, patients receive a total of 3,600 pulses per day, and a cumulative total of 50,400 pulses are delivered throughout the entire treatment period."
219048157|NCT07173413|OTHER|Telephone post-surgery physiotherapy follow-up|Post-operative physiotherapy follow-up delivered via a structured telephone consultation. The session focuses on recovery after lumbar spine surgery, addressing pain management, mobility, exercise recommendations, and guidance on daily activities. The physiotherapist evaluates the patient's status verbally, answers questions, and provides tailored advice to support safe rehabilitation without requiring the patient to attend the hospital physically.
219048158|NCT07173413|OTHER|In person post-operative physiotherapy follow-up|Post-operative physiotherapy follow-up delivered as an in-person consultation at the hospital. The session includes assessment of recovery after lumbar spine surgery, hands-on evaluation if needed, and tailored advice on pain management, mobility, exercise progression, and daily activity. This format allows the physiotherapist to physically observe and, if relevant, demonstrate exercises to ensure correct performance and safe rehabilitation.
219206541|NCT06500910|OTHER|Physical Exercise|10 weeks of child-friendly physical exercise program
219206542|NCT01937039|PROCEDURE|Sample collection|Blood, tissue, urine, and other samples may be collected
219206543|NCT06294691|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
219626376|NCT05666726|OTHER|Stress|Stress state induction
219626377|NCT05666726|BEHAVIORAL|Craving|Snack craving induction
219626378|NCT05666726|BEHAVIORAL|Frustration|Real effort task
219626379|NCT05666726|BEHAVIORAL|Negative valence emotion|Passive video watching with emotional valence
219626380|NCT03820063|DRUG|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
219626381|NCT04118062|BEHAVIORAL|Questionnaires|Questionnaires
219626382|NCT04118062|BEHAVIORAL|Semi-structured individual interviews|Semi-structured individual interviews
219626383|NCT04118062|OTHER|Focus Group|Focus Group
219626384|NCT04118062|OTHER|DELPHI Consensus Method|DELPHI Consensus Method
219626385|NCT06684106|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|UDCA together with statin in eligible participants
219626386|NCT06684106|DRUG|Placebo|placebo together with statin in ASCVD patients
219626387|NCT06695949|OTHER|Percutaneous neuromodulation.|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
219626388|NCT06695949|OTHER|Therapeutic Exercise.|These participants (n=50) will engage in resistance training for the cervical flexor muscles, following a progressive exercise program in a supine position with the head comfortably supported, as described by Falla et al. (2008). Participants will perform these exercises with a frequency of 3 days a week for 6 weeks, with each session lasting 30 minutes.
219626389|NCT04577807|BIOLOGICAL|Lerapolturev|Lerapolturev administered via direct lesion injection
219626390|NCT04577807|BIOLOGICAL|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
219626391|NCT01774682|PROCEDURE|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
219626392|NCT06441331|DRUG|Lutetium Lu 177-Edotreotide|lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
219626393|NCT06441331|OTHER|Amino Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
219626394|NCT06874959|DEVICE|Ear acupuncture|"(According to the guidelines provided in the BFA - Acupuncture Manual of the USAF Center for Integrative and Complementary Medicine.)~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khanh Phong auricular acupuncture needles (license: 287/BYTYDCT)~* Before needling: Disinfect the skin on both outer ears.~* Insertion depth: Auricular needles penetrate the skin to a depth of 1.3 mm. Insert the auricular needles alternately on the right and left sides at the following acupoints: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero point. The insertion process stops when one of the following three criteria is met: (1) The patient experiences a 40% reduction in pain on the Visual Analog Scale (VAS), (2) The patient refuses to continue the insertion, or (3) A total of 10 needles have been inserted.~* After needling: Patient may feel slight pain in the ear area or de qi (a sensation of aching, warmth, and redness at the needling site)."
219626395|NCT06874959|DEVICE|Electro-acupuncture|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khánh Phong ARLO acupuncture needles, size 0.3 x 25 mm (lincense: TKHQ:102664344900)~* Disinfect the lumbar region skin.~* Needle insertion: Insert needles perpendicular to the patient's skin, to a depth of 20 mm. Location: Dai truong du (BL25), Than du (BL23), Jiaji at L4-L5, L5-S1 (Ex-B2), Uy trung (BL40), Yeu duong quan (GV3). After insertion, attach the electrode clips to the needle ends.~* Electric stimulation: Use a current of 100Hz for 20 minutes - mixed wave.~* Post-needling: Patient may feel a sensation of de qi (aching, warmth, and redness at the needling site)."
219626396|NCT06874959|DRUG|Paracetamol 500 mg|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~* Prescriber: Traditional medicine doctor with a practicing certificate.~* Paracetamol 500mg x 9 tablets: Take 1 tablet per dose, to be used when the pain score on the Visual Analog Scale (VAS) is ≥ 30mm, not exceeding 6 tablets/day. (If the patient still has medication from the previous visit, only prescribe the total amount needed to make up 9 tablets)."
219626397|NCT06874959|DEVICE|Sham ear acupuncture|"Study uses patches with non-skin-penetrating cotton, at the intervention acupoint areas. Using acupoints matching with the intervention group helps reduce the patients' ability to predict their study group, and the non-penetrating and non-rotating cotton ensure that there is no analgesic effect on the lumbar area caused by auriculotherapy.~Acupoint location: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero points"
219626398|NCT07029932|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability, and PK data from SAD and previous MAD cohorts. Daily dosing will continue for a total of 7-10 consecutive days (as per schedule)."
219626399|NCT07029932|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive a matching placebo.
219626400|NCT06499129|BEHAVIORAL|Sensory ball, progressive relaxation exercise, training|The effect of sensory ball use on fatigue, peripheral neuropathy and anxiety will be examined
219626401|NCT07027046|PROCEDURE|Robotic surgical staging|The intervention includes hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping, with possible lymphadenectomy or omentectomy, depending on histology.
219626402|NCT07036692|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
219626403|NCT07036692|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
219626404|NCT06713369|DRUG|Saruparib (AZD5305)|PARP-inhibitor
219626405|NCT06713369|DRUG|[14C]-AZD5305 microtracer|IV radiolabeled microtracer
219626406|NCT06713369|DRUG|[14C]-AZD5305 (therapeutic dose)|IV radiolabeled PARP inhibitor
219626407|NCT04948580|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
219626408|NCT00259181|PROCEDURE|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
218937214|NCT04815148|DRUG|MH004 Ia(3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
218937215|NCT04815148|DRUG|MH004 Ib-1(0.1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
219626409|NCT02448485|PROCEDURE|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
219626410|NCT01825473|DRUG|Erythromycin|
218937216|NCT04815148|DRUG|MH004 Ib-1(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
218937217|NCT04815148|DRUG|MH004 Ib-1(1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
218937218|NCT04815148|DRUG|MH004 Ib-2(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
218937219|NCT04815148|DRUG|MH004 Ib-2(1%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
218937220|NCT04815148|DRUG|MH004 Ib-2(3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
218937221|NCT03146299|PROCEDURE|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
218937222|NCT03284281|DEVICE|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
219548858|NCT02600247|DRUG|Duloxetine|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
219548859|NCT02600247|DRUG|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
219626411|NCT01825473|DEVICE|Multi-channel intra-luminal impedance (MII) pH monitoring|
219626412|NCT01825473|DRUG|Placebo (D5W)|
219626413|NCT05359354|BIOLOGICAL|Personalized neoantigen tumor vaccine|Biological: neoantigen tumor vaccine with or without PD-1 In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1
219626414|NCT00722969|DRUG|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
219626415|NCT03048214|PROCEDURE|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
219626416|NCT03048214|PROCEDURE|General anaesthesia|Usual practice for upper limb surgeries.
219626417|NCT05479864|PROCEDURE|anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
219626418|NCT03177291|DRUG|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
218937223|NCT03284281|DEVICE|Sham Tragus stimulator|No stimulation will be performed
218937224|NCT05159336|DEVICE|tACS for auditory hallucinations via single arm|a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
219548860|NCT03410030|DRUG|Ascorbic Acid|combination therapy
219548861|NCT03410030|DRUG|Paclitaxel protein-bound|combination therapy
219548862|NCT03410030|DRUG|Cisplatin|combination therapy
219548863|NCT03410030|DRUG|Gemcitabine|combination therapy
219548864|NCT02597257|DRUG|Lidocaine HCl|lidocaine continuous infusion
219548865|NCT02597257|DRUG|Normal saline|Normal saline continuous infusion
219548866|NCT00869713|BIOLOGICAL|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
219548867|NCT05947097|DRUG|HSK21542 Injection|1ug/kg bolus for 2min±5s
219548868|NCT05501158|DRUG|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
219548869|NCT02090933|DRUG|Celecoxib|Given PO
219548870|NCT02090933|OTHER|Laboratory Biomarker Analysis|Correlative studies
219548871|NCT02090933|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
219548872|NCT04158687|DRUG|CTP-692|Administered as powder for oral solution.
219548873|NCT04158687|DRUG|Placebo|Administered as powder for oral solution.
219548874|NCT04229914|OTHER|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
219548875|NCT05458960|BEHAVIORAL|Social needs navigator program|4 months of assistance tailored to the needs of the participant
219548876|NCT05458960|BEHAVIORAL|Enhanced usual care|Referral to United Way 2-1-1
219548877|NCT01595841|DRUG|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
219548878|NCT03062176|DRUG|Anakinra|Anakinra (Kineret)
219548879|NCT05001191|OTHER|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
219548880|NCT02026362|BIOLOGICAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
219548881|NCT02026362|OTHER|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
219548882|NCT01169272|DEVICE|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
219548883|NCT03470116|DEVICE|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
219548884|NCT03470116|DEVICE|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
219548885|NCT05228717|DIAGNOSTIC_TEST|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
219548886|NCT02563418|DEVICE|Eye-tracking|
219548887|NCT02663856|OTHER|observational|Self assessment of ageing transition using a frailty index through MySAwH app
219548888|NCT06504121|DEVICE|Septal Occluder Device|Transcatheter PFO closure with any commercially available septal occluder device
219548889|NCT03609333|DEVICE|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
219626419|NCT03177291|DRUG|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
219626420|NCT03177291|DRUG|Paclitaxel|200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
219626421|NCT03177291|DRUG|Pemetrexed|500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
219626422|NCT00571727|DRUG|mecasermin|injections BID of rhIGF-1, mecasermin
219626423|NCT06779630|DEVICE|Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System|Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
219626424|NCT06802185|DRUG|ADA Liquid Filled Capsules (Test Product)|ADA liquid filled capsules containing 125 mg ibuprofen and 250 mg acetaminophen.
219626425|NCT06802185|DRUG|ADA Caplets (Reference Product)|ADA Caplets containing 125 mg ibuprofen and 250 mg acetaminophen.
219626426|NCT06802185|DRUG|Advil Liqui-gels (Reference Product)|Advil Liqui-gels containing 200 mg ibuprofen.
219626427|NCT06930716|DEVICE|Transcutaneous vagus nerve stimulation (taVNS)|A non-invasive nerve stimulator that stimulates the vagus nerve through the ear.
219626428|NCT06930716|DEVICE|Physical therapy using Hocoma|Progressive verticalization and mobilization using a robotic tilt table with robotic stepping (Erigo, Hocoma)
219626429|NCT06930716|BEHAVIORAL|Standard of Care|Standard of care with no study interventions. This will include observation of whatever rehabilitation or medical care the patient is currently receiving.
219626430|NCT06928402|OTHER|No intervention|no interventions will be performed by the research team
219626431|NCT06903884|DRUG|3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
219626432|NCT06903884|DRUG|0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
219626433|NCT06907784|DIAGNOSTIC_TEST|Pharmacogenomic testing|The PGx testing will analyse genetic variants across 16 key pharmacogenes in each given DNA sample, all of which focus on variants with established implications for drug response as recommended by published Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines Testing will be performed immediately in the intervention arm or at three months in the standard of care arm.
219626434|NCT06807021|DRUG|IP1 control cream (Vehicle base)|Without FS2
219626435|NCT06807021|DRUG|IP2 - 0.5% w/w FS2|FS2 in pharmaceutical compounding base
219626436|NCT07090148|BIOLOGICAL|pTVG-HP DNA vaccine|The vaccine will be injected into the outer side of the upper area of the arm in two adjacent sites, with 0.25 mL administered at each site.
219626437|NCT07090148|DRUG|Anti-PD-1 monoclonal antibody|Nivolumab is a potent human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Participants will receive two 10mg doses.
219626438|NCT02873637|DEVICE|under sartorial catheter|
219626439|NCT02873637|DEVICE|femoral catheter|
219626440|NCT06928272|DRUG|Pirfenidone|"Initial dose titration:~First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day)~Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day)~Maintenance dose:~Third week and thereafter (days 15-90): 3 capsules (801 mg), 3 times daily (2403 mg/day)"
219626441|NCT06928272|DRUG|Placebo for pirfenidone|"First week (days 1-7): 1 capsule, 3 times daily~Second week (days 8-14): 2 capsules, 3 times daily~Third week and thereafter (days 15-90): 3 capsules, 3 times daily"
219626442|NCT06928272|DRUG|Upadacitinib|1 capsule (15 mg), once daily for 90 days
219626443|NCT06928272|DRUG|Placebo for upadacitinib|1 capsule, once daily for 90 days
219626444|NCT05944562|DRUG|Tulmimetostat|Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.
219626445|NCT07102615|DRUG|Intracervical injection of Vasopressin|Intracervical injection of Vasopressin
219626446|NCT07102615|DRUG|Intracervical Injection of saline|Intracervical Injection of saline
219626447|NCT06773767|DRUG|150 mg trazodone hydrochloride|To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.
219626448|NCT06773767|DRUG|300 mg trazodone hydrochloride|To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state
219626449|NCT07103850|DIAGNOSTIC_TEST|Suicidal Crisis Syndrome Checklist (SCS-C)|The Suicidal Crisis Syndrome Checklist (SCS-C) is a clinician-rated tool designed to diagnose Suicidal Crisis Syndrome (SCS), a suicide-specific state associated with imminent risk. It includes Criterion A (entrapment)-a required symptom-and Criterion B, which requires at least one symptom from each of four domains: affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The checklist offers a structured assessment for identifying acute suicide risk, complementing traditional risk evaluations.
219626450|NCT07103850|DIAGNOSTIC_TEST|Suicide Crisis Inventory-Revised (SCS-2)|The Suicide Crisis Inventory-Revised (SCS-2) is a 61-item self-report scale developed to assess the severity of Suicidal Crisis Syndrome (SCS), a clinical state associated with imminent suicide risk. Items are rated on a Likert scale and grouped into five empirically derived factors: entrapment, affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The SCS-2 has shown strong internal consistency and predictive validity for suicidal behavior within weeks of discharge. It is currently undergoing cultural adaptation and psychometric validation in Spanish for use in high-risk psychiatric populations in Chile.
219626451|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219626452|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219626453|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219626454|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
219626455|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
219626456|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
219626457|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
219626458|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219626459|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
219626460|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
219626461|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
219626462|NCT06236815|DRUG|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
219626463|NCT06236815|DRUG|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
219626464|NCT06236815|DRUG|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
219626465|NCT05711615|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219626466|NCT05711615|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219626467|NCT05711615|PROCEDURE|Computed Tomography|Undergo CT scan
219626468|NCT05711615|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219626469|NCT05711615|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219626470|NCT05711615|DRUG|Peposertib|Given PO
219626471|NCT07107763|OTHER|short foot exercise|The short foot exercise group will receive stretching exercises and short foot exercises, administered three sessions per week for a duration of six weeks.
219626472|NCT07107763|OTHER|Mobilization|The mobilization group will undergo a program consisting of 3 sessions per week for a duration of 6 weeks. The sessions will begin with stretching exercises, followed by subtalar joint mobilization.
219626473|NCT07107763|COMBINATION_PRODUCT|Short foot exercise and mobilization|The combined intervention used in this group will include both of the approaches applied in the other two groups.
219626474|NCT07103720|DIAGNOSTIC_TEST|Skin Testing|Participants will undergo skin prick testing and intradermal test injections at 5 increasing concentrations of midazolam, ketamine and/or ondansetron during one single study visit.
219626475|NCT07110844|DRUG|Teclistamab|Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
219626476|NCT07110844|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
219626477|NCT06921317|DRUG|GVB-2001-high dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of high dose GVB-2001 will be injected intracamerally to the target interventional eye.
219626478|NCT06921317|DRUG|GVB-2001-low dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of low dose GVB-2001 will be injected intracamerally to the target interventional eye.
219626479|NCT07115680|OTHER|human participants, data or material|Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies
219626480|NCT07114380|DEVICE|Cold snare polypectomy|Unlike traditional hot snare polypectomy or endoscopic mucosal resection, which use electrocautery to resect larger or pedunculated polyps, cold snare polypectomy uses mechanical transection alone without cautery. The procedure is performed using a dedicated cold snare by experienced endoscopists.
219626481|NCT07116148|OTHER|The Homeostasis-Enrichment-Plasticity (HEP®) Approach|The HEPApproach intervention and clinical reasoning process follow a systematic order based on the data-driven decision-making model. There are 11 phases to the HEP Approach process. Phase 1 involves referral to the program. Phase 2 includes a meeting with the family to introduce them to the HEP Approach. Phase 3 is a comprehensive assessment of the child and family systems. Phase 4 is the identification of family and child strengths and challenges based on the assessment. Phase 5 involves formulating hypotheses about how underlying factors or systems impact the child's challenge areas. Phases 6 and 7 include collaborative goal setting and outcome measure identification with the family. Phase 8 is intervention planning. Phase 9 implements the intervention through an individualized process that generally involves four steps that prioritize different areas of need (e.g., self-regulation and homeostasis of the child, adaptation of the physical and social home environment to support succes
219626482|NCT07139990|RADIATION|Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|Radiographic response-adapted thoracic tumor radiotherapy given as single doses ('pulses') before standard of care chemoimmunotherapy cycles. Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction) Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction)
219626483|NCT07139990|RADIATION|Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|"Intervention: Fractionated stereotactic radiosurgery (SRS, 5 doses total) for brain metastasis given in two pulses (3 fractions + 2 fractions) with second pulse adapted to interim radiographic response Adaptive Changes Allowed: Omission of 2nd pulse in \>=25% responders or tumor target size/shape change in remainder"
219626484|NCT07137585|DRUG|Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
219626485|NCT07137585|DRUG|RO7204239|RO7204239 will be administered as per the schedule specified in the treatment arm.
219626486|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
219626487|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
219548890|NCT03856034|DEVICE|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
219548891|NCT04102345|OTHER|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
219548892|NCT04102345|DRUG|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
219548893|NCT03334149|OTHER|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
219548894|NCT04271072|OTHER|No intervention|No intervention
219548895|NCT05031858|OTHER|Respiratory physiotherapy|Respiratory physiotherapy
219548896|NCT01545349|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
219548897|NCT01545349|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
219548898|NCT01545349|BIOLOGICAL|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
219548899|NCT03028545|BEHAVIORAL|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
219548900|NCT00199654|PROCEDURE|PET|
219548901|NCT01741545|BIOLOGICAL|Pegylated-Interferon-lambda|
219548902|NCT01741545|DRUG|Ribavirin|
219548903|NCT01741545|DRUG|Daclatasvir|
219548904|NCT03406845|BEHAVIORAL|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
219548905|NCT01828294|DRUG|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
219548906|NCT00015665|DRUG|Voriconazole|
219548907|NCT06560450|DEVICE|Stride One|Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
219548908|NCT04628975|DEVICE|transillumination dispositif|infrared light
219548909|NCT05063630|PROCEDURE|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
219548910|NCT05063630|DRUG|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
219548911|NCT02464904|PROCEDURE|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
219548912|NCT02464904|OTHER|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
219548913|NCT00731367|DEVICE|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
219548914|NCT00731367|DEVICE|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
219548915|NCT01816360|OTHER|Olfactory aromatherapy|Inhalation of essential oils.
219548916|NCT01816360|OTHER|Yogatherapy|Yogatherapy respiratory exercises.
219548917|NCT02401139|DRUG|Ketamine|
219548918|NCT02401139|DRUG|Placebo|
219548919|NCT03271996|PROCEDURE|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
219548920|NCT03271996|PROCEDURE|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
219548921|NCT03330496|OTHER|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
219548922|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
219548923|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
219548924|NCT01853176|DRUG|Liposomal Injection Bupivacaine (Exparel)|
219548925|NCT01853176|DRUG|Standard bupivicaine|
219548926|NCT02082834|OTHER|abdominal MDCT examination|
219548927|NCT00198133|DRUG|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
219548928|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
219548929|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
219548930|NCT06359275|DRUG|PD-1|Toripalimab，240 mg/time，D1， Q3W
219548931|NCT06359275|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
219548932|NCT06359275|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，IV，D1，8，Q3W
219548933|NCT06359275|RADIATION|PULSAR|5-10 Gy per session, a total of 5 times.
219548934|NCT03332264|DEVICE|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
219548935|NCT03332264|DEVICE|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
219548936|NCT03332264|DEVICE|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
219548937|NCT00175669|DRUG|Botox injections|Data not known.
219548938|NCT01125527|BIOLOGICAL|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
219548939|NCT01125527|BIOLOGICAL|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
219548940|NCT04863144|OTHER|Blood samples|Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.
219548941|NCT05037318|BEHAVIORAL|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
219548942|NCT05037318|BEHAVIORAL|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
219548943|NCT06152796|DRUG|Paracetamol|Anti\_inflammatory drug
219548944|NCT06152796|DRUG|Ibuprofen|Non steroidal anti\_inflammatory drug
219548945|NCT01323127|PROCEDURE|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
219548946|NCT00000124|PROCEDURE|Brachytherapy|
219548947|NCT00000124|PROCEDURE|Eye Removal|
219548948|NCT03694106|BEHAVIORAL|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
219548949|NCT03200145|OTHER|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. \- Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. \- Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users."
219548950|NCT00496860|BIOLOGICAL|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
219548951|NCT05206162|DEVICE|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
219548952|NCT01219140|DIETARY_SUPPLEMENT|2 POMx Capsules|2 POMx Capsules daily
219548953|NCT01219140|DIETARY_SUPPLEMENT|2 placebo Capsules|2 placebo Capsules daily
219548954|NCT05320237|OTHER|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
219548955|NCT05797207|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
219548956|NCT05797207|PROCEDURE|Colonoscopy|Colonoscopy procedure
219548957|NCT01449188|DRUG|ondansetron|FDA approved drug used to treat nausea and vomiting
219548958|NCT01449188|DRUG|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
219548959|NCT01449188|OTHER|saline|USP saline IV solution used as placebo for ondansetron IV.
219548960|NCT03099915|OTHER|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
219548961|NCT02518945|DRUG|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
219548962|NCT02518945|DRUG|Insulin|
219548963|NCT02518945|DRUG|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
219548964|NCT02518945|DRUG|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
219548965|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
219548966|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
219548967|NCT04716582|BEHAVIORAL|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
219548968|NCT04716582|BEHAVIORAL|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
219548969|NCT04716582|BEHAVIORAL|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
219548970|NCT02247362|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
219548971|NCT02247362|OTHER|Placebo|Vaccine Diluent
219548972|NCT02531620|OTHER|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
219548973|NCT02531620|OTHER|Routine Care|Usual care for your disease process
219548974|NCT04993274|DIAGNOSTIC_TEST|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
219548975|NCT01887522|DRUG|Vinblastine + Nilotinib|"* Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
219548976|NCT01887522|DRUG|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
219548977|NCT00348764|DRUG|lauromacrogol|
219548978|NCT00028587|DRUG|bortezomib|Given IV
219548979|NCT00028587|DRUG|paclitaxel|Given IV
219548980|NCT00028587|DRUG|carboplatin|Given IV
219548981|NCT00028587|OTHER|laboratory biomarker analysis|Optional correlative studies
219548982|NCT01537887|DRUG|LY2484595|Administered orally once daily for 10 days.
219548983|NCT01537887|DRUG|Placebo|Administered orally once daily for 10 days.
219548984|NCT01537887|DRUG|Moxifloxacin|Single dose administered orally.
219548985|NCT01370083|BEHAVIORAL|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
219548986|NCT01370083|BEHAVIORAL|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
219548987|NCT05251727|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment
219548988|NCT05251727|DRUG|Placebo|Weight based dose of reconstituted treatment
219548989|NCT01167829|DRUG|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
219548990|NCT01167829|DRUG|Acyline|300 ug/kg injection on Day 0
219548991|NCT04286074|OTHER|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
219548992|NCT04286074|OTHER|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
219548993|NCT05744492|OTHER|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
219548994|NCT03774329|OTHER|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
219548995|NCT03774329|OTHER|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
219548996|NCT03291145|DRUG|Beta Blockers|With and without Beta Blockers
219548997|NCT03291145|DRUG|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
219548998|NCT00731939|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
219048159|NCT07172204|DRUG|Alternately treated with VA/low CHA regimen|"1. Induction Phase (4 alternating cycles):~   Participants will receive 4 cycles of alternating therapy:~  * VA Cycle:~     * Venetoclax 400 mg PO daily on Days 1-28~    * Azacitidine 75 mg/m² SC/IV daily on Days 1-7~  * Low-dose CHA Cycle:~     * Cladribine 5 mg/m² IV daily on Days 1-3~    * Homoharringtonine 1 mg/m² IV daily on Days 1-5~    * Cytarabine 20 mg SC every 12 hours on Days 1-10 Alternating sequence: VA → CHA → VA → CHA → VA → CHA → VA → CHA The interval between the VA to low-CHA is 2 weeks, and the interval between the two alternations (one alternation is VA plus low-CHA）is 4 weeks.~2. Maintenance Phase (24 months):~Following induction, participants will receive:~* Venetoclax 400 mg PO daily on Days 1-28~* Azacitidine 75 mg/m² SC/IV daily on Days 1-7 Repeated every 28 days for 24 cycles. The interval between the two cycles is 2 weeks."
219626488|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
219626489|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
219626490|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
219626491|NCT01125397|BEHAVIORAL|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
219626492|NCT07139106|DRUG|Ketamine hydrochloride infusion|single racemic ketamine hydrochloride 0.5 mg/kg infusion
219626493|NCT07141446|DRUG|Neem gel|1.5% Neem Gel in orabase formulation, twice daily application for 3 months
219626494|NCT07141446|DRUG|Triamcinolone Acetonide|0.1% oral paste to be applied twice daily for 3 months
219626495|NCT06944535|PROCEDURE|Modified Lip Repositioning Surgery (Retrospective)|Patients previously underwent a modified lip repositioning surgery technique without frenectomy and without myotomy. For this retrospective study, only existing medical records and clinical photographs were reviewed. No new surgical intervention was performed.
219626496|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
219626497|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219626498|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
219626499|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
219626500|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
219626501|NCT05723094|RADIATION|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
219626502|NCT05723094|OTHER|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
219626503|NCT01226160|PROCEDURE|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
219626504|NCT01226160|PROCEDURE|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
219626505|NCT06948825|DRUG|Metformin Hcl 850Mg Tab|Participants randomized to Metformin will have a prescription of Metformin 850mg orally twice a day. The participant will get blood drawn for testing, undergo a urine pregnancy test, and meet with the study provider to discuss the medication.
219048160|NCT07172737|OTHER|Respiratory Muscle Training|Respiratory Muscle Training with Telerehabilitation
219048161|NCT07172646|DRUG|SRSD216 injection|Administered SC.
219048162|NCT07172646|DRUG|Placebo|Administered SC.
219626506|NCT06948825|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will meet once a week via zoom with the study health counselor to go over lesson plans. After 4 weeks, participants will meet via zoom every other week.
219626507|NCT06948825|BEHAVIORAL|Enhanced Lifestyle Intervention|Participants in the Enhanced Lifestyle Intervention will meet every other week, and will get a free instacart membership to have access to free grocery delivery. Additionally, participants in this intervention will have a 1:1 virtual meeting focused on meal planning with the study health counselor.
219626508|NCT02573597|DRUG|Bupivacaine|Continuous or bolus administration
219626509|NCT02573597|DRUG|Sufentanil|Continuous or bolus administration
219626510|NCT04409145|DRUG|VT30|VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
219626511|NCT03285347|DEVICE|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
219626512|NCT07140809|BIOLOGICAL|JMT202 injection|Subcutaneous injection
219626513|NCT07140809|OTHER|Placebo|Matching Placebo
219626514|NCT07148245|PROCEDURE|Blood Sample|Blood samples will be collected
219626515|NCT07148245|OTHER|Health Related Quality of Life Questionnaires (HRQoL)|Participants may be given HRQoLs during the course of data collection
219626516|NCT07148245|OTHER|Medical Chart Review|Participants will undergo medical charts review during the course of data collection
219626517|NCT06952894|DEVICE|RUS Lung|The RUS Lung is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the thoracic surgical environments, allowing for the visualization of tumor, bronchovascular structures and thoracic organs during the surgical planning process and the operation. RUS Lung utilizes preoperative CT images of the patients to segment tumor, organs, blood vessels, and bronchus and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS Lung as a surgical navigation tool to simulate the surgery before performing the actual procedure.
219626518|NCT06953583|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
219626519|NCT06953583|DRUG|Placebo|Administered as specified in the treatment arm.
219626520|NCT07152392|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 500-mg glass vials as a Injection solution containing.
219626521|NCT07152392|OTHER|Follew-up|recived follow-up every six months
219626522|NCT07153146|DRUG|PN-881 Oral Solution|PN-881 Oral Solution
219626523|NCT07153146|DRUG|PN-881 Oral Tablet|PN-881 oral tablet
219626524|NCT07153146|DRUG|Placebo|Placebo
219626525|NCT07153120|DEVICE|Erich Arch Bars|Stainless steel plates with hooks for wire placement are adapted over the facial aspect of teeth so the wires would be inserted to go around the necks of teeth (circumdental wiring), then both maxillary and mandibular plates are ligated to each other in order to achieve MMF.
219626526|NCT07153120|DEVICE|Hybrid Arch Bars|Screw retained titanium plates with hooks for wires are adapted properly then self drilling self locking screws will be drilled in between roots of teeth to avoid injury, after fixation both jaws will be wired to accomplish MMF
219626527|NCT07153120|DEVICE|IMF Screws|A total of four self drilling screws two in the maxilla and the other two in the mandible will be inserted in the bone above and below teeth roots apices to avoid injury, to be ligated to each other in a vertical and an X pattern to achieve MMF.
219626528|NCT07152041|DRUG|olverembatinib|"All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen.~OVB is combined with Vincristine and Prednisone (VP) during the first 2 weeks and with blinatumomab during the last 4 weeks of remission induction in this protocol.~Patients will receive blinatumomab for 28 days as induction instead of CAT to improve induction response and avoid toxicity.~All patients will receive two cycles of HDMTX+Blina-14 and 4 times of triple intrathecal therapy (TIT) throughout the consolidation 1 phase.~To decrease the toxicities of high-dose AraC, the dosage will be reduced to 1 g/m2 in the consolidation 2 phase in contrast to 2 g/m2 in 2020 protocol.~Throughout the early Maintenance Therapy, dexamethasone and vincristine combination will be added with either venetoclax or daunorubicin alternatively for five cycles, given after MTX and 6-MP."
219626529|NCT07151092|BEHAVIORAL|Adolescent Grief Group|The intervention will include psycho-education, peer-support, and professional supportive counseling from licensed clinicians.
219626530|NCT07152717|DEVICE|A connected-health, pressure-sensing system for monitoring sub-bandage pressure during compression therapy|The Tight Alright system, developed by FeelTect Limited, consists of a wearable, pressure sensing device that measures sub-bandage pressure at three regions along the length of the lower leg. The wearable device transmits data wirelessly to a mobile app on a smart device, which then displays the data in real-time. The mobile app is also capable of transmitting data to a remote cloud database, via the internet, where it can be viewed on a remote dashboard (i.e., via a secure webpage).
219626531|NCT07151781|OTHER|Video-guided Mindfulness Exercise|Mindfulness interventions are emerging as effective, low-risk approaches to managing depression and enhancing emotional and maternal well-being in pregnant women. Rooted in ancient meditative practices that originated from Buddhist religion and traditions and adapted for clinical use, mindfulness intervention cultivates present-moment awareness and nonjudgmental acceptance of thoughts, emotions, and bodily sensations. Mostly, mindfulness interventions include elements such as mindful breathing and body scanning and have shown effectiveness in reducing depressive symptoms and enhancing emotional regulation. It is the ability to maintain attention to an immediate experience with a sense of adopting an open and accepting attitude toward that experience. However, further research is important to evaluate its effectiveness across diverse sociodemographic and socioeconomic settings.
219626532|NCT07151612|DRUG|Esculin and Digitalisglycosides Eye Drops|Interventions were performed using esculin and digitalis glycosides eye drops (Pharma Stulln GmbH). The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface. The treatment lasted for 1 month.
219626533|NCT07151612|DRUG|Normal saline solution|Sterile, preservative-free, and non-irritating dropper saline was used. The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface.
219626534|NCT07151638|DEVICE|Implantation (injection) of a new biomatrix for soft tissue support.|Implantation of a new injectable medical device, Fractomer Biomatrix, to study the safety of the product in healthy human participants.
219626535|NCT07151209|DRUG|Iparomlimab and Tuvonralimab combined with lenvatinib and SOX|Iparomlimab and Tuvonralimab:5 mg/kg Q3W lenvatinib:8 mg/day orally SOX：oxaliplatin (130 mg/m² Q3W intravenous infusion), and S-1 (40 mg/m² BID orally on days 1-14)
219626536|NCT07151157|DRUG|add-on sirolimus therapy|On the basis of the existing treatment, oral sirolimus will be added at a dose of two capsules per day, one in the morning and one in the evening.
219626537|NCT07152964|DEVICE|Caliper|Measure medial rectus tendon width with caliper intraoperative
219626538|NCT07152886|DRUG|Clostridium butyricum capsules|Clostridium butyricum capsules , 6 capsules tid (each capsule containing ≥6.3 × 10⁶ CFU of Clostridium butyricum).
219626539|NCT07152886|OTHER|placebo capsules|Oral administration of placebo capsules, 6 capsules tid., containing corn starch. The appearance and weight of the placebo capsules are identical to those of intervention group.
219626540|NCT07151599|DEVICE|Microneedling|Microneedling performed with an electronic pen and sterile disposable cartridge with 12 needles and 2mm depth, three treatment sessions at four-week intervals.
219626541|NCT07151599|DEVICE|Fractionated Er:Glass Laser combined to Fractionated Thulium Laser|Fractional Erbium:Glass laser will be applied first, focused on scarred areas (50 mJ, 15 ms e 100 PPA) , followed immediately by fractional Thulium 1927 nm over the full face (10 mJ, 1 ms e 100 PPA), three treatment sessions at four-week intervals.
219626542|NCT07151742|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|"Participants in this arm will receive a 12-week intradialytic combined exercise program, performed three times per week during the first two hours of hemodialysis. Each session will begin with a 10-minute warm-up and end with a 10-minute cool-down (stretching and breathing exercises).~Aerobic component: Supine cycling using a portable ergometer at 45-70% of maximum heart rate, monitored with pulse oximetry and Borg scale, progressively increased every 1-2 weeks.~Resistance component: Exercises with elastic bands and ankle weights targeting major upper and lower extremity muscle groups (non-fistula arm). Performed in 2 sets of 8-12 repetitions, with progressive loading based on ACSM guidelines.~All sessions will be supervised by trained physiotherapists and dialysis staff to ensure safety and adherence"
219626543|NCT07153159|DRUG|Etrasimod|Oral 2 milligrams tablet, once a day for 7 days
219626544|NCT07152067|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the macroscopic prostate tumor component defined at MRI
219048163|NCT07172048|DIAGNOSTIC_TEST|Foot pressure Distribution test|"This study is observational and does not involve any therapeutic or experimental intervention. Participants will be divided into two groups based on their scoliosis curve pattern:~Group 1: Adolescents with a major thoracic curve. Group 2: Adolescents with a major lumbar curve.~Each participant will undergo non-invasive assessments including:~Baropodometric foot pressure analysis during static standing to evaluate pressure distribution in both coronal and sagittal planes.~Radiographic evaluation to classify curve patterns using Cobb's angle, Central Sacral Vertical Line, and Plumb Line."
219626545|NCT07153354|DEVICE|patient-specific screw holes locating surgical guide and pre-bent plates|Virtual reduction of the fracture will be done, followed by 3D printing of the corrected mandible model. Plates will be pre-bent on the model, then scanned in position to create a surgical guide for accurate screw hole placement during surgery.
219626546|NCT07153354|DEVICE|2 titanium per-bent mini plates|The fixation will be performed according to established surgical principles for managing class iv mandibular fractures, without patient-specific planning
219626547|NCT07153094|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
219626548|NCT07151859|DEVICE|PN30 (RDM16)|PN30 is a viscoelastic, sterile gel, in a disposable prefilled syringe for intradermal infiltration.PN30 contains polynucleotides (3%). The polynucleotides contained in the device are substances of natural, fish-derived origin, highly purified.
219626549|NCT07155746|OTHER|Incremental walking exercise on an AlterG treadmill (anti-gravity)|One visit with their current weight (BW) One visit with simulated weight loss in adolescents to determine their normal weight (NW-SBW) One visit with simulated weight loss in adolescents to determine their overweight status (OW-SBW).
219626550|NCT07152340|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
219626551|NCT07152340|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
219626552|NCT07153172|DRUG|INV-347|Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
219626553|NCT07151131|OTHER|Watching Cartoons|"Cartoon Group Intervention Children assigned to the cartoon group will be taken from the clinic to the preoperative room. Approximately 30 minutes before being transferred to the operating room, children will be allowed to watch a cartoon of their choice on a 60-inch screen TV placed approximately 200 cm away. The duration of the cartoon viewing session will be limited to 20 minutes.~The measurement tools used in the study will be administered at five different time points:~Immediately before watching the cartoon,~Immediately after watching the cartoon but before being transferred to the operating room,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, at the discharge phase."
219626554|NCT07151131|OTHER|Reflexology|"Massage Group Intervention Children assigned to the massage group will be transferred from the clinic to the preoperative room. Approximately 30 minutes before being taken to the operating room, reflexology massage will be applied by the researcher physician Xxx XXXXX, who holds a valid reflexology certification. The massage will be administered to both the right and left feet, with 10 minutes per foot, for a total duration of 20 minutes.~The measurement tools used in the study will be applied at five distinct time points:~Before the massage,~Immediately after the massage but before operating room transfer,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, during the discharge phase."
219626555|NCT07151300|DEVICE|Ultrasound therapy unit|Ultrasound therapy unit
219626556|NCT07151300|BIOLOGICAL|Bee venom topical preparation (for phonophoresis)|Bee venom topical preparation (for phonophoresis)
219626557|NCT07151456|DRUG|Conventional 24-week glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg/kg/day (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg/kg/day (max 50mg); Weeks 9 - 10: Prednisolone 0.5mg/kg/day (max 40mg); Weeks 11 - 12: Prednisolone 0.4mg/kg/day (max 30mg); Weeks 13 - 16: Prednisolone 0.3mg/kg/day (max 25mg); Weeks 17 - 20: Prednisolone 0.2mg/kg/day (max 15 Weeks 21 - 24: Prednisolone 0.1mg/kg/day (max 10mg).
219048164|NCT07172373|PROCEDURE|antegrade flexible ureteroscopy-assisted PCNL|antegrade flexible ureteroscopy-assisted PCNL
219626558|NCT07151456|DRUG|short-term course (12 week) glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5-8: Prednisolone 1mg/kg/day (max 80mg) on alternate days; 9-12: Prednisolone 0.5mg/kg/day (max 40mg) on alternate days
219048165|NCT07172373|PROCEDURE|single PCNL|single PCNL
219626559|NCT07151911|DRUG|abemaciclib, olaparib and endocrine therapy|Patients receiving abemaciclib, olaparib and endocrine therapy.
219626560|NCT07151183|OTHER|No intervention|No intervention
219626561|NCT07154368|DRUG|Pemetrexed injection|Randomization to either JYP0322 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (JYP0322: platinum-based doublet-chemotherapy) ratio
219626562|NCT07154368|DRUG|Cross-over to JYP0322|Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by BICR, they will be given the opportunity to begin treatment with JYP0322 150mg tid. These subjects may continue treatment with JYP0322 if they are continuing to show clinical benefit until disease progression as judged by the investigator.
219626563|NCT07154368|DRUG|JYP0322 tablets|JYP0322, 150 mg, administered orally three times daily (tid) after meals; sample size (N) = 60.
219626564|NCT07153302|OTHER|Prunus dulcis (sweet almonds)|Almonds are functional food items that contain bone essential micronutrients.
219626565|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
219626566|NCT07151872|DRUG|QLS31905 for Injection|QLS31905 for Injection
219626567|NCT07151872|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection
219626568|NCT07151872|DRUG|Cisplatin for Injection|Cisplatin for Injection
219626569|NCT07151872|DRUG|QL2107 Injection|QL2107 Injection
219626570|NCT07151872|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
219626571|NCT07151872|DRUG|Capecitabine Tablets|Capecitabine Tablets
219626572|NCT07152379|DEVICE|INTERCEPT RBCs|Transfusion of fresh (≤14 days old) allogeneic INTERCEPT RBCs.
219626573|NCT07152795|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
219626574|NCT07152795|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
219626575|NCT07152678|DRUG|Nivolumab (240 mg)|After the first cycle of nivolumab administered in the screening phase (1st cycle), nivolumab in the study phase was administered intravenously over 30 minutes at a dose of 240 mg every 2 weeks for at least 2 doses, with 1 cycle after to first brachytherapy (2nd cycle), and 1 more cycle after to second brachytherapy (3rd cycle) if feasible. (each cycle was 2 weeks), until disease progression assessed by the investigator per RECIST version 1.1, or unacceptable toxicity.
219626576|NCT07152678|RADIATION|Brachytherapy|Brachytherapy protocol starts within 3 weeks after first cycle of nivolumab was administered. After brachytherapy applicator placement, CT simulation scan(s) with dummy source in place will be done for further planning procedure, including adjustment of the applicator and 3D treatment planning. High-dose-rate (HDR) 5-Gy per fraction is delivered to the gross tumor volume (GTV) of esophageal tumor(s), second treatment if applicable will be finished within 2 weeks after the first fraction, a total of 5-12 Gy in 1-2 fractions will be delivered. GTV coverage D90 should equal 100% of prescription. Efforts should be made to spare the adjacent normal organ and to avoid hot spot on normal esophageal mucosa. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.
219626577|NCT07152158|OTHER|multicomponent training combined with multi-professional intervention|The MCT protocol consisted of an initial three-week period of neuromotor adaptation characterized by low volume and intensity. In the subsequent weeks, a gradual progression of volume and intensity was implemented (Table 1), following a classic linear periodization model (Fleck \& Kraemer, 2017; Prestes et al., 2016).
219626578|NCT07151651|PROCEDURE|Endoscopic lumbar discectomy|Uniportal and boportal endoscopic lumbar discectomy (transforaminal or interlaminar)
219626579|NCT07151989|PROCEDURE|Mitral valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
219626580|NCT07152223|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
219626581|NCT07153068|BIOLOGICAL|supCD7 CART cells|Subjects screened to meet the requirements for supCD7 CART cells use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to supCD7 CART cells infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of supCD7 CART cells must be performed 24 hours after completion of chemotherapy preconditioning. supCD7 CART cells can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
219626582|NCT07151755|PROCEDURE|Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care|The patients will receive standard pars plana vitrectomy (PPV) combined with direct intra-arterial microneedle thrombolysis under microscopic visualization, in addition to standard clinical treatment for RAO. A 47G microneedle will be used to deliver thrombolytic agent intra-arterially per protocol.
219626583|NCT07151755|PROCEDURE|Standard Clinical Care Only|The patients will receive standard clinical treatment for RAO without vitrectomy or intra-arterial microneedle thrombolysis.
219626584|NCT07152639|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
219626585|NCT07152639|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
219626586|NCT07152639|BIOLOGICAL|5 IU TB-PPD|0.1 ml , one time, containing 5IU of active ingredients
219626587|NCT07152639|DIAGNOSTIC_TEST|IGRA|96-well/plate x 2 plates; 100 tubes/box x 1 box
219626588|NCT07151287|DIAGNOSTIC_TEST|TCCD|Patients receive non-invasive assessments of TCCD using bedside ultrasound.
219626589|NCT07151287|DIAGNOSTIC_TEST|ONSD|Patients receive non-invasive assessments of ONSD using bedside ultrasound.
219626590|NCT07151287|DIAGNOSTIC_TEST|ODH|Patients receive non-invasive assessments of ODH using bedside ultrasound.
219626591|NCT07151287|DIAGNOSTIC_TEST|Invasive ICP|Patients receive invasive assessments of ICP.
219626592|NCT07152626|DRUG|LITFULO|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
219626593|NCT07152626|PROCEDURE|LITFULO and UVB|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
219626594|NCT07151950|DEVICE|One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils|"This study explores the stakeholders' experiences in recommending and using Obi. Stakeholders/Participants include:~1. Persons with disabilities or conditions which prevent them from successfully using their upper extremities (UE) to self-feed independently~2. Caregivers of the persons with disabilities described above~3. Providers (OT, SLP, PT, ATP, etc.) who provide services to persons with disabilities"
219626595|NCT07153055|DRUG|Lurbinectedin|Two lurbinectedin does of 3.2 mg/m2 or 2.6 mg/m2. The initial starting dose is 3.2 mg/m2. Patients will receive lurbinectedin, until disease progression or unacceptable toxicity, once every 21 days.
219626596|NCT07153055|DRUG|Osimertinib|Two osimertinib does of 80 mg or 40 mg orally once daily, as assigned by the dose de-escalation cohort for each 21 day cycle.
219626597|NCT07166224|DEVICE|Oral-B Powered toothbrush|"Intervention Group B:~Participants receive standardized oral hygiene instructions and use an Oral-B iO powered toothbrush during the test period.~The Oral-B iO is an advanced powered toothbrush that combines oscillating-rotating and micro-vibrating bristle movements with real-time feedback technology. It is CE-marked for home use and designed to improve plaque removal and overall oral hygiene compared to manual toothbrushing. The device incorporates pressure sensors and guided brushing modes to support optimal brushing technique and patient adherence, which may contribute to improved periodontal outcomes."
219626598|NCT07166224|DEVICE|Dual-Light aPDT Treatment - Lumoral|"Intervention Group A:~Participants receive standardized oral hygiene instructions and use only a manual toothbrush during the test period, with the addition of an adjunctive antimicrobial photodynamic therapy (aPDT) device (Lumoral®).~The Lumoral® treatment device is a CE-marked antibacterial device intended for home use. It is designed to support the treatment and prevention of oral diseases caused by bacterial biofilms. The device functions by emitting light at a specific wavelength, which activates a CE-marked photosensitizing mouthrinse, Lumorinse®. This light-activated process enhances antibacterial efficacy, targeting pathogenic microorganisms in the oral cavity and supporting improved oral hygiene outcomes."
219626599|NCT07170800|DRUG|JDB0131 100mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
219626600|NCT07170800|DRUG|JDB0131 200mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 200 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
219626601|NCT07170800|DRUG|Delamanid (D)|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~Delamanid (D): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
219626602|NCT05687136|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
218937225|NCT04101942|BEHAVIORAL|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
218937226|NCT02334462|BIOLOGICAL|Pfs230D1M-EPA/Alhydrogel|
218937227|NCT02334462|BIOLOGICAL|Pfs25M-EPA/Alhydrogel|
218937228|NCT02334462|DRUG|TWINRIX|
218937229|NCT02334462|DRUG|Menactra|
218937230|NCT00685568|DRUG|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
218937231|NCT00685568|OTHER|placebo|Orally, twice daily for 3 months
218937232|NCT04496570|PROCEDURE|periodontal therapy|Non surgical periodontal therapy was performed to patients with peridontitis
218937233|NCT02439502|DEVICE|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
218937234|NCT05755243|DEVICE|glucose sensor|skin biopsy (punch)
218937235|NCT04812262|DRUG|DD01|The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
218937236|NCT04812262|DRUG|Placebo|Placebo drug of DD01, administered in a 1mL volume for injection
218937237|NCT04462588|DRUG|Cipro 400 MG in 200 ML Injection|medical tratment group
218937238|NCT04462588|DRUG|Flagyl I.V. RTU|medical tratment group
218937239|NCT04462588|PROCEDURE|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
218937240|NCT04724824|DEVICE|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
218937241|NCT04724824|DEVICE|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
219626603|NCT05687136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219626604|NCT05687136|PROCEDURE|Computed Tomography|Undergo CT
219626605|NCT05687136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218937242|NCT02083913|BEHAVIORAL|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
218937243|NCT02030236|DEVICE|Cooling|Temperature reached Duration of exposure to cold.
219626606|NCT05687136|DRUG|Peposertib|Given PO
219626607|NCT05687136|PROCEDURE|Positron Emission Tomography|Undergo PET
219626608|NCT05687136|DRUG|Tuvusertib|Given PO
219626609|NCT07182318|DIAGNOSTIC_TEST|The FIGO Nutrition Checklist|patient fulfilled the questionnaire twice. period of time 2-3 days
219626610|NCT07182305|DRUG|Efficacy of albendazole for early stage intervention of alveolar echinococcosis|Participants in the treatment arm will be treated with albendazole, 2 x 400 mg daily for the duration of the study. Treatment may be prolonged beyond the end of the study if clinically appropriate.
219626611|NCT07183566|DEVICE|Ct|Ct volume measurement of HCC after TACE or MWA
219626612|NCT07182006|BEHAVIORAL|Aerobic Exercise|Submaximal cardiovascular endurance testing on a treadmill
219626613|NCT07182864|DRUG|MH004 0.1% Ointment|MH004 0.1% ointment applied topically to the affected area as a thin film.
219626614|NCT07182864|DRUG|MH004 0.3% Ointment|MH004 0.3% ointment applied topically to the affected area as a thin film.
219626615|NCT07182864|DRUG|MH004 1.0% Ointment|MH004 1.0% ointment applied topically to the affected area as a thin film.
219626616|NCT07182864|DRUG|MH004 3.0% Ointment|MH004 3.0% ointment applied topically to the affected area as a thin film.
219626617|NCT07182864|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film.
219626618|NCT07182773|BEHAVIORAL|Exercise|The exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin \<9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain.
219626619|NCT07182656|DRUG|CIGB-814 (single-dose group)|CIGB-814, single ascending dose, SC injection
219626620|NCT07182656|DRUG|CIGB-814 placebo (single-dose group)|CIGB-814 placebo, single ascending dose, SC injection
219626621|NCT07182656|DRUG|CIGB-814 (multiple-dose group)|CIGB-814, multiple ascending dose, SC injection
219626622|NCT07182656|DRUG|CIGB-814 placebo (multiple-dose group)|CIGB-814 placebo, multiple ascending dose, SC injection
219626623|NCT07183696|OTHER|breathing exercises|"* breathing exercises as needed 3 times per week during dialysis sessions.~* chest percussion as needed 3 times per week during dialysis sessions.~* vibration as needed 3 times per week during dialysis sessions."
219626624|NCT07182708|DRUG|Firmonertinib Mesilate Tablets|Firmonertinib Mesilate Oral administration 160 mg once daily for 3 months before surgery. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment. After surgery, the treatment plan was determined by the researchers, with options including Firmonertinib Mesilate Tablets: Oral administration once daily, 80mg per dose, for 3 years or until disease progression or intolerable toxicity occurs.
219626625|NCT07182708|DRUG|Bevacizumab injection|Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment.
219626626|NCT07183761|BIOLOGICAL|Experimental Group|On day 0, day 7, and day 28 after enrollment, the study subjects will receive intramuscular injections of hUC-MSCs suspension in normal saline into the medial and lateral muscle groups of both lower legs. Concurrently, all patients will continue to receive conventional therapy.
219626627|NCT07183761|DRUG|Conventional therapy group|The conventional therapy include fundamental blood glucose management, basic treatment for diabetic neuropathy along with pain management therapy, as well as management of comorbidities and risk factors.
219626628|NCT07183124|DIAGNOSTIC_TEST|AI-Assisted 3D Imaging Model for Tumor and CRM Assessmen|This study uses an AI-assisted 3D imaging model to analyze existing CT and MRI images of stage II-III locally advanced rectal cancer patients. The system reconstructs tumor boundaries and spatial relationships, predicts circumferential resection margin (CRM) status, and supports staging assessment. No interventions are performed on participants, and all data are collected retrospectively from routine clinical care.
219626629|NCT07184450|BIOLOGICAL|BCMA/CD70-targetd CAR-T|Subjects underwent lymphocytetion cheotherapy and then received a single intravenous cell infusion
219626630|NCT07183280|OTHER|operation|Enucleation, spleen-preserving distal pancreatectomy, or duodenum-preserving pancreatic head resection, etc
219626631|NCT07183215|DRUG|Curcuminoid Standardized Turmeric Capsules|Samples were made from extracted turmeric and then optimized. The capsule formulation is made from turmeric rhizome extract which contains 30 mg of curcuminoids per capsule. In the study, standardized curcuminoid turmeric extract was given in capsules at 30 mg 3 times a day for 3 weeks
219626632|NCT07183215|OTHER|Placebo|The capsule formulation is made from maltose which contains 10 mg of curcuminoids per capsule. In the study, the capsule was given in capsules at 30 mg 3 times a day for 3 weeks.
218937244|NCT03347955|PROCEDURE|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
218937245|NCT03347955|PROCEDURE|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
219626633|NCT07183878|DRUG|Venetoclax|Venetoclax is administered orally at 400 mg/day for participants ≥14 years or 360 mg/m²/day for those aged 12-14 years, from day -14 to -8 before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dose is adjusted to 100 mg/day (or 90 mg/m²/day for pediatric patients) if used with strong CYP3A4 inhibitors such as posaconazole.
218937246|NCT06492863|GENETIC|FT-003|Administered via intraocular injection.
218937247|NCT02876536|DEVICE|TENS|The effect of TENS device will be compared in case and control groups.
219626634|NCT07183878|OTHER|None-placebo|Participants in this arm will not receive venetoclax as part of their conditioning regimen. They will undergo standard myeloablative conditioning with BUCY (busulfan, cyclophosphamide, and MeCCNU), prior to allogeneic hematopoietic stem cell transplantation. This arm serves as the active comparator to evaluate the addition of venetoclax in the experimental arm.
219626635|NCT07182279|DRUG|Brachytherapy|All patients will receive a single fraction of HDR-B (15Gy) 4-8 weeks prior to RALP. Patients with high genomic risk or node positivity will receive short course adjuvant AAB.
219626636|NCT07183748|DRUG|Psilocybin (drug)|0.4 grams
219626637|NCT07183748|OTHER|Placebo|Placebo
219626638|NCT07184138|DRUG|Interleukin-23 Inhibitors (IL-23i)|Adult patients will receive treatment with an interleukin-23 inhibitor (IL-23i), including guselkumab or risankizumab, as prescribed in routine clinical practice in China. This observational study does not mandate dosing, administration schedule, or concomitant medications; treatments follow standard of care. Patients will be prospectively monitored for clinical effectiveness, endoscopic outcomes, and safety over 52 weeks.
219626639|NCT07182422|DRUG|AST-120 (Kremezin®)|AST-120 (Kremezin®) Dosage: 6 g/day (2 g TID, oral) Duration: 14 days Background treatment: Standard post-AKD care
219626640|NCT07182461|DEVICE|Dynamic Tape|Dynamic Tape is a viscoelastic tape designed to assist movement and absorb load. The material is composed of either Nylon/Lycra or Recycled PET/Lycra.
219626641|NCT07182461|DEVICE|Swiss Ball|A 75 cm diameter Swiss ball was used to provide an unstable surface during the exercise intervention.
219626642|NCT07182461|DEVICE|Dumbbells|During the exercise intervention, 1 kg and 2 kg dumbbells were used as external resistance.
219626643|NCT07182461|DEVICE|Visual Feedback Laser Device|A headband was prepared to attach the laser pointer securely, allowing participants to wear it . This visual feedback laser device was used during proprioceptive training to provide real-time feedback.
219626644|NCT07183488|OTHER|Propionate followed by Butyrate|The participants will consume Short-chain fatty acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
219626645|NCT07183488|OTHER|Butyrate followed by Propionate|• The participants will consume Short-chain fatty acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
219626646|NCT07183488|OTHER|Propionate followed by Butyrate|• The participants will consume Short-Chain Fatty Acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
219626647|NCT07183488|OTHER|Butyrate followed by Propionate|The participants will consume Short-Chain Fatty Acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
219626648|NCT07182370|DIETARY_SUPPLEMENT|Capsules containing plant extracts, including resveratrol, ellagic acid and isoflavones|Eight-week intake of three capsules per day, containing a total of 2.1 g of plant extracts (PPs), including 150 mg of resveratrol (found in grapes and red wine), 100 mg of ellagic acid (present in strawberries, walnuts, pomegranate, etc.), and 50 mg of the isoflavone daidzein, among others (found in soy, red clover, etc.).
219626649|NCT07182370|DIETARY_SUPPLEMENT|Consumption of placebo|Daily intake of three capsules (2.1 g/day) of microcrystalline cellulose for eight weeks
219626650|NCT07183423|OTHER|Novel barrier repair topical product|Novel barrier product (containing ceramide, virgin coconut oil, cholesterol)
219626651|NCT07183423|OTHER|Petrolatum|Petrolatum application
219626652|NCT07183917|BEHAVIORAL|Forest Therapy and Mindfulness|Weekly 2-hour guided sessions for 8 consecutive weeks in natural forest environments. Each session includes mindful walking, multisensory awareness (sight, sound, smell, touch), breathing exercises, and guided relaxation practices. Facilitated by certified Forest Therapy and Mindfulness instructors. The intervention is non-invasive, focused on stress reduction, emotional regulation, and improved subjective well-being through mindful immersion in nature.
219626653|NCT07183917|BEHAVIORAL|Indoor Wellness Control|Weekly 2-hour structured sessions for 8 consecutive weeks conducted indoors (classroom or wellness center). Activities include health education talks on stress and wellness, guided music-based relaxation, and eco-friendly culinary tasting experiences. Designed to provide an active comparator condition controlling for attention, group interaction, and wellness-related content without exposure to forest environments or formal mindfulness practices.
219626654|NCT07183397|DIAGNOSTIC_TEST|VExUS & Cardiac Ultrasound|The VExUS system provides a semi-quantitative assessment of systemic venous congestion by integrating ultrasound evaluations of the inferior vena cava diameter, hepatic vein flow, portal pulsatility, and renal venous flow, offering a practical and comprehensive bedside tool
219626655|NCT07182149|DRUG|NRM-823|NRM-823 is a bispecific T-Cell Engager
219626656|NCT07183410|DIAGNOSTIC_TEST|Blood culture taken from an arterial catheter|Blood culture taken from an arterial catheter (instead of peripheral venous puncture)
219626657|NCT07183007|OTHER|Low gluten diet|Systemic lupus erythematosus patients with HLA-DQ2 or DQ-8 positive will be randomized to dietary intervention group or control group. Those who are randomized to dietary intervention group will get dietary planning and intervention from a nutritionist with low gluten diet
219626658|NCT07182591|DRUG|DS5361b|"Dose Escalation Part: DS5361b will be administered at escalating doses to determine the RDE.~Dose Expansion Part: DS5361b will be administered at RDE."
219626659|NCT07182591|DRUG|Pembrolizumab|"Dose Escalation Part: Pembrolizumab will be administered at a standard dose.~Dose Expansion Part: Pembrolizumab will be administered at a standard dose."
219626660|NCT07182357|BEHAVIORAL|Dementia Care Management Checklist for Hospice Transitions|"Intervention: After appropriate care partners of hospice-eligible PLWD are identified who will be receiving the checklist intervention, care managers will perform telephonic outreach to engage them in a conversation about care needs (as they would in typical clinical practice). The telephonic outreach will be followed up with a recommendation for follow up by a medical provider who may conduct a hospice care assessment and engage the care partner in decision-making surrounding the hospice referral and enrollment process.~This intervention was co-designed with care partners, home healthcare professionals, administrators, and medical providers. It is meant to be comprehensive and speak to the needs of all relevant parties engaged in the care of persons with dementia. It is developed so that it can be scaled and implemented widely."
219626661|NCT07183904|PROCEDURE|Hematoma Block|Injection of 5-10 mL of 2% mepivacaine directly into the fracture hematoma under aseptic conditions.
219626662|NCT07183904|PROCEDURE|Median Nerve Block|Injection of 3-5 mL of 2% mepivacaine adjacent to the median nerve at the wrist, using anatomical landmarks.
219626663|NCT07175467|OTHER|Haptic-asissted virtual simulation|The virtual reality application will be developed using the Unity game engine. The VR simulation environment, which will progress through scenarios, will include taking vital signs, performing aspiration, performing a nasogastric catheterization, oxygen therapy, performing physical examinations, and performing subcutaneous injections.
219626664|NCT07182071|BEHAVIORAL|Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
219626665|NCT07182071|BEHAVIORAL|Waitlist for Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
219626666|NCT07183553|OTHER|maintenance training|information has been provided in accordance with the content of the training booklet.
219626667|NCT07182526|DRUG|Quercetin|Quercetin 500 mg capsule daily after meal for three months
219626668|NCT07182526|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600mg SR capsule daily after meal for three months period.
219626669|NCT07182526|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin 500 mg daily for three months
219626670|NCT07182435|BIOLOGICAL|personalized neoantigen mRNA tumor vaccine|RH125 is a personalized neoantigen mRNA tumor vaccine which is constructed based on the results of patients' neoantigen sequencing.
219626671|NCT07181967|DRUG|Sodium Fluoride Varnish (5%)|Topical application of 5% sodium fluoride varnish (22,600 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the contralateral side of the mouth. Applied once using a disposable applicator per manufacturer's instructions. This distinguishes it from lower-concentration fluoride gels or multiple-application protocols in other clinical trials.
219626672|NCT07181967|DRUG|Silver Diamine Fluoride (38%)|"Topical application of 38% silver diamine fluoride solution (44,800 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the assigned side of the mouth. Applied once with a microbrush for 1 minute, per manufacturer's instructions, without subsequent rinsing. This concentration and protocol distinguish it from other concentrations of SDF or repeated-application protocols used in other clinical studies."
219626673|NCT07182201|BEHAVIORAL|Foot core control training|(1) Toe Yoga : When MTPJ1 actively dorsiflexes, the other four toes remain in contact with the ground. The subject lifts the big toe while the remaining four toes stay on the ground; conversely, when the big toe contacts the ground, the other four toes lift upward, alternating this pattern. (2)Doming: While keeping MTPJ1 in contact with the ground, elevate the foot arch. This exercise strengthens intrinsic foot muscle strength, helping stabilize the arch and first metatarsal. The subject tightens the toes, bringing the forefoot toward the heel to form and enhance the arch. Maintain all toes firmly planted on the ground, ensuring no ankle inversion, no forced flexion or extension of toes, and hold at maximum position. Perform training seated to avoid compensatory movements by external muscles during exercise. (3) Toe Abduction Exercises（4）Dynamic Exercise Progression
219626674|NCT07182201|BEHAVIORAL|CPF Conventional training|The key points of the exercise are as follows: (1) Fascia ball release of plantar fascia (2) Plantar fascia stretching (3) Gastrocnemius muscle stretching (4) Toe grab towel
219626675|NCT07183683|DEVICE|group 1: electrical stimulation of acupuncture points plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min electrical stimulation per foot with 10Hz and an intensity up to individual tolerance level.
219626676|NCT07183683|OTHER|group 2: acupressure plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min massage per foot
219626677|NCT07183774|DIAGNOSTIC_TEST|Sarcopenia will be assessed using the STAR (Sonographic Thigh Adjustment Ratio) method.|A detailed evaluation of shoulder MRI scans will be conducted. The presence and severity of supraspinatus tendon tears, as well as the presence of muscle atrophy (assessed using the tangent sign), will be recorded. In addition, tears in other rotator cuff tendons, signs of tendinitis, and any other pathological findings will also be documented.
219626678|NCT07176442|BEHAVIORAL|MOOC (E-Learning)|Participants complete a structured Massive Open Online Course (MOOC) hosted on Canvas. The course includes four 4-5 minute video modules on diabetic ketoacidosis, with interactive quizzes between modules.
219626679|NCT07176442|BEHAVIORAL|Simulation Training|Participants take part in a high-fidelity simulation session using a mannequin programmed for diabetic ketoacidosis management. Each session is followed by a structured debriefing led by the instructor.
219626680|NCT07176442|BEHAVIORAL|Educational Escape Game|Participants join a 30-minute educational escape game with 10 puzzles that guide them through the diagnosis and management of diabetic ketoacidosis. The activity emphasizes collaboration and problem-solving.
219626681|NCT07182110|DRUG|Dexamethasone enhanced TAP Block|20 ml Marcaine containing 0.25% bupivacaine + 4 mg dexamethasone + normal saline
219626682|NCT07182110|DRUG|Marcaine- 0.25%|20 ml solution containing 0.25% bupivacaine + normal saline
219626683|NCT07172009|OTHER|Chlorhexidine mouthwash|Rinsing the mouth with chlorhexidine mouthwash for 2 minutes before consuming 50 g of carbohydrates
219626684|NCT07172009|OTHER|Placebo mouthwash|Rinsing the mouth with placebo mouthwash for 2 minutes before consuming 50 g of carbohydrates
219626685|NCT07174726|BIOLOGICAL|Adeno-associated virus vector expressing a human RPGR gene|Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
219626686|NCT07184359|BEHAVIORAL|Traditional Learning|All participants will have access to the conventional teaching-learning process (lecture-based classes). These theoretical classes will be delivered as part of the Dental Radiology course. During the semester, the topics covered will include intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
219626687|NCT07184359|BEHAVIORAL|Passive Social Media|The second group (Passive Social Media Supplement Group) will participate in the conventional teaching-learning process, supplemented by the passive consumption of educational content on social media, produced by the third group. The materials consumed will include the following content: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
219626688|NCT07184359|BEHAVIORAL|Active Social Media|The third group (Active Social Media Engagement Group) will participate in the conventional teaching-learning process, supplemented by the creation of educational audiovisual materials, which will subsequently be shared on social media and accessed both by their own group and by the second group. The materials will cover the following topics: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
219626689|NCT07183618|PROCEDURE|Mental training group|"Mental Training Group: Residents in the Mental Training group received a mental preparation session led by an anaesthesia physician qualified in medical pedagogy. Inspired by the Breathe, Talk, See, Focus procedure"
219626690|NCT07183332|BEHAVIORAL|High frequency follow-up|Patients in the high-frequency group received regular follow-ups at a high frequency after discharge.
219626691|NCT07182331|DEVICE|Continuous Theta Burst Stimulation to Bilateral DLPFC|Participants receive continuous theta burst stimulation (cTBS) targeting both the left and right dorsolateral prefrontal cortex (DLPFC) during each session. Each hemisphere is stimulated with 600 pulses (triplets at 50 Hz repeated at 5 Hz) over \~40 seconds, at 80% of the individual's active motor threshold. Sessions are administered once daily over 10 treatment days.
219626692|NCT07182331|DEVICE|Sham Continuous Theta Burst Stimulation|Participants receive sham continuous theta burst stimulation (cTBS) to both the left and right dorsolateral prefrontal cortex (DLPFC) using a placebo coil that mimics the auditory and tactile sensations of real stimulation but does not produce a magnetic field capable of affecting brain activity. Coil positioning, session timing, and procedure match the active cTBS protocol, including consecutive stimulation to both hemispheres. Both participants and TMS technicians wear earplugs to mask subtle sound differences between active and sham coils. This setup maintains participant and operator blinding and controls for placebo-related effects.
219626693|NCT07183501|PROCEDURE|Combined hystroscopic and laparoscopic repair|Hystroscopic isthmoplasty will be done first to ensure removal of chronically inflamed Unhealthy edges of niche, then laparoscopic exison of scar will be dine, followed by repair of the defect
218937248|NCT01251341|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
218937249|NCT01251341|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
218937250|NCT01251341|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
218937251|NCT00602758|BEHAVIORAL|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
219048166|NCT07173530|DEVICE|Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).|A mask with Light Emitting Diodes wavelength 633nm will be placed over closed eyes for 15 minutes.
219626694|NCT07183189|DRUG|SHR-A2009 ; Aumolertinib|SHR-A2009 administered intravenously, Aumolertinib administered orally.
219626695|NCT07183189|DRUG|Aumolertinib|Aumolertinib administered orally
219626696|NCT07182136|PROCEDURE|Pancreaticoduodenectomy|Retrospective study evaluating postoperative NAFLD and metabolic outcomes in patients with stage I-II pancreatic cancer after PD.
219626697|NCT07182682|DRUG|sunvozertinib|Participants will receive oral administration of sunvozertinib 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
219626698|NCT07182682|DRUG|Matching Placebo|Participants will receive oral administration of placebo 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
219626699|NCT07182955|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Remote 4 weeks of high-intensity interval exercise training on three non-consecutive days of the week.
219626700|NCT07184346|OTHER|Control|Control Group
219626701|NCT07184346|DEVICE|Intra Oral Scanner|Experimental group 1
219626702|NCT07184346|DEVICE|Mod Jaw|4 D Jaw Tracker
219626703|NCT07182877|DEVICE|Closed-type peripheral cannula|We will use closed-type peripheral catheters (BD Nexia Closed IV Catheter System.
219626704|NCT07182877|DEVICE|Open type peripheral cannula|We will use POLYMED Ultra Intravenous cannula in the control arm
219626705|NCT07183072|OTHER|Questionnaire and functionality application for child and adult scleroderma patients|Scales and functionality tests will be applied to cases diagnosed with scleroderma
219626706|NCT07183982|DIAGNOSTIC_TEST|MoCA: Montreal Cognitive Assessment (MoCA) and Positive and Negative Syndrome Scale (PANSS)|"MoCA: A 30-point screening tool assessing attention, memory, language, visuospatial and executive functions; quick and sensitive to mild cognitive deficits.~PANSS: A 30-item scale rating positive, negative, and general psychopathology symptoms in psychotic disorders; widely used to track severity and change."
219626707|NCT07183982|BEHAVIORAL|Rehabilitation program in the form of : psychodynamic group therapy, music and art therapy , cognitive stimulation techniques|"Participants received a structured 6-month program designed to address persistent psychotic symptoms and associated deficits. The intervention included:~Art Therapy: Weekly sessions promoting self-expression, emotional regulation, and enhancement of social interaction.~Cognitive Stimulation: Structured group exercises aimed at improving attention, memory, executive functions, and problem-solving.~The program was delivered by a multidisciplinary team in a group of 10 patients, ensuring active participation, individualized support, and integration of therapeutic modalities."
219626708|NCT07183202|OTHER|Case-based learning (CBL)|"During the training session, students were given a detailed explanation of an artificial intelligence (AI)-assisted case presentation structured according to the ERAS protocol. They were briefed on the data collection tools they would need to complete before and after the session. A convenient time was set, considering all participants' accessibility, and students were provided a link they could access from their mobile phones, tablets, or computers. Students participated in the AI-assisted case session online using this link.~During the training process, a case scenario developed by the researchers and optimized with AI was presented to students on a digital platform. The case encompassed the entire patient care process, from diagnosis to discharge, simulating a real-life clinical environment. On the AI-assisted platform, students followed the case flow step by step, actively participating by entering their own responses at each stage of the clinical decision-making process. The plat"
219626709|NCT07182981|OTHER|Questionnaire application for child and adult scleroderma patients|Scales will be applied to cases diagnosed with scleroderma
219626710|NCT07176546|DRUG|Avacopan|BID dose of 30 mg TAVNEOS (3-10mg capsules)
219626711|NCT07176546|DRUG|Placebo|BID dose of 30mg TAVNEOS-matching placebo (3-10mg capsules)
219626712|NCT07183163|OTHER|Clinical and biochemical assessment|Assessment of peri-implant clinical parameters (probing depth, bleeding on probing, plaque index) and biochemical markers (IL-1β, TNF-α, MMP-8) in peri-implant crevicular fluid. No therapeutic or experimental intervention administered.
219626713|NCT07183865|RADIATION|radiotherapy|25-40Gy/5Fx or 15-30Gy/5Fx (previous pelvic radiation) for pelvic recurrence. 25-50GY/5Fx for all metastasis tumors. Dose Constraints are based on SABR-COMET 10 trial.
219626714|NCT07183865|DRUG|Irinotecan Hydrochloride Liposome|70mg/m2 (UGT1A1\*28 6/6) or 55mg/m2 (UGT1A1\*28 6/7), IV, q2w
219626715|NCT07183865|DRUG|5-FU|400 mg/m\^2 bolus over 2 hours followed by 2400 mg/m\^2 continuous infusion over 48 hours d1, q2w
219626716|NCT07183865|DRUG|Leucovorin|400mg/m2, IV, q2w
219626717|NCT07183865|DRUG|SG001|240mg, IV, q2w
219626718|NCT07183865|DRUG|C225|500 mg/m2, IV, q2w
219626719|NCT07183865|DRUG|Bevacizumab|5mg/kg, IV, q2w
219626720|NCT07183787|DRUG|Letrozole|Letrozole 2.5 mg orally once daily for 12 weeks.
219626721|NCT07183787|DRUG|danazol|Danazol 200 mg orally twice daily for 12 weeks.
219626722|NCT07184268|PROCEDURE|full mouth non-surgical scaling|All patients will receive a full mouth scaling using ultrasonic scalers and hand instrumentation
219626723|NCT07182890|DRUG|Clostridium butyricum|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily."
219626724|NCT07182890|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency)."
219626725|NCT07182214|OTHER|Collect blood sample|Collect venous blood sample from subjects prior fasting, any operation or treatment
219626728|NCT07184307|BIOLOGICAL|Platelet-Rich Plasma|Autologous platelet-rich plasma prepared from approximately 50 milliliters of venous blood using a two-step centrifugation protocol. Ten milliliters of platelet-rich plasma are obtained and injected into the sub-urothelial layer of the bladder wall during cystoscopy under anesthesia.
219626729|NCT07184307|DRUG|Intravesical Botulinum Toxin Injection|Botulinum toxin (100 units) reconstituted in 10 milliliters of saline and injected into the bladder detrusor muscle at multiple sites under cystoscopic guidance, sparing the trigone.
219626730|NCT07184372|OTHER|Radiofrequency and manual tecniques|"We apply manual tecniques while we use the radiofrequency, the treatment is divided into 3 phases:~* PHASE 1: With the patient in the supine position, treatment was performed along the diaphragm for 10 minutes, of which 5 minutes were spent with the capacitive electrode and the other 5 minutes with the resistive electrode. The plate was placed on the back at the level of the diaphragm.~* PHASE 2: The patient was placed in the lateral decubitus position on their right side and 3 minutes were spent with the capacitive electrode and 7 minutes with the resistive electrode. The patient was asked to breathe costal-diaphragmatically throughout the entire duration of the resistive electrode. The plate was placed on the right side, at lung level.~* PHASE 3: The same procedure was performed as in the second phase, only this time on the contralateral side, i.e., on the left side."
219626731|NCT07184372|OTHER|Manual tecniques|Manual techniques are used to increase inspiratory capacity, working on the diaphragm and rib cage to increase their mobility along with breathing exercises.
219626732|NCT07184372|OTHER|Placebo|The radiofrequency is turn off
219626733|NCT07184242|OTHER|Shoulder Exercise & Proprioceptive Training Program|"The study includes two intervention modalities. The experimental group will combine conventional treatment with a structured 12-week therapeutic exercise program, with two supervised group sessions per week (50-60 minutes), which will include proprioceptive somatosensory work, multi-joint strength exercises, and adapted specific movements. Progression will be individually adjusted based on each participant's pain tolerance, physical condition, and clinical progress, complemented by home activities and supporting educational materials.~The control group will receive only conventional treatment provided at their rehabilitation center and general guidelines on the benefits of physical activity according to WHO recommendations for people over 60 years of age."
219626734|NCT07183059|DIAGNOSTIC_TEST|Electromyography|"we will perform questionnaire, clinical neurological exam, nEMG and if applicable short exercise test on patients with variants in genes associated with mus-cular channelopathies.~Safety Monitoring and reporting: Needle EMG is generally well-tolerated, but transient mild proce-dural pain and discomfort are widespread and the most frequent side effect that patients will ex-perience. Hematomas are infrequent and, in most cases, asymptomatic and selflimiting. Moreover, the bleeding risk is reduced by the investigator's experience, testing superficial muscles (avoiding complications like compartment syndrome), and by not conducting an EMG when patient is treated with anticoagulants. Infectious complications at the site of needle insertion are extremely infre-quent since disposable needle electrodes are used. Needle insertion is avoided in in-jured/potential infected skin and will not be performed in immune-compromised patients and endocarditis risk."
218937252|NCT00602758|BEHAVIORAL|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
219626735|NCT07184333|BEHAVIORAL|Interprofessional Education with Digital Case Management for Home-Based Elder Care|A structured interprofessional education programme for nursing and physiotherapy students that includes: (1) a 3-hour workshop on frailty assessment, digital case documentation, and care planning; (2) a 30-minute orientation on home visit safety and communication; (3) supervised home visits to older adult participants involving health and fitness assessments, medication support, and health education; (4) use of a tablet-based digital case management platform for collaborative care documentation; and (5) a 4-week follow-up with personalised mobile health messages and a final home visit. The intervention aims to enhance students' clinical, collaborative, and digital competencies in community-based elder care.
219626736|NCT07183358|BEHAVIORAL|Family-supervised Multimodal Prehabilitation|"A comprehensive prehabilitation program initiated at the start of neoadjuvant chemotherapy and continued until the day before surgery. The intervention includes:~1. Nutritional support: individualized dietary counseling and supplementation plans supervised by clinical nutritionists;~2. Exercise training: home-based aerobic and resistance exercises monitored via wearable devices and weekly video/phone follow-ups;~3. Psychological support: structured counseling sessions to reduce anxiety, improve treatment adherence, and enhance quality of life.~Family members are trained to assist with supervision and compliance. The total duration is approximately 10-16 weeks, depending on the chemotherapy schedule."
219626737|NCT07183358|OTHER|Standard Care|Standard neoadjuvant chemotherapy followed by radical gastrectomy with standard ERAS-based perioperative management, without any additional prehabilitation intervention. Participants receive routine nutritional, nursing and medical care according to hospital guidelines. The aim is to maintain current clinical practice as the control condition for comparison with the experimental prehabilitation program.
218937253|NCT03405961|DEVICE|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
219626738|NCT07182786|DEVICE|LMA Gastro|LMA Gastro, is a laryngeal mask airway device that is specifically designed for air way management in GIT endoscopic procedures due to having a channel dedicated for endoscope introduction. the safety and efficacy of LMA Gastro was researched in many studies, but its role in preventing Hypercarbia during ERCP procedures is yet to be researched and tested.
219626739|NCT07183605|PROCEDURE|catheter flushing techniques|"Two catheter flushing techniques will be compared:~* Method A: A 5 mL flush performed with a syringe over 5 seconds.~* Method B: A 5 mL flush using a vacuum tube (standard discard tube)."
219626740|NCT03117179|OTHER|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
219626741|NCT05630781|DRUG|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional approximately 7 days and then scanned a final time.
219626742|NCT05630781|DRUG|Placebo|comparator taken for approximately 10 days
219626743|NCT05630781|DRUG|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
219626744|NCT03631017|DRUG|[18F]- PARPi|injection of a microdose (\< 100 ug) of \[18F\]- PARPi
219626745|NCT03631017|DIAGNOSTIC_TEST|PET/CT Scans|"Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
219626746|NCT06131372|DRUG|Cagrilintide|Participants will receive Cagrilintide subcutaneously.
219626747|NCT06131372|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
219626748|NCT06131372|DRUG|Placebo|Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
219641899|NCT02260869|PROCEDURE|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
219641900|NCT02260869|DEVICE|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
219641901|NCT04081090|BEHAVIORAL|Brain HQ Cognitive Modules|Online personalized cognitive therapy modules to address and improve neuroplasticity.
219641902|NCT02572596|DRUG|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
219641903|NCT02572596|DRUG|CTX|CTX 2.5/m2 for 2 days.
219641904|NCT02572596|DRUG|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
219641905|NCT06482723|DEVICE|mGlobal L+AS|The investigated dermal filler mGlobal L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
219641906|NCT06074809|DRUG|Modified Guizhi Fuling granules|Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
219641907|NCT06074809|OTHER|Placebo|Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
219641908|NCT06085144|DRUG|Galcanezumab|Receiving either 120mg or 300mg injections.
219641909|NCT00725790|DRUG|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
219641910|NCT00725790|DRUG|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
219641911|NCT04234295|PROCEDURE|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
219626749|NCT04166318|PROCEDURE|Biopsy|Undergo tissue biopsy
219626750|NCT04166318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219626751|NCT04166318|DRUG|Capecitabine|Given PO
219626752|NCT04166318|PROCEDURE|Computed Tomography|Undergo PET/CT
219626753|NCT04166318|OTHER|Fludeoxyglucose F-18|Receive FDG
219626754|NCT04166318|DRUG|Fluorouracil|Given IV
219626755|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219626756|NCT04166318|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219626757|NCT04166318|DRUG|Mitomycin|Given IV
219626758|NCT04166318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219626759|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
219626760|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
219626761|NCT06445101|OTHER|Participatory Approach|The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
219626762|NCT05975671|BEHAVIORAL|Multifaceted de-implementation strategy to reduce vancomycin overuse|"* Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
218937254|NCT02028208|DIAGNOSTIC_TEST|Ammoniated mercury|Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
219626763|NCT03245892|DRUG|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
219626764|NCT03245892|DRUG|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
219626765|NCT03245892|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery
219626766|NCT03245892|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
219626767|NCT03381183|DRUG|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
219626768|NCT03381183|DRUG|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m\^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
219626769|NCT04343495|DEVICE|Wearable Ultra Violet (UV) and blue-light sensors|Non-blinded
219626770|NCT04698395|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
219626771|NCT04698395|BEHAVIORAL|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
219626772|NCT06431932|DRUG|Fisetin|Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.
219626773|NCT06431932|DRUG|Placebo|Subjects will receive a corresponding number of placebo capsules for two consecutive days.
219626774|NCT00921609|DIAGNOSTIC_TEST|Oral glucose tolerance test|An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
219626775|NCT01016951|DRUG|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
219626776|NCT01016951|DRUG|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
219626777|NCT05608915|OTHER|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
219626778|NCT05608915|OTHER|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
219626779|NCT05608915|OTHER|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
219626780|NCT05608915|OTHER|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
219626781|NCT05608915|OTHER|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
219626782|NCT05608915|OTHER|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
219626783|NCT02184338|DRUG|BIBR 1017 BS powder|
219626784|NCT02184338|DRUG|Placebo|PEG 400
218937255|NCT02028208|DIAGNOSTIC_TEST|Aluminum chloride and aluminum lactate|Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
218937256|NCT02028208|DIAGNOSTIC_TEST|Sodium tetrachloropalladate|Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
218937257|NCT02837107|DIETARY_SUPPLEMENT|Mind Master|80ml Mind Master / day for 8 weeks
218937258|NCT02837107|DIETARY_SUPPLEMENT|Placebo|80ml a look-alike Placebo / day for 8 weeks
219641912|NCT06350695|DEVICE|low grade compression stockings (10-15 mmHg)|Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
219641913|NCT06350695|DEVICE|high grade compression stockings (20-30 mmHg)|Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
219626785|NCT03225209|OTHER|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
219626786|NCT06187688|OTHER|Questionnaire|Patients to complete a questionnaire on measurement of pain intensity.
219626787|NCT02565628|DRUG|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
219626788|NCT02565628|DRUG|Placebo|Placebo
219626789|NCT03892044|DRUG|Duvelisib|Given PO
219626790|NCT03892044|BIOLOGICAL|Nivolumab|Given IV
219626791|NCT02281435|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
219626792|NCT01259622|DRUG|saline|intravenous infusion
219626793|NCT01259622|DRUG|K201|intravenous infusion
219626794|NCT04568915|OTHER|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
219626795|NCT04568915|OTHER|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
219626796|NCT03795961|DEVICE|transcranial direct current electrical stimulation|anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
219626797|NCT04267289|BEHAVIORAL|Beating the Blues|Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
219626798|NCT05367609|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
219626799|NCT04785066|DRUG|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
219626800|NCT05826509|OTHER|Surgery alone|Radical prostatectomy with lymph node dissection will be performed.
219626801|NCT05826509|DRUG|Peri-operative darolutamide + surgery.|"Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment."
219626802|NCT06421753|DEVICE|SDSS|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
219626803|NCT06421753|DEVICE|Standard Electrical Stimulation During Functional Electrical Stimulation|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
219626804|NCT05442216|DRUG|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
219626805|NCT05442216|DRUG|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
219626806|NCT05442216|DRUG|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
219626807|NCT02617342|BEHAVIORAL|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
219048167|NCT07174180|OTHER|Exercise-heat stress with no hijab|Participants perform exercise in the heat with no hijab
219048168|NCT07174180|OTHER|Exercise-heat stress with a hijab|Participants perform exercise in the heat with a hijab
219626808|NCT05603897|OTHER|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
219626809|NCT05603897|OTHER|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
219626810|NCT03375918|OTHER|CONSULT-BP Educational Intervention|CONSULT-BP is a two sessions training provided to healthcare trainees over a 5-week period. The first session focused on (1) didactic overview of healthcare disparities, social drivers of health, implicit bias and systemic racism and (2) interactive discussions and patient storytelling videos to raise awareness of the bi-directional role of racial and ethnic identity among clinicians and patients. The second session focused on skill building and included (1) bias mitigation strategies based on the RELATE bias mitigation tool and (2) skill practice using 2 standardized patient simulated clinical encounters focusing on hypertension management challenges.
218937259|NCT02820948|DRUG|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
218937260|NCT03034070|DIAGNOSTIC_TEST|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
218937261|NCT01600534|BEHAVIORAL|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
218937262|NCT02803983|PROCEDURE|Pediatric hip plate|Children were treated with pediatric hip plate.
218937263|NCT02803983|PROCEDURE|Cannulated screw|Children were treated with cannulated screw.
218937264|NCT02236936|DIETARY_SUPPLEMENT|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
219626811|NCT04874012|DRUG|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
219626812|NCT04874012|OTHER|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
219626813|NCT05746390|BEHAVIORAL|Home Alone|See Home Alone description.
219626814|NCT06449209|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
219626815|NCT06449209|DRUG|BNT327 Dose Level 2 (DL2)|IV infusion
219626816|NCT06449209|DRUG|Etoposide|IV infusion
219626817|NCT06449209|DRUG|Carboplatin|IV infusion
219626818|NCT06449209|DRUG|Paclitaxel|IV infusion
219626819|NCT06449209|DRUG|Topotecan|IV infusion or oral capsules
218937265|NCT02236936|DIETARY_SUPPLEMENT|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
219626820|NCT04478084|BIOLOGICAL|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form:freeze-dried Route of administration: intradermal
219626821|NCT04478084|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried Route of administration: intradermal
219626822|NCT04478084|BIOLOGICAL|Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)|Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular
218937266|NCT02236936|BIOLOGICAL|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
218937267|NCT02236936|DRUG|Cisplatin|Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
218937268|NCT02236936|RADIATION|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
218937269|NCT00271284|DRUG|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
218937270|NCT00271284|DRUG|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
219626823|NCT04478084|BIOLOGICAL|Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)|Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
219626824|NCT06482957|OTHER|Surveys|Complete surveys
219626825|NCT06482957|OTHER|Blood Collection|Undergo blood collection
218937271|NCT02556528|BEHAVIORAL|Health Coaching|
218937272|NCT05861167|BIOLOGICAL|selective intensive induction therapy based on ustekinumab clinical decision-making tools|At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
218937273|NCT03373396|DIAGNOSTIC_TEST|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
218937274|NCT00822549|DRUG|intravenous morphine titration|intravenous morphine titration
219626826|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
219626827|NCT06482957|OTHER|Urine Collection|Undergo urine collection
219626828|NCT06482957|OTHER|Stool Collection|Undergo stool collection
219626829|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
219626830|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
219626831|NCT06668181|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
219626832|NCT06341998|DRUG|sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children|The planned treatment protocol comprised four cycles of the S-TIC regimen, which included sirolimus administered orally at a dose of 1 mg/m² from day 1 to day 21-28, nab-paclitaxel at a dose of 200 mg/m² on day 1, ifosfamide at a dose of 1200 mg/m² from day 2 to day 5, and carboplatin at a dose of 400 mg/m² on day 2. Additionally, mesna and sulfamethoxazole were prescribed to prevent hemorrhagic cystitis and Pneumocystis Jirovecii Pneumonia (PJP), respectively. Each cycle spanned a duration of three to four weeks. AFP levels were evaluated at the end of each cycle, and radiological assessments were conducted every two cycles. Surgical intervention decisions were made based on the results of these assessments.
219626833|NCT05933200|DRUG|Triheptanoin|Liquid for oral (PO) or enteral feeding tube administration
219626834|NCT05933200|DIETARY_SUPPLEMENT|MCT Oil|Liquid for oral (PO) or enteral feeding tube administration
219626835|NCT06424769|OTHER|Enhanced Digital Care|Participants will receive brief check-in surveys about their IBD symptoms once a month, via text messaging. If the survey response indicates significant symptoms, an alert will be sent to the participant's IBD care team and participant will receive more frequent surveys (weekly) over the next month. Participants and their IBD clinical team will be able to communicate by text for non-emergency IBD-related questions.
218937275|NCT01098513|DRUG|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
218937276|NCT01098513|DRUG|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
218937277|NCT01098513|DRUG|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
219626836|NCT06424769|OTHER|Education|Participants will receive education texts about IBD from trusted sources approximately twice a week. Topics will include: diet, medication adherence, fatigue, preventative care and other relevant issues.
219626837|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
219626838|NCT05990296|BEHAVIORAL|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
219626839|NCT05990296|BEHAVIORAL|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
219626840|NCT05990296|BEHAVIORAL|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
219626841|NCT06850571|DRUG|Bevacizumab Injection [Avastin]|1.25 mg intravitreal injection given once monthly for three consecutive months.
219626842|NCT06850571|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|2.0 mg intravitreal injection given once monthly for three consecutive months.
219626843|NCT05531773|OTHER|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
219626844|NCT06376500|DEVICE|tDCS with cognitive training programme|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
219626845|NCT05391841|DRUG|NOVOCART Inject|Autologous Chondrocyte Implantation
219626846|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
219626847|NCT04979793|DRUG|Placebo|Milk powder placebo
219626848|NCT04604873|OTHER|Hospital day care follow-up|Regular follow up every month in hospital day care
219626849|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
219626850|NCT03133455|OTHER|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
219626851|NCT05997264|BIOLOGICAL|AV7909 Full Dose (0.5 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
219626852|NCT05997264|BIOLOGICAL|AV7909 Half Dose (0.25 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
219626853|NCT05468164|DRUG|Selpercatinib|Administered orally
219626854|NCT05468164|DRUG|Omeprazole|Administered orally
219626855|NCT02438306|BIOLOGICAL|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
219626856|NCT02438306|OTHER|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
218937278|NCT04265105|DRUG|fluticasone-vilanterol|LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
218937279|NCT04265105|DRUG|Standard Preparation|inhaled SABA or Inhaled corticosteroid
218937280|NCT01543633|DRUG|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
218937281|NCT06519695|BEHAVIORAL|Multicomponent exercises|Performed exercise three times a week, one time at a community health service station and two times at home
219626857|NCT03007147|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219626858|NCT03007147|DRUG|Calaspargase Pegol|Given IV
218937282|NCT01632618|BEHAVIORAL|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
218937283|NCT01632618|BEHAVIORAL|Passive control intervention|Passive physical therapy approach to low back pain
219626859|NCT03007147|DRUG|Cyclophosphamide|Given IV
219626860|NCT03007147|DRUG|Cytarabine|Given IV, SC, or IT
219626861|NCT03007147|DRUG|Daunorubicin Hydrochloride|Given IV
219626862|NCT03007147|DRUG|Dexamethasone|Given PO or IV
219626863|NCT03007147|DRUG|Dexrazoxane Hydrochloride|Given IV
219626864|NCT03007147|DRUG|Doxorubicin|Given IV
219626865|NCT03007147|DRUG|Etoposide|Given IV
219626866|NCT03007147|BIOLOGICAL|Filgrastim|Given SC or IV
219626867|NCT03007147|DRUG|Ifosfamide|Given IV
219626868|NCT03007147|DRUG|Imatinib Mesylate|Given PO
219626869|NCT03007147|OTHER|Laboratory Biomarker Analysis|Correlative studies
219626870|NCT03007147|DRUG|Leucovorin Calcium|Given PO or IV
219626871|NCT03007147|DRUG|Levoleucovorin|Given PO or IV
219626872|NCT03007147|DRUG|Mercaptopurine|Given PO
219626873|NCT03007147|DRUG|Mercaptopurine|Given PO
219626874|NCT03007147|DRUG|Methotrexate|Given IT
219626875|NCT03007147|DRUG|Methylprednisolone|Given IV
219626876|NCT03007147|DRUG|Pegaspargase|Given IV
219626877|NCT03007147|DRUG|Prednisolone|Given PO
219626878|NCT03007147|OTHER|Questionnaire Administration|Ancillary studies
219626879|NCT03007147|DRUG|Therapeutic Hydrocortisone|Given IT
219626880|NCT03007147|DRUG|Thioguanine|Given PO
219626881|NCT03007147|DRUG|Vincristine Sulfate|Given IV
219626882|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
219048169|NCT07173400|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|Active TaVNS delivered with the VagusStim® device (Vagus Medical Technologies, Istanbul, Türkiye). The bipolar electrode was placed on the left cymba concha. Stimulation was applied for 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). Parameters included frequency 1-30 Hz, pulse width 50-250 μs, and current intensity individually adjusted (0.1-36 mA) to the participant's sensory threshold.
219048170|NCT07173400|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Sham stimulation delivered with the same VagusStim® device under identical conditions. The electrode was rotated and placed on the left earlobe, which lacks vagal innervation. Sessions lasted 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). No effective vagus nerve stimulation was delivered, preserving participant blinding.
219048171|NCT07172061|OTHER|PSV + sigh (Clinical PEEP and Clinical PEEP + 3 cmH₂O)|Each patient undergoes two sequential 15-minute steps: 1) pressure support ventilation at the clinical PEEP and 2) the same settings with PEEP increased by 3 cmH₂O. A ventilator-delivered sigh is programmed as one sustained inflation at 30 cmH₂O for 3 seconds every minute. All other ventilator parameters (trigger sensitivity, pressure support level, mandatory breath timing) remain unchanged. At the end of each step, inspiratory and expiratory holds are performed to collect respiratory mechanics and arterial blood gases; compliance during the sigh is calculated once flow is zero and airway pressure is stable.
219626883|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
219626884|NCT06370143|BEHAVIORAL|Questionnaire|The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered
219626885|NCT05573464|DRUG|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
219626886|NCT05573464|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
219626887|NCT05763290|OTHER|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
219626888|NCT06044454|OTHER|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
219626889|NCT04294628|PROCEDURE|Biopsy Procedure|Undergo biopsy
219626890|NCT04294628|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219626891|NCT04294628|PROCEDURE|Computed Tomography|Undergo CT scan
219626892|NCT04294628|PROCEDURE|Echocardiography Test|Undergo ECHO
219626893|NCT04294628|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219626894|NCT04294628|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219626895|NCT04294628|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219626896|NCT05443490|DIETARY_SUPPLEMENT|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10\^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
219626897|NCT05443490|OTHER|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
219626898|NCT03413384|DRUG|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
219626899|NCT03413384|OTHER|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
219626900|NCT00261209|DRUG|Collagenase|Collagenase injection into adhesion restricting tendon gliding
219626901|NCT00261209|DRUG|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
219626902|NCT04560270|DIAGNOSTIC_TEST|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
219626903|NCT05294237|BEHAVIORAL|Happy program|The Happy program consists of handball specific warm-up components and resistance training components and will be available online.
219626904|NCT05294237|BEHAVIORAL|Support|The support consists of a coach workshop at the beginning of the season and the opportunity for additional support for the coaches throughout the season.
219626905|NCT04846569|BEHAVIORAL|Transition Theory-based Intervention|The behavioral intervention is a theoretically driven curriculum focused on supporting mothers from pregnancy through postpartum in order to promote sustained HIV treatment adherence. Sessions utilize motivational interviewing and consist of a range of topics including motherhood, preparing for baby, disclosure, HIV education, adherence, birth experiences, support systems, and living positively.
219626906|NCT04846569|BEHAVIORAL|Enhanced Standard of Care Control|In addition to standard of care, participants receive the first session of the Transition Theory-based Intervention curriculum which focuses on motherhood and preparation for baby but does not discuss the transition from pregnancy to postpartum or the postpartum period.
219626907|NCT04158167|DRUG|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
219626908|NCT00382200|DRUG|decitabine|
219626909|NCT00382200|DRUG|tretinoin|
219626910|NCT00382200|GENETIC|DNA methylation analysis|
219626911|NCT00382200|GENETIC|cytogenetic analysis|
219626912|NCT00382200|GENETIC|microarray analysis|
219626913|NCT00382200|OTHER|flow cytometry|
219626914|NCT00382200|OTHER|immunohistochemistry staining method|
219626915|NCT06189937|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|"In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~1. Education on psychological trauma and its treatment, and basics of emotion regulation techniques~2. Education on anxiety and depressive disorders and their treatment~3. Muscle relaxation and stretching exercises~4. Education about depressive and grief-related disorders and disturbing memories protocol~5. Interoceptive exposure: head rotation and hyperventilation~6. Anxiety, worry, and stress~7. Anger and anger protocol; breathing exercises~8. Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants."
219626916|NCT00536939|DRUG|Enzastaurin|1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
219626917|NCT00536939|DRUG|Bevacizumab|10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
219626918|NCT00536939|DRUG|Paclitaxel|90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
219626919|NCT00536939|DRUG|Placebo|Oral, daily, until disease progression
219626920|NCT02989870|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
219626921|NCT02989870|DRUG|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
219626922|NCT02989870|DRUG|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
219626923|NCT06576349|BEHAVIORAL|Compassionate And Loving Mindset towards Heart Health Risk (CALM Hearts) Intervention|Self-compassion and health behaviour change intervention for women at risk for cardiovascular disease
219626924|NCT03391219|DRUG|injection bevacizumab|1.25 mg/0.05 cc bevacizumab
219626925|NCT03391219|DRUG|injection Combined Bevacizumab and Fasudil|1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
219626926|NCT04747119|OTHER|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
219626927|NCT04747119|OTHER|conventional selected physical therapy|"1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors"
219626928|NCT02840123|BIOLOGICAL|Autologous dendritic cells|
219626929|NCT02350491|OTHER|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
219626930|NCT02954601|DRUG|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
219626931|NCT02954601|DRUG|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
219626932|NCT02954601|DRUG|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
219626933|NCT02954601|OTHER|Placebo|fish oil placebo
219626934|NCT03667222|DRUG|minocycline topical gel|Once daily administration of BPX-04 minocycline gel for 12 weeks
219626935|NCT03667222|DRUG|topical gel vehicle|Once daily administration of BPX-04 gel vehicle for 12 weeks
219626936|NCT01438905|OTHER|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
219626937|NCT01438905|OTHER|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
219626938|NCT04391673|BEHAVIORAL|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
219626939|NCT06572059|OTHER|assesments for once|"* EDSS score (patient reports recorded in the physician's record will be used.)~* Demographic information~* Fatigue Severity Scale (FSS)~* Beck Depression Inventory (BDI)~* Kinesthetic and Visual Imagery Questionnaire (KSVI)~* Mental Chronometer Test (Nine-Hole Peg Test (DDPT)) will be used.)~* Jebson-Taylor Hand Function Test (JHEFT)~* Manual Ability Test (MAM-36)~* Multiple Sclerosis Impact Scale (MSIS-29)"
219641914|NCT02568020|DRUG|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
219641915|NCT01167738|DRUG|capecitabine|1250 mg/mq days 1-28 every 4 weeks
219048172|NCT07173192|BEHAVIORAL|Individual empowerment program|"Data collection tools will be applied to individuals in the experimental and control groups as a pre-test.~Individual empowerment training sessions will be applied to individuals in the experimental group totaling (6 sessions) as part of the individual empowerment program. No intervention will be performed on individuals in the control group; they will receive standard discharge education. Data collection tools will be applied to individuals in both groups for post-tests immediately after the experimental group completes all individual empowerment program sessions."
219626940|NCT04744649|DRUG|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
219626941|NCT04744649|DRUG|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
219626942|NCT03914716|DIAGNOSTIC_TEST|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
219626943|NCT06212414|BEHAVIORAL|Mind Programme|Intervention based on Acceptance and Commitment Therapy, mindfulness, and compassion approaches
219626944|NCT06212414|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening, and a sense of community between participants
219626945|NCT06310733|DRUG|LGG|Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
219626946|NCT06310733|DRUG|Placebo|Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
219626947|NCT01220466|DEVICE|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
219626948|NCT03466463|GENETIC|GNT0003|Intravenous infusion, single dose
219626949|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.
219626950|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.
219626951|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
219626952|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
219626953|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.
219626954|NCT00636246|DRUG|Placebo|Tablets, orally once per day for 8 weeks
219626955|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks
219048173|NCT07173426|DEVICE|Bioimpedance analysis|"Bioimpedance analysis involves electrodes attached to the patient's limbs which measures the resistance in the body to an imperceptible high-frequency, low-amplitude alternating electrical current. BIA measurements will include total body water (TBW), intracellular water (ICW), extracellular water (ECW), and the derived parameter dry weight. Results are available at the bedside within 2 minutes."
219048174|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with daily recombinant human growth hormone (rhGH)
219048175|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with weekly long-acting growth hormone (LAGH).
219048176|NCT07174089|OTHER|RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.|Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.
219626956|NCT00636246|DRUG|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
219626957|NCT01158846|DRUG|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
219626958|NCT01158846|DRUG|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
219626959|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg|orally once a day
219626960|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg|orally once a day
219626961|NCT05970510|DRUG|placebo|orally once a day
219626962|NCT00839683|DRUG|simvastatin|Tablets, Oral, 20 mg, Single Dose
219626963|NCT00839683|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
219626964|NCT00839683|DRUG|simvastatin|Oral, 40 mg, Single Dose
219626965|NCT00839683|DRUG|valsartan|Tablets, Oral, 320 mg, Single Dose
219626966|NCT00333983|DEVICE|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
219641916|NCT01167738|DRUG|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
219626967|NCT00333983|OTHER|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
219626968|NCT04227197|OTHER|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
219626969|NCT06041854|PROCEDURE|Freeze-dried bone allograft combined with Enamel Matrix derivative|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex."
219048177|NCT07173231|DEVICE|Immersive Virtual Reality Distraction (IVR)|The first experimental group will receive the INSPIRE® IVR intervention in addition to usual care. Developed by Paperplane Therapeutics®, INSPIRE® is specifically designed to help manage pain and anxiety in clinical settings. This intervention integrates immersive virtual environments with sensor-guided deep breathing techniques to engage the parasympathetic nervous system and promote relaxation. Within a calming forest environment, participants are guided to synchronize their breathing with the movement of a feather, encouraging breath control and relaxation. The immersive experience is enhanced through personalized therapeutic content and calming visual and auditory stimuli, helping to reduce anxiety while minimizing the risk of cybersickness. This program has been endorsed by a multidisciplinary team of healthcare professionals.
219048178|NCT07173231|DEVICE|Hypno-Virtual Reality Distraction (HVR)|The second experimental group will receive the HVR intervention in addition to usual care. This intervention, developed by HypnoVR, consists of a VR visual scenario combined with hypnotic verbal guidance specifically designed to reduce pain and anxiety during medical procedures. It is delivered through a validated and clinically approved HVR headset. The intervention includes reassuring and calming verbal suggestions aimed at helping participants regulate their emotions and manage anxiety throughout the procedure. Participants will be able to choose from 11 different visual scenarios, select their preferred language, and choose between a male or female voice for the hypnotic guidance. 6 different musical soundtracks will also be available to personalize the experience more.
219048179|NCT07173231|OTHER|Usual Care Group|The usual care group will only receive the standard preparation, which includes pre-treatment with Tylenol (1000mg) , Naproxen (500mg) and Ativan (1 mg) administered one hour prior to the procedure.
219048180|NCT07173348|OTHER|Hypnosis|Participants will undergo three 15-minute individual hypnosis intervention, conducted by a trained hypnotherapist, with a two-week interval between each session. A guide for the session has been developed by two experimented hypnotherapists specifically for this intervention and will be used for all sessions. A total of 3 hypnosis session will be realized.
219048181|NCT07173842|OTHER|Biobanking and Phenotypic Data Collection|This intervention involves the systematic collection of blood samples (EDTA tubes for DNA extraction) and detailed phenotypic/clinical data using the NeuroCybe Data Collector software. All biospecimens are processed and stored at the RTSGD-NeuroPsyBiT Biobank under ISO-compliant procedures. Data are entered into a secure on-premises server infrastructure (GDPR/KVKK compliant) for long-term use in genomic and epigenomic studies. No therapeutic intervention is applied; all activities are non-invasive and focused on sample and data acquisition.
219048182|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
219048183|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink (without liposomal)|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
219048184|NCT07172607|DIETARY_SUPPLEMENT|Placebo drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
219048185|NCT07174037|OTHER|Low spasticity group|low sapsticity (grade 1-2) unilateral ischemic stroke will be participate in this group
219048186|NCT07174037|OTHER|High spasticity group|high sapsticity (grade 3-4) unilateral ischemic stroke will be participate in this group
219048187|NCT07173439|DEVICE|Model Name: EMT-SR01;red|The investigational device incorporated both a driving simulation and an N-Back cognitive training function. These features were designed to engage and improve key cognitive abilities such as attention, working memory, and executive function, which are often impaired in individuals with ADHD. The combined use of driving tasks and N-Back exercises aimed to provide a comprehensive and interactive therapeutic intervention to reduce core ADHD symptoms.
219048188|NCT07173439|DEVICE|Model Name: EMT-SR01;red (Placebo)|The placebo device incorporated only the driving simulation function and excluded the N-Back cognitive training component. The driving simulation was designed as a sham intervention to mimic the user experience without providing the active therapeutic elements targeting cognitive functions. This setup enabled a controlled comparison with the active digital therapeutic device.
219048189|NCT03865836|BIOLOGICAL|ATB200|
219048190|NCT03865836|DRUG|AT2221|
219048191|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
219048192|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
219048193|NCT07172828|BEHAVIORAL|Virtual Reality-Based Rehabilitation|Participants receive 20 minutes of motor control exercises combined with 20 minutes of Pilates-inspired virtual reality games (5 repetitions per set). Training will be delivered three times per week, 40 minutes per session, for 8 weeks (24 sessions in total).
219626970|NCT06041854|PROCEDURE|Freeze-dried bone allograft|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed."
219626971|NCT00763425|PROCEDURE|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
219626972|NCT00763425|PROCEDURE|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
219048194|NCT07172828|BEHAVIORAL|Conventional Motor Control Exercises|Participants perform 40 minutes of progressive spinal stabilization and motor control exercises (10 repetitions per set), three times per week for 8 weeks (24 sessions in total).
219048195|NCT05391633|BEHAVIORAL|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
219048196|NCT05391633|BEHAVIORAL|Placebo Recording|60-minute blank recording played once daily for 14 total days.
219626973|NCT00570141|DEVICE|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
219626974|NCT06505707|BEHAVIORAL|Health Seeking Behavior Training Based on Motivational Interviewing Techniques|The Effect of Health Seeking Behavior Training Based on Motivational Interviewing Techniques on Health Seeking Behavior, Illness Self-Management and Anxiety in Migrant Elderly Women with Chronic Diseases.
219048197|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
219626975|NCT03783819|OTHER|Hypericum perforatum oil|Ointment containing Hypericum perforatum oil
219626976|NCT03783819|OTHER|Placebo|Ointment containing plant oils used in Hypericum perforatum oil production and dye
219626977|NCT03783819|PROCEDURE|SLS induced irritation|60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
219626978|NCT03783819|PROCEDURE|Tape-stripping|Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
219626979|NCT03783819|PROCEDURE|UV radiation|UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
219626980|NCT03783819|PROCEDURE|Intact skin|Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
219048198|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
219048199|NCT03890367|BIOLOGICAL|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219048200|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
219626981|NCT02992236|DRUG|VAS203|Infusion of NO-Synthase inhibitor VAS203
219626982|NCT02992236|DRUG|Saline|Infusion of saline
219626983|NCT06578533|DRUG|Sodium Zirconium Cyclosilicate|"The recommended starting dose of Lokelma is 10 g, administered three times a day.~If, at any time during the study, sK is \> 6.5 mEq/L, treatment for acute hyperkalemia will be started following common clinical practice and local protocols, and investigator will consider RAASi / MRA withdrawal, or downtitration. In this case (confirmed sK \> 6.5 mEq/L despite the maximum SZC dose) patient will leave the IP and will be counted as a treatment failure.~If sK is ≤ 3.0 mEq/L, discontinue SZC. The subject should immediately receive appropriate medical intervention.~If sK is between 3.1-5.1 mEq/L, pause SZC and re-evaluate in a week. This one-week SCZ treatment temporary discontinuation can only be applied once; if a new sK value between 3.1-5.1 mEq/L is detected, patient will leave the IP permanently.~Depending on the serum potassium levels at each visit, the dose of SZC will be adjusted."
219626984|NCT04358185|DRUG|Itacitinib (INCB039110)|Novel and small molecule selective inhibitor of JAK1
219626985|NCT06240169|PROCEDURE|DPC with MTA in AGEI|DPC using MTA in 18-40 years
219626986|NCT06240169|PROCEDURE|DPC with BD in AGEI|DPC using BD in 18-40 years
219626987|NCT06240169|PROCEDURE|DPC with MTA in AGEII|DPC using MTA in 41-60Years
219626988|NCT06240169|PROCEDURE|DPC with BD in AGEII|DPC using BD in 41-60Years
219626989|NCT02946372|PROCEDURE|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
219626990|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
219626991|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
219626992|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP)|syrup, 100 mg
219626993|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
219626994|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
219626995|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
219626996|NCT03683225|COMBINATION_PRODUCT|CTC-413|pramipexole ER, given with aprepitant
219626997|NCT01067781|BIOLOGICAL|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
219626998|NCT01067781|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
219048201|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
219048202|NCT01135810|BEHAVIORAL|Hypnosis|
219048203|NCT01135810|BEHAVIORAL|Meditation|
219048204|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
219048205|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
219048206|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
219048207|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
219626999|NCT05883072|BEHAVIORAL|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
219627000|NCT00801385|DRUG|erlotinib hydrochloride|
219627001|NCT00801385|DRUG|sorafenib tosylate|
219627002|NCT00801385|GENETIC|DNA analysis|
219627003|NCT00801385|GENETIC|mutation analysis|
219627004|NCT00801385|GENETIC|polymerase chain reaction|
219627005|NCT00801385|GENETIC|protein analysis|
219627006|NCT00801385|GENETIC|protein expression analysis|
219048208|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
219627007|NCT00801385|OTHER|immunohistochemistry staining method|
219627008|NCT00801385|OTHER|laboratory biomarker analysis|
219627009|NCT05765539|DEVICE|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~* One examination with the US machine by the midwife focused on 4 targets ;~* One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~* One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
219627010|NCT05493709|DRUG|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
219048209|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
219048210|NCT01636141|DRUG|Placebo gel|
219048211|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
219048212|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
219048213|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
219048214|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
219048215|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
219048216|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
219048217|NCT01707004|DRUG|decitabine|Given IV
219048218|NCT01707004|DRUG|fludarabine phosphate|Given IV
219627011|NCT05095818|OTHER|PrEP-RN|Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
219627012|NCT05779020|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
219627013|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
219627014|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
219627015|NCT06159166|DRUG|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
219627016|NCT06323928|DRUG|Lu AG09222|Lu AG09222 will be administered per the arm description.
219627017|NCT06323928|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per the arm description
219641917|NCT01167738|DRUG|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
219641918|NCT01167738|DRUG|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
219641919|NCT01167738|DRUG|metformin|2 g days 1-28 every 4 weeks
219048219|NCT01707004|DRUG|busulfan|Given IV
219048220|NCT01707004|DRUG|cyclophosphamide|Given IV
219048221|NCT01707004|DRUG|tacrolimus|Given PO or IV
219048222|NCT01707004|DRUG|mycophenolate mofetil|Given PO
219048223|NCT01707004|BIOLOGICAL|filgrastim|Given SC
219048224|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
219048225|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
219048226|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
219641920|NCT03105635|OTHER|Mixed method feasibility study|"Participating practices will receive the following:~1. Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~2. Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~3. Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~4. Navigator: The services of a Navigator"
219641921|NCT05197647|OTHER|Patients with symptomatic COVID-19 disease not requiring hospitalization.|Patients with symptomatic COVID-19 disease not requiring hospitalization.
219627018|NCT04489173|DRUG|trifluridine/tipiracil|"Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."
219627019|NCT06451263|BEHAVIORAL|Nudge|Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
219627020|NCT06474143|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
219627021|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
219048227|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
219627022|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
219627023|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
219627024|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
219627025|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
219627026|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
219627027|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
219627028|NCT03912064|DRUG|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
219627029|NCT03912064|BIOLOGICAL|CD25hi Treg depleted DLI|Donor lymphocyte product
219048228|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
219048229|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
219048230|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
219627030|NCT04556305|BEHAVIORAL|Mind|See arm description.
219627031|NCT04556305|BEHAVIORAL|Move|See arm description.
219627032|NCT03606785|DRUG|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
219627033|NCT03606785|DRUG|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
219627034|NCT00632060|PROCEDURE|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
219627035|NCT05353465|PROCEDURE|Radiofrequency denervation of the cervical facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the cervical facet joint with a three-tined expandable needle.
219627036|NCT00392366|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
219627037|NCT01646372|OTHER|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
219627038|NCT01646372|OTHER|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
219627039|NCT01595880|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
219627040|NCT01595880|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
219627041|NCT03125967|OTHER|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
219627042|NCT03125967|OTHER|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
219627043|NCT02323412|DRUG|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
219627044|NCT02323412|DRUG|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
219627045|NCT04903119|DRUG|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
219641922|NCT03258840|DIETARY_SUPPLEMENT|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
219641923|NCT03258840|DIETARY_SUPPLEMENT|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
219641924|NCT01283334|DRUG|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
219641925|NCT01283334|DRUG|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
219641926|NCT01283334|DRUG|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
219641927|NCT04265638|BEHAVIORAL|Exercise|One on one exercise with a cancer exercise specialist 1 hour 3 times a week for 12 weeks.
219627046|NCT04903119|DRUG|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
219627047|NCT04903119|DRUG|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
219627048|NCT04903119|DRUG|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
219627049|NCT04903119|DRUG|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
219627050|NCT04903119|DRUG|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
219627051|NCT04903119|DRUG|Encorafenib|encorafenib will be administered orally 450mg once daily for 28 consecutive days
219627052|NCT04903119|DRUG|Binimetinib|binimetinib will be administered orally 45mg twice daily for 28 consecutive days
219627053|NCT03808948|DEVICE|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
219627054|NCT04704310|BEHAVIORAL|Enhancing exercise training for adults with COPD: The roles of peers and functional tasks|A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
219627055|NCT03035617|DRUG|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
219627056|NCT03035617|OTHER|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
219627057|NCT01828723|BIOLOGICAL|SVF|
219627058|NCT03214224|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
219048231|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
219627059|NCT03214224|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
219627060|NCT05506618|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
219627061|NCT05506618|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
219627062|NCT02715193|BIOLOGICAL|REMD-477|
219627063|NCT02715193|BIOLOGICAL|Placebo Comparator|
219627064|NCT02595918|PROCEDURE|Metastasectomy|Undergo metastasectomy
219627065|NCT02595918|PROCEDURE|Nephrectomy|Undergo nephrectomy
219627066|NCT02595918|BIOLOGICAL|Nivolumab|Given IV
219627067|NCT00101270|DRUG|irinotecan hydrochloride|Given IV
219627068|NCT00101270|DRUG|oxaliplatin|Given IV
219627069|NCT04666987|DRUG|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
219627070|NCT05928078|BEHAVIORAL|intervention|Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
219627071|NCT02712320|DRUG|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
219048232|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
219048233|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
219627072|NCT05313503|OTHER|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
219627073|NCT01729390|OTHER|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
219627074|NCT05227859|PROCEDURE|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
219627075|NCT05227859|DEVICE|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
219048234|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
219627076|NCT05227859|DEVICE|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
219627077|NCT00685100|OTHER|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
219627078|NCT06016205|PROCEDURE|intrathecal morphine injection|Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
219627079|NCT06016205|PROCEDURE|ultrasound guided PECS2 block|ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
219627080|NCT01077297|DRUG|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
219627081|NCT04324424|DRUG|HMS5552|single dose of HMS5552 25mg
219627082|NCT03982511|BEHAVIORAL|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
219627083|NCT00491283|DEVICE|Swab Specimen Collection (QuickVue)|
219627084|NCT00568451|DRUG|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
219627085|NCT00568451|DRUG|paclitaxel|100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
219627086|NCT00568451|DRUG|temozolomide|150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
219627087|NCT02885545|DEVICE|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
219627088|NCT02885545|DRUG|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
219627089|NCT05266053|DEVICE|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
219627090|NCT05266053|OTHER|Standard wound dressing|Standard abdominal dressing at the time of cesarean
218937284|NCT00885222|DEVICE|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
219627091|NCT01593670|DRUG|Decitabine|administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
219627092|NCT01593670|DRUG|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
219627093|NCT01593670|BIOLOGICAL|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
219627094|NCT01593670|OTHER|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
219627095|NCT02767167|OTHER|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
219627096|NCT03426592|DRUG|Vitamin D3, 10000 Intl Units Oral Capsule|"Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
219627097|NCT03426592|DRUG|Placebo oral capsule|"Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
219627098|NCT03630926|DIAGNOSTIC_TEST|NV-VPAC1 PCa Urine Diagnostic Test|The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
219627099|NCT05645848|DEVICE|Ultrasonography|Abdominal ultrasound in pregnant women with placenta previa
219627100|NCT01343043|DRUG|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
219627101|NCT01343043|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
219627102|NCT01343043|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
219627103|NCT01294176|DRUG|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
219627104|NCT03517176|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
219627105|NCT03517176|DRUG|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
219627106|NCT03517176|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
219641928|NCT03467217|DRUG|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
219641929|NCT03467217|DRUG|Placebo losartan capsule|Matching placebo losartan oral capsule
219641930|NCT04833725|DEVICE|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
219627107|NCT05310682|OTHER|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
219627108|NCT02771067|PROCEDURE|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
219627109|NCT06449729|DIAGNOSTIC_TEST|Blood sample and urine collection|Blood sample and urine collection as per clinical practice
219627110|NCT06465862|DEVICE|TruTag System|TruTag technology system, consisting of microparticle-tagged Biktarvy and companion smartphone app.
219627111|NCT06465862|DRUG|Biktarvy Pill|Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
219627112|NCT06476301|DRUG|Rivaroxaban|To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
219627113|NCT02930772|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)"
219627114|NCT02996968|PROCEDURE|Self-removal|Self-discontinuation of a transurethral catheter
219627115|NCT01772810|DRUG|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
219627116|NCT03943043|DRUG|nab-paclitaxel|"Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~\- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D."
219627117|NCT06114381|OTHER|Home Based Physical Exercise|"Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response."
219627118|NCT06114381|DIETARY_SUPPLEMENT|Vitamin D3 Supplements|Vitamin D3 supplement (400mg) once daily.
219627119|NCT06114381|OTHER|Diet Management|Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
219627120|NCT06114381|BEHAVIORAL|Sun Exposure|Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
219627121|NCT03454334|DEVICE|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
219627122|NCT04029584|DRUG|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
219627123|NCT04029584|DRUG|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
219627124|NCT04029584|DRUG|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
219627125|NCT01387087|DRUG|ASP015K|oral
219627126|NCT01387087|DRUG|Placebo|oral
219627127|NCT01618175|DEVICE|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
219627128|NCT01918488|DIETARY_SUPPLEMENT|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
219627129|NCT01918488|DRUG|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
219627130|NCT00000807|DRUG|Etoposide|
219627131|NCT03207815|DRUG|Filgotinib|Tablet(s) administered orally
219627132|NCT03207815|DRUG|Placebo to match filgotinib|Tablet(s) administered orally
219627133|NCT03207815|DRUG|Prednisone|Tablet(s) administered orally
218937285|NCT00192634|DRUG|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
218937286|NCT00192634|DRUG|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
218937287|NCT01636518|PROCEDURE|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
218937288|NCT05261698|OTHER|Home-based Exercise Manual|in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
218937289|NCT05261698|OTHER|Conventional PT|In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
219048235|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
219048236|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
219627134|NCT04798794|OTHER|ECMO for neonates|Neonates (\<28 j) supported by ECMO for severe respiratory failure
219627135|NCT02444208|BEHAVIORAL|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
219627136|NCT02444208|BEHAVIORAL|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
219627137|NCT00391768|DRUG|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
219627138|NCT00452296|DRUG|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
219627139|NCT00452296|PROCEDURE|tight glycemic control|treatment with basal and bolus insulin
219627140|NCT05846100|PROCEDURE|Preprocedural spinal ultrasound|a preprocedural spinal ultrasound was performed in a non sterile manner with a sitting position.Both paramedian and transverse planes The intersection of the longitudinal and transverse lines is the point of needle insertion The distance from the skin to the dura mater is noted
219627141|NCT05846100|PROCEDURE|fictional preprocedure spinal ultrasound|fictional preprocedure spinal ultrasound Fictional ultrasound identification Screen device shut down
219627142|NCT01868737|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
219627143|NCT01868737|DIETARY_SUPPLEMENT|Placebo|MCT oil
219627144|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219627145|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219627146|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219627147|NCT03191383|DRUG|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219627148|NCT00172198|DRUG|Omegaven 10%|
219627149|NCT00070005|PROCEDURE|conventional surgery|
219627150|NCT00070005|PROCEDURE|management of therapy complications|
219627151|NCT03984500|OTHER|Education|SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
219627152|NCT01492907|RADIATION|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
219627153|NCT01492907|PROCEDURE|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
219627154|NCT04545671|OTHER|trifocal lens|not applicable as patients are already implanted with the trifocal lens
219627155|NCT05423288|PROCEDURE|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
219627156|NCT04208451|DIETARY_SUPPLEMENT|Alixir 400 Protect|During 30 days all patients take every day 30ml of Alixir 400 protect
219627157|NCT04022057|DRUG|Ropivacaine injection|Local anesthetic injection
219627158|NCT04022057|DRUG|Dextrose 5|Sham Injection
218937290|NCT00838513|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
218937291|NCT05213767|DRUG|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
218937292|NCT00842322|BEHAVIORAL|high fluid intake|fluid intake of 4 litres per day
218937293|NCT00842322|BEHAVIORAL|normal fluid intake|Fluid intake of 2 litres per day
218937294|NCT05952609|OTHER|Surefil One|Ion-releasing restoration
218937295|NCT05952609|OTHER|Cention N|Ion-releasing restoration
218937296|NCT05952609|OTHER|Bulkfil resin composite|resin composite (No ion-release)
218937297|NCT05988606|BEHAVIORAL|15 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 1 round of high-intensity interval training
218937298|NCT05988606|BEHAVIORAL|43 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 5 rounds of high-intensity interval training
218937299|NCT05988606|OTHER|Hot environment|Participants exercised in a hot environment, \~ 35 °C, \~40% relative humidity.
218937300|NCT05988606|OTHER|Temperate environment|Participants exercised in a temperate environment, \~ 22 °C, \~40% relative humidity.
218937301|NCT02416622|BIOLOGICAL|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
219627159|NCT00406367|DRUG|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
219627160|NCT00406367|DRUG|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
219627161|NCT00261586|DRUG|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
219627162|NCT00171210|DRUG|Deferasirox|Tablets taken orally once a day.
219627163|NCT01286610|DEVICE|ProMedVi Vibrosphere|vibration therapy
219627164|NCT01286610|DEVICE|schwa-medico MUSKELaktiv|Electrical muscle stimulation
219627165|NCT01286610|DEVICE|Galileo Home Plus (ICU)|vibration therapy
219627166|NCT00253435|BIOLOGICAL|Filgrastim|Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC \>=1500/uL for three consecutive days.
219627167|NCT00253435|DRUG|Carboplatin|"The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y."
219627168|NCT00253435|DRUG|Etoposide|The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
219627169|NCT00253435|DRUG|Melphalan|For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
219627170|NCT00253435|PROCEDURE|Peripheral blood stem cell infusion|Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10\^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10\^8 mononuclear cells/kg must be available.
219627171|NCT00253435|RADIATION|131I-MIBG|Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
219627172|NCT00253435|RADIATION|Radiation therapy|Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC \> 1000/uL, platelets \> 30,000 / uL, and is \> 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
219627173|NCT05917535|BEHAVIORAL|Mentalizing course|6 hour mental health education course about mentalizing.
219627174|NCT03910036|BIOLOGICAL|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
219627175|NCT04087993|DRUG|Polyglucoferron|intravenous administration
219627176|NCT04087993|DRUG|Ferric carboxymaltose|intravenous administration
219627177|NCT04087993|DRUG|Ferrous Sulfate|oral administration
219627178|NCT03632928|OTHER|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
219627179|NCT03632928|OTHER|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
219627180|NCT04610801|DRUG|Nasal Spray|Randomized to placebo and Xlear
219627181|NCT03324568|BEHAVIORAL|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
219627182|NCT03324568|BEHAVIORAL|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
219627183|NCT03187301|DRUG|APL-130277|APL-130277 single dose
219627184|NCT03187301|DRUG|Placebo|Placebo single dose
219627185|NCT03187301|DRUG|Moxifloxacin|moxifloxacin 400mg single dose
219627186|NCT02498704|PROCEDURE|Dry Needling|Trigger point dry needling to hamstring muscle group.
219048237|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
219048238|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
219627187|NCT02498704|OTHER|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
219627188|NCT03790501|OTHER|No intervention|As an observational study, no intervention will be associated with the study group.
219627189|NCT00000122|DRUG|5-Fluorouracil|
219627190|NCT04553939|DRUG|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
219627191|NCT04553939|DRUG|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
219627192|NCT00304096|BIOLOGICAL|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
219627193|NCT04730596|DRUG|Ketamine|Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.
219627194|NCT04730596|DRUG|Dexmedetomidine|Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.
219627195|NCT04730596|DRUG|Normal saline|Normal saline in a labeled syringe
219627196|NCT00133419|DRUG|Vitamin + Zinc + micronutrient mixture|
219627197|NCT00133419|DRUG|Vitamin A|
219627198|NCT00133419|DRUG|Vitamin A + Zinc|
219627199|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
219627200|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
219627201|NCT03827499|DIETARY_SUPPLEMENT|HMB dietary supplementation|Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
219627202|NCT03827499|OTHER|Multicomponent physical exercise program|Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
219627203|NCT02790099|DRUG|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
219627204|NCT02790099|DRUG|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
219627205|NCT05289336|PROCEDURE|Transoral Laser Microsurgery|
219627206|NCT05178615|OTHER|preoperative education|Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
219627207|NCT02158585|DRUG|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
219627208|NCT02158585|DRUG|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
219627209|NCT05005507|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
219627210|NCT05005507|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
219627211|NCT05005507|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
219627212|NCT05005507|DRUG|TAF|TAF film-coated tablet will be administered orally once daily.
219627213|NCT05005507|DRUG|ETV|ETV film-coated tablet will be administered orally once daily.
218937302|NCT00139477|DRUG|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
218937303|NCT00139477|BEHAVIORAL|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
218937304|NCT00139477|BEHAVIORAL|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
218937305|NCT01491984|DEVICE|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
219627214|NCT00942578|DRUG|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
219627215|NCT00942578|DRUG|Lenalidomide|Once daily days 1-14 of every 21
218937306|NCT01491984|DEVICE|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
218937307|NCT05162937|BIOLOGICAL|IL-17A antibody|Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
219627216|NCT00942578|DRUG|Docetaxel|75 mg/m\^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
219627217|NCT00942578|DRUG|Prednisone|10 mg orally every day
219627218|NCT04116840|DRUG|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
219627219|NCT04943146|DRUG|Prednisone 10 MG+aspirin 100MG|Discontinue medication based on early pregnancy outcome
219627220|NCT01223118|PROCEDURE|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
219627221|NCT01047059|DRUG|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
219627222|NCT01047059|DRUG|Fluoro-D-glucose|Tracer for PET imaging
219627223|NCT01047059|DRUG|Fluoro-L-thymidine|FLT-PET tracer for imaging
219627224|NCT01047059|DRUG|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
219627225|NCT02762942|DRUG|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
219627226|NCT02762942|DEVICE|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
219627227|NCT04381728|DEVICE|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
219627228|NCT01545531|DRUG|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
219627229|NCT06209723|OTHER|Vegetarian diet|Participants will follow a vegetarian diet during a period of five weeks
219627230|NCT00152334|DRUG|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
219627231|NCT05759741|DRUG|MIYAIRI 588|4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
219627232|NCT02375971|DRUG|Ranibizumab|Administered as an intravitreal injection
219627233|NCT02375971|PROCEDURE|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
219627234|NCT00754104|DRUG|ABT-869|0.25 mg/kg. daily.
219627235|NCT00754104|DRUG|Tarceva|150mg, daily.
219627236|NCT01640119|DIETARY_SUPPLEMENT|Bicarbonate|bicarbonate administration
219627237|NCT01504464|BIOLOGICAL|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
219627238|NCT01504464|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
219627239|NCT00963300|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
219627240|NCT00963300|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219627241|NCT00963300|PROCEDURE|magnetic resonance spectroscopic imaging|
219627242|NCT00963300|PROCEDURE|tissue-oxygen-level-dependent functional magnetic resonance imaging|
219627243|NCT02439541|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10\^7)
219627244|NCT02556775|BIOLOGICAL|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
219048239|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
219627245|NCT02556775|BIOLOGICAL|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
219048240|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
219048241|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
219627246|NCT01346059|DRUG|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
219627247|NCT01346059|DRUG|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
219627248|NCT00521820|DRUG|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
219627249|NCT00521820|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
219627250|NCT03754868|DIAGNOSTIC_TEST|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
219627251|NCT01510301|DEVICE|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
219627252|NCT00698672|DEVICE|charnley OGEE|charnley OGEE
219627253|NCT00698672|DEVICE|Spectron Reflection CoCr|Spectron Reflection CoCr
219627254|NCT00698672|DEVICE|Spectron XLPE CoCr|Spectron XLPE CoCr
219627255|NCT00698672|DEVICE|Spectron Reflection Oxinium|Spectron Reflection Oxinium
219627256|NCT00698672|DEVICE|Spectron XLPE CoCR|Spectron XLPE CoCR
219627257|NCT00034281|DRUG|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
219627258|NCT01780090|OTHER|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
219627259|NCT02840539|DRUG|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
219627260|NCT02344238|OTHER|ID Capsule|Capsule containing ingestible sensor
219627261|NCT02344238|DIETARY_SUPPLEMENT|Riboflavin|50mg
219627262|NCT02344238|BEHAVIORAL|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
219627263|NCT05002790|DIAGNOSTIC_TEST|Data collection group|"Magnetic resonance imaging (MRI) allows measurement of the axes described to suggest which head and neck position would provide best anatomical alignment to reduce anterior impingement.~All the MRI scans will be conducted using 3.0 Tesla (Optima 750w, GE Medical, Milwaukee, WI, USA) using the cervical spine section of the coil. T2-weighted images in the sagittal plane will be acquired using a fast recovery fast spin echo (FRFSE) technique. The scans will take around two and half minutes and a member of the anaesthetic investigator team will be present to facilitate positional changes and maintain consistency. MRI scanning will be performed in following 3 head and neck positions:~Neutral position, Sniffing position and the Extension position."
219627264|NCT02941211|DEVICE|Aqueduct -100|
219627265|NCT01698892|DRUG|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
219627266|NCT01698892|DRUG|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
219627267|NCT05031611|BEHAVIORAL|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
219627268|NCT04016129|BIOLOGICAL|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
219627269|NCT03540316|COMBINATION_PRODUCT|Two short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
219627270|NCT03540316|COMBINATION_PRODUCT|Two short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
219627271|NCT03540316|COMBINATION_PRODUCT|Four short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
219627272|NCT03540316|COMBINATION_PRODUCT|Four short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
219627273|NCT04806243|DRUG|Regorafenib Pill&Camrelizumab|Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
218937308|NCT06531785|DEVICE|chest ultrasound|Lung ultrasound to early diagnose ILD among rheumatoid arthritis patients
219048242|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
219627274|NCT02508350|DRUG|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
219627275|NCT02508350|OTHER|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
219627276|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
219627277|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
219627278|NCT01308021|BIOLOGICAL|Placebo|Placebo entero-coated capsules
219627279|NCT05047211|DRUG|Ferrous sulfate|one tablet 325 milligrams three times a day
219627280|NCT05047211|DRUG|Iron dextran|1000 mg intravenous infusion
219641931|NCT04530266|DIAGNOSTIC_TEST|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
219641932|NCT01770366|DEVICE|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
219641933|NCT01770366|DEVICE|Usual Care|
219641934|NCT00006024|DRUG|lomustine|
219641935|NCT00006024|DRUG|temozolomide|
219641936|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
219641937|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
219048243|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
219048244|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
219048245|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
219627281|NCT05103618|DRUG|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
219627282|NCT05103618|BEHAVIORAL|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
219627283|NCT06575985|OTHER|Heat acclimation and exercise training|10-day intervention consisting of daily 60-min exercise sessions aimed to induce increases in core body temperature, conducted in a climactic chamber set to 35°C and 50% relative humidity.
219627284|NCT06575985|OTHER|Thermo-neutral exercise training group|10-day intervention consisting of daily 60-min exercise sessions conducted in a climactic chamber set to 23°C and 50% relative humidity.
219627285|NCT06084481|DRUG|ABBV-400|Intravenous (IV) Infusion
219627286|NCT06084481|DRUG|Itraconazole (ITZ)|Oral Solution
219627287|NCT06094192|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
219627288|NCT00594165|DRUG|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
219627289|NCT02618291|OTHER|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
219627290|NCT02618291|OTHER|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
219627291|NCT02734537|DRUG|Cisplatin|Given IV
219627292|NCT02734537|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219627293|NCT02734537|OTHER|Laboratory Biomarker Analysis|Correlative studies
219627294|NCT04006639|PROCEDURE|Analgesic Technique|Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
219627295|NCT06575166|DEVICE|Abdominal wall tension|"Abdominal wall tension measurement All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
219627296|NCT06575166|DEVICE|Intra-abdominal pressure|Intra-abdominal pressure All patients will have their intra-abdominal pressure continuously monitored using Sentinel's FDA approved TraumaGuard catheter, a pressure-sensing urinary catheter.
219627297|NCT06505993|BEHAVIORAL|Health Communication|Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
219627298|NCT06505993|BEHAVIORAL|Health Communication + Structural|This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
219048246|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
219048247|NCT03853707|DRUG|Atezolizumab|Given IV
219048248|NCT03853707|DRUG|Capecitabine|Given PO
219627299|NCT02127515|PROCEDURE|Non Invasive Prenatal Testing|
219048249|NCT03853707|DRUG|Carboplatin|Given IV
219627300|NCT02127515|PROCEDURE|Invasive Prenatal Testing|
219627301|NCT07133399|DRUG|vicadrostat / empagliflozin combination 1|vicadrostat / empagliflozin combination 1
219627302|NCT07133399|DRUG|vicadrostat / empagliflozin 2|vicadrostat / empagliflozin 2
219048250|NCT03853707|DRUG|Ipatasertib|Given PO
219048251|NCT03853707|DRUG|Paclitaxel|Given IV
219048252|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
219048253|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
219048254|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
219048255|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
219048256|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
219048257|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
219048258|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
219627303|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
219627304|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
219627305|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
219627306|NCT06979609|DRUG|Oral Vancomycin Prophylaxis|125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days
219627307|NCT06979609|DRUG|Placebo|2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days
219627308|NCT06611839|DRUG|Ivosidenib, Venetoclax, Azacitidine|"phase I: Induction therapy：Ivosidenib 、Venetoclax、Azacitidine~Dose climbing stage: adopt the 3 + 3 design principle, and the dose level 0,-1and 1 are set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1,800mg d1-14 Azacitidine 75mg/m2/d, d1-7~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1, 600mg d1-14 Azacitidine 75mg/m2/d, d1-5~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-21 Azacitidine 75mg/m2/d, d1-7~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacitidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results"
219627309|NCT07001332|DEVICE|Elevate|The Elevate System is a catheter- mounted, self-expanding and retrievable, continuous-flow pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta, thus augmenting cardiac output and maintaining systemic arterial pressure during complex/high-risk coronary interventions. Subjects will receive an Elevate prior to their high-risk percutaneous intervention.
219627310|NCT07001332|DEVICE|Impella|Subjects will receive an Impella prior to their high-risk percutaneous intervention.
219627311|NCT03228667|DRUG|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
219627312|NCT03228667|DRUG|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
219627313|NCT03228667|DRUG|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
219627314|NCT03228667|DRUG|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
219627315|NCT03228667|DRUG|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
219627316|NCT03228667|DRUG|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
219627317|NCT03228667|DRUG|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
219627318|NCT03228667|DRUG|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
219627319|NCT03228667|DRUG|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
219627320|NCT03228667|DRUG|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
219627321|NCT03228667|DRUG|N-803 + Docetaxel + Pembrolizumab|The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
219627322|NCT03228667|DRUG|N-803 + Docetaxel + Nivolumab|The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
219048259|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
219048260|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
219048261|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
219048262|NCT03384446|OTHER|Implant-specific treatment|Implant brush
219048263|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
219627323|NCT07110610|DRUG|LTG-321|active investigational drug
219627324|NCT07110610|OTHER|Placebo|Placebo-to-match LTG-321
219627325|NCT07006727|DRUG|225Ac-ETN029|Radioligand therapy
219627326|NCT07006727|DRUG|111In-ETN029|Radioligand imaging agent
219627327|NCT06680622|DRUG|bemarituzumab, paclitaxel, ramucirumab|Cohort 2 will receive bemarituzumab plus SOC treatment with paclitaxel and ramucirumab
219627328|NCT06680622|DRUG|bemarituzumab, irinotecan|Cohort 1 will receive bemarituzumab plus SOC treatment with irinotecan
219627329|NCT06680622|DRUG|bemarituzumab, trifluridine/tipiracil|Cohort 3 will receive bemarituzumab plus SOC treatment with trifluridine/tipiracil
219627330|NCT06686056|COMBINATION_PRODUCT|AIM-CHD Mobile Health Intervention|The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.
219627331|NCT06686056|COMBINATION_PRODUCT|Usual post-discharge care|Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
219627332|NCT05379595|BIOLOGICAL|Amivantamab IV|Amivantamab will be administered as intravenous infusion.
219627333|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
219627334|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
219627335|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
219627336|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
219627337|NCT05379595|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
219627338|NCT07030257|DRUG|CP-383|Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells
219627339|NCT06263153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219627340|NCT06263153|PROCEDURE|Computed Tomography|Undergo CT
219627341|NCT06263153|BIOLOGICAL|Durvalumab|Given IV
219627342|NCT06263153|DRUG|Futibatinib|Given PO
219627343|NCT06263153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219627344|NCT06263153|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
219627345|NCT06706622|DRUG|Lu AF82422|Solution for infusion
218937309|NCT00482989|BIOLOGICAL|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
219627346|NCT06706622|DRUG|Placebo|Commercially available saline solution
219627347|NCT06707012|DRUG|Metformin Hydrochloride|"Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo"
219627348|NCT06758596|DRUG|Placebo Oral Capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
219627349|NCT06758596|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
219627350|NCT07060950|BIOLOGICAL|Blood sampling C1|"Blood samples will be collected at four key time points :~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
219627351|NCT07061613|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue.
219627352|NCT07059975|DRUG|Idarubicin Hydrochloride|Idarubicin is given in combination with fludarabine and cytarabine for Ida-FLA, and in combination with venetoclax and cytarabine for VIA.
219627353|NCT07059975|DRUG|Fludarabine|Fludarabine is given in combination with idarubicin and cytarabine for Ida-FLA.
219627354|NCT07059975|DRUG|Cytarabine (Ara-C)|Cytarabine is given in combination with other chemotherapy agents in every cycle and both arms.
219627355|NCT07059975|DRUG|Venetoclax|Venetoclax is given in combination with idarubicin and cytarabine for VIA.
219627356|NCT07059975|DRUG|Etoposide|Etoposide is given in combination with cytarabine for AE, as Intensification 1 for IR patients.
218937310|NCT00482989|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
218937311|NCT00616785|DRUG|cisplatin|
218937312|NCT00616785|DRUG|etoposide|
218937313|NCT00616785|DRUG|irinotecan hydrochloride|
218937314|NCT00616785|RADIATION|radiation therapy|
219627357|NCT07059975|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Rylaze is given in combination with cytarabine for Intensification 3 for IR patients.
219627358|NCT07059975|DRUG|Intrathecal triple|Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.
219627359|NCT07059975|OTHER|SOC|Low-Risk Patients will receive Texas childern's Hospital practice standard for de novo AML.
219627360|NCT07058467|OTHER|Joint Manipulation|"A joint manipulation is defined as a manual treatment by a clinician that uses controlled force to improve joint function. For the purpose of this study, the terms manipulation and mobilization may be used interchangeably. The knee joint is specifically defined as the tibiofemoral articulation for the purpose of this study.~All knee joint manipulation in this study will coincide with grade III or IV manipulations. This category coincides with evidence that mobilizations at or above grade III has the greatest impact on somatosensation and are most likely to produce a positive effect on neurocognitive function. Joint manipulation(s) will be delivered with a vector corresponding to the functional deficits found with manual joint palpation and will only occur with the involved ACLR knee. If both knees have experienced an ACL injury, the most recently injured knee will be manipulated."
219627361|NCT02082015|DEVICE|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
219627362|NCT01357837|DRUG|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
219627363|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
219627364|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
219627365|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
219627366|NCT00673439|DRUG|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
219627367|NCT00673439|DRUG|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
219627368|NCT02074241|OTHER|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
219627369|NCT01938638|DRUG|BAY1143572|
219627370|NCT06776250|DRUG|Tarlatamab|Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.
219627371|NCT04012021|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|"* T1-weighted and T2-weighted sequences~* quantitative magnetic resonance imaging approach~* proton spectrum analyses"
219627372|NCT02514486|BEHAVIORAL|Questionnaire|
219627373|NCT01879384|DEVICE|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
219627374|NCT06368297|DIETARY_SUPPLEMENT|Ketone Monoester Supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate \[β-HB\], and acetone).
219627375|NCT06368297|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet typically reduces total carbohydrate intake to less than 50 grams a day-less than the amount found in a medium plain bagel-and can be as low as 20 grams a day. Generally, popular ketogenic resources suggest an average of 70-80% fat from total daily calories, 5-10% carbohydrate, and 10-20% protein.
219627376|NCT06104020|OTHER|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
219627377|NCT06379997|DIETARY_SUPPLEMENT|Collagen, Hyaluronic Acid, Vitamin C, and Manganese|The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
219627378|NCT06379997|DRUG|Intra-articular infiltration|Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
219627379|NCT01421979|DIETARY_SUPPLEMENT|Energy Drink, Taurine, Caffeine|
219627380|NCT03585933|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis
219627381|NCT00925951|DEVICE|Wet Cupping|Wet cupping (Seongho trade \& company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
219627382|NCT00925951|DRUG|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
219627383|NCT01018927|DEVICE|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
219627384|NCT02448394|OTHER|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
219627385|NCT06319989|OTHER|Biplane Ultrasound|During a standard of care caudal epidural block, biplane ultrasound will be used.
219627386|NCT06319989|OTHER|Single plane ultrasound|During a standard of care caudal epidural block, single plane ultrasound will be used.
219627387|NCT06649955|DEVICE|Multi-site direct current stimulation (DCS)|The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
219627388|NCT06745908|DRUG|N-803|N-803 1.2 mg SC
219627389|NCT06745908|DRUG|Tislelizumab|Tislelizumab 200 mg IV
219627390|NCT06745908|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV
219627391|NCT07076199|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection
219627392|NCT07076199|DRUG|Insulin glargine|Insulin glargine will be administered as subcutaneous injection.
219627393|NCT07076199|DRUG|Insulin aspart|Insulin aspart will be administered as a subcutaneous injection.
219627394|NCT07081646|DRUG|AZD0120|Participants will receive AZD0120 via intravenous (IV) infusion.
219627395|NCT07084922|OTHER|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.
219627396|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
219627397|NCT07086794|DRUG|Placebo|The effects of placebo will be determined.
219627398|NCT07086794|DRUG|Cocaine (IV)|The effects of IV Cocaine will be determined.
219627399|NCT07086794|DRUG|Pentoxifylline|The effects of pentoxifylline will be determined.
219641938|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
219641939|NCT02796859|DRUG|Siltuximab|Investigational agent
219627400|NCT06834997|DRUG|Dronabinol Capsules|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
219627401|NCT06834997|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
219627402|NCT06746129|PROCEDURE|embryo transfer|transfer of embryo(s) into the uterine cavity
219627403|NCT03026140|DRUG|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
219627404|NCT03026140|DRUG|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
219627405|NCT03026140|DRUG|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
219627406|NCT03026140|DRUG|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
219627407|NCT03026140|DRUG|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29, in cohort 7 160mg on day 1, day 29 and day 57
219627408|NCT04594642|DRUG|AZD0486 IV|AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
219627409|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
219627410|NCT01215773|DRUG|Placebo|Matching to HEA 200 mg tablet, oral administration
219627411|NCT01215773|DRUG|BI 671800|High dose oral administration
219627412|NCT01215773|DRUG|BI 671800|Medium dose oral administration
219627413|NCT06906302|BEHAVIORAL|RISE|RISE is personalized, trauma-informed, empowerment-oriented and variable-length, consisting of an initial 60-minute session and up to 7 additional 45-minute sessions (1-8 sessions total).
219627414|NCT06906302|BEHAVIORAL|Advocacy-based ECAU|Advocacy-based ECAU is a single 60-minute trauma-informed counseling intervention that includes supportive education, validating and empathetic statements, safety planning, resource provision and referrals.
219627415|NCT06290778|BEHAVIORAL|Brief Unified Protocol|The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
219627416|NCT06290778|BEHAVIORAL|Psychoeducation|Psychoeducation regarding mental health challenges in fire service.
219627417|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
219627418|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
219627419|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
219627420|NCT06907875|BIOLOGICAL|EPI-321|EPI-321 IV Infusion
219627421|NCT07087834|OTHER|CASEM (Cancer Screenings Education for Men)|"Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session.~Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo"
219627422|NCT02975245|PROCEDURE|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
219627423|NCT04200937|DEVICE|Tactra Malleable|The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
219627424|NCT04200937|DEVICE|Spectra™ Concealable Penile Prothesis|The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
219627425|NCT04200937|DEVICE|AMS Ambicor™ Inflatable Penile Prosthesis|The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
219627426|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
219627427|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
218937315|NCT01209702|BIOLOGICAL|tocilizumab|Administered intravenously (iv) every 4 weeks
218937316|NCT01209702|DRUG|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
219627428|NCT06673043|DRUG|Anifrolumab|Anifrolumab 300 mg concentrate for solution for infusion
219627429|NCT07084558|DIAGNOSTIC_TEST|blood sample for Signatera (TM) test|ctDNA: Evaluation of ctDNA-status prior to treatment start (ctDNA not detected or ctDNA-positive) until the last of five follow-up visit
219627430|NCT07084558|DIAGNOSTIC_TEST|biopsy for Ki-67 assessment|Ki67: Evaluation of Ki-67-value after 3 weeks of aromatase inhibitor
219627431|NCT07084558|DIAGNOSTIC_TEST|FFPE tumor sample for Signatera (TM) test (archived)|Evaluation of ctDNA status prior to treatment start
219627432|NCT06877676|DRUG|TAR-200|Participants will undergo insertion of TAR-200 transurethrally into the bladder via catherization using the co-packed urinary placement catheter only in accordance with the Instructions for Use (IFU).
219627433|NCT00775853|DRUG|6-[18F]Fluorodopamine|
219627434|NCT00775853|DRUG|6-[18F]Fluorodopa|
219627435|NCT00775853|DRUG|13N-Ammonia|
219627436|NCT07092553|DEVICE|C-arm PCD-CBCT|A single research PCD-CBCT scan will be performed directly after the participant's SOC scan.
219627437|NCT07091318|BEHAVIORAL|Sleep quality improvement therapy|8 virtual CBTi sessions will be provided through a therapist weekly for the first four weeks and every other week for the last eight weeks of the study.
219627438|NCT07091318|BEHAVIORAL|Healthy Living|Health education emails and brief coaching calls will be provided weekly. The phone coaches will not provide counseling or goal setting but can clarify what participants had questions on like terms and concepts.
219627439|NCT07093073|DRUG|ssCART-19|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
219627440|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
219627441|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
219627442|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
219627443|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
219627444|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
219627445|NCT07088757|DRUG|standard dose indomethacin|Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.
219627446|NCT07088757|DRUG|low dose indomethacin|Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.
219627447|NCT07092033|DEVICE|Bimodal Neuromodulation|The device is a non-invasive stimulation device that consists of a controller that connects to headphones for sound delivery to the ears and connects to a mouth component that provides gentle electrical stimulation to the tongue surface. The sound is currently configured according to a tinnitus person's audiogram (i.e., hearing threshold profile for different sound frequencies) during device fitting. Individuals are recommended to use the device for 60 minutes daily (two 30-minute sessions consecutively or at different times of the day) for at least 12 weeks.
219627448|NCT07095920|DEVICE|Device: Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.
219627449|NCT07098715|DEVICE|Kerecis fish skin|To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.
219627450|NCT07022483|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg IV Q3W.
219627451|NCT07022483|DRUG|Chemotherapy|Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W followed by chemoradiotherapy.
219627452|NCT05272176|BEHAVIORAL|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
219627453|NCT07104292|BEHAVIORAL|PFMT|The motivation-informed intervention will tackle both exercise engagement and exercise adherence. Participating women will be introduced to the app and its videos following training. The participants will be introduced not only to muscle training, but also to muscle relaxation. The training will be recommended three to four times a week during pregnancy with further continuity after giving birth.
219627454|NCT07104292|BEHAVIORAL|Standard care|Standard care
219627455|NCT07096271|BEHAVIORAL|Get Better Together (GBT)|"Get Better Together is a couple-based, primary prevention program designed to reduce risk for suicidal thoughts and behaviors, problematic alcohol use, and intimate partner violence by addressing two transdiagnostic drivers: emotion dysregulation and relationship conflict. The intervention is an adaptation of the empirically supported Prevention and Relationship Enhancement Program (PREP), modified in collaboration with military stakeholders to meet the unique cultural and contextual needs of military couples.~The GBT curriculum includes approximately 10 hours of structured content presented using didactic instruction, video demonstrations, group discussions, and guided couple exercises. Skills focus on interpersonal emotion regulation (e.g., emotion identification, acceptance, reappraisal, and problem solving) and evidence-based communication strategies (e.g., structured communication strategies, conflict de-escalation)."
219641940|NCT02796859|DRUG|normal saline|Placebo
219627456|NCT07107906|BEHAVIORAL|The CONNECT Program|A group-based telehealth intervention grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and successful aging theories, aimed at reducing social isolation, loneliness, and mental health symptoms among adults 55+. Delivered over six weeks via group phone or Zoom sessions. The CONNECT Program includes 6 weekly 90-minute group sessions, with structured workbooks and homework. The CONNECT Program is delivered in two modalities (group telephone or Zoom videoconferencing).
219627457|NCT07107906|BEHAVIORAL|Community Participation as Usual (Service as Usual)|These community-based programs may include social, educational, or recreational group sessions that are already offered by local organizations - either in person, by phone, or virtually.
219627458|NCT06675565|DRUG|ALN-AGT01 RVR|ALN-AGT01 RVR will be administered subcutaneously (SC)
219627459|NCT06675565|DRUG|Placebo|Placebo will be administered SC
219627460|NCT06777433|DRUG|RAD101 (18F-FPIA)|A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
219627461|NCT07117240|DRUG|lixisenatide + glargine|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
219627462|NCT07117240|DRUG|Intensive insulin therapy|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
219627463|NCT07117539|DEVICE|visual bronchial blocker (VBB)|lung isolation with visual bronchial blocker
219627464|NCT07117539|DEVICE|double-lumen endotracheal tube (DLT)|lung isolation with double-lumen endotracheal tube
219627465|NCT03374865|OTHER|Facetalk|Area of interest: communication during Facetalk consultations
219627466|NCT03374865|OTHER|Face-to-face consultation|Area of interest: communication during face-to-face consultations
219627467|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
219627468|NCT01954576|DEVICE|NovoTTF-100A|
219627469|NCT01954576|PROCEDURE|Quality-of-life assessment|
219627470|NCT01954576|GENETIC|Laboratory biomarker analysis|
219627471|NCT06918964|DEVICE|transcutaneous auricular vagus nerve stimulation device|Place the stimulation device on the left auricle and set the stimulation parameters according to the following conditions: a. Waveform: biphase, square wave; b. Wave width: 200 μs; c. Frequency: Alternating between low frequency (4 Hz for 4 s), high frequency (40 Hz for 8 s), and a 4 s pause; d. Intensity: The maximum intensity that induces the strongest sensation the individual can tolerate without causing pain, usually 1.5-3.5 mA; e. Treatment duration: Each treatment lasted 30 minutes, twice daily (8:00, 16:00) for 10 days.
219627472|NCT06918964|DEVICE|Sham device|The sham taVNS group received the same parameters with a current intensity of 0.06 mA.
219627473|NCT07116499|DRUG|Placebo|Single oral dose of matching placebo
219627474|NCT07116499|DRUG|K-645 dose level 1|Single oral dose of K-645 dose level 1
219627475|NCT07116499|DRUG|K-645 dose level 2|Single oral dose of K-645 dose level 2
219627476|NCT07125157|BEHAVIORAL|Task-Specific Training with Biofeedback|Participants in this group will undergo task-specific training focused on improving balance and reducing fall risk. Real-time biofeedback (e.g., visual or auditory cues) will be integrated into the training to enhance motor learning and postural adjustments. Sessions will be supervised and conducted multiple times per week over the intervention period.
219627477|NCT07125157|BEHAVIORAL|Task-Specific Training without Biofeedback|Participants will receive task-specific training aimed at improving balance and fall prevention without any biofeedback assistance. The same set of functional exercises and session frequency will be followed as in the experimental group, ensuring the only difference is the absence of feedback stimuli.
219627478|NCT07133633|DRUG|Tulisokibart|Subcutaneous (SC) administration
219627479|NCT07133633|DRUG|Placebo|SC administration
219627480|NCT07139873|DRUG|DZD8586|Orally, 50 mg, once daily until treatment discontinuation criterion is met.
219627481|NCT07139873|DRUG|Bendamustine|Administered intravenously
219627482|NCT07139873|DRUG|Idelalisib|Administered orally
219627483|NCT07139873|DRUG|Rituximab|Administered intravenously
219627484|NCT07137312|PROCEDURE|Blood Draw|"Participants have a standard blood draw or apheresis on study. Some participants may provide a specimen via apheresis one time (the blood draw group) and then elect to provide a second optional specimen via a standard blood draw (the apheresis draw group) or vice versa."
219627485|NCT07137312|PROCEDURE|Apheresis|"Participants have a standard blood draw or apheresis on study. Apheresis is a procedure where blood is drawn from your body, specific components like plasma, platelets, and/or white blood cells are separated out, and the rest of the blood is returned. Some participants may provide a specimen via apheresis one time (the apheresis group) and then elect to provide a second optional specimen via a standard blood draw (the blood draw group) or vice versa."
219627486|NCT03581292|RADIATION|Radiation Therapy|Undergo radiation therapy
219627487|NCT03581292|DRUG|Temozolomide|Given PO
219627488|NCT03581292|DRUG|Veliparib|Given PO
219627489|NCT06934122|OTHER|manipulation with classical massage and spinal manipulation technique|All participants will first receive a massage to relax the muscles and then be manipulated with a spinal manipulation technique.
219627490|NCT06934603|OTHER|Clear Aligner Treatment|This study is observational. Only patients who are previously scheduled to receive clear aligner treatment from their orthodontic provider will be recruited.
219641941|NCT03281187|DRUG|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
219627491|NCT06934187|PROCEDURE|Carpal tunnel release|The operating surgeons will make a skin incision distally from the distal wrist crease and ulnar to the thenar crease. The appropriate tissues, including the subcutaneous tissue, palmar fascia, flexor retinaculum, and antebrachial fascia, will then be divided in CTR group. Haemostasis will be achieved using bipolar coagulation. The skin will be closed, and an appropriate dressing will be applied.
219627492|NCT06934187|PROCEDURE|Placebo surgery|Only an skin incision will be made and the same time as CTR operation takes will be waited until skin closure. An appropriate dressing will be applied.
219627493|NCT07140874|DRUG|Zinc citrate|Oral zinc citrate 30 mg daily
219627494|NCT07140874|DRUG|Placebo|Placebo
219627495|NCT07141277|OTHER|None (Observational study)|Not applicable since it's an observational study.
219627496|NCT06936462|DRUG|topical cyclosporine eyedrops and hyaluronic eyedrops|topical cyclosporine eyedrops and hyaluronic eyedrops
219627497|NCT06932081|DRUG|SGLT2 inhibitors|Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
219627498|NCT06880523|DRUG|STRIDE (durvalumab + tremelimumab)|As first treatment
219627499|NCT06880523|DRUG|Durvalumab|monotherapy every 4 weeks
219627500|NCT06880523|DRUG|Lenvatinib|Daily
219627501|NCT06737536|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
219627502|NCT06737536|OTHER|Placebo (NNC0662-0419)|Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
219627503|NCT05042102|COMBINATION_PRODUCT|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
219627504|NCT05042102|COMBINATION_PRODUCT|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
219627505|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
219627506|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
219627507|NCT01047527|DRUG|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
219627508|NCT06941441|OTHER|Home exercise program|A tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring
219627509|NCT06941532|DIETARY_SUPPLEMENT|GMP Intervention Product|Condition specific GMP based intervention product
219627510|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
219627511|NCT06943469|OTHER|Test formula|Partially hydrolyzed formula with synbiotics
219627512|NCT06943469|OTHER|Control formula|Intact protein formula without synbiotics
219627513|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
219627514|NCT07139236|PROCEDURE|Preoperative Endoscopic Ultrasound Elastography (EUS Elastography)|"All enrolled patients will undergo a preoperative EUS-E examination within one weeks prior to pancreaticoduodenectomy. The EUS-E will be performed by experienced endosonographers using a radial or linear array echoendoscope connected to a compatible ultrasound processor. Both qualitative (color mapping) and quantitative (strain ratio, strain histogram) data will be obtained. Multiple measurements of the strain ratio will be taken from a region of interest within the pancreatic parenchyma adjacent to the lesion. The mean strain ratio will be recorded for analysis. Standard EUS imaging will also be recorded.~Standard pancreaticoduodenectomy will be performed . Intraoperative pancreatic texture will be subjectively assessed by the surgeon and recorded. Postoperative monitoring for pancreatic fistula will follow established clinical guidelines."
219641942|NCT03281187|DRUG|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
219641943|NCT03281187|OTHER|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
219641944|NCT03281187|OTHER|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
219641945|NCT00481052|DRUG|Nilotinib|
219641946|NCT04635826|DRUG|Adderall 10Mg Tablet|Participants will be administered Adderall
219641947|NCT04635826|DRUG|Placebo|Participants will be administered placebo
219641948|NCT00964938|DEVICE|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
219641949|NCT00367731|DRUG|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
219641950|NCT04027725|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
219641951|NCT06513143|OTHER|CT images into virtual 3D model demonstration|The investigators have finished is personalized 3D model translation from CT images into virtual 3D model demonstrated in VR glasses using Synapse.
219627515|NCT06944353|BEHAVIORAL|STIRRED|"The STIRRED intervention is a behavioral intervention directed at the treating ED clinicians.~An Our Practice Advisory (OPA) will alert the clinician to the radiology finding of hepatic steatosis at the time of preparing the discharge materials. The OPA will prompt the clinician to discuss this finding with the patient and will automatically add hepatic steatosis to the discharge diagnoses and insert patient-facing discharge information about hepatic steatosis. It will additionally prompt the clinician to refer the patient for follow-up which will be stratified based on their fibrosis risk level."
219627516|NCT06948084|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219627517|NCT06948084|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219627518|NCT06948084|DRUG|Carfilzomib|Given IV
219627519|NCT06948084|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219627520|NCT06948084|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
219627521|NCT06948084|DRUG|Dexamethasone|Given PO or IV
219627522|NCT06948084|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
219627523|NCT06948084|DRUG|Pomalidomide|Given PO
219627524|NCT06948084|DRUG|Teclistamab|Given SC
219627525|NCT03293537|DIAGNOSTIC_TEST|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
219627526|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon physical optokinetic stimulation|The physical optokinetic stimulation consists of rotating stimulation in either direction using a physical disc (de Vestel, et al., 2022; Guerraz et al., 2001; van Ombergen et al., 2016). The assessment is conducted in complete dark, unless the fluorescent dots (approx. 11% covered of the disc area.). The disc has a diameter of 1 m. Stimulation time per trial will be 30 s.
219627527|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon virtual optokinetic stimulation|The virtual optokinetic stimulation is implemented in virtual reality goggles (Meta Quest 3, Meta Platforms, Menlo Park, CA, USA) applying oscillating and rotating stimulation in frontal and vertical axis with coherent or incoherent stimuli. The assessment in the virtual environment will be as similar as possible compared the physical stimulation. Hence, the virtual environment simulation complete dark, unless the fluorescent dots (approx. 15% covered of the disc area.). In addition to the rotating condition, the virtual dots are able to oscillate on the horizontal or vertical axis to create a more sensitive evaluation method than the physical one (Laurens et al., 2011). Stimulation time per trial will be 30 s.
219627528|NCT07140731|DEVICE|Symani Surgical System|To assess the safety and effectiveness of the Symani Surgical System
219627529|NCT07151885|DIAGNOSTIC_TEST|SHAPE|Use an ultrasound probe to scan the liver to locate the portal vein and hepatic vein. In the angiography mode, the portal vein and hepatic vein of the same depth were selected for measurement respectively. Ultrasound contrast agent was injected through the elbow vein to observe the changes of sub-harmonic signals in the portal vein and hepatic vein. Collect the sub-harmonic signal data of the portal vein and hepatic vein, and calculate the difference between the two, that is, the SHAPE gradient.
219627530|NCT07151833|DIETARY_SUPPLEMENT|GlucoBites (with Gynura procumbens)|Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.
219627531|NCT07151833|DIETARY_SUPPLEMENT|Control Cookies (without Gynura procumbens)|Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens.
219627532|NCT07151625|OTHER|Diet, whole food provided to participants over 5 x 9 day period|5 diets provided to participants over 9 days each and whole body protein synthesis, protein breakdown and protein balance assessed after each period.
219627533|NCT07151625|OTHER|Diet|5 different diet types
219627534|NCT07153211|DIAGNOSTIC_TEST|Immunological Factors|Assessment of interleukins and other molecues in CSF and blood of patients with SCS.
219627535|NCT07152782|DRUG|Neratinib|Neratinib, as an irreversible pan-HER tyrosine kinase inhibitor (TKI), holds a unique position in the treatment of HER2-positive breast cancer. From a molecular perspective, Neratinib irreversibly binds to the intracellular kinase domains of HER1 (EGFR), HER2, and HER4 through covalent bonds, comprehensively blocking signal transduction of the HER family. This mechanism of action is markedly different from reversible TKIs such as lapatinib. Neratinib's irreversible binding characteristic allows for a more sustained inhibition of target activity, maintaining anti-tumor effects even after drug plasma concentrations have decreased. This feature is particularly important for HER2-positive breast cancer, which requires continuous suppression of proliferative signals.
219627536|NCT07152782|DRUG|Trastuzumab Deruxtecan|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients"
219627537|NCT07151352|OTHER|Starting Condition - Barefoot|Participants walk barefoot along a 10-meter walkway without wearing shoes or socks.
219627538|NCT07151352|OTHER|Barefoot-Style Footwear|Participants walk along a 10-meter walkway wearing minimalist footwear with a 3 mm flexible sole, 0 mm heel drop, wide toe box, and no rigid heel counter.
219627539|NCT07151352|OTHER|Conventional Footwear with Heel Drop|Participants walk along a 10-meter walkway wearing structured footwear with a rigid sole (12 mm heel / 7 mm forefoot), 5 mm heel drop, reinforced heel counter, and narrow toe box.
219641952|NCT02787824|DRUG|Iron Sucrose Supplement|
219641953|NCT04480671|PROCEDURE|Level III support procedure|A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.
218937317|NCT00010829|BEHAVIORAL|American Heart Association Step 1 diet|
218937318|NCT00010829|BEHAVIORAL|American Heart Association Step 2 diet + 10 g/day flax seed|
219627540|NCT07153185|DEVICE|Dental Barrier Membrane|Patients treated with creos xenoprotect dental barrier membrane in the past
219627541|NCT07152561|DRUG|Zirconia crown cemented with Predicta® Bioactive Cement|• For the bioactive cement group (Predicta® Bioactive Cement), the prepared tooth will be dried using compressed air but not desiccated. Cement will be dispensed through the auto-mixtip directly into the crown, and the crown will be properly positioned over the tooth; cement will be allowed to self-set for 20 seconds while maintaining gentle pressure on the crown. Buccal and lingual margins will be flash-cured for 10 seconds each using a light-curing unit to immediately cure the excess cement for easier removal, and buccal and lingual surfaces will then be light-cured for an extra 10 seconds each.
219627542|NCT07152561|DRUG|Zirconia crown cemented with resin-cement|• For the resin-cement group, the tooth will be dried with compressed air but not desiccated. The sealant will be applied with the syringe; then, the crown will be appropriately positioned over the tooth, and cement will be allowed to self-set for 2 minutes and cured while maintaining gentle pressure on the crown. Excess cement will be removed before the cement is completely set.
219627543|NCT07152288|DRUG|HSK39297 tablets|oral
219627544|NCT07152288|DRUG|HSK39297 tablets|oral
219627545|NCT07152288|DRUG|HSK39297 tablets|oral
219627546|NCT07151729|DEVICE|Anodal tDCS|This anodal tDCS is applied over the contralateral dorsal premotor cortex (instead of the ipsilateral motor cortex in previous studies).
219627547|NCT07151729|DEVICE|Sham tDCS|Sham tDCS is applied
219627548|NCT07152600|DRUG|Saline (0.9%, sterile, for infusion)|Sailine as control
219627549|NCT07152600|DRUG|low dose Methylprednisolone|Methylprednisolone 0.5mg/kg ivgtt qd
219627550|NCT07152600|DRUG|Moderate dose Methylprednisolone|Methylprednisolone 1.0mg/kg ivgtt qd
219627551|NCT07151443|PROCEDURE|Conventional approach to infraclavicular block|Conventional approach to infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
219627552|NCT07151443|PROCEDURE|Retroclavicular approach to the infraclavicular block|Retroclavicular approach to the infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
219627553|NCT07149415|DRUG|Omaveloxolone|Oral capsules
219627554|NCT07149415|DRUG|Omeprazole|Oral tablet
219627555|NCT07152418|BIOLOGICAL|Lecanemab 10 mg/kg|Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.
219627556|NCT07152418|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
219627557|NCT07152028|OTHER|Exercise program with supervised and home-based components|The 12-week program targets balance, muscular strength, core endurance, and cardiovascular fitness. Weeks 1-6 are supervised; weeks 7-12 are home-based via a video catalogue. Walking ≥30 min on ≥2 non-training days is advised. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored via exercise diaries and weekly phone calls with adjustments as needed.
219627558|NCT07152028|OTHER|Fully supervised exercise program|The 12-week program is fully supervised and includes warm-up, balance, aerobic, strength, and core exercises. Walking ≥30 min on ≥2 non-training days is included. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored by a physiotherapist using exercise diaries.
219627559|NCT07149857|DRUG|Cilta-cel|Cilta-cel will be administered as intravenous infusion.
219627560|NCT07149857|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as intravenous infusion.
219627561|NCT07149857|DRUG|Induction therapy|Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd), will will be administered.
219627562|NCT07149857|DRUG|Fludarabine|Fludarabine will be administered as intravenous infusion.
219627563|NCT03598309|DRUG|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
219627564|NCT03598309|DRUG|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
218937319|NCT00010829|BEHAVIORAL|Macrobiotic dietary intervention|
218937320|NCT03934099|DRUG|LC350189 formulated capsule|Xanthine Oxidase Inhibitor
219627565|NCT03598309|OTHER|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
219627566|NCT07156786|DRUG|N-acetylcysteine (NAC)|N-Acetylcysteine effercescent 1200 mg orally twice a day for 7 days. One day before cisplatin based chemotherapy, on the chemotherapy day, and five days after.
219627567|NCT07156786|DRUG|Placebo|Patient will get placebo
219627568|NCT07160153|DIAGNOSTIC_TEST|Neurocognitive assessment|"Neurocognitive battery:~TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs~Other psychometrics:~The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)"
219627569|NCT07160153|DIAGNOSTIC_TEST|Urine toxicological assessment|Urine toxicological assessment
219627570|NCT07168928|BEHAVIORAL|School-Based Nutrition Education Program|The intervention consisted of an eight-week, school-based nutrition education programme delivered to fourth-grade students by a school dietitian. Sessions were conducted once per week and included interactive lectures, games, and educational activities focusing on healthy eating, food groups, balanced meals, and the risks of processed food consumption. In addition, parents of students in the intervention group received a four-week educational programme on child nutrition, meal planning, and healthy lifestyle practices.
219627571|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|Randomized in a 1:1 ratio through the randomization system, and assigned to medium-pressure group or low-pressure group.
219627572|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the high weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles.~In the high weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles."
219627573|NCT07168720|DRUG|placebo|In the high weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
219627574|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the low weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles.~In the low weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles."
219627575|NCT07168720|DRUG|Placebo|In the low weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
219627576|NCT07174440|DRUG|Ropivacaine (Epidural analgesia)|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
219627577|NCT07174440|DRUG|Dexmedetomidine|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
219627578|NCT07174440|DRUG|Iohexol|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care except for iohexol which is used for study purposes.
219627579|NCT07174440|PROCEDURE|QST Procedure|The QST procedure (test of buzzing sensation and temperature sensation through pads applied to your skin) to assess the numb areas.
219627580|NCT07183293|DRUG|Peginterferon alfa-2b combined with NAs|Subcutaneous injection therapy,Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
219627581|NCT07183293|DRUG|NAs|Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
219627582|NCT07184073|BEHAVIORAL|assessment Mini mental state examination|pre operatively four weeks postoperatively
219627583|NCT07184073|BEHAVIORAL|assessment FRAIL scale|pre operatively four weeks postoperatively
219627584|NCT07184073|OTHER|collecting cerebrospinal fluid during regional anesthesia|In the operating room regional anesthesia was administered according to the surgical plan
219627585|NCT07182253|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha® capsule|Single off-white capsule contains 300 mg Ashwagandha root extract powder only
219627586|NCT07182253|OTHER|Identical Placebo capsule|Single off-white capsule contains starch powder only
219627587|NCT07183085|BEHAVIORAL|Intervention|Digital mental health program incorporating personalized physical and mental health exercises focused on physical activity, sleep hygiene, and mindfulness.
219627588|NCT07183670|DIAGNOSTIC_TEST|decannulation protocol|"Step 1: The patient's clinical stability is confirmed. Step 2: Tolerance to the speaking valve is assessed. Step 3: The wearing time of the speaking valve is extended continuously for 4 h, and no tracheostomy cannula is used for sputum suction within 4 h.~Step 4: Cough strength is evaluated to be good before decannulation. Decannulation Criteria: Pass Step 1 + Step 2 + Step 3 + Step 4"
219627589|NCT07183176|DEVICE|Chattanooga CEFAR Tens|"* The patient will be assigned to one of two groups:~  1. The intervention group: called the REAL TENS group (R- TENS)~ 2. The control group: called the FAKE TENS group (F-TENS)~     Step 2: The doctor investigator 1 will place the TENS on the painful area identified by the patient, following the model proposed in appendix 1.~     Step 3: The doctor investigator 1 will explain to patients in both groups that they may feel a slight tingling sensation or no sensation at all.~     Step 4: The doctor investigator 1 will make the following settings on the TENS:~* For the interventional group (REAL TENS) a combined setting will be used:~  1. Tens Burst (P2) at 2Hz and 180 µs with an action on muscle pain.~ 2. Tens gate control (P9) at 100 Hz and 250 µs with an action focused on nociceptive pain.~* For the control group (FAKE TENS), the doctor will not make any real adjustments.~The patient will not be able to see the settings made by the doctor investigator 1.~Stage 5: The doctor investigator"
219627590|NCT07182604|OTHER|educational program on the POP prevention|During a regular prenatal class meeting, parents belonging to this group received information about POP and how to prevent it (a presentation by a physiotherapist, a video shown to all centers participating in the study, practical demonstrations of activities using a doll, and a brochure with prevention tips). The children were then assessed at birth to rule out congenital disorders and at 3 months to detect any POP and associated postural problems. They were then sent a questionnaire to assess their perceived quality of the educational intervention carried out by the physiotherapist during the prenatal course.
219627591|NCT07182344|DEVICE|Intermittent Theta Burst Stimulation to Right DLPFC|Participants receive intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC). The protocol consists of 600 pulses delivered in bursts of 3 pulses at 50 Hz, repeated at 5 Hz for 2 seconds, every 10 seconds, over approximately 3 minutes per session. Stimulation is delivered at 80% of the participant's active motor threshold. Ten sessions are administered across two weeks.
219641954|NCT04480671|PROCEDURE|Minimally Invasive Sacrocolpopexy|All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
218937321|NCT03934099|DRUG|Placebo|Matching placebo
218937322|NCT02380469|BEHAVIORAL|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
218937323|NCT04088058|DRUG|GXHPC1|autologous ADSCs
218937324|NCT00528450|DRUG|arsenic trioxide|
218937325|NCT00528450|DRUG|idarubicin|
218937326|NCT00528450|DRUG|tretinoin|
218937327|NCT02909543|OTHER|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
219627592|NCT07182344|DEVICE|Sham Intermittent Theta Burst Stimulation|Participants receive sham intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (DLPFC) using a placebo coil. The coil replicates the sound and scalp sensation of active stimulation without generating sufficient magnetic output to alter cortical excitability. Session length, coil placement, and stimulation parameters are matched to the active iTBS condition. To preserve blinding, both participants and administering staff wear earplugs to minimize auditory differences between sham and active coils. This condition serves as a placebo control for evaluating iTBS effects on attention in children with ADHD.
219627593|NCT07183033|BEHAVIORAL|VR-Based Resistance Training Intervention|"Participants in the intervention group will engage with a self-developed VR resistance training program entitled Kitten Crossing the Bridge. This program is designed to guide older adults through static lower-limb resistance exercises, while integrating rhythm control, spatial judgment, and visual feedback. The intervention will be administered over 4 weeks, with two sessions per week; each session will last approximately 20 minutes (excluding equipment setup and rest periods). All training sessions will be supervised by qualified staff to ensure participant safety and provide necessary support."
219627594|NCT07183033|BEHAVIORAL|Standardized Leg-Raising Training|Participants in the control group will implement a standardized leg-raising exercise protocol, which is designed to match the intensity and rhythm of the VR-based intervention. Training will be guided by pre-recorded verbal prompts and demonstration videos developed by the research team, ensuring procedural uniformity. Each session will last approximately 20 minutes (excluding equipment setup and rest periods), with two sessions per week over a 4-week duration. All sessions will be supervised by trained staff, who will monitor participant adherence and ensure safety throughout the process.
219627595|NCT07183254|OTHER|administration of questionnaires|"During this visit, the investigator will again explain the study objectives and procedure. Once these explanations have been provided, healthy volunteers will be able to give their informed consent to participate.~After signing the consent form, the following will be conducted during this visit:~* A medical examination.~* An electronic questionnaire including two consumption frequency assessment tools, adapted in French, to measure daily sugar and artificial sweetener intake.~* Five tests assess the level of dependence on alcohol, drugs (cannabis, solvents, tranquilizers, barbiturates, cocaine, stimulants, hallucinogens, or narcotics), gambling, video games, and possible eating disorders. Volunteers with a score deemed above the norm for at least one of these six tests will be excluded from this study.~* A urine screening test for drug use (cannabis, opiates, amphetamines, cannabinoids, benzodiazepines, cocaine) will be performed during this visit."
219627596|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI will take place in the days following the inclusion visit, depending on the availability of research slots in the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
219627597|NCT07183254|DIETARY_SUPPLEMENT|"Can distribution visit for subjects in the non/low sweetener consumption group"|During this visit, scheduled following the MRI, subjects will go to the PIC/CIC where they will be given cans for the 5 weeks of the nutritional intervention (660 ml of sweetened beverage, or 2 cans per day). Subjects will be advised to arrive by car if possible and to park in the PIC/CIC parking lot at the foot of the building. Drinks will be provided to the subject in one or two batches (with an additional visit to the center to pick up any missing drinks) at the subject's convenience. They will also receive instructions for completing the electronic questionnaire to assess daily sugar and sweetener consumption. Subjects will complete this questionnaire weekly, which they will receive by email. Their email address will be collected during this visit.
219627598|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI, post-nutritional intervention (5 weeks) in non- and low-sugar consumers: this exploration will take place depending on the availability of research slots at the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
219627599|NCT07182916|OTHER|No intervention|Only observation
219627600|NCT07182825|BEHAVIORAL|Modified Multifidus Lift Exercise (MLE)|A supervised stabilization exercise protocol designed to selectively activate the lumbar multifidus muscle. In the quadruped position, the contralateral knee is maintained approximately 10 cm above the ground while the participant performs controlled trunk stabilization. Sessions are conducted twice weekly for 6 weeks, each including warm-up (5 minutes brisk walk, mobilization, hamstring stretch), the modified Multifidus Lift Exercise with progressive repetitions (weeks 1-2: 8-10, weeks 3-4: 10-12, weeks 5-6: 12-15), and cool-down (static stretches). All sessions are supervised to ensure correct form, breathing control, and safety.
219627601|NCT07182292|DIETARY_SUPPLEMENT|Anti-Inflammatory Supplement|"A daily oral dose of Alisenoc™, an anti-inflammatory nutritional supplement specifically designed for older adults. Alisenoc™ contains olive oil polyphenols, omega-3 fatty acids (EPA/DHA), leucine-enriched protein, and antioxidant micronutrients to target inflammaging, sarcopenia, and nutritional deficiencies.~Participants will be followed at 12 weeks, and at 6 and 12 months for functional, biochemical, and clinical outcomes."
219627602|NCT07182292|DIETARY_SUPPLEMENT|Conventional Nutritional Supplement|"they will receive a conventional oral nutritional supplement that is isocaloric and protein-equivalent to the experimental product, but without anti-inflammatory ingredients.~This standard supplement reflects routine nutritional support typically provided in geriatric clinical practice for malnourished patients. It contains energy, protein, and micronutrients but no specific anti-inflammatory components such as olive polyphenols or omega-3 fatty acids."
219641955|NCT04480671|OTHER|Transperineal ultrasound of the Pelvic Floor|Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
218937328|NCT00045318|DRUG|exatecan mesylate|
218937329|NCT04796194|COMBINATION_PRODUCT|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
218937330|NCT00573144|DRUG|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
218937331|NCT00573144|DRUG|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
219627603|NCT07181980|OTHER|Intercostal mulligan mobilization with shoulder abduction|"Intercostal mulligan mobilization with shoulder abduction: is mulligain technique where the patient was Side lying with affected side up and the therapist Therapist placed ulnar side of his hand along the intercostal space of affected rib in oblique direction on the patient's wall of chest. Therapist's other hand hold the patient's elevated arm close to his abdomen 3sets 10 reptations~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching.~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set.~* Scapular strengthening exercises : two sets of ten repetitions~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
219627604|NCT07181980|OTHER|Exercise|"1.3.b. Therapeutic Exercise:~* Therapeutic exercise included: (prior to 3 month post mastectomy).~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching. .~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set. .~* Scapular strengthening exercises : Strengthening exercises performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5kg and progressed to 0.75 and then 1 kg.~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
219627605|NCT07182643|DIAGNOSTIC_TEST|Endometrial fluid|Endometrial fluid collection in the day of OPU
219627606|NCT07182643|DIAGNOSTIC_TEST|Endometrial biopsy|Endometrial biopsy on the OPU day, Pipelle
219627607|NCT07182643|DIAGNOSTIC_TEST|Follicular fluid|Follicular fluid sampling on the OPU day
219627608|NCT07184112|BEHAVIORAL|The Embedded Micro-Scenario Simulations (EMSS)|he Embedded Micro-Scenario Simulations (EMSS) for nursing students include a series of engaging clinical cases designed to bridge the theory-practice gap. In Prioritization of Care, students must prioritize three patients with varying degrees of urgency, honing their critical thinking skills. The Patient Education on Discharge scenario tasks them with effectively communicating self-care instructions. In End-of-Life Care, students provide compassionate support to a terminally ill patient and facilitate family discussions.
219627609|NCT07183735|DIETARY_SUPPLEMENT|BEAM Dream Powder|A powdered sleep supplement. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 3-6.
219627610|NCT07183735|DIETARY_SUPPLEMENT|Placebo Control|A powdered placebo product. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 1-2.
219627611|NCT07183228|BEHAVIORAL|Lifestyle Intervention for Obesity|A multimodal obesity lifestyle program delivered via the Eatit app. The dietitian-led intervention consists of 11 structured modules with weekly dietitian support (video consultations and messaging) during the first 11 weeks, followed by monthly video consultations up to six months. The program integrates behavior change techniques with individualized nutrition counseling provided by licensed dietitians.
219627612|NCT07183475|DIAGNOSTIC_TEST|Return to sports test|"The return-to-sport-tests are based on validated procedures commonly used in sports orthopedics, particularly following the stepwise testing concept described.~Initially, the participant's individual sport level is determined via structured anamnesis. This is then followed by level-specific functional testing. Participants who do not perform Level 1 testing correctly will not proceed to Level 2 testing-even if their anamnesis suggests a higher sport level. This stepwise approach ensures safety and prevents injury during the testing process."
219627613|NCT07182812|BEHAVIORAL|Blood Flow Restriction Sit-to-Stand Exercise|Participants perform sit-to-stand (STS) exercises with blood flow restriction applied using a pneumatic cuff placed on the thigh. Cuff pressure is set at 60-80% of the participant's systolic blood pressure. Sessions are supervised by a physiotherapist twice per week for six weeks.
219627614|NCT07182812|BEHAVIORAL|Sit-to-Stand Exercise without Blood Flow Restriction|Participants perform the same sit-to-stand (STS) exercise protocol as the experimental group, but without blood flow restriction. Sessions are supervised twice weekly for six weeks, and outcomes are assessed before and after the program.
219627615|NCT07182578|OTHER|Aquatic Occupational Therapy|Aquatic Occupational Therapy sessions will be 60 minutes long, with 45 minutes spent in the pool. Sessions will include a gentle floating, stretching, or aqua yoga warm-up and an ai chi cooldown. Exercises in the first month will include a focus on balance, breathing, and sensory work. Exercises in the second month will focus on building strength and endurance, while the third month will combine all of the above with dual-task completion. Activities will be graded down (made less difficult) or graded up (made more challenging) according to individual participant needs.
219627616|NCT07184320|BEHAVIORAL|AI-Based Video Education on Denture Care|The intervention consists of an AI-based educational video module, approximately 8 minutes in duration, designed to improve denture care practices. It uses step-by-step, visually engaging demonstrations with AI-guided narration to enhance understanding, recall, and adherence.
219627617|NCT07184320|BEHAVIORAL|Conventional Oral Health Instruction|Participants in the control group will receive conventional oral health education delivered verbally and chairside by the prosthodontic team. The standardized instruction includes information on denture hygiene techniques, appropriate storage of dentures overnight, mucosal care
218937332|NCT04574635|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218937333|NCT02699606|DRUG|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
218937334|NCT02114073|DRUG|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
218937335|NCT02114073|DRUG|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
219627618|NCT07183267|DEVICE|Photobiomodulation|Participants will received a daily treatment of photobiomodulation via a LED photobiomodulation device alongside their proton or photon treatment fraction. The photobiomodulation will be administered to the skin in the site of the patients proton or photon therapy treatment area.
219627619|NCT07183943|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Training was performed in different positions (decubitus, sitting, and standing) according to the specific exercise. the participants performed 10 minutes of diagonal scapula exercises (anterior and posterior elevation) and 30 minutes of upper limb diagonals (Flexion-Abduction-External Rotation and Extension-Abduction-Internal Rotation), including the 5 initial minutes of stretching.
219627620|NCT07183943|OTHER|Visual reality (VR)|The site of the intervention was a 20-square-meter room equipped with a multimedia projector, which projected the image on the wall at a height of 1 m and 20 cm. A professional physical therapist supervised the treatment continuously, and every participant received prior instructions on the conduct of the games. The therapeutic protocol included 4 electronic games: Balance Bubble Plus, Rhythm Parade, Tennis, and Box.
219627621|NCT07183943|OTHER|PNF and VR|The total duration of the sessions remained consistent. The participants performed 5 minutes of scapula diagonals and 15 minutes of upper limb diagonals in the weekly session. The games for the PNF/VR group were the same as those for the VR group, except for their duration. Whereas they were performed for 20 minutes each in the VR group, the session including 5 minutes of stretching.
219627622|NCT07184294|OTHER|Best Practice|Receive no massage therapy
219627623|NCT07184294|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
219627624|NCT07184294|PROCEDURE|Massage Therapy|Receive FL therapy
219627625|NCT07184294|PROCEDURE|Massage Therapy|Receive HNS therapy
219627626|NCT07184294|PROCEDURE|Massage Therapy|Receive HA therapy
219627627|NCT07184294|PROCEDURE|Massage Therapy|Receive combination FL, HNS, and HA therapy
219627628|NCT07184294|OTHER|Questionnaire Administration|Ancillary studies
219627629|NCT07184021|DRUG|Gemcitabine and Cisplatin (DD GC)|Participants will receive neoadjuvant ddGC, consisting of gemcitabine and cisplatin administered at shortened intervals (e.g., gemcitabine 1200 mg/m² on days 1 and 8, fractionated cisplatin 35 mg/m² on day 1and 8, every 14 days) with appropriate growth factor support. A total of four cycles are planned before radical cystectomy.
219627630|NCT07184463|OTHER|Evaluation of chronic pain at 3 and 6 months after thoracic surgery|The presence of persistent postoperative pain, defined as ipsilateral chest pain (on the same side as the surgery) occurring at rest and/or with coughing on a daily basis. Assessed by a 'yes' or 'no' response when asked at 3 and 6 months postoperatively.
219627631|NCT07183722|OTHER|Microbiota analysis|Analysis of microbiota in patients admitted to the following departments: General Anesthesia and Resuscitation, Cardio-Thoracic-Vascular Anesthesia and Resuscitation, Internal Medicine, and MeCAU.
219627632|NCT07182721|DRUG|SKB264 Plus Inetetamab|SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.
219627633|NCT07183020|DIAGNOSTIC_TEST|Oligoclonal bands and kappa free light chains (KFLC)|Comparison of oligoclonal bands and kappa free light chains (KFLC) in patients with multiple sclerosis (MS) / clinically isolated syndrome (CIS)
219627634|NCT07183462|DRUG|Intravenous Ampicillin followed by Oral Amoxicillin|This intervention consists of intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days
219627635|NCT07183462|DRUG|Ampicillin/Amoxicillin plus single-dose IV Azithromycin|This intervention includes intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days, plus a single dose of intravenous Azithromycin 1 gram administered once at the start of treatment
219627636|NCT07184255|OTHER|Patient Education Video Intervention|Animated video with high-contrast visuals and audio narration in the patient's preferred language, covering diagnosis, surgical steps, and post-operative positioning.
219627637|NCT07184411|OTHER|Activities-based locomotor training|Activities-based locomotor training involves placing the child in a partial body-weight supported (PBWS) system over a treadmill. The child is given assistance by trained clinicians to attempt standing and walking on the treadmill for 1 hour. The child then participates in play-based activities aimed to foster independence in an overground (regular) environment for 1 hour. The final hour of the 3-hour session is conducted in the PBWS system with a focus on standing and walking.
219627638|NCT07184411|OTHER|physical therapy|In this intervention, the child will attend their usual physical therapy sessions.
219627639|NCT07172581|BEHAVIORAL|Online low-FODMAP diet|Participants were invited to follow the online low-FODMAP diet offered by SOSCuisine®, characterized by three specific features. First, participants received customized weekly low-FODMAP menus based on the Monash University protocol. Second, a virtual assistant accompanied participants from the beginning to the end of the diet implementation, providing personalized recommendations tailored to individual's preferences and intensity of symptoms. For the reintroduction phase, the assistant guided individuals through the process of testing specific FODMAP subgroups, offering food suggestions based on individual preferences, and portion sizes. The last feature of the platform was the access to a peer support group on Facebook©, designed to foster communication among participants. This group allowed individuals to ask questions and receive valid answers, as the group was moderated by a FODMAP-specialized registered dietitian.
219627640|NCT07182448|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
219627641|NCT07183098|OTHER|Participiants at high risk of malnutrition who received standard nutritional care|The overall clinical managment of people by ward's staff includes also nutritional care. Within 24-48 h after hospitalization, the ward's nursing staff screens people for nutritional risk using the Malnutrition Universal Screening Tool (MUST) tool. The attending ward's physician prescribes nutritional support and laboratory analyses in accordance with people's clinical needs and the underlying disease. Ward's physician cllinical judgement guides the decision to reassess and monitor the people's nutritional risk and status.
219548999|NCT04652622|DEVICE|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
219549000|NCT05247723|DEVICE|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
219549001|NCT05247723|PROCEDURE|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
219549002|NCT00394485|DRUG|Procaterol|
219549003|NCT00394485|DRUG|Tiotropium|
219549004|NCT03123315|DEVICE|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
219549005|NCT02072096|DRUG|Glimepiride|Administered orally
219549006|NCT02072096|DRUG|Metformin|Administered orally
219549007|NCT02072096|DRUG|Pioglitazone|Administered orally
219549008|NCT02072096|DRUG|Acarbose|Administered orally
219549009|NCT02072096|DRUG|Linagliptin|Administered orally
219549010|NCT02072096|DRUG|Sitagliptin|Administered orally
219549011|NCT02072096|DRUG|Liraglutide|Administered subcutaneously (SC)
219549012|NCT02072096|DRUG|Insulin Glargine|Administered SC
219549013|NCT02072096|DRUG|Exenatide once weekly (QW)|Administered SC
219549014|NCT02072096|DRUG|Exenatide twice daily (BID)|Administered SC
219549015|NCT06626750|BEHAVIORAL|Summer Treatment Program for Pre-Kindergarteners and Kindergarteners|Children will be concurrently enrolled in our Summer Treatment Program for Pre-Kindergarteners and Kindergarteners (STP-PreK/K). The STP-PreK/K simulates a school-like schedule and runs for 7-weeks and last 7 hours/day, Monday through Friday, with periods of seatwork, large/small group activities, circle time, and classroom meetings along with a recreational period. Academic curriculum are individualized depending upon child's current level. The behavioral modification program uses a visual response cost system in which children lose points for not following classroom rules (these rules are operationalized and determined during the development phase). Dots earned are then used for daily and weekly rewards. In addition to the academic and behavioral modification program, one group of children will participate in social-emotional/self-regulation training exercises on a daily basis designed to teach them social skills and how to control their emotions, behaviors, and attention.
219549016|NCT06626750|BEHAVIORAL|School Readiness Parenting Program (SRPP)|The School Readiness Parenting Program (SRPP) helps parents of young children develop skills that support their child\&#39;s readiness for kindergarten and first grade. It focuses on positive parenting practices that enhance social, emotional, and cognitive development. The sessions cover managing child behaviors, promoting early literacy, and fostering problem-solving skills. Parents learn effective communication, consistent routines, and how to create a supportive home environment.
219549017|NCT06626750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a structured, goal-oriented therapy that helps individuals identify and change negative thought patterns and behaviors. It focuses on the link between thoughts, emotions, and actions to improve mental health. Specific to the current project, CBT can reduce stress by teaching parents to reframe unhelpful thoughts, manage challenging emotions, and develop effective coping strategies for difficult situations, leading to more positive parenting experiences.
219549018|NCT01748773|DRUG|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
219549019|NCT01748773|RADIATION|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
219549020|NCT01748773|DRUG|Capecitabine|Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
219549021|NCT01748773|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
219549022|NCT05138094|PROCEDURE|Minimally invasive simultaneous resection|One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.
219549023|NCT05138094|PROCEDURE|Minimally invasive two-stage resection|Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
219549024|NCT00764712|DRUG|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
219549025|NCT05912062|DRUG|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
219549026|NCT05912062|DRUG|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
219549027|NCT05912062|DRUG|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
219549028|NCT00955448|DEVICE|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
219549029|NCT00955448|PROCEDURE|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
219627642|NCT07183098|OTHER|Participiants at high risk of malnutrition who received specialized nutritional care|People referred to the Dietetic and Clinical Nutrition Service (DCNS) receive a structured, evidence-based diagnostic and therapeutic nutritional support. A dietitian performs a dietary assessment and the attending physicians of the DCNS prescribe a baseline set of laboratory analyses relevant for nutritional status. People referred to the DCNS are monitored regularly and systematically, daily or weekly according to the people's clinical condition and nutritional problems.
219627643|NCT07183098|OTHER|3 month-post discharge evaluation|Three months after discharge (follow-up), participiants of both groups were monitored through telephone interview to collect data regarding rate of hospital readmission, number of emergency department admissions, general practitioner visits, outpatient visits, diagnostic tests, daily medication use and survival.
219627644|NCT07183111|OTHER|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support
219627645|NCT07183111|OTHER|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support
219627646|NCT07183514|BIOLOGICAL|eggshell-derived calcium hydroxyapatite|eggshell-derived calcium hydroxyapatite will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
219627647|NCT07183514|BIOLOGICAL|Calcium hydroxide|Calcium hydroxide will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
219627648|NCT07183540|PROCEDURE|operation opportunity-within 6 weeks after the DC operation.|The autologous skull repair surgery will be completed within 6 weeks after the DC operation.
219627649|NCT07183540|PROCEDURE|operation opportunity-within 90 to 180 days after the DC operation.|The autologous skull repair surgery should be completed within 90 to 180 days after DC.
219627650|NCT06085781|OTHER|fMRI|Functional Magnetic Resonance Imaging
219627651|NCT06085781|OTHER|Oral Pimonidazole|200 mg and 300 mg tablets
219627652|NCT04960579|BIOLOGICAL|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
219627653|NCT04960579|DRUG|Rimiducid|Safety switch activator
219627654|NCT04413097|PROCEDURE|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
219627655|NCT04413097|PROCEDURE|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
219627656|NCT05945251|OTHER|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
219627657|NCT04286269|OTHER|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
219627658|NCT04286269|OTHER|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
219627659|NCT05234905|DRUG|Recombinant human adenovirus type 5＋Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter \>5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter \>10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
219627660|NCT02449486|DRUG|Ropivacaine|
219627661|NCT04216290|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
219627662|NCT04216290|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
219627663|NCT04216290|DRUG|Cisplatin|Given IV
219627664|NCT04216290|PROCEDURE|Computed Tomography|Undergo CT
219627665|NCT04216290|PROCEDURE|Cystoscopy|Undergo cystoscopy
219627666|NCT04216290|BIOLOGICAL|Durvalumab|Given IV
219627667|NCT04216290|DRUG|Fluorouracil|Given IV
219627668|NCT04216290|DRUG|Gemcitabine Hydrochloride|Given IV
219627669|NCT04216290|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219627670|NCT04216290|DRUG|Mitomycin|Given IV
219627671|NCT04216290|OTHER|Patient Observation|Undergo observation
219627672|NCT04216290|RADIATION|Radiation Therapy|Undergo radiation therapy
219627673|NCT00209261|DRUG|MINIRIN Oral Lyophilisate|
219627674|NCT00209261|DRUG|Minirin tablet|
219627675|NCT04671420|DRUG|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
219627676|NCT04671420|DRUG|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
219627677|NCT01529333|DEVICE|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
219627678|NCT01174823|DRUG|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
219627679|NCT01174823|DRUG|placebo comparator ophthalmic solution|sterile ophthalmic solution
219627680|NCT02767011|OTHER|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
219627681|NCT04341493|DRUG|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
219627682|NCT04341493|DRUG|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
219627683|NCT02063061|DEVICE|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
219627684|NCT02063061|DEVICE|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
219627685|NCT00188773|DRUG|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
219627686|NCT05904873|PROCEDURE|Mandibular Third Molar Surgery|All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
219627687|NCT00778219|DEVICE|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
219627688|NCT05801536|DEVICE|SCONE|This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
219627689|NCT03252977|OTHER|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
219627690|NCT03252977|OTHER|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
219627691|NCT00951743|DRUG|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
219627692|NCT06026735|OTHER|lung cancer with brain /leptomeningeal metastasis|Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
219627693|NCT01735916|DEVICE|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
219627694|NCT01735916|DEVICE|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
219627695|NCT05668416|OTHER|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
219627696|NCT01164189|BIOLOGICAL|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
219627697|NCT01164189|DRUG|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
219627698|NCT04031040|DEVICE|Genio(TM) system therapy|Hypoglossal nerve stimulation system
219627699|NCT02271646|DRUG|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
219627700|NCT04455412|PROCEDURE|Laser Assisted ICSI|using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
219048264|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
219048265|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
219048266|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
219627701|NCT03481868|BIOLOGICAL|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
219627702|NCT05003310|DEVICE|Active Stimulation|Stimulation will be turned ON and applied during each day of the period.
219627703|NCT05003310|DEVICE|Sham Stimulation|Sham stimulation will be provided during the period
219627704|NCT05003310|DRUG|Baricitinib|Baricitinib (2 mg) is administered daily during the period.
219627705|NCT05003310|DRUG|Background Treatment|Stable dose of standard background treatment (e.g., csDMARD therapy)
219627706|NCT03633123|DRUG|D_PLEX|D\_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
219627707|NCT03633123|OTHER|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
219627708|NCT04554810|OTHER|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
219627709|NCT06247605|DRUG|AL8326 tablets|10mg/tablet, Oral administration, once daily.
219627710|NCT06247605|DRUG|placebo|Oral administration, once daily.
219627711|NCT04815811|OTHER|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
219627712|NCT04815811|OTHER|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
219627713|NCT00833105|DEVICE|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
219627714|NCT01262222|OTHER|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
219048267|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
219048268|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
219627715|NCT02298153|DRUG|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
219627716|NCT02298153|DRUG|epacadostat|epacadostat: Oral daily dosing
219627717|NCT01575951|RADIATION|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
219048269|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
219627718|NCT01448473|OTHER|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
219627719|NCT01448473|OTHER|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
219627720|NCT01739231|BIOLOGICAL|ACE527|"3x10\^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II \[CS1, CS2, CS3\] and CFA/IV \[CS5, CS6\]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~* ACAM2025: a live, attenuated, CFA/I, LTB positive strain~* ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~* ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain."
219627721|NCT01739231|BIOLOGICAL|dmLT|A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
219627722|NCT01739231|BIOLOGICAL|CeraVacx placebo|CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
219627723|NCT01739231|BIOLOGICAL|H10407 challenge strain|Approximately 2 x 10\^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
219627724|NCT04860648|OTHER|lung ultrasound|doctors treat the patients combining the Lus results and clinical practice
219627725|NCT05783440|BEHAVIORAL|direct patient feedback|"Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone \> 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward."
219627726|NCT02127840|DRUG|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
219627727|NCT00275743|PROCEDURE|MRI|
219627728|NCT04547985|DRUG|Naltrexone HCl 50 MG Oral Tablet|Generic, oral tablet.
219627729|NCT04547985|DRUG|Placebo|Composed of filler material and encapsulated to appear identical to naltrexone.
219627730|NCT00502385|DRUG|AZD2171|
219627731|NCT01616238|DRUG|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
219627732|NCT00019929|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
219627733|NCT00019929|PROCEDURE|adjuvant therapy|
219627734|NCT05460819|OTHER|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
219627735|NCT05460819|OTHER|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
219627736|NCT04989478|OTHER|Fasting|After the standardized breakfast meal, all participants will only consume water for 24 hours
219627737|NCT01904526|DRUG|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
219627738|NCT05323812|DRUG|TW001|daily dose of 100 mg TW001/placebo
219627739|NCT05323812|DRUG|Placebo|daily dose of 100 mg TW001/placebo
219627740|NCT04152135|PROCEDURE|vena cava inferior diameter measurement|Ultrasound equipment with convex probe will be used to measure IVC diameters of the patients in supine position.The IVC sagittal section is described with the probe in the area of subxiphoid. IVC diameters at the junction point of the IVC and right atrium (2cm caudal) are standardized measurement.
219627741|NCT02389478|PROCEDURE|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
219627742|NCT02389478|PROCEDURE|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
219627743|NCT02554071|OTHER|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
219627744|NCT01310842|BEHAVIORAL|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
219627745|NCT01310842|DRUG|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
219627746|NCT01310842|BEHAVIORAL|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
219048270|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
219048271|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
219627747|NCT02509819|DEVICE|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
219549030|NCT03785730|PROCEDURE|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
219549031|NCT03785730|PROCEDURE|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
219549032|NCT03578939|PROCEDURE|Biopsy EUS guided|NGS Sequencing on Biopsy samples
219549033|NCT04724616|OTHER|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
219549034|NCT01634139|DRUG|Tiotropium low dose QD|2 actuations once daily in the evening
219549035|NCT01634139|DRUG|Tiotropium high dose QD|2 actuations once daily in the evening
219549036|NCT01634139|DRUG|Placebo|2 actuations once daily in the evening
219549037|NCT03680313|PROCEDURE|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
219549038|NCT06562400|DIETARY_SUPPLEMENT|Palmitoyl ethanolamide|PEA supplementation (600mg twice a day for three months)
219549039|NCT06562400|BEHAVIORAL|Ketogenic diet|Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
219549040|NCT05900713|OTHER|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
219549041|NCT05900713|OTHER|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
219549042|NCT05685498|BEHAVIORAL|Peer-led HIV self-testing among male fisherfolk in Uganda|This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
219549043|NCT00217113|BEHAVIORAL|Geriatric home visit and Action Plan|
219549044|NCT00774189|DRUG|clarithromycin 250 mg tablets|
219549045|NCT03798457|OTHER|No intervention|In this study there is no intervention
219549046|NCT05069571|OTHER|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
219549047|NCT00425308|DRUG|Everolimus + Cyclosporine|
219549048|NCT00425308|DRUG|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
219549049|NCT00425308|DRUG|Steroids|
219549050|NCT05412485|OTHER|Robotic assisted gait training|Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
219549051|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
219549052|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
219549053|NCT04748991|DRUG|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
219549054|NCT04748991|DRUG|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
219627748|NCT04463407|OTHER|Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students|An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.
219627749|NCT05459961|DIETARY_SUPPLEMENT|oral spermidine|oral supplement
219627750|NCT03079986|OTHER|Standard care irrespective of CL|Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
219627751|NCT03079986|OTHER|Dietary treatment (MCT-diet)|Dietary treatment with MCT-diet until resolution of CL.
219627752|NCT05990322|BEHAVIORAL|Project EMPOWER|Experimental Condition
219627753|NCT03514524|OTHER|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
219627754|NCT01071642|DRUG|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
219627755|NCT01071642|DRUG|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
219627756|NCT04122300|DRUG|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
218937336|NCT03948945|RADIATION|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
218937337|NCT04593264|OTHER|Self-guided pre-habilitation exercise program|A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
218937338|NCT04593264|OTHER|Traditional pre-habilitation|Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
218937339|NCT01695759|DRUG|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
218937340|NCT01695759|DRUG|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
218937341|NCT02090842|DIETARY_SUPPLEMENT|Ca-caseinate|
218937342|NCT02090842|DIETARY_SUPPLEMENT|Maltodextrin|
219627757|NCT04122300|DRUG|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
219627758|NCT02556320|DRUG|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
219627759|NCT02556320|BIOLOGICAL|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
219627760|NCT02300831|OTHER|Data Collection|Non interventional prospective data collection
219627761|NCT04231526|DRUG|Pembrolizumab|2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)
219627762|NCT04231526|PROCEDURE|Surgery|Standard of care surgery
219627763|NCT04283240|DRUG|Sildenafil|50 mg sildenafil, one dose
219627764|NCT04283240|DRUG|Placebo|Placebo
219627765|NCT04980430|DEVICE|Virtual Reality|Virtual Reality Demonstration
219627766|NCT00925704|DRUG|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
219627767|NCT00925704|DRUG|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
219627768|NCT00925704|DRUG|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
219627769|NCT03017404|DRUG|Doxorubicin Hydrochloride Liposome Injection|
219627770|NCT03017404|DRUG|Cyclophosphamide|
219627771|NCT03017404|DRUG|docetaxel|
219627772|NCT01244568|BEHAVIORAL|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
219627773|NCT00581672|BEHAVIORAL|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
219627774|NCT05602168|OTHER|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
219627775|NCT00216125|DRUG|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
219627776|NCT00216125|DRUG|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
219627777|NCT00216125|RADIATION|Radiation|Radiation 5940 cGy (180 cGy/day)
219627778|NCT00216125|DRUG|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
219627779|NCT05885425|BEHAVIORAL|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
219627780|NCT05885425|BEHAVIORAL|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
218937343|NCT02090842|DIETARY_SUPPLEMENT|Whey protein isolate|
218937344|NCT02625909|DRUG|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
218937345|NCT02625909|DRUG|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
218937346|NCT04310189|PROCEDURE|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
218937347|NCT01701947|BIOLOGICAL|Hemoleven|Replacement therapy
219627781|NCT03322202|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
219627782|NCT02044302|DRUG|Bupivacaine|
219627783|NCT02044302|DRUG|Botulinum Toxins|
219627784|NCT02044302|DRUG|Analgesics|
219627785|NCT02374970|OTHER|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
219627786|NCT02374970|OTHER|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
218937348|NCT03846206|DIETARY_SUPPLEMENT|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
218937349|NCT00483977|DRUG|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
218937350|NCT00483977|DRUG|Placebo|Placebo: oral for 2 weeks.
218937351|NCT00483977|DRUG|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
218937352|NCT00329355|DRUG|sumatriptan succinate/naproxen sodium|
218937353|NCT02367833|DRUG|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
219048272|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
219048273|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
219627787|NCT03971032|PROCEDURE|Hysteroscopy|Diagnostic procedure
219627788|NCT03971032|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
219627789|NCT04092556|DEVICE|transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
219627790|NCT02158156|BEHAVIORAL|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
219627791|NCT05261087|OTHER|No intervention|Individuals will not receive any interventions
219627792|NCT02899182|DRUG|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
219627793|NCT02899182|OTHER|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
219627794|NCT04646265|OTHER|periodontal treatment|non-surgical root debridement
219627795|NCT04644523|OTHER|Dermoscopy|"dermoscopy is currently used in daily practice in dermatology, for melanoma screening. Dermoscopy will be used in this study on peri-ungueal area.~This is a non-invasive and painless exam."
219627796|NCT00471224|OTHER|Observational Trial|No intervention is being used in this study.
219627797|NCT01808417|DRUG|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
219627798|NCT04161469|PROCEDURE|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
219627799|NCT04161469|PROCEDURE|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
219627800|NCT00998920|DRUG|S-equol|oral, BID, 14 days
219627801|NCT00998920|DRUG|Placebo|oral, BID, 14 days
219627802|NCT06117839|PROCEDURE|using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.|-There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
219627803|NCT01109485|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
219627804|NCT03956979|DRUG|JM-010 group A|JM-010 fixed combination drug (Group A) + Placebo 2
219627805|NCT03956979|DRUG|JM-010 group B|JM-010 fixed combination drug (Group B) + Placebo 1
219627806|NCT03956979|DRUG|Placebos|Placebo 1 + Placebo 2
219627807|NCT03827681|PROCEDURE|Trans Intrahepatic Portosystemic Shunt|"* The most common approach is through the right internal jugular approach.~* After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~* A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'~* A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein."
219627808|NCT03827681|PROCEDURE|Self Expanding Metallic Stent|"* At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~* The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~* The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~* After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide."
219627809|NCT03827681|DRUG|Vasoactive Agent|Vasoactive Agent
219627810|NCT01585415|DRUG|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
219048274|NCT00268528|BEHAVIORAL|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
219627811|NCT01585415|BIOLOGICAL|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
219627812|NCT01585415|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
219627813|NCT01585415|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
219627814|NCT01585415|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
219627815|NCT02529657|RADIATION|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
219627816|NCT02529657|PROCEDURE|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
219627817|NCT01912092|DEVICE|Askina Calgitrol paste|
219627818|NCT04598061|DRUG|Dexmedetomidine IV|Dexmedetomidine IV
219627819|NCT04230551|PROCEDURE|PTSMA|Alcohol Septal Ablation
219627820|NCT05598112|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
219627821|NCT05598112|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
219627822|NCT01412567|DRUG|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
219627823|NCT01412567|DRUG|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
219627824|NCT06181214|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
219627825|NCT06181214|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219627826|NCT06256601|DEVICE|Theracal (calcium silicate)|selective removal to soft dentin, restorations with calcium silicate
219627827|NCT06256601|DEVICE|Dycal (calcium hydroxide)|selective removal to soft dentin, restoration with calcium hydroxide
219627828|NCT05338840|OTHER|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
219048275|NCT00268528|OTHER|Laboratory Biomarker Analysis|Correlative studies
219048276|NCT00268528|DRUG|Mercaptopurine|Given PO
219048277|NCT00268528|DRUG|Methotrexate|Given PO
219048278|NCT00268528|OTHER|Questionnaire Administration|Ancillary studies
219048279|NCT00268528|OTHER|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
219048280|NCT00260923|DRUG|aliskiren|
219048281|NCT01509859|DEVICE|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
219627829|NCT05338840|OTHER|Medial gapping technique|12 sessions over 6 weeks
219627830|NCT01540201|OTHER|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
219627831|NCT01540201|OTHER|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
219627832|NCT06204263|OTHER|finger feeding|The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
219627833|NCT05603871|PROCEDURE|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres"
219627834|NCT01812109|DEVICE|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes \~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
219627835|NCT05584956|DRUG|L_carnitine|l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[
219627836|NCT05584956|DRUG|Sildenafil|selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
219627837|NCT01072773|DRUG|bortezomib|1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days
219627838|NCT01072773|DRUG|cyclophosphamide|300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
219627839|NCT01072773|DRUG|dexamethasone|40 mg, orally, on days 1, 8, 15 \& 22 every 28 days
219627840|NCT04276480|DRUG|Piperacillin-tazobactam|"At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.~The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days."
219627841|NCT03389074|PROCEDURE|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
219627842|NCT05808374|DRUG|HRS-5635|50mg HRS-5635；100mg HRS-5635；200mg HRS-5635；400mg HRS-5635；600mg HRS-5635；800mg HRS-5635
219627843|NCT05808374|DRUG|HRS-5635|100mg HRS-5635，Q4W；200mg HRS-5635 ，Q4W；400mg HRS-5635，Q4W；200mg HRS-5635, Q2W
219627844|NCT05808374|DRUG|HRS-5635|200mg HRS-5635，Q4W
219627845|NCT05808374|DRUG|Placebo|Placebo
219627846|NCT03977064|BEHAVIORAL|Life style change and weight reduction|Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
219627847|NCT06577129|OTHER|Ladder training|Players exercised three times a week for sixty minutes apiece on a ladder for eight weeks. The drills were divided into three categories: steady state drills, burst drills, and elastic reaction drills. While steady state training focused on agility and endurance, burst drills were more focused on fast foot movement. Elastic response drills targeted the reactive speed components of the lower leg.
219627848|NCT06577129|OTHER|Plyometric training|For eight weeks, the players performed a 60-minute plyometric training program three times a week. A fifteen-minute warm-up, stretching, and jogging session comes after the thirty minutes of plyometric training. The cool-down consists of fifteen minutes of light running and stretching.
219627849|NCT04005430|DRUG|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
219627850|NCT00925444|DEVICE|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
219627851|NCT00925444|DEVICE|Stapling|Stapling alon or associated with sealants
219627852|NCT04114929|OTHER|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
219627853|NCT04114929|OTHER|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
219627854|NCT02770794|DRUG|Infliximab|Discontinue infliximab; receive Infliximab when relapse
219627855|NCT04062929|BEHAVIORAL|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
219627856|NCT04129489|DRUG|Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
219627857|NCT02848144|OTHER|blood samples|
219627858|NCT02848144|OTHER|Collection of nosocomial infections|
219627859|NCT05429801|OTHER|Ozone therapy|Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
219627860|NCT03489668|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
219627861|NCT00169572|DRUG|Aprepitant|
219627862|NCT00169572|DRUG|Ondansetron|
219627863|NCT00169572|DRUG|GW679769|
219627864|NCT00169572|DRUG|Dexamethasone|
219627865|NCT01703572|DRUG|OMP-52M51|
219627866|NCT06019546|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
219627867|NCT04873921|OTHER|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
219627868|NCT04630002|DRUG|GSK3640254|GSK3640254 will be available as oral tablets.
219627869|NCT04630002|DRUG|Darunavir/Ritonavir (DRV/RTV)|DRV/RTV will be available as oral tablets.
219627870|NCT04630002|DRUG|Etravirine (ETR)|ETR will be available as oral tablets.
219627871|NCT06142500|GENETIC|Analysis of biological samples of saliva from testicular cancer patients and from their first-degree family members|The project aims to collect biological samples of saliva from testicular cancer patients and from their first-degree family members; demographic-clinical variables will be also collected in order to draft a comprehensive panel of genes and gene modifications related to the testicular cancer, combining this survey with a very detailed descprition of this cohort of patient in terms of clinical features and quality of life
219048282|NCT01509859|DEVICE|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith\&Nephew INTERTAN proximal femur nail device"
219048283|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
219048284|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
219048285|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
219627872|NCT02450149|DRUG|sorafenib|
219627873|NCT04644432|DRUG|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
219627874|NCT04644432|OTHER|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
219627875|NCT01555632|DRUG|atorvastatin calcium|Given PO
219627876|NCT01555632|DRUG|placebo|Given PO
219627877|NCT04487015|BEHAVIORAL|MP|The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.
219627878|NCT04487015|BEHAVIORAL|Call|A 30-45 minutes coaching consultation telephone/Skype call from the nutrition coaching to give social support. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
219048286|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
219627879|NCT04487015|BEHAVIORAL|MesC|Nutrition coach-led messaging (MesC) is where the mobile app (MP) has the text messaging feature activated, and the nutrition coach proactively initiates a conversation via text messaging up to three times a week to offer nutrition support to the participant. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
219627880|NCT05373732|BEHAVIORAL|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
219627881|NCT05373732|BEHAVIORAL|Health education control|didactic based classes in CVD risk factor reduction and prevention
219627882|NCT01984333|BEHAVIORAL|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
219627883|NCT00736697|DRUG|moxidectin|
219627884|NCT02592577|BIOLOGICAL|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
219627885|NCT05184205|DEVICE|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
219627886|NCT05184205|DEVICE|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
219627887|NCT04498182|DRUG|AR-15512 Ophthalmic Solution|Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)
219627888|NCT04498182|DRUG|AR-15512 Ophthalmic Solution Vehicle|Ophthalmic solution vehicle administered via topical ocular instillation
219627889|NCT02986022|BEHAVIORAL|Resilience|Self-efficacy, optimism, altruism, goal setting
219627890|NCT02986022|BEHAVIORAL|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
219627891|NCT05017350|PROCEDURE|radiofrequency ablation|Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.
219627892|NCT02907723|DEVICE|Sleep Recording|the device records movements during patients' sleep
219627893|NCT02367118|DRUG|Prednisone|
219627894|NCT02367118|DRUG|Placebo|
219627895|NCT03174535|DRUG|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
219627896|NCT05859919|DRUG|"The drug Rutan 0.1."|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose."
219627897|NCT05859919|OTHER|Basic treatment|"Basic treatment without the drug Rutan 0.1."
219627898|NCT00636519|BIOLOGICAL|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
219627899|NCT00636519|BIOLOGICAL|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
219627900|NCT02182843|BIOLOGICAL|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
219627901|NCT05388279|DRUG|JS012|JS012, i.v., q3w
219627902|NCT05388279|COMBINATION_PRODUCT|JS012 combine with chemotherapy|JS012 i.v., q3w combine with chemotherapy
219627903|NCT01330823|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
219627904|NCT01330823|DIETARY_SUPPLEMENT|Placebo|tartaric acid same dose like L-Carnitine as placebo
219627905|NCT00390871|DRUG|Fentanyl/Dexmedetomidine|
219627906|NCT00390871|DRUG|Fentanyl/Propofol|
219627907|NCT00390871|DRUG|Fentanyl|
219627908|NCT01729078|DIETARY_SUPPLEMENT|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
219627909|NCT01764360|OTHER|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
219627910|NCT06574776|OTHER|Observation and collecting data|In that single cohort we will collect data on MDRO infection and colonization prevalence, clinical characteristics, infections, causative organisms and mortality.
219627911|NCT00302380|RADIATION|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
219627912|NCT02318680|OTHER|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
219627913|NCT03853174|OTHER|Endurance Training ET|Endurance training were prformed. Intensity was gradually increased.
219627914|NCT03853174|OTHER|Resistance Training RT|Resistance training were prformed. Intensity was gradually increased.
219627915|NCT02667704|DRUG|Bosentan|
219627916|NCT02667704|DRUG|Nintedanib|
219627917|NCT03498430|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
219627918|NCT01534338|BEHAVIORAL|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
219627919|NCT01534338|BEHAVIORAL|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
219627920|NCT05874128|DEVICE|Prospective evaluation of HeartFocus Device (Software)|The primary objective of the study is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to analyze visually
219627921|NCT00832455|DRUG|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
219627922|NCT03010384|OTHER|Rehabilitation program|
219627923|NCT04181892|PROCEDURE|Coronally advanced flap + connective tissue graft|connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
219627924|NCT02764814|OTHER|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
219627925|NCT05829538|BEHAVIORAL|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
219627926|NCT05829538|BEHAVIORAL|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
219048287|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
219048288|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
219048289|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
219048290|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
219048291|NCT04368429|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
219048292|NCT04368429|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
219048293|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
219627927|NCT04653181|DRUG|Ferric carboxymaltose|Iron-arm treated with Ferric carboxymaltose, non-iron arm without
219627928|NCT02463903|BEHAVIORAL|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
219627929|NCT01203514|DRUG|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
219627930|NCT01203514|OTHER|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
219627931|NCT04687839|PROCEDURE|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
219627932|NCT04687839|OTHER|Transepidermal water loss (TEWL)|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
219627933|NCT04687839|OTHER|Macrophotography|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
219627934|NCT04687839|DEVICE|Wound healing medical device|Twice daily application on superficial wounds
219627935|NCT03137238|OTHER|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
219048294|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
219048295|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
219048296|NCT05250505|DEVICE|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
219048297|NCT05027945|PROCEDURE|Allogeneic HSCT|stem cell transplant on day 0
219048298|NCT05027945|DRUG|Busulfan test dose|0.8 mg/kg IV over 2 hours. May be skipped if real-time PKs are done during conditioning.
219627936|NCT00967239|GENETIC|DNA analysis|
219627937|NCT00967239|GENETIC|polymorphism analysis|
219627938|NCT00967239|OTHER|laboratory biomarker analysis|
219048299|NCT05027945|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
219048300|NCT05027945|DRUG|Tacrolimus|Starting on day +5, start at 0.02 mg/kg IV continuous infusion over 24 hours until day +180 and titrated to trough levels of 5-15 mg/ml.
219627939|NCT00967239|OTHER|pharmacogenomic studies|
219627940|NCT00223041|DRUG|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
219627941|NCT04424043|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
219627942|NCT04424043|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
219627943|NCT01328990|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
219627944|NCT01316003|OTHER|Optical coherence tomography|Optical coherence tomography
219627945|NCT01050933|DRUG|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
219627946|NCT00937079|OTHER|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
219627947|NCT06428279|BEHAVIORAL|Survey|survey
219627948|NCT04234490|PROCEDURE|Parenteral nutrition|Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
219627949|NCT05668208|DEVICE|E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)|ONSD measurement will be made using the E-CUBE i7 ultrasound system.
219627950|NCT01311271|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp"
219627951|NCT02721277|DRUG|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
219627952|NCT01193933|PROCEDURE|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
219627953|NCT05710653|BEHAVIORAL|Exercise training intervention|The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
219627954|NCT03422068|DRUG|BI 1015550|Tablet formulation
219627955|NCT03422068|DRUG|Placebo|Tablet formulation
219627956|NCT00001030|DRUG|Clarithromycin|
219627957|NCT00001030|DRUG|Rifabutin|
219627958|NCT02562001|DEVICE|Outpatient active group|active tDCS during 20 minutes before Lokomat training for outpatients
219627959|NCT02562001|DEVICE|Outpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for outpatients
219627960|NCT02562001|DEVICE|Inpatient active group|active tDCS during 20 minutes before Lokomat training for inpatients
219627961|NCT02562001|DEVICE|Inpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for inpatients
219627962|NCT04389164|PROCEDURE|Tissue-engineered skin grafts of autologous scar dermal scaffolds|"1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme."
219627963|NCT00950014|OTHER|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
219627964|NCT03577496|OTHER|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
219627965|NCT04903158|DRUG|test SHR3680 tablets|Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)
219627966|NCT04903158|DRUG|reference SHR3680 tablets|subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
219627967|NCT00011141|DRUG|Oral lactobacillus administration|
219627968|NCT00202124|DRUG|Tryptophan|
219627969|NCT03078764|OTHER|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
219627970|NCT03078764|OTHER|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
219627971|NCT01411800|DRUG|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
219627972|NCT01411800|DRUG|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
219627973|NCT04084418|OTHER|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
219627974|NCT04084418|OTHER|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
219627975|NCT01011816|BIOLOGICAL|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
219627976|NCT01011816|DRUG|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
219627977|NCT05496270|PROCEDURE|total mesorectal excision|
219627978|NCT06574152|DEVICE|PBM treatment|Immediately after the apical microsurgery, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, North Carolina, USA), with an 8 mm tip diameter . The laser tip will be placed following the outline of the incision flap in a contact mode . The power output of the laser will be 50 milliwatt (mW) and verified by a Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2
219627979|NCT06574152|DEVICE|PBM sham treatment|Immediately after the apical microsurgery, sham therapy will be performed without activating the laser.
219627980|NCT06574152|DEVICE|EMS|Patients will be anesthetized. All surgeries will be performed using a surgical microscope. After reflection of a mucoperiosteal flap, osteotomies will be performed to access the root apices and apical lesions. Root apices will be resected at 3 mm, and the pathological tissue curetted out. Next, root-end preparations will be made with ultrasonic tips and filled with calcium silicate-based materials. Methylene blue dye will be used for inspection after root-end resection before the root-end preparation and filling. After cleaning the osseous crypt, the wound margins will be reapproximated with 5-0 single interrupted sutures. A gauze will be placed for 30 minutes for wound compression. Sutures will be removed seven days postoperatively
219627981|NCT01472042|OTHER|Banyan Biomarkers|Biomarkers to detect specific proteins.
219627982|NCT00753285|DEVICE|Renal Denervation|
219627983|NCT01610674|OTHER|Tailored improvement strategy|"A step-wise implementation model is applied:~1\) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
219627984|NCT01438892|DRUG|tDMARDs|Traditional DMARDs for RA
219048301|NCT05027945|DRUG|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
219048302|NCT05027945|RADIATION|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
219048303|NCT05027945|DRUG|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
219627985|NCT01438892|DRUG|biodmards|Biologic DMARDs
219627986|NCT03794648|BEHAVIORAL|Mobile Interactive Supervised Therapy (MIST)|MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
219627987|NCT02462772|DRUG|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
219627988|NCT02462772|DRUG|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
219627989|NCT00178672|DEVICE|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
219627990|NCT00178672|PROCEDURE|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
219627991|NCT00178672|DEVICE|stenting|stenting of carotid arteries
219627992|NCT01448343|DEVICE|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
219627993|NCT05028790|DEVICE|Single vision contact lens|Participants will wear a single vision soft contact lens during the study visit
219627994|NCT05028790|DEVICE|Multifocal contact lens|Participants will wear a multifocal soft contact lens during the study visit
219627995|NCT00053690|BEHAVIORAL|Cognitive Behavior Treatment|
219048304|NCT05027945|DRUG|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
219627996|NCT04384003|DEVICE|Shear Wave Ultrasound Elastography|"Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa)."
219627997|NCT04384003|DEVICE|The 3-D Motion Analysis|The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
219627998|NCT04384003|DEVICE|Electromyographic|Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
219627999|NCT04384003|DIAGNOSTIC_TEST|Foot intrinsic muscle assessment and training device|The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing.
219628000|NCT05473832|OTHER|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
219628001|NCT05473832|OTHER|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
219628002|NCT05473832|OTHER|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
219628003|NCT05473832|OTHER|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
219628004|NCT04394949|BEHAVIORAL|Center for Independent Living SEEKS Team|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
219628005|NCT04394949|OTHER|Usual Care|Consumers will get same CIL services they would get if they were not enrolled in the study.
219628006|NCT01822093|BIOLOGICAL|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results \> 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
219628007|NCT06213584|OTHER|conservative rehabilitation|Hotpack + TENS + streching exercises
219628008|NCT06213584|OTHER|mullgan mobilization techniques|Passive mobilization techniques during active movements
219628009|NCT06213584|OTHER|pnf|hold relax active movements
219628010|NCT05818501|DEVICE|The dysphagia cups|"After the training period of the one of dysphagia cups, participants will start using cup to consume water during a designated period of time every day.~Participants consuming water with Cup A will drink from a static position with their chins towards their chests, the so-called Chin-Tuck maneuver. This position leads epiglottal naturally covering the trachea and causes liquid only ﬂowing to the esophagus and thus stomach. The restoring force of the membrane ensures a constant level of liquid at the upper edge of the cup and thus enables this preferred and safe drinking position.~Cup B limits the maximum volume of water flowing out of the Cup B designated by the staff. Controlled liquid flow prevents overflowing the mouth and gulping, thus reduces the risk of choking and liquid aspiration. Participants can choose to drink the water from Cup B with a straw when necessary."
219628011|NCT00343044|DRUG|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
219628012|NCT00343044|DRUG|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
219628013|NCT06418022|DEVICE|Trendelenburg positioning VTI|"There are essentially two arms, whereby the patients is being compared to themselves. The intervention arm is the same patient undergoing TP from the baseline supine position to determine the change in VTI after subjecting to TP.~We will be using a Sonosite PX ultrasound system, which is intended for diagnostic ultrasound imaging or fluid flow analysis of the human body and, more specifically, for our echocardiographic measurements of velocity time integral (VTI; surrogate for stroke volume and cardiac output). The Sonosite PX is a general-purpose ultrasound system intended for use by qualified physicians and healthcare professionals, for evaluation by ultrasound imaging or fluid flow analysis of the human body. This is an FDA-cleared (510K# K200964) commercial device legally marketed in the United States that is being used in accordance with labeling."
219628014|NCT00122837|DRUG|Duloxetine|
219628015|NCT00122837|DRUG|venlafaxine|
219628016|NCT00122837|DRUG|placebo|
219628017|NCT00561392|DRUG|Rivastigmine 5 and 10 cm^2 patch|
219628018|NCT00771342|DRUG|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
219628019|NCT00771342|DRUG|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
219628020|NCT02276755|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
219628021|NCT02276755|OTHER|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
219628022|NCT03704025|BEHAVIORAL|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
219628023|NCT03704025|BEHAVIORAL|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
219048305|NCT05027945|DRUG|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
219048306|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
219628024|NCT02254590|PROCEDURE|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
219628025|NCT05730361|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
219628026|NCT05730361|BIOLOGICAL|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is \> 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
219628027|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application"|"The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application."
219048307|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
219048308|NCT04406896|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
219628028|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application"|"The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application."
219628029|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Peek Acuity application"|"The presenting visual acuity will be assessed using the Peek Acuity application."
219628030|NCT04936100|OTHER|Assessment of distance and near visual acuity using the conventional methods|"The presenting visual acuity will be assessed using the conventional methods \[Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity\]"
219628031|NCT06392659|DRUG|VX-993|Suspension for Oral Administration.
219628032|NCT06392659|DRUG|Gemfibrozil|Tablets for Oral Administration.
219628033|NCT06392659|DRUG|Itraconazole|Capsules for Oral Administration.
219628034|NCT06392659|DRUG|Midazolam|Solution for Oral Administration.
219628035|NCT01741688|BIOLOGICAL|Tocilizumab|Tocilizumab was administered according to the local label.
219628036|NCT02854332|DEVICE|tDCS session|Direct current transcranial magnetic stimulation
219628037|NCT02854332|DEVICE|rTMS session|Repetitive transcranial magnetic stimulation.
219628038|NCT04173156|DEVICE|Labrida Bioclean|The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
219628039|NCT04173156|DEVICE|Gracey Periodontal curettes|Regular commercially available area specific and medical grade steel Gracey periodontal curettes
219628040|NCT05791136|RADIATION|Radiotherapy|95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
219628041|NCT05791136|DRUG|Toripalimab|Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
219628042|NCT01514292|DEVICE|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
219628043|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
219628044|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
219628045|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
218937354|NCT02367833|DRUG|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
219048309|NCT05666310|DRUG|Denosumab|Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
219628046|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
219628047|NCT05970523|OTHER|Core Stabilization Exercises|Core stabilization exercises are known as a very effective exercise method based on the motor learning principle, performed with the individual's own body weight to strengthen the muscles, improve balance, posture, trunk muscle endurance and flexibility.Each exercise was performed for 7-8 seconds with 10 repetitions. Progression in the exercises was achieved by increasing the difficulty level of the exercises according to the participant's condition once every two weeks.
219628048|NCT02391922|BEHAVIORAL|First aid course|
219628049|NCT02391922|BEHAVIORAL|First aid instructions by mobile phone|
218937355|NCT02367833|DRUG|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
218937356|NCT04276948|DIETARY_SUPPLEMENT|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
219628050|NCT01116271|DRUG|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
219628051|NCT01116271|DRUG|Irinotecan|180mg/m2, IV, Day 1\& 15 of each cycle
219628052|NCT05698901|DRUG|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
219628053|NCT05733169|OTHER|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
219048310|NCT05666310|DRUG|Zoledronic Acid|Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
219628054|NCT05733169|OTHER|Frequency lowering reference|Current frequency lowering parametrization
219628055|NCT06095921|BEHAVIORAL|Self Management Intervention Program|SSc, the course of the disease, symptoms and coping strategies, medications and treatment methods? The importance of exercise for individuals with SSc, and how to create an action plan for an exercise? were discussed. What are fatigue and its symptoms? How can we protect our articular-energy and how should a quality rest be? What is pain and what are coping approaches? What is the pain-related area of influence? What are body image problems, how to use problem solving approach and what is its importance? What is Stress? What is mindfulness? What are mindfulness exercises? What are the ways to cope with stress? What are the daily life occupations and how can we facilitate them? How can we solve problems in difficult occupations? How to create an occupation plan to facilitate daily occupations? What are oral stretching exercises and how to do them? What are the factors affecting sleep? What is advocacy and why is it important? Answers to these questions were sought.
219628056|NCT02480569|OTHER|FFR Measurement|
219628057|NCT02198664|BIOLOGICAL|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
219628058|NCT03991650|BEHAVIORAL|Monitoring with a device|Participants will be monitored by an App.
219628059|NCT06476119|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy according to local/ national guidelines
219628060|NCT06476119|OTHER|No adjuvant chemotherapy|no adjuvant chemotherapy
219628061|NCT04039568|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
219628062|NCT04039568|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
219628063|NCT03680586|DRUG|Radiation Therapy|Undergo ultra low-dose radiation
219628064|NCT06624293|DIAGNOSTIC_TEST|BNP|Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
219628065|NCT06967480|DRUG|Ravulizumab|Participants will receive Ravulizumab.
219628066|NCT02600156|PROCEDURE|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
219628067|NCT02392572|DRUG|Akt/ERK Inhibitor ONC201|Given PO
219628068|NCT02392572|DRUG|Venetoclax|Given PO
219628069|NCT02251821|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
219048311|NCT05666310|OTHER|Denosumab Placebo|Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
219048312|NCT05666310|OTHER|Zoledronic Acid Placebo|Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
219048313|NCT06831019|DIAGNOSTIC_TEST|Oxidative stress markers|We will measure markers of oxidative stress in the follicular fluid, semen, and blood and correlate this with IVF and reproductive outcomes
219628070|NCT02251821|DRUG|Busulfan|Given IV
219628071|NCT02251821|DRUG|Cyclophosphamide|Given IV
219628072|NCT02251821|DRUG|Fludarabine Phosphate|Given IV
219628073|NCT02251821|OTHER|Laboratory Biomarker Analysis|Correlative studies
219628074|NCT02251821|DRUG|Melphalan|Given IV
219628075|NCT02251821|DRUG|Methotrexate|Given IV
219628076|NCT02251821|DRUG|Mycophenolate Mofetil|Given IV or PO
219628077|NCT02251821|DRUG|Ruxolitinib|Given PO
219628078|NCT02251821|DRUG|Tacrolimus|Given IV or PO
219628079|NCT02251821|RADIATION|Total-Body Irradiation|Undergo TBI
219628080|NCT02251821|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
219628081|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
219628082|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
219628083|NCT01262872|BIOLOGICAL|Synflorix™|Intramuscular injection
219628084|NCT01262872|BIOLOGICAL|Prevnar13™|Intramuscular injection
219628085|NCT01262872|BIOLOGICAL|Tritanrix™-HepB/Hib|Intramuscular injection
219628086|NCT01262872|BIOLOGICAL|Polio Sabin™|Orally
219628087|NCT01262872|BIOLOGICAL|M-Vac™|Intramuscular injection
219628088|NCT01262872|BIOLOGICAL|Stamaril™|Intramuscular injection
219628089|NCT03807427|BEHAVIORAL|READY-Nepal|Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
219628090|NCT03332355|DRUG|PAC-1 Compound|PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
219628091|NCT02254317|DIETARY_SUPPLEMENT|0 mg placebo|Not containing GSE (Placebo)
219628092|NCT02254317|DIETARY_SUPPLEMENT|300 mg GSE|300 mg GSE
219628093|NCT02254317|DIETARY_SUPPLEMENT|600 mg GSE|Containing 600 mg of GSE
219628094|NCT02254317|DIETARY_SUPPLEMENT|900 mg GSE|Containing 900 mg of GSE
219628095|NCT04849403|PROCEDURE|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
219628096|NCT02843048|BEHAVIORAL|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
219628097|NCT02843048|BEHAVIORAL|Standard medical care|Standard follow-up medical care following bariatric surgery
219628098|NCT00097448|DRUG|prednisone|Oral, 19 days
219628099|NCT00097448|DRUG|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
219628100|NCT06302673|DEVICE|Laserpuncture|Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
219628101|NCT06302673|DEVICE|Sham Laserpuncture|Sham Laserpuncture: The laser is turned on but not activated at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan).
219628102|NCT03410576|PROCEDURE|Carotid artery stenting|Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
219628103|NCT03410576|PROCEDURE|Carotid endarterectomy|Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
219628104|NCT06119776|PROCEDURE|Whipple over the splenic artery|Treatment for pancreatic ductal cell adenocarcinoma
219628105|NCT06119776|PROCEDURE|Total pancreatectomy|Treatment for pancreatic ductal cell adenocarcinoma
219628106|NCT04845750|DEVICE|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
219628107|NCT02839304|DEVICE|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
219628108|NCT02123264|DRUG|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
219628109|NCT00686608|DIETARY_SUPPLEMENT|glucose|0.3mg/kg of glucose
219628110|NCT00686608|DIETARY_SUPPLEMENT|fructose|fructose IV bolus
219628111|NCT00686608|DIETARY_SUPPLEMENT|saline|IV saline
219628112|NCT00365794|DRUG|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
219628113|NCT03504319|OTHER|Exposure to high-fat smoothie|Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
219628114|NCT02615782|DRUG|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
219628115|NCT00745901|DRUG|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
219628116|NCT03238560|DRUG|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
218937357|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
218937358|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
218937359|NCT01976741|DRUG|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
218937360|NCT04565704|DEVICE|Biopsy imaged by Optical imaging device.|
218937361|NCT00670306|DRUG|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
218937362|NCT02069860|DEVICE|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
218937363|NCT03375697|DRUG|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
218937364|NCT03375697|DRUG|Placebo|Subjects will receive matching placebo intravenously.
219048314|NCT06401486|DEVICE|Videolaryngoscope|For patients assigned to the videolaryngoscope Group, the operator will use a video laryngoscope on the first laryngoscopy attempt.
219628117|NCT04059835|OTHER|OptiBra study|compare two different bra after breast cancer surgery
219628118|NCT00929370|DRUG|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
219628119|NCT00515970|PROCEDURE|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
219628120|NCT00515970|PROCEDURE|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
219628121|NCT00515970|PROCEDURE|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
219628122|NCT00515970|PROCEDURE|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
219628123|NCT02365441|DRUG|Regorafenib|
219628124|NCT02365441|DRUG|imatinib|
219628125|NCT02631642|DRUG|HMPL-689|selective PI3Kδ inhibitor
219628126|NCT02631642|DRUG|HMPL-689 placebo|placebo of HMPL-689
219628127|NCT02449031|DRUG|TOBI® PODHALER®|
219628128|NCT02449031|DRUG|TOBI®|tobramycin inhalation solution, USP
219628129|NCT02449031|DRUG|Bethkis®|tobramycin inhalation solution
219628130|NCT02449031|DRUG|Cayston®|aztreonam for inhalation solution
219628131|NCT04900428|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
219628132|NCT04900428|DRUG|Placebo|Diluent solution
219628133|NCT06140056|OTHER|Airway pressure release ventilation|Mechanical ventilation mode
219628134|NCT06140056|OTHER|Volumen controlled mechanical ventilation|Mechanical ventilation mode
219628135|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by single urine filtration|The urine samples of children participating in the initial screening will be tested with a single urine filtration by human microscopy.
219628136|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by quintuple urine filtration|Five urine samples will be collected from children participating in the diagnostic study over five days. Each of the five urine samples collected per participant will be tested with a single urine filtration by human microscopy.
219628137|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by artificial intelligence (AI) microscopy|The urine samples collected on Day 5 of the diagnostic study will be tested with artificial intelligence (AI) microscopy.
219628138|NCT06808750|DIAGNOSTIC_TEST|Haematuria assessment using reagent strips|The urine samples collected from children participating in the initial screening and in the diagnostic study, respectively, will be tested with reagent strips.
219628139|NCT06808750|DIAGNOSTIC_TEST|S. haematobium antigen detection by up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA).
219628140|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by recombinase polymerase amplification assay (RPA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the recombinase polymerase amplification assay (RPA).
219628141|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by qPCR|The urine samples collected on Day 5 of the diagnostic study will be tested with qPCR
219628142|NCT06983275|DEVICE|Vibrational stimulation|Fifteen minutes before bedtime, participants will wear a vibration stimulation device on the forehead while lying down in a comfortable position. The stimulation intensity will be set to 60% of the device's maximum output. Participants will receive a 15-minute session of 40 Hz vibration stimulation with a 50% duty cycle: 15 seconds of stimulation followed by 15 seconds of rest, repeated continuously. After the session, participants will remove the device and prepare for sleep immediately.
219628143|NCT06983275|OTHER|Sham|Fifteen minutes before bedtime, participants will lie down in a comfortable position and listen to the 40 Hz noise generated by the vibration device (without receiving actual vibration). After the session, they will remove the device and prepare for sleep immediately.
219628144|NCT06983938|DEVICE|Double Perclose Proglide|Upon completion of valve replacement, closure will proceed using two Perclose Proglide devices.
219628145|NCT06983938|DEVICE|Single Perclose Proglide plus Angioseal|Upon completion of valve replacement, closure will proceed using one Perclose Proglide device plus one Angioseal device.
219628146|NCT01862978|DRUG|Heparin|
219628147|NCT01862978|DRUG|Nadroparin|
219628148|NCT01862978|DRUG|Placebo|
219048315|NCT06401486|DEVICE|Macintosh laryngoscope|For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
219048316|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
219048317|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
219628149|NCT06509087|PROCEDURE|Transarterial microembolization (TAME)|TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
219628150|NCT04299815|DRUG|Oral Sodium Lactate|25 grams of D/L lactate dissolved in 300mL water.
219628151|NCT04299815|DRUG|Intravenous sodium lactate|intravenous sodium lactate + oral sodium-chlorid solution
219628152|NCT03152877|DRUG|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
219628153|NCT03152877|DRUG|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
219628154|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
219628155|NCT06543277|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired taVNS over six weeks, followed by a 90-day home exercise program.
219628156|NCT06674226|DRUG|Ciprofol|0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance
219628157|NCT06674226|DRUG|Propofol|1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
219628158|NCT06866106|BEHAVIORAL|Positive Psychology (PP) Intervention|This is an adapted, optimized, phone-based, 9-week positive psychology (PP) intervention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review PP exercises that they have independently completed in between phone sessions. The PP exercises will be completed in a treatment manual that describes the PP exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
219628159|NCT06866106|BEHAVIORAL|Educational Intervention|This is an educational intervention that will match the PP intervention in terms of both time and attention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review educational exercises that they have independently completed in between phone sessions. The exercises will be completed in a treatment manual that describes the exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
219628160|NCT06625437|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
219628161|NCT07023224|OTHER|Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)|The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
219628162|NCT07138417|OTHER|Compassion-Based Family Therapy|"Draw ideas from traditional Chinese culture, the investigators have developed the compassion-based family intervention therapy to improve the mental health of both parents and children by enhancing their synchronization.~The 6-week program followed a progressive thematic structure. Week 1 focuses on introduction and connection, themed Setting Sail: The Additions and Subtractions for a Happy Family. Weeks 2 and 3 address self-compassion: Week 2 is themed Self-compassion: Embrace yourself with compassion here and now.; Week 3 is themed Self-compassion: Accepting growing pains.. Weeks 4 and 5 explored developing compassion for others: Week 4 is themed Listening to the heart: Enhancing communication, bringing us closer.; Week 5 is themed Building a harbor together: Managing conflict, creating happiness Week 6 involves integration and review, themed Integrating knowledge and action: Practicing compassion, lighting the path forward."
219628163|NCT03231813|PROCEDURE|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
219628164|NCT03231813|OTHER|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
219628165|NCT01610817|OTHER|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
219628166|NCT05710328|DRUG|Chemotherapy|Receive standard of care chemotherapy
219628167|NCT05710328|PROCEDURE|Computed Tomography|Undergo PET/CT
219628168|NCT05710328|OTHER|Fludeoxyglucose F-18|Given IV
219628169|NCT05710328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219628170|NCT05710328|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
219628171|NCT06839222|DEVICE|Hydrogel OA 2%|Hydrogel OA 2% is a sterile, nonpyrogenic viscoelastic hydrogel suspension, designed using highly purified biopolymers in a phosphate-buffered saline solution. The main component is a cross-linked protein (ultra-pure bovine gelatin). The other main component is a polysaccharide cellulose nanocrystal (CNC) that acts as the crosslinker. Hydrogel OA 2% is supplied in pre-filled 2.25ml Luer lock syringe. Each package contains one syringe containing 2.0 mL Hydrogel OA 2%. Hydrogel OA 2% is designed to provide symptomatic relief by restoring joint lubrication and cushioning, potentially leading to reduced pain and improved joint function. The device is suitable for use in early and moderate OA (Kellgren and Lawrence, K\&L, II-III).
219628172|NCT06839222|DEVICE|Hyaluronic Acid (Durolane)|DUROLANE contains 20 mg/mL of stabilized non-animal hyaluronic acid in buffered physiological sodium chloride solution pH 7. DUROLANE is a sterile, transparent viscoelastic gel supplied in a 3 mL glass syringe.
219628173|NCT00753311|DRUG|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
219628174|NCT06469437|BEHAVIORAL|Providing the physicians with a proposed glycated hemoglobin target|"Through the geriatric assessment, the investigators will categorize the groups proposed by the Diabetes Canada Clinical Practice Guidelines Expert Committee guideline recommendations into functionally independent, functionally dependent and frail. The investigators will provide the physician with the glycated hemoglobin target proposed by the guideline."
218937365|NCT00773214|BEHAVIORAL|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
219628175|NCT03746847|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
219628176|NCT02264626|DRUG|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
219628177|NCT06409273|OTHER|Hybrid course on medical thesis for post graduates general practice students|Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.
219628178|NCT06409273|OTHER|Face-to-face teaching on medical thesis for post graduates general practice students|Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.
219628179|NCT04712214|DEVICE|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
219628180|NCT00867659|DRUG|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
219628181|NCT00528047|DRUG|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
219628182|NCT00361647|PROCEDURE|Diagnostic screening for occult malignancy|
219628183|NCT06767813|DRUG|TQB2868 injection|TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
219628184|NCT06767813|DRUG|Gemcitabine injection|Gemcitabine injection
219628185|NCT06767813|DRUG|Albumin paclitaxel injection|Albumin paclitaxel injection
219628186|NCT06767813|DRUG|Anlotinib capsules|Anlotinib capsules
219628187|NCT01547429|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
219628188|NCT02565680|DRUG|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
219628189|NCT02565680|DRUG|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
219628190|NCT00000967|DRUG|Interferon alfa-2a|
219628191|NCT00000967|DRUG|Zidovudine|
218937366|NCT05821881|OTHER|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
218937367|NCT04995952|BEHAVIORAL|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
218937368|NCT04995952|BEHAVIORAL|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
218937369|NCT00545636|OTHER|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
218937370|NCT04650529|DEVICE|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
218937371|NCT01210404|DRUG|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
219628192|NCT03783767|BEHAVIORAL|Leadership Intervention|Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
219628193|NCT05510037|OTHER|no intervention|no intervention was needed
219628194|NCT04766177|DRUG|Bumetanide|bumetanide 0.5 mg twice daily
219628195|NCT04766177|DRUG|Placebo|placebo tablets twice daily
219628196|NCT06749457|DRUG|AZD7760|Participants will receive AZD7760 as a single intravenous infusion.
219628197|NCT06749457|OTHER|Placebo|Participants will be administered placebo through intravenous infusion.
219628198|NCT02565745|COMBINATION_PRODUCT|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
219628199|NCT02565745|OTHER|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
219628200|NCT03877380|OTHER|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
219628201|NCT03845686|DIAGNOSTIC_TEST|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
219628202|NCT04563663|PROCEDURE|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
219628203|NCT06760637|DRUG|PF-07220060|CDK4 inhibitor
219048318|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
218937372|NCT00946283|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
218937373|NCT00063843|BIOLOGICAL|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
218937374|NCT02877771|DEVICE|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
218937375|NCT04588467|OTHER|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
218937376|NCT04588467|PROCEDURE|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
219048319|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
219048320|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
219048321|NCT04895579|DRUG|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
219628204|NCT06760637|DRUG|letrozole|endocrine therapy
219628205|NCT06760637|DRUG|abemaciclib|CDK4/6 inhibitor
219628206|NCT06760637|DRUG|palbociclib|CDK4/6 inhibitor
219628207|NCT06760637|DRUG|ribociclib|CDK4/6 inhibitor
219628208|NCT03691454|DRUG|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
219628209|NCT03691454|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
219628210|NCT07060118|DIETARY_SUPPLEMENT|Gluten Free Diet in Hashimoto's Hypothyroidism|Gluten Free Diet in patients with Hashimoto's Hypothyroidism
219628211|NCT02743325|PROCEDURE|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
219628212|NCT02743325|PROCEDURE|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
219628213|NCT01008566|BIOLOGICAL|Cixutumumab|Given IV
219628214|NCT01008566|OTHER|Laboratory Biomarker Analysis|Correlative studies
219628215|NCT01008566|DRUG|Sorafenib Tosylate|Given orally
219628216|NCT03622125|DIAGNOSTIC_TEST|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
219628217|NCT02701465|OTHER|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
219628218|NCT02701465|OTHER|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
219628219|NCT00970346|DRUG|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
219628220|NCT01735084|BIOLOGICAL|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
219628221|NCT01735084|BIOLOGICAL|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
219628222|NCT01344421|PROCEDURE|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
219628223|NCT04696302|BEHAVIORAL|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
219628224|NCT05348759|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry was performed by trained nurse at division of pulmonology, Vajira hospital. The forced vital capacity (FVC), forced expiratory volume in first second of exhalation (FEV1), forced mid-expiratory flow (FEF25-75%), and the FEV1/FVC ratio before and after bronchodilators (2 puffs of salbutamol via spacer) were collected in all cases. Total lung capacity (TLC) using the spirometry (Masterscreen PFT, Jaeger, Germany) and diffusion capacity of carbon monoxide was performed in selected case with abnormalities of lung parenchyma found from computed tomography of the chest.
219628225|NCT05348759|DIAGNOSTIC_TEST|Chest computer scan|High-resolution computed tomography (HRCT) was performed in a single breath-hold on a 128 slice multidetector computed tomography (MDCT) scanner (Philips Healthcare Nederland B.V, Ingenuity 128, Netherlands). HRCT was performed with the patient in the supine position during end-inspiration, supine position during end-expiration, and prone position during end-inspiration with 1 millimeter (mm) slice thickness.
219628226|NCT03859427|DRUG|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
219628227|NCT03859427|DRUG|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
219628228|NCT03859427|DRUG|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
219628229|NCT03859427|DRUG|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
219628230|NCT01111773|DRUG|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
219628231|NCT05059873|DRUG|Prednisone|Oral prednisone 40mg/day for five consecutive days
219628232|NCT05059873|DRUG|Placebo|Oral placebo of 40mg/day for five consecutive days
219628233|NCT03392727|DEVICE|Study Box|Baby box (bassinet) with infant items
219628234|NCT03392727|DEVICE|Community Box|Baby box (bassinet)
219628235|NCT03392727|BEHAVIORAL|Education Session|Face to face education and baby box orientation session
219628236|NCT03392727|BEHAVIORAL|Online Education|Online baby box education
219628237|NCT05328739|OTHER|home care|home care program
219628238|NCT01700972|PROCEDURE|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
219628239|NCT02503540|DRUG|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
219628240|NCT02932501|PROCEDURE|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
218937377|NCT05334212|DEVICE|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
218937378|NCT06214234|PROCEDURE|Band ligation|Band ligation in variceal bleeding
218937379|NCT01900210|BEHAVIORAL|WaySafe|
218937380|NCT02677519|DRUG|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
218937381|NCT05226637|DEVICE|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
219628241|NCT02932501|PROCEDURE|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
219628242|NCT02932501|PROCEDURE|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
219628243|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
219628244|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
219628245|NCT01662492|DRUG|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
219628246|NCT01674881|OTHER|Mindfulness-Based Cognitive Therapy|"MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD."
219628247|NCT01674881|OTHER|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
219628248|NCT04933019|GENETIC|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
219628249|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
219628250|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
219628251|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
219628252|NCT00550355|DRUG|Placebo|3 doses of Placebo administered over 12 weeks
219628253|NCT05228223|DIAGNOSTIC_TEST|Neuromuscular monitoring|TOF monitoring
219628254|NCT05228223|OTHER|reverse of NMB with sugammadex|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
219628255|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin low dose|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg
219628256|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin high dose|patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
219628257|NCT02844413|OTHER|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
219628258|NCT00605618|DRUG|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
219628259|NCT03175536|OTHER|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of \>$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
219628260|NCT03588403|RADIATION|TOMO|Tomotherapy
219628261|NCT03588403|RADIATION|IMRT|Intensity modulated radiotherapy
219628262|NCT02442947|OTHER|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment \[charcoal base\], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
219628263|NCT04361773|RADIATION|Photobiomodulation|Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
219628264|NCT04361773|OTHER|Sham Photobiomodulation|Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
219628265|NCT02590744|BEHAVIORAL|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
219628266|NCT02590744|BEHAVIORAL|non-eye patch|do not cover the sick eye with eye patch preoperatively
219628267|NCT01804946|DRUG|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
219628268|NCT01804946|DRUG|Oseltamivir|Safety and Efficiency in treatment of Influenza
219628269|NCT01066832|DRUG|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
219628270|NCT06456775|BEHAVIORAL|Tele-SSM|Tele-SSM an individual-level psychosocial intervention based on cognitive behavior therapy principles and non-violent communication. The intervention consists of the following 10 sessions delivered through 10 weekly coaching calls delivered by Zoom (audio only).
219628271|NCT02729259|BEHAVIORAL|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
219628272|NCT02729259|BEHAVIORAL|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
219628273|NCT02729259|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
219628274|NCT00722137|DRUG|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
219628275|NCT00722137|DRUG|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
219628276|NCT00722137|DRUG|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
218937382|NCT05226637|DEVICE|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
218937383|NCT04945057|DEVICE|Mindpax monitoring system|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
219628277|NCT00722137|DRUG|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
219628278|NCT00722137|DRUG|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
219628279|NCT00722137|DRUG|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
219628280|NCT06189300|OTHER|Education and counseling intervention|In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
219628281|NCT01160705|DRUG|docetaxel|
219628282|NCT01160705|GENETIC|RNA analysis|
219628283|NCT01160705|GENETIC|reverse transcriptase-polymerase chain reaction|
219628284|NCT01160705|OTHER|circulating tumor cell analysis|
219628285|NCT01160705|OTHER|laboratory biomarker analysis|
219628286|NCT04033354|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
219628287|NCT04033354|DRUG|carboplatin and nab paclitaxel|chemotherapeutics
219628288|NCT04033354|DRUG|Placebo|Placebo
219628289|NCT02853877|BEHAVIORAL|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
219628290|NCT03525080|DIAGNOSTIC_TEST|PET imagery|Every patients will have a PET imagery in addition to standard MRI
219628291|NCT06231225|BEHAVIORAL|Incentive Spirometer respiratory training|The incentive spirometer is a handheld mechanical breathing device that uses a one-way valve to prevent exhalation. It consists of a corrugated tube and a nozzle connected to three consecutive plastic chambers, each containing a ball. The external chambers are marked with the minimum flow required to raise the ball internally. The ball rises when the patient performs slow, deep breathing through the nozzle. If the patient breathes too quickly, the balls in the chambers rise to the top, and if breathing is too slow, the balls fall to the bottom. The number of increasing balls measures the volume of inhaled air. When all three balls reach the top of the chambers, the patient's flow rate can reach 1200 ml/s. After the patient has maximized their inhalation, they are asked to hold the balls in the same position for more than 3 sec.
219628292|NCT02308930|DIETARY_SUPPLEMENT|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
219628293|NCT02308930|DIETARY_SUPPLEMENT|Vitamins supplement (Vitamins A,D, E and corn oil)|
219628294|NCT00836225|DRUG|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
219628295|NCT07069400|OTHER|No intervention|This is an observational study
219628296|NCT05482217|BEHAVIORAL|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
219628297|NCT05395117|DRUG|AZD5462|"Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin"
219628298|NCT05395117|DRUG|Midazolam|Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
219628299|NCT05395117|DRUG|Rosuvastatin|Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
219628300|NCT05395117|DRUG|Digoxin|Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
219628301|NCT05090436|OTHER|Schroth Exercise|two month (three session per week)
219628302|NCT05090436|OTHER|Functional Electrical Stimulation (physiotherapy techniques)|two month (three session per week)
219628303|NCT00400023|DRUG|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
219628304|NCT00400023|DRUG|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
219628305|NCT00848718|DRUG|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
219628306|NCT00848718|DRUG|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
219628307|NCT00848718|DRUG|erlotinib|Administered daily (QD) PO in each 21-day cycle
219628308|NCT00848718|DRUG|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
219628309|NCT00848718|DRUG|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
219628310|NCT00848718|DRUG|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
219628311|NCT04253418|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.
219628312|NCT02689154|DEVICE|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
219628313|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with Co-Cr framework|The intervention is made from polymethylmethacrylate reinforced with cobalt chromium ( Co-Cr) framework.
219628314|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with PEEK framework|The intervention is made from polymethylmethacrylate reinforced with Polyetherketoneketone ( PEEK) framework.
218937384|NCT03904992|OTHER|Progressive web app|Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
218937385|NCT02433470|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
218937386|NCT02467634|BIOLOGICAL|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
218937387|NCT03159962|DEVICE|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
218937388|NCT03159962|DEVICE|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
218937389|NCT05922865|DEVICE|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
218937390|NCT05922865|BEHAVIORAL|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
218937391|NCT05106764|OTHER|No intervention|This is non-interventional study.
218937392|NCT03239561|DRUG|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
219628315|NCT05369897|DEVICE|VR training|The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
219628316|NCT05369897|DEVICE|VR activity|High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
219628317|NCT06231329|DEVICE|ultrasound elastography|examining patient's testis with ultrasound elastography technique and collect data and results
219628318|NCT06261489|DRUG|THC|Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
219628319|NCT06261489|DRUG|CBD|Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
219628320|NCT05006079|DRUG|Morphine|immediate release oral 15mg dose
219628321|NCT05006079|DRUG|Alprazolam|oral 0.25mg dose
219628322|NCT05006079|DRUG|Placebo|Lactose
219628323|NCT02563054|DRUG|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
219628324|NCT02563054|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
219628325|NCT02563054|DRUG|Cisplatin|Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
219628326|NCT06136533|OTHER|Assessment-OHS|Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
219628327|NCT06136533|OTHER|Assessment-Sarcopenic Obesity With OHS|The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
219628328|NCT02757053|DEVICE|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
219628329|NCT02418182|DRUG|Acetaminophen|Acetaminophen total dose of 1000mg
219628330|NCT02418182|DRUG|placebo|subjects randomized to this group will be given placebo tablets
219048322|NCT04895579|DRUG|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
219628331|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
219628332|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health."
219628333|NCT03334344|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
219628334|NCT07065773|DRUG|Trichostatin A|Topical Study Drug
219628335|NCT04090229|DRUG|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
219628336|NCT04090229|DRUG|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
219628337|NCT04774627|DRUG|PARP inhibitor|All patients treated at least with 1 PARPi
219628338|NCT02431676|DRUG|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
219628339|NCT02431676|BEHAVIORAL|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
219628340|NCT02431676|BEHAVIORAL|Self-control weight loss|
219628341|NCT01776437|DRUG|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
219628342|NCT06833190|DRUG|REGN5381|Administered per the protocol
219628343|NCT06833190|DRUG|Placebo|Administered per the protocol
219628344|NCT02576080|DRUG|Imatinib|
219628345|NCT02576080|OTHER|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
219628346|NCT03721874|DRUG|Dapagliflozin 10mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2."
219628347|NCT03721874|DRUG|Placebo matching to Dapagliflozin 10 mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2."
219628348|NCT01057147|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
219628349|NCT01057147|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
219628350|NCT05053945|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|"To set up a prospective study and registry (HAR-P) for patients with H. pylori infection, atrophic gastritis or intestinal metaplasia to evaluate their clinical features and outcomes. The objectives include:~1. Assess the short- and long-term patient outcomes of H. pylori patients~2. Characterize factors involved in the progression or regression of pre-neoplastic lesions, namely atrophic gastritis and intestinal metaplasia~3. Gather information for a better understanding on the efficacy and role of surveillance~4. Potential for the development of new screening/surveillance strategies and tools for better risk stratification of patients~5. Establish a biobank for H. pylori, atrophic gastritis and intestinal metaplasia patients"
219628351|NCT05189977|DRUG|Propranolol|"Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
219628352|NCT05189977|DRUG|Prazosin|"Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
219628353|NCT07071909|BIOLOGICAL|Commercial CAR-T|Twenty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
219628354|NCT07071909|BIOLOGICAL|Investigational CAR-T|Thirty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
219628355|NCT03914612|DRUG|Carboplatin|Given IV
219628356|NCT03914612|PROCEDURE|Computed Tomography|Undergo CT scan
219628357|NCT03914612|DRUG|Paclitaxel|Given IV
219628358|NCT03914612|BIOLOGICAL|Pembrolizumab|Given IV
219628359|NCT03914612|OTHER|Placebo Administration|Given IV
219628360|NCT03914612|OTHER|Quality-of-Life Assessment|Ancillary studies
219628361|NCT03914612|OTHER|Questionnaire Administration|Ancillary studies
219628362|NCT06506916|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
219628363|NCT06752876|DRUG|CB-010|CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
219628364|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|"* All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience.~* Targeted muscles:~* \*Iliocostalis lumborum (ICL)\*~* \*Longissimus thoracis (LT)\*~* \*Multifidus (M)\*~* Interventions will be performed from the right side, between the L2-L5 levels.~* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant."
219628365|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|\*All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience. \* Targeted muscles: \* \*Iliocostalis lumborum (ICL)\* \* \*Longissimus thoracis (LT)\* \* \*Multifidus (M)\* \* Interventions will be performed from the right side, between the L2-L5 levels. \* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant. After each intervention, the needle tip position will be evaluated by a second specialist with \*high-resolution linear probe ultrasound\*.
219628366|NCT07079033|PROCEDURE|Blinded Dry Needling|Dry needling is performed using anatomical landmarks without ultrasound guidance. Needle placement is then confirmed via ultrasound imaging.
219628367|NCT07075081|OTHER|Ceremony|Lifecourse ceremony led by Elders that used to be offered to everyone prior to colonization
219628368|NCT07078019|OTHER|Voice Recording Procedure|"Participants will be asked to read a standardized one-minute text aloud in a quiet room. Their voices will be recorded using a high-quality microphone. The recordings will later be analyzed for acoustic features such as pitch, speech rate, pauses, and intonation.~This procedure is non-invasive and does not involve any clinical or pharmacological intervention."
219628369|NCT07077616|BIOLOGICAL|Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;|"TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)~* TAMAVAQ VACCINE : Each one of our TAMAVAQ VACCINE is consisted of 1-35 (LIMPs, ASPs, and bEPTs) Personalised Synthetic Neoantigenic Peptides mixed with GBM TAAs, including MAGE-1, HER-2, gp100, AIM-2, TRP-2, EphA2,105 survivin50, IL13Rα2, heat-shock peptide protein complex-96 (HSPPC-96), and Smac-TLR7/8 peptides.~* TAMAVAQ vaccine products are composed of 1-35 peptides from the Biogenea Pharmaceuticals Ltd warehouse.~* TAMAVAQ vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with TAMAVAC VACCINE"
219628370|NCT06858839|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
219628371|NCT06858839|DRUG|Placebo|Placebo will be administered SC.
219628372|NCT05649748|DRUG|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
219628373|NCT05649748|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
219628374|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
219628375|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
219628376|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
219628377|NCT07080034|OTHER|Placebo|injection
219628378|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
219628379|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
219628380|NCT05346198|DRUG|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
219628381|NCT06300190|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion type IV
219628382|NCT06300190|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion type IV
219628383|NCT04434729|DEVICE|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
219628384|NCT06764849|PROCEDURE|CONVENTIONAL OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the conventional technique described by Milligan-Morgan
219628385|NCT06764849|PROCEDURE|MINIMALLY INVASIVE OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the tecnique described by Milligan Morgan, using a minimally invasive approach.
219628386|NCT05198154|DIAGNOSTIC_TEST|ctDNA detection|High-depth sequencing method is used to detecting ctDNA.
219628387|NCT01305421|PROCEDURE|grip test|Muscle strength measurement by hand-held dynamometer
219628388|NCT00188474|BEHAVIORAL|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
219628389|NCT03350282|DIETARY_SUPPLEMENT|GAA-creatine|
219628390|NCT03350282|DIETARY_SUPPLEMENT|Creatine|
219628391|NCT03646383|PROCEDURE|Radiofrequency ablation|The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
219628392|NCT06914921|DIETARY_SUPPLEMENT|Peppermint Oil|"Enteric-coated peppermint oil capsules (\~180 mg total peppermint oil/ capsule) to ensure release in the small intestine.~1 capsule three times daily, 30 minutes before meals, for 12 weeks."
219628393|NCT06914921|DRUG|A standard antispasmodic|A standard antispasmodic (e.g., mebeverine 135 mg). 1 tablet three times daily, before meals, for 12 weeks.
219628394|NCT06932965|BEHAVIORAL|Cervical Stabilization Group|Participants performed supervised cervical stabilization exercises for 8 weeks, 3 sessions per week.
219628395|NCT06932965|BEHAVIORAL|combined group|Participants performed both exercise protocols as described above over the same period
219628396|NCT06931145|DRUG|Benmelstobart|Benmelstobart injection, 1200 mg/dose, given once every 21 days, intravenously.
219628397|NCT06931145|DRUG|Anlotinib|"Anlotinib hydrochloride capsules, 8 mg/dose, administered orally for 2 consecutive weeks and stopped for 1 week.~During the course of the study, subjects may be adjusted upward to a dose of 12 mg if well tolerated, as determined by the investigator, and the dose of anlotinib hydrochloride may be adjusted downward during the course of the study due to drug-related adverse events."
219628398|NCT06931145|DRUG|Carboplatin or cisplatin|Carboplatin for injection, administered on day 1, AUC 5 mg/mL/min, intravenously (maximal dose used is 750 mg); or cisplatin administered on day 1, 75-80mg/m2, IV.
219628399|NCT06931145|DRUG|Etoposide|Etoposide injection, 100mg/m2 on days 1, 2 and 3, IV.
219628400|NCT06934512|DEVICE|Needleless jet injector|To assess the pain score through (VAS) scale of needleless jet injector for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
219628401|NCT06934512|PROCEDURE|Conventional needle injection|To assess the pain score through (VAS) scale of traditional needle injection for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
219628402|NCT06934590|DRUG|RX001|Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection
219628403|NCT06941064|DIAGNOSTIC_TEST|Anthropometric and sports performance assessment|"According to the International Society for the Advancement of Kinanthropometry (ISAK) standards, sixteen anthropometric variables have been assessed to characterize the athlete's anthropometric profile. The counter-movement jump assessments were conducted using a ForceDecks Max platform. During matches, the players' GPS-derived external Load Metrics were monitored using 18 Hz WIMU Pro GPS units. Normality tests of all variables will be performed.~Certificated anthropometrists performed the anthropometric assessment twice. A third measurement will be performed if the difference between these measures exceeds 5% for skinfolds and 1% for all other variables. Countermovement jump tests were conducted in duplicate, and the higher measurements were recorded. In-match GPS-derived external load metrics of different matches will be downloaded and analyzed."
219628404|NCT06940479|PROCEDURE|GAE procedure|Genicular artery embolization
219628405|NCT06939764|OTHER|Geriatric Screening using the sG8 scale|Geriatric screening using the sG8 scale
219628406|NCT06941103|OTHER|Spinal stabilization exercise training and recommendation|"Spinal stabilization exercise training will be applied 3 days a week for 8 weeks under the supervision of a specialist physiotherapist. Exercises consist of a 5-10 minute warm-up period, 40 minutes SSET and a 5-10 minute cool-down period.~Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues."
219628407|NCT06941103|OTHER|Recommendation|Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues.
219206544|NCT04282304|BEHAVIORAL|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
219628408|NCT06940856|OTHER|Incomplete response|"Infants died before 36 weeks PMA, infants diagnosed to have BPD at 36 weeks PMA and infants developed major complications before 36 weeks PMA:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
219628409|NCT06940856|OTHER|Complete response|"Infants discharged before 36 weeks PMA and infants who reached 36 weeks PMA without BPD and major complications:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
219628410|NCT06940856|OTHER|Bad response|Infants died before 36 weeks PMA and infants diagnosed to have BPD at 36 weeks PMA
219628411|NCT06940115|OTHER|titanium trapezoidal plates|ORIF subcondylar fracture using trapezoidal titanium plates
219628412|NCT06940115|OTHER|PEEK trapezoidal plates|ORIF subcondylar fracture using trapezoidal PEEK plates
219628413|NCT06940700|DRUG|SHR4597|SHR4597
219628414|NCT06940700|DRUG|Budesonide inhalant|Budesonide inhalant
218937393|NCT06554366|DEVICE|GentleWave|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the GentleWave procedure will be performed
219628415|NCT06940362|BEHAVIORAL|Changing narrative intervention modules|Training and mentoring of 12-16 year old youth in non-violent personal/career trajectories, supported by a social media campaign and a community steering committee.
219628416|NCT06939829|DRUG|treatment with CAZ-AVI|Randomize subjects to receive CAZ-AVI via either continuous infusion or intermittent infusion. The total daily dose and dosing interval should be determined according to the subject's body weight, renal function, and estimated drug clearance based on standard prescribing guidelines. Regardless of administration method, the same criteria for dose adjustment (including indications for modification and monitoring parameters) must be consistently applied to both control and experimental groups.
219628417|NCT06940466|OTHER|Online cognitive intervention|A 4 x 2-hour intervention with the following key components: education about menopause and cognition, cognitive strategies (memory, attention and executive functioning), CBT techniques and emotional support.
219628418|NCT06940570|DRUG|PCA plus methadone (Experimental)|This study is novel. There are no other interventions to distinguish in this or another study.
218937394|NCT06554366|DEVICE|EdgePro laser irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the EdgePro procedure will be performed
218937395|NCT06554366|DEVICE|Irrisafe passive ultrasonic irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the passive ultrasonic irrigation procedure will be performed
219628419|NCT06940570|DRUG|PCA Alone (SOC)|PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).
219628420|NCT06941116|DIAGNOSTIC_TEST|Steroid-Based Screening (LC-MS/MS)|This diagnostic intervention is a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based steroid profiling assay. It measures a panel of 21 adrenal steroid hormones (e.g., aldosterone, 18-hydroxycortisol, 18-oxocortisol, corticosterone) from plasma samples. In this study, it is used to screen for Primary Aldosteronism (PA) while patients remain on their usual antihypertensive medications. By comparing these steroid profiles against standard aldosterone-renin measurements, the method aims to reduce the need for medication washout and improve diagnostic accuracy for PA.
219628421|NCT06941558|DEVICE|INFINITY™ with ADAPTIS™ and EVERLAST™|The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly.
219628422|NCT06940102|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day)
219628423|NCT06940102|DRUG|TKI-Based Therapy|TKI-Based Therapy
219628424|NCT00901550|DRUG|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
219628425|NCT00901550|DRUG|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
219628426|NCT05871281|PROCEDURE|Pelvic floor muscle exercises|Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
219628427|NCT07151378|DRUG|LECIG (levodopa, carbidopa, entacapone intestinal gel)|intestinal L-Dopa + entacapone (Lecigon®)
219048323|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
219628428|NCT07151378|DRUG|Best oral medication|Best oral medication
219628429|NCT07151703|PROCEDURE|Intranasal Injection of Autologous PRP|Under topical anesthesia and decongestion, approximately 1 mL of freshly prepared autologous platelet-rich plasma will be injected into multiple sites of the olfactory cleft mucosa bilaterally using a 25-gauge needle under endoscopic guidance. Single treatment session.
219628430|NCT07151703|PROCEDURE|Carrier-Assisted Topical Application of Autologous PRP|Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of freshly prepared autologous platelet-rich plasma. Under endoscopic guidance, two pieces will be placed gently into each olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain briefly to allow PRP diffusion before dissolving naturally or being removed. Single treatment session.
219628431|NCT07151703|COMBINATION_PRODUCT|platelet-rich plasma|This study adopts a fully automated, closed-system PRP preparation technique to ensure the stability of the blood product. A total of 60 mL of whole blood is drawn and processed using the Phoenix Q1 centrifuge (TFDA Medical Device Manufacturing License No. 004461) for blood component separation in a closed, sterile environment. An optical sensor identifies and automatically collects the buffy coat layer (rich in platelets and monocytes), yielding approximately 6 mL of autologous platelet-rich plasma (PRP). The centrifugation and PRP collection process takes about 5 minutes. Compared with traditional methods requiring manual identification and collection, this approach enhances the precision and safety of centrifugation-based preparation.
219628432|NCT07151703|DEVICE|olfactory training|Participants will perform olfactory training for 12 weeks following the PRP intervention. Training is conducted twice daily using four odor bottles containing standardized odorants from Sigma-Aldrich (Germany): lemon (citronellal, #27470), rose (phenylethanol, #77861), clove (eugenol, #W246700), and eucalyptus (eucalyptol, #C80601). Each odor is sniffed gently for about 20 seconds, with a 20-second pause between bottles. Participants will record the perceived intensity of each odor in a training diary after every session.
219628433|NCT07153042|BEHAVIORAL|Biweekly monitoring and feedback (BMF)|School coordinators will monitor teachers' implementation progress biweekly and provide feedback to teachers.
219628434|NCT07153042|BEHAVIORAL|Site-based assistance and mentorship (SAM)|High-performing teachers will serve as team leaders and guide non-responding teachers on preparation and planning. The team leader will promote group activities and enhance interaction among teachers in these meetings.
219628435|NCT07153042|BEHAVIORAL|Enhanced site-based assistance and mentorship (Enhanced SAM)|A FOYC coach (with FOYC implementation and training experience) will provide tailored in-person support, facilitate goal-setting, opportunities to interact with consultants, supportive text messaging, continuing education, networking strategies, and monthly check-ins.
219628436|NCT07153042|BEHAVIORAL|FOYC+CImPACT|"Focus on Youth in the Caribbean (FOYC) is an evidence-based, eight-session life skills curriculum designed to reduce risk-taking behaviors related to HIV/STI transmission and teen pregnancy. Woven throughout FOYC is a decision-making model that provides guidance and practice in problem solving with a focus on how to obtain factual information on sexual health.~CImPACT is a single-session intervention including a 24-min educational video filmed in The Bahamas. The video focuses on effective parent-adolescent communication and listening strategies related to difficult topics including safe-sex followed by two role-plays for the parent and youth, a discussion, and a condom demonstration."
219048324|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
219628437|NCT07151586|DRUG|Sacituzumab Govitecan / Trastuzumab Deruxtecan|"Sacituzumab govitecan is administered intravenously at a dose of 10 mg/kg on Day 1 and Day 8 of each 3-week cycle. In this study, patients receive two cycles of sacituzumab govitecan followed by two cycles of trastuzumab deruxtecan, alternating throughout the study.~Trastuzumab deruxtecan is administered intravenously at a dose of 5.4 mg/kg on Day 1 of each 3-week cycle. In this study, patients receive two cycles of trastuzumab deruxtecan followed by two cycles of sacituzumab govitecan, alternating throughout the study.~Both Treatment are continued until disease progression as defined by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or the end of the study."
219628438|NCT07155317|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
219628439|NCT07155317|PROCEDURE|Biospecimen Collection|Undergo check swab and blood sample collection
219628440|NCT07155317|PROCEDURE|Computed Tomography|Undergo CT
219628441|NCT07155317|BIOLOGICAL|Ipilimumab|Given IV
219628442|NCT07155317|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219628443|NCT07155317|OTHER|Medical Device Usage and Evaluation|Wear an actigraphy device
219628444|NCT07155317|BIOLOGICAL|Nivolumab|Given IV
219628445|NCT07155317|OTHER|Questionnaire Administration|Ancillary studies
219628446|NCT07163208|DEVICE|Low-Level Laser Therapy (LLLT)|Low-level laser therapy using the Omega XP Model with wavelengths of 675nm (30mW), 820nm (200mW), or 46-cluster LED probe (mixed wavelengths: 660nm, 950nm, 870nm, 880nm, 940nm, 820nm), applied three times weekly for 30 minutes over 6 weeks to target cervical lymphatic chain, musculature, and trigger points for pain relief in cervicogenic headache.
219628447|NCT07163208|OTHER|Routine Physical Therapy (RPT)|Warm-up: Active cervical ROM (5-10 reps, pain-free range). Stretching: Upper trapezius, levator scapulae, SCM; hold 15-30 sec, 3-5 reps, NRS ≤ 3/10. Therapeutic exercises: cervical deep flexors, scapular stabilization (2-3 sets × 10-15 reps, Borg 11-13), progressed weekly. Modalities: Hot pack 15 min at 40-45°C; TENS 80-100 Hz, 50-100 µs pulse width, 20 min. Frequency: 3× weekly for 6 weeks. Safety: contraindications screened; pain/exertion monitored pre/post.
219628448|NCT07166081|DRUG|BGM0504|Administered orally
219628449|NCT07166081|DRUG|BGM0504|Administered orally
219628450|NCT07166081|DRUG|BGM0504|Administered orally
219628451|NCT07166081|DRUG|Placebo|Administered orally
219628452|NCT07166081|DRUG|BGM0504|Administered orally
219628453|NCT07173985|BEHAVIORAL|Standard FIT kit|Receive a standard FIT kit
219628454|NCT07173985|BEHAVIORAL|Enhanced FIT kit|Receive a enhanced FIT kit that includes a video brochure, disposable gloves, and a disposable stool collection device
219628455|NCT07173985|BEHAVIORAL|Telephone patient navigation|Receive telephone-based patient navigation
219628456|NCT07173985|BEHAVIORAL|Text message patient navigation|Receive text message-based patient navigation
219628457|NCT07174115|DRUG|HTMC0658|HTMC0658 tablet
219628458|NCT07174271|OTHER|Patient satisfaction survey upon completion of anterior composite restorations and during follow-up sessions|"This study focuses on evaluating patient satisfaction with anterior composite restorations immediately after treatment and during subsequent follow-up visits. A structured questionnaire, based on modifications of the Fédération Dentaire Internationale (FDI) criteria, was administered to patients. Since the original FDI criteria were primarily designed for dentist-based evaluation, the questions were adapted into a patient-friendly format.~Participants were asked to rate restorations across multiple domains, including esthetic anatomical form, color harmony and translucency, surface smoothness, the condition of the adjacent mucosa, and post-operative sensitivity and tooth vitality. Each parameter was scored on a numerical scale ranging from 0 to 10, allowing patients to express their subjective perception of treatment outcomes.~By collecting these patient-reported outcomes both immediately after the procedure and during follow-up sessions, the study aims to provide a comprehensive under"
219628459|NCT07182617|BEHAVIORAL|Standard Coaching (SOC)|Participants received BetterNight's standard CPAP coaching program. Monitoring was conducted through manufacturer platforms (ResMed AirView, Philips Care Orchestrator) and BetterNight's internal Clarity dashboard. Coaches contacted patients at scheduled checkpoints (10, 20, 45, 60, and 80 days) to provide education, support, and troubleshooting to help patients achieve Medicare adherence.
219628460|NCT07182617|BEHAVIORAL|MonitAir RPM|Participants received the standard BetterNight coaching program enhanced with the MonitAir remote patient monitoring platform. MonitAir enabled weekly reviews of CPAP usage data, automated text follow-ups, and at least one interactive telehealth visit per month. Coaches escalated issues such as poor adherence, high residual AHI, or mask leak to physicians as needed. The intervention aimed to improve CPAP adherence and patient satisfaction compared with standard care.
219628461|NCT07183852|DRUG|Autologous Tumor Infiltrating Lymphocytes (TIL)|Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion
219628462|NCT07183852|DRUG|Melphalan|1 mg/kg, IV
219628463|NCT07183852|DRUG|Interleukin-2|2 MIU, subcutaneous twice daily for up to 14 days.
219628464|NCT07183644|DEVICE|Pulse Dye laser|"Pulse Dye Laser (PDL) standard settings. This is the same procedure children would receive as standard of care if these individuals were not participating in this study.~The surgeon will perform 1 pass with the PDL over the area of the Port wine birthmark (PWB)."
219628465|NCT07183644|DEVICE|Pulse Dye Laser (PDL) pulse width stacking|"This procedure is used for some patients as standard of care depending on the severity and depth of the lesion.~The surgeon will perform 3 passes with the PDL over the PWB, gradually increasing the pulse duration with each pass to effectively target both superficial and deeper blood vessels."
219628466|NCT07183644|DEVICE|Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser.|The combination of these two lasers is one of the investigational treatments. The surgeon will perform 1 pass per laser over the PWB. The 1st pass will be with the PDL to target the blood vessels closer to the top of the skin, followed by a 2nd pass with the Nd:YAG laser to target the blood vessels that deeper in the skin.
219628467|NCT07183644|DEVICE|IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL)|The surgeon will perform 1 pass with the IPL followed by 1 pass with the PDL over the PWB
219628468|NCT07183644|DEVICE|Cupping followed by Pulse Dye Laser (PDL)|The combination of these modalities is one of the experimental procedures. The surgeon will place a small suction cup over the PWB target region of the PDL for a few seconds to stop the blood flow and accumulate the blood in that spot. The PDL treatment will then quickly proceed. Since the PDL targets red blood cells, it will allow the laser to target the pooled blood in the abnormal blood vessels better.
219628469|NCT07184203|DRUG|Itraconazole (ITZ)|therapy for tinea capitis orally
219628470|NCT07184125|DRUG|To measure anxiolysis, satisfaction level of patient after receiving Midazolam|Anxiety \& satisfaction
219628471|NCT07182539|OTHER|PRVC ventilation|Ventilation in PRVC mode.
219628472|NCT07182539|OTHER|VCV ventilation|Ventilation in VCV mode.
219628473|NCT07182552|DRUG|NTB003|NTB003 dose 1, dose 2, dose 3, dose 4
219628474|NCT07182552|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
219628485|NCT03117478|OTHER|Magneto-encephalography (MEG)|Magneto-encephalography
219628486|NCT03117478|OTHER|Electro-encephalography (EEG)|Electro-encephalography
219628487|NCT03117478|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
219628488|NCT03117478|OTHER|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
219628489|NCT03117478|OTHER|Meditation|Meditation
219628490|NCT05069116|OTHER|Training in surgery|The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
219628491|NCT02999269|DEVICE|MECTA Spectrum 5000Q Amplitude|Current
219628492|NCT00513045|BEHAVIORAL|IRT|Cognitive behavior intervention
219628493|NCT00513045|BEHAVIORAL|Exposure|Exposure intervention
219628494|NCT06667219|BEHAVIORAL|A relevant physical fitness training program intervention|"54children who participated in after-school sports activities in Guangzhou Kindergarten (Guangzhou, China) were randomly selected as the experimental group.~Intervention group Length:12 weeks, 40 minutes, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program , as follows: Week 1 / 4 first: Run quickly;Durian ball;Throw;Fast jogging (200 m) Week 1 / 4 second: Dodge run,Raise your legs high and go over the small hurdles; Durian ball (standing on one foot);standing long jump Week 2 / 5 first: Bow step transformation jump;Throw;Turn back 10 meters Week 2 / 5 second: Hop ;Stand on one foot with your eyes open Week 3 / 6 first:Skip over the small hurdles;Durian ball (standing on one foot);Throw; Fast jogging (200 m) Week 3 / 6 second:Jump on your feet and dodge running;Durian ball (squat);Jump support Weeks 7-12,Repeat the above content. FMS index was tested before the experiment, and once after the intervention."
219628495|NCT06667219|BEHAVIORAL|control group,Physical exercise using kindergarten standards|"54 children who did not participate in after-school sports activities were selected as the control group.~control group Duration: 12 weeks. Content: Physical exercise using kindergarten standards. FMS index was tested the same to intervention group before the test and FMS index was measured once again after 12 weeks."
219628496|NCT02946476|OTHER|prognostic impact of non cardiac comorbidities|
219628497|NCT01120184|DRUG|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
219628498|NCT01120184|DRUG|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
219628499|NCT01120184|DRUG|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
219628500|NCT01120184|DRUG|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
219628501|NCT01120184|DRUG|trastuzumab [Herceptin]|trastuzumab \[Herceptin\] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
219628502|NCT01120184|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
219628503|NCT04003636|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
219628504|NCT04003636|DRUG|Gemcitabine|Gemcitabine by IV infusion
219628505|NCT04003636|DRUG|Cisplatin|Cisplatin by IV infusion
219628506|NCT04003636|DRUG|Placebo|Placebo to pembrolizumab
219628507|NCT03611647|DIETARY_SUPPLEMENT|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
219628508|NCT03611647|DIETARY_SUPPLEMENT|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
219628509|NCT05058482|DEVICE|embolism|Cerebral arteriovenous malformation embolism
219628510|NCT01747031|DEVICE|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
219628511|NCT04536974|DIAGNOSTIC_TEST|SEFI tool|Detect the risk of malnutrition with the SEFI tool
219628512|NCT04519372|DIAGNOSTIC_TEST|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
219628513|NCT04771572|DRUG|LP-118|novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
219628514|NCT01537601|PROCEDURE|Circumcision|Circumcision
219628515|NCT01537601|OTHER|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
219628516|NCT04781803|DRUG|Cyclosporine|Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant
219628517|NCT00005055|DRUG|glufosfamide|
219628518|NCT01074801|OTHER|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
219628519|NCT01074801|OTHER|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
219628520|NCT02678793|DRUG|CNTX-4975|
219628521|NCT06436911|DRUG|COVIGENIX VAX- 002|ENTVAX-001-01
219628522|NCT02019316|DIETARY_SUPPLEMENT|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
219628523|NCT02019316|DIETARY_SUPPLEMENT|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
219628524|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
219628525|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.
219628526|NCT03821454|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
219628527|NCT03821454|DRUG|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
219628528|NCT02838797|DRUG|RQ-00000010|orally administered serotonin 4 receptor partial agonist
219628529|NCT02838797|DRUG|Placebo|oral acetate buffer
219628530|NCT05651048|OTHER|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
219628531|NCT05651048|OTHER|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
219628532|NCT05651048|OTHER|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
219628533|NCT02348788|DRUG|Artemether-lumefantrine + Primaquine|
219628534|NCT02348788|DRUG|Chloroquine + Primaquine|
219628535|NCT00457145|DRUG|Ranibizumab|
219628536|NCT05561270|DEVICE|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
218937396|NCT04393454|DRUG|Sirolimus 2mg Tablet|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
218937397|NCT04079140|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
218937398|NCT04079140|DRUG|placebo|one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
219628537|NCT05561270|DEVICE|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
219628538|NCT00312273|DRUG|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
219628539|NCT03656068|DRUG|Nitazoxanide 500mg BID|Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
219628540|NCT02649491|OTHER|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
219628541|NCT05749744|OTHER|cardiac telerehabilitation program by videoconference|"* A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training~* Exercise training for 3 weeks via distance coaching~* Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week.~* Medical follow-up via teleconsultation~* Psychological and/or dietetic follow-up if necessary.~* Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP).~* Appointment with an association Cœur et Santé and Sport-Santé 42 or setting up of an individual physical activity"
219628542|NCT02333344|DRUG|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
219628543|NCT02040103|DEVICE|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
219628544|NCT00020072|OTHER|laboratory biomarker analysis|
219628545|NCT04033731|BEHAVIORAL|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
219628546|NCT03040778|DRUG|Pentoxifylline|Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
219628547|NCT03040778|DRUG|Placebo|Placebo tablets
219628548|NCT03040778|DRUG|Tocopherol|Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
219628549|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d0.
219628550|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d8±1.
219628551|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d30±2.
218937399|NCT02564835|OTHER|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
218937400|NCT02564835|OTHER|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
219628552|NCT06477133|DRUG|Magnesium sulfate|Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
219628553|NCT03829605|OTHER|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
219628554|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
219628555|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
219628556|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
219628557|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
219628558|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
219048325|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
219628559|NCT01444339|BIOLOGICAL|Placebo|0.5 mL, intramuscular
219628560|NCT00810212|PROCEDURE|PLF with autograft|6 subjects
219628561|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects low dose
219628562|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects medium dose
219628563|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects high dose
219628564|NCT03270657|DEVICE|IPG; RC+S|We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
219628565|NCT00162981|DRUG|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
219628566|NCT00162981|DRUG|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
219628567|NCT00017810|BEHAVIORAL|Dietary intervention|"The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods"
219628568|NCT00017810|BEHAVIORAL|HIV Self-Care|Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
219628569|NCT04181086|PROCEDURE|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
219628570|NCT04930744|DRUG|Isoniazid|Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.
219628571|NCT04930744|DRUG|Rifampicin|Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.
219628572|NCT04930744|DRUG|Ethambutol|Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.
219628573|NCT04930744|DRUG|Pyrazinamide|Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.
219628574|NCT04930744|DRUG|Metformin hydrochoride|Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
219628575|NCT04977895|DIAGNOSTIC_TEST|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
219628576|NCT01323517|DRUG|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
219628577|NCT03154541|DRUG|Synrinse|"Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse."
219628578|NCT03312036|DEVICE|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
219628579|NCT04453319|PROCEDURE|Femoral Wound Closure and dressing|Femoral Wound Closure and dressing
219628580|NCT04181021|BEHAVIORAL|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
219048326|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
219048327|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
219048328|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
219048329|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
219048330|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
219048331|NCT02320019|DRUG|Placebo|Placebo matching YH14618
219048332|NCT02320019|DRUG|YH14618|
219048333|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
219048334|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
219048335|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
219048336|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
219048337|NCT03388073|OTHER|Placebo|Placebo
219628581|NCT06250621|PROCEDURE|Implant placement|"Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing."
219628582|NCT00455403|DRUG|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
219628583|NCT00455403|DRUG|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
219628584|NCT01985243|BEHAVIORAL|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
219628585|NCT01985243|BEHAVIORAL|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings \& business literacy program for young female adolescents to encourage them to stay in school.
219628586|NCT04162743|DRUG|Trazodone|take trazodone 100mg before polysomnography
219628587|NCT04162743|DRUG|Placebo oral tablet|take placebo oral tablet before polysomnography
219628588|NCT01408290|BIOLOGICAL|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
218937401|NCT05812729|BEHAVIORAL|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
218937402|NCT05167825|DRUG|Macitentan|Macitentan will be administered orally as a tablet.
219628589|NCT01408290|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
219628590|NCT01408290|BIOLOGICAL|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
219628591|NCT01408290|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
219628592|NCT03513237|PROCEDURE|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
218937403|NCT01224145|DRUG|5x5cm bupivacaine collagen sponges|
218937404|NCT02230033|DRUG|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
218937405|NCT02230033|DRUG|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
218937406|NCT02230033|DRUG|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
218937407|NCT03389958|OTHER|Counseling and provision of contraception|Provider training, availability of contraceptive methods
218937408|NCT01906606|BEHAVIORAL|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
219048338|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
219628593|NCT03015337|BEHAVIORAL|New physical education instructions|
219628594|NCT02391688|DRUG|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
219628595|NCT02391688|DRUG|Bupropion|
219628596|NCT02391688|DRUG|Fexofenadine|
219628597|NCT00350207|DRUG|Tiotropium bromide|
219628598|NCT00350207|DRUG|Placebo|
219628599|NCT00350207|DRUG|Salmeterol xinafoate|
219628600|NCT03342378|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
219628601|NCT03342378|DIAGNOSTIC_TEST|PET-MRI|All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
219628602|NCT00495391|DRUG|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
219628603|NCT00495391|DRUG|Placebo|One oral placebo tablet twice daily for 52 weeks.
219628604|NCT00495391|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
219628605|NCT00495391|DRUG|Ribavirin|1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
219048339|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
219048340|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
219628606|NCT03813173|PROCEDURE|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
219628607|NCT01492829|BEHAVIORAL|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
219048341|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
219048342|NCT04916249|DRUG|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
219048343|NCT04916249|OTHER|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
219628608|NCT01366924|DIETARY_SUPPLEMENT|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
219048344|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
219048345|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
219628609|NCT01366924|OTHER|Endurance exercise|60 minute endurance exercise session
219628610|NCT06347224|PROCEDURE|Virtual placement of lag screws in both columns of the acetabulum on 3D pelvic CT models.|The intervention aims to simulate a percutaneous fixation technique that could be applied in a real surgical environment, offering insights into the potential for personalized surgical planning and optimization of outcomes for patients with acetabular fractures. This virtual approach allows for the exploration of various screw placement strategies without the ethical and practical constraints of direct clinical experimentation.
219628611|NCT04604756|DRUG|Losartan|administration of losartan (50 mg) (oral)
219628612|NCT04604756|DRUG|Placebo Oral Tablet|administration of placebo (oral)
219628613|NCT03566199|DRUG|Panobinostat Nanoparticle Formulation MTX110|Given IT
219628614|NCT03566199|DRUG|Convection-Enhanced Delivery (CED)|Undergo CED
219628615|NCT02352571|BIOLOGICAL|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
219628616|NCT04509076|BEHAVIORAL|PrEP iT! (plus usual PrEP care)|"The PrEP iT! intervention is a mobile-optimized website, with the following components:~* PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~* Tailored feedback on PrEP adherence/non-adherence~* PrEP and sexual health information tailored for YMSM~* Text message reminders for PrEP adherence and healthcare appointments~* An ask the expert feature"
219628617|NCT04509076|BEHAVIORAL|Usual PrEP care|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
219628618|NCT06577168|OTHER|Levonogestrel Intrauterine system (LNG-IUS)|Contraception method
219628619|NCT03707223|BEHAVIORAL|The Interfaces Program|career development program
219628620|NCT03707223|BEHAVIORAL|IPS|supported employment using the individual placement and support (IPS) model
219628621|NCT00459862|OTHER|laboratory biomarker analysis|Correlative study
219628622|NCT00459862|DRUG|pazopanib hydrochloride|Given orally
219628623|NCT00038402|DRUG|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
219048346|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
219048347|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
219048348|NCT06297356|DEVICE|Stress ball|Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
219048349|NCT05002946|DRUG|SP-104|single oral dose
219628624|NCT00038402|DRUG|Taxol|225 mg/m\^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
219628625|NCT00038402|DRUG|Fluorouracil|500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
219628626|NCT00038402|DRUG|Cytoxan|500 mg/m\^2 on Day 1 of each cycle for 4 cycles.
219628627|NCT00038402|DRUG|Epirubicin|75 mg/m\^2 IV on Day 1 of each cycle for 4 cycles.
219628628|NCT01953302|PROCEDURE|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
219048350|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
219048351|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
219048352|NCT01700179|DRUG|ACH-0143102|
219048353|NCT01700179|DRUG|Ribavirin|
219048354|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
219048355|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
219048356|NCT00753207|DRUG|epirubicin hydrochloride|
219048357|NCT00753207|DRUG|lapatinib ditosylate|
219048358|NCT00753207|OTHER|biomarker analysis|
219048359|NCT00753207|OTHER|immunohistochemistry staining method|
219048360|NCT00753207|OTHER|liquid chromatography|
219048361|NCT00753207|OTHER|mass spectrometry|
219628629|NCT05340764|DRUG|Infliximab|Infliximab is an effective and commonly used medication to treat patients with IBD
219628630|NCT02361099|OTHER|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
219628631|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
219628632|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
219628633|NCT05335837|PROCEDURE|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
219628634|NCT05392842|DIETARY_SUPPLEMENT|Corchorus Olitorius Buccal fast dissolving Films|Corchorus Olitorius Buccal fast dissolving Films
219628635|NCT05392842|DIETARY_SUPPLEMENT|plain mucoadhesive fast dissolving film|plain mucoadhesive fast dissolving film
219628636|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
219628637|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
219628638|NCT05261542|DIAGNOSTIC_TEST|flow cytometry|evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
219048362|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
219048363|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
219048364|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
219048365|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
219628639|NCT03425591|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
219048366|NCT00667342|DRUG|Cisplatin|Given IV.
219048367|NCT00667342|DRUG|Doxorubicin|Given IV.
219048368|NCT00667342|DRUG|Methotrexate|Given IV.
219048369|NCT00667342|DRUG|Ifosfamide|Given IV.
219048370|NCT00667342|DRUG|etoposide|Given IV.
219048371|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
219048372|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
219048373|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
219206545|NCT04282304|BEHAVIORAL|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week."
219206546|NCT06776471|OTHER|Resin-based flowable filling material|Preventive restoration
219628640|NCT03285828|BEHAVIORAL|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~1. Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~2. Lectures and the distribution of memory aids.~3. Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~4. Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
219628641|NCT05820529|PROCEDURE|adenotonsillectomy|removal of adenoid,tonsil in one session
219628642|NCT05820529|PROCEDURE|adenoidectomy|removal of adenoid
219628643|NCT05820529|PROCEDURE|tonsillectomy|removal of tonsil
219628644|NCT03313180|DRUG|Nintedanib|Administered twice daily
219628645|NCT01966120|DRUG|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
219628646|NCT01966120|DRUG|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
219048374|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
219628647|NCT01966120|PROCEDURE|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
219628648|NCT00461630|DRUG|ER niacin/laropiprant|
219628649|NCT00461630|DRUG|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
219628650|NCT00461630|DRUG|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
219628651|NCT05468294|DRUG|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
219628652|NCT05468294|DRUG|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
219628653|NCT04600765|DIAGNOSTIC_TEST|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
219628654|NCT00444522|DRUG|Alprazolam thermal aerosol|
219048375|NCT03828305|OTHER|Control Group|No intervention
219628655|NCT05087264|DRUG|Indocyanine green|ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
219628656|NCT02920502|DIETARY_SUPPLEMENT|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
219628657|NCT02920502|DIETARY_SUPPLEMENT|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
219628658|NCT02920502|DIETARY_SUPPLEMENT|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
219628659|NCT02920502|OTHER|Arm 1: Placebo|One time dose of Placebo
219628660|NCT01215396|DIETARY_SUPPLEMENT|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
219628661|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
219628662|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
219628663|NCT02546375|DRUG|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
219628664|NCT04640454|PROCEDURE|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
219628665|NCT03872206|BIOLOGICAL|HPN536 Fixed IV 6 to 560 ng/kg|Fixed dose IV cohorts at doses from 6 to 560 ng/kg
219628666|NCT03872206|BIOLOGICAL|HPN536 1 Prime Step IV 600-1200 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)
219628667|NCT03872206|BIOLOGICAL|2 Prime Step IV 900-14000 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
219628668|NCT04183296|DRUG|propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
219628669|NCT04183296|DRUG|sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
219628670|NCT00442897|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
219628671|NCT00442897|DRUG|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
219628672|NCT04396262|OTHER|Food-1|HTD-blueberry beverage with white bread.
219048376|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
219048377|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
219048378|NCT01978405|DRUG|Alpha lipoic acid|
219048379|NCT06518356|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).
219628673|NCT04396262|OTHER|Food-2|Sweetened water with white bread as a control.
219628674|NCT02564653|BEHAVIORAL|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
219048380|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
219048381|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
219628675|NCT02564653|BEHAVIORAL|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
219628676|NCT00513981|DRUG|leucovorin calcium|
219628677|NCT00513981|DRUG|methotrexate|
219628678|NCT00513981|OTHER|mass spectrometry|
219628679|NCT00513981|OTHER|pharmacological study|
219628680|NCT01821235|DRUG|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
219628681|NCT01821235|DRUG|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
219628682|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
219628683|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
219628684|NCT02368535|OTHER|Survey|25-item questionnaire on pereception of interdisciplinary rounds
219628685|NCT05628935|PROCEDURE|peripheral nerve block|local anesthetic application to the brachial plexus
219628686|NCT05971784|OTHER|Telerehabilitation Group|The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
219628687|NCT05971784|OTHER|Control Group|The group that will receive an exercise program consisting of balance and walking activities
219628688|NCT05541003|DRUG|NBT-NM108|All patients will consume NBT-NM108 in the form of 2 muffins daily.
219628689|NCT02689193|OTHER|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
219628690|NCT03680378|DRUG|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
219048382|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
219048383|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
219628691|NCT06116188|DIAGNOSTIC_TEST|FDG-PET study|"Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with \[18F\]-FDG-PET/CT."
219048384|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
219048385|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
219048386|NCT01010581|DRUG|Placebo|oral administration
219048387|NCT01010581|DRUG|Methotrexate|oral administration
219048388|NCT01010581|DRUG|Folic Acid|oral administration
219048389|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
219048390|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
219048391|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
219628692|NCT03986307|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
219628693|NCT03986307|OTHER|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
219628694|NCT03986307|DIETARY_SUPPLEMENT|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
219628695|NCT02645240|DRUG|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
219628696|NCT00618592|DIETARY_SUPPLEMENT|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
219628697|NCT04725162|RADIATION|18F-FDG|All subjects received 18F-FDG PET examination.
219628698|NCT00353509|DEVICE|Device Closure of a Septal Defect|
219628699|NCT01788631|DRUG|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-\[4-\[(methylamino)carbonyl\]-1H-pyrazol-1-yl\]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
219628700|NCT01788631|DRUG|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
219628701|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
219628702|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
219628703|NCT00891020|DRUG|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
219048392|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
219048393|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
219206547|NCT06776393|OTHER|ultrasound|"Dynamic translaryngeal Ultrasound Motion mode ultrasound of the laryngeal region during phonation Acoustic recordings VHI questionnaires "
219628704|NCT00256412|DRUG|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
219628705|NCT00256412|DRUG|Placebo|4 capsules of placebo each day
219628706|NCT02042989|DRUG|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
219628707|NCT02042989|DRUG|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
219628708|NCT04737629|BEHAVIORAL|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
219628709|NCT04737629|BEHAVIORAL|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
219628710|NCT04737629|BEHAVIORAL|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
219628711|NCT00436189|PROCEDURE|Blood Draw|
219628712|NCT03188289|DRUG|Placebo gel|Placebo is the control group treated with a placebo gel.
219628713|NCT03188289|DRUG|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
218937409|NCT02038361|GENETIC|blood draw|
219628714|NCT03188289|DRUG|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
218937410|NCT03304249|BEHAVIORAL|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
219628715|NCT03188289|DRUG|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
219628716|NCT03291080|DRUG|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
218937411|NCT03304249|OTHER|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
218937412|NCT01866085|PROCEDURE|AdVance® sling procedure|
219628717|NCT03291080|DRUG|Extracted capsules 13-CRA|Extracted capsules 13-CRA
219628718|NCT01932060|DRUG|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
219628719|NCT03137160|BIOLOGICAL|Ixekizumab|Injection
219628720|NCT01339260|DRUG|Netupitant and Palonosetron|
219628721|NCT01339260|DRUG|Palonosetron|
219628722|NCT01339260|DRUG|Dexamethasone|
219628723|NCT00156780|DRUG|AI-700|
219628724|NCT04110626|OTHER|Questionnaires|The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
219628725|NCT04110626|OTHER|Non-directive Interviews|The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
219628726|NCT04504448|DRUG|HNC664 capsules Single dose|HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
219628727|NCT04504448|DRUG|HNC664 placebos Single dose|HNC664 placebos single ascending doses,PO,Single dose, matching placebo
219628728|NCT04504448|DRUG|HNC664 capsules FED|HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
219628729|NCT03114930|OTHER|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
219628730|NCT02364830|DRUG|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
219628731|NCT02364830|OTHER|Placebo|One Placebo Capsule/Day for 4 Weeks
219628732|NCT02364830|DRUG|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
218937413|NCT01866085|PROCEDURE|ARGUS Sling procedure|
219628733|NCT04735601|PROCEDURE|Ahmed Valve|Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
219628734|NCT00285740|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) in a Group Format|
219628735|NCT06497530|DRUG|Serplulimab|"Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle for 4 cycles in the induction phase.~Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle in the maintenance phase."
219628736|NCT06497530|DRUG|Lurbinectedin|Lurbinectedin will be administered intravenously at a fixed dose of 4 mg on Day 1 of each 21-day cycle in the maintenance phase.
219628737|NCT06497530|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
219628738|NCT06497530|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
219628739|NCT03074825|DRUG|Chiauranib|Take 50mg orally once daily
219628740|NCT04505930|BEHAVIORAL|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
219628741|NCT04505930|BEHAVIORAL|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
219628742|NCT04412655|DEVICE|Percutaneous Coronary Revascularization for STEMI|Percutaneous Mechanical Reperfusion for STEMI
219628743|NCT04944914|DRUG|camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy
219628744|NCT04944914|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.
219628745|NCT00320710|DRUG|Zoledronic acid|4mg IV
219628746|NCT00320710|DRUG|Placebo|Placebo to zoledronic acid
219628747|NCT05372835|OTHER|La Chlogen mouthwash|Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
219628748|NCT05372835|OTHER|water|Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
219628749|NCT05372835|OTHER|La Chlogen mouthwash and La Chlogen periodontal flosser|Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
219628750|NCT03448419|DRUG|Empagliflozin|Film-coated tablet
218937414|NCT06218498|DEVICE|ablative fractional 2940-nm Er: YAG laser|Ablative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
219628751|NCT03448419|DRUG|Placebo|Film-coated tablet
219628752|NCT05029518|DRUG|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
219628753|NCT02841995|DRUG|Belumosudil (KD025)|Pharmaceutical form: Capsules or Tablets Route of administration: Oral
218937415|NCT06218498|DEVICE|non-ablative fractional 1565nm|Non-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
219628754|NCT01117922|OTHER|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
219628755|NCT01117922|OTHER|Usual Care Group|
219628756|NCT02283424|DRUG|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
219628757|NCT02283424|DRUG|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
219628758|NCT02639624|DRUG|Low bicarbonate dialysate First|
219628759|NCT02639624|DRUG|Normal bicarbonate dialysate First|
219628760|NCT02639624|DRUG|Normal bicarbonate dialysate|
219628761|NCT02639624|DRUG|Low bicarbonate dialysate|
219628762|NCT01227590|DRUG|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
219628763|NCT06182202|DEVICE|Powered Prosthesis|Custom in-house powered prosthetic device (used in prior studies, see Citations).
219628764|NCT02875626|DRUG|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
219628765|NCT01703260|DRUG|Roflumilast|Roflumilast dose
219628766|NCT01703260|DRUG|Pioglitazone|Pioglitazone dose
219628767|NCT01703260|DRUG|Placebo|Pioglitazone placebo-matching dose
219628768|NCT01703260|DRUG|Placebo|Roflumilast placebo-matching dose
219628769|NCT04876326|BIOLOGICAL|Autologous Adipose Mesenchymal Stem Cell Implantation|"Before taking adipose tissue, each subject was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Adipose tissue was taken through 5 grams of subcutaneous fat biopsy from the abdomen of each subject and put into a transport medium and then sent to the RSCM-FKUI cGMP IPT Stem Cells Laboratory for immediate isolation of mesenchymal stem cells.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in 2cc physiological NaCl transport medium just before implantation.~The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe."
219628770|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|"Before taking the umbilical cord tissue, a pregnant woman's donor was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory at the UPT TK Stem Cells RSCM-FKUI for isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in a suitable transport medium just prior to implantation."
219628771|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation|"Before taking adipose and umbilical cord tissue, each subject was screened. -For Adipose tissue : The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe.~-Uc-MSC : Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory to have isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~Later it will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture."
219628772|NCT03227744|BEHAVIORAL|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
219628773|NCT03227744|OTHER|Surveys|MAX-PC, GAD and FACT-P
219628774|NCT00003646|DRUG|allovectin-7|
219628775|NCT02215369|DEVICE|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
219628776|NCT00413946|DRUG|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
219628777|NCT00413946|DRUG|saline|three doses of 1.0 ml saline per body weight
219628778|NCT04075214|DEVICE|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
219628779|NCT03353714|OTHER|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
218937416|NCT06218498|DRUG|5% Minoxidil|topical 5% minoxidil, 1 ml, twice daily
218937417|NCT06896994|DRUG|esketamine group|In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.
218937418|NCT06896994|DRUG|control group|receiving the combination of pregabalin and duloxetine
218937419|NCT05336383|DRUG|Radiation Therapy|Given by Infusion
218937420|NCT06890416|BIOLOGICAL|RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE|Intramuscular injection
218937421|NCT06890416|BIOLOGICAL|HZ/su VACCINE|intramuscular injection
218937422|NCT07062003|PROCEDURE|Biopsy Procedure|Undergo biopsy
218937423|NCT07062003|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218937424|NCT07062003|PROCEDURE|Computed Tomography|Undergo CT
218937425|NCT07062003|OTHER|Medical Device Usage and Evaluation|Undergo MBRT with tungsten slit collimator
219628780|NCT02146014|OTHER|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
219628781|NCT02146014|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
219628782|NCT04382781|DRUG|NO-Immunosuppressive|Patients not receiving immunosuppressive drugs
219628783|NCT04382781|DRUG|Immunosuppressive|Patients receiving immunosuppressive drugs (overall, and specific drugs)
219628784|NCT04382781|DRUG|Immunoglubulins|Patients receiving immunoglubulins
219628785|NCT03089723|BEHAVIORAL|Visual Analog Scale (VAS)|Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months
219628786|NCT03089723|BEHAVIORAL|Range of Motion (ROM)|submitted to ROM at at baseline, 1 month, 3 months and 6 months
219628787|NCT03089723|BEHAVIORAL|Palmar grip strength|submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months
219628788|NCT03089723|BEHAVIORAL|Lateral grip strength|submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months
219628789|NCT03089723|BEHAVIORAL|Pulp-pulp pinch strength|submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months
219628790|NCT03089723|DRUG|Lavage with physiologic saline solution|Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.
219628791|NCT03089723|DRUG|Lavage with physiologic saline solution and Osteonil® Mini|Joint lavage with physiologic saline solution and Osteonil® Mini
219628792|NCT03089723|BEHAVIORAL|Quick Dash|Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months
219628793|NCT03089723|BEHAVIORAL|Sollerman Test|Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
219628794|NCT00175123|DRUG|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
219628795|NCT02756143|BEHAVIORAL|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
219628796|NCT00212550|PROCEDURE|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
219628797|NCT00619450|OTHER|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
219628798|NCT05739838|DEVICE|Biolase ;Low Level Laser|Low Level laser ,940 nm
219628799|NCT02445638|OTHER|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
219628800|NCT02445638|OTHER|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
219628801|NCT06340113|PROCEDURE|MCKENZIE AND STABILIZATION EXERCISES|"In this group 11 participants will receive McKenzie protocol with stabilization exercises. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week. At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold"
219628802|NCT06340113|PROCEDURE|MULLIGAN AND STABILIZATION EXERCISES|. The technique will include Self-sustained Natural Apophyseal Glide (SNAGs), Natural Apophyseal Glides (NAGs), and mobilization techniques.. The participants will receive three sets of Mulligan Mobilization, each set involving 10 repetitions of the exercise, with an interval of 15 to 20 seconds between the sets.At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold.
219048394|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
219628803|NCT05885503|BIOLOGICAL|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
219628804|NCT05885503|BIOLOGICAL|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
219628805|NCT06116279|DEVICE|Insertion of electrode during planned neurosurgery for epilepsy|A novel, 300 micrometer, ultraflexible, low-impedance electrode proposes to cause minimal parenchymal (brain tissue) damage, and provide multiple contacts at multiple depths to allow unit-level recordings for a period of 15 minutes.
219048395|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
219048396|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
219048397|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
219628806|NCT02531308|DRUG|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
219628807|NCT02531308|DRUG|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
219628808|NCT02531308|DRUG|Cyclophosphamide|Interferes with DNA replication
219628809|NCT02531308|DRUG|Doxorubicin|anthracycline antitumor antibiotic
219628810|NCT02531308|DRUG|Vincristine|Inhibits cell mitosis causing cell death.
219628811|NCT02531308|DRUG|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
219628812|NCT02531308|DRUG|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
219628813|NCT01937611|DRUG|Dexmedetomidine|Dexmedetomidine
219628814|NCT01937611|DRUG|Midazolam|Midazolam
219628815|NCT02825628|DRUG|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
219628816|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
219628817|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
219628818|NCT06574477|PROCEDURE|Planning of alignment with HoloLens 2|Planning of attachment position and traction direction with HoloLens 2 goggles
219628819|NCT06574477|PROCEDURE|No planning of alignment with HoloLens 2|No planning of attachment position and traction direction with HoloLens 2 goggles
218937426|NCT07062003|RADIATION|Minibeam Radiation Therapy|Undergo MBRT with tungsten slit collimator
219628820|NCT04367545|DIAGNOSTIC_TEST|Saliva collection|Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
219628821|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive live phone call
219628822|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive IVR phone messages
219628823|NCT04548193|OTHER|Educational Intervention|Receive educational materials
219628824|NCT04548193|OTHER|Questionnaire Administration|Ancillary studies
219628825|NCT00630825|DRUG|LY2189265|
219628826|NCT00630825|DRUG|Placebo|
218937427|NCT06762054|DRUG|Continue DTG-based antiretroviral therapy|Participants will continue on DTG-based ART after enrollment for up to 12 months
218937428|NCT06762054|BEHAVIORAL|Enhanced adherence counselling|Participants with VL ≥200 copies/mL will undergo enhanced adherence counselling
218937429|NCT07062783|OTHER|Breathing exercise|Volunteers participating in the study who were included in the experimental group performed breathing exercises every day for three weeks. They were taught to focus their attention on the hand on their abdominal area while breathing slowly through their nose and to increase abdominal movement while reducing chest movement. They were warned that during inspiration, as air filled their lungs, the hand on their abdomen should rise upward and the hand on their chest should not move excessively. Participants continued the training until they performed the exercise correctly. The diaphragmatic breathing exercise was performed for 10 minutes in the supine position during the first week, in the semi-sitting and/or sitting position during the second week, and in the standing position during the final week.
218937430|NCT07062783|OTHER|Aerobic Exercise|The ratios determined as reference values for walking training in healthy adults (reference value for women = (2.11\*height) - (2.29\*body weight) - (5.78\*age) + 667 meters - reference value for men = (7.57\*height) - (1.76\*body weight) - (5.0 2\*age) - 309 meters) was performed at 80% intensity for at least 30 minutes on at least 3 days a week for 3 weeks. Aerobic exercise was considered for 3 weeks to facilitate adaptation to exercise and sustainability.
218937431|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
219048398|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
218937432|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
218937433|NCT06890897|DRUG|Esketamine group|Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients
218937434|NCT06890897|DRUG|PRF group|Patients in the control group will receive PRF+standardized treatment
219048399|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
219048400|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
219628827|NCT05374122|DIAGNOSTIC_TEST|DSOC with AI biopsy guidance|Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
219628828|NCT05374122|DIAGNOSTIC_TEST|DSOC biopsy without AI guidance|"Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies."
219628829|NCT00351195|DRUG|Etoposide|
219628830|NCT00351195|DRUG|Oxaliplatin|
219628831|NCT00351195|DRUG|Capecitabine|
219628832|NCT04654195|GENETIC|polymorphism analysis|DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.
219628833|NCT04654195|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
219628834|NCT05268224|DIAGNOSTIC_TEST|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
219628835|NCT03863639|DIAGNOSTIC_TEST|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
219628836|NCT03863639|DIAGNOSTIC_TEST|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
219628837|NCT02478424|DRUG|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
219628838|NCT02478424|DRUG|cyclosporine|
219628839|NCT02478424|DRUG|Methotrexate|
219628840|NCT02000635|OTHER|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
219628841|NCT02275819|OTHER|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
219628842|NCT01396135|DRUG|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
219628843|NCT01396135|DRUG|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
219628844|NCT01396135|DRUG|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
218937435|NCT04829240|BEHAVIORAL|Veterans Anxiety Skills Training Intervention|Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms
219628845|NCT01396135|DRUG|Placebo|Single dose of placebo given as a matching number of oral tablets
219628846|NCT01396135|DRUG|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
219628847|NCT01396135|DRUG|Placebo|Multiple doses of placebo given as a matching number of oral tablets
219628848|NCT03870932|OTHER|Motor Imagery physical therapy|
219628849|NCT03870932|OTHER|Conventional physical therapy|
219628850|NCT03892642|DRUG|Avelumab|"Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment"
219628851|NCT03892642|BIOLOGICAL|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
219628852|NCT03929133|DEVICE|automatic screening machine on congenital heart disease|
219628853|NCT04670549|OTHER|Implementation of treatment guidelines|To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
219628854|NCT02211209|DRUG|Volanesorsen|
219628855|NCT02211209|DRUG|Placebo|
219628856|NCT01544985|DRUG|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
219628857|NCT01544985|DRUG|placebo po|sterile water
219628858|NCT06163885|OTHER|Stoma care education with flipped classroom|Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
218937436|NCT04829240|BEHAVIORAL|PCMHI Usual Care|Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
219628859|NCT06163885|OTHER|Stoma care education with peer-supported education model|Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
219628860|NCT05496647|OTHER|Virtual Reality|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Preferred video will be watched with Virtual Reality Glasses for approximately 20 minutes during the process, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form, Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; At the 1st hour after the procedure, Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale and Satisfaction Evaluation Form will be filled."
219628861|NCT05496647|OTHER|Music Therapy|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; During the procedure, the preferred music for Music Therapy will be played for approximately 20 minutes, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
219628862|NCT05496647|OTHER|Stress Ball Application|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Stress ball will be played for approximately 20 minutes during the process.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
219628863|NCT05496647|OTHER|Control|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; Women in the control group will not undergo any intervention other than routine surgery.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure, the Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
219628864|NCT04111120|DIAGNOSTIC_TEST|SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI|Coagulation assessment using heparinase treated SONOCLOT
219628865|NCT01695174|DRUG|Xifaxan|
219628866|NCT03497520|BEHAVIORAL|asymmetric spinal stabilization exercise|"The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~* before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~* after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity"
219628867|NCT01719367|DRUG|Atenolol|
219628868|NCT01086631|DRUG|Rituximab|
219628869|NCT02792062|DRUG|TAK-385 40 mg|TAK-385 40 mg tablet
219628870|NCT04297748|COMBINATION_PRODUCT|89Zirconium-M7824|PET imaging agent
219628871|NCT04297748|DRUG|M7824|Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
219628872|NCT03220269|OTHER|Out-of-hospital cardiac arrest (OHCA)|Data collection
219628873|NCT03220269|OTHER|In-hospital cardiac arrest (IHCA)|Data collection
219628874|NCT04932369|BEHAVIORAL|Emotion Regulation training based on DBT|trained about emotion regulation and problem solving during eight 90-min group sessions
219628875|NCT04895657|DRUG|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
218937437|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
218937438|NCT05731544|DRUG|BMF-219|Investigational Product
218937439|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
219628876|NCT04895657|DRUG|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
219628877|NCT01216241|DRUG|Daptomycin|8 MG/KG IV
219628878|NCT01216241|OTHER|Saline Placebo|50 ml normal saline once daily
219628879|NCT01216241|DRUG|Daptomycin|8 mg/kg once daily
219628880|NCT05598424|DRUG|Oral Glucocorticoids|Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
219628881|NCT00002596|BIOLOGICAL|bleomycin sulfate|
219628882|NCT00002596|BIOLOGICAL|filgrastim|
219628883|NCT00002596|DRUG|carboplatin|
219628884|NCT00002596|DRUG|cisplatin|
219628885|NCT00002596|DRUG|cyclophosphamide|
219628886|NCT00002596|DRUG|etoposide|
219628887|NCT00002596|PROCEDURE|autologous bone marrow transplantation|
219628888|NCT00002596|PROCEDURE|bone marrow ablation with stem cell support|
219628889|NCT00002596|PROCEDURE|conventional surgery|
219628890|NCT00002596|PROCEDURE|peripheral blood stem cell transplantation|
219628891|NCT00002596|RADIATION|radiation therapy|
219628892|NCT04726696|BEHAVIORAL|ROLE-AP programme|The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
219628893|NCT01626196|OTHER|No intervention|This was an observational study
219628894|NCT05711355|PROCEDURE|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
219628895|NCT05711355|PROCEDURE|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
219628896|NCT03309943|DRUG|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
219628897|NCT03309943|DRUG|Placebo|Participants will take one dose of Placebo on two separate occasions.
219628898|NCT06362538|OTHER|International Physical Activity Questionnaire|Assessments of physical activity level and functional capabilities (aerobic capacity, muscular strength and power, flexibility
219628899|NCT06362538|OTHER|Six minute walking test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
219628900|NCT06362538|OTHER|SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21.|Evaluation of the quality of life, the psychological sphere (anxiety, stress, depression) and the quality of sleep
219628901|NCT06362538|OTHER|MEDAS|Evaluation of adherence to the Mediterranean diet
219628902|NCT06362538|OTHER|Intima-media thickness (IMT)|Bmode ultrasonography
219628903|NCT06362538|BIOLOGICAL|Blood sampling|Measurement of parameters for defining cardiovascular risk and biomarkers.
219628904|NCT06362538|BIOLOGICAL|Stool Sample Culture Test|Evaluation of Gut Microbiota
219628905|NCT00023855|DRUG|bortezomib|
219628906|NCT00023855|DRUG|doxorubicin hydrochloride|
219628907|NCT03895008|OTHER|Cardia and Non-cardia gastric cancer|We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
219628908|NCT02530723|OTHER|power training|Resistance training machines with CAM devices will be used for training.
219628909|NCT02923323|DEVICE|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
219628910|NCT02923323|BEHAVIORAL|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
219628911|NCT00931255|DRUG|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
219628912|NCT00931255|DRUG|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
219628913|NCT02817295|OTHER|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
219628914|NCT00004990|DRUG|Dexamethasone|
219628915|NCT01372995|DRUG|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
219628916|NCT01372995|DRUG|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
219628917|NCT01372995|OTHER|Inactive substance|Inactive substance given enterally for 5 days.
219628918|NCT01890681|BEHAVIORAL|Baby NAP SACC|
219628919|NCT01890681|BEHAVIORAL|Back to Sleep|
219628920|NCT04275739|BEHAVIORAL|Academic Episodic Future Thinking|Brief Academic goal related EFT intervention involving desirable outcomes of current academic goals
219628921|NCT04275739|OTHER|Vivid Memory Task|Matched for time control task involving recall of vivid memories of distinct events/actions from a children's story
219628922|NCT01661335|DRUG|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
219628923|NCT01661335|DRUG|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
219628924|NCT00131313|DRUG|Nipent, Cytoxan, Rituxan|
219628925|NCT06297018|BEHAVIORAL|Bioenergy application|Bioenergy application: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
219628926|NCT01483963|BIOLOGICAL|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
219628927|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
219628928|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
219628929|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
219628930|NCT01483963|OTHER|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
219628931|NCT04122742|PROCEDURE|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
219628932|NCT04122742|OTHER|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
219628933|NCT04122742|OTHER|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
219628934|NCT04122742|OTHER|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
219628935|NCT04122742|BIOLOGICAL|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
219628936|NCT03710837|OTHER|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
219628937|NCT03710837|OTHER|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
219628938|NCT05775393|PROCEDURE|Serratus anterior plane block for MRM|"They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study."
219628939|NCT03123393|DRUG|TAK-659|TAK-659 Tablets
219628940|NCT05863260|DRUG|Treatment Group|Treatment Group
219628941|NCT03289026|DRUG|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
219628942|NCT01230086|DEVICE|ICD Implantation without DFT testing|Implantation
219628943|NCT01230086|DEVICE|Upper limit of vulnerability testing|Upper limit of vulnerability testing
219628944|NCT01230086|DEVICE|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
219628945|NCT04009525|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
219628946|NCT04009525|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
219628947|NCT04009525|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
219628948|NCT04009525|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
219628949|NCT04009525|DRUG|cyclosporine A|cyclosporine A
219628950|NCT04009525|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
218937440|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
218937441|NCT03969784|OTHER|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
219628951|NCT04009525|DRUG|Tacrolimus|Tacrolimus
219628952|NCT04009525|DRUG|Methotrexate|Methotrexate
218937442|NCT02102204|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
219628953|NCT00427648|DRUG|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
219628954|NCT00427648|DRUG|placebo|normal saline
218937443|NCT03425474|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
218937444|NCT03425474|DRUG|Propofol|Initial dose plus supplemental doses as necessary
219628955|NCT01631539|DEVICE|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
219628956|NCT01631539|DRUG|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
219628957|NCT01631539|DRUG|5 FU|every 2 weeks IV
219628958|NCT01631539|DRUG|Irinotecan|every 4 weeks chemoembolization
219628959|NCT02536079|DRUG|NeuroAiD|
219628960|NCT04445038|DRUG|610|Recombinant anti-IL-5 Humanized Monoclonal Antibody
219628961|NCT04445038|DRUG|Placebo|Placebo
219628962|NCT03415971|PROCEDURE|EMG befor denture treatment|
219628963|NCT03415971|PROCEDURE|EMG in a month after termination of treatment|
219628964|NCT03415971|PROCEDURE|EMG in a 3 months after termination of treatment|
219628965|NCT05618678|BEHAVIORAL|DIGNITY|DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
219628966|NCT05618678|BEHAVIORAL|Infection Control|This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
218937445|NCT01597167|DIETARY_SUPPLEMENT|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
218937446|NCT02130791|BEHAVIORAL|Sleep|
218937447|NCT00202475|PROCEDURE|eythrocytapheresis|machinal collection of erythrocytes
218937448|NCT00202475|PROCEDURE|whole blood collection|collection of whole blood
218937449|NCT04628910|OTHER|Simulated Flotation Therapy|"The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions."
218937450|NCT04628910|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
218937451|NCT05661188|DRUG|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
218937452|NCT01865552|BIOLOGICAL|SB4|SC administration
218937453|NCT01865552|BIOLOGICAL|EU sourced Enbrel|SC administration
218937454|NCT01865552|BIOLOGICAL|US sourced Enbrel|SC administration
219628967|NCT06175078|DEVICE|Ultrasound Imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
218937455|NCT05957471|DRUG|Drug: BC3195 for Injection|BC3195 via intravenous(IV).
218937456|NCT02714972|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
218937457|NCT00369291|BIOLOGICAL|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
218937458|NCT00369291|BIOLOGICAL|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
219628968|NCT02185326|DRUG|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
219628969|NCT03809780|DRUG|Lenalidomide|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
219628970|NCT03809780|DRUG|Dexamethasone|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
219628971|NCT01332760|OTHER|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
219628972|NCT01332760|OTHER|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
219628973|NCT01421680|DIETARY_SUPPLEMENT|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
219628974|NCT03576963|DRUG|Guadecitabine|Given SC
219628975|NCT03576963|BIOLOGICAL|Nivolumab|Given IV
219628976|NCT00336401|DRUG|Sevoflurane or Propofol|
219628977|NCT03369886|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
219628978|NCT02431286|DRUG|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
219628979|NCT02431286|DRUG|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
219628980|NCT02431286|DRUG|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
219628981|NCT00376155|DRUG|sulfadoxine /pyrimethamine plus amodiaquine|
219628982|NCT04244955|OTHER|Semi-directive interviews|The interviews, carried out by the child psychiatrist, will be semi-directive and short (15 to 30 minutes) one-on-one with the child or adolescent so that the presence of the parents does not influence the responses. The CPTS-RI index, which has 20 questions, will be filled, as well as other questions to understand what is problematic for the child.
219628983|NCT01117038|DRUG|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
219048401|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
219048402|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
219628984|NCT01117038|DRUG|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
219628985|NCT02079350|DRUG|%6 HES and %4 Gelofusine|
219628986|NCT05486195|DRUG|SDI-118|SDI-118 Powder in Capsule
219628987|NCT05486195|DRUG|Placebo|Matching Placebo
219628988|NCT00289419|DRUG|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
219628989|NCT00289419|DRUG|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
219628990|NCT05666635|BIOLOGICAL|LTC004|"LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period.~Phase Ib indication exploration~Other Name: LTC004 for Injection"
219628991|NCT04614935|BEHAVIORAL|Action Plan|See arm description.
219628992|NCT03194633|DRUG|Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Nifedipine GITS 60 mg (once per day)
219628993|NCT05643469|OTHER|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
219628994|NCT05643469|OTHER|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
219628995|NCT05408208|DRUG|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
219628996|NCT05408208|DRUG|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
219628997|NCT04028609|BEHAVIORAL|Healthy at Home|In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
219628998|NCT04028609|OTHER|Services as Usual|Routine medical services
219048403|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
219628999|NCT00905983|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
219629000|NCT06534593|OTHER|Standard medical treatment|Standard medical treatment
219629001|NCT06534593|DEVICE|Lumbar Traction|Lumbar traction using traction table
219629002|NCT06534593|OTHER|Mckenzie Extension Protocol|Mckenzie Extension Exercises
219629003|NCT06534593|DEVICE|Interferential Therapy|Interferential Therapy for 20 minutes
219629004|NCT06534593|DEVICE|Heat Therapy|Heat Therapy for 20 minutes
219629005|NCT06534593|OTHER|Sustained Natural Apophyseal Glides (SNAGs)|3-5 reptations of Mulligan's lumbar extension Sustained Natural Apophyseal Glides (SNAGs)
219629006|NCT00386360|DRUG|Placebo comparator|oral weekly for one year
219629007|NCT00386360|DRUG|risedronate|35 mg risedronate, once a week for one year
219629008|NCT06286527|OTHER|anonymous self-administered online questionnaire|proposition to participate through billboards with a QR code leading to the questionnaire.
219629009|NCT01149980|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
219629010|NCT02724657|OTHER|Buteyko Method|Intervention will be held twice a week during 3 weeks.
219629011|NCT03870269|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
219629012|NCT05760196|DRUG|GM-CSF|PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
219629013|NCT01681212|DRUG|Ipilimumab|
219629014|NCT01681212|DRUG|Dacarbazine|
219629015|NCT00093314|DRUG|HuMax-CD20|
219629016|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
219629017|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
219629018|NCT00730535|DRUG|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
219629019|NCT04519268|DIAGNOSTIC_TEST|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) \& consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations \& required preparations, peri-operative course and post-operative outcome will be collected."
219629020|NCT01314339|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
219629021|NCT00230659|OTHER|Blood sample to be taken.|Blood sample to be taken.
219629022|NCT01069042|DRUG|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
219629023|NCT03378674|DRUG|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
219629024|NCT03293992|DRUG|0.01% RO7058584|Once daily morning administration for 7 days
219629025|NCT03293992|DRUG|0.1% RO7058584|Once daily morning administration for 7 days
219629026|NCT03293992|DRUG|1% RO7058584|Once daily morning administration for 7 days
219629027|NCT03293992|DRUG|Matching Placebo|Once daily morning administration for 7 days
219629028|NCT03293992|DRUG|Latanoprost 0.005%|Once daily morning or evening dosing
219629029|NCT00113048|DRUG|CAMPATH (alemtuzumab)|
218937459|NCT01278940|BIOLOGICAL|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
218937460|NCT01278940|PROCEDURE|IL-2|IL-2 were administrated by intranodal injection
218937461|NCT00001068|DRUG|Lamivudine|
218937462|NCT01374230|PROCEDURE|Total knee arthroplasty|Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
218937463|NCT04140578|DRUG|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
218937464|NCT03690752|DEVICE|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
219629030|NCT04040140|OTHER|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
219629031|NCT01805466|DEVICE|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
219629032|NCT01805466|DEVICE|Conventional CPB|conventional miniature cardiopulmonary bypass technique
219629033|NCT01575834|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
219629034|NCT01575834|DRUG|Placebo|Administered by subcutaneous injection once a month (QM)
219629035|NCT01575834|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
219629036|NCT01927315|DRUG|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
219629037|NCT01927315|DRUG|Placebo|Oral Placebo tablets once daily
219629038|NCT03948412|DEVICE|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
219629039|NCT03948412|OTHER|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
219629040|NCT01324986|PROCEDURE|Laparoscopic anti-reflux surgery|
219629041|NCT05175391|OTHER|Meat based protein with added spice; Plant based protein with added spice|Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
219629042|NCT00470717|PROCEDURE|Weekly telephone call|Details of feeding and health/sickness will be obtained
219629043|NCT01905917|OTHER|Tele-rehabilitation|
219629044|NCT03542942|OTHER|treatment with EXIT-target volume|exclusion of the unaffected part of the uterus out of the treatment field
219629045|NCT05229159|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Segmental multi-frequency bioelectrical impedance analysis are carried out at all patient admitted to our ICU for postoperative care after cardiac surgery with cardiopulmonary bypass. Our objective is to evaluate the relevance of phase angle to predict mortality or a prolonged hospital length of stay. Phase angle is evaluated at ICU admission and will be compared to well-known prognostic scores computed in preoperative (EuroSCORE II) and at day one after surgery (SOFA, CASUS and SAPS II).
219629046|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
219629047|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
219629048|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
219629049|NCT01834742|DRUG|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
219629050|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
219629051|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
219629052|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
219629053|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
219629054|NCT00669500|BEHAVIORAL|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
219629055|NCT05990179|OTHER|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
219629056|NCT04424420|DRUG|Paracetamol|Paracetamol oral tablet
219629057|NCT04424420|DRUG|Ibuprofen|Ibuprofen oral tablet
219629058|NCT04424420|DRUG|Placebo oral tablet|Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
219629059|NCT00002691|BIOLOGICAL|filgrastim|
219629060|NCT00002691|DRUG|asparaginase|
219629061|NCT00002691|DRUG|cyclophosphamide|
219629062|NCT00002691|DRUG|cytarabine|
219629063|NCT00002691|DRUG|daunorubicin hydrochloride|
219048404|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
219629064|NCT00002691|DRUG|dexamethasone|
219629065|NCT00002691|DRUG|etoposide|
219629066|NCT00002691|DRUG|leucovorin calcium|
219629067|NCT00002691|DRUG|mesna|
219629068|NCT00002691|DRUG|methotrexate|
219629069|NCT00002691|DRUG|vincristine sulfate|
219629070|NCT01548040|DEVICE|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
219629071|NCT01548040|DEVICE|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
219629072|NCT01225016|DRUG|Definity contrast agent|Thyroid ultrasound using contrast agent
219629073|NCT01069510|DRUG|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
219629074|NCT01069510|OTHER|Placebo|Placebo daily for 12 months
219629075|NCT05170048|DRUG|EG-301|The investigation drug, EG-301 Tablets 150mg, is for oral use.
219629076|NCT05170048|DIETARY_SUPPLEMENT|AREDS2 supplements|AREDS2 supplement is the stand of care
219629077|NCT01742988|DRUG|fimepinostat|
219629078|NCT01742988|DRUG|Rituximab|
219629079|NCT01742988|DRUG|venetoclax|
219629080|NCT06577194|DRUG|Sintilimab + IL-2 Combined with CAPOX|Sintilimab + IL-2 Combined with Capox
219629081|NCT06577194|RADIATION|Short-course radiotherapy|Short-course radiotherapy+IL-2
219629082|NCT03858998|OTHER|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
219629083|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
219629084|NCT01441557|DRUG|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
219629085|NCT02430246|DIETARY_SUPPLEMENT|Urex Plus|Probiotic
219629086|NCT02430246|OTHER|Placebo|capsule without active ingredient
219629087|NCT02430246|DIETARY_SUPPLEMENT|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
219629088|NCT01152879|DIETARY_SUPPLEMENT|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
219048405|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
219629089|NCT04817592|PROCEDURE|Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure for correction of Myopia
219629090|NCT06278077|DRUG|Neurexan|The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
219629091|NCT06278077|DRUG|Placebo|Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
219629092|NCT06494397|DRUG|VHX-896 and iloperidone|oral tablet
219629093|NCT06494397|DRUG|Iloperidone and VHX-896|oral tablet
219629094|NCT05330221|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
219629095|NCT05330221|DRUG|PHARM-PAL2|"All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention."
219629096|NCT00274300|BIOLOGICAL|pPJV7630 administered by PMED|
219629097|NCT05035290|DEVICE|Negative pressure ventilation|Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
219629098|NCT00305019|DRUG|clevudine|
219629099|NCT01742546|DEVICE|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
219629100|NCT06214195|DRUG|Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)|Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
219629101|NCT02220764|DEVICE|Teeth abutment|
219048406|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
219629102|NCT02220764|DEVICE|Implant abutments|
219629103|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~* The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
219629104|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
219629105|NCT05000164|DEVICE|Bausch + Lomb Ultra® Multifocal for Astigmatism|Study Lens
219048407|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
219048408|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
219048409|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
219629106|NCT02996825|DRUG|Gemcitabine|Given IV
219629107|NCT02996825|DRUG|Gemcitabine Hydrochloride|Given IV
219629108|NCT02996825|OTHER|Laboratory Biomarker Analysis|Correlative studies
219629109|NCT02996825|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
219629110|NCT02996825|OTHER|Pharmacological Study|Correlative studies
219629111|NCT04275011|OTHER|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (\~80% 1RM) or 6 (\~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
219629112|NCT04275011|OTHER|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
219629113|NCT02892890|PROCEDURE|Muscle Magnetic Resonance Imaging (RMI) evaluation|
219629114|NCT02892890|DEVICE|MRI|
219629115|NCT02464332|DRUG|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
219629116|NCT02422446|DRUG|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
219629117|NCT04467567|OTHER|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
219629118|NCT02523508|BEHAVIORAL|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
219629119|NCT02523508|OTHER|Control group|Passive limb mobilization which did not involve the spine
219629120|NCT00999609|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
219629121|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
219629122|NCT06974279|DEVICE|Precision TMS with SFA|Excitatory TMS delivered using a precision site finding approach and intermittent theta burst stimulation protocol
219629123|NCT06974279|DEVICE|Control TMS with SFA|Excitatory TMS using intermittent theta burst stimulation delivered to a control vertex site.
219048410|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
219048411|NCT00646204|DRUG|Memantine|10 mg bid
219629124|NCT04956120|DEVICE|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
219629125|NCT04956120|DEVICE|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
219629126|NCT06310655|RADIATION|Proton SBRT|Patients will receive SBRT over 5 days, either every day or every other day, to a dose of 25-50 Gy.
219629127|NCT04566978|DRUG|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
219629128|NCT04566978|DIAGNOSTIC_TEST|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~* Within one to four hours following injection of tracer on Day 1~* 24-72 hours post-injection (Day 2-4)~* 20-168 hours post-injection (once during days 5-7)"
219629129|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
219629130|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
219629131|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
219629132|NCT04697940|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|"Phase I dose escalation (3+3) : dose 1 (0.5 × 10\^6 cells per kg) dose 2 (2 × 10\^6 cells per kg) dose 3 (5 × 10\^6 cells per kg)~Phase II: Appropriate dose"
219629133|NCT04697940|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
219629134|NCT04697940|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
219048412|NCT00646204|DRUG|placebo|2 tabs bid
219629135|NCT05863195|BIOLOGICAL|Bevacizumab|Given IV
219629136|NCT05863195|BIOLOGICAL|Cetuximab|Given IV
219629137|NCT05863195|PROCEDURE|Computed Tomography|Undergo SPECT/CT and/or CT
219629138|NCT05863195|DRUG|Floxuridine|Given via HAI pump
219629139|NCT05863195|DRUG|Fluorouracil|Given IV
219629140|NCT05863195|PROCEDURE|Implantation|Undergo surgery to place the HAI pump
219629141|NCT05863195|PROCEDURE|Intrahepatic Infusion Procedure|Undergo HAI
219629142|NCT05863195|DRUG|Irinotecan|Given IV
219629143|NCT05863195|DRUG|Leucovorin|Given IV
219629144|NCT05863195|DRUG|Oxaliplatin|Given IV
219629145|NCT05863195|BIOLOGICAL|Panitumumab|Given IV
219629146|NCT05863195|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
218937465|NCT03690752|DEVICE|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
218937466|NCT06067152|DEVICE|EIT measurement|Evaluation of mechanical ventilation and ventilation distribution through EIT. Mechanical ventilation is set by the physician according to clinical protocolized criteria
218937467|NCT06067152|DEVICE|Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial|"SRMs will be performed with a standardized ventilation protocol. Patient will be sedated, paralyzed and ventilated in pressure controlled mode, FIO2 to obtain SPO2\> 92%, RR 25, I:E =1:1.5. Alarm of pressure limit will be set at 35 cmH2O. The ventilator will be equipped with inspiratory and expiratory hold taste. Inspiratory and expiratory occlusion will be held for 5 seconds, data will be stored and analyzed with the ventilator own tool.~Decremental PEEP trial will start if plateau pressure 30 cmH2O will be reached or end inspiratory transpulmonary pressure will exceed 28 cmH2O value. Once reached this level of plateau or transpulmonary pressure, PEEP will be reduced in three steps from 12, 10 and finally to 8 cmH2O every 20 minutes"
218937468|NCT06067152|DEVICE|Setting of EIT-guided mechanical ventilation|Mechanical ventilation is set according to EIT measurement
218937469|NCT06067152|DEVICE|Reevaluation after 24 h|Evaluation of mechanical ventilation and ventilation distribution through EIT after 24h of ventilation EIT-guided
218937470|NCT00857714|DRUG|lapatinib|1500 mg lapatinib for 14-21 days
218937471|NCT03085797|DRUG|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
218937472|NCT03085797|DRUG|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
218937473|NCT03085797|DRUG|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
218937474|NCT01837823|DRUG|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
218937475|NCT00865540|DRUG|prednisolone acetate 1%|1 drop every 8h two days before surgery
218937476|NCT00865540|DRUG|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
218937477|NCT00865540|DRUG|nepafenac 0.1%|1 drop every 8h two days before surgery
219048413|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
219048414|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
219048415|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
219629147|NCT03331796|DEVICE|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
219629148|NCT03331796|DEVICE|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
219629149|NCT03331796|DEVICE|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
219629150|NCT03598842|DIETARY_SUPPLEMENT|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
219629151|NCT03598842|DIETARY_SUPPLEMENT|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
219629152|NCT03598842|DRUG|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
219629153|NCT04322097|DEVICE|Lingual Muscle Stimulation|Tongue protrudor muscles will be stimulated
219629154|NCT04322097|OTHER|Mandibular advancement|Outcome variables will be assess with and without mandibular advancement
219629155|NCT04322097|OTHER|Postural maneuvers|Outcome variables will be measured with and without postural maneuvers
219629156|NCT04322097|OTHER|Digital Morphometrics|A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).
219629157|NCT04322097|OTHER|Tongue Force Exercise|The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.
218937478|NCT00865540|DRUG|methylcellulose 0.5%|1 drop every 8h two days before surgery
219629158|NCT04322097|OTHER|Magnetic resonance imaging (MRI)|The patient will undergo an MRI scan of the head and neck.
218937479|NCT00792493|DRUG|ORM-12741|Alternating panel multiple dose escalation
218937480|NCT00047164|BIOLOGICAL|ipilimumab|
218937481|NCT02643134|PROCEDURE|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
218937482|NCT02643134|DEVICE|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
219048416|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
219048417|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
219048418|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
219629159|NCT04322097|OTHER|Polysomnography (PSG) - Split Night|The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
219629160|NCT00726193|DEVICE|OsteoGen|OsteoGen Implatable stimulator
219629161|NCT03228888|OTHER|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
219629162|NCT06199284|DEVICE|Atalante exoskeleton|The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
219629163|NCT05405504|DEVICE|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
219629164|NCT01753570|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
219629165|NCT01753570|DRUG|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
219629166|NCT01753570|DRUG|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
219629167|NCT01753570|DRUG|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
219629168|NCT01753570|DRUG|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
219629169|NCT04709562|DEVICE|High Velocity Nasal Insufflation (HVNI)|The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.
219629170|NCT04709562|DEVICE|Noninvasive Positive Pressure Ventilation (NIPPV)|The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
219629171|NCT04744025|DEVICE|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
219629172|NCT04744025|OTHER|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
219629173|NCT01000155|DRUG|vorinostat|
219629174|NCT00537849|DEVICE|Sonablate 500(SB-500)|
219629175|NCT03193684|DRUG|Empagliflozin 25 MG|subjects will receive daily dose of 25mg of empagliflozin for 3 months
219629176|NCT03193684|DRUG|Control|Placebo
219629177|NCT03303235|DRUG|Methylergonovine|IV vs IM
219629178|NCT06263933|OTHER|Insight Scale|Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
219629179|NCT06263933|OTHER|Semi-directional interviews|"In the end of the intervention. In the end of DIPEM Or in the end of control group.~This intervention will be held after one month of hospitalization."
218937483|NCT04841642|OTHER|MANUAL THERAPY|The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
218937484|NCT04841642|OTHER|THERAPEUTIC EXERCISE|"The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
218937485|NCT01697514|DRUG|LY2940680|Capsule administered orally.
218937486|NCT01697514|DRUG|LY2940680|Powder administered orally (may be sprinkled on soft food).
218937487|NCT01132781|DRUG|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
218937488|NCT01132781|DRUG|Placebo (Placebo Group)|200 mg twice daily of placebo drug
218937489|NCT00004554|DRUG|naltrexone (Revia)|100mg/day
218937490|NCT00004554|DRUG|sertraline (Zoloft)|200mg/day
218937491|NCT00004554|DRUG|Placebo|Placebo
219629180|NCT06263933|OTHER|routine care|routine care
219629181|NCT06263933|OTHER|session of mutual assistance with a mediator psychologist|session of mutual assistance with a mediator psychologist
219629182|NCT02052024|DRUG|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
219629183|NCT02052024|DRUG|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
219629184|NCT03480490|DIAGNOSTIC_TEST|Pleural fluid C-reactive protein|"C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.~The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.~Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.~c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.~Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion."
219629185|NCT00720213|DEVICE|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
219629186|NCT00720213|DEVICE|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
219629187|NCT00620945|DRUG|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
219629188|NCT02092298|DRUG|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
219629189|NCT02092298|DRUG|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
219629190|NCT02092298|DRUG|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
219629191|NCT02462798|OTHER|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
219629192|NCT02462798|OTHER|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
219629193|NCT04997330|DEVICE|Active rTMS|Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
219629194|NCT04997330|DEVICE|Sham rTMS|Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
219629195|NCT01808066|DEVICE|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
219629196|NCT04418557|DIAGNOSTIC_TEST|RT-PCR and antibody testing|Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
219629197|NCT01420068|DRUG|SPP100|
219629198|NCT04570839|DRUG|COM701 in combination with BMS-986207 and nivolumab.|Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
219629200|NCT03088202|OTHER|Educational program|E-learning lectures, group exercises, skills training
219629201|NCT03088202|OTHER|Standardized care pathways|Pathways for systematic follow-up
219629202|NCT03088202|OTHER|Early palliative care|Compulsory referral to palliative care at inclusion
219629203|NCT01935141|PROCEDURE|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
219629204|NCT01935141|DEVICE|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
219629205|NCT01935141|DRUG|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
219629206|NCT03034980|OTHER|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
219629207|NCT03469700|OTHER|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
219629208|NCT03469700|OTHER|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
219629209|NCT03469700|OTHER|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
219629210|NCT00758290|DRUG|Triclosan/Fluoride|Brush twice daily for 3 weeks
219629211|NCT00758290|DRUG|Fluoride/triclosan|Brush daily for 3 weeks
219629212|NCT03137641|OTHER|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
219629213|NCT04505657|DRUG|celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
219629214|NCT04505657|DRUG|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
219629215|NCT04505657|DRUG|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
219629216|NCT00884117|DRUG|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
219629217|NCT04593485|DRUG|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
219629218|NCT01822730|DRUG|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
219629219|NCT01822730|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
219629220|NCT04863001|DRUG|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
219629221|NCT04698044|DIAGNOSTIC_TEST|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
219629222|NCT00497523|DRUG|Beclomethasone dipropionate|
219629223|NCT00497523|DRUG|Beclomethasone dipropionate/Salbutamol combination|
219629224|NCT00497523|DRUG|Salbutamol|
219629225|NCT04830969|DRUG|Chlorhexidine gluconate oral rinse|Paroex® is a non-alcohol chlorhexidine preparation. Participants are to use 15 mL morning and evening for 3 months. With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste. There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general. The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur. If there is any alteration in taste, it should go away when use of chlorhexidine stops.
219629226|NCT04830969|PROCEDURE|Scaling & Root Planing|SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
219629227|NCT04830969|DEVICE|Soft Picks|Soft Picks are a rubber interdental bristle cleaner. Participants are to use Soft Picks morning and evening for all 12 months of the study. They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal). Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
219629228|NCT02473939|DRUG|VR942 delivered via a Vectura Dry Powder Inhaler|
219629229|NCT02473939|DRUG|Placebo delivered via a Vectura Dry Powder Inhaler|
219629230|NCT05376774|OTHER|Admitted to intensive care units|Admitted to intensive care units
219629231|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
219629232|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
219629233|NCT06575556|DIAGNOSTIC_TEST|Cardiac CT and MRI|"• Cardiac MRI Protocol~The cardiac MRI protocol will include cine imaging, aortic flow, and 3D navigator of the aorta. These sequences will be performed to assess aortic root dimensions, including aortic root, sinuses of Valsalva, and sinotubular junction and ascending aorta diameters.~• CT Aortography Protocol:~The CT aortography protocol will include non-contrast and contrast-enhanced CT imaging. The non-contrast images will be used for calcium scoring, while the contrast-enhanced images will be used to assess aortic root dimensions"
218937492|NCT02686723|OTHER|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
219629234|NCT04700917|BEHAVIORAL|Cognitive Behavioural Therapy|Internet-Based CBT
219629235|NCT05209568|DIETARY_SUPPLEMENT|Gluten Powder|Single oral dose of gluten powder
219629236|NCT02170220|DRUG|Vortioxetine|Vortioxetine tablets
218937493|NCT00306826|DRUG|pioglitazone|
219629237|NCT02771847|BEHAVIORAL|survey|anonym survey is given to people
219629238|NCT01786993|DEVICE|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
219629239|NCT01786993|DEVICE|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
219629240|NCT03977870|OTHER|vital status determination|consultation of national registries
219629241|NCT04983472|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be taken during supine, normal sitting and dyspnea reduction positions. Individuals with chronic obstructive pulmonary disease will be asked to perform normal breathing, pursed lip breathing, and breathing control during these positions. Respiratory muscle activation measurement of individuals will be taken during different breathing patterns in each position. Respiratory functions will be evaluated with pulmonary function test, respiratory muscle strength, intraoral pressure measurement device, respiratory muscle activation with surface electromyographic device, health status disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
219629242|NCT02482688|BEHAVIORAL|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
219629243|NCT00941486|DRUG|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
219629244|NCT00941486|DRUG|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
219629245|NCT04796532|OTHER|Home based HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Home-HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
219629246|NCT04796532|OTHER|Traditional HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional HIIT group participants will attend a group HIIT workout sessions supervised by a specialised instructor in a sport facility. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
219629247|NCT03547375|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
219629248|NCT04287075|PROCEDURE|Surgical Management of Neuroma|Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
219629249|NCT02545959|DRUG|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
219629250|NCT02545959|DRUG|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
219629251|NCT02545959|DRUG|Rituximab IV|Blood infusion of rituximab (375mg/m2)
219629252|NCT00971438|PROCEDURE|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
219629253|NCT01737632|BEHAVIORAL|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
219629254|NCT01737632|BEHAVIORAL|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
219629255|NCT00813384|DRUG|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
219629256|NCT06485102|PROCEDURE|Carotid Surgery in patients with symptomatic or asymptomatic stenosis|Carotid Surgery in patients with symptomatic or asymptomatic stenosis
219629257|NCT02768480|OTHER|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
219629258|NCT02768480|OTHER|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
219629259|NCT06684821|PROCEDURE|Racz catheter|Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.
219629260|NCT06684821|PROCEDURE|Classic lumber fixation|Patients will undergo classic lumber fixation.
219629261|NCT02518061|OTHER|No intervention|This is a retrospective study
218937494|NCT00306826|DRUG|simvastatin|
218937495|NCT00306826|DRUG|pioglitazone + simvastatin|
218937496|NCT01934595|DIETARY_SUPPLEMENT|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
218937497|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
218937498|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
218937499|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
218937500|NCT04765267|DIETARY_SUPPLEMENT|Zinc sulphate heptahydrate|Dietary supplements
218937501|NCT02914301|DEVICE|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
218937502|NCT02914301|DEVICE|Placebo|No Mobile App, Usual care
218937503|NCT03213171|BEHAVIORAL|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
218937504|NCT03213171|BEHAVIORAL|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
218937505|NCT01145677|DRUG|Topiramate|Topiramate 100-300 mg/day orally twice per day
218937506|NCT06392399|DEVICE|cooled radiofrequency ,|In Cooled RF, after placement of the introducer needle, the 18 gauge internally cooled RF electrode is used for 90 seconds at a temperature of 60°C.
218937507|NCT06392399|DEVICE|conventional radiofrequency|In conventional RF group lesion will be performed at 80°C for 120 seconds.
219629262|NCT02198170|DRUG|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
219629263|NCT02198170|DRUG|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
219629264|NCT00569972|DRUG|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
219629265|NCT00569972|DRUG|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
219629266|NCT00569972|DRUG|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
219629267|NCT00569972|DRUG|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
219629268|NCT00569972|DRUG|Placebo|Matched oral placebo for weeks 2-7.
219629269|NCT06577012|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (XJ, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
219629270|NCT00379418|DRUG|Abciximab|
219629271|NCT03077815|OTHER|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2\~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
219629272|NCT06733181|OTHER|REMINDER intervention|The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
219629273|NCT02940262|RADIATION|Gallium Ga 68 Gozetotide|Given IV
219629274|NCT02940262|OTHER|Laboratory Biomarker Analysis|Correlative studies
219629275|NCT02940262|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
219629276|NCT05577533|BEHAVIORAL|O-Kidia game battery|Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.
219629277|NCT05577533|BEHAVIORAL|O-Brain|Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
219629278|NCT03852654|DRUG|18F-DCFPyL|"Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan."
219629279|NCT04933344|OTHER|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
219629280|NCT05089591|DEVICE|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
219629281|NCT05089591|DEVICE|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
219629282|NCT01868802|DRUG|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
219629283|NCT01868802|DRUG|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
219629284|NCT04099745|DEVICE|CGM|Continuous Glucose Monitoring System
219629285|NCT04099745|DEVICE|FGM|Flash glucose monitoring System
219629286|NCT00262197|BEHAVIORAL|Customized Physician Intervention|
219629287|NCT00262197|BEHAVIORAL|Customized Patient Intervention|
219629288|NCT04939298|DEVICE|Ultrasound|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
219629289|NCT04021888|OTHER|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
219629290|NCT04061174|OTHER|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
219629291|NCT04061174|OTHER|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
219629292|NCT05173155|PROCEDURE|surgical approach|Comparison of short-term outcomes (patient mobility, quality of life, function, pain, and safety parameters) for the direct anterior approach and Lateral approach for hemiarthroplasty for patients who have experienced a femoral-neck hip fracture.
219629293|NCT02641743|DIETARY_SUPPLEMENT|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (\>50%)
219629294|NCT02641743|DIETARY_SUPPLEMENT|standard balanced formula|
219629295|NCT02003404|DEVICE|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
219629296|NCT02003404|DEVICE|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
219629297|NCT02100462|DRUG|Chlorthalidone 12.5 mg|
219629298|NCT02100462|DRUG|Hydrochlorothiazide 25 mg|
219629299|NCT02100462|DRUG|Aspirin 81 mg|
219629300|NCT06035965|OTHER|Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)|19 items assessing post-surgery satisfaction.
219629301|NCT06035965|OTHER|Quality of Life in Epilepsy Inventory (QOLIE-31)|31 items to assess different dimensions of quality of life
219629302|NCT06035965|OTHER|Generalized Anxiety Disorder 7 (GAD7)|7 items, rated from 0 to 3, to detect anxiety disorders.
219629303|NCT06035965|OTHER|Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|to screen for depressive disorders
219629304|NCT06035965|OTHER|Evaluation of Changes in Daily Life after Epilepsy Surgery (EVOCQUE)|self-questionnaire developed by the Toulouse epileptology team in 2023 for patients who have undergone epilepsy surgery. It aims to collect the feelings of patients concerning the changes induced by surgery in their daily life according to a 7-point Likert scale.
218937508|NCT06392399|DEVICE|neurolysis of ganglion|In neurolytic block, Once the position of the needle tip confirmed, 4 - 6 mL of 8% phenol in saline will be injected followed by 1 mL of saline to avoid the deposition of phenol within the intervertebral disc material.
219629305|NCT02712554|DRUG|CL-108|7.5 mg/325 mg/12.5 mg tablet
219629306|NCT02712554|DRUG|M366|7.5 mg/325 mg tablet
219629307|NCT02712554|DRUG|Placebo|
219629308|NCT01095276|DRUG|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
219629309|NCT01095276|DRUG|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
219629310|NCT03649568|OTHER|Pork|1 oz lean pork
219629311|NCT03649568|OTHER|Egg|1 large whole egg
219629312|NCT03649568|OTHER|Black beans|0.5 cups cooked black beans
219629313|NCT03649568|OTHER|Almonds|1 oz almonds
219629314|NCT02045342|OTHER|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
219629315|NCT02045342|OTHER|Placebo|Ingest 500ml of placebo prior to metabolic measures.
219629316|NCT01129557|DRUG|Aliskiren|
219629317|NCT01129557|DRUG|Valsartan|
219629318|NCT05962723|PROCEDURE|EUS|EUS examination and cystic fluid will be aspirated for analysis, including cystic fluid Glucose, CEA, amylase. Morey's biopsy will be done in the cases feasible for biopsy.
219629319|NCT00669669|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
219629320|NCT00669669|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
219629321|NCT00669669|DRUG|Carmustine|Given IV
219629322|NCT00669669|BIOLOGICAL|Filgrastim|Given SC
219629323|NCT00669669|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
219629324|NCT00669669|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
219629325|NCT00669669|OTHER|Laboratory Biomarker Analysis|Correlative studies
219629326|NCT00669669|DRUG|O6-Benzylguanine|Given IV
219629327|NCT00669669|DRUG|Plerixafor|Given SC
219629328|NCT00669669|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219629329|NCT00669669|DRUG|Temozolomide|Given PO
219629330|NCT02935127|PROCEDURE|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
219629331|NCT02935127|PROCEDURE|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
219629332|NCT02219880|DIETARY_SUPPLEMENT|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
219629333|NCT02219880|DIETARY_SUPPLEMENT|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
219629334|NCT03144661|DRUG|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
219629335|NCT03859479|PROCEDURE|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
219629336|NCT03859479|PROCEDURE|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
219629337|NCT07151417|DRUG|PAI|Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg
219629338|NCT07151417|DRUG|PAI + steroid|Standard PAI + 40mg methylprednisolone (n = 40)
219629339|NCT07151417|DRUG|PAI + zilretta|Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)
219629340|NCT07153198|OTHER|VIPP-SD|Consists of four sessions (with the option of one or two additional booster sessions), held biweekly, depending on the family's needs and availability. Specifically, VIPP-SD addresses disciplinary strategies alongside sensitivity themes through: (1) the differentiation between attachment and exploration behaviors; interpretation of child's behavior and significance of a sensitive response to it; and the importance of sharing emotions (2) the application of distraction and induction as non-coercive techniques in response to challenging child behaviours or conflict-prone situations; (3) the utilization of positive reinforcement, whereby parents praise adaptive behaviours and ignore maladaptive, attention-seeking actions; (4) the implementat of a sensitive interaction pause to de-escalate conflict or temper tantrums; and (5) the demonstration of empathy towards the child in conjunction with consistent disciplinary approaches and explicit boundary-setting
219629341|NCT07152353|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
219629342|NCT06529419|DRUG|AZD8630|The drug will be administered by inhalation
219629343|NCT06529419|DRUG|Placebo|The placebo will be administered by inhalation
219629344|NCT06529419|DEVICE|Inhaler|The drug/placebo will be administered by inhalation using the inhaler
219629345|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 1 for 20 minutes once per day
219629346|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 2 for 20 minutes once per day
219629347|NCT07163221|DEVICE|Sham ultrasound stimulation (control)|Sham ultrasound stimulation for 20 minutes once per day
219048419|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
219629348|NCT07163221|DRUG|Conventional Synthetic DMARD|All subjects will take at least one type of conventional synthetic DMARD at the same stable dose for at least 8 weeks prior to the treatment period and continuing through study close out
219629349|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
219629350|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
219048420|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
219629351|NCT07170930|OTHER|Friendly Match-Play Exposure: extended vs. limited|This research explores the multidimensional physiological and biochemical responses to differing volumes of friendly match-play (i.e., extended vs. limited) during the late pre-season phase in soccer players.
219629352|NCT07174739|DEVICE|Quantum Molecular Resonance (QMR) Treatment|Quantum Molecular Resonance (QMR) treatment will be administered using the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy) according to the protocol recommended by the manufacturer. The device features a contact electrode embedded in a mask worn over the participant's closed eyes, and it delivers stimulation to the epidermis of the closed eyelids, extending up to the lid border with an intensity setting of 4-5 on a scale of 0-10. The treatment is non-invasive and painless.
219629353|NCT07175376|OTHER|Supportive Care|Geriatric assessment (GA) -guided supportive care and weekly Patient Reported Outcomes (PRO) symptom assessment
219629354|NCT07182032|DRUG|ketamine|Participants will receive general anesthesia with protocoled ketamine infusion
219629355|NCT07183969|OTHER|lower limb muscle strength training program|"Each plyometric training session consists of warm-up stretching, lower limb plyometrics, and gentle stretching.~Warm-up stretching, there are 6 movements, push the window, pull the rope, hands up, stretch from side to side, lift one foot and open and close both feet. Do 10 repetitions of each movement, 2 rounds, and keep breathing normally for a few repetitions.~Lower Extremity Plyometrics: 3 rounds of 6 plyometrics with 1 minute of recovery time between each round. The six lower body plyometrics exercises are performed by gradually increasing the load in a manner that increases the number of seconds the exercise is held.~Gentle Stretching: Continuous training of muscles makes them tense, stretching can lengthen muscle fibers, increase muscle elasticity, and improve blood circulation to eliminate post-training fatigue (H.K. Chen, 2022). Perform each gentle stretching movement left and right once, hold for 30 seconds each time, and keep breathing normally (no shutting up of breath)."
219048421|NCT05878938|DRUG|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
219629356|NCT07182396|PROCEDURE|Experimental Group|"VIDEO GAME-TAPD: Week 1st-6th: Start with kids level and progress upto expert level and Participants will automatically progress to advanced level based on their individual ability and progress in game in progressing weeks.~(kids level to expert level: according to game levels) Hand eye coordination game:Tap changing illuminating squares. Week1- 3 repetitions(2sets),Week2- 4 repetitions(2 sets),Week3- 5 repetitions(2 sets),Week4- 6 repetitions(2 sets),Week5- 7 repetitions(2 sets),Week6- 8 repetitions(2 sets) Ball tossing intervention:Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week"
219629357|NCT07182396|PROCEDURE|Control Group|"Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week e.g~* Day 1: 20 reps per week~* Day 2: 30 reps per week~* Day 3: 40 reps per week Progression: Participants will progress to advanced level based on their individual ability and progress. Levels of complexity will be adjusted according to patient progress."
219629358|NCT07175961|OTHER|Multicomponent telehealth care coordination|Participants randomised into the intervention group will be assigned a recovery navigator prior to discharge from hospital. The recovery navigator will provide the participant with a study tailored discharge summary, arrange the patients first appointment with their general practitioner and will ensure medications are reconciled prior to hospital discharge. The recovery coordinator will arrange weekly calls with the participant for the first 4 weeks and then fortnightly until week 12 to set recovery goals and assess recovery goals and navigator further primary care support if required. Participants will also be called at Day 90 and 180 by outcome assessors to collected patient reported outcomes.
219629359|NCT07183527|BEHAVIORAL|CARES|Integrated screening and stepped collaborative care
219629360|NCT07183527|BEHAVIORAL|Standard of Care (SOC)|Screening and referral of patient to provider in the community or cancer center
219629361|NCT07183241|BEHAVIORAL|Physical exercise and cognitive exercises|The intervention will be based on the Vivifrail program, which is a multicomponent physical exercise program designed specifically for older adults.
219629362|NCT07183306|DRUG|HT-101|HT-101 given by subcutaneous injection.
219629363|NCT07183306|DRUG|HT-102|HT-102 given by subcutaneous injection.
219629364|NCT07182799|DIAGNOSTIC_TEST|Plaque vulnerability assessment|"The purpose of the OCT-AGEM registry is to confirm the clinical utility of plaque OCT assessment over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-based plaque vulnerability criteria:~* Minimum lumen area \<3.5 mm2;~* Fibrous cap minimum thickness \<65 µm;~* Lipid arc extension \>180°;~* Presence of macrophages;~* Superficial and deep calcified nodules~* Ulceration/Erosion/Dissection~* Layered tissue~* Optical flow ratio (OFR)"
219629365|NCT07182799|DIAGNOSTIC_TEST|Stent implantation optimization|The purpose of the OCT-AGEM registry is to confirm the clinical utility of OCT guidance during PCI over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-derived plaque/stent parameters reported in expert consensus OCT documents, utilizing the cut-off points identified in the previous OCT registries
219629366|NCT07184216|BEHAVIORAL|Person-centered care intervention|The intervention will be delivered by primary care nurses, in coordination with doctors, social workers, and psychologists from each center. Nurses, previously trained in person-centred care, will collect the family narrative regarding their experiences, needs, goals, and available resources. Based on this, a health plan will be co-created with the family, incorporating short- and long-term objectives, concrete actions, and the supports required. The plan will be reviewed and adapted in monthly follow-up consultations during a three-month period.
219629367|NCT07182994|PROCEDURE|Elbow joint immobilization|Immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients on the success of the technique
219629368|NCT07182994|PROCEDURE|Arm restraint without elbow immobilization|Use of arm restraint without immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients.
219629369|NCT07183371|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
219629370|NCT07183371|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
219629371|NCT07183371|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
218937509|NCT04785469|OTHER|Low-load eccentric training|"* Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
219048422|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
219629372|NCT07183371|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
219629373|NCT07183371|BIOLOGICAL|Rabivax-S|Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients
219629374|NCT07183371|BIOLOGICAL|Menveo|Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.
219629375|NCT07183371|BIOLOGICAL|Avaxim 80|Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).
219629376|NCT07184437|DEVICE|OVD-F device Minivisc®PLUS 14 mg/ml|MINIVISC® PLUS 14 mg/ml is intended to protect, lubricate and support delicate ophthalmic cells or tissues, to assist in maintaining intraocular space and to enhance visualization during surgery.
219629377|NCT07183046|BEHAVIORAL|Implementation Intention Guide|The intervention is the addition of implementation intention guide document provided with the FIT. This is a one-page piece of paper that was developed by the investigator team and finalized with input/feedback from patient partners. The implementation intention guide includes instructions about the importance of developing a plan to complete FIT. It also includes fillable fields for participants to enter their plan for when to complete, where to store, when to return, and where to return their FIT. Participants will also be able to follow a QR code on the implementation intention guide document to a link to complete an anonymous, electronic version of the guide and share feedback on the intervention.
219629378|NCT07183384|BIOLOGICAL|Mesenchymal Stem Cell-Derived Exosomes|Mesenchymal stem cell-derived exosomes isolated from adipose-derived stem cells (ASC). The exosomes contain bioactive molecules including microRNAs (particularly miR-126-3p), proteins, and lipids that promote endothelial repair and regeneration. The product is manufactured under GMP conditions and administered as a single Intravenous or Intramuscular infusion.
219629379|NCT07183384|OTHER|Placebo (Sterile Saline Solution)|Sterile saline solution (0.9% sodium chloride) administered Intravenous or Intramuscular as placebo control. The volume and administration method are identical to the active treatment to maintain blinding.
219629380|NCT05672602|DIAGNOSTIC_TEST|Measurement of ncRNAs and cytokines|Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
219629381|NCT00000427|DRUG|Parathyroid hormone|
219629382|NCT00000427|DRUG|Alendronate|
219629383|NCT05760989|DEVICE|Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|Replacement of the native tricuspid valve through a transcatheter approach
219629384|NCT00570687|DRUG|Technosphere Insulin|Inhalation 15U/30U
219629385|NCT06089343|DIAGNOSTIC_TEST|Coronary CT angiography|Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
219629386|NCT06683131|DRUG|Tafolecimab|450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then every month till totally 12 months.
219629387|NCT05736120|OTHER|No treatment given|No treatment given
219629388|NCT05709678|OTHER|Standard Education|Sport nutrition education
219629389|NCT05709678|OTHER|Enhanced Education|Sport nutrition education with peer testimonials on negative effects of REDs
219629390|NCT06229561|COMBINATION_PRODUCT|Acellular Dermal Matrix|Feasibility of soft tissue graft after immediate implant placement
219629391|NCT01912586|OTHER|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
219048423|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
219048424|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
219629392|NCT01015365|PROCEDURE|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
219629393|NCT04707521|BEHAVIORAL|3M tape ship-shaped combined with strap fixing method|During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
219629394|NCT05931172|OTHER|Dual tasking|"Dual-task training is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Dual tasking is given by therapist in unexpected directions to challenge patients reactive balance. In this study dual tasking will be given manually and on hurdles.~Daily 45 mins of exercise sessions of dual-task training like walking with talking , walking with a filled cup of water, walking with looking on clock performed for total eight weeks and 5 days a week."
219629395|NCT05931172|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session will be given to patients. 45 mins session/each day for 5 days a week."
219629396|NCT01624740|DEVICE|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
219629397|NCT01624740|DEVICE|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
219629398|NCT00894439|DRUG|BLI-489/Piperacillin|
219629399|NCT00894439|DRUG|BLI-489|
219629400|NCT00894439|DRUG|Piperacillin|
219629401|NCT05125796|DRUG|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
219629402|NCT05125796|DRUG|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
219629403|NCT05125796|DRUG|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
219629404|NCT05125796|DRUG|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
219629405|NCT02346838|DIETARY_SUPPLEMENT|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
219629406|NCT02346838|DIETARY_SUPPLEMENT|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
219629407|NCT06510270|DRUG|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group
219629408|NCT06510270|DRUG|Loop diuretics|Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
219629409|NCT06510270|DRUG|Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)|Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
219629410|NCT01754350|DIETARY_SUPPLEMENT|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to \< 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
219629411|NCT01754350|DIETARY_SUPPLEMENT|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
219629412|NCT03804450|PROCEDURE|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
219629413|NCT06531941|DRUG|400 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients who received Placebo in the Phase 2 MBX-2H1002 study, will initiate treatment with 400 µg subcutaneous MBX 2109 once-weekly"
219629414|NCT06531941|DRUG|200-1600 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients treated with MBX 2109 in the Phase 2 MBX-2H1002 study will continue at the screening visit in the extension study on the same dose they were receiving at the Week 11 Visit in Study MBX-2H1002.~The maximum allowed dose is 1600 μg weekly administered subcutaneously in the abdomen, rotating injection sites. Doses of MBX 2109 study drug greater than 1000 μg will be administered subcutaneously in two separate, equal injections."
219629415|NCT01102257|DRUG|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
219629416|NCT01102257|DRUG|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
219629417|NCT02025140|DEVICE|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
219629418|NCT02025140|DEVICE|conventional anesthesia syringe|Active control
219629419|NCT05404646|OTHER|Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy|Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.
219629420|NCT05404646|OTHER|Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy|Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
219629421|NCT02525783|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty
219629422|NCT01508611|OTHER|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
219629423|NCT01508611|BEHAVIORAL|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
219629424|NCT03048747|DRUG|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
219629425|NCT05717296|OTHER|anxiety survey|surgery and anesthesia anxiety questionnaire
219629426|NCT05717296|OTHER|scale of satisfaction|scale of satisfaction of multimedia
219629427|NCT05717296|OTHER|Multimedia Information|"Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive."
219629428|NCT00426946|DRUG|Reboxetine|
219629429|NCT03711708|DRUG|Zoloft Oral Solution|Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
219629430|NCT03711708|DRUG|Zoloft tablets|Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
219629431|NCT00866281|DRUG|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
219629432|NCT01894841|BEHAVIORAL|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
219629433|NCT01894841|OTHER|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
219629434|NCT02235064|DRUG|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
219629435|NCT02235064|DRUG|Placebo|Capsule containing cellulose powder of same color as experimental arm
219629436|NCT06516237|PROCEDURE|to determine molecular and epigenetic biomarkers|In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers.
219629437|NCT04542486|PROCEDURE|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
219629438|NCT04542486|PROCEDURE|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
219629439|NCT00730483|DRUG|PVA microporous hydrospheres/doxorubicin hydrochloride|
219629440|NCT00529087|DRUG|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
219629441|NCT00529087|OTHER|placebo|placebo
219629442|NCT03538860|BEHAVIORAL|Active comparator: Human interpreter|A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
219629443|NCT03538860|BEHAVIORAL|Intervention: Asynchronous Telepsychiatry|A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
219629444|NCT04001725|DRUG|Dexamethasone|A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
219629445|NCT04001725|DRUG|Metformin|A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
219629446|NCT00318474|DRUG|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
219629447|NCT00318474|DRUG|MMF Placebo|Placebo only, oral administration
219629448|NCT00318474|DRUG|ACEi|Administer same as pre-treatment regimen.
219629449|NCT00318474|DRUG|FOS|Administer same as pre-treatment regimen
219629450|NCT01346566|DEVICE|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
219629451|NCT01888172|BEHAVIORAL|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
219629452|NCT01888172|DEVICE|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
219629453|NCT01888172|BEHAVIORAL|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
219629454|NCT03208335|DRUG|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
219629455|NCT03628664|RADIATION|CT scan|Assessment of the actual posterior condylar angle using the CT scan
219629456|NCT06577688|OTHER|Blood pressure measurement|Blood pressure measurement using a standard cuff device and a smartphone
219629457|NCT01775813|DRUG|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
219629458|NCT01775813|DRUG|Placebo|Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
219629459|NCT05117502|DEVICE|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
219629460|NCT05117502|DEVICE|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
219629461|NCT05749705|OTHER|Fat to Lean Mass Ratio|"The study will be conducted for people who suffer from excess fat mass and their age is over 18 years.~years will be calculated with G power"
219629462|NCT05953519|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
219629463|NCT02680808|DRUG|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
219629464|NCT05225610|OTHER|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
219629465|NCT05225610|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
219629466|NCT05225610|DRUG|normal Saline|5 ml saline will be administered.
219629467|NCT03531203|DIETARY_SUPPLEMENT|Soursop supplementation|The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
219629468|NCT03531203|OTHER|Placebo|Control group (without soursop group) was left without treatment during study period
219048425|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
219048426|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
219629469|NCT04679766|PROCEDURE|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
219629470|NCT02918565|BEHAVIORAL|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
219629471|NCT02918565|BEHAVIORAL|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
219629472|NCT02918565|BEHAVIORAL|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
219629473|NCT02918565|BEHAVIORAL|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
219629474|NCT02014311|PROCEDURE|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
219629475|NCT02014311|PROCEDURE|CTA guided treatment strategy|CTA guided treatment strategy
219629476|NCT06208839|DEVICE|SBIRT/eIntervention for those with moderate risk drug or alcohol use|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
219629477|NCT06208839|DEVICE|SBIRT/eIntervention those assessed with high risk.|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
219629478|NCT06208839|OTHER|SBIRT/TAU for those with moderate risk drug or alcohol use|Treatment as usual
219629479|NCT06208839|OTHER|SBIRT/TAU for those assessed with high risk.|Treatment as usual for high risk group
219629480|NCT01964482|OTHER|Strength training|Strength training followed by intake of a protein drink
218937510|NCT04785469|OTHER|Usual care|"* Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + \[0.002x6-Minute walk work (6MWW)\]. \[Sex: female = 0; male:1\] \[6MWW = 6-Minute walk distance x weight in kg\].~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
218937511|NCT01782248|OTHER|Questionnary and IRM|
218937512|NCT04956913|DEVICE|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
218937513|NCT04956913|DEVICE|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
219629481|NCT03809338|DIAGNOSTIC_TEST|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
219629482|NCT05326529|OTHER|Hospital Based Cardiac Rehabilitation Exercise Classes|Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
219629483|NCT05326529|OTHER|Web-based Cardiac Rehabilitation Exercise Sessions|Participants will complete 8 weeks of Web-based CR exercise sessions using the MyHeart app. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
219629484|NCT03160690|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
218937514|NCT05751018|DRUG|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
219629485|NCT02590549|PROCEDURE|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
219629486|NCT02590549|DEVICE|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
219629487|NCT02909335|DRUG|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
219629488|NCT02909335|DRUG|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
219629489|NCT02909335|DRUG|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
219629490|NCT02909335|DRUG|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
219629491|NCT00427102|DRUG|Oral MRX-1024|
219629492|NCT00427102|PROCEDURE|Standard Fractionation Radiation Therapy|
219629493|NCT00427102|DRUG|High-Dose Cisplatin Chemotherapy|
219629494|NCT01534442|DRUG|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
219629495|NCT01534442|DRUG|Placebo|
219629496|NCT05576272|DRUG|QL1706|5 mg/kg#D1#Q3W IV, 4-6 cycles
219629497|NCT05576272|DRUG|Carrelizumab|200mg#D1#Q3W IV, 4-6 cycles
219629498|NCT05576272|DRUG|Gemcitabine|1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles
219629499|NCT05576272|DRUG|Cisplatin|80mg/m2#D1#Q3W IV, 4-6 cycles
219629500|NCT01379768|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
219629501|NCT01379768|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
219629502|NCT01379768|DEVICE|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
219629503|NCT01513720|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
219629504|NCT01513720|DRUG|Lamictal®|Lamictal® 200 mg Tablets
218937515|NCT02088138|DEVICE|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
219629505|NCT03748173|COMBINATION_PRODUCT|Aerosolized Infasurf|Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
219629506|NCT00781040|OTHER|Severe sepsis vs. non-severe sepsis|To compare these two groups
219629507|NCT05221151|DRUG|Melatonin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
219629508|NCT05221151|DRUG|Pregabalin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
219629509|NCT05221151|DRUG|Ondansetron 4 MG|before spinal anaesthesia
219629510|NCT03773406|DEVICE|Offline tDCS-before therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
219629511|NCT03773406|DEVICE|Sham tDCS|Stimulation will be given for a total 30 seconds (including ramp-up and ramp-down of current) and then the tDCS device will be turned off. The brief stimulation will produce tDCS-induced sensation so that participants will not be aware when the tDCS was turned off .We will use standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
219629512|NCT03773406|DEVICE|Offline tDCS-after therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
219629513|NCT03773406|DEVICE|Online tDCS|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
219629514|NCT04527289|DRUG|Amantadine (100mg) as add on therapy.|Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
219629515|NCT04527289|DRUG|Placebo|patients will be managed with placebo as add on to the standard regimen.
219629516|NCT03647618|OTHER|Ultrasound|Ultrasound-guided regional anaesthesia
219629517|NCT00168363|DRUG|brimonidine|
219629518|NCT00708552|DRUG|SB-742457|investigational drug
219629519|NCT00708552|DRUG|Donepezil|comparator
219629520|NCT00708552|DRUG|Placebo|comparator
219629521|NCT01257113|OTHER|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
219629522|NCT01257113|OTHER|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
219629523|NCT04163133|PROCEDURE|two days later trigger than regular timing|During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
219629524|NCT02418390|PROCEDURE|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
219629525|NCT06575504|DIAGNOSTIC_TEST|Ultrasonographical examination|Study size and Doppler / blood flow / of the suprarenal gland
219629526|NCT00126256|DRUG|5-fluorouracil|
219629527|NCT00126256|DRUG|leucovorin|
219629528|NCT00126256|DRUG|irinotecan|
218937516|NCT02088138|DEVICE|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
219629529|NCT00126256|DRUG|oxaliplatin|
219629530|NCT00070720|BEHAVIORAL|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
218937517|NCT04078646|OTHER|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
218937518|NCT04078646|OTHER|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
218937519|NCT04078646|OTHER|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
219629531|NCT06045455|DIAGNOSTIC_TEST|Multimodal brain CT|Multimodal brain CT includes NCCT, CTP, and CTA
219629532|NCT06045455|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
219629533|NCT00143442|DRUG|[S,S]-Reboxetine|
218937520|NCT00436345|DRUG|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
218937521|NCT00436345|DRUG|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
218937522|NCT03609606|DRUG|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
218937523|NCT03609606|DRUG|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
219629534|NCT01803672|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
219629535|NCT01803672|BEHAVIORAL|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
219629536|NCT03192449|DRUG|Albendazole.|Single dose 400mg orally
219629537|NCT02395250|BIOLOGICAL|anti-GPC3 CAR T|
219629538|NCT02498197|BEHAVIORAL|Participatory Intervention|
219629539|NCT02498197|BEHAVIORAL|Control|
219629540|NCT04769193|OTHER|Adipeau face cream|Adipeau face cream contains the natural actives Carthamus Tinctorius (Safflower) Seed Oil and Kaempferia Parviflora Rhizome Extract (Black Ginger).
219629541|NCT00780884|DEVICE|acupuncture|16 sessions of acupuncture treatment, twice a week.
219629542|NCT00784329|DEVICE|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
219629543|NCT02323373|DRUG|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
219629544|NCT02323373|DRUG|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
219629545|NCT02323373|DRUG|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
219629546|NCT03004781|BEHAVIORAL|Parenting program|
219629547|NCT05864703|PROCEDURE|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
219629548|NCT05864703|PROCEDURE|Sham|Instrument-assisted light touch to neck
219629549|NCT03195829|BEHAVIORAL|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
219629550|NCT03195829|BEHAVIORAL|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
219629551|NCT00375973|DRUG|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
219629552|NCT00375973|DRUG|Placebo|Sugar pill dose comparable to duloxetine
219629553|NCT02166931|DIETARY_SUPPLEMENT|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
219629554|NCT06298448|DIAGNOSTIC_TEST|laboratory experiments before and after mepolizumab treatment|Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome
219629555|NCT02588612|DRUG|letetresgene autoleucel (GSK3377794)|letetresgene autoleucel (GSK3377794) as an IV infusion.
219629556|NCT02588612|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
219629557|NCT02588612|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
219629558|NCT03053037|PROCEDURE|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
219629559|NCT02594293|DRUG|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
219629560|NCT04996901|OTHER|no intervention|no intervention
219629561|NCT01915602|DRUG|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
219629562|NCT01915602|DRUG|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
219629563|NCT04894825|DRUG|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
219629564|NCT04894825|DRUG|M108|IV infusion Q3W. (21-day cycles)
219629565|NCT04287257|DEVICE|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
219629566|NCT05261516|DRUG|Magnesium Sulfate|The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
219629567|NCT06205914|PROCEDURE|fixation of patella fractures by craniofacial mesh plate osteosynthesis augmented by screws|patellar fracture fixation using MatrixNEURO Contourable Mesh plates (Synthes®). Made of titanium with an incredibly low profile
219629568|NCT04432610|DRUG|Bisoprolol versus Nebivolol|All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period
219629569|NCT01707394|DRUG|Apixaban|Specified dose on specified days
219629570|NCT03097276|PROCEDURE|blood sample|blood sample will be collected
219629571|NCT03097276|RADIATION|CT scan|CT scan
219629572|NCT02042014|DRUG|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
219629573|NCT00551239|BIOLOGICAL|rituximab|Given IV
219629574|NCT00551239|DRUG|fludarabine phosphate|Given IV
219629575|NCT00551239|DRUG|pixantrone dimaleate|Given IV
219629576|NCT05017675|OTHER|High fructose diet|"4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5"
219629577|NCT05017675|OTHER|High saturated fat diet|"4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20"
219629578|NCT04557215|DRUG|Rifaximin|Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
219629579|NCT04557215|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a clinically approved mucolytic agent.
219629580|NCT04557215|DRUG|Placebo|An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
219629581|NCT01846364|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
219629582|NCT00558701|DEVICE|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
219629583|NCT00558701|DEVICE|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
219629584|NCT01496001|PROCEDURE|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
219629585|NCT01496001|OTHER|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
219629586|NCT06535334|DRUG|Chemotherapy|Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
219629587|NCT05576935|BEHAVIORAL|Stroop task|The task is partitioned in 4 blocks of 360 stimuli and each word will be presented on screen in 34 point font for 1000 ms with an inter-stimulus interval based on their performance on the Stroop max test. This max test will be performed during the familiarization trial, and is divided in blocks of 96 stimuli. After each block, the accuracy (ACC) will be calculated. When ACC \> 85%, the difficulty of the Stroop task will be increased by decreasing the stimulus presentation time (SPT). If ACC \< 85%, this block will be considered as an 'error' and the subject must redo the block without changing the SPT. The first block will have a SPT of 1500 ms. When the required ACC is achieved, the SPT will decrease in the following order: 1100, 900, 800,… to determine the individualized cognitive load. When the subject makes 3 errors in a row, or 5 errors during the whole trial, the trial will end. The SPT of the last block will be considered as the maximum capacity of that individual.
219629588|NCT05576935|BEHAVIORAL|Documentary|In order to avoid under- and over-arousal, participants will have the opportunity to choose between several documentaries. The participants will also receive a list of the available documentaries (based on selections from Netflix and Disney+) after the familiarization trial so that the trial can go as smoothly as possible.
219629589|NCT03677284|OTHER|Time assistive products|The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
219629590|NCT03677284|OTHER|Information brochure|The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
219629591|NCT00105079|DRUG|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
219629592|NCT00105079|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
219629593|NCT00105079|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
219629594|NCT00105079|DRUG|Ritonavir|100 mg po bid
219629595|NCT02387671|BEHAVIORAL|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
219629596|NCT02387671|BEHAVIORAL|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
219629597|NCT02387671|BEHAVIORAL|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
219629598|NCT02387671|BEHAVIORAL|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue \& dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
219629599|NCT01569971|OTHER|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
219629600|NCT02028260|DRUG|Modafinil|200 mg daily
219629601|NCT02028260|DRUG|Placebo|similar appearing inert tablet
219629602|NCT00418860|DRUG|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
219629603|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
219629604|NCT03058562|DRUG|Placebo Comparator|Matching Placebo
219629605|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
219629606|NCT05487001|PROCEDURE|dexamethasone group|"1\) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
219629607|NCT05487001|PROCEDURE|sham group|"2\) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
219629608|NCT04791722|BEHAVIORAL|Adaptive Intervention|The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
219629609|NCT01297517|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
219629610|NCT01297517|DRUG|Brinzolamide ophthalmic suspension, 1%|
219629611|NCT01297517|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
219629612|NCT04415164|DRUG|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
219629613|NCT04415164|DRUG|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
219629614|NCT04415164|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
219629615|NCT02637206|DRUG|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
219629616|NCT02637206|DRUG|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
219629617|NCT02637206|DRUG|Empty Patch|Empty patches without any ingredients will be used as negative control.
219629618|NCT04189315|DRUG|asfotase alfa|Asfotase alfa is administered subcutaneously.
219629619|NCT02156037|BEHAVIORAL|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
219629620|NCT02156037|BEHAVIORAL|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
219629621|NCT02677571|PROCEDURE|Paravertebral Thoracic block|
219629622|NCT02677571|PROCEDURE|Pectorals nerve block|
219629623|NCT02677571|DRUG|Levobupivacaine 0.25%|
219629624|NCT02677571|DRUG|Morphine|
219629625|NCT00872911|DIETARY_SUPPLEMENT|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
219629626|NCT00872911|DRUG|Exercise|progressive exercise training
219629627|NCT04806711|DEVICE|Menicon Z Night|Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
219629628|NCT04806711|DEVICE|Control|Distance, single-vision glasses were used as a control
219629629|NCT05360147|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
219629630|NCT05360147|DRUG|Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides|oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
219629631|NCT01870011|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
219629632|NCT01870011|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
219629633|NCT00879905|DRUG|HSP990|
219629634|NCT00297440|BEHAVIORAL|Cognitive-behavioral treatment|
219629635|NCT00297440|BEHAVIORAL|Exercise|
219629636|NCT00937027|DRUG|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
219629637|NCT01155180|DRUG|Leptin|Hormone - daily self injections for 6 months
219629638|NCT01155180|DRUG|Placebo|Placebo
219629639|NCT00775229|DRUG|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
219629640|NCT00775229|DRUG|Placebo|pill, by mouth, daily
219629641|NCT03742362|DEVICE|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
219629642|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
219629643|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
219629644|NCT05517148|DEVICE|Therapeutic VR|Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
219629645|NCT02604992|DRUG|Treatment A|Dronabinol oral solution, under fed conditions
219629646|NCT02604992|DRUG|Treatment B|Dronabinol oral capsule, under fed conditions
219629647|NCT02604992|DRUG|Treatment C|Dronabinol oral capsule, under fasted conditions
219629648|NCT02230904|DRUG|Rotigotine (Test product PR 2.3.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
219629649|NCT02230904|DRUG|Rotigotine (Reference product PR 2.1.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
219629650|NCT02754804|DEVICE|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
219629651|NCT03964857|OTHER|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
219629652|NCT03964857|OTHER|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
219629653|NCT03964857|OTHER|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
219629654|NCT05252572|BIOLOGICAL|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
219629655|NCT06445712|BEHAVIORAL|Parental Support Cold Pressor Task|Child will submerge their hand in cold water alone and holding the hand of a parent.
219629656|NCT03458481|DRUG|SOF|400 mg tablet administered orally once daily
219629657|NCT03458481|DRUG|DAG181|Capsule administered orally once daily
219629658|NCT01852149|DEVICE|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
219629659|NCT04090671|DIAGNOSTIC_TEST|Multidimensional Dyspnea Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
219629660|NCT00921531|DRUG|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
219629661|NCT00921531|DRUG|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
219629662|NCT00616148|DRUG|YKP3089|Oral dosage form
219629663|NCT00616148|DRUG|Placebo|
219629664|NCT05978050|DRUG|nimotuzumab plus paclitaxel|Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
219629665|NCT05978050|DRUG|placebo plus paclitaxel|placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
219629666|NCT04203446|OTHER|Assessment of correctness of inhaling technique|Assessment of correctness of inhaling technique in patients with asthma or COPD
219629667|NCT01464424|DRUG|Travoprost 0.004% ophthalmic solution|
219629668|NCT01464424|DRUG|Bimatoprost 0.01% ophthalmic solution|
219629669|NCT01994434|PROCEDURE|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
218937524|NCT03609606|DRUG|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
218937525|NCT06319950|DRUG|Furmonertinib|Furmonertinib, 160mg po qd
219629670|NCT03197038|BEHAVIORAL|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
219629671|NCT03197038|BEHAVIORAL|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
219629672|NCT05787717|OTHER|Parental presence|The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
219629673|NCT02069041|BIOLOGICAL|Ramucirumab|Administered IV.
219629674|NCT02069041|DRUG|FOLFOX4|Administered IV.
219629675|NCT02958735|OTHER|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
218937526|NCT06319950|DRUG|Osimertinib|Osimertinib，80mg po qd
219629676|NCT00264719|DRUG|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
219629677|NCT00264719|DRUG|placebo|placebo 10 mg
219629678|NCT04393519|DEVICE|TIPS procedure|Implantation of TIPS for portal hypertension
219629679|NCT00771719|DRUG|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
219629680|NCT00152802|BIOLOGICAL|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
219629681|NCT00152802|BIOLOGICAL|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
219629682|NCT04981002|OTHER|Telemedicine Consultation with self orthopedic exam|Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
219629683|NCT04981002|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
219629684|NCT04023032|BEHAVIORAL|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
219629685|NCT01797887|BEHAVIORAL|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
219629686|NCT03882983|DRUG|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:"
219629687|NCT00167583|DRUG|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
219629688|NCT00167583|DRUG|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
219629689|NCT04740398|DRUG|CBP-1008|CBP-1008 for injection; IV infusion; Infusion for 90 minutes
219629690|NCT05296083|DIETARY_SUPPLEMENT|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
219629691|NCT03669926|RADIATION|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
219629692|NCT03268226|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
219629693|NCT00789373|DRUG|Pemetrexed|Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
219629694|NCT00789373|DRUG|Cisplatin|Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
219629695|NCT00789373|DRUG|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
219629696|NCT00789373|DRUG|Pemetrexed|Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
219629697|NCT00789373|OTHER|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
219629698|NCT00142831|DRUG|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
219629699|NCT04386330|BEHAVIORAL|Distance-delivered NET|One-on-one intervention delivered by a paraprofessional; 12 weekly videoconference sessions at 90 minutes.
219629700|NCT01214291|DRUG|Toremifene|Toremifene 80mg daily
219629701|NCT01775059|DEVICE|Integrated sensor and infusion set.|
218937527|NCT05358613|BEHAVIORAL|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
218937528|NCT00568165|PROCEDURE|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
218937529|NCT00568165|PROCEDURE|Standard care|Standard care
218937530|NCT01623713|DRUG|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
218937531|NCT01623713|DRUG|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
218937532|NCT00254384|DRUG|Cisplatin|Given IV
218937533|NCT00254384|DRUG|Docetaxel|Given IV
218937534|NCT00254384|DRUG|Erlotinib|Given PO
218937535|NCT00254384|DRUG|Erlotinib Hydrochloride|Given PO
218937536|NCT00254384|OTHER|Laboratory Biomarker Analysis|Correlative studies
219629702|NCT04573049|DRUG|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
219629703|NCT04573049|OTHER|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
219629704|NCT01511978|DRUG|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
219629705|NCT01511978|DRUG|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
219629706|NCT02187198|DRUG|Buprenorphine|
219629707|NCT06444776|DIAGNOSTIC_TEST|Repetitive (semi-)objective and subjective taste, smell, and saliva analysis|"Study participants will undergo repetitive assessments of their taste, smell and saliva, using quality of life questionnaires, taste strips, sniffin sticks, and analysis of salivary function and composition.~Assessments will be done before treatment, in the 4th week (+/- 1 week) and last week of radiation therapy (+/- 1 week), and at 6 months (+/- 1 months) and 1 and 2 years post-therapy (+/- 3 months).~At the minimum, participants are expected to complete the assessments at baseline and 1 year after the end of radiation therapy. Assessments at all other time points are strongly encouraged but will be optional."
219629708|NCT03321968|BIOLOGICAL|Quadrivalent VLP Influenza Vaccine|Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
219629709|NCT05071625|PROCEDURE|percutaneous vertebroplasty|percutaneous vertebroplasty under combined CT/fluoroscopy guidance for non-union after posterior fixation performed for a traumatic non-neurologic thoraco-lumbar vertebral fracture.
219629710|NCT01532518|DRUG|Nepadutant|Nepadutant oral solution
219629711|NCT05258266|DRUG|ZX-101A|Q.D., oral dosing
219629712|NCT06294639|DRUG|Esketamine|esketamine will be given intravenously
219629713|NCT00407238|DEVICE|Multi-purpose solutions (polyquaternium-1 and PHMB)|
219629714|NCT04332081|DEVICE|hyperbaric oxygen therapy (HBOT)|The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
219629715|NCT03805035|DEVICE|electroacupuncture|Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
219629716|NCT03805035|DRUG|antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
219629717|NCT03805035|DRUG|antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
218937537|NCT03482960|DRUG|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses."
218937538|NCT03482960|DRUG|PFP|"* Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
218937539|NCT04494997|OTHER|Survey Questionnaire|"This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent."
218937540|NCT04159311|OTHER|Osteopathy|testing osteopathy Vs Treating osteopathy
218937541|NCT02056262|OTHER|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
218937542|NCT02056262|BIOLOGICAL|Saliva sampling|A saliva sample will be harvested.
218937543|NCT02056262|BIOLOGICAL|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
219048427|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
219048428|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
219048429|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
219048430|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
219048431|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
219629718|NCT03805035|DEVICE|acupuncture|Minimal needling at ST36 and GB34
219048432|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
219629719|NCT02074423|DIETARY_SUPPLEMENT|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
219629720|NCT02074423|DIETARY_SUPPLEMENT|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
219629721|NCT00002924|OTHER|mutation analysis|
219629722|NCT02307422|GENETIC|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
219629723|NCT00225524|DRUG|Effexor XR|
219629724|NCT03667885|DIAGNOSTIC_TEST|Blood sample|basic blood sample
219629725|NCT03667885|DIAGNOSTIC_TEST|urine sample|basic urine sample
219629726|NCT03667885|DIAGNOSTIC_TEST|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
219629727|NCT02609971|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
219629728|NCT04754828|OTHER|Assigned to a rounding style|Team rounded on new admissions either in hallway or at the bedside
219629729|NCT02249728|DRUG|IV PBT2 microtracer and oral PBT2 single dose|
219629730|NCT02249728|DRUG|oral 14C-PBT2|
219629731|NCT00940615|OTHER|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
219629732|NCT00940615|OTHER|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
219629733|NCT02155283|DEVICE|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
219629734|NCT03061825|DEVICE|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
219629735|NCT00232739|DEVICE|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
219629736|NCT02679417|BEHAVIORAL|exercise|12 weeks of aerobic or resistant exercise
219629737|NCT00857090|DRUG|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
219629738|NCT00857090|DRUG|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
219629739|NCT02744430|DRUG|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
219629740|NCT02744430|OTHER|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
219629741|NCT02282813|DRUG|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
219629742|NCT02282813|DRUG|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
219629743|NCT02282813|DRUG|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
219629744|NCT02282813|DRUG|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
219629745|NCT05943236|DEVICE|Radiographic assessment of the medial-distal tibial angle|A long ankle view will be generated within a standard radiographic assessment and the medial-distal tibial angle will be assessed.
219629746|NCT02921984|DRUG|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
219629747|NCT02921984|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
219629748|NCT02921984|DRUG|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
219629749|NCT02921984|DRUG|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
219629750|NCT02778009|RADIATION|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
219629751|NCT02778009|OTHER|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
219629752|NCT02778009|OTHER|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
219629753|NCT02778009|OTHER|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
219629754|NCT03135054|DRUG|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
219629755|NCT03135054|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
219629756|NCT00463047|DRUG|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
219629757|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
219629758|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
219629759|NCT03283787|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
219629760|NCT01735721|PROCEDURE|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
219629761|NCT01034436|DIETARY_SUPPLEMENT|fatty acid quality and overweight|Duration 12 weeks
219629762|NCT06684093|DEVICE|Back squat with Blood flow restriction machine|The blood flow restriction (BFR) machine is a specialized device designed to safely apply controlled pressure to the proximal limbs during exercise. It typically consists of adjustable cuffs or bands that are placed around the upper arms or thighs, which are connected to a pressure monitoring system. The device enables practitioners to restrict venous blood flow while allowing arterial blood flow to the working muscles. This method enhances the effects of low-intensity resistance training by promoting muscle hypertrophy and strength gains, similar to those achieved through high-intensity training. The BFR machine is commonly used in rehabilitation settings and athletic training programs to optimize performance and recovery while minimizing the risk of injury.
219629763|NCT06684093|BEHAVIORAL|Back squats|Back squats without any blood flow restriction
219629764|NCT02847091|DRUG|Ipragliflozin|Oral administration, 50mg once daily
219629765|NCT02847091|DRUG|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
219629766|NCT00434174|DRUG|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
219629767|NCT00434174|DRUG|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
219629768|NCT06683404|DEVICE|Electrochemotherapy (ECT)|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.
219629769|NCT06683404|DRUG|Bleomycin|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
219629770|NCT01175096|DRUG|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
219629771|NCT06154980|PROCEDURE|Preoperative Ultrasound TLIP|TLIP will be performed in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique.
219629772|NCT06154980|PROCEDURE|Intraoperative TLIP|TLIP will be performed intraoperatively with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks under direct surgical visualization.
219629773|NCT00426166|DEVICE|Low Level Laser Therapy|7500 megawatts with a 980 nm treatment beam every 48 hours for two weeks beginning at suture removal.
219629774|NCT03366480|DRUG|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
219629775|NCT00799890|DRUG|Sunphenon EGCG|200-800mg (1-4 capsules)
219629776|NCT00799890|DRUG|Placebo|1-4 capsules
219629777|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
219629778|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
219629779|NCT02437773|BEHAVIORAL|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
219629780|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
219629781|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
219629782|NCT02437773|BEHAVIORAL|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
219629783|NCT02437773|OTHER|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
219629784|NCT02437773|OTHER|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
218937544|NCT01783704|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
218937545|NCT01783704|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
219629785|NCT05788172|OTHER|Iron isotope dilution|Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.
219629786|NCT05788172|OTHER|Alkaline hematin method|Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.
219629787|NCT03563430|OTHER|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
219629788|NCT03563430|OTHER|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
219629789|NCT03563430|OTHER|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
219629790|NCT03266146|DRUG|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
219629791|NCT03266146|DRUG|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
219629792|NCT02446067|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
219629793|NCT04037787|PROCEDURE|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
219629794|NCT02560922|BEHAVIORAL|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
219629795|NCT04227223|DIAGNOSTIC_TEST|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
219629796|NCT03493854|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
219629797|NCT03493854|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
219629798|NCT03493854|DRUG|Docetaxel|As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
219629799|NCT03493854|DRUG|Paclitaxel|As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
219629800|NCT03493854|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
219629801|NCT03493854|DRUG|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
219629802|NCT03493854|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
219629803|NCT03493854|DRUG|Trastuzumab SC|After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
219629804|NCT03493854|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
219629805|NCT03493854|RADIATION|Post-operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
219629806|NCT03493854|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
219629807|NCT02458144|PROCEDURE|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
219629808|NCT01864902|BIOLOGICAL|CART33 cells|genetically modified lymphocyte therapy
219629809|NCT01864902|BIOLOGICAL|anti-CD33 CART|
219629810|NCT01864902|BIOLOGICAL|anti-CD33 CAR T cells|
219629811|NCT00739661|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
219629812|NCT00739661|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
219629813|NCT03066713|OTHER|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
219629814|NCT03066713|OTHER|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
219629815|NCT03066713|OTHER|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
219629816|NCT03066713|OTHER|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
219629817|NCT00722774|BIOLOGICAL|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
219629818|NCT04316104|BEHAVIORAL|CuidaTXT|Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
219629819|NCT05343364|DRUG|Vonoprazan|Oral Tablet
219629820|NCT04351113|DIETARY_SUPPLEMENT|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
219629821|NCT04351113|DIETARY_SUPPLEMENT|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
219629822|NCT04351113|OTHER|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
219629823|NCT04351113|OTHER|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
219629824|NCT04351113|OTHER|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
219629825|NCT04351113|OTHER|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
219629826|NCT04351113|OTHER|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
219629827|NCT02358239|PROCEDURE|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
218937546|NCT01783704|BEHAVIORAL|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
218937547|NCT03544762|DRUG|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
219629828|NCT04076163|OTHER|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
219629829|NCT00947921|PROCEDURE|Plasty|Restrictive Annuloplasty
219629830|NCT00947921|PROCEDURE|Prosthesis|Valve replacement
219629831|NCT01868906|DRUG|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
219629832|NCT01868906|PROCEDURE|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
218937548|NCT01563653|PROCEDURE|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
219629833|NCT01868906|DEVICE|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
219629834|NCT01868906|PROCEDURE|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
219629835|NCT01868906|RADIATION|Radiotherapy|Standard radiation therapy
219629836|NCT01868906|DRUG|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
219629837|NCT04785872|OTHER|Education|NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
219629838|NCT05854004|DIAGNOSTIC_TEST|Therapeutic Ultrasound|Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
219629839|NCT05854004|DIAGNOSTIC_TEST|Myofascial Release Technique|Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
219629840|NCT03588143|DEVICE|Electrical stimulation|Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
219629841|NCT05058079|BEHAVIORAL|Intraoperative Hand Held|Intraoperative hand holding
219629842|NCT02531048|DEVICE|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
219629843|NCT02531048|DEVICE|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
219629844|NCT02531048|DEVICE|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
219629845|NCT02531048|DEVICE|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
219629846|NCT02105987|DRUG|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
219629847|NCT02105987|DRUG|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
219629848|NCT06443528|DIAGNOSTIC_TEST|lung ultrasound|All enrolled infants underwent LUS examination performed by two ultrasound physicians. Monitoring included a complete lung scan in the first 24 hours of life (T0) and at day 3 (T1). All neonates underwent weekly ultrasound examinations until 36 weeks postmenstrual age (T2, T3…), so that the T2 scan was carried out at the end of the first week of life. LUS was performed according to a standardized protocol \[13\] when the neonate was in a quiet state, during routine clinical care to minimise discomfort. All ultrasound images and videos were digitally recorded, anonymised, and reviewed by a senior independent ultrasonographer blinded to patients' clinical information. Each lung was divided into three regions according to the anterior and posterior axillary lines and the mammary line. The regions were the upper-anterior, lower-anterior, and latera regions.
219629849|NCT03856411|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
219629850|NCT02350283|DEVICE|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
219629851|NCT00001000|DRUG|Ampligen|
219629852|NCT00204906|DIETARY_SUPPLEMENT|vitamin D supplementation|
219629853|NCT02841761|DRUG|Midalozam|Syrup for oral use
219629854|NCT02841761|DRUG|Aprocitentan|Capsules for oral use
219629855|NCT04991441|DIETARY_SUPPLEMENT|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
218937549|NCT02078960|DRUG|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
219629856|NCT04991441|DIETARY_SUPPLEMENT|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
219629857|NCT03569410|BEHAVIORAL|increased protein intake via natural foods|Patients had to eat 1.4g/kg/day of natural protein.
219629858|NCT03569410|BEHAVIORAL|increase protein intake via protein supplements|Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
219629859|NCT05410665|PROCEDURE|Standard treatments for sepsis|Standard treatments for others
219629860|NCT05754905|OTHER|Magnetic resonance examination|the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
219629861|NCT00920439|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration.
219629862|NCT03507868|PROCEDURE|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
219629863|NCT02266784|BEHAVIORAL|Contingency Management (CM)|
219629864|NCT02266784|DRUG|Transdermal nicotine skin patches (i.e. Habitrol)|
219629865|NCT02266784|OTHER|Supportive Counseling|
219629866|NCT01252095|DRUG|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
219629867|NCT01244438|DRUG|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
219629868|NCT00655993|DRUG|simvastatin|40 mg po daily
219629869|NCT05060536|PROCEDURE|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
219629870|NCT05060536|PROCEDURE|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
219629871|NCT03468491|OTHER|combined training|The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping
219629872|NCT03468491|OTHER|Proximal training|1\. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
219629873|NCT00180882|DRUG|rituximab|
219629874|NCT03981250|BEHAVIORAL|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
219629875|NCT01978132|PROCEDURE|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
219629876|NCT00291070|DRUG|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
219629877|NCT02554682|BEHAVIORAL|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
219629878|NCT02554682|BEHAVIORAL|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
219629879|NCT02554682|BEHAVIORAL|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
219629880|NCT05017792|BIOLOGICAL|Astrazenica vaccine|COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
219629881|NCT03225469|BEHAVIORAL|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
218937550|NCT04248491|DEVICE|BTL Emsella chair|Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
219629882|NCT04948502|DEVICE|SaExten vena cava filter system|Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
219629883|NCT04948502|DEVICE|Denali inferior vena cava filter|Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
219629884|NCT01699373|PROCEDURE|Ultrasound scan|Pre-procedural ultrasound scan was performed
219629885|NCT03894826|DRUG|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
219629886|NCT06041451|DRUG|Intravenous Immunoglobulins, Human|patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
219629887|NCT06041451|DRUG|Methylprednisolone 500 MG Injection|patients were treated with methylprednisolone
219629888|NCT00290953|DRUG|SR48692|
219629889|NCT03529513|DIAGNOSTIC_TEST|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
219629890|NCT03529513|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
219629891|NCT03529513|DIAGNOSTIC_TEST|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
219629892|NCT06509633|OTHER|Pain Neuroscience education and standard rehabilitation regime|Median nerve gliding exercises, wrist and forearm muscle stretches, wrist mobilizations and finger joint mobilizations
219629893|NCT06509633|OTHER|standard Rehabilitation regime|standard Rehabilitation regime
219629894|NCT05799833|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)|4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.
219629895|NCT01004497|DRUG|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
219629896|NCT01004497|DRUG|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
219629897|NCT01004497|DRUG|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 \& 11
219629898|NCT01004497|DRUG|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 \& 11
219629899|NCT01004497|DRUG|Dexamethasone|40 mg/day, IV push, days 1-4 \& days 11-14
219629900|NCT01004497|DRUG|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
219629901|NCT01004497|DRUG|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
219629902|NCT06577974|DRUG|Combined contraceptive pills (Yasmin)|medical pretreatment prior to ICSI
219629903|NCT03171805|DRUG|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
219629904|NCT01677468|PROCEDURE|Intermediate embolization|TACE with substasis using gelfoam
219048433|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
219048434|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
219629905|NCT01677468|PROCEDURE|Complete embolization|TACE with complete embolization using gelfoam
219629906|NCT05574218|PROCEDURE|Glycine air powder|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.
219629907|NCT05574218|PROCEDURE|Rubber cup polishing|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
219629908|NCT04856306|OTHER|Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure|See previous descriptions
219629909|NCT04856306|DRUG|Elagolix Oral Product|See group 3 description
219629910|NCT03464188|BEHAVIORAL|Project Cornerstone|"Project Cornerstone basic elements are:~1. The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~2. 6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~3. Regular caregiver distress thermometer screening and problem support and self-care coaching.~4. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death."
219629911|NCT03107390|OTHER|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
219629912|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 5/500 mg|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
219629913|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 10/1000 mg|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
219629914|NCT04856007|DRUG|Dapagliflozin 5 mg + Metformin 500 mg XR|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
219629915|NCT04856007|DRUG|Dapagliflozin 10 mg + Metformin 1000 mg XR|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
219629916|NCT04338841|OTHER|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
219629917|NCT05160623|DRUG|Povidone-Iodine 1 % Topical Solution|Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
219629918|NCT05160623|DRUG|Eyelid cleansing wipes|EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
219629919|NCT02798380|DRUG|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
219629920|NCT04430556|DRUG|Sertraline|Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
219629921|NCT05836350|DRUG|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
219048435|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
219048436|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
219048437|NCT03996200|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
219048438|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
219629922|NCT05836350|DRUG|4.8 g/m^2/day placebo|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
219629923|NCT03038568|DIAGNOSTIC_TEST|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
219629924|NCT04964050|DRUG|Capozide|Capozide will be administered as per the treatment sequence.
219629925|NCT04964050|DRUG|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
219629926|NCT01636271|DRUG|darapladib|darapladib enteric coated tablets 160 mg
219629927|NCT01636271|DRUG|placebo|placebo
219629928|NCT03608033|BIOLOGICAL|OMS721|Biological: OMS721
219629929|NCT03608033|OTHER|Vehicle (D5W or saline)|5% Dextrose in water or normal saline solution
219629930|NCT01495650|BEHAVIORAL|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
219629931|NCT01153815|DRUG|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
219629932|NCT01153815|DRUG|placebo|placebo
219629933|NCT05214651|PROCEDURE|novel double row|The large - massive rotator cuff tears in in this group will be treated using a novel double row repairing techniques.
219629934|NCT05214651|PROCEDURE|suture bridge double row|The large - massive rotator cuff tears in in this group will be treated using a suture bridge double row repairing techniques.
219629935|NCT03228979|OTHER|Structured Semi-Interactive Stroke Prevention Package|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
219629936|NCT05845632|OTHER|Treatment|Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.
219629937|NCT00521105|OTHER|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
219629938|NCT05791097|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle
219629939|NCT05791097|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
219048439|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
219048440|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
219629940|NCT05791097|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
219629941|NCT05791097|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of pembrolizumab will be administered on Day 1 of each 21-day cycle
219629942|NCT05791097|DRUG|Carboplatin|Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle
219629943|NCT05791097|DRUG|Cisplatin|Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle
219629944|NCT05791097|DRUG|Pemetrexed|Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle
219629945|NCT05791097|DRUG|Paclitaxel|Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle
219629946|NCT05791097|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle
219629947|NCT02533440|PROCEDURE|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
219629948|NCT02533440|PROCEDURE|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
219629949|NCT06545539|OTHER|Fall Preparedness Exercise Class|The class will be held bi-weekly at two different locations. To ensure consistency across groups, the instructor(s) will adhere to a standardized class outline. Exercise modifications will be provided as necessary to adjust the intensity, ensuring all participants can follow the program.
219629950|NCT03274388|PROCEDURE|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
219629951|NCT03274388|PROCEDURE|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
219629952|NCT00000668|DRUG|Ganciclovir|
219629953|NCT01890122|DRUG|Alogliptin|Alogliptin tablets
219629954|NCT01890122|DRUG|Metformin HCl|Metformin HCl capsules
219629955|NCT01890122|DRUG|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
219629956|NCT01890122|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets
219629957|NCT01890122|DRUG|Metformin Placebo|Metformin placebo-matching capsules
219629958|NCT01890122|DRUG|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
219629959|NCT01672502|BEHAVIORAL|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
219629960|NCT01672502|OTHER|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
219629961|NCT01672502|OTHER|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
219629962|NCT03023215|PROCEDURE|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
219629963|NCT03023215|PROCEDURE|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
219629964|NCT03023215|BEHAVIORAL|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
219629965|NCT03023215|PROCEDURE|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
219629966|NCT03920839|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks.
219629967|NCT03920839|DRUG|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
219629968|NCT03920839|DRUG|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
219629969|NCT03920839|DRUG|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
218937551|NCT04595890|DEVICE|Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)|Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
218937552|NCT04595890|OTHER|Saline injection|Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
218937553|NCT01737593|DRUG|Acetaminophen|
218937554|NCT00951197|OTHER|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
219629970|NCT03920839|DRUG|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
219629971|NCT03920839|DRUG|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
219629972|NCT01123811|DRUG|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
219629973|NCT04295408|PROCEDURE|Pericapsular nerve group block with saline solution|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
219629974|NCT04295408|PROCEDURE|Pericapsular nerve group block with ropivacaine|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
219629975|NCT02841839|DRUG|Stannous Fluoride|
219629976|NCT05386459|DRUG|Interferon Gamma|injection form
219629977|NCT02555228|DRUG|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
219629978|NCT02555228|OTHER|Water|5mls of water is given at least 30 minutes before the gastroscopy.
219629979|NCT02894372|DEVICE|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
219629980|NCT02894372|DEVICE|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
219629981|NCT00475488|PROCEDURE|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
219629982|NCT03585023|DIAGNOSTIC_TEST|Spontaneous miscarriage|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
219629983|NCT03585023|DIAGNOSTIC_TEST|Voluntary pregnancy interruption|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
219629984|NCT02062450|DEVICE|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
219629985|NCT02062450|DEVICE|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
219629986|NCT02045069|DRUG|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
219629987|NCT02045069|DRUG|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
219629988|NCT02045069|DRUG|Placebo|Placebo once daily for 3 days
219629989|NCT04119869|OTHER|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
219629990|NCT05018182|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
219629991|NCT05018182|DRUG|Irinotecan|Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
219629992|NCT05018182|DRUG|Folinic Acid|Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
219629993|NCT05018182|DRUG|5FU|5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
219629994|NCT05018182|DRUG|Capecitabine|Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
219629995|NCT02726009|DRUG|Degarelix|
219629996|NCT05419219|DEVICE|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
219048441|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
219629997|NCT01221519|DRUG|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
219629998|NCT05643703|PROCEDURE|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
219629999|NCT06577909|DRUG|Prednisone|Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.
219630000|NCT06577909|DRUG|IVIg|IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14
219630001|NCT02691052|OTHER|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
219630002|NCT02706431|PROCEDURE|Hyperventilation|
219630003|NCT02856932|OTHER|Conventional high viscosity glass ionomer|Dental restorative material
219630004|NCT02856932|OTHER|Glass ionomer with glass hybrid technology|Dental restorative material
219630005|NCT02104674|DRUG|lebrikizumab|Given SC on Days 1, 29, and 57
219630006|NCT02104674|DRUG|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
219630007|NCT02104674|OTHER|placebo|SC injection given on Days 1, 29, and 57
219630008|NCT02591160|PROCEDURE|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
219630009|NCT04154254|DIAGNOSTIC_TEST|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
219630010|NCT04597177|RADIATION|ST-IMRT SW-IMRT|
219630011|NCT06322641|OTHER|No treatment given|No treatment given
219630012|NCT06670079|BEHAVIORAL|Prolonged exposure therapy + incentives for therapy session attendance|Prolonged exposure therapy plus incentives for therapy session attendance
219630013|NCT05046262|DRUG|Calcium chloride|Calcium electroporation
219630014|NCT03308097|BEHAVIORAL|PrEP Mobile Messaging Intervention|See group description
219630015|NCT03308097|BEHAVIORAL|Enhanced Standard of Care|See group description
219630016|NCT02035371|DRUG|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
219630017|NCT02035371|DRUG|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
219630018|NCT04153461|PROCEDURE|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
219630019|NCT04153461|PROCEDURE|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
219630020|NCT06569199|DEVICE|Functional Bracing|Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Braces will be applied to participants in the emergency department. As these braces are designed to allow for positional adjustments, if deemed necessary adjustments will be made by the attending orthopaedic surgeon at subsequent follow-up visit(s).
219630021|NCT06569199|DEVICE|Hip Spica Cast|The current standard of care for diaphyseal pediatric hip fractures in children aged 6 months to 5 years old is hip spica casting. A hip spica is a hard cast that covers a child's body from the chest down to their knees or ankles allowing for fracture immobilization to promote healing. Application of the spica cast occurs in the operating room and requires a general anaesthetic. Caring for a child in a hip spica cast presents significant challenges for caregivers due to the cast's cumbersome size and restricted mobility which makes routine caregiver activities like daily hygiene, toileting, transportation and skin surveillance difficult. Inadequate maintenance of the spica cast may result in skin complications, necessitating extra visits for cast adjustments, or potentially requiring revision casting in the operating room.
219630022|NCT01934582|DRUG|UT-15C SR|
219630023|NCT01934582|DRUG|treprostinil diethanolamine|Open label study drug.
219630024|NCT03364660|DEVICE|Acute epidural stimulation for cardiovascular stability|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.
219630025|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.
219630026|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.
219630027|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability plus Stand Training|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
219630028|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
219630029|NCT06509958|DRUG|HR18034|HR18034
219630030|NCT06509958|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection
219630031|NCT03866252|DRUG|LSD|LSD administration per os
219630032|NCT04311333|DIAGNOSTIC_TEST|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
219630033|NCT04311333|DIAGNOSTIC_TEST|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
219630034|NCT04311333|DIAGNOSTIC_TEST|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
219630035|NCT04311333|DIAGNOSTIC_TEST|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
219630036|NCT06443957|DRUG|Intranasal normal saline|The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
219048442|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
219630037|NCT06443957|DRUG|Intranasal insulin-20U|The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
219630038|NCT06443957|DRUG|Intranasal insulin-40U|The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
219630039|NCT03907761|PROCEDURE|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
219630040|NCT03019237|DRUG|anti-IgE|intranasal anti-IgE
219630041|NCT03019237|OTHER|intranasal allergen|intranasal allergen
219630042|NCT03019237|OTHER|intranasal saline|intranasal placebo
219630043|NCT03926832|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
219630044|NCT02907177|DRUG|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
219630045|NCT02907177|OTHER|Placebo|One tablet of matching placebo administered orally once daily in the morning
219630046|NCT06123637|BEHAVIORAL|Analgesia nociception index-guided anesthesia|Maintaining the blood pressure based on analgesia nociception index of \>50 value
219630047|NCT06123637|BEHAVIORAL|Standard anesthesia|Maintaining the blood pressure based on anesthesiologist's decision
219048443|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
219630048|NCT01453088|DRUG|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
219630049|NCT01453088|DRUG|Bortezomib|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
219630050|NCT06621914|DEVICE|BFR 80|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
219630051|NCT06621914|DEVICE|BFR40|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 40% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
219630052|NCT02355392|OTHER|Telemedical home blood pressure measurements|
219630053|NCT00731354|DEVICE|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
219630054|NCT00731354|DEVICE|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
219630055|NCT06555003|DRUG|Drug-Eluting Embolic Bead|A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
218937555|NCT04380246|OTHER|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
218937556|NCT05867771|DRUG|PM1022|PM1022 Injection
219549055|NCT01058213|BEHAVIORAL|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (\~1-2 seconds for concentric and eccentric contraction) will be used.
219549056|NCT01058213|BEHAVIORAL|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
219549057|NCT02754076|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
219549058|NCT03520972|DRUG|PB-119 75ug|60 eligible patients will be included in this group
219549059|NCT03520972|DRUG|PB-119 150ug|60 eligible patients will be included in this group
219549060|NCT03520972|DRUG|PB-119 200ug|60 eligible patients will be included in this group
219549061|NCT03520972|DRUG|placebo|60 eligible patients will be included in this group
219549062|NCT05444803|OTHER|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
219549063|NCT05444803|OTHER|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
219549064|NCT03392051|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
219549065|NCT03392051|DRUG|Clopidogrel|75mg tablet administered orally
219549066|NCT05778630|OTHER|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
219549067|NCT05778630|OTHER|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
219549068|NCT03271125|BEHAVIORAL|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
219549069|NCT03271125|BEHAVIORAL|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
219549070|NCT01719770|DRUG|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
219549071|NCT01719770|OTHER|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
219549072|NCT00822744|DRUG|SSR411298|"Form: capsule~Route: oral administration with food"
219549073|NCT00822744|DRUG|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
219549074|NCT00822744|DRUG|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
219549075|NCT01758601|OTHER|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
219549076|NCT01758601|OTHER|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
219549077|NCT02705573|DRUG|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
219630056|NCT06555003|DRUG|Chemotherapy drug|Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
219630057|NCT01270568|OTHER|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
219630058|NCT01270568|BEHAVIORAL|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
219630059|NCT01270568|BEHAVIORAL|Recollection|Subjects record daily events on a weekly basis for 8 weeks
219630060|NCT01862926|DRUG|Rituximab|
219630061|NCT01862926|DRUG|Cyclophosphamide|
219630062|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
219630063|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
219630064|NCT02012322|DIETARY_SUPPLEMENT|Placebo|Three month period
219630065|NCT06875440|DRUG|CHX mouthwash|A total of 84 individuals diagnosed with gingivitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a twice-daily dose of CHX, while Group B received a daily dose of Green tea. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total Neutrophil level and determine if there were any changes over time.
219630066|NCT04301011|BIOLOGICAL|TBio-6517|Engineered Oncolytic Vaccinia Virus
219630067|NCT04301011|BIOLOGICAL|Pembrolizumab|Immune checkpoint inhibitor.
219630068|NCT03408938|DEVICE|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
219630069|NCT01487395|DRUG|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
219630070|NCT01487395|DRUG|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
219630071|NCT04699474|DEVICE|Leg ergometer|Leg cycling in bed using motorized ergometer
219630072|NCT04931732|BIOLOGICAL|ctDNA analysis|ctDNA analysis of patients with suspected primary glioma tumors and in patients with suspected recurrence.
219549078|NCT00114504|DRUG|simvastatin|simvastatin 5-10 mg/day
219549079|NCT04443790|DRUG|Leptin Human|
219549080|NCT00018616|BEHAVIORAL|MEMS caps|
219549081|NCT01694563|DEVICE|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
219630073|NCT05374031|OTHER|descriptive study|descriptive study
219549082|NCT01754935|DRUG|VX-509|50 mg oral tablet
219549083|NCT01754935|DRUG|VX-509 matching placebo|0 mg oral tablet
219549084|NCT05716490|DEVICE|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
219549085|NCT05716490|OTHER|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
219549086|NCT01266902|DRUG|Rilpivirine|25 mg once daily
219549087|NCT00833534|BIOLOGICAL|rituximab|Given IV
219549088|NCT00833534|DRUG|lenalidomide|Given orally
219549089|NCT03118687|OTHER|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
218937557|NCT05046327|DRUG|Avatrombopag 20 mg Oral Tablet|Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
218937558|NCT02536417|DRUG|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
219549090|NCT02352233|PROCEDURE|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
219549091|NCT01466894|BIOLOGICAL|IMM 124-E|Tablets orally twice a day for 24 weeks
219549092|NCT01466894|BIOLOGICAL|Placebo|Tablets orally twice daily for 24 weeks
219549093|NCT03068780|DRUG|Oleogel-S10|10% birch bark extract in 90% sunflower oil
219549094|NCT03068780|DRUG|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
219549095|NCT01870258|OTHER|ANN prediction of myocardial infarction|
219549096|NCT04846686|BIOLOGICAL|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
219549097|NCT03334734|DRUG|PBTZ169|Once a day for 14 days
219549098|NCT03334734|DRUG|Isoniazid|Once a day for 14 days
219549099|NCT00830414|DRUG|medroxyprogesterone acetate|IM Injection
219549100|NCT00830414|DRUG|medroxyprogesterone acetate|IM injection
219549101|NCT05323981|DRUG|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
219549102|NCT05323981|DRUG|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
219549103|NCT05323981|DRUG|Perjeta|Intravenous drip of 420mg PERJETA
219549104|NCT05544123|OTHER|pathological stage|breast cancer molecular subtyping and pathological TNM stage
219549105|NCT00894855|BEHAVIORAL|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
219549106|NCT00894855|BEHAVIORAL|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
219549107|NCT00894855|OTHER|dermatologist skin exam|Full body skin exam.
219549108|NCT02426918|DRUG|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
219549109|NCT02426918|DRUG|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
219549110|NCT02426918|DRUG|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
219549111|NCT02426918|DRUG|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
219549112|NCT02426918|DRUG|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
219549113|NCT02426918|DRUG|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
219549114|NCT01496118|DRUG|panobinostat|Specified dose on specified days
219549115|NCT01496118|DRUG|carfilzomib|Specified dose on specified days
219549116|NCT02845336|DRUG|Celecoxib|celecoxib 100mg PO twice per day for 3 months
219549117|NCT02845336|DRUG|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
219549118|NCT03793803|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
219549119|NCT00976443|DRUG|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
219549120|NCT00976443|DRUG|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
219549121|NCT03780608|DRUG|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
219549122|NCT03780608|DRUG|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
219549123|NCT02045108|BEHAVIORAL|Active Retraining|
219549124|NCT02045108|DEVICE|Sham TDCS|
219630074|NCT02731430|DRUG|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
219630075|NCT02731430|DRUG|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
219630076|NCT06874647|OTHER|AI-generated report for reference|The Janus-Pro-CXR group has the AI-generated report for reference and can make changes to the AI-generated report. Another group completes the report independently.
219630077|NCT02120118|RADIATION|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
219630078|NCT02120118|OTHER|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
219549125|NCT02045108|DEVICE|Active TDCS|
219549126|NCT02045108|BEHAVIORAL|Sham Retraining|
219549127|NCT03723733|BEHAVIORAL|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
219630079|NCT02120118|DRUG|Cisplatin|30mg/m2
219630080|NCT02120118|DRUG|Taxotere|20mg/m2
219630081|NCT01347723|OTHER|scrambler therapy|Undergo scrambler therapy
219630082|NCT01347723|OTHER|questionnaire administration|Ancillary studies
219630083|NCT01347723|PROCEDURE|management of therapy complications|Undergo scrambler therapy
219630084|NCT01069601|BIOLOGICAL|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
219630085|NCT05689346|DEVICE|high tone power therapy|high tone power therapy
219630086|NCT05689346|OTHER|traditional physical therapy exercises|traditional physical therapy exercises for improving balance
219630087|NCT01931436|DRUG|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
219630088|NCT02174510|DRUG|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
219630089|NCT02174510|DRUG|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
219630090|NCT02174510|DRUG|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
219630091|NCT02174510|DRUG|placebo|
219630092|NCT01174381|BEHAVIORAL|lifestyle modification|Lifestyle modification for six months
219630093|NCT00953654|OTHER|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
219630094|NCT00953654|OTHER|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
218937559|NCT02536417|DRUG|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
218937560|NCT02250729|OTHER|intradermal pholcodine allergy test in cases|
218937561|NCT02250729|OTHER|Blood sampling|
218937562|NCT00787618|DRUG|50 mg Proellex|Single dose
218937563|NCT03181646|DRUG|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
218937564|NCT05086029|DIAGNOSTIC_TEST|Superb Microvascular Imaging|Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
218937565|NCT04995458|PROCEDURE|composite-ceramic|To assess the clinical performance of composite-ceramic crowns
218937566|NCT04995458|PROCEDURE|Monolithic zirconia|To assess the clinical performance of monolithic z¡irconia crowns
218937567|NCT02584556|DRUG|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
219630095|NCT01709487|PROCEDURE|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
219630096|NCT02746250|DRUG|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
219630097|NCT01124994|PROCEDURE|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
219630098|NCT01603693|DEVICE|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
219630099|NCT01603693|DEVICE|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
219630100|NCT01875146|OTHER|4x4 min HIT|Conventional 4x4 min high-intensity interval training
219630101|NCT01875146|OTHER|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
219630102|NCT01875146|OTHER|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
219630103|NCT01875146|OTHER|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
219630104|NCT01030302|DRUG|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
219048444|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
219048445|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
219048446|NCT02880566|PROCEDURE|Scalp block|Full scalp block
219048447|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
219048448|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
219048449|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
219048450|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
219048451|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
219048452|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
219048453|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
219048454|NCT01340976|DRUG|LY2787106|Administered IV.
219048455|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
219048456|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
219048457|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
219048458|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
219048459|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
219048460|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
219048461|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
219048462|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
219048463|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
219630105|NCT02570464|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
219630106|NCT02570464|BIOLOGICAL|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
219630107|NCT05509387|DEVICE|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
219630108|NCT05232760|DEVICE|Supera™ Peripheral Stent System|The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
219630109|NCT01334229|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
219048464|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
219630110|NCT01334229|DRUG|Placebo|Placebo for 6 weeks
219630111|NCT05049395|DEVICE|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
219630112|NCT05049395|DEVICE|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
219630113|NCT00153179|DRUG|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
219048465|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
219048466|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
219048467|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
219048468|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
219048469|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
219048470|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
219048471|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
219630114|NCT00153179|DRUG|placebo|matching placebo
219630115|NCT05265338|DRUG|KC1036|60mg QD
219630116|NCT02627313|DEVICE|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
219630117|NCT00894621|DRUG|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
219630118|NCT00894621|DRUG|Placebo|
218937568|NCT02584556|DRUG|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
219630119|NCT05751213|OTHER|knack technique.|"It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)"
219630120|NCT05751213|OTHER|pelvic floor muscle exercises|It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
219630121|NCT04495829|DEVICE|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
219630122|NCT03433573|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
219630123|NCT01445782|DRUG|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
219630124|NCT01445782|DRUG|Placebo|Multiple dose, oral inhalation (nebuliser solution)
219630125|NCT00691730|OTHER|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
219630126|NCT03807544|DEVICE|TENS|Transcutaneous electrical nerve stimulation
219630127|NCT05442229|OTHER|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
219630128|NCT03111940|PROCEDURE|Optimisation of the result of intracoronary stenting according to specific algorithm|
219630129|NCT01800747|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
219630130|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
219630131|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
219630132|NCT02696343|DEVICE|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
219630133|NCT02696343|DEVICE|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
219630134|NCT05775887|BIOLOGICAL|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
219630135|NCT05775887|BIOLOGICAL|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
219630136|NCT05581277|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
219630137|NCT00509951|BEHAVIORAL|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
218937569|NCT03966339|DRUG|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
218937570|NCT00587496|DRUG|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
218937571|NCT00587496|DRUG|placebo|lactose placebo capsule, six per day for 30 days
218937572|NCT00587496|DRUG|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
218937573|NCT02995824|OTHER|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) \[lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)\] \[Group 1\] versus other ART regimens including boosted PI or NNRTIs \[Group 2\] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
218937574|NCT01944852|DRUG|Icodextrin|
218937575|NCT00741845|DRUG|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
219630138|NCT00509951|BEHAVIORAL|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
219630139|NCT01628731|DRUG|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
219630140|NCT01628731|DRUG|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
219630141|NCT01461694|DEVICE|Intense Pulsed Light (IPL)|Half Face Treated with IPL
219630142|NCT01461694|DEVICE|Alexandrite Laser|Half face treated with Alexandrite Laser
219630143|NCT04578873|DRUG|QPX7831|capsule
219630144|NCT04578873|DRUG|placebo comparator|oral matched placebo capsule
219630145|NCT04753008|DRUG|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
219630146|NCT05051852|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
219630147|NCT03452670|BEHAVIORAL|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
219549128|NCT05448209|BEHAVIORAL|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
219549129|NCT06003933|DRUG|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
219549130|NCT06003933|DRUG|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
219549131|NCT06003933|DEVICE|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
219549132|NCT06003933|DEVICE|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
218937576|NCT02597478|DRUG|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
218937577|NCT02597478|PROCEDURE|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
218937578|NCT02597478|BEHAVIORAL|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
218937579|NCT02597478|BEHAVIORAL|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
218937580|NCT02597478|BEHAVIORAL|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
219549133|NCT04702685|DRUG|Ropivacaine|Local anesthetic for injection
219549134|NCT04702685|OTHER|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
219549135|NCT04076007|DIETARY_SUPPLEMENT|Beetroot juice|
218937581|NCT01652469|DRUG|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
218937582|NCT01652469|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
218937583|NCT06050824|DRUG|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
218937584|NCT01334619|PROCEDURE|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
218937585|NCT04726540|OTHER|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
219549136|NCT04076007|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|
219549137|NCT05865652|DIAGNOSTIC_TEST|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
219549138|NCT02974907|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
219549139|NCT02974907|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
219549140|NCT04302961|OTHER|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
219549141|NCT04302961|OTHER|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
219630148|NCT03452670|OTHER|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
219630149|NCT05514015|DRUG|rituximab combined with corticosteroids|"Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;"
219630150|NCT05514015|DRUG|rituximab|Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
219630151|NCT02188147|DEVICE|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
219630152|NCT01022476|DRUG|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
219630153|NCT02473172|DEVICE|Pressure Support ventilation|Assisted mechanical ventilation
219630154|NCT02473172|DEVICE|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
219630155|NCT06438614|DRUG|HITS|Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF. Irinotecan 50mg/m2/day IV will be administered from day 1-5concurrently with temozolomide 150mg/m2/day orally. Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11
219630156|NCT06438614|DRUG|Naxitamab + GM-CSF cycles|Patients that achieve CR after 2 or 4 cycles of HITS will move on to 5 cycles of Naxitamab + GM-CSF cycles.
219630157|NCT06438614|DRUG|NICE|Patients that do not have an objective response (CR/PR) will receive NICE within 3 weeks from last dose. Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2). Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and 11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11. Ifosfamide 1.5 gr/m2/day IV will be administered from day 1-3 concurrently with etoposide 100 mg/m2/day IV. Carboplatin 400 mg/m2/day IV will be administered on day 1
219630158|NCT06411964|DIETARY_SUPPLEMENT|Prebiotic|Commercially available supplement (Bimuno)
219630159|NCT06411964|DIETARY_SUPPLEMENT|Placebo control|maltodextrin control supplement
219630160|NCT00616213|BIOLOGICAL|filgrastim|filgrastim will be administered at a standard dose and schedule
219630161|NCT00616213|DRUG|PR104|PR104 is administered intravenously once every 21 days
219630162|NCT00616213|OTHER|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
219630163|NCT00160849|DRUG|Lopinavir/r|
219630164|NCT01537042|DRUG|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
219630165|NCT01537042|DRUG|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
219630166|NCT03911232|DRUG|sugammadex|standard general anesthesia protocol with sugammadex
219630167|NCT03125252|OTHER|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~* thirst~* noise~* pain and well-being~* sleep~* isolation"
219630168|NCT03125252|OTHER|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~* Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~* Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~* Use of reference antipsychotic pharmacological means"
219630169|NCT05550233|DEVICE|drug-coated balloon|drug-coated balloon in big de novo coronary disease
218937586|NCT02649751|DRUG|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
218937587|NCT02649751|DRUG|Placebo|The placebo treatment is lactose capsule.
219630170|NCT01395147|DRUG|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
219630171|NCT00979654|DRUG|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
219630172|NCT04145154|OTHER|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
219630173|NCT05908877|OTHER|History and Clinical evaluation|"HISTORY and CLINICAL EVALUATION and recording of the following parameters:~* Gestational Age~* Birth Weight~* Gender~* Weaning habits~* Anthropometric indices: actual age; actual weight; actual height; body mass index BMI (kg/m2) + percentile; waist circumference; age for height; weight for height; height for age; height standard deviation score (SDS)~* Vital parameters: heart rate (beats/min); respiratory rate (breaths/min); blood pressure (mmHg)~* Adipose tissue~* Subcutaneous fat tissue distribution~* Acanthosis Nigricans~* Stretch marks (striae)~* Tanner Puberty Stage"
219630174|NCT05908877|DIAGNOSTIC_TEST|Biological evaluation of the metabolic syndrome and components|"LABORATORY INVESTIGATIONS will include:~* Lipid Profile: total cholesterol (mmol/L); LDL - cholesterol (mmol/L); HDL - cholesterol (mmol/L); triglycerides (mmol/L)~* Glucose - Insulin Profile: HbA1c (%); serum glucose (mmol/L); insulinemia (µUI/mL); HOMA Index~* Liver Function: alanine aminotransferase (ALT or TGP) (U/L); gamma glutamyl transferase (GGT) (U/L)~* Cardio-Vascular Risk - Inflammation - Oxidative Stress: ultrasensitive C-reactive protein (ng/mL); leptin (ng/mL); adiponectin (ng/mL); serum selenium (μg/L); glutathione peroxidase (GPx) (U/L)"
218937588|NCT05151029|DEVICE|Elastography|new dignostic tool
218937589|NCT00718653|DIETARY_SUPPLEMENT|Lutein|Lutein (12 mg/d)
218937590|NCT00718653|DIETARY_SUPPLEMENT|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
219630175|NCT05908877|DIAGNOSTIC_TEST|Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage|"ULTRASOUND EVALUATION by:~* Carotid Intima-Media Thickness (cIMT) Measurement using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a high frequency linear array probe (5-13 MHz) and a semi-automated software (Auto IMT+), according to the Mannheim Consensus~* Measurements of Visceral-to-Subcutaneous-Fat Ratio using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a 7.5 (12) MHz linear transducer for subcutaneous fat and a 3.5 MHz convex transducer for visceral fat measurement~* Ultrasound Quantification of Hepatic Steatosis: assessed with B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) using 3.5 MHz convex transducer; increased liver echogenicity, blurring of vascular margins and increased acoustic attenuation are the parameters considered in the quantification of hepatic steatosis"
219630176|NCT05908877|OTHER|Nutritional assessment|"NUTRITION CONSULT Initial consult will include: food habits survey aiming at identifying the nutritional factors that led to an increased Body Mass Index (BMI) and recommendations At reevaluations the food diary of the patients will be evaluated and recommendations will be adapted accordingly.~The final visit will include evaluation of the food diary looking to identify the factors that have or have not helped to normalize BMI in order to recommend a long-term healthy lifestyle."
219630177|NCT05908877|BEHAVIORAL|Psychological evaluation of the impact of obesity/overweight|"PSYCHOLOGICAL ASSESSMENT by:~Evaluation of pediatric health-related quality of life will be assessed with Pediatric Quality of Life Inventory (PedsQL). The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life.~Another questionnaire that will be used is the the Rosenberg Self-Esteem Scale. It is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. A higher score means higher self-esteem.~Drawing in children is a communicative tool, many times more than reading or language. It can measure the image of the self and the image of the others and is representative of the unconscious.~Questionnaires and drawing interpretation will be done at the initial presentation and at every control visit."
219630178|NCT01969773|DRUG|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
219630179|NCT01969773|DRUG|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
219630180|NCT03055676|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
219630181|NCT03055676|OTHER|Late drain removal|Removing drain(s) on postoperative day 5 or later
219630182|NCT02925962|OTHER|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
219630183|NCT02925962|OTHER|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
219630184|NCT01446302|DIETARY_SUPPLEMENT|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
219630185|NCT01734005|DIETARY_SUPPLEMENT|Red Ginseng|Red Ginseng (1.4g/day)
219630186|NCT01734005|DIETARY_SUPPLEMENT|Placebo|Placebo (1.4g/day)
219630187|NCT05362617|DRUG|FOLFIRI|FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
219630188|NCT04509336|DRUG|Orphenadrine|100 mg twice daily
219630189|NCT04509336|DRUG|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
219630190|NCT00204919|DRUG|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
219630191|NCT00204919|DRUG|placebo|once-monthly placebo capsules
219630192|NCT00457002|DRUG|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
219630193|NCT00457002|DRUG|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
219630194|NCT05776264|BEHAVIORAL|Music Condition|During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.
219630195|NCT05776264|BEHAVIORAL|Podcast Condition|During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
219630196|NCT01149564|DRUG|iv ibuprofen|
219630197|NCT01149564|DRUG|oral ibuprofen|
219630198|NCT00249340|BEHAVIORAL|Weight Watchers|
219048472|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
219630199|NCT00249340|BEHAVIORAL|brief behavioral weight loss treatment|
219630200|NCT00249340|BEHAVIORAL|brief behavioral + Weight Watchers combined treatment|
219630201|NCT05270616|PROCEDURE|robotic surgery|minimally invasive surgery using the Davinci robotic system
219630202|NCT05270616|PROCEDURE|uniport surgery|VATS minimally invasive surgery under the uniportal status
219630203|NCT05270616|PROCEDURE|multiple- port surgery|VATS minimally invasive surgery under the multiple- port status
219630204|NCT04539184|OTHER|Motion Style Acupuncture Treatment (MSAT)|MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
219630205|NCT04539184|OTHER|Acupuncture|General acupuncture
219630206|NCT06524869|DIAGNOSTIC_TEST|Isokinetic neuromuscular assessment|All sports patients who had a muscle evaluation in addition to functional testing at 6-12 months after ACLR since March 2024
219630207|NCT05464966|DRUG|Glucose insulin potassium|After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
219048473|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
219048474|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
219048475|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
219048476|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
219630208|NCT00454246|DRUG|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
219630209|NCT00454246|DRUG|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
219630210|NCT00454246|DRUG|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
219630211|NCT02283268|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
219630212|NCT02185118|DRUG|oxygen|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
219048477|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
219048478|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
219630213|NCT02185118|DRUG|Sevoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
219630214|NCT02185118|DRUG|Isoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
219630215|NCT06237738|BEHAVIORAL|Stress Ball Use|The intervention in this study involves the use of stress balls provided to participants in the intervention group. These are specially designed medium-firm silicone balls intended for squeezing with the hand opposite the one receiving cannulation during hemodialysis sessions. The primary objective of this intervention is to offer a simple, non-pharmacological method to potentially alleviate the pain associated with the cannulation process. Participants are instructed to use the stress ball for a period of three minutes before the start of cannulation. This activity is hypothesized to focus the participant's attention and possibly reduce the perception of pain, contributing to a more comfortable and less distressing cannulation experience.
219630216|NCT05563779|OTHER|Volume Control mode|Volume Control mode for mechanical ventilation
219630217|NCT05563779|OTHER|Pressure Control mode|Pressure Control mode for mechanical ventilation
219630218|NCT05563779|OTHER|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
219630219|NCT03555318|OTHER|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
219630220|NCT03555318|OTHER|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
219048479|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
219048480|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
219048481|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
219048482|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
219630221|NCT03555318|OTHER|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
219630222|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
219630223|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
219630224|NCT01594736|DRUG|ORSIRO|due randomization ORSIRO will be implanted
219630225|NCT01594736|DEVICE|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
219630226|NCT04384575|DIAGNOSTIC_TEST|blind spots|missed part during map the entire stomach through endoscopy
219630227|NCT03349073|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
219630228|NCT02497560|DIETARY_SUPPLEMENT|proprietary formula|
219630229|NCT05416580|DRUG|UDCA (Ursodeoxycholic acid)|UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
219630230|NCT05416580|DRUG|Placebo|Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
219630231|NCT05416580|DRUG|Metformin|Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
219630232|NCT04452214|DRUG|CAN04|Administered intravenously
218937591|NCT00796978|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
218937592|NCT00796978|OTHER|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
218937593|NCT00796978|PROCEDURE|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
219630233|NCT04452214|DRUG|Pembrolizumab|Administered intravenously
219630234|NCT04452214|DRUG|Carboplatin|Administered intravenously
219630235|NCT04452214|DRUG|Pemetrexed|Administered intravenously
219630236|NCT03132857|OTHER|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
219630237|NCT01135329|DRUG|Fludarabine|30 mg/m\^2 IV daily on Day -6 through Day -2.
219630238|NCT01135329|DRUG|Busulfan|1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
219630239|NCT01135329|DRUG|Cyclophosphamide|50 mg/kg IV daily on Day +3 and Day +4.
219630240|NCT01135329|DRUG|Mycophenolate Mofetil|15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
219630241|NCT01135329|DRUG|Tacrolimus|Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
219630242|NCT03942458|DRUG|Vicagrel 6mg|Vicagrel 24mg loading followed by 6mg/day for 6 days
219630243|NCT03942458|DRUG|Clopidogrel 75mg|Clopidogrel 300mg loading followed by 75mg/day for 6 days
219630244|NCT03850470|DIAGNOSTIC_TEST|clinical examination|Thorough examination including history, screening, motion testing, strength testing, special testing
219630245|NCT03850470|OTHER|MRI|Low field MRI .25 Tesla
219630246|NCT02030340|PROCEDURE|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
219630247|NCT03417557|DEVICE|Comfilcon A lens (test)|contact lens
219630248|NCT03417557|DEVICE|Omafilcon B lens (control)|contact lens
219630249|NCT04963322|OTHER|extracorporeal membrane oxygenation therapy|Extracorporeal membrane oxygenation for the management of severe refractory heart and lung dysfunction
219630250|NCT02075216|PROCEDURE|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
219630251|NCT02075216|BIOLOGICAL|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
219630252|NCT05677256|BIOLOGICAL|nOPV2|Vaccination
219630253|NCT01692925|DRUG|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
219630254|NCT01692925|DRUG|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
219630255|NCT04506463|DRUG|MM-II dose I|Intra-articular injection
219630256|NCT04506463|DRUG|MM-II dose II|Intra-articular injection
219630257|NCT04506463|DRUG|MM-II dose III|Intra-articular injection
219630258|NCT04506463|DRUG|Placebo|Intra-articular injection
219630259|NCT04506463|DRUG|Placebo|Intra-articular injection
219630260|NCT04506463|DRUG|Placebo|Intra-articular injection
219630261|NCT05593081|GENETIC|HLA|Distinguish based on clinical features
219630262|NCT01475708|DRUG|Doxycycline|100 mg PO bid, 14 days
219630263|NCT03428503|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
219630264|NCT03428503|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
219630265|NCT02854956|BEHAVIORAL|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~* The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~* The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~* The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~* The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~* The Nisonger child behavior rating form which allow to assess the behavior disorders~* Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~* Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
219630266|NCT03303456|OTHER|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
219630267|NCT02359487|BEHAVIORAL|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
219630268|NCT02359487|BEHAVIORAL|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
219630269|NCT02528006|DEVICE|Type 2 Thyroplasty using Titanium Bridges|
219630270|NCT00003118|DRUG|cisplatin|
219630271|NCT00003118|DRUG|fluorouracil|
219630272|NCT00003118|PROCEDURE|surgical procedure|
219048483|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
219630273|NCT00003118|RADIATION|radiation therapy|
219630274|NCT01702285|DRUG|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
219630275|NCT00707681|DRUG|MS-20|4 ml/vial
219630276|NCT00707681|DRUG|Placebo|4ml/vial
219630277|NCT01085630|DRUG|pemetrexed disodium|Given IV
219630278|NCT01085630|OTHER|clinical observation|
219630279|NCT00032149|BIOLOGICAL|bleomycin sulfate|
219630280|NCT00032149|BIOLOGICAL|filgrastim|
219630281|NCT00032149|DRUG|cyclophosphamide|
219630282|NCT00032149|DRUG|etoposide|
219630283|NCT00032149|DRUG|mitoxantrone hydrochloride|
219630284|NCT00032149|DRUG|prednisolone|
219630285|NCT00032149|DRUG|vincristine sulfate|
219630286|NCT03643601|OTHER|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
219630287|NCT05977660|DIAGNOSTIC_TEST|Cumberland ankle instability tool for diagnose to determine ankle instability and its severity|CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
219630288|NCT06146465|OTHER|speciality|Not
219630289|NCT01357499|DEVICE|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
219630290|NCT01357499|DEVICE|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
219630291|NCT01017874|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
219630292|NCT01017874|DRUG|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
219630293|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
219630294|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
219048484|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
219549142|NCT02420353|DRUG|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
219549143|NCT02420353|DRUG|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
219549144|NCT00004933|DRUG|hydroxyurea|0.5 to 5 grams PO per day
219549145|NCT00004933|DRUG|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
219549146|NCT02827097|DRUG|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
219549147|NCT02827097|DRUG|denogan|administration of denogan
219549148|NCT04146805|DRUG|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
219549149|NCT04146805|DRUG|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
219549150|NCT03106545|DRUG|Liposome bupivacaine|
219549151|NCT03954483|DRUG|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
219549152|NCT03954483|DRUG|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
219549153|NCT03954483|DRUG|Placebo oral tablet|Orally administered prior to experiments.
219549154|NCT01337427|DRUG|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
219549155|NCT00182260|DRUG|Proton Pump Inhibitors|
219549156|NCT00182260|PROCEDURE|Laparoscopic Nissen Fundoplication|
219549157|NCT04847401|DIAGNOSTIC_TEST|H. pylori stool antigen|using H. pylori antigen kits in stool
219549158|NCT04703504|OTHER|Multiple intervention program|Support for patient follow-up assisted by a computer program
219549159|NCT04125862|DIAGNOSTIC_TEST|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
219549160|NCT04125862|DIAGNOSTIC_TEST|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
219549161|NCT04125862|DIAGNOSTIC_TEST|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
219549162|NCT04125862|DIAGNOSTIC_TEST|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
219549163|NCT04608448|DRUG|Rapamycin Topical Ointment|8% topical rapamycin ointment
219549164|NCT04608448|OTHER|Placebo|Petrolatum ointment containing no active ingredient
219549165|NCT01149057|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
219549166|NCT01325740|DRUG|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
219549167|NCT02749604|PROCEDURE|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
219549168|NCT02749604|PROCEDURE|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
219549169|NCT02028039|DRUG|IPI-145|75 mg orally twice daily for 4 weeks.
219630295|NCT04025060|BEHAVIORAL|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
219630296|NCT04025060|BEHAVIORAL|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
219630297|NCT04025060|BEHAVIORAL|Regular soda|Subjects are asked to consume regular soda daily for two weeks
219630298|NCT05519826|DEVICE|Vascular surgery|"POLYMAILLE® EXTRA THIN vascular prostheses are indicated for replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral) and/or femoro-popliteal bypass above the knee."
219630299|NCT02055924|DRUG|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
219630300|NCT02439060|OTHER|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
219630301|NCT02894645|DRUG|Prednisolone|Oral
219630302|NCT02894645|DRUG|Dexamethasone|Oral
219630303|NCT02894645|DRUG|L-Asparaginase|Intramuscular injection
219630304|NCT02894645|DRUG|Vincristine|Intravenous
219630305|NCT02894645|DRUG|Methotrexate|Intrathecal/ Intravenous/ Oral
219630306|NCT02894645|DRUG|Daunorubicin|Intravenous
219630307|NCT02894645|DRUG|Doxorubicin|Intravenous
219630308|NCT02894645|DRUG|Cyclophosphamide|Intravenous
219630309|NCT02894645|DRUG|Cytarabine|Intravenous/ Subcutaneous injection
219630310|NCT02894645|DRUG|6-Mercaptopurine|Oral
219630311|NCT02894645|DRUG|Thioguanine|Oral
219630312|NCT02894645|DRUG|Fludarabine|Intravenous
219630313|NCT02894645|DRUG|Imatinib|Oral (For BCR-ABL ALL only)
219630314|NCT06367504|DIETARY_SUPPLEMENT|DBMF|Once a day daily 30 minutes before lunch
219630315|NCT06367504|DIETARY_SUPPLEMENT|Placebo|Once a day daily 30 minutes before lunch
219630316|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
219630317|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
219630318|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
219630319|NCT00865228|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
219630320|NCT03004651|OTHER|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
219630321|NCT03004651|OTHER|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
219630322|NCT01702623|DRUG|Oxcarbazepine|
219630323|NCT04028050|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
219630324|NCT04028050|DRUG|Carboplatin|Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
219630325|NCT04028050|DRUG|Etoposide|Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
219630326|NCT06133608|OTHER|MOBILIZATION TRAINING|"Things to consider in the hospital in the early period after surgery: The first day in the hospital after surgery, the importance of the abduction pillow and early mobilization,~* Exercises performed in bed in the early period after surgery: Exercises such as ankle pump, ankle rotation, bed-supported knee bending, hip contraction, opening exercise, thigh exercise, straight leg raise,~* Early standing up: Activities such as sitting in bed or on a chair, standing up with the help of a walker, walking,~* Exercises performed while standing: Exercises such as lifting the knee, opening the leg to the side,~* Daily living activities: It will provide information on regulating ADLs such as bathing, dressing, using the toilet, getting into and driving the car, going up and down stairs, eating, sleeping, doing housework, sexual life, and information about the safety precautions that should be taken at home."
219048485|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
219048486|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
219048487|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
219630327|NCT06576999|DEVICE|Sensor-based Balance Training|10 sessions of sensor-based balance training with exergaming feedback. For this training an adaptive integrated audio-visual feedback system composed of five IMUs and a force platform connected wirelessly to a computer has been used. The training protocol include exercises of balance control, encompassing a total of five distinct exercises: i) Latero-lateral load shifting while seated; ii) Load shifting while standing: latero-lateral and antero-posterior, to simulate the balance control performed during the day; iii) Load control during sit-to-stand; iv) Gait swing and loading phase response: to stimulate a correct load shifting during the swing and stance phase; v) Latero-lateral load shifting with knee flexion.
219630328|NCT06576999|OTHER|Usual Balance Trainging|10 sessions of usual balance training. The training includes: gait control exercises, weight shifting, and relies on both stable surfaces (i.e., steps) and unstable surfaces (i.e., oscillating platforms and various-sized fitballs). The protocol encompassed the application of stabilization techniques and the reaching of targets with the upper limb during upright position emulating the activity of daily living.
219630329|NCT01925430|DEVICE|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
219630330|NCT01925430|DEVICE|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
219630331|NCT04029025|PROCEDURE|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
219630332|NCT04029025|PROCEDURE|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
219630333|NCT04029025|PROCEDURE|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
219630334|NCT01346696|DEVICE|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
219630335|NCT05350618|OTHER|Ultrasound evaluation|A single transperineal ultrasound assessment session
219630336|NCT05233553|OTHER|control of liver enzymes|follow-up with clinical and laboratory measurements
219630337|NCT01854190|DEVICE|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
219630338|NCT00878943|DRUG|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
219630339|NCT02737488|BEHAVIORAL|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
219630340|NCT02737488|BEHAVIORAL|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
219048488|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
219048489|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
219048490|NCT00117091|DRUG|Anakinra (Kineret®)|
219048491|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
219048492|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
219048493|NCT04878705|DRUG|placebo|a single subcutaneous injection
219048494|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
219048495|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
219048496|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
219048497|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
219048498|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
219048499|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
219549170|NCT02028039|BEHAVIORAL|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
219549171|NCT00654186|DRUG|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
219549172|NCT06562179|DEVICE|da Vinci SP® Single-Port Robotic Surgical System|The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
219549173|NCT01394419|DRUG|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
219549174|NCT01394419|DRUG|Saline|Equal volume of normal saline
219549175|NCT01685255|DRUG|Epacadostat|
219549176|NCT01685255|DRUG|tamoxifen|
219549177|NCT00577655|DRUG|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
219549178|NCT00577655|DRUG|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
219549179|NCT00577655|DRUG|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
219549180|NCT01198938|OTHER|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
219549181|NCT06377410|DRUG|Syrup Prospan|Participant with stable COPD who received Syrup prospan for 1 month
219549182|NCT06377410|DRUG|N-Acetylcysteine|Participant with stable COPD who received N-Acetylcysteine for 1 month
219549183|NCT03008655|PROCEDURE|intradermal tranexamic acid|intradermal tranexamic acid injection
219549184|NCT03008655|DEVICE|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
219549185|NCT02504450|DRUG|Adasuve|Inhaled medication to treat acute agitation in the emergency department
219549186|NCT02504450|DRUG|Alternative medications|Medication given to treat acute agitation in the emergency department
219549187|NCT01632423|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
219549188|NCT02236858|DEVICE|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
219549189|NCT02236858|DEVICE|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
219549190|NCT04778358|DRUG|Follitropin Delta, Recombinant|15 µg of follitropin delta will be administered subcutaneously daily
219549191|NCT00837564|OTHER|CBASP psychotherapy|specific psychotherapy for chronic depression
219549192|NCT00837564|DRUG|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
219549193|NCT01793584|PROCEDURE|Laparoscopic hysterectomy|LAVH, TLH
219549194|NCT01793584|PROCEDURE|Abdominal hysterectomy|TAH
219630341|NCT04083885|OTHER|Virtual Reality|Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week for 8 weeks. Sessions will be 20-30 minutes long, depending on tolerance.
219630342|NCT02006589|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
219630343|NCT02006589|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
219630344|NCT01610089|OTHER|stable isotope infusion|"Control subjects: \[15N2-ureido\] arginine (0.69 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of \[15N2-ureido\] arginine (0.69 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,\[15N2-ureido\] arginine (4.14 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of \[15N2-ureido\] arginine (4.14 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr)."
219630345|NCT04236492|PROCEDURE|Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
219630346|NCT02810366|OTHER|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
219630347|NCT00937274|OTHER|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
219630348|NCT00937274|OTHER|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
219630349|NCT00937274|OTHER|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
219630350|NCT00932048|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
219630351|NCT04477148|DEVICE|endotracheal intubation|patients were intubated with 3 different blades
219630352|NCT03946319|DIAGNOSTIC_TEST|Introspect Health|Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
219630353|NCT01706341|DRUG|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
219630354|NCT01706341|DRUG|acetate Ringer's solution containing no glucose|
219630355|NCT01706341|DRUG|acetate Ringer's solution containing 1% glucose|
219630356|NCT02348918|DRUG|Luminate 1.0mg|
219630357|NCT02348918|DRUG|Luminate 2.0mg|
219630358|NCT02348918|DRUG|Luminate 3.0mg|
219630359|NCT02348918|DRUG|Avastin|
219630360|NCT02348918|DRUG|Luminate 0.5mg|
219630361|NCT04545008|DRUG|Famotidine|Oral Famotidine
219630362|NCT04545008|DRUG|N-Acetyl cysteine|Oral N-Acetyl Cysteine
219630363|NCT00506415|DRUG|Rivastigmine 5 cm^2|5 cm\^2 transdermal patch
219630364|NCT00506415|DRUG|Rivastigmine 10 cm^2|10 cm\^2 transdermal patch.
219630365|NCT00506415|DRUG|Rivastigmine 15 cm^2|15 cm\^2 transdermal patch.
219630366|NCT00506415|DRUG|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm\^2.
219630367|NCT00506415|DRUG|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm\^2.
219630368|NCT05428683|DRUG|intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis|At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
219630369|NCT01742130|DRUG|sodium bicarbonate solution|
219630370|NCT01742130|DRUG|Isotonic saline|
219630371|NCT04578457|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
219630372|NCT04578457|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
219630373|NCT04578457|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
219630374|NCT04578457|DEVICE|Hearing Aid with NR(3)|Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
219630375|NCT03950830|DRUG|Disulfiram|Disulfiram 400mg daily, continuously
219630376|NCT03062930|BEHAVIORAL|Track 1|Training of non-paretic arm followed by sham condition
219630377|NCT03062930|BEHAVIORAL|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
219630378|NCT04674215|BEHAVIORAL|Turning in Bed|Preoperative Turning in Bed Training
219630379|NCT04674215|BEHAVIORAL|Mobilization|Preoperative Mobilization Training
219630380|NCT04674215|OTHER|information|Routine Clinical Care
219630381|NCT06577844|OTHER|video support|video support provided to the patient before surgery
219630382|NCT06577740|OTHER|Otago Exercise|Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.
219630383|NCT06577740|OTHER|Dual Task Focused Otago Exercise|After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.
219630384|NCT00410540|DRUG|OROS hydromorphone HCL ; Morphine sulfate|
219630385|NCT03039504|DIETARY_SUPPLEMENT|Potensa, a succinate-based dietary supplement|Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
219630386|NCT03039504|DIETARY_SUPPLEMENT|Placebo|Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
219630387|NCT03525223|PROCEDURE|Change of dialysate [Na+]|Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
219630388|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Double Nasoseptal Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~-On one side full sized nasoseptal flap will be elevated and a smaller sized nasoseptal flap will be elevated on the other side."
219630389|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Rescue Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~\- A horizontal incision will be performed in the nasal septum in a posterior to anterior direction starting from the sphenoid ostium to a point opposite anterior end of the middle turbinate ( approximately up to one half of septum)."
219630390|NCT00717912|OTHER|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
219630391|NCT00717912|OTHER|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
219630392|NCT00717912|OTHER|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
219630393|NCT02007681|BEHAVIORAL|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
219630394|NCT05284786|DEVICE|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
219630395|NCT01051596|DRUG|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
219630396|NCT01051596|DRUG|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
219630397|NCT03809663|DRUG|Tezepelumab|Solution for injection
219630398|NCT03809663|OTHER|Placebo|Placebo solution for injection
219630399|NCT01999816|BEHAVIORAL|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
219630400|NCT04711590|OTHER|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
219630401|NCT01411150|DRUG|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
219630402|NCT03641014|OTHER|pH Effect on blastocyst formation|to investigate which pH is suitable for each stage of embryo development
219630403|NCT03451890|DRUG|E2730|oral capsule
219630404|NCT03451890|DRUG|Placebo|oral capsule
219630405|NCT03725306|DEVICE|Librata|Hyperthermic endomyometrial treatment via Librata catheter and balloon device
219630406|NCT03248999|DIAGNOSTIC_TEST|rectal swab|stool samples by rectal swab
219630407|NCT02514499|OTHER|Questionnaires|
219630408|NCT05658770|BEHAVIORAL|5 days/ week|"The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1.~The exercises to be carried out in phase 1 are:~Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.~Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.~Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO."
219630409|NCT05658770|BEHAVIORAL|3 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
219630410|NCT05658770|BEHAVIORAL|2 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
219630411|NCT05772949|DEVICE|Experimental group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study."
218937594|NCT00796978|PROCEDURE|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
218937595|NCT02059096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
219630412|NCT05772949|DEVICE|Wait-list control group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids."
219630413|NCT05358054|OTHER|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
219630414|NCT05358054|OTHER|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
219630415|NCT00216580|DRUG|Risperidone, long-acting injectable|
219630416|NCT04911777|DRUG|Pentarlandir™ UPPTA|Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
219630417|NCT04911777|DRUG|Placebo|The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
219630418|NCT02485262|DRUG|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
219630419|NCT00510211|DRUG|olanzapine|
219630420|NCT03387371|DEVICE|Ultrasonics|ultrasonic scalers
219630421|NCT03387371|DEVICE|Gracey Curettes|Spesific gracey curettes
219630422|NCT03387371|DEVICE|Er:YAG Laser|2940 nm wavelenght Er:YAG laser
219630423|NCT01818271|BEHAVIORAL|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
219630424|NCT01818271|BEHAVIORAL|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program."
219630425|NCT04529629|OTHER|surgery or drug|pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
219630426|NCT05951829|OTHER|Action Observation Therapy|Action Observation Therapy Mirror Therapy
219630427|NCT00294866|DRUG|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
219630428|NCT05860192|DEVICE|Virtual Reality|Use of this virtual reality headset to deliver a single mindfulness session
219630429|NCT05860192|OTHER|application for mindfulness|Application used to realize mindfulness in virtual reality
219630430|NCT03903991|OTHER|Temperature recording|Tympanic and oesophageal temperatures will be recorded during the procedure
219630431|NCT04633967|DRUG|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
219630432|NCT05333601|BEHAVIORAL|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
218937596|NCT04655937|OTHER|Acceptance and Commitment Therapy|9 x two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
219630433|NCT03563963|DRUG|Ropivacaine 0.5% Injectable Solution|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
219630434|NCT03563963|DRUG|Lidocaine 2% Preservative-Free Injectable Solution|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
219630435|NCT03563963|OTHER|Air|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
219630436|NCT03627663|BEHAVIORAL|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
219630437|NCT05131217|OTHER|Acute bout of Continuous Moderate Intensity Exercise|In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.
218937597|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
219630438|NCT05131217|OTHER|Acute bout of High Intensity Interval Training|In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.
219630439|NCT05131217|OTHER|Control|In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
219630440|NCT03023917|PROCEDURE|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
219630441|NCT03023917|PROCEDURE|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
219630442|NCT06574932|BEHAVIORAL|Multi-Strategic Approach|The experimental group will be engaged in multi-strategy approaches including screen time and sanity challenges, weekly screen-free days, screen time reduction goals, screen time tracking, structured daily routines, parental involvement, and monitoring, family media plans, alternative engagements, and promotion of offline social interactions.
219630443|NCT03538288|DEVICE|rTMS|rTMS will be applied at 10 Hz to the DLPFC
219630444|NCT00749073|DEVICE|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
219630445|NCT01701440|DEVICE|Biofusionary Bebe|
219630446|NCT03307772|DIETARY_SUPPLEMENT|Probiotics|
219630447|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics|
219630448|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|
219630449|NCT03307772|DIETARY_SUPPLEMENT|Placebo|
219630450|NCT06344195|DRUG|Valacyclovir 500 mg|Valtrex 2g immediate dose followed by 500mg 2 times daily for 3 days along with the analgesic (SOS, if needed) for 6 days
219630451|NCT06344195|DRUG|Naproxen Sodium 550mg|550mg (as needed, SOS) for 6 days
219630452|NCT04994210|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
219630453|NCT04994210|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
219630454|NCT03189095|BEHAVIORAL|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
219630455|NCT05206006|OTHER|routine care|The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
218937598|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
219630456|NCT05206006|OTHER|Computerized Decision support app (CDSA)|Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice. This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
219630457|NCT02409199|DRUG|Docetaxel|
219630458|NCT02409199|DRUG|apatinib|
219630459|NCT02391415|BIOLOGICAL|VPM1002|Tuberculosis vaccine
219630460|NCT02391415|BIOLOGICAL|BCG|commercially available live vaccine BCG
219630461|NCT02391415|BIOLOGICAL|VPM1002(Hyg+)|Tuberculosis vaccine
219630462|NCT06378593|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
219630463|NCT04262089|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
219630464|NCT06236789|DRUG|Ifosfamide/mesna|Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
219630465|NCT01599260|OTHER|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
219630466|NCT05245526|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
219630467|NCT01075165|OTHER|silicone spray|application of silicone spray to predefined area qd 12 weeks
219630468|NCT01075165|OTHER|saline spray|application of saline spray to predefined area qd 12 weeks
219630469|NCT05831501|PROCEDURE|Trans abdominis plane block|Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
218937599|NCT03253341|BEHAVIORAL|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
218937600|NCT03253341|BEHAVIORAL|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
218937601|NCT04282746|DRUG|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
218937602|NCT01056302|PROCEDURE|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
218937603|NCT05324761|DRUG|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
218937604|NCT05324761|DRUG|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
218937605|NCT02558647|BEHAVIORAL|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
218937606|NCT02558647|BEHAVIORAL|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
218937607|NCT05380479|DRUG|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
218937608|NCT05380479|DRUG|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
218937609|NCT06704633|DRUG|Sacubitril / Valsartan Oral Tablet|A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
218937610|NCT03547024|DRUG|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
218937611|NCT03547024|DRUG|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
218937612|NCT03547024|DRUG|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
219630470|NCT01215591|PROCEDURE|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
219630471|NCT03153904|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
219630472|NCT03153904|OTHER|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
219630473|NCT00255463|DRUG|Anastrazole|
219630474|NCT00255463|DRUG|Gefitinib|
219630475|NCT00205023|PROCEDURE|Sonohysterography|SHG during surgery for endometrial cancer.
219630476|NCT06090825|OTHER|Observational study|Observational study
219630477|NCT05208463|BEHAVIORAL|Joint Academy|Digitally deliverd exercise and education first line treatment for hip and knee osteoarthritis
219630478|NCT03754335|PROCEDURE|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
219630479|NCT04351919|DRUG|Hydroxychloroquine|400mg per day during 10 days
219630480|NCT04351919|DRUG|Azithromycin|500 mg per day during 5 days
219630481|NCT05844293|DRUG|FXI-GalNAc-siRNA|FXI-GalNAc-siRNA solution for injection
219630482|NCT05844293|OTHER|Placebo|Saline
219630483|NCT05914493|OTHER|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
219630484|NCT01255345|OTHER|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
219630485|NCT05792033|OTHER|Prospective registry|Prospective registry of patients with primary diagnosis of T1 urinary bladder cancer
219630486|NCT05300711|PROCEDURE|Bilateral salpingectomy|Removal of both fallopian tubes.
219630487|NCT05300711|PROCEDURE|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
219630488|NCT00584493|DRUG|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
219630489|NCT02053766|DRUG|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
219630490|NCT02053766|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
219630491|NCT02053766|DRUG|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
219630492|NCT04411901|DRUG|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
218937613|NCT03547024|DRUG|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
218937614|NCT05861349|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
219630493|NCT02356939|DEVICE|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
219630494|NCT02356939|PROCEDURE|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
219630495|NCT03510039|BEHAVIORAL|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
219630496|NCT03510039|OTHER|Usual care|"Group Before : usual care by nurses"
219630497|NCT03569930|DRUG|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
218937615|NCT05861349|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
218937616|NCT03338127|DIAGNOSTIC_TEST|renal function test|2 ml blood sample to be investigated for renal function test
218937617|NCT01698034|BEHAVIORAL|Volunteering|Weekly volunteering with elementary school children in after school programs
219630498|NCT03569930|DRUG|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
219630499|NCT03569930|BEHAVIORAL|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
219630500|NCT04027530|DRUG|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
219630501|NCT03955822|OTHER|Phone survey|Phone Survey in order to evaluate adverse effect of the permanently implanted birth control device for women (Essure) will be proposed to wmen Treated between 2002 and 2017 with Essure.
219630502|NCT05990712|DIETARY_SUPPLEMENT|Omega-3|Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
219630503|NCT05990712|DRUG|Trehalose|Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
219630504|NCT05990712|DRUG|Zocular Eyelid System Treatment|A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
219630505|NCT05990712|OTHER|Blephadex cleansing eyelid wipes|Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
219630506|NCT05497310|DRUG|Arsenic trioxide|Patients will receive ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
219630507|NCT05497310|DRUG|all-trans retinoic acid|Patients will receive ATRA 25/mg/m2/day for 28 continuous days without interruption.
219630508|NCT04409223|DRUG|Famitinib capsules|Oral KIT/PDGFRA kinase inhibitor
219630509|NCT04409223|DRUG|Sunitinib Capsules|Oral receptor tyrosine kinase (RTK) inhibitor
219630510|NCT05737381|OTHER|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
219630511|NCT01343810|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
219630512|NCT01343810|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
219630513|NCT02414243|OTHER|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
219630514|NCT02414243|OTHER|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
218937618|NCT00771953|DRUG|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
218937619|NCT00771953|DRUG|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
218937620|NCT00771953|DRUG|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
218937621|NCT06153303|BEHAVIORAL|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
218937622|NCT05520554|OTHER|Development of the Telerehabilitation Satisfaction Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
218937623|NCT01254708|DRUG|Ambisome ®|liposomal amphotericin B
219630515|NCT00113581|DRUG|EMD 72000 (matuzumab) + ECX|
219630516|NCT01489436|PROCEDURE|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
219630517|NCT01489436|PROCEDURE|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
219630518|NCT05817149|PROCEDURE|Blood samples|Blood samples
219630519|NCT04714879|OTHER|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
219630520|NCT04714879|OTHER|Device: no stimulation|sham stimulation
219630521|NCT01609296|DEVICE|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
219630522|NCT02928653|DIETARY_SUPPLEMENT|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
219630523|NCT06325735|DIAGNOSTIC_TEST|None intervention|None intervention, observational study
219630524|NCT00628212|DRUG|Teneligliptin 10mg|
219630525|NCT00628212|DRUG|Teneligliptin 20 mg|
219630526|NCT00628212|DRUG|Teneligliptin 40 mg|
219630527|NCT00628212|DRUG|Placebo|
219630528|NCT01961739|DRUG|2% lidocaine|Topical application, twice per day for 15 consecutive days
219630529|NCT01961739|DRUG|placebo|topical application, twice per day for 15 consecutive days
219630530|NCT06001710|DEVICE|Needleless jet injector|Device consist of injection pen, ampule and activator.
219630531|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
219630532|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
219630533|NCT02511938|OTHER|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
218937624|NCT01254708|DRUG|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
218937625|NCT05211583|DIAGNOSTIC_TEST|Serum progesterone levels|In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
219630534|NCT02511938|OTHER|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
219630535|NCT03792399|BEHAVIORAL|feedback counseling|Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
219630536|NCT03390972|DRUG|Placebo|Placebo (NaCl 0.9%) TCI infusion
219630537|NCT03390972|DRUG|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
219630538|NCT05282992|DIETARY_SUPPLEMENT|Native type II collagen|1 capsule/day
218937626|NCT06116513|DEVICE|S53P4 bioactive glass granules|During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
219630539|NCT05282992|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
219630540|NCT02523183|DRUG|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
219630541|NCT06307132|OTHER|Aximus capsules（test）|Aximus capsules test preparation
219630542|NCT06307132|DRUG|Aximus capsules（reference）|Aximus capsules reference preparation
219630543|NCT00080756|BIOLOGICAL|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
219630544|NCT00080756|DRUG|deslorelin|1mg/100ul per day as a nasal spray
219630545|NCT00080756|DRUG|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
219048500|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
219630546|NCT00080756|PROCEDURE|therapeutic conventional surgery|Undergo risk reduction mastectomy
219630547|NCT00080756|OTHER|active surveillance|Undergo continued surveillance
219630548|NCT00080756|PROCEDURE|quality-of-life assessment|Ancillary studies
219630549|NCT00080756|OTHER|laboratory biomarker analysis|Correlative studies
219630550|NCT00546377|BIOLOGICAL|filgrastim|
219630551|NCT00546377|BIOLOGICAL|pegfilgrastim|
219630552|NCT00546377|BIOLOGICAL|rituximab|
219630553|NCT00546377|BIOLOGICAL|sargramostim|
219630554|NCT00546377|DRUG|cyclophosphamide|
219630555|NCT00546377|DRUG|mitoxantrone hydrochloride|
219630556|NCT00546377|DRUG|pentostatin|
219630557|NCT00546377|GENETIC|fluorescence in situ hybridization|
219630558|NCT00546377|GENETIC|gene rearrangement analysis|
219630559|NCT00546377|GENETIC|polymerase chain reaction|
219630560|NCT00546377|GENETIC|protein expression analysis|
219630561|NCT00546377|OTHER|flow cytometry|
219630562|NCT00546377|PROCEDURE|biopsy|
219630563|NCT03442608|PROCEDURE|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
219630564|NCT03020992|DRUG|Certolizumab Pegol|"* pharmaceutical form: solution for infusion in prefilled syringe~* concentration: 200 mg/mL~* route of administration: subcutaneous"
219630565|NCT02915731|DIETARY_SUPPLEMENT|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
219630566|NCT01006122|DRUG|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
219630567|NCT01006122|DRUG|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
219630568|NCT02949596|BEHAVIORAL|Quality of life and quality of sexual life questionnaires|
219630569|NCT05519917|DRUG|Afatinib|Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
219630570|NCT01501539|PROCEDURE|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
219630571|NCT01501539|PROCEDURE|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
219630572|NCT04439942|OTHER|cardiac magnetic resonance imaging (MRI)|Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.
219630573|NCT05008432|DIAGNOSTIC_TEST|Home sleep apnea testing|Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
219630574|NCT02094352|DRUG|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
219630575|NCT02094352|DRUG|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
219630576|NCT02094352|DRUG|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
219630577|NCT02094352|DRUG|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
219630578|NCT04168723|DRUG|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
219630579|NCT04168723|DRUG|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
219630580|NCT04168723|DRUG|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
219630581|NCT04168723|DRUG|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
219630582|NCT02312323|DEVICE|Definitive 65 HPT contact lenses|
219630583|NCT02312323|DEVICE|Definitive 65 contact lenses|
219630584|NCT06574646|DEVICE|LAL+|LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.
219630585|NCT06574646|DEVICE|Clareon Vivity Toric IOL|Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
219630586|NCT03474185|BEHAVIORAL|Taking Charge of your Heart Health patient education classes|"Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management"
219630587|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
219630588|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
219630589|NCT02932774|DRUG|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
219630590|NCT02932774|DRUG|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
219630591|NCT02932774|OTHER|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
219630592|NCT03365635|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]|Same as described in arm description
219630593|NCT05475990|DRUG|Hydroxyethyl starch|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219630594|NCT05475990|DRUG|Crystalloid|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219630595|NCT05748743|PROCEDURE|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
219630596|NCT03028207|PROCEDURE|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
219630597|NCT03028207|OTHER|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
219630598|NCT05801705|DRUG|Aromatase inhibitor|Aromatase inhibitor includes Arimidex, Aromasin, Femara.
219630599|NCT05801705|PROCEDURE|ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin
219630600|NCT05801705|DRUG|Tamoxifen|tamoxifen,10mg, bid
219630601|NCT05801705|DRUG|toremifene|toremifene, 60 mg, qd
219630602|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
219630603|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
219630604|NCT00968747|BEHAVIORAL|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
219630605|NCT00968747|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
219630606|NCT01268670|DRUG|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
219630607|NCT01268670|DRUG|Oxycodone|Subjects will receive topical LET and oral oxycodone.
219630608|NCT01268670|OTHER|Placebo|Subjects will receive topical LET and oral placebo.
219630609|NCT04279431|DEVICE|EEG Recording|EEG recording acquired on BrainScope One device.
219630610|NCT04279431|OTHER|Neurocognitive Tests|Cognitive performance tests performed on BrainScope One device.
219630611|NCT04279431|OTHER|Clinician Evaluation|Clinician evaluation performed as part of standard of care at the clinical site.
219630612|NCT04279431|OTHER|22-item CSI|Self assessed 22-item Concussion Symptom Inventory (CSI).
219048501|NCT06459518|OTHER|Bowen Therapy along with conventional therapy|"Bowen Technique Group Assignment: Participants will be assigned to undergo targeted Bowen Technique therapy sessions.~Session Details: The therapy sessions will include:~* Gentle, rolling-type maneuvers~* Specific placements of fingers and thumbs~* Focus on muscles, tendons, and ligaments associated with neck pain Therapeutic Pauses: There will be intentional pauses between sets of moves to allow the body time to respond to the therapeutic stimulation.~Conventional Therapy: Hot pack, TENS, Passive Stretching 2 times a week for 4 weeks"
219048502|NCT06459518|OTHER|Muscle Energy Technique with Conventional Therapy|"MET Session Structure: Participants will engage in Muscle Energy Technique (MET) sessions that focus on:~* Isometric muscle contractions, where muscles are contracted without changing length.~* Therapist-guided, controlled contractions against specific resistance.~* Relaxation Periods: Each contraction session will be followed by a period of relaxation to allow muscles to recover and respond to the therapy.~conventional therapy: Hot pack, TENS, Passive Stretching 2times a week for 4 weeks."
219048503|NCT04408820|DRUG|Roxadustat|Oral
219630613|NCT02699346|DEVICE|HS-1000 recording|
219630614|NCT01791894|DRUG|arsenic trioxide|Given IV
219630615|NCT00660517|DRUG|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
219630616|NCT00660517|DRUG|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
219630617|NCT00660517|DRUG|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
219630618|NCT00660517|DRUG|placebo|placebo nasal spray one spray per nostril two times a day
219630619|NCT02268916|BEHAVIORAL|Counseling|OT led counseling
219630620|NCT02268916|BEHAVIORAL|Usual education|At the end of the study, will receive OT-led counseling
219630621|NCT02291042|DRUG|B+O Suppository|
219630622|NCT02418949|DRUG|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
219630623|NCT02418949|DRUG|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
219630624|NCT02418949|OTHER|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
219630625|NCT02418949|OTHER|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
219630626|NCT03926117|BIOLOGICAL|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
219630627|NCT03146806|DRUG|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
219630628|NCT03972748|DRUG|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
219630629|NCT01265862|PROCEDURE|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
219630630|NCT01265862|PROCEDURE|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
219630631|NCT03678610|OTHER|Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A|Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
219630632|NCT05953935|DEVICE|OKTO|Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz
219630633|NCT05953935|DEVICE|Standard clinical procedures|standard clinical procedures
219048504|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
219206548|NCT05923255|PROCEDURE|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
219630634|NCT03918824|OTHER|Data extraction from medical files|Data extraction from medical files
219630635|NCT00140387|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
219630636|NCT05513482|DIAGNOSTIC_TEST|Tissue Doppler Imaging|With tissue Doppler ultrasonography (TDI), the maximum contraction rate of the diaphragm, maximum relaxation rate, and integral against time will be examined.
219630637|NCT05513482|DIAGNOSTIC_TEST|M Mode Imaging|Diaphragm displacement during inspiration and expiration will be measured with M mode imaging
219630638|NCT02705365|OTHER|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
219630639|NCT02705365|OTHER|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
219630640|NCT04733066|DRUG|Teduglutide|Intervention group consists of patients, who receive teduglutide within routine medical care
219630641|NCT01159041|BEHAVIORAL|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
219630642|NCT01159041|BEHAVIORAL|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
219630643|NCT03138213|PROCEDURE|Total laparoscopic pancreaticoduodenectomy|Total laparoscopic pancreaticoduodenectomy
219630644|NCT03138213|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
219630645|NCT04526288|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
219630646|NCT04526288|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219630647|NCT05399784|BEHAVIORAL|Early postpartum visit|The early postpartum visit will be an in-person visit with a medical provider at 14-21 days postpartum.
219630648|NCT05399784|BEHAVIORAL|Standard postpartum visit|The standard postpartum visit will occur at 35 to 56 days postpartum.
219630649|NCT01315938|DRUG|Abatacept Active Treatment|Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
219630650|NCT01315938|DRUG|Abatacept Delayed-Onset Treatment|Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
219630651|NCT00605631|DEVICE|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
219630652|NCT00086138|DRUG|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
219630653|NCT00086138|DRUG|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
219630654|NCT03690843|OTHER|Test Battery|All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
219630655|NCT05079542|PROCEDURE|Timepoint of Implant placement of Bonelevel tapered implants|Implant surgery on different time points
219630656|NCT05079542|COMBINATION_PRODUCT|Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia|Tooth restoration with a certain material
219630657|NCT02407613|DEVICE|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
219630658|NCT02684097|DRUG|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
219630659|NCT02684097|DRUG|Placebo|Matching placebo given every two weeks for 24 weeks
219630660|NCT06111378|DIETARY_SUPPLEMENT|fish oil|fish oil
219630661|NCT06111378|DIETARY_SUPPLEMENT|linseed oil|linseed oil
219630662|NCT06111378|DIETARY_SUPPLEMENT|walnut oil|walnut oil
219630663|NCT00460811|DRUG|Linaclotide Acetate|Oral, once daily
219630664|NCT00460811|DRUG|Matching placebo|Oral, once daily
219630665|NCT05468905|OTHER|None of intervention|None of intervention
219630666|NCT01902745|BEHAVIORAL|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
219630667|NCT01373502|DEVICE|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
219630668|NCT01373502|DEVICE|Taxus Liberté Stent|Taxus Liberté Coronary Stent
219630669|NCT02748356|DRUG|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
219630670|NCT01602861|DRUG|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
219630671|NCT01602861|DRUG|placebo|
219630672|NCT06575231|DIAGNOSTIC_TEST|in-vitro|responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.
219630673|NCT00996125|BIOLOGICAL|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
219630674|NCT00996125|OTHER|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
219630675|NCT01888055|DEVICE|transcranial direct current stimulation|
219630676|NCT01888055|DEVICE|sham stimulation|
219630677|NCT00922064|PROCEDURE|ECT|ECT series consisting of 6 to 14 ECTs
219630678|NCT03545685|OTHER|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
219630679|NCT03279757|DRUG|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630680|NCT03279757|DRUG|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630681|NCT03279757|DRUG|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630682|NCT03279757|DRUG|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630683|NCT03279757|DRUG|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630684|NCT03279757|DRUG|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630685|NCT03279757|DEVICE|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
219630686|NCT00664573|BIOLOGICAL|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
219630687|NCT04521179|DRUG|KN026 combination|30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
219630688|NCT06128902|OTHER|tele health|home based exercise and telenursing
219630689|NCT06237569|DRUG|Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia|"A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth."
219630690|NCT03546491|DRUG|Preventive Gel|0.4% Stannous Fluoride
218937627|NCT04174404|OTHER|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
219630691|NCT03546491|DRUG|Marketed Control|0.243% Sodium Fluoride
219630692|NCT05031195|OTHER|1st tertile, 2nd tertile, 3rd tertile|Patients will be divided into 3 groups according to the preoperative NLR value.
219630693|NCT02284061|OTHER|physical activities adapted to children|
219630694|NCT04106804|DRUG|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
219630695|NCT06576154|DRUG|Cefazolin 1000 MG|"* Medication: Cefazolin~* Dosage: 1 gram~* Administration Timing: A single dose will be administered preoperatively."
219630696|NCT04902638|PROCEDURE|Intraarticular injection of dexamethasone|Intraarticular injection of dexamethasone
219630697|NCT00237458|DRUG|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
219630698|NCT05161052|DEVICE|Corvis ST (dynamic Scheimpflug technology)|"* Measurement of corneal stiffness parameters { Deformation Amlitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~* Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth"
219630699|NCT00054431|DRUG|imatinib mesylate|Given orally
219630700|NCT00054431|DRUG|decitabine|Given IV
219630701|NCT00054431|OTHER|laboratory biomarker analysis|Correlative studies
219630702|NCT00952068|DRUG|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
219630703|NCT05183165|OTHER|Patients with Wilson's disease declaring pregnancy,|Blood and urine biological assessment Dietary assessment
219630704|NCT05334524|OTHER|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises"
219630705|NCT05334524|OTHER|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension"
219630706|NCT04331067|DRUG|Paclitaxel|-Given standard of care
219630707|NCT04331067|DRUG|Carboplatin|-Given standard of care
219630708|NCT04331067|BIOLOGICAL|Nivolumab|-Given standard of care
219630709|NCT04331067|BIOLOGICAL|Cabiralizumab|-Will be provided by Bristol Myers Squibb
219630710|NCT04331067|PROCEDURE|Tumor biopsy|-Baseline, week 5, surgery, and at time of relapse (optional)
219630711|NCT04331067|PROCEDURE|Bone marrow|-Time of port placement (baseline), time of surgery, and time of recurrence (optional)
219630712|NCT04331067|PROCEDURE|Blood draw|-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
219630713|NCT05870371|BEHAVIORAL|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
219630714|NCT05870371|BEHAVIORAL|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
219630715|NCT05870371|BEHAVIORAL|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
219630716|NCT03027141|BEHAVIORAL|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
219630717|NCT00020787|BIOLOGICAL|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
219630718|NCT00020787|DRUG|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
219630719|NCT00020787|DRUG|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
219630720|NCT02147834|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
219630721|NCT02147834|DRUG|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
219630722|NCT04918017|DRUG|Treatment based on subtypes: Esomeprazole or Itopride|"Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)"
219630723|NCT04918017|DRUG|Treatment with proton pump inhibitor regardless of subtype: Esomeprazole|Esomeprazole 40mg OD
219630724|NCT06320184|DIAGNOSTIC_TEST|Artificial Intelligence risk model|Combining blood-based biomarkers, radiologic parameters, clinical features, and AI tools to create a robust model to predict lung cancer risk.
219630725|NCT05315037|OTHER|Resistance Training|"Bench press: Exercise performed with participant lying supine with hands in prone position. Barbell is lowered vertically from fully extended elbow position to sternum, then returned to starting position. Barbell will be weighted with plates dependent on their strength and workout demands.~Deadlift: Consists of gripping bar while in a squat position. Extension of ankles, knees, and hips while gripping the bar brings the weight up until joints are locked completing the exercise concentric portion. The eccentric lowering of the weight follows and consists of flexion of joints.~Seated overhead press machine: This multi-joint exercise, deltoid and trapezius are the prime movers and triceps are secondary movers, with hands on the grips and a position allowing back and buttocks to be completely supported. They push against a load vertically until glenohumeral joint fully extends, then load is returned to starting position and process continues until all repetitions desired are achieved"
219630726|NCT01873846|DEVICE|Silicone Hydrogel Contact Lens|
219630727|NCT00046137|DRUG|teriparatide|
219630728|NCT00046137|DRUG|raloxifene|
219630729|NCT00046137|DRUG|placebo|
219630730|NCT04524793|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
219630731|NCT04524793|OTHER|Physical examinations|GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
219630732|NCT04486937|DRUG|S410914 tablet|S410914 tablet
219630733|NCT04227431|OTHER|Insulin degludec|Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
219630734|NCT00239265|DRUG|Tamuslosin|
219630735|NCT02056210|DRUG|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
219630736|NCT04712162|OTHER|Other|Compare time to awakening and quality of recovery after general anesthesia between two groups.
219630737|NCT03721796|OTHER|Audio recording of initial consultation and debriefing interviews.|Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
219630738|NCT01657721|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
219630739|NCT02627664|OTHER|observational study|natural history of non dopaminergic signs
219630740|NCT06055517|RADIATION|Pulsed low dose-rate radiotherapy (pLDRT)|Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
219630741|NCT02203721|DEVICE|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
219630742|NCT02203721|DEVICE|TECNIS Monofocal IOL, Model ZCB00|
219206549|NCT05923255|PROCEDURE|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
219206550|NCT06297967|DRUG|Acetic Acid|The intervention treatment will consist of cleaning with water and soap, application of a compress soaked in 2% dilution of glacial acetic acid (CAS 64-19-7) for 15 minutes, irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the ulcer bed. Depending on the amount of exudate, more or less alginate will be added as a secondary dressing. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
219630743|NCT02830503|PROCEDURE|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
219630744|NCT02189005|DIETARY_SUPPLEMENT|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
219630745|NCT02189005|DIETARY_SUPPLEMENT|Placebo|
219630746|NCT00243126|BEHAVIORAL|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
219630747|NCT04408170|DIAGNOSTIC_TEST|Point-of-care test for SARS-CoV-2|Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
219630748|NCT06589219|DRUG|CMR316|CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
219630749|NCT06589219|DRUG|Placebo|Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
219630750|NCT02972879|PROCEDURE|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
218937628|NCT04174404|OTHER|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
218937629|NCT05680441|OTHER|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
218937630|NCT00006117|DRUG|gemcitabine hydrochloride|
218937631|NCT00006117|DRUG|oxaliplatin|
218937632|NCT05787548|BEHAVIORAL|Contact information|Information on how to contact Geisinger if the patient needs care
218937633|NCT05787548|BEHAVIORAL|Urgent care map|A map of the patient's nearest Geisinger urgent care location, with information about urgent care
218937634|NCT05787548|BEHAVIORAL|Self-triage chart|A chart demonstrating what to do in response to several common conditions where the patient might be compelled to visit the ED
219630751|NCT02972879|PROCEDURE|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~* LASER 904nm~* P: 1.5W/cm²~* 30mV/cm²~* Area 2 cm²~* 1 Joule por ponto ( in the A1 pulley)"
218937635|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
218937636|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
219630752|NCT02972879|PROCEDURE|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
219630753|NCT02972879|PROCEDURE|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
219630754|NCT02441738|PROCEDURE|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
219630755|NCT02441738|PROCEDURE|Catheter Ablation|The procedure will be performed following standard of care guidelines.
219630756|NCT04749485|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
219630757|NCT05002231|DRUG|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
219630758|NCT05002231|DRUG|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
219630759|NCT05002231|DRUG|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
219630760|NCT05024188|DRUG|Antibiotics|Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
218937637|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of breast milk|Daily oral consumption of breast milk
218937638|NCT05048524|DRUG|S-1, leucovorin, oxaliplatin and gemcitabine|"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day"
219048505|NCT01740596|DEVICE|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
219048506|NCT03670810|DRUG|Lasmiditan|Administered orally.
219630761|NCT05024188|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
219630762|NCT05024188|OTHER|Cellules Pills|7 days of cellules placebo pills.
219630763|NCT05024188|OTHER|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
219630764|NCT04178460|DRUG|Niraparib combined with MGD013|"The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)."
219630765|NCT02191774|PROCEDURE|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
219630766|NCT05392205|DIAGNOSTIC_TEST|18F-FDG|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
219630767|NCT05284318|DRUG|Antibiotics treatment|After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.
219630768|NCT06576700|BIOLOGICAL|Grape Seed Extracts|2 capsules/day for 8 weeks
219630769|NCT02353546|BEHAVIORAL|CALM|
219630770|NCT03355131|BEHAVIORAL|Adapted NASA's Mission X program|8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
219630771|NCT02568293|OTHER|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
219630772|NCT02568293|OTHER|Saline|Saline is used as a control.
219630773|NCT00327873|OTHER|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
219630774|NCT00327873|OTHER|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
219630775|NCT05979012|BEHAVIORAL|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
219630776|NCT05979012|BEHAVIORAL|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
219630777|NCT03692234|DIETARY_SUPPLEMENT|125 mg L-homoarginine|capsules for oral supplementation
219630778|NCT03692234|OTHER|placebo|capsules for oral supplementation
218937639|NCT03364270|DRUG|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
219048507|NCT03670810|DRUG|Placebo|Administered orally.
219048508|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
219630779|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; low dose
219630780|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; middle dose
219630781|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; high dose
219630782|NCT06672172|DRUG|HRS-7535 placebo tablet|HRS-7535 placebo tablet
219630783|NCT01368601|PROCEDURE|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
219630784|NCT05006287|DRUG|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
219630785|NCT05006287|DRUG|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
219630786|NCT06399380|OTHER|Manual mobilization of the carpal bones.|The mobilization of the carpal bones will be done in the following way: patient in supine position, with elbow flexion of approximately 90º, so that the forearm and wrist are almost vertical. The examiner positions the thumb on the dorsal aspect of the scaphoid and trapezius, and the index finger on the dorsal aspect of the piriformis and hamate. Next, a manual ventral force is applied until the resistance of the wrist tissues is felt for 30 seconds. The technique will be repeated 5 times, with a 10-second rest between each application.
219630787|NCT06399380|OTHER|Placebo|A technique will be performed that will have no effect; the hands will be placed at a point that will not be the carpal tunnel, such as the forearm.
219630788|NCT02514720|OTHER|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
219630789|NCT00708461|BEHAVIORAL|weight gain prevention|"1. Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~2. Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~3. Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~4. Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
219630790|NCT00580151|DRUG|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
219630791|NCT00580151|DRUG|placebo|1 dose every 6 hours
219630792|NCT01786161|DRUG|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
219630793|NCT01786161|DRUG|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
219630794|NCT00408642|BEHAVIORAL|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
219630795|NCT00408642|BEHAVIORAL|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
218937640|NCT01051154|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
218937641|NCT01051154|DIETARY_SUPPLEMENT|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
218937642|NCT04404400|DRUG|Investigational products administration|"Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
218937643|NCT04404400|DRUG|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
218937644|NCT05819255|OTHER|Non-Interventional|"This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs.~The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology."
218937645|NCT05246514|DRUG|Trastuzumab deruxtecan|administered as an IV infusion
218937646|NCT02910986|BEHAVIORAL|Written educational brochure|Written educational brochure about breast density
218937647|NCT02910986|BEHAVIORAL|Promotora interaction|Promotora education about breast density
218937648|NCT05667454|DRUG|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
218937649|NCT05667454|DRUG|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
219630796|NCT04865263|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
219630797|NCT00745342|BEHAVIORAL|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
219630798|NCT00363233|DRUG|flax lignans|
219630799|NCT01796392|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
219630800|NCT01796392|OTHER|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
219630801|NCT05182060|BEHAVIORAL|Transition Intervention|"We will implement a bundle of care transition safety strategies with the assistance of home care coordinators at the study site and corresponding home health provider teams (nurses, rehabilitation therapists).~Home care coordinators will approach patients at the study site being referred for home health and provide resources to assist them with preparing for their transition home. These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list. The study team will contact the older adult and caregiver by telephone within 48 hours of the home visit to confirm eligibility, explain the study, obtain consent for participation, and ask them to complete the the Hospital-to-Home Health Transition Quality Index (H3TQ) over the phone. Home health providers in the home will also complete the H3TQ."
219630802|NCT04000139|DRUG|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
219630803|NCT04000139|DRUG|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
219630804|NCT04912908|OTHER|Images taken during knee replacement surgery|Images taken during knee replacement surgery will be compared to CT-Scan that was performed before surgery
219630805|NCT01225250|DEVICE|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
219630806|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
219630807|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
219630808|NCT02134431|DEVICE|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
219630809|NCT03517540|DRUG|Tropifexor (LJN452)|Comparison with monotherapy and different combination doses
219630810|NCT03517540|DRUG|Cenicriviroc (CVC)|Comparison with monotherapy and different combination doses
219630811|NCT02473627|DRUG|DS-1971a|200mg tablet
219630812|NCT02473627|DRUG|midazolam hydrochloride|2.5mg oromucosal liquid
219630813|NCT02473627|DRUG|Omeprazole|20mg gastro-resistant capsule
218937650|NCT00122551|PROCEDURE|Intermittent antiretroviral therapy|
218937651|NCT06338137|DEVICE|Holmium Yag laser|Use two laser energy low and high to reach the optimal setting for stone dusting
218937652|NCT00261261|BEHAVIORAL|ADVANCE|
218937653|NCT00261261|DRUG|Midazolam|
218937654|NCT00261261|PROCEDURE|Parental presence|
218937655|NCT01765257|DRUG|AZILECT®|
218937656|NCT01765257|DRUG|Placebo|
219630814|NCT02473627|DRUG|Pioglitazone hydrochloride|15mg tablet
218937657|NCT04607317|BEHAVIORAL|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
218937658|NCT04607317|BEHAVIORAL|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
219048509|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
219048510|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
219630815|NCT02473627|DRUG|Buproprion|150mg Prolonged release tablet
219630816|NCT02473627|DRUG|Tolbutamide|500mg tablet
219630817|NCT04691362|DRUG|Tranexamic Acid Oral Product|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
219630818|NCT04691362|DRUG|Tranexamic acid injection|Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
218937659|NCT04607317|BEHAVIORAL|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
219048511|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
219630819|NCT01842230|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)"
219630820|NCT01842230|DRUG|Telmisartan 80mg and S-amlodipine 5mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)"
219630821|NCT01779440|BEHAVIORAL|Electronic Decision Support System|
219630822|NCT02248844|BIOLOGICAL|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
219630823|NCT01545167|GENETIC|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
219630824|NCT01205269|DRUG|AZD8683, 50 mcg|Dry powder for inhalation, single dose
219630825|NCT01205269|DRUG|Placebo|Dry powder for inhalation, single dose
219630826|NCT01205269|DRUG|AZD8683, 200 mcg|Dry powder for inhalation, single dose
219630827|NCT02192463|DRUG|NVP ER 300 mg (KCR 20%) Medium Release|
218937660|NCT00158418|PROCEDURE|Cemented Humeral Stem|
219048512|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
219048513|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
219048514|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
219630828|NCT02192463|DRUG|NVP ER 300 mg (KCR 25%) Medium Release|
219630829|NCT02192463|DRUG|NVP ER 300 mg (KCR 30%) Slow Release|
219630830|NCT02192463|DRUG|NVP ER 400 mg (KCR 25%) Medium Release|
219630831|NCT02192463|DRUG|NVP ER 300 mg (KCR 40%) Slow Release|
219630832|NCT02192463|DRUG|NVP ER 300 mg (ECR 20%) Fast Release|
219630833|NCT02192463|DRUG|NVP ER 400 mg (KCR 20%) Medium Release|
219630834|NCT02192463|DRUG|NVP ER 400 mg (KCR 30%) Slow Release|
219630835|NCT02192463|DRUG|NVP ER 400 mg (KCR 40%) Slow Release|
219630836|NCT02192463|DRUG|NVP ER 400 mg (ECR 20%) Fast Release|
219630837|NCT02192463|DRUG|Nevirapine immediate release (IR) 200 mg|
219048515|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
219630838|NCT04131660|DEVICE|AVAPS-AE mode during NIV|NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) \* Size (m) \* 23).
219630839|NCT04131660|DEVICE|S/T mode during NIV|"NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support."
219630840|NCT01408303|DRUG|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
219630841|NCT01408303|DRUG|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
219630842|NCT01408303|DRUG|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
219630843|NCT04667923|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
219630844|NCT04667923|DIAGNOSTIC_TEST|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
219630845|NCT04667923|DIAGNOSTIC_TEST|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
218937661|NCT00158418|PROCEDURE|Uncemented Humeral Stem|
218937662|NCT02252796|RADIATION|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
218937663|NCT02252796|DRUG|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
219630846|NCT04667923|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension
219630847|NCT04667923|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
219630848|NCT04667923|DIAGNOSTIC_TEST|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
219630849|NCT01207687|BIOLOGICAL|bevacizumab|Given IV
219630850|NCT01207687|OTHER|laboratory biomarker analysis|Correlative studies
219630851|NCT01207687|PROCEDURE|quality-of-life assessment|Ancillary studies
219630852|NCT02280837|OTHER|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
219630853|NCT05258305|DEVICE|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
219630854|NCT00765505|BEHAVIORAL|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
219630855|NCT00765505|BEHAVIORAL|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
219630856|NCT00006105|DRUG|amifostine trihydrate|
219630857|NCT00006105|DRUG|cisplatin|
219630858|NCT00006105|DRUG|gemcitabine hydrochloride|
218937664|NCT02252796|DRUG|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
218937665|NCT02252796|RADIATION|Image-guided IMRT|Given during chemo-radiation phase
219048516|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
219630859|NCT00006105|PROCEDURE|adjuvant therapy|
219630860|NCT02685176|DEVICE|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
219630861|NCT02685176|OTHER|No heat|No active heating provided post cooling
219630862|NCT00333827|DRUG|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
219630863|NCT00333827|PROCEDURE|cell|stem cell
219630864|NCT01129427|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
219630865|NCT01129427|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
219630866|NCT01129427|DRUG|Pantoprazole|"Pharmaceutical form: delayed-release tablet~Route of administration: oral"
219630867|NCT03776266|PROCEDURE|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
219630868|NCT04368546|DRUG|Sunitinib|
219630869|NCT04491825|DIAGNOSTIC_TEST|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
219630870|NCT01486446|DRUG|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
219630871|NCT01486446|DRUG|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
219630872|NCT05066425|DIETARY_SUPPLEMENT|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
219630873|NCT05066425|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
219630874|NCT01801865|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|
218937666|NCT04856839|DIAGNOSTIC_TEST|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
218937667|NCT03314922|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
218937668|NCT04551872|BEHAVIORAL|Digital weight loss intervention|Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
218937669|NCT02290678|BEHAVIORAL|Adventure-based Programming|
218937670|NCT04335019|OTHER|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
219048517|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
219048518|NCT05620823|DRUG|Placebo|Oral; Tablet
219630875|NCT00523848|DRUG|bortezomib|IV
219630876|NCT00523848|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
219630877|NCT00523848|DRUG|thalidomide|Oral
219630878|NCT03856125|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency - 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week"
219630879|NCT03856125|OTHER|Sham PENS plus exercise|"The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~* Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~\- Administration - One per week"
219630880|NCT05063422|DRUG|polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose|3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
219630881|NCT01938092|DRUG|Diazepam|
219630882|NCT01938092|DRUG|Placebo|
219630883|NCT01367886|DRUG|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
219630884|NCT04939831|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
219630885|NCT04939831|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
219630886|NCT02536092|DEVICE|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
219630887|NCT01006304|DRUG|JNJ-39439335, Placebo|
219630888|NCT05237167|PROCEDURE|Shoulder reduction|This is standard of care and only measure as a time component outcome in the study
219630889|NCT01884246|BEHAVIORAL|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
219630890|NCT01884246|OTHER|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
219630891|NCT06370169|DEVICE|Endoscopic ultrasound placement of Coil and glue|The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue
219630892|NCT02174692|OTHER|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets"
219630893|NCT00985504|DRUG|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
219630894|NCT00985504|DRUG|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
219630895|NCT03729167|PROCEDURE|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
219630896|NCT00574704|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
219630897|NCT00574704|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
219630898|NCT00574704|DRUG|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
219630899|NCT00574704|DRUG|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
219630900|NCT03711786|OTHER|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
219630901|NCT03711786|OTHER|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
219630902|NCT00371410|PROCEDURE|vitrectomy|
219630903|NCT00371410|DRUG|intravitreal triamcinolone acetonide|
219630904|NCT00371410|PROCEDURE|macular focal laser photocoagulation|
219630905|NCT04993716|OTHER|observational|Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
219630906|NCT02972619|OTHER|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
219630907|NCT00762814|DEVICE|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
219630908|NCT00004208|DRUG|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
219630909|NCT00004208|BEHAVIORAL|Supportive care|Patients randomized to this arm will be treated as outpatients.
219630910|NCT01057316|DEVICE|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
219630911|NCT01057316|DEVICE|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
219630912|NCT01057316|DEVICE|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
219630913|NCT01982617|OTHER|Motivational Interviewing|
219630914|NCT01982617|OTHER|Psychoeducation|
219630915|NCT02688543|PROCEDURE|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
218937671|NCT06045702|PROCEDURE|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
219630916|NCT02688543|RADIATION|radiofrequency ablation|
219630917|NCT02688543|DEVICE|ultrasound|
219630918|NCT02566213|OTHER|Parabolic flight|
219630919|NCT02566213|OTHER|Motor skills measurements|"* the kinematics measurements of the right hand with a motion analysis system;~* the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~* the measurement of position of the moved object with an inductive position encoder."
218937672|NCT04380519|DRUG|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
218937673|NCT04380519|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
219630920|NCT02553018|DRUG|Methotrexate|
219630921|NCT03836690|BIOLOGICAL|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
219630922|NCT00466245|DRUG|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
219630923|NCT00466245|DRUG|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
219630924|NCT00715273|DRUG|Atorvastatin|10 to 80 mg of atorvastatin each day
219630925|NCT00715273|DRUG|Niacin|2000 mg of niacin each day
219630926|NCT00715273|DRUG|Colesevelam|3.8 g of colesevelam each day
218937674|NCT04380519|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
218937675|NCT06259370|BEHAVIORAL|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
218937676|NCT01727024|DRUG|Tiotropium|Tiotropium via Respimat® device once a day
218937677|NCT01727024|DRUG|Indacaterol|Indacaterol via Breezhaler® device once a day
219630927|NCT00715273|DRUG|Placebo Niacin|Placebo niacin each day
219630928|NCT00715273|DRUG|Placebo Colesevelam|Placebo colesevelam each day
219630929|NCT03379727|DRUG|Midostaurin|Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
219630930|NCT03379727|DRUG|Cytarabine|Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion
219630931|NCT03379727|DRUG|anthracycline ((daunorubicin or idarubicin): Induction Phase only|daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
219630932|NCT06270576|DRUG|Lipopolysaccharides|LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.
219630933|NCT02481089|OTHER|validation group|
219630934|NCT03726827|OTHER|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
219630935|NCT00170027|DEVICE|Magnetocardiograph|
219630936|NCT00712192|PROCEDURE|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
219630937|NCT01837264|DEVICE|Magellan®|
219630938|NCT00651833|DRUG|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
219630939|NCT02367651|DRUG|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
219630940|NCT02367651|DRUG|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
219630941|NCT01076673|BIOLOGICAL|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
219630942|NCT01076673|DRUG|Hyaluronic Acid|Hyaluronic acid injections
219630943|NCT00697905|DRUG|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
219630944|NCT00697905|DRUG|Carboplatin|Intravenous following Gemcitabine infusion on day 1
219630945|NCT00697905|DRUG|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
219630946|NCT00697905|DRUG|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
219630947|NCT02972905|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
219630948|NCT02972905|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
219630949|NCT04356547|DEVICE|Fiberoptic intubation with laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
219630950|NCT04356547|DEVICE|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
219630951|NCT04031846|DRUG|Rotarix™|Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
219630952|NCT04031846|DRUG|Infanrix™ hexa|Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
219630953|NCT04031846|DRUG|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
219630954|NCT04031846|DRUG|Prevenar 13™|13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
219630955|NCT05695612|OTHER|Novaloc Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
219630956|NCT05695612|OTHER|Locator Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
219630957|NCT02229760|DRUG|Tipranavir capsules|
219630958|NCT02229760|DRUG|Ritonavir capsules|
219630959|NCT00012376|DRUG|bryostatin 1|Given IV
219630960|NCT00012376|BIOLOGICAL|sargramostim|Given subcutaneously
219630961|NCT00012376|OTHER|laboratory biomarker analysis|Correlative studies
219630962|NCT00012376|OTHER|pharmacological study|Correlative studies
219630963|NCT04104503|DRUG|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
219630964|NCT04104503|DRUG|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
219630965|NCT04104503|DRUG|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
219630966|NCT04632082|BEHAVIORAL|Telepsychoeducation with personalized videos|1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation
219630967|NCT04632082|BEHAVIORAL|Telepsychoeducation without personalized videos|1 session with a psychologist focused on reassurance and aspects of the outbreak
219630968|NCT04723927|OTHER|Older adults|The data for motor function and gait pattern analysis was obtained.
219630969|NCT02180529|DRUG|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
219630970|NCT02180529|DRUG|Placebo|
219630971|NCT03313557|DRUG|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
219630972|NCT00786760|OTHER|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
219630973|NCT00786760|OTHER|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
219630974|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
219630975|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
219630976|NCT00772876|DRUG|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
219630977|NCT00042159|DEVICE|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
219630978|NCT06491173|DEVICE|InfraScanner 2500™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
219630979|NCT04007120|DRUG|RVT-1601|Inhaled RVT-1601 administered once daily over two days
219630980|NCT06868654|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
219630981|NCT06868654|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
219630982|NCT06868654|DRUG|Bortezomib|Proteasome Inhibitor
219630983|NCT06868654|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
219630984|NCT06521697|DRUG|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline
219630985|NCT06521697|DEVICE|Minimal flow sevoflurane|Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)
219630986|NCT04138498|DRUG|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
219630987|NCT04138498|DRUG|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
219630988|NCT04138498|DRUG|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
219630989|NCT04138498|DRUG|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
219630990|NCT05306691|DRUG|Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
218937678|NCT05228691|OTHER|Evaluation and Education|A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
218937679|NCT04095429|BEHAVIORAL|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
218937680|NCT04095429|BEHAVIORAL|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
218937681|NCT01613898|BIOLOGICAL|Blood tests|Blood tests
218937682|NCT00349050|DEVICE|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
218937683|NCT00349050|PROCEDURE|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
218937684|NCT00250289|DEVICE|a mucosal sticker with herbal formula|
218937685|NCT01580215|DEVICE|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
218937686|NCT00830297|DRUG|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
218937687|NCT00830297|DRUG|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
219630991|NCT06928493|OTHER|oral examination|"The pre-examination behaviors and attitudes of the children included in the study were measured by an independent dentist (Ş.Y.İ) using the Frankl Behavior Rating Scale (FS). Following this, the children were randomly divided into two groups PCC and CCC . The oral examination of PCC group was done in an isolated dental environment with white overalls, an FFP3 mask, and a visor. The oral examination of CCC group was done in normal dental environment with a standard white coat and surgical mask.After that, patients were asked to draw themselves or the pediatric dentist who performed the examination. A child psychiatrist (B.A.S.) and a pediatric dentist (R.D) with an internationally valid Child Drawing Analysis training certificate evaluated the children's drawings independently."
219630992|NCT01777282|DRUG|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
219630993|NCT01777282|DRUG|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
219630994|NCT01777282|DRUG|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
219630995|NCT01777282|DRUG|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
219630996|NCT01777282|DRUG|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
219630997|NCT01777282|DRUG|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
219630998|NCT03990467|BIOLOGICAL|Plasma dosage of amikacin, piperacillin and tazobactam|Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
219630999|NCT03953976|RADIATION|Intensity modulated radiation therapy (IMRT)|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
219631000|NCT06914934|DIETARY_SUPPLEMENT|High-dose resveratrol 500 mg/day|High-dose resveratrol 500 mg/day (preferably a high-bioavailability formulation, e.g., trans-resveratrol with piperine or liposomal).
219631001|NCT06914934|OTHER|Placebo|Placebo capsules, identical in appearance and schedule.
219631002|NCT06313398|BIOLOGICAL|Biotin-labeled red blood cells|Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)
219631003|NCT01131455|BIOLOGICAL|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
219631004|NCT00764660|DRUG|SCH 900435|tablets
219631005|NCT00764660|DRUG|Placebo|tablets
219631006|NCT06919055|OTHER|PCG auditory stimulation|PCG auditory stimulation during mental stress
219631007|NCT06919055|OTHER|MHR stimulation|MHR auditory stimulation during mental stress
219631008|NCT06919055|OTHER|Control-no treatment|no stimulation during mental stress
219631009|NCT06922123|BEHAVIORAL|Tactile stimulation|Patients will undergo a resting-state EEG and fNIRS recording, followed by the administration of the SECONDs scale. Tactile stimulation will then be performed on eight areas of the body (internal and external forearms, palms and backs of the hands on both sides) using six different stimuli categorized as pleasant, neutral, or unpleasant. Stimuli will be applied manually in randomized blocks. EEG and fNIRS data will be recorded before, during, and after stimulation. Behavioural responses will be evaluated through video analysis by independent raters. The session will last approximately 90 minutes.
219631010|NCT06922123|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a non-invasive neurophysiological monitoring device used to record the brain's electrical activity (EEG) through frontal electrodes. In this study, SedLine is employed to measure resting-state and stimulus-evoked cortical responses in patients with disorders of consciousness (DoC), in combination with functional near-infrared spectroscopy (fNIRS). The EEG signals are used to assess changes in neural activity before, during, and after tactile stimulation with various affective valences (pleasant, neutral, unpleasant). This combined multimodal approach enhances the understanding of sensory processing and cortical reactivity in patients with impaired consciousness.
219631011|NCT05354869|DEVICE|Urostym|electric pelvic floor muscle stimulator
219631012|NCT05354869|BEHAVIORAL|Standard care|patient education on home exercises and stretching
219631013|NCT05963633|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
219631014|NCT05963633|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
219631015|NCT04089579|BIOLOGICAL|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
219048519|NCT05619705|BEHAVIORAL|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
219631016|NCT04089579|OTHER|Placebo Infusion|Placebo comparative infusion
219631017|NCT05992337|DIAGNOSTIC_TEST|Blood sampling|Blood sample collection for mRNA determination
219631018|NCT05992337|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for detection of ventricular dysfunction
219631019|NCT05992337|DIAGNOSTIC_TEST|Cardio MRI|MRI for early detection of myocardial impairment caused by chemotherapy
219631020|NCT05992337|DIAGNOSTIC_TEST|24-hours monitoring of ECG|Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
219631021|NCT05992337|DIAGNOSTIC_TEST|24 hours monitoring of BP|Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
219631022|NCT06931704|DRUG|Elranatamab|"Each injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible.~Each participant may receive study intervention for a maximum of 24 cycles."
219631023|NCT06931704|DRUG|Daratumumab|1800 mg will be administrated every cycles
219048520|NCT05619705|BEHAVIORAL|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
219048521|NCT04648046|DRUG|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
219631024|NCT06931704|DRUG|Lenalidomide|Daily administarted during 21 days, at each cycle
219631025|NCT06940076|DRUG|gayo arabica coffee skin extract cream|Assessment of glagou scale, skin analyzer, corneometer, and tewameter was done before and after the treatment . The subject will receive directions on how to use the cream before the study starts. The cream was used 2 times daily (7.40 AM and 1.00 PM) for 8 weeks.
219631026|NCT06940765|DEVICE|GID SVF-2 Device System|The GID SVF-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue.
219631027|NCT06941168|PROCEDURE|Robotic Total Gastrectomy and Laparoscopic Total Gastrectomy|"RTG:Robotic total gastrectomy with D2 lymphadenectomy performed using the Da Vinci Surgical System, following the Japanese Gastric Cancer Treatment Guidelines.~LTG:Laparoscopic total gastrectomy with D2 lymphadenectomy performed by experienced surgeons following standardized procedures, based on the Japanese Gastric Cancer Treatment Guidelines."
219631028|NCT06941207|BEHAVIORAL|virtual reality video viewing group|The caregivers, the first group in the experimental group, will be shown a total of 8 sessions of virtual reality-based videos (nature, forest walks and city tours, etc.) for an average of 30 minutes, twice a week for 4 weeks.
219631029|NCT06941207|BEHAVIORAL|benson relaxation exercise group|The second group in the experimental group, the caregivers, will have a total of 8 sessions of Benson relaxation exercises for 20-25 minutes, twice a week for 4 weeks.
219631030|NCT06940583|OTHER|VR|Participants will view a relaxing virtual environment (e.g. nature landscapes, lightly animated themes) for 5 minutes prior to the colposcopy procedure and during the colposcopy wearing a VR headset.
219631031|NCT06940583|OTHER|Podcast|Participants will listen to a podcast of relaxing or informative content for 5 minutes before and 5 minutes during colposcopy. The content will be selected according to individual preferences (e.g. storytelling, humorous content or educational content).
219631032|NCT06941285|OTHER|Data collection|Data collection
219631033|NCT06940661|DRUG|Obinutuzumab|"Patient will receive 1000 milligrams intravenous (IV) infusion on week 0, week 2, week 24 and week 26.~Patients will receive the same standardized glucocorticoid tapering schedule (prescribe as a standard of care management and considered as auxiliary medicinal product)~Premedication for obinutuzumab infusion related reactions (considered as auxiliary medicinal products) :~* 100 mg methylpredinisolone~* 1000 mg paracetamol~* 5 mg dexchlorpheniramine"
219631034|NCT06940687|BEHAVIORAL|Pre-recorded Music Session|A pre-recorded concert session
219631035|NCT06940687|BEHAVIORAL|Live Music Session|A 45-minute live music performance
219631036|NCT02511418|DRUG|Simvastatin|
219631037|NCT06940947|PROCEDURE|eFTR|endoscopic full thickness resection
219631038|NCT06940947|PROCEDURE|Surgery|standard-of-care surgery
219631039|NCT06939998|PROCEDURE|FOBIET|"an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.~After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them."
219631040|NCT06939998|PROCEDURE|CFOBI|a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
219631041|NCT05311059|PROCEDURE|Laparoscopic ovarian drilling|Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
219631042|NCT03103152|DRUG|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
219631043|NCT03103152|DRUG|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).
219631044|NCT03103152|DRUG|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
219631045|NCT03103152|DRUG|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.
219631046|NCT03103152|DRUG|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
219631047|NCT03103152|DRUG|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
219048522|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
219631048|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
219631049|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
219048523|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
219048524|NCT04648046|OTHER|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
219631050|NCT06364891|OTHER|VMMC NEXUS Digital application|A handheld digital application which supports segmentation of potential VMMC Clients
219631051|NCT06139575|DRUG|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
219631052|NCT06194240|BEHAVIORAL|DiabACT|E-program proposed to diabetic patients based on ACT therapy.
219631053|NCT04385082|DRUG|Active Cannabis|Smoked cannabis with THC
219631054|NCT04385082|DRUG|Placebo Cannabis|Placebo smoked cannabis (no THC)
219631055|NCT03158064|DRUG|Durvalumab|1500 mg by IV
219631056|NCT03158064|DRUG|Tremelimumab|"75 mg by IV~\*300mg"
219048525|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
219048526|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
219631057|NCT04978168|BEHAVIORAL|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
219631058|NCT04978168|BEHAVIORAL|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 6 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
219631059|NCT04978168|BEHAVIORAL|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
219631060|NCT05301114|BEHAVIORAL|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
219631061|NCT05940168|BEHAVIORAL|I-Navigator ACT|The intervention is an internet-delivered ten module Acceptance and Commitment Therapy treatment program for stressed and distressed parents of children with disabilities. The contents of the program is mostly text based, but also includes videos, mindfulness exercises and written exercises, as well as homework between modules.
219631062|NCT05940168|BEHAVIORAL|Navigator ACT group|The intervention is a five session Acceptance and Commitment Therapy group treatment for stressed and distressed parents of children with disabilities. All five sessions have different themes and are held by two group leaders. Sessions are around two and a half hours long. Homework is given between sessions.
219631063|NCT06794086|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy (SBRT) is a highly precise form of external beam radiation therapy used to treat tumors in various parts of the body. Enrolled patients will initiate SBRT treatment within 2 weeks after the first course of chemotherapy. Intensity-modulated radiation therapy (IMRT) will be used, with the gross tumor volume (GTV) receiving a dose of 8-12 Gy in 5 fractions, resulting in a total dose of 40-60 Gy. The biologically effective dose (BED) is equivalent to 72-132 Gy. The treatment will be administered from Monday to Friday.
219631064|NCT06794086|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody is a type of immunotherapy drug designed to treat various cancers by targeting the programmed death receptor-1 (PD-1) pathway.The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1. Participants will be considered eligible only if they have completed four or more cycles of PD-1 monoclonal antibody treatment both before and after SBRT.
219631065|NCT06794086|DRUG|Chemotherapy|Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy. During chemotherapy or chemoradiotherapy, optimal supportive care will be provided.
219631066|NCT05976997|DRUG|Duvelisib, Chidamide|Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
219631067|NCT01608802|OTHER|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
219631068|NCT01608802|OTHER|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
219631069|NCT06067906|OTHER|Hypocaloric diet|Hypocaloric diet
219631070|NCT06067906|OTHER|Dissociated diet|Dissociated diet
219631071|NCT05676606|DEVICE|Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.|Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
219631072|NCT01068678|DRUG|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
219631073|NCT01068678|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219631074|NCT00840567|PROCEDURE|Skin biopsy|
219631075|NCT00840567|PROCEDURE|Blood draw & sample|
219631076|NCT00004828|DRUG|liothyronine I 131|
219048527|NCT06350513|OTHER|Animation movie, story book|"Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused."
219206551|NCT06297967|DRUG|Prontosan|The treatment includes ulcer cleansing with water and soap, application of ProntosanⓇ compress for 15 minutes, subsequent irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the wound bed. More or less alginate will be applied depending on the amount of exudate. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
219631077|NCT04080388|DIAGNOSTIC_TEST|Lung Impedance Device|The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
219631078|NCT04080388|DRUG|Anti-congestive treatment|Continuation of in-hospital anti-congestive treatment
219631079|NCT04170738|DRUG|Adderall|3 weeks of Adderall
219631080|NCT01808781|OTHER|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
219631081|NCT01808781|OTHER|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
219631082|NCT01534039|DEVICE|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
219631083|NCT01534039|DEVICE|FormaFlex|Hollister skin barrier for ostomy patients
219631084|NCT02901210|PROCEDURE|Modified delorme procedure|
219631085|NCT02514798|OTHER|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
219631086|NCT02514798|OTHER|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
219631087|NCT02514798|OTHER|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
219631088|NCT02514798|DEVICE|High-flow humidified nasal oxygen delivery system|
219631089|NCT02514798|DEVICE|CPAP (Positive Control)|
219631090|NCT06167837|DRUG|Metoclopramide Sulfone|Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD
219631091|NCT06167837|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml IV 30-60 minutes before EGD
219631092|NCT00579579|BEHAVIORAL|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
219631093|NCT03441802|OTHER|High quality extra virgin olive oil|Cases and controls were given 40 g/die high quality extra virgin olive oil
219631094|NCT03236961|DRUG|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
219631095|NCT03236961|DRUG|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
219631096|NCT03055338|DRUG|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
219631097|NCT03055338|DRUG|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
219631098|NCT03055338|DRUG|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
219631099|NCT03055338|DRUG|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
219631100|NCT05601115|PROCEDURE|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
218937688|NCT05149235|OTHER|early mobilization group|Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).
218937689|NCT05149235|DEVICE|physio adventure|The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.
219631101|NCT05601115|PROCEDURE|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
219631102|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
219631103|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
219631104|NCT00975611|DRUG|Placebo|tablets BID, for 4 weeks
219631105|NCT04173780|DRUG|Atropine 0.01%|1 drop per day in both eyes for 1 year
219631106|NCT04173780|DRUG|Placebo|1 drop per day in both eyes for 1 year
219631107|NCT03058705|DRUG|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
219631108|NCT03058705|DEVICE|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
219631109|NCT02056015|DRUG|[68Ga]MLN6907|IV Administration of \[68Ga\]MLN6907 on Day 1
219631110|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
219631111|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
219631112|NCT02608983|DIETARY_SUPPLEMENT|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
219631113|NCT00294372|DRUG|BILR 355 BS|
219631114|NCT00294372|DRUG|Placebo|
218937690|NCT05149235|OTHER|placebo|Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
218937691|NCT00610454|DRUG|Levetiracetam|
218937692|NCT00486291|DRUG|VI-0521|phentermine 15mg/topiramate 100mg
218937693|NCT00486291|DRUG|Placebo|matched placebo
218937694|NCT02497742|OTHER|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
219631115|NCT05234736|DRUG|CBL-514|CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)
219631116|NCT03530592|DEVICE|Seated Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
218937695|NCT04135287|DRUG|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
219631117|NCT06570148|OTHER|semi-directed interview or focus group|Participants will be recruited using purposive sampling with maximum variation. If they meet the inclusion criteria, they will be invited to take part in an online interview or focus group, lasting between 40 minutes and 1.5 hours. During the Zoom interview or focus group, they will be asked to answer several pre-defined open-ended questions based on an interview grid co-constructed with the co-investigators, including a patient partner and parent partners. They will be asked to answer closed socio-demographic questions at the end of the interview or focus group. The Zoom meeting will be recorded (audio) and then transcribed into anonymized written form.
219631118|NCT06661226|OTHER|Accleration drills|14 participants will be in experimental group A, giving them acceleration drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
219048528|NCT05263947|DRUG|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
219048529|NCT06048913|DRUG|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of nimotuzumab is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
219631119|NCT06661226|OTHER|Change in Direction Drills|14 participants will be in experimental group B, giving them Change in direction drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
219631120|NCT00787982|DEVICE|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
219631121|NCT01625819|BEHAVIORAL|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
219631122|NCT01625819|BEHAVIORAL|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
219631123|NCT01625819|BEHAVIORAL|Health Education|32 1-hour bi-weekly group sessions of health education
219631124|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
219631125|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
219631126|NCT01682226|BIOLOGICAL|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
219631127|NCT05709028|DRUG|Fosfomycin|"Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~* Children ≥ 6 months to \<1 year old will be administered 30ml (=1g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥12 and \<18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose."
219631128|NCT05709028|DRUG|Standard of care antibiotics|Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
219048530|NCT06048913|DRUG|S-1|Oral chemotherapy with the S-1 regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral S-1 course from Monday to Friday is synchronized with radiation therapy.
219206552|NCT06315166|DEVICE|triLift/Legend Pro+ Fractional RF System|The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.
219206553|NCT03218306|DEVICE|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
219206554|NCT03218306|OTHER|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
219206555|NCT02726386|DRUG|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
219631129|NCT00915408|DRUG|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
219631130|NCT00915408|DRUG|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
219631131|NCT00915408|DRUG|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
219631132|NCT06960681|DIAGNOSTIC_TEST|External validity of the SFA score|Testing the external validity of the SFA score for the detection of in adult emergency departments
219631133|NCT03458832|DIAGNOSTIC_TEST|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
219631134|NCT03458832|DEVICE|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
219631135|NCT05007431|OTHER|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
219631136|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
219631137|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
219631138|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
219631139|NCT00655408|DRUG|elemental iron|Iron supplementation.
219631140|NCT02128854|BEHAVIORAL|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
219631141|NCT02037178|OTHER|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
219631142|NCT02037178|OTHER|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
219631143|NCT02151851|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
219631144|NCT02151851|DRUG|Methotrexate|"* Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral"
219206556|NCT00704769|DRUG|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
219206557|NCT04008186|DRUG|Omaveloxolone|50 mg capsules
219206558|NCT04008186|DRUG|Midazolam oral solution|2 mg/mL oral solution
219206559|NCT04008186|DRUG|Repaglinide 1 MG|1 mg tablet
219631145|NCT02151851|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringes~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
219631146|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
219631147|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
219631148|NCT02159053|BIOLOGICAL|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
219631149|NCT02143505|DRUG|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
219631150|NCT01663961|DRUG|YM178 OCAS|oral
219631151|NCT01663961|DRUG|Digoxin|oral
219631152|NCT06035367|DEVICE|Non-invasive continuous monitoring device to record photoacoustic signal|"Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal."
219631153|NCT04105296|DEVICE|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
219631154|NCT00229996|DRUG|Oral Contraceptive|
219631155|NCT00229996|DRUG|Depot-Leuprolide/Norethindrone|
219631156|NCT05598450|DEVICE|rTMS and MEG for auditory hallucinations via self controlled clinical trials|"a 4 weeks, weekly 345（23min\*3times\*5day） minutes, 1Hz, 100%RMT-rTMS protocol~Detail precedure:~Before intervention, each patient was scheduled to collect three magnetoencephalogram data sessions. Apply MEG technology to calculate possible locations and determine three intervention targets. Pseudo stimulation in the first week, 5-day intervention, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. Evaluate the scale after the first week of pseudo stimulation. Week 2-4 real stimulation, intervention 5 days a week, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. After the end of the fourth week, evaluate the scale. And follow-up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th days after the intervention."
219631157|NCT03824795|DRUG|MGB-BP-3|MGB-BP-3
219206560|NCT04008186|DRUG|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
219206561|NCT04008186|DRUG|Rosuvastatin|10 mg tablet
219206562|NCT04008186|DRUG|Digoxin tablet|0.25 mg tablet
219206563|NCT04008186|DRUG|Gemfibrozil Tablets|600 mg tablet
219631158|NCT01135381|BEHAVIORAL|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
219631159|NCT03032042|DRUG|Azithromycin|
219631160|NCT03032042|DRUG|Albendazole|
219631161|NCT03032042|DRUG|Delayed treatment|Albendazole+Azithromycin
219631162|NCT04625881|DIETARY_SUPPLEMENT|Apple derived fiber|This is a combination of soluble and insoluble fiber
219631163|NCT06329349|OTHER|Exercise|12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)
219631164|NCT06329349|OTHER|Combined Exercise + Diet|12 weeks, 25% caloric reduction, based on PMID: 37069434
219631165|NCT05174832|DRUG|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
219206564|NCT04008186|DRUG|Itraconazole capsule|100 mg capsule
219206565|NCT04008186|DRUG|Verapamil Pill|120 mg tablet
219206566|NCT04955431|BEHAVIORAL|Sleep Restriction|Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
219206567|NCT04955431|BEHAVIORAL|Normal Sleep|Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
219206568|NCT03918252|DRUG|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
219631166|NCT05174832|DRUG|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
219631167|NCT05174832|DRUG|Pembrolizumab|200 mg IV every 21 days
219631168|NCT05174832|DRUG|Olaparib|300 mg PO BID
219631169|NCT01540487|DRUG|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
219631170|NCT01540487|DRUG|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
219631171|NCT05997069|OTHER|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|"Posterior-anterior vertebral mobilizations of the lumbar spine are achieved by applying a force on to a spinous process in a posteroanterior direction (Back to front).~Prone press-up exercise is started in the prone position (lying on stomach) on a flat surface. Participant keeps hands underneath the shoulders then press up his or her upper body while trying to keep the hips on the floor."
219631172|NCT05997069|OTHER|Conventional physiotherapy|Traditionally used physiotherapy for the treatment of nonspecific low back pain (thermotherapy and general stretching exercises)
219631173|NCT05163457|OTHER|Data collection|frailty evaluation
219631174|NCT05025644|DRUG|Pre and post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~* Post-CPB provocation test at the DBT-pd achieved preoperatively."
219631175|NCT05025644|DRUG|Post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB no intervention will be required.~* Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is \>16 mmHg."
219631176|NCT04981808|DEVICE|Telemonitoring|Telemonitoring of CGM and insulin pen data
219631177|NCT06573450|OTHER|questionnaire survey|subjects fill out questionnaires
219631178|NCT06137859|BEHAVIORAL|Weekly-based functional fitness training|Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
219631179|NCT06137859|BEHAVIORAL|Mastering Physical Literacy Class|"A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us."
219631180|NCT06137859|BEHAVIORAL|Daily based reflective writing|At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
219631181|NCT06137859|BEHAVIORAL|Buddy Peers Support Group|Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
219631182|NCT01256164|DEVICE|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
219631183|NCT01256164|DEVICE|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
219631184|NCT05422378|DRUG|STP705|STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
219631185|NCT01356303|DRUG|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
219631186|NCT03503370|DRUG|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
219631187|NCT03503370|DRUG|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
219631188|NCT04232917|DRUG|2LPAPI®|Treatment
219631189|NCT04232917|DRUG|Placebo|Placebo
219631190|NCT04353544|OTHER|delayed cord clamping|delayed cord clamping
219631191|NCT06684249|PROCEDURE|Nerve Block Injections|This intervention involves the administration of supratrochlear and greater occipital nerve block injections. The injections consist of a mixture of local anesthetics and corticosteroids, designed to reduce the frequency and severity of migraine episodes. The procedure will be repeated every 12 weeks for a total duration of 6 months to assess the long-term efficacy and safety in managing chronic migraine.
219631192|NCT06684249|DRUG|Botulinum Toxin A|Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.
219631193|NCT03773172|DRUG|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
219631194|NCT03773172|DRUG|Placebo|The placebo will mimic the active treatment.
219631195|NCT06482788|DRUG|Adebrelimab (anti-PD-L1) + XELOX|"Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks)."
219631196|NCT04292262|OTHER|Observational|Observational
219631197|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation|"Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.~Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used."
219631198|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.
219631199|NCT06581341|DEVICE|Percutaneous Tibial Nerve Stimulation|Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
219631200|NCT05154175|DEVICE|Ottobock helmet|Patients treated in current practice
219631201|NCT02974686|DRUG|Everolimus|
219631202|NCT02974686|DRUG|Mycophenolic Acid|
219631203|NCT02862665|DRUG|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
219631204|NCT02862665|DRUG|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
219631205|NCT01977755|DRUG|danegaptide|
219631206|NCT01977755|DRUG|Placebo|
219631207|NCT06377813|OTHER|Mode-Kinetic Chain Exercise With Core Stability Exercises|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
219048531|NCT06048913|RADIATION|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
219048532|NCT04198116|DRUG|Varenicline|Varenicline 2mg/day
219631208|NCT06377813|OTHER|Mode-Kinetic Chain Exercise|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
219631209|NCT02114424|DEVICE|Positional vibrator belt|Belt with vibarator to avoid sleep supine
219631210|NCT06139471|BEHAVIORAL|Virtual Reality-Enhanced Gagne's Instructional Model|Virtual Reality-Enhanced Gagne's Instructional Model
219048533|NCT04198116|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
219631211|NCT04228679|DEVICE|Erbium laser|Erbium laser device
219048534|NCT06013618|DRUG|Naxitamab monotherapy|Naxitamab is administered on days 1, 3, and 5
219048535|NCT06013618|DRUG|GM-CSF|Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
219048536|NCT06013618|DRUG|Irinotecan|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
219048537|NCT06013618|DRUG|Temozolomide|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
219631212|NCT04228679|DEVICE|Sham Laser|Sham laser device
219631213|NCT03367182|DRUG|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
219631214|NCT03367182|DRUG|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
219631215|NCT03367182|DRUG|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
219631216|NCT03367182|DRUG|Bevacizumab|Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
219631217|NCT00298272|BIOLOGICAL|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
219631218|NCT00298272|DRUG|Placebo|Participants will receive placebo on Day 1 and Day 15
219631219|NCT00298272|DRUG|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
219631220|NCT00298272|DRUG|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
219631221|NCT00298272|DRUG|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
219631222|NCT00298272|DRUG|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
219631223|NCT00298272|DIETARY_SUPPLEMENT|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
219631224|NCT03522012|DRUG|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
219631225|NCT02503124|BEHAVIORAL|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
219631226|NCT02503124|DEVICE|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
219631227|NCT02503124|OTHER|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
219631228|NCT02503124|OTHER|Informative meeting|A short sleep hygiene consultation.
219048538|NCT06013618|DRUG|Naxitamab in combination therapy|Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
219048539|NCT06013618|DRUG|GM-CSF with combination regimen|GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
219048540|NCT06013618|DRUG|Sintilimab|Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
219206569|NCT03918252|DRUG|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
219631229|NCT02503124|DRUG|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
219631230|NCT04168112|DRUG|Dextenza|Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
219631231|NCT04168112|DRUG|Prednisolone Acetate|post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
219631232|NCT01598064|DIETARY_SUPPLEMENT|GK#10|GK#10, 1 pack tid
219631233|NCT01598064|DRUG|Placebo|Placebo 1 pack tid po
219631234|NCT05587595|OTHER|questionnaires & data collection|questionnaires
219631235|NCT04939233|DEVICE|Exoskeleton glove|A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
219631236|NCT03379766|DEVICE|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
219631237|NCT03379766|DEVICE|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
219631238|NCT02984865|DRUG|Sulfentanyl|
219631239|NCT02984865|DRUG|Nalbuphine|
219631240|NCT02984865|DRUG|flubiprofen axetil|
219631241|NCT02984865|PROCEDURE|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
219631242|NCT02225639|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
219048541|NCT02909556|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
219048542|NCT05098353|DRUG|Quetiapine|25-75 mg per day for 6 weeks
219048543|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
219048544|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
219048545|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219048546|NCT03523117|DRUG|Ferric carboxymaltose|Intravenous iron
219048547|NCT03523117|DRUG|Ferrous Sulfate|oral iron therapy
219206570|NCT03990233|DRUG|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
219631243|NCT02225639|DRUG|Placebo|Oral placebo capsule
219631244|NCT02225639|DRUG|PRC-063 35 mg|Oral 35 mg capsule - active
219631245|NCT02225639|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
219631246|NCT02225639|DRUG|PRC-063 55 mg|Oral 55 mg capsule - active
219631247|NCT02225639|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
219631248|NCT02225639|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
219631249|NCT02225639|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
219631250|NCT02575326|OTHER|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
219631251|NCT02575326|BEHAVIORAL|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
219631252|NCT01636193|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
219631253|NCT01636193|OTHER|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
219631254|NCT04860973|DEVICE|Weighted blankets|Weighted blankets given to patient for 7 days/nights
219631255|NCT01063426|DRUG|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
219631256|NCT01063426|DRUG|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
219631257|NCT05061940|DIAGNOSTIC_TEST|Tumor Profiling|Testing TAA and HPV expression. HLA typing.
219631258|NCT05042661|DEVICE|acupuncture-like transcutaneous electrical nerve stimulation|The intervention group performed Al-TENS therapy 3 times a week for at least 20 minutes each time for 4 consecutive weeks. The second, fourth, and eighth week after the intervention.
219631259|NCT04682717|DEVICE|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to \<30% of baseline or absolute MAP \<60 mmHg. MAP \<55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR \<50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
219631260|NCT04431349|DRUG|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
219631261|NCT04431349|DRUG|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
219631262|NCT00044070|DRUG|YM872 (zonampanel)|
218937696|NCT04220476|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
219048548|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
219631263|NCT04159857|PROCEDURE|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
219631264|NCT01344824|BIOLOGICAL|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
219631265|NCT01344824|DRUG|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
219631266|NCT01344824|DRUG|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
219631267|NCT01344824|DRUG|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
219631268|NCT03492723|DIETARY_SUPPLEMENT|Aged Garlic Extract|NR
219631269|NCT00780130|OTHER|No Intervention|male \& female college students ages 20 to 50, asymptomatic normals
219631270|NCT06246240|OTHER|Chewing gum with vitamin C|Will chew vitamin C gum as soon as nausea begins
218937697|NCT04220476|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
218937698|NCT04220476|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
218937699|NCT00973713|DRUG|RAD001|10mg/d
218937700|NCT02121821|BEHAVIORAL|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
218937701|NCT02163603|PROCEDURE|Pelvic osteotomy|
219631271|NCT06321406|DEVICE|NMES (neuromuscular electrical stimulation)|With this application, swallowing muscles are stimulated and muscle strength increases.
219631272|NCT06321406|BEHAVIORAL|Exercise|Traditional Conservative swallowing treatment
219631273|NCT03740087|OTHER|Omnivorous diet|Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
219631274|NCT03740087|OTHER|Vegan diet|Used as a baseline for miRNA levels in blood
219631275|NCT03738670|PROCEDURE|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
219631276|NCT00409487|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
219631277|NCT00409487|DRUG|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
219631278|NCT02273063|DEVICE|Transcranial Magnetic Stimulation (TMS)|Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
219631279|NCT03324386|BEHAVIORAL|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
219631280|NCT03324386|BEHAVIORAL|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
219631281|NCT03324386|BEHAVIORAL|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
219631282|NCT03324386|OTHER|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
219631283|NCT00114439|DRUG|Lithium carbonate|
219631284|NCT04955314|OTHER|PA vertebral mobilization|A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
219631285|NCT04274010|DIAGNOSTIC_TEST|PillCamTM Crohn's capsule|Capsule endoscopy for small and large bowel to assess Crohn's disease activity.
219631286|NCT04274010|DIAGNOSTIC_TEST|Magnetic resonance enterography|MRI scan of small bowel to assess small bowel Crohn's disease activity.
219631287|NCT04274010|PROCEDURE|Ileo-colonoscopy|Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
219631288|NCT06451536|DIAGNOSTIC_TEST|Ga-68 FAPI PET/CT|imaging of FAP expression of tumor before immunotherapy
219631289|NCT06445803|BIOLOGICAL|KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）|"CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)"
219631290|NCT01762436|DRUG|bisoprolol|
219631291|NCT01762436|DRUG|atenolol|
219631292|NCT04048213|OTHER|questionnaire|questionnaire send to the parents
219631293|NCT00125749|BIOLOGICAL|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
219631294|NCT03743805|DRUG|Flumazenil|0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
219631295|NCT03743805|DRUG|Naloxone|0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
219631296|NCT01372293|DRUG|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
219631297|NCT01501461|PROCEDURE|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
219631298|NCT04152811|BEHAVIORAL|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
219631299|NCT04152811|OTHER|Usual Diabetes Care|Usual Diabetes Care
219631300|NCT01295671|BEHAVIORAL|Provision of beverages|Home delivery of specified beverage type
219631301|NCT06127693|DRUG|Tetravalent Influenza Vaccine|All participants will receive the tetravalent influenza vaccine
219631302|NCT06127693|BEHAVIORAL|High-frequency electrical stimulation|All participants will receive High-frequency electrical stimulation
219048549|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
219048550|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
219048551|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
219048552|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
219048553|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
219631303|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
219631304|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
219631305|NCT06326398|OTHER|Stoma Care|Nursing students practice stoma care with low and high fidelity simulation
219631306|NCT02975388|DRUG|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
219631307|NCT03205956|DRUG|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
219631308|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
219631309|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
219631310|NCT04180514|DIAGNOSTIC_TEST|intradialytic hypotension episode|Intradialytic hypotension episode under regular hemodialysis
219631311|NCT03246308|RADIATION|Phototherapy|Taking blood sample.
219631312|NCT02395848|DRUG|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
219631313|NCT03558763|DEVICE|Telemonitoring|During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.
219631314|NCT03558763|OTHER|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
219631315|NCT03829826|BIOLOGICAL|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
219631316|NCT03030560|DRUG|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
219631317|NCT03030560|DRUG|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
219631318|NCT03253549|DEVICE|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
219631319|NCT05053022|DEVICE|Skinpen Precision System|Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.
219631320|NCT02610374|OTHER|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
219631321|NCT02610374|OTHER|Western-type Diet|A diet higher in fats and lower in carbohydrates
219631322|NCT02469935|PROCEDURE|ultrasound|surgeon-performed ultrasound
219048554|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
219631323|NCT04044066|BIOLOGICAL|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
219631324|NCT05704374|DIAGNOSTIC_TEST|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
219631325|NCT05704374|DRUG|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
219631326|NCT02600468|DRUG|Orencia|
219631327|NCT00616343|DRUG|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
219631328|NCT03373084|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
219631329|NCT03373084|OTHER|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
219631330|NCT03373084|OTHER|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
219631331|NCT02809079|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
219631332|NCT02809079|DRUG|Prednisone|prednisone 10mg Qd
219631333|NCT06482190|DRUG|RSN0402 Part 1|Participants will receive single ascending doses of 2mg, 4mg, 8mg, 12 mg, and 16mg of RSN0402 or placebo on Day 1 for Cohort 1 to 5. Cohort 2(4mg) will also a single dose of 150 mg nintedanib soft capsule will be administered orally after at least 7-days washout period.
219631334|NCT06482190|DRUG|RSN0402 Part 2|Participants will receive multiple ascending doses of 4mg ,8mg,12mg ,16mg of RSN0402 or placebo administered once daily from Day 1 to Day 7 for Cohort 6 to 9.
219631335|NCT06482190|DRUG|Placebo|Participants will receive matching placebo across Part 1 and Part 2 of the study.
219631336|NCT02126579|BIOLOGICAL|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
219631337|NCT02126579|OTHER|PolyICLC|1 mL administered half intradermally and half subcutaneously
219631338|NCT02126579|OTHER|Resiquimod|500 mg applied to vaccine site after vaccine administration
219631339|NCT02126579|OTHER|IFA|2 mL administered half intradermally and half subcutaneously
219048555|NCT03898661|DRUG|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
219631340|NCT02295046|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
219631341|NCT00911469|DRUG|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
219631342|NCT00911469|DRUG|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
219048556|NCT02851537|OTHER|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
219048557|NCT04700696|BEHAVIORAL|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
219206571|NCT03990233|DRUG|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
219048558|NCT04700696|BEHAVIORAL|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
219631343|NCT00981214|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
219631344|NCT00935402|BEHAVIORAL|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
219631345|NCT03324555|DRUG|ORIC-101|Oral suspension
219631346|NCT00675012|DRUG|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
219631347|NCT00675012|DRUG|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
219631348|NCT00675012|DRUG|capecitabine|orally 825 mg/sqm 2qDx14
219048559|NCT04700696|BEHAVIORAL|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
219631349|NCT04229095|DRUG|Suvorexant 20 mg|Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit
219631350|NCT04229095|DRUG|Placebo oral tablet|Single-dose administration of placebo given on an inpatient clinical research unit
219631351|NCT06144216|OTHER|CLOE Outreach Intervention|The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
219631352|NCT03574272|OTHER|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
219631353|NCT02056041|PROCEDURE|Hepatectomy|
219631354|NCT03079141|DRUG|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
219631355|NCT03079141|OTHER|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
219631356|NCT02371317|BEHAVIORAL|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
219631357|NCT02371317|BEHAVIORAL|Stress Management Education|Patients are randomized to an intervention
219631358|NCT02371317|OTHER|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
219631359|NCT05322941|DRUG|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
219631360|NCT05322941|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
219631361|NCT01780038|BEHAVIORAL|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
219631362|NCT01780038|BEHAVIORAL|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
219631363|NCT06462950|BEHAVIORAL|Do men and women differ in their reactions to the experimental conditions.|Do men and women differ in their reactions to the experimental conditions.
219631364|NCT05349110|DEVICE|Computer-aided diagnosis (CADx) systems|"* AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~* CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan)."
219048560|NCT04734444|DEVICE|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
219048561|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
219631365|NCT01237041|DRUG|Niacin First|Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
219631366|NCT01237041|DRUG|Placebo First|Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
219631367|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 250mg|Niacin 250 mg po three times at 2 hour intervals on an inpatient day
219631368|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 500mg|Niacin 500 mg po three times at 2 hour intervals on an inpatient day
219048562|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
219048563|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
219631369|NCT01237041|DRUG|Dose-Establishing Study 2 Niacin 500mg|Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
219048564|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
219048565|NCT02611492|DRUG|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
219048566|NCT02611492|DRUG|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
219631370|NCT02529449|DRUG|Placebo|Oral
219631371|NCT02529449|DRUG|ASP1941|Oral
219631372|NCT00563641|OTHER|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
219631373|NCT00563641|OTHER|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
219631374|NCT06189144|OTHER|Emollient cream treatment|Rilastil Difesa Sterile cream
219631375|NCT06189144|OTHER|no treatment|no treatment
219631376|NCT04333095|DRUG|Liposomal bupivacaine|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
219631377|NCT04333095|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
219631378|NCT02430649|PROCEDURE|Irreversible electroporation (IRE)|
219631379|NCT02430649|DEVICE|NanoKnife|
219631380|NCT02355938|DRUG|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
219631381|NCT02355938|DRUG|Placebo|1 dose of placebo every 6 hours x 2 doses
219631382|NCT02355938|DRUG|Vancomycin|Vancomycin 125 mg every 6 hours
219631383|NCT05457218|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)
219631384|NCT05457218|DIETARY_SUPPLEMENT|IPC80|The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)
219631385|NCT05457218|DIETARY_SUPPLEMENT|Whole Buffalo Powder|The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)
219631386|NCT04176419|DRUG|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
219631387|NCT04176419|DRUG|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
219631388|NCT04176419|DRUG|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
219631389|NCT04176419|DRUG|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
219631390|NCT04176419|DRUG|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
219631391|NCT04176419|DRUG|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
219631392|NCT04176419|DRUG|Gabapentin|600 mg orally at time of check in to the preoperative unit
219631393|NCT04176419|DRUG|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
219631394|NCT04176419|DRUG|Celecoxib|200 mg orally at time of check in to the preoperative unit
219631395|NCT04176419|DRUG|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
219631396|NCT05924191|DEVICE|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
219631397|NCT05924191|DRUG|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
219631398|NCT05924191|DEVICE|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
219631399|NCT05924191|DRUG|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
219631400|NCT02609607|DRUG|Bisacodyl|Rectal suppository
219631401|NCT02609607|OTHER|Placebo|Rectal suppository
219631402|NCT06327529|OTHER|SER 118|Bean High in Phytic Acid and High in Inhibitory Polyphenols
219631403|NCT06327529|OTHER|LMP 1001|Bean Low in Phytic Acid and High in Inhibitory Polyphenols
219631404|NCT06327529|OTHER|LPA 586|Bean Low in Phytic Acid and Low in Inhibitory Polyphenols
219631405|NCT06327529|OTHER|KAT B1|Bean High in Phytic Acid and Low in Inhibitory Polyphenols
219631406|NCT01317095|DEVICE|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
219631407|NCT01761604|DEVICE|Nasal ganglion block for TN|
219631408|NCT03168711|DRUG|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
219631409|NCT03168711|DRUG|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
219631410|NCT06022315|COMBINATION_PRODUCT|caloric restrction high carbohydrate low fat diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
219631411|NCT06022315|COMBINATION_PRODUCT|caloric restrction high fat low carbohydrate diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
219631412|NCT06142487|OTHER|Silk Pillowcase|100% Mulberry Silk Pillowcase
219631413|NCT06142487|OTHER|Cotton Pillowcase|100% Cotton Pillowcase
219631414|NCT03254745|OTHER|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
219631415|NCT01010412|DEVICE|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
219631416|NCT01010412|DEVICE|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
219631417|NCT05361577|DEVICE|Exoplulse Mollii suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
219631418|NCT05361577|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
219631419|NCT06578026|BEHAVIORAL|Resilience Builder Program|The Resilience Builder Program® group therapy will meet for one class period once a week during the semester (12 sessions). The group aims to improve resilience skills: areas such as the ability to control emotions and behavior, social skills and interactions with peers, problem-solving skills, ability to be flexible in different situations, self-esteem, and optimistic thinking. The groups involve the group leader presenting a new topic and skill, the students discussing this topic and developing strategies associated with the skill, the students practicing the skill while getting feedback from the group leader, and a period focused on self-control strategies. A letter reviewing each session will be sent home to the parent/guardian each week. Also, each child will be asked to do an assignment between weekly sessions to help him/her practice new skills.
219631420|NCT02529046|DIETARY_SUPPLEMENT|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
219631421|NCT02529046|BEHAVIORAL|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
219631422|NCT01450215|DRUG|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
219631423|NCT03408769|OTHER|Medical questionnaire|"* Brief Index of Sexual Functioning for Women questionnaire~* Quality of life questionnaire (EORTC QLQ-BR23)~* Partnership questionnaire (partnerschaftsfragebogen; PFB)~* Short interview about their sexual intimacy"
219631424|NCT01202578|DEVICE|tympanostomy tube|tympanostomy tube delivery system
219631425|NCT00184717|DRUG|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
219631426|NCT00184717|DRUG|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
219631427|NCT02209051|OTHER|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
219631428|NCT02209051|OTHER|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
219631429|NCT04831853|OTHER|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
219631430|NCT04831853|OTHER|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
219631431|NCT05566899|PROCEDURE|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
219631432|NCT04843917|DIAGNOSTIC_TEST|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
219631433|NCT02877004|DEVICE|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
219048567|NCT02611492|DRUG|Aracytine (Ara C)|Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
219631434|NCT02877004|DEVICE|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
219631435|NCT02877004|DEVICE|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
219048568|NCT02611492|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
219631436|NCT01671228|OTHER|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
219048569|NCT02611492|DRUG|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
219048570|NCT02611492|DRUG|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
219048571|NCT02611492|DRUG|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
219048572|NCT02611492|DRUG|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
219048573|NCT02611492|DRUG|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
219048574|NCT04152122|DIAGNOSTIC_TEST|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
219048575|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
218937702|NCT02499133|OTHER|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
218937703|NCT04073524|OTHER|Nature-Body-Mind-Community|The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
218937704|NCT04073524|OTHER|Treatment as usual|Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
218937705|NCT00102583|DRUG|Subconjunctival Cyclosporine Implant|
218937706|NCT03739034|BEHAVIORAL|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
218937707|NCT02476266|OTHER|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
218937708|NCT02010450|OTHER|Wearable Blanket (Sleep Sack)|
218937709|NCT02010450|OTHER|Incentive Item|
218937710|NCT04783090|DRUG|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
218937711|NCT04710472|DEVICE|Mentora App|"Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria."
218937712|NCT02305810|DRUG|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
218937713|NCT00126490|BIOLOGICAL|Aldesleukin|Given subcutaneously
218937714|NCT00126490|BIOLOGICAL|Bevacizumab|Given IV
218937715|NCT00126490|OTHER|Laboratory Biomarker Analysis|Correlative studies
218937716|NCT00654433|BIOLOGICAL|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
218937717|NCT01931371|PROCEDURE|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
218937718|NCT01931371|PROCEDURE|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
218937719|NCT05118880|OTHER|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
218937720|NCT05606471|DRUG|Semaglutide Pen Injector [Ozempic]|Glucagon-like peptide 1 (GLP-1) receptor agonist
218937721|NCT05606471|DIETARY_SUPPLEMENT|Very-low Calorie Diet|Total meal replacement with a limit of 800 kilocalories per day
218937722|NCT01968655|BIOLOGICAL|OBI-1|OBI-1 is a B domain deleted recombinant porcine factor VIII
218937723|NCT06480487|BEHAVIORAL|Feedback provided face to face|Feedback will be provided face-to-face.
218937724|NCT06480487|BEHAVIORAL|Feedback provided by electronic mail|Feedback will be provided by electronic mail.
218937725|NCT06480487|BEHAVIORAL|Feedback provided by researchers|Feedback will be provided by researchers.
218937726|NCT06480487|BEHAVIORAL|Feedback provided by authoritative bodies|Feedback will be provided by authoritative bodies.
219048576|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
219048577|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
219048578|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
219048579|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
219631437|NCT01671228|OTHER|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
219631438|NCT01671228|OTHER|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
219631439|NCT02633293|DRUG|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
219631440|NCT03104140|DRUG|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
219631441|NCT03104140|DRUG|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
219631442|NCT00238472|DRUG|nateglinide|
219631443|NCT01212237|PROCEDURE|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
219631444|NCT00778817|BIOLOGICAL|IMC-A12|Given IV
219631445|NCT00778817|DRUG|mitotane|Given orally
219631446|NCT03357523|DEVICE|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
219631447|NCT03357523|DEVICE|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
219631448|NCT03357523|DEVICE|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
219631449|NCT03357523|DEVICE|Heating bag|Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
219631450|NCT00192231|BIOLOGICAL|CAIV-T|
219631451|NCT03719469|DIETARY_SUPPLEMENT|Green tea group|
219631452|NCT04410107|DIAGNOSTIC_TEST|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
219631453|NCT04410107|DIAGNOSTIC_TEST|Exercise capacity|6-minute walk test (6MWT distance)
219631454|NCT04410107|DIAGNOSTIC_TEST|Exercise physiology|Cardiopulmonary exercise test (CPET)
219631455|NCT04410107|DIAGNOSTIC_TEST|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
219631456|NCT04410107|DIAGNOSTIC_TEST|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
219631457|NCT02838732|DIETARY_SUPPLEMENT|L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)|
219631458|NCT02356588|DRUG|Sufentanil Tablet 30 mcg|
219631459|NCT02356588|DRUG|Placebo Tablet|
219631460|NCT01418378|DEVICE|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
219631461|NCT01418378|DEVICE|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
218937727|NCT06480487|BEHAVIORAL|Feedback provided with peer comparision|Feedback will be provided with peer comparison.
218937728|NCT06480487|BEHAVIORAL|Feedback provided without peer comparision|Feedback will be provided without peer comparision.
218937729|NCT03399396|BEHAVIORAL|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
218937730|NCT02124317|DRUG|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
219048580|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
219631462|NCT01659827|OTHER|Marcaine|Injection of 2cc of Marcaine
219631463|NCT01659827|OTHER|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
219631464|NCT01659827|OTHER|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
219631465|NCT01659827|OTHER|Saline|Injection of 1.25cc of Saline
219631466|NCT01987089|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
219631467|NCT00702767|DRUG|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
219631468|NCT03538730|BEHAVIORAL|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
219631469|NCT04390490|DEVICE|Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor|Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
219631470|NCT05888363|OTHER|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
219631471|NCT02838823|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
218937731|NCT02124317|DRUG|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
219048581|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
219048582|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
219631472|NCT03866681|DRUG|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
219631473|NCT01641458|OTHER|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G\>A, c.1679T\>G, HapB3/c.1129-5923C\>G and c.2846A\>T).
219631474|NCT01641458|OTHER|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
219631475|NCT01591135|DRUG|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
219631476|NCT01591135|DRUG|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
219631477|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
219631478|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
219631479|NCT05020158|OTHER|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
219631480|NCT00722358|DRUG|BMS-650032|"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"
219631481|NCT00722358|DRUG|Placebo|"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"
219048583|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
219048584|NCT03770468|PROCEDURE|Blood drawl|
219048585|NCT00274599|DRUG|Telmisartan|
219048586|NCT00274599|DRUG|Ramipril|
219631482|NCT03150719|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
219631483|NCT03150719|DRUG|Ivacaftor|IVA 150 mg tablet.
219631484|NCT03150719|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
219631485|NCT03150719|DRUG|Placebo|Placebo matched to IVA tablet.
218937732|NCT00975780|OTHER|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
218937733|NCT00975780|OTHER|Usual oral care|Usual oral care and feeding positioning
219048587|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
219048588|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
219048589|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
219048590|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
219048591|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
219631486|NCT01790984|OTHER|High sugar low starch diet|
219631487|NCT01790984|OTHER|Low sugar high starch diet|
219631488|NCT02597504|OTHER|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
219631489|NCT02597504|DEVICE|Quick Test|Quick Test, computerized test will be administered to all subjects.
218937734|NCT00985699|GENETIC|polymorphism analysis|
218937735|NCT00985699|OTHER|laboratory biomarker analysis|
218937736|NCT00985699|OTHER|pharmacogenomic studies|
219048592|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
219048593|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
219048594|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
219048595|NCT03534856|BEHAVIORAL|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
219048596|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
219048597|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
219048598|NCT05263427|DEVICE|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
219048599|NCT00116389|DRUG|talabostat mesylate tablets|
219048600|NCT00116389|DRUG|gemcitabine|
219048601|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
219206572|NCT05855954|COMBINATION_PRODUCT|controlled low central venous pressure technique (CLCVP)|20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.
219631490|NCT00640757|DIETARY_SUPPLEMENT|Methionine deficient diet|Hominex with a low protein diet
219631491|NCT00640757|DIETARY_SUPPLEMENT|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
219048602|NCT02538926|DRUG|Asparaginase|Given IM or IV
219048603|NCT02538926|DRUG|Cyclophosphamide|Given IV
219048604|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
219048605|NCT02538926|DRUG|Etoposide|Given IV
219048606|NCT02538926|DRUG|Imatinib Mesylate|Given PO
219048607|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
219048608|NCT02538926|DRUG|Prednisone|Given PO
219048609|NCT02538926|BIOLOGICAL|Rituximab|Given IV
219048610|NCT02538926|DRUG|Vincristine Sulfate|Given IV
219048611|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
219048612|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
219048613|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
219048614|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
219631492|NCT01997476|PROCEDURE|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
219631493|NCT00383760|DRUG|eribulin mesylate|Given IV
219631494|NCT04303689|DRUG|Colchicine Tablets|patients with essential hypertension are randomized to receive either 3 weeks of colchicine
219631495|NCT04303689|DRUG|Placebo|patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
219631496|NCT00571740|BIOLOGICAL|bevacizumab|Given IV
219048615|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
219048616|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
219048617|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
219048618|NCT05142683|OTHER|Treatment As Usual|Various typical interventions for adolescents with depression.
219048619|NCT05142683|OTHER|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
219048620|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
219206573|NCT05071105|RADIATION|Stereotactic Body Radiation Therapy|In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
219631497|NCT00571740|BIOLOGICAL|cetuximab|Given IV
219631498|NCT00571740|DRUG|fluorouracil|Given IV
219631499|NCT00571740|DRUG|leucovorin calcium|Given IV
219631500|NCT00571740|DRUG|oxaliplatin|Given IV
219631501|NCT04200989|BIOLOGICAL|Peanut allergen|Intralymphatic immunotherapy injections.
219631502|NCT01812460|OTHER|Intervention-training-group|As descriped in Arm Description
219631503|NCT05944848|DRUG|1 mg CL-197 capsules|Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
219631504|NCT05944848|DRUG|10 mg CL-197 capsules or CL-197 placebo|Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
219631505|NCT05944848|DRUG|30 mg CL-197 capsules or CL-197 placebo|Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
219631506|NCT05944848|DRUG|60 mg CL-197 capsules or CL-197 placebo|Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
219631507|NCT05944848|DRUG|100 mg CL-197 capsules or CL-197 placebo|Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
219048621|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
219048622|NCT02082717|DRUG|potassium chloride replacement|
219631508|NCT03839004|BEHAVIORAL|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
219631509|NCT00004872|BIOLOGICAL|recombinant human endostatin|
219631510|NCT04021030|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
219631511|NCT05519930|OTHER|hereditary high risk pancreatic cancer|Data collection trial for hereditary high risk pancreatic cancer patients.
219631512|NCT04816617|BEHAVIORAL|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
219631513|NCT04816617|BEHAVIORAL|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
219631514|NCT02711696|BEHAVIORAL|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
219631515|NCT04608396|DRUG|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
219631516|NCT04608396|DRUG|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
219631517|NCT01063738|DIETARY_SUPPLEMENT|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
219631518|NCT01063738|OTHER|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
219631519|NCT01063738|OTHER|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
219631520|NCT01063738|DIETARY_SUPPLEMENT|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
219631521|NCT05010538|DRUG|Sarecycline|60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.
219631522|NCT04103125|DEVICE|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
219631523|NCT01450306|DRUG|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
219631524|NCT01450306|BEHAVIORAL|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
219631525|NCT01450306|DRUG|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
219631526|NCT03784742|OTHER|Nitrate rich beetroot juice|James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
219631527|NCT03784742|OTHER|Placebo beetroot juice|James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
219631528|NCT03239249|OTHER|IKO-model|A systematic model for drop-out prevention.
219631529|NCT03239249|OTHER|Treatment as usual|Schools randomized to control group (22) work as previously with school dropout
219631530|NCT05522998|DRUG|Ciprofol|Ciprofol (0.4-0.5mg/kg) for anesthesia induction
219631531|NCT05522998|DRUG|Propofol|propofol(2-2.5mg/kg) for anesthesia induction
219631532|NCT04757025|DEVICE|Electrical Impedance Tomography|In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
219631533|NCT04757025|DEVICE|Peripheral arterial Saturation|The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
219631534|NCT06134310|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
219048623|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
219048624|NCT00215826|DRUG|Alferon LDO|
219048625|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
219048626|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
219048627|NCT00226616|DRUG|Zinc|
219048628|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
219631535|NCT06134310|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
219631536|NCT06134310|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
219631537|NCT06134310|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
219631538|NCT02829320|DRUG|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
219631539|NCT02829320|DRUG|Iron|Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
219631540|NCT03403140|DRUG|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
219631541|NCT01976962|RADIATION|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
219631542|NCT01691560|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
218937737|NCT01056016|OTHER|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
219631543|NCT01691560|DRUG|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
219631544|NCT01691560|DRUG|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
219631545|NCT01691560|DRUG|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
219631546|NCT05644626|DRUG|BGB-B167|Intravenous administration
219631547|NCT05644626|DRUG|Tislelizumab|Intravenous administration
219631548|NCT01051791|DRUG|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
219631549|NCT01041157|OTHER|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
219631550|NCT00288626|DRUG|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
219631551|NCT00288626|DRUG|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
219631552|NCT00288626|PROCEDURE|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
219631553|NCT02821026|PROCEDURE|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
219631554|NCT02821026|DRUG|Anti-Thymocyte Globulin|
218937738|NCT02857634|DEVICE|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
219631555|NCT02821026|DRUG|Mycophenolate mofetil|
219631556|NCT02821026|DRUG|Tacrolimus|
219631557|NCT02821026|DRUG|Etanercept|
219631558|NCT02821026|DRUG|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
219631559|NCT01588769|BIOLOGICAL|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
219631560|NCT01506401|DEVICE|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
219631561|NCT01506401|PROCEDURE|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart
219631562|NCT01292512|OTHER|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
219631563|NCT01789112|OTHER|Blood sample|Taking of blood sample
219631564|NCT02752243|DRUG|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
218937739|NCT00950820|DRUG|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
219631565|NCT05664022|PROCEDURE|Global postural reeducation|"The GPR involves a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles, and enhancing the contraction of antagonist's muscles, thus avoiding postural asymmetry.~The GPR method includes eight therapeutic postures, lying, sitting or standing, to be held for 15/20 minutes each. Postures can be variously combined during sessions. Postures are chosen on the basis of some parameters, such as the amount of pain, load capacity and age of the patient, and muscle chains to be stretched. to increase the standardization of treatment, it will be proposed only 2 or 3 postures."
219631566|NCT02192996|DIETARY_SUPPLEMENT|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
219631567|NCT05009693|OTHER|White Light Application|White Light Therapy
219631568|NCT00245128|DRUG|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
219631569|NCT05390333|BEHAVIORAL|Self-Care Sampler for Family Carer Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
219631570|NCT02819037|PROCEDURE|gas chromatography|
219631571|NCT02819037|PROCEDURE|Stool analysis for detection of malabsorption|
219631572|NCT01585051|DRUG|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
219631573|NCT01585051|DRUG|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
219631574|NCT02522364|DEVICE|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
219631575|NCT02522364|OTHER|Standard|Clinical and intermittent electrocardiographic follow-up of patients
219631576|NCT01462760|DEVICE|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
219631577|NCT01462760|DEVICE|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
219631578|NCT03155464|PROCEDURE|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
219631579|NCT03155464|DRUG|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
219631580|NCT02569970|DRUG|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
218937740|NCT00950820|DRUG|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
219048629|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
219631581|NCT02569970|DRUG|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
219631582|NCT00114075|PROCEDURE|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
219631583|NCT00114075|PROCEDURE|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
219631584|NCT01081769|DRUG|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
219631585|NCT01081769|DRUG|oral antipsychotics|daily treatment according to local label for maximally 24 months
219631586|NCT01733940|DEVICE|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
219631587|NCT01733940|DEVICE|Application of a dressing without clorhexidine gluconate|
219631588|NCT01566266|DRUG|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
219631589|NCT01566266|DRUG|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
219631590|NCT01633723|DRUG|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
219631591|NCT01633723|DRUG|Placebo of DA-6886|DA-6886 placebo
219631592|NCT00507455|DRUG|solifenacin succinate|Solifenacin succinate tablets
219631593|NCT00507455|DRUG|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
219631594|NCT00507455|DRUG|Placebo to solifenacin|
219631595|NCT00507455|DRUG|Placebo to tamsulosin|
219631596|NCT06131814|OTHER|2 groups|up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
219631597|NCT00090714|GENETIC|pVGI.1(VEGF2)|
219631598|NCT01168414|DRUG|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
219631599|NCT01168414|DRUG|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
219631600|NCT01509313|DEVICE|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
219631601|NCT01509313|DEVICE|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
219631602|NCT05109533|OTHER|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
219631603|NCT04303806|DRUG|rosuvastatin|receive rosuvastatin orally once daily.
219631604|NCT03803007|DRUG|Intravenous ACT017 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
219631605|NCT03803007|OTHER|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
218937741|NCT04976582|DEVICE|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
218937742|NCT05656144|DEVICE|Cadonilimab|AK104, 6mg/kg, Q2W
218937743|NCT00241189|DRUG|rapamycin|
218937744|NCT00241189|DRUG|methotrexate|
218937745|NCT05494515|PROCEDURE|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
218937746|NCT03051178|DEVICE|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
219631606|NCT04440215|OTHER|Telerehabilitation and team meetings and team care plans|A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.
219631607|NCT04440215|OTHER|Usual care|Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
219631608|NCT01317888|DRUG|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
219631609|NCT05617157|OTHER|Stair stepping|stepping up and down 32 stairs for 1 minute
219631610|NCT01226966|DRUG|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
219631611|NCT05284331|OTHER|addition of two follow-up visits post infection|"Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection"
219631612|NCT01137149|BEHAVIORAL|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
219631613|NCT01137149|BEHAVIORAL|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
219631614|NCT06119815|DIAGNOSTIC_TEST|CO2 GAP|"CO2 gap will be measured by insertion of radial arterial cannula and internal jugular C.V.P~* I.V.C collapsibility will be measured by abdominal us at the subcostal area and the IVC diameters will be measured in M-mode coupled to 2D mode 3 cm before the IVC joined the right atrium to ensure that IVC diameter measurements are accurate and that the inter- and intra-observer variability of IVC can be minimized. The IVC collapsibility index (IVCCI) will be calculated as follows: (maximum diameter on expiration (IVC max) - minimum diameter on inspiration (IVC min).~* Echocardiography for all patients to asses cardiac index in a parasternal (2D) view. The aortic diameter (AoD) will be measured at the aortic valve annulus. The aortic area (AA) will be calculated using the formula: AA = π × (AoD2/ 4). We measured the aortic blood flow using pulsed"
219631615|NCT04476693|OTHER|Breakfast consumption|"Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed."
219631616|NCT04476693|OTHER|Breakfast Omission|Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast \[milk (ml)+ orange juice (ml)\].
219631617|NCT03245528|DRUG|LJPC-501|angiotensin II
219631618|NCT06564298|DRUG|Sintilimab|Sintilimab 200mg iv.gtt d1, every 21 days
219631619|NCT06564298|DRUG|Ramucirumab|Ramucirumab 10mg/kg iv.gtt d1, every 21 days
219631620|NCT06564298|DRUG|SOX/XELOX|SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
219631621|NCT01579786|PROCEDURE|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
219631622|NCT01964222|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
219631623|NCT03883230|DIAGNOSTIC_TEST|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
219631624|NCT06363331|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
219631625|NCT01972243|OTHER|no intervention|
219631626|NCT00501410|DRUG|5-FU|2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2.
219631627|NCT00501410|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8
219631628|NCT00501410|DRUG|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
219631629|NCT00501410|DRUG|Leucovorin|400 mg/m\^2 by vein on day 1.
219631630|NCT00501410|DRUG|Oxaliplatin|85 mg/m\^2 by vein on day 1.
219631631|NCT01737710|BIOLOGICAL|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
218937747|NCT04805398|BIOLOGICAL|CM310|300 mg every two weeks
218937748|NCT04805398|BIOLOGICAL|Placebo|300 mg every two weeks
218937749|NCT04749992|PROCEDURE|Polysomnographic examination in sleep laboratory (PSG measurement)|Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
219631632|NCT01737710|BIOLOGICAL|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
219631633|NCT01360242|PROCEDURE|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
219631634|NCT01360242|PROCEDURE|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
219631635|NCT05684861|DRUG|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
219631636|NCT05684861|DIAGNOSTIC_TEST|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
219631637|NCT05711251|OTHER|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
219631638|NCT04120649|PROCEDURE|hysterectomy|total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
219631639|NCT03178188|DEVICE|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
219631640|NCT03178188|DEVICE|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
219631641|NCT05930626|OTHER|Biomarkers of acrylamide, glycidol, POPs, PFAS|These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.
219631642|NCT04160234|OTHER|web-based questionnaires|Patients will be asked to complete web-based questionnaires on a tablet computer
219631643|NCT06461936|DRUG|Sintilimab|Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
219631644|NCT06461936|DRUG|Lenvatinib|Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
219631645|NCT03945955|DIETARY_SUPPLEMENT|Melatonin|Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
219631646|NCT03945955|OTHER|Placebo|Placebo
219631647|NCT04707677|DEVICE|Titanium and ceramic dental Implants|Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
219631648|NCT05347576|DRUG|CKD-393(2)|QD, PO
219631649|NCT05347576|DRUG|CKD-501, D759, D150, D029|QD, PO
219631650|NCT03363776|BIOLOGICAL|BMS-986277|Specified dose on specified days
219631651|NCT03363776|BIOLOGICAL|Nivolumab|Specified dose on specified days
219631652|NCT00942890|DEVICE|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
219631653|NCT00942890|BEHAVIORAL|TMARP standard of care|The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
219631654|NCT03451591|DRUG|Isosorbide Mononitrate XL (ISMN)|Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
219631655|NCT03451591|DRUG|Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.
219631656|NCT03451591|DRUG|ISMN XL and Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
219631657|NCT03451591|OTHER|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
219631658|NCT00968643|RADIATION|radiation therapy|Given in multiple fractions or as a single fraction
219631659|NCT06352008|DRUG|Anlotinib|12mg once a day, taken orally before breakfast for 2 consecutive weeks and stopped for 1 week. Without special circumstances, it is recommended to take at a fixed time every day; If there is a missing dose during the administration, confirm that the time before the next administration is less than 12 hours, no more refilling. The maximum duration of drug use is tentatively 1 year.
219631660|NCT04974996|DRUG|Loncastuximab tesirine|Intravenous (IV) infusion
219631661|NCT04974996|DRUG|Prednisone|Orally via tablet or capsule
219631662|NCT04974996|DRUG|Rituximab|Intravenous (IV) infusion
219631663|NCT04974996|DRUG|Cyclophosphamide|Intravenous (IV) infusion
219631664|NCT04974996|DRUG|Doxorubicin|Intravenous (IV) infusion
219631665|NCT04974996|DRUG|Vincristine|Intravenous (IV) infusion
219631666|NCT03157271|OTHER|Intramuscular Dry Needling|Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
219631667|NCT00861393|BEHAVIORAL|CBT|12 Session CBT group
219631668|NCT00861393|BEHAVIORAL|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
219631669|NCT00926471|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
219631670|NCT01875757|DRUG|Vitamin D3|
219631671|NCT01875757|DRUG|Placebo|
219631672|NCT03928587|DIETARY_SUPPLEMENT|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
219631673|NCT03928587|DIETARY_SUPPLEMENT|Placebo|Placebo once daily for 12 months
219631674|NCT01022320|PROCEDURE|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
219631675|NCT06253364|DRUG|PD-1 monoclonal antibody and lenvatinib|"Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months."
219631676|NCT03124589|BEHAVIORAL|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
219631677|NCT06299384|OTHER|LyssnCrisis|LyssnCrisis is an AI-based coding and feedback tool for implementation in crisis counseling settings, training counselors (call-takers) in suicide risk assessment skills.
219631678|NCT05865496|DRUG|611|611 subcutaneous (SC) injection.
219631679|NCT05865496|DRUG|Placebo|Placebo subcutaneous (SC) injection.
219631680|NCT05047705|BEHAVIORAL|Distress Tolerance Skills Training|Individuals with TS will receive distress tolerance skill training. Therapeutic skill training will consist of 4 weekly 1-hour sessions. Skill training will occur either in-person or remotely via videoconferencing software. Sessions will focus on building participants' distress tolerance skills with strategies drawn from third-wave CBT.
219631681|NCT03383640|OTHER|Active exercises|Active flexion movements every waking hour of the replanted digits
219631682|NCT03728348|DIAGNOSTIC_TEST|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
219631683|NCT03728348|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
219631684|NCT03356639|DRUG|ASP6981|Oral
219631685|NCT03356639|DRUG|Placebo|Oral
219631686|NCT00573274|DEVICE|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
219631687|NCT02737969|DEVICE|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
219631688|NCT00663390|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
219631689|NCT02861807|DEVICE|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
219631690|NCT01632293|BEHAVIORAL|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
219631691|NCT03416205|DEVICE|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
219631692|NCT03416205|DEVICE|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
219631693|NCT03416205|DEVICE|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
219631694|NCT03543748|DEVICE|Transcranial Magnetic Stimulation|A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.
219631695|NCT03543748|DEVICE|Sham Transcranial Magnetic Stimulation|The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
219631696|NCT02484846|BEHAVIORAL|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
219631697|NCT05928507|DIAGNOSTIC_TEST|Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections|"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."
219631698|NCT06261307|BEHAVIORAL|Music intervention|Group intervention focusing on musical activities
219631699|NCT06261307|BEHAVIORAL|Circus intervention|Group intervention focusing on acrobatics and circus activities
219631700|NCT00410813|DRUG|dasatinib|given orally
219631701|NCT02405546|OTHER|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
219631702|NCT02405546|OTHER|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
219631703|NCT01257334|DRUG|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
219631704|NCT02691949|DRUG|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
219631705|NCT00271063|DRUG|Liposomal Annamycin|3-day IV infusion
219631706|NCT02761421|OTHER|observation study|observation study
219631707|NCT04504188|DEVICE|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
219631708|NCT06575023|PROCEDURE|Tamponade of lower uterine segment in management of placenta accreta spectrum cases|To compare the efficacy of lower uterine tamponade and partial lower myometrial resection in the management of intraoperative bleeding in cases with placenta accreta spectrum
219631709|NCT06575023|PROCEDURE|partial myometrial resection of lower uterine segment in management of placenta accreta spectrum cases|tamponade vs partial myomertial resection of lower uterine segment in managment of placenta accreta spectrum cases
219631710|NCT03600402|OTHER|Experimental|6 sessions of ankle manual therapy
219631711|NCT03600402|OTHER|Control|6 sessions of placebo intervention
219631712|NCT04657588|DEVICE|Navina anal insert|The Navina anal device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.
219631713|NCT04657588|OTHER|Care as usual|Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
219631714|NCT02533245|OTHER|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
219631715|NCT02533245|OTHER|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
219631716|NCT02533245|OTHER|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
219631717|NCT04237064|DIAGNOSTIC_TEST|Photoacoustic imaging|Photoacoustic imaging
219631718|NCT06197438|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
219631719|NCT06197438|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
219048630|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
219631720|NCT06197438|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
219631721|NCT06197438|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
219631722|NCT06197438|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.
219631723|NCT06197438|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.
219048631|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
219631724|NCT01391208|DRUG|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
219631725|NCT00812981|BIOLOGICAL|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
219631726|NCT00812981|BIOLOGICAL|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
219631727|NCT02758938|OTHER|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
219631728|NCT01725581|PROCEDURE|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
219631729|NCT05349981|DEVICE|Phonak Lyric self-replacement procedure|The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
219631730|NCT05905523|OTHER|Assessing prewriting skills in children|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
219631731|NCT02199795|DEVICE|Contralaterally Controlled Neuromuscular Electrical Stimulation|
219631732|NCT02199795|DEVICE|Cyclic Neuromuscular Electrical Stimulation|
219631733|NCT05088174|DRUG|Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule|"Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule"
219631734|NCT04861350|OTHER|motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
219631735|NCT04861350|OTHER|physical training|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
219631736|NCT04861350|OTHER|combine physical training and motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
219631737|NCT00937469|BEHAVIORAL|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
219631738|NCT00937469|OTHER|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
219631739|NCT00182455|DRUG|Topiramate|25 - 400 mg/day x 12 weeks
219631740|NCT00182455|DRUG|Placebo|25 - 400 mg/day x 12 weeks
219631741|NCT03485742|OTHER|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
218937750|NCT04202042|OTHER|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
218937751|NCT04202042|OTHER|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
218937752|NCT02270294|OTHER|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
219631742|NCT02488343|BEHAVIORAL|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
219631743|NCT05121311|DIAGNOSTIC_TEST|NeoprediX B1 algorithm|Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
219631744|NCT00279461|DRUG|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
219631745|NCT00279461|DRUG|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
219631746|NCT01707966|DRUG|Orteronel|
219631747|NCT01707966|DRUG|Placebo|
219631748|NCT00468351|PROCEDURE|Intravitreal Injection of 1,5 mg of bevacizumab|
219631749|NCT00468351|PROCEDURE|Intravitreal injection of 4 mg of Triamcinolone acetonide|
219631750|NCT02541357|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
219631751|NCT02541357|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
219048632|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
219631752|NCT05846490|DEVICE|CPAP|Continuous positive airway pressure + anti-hypertensive treatment intensification (if necessary)
219631753|NCT05846490|DRUG|Usual care|Anti-hypertensive treatment intensification (if necessary)
219631754|NCT04408339|OTHER|No Intervention|No Intervention
219631755|NCT06159751|OTHER|serum albumin level|serum albumin level in gonarthrosis
219631756|NCT02818946|DEVICE|MRI|Detection of cancer by MRI for pathologic nipple discharge
219631757|NCT05383365|OTHER|Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise|"The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action."
219631758|NCT05383365|OTHER|Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)|"The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes."
219631759|NCT06665321|BEHAVIORAL|Internet-based psychodynamic therapy (IPDT)|The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.
219631760|NCT03346681|DRUG|N-acetyl cysteine|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
219631761|NCT04922255|DEVICE|Reusable Underwear|Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
219631762|NCT04922255|DEVICE|Disposable urethral support|The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
218937753|NCT02270294|OTHER|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
218937754|NCT03769610|OTHER|Inpatient Foley catheter|
218937755|NCT03769610|OTHER|Outpatient Foley catheter|
218937756|NCT05918471|DIETARY_SUPPLEMENT|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
218937757|NCT01598506|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
218937758|NCT00001027|DRUG|Pentamidine isethionate|
218937759|NCT03873792|DIAGNOSTIC_TEST|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
219048633|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
219048634|NCT06384729|DEVICE|EXOPULSE Mollii Ⓡ|The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
219048635|NCT05220397|BIOLOGICAL|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
219631763|NCT04922255|BEHAVIORAL|Pelvic floor physical therapy|Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
219631764|NCT00683124|DRUG|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
219048636|NCT05220397|OTHER|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
219048637|NCT05220397|OTHER|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
219631765|NCT00683124|DRUG|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
219631766|NCT00683124|DRUG|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
219631767|NCT02677922|DRUG|AG-120|Specified dose on specified days
219631768|NCT02677922|DRUG|Azacitidine|Specified dose on specified days
219631769|NCT02677922|DRUG|AG-221|Specified dose on specified days
219631770|NCT05283135|DRUG|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
219631771|NCT05310071|DRUG|Aducanumab|Administered as specified in the treatment arm.
219631772|NCT05310071|DRUG|Placebo|Administered as specified in the treatment arm.
219631773|NCT00439985|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
219631774|NCT03752034|OTHER|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
219631775|NCT01012726|PROCEDURE|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
219631776|NCT03261414|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
219631777|NCT03261414|PROCEDURE|usual care|Standard care before induction of anesthesia
218937760|NCT04249986|BEHAVIORAL|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
219631778|NCT00266292|BEHAVIORAL|Fish oil (Bio-Marine, Pharma Nord)|
219631779|NCT00266292|BEHAVIORAL|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
219631780|NCT06576336|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy
219631781|NCT02570789|DRUG|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
219631782|NCT05816629|DIAGNOSTIC_TEST|Multiparameter ultrasound based-AI|Multiparameter ultrasound based-AI for the diagnosis of thyroid nodules
218937761|NCT02891135|OTHER|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
219048638|NCT05418556|DRUG|aspirin|DAPT strategy
219048639|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
219048640|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
219631783|NCT02001311|DRUG|Chlorhexidine gluconate|
219631784|NCT04205643|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
219631785|NCT04205643|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
219631786|NCT01788826|PROCEDURE|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
219631787|NCT01788826|PROCEDURE|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
219631788|NCT03337087|DRUG|Fluorouracil|Given IV
219631789|NCT03337087|DRUG|Irinotecan Sucrosofate|Given IV
219631790|NCT03337087|OTHER|Laboratory Biomarker Analysis|Correlative studies
219631791|NCT03337087|DRUG|Leucovorin Calcium|Given IV
219631792|NCT03337087|DRUG|Rucaparib|Given PO
219631793|NCT05877118|BEHAVIORAL|Enhanced Overdose Education (EOE)|"EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~* Express confidence in naloxone~* Provide a clear statement about suitability (You are an excellent candidate for naloxone)~* Begin discussion using presumptive language (You must be ready for an overdose)"
219631794|NCT05877118|BEHAVIORAL|Standard education|Written instructions that accompany a kit prescription in many EDs throughout the country.
219631795|NCT02231567|OTHER|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
219631796|NCT02231567|OTHER|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
219631797|NCT01871844|DRUG|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
219631798|NCT01871844|DRUG|octreotide 50 mcg tid|
219631799|NCT01871844|DRUG|Placebo|
219631800|NCT05847374|DEVICE|Polysomnography|Sleep architecture will be recorded using portable PSG (Prodigy) from 24:00 to 8:00. Pulse oximetry (SpO2) and heart rate were recorded continuously during the PSG. Simultaneously, the waveforms from the ventilator were recorded using Bettercare (R) system.
219631801|NCT02921724|DEVICE|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~1. Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~2. Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
219631802|NCT00018187|DRUG|Bupropion|
219631803|NCT00018187|DRUG|Mecamylamine|
219631804|NCT00018187|DRUG|Nicotine Patch|
219631805|NCT05905315|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme.
219631806|NCT05905315|COMBINATION_PRODUCT|Chemoradiation|According to standard treatment.
219631807|NCT00865878|DRUG|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
219631808|NCT00865878|OTHER|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
219631809|NCT03549728|DRUG|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
219631810|NCT03549728|PROCEDURE|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
219631811|NCT03515811|DEVICE|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
219631812|NCT06349226|OTHER|cell isolation from intervertebral disc tissue and biomarker investigation|metabolomic, cellular and molecular analysis on intervertebral disc derived cells and investigation of tissue neuroinflammatory and pain-related biomarkers
219631813|NCT05107492|DRUG|450mg|following a single subcutaneous dose of PF-06480605 450 mg
219631814|NCT05107492|DRUG|150mg|following a single subcutaneous dose of PF-06480605 150 mg
219631815|NCT05107492|DRUG|Placebo|following a single subcutaneous dose of placebo
219631816|NCT03428243|DEVICE|truSculpt|Device comparison of Circumference measurement at Baseline vs 18 months post treatment
219631817|NCT04339062|DRUG|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
219631818|NCT04339062|DRUG|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
219631819|NCT04339062|DRUG|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
219631820|NCT04339062|DRUG|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
219631821|NCT02748642|DRUG|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
219631822|NCT02748642|DRUG|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
219631823|NCT01514981|DRUG|AMG 761|Single dose of AMG 761 on study day 1.
219631824|NCT01514981|DRUG|Placebo|Single dose of placebo on study day 1.
219631825|NCT02523755|DRUG|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
219631826|NCT02523755|DRUG|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
219631827|NCT06388460|OTHER|Asthma Link|Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
219048641|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
218937762|NCT05915156|OTHER|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
218937763|NCT06361836|BIOLOGICAL|SBT777101|Experimental treatment
219549195|NCT04565587|OTHER|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
219549196|NCT04275349|DRUG|Xingnaojing injection within 24 hours of symptom onset|intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
219549197|NCT03049384|OTHER|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
219549198|NCT03049384|OTHER|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
219549199|NCT04461587|DRUG|Pirfenidone|see previous entries
219549200|NCT06559800|BEHAVIORAL|YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality|A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
219549201|NCT01930409|BEHAVIORAL|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises"
219549202|NCT01930409|BEHAVIORAL|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
219549203|NCT03948022|DRUG|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
219549204|NCT03948022|DRUG|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
219549205|NCT03948022|DRUG|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
219549206|NCT03103711|BEHAVIORAL|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
219549207|NCT03141853|OTHER|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
219549208|NCT03141853|OTHER|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
219549209|NCT05643833|OTHER|no intervention|no intervention
219549210|NCT03639077|DEVICE|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
219549211|NCT03639077|DEVICE|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
219549212|NCT02949167|BEHAVIORAL|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
219549213|NCT05319847|DIETARY_SUPPLEMENT|Daily Skin Supplement - Fountain of Youth|Skincare supplement
219549214|NCT05153304|BIOLOGICAL|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
219549215|NCT05153304|DRUG|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
219549216|NCT03461380|DIETARY_SUPPLEMENT|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
219549217|NCT03461380|DIETARY_SUPPLEMENT|Low Dose Black Cohosh|6.5 mg black cohosh
219549218|NCT03461380|DIETARY_SUPPLEMENT|High Dose Black Cohosh|500 mg black cohosh
219549219|NCT03461380|DIETARY_SUPPLEMENT|Placebo|600 mg excipient
219549220|NCT00875524|BIOLOGICAL|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
219549221|NCT00875524|BIOLOGICAL|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
219631828|NCT06388460|OTHER|Enhanced Usual Care|Providers enroll patients to receive an asthma educational workbook
219631829|NCT04812223|PROCEDURE|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
218937764|NCT03452163|DEVICE|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
219549222|NCT03249844|DRUG|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
218937765|NCT03452163|DEVICE|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
218937766|NCT00855881|DRUG|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
218937767|NCT02379663|DRUG|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
218937768|NCT02379663|DRUG|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
219549223|NCT03542669|DRUG|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
219549224|NCT03542669|DRUG|Doxorubicin|Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
219549225|NCT02942082|OTHER|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
219549226|NCT02942082|OTHER|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
219549227|NCT00672373|DRUG|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
219549228|NCT00672373|DRUG|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
219549229|NCT06562101|PROCEDURE|Intra-articular Stromal Vascular Fraction Injection|Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
219549230|NCT02672267|BIOLOGICAL|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
219549231|NCT02672267|OTHER|Placebo|Lactated Ringer's Solution
219549232|NCT06445049|OTHER|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~\- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
219549233|NCT04866979|DEVICE|Experimental: Continuous TBS (cTBS)|Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.
219549234|NCT04866979|DEVICE|Intermittent TBS (iTBS)|Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.
219549235|NCT04866979|BEHAVIORAL|Cognitive training (CT).|Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.
219549236|NCT04866979|DEVICE|Sham Stimulation (shamTBS)|"Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
219549237|NCT01305109|BIOLOGICAL|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
219549238|NCT01305109|BIOLOGICAL|Placebo|3 doses of 0.5 mL at 4 week intervals
219549239|NCT03791307|OTHER|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
219549240|NCT03791307|OTHER|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
219549241|NCT00538109|DRUG|Glivec®/Gleevec®|Chemotherapy
219549242|NCT03065751|DEVICE|Plasmaexchange|TPE against fresh frozen plasma
219549243|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
219549244|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
219549245|NCT06403033|DEVICE|Mini-implant-supported Twin-Block|Mini-implants will support the Twin-Block appliance during the functional treatment.
219549246|NCT06403033|DEVICE|Twin-Block|This is the main appliance that will be used to correct the Class II deformity.
218937769|NCT02379663|OTHER|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
218937770|NCT02321670|PROCEDURE|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
218937771|NCT02321670|PROCEDURE|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
219631830|NCT04812223|PROCEDURE|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
219631831|NCT04812223|PROCEDURE|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
219631832|NCT02421705|OTHER|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
219631833|NCT04710654|OTHER|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
219631834|NCT04710654|OTHER|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
219631835|NCT04710654|OTHER|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
219631836|NCT04710654|OTHER|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
219631837|NCT04710654|OTHER|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
219631838|NCT05372432|OTHER|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
219631839|NCT05372432|OTHER|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
219631840|NCT00662584|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
219631841|NCT03418688|DRUG|COR388|COR388 administered for 10 or 28 days.
219631842|NCT03418688|DRUG|Placebo|Placebo administered for 10 or 28 days.
219631843|NCT04398108|DRUG|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
219631844|NCT01629251|DEVICE|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
219631845|NCT03771911|DEVICE|AED|Instructions provided by an AED
219631846|NCT03771911|DEVICE|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
218937772|NCT03632486|OTHER|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines."
218937773|NCT03420352|DIAGNOSTIC_TEST|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
218937774|NCT05741749|DEVICE|Socket Seal Abutment|Customized Healing Abutment
219048642|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
219631847|NCT05508048|BEHAVIORAL|The existential approach and logotherapy-based psychosocial support program|Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
219631848|NCT03495531|DEVICE|Virtual Reality|Virtual Reality headset with calming scenery
219631849|NCT06174103|DEVICE|BiVACOR TAH System|The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
219631850|NCT04242810|DEVICE|rTMS|TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.
219631851|NCT04242810|DEVICE|Sham rTMS|An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.
219631852|NCT04242810|PROCEDURE|MRI scan|Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.
219631853|NCT00718614|PROCEDURE|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
219631854|NCT04653038|DRUG|MGD013|A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
219631855|NCT00677521|DRUG|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
219631856|NCT00413582|DRUG|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
219631857|NCT00413582|DRUG|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
219631858|NCT06031740|PROCEDURE|Sclerotherapy with 1.5% polidocanol|"2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~\- Group 2: Foam sclerotherapy."
219631859|NCT06031740|PROCEDURE|Foam sclerotherapy.|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
219631860|NCT03778892|BEHAVIORAL|'Project Raincoat' Mobile Phone Application|Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
219631861|NCT00674960|RADIATION|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
219631862|NCT02892773|DEVICE|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times per therapy session.~* Each I.S. therapy session will last about 15 minutes, 3 times per day.~* Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
219631863|NCT02892773|DEVICE|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times.~* Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~* Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
219631864|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
219631865|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
219631866|NCT06775340|DRUG|RSS0343 Tabella|RSS0343 tablets, oral;
219048643|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
219048644|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
219048645|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
219048646|NCT04953923|DRUG|Placebo|Capsule for oral administration
219631867|NCT05675930|DEVICE|Photobiomodulation Therapy|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
219631868|NCT05675930|OTHER|Placebo sham device|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
219631869|NCT05368493|OTHER|MRI task|Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
219631870|NCT06019845|DEVICE|MAGiC™|Robotic magnetic radiofrequency (RF) ablation catheter
219631871|NCT03208166|DEVICE|Doctormate|Ischemic conditioning device
219631872|NCT03208166|OTHER|Usual Care|Standard medical care
219631873|NCT03668119|BIOLOGICAL|Nivolumab|Specified dose on specified days
219631874|NCT03668119|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219631875|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with IUD
219631876|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with EUD
219631877|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with IUD
219631878|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with EUD
219631879|NCT02252393|OTHER|quality-of-life assessment|Ancillary studies
219631880|NCT05355051|DRUG|Azacytidine|Given by Vein (IV)
219631881|NCT05355051|DRUG|Pembrolizumab|Given by Vein (IV)
219631882|NCT05977335|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.
219631883|NCT04973930|BEHAVIORAL|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
219631884|NCT04973930|DRUG|Venlafaxine HCl ER|FDA-approved antidepressant medications
219631885|NCT05336227|BEHAVIORAL|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
219631886|NCT04850989|DEVICE|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
219631887|NCT03466684|OTHER|BIA-guided fluid resuscitation protocol|"In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA."
219631888|NCT03466684|OTHER|Traditional fluid resuscitation protocol|Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
219631889|NCT00789841|DEVICE|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
219631890|NCT00347958|BIOLOGICAL|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
219631891|NCT06576635|DRUG|Docetaxel|75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle
219631892|NCT06576635|DRUG|Paclitaxel|135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle
219631893|NCT06576635|DRUG|Gemcitabine|"1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)"
219048647|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
219549247|NCT05800262|BEHAVIORAL|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
219549248|NCT04797936|DRUG|BNO 1030|Imupret 25 drops х 6 times per day for 14 days
219549249|NCT04797936|OTHER|Standard care|isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
219549250|NCT02290262|OTHER|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
219549251|NCT06298162|OTHER|2 years after RYGB, no intervention. MRI measurement. Observational.|no intervention. MRI measurement. Observation.
219549252|NCT01127113|OTHER|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
219549253|NCT01127113|OTHER|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
219549254|NCT02342873|PROCEDURE|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
219549255|NCT02342873|PROCEDURE|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
219549256|NCT06389227|OTHER|dynamic ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
219549257|NCT06389227|OTHER|traditional training group|The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
219549258|NCT01978873|DRUG|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
219549259|NCT01978873|DRUG|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
219549260|NCT01421862|GENETIC|DNA methylation analysis|
219549261|NCT01421862|GENETIC|RNA analysis|
219549262|NCT01421862|GENETIC|gene expression analysis|
219549263|NCT01421862|GENETIC|microarray analysis|
219549264|NCT01421862|GENETIC|mutation analysis|
219549265|NCT01421862|GENETIC|nucleic acid sequencing|
219549266|NCT01421862|OTHER|laboratory biomarker analysis|
219549267|NCT04943822|OTHER|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
219549268|NCT01087502|DRUG|Glimepiride|1-4 mg daily after 12 weeks
219549269|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
219549270|NCT01087502|DRUG|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
219549271|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
219549272|NCT01087502|DRUG|Linagliptin|5 mg once daily
219549273|NCT04837664|DRUG|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
219549274|NCT04837664|DRUG|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
219549275|NCT04837664|DRUG|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
219549276|NCT00053339|DRUG|tamoxifen|
219549277|NCT00053339|DRUG|trastuzumab|
219549278|NCT03708536|DRUG|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
219631894|NCT06576635|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle
219048648|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
219048649|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
219048650|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
219549279|NCT03708536|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
219549280|NCT03708536|DRUG|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
219549281|NCT00157521|DRUG|L-arginine|
219549282|NCT04403035|DIAGNOSTIC_TEST|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
219549283|NCT05624424|DRUG|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
219549284|NCT05624424|DRUG|Propofol|Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
219549285|NCT05624424|DRUG|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
219549286|NCT05624424|DRUG|Sufentanil|Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
219631895|NCT06576635|DRUG|Vinorelbine|30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle
219631896|NCT00754234|BEHAVIORAL|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
219048651|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
219048652|NCT04143451|BIOLOGICAL|Vaxigrip tetra|quadrivalent influenza vaccine
219048653|NCT04143451|BIOLOGICAL|Fluzone high-dose|high-dose trivalent influenza vaccine
219048654|NCT04143451|DRUG|Aldara 5% Topical Cream|imiquimod cream
219048655|NCT04143451|DRUG|Aqueous cream BP|inactive aqueous cream
219631897|NCT06255756|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
219631898|NCT06255756|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
219631899|NCT06255756|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
219631900|NCT02693470|DRUG|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
219631901|NCT02504242|DEVICE|Inject BMP|
219631902|NCT02504242|PROCEDURE|Locally Harvested Bone|
219631903|NCT01941849|DRUG|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
219631904|NCT01941849|RADIATION|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
219631905|NCT00001680|DRUG|Thalidomide|
219631906|NCT01242670|BIOLOGICAL|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
219631907|NCT02318355|OTHER|normal saline|Crystalloid intravenous solution
219631908|NCT02318355|OTHER|lactated ringers|Crystalloid intravenous solution
219631909|NCT03567395|DIETARY_SUPPLEMENT|Melatonin|Melatonin (5 mg sublingual tablet) administered for 3 days
219631910|NCT03567395|DIETARY_SUPPLEMENT|Honey|Raw Honey (1.5 tablespoons) administered for 3 days
219631911|NCT05243433|DEVICE|Laparoscopic surgery using the Maestro Platform|Laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy performed using the Maestro Platform.
219631912|NCT03304977|OTHER|questionnaire via smartphone|questionnaire via smartphone
219631913|NCT02953210|DRUG|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
219631914|NCT02953210|DRUG|Lidocaine Hydrochloride|continuous infusion intravenous
219631915|NCT02953210|DRUG|Fentanyl Hydrochloride|intravenous
219048656|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
219048657|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
219631916|NCT02953210|DRUG|Clonidine Hydrochloride|clonidine intravenous pre induction
219631917|NCT02953210|DRUG|Midazolam Hydrochloride|premedication
219631918|NCT02953210|DRUG|Isoflurane Volatile Liquid|maintenance of general anesthesia
219631919|NCT02953210|DRUG|Rocuronium Injectable Solution|induction of general anesthesia
219631920|NCT02953210|DRUG|Propofol 1 % Injectable Suspension|induction of general anesthesia
219631921|NCT02953210|DRUG|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
219631922|NCT02953210|DRUG|Ranitidine Hydrochloride|at the end of the procedure
219631923|NCT02953210|DRUG|Ondansetron Hydrochloride|at the end of the procedure
219631924|NCT02953210|DRUG|Ketorolac Injectable Solution|at the of the procedure
218937775|NCT04944199|OTHER|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
218937776|NCT01103193|DRUG|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
218937777|NCT01103193|DRUG|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
218937778|NCT02156934|BIOLOGICAL|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
218937779|NCT04468152|BEHAVIORAL|Dietary habits and intake|Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
218937780|NCT00433134|BEHAVIORAL|Adherence|
218937781|NCT00946387|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
219048658|NCT00637195|BIOLOGICAL|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
218937782|NCT00946387|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
218937783|NCT03001817|DRUG|K-877|
218937784|NCT03001817|DRUG|Fenofibrate|
218937785|NCT03001817|DRUG|Placebo (for K-877)|
218937786|NCT03001817|DRUG|Placebo (for Fenofibrate)|
219048659|NCT00637195|BIOLOGICAL|Engerix™|Intramuscular administration, 4 doses.
219549287|NCT05624424|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
219549288|NCT05624424|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
219549289|NCT02588781|DRUG|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
219549290|NCT01151618|DEVICE|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
219549291|NCT04031235|BEHAVIORAL|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
219549292|NCT04031235|BEHAVIORAL|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
219549293|NCT01632306|DRUG|LY2090314|LY2090314 administered IV
219549294|NCT01632306|DRUG|FOLFOX|FOLFOX administered IV
219549295|NCT01632306|DRUG|Gemcitabine|Gemcitabine administered IV
219549296|NCT01632306|DRUG|Nab-paclitaxel|Nab-paclitaxel administered IV
219549297|NCT02510872|OTHER|18F-FDG PET combined with CT with iodinated contrast injection|
219549298|NCT02510872|OTHER|18F-FDG PET combined with CT without injection|
219549299|NCT04385485|PROCEDURE|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
219549300|NCT04385485|PROCEDURE|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
219549301|NCT05388071|OTHER|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
219549302|NCT05264207|BEHAVIORAL|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
219549303|NCT05264207|BEHAVIORAL|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
219549304|NCT00070122|DRUG|oxaliplatin|Given IV
219549305|NCT00070122|DRUG|leucovorin calcium|Given IV
219549306|NCT00070122|DRUG|capecitabine|Given orally
219549307|NCT00070122|BIOLOGICAL|bevacizumab|Given IV
219549308|NCT00070122|DRUG|fluorouracil|Given IV
219549309|NCT00070122|OTHER|laboratory biomarker analysis|Correlative studies
219631925|NCT02953210|DRUG|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
218937787|NCT00995800|DRUG|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
218937788|NCT03005405|PROCEDURE|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
218937789|NCT03005405|PROCEDURE|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
219048660|NCT03867513|OTHER|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
219631926|NCT06682689|DEVICE|transcutaneous vagus nerve stimulation|Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
219631927|NCT00915018|DRUG|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
219631928|NCT00915018|DRUG|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
219631929|NCT00915018|DRUG|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
219631930|NCT02752113|DRUG|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
219631931|NCT02752113|DRUG|Metformin and Insulin sc|Metformin and Insulin sc
219631932|NCT03258918|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
219631933|NCT00326716|DRUG|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
219631934|NCT04353713|DIETARY_SUPPLEMENT|40% Dextrose Gel|Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
219631935|NCT04353713|DIETARY_SUPPLEMENT|2% carboxymethylcellulose gel|placebo
219631936|NCT00684411|DRUG|Imatinib mesylate|
219631937|NCT03871751|BEHAVIORAL|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
219631938|NCT04258644|DRUG|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Combination therapy of 4 drugs, 21 days for one cycle.
219631939|NCT05253573|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
219631940|NCT05253573|BEHAVIORAL|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
218937790|NCT03005405|PROCEDURE|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
218937791|NCT03855059|DRUG|Placebos|This will be a saline solution of given IV or perineural.
218937792|NCT03855059|DRUG|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
218937793|NCT00210912|DRUG|topiramate|
218937794|NCT00035932|DRUG|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
218937795|NCT00035932|DRUG|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
218937796|NCT00035932|DRUG|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
219631941|NCT05253573|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
218937797|NCT02902562|PROCEDURE|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
219631942|NCT06573606|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
219631943|NCT05250570|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
218937798|NCT02902562|PROCEDURE|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
218937799|NCT06406543|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|an oral solution of vitamin D in a refined olive oil solution
218937800|NCT01388335|DRUG|warfarin|Administered orally
218937801|NCT01388335|DRUG|enzastaurin|Administered orally
218937802|NCT02829801|BEHAVIORAL|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
218937803|NCT02829801|BEHAVIORAL|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
218937804|NCT04292418|DRUG|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
218937805|NCT02087696|DRUG|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
218937806|NCT02268175|DRUG|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
218937807|NCT02268175|DRUG|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
218937808|NCT02268175|DRUG|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
218937809|NCT02268175|DRUG|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
218937810|NCT01688349|OTHER|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
218937811|NCT02752282|OTHER|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
218937812|NCT02752282|OTHER|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
219048661|NCT01092247|OTHER|Nutritional support with Standard diet|Nutritional support with Standard diet
219631944|NCT05250570|BEHAVIORAL|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
219631945|NCT00109655|BIOLOGICAL|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
219048662|NCT01092247|OTHER|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
219048663|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
219631946|NCT00901108|PROCEDURE|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
219631947|NCT00901108|PROCEDURE|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
219631948|NCT04490512|BIOLOGICAL|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
219631949|NCT05203796|DEVICE|Transcutaneous pulsed electrical stimulation (NuEyne 02)|Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
218937813|NCT01681719|DEVICE|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
219631950|NCT05203796|DEVICE|Sham stimulation|Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
219631951|NCT05125848|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
219631952|NCT03255161|BEHAVIORAL|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
219631953|NCT04181528|DEVICE|Total knee arthroplasty implant|In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
219631954|NCT01112488|OTHER|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
219631955|NCT05209815|BEHAVIORAL|Questionnaire|Questionnaire
219631956|NCT06328556|DRUG|botulinum toxin type A|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.
219631957|NCT06328556|PROCEDURE|Injection|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
218937814|NCT01681719|DEVICE|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
218937815|NCT01681719|DEVICE|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
218937816|NCT04638361|OTHER|Questionnaires|To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
219048664|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
219631958|NCT00058656|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
219631959|NCT04694599|DEVICE|Low flow oxygen|Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
219631960|NCT05445414|DEVICE|"SteWARdS Antibiotic Defense app"|"The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games."
219631961|NCT01232413|DRUG|Placebo|Oral
219631962|NCT01232413|DRUG|ASP1941|Oral
219631963|NCT01232413|DRUG|Moxifloxacin|Oral
219631964|NCT02774330|OTHER|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
219631965|NCT01551914|DEVICE|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
219631966|NCT01551914|DEVICE|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
219631967|NCT01311765|OTHER|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
219631968|NCT06287476|OTHER|Acute exercise bout on visit 2 and 3|1\) a 5-minute warm-up, 2) 4 minutes at 60% of the maximal workload (determined on Study Day 1), 3) 2 minutes active break at 15 watt, 4) 4 minutes at maximal workload.
219631969|NCT05978544|DRUG|Itolizumab|Patients to be treated with Itolizumab.
219631970|NCT02276560|DRUG|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
219631971|NCT02276560|DRUG|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
219631972|NCT02276560|DRUG|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
219631973|NCT00794248|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
219631974|NCT00794248|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
219631975|NCT01024140|DRUG|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
219631976|NCT02058537|DRUG|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
219631977|NCT03629938|OTHER|evaluation|evaluation and classification of medial longitudinal arch height of foot in adults
219631978|NCT04664023|PROCEDURE|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
219631979|NCT04664023|PROCEDURE|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
219631980|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
219631981|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
218937817|NCT03501108|OTHER|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
218937818|NCT06433492|DEVICE|Intra-articular injection|Three doses of intra-articular injection administered in weekely intervals.
218937819|NCT05711563|OTHER|Observational study|Observational study
219048665|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
219631982|NCT01561326|BEHAVIORAL|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
219631983|NCT01584986|BIOLOGICAL|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
219631984|NCT04601519|OTHER|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
219631985|NCT01415817|OTHER|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
219631986|NCT00641030|DRUG|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
219631987|NCT00641030|DRUG|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
219631988|NCT00641030|GENETIC|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
219048666|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
219048667|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
219048668|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
219048669|NCT03244228|DRUG|HTL0016878|Oral solution
219048670|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
219048671|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
219549310|NCT04091763|DRUG|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
219549311|NCT04091763|DEVICE|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
219549312|NCT00988468|PROCEDURE|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
219549313|NCT00988468|BEHAVIORAL|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
219549314|NCT00988468|BEHAVIORAL|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
219549315|NCT01156987|DEVICE|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
219549316|NCT04551183|OTHER|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
219549317|NCT04551183|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
219549318|NCT04509154|OTHER|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
219549319|NCT04509154|OTHER|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
219549320|NCT04584086|DEVICE|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation."
219549321|NCT00380588|DRUG|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
219549322|NCT00380588|DRUG|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
219549323|NCT01723683|DRUG|Surfactant|
219631989|NCT00641030|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
219631990|NCT00641030|OTHER|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
219631991|NCT00641030|OTHER|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
219631992|NCT00641030|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
219631993|NCT02892539|RADIATION|Coronary Angiography|
219631994|NCT05901441|DRUG|Hydromorphone|For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
219631995|NCT05901441|DRUG|Sufentanil|For those in SF group: they will be administered with 40 ug/ml sufentanil
219631996|NCT05901441|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
218937820|NCT04080167|BEHAVIORAL|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
218937821|NCT04080167|BEHAVIORAL|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
218937822|NCT03808259|DRUG|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
218937823|NCT03808259|DRUG|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
218937824|NCT03808259|DRUG|Placebo|Participants will receive matching placebo.
218937825|NCT04893304|DEVICE|co2 laser|types of laser
218937826|NCT02931773|DEVICE|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
218937827|NCT02389153|BEHAVIORAL|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
218937828|NCT01612832|DRUG|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
218937829|NCT01612832|OTHER|Control|pain treatment as customary in the department
218937830|NCT03639909|PROCEDURE|sweating function|Sweating dysfunction by Sudoscan
218937831|NCT03639909|PROCEDURE|Cardiovascular function|Cardiovascular (CV) tests
218937832|NCT00295373|DRUG|Rosuvastatin|
218937833|NCT00295373|BEHAVIORAL|Exercise Training|
219549324|NCT05088551|OTHER|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
219549325|NCT00919516|PROCEDURE|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
219549326|NCT05578794|OTHER|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
219549327|NCT00241982|DRUG|long-circulating liposomal prednisolone|
219549328|NCT01880476|OTHER|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
219549329|NCT03682276|BIOLOGICAL|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
219549330|NCT03682276|BIOLOGICAL|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
219549331|NCT02313662|DEVICE|NBI and PDD|
219549332|NCT04965831|DRUG|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
219631997|NCT05478460|OTHER|Hookwire localization|Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
219631998|NCT02893150|BEHAVIORAL|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
219631999|NCT02893150|BEHAVIORAL|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
219048672|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
219048673|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
219048674|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
219048675|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
219048676|NCT05158205|BEHAVIORAL|Yoga|12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
219048677|NCT05158205|BEHAVIORAL|Slow, deep breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
219632000|NCT02893150|BEHAVIORAL|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems\[47\]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
219632001|NCT04859400|DIETARY_SUPPLEMENT|Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)|The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
219632002|NCT04859400|BEHAVIORAL|Standardized nutritional program|During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
219632003|NCT04859400|BEHAVIORAL|Standardized exercise program|In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
219632004|NCT06191952|DIAGNOSTIC_TEST|Cognigram|Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.
219632005|NCT06191952|DIAGNOSTIC_TEST|Subjective cognitive decline questionnaire (SCD-Q)|The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).
218937834|NCT05970354|DRUG|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
219048678|NCT05158205|BEHAVIORAL|Control breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
218937835|NCT05970354|DRUG|VersaPro Cream Base for Compounding|Placebo
218937836|NCT03446404|DIAGNOSTIC_TEST|Standing Computed Tomography|Provides weight bearing 3D view of knees.
218937837|NCT00520806|DRUG|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
218937838|NCT00520806|DRUG|Placebo|Intravenous infusion for 48 h
218937839|NCT02167139|DRUG|Humira (adalimumab)|
218937840|NCT02167139|DRUG|SB5 (proposed biosimilar to adalimumab)|
219048679|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
219048680|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
219048681|NCT05532176|OTHER|Posture standards|Dynamic and static Postural measurements according to four types of tests
219048682|NCT06644170|BEHAVIORAL|Behavioral Intervention|Attend individual visits
219048683|NCT06644170|BEHAVIORAL|Group Therapy|Attend group visits
219048684|NCT06644170|DRUG|Psilocybin|Given PO
219632006|NCT06191952|DIAGNOSTIC_TEST|blood-based biomarkers|Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.
219632007|NCT06191952|DIAGNOSTIC_TEST|ki:elements digital speech biomarker for cognition (ki:e SB-C)|The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.
219632008|NCT04893447|BEHAVIORAL|SPI+|Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.
219632009|NCT04893447|BEHAVIORAL|SP+CC (Caring Contacts)|SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
219632010|NCT02965001|DRUG|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
219632011|NCT05999201|OTHER|craniocervical neural mobilization|the patients will receive The craniocervical neural mobilization in the form of passive craniocervical flexion in which An anterior rotation of the head will be done which stimulates the meninges.To increase mechanical stress in the nervous system, patients will be asked to do a descent and retropulsion of the shoulders while gradually extending both elbows. in addition to Passive lateral cervical sliding and Craniocervical flexion with mouth opening.The neural mobilization should be mild, progressive, and slow. The protocol lasted 15 minutes and also the patients will receive selected physiotherapy program
219632012|NCT05999201|OTHER|selected physiotherapy program|the patients will receive selected physiotherapy program in the form of Suboccibital muscles inhibition suboccipital inhibition technique (SIT), from supine lying position, the therapist will sit at the patient's head head with the elbows rested on the surface of the table. Then, the therapist will place both hands behind the head of the patient with the palms facing upwards, the fingers flexed, and the finger pads positioned on the posterior arch of the atlas to allow the occiput to rest in the palm of the hands. the patients will receive also trigger point release technique in the form of An ischemic compression for sternocleidomastoid muscle, temporal muscle, upper trapezius muscle and splines muscles
218937841|NCT04038021|BEHAVIORAL|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
218937842|NCT04038021|BEHAVIORAL|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
218937843|NCT04413617|DRUG|PF-06650833|400 mg
218937844|NCT04413617|DRUG|PF-06651600|100 mg
218937845|NCT04413617|DRUG|Tofacitinib|11 mg
218937846|NCT04721301|COMBINATION_PRODUCT|Nivolumab plus Ipilimumab plus Maraviroc|In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
218937847|NCT05739201|PROCEDURE|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
218937848|NCT05739201|PROCEDURE|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
218937849|NCT05739201|PROCEDURE|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
219048685|NCT06644170|OTHER|Questionnaire Administration|Ancillary studies
219632013|NCT05446701|DIAGNOSTIC_TEST|serum level of FAM19A5|Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
219632014|NCT04471688|DIAGNOSTIC_TEST|infectious disease screening|Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
219632015|NCT01512004|DRUG|Propiverine Hydrochloride|drug of oral capsule
219632016|NCT01512004|DRUG|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
219632017|NCT03136237|DRUG|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
219632018|NCT03136237|DRUG|Digoxin|Day 1 of Cohort 1
219632019|NCT03136237|DRUG|BCX7353 + digoxin|Day 19 of Cohort 1
219632020|NCT03136237|DRUG|Rosuvastatin|Day 1 of Cohort 2
219632021|NCT03136237|DRUG|rosuvastatin + BCX7353|Day 15 of Cohort 1
219632022|NCT03136237|DRUG|Cyclosporine + BCX7353|Day 14 of Cohort 3
219632023|NCT02861105|DRUG|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
219632024|NCT02861105|OTHER|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
219632025|NCT01609010|DRUG|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
219632026|NCT01609010|DRUG|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
219632027|NCT06210113|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
219632028|NCT00651261|DRUG|cytarabine|Given IV
219632029|NCT00651261|DRUG|daunorubicin|Given IV
219632030|NCT00651261|DRUG|midostaurin|Given orally
219632031|NCT00651261|OTHER|placebo|Given orally
219632032|NCT00651261|DRUG|dexamethasone acetate|ocular medication administration
219632033|NCT02110303|DRUG|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
219632034|NCT02110303|DRUG|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
219632035|NCT03095144|DEVICE|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
219632036|NCT03095144|DEVICE|General anesthesia|Pyloromyotomy under general anesthesia
219048686|NCT03492333|OTHER|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
219632037|NCT00687271|DRUG|MK-6213|MK-6213 160 mg for 4 weeks.
219632038|NCT00687271|DRUG|Atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
219632039|NCT00687271|DRUG|Placebo for MK-6312 160 mg|
219632040|NCT00687271|DRUG|Placebo for Atorvastatin 20 mg|
219632041|NCT01542489|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
219632042|NCT01542489|DRUG|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
219632043|NCT01542489|DRUG|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
219632044|NCT00280280|DRUG|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
219632045|NCT02618603|DRUG|Botulinum toxin A|
219632046|NCT02618603|DRUG|Triamcinolone Acetonide|
219632047|NCT02314260|OTHER|bishop score calculation|Assessment of bishop score by vaginal examination
219632048|NCT02314260|OTHER|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
219549333|NCT01230229|PROCEDURE|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
219549334|NCT01230229|OTHER|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
219549335|NCT01175330|DRUG|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
219549336|NCT01175330|DRUG|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
219549337|NCT05692791|DIAGNOSTIC_TEST|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
219549338|NCT05692791|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
219549339|NCT03567122|OTHER|Internal Focus of Attention|Information already included in arm/group descriptions.
219549340|NCT03567122|OTHER|External Focus of Attention|Information already included in arm/group descriptions.
219549341|NCT03567122|OTHER|Control|Information already included in arm/group descriptions.
219549342|NCT03720548|DRUG|LY3372993|Administered IV.
219549343|NCT03720548|DRUG|Placebo|Administered IV.
219549344|NCT03366428|DRUG|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
219549345|NCT02663661|PROCEDURE|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
219549346|NCT02663661|OTHER|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
219549347|NCT05818345|BEHAVIORAL|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
219549348|NCT02684786|DRUG|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
219549349|NCT02684786|PROCEDURE|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
219549350|NCT02684786|DRUG|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
219549351|NCT01980173|PROCEDURE|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
219632049|NCT02314260|OTHER|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
219632050|NCT02314260|PROCEDURE|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
219632051|NCT00126347|PROCEDURE|supplementation with betaine, serine, and folic acid|
219632052|NCT06649968|DEVICE|DESC-Glove (active)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, receiving vibratory stimuli that are synchronized with the exercises being performed.
219632053|NCT06649968|DEVICE|DESC-Glove (sham)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, but will not receive any vibratory stimuli.
219632054|NCT06649968|OTHER|Traditional rehabilitation|Traditional rehabilitation treatment for the upper limb. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20- minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. The DESC- Glove will not be used during this treatment.
219549352|NCT01980173|DEVICE|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
219549353|NCT00185120|DRUG|Olmesartan medoxomil|
219549354|NCT00185120|DRUG|Hydroclorothiazide|
219549355|NCT00185120|DRUG|Benazepril|
219549356|NCT00185120|DRUG|Amlodipine|
219549357|NCT00804973|DRUG|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
219549358|NCT00804973|DRUG|Placebo injection|saline solution, injection, once
219549359|NCT00804973|DRUG|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
219549360|NCT00804973|DRUG|Placebo capsule|4 capsules, once
219549361|NCT01916694|DEVICE|Blue tooth enabled glucose meter with smart phone application|
219549362|NCT01916694|BEHAVIORAL|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
219549363|NCT00061776|DRUG|Capsaicin Dermal Patch|
219549364|NCT00903292|DRUG|erlotinib (Tarceva)|chemotherapy with erlotinib
219549365|NCT00903292|DRUG|pemetrexed (Alimta)|Chemotherapy with pemetrexed
219549366|NCT01820091|DRUG|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
219549367|NCT01820091|DRUG|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
219549368|NCT06316180|DRUG|drospirenone/estetrol 3mg/14.2mg|Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
219549369|NCT00844974|OTHER|Prevalence|Mood and cognitive assessments
219549370|NCT05232773|PROCEDURE|Assessment|Evaluation of clinical and kinematic parameters
219549371|NCT06411392|RADIATION|Stereotactic Antiarrhythmic Radiotherapy|Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
219549372|NCT00169130|DRUG|doxorubicin|
219549373|NCT00169130|DRUG|cyclophosphamide|
219549374|NCT00169130|PROCEDURE|Autologous stem cell transplantation|
219549375|NCT00834314|PROCEDURE|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
219549376|NCT00834314|PROCEDURE|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
219549377|NCT01781117|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
219549378|NCT01781117|DEVICE|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
219549379|NCT01714284|BEHAVIORAL|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
219549380|NCT01714284|BEHAVIORAL|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
219549381|NCT00459407|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
219549382|NCT00459407|DRUG|placebo|Given orally
219549383|NCT00459407|OTHER|immunohistochemistry staining method|Correlative studies
219549384|NCT00459407|OTHER|immunoenzyme technique|Correlative studies
219549385|NCT00459407|OTHER|laboratory biomarker analysis|Correlative studies
219549386|NCT00459407|PROCEDURE|biopsy|Undergo biopsy
219549387|NCT00459407|OTHER|mass spectrometry|Correlative studies
219549388|NCT00459407|OTHER|high performance liquid chromatography|Correlative studies
219549389|NCT05204537|PROCEDURE|Lung parenchyma resection|Lung parenchyma removal
219549390|NCT05204537|PROCEDURE|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
219048687|NCT06160076|DEVICE|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
219549391|NCT05698407|DRUG|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
219549392|NCT05698407|DRUG|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
219549393|NCT01336088|DRUG|ADX48621|oral administration
219549394|NCT01336088|DRUG|Placebo|oral administration
219549395|NCT03330132|BIOLOGICAL|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
219549396|NCT03330132|BIOLOGICAL|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
219632055|NCT06407765|OTHER|Dual task training|Dual task training incorporates both cognitive and motor tasks. Tasks like walking and asking the patient to point towards objects, collect start from the objects hanging above the patient and asking the patient to name the objects shown to him/her. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
219632056|NCT06407765|OTHER|Dual task training with backward walking|This group will get both dual task training and backward walking. For dual task training same protocol as active comparator is followed. For backward walking; the patient is firstly asked to walk backward with complete physiotherapist assistance. Secondly, the patient is asked to walk for 15 m through the treatment room's hallway while holding a safety bar with the hand on the unaffected side. Third, without using a safety bar, the participants were urged to walk freely. Lastly, the participants tried to walk backwards at a reasonable pace while progressively increasing their distance travelled and speed. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
219632057|NCT00858533|BEHAVIORAL|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
219632058|NCT02780726|DRUG|roxadustat|Oral
219632059|NCT05525403|OTHER|Knee Extension Exercise|Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
219632060|NCT05525403|OTHER|Quiet Rest|Participants will sit quietly for two minutes, three times.
219632061|NCT02463929|DRUG|Diphenhydramine|Intravenous Injection
218937850|NCT06425835|OTHER|VR device|"The VR device consists of a pair of VR glasses with a video previously chosen and installed. Patient preparation must be done before initiating the protocol.~The first step is to choose patient candidates for VR who are understanding and interested. Guardian approval is required; then it is necessary to explain the principle, the stages and the benefits of the care.~The intensity of pain is calculated according to the visual analog scale before, during the procedure and 30 minutes after as well as the max VAS during the procedure, the 'Children Fear Scale', the satisfaction score and any adverse effects are noted."
218937851|NCT01553370|OTHER|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
218937852|NCT01553370|OTHER|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
218937853|NCT00641368|BEHAVIORAL|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
219632062|NCT02463929|DRUG|normal saline|Intravenous Injection
219632063|NCT02463929|DRUG|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
219632064|NCT02463929|DRUG|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
219632065|NCT02463929|DRUG|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
219632066|NCT06684184|DRUG|Blinatumomab|The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.
219632067|NCT05164484|DEVICE|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
219632068|NCT06149364|BEHAVIORAL|ISKE|"The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken."
218937854|NCT00641368|OTHER|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
218937855|NCT04205383|OTHER|biological analyses|The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.
218937856|NCT00989872|DRUG|EDP-322|
219632069|NCT04793009|DEVICE|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
219632070|NCT01333904|DRUG|PUR118|inhaled
219632071|NCT04439968|OTHER|Clinical algorithm|In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
218937857|NCT00488553|BEHAVIORAL|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
218937858|NCT05322668|DEVICE|Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)|"All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~* Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~* Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin"
219048688|NCT06160076|DEVICE|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
219048689|NCT00799968|DRUG|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
219048690|NCT00799968|DRUG|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
219048691|NCT03025828|DRUG|ACTHar|for 6 months
219048692|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
219048693|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
219549397|NCT03330132|BIOLOGICAL|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
219549398|NCT03330132|BIOLOGICAL|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
219549399|NCT00659828|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
219549400|NCT04385251|OTHER|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"
219549401|NCT00408577|DRUG|L-arginine|
219549402|NCT01824576|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
219549403|NCT00028873|DRUG|docetaxel|
219549404|NCT00028873|DRUG|laniquidar|
219549405|NCT00028873|DRUG|paclitaxel|
219549406|NCT03438643|DIAGNOSTIC_TEST|Blood samples|Blood samples (42mL) will be taken before and during treatment.
219549407|NCT03438643|DIAGNOSTIC_TEST|skin biopsy|skin biopsy will be taken before and during treatment.
219549408|NCT05233254|BEHAVIORAL|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
219549409|NCT05674188|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
219549410|NCT02208973|DRUG|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
219549411|NCT02208973|DRUG|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
219549412|NCT00734825|OTHER|Omnipaque|oral contrast for CT scan
219549413|NCT02775994|DRUG|Canakinumab|interleukin beta (IL-1) antagonist
219549414|NCT00154258|DRUG|Clozapine|
219549415|NCT00735176|PROCEDURE|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
219549416|NCT00735176|PROCEDURE|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
219549417|NCT06181422|DRUG|Metformin|metformin 500 mg
219549418|NCT06181422|DRUG|Lactoferrin|lactoferrin 100 mg
219549419|NCT02835157|DRUG|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
219549420|NCT02835157|DRUG|0.9%sodium chloride|saline as boluses would be administered
219549421|NCT01246453|DRUG|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
219549422|NCT03727139|DRUG|Rasagiline|Rasagiline Tablets
219549423|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
219048694|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
219632072|NCT05483686|BEHAVIORAL|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
219632073|NCT05483686|BEHAVIORAL|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
219632074|NCT01543178|DRUG|open-label rifaximin|550 mg three times a day (open-label)
219632075|NCT01543178|DRUG|double-blind placebo|3 times a day (double-blind)
219632076|NCT01543178|DRUG|double-blind rifaximin|550 mg three times a day (double-blind)
219632077|NCT04150978|OTHER|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
219632078|NCT04150978|OTHER|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
219632079|NCT04150978|DRUG|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
219632080|NCT06046495|DRUG|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
219632081|NCT04587869|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
219632082|NCT03351608|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
219632083|NCT03351608|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
219632084|NCT03351608|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
219632085|NCT03351608|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
219632086|NCT04400383|DRUG|AB011 Injection|"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."
219632087|NCT02727478|OTHER|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
219632088|NCT01077778|PROCEDURE|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
219632089|NCT03230578|OTHER|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
219632090|NCT00933907|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks
219632091|NCT00000115|DRUG|Acetazolamide|
219632092|NCT02334878|BIOLOGICAL|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
219632093|NCT02334878|PROCEDURE|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40\*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra \& through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted \& the remaining tape cut off at the level of the skin.
219632094|NCT01408511|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
219632095|NCT05961956|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
219632096|NCT05031312|PROCEDURE|inferior oblique weakening|inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
219632097|NCT00808210|DRUG|Infliximab|Intravenous repeating dose
219632098|NCT00808210|DRUG|Methotrexate|Oral or parenteral repeating dose
219632099|NCT00808210|DRUG|Methylprednisolone|Intravenous repeating dose
219632100|NCT00808210|DRUG|Ocrelizumab|Intravenous repeating dose
219632101|NCT00808210|DRUG|Placebo|Intravenous repeating dose
219632102|NCT03816020|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside capsules 250mg x 2 BID
219632103|NCT03816020|OTHER|Placebo|Placebo capsules BID
219048695|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
219048696|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
219632104|NCT04651933|GENETIC|Homologous recombination deficiency model|A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
219632105|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
219632106|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
219632107|NCT04178902|DRUG|ABBV-467|Intravenous (IV) Infusion
219632108|NCT04752956|OTHER|"Total nasal symptom score (TNSS)"|TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
219632109|NCT04752956|BEHAVIORAL|"Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)"|"PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment."
219632110|NCT04752956|DIAGNOSTIC_TEST|Nasal cytology|In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
219632111|NCT04752956|DIAGNOSTIC_TEST|anterior rhinomanometry|Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
219632112|NCT03877068|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
219632113|NCT03877068|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
219632114|NCT01757093|DEVICE|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
219632115|NCT01757093|DEVICE|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
219632116|NCT05440045|DRUG|6MW3211|6MW3211 injection, 30mg/kg, Q2W
219632117|NCT01699672|OTHER|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
219048697|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
219048698|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
219632118|NCT04888793|DIAGNOSTIC_TEST|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
219632119|NCT06088680|DEVICE|Glycar Pericardial Patch|Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
219632120|NCT02093780|BEHAVIORAL|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
219048699|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
219048700|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
219632121|NCT02093780|BEHAVIORAL|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
219632122|NCT00640120|DEVICE|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
219632123|NCT03915301|PROCEDURE|Satisfaction assessed by the VAS [followed by its scale information in the Description]|Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
219632124|NCT04723446|DRUG|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
219632125|NCT04723446|DRUG|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
219632126|NCT04723446|OTHER|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum \& Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
219632127|NCT04723446|OTHER|No rinsing|No rinsing
219632128|NCT02851121|OTHER|Sensorial stimulations|
219632129|NCT02851121|OTHER|Experimental protocols|
219632130|NCT02851121|BEHAVIORAL|Emotional protocols|
219632131|NCT02851121|OTHER|Protocol with a spatial dimension|
219632132|NCT00571142|PROCEDURE|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
219632133|NCT00571142|PROCEDURE|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
219632134|NCT04483830|DRUG|Sulodexide|an oral dose of 2 capsules each day for 21 days
219632135|NCT04483830|DRUG|Placebo|an oral dose of 2 capsules each day for 21 days
219632136|NCT04743544|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
219632137|NCT04439474|DRUG|Vitamin D3|For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
219632138|NCT04439474|DRUG|Routine treatment|In this group, patients receive their usual medications and treatments
219632139|NCT02108548|DRUG|ASP7657|oral
219632140|NCT02108548|DRUG|Placebo|oral
219632141|NCT02108548|DRUG|naproxen|oral
219632142|NCT06303401|OTHER|SI joint thrust manipulation|"experimental group given the thrust manipulation along with heating pad. 3 sessions per week will be given for 4 weeks. The pain measure by using NPRS, functional status and disability through ODI will be evaluated.~after every 3 sessions."
219632143|NCT06303401|OTHER|pelvic stabilization exercises|Heating pad for 10- 15 mints Pelvic stabilization exercises include Bridging (3 sets x 10 reps with 10 secs hold) Pelvic Tilt exercise(3 sets x 10 reps with 10 secs hold) Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold) clamshell Exercise (3 sets x 10 reps with 10 secs hold) .3 sessions per week will be given for 4 weeks. The pain using NPRS , functional status and disability will be evaluated by using ODI after every 3 sessions.
219632144|NCT01020630|DRUG|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
219632145|NCT01020630|DRUG|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
219632146|NCT02690818|BEHAVIORAL|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
219632147|NCT04646343|OTHER|administration of F-CISS and F-PWES pre version|the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.
219632148|NCT04646343|OTHER|administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36|The administration will required 25 minutes
219632149|NCT06224556|COMBINATION_PRODUCT|Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program|"Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed."
219632150|NCT05042999|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
219632151|NCT00840957|BIOLOGICAL|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
219632152|NCT03230058|DRUG|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
219632153|NCT00768703|DEVICE|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
219632154|NCT01631643|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
219632155|NCT02368223|DEVICE|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
219632156|NCT03885895|DRUG|Tranexamic Acid Injectable Product|Ampoules used for intradermal injection
219632157|NCT03885895|DEVICE|Q switched KTP (532nm)|LASER
219632158|NCT03561714|BEHAVIORAL|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
219632159|NCT00540150|BIOLOGICAL|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
219632160|NCT02019264|DRUG|Lorcaserin hydrochloride|APD356 10 mg twice daily
219632161|NCT02019264|DRUG|Placebo|Placebo twice daily
219632162|NCT02682303|DEVICE|Elastic Bandage (Idealplast C®)|"Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
219632163|NCT02682303|DEVICE|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group."
219632164|NCT05244070|DRUG|BMS-986403|Specified dose on specified days
219632165|NCT05244070|DRUG|Fludarabine|Specified dose on specified days
219632166|NCT05244070|DRUG|Cyclophosphamide|Specified dose on specified days
219632167|NCT00089687|DRUG|GBR 12909|
219632168|NCT03306628|OTHER|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
219632169|NCT03786328|BEHAVIORAL|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
219632170|NCT03786328|BEHAVIORAL|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
219632171|NCT02087540|DRUG|Telmisartan 80mg|
219632172|NCT02087540|DRUG|Rosuvastatin 20mg|
219632173|NCT02087540|DRUG|Rosuvastatin 10mg|
219632174|NCT02087540|DRUG|Placebo(for Telmisartan 80mg)|
219632175|NCT02087540|DRUG|Placebo(for Rosuvastatin 20mg)|
219632176|NCT02087540|DRUG|Placebo(for Rosuvastatin 10mg)|
219632177|NCT05494944|PROCEDURE|ThuLEP|Minimal invasive prostate intervention
219632178|NCT03929120|BIOLOGICAL|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
219632179|NCT05552248|DEVICE|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
219632180|NCT05552248|OTHER|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
219632181|NCT05552248|DEVICE|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
219632182|NCT05552248|OTHER|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
219632183|NCT00562172|DRUG|Insulin glargine|Once daily in the morning
219632184|NCT00562172|DRUG|Glimepiride|Once daily in the morning
219632185|NCT00562172|DRUG|Metformin|At least 1000 mg/day
219632186|NCT02582892|DRUG|Vit D|20 mg/day
219632187|NCT02906501|PROCEDURE|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
219632188|NCT02906501|PROCEDURE|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
219632189|NCT04614025|BIOLOGICAL|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
219632190|NCT00703586|DRUG|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
219632191|NCT01921322|DEVICE|Pump|722 Paradigm Real-Time System
219632192|NCT01921322|OTHER|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
219632193|NCT04994691|OTHER|No Message|No messages are sent
219632194|NCT04994691|OTHER|Standard message|2 MyChart reminders that child is overdue for well child check visit
219632195|NCT04994691|OTHER|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
219632196|NCT04359940|DIAGNOSTIC_TEST|Cardiac MRI|For clinical surveillance
219632197|NCT01154114|DRUG|darapladib|darapladib 40 mg oral dose
219632198|NCT06534099|OTHER|Control|Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
219632199|NCT06534099|OTHER|Experimental|The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
219632200|NCT02573181|BIOLOGICAL|V114|V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
219632201|NCT02573181|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
219632202|NCT03143985|DRUG|Vactosertib|Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
219632203|NCT03143985|DRUG|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
219632204|NCT05057598|OTHER|Community-based participatory research on diet and lifestyle|"The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information.~The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week."
218937859|NCT05680688|OTHER|Manual Therapy|"* Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
219632205|NCT02271152|PROCEDURE|FAST mapping and ablation|
219632206|NCT02271152|PROCEDURE|PVI|
219632207|NCT02251457|DRUG|Ranolazine|Ranexa is FDA approved for chronic angina
219632208|NCT03850496|DEVICE|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
219365923|NCT03728387|OTHER|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
219632209|NCT02846181|DRUG|[14C]-SK-1405|
219632210|NCT03731819|DIAGNOSTIC_TEST|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
219632211|NCT02605343|OTHER|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
219632212|NCT00044629|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|
219632213|NCT00044629|DRUG|zolpidem tartrate (Ambien)|
219632214|NCT00044629|DRUG|Placebo|
219632215|NCT02084108|OTHER|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
219632216|NCT00081224|DRUG|capecitabine|
219632217|NCT00081224|DRUG|celecoxib|
219632218|NCT00081224|RADIATION|radiation therapy|
219632219|NCT00081224|PROCEDURE|surgery|
218937860|NCT04162860|DEVICE|Eso-SPONGE® device|Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
219632220|NCT06340841|BEHAVIORAL|Personal Incentives|The participant receives incentives directly if they complete an activity on a given day.
218937861|NCT04106076|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
218937862|NCT02801019|OTHER|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
218937863|NCT02801019|OTHER|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
218937864|NCT02657408|DRUG|BI 1026706|
219632221|NCT06340841|BEHAVIORAL|Personal Restorative Incentives|The participant receives incentives directly if they complete an activity on a given day. They are given an additional incentive to return to completing activities if they did not complete an activity on a prior day.
218937865|NCT02657408|DRUG|Placebo|
218937866|NCT05398913|DRUG|Rimonabant|Rimonabant
218937867|NCT00863213|PROCEDURE|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
219632222|NCT06340841|BEHAVIORAL|Charity Incentives|The participant earns compensation for charity if they complete an activity on a given day.
219048701|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
219048702|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
219048703|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
219048704|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
219048705|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
219048706|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
219048707|NCT05233462|OTHER|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
219048708|NCT05233462|OTHER|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
219632223|NCT06340841|BEHAVIORAL|Charity Restorative Incentives|The participant earns compensation for charity if they complete an activity on a given day. They are given an additional incentive for charity to return to completing activities if they did not complete an activity on a prior day.
219632224|NCT00737906|PROCEDURE|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
219632225|NCT03356080|DRUG|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
219632226|NCT03356080|DRUG|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
219632227|NCT03356080|DRUG|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
219632228|NCT03356080|DRUG|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
219632229|NCT05628428|OTHER|Exercise to strengthen neck area.|An exercise protocol will be carried out through educational videos. There will be a total of four videos which will pose exercises for two weeks each. These exercises will be done twice a week. A reminder will be sent by email on the days that they must be carried out.
219632230|NCT05628428|OTHER|Information|Information will be provided on neck pain and how exercise is able to help prevent it.
219632231|NCT01814696|DEVICE|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
219632232|NCT02084732|DRUG|Sorafenib|drug
219632233|NCT02146196|DEVICE|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
219632234|NCT02146196|DEVICE|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
219632235|NCT06181188|DRUG|Ketamine|Patients will receive a combination of ketamine and midazolam for conscious sedation
219632236|NCT06181188|DRUG|Midazolam|Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
219632237|NCT06181188|DRUG|Fentanyl|Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
219632238|NCT06180096|DRUG|Riociguat film coated tablets|1 tablet of 2.5 mg Riociguat
219632239|NCT06180096|DRUG|Adempas Filmtabletten|1 tablet of 2.5 mg Riociguat
219632240|NCT06574971|DEVICE|Low intensity focused ultrasound using the NeurGear Zenbud|The NeurGear Zenbud is a wearable earbud that delivers low intensity focused ultrasound to the auricular branch of the vagus nerve
219632241|NCT03656653|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
219632242|NCT03755557|DRUG|Rhinocort|Application of a nasal spray
219632243|NCT03755557|DRUG|Budesolv|Application of a nasal spray
219632244|NCT03755557|OTHER|Placebo|Application of a nasal spray
219632245|NCT00001504|DRUG|9-cis-Retinoic Acid|
219632246|NCT05424510|DRUG|Ringer's Lactate|500 ml of Ringer's Lactate
219632247|NCT05424510|OTHER|IV line|Placing of an IV line before surgery
219632248|NCT01564108|DRUG|Ranibizumab|Series of intravitreal injections of Ranibizumab
219632249|NCT02730403|OTHER|Treatment As Usual|
219632250|NCT06682403|BEHAVIORAL|Received cable lock as default|Participants will receive a cable lock as the default safety device option after filling out the survey. If the participant took a cable lock during their hospital visit and noted this in the survey, they will not be shipped a cable lock. If participants did not take a cable lock and noted this in the survey, they will be shipped a cable lock.
219632251|NCT06682403|BEHAVIORAL|Choice between cable lock or lock box|Participant will have the option to select a lock box or cable lock shipped to their address after filling out the study survey.
219632252|NCT02266797|DRUG|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
219048709|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
219048710|NCT01650363|OTHER|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
219048711|NCT01650363|DRUG|Homeopathic placebo medication|2-3 mm small spheric suger pils
219365924|NCT03360760|DRUG|Doxorubicin|60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
219632253|NCT02266797|OTHER|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
219632254|NCT01391858|DRUG|lyrica|150mg of pregabalin/placebo
219632255|NCT04435418|DRUG|Apixaban|The decision to treat with apixaban and the timing of initiation will be at the attending physicians' discretion, independent of enrolment in EASSE.
219632256|NCT02162537|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
219632257|NCT02162537|DRUG|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
219632258|NCT02162537|DRUG|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
219632259|NCT02162537|RADIATION|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
219206574|NCT06978257|BEHAVIORAL|Digital positive affect intervention (PAI)|"The Positive Affect Intervention (PAI) is a fully digital, self-guided program uniquely designed to deliver weekly 30-minute online sessions focused on cultivating positive emotions, meaning, and engagement, alongside daily ecological momentary prompts delivered thrice daily over six weeks. Distinctively, the intervention seamlessly integrates multimedia content (e.g., brief weekly videos introducing each session's core principles), practical exercises, and in-the-moment reflection, aiming to reinforce positive affect skills in real time. Its structure not only emphasizes proactive skill application through digital reminders but also systematically assesses user engagement and perceived helpfulness via ecological momentary assessments and post-session feedback questionnaires.~Unlike conventional digital interventions that primarily focus on symptom reduction through passive content consumption, this PAI leverages continuous ecological momentary engagement via a dedicated mobile app, e"
219632260|NCT02707484|DRUG|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
219632261|NCT02707484|DRUG|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
219632262|NCT02707484|DRUG|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
219632263|NCT00663416|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
219632264|NCT00663416|DRUG|Saline placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
219632265|NCT01901458|DEVICE|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
219632266|NCT01901458|DEVICE|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
219632267|NCT02119403|OTHER|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
219632268|NCT06266195|DIAGNOSTIC_TEST|sierological test|sierological test: circulant vescicles
219632269|NCT01049256|OTHER|carbon dioxide|sinusoidal carbon dioxide administration
219632270|NCT03039764|DEVICE|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
219632271|NCT05643742|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
219632272|NCT05099497|OTHER|Using Practice Facilitators to Support Physicians|Utilize practice facilitators to empower family physicians to contact those who remain unvaccinated have better access to the COVID-19 vaccine.
219632273|NCT02293512|BEHAVIORAL|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
218937868|NCT00863213|DRUG|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
219632274|NCT02293512|BEHAVIORAL|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
219632275|NCT02293512|BEHAVIORAL|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
219632276|NCT04245748|DRUG|Escitalopram|Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
219632277|NCT04245748|DRUG|Duloxetine|Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
219632278|NCT04950348|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
219632279|NCT04950348|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
218937869|NCT01693978|BEHAVIORAL|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007)."
218937870|NCT01693978|BEHAVIORAL|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
218937871|NCT02471326|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
218937872|NCT03866876|OTHER|Eucapnic pH|Collection of Biological marker (proposed by Racinet): eucapnic pH
218937873|NCT04165421|BEHAVIORAL|Family intervention group|Education and Family conversations
218937874|NCT05805319|OTHER|increasing total fiber intake|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
218937875|NCT00324961|DRUG|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
218937876|NCT04193644|BEHAVIORAL|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
218937877|NCT04193644|BEHAVIORAL|Walking training|Walking training with moderate intensity
219048712|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
219632280|NCT05333302|BIOLOGICAL|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.
219632281|NCT05333302|DRUG|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
219632282|NCT00488644|DRUG|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
219632283|NCT00488644|DRUG|Liothyronine|15 mcg PO Daily for 8 Weeks
219632284|NCT03221816|DRUG|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
219632285|NCT03221816|DRUG|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
219632286|NCT05356520|PROCEDURE|Endoscopy Ivor-lewis|Endoscopy Ivor-lewis
219632287|NCT05356520|PROCEDURE|Laparoscopic transabdominal enlarged gastrectomy|Laparoscopic transabdominal enlarged gastrectomy
219632288|NCT05349656|PROCEDURE|TQL block|Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle
219632289|NCT05349656|PROCEDURE|PENG block|Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
219632290|NCT06142994|DIETARY_SUPPLEMENT|Atusin CAP|This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
219632291|NCT06142994|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
219632292|NCT02977572|DEVICE|Non-Invasive Ventilation|In arm description
219632293|NCT02977572|DEVICE|Continuous Positive AirwayPressure CPAP|In arm description
219632294|NCT04750265|DEVICE|Robotic assisted early mobilization|Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
219632295|NCT03957473|DEVICE|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
219632296|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily
219632297|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
219632298|NCT01197534|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
219632299|NCT01741987|OTHER|Optive ®|instilation of 1 drop each eye 4 times per day
219632300|NCT01741987|OTHER|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
219632301|NCT03117153|OTHER|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
219632302|NCT03117153|OTHER|placebo|same flavor solution, brush three times daily
219632303|NCT05630287|DRUG|[14C]-Selpercatinib|Administered as an oral solution
219632304|NCT05630287|DRUG|Selpercatinib|Administered orally
219048713|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
219048714|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
219632305|NCT05630287|DRUG|[14C]-Selpercatinib|Administered intravenously
219632306|NCT04407182|DIETARY_SUPPLEMENT|Viusid and Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days."
219632307|NCT02783495|BEHAVIORAL|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
219632308|NCT04867226|DRUG|Colchicine 0.5 MG|participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .
219632309|NCT04867226|DRUG|usual care treatment|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
219632310|NCT05696990|OTHER|3/7 Resistance Training Method|3/7 Resistance Training Method
219632311|NCT05696990|OTHER|3X9 Resistance Training Method|3X9 Resistance Training Method
219632312|NCT03101631|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* CrCl~* Presence of geriatric syndromes"
219632313|NCT03490552|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.
219632314|NCT01322243|OTHER|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
219048715|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
219048716|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
219048717|NCT01020019|DRUG|Placebo|Placebo control
219632315|NCT03919552|DRUG|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
219632316|NCT03919552|DRUG|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
219632317|NCT03919552|RADIATION|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
219632318|NCT03919552|RADIATION|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
219632319|NCT04439877|BEHAVIORAL|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
219632320|NCT03622060|DRUG|Nitroglycerin|200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal
219632321|NCT05999071|DIETARY_SUPPLEMENT|Coriandrum sativum seeds|Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
219632322|NCT03527589|DEVICE|Prostate artery embolization|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
219632323|NCT02683928|BIOLOGICAL|GBR 830|
219632324|NCT02683928|BIOLOGICAL|Placebo|
219632325|NCT03686059|DRUG|Omega 3|daily intake of 250 mg
219632326|NCT03686059|DEVICE|punctal plug|punctal plug will be inserted in inferior punctum
219632327|NCT05713890|OTHER|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|"Observation of a VR scenario depicting multiple repetitions of a specific upper limb motor task belonging to typical activities of daily living, followed by mental imagination of the action observed and then by the execution of the same task, using objects provided in a kit.~In each session, patients will watch 2 different videos and will perform the two corresponding actions. The time scheduled for observation, imagery and execution of each action will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes. New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
219632328|NCT05713890|OTHER|Home-based landscape observation with virtual-reality for upper limb rehabilitation|"Observation of virtually explorable landscapes followed by rest with eyes closed without focusing on any thought in particular and then execution of the same actions requested to VR-AOT-group. In each session, patients will explore 2 different landscapes and perform 2 different actions. The time scheduled for observation, rest and action execution will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes.New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
219632329|NCT00723502|DRUG|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
219632330|NCT00723502|DRUG|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
219632331|NCT02824055|DRUG|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
219632332|NCT02824055|DRUG|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
219632333|NCT03723850|DEVICE|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
219632334|NCT03723850|DEVICE|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
219632335|NCT02146937|DRUG|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
219632336|NCT01749475|DRUG|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
219632337|NCT01749475|OTHER|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
219048718|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
219048719|NCT03566628|OTHER|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
219048720|NCT03566628|OTHER|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
219048721|NCT03748940|DRUG|LY3074828|Administered SC
219048722|NCT03748940|DRUG|Placebo|Administered SC
219048723|NCT03748940|DRUG|LY900021|Administered SC
219048724|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
219048725|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
219048726|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
219048727|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
219048728|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
219632338|NCT03147690|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
219365925|NCT03360760|DRUG|Cisplatin|100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
219632339|NCT05584033|DIAGNOSTIC_TEST|Mansora Arabic test battery for childhood apraxia of speech|Searching of apraxia of speech in children with Specific Language Impairment in able to better management of these cases.
219632340|NCT04521062|DEVICE|Dilapan S|Placement of Dilapan S
219632341|NCT03739086|PROCEDURE|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
219632342|NCT03393325|OTHER|Observation of treatment with Tadalafil-Delivra|Tadalafil 2% in a Delivra base (Transdermal Application)
219632343|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 100 μg/mL
219632344|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 200 μg/mL
219048729|NCT00021268|DRUG|tocladesine|
219048730|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
219048731|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
219048732|NCT00649337|PROCEDURE|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
219365926|NCT03360760|DRUG|Methotrexate|High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
219632345|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 300 μg/mL
219632346|NCT00656825|DRUG|Placebo|Placebo will be randomly given to 4 subjects in each panel
219632347|NCT00033722|DIETARY_SUPPLEMENT|folic acid|
219632348|NCT00033722|DRUG|lometrexol|
219632349|NCT06571721|OTHER|Topical Product: Almond Oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
219632350|NCT06571721|OTHER|Topical Product: Almond oil augmented with 0.5% Vitamin E|1-2 Drops of randomized topical product will be applied on entire face nightly.
219632351|NCT06571721|OTHER|Topical Product: 0.025% Tretinoin oil augmented with castor oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
219632352|NCT03388684|PROCEDURE|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
219632353|NCT02589639|DRUG|Empagliflozin|
219632354|NCT02589639|DRUG|Placebo|
219632355|NCT02589639|DRUG|Placebo|For blinding purposes
219632356|NCT03389204|OTHER|PHYSICAL THERAPY|EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
219632357|NCT01014169|BEHAVIORAL|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
219632358|NCT04120259|DRUG|Metformin Oral Tablet|A biguanide drug used as a first line therapy for Diabetes MellitusType 2
219632359|NCT04120259|DIETARY_SUPPLEMENT|Vinegar|A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
219632360|NCT00255866|BEHAVIORAL|Skills training for the care of dementia patients|
219632361|NCT04063553|OTHER|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
219632362|NCT04063553|OTHER|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
219632363|NCT05827133|OTHER|No intervention|No intervention
219632364|NCT00357799|DEVICE|VeinViewer|Using the VeinViewer, IV attempts will be made
219632365|NCT02596555|DRUG|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
219632366|NCT04722705|DEVICE|fractional Er:YAG laser|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
219632367|NCT04722705|DEVICE|Intense pulse light|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
219632368|NCT02593097|DRUG|Metformin|Metformin 500mg twice daily
219632369|NCT02593097|DRUG|Matching Placebo|Matching Placebo twice daily
219632370|NCT05316961|DEVICE|Active PEMF|PEMF 1.5mT, 10Hz, 10 minutes
219632371|NCT05316961|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
219632372|NCT05316961|OTHER|Eccentric exercise|Eccentric exercise, 10 repetitions, 3 sets
219632373|NCT01413126|DIETARY_SUPPLEMENT|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
219632374|NCT00703157|PROCEDURE|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
219632375|NCT00703157|PROCEDURE|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
219632376|NCT04195204|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
219632377|NCT04195204|DRUG|Placebos|Investigators administrated intravenously saline solution as a placebo
219632378|NCT02295969|DRUG|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
219632379|NCT05446857|DRUG|Glecaprevir / Pibrentasvir Pill|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
219632380|NCT03085966|BIOLOGICAL|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
219632381|NCT04018846|PROCEDURE|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
219632382|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
219632383|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
219632384|NCT00979316|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
219632385|NCT00979316|DRUG|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
219632386|NCT01567917|PROCEDURE|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~\- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
218937878|NCT03162367|BIOLOGICAL|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
218937879|NCT03162367|DRUG|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
218937880|NCT02912858|DEVICE|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
218937881|NCT01819532|PROCEDURE|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
219632387|NCT06410677|DIAGNOSTIC_TEST|DNA Sequencing, RNA Sequencing|"High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.~RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates."
219632388|NCT04075071|BEHAVIORAL|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
219632389|NCT05433532|DRUG|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
219632390|NCT05433532|DRUG|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
219632391|NCT05433532|DRUG|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
219632392|NCT03702335|BEHAVIORAL|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
219632393|NCT06939959|DRUG|Artificial tear|commercially available artificial tears will be used consisting of same ingredients.
219632394|NCT06939959|DRUG|insulin human|injection humulin will be used to make topical insulin drops
219632395|NCT06369454|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
219632396|NCT03074058|DRUG|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
219632397|NCT03074058|DRUG|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
219632398|NCT06610097|OTHER|Nutritional Counseling|The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as (1) a 60-minute initial telehealth consultation within the first week of study enrollment, and (2) up to two 30-minute follow-ups throughout the study, ideally the first follow-up within 6 weeks of study enrollment. These sessions will be led by a registered dietitian using cultural awareness and symptom assessment.
219632399|NCT00801489|DRUG|Cytarabine|Given IV
219632400|NCT00801489|DRUG|Decitabine|Given IV
219632401|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
219632402|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
219632403|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
219632404|NCT00801489|DRUG|Idarubicin|Given IV
219632405|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
219632406|NCT02671838|BEHAVIORAL|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
219632407|NCT06286683|DEVICE|lung ultrasound|Used to diagnose and monitor pulmonary aeration in the context of prolonged decubitus disorders (atelectasis) via the lung ultrasound score (LUS).
219632408|NCT06286683|DEVICE|Transcranial Doppler|Non-invasive, bedside method of measuring cerebral blood flow.
219632409|NCT06286683|DEVICE|near-infrared spectroscopy (NIRS)|Non-invasive, bedside method of cerebral oximetry that requires no advanced expertise.
219632410|NCT06286683|DEVICE|clinical examination|clinical examination
219632411|NCT00816998|PROCEDURE|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
218937882|NCT01819532|PROCEDURE|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
218937883|NCT01839669|DEVICE|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
219048733|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
219632412|NCT00816998|PROCEDURE|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
219632413|NCT02522884|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
218937884|NCT01839669|PROCEDURE|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
218937885|NCT01839669|DEVICE|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
218937886|NCT05915598|OTHER|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
219632414|NCT05063279|OTHER|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
219632415|NCT05657561|OTHER|early mobilization|Mobilization training was given to the intervention group.
219632416|NCT03970005|BEHAVIORAL|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
219632417|NCT03494634|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
219632418|NCT01521520|DRUG|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
219632419|NCT02078245|OTHER|MRI|MRI
218937887|NCT05915598|OTHER|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
219048734|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
219048735|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
219632420|NCT02630251|DRUG|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
219632421|NCT04063293|BIOLOGICAL|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
219632422|NCT03092778|PROCEDURE|Cryoablation|"A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn."
219632423|NCT02968173|DRUG|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
219632424|NCT00161005|PROCEDURE|PCI|Immediate transport to invasive center after thrombolysis
219632425|NCT02670525|GENETIC|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
219632426|NCT02125383|PROCEDURE|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
219632427|NCT02125383|PROCEDURE|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
219632428|NCT00124501|BEHAVIORAL|Biofeedback-assisted relaxation training|10 sessions BART
218937888|NCT02893956|PROCEDURE|echocardiography with postural support|
218937889|NCT02893956|PROCEDURE|echocardiography with standard condition (usual)|
218937890|NCT02397629|OTHER|This study has no intervention|
218937891|NCT04655651|OTHER|No intervention|There is no intervention for both groups.
219048736|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
219048737|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
219048738|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
219048739|NCT02149433|DRUG|Placebo|
219048740|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
219048741|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
219048742|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
219632429|NCT06305455|BIOLOGICAL|Escherichia coli ESBL|To evaluate the change in the resistance profile of infections of community origin caused by Escherichia coli, isolated from any culture material in patients admitted to the intensive care unit of a tertiary hospital.
218937892|NCT00333099|DIETARY_SUPPLEMENT|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
218937893|NCT00333099|OTHER|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
218937894|NCT01719744|DRUG|ENMD-2076|
219632430|NCT05823935|PROCEDURE|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
219632431|NCT05823935|PROCEDURE|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
219632432|NCT04689620|DEVICE|laser|treating the venous ulcer with laser
219632433|NCT00591565|DRUG|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
219632434|NCT02788409|OTHER|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
219632435|NCT02588768|DEVICE|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
219632436|NCT00937365|BEHAVIORAL|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
219632437|NCT00937365|PROCEDURE|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
219632438|NCT00937365|PROCEDURE|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
219632439|NCT03938350|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Training|Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
219632440|NCT02980068|DRUG|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
219632441|NCT02980068|DRUG|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
219632442|NCT05468684|OTHER|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
219632443|NCT06574763|DRUG|RC48/Carboplatin|RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
219632444|NCT03935139|BIOLOGICAL|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
219632445|NCT03935139|BIOLOGICAL|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
219632446|NCT03935139|BIOLOGICAL|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
219632447|NCT03935139|BIOLOGICAL|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
219632448|NCT03935139|PROCEDURE|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
219632449|NCT03808181|DEVICE|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
219632450|NCT03472430|DEVICE|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
219632451|NCT03472430|DEVICE|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
219632452|NCT06710353|DRUG|Albumin solution|"A 20% albumin solution is administered over one hour starting from the induction of anesthesia, using the following formula:~(4.0-preoperative serum albumin (g/dL))×plasma volume (kg×0.65-0.8 dL)"
219632453|NCT06710353|DRUG|Crystalloid solutions|The same volume of crystalloid solution as the administered albumin is infused.
219632454|NCT01099618|DRUG|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
219632455|NCT01099618|DRUG|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
219048743|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
219048744|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
219048745|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
219048746|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
219048747|NCT04552366|BIOLOGICAL|Ad5-nCoV|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
219048748|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
219048749|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
219048750|NCT00000327|DRUG|Heroin Dependence|
219048751|NCT02903667|DEVICE|Bone grafting|
219048752|NCT02423941|PROCEDURE|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
219048753|NCT02423941|PROCEDURE|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
219048754|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
219048755|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
219048756|NCT02346240|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"
219048757|NCT02346240|BIOLOGICAL|Etanercept|"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"
219048758|NCT02346240|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
219048759|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
219048760|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
219048761|NCT01573624|DRUG|FF/GSK573719|100/15.6
219632456|NCT01099618|DRUG|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
219632457|NCT05691582|DEVICE|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
219632458|NCT03464331|BEHAVIORAL|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
219632459|NCT03464331|BEHAVIORAL|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON\_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
219632460|NCT05547139|OTHER|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
219632461|NCT06107569|OTHER|Fecal microbiota transplant (Promicrobioma)|Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)
219632462|NCT06107569|DRUG|Antibiotic|Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
219632463|NCT00161603|BEHAVIORAL|Semi-structured, open-ended interviews|
219632464|NCT05876806|DRUG|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
219048762|NCT01573624|DRUG|FF/GSK573719|100/31.25
219048763|NCT01573624|DRUG|FF/GSK573719|100/62.5
219632465|NCT05876806|DRUG|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
219632466|NCT01452243|DRUG|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
219632467|NCT00213109|DRUG|Miglitol|
219632468|NCT02254382|DEVICE|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
219632469|NCT04454255|BEHAVIORAL|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
219048764|NCT01573624|DRUG|FF/GSK573719|100/125
219365927|NCT03360760|DRUG|Ifosfamide|12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
219048765|NCT01573624|DRUG|FF/GSK573719|100/250
219048766|NCT01573624|DRUG|FF|100
219048767|NCT01573624|DRUG|FF/VI|100/25
219048768|NCT06236009|DRUG|TAK-004|TAK-004 subcutaneous injections.
219365928|NCT03360760|PROCEDURE|definitive surgery|Including limb-sparing procedure and amputation
219365929|NCT03360760|OTHER|pre surgical chemotherapy|chemotherapy that given before definitive surgery
219632470|NCT04454255|BEHAVIORAL|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
219632471|NCT03564119|DRUG|S5G4T-1|Once a day topical cream
219632472|NCT03564119|DRUG|S5G4T-2|Once a day topical cream
219632473|NCT00508599|OTHER|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
218937895|NCT05298449|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
218937896|NCT05298449|DRUG|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
218937897|NCT01148992|DRUG|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
218937898|NCT01148992|DRUG|Placebo|0mg
218937899|NCT03494907|DRUG|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
218937900|NCT03494907|OTHER|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
218937901|NCT03494907|OTHER|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
218937902|NCT03494907|DRUG|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
218937903|NCT00781573|DRUG|Clopidogrel|Clopidogrel, 75 mg QD, for one year
218937904|NCT03545971|DRUG|IBI310|IBI310 is anti CTLA-4 antibody
218937905|NCT03545971|DRUG|Sintilimab|PD-1 monoclonal antibody
218937906|NCT03617016|DRUG|Domperidone|Participants will receive domperidone tablets orally.
219048769|NCT06236009|DRUG|Placebo|Matching- placebo subcutaneous injections.
219048770|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
219048771|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
219048772|NCT03244306|BIOLOGICAL|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
219048773|NCT05382208|DRUG|Doxycycline|Doxycycline 100 mg orally twice a day.
219048774|NCT05382208|DRUG|Placebo|Matching placebo orally twice a day.
219048775|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
219048776|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
219048777|NCT05700552|BEHAVIORAL|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
219048778|NCT02961699|DEVICE|Transpose ® RT System|adipose-derived stem cell therapy
219632474|NCT00634036|DRUG|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
219632475|NCT00634036|DRUG|placebo|matching placebo (inert tablet)
219632476|NCT01946828|DEVICE|FIM|Field Induced Mydriasis device
218937907|NCT03617016|DRUG|Placebo|Participants will receive matching placebo to domperidone tablets orally.
218937908|NCT05300919|OTHER|Measurement based care|Measurement-based care based on arm.
218937909|NCT05475574|OTHER|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
218937910|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
218937911|NCT03649997|DRUG|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
218937912|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
218937913|NCT05854784|DRUG|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
218937914|NCT04463108|OTHER|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
218937915|NCT05710627|DEVICE|TENEX|Use of TENEX device for sectioning of the gluteus medius and ITB tendons.
219632477|NCT02431611|BEHAVIORAL|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
219632478|NCT02431611|BEHAVIORAL|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
219632479|NCT04573322|DRUG|Trans Sodium Crocetinate|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
219632480|NCT04573322|DRUG|Normal saline|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
219632481|NCT02811965|OTHER|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
219632482|NCT02811965|OTHER|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
219632483|NCT02811965|DEVICE|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
219632484|NCT02811965|DEVICE|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
219632485|NCT02811965|DEVICE|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
219632486|NCT02811965|DEVICE|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
219632487|NCT03896022|DEVICE|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
219632488|NCT03896022|DEVICE|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
219632489|NCT03896022|DEVICE|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
219632490|NCT03207269|OTHER|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
219632491|NCT02438423|BIOLOGICAL|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
219632492|NCT02438423|OTHER|Placebo|
219632493|NCT01341275|BIOLOGICAL|hepatitis B vaccine|10 ug dose, one-time administration
219632494|NCT01341275|BIOLOGICAL|hepatitis B vaccine|20 ug dose, one-time administration
219632495|NCT02401152|OTHER|Sports drink 1|Sports drink with a specific source of CHO.
219632496|NCT02401152|OTHER|Sports drink 2|Sports drink with a specific source of CHO
219632497|NCT02401152|OTHER|Placebo|iso-caloric sports drink with maltodextrin as CHO source
219632498|NCT05503537|PROCEDURE|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
219632499|NCT05503537|PROCEDURE|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
219632500|NCT05503537|PROCEDURE|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
219632501|NCT03253900|DEVICE|Stable rowing simulator|a standard stable/fixed rowing simulator
219632502|NCT03253900|DEVICE|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
219632503|NCT03253900|DEVICE|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
219632504|NCT03858751|DRUG|Placebo oral capsule|Placebo capsule before bedtime
219632505|NCT03858751|DRUG|LTM1201AZ|LTM1201AZ oral capsule before sleep
219632506|NCT03858751|DRUG|LTM1201AT|LTM1201AT oral capsule before sleep
218937916|NCT03646396|DRUG|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
219632507|NCT03858751|DRUG|LTM1201AG|LTM1201AG oral capsule before sleep
219632508|NCT03858751|DRUG|LTM1201AD|LTM1201AD oral capsule before sleep
219632509|NCT00107861|DRUG|Ad.hIFN-β (BG00001, IDEC-201)|
219632510|NCT02245009|PROCEDURE|Cardioversion|
219632511|NCT01195311|DRUG|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
219632512|NCT02939677|OTHER|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
219632513|NCT06511635|OTHER|Qualitative interview|Interview between participant and a researcher, in order to identity the determinants of participation in a clinical trial among participants in the CMVictory vaccine trial.
219632514|NCT06511635|OTHER|Quantitative questionnaire|Anonymous online survey using a 3-part questionnaire, studying knowledge of clinical research and the determinants of participation in a preventive vaccine study in a population of young women (aged 18-40).
219632515|NCT00543881|DEVICE|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
219632516|NCT00543881|DEVICE|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
219048779|NCT02961699|OTHER|debridement/dressing of wound|standard of care debridement and wound dressing
219048780|NCT01889017|OTHER|patient questionnaire (tablet pc based)|
219048781|NCT03718611|DRUG|BR9001|BR9001 is a test drug as generic
219048782|NCT03718611|DRUG|BR900A|BR900A is a reference drug
219048783|NCT03906318|DRUG|Iticitinib|
219048784|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
219048785|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
219048786|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
219206575|NCT06978257|BEHAVIORAL|Self-monitoring intervention|The self-monitoring intervention serves as an active comparator designed to isolate the effects of mood self-awareness without introducing therapeutic content. Participants in this arm receive daily prompts via the Qualtrics mEMA mobile app, three times per day over a six-week period, instructing them to track their mood and emotional states through brief ecological momentary assessments (EMAs). Unlike the digital positive affect intervention, this arm does not include psychoeducational material, skills training, or active enhancement strategies; instead, it focuses solely on routine self-monitoring to control for digital engagement and expectancy effects. This minimalist structure allows for a clean contrast between passive self-observation and active therapeutic engagement, enabling robust evaluation of the added value of the Positive Affect Intervention beyond self-monitoring alone
219632517|NCT01136941|DRUG|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
219632518|NCT03059043|DEVICE|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
219632519|NCT03059043|DEVICE|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
219632520|NCT01493518|DRUG|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
219632521|NCT01194232|DRUG|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
219632522|NCT00314327|DRUG|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
219632523|NCT03975673|PROCEDURE|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
219632524|NCT05691127|DIAGNOSTIC_TEST|Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine|I will use these investigations in my study
219632525|NCT01036282|BEHAVIORAL|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
219632526|NCT01036282|BEHAVIORAL|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
219632527|NCT02920762|OTHER|on-interventional study - retrospective database review|
219632528|NCT02741076|DRUG|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
219365930|NCT02120755|BIOLOGICAL|AmnioClear™ Human Allograft Amniotic Membrane|
219365931|NCT05504200|OTHER|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
219632529|NCT02741076|DRUG|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
219632530|NCT02040129|DEVICE|Acrysof Toric IOL|Lens implantation following cataract surgery
219632531|NCT06143280|OTHER|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
219632532|NCT03105180|OTHER|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
219632533|NCT01115244|DRUG|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
219632534|NCT02965573|BIOLOGICAL|ARGX-113|
219632535|NCT02965573|DRUG|Placebo|
219048787|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
219048788|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
219048789|NCT05012605|OTHER|Observation|Observe physical function and sleep disorder symptoms following stroke
219048790|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
219048791|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
218937917|NCT06121544|DIAGNOSTIC_TEST|Plasma tau|Plasma levels of different p-tau and np-tau species
218937918|NCT06121544|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|Plasma levels of Ab42/Ab40 ratio
219048792|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
219048793|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
219048794|NCT06167395|DIETARY_SUPPLEMENT|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
219048795|NCT06099197|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
219048796|NCT06099197|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
219048797|NCT06968845|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
219048798|NCT06968845|DEVICE|Dry Powder Inhaler|Plastiape Monodose RS01 Model 7
219048799|NCT06968845|DRUG|Placebo|Lactose powder
219048800|NCT04249804|DRUG|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
219048801|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
219048802|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
219048803|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
219048804|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
219048805|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
219048806|NCT02165111|DRUG|Onabotulinumtoxin A|
219048807|NCT02165111|DRUG|sterile saline solution|
219048808|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
219632536|NCT05179889|DRUG|mFOLFIRINOX|"Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
219048809|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
219632537|NCT05179889|DRUG|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
219632538|NCT02763930|OTHER|Control diet|
219632539|NCT02763930|OTHER|Milk diet|
219048810|NCT05137795|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
219365932|NCT01484067|DEVICE|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
219632540|NCT02763930|OTHER|GABA-rich cheese diet|
218937919|NCT06121544|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|Positron emission tomography (PET) imaging of amyloid-β plaques
218937920|NCT06121544|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
218937921|NCT06121544|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Different MRI sequences relevant for brain imaging
218937922|NCT06491914|DRUG|Aflibercept 8 mg|Administered by intravitreal (IVT) injection
218937923|NCT05389995|DRUG|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
218937924|NCT05389995|DRUG|Crystal light|7 days crystal light followed by 24 hour urine collection
218937925|NCT05389995|DRUG|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
218937926|NCT03629951|DRUG|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
219048811|NCT05137795|DRUG|Placebo|Normal Saline Inhalation
219048812|NCT05137795|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
219048813|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
219048814|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
219048815|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
219048816|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
219048817|NCT00972803|DRUG|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
219048818|NCT00972803|DRUG|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
219048819|NCT00972803|DRUG|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
219048820|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
219048821|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
219048822|NCT00153491|DRUG|artemether-lumefantrine|
219048823|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
218937927|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
218937928|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
218937929|NCT03977181|BEHAVIORAL|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
218937930|NCT03977181|BEHAVIORAL|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
218937931|NCT03350672|DRUG|FTC/TAF|Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
218937932|NCT00003278|DRUG|dexamethasone|
219206576|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
219048824|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
219048825|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
219048826|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
219048827|NCT03706690|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
219048828|NCT03706690|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
219048829|NCT04450966|BEHAVIORAL|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
219048830|NCT00496847|DRUG|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
219048831|NCT00496847|DRUG|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
219048832|NCT02098109|DRUG|XM02 Filgrastim|
219048833|NCT02098109|DRUG|Filgrastim|
219048834|NCT02098109|PROCEDURE|Apheresis|
219048835|NCT02098109|DRUG|Plerixafor|
219048836|NCT02098109|PROCEDURE|Stem Cell Transplant|
219206577|NCT06982274|DRUG|Realgar-Indigo Naturalis Formulation|Oral Arsenic (Realgar-Indigo Naturalis Formulation) plus ATRA for low-intermediate risk APL pts, combined with daunorubicin for high-risk during induction
219048837|NCT04021264|DRUG|Ropivacaine-Sufentanil|Local anesthetic injection
219048838|NCT04021264|DRUG|Dextrose 5|Sham injection
219048839|NCT03679871|OTHER|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
219048840|NCT00747968|DRUG|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
219048841|NCT04123496|DEVICE|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
219365933|NCT00988247|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
219048842|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
218937933|NCT00003278|RADIATION|radiation therapy|
218937934|NCT02321709|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
218937935|NCT02321709|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
218937936|NCT00567814|DRUG|Metyrapone|Twice daily
218937937|NCT00567814|DRUG|Oxazepam|Twice Daily
218937938|NCT00567814|DRUG|Placebo|Twice daily
218937939|NCT03879161|DEVICE|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
218937940|NCT03369262|DRUG|OBE022|Oral
218937941|NCT03369262|DRUG|Placebos|Oral
218937942|NCT03369262|DRUG|Atosiban|I.V.
218937943|NCT05694416|DRUG|Etoposide Plus Cisplatin|Etoposide Plus Cisplatin ivdrip d1-5
219048843|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
219206578|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
219206579|NCT06651515|BIOLOGICAL|Allogeneic Pancreatic Endocrine Cell Clusters|Allogeneic Pancreatic Endocrine Cell Clusters
218937944|NCT04348916|BIOLOGICAL|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
218937945|NCT04348916|BIOLOGICAL|pembrolizumab|Anti-PD-1 monoclonal antibody
219206580|NCT06599788|BEHAVIORAL|Standard work pace|Participants will work at a standard pace of one box per minute during the box carrying protocol
218937946|NCT01459497|RADIATION|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
218937947|NCT01459497|RADIATION|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
218937948|NCT00722306|DRUG|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
218937949|NCT04298671|BEHAVIORAL|Yoga-Pilates|As above
218937950|NCT02457143|BEHAVIORAL|Letter|
218937951|NCT02457143|BEHAVIORAL|Phone call|
218937952|NCT03414931|DRUG|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
218937953|NCT03414931|DRUG|Sertraline|Use of SSRI as an active comparator
218937954|NCT03414931|DRUG|Placebo - Cap|Use of placebo as a comparator
218937955|NCT02502617|DIETARY_SUPPLEMENT|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
218937956|NCT01957046|DRUG|Laxative|
218937957|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
218937958|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
218937959|NCT04518358|BEHAVIORAL|Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges|During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
218937960|NCT05346068|DEVICE|OPN™ NCB Super High Pressure PCI Balloon|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
219048844|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
218937961|NCT05346068|DEVICE|Shockwave™ C2 IVL Catheter|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
218937962|NCT03530124|BIOLOGICAL|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
218937963|NCT03530124|BIOLOGICAL|DTaP|ACIP Recommended vaccine
218937964|NCT03530124|BIOLOGICAL|HBV|ACIP Recommended vaccine
218937965|NCT03530124|BIOLOGICAL|IPV|ACIP Recommended vaccine
218937966|NCT03530124|BIOLOGICAL|Hib|ACIP Recommended vaccine
218937967|NCT05915481|DRUG|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
218937968|NCT05915481|RADIATION|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
219048845|NCT03728894|DRUG|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
219048846|NCT03728894|DRUG|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
219048847|NCT03072485|DRUG|Sirolimus|Topical sirolimus applied to the skin
219048848|NCT03072485|DRUG|Metformin|Topical metformin applied to the skin
219048849|NCT03072485|DRUG|Diclofenac|Topical diclofenac applied to the skin
219048850|NCT04917276|DIAGNOSTIC_TEST|Circulating tumor cell|Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
219206581|NCT06599788|BEHAVIORAL|Reduced-pace work|Participants will work at a slower pace than the standard work pace of the box carrying protocol
219206582|NCT06599788|BEHAVIORAL|Increased-pace work|Participants will work at a faster pace than the standard work pace of the box carrying protocol
219206583|NCT06599788|BEHAVIORAL|Additional rest breaks|Participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
219206584|NCT05446662|OTHER|music therapy|Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
219048851|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
219048852|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
219365934|NCT00988247|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
218937969|NCT04436848|OTHER|This is a non-interventional study|This is a non-interventional study
218937970|NCT03192553|BEHAVIORAL|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
218937971|NCT03192553|BEHAVIORAL|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
218937972|NCT03192553|BEHAVIORAL|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
218937973|NCT03192553|BEHAVIORAL|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
218937974|NCT06313918|OTHER|High intensity training (HIT)|Please see information already included in the arm descriptions.
218937975|NCT01047553|DRUG|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
218937976|NCT01583296|BEHAVIORAL|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
218937977|NCT01583296|BEHAVIORAL|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
218937978|NCT01063283|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 intravenously over 10 minutes
218937979|NCT01063283|DRUG|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
218937980|NCT01063283|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
218937981|NCT01063283|DRUG|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
218937982|NCT02111304|DRUG|iOWH032|
218937983|NCT05358769|DIETARY_SUPPLEMENT|Incoxil food supplement and pelvic floor muscle exercise|"Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.~Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity."
218937984|NCT05358769|OTHER|Pelvic floor muscle exercise|Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
218937985|NCT03179319|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
218937986|NCT03292367|PROCEDURE|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
218937987|NCT03613961|DRUG|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
218937988|NCT03651401|DEVICE|Scapular muscle endurance test|The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
218937989|NCT03651401|OTHER|Pain intensity|"Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20."
218937990|NCT03651401|DEVICE|Upper Limb Functional Performance|The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
218937991|NCT00267566|BEHAVIORAL|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
218937992|NCT01120717|DRUG|QVA149|capsules for inhalation, delivered by an SDDPI
218937993|NCT01120717|DRUG|Placebo|capsules for inhalation, delivered by an SDDPI
219206585|NCT05446662|OTHER|aromatherapy|Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
218937994|NCT05343624|DEVICE|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
218937995|NCT05766696|PROCEDURE|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
218937996|NCT05766696|PROCEDURE|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
218937997|NCT03117140|DRUG|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
218937998|NCT03117140|DRUG|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
218937999|NCT03117140|DRUG|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
218938000|NCT03117140|DRUG|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
218938001|NCT00416221|DRUG|Lexapro, an antidepressant medicine|
218938002|NCT00416221|BEHAVIORAL|Physical Activity|
218938003|NCT00416221|BEHAVIORAL|Mood Management Skills|
218938004|NCT00416221|BEHAVIORAL|Personalized support from a Family Nurse Practitioner|
218938005|NCT00356304|BEHAVIORAL|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
218938006|NCT00356304|BEHAVIORAL|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
218938007|NCT01493076|DEVICE|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
218938008|NCT03465969|DRUG|tacrolimus|oral
219048853|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
218938009|NCT02403440|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
219048854|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
219048855|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
219048856|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
219048857|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
219048858|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
219048859|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
219048860|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
218938010|NCT01267214|DRUG|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
218938011|NCT01267214|PROCEDURE|Osteotomy alone|no injection
219048861|NCT04321304|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
218938012|NCT06422897|OTHER|anterior segment optical coherence tomography|surgically treated corneal perforation by amniotic membrane graft and platelet rich plasma clot is assessed by anterior segment optical coherence tomography 1 month postoperative
218938013|NCT02019797|DRUG|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
218938014|NCT02640456|BIOLOGICAL|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
218938015|NCT02640456|PROCEDURE|Type of surgery|Surgical approach and complications.
218938016|NCT02640456|BIOLOGICAL|Biochemistry|Amylase concentration i pus aspirates.
218938017|NCT02640456|BIOLOGICAL|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
219048862|NCT04321304|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
219048863|NCT04321304|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
219048864|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
219048865|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
219048866|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
219365935|NCT03281642|OTHER|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
219365936|NCT04120922|OTHER|calcium carbonate|See arm description
219365937|NCT04120922|OTHER|sevelamer carbonate|See arm description
219365938|NCT01067131|BIOLOGICAL|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
219365939|NCT01067131|BIOLOGICAL|PEV7C9|capsule intravaginal application contains excipient only
219048867|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
219048868|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
218938018|NCT01145976|DRUG|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
218938019|NCT01145976|DRUG|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
219048869|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
218938020|NCT01637129|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
219048870|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
219048871|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
219048872|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
219048873|NCT00017758|DRUG|Pravastatin sodium|
219048874|NCT00017758|DRUG|Simvastatin|
219048875|NCT00017758|DRUG|Atorvastatin calcium|
219048876|NCT00017758|DRUG|Nelfinavir mesylate|
219048877|NCT00017758|DRUG|Efavirenz|
219048878|NCT00259558|DRUG|retarded release phosphatidylcholine|
219048879|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
219048880|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
218938021|NCT01637129|DEVICE|Sham Magnetic Stimulation|Sham Magnetic Stimulation
218938022|NCT02504216|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
219048881|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
219048882|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
218938023|NCT02504216|DRUG|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
218938024|NCT03061396|OTHER|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
219048883|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
219048884|NCT00648219|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
219048885|NCT00648219|DRUG|Benicar® Tablets 40 mg|40mg, single dose fed
219048886|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
218938025|NCT03061396|OTHER|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
218938026|NCT02544516|OTHER|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
218938027|NCT02544516|OTHER|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
218938028|NCT02731105|DRUG|Acnatac® Gel left face|topical application
218938029|NCT02731105|DRUG|Epiduo® Gel right face|topical application
218938030|NCT02731105|DRUG|Acnatac® Gel right face|topical application
219048887|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
219048888|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
219048889|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
219048890|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
219048891|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
218938031|NCT02731105|DRUG|Epiduo® Gel left face|topical application
218938032|NCT02591225|DRUG|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
218938033|NCT02591225|DRUG|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
218938034|NCT02475694|OTHER|No intervention|No treatment
218938035|NCT05605886|DRUG|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
218938036|NCT05605886|DRUG|placebo|placebo
218938037|NCT02451709|DEVICE|Activated Smartinhaler or Smartturbo|Medication reminder alarms
218938038|NCT02451709|OTHER|Feedback of adherence data|Review of adherence data with action planning
218938039|NCT02451709|DEVICE|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
218938040|NCT04539769|PROCEDURE|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
218938041|NCT04539769|PROCEDURE|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
218938042|NCT04539769|PROCEDURE|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
218938043|NCT00862082|DRUG|PR104 550 mg/m^2 + sorafenib|550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
218938044|NCT00862082|DRUG|PR104 770 mg/m^2 + sorafenib|770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
218938045|NCT05161013|DIAGNOSTIC_TEST|LINFU™|A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.
218938046|NCT02608671|PROCEDURE|Skin adhesive tape|
218938047|NCT00574522|RADIATION|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
218938048|NCT01383343|BIOLOGICAL|Bevacizumab|Given IV
218938049|NCT01383343|DRUG|Fluorouracil|Given IV
218938050|NCT01383343|DRUG|Irinotecan Hydrochloride|Given IV
218938051|NCT01383343|DRUG|Leucovorin Calcium|Given IV
218938052|NCT01383343|DRUG|Sorafenib Tosylate|Given PO
219048892|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
219048893|NCT01894789|DRUG|Ticagrelor|Blinded administration of ticagrelor for 10 days
219206586|NCT05446662|OTHER|Progressive Relaxation Exercises|Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
218938053|NCT00517855|BIOLOGICAL|PRTX-100 (Staphylococcal protein A)|
218938054|NCT02486185|OTHER|SCREENING TEST|"* Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
218938055|NCT04949321|OTHER|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
218938056|NCT03703193|OTHER|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
218938057|NCT03703193|OTHER|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
218938058|NCT02256709|DRUG|BIBP 5371 CL tablet|single rising daily doses
218938059|NCT02256709|DRUG|BIBP 5371 CL solution|
218938060|NCT02256709|OTHER|High fat, high caloric breakfast|
218938061|NCT02256709|DRUG|Placebo tablet|
218938062|NCT02256709|DRUG|BIBP 5371 CL tablet high dose|
218938063|NCT02256709|DRUG|Placebo drinking solution|
218938064|NCT02256709|DRUG|BIBP 5371 CL tablet low dose|
219048894|NCT01894789|DRUG|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
219206587|NCT05446662|OTHER|Hand massage|Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
219365940|NCT01067131|BIOLOGICAL|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
218938065|NCT05465252|DIETARY_SUPPLEMENT|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
218938066|NCT05465252|DIETARY_SUPPLEMENT|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
218938067|NCT01486095|DEVICE|AXXESS + Biomatrix Biolimus Eluting stent|NAP
218938068|NCT01486095|DEVICE|Culotte technique with Xience V or Xience Prime stents|NAP
218938069|NCT00388193|DRUG|RITUXIMAB|375 mg/m2/d day 1
218938070|NCT04421703|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
218938071|NCT00223080|BIOLOGICAL|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
218938072|NCT00223080|OTHER|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
218938073|NCT02598583|BIOLOGICAL|ALXN1210|Participants were administered ravulizumab as an IV infusion every 4 weeks.
218938074|NCT03098004|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
218938075|NCT03237286|DRUG|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
219048895|NCT02353247|DRUG|Norethindrone acetate|
219048896|NCT00665184|BEHAVIORAL|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
219048897|NCT00665184|BEHAVIORAL|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
218938076|NCT03237286|BEHAVIORAL|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
218938077|NCT05785676|DEVICE|Filter implantation|Implantation of OATF ALN vena cava filter
219048898|NCT03144882|DRUG|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
219048899|NCT03144882|DRUG|Placebo|placebo
218938078|NCT04618848|DIAGNOSTIC_TEST|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
218938079|NCT04286048|OTHER|Weight implement|"The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement."
218938080|NCT00948441|DRUG|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
219048900|NCT01148602|OTHER|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
219048901|NCT01822132|DRUG|Extended release naltrexone|
219048902|NCT01822132|DRUG|Placebo|
219048903|NCT01018199|OTHER|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
219048904|NCT01018199|OTHER|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
219048905|NCT04389125|DIETARY_SUPPLEMENT|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
219048906|NCT04389125|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
219048907|NCT04601545|BEHAVIORAL|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
219048908|NCT04601545|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
219048909|NCT05873465|DRUG|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
219048910|NCT05873465|PROCEDURE|Extraction of teeth|The necessary teeth will be extracted
219048911|NCT04745897|OTHER|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
219048912|NCT04745897|OTHER|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
219048913|NCT05281614|DRUG|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
219048914|NCT05281614|DRUG|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
218938081|NCT00948441|OTHER|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
218938082|NCT00056797|BIOLOGICAL|ALVAC HIV vaccine (vCP1452)|
218938083|NCT00056797|DRUG|Interleukin-2|
218938084|NCT02422459|BEHAVIORAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
219048915|NCT03196466|BIOLOGICAL|Valproic acid|titration
219048916|NCT03196466|BIOLOGICAL|carbamazepine|titration
219048917|NCT03196466|BIOLOGICAL|phenobarbital|titration
219048918|NCT03196466|BIOLOGICAL|phenytoin|titration
218938085|NCT02093819|DRUG|Placebo to BI 416970|single rising doses
219048919|NCT03196466|BIOLOGICAL|levetiracetam|titration
219048920|NCT03196466|BIOLOGICAL|lamotrigine|titration
219048921|NCT03196466|BIOLOGICAL|topiramate|titration
219048922|NCT03196466|BIOLOGICAL|oxcarbazepine|titration
219048923|NCT03196466|BIOLOGICAL|stiripentol|titration
219048924|NCT03196466|BIOLOGICAL|clobazam|titration
219048925|NCT03196466|BIOLOGICAL|brivaracétam|titration
219048926|NCT03196466|BIOLOGICAL|felbamate|titration
219048927|NCT03196466|BIOLOGICAL|lacosamide|titration
218938086|NCT02093819|DRUG|BI 416970|single rising doses
218938087|NCT02267798|OTHER|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
218938088|NCT02267798|DEVICE|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
218938089|NCT00925925|OTHER|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
218938090|NCT05829369|OTHER|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
218938091|NCT05829369|OTHER|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
218938092|NCT05829369|OTHER|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
218938093|NCT03500224|DRUG|[14C]-TAK-954|\[14C\]-TAK-954 intravenous infusion.
218938094|NCT04181125|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
219048928|NCT03196466|BIOLOGICAL|rufinamide|titration
219048929|NCT03196466|BIOLOGICAL|gabapentine|titration
219048930|NCT03196466|BIOLOGICAL|pregabaline|titration
219048931|NCT03196466|BIOLOGICAL|sultiame|titration
219048932|NCT03196466|BIOLOGICAL|tiagabine|titration
219632541|NCT05595967|BEHAVIORAL|Health education intervention|Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise. Both two session will be delivered by primary healthcare women workers in small groups (about 20 women per group). The local healthcare workers are responsible for making appointment with each participant through group activities. Each participant will receive a healthy calendar practice to record the number of exercises per day which will be supervised by primary healthcare workers. All healthcare workers are required to attend a full-day workshop organized base on the scheme and teaching materials developed by our research team. The contents of the workshop include: (1) introduction of pelvic floor dysfunction; (2) risk factors and prevention of pelvic floor dysfunction; (3) kegel movement; (4) methods of dealing with severe illness; (5) a standard procedure of group activities or one-on-one activities; (6) skills needed for the delivery of health education intervention.
219632542|NCT06155344|OTHER|Food Frequency Questionnaire|We will obtain a global index of vegetalization of the diet (the Plant based Diet Index: PDI) from data obtained using semi-quantitative questionnaires on food frequency (Food Frequency Questionnaire (FFQ)) validated on the national ELFE cohort (French Longitudinal Study from Childhood (https://www.elfe-france.fr)) and completed by women in the 1st trimester of pregnancy (T1) and at delivery.
219048933|NCT03196466|BIOLOGICAL|vigabatrine|titration
219632543|NCT06155344|OTHER|Collection of 4 mL maternal blood|One tube collection of 4 mL maternal blood in the first trimester and at delivery.
219048934|NCT03196466|BIOLOGICAL|mesuximide|titration
219048935|NCT03196466|BIOLOGICAL|primidone|titration
219048936|NCT03196466|BIOLOGICAL|perampanel|titration
219048937|NCT03196466|BIOLOGICAL|ethosuximide|titration
219048938|NCT03196466|BIOLOGICAL|zonisamide|titration
218938095|NCT04181125|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
218938096|NCT00268853|DRUG|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
219048939|NCT03196466|BIOLOGICAL|cannabidiol|titration
219048940|NCT03196466|OTHER|genetic polymorphisms|genetic polymorphisms
219048941|NCT00719004|PROCEDURE|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
219048942|NCT06362135|DEVICE|Virtual Home Visit|The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
219048943|NCT06362135|DEVICE|Control Group|"Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned."
219048944|NCT00005669|DRUG|Metformin HCL|Medication studied for ability to alter body weight and body composition.
219048945|NCT00005669|DRUG|Placebo|Control capsules for metformin
218938097|NCT00268853|DRUG|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
218938098|NCT00713297|BEHAVIORAL|satisfaction questionnaire|Satisfaction questionnaire
218938099|NCT01167244|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
218938100|NCT01324401|DRUG|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
218938101|NCT01885585|DRUG|Apixaban|
218938102|NCT05969847|RADIATION|split-course hypofraction radiotherapy|After reaching a cumulative radiotherapy dose of 25Gy in the entire pelvic cavity (PTV1), the treatment field was subsequently narrowed to solely focus on the primary tumor (PTV2), with a total dose of 35Gy administered. All patients will undergo fractionated radiotherapy, following a regimen of 7Gy per fraction, delivered every 3 weeks for five cycles.
218938103|NCT05969847|DRUG|CAPOX|Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
218938104|NCT05969847|DRUG|Envafolimab|Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
218938105|NCT05969847|PROCEDURE|Local excision|Local full-thickness resection is employed for patients with clinical complete response (cCR) or near-clinical complete response (ncCR) following TNT.
218938106|NCT03574181|OTHER|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
218938107|NCT03233321|OTHER|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
218938108|NCT03233321|OTHER|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
218938109|NCT04121585|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
219048946|NCT03029689|DRUG|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
219048947|NCT03029689|DRUG|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
219048948|NCT03029689|DRUG|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
219048949|NCT03057028|DRUG|Anakinra|
219048950|NCT05206474|DEVICE|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
219048951|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
219048952|NCT03489395|DRUG|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
219206588|NCT06990386|BEHAVIORAL|self-management program|Self-management booklet based on the self-management framework consisting of 4 categories: a) self-monitoring, which consisted of self-observation and self-recording of DU and RP; b) performing special tasks to manage the disease, including keeping warm, maintaining moisture, and taking traumatic wound precautions; c) information seeking; and d) self-adjustment based on disease activity and treatment.
219365941|NCT01067131|BIOLOGICAL|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
219632544|NCT06033027|DEVICE|Carbonhand|During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
219632545|NCT04717752|DRUG|Ovidrel|recombinant human chorionic gonadotropin for injection
218938110|NCT01586130|OTHER|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
218938111|NCT00522899|BEHAVIORAL|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
218938112|NCT00522899|BEHAVIORAL|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
218938113|NCT00522899|BEHAVIORAL|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
218938114|NCT00522899|BEHAVIORAL|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
218938115|NCT04021693|OTHER|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
219048953|NCT02850003|DRUG|IDP-120 Gel|Gel
219632546|NCT04717752|DRUG|Troprilin|triptorelin acetate injection
219048954|NCT00367172|BEHAVIORAL|Directly Administered Antiretroviral Therapy|
219632547|NCT03809975|OTHER|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 \< BMI \<32.5; Psychology: PEG \> 4 or PHQ-4 \> 5 or PAM level \< 3"
219632548|NCT03809975|OTHER|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
219632549|NCT06280859|BEHAVIORAL|Hoosier Sport|Hoosier Sport is a sport-based youth development intervention. The intervention targets physical activity levels, exercise and nutrition knowledge, and leadership skills. The intervention is delivered in person twice a week (Tue/Thu) during PE class. Each class lasts 45-minutes, and covers sport skills, and then a brief lecture and activity on exercise/nutrition/leadership skills. Additionally, once a week Hoosier Sport is delivered virtually (via Zoom) during home room for 20-minutes. This involves activities to allow the students to be active during the school-day.
219632550|NCT02382575|DRUG|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
219632551|NCT02382575|DRUG|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
218938116|NCT01122121|DRUG|Leuprorelin SR|Leuprorelin SR injection
219632552|NCT00987337|DRUG|Filibuvir|300 mg BID
219632553|NCT00987337|DRUG|Filibuvir|600 mg BID
219632554|NCT00987337|DRUG|Placebo|BID
218938117|NCT01122121|RADIATION|Radiotherapy|Radiotherapy 70 +/- 4 Gy
219632555|NCT05159947|DRUG|SPT-07A injection|20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
219632556|NCT05159947|OTHER|placebo|2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
219632557|NCT02109627|DRUG|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
219632558|NCT02109627|DRUG|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
218938118|NCT01122121|DRUG|Flutamide|Flutamide tablets
218938119|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
218938120|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
218938121|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
218938122|NCT01708902|DRUG|Metformin 500mg|Metformin 500mg BID
218938123|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
219048955|NCT02665208|OTHER|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
219048956|NCT02665208|DRUG|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
219048957|NCT02665208|BEHAVIORAL|Text Message Intervention (TMI)|
219048958|NCT00273572|OTHER|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
218938124|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
218938125|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
218938126|NCT01708902|DRUG|Metformin 1000mg|Metformin 1000mg BID
218938127|NCT00725062|BIOLOGICAL|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10\^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10\^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10\^7 CD4+CD25 cells/kg
218938128|NCT00725062|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
219048959|NCT00273572|OTHER|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
218938129|NCT00224640|DRUG|Iron chelating intervention|Iron chelating intervention
218938130|NCT03699215|DRUG|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
218938131|NCT03699215|DRUG|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
218938132|NCT02879201|PROCEDURE|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
218938133|NCT06326333|PROCEDURE|Combined parasternal block and serratus anterior plane block|"The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally."
218938134|NCT00422682|DRUG|bsi-201 + topotecan|21 day cycle
218938135|NCT00422682|DRUG|bsi-201 + temozolomide|28 day cycle
218938136|NCT00422682|DRUG|bsi-201 + gemcitabine|28 day cycle
218938137|NCT00422682|DRUG|bsi-201 + carboplatin/paclitaxel|21 day cycle
218938138|NCT02921334|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
218938139|NCT05569590|DRUG|Propolis|Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
218938140|NCT05569590|DRUG|hydrogen peroxide 35%|hydrogen peroxide 35%
219048960|NCT03886558|OTHER|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
219632559|NCT03011827|OTHER|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
219632560|NCT04432766|DRUG|BAT2020|After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
218938141|NCT05569590|OTHER|fluoride varnish|fluoride varnish
218938142|NCT02152956|BIOLOGICAL|Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
218938143|NCT02152956|BIOLOGICAL|Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938144|NCT02152956|BIOLOGICAL|Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938145|NCT02152956|BIOLOGICAL|Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938146|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938147|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
218938148|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938149|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938150|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938151|NCT02152956|DRUG|Ruxolitinib|Oral inhibitor of JAK kinase
218938152|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
218938153|NCT02445794|DRUG|Low dose cohort|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
219632561|NCT02571673|BEHAVIORAL|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
219632562|NCT02276248|RADIATION|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
218938154|NCT02445794|DRUG|High dose cohort|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
218938155|NCT00530387|DRUG|19 organic sunscreen filters and 5 topical NSAIDs|
219632563|NCT02276248|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
219632564|NCT00086619|DRUG|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
219632565|NCT00489918|DRUG|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
219632566|NCT00489918|DRUG|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
219632567|NCT02748213|DRUG|Xeloda|Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.
219632568|NCT02748213|DRUG|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
219632569|NCT02748213|DRUG|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
218938156|NCT04381182|DEVICE|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
218938157|NCT06020872|OTHER|Health literacy program|Health literacy program was the health education related to healthy plate.
218938158|NCT01996761|DRUG|porcine brain peptide (Cerebrolysin)|
218938159|NCT01996761|DRUG|Placebo|
218938160|NCT02869659|BEHAVIORAL|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
218938161|NCT02869659|BEHAVIORAL|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
218938162|NCT02081885|PROCEDURE|Tricalcium Phosphate / Chitosan|
218938163|NCT02081885|PROCEDURE|Autologous Graft|
218938164|NCT00835562|PROCEDURE|Non-surgical management|Non-surgical management (physiotherapy and self-training)
218938165|NCT00835562|PROCEDURE|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
218938166|NCT00835562|PROCEDURE|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
218938167|NCT01420094|DRUG|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter \[mL\]) between 1-4 hours post dental surgery.
218938168|NCT01420094|DRUG|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
218938169|NCT01420094|DRUG|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
218938170|NCT04189224|DEVICE|JJV Investigational Multifocal Contact Lens|TEST
218938171|NCT04189224|DEVICE|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
218938172|NCT00159887|DRUG|Sildenafil citrate|
218938173|NCT01469611|BIOLOGICAL|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
218938174|NCT04078906|OTHER|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
218938175|NCT00692263|DRUG|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
218938176|NCT00692263|DRUG|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
218938177|NCT00692263|DRUG|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
218938178|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
218938179|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
218938180|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
218938181|NCT03546205|DRUG|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
218938182|NCT05163275|DIAGNOSTIC_TEST|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
218938183|NCT04643613|DIETARY_SUPPLEMENT|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
218938184|NCT04185051|DRUG|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
218938185|NCT04185051|DRUG|Placebo|Participants will receive matching placebo oral capsules.
218938186|NCT03089918|DRUG|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
218938187|NCT03174938|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
218938188|NCT03174938|DIAGNOSTIC_TEST|[18F]-RO6958948|PET imaging of Tau aggregates
218938189|NCT03174938|DIAGNOSTIC_TEST|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
218938190|NCT03174938|DIAGNOSTIC_TEST|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
218938191|NCT03593954|DRUG|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
218938192|NCT03593954|DRUG|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
218938193|NCT04198714|PROCEDURE|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
218938194|NCT01064947|DRUG|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
218938195|NCT05348213|DRUG|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
218938196|NCT05348213|DRUG|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
218938197|NCT05348213|DRUG|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
218938198|NCT05348213|DRUG|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
218938199|NCT05348213|DRUG|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
218938200|NCT02970942|DRUG|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
218938201|NCT02970942|DRUG|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
219048961|NCT04107480|PROCEDURE|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
219206589|NCT06990386|BEHAVIORAL|Video guide and usual education|Video guide was the hand and joint exercise video guide that included a 3.27-minute educational video on 6 basic daily hand exercises including: a) stretching wrist flexion and extension, b) range of motion (ROM) ulnar and radial deviation, c) ROM finger abduction and adduction, d) finger pincer, e) finger flexion and extension, and f) finger grab.
219632570|NCT04273113|OTHER|Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety|Patients asked to complete these 4 questionnaires pre, during and post biofeedback training
219632571|NCT04273113|BEHAVIORAL|HRV Biofeedback (Healing Rhythms)|Sensors placed on fingers to capture heart rate and skin temperature
219632572|NCT00987818|OTHER|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
218938202|NCT06651905|DRUG|Dexmedetomidine|The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
218938203|NCT06651905|DRUG|Superior laryngeal nerve block|The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
218938204|NCT00508196|OTHER|RVP-min|DDD pacing with long AV delay
218938205|NCT00508196|OTHER|RVP-max|DDD pacing with short AV delay
218938206|NCT06655025|DRUG|Dexmedetomidine|Dexmedetomidine infusion during open heart surgery
218938207|NCT06654115|DEVICE|Wireless Physiologic Monitoring|YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
219632573|NCT00224861|BEHAVIORAL|Self-Management|
218938208|NCT00169065|DRUG|Clozapine|
218938209|NCT00169065|DRUG|Olanzapine|
218938210|NCT06444191|DRUG|Rilzabrutinib|Rilzabrutinib tablet(s) administered orally
218938211|NCT04761328|BEHAVIORAL|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
218938212|NCT06592937|OTHER|Invasive ventilation|Invasive ventilation and respiratory support
218938213|NCT04282330|DIAGNOSTIC_TEST|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
218938214|NCT02529553|DRUG|LY3076226|Administered IV
218938215|NCT00610298|DEVICE|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
218938216|NCT00488683|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
218938217|NCT00488683|BIOLOGICAL|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
219048962|NCT04107480|DRUG|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
219048963|NCT06471036|OTHER|Care Champion Intervention|The care champion will communicate with the patient according to an algorithm and will emphasize adherence to appropriate lipid lowering therapy, LDL-C retesting, and outpatient follow-up. The care champion will also facilitate communication of any challenges or issues with the patient's outpatient care team. Of note, the care champion will NOT be responsible for prescriptions or drug management.
218938218|NCT00488683|BIOLOGICAL|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
219206590|NCT06990386|BEHAVIORAL|Telephone notification, video guide and usual education|Telephone notifications consisted of weekly calls for further continuity and engagement with hand exercises. Each call lasted about 10 minutes, providing problem-solving support, knowledge reinforcement, and motivation to encourage adherence to the program.
219206591|NCT05727163|DRUG|Dexamethasone|25mg via HAI (Pre-chemotherapy)
219206592|NCT05727163|DRUG|Anisodamine|10 mg via HAI (Pre-chemotherapy)
219632574|NCT00224861|BEHAVIORAL|Adherence|
219632575|NCT03454061|OTHER|physical activity|Physical education program (PEP) of 16-week length
219632576|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
219632577|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
218938219|NCT00488683|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
218938220|NCT00488683|BIOLOGICAL|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
218938221|NCT06600945|OTHER|Cataract surgery|With local anesthetic in peribulbar anesthesia
218938222|NCT06591078|OTHER|electropuncture|"The needle was retained for 30 minutes. During the retention period, the needle was lifted and twisted for 3 times with even small amplitude every 10 minutes, and the complement method was performed for 3 times. No manipulation before the needle, cotton ball press directly out of the needle.~④ Frequency, course and time: Start at the same time as immunotherapy, and complete 1-2 times of electroacupuncture treatment per week; Electroacupuncture was performed 4 times per 28 days. The number of electroacupuncture treatment cycles and the number of immunotherapy courses should be consistent."
218938223|NCT04509726|DRUG|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
218938224|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from optoelectronic system|The raw data acquired from motion capture system were processed with Smart Analyzer software (BTS Bioengineering, Milano, Italy). First, the 3D data were filtered and interpolated in case of missing data for short time. Then spatial-temporal parameters (cycle duration, cadence, gait speed, stance phase, swing phase, double-support phase, stride length and step width) and conventional kinematic parameters of traditional Davis marker-set protocols were computed.
218938225|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from markerless system|The two videos were elaborated using OpenPose that returns a set of 25 2D keypoints coordinates for body pose estimation for each video. Key-points were located in relevant body landmarks and it were used to determine the 2D Cartesian coordinates on the sagittal plane and on the frontal plane. The data calculated with routines were filtered and interpolated in case of missing data. With respect to kinematic parameters, the segment and joint angles were measured from the estimated feature points of each joint. Spatiotemporal gait parameters were calculated using successive heel strike and toe-off events.
218938226|NCT04549545|DEVICE|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
218938227|NCT04549545|DEVICE|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
218938228|NCT04478942|DRUG|Misoprostol Oral Product|Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.
219206593|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 via HAI over 3 hours
219206594|NCT05727163|DRUG|Leucovorin|200 mg/m2 via HAI
219206595|NCT05727163|DRUG|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
219206596|NCT05727163|DRUG|Irinotecan|150 mg/m2 intravenously
219206597|NCT05727163|DRUG|Bevacizumab|5 mg/kg intravenously
219206598|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 intravenously over 3 hours
219206599|NCT05727163|DRUG|Leucovorin|200 mg/m2 intravenously
219048964|NCT05983497|OTHER|Self-Care Skill Educational Intervention|An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
218938229|NCT04478942|DRUG|Intravenous Oxytocin|Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
219048965|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
219048966|NCT01891851|DRUG|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
219048967|NCT01891851|DRUG|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
219048968|NCT01247090|DRUG|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
218938230|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
218938231|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
218938232|NCT04554914|BIOLOGICAL|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
219206600|NCT05727163|DRUG|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
219048969|NCT01247090|DRUG|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
219206601|NCT06996834|DEVICE|Non-Invasive ventilation (NIV)|Participants in this arm will receive noninvasive ventilation using bilevel positive airway pressure (BiPAP) delivered via a full-face mask to support ventilation in patients with acute hypoxemic respiratory failure due to CAP.
219632578|NCT03051451|DRUG|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
218938233|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
218938234|NCT05886413|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application, the investigators will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery. The investigators will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
218938235|NCT05475483|DRUG|Placebo capsules|Treatment was blind for the whole duration of the study.
218938236|NCT05475483|DRUG|SOM3355 200 mg capsules|Treatment was blind for the whole duration of the study.
219048970|NCT01247090|DRUG|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
219632579|NCT05087511|OTHER|motor and sensory development assessment|Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.
219632580|NCT03373877|DRUG|PU-H71|PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
219632581|NCT03373877|DRUG|Ruxolitinib|Dosing will be in accordance with current package insert and dose subject was on during study entry.
219632582|NCT05383430|DIAGNOSTIC_TEST|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
218938237|NCT05475483|DRUG|SOM3355 300 mg capsules|Treatment was blind for the whole duration of the study.
218938238|NCT06015152|DRUG|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|\[ARAZLO\]
219048971|NCT01226719|DRUG|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
219632583|NCT05122182|DRUG|Candesartan Cilexetil|Angiotensin Receptor Blocker (ARB)
219632584|NCT05122182|DRUG|Repagermanium|C-C chemokine receptor type 2 (CCR2) antagonist
219206602|NCT06996834|DEVICE|High Velocity Nasal Insufflation|Participants in this arm will receive high-velocity nasal insufflation therapy, a type of high-flow nasal cannula (HFNC) therapy that delivers heated and humidified oxygen at high flow rates to support patients with acute hypoxemic respiratory failure resulting from community-acquired pneumonia (CAP).
219365942|NCT01633957|OTHER|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
218938239|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
218938240|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
218938241|NCT01006291|DRUG|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
218938242|NCT00234754|PROCEDURE|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
218938243|NCT03114540|DRUG|GBT440|Oral
218938244|NCT03079102|DRUG|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
219048972|NCT01226719|DRUG|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
219048973|NCT01226719|DRUG|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
219048974|NCT01226719|DRUG|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
219632585|NCT05122182|DRUG|Candesartan Placebo|Angiotensin Receptor Blocker (ARB) placebo
219632586|NCT05122182|DRUG|Repagermanium Placebo|C-C chemokine receptor type 2 (CCR2) antagonist placebo
219632587|NCT02914782|OTHER|Observational Study|
218938245|NCT03079102|DRUG|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
218938246|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
218938247|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
218938248|NCT01440192|BIOLOGICAL|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
218938249|NCT05289518|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
218938250|NCT05289518|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
218938251|NCT02052492|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
219632588|NCT03063060|OTHER|vitamin D levels and Calcium levels examination|observational
219048975|NCT01226719|DRUG|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
219048976|NCT00006916|BIOLOGICAL|bleomycin|
219048977|NCT00006916|DEVICE|Ommaya reservoir|
219048978|NCT00006916|RADIATION|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
219048979|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
219048980|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
219048981|NCT00122720|DRUG|Darbepoetin Alfa|
219632589|NCT03199560|DRUG|Tc 99m tilmanocept|lymphatic mapping agent
219632590|NCT03199560|DRUG|Tc 99m filtered sulfur colloid|lymphatic mapping agent
219632591|NCT01209520|DRUG|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
219632592|NCT01209520|DRUG|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
219632593|NCT01209520|DRUG|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
219632594|NCT01209520|DRUG|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
219632595|NCT01209520|PROCEDURE|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
219632596|NCT01209520|PROCEDURE|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
219632597|NCT01209520|DRUG|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
218938252|NCT03716167|DEVICE|Summus Laser|infrared laser treatment
218938253|NCT03716167|DEVICE|Summus Laser Sham|non-infrared light
218938254|NCT02923921|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus FOLFOX
218938255|NCT02923921|DRUG|FOLFOX|FOLFOX Alone
218938256|NCT05310175|DEVICE|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
218938257|NCT05310175|DEVICE|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
218938258|NCT05133531|DRUG|Ravulizumab|Administered Intravenous (IV) per the protocol
218938259|NCT05133531|DRUG|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
219048982|NCT04712604|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
219048983|NCT04007172|PROCEDURE|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
219365943|NCT01633957|OTHER|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
218938260|NCT05133531|DRUG|Cemdisiran|Administered SC per the protocol
218938261|NCT05133531|DRUG|Eculizumab|Administered IV per the protocol
218938262|NCT04058132|DRUG|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo\[4,3-d\]pyrimidin-5-yl)-4- ethoxyphenyl\]sulfonyl\]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
218938263|NCT04058132|DEVICE|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
219632598|NCT01209520|DRUG|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
219632599|NCT01209520|DRUG|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
218938264|NCT04058132|OTHER|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
218938265|NCT04058132|OTHER|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
218938266|NCT04058132|DRUG|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
218938267|NCT04058132|PROCEDURE|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
218938268|NCT04058132|OTHER|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
218938269|NCT01426841|RADIATION|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
218938270|NCT04230135|DEVICE|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
218938271|NCT00609531|DRUG|Citalopram|Pill, 5-20mg once a day for twelve weeks
218938272|NCT00609531|DRUG|Placebo|Placebo pill once a day for twelve weeks
218938273|NCT05094388|OTHER|Admitted to intensive care units|Admitted to intensive care units
219632600|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
219632601|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
219632602|NCT01200147|OTHER|study withdrawn no details|
219632603|NCT06578260|BEHAVIORAL|Peer support groups with a solution-focused approach|To investigate the effectiveness of a support group intervention using a solution-focused approach among school children in 5th-7th grade in southeastern Norway
218938274|NCT04177576|BIOLOGICAL|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
218938275|NCT04860778|DIETARY_SUPPLEMENT|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
218938276|NCT00778843|DIETARY_SUPPLEMENT|Viusid|Viusid, three oral sachets daily during 24 weeks
219632604|NCT01035294|BEHAVIORAL|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
219632605|NCT01035294|BEHAVIORAL|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
219632606|NCT00961350|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
219632607|NCT00961350|DRUG|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
219632608|NCT06537427|OTHER|Data collection|"The data to be collected are the following:~* Demographic data: gender and age of the patient at diagnosis of SCI;~* Drug assumption and drug abuse at the time of SCI;~* A complete assessment of patients' comorbidities;~* Complete neurological examination on admission and at 6-8 months follow-up according to ASIA protocol;~* Neuro-radiological data: spinal CT and MRI performed within 48 hours of admission to document the type, level and extent of the lesion of the spine and the spinal cord;~* CSF pressure, chemical and biological markers;~* Serum chemical and biological markers;~* Data coming from surgical procedure: type of decompression, type of stabilization, extension of the stabilization, surgical approach, staged surgery, timing of surgery, length of surgery, eventual intraoperative, postoperative or long-term surgical-related complications \[13\];~* Data on hospitalization: length of stay, hospital-acquired infections, any adverse event occurred during hospitalisation."
219632609|NCT05654376|BEHAVIORAL|Art therapy|"Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences)."
219632610|NCT05435729|DRUG|DSP-9632P 27.5 mg|Single dose of DSP-9632P 27.5 mg
219632611|NCT05435729|DRUG|DSP-9632P 82.5 mg|Single dose of DSP-9632P 82.5 mg
219632612|NCT05435729|DRUG|Placebo|Placebo for DSP-9632P
219632613|NCT05435729|DRUG|DSP-9632P 55.0 mg|Multiple dose of DSP-9632P 55.0 mg
219632614|NCT05435729|DRUG|Levodopa formulation|Single dose of Levodopa formulation
218938277|NCT00778843|OTHER|Placebo|Placebo three oral sachets daily during 24 weeks
218938278|NCT00479687|DEVICE|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
218938279|NCT00479687|DEVICE|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
218938280|NCT00295880|PROCEDURE|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
218938281|NCT02064413|DEVICE|ESS310 (BAY1454032)|
218938282|NCT01474239|DRUG|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
218938283|NCT01474239|DRUG|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
218938284|NCT03563924|OTHER|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
218938285|NCT04708314|DRUG|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
218938286|NCT04591678|DRUG|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
218938287|NCT01757249|DRUG|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
218938288|NCT01282619|DRUG|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
218938289|NCT01282619|DRUG|huperzine A|Tablet, 200µg twice a day, 24 weeks
218938290|NCT01282619|DRUG|Placebo|placebo orally twice a day
218938291|NCT01715012|BIOLOGICAL|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
218938292|NCT01715012|DRUG|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
218938293|NCT05150899|DRUG|Tamsulosin Hcl 0.4Mg Cap|alpha blocker
218938294|NCT05150899|DRUG|fexofenadine 180 mg Oral tablet|antihistaminic
218938295|NCT03192371|BIOLOGICAL|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
218938296|NCT02269579|DRUG|CPX-351|
218938297|NCT04415671|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
218938298|NCT04415671|OTHER|Placebo|Placebo
219632615|NCT04825691|DIAGNOSTIC_TEST|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
219632616|NCT02678065|DEVICE|InPact Admiral DEB|
219632617|NCT06578676|DRUG|Empagliflozin 25 MG|PO, QD
219632618|NCT06578676|DRUG|Ezetimibe/Rosuvastatin 10/10mg|PO, QD
219206603|NCT06996028|OTHER|Strengthening domain, Balance domain, Coordination domain, Gait domain|The experimental group will engage in a structured exercise program targeting strength, balance, gait, and coordination. Strength exercises include sit-to-stand, step-ups, vertical jumping, and stair climbing. Balance training involves tandem walking, one-leg standing, and balancing on unstable surfaces. Gait exercises include bridging, clamshells, and heel rises, while coordination activities involve ball kicking, hopping through squares, and galloping/skipping. The program runs for 2 hours per day, 5 days a week, over 6 weeks, with sessions optionally split into shorter segments.
218938299|NCT04458090|BEHAVIORAL|A decision aid for patients considering Hospice care.|A 12 page booklet and 17 min video describing hospice care
218938300|NCT02120183|BEHAVIORAL|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
218938301|NCT02175199|DEVICE|Lotrafilcon B contact lenses with color printing|
218938302|NCT02175199|DEVICE|Phemfilcon A contact lenses with color printing|
218938303|NCT06126211|DEVICE|Assessment|"The hand grip strength of each individuals was measured by the Electronic Camry Dynamometer (Model EH101, Zhongs-han Camry Electronic Co. Ltd. China: 90 kg capacity, 356 g weight) and Jamar Hydraulic Hand Grip Dynamometer (Model J00105, Lafayette Instrument Com-pany. USA: 90 kg capacity, 727 g weight). The assessments of the upper extremity were performed bilaterally.~Camry Electronic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Camry Electronic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left).~Jamar Hydraulic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Jamar Hydraulic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left)."
219632619|NCT06578676|DRUG|Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg|PO, QD
218938304|NCT01794143|DRUG|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
218938305|NCT01794143|DRUG|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
219632620|NCT03924180|DIETARY_SUPPLEMENT|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
219632621|NCT01574365|DRUG|RTA 402|
219632622|NCT03617380|OTHER|Usual Care|patients participating Usual Care discharge services
219632623|NCT03617380|OTHER|PharmD TOC|patients participating in a community pharmacy-based Transitions of Care Program (PHARMD-TOC)
218938306|NCT01794143|DRUG|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
219632624|NCT03952273|COMBINATION_PRODUCT|PCI with BioMatrix Alpha™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
219632625|NCT03952273|COMBINATION_PRODUCT|PCI with Combo™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
219632626|NCT00466362|BEHAVIORAL|The Evje Model|Lifestyle intervention
219632627|NCT06043505|OTHER|Echographic hemodynamic algorithm guiding fluid resuscitation|"Ultrasound Hemodynamic Algorithm (UHA):~1. st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~   E/Ea \>14 and/or E/A \>2~  * YES =\> No filling test =\> Bilateral anterior B lines on lung ultrasound =\> YES =\> Consider administration of diuretics~  * NO =\> Step 2~2. nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase \>15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~   * YES =\> consider 250ml bolus filling~  * NO =\> stop vascular filling~3. rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~   * YES =\> depletion~  * NO =\> stop vascular filling"
219632628|NCT00415727|DEVICE|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
219632629|NCT06831448|DEVICE|Prototype dressing|Five-layer foam dressing with polyurethane, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE. Size: 10cm x 10 cm. Topical application. Single use.
219632630|NCT06831448|DEVICE|Marketed dressing 1|Five-layer foam dressing with polyurethane, polyethylene, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive, polypropylene. Size: 12.9cm × 12.9cm. Topical application. Single use.
219632631|NCT06831448|DEVICE|Marketed dressing 2|Five-layer foam dressing with silicone, polyurethane, polyacrylate, cotton, viscose, polyester and polyolefin. Size: 10cm x 10 cm. Topical application. Single use.
219632632|NCT00485251|PROCEDURE|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
219632633|NCT00485251|PROCEDURE|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
219632634|NCT00485251|PROCEDURE|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
219632635|NCT00485251|PROCEDURE|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
219632636|NCT05137782|OTHER|Specialty Palliative Care|Specialty palliative care, as opposed to primary palliative care.
219632637|NCT01193374|BEHAVIORAL|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
219632638|NCT01193374|BEHAVIORAL|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
219632639|NCT01193374|BEHAVIORAL|basic educational brochure|Booklet by ADA sent x 1.
219632640|NCT03640390|DRUG|Dexmedetomidine|This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.
219632641|NCT03640390|DRUG|Magnesium Sulphate|This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
219632642|NCT03640390|DRUG|Normal saline|This group will receive normal saline infusion
219632643|NCT04663633|OTHER|Core stability training|Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
219632644|NCT05399940|DIAGNOSTIC_TEST|Serum PSA,Delta Neutrophil Index(DNI),WBC|Urine culture, prostate volume
219632645|NCT02134015|DRUG|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
219632646|NCT02134015|DRUG|Erlotinib|Oral erlotinib 150 mg/day
218938307|NCT01794143|DRUG|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
218938308|NCT03257449|DIETARY_SUPPLEMENT|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
218938309|NCT00459732|DIETARY_SUPPLEMENT|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
218938310|NCT00459732|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
218938311|NCT01257061|DRUG|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
218938312|NCT01257061|DRUG|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
218938313|NCT00250328|DEVICE|LapCAC Laparoscopic Compression Anastomosis Clip|
218938314|NCT04502173|DEVICE|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
218938315|NCT02789930|OTHER|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
218938316|NCT06291818|DEVICE|temporary magnetic system for tarsorrhaphy (MST)|cutting-edge technology has produced smaller magnets with stronger magnetic fields, prompting experts to revisit the use of magnets to facilitate eyelid closure
218938317|NCT03344770|DEVICE|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
218938318|NCT03344770|DEVICE|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
218938319|NCT04344964|OTHER|None - NA|Observational study
218938320|NCT01017380|DRUG|Celecoxib|celecoxib 400 mg 1 cap before surgery
219048984|NCT04007172|DEVICE|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
219632647|NCT02134015|DRUG|Placebo|Placebo infusion every 3 weeks
219632648|NCT06626230|DRUG|Curcuminoid Capsules|"500 mg curcuminoids from C3 Complex capsule. Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period.~Escalating doses"
219632649|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
219632650|NCT06909734|BEHAVIORAL|Trauma-Informed Motivational Interviewing|"Trauma-Informed Motivational Interviewing: Core Principles~TIMI integrates two evidence-based approaches: Trauma-Informed Care (TIC) and Motivational Interviewing (MI). TIC emphasises understanding and acknowledging the impact of trauma on individuals' behaviours and emotional well-being. MI, a client-centred approach, fosters intrinsic motivation for change by exploring ambivalence and strengthening personal autonomy."
219632651|NCT02042755|DEVICE|trifocal intraocular lens|Standard cataract surgery
219632652|NCT04540419|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
219632653|NCT04540419|BIOLOGICAL|Placebo|Intramuscular administration
219632654|NCT03697343|RADIATION|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
219632655|NCT03697343|RADIATION|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
219632656|NCT04378725|BEHAVIORAL|School-based smoking prevention and cessation program (The KOTAK program)|"Advance Intervention: Following the screening process, this intervention package was inclusive of group-briefing for the smokers in at least 3 subsequent sessions in one academic year. The content delivered by the dentist were based on the KOTAK guidebook consisted of 8 Modules.The modules were as follows:~1. Introduction: Identifying students who smoke~2. Cigarette and addiction~3. The danger of smoking and passive smokers~4. Advantages of smoke-free lifestyle and adolescent perception on smoking~5. Legal and religious perception of smoking~6. The benefits of smoking cessation~7. Preparation and how to stop smoking~8. Nicotine withdrawal symptom and relapse prevention~The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval."
219632657|NCT01507792|DRUG|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
219632658|NCT01507792|DRUG|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
219632659|NCT06575257|DRUG|Darolutamide|600 mg orally twice daily for 12 weeks before radical prostatectomy
219632660|NCT06575257|DRUG|Goserelin 3.6 mg|3.6 mg goserelin hypodermic once per 4 weeks
219632661|NCT00454688|DRUG|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
219632662|NCT00454688|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
219632663|NCT00617890|BIOLOGICAL|robatumumab|Robatumumab IV every two weeks until disease progression.
219632664|NCT04357665|PROCEDURE|Bilateral TAPP Repair|laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
219632665|NCT04357665|PROCEDURE|Open PP Repair|Open pre-peritoneal repair using single mesh fixed by sutures
219632666|NCT04357665|PROCEDURE|Bilateral Lichtenstein Repair|Bilateral Lichtenstein Repair using 2 separate meshes fixed by sutures
219632667|NCT03266315|BIOLOGICAL|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
219632668|NCT03266315|OTHER|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
219632669|NCT06045325|DIAGNOSTIC_TEST|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
218938321|NCT01017380|DRUG|etoricoxib|120 mg 1 tab before surgery
218938322|NCT00045461|DRUG|carboplatin|
218938323|NCT00045461|DRUG|ifosfamide|
218938324|NCT00045461|PROCEDURE|hyperthermia treatment|
219048985|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
218938325|NCT03933891|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
218938326|NCT05480111|DRUG|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
218938327|NCT05480111|DRUG|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
218938328|NCT05480111|DRUG|Sham Local|20 mls of normal saline given at incision site
219048986|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
219365944|NCT03948932|DEVICE|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
218938329|NCT05480111|DRUG|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
218938330|NCT00935922|DIETARY_SUPPLEMENT|Flaxseed|Flaxseed omega-3 fatty acids and lignans
218938331|NCT04851405|BEHAVIORAL|Otago Exercise Programme+ (OEP+)|"Physiotherapists (PTs) will receive OEP and BAP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 phone calls).~Older adults will have access to the OEP app."
218938332|NCT04851405|BEHAVIORAL|Otago Exercise Programme (OEP)|PTs will receive OEP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 follow-up phone calls).
218938333|NCT02814500|DRUG|DP-R212|Investigational product is prescribed to all of randomized subjects
218938334|NCT02814500|DRUG|Amlodipine|Investigational product is prescribed to all of randomized subjects
218938335|NCT02814500|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
219048987|NCT03703635|DEVICE|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.
219048988|NCT03703635|DRUG|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
219048989|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
219048990|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
218938336|NCT01322841|OTHER|CHICA Diagnosis Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
218938337|NCT01322841|OTHER|CHICA Placebo|This was CHICA without the screening module
219048991|NCT01301222|DRUG|Inj. Octreotide|100 mcg subcutaneously for 5 days
219632670|NCT06045325|DIAGNOSTIC_TEST|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
219632671|NCT06045325|DIAGNOSTIC_TEST|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
219632672|NCT06045325|DIAGNOSTIC_TEST|Atlas 9000|Diagnostic assessment to measure white-to-white.
219632673|NCT06045325|DIAGNOSTIC_TEST|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
219632674|NCT06045325|DIAGNOSTIC_TEST|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
219048992|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
219365945|NCT03948932|DEVICE|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
219365946|NCT02661594|DRUG|APD421 5 mg|Therapeutic dose of amisulpride
219365947|NCT02661594|DRUG|APD421 40 mg|Supra-therapeutic dose of amisulpride
219365948|NCT02661594|DRUG|Moxifloxacin|Positive control for assay sensitivity
219365949|NCT02661594|DRUG|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
219632675|NCT06045325|DIAGNOSTIC_TEST|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
219632676|NCT06045325|DIAGNOSTIC_TEST|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
219632677|NCT06045325|DIAGNOSTIC_TEST|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
219632678|NCT02640950|DEVICE|NeuroStar TMS|Transcranial Magnetic Stimulation
219632679|NCT05066204|OTHER|Sequence of teaching-/learningmethod|see: arm/group descriptions
219632680|NCT01431690|DRUG|warfarin|A single 25 mg dose of warfarin
219632681|NCT01431690|DRUG|omefas|4 x 1 g capsule dose of Epanova®
219632682|NCT01431690|DRUG|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
219632683|NCT05126069|DEVICE|Ab interno gelatin microstent|Ab interno gelatin microstent
219632684|NCT05126069|PROCEDURE|Trabeculectomy|Trabeculectomy
219632685|NCT00904358|DIAGNOSTIC_TEST|cross sectional area|
219632686|NCT00044018|DRUG|CDC-501|
219632687|NCT05809232|OTHER|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
218938338|NCT04980742|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution
218938339|NCT01095198|DEVICE|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
218938340|NCT01095198|OTHER|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
218938341|NCT02560545|DRUG|Cannabis oil|Cannabis oil 20% THC
218938342|NCT00283335|DRUG|gemfibrozil|
218938343|NCT00283335|OTHER|Placebo|Matching placebo tablets taken once per day
218938344|NCT03263949|OTHER|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
219048993|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
219048994|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
219048995|NCT02322554|BIOLOGICAL|Cellular and tissue based products|Procedure: Application of device or biological to wounds
219048996|NCT01607983|DRUG|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
219048997|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
219048998|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
219048999|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
219049000|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
219049001|NCT01955070|OTHER|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
218938345|NCT05090774|BEHAVIORAL|Adapted Otago Exercise Program (OEP)|A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
219049002|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
219206604|NCT06996028|OTHER|Lower extremity strengthening, Cardiorespiratory endurance|Group B will follow the PEDALS program, involving stationary cycling three times a week for 30 minutes per session. Each session includes lower-limb strengthening with gradual resistance progression and cardiorespiratory endurance training aimed at increasing cycling duration to 15-30 minutes. Proper bike setup and participant support are ensured, and each session ends with a cool-down period of pedaling without resistance until heart rate returns near baseline.
219365950|NCT00289913|BIOLOGICAL|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
218938346|NCT05633017|COMBINATION_PRODUCT|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
218938347|NCT02767349|DRUG|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
218938348|NCT02817425|DRUG|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
218938349|NCT02817425|DRUG|SOX|S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
219049003|NCT06087965|DRUG|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
219049004|NCT04334499|OTHER|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
219049005|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
219049006|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
219049007|NCT03467425|DRUG|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
219049008|NCT03467425|DRUG|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
219049009|NCT03467425|DRUG|LAMA|LAMA as prescribed by the physician.
219049010|NCT03467425|DRUG|LABA|LABA as prescribed by the physician.
219049011|NCT03467425|DRUG|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
219049012|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
218938350|NCT02817425|DRUG|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
219049013|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
219049014|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
219049015|NCT02318693|DRUG|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
219049016|NCT02318693|DRUG|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
219049017|NCT00025883|DRUG|Metreleptin|Drug treatment
219049018|NCT03080961|DEVICE|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
219049019|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
219049020|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
219049021|NCT00578500|PROCEDURE|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
219049022|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
219049023|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
219049024|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
219365951|NCT00289913|BIOLOGICAL|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
219365952|NCT00289913|BIOLOGICAL|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
219632688|NCT04244552|BIOLOGICAL|ATRC-101|ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
219632689|NCT04244552|BIOLOGICAL|Pembrolizumab|Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
219632690|NCT04244552|DRUG|Pegylated liposomal doxorubicin (PLD)|Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
219632691|NCT00154284|DRUG|Everolimus (Certican)|
219632692|NCT00154284|DRUG|Cyclosporine (Neoral)|
219632693|NCT00154284|DRUG|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
219632694|NCT00154284|DRUG|Basiliximab (Simulect)|
219632695|NCT04917003|OTHER|RIC plus EDAS|Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
219632696|NCT04917003|OTHER|EDAS|Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
219632697|NCT03023618|DEVICE|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
219632698|NCT01090349|DEVICE|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
218938351|NCT02122757|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
218938352|NCT02122757|DEVICE|sham Cefaly tDCS|2mA during 30sec
219049025|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
219049026|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
219049027|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
219049028|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
219049029|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
219632699|NCT01090349|DEVICE|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
218938353|NCT01401660|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
218938354|NCT03983317|DEVICE|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
218938355|NCT03991897|DIETARY_SUPPLEMENT|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
218938356|NCT03991897|DIETARY_SUPPLEMENT|Isocaloric diet|Patients will follow an isocaloric diet
218938357|NCT03991897|DIETARY_SUPPLEMENT|Ketone ester supplementation|25g of a ketone monoester, ingested 3 times a day for a period of 12 weeks. Ingestion is separated from a meal and interspersed by at least 4 hours to ensure maximal available ketone bodies circulating in the blood.
218938358|NCT02904213|BIOLOGICAL|ComBe Five (Liquid)|
218938359|NCT01761162|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
218938360|NCT01761162|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
218938361|NCT02998957|DEVICE|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
218938362|NCT02998957|DEVICE|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
218938363|NCT03205449|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
218938364|NCT03205449|OTHER|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
218938365|NCT03565952|OTHER|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
218938366|NCT03565952|OTHER|Control group|The control group does not receive treatment
218938367|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
218938368|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
218938369|NCT03595995|BIOLOGICAL|UB-621|Monoclonal antibody by SC injection
218938370|NCT03595995|OTHER|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
218938371|NCT00323011|DRUG|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
218938372|NCT04480970|DEVICE|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
218938373|NCT00271713|DRUG|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
218938374|NCT00271713|DRUG|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
218938375|NCT01541683|OTHER|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
218938376|NCT01541683|OTHER|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
219049030|NCT04174313|DIAGNOSTIC_TEST|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning."
218938377|NCT02741518|BIOLOGICAL|Fecal Microbiota Transplantation|This is pre-screened fecal material that has been encapsulated
218938378|NCT02741518|OTHER|Placebo|These are capsules that have no fecal material in them.
218938379|NCT01349049|DRUG|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
218938380|NCT01349049|DRUG|PLX3397|The drug product is available in capsule form, to be taken orally.
218938381|NCT03140215|DEVICE|laryngeal mask insertion (Baska)|
218938382|NCT03140215|DEVICE|laryngeal mask insertion (I-gel )|
218938383|NCT05350696|DRUG|Erector Spinae plane block (plain pubivicaine)|"The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance."
218938384|NCT05350696|DRUG|Intravenous morphine group|patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
218938385|NCT06092944|PROCEDURE|Catheterization|Before the operation,the patient was placed in the left lateral position.The catheter（soft tip epidural catheter 20-gauge-100 cm） was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level。
218938386|NCT06092944|PROCEDURE|Single nerve block|Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
218938387|NCT06092944|PROCEDURE|Continuous nerve block|After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
218938388|NCT06092944|PROCEDURE|PCIA|After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min
218938389|NCT02384798|OTHER|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
218938390|NCT02384798|OTHER|interval training|interval training
219049031|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
219049032|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
219049033|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
219049034|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
219049035|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
219049036|NCT05864274|DEVICE|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
219049037|NCT06575374|DRUG|Letermovir|Given by mouth or intravenously
219049038|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
219049039|NCT06466850|BIOLOGICAL|Exosome|intra-articular injection is suggested for two times: day 1and day 90
219632700|NCT03487627|BEHAVIORAL|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
219632701|NCT03487627|BEHAVIORAL|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
219632702|NCT00566020|DRUG|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
219632703|NCT00010010|DRUG|exemestane|
219632704|NCT00010010|DRUG|goserelin acetate|
219632705|NCT04959981|DRUG|ERAS-007|Administered orally
218938391|NCT01170533|DRUG|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
218938392|NCT03647813|RADIATION|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
218938393|NCT03647813|RADIATION|Placebo|The same laser protocol was followed but with the device switched off.
218938394|NCT02933450|DRUG|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
218938395|NCT02358291|PROCEDURE|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
218938396|NCT02358291|PROCEDURE|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
218938397|NCT02358291|PROCEDURE|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
218938398|NCT03117452|BEHAVIORAL|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
218938399|NCT03168958|DRUG|Methadone|Methadone will be provided at induction of anesthesia
218938400|NCT03168958|DRUG|Saline|Saline will be administered at induction of anesthesia
219049040|NCT04127578|BIOLOGICAL|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
219049041|NCT04127578|DRUG|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
219049042|NCT04127578|DRUG|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
219049043|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
219049044|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, Sham condition|sham
219049045|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
219049046|NCT02026115|BEHAVIORAL|PAINReportIt|PAINReportIt is a software program developed with an electronic McGill Pain Questionnaire (MPQ) and now includes questions about analgesics used by patients and a shortened version of the pain Barriers Questionnaire (BQ). It is designed as an interactive, touch screen way to assess pain. It can be self-administered and requires little or no patient computer experience and little or no provider time. The patient can read instructions on-screen and practice all types of selection responses found the program. Directions from the paper tools were modified to address the touch screen method of recording responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both individuals authorized the modifications, format, and computerized use of the tools.
219049047|NCT02026115|BEHAVIORAL|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
219049048|NCT02026115|BEHAVIORAL|PAINUCope|We tested the PAINUCope piece of the intervention in 3 completed studies. PAINUCope is a multimedia, computer generated tool that gives tailored information to overcome patients' misconceptions about pain and help them engage in activities that help reduce their pain. PAINUCope focuses on 2 crucial aspects of pain management: 1) reporting cancer pain and 2) safe and effective use of pain medicines. The educational materials are written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt guide the specific information shared via PAINUCope.
219049049|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
219049050|NCT04084769|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
219049051|NCT04084769|BIOLOGICAL|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219049052|NCT04084769|BIOLOGICAL|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219049053|NCT03390504|DRUG|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
219049054|NCT03390504|DRUG|Vinflunine|Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
219049055|NCT03390504|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
219049056|NCT03390504|DRUG|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
219049057|NCT03390504|DEVICE|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
219632706|NCT04959981|DRUG|ERAS-601|Administered orally
218938401|NCT01670305|PROCEDURE|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
218938402|NCT01670305|PROCEDURE|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
218938403|NCT01670305|PROCEDURE|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
218938404|NCT01670305|PROCEDURE|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
218938405|NCT01670305|PROCEDURE|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
218938406|NCT01717053|DRUG|Abiraterone acetate|1000 mg orally once a day for 6 months.
218938407|NCT01717053|DRUG|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
218938408|NCT01717053|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
218938409|NCT01717053|DRUG|Prednisone|5 mg tablet once daily for 6 months.
218938410|NCT01464281|DRUG|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
218938411|NCT03856281|DEVICE|Intermittent Pneumatic Compression|Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
218938412|NCT05212545|DIETARY_SUPPLEMENT|Placebo|maltodextrin taken daily for 4 weeks with water
218938413|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
218938414|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
218938415|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
218938416|NCT04030156|PROCEDURE|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
219049058|NCT03301220|DRUG|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
219049059|NCT03492177|DRUG|selexipag (Uptravi)|Film-coated tablets for oral administration
219049060|NCT05660265|DRUG|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
219049061|NCT05660265|OTHER|Placebo|Matching placebo will be administered.
219049062|NCT03546686|DRUG|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
219049063|NCT03546686|PROCEDURE|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
219049064|NCT03546686|PROCEDURE|Breast Surgery|Standard-of-care definitive surgery.
219049065|NCT03546686|DRUG|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
219049066|NCT03546686|DRUG|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
219049067|NCT03652064|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
218938417|NCT04681352|DEVICE|Octave-Ultherapy treatment|Micro-focused ultrasound delivered below the surface of the skin.
218938418|NCT05722444|OTHER|Nighttime Feminine Product|"During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak"
218938419|NCT04952155|DRUG|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
218938420|NCT01039129|PROCEDURE|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
219049068|NCT03652064|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
219049069|NCT03652064|DRUG|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
219049070|NCT03652064|DRUG|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
219049071|NCT04816734|OTHER|Self-report questionnaires|"Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home."
219049072|NCT06505954|OTHER|Survey study|Survey study among medical students about lower urinary tract symptoms
219365953|NCT04173741|OTHER|USG measurement|IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
218938421|NCT01039129|PROCEDURE|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
218938422|NCT01039129|PROCEDURE|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
218938423|NCT03220451|PROCEDURE|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
218938424|NCT01643772|DRUG|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
218938425|NCT02398006|OTHER|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
218938426|NCT02398006|OTHER|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
218938427|NCT00732446|DRUG|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
218938428|NCT00732446|DRUG|Moxifloxacin|moxifloxacin 0,5% qid and
218938429|NCT00732446|DRUG|Dexamethasone|dexamethasone 0,1% qid
218938430|NCT02453815|PROCEDURE|non-cardiac surgery|all surgical procedures except cardiac
218938431|NCT02453815|OTHER|arterial catheter|arterial catheter
218938432|NCT05180396|OTHER|Questionnaires|Application of a study based questionnaire described in the protocol
218938433|NCT01793870|DRUG|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
218938434|NCT01793870|DRUG|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
219049073|NCT06974877|DRUG|124I AT-01|124I-AT-01 is an amyloid-reactive synthetic 45-L amino acid polypeptide radiolabeled with iodine-124, with a theoretical molecular weight of 4763.6 Da (based on amino acid sequence). The polypeptide, AT-01, is not pharmacologically active. 124I-AT-01 binds many forms of human and murine amyloid and is intended to be a PET imaging agent for the detection of amyloid deposits.
219049074|NCT06282926|DIAGNOSTIC_TEST|Echocardiography assessment|"Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound."
219049075|NCT04197713|DRUG|Adavosertib|Given PO
218938435|NCT01793870|DRUG|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
219049076|NCT04197713|DRUG|Olaparib|Given PO
219049081|NCT06821945|DRUG|BR5402A|Subjects take the investigational products once a day
219049082|NCT06821945|DRUG|BR5402A-1|Subjects take the investigational products once a day
219049083|NCT06821945|DRUG|BR5402B|Subjects take the investigational products once a day
219049084|NCT06821945|DRUG|BR5402B-1|Subjects take the investigational products once a day
219049085|NCT06821945|DRUG|BR5402C|Subjects take the investigational products once a day
219049086|NCT06821945|DRUG|BR5402C-1|Subjects take the investigational products once a day
219049087|NCT06821945|DRUG|BR5402D|Subjects take the investigational products once a day
218938436|NCT05344196|BEHAVIORAL|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
219049088|NCT06821945|DRUG|BR5402D-1|Subjects take the investigational products once a day
219049089|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
219049090|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
219049091|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
219049092|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
219049093|NCT06282315|DRUG|Pre-screening Phase|"The entire school population will be invited to participate in the study. The purpose of this phase is to confirm participant eligibility for enrolment in the study based on the inclusion and exclusion criteria. Given the context in which the clinical trial is being conducted, in many instances, group meetings with the parents/guardians of potential participants in the community or at school might be necessary as part of the informed consent process. This consent process may be performed up to three months before the start of the screening visit activities.~Participants and parents/guardians of subjects will be asked to confirm in writing their agreement to participate in the trial before any study-specific procedure is conducted. In addition, written assent will be sought for participants over 12 years of age."
219049094|NCT06282315|DRUG|Screenig Phase|"The purpose of the screening visit is to confirm subject eligibility for enrolment in the study based on the inclusion/exclusion criteria. Screening visits in a particular school can be performed between 14 and 7 days before the intervention (Day 0).~To continue with the screening activities, participants must have signed written consent from their parent or legal guardian, and in the case of participants aged 12 years or older, they must also have a signed assent form before any specific study procedure is performed.If the consent/assent process has not been finalized during the pre-screening phase, this can be completed during the screening visit, but always before any trial procedure.~All participants who consent to participate in the trial will be given a Participant Screening Number, which will be assigned sequentially as the informed and assent forms are signed."
218938437|NCT01009372|BEHAVIORAL|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
218938438|NCT03982134|DRUG|PDR001|PDR001 is a humanized IgG4 antibody
218938439|NCT03982134|DRUG|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
218938440|NCT06471283|OTHER|physical activity|Exercising physical activity during dialysis
218938441|NCT01429025|BIOLOGICAL|rituximab|IV
218938442|NCT01429025|DRUG|bendamustine|IV
218938443|NCT01429025|DRUG|lenalidomide|PO
218938444|NCT03599232|OTHER|Formative objective structured clinical examination (OSCE)|
218938445|NCT03457441|OTHER|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
218938446|NCT03457441|DEVICE|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
219365954|NCT01989130|DEVICE|Roche AMPLICOR CT/NG|
219365955|NCT01989130|DEVICE|Cepheid Xpert CT/NG Test|
219049095|NCT06282315|DRUG|Randomization|Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.
219049096|NCT06282315|DRUG|Baseline Effectiveness Cohort|"Before the administration of the study drug at school, participants selected for the Effectiveness Cohort will perform an additional study visit during which they will provide the study team with a stool sample for STH analysis. A dried blood spot (DBS) sample will also be taken to test for S. stercoralis.~Sampling of the baseline effectiveness cohort will be conducted within 7 days before the start of the school study intervention. In addition to the delivery of the stool/blood sample, participants from the effectiveness cohort will be evaluated for scabies by designated study personnel following the IACs simplified criteria."
219365956|NCT01124565|DRUG|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
219632707|NCT04959981|DRUG|Osimertinib|Administered orally
219632708|NCT04959981|DRUG|Sotorasib|Administered orally
219632709|NCT04397016|BEHAVIORAL|Option Grid Decision Aid|-A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions
218938447|NCT05186415|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
218938448|NCT00062231|DRUG|amoxicillin-clavulanate potassium|
218938449|NCT00062231|DRUG|ciprofloxacin|
218938450|NCT00062231|DRUG|moxifloxacin hydrochloride|
218938451|NCT00062231|PROCEDURE|management of therapy complications|
218938452|NCT02810444|BIOLOGICAL|IgG Next Generation (BT595)|
218938453|NCT02249637|PROCEDURE|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
218938454|NCT05401058|DRUG|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
218938455|NCT05401058|DRUG|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
218938456|NCT02785770|DRUG|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
218938457|NCT02785770|DRUG|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
218938458|NCT02785770|DRUG|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
219632710|NCT02786875|OTHER|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI\<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
219632711|NCT02786875|OTHER|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
219632712|NCT02786875|BEHAVIORAL|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
219632713|NCT02786875|BEHAVIORAL|Basic physical activity|General recommendations for physical activity
219632714|NCT02786875|DRUG|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
219632715|NCT02786875|DRUG|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
219632716|NCT06063070|DRUG|Fluzoparib Capsules|oral
219632717|NCT06063070|DRUG|Bevacizumab|Injectable solution
219632718|NCT03805568|DRUG|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
219632719|NCT03805568|DRUG|remifentanil infusion group|remifentanil as anaesthetic adjuvant
219632720|NCT01146093|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
218938459|NCT03488511|OTHER|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
218938460|NCT02452827|OTHER|Biomechanical parameters|
218938461|NCT02452827|OTHER|MRI|MRI of cervical spine
218938462|NCT05880290|PROCEDURE|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
218938463|NCT05481957|DRUG|Vortioxetine|5-10mg for 16 weeks
218938464|NCT05481957|DRUG|valprote|500\~1000mg for 16 weeks
218938465|NCT01624311|OTHER|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
218938466|NCT01624311|OTHER|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
218938467|NCT05331859|DRUG|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
219632721|NCT00918411|DRUG|Ramosetron|oral
219632722|NCT00918411|DRUG|Placebo|oral
218938468|NCT05331859|DRUG|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
218938469|NCT05331859|DRUG|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
218938470|NCT05423353|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
218938471|NCT05423353|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
218938472|NCT03704753|DRUG|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
219632723|NCT03159871|DEVICE|Stratafix suture|Stratafix barbed sutures during C-Sections.
218938473|NCT03704753|DRUG|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
218938474|NCT01976039|OTHER|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
218938475|NCT02903459|OTHER|Transversal Study so there is no intervention|
218938476|NCT04518995|DRUG|CTP-543 matching placebo|Administered as tablets.
218938477|NCT04518995|DRUG|CTP-543|Administered as tablets.
218938478|NCT04518995|DRUG|CTP-543|Administered as tablets.
218938479|NCT00345644|DRUG|risedronate|risedronate sodium 35 mg tablets (once a week dose)
218938480|NCT00345644|DRUG|risedronate placebo|placebo for risedronate tablets (once a week dose)
218938481|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
218938482|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
218938483|NCT00639743|DRUG|placebo ( group B)|placebo ( group B)
218938484|NCT00639743|DRUG|tenecteplase (group A)|tenecteplase (group A)
218938485|NCT02835053|OTHER|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
218938486|NCT05950152|DRUG|Meloxicam Injection 30mg|meloxicam injection 30mg every 24 hours for up to 2 dose
218938487|NCT05950152|DRUG|Meloxicam Injection 60mg|meloxicam injection 60mg every 24 hours for up to 2 dose
218938488|NCT05950152|DRUG|Nacl 0.9%|IV Placebo every 24 hours for up to 2 doses
218938489|NCT00904410|OTHER|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
218938490|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
218938491|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
218938492|NCT04642001|RADIATION|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
218938493|NCT04642001|COMBINATION_PRODUCT|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
218938494|NCT04397666|DIAGNOSTIC_TEST|conjunctival RT PCR|conjunctival sample in covid-19 patients
218938495|NCT05987176|DRUG|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
218938496|NCT06052449|BEHAVIORAL|Social determinants of health screening assessment and referral process|Unite Us is an electronic SDoH screening and referral tool assessing: (1) financial resource strain; (2) housing stability; (3) transportation needs; and (4) food insecurity. Upon completion, the Unite Us platform identifies a list of geographically-tailored resources to connect the individual in need. A staff member will administer the SDoH screening and referral tool, review the results with the participant, and use the geographically-tailored resources to make SDoH-related referrals.
219632724|NCT03159871|DEVICE|Vicryl suture|Standart Vicryl suture during C- Sections.
219632725|NCT03073031|DEVICE|Tablet: Samsung Galaxy Tab A|
219632726|NCT05280626|DRUG|Sintilimab|After one cycle of standard R-CHOP chemotherapy, Group A uses Sintilimab with R-CHOP, with Sintilimab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
219632727|NCT05280626|DRUG|Rituximab|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP for 5 cycles. After 5 cycles, CR patients in group B are followed up for observation.
219632728|NCT02657122|DRUG|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
219049097|NCT06282315|DRUG|Day 0 Trial Intervention|"Within seven days after the first sample for the baseline effectiveness cohort is collected, the school's mass administration of the allocated drug will take place. All participants included in the list of eligible subjects from a particular randomized school will receive a single dose of the medication administered to their school (FDC or ALB). Before the administration, participants will be asked about any medical condition that has arisen since the last study visit, in which case information will be documented as a concomitant disease.~In case a participant vomits within one hour after the study drug intake (during the study physician observation period), the participant will continue participating in the trial and may still participate in the effectiveness cohort. If they are chosen for the day 21 or month 11 effectiveness cohort, an additional sensitivity analysis will be performed without including these participants, considered as Intervention Fail."
219049098|NCT06282315|DRUG|Active Surveillance (study visit Day 1, Day 2 and Day 7)|Active safety surveillance will be performed at school during the trial intervention on day 0 until day 7 post-intervention. The assessment will include recording of all AEs and SAEs presented by study participants from the intake of the study drugs, and for two additional days (Day 1 and Day 2 study visits). During active surveillance, participants will be visited by a study physician at school during the study intervention, on day one and day two, and they will be questioned about any potential AE or change in a pre-existing condition. In addition, a final safety visit will be conducted to all participants at Day 7 to collect data on any potential AE occurred between day 2 and the end of the surveillance period and to perform a follow up of any AE ongoing after Day 2 visit.
219049099|NCT06282315|DRUG|Passive Surveillance|Passive surveillance will be carried out by monitoring AEs in health facilities near the schools involved in the study for six days after the intervention until Day 7 (end of the safety surveillance period). Although AE will be actively monitored during the scheduled study visits, this passive surveillance will allow for the identification of AEs and potential SAEs that might occur and remained underreported in case the participant does not attend school during the active safety surveillance period. In addition, a diary cards will be given to participants to write any AE they may have from Day 2 to Day 6 post intervention.
218938497|NCT06052449|BEHAVIORAL|Current practice - Community-based lunch cancer screening (LungTalk)|The current practice during community events is to offer LungTalk. LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled LCS knowledge and health beliefs (p \< 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% Confidence Interval (CI), 1.03, 3.85, p = 0.03.
218938498|NCT01310205|DRUG|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
218938499|NCT00222664|BIOLOGICAL|Hep-V Vax|
219049100|NCT06282315|DRUG|Post-Treatment Effectiveness Evaluation|"Post-treatment effectiveness evaluation will be performed by measuring the prevalence of STH at two time points: 21 days after the intervention (± 7 days) and 11 months after intervention (± 28 days). Additionally, the reduction in S. stercoralis seroprevalence will be evaluated 11 months after the intervention.~These participants will be tested for STH by Kato-Katz at the two post-treatment time points (day 21 and month 11) and for S. stercoralis by NIE ELISA at 11 months. The diagnostic test will be the same as in the intervention of Baseline Effectiveness Cohort.~As part of the genetic monitoring pilot study and the microbiome analysis, the same samples will be collected as described in the intervection of Baseline Effectiveness Cohort."
219049101|NCT03026998|PROCEDURE|MRI|MRI will be performed each year during 10 years.
218938500|NCT03336437|DRUG|Estradiol vaginal ring|Estradiol 2mg vaginal ring
218938501|NCT03336437|OTHER|Placebo vaginal ring|Silicone vaginal ring without any active estradiol
218938502|NCT05173116|OTHER|Medical Outcomes Study Short Form 36 (SF 36)|completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
218938503|NCT05173116|OTHER|observationnal study|data collection
218938504|NCT04702919|OTHER|Registration|Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.
218938505|NCT04702919|OTHER|Auditive oddball task|Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
218938506|NCT05091775|DRUG|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
219049102|NCT06808204|OTHER|Questionnaire|Quality of life questionnaire : Peds QL 4.0 (Pediatric Quality of Life )
219049103|NCT06808204|OTHER|questionnaire|Physical activity level : Ricci and Gagnon questionnaire
219049104|NCT06808204|OTHER|questionnaire|Anxiety questionnaire : State and Trait Inventory
219049105|NCT06808204|OTHER|questionnaire|Depression questionnaire : Child Depression Inventory
219049106|NCT06808204|OTHER|questionnaire|Child Depression Inventory
218938507|NCT00085176|PROCEDURE|management of therapy complications|
218938508|NCT00085176|PROCEDURE|psychosocial assessment and care|
219365957|NCT04568850|DIAGNOSTIC_TEST|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
218938509|NCT01320137|PROCEDURE|Blood withdrawal|Blood sampling
218938510|NCT02934100|DEVICE|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
218938511|NCT02934100|DEVICE|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
219049107|NCT06808204|OTHER|questionnaire|Quality of life of parents before and after transcatheter ablation
219049108|NCT02259413|BEHAVIORAL|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
219049109|NCT04850378|DRUG|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
219049110|NCT04850378|DRUG|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
219049111|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
219049112|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
219049113|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
219049114|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
219049115|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
219049116|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
219049117|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
219206605|NCT06995989|OTHER|energy conservation techniques with pursed lip breathing|"Group A will receive energy conservation techniques with pursed lip breathing with~1 session a day for total 5 days in a week. 1 session will consist of 3 cycles of pursed lip breathing for duration of 10 minutes with a break of 20 minutes in between. ECTs will be trained for 2 weeks. A detailed manual will be developed to ensure the consistency of the training for all subjects. Examples of interventions are training to use ergonomic principles along with pursed lip breathing. The subjects were trained to place their equipment at chest height; they were trained to work at paced speed and in some cases instructed to use technical aids."
219632729|NCT02657122|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
219632730|NCT02657122|DRUG|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
219632731|NCT02657122|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
219049118|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219049119|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
219049120|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
219632732|NCT00886444|DRUG|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
219632733|NCT00781729|BEHAVIORAL|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
219632734|NCT00781729|BEHAVIORAL|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
219632735|NCT04134767|BEHAVIORAL|Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
219049121|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
219049122|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
219049123|NCT01157481|DRUG|Conventional therapy|Conventional therapy
219049124|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
219632736|NCT04134767|BEHAVIORAL|Overdose Education|Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
219049125|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
219049126|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
219049127|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
219049128|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
219049129|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
219049130|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
219049131|NCT01929668|DRUG|polyethylene glycol|
219049132|NCT01929668|DRUG|Ascorbic Acid|
219632737|NCT03486080|DRUG|Dutogliptin Tartrate|Active treatment
218938512|NCT02934100|DEVICE|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
218938513|NCT02934100|DEVICE|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
218938514|NCT02859870|DEVICE|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
218938515|NCT01076439|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
218938516|NCT01076439|DRUG|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
218938517|NCT01076439|DRUG|Saline Nasal Spray|Placebo
218938518|NCT02049541|DRUG|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
218938519|NCT02049541|BIOLOGICAL|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
218938520|NCT02049541|OTHER|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
218938521|NCT02049541|OTHER|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
218938522|NCT00545272|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
218938523|NCT00545272|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
218938524|NCT00545272|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
218938525|NCT00545272|DRUG|placebo to formoterol|Placebo AEROLIZER® device
218938526|NCT00545272|DRUG|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
219049133|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
219049134|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
219049135|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
219049136|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
219049137|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
219049138|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
219049139|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
219049140|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
219049141|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
219049142|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
219049143|NCT00949780|DRUG|Chloral Hydrate|
219049144|NCT04031885|DRUG|Abemaciclib|Administered orally
219049145|NCT04031885|DRUG|Fulvestrant|Administered IM
219206606|NCT06995989|OTHER|pursed lip breathing|pursed lip breathing
219632738|NCT03486080|DRUG|Filgrastim Injectable Product|Active treatment
219632739|NCT03486080|DRUG|Placebos|placebo control
218938527|NCT04491604|BIOLOGICAL|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
219049146|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
219049147|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
219049148|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
219049149|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
219049150|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
219206607|NCT06997575|DRUG|Magnesium Sulphate infusion|Infusion of 20% MgSO4 solution
218938528|NCT04491604|OTHER|Placebo|Matching masked inactive topical gel
218938529|NCT04455152|BEHAVIORAL|self-control|avoiding eating sweets as a way of building self-control strength
219206608|NCT06997575|DRUG|Magnesium sulphate intramuscular|Intramuscular injections will be instituted in gluteal region.
219206609|NCT06860685|DIETARY_SUPPLEMENT|gum chewing|Participants allocated to chewing gum will be instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily from the first postoperative morning until oral dietary intake. They were instructed to chew the piece of gum for at least 10 minutes.
219206610|NCT06617364|PROCEDURE|gastrointestinal transit time measurement using MSOT and ICG contrast agent|The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
218938530|NCT01882608|OTHER|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
218938531|NCT01585506|OTHER|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
218938532|NCT01585506|OTHER|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
218938533|NCT00199303|DRUG|pre-operatively followed by 30 mg three times per day after surgery|
218938534|NCT00262938|BEHAVIORAL|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
218938535|NCT00262938|OTHER|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
218938536|NCT00262938|OTHER|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
219049151|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
219049152|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
219049153|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
219049154|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
219049155|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
219049156|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
219049157|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
218938537|NCT00262938|OTHER|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
218938538|NCT00262938|PROCEDURE|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
218938539|NCT06458816|DEVICE|Non-Invasive Knee Joint Distraction|Non-invasive Distraction device
218938540|NCT06458816|PROCEDURE|Manual Joint Distraction|no device. manual distraction.
218938541|NCT04995367|DEVICE|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
218938542|NCT00373893|DRUG|Lidoderm Patch|
218938543|NCT01146743|PROCEDURE|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
218938544|NCT01146743|PROCEDURE|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
218938545|NCT02756416|DEVICE|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
218938546|NCT02756416|DEVICE|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
218938547|NCT02756416|DEVICE|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
218938548|NCT04880291|DRUG|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
218938549|NCT04880291|DRUG|Placebo|Matched placebo
219049158|NCT06794047|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablets, please instruct the patient to swallow with water, 500mg twice daily, morning and evening.
219049159|NCT06794047|OTHER|Placebo|Tablets with the same material, flavor, and appearance as the intervention group.
219049160|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
219049161|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
218938550|NCT06201806|OTHER|Test food breakfast with NCS or witout NCS|"Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups."
219049162|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
219049163|NCT00178438|DEVICE|Capsule Endoscopy|
218938551|NCT02299583|OTHER|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
218938552|NCT01112449|OTHER|Placebo|no active medication
218938553|NCT01112449|DIETARY_SUPPLEMENT|selenomethionine|200 µg/day of selenomethionine (SM)
218938554|NCT01112449|DIETARY_SUPPLEMENT|low dose selenized-yeast|200 µg/day of SY
219049164|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
219049165|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
219049166|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
219049167|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
219049168|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
219049169|NCT02665481|BEHAVIORAL|MBSR|
219206611|NCT06997406|DIETARY_SUPPLEMENT|Inner ear support|"FB-1603 (150 mg): A cold water extract of Arthrospira maxima (a species of blue-green algae), rich in the antioxidant pigment C-phycocyanin (C-PC).~GABA (126 mg): A natural calming neurotransmitter that can help reduce nerve-related overactivity.~γ-Oryzanol (12 mg): A component from rice bran oil, known for its antioxidant properties.~Sesamin (12 mg): A compound from sesame seeds, with potential neuroprotective and anti-inflammatory benefits."
219049170|NCT02665481|BEHAVIORAL|Exercise|
219049171|NCT02665481|BEHAVIORAL|Health Education|
219365958|NCT04381208|DIAGNOSTIC_TEST|Complete clinical examination|Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)
219365959|NCT02530645|BEHAVIORAL|OnTrack|
218938555|NCT01112449|DIETARY_SUPPLEMENT|high dose selenized-yeast|285 µg/day of SY
219049172|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
219049173|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
219049174|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
219049175|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
219049176|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
219049177|NCT05397379|DRUG|HEC96719|Oral tablets
219049178|NCT05397379|DRUG|Placebo|Comparator
219049179|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
219049180|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
219049181|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
219049182|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
219049183|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
219049184|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
219049185|NCT05717998|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219049186|NCT05717998|PROCEDURE|Computed Tomography|Undergo cardiac PET/CT
219049187|NCT05717998|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
219049188|NCT05717998|PROCEDURE|Positron Emission Tomography|Undergo cardiac PET/CT
219632740|NCT04028804|PROCEDURE|FDG PET|Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.
218938556|NCT00484757|DRUG|Orexine A|
218938557|NCT01454141|OTHER|Cognitive Control Training|Three sessions of CCT.
218938558|NCT01454141|OTHER|Peripheral Vision Task|Three sessions of PVT.
218938559|NCT00842491|DRUG|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
219049189|NCT06366490|BIOLOGICAL|Innocell Autologous Cellular Immunotherapy|Innocell Autologous Cellular Immunotherapy
219365960|NCT02530645|BEHAVIORAL|Treatment as Usual|
218938560|NCT00842491|DRUG|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
218938561|NCT00842491|DRUG|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
218938562|NCT02302612|BEHAVIORAL|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
219049190|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
219049191|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
219049192|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
219049193|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
219049194|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
219049195|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
218938563|NCT02302612|OTHER|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
219049196|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
219049197|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
219049198|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
219049199|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
219049200|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
219365961|NCT02530645|BEHAVIORAL|Brief Motivational Interviewing|
219365962|NCT00563147|DRUG|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
218938564|NCT03378713|DRUG|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
218938565|NCT03378713|DRUG|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
218938566|NCT03378713|DRUG|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
218938567|NCT01335737|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4 times/week
218938568|NCT01335737|BEHAVIORAL|Wait list|wait list control condition
218938569|NCT03189238|BIOLOGICAL|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
218938570|NCT00373113|DRUG|Capecitabine|1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
218938571|NCT00373113|DRUG|Sunitinib malate|37.5 mg daily, continuous dosing
218938572|NCT00472680|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
219049201|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
219049202|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
219632741|NCT04028804|PROCEDURE|FLT PET|The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
219632742|NCT05883657|DEVICE|Condition 1 : Prototypes (816-v1) every weeks|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
218938573|NCT00472680|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
218938574|NCT00472680|BEHAVIORAL|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
218938575|NCT04316403|PROCEDURE|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
218938576|NCT04129437|DRUG|Ibuprofen|Weight based ibuprofen dosing
219049203|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
219049204|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
219049205|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
219049206|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
218938577|NCT04129437|PROCEDURE|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
218938578|NCT04313413|OTHER|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
218938579|NCT00522938|DRUG|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
218938580|NCT00522938|DRUG|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
218938581|NCT00888186|DRUG|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
218938582|NCT00003560|DRUG|carboplatin|
218938583|NCT00003560|DRUG|docetaxel|
218938584|NCT02173509|OTHER|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
218938585|NCT05905978|PROCEDURE|Corneal donors predisposed by CXL|Corneal donors predisposed by CXL and DALK procedure was conducted in patients
218938586|NCT05905978|PROCEDURE|Corneal donors stored in corneal storage media|Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
218938587|NCT02155478|DEVICE|ISERT 250 (HOYA, Japan): a standard IOL|
218938588|NCT02155478|DEVICE|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
219049207|NCT00309933|PROCEDURE|cognitive assessment|
219049208|NCT00309933|PROCEDURE|psychosocial assessment and care|
219049209|NCT00309933|PROCEDURE|quality-of-life assessment|
219049210|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
218938589|NCT00975689|DRUG|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
218938590|NCT06098742|DRUG|Antareit|A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
218938591|NCT04011358|OTHER|Sleeping Monitor|to evaluate obstructive sleep apnea
218938592|NCT06027645|BEHAVIORAL|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
218938593|NCT02949479|BEHAVIORAL|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
218938594|NCT00675467|BEHAVIORAL|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
218938595|NCT00675467|BEHAVIORAL|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
218938596|NCT01227135|DRUG|hydroxychloroquine|
218938597|NCT01227135|DRUG|imatinib mesylate|
218938598|NCT01227135|GENETIC|cytogenetic analysis|
219049211|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
219049212|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
219049213|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
219049214|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
219049215|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
219049216|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
219049217|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
218938599|NCT01227135|GENETIC|polymerase chain reaction|
218938600|NCT01227135|OTHER|laboratory biomarker analysis|
218938601|NCT01227135|OTHER|pharmacological study|
218938602|NCT06111118|DEVICE|ThermaCare HeatWraps|ThermaCare HeatWraps application
218938603|NCT01701232|BIOLOGICAL|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
218938604|NCT06471192|PROCEDURE|PPCI|PPCI for patients of STEMI to assess thrombus burden
218938605|NCT05136950|PROCEDURE|Secondary in-the-bag IOL fixation|The experimental group with secondary IOL fixated in the capsular bag
218938606|NCT05136950|PROCEDURE|Secondary ciliary sulcus IOL fixation|The control group with secondary IOL fixated in the ciliary sulcus
218938607|NCT02809040|OTHER|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
218938608|NCT02809040|OTHER|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
218938609|NCT02873351|DRUG|carbidopa-levodopa 25-100 mg|included in arm description
219049218|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
219049219|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
218938610|NCT02873351|DRUG|placebo for carbidopa-levodopa 25-100 mg|included in arm description
219049220|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
219049221|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
219049222|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
219049223|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
219049224|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
218938611|NCT05035602|OTHER|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
218938612|NCT03890042|DRUG|Dienogest group|VISANNE 2MG Tablet once daily
218938613|NCT03890042|DRUG|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
218938614|NCT03890042|RADIATION|Ultrasound|ultrasound assessment of uterine volume
218938615|NCT03890042|OTHER|visual analogue scale|visual analogue scale for assessment of pain
218938616|NCT03763097|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
218938617|NCT03005015|DRUG|Lenvatinib|
218938618|NCT03005015|DRUG|Doxorubicin|
219049225|NCT03245567|OTHER|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
219049226|NCT03245567|OTHER|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
219049227|NCT05439226|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
219049228|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
219049229|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
219049230|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
219049231|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
219049232|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
219049233|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
219049234|NCT05669092|RADIATION|SCRT|25Gy/5fx
219049235|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
219049236|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
219206612|NCT06677112|PROCEDURE|Selective surgical staging|Intraoperative Consultation, performed by pathologist and surgeon jointly. The uterus is inspected for extra-corpus spread (cervix, parametria, adnexa, distant). The surgical pathologist will evaluate the uterus according to the IOC Worksheet and promptly notify the surgeon of the results. The IOC will include evaluation for extra-corpus disease, lesion measurement, frozen section (to confirm measured lesion is malignant, cell type, and re-grading of tumor). Non-sentinel nodes will be handled according to institutional standard-of-care practice.
218938619|NCT01402102|DIETARY_SUPPLEMENT|Aged garlic powder|Aged garlic powder(6.0g/day)
219049237|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
219049238|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
219049239|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
219049240|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
218938620|NCT01402102|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder(6.0g/day)
218938621|NCT05873907|DRUG|AMG 592|Administered as SC injection
218938622|NCT05873907|OTHER|Placebo|Administered as SC injection
219049241|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
218938623|NCT00522769|BEHAVIORAL|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
218938624|NCT05043142|DIAGNOSTIC_TEST|ELISA test for the antibodies to COVID-2019.|Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.
218938625|NCT04653597|PROCEDURE|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order
218938626|NCT04653597|PROCEDURE|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
219049242|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
219049243|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
219049244|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
219049245|NCT02182544|DRUG|WAL801CL dry syrup|
219049246|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
219049247|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
219049248|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
219049249|NCT05682547|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
219049250|NCT05682547|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
219049251|NCT00824863|DRUG|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
219049252|NCT06843668|DRUG|EMA colistin dosing strategy|The EMA colistin group will receive I.V colistin based on creatinine clearance (mL/min) level , with fixed loading dose 9 MIU equivalent to 300 mg of colistin-based activity (CBA). The maintenance dose will be administered after 12 h following the loading dose over 1 h every 12h (twice daily).
218938627|NCT02324634|DEVICE|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
218938628|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
218938629|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
218938630|NCT03885167|OTHER|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
219049253|NCT06843668|DRUG|US FDA colistin dosing strategy|The weight-based colistin group will receive I.V. colistin based on the lower (ideal body weight or actual body weight) with a loading dose of (4) X (patient weight in kg). Loading dose might exceed 300 mg.
219049254|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
219049255|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
219049256|NCT00486122|DRUG|Atomoxetine Hydrochloride|
219049257|NCT00486122|DRUG|Placebo|
219049258|NCT06289257|DIAGNOSTIC_TEST|Vitamin D level|Vitamin D level in blood
219049259|NCT06289257|OTHER|Vitamin D receptor|Vitamin D receptor in endometriosis tissue
219049260|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
219206613|NCT06677112|PROCEDURE|REFLEX|The surgeon will perform a side-specific lymphadenectomy when there is no mapping on a hemipelvis (no tracer uptake in nodes). If neither side has successful Sentinel Node mapping, the surgeon performs a complete pelvic lymphadenectomy. Surgeons will remove the para-aortic lymph nodes at their discretion.
218938631|NCT02340351|DEVICE|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
218938632|NCT02340351|PROCEDURE|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
219206614|NCT06997484|DRUG|HL-400|Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.
218938633|NCT01305577|DRUG|Deoxycholic acid injection|
218938634|NCT01305577|DRUG|Placebo|Phosphate buffered saline placebo for injection
218938635|NCT03928977|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
218938636|NCT02750241|BEHAVIORAL|Active video game-based intervention|"* Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~* Participate in self-paced home sessions~* Monitor daily, weekly, and monthly steps using Wii Fit Meter~* Feedback on physical activity and physical function"
218938637|NCT02750241|BEHAVIORAL|Pedometer|"* Attend 3 monthly UTMB Breast Cancer Support Group Sessions~* Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~* Feedback on physical activity and physical function"
218938638|NCT02967341|OTHER|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
218938639|NCT00257270|DRUG|gabapentin|
218938640|NCT02922686|DRUG|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
219049261|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
219049262|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
219049263|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II\_G20210A Mutation;
219049264|NCT05764213|BEHAVIORAL|Listening to Women & Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
218938641|NCT02922686|DRUG|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
218938642|NCT02922686|DRUG|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
219049265|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
218938643|NCT00914108|BEHAVIORAL|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
218938644|NCT02809222|OTHER|Samples|Blood samples
219049266|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
218938645|NCT02809222|OTHER|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
218938646|NCT00000303|DRUG|Baclofen|
219049267|NCT00315276|DRUG|Modafinil|
219049268|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
219049269|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
219049270|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
218938647|NCT00905645|DEVICE|Silimed Gel-Filled Mammary Implant|
219049271|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
219049272|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
219049273|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
219049274|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
219049275|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
219049276|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
219049277|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
219049278|NCT02246504|DEVICE|HIFU treatment|
219049279|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
219206615|NCT06997484|DRUG|Placebo|Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo.
218938648|NCT02408757|PROCEDURE|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
218938649|NCT02364336|DRUG|Peginterferon alfa-2a|
219049280|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
219049281|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
219049282|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
219049283|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
219049284|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
219049285|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
219049286|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
219049287|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
219049288|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
219049289|NCT05044234|DRUG|Cedirogant|Capsule, Oral
219049290|NCT05044234|DRUG|Placebo|Capsule, Oral
219049291|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
218938650|NCT03020940|DRUG|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
218938651|NCT01731938|BIOLOGICAL|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
218938652|NCT01731938|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
218938653|NCT02766556|DRUG|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
218938654|NCT02766556|PROCEDURE|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
218938655|NCT02766556|DRUG|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
218938656|NCT04931888|BEHAVIORAL|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
218938657|NCT03701035|BEHAVIORAL|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
218938658|NCT03701035|BEHAVIORAL|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
218938659|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
218938660|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
218938661|NCT00960726|DRUG|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
218938662|NCT05946356|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
218938663|NCT00229424|DRUG|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
218938664|NCT00229424|DRUG|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
218938665|NCT00229424|OTHER|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
218938666|NCT05657574|DRUG|D377|oral, once daily, 8 weeks
218938667|NCT05657574|DRUG|CKD-331|oral, once daily, 8 weeks
219049292|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
219049293|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
218938668|NCT05657574|DRUG|D086|oral, once daily, 8 weeks
218938669|NCT05657574|DRUG|Placebo (for D377)|oral, once daily, 8 weeks
218938670|NCT05657574|DRUG|Placebo (for CKD-331)|oral, once daily, 8 weeks
218938671|NCT05657574|DRUG|Placebo (for D086)|oral, once daily, 8 weeks
218938672|NCT04384081|DRUG|BI 456906|Solution for injection
218938673|NCT04384081|DRUG|Placebo|Solution for injection
218938674|NCT05573269|DIETARY_SUPPLEMENT|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
218938675|NCT05573269|OTHER|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
218938676|NCT00778661|DRUG|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
218938677|NCT02136069|DRUG|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
218938678|NCT02136069|DRUG|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
218938679|NCT02136069|OTHER|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
218938680|NCT02136069|OTHER|Placebo (Injection)|Administered by SC injection Q4W until Week 52
219049294|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
219049295|NCT02251665|OTHER|No intervention|a single-center prospective observational study
219049296|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
219049297|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
218938681|NCT05395273|DEVICE|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
218938682|NCT04538144|OTHER|Hot and Humid Trial|Individuals will be exposed to a simulated heat wave (hot and humid) condition.
218938683|NCT04538144|OTHER|Hot and Dry Trial|Individuals will be exposed to a simulated heat wave (hot and dry) condition.
218938684|NCT05627323|BIOLOGICAL|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
219049298|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
219206616|NCT06865092|BIOLOGICAL|injectable platelet-rich fibrin|Blood samples were collected in two 10 ml plastic tubes without anticoagulant. The tubes were centrifuged for 3 min at 2500 rpm in a centrifuge device and i-prf was obtained.
219206617|NCT06865092|BIOLOGICAL|titanium-prepared platelet-rich fibrin|The blood was drawn into a 20 ml syringe and immediately divided into two sterile grade IV titanium tubes containing 10 ml of blood. The tubes were placed opposite each other and centrifuged at 2700 rpm for 12 minutes at room temperature and t-prf was obtained.
218938685|NCT01871740|DRUG|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
218938686|NCT01871740|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
219206618|NCT06865092|DRUG|Hyaluronic Acid (HA)|0.8% hyaluronic acid (HA) gel (Gengigel) was applied to the wound sites.
219632743|NCT05883657|DEVICE|Condition 2 : Prototypes (816-v1) every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
219632744|NCT06489470|PROCEDURE|Strokectomy/Necrosectomy|After obtaining CT-/MRT-perfusion, the infarcted area (e.g. infarct core) of malignant MCA-infarction is localized. By using the neuronavigation, surgical resection of necrotic tissue is performed in a non-eloquent area until the space occupying effect is released. At the end of the surgery, the bone flap is reinserted and fixated.
219632745|NCT00300885|DRUG|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
219632746|NCT00300885|DRUG|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
218938687|NCT05612932|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
218938688|NCT05612932|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
218938689|NCT05140876|BEHAVIORAL|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
218938690|NCT03571685|BEHAVIORAL|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
218938691|NCT03422328|DRUG|macitentan|macitentan 10 mg, film-coated tablet, oral use
218938692|NCT02185495|BEHAVIORAL|Observer nodule detection|Radiologists will detect the nodules.
218938693|NCT02185495|DEVICE|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
218938694|NCT01092546|DRUG|[18F]Flutemetamol|All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
218938695|NCT05407662|OTHER|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
218938696|NCT03171467|PROCEDURE|Salpingectomy|
219049299|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
219049300|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
219049301|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
219206619|NCT06865092|OTHER|control group|Nothing has applied.
219206620|NCT06619483|DRUG|BAY3018250 Dose 1|Single dose
219206621|NCT06619483|DRUG|Placebo|Matching placebo to BAY3018250
219206622|NCT06619483|DRUG|BAY3018250 Dose 2|Single dose
219632747|NCT01019395|DRUG|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
219632748|NCT00001409|DRUG|Interleukin-2|
219632749|NCT05648942|DIAGNOSTIC_TEST|Anemia testing|Patients will undergo a point of care test to identify possible anemia
219632750|NCT04373395|PROCEDURE|D-CLAG|Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
219632751|NCT04213066|DEVICE|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
219632752|NCT01985529|OTHER|Exercise|
219632753|NCT02086149|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
219632754|NCT02086149|BEHAVIORAL|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
218938697|NCT04550598|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
218938698|NCT04550598|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
218938699|NCT05724511|DRUG|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
218938700|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
218938701|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
218938702|NCT06143930|OTHER|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
218938703|NCT06143930|OTHER|strengthening ex|Therapeutic strengthening training program for lower extremities.
218938704|NCT02288455|DEVICE|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
218938705|NCT05944484|BEHAVIORAL|low caloric diet, ultrasound cavitation,Kegel exercises|"* low caloric diet (800-1200) calories/day,). According to each patient, diet contained (carbohydrate protein, fats, minerals, vitamins). 50 to 55% of total calories are carbohydrates, 10 to 15% of total calories protein. Fat limited to less than about 28% of daily total calories .Women took 1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman allowed to change the types of food to avoid boarding.~* ultrasound cavitation emits low-frequency ultrasound 40 khz for 30 minutes on abdomen twice/ week with 3 days apart for 12 weeks.~kegel exercise: Each woman in the study took the same Kegel exercise program performed the Kegel exercise for 12 weeks (3 sessions per week)"
218938706|NCT02014701|PROCEDURE|Echocardiogram|"1. Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~2. Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
218938707|NCT01787721|PROCEDURE|Ankle manipulation|
218938708|NCT01787721|OTHER|Sham manipulation|
218938709|NCT03328208|OTHER|Comfort Talk® app|Test app
218938710|NCT03328208|OTHER|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
218938711|NCT04729023|PROCEDURE|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
219206623|NCT06866093|OTHER|Lifestyle|Participants are asked to answer online survey questions about their anthropomethry, clinical conditions, socio-economical status, dietary habits, physical activity levels, quality of life, sleep quality and pshycological distress.
219206624|NCT06775028|OTHER|iABC platform use|The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
219206625|NCT04037007|PROCEDURE|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
219632755|NCT05473949|DRUG|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
219632756|NCT05473949|DRUG|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
218938712|NCT04729023|PROCEDURE|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
219049302|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
218938713|NCT03333772|BEHAVIORAL|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
218938714|NCT01984528|BIOLOGICAL|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
218938715|NCT02328365|OTHER|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
218938716|NCT05376033|OTHER|root canal filling with Ceraseal sealer|root canal filling with Ceraseal sealer
218938717|NCT05377229|DEVICE|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
218938718|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
219049303|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
219049304|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
219206626|NCT04037007|PROCEDURE|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
219632757|NCT04824326|BEHAVIORAL|PSAI-CA|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
219632758|NCT03382626|DEVICE|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
219632759|NCT03382626|DEVICE|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
219632760|NCT03382626|DEVICE|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
219632761|NCT02129413|DEVICE|Delta system|
218938719|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
218938720|NCT03511807|OTHER|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
219049305|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
219206627|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
218938721|NCT03511807|OTHER|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
218938722|NCT02918513|BEHAVIORAL|Wellness Element 1 - Exercise|1\. Daily wellness element focusing on Exercise; adherence documented online daily
218938723|NCT02918513|BEHAVIORAL|Wellness Element 2 - Mindfulness|2\. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
218938724|NCT02918513|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|3\. Daily wellness element focusing on sleep hygiene; adherence documented online daily
218938725|NCT02918513|BEHAVIORAL|Wellness Element 4 - Social Connectedness|4\. Daily wellness element focusing on Social Connectedness; adherence documented online daily
218938726|NCT02918513|BEHAVIORAL|Wellness Element 5 - Nutrition|5\. Daily wellness element focusing on Nutrition; adherence documented online daily
218938727|NCT02918513|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|6\. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
218938728|NCT02918513|BEHAVIORAL|Wellness Element 7 - Motivational Messages|7\. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
218938729|NCT00742144|DRUG|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
218938730|NCT02897856|DRUG|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
218938731|NCT02897856|DRUG|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
218938732|NCT04756908|DEVICE|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
218938733|NCT05002075|OTHER|m-health cardiac rehabilitation|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California). This app includes a patient-facing iOS and Android compatible smartphone app and an integrated hospital-facing online dashboard for remote monitoring and care coordination by a trained coach
218938734|NCT03193827|DEVICE|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
219049306|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
218938735|NCT03193827|DEVICE|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
218938736|NCT01753648|DEVICE|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
218938737|NCT01753648|OTHER|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
219049307|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
219049308|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
219049309|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
219049310|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
219049311|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
219049312|NCT00225706|DRUG|Caldolor|
219049313|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
219049314|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
219632762|NCT00444938|DEVICE|H1 -coil TMS device|
219632763|NCT00603902|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
219632764|NCT00603902|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
219632765|NCT00603902|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
219632766|NCT01652768|OTHER|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
219632767|NCT01652768|OTHER|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~1. Introduce the palliative care team concept.~2. Provide contact information for the palliative care team given~3. Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~4. Offer community resources to patient and caregiver (Appendix B)~5. Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~6. Provide supportive care"
218938738|NCT01753648|OTHER|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
219049315|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
219049316|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
218938739|NCT01367951|PROCEDURE|Surgical fixation|"* The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
219049317|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
219632768|NCT01652768|OTHER|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~1. Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~2. Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~3. Provide supportive care."
219632769|NCT01652768|OTHER|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care"
218938740|NCT01805791|DRUG|HMPL-004 1800 mg/day|Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
218938741|NCT01805791|DRUG|Placebo|Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
218938742|NCT01805791|DRUG|HMPL-004 2400 mg/day|Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
218938743|NCT00357669|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
218938744|NCT00357669|DRUG|Brivaracetam 50 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
219049318|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
219049319|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
219049320|NCT06153108|DEVICE|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
219632770|NCT01652768|OTHER|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Administer Symptom Assessment Tool~3. Provide pain and/or symptom management intervention~4. Provide supportive care"
219632771|NCT01652768|OTHER|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Re-assess pain and/or symptom management issues and /or intervention~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care."
219632772|NCT01676935|DRUG|ABT-126|See arm description
218938745|NCT00357669|OTHER|Placebo|"* Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use"
219049321|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
219632773|NCT06325839|OTHER|HypnoBirthing training and oxytocin massage group|HypnoBirthing training and oxytocin massage were applied for a total of 12 hours for 4 weeks with the experimental group.
219632774|NCT00003113|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
219049322|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
219049323|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
219049324|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
219049325|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
219049326|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
219049327|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
219049328|NCT02142452|OTHER|Usual Prenatal Care|
219049329|NCT00001996|DRUG|Atovaquone|
219049330|NCT00001996|DRUG|Pentamidine isethionate|
218938746|NCT05634668|OTHER|Interviewing sheet|"1. . Interviewing sheet: It was designed by the researchers and used to obtain subjects' sociodemographic data; their age, menopausal age, gravidity, parity, BMI, residency, occupation, education level, hot flashes, sweating, and daily habits.~2. . Menopause specific quality of life questionnaire (MENQOL): MENQOL was designed by Hilditch and used to assess the presence of menopausal symptoms, its severity, and the degree to which they adversely affect women's life. It consisted of 29 items categorized into four domains~3. . Pittsburgh Sleep Quality Index (PSQI): The PSQI was a self-report scale consisting of 7 components and 19 questions. PSQI studies quality of sleep in the recent month."
218938747|NCT02019485|DRUG|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
219049331|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
219632775|NCT00003113|DRUG|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
219632776|NCT00003113|DRUG|etoposide|Etoposide is given on days 1-3.
219632777|NCT00003113|DRUG|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
219632778|NCT00003113|DRUG|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
219632779|NCT00003113|RADIATION|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
219632780|NCT06580717|DRUG|enavogliflozin 0.3mg|"Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
219632781|NCT06580717|DRUG|enavogliflozin Placebo|"A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
219632782|NCT02889939|OTHER|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
219632783|NCT01180699|BIOLOGICAL|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
219632784|NCT02366637|DRUG|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
219632785|NCT02366637|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
218938748|NCT02019485|DRUG|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
218938749|NCT03637439|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
219632786|NCT02145442|DIETARY_SUPPLEMENT|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
218938750|NCT03637439|OTHER|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
218938751|NCT05055206|DIAGNOSTIC_TEST|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
218938752|NCT03112577|DRUG|REGN3500|Intravenous (IV) use
218938753|NCT03112577|DRUG|Dupilumab|Subcutaneous (SC) use
218938754|NCT03112577|DRUG|Placebo|Matching placebo
218938755|NCT03112577|DRUG|Fluticasone propionate|Inhalation use
219049332|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
219049333|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
219049334|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
219049335|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
218938756|NCT02885116|DEVICE|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
218938757|NCT02885116|DEVICE|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
218938758|NCT04379622|OTHER|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
218938759|NCT02487017|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
218938760|NCT02487017|BIOLOGICAL|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
219049336|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
219049337|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
219049338|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
219049339|NCT01873989|DRUG|Testosterone replacement|
219049340|NCT01873989|OTHER|Waitlist control|
218938761|NCT05870696|DIAGNOSTIC_TEST|PrecogColo Dx test|the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer
218938762|NCT03795870|DIETARY_SUPPLEMENT|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
218938763|NCT03795870|DIETARY_SUPPLEMENT|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
218938764|NCT04960124|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
218938765|NCT04059159|DEVICE|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
218938766|NCT04571697|DRUG|Methotrexate|No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
219049341|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
219049342|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
219049343|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
219049344|NCT00211471|DRUG|anecortave acetate|
219049345|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
219632787|NCT01033032|DRUG|Amrubicin|"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
219049346|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
219049347|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
218938767|NCT04571697|DRUG|Anti-TNF|No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
218938768|NCT04342325|BIOLOGICAL|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
218938769|NCT00000716|DRUG|Zidovudine|
218938770|NCT04145661|DEVICE|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
218938771|NCT04145661|DEVICE|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
218938772|NCT05927155|DRUG|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
218938773|NCT05927155|DRUG|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
218938774|NCT03454360|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
219632788|NCT02944552|DRUG|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
219632789|NCT02944552|DRUG|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
218938775|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
218938776|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
218938777|NCT01749189|DIETARY_SUPPLEMENT|Blend|22 grams of protein/day
218938778|NCT01749189|DIETARY_SUPPLEMENT|Whey|22 grams of protein/day
218938779|NCT01749189|DIETARY_SUPPLEMENT|Placebo|22 grams of carbohydrate/day
218938780|NCT02853058|RADIATION|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
218938781|NCT02853058|RADIATION|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
218938782|NCT02781259|PROCEDURE|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
218938783|NCT02781259|DRUG|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
218938784|NCT02781259|DEVICE|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
219049348|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
219049349|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
219049350|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
219049351|NCT00075868|DRUG|octreotide acetate|
219049352|NCT00075868|OTHER|Placebo|
219049353|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
219049354|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
219049355|NCT00895219|OTHER|Breathing re-training|Breathing re-training
219049356|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
219049357|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
219049358|NCT00004144|DRUG|bryostatin 1|
219632790|NCT02944552|DRUG|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
219632791|NCT02309411|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
219632792|NCT00471341|DRUG|Celecoxib|
219632793|NCT00471341|DRUG|placebo|
219632794|NCT03656692|DRUG|Acthar Gel|Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
218938785|NCT01247272|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
218938786|NCT01247272|DRUG|PROZAC WEEKLY®|90 mg Capsules
218938787|NCT06299332|DEVICE|Device treatment|20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit
218938788|NCT05019911|DEVICE|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
219049359|NCT00004144|DRUG|gemcitabine hydrochloride|
219049360|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
219049361|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
219049362|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
219049363|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
219049364|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
219049365|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
219049366|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
219632795|NCT00904761|OTHER|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
219632796|NCT00299338|DRUG|SP01A|
219632797|NCT01134107|DRUG|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
219632798|NCT01134107|DRUG|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
219632799|NCT02463851|DEVICE|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
219632800|NCT02463851|DEVICE|Contact Force single-tip ablation catheter|
219632801|NCT03551171|DRUG|ZL-2306 (niraparib)|"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."
219632802|NCT00281177|BEHAVIORAL|Asthma Disparity Reduction Strategy|
218938789|NCT05019911|DEVICE|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
219049367|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
218938790|NCT01436929|DRUG|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
218938791|NCT01436929|DRUG|Placebo|Placebo 1tab bid
218938792|NCT03815266|DIAGNOSTIC_TEST|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
219049368|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
219049369|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
219049370|NCT02331446|BEHAVIORAL|Physical exercise intervention|
219206628|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
219206629|NCT01996436|DRUG|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
219206630|NCT01996436|DRUG|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
219206631|NCT01996436|DRUG|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
219206632|NCT06870123|DEVICE|TT cup and ST-C cup|Patients are allocated in 2 different group (one with ST-C Cup and another one with TT Cup)
218938793|NCT03815266|DIAGNOSTIC_TEST|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
218938794|NCT03815266|DIAGNOSTIC_TEST|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
218938795|NCT03815266|DIAGNOSTIC_TEST|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
218938796|NCT03815266|DIAGNOSTIC_TEST|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
218938797|NCT03815266|DIAGNOSTIC_TEST|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
218938798|NCT03815266|DIAGNOSTIC_TEST|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
218938799|NCT03815266|DIAGNOSTIC_TEST|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
218938800|NCT00052117|DRUG|capravirine|
218938801|NCT00052117|DRUG|Kaletra|
219206633|NCT06866600|BIOLOGICAL|low dose CABG+iPSC-CMs|CABG+0.5×10\^8 iPSC-CMs
219206634|NCT06866600|BIOLOGICAL|High dose CABG/LVAD+iPSC-CMs|CABG+1.5×10\^8 iPSC-CMs or LVAD+1.5×10\^8 iPSC-CMs
219049371|NCT00054613|DRUG|Methoxsalen|
219049372|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
219049373|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
219049374|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
219049375|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
219206635|NCT06866600|OTHER|CABG/LVAD+Saline|CABG/LVAD+Saline
219206636|NCT06875050|OTHER|Mediterranean diet|Tailored dietary plan following Mediterranean diet to cover macronutrients needs according to recommended daily allowance (RDA) for age
219206637|NCT06875050|DIETARY_SUPPLEMENT|Fat soluble vitamins supplementation|Fat soluble vitamins supplementation (150 μg vitamin A, 2000 IU vitamin D, 100 mg vitamin E and 1000 μg vitamin K).
219206638|NCT06875050|DIETARY_SUPPLEMENT|Antioxidant Supplement|Antioxidant supplements in specific doses in oral liquid form (200 mg vitamin E, 300 mg vitamin C, 90 μg Se, 500 μg vitamin A, 30 mg zinc, 3 mg copper and 2000 IU vitamin D).
219632803|NCT04012593|BEHAVIORAL|Diary|
219049376|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
219632804|NCT01478672|PROCEDURE|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
219632805|NCT02760823|DRUG|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
219632806|NCT02760823|DRUG|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
219632807|NCT05354856|DRUG|Indocyanine green|A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
219632808|NCT03161743|PROCEDURE|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
219632809|NCT01951534|BEHAVIORAL|Breast Reconstruction Decisional Aid (BRDA)|
219632810|NCT01951534|BEHAVIORAL|Usual Care|
219632811|NCT01656135|OTHER|Blood drawing for immune monitoring and questionnaires|
219632812|NCT06476912|OTHER|weight-shifting exercise|lateral weight-shifting balance training and VNS
219632813|NCT02521142|OTHER|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
218938802|NCT00052117|DRUG|2 NRTIs|
218938803|NCT04240548|RADIATION|Regional Nodal Irradiation|
218938804|NCT01349400|OTHER|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
218938805|NCT01349400|PROCEDURE|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
218938806|NCT04030273|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
218938807|NCT05779189|BEHAVIORAL|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
218938808|NCT05779189|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
218938809|NCT04837378|OTHER|Abdominal Massage|The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
219049377|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
219049378|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
219049379|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
219049380|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
219049381|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
219049382|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
219632814|NCT02521142|OTHER|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
219632815|NCT02521142|OTHER|OCT|non-invasive imaging of retinal and choroidal structures.
219632816|NCT02521142|OTHER|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
219049383|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
219049384|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
219632817|NCT01644292|OTHER|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
219632818|NCT03250754|DEVICE|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
219632819|NCT06682845|OTHER|Collection of data in patients' medical files|"* Demographic data~* Health data: body mass index, weight, tobacco consumption, history of hyperglycemia/ diabetes mellitus, Eastern Cooperative Oncology Group (ECOG) status, glomerular filtration rate, hemoglobin rate~* Cancer-related data: date of diagnosis, tumoral site, tumor histology type, histology grade, date of first metastases involvement, presence of visceral metastases, presence of liver metastases, presence of lymph node-only metastases~* Treatment-related data: previous line of treatment, co-treatment with anti-PD1, enfortumab vedotin (EV) treatment start date, EV treatment end date, EV posology, presence of EV reduction of dose or increased interval between perfusions, number of EV cycles~* Adverse events (AE)-related data: occurrence of cutaneous AE, grade of cutaneous AE, date of cutaneous AE, type of cutaneous AE, management of cutaneous AE, discontinuation of EV treatment, rechallenge of EV treatment~* Outcomes data: best overall response rate"
218938810|NCT04837378|OTHER|In-bed Exercise|In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
218938811|NCT00549003|DEVICE|Rapid Diagnostic Test for P. falciparum malaria|
218938812|NCT05741619|OTHER|Long-term outcome|Autonomy, physical examination, behavioural disorders
218938813|NCT05440552|DIAGNOSTIC_TEST|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
218938814|NCT05440552|DIAGNOSTIC_TEST|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
218938815|NCT04105504|DRUG|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
218938816|NCT04105504|DRUG|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
219049385|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
219049386|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
219049387|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
219365963|NCT01202461|PROCEDURE|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
219365964|NCT02538302|DRUG|Minirin|Minirin 5 to 10 mg daily for 6 months
219365965|NCT02538302|DRUG|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
219365966|NCT01169779|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
218938817|NCT06265662|BEHAVIORAL|A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand|The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
218938818|NCT03193593|DRUG|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
218938819|NCT03193593|DRUG|EB-001|Single injection of EB-001 into Pectoralis Muscle
219049388|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
219049389|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
219049390|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
219049391|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
219049392|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
219049393|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
219049394|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
219049395|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
219049396|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
219049397|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
219049398|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
219049399|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
219049400|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
219049401|NCT01358981|DRUG|LY2881835|Administered orally
219049402|NCT01358981|DRUG|Placebo|Administered orally
219049403|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
219049404|NCT03440671|BIOLOGICAL|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
219049405|NCT03440671|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
219049406|NCT02600637|BEHAVIORAL|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
218938820|NCT05852613|DEVICE|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
218938821|NCT05852613|COMBINATION_PRODUCT|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
218938822|NCT00316043|BEHAVIORAL|Written information for parents|
218938823|NCT00316043|BEHAVIORAL|Distance learning package for General Practitioners|
218938824|NCT00316043|BEHAVIORAL|Distance learning package for practice assistants|
218938825|NCT05454072|PROCEDURE|Sinonasal Microbiota Transfer|Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
218938826|NCT05454072|PROCEDURE|Sham Sinonasal Microbiota Transfer|Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
218938827|NCT00253162|DRUG|risperidone|
218938828|NCT04074408|PROCEDURE|stereotactic surgery|stereotactic aspiration surgery
219049407|NCT02600637|BEHAVIORAL|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
218938829|NCT04074408|BIOLOGICAL|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
218938830|NCT04074408|BIOLOGICAL|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
219049408|NCT05304260|OTHER|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
219049409|NCT02815228|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
219049410|NCT06562881|OTHER|Scheduling Navigation|Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.
218938831|NCT05102032|PROCEDURE|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
219049411|NCT06562881|OTHER|Without Scheduling Navigation|Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
218938832|NCT05102032|PROCEDURE|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
218938833|NCT03313817|DEVICE|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
218938834|NCT00456391|PROCEDURE|Medical history|
218938835|NCT00456391|PROCEDURE|Brain CT scan|
219049412|NCT04437966|BEHAVIORAL|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
219049413|NCT02519712|DRUG|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
219049414|NCT02519712|PROCEDURE|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
219206639|NCT06874543|OTHER|visceral osteopathic manual therapy|In the study, relaxation techniques, hepato-gastric ligamentum mobilization, pyloric valve mobilization, sphincter odi mobilization, sphincter ilio-jejunum mobilization, cecal valve mobilization, iliopsoas and iliacus mobilization, peritoneal mobilization, intestine, kidney, bladder, stomach, liver and bladder organ mobilizations will be applied to the experimental group patients as VOMT program. Until the next session, bladder mobilization will be taught as a home program and they will be asked to do it every day. After VOMT is applied by the physiotherapist once a week, a total of 4 times, the evaluation scales will be applied again. In order to see the long-term effect, the patients will be evaluated again in the first month and the third month after the end of the treatment. The forms will be filed as pre-treatment, post-treatment, first month and third month data and will be entered into the computer and recorded
219206640|NCT06874179|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement 0|optic nerve sheath diameter (ONSD) measured via ultrasonography before intubation
219632820|NCT05797961|BEHAVIORAL|HIV self-testing with online supervision|A pilot study to assess the feasibility of HIV self-testing with online supervision
219632821|NCT05797961|OTHER|Control|venue-based HIV testing
219632822|NCT01704690|DRUG|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
219632823|NCT01704690|DRUG|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
219632824|NCT01704690|DRUG|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
219632825|NCT03092765|DRUG|E6011|Intravenous administration
218938836|NCT02797613|BEHAVIORAL|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
218938837|NCT00110721|DRUG|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
218938838|NCT00186134|BEHAVIORAL|physical activity|
218938839|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
218938840|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
218938841|NCT02578758|OTHER|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
219049415|NCT05675553|DEVICE|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
219049416|NCT05675553|OTHER|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
219049417|NCT00560690|DRUG|Metformin|500 mg oral three times a day for 6 months
219049418|NCT00560690|DRUG|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
219049419|NCT00560690|DRUG|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
219049420|NCT06317311|BIOLOGICAL|Dostarlimab|Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
219049421|NCT06317311|DRUG|Carboplatin|Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
219632826|NCT03092765|DRUG|Placebo|Intravenous administration
219632827|NCT02362672|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
219632828|NCT02362672|DRUG|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
219632829|NCT00695292|DRUG|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
219632830|NCT00695292|DRUG|Carboplatin|carboplatin AUC=4 on Day 1
219632831|NCT00695292|DRUG|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
219632832|NCT00998075|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
219632833|NCT00998075|DRUG|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
219632834|NCT00998075|DRUG|ASA|Tablet, oral, single dose
219632835|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
219632836|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
219632837|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
219632838|NCT04494061|PROCEDURE|blood collection|Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
219632839|NCT06665048|DRUG|Oxycodone HCl|Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
219632840|NCT00932308|DIETARY_SUPPLEMENT|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
219632841|NCT00932308|DIETARY_SUPPLEMENT|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
219049422|NCT06317311|DRUG|Paclitaxel|Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
219049423|NCT06109584|DEVICE|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
219049424|NCT03846258|DRUG|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
219049425|NCT03846258|DRUG|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
219049426|NCT01462357|BIOLOGICAL|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
219049427|NCT01462357|BIOLOGICAL|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
219049428|NCT01462357|DRUG|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
218938842|NCT05111730|DEVICE|The Shock wave Therapy.|Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
218938843|NCT02121080|DRUG|REGN2222(SAR438584)|
218938844|NCT02121080|DRUG|placebo|
218938845|NCT05006001|DRUG|Colchicine and NSAID|Colchicine and nonsteroidal anti-inflammatory drug combination therapy
218938846|NCT02879188|OTHER|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
218938847|NCT02879188|OTHER|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
218938848|NCT00438568|DRUG|Regular Insulin|administered intra-nasally twice a day for 16 weeks
218938849|NCT00438568|DRUG|Placebo|administered intra-nasally twice a day for 16 weeks
218938850|NCT00002076|DRUG|Fluconazole|
218938851|NCT05048966|BEHAVIORAL|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
218938852|NCT05048966|BEHAVIORAL|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
218938853|NCT00947882|DRUG|Placebo|Mannitol 50 mg/mL solution
218938854|NCT00947882|DRUG|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
218938855|NCT00947882|DRUG|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
218938856|NCT00947882|DRUG|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
218938857|NCT02644876|DRUG|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
219049429|NCT02994862|OTHER|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
219049430|NCT02994862|OTHER|Conventional Bonding|Normal Bonding Protocol
219365967|NCT01169779|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
218938858|NCT02644876|DRUG|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
218938859|NCT05268913|DIAGNOSTIC_TEST|MRI scan|Participants will undertake a magnetic resonance imaging scan.
218938860|NCT05268913|BIOLOGICAL|Blood test|Participants will undertake a fasting blood test.
218938861|NCT05870943|PROCEDURE|Hybrid Argon Plasma Coagulation|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach.
218938862|NCT05870943|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
218938863|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|"Group A:~1. Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~2. Treatment will focus on the patient's needs and in accordance with the physicians requests.~3. Three months post initial treatment re-assessment will be conducted."
218938864|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
218938865|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
218938866|NCT02219867|DRUG|Ketamine|Drug (including placebo)
218938867|NCT00329797|DIETARY_SUPPLEMENT|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
218938868|NCT00329797|DIETARY_SUPPLEMENT|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
218938869|NCT00329797|RADIATION|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
218938870|NCT00329797|DRUG|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
218938871|NCT00329797|DIETARY_SUPPLEMENT|Vitamin D|400 IU (10μg), orally each day for 3 years.
218938872|NCT00860548|DRUG|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
218938873|NCT06178601|DRUG|RC48-ADC|RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
218938874|NCT06178601|DRUG|AK104|AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
218938875|NCT03220906|OTHER|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
218938876|NCT00161343|BEHAVIORAL|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
219049431|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
219049432|NCT01482767|DRUG|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
219049433|NCT01482767|DRUG|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
219049434|NCT01482767|DRUG|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
219049435|NCT01261858|DEVICE|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
219049436|NCT02995785|OTHER|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
219049437|NCT02995785|OTHER|traditional training|traditional training:Give TMS online lecture(15-min).
219049438|NCT02976896|DRUG|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
218938877|NCT00653926|DRUG|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
218938878|NCT00653926|DRUG|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
218938879|NCT05751603|DRUG|sugammadex|sugammadex is administered just after extubation
218938880|NCT06518018|RADIATION|HDR brachytherapy (30Gy single fraction)|Study Group receives a novel triple combination therapy for advanced NSCLC in the second-line setting. The treatment begins with a single fraction of high-dose rate (HDR) brachytherapy, delivering 30 Gy locally to the tumor site. This is followed within 1-3 days by systemic therapy, combining immunotherapy and chemotherapy , both administered intravenously.
219049439|NCT00806546|DRUG|NP101|NP101 study patch four hour application
219049440|NCT01398111|DRUG|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
219049441|NCT01398111|DRUG|Glycopyrrolate|glycopyrrolate pMDI
219049442|NCT01398111|DRUG|Formoterol|formoterol pMDI
219049443|NCT01398111|DRUG|Placebo|placebo pMDI
219049444|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
219049445|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
219632842|NCT06214663|OTHER|0.9 NaCl solution|Saline injections will be administered over the sacral area (both posterior iliac spines and 2 cm downward and medial), and this technique was described by Lytzen et al in 1989 and later standardized. The results will be compared between the three groups.
219049446|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
219049447|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
219049448|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
219049449|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
219365968|NCT01169779|DEVICE|Pen auto-injector|
219632843|NCT04742400|DRUG|tolebrutinib 60mg|60 mg orally
219632844|NCT04742400|DRUG|tolebrutinib 120mg|120 mg orally
219632845|NCT02480673|DIETARY_SUPPLEMENT|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
219632846|NCT02480673|DIETARY_SUPPLEMENT|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
219632847|NCT02480673|BEHAVIORAL|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
219632848|NCT05879289|DIETARY_SUPPLEMENT|A power supplement|A dietary supplement containing vitamins and collagen
218938881|NCT06518018|DRUG|Immunotherapy|Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
218938882|NCT02084121|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
219549424|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
218938883|NCT03370432|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
218938884|NCT03615443|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
218938885|NCT01405144|DRUG|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
218938886|NCT01405144|PROCEDURE|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
219206641|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 1|optic nerve sheath diameter measurement 1 via ultrasonography after intubation 1st minute
219549425|NCT02907125|BEHAVIORAL|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
219549426|NCT06170762|OTHER|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
219549427|NCT06170762|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
219549428|NCT06170762|OTHER|MTA|MTA
219549429|NCT00822887|DRUG|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
219549430|NCT00822887|RADIATION|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
219549431|NCT00344513|DRUG|Beta-blockers including Carvedilol|
219549432|NCT00344513|DRUG|ACE inhibitors|
219549433|NCT00858403|DRUG|Dasatinib|Take tablets of Dasatinib by mouth once a day.
219549434|NCT04738864|DIAGNOSTIC_TEST|ultrasound|extracranial and intracranial ultrasound assessment
219549435|NCT02193022|DRUG|Miltefosine|
219549436|NCT00363077|BIOLOGICAL|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
219549437|NCT00363077|BIOLOGICAL|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
219549438|NCT06449690|PROCEDURE|Dog-assisted therapy|Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
219549439|NCT06449690|PROCEDURE|Occupational activities|Occupational activities consist of origami, relaxation, sports or board games sessions.
219549440|NCT00867763|PROCEDURE|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
219549441|NCT00867763|PROCEDURE|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
219549442|NCT01120028|DRUG|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
219549443|NCT01120028|DRUG|Basiliximab|20 mg intravenously, two doses 96 hours apart
219549444|NCT01120028|DRUG|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
219549445|NCT01120028|DRUG|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
219549446|NCT00510848|PROCEDURE|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
219549447|NCT00510848|PROCEDURE|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
219549448|NCT04264221|BEHAVIORAL|New management mode|"* New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
219549449|NCT01923909|DRUG|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
219549450|NCT01923909|DRUG|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
219549451|NCT02113722|PROCEDURE|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
219549452|NCT02113722|PROCEDURE|Standard of Care|Medical therapy
219549453|NCT05370807|DRUG|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
219549454|NCT05370807|DRUG|Triplet therapy|Regorafenib in combination with BRAF- / MEK- inhibitors
219549455|NCT04817722|DRUG|Intravenous Solution|Intraoperative hydration
219049450|NCT05878548|PROCEDURE|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
219049451|NCT01148004|DRUG|Fenofibrate|
219049452|NCT01148004|DRUG|Ritonavir|
219632849|NCT06242548|OTHER|physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)|"organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
219632850|NCT05922566|COMBINATION_PRODUCT|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
219632851|NCT05967013|COMBINATION_PRODUCT|Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.|"All injections with ZENEO® injector will be performed in the thigh. Due to MRI performance constraints, injection sites will be identified on the same thigh/leg at each treatment period: first leg on treatment period 1, opposite leg on treatment period 2.~At each treatment period, two injection sites will be identified spaced 8 to 15 cm apart. The 2 injections should be performed on the same leg at each treatment period.~In total, 2 injections will be performed per treatment period, and subjects will receive 4 injections during the study :~* 2 injections on bare skin: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector.~* 2 injections through clothing: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector."
219632852|NCT04687137|DRUG|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
219632853|NCT01422564|DEVICE|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
219632854|NCT01422564|DEVICE|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
219632855|NCT03648320|OTHER|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
219632856|NCT02321657|OTHER|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
219632857|NCT02321657|OTHER|Toys, books and games|Games, books and toys used to distract
219632858|NCT00735969|DRUG|Peginterferon|
219632859|NCT00735969|DRUG|Ribavirin|
219632860|NCT03925948|BEHAVIORAL|PLAN 4 Success-Diabetes|The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
219632861|NCT01372618|DRUG|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
219632862|NCT02801617|DRUG|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
218938887|NCT05270252|OTHER|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright \& Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
218938888|NCT01206218|DRUG|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
218938889|NCT01206218|DRUG|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
218938890|NCT05196321|OTHER|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
218938891|NCT06227104|DEVICE|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
218938892|NCT01430052|DRUG|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
219049453|NCT01148004|DRUG|Lopinavir/Ritonavir|
219049454|NCT02362165|DRUG|Cyclophosphamide|500mg/d,once-weekly,per oral.
219049455|NCT02362165|DRUG|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
219049456|NCT02362165|DRUG|Dexamethasone|40mg/d,once-weekly,per oral
219049457|NCT02362165|DRUG|Doxorubicin|9mg/㎡,d1-4
219049458|NCT02611622|BEHAVIORAL|LUMA ENT™|
219049459|NCT02611622|OTHER|Survey|Demographic and Patient Satisfaction Survey
219049460|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
219049461|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
218938893|NCT01430052|DRUG|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
218938894|NCT04911608|OTHER|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
218938895|NCT04911608|OTHER|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
218938896|NCT02949791|PROCEDURE|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
219049462|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
219049463|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
219049464|NCT02367599|DRUG|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
219206642|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 2|optic nerve sheath diameter measurement via ultrasonography after intubation 5th minute
219206643|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 3|optic nerve sheath diameter measurement via ultrasonography after intubation 10th minute
219049465|NCT03385239|DRUG|ISIS 678354|ISIS 678354 solution for SC injection.
219049466|NCT03385239|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl).
219049467|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
219206644|NCT06874179|PROCEDURE|Pre-intubation oropharyngeal topical %10 lidocaine|Pre-intubation oropharyngeal topical %10 lidocaine
218938897|NCT02949791|OTHER|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
219206645|NCT06874179|PROCEDURE|Pre-intubation intravenous %2 lidocaine|Pre-intubation intravenous %2 lidocaine
219632863|NCT02801617|DRUG|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
219632864|NCT03524417|BIOLOGICAL|Equine rabies immunoglobulin injection on day 7|The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
219632865|NCT01954056|DRUG|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
218938898|NCT02949791|OTHER|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
218938899|NCT01385527|BEHAVIORAL|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
218938900|NCT01385527|DRUG|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
218938901|NCT01858935|DRUG|ND-L02-s0201 Injection|Single IV infusion.
218938902|NCT01858935|DRUG|Placebo|Single IV infusion.
218938903|NCT05317741|DRUG|IA-14069|Subjects received IA-14069 tablet orally on Day 1.
218938904|NCT05317741|DRUG|Placebo|Subjects received matching placebo tablet orally on Day 1.
218938905|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
219049468|NCT04952220|DEVICE|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
219049469|NCT04732637|DIAGNOSTIC_TEST|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
219049470|NCT01574703|DRUG|placebo|All dosing to have taken place per study A3051123
219049471|NCT01574703|DRUG|varenicline tartrate|All dosing to have taken place per study A3051123
219049472|NCT01574703|DRUG|bupropion hydrochloride|All dosing to have taken place per study A3051123
219049473|NCT01574703|DRUG|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
219049474|NCT04906642|DEVICE|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
219049475|NCT04906642|OTHER|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
219206646|NCT06873984|OTHER|compression products|"Compression Group (CG):~Participants received individually fitted, round-knit compression stockings with a pressure of 23-32 mmHg (Class 2, RAL-GZG standard).~Compression garments were selected based on circumference measurements taken in the morning to ensure proper fit.~Participants were instructed to wear the stockings for approximately 9 hours per day.~The compression garments were provided by the same manufacturer (Medi GmbH \& Co., Bayreuth, Germany).~Additionally, participants were advised to engage in daily physical activity (walking for at least 20 minutes per day) while wearing compression.~Comprehensive education was provided on skin care, self-manual lymph drainage (simple lymph drainage, SLD), and lymphedema prevention."
219206647|NCT06347809|OTHER|Non-Interventional Study|Non-Interventional Study
219365969|NCT01169779|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
219049476|NCT05339607|OTHER|Thermal ablation of resection margins by STSC and biliary orifice by cystotome.|Patients who are eligible will undergo thermal ablation of the resection margins.
218938906|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
218938907|NCT04274946|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
219049477|NCT05558293|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
219049478|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
219049479|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
219049480|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
219632866|NCT01954056|DRUG|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
219049481|NCT04401891|BEHAVIORAL|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
219049482|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219049483|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
219049484|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
219049485|NCT03325907|DEVICE|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
219632867|NCT00392340|BIOLOGICAL|filgrastim|
219632868|NCT00392340|DRUG|doxorubicin hydrochloride|
219632869|NCT00392340|DRUG|topotecan hydrochloride|
218938908|NCT00327197|DRUG|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
219206648|NCT06693076|PROCEDURE|Laparoscopic cholecystectomy|The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
218938909|NCT00327197|PROCEDURE|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
218938910|NCT02888938|OTHER|pelvic radiography|
218938911|NCT02888938|OTHER|pelvic MRI|
218938912|NCT02888938|OTHER|pelvic CT-scan|
218938913|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
219049486|NCT01865825|RADIATION|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
219049487|NCT03759756|OTHER|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
219049488|NCT03759756|OTHER|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
219049489|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
219206649|NCT06692621|DRUG|Oxytocin|Medicines were administered in appropriate doses
219206650|NCT06692621|DRUG|Carbetocin|Medicines were administered in appropriate doses
219206651|NCT06693570|OTHER|Intact Fish Skin Graft (IFSG) + Standard of Care|Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219632870|NCT00392340|DRUG|vincristine sulfate|
219632871|NCT06110494|DRUG|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
219632872|NCT06110494|DRUG|NaOCl|Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
219632873|NCT06110494|DRUG|NaCl|Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
219632874|NCT06110494|DRUG|supplementary irrigation|"All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously"
219632875|NCT03095326|DIETARY_SUPPLEMENT|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
219632876|NCT03095326|DRUG|Sucrose|Placebo of sucrose syrup
219632877|NCT03095326|BIOLOGICAL|PCV Vaccine|Pneumococcal conjugate vaccine
219632878|NCT03095326|BIOLOGICAL|PPV Vaccine|Pneumococcal polysaccharide vaccine
219632879|NCT02289248|DRUG|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
219049490|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
219049491|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
219049492|NCT04561401|DEVICE|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
219632880|NCT02289248|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
218938914|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
218938915|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
218938916|NCT02685137|DRUG|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
218938917|NCT02685137|OTHER|Sham Injection|nothing
218938918|NCT03290924|BEHAVIORAL|Low dose high frequency health worker training approach|"* Two 4-day training sessions for skilled birth attendants~* 1-day peer practice coordinator training after first training session~* Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~* SMS reminder messages and quizzes~* Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~* Health information officer training~* Data collection and use training~* Supply of simulators, newborn resuscitation equipment, and delivery sets"
218938919|NCT03290924|BEHAVIORAL|Active Comparison|Training on data collection and reporting
218938920|NCT04449263|DEVICE|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
219049493|NCT04561401|OTHER|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
219049494|NCT01524770|BIOLOGICAL|Dulaglutide|Administered by subcutaneous (SC) injection
219049495|NCT05545670|DRUG|Placebo|not containing drugs
219049496|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
219206652|NCT06693570|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219632881|NCT06272539|PROCEDURE|Exercise|The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.
218938921|NCT04449263|DEVICE|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
218938922|NCT04449263|DEVICE|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
218938923|NCT06175949|DRUG|HRS-7085 Tablets|HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
218938924|NCT06175949|DRUG|HRS-7085 simulant|PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
218938925|NCT00888719|DRUG|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
218938926|NCT00888719|DRUG|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
218938927|NCT00888719|DRUG|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
218938928|NCT05895474|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
219049497|NCT05508412|BEHAVIORAL|CancerPEP|CancerPEP
219049498|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
219365970|NCT01169779|DRUG|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
219365971|NCT03512548|DRUG|Relacorilant 350mg|Relacorilant 350mg
219632882|NCT06272539|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
219632883|NCT05127317|DIAGNOSTIC_TEST|Mechanical power|"In our study, mechanical power (MP) will be calculated during mechanical ventilation in patients who will be operated under general anesthesia.~MP will be calculated with the simplified formula applied by Gattinoni et al. MPvcv: RR x Tv x (PIP-\[(Pplat-PEEP)/2\]) x 0.098(2) In pressure-controlled ventilation, the simplified MP formula of Becher et al. well be used.~MPpcv: RR x Tv x (ΔPinsp + PEEP) x 0.098 (11)~For MP calculated according to the weight of the patients; Indexed MP: MP /kg according to IBW. For the force applied to the lungs in each inspiration; Dynamic power (mJ/min): Vt x RR x \[(Pplato+ tPEEP)/2\]. For the driver power that provides the gas flow; Driving power (mJ/min): Vt x RR x \[ (Pplat - tPEEP) / 2\]. Calculating mechanical energy; Mechanical energy (mJ/kg): 0.098 x (V x kg ) x (PIP - \[(P plateau- PEEP) / 2\]) formulas were used"
219632884|NCT00002202|DRUG|Indinavir sulfate|
219632885|NCT00002202|DRUG|Amprenavir|
219632886|NCT02148978|DRUG|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
219632887|NCT04319263|DRUG|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
219632888|NCT04596410|RADIATION|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
219632889|NCT04596410|RADIATION|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
219632890|NCT03660111|DIAGNOSTIC_TEST|spirometry|only measurement of spirometry
219632891|NCT06578689|BEHAVIORAL|Education|The control group received standard care, while the intervention group received standard care supplemented with formal educational session followed by ongoing education on foot care using mobile health by a clinical pharmacist.
219632892|NCT02647190|DRUG|Erwinia Chrysanthemi asparaginase|
219632893|NCT03279822|OTHER|not any intervention|not any intervention
219632894|NCT01155934|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
219632895|NCT02914613|DRUG|SF0166 Topical Ophthalmic Solution|
219632896|NCT02461966|OTHER|Aflatoxin|Evaluation of Aflatoxin level
218938929|NCT03368690|DIETARY_SUPPLEMENT|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
218938930|NCT03368690|OTHER|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
219049499|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
219049500|NCT03023566|DRUG|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
219049501|NCT04004728|PROCEDURE|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
219049502|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
219049503|NCT00186004|DEVICE|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
219049504|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
219049505|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
219049506|NCT04809909|PROCEDURE|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
219632897|NCT03907748|OTHER|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
218938931|NCT02194374|PROCEDURE|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
219049507|NCT04809909|PROCEDURE|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
219049508|NCT05028504|DRUG|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219365972|NCT03512548|DRUG|Itraconazole|Itraconazole 200 mg
219365973|NCT03512548|DRUG|Relacorilant 300mg|Relacorilant 300mg
219632898|NCT03907748|OTHER|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
219632899|NCT00274612|DRUG|Telmisartan|
219632900|NCT00274612|DRUG|Ramipril|
219632901|NCT04940793|DEVICE|POD FT|Cataract surgery
219632902|NCT03616873|OTHER|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
219632903|NCT01188330|BEHAVIORAL|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
219632904|NCT01188330|BEHAVIORAL|Conventional|no Comprehensive Geriatric assessment
219632905|NCT03612596|BEHAVIORAL|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
219632906|NCT03612596|BEHAVIORAL|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
219632907|NCT03325816|DRUG|Nivolumab|Nivolumab is administered intravenously
218938932|NCT02194374|DRUG|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
218938933|NCT02194374|DRUG|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
218938934|NCT02194374|DRUG|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
218938935|NCT02194374|DRUG|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
218938936|NCT03037580|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
218938937|NCT03037580|DRUG|Placebo|Placebo (sugar pill) for TID oral administration
219049509|NCT05028504|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
219049510|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
219049511|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
219049512|NCT02682420|DEVICE|everlinQ endoAVF System|
219049513|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
219365974|NCT02141893|BEHAVIORAL|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
219365975|NCT02141893|BEHAVIORAL|CALMA|Family Education Intervention on management of pediatric asthma
219365976|NCT04111614|DRUG|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
219049514|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
218938938|NCT02087423|DRUG|MEDI4736|MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
218938939|NCT04609644|OTHER|Digital Tools for Asthma Self-Management|Please see description of active study arm.
218938940|NCT02246465|DRUG|RXI-109|
219049515|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
219049516|NCT01387607|DRUG|placebo|Placebo, twice daily
219049517|NCT05361681|OTHER|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
219049518|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
219049519|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
219049520|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
219365977|NCT04111614|DRUG|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
219365978|NCT05714904|DRUG|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
219632908|NCT03325816|RADIATION|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
219632909|NCT03421210|DRUG|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
219632910|NCT04851990|OTHER|To Better Days Large Patch|Large patch containing vitamin D \& Dextrose for transdermal absorption
219632911|NCT04851990|OTHER|To Better Days Small Patch|Small patch containing vitamin D \& Dextrose for transdermal absorption
219632912|NCT04679532|OTHER|Gx sweat patch|Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay
219632913|NCT04679532|OTHER|Reference sweat patch|Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
219632914|NCT04604171|BEHAVIORAL|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
218938941|NCT00026169|DRUG|imatinib mesylate|Given orally
218938942|NCT00026169|OTHER|laboratory biomarker analysis|Correlative studies
219049521|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
219049522|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
219049523|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
219049524|NCT02617550|DRUG|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
219049525|NCT02617550|DRUG|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
219049526|NCT02617550|DRUG|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
219049527|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
219049528|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
219049529|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
219049530|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
219365979|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
219632915|NCT04604171|BEHAVIORAL|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
219632916|NCT04604171|BEHAVIORAL|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
219632917|NCT03259464|DRUG|BI 685509|3 sequential dose groups
219632918|NCT03259464|DRUG|Placebo|3 sequential dose groups
219632919|NCT04062201|DRUG|Bedaquiline Oral Tablet|Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - \>50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
219632920|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
219632921|NCT04062201|DRUG|Delamanid in Oral Dosage Form|Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - \>50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
219632922|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
219632923|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
219632924|NCT04062201|DRUG|Isoniazid Oral Product|Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group \>50kg: 600mg daily
219632925|NCT04062201|DRUG|Ethambutol Oral Product|Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group \>50kg: 1200mg daily
219632926|NCT04062201|DRUG|Pyrazinamide Oral Product|Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group \>50kg: 2000mg daily
219632927|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
219632928|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
219632929|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
219632930|NCT01210846|DRUG|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
219632931|NCT05875896|PROCEDURE|Total wrist fusion|Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
219632932|NCT02118116|OTHER|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
219632933|NCT04586816|COMBINATION_PRODUCT|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
218938943|NCT00026169|OTHER|pharmacological study|Correlative studies
219049531|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
219365980|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
219632934|NCT04586816|COMBINATION_PRODUCT|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
219632935|NCT04586816|COMBINATION_PRODUCT|vehicle|vehicle cream base only
219632936|NCT02322112|OTHER|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
219632937|NCT02322112|OTHER|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
218938944|NCT02470000|DEVICE|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
218938945|NCT02470000|DEVICE|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
218938946|NCT02470000|OTHER|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
218938947|NCT01779258|DRUG|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
218938948|NCT01779258|DEVICE|Atopiclair®|1 application in the morning, in the afternoon and in the evening
218938949|NCT01779258|DRUG|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
218938950|NCT01779258|DRUG|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
218938951|NCT04803240|DEVICE|Thealoz Duo|Non applicable
219049532|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
219049533|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
219049534|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
219049535|NCT00844792|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
219365981|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
219365982|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
219632938|NCT02322112|OTHER|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
219632939|NCT02541513|DRUG|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
219632940|NCT06143241|DEVICE|Threshold IMT|Threshold is used in respiratory muscle training in the form of resistance loading.
219632941|NCT06143241|DRUG|Antiepileptic medication|They will continue their antiepileptic medication prescribed by their doctor.
218938952|NCT00442364|DRUG|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
218938953|NCT00442364|PROCEDURE|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
218938954|NCT00357279|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
218938955|NCT00357279|DRUG|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
218938956|NCT00217178|DRUG|Vitamins: Folic acid, B6, B12|
218938957|NCT00530816|DRUG|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
218938958|NCT04801056|DRUG|TB006|TB006 monoclonal antibody
218938959|NCT04801056|OTHER|Placebo|Placebo i.v. infusion
218938960|NCT04473287|OTHER|reflexology practice|Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
219049536|NCT00844792|DRUG|Placebo|Twice a day with meals.
219049537|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
219365983|NCT00892580|DRUG|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
219632942|NCT04664036|DIAGNOSTIC_TEST|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
219632943|NCT04664036|DIAGNOSTIC_TEST|elastography|elastography to compare liver stiffness indices
219632944|NCT04664036|DIAGNOSTIC_TEST|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
219632945|NCT04664036|DIAGNOSTIC_TEST|FLI|the FLI is a score panel designed to screen for NAFLD
219632946|NCT04664036|DIAGNOSTIC_TEST|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
219632947|NCT04664036|DIAGNOSTIC_TEST|NFS|the NFS is a score panel designed to screen for significant fibrosis
219632948|NCT00098436|DRUG|laromustine|
219632949|NCT00098436|DRUG|temozolomide|
219632950|NCT00000918|DRUG|Indinavir sulfate|
219632951|NCT00000918|DRUG|Lamivudine/Zidovudine|
219632952|NCT00000918|DRUG|Ritonavir|
219632953|NCT00000918|DRUG|Amprenavir|
219632954|NCT00000918|DRUG|Efavirenz|
219632955|NCT00000918|DRUG|Saquinavir|
219632956|NCT00000918|DRUG|Lamivudine|
219632957|NCT00000918|DRUG|Stavudine|
218938961|NCT05094778|PROCEDURE|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
219632958|NCT00000918|DRUG|Zidovudine|
219632959|NCT00000918|DRUG|Didanosine|
219632960|NCT03777436|DRUG|Apremilast|Oral
219632961|NCT03777436|OTHER|Placebo|Oral
219632962|NCT03080064|BEHAVIORAL|Health Coach Intervention|Please see arm description.
219632963|NCT05209464|DEVICE|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
219632964|NCT00676364|DRUG|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
219632965|NCT00676364|DRUG|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
219632966|NCT06578403|DEVICE|external microneedling|external micro\_needling
219632967|NCT06578403|OTHER|minimally invasive non- surgical periodontal therapy|minimally invasive non- surgical periodontal therapy
219632968|NCT06578403|DEVICE|internal micro_needling|internal micro\_ needling
219632969|NCT03636802|OTHER|Questionnaire BPI|Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
219632970|NCT00447343|PROCEDURE|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart."
219632971|NCT00447343|PROCEDURE|fMRI and MRS scan|A scan pre-op and 6 months post-op.
219632972|NCT03821259|OTHER|Psychological measures|Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
219632973|NCT01342770|OTHER|Laboratory Biomarker Analysis|Correlative studies
219632974|NCT01342770|DRUG|Pioglitazone Hydrochloride|Given PO
219632975|NCT01342770|OTHER|Quality-of-Life Assessment|Ancillary studies
219632976|NCT02169375|OTHER|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
219632977|NCT02316600|DEVICE|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
219632978|NCT02877875|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
219632979|NCT02877875|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
219632980|NCT02877875|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
219632981|NCT00869999|DRUG|Everolimus|Taken orally once daily in the morning
219632982|NCT00869999|DRUG|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
219632983|NCT01146899|OTHER|Provider Alert|Provider influenza vaccine alert
219632984|NCT00552370|DRUG|Lantus®|
219632985|NCT02236871|BEHAVIORAL|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
219632986|NCT02236871|BEHAVIORAL|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
219632987|NCT02127411|BEHAVIORAL|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
219632988|NCT03788993|OTHER|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
218938962|NCT05444595|BEHAVIORAL|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
218938963|NCT05444595|BEHAVIORAL|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
218938964|NCT00800254|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
218938965|NCT00800254|OTHER|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
218938966|NCT03399201|PROCEDURE|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
219632989|NCT03788993|OTHER|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
219632990|NCT02186860|BIOLOGICAL|CAR-T cells|Given IV
218938967|NCT03399201|PROCEDURE|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
218938968|NCT03399201|DIAGNOSTIC_TEST|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
218938969|NCT06230211|OTHER|Music Therapy|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
218938970|NCT06230211|OTHER|Maternal Voice|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
218938971|NCT03761368|PROCEDURE|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
218938972|NCT03761368|PROCEDURE|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
218938973|NCT00543530|DRUG|MK0831|
218938974|NCT02224001|PROCEDURE|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
218938975|NCT01454817|BEHAVIORAL|Quality of life|Improving Quality of Life
218938976|NCT01240824|DRUG|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
218938977|NCT00457457|DRUG|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
218938978|NCT00457457|DRUG|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
218938979|NCT03835364|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
218938980|NCT00464191|DRUG|escitalopram|
218938981|NCT04066231|DEVICE|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
218938982|NCT04066231|DRUG|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
218938983|NCT06230900|OTHER|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
218938984|NCT06230900|COMBINATION_PRODUCT|14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
218938985|NCT02758184|DEVICE|ROTEM-based coagulation monitoring|
218938986|NCT02758184|PROCEDURE|Spine surgery|
219632991|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® 5-Methyltetrahydrofolate|5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
219049538|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
219049539|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
219049540|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
219049541|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
219049542|NCT04204018|OTHER|Experimental Arm|"* First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
219049543|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
219049544|NCT00569686|DRUG|placebo|placebo
219049545|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
218938987|NCT02587273|DRUG|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
218938988|NCT06147388|DIAGNOSTIC_TEST|Colposcopy|No surgery, observation
218938989|NCT00899431|DRUG|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
218938990|NCT00899431|DRUG|Fludarabine|30 mg/m\^2 intravenously daily on days -5, -4, -3.
218938991|NCT00899431|DRUG|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
218938992|NCT00899431|DRUG|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
218938993|NCT00899431|PROCEDURE|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
218938994|NCT00899431|DRUG|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
218938995|NCT00899431|DRUG|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
218938996|NCT01193504|DRUG|Pred Forte|Pred Forte BID for 4 weeks postop
218938997|NCT01193504|DRUG|Lotemax|Lotemax BID for 4 weeks postop.
218938998|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 500 mg/m\^2 IV over 2 hours every other week
219049546|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
219049547|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
219049548|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
218938999|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 750 mg/m\^2 IV over 3 hours every other week
218939000|NCT04483648|OTHER|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
218939001|NCT05131724|OTHER|Treadmill training with virtual reality|The virtual environment will be composed of obstacles, different paths, and narrow and deviated corridors. Walking through this environment will require the infant to coordinate walking behaviour and adjust the length, height, and width of steps to negotiate the obstacles on the television screen placed at the infant's eye level in front of the treadmill. The speed, orientation, size, frequency of appearance, and shape of the obstacles will be manipulated according to individual performance following a standardized protocol. The virtual system will provide visual and auditory feedback on the success or failure of the activity to enhance motor learning. In addition, the characteristics of the environment (e.g., visibility, configuration, and distractions) will be adjusted to increase the complexity of the training.
219049549|NCT00192452|DRUG|MEDI-507|
219049550|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
219049551|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
218939002|NCT05131724|OTHER|Treadmill training|The RAM870A of the Medisoft treadmill will be used. Two treadmill training sessions will be held before the onset of the intervention to familiarize the children with the equipment. During these two sessions, the treadmill training and speed will be set according to the following procedures: the ground walking speed of each child will be determined through the baseline 6MWT, then the training velocity will be set at 50% of the maximum ground speed established during the 6MWT and increased gradually based on the tolerance of each child (i.e., no complaint of fatigue, heart rate not exceeding 70% of the maximum heart rate, and a lack of gait shuffling, buckling or dragging steps more than 5 seconds during walking).
218939003|NCT01432483|DRUG|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
218939004|NCT04723797|OTHER|Physical activity|Physical activity program consisting of running and/or cycling
218939005|NCT05933252|OTHER|Augmented reality (AR)|an app on an iPad every 15 minutes
218939006|NCT04313361|OTHER|No intervention|No drug will be administered as part of this study.
219049552|NCT02687906|DRUG|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
219632992|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® Placebo|The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
219632993|NCT04478695|DRUG|AMG 330|Continuous intravenous (IV) infusion.
219049553|NCT06152744|OTHER|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
219049554|NCT05355870|BEHAVIORAL|Cognitive Training Intervention|Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
219632994|NCT04478695|DRUG|Pembrolizumab|Intravenous (IV) infusion.
219632995|NCT03525938|PROCEDURE|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
218939007|NCT03478826|OTHER|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
218939008|NCT03478826|OTHER|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
218939009|NCT03478826|OTHER|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
218939010|NCT03462693|OTHER|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
218939011|NCT00238355|DRUG|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
218939012|NCT00238355|DRUG|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
218939013|NCT05036330|OTHER|Clinical Evaluation|Undergo speech and swallow evaluation
218939014|NCT05036330|PROCEDURE|Physical Examination|Undergo examination of TEP and laryngectomy stoma
218939015|NCT05036330|OTHER|Quality-of-Life Assessment|Complete questionnaires
218939016|NCT05036330|OTHER|Questionnaire Administration|Complete questionnaires
218939017|NCT02902146|DEVICE|Bougie|
218939018|NCT02902146|DEVICE|Endotracheal tube|
218939019|NCT01441232|DRUG|LX4211|400 mg of LX4211 administered as two 200 mg tablets
218939020|NCT01441232|DRUG|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
218939021|NCT01253577|DEVICE|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
218939022|NCT01253577|DEVICE|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
218939023|NCT03204240|OTHER|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
218939024|NCT02509026|BIOLOGICAL|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
218939025|NCT01539460|PROCEDURE|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
218939026|NCT04652037|DEVICE|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
218939027|NCT03265652|DEVICE|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
219632996|NCT01191125|OTHER|medical food with AN777|Two(220 mL)servings every day for six months
218939028|NCT03265652|DEVICE|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
219632997|NCT01191125|OTHER|oral nutritional formula|Two (220 mL) servings daily for six months
219206653|NCT06044571|OTHER|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
219632998|NCT02158325|PROCEDURE|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
219632999|NCT00644917|DRUG|Xenaderm|20mg under Finn chambers
219633000|NCT00644917|DRUG|Placebo|20mg under Finn chambers
219633001|NCT01872117|OTHER|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
219633002|NCT01872117|OTHER|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
219633003|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
219633004|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
219633005|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
218939029|NCT05533866|COMBINATION_PRODUCT|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
218939030|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
218939031|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
218939032|NCT03390114|BEHAVIORAL|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
218939033|NCT00644891|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
218939034|NCT00644891|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
218939035|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
219206654|NCT06044571|BEHAVIORAL|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
219633006|NCT01544842|DRUG|0.1 % tacrolimus ointment|applied topically to oral mucosa
219633007|NCT01544842|DRUG|0.1 % triamcinolone paste|applied topically to oral mucosa
219633008|NCT01544842|DRUG|Orabase paste|applied topically to oral mucosa
219633009|NCT05330156|PROCEDURE|Transurethral resection of the prostate|\- After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
219633010|NCT05330156|PROCEDURE|transurethral enucleation of prostate|After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
219633011|NCT00758485|DRUG|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
219633012|NCT00758485|DRUG|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
218939036|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
218939037|NCT05772351|DRUG|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
218939038|NCT01317459|BEHAVIORAL|Guided self-determination|Group counselling
218939039|NCT01303224|DRUG|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
218939040|NCT01303224|DRUG|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
218939041|NCT01303224|DRUG|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
218939042|NCT01303224|DRUG|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
218939043|NCT00566384|DRUG|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
218939044|NCT00566384|DRUG|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
218939045|NCT05194371|RADIATION|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
218939046|NCT01258322|DRUG|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
218939047|NCT03796520|DIAGNOSTIC_TEST|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age \> 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
218939048|NCT01574183|DRUG|Vilazodone|up to 40 mg capsule daily
218939049|NCT01574183|DRUG|Placebo|up to 40 mg capsule daily
218939050|NCT02715440|DRUG|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
218939051|NCT06438510|PROCEDURE|Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)|All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
218939052|NCT04228029|DEVICE|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
218939053|NCT04228029|DRUG|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
218939054|NCT05086614|DRUG|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
218939055|NCT02870478|DRUG|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
218939056|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
218939057|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
218939058|NCT03264729|OTHER|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
219049555|NCT06019988|OTHER|Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening|All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
219049556|NCT05703178|BEHAVIORAL|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
218939059|NCT03264729|OTHER|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
218939060|NCT03264729|OTHER|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
218939061|NCT05941871|OTHER|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
218939062|NCT05941871|OTHER|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
218939063|NCT06273696|DEVICE|ShangRing|The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
219049557|NCT05703178|OTHER|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
219049558|NCT02019849|DEVICE|Plasmafit® Total Hip Arthroplasty|
219049559|NCT06412107|OTHER|True acupressure|Participants will receive a 7-week true self-acupressure practice and a 12-week follow-up.
219049560|NCT06412107|OTHER|Sham acupressure|Participants will receive a 7-week sham self-acupressure practice and a 12-week follow-up.
219049561|NCT06412107|OTHER|Usual care|Routine methods of treatment and care along with an updated education booklet.
219049562|NCT06328894|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219049563|NCT06328894|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219049564|NCT06328894|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219049565|NCT06485271|DRUG|Camrelizumab|200mg,iv,d1,Q2W/Q3W
219049566|NCT06485271|DRUG|apatinib|250mg,qd
219049567|NCT06485271|DRUG|chemotherapy|Standard treatment
219049568|NCT05177042|DRUG|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
219049569|NCT05569954|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
219049570|NCT05569954|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
219049571|NCT01660412|DRUG|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
219049572|NCT01660412|DRUG|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
219206655|NCT06418997|BEHAVIORAL|CBI|CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
218939064|NCT03846518|DEVICE|Hyrax|Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
218939065|NCT03846518|DEVICE|mini Hyrax|Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
218939066|NCT05622253|COMBINATION_PRODUCT|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
218939067|NCT02834793|DRUG|Placebo|Participants will receive matching placebo in Randomization phase.
218939068|NCT02834793|DRUG|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
218939069|NCT03811236|OTHER|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
218939070|NCT03961698|DRUG|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
218939071|NCT03961698|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
218939072|NCT03961698|DRUG|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
218939073|NCT03961698|DRUG|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
218939074|NCT01049009|DRUG|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
218939075|NCT01049009|DRUG|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
218939076|NCT04709133|PROCEDURE|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
219049573|NCT06639490|DEVICE|RUS GA|he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
218939077|NCT02350478|DRUG|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
219049574|NCT06639490|PROCEDURE|standard treatment|Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
219049575|NCT03118128|DRUG|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
219206656|NCT02823327|GENETIC|Laboratory Biomarker Analysis|Correlative studies
219633013|NCT02347774|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
218939078|NCT02350478|DRUG|Placebo|The subject will receive placebo orally once daily for 12 weeks.
218939079|NCT00622440|DRUG|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
218939080|NCT00622440|DRUG|Placebo|Placebo twice daily for 48 weeks.
219049576|NCT02184221|DEVICE|High frequency stimulation|The parameter of DMS: alpha frequency
219049577|NCT02184221|DEVICE|Low frequency stimulation|The parameter of DMS: 0.5Hz
219206657|NCT02823327|OTHER|Medical Chart Review|Medical chart review is performed
219206658|NCT03740191|OTHER|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
219206659|NCT03740191|RADIATION|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
219633014|NCT02347774|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
219633015|NCT02347774|DRUG|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
219633016|NCT03269630|OTHER|No intervention. Biospecimen collection only|Biospecimen collection
218939081|NCT05571566|OTHER|Educational Book|An educational book with information about appendicitis for patients, parents and caregivers
219049578|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219049579|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
219633017|NCT04758468|BEHAVIORAL|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
219633018|NCT04758468|BEHAVIORAL|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
219633019|NCT00921557|DRUG|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
219633020|NCT00921557|DRUG|Placebo|Oral tablet taken once weekly
219633021|NCT00921557|DIETARY_SUPPLEMENT|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
218939082|NCT05704569|DIAGNOSTIC_TEST|measurement of multiple biomarkers|All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
218939083|NCT04132271|OTHER|Personalized diet|Modified texture and volumen diet according to the OD specifications
218939084|NCT04132271|OTHER|Control|Nutritional Recommendations according to the OD specifications
218939085|NCT01179113|DRUG|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
218939086|NCT01179113|DRUG|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
218939087|NCT04875000|OTHER|Remineralizing agent I application|Application of UltraEZ remineralizing agent to the bleached teeth
218939088|NCT04875000|OTHER|Remineralizing agent II application|Application of 2.5% arginine solution to the bleached teeth
218939089|NCT04875000|OTHER|Remineralizing agent III application|Application of 2.5% nano-hydroxyapatite solution to the bleached teeth
218939090|NCT03799042|DEVICE|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
218939091|NCT03799042|BEHAVIORAL|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
218939092|NCT01667419|DRUG|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
218939093|NCT01667419|DRUG|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
219049580|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
219206660|NCT03740191|RADIATION|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
219633022|NCT00846248|DIETARY_SUPPLEMENT|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
219633023|NCT00846248|DIETARY_SUPPLEMENT|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
219633024|NCT00656292|DRUG|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
219633025|NCT00656292|DRUG|Placebo|1 pill po/NG every day x 6 days
219206661|NCT06828653|DEVICE|Part A First Wear Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFOs during Weeks 1 through 3.
219206662|NCT06828653|DEVICE|Part A First Wear Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFOs during Weeks 1 through 3.
219206663|NCT06828653|DEVICE|Part A Second Wear Period: Traditional AFO(s)|Participants wear traditionally produced AFOs during Weeks 4 through 6.
218939094|NCT01206088|DRUG|nilotinib|administration of nilotinib as 2nd line
218939095|NCT01094145|OTHER|Deep brain stimulation|DBS in the Nucleus basalis Meynert
218939096|NCT05200234|DRUG|Nattokinase|Nattokinase + standard treatment
218939097|NCT05200234|DRUG|Placebo|Placebo+ standard treatment
218939098|NCT04364984|DRUG|Angiotensin converting enzyme inhibitor|routine drug intake
219049581|NCT06824181|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219049582|NCT06824181|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219049583|NCT06824181|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219049584|NCT06824181|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
219049585|NCT06824181|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
219633026|NCT04112043|BEHAVIORAL|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
218939099|NCT04364984|DRUG|Angiotensin Receptor Blockers|routine drug intake
218939100|NCT04364984|DRUG|Direct renin inhibitor|routine drug intake
218939101|NCT05967507|DEVICE|Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
218939102|NCT05967507|DEVICE|High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
218939103|NCT04707300|DRUG|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
218939104|NCT05819853|DRUG|Semaglutide Injectable Product (Wegovy and/or Ozempic)|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
218939105|NCT04988841|DRUG|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
218939106|NCT04988841|DRUG|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
218939107|NCT04988841|DRUG|Nivolumab|AntiPD1 ( immunothérapy)
218939108|NCT04988841|DRUG|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
218939109|NCT04988841|DRUG|Normacol|hypertonic enema solution
218939110|NCT04988841|DRUG|Placebo of Maat013|expérimental drug placebo of MaaT013
218939111|NCT06331013|RADIATION|CyberKnife ultra-hypofractionated SBRT|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
218939112|NCT01941186|OTHER|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
218939113|NCT04856085|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
218939114|NCT04856085|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
218939115|NCT04856085|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
218939116|NCT02722304|BIOLOGICAL|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
218939117|NCT02722304|BIOLOGICAL|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
218939118|NCT02722304|BIOLOGICAL|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
218939119|NCT02722304|BIOLOGICAL|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
218939120|NCT02722304|BIOLOGICAL|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
218939121|NCT01125696|DRUG|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
218939122|NCT01125696|DRUG|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
218939123|NCT02592096|DRUG|0.1% Pazufloxacin Mesilate Ear Drops|
219049586|NCT06824181|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
218939124|NCT02592096|DRUG|0.3% Pazufloxacin Mesilate Ear Drops|
218939125|NCT02592096|DRUG|0.5% Pazufloxacin Mesilate Ear Drops|
218939126|NCT02592096|DRUG|Pazufloxacin mesilate injection|
218939127|NCT04737304|DRUG|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
218939128|NCT03018262|DEVICE|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
219049587|NCT06824181|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219633027|NCT04112043|DRUG|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
218939129|NCT03018262|DEVICE|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
218939130|NCT03018262|DEVICE|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
218939131|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
218939132|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
218939133|NCT02232568|BEHAVIORAL|Feedback|
218939134|NCT01013103|DRUG|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
219049588|NCT06824181|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
219049589|NCT06824181|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
219633028|NCT05835037|DRUG|Zinc Gluconate 30 MG|Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
218939135|NCT01013103|DRUG|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
218939136|NCT01068600|DRUG|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
218939137|NCT01068600|DRUG|Placebo to indacaterol|Once daily via SDDPI
218939138|NCT02644109|DIETARY_SUPPLEMENT|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
218939139|NCT02644109|DIETARY_SUPPLEMENT|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
218939140|NCT05417763|DEVICE|Randomized physiological measurements by the two systems|To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
218939141|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
218939142|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
218939143|NCT01519869|DRUG|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
218939144|NCT03023813|OTHER|Intervention|Written material provided.
218939145|NCT02575690|DIETARY_SUPPLEMENT|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
218939146|NCT02575690|OTHER|Placebo|Individuals receive a placebo daily, for 3 months.
218939147|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
218939148|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
219049590|NCT06824181|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
219049591|NCT04920448|DRUG|N-Acetyl cysteine|Administered as specified in the treatment arm
218939149|NCT04296838|DRUG|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
218939150|NCT03345290|DEVICE|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
218939151|NCT03345290|DEVICE|Central blood pressure measurement|Central blood pressure measurement
218939152|NCT03345290|OTHER|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
218939153|NCT00577798|PROCEDURE|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
219049592|NCT05741658|DRUG|Dapagliflozin 10mg Tab|Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
219049593|NCT06995300|PROCEDURE|minimally invasive decompression via the posterior approach|All patients will undergo minimally invasive isolated decompression via the posterior approach to the cervical spine.
219206664|NCT06828653|DEVICE|Part A Second Wear Period: Digital AFO(s)|Participants wear digitally produced AFOs during Weeks 4 through 6.
219206665|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFO(s) during Weeks 7 through 14.
219206666|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFO(s) during Weeks 7 through 14.
219206667|NCT06062160|OTHER|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
219049594|NCT05269628|DRUG|Cannabidiol (CBD)|"Epidiolex® dose will be 0.5 mL (50 mg) twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 1 mL (100 mg) twice daily for the remainder of the treatment interval (full dose). If the full dose (100 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (50 mg twice daily).~Participants who go back to the half-dose of Cannabidiol (50 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 100 mg Cannabidiol per day. Participants who are tolerating the full-dose of medication (Cannabidiol 100 mg twice daily) will not be allowed to combine these doses into one daily dose."
219049595|NCT05269628|DRUG|Tetrahydrocannabinol (THC)|"Dronabinol dose will be 2.5 mg twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 5 mg twice daily for the remainder of the treatment interval (full dose). If the full dose (5 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (2.5 mg twice daily).~Participants who go back to the half-dose of Dronabinol (2.5 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 5 mg Dronabinol per day. Participants who are tolerating the full-dose of medication (Dronabinol 5 mg BID) will not be allowed to combine these doses into one daily dose."
219049596|NCT05269628|DRUG|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
219049597|NCT05269628|DRUG|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
219049598|NCT04107636|PROCEDURE|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
219049599|NCT04107636|PROCEDURE|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
219049600|NCT07019246|DRUG|EP mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
219049601|NCT07019246|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
219049602|NCT06462131|BEHAVIORAL|Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)|In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
219049603|NCT07023653|PROCEDURE|All-Inside Techniques|All-inside ACL reconstruction technique avoids creating full-length bone tunnels. Instead, it uses retrograde drilling to form bone sockets, and the graft is secured with adjustable-loop suspensory fixation on both the femur and tibia.
219049604|NCT07023653|PROCEDURE|Complete Tibial Tunnel techniques|Complete Tibial Tunnel Technique is a conventional technique for ACL reconstruction which involves the creation of full-length bone tunnels in the tibia for graft passage via an anterograde approach. Graft fixation is typically achieved using a bio-interference screw on the tibial side and a fixed-loop suspensory device on the femoral side
219049605|NCT07025733|DEVICE|Semiconductor Embedded Sock|Semiconductor Embedded sock will be given to this intervention arm
219049606|NCT07025733|DEVICE|Control Compression Sock|Control sock that is just compression sock
219633029|NCT05835037|DRUG|Placebo|Participants will take one placebo tablet per day for 1 year
219633030|NCT02882581|RADIATION|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
218939154|NCT03294564|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
218939155|NCT03294564|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
219049607|NCT07025772|BEHAVIORAL|ST+ABR|ST+ABR participants will complete seven weekly sessions of 15 minutes of computerized training (ABR), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
219206668|NCT06689995|OTHER|Bio-immune Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
219206669|NCT06689995|OTHER|Placebo|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
219206670|NCT06631131|DEVICE|Distalization with clear aligners supported by Class II elastics|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
219633031|NCT04157296|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.
218939156|NCT06193122|DEVICE|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
219049608|NCT07025772|BEHAVIORAL|ST+Sham|ST+Sham participants will complete seven weekly sessions of 15 minute computerized control sessions (AAT), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
218939157|NCT05304533|DRUG|MYK-224|Specified dose on specified days
218939158|NCT05304533|DRUG|Itraconazole|Specified dose on specified days
219049609|NCT07025772|BEHAVIORAL|ST Only|ST Only will consist of 7 weekly 45-minute sessions of standard treatment (CBT+NRT) for smoking cessation.
219633032|NCT04157296|BEHAVIORAL|computerized cognitive training (CCT)|CCT intervention will consist of approximately 30 minutes of CCT games prior to each CBT session, to engage cognitive control capacity prior to receipt of CBT. The CCT games will be designed to target focused attention, response inhibition, working memory and multiple simultaneous attention to constitute a general executive function training, and activate neural systems associated with executive function/cognitive control. Difficulty of the games will be titrated individually and by session to avoid boredom and progressively activate the functional systems underlying cognitive control.
218939159|NCT05304533|DRUG|Verapamil|Specified dose on specified days
218939160|NCT02188901|OTHER|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) \[GE healthcare\]
218939161|NCT05996302|BEHAVIORAL|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
218939162|NCT00518089|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
218939163|NCT00518089|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
218939164|NCT01406613|OTHER|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
219633033|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
219633034|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
219633035|NCT00212342|DRUG|Norethisterone,Ethinylestradiol|
218939165|NCT00312195|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
218939166|NCT00312195|DRUG|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
218939167|NCT01956721|PROCEDURE|Exercise training,|
218939168|NCT01956721|PROCEDURE|Muscle biopsy|
218939169|NCT05044299|DEVICE|Isoped|Isoped is a mechanical device allowing movement of lower extremities in a forward and backward motion, with phone-based app to control resistance load
218939170|NCT02511106|DRUG|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
218939171|NCT02511106|DRUG|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
218939172|NCT02511106|DRUG|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
218939173|NCT00480467|DRUG|SAM-315|
218939174|NCT05178719|DEVICE|PMA-zeolite|given for a total period of 4 years
218939175|NCT02578303|OTHER|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
218939176|NCT05391490|GENETIC|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
218939177|NCT04734561|OTHER|Inspiratory muscle training group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
218939178|NCT04734561|OTHER|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
218939179|NCT04734561|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
218939180|NCT04734561|OTHER|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
219049610|NCT07024862|BIOLOGICAL|nivolumab + ipilimumab|First-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC)
219049611|NCT07024368|DEVICE|Reliability of the Sensory Organization Test on the SMART Balance Master across multiple administrations|"The Sensory Organization Test (SOT) on the SMART Balance Master® will be administered a total of five times. On the first day, participants will complete three SOT sessions, each separated by a 20-minute break. An additional SOT will be conducted on day 45, followed by a final SOT on day 50.~SOT test scores will be analyzed using Equilibrium Scores (ESs), which provide information on the integration of multiple sensory systems involved in balance through a linear measurement method. Additionally, scores will be evaluated using Multiscale Entropy (MSE), a non-linear model for assessing complexity in postural stability."
219633036|NCT00212342|DRUG|Sugar pill|
219633037|NCT05630261|BEHAVIORAL|Self-help CBT-I|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) sleep hygiene, (c) stimulus control, (d) sleep restriction, (e) cognitive restructuring, and (f) positive psychology. Each weekly session will be divided into 6-8 chapters. Chapters are supported by short videos and interactive games. Homework activities will be assigned after each session.
219633038|NCT05630261|BEHAVIORAL|Self-help CBT-D|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) emotion management, (c) cognitive restructuring, (d) behavioral activation, and (e) positive psychology. Each weekly session will be divided into 6-8 chapters. Some chapters are supported by short videos and e-worksheets. Homework activities will be assigned after each session, which include weekly record of emotions or between-session practice.
219633039|NCT02012361|PROCEDURE|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
218939181|NCT04477278|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
218939182|NCT04477278|BEHAVIORAL|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
218939183|NCT06332417|OTHER|Ba-Duan-Jin Based Deep Breathing Exercises|"Pressing Up to the Heavens: Deep inhales while raising arms, promoting lung expansion.~Drawing the Bow to Shoot the Eagle: Stretching exercises to improve flexibility and posture."
218939184|NCT06332417|OTHER|FET (Forced Expiratory Technique)|The forced expiratory technique sometimes referred to as a 'huff', is used to help force secretions (phlegm) up the throat so it can be removed via the mouth without the pain of coughing.
218939185|NCT03399929|OTHER|Post Acute Rehabiltation|
218939186|NCT00947167|DRUG|pertuzumab|840 mg, 420 mg, iv
218939187|NCT00947167|DRUG|erlotinib|150 mg, PO
219049612|NCT07023913|OTHER|kinetic Control exercises|Kinetic Control exercises consist of 45-minute sessions, with 3 sessions per week for 8 weeks. The framework for testing and rehabilitation includes initial assessment, rehabilitation before failure, and retesting the same position. Biofeedback measures scapular retraction, and biofeedback pressure training assesses and improves scapular stabilizer control by monitoring pressure changes during specific movements.
219049613|NCT07023913|OTHER|traditional treatment|traditional therapy inform of stretching and strengthening exercise as shoulder roll, arm circle, wall climb, back climb and hand behind neck. Patients will receive 3 sessions per week for 8 weeks, the time of session is 45 - 60 min according to patient ability
219049614|NCT07023861|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.
219049615|NCT07023861|DRUG|89Zr-LNCab190|89Zr-LNCab190 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
219633040|NCT02012361|PROCEDURE|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
219633041|NCT02012361|PROCEDURE|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
219633042|NCT04284098|OTHER|General anesthesia (GA).|Patients received standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
219633043|NCT04284098|OTHER|PECS block using bupivacaine .|The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%, after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
219633044|NCT04284098|OTHER|PECS block using bupivacaine and dexmedetomidine|D group:The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%+dexmedetomidine (1µg/kg) after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
219633045|NCT01398969|BIOLOGICAL|Fresh FMT|Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
219633046|NCT01398969|BIOLOGICAL|Frozen-and-Thawed FMT|Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
219633047|NCT02892110|DRUG|Varenicline|2 mg daily
219633048|NCT02892110|DRUG|Placebo|2 mg daily
219633049|NCT03468114|BEHAVIORAL|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
219633050|NCT03468114|BEHAVIORAL|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
218939188|NCT00664001|DIETARY_SUPPLEMENT|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
218939189|NCT00664001|DIETARY_SUPPLEMENT|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
218939190|NCT06464978|DEVICE|Stapler Reinforcement Patch|Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
218939191|NCT06464978|DEVICE|Standard Stapler|Participants in this group will receive gastrojejunostomy with the use of Standard Stapler
218939192|NCT04286906|OTHER|Questionnaire|MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
218939193|NCT05613062|DRUG|Modified Huang-Lian-Jie-Du Decoction (MHLJDD)|Chinese medicine granules for 12 weeks twice daily
218939194|NCT05613062|DRUG|Placebo|Placebo granules for 12 weeks twice daily
218939195|NCT02806583|OTHER|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
219049616|NCT07023861|DRUG|89Zr-LNCab002|89Zr-LNCab002 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
219049617|NCT07023861|DRUG|89Zr-LNCab072|89Zr-LNCab072 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
219049618|NCT02239536|PROCEDURE|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
218939196|NCT06424314|DIAGNOSTIC_TEST|Monitoring of respiratory mechanics parameters|Physiologic recording instrumentation measure maximal transdiaphragmatic pressure，twitch diaphragmatic pressure and maximal diaphragmatic electromyography
218939197|NCT00344487|DRUG|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
219633051|NCT06576310|DEVICE|Mandibular Advancement Device|In this research, participation in the protocol seamlessly integrates into routine care at the Odontology Department of the University Hospital of Toulouse. The visits include the provision of the orthosis at 3 weeks (T1), with EMGs and digital occlusal analysis. The 6-week follow-up visit (T2) adjusts therapeutic propulsion, subjectively resolving symptoms related to OSAS. At the T0 visit, the researchers collect the polysomnographic monitoring before fitting the orthosis (carried out in the patient's reference sleep laboratory) to assess treatment efficiency. The end-of-research visit (6 months after T1) comprehensively collects data, including questionnaires on stress, anxiety, sleep quality and quantity, oral habits, temporo mandibular dysfunction pain, and quality of life. Moreover, the researchers collect the polysomnographic monitoring after 3 months fitting the orthosis (carried out in the same patient's reference sleep laboratory than before fitting the orthosis).
218939198|NCT00597324|PROCEDURE|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
218939199|NCT05768607|PROCEDURE|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
218939200|NCT05768607|PROCEDURE|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
218939201|NCT05768607|PROCEDURE|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
218939202|NCT05843669|DRUG|Guafenesin tablets|During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
218939203|NCT06638216|OTHER|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
218939204|NCT05065424|DRUG|IV Atropine and Fentanyl Premedication Arm|"Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
218939205|NCT05065424|DRUG|IV Normal Saline Placebo Arm|"Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
218939206|NCT06795139|BEHAVIORAL|Trial Enrollment Diversity Dashboard Behavioral|A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
218939207|NCT04616677|DRUG|JNJ-42847922|JNJ-42847922 tablet will be administered orally.
218939208|NCT04950816|BEHAVIORAL|tailored MBI (.b)|The session will include brief didactic presentations, videos, and mindfulness practice followed by inquiry. We anticipate that sessions will take place twice a week. Sessions will be held on site at the Covenant House Texas (CHT) shelter in a quiet, designated learning space to ease access to sessions for the participants and to assure access to shelter staff (e.g., social workers and case managers) and services (e.g., food and shelter). CHT has onsite, weekday clinical and mental health care and established protocols for accessing needed resources 24/7. Selection criteria for the interventionist include maintaining a personal mindfulness practice for at least two years, trained in .b, and prior experience working with high-risk youth. The interventionist will receive additional training in Trauma-Informed Care as well as study procedures.
219049619|NCT02239536|PROCEDURE|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
219049620|NCT07061977|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219633052|NCT01017770|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
219633053|NCT01017770|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
219633054|NCT04396197|OTHER|Physiotherapy|Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
219633055|NCT02308891|DRUG|lactated Ringer's solution (vigorous hydration arm)|"* Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
218939209|NCT04950816|BEHAVIORAL|attention control condition|Participants will receive no training in MBI or meditation. Topics covered may include physical activity, nutrition, managing weight, understanding adolescence, personal care, avoiding tobacco, alcohol, and drugs though this will be finalized in YR-1 with the HYWG and advisory panel. The HT program will be led by a positive adult instructor with training in health education or a related field and experience working with YEH.
219049621|NCT07061977|RADIATION|Brachytherapy|Undergo brachytherapy
218939210|NCT05518773|OTHER|Observational|Observational
218939211|NCT04373317|DRUG|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
219049622|NCT07061977|DRUG|Carboplatin|Given IV
219049623|NCT07061977|PROCEDURE|Chest Radiography|Undergo chest x-ray
219049624|NCT07061977|DRUG|Cisplatin|Given IV
219049625|NCT07061977|PROCEDURE|Computed Tomography|Undergo CT scan
219049626|NCT07061977|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219049627|NCT07061977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219049628|NCT07061977|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219049629|NCT07061977|BIOLOGICAL|Pembrolizumab|Given IV
219049630|NCT07061977|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219633056|NCT02308891|DRUG|lactated Ringer's solution (standard hydration arm)|\- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
219633057|NCT02308891|DEVICE|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
219633058|NCT03350789|DEVICE|Real acupuncture|manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 \& L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
219633059|NCT03350789|DEVICE|Sham acupuncture|sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
219049631|NCT07071311|BEHAVIORAL|Growth Mindset Intervention|"This single-session growth mindset intervention consists of reading and reflective writing activities that present mental health as something that can be improved, rather than something fixed. The goal is to show that adopting a growth mindset of mental health can encourage more proactive mental health behaviors.~To begin, participants will read stories of three employees who share their personal experiences navigating mental health challenges in the workplace. Each story highlights the employee's struggles, how they came to see mental health as changeable, and the steps they took to care for their well-being (e.g., practicing self-care or seeking therapy). After reading, participants will complete a short reflective essay in response to three prompts. These prompts guide them to examine their own mindset about mental health, endorse a growth mindset towards mental health, and outline specific actions they can take to proactively support their own mental well-being."
219049632|NCT07071311|BEHAVIORAL|Digital Technology Condition|"This single-session control exercise aims to encourage the use of digital technology in the workplace. It positions participants as experts who provide guidance to others on how to use digital tools more effectively at work.~First, participants will read stories about employees' experiences navigating their workload with the help of workplace technology. Each story highlights the employee's initial struggles with learning new digital tools and how they eventually recognized the value of these technologies. This includes examples of how they viewed digital learning as manageable and took proactive steps-such as seeking help from colleagues or setting aside time to practice. Then, participants will complete a short reflective essay in response to three writing prompts. These prompts guide them to reflect on their own experiences with digital tools and offer practical advice to others on how to use new technologies effectively in the workplace."
219633060|NCT04715074|BEHAVIORAL|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
219633061|NCT04715074|BEHAVIORAL|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
219633062|NCT02235844|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|
219049633|NCT07068919|BEHAVIORAL|Seizure diary|collection of a seizure diary during 3 months
219049634|NCT07068919|BEHAVIORAL|Questionnaries|Daily self-assessment via the Epiday application during 3 months
219049635|NCT06894212|DRUG|SEP-363856|tablet
219049636|NCT06894212|OTHER|Placebo|tablet
219049637|NCT07067632|DRUG|Antihypertensive treatment|"Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP~Control groups receiving placebo, standard of care, or no intervention"
219633063|NCT03674112|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
219633064|NCT03674112|DRUG|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
219633065|NCT03674112|DRUG|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
218939212|NCT04373317|DRUG|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate"
218939213|NCT04760769|DRUG|Tavapadon|Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
218939214|NCT03162627|DRUG|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
218939215|NCT03162627|DRUG|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
218939216|NCT03954574|DIAGNOSTIC_TEST|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
218939217|NCT05461170|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
218939218|NCT05461170|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
218939219|NCT05461170|DRUG|NRTI|NRTI given orally.
218939220|NCT03963258|DEVICE|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
219049638|NCT06772025|OTHER|No investigational study intervention|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.
219049639|NCT06466837|BEHAVIORAL|Just-in-time intervention|The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder
219633066|NCT05537818|DEVICE|AVPI Device|"The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app"
219633067|NCT02539433|PROCEDURE|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
219633068|NCT02389387|OTHER|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
219633069|NCT01263236|DRUG|LY2940094|Administered orally
219633070|NCT01263236|DRUG|Placebo|Administered orally
219633071|NCT03189693|OTHER|PVB|nerve stimulator-guided PVB will be performed at two levels
218939221|NCT03963258|OTHER|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
218939222|NCT00042003|DRUG|decitabine (5-aza-2'deoxycytidine)|
218939223|NCT05379998|OTHER|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
218939224|NCT05379998|OTHER|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
219049640|NCT06466837|BEHAVIORAL|Active control|The control group participants will receive six nursing consultations during the 3-month program period.
219049641|NCT06832787|DEVICE|Negative Pressure Wound Therapy|NPWT applied over wound without any adjuncts
219049642|NCT06832787|DEVICE|Kerecis|Kerecis Omega3 Wound Dressing is derived from fish skin and is used as a dermal substitute.
219049643|NCT06832787|DEVICE|Delayed primary closure with local flap|Delayed primary closure with local flap to close wound
219049644|NCT06901037|OTHER|A chatbot-based intervention|A smartphone-delivered AI-based chatbot program designed to provide personalized physical activity and dietary recommendations
219049645|NCT07064876|DRUG|Serplulimab|PD-1 inhibitor, 300 mg intravenous infusion, once every 3 weeks (Q3W) for up to 6 cycles, starting after cryoablation recovery and in the absence of major procedural complications.
219049646|NCT07064876|PROCEDURE|CT-guided Cryoablation|Percutaneous cryoablation performed under CT guidance to achieve local tumor ablation. Procedure done once (per-protocol) prior to systemic therapy.
219633072|NCT03189693|OTHER|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
219633073|NCT03189693|OTHER|GA|All patients will receive general anesthesia.
219049647|NCT04078828|PROCEDURE|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
218939225|NCT04469335|DEVICE|mobile neurofeedback|"to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain\_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well."
218939226|NCT04469335|DEVICE|Sham mobile neurofeedback|"It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study."
218939227|NCT04469335|DEVICE|medication + mobile neurofeedback|The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
219049648|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
219049649|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
219049650|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day prior to surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
219049651|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given days prior to surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
219049652|NCT06841341|DIAGNOSTIC_TEST|electromyography|electromyography of a set of muscles usually examined during diagnosis of ALS (typically tongue, bilateral deltoid, first dorsal interosseur, abductor pollicis brevis, paraspinals, vastus lateralis, anterior tibialis and additionally bilateral sternocleidomastoideus and rectus abdominis). In each muscle recording in relaxation and in maximal voluntary effort will be done. The presence of signs of acute (fibrillations, sharp waves) and chronic (fasciculations, reduction of the recording of the effort) denervation as well as presence of activity coupled with the rhythm of respiration will be assessed.
219049653|NCT06841341|DIAGNOSTIC_TEST|ultrasonography|Ultrasonographic measurements include cross-sectional area (CSA) and diameter of bilateral phrenicus, vagus and accessory nerves as well as diameter of diaphragm. The diameter of diaphragm will be measured during normal, quiet respiration as well as at the peak inspiration and expiration.
219049654|NCT06841341|DIAGNOSTIC_TEST|Arterial blood gas analysis|Assessment of partial oxygen (PaO2) and partial carbondioxide pressure (PaCO2) in arterial blood.
219049655|NCT06841341|DIAGNOSTIC_TEST|slow vital capacity|Slow vital capacity (SVC) will be measured as the full exhalation done after inspiration which will follow a period of quiet breathing. The test will be performed thrice and the final value will be the average value.
219049656|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
219049657|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
219049658|NCT01038778|DRUG|Entinostat|Given PO
219049659|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
219049660|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
219049661|NCT01038778|OTHER|Pharmacological Study|Correlative studies
219049662|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
219049663|NCT06830200|PROCEDURE|Non-surgical periodontal treatment with chitosan brush|Non-surgical treatment of pre-implantitis with chitosan brush
219049664|NCT06830200|DEVICE|Non-surgical treatment of pre-implantitis with titanium curette|Description: Non-surgical treatment of pre-implantitis with titanium curette
219049665|NCT06896435|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
219049666|NCT06896435|BEHAVIORAL|Relaxing Video|Participants are asked to view weekly videos lasting 15 minutes each to engage in relaxation exercises.
219049667|NCT07074353|DRUG|NALIRI|Irinotecan liposomes
219049668|NCT07074353|RADIATION|LCRT|Long-course concurrent chemoradiotherapy
219049669|NCT07074353|DRUG|FOLFOX|Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)
219049670|NCT04768101|DRUG|[11C]-PIB|\[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
219049671|NCT07075523|OTHER|Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers|Pathognomonic magnetic resonance imaging; neurocognitive assessments with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); quality of life assessment with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30; measurement of liquid biomarkers.
219049672|NCT07082387|OTHER|External oblique and rectus abdominis plane block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.
219049673|NCT07082387|OTHER|Quadratus lumborum block|Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.
219049674|NCT07082374|OTHER|Dual subsartorial block|Patients will receive dual subsartorial block (DSB).
218939228|NCT04469335|DEVICE|medication + Sham mobile neurofeedback|The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
218939229|NCT05429385|DRUG|HLX70|Single-dose, intravenous infusion
218939230|NCT05429385|DRUG|Placebo|Single-dose, intravenous infusion
218939231|NCT02659891|BIOLOGICAL|IVIg|
218939232|NCT02659891|OTHER|Placebo|
218939233|NCT00073476|DRUG|traxiprodil (CP-101,606)|
218939234|NCT00272103|DRUG|Itopride (drug)|
218939235|NCT04976543|DRUG|nadroparin calcium-warfarin sequential anticoagulation|The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
218939236|NCT02616796|BEHAVIORAL|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
218939237|NCT01508806|DRUG|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
218939238|NCT01262820|DRUG|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
218939239|NCT01575626|DRUG|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
218939240|NCT03327103|BEHAVIORAL|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
218939241|NCT01933685|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
218939242|NCT01933685|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
219049675|NCT07082374|OTHER|Adductor canal block|Patients will receive an adductor canal block (ACB).
219049676|NCT07082374|OTHER|Femoral nerve block|Patients will receive a femoral nerve block (FNB).
219633074|NCT03189693|OTHER|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
219633075|NCT02882360|DEVICE|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
218939243|NCT02784067|DRUG|Sucraid|Study drug
218939244|NCT02784067|DRUG|Placebo|Sucraid placebo
218939245|NCT04836780|DRUG|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
218939246|NCT06020989|DRUG|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
218939247|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
218939248|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
218939249|NCT03059680|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
218939250|NCT04656327|OTHER|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
218939251|NCT02211170|DRUG|BIBR 796 BS, low dose|
218939252|NCT02211170|DRUG|BIBR 796 BS, high dose|
218939253|NCT02211170|DRUG|Placebo|
218939254|NCT02211170|DRUG|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
218939255|NCT03985969|DRUG|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
218939256|NCT03985969|DRUG|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
218939257|NCT00104520|DRUG|AZLI 75 mg two times a day (BID)/three times a day (TID)|
218939258|NCT00104520|DRUG|Placebo two times a day (BID)/three times a day (TID)|
218939259|NCT06140030|BEHAVIORAL|Mindfulness training|Mindfulness-training mobile health application
218939260|NCT01862237|OTHER|Intervention|"* blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery."
218939261|NCT01151904|DRUG|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
219049677|NCT07085962|DRUG|Calculus bovis sativus|Calculus bovis sativus 200mg qd
219049678|NCT07085962|DRUG|Placebo|Placebo 200mg qd
219633076|NCT02882360|OTHER|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
219633077|NCT02972684|DEVICE|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
219633078|NCT03711565|DEVICE|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
219049679|NCT07085780|OTHER|LEP|"1. Apply a thin, even layer of the Lep directly onto the clean and dry affected area.~2. Cover the application with a layer of clean cotton.~3. Allow the Lep to remain on the area for at least 2 days,~4. Avoiding exposure to direct heat or open flame during this period.~5. In this study, on Day 04, gently remove the Lep using warm water and soft cotton cloth and thoroughly cleanse the area with mild soap and water."
219049680|NCT07085039|DRUG|Ruxolitinib|Participants will take the study drug in a tablet form, by mouth, every day for the next year, as long as it is helping with their disease and not causing unacceptable side effects.
219049681|NCT07087067|DRUG|Aspirin 75 mg|patients received aspirin 75 mg daily prior to 12 weeks gestation
219049682|NCT07085416|DEVICE|Sensor-enabled Athletic X Ankle Brace (sXAB)|The intervention is a sensor-enabled version of the TayCo Brace, Inc. Athletic X Ankle Brace (sXAB), which integrates commercially available inertial measurement units (IMUs) into the structure of the brace. The brace is worn on the ankle of the dominant limb during functional movement tasks to evaluate its ability to produce valid gait and balance metrics compared to laboratory-grade measurement systems.
219049683|NCT07084987|OTHER|neonatal massage|Standardized neonatal massage before phototherapy
218939262|NCT01151904|DRUG|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
218939263|NCT03830619|DIAGNOSTIC_TEST|collect samples|collect serum samples and clinical features
218939264|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP)|"Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions."
219049684|NCT07084987|OTHER|Tub Bathing|Tub bath before phototherapy
219049685|NCT07084987|OTHER|sponge bath|Sponge (wipe) bath before phototherapy
219049686|NCT07085988|OTHER|Rapid glitter|Patients with nasopharyngeal carcinoma are given rapid gamin during concurrent chemoradiotherapy
219049687|NCT07086378|DEVICE|Oxygenating Bite Block|Oxygenating Bite Block will be used instead of the standard bite block.
219049688|NCT07086937|DRUG|Nitazoxanide|Children were given nitazoxanide, PPI, and clarithromycin for 14 days.
219633079|NCT03711565|DEVICE|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
219633080|NCT05198063|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
219633081|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
219633082|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
219633083|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
218939265|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)|Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
218939266|NCT01026324|DRUG|dinaciclib|Given IV
218939267|NCT01026324|OTHER|pharmacological study|Correlative studies
218939268|NCT01026324|OTHER|laboratory biomarker analysis|Correlative studies
218939269|NCT01311141|DRUG|doripenem|doripenem once i.v.500mg
218939270|NCT03616301|DRUG|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
218939271|NCT03616301|DRUG|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
218939272|NCT03358264|DIETARY_SUPPLEMENT|L-citrulline|Amino acid supplement
218939273|NCT06176911|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
219049689|NCT07086937|DRUG|Metronidazole|Children received MTZ, PPI, and clarithromycin for 14 days.
219049690|NCT07086937|DRUG|PPI|Children were given omeprazole for 14 days.
219049691|NCT07086937|DRUG|Clarithromycin|Children were given clarithromycin for 14 days.
219206671|NCT06631131|DEVICE|Distalization with clear aligners supported by miniscrew|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
219206672|NCT05244317|DEVICE|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
218939274|NCT06176911|DRUG|Danazol|200 mg twice daily.
218939275|NCT05188053|DRUG|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
218939276|NCT05188053|DRUG|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
218939277|NCT05405686|DRUG|Lutropin alfa|addition of recombinant luteinizing hormone
218939278|NCT05405686|DRUG|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
219206673|NCT05244317|DEVICE|splint|Removable splint
219633084|NCT03453099|OTHER|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~1. An abbreviated version of the Caffeine Assessment Tool (CAT)~2. Sleep Questionnaire (SQ)~3. Surgical Fear Questionnaire (SFQ)~4. WHO Alcohol AUDIT Tool~5. WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
219633085|NCT03453099|OTHER|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
219633086|NCT04820699|OTHER|post isometric relaxation and muligan bent leg raise|6 week intervention
219633087|NCT04820699|OTHER|muligan bent leg raise|muligan bent leg raise
219633088|NCT02620176|DEVICE|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
219633089|NCT04116060|DIETARY_SUPPLEMENT|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
219633090|NCT04116060|DIETARY_SUPPLEMENT|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
219633091|NCT04346667|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
219633092|NCT04346667|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
219633093|NCT04346667|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
219633094|NCT04346667|DRUG|Placebo|Standard of Care plus placebo
219633095|NCT05681325|DIETARY_SUPPLEMENT|green tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
219633096|NCT05681325|DIETARY_SUPPLEMENT|matcha tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
219633097|NCT01905020|OTHER|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
219633098|NCT01905020|OTHER|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
219633099|NCT03121001|DRUG|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
219633100|NCT03121001|DRUG|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
219633101|NCT03121001|DRUG|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
219633102|NCT03121001|RADIATION|Total body irradiation|3 Gy on day -1
219633103|NCT03121001|PROCEDURE|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
219633104|NCT03121001|DRUG|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
219633105|NCT03121001|DRUG|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
219633106|NCT00832572|DRUG|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
219633107|NCT00832572|DRUG|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
219633108|NCT04754386|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening Oral fluid-based HIV test|The project offers HIV oral test kits to index parents/caregivers with children eligible for index testing services at facility settings to expand access to HIV testing and treatment services for children, and to ensure that all children who screen positive with an oral fluid-based HIV screening kit are linked to confirmatory testing, and newly diagnosed children are initiated on ART.
218939279|NCT05405686|DIAGNOSTIC_TEST|Endometrial biopsy|pipelle de cornier biopsy
218939280|NCT03182569|DEVICE|FLEXIBLE CATHETER|
218939281|NCT03182569|DEVICE|hourly rigid needle puncture|
218939282|NCT00238641|DRUG|Botulinum Toxin type B|
218939283|NCT00794313|DRUG|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
218939284|NCT00794313|DRUG|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
218939285|NCT00794313|DRUG|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
219206674|NCT06631898|OTHER|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
219633109|NCT05903625|DIETARY_SUPPLEMENT|Control Group - Standard White Bread|Participants consume commercially available standard white bread, serving as the control intervention.
219633110|NCT05903625|DIETARY_SUPPLEMENT|Lysine Group - Lysine-Fortified Bread|Participants consume bread fortified with lysine, an essential amino acid, in a specified dosage, frequency, and duration.
219633111|NCT05903625|DIETARY_SUPPLEMENT|Phosphorus Group - Phosphorus-Fortified Bread|Participants consume bread fortified with phosphorus, an essential mineral, in a specified dosage, frequency, and duration
219633112|NCT05903625|DIETARY_SUPPLEMENT|Lysine and Phosphorus Group - Double Fortified Bread|Double Fortified Bread: Participants consume bread fortified with both lysine and phosphorus in specified dosages, frequencies, and durations.
219633113|NCT05193539|BEHAVIORAL|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
219633114|NCT05193539|BEHAVIORAL|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
219633115|NCT00933621|PROCEDURE|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
219633116|NCT01704118|DEVICE|I-gel|Supraglottic airway device
219633117|NCT01704118|DEVICE|ProSeal Laryngeal mask|Supraglottic airway device
219633118|NCT04717531|DRUG|Pyrotinib|400mg, qd, po, day 1-21
219633119|NCT04717531|DRUG|Trastuzumab|6 mg/kg, day 1
218939286|NCT05895019|DRUG|Propofol|Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
218939287|NCT02344524|DEVICE|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
218939288|NCT03629496|OTHER|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
218939289|NCT05381857|OTHER|Human Biological Samples|Blood, urine, nasal swab, fecal samples
219633120|NCT04717531|DRUG|Pertuzumab|420 mg, day 1
219633121|NCT04717531|DRUG|Docetaxel|100 mg/m2, day 1
218939290|NCT00752804|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
218939291|NCT00752804|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
218939292|NCT00752804|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
218939293|NCT02447302|DRUG|Etrasimod|
218939294|NCT02447302|DRUG|Placebo|
218939295|NCT03672890|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
218939296|NCT01901250|DIETARY_SUPPLEMENT|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
218939297|NCT01901250|DIETARY_SUPPLEMENT|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
218939298|NCT01901250|BEHAVIORAL|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
219633122|NCT04717531|DRUG|Epirubicin|90mg/m2, day 1
219633123|NCT04717531|DRUG|Cyclophosphamide|600 mg/m2, day 1
219633124|NCT02049892|OTHER|Metal Ion Levels|
219633125|NCT06046781|OTHER|physical exercise|The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
219633126|NCT02097238|DRUG|Eribulin Mesylate|Given IV
219633127|NCT02097238|OTHER|Pharmacological Study|Correlative studies
219633128|NCT00835224|DRUG|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
219633129|NCT00835224|DRUG|Midodrine|To treat low blood pressure.
219633130|NCT00835224|DRUG|Placebo|A pill with an inactive substance that looks like the study drug.
219633131|NCT06334328|BEHAVIORAL|Virtual reality based mindful movement therapy|VR-MMT combines VR games, multisensory and cognitive stimulation, hand-eye and full body coordination, creative processes, expressive movement, mindfulness practice, and social connectedness.
219633132|NCT00006483|BIOLOGICAL|sargramostim|
219633133|NCT03064698|OTHER|Post-partum Doppler ultrasound|Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
219633134|NCT05832853|BEHAVIORAL|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
219633135|NCT05832853|BEHAVIORAL|Wu Qin Xi, resistance training and endurance training|During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
219633136|NCT05832853|BEHAVIORAL|Resistance training and endurance training|Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
219633137|NCT01106911|DEVICE|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
219633138|NCT00505960|BEHAVIORAL|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
218939299|NCT01901250|DEVICE|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
218939300|NCT01901250|DEVICE|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
218939301|NCT00284453|PROCEDURE|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
218939302|NCT00006100|BIOLOGICAL|aldesleukin|
219049692|NCT07085715|DIAGNOSTIC_TEST|Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)|"The TESTATE website (https://testate.org/) will be expanded to include the offer of free HBV/HCV/HIV self-sampling kit. Users will log in and complete a sociodemographic, behavioral and hepB vaccination survey, which will include the HCVMOSAIC questionnaire. Users identified at HCV risk will be sent a DBS collection kit by post to detect HCV RNA, HBsAg and HIV Ab. Participants will self-collect the DBS sample by finger prick at home and send them to the laboratory by post. The results will be delivered online. All participants who return samples will receive an acceptance survey by email.~All participants recruited into the study will be provided with online information about the study and given the opportunity to ask questions and clarify queries to the field coordinator by email or phone."
219049693|NCT07085806|DRUG|Pentoxifylline (also known as oxpentifylline)|Intravenous injection Pentoxifylline 1 mg/kg/hr dissolved in Plasma Lyte/0.9% Normal saline from12 hours before the surgery to 72 hours after the Surgery
219049694|NCT07085806|OTHER|Plasmalyte|Plasmalyte
219049695|NCT07085949|OTHER|5 cmH2O PEEP|5 cmH2O PEEP will be administered during mechanical ventilation
218939303|NCT00006100|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
219049696|NCT07085949|OTHER|10 cmH2O PEEP|10 cmH2O PEEP will be administered during mechanical ventilation
219049697|NCT07085559|DRUG|Metabolically Armed BCMA CAR-T cells.|Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.
219049698|NCT07085832|OTHER|Education (ALS provider course) in Egypt|Participants complete an ALS course, including theoretical and practical components focused on scenario based simulations for CPR and chest compressions.
219633139|NCT05393869|OTHER|Health communications|Participants are assigned to view health communications with risk and efficacy statements.
218939304|NCT00006100|DRUG|fludarabine phosphate|
219049699|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 1|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
219049700|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 2|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
219049701|NCT07080216|BIOLOGICAL|ZG005|ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)
218939305|NCT00006100|PROCEDURE|peripheral blood stem cell transplantation|
218939306|NCT04401683|DEVICE|Home-based rehabilitation with a digital biofeedback system|"Participants in the experimental group will perform a 12-week digital exercise program, to be performed independently at home using the SWORD Phoenix® medical device, under remote monitoring from a physical therapist.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
218939307|NCT04401683|OTHER|Conventional home-based rehabilitation|"Participants in the control group will benefit from a 12-week home-based rehabilitation program, consisting of 12 face-to-face sessions (1 per week) with a physical therapist, complemented by additional non-supervised sessions. Both supervised and unsupervised sessions will follow the same set of exercises defined for the experimental group.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
218939308|NCT00463723|DRUG|FK506 0.06% (eye drops)|
218939309|NCT03111641|DIAGNOSTIC_TEST|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
219049702|NCT07080216|DRUG|Gecacitinib|Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.
219049703|NCT07080216|BIOLOGICAL|Bevacizumab|Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)
219633140|NCT05140746|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
219206675|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
218939310|NCT04341519|BEHAVIORAL|PTSD|"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days"
218939311|NCT04341519|BEHAVIORAL|Burnout|Symptoms of burnout as assessed by the Maslash Burnout Inventory
218939312|NCT03892304|OTHER|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
218939313|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention handbook
218939314|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention research nurse coaching
218939315|NCT03686007|OTHER|Informational Intervention|Receive ASCO print materials
218939316|NCT03686007|OTHER|Informational Intervention|Receive CRA assistance
218939317|NCT03686007|OTHER|Media Intervention|View the MSM intervention videos
218939318|NCT03686007|OTHER|Media Intervention|View American Cancer Society (ACS) videos
218939319|NCT01867697|DRUG|Cetuximab|
218939320|NCT01867697|DRUG|Irinotecan|
218939321|NCT01867697|DRUG|Oxaliplatin|
218939322|NCT01867697|DRUG|Folinic Acid|
218939323|NCT01867697|DRUG|Calcium Carbonate|
218939324|NCT03736642|BIOLOGICAL|blood sampling|12 ml sample
218939325|NCT03736642|OTHER|stool sampling|20 g sample
218939326|NCT03736642|OTHER|urine sampling|18 ml sample
218939327|NCT03736642|DIAGNOSTIC_TEST|neuropsychological tests|"* Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale"
218939328|NCT02752581|DEVICE|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
218939329|NCT02752581|DEVICE|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
218939330|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
219206676|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
219206677|NCT06686875|OTHER|Questionnaire|Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
218939331|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
218939332|NCT06517485|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
218939333|NCT00614068|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
218939334|NCT00614068|BEHAVIORAL|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
218939335|NCT00152919|DRUG|Meloxicam|
218939336|NCT01614483|OTHER|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
218939337|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
218939338|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
218939339|NCT00687141|DRUG|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
218939340|NCT00687141|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
218939341|NCT04787536|PROCEDURE|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
218939342|NCT04927624|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
218939343|NCT04927624|PROCEDURE|quoadratus lumborum block|quoadratus lumborum block
219206678|NCT06687603|DEVICE|EsoCheck|FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.
219049704|NCT07086066|OTHER|Diaphragm mobilization|This group underwent treatment three times a week, with each session lasting 40 to 60 minutes, over a period of six weeks. Diaphragm mobilization included techniques aimed at increasing muscle elasticity, improving postural balance, and reducing pain by stimulating the sympathetic and parasympathetic nervous systems. In each session, participants received 20 minutes of TENS and 10 minutes of cryotherapy. Following this, diaphragm mobilization was applied. During the application, participants were positioned comfortably in the supine position. The physiotherapist palpated the diaphragm, instructed the participant in diaphragmatic breathing, and asked them to take a deep diaphragmatic breath. During expiration, the diaphragm was mobilized in the posterior and inferior directions. This mobilization was performed 10 times per session. Following that, posterior glide and inferior glide techniques were performed.
219633141|NCT04641325|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
219633142|NCT03523364|DEVICE|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
219049705|NCT07086066|OTHER|conventional physical therapy|As with the experimental group, therapy will be delivered three times per week for six weeks, with each session lasting between 40 and 60 minutes. Each session will include 20 minutes of TENS and 10 minutes of cryotherapy, followed by posterior and inferior gliding techniques on the glenohumeral joint and capsular stretching. Functional exercises will also include wand exercises (two sets of 10 repetitions) and finger ladder exercises targeting shoulder flexion and abduction, but without the addition of diaphragm mobilization techniques.
218939344|NCT04619771|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
218939345|NCT04522830|DRUG|BTL-TML-COVID|"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
218939346|NCT04522830|DRUG|Placebo|"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
218939347|NCT01456897|DRUG|OPC-34712|orally administered once daily
218939348|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
218939349|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
218939350|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
219049706|NCT07086274|DEVICE|Individualized location-based Repetitive Transcranial Magnetic Stimulation|Enhancing targeting accuracy through personalized target localization to improve the analgesic response rate of rTMS.
219049707|NCT07086274|DEVICE|Traditional location-based Repetitive Transcranial Magnetic Stimulation|Recent studies have shown that the dorsolateral prefrontal cortex (DLPFC) plays an inhibitory role in the human pain pathway. High-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left DLPFC has been found to improve chronic migraine.
219206679|NCT06687603|DIAGNOSTIC_TEST|EsoGuard|Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.
219206680|NCT06687343|DIETARY_SUPPLEMENT|EAA Supplement|Dissolved in water and ingested 4 times a day
219206681|NCT06687343|DIETARY_SUPPLEMENT|NEAA Supplement|Dissolved in water and ingested 4 times a day
219633143|NCT03232879|BEHAVIORAL|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
219633144|NCT03232879|BEHAVIORAL|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
219633145|NCT02315404|PROCEDURE|CAP|CAP fitted to the end of the endoscope
219633146|NCT02811146|DEVICE|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
219633147|NCT02811146|OTHER|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
219633148|NCT01421823|DRUG|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
219633149|NCT01421823|DRUG|Placebo|2 weeks local treatment with placebo ointment
219633150|NCT04971135|DRUG|SAN711|SAN711 liquid formulation
218939351|NCT05961007|DRUG|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
219049708|NCT07085065|DEVICE|VR session|"Standard care: Standard care. In both the external control group and the intervention group during Period 1, painful procedures will be performed ccording to usual clinical practice by trained healthcare professionals.~VR session: The device includes a VR headset connected to a smartphone, which displays immersive visual content, along with headphones that deliver audio content. Scenarios are culturally and demographically adapted to the study population. The duration of each VR session will correspond to the time required for each painful procedure."
218939352|NCT05779618|OTHER|no intervention|observational study, all data collected are binary
218939353|NCT06057727|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
218939354|NCT06057727|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
218939355|NCT06057727|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
218939356|NCT06057727|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
218939357|NCT03304938|DRUG|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
218939358|NCT03304938|DRUG|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
218939359|NCT00493051|BIOLOGICAL|GAM501|Ad5PDGF-B formulated in a collagen gel
218939360|NCT00493051|BIOLOGICAL|Placebo|Collagen gel
218939361|NCT00493051|OTHER|Standard of care|moist dressing changes daily
218939362|NCT00930072|DRUG|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
218939363|NCT01396070|DRUG|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
218939364|NCT03722004|BIOLOGICAL|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
218939365|NCT03722004|BIOLOGICAL|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
218939366|NCT03722004|BIOLOGICAL|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
218939367|NCT01561313|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
218939368|NCT01810536|DEVICE|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
218939369|NCT01810536|DEVICE|Venturi mask|
218939370|NCT02640196|DEVICE|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
218939371|NCT02640196|DEVICE|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
219633151|NCT04971135|OTHER|Placebo|Matching placebo
218939372|NCT02640196|DEVICE|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
218939373|NCT02640196|DEVICE|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
218939374|NCT02377739|OTHER|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
218939375|NCT02605265|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
218939376|NCT02605265|DRUG|Capecitabine|
218939377|NCT02605265|DRUG|Irinotecan|
218939378|NCT02605265|DRUG|Oxaliplatin|
218939379|NCT04254913|DRUG|MT-1186|Suspension
218939380|NCT04464018|OTHER|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
218939381|NCT02045641|PROCEDURE|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
218939382|NCT04621149|OTHER|chlorine dioxide|chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
218939383|NCT04621149|DIETARY_SUPPLEMENT|zinc acetate|zinc acetate lozenges have been suggested to have antiviral properties
218939384|NCT04621149|DRUG|Famotidine|famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
218939385|NCT04621149|OTHER|placebo|filtered water
218939386|NCT04621149|DIETARY_SUPPLEMENT|lactoferrin, green tea extract|lactoferrin and green tea extract are dietary supplements
218939387|NCT01396057|DRUG|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
218939388|NCT01396057|OTHER|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
218939389|NCT01396057|OTHER|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
218939390|NCT02695420|DRUG|25 mg Omecamtiv Mecarbil|oral tablet
218939391|NCT02695420|DRUG|Placebo|oral tablet
218939392|NCT02695420|DRUG|37.5 mg Omecamtiv Mecarbil|oral tablet
218939393|NCT02695420|DRUG|50 mg Omecamtiv Mecarbil|oral tablet
218939394|NCT04655170|DRUG|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
218939395|NCT04655170|DRUG|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
218939396|NCT03881215|PROCEDURE|Platelet Rich Plasma|Platelet Rich Plasma
218939397|NCT03881215|PROCEDURE|intra-uterine balloon|intra-uterine balloon
218939398|NCT03412240|PROCEDURE|Induced pacing of the heart|Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
218939399|NCT04535453|BIOLOGICAL|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
218939400|NCT04535453|OTHER|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
218939401|NCT00416039|DRUG|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
218939402|NCT00416039|DRUG|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
218939403|NCT00695929|DRUG|Levosimendan|Intravenous injection
218939404|NCT00695929|DRUG|Milrinone|Intravenous injection
218939405|NCT01911962|PROCEDURE|transvaginal laparoscopic surgery|
218939406|NCT01245569|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
218939407|NCT01245569|DRUG|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
218939408|NCT05507112|DRUG|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
218939409|NCT05507112|DRUG|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
219633152|NCT04920201|OTHER|Over-ground walking without GEMS-H|Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)
218939410|NCT05507112|RADIATION|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
218939411|NCT03843008|DIETARY_SUPPLEMENT|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
218939412|NCT02174822|DRUG|AVP-786|
218939413|NCT02174822|DRUG|Paroxetine|
218939414|NCT02174822|DRUG|Duloxetine|
218939415|NCT03282214|BEHAVIORAL|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
218939416|NCT02929407|DRUG|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
218939417|NCT02929407|DRUG|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
218939418|NCT00916929|DEVICE|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
218939419|NCT03043105|DRUG|Thalidomide, cyclophosphamide and prednisone|"* Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
218939420|NCT06259656|DIAGNOSTIC_TEST|COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)|Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
218939421|NCT05721599|BEHAVIORAL|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
219206682|NCT06687343|DIETARY_SUPPLEMENT|Maltodextrin Supplement|Dissolved in water and ingested 4 times a day
219633153|NCT04920201|DEVICE|Over-ground walking with GEMS-H with resist mode|Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
219633154|NCT04920201|DEVICE|Stair ascent with GEMS-H with assist mode|Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
219633155|NCT04920201|DEVICE|Incline walking with GEMS-H with assist mode|Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
218939422|NCT02413151|BEHAVIORAL|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
218939423|NCT02413151|DEVICE|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
218939424|NCT00002618|BIOLOGICAL|filgrastim|
218939425|NCT00002618|DRUG|cytarabine|
218939426|NCT00002618|DRUG|doxorubicin hydrochloride|
218939427|NCT00002618|DRUG|leucovorin calcium|
219049709|NCT07085221|COMBINATION_PRODUCT|hospital external management|"(I) Symptom management: After enrollment, health managers regularly promoted health education to enhance patients' awareness of the disease and adherence to post-discharge management. Simultaneously, patients were managed via a digital platform, with each patient being provided with a chip-implanted sphygmomanometer to monitor their blood pressure and pulse in real time. If patients develop symptoms, they can report them in real-time and generate alerts to health managers. Through internal clinical decision-making algorithms, the telemedicine team would conduct clinical evaluations and seek decision guidance from clinical cardiologists if necessary.~(II) Clinical evaluation: the system stratified patients by risk levels and determined the frequency and intensity of management accordingly, with blood pressure and heart rate monitored daily. The digital management system automatically transmitted abnormal data to a doctor's assistant, with early detection of life-threatening complication"
219049710|NCT07085364|BEHAVIORAL|Attentional focus|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. Participants will be instructed to look at and step on specific markers/labels that will be attached along the walking paths.
219049711|NCT07085364|BEHAVIORAL|Control|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. No markers/labels will be attached and no relevant instructions will be provided apart from the general instruction.
219049712|NCT07086287|DRUG|rhBNP and standard basic treatment|After administering a bolus of rhBNP at 1.5-2 μg/kg intravenously, a maintenance dose of 0.0075-0.01 μg/kg/min is continuously infused intravenously for 72 hours, with the dosage adjusted based on blood pressure and heart rate; the control group receives standard basic treatment.
219049713|NCT07085858|DIETARY_SUPPLEMENT|yeast β-glucan|Participants in the intervention group will take yeast β-glucan capsules daily. Each capsule contains 250 mg of yeast β-glucan, along with an appropriate amount of maltodextrin and silicon dioxide. All participants in the intervention group will take two capsules once daily, swallowed with warm water after meals.
219049714|NCT07085858|DIETARY_SUPPLEMENT|placebo|Participants in the placebo group will take two placebo capsules once daily in the same manner. The placebo capsules are identical to the intervention capsules in form, taste, appearance, and packaging, but contain only maltodextrin and a small amount of silicon dioxide.
219049715|NCT07085208|PROCEDURE|Unsupervised Machine Learning for Clinical Phenotyping|This is a data-driven study that uses an unsupervised machine learning algorithm to perform clustering on patient multimodal features. These features include: preoperative demographics, comorbidities, and laboratory data; surgical information; and high-resolution intraoperative data, most notably continuous vital sign trajectories.
219633156|NCT02995174|DEVICE|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
218939428|NCT00002618|DRUG|mercaptopurine|
218939429|NCT00002618|DRUG|methotrexate|
218939430|NCT00002618|DRUG|prednisone|
218939431|NCT00002618|DRUG|vincristine sulfate|
218939432|NCT00002618|RADIATION|low-LET cobalt-60 gamma ray therapy|
218939433|NCT00002618|RADIATION|low-LET electron therapy|
218939434|NCT00002618|RADIATION|low-LET photon therapy|
218939435|NCT03156296|DRUG|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
219049716|NCT07087236|BEHAVIORAL|Maximum Cognitive Load|Participants will perform a working memory task (through N-back 1-to-3) to evaluate the upper limit of cognitive demand.
218939436|NCT03156296|DRUG|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
218939437|NCT01236976|DEVICE|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
218939438|NCT01236976|DEVICE|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
218939439|NCT01236976|OTHER|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
218939440|NCT01236976|OTHER|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
218939441|NCT00982059|OTHER|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
219633157|NCT02995174|DEVICE|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
219633158|NCT04468568|DRUG|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
219633159|NCT04468568|DRUG|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
219633160|NCT03303313|DRUG|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
219633161|NCT03799640|OTHER|Standard Yoga|Yoga using standard poses and linear movements
219633162|NCT03799640|OTHER|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
219633163|NCT03799640|OTHER|Educational Control|Lectures on health and fitness
219049717|NCT07087236|BEHAVIORAL|Mental active/pasive activities|"Participants will engage in 7 activities, presented in a randomly assigned order across two separate days, to assess their impact on cognitive load:~1. playing a videogame (Tetris ®)~2. listening a podcast (including a final question)~3. watching a documentary (including a final question)~4. reading a document extract (including a final question)~5. watch a reality show extract (including a final question)~6. listening music, they like it~7. scrolling their Tik-Tok/Instagram"
219049718|NCT07087236|BEHAVIORAL|Baseline Cognitive Load|Participants will sit quietly for 5 minutes to establish baseline spontaneous neurophysiological parameters.
218939442|NCT01360736|BEHAVIORAL|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
218939443|NCT01286909|DIETARY_SUPPLEMENT|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
218939444|NCT00850421|DRUG|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
218939445|NCT03308721|DRUG|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
219049719|NCT04740034|DRUG|AMG 340|AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
219049720|NCT06929923|DEVICE|Pro-2-Cool Device|"The Pro-2-Cool Device is a non-invasive hypothermic therapy (cold therapy) device that provides localized cooling of the head and neck. Water and isopropyl alcohol cooled to 6°C by the chiller assembly circulate through the cooling garment to create conductive heat transfer from the scalp and carotid arteries, thus achieving cooling of the brain."
219206683|NCT06691256|DEVICE|HiDO-ALZ|HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
219633164|NCT05864079|DIAGNOSTIC_TEST|Platelet count|Platelet count in study groups
219633165|NCT05864079|DIAGNOSTIC_TEST|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
219633166|NCT05864079|DIAGNOSTIC_TEST|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
219633167|NCT02597439|DRUG|Omega-3 fatty acids|
219633168|NCT02597439|OTHER|Placebo|
219633169|NCT04565197|BIOLOGICAL|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
219633170|NCT01644799|DRUG|idelalisib|oral
219633171|NCT01644799|DRUG|lenalidomide|oral
219633172|NCT00954941|DRUG|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
219633173|NCT00954941|DRUG|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
219633174|NCT04709146|DIAGNOSTIC_TEST|Audio-Vestibular evaluation|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
219633175|NCT05524168|RADIATION|SBRT|SBRT for metastatic lesions
219633176|NCT05524168|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
219633177|NCT05524168|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
219633178|NCT05524168|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
218939446|NCT03308721|DRUG|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
218939447|NCT04370119|DIAGNOSTIC_TEST|Nasal swab|SARS-CoV-2 PCR
218939448|NCT04370119|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
218939449|NCT02949895|DRUG|BMS-986012|
219049721|NCT06929845|PROCEDURE|organoids models|Enrolled patients will undergo liver biopsy with sampling of tumor tissue and adjacent nontumor liver parenchyma. Alternatively, patients who are candidates for surgical resection of HCC will be enrolled. The tumor tissue obtained will be used partly for histological confirmation of HCC and then included in kerosene, partly used for organoid construction, and the nontumor tissue will be used solely for organoids. Genomic and transcriptomic changes resulting from the integration of PDO of HCC with the gut microbiota and host immune cells derived from the patient will be evaluated. In addition, PDOs from HCC will be tested for the efficacy of systemic therapies (ICI and TKI) and understand possible modifying co-factors.
219049722|NCT06896825|BEHAVIORAL|Self-monitoring|All participants will receive a Garmin and use the associated app to monitor their weekly physical activity (in Intensity Minutes, the term used by Garmin for moderate to vigorous physical activity). Enrolled participants are insufficiently active (engaging in 60 minutes or less of moderate to vigorous physical activity per week) and will receive weekly text messages to incrementally increase physical activity over the course of the study. Goals will be 20% greater than the number of Intensity Minutes from the previous week, with the ultimate goal of reaching 150 Intensity Minutes or more per week, aligning with national activity guidelines.
219049723|NCT07086001|BEHAVIORAL|stress management and coping|Online intervention focusing on stress and coping in university students. All resources were grouped in five main categories: Managing Stress, Enhancing Performance, Adulting, Socialising, and Well-being. The resource was hosted on a website and presented information in several multimedia formats (i.e., text, audio, video, interactive infographic) to account for diversity of preferences. All students in the intervention groups were provided with unlimited access to the intervention. Furthermore, all students were asked to complete screener questions on their stress and coping but only students in the directed group were directed to one of three unique pages on the website based on their responses on the screening questionnaire demonstrating low, moderate, or high need for support around stress and coping.
219049724|NCT07085689|DEVICE|Sodium Fluoride Varnish (5%)|After isolating and drying the teeth to be treated using cotton rolls, 5% sodium fluoride (NaF) varnish (Proshield Varnish, President Dental, Munich, Germany) was applied to the tooth surfaces in two thin layers with the help of a disposable microbrush. The cotton rolls were then removed to allow the varnish to come into contact with saliva and harden. After the procedure, participants were advised to avoid consuming hard foods and brushing their teeth for 4 to 6 hours.
219049725|NCT07085689|DEVICE|Silver diamine fluoride- potassium iodide|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% silver diamine fluoride (Riva Star, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
219206684|NCT06871319|DIAGNOSTIC_TEST|periapical x-ray, orthopantomography|Radiographic exams such as periapical x-rays and orthopantomography are necessary to evaluate the root canal system of teeth.
219206685|NCT06689488|DEVICE|Ablation|Bronchoscopy and microwave ablation prior to surgical resection.
219206686|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
219633179|NCT05567653|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 (Sanprobi Stress)|3-month, multi-strain probiotic supplementation (one a day, 3 x 10⁹ CFU)
219633180|NCT05567653|DIETARY_SUPPLEMENT|Starch (placebo)|3-month placebo
219633181|NCT02158013|OTHER|Levorag Emulgel|
219633182|NCT02158013|DRUG|Diltiazem|
219633183|NCT03552055|OTHER|Non-interventional Study|no interventions in this study, just specimen collection
218939450|NCT02949895|DRUG|Cisplatin|
218939451|NCT02949895|DRUG|Etoposide|
218939452|NCT05418543|PROCEDURE|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
218939453|NCT03497013|DEVICE|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
218939454|NCT03497013|DEVICE|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
218939455|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
218939456|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
218939457|NCT00152269|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
218939458|NCT00152269|DRUG|Asoprisnil|25mg Tablet, oral Daily for 12 months
218939459|NCT00152269|DRUG|Placebo|Placebo, Tablet, oral Daily for 12 months
218939460|NCT02327663|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
218939461|NCT02442804|DIETARY_SUPPLEMENT|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
218939462|NCT02442804|OTHER|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
218939463|NCT02464280|OTHER|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
218939464|NCT02464280|OTHER|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
218939465|NCT02464280|OTHER|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
219049726|NCT07085689|DEVICE|Aqueous Silver Fluoride|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% aqueous silver fluoride (Riva Star Aqua, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
218939466|NCT02036853|DRUG|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
218939467|NCT04269798|OTHER|Traditional Treatment|conventional rehabilitation program for lower limb, balance and gait training
218939468|NCT01755819|DEVICE|Biocomposite interference screw|
218939469|NCT01755819|DEVICE|Extracortical ACL Tightrope fixation|
218939470|NCT05493800|DRUG|MIT-001|Corresponding dose of MIT-001 IV injection during 0.5\~1hr
218939471|NCT05493800|DRUG|normal saline|normal saline IV injection
218939472|NCT02375334|OTHER|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
219359946|NCT04802473|PROCEDURE|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
219633184|NCT01644708|BEHAVIORAL|Self empowerment|"1\. Group meeting, introducing the method and the assessment tools~1. Self-empowerment,~2. Handing over the journal,~3. Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
219633185|NCT00890370|PROCEDURE|Airway clearance technique|
218939473|NCT01640834|DRUG|LY2409021|Administered orally
218939474|NCT01640834|DRUG|Placebo|Administered orally
218939475|NCT01640834|DRUG|Glucagon|Administered via intramuscular injection
218939476|NCT00254930|DRUG|risperidone|
218939477|NCT04335734|PROCEDURE|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
218939478|NCT04335734|PROCEDURE|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
218939479|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLE494
218939480|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLF497
218939481|NCT01035411|DRUG|AZD9668|2 x 30 mg tablet variant 1
218939482|NCT01742286|DRUG|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
218939483|NCT03783715|DRUG|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
219633186|NCT02693145|OTHER|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
219633187|NCT00694473|DEVICE|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
219633188|NCT06138262|OTHER|Health promotion of education pre-conception nutritional preparation|Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
219633189|NCT03004638|DRUG|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
219633190|NCT03004638|DRUG|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
218939484|NCT03200886|DEVICE|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
218939485|NCT03200886|DRUG|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
218939486|NCT04530136|DRUG|Ruconest|Patients will be randomized to Ruconest or Standard of Care
218939487|NCT06522542|DRUG|systematic therapy|All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
218939488|NCT04152564|PROCEDURE|levo-bupivacaine infusion via Thoracic epidural catheter|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
218939489|NCT04152564|PROCEDURE|levo-bupivacaine infusion via preperitoneal catheter|At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
218939490|NCT03415711|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billion sachets
218939491|NCT03415711|DRUG|Mesalamine|Mesalamine 2.4 g/day in once daily administration.
218939492|NCT03415711|DRUG|Placebo|sachets with maltose, cornstarch and dioxide
218939493|NCT01537614|DRUG|COLIMYCINE inhalation|2 MILLION UI
218939494|NCT01537614|DRUG|COLIMYCINE injectable|2 MILLIONS UI
218939495|NCT04121793|DEVICE|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
218939496|NCT03546452|DIAGNOSTIC_TEST|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
218939497|NCT03174600|OTHER|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
218939498|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
219359947|NCT03561584|DRUG|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
218939499|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral dose
219359948|NCT03561584|DRUG|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
219359949|NCT04271332|DRUG|Arbaclofen|Arbaclofen tablet
219359950|NCT04271332|DRUG|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
219359951|NCT01641120|DRUG|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
219633191|NCT03004638|DRUG|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
219633192|NCT03004638|DRUG|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
219633193|NCT03004638|DRUG|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
219633194|NCT03004638|DRUG|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
219633195|NCT04249102|DEVICE|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
219633196|NCT04249102|DEVICE|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
218939500|NCT03561467|OTHER|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
218939501|NCT03351283|OTHER|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
218939502|NCT03351283|OTHER|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
218939503|NCT04240132|OTHER|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
218939504|NCT01387542|DRUG|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
218939505|NCT00980967|OTHER|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
218939506|NCT00870519|DRUG|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
218939507|NCT00870519|DRUG|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
218939508|NCT03601117|DEVICE|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
218939509|NCT03601117|DEVICE|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
218939510|NCT00773318|PROCEDURE|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
218939511|NCT01010867|DRUG|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10\^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
218939512|NCT04023734|BEHAVIORAL|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
218939513|NCT04023734|BEHAVIORAL|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
218939514|NCT04023734|BEHAVIORAL|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
219049727|NCT07085689|DEVICE|Hydroxyethyl Methacrylate and Glutaraldehyde|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. One to two drops of a desensitizing agent containing hydroxyethyl methacrylate and glutaraldehyde (Gluma, Heraeus Kulzer GmbH, Hanau, Germany) were applied to the tooth surface using a disposable microbrush in a rubbing motion. After waiting for 30-60 seconds, the tooth surface was completely dried until the liquid disappeared and the surface lost its shine, and then rinsed with water.
219049728|NCT07086495|OTHER|Aromatherapy|Participants inhaled lavender essential oil (3 drops in 100 ml water) via diffuser during a 15-minute post-exercise recovery period following the Bruce treadmill protocol.
219049729|NCT07086495|OTHER|Placebo Diffuser (No Essential Oil)|Participants were 